,pmid,ti,ab,year,punchline_text,population,interventions,outcomes,population_mesh,interventions_mesh,outcomes_mesh,num_randomized,prob_low_rob,punchline_text,authors,journal,dois 0,32342496,Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial.,"AIM To assess the efficacy, safety, and tolerability of oromucosal nabiximols cannabinoid medicine as adjunct therapy for children with spasticity due to cerebral palsy/traumatic central nervous system injury with inadequate response to existing treatment. METHOD Overall, 72 patients (mean [SD] age 12y 4mo [3y 1mo], range 8-18y) were randomized at a ratio of 2:1 to receive nabiximols (n=47; 29 males, 18 females) or placebo (n=25; 15 males, 10 females) for 12 weeks (12 sprays/day max. based on clinical response/tolerability). The primary outcome was change from baseline in level of spasticity on a 0 to 10 Numerical Rating Scale (NRS), assessed by the primary caregiver at 12 weeks. Secondary outcomes included additional measures for spasticity, sleep quality, pain, health-related quality of life, comfort, depression, and safety. RESULTS There was no significant difference in the spasticity 0 to 10 NRS between nabiximols versus placebo groups after 12 weeks. No statistically significant differences were observed for any secondary endpoint. Adverse events were predominantly mild or moderate in severity; however, three cases of hallucinations were reported. INTERPRETATION Nabiximols was generally well tolerated; however, neuropsychiatric adverse events were observed. No significant reduction in spasticity with nabiximols treatment versus placebo was observed. WHAT THIS PAPER ADDS Oromucosal nabiximols is generally well tolerated by paediatric patients. However, three cases of hallucinations were observed, one of which involved auditory hallucinations and a suicide attempt. Oromucosal nabiximols versus placebo did not reduce cerebral palsy/central nervous system injury-related spasticity.",2020,There was no significant difference in the spasticity 0 to 10 NRS between nabiximols versus placebo groups after 12 weeks.,"['n=47; 29 males, 18 females) or', '72 patients (mean [SD] age 12y 4mo [3y 1mo], range 8-18y', 'paediatric patients', 'children with spasticity due to cerebral palsy/traumatic central nervous system injury', 'paediatric spasticity in cerebral palsy or traumatic brain injury']","['nabiximols cannabinoid medicine', 'nabiximols', 'oromucosal nabiximols cannabinoid medicine', 'placebo']","['spasticity 0', 'Adverse events', 'change from baseline in level of spasticity on a 0 to 10 Numerical Rating Scale (NRS', 'Efficacy and safety', 'spasticity', 'additional measures for spasticity, sleep quality, pain, health-related quality of life, comfort, depression, and safety', 'neuropsychiatric adverse events', 'cerebral palsy/central nervous system injury-related spasticity', 'efficacy, safety, and tolerability']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C1264238', 'cui_str': 'Injury of central nervous system'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}]","[{'cui': 'C2347556', 'cui_str': 'nabiximols'}, {'cui': 'C0006864', 'cui_str': 'cannabinoids'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1299004', 'cui_str': 'Oromucosal route'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C1264238', 'cui_str': 'Injury of central nervous system'}]",72.0,0.447635,There was no significant difference in the spasticity 0 to 10 NRS between nabiximols versus placebo groups after 12 weeks.,"[{'ForeName': 'Charlie', 'Initials': 'C', 'LastName': 'Fairhurst', 'Affiliation': ""Department of Paediatric Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Ram', 'Initials': 'R', 'LastName': 'Kumar', 'Affiliation': ""Department of Paediatric Neurology, Alder Hey Children's Hospital, Liverpool, UK.""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Checketts', 'Affiliation': 'GW Research Ltd, Cambridge, UK.'}, {'ForeName': 'Bola', 'Initials': 'B', 'LastName': 'Tayo', 'Affiliation': 'GW Research Ltd, Cambridge, UK.'}, {'ForeName': 'Susie', 'Initials': 'S', 'LastName': 'Turner', 'Affiliation': ""Department of Paediatric Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.""}]",Developmental medicine and child neurology,['10.1111/dmcn.14548'] 1,32343001,Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper.,"BACKGROUND Late-night supper increases the risk of postprandial reflux from the acid pocket especially in obesity. An alginate-based, raft-forming medication may be useful for obese patients with GERD. AIMS To compare the efficacy of Gaviscon Advance (Reckitt Benckiser, UK) and a non-alginate antacid in post-supper suppression of the acid pocket and post-prandial reflux among obese participants. METHODS Participants underwent 48 h wireless and probe-based pH-metry recording of the acid pocket and lower oesophagus, respectively, and were randomised to single post-supper (10 pm) dose of either Gaviscon Advance or a non-alginate antacid on the second night. Primary outcomes were suppression of median pH of acid pocket and lower oesophagus, measured every 10-minutes post-supper for 1 h. Secondary outcomes were suppression of % time pH < 4 at lower oesophagus and improvement in frequency and visual analogue score (VAS) of regurgitation. RESULTS Of the 81 screened participants, 55 were excluded and 26 (mean age 33.5 years, males 77.8% and BMI 32.8 kg/m 2 ) were randomised to Gaviscon Advance (n = 13) or antacid (n = 13). Median pH of the acid pocket but not the lower oesophagus was suppressed with Gaviscon Advance vs antacid (all P < 0.04) Gaviscon Advance but not antacid significantly reduced in % time pH < 4, symptom frequency and VAS on day 2 vs day 1 (all P < 0.05). CONCLUSIONS Among obese individuals, Gaviscon Advance was superior to a non-alginate antacid in post-supper suppression of the acid pocket. (Clinical trial registration unique identifier: NCT03516188).",2020,"Among obese individuals, Gaviscon Advance is was superior to a non-alginate antacid in post-supper suppression of the acid pocket.","['Participants underwent 48\xa0h wireless and probe-based pH-metry recording of the acid pocket and lower oesophagus, respectively', 'Of the 81 screened participants, 55 were excluded and 26 (mean age 33.5\xa0years, males 77.8% and BMI 32.8\xa0kg/m 2 ', 'obese individuals after late-night supper', 'obese participants', 'obese patients with GERD']","['Gaviscon Advance (Reckitt Benckiser, UK) and a non-alginate antacid', 'antacid', 'Gaviscon Advance', 'Gaviscon Advance vs antacid', 'Gaviscon Advance vs non-alginate antacid', 'Gaviscon Advance or a non-alginate antacid']","['suppression of % time pH', 'Median pH of the acid pocket', 'symptom frequency and VAS', 'frequency and visual analogue score (VAS) of regurgitation', 'suppression of median pH of acid pocket and lower oesophagus']","[{'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0014876', 'cui_str': 'Esophageal structure'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C4048877', 'cui_str': 'Supper'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017168', 'cui_str': 'Gastroesophageal reflux disease'}]","[{'cui': 'C0061146', 'cui_str': 'Gaviscon'}, {'cui': 'C0002040', 'cui_str': 'Alginates'}, {'cui': 'C0003138', 'cui_str': 'Antacid'}]","[{'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0436350', 'cui_str': 'Symptom frequency'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0232605', 'cui_str': 'Regurgitates after swallowing'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0014876', 'cui_str': 'Esophageal structure'}]",81.0,0.0540182,"Among obese individuals, Gaviscon Advance is was superior to a non-alginate antacid in post-supper suppression of the acid pocket.","[{'ForeName': 'Mohd Adli', 'Initials': 'MA', 'LastName': 'Deraman', 'Affiliation': 'School of Medical Sciences, Universiti Sains Malaysia, Kota Bahru, Malaysia.'}, {'ForeName': 'Muhammad Ilham', 'Initials': 'MI', 'LastName': 'Abdul Hafidz', 'Affiliation': 'Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Malaysia.'}, {'ForeName': 'Rona Marie', 'Initials': 'RM', 'LastName': 'Lawenko', 'Affiliation': 'De La Salle Health Sciences Institute, Dasmarinas, Philippines.'}, {'ForeName': 'Zheng Feei', 'Initials': 'ZF', 'LastName': 'Ma', 'Affiliation': 'School of Medical Sciences, Universiti Sains Malaysia, Kota Bahru, Malaysia.'}, {'ForeName': 'Mung Seong', 'Initials': 'MS', 'LastName': 'Wong', 'Affiliation': 'School of Medical Sciences, Universiti Sains Malaysia, Kota Bahru, Malaysia.'}, {'ForeName': 'Cathal', 'Initials': 'C', 'LastName': 'Coyle', 'Affiliation': 'Reckitt Benckiser, Slough, UK.'}, {'ForeName': 'Yeong Yeh', 'Initials': 'YY', 'LastName': 'Lee', 'Affiliation': 'School of Medical Sciences, Universiti Sains Malaysia, Kota Bahru, Malaysia.'}]",Alimentary pharmacology & therapeutics,['10.1111/apt.15746'] 2,32339370,Histology of augmented autogenous bone covered by a platelet-rich fibrin membrane or deproteinized bovine bone mineral and a collagen membrane: A pilot randomized controlled trial.,"OBJECTIVES This study aimed to evaluate histologic and histomorphometric bone characteristics with a focus on vitality after lateral alveolar ridge augmentation using an autogenous bone graft as a block covered by either a platelet-rich fibrin (PRF) membrane (test group) or a standard procedure involving coverage of the bone block with a deproteinized bovine bone mineral and a resorbable collagen membrane (control group). MATERIAL AND METHODS A total of 27 (test = 14, control = 13) partially edentulous patients with indication for bone block augmentation before implant installation were included. For analyses, a biopsy of augmented bone was retrieved six months after bone grafting. RESULTS Histologic evaluation of augmented bone revealed a predominance of non-vital bone toward the periosteum and few localized areas of vital bone in the center of the graft in both groups. In contrast, augmented bone toward the native bone demonstrated extensive bone remodeling in both groups. Histomorphometric analyses demonstrated a mean of 14% vital bone, 80% non-vital bone, 5% soft tissue, and 1% blood vessels in the test group. In the control group, the corresponding shares were 14% vital bone, 63% non-vital bone, 22% soft tissue, and 1% blood vessels. We observed no significant differences between the groups (p > .05). CONCLUSION In conclusion, a comparable low bone vitality of augmented bone was observed in the PRF and in the control group. Consequently, the present study could not verify the potential beneficial effect of a PRF membrane on bone vitality of an autogenous bone graft used as a block.",2020,"RESULTS Histologic evaluation of augmented bone revealed a predominance of non-vital bone towards the periosteum and few localized areas of vital bone in the center of the graft in both groups.","['A total of 27 (test = 14, control = 13) partially edentulous patients with indication for bone block augmentation before implant installation were included']","['PRF membrane', 'platelet-rich fibrin (PRF) membrane (test group) or a standard procedure involving coverage of the bone block with a deproteinized bovine bone mineral and a resorbable collagen membrane (control group', 'platelet-rich fibrin membrane or deproteinized bovine bone mineral and a collagen membrane']","['bone vitality', 'low bone vitality of augmented bone']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0026644', 'cui_str': 'Edentulous'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C1293164', 'cui_str': 'Bone block procedure'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C4505052', 'cui_str': 'Leukocyte- and Platelet-Rich Fibrin'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C1293164', 'cui_str': 'Bone block procedure'}, {'cui': 'C0007452', 'cui_str': 'Cattle'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",80.0,0.0407757,"RESULTS Histologic evaluation of augmented bone revealed a predominance of non-vital bone towards the periosteum and few localized areas of vital bone in the center of the graft in both groups.","[{'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Hartlev', 'Affiliation': 'Department of Dentistry and Oral Health, Section for Oral Surgery and Oral Pathology, Aarhus University, Aarhus C, Denmark.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Erik Nørholt', 'Affiliation': 'Department of Dentistry and Oral Health, Section for Oral Surgery and Oral Pathology, Aarhus University, Aarhus C, Denmark.'}, {'ForeName': 'Rubens', 'Initials': 'R', 'LastName': 'Spin-Neto', 'Affiliation': 'Department of Dentistry and Oral Health, Section for Oral Radiology, Aarhus University, Aarhus C, Denmark.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kraft', 'Affiliation': 'Department of Dentistry and Oral Health, Section of Orthodontics, Aarhus University, Aarhus C, Denmark.'}, {'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Schou', 'Affiliation': 'Faculty of Health Sciences, Department of Periodontology, School of Dentistry, University of Copenhagen, Copenhagen N, Denmark.'}, {'ForeName': 'Flemming', 'Initials': 'F', 'LastName': 'Isidor', 'Affiliation': 'Department of Dentistry and Oral Health, Section for Prosthetic Dentistry, Aarhus University, Aarhus C, Denmark.'}]",Clinical oral implants research,['10.1111/clr.13605'] 3,32339648,Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.,"BACKGROUND The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma (aRCC). We report updated efficacy data from the second interim analysis. PATIENTS AND METHODS Treatment-naive patients with aRCC were randomized (1 : 1) to receive avelumab (10 mg/kg) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The two independent primary end points were PFS and overall survival (OS) among patients with programmed death ligand 1-positive (PD-L1+) tumors. Key secondary end points were OS and PFS in the overall population. RESULTS Of 886 patients, 442 were randomized to the avelumab plus axitinib arm and 444 to the sunitinib arm; 270 and 290 had PD-L1+ tumors, respectively. After a minimum follow-up of 13 months (data cut-off 28 January 2019), PFS was significantly longer in the avelumab plus axitinib arm than in the sunitinib arm {PD-L1+ population: hazard ratio (HR) 0.62 [95% confidence interval (CI) 0.490-0.777]}; one-sided P < 0.0001; median 13.8 (95% CI 10.1-20.7) versus 7.0 months (95% CI 5.7-9.6); overall population: HR 0.69 (95% CI 0.574-0.825); one-sided P < 0.0001; median 13.3 (95% CI 11.1-15.3) versus 8.0 months (95% CI 6.7-9.8)]. OS data were immature [PD-L1+ population: HR 0.828 (95% CI 0.596-1.151); one-sided P = 0.1301; overall population: HR 0.796 (95% CI 0.616-1.027); one-sided P = 0.0392]. CONCLUSION Among patients with previously untreated aRCC, treatment with avelumab plus axitinib continued to result in a statistically significant improvement in PFS versus sunitinib; OS data were still immature. CLINICAL TRIAL NUMBER NCT02684006.",2020,OS data were immature (PD-L1+ population: HR 0.828,"['886 patients', 'advanced renal cell carcinoma (aRCC', 'patients with advanced renal cell carcinoma', 'Treatment-naïve patients with aRCC']","['axitinib (5 mg) orally twice daily or sunitinib', 'avelumab plus axitinib versus sunitinib', 'avelumab', 'avelumab plus axitinib']","['progression-free survival (PFS', 'PFS', 'OS and PFS in the overall population', 'PFS and overall survival (OS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007134', 'cui_str': 'Renal cell carcinoma'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C1700874', 'cui_str': 'axitinib'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C1176020', 'cui_str': 'sunitinib'}, {'cui': 'C4055417', 'cui_str': 'avelumab'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0032659', 'cui_str': 'Population'}]",,0.268726,OS data were immature (PD-L1+ population: HR 0.828,"[{'ForeName': 'T K', 'Initials': 'TK', 'LastName': 'Choueiri', 'Affiliation': ""Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, USA. Electronic address: toni_choueiri@dcfi.harvard.edu.""}, {'ForeName': 'R J', 'Initials': 'RJ', 'LastName': 'Motzer', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, USA.'}, {'ForeName': 'B I', 'Initials': 'BI', 'LastName': 'Rini', 'Affiliation': 'Cleveland Clinic, Cleveland, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Haanen', 'Affiliation': 'Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'M T', 'Initials': 'MT', 'LastName': 'Campbell', 'Affiliation': 'The University of Texas MD Anderson Cancer Center, Houston, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Venugopal', 'Affiliation': 'University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Kollmannsberger', 'Affiliation': 'British Columbia Cancer Agency, Vancouver Centre, Vancouver, Canada.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Gravis-Mescam', 'Affiliation': 'Institut Paoli-Calmettes, Department of Medical Oncology, Aix-Marseille Université, Inserm, CNRS, CRCM, Marseille, France.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Uemura', 'Affiliation': 'Osaka University Hospital, Osaka, Japan.'}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Lee', 'Affiliation': 'University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.'}, {'ForeName': 'M-O', 'Initials': 'MO', 'LastName': 'Grimm', 'Affiliation': 'Jena University Hospital, Department of Urology, Jena, Germany.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Gurney', 'Affiliation': 'Macquarie University, Sydney, Australia.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Schmidinger', 'Affiliation': 'Clinical Division of Oncology, Department of Medicine I Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Larkin', 'Affiliation': 'Royal Marsden NHS Foundation Trust, London, UK.'}, {'ForeName': 'M B', 'Initials': 'MB', 'LastName': 'Atkins', 'Affiliation': 'Georgetown University Medical Center, Washington, DC.'}, {'ForeName': 'S K', 'Initials': 'SK', 'LastName': 'Pal', 'Affiliation': 'City of Hope National Medical Center, Duarte, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Pfizer, Cambridge, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Mariani', 'Affiliation': 'Pfizer Italia SRL, Milan, Italy.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Krishnaswami', 'Affiliation': 'Pfizer, Groton, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Cislo', 'Affiliation': 'Pfizer, New York, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Chudnovsky', 'Affiliation': 'Pfizer, Cambridge, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Fowst', 'Affiliation': 'Pfizer Italia SRL, Milan, Italy.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Huang', 'Affiliation': 'Pfizer, Groton, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'di Pietro', 'Affiliation': 'Pfizer Italia SRL, Milan, Italy.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Albiges', 'Affiliation': 'Institut Gustave Roussy, Villejuif, France.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2020.04.010'] 4,32276603,Agreement between the Schedule for the Evaluation of Individual Quality of Life-Direct Weighting (SEIQoL-DW) interview and a paper-administered adaption.,"BACKGROUND The Schedule for the Evaluation of Individual Quality of Life-Direct Weighting (SEIQoL-DW) is a prevalent face-to-face interview method for measuring quality of life by integrating respondent-generated dimensions. To apply this method in clinical trials, a paper-administered alternative would be of interest. Therefore, our study aimed to analyze the agreement between the SEIQoL-DW and a paper questionnaire version (SEIQoL-PF/G). METHODS In a crossover design, both measures were completed in a random sequence. 104 patients at a heart surgery hospital in Germany were randomly assigned to receive either the SEIQoL-DW or the SEIQoL-PF/G as the first measurement in the sequence. Patients were approached on their earliest stable day after surgery. The average time between both measurements was 1 day (mean 1.3; SD 0.8). Agreement regarding the indices, ratings, and weightings of nominated life areas (cues) was explored using Bland-Altman plots with 95% limits of agreement (LoA). Agreement of the SEIQoL indices was defined as acceptable if the LoA did not exceed a threshold of 10 scale points. Data from n = 99 patients were included in the agreement analysis. RESULTS Both measures led to similarly nominated cues. The most frequently nominated cues were ""physical health"" and ""family"". In the Bland-Altman plot, the indices showed a mean of differences of 2 points (95% CI, - 1 to 6). The upper LoA showed a difference of 36 points (95% CI, 30 to 42), and the lower LoA showed a difference of - 31 points (95% CI, - 37 to - 26). Thus, the LoAs and confidence intervals exceeded the predefined threshold. The Bland-Altman plots for the cue levels and cue weights showed similar results. The SEIQoL-PF/G version showed a tendency for equal weighting of cues, while the weighting procedure of the SEIQoL-DW led to greater variability. CONCLUSIONS For cardiac surgery patients, use of the current version of the SEIQoL-PF/G as a substitute for the SEIQoL-DW is not recommended. The current questionnaire weighting method seems to be unable to distinguish weighting for different cues. Therefore, the further design of a weighting method without interviewer support as a paper-administered measure of individual quality of life is desirable.",2020,"The upper LoA showed a difference of 36 points (95% CI, 30 to 42), and the lower LoA showed a difference of - 31 points (95% CI, - 37 to - 26).","['Data from n\u2009=\u200999 patients were included in the agreement analysis', 'For cardiac surgery patients', '104 patients at a heart surgery hospital in Germany']",['SEIQoL-DW or the SEIQoL-PF/G'],['average time'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0017480', 'cui_str': 'Germany'}]","[{'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439851', 'cui_str': 'Direct'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}]",99.0,0.0367077,"The upper LoA showed a difference of 36 points (95% CI, 30 to 42), and the lower LoA showed a difference of - 31 points (95% CI, - 37 to - 26).","[{'ForeName': 'Marion', 'Initials': 'M', 'LastName': 'Burckhardt', 'Affiliation': 'Institute of Health and Nursing Science, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Fleischer', 'Affiliation': 'Institute of Health and Nursing Science, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.'}, {'ForeName': 'Almuth', 'Initials': 'A', 'LastName': 'Berg', 'Affiliation': 'Institute of Health and Nursing Science, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany. almuth.berg@medizin.uni-halle.de.'}]",BMC medical research methodology,['10.1186/s12874-020-00961-9'] 5,32340585,"Comparative study of observed actions, motor imagery and control therapeutic exercise on the conditioned pain modulation in the cervical spine: a randomized controlled trial.","Aim: The aim of this study was to compare the effects of cervical exercise, motor imagery (MI) and action observation (AO) of cervical exercise actions on conditioned pain modulation and pressure pain thresholds. The second objective was to assess the effects of these interventions on cervical motor activity (ranges of motion and muscle endurance), attention, and the ability to generate motor images. Study design: Single-blinded randomized controlled trial. Materials and methods: Fifty-four healthy subjects were randomly assigned to each group. Response conditioned pain modulation, pressure pain threshold, were the main variables. The secondary outcome measures included, cervical range of motion, Neck flexor endurance test, mental movement representation associated and psychosocial variables. Results: All groups showed significant differences in time factor for all evaluated variables ( p  < .01) except pressure pain threshold over the tibial region. The post hoc analysis revealed significant within-group differences in the AE and AO groups in conditioned pain modulation ( p  < .05), with medium effect size in time [AE ( d -0.61); AO ( d -0.74)]. Conclusion: The results showed that within-group changes in conditioned pain modulation, cervical muscle endurance, and attention where founded only in the AE and AO groups. Variations in pain thresholds at pressure in the trapezium area were also obtained in the three groups. Changes in the ranges of flexion-extension and rotation movement were presented exclusively in the exercise group, and in the capacity to generate motor images only in the AO group. However, there was no difference in the pressure pain threshold over the tibial region.",2020,All groups showed significant differences in time factor for all evaluated variables ( p  < .01) except pressure pain threshold over the tibial region.,"['cervical spine', 'Materials and methods: Fifty-four healthy subjects']","['cervical exercise, motor imagery (MI) and action observation (AO) of cervical exercise actions', 'observed actions, motor imagery and control therapeutic exercise']","['time factor', 'conditioned pain modulation, cervical muscle endurance, and attention', 'pressure pain', 'Response conditioned pain modulation, pressure pain threshold', 'conditioned pain modulation and pressure pain thresholds', 'cervical range of motion, Neck flexor endurance test, mental movement representation associated and psychosocial variables', 'medium effect size in time [AE', 'cervical motor activity (ranges of motion and muscle endurance), attention, and the ability to generate motor images', 'conditioned pain modulation', 'flexion-extension and rotation movement']","[{'cui': 'C0728985', 'cui_str': 'Structure of cervical vertebral column'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}]","[{'cui': 'C0040225', 'cui_str': 'Time Factors'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0033963', 'cui_str': 'Psychosocial Factors'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0444509', 'cui_str': 'Flexion/extension'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}]",54.0,0.0766365,All groups showed significant differences in time factor for all evaluated variables ( p  < .01) except pressure pain threshold over the tibial region.,"[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Morales Tejera', 'Affiliation': 'Escuela Internacional de Doctorado, Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, Alcorcón, Spain.'}, {'ForeName': 'Josue', 'Initials': 'J', 'LastName': 'Fernandez-Carnero', 'Affiliation': 'La Paz Hospital Institute for Health Research, IdiPAZ, Madrid, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Suso-Martí', 'Affiliation': 'Motion in Brains Research Group, Institute of Neuroscience and Sciences of the Movement (INCIMOV), Centro Superior de Estudios Universitarios La Salle, Universidad Autónoma de Madrid, Madrid, España.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Cano-de-la-Cuerda', 'Affiliation': 'Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Rey Juan Carlos University, Madrid, Spain.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Lerín-Calvo', 'Affiliation': 'Departamento de Fisioterapia, Centro Superior de Estudios Universitarios La Salle, Universidad Autónoma de Madrid, Madrid, España.'}, {'ForeName': 'Lorena', 'Initials': 'L', 'LastName': 'Remón-Ramiro', 'Affiliation': 'Departamento de Fisioterapia, Centro Superior de Estudios Universitarios La Salle, Universidad Autónoma de Madrid, Madrid, España.'}, {'ForeName': 'Roy', 'Initials': 'R', 'LastName': 'La Touche', 'Affiliation': 'La Paz Hospital Institute for Health Research, IdiPAZ, Madrid, Spain.'}]",Somatosensory & motor research,['10.1080/08990220.2020.1756244'] 6,32340597,Impact of Behavioral Health Homes on Cost and Utilization Outcomes.,"OBJECTIVE This study evaluated the impact of two behavioral health home (BHH) approaches, provider-supported care and self-directed care, on health care utilization and cost outcomes among adult Medicaid recipients with serious mental illness. METHODS Eleven community mental health provider sites were randomly assigned to one of the BHH approaches, which each site implemented over a 2-year period. In both approaches, staff were trained in wellness coaching to support patients' progress toward general health and wellness goals. Provider-supported sites employed a full-time on-site registered nurse, who provided consultation to patients and wellness coaches. Each approach had a consistently enrolled treatment group (combined N=859) with a matched comparison cohort that was identified for analysis. Approaches were compared with each other and with baseline, and differences between each approach and its comparison cohort were examined by using analysis of covariance to determine impact on total health care cost, prescription costs, and use and cost of general medical and behavioral health services. RESULTS Relative to its comparison cohort, each approach achieved significant reductions in total cost (15% for provider-supported care and 26% for self-directed care) and increases in use of outpatient general medical services (43% for provider-supported care and 29% for self-directed care). Compared with self-directed care, provider-supported care resulted in approximately 28% lower use of general medical inpatient services and 26% lower related costs. CONCLUSIONS BHH approaches in community mental health settings can produce health care savings and decrease use of inpatient health care.",2020,"Compared with self-directed care, provider-supported care resulted in approximately 28% lower use of general medical inpatient services and 26% lower related costs. ","['Eleven community mental health provider sites', 'adult Medicaid recipients with serious mental illness']","['behavioral health home (BHH) approaches, provider-supported care and self-directed care']","['total cost', 'Cost and Utilization Outcomes', 'total health care cost, prescription costs, and use and cost of general medical and behavioral health services']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0025071', 'cui_str': 'Medicaid coverage'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}]","[{'cui': 'C0870196', 'cui_str': 'Behavioral health'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439851', 'cui_str': 'Direct'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0085552', 'cui_str': 'Health Costs'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0870196', 'cui_str': 'Behavioral health'}, {'cui': 'C0557854', 'cui_str': 'Services'}]",11.0,0.0292273,"Compared with self-directed care, provider-supported care resulted in approximately 28% lower use of general medical inpatient services and 26% lower related costs. ","[{'ForeName': 'James', 'Initials': 'J', 'LastName': 'Highland', 'Affiliation': 'BerryDunn, Portland, Maine (Highland), Phoenix (Ji), and Honolulu (Kukla); UPMC Center for High-Value Health Care (Nikolajski, Kogan) and Community Care Behavioral Health Organization (Schuster), UPMC Insurance Services Division, Pittsburgh.'}, {'ForeName': 'Cara', 'Initials': 'C', 'LastName': 'Nikolajski', 'Affiliation': 'BerryDunn, Portland, Maine (Highland), Phoenix (Ji), and Honolulu (Kukla); UPMC Center for High-Value Health Care (Nikolajski, Kogan) and Community Care Behavioral Health Organization (Schuster), UPMC Insurance Services Division, Pittsburgh.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Kogan', 'Affiliation': 'BerryDunn, Portland, Maine (Highland), Phoenix (Ji), and Honolulu (Kukla); UPMC Center for High-Value Health Care (Nikolajski, Kogan) and Community Care Behavioral Health Organization (Schuster), UPMC Insurance Services Division, Pittsburgh.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Ji', 'Affiliation': 'BerryDunn, Portland, Maine (Highland), Phoenix (Ji), and Honolulu (Kukla); UPMC Center for High-Value Health Care (Nikolajski, Kogan) and Community Care Behavioral Health Organization (Schuster), UPMC Insurance Services Division, Pittsburgh.'}, {'ForeName': 'Matt', 'Initials': 'M', 'LastName': 'Kukla', 'Affiliation': 'BerryDunn, Portland, Maine (Highland), Phoenix (Ji), and Honolulu (Kukla); UPMC Center for High-Value Health Care (Nikolajski, Kogan) and Community Care Behavioral Health Organization (Schuster), UPMC Insurance Services Division, Pittsburgh.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Schuster', 'Affiliation': 'BerryDunn, Portland, Maine (Highland), Phoenix (Ji), and Honolulu (Kukla); UPMC Center for High-Value Health Care (Nikolajski, Kogan) and Community Care Behavioral Health Organization (Schuster), UPMC Insurance Services Division, Pittsburgh.'}]","Psychiatric services (Washington, D.C.)",['10.1176/appi.ps.201900141'] 7,32340846,3-Dimensional printing templates guiding versus free hand technique for cervical lateral mass screw fixation: A prospective study.,"OBJECTIVE In this randomized, single blind and controlled study, the feasibility and precision of 3-dimensional printing templates for cervical lateral mass screw insertion was evaluated. METHODS A total of 6 patients (72 screws), who were diagnosed with cervical spondylotic myelopathy (CSM) and developmental cervical spinal stenosis, were randomly divided into A and B two groups. All subjects underwent modified posterior surgery with using cervical lateral mass screws insertion (C4-C6). Group A underwent surgeries with screw insertion assisted by the guidance of 3-dimensional printing templates and Group B underwent surgeries with screw insertion by freehand. The criteria of the accuracy of screw placement were set as the main evaluation indicators. RESULTS There was no significant difference between the 2 groups in age, improvement rate of JOA, operation time and blood loss. According to Bayard's criteria, 32 screws (88.9%) were described as ""acceptable"" in group A and 22 screws (61.1%) were described as ""acceptable"" in Group B (P < 0.05). Based on our criteria, the ""excellent and good"" rate of screws was 83.3% in group A and 47.2% in Group B, respectively (P < 0.05). The precision of screws' location in Group A was superior to that in Group B. CONCLUSIONS 3-Dimensional printing screw insertion templates may achieve (1) comprehensive visualization of the cervical vertebrae and lateral mass and the individual surgical planning using the 3-dimensional model preoperatively. (2) increasing the accuracy of cervical lateral mass screw insertion.",2020,"There was no significant difference between the 2 groups in age, improvement rate of JOA, operation time and blood loss.","['6 patients (72 screws), who were diagnosed with cervical spondylotic myelopathy (CSM) and developmental cervical spinal stenosis']","['surgeries with screw insertion assisted by the guidance of 3-dimensional printing templates and Group B underwent surgeries with screw insertion by freehand', '3-Dimensional printing templates guiding versus free hand technique', 'modified posterior surgery with using cervical lateral mass screws insertion (C4-C6', '3-dimensional printing templates']","[""precision of screws' location"", 'accuracy of cervical lateral mass screw insertion', 'excellent and good"" rate of screws', 'rate of JOA, operation time and blood loss']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005975', 'cui_str': 'Bone screw'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0005956', 'cui_str': 'Bone marrow disorder'}, {'cui': 'C0458003', 'cui_str': 'Developmental'}, {'cui': 'C0158280', 'cui_str': 'Spinal stenosis in cervical region'}]","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0005975', 'cui_str': 'Bone screw'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C3849992', 'cui_str': 'Three-Dimensional Printing'}, {'cui': 'C4317132', 'cui_str': 'Template'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0456980', 'cui_str': 'Hand endodontic technique'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}]","[{'cui': 'C0005975', 'cui_str': 'Bone screw'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]",6.0,0.0246081,"There was no significant difference between the 2 groups in age, improvement rate of JOA, operation time and blood loss.","[{'ForeName': 'Shitong', 'Initials': 'S', 'LastName': 'Feng', 'Affiliation': 'Department of Orthopaedics, Beijing Friendship Hospital, Capital Medical University, 100050, China.'}, {'ForeName': 'Jisheng', 'Initials': 'J', 'LastName': 'Lin', 'Affiliation': 'Department of Orthopaedics, Beijing Friendship Hospital, Capital Medical University, 100050, China.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Su', 'Affiliation': 'Department of Orthopaedics, Beijing Friendship Hospital, Capital Medical University, 100050, China.'}, {'ForeName': 'Hai', 'Initials': 'H', 'LastName': 'Meng', 'Affiliation': 'Department of Orthopaedics, Beijing Friendship Hospital, Capital Medical University, 100050, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Orthopaedics, Beijing Friendship Hospital, Capital Medical University, 100050, China. Electronic address: spineyang@126.com.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Fei', 'Affiliation': 'Department of Orthopaedics, Beijing Friendship Hospital, Capital Medical University, 100050, China. Electronic address: spinefei@126.com.'}]",Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,['10.1016/j.jocn.2020.04.008'] 8,32340910,The impact of heart rate-based drowsiness monitoring on adverse driving events in heavy vehicle drivers under naturalistic conditions.,"OBJECTIVES This study examined the influence of a wrist-worn heart rate drowsiness detection device on heavy vehicle driver safety and sleep and its ability to predict driving events under naturalistic conditions. DESIGN Prospective, non-randomized trial. SETTING Naturalistic driving in Malaysia. PARTICIPANTS Heavy vehicle drivers in Malaysia were assigned to the Device (n = 25) or Control condition (n = 34). INTERVENTION Both conditions were monitored for driving events at work over 4-weeks in Phase 1, and 12-weeks in Phase 2. In Phase 1, the Device condition wore the device operated in the silent mode (i.e., no drowsiness alerts) to examine the accuracy of the device in predicting driving events. In Phase 2, the Device condition wore the device in the active mode to examine if drowsiness alerts from the device influenced the rate of driving events (compared to Phase 1). MEASUREMENTS All participants were monitored for harsh braking and harsh acceleration driving events and self-reported sleep duration and sleepiness daily. RESULTS There was a significant decrease in the rate of harsh braking events (Rate ratio = 0.48, p < 0.05) and a fall in subjective sleepiness (p < 0.05) when the device was operated in the active mode (compared to the silent mode). The device predicted when no driving events were occurring (specificity=98.81%), but had low accuracy in detecting when a driving event did occur (sensitivity=6.25%). CONCLUSIONS Including drowsiness detection devices in fatigue management programs appears to alter driver behaviour, improving safety despite the modest accuracy. Longer term studies are required to determine if this change is sustained.",2020,"There was a significant decrease in the rate of harsh braking events (Rate ratio = 0.48, p < 0.05) and a fall in subjective sleepiness (p < 0.05) when the device was operated in the active mode (compared to the silent mode).","['heavy vehicle drivers under naturalistic conditions', 'Heavy vehicle drivers in Malaysia', 'Naturalistic driving in Malaysia']","['Control condition', 'heart rate-based drowsiness monitoring', 'wrist-worn heart rate drowsiness detection device']","['rate of driving events', 'subjective sleepiness', 'harsh braking and harsh acceleration driving events and self-reported sleep duration and sleepiness daily', 'rate of harsh braking events']","[{'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0684312', 'cui_str': 'Vehicle driver'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0024552', 'cui_str': 'Malaysia'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0000894', 'cui_str': 'Acceleration'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0424574', 'cui_str': 'Duration of sleep'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0337108', 'cui_str': 'Brake'}]",,0.0251325,"There was a significant decrease in the rate of harsh braking events (Rate ratio = 0.48, p < 0.05) and a fall in subjective sleepiness (p < 0.05) when the device was operated in the active mode (compared to the silent mode).","[{'ForeName': 'Alexander P', 'Initials': 'AP', 'LastName': 'Wolkow', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, 18 Innovation Walk, Clayton, VIC, Australia.'}, {'ForeName': 'Shantha M W', 'Initials': 'SMW', 'LastName': 'Rajaratnam', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, 18 Innovation Walk, Clayton, VIC, Australia.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Wilkinson', 'Affiliation': 'Institute for Breathing and Sleep, Department of Respiratory and Sleep Medicine, Austin Health, 145 Studley Road, PO Box 5555, Heidelberg, VIC, Australia.'}, {'ForeName': 'Dexter', 'Initials': 'D', 'LastName': 'Shee', 'Affiliation': 'Neurobusiness Behavioural Laboratory, Monash University Malaysia, Building 6B, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Baker', 'Affiliation': 'Shell International, Carel van Bylandtlaan 16, The Hague, the Netherlands.'}, {'ForeName': 'Teri', 'Initials': 'T', 'LastName': 'Lillington', 'Affiliation': 'Shell International, Carel van Bylandtlaan 16, The Hague, the Netherlands.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Roest', 'Affiliation': 'Shell International, Carel van Bylandtlaan 16, The Hague, the Netherlands.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Marx', 'Affiliation': 'Shell International, Carel van Bylandtlaan 16, The Hague, the Netherlands.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Chew', 'Affiliation': 'Neurobusiness Behavioural Laboratory, Monash University Malaysia, Building 6B, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Tucker', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, 18 Innovation Walk, Clayton, VIC, Australia.'}, {'ForeName': 'Shamsul', 'Initials': 'S', 'LastName': 'Haque', 'Affiliation': 'Jeffrey Cheah School of Medicine and Health Sciences, Department of Psychology, Monash University Malaysia, Jalan Lagoon Selatan, 47500 Bandar Sunway, Selangor Darul Ehsan, Malaysia.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Schaefer', 'Affiliation': 'Neurobusiness Behavioural Laboratory, Monash University Malaysia, Building 6B, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Howard', 'Affiliation': 'Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, 18 Innovation Walk, Clayton, VIC, Australia; Institute for Breathing and Sleep, Department of Respiratory and Sleep Medicine, Austin Health, 145 Studley Road, PO Box 5555, Heidelberg, VIC, Australia. Electronic address: mark.howard@austin.org.au.'}]",Sleep health,['10.1016/j.sleh.2020.03.005'] 9,32340781,OPtical frequency domain imaging vs. INtravascular ultrasound in percutaneous coronary InterventiON in patients with Acute Coronary Syndrome: Study protocol for a randomized controlled trial.,"BACKGROUND A recent clinical trial demonstrated that optical frequency domain imaging (OFDI) guidance in percutaneous coronary intervention (PCI) is noninferior to intravascular ultrasound (IVUS) guidance in patients with coronary artery disease with regard to target vessel failure (composed of cardiac death, myocardial infarction attributed to the target vessel, and clinically-driven target vessel revascularization) at 12 months. The impact of OFDI guidance in PCI for patients with acute coronary syndrome (ACS) remains uncertain. METHODS OPINION ACS is a multicenter, prospective, randomized, controlled, open-label, parallel group, non-inferiority trial in Japan. Eligible patients will be randomly assigned to receive either OFDI- or IVUS-guided PCI. PCI is performed using the sirolimus-eluting stent in accordance with certain OFDI and IVUS criteria for optimal stent deployment. All patients will undergo follow-up angiography and OFDI imaging at 8 months. The primary endpoint is the minimum lumen area, as measured by OFDI at 8 months. CONCLUSION The OPINION ACS trial outcomes will provide insights regarding the impact of OFDI-guided PCI on in-stent restenosis at 8 months in patients with ACS.",2020,The OPINION ACS trial outcomes will provide insights regarding the impact of OFDI-guided PCI on in-stent restenosis at 8 months in patients with ACS.,"['Japan', 'patients with acute coronary syndrome (ACS', 'patients with coronary artery disease with regard to target vessel failure', 'patients with ACS', 'patients with Acute Coronary Syndrome', 'Eligible patients']","['intravascular ultrasound (IVUS) guidance', 'percutaneous coronary intervention (PCI', 'OFDI guidance', 'OFDI- or IVUS-guided PCI', 'OPtical frequency domain imaging vs. INtravascular ultrasound', 'optical frequency domain imaging (OFDI) guidance', 'percutaneous coronary InterventiON']","['minimum lumen area, as measured by OFDI at 8 months']","[{'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0449618', 'cui_str': 'Target vessel'}, {'cui': 'C0231174', 'cui_str': 'Failure'}]","[{'cui': 'C0442123', 'cui_str': 'Intravascular'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0442972', 'cui_str': 'Imaging guidance'}, {'cui': 'C4682863', 'cui_str': 'Volumetric laser endomicroscopy'}, {'cui': 'C0181090', 'cui_str': 'Guide'}]","[{'cui': 'C0524461', 'cui_str': 'Structure of lumen of body system'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C4682863', 'cui_str': 'Volumetric laser endomicroscopy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",,0.103243,The OPINION ACS trial outcomes will provide insights regarding the impact of OFDI-guided PCI on in-stent restenosis at 8 months in patients with ACS.,"[{'ForeName': 'Hiromasa', 'Initials': 'H', 'LastName': 'Otake', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. Electronic address: hotake@med.kobe-u.ac.jp.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Kubo', 'Affiliation': 'Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.'}, {'ForeName': 'Toshiro', 'Initials': 'T', 'LastName': 'Shinke', 'Affiliation': 'Division of Cardiology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Kiyoshi', 'Initials': 'K', 'LastName': 'Hibi', 'Affiliation': 'Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan.'}, {'ForeName': 'Shigemitsu', 'Initials': 'S', 'LastName': 'Tanaka', 'Affiliation': 'Division of Cardiology, Tokai University School of Medicine, Isehara, Japan.'}, {'ForeName': 'Masaru', 'Initials': 'M', 'LastName': 'Ishida', 'Affiliation': 'Division of Cardiology, Iwate Medical University, Yahaba-cho, Japan.'}, {'ForeName': 'Toru', 'Initials': 'T', 'LastName': 'Kataoka', 'Affiliation': 'Division of Cardiology, Bell Land General Hospital, Sakai, Japan.'}, {'ForeName': 'Tomofumi', 'Initials': 'T', 'LastName': 'Takaya', 'Affiliation': 'Division of Cardiovascular Medicine, Hyogo Prefectural Himeji Cardiovascular Center, Himeji, Hyogo, Japan.'}, {'ForeName': 'Masamichi', 'Initials': 'M', 'LastName': 'Iwasaki', 'Affiliation': 'Department of Cardiology, Hyogo Prefectural Awaji Medical Center, Sumoto, Hyogo, Japan.'}, {'ForeName': 'Shinjo', 'Initials': 'S', 'LastName': 'Sonoda', 'Affiliation': 'The Second Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.'}, {'ForeName': 'Tetsuya', 'Initials': 'T', 'LastName': 'Ioji', 'Affiliation': 'Division of Medical Statistics, Translational Research Center for Medical Innovation, Kobe, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Akasaka', 'Affiliation': 'Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.'}]",Journal of cardiology,['10.1016/j.jjcc.2020.03.010'] 10,32342247,Investigation of fluctuations in blood glucose level due to dietary restrictions during impacted mandibular third molar extraction under intravenous sedation: effect of perioperative glucose administration.,"OBJECTIVE We aimed to investigate the usefulness of glucose administration for maintaining perioperative glycemic control in patients with dietary restrictions during 4 h prior to impacted mandibular third molar extraction under intravenous sedation. METHODS Fifty-four individuals scheduled to undergo extraction of impacted mandibular third molars under intravenous sedation, with preoperative blood glucose levels (GL) of 70-110 mg/dL, were evaluated and divided into 3 groups (n = 18 each): control group receiving glucose-free sodium lactate Ringer's solution, perioperative GL group receiving 100 mL of 5% glucose solution immediately after local anesthesia, and postoperative GL group receiving 100 mL of 5% glucose solution immediately after surgery completion. Blood glucose levels, systolic blood pressure, diastolic blood pressure, and heart rate were measured. RESULTS Glucose levels of those in the control and perioperative GL groups decreased within the standard range 90 min after surgery, compared with the preoperative blood glucose level. However, in the postoperative GL group, glucose levels were similar to the preoperative levels. Systolic and diastolic blood pressure and heart rate were not affected by glucose administration, and sedation could be maintained without an invasive procedure. CONCLUSIONS Following a restriction on eating and drinking 4 h prior to surgery, the blood glucose level gradually decreased in the perioperative period but remained within the reference range until 90 min following surgery. The administration of 100 mL 5% glucose solution immediately after surgery was sufficient for the prevention of postoperative hypoglycemia. This approach may be useful for perioperative glycemic control during third molar extraction.",2020,"RESULTS Glucose levels of those in the control and perioperative GL groups decreased within the standard range 90 min after surgery, compared with the preoperative blood glucose level.","['Fifty-four individuals scheduled to undergo extraction of impacted mandibular third molars under intravenous sedation, with preoperative blood glucose levels (GL) of 70-110\xa0mg/dL, were evaluated and divided into 3 groups (n\u2009=\u200918 each', 'patients with dietary restrictions during 4\xa0h prior to impacted mandibular third molar extraction under intravenous sedation']","['glucose administration', ""control group receiving glucose-free sodium lactate Ringer's solution, perioperative GL group receiving 100\xa0mL of 5% glucose solution immediately after local anesthesia, and postoperative GL group receiving 100\xa0mL of 5% glucose solution""]","['blood glucose level', 'glucose levels', 'Systolic and diastolic blood pressure and heart rate', 'Blood glucose levels, systolic blood pressure, diastolic blood pressure, and heart rate', 'preoperative blood glucose level', 'Glucose levels']","[{'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026369', 'cui_str': 'Structure of wisdom tooth'}, {'cui': 'C0412775', 'cui_str': 'Intravenous sedation'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0332152', 'cui_str': 'Before'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0142874', 'cui_str': 'Sodium lactate'}, {'cui': 'C0073386', 'cui_str': 'Ringers Solution'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]","[{'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}]",54.0,0.0361795,"RESULTS Glucose levels of those in the control and perioperative GL groups decreased within the standard range 90 min after surgery, compared with the preoperative blood glucose level.","[{'ForeName': 'Mio', 'Initials': 'M', 'LastName': 'Sekine', 'Affiliation': 'Anesthesiology and Resuscitation, The Nippon Dental University Graduate School of Life Dentistry at Niigata, Niigata, Japan. mi0@ngt.ndu.ac.jp.'}, {'ForeName': 'Yuya', 'Initials': 'Y', 'LastName': 'Tomita', 'Affiliation': 'Department of Dental Anesthesiology, The Nippon Dental University School of Life Dentistry at Niigata, 1-8 Hamauracho Chuoku, Niigata, 951-8580, Japan.'}, {'ForeName': 'Asami', 'Initials': 'A', 'LastName': 'Iguchi', 'Affiliation': 'Department of Dental Anesthesiology, The Nippon Dental University School of Life Dentistry at Niigata, 1-8 Hamauracho Chuoku, Niigata, 951-8580, Japan.'}, {'ForeName': 'Kazuyuki', 'Initials': 'K', 'LastName': 'Fujii', 'Affiliation': 'Anesthesiology and Resuscitation, The Nippon Dental University Graduate School of Life Dentistry at Niigata, Niigata, Japan.'}]",Oral and maxillofacial surgery,['10.1007/s10006-020-00843-w'] 11,32352222,Cluster-randomized crossover trial of chlorhexidine-alcohol versus iodine-alcohol for prevention of surgical-site infection (SKINFECT trial).,,2020,,[],['chlorhexidine-alcohol versus iodine-alcohol'],[],[],"[{'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0021966', 'cui_str': 'Iodide salt'}]",[],,0.0806753,,"[{'ForeName': 'L S', 'Initials': 'LS', 'LastName': 'Aho Glélé', 'Affiliation': 'Epidemiology and Infection Control Department, 21000, Dijon, France.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Ortega-Deballon', 'Affiliation': 'Digestive Surgery Department, Dijon University Hospital, 14\xa0Rue Paul Gaffarel, 21000, Dijon, France.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Guilloteau', 'Affiliation': 'Epidemiology and Infection Control Department, 21000, Dijon, France.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Keita-Perse', 'Affiliation': 'Epidemiology and Infection Control Department, Monaco Hospital, Monaco.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Astruc', 'Affiliation': 'Epidemiology and Infection Control Department, 21000, Dijon, France.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Lepelletier', 'Affiliation': 'Epidemiology and Infection Control Department, Nantes University Hospital, Nantes, France.'}]",BJS open,['10.1002/bjs5.50285'] 12,32347143,"HIV Self-Testing Can Be Liberating to HIV-Positive Women and Their Sexual Partners: A Qualitative Study in Kisumu, Western Kenya.","BACKGROUND Nearly half of Kenyan men with HIV-positive partners do not know their partner's status. We carried out a qualitative substudy to explore the experiences of a sample of HIV-positive women when distributing HIV self-tests (HIVST) to their sexual partners. METHODS HIV-positive women were invited for in-depth interviews to share their experiences in offering HIVST to their partners and how self-testing impacted their relationships. RESULTS Two hundred ninety-seven women were randomized to HIVST, 12 of whom self-reported being HIV positive and 11 participated in the interview. Self-testing procedures and interpretation of results were well understood. Participants were strategic in approaching their partners, thus avoided partner violence. Couple testing was high, which strengthened relationships, improved condom use, and empowered women to make joint decisions concerning their health. CONCLUSIONS Giving HIV-positive women HIVST kits to distribute to their male partners is feasible and safe. Providers who have challenges reaching male partners with testing should consider HIVST.",2020,"Couple testing was high, which strengthened relationships, improved condom use, and empowered women to make joint decisions concerning their health. ","['Kisumu, Western Kenya', 'Kenyan men with HIV-positive partners', 'HIV-Positive Women and Their Sexual Partners', 'HIV-positive women when distributing HIV self-tests (HIVST) to their sexual partners', 'HIV-positive women were invited for in-depth interviews to share their experiences in offering HIVST to their partners and how self-testing impacted their relationships', 'Two hundred ninety-seven women were randomized to HIVST, 12 of whom self-reported being HIV positive and 11 participated in the interview']",[],[],"[{'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0337839', 'cui_str': 'Kenyans'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0019699', 'cui_str': 'HIV positive'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0036911', 'cui_str': 'Sexual partners'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439073', 'cui_str': '97'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}]",[],[],297.0,0.0372823,"Couple testing was high, which strengthened relationships, improved condom use, and empowered women to make joint decisions concerning their health. ","[{'ForeName': 'Kawango', 'Initials': 'K', 'LastName': 'Agot', 'Affiliation': 'Impact Research and Development Organization, Kisumu, Kenya.'}, {'ForeName': 'Gift-Noelle', 'Initials': 'GN', 'LastName': 'Wango', 'Affiliation': 'Nyanza Initiative for Girls Education and Empowerment, Kisumu, Kenya.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Obonyo', 'Affiliation': 'Impact Research and Development Organization, Kisumu, Kenya.'}, {'ForeName': 'Harsha', 'Initials': 'H', 'LastName': 'Thirumurthy', 'Affiliation': 'Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}]",Journal of the International Association of Providers of AIDS Care,['10.1177/2325958220919230'] 13,32344285,"Non-thyroidal illness syndrome, the hidden player in the septic shock induced myocardial contractile depression.","Septic shock causes high mortality in hospitalized patients, especially in those that develop myocardial dysfunction as an early complication. The myocardial dysfunction of septic shock is characterized by a decrease in ventricular relaxation (diastolic dysfunction) and reduced ventricular ejection fraction (systolic dysfunction). Most patients with septic shock have low serum thyroid hormone levels, a condition known as non-thyroidal illness syndrome. Thyroid hormones sustain myocardial contractility and energy metabolism. Septic shock non-thyroidal illness syndrome causes myocardial hypothyroidism, and hypothyroidism causes myocardial dysfunction that resembles the myocardial depression of septic shock. We hypothesize that the myocardial hypothyroidism that occurs during septic shock has a causal role in the pathogenesis of septic shock-induced myocardial dysfunction. Thyroid hormones regulate the calcium cycle, the phenotype of contractile proteins, adrenergic response, and fatty acid transport and oxidation in the cardiomyocytes. Therefore, the administration of levothyroxine and liothyronine to normalize thyroid hormones level within the myocardium will improve the myocardial function. The hypothesis will be tested in humans with septic shock by performing a prospective, randomized, placebo-controlled study to compare the effect of thyroid hormone administration with placebo on myocardial function. The proposed hypothesis challenges the idea that non-thyroidal illness syndrome is a beneficial response of the thyroid hormone axis to illness and that thyroid hormone replacement is detrimental. The administration of thyroid hormone in order to prevent and reverse myocardial hypothyroidism during septic shock is a new theoretical concept on thyroid hormone metabolism and action at the tissue level during non-thyroidal illness syndrome. If the hypothesis is correct, clinicians should consider cardiac hypothyroidism as a central player in myocardial dysfunction caused by sepsis. Thyroid hormone replacement should be incorporated into the armamentarium of septic shock treatment.",2020,The myocardial dysfunction of septic shock is characterized by a decrease in ventricular relaxation (diastolic dysfunction) and reduced ventricular ejection fraction (systolic dysfunction).,"['hospitalized patients', 'humans with septic shock']","['Thyroid hormone replacement', 'levothyroxine and liothyronine', 'thyroid hormone', 'placebo']","['low serum thyroid hormone levels', 'ventricular relaxation (diastolic dysfunction) and reduced ventricular ejection fraction (systolic dysfunction', 'myocardial function']","[{'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0036983', 'cui_str': 'Septic shock'}]","[{'cui': 'C0040135', 'cui_str': 'Thyroid hormone'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0040165', 'cui_str': 'levothyroxine'}, {'cui': 'C0041014', 'cui_str': 'liothyronine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0040135', 'cui_str': 'Thyroid hormone'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0520863', 'cui_str': 'Diastolic dysfunction'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0749225', 'cui_str': 'Systolic dysfunction'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",,0.205492,The myocardial dysfunction of septic shock is characterized by a decrease in ventricular relaxation (diastolic dysfunction) and reduced ventricular ejection fraction (systolic dysfunction).,"[{'ForeName': 'Joaquin', 'Initials': 'J', 'LastName': 'Lado-Abeal', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Truman Medical Centers and University of Missouri Kansas City, MO, USA. Electronic address: joaquin.lado@tmcmed.org.'}]",Medical hypotheses,['10.1016/j.mehy.2020.109775'] 14,32345787,Treatment for vaginal atrophy using microablative fractional CO2 laser: a randomized double-blinded sham-controlled trial.,"OBJECTIVE The aim of this study was to evaluate the efficacy of vaginal CO2 laser for the treatment of vaginal atrophy compared to the sham procedure. METHODS Between June 2016 and May 2017, postmenopausal women with moderate to severe intensity of any vaginal atrophy symptoms (VAS) were invited to participate in the study. A total of 88 women were randomized to receive treatment with either vaginal CO2 laser or sham procedures every 4 weeks for three sessions. Both the participants and the evaluators were blinded to the treatment. Vaginal Health Index (VHI) score (primary outcome), VAS score, and the item for vaginal dryness from the International Consultation on Incontinence Modular Questionnaire-Vaginal Symptoms questionnaire were compared between the two groups by intention-to-treat analysis at 12 weeks after treatment. RESULTS Eighty-eight women were enrolled into the study and nine women were lost to follow-up. After 12 weeks of laser treatment, the VHI, VAS, and International Consultation on Incontinence Modular Questionnaire-Vaginal Symptoms (item for vaginal dryness) scores were significantly improved. For VHI and VAS scores the mean difference between the laser group versus the sham group was 1.37 (95% CI: 0.12-2.63), P < 0.001 and -1.52 (95% CI: -2.21 to -0.82), P = 0.03, respectively. CONCLUSIONS This study demonstrated that the application of microablative fractional CO2 laser was effective in treating vaginal atrophy. It could be a promising alternative treatment for postmenopausal women with vaginal atrophy. : Video Summary:http://links.lww.com/MENO/A582.",2020,"After 12 weeks of laser treatment, the VHI, VAS, and International Consultation on Incontinence Modular Questionnaire-Vaginal Symptoms (item for vaginal dryness) scores were significantly improved.","['postmenopausal women with moderate to severe intensity of any vaginal atrophy symptoms (VAS', 'Between June 2016 and May 2017', 'Eighty-eight women were enrolled into the study and nine women', 'postmenopausal women with vaginal atrophy', 'A total of 88 women']","[' Video Summary:http://links.lww.com/MENO/A582', 'microablative fractional CO2 laser', 'vaginal CO2 laser']","['Vaginal Health Index (VHI) score (primary outcome), VAS score, and the item for vaginal dryness from the International Consultation on Incontinence Modular Questionnaire-Vaginal Symptoms questionnaire', 'For VHI and VAS scores', 'VHI, VAS, and International Consultation on Incontinence Modular Questionnaire-Vaginal Symptoms (item for vaginal dryness) scores']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0241616', 'cui_str': 'Atrophy of vagina'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4517898', 'cui_str': '88'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0392251', 'cui_str': 'Carbon dioxide laser device'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}]","[{'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0241616', 'cui_str': 'Atrophy of vagina'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0241633', 'cui_str': 'Vaginal dryness'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",88.0,0.201694,"After 12 weeks of laser treatment, the VHI, VAS, and International Consultation on Incontinence Modular Questionnaire-Vaginal Symptoms (item for vaginal dryness) scores were significantly improved.","[{'ForeName': 'Purim', 'Initials': 'P', 'LastName': 'Ruanphoo', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Suvit', 'Initials': 'S', 'LastName': 'Bunyavejchevin', 'Affiliation': ''}]","Menopause (New York, N.Y.)",['10.1097/GME.0000000000001542'] 15,32345788,The Women's Health Initiative trials of menopausal hormone therapy: lessons learned.,"OBJECTIVE The Women's Health Initiative (WHI) assessed oral conjugated equine estrogens (CEE) taken with or without medroxyprogesterone acetate (MPA) for prevention of chronic disease in postmenopausal women aged 50-79 years. METHODS Women with an intact uterus (n = 16,608) were randomized to CEE+ MPA therapy or placebo for a median of 5.6 years; women with hysterectomy (n = 10,739) were randomized to CEE-alone therapy or placebo for a median of 7.2 years. Both cohorts have been followed for 18 years. RESULTS In the overall study population (mean age, 63 y), neither estrogen-progestin therapy (EPT) nor estrogen-only therapy prevented coronary heart disease or led to a favorable balance of chronic-disease benefits and risks. Subgroup analyses, however, suggest that timing of hormone therapy (HT) initiation influences the relation between HT and coronary risk, as well as its overall benefit-risk balance, with more favorable effects in women who are younger (age < 60 year) or recently menopausal (within 10 year) than in women who are older or further past the menopausal transition. In younger women who entered the trial of estrogen-only therapy with oophorectomy, the intervention was associated with a significant 32% reduction in all-cause mortality over long-term follow-up. CONCLUSIONS WHI findings indicate important differences in HT-related clinical outcomes by age and time since menopause. Systemic HT has an acceptable safety profile for menopause management when initiated among healthy women who are younger (or recently menopausal) and not at elevated risk for cardiovascular disease or breast cancer. Initiation of treatment in older women who are distant from menopause onset, however, should be avoided. Other HT formulations and routes of delivery warrant further study.(WHI clinicaltrials.gov identifier: NCT00000611).",2020,Systemic HT has an acceptable safety profile for menopause management when initiated among healthy women who are younger (or recently menopausal) and not at elevated risk for cardiovascular disease or breast cancer.,"['older women who are distant from menopause onset', 'Women with an intact uterus (n\u200a=\u200a16,608', 'for a median of 5.6 years; women with hysterectomy (n\u200a=\u200a10,739', 'In the overall study population (mean age, 63 y), neither estrogen-progestin therapy (EPT) nor estrogen-only therapy prevented coronary heart disease or led to a favorable balance of chronic-disease benefits and risks', 'women who are younger (age < 60 year) or recently menopausal (within 10 year) than in women who are older or further past the menopausal transition', 'postmenopausal women aged 50-79 years', 'healthy women who are younger (or recently menopausal) and not at elevated risk for cardiovascular disease or breast cancer']","['Systemic HT', 'CEE-alone therapy or placebo', 'oral conjugated equine estrogens (CEE) taken with or without medroxyprogesterone acetate (MPA', 'CEE+ MPA therapy or placebo', 'menopausal hormone therapy']",['cause mortality'],"[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0443203', 'cui_str': 'Distant'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C4517794', 'cui_str': '5.6'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C0279495', 'cui_str': 'Progestogen hormone therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C0687742', 'cui_str': 'Risks and Benefits'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0301869', 'cui_str': 'Conjugate'}, {'cui': 'C0019944', 'cui_str': 'Equus caballus'}, {'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0065864', 'cui_str': 'Medroxyprogesterone acetate'}, {'cui': 'C0282402', 'cui_str': 'Hormone replacement therapy'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",16608.0,0.209041,Systemic HT has an acceptable safety profile for menopause management when initiated among healthy women who are younger (or recently menopausal) and not at elevated risk for cardiovascular disease or breast cancer.,"[{'ForeName': 'JoAnn E', 'Initials': 'JE', 'LastName': 'Manson', 'Affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School.""}, {'ForeName': 'Shari S', 'Initials': 'SS', 'LastName': 'Bassuk', 'Affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School.""}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Kaunitz', 'Affiliation': 'University of Florida College of Medicine Jacksonville, Jacksonville, FL.'}, {'ForeName': 'JoAnn V', 'Initials': 'JV', 'LastName': 'Pinkerton', 'Affiliation': 'Division of Midlife Health, University of Virginia Health System, Charlottesville, VA.'}]","Menopause (New York, N.Y.)",['10.1097/GME.0000000000001553'] 16,32347779,"Re: Ejaculatory Hood Sparing versus Standard Laser Photoselective Vaporization of the Prostate: Sexual and Urodynamic Assessment through a Double Blinded, Randomized TrialA. E. Abolazm, A. S. El-Hefnawy, M. Laymon, A. B. Shehab-El-Din and A. M. Elshal J Urol 2020; 203: 792-801.",,2020,,[],['Re: Ejaculatory Hood Sparing Versus Standard Laser Photoselective Vaporization'],[],[],"[{'cui': 'C0013746', 'cui_str': 'Ejaculation'}, {'cui': 'C1843661', 'cui_str': 'Spastic Paraplegia, Ataxia, And Mental Retardation'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0348007', 'cui_str': 'Laser Ablation'}]",[],,0.41547,,"[{'ForeName': 'Sheng', 'Initials': 'S', 'LastName': 'Hu', 'Affiliation': 'Department of Geriatric Urology, Xiangya Hospital of Central South University, Changsha, Hu Nan, China.'}, {'ForeName': 'Xiaobo', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Geriatric Urology, Xiangya Hospital of Central South University, Changsha, Hu Nan, China.'}, {'ForeName': 'Xiong', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Geriatric Urology, Xiangya Hospital of Central South University, Changsha, Hu Nan, China.'}]",The Journal of urology,['10.1097/JU.0000000000001093'] 17,32347785,"Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China.","Mismatch between circulating influenza B viruses and vaccine strains occurs frequently. In a randomized, double-blind, controlled phase III clinical study, healthy children aged 6-35 months were randomized into three groups at a ratio of 2:1:1, received two doses of quadrivalent influenza vaccines (QIVs) or licensed trivalent influenza vaccines (TIVs). The primary objective was to evaluate the non-inferiority immunogenicity of QIV compared with the two TIVs, containing B/Victoria or B/Yamagata strain. Safety information was collected for 28 days after each vaccination. Serious adverse events (SAEs) were monitored for 6 months after the second vaccination. A total of 2146 subjects (QIV: 1069, TIV-Vic: 540, TIV-Yam: 537) were enrolled in this study. QIV was found non-inferior to TIVs for shared strains (A/H1N1 and A/H3N2) and corresponding BY strain based on hemagglutination inhibition (HI) antibodies 28 days after the second dose of vaccination. The resulted geometric mean titer (GMT) ratios (QIV/TIV) were 0.98 (0.89, 1.07) for H1N1, 0.95 (0.85, 1.05) for H3N2 and 0.89 (0.81, 0.98) for BY. And the seroconversion rate differences (QIV-TIV) were -0.46% (-3.24%, 2.31%) for H1N1, -1.95% (-5.54%, 1.65%) for H3N2 and -3.58% (-8.11%, 0.95%) for BY. The BV strain in QIV did not reach the non-inferiority criteria, with GMT of 1:52.25 (vs. 1:61.02 of TIV-Vic) and seroconversion rate of 59.49% (vs. 66.85% of TIV-Vic). No increased safety concerns occurred in QIV group. Candidate QIV can provide good protection for children aged 6 to 35 months, and its immunogenicity and safety were proved. CLINICAL TRIALS REGISTRATION ClinicalTrials.gov number: NCT03859141.",2020,QIV was found non-inferior to TIVs for shared strains (A/H1N1 and A/H3N2) and corresponding BY strain based on hemagglutination inhibition (HI) antibodies 28 days after the second dose of vaccination.,"['healthy children aged 6-35 months', 'children aged 6-35 months in China', '2146 subjects (QIV: 1069, TIV-Vic: 540']","['quadrivalent influenza vaccines (QIVs) or licensed trivalent influenza vaccines (TIVs', 'inactivated quadrivalent influenza vaccine']","['seroconversion rate', 'Safety information', 'non-inferiority immunogenicity of QIV', 'geometric mean titer (GMT) ratios (QIV/TIV', 'Serious adverse events (SAEs', 'safety concerns', 'seroconversion rate differences (QIV-TIV', 'Immunogenicity and safety', 'QIV']","[{'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0574482', 'cui_str': 'Tiv language'}, {'cui': 'C5192767', 'cui_str': '540'}]","[{'cui': 'C4318638', 'cui_str': 'Quadrivalent Influenza Vaccine'}, {'cui': 'C0021403', 'cui_str': 'Influenza virus vaccine'}]","[{'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0237666', 'cui_str': 'Inferiority feeling'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0574482', 'cui_str': 'Tiv language'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",2146.0,0.373521,QIV was found non-inferior to TIVs for shared strains (A/H1N1 and A/H3N2) and corresponding BY strain based on hemagglutination inhibition (HI) antibodies 28 days after the second dose of vaccination.,"[{'ForeName': 'Yuemei', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Clinical Trials Assessment Department, Jiangsu Provincial Center for Disease Control and Prevention , Nanjing, China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Shao', 'Affiliation': 'Division of Respiratory Virus Vaccines, National Institutes for Food and Drug Control , Beijing, China.'}, {'ForeName': 'Yuansheng', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Clinical Research Department, Sinovac Biotech Co., LTD ., Beijing, China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Liang', 'Affiliation': 'Clinical Trials Assessment Department, Jiangsu Provincial Center for Disease Control and Prevention , Nanjing, China.'}, {'ForeName': 'Ningning', 'Initials': 'N', 'LastName': 'Jia', 'Affiliation': 'Clinical Research Department, Sinovac Biotech Co., LTD ., Beijing, China.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Chu', 'Affiliation': 'Clinical Trials Assessment Department, Jiangsu Provincial Center for Disease Control and Prevention , Nanjing, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': 'Quality Assurance Department, Sinovac Biotech Co., LTD ., Beijing, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Quality Assurance Department, Sinovac Biotech Co., LTD ., Beijing, China.'}, {'ForeName': 'Changgui', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Division of Respiratory Virus Vaccines, National Institutes for Food and Drug Control , Beijing, China.'}, {'ForeName': 'Fengcai', 'Initials': 'F', 'LastName': 'Zhu', 'Affiliation': 'Clinical Trials Assessment Department, Jiangsu Provincial Center for Disease Control and Prevention , Nanjing, China.'}]",Human vaccines & immunotherapeutics,['10.1080/21645515.2020.1721994'] 18,32346886,Predictors of genetic testing uptake in newly diagnosed breast cancer patients.,"BACKGROUND AND OBJECTIVES Many newly diagnosed breast cancer patients do not receive genetic counseling and testing at the time of diagnosis. We examined predictors of genetic testing (GT) in this population. METHODS Within a randomized controlled trial of proactive rapid genetic counseling and testing vs usual care, patients completed a baseline survey within 6 weeks of breast cancer diagnosis but before a definitive survey. We conducted a multinomial logistic regression to identify predictors of GT timing/uptake. RESULTS Having discussed GT with a surgeon was a dominant predictor (χ 2 (2, N = 320) = 70.13; P < .0001). Among those who discussed GT with a surgeon, patients who had made a final surgery decision were less likely to receive GT before surgery compared with postsurgically (OR [odds ratio] = 0.24; 95% confidence interval [CI] = 0.12-0.49) or no testing (OR = 0.28; 95% CI = 0.14-0.56). Older patients (OR = 0.95; 95% CI = 0.91-0.99) and participants enrolled in New York/New Jersey (OR = 0.22; 95% CI = 0.07-0.72) were less likely to be tested compared with receiving results before surgery. Those with higher perceived risk (OR = 1.02; 95% CI = 1.00-1.03) were more likely to receive results before surgery than to not be tested. CONCLUSIONS This study highlights the role of patient-physician communication about GT as well as patient-level factors that predict presurgical GT.",2020,"Those with higher perceived risk (OR = 1.02; 95% CI = 1.00-1.03) were more likely to receive results before surgery than to not be tested. ",['newly diagnosed breast cancer patients'],"['proactive rapid genetic counseling and testing vs usual care', 'genetic testing (GT']",['final surgery decision'],"[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0017382', 'cui_str': 'Genetic counseling'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0679560', 'cui_str': 'Genetic test'}]","[{'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]",,0.139548,"Those with higher perceived risk (OR = 1.02; 95% CI = 1.00-1.03) were more likely to receive results before surgery than to not be tested. ","[{'ForeName': 'Mary K', 'Initials': 'MK', 'LastName': 'Ladd', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Beth N', 'Initials': 'BN', 'LastName': 'Peshkin', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Claudine', 'Initials': 'C', 'LastName': 'Isaacs', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Gillian', 'Initials': 'G', 'LastName': 'Hooker', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Shawna', 'Initials': 'S', 'LastName': 'Willey', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Heiddis', 'Initials': 'H', 'LastName': 'Valdimarsdottir', 'Affiliation': 'Department of Population Health Science and Policy, Center for Behavioral Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Tiffani', 'Initials': 'T', 'LastName': 'DeMarco', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': ""O'Neill"", 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Savannah', 'Initials': 'S', 'LastName': 'Binion', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Marc D', 'Initials': 'MD', 'LastName': 'Schwartz', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of surgical oncology,['10.1002/jso.25956'] 19,32348036,"Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects.","Dupilumab is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases, including atopic dermatitis and asthma. Six phase 1 studies investigated the pharmacokinetics, pharmacodynamics, safety, and tolerability of dupilumab in healthy subjects. Two randomized, double-blind, placebo-controlled, sequential studies assessed safety and tolerability of single escalating dupilumab doses administered intravenously or subcutaneously (one included various racial groups, and one included exclusively Japanese subjects); 3 randomized, parallel-group, single-dose studies compared the pharmacokinetic profiles of different dupilumab products and formulations after single subcutaneous doses; and one study assessed dupilumab administered as fast versus slow subcutaneous injections. Dupilumab concentrations in serum were measured in all studies, and total immunoglobulin E (IgE) and thymus- and activation-regulated chemokine (TARC) concentrations were measured in 2 studies as pharmacodynamic markers. Across the phase 1 studies, dupilumab exhibited target-mediated pharmacokinetics consisting of parallel linear and nonlinear elimination, with the target-mediated phase highly dominated by nonlinearity at lower drug concentrations. Systemic exposure and tolerability of dupilumab were consistent irrespective of differences in product, formulation, or racial background. Dupilumab reduced circulating concentrations of total IgE and TARC, indicating blockade of IL-4Rα-mediated signaling. Dupilumab had a favorable safety profile across the wide range of doses administered. Together, these findings support the continued development and use of dupilumab in treatment of type 2 diseases.",2020,"Dupilumab reduced circulating concentrations of total IgE and TARC, indicating blockade of IL-4Rα-mediated signaling.","['various racial groups, and one included exclusively Japanese subjects', 'healthy subjects', 'Healthy Adult Subjects']","['α subunit (IL-4Rα) of IL-4 heterodimeric type', 'dupilumab administered as fast versus slow subcutaneous injections', 'placebo']","['circulating concentrations of total IgE and TARC', 'total immunoglobulin E (IgE) and thymus- and activation-regulated chemokine (TARC) concentrations', 'Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab', 'safety and tolerability', 'Systemic exposure and tolerability of dupilumab', 'pharmacokinetics, pharmacodynamics, safety, and tolerability', 'Dupilumab concentrations in serum']","[{'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0599220', 'cui_str': 'Protein Subunit'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0021758', 'cui_str': 'Interleukin-4'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C3660996', 'cui_str': 'dupilumab'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0021499', 'cui_str': 'Subcutaneous injection'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0428539', 'cui_str': 'Total immunoglobulin measurement'}, {'cui': 'C0020846', 'cui_str': 'Immunoglobulin E'}, {'cui': 'C0539535', 'cui_str': 'CCL17 protein, human'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3660996', 'cui_str': 'dupilumab'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",,0.158021,"Dupilumab reduced circulating concentrations of total IgE and TARC, indicating blockade of IL-4Rα-mediated signaling.","[{'ForeName': 'Zhaoyang', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Sanofi Genzyme, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Allen', 'Initials': 'A', 'LastName': 'Radin', 'Affiliation': 'Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Sanofi, Bridgewater, New Jersey, USA.'}, {'ForeName': 'Jennifer D', 'Initials': 'JD', 'LastName': 'Hamilton', 'Affiliation': 'Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Miyuki', 'Initials': 'M', 'LastName': 'Kajiwara', 'Affiliation': 'Sanofi KK, Tokyo, Japan.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Davis', 'Affiliation': 'Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Yoshinori', 'Initials': 'Y', 'LastName': 'Takahashi', 'Affiliation': 'Sanofi KK, Tokyo, Japan.'}, {'ForeName': 'Setsuo', 'Initials': 'S', 'LastName': 'Hasegawa', 'Affiliation': 'Sekino Clinical Pharmacology Clinic, Tokyo, Japan.'}, {'ForeName': 'Jeffrey E', 'Initials': 'JE', 'LastName': 'Ming', 'Affiliation': 'Sanofi, Bridgewater, New Jersey, USA.'}, {'ForeName': 'A Thomas', 'Initials': 'AT', 'LastName': 'DiCioccio', 'Affiliation': 'Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Yongtao', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Sanofi, Bridgewater, New Jersey, USA.'}, {'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Kovalenko', 'Affiliation': 'Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Lu', 'Affiliation': 'Sanofi, Bridgewater, New Jersey, USA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Ortemann-Renon', 'Affiliation': 'Sanofi, Bridgewater, New Jersey, USA.'}, {'ForeName': 'Marius', 'Initials': 'M', 'LastName': 'Ardeleanu', 'Affiliation': 'Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Brian N', 'Initials': 'BN', 'LastName': 'Swanson', 'Affiliation': 'Sanofi, Bridgewater, New Jersey, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.798'] 20,32353816,Effects of a Mindfulness-based Intervention on diurnal cortisol pattern in disadvantaged families: A randomized controlled trial.,"OBJECTIVE The present study examined the psychophysiological effects of Family-based Mindfulness Intervention (FBMI) on children and parents from disadvantaged families. METHODS This randomized controlled trial recruited parents and their children from 51 disadvantaged families in Hong Kong and randomized them into FBMI (n = 26) and waitlist control (n = 25) groups. The parent intervention included 6 sessions and the child intervention included 8 sessions with 2 half-hour joint programs. Both interventions lasted 9 hours in total each. All participants completed four salivary cortisol measures after wakeup, before lunchtime, late-afternoon, and before sleep at baseline and end of the intervention. The diurnal cortisol pattern was summarized by the morning cortisol, evening cortisol, mean cortisol, and diurnal cortisol slope. RESULTS Compared to the control group, children in the FBMI group showed significant increases in morning cortisol (d = 0.50, p =  0.03) and significant decreases in diurnal cortisol slopes (d = 0.50, p =  0.04) at the end of intervention. Parents in the FBMI group displayed significant decreases in evening cortisol (d = 0.50, p =  0.04) compared to the control group at the end of intervention. No significant treatment effects were found on the mean cortisol. DISCUSSION The present findings suggest that FBMI could improve the diurnal cortisol slope and cortisol levels of the children and parents from disadvantaged families, respectively. Future studies should elucidate its potential benefits on neuroendocrine functioning.",2020,"Parents in the FBMI group displayed significant decreases in evening cortisol (d = 0.50, p =  0.04) compared to the control group at the end of intervention.","['children and parents from disadvantaged families', 'parents and their children from 51 disadvantaged families in Hong Kong and randomized them into FBMI (n\u202f=\u202f26) and waitlist control (n\u202f=\u202f25) groups', 'disadvantaged families']","['Mindfulness-based Intervention', 'FBMI', 'Family-based Mindfulness Intervention (FBMI', 'child intervention included 8 sessions with 2 half-hour joint programs']","['morning cortisol, evening cortisol, mean cortisol, and diurnal cortisol slope', 'diurnal cortisol slopes', 'morning cortisol', 'evening cortisol', 'diurnal cortisol slope and cortisol levels', 'salivary cortisol measures', 'mean cortisol', 'diurnal cortisol pattern']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0012613', 'cui_str': 'Disadvantaged'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0019907', 'cui_str': 'Hong Kong'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1442458', 'cui_str': 'Thirty minutes'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0587117', 'cui_str': 'Evening'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}]",51.0,0.0257721,"Parents in the FBMI group displayed significant decreases in evening cortisol (d = 0.50, p =  0.04) compared to the control group at the end of intervention.","[{'ForeName': 'Rainbow T H', 'Initials': 'RTH', 'LastName': 'Ho', 'Affiliation': 'Centre on Behavioral Health, The University of Hong Kong, Hong Kong; Department of Social Work & Social Administration, The University of Hong Kong, Hong Kong.'}, {'ForeName': 'Herman H M', 'Initials': 'HHM', 'LastName': 'Lo', 'Affiliation': 'Department of Applied Social Sciences, The Hong Kong Polytechnic University, Hong Kong. Electronic address: herman.lo@polyu.edu.hk.'}, {'ForeName': 'Ted C T', 'Initials': 'TCT', 'LastName': 'Fong', 'Affiliation': 'Centre on Behavioral Health, The University of Hong Kong, Hong Kong; Department of Social Work & Social Administration, The University of Hong Kong, Hong Kong.'}, {'ForeName': 'C W', 'Initials': 'CW', 'LastName': 'Choi', 'Affiliation': 'Department of Applied Social Sciences, The Hong Kong Polytechnic University, Hong Kong.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2020.104696'] 21,32348796,Food-based social comparisons influence liking and consumption.,"This study examined the effects of food-based social comparisons on hedonic ratings and consumption of a meal. Participants were randomly assigned to one of three experimental conditions in which they were led to believe that they got a worse meal, a better meal, or the same meal as another participant. They then tasted and rated their own meal. Subsequent liking and ad lib food consumption were measured. Participants who were told that another person got a better meal than they did (upward comparison) liked their meal less than if they were told that another person received either the same meal as they did or a worse meal (downward comparison). Similarly, participants who were in the upward comparison condition ate less food than if they were in the control or downward comparison conditions. Consumption was mediated by liking. The results suggest that being told that someone else is eating a meal that is higher or lower in hedonic value than one's own meal induces hedonic contrast and influences liking and consumption.",2020,"Participants were randomly assigned to one of three experimental conditions in which they were led to believe that they got a worse meal, a better meal, or the same meal as another participant.",['Participants who were told that another person got a better meal than they did (upward comparison) liked their meal less than if they were told that another person'],['food-based social comparisons'],"['hedonic contrast and influences liking and consumption', 'hedonic ratings and consumption of a meal', 'Subsequent liking and ad lib food consumption']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C1282911', 'cui_str': 'Upward'}, {'cui': 'C0439092', 'cui_str': '<'}]","[{'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0016452', 'cui_str': 'Foods'}]",,0.0296622,"Participants were randomly assigned to one of three experimental conditions in which they were led to believe that they got a worse meal, a better meal, or the same meal as another participant.","[{'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Mills', 'Affiliation': 'Department of Psychology, York University, Toronto, ON, M3J 1P3, Canada. Electronic address: jsmills@yorku.ca.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Polivy', 'Affiliation': 'Department of Psychology, University of Toronto, Toronto, ON, M3J 1P3, Canada.'}, {'ForeName': 'Ayesha', 'Initials': 'A', 'LastName': 'Iqbal', 'Affiliation': 'Department of Psychology, York University, Toronto, ON, M3J 1P3, Canada.'}]",Appetite,['10.1016/j.appet.2020.104720'] 22,32349746,"Comparison of explicit values clarification method (VCM), implicit VCM and no VCM decision aids for men considering prostate cancer screening: protocol of a randomized trial.","BACKGROUND Screening with prostate-specific antigen (PSA) test for prostate cancer is considered a preference sensitive decision; meaning it does not only depend on what is best from a medical point of view, but also from a patient value standpoint. Decision aids are evidence-based tools which are shown to help people feel clearer about their values; therefore it has been advocated that decision aids should contain a specific values clarification method (VCM). VCMs may be either implicit or explicit, but the evidence concerning the best method is scarce. We aim to compare the perceived clarity of personal values in men considering PSA screening using decision aids with no VCM versus an implicit VCM versus an explicit VCM. METHODS Male factory employees from an industrial facility in the Northern region of Portugal aged 50 to 69 years old will be randomly assigned to one of three decision aid groups used to support prostate cancer screening decisions: (i) decision aid with information only (control), (ii) decision aid with information plus an implicit VCM, (iii) decision aid with information plus an explicit VCM. Men will be allowed release time from work to attend a session at their workplace. After a brief oral presentation, those willing to participate in the study will fill the baseline questionnaire, plus a 5 point-Likert scale question about intentions to undergo screening, and will then receive the intervention materials to complete. We estimated a total sample size of 276 participants; with 92 in each group. The primary outcome will be the perceived clarity of personal values assessed by the Portuguese validated translation of the three subscales of the Decisional Conflict Scale. Secondary outcomes will be intention to be screened (before and after the intervention), the total score from the Decisional Conflict Scale and the self-report of having or not undergone screening at 6 months. DISCUSSION This study will add to the body of evidence on the role of decision aids to support health preference-sensitive choices and provide further insight on the impact of different methods for eliciting people's values embedded within a decision aid. TRIAL REGISTRATION NCT03988673 - clinicalTrials.gov (2019/06/17).",2020,"We aim to compare the perceived clarity of personal values in men considering PSA screening using decision aids with no VCM versus an implicit VCM versus an explicit VCM. ","['total sample size of 276 participants; with 92 in each group', 'men considering PSA screening using decision aids with no', 'men considering prostate cancer screening', 'Male factory employees from an industrial facility in the Northern region of Portugal aged 50 to 69\u2009years old']","['VCM versus an implicit VCM', 'explicit values clarification method (VCM), implicit VCM and no VCM decision aids', 'decision aid groups used to support prostate cancer screening decisions: (i) decision aid with information only (control), (ii) decision aid with information plus an implicit VCM, (iii) decision aid with information plus an explicit VCM']","['total score from the Decisional Conflict Scale and the self-report of having or not undergone screening at 6\u2009months', 'perceived clarity of personal values assessed by the Portuguese validated translation of the three subscales of the Decisional Conflict Scale']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0086104', 'cui_str': 'Decision Aids'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0442614', 'cui_str': 'Factory'}, {'cui': 'C0599987', 'cui_str': 'Employee'}, {'cui': 'C0442620', 'cui_str': 'Industrial plant'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0032729', 'cui_str': 'Portugal'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0150401', 'cui_str': 'Values clarification'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C1319687', 'cui_str': 'No value'}, {'cui': 'C0086104', 'cui_str': 'Decision Aids'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0231394', 'cui_str': 'Decisional conflict'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0486588', 'cui_str': 'Clarity (property)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0032730', 'cui_str': 'Portuguese'}, {'cui': 'C0040712', 'cui_str': 'Translations'}]",276.0,0.0841233,"We aim to compare the perceived clarity of personal values in men considering PSA screening using decision aids with no VCM versus an implicit VCM versus an explicit VCM. ","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Baptista', 'Affiliation': 'Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Al. Prof. Hernâni Monteiro, 4200 - 319, Porto, Portugal. baptistas@med.up.pt.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Heleno', 'Affiliation': 'Comprehensive Health Research Center (CHRC), Universidade NOVA de Lisboa, Lisboa, Portugal.5 - NOVA Medical School|Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisbon, Portugal.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Teixeira', 'Affiliation': 'Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Al. Prof. Hernâni Monteiro, 4200 - 319, Porto, Portugal.'}, {'ForeName': 'K L', 'Initials': 'KL', 'LastName': 'Taylor', 'Affiliation': 'Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C, United States of America.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Martins', 'Affiliation': 'Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Al. Prof. Hernâni Monteiro, 4200 - 319, Porto, Portugal.'}]",BMC medical informatics and decision making,['10.1186/s12911-020-1094-3'] 23,32353101,The influence of a doppler ultrasound in arteriovenous fistula for dialysis failure related to some risk factors.,"INTRODUCTION The increasing prevalence of chronic kidney disease has increased the demand for arteriovenous fistula (AVF) care. The objective of this study was to assess the relationship between some risk factors for AVF failure (advanced age, female sex, diabetes, obesity, central venous catheter, previous fistula, and hospitalization) and having a Doppler ultrasound performed preoperatively. METHODS A prospective study was performed with 228 dialysis patients from Imperatriz, Maranhão. Half of the sample was randomly selected to receive preoperative Doppler ultrasound and the other half did not, from the period of October 2016 to September 2018. RESULTS There were 53 total failures corresponding to 23.2% of our sample, which is almost double that of the patients in the clinical group. Considering the failures and risk factors associated with the overall sample, there was a statistically significant association between a central venous catheter on the same side of the AVF with P = 0.04 (Odds Ratio 1.24) and obesity with P = 0.05 (Odds Ratio 1.36), which was not repeated in the Doppler ultrasound group individually. There was no statistically significant difference between the Doppler group and clinical group with respect to the amount of days of previous AVF hospitalization and failure. CONCLUSIONS We concluded that the reduction of failures with an introduction of the Doppler was statistically significant in the overall sample, but establishing a relationship between specific risk factors and failure was only possible with two of the risk factors in the study - obesity and central venous catheter on the same side of the AVF.",2020,"There was no statistically significant difference between the Doppler group and clinical group with respect to the amount of days of previous AVF hospitalization and failure. ","['228 dialysis patients from Imperatriz, Maranhão']","['preoperative Doppler ultrasound', 'doppler ultrasound']",['AVF hospitalization and failure'],"[{'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0162481', 'cui_str': 'Doppler ultrasound'}]","[{'cui': 'C0003855', 'cui_str': 'Arteriovenous fistula'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0231174', 'cui_str': 'Failure'}]",,0.0189298,"There was no statistically significant difference between the Doppler group and clinical group with respect to the amount of days of previous AVF hospitalization and failure. ","[{'ForeName': 'Jocefábia Reika Alves', 'Initials': 'JRA', 'LastName': 'Lopes', 'Affiliation': 'Faculdade de Medicina do ABC, Santo André, SP, Brasil.'}, {'ForeName': 'Ana Lígia de Barros', 'Initials': 'ALB', 'LastName': 'Marques', 'Affiliation': 'Universidade Federal do Maranhão, Imperatriz, MA, Brasil.'}, {'ForeName': 'João Antonio', 'Initials': 'JA', 'LastName': 'Correa', 'Affiliation': 'Faculdade de Medicina do ABC, Santo André, SP, Brasil.'}]",Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia,['10.1590/2175-8239-JBN-2019-0080'] 24,32350975,"Onabotulinumtoxin Type A reconstitution with preserved versus preservative-free saline in chronic migraine (B-RECON). A randomised, double-blind trial.","INTRODUCTION Onabotulinumtoxin type A (BoNTA) is manufactured as powder that requires reconstitution with normal saline prior to injection. Previous literature has suggested that preserved saline (PS) exerts a local anaesthetic effect, and reduces the procedure discomfort when used in reconstitution in lieu of preservative-free saline (PFS). However, this was mainly studied in the aesthetics indications of BoNTA, and never in its use for the treatment of chronic migraine. The distinction is important as chronic migraine population suffers high incidence of scalp allodynia which makes it more prone to injection site pain. In addition, the pain of the procedure itself may be related to the spike of migraine frequency in the immediate postprocedural period which can occur in up to 5% of patients receiving the treatment. Our trial aimed to study the difference in procedural pain scale, and postprocedural headache rating with the use of PS vs PFS in constitution of BoNTA when used as a treatment for chronic migraine. METHODS 68 subjects were consecutively enrolled in an outpatient setting at a large tertiary headache centre over a period of 6 months. Subjects were randomised into PS or PFS group. BoNTA was administered as per standard protocol in both groups. Injection site pain scores and frequency of headache days in the immediate following week were recorded. Wilcoxon rank sum tests were used to compare differences in between groups using SPSS software. RESULTS Analysis (SAS V 9.4) revealed that those receiving [PF] had significantly higher procedure pain scores than those receiving [P] (5.3 vs 3.2, respectively). There was no difference in the headache or migraine frequency in the immediate postprocedural period. CONCLUSION This study supports the use of PS (bacteriostatic) over PFS for reconstitution of BoNTA in chronic migraine as it reduces the discomfort of the injection sites.",2020,"There was no difference in the headache or migraine frequency in the immediate post procedural period. ",['68 subjects were consecutively enrolled in an outpatient setting at a large tertiary headache center over a period of 6 months'],"['Onabotulinumtoxin', 'Onabotulinumtoxin Type A reconstitution with preserved versus preservative-free saline', 'preserved saline (bacteriostatic) over preservative-free saline', 'PS or PFS', 'preservative-free saline', 'saline (PS', 'Preserved (bacteriostatic) saline']","['headache or migraine frequency', 'procedure pain scores', 'procedural pain scale, and post-procedural headache rating', 'Injection site pain scores and frequency of headache days']","[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0033086', 'cui_str': 'Drug preservative'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C1619712', 'cui_str': 'Procedural pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1696683', 'cui_str': 'Post procedural headache'}, {'cui': 'C0151828', 'cui_str': 'Injection site pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0857361', 'cui_str': 'Headache occurring'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",68.0,0.0863709,"There was no difference in the headache or migraine frequency in the immediate post procedural period. ","[{'ForeName': 'Awss', 'Initials': 'A', 'LastName': 'Zidan', 'Affiliation': 'Department of Neurology, SUNY Upstate Medical University, Syracuse, NY, USA.'}, {'ForeName': 'Sharmeen', 'Initials': 'S', 'LastName': 'Hussaini', 'Affiliation': 'Department of Neurology, SUNY Upstate Medical University, Syracuse, NY, USA.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Gibson', 'Affiliation': 'Department of Neurology, SUNY Upstate Medical University, Syracuse, NY, USA.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Brooks', 'Affiliation': 'Center for Research and Evaluation, SUNY Upstate Medical University, Syracuse, NY, USA.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Mejico', 'Affiliation': 'Department of Neurology, SUNY Upstate Medical University, Syracuse, NY, USA.'}]",International journal of clinical practice,['10.1111/ijcp.13522'] 25,32348700,Economic evaluation of a combined screening and stepped-care treatment program targeting psychological distress in patients with metastatic colorectal cancer: A cluster randomized controlled trial.,"BACKGROUND Psychological distress is highly prevalent among patients with metastatic colorectal cancer. AIMS To perform an economic evaluation of a combined screening and treatment program targeting psychological distress in patients with metastatic colorectal cancer in comparison with usual care. DESIGN Societal costs were collected alongside a cluster randomized controlled trial for 48 weeks. A total of 349 participants were included. SETTING Participants were recruited from oncology departments at 16 participating hospitals in the Netherlands. METHODS Outcome measures were the Hospital Anxiety and Depression Scale and quality-adjusted life-years. Missing data were imputed using multiple imputation. Uncertainty was estimated using bootstrapping. Cost-effectiveness planes and cost-effectiveness acceptability curves were estimated to show uncertainty surrounding the cost-effectiveness estimates. Sensitivity analyses were performed to check robustness of results. RESULTS Between treatment arms, no significant differences were found in Hospital Anxiety and Depression Scale score (mean difference: -0.058; 95% confidence interval: -0.13 to 0.011), quality-adjusted life-years (mean difference: 0.042; 95% confidence interval: -0.015 to 0.099), and societal costs (mean difference: -1152; 95% confidence interval: -5058 to 2214). Cost-effectiveness acceptability curves showed that the probability of cost-effectiveness was 0.64 and 0.74 at willingness-to-pay values of €0 and €10,000 per point improvement on the Hospital Anxiety and Depression Scale, respectively. The probability that the intervention was cost-effective compared to usual care for quality-adjusted life-years was 0.64 and 0.79 at willingness-to-pay values of €0 and €20,000 per quality-adjusted life-year, respectively. CONCLUSION The intervention is dominant over usual care, primarily due to lower costs in the intervention group. However, there were no statistically significant differences in clinical effects and the uptake of the intervention was quite low. Therefore, widespread implementation cannot be recommended.",2020,"The probability that the intervention was cost-effective compared to usual care for quality-adjusted life-years was 0.64 and 0.79 at willingness-to-pay values of €0 and €20,000 per quality-adjusted life-year, respectively. ","['A total of 349 participants were included', 'patients with metastatic colorectal cancer in comparison with usual care', 'Participants were recruited from oncology departments at 16 participating hospitals in the Netherlands', 'patients with metastatic colorectal cancer']","['combined screening and treatment program targeting psychological distress', 'combined screening and stepped-care treatment program']","['probability of cost-effectiveness', 'Hospital Anxiety and Depression Scale score', 'Hospital Anxiety and Depression Scale and quality-adjusted life-years', 'cost-effective', 'Hospital Anxiety and Depression Scale', 'Cost-effectiveness planes and cost-effectiveness acceptability curves', 'Cost-effectiveness acceptability', 'quality-adjusted life-years', 'societal costs']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0205134', 'cui_str': 'Curved'}]",349.0,0.193851,"The probability that the intervention was cost-effective compared to usual care for quality-adjusted life-years was 0.64 and 0.79 at willingness-to-pay values of €0 and €20,000 per quality-adjusted life-year, respectively. ","[{'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'El Alili', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Claudia S E W', 'Initials': 'CSEW', 'LastName': 'Schuurhuizen', 'Affiliation': 'Department of Medical Oncology, Amsterdam UMC, Vrije Universtiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Annemarie M J', 'Initials': 'AMJ', 'LastName': 'Braamse', 'Affiliation': 'Department of Medical Psychology, Amsterdam UMC, Academic Medical Center, Cancer Center Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Aartjan T F', 'Initials': 'ATF', 'LastName': 'Beekman', 'Affiliation': 'Department of Psychiatry, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health Research institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Mecheline H', 'Initials': 'MH', 'LastName': 'van der Linden', 'Affiliation': 'Department of Medical Psychology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Inge R', 'Initials': 'IR', 'LastName': 'Konings', 'Affiliation': 'Department of Medical Oncology, Amsterdam UMC, Vrije Universtiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Joost', 'Initials': 'J', 'LastName': 'Dekker', 'Affiliation': 'Department of Psychiatry, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health Research institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Judith E', 'Initials': 'JE', 'LastName': 'Bosmans', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}]",Palliative medicine,['10.1177/0269216320913463'] 26,32348714,Precision and Safety of an Intravascular Temperature Management System for Postcardiac Arrest Syndrome Patients: A Multicenter Clinical Trial (COOL-ARREST JP).,"Rapid induction and maintaining a target temperature of 32.0-36.0°C within a narrow range for <24 hours are essential, but those are very hard to perform in postcardiac arrest syndrome (PCAS) patients. We investigated the usability of an intravascular temperature management (IVTM) system with neurolept-anesthesia (NLA; droperidol and fentanyl). Single-arm, prospective multicenter trial was carried out in the seven university and the three affiliated hospitals. In the 24 comatose PCAS patients, the target temperature (33.0°C) was rapidly induced and maintained for 24 hours using an IVTM system with NLA. The rewarming speed was 0.1°C/h until 36.5°C and was maintained for 24 hours. The primary end point was the ability to achieve ≤34.0°C for <3 hours after starting cooling, and the secondary end points were the cooling rate, deviation from the target temperature, and adverse events. Cerebral Performance Category (CPC) score at 14 days was also evaluated. Statistical analyses were performed by SPSS software, using the intention-to-treat data sets. The target temperature of ≤34.0°C was reached by 45 minutes (35-73 minutes) and was within 3 hours in all patients. The cooling rate from 36.4°C to 33.0°C was 2.7°C/h (2.4-3.6°C/h). The temperature of 33.1°C (33.1-33.1°C) and 36.7°C (36.6-36.9°C) for 24 hours each was held during the maintenance and the after rewarming phases, respectively. Temperature deviations >0.2°C from 33.0°C in the maintenance phase occurred once each in two patients. The favorable neurological outcomes (CPC1, 2) were relatively good (50%). Five patients experienced serious adverse events; none was device related. We rapidly achieved therapeutic hypothermia within a narrow temperature range without major complications using the IVTM system with NLA in PCAS patients.",2020,We rapidly achieved therapeutic hypothermia within a narrow temperature range without major complications using the IVTM system with NLA in PCAS patients.,"['seven university and the three affiliated hospitals', '24 comatose PCAS patients', 'Postcardiac Arrest Syndrome Patients', 'PCAS patients']","['Intravascular Temperature Management System', 'intravascular temperature management (IVTM) system with neurolept-anesthesia (NLA; droperidol and fentanyl']","['cooling rate', 'ability to achieve ≤34.0°C', 'cooling rate, deviation from the target temperature, and adverse events', 'Cerebral Performance Category (CPC) score', 'rewarming speed', 'serious adverse events']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0009421', 'cui_str': 'Coma'}, {'cui': 'C4285706', 'cui_str': 'Post cardiac arrest syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0442123', 'cui_str': 'Intravascular'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0013136', 'cui_str': 'Droperidol'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}]","[{'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0012727', 'cui_str': 'Displacement'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}]",2.0,0.0424732,We rapidly achieved therapeutic hypothermia within a narrow temperature range without major complications using the IVTM system with NLA in PCAS patients.,"[{'ForeName': 'Tsuyoshi', 'Initials': 'T', 'LastName': 'Maekawa', 'Affiliation': 'Yamaguchi Prefectural University, Yamaguchi, Japan.'}, {'ForeName': 'Kotaro', 'Initials': 'K', 'LastName': 'Kaneda', 'Affiliation': 'Advanced Medical Emergency and Critical Care Medicine, Yamaguchi University Hospital, Yamaguchi, Japan.'}, {'ForeName': 'Ryosuke', 'Initials': 'R', 'LastName': 'Tsuruta', 'Affiliation': 'Advanced Medical Emergency and Critical Care Medicine, Yamaguchi University Hospital, Yamaguchi, Japan.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Kuroda', 'Affiliation': 'Emergency Medical Center, Kagawa University Hospital, Miki, Japan.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Nagao', 'Affiliation': 'Cardiovascular Disease Center, Nihon University Hospital (Surugadai), Nihon University Hospital, Tokyo, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Rinka', 'Affiliation': 'Emergency and Critical Medical Care Center, Osaka City General Hospital, Osaka, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Takahashi', 'Affiliation': 'Kumamoto Medical Center, Kumamoto, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Yokota', 'Affiliation': 'Emergency and Critical Care Medicine, Nippon Medical School Hospital, Tokyo, Japan.'}, {'ForeName': 'Shin-Ichi', 'Initials': 'SI', 'LastName': 'Shirai', 'Affiliation': 'Cardio-Vascular Center, Kokura Memorial Hospital, Fukuoka, Japan.'}, {'ForeName': 'Mamoru', 'Initials': 'M', 'LastName': 'Hase', 'Affiliation': 'Department of Traumatology and Critical Care Medicine, Sapporo Medical University Hospital, Sapporo, Japan.'}, {'ForeName': 'Joji', 'Initials': 'J', 'LastName': 'Kotani', 'Affiliation': 'Center for Emergency and Critical Care Medicine, Kobe University Hospital, Kobe University Hospital, Kobe, Japan.'}, {'ForeName': 'Shigeatsu', 'Initials': 'S', 'LastName': 'Endo', 'Affiliation': 'Advanced Emergency and Critical Care Center, Iwate Medical University Hospital, Morioka, Japan.'}]",Therapeutic hypothermia and temperature management,['10.1089/ther.2019.0046'] 27,32291649,"Grapheme-color associations can transfer to novel graphemes when synesthetic colors function as grapheme ""discriminating markers"".","Synesthesia is a condition in which the perception of a stimulus in one modality automatically triggers a secondary sensation in another modality or processing stream. Our study focused on grapheme-color synesthesia, in which the visual perception of letters or numbers (graphemes) induces a specific color sensation (the synesthetic color). Grapheme-color synesthetes do not typically experience colors for novel graphemes. However, synesthetic colors associated with familiar graphemes can be transferred to graphemes learned later, even in adulthood. A previous study has shown that such a transfer can take place after only a 10-min writing exercise. In this study, we found that this immediate transfer occurs only when the synesthetic colors for familiar graphemes contribute to the discrimination of the graphemes to be learned. Synesthetes learned six novel graphemes, each of which was arbitrarily associated with one of six familiar graphemes. Half of the synesthetes were assigned to the heterogeneous condition, in which the synesthetic colors of one group of familiar graphemes were different from one another. The other half of the synesthetes were assigned to the homogeneous condition, in which the various colors of a whole group of familiar graphemes were categorically the same. After this learning session, less transfer of synesthetic colors to novel graphemes from the corresponding familiar graphemes occurred in the homogeneous condition than in the heterogeneous condition. These results support the view that synesthetic colors for graphemes may function as a grapheme acquisition aid.",2020,"After this learning session, less transfer of synesthetic colors to novel graphemes from the corresponding familiar graphemes occurred in the homogeneous condition than in the heterogeneous condition.",[],[],[],[],[],[],,0.0132761,"After this learning session, less transfer of synesthetic colors to novel graphemes from the corresponding familiar graphemes occurred in the homogeneous condition than in the heterogeneous condition.","[{'ForeName': 'Kyuto', 'Initials': 'K', 'LastName': 'Uno', 'Affiliation': 'Department of Psychology, Graduate School of Humanities and Sociology, The University of Tokyo, Tokyo, Japan. uno@l.u-tokyo.ac.jp.'}, {'ForeName': 'Michiko', 'Initials': 'M', 'LastName': 'Asano', 'Affiliation': 'Department of Psychology, College of Contemporary Psychology, Rikkyo University, Saitama, Japan.'}, {'ForeName': 'Hana', 'Initials': 'H', 'LastName': 'Kadowaki', 'Affiliation': 'Department of Psychology, Faculty of Letters, The University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Kazuhiko', 'Initials': 'K', 'LastName': 'Yokosawa', 'Affiliation': 'Department of Psychology, Graduate School of Humanities and Sociology, The University of Tokyo, Tokyo, Japan.'}]",Psychonomic bulletin & review,['10.3758/s13423-020-01732-9'] 28,32353619,Suture Tape Reduces Quadriceps Tendon Repair Gap Formation Compared With High-Strength Suture: A Cadaveric Biomechanical Analysis.,"PURPOSE To compare the biomechanical differences between quadriceps tendon (QT) repair with high-strength suture (HSS) versus suture tape (ST) with varying number of suture passes. METHODS In total, 28 fresh-frozen QTs were randomized into 2 groups: (1) HSS; or (2) ST; specimens were then further randomized into subgroups of either 4 or 6 suture passes. Specimens were secured within a materials testing system and a 150-N preload was applied for 10 seconds followed by a cyclic loading protocol between 50 N and 250 N for 1000 cycles. Video was used to follow tracking markers used to calculate the magnitude of tendon displacement. Two-way univariate analysis of variance was used to determine the effect of suture type and passes on the displacement after preloading and mixed repeated-measures analysis of variance was used to determine the effect of suture type and passes on displacement following cyclic loading. RESULTS There were large increases in displacement following the preload across all conditions (7.82 ± 3.64 mm), with no statistically significant differences between groups. There was a significant difference in the mean (± standard deviation) displacement between the ST (5.24 ± 2.82 mm) and HSS (7.93 ± 2.91 mm) starting at 200 cycles, which became more pronounced with successive testing out to 1000 cycles (P = .021). There were no significant difference with respect to the number of suture or tape passes. CONCLUSIONS Following preloading at 150 N, significant displacement occurred in both QT repair groups. ST demonstrated significantly less displacement than HSS under cyclic loading and had greater ultimate failure loads. CLINICAL RELEVANCE When performing QT repair, emphasis should be placed on appropriate pretensioning of sutures to at least 150 N before knot-tying. In addition, where available, ST should be used over HSS to reduce further cyclic elongation and improve ultimate failure loads.",2020,ST demonstrated significantly less displacement than HSS under cyclic loading and had greater ultimate failure loads.conclusion,['28 fresh-frozen QTs'],"['quadriceps tendon (QT) repair with high-strength suture (HSS) versus suture tape (ST', 'HSS; or ii) ST', 'High Strength Suture', 'Suture Tape']","['number of suture or tape passes.results', 'Quadriceps Tendon Repair Gap Formation', 'ultimate failure loads.conclusion', 'mean (±SD) displacement']","[{'cui': 'C0443224', 'cui_str': 'Fresh'}, {'cui': 'C0016701', 'cui_str': 'Freezing'}]","[{'cui': 'C0224941', 'cui_str': 'Structure of quadriceps tendon'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0343138', 'cui_str': 'Strapping procedure'}]","[{'cui': 'C0457280', 'cui_str': 'Number of sutures'}, {'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C0547072', 'cui_str': 'Repair of quadriceps'}, {'cui': 'C0061928', 'cui_str': 'GTPase-Activating Protein'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}]",,0.0324435,ST demonstrated significantly less displacement than HSS under cyclic loading and had greater ultimate failure loads.conclusion,"[{'ForeName': 'Philip P', 'Initials': 'PP', 'LastName': 'Roessler', 'Affiliation': 'Fowler Kennedy Sports Medicine Clinic, 3M Center, Western University, London Ontario, Canada.'}, {'ForeName': 'Timothy A', 'Initials': 'TA', 'LastName': 'Burkhart', 'Affiliation': 'Lawson Health Research Institute, Mechanical and Materials Engineering, Western University, London Ontario, Canada.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Getgood', 'Affiliation': 'Fowler Kennedy Sports Medicine Clinic, 3M Center, Western University, London Ontario, Canada.'}, {'ForeName': 'Ryan M', 'Initials': 'RM', 'LastName': 'Degen', 'Affiliation': 'Fowler Kennedy Sports Medicine Clinic, 3M Center, Western University, London Ontario, Canada. Electronic address: Ryan.degen@lhsc.on.ca.'}]",Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association,['10.1016/j.arthro.2020.04.020'] 29,32354466,The Efficacy of Distraction Cards and Kaleidoscope for Reducing Pain During Phlebotomy: A Randomized Controlled Trial.,"PURPOSE The purpose of this study was to determine the efficacy of distraction cards and a kaleidoscope in reducing pain during phlebotomy procedures among children aged 6 to 12. DESIGN This randomized controlled study involved intervention groups and a control group. METHODS Data were obtained by the use of an information form and the visual analog scale. Data were analyzed with descriptive statistics as well as Kruskal-Wallis, Wilcoxon, and post hoc tests. FINDINGS During the phlebotomy, children in the control group experienced more pain than children in the distraction cards group and kaleidoscope group (P < .001). There was no significant difference between pain scores of the two intervention groups (P > .05). Both methods were found to be effective in reducing pain. CONCLUSIONS It may be helpful to inform children and parents about the process before procedural interventions. Nurses would likely benefit from education on the use of distraction cards and kaleidoscope to be used during procedural interventions.",2020,"During the phlebotomy, children in the control group experienced more pain than children in the distraction cards group and kaleidoscope group (P < .001).",['children aged 6 to 12'],"['distraction cards and a kaleidoscope', 'Distraction Cards and Kaleidoscope']","['pain scores', 'Pain', 'visual analog scale', 'pain']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0150189', 'cui_str': 'Distraction training'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",,0.0656528,"During the phlebotomy, children in the control group experienced more pain than children in the distraction cards group and kaleidoscope group (P < .001).","[{'ForeName': 'Remziye', 'Initials': 'R', 'LastName': 'Semerci', 'Affiliation': 'Department of Child Health and Disease Nursing, Faculty of Health Sciences, Trakya University, Edirne, Turkey. Electronic address: remziyesemerci@gmail.com.'}, {'ForeName': 'Melahat', 'Initials': 'M', 'LastName': 'Akgün Kostak', 'Affiliation': 'Department of Child Health and Disease Nursing, Faculty of Health Sciences, Trakya University, Edirne, Turkey.'}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2020.02.003'] 30,32354590,Reducing Pain During Emergency Arterial Sampling Using Three Anesthetic Methods: A Randomized Controlled Clinical Trial.,"BACKGROUND Taking a sample of arterial blood is widely reported as a cause of significant pain. OBJECTIVES To compare three anesthetic methods with standard practice (no anesthesia) to establish which was the most effective in reducing pain caused by radial artery puncture in patients requiring an arterial blood gas test in the emergency department (ED). METHODS A randomized controlled trial was conducted to compare the effectiveness between anesthetic cream, cryoanalgesia, and subcutaneous mepivacaine in reducing pain caused by radial artery puncture in ED patients. RESULTS After comparing perceived pain during arterial puncture, the lowest median score was obtained in the mepivacaine group (1 interquartile range 0.6-1.3) and the highest median score in the control group (5 interquartile range 4.0-7.0). When comparing the control group with the three intervention groups, the Kruskal-Wallis test showed that mepivacaine (p = 0.023) and cryoanalgesia (p = 0.012) were associated with significantly lower pain scores. The anesthetic cream (p = 0.861) intervention group did not produce a statistically significant median difference compared with the control group. CONCLUSIONS The results of this study encourage the use of anesthetic methods like cryoanalgesia or mepivacaine for their proven effectiveness in reducing or eliminating pain during arterial puncture.",2020,"The anesthetic cream (p = 0.861) intervention group did not produce a statistically significant median difference compared with the control group. ","['patients requiring an arterial blood gas test in the emergency department (ED', 'ED patients']","['standard practice (no anesthesia', 'anesthetic cream, cryoanalgesia, and subcutaneous mepivacaine', 'mepivacaine']","['pain scores', 'Reducing Pain', 'pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150411', 'cui_str': 'Analysis of arterial blood gases and pH'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0524318', 'cui_str': 'Cryoanalgesia'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0025384', 'cui_str': 'Mepivacaine'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.296661,"The anesthetic cream (p = 0.861) intervention group did not produce a statistically significant median difference compared with the control group. ","[{'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Pagnucci', 'Affiliation': 'Department of Clinical and Experimental Medicine, Universita degli Studi di Pisa Dipartimento di Medicina Clinica e Sperimentale, Pisa, Italy.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Pagliaro', 'Affiliation': 'Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Maccheroni', 'Affiliation': 'Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Sichi', 'Affiliation': 'Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Scateni', 'Affiliation': 'Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Tolotti', 'Affiliation': 'Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland.'}]",The Journal of emergency medicine,['10.1016/j.jemermed.2020.03.027'] 31,32349025,The Effect of Cell Phones on Attention and Learning in Nursing Students.,"The use of cell phones can have a negative effect on nursing students' academic performance. The purpose of this study was to identify the effects that problematic cell phone use and nomophobia have on learning in nursing students. A quasi-experimental study was carried out among nursing students, with a control group (n = 61, 49.2%) and an experimental group (n = 63, 50.8%). The experimental group left their cell phones, in sound or vibration mode, as they normally kept them, on a table located in the corner of the classroom. Both groups showed higher-than-average levels of nomophobia at the beginning of the class. As for problematic cell phone use and attention, it was found that there were statistically significant differences in both cases (U = 1355.500, Z = -2.830, P = .005; U = 1449.000, Z = -2.363, P = .018, respectively), and the experimental group had higher average scores, as well as in those related to knowledge. A relationship has been found between nomophobia and problematic cell phone use. Students who do not have access to their cell phones during class perceive more problematic cell phone usage, in addition to paying closer attention during class. Because of this, it is important to create policies and norms restricting cell phone use during all types of academic training among nursing students.",2020,"As for problematic cell phone use and attention, it was found that there were statistically significant differences in both cases (U = 1355.500, Z = -2.830, P = .005; U = 1449.000, Z = -2.363, P = .018, respectively), and the experimental group had higher average scores, as well as in those related to knowledge.","['nursing students, with a control group (n = 61, 49.2%) and an experimental group (n = 63, 50.8', 'nursing students', 'Nursing Students']",['Cell Phones'],[],"[{'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C1136359', 'cui_str': 'Cellular Phone'}]",[],,0.0135394,"As for problematic cell phone use and attention, it was found that there were statistically significant differences in both cases (U = 1355.500, Z = -2.830, P = .005; U = 1449.000, Z = -2.363, P = .018, respectively), and the experimental group had higher average scores, as well as in those related to knowledge.","[{'ForeName': 'Lorena', 'Initials': 'L', 'LastName': 'Gutiérrez-Puertas', 'Affiliation': 'Author Affiliations: Department of Nursing, Physiotherapy and Medicine, Faculty of Health Sciences (Dr Gutiérrez-Puertas and Ms Gutiérrez-Puertas) and Department of Nursing, Physiotherapy and Medicine, Faculty of Health Sciences, Research Group of Health Sciences CTS-451 (Drs Márquez-Hernández, Granados-Gámez, and Aguilera-Manrique), University of Almeria, Spain.'}, {'ForeName': 'Verónica V', 'Initials': 'VV', 'LastName': 'Márquez-Hernández', 'Affiliation': ''}, {'ForeName': 'Vanesa', 'Initials': 'V', 'LastName': 'Gutiérrez-Puertas', 'Affiliation': ''}, {'ForeName': 'Genoveva', 'Initials': 'G', 'LastName': 'Granados-Gámez', 'Affiliation': ''}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Aguilera-Manrique', 'Affiliation': ''}]","Computers, informatics, nursing : CIN",['10.1097/CIN.0000000000000626'] 32,32355123,Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.,"INTRODUCTION Chronic hepatitis B (CHB) remains a major worldwide public health concern. Besifovir dipivoxil maleate (BSV) is a new promising treatment for CHB. However, long-term efficacy and safety have not yet been evaluated. Therefore, the goal of the study is to determine the antiviral efficacy and safety of BSV treatment over a 144-week duration (BSV-BSV) in comparison with those of a sequential treatment with tenofovir disoproxil fumarate (TDF) followed by a 96-week duration BSV administration (TDF-BSV). METHODS After 48 weeks of a double-blind comparison between BSV and TDF treatments, patients continued the open-label BSV study. We evaluated antiviral efficacy and drug safety up to 144 weeks for BSV-BSV and TDF-BSV groups. The primary endpoint was a virological response (hepatitis B virus DNA < 69 IU/mL). RESULTS Among the 197 patients enrolled, 170 and 158 patients entered the second-year and third-year open-label phase extensional study, respectively, whereas 153 patients completed the 144-week follow-up. The virological response rate over the 144-week period was 87.7% and 92.1% in BSV-BSV and TDF-BSV groups, respectively (P = 0.36). The rates of ALT normalization and HBeAg seroconversion were similar between the groups. No drug-resistant mutations to BSV were noted. Bone mineral density and renal function were well preserved in the BSV-BSV group and were significantly improved after switching therapy in TDF-BSV patients. DISCUSSION This extensional study of a phase 3 trial (NCT01937806) suggests that BSV treatment is efficacious and safe for long-term use in treatment-naïve and TDF-experienced patients with CHB.",2020,"Bone mineral density and renal function were well preserved in the BSV-BSV group and were significantly improved after switching therapy in TDF-BSV patients. ","['Chronic Hepatitis B', '197 patients enrolled, 170 and 158 patients entered the second-year and third-year open-label phase extensional study, respectively, whereas 153 patients completed the 144-week follow-up', 'TDF-BSV patients']","['Besifovir dipivoxil maleate (BSV', 'tenofovir disoproxil fumarate (TDF', 'BSV', 'Besifovir Dipivoxil Maleate 144-Week', 'BSV and TDF']","['rates of ALT normalization and HBeAg seroconversion', 'virological response (hepatitis B virus DNA', 'antiviral efficacy and drug safety', 'Bone mineral density and renal function', 'antiviral efficacy and safety', 'virological response rate']","[{'cui': 'C0524909', 'cui_str': 'Chronic type B viral hepatitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C4080032', 'cui_str': 'besifovir'}, {'cui': 'C0024572', 'cui_str': 'Maleates'}]","[{'cui': 'C4080032', 'cui_str': 'besifovir'}, {'cui': 'C0024572', 'cui_str': 'Maleates'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0019167', 'cui_str': 'Hepatitis B e antigen'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C0369332', 'cui_str': 'Hepatitis B virus DNA'}, {'cui': 'C0003451', 'cui_str': 'Antiviral'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}]",197.0,0.0320824,"Bone mineral density and renal function were well preserved in the BSV-BSV group and were significantly improved after switching therapy in TDF-BSV patients. ","[{'ForeName': 'Hyung Joon', 'Initials': 'HJ', 'LastName': 'Yim', 'Affiliation': 'Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Won', 'Initials': 'W', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea.'}, {'ForeName': 'Sang Hoon', 'Initials': 'SH', 'LastName': 'Ahn', 'Affiliation': 'Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Jin Mo', 'Initials': 'JM', 'LastName': 'Yang', 'Affiliation': 'Department of Internal Medicine, Catholic University Medical College St. Vincent, Suwon, Korea.'}, {'ForeName': 'Jae Young', 'Initials': 'JY', 'LastName': 'Jang', 'Affiliation': 'Department of Internal Medicine, College of Medicine, Soonchunhyang University, Seoul, Korea.'}, {'ForeName': 'Yong Oh', 'Initials': 'YO', 'LastName': 'Kweon', 'Affiliation': 'Department of Internal Medicine, Kyungpook National University College of Medicine, Daegu, Korea.'}, {'ForeName': 'Yong Kyun', 'Initials': 'YK', 'LastName': 'Cho', 'Affiliation': 'Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Yoon Jun', 'Initials': 'YJ', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Gun Young', 'Initials': 'GY', 'LastName': 'Hong', 'Affiliation': 'Department of Internal Medicine, Kwangju Christian Hospital, Gwangju, Korea.'}, {'ForeName': 'Dong Joon', 'Initials': 'DJ', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea.'}, {'ForeName': 'Young Kul', 'Initials': 'YK', 'LastName': 'Jung', 'Affiliation': 'Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Soon Ho', 'Initials': 'SH', 'LastName': 'Um', 'Affiliation': 'Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Joo Hyun', 'Initials': 'JH', 'LastName': 'Sohn', 'Affiliation': 'Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Jin Woo', 'Initials': 'JW', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea.'}, {'ForeName': 'Sung Jae', 'Initials': 'SJ', 'LastName': 'Park', 'Affiliation': 'Department of Internal Medicine, Paik Hospital, Inje University, Busan, Korea.'}, {'ForeName': 'Byung Seok', 'Initials': 'BS', 'LastName': 'Lee', 'Affiliation': 'Department of Gastroenterology and Hepatology, Chungnam National University School of Medicine, Daejeon, Korea.'}, {'ForeName': 'Ju Hyun', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Gacheon University College of Medicine, Incheon, Korea.'}, {'ForeName': 'Hong Soo', 'Initials': 'HS', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea.'}, {'ForeName': 'Seung Kew', 'Initials': 'SK', 'LastName': 'Yoon', 'Affiliation': 'Department of Internal Medicine, Catholic University of Korea, Seoul, Korea.'}, {'ForeName': 'Moon Young', 'Initials': 'MY', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.'}, {'ForeName': 'Kwan Sik', 'Initials': 'KS', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Young Suk', 'Initials': 'YS', 'LastName': 'Lim', 'Affiliation': 'Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.'}, {'ForeName': 'Wan Sik', 'Initials': 'WS', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Chonnam University Medical School, Gwangju, Korea.'}, {'ForeName': 'Kwang-Hyub', 'Initials': 'KH', 'LastName': 'Han', 'Affiliation': 'Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}]",The American journal of gastroenterology,['10.14309/ajg.0000000000000605'] 33,32353246,Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial.,"Rationale: Excessive daytime sleepiness in patients with obstructive sleep apnea is associated with substantial burden of illness. Objectives: To assess treatment effects of solriamfetol, a dopamine/norepinephrine reuptake inhibitor, on daily functioning, health-related quality of life, and work productivity in participants with obstructive sleep apnea and excessive daytime sleepiness as additional outcomes in a 12-week phase 3 trial (www.clinicaltrials.gov identifier NCT02348606). Methods: Participants ( N  = 476) were randomized to solriamfetol 37.5, 75, 150, or 300 mg or to placebo. Outcome measures included the Functional Outcomes of Sleep Questionnaire short version, Work Productivity and Activity Impairment Questionnaire: Specific Health Problem, and 36-item Short Form Health Survey version 2. A mixed-effects model with repeated measures was used for comparisons with placebo. Results: Demographics, baseline disease characteristics, daily functioning, health-related quality of life, and work productivity were similar across groups. At Week 12, increased functioning and decreased impairment were observed with solriamfetol 150 and 300 mg (mean difference from placebo [95% confidence interval]) on the basis of Functional Outcomes of Sleep Questionnaire total score (1.22 [0.57 to 1.88] and 1.47 [0.80 to 2.13], respectively), overall work impairment (-11.67 [-19.66 to -3.69] and -11.75 [-19.93 to -3.57], respectively), activity impairment (-10.42 [-16.37 to -4.47] and -10.51 [-16.59 to -4.43], respectively), physical component summary (2.07 [0.42 to 3.72] and 1.91 [0.22 to 3.59], respectively), and mental component summary (150 mg only, 2.05 [0.14 to 3.96]). Common adverse events were headache, nausea, decreased appetite, and anxiety. Conclusions: Solriamfetol improved measures of functioning, quality of life, and work productivity in participants with obstructive sleep apnea and excessive daytime sleepiness. Safety was consistent with previous studies.Clinical trial registered with www.clinicaltrials.gov (NCT02348606).",2020,"At week 12, increased functioning and decreased impairment were observed with solriamfetol 150 and 300 milligrams (mean difference from placebo [95% confidence interval]): Functional Outcomes of Sleep Questionnaire total score (1.22 [0.57, 1.88]) and (1.47 [0.80, 2.13], respectively), overall work impairment (-11.67 [-19.66, -3.69] and -11.75","['patients with obstructive sleep apnea', 'Participants (N=476', 'participants with obstructive sleep apnea and excessive daytime sleepiness']","['Solriamfetol', 'placebo']","['Functional Outcomes of Sleep Questionnaire short version, Work Productivity and Activity Impairment questionnaire for Specific Health Problem, and 36-Item Short Form Health Survey version 2', 'respectively) activity impairment ', 'functioning, quality of life, and work productivity', 'increased functioning and decreased impairment', 'Quality of Life Measures', 'headache, nausea, decreased appetite, and anxiety', 'overall work impairment', 'Demographics, baseline disease characteristics, daily functioning, health-related quality of life, and work productivity', 'daily functioning, health-related quality of life, and work productivity', 'Functional Outcomes of Sleep Questionnaire total score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C4551761', 'cui_str': 'Excessive daytime sleepiness'}]","[{'cui': 'C4726765', 'cui_str': 'Solriamfetol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0033269', 'cui_str': 'Productivity'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0232462', 'cui_str': 'Decrease in appetite'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",476.0,0.19542,"At week 12, increased functioning and decreased impairment were observed with solriamfetol 150 and 300 milligrams (mean difference from placebo [95% confidence interval]): Functional Outcomes of Sleep Questionnaire total score (1.22 [0.57, 1.88]) and (1.47 [0.80, 2.13], respectively), overall work impairment (-11.67 [-19.66, -3.69] and -11.75","[{'ForeName': 'Terri E', 'Initials': 'TE', 'LastName': 'Weaver', 'Affiliation': 'University of Illinois at Chicago College of Nursing, Chicago, Illinois.'}, {'ForeName': 'Christopher L', 'Initials': 'CL', 'LastName': 'Drake', 'Affiliation': 'Henry Ford Hospital Sleep Disorders and Research Center, Detroit, Michigan.'}, {'ForeName': 'Heike', 'Initials': 'H', 'LastName': 'Benes', 'Affiliation': 'Somni Bene Institut für Medizinische Forschung und Schlafmedizin Schwerin GmbH, Schwerin, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Stern', 'Affiliation': 'Advanced Respiratory and Sleep Medicine, PLLC, Huntersville, North Carolina.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Maynard', 'Affiliation': 'CTI Clinical Research Center, Cincinnati, Ohio.'}, {'ForeName': 'Stephen G', 'Initials': 'SG', 'LastName': 'Thein', 'Affiliation': 'Pacific Research Network, Evolution Research Group, LLC, San Diego, California.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Andry', 'Affiliation': 'Sleep Therapy & Research Center, San Antonio, Texas.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Hudson', 'Affiliation': 'FutureSearch Trials of Neurology LP, Austin, Texas.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Chen', 'Affiliation': 'Jazz Pharmaceuticals, Palo Alto, California.'}, {'ForeName': 'Lawrence P', 'Initials': 'LP', 'LastName': 'Carter', 'Affiliation': 'Jazz Pharmaceuticals, Palo Alto, California.'}, {'ForeName': 'Morgan', 'Initials': 'M', 'LastName': 'Bron', 'Affiliation': 'Jazz Pharmaceuticals, Palo Alto, California.'}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Lee', 'Affiliation': 'Jazz Pharmaceuticals, Palo Alto, California.'}, {'ForeName': 'Jed', 'Initials': 'J', 'LastName': 'Black', 'Affiliation': 'Jazz Pharmaceuticals, Palo Alto, California.'}, {'ForeName': 'Richard K', 'Initials': 'RK', 'LastName': 'Bogan', 'Affiliation': 'SleepMed, Inc., Columbia, South Carolina; and.'}]",Annals of the American Thoracic Society,['10.1513/AnnalsATS.202002-136OC'] 34,32242978,Incentive spirometry to prevent acute chest syndrome in adults with sickle cell disease; a randomized controlled trial.,,2020,,['adults with sickle cell disease'],['Incentive spirometry'],[],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0002895', 'cui_str': 'Sickling disorder due to hemoglobin S'}]","[{'cui': 'C0454512', 'cui_str': 'Incentive spirometry'}]",[],,0.151465,,"[{'ForeName': 'Charlotte F J', 'Initials': 'CFJ', 'LastName': 'van Tuijn', 'Affiliation': 'Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.'}, {'ForeName': 'Aafke E', 'Initials': 'AE', 'LastName': 'Gaartman', 'Affiliation': 'Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.'}, {'ForeName': 'Erfan', 'Initials': 'E', 'LastName': 'Nur', 'Affiliation': 'Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.'}, {'ForeName': 'Anita W', 'Initials': 'AW', 'LastName': 'Rijneveld', 'Affiliation': 'Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Bart J', 'Initials': 'BJ', 'LastName': 'Biemond', 'Affiliation': 'Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.'}]",American journal of hematology,['10.1002/ajh.25805'] 35,32356581,Diabetic retinopathy progression 6 months post-cataract surgery with intravitreous bevacizumab vs triamcinolone: A secondary analysis of the DiMECAT trial.,"IMPORTANCE Diabetic retinopathy (DR) may progress following cataract surgery due to surgery-induced inflammation. The effect of intravitreal bevacizumab (BVB) and triamcinolone acetonide (TCA), which have differing anti-inflammatory properties, on DR progression following cataract surgery has not been reported. BACKGROUND To report the progression of DR in diabetic patients undergoing cataract extraction treated with intravitreal BVB or TCA during the surgery. DESIGN Post hoc analysis of 6-month data from a prospective, randomized, double-masked clinical trial. PARTICIPANTS Diabetic patients with clinically significant cataract and fovea involving diabetic macular oedema (DME), or a recent history of DME. METHODS Participants were randomly allocated 1:1 to receive intravitreal BVB 1.25 mg or TCA 4 mg during and post-cataract surgery as needed. The rate of DR progression between groups was compared. MAIN OUTCOME MEASURES DR progression. RESULTS There were 61 eyes included. Patients receiving BVB were older than those receiving TCA (70.2 vs 64.3 years; P < .05). Three participants (10.7%) in the BVB and three (9.09%) in the TCA group had a one-step progression, while none in BVB and only one (3%) in the TCA group demonstrated two-step DR progression. In the majority of these patients, DR progression was from mild to moderate non-proliferative diabetic retinopathy. CONCLUSION AND RELEVANCE In this study, BVB and TCA groups had a similar, and lower rate of DR progression compared to previous studies where no adjunctive treatment was administered, suggesting that patients with DME may benefit from either intraoperative intravitreous BVB or TCA injection to reduce the risk of DR progression following cataract surgery.",2020,Patients receiving BVB were older than those receiving TCA (70.2 vs 64.3 years; P < 0.05).,"['Participants', ' Diabetic patients with clinically significant cataract and fovea involving diabetic macular oedema (DME), or a recent history of DME', 'diabetic patients undergoing cataract extraction treated with', 'Diabetic retinopathy (DR']","['intravitreal bevacizumab (BVB', 'TCA injection', 'TCA', 'intravitreal BVB or TCA', 'intravitreous bevacizumab vs triamc1inolone', 'intravitreal BVB 1.25 mg or TCA', 'triamcinolone acetonide (TCA']","['Diabetic retinopathy progression', '2-step DR progression', 'risk of DR progression', 'rate of DR progression', 'DR progression']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C0016622', 'cui_str': 'Structure of fovea centralis'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0730285', 'cui_str': 'Macular edema due to diabetes mellitus'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0011884', 'cui_str': 'Retinopathy due to diabetes mellitus'}]","[{'cui': 'C1517572', 'cui_str': 'Intravitreal route'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0040866', 'cui_str': 'Triamcinolone acetonide'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C4517497', 'cui_str': '1.25'}]","[{'cui': 'C0011884', 'cui_str': 'Retinopathy due to diabetes mellitus'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",61.0,0.0698005,Patients receiving BVB were older than those receiving TCA (70.2 vs 64.3 years; P < 0.05).,"[{'ForeName': 'Muhammad B', 'Initials': 'MB', 'LastName': 'Sasongko', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Rogers', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Marios', 'Initials': 'M', 'LastName': 'Constantinou', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Sukhpal S', 'Initials': 'SS', 'LastName': 'Sandhu', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Sanjeewa S', 'Initials': 'SS', 'LastName': 'Wickremasinghe', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Salmaan', 'Initials': 'S', 'LastName': 'Al-Qureshi', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Lyndell L', 'Initials': 'LL', 'LastName': 'Lim', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.'}]",Clinical & experimental ophthalmology,['10.1111/ceo.13771'] 36,32361414,Neural correlates of NOS1 ex1f-VNTR allelic variation in panic disorder and agoraphobia during fear conditioning and extinction in fMRI.,"Neuronal nitric oxide synthase (NOS-I) impacts on fear/anxiety-like behavior in animals. In humans, the short (S) allele of a functional promotor polymorphism of NOS1 (NOS1 ex1f-VNTR) has been shown to be associated with higher anxiety and altered fear conditioning in healthy subjects in the amygdala and hippocampus (AMY/HIPP). Here, we explore the role of NOS1 ex1f-VNTR as a pathophysiological correlate of panic disorder and agoraphobia (PD/AG). In a sub-sample of a multicenter cognitive behavioral therapy (CBT) randomized controlled trial in patients with PD/AG (n = 48: S/S-genotype n=15, S/L-genotype n=21, L/L-genotype n=12) and healthy control subjects, HS (n = 34: S/S-genotype n=7, S/L-genotype n=17, L/L-genotype=10), a differential fear conditioning and extinction fMRI-paradigm was used to investigate how NOS1 ex1f-VNTR genotypes are associated with differential neural activation in AMY/HIPP. Prior to CBT, L/L-allele carriers showed higher activation than S/S-allele carriers in AMY/HIPP. A genotype × diagnosis interaction revealed that the S-allele in HS was associated with a pronounced deactivation in AMY/HIPP, while patients showed contrary effects. The interaction of genotype × stimulus type (CS+, conditioned stimulus associated with an aversive stimulus vs. CS-, unassociated) showed effects on differential learning in AMY/HIPP. All effects were predominately found during extinction. Genotype associated effects in patients were not altered after CBT. Low statistical power due to small sample size in each subgroup is a major limitation. However, our findings provide first preliminary evidence for dysfunctional neural fear conditioning/extinction associated with NOS1 ex1f-VNTR genotype in the context of PD/AG, shedding new light on the complex interaction between genetic risk, current psychopathology and treatment-related effects.",2020,Genotype associated effects in patients were not altered after CBT.,"['n\xa0=\xa048', 'healthy subjects', 'animals', 'patients with PD/AG', 'panic disorder and agoraphobia during fear conditioning and extinction in fMRI']",['cognitive behavioral therapy (CBT'],['Neuronal nitric oxide synthase (NOS-I) impacts on fear/anxiety-like behavior'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0003062', 'cui_str': 'Kingdom Animalia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030319', 'cui_str': 'Panic disorder'}, {'cui': 'C0001818', 'cui_str': 'Agoraphobia'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0015347', 'cui_str': 'Psychological Extinction'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0669368', 'cui_str': 'Nitric Oxide Synthase, Type I'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",,0.0249077,Genotype associated effects in patients were not altered after CBT.,"[{'ForeName': 'Isabelle C', 'Initials': 'IC', 'LastName': 'Ridderbusch', 'Affiliation': 'Department of Psychiatry and Psychotherapy & Center for Mind, Brain and Behavior - CMBB, Philipps-Universität Marburg, Marburg, Germany. Electronic address: isabelle.ridderbusch@med.uni-marburg.de.'}, {'ForeName': 'Yunbo', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Psychiatry and Psychotherapy & Center for Mind, Brain and Behavior - CMBB, Philipps-Universität Marburg, Marburg, Germany.'}, {'ForeName': 'Heike', 'Initials': 'H', 'LastName': 'Weber', 'Affiliation': 'Department of Psychiatry, Psychosomatics, and Psychotherapy, University Hospital of Würzburg, Würzburg, Germany; Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Reif', 'Affiliation': 'Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Herterich', 'Affiliation': 'Clinical Chemistry and Laboratory Medicine, University Hospital Würzburg, Würzburg, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Ströhle', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Pfleiderer', 'Affiliation': 'Medical Faculty, University of Münster and Department Clinical Radiology, University Hospital Münster, Münster, Germany.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Arolt', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital Münster, Münster, Germany.'}, {'ForeName': 'Hans-Ulrich', 'Initials': 'HU', 'LastName': 'Wittchen', 'Affiliation': 'Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, Germany; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität (LMU), München, Germany.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Lueken', 'Affiliation': 'Department of Psychology, Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Tilo', 'Initials': 'T', 'LastName': 'Kircher', 'Affiliation': 'Department of Psychiatry and Psychotherapy & Center for Mind, Brain and Behavior - CMBB, Philipps-Universität Marburg, Marburg, Germany.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Straube', 'Affiliation': 'Department of Psychiatry and Psychotherapy & Center for Mind, Brain and Behavior - CMBB, Philipps-Universität Marburg, Marburg, Germany.'}]",NeuroImage. Clinical,['10.1016/j.nicl.2020.102268'] 37,32368935,A Randomized Controlled Trial of Bone-Patellar Tendon-Bone Anterior Cruciate Ligament Reconstruction With and Without Lateral Extra-articular Tenodesis: 19-Year Clinical and Radiological Follow-up.,"BACKGROUND Arthroscopic anterior cruciate ligament (ACL) reconstruction (ACLR) with a bone-patellar tendon-bone graft (BTB) is a reliable surgical option for the control of anterior knee laxity after ACL injury. The addition of a lateral extra-articular tenodesis (LET) may improve control of rotation knee laxity and improve short-term graft survival in high-risk patients. PURPOSE The aims of this study were to compare long-term patient-reported outcomes, graft survival, and risk of osteoarthritis between ACLR with and without LET. STUDY DESIGN Randomized controlled trial; Level of evidence, 2. METHODS This study included 121 consecutive knees (120 patients) presenting to a single center with an ACL rupture between 1998 and 1999. In total, 61 knees were randomized to an isolated BTB ACLR, and 60 knees were randomized to a BTB ACLR with an extra-articular lateral tenodesis with gracilis tendon (modified Lemaire). RESULTS Eighty knees in 79 patients (66%) were available for follow-up at a postoperative mean of 19.4 years (range, 19-20.2). Of those patients, 43 had a clinical examination and completed patient-reported outcome questionnaires, and the other 37 patients were evaluated through the questionnaires alone. Standard radiographs were available for 45 patients and laximetry (TELOS) for 42 patients. Mean subjective International Knee Documentation Committee score at last follow-up was 81.8, and no differences were noted between the BTB and BTB-LET groups ( P = .7). Two-thirds of patients were still participating in pivoting sports. A total of 17 knees (21%) experienced a graft failure, 5 of which (6%) underwent revision ACLR. There was no significant difference in graft failure risk between the BTB group (29%) and the BTB-LET group (13%; P = .1). Lateral tibiofemoral osteoarthritis was significantly more frequent in the BTB-LET group (59%) as compared with the BTB group (22%; P = .02). Lateral compartment osteoarthritis was correlated with partial lateral meniscectomy. CONCLUSION There were no significant differences in long-term patient-reported outcomes after ACLR with or without an LET. LET may increase the risk of lateral compartment osteoarthritis at long-term follow-up. There was a trend toward decreased graft failure risk with the addition of LET but this study was underpowered to assess this outcome.",2020,Lateral tibiofemoral osteoarthritis was significantly more frequent in the BTB-LET group (59%) as compared with the BTB group (22%; P = .02).,"['61 knees were randomized to an isolated BTB ACLR, and 60 knees', 'high-risk patients', '45 patients and laximetry (TELOS) for 42 patients', '121 consecutive knees (120 patients) presenting to a single center with an ACL rupture between 1998 and 1999', 'Eighty knees in 79 patients (66%) were available for follow-up at a postoperative mean of 19.4 years (range, 19-20.2']","['Bone-Patellar Tendon-Bone Anterior Cruciate Ligament Reconstruction With and Without Lateral Extra-articular Tenodesis', 'LET', 'BTB ACLR with an extra-articular lateral tenodesis with gracilis tendon (modified Lemaire', 'Arthroscopic anterior cruciate ligament (ACL) reconstruction (ACLR) with a bone-patellar tendon-bone graft (BTB', 'lateral extra-articular tenodesis (LET']","['graft failure risk', 'Mean subjective International Knee Documentation Committee score', 'Lateral compartment osteoarthritis', 'graft survival, and risk of osteoarthritis', 'risk of lateral compartment osteoarthritis', 'Lateral tibiofemoral osteoarthritis', 'rotation knee laxity and improve short-term graft survival', 'graft failure']","[{'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C3658331', 'cui_str': 'Bone-Patellar Tendon-Bone Grafts'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0409312', 'cui_str': 'Rupture of anterior cruciate ligament'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4709305', 'cui_str': '19.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C4517642', 'cui_str': '20.2'}]","[{'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0206332', 'cui_str': 'Structure of patellar ligament'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0205135', 'cui_str': 'Extra-articular'}, {'cui': 'C0185441', 'cui_str': 'Fixation of tendon'}, {'cui': 'C3658331', 'cui_str': 'Bone-Patellar Tendon-Bone Grafts'}, {'cui': 'C0448621', 'cui_str': 'Tendon of gracilis'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0078960', 'cui_str': 'Structure of anterior cruciate ligament of knee joint'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}]","[{'cui': 'C1262018', 'cui_str': 'Transplant failure'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0175636', 'cui_str': 'Documentation procedure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0018131', 'cui_str': 'Graft Survival'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0332536', 'cui_str': 'Laxity'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]",61.0,0.143888,Lateral tibiofemoral osteoarthritis was significantly more frequent in the BTB-LET group (59%) as compared with the BTB group (22%; P = .02).,"[{'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Castoldi', 'Affiliation': 'Institut Universitaire Locomoteur et du Sport, Department of Orthopaedic Surgery, Centre Hospitalo-Universitaire de Nice, Nice, France.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Magnussen', 'Affiliation': 'Department of Orthopaedics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.'}, {'ForeName': 'Stanislas', 'Initials': 'S', 'LastName': 'Gunst', 'Affiliation': 'Department of Orthopedic Surgery and Sport Medicine, Croix-Rousse Hospital, FIFA Medical Center of Excellence, Lyon, France.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Batailler', 'Affiliation': 'Department of Orthopedic Surgery and Sport Medicine, Croix-Rousse Hospital, FIFA Medical Center of Excellence, Lyon, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Neyret', 'Affiliation': 'Infirmerie Protestante, Caluire, France.'}, {'ForeName': 'Sébastien', 'Initials': 'S', 'LastName': 'Lustig', 'Affiliation': 'Department of Orthopedic Surgery and Sport Medicine, Croix-Rousse Hospital, FIFA Medical Center of Excellence, Lyon, France.'}, {'ForeName': 'Elvire', 'Initials': 'E', 'LastName': 'Servien', 'Affiliation': 'Department of Orthopedic Surgery and Sport Medicine, Croix-Rousse Hospital, FIFA Medical Center of Excellence, Lyon, France.'}]",The American journal of sports medicine,['10.1177/0363546520914936'] 38,32359104,Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.,"AIM The safety and efficacy of nalmefene in Japanese patients with high or very high World Health Organization drinking risk level of alcohol dependence were assessed in a multicenter, randomized, double-blind, placebo-controlled, phase 3 (lead-in) study. Here, the long-term safety and efficacy of nalmefene in an open-label extension of the lead-in study are presented. METHODS Patients who completed the 24-week lead-in study were eligible for the extension study, where they were treated with nalmefene 20 mg as needed for 24 weeks. The long-term safety and efficacy of nalmefene 20 mg during the total 48-week period were evaluated. Treatment-emergent adverse events during the study period were recorded and change from baseline in the number of heavy drinking days and total alcohol consumption were calculated. RESULTS Overall, long-term nalmefene 20 mg was well tolerated; the main treatment-emergent adverse events reported in ≥5% of patients included nasopharyngitis (37.2%), nausea (36.5%), somnolence (21.2%), dizziness (16.8%), malaise (14.6%), and vomiting (12.4%). The number of heavy drinking days and total alcohol consumption decreased from baseline to 48 weeks (mixed model for repeated measures, least squares mean ± standard error, -15.09 ± 0.77 days/month and -53.20 ± 2.29 g/day, respectively) during the study. CONCLUSION This long-term evaluation in Japanese patients with high or very high drinking risk levels of alcohol dependence indicated that nalmefene was safe, well tolerated, and efficacious.",2020,"The number of heavy drinking days and total alcohol consumption decreased from baseline to 48 weeks (mixed model for repeated measures, least squares mean ± standard error, -15.09 ± 0.77 days/month and -53.20 ± 2.29 g/day, respectively) during the study. ","['Japanese patients with alcohol dependence', 'Patients who completed the 24-week lead-in study were eligible for the extension study, where they were treated with nalmefene 20 mg as needed for 24\u2009weeks', 'Japanese patients with high or very high World Health Organization drinking risk level of alcohol dependence', 'Japanese patients with a high or very high drinking risk levels of alcohol dependence']","['nalmefene', 'placebo']","['dizziness', 'tolerated', 'number of heavy drinking days and total alcohol consumption', 'malaise', 'vomiting', 'safety and efficacy', 'somnolence', 'nasopharyngitis', 'nausea']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001973', 'cui_str': 'Alcohol dependence'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C1720688', 'cui_str': 'As needed for'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0442804', 'cui_str': 'Very high'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}]","[{'cui': 'C0068377', 'cui_str': 'nalmefene'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0556347', 'cui_str': 'Drinking day'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0231218', 'cui_str': 'Malaise'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",,0.235028,"The number of heavy drinking days and total alcohol consumption decreased from baseline to 48 weeks (mixed model for repeated measures, least squares mean ± standard error, -15.09 ± 0.77 days/month and -53.20 ± 2.29 g/day, respectively) during the study. ","[{'ForeName': 'Susumu', 'Initials': 'S', 'LastName': 'Higuchi', 'Affiliation': 'National Hospital Organization, Kurihama Medical and Addiction Center, Yokosuka, Japan.'}, {'ForeName': 'Masayoshi', 'Initials': 'M', 'LastName': 'Takahashi', 'Affiliation': 'Department of Clinical Management, Clinical Development Headquarters, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Yoshiyuki', 'Initials': 'Y', 'LastName': 'Murai', 'Affiliation': 'Department of Clinical Management, Clinical Development Headquarters, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Kana', 'Initials': 'K', 'LastName': 'Tsuneyoshi', 'Affiliation': 'Department of Biometrics, Clinical Development Headquarters, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan.'}, {'ForeName': 'Izuru', 'Initials': 'I', 'LastName': 'Nakamura', 'Affiliation': 'Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Didier', 'Initials': 'D', 'LastName': 'Meulien', 'Affiliation': 'Clinical Research and Development, H. Lundbeck A/S, Valby, Denmark.'}, {'ForeName': 'Hisatsugu', 'Initials': 'H', 'LastName': 'Miyata', 'Affiliation': 'Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan.'}]",Psychiatry and clinical neurosciences,['10.1111/pcn.13017'] 39,32367737,Exploring factors influencing recruitment results of nurses recruiting diabetes patients for a randomized controlled trial.,"BACKGROUND Effective recruitment of patients by health professionals is challenging but pivotal to the success of clinical trials. Many trials fail to include the required number of participants, which affects the power of the study, generalizability of results, and timely dissemination of positive outcomes. Existing research is inconclusive regarding factors influencing recruitment results, and most research does not focus on perceptions of recruiting health professionals themselves. Therefore, thorough evaluations of recruitment facilitators and barriers in trials are needed in order to optimize future patient recruitment in trials. We observed divergent recruitment results among nurses who recruited diabetes patients to our trial, which examined the effectiveness of an eHealth programme. Therefore, we aimed to describe nurses' recruitment results and related shifts over time, and to qualitatively explore factors influencing nurses' recruitment results. METHODS Nurses' recruitment results and related temporal shifts were derived from trial data (NTR6840). Based on their recruitment results, nurses were categorized as non-, low-, medium-, or high-recruiters. Subsequently, a subset of nurses per group participated in an individual semi-structured telephone interview. Interviews were analysed using NVivo software, applying an inductive coding approach. RESULTS Ninety-six nurses participated in our trial and recruited on average seven patients (range: 0-32). Fifteen nurses did not recruit any patients. Most patients were recruited close to recruitment onset. Nurses who did not recruit patients close to recruitment onset generally ended up recruiting no patients. Data show a relatively high number of early recruited patients that progressively declined over time. High-recruiters were generally successful throughout the entire recruitment period. Recruitment facilitators and barriers comprised organizational, study, patient, and especially recruiter characteristics. Contrary to non- and low-recruiters, medium- and high-recruiters reported more in-depth knowledge about the study and trial requirements, expressed more personal participation-related benefits and fewer barriers, and incorporated more recruitment activities, reminders, and barrier-focused coping strategies. CONCLUSION AND IMPLICATIONS To optimize patient recruitment to clinical trials, suggested intervention targets include the continued inclusion of recruiters after initial recruitment onset and the encouragement of early recruitment success. A personalized approach may aid recruiters to become and remain successful. Primarily, it is important to provide recruiters with sufficient information on trial requirements and to address salient benefits for participation in the trial, both for themselves and for their patients. Finally, teaching recruiters skills on how to overcome barriers may further enhance motivation and recruitment capacities.",2020,"Contrary to non- and low-recruiters, medium- and high-recruiters reported more in-depth knowledge about the study and trial requirements, expressed more personal participation-related benefits and fewer barriers, and incorporated more recruitment activities, reminders, and barrier-focused coping strategies. ","['nurses recruiting diabetes patients', 'nurses who recruited diabetes patients', 'patients by health professionals', 'Ninety-six nurses participated in our trial and recruited on average seven patients (range: 0-32']",[],[],"[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C4319625', 'cui_str': '96'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]",[],[],96.0,0.133276,"Contrary to non- and low-recruiters, medium- and high-recruiters reported more in-depth knowledge about the study and trial requirements, expressed more personal participation-related benefits and fewer barriers, and incorporated more recruitment activities, reminders, and barrier-focused coping strategies. ","[{'ForeName': 'Stan', 'Initials': 'S', 'LastName': 'Vluggen', 'Affiliation': 'Department of Health Promotion, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Ciska', 'Initials': 'C', 'LastName': 'Hoving', 'Affiliation': 'Department of Health Promotion, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Lieve', 'Initials': 'L', 'LastName': 'Vonken', 'Affiliation': 'Department of Health Promotion, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Nicolaas C', 'Initials': 'NC', 'LastName': 'Schaper', 'Affiliation': 'Department of Endocrinology and Internal Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands.'}, {'ForeName': 'Hein', 'Initials': 'H', 'LastName': 'de Vries', 'Affiliation': 'Department of Health Promotion, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.'}]","Clinical trials (London, England)",['10.1177/1740774520914609'] 40,32361265,Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma.,"BACKGROUND Necuparanib, a rationally engineered low-molecular-weight heparin, combined with gemcitabine/nab-paclitaxel showed an encouraging safety and oncologic signal in a phase Ib trial. This randomised multicentre phase II trial evaluates the addition of necuparanib or placebo to gemcitabine/nab-paclitaxel in untreated metastatic pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS Eligibility included 18 years, histologically or cytologically confirmed metastatic PDAC, measurable disease and Eastern Co-Operative Oncology Group performance status of 0-1. Patients were randomly assigned to necuparanib (5 mg/kg subcutaneous injection once daily) or placebo (subcutaneous injection once daily) and gemcitabine/nab-paclitaxel on days 1, 8 and 15 of 28-day cycles. The primary end-point was median overall survival (OS), and secondary end-points included median progression-free survival, response rates and safety. RESULTS One-hundred ten patients were randomised, 62 to necuparanib arm and 58 to placebo arm. The futility boundary was crossed at a planned interim analysis, and the study was terminated by the Data Safety Monitoring Board. The median OS was 10.71 months (95% confidence interval [CI]: 7.95-11.96) for necuparanib arm and 9.99 months (95% CI: 7.85-12.85) for placebo arm (hazard ratio: 1.12, 95% CI: 0.66-1.89, P-value: 0.671). The necuparanib arm had a higher incidence of haematologic toxicity relative to placebo patients (83% and 70%). CONCLUSION The addition of necuparanib to standard of care treatment for advanced PDAC did not improve OS. Safety was acceptable. No further development of necuparanib is planned although targeting the coagulation cascade pathway remains relevant in PDAC. NCT01621243.",2020,"The necuparanib arm had a higher incidence of haematologic toxicity relative to placebo patients (83% and 70%). ","['One-hundred ten patients were randomised, 62 to necuparanib arm and 58 to', 'untreated metastatic pancreatic ductal adenocarcinoma (PDAC', 'Eligibility included 18 years, histologically or cytologically confirmed metastatic PDAC, measurable disease and Eastern Co-Operative Oncology Group performance status of 0-1', 'untreated metastatic pancreas ductal adenocarcinoma']","['gemcitabine/nab-paclitaxel', 'gemcitabine and nab-paclitaxel with necuparanib or placebo', 'necuparanib (5\xa0mg/kg subcutaneous injection once daily) or placebo (subcutaneous injection once daily) and gemcitabine/nab-paclitaxel', 'necuparanib or placebo to gemcitabine/nab-paclitaxel', 'placebo']","['median OS', 'haematologic toxicity', 'median overall survival (OS), and secondary end-points included median progression-free survival, response rates and safety', 'safety and oncologic signal']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C1335302', 'cui_str': 'Ductal adenocarcinoma of pancreas'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0771711', 'cui_str': 'Pancreas extract'}, {'cui': 'C0001418', 'cui_str': 'Adenocarcinoma'}]","[{'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0021499', 'cui_str': 'Subcutaneous injection'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205488', 'cui_str': 'Hematologic'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205478', 'cui_str': 'Oncologic'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}]",110.0,0.686627,"The necuparanib arm had a higher incidence of haematologic toxicity relative to placebo patients (83% and 70%). ","[{'ForeName': 'Eileen M', 'Initials': 'EM', 'LastName': ""O'Reilly"", 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: oreillye@mskcc.org.'}, {'ForeName': 'Diletta', 'Initials': 'D', 'LastName': 'Barone', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.'}, {'ForeName': 'Devalingam', 'Initials': 'D', 'LastName': 'Mahalingam', 'Affiliation': 'Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA.'}, {'ForeName': 'Tanios', 'Initials': 'T', 'LastName': 'Bekaii-Saab', 'Affiliation': 'Mayo Clinic Cancer Center, Scottsdale, AZ, USA; ACCRU Research Consortium, Rochester, MN, USA.'}, {'ForeName': 'Spencer H', 'Initials': 'SH', 'LastName': 'Shao', 'Affiliation': 'Compass Oncology, Rose Quarter Cancer Center, Portland, OR, USA.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Wolf', 'Affiliation': 'Momenta Pharmaceuticals, Inc., 301 Binney Street, Cambridge, MA 02142, USA.'}, {'ForeName': 'Molly', 'Initials': 'M', 'LastName': 'Rosano', 'Affiliation': 'Momenta Pharmaceuticals, Inc., 301 Binney Street, Cambridge, MA 02142, USA.'}, {'ForeName': 'Silva', 'Initials': 'S', 'LastName': 'Krause', 'Affiliation': 'Momenta Pharmaceuticals, Inc., 301 Binney Street, Cambridge, MA 02142, USA.'}, {'ForeName': 'Donald A', 'Initials': 'DA', 'LastName': 'Richards', 'Affiliation': 'Texas Oncology, US Oncology Research, 910 East Houston Street, Tyler, TX 71702, USA.'}, {'ForeName': 'Kenneth H', 'Initials': 'KH', 'LastName': 'Yu', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Roach', 'Affiliation': 'Momenta Pharmaceuticals, Inc., 301 Binney Street, Cambridge, MA 02142, USA.'}, {'ForeName': 'Keith T', 'Initials': 'KT', 'LastName': 'Flaherty', 'Affiliation': 'Massachussetts General Hospital, 55 Fruit Street, Boston, MA 02114-2696, USA.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Ryan', 'Affiliation': 'Massachussetts General Hospital, 55 Fruit Street, Boston, MA 02114-2696, USA.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2020.03.005'] 41,32360105,Innovative Devices Did Not Provide Superior Total Knee Arthroplasty Outcomes in Post-Operative Rehabilitation: Results From a Four-Arm Randomized Clinical Trial.,"BACKGROUND Orthopedic surgeons face an increasing array of post-TKA (total knee arthroplasty) rehabilitation interventions that entail innovative equipment and devices, but their relative effectiveness remains unknown. The study compared patient outcomes among primary unilateral TKA patients participating in one of 4 post-TKA rehabilitation interventions-a standard-of-care intervention and 3 more recently developed physical therapy interventions. METHODS The Knee Arthroplasty Rehabilitation Outcomes Study is a 4-arm randomized clinical trial conducted across 15 outpatient rehabilitation clinics. The trial evaluated 4 alternative interventions: (1) a stationary recumbent bike (control intervention); (2) a body weight-adjustable treadmill; (3) a recumbent bike and use of a patterned electrical neuromuscular stimulation device; and (4) a body weight-adjustable treadmill and a patterned electrical neuromuscular stimulation device. The study's outcome measures were patient walking speed and the Knee injury and Osteoarthritis Outcome Score (KOOS) measured at therapy discharge and at follow-up. RESULTS The study enrolled 363 TKA patients with 90-92 patients in each of the 4 study arms. Participants were similar across the 4 groups: They were about 63 years old, 61% female, 67% white, living at home, overweight (mean body mass index = 31.6), with mostly private insurance (61%) or Medicare (32%). Walking speed was similar at admission and discharge; KOOS scores were similar at admission, discharge, and follow-up across the 4 intervention groups. CONCLUSION The study found no statistical or clinically meaningful differences across the 4 study arms in walking speed or KOOS outcomes. Clinicians, payers, and policy makers will want to encourage providers and patients to use the least expensive intervention since each provide similar outcomes. TRIAL REGISTRATION NCT02426190; https://clinicaltrials.gov/ct2/show/NCT02426190?term=NCT02426190&cntry=US&rank=1.",2020,"Walking speed was similar at admission and discharge; KOOS scores were similar at admission, discharge, and follow-up across the 4 intervention groups. ","['15 outpatient rehabilitation clinics', 'Participants were similar across the 4 groups: They were about 63 years old, 61% female, 67% white, living at home, overweight (mean body mass index\xa0= 31.6), with mostly private insurance (61%) or Medicare (32', '363 TKA patients with 90-92 patients in each of the 4 study arms', 'primary unilateral TKA patients participating in one of 4 post-TKA rehabilitation interventions-a standard-of-care intervention and 3 more recently developed physical therapy interventions', 'Post-Operative Rehabilitation']",['stationary recumbent bike (control intervention); (2) a body weight-adjustable treadmill; (3) a recumbent bike and use of a patterned electrical neuromuscular stimulation device; and (4) a body weight-adjustable treadmill and a patterned electrical neuromuscular stimulation device'],"['Walking speed', 'walking speed or KOOS outcomes', 'patient walking speed and the Knee injury and Osteoarthritis Outcome Score (KOOS']","[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C3839785', 'cui_str': 'Rehabilitation clinic'}, {'cui': 'C0441876', 'cui_str': 'Group 4'}, {'cui': 'C3874886', 'cui_str': 'Is about'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0021672', 'cui_str': 'Insurance'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]","[{'cui': 'C0439835', 'cui_str': 'Stationary'}, {'cui': 'C0444334', 'cui_str': 'Recumbent body position'}, {'cui': 'C0005375', 'cui_str': 'Bicycle'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0454448', 'cui_str': 'Neuromuscular stimulation'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C3476088', 'cui_str': 'Knee Injury and Osteoarthritis Outcome Score'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",363.0,0.108023,"Walking speed was similar at admission and discharge; KOOS scores were similar at admission, discharge, and follow-up across the 4 intervention groups. ","[{'ForeName': 'Gerben', 'Initials': 'G', 'LastName': 'DeJong', 'Affiliation': 'Research Division, MedStar National Rehabilitation Hospital, Washington, DC; Department of Rehabilitation Medicine, Georgetown University School of Medicine, Washington, DC.'}, {'ForeName': 'Chinghui Jean', 'Initials': 'CJ', 'LastName': 'Hsieh', 'Affiliation': 'Research Division, MedStar National Rehabilitation Hospital, Washington, DC; MedStar Health Research Institute, Hyattsville, MD.'}, {'ForeName': 'Michele T', 'Initials': 'MT', 'LastName': 'Vita', 'Affiliation': 'MedStar Health Physical Therapy, Washington, DC.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Zeymo', 'Affiliation': 'MedStar Health Research Institute, Hyattsville, MD; Department of Biostatistics and Biomedical Informatics, MedStar Health Research Institute, Hyattsville, MD.'}, {'ForeName': 'Henry R', 'Initials': 'HR', 'LastName': 'Boucher', 'Affiliation': 'Department of Orthopedic Surgery, MedStar Union Memorial Hospital, Baltimore, MD.'}, {'ForeName': 'Savyasachi C', 'Initials': 'SC', 'LastName': 'Thakkar', 'Affiliation': 'MedStar Orthopaedic Institute at MedStar Georgetown University Hospital and MedStar Washington Hospital Center, Washington, DC.'}]",The Journal of arthroplasty,['10.1016/j.arth.2020.03.048'] 42,32366577,The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes.,"OBJECTIVE To examine whether low baseline diastolic blood pressure (DBP) modifies the effects of intensive systolic blood pressure (SBP) lowering on cardiovascular outcomes in type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS The Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial (ACCORD BP), a two-by-two factorial randomized controlled trial, examined effects of SBP (<120 vs. <140 mmHg) and glycemic (HbA 1c <6% vs. 7.0-7.9% [<42 vs. 53-63 mmol/mol]) control on cardiovascular events in T2DM ( N = 4,731). We examined whether effects of SBP control on cardiovascular composite were modified by baseline DBP and glycemic control. RESULTS Intensive SBP lowering decreased the risk of the cardiovascular composite (hazard ratio [HR] 0.76 [95% CI 0.59-0.98]) in the standard glycemic arm but not in the intensive glycemic arm (HR 1.06 [95% CI 0.81-1.40]). Spline regression models relating the effects of the intervention on the cardiovascular composite across the range of baseline DBP did not show evidence of effect modification by low baseline DBP for the cardiovascular composite in the standard or intensive glycemic arms. The relation between the effect of the intensive SBP intervention and baseline DBP was similar between glycemic arms for the cardiovascular composite three-way interaction ( P = 0.83). CONCLUSIONS In persons with T2DM, intensive SBP lowering decreased the risk of cardiovascular composite end point irrespective of baseline DBP in the setting of standard glycemic control. Hence, low baseline DBP should not be an impediment to intensive SBP lowering in patients with T2DM treated with guideline-recommended standard glycemic control.",2020,"The relation between the effect of the intensive SBP intervention and baseline DBP was similar between glycemic arms for the cardiovascular composite three-way interaction ( P = 0.83). ","['Type 2 Diabetes', 'type 2 diabetes mellitus (T2DM']","['low baseline diastolic blood pressure (DBP', 'Intensive Blood Pressure Lowering', 'intensive SBP intervention', 'intensive systolic blood pressure (SBP) lowering', 'SBP control', 'SBP']","['cardiovascular events', 'risk of the cardiovascular composite (hazard ratio [HR', 'risk of cardiovascular composite', 'cardiovascular outcomes']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C4274392', 'cui_str': 'Baseline diastolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0567952,"The relation between the effect of the intensive SBP intervention and baseline DBP was similar between glycemic arms for the cardiovascular composite three-way interaction ( P = 0.83). ","[{'ForeName': 'Olesya L', 'Initials': 'OL', 'LastName': 'Ilkun', 'Affiliation': 'Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Greene', 'Affiliation': 'Division of Biostatistics, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'Alfred K', 'Initials': 'AK', 'LastName': 'Cheung', 'Affiliation': 'Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'Paul K', 'Initials': 'PK', 'LastName': 'Whelton', 'Affiliation': 'Tulane University School of Public Health and Tropical Medicine, New Orleans, LA.'}, {'ForeName': 'Guo', 'Initials': 'G', 'LastName': 'Wei', 'Affiliation': 'Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Boucher', 'Affiliation': 'Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Ambrosius', 'Affiliation': 'Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC.'}, {'ForeName': 'Glenn M', 'Initials': 'GM', 'LastName': 'Chertow', 'Affiliation': 'Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA.'}, {'ForeName': 'Srinivasan', 'Initials': 'S', 'LastName': 'Beddhu', 'Affiliation': 'Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, UT srinivasan.beddhu@hsc.utah.edu.'}]",Diabetes care,['10.2337/dc19-2047'] 43,32366761,Comparison of 10- versus 14-gauge angiocatheter for treatment of tension pneumothorax and tension-induced pulseless electrical activity with hemorrhagic shock: Bigger is still better.,"BACKGROUND Little is known regarding the effect of hemorrhagic shock on the diagnosis and treatment of tension pneumothorax (tPTX). Recently, the Tactical Combat Casualty Care guidelines included the 10-gauge angiocatheter (10-g AC) as an acceptable alternative to the 14-g AC. This study sought to compare these two devices for decompression of tPTX and rescue from tension-induced pulseless electric activity (tPEA) in the setting of a concomitant 30% estimated blood volume hemorrhage. METHODS Following a controlled hemorrhage, carbon dioxide was insufflated into the chest to induce either tPTX or tPEA. Tension pneumothorax was defined as a reduction in cardiac output by 50%, and tPEA was defined as a loss of arterial waveform with mean arterial pressure less than 20 mm Hg. The affected hemithorax was decompressed using a randomized 14-g AC or 10-g AC while a persistent air leak was maintained after decompression. Successful rescue from tPTX was defined as 80% recovery of baseline systolic blood pressure, while successful return of spontaneous circulation following tPEA was defined as a mean arterial pressure greater than 20 mm Hg. Primary outcome was success of device. RESULTS Eighty tPTX and 50 tPEA events were conducted in 38 adult Yorkshire swine. There were no significant differences in the baseline characteristics between animals or devices. In the tPTX model, the 10-g AC successfully rescued 90% of events, while 14-g AC rescued 80% of events (p = 0.350). In the tPEA model, the 10-g AC rescued 87% of events while the 14 AC rescued only 48% of events (p = 0.006). CONCLUSION The 10-g AC was vastly superior to the 14-g AC for return of spontaneous circulation following tPEA in the setting of 30% hemorrhage. These findings further support the importance of larger caliber devices that facilitate rapid recovery from tPTX, particularly in the setting of polytrauma. LEVEL OF EVIDENCE Therapeutic, level II.",2020,The 10g AC was vastly superior to the 14g AC for return of spontaneous circulation following tPEA in the setting of 30% hemorrhage.,['38 adult Yorkshire swine'],['tPTX'],"['cardiac output', 'blood volume (EBV) hemorrhage', 'success of device', 'baseline systolic blood pressure']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0039005', 'cui_str': 'Suidae'}]","[{'cui': 'C0264558', 'cui_str': 'Tension pneumothorax'}]","[{'cui': 'C0007165', 'cui_str': 'Cardiac output'}, {'cui': 'C0005850', 'cui_str': 'Blood volume'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C4274438', 'cui_str': 'Baseline systolic blood pressure'}]",14.0,0.0584664,The 10g AC was vastly superior to the 14g AC for return of spontaneous circulation following tPEA in the setting of 30% hemorrhage.,"[{'ForeName': 'Emily A', 'Initials': 'EA', 'LastName': 'Norris', 'Affiliation': 'From the Department of Surgery (E.A.N., C.S.M., M.L.L., J.L.F., S.D.J.), and Combat Trauma Research Group (E.A.N., C.S.M., M.L.L., M.R.B., J.L.F.), Naval Medical Center Portsmouth, Portsmouth, Virginia; and Navy Trauma Training Center (T.M.P.), LAC+USC Medical Center, Los Angeles, California.'}, {'ForeName': 'Christian S', 'Initials': 'CS', 'LastName': 'McEvoy', 'Affiliation': ''}, {'ForeName': 'Matthew L', 'Initials': 'ML', 'LastName': 'Leatherman', 'Affiliation': ''}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Boboc', 'Affiliation': ''}, {'ForeName': 'Jamie L', 'Initials': 'JL', 'LastName': 'Fitch', 'Affiliation': ''}, {'ForeName': 'Shane D', 'Initials': 'SD', 'LastName': 'Jensen', 'Affiliation': ''}, {'ForeName': 'Travis M', 'Initials': 'TM', 'LastName': 'Polk', 'Affiliation': ''}]",The journal of trauma and acute care surgery,['10.1097/TA.0000000000002724'] 44,32358602,Comments on Aydin et al: The Effectiveness of Dry Needling and Exercise Therapy in Patients with Dizziness Caused by Cervical Myofascial Pain Syndrome; a Prospective Randomized Clinical Study.,,2020,,['Patients with Dizziness Caused by Cervical Myofascial Pain Syndrome'],['Dry Needling and Exercise Therapy'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0458110', 'cui_str': 'Myofascial pain syndrome of neck'}]","[{'cui': 'C0394648', 'cui_str': 'Dry needle acupuncture'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}]",[],,0.0162506,,"[{'ForeName': 'Willem', 'Initials': 'W', 'LastName': 'De Hertogh', 'Affiliation': 'Rehabilitation Sciences and Physiotherapy Universiteit Antwerpen, Antwerp, Belgium.'}, {'ForeName': 'Luc', 'Initials': 'L', 'LastName': 'Vereeck', 'Affiliation': 'Rehabilitation Sciences and Physiotherapy Universiteit Antwerpen, Antwerp, Belgium.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'De Vestel', 'Affiliation': 'Rehabilitation Sciences and Physiotherapy Universiteit Antwerpen, Antwerp, Belgium.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Van Rompaey', 'Affiliation': 'Translational Neurosciences, Universiteit Antwerpen, Antwerp, Belgium.'}, {'ForeName': 'René', 'Initials': 'R', 'LastName': 'Castien', 'Affiliation': 'General Practice & Elderly Care Medicine, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.'}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pnaa119'] 45,32358610,"Authors' Reply: Letter to the Editor Regarding ""The Effectiveness of Dry Needling and Exercise Therapy in Patients with Dizziness Caused by Cervical Myofascial Pain Syndrome; Prospective Randomized Clinical Study"".",,2020,,['Patients with Dizziness Caused by Cervical Myofascial Pain Syndrome'],['Dry Needling and Exercise Therapy'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0458110', 'cui_str': 'Myofascial pain syndrome of neck'}]","[{'cui': 'C0394648', 'cui_str': 'Dry needle acupuncture'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}]",[],,0.0201219,,"[{'ForeName': 'Tuğba', 'Initials': 'T', 'LastName': 'Aydın', 'Affiliation': 'Istanbul Physical Medicine Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Ilhan', 'Initials': 'I', 'LastName': 'Karacan', 'Affiliation': 'Istanbul Physical Medicine Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pnaa116'] 46,32299853,Experimental dyspnoea interferes with locomotion and cognition: a randomised trial.,"BACKGROUND Chronic respiratory diseases are associated with cognitive dysfunction, but whether dyspnoea by itself negatively impacts on cognition has not been demonstrated. Cortical networks engaged in subjects experiencing dyspnoea are also activated during other tasks that require cognitive input and this may provoke a negative impact through interference with each other. METHODS This randomised, crossover trial investigated whether experimentally-induced dyspnoea would negatively impact on locomotion and cognitive function among 40 healthy adults. Crossover conditions were unloaded breathing or loaded breathing using an inspiratory threshold load. To evaluate locomotion, participants were assessed by the Timed Up and Go (TUG) test. Cognitive function was assessed by categorical and phonemic verbal fluency tests, the Trail Making Tests (TMTs) A and B (executive function), the CODE test from the Wechsler Adult Intelligence Scale (WAIS)-IV (processing speed) and by direct and indirect digit span (working memory). RESULTS The mean time difference to perform the TUG test between unloaded and loaded breathing was -0.752 s (95% CI -1.012 to -0.492 s) (p<0.001). Executive function, processing speed and working memory performed better during unloaded breathing, particularly for subjects starting first with the loaded breathing condition. CONCLUSION Our data suggest that respiratory threshold loading to elicit dyspnoea had a major impact on locomotion and cognitive function in healthy adults.",2020,The mean time difference to perform the Timed Up and Go test between unloaded and loaded breathing was -0.752 s (-1.012 to -0.492,"['healthy adults', '40 healthy adults', 'subjects starting first with the loaded breathing condition', 'subjects experiencing dyspnea']",['unloaded breathing or loaded breathing using an inspiratory threshold load'],"['Executive function, processing speed and working memory', 'mean time difference to perform the Timed Up and Go test between unloaded and loaded breathing', 'locomotion and cognitive function', 'categorical and phonemic verbal fluency tests, the Trail Making Test A and B (executive function), the CODE test from the WAIS-IV (processing speed), and by direct and indirect digit span (working memory', 'Cognitive function']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}]","[{'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0023946', 'cui_str': 'Locomotor Activity'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0009219', 'cui_str': 'Coding'}, {'cui': 'C0204456', 'cui_str': 'Wechsler adult intelligence scale'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0439852', 'cui_str': 'Indirect'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}]",40.0,0.0411492,The mean time difference to perform the Timed Up and Go test between unloaded and loaded breathing was -0.752 s (-1.012 to -0.492,"[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Lawi', 'Affiliation': 'Division of Pulmonary Diseases, Geneva University Hospitals, Geneva, Switzerland.'}, {'ForeName': 'Elise', 'Initials': 'E', 'LastName': 'Dupuis-Lozeron', 'Affiliation': 'Clinical Research Centre and Division of Clinical Epidemiology, Dept of Health and Community Medicine, Geneva University Hospitals, Geneva, Switzerland.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Berra', 'Affiliation': 'Division of Pulmonary Diseases, Geneva University Hospitals, Geneva, Switzerland.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Allali', 'Affiliation': 'University of Geneva Faculty of Medicine, Geneva, Switzerland.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Similowski', 'Affiliation': 'AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Intensive Care Unit and Respiratory Division (Département ""R3S""), Paris, France.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Adler', 'Affiliation': 'Division of Pulmonary Diseases, Geneva University Hospitals, Geneva, Switzerland dan.adler@hcuge.ch.'}]",The European respiratory journal,['10.1183/13993003.00054-2020'] 47,32358474,"Impact of a Mindfulness-Based, Workplace Group Yoga Intervention on Burnout, Self-Care, and Compassion in Health Care Professionals: A Pilot Study.","OBJECTIVE To investigate whether a workplace, group mindfulness-based yoga intervention could help manage burnout and improve wellbeing among health care professionals. METHODS A total of 43 health care professionals participated in 8-week supervised workplace, group mindfulness-based yoga activities. The authors used a single-sample, pre-post design. At two points in time (baseline and postintervention), participants completed a set of online measures assessing burnout, depression, anxiety, stress, resilience, and compassion. The authors used linear mixed model analysis to assess changes in outcome measures. RESULTS Participants had improvements after the 8-week intervention. At postintervention, they had significantly better scores on personal accomplishment, depression, anxiety, stress, perceived resilience, and compassion. Participants had a positive perception of the yoga intervention. CONCLUSION Group mindfulness-based yoga program may be convenient and low-cost approach to support health and wellbeing among health care professionals.",2020,"At postintervention, they had significantly better scores on personal accomplishment, depression, anxiety, stress, perceived resilience, and compassion.","['43 health care professionals participated in eight-week', 'Participants had a positive perception of the yoga intervention']","['Mindfulness-based, Workplace Group Yoga Intervention', 'workplace, group mindfulness-based yoga intervention', 'supervised workplace, group mindfulness-based yoga activities']","['personal accomplishment, depression, anxiety, stress, perceived resilience, and compassion', 'online measures assessing burnout, depression, anxiety, stress, resilience, and compassion']","[{'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0162579', 'cui_str': 'Work environment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state'}]",,0.0217367,"At postintervention, they had significantly better scores on personal accomplishment, depression, anxiety, stress, perceived resilience, and compassion.","[{'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Ofei-Dodoo', 'Affiliation': 'Wichita Department of Family and Community Medicine (Dr Ofei-Dodoo, Dr Nilsen); and Wichita Family Medicine Residency Program at Wesley Medical Center (Dr Cleland-Leighton, Dr Cloward, Dr Casey), University of Kansas School of Medicine, Wichita, Kansas.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Cleland-Leighton', 'Affiliation': ''}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Nilsen', 'Affiliation': ''}, {'ForeName': 'Jacob L', 'Initials': 'JL', 'LastName': 'Cloward', 'Affiliation': ''}, {'ForeName': 'Eastin', 'Initials': 'E', 'LastName': 'Casey', 'Affiliation': ''}]",Journal of occupational and environmental medicine,['10.1097/JOM.0000000000001892'] 48,32357128,The Clinical and Cost-Effectiveness of Telerehabilitation for People With Nonspecific Chronic Low Back Pain: Randomized Controlled Trial.,"BACKGROUND Telerehabilitation can facilitate multidisciplinary management for people with nonspecific chronic low back pain (NCLBP). It provides health care access to individuals who are physically and economically disadvantaged. OBJECTIVE This study aimed to evaluate the clinical and cost-effectiveness of telerehabilitation compared with a clinic-based intervention for people with NCLBP in Nigeria. METHODS A cost-utility analysis alongside a randomized controlled trial from a health care perspective was conducted. Patients with NCLBP were assigned to either telerehabilitation-based McKenzie therapy (TBMT) or clinic-based McKenzie therapy (CBMT). Interventions were carried out 3 times weekly for a period of 8 weeks. Patients' level of disability was measured using the Oswestry Disability Index (ODI) at baseline, week 4, and week 8. To estimate the health-related quality of life of the patients, the ODI was mapped to the short-form six dimensions instrument to generate quality-adjusted life years (QALYs). Health care resource use and costs were assessed based on the McKenzie extension protocol in Nigeria in 2019. Descriptive and inferential data analyses were also performed to assess the clinical effectiveness of the interventions. Bootstrapping was conducted to generate the point estimate of the incremental cost-effectiveness ratio (ICER). RESULTS A total of 47 patients (TBMT, n=21 and CBMT, n=26), with a mean age of 47 (SD 11.6) years for telerehabilitation and 50 (SD 10.7) years for the clinic-based intervention, participated in this study. The mean cost estimates of TBMT and CBMT interventions per person were 22,200 naira (US $61.7) and 38,200 naira (US $106), respectively. QALY gained was 0.085 for TBMT and 0.084 for CBMT. The TBMT arm was associated with an additional 0.001 QALY (95% CI 0.001 to 0.002) per participant compared with the CBMT arm. Thus, the ICER showed that the TBMT arm was less costly and more effective than the CBMT arm. CONCLUSIONS The findings of the study suggested that telerehabilitation for people with NCLBP was cost saving. Given the small number of participants in this study, further examination of effects and costs of the interventions is needed within a larger sample size. In addition, future studies are required to assess the cost-effectiveness of this intervention in the long term from the patient and societal perspective.",2020,The TBMT arm was associated with an additional 0.001 QALY (95% CI 0.001 to 0.002) per participant compared with the CBMT arm.,"['individuals who are physically and economically disadvantaged', 'Patients with NCLBP', 'People With Nonspecific Chronic Low Back Pain', '47 patients (TBMT, n=21 and CBMT, n=26) with a mean age of 47 (SD 11.6) years for telerehabilitation and 50 (SD 10.7) years for clinic-based intervention participated in this study', 'people with nonspecific chronic low back pain (NCLBP', 'people with NCLBP in Nigeria']","['TBMT', 'telerehabilitation compared with clinic-based intervention', 'telerehabilitation-based McKenzie therapy (TBMT) or clinic-based McKenzie therapy (CBMT']","['Oswestry Disability Index (ODI', 'level of disability', 'incremental cost-effectiveness ratio (ICER', 'mean costs estimate of TBMT']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0013556', 'cui_str': 'Economics'}, {'cui': 'C0012613', 'cui_str': 'Disadvantaged'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C4042802', 'cui_str': 'Remote Rehabilitation'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4708782', 'cui_str': '11.6'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C5191365', 'cui_str': '10.7'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0028075', 'cui_str': 'Nigeria'}]","[{'cui': 'C4042802', 'cui_str': 'Remote Rehabilitation'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C4042802', 'cui_str': 'Remote Rehabilitation'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",47.0,0.12828,The TBMT arm was associated with an additional 0.001 QALY (95% CI 0.001 to 0.002) per participant compared with the CBMT arm.,"[{'ForeName': 'Francis', 'Initials': 'F', 'LastName': 'Fatoye', 'Affiliation': 'Faculty of Health, Psychology and Social Care, Manchester Metropolitan University, Manchester, United Kingdom.'}, {'ForeName': 'Tadesse', 'Initials': 'T', 'LastName': 'Gebrye', 'Affiliation': 'Faculty of Health, Psychology and Social Care, Manchester Metropolitan University, Manchester, United Kingdom.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Fatoye', 'Affiliation': 'Faculty of Health, Psychology and Social Care, Manchester Metropolitan University, Manchester, United Kingdom.'}, {'ForeName': 'Chidozie E', 'Initials': 'CE', 'LastName': 'Mbada', 'Affiliation': 'College of Health Sciences, Obafemi Awolowo University, Osun, Nigeria.'}, {'ForeName': 'Mistura I', 'Initials': 'MI', 'LastName': 'Olaoye', 'Affiliation': 'College of Health Sciences, Obafemi Awolowo University, Osun, Nigeria.'}, {'ForeName': 'Adesola C', 'Initials': 'AC', 'LastName': 'Odole', 'Affiliation': 'College of Medicine, University of Ibadan, Oyo, Nigeria.'}, {'ForeName': 'Olumide', 'Initials': 'O', 'LastName': 'Dada', 'Affiliation': 'College of Medicine, University of Ibadan, Oyo, Nigeria.'}]",JMIR mHealth and uHealth,['10.2196/15375'] 49,32367400,Length Polymorphisms in the Angiotensin I-Converting Enzyme Gene and the Serotonin-Transporter-Linked Polymorphic Region Constitute a Risk Haplotype for Depression in Patients with Coronary Artery Disease.,"Genetic variations affecting the course of depressive symptoms in patients with coronary artery disease (CAD) have not yet been well studied. Therefore, we set out to investigate whether distinct haplotypes of the two insertion/deletion polymorphisms in the serotonin-transporter-linked polymorphic region (5-HTTLPR) and the angiotensin I-converting enzyme (ACE) gene located on chromosome 17 can be identified as risk factors for trajectories of depression. Clinical and genotyping data were derived from 507 depressed CAD patients participating in the randomized, controlled, multicenter Stepwise Psychotherapy Intervention for Reducing Risk in Coronary Artery Disease (SPIRR-CAD) trial, of whom the majority had an acute cardiac event before study inclusion. Depression scores on the Hospital Anxiety and Depression Scale (HADS) were assessed at baseline and at five follow-up time points up to 2 years after study entrance. At baseline, depression scores did not significantly differ between patients carrying the risk haplotype ACE D/D, 5-HTTLPR I/I (n = 46) and the non-risk haplotypes (n = 461, 10.9 ± 2.7 versus 10.4 ± 2.5, p = 0.254). HADS-depression scores declined from study inclusion during the first year irrespective of the genotype. At each follow-up time point, HADS-depression scores were significantly higher in ACE D/D, 5-HTTLPR I/I carriers than in their counterparts. Two years after study inclusion, the mean HADS depression score remained 1.8 points higher in patients with the risk haplotype as compared to subjects not carrying this haplotype (9.9 ± 4.2 versus 8.1 ± 4.0, p = 0.009). In summary, the presence of the ACE D/D, 5-HTTLPR I/I haplotype may be a vulnerability factor for comorbid depressive symptoms in CAD patients.",2020,"At baseline, depression scores did not significantly differ between patients carrying the risk haplotype ACE D/D, 5-HTTLPR","['Patients with Coronary Artery Disease', '507 depressed CAD patients participating', 'CAD patients', 'patients with coronary artery disease (CAD']","['Psychotherapy Intervention', '5-HTTLPR']","['Depression scores', 'depression scores', 'HADS-depression scores', 'mean HADS depression score', 'Hospital Anxiety and Depression Scale (HADS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0450381', 'cui_str': '507'}, {'cui': 'C0344315', 'cui_str': 'Depressed mood'}]","[{'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",507.0,0.0420776,"At baseline, depression scores did not significantly differ between patients carrying the risk haplotype ACE D/D, 5-HTTLPR","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Meyer', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center and German Center for Cardiovascular Research, Partner Site Göttingen, Göttingen, Germany. thomas.meyer@med.uni-goettingen.de.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Rothe', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center and German Center for Cardiovascular Research, Partner Site Göttingen, Göttingen, Germany.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Staab', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center and German Center for Cardiovascular Research, Partner Site Göttingen, Göttingen, Germany.'}, {'ForeName': 'Hans-Christian', 'Initials': 'HC', 'LastName': 'Deter', 'Affiliation': 'Department of Psychosomatics and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Stella V', 'Initials': 'SV', 'LastName': 'Fangauf', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center and German Center for Cardiovascular Research, Partner Site Göttingen, Göttingen, Germany.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Hamacher', 'Affiliation': 'Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Hellmich', 'Affiliation': 'Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Jünger', 'Affiliation': 'The German National Institute for State Examinations in Medicine, Pharmacy and Psychotherapy, Mainz, Germany.'}, {'ForeName': 'Karl-Heinz', 'Initials': 'KH', 'LastName': 'Ladwig', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Michal', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Petrowski', 'Affiliation': 'Department of Psychotherapy and Psychosomatics, Technical University of Dresden, Dresden, Germany.'}, {'ForeName': 'Joram', 'Initials': 'J', 'LastName': 'Ronel', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Clinic Barmelweid, Barmelweid, Switzerland.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Söllner', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany.'}, {'ForeName': 'Cora', 'Initials': 'C', 'LastName': 'Weber', 'Affiliation': 'Department of Psychosomatics and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'de Zwaan', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Redford B', 'Initials': 'RB', 'LastName': 'Williams', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Albus', 'Affiliation': 'Department of Psychosomatics and Psychotherapy, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Herrmann-Lingen', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center and German Center for Cardiovascular Research, Partner Site Göttingen, Göttingen, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Biochemical genetics,['10.1007/s10528-020-09967-w'] 50,32366156,"Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.","OBJECTIVES Fixed-dose combination (FDC) therapy can improve outcomes in type 2 diabetes (T2D). We evaluated the bioequivalence of 2 doses of an FDC of extended-release metformin (metformin XR), empagliflozin, a sodium-glucose co-transporter 2 inhibitor, and linagliptin, a dipeptidyl peptidase-4 inhibitor, versus corresponding free tablet combinations. METHODS Two randomized, open-label, two-way crossover studies in healthy adults compared: 2 FDC tablets of empagliflozin 5 mg/linagliptin 2.5 mg/metformin XR 1000 mg (Study 1; N = 30), 1 FDC tablet of empagliflozin 25 mg/linagliptin 5 mg/metformin XR 1000 mg (Study 2; N = 30) versus corresponding dose of free combinations. Subjects received study medication under fed conditions; washout was ≥35 days between treatments. Primary endpoints: area under the plasma concentration-time curve (AUC) from time 0 to last quantifiable data point for empagliflozin and metformin; AUC from time 0 to 72 hours for linagliptin, and peak plasma concentration (C max ) for empagliflozin, linagliptin, and metformin. Bioequivalence was defined as adjusted geometric mean ratios (FDC: free combination) and two-sided 90% confidence intervals (CIs) of AUC and C max for each component within 80.00-125.00%. RESULTS Study 1: 27/29 and 28/30 treated participants were included in the pharmacokinetic analysis for the FDC and free combination periods, respectively. Study 2: 29/29 treated participants were included in the pharmacokinetic analysis for both periods. The adjusted geometric mean ratios of FDCs to their respective free tablet combinations and two-sided 90% CIs were all within the predefined range. The shapes of the mean plasma concentration-time profile of empagliflozin, linagliptin, and metformin XR were similar for subjects in the FDC and free combination groups in both studies. No serious adverse events were reported. CONCLUSION The evaluated doses of empagliflozin/linagliptin/metformin XR FDC tablets were bioequivalent to the corresponding free combinations. Based on these two bioequivalence studies and existing phase 3 data, the FDA has recently approved this triple FDC to improve glycemic control in adults with T2D.",2020,The evaluated doses of empagliflozin/linagliptin/metformin XR FDC tablets were bioequivalent to the corresponding free combinations.,"['healthy adults compared: 2', 'adults with T2D', 'Study 1: 27/29 and 28/30 treated participants were included in the pharmacokinetic analysis for the FDC and free combination periods, respectively', 'patients with type 2 diabetes']","['empagliflozin/linagliptin/metformin XR FDC tablets', 'empagliflozin, linagliptin, and metformin', 'Triple fixed-dose combination empagliflozin, linagliptin, and metformin', 'FDC of extended-release metformin (metformin XR), empagliflozin, a sodium-glucose co-transporter 2 inhibitor, and linagliptin, a dipeptidyl peptidase-4 inhibitor', 'FDC tablets of empagliflozin 5 mg/linagliptin 2.5 mg/metformin XR', 'FDC) therapy', 'FDC tablet of empagliflozin 25 mg/linagliptin 5 mg/metformin XR']","['area under the plasma concentration-time curve (AUC) from time 0 to last quantifiable data point for empagliflozin and metformin; AUC from time 0 to 72\xa0hours for linagliptin, and peak plasma concentration (C max ', 'adjusted geometric mean ratios of FDCs', 'mean plasma concentration-time profile of empagliflozin, linagliptin, and metformin XR', 'serious adverse events']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C3871442', 'cui_str': 'linagliptin and empagliflozin'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C2746078', 'cui_str': 'Linagliptin'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C4301634', 'cui_str': 'Sodium-glucose co-transporter 2 (SGLT2) inhibitors'}, {'cui': 'C1827106', 'cui_str': 'Dipeptidyl peptidase IV inhibitor'}, {'cui': 'C4050744', 'cui_str': 'empagliflozin 5 MG'}, {'cui': 'C3265893', 'cui_str': 'Linagliptin 2.5 MG'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C3883488', 'cui_str': 'empagliflozin 25 MG / Linagliptin 5 MG [Glyxambi]'}]","[{'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C2746078', 'cui_str': 'Linagliptin'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.0607173,The evaluated doses of empagliflozin/linagliptin/metformin XR FDC tablets were bioequivalent to the corresponding free combinations.,"[{'ForeName': 'Ildiko', 'Initials': 'I', 'LastName': 'Lingvay', 'Affiliation': 'Department of Internal Medicine/Endocrinology and Department of Population and Data Sciences, UT Southwestern Medical Center , Dallas, TX, USA.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Beetz', 'Affiliation': 'Global Clinical Operations, Early Trials, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach an der Riß, Germany.'}, {'ForeName': 'Regina', 'Initials': 'R', 'LastName': 'Sennewald', 'Affiliation': 'Global Clinical Operations, Early Trials, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach an der Riß, Germany.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Schuler-Metz', 'Affiliation': 'Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach an der Riß, Germany.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Bertulis', 'Affiliation': 'Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach an der Riß, Germany.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Loley', 'Affiliation': 'Biostatistics and Data Sciences, Clinical Statistics, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach an der Riß, Germany.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Lang', 'Affiliation': 'Biostatistics and Data Sciences, Clinical Statistics, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach an der Riß, Germany.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Lippert', 'Affiliation': 'Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach an der Riß, Germany.'}, {'ForeName': 'Jisoo', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Clinical Development & Cardiometabolism and Respiratory Medicine, Boehringer Ingelheim International GmbH , Ingelheim, Germany.'}, {'ForeName': 'Linda Shapiro', 'Initials': 'LS', 'LastName': 'Manning', 'Affiliation': 'Clinical Development & Medical Affairs - Cardiometabolism, Boehringer Ingelheim Pharmaceuticals Inc , Ridgefield, CT, USA.'}, {'ForeName': 'Derek', 'Initials': 'D', 'LastName': 'Terada', 'Affiliation': 'Clinical Development & Medical Affairs - Cardiometabolism, Boehringer Ingelheim Pharmaceuticals Inc , Ridgefield, CT, USA.'}]",Postgraduate medicine,['10.1080/00325481.2020.1750228'] 51,32363411,Building Emotional Resilience in Youth in Lebanon: a School-Based Randomized Controlled Trial of the FRIENDS Intervention.,"In Lebanon, approximately one in four adolescents suffers from a psychiatric disorder. Alarmingly, 94% of adolescents with a mental disorder have not sought any treatment. This study assessed the effectiveness of an evidence-based school-based universal mental health intervention (the FRIENDS program) in reducing depression and anxiety symptoms in middle school students in Lebanon. A total of 280 6th graders aged 11-13 years were recruited from 10 schools in Beirut. Schools were matched on size and tuition and randomly assigned to intervention or control groups. The FRIENDS program was translated into Arabic, adapted, and then implemented by trained mental health professionals during 10 classroom sessions over 3 months. We assessed sociodemographic and relevant psychological symptoms by self-report, using the Scale for Childhood Anxiety and Related Disorders (SCARED), Mood and Feelings Questionnaire (MFQ), and Strengths and Difficulties Questionnaire (SDQ), at baseline. We re-administered these scales at 3 months post-intervention. There was a significant time × group interaction for the SDQ emotional score (p = 0.011) and total MFQ score (p = 0.039) indicating significant improvement in depressive and emotional symptoms in the intervention group. Subgroup analysis by gender showed a significant time × group interaction for the total SCARED score (p = 0.025) in females but not in males (p = 0.137), consistent with a reduction of anxiety symptoms in this stratum of the intervention group as compared with the control group. The FRIENDS program was effective in reducing general emotional and depressive symptoms among middle school students in this Lebanese study population. This intervention provides an opportunity for promoting mental health in Lebanese schools and reducing the treatment gap in mental health care.",2020,"Subgroup analysis by gender showed a significant time × group interaction for the total SCARED score (p = 0.025) in females but not in males (p = 0.137), consistent with a reduction of anxiety symptoms in this stratum of the intervention group as compared with the control group.","['A total of 280 6th graders aged 11-13\xa0years were recruited from 10 schools in Beirut', 'Youth in Lebanon', 'adolescents with a mental disorder', 'middle school students in Lebanon', 'middle school students in this Lebanese study population']",['evidence-based school-based universal mental health intervention (the FRIENDS program'],"['Childhood Anxiety and Related Disorders (SCARED), Mood and Feelings Questionnaire (MFQ), and Strengths and Difficulties Questionnaire (SDQ', 'Building Emotional Resilience', 'anxiety symptoms', 'total SCARED score', 'depressive and emotional symptoms', 'general emotional and depressive symptoms', 'depression and anxiety symptoms', 'SDQ emotional score', 'total MFQ score']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0023190', 'cui_str': 'Lebanon'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0557797', 'cui_str': 'Middle school'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0175671', 'cui_str': 'Universal'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0079382', 'cui_str': 'Friend'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3472494', 'cui_str': 'Strengths and difficulties questionnaire'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",280.0,0.0621785,"Subgroup analysis by gender showed a significant time × group interaction for the total SCARED score (p = 0.025) in females but not in males (p = 0.137), consistent with a reduction of anxiety symptoms in this stratum of the intervention group as compared with the control group.","[{'ForeName': 'Fadi T', 'Initials': 'FT', 'LastName': 'Maalouf', 'Affiliation': 'Department of Psychiatry, Faculty of Medicine, American University of Beirut, P.O. Box 11-0236, Riad El-Solh/Beirut, 1107 2020, Lebanon. fm38@aub.edu.lb.'}, {'ForeName': 'Loay', 'Initials': 'L', 'LastName': 'Alrojolah', 'Affiliation': 'Department of Psychiatry, Faculty of Medicine, American University of Beirut, P.O. Box 11-0236, Riad El-Solh/Beirut, 1107 2020, Lebanon.'}, {'ForeName': 'Lilian', 'Initials': 'L', 'LastName': 'Ghandour', 'Affiliation': 'Department of Epidemiology and Population, Faculty of Health Sciences, American University of Beirut, P.O. Box 11-0236, Riad El-Solh/Beirut, 1107 2020, Lebanon. lg01@aub.edu.lb.'}, {'ForeName': 'Rima', 'Initials': 'R', 'LastName': 'Afifi', 'Affiliation': 'Community and Behavioral, College of Public Health, University of Iowa, Iowa, IA, USA.'}, {'ForeName': 'Leyla Akoury', 'Initials': 'LA', 'LastName': 'Dirani', 'Affiliation': 'Department of Psychiatry, Faculty of Medicine, American University of Beirut, P.O. Box 11-0236, Riad El-Solh/Beirut, 1107 2020, Lebanon.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Barrett', 'Affiliation': 'Edith Cowan University, Joondalup, Western Australia, Australia.'}, {'ForeName': 'Rima', 'Initials': 'R', 'LastName': 'Nakkash', 'Affiliation': 'Department of Health Promotion and Community Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.'}, {'ForeName': 'Wael', 'Initials': 'W', 'LastName': 'Shamseddeen', 'Affiliation': 'Department of Psychiatry, Faculty of Medicine, American University of Beirut, P.O. Box 11-0236, Riad El-Solh/Beirut, 1107 2020, Lebanon.'}, {'ForeName': 'Farah', 'Initials': 'F', 'LastName': 'Tabaja', 'Affiliation': 'Department of Psychiatry, Faculty of Medicine, American University of Beirut, P.O. Box 11-0236, Riad El-Solh/Beirut, 1107 2020, Lebanon.'}, {'ForeName': 'Courtney M', 'Initials': 'CM', 'LastName': 'Yuen', 'Affiliation': 'Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Anne E', 'Initials': 'AE', 'LastName': 'Becker', 'Affiliation': 'Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-020-01123-5'] 52,32363552,Influence of the position of the antrostomy in sinus floor elevation on the healing of mini-implants: a randomized clinical trial.,"AIM To evaluate histologically the healing of mini-implants installed after sinus floor elevation using a lateral approach and placing the antrostomy at different level from the sinus floor. MATERIAL AND METHODS Sinus floor elevation using a lateral approach was performed in 24 healthy volunteers. The antrostomy was randomly placed either close to the base of the sinus floor (group base) or at about 3-4 mm cranially to it (group standard). After 6 months of healing, mini-implants were installed within the grafted region, through the alveolar crest. Three months later, biopsies were collected. RESULTS Sixteen biopsies from 16 patients were available for histological analyses. The new bone reached fractions of 40.9 ± 11.9% and 48.5 ± 20.1% at the base and standard groups, respectively (p = 0.208). Xenograft particles were found in contact with the implant surface at percentages of 12.1 ± 11.0% in the base group, and 15.9 ± 23.7% in the standard group (p = 0.674). CONCLUSIONS Based on the present study, the choice of one or the other position of antrostomy did not influence significantly the outcome and, therefore, should be left to the preference of the surgeon.",2020,"Xenograft particles were found in contact with the implant surface at percentages of 12.1 ± 11.0% in the base group, and 15.9 ± 23.7% in the standard group (p = 0.674). ","['24 healthy volunteers', 'Sixteen biopsies from 16 patients were available for histological analyses']",[],"['Xenograft particles', 'healing of mini-implants']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]",[],"[{'cui': 'C0520484', 'cui_str': 'Xenogeneic transplantation'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0021102', 'cui_str': 'Implant'}]",24.0,0.0279627,"Xenograft particles were found in contact with the implant surface at percentages of 12.1 ± 11.0% in the base group, and 15.9 ± 23.7% in the standard group (p = 0.674). ","[{'ForeName': 'Atsuya', 'Initials': 'A', 'LastName': 'Hirota', 'Affiliation': 'Department of Oral Implantology, Osaka Dental University, Osaka, Japan.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Iezzi', 'Affiliation': 'Dept. of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy.'}, {'ForeName': 'Adriano', 'Initials': 'A', 'LastName': 'Piattelli', 'Affiliation': 'Dept. of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Ferri', 'Affiliation': 'Corporación Universitaria Rafael Núñez, Cartagena, Colombia.'}, {'ForeName': 'Kazushige', 'Initials': 'K', 'LastName': 'Tanaka', 'Affiliation': 'Department of Oral Implantology, Osaka Dental University, Osaka, Japan.'}, {'ForeName': 'Karol Alí', 'Initials': 'KA', 'LastName': 'Apaza Alccayhuaman', 'Affiliation': 'ARDEC Academy, Viale Giovanni Pascoli 67, 47923, Rimini, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Botticelli', 'Affiliation': 'ARDEC Academy, Viale Giovanni Pascoli 67, 47923, Rimini, Italy. daniele.botticelli@gmail.com.'}]",Oral and maxillofacial surgery,['10.1007/s10006-020-00846-7'] 53,32360128,Efficacy of Cartoon Viewing Devices During Phlebotomy in Children: A Randomized Controlled Trial.,"PURPOSE The purpose of this study was to examine the efficacy of different cartoon viewing devices during phlebotomy in children. DESIGN This study was a prospective, randomized controlled trial. METHODS The study included inpatients from the Biochemical Laboratory of a private university hospital in Turkey and was conducted between September 2017 and April 2018. A computer-based random number generator was used to randomly assign the patients into three groups (virtual reality [VR], tablet, and control) with 40 children each. Data were collected using the Wong-Baker FACES Pain Rating Scale and the Children's Fear Scale. Pain and anxiety scores were reported by children, parents, and observers in tablet and control groups. In the VR group, pain and anxiety were determined only by children's reports. FINDINGS According to the children reports, the VR group reported significantly less pain and anxiety than those in the tablet and control groups (P < .05). CONCLUSIONS The cartoon distraction performed using a VR device reduced the perception of pain and anxiety during phlebotomy in school-age children.",2020,"According to the children reports, the VR group reported significantly less pain and anxiety than those in the tablet and control groups (P ","['inpatients from the Biochemical Laboratory of a private university hospital in Turkey and was conducted between September 2017 and April 2018', 'Children', 'school-age children', 'children']","['cartoon distraction performed using a VR device', 'Cartoon Viewing Devices', 'cartoon viewing devices']","['perception of pain and anxiety', 'Pain and anxiety scores', 'pain and anxiety', ""Baker FACES Pain Rating Scale and the Children's Fear Scale""]","[{'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0033175', 'cui_str': 'Private Room'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0041400', 'cui_str': 'Turkey - country'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0007306', 'cui_str': 'Cartoons'}, {'cui': 'C0150189', 'cui_str': 'Distraction training'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0238749', 'cui_str': 'Baker, general'}, {'cui': 'C0015468', 'cui_str': 'Pain in face'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0015726', 'cui_str': 'Fear'}]",,0.0298337,"According to the children reports, the VR group reported significantly less pain and anxiety than those in the tablet and control groups (P ","[{'ForeName': 'Demet', 'Initials': 'D', 'LastName': 'İnangil', 'Affiliation': 'Fundamentals of Nursing Department, University of Health Sciences, Hamidiye Faculty of Nursing, Istanbul, Turkey. Electronic address: demet.inangil@sbu.edu.tr.'}, {'ForeName': 'Merdiye', 'Initials': 'M', 'LastName': 'Şendir', 'Affiliation': 'Fundamentals of Nursing Department, University of Health Sciences, Hamidiye Faculty of Nursing, Istanbul, Turkey.'}, {'ForeName': 'Funda', 'Initials': 'F', 'LastName': 'Büyükyılmaz', 'Affiliation': 'Fundamentals of Nursing Department, Istanbul University-Cerrahpasa Florence Nightingale Faculty of Nursing, Istanbul, Turkey.'}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2020.01.008'] 54,32360129,The Effect of Active Warming on Postoperative Hypothermia on Body Temperature and Thermal Comfort: A Randomized Controlled Trial.,"PURPOSE The purpose of this study was to determine the effect of active warming method in temperature control and thermal comfort in hypothermia after surgery. DESIGN A randomized controlled trial. METHODS The study sample consisted of 64 male and female postanesthesia care unit and intensive care unit neurosurgery postoperative inpatients. The experimental group was warmed using the active warming method, and the control group's routine care was continued via a cotton blanket. Patients were warmed until their tympanic body temperature reached 37°C. FINDINGS The time needed to adequately warm patients was approximately twice as short in those who received active warming as compared with the control group. The perception of thermal comfort was significantly higher in the first hour in patients who received the active warming method (P < .05). CONCLUSIONS The active warming method resulted in a shorter time to warming in hypothermia after surgery and an increase in the perception of thermal comfort and body temperature.",2020,The active warming method resulted in a shorter time to warming in hypothermia after surgery and an increase in the perception of thermal comfort and body temperature.,"['hypothermia after surgery', '64 male and female postanesthesia care unit and intensive care unit neurosurgery postoperative inpatients']",[],"['perception of thermal comfort and body temperature', 'perception of thermal comfort', 'Body Temperature and Thermal Comfort']","[{'cui': 'C0020672', 'cui_str': 'Hypothermia'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0262723', 'cui_str': 'Postanesthesia care'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0027926', 'cui_str': 'Neurosurgery'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}]",[],"[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}]",64.0,0.0882747,The active warming method resulted in a shorter time to warming in hypothermia after surgery and an increase in the perception of thermal comfort and body temperature.,"[{'ForeName': 'Aysel', 'Initials': 'A', 'LastName': 'Özsaban', 'Affiliation': 'Department of Nursing, Faculty of Health Sciences, Karadeniz Technical University, Trabzon, Turkey. Electronic address: ayselates87@gmail.com.'}, {'ForeName': 'Rengin', 'Initials': 'R', 'LastName': 'Acaroğlu', 'Affiliation': 'Department of Fundamentals of Nursing, Florence Nightingale Faculty of Nursing, İstanbul University-Cerrahpaşa, Istanbul, Turkey.'}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2019.12.006'] 55,32372568,Delayed meal timing after exercise is associated with reduced appetite and energy intake in adolescents with obesity.,"BACKGROUND While the beneficial effects of exercise on appetite might depend on its timing during the day or relative to a meal, this remains poorly explored in youth. OBJECTIVES To examine the importance of meal timing (+30 vs +90 minutes) after performing exercise on energy intake, appetite and food reward in adolescents with obesity. METHODS Eighteen adolescents with obesity randomly completed three conditions: (a) lunch (12:00 pm) set 30 minutes after a rest session (11:00 am); (b) lunch (12:00 pm) set 30 minutes after an exercise session (11:00 am)(MEAL-30); (c) lunch (01:00 pm) set 90 minutes after an exercise session (11:00 am)(MEAL-90). Lunch and dinner ad libitum energy intake was assessed, food reward (LFPQ) assessed before and after lunch, and before dinner, appetite sensations were assessed at regular intervals. RESULTS Energy intake was lower at MEAL-90 than MEAL-30 and CON at lunch (P < .05 and P < .01, respectively) and lunch + dinner combined (P < .001). A decrease in intake (g) of protein, fat and carbohydrate was observed. Post-exercise hunger was lower on MEAL-90 compared with CON. No condition effects were found at lunch for food reward. CONCLUSIONS Delaying the timing of the meal after exercise might help affect energy balance by decreasing ad libitum energy intake without increasing hunger and by improving satiety in adolescents with obesity.",2020,"RESULTS Energy intake was lower at MEAL-90 than MEAL-30 and CON at lunch (P < .05 and P < .01, respectively) and lunch + dinner combined (P < .001).","['adolescents with obesity', 'Eighteen adolescents with obesity randomly completed three conditions: (a']",['lunch (12:00 pm) set 30\u2009minutes after a rest session (11:00 am); (b) lunch (12:00 pm) set 30\u2009minutes after an exercise session (11:00 am)(MEAL-30); (c) lunch (01:00 pm'],"['Energy intake', 'intake (g) of protein, fat and carbohydrate', 'appetite and energy intake']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C2697949', 'cui_str': 'Lunch'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}]",18.0,0.0208892,"RESULTS Energy intake was lower at MEAL-90 than MEAL-30 and CON at lunch (P < .05 and P < .01, respectively) and lunch + dinner combined (P < .001).","[{'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Fillon', 'Affiliation': 'AME2P, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.'}, {'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Beaulieu', 'Affiliation': 'School of Psychology, Faculty of Medicine and Health, Leeds, UK.'}, {'ForeName': 'Maud', 'Initials': 'M', 'LastName': 'Miguet', 'Affiliation': 'AME2P, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.'}, {'ForeName': 'Mélina', 'Initials': 'M', 'LastName': 'Bailly', 'Affiliation': 'AME2P, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Finlayson', 'Affiliation': 'School of Psychology, Faculty of Medicine and Health, Leeds, UK.'}, {'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Julian', 'Affiliation': 'CHU Clermont-Ferrand, Clermont-Ferrand, France.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Masurier', 'Affiliation': 'UGECAM Nutrition Obesity Ambulatory Hospital, Clermont-Ferrand, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Pereira', 'Affiliation': 'Biostatistics Unit (DRCI), Clermont-Ferrand University Hospital, Clermont-Ferrand, France.'}, {'ForeName': 'Martine', 'Initials': 'M', 'LastName': 'Duclos', 'Affiliation': 'AME2P, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Boirie', 'Affiliation': 'AME2P, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Thivel', 'Affiliation': 'AME2P, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.'}]",Pediatric obesity,['10.1111/ijpo.12651'] 56,32362479,Effect of Flurbiprofen and S-Flurbiprofen Patches on Multimodal Pain Management After Total Knee Arthroplasty: A Prospective Randomized Controlled Trial.,"BACKGROUND Total knee arthroplasty (TKA) is an established procedure for knee osteoarthritis. Multimodal analgesia is reportedly more effective for postoperative analgesia. We investigated the efficacy of 2 patches after TKA. METHODS Seventy-nine knees that underwent unilateral TKA for osteoarthritis were included. Oral administration, local periarticular analgesic injection, and patches were adopted for pain management. The knees were randomly assigned to the flurbiprofen patch (FPP), S-flurbiprofen patch (SFPP), and control (no patch) groups. Patch treatment was continued for 14 days. Pain according to the visual analog scale, knee flexion angle, renal dysfunction, gastrointestinal injury, duration of hospitalization, dermatitis, and the rate of using additional oral nonsteroidal anti-inflammatory drugs were compared (from preoperative to postoperative day 14). RESULTS The FPP, SFPP, and control groups included 29, 27, and 23 knees, respectively. Visual analog scale was lower in the FPP and SFPP groups than in the control group on days 1 and 3 (day 1: 24.4, 25.0, and 39.4, respectively; day 3: 25.5, 23.3, and 39.3, respectively). Knee flexion angle was larger in the SFPP group than in the control group on days 7 and 14 (day 7: 89.8° and 76.6°, respectively; day 14: 98.3° and 84.2°, respectively). Neither renal dysfunction nor gastrointestinal injury was confirmed. The duration of hospitalization did not differ among the groups. Dermatitis occurred only in the SFPP group. The rate of using additional oral nonsteroidal anti-inflammatory drugs was higher in the control group. CONCLUSION Both patches were effective and safe as part of multimodal analgesia for postoperative TKA.",2020,"Visual analog scale was lower in the FPP and SFPP groups than in the control group on days 1 and 3 (day 1: 24.4, 25.0, and 39.4, respectively; day 3: 25.5, 23.3, and 39.3, respectively).","['After Total Knee Arthroplasty', 'Seventy-nine knees that underwent unilateral TKA for osteoarthritis were included']","['SFPP', 'Flurbiprofen and S-Flurbiprofen Patches', 'flurbiprofen patch (FPP), S-flurbiprofen patch (SFPP), and control (no patch', 'Total knee arthroplasty (TKA']","['Visual analog scale', 'Multimodal Pain Management', 'Dermatitis', 'Knee flexion angle', 'rate of using additional oral nonsteroidal anti-inflammatory drugs', 'renal dysfunction nor gastrointestinal injury', 'Pain according to the visual analog scale, knee flexion angle, renal dysfunction, gastrointestinal injury, duration of hospitalization, dermatitis, and the rate of using additional oral nonsteroidal anti-inflammatory drugs', 'duration of hospitalization']","[{'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0016377', 'cui_str': 'Flurbiprofen'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0011603', 'cui_str': 'Dermatitis'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}, {'cui': 'C1565489', 'cui_str': 'Renal impairment'}, {'cui': 'C0160345', 'cui_str': 'Injury of gastrointestinal tract'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",,0.0381315,"Visual analog scale was lower in the FPP and SFPP groups than in the control group on days 1 and 3 (day 1: 24.4, 25.0, and 39.4, respectively; day 3: 25.5, 23.3, and 39.3, respectively).","[{'ForeName': 'Masaki', 'Initials': 'M', 'LastName': 'Tsuji', 'Affiliation': 'Department of Orthopaedic Surgery, Yokohama City University Medical Center, Yokohama, Japan.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Kobayashi', 'Affiliation': 'Department of Orthopaedic Surgery, Yokohama City University Medical Center, Yokohama, Japan.'}, {'ForeName': 'Yohei', 'Initials': 'Y', 'LastName': 'Yukizawa', 'Affiliation': 'Department of Orthopaedic Surgery, Yokohama City University Medical Center, Yokohama, Japan.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Oishi', 'Affiliation': 'Department of Orthopaedic Surgery, Yokohama City University Medical Center, Yokohama, Japan.'}, {'ForeName': 'Shu', 'Initials': 'S', 'LastName': 'Takagawa', 'Affiliation': 'Department of Orthopaedic Surgery, Yokohama City University Medical Center, Yokohama, Japan.'}, {'ForeName': 'Yutaka', 'Initials': 'Y', 'LastName': 'Inaba', 'Affiliation': 'Department of Orthopaedic Surgery, Yokohama City University School of Medicine, Yokohama, Japan.'}]",The Journal of arthroplasty,['10.1016/j.arth.2020.04.006'] 57,32362548,The Optimal Length of Insertion for Central Venous Catheters Via the Right Internal Jugular Vein in Pediatric Cardiac Surgical Patients.,"OBJECTIVES The primary objective was to identify the best among 4 techniques that could predict the length of central venous catheter insertion through the right internal jugular vein, which, in turn, would ensure the ideal placement of the catheter tip in pediatric cardiac surgical patients. The techniques evaluated were those based on operator experience, topography/landmark methods, and one that relied on a patient's height-related formula. Based on the outcome of the study, the possibility of arriving at a formula was investigated that would predict with reasonable certainty the ideal length of catheter to be inserted for the correct catheter placement through the right internal jugular vein in pediatric cardiac surgical patients belonging to the authors' geographic area. DESIGN A prospective observational study. SETTING Tertiary care cardiac center. PARTICIPANTS Children younger than 5 years of age undergoing cardiac surgery. INTERVENTIONS Right internal jugular vein cannulation by the Seldinger technique method. MEASUREMENTS AND MAIN RESULTS A total of 120 children aged younger than 5 years undergoing cardiac surgery were included in the study. The participants were randomized to 4 groups: group 1 (n = 30), the length of the central venous catheter was determined empirically by the operator based on clinical experience; group 2 (n = 30), the depth of insertion of the catheter was determined by the distance from the site of skin puncture to the second intercostal space; group 3 (n = 30), the depth of insertion of the catheter was determined by the distance from the skin puncture site to the third intercostal space; and group 4 (n = 30), the length of catheter was determined by a height-based formula that was followed routinely at the authors' institution. Central venous catheterization through the right internal jugular vein was performed according to out-of-plane ultrasound guidance in all patients. The ideal catheter tip location was assumed to be at the level of the carina or within 1.5 cm proximal to it. The number of patients who had ideal catheter tip placement were recorded from postoperative chest radiograph in all groups. Any relationship between acceptable catheter tip and demographic data (mean ranks of age, height, weight, and body surface area) of the patients were studied. RESULTS The central vein catheter tip was at the level of the carina or within 1.5 cm in more patients in group 2 (39%, p = 0.02) compared with the other groups. This was followed by group 4 (40%), group 3 (30%), and group 1 (23%). There was a statistically significant difference in the mean distance between catheter tip and carina, with group 2 patients having the tip closest to the carina (p = 0.03). There was a significant correlation between acceptable catheter tip positioning and a patient's height (p = 0.04). A new formula was developed based on this correlation. CONCLUSIONS A landmark-based topographic method in which the length of insertion of the catheter was determined by the distance from the skin puncture site to the second intercostal space for achieving correct placement of the catheter tip was found to be more reliable compared with other techniques. Height-based formula has the disadvantage of being affected by the skin puncture site. Assuming that a skin puncture at the midpoint between the right mastoid process and clavicular insertion of sternocleidomastoid muscle insertion is ensured, a new formula based on height has been proposed.",2020,There was a significant correlation between acceptable catheter tip positioning and a patient's height (p = 0.04).,"['Tertiary care cardiac center', 'Pediatric Cardiac Surgical Patients', ""pediatric cardiac surgical patients belonging to the authors' geographic area"", 'pediatric cardiac surgical patients', '120 children aged younger than 5 years undergoing cardiac surgery', 'Children younger than 5 years of age undergoing cardiac surgery']",['Right internal jugular vein cannulation by the Seldinger technique method'],"['central vein catheter tip', 'Optimal Length of Insertion for Central Venous Catheters', 'mean distance', 'postoperative chest radiograph']","[{'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3812881', 'cui_str': 'Author'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}]","[{'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0226550', 'cui_str': 'Internal jugular vein structure'}, {'cui': 'C0917707', 'cui_str': 'Cannulation'}, {'cui': 'C0441701', 'cui_str': 'Seldinger technique'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0444299', 'cui_str': 'Catheter tip'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C1145640', 'cui_str': 'Central venous catheter'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C1306645', 'cui_str': 'Plain radiography'}]",120.0,0.0302369,There was a significant correlation between acceptable catheter tip positioning and a patient's height (p = 0.04).,"[{'ForeName': 'Madan Mohan', 'Initials': 'MM', 'LastName': 'Maddali', 'Affiliation': 'Department of Cardiac Anesthesia, National Heart Center, Royal Hospital, Muscat, Oman. Electronic address: madanmaddali@hotmail.com.'}, {'ForeName': 'Fathiya', 'Initials': 'F', 'LastName': 'Al-Shamsi', 'Affiliation': 'Anesthesia Residency Training Program, Oman Medical Specialty Board, Muscat, Oman.'}, {'ForeName': 'Nishant Ram', 'Initials': 'NR', 'LastName': 'Arora', 'Affiliation': 'Department of Cardiac Anesthesia, National Heart Center, Royal Hospital, Muscat, Oman.'}, {'ForeName': 'Sathiya Murthi', 'Initials': 'SM', 'LastName': 'Panchatcharam', 'Affiliation': 'Department of Studies and Research, Oman Medical Specialty Board, Muscat, Oman.'}]",Journal of cardiothoracic and vascular anesthesia,['10.1053/j.jvca.2020.03.007'] 58,32362552,"Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial.","PURPOSE To generate conclusive evidence regarding the noninferiority of intravitreal bevacizumab compared with ranibizumab in patients with diabetic macular edema (DME). DESIGN Comparative, randomized, double-masked, multicenter, noninferiority clinical trial. PARTICIPANTS Eligible patients were older than 18 years, diagnosed with type 1 or type 2 diabetes mellitus, with glycosylated hemoglobin of less than 12%, central area thickness of more than 325 μm, and visual impairment from DME with a best-corrected visual acuity (BCVA) between 24 letters and 78 letters. METHODS From June 2012 through February 2018, a total of 170 participants were randomized to receive 6 monthly injections of either 1.25 mg bevacizumab (n = 86) or 0.5 mg ranibizumab (n = 84). MAIN OUTCOME MEASURES Primary outcome was change in BCVA from baseline to month 6 compared between the 2 treatment arms. The noninferiority margin was 3.5 letters. RESULTS The difference in mean BCVA between treatment arms was 1.8 letters in favor of ranibizumab after 6 months of follow-up; BCVA improved by 4.9±6.7 letters in the bevacizumab group and 6.7±8.7 letters in the ranibizumab group. The lower bound of the 2-sided 90% confidence interval (CI) was -3.626 letters, exceeding the noninferiority margin of 3.5 letters. Central area thickness decreased more with ranibizumab (138.2±114.3 μm) compared with bevacizumab (64.2±104.2 μm). In a post hoc subgroup analysis, participants with a worse BCVA at baseline (≤69 letters) improved by 6.7±7.0 letters with bevacizumab and 10.4±10.0 letters with ranibizumab, and central area thickness decreased significantly more in the ranibizumab arm of this subgroup compared with the bevacizumab arm. Participants with an initially better BCVA at baseline (≥70 letters) did not demonstrate differences in BCVA or OCT outcomes between treatment arms. CONCLUSIONS Based on change in BCVA from baseline to month 6, the noninferiority of 1.25 mg bevacizumab to 0.5 mg ranibizumab was not confirmed. Only the subgroup of patients with a lower BCVA at baseline showed better visual acuity and anatomic outcomes with ranibizumab. Our study confirmed the potential differential efficacy of anti-vascular endothelial growth factor agents in the treatment of DME as well as the difference in response between patient groups with different baseline visual acuities.",2020,Central area thickness decreased more with ranibizumab (138.2±114.3 μm) compared with bevacizumab (64.2±104.2 μm).,"['From June 2012 through February 2018, a total of 170 participants', 'patients with diabetic macular edema (DME', 'Patients with Diabetic Macular Edema (BRDME', 'Eligible patients were older than 18 years, diagnosed with type 1 or type 2 diabetes mellitus, with glycosylated hemoglobin of less than 12%, central area thickness of more than 325 μm, and visual impairment from DME with a best-corrected visual acuity (BCVA) between 24 letters and 78 letters']","['anti-vascular endothelial growth factor agents', 'Bevacizumab and\xa0Ranibizumab', 'ranibizumab', 'bevacizumab']","['mean BCVA', 'central area thickness', 'change in BCVA', 'visual acuity and anatomic outcomes', 'BCVA or OCT outcomes', 'Central area thickness', 'BCVA']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0730285', 'cui_str': 'Macular edema due to diabetes mellitus'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0017853', 'cui_str': 'Glycosylated hemoglobin'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C4517714', 'cui_str': '325'}, {'cui': 'C0042798', 'cui_str': 'Dim vision'}, {'cui': 'C1690532', 'cui_str': 'Best corrected visual acuity'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0282413', 'cui_str': 'Letters as Topic'}]","[{'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C1566537', 'cui_str': 'ranibizumab'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0220784', 'cui_str': 'Anatomic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0029279', 'cui_str': 'Ornithine carbamoyltransferase'}]",170.0,0.494608,Central area thickness decreased more with ranibizumab (138.2±114.3 μm) compared with bevacizumab (64.2±104.2 μm).,"[{'ForeName': 'Maartje J C', 'Initials': 'MJC', 'LastName': 'Vader', 'Affiliation': 'Department of Ophthalmology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Ann-Sofie M E', 'Initials': 'AME', 'LastName': 'Schauwvlieghe', 'Affiliation': 'Department of Ophthalmology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Frank D', 'Initials': 'FD', 'LastName': 'Verbraak', 'Affiliation': 'Department of Ophthalmology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Greetje', 'Initials': 'G', 'LastName': 'Dijkman', 'Affiliation': 'Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Johanna M M', 'Initials': 'JMM', 'LastName': 'Hooymans', 'Affiliation': 'Department of Ophthalmology, University Medical Center Groningen and W. J. Kolff Institute, Graduate School of Medical Sciences, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Leonoor I', 'Initials': 'LI', 'LastName': 'Los', 'Affiliation': 'Department of Ophthalmology, University Medical Center Groningen and W. J. Kolff Institute, Graduate School of Medical Sciences, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Aeilko H', 'Initials': 'AH', 'LastName': 'Zwinderman', 'Affiliation': 'Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Tunde', 'Initials': 'T', 'LastName': 'Peto', 'Affiliation': 'Department of Ophthalmology, Queens University Belfast, Belfast, United Kingdom.'}, {'ForeName': 'Carel B', 'Initials': 'CB', 'LastName': 'Hoyng', 'Affiliation': 'Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'Redmer', 'Initials': 'R', 'LastName': 'van Leeuwen', 'Affiliation': 'Department of Ophthalmology, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Johannes R', 'Initials': 'JR', 'LastName': 'Vingerling', 'Affiliation': 'Department of Ophthalmology, Erasmus University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Annette C', 'Initials': 'AC', 'LastName': 'Moll', 'Affiliation': 'Department of Ophthalmology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Janneke J C', 'Initials': 'JJC', 'LastName': 'van Lith-Verhoeven', 'Affiliation': 'Department of Ophthalmology, Elisabeth-TweeSteden (ETZ) Hospital, Tilburg, The Netherlands.'}, {'ForeName': 'Marcel G W', 'Initials': 'MGW', 'LastName': 'Dijkgraaf', 'Affiliation': 'Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Reinier O', 'Initials': 'RO', 'LastName': 'Schlingemann', 'Affiliation': 'Department of Ophthalmology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Lausanne, Switzerland. Electronic address: r.o.schlingemann@amsterdamumc.nl.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Ophthalmology. Retina,['10.1016/j.oret.2020.02.008'] 59,32374395,Association of Neurodevelopmental Outcomes With Environmental Exposure to Cyclohexanone During Neonatal Congenital Cardiac Operations: A Secondary Analysis of a Randomized Clinical Trial.,"Importance Cyclohexanone is an industrial solvent used as a coupling agent in medical plastics. Perioperative exposure to cyclohexanone could play a role in lower scores on measures of neurodevelopmental outcomes after neonatal cardiac operations. Objective To examine the presence and association of serum cyclohexanone level with neonatal cardiac operations and neurodevelopmental outcomes. Design, Setting, and Participants This ad hoc secondary analysis used data from the Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass randomized clinical trial. The cohort included neonates younger than 31 days and with at least 37 weeks postgestational age at surgical treatment who were enrolled at a single center between June 1, 2012, and October 31, 2016, and who had completed a neurodevelopmental assessment at age 12 months. Data were analyzed from July 8 to August 20, 2019. Exposures Serum cyclohexanone and its metabolites were measured preoperatively (prior to skin incision), postoperatively (immediately after the surgical procedure was completed), and 12 hours postoperatively. Cyclohexanone and the molar sum of its metabolites were examined at each point and as a geometric mean of all 3 points. Main Outcomes and Measures Neurodevelopment was assessed at age 12 months with the Bayley Scales of Infant and Toddler Development III, assessing cognitive, language, and motor function composite scores standardized to a population mean (SD) of 100 (15). Linear regression models were used to determine covariate-adjusted differences in 12-month cognitive, language, and motor composite scores per interquartile range increase in cyclohexanone level or summed metabolite molar concentrations. Results Among 85 included neonates, mean (SD) age at surgical treatment was 9.7 (5.3) days, 49 (58%) were boys, and 54 (64%) underwent corrective repair. Mean (SD) Bayley Scales of Infant and Toddler Development III composite scores were 108.2 (12.2) for cognitive function, 104.7 (11.0) for language function, and 94.7 (15.7) for motor function. Median (interquartile range) cyclohexanone levels increased approximately 3-fold from immediately prior to surgical treatment to immediately after surgical treatment (572 [389-974] vs 1744 [1469-2291] μg/L; P = .001). In adjusted analyses, higher geometric mean cyclohexanone levels were associated with significantly lower composite scores for cognitive (-4.23; 95% CI, -7.39 to -1.06; P = .01) and language (-3.65; 95% CI, -6.41 to -0.88; P = .01) function. The difference in composite scores for motor function among infants with higher geometric mean cyclohexanone levels was not statistically significant(-3.93, 95% CI: -8.19 to 0.33, P = .07). Conclusions and Relevance The findings of this secondary analysis of a randomized clinical trial suggest that infants who underwent neonatal cardiac surgical treatment with cardiopulmonary bypass had substantial cyclohexanone levels, which were associated with adverse neurodevelopmental function at age 12 months. Trial Registration ClinicalTrials.gov identifier: NCT01579513.",2020,"The difference in composite scores for motor function among infants with higher geometric mean cyclohexanone levels was not statistically significant(-3.93, 95% CI: -8.19 to 0.33, P = .07). ","['Neonates Undergoing Cardiopulmonary Bypass randomized clinical trial', 'cohort included neonates younger than 31 days and with at least 37 weeks postgestational age at surgical treatment who were enrolled at a single center between June 1, 2012, and October 31, 2016, and who had completed a neurodevelopmental assessment at age 12 months', '85 included neonates', 'Neonatal Congenital Cardiac Operations']","['cyclohexanone', 'neonatal cardiac surgical treatment with cardiopulmonary bypass', 'Environmental Exposure to Cyclohexanone', 'Cyclohexanone', 'Corticosteroid Therapy']","['adverse neurodevelopmental function', 'Median (interquartile range) cyclohexanone levels', 'composite scores for motor function', 'Mean (SD) Bayley Scales of Infant and Toddler Development III composite scores', 'neurodevelopmental outcomes', 'Exposures\n\n\nSerum cyclohexanone and its metabolites', 'Bayley Scales of Infant and Toddler Development III, assessing cognitive, language, and motor function composite scores standardized to a population mean (SD) of 100 (15', 'geometric mean cyclohexanone levels']","[{'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0009678', 'cui_str': 'congenital'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}]","[{'cui': 'C0010571', 'cui_str': 'Cyclohexanones'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}, {'cui': 'C0014412', 'cui_str': 'Environmental exposure'}, {'cui': 'C0149783', 'cui_str': 'Administration of steroid'}]","[{'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0010571', 'cui_str': 'Cyclohexanones'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0682053', 'cui_str': 'Toddler'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1704407', 'cui_str': '100'}]",,0.168514,"The difference in composite scores for motor function among infants with higher geometric mean cyclohexanone levels was not statistically significant(-3.93, 95% CI: -8.19 to 0.33, P = .07). ","[{'ForeName': 'Allen D', 'Initials': 'AD', 'LastName': 'Everett', 'Affiliation': 'Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Jessie P', 'Initials': 'JP', 'LastName': 'Buckley', 'Affiliation': 'Johns Hopkins Bloomberg School of Public Health, Department of Environmental Health and Engineering, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Ellis', 'Affiliation': ""Molecular Determinants Core, Johns Hopkins All Children's Hospital, St Petersburg, Florida.""}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Graham', 'Affiliation': 'Department of Anesthesia and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Griffiths', 'Affiliation': 'Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Melania', 'Initials': 'M', 'LastName': 'Bembea', 'Affiliation': 'Department of Anesthesia and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Eric M', 'Initials': 'EM', 'LastName': 'Graham', 'Affiliation': 'Department of Pediatrics, Division of Cardiology, Medical University of South Carolina; Charleston.'}]",JAMA network open,['10.1001/jamanetworkopen.2020.4070'] 60,32359142,Dose-response effects of dietary protein on muscle protein synthesis during recovery from endurance exercise in young men: a double-blind randomized trial.,"BACKGROUND Protein ingestion increases skeletal muscle protein synthesis rates during recovery from endurance exercise. OBJECTIVES We aimed to determine the effect of graded doses of dietary protein co-ingested with carbohydrate on whole-body protein metabolism, and skeletal muscle myofibrillar (MyoPS) and mitochondrial (MitoPS) protein synthesis rates during recovery from endurance exercise. METHODS In a randomized, double-blind, parallel-group design, 48 healthy, young, endurance-trained men (mean ± SEM age: 27 ± 1 y) received a primed continuous infusion of l-[ring-2H5]-phenylalanine, l-[ring-3,5-2H2]-tyrosine, and l-[1-13C]-leucine and ingested 45 g carbohydrate with either 0 (0 g PRO), 15 (15 g PRO), 30 (30 g PRO), or 45 (45 g PRO) g intrinsically l-[1-13C]-phenylalanine and l-[1-13C]-leucine labeled milk protein after endurance exercise. Blood and muscle biopsy samples were collected over 360 min of postexercise recovery to assess whole-body protein metabolism and both MyoPS and MitoPS rates. RESULTS Protein intake resulted in ∼70%-74% of the ingested protein-derived phenylalanine appearing in the circulation. Whole-body net protein balance increased dose-dependently after ingestion of 0, 15, 30, or 45 g protein (mean ± SEM: -0.31± 0.16, 5.08 ± 0.21, 10.04 ± 0.30, and 13.49 ± 0.55 μmol phenylalanine · kg-1 · h-1, respectively; P < 0.001). 30 g PRO stimulated a ∼46% increase in MyoPS rates (%/h) compared with 0 g PRO and was sufficient to maximize MyoPS rates after endurance exercise. MitoPS rates were not increased after protein ingestion; however, incorporation of dietary protein-derived l-[1-13C]-phenylalanine into de novo mitochondrial protein increased dose-dependently after ingestion of 15, 30, and 45 g protein at 360 min postexercise (0.018 ± 0.002, 0.034 ± 0.002, and 0.046 ± 0.003 mole percentage excess, respectively; P < 0.001). CONCLUSIONS Protein ingested after endurance exercise is efficiently digested and absorbed into the circulation. Whole-body net protein balance and dietary protein-derived amino acid incorporation into mitochondrial protein respond to increasing protein intake in a dose-dependent manner. Ingestion of 30 g protein is sufficient to maximize MyoPS rates during recovery from a single bout of endurance exercise.This trial was registered at trialregister.nl as NTR5111.",2020,30 g PRO stimulated a ∼46% increase in MyoPS rates (%/h) compared with 0 g PRO and was sufficient to maximize MyoPS rates after endurance exercise.,"['48 healthy, young, endurance-trained men (mean\xa0±\xa0SEM age: 27\xa0±\xa01 y) received a', 'young men']","['l-[1-13C]-phenylalanine and l-[1-13C]-leucine labeled milk protein after endurance exercise', 'dietary protein co-ingested with carbohydrate', 'dietary protein', 'Protein ingestion', 'primed continuous infusion of l-[ring-2H5]-phenylalanine, l-[ring-3,5-2H2]-tyrosine, and l-[1-13C]-leucine and ingested 45 g carbohydrate with either 0 (0 g PRO', 'endurance exercise']","['incorporation of dietary protein-derived l-[1-13C]-phenylalanine into de novo mitochondrial protein', 'muscle protein synthesis', 'whole-body protein metabolism, and skeletal muscle myofibrillar (MyoPS) and mitochondrial (MitoPS) protein synthesis rates', 'MyoPS rates', 'Blood and muscle biopsy samples', 'MitoPS rates']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0262878', 'cui_str': 'Scanning electron microscope'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0031453', 'cui_str': 'Phenylalanine'}, {'cui': 'C0023401', 'cui_str': 'Leucine'}, {'cui': 'C0026138', 'cui_str': 'Milk protein'}, {'cui': 'C0419120', 'cui_str': 'Muscular endurance development exercise'}, {'cui': 'C0012177', 'cui_str': 'Proteins, Dietary'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0331021', 'cui_str': 'Ligustrum vulgare'}, {'cui': 'C0444889', 'cui_str': 'Continuous infusion'}, {'cui': 'C0521164', 'cui_str': 'Annular shape'}, {'cui': 'C0041485', 'cui_str': 'Tyrosine'}, {'cui': 'C0033382', 'cui_str': 'Proline'}]","[{'cui': 'C0243126', 'cui_str': 'incorporation'}, {'cui': 'C0012177', 'cui_str': 'Proteins, Dietary'}, {'cui': 'C0031453', 'cui_str': 'Phenylalanine'}, {'cui': 'C0949610', 'cui_str': 'Mitochondrial Protein'}, {'cui': 'C0026832', 'cui_str': 'Muscle Protein'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0587033', 'cui_str': 'Muscle biopsy sample'}]",,0.0582953,30 g PRO stimulated a ∼46% increase in MyoPS rates (%/h) compared with 0 g PRO and was sufficient to maximize MyoPS rates after endurance exercise.,"[{'ForeName': 'Tyler A', 'Initials': 'TA', 'LastName': 'Churchward-Venne', 'Affiliation': 'NUTRIM School of Nutrition and Translational Research in Metabolism, Department of Human Biology, Maastricht University Medical Center+, Maastricht, Netherlands.'}, {'ForeName': 'Philippe J M', 'Initials': 'PJM', 'LastName': 'Pinckaers', 'Affiliation': 'NUTRIM School of Nutrition and Translational Research in Metabolism, Department of Human Biology, Maastricht University Medical Center+, Maastricht, Netherlands.'}, {'ForeName': 'Joey S J', 'Initials': 'JSJ', 'LastName': 'Smeets', 'Affiliation': 'NUTRIM School of Nutrition and Translational Research in Metabolism, Department of Human Biology, Maastricht University Medical Center+, Maastricht, Netherlands.'}, {'ForeName': 'Milan W', 'Initials': 'MW', 'LastName': 'Betz', 'Affiliation': 'NUTRIM School of Nutrition and Translational Research in Metabolism, Department of Human Biology, Maastricht University Medical Center+, Maastricht, Netherlands.'}, {'ForeName': 'Joan M', 'Initials': 'JM', 'LastName': 'Senden', 'Affiliation': 'NUTRIM School of Nutrition and Translational Research in Metabolism, Department of Human Biology, Maastricht University Medical Center+, Maastricht, Netherlands.'}, {'ForeName': 'Joy P B', 'Initials': 'JPB', 'LastName': 'Goessens', 'Affiliation': 'NUTRIM School of Nutrition and Translational Research in Metabolism, Department of Human Biology, Maastricht University Medical Center+, Maastricht, Netherlands.'}, {'ForeName': 'Annemie P', 'Initials': 'AP', 'LastName': 'Gijsen', 'Affiliation': 'NUTRIM School of Nutrition and Translational Research in Metabolism, Department of Human Biology, Maastricht University Medical Center+, Maastricht, Netherlands.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Rollo', 'Affiliation': 'Gatorade Sports Science Institute, Leicester, United Kingdom.'}, {'ForeName': 'Lex B', 'Initials': 'LB', 'LastName': 'Verdijk', 'Affiliation': 'NUTRIM School of Nutrition and Translational Research in Metabolism, Department of Human Biology, Maastricht University Medical Center+, Maastricht, Netherlands.'}, {'ForeName': 'Luc J C', 'Initials': 'LJC', 'LastName': 'van Loon', 'Affiliation': 'NUTRIM School of Nutrition and Translational Research in Metabolism, Department of Human Biology, Maastricht University Medical Center+, Maastricht, Netherlands.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqaa073'] 61,31813584,Testing Alertness of Emergency Physicians: A Novel Quantitative Measure of Alertness and Implications for Worker and Patient Care.,"BACKGROUND Establishing practical solutions to manage fatigue in health care settings could reduce errors. Predictive Safety SRP Inc.'s AlertMeter is a 2-min cognitive assessment tool currently used in high-hazard industries to identify fatigued staff. OBJECTIVE No prior study has attempted to address fatigue in emergency medicine (EM). We objectively assessed provider alertness to determine potential application of software-based fatigue recognition for risk reduction. METHODS In a double-blind, prospective evaluation from July 1 to September 30, 2016, we applied the AlertMeter to EM residents at an academic level I trauma center. The tool was applied before and after shifts to evaluate alertness in three types of shifts: day, evening, and night. All residents were invited to participate-27 of 30 enrolled. Analysis of covariance (ANCOVA) was implemented to examine shift and completion effects on alertness score using baseline score as a covariate. Additionally, three separate ANCOVAs were conducted to examine alertness score differences between portion (start vs. end) and type of shift (day, evening, or night). RESULTS Residents were significantly less alert at the completion of the evening shift. Scores at the end of the night shift were significantly lower than the start of the night shift. CONCLUSIONS Alertness software can be reliably integrated into the emergency department. Alertness was lower at the end of the evening shift and end of the night shift. This work could have positive implications on shift and task scheduling and potentially reduce errors in patient care by quantifying providers' fatigue and identifying areas for countermeasures.",2020,"RESULTS Residents were significantly less alert at the completion of the evening shift.","['July 1 to September 30, 2016, we applied the AlertMeter to EM residents at an academic level I trauma center', 'All residents were invited to participate-27 of 30 enrolled', 'Emergency Physicians', 'Worker and Patient Care']",[],['Alertness'],"[{'cui': 'C0013964', 'cui_str': 'Emergency medicine'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0441925', 'cui_str': 'Level I'}, {'cui': 'C0040786', 'cui_str': 'Trauma center'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",[],[],,0.0255933,"RESULTS Residents were significantly less alert at the completion of the evening shift.","[{'ForeName': 'Brian A', 'Initials': 'BA', 'LastName': 'Ferguson', 'Affiliation': 'Department of Emergency Medicine, University of Louisville, Louisville, Kentucky.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Lauriski', 'Affiliation': 'Predictive Safety SRP Inc., PRISM Services, Centennial, Colorado.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Huecker', 'Affiliation': 'Department of Emergency Medicine, University of Louisville, Louisville, Kentucky.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Wichmann', 'Affiliation': 'Predictive Safety SRP Inc., PRISM Services, Centennial, Colorado.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Shreffler', 'Affiliation': 'Department of Emergency Medicine, University of Louisville, Louisville, Kentucky.'}, {'ForeName': 'Hugh', 'Initials': 'H', 'LastName': 'Shoff', 'Affiliation': 'Department of Emergency Medicine, University of Louisville, Louisville, Kentucky.'}]",The Journal of emergency medicine,['10.1016/j.jemermed.2019.10.032'] 62,32378726,High-intensity arm resistance training does not lead to better outcomes than low-intensity resistance training in patients after subacute stroke: A randomized controlled trial.,"OBJECTIVE To describe the effects of 2 levels of intensity of arm resistance training on grip strength, arm function, activities, participation, and adverse events in patients with subacute stroke. DESIGN A randomized controlled and preregistered trial with concealed allocation, assessor blinding and intention-to-treat analysis. PATIENTS Patients with subacute stroke and upper extremity hemiparesis. METHODS After randomization the experimental group received a 3-week high-intensity arm resistance training (HIT). The control group completed a 3-week low-intensity arm resistance training (LIT). The primary outcome was grip strength. Secondary outcomes included the Motricity Index, Fugl-Meyer Assessment for the upper limb, Box and Block Test, Goal Attainment Scale, Modified Ashworth Scale, and adverse events. All outcomes were assessed at baseline and after 3 weeks of intervention. RESULTS A total of 43 patients were investigated (HIT, n = 23; LIT, n = 20). All primary and secondary outcomes improved after the 3-week training, but no significant between-group differences were found. Adverse events occurred in 5% of training sessions (19/369). CONCLUSION The results of this study did not show differential effects on any outcome of 2 forms of arm resistance training in patients with subacute stroke.",2020,"Secondary outcomes included the Motricity Index, Fugl-Meyer Assessment for the upper limb, Box and Block Test, Goal Attainment Scale, Modified Ashworth Scale, and adverse events.","['patients with subacute stroke', '43 patients were investigated (HIT, n\u2009=\u200923; LIT, n\u2009=\u200920', 'patients after subacute stroke', 'Patients with subacute stroke and upper extremity hemiparesis']","['3-week high-intensity arm resistance training (HIT', 'low-intensity resistance training', 'High-intensity arm resistance training', '3-week low-intensity arm resistance training (LIT']","['Adverse events', 'grip strength, arm function, activities, participation, and adverse events', 'Motricity Index, Fugl-Meyer Assessment for the upper limb, Box and Block Test, Goal Attainment Scale, Modified Ashworth Scale, and adverse events', 'grip strength']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205365', 'cui_str': 'Subacute'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0018989', 'cui_str': 'Hemiparesis'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0451322', 'cui_str': 'Motricity index'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0006080', 'cui_str': 'Boxing'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C4707572', 'cui_str': 'Modified Ashworth Scale'}]",43.0,0.0821925,"Secondary outcomes included the Motricity Index, Fugl-Meyer Assessment for the upper limb, Box and Block Test, Goal Attainment Scale, Modified Ashworth Scale, and adverse events.","[{'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Högg', 'Affiliation': 'Department of Physiotherapy, Asklepios Kliniken Schildautal, , Seesen, Germany.'}, {'ForeName': 'Manfred', 'Initials': 'M', 'LastName': 'Holzgraefe', 'Affiliation': ''}, {'ForeName': 'Carolin', 'Initials': 'C', 'LastName': 'Drüge', 'Affiliation': ''}, {'ForeName': 'Frederik', 'Initials': 'F', 'LastName': 'Hauschild', 'Affiliation': ''}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Herrmann', 'Affiliation': ''}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Obermann', 'Affiliation': ''}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Mehrholz', 'Affiliation': ''}]",Journal of rehabilitation medicine,['10.2340/16501977-2686'] 63,32374272,Self-Administered Skills-Based Virtual Reality Intervention for Chronic Pain: Randomized Controlled Pilot Study.,"BACKGROUND Patients with chronic pain often have limited access to comprehensive care that includes behavioral pain management strategies. Virtual reality (VR) is an immersive technology and emerging digital behavioral pain therapy with analgesic efficacy for acute pain. We found no scientific literature on skills-based VR behavioral programs for chronic pain populations. OBJECTIVE The primary aim of this study is to evaluate the feasibility of a self-administered VR program that included content and skills informed by evidence-based behavioral treatment for chronic pain. The secondary aim is to determine the preliminary efficacy of the VR program in terms of average pain intensity and pain-related interference with activity, stress, mood, and sleep, and its impact on pain-related cognition and self-efficacy. The tertiary aim was to conduct a randomized controlled trial (RCT) and compare the VR treatment with an audio-only treatment. This comparison isolated the immersive effects of the VR program, thereby informing potential mechanisms of effect. METHODS We conducted an RCT involving a web-based convenience sample of adults (N=97) aged 18-75 years with self-reported chronic nonmalignant low back pain or fibromyalgia, with an average pain intensity >4 over the past month and chronic pain duration >6 months. Enrolled participants were randomly assigned to 1 of 2 unblinded treatments: (1) VR: a 21-day, skills-based VR program for chronic pain; and (2) audio: an audio-only version of the 21-day VR program. The analytic data set included participants who completed at least 1 of 8 surveys administered during the intervention period: VR (n=39) and audio (n=35). RESULTS The VR and audio groups launched a total of 1067 and 1048 sessions, respectively. The majority of VR participants (n=19/25, 76%) reported no nausea or motion sickness. High satisfaction ratings were reported for VR (n=24/29, 83%) and audio (n=26/33, 72%). For VR efficacy, symptom improvement over time was found for each pain variable (all P<.001), with results strengthening after 2 weeks. Importantly, significant time×group effects were found in favor of the VR group for average pain intensity (P=.04), pain-related inference with activity (P=.005), sleep (P<.001), mood (P<.001), and stress (P=.003). For pain catastrophizing and pain self-efficacy, we found a significant declining trend for both treatment groups. CONCLUSIONS High engagement and satisfaction combined with low levels of adverse effects support the feasibility and acceptability of at-home skills-based VR for chronic pain. A significant reduction in pain outcomes over the course of the 21-day treatment both within the VR group and compared with an audio-only version suggests that VR has the potential to provide enhanced treatment and greater improvement across a range of pain outcomes. These findings provide a foundation for future research on VR behavioral interventions for chronic pain.",2020,"For VR efficacy, symptom improvement over time was found for each pain variable (all P<.001) with results strengthening after two weeks.","['participants who completed at least one of eight surveys administered during the intervention period: VR (n=39) and Audio (n=35', 'online convenience sample of adults (N=97) 18-65 years of age with self-reported chronic non-malignant chronic low back pain or fibromyalgia with an average pain intensity > 4 over the past month, and chronic pain duration > 6 months', 'acute pain', 'chronic pain', 'Chronic Pain', 'Patients with chronic pain', 'Methods']","['self-administered VR program', 'Self-Administered Skills-Based Virtual Reality Intervention', 'RCT', 'Virtual reality (VR', 'VR: a 21-day, skills-based VR program for chronic pain; and (2) Audio: an audio-only version of the 21-day VR program', 'VR program']","['average pain intensity and pain-related interference with activity, stress, mood, and sleep, and its impact on pain-related cognition and self-efficacy', 'pain-catastrophizing and pain self-efficacy', 'nausea or motion sickness', 'feasibility and acceptability', 'High satisfaction ratings', 'pain-related inference with activity (P=.005), sleep (P<.001), mood (P<.001), and stress', 'pain outcomes', 'average pain intensity', 'adverse effects']","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205282', 'cui_str': 'Malignant'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0184567', 'cui_str': 'Acute pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C2607870', 'cui_str': 'Version'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0026603', 'cui_str': 'Motion sickness'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",,0.0617575,"For VR efficacy, symptom improvement over time was found for each pain variable (all P<.001) with results strengthening after two weeks.","[{'ForeName': 'Beth D', 'Initials': 'BD', 'LastName': 'Darnall', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Palo Alto, CA, United States.'}, {'ForeName': 'Parthasarathy', 'Initials': 'P', 'LastName': 'Krishnamurthy', 'Affiliation': 'C.T. Bauer College of Business, University of Houston, Houston, TX, United States.'}, {'ForeName': 'Jeannette', 'Initials': 'J', 'LastName': 'Tsuei', 'Affiliation': 'AppliedVR, Inc, Los Angeles, CA, United States.'}, {'ForeName': 'Jorge D', 'Initials': 'JD', 'LastName': 'Minor', 'Affiliation': 'L.A. Pain & Wellness Institute, Los Angeles, CA, United States.'}]",JMIR formative research,['10.2196/17293'] 64,32371401,Limit of detection of troponin discharge strategy versus usual care: randomised controlled trial.,"INTRODUCTION The clinical effectiveness of a 'rule-out' acute coronary syndrome (ACS) strategy for emergency department patients with chest pain, incorporating a single undetectable high-sensitivity cardiac troponin (hs-cTn) taken at presentation, together with a non-ischaemic ECG, remains unknown. METHODS A randomised controlled trial, across eight hospitals in the UK, aimed to establish the clinical effectiveness of an undetectable hs-cTn and ECG (limit of detection and ECG discharge (LoDED)) discharge strategy. Eligible adult patients presented with chest pain; the treating clinician intended to perform investigations to rule out an ACS; the initial ECG was non-ischaemic; and peak symptoms occurred <6 hours previously. Participants were randomised 1:1 to either the LoDED strategy or the usual rule-out strategy. The primary outcome was discharge from the hospital within 4 hours of arrival, without a major adverse cardiac event (MACE) within 30 days. RESULTS Between June 2018 and March 2019, 632 patients were randomised; 3 were later withdrawn. Of 629 patients (age 53.8 (SD 16.1) years, 41% women), 7% had a MACE within 30 days. For the LoDED strategy, 141 of 309 (46%) patients were discharged within 4 hours, without MACE within 30 days, and for usual care, 114 of 311 (37%); pooled adjusted OR 1.58 (95% CI 0.84 to 2.98). No patient with an initial undetectable hs-cTn had a MACE within 30 days. CONCLUSION The LoDED strategy facilitates safe early discharge in >40% of patients with chest pain. Clinical effectiveness is variable when compared with existing rule-out strategies and influenced by wider system factors. TRIAL REGISTRATION NUMBER ISRCTN86184521.",2020,"For the LoDED strategy, 141 of 309 (46%) patients were discharged within 4 hours, without MACE within 30 days, and for usual care, 114 of 311 (37%); pooled adjusted OR 1.58 (95% CI 0.84 to 2.98).","['patients with chest pain', 'Between June 2018 and March 2019', 'Eligible adult patients presented with chest pain', 'emergency department patients with chest pain, incorporating a single undetectable high-sensitivity cardiac troponin (hs-cTn) taken at presentation, together with a non-ischaemic ECG, remains unknown', '629 patients (age 53.8 (SD 16.1) years, 41% women), 7% had a MACE within 30 days', '632 patients were randomised; 3 were later withdrawn']","['MACE', 'LoDED strategy or the usual rule-out strategy', 'troponin discharge strategy']","['clinical effectiveness of an undetectable hs-cTn and ECG (limit of detection and ECG discharge (LoDED)) discharge strategy', 'discharge from the hospital within 4\u2009hours of arrival, without a major adverse cardiac event (MACE']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008031', 'cui_str': 'Chest pain'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C1096316', 'cui_str': 'Cardiac troponin'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0449450', 'cui_str': 'Presentation'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4319689', 'cui_str': '16.1'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C2718050', 'cui_str': 'Limits of Detection'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0041199', 'cui_str': 'Troponin'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}]","[{'cui': 'C3850123', 'cui_str': 'Treatment Effectiveness'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C1096316', 'cui_str': 'Cardiac troponin'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C2718050', 'cui_str': 'Limits of Detection'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1292426', 'cui_str': '4 hours'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",632.0,0.276477,"For the LoDED strategy, 141 of 309 (46%) patients were discharged within 4 hours, without MACE within 30 days, and for usual care, 114 of 311 (37%); pooled adjusted OR 1.58 (95% CI 0.84 to 2.98).","[{'ForeName': 'Edward Watts', 'Initials': 'EW', 'LastName': 'Carlton', 'Affiliation': 'Emergency Department, North Bristol NHS Trust, Bristol, UK eddcarlton@gmail.com.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Ingram', 'Affiliation': 'Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'Hazel', 'Initials': 'H', 'LastName': 'Taylor', 'Affiliation': 'Research Design Service South West, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Glynn', 'Affiliation': 'Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Kandiyali', 'Affiliation': 'Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Campbell', 'Affiliation': 'Peninsula Clinical Trials Unit, University of Plymouth, Plymouth, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Beasant', 'Affiliation': 'Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'Shahid', 'Initials': 'S', 'LastName': 'Aziz', 'Affiliation': 'Cardiology, North Bristol NHS Trust, Westbury on Trym, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Beresford', 'Affiliation': 'Biochemistry, North Bristol NHS Trust, Westbury on Trym, UK.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Kendall', 'Affiliation': 'Emergency Department, North Bristol NHS Trust, Bristol, UK.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Reuben', 'Affiliation': 'Emergency Department, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.'}, {'ForeName': 'Jason E', 'Initials': 'JE', 'LastName': 'Smith', 'Affiliation': 'Emergency Department, Derriford Hospital, Plymouth, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Chapman', 'Affiliation': 'Peninsula Clinical Trials Unit, University of Plymouth, Plymouth, UK.'}, {'ForeName': 'Siobhan', 'Initials': 'S', 'LastName': 'Creanor', 'Affiliation': 'Centre for Medical Statistics, Plymouth University, Plymouth, UK.'}, {'ForeName': 'Jonathan Richard', 'Initials': 'JR', 'LastName': 'Benger', 'Affiliation': 'Academic Department of Emergency care, The University Hospitals NHS Foundation trust, Bristol, UK.'}]",Heart (British Cardiac Society),['10.1136/heartjnl-2020-316692'] 65,32379217,"A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety.","OBJECTIVE The aim of this study was to select the minimum effective dose of estetrol (E4) for the treatment of vasomotor symptoms in postmenopausal women. METHODS This was a multicenter, randomized, double-blind, placebo-controlled study. Postmenopausal women (n = 257, of whom 32 were hysterectomized) aged 40 to 65 years, with ≥7 moderate to severe hot flushes (HFs) per day, or 50 or more moderate to severe HFs weekly, received 2.5, 5, 10, or 15 mg E4, or placebo once-daily for a period of 12 weeks. Efficacy was assessed by recording the frequency and severity of HFs. Overall safety was assessed by recording adverse events, measuring endometrial thickness, and monitoring bleeding patterns. Treatment groups were compared using analysis of covariance. RESULTS The frequency of moderate to severe HFs decreased with all E4 doses. The difference in the percentage change of weekly HF frequency was significant for 15 mg E4 versus placebo at both W4 (-66% vs -49%, P = 0.032) and W12 (-82% vs -65%, P = 0.022). The decrease in severity of HFs was significantly more pronounced for 15 mg E4 than for placebo at both W4 (-0.59 vs -0.33, P = 0.049) and W12 (-1.04 vs -0.66, P = 0.049); the other doses failed to achieve statistical significance. In nonhysterectomized women, endometrial thickness increased during treatment and normalized following progestin treatment at study completion. No endometrial hyperplasia was observed. CONCLUSIONS Estetrol 15 mg is considered to be the minimum effective daily oral dose for treatment of vasomotor symptoms. Its current seemingly favorable safety profile is further to be confirmed in phase 3 clinical development. : Video Summary:http://links.lww.com/MENO/A591.",2020,The decrease in severity of HFs was significantly more pronounced for 15 mg E4 than for placebo at both W4 (-0.59 vs -0.33,"['postmenopausal women', 'Postmenopausal women (n\u200a=\u200a257, of whom 32 were hysterectomized) aged 40 to 65 years, with ≥7 moderate to severe hot flushes (HFs) per day, or 50 or more moderate to severe HFs weekly, received 2.5, 5, 10, or 15\u200amg E4, or', 'postmenopausal women (E4Relief']","['placebo', ' Video Summary:http://links.lww.com/MENO/A591', 'estetrol (E4']","['severity of HFs', 'Vasomotor symptoms and overall safety', 'frequency and severity of HFs', 'adverse events, measuring endometrial thickness, and monitoring bleeding patterns', 'endometrial thickness', 'endometrial hyperplasia', 'percentage change of weekly HF frequency', 'Overall safety', 'Efficacy', 'frequency of moderate to severe HFs']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0600142', 'cui_str': 'Menopausal flushing'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C3844011', 'cui_str': '2.5'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0014899', 'cui_str': '15 alpha-Hydroxyestriol'}]","[{'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600142', 'cui_str': 'Menopausal flushing'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0014173', 'cui_str': 'Endometrial hyperplasia'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}]",,0.222659,The decrease in severity of HFs was significantly more pronounced for 15 mg E4 than for placebo at both W4 (-0.59 vs -0.33,"[{'ForeName': 'Ulysse', 'Initials': 'U', 'LastName': 'Gaspard', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Liège, Liège, Belgium.'}, {'ForeName': 'Mélanie', 'Initials': 'M', 'LastName': 'Taziaux', 'Affiliation': 'Mithra Pharmaceuticals, Liège, Belgium.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Mawet', 'Affiliation': 'Mithra Pharmaceuticals, Liège, Belgium.'}, {'ForeName': 'Maud', 'Initials': 'M', 'LastName': 'Jost', 'Affiliation': 'Mithra Pharmaceuticals, Liège, Belgium.'}, {'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Gordenne', 'Affiliation': 'Mithra Pharmaceuticals, Liège, Belgium.'}, {'ForeName': 'Herjan J T', 'Initials': 'HJT', 'LastName': 'Coelingh Bennink', 'Affiliation': 'Pantarhei Bioscience, Zeist, The Netherlands.'}, {'ForeName': 'Rogerio A', 'Initials': 'RA', 'LastName': 'Lobo', 'Affiliation': 'Columbia University Medical Center, New York, NY.'}, {'ForeName': 'Wulf H', 'Initials': 'WH', 'LastName': 'Utian', 'Affiliation': 'Case Western Reserve University School of Medicine, Cleveland, OH.'}, {'ForeName': 'Jean-Michel', 'Initials': 'JM', 'LastName': 'Foidart', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Liège, Liège, Belgium.'}]","Menopause (New York, N.Y.)",['10.1097/GME.0000000000001561'] 66,32377858,High definition three-dimensional exoscope (VITOM 3D) for microsurgery training: a preliminary experience.,"PURPOSE To assess the feasibility of a high definition 3D exoscope (VITOM ® ) for microsurgery training in a cohort of naïve medical students. METHODS Twenty-two consecutive medical students performed a battery of four exercises assessing basic microsurgical skills. The students were randomized in two different groups based on two different VITOM ® holding systems (VERSACRANE™ and ARTip™ cruise). Participants self-reported the VITOM ® system quality on a 4-point Likert scale (VITOM Quality Assessment Tool). The time needed to complete the exercises was analyzed. RESULTS All students successfully completed the training, and no technical issues were raised during the simulation. The majority of the individual items were judged ""good"" or ""very good"" (n = 187; 94.4%), regardless of the two groups. ""Image quality"" (n = 21; 95%), ""magnification rate"" (n = 20; 91%), ""stereoscopic effect"" (n = 19; 86%), and ""focusing"" (n = 18; 82%) represented the best-rated items. No statistically significant difference between the two groups was measured in almost all items of the VITOM Quality Assessment Tool (p > 0.05). The time needed to perform each exercise showed a statistically significant difference between groups in two tests (p < 0.05). CONCLUSION This study demonstrated the feasibility of a VITOM-based microsurgery training. The students' subjective assessment of the VITOM ® 3D system was promising in terms of technological quality and technical feasibility. Further studies are recommended to define which VITOM ® holding system could be more appropriate for microsurgery training.",2020,The students' subjective assessment of the VITOM ® 3D system was promising in terms of technological quality and technical feasibility.,"['microsurgery training in a cohort of naïve medical students', 'Twenty-two consecutive medical students']","['four exercises assessing basic microsurgical skills', 'VITOM-based microsurgery training', 'high definition 3D exoscope (VITOM ® ']","['time needed to perform each exercise', 'VITOM ® system quality on a 4-point Likert scale (VITOM Quality Assessment Tool', 'magnification rate', 'VITOM Quality Assessment Tool']","[{'cui': 'C0026035', 'cui_str': 'Microsurgery'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C4284772', 'cui_str': '22'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0026035', 'cui_str': 'Microsurgery'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C3539107', 'cui_str': 'Definition'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0451267', 'cui_str': 'Likert scale'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0336791', 'cui_str': 'Tool'}]",22.0,0.0174803,The students' subjective assessment of the VITOM ® 3D system was promising in terms of technological quality and technical feasibility.,"[{'ForeName': 'Armando', 'Initials': 'A', 'LastName': 'De Virgilio', 'Affiliation': 'Otorhinolaryngology Unit, IRCCS Humanitas Clinical and Research Center, Via Manzoni 56, 20089, Rozzano, MI, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Costantino', 'Affiliation': 'Otorhinolaryngology Unit, IRCCS Humanitas Clinical and Research Center, Via Manzoni 56, 20089, Rozzano, MI, Italy. andrea.costantino94@gmail.com.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Ebm', 'Affiliation': 'Simulation Center, Humanitas University, Via Rita Levi Montalcini, 4, 20090, Pieve Emanuele, MI, Italy.'}, {'ForeName': 'Valerio', 'Initials': 'V', 'LastName': 'Conti', 'Affiliation': 'Otorhinolaryngology Unit, IRCCS Humanitas Clinical and Research Center, Via Manzoni 56, 20089, Rozzano, MI, Italy.'}, {'ForeName': 'Tiziana', 'Initials': 'T', 'LastName': 'Mondello', 'Affiliation': 'Otorhinolaryngology Unit, IRCCS Humanitas Clinical and Research Center, Via Manzoni 56, 20089, Rozzano, MI, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Di Bari', 'Affiliation': 'Otorhinolaryngology Unit, IRCCS Humanitas Clinical and Research Center, Via Manzoni 56, 20089, Rozzano, MI, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Cugini', 'Affiliation': 'Otorhinolaryngology Unit, IRCCS Humanitas Clinical and Research Center, Via Manzoni 56, 20089, Rozzano, MI, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Mercante', 'Affiliation': 'Otorhinolaryngology Unit, IRCCS Humanitas Clinical and Research Center, Via Manzoni 56, 20089, Rozzano, MI, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Spriano', 'Affiliation': 'Otorhinolaryngology Unit, IRCCS Humanitas Clinical and Research Center, Via Manzoni 56, 20089, Rozzano, MI, Italy.'}]",European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,['10.1007/s00405-020-06014-7'] 67,32383125,Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial.,"BACKGROUND The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 causing the coronavirus disease (COVID-19) pandemic. Currently, there is a lack of evidence-based therapies to prevent COVID-19 following exposure to the virus, or to prevent worsening of symptoms following confirmed infection. We describe the design of a clinical trial of hydroxychloroquine for post-exposure prophylaxis (PEP) and pre-emptive therapy (PET) for COVID-19. METHODS We will conduct two nested multicentre international double-blind randomized placebo-controlled clinical trials of hydroxychloroquine for: 1) PEP of asymptomatic household contacts or healthcare workers exposed to COVID-19 within the past four days, and 2) PET for symptomatic outpatients with COVID-19 showing symptoms for less than four days. We will recruit 1,500 patients each for the PEP and PET trials. Participants will be randomized 1:1 to receive five days of hydroxychloroquine or placebo. The primary PEP trial outcome will be the incidence of symptomatic COVID-19. The primary PET trial outcome will be an ordinal scale of disease severity (not hospitalized, hospitalized without intensive care, hospitalization with intensive care, or death). Participant screening, informed consent, and follow-up will be exclusively internet-based with appropriate regulatory and research ethics board approvals in Canada and the United States. DISCUSSION These complementary randomized-controlled trials are innovatively designed and adequately powered to rapidly answer urgent questions regarding the effectiveness of hydroxychloroquine to reduce virus transmission and disease severity of COVID-19 during a pandemic. In-person participant follow-up will not be conducted to facilitate social distancing strategies and reduce risks of exposure to study personnel. Innovative trial approaches are needed to urgently assess therapeutic options to mitigate the global impact of this pandemic. TRIALS REGISTRATION clinicaltrials.gov (NCT04308668); registered 16 March, 2020.",2020,In-person participant follow-up will not be conducted to facilitate social distancing strategies and reduce risks of exposure to study personnel.,"['severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2', 'symptomatic outpatients with COVID-19 showing symptoms for less than four days', '1,500 patients each for the PEP and PET trials']","['hydroxychloroquine or placebo', 'Post-exposure prophylaxis or pre-emptive therapy', 'hydroxychloroquine', 'hydroxychloroquine for post-exposure prophylaxis (PEP) and pre-emptive therapy (PET', 'placebo']","['incidence of symptomatic COVID-19', 'ordinal scale of disease severity (not hospitalized, hospitalized without intensive care, hospitalization with intensive care, or death']","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1443861', 'cui_str': 'Post-exposure prophylaxis'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1443861', 'cui_str': 'Post-exposure prophylaxis'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0439080', 'cui_str': 'Ordinal number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",1500.0,0.697151,In-person participant follow-up will not be conducted to facilitate social distancing strategies and reduce risks of exposure to study personnel.,"[{'ForeName': 'Sylvain A', 'Initials': 'SA', 'LastName': 'Lother', 'Affiliation': 'Department of Internal Medicine, Section of Critical Care, University of Manitoba, Winnipeg, MB, Canada. slother@manitoba-physicians.ca.'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Abassi', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Alyssa', 'Initials': 'A', 'LastName': 'Agostinis', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Ananta S', 'Initials': 'AS', 'LastName': 'Bangdiwala', 'Affiliation': 'Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Cheng', 'Affiliation': 'Divisions of Infectious Diseases & Medical Microbiology, McGill University Health Centre, Montreal, QC, Canada.'}, {'ForeName': 'Glen', 'Initials': 'G', 'LastName': 'Drobot', 'Affiliation': 'Department of Medicine, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Engen', 'Affiliation': 'Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Kathy H', 'Initials': 'KH', 'LastName': 'Hullsiek', 'Affiliation': 'Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'Kelly', 'Affiliation': 'Department of Pediatrics and Child Health, Department of Pharmacology, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'Todd C', 'Initials': 'TC', 'LastName': 'Lee', 'Affiliation': 'Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Sarah M', 'Initials': 'SM', 'LastName': 'Lofgren', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Lauren J', 'Initials': 'LJ', 'LastName': 'MacKenzie', 'Affiliation': 'Section of Infectious Diseases, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Marten', 'Affiliation': 'Critical Care Research, St-Boniface Hospital, Winnipeg, MB, Canada.'}, {'ForeName': 'Emily G', 'Initials': 'EG', 'LastName': 'McDonald', 'Affiliation': 'Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Okafor', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Katelyn A', 'Initials': 'KA', 'LastName': 'Pastick', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Matthew F', 'Initials': 'MF', 'LastName': 'Pullen', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Radha', 'Initials': 'R', 'LastName': 'Rajasingham', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Ilan', 'Initials': 'I', 'LastName': 'Schwartz', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Caleb P', 'Initials': 'CP', 'LastName': 'Skipper', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Alexis F', 'Initials': 'AF', 'LastName': 'Turgeon', 'Affiliation': 'CHU de Québec - Université Laval Research Centre, Population Health and Optimal Health Practices Research Unit Trauma - Emergency - Critical Care Medicine, Université Laval, Quebec, QC, Canada.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Zarychanski', 'Affiliation': 'Department of Internal Medicine, Section of Critical Care, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Boulware', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}]",Canadian journal of anaesthesia = Journal canadien d'anesthesie,['10.1007/s12630-020-01684-7'] 68,32380460,Pilot Randomized Trial of a Transdisciplinary Geriatric and Palliative Care Intervention for Older Adults With Cancer.,"BACKGROUND Oncologists often struggle with managing the unique care needs of older adults with cancer. This study sought to determine the feasibility of delivering a transdisciplinary intervention targeting the geriatric-specific (physical function and comorbidity) and palliative care (symptoms and prognostic understanding) needs of older adults with advanced cancer. METHODS Patients aged ≥65 years with incurable gastrointestinal or lung cancer were randomly assigned to a transdisciplinary intervention or usual care. Those in the intervention arm received 2 visits with a geriatrician, who addressed patients' palliative care needs and conducted a geriatric assessment. We predefined the intervention as feasible if >70% of eligible patients enrolled in the study and >75% of eligible patients completed study visits and surveys. At baseline and week 12, we assessed patients' quality of life (QoL), symptoms, and communication confidence. We calculated mean change scores in outcomes and estimated intervention effect sizes (ES; Cohen's d) for changes from baseline to week 12, with 0.2 indicating a small effect, 0.5 a medium effect, and 0.8 a large effect. RESULTS From February 2017 through June 2018, we randomized 62 patients (55.9% enrollment rate [most common reason for refusal was feeling too ill]; median age, 72.3 years; cancer types: 56.5% gastrointestinal, 43.5% lung). Among intervention patients, 82.1% attended the first visit and 79.6% attended both. Overall, 89.7% completed all study surveys. Compared with usual care, intervention patients had less QoL decrement (-0.77 vs -3.84; ES = 0.21), reduced number of moderate/severe symptoms (-0.69 vs +1.04; ES = 0.58), and improved communication confidence (+1.06 vs -0.80; ES = 0.38). CONCLUSIONS In this pilot trial, enrollment exceeded 55%, and >75% of enrollees completed all study visits and surveys. The transdisciplinary intervention targeting older patients' unique care needs showed encouraging ES estimates for enhancing patients' QoL, symptom burden, and communication confidence.",2020,"Compared with usual care, intervention patients had less QoL decrement (-0.77 vs -3.84; ES = 0.21), reduced number of moderate/severe symptoms (-0.69 vs +1.04; ES = 0.58), and improved communication confidence (+1.06 vs -0.80; ES = 0.38). ","['Older Adults With Cancer', '62 patients (55.9% enrollment rate [most common reason for refusal was feeling too ill]; median age, 72.3 years; cancer types: 56.5% gastrointestinal, 43.5% lung', 'Patients aged ≥65 years with incurable gastrointestinal or lung cancer', 'eligible patients enrolled in the study and >75% of eligible patients completed study visits and surveys', 'older adults with cancer', 'From February 2017 through June 2018', 'older adults with advanced cancer']","['Transdisciplinary Geriatric and Palliative Care Intervention', 'transdisciplinary intervention', 'transdisciplinary intervention or usual care']","['QoL decrement', 'reduced number of moderate/severe symptoms', ""patients' quality of life (QoL), symptoms, and communication confidence"", 'communication confidence']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0040809', 'cui_str': 'Refusal of treatment by patient'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0231218', 'cui_str': 'Malaise'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}]","[{'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0436345', 'cui_str': 'Symptom severe'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}]",62.0,0.108189,"Compared with usual care, intervention patients had less QoL decrement (-0.77 vs -3.84; ES = 0.21), reduced number of moderate/severe symptoms (-0.69 vs +1.04; ES = 0.58), and improved communication confidence (+1.06 vs -0.80; ES = 0.38). ","[{'ForeName': 'Ryan D', 'Initials': 'RD', 'LastName': 'Nipp', 'Affiliation': '1Department of Medicine, Division of Hematology and Oncology, and.'}, {'ForeName': 'Brandon', 'Initials': 'B', 'LastName': 'Temel', 'Affiliation': '1Department of Medicine, Division of Hematology and Oncology, and.'}, {'ForeName': 'Charn-Xin', 'Initials': 'CX', 'LastName': 'Fuh', 'Affiliation': '1Department of Medicine, Division of Hematology and Oncology, and.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Kay', 'Affiliation': '1Department of Medicine, Division of Hematology and Oncology, and.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Landay', 'Affiliation': '1Department of Medicine, Division of Hematology and Oncology, and.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Lage', 'Affiliation': '1Department of Medicine, Division of Hematology and Oncology, and.'}, {'ForeName': 'Esteban', 'Initials': 'E', 'LastName': 'Franco-Garcia', 'Affiliation': '2Department of Medicine, Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Scott', 'Affiliation': '2Department of Medicine, Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Stevens', 'Affiliation': '2Department of Medicine, Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Terrence', 'Initials': 'T', 'LastName': ""O'Malley"", 'Affiliation': '2Department of Medicine, Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Supriya', 'Initials': 'S', 'LastName': 'Mohile', 'Affiliation': '4Department of Medicine, Division of Hematology and Oncology, University of Rochester Medical Center, Rochester, New York.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Dale', 'Affiliation': '5Department of Supportive Care Medicine, City of Hope National Medical Center, Duarte, California.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Traeger', 'Affiliation': '6Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; and.'}, {'ForeName': 'Ardeshir Z', 'Initials': 'AZ', 'LastName': 'Hashmi', 'Affiliation': '7Department of Internal Medicine and Geriatrics, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Vicki', 'Initials': 'V', 'LastName': 'Jackson', 'Affiliation': '2Department of Medicine, Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Joseph A', 'Initials': 'JA', 'LastName': 'Greer', 'Affiliation': '6Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; and.'}, {'ForeName': 'Areej', 'Initials': 'A', 'LastName': 'El-Jawahri', 'Affiliation': '1Department of Medicine, Division of Hematology and Oncology, and.'}, {'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Temel', 'Affiliation': '1Department of Medicine, Division of Hematology and Oncology, and.'}]",Journal of the National Comprehensive Cancer Network : JNCCN,['10.6004/jnccn.2019.7386'] 69,32391656,Long-term outcomes after perioperative treatment with omega-3 fatty acid supplements in colorectal cancer.,"BACKGROUND This study aimed to evaluate the effect of perioperative supplementation with omega-3 fatty acids (n-3 FA) on perioperative outcomes and survival in patients undergoing colorectal cancer surgery. METHODS Patients scheduled for elective resection of colorectal cancer between 2007 and 2010 were randomized to either an n-3 FA-enriched oral nutrition supplement (ONS) twice daily or a standard ONS (control) for 7 days before and after surgery. Outcome measures, including postoperative complications, 3-year cumulative incidence of local or metastatic colorectal cancer recurrence and 5-year overall survival, were compared between the groups. RESULTS Of 148 patients enrolled in the study, 125 (65 patients receiving n-3 FA-enriched ONS and 60 receiving standard ONS) were analysed. There were no differences in postoperative complications after surgery (P = 0·544). The risk of disease recurrence at 3 years was similar (relative risk 1·66, 95 per cent c.i. 0·65 to 4·26).The 5-year survival rate of patients treated with n-3 FA was 69·2 (95 per cent c.i. 56·5 to 78·9) per cent, compared with 81·7 (69·3 to 89·4) per cent in the control group (P = 0·193). After adjustment for age, stage of disease and adjuvant chemotherapy, n-3 FA was associated with higher mortality compared with controls (hazard ratio 1·73, 95 per cent c.i. 1·06 to 2·83; P = 0·029). The interaction between n-3 FA and adjuvant chemotherapy was not statistically significant. CONCLUSION Perioperative supplementation with n-3 FA did not confer a survival benefit in patients undergoing colorectal cancer surgery. n-3 FA did not benefit the subgroup of patients treated with adjuvant chemotherapy or decrease the risk of disease recurrence.",2020,"The risk of disease recurrence at 3 years was similar (relative risk 1·66, 95 per cent c.i.","['Patients scheduled for elective resection of colorectal cancer between 2007 and 2010', '148 patients enrolled in the study, 125 (65 patients receiving', 'colorectal cancer', 'patients undergoing colorectal cancer surgery']","['adjuvant chemotherapy', 'omega-3 fatty acids (n-3 FA', 'n-3 FA', 'n-3 FA-enriched ONS and 60 receiving standard ONS', 'omega-3 fatty acid supplements', 'n-3 FA-enriched oral nutrition supplement (ONS) twice daily or a standard ONS (control', 'n-3 FA and adjuvant chemotherapy']","['5-year survival rate', 'survival benefit', 'postoperative complications, 3-year cumulative incidence of local or metastatic colorectal cancer recurrence and 5-year overall survival', 'postoperative complications', 'risk of disease recurrence', 'perioperative outcomes and survival', 'higher mortality']","[{'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0679254', 'cui_str': 'Disease recurrence'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",148.0,0.24371,"The risk of disease recurrence at 3 years was similar (relative risk 1·66, 95 per cent c.i.","[{'ForeName': 'L Schmidt', 'Initials': 'LS', 'LastName': 'Sørensen', 'Affiliation': 'Department of Gastrointestinal Surgery, Aalborg, Denmark.'}, {'ForeName': 'S Ladefoged', 'Initials': 'SL', 'LastName': 'Rasmussen', 'Affiliation': 'Department of Gastrointestinal Surgery, Aalborg, Denmark.'}, {'ForeName': 'P C', 'Initials': 'PC', 'LastName': 'Calder', 'Affiliation': 'Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'M Nytoft', 'Initials': 'MN', 'LastName': 'Yilmaz', 'Affiliation': 'Department of Oncology, Aalborg, Denmark.'}, {'ForeName': 'E Berg', 'Initials': 'EB', 'LastName': 'Schmidt', 'Affiliation': 'Department of Cardiology, Aalborg, Denmark.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Thorlacius-Ussing', 'Affiliation': 'Department of Gastrointestinal Surgery, Aalborg, Denmark.'}]",BJS open,['10.1002/bjs5.50295'] 70,32289353,Risk of contamination when planning psychological therapy trials can be assessed using a simple framework.,"OBJECTIVES The objective of this study was to develop and pilot a standard framework that could be used to assess risk of contamination in psychological therapy trials, at the protocol development stage. STUDY DESIGN AND SETTING We developed and piloted a risk of contamination framework on a sample of 100 psychological therapy trial protocols registered on the International Standard Randomised Controlled Trial Number (ISRCTN) registry (www.isrctn.com). We assessed all protocols as being low or high risk via three possible sources of contamination: 1) participants in the control arm, 2) participants in the intervention arm, 3) therapists in the intervention arm. RESULTS Overall, we found that the risk of contamination across all three sources was low for most studies (86 of 100 trial protocols; 86%). We identified 14 studies that had a potentially high risk for contamination. Most of these (N = 10) were identified as risk of contamination arising from a therapist in the intervention arm. CONCLUSION The risk of contamination framework we piloted in this study could be a helpful tool for researchers aiming to identify and manage risk of contamination in their trial protocol development. We found that the risk of contamination was relatively low in the psychological therapy trials we sampled for this study, as measured by our framework, and could usually be mitigated through reasonable adjustments to the study design.",2020,"Overall, we found that the risk of contamination across all three sources was low for most studies (86 of 100 trial protocols; 86%).","['contamination: 1) participants in the control arm, 2) participants in the intervention arm, 3) therapists in the intervention arm']",[],['risk of contamination'],"[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],"[{'cui': 'C0035647', 'cui_str': 'Risk of'}]",10.0,0.109149,"Overall, we found that the risk of contamination across all three sources was low for most studies (86 of 100 trial protocols; 86%).","[{'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Jacobsen', 'Affiliation': ""Department of Psychology, University of Bath, Bath BA2 7AY; King's College London, Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), De Crespigny Park, London SE5 8AF. Electronic address: p.c.jacobsen@bath.ac.uk.""}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Wood', 'Affiliation': 'Acute and Rehabilitation Directorate Psychology Team, North East London NHS Foundation Trust, Goodmayes Hospital, Barley Lane, Ilford IG3 8XJ; Division of Psychiatry, University College London, Maple House, 149 Tottenham Court Road W1T 7DN.'}]",Journal of clinical epidemiology,['10.1016/j.jclinepi.2020.04.005'] 71,32389019,Effects of auricular acupuncture on appetite in patients with advanced cancer: a pilot randomized controlled trial.,"BACKGROUND Over half of patients with advanced cancer report appetite loss or anorexia. Previous studies have shown the benefit of acupuncture for cancer-related nausea and vomiting, but limited evidence exists for its role in appetite improvement. Our study aimed to evaluate the feasibility and safety of auricular acupuncture to improve appetite for cancer patients with advanced disease. METHODS We performed a two-arm parallel, pilot randomized controlled trial (RCT) of auricular acupuncture versus usual care control in patients with stage III or IV cancer who experienced appetite loss. The primary outcome was changed in the Simplified Nutritional Appetite Questionnaire (SNAQ; score range, 4-20) between two groups from baseline to weeks 2 and 4, with secondary outcomes including change in weight, as well as an additional evaluation at week 8 for durability of treatment effects. We used independent two-sample t-test for the change in mean score for each outcome during or after treatment. We assessed the interaction between time and treatment from baseline to weeks 2, 4, and 8 using mixed-effects models by ANOVA test. RESULTS We randomized 55 patients to auricular acupuncture (N=27) or control group (N=28). By week 4, the auricular acupuncture group had a significantly higher escalation in the SNAQ score than the control group compared with baseline [mean difference 3.69; 95% confidential interval (95% CI): 2.5, 4.8; P<0.001] and experienced a 51.4% improvement in appetite. From baseline to weeks 2 and 4, patients lost a little weight in the control group but gained weight in the auricular acupuncture group. Between baseline and week 4, change in the SNAQ score was significantly associated with change in weight (P=0.001). No adverse events (AEs) were reported during the study. CONCLUSIONS Compared to usual care, auricular acupuncture is feasible and safe to improve appetite and help patients with advanced cancer gain weight.",2020,"By week 4, the auricular acupuncture group had a significantly higher escalation in the SNAQ score than the control group compared with baseline [mean difference 3.69; 95% confidential interval (95% CI): 2.5, 4.8; P<0.001] and experienced a 51.4% improvement in appetite.","['patients with advanced cancer', 'N=27) or control group (N=28', 'patients with advanced cancer gain weight', 'patients with stage III or IV cancer who experienced appetite loss', 'cancer patients with advanced disease', 'patients with advanced cancer report appetite loss or anorexia']","['usual care, auricular acupuncture', 'acupuncture', 'auricular acupuncture']","['Simplified Nutritional Appetite Questionnaire (SNAQ; score range, 4-20', 'SNAQ score', 'appetite', 'change in weight, as well as an additional evaluation at week 8 for durability of treatment effects', 'feasibility and safety', 'gained weight']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0003123', 'cui_str': 'Anorexia'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0684224', 'cui_str': 'Report'}]","[{'cui': 'C0752217', 'cui_str': 'Ear Acupuncture'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}]","[{'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}]",55.0,0.345349,"By week 4, the auricular acupuncture group had a significantly higher escalation in the SNAQ score than the control group compared with baseline [mean difference 3.69; 95% confidential interval (95% CI): 2.5, 4.8; P<0.001] and experienced a 51.4% improvement in appetite.","[{'ForeName': 'Lingyun', 'Initials': 'L', 'LastName': 'Sun', 'Affiliation': 'Clinical Cancer Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.'}, {'ForeName': 'Jun J', 'Initials': 'JJ', 'LastName': 'Mao', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, Bendheim Integrative Medicine Center, New York, NY, USA.'}, {'ForeName': 'Qun', 'Initials': 'Q', 'LastName': 'Liu', 'Affiliation': 'Department of Integrative Chinese and Western Medicine, Cancer Hospital of Peking University, Beijing 100142, China.'}, {'ForeName': 'Yufei', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Clinical Cancer Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'He', 'Affiliation': 'Clinical Cancer Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China. hebinbj68@163.com.'}]",Annals of palliative medicine,['10.21037/apm.2020.04.24'] 72,32393405,Experimental manipulation of beliefs about the importance of thoughts and the effect on an aggressive impulse.,"BACKGROUND Cognitive models of obsessive-compulsive disorder attribute a causal role to maladaptive beliefs. AIMS To test this hypothesis, we manipulated Overimportance of Thoughts (OT) beliefs and experimentally evaluated their effect on the response to an induced aggressive impulse. METHOD Eighty-five participants completed a battery of self-report instruments assessing obsession symptoms, thought control, affectivity and obsessive beliefs, and were then randomly assigned to two conditions. In the experimental condition participants read a scientific abstract on the importance of thought control whilst those in the control condition read a neutral abstract. All participants identified a loved person and imagined feeling the impulse to stab this person, then completed again OT beliefs measures (Overimportance of Thought, Moral-Thought Action Fusion and Thought Action Fusion Likelihood). RESULTS The Moral component of the Thought Action Fusion was reduced by reading a brief text about the possibility and desirability of thought control. However, experimentally induced changes in beliefs did not yield differences in the intrusiveness of the aggressive impulse. CONCLUSIONS Some beliefs can be modified through a single session in which information similar to what could be obtained in quotidian life is provided.",2020,"However, experimentally induced changes in beliefs did not yield differences in the intrusiveness of the aggressive impulse. ","['Eighty-five participants completed a battery of self-report instruments assessing obsession symptoms, thought control, affectivity and obsessive beliefs']",[],[],"[{'cui': 'C4517892', 'cui_str': '85'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0233697', 'cui_str': 'Obsessional thoughts'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0006122', 'cui_str': 'Brainwashing'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}]",[],[],85.0,0.0437257,"However, experimentally induced changes in beliefs did not yield differences in the intrusiveness of the aggressive impulse. ","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Jiménez-Ros', 'Affiliation': 'Psychology Research Centre (CIP/UAL) and Universidade do Algarve, Portugal.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Faísca', 'Affiliation': 'Centre for Biomedical Research (CBMR) and Universidade do Algarve, Portugal.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Martins', 'Affiliation': 'Universidade do Algarve.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Janeiro', 'Affiliation': 'Psychology Research Centre (CIP/UAL) and Universidade do Algarve, Portugal.'}, {'ForeName': 'A T', 'Initials': 'AT', 'LastName': 'Martins', 'Affiliation': 'Centre for Biomedical Research (CBMR) and Universidade do Algarve, Portugal.'}]",Behavioural and cognitive psychotherapy,['10.1017/S1352465820000120'] 73,32392422,Mild dehydration impaired intermittent sprint performance and thermoregulation in females.,"The effects of mild dehydration during ice hockey are well-studied in males but not females. In a randomized, crossover design, 11 female varsity hockey players drank no fluid (1.7% ± 0.3% body mass loss) or water to maintain hydration during simulated-hockey exercise. Core temperature ( P < 0.01) and perceived fatigue ( P = 0.02) were higher and sprint power lower ( P < 0.01) when mildly dehydrated. Thus, mild dehydration may impair hockey performance and thermoregulation while increasing perceived fatigue in females. Novelty Female stop-and-go sport athletes may benefit their in-game sprint performance and thermoregulation by following personalized in-game hydration to prevent becoming mildly dehydrated.",2020,Core temperature (P<0.01) and perceived fatigue (P=0.02) were higher and sprint power lower (P<0.01) when mildly dehydrated.,"['females', '11 female varsity hockey players drank no fluid (1.7±0.3% body mass loss) or water to maintain hydration during simulated-hockey exercise']",[],['Core temperature (P<0.01) and perceived fatigue'],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0016074', 'cui_str': 'Field hockey'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C1321013', 'cui_str': 'Hydration status'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",[],"[{'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}]",11.0,0.11411,Core temperature (P<0.01) and perceived fatigue (P=0.02) were higher and sprint power lower (P<0.01) when mildly dehydrated.,"[{'ForeName': 'Rachel L', 'Initials': 'RL', 'LastName': 'Driscoll', 'Affiliation': 'Department of Psychology, University of Guelph, Guelph, ON N1G 2W1, Canada.'}, {'ForeName': 'Devin G', 'Initials': 'DG', 'LastName': 'McCarthy', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON L8S 4L8, Canada.'}, {'ForeName': 'Matthew S', 'Initials': 'MS', 'LastName': 'Palmer', 'Affiliation': 'Department of Human Kinetics, St. Francis Xavier University, Antigonish, NS B2G 2W5, Canada.'}, {'ForeName': 'Lawrence L', 'Initials': 'LL', 'LastName': 'Spriet', 'Affiliation': 'Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2020-0040'] 74,32400000,"A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.","LESSONS LEARNED FLC is a complex cancer with many implicated oncogenic pathways. Single or dual targeting does not appear to alter the natural history of the cancer, and novel therapeutics are needed. Estrogen deprivation therapy with letrozole and leuprolide, alone or in combination with the mTOR inhibitor, everolimus, did not demonstrate clinical activity in advanced fibrolamellar carcinoma. The study drugs were well tolerated when administered as single agents or in combination in this patient population. This study demonstrates that, despite the rarity of FLC, multicenter therapeutic clinical trials are feasible and support the value of this consortium. BACKGROUND Fibrolamellar carcinoma (FLC) is an uncommon malignancy in young people and is sometimes associated with pregnancy and oral contraceptive use. Immunohistochemical staining and genetic profiling of FLC tumor specimens have revealed aromatase overexpression. The overexpression of mTOR and S6 kinase has been noted in 25% of FLC. On the basis of interaction between estrogen and the PI3K/Akt/mTOR pathway, we hypothesized that suppression of estrogen and mTOR signaling could have antineoplastic activity in FLC. METHODS Patients were randomized to arm A (everolimus), arm B (letrozole/leuprolide; estrogen deprivation therapy [EDT]), or arm C (everolimus/letrozole/leuprolide). Upon disease progression, patients in arm A or B could proceed to part 2 (everolimus/letrozole/leuprolide). The primary endpoint was progression-free survival (PFS) at 6 months (PFS6) assessed using a Simon's minimax two-stage design, hypothesizing an improvement in PFS6 from 40% to 64% with the study regimen. RESULTS Twenty-eight patients were enrolled. An unplanned analysis was performed because of perceived concern for lack of efficacy. Stable disease was observed in 9 of 26 evaluable patients (35%). PFS6 was 0%. Median overall survival (OS) was 12.4 months (95% confidence interval [CI], 7.4-20.9) for the whole study cohort. Grade 3 adverse events in ≥10% of patients were nausea (11%), vomiting (11%), anemia (11%), elevated aspartate transaminase (AST; 32%), alanine transaminase (ALT; 36%), and alkaline phosphatase (14%). All 28 patients experienced an event for PFS outcome, and four deaths were due to disease progression. CONCLUSION Neither EDT nor mTOR inhibition improved outcomes in FLC. Other treatment strategies are needed.",2020,"Median overall survival (OS) was 12.4 months (95% confidence interval [CI], 7.4-20.9) for the whole study cohort.","['Patients with Unresectable Fibrolamellar Carcinoma', 'advanced fibrolamellar carcinoma', 'Twenty-eight patients were enrolled', 'Patients']","['Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT', 'everolimus/letrozole/leuprolide', 'Estrogen deprivation therapy with letrozole and leuprolide, alone or in combination with the mTOR inhibitor, everolimus', 'everolimus), arm B (letrozole/leuprolide; estrogen deprivation therapy [EDT]), or arm C (everolimus/letrozole/leuprolide', 'FLC']","['Stable disease', 'overexpression of mTOR and S6 kinase', 'elevated aspartate transaminase', 'vomiting', 'anemia', 'nausea', 'Median overall survival (OS', 'Grade 3 adverse events', ""progression-free survival (PFS) at 6 months (PFS6) assessed using a Simon's minimax two-stage design, hypothesizing an improvement in PFS6"", 'alanine transaminase (ALT; 36%), and alkaline phosphatase']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0334287', 'cui_str': 'Hepatocellular carcinoma, fibrolamellar'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C4283787', 'cui_str': '28'}]","[{'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0085272', 'cui_str': 'Leuprolide'}, {'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C1307407', 'cui_str': 'FRAP1 protein, human'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0334287', 'cui_str': 'Hepatocellular carcinoma, fibrolamellar'}]","[{'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1307407', 'cui_str': 'FRAP1 protein, human'}, {'cui': 'C0073337', 'cui_str': 'Ribosomal Protein S6 Kinase'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0220989', 'cui_str': 'Acquired partial lipodystrophy'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}]",28.0,0.0597627,"Median overall survival (OS) was 12.4 months (95% confidence interval [CI], 7.4-20.9) for the whole study cohort.","[{'ForeName': 'Imane', 'Initials': 'I', 'LastName': 'El Dika', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Mayer', 'Affiliation': 'Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Alan P', 'Initials': 'AP', 'LastName': 'Venook', 'Affiliation': 'University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Marinela', 'Initials': 'M', 'LastName': 'Capanu', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'LaQuaglia', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Kobos', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Allison F', 'Initials': 'AF', 'LastName': ""O'Neill"", 'Affiliation': 'Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Joanne F', 'Initials': 'JF', 'LastName': 'Chou', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Ly', 'Affiliation': 'Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Celina', 'Initials': 'C', 'LastName': 'Ang', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Eileen M', 'Initials': 'EM', 'LastName': ""O'Reilly"", 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Gordan', 'Affiliation': 'University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Ghassan K', 'Initials': 'GK', 'LastName': 'Abou-Alfa', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York, USA.'}]",The oncologist,['10.1634/theoncologist.2020-0367'] 75,32333853,Evaluation of Venous Thromboembolism Recurrence Scores in an Unprovoked Pulmonary Embolism Population: A Post-hoc Analysis of the PADIS-PE trial.,"BACKGROUND We aimed to validate the Men Continue and HERDOO2 (HERDOO2), D-dimer, age, sex, hormonal therapy (DASH), and updated Vienna recurrent venous thromboembolism prediction models in a population composed entirely of first unprovoked pulmonary embolism, and to analyze the impact of the addition of the pulmonary vascular obstruction index (PVOI) on score accuracy. METHODS Analyses were based on the double-blind, randomized PADIS-PE trial, which included 371 unprovoked pulmonary embolism patients initially treated for 6 months, successively randomized to receive an additional 18 months of warfarin or placebo, and subsequently followed-up for 2 years. RESULTS The HERDOO2, DASH, and updated Vienna scores displayed C-statistics of 0.61 (95% CI 0.54-0.68), 0.60 (95% CI 0.53-0.66), and 0.58 (95% CI 0.51-0.66), respectively. Only the HERDOO2 score identified low recurrence risk patients (<3%/year) after anticoagulation was stopped. When added to either of the prediction models, PVOI measured at pulmonary embolism diagnosis, after 6 months of anticoagulation, or both, improved scores' C-statistics between +0.06 and +0.11 points and consistently led to identifying at least 50% of patients who experienced recurrence but in whom the scores would have indicated against extended anticoagulation. CONCLUSIONS In patients with a first unprovoked pulmonary embolism, the HERDOO2 score is able to identify patients with a low recurrence risk after treatment discontinuation. Addition of PVOI improves accuracy of all scores. CLINICAL TRIALS REGISTRATION URL: http://www.controlled-trials.com. Unique identifier: NCT00740883.",2020,"The HERDOO2, DASH and Updated Vienna scores displayed c-statistics of 0.61 (95%CI 0.54-0.68), 0.60 (95%CI 0.53-0.66) and 0.58 (95%CI 0.51-0.66) respectively.",['371 unprovoked pulmonary embolism patients initially treated during 6 months'],"['PVOI', 'warfarin or placebo']",['Venous Thromboembolism Recurrence Scores'],"[{'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C1096458', 'cui_str': 'Vascular occlusion'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",371.0,0.625721,"The HERDOO2, DASH and Updated Vienna scores displayed c-statistics of 0.61 (95%CI 0.54-0.68), 0.60 (95%CI 0.53-0.66) and 0.58 (95%CI 0.51-0.66) respectively.","[{'ForeName': 'Leela', 'Initials': 'L', 'LastName': 'Raj', 'Affiliation': 'Département de Médecine Interne et Pneumologie, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, and EA 3878, CIC INSERM 1412, Brest, France; McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Presles', 'Affiliation': 'Unité de Recherche Clinique, Innovation et Pharmacologie, Centre Hospitalo-Universitaire de Saint-Etienne, and INSERM U1059 SAINBIOSE, Université Jean Monnet, France; F-CRIN INNOVTE, Saint Etienne, France.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Le Mao', 'Affiliation': 'Département de Médecine Interne et Pneumologie, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, and EA 3878, CIC INSERM 1412, Brest, France; F-CRIN INNOVTE, Saint Etienne, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Robin', 'Affiliation': 'F-CRIN INNOVTE, Saint Etienne, France; Service de Médecine Nucléaire and EA 3878, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Sanchez', 'Affiliation': 'F-CRIN INNOVTE, Saint Etienne, France; Université Paris Descartes, Université Sorbonne Paris Cité, France; Service de Pneumologie et de Soins intensifs, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; INSERM UMR S 1140, France.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Pernod', 'Affiliation': 'F-CRIN INNOVTE, Saint Etienne, France; Département de Médecine Vasculaire, Centre Hospitalo-Universitaire de Grenoble, Université de Grenoble 1, France.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Bertoletti', 'Affiliation': 'F-CRIN INNOVTE, Saint Etienne, France; Service de Médecine Vasculaire et Thérapeutique, Unité de Pharmacologie Clinique, CIC1408, Centre Hospitalo-Universitaire de Saint-Etienne, and INSERM U1059 SAINBIOSE, Université Jean Monnet, France.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Jego', 'Affiliation': 'F-CRIN INNOVTE, Saint Etienne, France; Service de Médecine Interne, Centre Hospitalo-Universitaire de Rennes, Université de Rennes 1, France.'}, {'ForeName': 'Catherine A', 'Initials': 'CA', 'LastName': 'Lemarié', 'Affiliation': 'Département de Médecine Interne et Pneumologie, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, and EA 3878, CIC INSERM 1412, Brest, France; F-CRIN INNOVTE, Saint Etienne, France.'}, {'ForeName': 'Florent', 'Initials': 'F', 'LastName': 'Leven', 'Affiliation': 'Service de Cardiologie and EA 3878, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, France.'}, {'ForeName': 'Clément', 'Initials': 'C', 'LastName': 'Hoffmann', 'Affiliation': ""Service d'Echo-doppler Vasculaire, and EA 3878, CIC INSERM 1412, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, France.""}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Planquette', 'Affiliation': 'F-CRIN INNOVTE, Saint Etienne, France; Université Paris Descartes, Université Sorbonne Paris Cité, France; Service de Pneumologie et de Soins intensifs, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; INSERM UMR S 1140, France.'}, {'ForeName': 'Pierre-Yves', 'Initials': 'PY', 'LastName': 'Le Roux', 'Affiliation': 'F-CRIN INNOVTE, Saint Etienne, France; Service de Médecine Nucléaire and EA 3878, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, France.'}, {'ForeName': 'Pierre-Yves', 'Initials': 'PY', 'LastName': 'Slaun', 'Affiliation': 'F-CRIN INNOVTE, Saint Etienne, France; Service de Médecine Nucléaire and EA 3878, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, France.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Nonent', 'Affiliation': 'Service de Radiologie, and EA 3878, CIC INSERM 1412, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Girard', 'Affiliation': 'F-CRIN INNOVTE, Saint Etienne, France; Département Thoracique, Institut Mutualiste Montsouris, Paris, France.'}, {'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Lacut', 'Affiliation': 'Département de Médecine Interne et Pneumologie, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, and EA 3878, CIC INSERM 1412, Brest, France; F-CRIN INNOVTE, Saint Etienne, France.'}, {'ForeName': 'Solen', 'Initials': 'S', 'LastName': 'Mélac', 'Affiliation': 'Département de Médecine Interne et Pneumologie, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, and EA 3878, CIC INSERM 1412, Brest, France; F-CRIN INNOVTE, Saint Etienne, France.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Guégan', 'Affiliation': 'Département de Médecine Interne et Pneumologie, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, and EA 3878, CIC INSERM 1412, Brest, France; F-CRIN INNOVTE, Saint Etienne, France.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Mismetti', 'Affiliation': 'F-CRIN INNOVTE, Saint Etienne, France; Service de Médecine Vasculaire et Thérapeutique, Unité de Pharmacologie Clinique, CIC1408, Centre Hospitalo-Universitaire de Saint-Etienne, and INSERM U1059 SAINBIOSE, Université Jean Monnet, France.'}, {'ForeName': 'Silvy', 'Initials': 'S', 'LastName': 'Laporte', 'Affiliation': 'Unité de Recherche Clinique, Innovation et Pharmacologie, Centre Hospitalo-Universitaire de Saint-Etienne, and INSERM U1059 SAINBIOSE, Université Jean Monnet, France; F-CRIN INNOVTE, Saint Etienne, France.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Meyer', 'Affiliation': 'F-CRIN INNOVTE, Saint Etienne, France; Université Paris Descartes, Université Sorbonne Paris Cité, France; Service de Pneumologie et de Soins intensifs, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; INSERM UMR S 1140, France.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Leroyer', 'Affiliation': 'Département de Médecine Interne et Pneumologie, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, and EA 3878, CIC INSERM 1412, Brest, France; F-CRIN INNOVTE, Saint Etienne, France.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Tromeur', 'Affiliation': 'Département de Médecine Interne et Pneumologie, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, and EA 3878, CIC INSERM 1412, Brest, France; F-CRIN INNOVTE, Saint Etienne, France.'}, {'ForeName': 'Francis', 'Initials': 'F', 'LastName': 'Couturaud', 'Affiliation': 'Département de Médecine Interne et Pneumologie, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, and EA 3878, CIC INSERM 1412, Brest, France; F-CRIN INNOVTE, Saint Etienne, France. Electronic address: francis.couturaud@chu-brest.fr.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': 'Département de Médecine Interne et Pneumologie, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, and EA 3878, CIC INSERM 1412, Brest, France.'}]",The American journal of medicine,['10.1016/j.amjmed.2020.03.040'] 76,32335270,"The effect of acute intragastric vs. intravenous alcohol administration on inflammation markers, blood lipids and gallbladder motility in healthy men.","Ethanol intake increases plasma concentrations of triglycerides and chronic ethanol use impairs lipid metabolism and causes chronic inflammation. The gut plays an important role in metabolic handling of nutrients, including lipids, and a leaky gut associated with alcohol intake, allowing inflammatory signals to the portal vein, has been proposed to constitute a mechanism by which ethanol induces hepatic inflammation. We compared the effects of enteral and parenteral administration of ethanol on a range of circulating inflammation markers (including soluble CD163, a marker of liver macrophage activation), lipids, cholecystokinin (CCK) and fibroblast growth factor 19 (FGF19) as well as gallbladder volume. On two separate and randomized study days, we subjected healthy men (n = 12) to double-blinded intragastric ethanol infusion (IGEI) and isoethanolemic intravenous ethanol infusion (IVEI). Blood was sampled and ultrasonographic evaluation of gallbladder volume was performed at frequent intervals for 4 h after initiation of ethanol administration on both days. Little or no effects were observed on plasma levels of inflammation markers during IGEI and IVEI, respectively. Circulating levels of total, low-density lipoprotein and high-density lipoprotein cholesterol decreased after ethanol administration independently of the administration form. Triglyceride and very low-density lipoprotein (VLDL) cholesterol concentrations increased more after IGEI compared to IVEI. IVEI had no effect on plasma CCK and caused an increased gallbladder volume whereas IGEI elicited a CCK response (P < 0.0001) without affecting gallbladder volume. Circulating FGF19 concentrations decreased equally in response to both ethanol administration forms. In conclusion, by evaluating a range of circulating inflammation markers during IGEI and IVEI we were not able to detect signs of systemic low-grade inflammation originating from the presence of ethanol in the gut. IVEI increased gallbladder volume whereas IGEI increased plasma CCK (with neutral effect on gallbladder volume), increased plasma VLDL cholesterol and triglyceride concentrations; indicating that the enteral route of administration may influence ethanol's effects on lipid metabolism.",2020,"Circulating levels of total, low-density lipoprotein and high-density lipoprotein cholesterol decreased after ethanol administration independently of the administration form.","['healthy men', 'subjected healthy men (n=12) to']","['double-blinded intragastric ethanol infusion (IGEI) and isoethanolemic intravenous ethanol infusion (IVEI', 'Ethanol intake', 'acute intragastric vs. intravenous alcohol', 'ethanol']","['Triglyceride and very low-density lipoprotein (VLDL) cholesterol concentrations', 'plasma VLDL cholesterol and triglyceride concentrations', 'inflammation markers, blood lipids and gallbladder motility', 'Circulating levels of total, low-density lipoprotein and high-density lipoprotein cholesterol', 'lipid metabolism', 'plasma levels of inflammation markers', 'IVEI increased gallbladder volume whereas IGEI increased plasma CCK', 'gallbladder volume', 'Circulating FGF19 concentrations', 'plasma CCK', 'circulating inflammation markers (including soluble CD163, a marker of liver macrophage activation), lipids, cholecystokinin (CCK) and fibroblast growth factor 19 (FGF19']","[{'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0442113', 'cui_str': 'Intragastric'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}]","[{'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023825', 'cui_str': 'Very low density lipoprotein'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0023826', 'cui_str': 'VLDL cholesterol'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0016976', 'cui_str': 'Gallbladder structure'}, {'cui': 'C0007608', 'cui_str': 'Motility, Cell'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0442113', 'cui_str': 'Intragastric'}, {'cui': 'C0008328', 'cui_str': 'Cholecystokinin'}, {'cui': 'C1431711', 'cui_str': 'FGF19 protein, human'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0251113', 'cui_str': 'CD163 antigen'}, {'cui': 'C0022801', 'cui_str': 'Kupffer cell'}]",,0.130521,"Circulating levels of total, low-density lipoprotein and high-density lipoprotein cholesterol decreased after ethanol administration independently of the administration form.","[{'ForeName': 'Amalie R', 'Initials': 'AR', 'LastName': 'Lanng', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Lærke S', 'Initials': 'LS', 'LastName': 'Gasbjerg', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Natasha C', 'Initials': 'NC', 'LastName': 'Bergmann', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.'}, {'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Gillum', 'Affiliation': 'Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Jens F', 'Initials': 'JF', 'LastName': 'Rehfeld', 'Affiliation': 'Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Mads M', 'Initials': 'MM', 'LastName': 'Helsted', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.'}, {'ForeName': 'Holger J', 'Initials': 'HJ', 'LastName': 'Møller', 'Affiliation': 'Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Henning', 'Initials': 'H', 'LastName': 'Grønbæk', 'Affiliation': 'Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Vilsbøll', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Steno Diabetes Center Copenhagen, Gentofte, Copenhagen, Denmark.'}, {'ForeName': 'Filip K', 'Initials': 'FK', 'LastName': 'Knop', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Steno Diabetes Center Copenhagen, Gentofte, Copenhagen, Denmark. Electronic address: filipknop@dadlnet.dk.'}]","Alcohol (Fayetteville, N.Y.)",['10.1016/j.alcohol.2020.04.006'] 77,32203231,Polyphenol-rich tea decreases iron absorption from fortified wheat bread in Senegalese mother-child pairs and bioavailability of ferrous fumarate is sharply lower in children.,"BACKGROUND/OBJECTIVES Fractional iron absorption (FAFe) from ferrous fumarate (FeFum) and ferrous sulfate (FeSO 4 ) in adults is generally comparable. While FeFum is commonly used to fortify infant foods, FAFe from FeFum in young children and infants may be decreased compared with FeSO 4 and this effect has not been assessed in inhibitory vs noninhibitory meals. Previous studies also reported FAFe to be strongly correlated in mother-child pairs. Our objective was to measure FAFe from fortified bread labeled with 58 FeSO 4 and 57 FeFum in mother-child pairs with and without a commonly consumed herbal tea of Combretum micranthum (Tisane Kinkéliba, TK). METHODS Senegalese mother-child pairs (n = 17) were randomly assigned to receive, in a 2 × 2 factorial design, fortified bread with 58 FeSO 4 or 57 FeFum consumed with TK or water. FAFe was assessed by measuring erythrocyte incorporation of stable iron-isotopes 14 days after administration. RESULTS In children, relative bioavailability (RBV) from FeFum was 51 and 64% compared with FeSO 4 when served with TK or water (both, P < 0.05). In mothers, the presence of TK decreased FAFe by 56% (P < 0.05) and 50% (P = 0.077) and in children by 65 and 72% (both, P < 0.0001), in the meals with 58 FeSO 4 and 57 FeFum, respectively. After adjustment for plasma ferritin, there was a positive correlation between FAFe in mothers and children (r = 0.4142, P = 0.001). CONCLUSIONS In Senegalese women and children, herbal tea decreased FAFe from a wheat-based meal. The RBV of FeFum was low in children but not in their mothers. FAFe was modestly correlated in mother-child pairs, possibly due to shared genetic, epigenetic or environmental background.",2020,"In mothers, the presence of TK decreased FAFe by 56% (P < 0.05) and 50% (P = 0.077) and in children by 65 and 72% (both, P < 0.0001), in the meals with 58 FeSO 4 and 57 FeFum, respectively.","['Senegalese mother-child pairs (n\u2009', '17']","['ferrous fumarate (FeFum) and ferrous sulfate (FeSO 4 ', 'fortified bread with 58 FeSO 4 or 57 FeFum consumed with TK or water', 'TK or water', 'Polyphenol-rich tea']","['erythrocyte incorporation', 'RBV of FeFum', 'relative bioavailability (RBV', 'FAFe', 'presence of TK decreased FAFe']","[{'cui': 'C0337846', 'cui_str': 'Senegalese (ethnic group)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0060276', 'cui_str': 'Ferrous fumarate'}, {'cui': 'C0060282', 'cui_str': 'ferrous sulfate'}, {'cui': 'C0006138', 'cui_str': 'Bread'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0071649', 'cui_str': 'Polyphenol (substance)'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C0039400', 'cui_str': 'Tea'}]","[{'cui': 'C0014792', 'cui_str': 'Blood Corpuscles, Red'}, {'cui': 'C0243126', 'cui_str': 'incorporation'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}]",,0.0995514,"In mothers, the presence of TK decreased FAFe by 56% (P < 0.05) and 50% (P = 0.077) and in children by 65 and 72% (both, P < 0.0001), in the meals with 58 FeSO 4 and 57 FeFum, respectively.","[{'ForeName': 'Ndèye Fatou', 'Initials': 'NF', 'LastName': 'Ndiaye', 'Affiliation': 'Laboratoire de Nutrition, Département de Biologie Animale, Faculté des Sciences et Techniques, Université Cheikh Anta Diop de Dakar, Dakar, Senegal. nfndiaye@ita.sn.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Idohou-Dossou', 'Affiliation': 'Laboratoire de Nutrition, Département de Biologie Animale, Faculté des Sciences et Techniques, Université Cheikh Anta Diop de Dakar, Dakar, Senegal.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Bürkli', 'Affiliation': 'Laboratory of Human Nutrition, Institute of Food Nutrition and Health, ETH Zürich, Zürich, Switzerland.'}, {'ForeName': 'Adama', 'Initials': 'A', 'LastName': 'Diouf', 'Affiliation': 'Laboratoire de Nutrition, Département de Biologie Animale, Faculté des Sciences et Techniques, Université Cheikh Anta Diop de Dakar, Dakar, Senegal.'}, {'ForeName': 'Cheikh', 'Initials': 'C', 'LastName': 'Loucoubar', 'Affiliation': 'Institut Pasteur de Dakar, Dakar, Senegal.'}, {'ForeName': 'Amadou Tidiane', 'Initials': 'AT', 'LastName': 'Guiro', 'Affiliation': 'Laboratoire de Nutrition, Département de Biologie Animale, Faculté des Sciences et Techniques, Université Cheikh Anta Diop de Dakar, Dakar, Senegal.'}, {'ForeName': 'Michael Bruce', 'Initials': 'MB', 'LastName': 'Zimmermann', 'Affiliation': 'Laboratory of Human Nutrition, Institute of Food Nutrition and Health, ETH Zürich, Zürich, Switzerland.'}, {'ForeName': 'Salimata', 'Initials': 'S', 'LastName': 'Wade', 'Affiliation': 'Laboratoire de Nutrition, Département de Biologie Animale, Faculté des Sciences et Techniques, Université Cheikh Anta Diop de Dakar, Dakar, Senegal.'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Moretti', 'Affiliation': 'Laboratory of Human Nutrition, Institute of Food Nutrition and Health, ETH Zürich, Zürich, Switzerland.'}]",European journal of clinical nutrition,['10.1038/s41430-020-0601-z'] 78,32337693,Effect of Sheng Xue Ning Tablets on Renal Anemia in Patients Subject to Maintenance Hemodialysis and Safety Evaluation: A Multi-setting Prospective Randomized Study.,"This study compared Sheng Xue Ning (SXN) tablets with ferrous succinate (FS) tablets in terms of their efficacy for the treatment of iron-deficient renal anemia and safety in patients subject to maintenance hemodialysis (MHD). A total of 94 patients undergoing MHD were randomly assigned to an experiment group (receiving oral SXN tablets, SXN group) and a control group (orally given FS tablets, FS group) and followed up for 12 weeks. Erythropoietin (EPO) was used in both groups. The efficacy was assessed by detecting the subsequent changes in hemoglobin (Hb), serum iron (SI), SF and transferrin saturation (TSAT). At the 12th week, Hb and TSAT levels in both groups were significantly increased compared to those in the screening period (P<0.05). However, no significant difference in Hb and TSAT was found between the two groups. The average weekly EPO dosage used was lower in SXN group than in FS group (P<0.05) at the 10th week and the 12th week. Our study showed that SXN tablets can effectively ameliorate renal anemia and keep iron metabolism stable in MHD patients, and its efficacy is virtually close to that of FS tablets. Meanwhile, SXN tablets can reduce the dosage of EPO and have a good safety profile.",2020,The average weekly EPO dosage used was lower in SXN group than in FS group (P<0.05) at the 10th week and the 12th week.,"['MHD patients', '94 patients undergoing MHD', 'patients subject to maintenance hemodialysis (MHD', 'Patients Subject to Maintenance Hemodialysis and Safety Evaluation']","['Sheng Xue Ning Tablets', 'experiment group (receiving oral SXN tablets, SXN', 'Sheng Xue Ning (SXN) tablets with ferrous succinate (FS) tablets', 'Erythropoietin (EPO', 'SXN tablets']","['hemoglobin (Hb), serum iron (SI), SF and transferrin saturation (TSAT', 'Hb and TSAT', 'Hb and TSAT levels', 'renal anemia', 'Renal Anemia', 'average weekly EPO dosage']","[{'cui': 'C4040576', 'cui_str': 'Maintenance hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}]","[{'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0060281', 'cui_str': 'ferrous succinate'}, {'cui': 'C0014822', 'cui_str': 'erythropoietin'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C1318312', 'cui_str': 'Serum iron measurement'}, {'cui': 'C1277709', 'cui_str': 'Transferrin saturation'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1142276', 'cui_str': 'Renal anemia'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0014822', 'cui_str': 'erythropoietin'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]",94.0,0.0117874,The average weekly EPO dosage used was lower in SXN group than in FS group (P<0.05) at the 10th week and the 12th week.,"[{'ForeName': 'Xiao-Jing', 'Initials': 'XJ', 'LastName': 'Tang', 'Affiliation': 'Department of Nephrology, Changzheng Hospital, the Second Military Medical University, Shanghai, 20003, China.'}, {'ForeName': 'Shu', 'Initials': 'S', 'LastName': 'Rong', 'Affiliation': 'Department of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.'}, {'ForeName': 'Chang-Lin', 'Initials': 'CL', 'LastName': 'Mei', 'Affiliation': 'Department of Nephrology, Changzheng Hospital, the Second Military Medical University, Shanghai, 20003, China. chlmei1954@126.com.'}, {'ForeName': 'Zhao-Hui', 'Initials': 'ZH', 'LastName': 'Ni', 'Affiliation': 'Department of Nephrology, Renji Hospital, Jiaotong University, Shanghai, 200003, China.'}, {'ForeName': 'Geng-Ru', 'Initials': 'GR', 'LastName': 'Jiang', 'Affiliation': 'Department of Nephrology, Xinhua Hospital, Jiaotong University, Shanghai, 200092, China.'}, {'ForeName': 'Wei-Jie', 'Initials': 'WJ', 'LastName': 'Yuan', 'Affiliation': 'Department of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.'}, {'ForeName': 'Nian-Song', 'Initials': 'NS', 'LastName': 'Wang', 'Affiliation': ""Department of Nephrology, the Sixth People's Hospital, Jiaotong University, Shanghai, 200233, China.""}, {'ForeName': 'Zhi-Yong', 'Initials': 'ZY', 'LastName': 'Guo', 'Affiliation': 'Department of Nephrology, Changhai Hospital, the Second Military Medical University, Shanghai, 200433, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': 'Department of Nephrology, Tongji Hospital, Tongji University, Shanghai, 200065, China.'}, {'ForeName': 'Hai-Dong', 'Initials': 'HD', 'LastName': 'Yan', 'Affiliation': 'Department of Nephrology, East Hospital, Tongji University, Shanghai, 200120, China.'}, {'ForeName': 'Li-Ming', 'Initials': 'LM', 'LastName': 'ZHang', 'Affiliation': 'Department of Nephrology, Zhabei District Central Hospital, Changzhen Hospital, Shanghai, 200070, China.'}]",Current medical science,['10.1007/s11596-020-2179-z'] 79,32337698,Efficacy of Electro-acupuncture in Treatment of Functional Constipation: A Randomized Controlled Trial.,"Functional constipation (FC) is a chronic disease that significantly affects the life quality of patients. Acupuncture has been used for the treatment of FC for many years, but its effectiveness has not been scientifically assessed. The present study aimed to evaluate the efficacy of electro-acupuncture (EA) in relieving the symptoms, mental states and quality of life (QOL) of FC patients. A total of 96 FC patients were randomly allocated into EA, mosapride & sham EA group (MS) and mosapride control group (MC). In the EA group, patients were treated with 16 sessions of needling at Quchi (LI11) and Shangjuxu (ST37) bilaterally, 5 times a week in the first 2 weeks, and 3 times a week in the last 2 weeks. In the MC group, patients were treated with 5 mg mosapride citrate three times a day for 4 weeks. In the MS group, patients underwent sham EA and the same mosapride citrate treatment as in the MC group. The primary outcome was the number of weekly spontaneous bowel movements (SBMs). The secondary outcomes included stool consistency, intensity of defecating difficulty, 36-Item Short-Form Health Survey (SF-36), Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), and the validated Patient Assessment of Constipation-Quality of Life (PAC-QOL). The results showed that as compared with the baseline, EA significantly improved the weekly SBMs, stool consistency and intensity of defecating difficulty (P<0.05). It also partly ameliorated the PAC-QOL, SF-36, SDS and SAS scores when compared with MC or MS group (P<0.05). However, no significant difference was observed between MS and MC groups in bowel function outcomes and QOL scores. It was concluded that EA could effectively improve bowel function, mental states and QOL of FC patients.",2020,"It also partly ameliorated the PAC-QOL, SF-36, SDS and SAS scores when compared with MC or MS group (P<0.05).","['96 FC patients', 'Functional Constipation']","['electro-acupuncture (EA', 'EA, mosapride & sham', 'Acupuncture', 'Electro-acupuncture', 'EA']","['bowel function outcomes and QOL scores', 'bowel function, mental states and QOL', 'stool consistency, intensity of defecating difficulty, 36-Item Short-Form Health Survey (SF-36), Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), and the validated Patient Assessment of Constipation-Quality of Life (PAC-QOL', 'number of weekly spontaneous bowel movements (SBMs', 'weekly SBMs, stool consistency and intensity of defecating difficulty', 'symptoms, mental states and quality of life (QOL', 'Functional constipation (FC', 'PAC-QOL, SF-36, SDS and SAS scores']","[{'cui': 'C0401146', 'cui_str': 'Constipation - functional'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0526501', 'cui_str': 'mosapride'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0278060', 'cui_str': 'Mental state'}, {'cui': 'C0426740', 'cui_str': 'Consistency of stool'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0033036', 'cui_str': 'Atrial premature complex'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0401146', 'cui_str': 'Constipation - functional'}]",96.0,0.0313138,"It also partly ameliorated the PAC-QOL, SF-36, SDS and SAS scores when compared with MC or MS group (P<0.05).","[{'ForeName': 'Xiao-Hu', 'Initials': 'XH', 'LastName': 'Xu', 'Affiliation': 'Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Ming-Min', 'Initials': 'MM', 'LastName': 'Zhang', 'Affiliation': 'Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Sha-Bei', 'Initials': 'SB', 'LastName': 'Xu', 'Affiliation': 'Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Cui-Hong', 'Initials': 'CH', 'LastName': 'Zheng', 'Affiliation': 'Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. chzheng@tjh.tjmu.edu.cn.'}, {'ForeName': 'Guang-Ying', 'Initials': 'GY', 'LastName': 'Huang', 'Affiliation': 'Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. gyhuang@tjh.tjmu.edu.cn.'}]",Current medical science,['10.1007/s11596-020-2188-y'] 80,32337700,Effect of Nalmefene on Delayed Neurocognitive Recovery in Elderly Patients Undergoing Video-assisted Thoracic Surgery with One Lung Ventilation.,"The intravenous use of nalmefene has been found to exert neuroprotective effect in patients with severe traumatic brain injury and acute cerebral infarction; nonetheless, it is unknown whether nalmefene alleviates delayed neurocognitive recovery. Our purpose of the current research was to clarify the impact of nalmefene on delayed neurocognitive recovery in aged patients experiencing video-assisted thoracic surgery (VATS) with intraoperative use of one lung ventilation (OLV). The present study involved 120 patients undergoing selective VATS, randomized to accept low-dose nalmefene (N1 group, n=40), high-dose nalmefene (N2 group, n=40) or equal volume of physiologic saline (control group, n=40). A battery of neuropsychological tests were used to estimate cognitive function 1 day before surgery (t 0 ) and 10 days after surgery or before discharge (t 1 ). Regional cerebral oxygen saturation (rSO 2 ) was detected 5 min before induction (t 0 ), 5 min after induction (t 1 ), 15 and 60 min after onset of OLV (t 2 and t 3 ), and 15 min after termination of OLV (t 4 ). The plasma values of interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α and adiponectin (ADP) were also detected prior to induction of anesthesia (T0), 1 h, 2 h and 6 h after surgery (T1, T2, T3). On t 1 , delayed neurocognitive recovery occurred in 5/40 (12.5%) patients of N1 group, in 5/40 (12.5%) patients of N2 group and in 13/40 (32.5%) patients of control group (P0.05). There were no statistical differences in rSO 2 among three groups at different time points. At T1, T2 and T3, IL-1β, IL-6 and TNF-α values significantly increased and ADP value significantly decreased (P0.05) in control group. In contrast, at T1, T2 and T3, IL-1β, IL-6 and TNF-α values decreased and ADP value decreased less in N1 and N2 groups (P0.05). At T1, T2 and T3, IL-1β, IL-6 and TNF-α concentrations presented a trend of N2 group N1 group control group and ADP presented a trend of N2 groupN1 groupcontrol group (P0.05). The result of our present research supports the hypothesis that the perioperative intravenous treatment with nalmefene to VATS with OLV ameliorates postoperative cognitive function and decreases the incidence of delayed neurocognitive recovery, most likely by suppression of inflammatory responses.",2020,"At T1, T2 and T3, IL-1β, IL-6 and TNF-α concentrations presented a trend of N2 group N1 group control group and ADP presented a trend of N2 groupN1 groupcontrol group (P0.05).","['patients with severe traumatic brain injury and acute cerebral infarction', 'aged patients experiencing video-assisted thoracic surgery (VATS) with intraoperative use of one lung ventilation (OLV', 'Elderly Patients Undergoing Video-assisted Thoracic Surgery with One Lung Ventilation', '120 patients undergoing selective VATS, randomized to accept low-dose nalmefene (N1 group, n=40']","['Nalmefene', 'high-dose nalmefene (N2 group, n=40) or equal volume of physiologic saline (control']","['T2 and T3, IL-1β, IL-6 and TNF-α values', 'delayed neurocognitive recovery', 'ADP value', 'plasma values of interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α and adiponectin (ADP', 'Regional cerebral oxygen saturation (rSO 2 ', 'T2 and T3, IL-1β, IL-6 and TNF-α concentrations', 'postoperative cognitive function', 'T2 and T3, IL-1β, IL-6 and TNF-α values decreased and ADP value', 'Delayed Neurocognitive Recovery']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0007785', 'cui_str': 'Cerebral infarction'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0752151', 'cui_str': 'Surgery, Thoracic, Video-Assisted'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0559312', 'cui_str': 'One lung ventilation'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0068377', 'cui_str': 'nalmefene'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0068377', 'cui_str': 'nalmefene'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0001459', 'cui_str': 'Adenosine diphosphate'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C4273907', 'cui_str': 'Cerebral oxygen saturation'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}]",120.0,0.0301072,"At T1, T2 and T3, IL-1β, IL-6 and TNF-α concentrations presented a trend of N2 group N1 group control group and ADP presented a trend of N2 groupN1 groupcontrol group (P0.05).","[{'ForeName': 'Meng-Yun', 'Initials': 'MY', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.'}, {'ForeName': 'Zheng-Gang', 'Initials': 'ZG', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.'}, {'ForeName': 'Jian-Juan', 'Initials': 'JJ', 'LastName': 'Ke', 'Affiliation': 'Department of Anesthesiology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.'}, {'ForeName': 'Xiao-Bo', 'Initials': 'XB', 'LastName': 'Feng', 'Affiliation': 'Department of Anesthesiology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China. 283647213@qq.com.'}]",Current medical science,['10.1007/s11596-020-2170-8'] 81,32378975,Effect of neuromuscular electrical stimulation on skeletal muscle size and function in patients with breast cancer receiving chemotherapy.,"Exercise has numerous benefits for patients with cancer, but implementation is challenging because of practical and logistical hurdles. This study examined whether neuromuscular electrical stimulation (NMES) can serve as a surrogate for classic exercise by eliciting an exercise training response in skeletal muscle of women diagnosed with breast cancer undergoing chemotherapy. Patients ( n = 22) with histologically confirmed stage I, II, or III breast cancer scheduled to receive neoadjuvant or adjuvant chemotherapy were randomized to 8 wk of bilateral neuromuscular electrical stimulation (NMES; 5 days/wk) to their quadriceps muscles or control. Biopsy of the vastus lateralis was performed at baseline and after 8 wk of intervention to assess muscle fiber size, contractility, and mitochondrial content. Seventeen patients (8 control/9 NMES) completed the trial and were included in analyses. NMES promoted muscle fiber hypertrophy ( P < 0.001), particularly in fast-twitch, myosin heavy chain (MHC) IIA fibers ( P < 0.05) and tended to induce fiber type shifts in MHC II fibers. The effects of NMES on single-muscle fiber contractility were modest, and it was unable to prevent declines in the function in MHC IIA fibers. NMES did not alter intermyofibrillar mitochondrial content/structure but was associated with reductions in subsarcolemmal mitochondria. Our results demonstrate that NMES induces muscle fiber hypertrophy and fiber type shifts in MHC II fibers but had minimal effects on fiber contractility and promoted reductions in subsarcolemmal mitochondria. Further studies are warranted to evaluate the utility of NMES as an exercise surrogate in cancer patients and other conditions. NEW & NOTEWORTHY This is the first study to evaluate whether neuromuscular electrical stimulation (NMES) can be used as an exercise surrogate to improve skeletal muscle fiber size or function in cancer patients receiving treatment. We show that NMES promoted muscle fiber hypertrophy and fiber type shifts but had minimal effects on single-fiber contractility and reduced subsarcolemmal mitochondria.",2020,"NMES promoted muscle fiber hypertrophy (P<0.001), particularly in fast-twitch, myosin heavy chain (MHC)","['patients with cancer', 'Seventeen patients (8 control/9 NMES) completed the trial and were included in analyses', 'Patients (n=22) with histologically-confirmed, stage I, II or III breast cancer scheduled to receive', 'women diagnosed with breast cancer undergoing chemotherapy', 'patients with breast cancer receiving chemotherapy']","['neuromuscular electrical stimulation', 'NMES', 'neuromuscular electrical stimulation (NMES', 'neoadjuvant or adjuvant chemotherapy', 'bilateral neuromuscular electrical stimulation (NMES; 5 days/week) to their quadriceps muscles or control', 'Exercise']","['fast-twitch, myosin heavy chain (MHC', 'skeletal muscle size and function', 'muscle fiber hypertrophy', 'subsarcolemmal mitochondria']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0677547', 'cui_str': 'days/week'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0231530', 'cui_str': 'Muscle twitch'}, {'cui': 'C0027100', 'cui_str': 'Myosin Heavy Chain'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0333759', 'cui_str': 'Muscle fiber hypertrophy'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}]",22.0,0.0485888,"NMES promoted muscle fiber hypertrophy (P<0.001), particularly in fast-twitch, myosin heavy chain (MHC)","[{'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Toth', 'Affiliation': 'Department of Medicine, University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Thomas B', 'Initials': 'TB', 'LastName': 'Voigt', 'Affiliation': 'Department of Medicine, University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Timothy W', 'Initials': 'TW', 'LastName': 'Tourville', 'Affiliation': 'Department of Orthopedics and Rehabilitation, University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Shannon M', 'Initials': 'SM', 'LastName': 'Prior', 'Affiliation': 'Vermont Cancer Center, University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Blas A', 'Initials': 'BA', 'LastName': 'Guigni', 'Affiliation': 'Department of Medicine, University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Axel V', 'Initials': 'AV', 'LastName': 'Schlosberg', 'Affiliation': 'Department of Medicine, University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Isaac B', 'Initials': 'IB', 'LastName': 'Smith', 'Affiliation': 'Department of Medicine, University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Taylor J', 'Initials': 'TJ', 'LastName': 'Forest', 'Affiliation': 'Department of Medicine, University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Kaufman', 'Affiliation': 'Department of Medicine, University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Marie E', 'Initials': 'ME', 'LastName': 'Wood', 'Affiliation': 'Department of Medicine, University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Hibba', 'Initials': 'H', 'LastName': 'Rehman', 'Affiliation': 'Department of Medicine, University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Dittus', 'Affiliation': 'Department of Medicine, University of Vermont, Burlington, Vermont.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00203.2020'] 82,32376293,Automatic regulation of the endotracheal tube cuff pressure with a portable elastomeric device. A randomised controlled study.,"BACKGROUND Intermittent manual correction of the endotracheal tube cuff pressure (P cuff ) may delay the detection of underinflation (source of contaminated oropharyngeal content microaspiration) or overinflation (exposing to airway damage). Devices for automated continuous correction of P cuff are appealing but some are inconvenient, expensive or even harmful. This prospective randomised controlled study tested whether the tracoe Smart Cuff Manager™ reduced the rate of patients undergoing≥1 episode of underinflation (P cuff <20 cmH 2 O), as compared with routine manual P cuff correction. The rate of patients with≥1 overinflation episode (P cuff >30 cmH 2 O) and the incidence of under/overinflation were also compared. METHODS Patients with acute brain injury and likely to receive invasive mechanical ventilation for>48h were randomly allocated to receive, during 48h, automated P cuff correction (combined with manual correction) or manual correction alone. P cuff was measured with a dedicated manual manometer, at least every 8h. RESULTS Sixty patients were included and randomised (32 patients with manual and 28 with automated P cuff correction) for 506 measurements of P cuff (269 and 237, respectively). Automated correction of P cuff was associated with a lower rate of patients with≥1 episode of underinflation (63% and 18%, respectively, P<0.001), a lower incidence of underinflation episodes (15% vs. 2%; P<0.001), a lower rate of manual corrections (77% vs. 58%; P<0.001). For overinflation, there were no significant between-groups differences (2% vs. 2%). The incidence of early respiratory infections was similar in both groups (29% vs. 25%, P=0.78). CONCLUSIONS The adjunction of continuous P cuff control with the Tracoe Smart Cuff Manager™ to routine manual intermittent correction reduced the incidence of P cuff underinflation episodes without provoking overinflation. TRIAL REGISTRATION ClinicalTrials NCT03330379. Registered 6 November 2017, https://clinicaltrials.gov/ct2/show/NCT03330379.",2020,"The incidence of early respiratory infections was similar in both groups (29% vs. 25%, p = 0.78). ","['Sixty patients were included and randomised (32 patients with manual and 28 with automated Pcuff correction) for 506 measurements of Pcuff (269 and 237, respectively', 'patients undergoing ≥ 1 episode of underinflation (Pcuff<20 cmH2O', 'Patients with acute brain injury and likely to receive invasive mechanical ventilation for > 48 h']","['automated Pcuff correction (combined with manual correction) or manual correction alone', 'endotracheal tube cuff pressure (Pcuff', 'Tracoe Smart Cuff ManagerTM', 'endotracheal tube cuff pressure with a portable elastomeric device']","['lower rate of manual corrections', 'Pcuff', 'incidence of early respiratory infections', 'underinflation episodes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0439476', 'cui_str': 'cmH2O'}, {'cui': 'C0085742', 'cui_str': 'Acute Brain Injuries'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}, {'cui': 'C1868981', 'cui_str': 'Invasive mechanical ventilation'}]","[{'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0180212', 'cui_str': 'Endotracheal tube cuff'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0235048', 'cui_str': 'Smarting pain'}, {'cui': 'C0441107', 'cui_str': 'Device cuff'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0035243', 'cui_str': 'Respiratory tract infection'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}]",60.0,0.0808773,"The incidence of early respiratory infections was similar in both groups (29% vs. 25%, p = 0.78). ","[{'ForeName': 'Jérôme E', 'Initials': 'JE', 'LastName': 'Dauvergne', 'Affiliation': ""Service d'anesthésie-réanimation, hôpital Laënnec, centre hospitalier universitaire de Nantes, boulevard Jacques-Monod, Saint-Herblain, 44093 Nantes cedex 1, France. Electronic address: jerome.dauvergne@chu-nantes.fr.""}, {'ForeName': 'Anne-Laure', 'Initials': 'AL', 'LastName': 'Geffray', 'Affiliation': ""Service d'anesthésie-réanimation, Hôtel-Dieu, centre hospitalier universitaire, 44093, Nantes, France.""}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Asehnoune', 'Affiliation': ""Service d'anesthésie-réanimation, Hôtel-Dieu, centre hospitalier universitaire, 44093, Nantes, France.""}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Rozec', 'Affiliation': ""Service d'anesthésie-réanimation, hôpital Laënnec, centre hospitalier universitaire de Nantes, boulevard Jacques-Monod, Saint-Herblain, 44093 Nantes cedex 1, France.""}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Lakhal', 'Affiliation': ""Service d'anesthésie-réanimation, hôpital Laënnec, centre hospitalier universitaire de Nantes, boulevard Jacques-Monod, Saint-Herblain, 44093 Nantes cedex 1, France. Electronic address: lakhal_karim@yahoo.fr.""}]","Anaesthesia, critical care & pain medicine",['10.1016/j.accpm.2020.04.007'] 83,32380852,Enhanced rehabilitation guidance after arthroscopic capsulolabral repair of the shoulder: a randomized controlled trial.,"OBJECTIVE To compare the effects of a 12-month home-based exercise program to usual care in patients after arthroscopic capsulolabral repair of the shoulder. DESIGN Randomized controlled trial. SETTING Outpatient physical and rehabilitation medicine clinic. SUBJECTS Forty-five patients (mean age: 35 years; standard deviation (SD): 10 years) who underwent arthroscopic capsulolabral repair due to labral lesion were randomized into an exercise group (EG) or a control group (CG). INTERVENTION The EG received a 12-month home-based additional exercise program with four physiotherapy follow-up visits, while the CG received standard postoperative exercise instructions. MAIN MEASURES Self-reported shoulder disability was assessed with the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES) and quality of life with the Short-Form (SF)-36 Health Survey. The function of the operated shoulder was evaluated with strength and range of motion measurements. RESULTS No between-group differences were observed in any of the outcomes at the follow-up. Mean ASES score improved by 16 (95% confidence interval (CI): 10-23) points from the baseline 78 (SD: 17) in the EG and 13 (95% CI: 7-19) points from the baseline 79 (SD: 17) in the CG. Both groups achieved a significant improvement in the dimensions of Physical Functioning, Role-Physical, and Bodily Pain of the SF-36 and in every aspect of strength and range of motion measures. In EG, exercise adherence was moderate (52%) during the first six months and poor (22%) during the last six months. CONCLUSION Home-based additional exercises with four outpatient follow-up visits did not improve outcome after arthroscopic capsular repair of the shoulder.",2020,"Both groups achieved a significant improvement in the dimensions of Physical Functioning, Role-Physical, and Bodily Pain of the SF-36 and in every aspect of strength and range of motion measures.","['arthroscopic capsulolabral repair of the shoulder', 'Outpatient physical and rehabilitation medicine clinic', 'patients after arthroscopic capsulolabral repair of the shoulder', 'Forty-five patients (mean age: 35\u2009years; standard deviation (SD): 10\u2009years) who underwent arthroscopic capsulolabral repair due to labral lesion']","['home-based exercise program', 'home-based additional exercise program with four physiotherapy follow-up visits, while the CG received standard postoperative exercise instructions', 'exercise group (EG) or a control group (CG']","['Self-reported shoulder disability', 'exercise adherence', 'American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES) and quality of life with the Short-Form (SF)-36 Health Survey', 'Mean ASES score', 'dimensions of Physical Functioning, Role-Physical, and Bodily Pain of the SF-36 and in every aspect of strength and range of motion measures']","[{'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0031813', 'cui_str': 'Physical Medicine and Rehabilitation'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0589121', 'cui_str': 'Follow-up visit'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",,0.0607013,"Both groups achieved a significant improvement in the dimensions of Physical Functioning, Role-Physical, and Bodily Pain of the SF-36 and in every aspect of strength and range of motion measures.","[{'ForeName': 'Juhani', 'Initials': 'J', 'LastName': 'Multanen', 'Affiliation': 'Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.'}, {'ForeName': 'Pauli', 'Initials': 'P', 'LastName': 'Kiuru', 'Affiliation': 'Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.'}, {'ForeName': 'Kirsi', 'Initials': 'K', 'LastName': 'Piitulainen', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Central Finland Hospital District, Jyväskylä, Finland.'}, {'ForeName': 'Jari', 'Initials': 'J', 'LastName': 'Ylinen', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Central Finland Hospital District, Jyväskylä, Finland.'}, {'ForeName': 'Juha', 'Initials': 'J', 'LastName': 'Paloneva', 'Affiliation': 'Department of Surgery, Central Finland Hospital District, Jyväskylä, Finland.'}, {'ForeName': 'Arja', 'Initials': 'A', 'LastName': 'Häkkinen', 'Affiliation': 'Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.'}]",Clinical rehabilitation,['10.1177/0269215520919472'] 84,32385158,Common and dissociable effects of oxytocin and lorazepam on the neurocircuitry of fear.,"Benzodiazepines (BZDs) represent the gold standard of anxiolytic pharmacotherapy; however, their clinical benefit is limited by side effects and addictive potential. Consequently, there is an urgent need to develop novel and safe anxiolytics. The peptide hormone oxytocin (OXT) exhibits anxiolytic-like properties in animals and humans, but whether OXT and BZDs share similar effects on the neural circuitry of fear is unclear. Therefore, the rationale of this ultra-high-field functional MRI (fMRI) study was to test OXT against the clinical comparator lorazepam (LZP) with regard to their neuromodulatory effects on local and network responses to fear-related stimuli. One hundred twenty-eight healthy male participants volunteered in this randomized double-blind, placebo-controlled, between-group study. Before scanning using an emotional face-matching paradigm, participants were randomly administered a single dose of OXT (24 IU), LZP (1 mg), or placebo. On the behavioral level, LZP, but not OXT, caused mild sedation, as evidenced by a 19% increase in reaction times. On the neural level, both OXT and LZP inhibited responses to fearful faces vs. neutral faces within the centromedial amygdala (cmA). In contrast, they had different effects on intra-amygdalar connectivity; OXT strengthened the coupling between the cmA and basolateral amygdala, whereas LZP increased the interplay between the cmA and superficial amygdala. Furthermore, OXT, but not LZP, enhanced the coupling between the cmA and the precuneus and dorsomedial prefrontal cortex. These data implicate inhibition of the cmA as a common denominator of anxiolytic action, with only OXT inducing large-scale connectivity changes of potential therapeutic relevance.",2020,"On the neural level, both OXT and LZP inhibited responses to fearful faces vs. neutral faces within the centromedial amygdala (cmA).",['One hundred twenty-eight healthy male participants volunteered'],"['Benzodiazepines (BZDs', 'oxytocin and lorazepam', 'OXT', 'LZP', 'peptide hormone oxytocin (OXT', 'lorazepam (LZP', 'placebo']","['neurocircuitry of fear', 'reaction times']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0024002', 'cui_str': 'Lorazepam'}, {'cui': 'C0597192', 'cui_str': 'Peptide hormone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}]",128.0,0.100533,"On the neural level, both OXT and LZP inhibited responses to fearful faces vs. neutral faces within the centromedial amygdala (cmA).","[{'ForeName': 'Ann-Kathrin', 'Initials': 'AK', 'LastName': 'Kreuder', 'Affiliation': 'Division of Medical Psychology, Department of Psychiatry and Psychotherapy, University Hospital Bonn, 53105 Bonn, Germany.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Scheele', 'Affiliation': 'Division of Medical Psychology, Department of Psychiatry and Psychotherapy, University Hospital Bonn, 53105 Bonn, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Schultz', 'Affiliation': 'Center for Economics and Neuroscience, University of Bonn, 53113 Bonn, Germany.'}, {'ForeName': 'Juergen', 'Initials': 'J', 'LastName': 'Hennig', 'Affiliation': 'Division of Personality Psychology and Individual Differences, University of Giessen, 35390 Giessen, Germany.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Marsh', 'Affiliation': 'Department of Psychiatry, School of Medicine & Health Sciences, University of Oldenburg, 26129 Oldenburg, Germany.'}, {'ForeName': 'Torge', 'Initials': 'T', 'LastName': 'Dellert', 'Affiliation': 'Institute of Medical Psychology and Systems Neuroscience, University of Muenster, 48149 Muenster, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Ettinger', 'Affiliation': 'Department of Psychology, University of Bonn, 53113 Bonn, Germany.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Philipsen', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital Bonn, 53105 Bonn, Germany.'}, {'ForeName': 'Mari', 'Initials': 'M', 'LastName': 'Babasiz', 'Affiliation': 'Division of Medical Psychology, Department of Psychiatry and Psychotherapy, University Hospital Bonn, 53105 Bonn, Germany.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Herscheid', 'Affiliation': 'Division of Medical Psychology, Department of Psychiatry and Psychotherapy, University Hospital Bonn, 53105 Bonn, Germany.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Remmersmann', 'Affiliation': 'Division of Medical Psychology, Department of Psychiatry and Psychotherapy, University Hospital Bonn, 53105 Bonn, Germany.'}, {'ForeName': 'Ruediger', 'Initials': 'R', 'LastName': 'Stirnberg', 'Affiliation': 'Division of MR Physics, German Center for Neurodegenerative Diseases, 53175 Bonn, Germany.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Stöcker', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital Bonn, 53105 Bonn, Germany.'}, {'ForeName': 'René', 'Initials': 'R', 'LastName': 'Hurlemann', 'Affiliation': 'Division of Medical Psychology, Department of Psychiatry and Psychotherapy, University Hospital Bonn, 53105 Bonn, Germany; renehurlemann@icloud.com.'}]",Proceedings of the National Academy of Sciences of the United States of America,['10.1073/pnas.1920147117'] 85,32386810,Femtosecond Laser-Assisted Cataract Surgery Versus Phacoemulsification Cataract Surgery (FACT): A Randomized Noninferiority Trial.,"PURPOSE To report the 3-month results of a randomized trial (Femtosecond Laser-Assisted Cataract Trial [FACT]) comparing femtosecond laser-assisted cataract surgery (FLACS) with standard phacoemulsification cataract surgery (PCS). DESIGN Multicenter, randomized controlled trial funded by the UK National Institute of Health Research (HTA 13/04/46/). PARTICIPANTS Seven hundred eighty-five patients with age-related cataract. METHODS This trial took place in 3 hospitals in the UK National Health Service (NHS). Randomization (1:1) was stratified by site, surgeon, and 1 or both eyes eligible using a secure web-based system. Postoperative assessments were masked to the allocated intervention. The primary outcome was unaided distance visual acuity (UDVA) in the study eye at 3 months. Secondary outcomes included corrected distance visual acuity, complications, and patient-reported outcomes measures. The noninferiority margin was 0.1 logarithm of the minimum angle of resolution (logMAR). ISRCTN.com registry, number ISRCTN77602616. MAIN OUTCOME MEASURES We enrolled 785 participants between May 2015 and September 2017 and randomly assigned 392 to FLACS and 393 to PCS. At 3 months postoperatively, mean UDVA difference between treatment arms was -0.01 logMAR (-0.05 to 0.03), and mean corrected distance visual acuity difference was -0.01 logMAR (95% confidence interval [CI], -0.05 to 0.02). Seventy-one percent of both FLACS and PCS cases were within ±0.5 diopters (D) of the refractive target, and 93% of FLACS and 92% of PCS cases were within ±1.0 D. There were 2 posterior capsule tears in the PCS arm and none in the FLACS arm. There were no significant differences between arms for any secondary outcome. CONCLUSIONS Femtosecond laser-assisted cataract surgery is not inferior to conventional PCS surgery 3 months after surgery. Both methods are as good in terms of vision, patient-reported health, and safety outcomes at 3 months. Longer-term outcomes of the clinical effectiveness and cost-effectiveness are awaited.",2020,"There were no significant differences between arms for any secondary outcome. ","['Seven hundred eighty-five patients with age-related cataract', '785 participants between May 2015 and September 2017 and randomly assigned 392 to FLACS and 393 to PCS', '3 hospitals in the UK National Health Service (NHS']","['standard phacoemulsification cataract surgery (PCS', 'Femtosecond Laser-Assisted Cataract Surgery Versus Phacoemulsification Cataract Surgery (FACT', 'Femtosecond Laser-Assisted Cataract Trial [FACT', 'femtosecond laser-assisted cataract surgery (FLACS', 'Femtosecond laser-assisted cataract surgery']","['clinical effectiveness and cost-effectiveness', 'unaided distance visual acuity (UDVA', 'mean UDVA difference', 'corrected distance visual acuity, complications, and patient-reported outcomes measures', 'mean corrected distance visual acuity difference']","[{'cui': 'C4517862', 'cui_str': '700'}, {'cui': 'C4517892', 'cui_str': '85'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C1531960', 'cui_str': 'Femtosecond pulsed laser device'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C4517754', 'cui_str': '393'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0027462', 'cui_str': 'National Health Services'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C1531960', 'cui_str': 'Femtosecond pulsed laser device'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C3850123', 'cui_str': 'Treatment Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0439846', 'cui_str': 'Unaided'}, {'cui': 'C0429537', 'cui_str': 'Distance visual acuity'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",785.0,0.436528,"There were no significant differences between arms for any secondary outcome. ","[{'ForeName': 'Alexander C', 'Initials': 'AC', 'LastName': 'Day', 'Affiliation': 'The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; Moorfields Eye Hospital, London, United Kingdom; UCL Institute of Ophthalmology, London, United Kingdom. Electronic address: alex.day@ucl.ac.uk.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Burr', 'Affiliation': 'School of Medicine, University of St. Andrews, Fife, Scotland.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Bennett', 'Affiliation': 'UCL Comprehensive Clinical Trials Unit, London, United Kingdom.'}, {'ForeName': 'Catey', 'Initials': 'C', 'LastName': 'Bunce', 'Affiliation': ""Department of Primary Care & Public Health Sciences, King's College London, London, United Kingdom.""}, {'ForeName': 'Caroline J', 'Initials': 'CJ', 'LastName': 'Doré', 'Affiliation': 'UCL Comprehensive Clinical Trials Unit, London, United Kingdom.'}, {'ForeName': 'Gary S', 'Initials': 'GS', 'LastName': 'Rubin', 'Affiliation': 'UCL Institute of Ophthalmology, London, United Kingdom.'}, {'ForeName': 'Mayank A', 'Initials': 'MA', 'LastName': 'Nanavaty', 'Affiliation': 'Sussex Eye Hospital, Brighton & Sussex University Hospitals NHS Trust, Eastern Road, Brighton, United Kingdom.'}, {'ForeName': 'Kamaljit S', 'Initials': 'KS', 'LastName': 'Balaggan', 'Affiliation': 'Wolverhampton and Midlands Eye Infirmary, New Cross Hospital, Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, United Kingdom.'}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Wilkins', 'Affiliation': 'The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; Moorfields Eye Hospital, London, United Kingdom.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Ophthalmology,['10.1016/j.ophtha.2020.02.028'] 86,32394880,Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial.,"New dengue vaccines are needed to prevent this globally expanding vector-borne disease. The V180 vaccine candidate consists of four recombinant, soluble, dengue virus envelope glycoproteins and has been previously evaluated in two clinical trials for safety and immunogenicity in Flavivirus -naive participants (NCT01477580 and NCT0093642). Here, we report on a randomized, placebo-controlled, double-blind study of the safety and immunogenicity of the V180 vaccine in subjects who have previously received the live attenuated tetravalent vaccine (LATV) developed by the National Institute of Allergy and Infectious Diseases (protocol #V180-002 [CIR-301]). The study was designed to evaluate whether this recombinant subunit vaccine could boost the neutralizing antibody responses induced by dengue LATV. Twenty participants who had previously received one or two doses of dengue LATV were randomized and received a single dose of V180 nonadjuvanted ( N = 8), V180 adjuvanted with Alhydrogel™ (aluminum hydroxide gel, Brenntag Biosector, Frederikssund, Denmark) ( N = 8), or placebo ( N = 4). Immunogenicity was measured using a plaque reduction neutralization test at days 1, 15, 28, and 180 after vaccination. In addition, vaccine safety (solicited and unsolicited adverse events) was assessed using a vaccination report card for 28 days following vaccination, and serious adverse events were captured from the time of informed consent through the final study visit at 6 months after vaccination. The results of the study demonstrate that the V180 vaccine is generally well tolerated and immunogenic in these dengue-seropositive volunteers.",2020,The results of the study demonstrate that the V180 vaccine is generally well tolerated and immunogenic in these dengue-seropositive volunteers.,"['Adults', 'Twenty participants who had previously received one or two doses of dengue LATV', 'subjects who have previously received the live attenuated tetravalent vaccine (LATV) developed by the National Institute of Allergy and Infectious Diseases (protocol #V180-002 [CIR-301']","['V180 adjuvanted with Alhydrogel™ (aluminum hydroxide gel, Brenntag Biosector, Frederikssund, Denmark) ', 'placebo', 'Tetravalent Recombinant Subunit Dengue Vaccine', 'recombinant subunit vaccine', 'Live Attenuated Tetravalent Dengue Vaccine', 'V180 vaccine']","['vaccine safety (solicited and unsolicited adverse events', 'tolerated and immunogenic', 'neutralizing antibody responses', 'Immunogenicity and Safety', 'Immunogenicity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011311', 'cui_str': 'Dengue'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C1513895', 'cui_str': 'National Institute of Allergy and Infectious Diseases'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0733770', 'cui_str': 'Alhydrogel'}, {'cui': 'C0002372', 'cui_str': 'algeldrate'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0599220', 'cui_str': 'Protein Subunit'}, {'cui': 'C1548477', 'cui_str': 'Dengue Vaccines'}, {'cui': 'C0887892', 'cui_str': 'Vaccines, Subunit'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0282682', 'cui_str': 'Blocking antibody'}]",20.0,0.508172,The results of the study demonstrate that the V180 vaccine is generally well tolerated and immunogenic in these dengue-seropositive volunteers.,"[{'ForeName': 'Anna P', 'Initials': 'AP', 'LastName': 'Durbin', 'Affiliation': 'Department of International Health, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Kristen K', 'Initials': 'KK', 'LastName': 'Pierce', 'Affiliation': 'Department of Microbiology and Molecular Genetics, Vaccine Testing Center, Larner College of Medicine, University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Beth D', 'Initials': 'BD', 'LastName': 'Kirkpatrick', 'Affiliation': 'Department of Microbiology and Molecular Genetics, Vaccine Testing Center, Larner College of Medicine, University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Palmtama', 'Initials': 'P', 'LastName': 'Grier', 'Affiliation': 'Department of International Health, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Beulah P', 'Initials': 'BP', 'LastName': 'Sabundayo', 'Affiliation': 'Department of International Health, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'He', 'Affiliation': 'Department of International Health, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Sausser', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Amy Falk', 'Initials': 'AF', 'LastName': 'Russell', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Martin', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Hyatt', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Cook', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Jeffrey R', 'Initials': 'JR', 'LastName': 'Sachs', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Andrew Wen-Tseng', 'Initials': 'AW', 'LastName': 'Lee', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Liman', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Beth-Ann', 'Initials': 'BA', 'LastName': 'Coller', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Stephen S', 'Initials': 'SS', 'LastName': 'Whitehead', 'Affiliation': 'Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.20-0042'] 87,32333883,Effects of 20-year infancy-onset dietary counselling on cardiometabolic risk factors in the Special Turku Coronary Risk Factor Intervention Project (STRIP): 6-year post-intervention follow-up.,"BACKGROUND Primordial and primary prevention is the cornerstone for cardiometabolic health. In the randomised, controlled Special Turku Coronary Risk Factor Intervention Project (STRIP; n=1116), a 20-year dietary counselling intervention was given to children biannually from infancy, and cardiometabolic health benefits had been observed among the participants in the intervention group. Here, we report on the key results of the first follow-up done 6 years after the end of the intervention, at age 26 years. METHODS The randomised controlled STRIP study recruited children at age 5 months from well-baby clinics in Turku, Finland, and randomly assigned them to either an intervention or control group; group allocation was unmasked. The intervention introduced participants to a heart-healthy diet, characterised by low proportional intake of saturated fat and cholesterol, by dietary counselling and nutrition education sessions to parents and children from the age of 7 months to 20 years. Children in the control group received only the basic health education given at Finnish well-baby clinics and school health care. We assessed diet, lifestyle, and cardiometabolic risk factor data, including blood pressure, anthropometry, serum biochemistry (lipids, apolipoproteins, glucose, and insulin), and homoeostatic model assessment of insulin resistance (HOMA-IR) in the participants at age 26 years. FINDINGS 1116 children were included in the original STRIP study, of whom 551 provided data at the age 26 years follow-up, and data for 507 participants were analysed (243 in the intervention group and 264 in the control group). At follow-up, those who had been in the intervention group had slightly lower mean intake of saturated fat as a proportion of total energy intake than the control group (13·0% [SD 3·3] vs 13·7% [3·6], p=0·049). A higher proportion of participants in the intervention group achieved the targeted monounsaturated and polyunsaturated fat to saturated fat ratio of more than 2:1 than the control group (78 [39%] of 200 vs 70 [30%] of 235; risk ratio [RR] 1·16 [95% CI 1·01-1·33]; p=0·035). A higher proportion of intervention group participants met the ideal total cholesterol concentration of less than 5·17 mmol/L (194 [81%] of 240 vs 187 [72%] of 261; RR 1·45 [1·05-2·01], p=0·024) and optimal LDL cholesterol concentration of less than 3·0 mmol/L (166 [69%] of 240 vs 158 [61%] of 251; RR 1·30 [1·03-1·66], p=0·031). Those who received the intervention had lower glucose (5·00 mmol/L [SD 0·43] vs 5·07 mmol/L [0·46], p=0·040) and HOMA-IR (median 1·44 [IQR 1·09-1·91] vs 1·62 [1·22-2·09], p=0·037) than the participants in the control group. INTERPRETATION Previously observed intervention effects during the 20-year counselling were largely maintained into adulthood 6 years after the withdrawal of the intervention. Dietary counselling introduced in infancy thus provided a sustained benefit to diet quality and cardiometabolic risk factor levels. FUNDING Academy of Finland, Juho Vainio Foundation, Finnish Foundation for Cardiovascular Research, Finnish Ministry of Education and Culture, Finnish Cultural Foundation, Sigrid Jusélius Foundation, Special Governmental grants for Health Sciences Research (Turku University Hospital), Yrjö Jahnsson Foundation, Finnish Medical Foundation, and Turku University Foundation.",2020,Previously observed intervention effects during the 20-year counselling were largely maintained into adulthood 6 years after the withdrawal of the intervention.,"['1116 children were included in the original STRIP study, of whom 551 provided data at the age 26 years follow-up, and data for 507 participants were analysed (243 in the intervention group and 264 in the control group', 'children at age 5 months from well-baby clinics in Turku, Finland', 'participants at age 26 years']","['20-year infancy-onset dietary counselling', 'heart-healthy diet, characterised by low proportional intake of saturated fat and cholesterol, by dietary counselling and nutrition education sessions', 'basic health education given at Finnish well-baby clinics and school health care', '20-year dietary counselling intervention']","['optimal LDL cholesterol concentration', 'ideal total cholesterol concentration', 'diet, lifestyle, and cardiometabolic risk factor data, including blood pressure, anthropometry, serum biochemistry (lipids, apolipoproteins, glucose, and insulin), and homoeostatic model assessment of insulin resistance (HOMA-IR', 'total energy intake', 'cardiometabolic risk factors', 'targeted monounsaturated and polyunsaturated fat to saturated fat ratio', 'HOMA-IR']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205313', 'cui_str': 'Original'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0450381', 'cui_str': '507'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0458075', 'cui_str': 'Well baby'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0016132', 'cui_str': 'Finland'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0231330', 'cui_str': 'Infancy'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205351', 'cui_str': 'Proportional'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0418901', 'cui_str': 'Health education given'}, {'cui': 'C0016134', 'cui_str': 'Finnish language'}, {'cui': 'C0458075', 'cui_str': 'Well baby'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0036372', 'cui_str': 'Nursing, School'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0005477', 'cui_str': 'Biochemistry'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0003591', 'cui_str': 'Apolipoprotein'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0597423', 'cui_str': 'Saturated fat'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",1116.0,0.0313873,Previously observed intervention effects during the 20-year counselling were largely maintained into adulthood 6 years after the withdrawal of the intervention.,"[{'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Pahkala', 'Affiliation': 'Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland; Paavo Nurmi Centre, Sports and Exercise Medicine Unit, Department of Health and Physical Activity, University of Turku, Turku, Finland; Centre for Population Health Research, Turku University Hospital, University of Turku, Turku, Finland. Electronic address: katja.pahkala@utu.fi.'}, {'ForeName': 'Tomi T', 'Initials': 'TT', 'LastName': 'Laitinen', 'Affiliation': 'Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland; Centre for Population Health Research, Turku University Hospital, University of Turku, Turku, Finland.'}, {'ForeName': 'Harri', 'Initials': 'H', 'LastName': 'Niinikoski', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine, Turku University Hospital, University of Turku, Turku, Finland.'}, {'ForeName': 'Noora', 'Initials': 'N', 'LastName': 'Kartiosuo', 'Affiliation': 'Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland; Centre for Population Health Research, Turku University Hospital, University of Turku, Turku, Finland.'}, {'ForeName': 'Suvi P', 'Initials': 'SP', 'LastName': 'Rovio', 'Affiliation': 'Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland; Centre for Population Health Research, Turku University Hospital, University of Turku, Turku, Finland.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Lagström', 'Affiliation': 'Centre for Population Health Research, Turku University Hospital, University of Turku, Turku, Finland; Department of Public Health, Turku University Hospital, University of Turku, Turku, Finland.'}, {'ForeName': 'Britt-Marie', 'Initials': 'BM', 'LastName': 'Loo', 'Affiliation': 'Joint Clinical Biochemistry Laboratory, Turku University Hospital, University of Turku, Turku, Finland.'}, {'ForeName': 'Pia', 'Initials': 'P', 'LastName': 'Salo', 'Affiliation': 'Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland; Centre for Population Health Research, Turku University Hospital, University of Turku, Turku, Finland.'}, {'ForeName': 'Eero', 'Initials': 'E', 'LastName': 'Jokinen', 'Affiliation': ""Department of Pediatrics, New Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.""}, {'ForeName': 'Costan G', 'Initials': 'CG', 'LastName': 'Magnussen', 'Affiliation': 'Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland; Centre for Population Health Research, Turku University Hospital, University of Turku, Turku, Finland; Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Juonala', 'Affiliation': 'Department of Medicine, Division of Medicine, Turku University Hospital, University of Turku, Turku, Finland.'}, {'ForeName': 'Olli', 'Initials': 'O', 'LastName': 'Simell', 'Affiliation': 'Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland; Centre for Population Health Research, Turku University Hospital, University of Turku, Turku, Finland.'}, {'ForeName': 'Antti', 'Initials': 'A', 'LastName': 'Jula', 'Affiliation': 'Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland.'}, {'ForeName': 'Tapani', 'Initials': 'T', 'LastName': 'Rönnemaa', 'Affiliation': 'Department of Medicine, Division of Medicine, Turku University Hospital, University of Turku, Turku, Finland.'}, {'ForeName': 'Jorma', 'Initials': 'J', 'LastName': 'Viikari', 'Affiliation': 'Department of Medicine, Division of Medicine, Turku University Hospital, University of Turku, Turku, Finland.'}, {'ForeName': 'Olli T', 'Initials': 'OT', 'LastName': 'Raitakari', 'Affiliation': 'Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland; Centre for Population Health Research, Turku University Hospital, University of Turku, Turku, Finland; Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, University of Turku, Turku, Finland.'}]",The Lancet. Child & adolescent health,['10.1016/S2352-4642(20)30059-6'] 88,32283187,Mediators of intervention effects on dietary fat intake in low-income overweight or obese women with young children.,"PURPOSE We investigated whether autonomous motivation and self-efficacy might mediate the association between a lifestyle behavior intervention and dietary fat intake in low-income overweight or obese women with young children. METHODS Participants were randomized to an intervention or comparison group. Intervention participants received a 16-week intervention aimed to prevent weight gain through promotion of stress management, healthy eating and physical activity. During the intervention phase, participants viewed a designated video lesson at home and dialed in a peer support group teleconference every week (weeks 1-4) then every other week (weeks 5-16). Potential mediation effects were analyzed using sequential mixed-effects linear models and path analysis. RESULTS The intervention led to increased autonomous motivation (β = 0.34, standard error [SE] = 0.15, P = 0.005), which subsequently increased self-efficacy (β = 0.18, SE = 0.35, P < 0.001), and higher levels of self-efficacy were associated with decreased dietary fat intake (β = -0.22, SE = 0.28, P < 0.001). In other words, autonomous motivation and self-efficacy mediated the association between the lifestyle behavior intervention and dietary fat intake. CONCLUSION To decrease dietary fat intake for low-income overweight or obese women with young children, strategies, such as those promoting peer encouragement, may be warranted in interventions to enhance autonomous motivation and/or practical skills for increasing self-efficacy.",2020,"The intervention led to increased autonomous motivation (β = 0.34, standard error [SE] = 0.15, P = 0.005), which subsequently increased self-efficacy (β = 0.18, SE = 0.35, P < 0.001), and higher levels of self-efficacy were associated with decreased dietary fat intake (β = -0.22, SE = 0.28, P < 0.001).","['Participants', 'low-income overweight or obese women with young children']","['16-week intervention aimed to prevent weight gain through promotion of stress management, healthy eating and physical activity', 'lifestyle behavior intervention and dietary fat intake']","['dietary fat intake', 'autonomous motivation', 'self-efficacy', 'higher levels of self-efficacy']","[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2744535', 'cui_str': 'CD69 protein, human'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0425440', 'cui_str': 'Dietary fat intake'}]","[{'cui': 'C0425440', 'cui_str': 'Dietary fat intake'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.0336699,"The intervention led to increased autonomous motivation (β = 0.34, standard error [SE] = 0.15, P = 0.005), which subsequently increased self-efficacy (β = 0.18, SE = 0.35, P < 0.001), and higher levels of self-efficacy were associated with decreased dietary fat intake (β = -0.22, SE = 0.28, P < 0.001).","[{'ForeName': 'Mei-Wei', 'Initials': 'MW', 'LastName': 'Chang', 'Affiliation': 'The Ohio State University College of Nursing, 1585 Neil Avenue, Columbus, OH, 43210, USA. Electronic address: chang.1572@osu.edu.'}, {'ForeName': 'Alai', 'Initials': 'A', 'LastName': 'Tan', 'Affiliation': 'The Ohio State University College of Nursing, 1585 Neil Avenue, Columbus, OH, 43210, USA.'}, {'ForeName': 'Jiying', 'Initials': 'J', 'LastName': 'Ling', 'Affiliation': 'Michigan State University College of Nursing, 1355 Bogue St, East Lansing, MI, 48824, USA. Electronic address: lingjiyi@msu.edu.'}, {'ForeName': 'Duane T', 'Initials': 'DT', 'LastName': 'Wegener', 'Affiliation': 'The Ohio State University Department of Psychology, 1835 Neil Avenue, Columbus, OH, 43210, USA. Electronic address: wegener.1@osu.edu.'}, {'ForeName': 'Lorraine B', 'Initials': 'LB', 'LastName': 'Robbins', 'Affiliation': 'Michigan State University College of Nursing, 1355 Bogue St, East Lansing, MI, 48824, USA. Electronic address: robbin76@msu.edu.'}]",Appetite,['10.1016/j.appet.2020.104700'] 89,32315965,Baduanjin mind-body exercise improves logical memory in long-term hospitalized patients with schizophrenia: A randomized controlled trial.,"Neurocognitive impairment is one of the core symptoms in schizophrenia and poses a great challenge to effective treatment. Sixty-one long-term hospitalized patients with schizophrenia were recruited and randomly assigned to two groups: Baduanjin exercise and brisk walking. Patients in the Baduanjin group received 24 weeks of Baduanjin training (5 days/week, 40 min/day), while patients in the brisk walking group received 24 weeks of brisk walking (5 days/week, 40 min/day). Scores on the Wechsler Memory Scale, Digit Symbol Substitution Test (DSST), and the positive and negative syndrome scale were used to evaluate the logical memory (LM), processing speed, and clinical symptoms of all participants, while the score of Trail Making Test-A (TMT-A) was applied to assess the visual attention and graphomotor speed, at baseline and the 16th week and 24th week of intervention. The one-way repeated measures analysis of variance (ANOVA) was used to test the differences in neurocognitive changes between the two groups. Repeated measures ANOVA showed significant differences between the two groups in the LM immediate (F = 6.21, p = 0.003) and LM delayed (F=5.60, p = 0.005) scores, but not in the completion times of TMT-A (F=.22, p = 0.806) or DSST scores (F=0.97, p = 0.328). A significant effect of time was also detected in the LM immediate (F=10.24, p = 0.000) and LM delayed (F=4.93, p = 0.009) scores and in the completion time of the TMT-A (F=33.10, p = 0.000), but not in the DSST scores (F=2.12, p = 0.122). Baduanjin exercise could improve logical memory in the long-term hospitalized patients with schizophrenia.",2020,"Repeated measures ANOVA showed significant differences between the two groups in the LM immediate (F = 6.21, p = 0.003) and LM delayed (F=5.60, p = 0.005) scores, but not in the completion times of TMT-A (F=.22, p = 0.806) or DSST scores (F=0.97, p = 0.328).","['long-term hospitalized patients with schizophrenia', 'hospitalized patients with schizophrenia', 'Sixty-one long-term hospitalized patients with schizophrenia']","['Baduanjin exercise', 'Baduanjin training', 'brisk walking group received 24 weeks of brisk walking', 'Baduanjin exercise and brisk walking', 'Baduanjin mind-body exercise']","['LM immediate', 'logical memory (LM), processing speed, and clinical symptoms', 'neurocognitive changes', 'LM delayed', 'logical memory', 'visual attention and graphomotor speed', 'completion time of the TMT-A', 'Wechsler Memory Scale, Digit Symbol Substitution Test (DSST), and the positive and negative syndrome scale', 'DSST scores']","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C4517832', 'cui_str': '61'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0443162', 'cui_str': 'Brisk'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}]","[{'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0589102', 'cui_str': 'Visual attention'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0451575', 'cui_str': 'Wechsler memory scale'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0451383', 'cui_str': 'Positive and negative syndrome scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",61.0,0.0321369,"Repeated measures ANOVA showed significant differences between the two groups in the LM immediate (F = 6.21, p = 0.003) and LM delayed (F=5.60, p = 0.005) scores, but not in the completion times of TMT-A (F=.22, p = 0.806) or DSST scores (F=0.97, p = 0.328).","[{'ForeName': 'Mingli', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': ""Mental Health Center and Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China; The Mental Rehabilitation Centers, Karamay Municipal People's Hospital, Karamay, Xinjiang 830054, China. Electronic address: limingli0517@qq.com.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Fang', 'Affiliation': ""The Mental Rehabilitation Centers, Karamay Municipal People's Hospital, Karamay, Xinjiang 830054, China.""}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': ""The Mental Rehabilitation Centers, Karamay Municipal People's Hospital, Karamay, Xinjiang 830054, China.""}, {'ForeName': 'Yali', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': ""The Mental Rehabilitation Centers, Karamay Municipal People's Hospital, Karamay, Xinjiang 830054, China.""}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Shen', 'Affiliation': ""The Mental Rehabilitation Centers, Karamay Municipal People's Hospital, Karamay, Xinjiang 830054, China.""}, {'ForeName': 'Yiming', 'Initials': 'Y', 'LastName': 'Yusubujiang', 'Affiliation': ""The Mental Rehabilitation Centers, Karamay Municipal People's Hospital, Karamay, Xinjiang 830054, China.""}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Luo', 'Affiliation': ""The Mental Rehabilitation Centers, Karamay Municipal People's Hospital, Karamay, Xinjiang 830054, China. Electronic address: 577827619@qq.com.""}]",Asian journal of psychiatry,['10.1016/j.ajp.2020.102046'] 90,32196898,Safety and efficacy of step-down to oral outpatient treatment versus inpatient antimicrobial treatment in pediatric cancer patients with febrile neutropenia: A noninferiority multicenter randomized clinical trial.,"BACKGROUND It has been suggested that low-risk febrile neutropenia (FN) episodes can be treated in a step-down manner in the outpatient setting. This recommendation has been limited to implementation in middle-income countries due to concerns about infrastructure and lack of trained personnel. We aimed to determine whether early step-down to oral antimicrobial outpatient treatment is not inferior in safety and efficacy to inpatient intravenous treatment in children with low-risk FN. PROCEDURE A noninferiority randomized controlled clinical trial was conducted in three hospitals in Mexico City. Low-risk FN was identified in children younger than 18 years. After 48 to 72 hours of intravenous treatment, children were randomly allocated to receive outpatient oral treatment (experimental arm, cefixime) or to continue inpatient treatment (standard of care, cefepime). Daily monitoring was performed until neutropenia resolution. The presence of any unfavorable clinical outcome was the endpoint of interest. We performed a noninferiority test for comparison of proportions. RESULTS We identified 1237 FN episodes; 117 cases were randomized: 60 to the outpatient group and 57 for continued inpatient treatment. Of the FN episodes, 100% in the outpatient group and 93% in the inpatient group had a favorable outcome (P < 0.001). The mean duration of antibiotics was 4.1 days (SD 2.5; 95% CI, 3.4-4.8 days) in the outpatient group and 4.4 days (SD 2.5; 95% CI, 3.7-5.0 days) in the inpatient group (P = 0.70). CONCLUSIONS In our population, step-down oral outpatient treatment of low-risk FN was as safe and effective as inpatient intravenous treatment. Clinical Trials Identifier: NCT04000711.",2020,"In our population, step-down oral outpatient treatment of low-risk FN was as safe and effective as inpatient intravenous treatment.","['1237 FN episodes; 117 cases were randomized: 60 to the outpatient group and 57 for continued inpatient treatment', 'children younger than 18 years', 'children with low-risk FN', 'pediatric cancer patients with febrile neutropenia', 'three hospitals in Mexico City']","['outpatient oral treatment (experimental arm, cefixime', 'step-down to oral outpatient treatment versus inpatient antimicrobial treatment']","['Safety and efficacy', 'safety and efficacy', 'mean duration of antibiotics']","[{'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0746883', 'cui_str': 'Febrile Neutropenia'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0025885', 'cui_str': 'Mexico'}, {'cui': 'C0008848', 'cui_str': 'Cities'}]","[{'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0060400', 'cui_str': 'Cefixime'}, {'cui': 'C1261552', 'cui_str': 'Step'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C1136254', 'cui_str': 'Microbicides'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}]",117.0,0.139808,"In our population, step-down oral outpatient treatment of low-risk FN was as safe and effective as inpatient intravenous treatment.","[{'ForeName': 'Martha J', 'Initials': 'MJ', 'LastName': 'Avilés-Robles', 'Affiliation': 'Infectious Diseases Department, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Reyes-López', 'Affiliation': 'Center of Economics and Social Studies in Health, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.'}, {'ForeName': 'Francisco J', 'Initials': 'FJ', 'LastName': 'Otero-Mendoza', 'Affiliation': 'Infectious Diseases Department, Instituto Nacional de Pediatría, Mexico City, Mexico.'}, {'ForeName': 'Amilcar U', 'Initials': 'AU', 'LastName': 'Valencia-Garin', 'Affiliation': 'Division of Pediatric, Hospital Juárez de México, Mexico City, Mexico.'}, {'ForeName': 'José G', 'Initials': 'JG', 'LastName': 'Peñaloza-González', 'Affiliation': 'Division of Pediatric, Hospital Juárez de México, Mexico City, Mexico.'}, {'ForeName': 'Rómulo E', 'Initials': 'RE', 'LastName': 'Rosales-Uribe', 'Affiliation': 'Subdivision of Integral Attention to the Patient, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.'}, {'ForeName': 'Onofre', 'Initials': 'O', 'LastName': 'Muñoz-Hernández', 'Affiliation': 'National Medical Arbitration Commission, Mexico City, Mexico.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Garduño-Espinosa', 'Affiliation': 'Research Department, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Juárez-Villegas', 'Affiliation': 'Oncology Department, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Zapata-Tarrés', 'Affiliation': 'Oncology Department, Instituto Nacional de Pediatría, Mexico City, Mexico.'}]",Pediatric blood & cancer,['10.1002/pbc.28251'] 91,32246953,Teaching people to eat according to appetite - Does the method of glucose measurement matter?,"BACKGROUND Hunger training teaches people to eat according to their appetite using pre-prandial glucose measurement. Previous hunger training interventions used fingerprick blood glucose, however continuous glucose monitoring (CGM) offers a painless and convenient form of glucose monitoring. The aim of this randomised feasibility trial was to compare hunger training using CGM with fingerprick glucose monitoring in terms of adherence to the protocol, acceptability, weight, body composition, HbA1c, psychosocial variables, and the relationship between adherence measures and weight loss. METHODS 40 adults with obesity were randomised to either fingerpricking or scanning with a CGM and followed identical interventions for 6 months, which included 1 month of only eating when glucose was under their individualised glucose cut-off. For months 2-6 participants relied on their sensations of hunger to guide their eating and filled in a booklet. RESULTS 90% of the fingerpricking group and 85% of the scanning group completed the study. Those using the scanner measured their glucose an extra 1.9 times per day (95% CI 0.9, 2.8, p < 0.001) compared with those testing by fingerprick. Both groups lost similar amounts of weight over 6 months (on average 4 kg), were satisfied with the hunger training program and wanted to measure their glucose again within the next year. There were no differences between groups in terms of intervention acceptability, weight, body composition, HbA1c, eating behaviours, or psychological health. Frequency of glucose testing and booklet entry both predicted a clinically meaningful amount of weight loss. CONCLUSIONS Either method of measuring glucose is effective for learning to eat according to hunger using the hunger training program. As scanning with a CGM encouraged better adherence to the protocol without sacrificing outcome results, future interventions should consider using this new technology in hunger training programs.",2020,"There were no differences between groups in terms of intervention acceptability, weight, body composition, HbA1c, eating behaviours, or psychological health.",['40 adults with obesity'],"['continuous glucose monitoring (CGM', 'hunger training using CGM with fingerprick glucose monitoring', 'fingerpricking or scanning with a CGM and followed identical interventions for 6 months, which included 1 month of only eating when glucose was under their individualised glucose cut-off']","['intervention acceptability, weight, body composition, HbA1c, eating behaviours, or psychological health', 'adherence to the protocol, acceptability, weight, body composition, HbA1c, psychosocial variables']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0202048', 'cui_str': 'Glucose measurement by monitoring device'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0000925', 'cui_str': 'Incised wound'}, {'cui': 'C1518543', 'cui_str': 'Off'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0015745', 'cui_str': 'Eating Behavior'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0033963', 'cui_str': 'Psychosocial Factors'}]",40.0,0.0289517,"There were no differences between groups in terms of intervention acceptability, weight, body composition, HbA1c, eating behaviours, or psychological health.","[{'ForeName': 'Michelle R', 'Initials': 'MR', 'LastName': 'Jospe', 'Affiliation': 'Department of Medicine, University of Otago, PO Box 56, Dunedin, 9054, New Zealand. Electronic address: michelle.jospe@otago.ac.nz.'}, {'ForeName': 'Willemijn E', 'Initials': 'WE', 'LastName': 'de Bruin', 'Affiliation': 'Department of Medicine, University of Otago, PO Box 56, Dunedin, 9054, New Zealand. Electronic address: w.debruin@otago.ac.nz.'}, {'ForeName': 'Jillian J', 'Initials': 'JJ', 'LastName': 'Haszard', 'Affiliation': 'Centre for Biostatistics, University of Otago, PO Box 56, Dunedin, 9054, New Zealand. Electronic address: jill.haszard@otago.ac.nz.'}, {'ForeName': 'Jim I', 'Initials': 'JI', 'LastName': 'Mann', 'Affiliation': 'Department of Medicine, University of Otago, PO Box 56, Dunedin, 9054, New Zealand. Electronic address: jim.mann@otago.ac.nz.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Brunton', 'Affiliation': 'Information Technology Services, University of Otago, PO Box 56, Dunedin, 9054, New Zealand. Electronic address: mark.brunton@otago.ac.nz.'}, {'ForeName': 'Rachael W', 'Initials': 'RW', 'LastName': 'Taylor', 'Affiliation': 'Department of Medicine, University of Otago, PO Box 56, Dunedin, 9054, New Zealand. Electronic address: rachael.taylor@otago.ac.nz.'}]",Appetite,['10.1016/j.appet.2020.104691'] 92,32362226,Randomized Trial of a Mobile Personal Health Record for Behavioral Health Homes.,"OBJECTIVE Behavioral health homes, which provide onsite primary medical care in mental health clinics, face challenges in integrating information across multiple health records. This study tested whether a mobile personal health record application improved quality of medical care for individuals treated in these settings. METHODS This randomized study enrolled 311 participants with a serious mental illness and one or more cardiometabolic risk factors across two behavioral health homes to receive a mobile personal health record application (N=156) or usual care (N=155). A secure mobile personal health record (mPHR) app provided participants in the intervention group with key information about diagnoses, medications, and laboratory test values and allowed them to track health goals. The primary study outcome was a chart-derived composite measure of quality of cardiometabolic and preventive services. RESULTS At 12-month follow-up, participants in the mPHR group maintained high quality of care (70% of indicated services at baseline and at 12-month follow-up), in contrast to a decline in quality for the usual-care group (71% at baseline and 67% at follow-up), resulting in a statistically significant but clinically modest differential impact between the groups. No differences between the study groups were found in secondary self-reported outcomes, including delivery of chronic illness care, patient activation, and quality of life related to mental or general medical health. CONCLUSIONS Use of a mPHR app was associated with a statistically significant but clinically modest differential benefit for quality of medical care among individuals with serious mental illness and comorbid cardiometabolic conditions.",2020,"No differences between the study groups were found in secondary self-reported outcomes, including delivery of chronic illness care, patient activation, and quality of life related to mental or general medical health. ","['individuals treated in these settings', 'Behavioral Health Homes', 'individuals with serious mental illness and comorbid cardiometabolic conditions', '311 participants with a serious mental illness and one or more cardiometabolic risk factors across two behavioral health homes to receive a mobile personal health record application (N=156) or usual care (N=155']","['mobile personal health record application', 'Mobile Personal Health']","['delivery of chronic illness care, patient activation, and quality of life related to mental or general medical health', 'quality of care', 'chart-derived composite measure of quality of cardiometabolic and preventive services', 'quality of medical care']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0870196', 'cui_str': 'Behavioral health'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0018739', 'cui_str': 'Personal Health Records'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C0018739', 'cui_str': 'Personal Health Records'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C3853034', 'cui_str': 'Patient Activation'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0034379', 'cui_str': 'Quality of Care'}, {'cui': 'C0684240', 'cui_str': 'Chart'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0199175', 'cui_str': 'Preventive service'}, {'cui': 'C0496675', 'cui_str': 'Medical care'}]",311.0,0.0822591,"No differences between the study groups were found in secondary self-reported outcomes, including delivery of chronic illness care, patient activation, and quality of life related to mental or general medical health. ","[{'ForeName': 'Benjamin G', 'Initials': 'BG', 'LastName': 'Druss', 'Affiliation': 'Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta.'}, {'ForeName': 'Jianheng', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Tapscott', 'Affiliation': 'Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta.'}, {'ForeName': 'Cathy A', 'Initials': 'CA', 'LastName': 'Lally', 'Affiliation': 'Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta.'}]","Psychiatric services (Washington, D.C.)",['10.1176/appi.ps.201900381'] 93,32360399,Effect of different exercise training intensities on musculoskeletal and neuropathic pain in inactive individuals with type 2 diabetes - Preliminary randomised controlled trial.,"AIMS People with type 2 diabetes (T2D) have a greater prevalence of musculoskeletal and neuropathic pain. This exploratory analysis investigated whether exercise of different intensities leads to changes in self-reported musculoskeletal pain or symptoms of diabetic neuropathy in inactive individuals with type 2 diabetes. METHODS Thirty-two inactive adults with T2D (59% male, mean age 58.7 ± 9.1yrs, median HbA 1c 7.8%) were randomised to usual care (CON), supervised combined aerobic and resistance moderate-intensity continuous training (C-MICT), or supervised combined high-intensity interval training (C-HIIT). At baseline and 8-weeks, musculoskeletal and neuropathic pain were evaluated using a modified Nordic Musculoskeletal Questionnaire and the Neuropathy Total Symptom Score-6 respectively. Quantitative sensory testing was used to determine thermal, mechanical and vibration detection thresholds, as well as pain pressure thresholds. Adverse events were recorded throughout the intervention. RESULTS Compared to CON, reduction in musculoskeletal pain intensity was significantly greater for C-HIIT (MD -5.4, 95% CI [-10.6 to -0.2], p = 0.04) and non-significantly greater for C-MICT (MD -5.9 [-12.4 to 0.7], p = 0.08). Changes in neuropathy symptoms were not different between C-HIIT and CON (MD 1.0 [-0.9 to 2.8], p = 0.31), or C-MICT and CON (MD 0.2 [-3.1 to 3.6], p = 0.89). No differences in sensory function were observed between groups. Similar rates of adverse events were seen in both exercise interventions (19 C-HIIT; 17 C-MICT), all but one of which were mild. CONCLUSIONS Preliminary data suggests 8-weeks of high-intensity combined aerobic and resistance exercise may be safely prescribed for inactive individuals with T2D and may reduce musculoskeletal pain but not neuropathic symptoms. TRIAL REGISTRATION ACTRN12615000475549.",2020,"Compared to CON, reduction in musculoskeletal pain intensity was significantly greater for C-HIIT (MD -5.4, 95% CI [","['inactive individuals with type 2 diabetes', 'Thirty-two inactive adults with T2D (59% male, mean age 58.7±9.1yrs, median HbA 1c 7.8', 'People with type 2 diabetes (T2D', 'Inactive Individuals with Type 2 Diabetes']","['usual care (CON), supervised combined aerobic and resistance moderate-intensity continuous training (C-MICT), or supervised combined high-intensity interval training (C-HIIT', 'CON', 'Different Exercise Training Intensities']","['modified Nordic Musculoskeletal Questionnaire and the Neuropathy Total Symptom Score-6 respectively', 'sensory function', 'Adverse events', 'Musculoskeletal and Neuropathic Pain', 'musculoskeletal pain intensity', 'neuropathy symptoms', 'adverse events', 'pain pressure thresholds', 'musculoskeletal and neuropathic pain', 'musculoskeletal pain']","[{'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0442874', 'cui_str': 'Neuropathy'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0027796', 'cui_str': 'Neuralgia'}, {'cui': 'C0026858', 'cui_str': 'Musculoskeletal pain'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}]",32.0,0.143575,"Compared to CON, reduction in musculoskeletal pain intensity was significantly greater for C-HIIT (MD -5.4, 95% CI [","[{'ForeName': 'Emily R', 'Initials': 'ER', 'LastName': 'Cox', 'Affiliation': 'School of Human Movement and Nutrition Sciences, The University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Trishan', 'Initials': 'T', 'LastName': 'Gajanand', 'Affiliation': 'School of Human Movement and Nutrition Sciences, The University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Nicola W', 'Initials': 'NW', 'LastName': 'Burton', 'Affiliation': 'School of Applied Psychology, Griffith University, Mt Gravatt, Queensland, Australia.'}, {'ForeName': 'Jeff S', 'Initials': 'JS', 'LastName': 'Coombes', 'Affiliation': 'School of Human Movement and Nutrition Sciences, The University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Brooke K', 'Initials': 'BK', 'LastName': 'Coombes', 'Affiliation': 'School of Allied Health Sciences, Griffith University, Nathan, Queensland, Australia. Electronic address: b.coombes@griffith.edu.au.'}]",Diabetes research and clinical practice,['10.1016/j.diabres.2020.108168'] 94,32372407,Efficacy of a novel post-foaming dental gel on gingival inflammation: A randomized controlled clinical trial.,"BACKGROUND A pilot randomized controlled clinical trial was performed to evaluate the efficacy of a post-foaming dental gel containing cetylpridinium chloride (CPC), hydrogen peroxide (H 2 O 2 ), sodium bicarbonate, and antioxidants on periodontal/oral health. METHODS Individuals with gingivitis or mild-moderate periodontitis (n=36) were included and randomly assigned to Group 1 and 2 with foaming gel loaded on a mouthpiece with a light source and controlled warming heat built-in unit or on a toothbrush, respectively, in addition to regular twice-daily brushing. Group 3 served as control with twice daily brushing and further assigned split-mouth to Group 3a-un-flossed and Group 3b-flossed. Gingival index (GI) and bleeding on probing (BOP) were evaluated in addition to plaque index (PI), pocket depth, and clinical attachment level at days 14, 28, 42 (treatment), and 60 (maintenance). Subgingival plaque microbial profiles and gingival crevicular fluid (GCF) cytokine levels were determined by DNA-DNA hybridization and multiplexing assays, respectively. Exploratory analyses included esthetic outcomes: changes in tooth color and levels of volatile sulfur compounds in breath. Statistical analyses were conducted using ANOVA with a post hoc analysis of Fisher's LSD. RESULTS Use of post-foaming gel in both test groups resulted in significant changes in GI and BOP at Day 42 compared to control and un-flossed control (P<0.05). Device-enhanced foaming gel significantly reduced the PI in Group 1 at Day 42 compared to control and un-flossed control (P=0.02; P=0.007, respectively). GCF IL-6 and TNF-α levels were significantly reduced in Group 2 compared to control (P IL-6 =0.01, P TNF-α =0.02). Post-foaming gel resulted in greater reductions in periodontopathogens, whereas health-associated species remained stable. Despite cessation of adjunct treatments, Group 1 and 2 continued having reduced levels of GI, BOP, and PI at Day 60 (P<0.05). CONCLUSIONS The novel post-foaming dental gel improves oral health by reducing gingival inflammation at the local site in addition to better esthetic outcomes.",2020,"GCF IL-6 and TNF-α levels were significantly reduced in Group 2 compared to control (p IL-6 = 0.01, p TNF-α = 0.02).",['Individuals with gingivitis or mild-moderate periodontitis (n = 36'],"['foaming gel loaded on a mouthpiece with a light source and controlled warming heat built-in unit or on a toothbrush, respectively, in addition to regular twice-daily brushing', 'post-foaming dental gel containing cetylpridinium chloride (CPC), hydrogen peroxide, sodium bicarbonate and antioxidants', 'novel post-foaming dental gel', 'control with twice daily brushing and further assigned split-mouth to Group 3a-un-flossed and Group 3b-flossed']","['Device-enhanced foaming gel significantly reduced the PI', 'gingival inflammation', 'GI and BOP', 'levels of GI, BOP and PI at Day-60', 'Subgingival plaque microbial profiles and gingival crevicular fluid (GCF) cytokine levels', 'GCF IL-6 and TNF-α levels', 'tooth color and levels of volatile sulfur compounds in breath', 'plaque index (PI), pocket depth and clinical attachment level', 'Gingival index (GI) and bleeding on probing (BOP']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0031099', 'cui_str': 'Periodontitis'}]","[{'cui': 'C0991510', 'cui_str': 'Foam'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0181633', 'cui_str': 'Light source'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0183975', 'cui_str': 'Toothbrush'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C1272952', 'cui_str': 'Dental gel'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0008203', 'cui_str': 'Chloride salt'}, {'cui': 'C0020281', 'cui_str': 'Hydrogen Peroxide'}, {'cui': 'C0074722', 'cui_str': 'Sodium Bicarbonate'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0441870', 'cui_str': 'Group 3A'}, {'cui': 'C0441871', 'cui_str': 'Group 3B'}]","[{'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0991510', 'cui_str': 'Foam'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0017574', 'cui_str': 'Gingivitis'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0399451', 'cui_str': 'Subgingival plaque'}, {'cui': 'C0017564', 'cui_str': 'Gingival Exudate'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0475833', 'cui_str': 'Tooth color'}, {'cui': 'C0443769', 'cui_str': 'Volatile agent'}, {'cui': 'C0038776', 'cui_str': 'Sulfur compound'}, {'cui': 'C0225386', 'cui_str': 'Breath'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}]",36.0,0.0523912,"GCF IL-6 and TNF-α levels were significantly reduced in Group 2 compared to control (p IL-6 = 0.01, p TNF-α = 0.02).","[{'ForeName': 'Jonathan B', 'Initials': 'JB', 'LastName': 'Levine', 'Affiliation': 'GLO Science, Inc., New York, New York, USA.'}, {'ForeName': 'Jordan', 'Initials': 'J', 'LastName': 'Goncalves', 'Affiliation': 'GLO Science, Inc., New York, New York, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Nguyen', 'Affiliation': 'Center for Clinical and Translational Research, The Forsyth Institute, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Nguyen', 'Affiliation': 'Center for Clinical and Translational Research, The Forsyth Institute, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Hatice', 'Initials': 'H', 'LastName': 'Hasturk', 'Affiliation': 'Center for Clinical and Translational Research, The Forsyth Institute, Cambridge, Massachusetts, USA.'}]",Journal of periodontology,['10.1002/JPER.19-0594'] 95,32386407,Reflection on modern methods: when is a stepped-wedge cluster randomized trial a good study design choice?,"The stepped-wedge cluster randomized trial (SW-CRT) involves the sequential transition of clusters (such as hospitals, public health units or communities) from control to intervention conditions in a randomized order. The use of the SW-CRT is growing rapidly. Yet the SW-CRT is at greater risks of bias compared with the conventional parallel cluster randomized trial (parallel-CRT). For this reason, the CONSORT extension for SW-CRTs requires that investigators provide a clear justification for the choice of study design. In this paper, we argue that all other things being equal, the SW-CRT is at greater risk of bias due to misspecification of the secular trends at the analysis stage. This is particularly problematic for studies randomizing a small number of heterogeneous clusters. We outline the potential conditions under which an SW-CRT might be an appropriate choice. Potentially appropriate and often overlapping justifications for conducting an SW-CRT include: (i) the SW-CRT provides a means to conduct a randomized evaluation which otherwise would not be possible; (ii) the SW-CRT facilitates cluster recruitment as it enhances the acceptability of a randomized evaluation either to cluster gatekeepers or other stakeholders; (iii) the SW-CRT is the only feasible design due to pragmatic and logistical constraints (for example the roll-out of a scare resource); and (iv) the SW-CRT has increased statistical power over other study designs (which will include situations with a limited number of clusters). As the number of arguments in favour of an SW-CRT increases, the likelihood that the benefits of using the SW-CRT, as opposed to a parallel-CRT, outweigh its risks also increases. We argue that the mere popularity and novelty of the SW-CRT should not be a factor in its adoption. In situations when a conventional parallel-CRT is feasible, it is likely to be the preferred design.",2020,Yet the SW-CRT is at greater risks of bias compared with the conventional parallel cluster randomized trial (parallel-CRT).,[],[],[],[],[],[],,0.0694736,Yet the SW-CRT is at greater risks of bias compared with the conventional parallel cluster randomized trial (parallel-CRT).,"[{'ForeName': 'Karla', 'Initials': 'K', 'LastName': 'Hemming', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Taljaard', 'Affiliation': 'Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.'}]",International journal of epidemiology,['10.1093/ije/dyaa077'] 96,32386476,The relationship between postoperative opioid consumption and the incidence of hypoxemic events following total hip arthroplasty: a post hoc analysis.,"Background Postoperative opioid analgesia may cause respiratory depression. We assessed whether following total hip arthroplasty, placebo-adjusted reductions in morphine consumption at 48 hours with parecoxib (47.0%), propacetamol (35.1%) or parecoxib plus propacetamol (67.9%) translated into a reduction in hypoxemic events. Methods This was a post hoc analysis of a randomized, placebo-controlled, noninferiority study. Patients were randomly assigned to receive intravenous parecoxib (40 mg twice daily), propacetamol (2 g 4 times daily), parecoxib plus propacetamol (40 mg twice daily + 2 g 4 times daily) or placebo. Dose, date and time of morphine administration via patient-controlled analgesia were monitored throughout the study. In patients not receiving supplemental oxygen, peripheral blood oxygenation was assessed continuously for 48 hours after surgery. Hypoxemia was defined as peripheral oxygen saturation less than 90%. The times and oximeter readings of hypoxemic events were recorded. Pearson correlation coefficient was used to assess for correlations between cumulative morphine consumption at 48 hours and mean number of hypoxemic events. Results A significantly smaller proportion of patients who received the combined treatment with parecoxib and propacetamol had hypoxemia versus placebo (2.8% v. 13.2%, p < 0.05), and the mean number of hypoxemic events was significantly smaller for parecoxib (0.12), propacetamol (0.06) and parecoxib plus propacetamol (0.03) versus placebo (0.36; all p < 0.05). There was no correlation between the reduction in cumulative morphine consumption at 48 hours and the mean number of hypoxemic events in any treatment group (all p > 0.1). Conclusion Following total hip arthroplasty, a greater than 70% reduction in morphine consumption may be necessary to translate into a corresponding reduction in hypoxemic events.",2020,"A significantly smaller proportion of patients who received the combined treatment with parecoxib and propacetamol had hypoxemia versus placebo (2.8% v. 13.2%, p < 0.05), and the mean number of hypoxemic events was significantly smaller for parecoxib (0.12), propacetamol (0.06) and parecoxib plus propacetamol (0.03) versus placebo (0.36; all p < 0.05).",['total hip arthroplasty'],"['parecoxib plus propacetamol', 'morphine', 'intravenous parecoxib', 'total hip arthroplasty, placebo', 'parecoxib', 'placebo']","['peripheral oxygen saturation less', 'mean number of hypoxemic events', 'hypoxemia', 'cumulative morphine consumption', 'morphine consumption', 'Hypoxemia', 'times and oximeter readings of hypoxemic events', 'hypoxemic events', 'peripheral blood oxygenation']","[{'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}]","[{'cui': 'C0915142', 'cui_str': 'parecoxib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0084186', 'cui_str': 'propacetamol'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2317096', 'cui_str': 'Peripheral oxygen saturation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0700292', 'cui_str': 'Hypoxemia'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0182117', 'cui_str': 'Oxygen analyzer'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}]",,0.254389,"A significantly smaller proportion of patients who received the combined treatment with parecoxib and propacetamol had hypoxemia versus placebo (2.8% v. 13.2%, p < 0.05), and the mean number of hypoxemic events was significantly smaller for parecoxib (0.12), propacetamol (0.06) and parecoxib plus propacetamol (0.03) versus placebo (0.36; all p < 0.05).","[{'ForeName': 'Margaret Noyes', 'Initials': 'MN', 'LastName': 'Essex', 'Affiliation': 'From Pfizer Inc., New York, NY (Essex, Pan, Cheung); the Department of Anesthesiology, University of Brussels, Brussels, Belgium (Camu); the Department of Anaesthesiology, Balgrist University Hospital, Zurich, Switzerland (Borgeat); and Pfizer Inc., Mexico City, Mexico (Salomon).'}, {'ForeName': 'Frederic', 'Initials': 'F', 'LastName': 'Camu', 'Affiliation': 'From Pfizer Inc., New York, NY (Essex, Pan, Cheung); the Department of Anesthesiology, University of Brussels, Brussels, Belgium (Camu); the Department of Anaesthesiology, Balgrist University Hospital, Zurich, Switzerland (Borgeat); and Pfizer Inc., Mexico City, Mexico (Salomon).'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Borgeat', 'Affiliation': 'From Pfizer Inc., New York, NY (Essex, Pan, Cheung); the Department of Anesthesiology, University of Brussels, Brussels, Belgium (Camu); the Department of Anaesthesiology, Balgrist University Hospital, Zurich, Switzerland (Borgeat); and Pfizer Inc., Mexico City, Mexico (Salomon).'}, {'ForeName': 'P Arline', 'Initials': 'PA', 'LastName': 'Salomon', 'Affiliation': 'From Pfizer Inc., New York, NY (Essex, Pan, Cheung); the Department of Anesthesiology, University of Brussels, Brussels, Belgium (Camu); the Department of Anaesthesiology, Balgrist University Hospital, Zurich, Switzerland (Borgeat); and Pfizer Inc., Mexico City, Mexico (Salomon).'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Pan', 'Affiliation': 'From Pfizer Inc., New York, NY (Essex, Pan, Cheung); the Department of Anesthesiology, University of Brussels, Brussels, Belgium (Camu); the Department of Anaesthesiology, Balgrist University Hospital, Zurich, Switzerland (Borgeat); and Pfizer Inc., Mexico City, Mexico (Salomon).'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Cheung', 'Affiliation': 'From Pfizer Inc., New York, NY (Essex, Pan, Cheung); the Department of Anesthesiology, University of Brussels, Brussels, Belgium (Camu); the Department of Anaesthesiology, Balgrist University Hospital, Zurich, Switzerland (Borgeat); and Pfizer Inc., Mexico City, Mexico (Salomon).'}]",Canadian journal of surgery. Journal canadien de chirurgie,['10.1503/cjs.010519'] 97,32387716,Hypertension during Diabetic Ketoacidosis in Children.,"OBJECTIVES To characterize hemodynamic alterations occurring during diabetic ketoacidosis (DKA) in a large cohort of children and to identify clinical and biochemical factors associated with hypertension. STUDY DESIGN This was a planned secondary analysis of data from the Pediatric Emergency Care Applied Research Network Fluid Therapies Under Investigation in DKA Study, a randomized clinical trial of fluid resuscitation protocols for children in DKA. Hemodynamic data (heart rate, blood pressure) from children with DKA were assessed in comparison with normal values for age and sex. Multivariable statistical modeling was used to explore clinical and laboratory predictors of hypertension. RESULTS Among 1258 DKA episodes, hypertension was documented at presentation in 154 (12.2%) and developed during DKA treatment in an additional 196 (15.6%), resulting in a total of 350 DKA episodes (27.8%) in which hypertension occurred at some time. Factors associated with hypertension at presentation included more severe acidosis, (lower pH and lower pCO 2 ), and stage 2 or 3 acute kidney injury. More severe acidosis and lower Glasgow Coma Scale scores were associated with hypertension occurring at any time during DKA treatment. CONCLUSIONS Despite dehydration, hypertension occurs in a substantial number of children with DKA. Factors associated with hypertension include greater severity of acidosis, lower pCO 2, and lower Glasgow Coma Scale scores during DKA treatment, suggesting that hypertension might be centrally mediated.",2020,"More severe acidosis and lower Glasgow Coma Scale (GCS) scores were associated with hypertension occurring at any time during DKA treatment. ","['children with DKA', 'children in DKA', 'Hypertension During Diabetic Ketoacidosis in Children']",[],"['severity of acidosis, lower PCO 2 and lower GCS scores', 'Hemodynamic data (heart rate, blood pressure', 'severe acidosis and lower Glasgow Coma Scale (GCS) scores', 'hypertension']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011880', 'cui_str': 'Diabetic ketoacidosis'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]",[],"[{'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0001122', 'cui_str': 'Acidosis'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C0017594', 'cui_str': 'Glasgow coma scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]",,0.0665684,"More severe acidosis and lower Glasgow Coma Scale (GCS) scores were associated with hypertension occurring at any time during DKA treatment. ","[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'DePiero', 'Affiliation': 'Division of Emergency Medicine, Department of Pediatrics, Nemours/A.I. DuPont Hospital for Children, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA.'}, {'ForeName': 'Nathan', 'Initials': 'N', 'LastName': 'Kuppermann', 'Affiliation': 'Department of Emergency Medicine, University of California Davis Health, University of California Davis, School of Medicine, Sacramento, CA; Department of Pediatrics, University of California Davis Health, University of California Davis, School of Medicine, Sacramento, CA.'}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Brown', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Children's National Medical Center, The George Washington School of Medicine and Health Sciences, Washington, DC.""}, {'ForeName': 'Jeff E', 'Initials': 'JE', 'LastName': 'Schunk', 'Affiliation': 'Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'Julie K', 'Initials': 'JK', 'LastName': 'McManemy', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX.""}, {'ForeName': 'Arleta', 'Initials': 'A', 'LastName': 'Rewers', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, The Colorado Children's Hospital, University of Colorado-Denver School of Medicine, Denver, CO.""}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Stoner', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University School of Medicine, Columbus, OH.""}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Tzimenatos', 'Affiliation': 'Department of Emergency Medicine, University of California Davis Health, University of California Davis, School of Medicine, Sacramento, CA.'}, {'ForeName': 'Aris', 'Initials': 'A', 'LastName': 'Garro', 'Affiliation': 'Departments of Emergency Medicine and Pediatrics, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI.'}, {'ForeName': 'Sage R', 'Initials': 'SR', 'LastName': 'Myers', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.""}, {'ForeName': 'Kimberly S', 'Initials': 'KS', 'LastName': 'Quayle', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, St. Louis Children's Hospital, Washington University School of Medicine in St. Louis, St. Louis, MO.""}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Trainor', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL.""}, {'ForeName': 'Maria Y', 'Initials': 'MY', 'LastName': 'Kwok', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, New York Presbyterian Morgan Stanley Children's Hospital, Columbia University College of Physicians and Surgeons, New York, NY.""}, {'ForeName': 'Lise E', 'Initials': 'LE', 'LastName': 'Nigrovic', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA.""}, {'ForeName': 'Cody S', 'Initials': 'CS', 'LastName': 'Olsen', 'Affiliation': 'Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'T Charles', 'Initials': 'TC', 'LastName': 'Casper', 'Affiliation': 'Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Ghetti', 'Affiliation': 'Department of Psychology, University of California Davis, Sacramento, CA.'}, {'ForeName': 'Nicole S', 'Initials': 'NS', 'LastName': 'Glaser', 'Affiliation': 'Department of Pediatrics, University of California Davis Health, University of California Davis, School of Medicine, Sacramento, CA. Electronic address: nsglaser@ucdavis.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Journal of pediatrics,['10.1016/j.jpeds.2020.04.066'] 98,32396966,Kinesiotaping Diminishes Delayed Muscle Soreness but does not Improve Muscular Performance.,"This study aimed at determining the effect of kinesio-taping (KT) on muscle performance and delayed onset muscle soreness (DOMS) after exercise induced muscle damaged. Sixty-six healthy men volunteered to participate (age:18-25 y/o), who performed 200 isokinetic lengthening contractions of the dominant quadriceps. Then subjects were randomized to either control (no treatment), sham (no tape tension), or KT (10% tape tension) groups. Muscle performance was assessed by peak torque and muscular work during maximal isometric and concentric isokinetic contractions. DOMS intensity was assessed using a visual analog scale. Measurements were taken pre-exercise (Pre), 48 h and 96 h post-exercise. Repeated measures ANOVA was used for comparisons within group, and ANCOVA for comparisons among groups. Muscle damage was confirmed in all participants by an increase in CK activity level (p<0.01). Decrease in isometric and isokinetic peak torque was detected at 48 h in the control and sham groups (p<0.01). Muscular work decreased in all groups at 48 h (p<0.01). No differences between groups were detected in muscular performance variables. Increase in DOMS intensity was determined in all groups at 48 h. Comparisons between groups showed lower DOMS intensity in the KT group at 48 h. KT decreased DOMS intensity perception after exercise-induced muscle damage; however, it did not impact muscular performance.",2020,Decrease in isometric and isokinetic peak torque was detected at 48 h in the control and sham groups (p<0.01).,"['Sixty-six healthy men volunteered to participate (age:18-25\u2009y/o), who performed 200 isokinetic lengthening contractions of the dominant quadriceps']","['control (no treatment), sham (no tape tension), or KT', 'kinesio-taping (KT']","['CK activity level', 'muscle performance and delayed onset muscle soreness (DOMS', 'isometric and isokinetic peak torque', 'Muscle performance', 'Muscle damage', 'peak torque and muscular work during maximal isometric and concentric isokinetic contractions', 'DOMS intensity', 'muscular performance variables', 'Muscular work', 'Delayed Muscle Soreness', 'DOMS intensity perception', 'Muscular Performance']","[{'cui': 'C4517841', 'cui_str': '66'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0441592', 'cui_str': 'Surgical lengthening - action'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C0233494', 'cui_str': 'Tension'}]","[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage NOS'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439744', 'cui_str': 'Concentric'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]",66.0,0.0608429,Decrease in isometric and isokinetic peak torque was detected at 48 h in the control and sham groups (p<0.01).,"[{'ForeName': 'Maria Alejandra', 'Initials': 'MA', 'LastName': 'Camacho', 'Affiliation': 'Physical Therapy School, Universidad Industrial de Santander, Bucaramanga, Colombia.'}, {'ForeName': 'Esperanza', 'Initials': 'E', 'LastName': 'Herrera', 'Affiliation': 'Physical Therapy School, Universidad Industrial de Santander, Bucaramanga, Colombia.'}, {'ForeName': 'Jose Angelo', 'Initials': 'JA', 'LastName': 'Barela', 'Affiliation': 'Instituto de Biociências, Universidade Estadual Paulista Julio de Mesquita Filho, Instituto de Biociência Campus de Rio Claro, Rio Claro, Brazil.'}, {'ForeName': 'Diana Carolina', 'Initials': 'DC', 'LastName': 'Delgado-Diaz', 'Affiliation': 'Physical Therapy School, Universidad Industrial de Santander, Bucaramanga, Colombia.'}]",International journal of sports medicine,['10.1055/a-1088-5223'] 99,32234313,Does misperception of fruit and vegetable intake adequacy affect progression through the stages of behavior change after nutritional intervention?,"Pseudomaintenance (PM) is a Transtheoretical Model (TTM) stage of change that refers to individuals who believe they eat enough fruit and vegetables (FV) despite their low FV intake. It is not known how they change behavior after usual TTM-based interventions. Thus, this randomized controlled community trial describes the effect of PM on progression through the stages of change for FV intake among adult and elderly health promotion service users after TTM-based intervention. The stage of change for FV intake was assessed; FV intake was estimated from brief validated questions at baseline (n = 3414) and follow-up (n = 1782). Individuals whose perception of adequacy matched the estimated intake were labeled as ""concordant perception,"" while those with low intake who believed that their intake was adequate were classified as being in PM. The intervention group received the intervention while the control group received usual care. The prevalence of ""no stage progression"" at follow-up was close to 50% for those in PM at baseline. After adjustment for demographics, randomization, self-efficacy, decisional balance, and baseline intake, users in PM at baseline had higher odds [OR = 1.53 (1.21-1.94)] of progressing to higher stages for fruit and no difference in progression for vegetables. We propose strategies to approach FV intake in future studies and reinforce the need for additional trials aimed at describing changes in FV intake among individuals in PM, in order to continue answering the scientific questions that we began to investigate.",2020,"The prevalence of ""no stage progression"" at follow-up was close to 50% for those in PM at baseline.",['adult and elderly health promotion service users after TTM-based intervention'],"['Pseudomaintenance (PM', 'intervention while the control group received usual care', 'PM']","['self-efficacy, decisional balance, and baseline intake, users in PM', 'prevalence of ""no stage progression', 'FV intake']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0018738', 'cui_str': 'Health promotion'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0040953', 'cui_str': 'Trichotillomania'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}]",,0.0477207,"The prevalence of ""no stage progression"" at follow-up was close to 50% for those in PM at baseline.","[{'ForeName': 'Maria Cecília Ramos de', 'Initials': 'MCR', 'LastName': 'Carvalho', 'Affiliation': 'Universidade Federal de Minas Gerais, Grupo de Pesquisa de Intervenções em Nutrição, 190 Alfredo Balena Avenue, Nursing School, Room 316, Santa Efigênia, 30130-100, Belo Horizonte, MG, Brazil. Electronic address: ceciliaramosnutri@gmail.com.'}, {'ForeName': 'Mariana Carvalho de', 'Initials': 'MC', 'LastName': 'Menezes', 'Affiliation': 'Universidade Federal de Ouro Preto, Escola de Nutrição, Departamento de Nutrição Clínica e Social, Programa de Pós-Graduação em Saúde e Nutrição, Grupo de Pesquisa de Intervenções em Nutrição, Dois Street, Morro do Cruzeiro Campus, Nutrition School, Room 65, 35400-000, Ouro Preto, MG, Brazil. Electronic address: marysnut@gmail.com.'}, {'ForeName': 'Natacha', 'Initials': 'N', 'LastName': 'Toral', 'Affiliation': 'Universidade de Brasilia, Faculdade de Ciências da Saúde, Departamento de Nutrição, Programa de Pós-Graduação em Nutrição Humana, Darcy Ribeiro Campus, Health Sciences School, 70910-900, Brasília (North Wing), DF, Brazil. Electronic address: natachatoral@hotmail.com.'}, {'ForeName': 'Aline Cristine Souza', 'Initials': 'ACS', 'LastName': 'Lopes', 'Affiliation': 'Universidade Federal de Minas Gerais, Escola de Enfermagem, Departamento de Nutrição, Programa de Pós-Graduação em Nutrição e Saúde, Grupo de Pesquisa de Intervenções em Nutrição, 190 Alfredo Balena Avenue, Nursing School, Room 316, Santa Efigênia, 30130-100, Belo Horizonte, MG, Brazil. Electronic address: alinelopesenf@gmail.com.'}]",Appetite,['10.1016/j.appet.2020.104682'] 100,32363926,Using Low-Calorie Orange Juice as a Dietary Alternative to Alkali Therapy.,"Purpose: The pursuit of a dietary source to increase urine pH and citrate in stone formers has been ongoing for >30 years. Early evidence showed that orange juice (OJ) contains alkali and citrate, but high sugar and ascorbic acid content limited the use of OJ as a viable daily source of alkali. Recently, novel low-calorie OJs have emerged and could potentially be a better option. Methods: Beverages with high concentrations of alkali citrate and malate were identified using ion chromatography. Two low-calorie OJ beverages, in addition to crystal light lemonade beverage (CLLB), were chosen. Healthy volunteers (5 men, 5 women) drank 1 L of OJ or CLLB with 1 L water daily for 7 days, and then completed a 24-hour urinalysis. A washout week was instituted between trial weeks. The study design is a prospective randomized crossover control trial. A paired analysis using comparison of means was used to evaluate low-calorie OJ and CLLB. Volunteers had no prior history of kidney stones and maintained a journal with beverage compliance, side effect (SE), and dietary consumption data. Results: Tropicana 50 (TRP50), Kroger low-calorie OJ (KLCO), and CLLB were found to have a total alkali content of 56.60, 47.9, and 17.3 mEq/L, respectively, based on ion chromatography. Consumption of all three beverages raised urinary citrate (116.6 [-118 to 373, 177.9 [-3 to 359], 155.6 [-4 to 237] ▵mg/day 95% confidence interval) and urinary pH (0.25 [0.08-0.53], 0.74 [0.41-1.07 p  < 0.05], 0.25 [0.25-0.64]), respectively, compared with water phase. Based on journal entries by volunteers, TRP50 had the most SEs (90% participants) felt to be a result of the artificial sweetener (Stevia ® ). Conclusion: Low-calorie OJs, and to a lesser extent CLLB, have alkali and citrate based on ion chromatography. Daily consumption by healthy volunteers of KLCO can raise urinary pH.",2020,"Based on volunteer journal entries , TRP50 had the most side effects (90% participants) felt to be a result of the artificial sweetener (Stevia ®). ","['Tropicana 50 (TRP50', 'Volunteers had no prior history of kidney stones and maintained a journal with beverage compliance, side effect, and dietary consumption data', 'Healthy volunteers (5 men, 5 women) drank 1L of OJ or CLLB with 1L water daily for 7 days and then completed a 24-hour urinalysis', 'healthy volunteers of', 'Beverages with high concentrations of alkali citrate and malate were identified using ion chromatography']","['orange juice (OJ', 'Low-calorie Orange Juice', 'KLCO']","['urinary pH', 'Kroger low calorie OJ (KLCO) and CLLB']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C1998388', 'cui_str': 'History of calculus of kidney'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0162443', 'cui_str': 'Journals as Topic'}, {'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0452458', 'cui_str': 'Orange juice'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0042014', 'cui_str': 'Urinalysis'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0008857', 'cui_str': 'Citrates'}, {'cui': 'C0024546', 'cui_str': 'Malates'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0022023', 'cui_str': 'Ions'}, {'cui': 'C0008550', 'cui_str': 'Chromatography'}]","[{'cui': 'C0452458', 'cui_str': 'Orange juice'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0439259', 'cui_str': 'kcal'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0452458', 'cui_str': 'Orange juice'}]",2.0,0.028547,"Based on volunteer journal entries , TRP50 had the most side effects (90% participants) felt to be a result of the artificial sweetener (Stevia ®). ","[{'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Large', 'Affiliation': 'From Indiana University Department of Urology and Litholink Corporation, Laboratory Corporation of America Holdings, Indianapolis, Indiana, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Williams', 'Affiliation': 'From Indiana University Department of Urology and Litholink Corporation, Laboratory Corporation of America Holdings, Indianapolis, Indiana, USA.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Asplin', 'Affiliation': 'From Indiana University Department of Urology and Litholink Corporation, Laboratory Corporation of America Holdings, Indianapolis, Indiana, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Krambeck', 'Affiliation': 'From Indiana University Department of Urology and Litholink Corporation, Laboratory Corporation of America Holdings, Indianapolis, Indiana, USA.'}]",Journal of endourology,['10.1089/end.2020.0031'] 101,32360692,Acute and residual mood and cognitive performance of young adults following smoked cannabis.,"OBJECTIVES To examine acute and residual mood and cognitive performance in young adult regular cannabis users following smoked cannabis. METHODS Ninety-one healthy young adults completed this double-blind, placebo-controlled, parallel-groups study. Participants were randomized to receive active (12.5% THC) or placebo cannabis with a 2:1 allocation ratio, and mood [Profile of Mood States (POMS)] and cognitive performance [Hopkins Verbal Learning Test - Revised (HVLT-R), Digit Symbol Substitution Test (DSST), Continuous Performance Test (CPT), grooved pegboard (GPB)] were assessed before and 1, 24, and 48 (h) after smoking cannabis ad libitum. High and Low THC groups were based on blood THC concentrations. RESULTS One hour after smoking cannabis, compared to Placebo, in both the High and Low THC groups, there were increases in POMS Arousal and Positive Mood, and in the High THC group only, increases in Confusion, Friendliness, and Elation, and a decrease in Fatigue. Increases in Friendliness and Elation in the High THC group remained significant for 24 h. The only significant acute effect of cannabis on cognition was a decrease in the percent of words retained in the HVLT-R in the High THC group compared to Placebo (mean difference = 15.8%, 95% CI = 3.6-28.0%, p = 0.006). Unexpectedly, compared to Placebo, both the High and Low THC groups improved in DSST performance at 48 h (p ≤ 0.016). CONCLUSIONS Under the present experimental conditions, in young regular cannabis users, smoking cannabis ad libitum had significant effects on mood, some of which persisted 24 h later, yet minimal effects on cognition, and no evidence of residual cognitive impairment.",2020,"Unexpectedly, compared to Placebo, both the High and Low THC groups improved in DSST performance at 48 h (p ≤ 0.016). ","['young adult regular cannabis users following smoked cannabis', 'Ninety-one healthy young adults', 'young adults following smoked cannabis', 'young regular cannabis users']","['High and Low', 'Placebo', 'placebo cannabis with a 2:1 allocation ratio, and mood', 'placebo']","['Confusion, Friendliness, and Elation', 'blood THC concentrations', 'Fatigue', 'Mood States (POMS)] and cognitive performance [Hopkins Verbal Learning Test - Revised (HVLT-R), Digit Symbol Substitution Test (DSST), Continuous Performance Test (CPT), grooved pegboard (GPB', 'Friendliness and Elation', 'Acute and residual mood and cognitive performance', 'POMS Arousal and Positive Mood', 'DSST performance']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0332239', 'cui_str': 'Young'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0026516', 'cui_str': 'Mood'}]","[{'cui': 'C0009676', 'cui_str': 'Confusional state'}, {'cui': 'C0233492', 'cui_str': 'Elation'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0451394', 'cui_str': 'Profile of mood states'}, {'cui': 'C0042531', 'cui_str': 'Verbal learning'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C3490329', 'cui_str': 'glycerol phenylbutyrate'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]",91.0,0.263829,"Unexpectedly, compared to Placebo, both the High and Low THC groups improved in DSST performance at 48 h (p ≤ 0.016). ","[{'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Matheson', 'Affiliation': ""Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, 27 King's College Circle, Toronto, Ontario M5S3H7, Canada; Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, Ontario M5S2S1, Canada. Electronic address: justin.matheson@camh.ca.""}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Mann', 'Affiliation': 'Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, Ontario M5S2S1, Canada; Dalla Lana School of Public Health, University of Toronto, 155 College Street, Toronto, Ontario M5T3M7, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T1R8, Canada.'}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Sproule', 'Affiliation': 'Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S3M2, Canada; Pharmacy Department, Centre for Addiction and Mental Health, 1001 Queen Street, Toronto, Ontario M6J1H4, Canada; Department of Psychiatry, Faculty of Medicine, University of Toronto, 250 College Street, Toronto, Ontario M5T1R8, Canada.'}, {'ForeName': 'Marilyn A', 'Initials': 'MA', 'LastName': 'Huestis', 'Affiliation': 'Institute of Emerging Health Professions, Thomas Jefferson University, 1020 Walnut Street, Philadelphia, PA 19107, United States.'}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Wickens', 'Affiliation': 'Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, Ontario M5S2S1, Canada; Dalla Lana School of Public Health, University of Toronto, 155 College Street, Toronto, Ontario M5T3M7, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T1R8, Canada.'}, {'ForeName': 'Gina', 'Initials': 'G', 'LastName': 'Stoduto', 'Affiliation': 'Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, Ontario M5S2S1, Canada.'}, {'ForeName': 'Tony P', 'Initials': 'TP', 'LastName': 'George', 'Affiliation': ""Department of Psychiatry, Faculty of Medicine, University of Toronto, 250 College Street, Toronto, Ontario M5T1R8, Canada; Addictions Division, Centre for Addiction and Mental Health, 100 Stokes Street, Toronto, Ontario M6J1H4, Canada; Institute of Medical Sciences, University of Toronto, 1 King's College Circle, Room 2374, Toronto, Ontario M5S 1A8, Canada.""}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Rehm', 'Affiliation': 'Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, Ontario M5S2S1, Canada; Dalla Lana School of Public Health, University of Toronto, 155 College Street, Toronto, Ontario M5T3M7, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T1R8, Canada; Department of Psychiatry, Faculty of Medicine, University of Toronto, 250 College Street, Toronto, Ontario M5T1R8, Canada.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Le Foll', 'Affiliation': ""Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, 27 King's College Circle, Toronto, Ontario M5S3H7, Canada; Department of Psychiatry, Faculty of Medicine, University of Toronto, 250 College Street, Toronto, Ontario M5T1R8, Canada; Addictions Division, Centre for Addiction and Mental Health, 100 Stokes Street, Toronto, Ontario M6J1H4, Canada; Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, Ontario M5S2S1, Canada; Department of Family and Community Medicine, University of Toronto, 500 University Avenue, 5th Floor, Toronto, Ontario M5G 1V7, Canada.""}, {'ForeName': 'Bruna', 'Initials': 'B', 'LastName': 'Brands', 'Affiliation': ""Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, 27 King's College Circle, Toronto, Ontario M5S3H7, Canada; Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, Ontario M5S2S1, Canada; Controlled Substances and Cannabis Directorate, Health Canada, Ottawa, Ontario, Canada.""}]","Pharmacology, biochemistry, and behavior",['10.1016/j.pbb.2020.172937'] 102,32379216,"The effects of a new, improved Chinese medicine, Gengnianchun formula granules, on hot flushes, depression, anxiety, and sleep in Chinese peri- and postmenopausal women: a randomized placebo-controlled trial.","OBJECTIVE The aim of the study was to investigate the effectiveness and safety of a new, improved herbal formula of a traditional Chinese medicine, improved Gengnianchun (I-GNC), on hot flushes, depression, anxiety, and sleep in peri- and postmenopausal women in China. METHODS A randomized, single-blind, placebo-controlled trial of peri- and postmenopausal women with Kupperman Index (KMI) scores of 15 or higher was conducted for 12 weeks. Hot flush frequencies, KMI scores, Hamilton depression scale scores, Hamilton anxiety scale scores, and Pittsburgh Sleep Quality Index scores were evaluated. Each outcome was evaluated every 4 weeks. RESULTS Ninety-eight participants completed the study. The I-GNC formula significantly reduced the mean (SD) frequency of hot flushes from 7 (4.554) to 1.2 (1.675) in the I-GNC group and from 6.74 (3.43) to 3.66 (2.635) in the placebo group (P < 0.01). The KMI (P < 0.01), Hamilton depression scale (P < 0.01), and Hamilton anxiety scale (P < 0.01) scores decreased in both groups after treatment, and significant differences were observed between the two groups (P < 0.01); however, no significant difference in the Pittsburgh Sleep Quality Index score was observed. I-GNC had no effect on serum follicle-stimulating hormone or E2 levels. There were no obvious adverse effects. CONCLUSIONS The traditional Chinese medicine herbal formula I-GNC can alleviate the symptoms of menopausal syndrome and improve quality of life among peri- and postmenopausal women. I-GNC is safe and has no notable adverse effects.",2020,"Hot flush frequencies, KMI scores, Hamilton depression scale scores, Hamilton anxiety scale scores, and Pittsburgh Sleep Quality Index scores were evaluated.","['peri- and postmenopausal women with Kupperman Index (KMI) scores of 15 or higher was conducted for 12 weeks', 'Chinese peri- and postmenopausal women', 'peri- and postmenopausal women in China', 'Ninety-eight participants completed the study', 'peri- and postmenopausal women']","['traditional Chinese medicine, improved Gengnianchun (I-GNC', 'placebo']","['quality of life', 'Hamilton anxiety scale', 'hot flushes, depression, anxiety, and sleep', 'Pittsburgh Sleep Quality Index score', 'Hamilton depression scale', 'Hot flush frequencies, KMI scores, Hamilton depression scale scores, Hamilton anxiety scale scores, and Pittsburgh Sleep Quality Index scores', 'serum follicle-stimulating hormone or E2 levels', 'mean (SD) frequency of hot flushes']","[{'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C4319627', 'cui_str': '98'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0600142', 'cui_str': 'Menopausal flushing'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C4545801', 'cui_str': 'Pittsburgh Sleep Quality Index score'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0857927', 'cui_str': 'Serum follicle stimulating hormone'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",98.0,0.180851,"Hot flush frequencies, KMI scores, Hamilton depression scale scores, Hamilton anxiety scale scores, and Pittsburgh Sleep Quality Index scores were evaluated.","[{'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ""Obstetrics and Gynecology Hospital, Fudan University, Shanghai, People's Republic of China.""}, {'ForeName': 'Yuankui', 'Initials': 'Y', 'LastName': 'Cao', 'Affiliation': ''}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': ''}]","Menopause (New York, N.Y.)",['10.1097/GME.0000000000001558'] 103,32376981,Longitudinal follow-up after telephone disclosure in the randomized COGENT study.,"PURPOSE To better understand the longitudinal risks and benefits of telephone disclosure of genetic test results in the era of multigene panel testing. METHODS Adults who were proceeding with germline cancer genetic testing were randomized to telephone disclosure (TD) with a genetic counselor or in-person disclosure (IPD) (i.e., usual care) of test results. All participants who received TD were recommended to return to meet with a physician to discuss medical management recommendations. RESULTS Four hundred seventy-three participants were randomized to TD and 497 to IPD. There were no differences between arms for any cognitive, affective, or behavioral outcomes at 6 and 12 months. Only 50% of participants in the TD arm returned for the medical follow-up appointment. Returning was associated with site (p < 0.0001), being female (p = 0.047), and not having a true negative result (p < 0.002). Mammography was lower at 12 months among those who had TD and did not return for medical follow-up (70%) compared with those who had TD and returned (86%) and those who had IPD (87%, adjusted p < 0.01). CONCLUSION Telephone disclosure of genetic test results is a reasonable alternative to in-person disclosure, but attention to medical follow-up may remain important for optimizing appropriate use of genetic results.",2020,"Returning was associated with site (p < 0.0001), being female (p = 0.047), and not having a true negative result (p < 0.002).","['Four hundred seventy-three participants were randomized to TD and 497 to IPD', 'Adults who were proceeding with germline cancer genetic testing']","['telephone disclosure (TD) with a genetic counselor or in-person disclosure (IPD)\xa0(i.e., usual care']","['cognitive, affective, or behavioral outcomes', 'Mammography']","[{'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0012625', 'cui_str': 'Information Disclosure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0679560', 'cui_str': 'Genetic test'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0012625', 'cui_str': 'Information Disclosure'}, {'cui': 'C0587719', 'cui_str': 'Genetic counselor'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}]",473.0,0.0669023,"Returning was associated with site (p < 0.0001), being female (p = 0.047), and not having a true negative result (p < 0.002).","[{'ForeName': 'Madison K', 'Initials': 'MK', 'LastName': 'Kilbride', 'Affiliation': 'Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Brian L', 'Initials': 'BL', 'LastName': 'Egleston', 'Affiliation': 'Fox Chase Cancer Center, Temple University Health System, Biostatistics and Bioinformatics Facility, Philadelphia, PA, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Hall', 'Affiliation': 'Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.'}, {'ForeName': 'Linda J', 'Initials': 'LJ', 'LastName': 'Patrick-Miller', 'Affiliation': 'Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL, USA.'}, {'ForeName': 'Mary B', 'Initials': 'MB', 'LastName': 'Daly', 'Affiliation': 'Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Ganschow', 'Affiliation': 'Department of Internal Medicine, The John H. Stroger Jr. Hospital of Cook County, Chicago, IL, USA.'}, {'ForeName': 'Generosa', 'Initials': 'G', 'LastName': 'Grana', 'Affiliation': 'Division of Hematology-Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ, USA.'}, {'ForeName': 'Olufunmilayo I', 'Initials': 'OI', 'LastName': 'Olopade', 'Affiliation': 'Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL, USA.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Fetzer', 'Affiliation': 'Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Brandt', 'Affiliation': 'Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Rachelle', 'Initials': 'R', 'LastName': 'Chambers', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.'}, {'ForeName': 'Dana F', 'Initials': 'DF', 'LastName': 'Clark', 'Affiliation': 'Division of Hematology-Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ, USA.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Forman', 'Affiliation': 'Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.'}, {'ForeName': 'Rikki', 'Initials': 'R', 'LastName': 'Gaber', 'Affiliation': 'Department of Internal Medicine, The John H. Stroger Jr. Hospital of Cook County, Chicago, IL, USA.'}, {'ForeName': 'Cassandra', 'Initials': 'C', 'LastName': 'Gulden', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.'}, {'ForeName': 'Janice', 'Initials': 'J', 'LastName': 'Horte', 'Affiliation': 'Division of Hematology-Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ, USA.'}, {'ForeName': 'Jessica M', 'Initials': 'JM', 'LastName': 'Long', 'Affiliation': 'Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Terra', 'Initials': 'T', 'LastName': 'Lucas', 'Affiliation': 'Department of Internal Medicine, The John H. Stroger Jr. Hospital of Cook County, Chicago, IL, USA.'}, {'ForeName': 'Shreshtha', 'Initials': 'S', 'LastName': 'Madaan', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Mattie', 'Affiliation': 'Division of Hematology-Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ, USA.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'McKenna', 'Affiliation': 'Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Montgomery', 'Affiliation': 'Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Nielsen', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.'}, {'ForeName': 'Jacquelyn', 'Initials': 'J', 'LastName': 'Powers', 'Affiliation': 'Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Rainey', 'Affiliation': 'Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Rybak', 'Affiliation': 'Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Savage', 'Affiliation': 'Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Seelaus', 'Affiliation': 'Department of Internal Medicine, The John H. Stroger Jr. Hospital of Cook County, Chicago, IL, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Stoll', 'Affiliation': 'Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, The University of Chicago, Chicago, IL, USA.'}, {'ForeName': 'Jill E', 'Initials': 'JE', 'LastName': 'Stopfer', 'Affiliation': 'Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Xinxin Shirley', 'Initials': 'XS', 'LastName': 'Yao', 'Affiliation': 'Division of Hematology-Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ, USA.'}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Domchek', 'Affiliation': 'Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Angela R', 'Initials': 'AR', 'LastName': 'Bradbury', 'Affiliation': 'Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, USA. Angela.Bradbury@uphs.upenn.edu.'}]",Genetics in medicine : official journal of the American College of Medical Genetics,['10.1038/s41436-020-0808-3'] 104,32380271,Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression.,"We investigated the efficacy of tumour necrosis factor (TNF)-α antagonist infliximab on a measure of anhedonia amongst individuals with bipolar I/II depression (ClinicalTrials.gov identifier NCT02363738). Adults (ages 18-65) with bipolar I/II disorder currently experiencing a major depressive episode with a higher probability of inflammatory activity (i.e., meeting one or more of the following inflammatory/metabolic criteria: obesity and dyslipidemia/hypertension, daily cigarette smoking, diabetes mellitus, migraine, inflammatory bowel disease, and/or C-reactive protein level of ⩾5 mg/L) were enrolled in a double-blind, 12-week clinical trial of adjunctive infliximab (5 mg/kg) and saline control, which were administered at weeks 0, 2, and 6. The primary outcome measure for the present secondary analysis was change in the Snaith-Hamilton Pleasure Scale (SHAPS) total score between placebo- and infliximab-treated subjects from baseline to weeks 6 and 12. Plasma concentrations of TNF-α and soluble TNF receptors (sTNFR) 1 and 2 were assessed at weeks 0, 2, 6, and 12. Sixty eligible adults received treatment with infliximab (n=29) or placebo (n=31); 47 subjects completed the study (infliximab: n=21, placebo: n=26). Overall, infliximab-randomized subjects exhibited significantly larger increases in SHAPS total score, denoting greater reductions in anhedonic symptoms, when compared to placebo-randomized subjects (treatment × time interaction effect: χ 2 =7.15,df=2,p=0.03). Anti-anhedonic efficacy was moderated by baseline plasma levels of TNF-α and sTNFR1, but not by changes in TNF-α or sTNFR1 concentrations. Baseline and changes in sTNFR2 concentrations did not moderate anti-anhedonic efficacy. Infliximab significantly improved a measure of anhedonia relative to placebo in adults with bipolar I/II depression at week 6; intervention efficacy was not sustained 6 weeks after the final infusion.",2020,"Anti-anhedonic efficacy was moderated by baseline plasma levels of TNF-α and sTNFR1, but not by changes in TNF-α or sTNFR1 concentrations.","['n=31); 48 subjects completed the study ', 'Sixty eligible adults received treatment with', 'Adults (ages 18-65) with bipolar I/II disorder currently experiencing a major depressive episode with a higher probability of inflammatory activity (i.e., meeting one or more of the following inflammatory/metabolic criteria: obesity and dyslipidemia/hypertension, daily cigarette smoking, diabetes mellitus, migraine, inflammatory bowel disease, and/or C-reactive protein level of ⩾5 mg/L', 'Anhedonia in Bipolar I/II Depression']","['Adjunctive Infliximab vs. Placebo', 'adjunctive infliximab', 'tumour necrosis factor (TNF)-α antagonist infliximab', 'Infliximab', 'infliximab: n=21, placebo', 'infliximab', 'placebo']","['anhedonia relative', 'anhedonic symptoms', 'Plasma concentrations of TNF-α and soluble TNF receptors (sTNFR', 'SHAPS total score', 'Snaith-Hamilton Pleasure Scale (SHAPS) total score', 'sTNFR2 concentrations']","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0443156', 'cui_str': 'Bipolar'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0024517', 'cui_str': 'Major depression, single episode'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemia'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0021390', 'cui_str': 'Inflammatory bowel disease'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement'}, {'cui': 'C0439268', 'cui_str': 'mg/L'}, {'cui': 'C0178417', 'cui_str': 'Anhedonia'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]","[{'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1456820', 'cui_str': 'Tumor necrosis factor alpha'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}]","[{'cui': 'C0178417', 'cui_str': 'Anhedonia'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1456820', 'cui_str': 'Tumor necrosis factor alpha'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0679105', 'cui_str': 'Pleasure'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",60.0,0.341386,"Anti-anhedonic efficacy was moderated by baseline plasma levels of TNF-α and sTNFR1, but not by changes in TNF-α or sTNFR1 concentrations.","[{'ForeName': 'Yena', 'Initials': 'Y', 'LastName': 'Lee', 'Affiliation': 'Institute of Medical Science, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.'}, {'ForeName': 'Rodrigo B', 'Initials': 'RB', 'LastName': 'Mansur', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Brietzke', 'Affiliation': ""Psychiatry; Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada.""}, {'ForeName': 'Nicole E', 'Initials': 'NE', 'LastName': 'Carmona', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychology, Ryerson University, Toronto, ON, Canada.'}, {'ForeName': 'Mehala', 'Initials': 'M', 'LastName': 'Subramaniapillai', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.'}, {'ForeName': 'Zihang', 'Initials': 'Z', 'LastName': 'Pan', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Margarita', 'Initials': 'M', 'LastName': 'Shekotikhina', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Rosenblat', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Trisha', 'Initials': 'T', 'LastName': 'Suppes', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA; VA Palo Alto Health Care System, Palo Alto, CA, USA.'}, {'ForeName': 'Victoria E', 'Initials': 'VE', 'LastName': 'Cosgrove', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Nicole E', 'Initials': 'NE', 'LastName': 'Kramer', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Roger S', 'Initials': 'RS', 'LastName': 'McIntyre', 'Affiliation': 'Institute of Medical Science, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Department of Pharmacology, University of Toronto, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada. Electronic address: Roger.McIntyre@uhn.ca.'}]","Brain, behavior, and immunity",['10.1016/j.bbi.2020.04.063'] 105,32381495,Video-observed therapy and medication adherence for tuberculosis patients: randomised controlled trial in Moldova.,"INTRODUCTION The effectiveness of video-observed therapy (VOT) for treating tuberculosis (TB) has not been measured in low- and middle-income countries (LMICs), where >95% of TB cases and deaths occur. In this study, we analyse the effectiveness and patient cost-difference of VOT compared to clinic-based directly observed therapy (DOT) in improving medication adherence in Moldova, a LMIC in Eastern Europe. METHODS The study was a two-arm individually randomised trial with 197 TB patients (n=99 DOT control group; n=98 VOT treatment group; multidrug-resistant TB cases were excluded). The primary outcome was observed medication adherence, measured by the number of days that a patient failed to be observed adhering to medication for every 2-week period during the course of their treatment. RESULTS VOT significantly decreased nonadherence by 4 days (95% CI 3.35-4.67 days, p<0.01) per 2-week period: 5.24 days missed per 2-week period for DOT and 1.29 days for VOT. VOT patients spent MDL 504 (∼EUR 25) (95% CI MDL 277-730, p<0.01) and 58 h (95% CI 48-68 h, p<0.01) less on their treatment. In addition, VOT increased self-reported satisfaction with treatment. We found no significant results pertaining to treatment success, patient wellbeing or patient employment status and some evidence of an increase in side-effects. DISCUSSION In this trial, VOT increased observed medication adherence for TB patients in Moldova, a LMIC, when compared to clinic-based DOT. Additionally, VOT significantly reduced the time and money patients spent on their treatment.",2020,"We found no significant results pertaining to treatment success, patient well-being or patient employment status and some evidence of an increase in side effects. ","['Moldova, a LMIC in Eastern Europe', '197 TB patients (n=99 in DOT control group; 98 in VOT treatment group, MDR-TB cases were excluded', 'TB patients: RCT in Moldova']","['Video observed therapy (VOT', 'Video Observed Therapy (VOT', 'clinic-based Directly Observed Therapy (DOT', 'VOT']","['medication adherence', 'number of days that a patient failed to be observed adhering to medication', 'VOT', 'VOT patients spent 504 Moldovan Leu (MDL', 'side effects']","[{'cui': 'C0026374', 'cui_str': 'Moldavia'}, {'cui': 'C0015177', 'cui_str': 'East European country'}, {'cui': 'C0041296', 'cui_str': 'Tuberculosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0206526', 'cui_str': 'Multidrug resistant tuberculosis'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0872145', 'cui_str': 'Directly Observed Therapy'}]","[{'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0035827', 'cui_str': 'Rumanian language'}, {'cui': 'C0023401', 'cui_str': 'Leucine'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",197.0,0.085522,"We found no significant results pertaining to treatment success, patient well-being or patient employment status and some evidence of an increase in side effects. ","[{'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Ravenscroft', 'Affiliation': 'Behavioural Insights Team, London, UK luke.ravenscroft@bi.team.'}, {'ForeName': 'Stewart', 'Initials': 'S', 'LastName': 'Kettle', 'Affiliation': 'Behavioural Insights Team, London, UK.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Persian', 'Affiliation': 'Behavioural Insights Team, London, UK.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Ruda', 'Affiliation': 'Behavioural Insights Team, London, UK.'}, {'ForeName': 'Lilian', 'Initials': 'L', 'LastName': 'Severin', 'Affiliation': 'Act For Involvement, Chișinău, Moldova.'}, {'ForeName': 'Svetlana', 'Initials': 'S', 'LastName': 'Doltu', 'Affiliation': 'Act For Involvement, Chișinău, Moldova.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Schenck', 'Affiliation': 'Carnegie Mellon University, Pittsburgh, PA, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Loewenstein', 'Affiliation': 'Carnegie Mellon University, Pittsburgh, PA, USA.'}]",The European respiratory journal,['10.1183/13993003.00493-2020'] 106,32381556,Effect of a Digital Health Intervention on Decreasing Barriers and Increasing Facilitators for Colorectal Cancer Screening in Vulnerable Patients.,"BACKGROUND Colorectal cancer is the second leading cause of cancer-related death in the United States, in part, because one third of Americans fail to get screened. In a prior randomized controlled trial, we found that an iPad patient decision aid called Mobile Patient Technology for Health-CRC (mPATH-CRC) doubled the proportion of patients who completed colorectal cancer screening. METHODS All data for the current analysis were collected as part of a randomized controlled trial to determine the impact of mPATH-CRC on receipt of colorectal cancer screening within 24 weeks. Participants were enrolled from six community-based primary care practices between June 2014 and May 2016 and randomized to either usual care or mPATH-CRC. Six potential mediators of the intervention effect on screening were considered. The Iacobucci method was used to assess the significance of the mediation. RESULTS A total of 408 patients had complete data for all potential mediators. Overall, the potential mediators accounted for approximately three fourths (76.3%) of the effect of the program on screening completion. Perceived benefits, self-efficacy, ability to state a screening decision, and patient-provider discussion were statistically significant mediators. Patient-provider discussion accounted for the largest proportion of the effect of mPATH-CRC (70.7%). CONCLUSIONS mPATH-CRC increased completion of colorectal cancer screening by affecting patient-level and system-level mediators. However, the most powerful mediator was the occurrence of a patient-provider discussion about screening. Digital interventions like mPATH-CRC are an important adjunct to the patient-provider encounter. IMPACT Understanding the factors that mediated mPATH-CRC's success is paramount to developing other effective interventions.",2020,"Perceived benefits, self-efficacy, ability to state a screening decision, and patient/provider discussion were statistically significant mediators.","['Colorectal cancer (CRC', 'Participants were enrolled from 6 community-based primary care practices between June 2014 and May 2016 and randomized to either', '408 patients had complete data for all potential mediators', 'Colorectal Cancer Screening in Vulnerable Patients', 'iPad patient decision aid called Mobile Patient Technology for Health-CRC (mPATH-CRC) doubled the proportion of patients who completed CRC screening']","['usual care or mPATH-CRC', 'Digital Health Intervention']","['Perceived benefits, self-efficacy, ability to state a screening decision, and patient/provider discussion', 'completion of CRC screening']","[{'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C4517769', 'cui_str': '408'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086104', 'cui_str': 'Decision Aids'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205173', 'cui_str': 'Double'}]","[{'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}]",408.0,0.0654856,"Perceived benefits, self-efficacy, ability to state a screening decision, and patient/provider discussion were statistically significant mediators.","[{'ForeName': 'Nancy M', 'Initials': 'NM', 'LastName': 'Denizard-Thompson', 'Affiliation': 'Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina. ndenizar@wakehealth.edu.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Miller', 'Affiliation': 'Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Anna C', 'Initials': 'AC', 'LastName': 'Snavely', 'Affiliation': 'Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'John G', 'Initials': 'JG', 'LastName': 'Spangler', 'Affiliation': 'Department of Family and Community Medicine, Wake Forest School of Medicine, Winston Salem, North Carolina.'}, {'ForeName': 'L Doug', 'Initials': 'LD', 'LastName': 'Case', 'Affiliation': 'Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Kathryn E', 'Initials': 'KE', 'LastName': 'Weaver', 'Affiliation': 'Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}]","Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",['10.1158/1055-9965.EPI-19-1199'] 107,32384578,"Investigation of topical intranasal cocaine for sinonasal procedures: a randomized, phase III clinical trial.","BACKGROUND The objective of this trial was to demonstrate the clinical efficacy and safety of topical cocaine as part of the effort to gain regulatory approval from the United States Food and Drug Administration. METHODS This phase III, randomized, prospective, double-blind, multicenter, single-dose, placebo- and dose-controlled, parallel-group study aimed to evaluate the safety and efficacy of topical intranasal cocaine (RX0041-002). A total of 925 subjects were screened and a total of 648 subjects were randomized: 95 to placebo; 275 to 4% RX0041-002; and 278 to 8% RX0041-002. Efficacy was assessed with subjective pain intensity scores using the visual numeric rating scale and objectively using the von Frey filament test. Adverse events (AEs), vital signs, Holter monitoring, nasal irritation on visual examination, and smell assessment were recorded. The placebo and experimental groups were compared using a two-tailed Fisher's exact test. RESULTS Topical 4% and 8% cocaine achieved significant subject analgesia, the primary efficacy endpoint. Both doses were safe and well-tolerated, with a safety profile similar to placebo. In the 4% and 8% groups, headache (1.5% and 2.5%, respectively), epistaxis (0.7% and 1.1%), and anxiety (0.7% and 0%) were the only AEs reported by >1 subject. No cardiovascular AEs, serious AEs, or deaths occurred. A higher percentage of subjects in the 4% and 8% groups compared with the placebo group had a modest increase in either systolic or diastolic blood pressure. CONCLUSION Topical 4% and 8% cocaine is an effective anesthetic that can be safely administered for nasal procedures.",2020,Efficacy was assessed with subjective pain intensity scores using the visual numeric rating scale and objectively using the von Frey filament test.,"['925 subjects were screened and a total of 648 subjects were randomized: 95 to', 'sinonasal procedures']","['topical intranasal cocaine (RX0041-002', 'cocaine', 'topical intranasal cocaine', 'topical cocaine', 'placebo']","['headache', 'significant subject analgesia', 'anxiety', 'subjective pain intensity scores', 'systolic or diastolic blood pressure', 'visual numeric rating scale and objectively using the von Frey filament test', 'safety and efficacy', 'Efficacy', 'safe and well-tolerated', 'No cardiovascular AEs, serious AEs, or deaths', 'epistaxis', 'Adverse events (AEs), vital signs, Holter monitoring, nasal irritation on visual examination, and smell assessment']","[{'cui': 'C4517904', 'cui_str': '925'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C3208689', 'cui_str': 'Cocaine-containing product in cutaneous dose form'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0162473', 'cui_str': 'Auriculotemporal syndrome'}, {'cui': 'C0010851', 'cui_str': 'Cytoskeletal Filaments'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0013801', 'cui_str': 'Electrocardiography, Holter'}, {'cui': 'C0240557', 'cui_str': 'Irritation of nose'}, {'cui': 'C0199219', 'cui_str': 'Inspection'}, {'cui': 'C0037361', 'cui_str': 'Sense of smell, function'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",925.0,0.302563,Efficacy was assessed with subjective pain intensity scores using the visual numeric rating scale and objectively using the von Frey filament test.,"[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'McGrath', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Philadelphia College of Osteopathic Medicine, Philadelphia, PA.'}, {'ForeName': 'Alexa', 'Initials': 'A', 'LastName': 'McGrath', 'Affiliation': 'Philadelphia College of Osteopathic Medicine, Philadelphia, PA.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Burdett', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Philadelphia College of Osteopathic Medicine, Philadelphia, PA.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Shokri', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Penn State Hershey Medical Center, Hershey, PA.'}, {'ForeName': 'Jason E', 'Initials': 'JE', 'LastName': 'Cohn', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Philadelphia College of Osteopathic Medicine, Philadelphia, PA.'}]",International forum of allergy & rhinology,['10.1002/alr.22561'] 108,32386939,Effect of Protective Cover on the Quality of Life of Patients With Tracheostomy-A Quasi-Experimental Study.,"PURPOSE Patients with tracheostomy experience problems such as the inability to speak, swallowing disorders, and impairment of body image. These problems adversely affect patients' quality of life (QoL). This study aimed to investigate the effect of discharge training and the use of a protective cover on the QoL of patients with tracheostomy and the problems experienced after discharge. DESIGN A quasi-experimental study. METHODS All patients (n = 24) were followed for 3 months after the preoperative period. Patients in the control group (CG) received routine care after surgery, whereas patients in the intervention group (IG) received routine care, discharge training, and a protective stoma cover. FINDINGS The 90th postdischarge day QoL scores between the CG and IG were statistically significant. Respiratory problems were the most common postdischarge problems in both groups. Patients in the CG significantly experienced more problems than those in the IG during the postdischarge period. CONCLUSIONS This study provides that patients can benefit from discharge training and protective cover and that health care professionals become aware of the cover for future use.",2020,"Patients in the CG significantly experienced more problems than those in the IG during the postdischarge period. ","['patients with tracheostomy and the problems experienced after discharge', 'Patients With Tracheostomy-A Quasi-Experimental Study', 'Patients with tracheostomy experience problems']","['discharge training', 'routine care, discharge training, and a protective stoma cover', 'Protective Cover']","['90th postdischarge day QoL scores', ""patients' quality of life (QoL"", 'Quality of Life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040590', 'cui_str': 'Tracheostomy'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C2985410', 'cui_str': 'Controlled Clinical Trials, Non-Randomized'}]","[{'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C1955856', 'cui_str': 'Stoma site'}, {'cui': 'C0439844', 'cui_str': 'Covered'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",24.0,0.0315949,"Patients in the CG significantly experienced more problems than those in the IG during the postdischarge period. ","[{'ForeName': 'Çiğdem Canbolat', 'Initials': 'ÇC', 'LastName': 'Seyman', 'Affiliation': 'Faculty of Nursing, Department of Surgical Nursing, Hacettepe University, Ankara, Turkey. Electronic address: cigdem_canbolat@hotmail.com.'}, {'ForeName': 'Sevilay Şenol', 'Initials': 'SŞ', 'LastName': 'Çelik', 'Affiliation': 'Faculty of Nursing, Koç University, İstanbul, Turkey.'}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2020.01.013'] 109,32387453,"Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel.","BACKGROUND Primary tumour location (PTL) is being adopted by clinicians to guide treatment decisions in metastatic colorectal cancer (mCRC). Here we test PTL as a predictive marker for panitumumab efficacy, and examine its relationship with an extended biomarker profile. We also examine rectal tumours as a separate location. PATIENTS AND METHODS mCRC patients from the second-line PICCOLO trial of irinotecan versus irinotecan/panitumumab (IrPan). PTL was classified as right-PTL, left-PTL or rectal-PTL. PTL was assessed as a predictive biomarker for IrPan effect in RAS-wild-type (RAS-wt) patients (compared with irinotecan alone), then tested for independence alongside an extended biomarker profile (BRAF, epiregulin/amphiregulin (EREG/AREG) and HER3 mRNA expression). RESULTS PTL data were available for 1180 patients (98.5%), of whom 558 were RAS-wt. High HER3 expression was independently predictive of panitumumab overall survival improvement, but PTL and EREG/AREG were not. IrPan progression-free survival (PFS) improvement compared with irinotecan was seen in left-PTL [hazard ratio (HR) = 0.61, P = 0.002) but not right-PTL (HR = 0.98, P = 0.90) (interaction P = 0.05; RAS/BRAF-wt interaction P = 0.10), or in rectal-PTL (HR = 0.82, P = 0.20) (interaction P = 0.14 compared with left-PTL; RAS/BRAF-wt interaction P = 0.04). Patients with right-PTL and high EREG/AREG or HER3 expression, had IrPan PFS improvement (high EREG/AREG HR = 0.20, P = 0.04; high HER3 HR = 0.33, P = 0.10) compared with irinotecan. Similar effect was seen for rectal-PTL patients (high EREG/AREG HR = 0.44, P = 0.03; high HER3 HR = 0.34, P = 0.05). CONCLUSIONS RAS-wt patients with left-PTL are more likely to have panitumumab PFS advantage than those with right-PTL or rectal-PTL. However, an extended biomarker panel demonstrated significant heterogeneity in panitumumab PFS effect within a tumour location. AREG/EREG and HER3 mRNA expression identifies patients with right-PTL or rectal-PTL who achieve similar PFS effect with panitumumab as left-colon patients. Testing could provide a more reliable basis for clinical decision making. Further validation and development of these biomarkers is required to optimise routine patient care. CLINICAL TRIAL REGISTRATION ISRCTN identifier: ISRCTN93248876.",2020,"IrPan PFS improvement compared with irinotecan was seen in left-PTL (HR=0.61,p=0.002) but not right-PTL (HR=0.98,p=0.90)(interaction p=0.05; RAS/BRAF-wt interaction p=0.10), or in rectal-PTL (HR=0.82,p=0.20)(interaction p=0.14 compared with left-PTL; RAS/BRAF-wt interaction p=0.04).","['advanced colorectal cancer (aCRC', 'advanced right-colon, left-colon and rectal cancers', '1180 patients in a phase III trial of panitumumab with an extended biomarker panel', 'aCRC patients from the second-line PICCOLO trial of']","['irinotecan /panitumumab', 'irinotecan versus irinotecan/panitumumab', 'panitumumab', 'irinotecan']","['IrPan PFS improvement', 'High HER3 expression', 'EREG/AREG or HER3 expression, had IrPan PFS improvement']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C1305188', 'cui_str': 'Right colon structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0009368', 'cui_str': 'Colonic'}, {'cui': 'C0007113', 'cui_str': 'Rectal cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0879427', 'cui_str': 'panitumumab'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0879427', 'cui_str': 'panitumumab'}]","[{'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0072460', 'cui_str': 'Proto-Oncogene Protein erbB-3'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C3884279', 'cui_str': 'EREG protein, human'}, {'cui': 'C3884535', 'cui_str': 'AREG protein, human'}]",558.0,0.0774107,"IrPan PFS improvement compared with irinotecan was seen in left-PTL (HR=0.61,p=0.002) but not right-PTL (HR=0.98,p=0.90)(interaction p=0.05; RAS/BRAF-wt interaction p=0.10), or in rectal-PTL (HR=0.82,p=0.20)(interaction p=0.14 compared with left-PTL; RAS/BRAF-wt interaction p=0.04).","[{'ForeName': 'J F', 'Initials': 'JF', 'LastName': 'Seligmann', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK. Electronic address: j.seligmann@leeds.ac.uk.""}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Elliott', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Richman', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.""}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Hemmings', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Brown', 'Affiliation': 'Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Jacobs', 'Affiliation': 'Molecular Digestive Oncology Unit, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Williams', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Tejpar', 'Affiliation': 'Molecular Digestive Oncology Unit, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'J H', 'Initials': 'JH', 'LastName': 'Barrett', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.""}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Quirke', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Seymour', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.""}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2020.04.476'] 110,32388694,Supporting Infant Emotion Regulation Through Attachment-Based Intervention: a Randomized Controlled Trial.,"Infant emotion regulation has long-term implications for human development, highlighting the need for preventive interventions that support emotion regulation early in life. Such interventions may be especially important for infants higher in emotional reactivity who need to regulate their emotions more frequently and intensely than infants lower in emotional reactivity. The current randomized trial examined main and moderated effects of an attachment-based intervention on (a) infants' use of mother-oriented and self-soothing emotion regulation strategies and (b) infant emotion dysregulation in 186 low-income, predominantly Latino infants. We tested the brief (10-session) Attachment and Biobehavioral Catch-up (ABC) intervention in the context of home-based federal Early Head Start (EHS) services. Control participants received home-based EHS plus 10 weekly books. Intent-to-treat analyses with covariates revealed main effects of the intervention on infants' use of mother-oriented emotion regulation strategies during a brief (40-s) novel and potentially fear-inducing procedure (d = 0.31). Infant emotional reactivity moderated intervention impacts on mother-oriented emotion regulation strategies and on infant emotion dysregulation: We found stronger effects of the intervention for infants relatively higher in emotional reactivity. Findings are discussed in terms of the preventive value of attachment-based interventions for supporting early emotion regulation.",2020,Intent-to-treat analyses with covariates revealed main effects of the intervention on infants' use of mother-oriented emotion regulation strategies during a brief (40-s) novel and potentially fear-inducing procedure (d = 0.31).,"['186 low-income, predominantly Latino infants', 'infants relatively higher in emotional reactivity']","['home-based EHS plus 10 weekly books', 'attachment-based intervention', 'brief (10-session) Attachment and Biobehavioral Catch-up (ABC) intervention', 'mother-oriented and self-soothing emotion regulation strategies and (b) infant emotion dysregulation']",['infant emotion dysregulation'],"[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0006002', 'cui_str': 'Book'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0231617', 'cui_str': 'Catch'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}]","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}]",186.0,0.0256925,Intent-to-treat analyses with covariates revealed main effects of the intervention on infants' use of mother-oriented emotion regulation strategies during a brief (40-s) novel and potentially fear-inducing procedure (d = 0.31).,"[{'ForeName': 'Allison D', 'Initials': 'AD', 'LastName': 'Hepworth', 'Affiliation': 'University of Maryland School of Social Work, 525 West Redwood St., Baltimore, MD, 21201, USA. allison.hepworth@ssw.umaryland.edu.'}, {'ForeName': 'Lisa J', 'Initials': 'LJ', 'LastName': 'Berlin', 'Affiliation': 'University of Maryland School of Social Work, 525 West Redwood St., Baltimore, MD, 21201, USA.'}, {'ForeName': 'Tiffany L', 'Initials': 'TL', 'LastName': 'Martoccio', 'Affiliation': 'University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Erin N', 'Initials': 'EN', 'LastName': 'Cannon', 'Affiliation': 'University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Rebecca H', 'Initials': 'RH', 'LastName': 'Berger', 'Affiliation': 'University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Brenda Jones', 'Initials': 'BJ', 'LastName': 'Harden', 'Affiliation': 'University of Maryland, College Park, MD, USA.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-020-01127-1'] 111,32395836,Effectiveness of an avatar educational application for improving heart failure patients' knowledge and self-care behaviors: A pragmatic randomized controlled trial.,"AIM To evaluate the effectiveness of education using avatars for improving patients' heart failure knowledge and self-care. BACKGROUND A lack of knowledge and self-care contributes to poor outcomes and rehospitalization for people with heart failure. DESIGN A multi-centred, non-blinded pragmatic randomized controlled trial. METHODS Heart failure patients were randomly assigned to intervention (avatar education application) or usual care groups. Participants were followed up at baseline, 30 and 90 days. ANCOVA was used to compare the scores of heart failure knowledge and self-care, between the two groups. Fisher's exact test was used to compare the two groups' heart failure-cause readmission. Bivariate exact binary logistic regression was used to identify the predictors associated with baseline levels of knowledge. RESULTS A total of 36 participants were recruited (between October 2018 - March 2019). The mean age of participants was 67.5 (SD 11.3) years. At enrolment, approximately half (47.2%) have been living with Heart Failure for over 5 years. Two groups were comparable at baseline in their demographic and clinical characteristics. At 90 days, the intervention group participants had a higher increase in knowledge score on the Dutch Heart Failure Knowledge Scales compared with the control group (22.2% versus 3.7% P = .002, partial η 2  = 0.262, 95% CI -2.755 to -0.686). There was no between-group difference observed at 30- or 90-day follow-up, on self-care behaviour (Self-care of heart failure index) or healthcare use. Overall satisfaction with the avatar app was 91.3%. CONCLUSION The addition of a co-designed avatar app to usual care improved knowledge in our group of Heart Failure participants at 30 days and continued to increase up to 90 days. The results suggest that our avatar app was perceived as an enjoyable and engaging means of delivering critical knowledge and self-care information. IMPACT Heart failure is associated with poor clinical outcomes (i.e., readmission rates and mortality rate) and substantial economic burden. The effectiveness of Heart Failure patient education using avatar have not been investigated previously. In this study, the avatar app improved knowledge and self-care behaviours. This innovation could be used at the bedside, at home by nurses, patients and families. TRIAL REGISTRATION Australian New Zealand Trial Registry ACTRN12617001403325.",2020,"At 90 days, the intervention group participants had a higher increase in knowledge score on the Dutch Heart Failure Knowledge Scales compared with the control group (22.2% vs. 3.7% p = 0.002, partial η 2 =0.262, 95% CI -2.755, -0.686).","['Heart failure patients', 'The\u202fmean\xa0age\u202fof participants was\u202f67.5 (SD 11.3) years', 'A total of 36 participants were recruited (between October 2018 and March 2019', 'people with heart failure']","['avatar educational application', 'intervention (avatar education application) or usual care groups']","['knowledge score on the Dutch Heart Failure Knowledge Scales', '30-day or 90-day follow-up, on self-care behaviour (Self-care of heart failure index) or healthcare use', 'scores of heart failure knowledge and self-care', ""heart failure patients' knowledge and self-care behaviors"", 'Overall\u202fsatisfaction', 'knowledge and self-care behaviors']","[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0474417', 'cui_str': 'Self-care behavior'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",36.0,0.0906889,"At 90 days, the intervention group participants had a higher increase in knowledge score on the Dutch Heart Failure Knowledge Scales compared with the control group (22.2% vs. 3.7% p = 0.002, partial η 2 =0.262, 95% CI -2.755, -0.686).","[{'ForeName': 'Parichat', 'Initials': 'P', 'LastName': 'Wonggom', 'Affiliation': 'Department of Adult Nursing, Faculty of Nursing, Khon Kaen University, Thailand.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Nolan', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.'}, {'ForeName': 'Robyn A', 'Initials': 'RA', 'LastName': 'Clark', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.'}, {'ForeName': 'Tracey', 'Initials': 'T', 'LastName': 'Barry', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Burdeniuk', 'Affiliation': 'Department of Cardiology, Southern Adelaide Local Health Network, Adelaide, SA, Australia.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Nesbitt', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': ""O'Toole"", 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.'}, {'ForeName': 'Huiyun', 'Initials': 'H', 'LastName': 'Du', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.'}]",Journal of advanced nursing,['10.1111/jan.14414'] 112,32398580,Transverse vs. parasagittal in-plane approaches in ultrasound-guided paravertebral block using a microconvex probe: A randomised controlled trial.,"BACKGROUND Several approaches have been proposed for ultrasound-guided thoracic paravertebral block, but the best approach remains unclear. OBJECTIVE We compared two ultrasound-guided in-plane approaches using a microconvex probe, transverse and parasagittal. We assessed whether either approach would facilitate successful catheter placement in the paravertebral space. DESIGN Randomised controlled trial. SETTING University hospital, July 2015 to March 2016. PATIENTS Sixty patients scheduled to undergo thoracotomy were randomly allocated into two groups. INTERVENTIONS A microconvex probe was placed transversely between adjacent ribs (transverse) or sagittally between adjacent transverse processes (parasagittal). When the Tuohy needle reached the paravertebral space, a catheter was inserted to a depth of 4 cm. Then, 0.5-ml radiocontrast was injected through the catheter under fluoroscopy. MAIN OUTCOME MEASURES The primary outcome was successful catheter placement in the paravertebral space; secondary outcomes were 0 to 100 mm visual analogue scale pain score and morphine consumption in the first 24 h. RESULTS All patients received the allocated paravertebral block. Correct catheter placement occurred in 23 (77%) and 24 patients (80%) using the transverse (n=30) and parasagittal approaches (n=30), respectively (P = 1.00). Five patients were excluded due to changes in surgical procedure. Postoperative pain, represented by median [IQR] visual analogue scale score, was 19.5 [12 to 25] at rest and 55 [44 to 77] on movement with the transverse approach (n=28) vs. 22 [12 to 33.5] at rest and 59 [41.5 to 75] on movement with the parasagittal approach (n=27) (P = 0.57 at rest, P = 0.76 on movement). Median morphine consumption was 11.5 [5 to 21] and 11 [5 to 18] mg in the transverse and parasagittal approaches, respectively (P = 0.99). CONCLUSION There were no clinically significant differences between approaches for continuous ultrasound-guided thoracic paravertebral block using a microconvex probe, and both approaches achieved a high rate of correct catheter placement. TRIAL REGISTRATION UMIN Clinical Trials Registry identifier: UMIN000015988.",2020,"There were no clinically significant differences between approaches for continuous ultrasound-guided thoracic paravertebral block using a microconvex probe, and both approaches achieved a high rate of correct catheter placement. ","['University hospital, July 2015 to March 2016', 'Sixty patients scheduled to undergo thoracotomy']",[],"['Median morphine consumption', 'successful catheter placement in the paravertebral space; secondary outcomes were 0 to 100\u200amm visual analogue scale pain score and morphine consumption', 'Correct catheter placement', 'Postoperative pain', 'median [IQR] visual analogue scale score']","[{'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0039991', 'cui_str': 'Chest wall incision'}]",[],"[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0883301', 'cui_str': 'Catheter placement'}, {'cui': 'C0442150', 'cui_str': 'Paravertebral'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C2732809', 'cui_str': 'Visual analog scale pain score'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",5.0,0.212423,"There were no clinically significant differences between approaches for continuous ultrasound-guided thoracic paravertebral block using a microconvex probe, and both approaches achieved a high rate of correct catheter placement. ","[{'ForeName': 'Tasuku', 'Initials': 'T', 'LastName': 'Fujii', 'Affiliation': 'Department of Anaesthesiology, Nagoya University Graduate School of Medicine (TF, KN), Department of Surgical Center (YS) and Department of Anaesthesiology, Nagoya University Hospital, Nagoya, Japan (SS).'}, {'ForeName': 'Yasuyuki', 'Initials': 'Y', 'LastName': 'Shibata', 'Affiliation': ''}, {'ForeName': 'Sonoe', 'Initials': 'S', 'LastName': 'Shinya', 'Affiliation': ''}, {'ForeName': 'Kimitoshi', 'Initials': 'K', 'LastName': 'Nishiwaki', 'Affiliation': ''}]",European journal of anaesthesiology,['10.1097/EJA.0000000000001223'] 113,32398581,"Prophylactic norepinephrine infusion or leg wrapping for postspinal hypotension in elective caesarean delivery: A randomised, double-blind, placebo-controlled trial.","BACKGROUND Because of its alpha and beta agonist properties, norepinephrine infusion is currently being studied for the prevention of spinal hypotension during caesarean delivery. Vasopressor infusions are not always possible if there is an unavailability of infusion pumps. Leg wrapping with crepe bandage is an effective technique for prevention of postspinal hypotension and could be useful in resource-poor settings. OBJECTIVE The aim of this study was to compare the incidence of hypotension with norepinephrine infusion or leg wrapping with a control group in women undergoing caesarean delivery with spinal anaesthesia. DESIGN Randomised, double-blind, controlled trial. SETTING Single centre, tertiary level institute, India.Study period 3 April 2018 to 31 March 2019. PATIENTS One hundred and forty-four women aged 19 to 40 years with a singleton pregnancy. INTERVENTION In group Leg Wrapping, crepe bandage was applied tightly from metatarsus to groin. Group Norepinephrine and the control group received sham leg wrapping. In group Norepinephrine, the women received a norepinephrine infusion according to their body weight, while group Leg Wrapping and the control group received a 0.9% normal saline infusion at a similar rate. All three groups received a 500 ml co-load of Ringer's solution over 15 min. Noninvasive SBP was monitored every 2 min until delivery, and every 5 min thereafter. Any hypotensive event (SBP < 20% of baseline) was treated with an intravenous bolus of norepinephrine (7.5 μg). MAIN OUTCOME MEASURES The primary outcome was the incidence of hypotension. The secondary outcomes were performance error measurements, and the incidences of hypertension, bradycardia, norepinephrine rescue bolus and neonatal outcomes. RESULTS The incidences of hypotension were significantly lower in the norepinephrine infusion group and the leg wrapping groups than the control group (P values 0.021 for both). Performance error calculations showed that SBP was maintained closer to baseline with the norepinephrine infusion. CONCLUSION Norepinephrine infusion and leg wrapping can both reduce the incidence of postspinal hypotension during elective caesarean delivery compared with saline infusion alone. TRIAL REGISTRATION Clinical trial number and registry URL: CTRI/2018/04/012917 registered at Clinical Trial Registry of India http://www.ctri.nic.in/Clinicaltrials/login.php.",2020,The incidences of hypotension were significantly lower in the norepinephrine infusion group and the leg wrapping groups than the control group (P values 0.021 for both).,"['Study period 3 April 2018 to 31 March 2019', 'postspinal hypotension in elective caesarean delivery', 'Single centre, tertiary level institute, India', 'One hundred and forty-four women aged 19 to 40 years with a singleton pregnancy', 'women undergoing caesarean delivery with spinal anaesthesia']","['saline infusion alone', 'norepinephrine infusion', 'Prophylactic Norepinephrine infusion and Leg Wrapping', 'Norepinephrine', ""500\u200aml co-load of Ringer's solution"", 'Vasopressor infusions', 'Leg wrapping with crepe bandage', 'norepinephrine', 'sham leg wrapping', 'normal saline infusion', 'norepinephrine infusion or leg wrapping with a control group', 'placebo']","['postspinal hypotension', 'Noninvasive SBP', 'incidence of hypotension', 'performance error measurements, and the incidences of hypertension, bradycardia, norepinephrine rescue bolus and neonatal outcomes', 'incidences of hypotension']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}]","[{'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0445414', 'cui_str': 'Wrapping'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0073386', 'cui_str': 'Ringers Solution'}, {'cui': 'C0042397', 'cui_str': 'Vasoconstrictor agent'}, {'cui': 'C0460462', 'cui_str': 'Cotton crepe bandage'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",144.0,0.410984,The incidences of hypotension were significantly lower in the norepinephrine infusion group and the leg wrapping groups than the control group (P values 0.021 for both).,"[{'ForeName': 'Monisha', 'Initials': 'M', 'LastName': 'Sundararajan', 'Affiliation': 'From the Department of Anaesthesiology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth (Deemed University), Puducherry, India (MS, CR, RP, RM).'}, {'ForeName': 'Charulatha', 'Initials': 'C', 'LastName': 'Ravindran', 'Affiliation': ''}, {'ForeName': 'Rani', 'Initials': 'R', 'LastName': 'Ponnusamy', 'Affiliation': ''}, {'ForeName': 'Ravishankar', 'Initials': 'R', 'LastName': 'Murugesan', 'Affiliation': ''}]",European journal of anaesthesiology,['10.1097/EJA.0000000000001231'] 114,31009399,Prospective randomized trial of paclitaxel-coated balloon versus bare-metal stent in high bleeding risk patients with de novo coronary artery lesions.,"BACKGROUND In patients with high bleeding risk, percutaneous coronary intervention is still debated. This study compared 9-month angiographic and physiologic results in patients with high bleeding risk and de novo coronary lesions treated with either paclitaxel-coated balloon (PCB) or bare-metal stent (BMS). PATIENTS AND METHODS A total of 40 patients (40 lesions) with high bleeding risk who underwent successful balloon angioplasty with fractional flow reserve (FFR) after balloon angioplasty more than 0.80 were randomized 1: 1 to treatment with PCB versus BMS. Dual antiplatelet therapy was limited to 1 month after the procedure. RESULTS Baseline clinical and lesional characteristics were well balanced between the two groups. There was no significant difference in the postprocedural FFR (0.87 ± 0.06 in PCB vs. 0.89 ± 0.06 in BMS, P = 0.254). At 9 months, late luminal loss was significantly lower in the PCB group (0.2 ± 0.3 vs. 1.2 ± 0.8 mm, P < 0.001). Restenosis only occurred in the BMS group (0 vs. 25.0%, P = 0.049). CONCLUSION In patients with high bleeding risk, FFR-guided PCB treatment showed superior efficacy in terms of angiographic and physiologic patency compared with BMS at mid-term follow-up with only 1 month of dual antiplatelet therapy (Clinicaltrials.gov identifier, NCT02456402).",2019,"In patients with high bleeding risk, FFR-guided PCB treatment showed superior efficacy in terms of angiographic and physiologic patency compared with BMS at mid-term follow-up with only 1 month of dual antiplatelet therapy (Clinicaltrials.gov identifier, NCT02456402).","['patients with high bleeding risk and de novo coronary lesions treated with either', 'high bleeding risk patients with de novo coronary artery lesions', 'patients with high bleeding risk, percutaneous coronary intervention', '40 patients (40 lesions) with high bleeding risk who underwent']","['PCB', 'PCB versus BMS', 'BMS', 'paclitaxel-coated balloon (PCB) or bare-metal stent (BMS', 'paclitaxel-coated balloon versus bare-metal stent', 'successful balloon angioplasty with fractional flow reserve (FFR) after balloon angioplasty']","['Restenosis', 'postprocedural FFR', 'late luminal loss', 'angiographic and physiologic patency']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0205042', 'cui_str': 'Coronary artery structure'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}]","[{'cui': 'C0032447', 'cui_str': 'PCBs'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0453946', 'cui_str': 'Coat (physical object)'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft (physical object)'}, {'cui': 'C2825200', 'cui_str': 'Bare metal stent (physical object)'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0002996', 'cui_str': 'Dilation, Transluminal Arterial'}, {'cui': 'C1299469', 'cui_str': 'Fractional flow reserve'}]","[{'cui': 'C0333186', 'cui_str': 'Restenosis'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0699493', 'cui_str': 'Luminal'}, {'cui': 'C0205463', 'cui_str': 'Physiologic (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}]",40.0,0.0468016,"In patients with high bleeding risk, FFR-guided PCB treatment showed superior efficacy in terms of angiographic and physiologic patency compared with BMS at mid-term follow-up with only 1 month of dual antiplatelet therapy (Clinicaltrials.gov identifier, NCT02456402).","[{'ForeName': 'Eun-Seok', 'Initials': 'ES', 'LastName': 'Shin', 'Affiliation': 'Department of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan.'}, {'ForeName': 'Joo Myung', 'Initials': 'JM', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Samsung Medical Center, Division of Cardiology, Heart Vascular Stroke Institute, Sungkyunkwan University School of Medicine, Seoul.'}, {'ForeName': 'Ae-Young', 'Initials': 'AY', 'LastName': 'Her', 'Affiliation': 'Department of Internal Medicine, Division of Cardiology.'}, {'ForeName': 'Ju-Hyun', 'Initials': 'JH', 'LastName': 'Chung', 'Affiliation': 'Department of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan.'}, {'ForeName': 'Kyung', 'Initials': 'K', 'LastName': 'Eun Lee', 'Affiliation': 'Department of Mechanical and Biomedical Engineering, Kangwon National University, Chuncheon.'}, {'ForeName': 'Scot', 'Initials': 'S', 'LastName': 'Garg', 'Affiliation': 'Department of Cardiology, East Lancashire Hospitals NHS Trust, Blackburn, Lancashire, UK.'}, {'ForeName': 'Chang-Wook', 'Initials': 'CW', 'LastName': 'Nam', 'Affiliation': 'Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu.'}, {'ForeName': 'Joon-Hyung', 'Initials': 'JH', 'LastName': 'Doh', 'Affiliation': 'Division of Cardiology, Inje University Ilsan Paik Hospital, Goyang, Republic of Korea.'}, {'ForeName': 'Bon-Kwon', 'Initials': 'BK', 'LastName': 'Koo', 'Affiliation': 'Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea.'}]",Coronary artery disease,['10.1097/MCA.0000000000000755'] 115,32372290,Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.,"INTRODUCTION The aim of this analysis was to characterize the safety and tolerability of empagliflozin in patients with type 2 diabetes mellitus (T2DM) who were randomized to empagliflozin (10/25 mg) or placebo in clinical trials. METHODS Pooled data from 20 trials were analyzed for patients with T2DM treated with empagliflozin 10 mg (n = 4858), empagliflozin 25 mg (n = 5057), or placebo (n = 4904). The dataset comprised 15 randomized phase I-III trials, an extension trial and dose escalation studies. Adverse events (AEs) were assessed descriptively in participants who took ≥ 1 dose of study drug. AE incidence rates per 100 patient-years were calculated to adjust for differences in drug exposure between trials. RESULTS Total exposure was 16,480 and 7857 patient-years in the pooled empagliflozin 10/25 mg and placebo groups, respectively. The incidence of any AEs, AEs leading to treatment discontinuation, severe AEs, and serious AEs was similar across groups. The frequency of serious AEs requiring hospitalization was 18.6% for the empagliflozin 10/25 mg group and 21.3% for the placebo group. The empagliflozin 10/25 mg group was not associated with a higher rate of confirmed hypoglycemia versus placebo, except in patients co-administered insulin and/or a sulfonylurea (31.5% vs. 30.2%, respectively). The incidence of events consistent with urinary tract infections (UTI) was also similar for the empagliflozin 10/25 mg group versus placebo (9.27 vs. 9.70/100 patient-years, respectively). History of UTI was identified as a risk factor for UTI during treatment. Events consistent with genital infections occurred more frequently with empagliflozin 10/25 mg than placebo (3.54 vs. 0.95/100 patient-years, respectively). The frequency of AEs consistent with volume depletion was similar across groups, but higher with empagliflozin 10/25 mg than placebo in patients aged 75 to < 85 years and those on loop diuretics at baseline. CONCLUSION This comprehensive analysis confirms that both empagliflozin 10 mg and 25 mg are well tolerated in patients with T2DM, reinforcing the established clinical safety profile of empagliflozin.",2020,Events consistent with genital infections occurred more frequently with empagliflozin,"['10\xa0mg (n\u2009=\u20094858', 'Total exposure was 16,480 and 7857 patient-years in the pooled', 'Patients with Type 2 Diabetes Mellitus', 'patients with type 2 diabetes mellitus (T2DM', 'Pooled data from 20 trials were analyzed for patients with T2DM treated with', 'patients with T2DM']","['empagliflozin 25\xa0mg (n\u2009=\u20095057), or placebo', 'Empagliflozin', 'empagliflozin', 'placebo']","['AE incidence rates', 'genital infections', 'higher rate of confirmed hypoglycemia', 'safety and tolerability', 'incidence of any AEs, AEs leading to treatment discontinuation, severe AEs, and serious AEs', 'Adverse events (AEs', 'incidence of events consistent with urinary tract infections (UTI', 'frequency of AEs consistent with volume depletion', 'frequency of serious AEs requiring hospitalization']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0337051', 'cui_str': 'Pool'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C3848772', 'cui_str': 'empagliflozin 25 MG [Jardiance]'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3490348', 'cui_str': 'empagliflozin'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0729552', 'cui_str': 'Genital infection'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0546884', 'cui_str': 'Hypovolemia'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",,0.314442,Events consistent with genital infections occurred more frequently with empagliflozin,"[{'ForeName': 'Ona', 'Initials': 'O', 'LastName': 'Kinduryte Schorling', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Clark', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': 'Isabella', 'Initials': 'I', 'LastName': 'Zwiener', 'Affiliation': 'Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Kaspers', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': 'Jisoo', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': 'Hristo', 'Initials': 'H', 'LastName': 'Iliev', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany. hristo.iliev@boehringer-ingelheim.com.'}]",Advances in therapy,['10.1007/s12325-020-01329-7'] 116,32371123,Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study.,"BACKGROUND The impact of rituximab on health-related quality of life (HRQoL) in primary central nervous system lymphoma patients is not well known. We determined the impact of rituximab added to standard high-dose methotrexate-based treatment on HRQoL in patients in a large randomised trial. PATIENTS AND METHODS Patients from a large phase III trial (HOVON 105/ALLG NHL 24), randomly assigned to receive standard chemotherapy with or without rituximab and followed by 30 Gy whole brain radiotherapy (WBRT) in patients ≤60 years, completed the EORTC QLQ-C30 and QLQ-BN20 questionnaires before and during treatment, and up to 24 months of follow-up or progression. Differences between treatment arms over time in global health status, role functioning, social functioning, fatigue, and motor dysfunction were assessed. Differences ≥10 points were deemed clinically relevant. The effect of WBRT on HRQoL was analysed in irradiated patients. RESULTS A total of 160/175 patients eligible for the HRQoL study completed at least one questionnaire and were included. Over time, scores improved statistically significantly and were clinically relevant in both arms. Between arms, there were no differences on any scale (range: -3.8 to +4.0). Scores on all scales were improved to a clinically relevant extent at 12 and 24 months compared with baseline in both arms, except for fatigue and motor dysfunction at 12 months (-7.4 and -8.8, respectively). In irradiated patients (n = 59), scores in all preselected scales, except motor dysfunction, remained stable up to 24 months compared with shortly after WBRT, overall mean difference ranging between 0.02 and 4.570. CONCLUSION Compared with baseline, treatment resulted in improved HRQoL scores. The addition of rituximab to standard chemotherapy did not impact HRQoL over time. WBRT did not result in deterioration of HRQoL in the first 2 years.",2020,"Scores on all scales were improved to a clinically relevant extent at 12 and 24 months compared to baseline in both arms, except for fatigue and motor dysfunction at 12 months (-7.4 and -8.8, respectively).","['160/175 patients eligible for the HRQoL study completed at least one questionnaire and were included', 'Patients from a large phase III trial (HOVON 105/ALLG NHL 24', 'irradiated patients', 'primary central nervous system lymphoma patients']","['standard chemotherapy with or without rituximab and followed by 30Gy whole brain radiotherapy (WBRT', 'chemotherapy with or without rituximab', 'rituximab to standard chemotherapy', 'rituximab', 'WBRT', 'rituximab added to standard high-dose methotrexate-based treatment']","['health-related quality of life (HRQoL', 'fatigue and motor dysfunction', 'HRQoL', 'global health status, role functioning, social functioning, fatigue, and motor dysfunction', 'HRQoL scores', 'deterioration of HRQoL', 'Health-related quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0024305', 'cui_str': 'Malignant lymphoma, non-Hodgkin'}, {'cui': 'C1277077', 'cui_str': 'Irradiated blood product'}, {'cui': 'C0280803', 'cui_str': 'Primary central nervous system lymphoma'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C1520143', 'cui_str': 'Whole brain radiation therapy'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0521654', 'cui_str': 'Motor dysfunction'}, {'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}]",,0.17791,"Scores on all scales were improved to a clinically relevant extent at 12 and 24 months compared to baseline in both arms, except for fatigue and motor dysfunction at 12 months (-7.4 and -8.8, respectively).","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'van der Meulen', 'Affiliation': 'Department of Neuro-Oncology, Erasmus MC Cancer Institute, Brain Tumor Center, University Medical Center, Rotterdam, The Netherlands. Electronic address: m.vandermeulen.2@erasmusmc.nl.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Bakunina', 'Affiliation': 'HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Nijland', 'Affiliation': 'Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'M C', 'Initials': 'MC', 'LastName': 'Minnema', 'Affiliation': 'Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Cull', 'Affiliation': 'Haematology Department, Sir Charles Gairdner Hospital and PathWest Laboratory Medicine, Nedlands, Australia; University of Western Australia, Crawley, Australia.'}, {'ForeName': 'W B C', 'Initials': 'WBC', 'LastName': 'Stevens', 'Affiliation': 'Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'J W', 'Initials': 'JW', 'LastName': 'Baars', 'Affiliation': 'Department of Hemato-Oncology, Antoni van Leeuwenhoek Hospital/Dutch Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'K D', 'Initials': 'KD', 'LastName': 'Mason', 'Affiliation': 'Department of Hematology, Royal Melbourne Hospital, Melbourne, Australia.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Beeker', 'Affiliation': 'Department of Hematology, Spaarne Gasthuis, Haarlem, The Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Beijert', 'Affiliation': 'Department of Radiotherapy, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'M J B', 'Initials': 'MJB', 'LastName': 'Taphoorn', 'Affiliation': 'Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands; Department of Neurology, Haaglanden Medical Center, The Hague, The Netherlands.'}, {'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'van den Bent', 'Affiliation': 'Department of Neuro-Oncology, Erasmus MC Cancer Institute, Brain Tumor Center, University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Issa', 'Affiliation': 'Department of Hematology, Middlemore Hospital, Auckland, New Zealand.'}, {'ForeName': 'J K', 'Initials': 'JK', 'LastName': 'Doorduijn', 'Affiliation': 'Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'J E C', 'Initials': 'JEC', 'LastName': 'Bromberg', 'Affiliation': 'Department of Neuro-Oncology, Erasmus MC Cancer Institute, Brain Tumor Center, University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Dirven', 'Affiliation': 'Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands; Department of Neurology, Haaglanden Medical Center, The Hague, The Netherlands.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2020.04.014'] 117,32379483,A Sensory Stimulation Protocol to Modulate Cough Sensitivity: A Randomized Controlled Trial Safety Study.,"Purpose This study evaluated the safety and efficacy of a sensory stimulation protocol that was designed to modulate citric acid cough thresholds as a potential treatment for silent aspiration. Method Healthy adults ( n = 24) were randomly assigned to one of three sensory stimulation groups: (a) high-intensity ultrasonically nebulized distilled water (UNDW) inhalations (1.6 ml/min); (b) low-intensity UNDW inhalations (0.5 ml/min); and (3) control, 0.9% saline inhalations (1.6 ml/min). Sensory stimulation was delivered once a day, for 4 consecutive days. Citric acid cough thresholds were determined at baseline, Day 3, and Day 5 to evaluate changes in cough sensitivity. Spirometry was undertaken before, during, and after each sensory stimulation session to monitor for bronchoconstriction. Results No participant showed evidence of bronchoconstriction during the sensory stimulation protocol. There was an interaction effect between day and group on suppressed cough thresholds, χ 2 (4) = 11.32, p = .02. When compared to the control group, there was a decrease in citric acid cough thresholds across Days 1-5 in the high-intensity (-1.8 doubling concentrations, 95% confidence interval [-2.88, -0.72], p = .01) and low-intensity (-1.3 doubling concentrations, 95% confidence interval [-2.4, -0.2], p = .03) UNDW inhalation groups, representing a sensitization effect of UNDW inhalations on cough sensitivity. Conclusions The UNDW sensory stimulation protocol was safe in healthy adults. The findings provide preliminary evidence that UNDW inhalations sensitize laryngeal afferents related to citric acid-induced cough induction. The therapeutic potential of the UNDW sensory stimulation protocol will be explored in patients with reduced cough sensitivity who are at risk of silent aspiration and aspiration pneumonia. Plain Language Summary This study explored the safety and efficacy of a sensory stimulation protocol that was designed to modulate cough sensitivity as a potential treatment for silent aspiration. The study revealed that inhalations of nebulized distilled water were safe and increased cough sensitivity, when compared to control saline inhalations.",2020,"The study revealed that inhalations of nebulized distilled water were safe and increased cough sensitivity, when compared to control saline inhalations.","['Method Healthy adults ( n = 24', 'silent aspiration', 'healthy adults', 'patients with reduced cough sensitivity who are at risk of silent aspiration and aspiration pneumonia']","['Sensory Stimulation Protocol', 'sensory stimulation groups: (a) high-intensity ultrasonically nebulized distilled water (UNDW) inhalations (1.6 ml/min); (b) low-intensity UNDW inhalations', 'UNDW inhalations', 'sensory stimulation protocol']","['bronchoconstriction', 'Cough Sensitivity', 'cough sensitivity', 'safety and efficacy', 'Citric acid cough thresholds', 'safe and increased cough sensitivity', 'citric acid cough thresholds', 'low-intensity']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C4324315', 'cui_str': 'Silent aspiration'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0032290', 'cui_str': 'Aspiration pneumonia'}]","[{'cui': 'C0150763', 'cui_str': 'Sensory stimulation'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C4517508', 'cui_str': '1.6'}, {'cui': 'C0439445', 'cui_str': 'mL/min'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}]","[{'cui': 'C0079043', 'cui_str': 'Bronchial Constriction'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0055819', 'cui_str': 'Citric Acid'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}]",24.0,0.0962598,"The study revealed that inhalations of nebulized distilled water were safe and increased cough sensitivity, when compared to control saline inhalations.","[{'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Wallace', 'Affiliation': 'Department of Communication Disorders, Rose Centre for Stroke Recovery and Research, University of Canterbury, Christchurch, New Zealand.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Guiu Hernandez', 'Affiliation': 'Department of Communication Disorders, Rose Centre for Stroke Recovery and Research, University of Canterbury, Christchurch, New Zealand.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Epton', 'Affiliation': 'Canterbury Respiratory Research Group, Christchurch Hospital, New Zealand.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Ploen', 'Affiliation': 'Respiratory Physiology Laboratory, Christchurch Hospital, New Zealand.'}, {'ForeName': 'Maggie-Lee', 'Initials': 'ML', 'LastName': 'Huckabee', 'Affiliation': 'Department of Communication Disorders, Rose Centre for Stroke Recovery and Research, University of Canterbury, Christchurch, New Zealand.'}, {'ForeName': 'Phoebe', 'Initials': 'P', 'LastName': 'Macrae', 'Affiliation': 'Department of Communication Disorders, Rose Centre for Stroke Recovery and Research, University of Canterbury, Christchurch, New Zealand.'}]",American journal of speech-language pathology,['10.1044/2020_AJSLP-19-00180'] 118,32380069,"Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.","BACKGROUND Use of maintenance antibiotic therapy with the macrolide azithromycin is increasing in a number of chronic respiratory disorders including primary ciliary dyskinesia (PCD). However, evidence for its efficacy in PCD is lacking. We aimed to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in patients with PCD. METHODS The Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia (BESTCILIA) trial was a multicentre, double-blind, parallel group, randomised, placebo-controlled phase 3 trial done at 6 European PCD clinics (tertiary paediatric care centres and university hospitals in Denmark, Germany, Netherlands, Switzerland, and UK). Patients with a confirmed diagnosis of PCD, aged 7-50 years old, and predicted FEV 1 greater than 40% were recruited. Participants were randomly assigned (1:1), stratified by age and study site, via a web-based randomisation system to azithromycin 250 mg or 500 mg as tablets according to bodyweight ('}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C3839839', 'cui_str': 'Pediatric care'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0035204', 'cui_str': 'Disorder of respiratory system'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}]","[{'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0677908', 'cui_str': 'Maintenance therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0983950', 'cui_str': 'Azithromycin 250 MG'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0003240', 'cui_str': 'Macrolide antibiotic product'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",102.0,0.744903,"Four serious adverse events were reported, occurring in one (2%) of 47 participants in the azithromycin group and in three (7%) of 41 participants in the placebo group.","[{'ForeName': 'Helene E', 'Initials': 'HE', 'LastName': 'Kobbernagel', 'Affiliation': 'Danish Primary Ciliary Dyskinesia Centre, Paediatric Pulmonary Service, Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Frederik F', 'Initials': 'FF', 'LastName': 'Buchvald', 'Affiliation': 'Danish Primary Ciliary Dyskinesia Centre, Paediatric Pulmonary Service, Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Eric G', 'Initials': 'EG', 'LastName': 'Haarman', 'Affiliation': ""Department of Pediatric Pulmonology, Emma Children's Hospital, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Netherlands.""}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Casaulta', 'Affiliation': 'Division of Respiratory Medicine, Department of Pediatrics, Inselspital and University of Bern, Bern, Switzerland.'}, {'ForeName': 'Samuel A', 'Initials': 'SA', 'LastName': 'Collins', 'Affiliation': 'Primary Ciliary Dyskinesia Centre, National Institute for Health Research Biomedical Research Centre, University of Southampton, Southampton, UK.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Hogg', 'Affiliation': 'Primary Ciliary Dyskinesia Centre, Paediatric Respiratory Department, Royal Brompton Hospital, London, UK.'}, {'ForeName': 'Claudia E', 'Initials': 'CE', 'LastName': 'Kuehni', 'Affiliation': 'Division of Respiratory Medicine, Department of Pediatrics, Inselspital and University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Jane S', 'Initials': 'JS', 'LastName': 'Lucas', 'Affiliation': 'Primary Ciliary Dyskinesia Centre, National Institute for Health Research Biomedical Research Centre, University of Southampton, Southampton, UK.'}, {'ForeName': 'Claus E', 'Initials': 'CE', 'LastName': 'Moser', 'Affiliation': 'Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Alexandra L', 'Initials': 'AL', 'LastName': 'Quittner', 'Affiliation': ""Nicklaus Children's Research Institute, Miami, FL, USA.""}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Raidt', 'Affiliation': ""Department of General Pediatrics, University Children's Hospital Muenster, Muenster, Germany.""}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Rosthøj', 'Affiliation': 'Section of Biostatistics, Department of Public Health, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Anne L', 'Initials': 'AL', 'LastName': 'Sørensen', 'Affiliation': 'Section of Biostatistics, Department of Public Health, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Thomsen', 'Affiliation': 'Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Claudius', 'Initials': 'C', 'LastName': 'Werner', 'Affiliation': ""Helios Children's Hospital Schwerin, Schwerin, Germany; Department of General Pediatrics, University Children's Hospital Muenster, Muenster, Germany.""}, {'ForeName': 'Heymut', 'Initials': 'H', 'LastName': 'Omran', 'Affiliation': ""Department of General Pediatrics, University Children's Hospital Muenster, Muenster, Germany.""}, {'ForeName': 'Kim G', 'Initials': 'KG', 'LastName': 'Nielsen', 'Affiliation': 'Danish Primary Ciliary Dyskinesia Centre, Paediatric Pulmonary Service, Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Electronic address: kim.g.nielsen@regionh.dk.'}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(20)30058-8'] 119,32384122,Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: A randomized controlled trial.,"BACKGROUND In the primary analysis of a 12-month double-blind randomized active placebo-controlled trial, treatment of children with cystic fibrosis (CF) and pancreatic insufficiency (PI) with a readily absorbable structured lipid (Encala™, Envara Health, Wayne, PA) was safe, well-tolerated and improved dietary fat absorption (stool coefficient of fat absorption [CFA]), growth, and plasma fatty acids (FA). OBJECTIVE To determine if the Encala™ treatment effect varied by severity of baseline fat malabsorption. METHODS Subjects (n = 66, 10.5±3.0 yrs, 39% female) with baseline CFA who completed a three-month treatment with Encala™ or a calorie and macronutrient-matched placebo were included in this subgroup analysis. Subjects were categorized by median baseline CFA: low CFA (<88%) and high CFA (≥88%). At baseline and 3-month evaluations, CFA (72-hour stool, weighed food record) and height (HAZ), weight (WAZ) and BMI (BMIZ) Z-scores were calculated. Fasting plasma fatty acid (FA) concentrations were also measured. RESULTS Subjects in the low CFA subgroup had significantly improved CFA (+7.5±7.2%, mean 86.3±6.7, p = 0.002), and reduced stool fat loss (-5.7±7.2 g/24 hours) following three months of EncalaTM treatment. These subjects also had increased plasma linoleic acid (+20%), α-linolenic acid (+56%), and total FA (+20%) (p≤0.005 for all) concentrations and improvements in HAZ (0.06±0.08), WAZ (0.17±0.16), and BMIZ (0.20±0.25) (p≤0.002 for all). CFA and FA were unchanged with placebo in the low CFA group, with some WAZ increases (0.14±0.24, p = 0.02). High CFA subjects (both placebo and Encala™ groups) had improvements in WAZ and some FA. CONCLUSIONS Subjects with CF, PI and more severe fat malabsorption experienced greater improvements in CFA, FA and growth after three months of Encala™ treatment. Encala™ was safe, well-tolerated and efficacious in patients with CF and PI with residual fat malabsorption and improved dietary energy absorption, weight gain and FA status in this at-risk group.",2020,"Encala™ was safe, well-tolerated and efficacious in patients with CF and PI with residual fat malabsorption and improved dietary energy absorption, weight gain and FA status in this at-risk group.","['children with cystic fibrosis', 'children with cystic fibrosis (CF) and pancreatic insufficiency (PI', 'Subjects (n = 66, 10.5±3.0 yrs, 39% female) with baseline CFA who completed a three-month treatment with Encala™ or a']","['calorie and macronutrient-matched placebo', 'WAZ', 'placebo']","['residual fat malabsorption and growth', 'plasma linoleic acid', 'safe, well-tolerated and efficacious', 'Fasting plasma fatty acid (FA) concentrations', 'CFA', 'total FA', 'CFA and FA', 'CFA (72-hour stool, weighed food record) and height (HAZ), weight (WAZ) and BMI (BMIZ) Z-scores', 'concentrations and improvements in HAZ', 'dietary energy absorption, weight gain and FA status', 'stool fat loss', 'dietary fat absorption (stool coefficient of fat absorption [CFA]), growth, and plasma fatty acids (FA', 'CFA, FA and growth', 'α-linolenic acid']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0010674', 'cui_str': 'Cystic fibrosis'}, {'cui': 'C0030293', 'cui_str': 'Pancreatic insufficiency'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C4082119', 'cui_str': 'Three months'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0554103', 'cui_str': 'Intestinal malabsorption of fat'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0023749', 'cui_str': 'Linoleic acid'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0012171', 'cui_str': 'Dietary fat'}, {'cui': 'C0443214', 'cui_str': 'Fat absorption'}, {'cui': 'C0051405', 'cui_str': 'alpha-Linolenic Acid'}]",,0.119462,"Encala™ was safe, well-tolerated and efficacious in patients with CF and PI with residual fat malabsorption and improved dietary energy absorption, weight gain and FA status in this at-risk group.","[{'ForeName': 'Virginia A', 'Initials': 'VA', 'LastName': 'Stallings', 'Affiliation': ""Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, United States of America.""}, {'ForeName': 'Alyssa M', 'Initials': 'AM', 'LastName': 'Tindall', 'Affiliation': ""Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, United States of America.""}, {'ForeName': 'Maria R', 'Initials': 'MR', 'LastName': 'Mascarenhas', 'Affiliation': ""Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, United States of America.""}, {'ForeName': 'Asim', 'Initials': 'A', 'LastName': 'Maqbool', 'Affiliation': ""Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, United States of America.""}, {'ForeName': 'Joan I', 'Initials': 'JI', 'LastName': 'Schall', 'Affiliation': ""Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, United States of America.""}]",PloS one,['10.1371/journal.pone.0232685'] 120,32386747,Effect of immune regulatory pathways after immunization with GMZ2 malaria vaccine candidate in healthy lifelong malaria-exposed adults.,"BACKGROUND Despite appreciable immunogenicity in malaria-naive populations, many candidate malaria vaccines are considerably less immunogenic in malaria-exposed populations. This could reflect induction of immune regulatory mechanisms involving Human Leukocyte Antigen G (HLA-G), regulatory T (Treg), and regulatory B (Breg) cells. Here, we addressed the question whether there is correlation between these immune regulatory pathways and both plasmablast frequencies and vaccine-specific IgG concentrations. METHODS Fifty Gabonese adults with lifelong exposure to Plasmodium spp were randomized to receive three doses of either 30 µg or 100 µg GMZ2-CAF01, or 100 µg GMZ2-alum, or control vaccine (rabies vaccine) at 4-week intervals. Only plasma and peripheral blood mononuclear cells isolated from blood samples collected before (D0) and 28 days after the third vaccination (D84) of 35 participants were used to measure sHLA-G levels and anti-GMZ2 IgG concentrations, and to quantify Treg, Breg and plasmablast cells. Vaccine efficacy was assessed using controlled human malaria infection (CHMI) by direct venous inoculation of Plasmodium falciparum sporozoites (PfSPZ Challenge). RESULTS The sHLA-G concentration increased from D0 to D84 in all GMZ2 vaccinated participants and in the control group, whereas Treg frequencies increased only in those receiving 30 µg or 100 µg GMZ2-CAF01. The sHLA-G level on D84 was associated with a decrease of the anti-GMZ2 IgG concentration, whereas Treg frequencies on D0 or on D84, and Breg frequency on D84 were associated with lower plasmablast frequencies. Importantly, having a D84:D0 ratio of sHLA-G above the median was associated with an increased risk of P. falciparum infection after sporozoites injection. CONCLUSION Regulatory immune responses are induced following immunization. Stronger sHLA-G and Treg immune responses may suppress vaccine induced immune responses, and the magnitude of the sHLA-G response increased the risk of Plasmodium falciparum infection after CHMI. These findings could have implications for the design and testing of malaria vaccine candidates in semi-immune individuals.",2020,"The sHLA-G level on D84 was associated with a decrease of the anti-GMZ2 IgG concentration, whereas Treg frequencies on D0 or on D84, and Breg frequency on D84 were associated with lower plasmablast frequencies.","['Fifty Gabonese adults with lifelong exposure to Plasmodium spp', 'healthy lifelong malaria-exposed adults']","['30\xa0µg or 100\xa0µg GMZ2-CAF01, or 100\xa0µg GMZ2-alum, or control vaccine (rabies vaccine', 'GMZ2 malaria vaccine candidate']","['Vaccine efficacy', 'sHLA-G levels and anti-GMZ2 IgG concentrations', 'anti-GMZ2 IgG concentration', 'Only plasma and peripheral blood mononuclear cells', 'sHLA-G concentration', 'risk of P. falciparum infection']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4274169', 'cui_str': 'Lifelong'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0032148', 'cui_str': 'Plasmodium'}, {'cui': 'C0074992', 'cui_str': 'sphingosine 1-phosphate'}, {'cui': 'C0024530', 'cui_str': 'Malaria'}]","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0051522', 'cui_str': 'aluminum sulfate'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0034496', 'cui_str': 'Rabies vaccine'}, {'cui': 'C0206255', 'cui_str': 'Malarial Vaccines'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]",35.0,0.0706217,"The sHLA-G level on D84 was associated with a decrease of the anti-GMZ2 IgG concentration, whereas Treg frequencies on D0 or on D84, and Breg frequency on D84 were associated with lower plasmablast frequencies.","[{'ForeName': 'Odilon', 'Initials': 'O', 'LastName': 'Nouatin', 'Affiliation': ""Centre de Recherches Médicales de Lambaréné, BP: 242 Lambaréné, Gabon; Institut für Tropenmedizin, Universität Tubingen, Wilhelmstraβe 27, D-72074 Tübingen, Germany; Germany; German Centre for Infection Research (DZIF), Partner Site Tübingen, Germany; Département de Biochimie et de Biologie Cellulaire, Faculté des Sciences et Techniques, Université d'Abomey-Calavi, Cotonou, Benin. Electronic address: paterneodilon@gmail.com.""}, {'ForeName': 'Ulysse', 'Initials': 'U', 'LastName': 'Ateba Ngoa', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné, BP: 242 Lambaréné, Gabon. Electronic address: ulyssus7000@gmail.com.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Ibáñez', 'Affiliation': 'Institut für Tropenmedizin, Universität Tubingen, Wilhelmstraβe 27, D-72074 Tübingen, Germany.'}, {'ForeName': 'Jean Claude', 'Initials': 'JC', 'LastName': 'Dejon-Agobe', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné, BP: 242 Lambaréné, Gabon; Institut für Tropenmedizin, Universität Tubingen, Wilhelmstraβe 27, D-72074 Tübingen, Germany.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Mordmüller', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné, BP: 242 Lambaréné, Gabon; Institut für Tropenmedizin, Universität Tubingen, Wilhelmstraβe 27, D-72074 Tübingen, Germany; Germany; German Centre for Infection Research (DZIF), Partner Site Tübingen, Germany. Electronic address: benjamin.mordmueller@uni-tuebingen.de.'}, {'ForeName': 'Jean Ronald', 'Initials': 'JR', 'LastName': 'Edoa', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné, BP: 242 Lambaréné, Gabon; Institut für Tropenmedizin, Universität Tubingen, Wilhelmstraβe 27, D-72074 Tübingen, Germany. Electronic address: j.ronaldedoa@cermel.org.'}, {'ForeName': 'Fabrice', 'Initials': 'F', 'LastName': 'Mougeni', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné, BP: 242 Lambaréné, Gabon.'}, {'ForeName': 'Sina', 'Initials': 'S', 'LastName': 'Brückner', 'Affiliation': 'Institut für Tropenmedizin, Universität Tubingen, Wilhelmstraβe 27, D-72074 Tübingen, Germany. Electronic address: sinab@gmx.net.'}, {'ForeName': 'Aurore', 'Initials': 'A', 'LastName': 'Bouyoukou Hounkpatin', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné, BP: 242 Lambaréné, Gabon; Institut für Tropenmedizin, Universität Tubingen, Wilhelmstraβe 27, D-72074 Tübingen, Germany.'}, {'ForeName': 'Meral', 'Initials': 'M', 'LastName': 'Esen', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné, BP: 242 Lambaréné, Gabon; Institut für Tropenmedizin, Universität Tubingen, Wilhelmstraβe 27, D-72074 Tübingen, Germany; Germany; German Centre for Infection Research (DZIF), Partner Site Tübingen, Germany. Electronic address: meral.esen@uni-tuebingen.de.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Theisen', 'Affiliation': 'Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark and Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen, and Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Denmark. Electronic address: mth@ssi.dk.'}, {'ForeName': 'Kabirou', 'Initials': 'K', 'LastName': 'Moutairou', 'Affiliation': ""Département de Biochimie et de Biologie Cellulaire, Faculté des Sciences et Techniques, Université d'Abomey-Calavi, Cotonou, Benin. Electronic address: kamoutairo@yahoo.fr.""}, {'ForeName': 'Stephen L', 'Initials': 'SL', 'LastName': 'Hoffman', 'Affiliation': 'Sanaria Inc, Rockville, MD 20850, USA. Electronic address: slhoffman@sanaria.com.'}, {'ForeName': 'Saadou', 'Initials': 'S', 'LastName': 'Issifou', 'Affiliation': 'Fondation pour la Recherche Scientifique, 72 BP45 Cotonou, Benin. Electronic address: isaadou2002@yahoo.fr.'}, {'ForeName': 'Adrian J F', 'Initials': 'AJF', 'LastName': 'Luty', 'Affiliation': ""Centre d'Etude et de Recherche sur le Paludisme Associé à la Grossesse et à l'Enfance, Faculté des Sciences de la Santé, Université d'Abomey-Calavi, Cotonou, MERIT UMR D216, Benin; Université de Paris, MERIT, IRD, Paris, France. Electronic address: adrian.luty@ird.fr.""}, {'ForeName': 'Marguerite M', 'Initials': 'MM', 'LastName': 'Loembe', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné, BP: 242 Lambaréné, Gabon; Institut für Tropenmedizin, Universität Tubingen, Wilhelmstraβe 27, D-72074 Tübingen, Germany; Germany; German Centre for Infection Research (DZIF), Partner Site Tübingen, Germany. Electronic address: mmassingaloembe@cermel.org.'}, {'ForeName': 'Selidji Todagbé', 'Initials': 'ST', 'LastName': 'Agnandji', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné, BP: 242 Lambaréné, Gabon; Institut für Tropenmedizin, Universität Tubingen, Wilhelmstraβe 27, D-72074 Tübingen, Germany; Germany; German Centre for Infection Research (DZIF), Partner Site Tübingen, Germany. Electronic address: agnandjis@cermel.org.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Lell', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné, BP: 242 Lambaréné, Gabon; Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria. Electronic address: bertrand.lell@cermel.org.'}, {'ForeName': 'Peter G', 'Initials': 'PG', 'LastName': 'Kremsner', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné, BP: 242 Lambaréné, Gabon; Institut für Tropenmedizin, Universität Tubingen, Wilhelmstraβe 27, D-72074 Tübingen, Germany; Germany; German Centre for Infection Research (DZIF), Partner Site Tübingen, Germany. Electronic address: peter.kremsner@uni-tuebingen.de.'}, {'ForeName': 'Ayôla Akim', 'Initials': 'AA', 'LastName': 'Adegnika', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné, BP: 242 Lambaréné, Gabon; Institut für Tropenmedizin, Universität Tubingen, Wilhelmstraβe 27, D-72074 Tübingen, Germany; Germany; German Centre for Infection Research (DZIF), Partner Site Tübingen, Germany; Leiden University Medical Centre (LUMC), 2333 ZA Leiden, the Netherlands. Electronic address: aadegnika@cermel.org.'}]",Vaccine,['10.1016/j.vaccine.2020.04.046'] 121,32394723,"Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression.","Limited data exist on the effects of contraceptives on HIV disease progression. We studied the association between intramuscular injectable depot medroxyprogesterone acetate (DMPA-IM), the copper intrauterine device (IUD), and the levonorgestrel (LNG) implant on markers of HIV disease progression at the time of HIV detection and 3 months postdetection and time from detection to CD4 count <350 cells/mm 3 . Among women initiating antiretroviral therapy (ART), we studied the effect of contraceptive group on time from ART initiation to viral load (VL) <40 copies/mL. We included women 16-35 years randomized to DMPA-IM, copper IUD, or LNG implant with incident HIV infection during the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial ( n  = 382). We analyzed HIV VL and CD4 cell count according to participants' randomized method and also conducted a ""continuous use"" analysis that excluded follow-up time after method discontinuation. We used adjusted linear models to compare mean VL and CD4 cell levels by contraceptive group up to the time of ART initiation. We compared time from HIV detection to CD4 count <350 cells/mm 3 and, following ART initiation, time to viral suppression (VL <40 copies/mL) using Cox proportional hazards models. At HIV detection, women allocated to DMPA-IM had lower VL relative to copper IUD (-0.28 log 10 copies/mL; 95% confidence interval [CI]: -0.55 to -0.01) and LNG implant (-0.27, CI: -0.55 to 0.02) and higher mean CD4 than copper IUD users by 66 cells/mm 3 (CI: 11-121). In continuous use analyses women allocated to DMPA-IM progressed to CD4 < 350 cells/mm 3 slower than copper IUD users (hazard ratio [HR] = 0.6, CI: 0.3-1.1), whereas copper IUD users progressed faster than LNG implant users (HR = 1.8, CI: 1.0-3.3). Time to viral suppression was faster for DMPA-IM than copper IUD (HR = 1.5, CI: 1.0-2.3) and LNG implant 1.4 (CI: 0.9-2.2) users. We found no evidence of more rapid early HIV disease progression among women using DMPA-IM than among women using copper IUD or LNG implant. Our finding of more rapid progression among copper IUD compared with DMPA-IM users should be interpreted cautiously.",2020,"Women using DMPA-IM (HR= 0.6, CI: 0.3, 1.1) and LNG implant (HR = 0.6, CI: 0.3, 1.0) progressed to CD4 <350 slower than copper IUD users and time to viral suppression was faster for DMPA-IM than copper IUD (HR=1.5 (CI: 1.0, 2.3) and LNG implant 1.4 (CI: 0.9-2.2) users in continuous use analysis. ","['women using DMPA-IM', 'women 16-35 years randomized to']","['DMPA-IM, copper IUD, or levonorgestrel implant', 'DMPA-IM, the copper IUD and levonorgestrel (LNG) implant', 'depot medroxyprogesterone acetate, copper intrauterine devices, and levonorgestrel implants']","['mean viral load and CD4 cell levels', 'time to viral suppression', 'VL relative to copper IUD', 'HIV viral load and CD4 cell count', 'early HIV disease progression', 'time to CD4 count <350 cells/mm3 and viral suppression']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0067376', 'cui_str': 'N,N-dimethyl-4-anisidine'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0067376', 'cui_str': 'N,N-dimethyl-4-anisidine'}, {'cui': 'C0009968', 'cui_str': 'Copper'}, {'cui': 'C0015927', 'cui_str': 'Fetal death'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0065864', 'cui_str': 'Medroxyprogesterone acetate'}, {'cui': 'C0021901', 'cui_str': 'Copper Intrauterine Devices'}, {'cui': 'C0023566', 'cui_str': 'Levonorgestrel'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0039215', 'cui_str': 'T lymphocyte positive for CD4 antigen'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}, {'cui': 'C0009968', 'cui_str': 'Copper'}, {'cui': 'C0015927', 'cui_str': 'Fetal death'}, {'cui': 'C1168369', 'cui_str': 'HIV viral load'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Cell Counts'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C1141957', 'cui_str': 'HIV disease progression'}, {'cui': 'C4517735', 'cui_str': '350'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0439243', 'cui_str': 'uL'}]",382.0,0.424447,"Women using DMPA-IM (HR= 0.6, CI: 0.3, 1.1) and LNG implant (HR = 0.6, CI: 0.3, 1.0) progressed to CD4 <350 slower than copper IUD users and time to viral suppression was faster for DMPA-IM than copper IUD (HR=1.5 (CI: 1.0, 2.3) and LNG implant 1.4 (CI: 0.9-2.2) users in continuous use analysis. ","[{'ForeName': 'Charles S', 'Initials': 'CS', 'LastName': 'Morrison', 'Affiliation': 'FHI 360, Durham, North Carolina, USA.'}, {'ForeName': 'G Justus', 'Initials': 'GJ', 'LastName': 'Hofmeyr', 'Affiliation': 'Effective Care Research Unit, Department of Obstetrics and Gynaecology, University of Witwatersrand/Fort Hare/Walter Sisulu, East London, South Africa.'}, {'ForeName': 'Katherine K', 'Initials': 'KK', 'LastName': 'Thomas', 'Affiliation': 'Department of Global Health, University of Washington, Seattle, USA.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Rees', 'Affiliation': 'Wits Reproductive Health and HIV Institute (Wits RHI), University of Witswatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Neena', 'Initials': 'N', 'LastName': 'Philip', 'Affiliation': 'Mailman School of Public Health, ICAP at Columbia University, New York, USA.'}, {'ForeName': 'Thesla', 'Initials': 'T', 'LastName': 'Palanee-Phillips', 'Affiliation': 'Wits Reproductive Health and HIV Institute (Wits RHI), University of Witswatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Kavita', 'Initials': 'K', 'LastName': 'Nanda', 'Affiliation': 'FHI 360, Durham, North Carolina, USA.'}, {'ForeName': 'Gonasagrie', 'Initials': 'G', 'LastName': 'Nair', 'Affiliation': 'Emavundleni Research Center, Capetown, South Africa.'}, {'ForeName': 'Maricianah', 'Initials': 'M', 'LastName': 'Onono', 'Affiliation': 'KEMRI-RCTP Study Center, Kisumu, Kenya.'}, {'ForeName': 'Timothy D', 'Initials': 'TD', 'LastName': 'Mastro', 'Affiliation': 'FHI 360, Durham, North Carolina, USA.'}, {'ForeName': 'Maggie', 'Initials': 'M', 'LastName': 'Lind', 'Affiliation': 'Department of Global Health, University of Washington, Seattle, USA.'}, {'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Heffron', 'Affiliation': 'Department of Global Health, University of Washington, Seattle, USA.'}, {'ForeName': 'Vinodh', 'Initials': 'V', 'LastName': 'Edward', 'Affiliation': 'The Aurum Institute, Johannesburg, South Africa.'}, {'ForeName': 'Jen', 'Initials': 'J', 'LastName': 'Deese', 'Affiliation': 'FHI 360, Durham, North Carolina, USA.'}, {'ForeName': 'Mags', 'Initials': 'M', 'LastName': 'Beksinska', 'Affiliation': 'MatCH Research Unit (MRU), Faculty of Health Sciences, Department of Obstetrics and Gynecology, University of the Witwatersrand, Durban, South Africa.'}, {'ForeName': 'Ivana', 'Initials': 'I', 'LastName': 'Beesham', 'Affiliation': 'MatCH Research Unit (MRU), Faculty of Health Sciences, Department of Obstetrics and Gynecology, University of the Witwatersrand, Durban, South Africa.'}, {'ForeName': 'Jeffrey S A', 'Initials': 'JSA', 'LastName': 'Stringer', 'Affiliation': 'Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.'}, {'ForeName': 'Jared M', 'Initials': 'JM', 'LastName': 'Baeten', 'Affiliation': 'Department of Global Health, University of Washington, Seattle, USA.'}, {'ForeName': 'Khatija', 'Initials': 'K', 'LastName': 'Ahmed', 'Affiliation': 'Setshaba Research Center, Soshanguve, South Africa.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",AIDS research and human retroviruses,['10.1089/AID.2020.0015'] 122,32333733,Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results.,"INTRODUCTION To report 2-year safety and effectiveness of the Aquablation procedure for the treatment of men with symptomatic benign prostatic hyperplasia (BPH) and large-volume 80-150 cc prostates. MATERIALS AND METHODS Between September-December 2017, 101 men with moderate-to-severe BPH symptoms and prostate volumes of 80-150 cc underwent an ultrasound-guided robotically executed Aquablation procedure in a prospective multicenter international clinical trial (WATER II). Baseline, procedural and follow up parameters were recorded at baseline and scheduled postoperative visits. Herein we report 2-year safety and efficacy for this cohort. RESULTS Mean prostate volume was 107 cc (range 80-150 cc). Mean IPSS improved from 23.2 at baseline to 5.8 at 2 years (17-point improvement, p < .0001). Mean IPSS quality of life improved from 4.6 at baseline to 1.1 at 2 years (p < .0001). Maximum urinary flow increased from 8.7 to 18.2 cc/sec. Two subjects underwent a repeat procedure for BPH symptoms over the 2-year follow up period. By 2 years or study exit, all but 2 of 74 subjects stopped taking alpha blockers. Similarly, all but 4 of 32 subjects stopped taking 5α-reductase inhibitors. CONCLUSIONS Two-year prospective multicenter follow up demonstrated that the Aquablation procedure is safe and effective in the treatment of men with LUTS due to BPH and prostates 80-150 cc with durable treatment efficacy, acceptable safety profile and a low retreatment rate. ClinicalTrials.gov number, NCT03123250.",2020,Mean IPSS quality of life improved from 4.6 at baseline to 1.1 at 2 years (p < .0001).,"['Between September-December 2017', 'men with symptomatic benign prostatic hyperplasia (BPH) and large-volume 80-150 cc prostates', '74 subjects stopped taking alpha blockers', '32 subjects stopped taking 5α-reductase inhibitors', '101 men with moderate-to-severe BPH symptoms and prostate volumes of 80-150 cc underwent an']","['ultrasound-guided robotically executed Aquablation procedure', 'Aquablation procedure']","['Mean IPSS quality of life', 'Mean prostate volume', '2-year safety and efficacy', 'safe and effective', 'Maximum urinary flow', 'BPH symptoms', 'Mean IPSS']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0005001', 'cui_str': 'Hypertrophy, Benign Prostatic'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0450446', 'cui_str': 'Stops'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0001641', 'cui_str': 'Alpha adrenergic receptor antagonist'}, {'cui': 'C0030016', 'cui_str': 'Oxidoreductase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1504431', 'cui_str': 'Idiopathic pneumonia syndrome'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0012797', 'cui_str': 'Diuresis'}, {'cui': 'C0005001', 'cui_str': 'Hypertrophy, Benign Prostatic'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",101.0,0.0240883,Mean IPSS quality of life improved from 4.6 at baseline to 1.1 at 2 years (p < .0001).,"[{'ForeName': 'Mihir', 'Initials': 'M', 'LastName': 'Desai', 'Affiliation': 'University of Southern California, Institute of Urology, Los Angeles, California, USA.'}, {'ForeName': 'Mo', 'Initials': 'M', 'LastName': 'Bidair', 'Affiliation': ''}, {'ForeName': 'Naeem', 'Initials': 'N', 'LastName': 'Bhojani', 'Affiliation': ''}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Trainer', 'Affiliation': ''}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Arther', 'Affiliation': ''}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Kramolowsky', 'Affiliation': ''}, {'ForeName': 'Leo', 'Initials': 'L', 'LastName': 'Doumanian', 'Affiliation': ''}, {'ForeName': 'Dean', 'Initials': 'D', 'LastName': 'Elterman', 'Affiliation': ''}, {'ForeName': 'Ronald P', 'Initials': 'RP', 'LastName': 'Kaufman', 'Affiliation': ''}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Lingeman', 'Affiliation': ''}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Krambeck', 'Affiliation': ''}, {'ForeName': 'Gregg', 'Initials': 'G', 'LastName': 'Eure', 'Affiliation': ''}, {'ForeName': 'Gopal', 'Initials': 'G', 'LastName': 'Badlani', 'Affiliation': ''}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Plante', 'Affiliation': ''}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Uchio', 'Affiliation': ''}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Gin', 'Affiliation': ''}, {'ForeName': 'Larry', 'Initials': 'L', 'LastName': 'Goldenberg', 'Affiliation': ''}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Paterson', 'Affiliation': ''}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'So', 'Affiliation': ''}, {'ForeName': 'Mitchell R', 'Initials': 'MR', 'LastName': 'Humphreys', 'Affiliation': ''}, {'ForeName': 'Claus G', 'Initials': 'CG', 'LastName': 'Roehrborn', 'Affiliation': ''}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Kaplan', 'Affiliation': ''}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Motola', 'Affiliation': ''}, {'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': 'Zorn', 'Affiliation': ''}]",The Canadian journal of urology,[] 123,32289619,Serum osteoprotegerin as a long-term predictor for patients with stable coronary artery disease and its association with diabetes and statin treatment: A CLARICOR trial 10-year follow-up substudy.,"BACKGROUND AND AIMS Elevated circulating levels of osteoprotegerin (OPG) are known to add to the prediction of cardiovascular mortality. Our objective was to clarify the long-term risk associated with serum OPG and the possible influence of diabetes and statins on OPG levels in patients with stable coronary artery disease (CAD). METHODS We assessed the placebo-treated group (n = 1998) from the CLARICOR trial (NCT00121550), a cohort with stable CAD. At entry, 15% of the participants had diabetes and 41% received statins. Serum OPG levels were measured in blood drawn at randomization. Participants were followed through public registers for 10 years. RESULTS OPG levels correlated positively with diabetes status, age, CRP and female sex, but negatively with the use of statins. CAD participants with diabetes had significantly elevated serum OPG levels compared to participants without diabetes, p < 0.0001. The participants without diabetes treated with statins presented with significantly lower serum OPG levels than the corresponding non-statin-users (p < 0.0001). However, statin use showed no association with OPG levels in the participants with diabetes. High OPG levels at entry showed long-term associations with all-cause mortality and cardiovascular events (hazard ratio associated with factor 10 OPG increase 15.9 (95% CI 11.0-22.9) and 6.38 (4.60-8.90), p = 0.0001, even after adjustment for standard predictors (3.16 (1.90-5.25) and 2.29 (1.53-3.44), p < 0.0001). CONCLUSIONS Circulating OPG holds long-term independent predictive ability for all-cause mortality and cardiovascular events in CAD participants. OPG levels were associated with diabetes, age, and female sex and statin treatment was associated with lower OPG levels in the absence of diabetes.",2020,"CAD participants with diabetes had significantly elevated serum OPG levels compared to participants without diabetes, p < 0.0001.","['Participants were followed through public registers for 10 years', 'participants with diabetes', 'patients with stable coronary artery disease and its association with diabetes and statin treatment', 'CAD participants', 'CAD participants with diabetes', 'patients with stable coronary artery disease (CAD']","['statins', 'placebo']","['High OPG levels', 'Serum OPG levels', 'OPG levels', 'mortality and cardiovascular events', 'serum OPG levels', 'Serum osteoprotegerin']","[{'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0538161', 'cui_str': 'Tumor Necrosis Factor Receptor 11b'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",,0.0879435,"CAD participants with diabetes had significantly elevated serum OPG levels compared to participants without diabetes, p < 0.0001.","[{'ForeName': 'Mette', 'Initials': 'M', 'LastName': 'Bjerre', 'Affiliation': 'Medical Research Laboratory, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Electronic address: mette.bjerre@clin.au.dk.'}, {'ForeName': 'Jørgen', 'Initials': 'J', 'LastName': 'Hilden', 'Affiliation': 'Department of Biostatistics, Institute of Public Health Research, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Winkel', 'Affiliation': 'The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Gorm Boje', 'Initials': 'GB', 'LastName': 'Jensen', 'Affiliation': 'Department of Cardiology, Hvidovre Hospital, Copenhagen University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Kjøller', 'Affiliation': 'The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Department of Cardiology, S, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Sajadieh', 'Affiliation': 'Department of Cardiology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Kastrup', 'Affiliation': 'Department of Cardiology, Rigshospitalet University of Copenhagen, Denmark.'}, {'ForeName': 'Hans Jørn', 'Initials': 'HJ', 'LastName': 'Kolmos', 'Affiliation': 'Department of Clinical Microbiology, Odense University Hospital, Denmark.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Larsson', 'Affiliation': 'Department of Medical Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Ärnlöv', 'Affiliation': 'Department of Neurobiology, Care Sciences and Society/Division of Family Medicine, Karolinska Institute, Stockholm, Sweden; Department of Health and Social Sciences, Dalarna University, Falun, Sweden.'}, {'ForeName': 'Janus Christian', 'Initials': 'JC', 'LastName': 'Jakobsen', 'Affiliation': 'The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Department of Cardiology, Holbæk Hospital, Holbæk, Denmark; Department of Regional Health Research, The Faculty of Health Sciences, University of Southern, Denmark.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Gluud', 'Affiliation': 'The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.'}]",Atherosclerosis,['10.1016/j.atherosclerosis.2020.03.030'] 124,32251766,Temperament profiles are associated with dietary behavior from childhood to adulthood.,"BACKGROUND AND OBJECTIVES Temperament may be associated with eating behaviors over the lifespan. This study examined the association of toddlerhood temperament with dietary behavior and dietary intervention outcomes across 18 years. METHODS The study comprised 660 children (52% boys) from The Special Turku Intervention Project (STRIP), which is a longitudinal randomized controlled trial from the age of 7 months until the age of 20 years (1990-2010). Temperament was assessed using Carey temperament scales when the participants were 2 years of age. Latent profile analysis yielded three temperament groups, which were called negative/low regulation (19% of the children), neutral/average regulation (52%) and positive/high regulation (28%). Dietary behavior was examined from 2 to 20 years of age using food records, which were converted into a diet score (mean = 15.7, SD 4.6). Mixed random-intercept growth curve analysis was the main analytic method. RESULTS Dietary behavior showed a significant quadratic U-shaped curve over time (B for quadratic association = 0.39, P<.001; B for linear association = 0.09, P = 0.58). Children in the negative/low regulation temperament group had a lower diet score (less healthy diet) across the 18 years compared to children in the neutral/average or in the positive/high regulation group. Temperament was not associated with the rate of change in diet over time. Temperament did not have any interactive effects with the intervention (F [2, 627], P = 0.72). CONCLUSION Children with a temperament profile characterized by high negative mood, high irregularity and high intensity in emotion expression constitute a risk group for less healthy eating over the lifespan.",2020,"Temperament did not have any interactive effects with the intervention (F [2, 627], P = 0.72). ","['18 years', '660 children (52% boys) from The Special Turku Intervention Project (STRIP), which is a longitudinal randomized controlled trial from the age of 7 months until the age of 20 years (1990-2010']",[],"['lower diet score', 'Carey temperament scales', 'Dietary behavior']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517845', 'cui_str': '660'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0282440', 'cui_str': 'Randomized Controlled Trials as Topic'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",[],"[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0039474', 'cui_str': 'Temperament'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",660.0,0.0437514,"Temperament did not have any interactive effects with the intervention (F [2, 627], P = 0.72). ","[{'ForeName': 'Jari', 'Initials': 'J', 'LastName': 'Lipsanen', 'Affiliation': 'Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Finland.'}, {'ForeName': 'Marko', 'Initials': 'M', 'LastName': 'Elovainio', 'Affiliation': 'Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Finland; National Institute for Health and Welfare, Finland.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Hakulinen', 'Affiliation': 'Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Finland.'}, {'ForeName': 'Mark S', 'Initials': 'MS', 'LastName': 'Tremblay', 'Affiliation': 'Healthy Active Living and Obesity Research Group, CHEO Research Institute, Ottawa, Canada.'}, {'ForeName': 'Suvi', 'Initials': 'S', 'LastName': 'Rovio', 'Affiliation': 'Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Finland.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Lagström', 'Affiliation': 'Department of Public Health, University of Turku, Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Johanna M', 'Initials': 'JM', 'LastName': 'Jaakkola', 'Affiliation': 'Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Finland.'}, {'ForeName': 'Antti', 'Initials': 'A', 'LastName': 'Jula', 'Affiliation': 'National Institute for Health and Welfare, Finland.'}, {'ForeName': 'Tapani', 'Initials': 'T', 'LastName': 'Rönnemaa', 'Affiliation': 'Department of Medicine, University of Turku and Division of Medicine, Turku University Hospital, Finland.'}, {'ForeName': 'Jorma', 'Initials': 'J', 'LastName': 'Viikari', 'Affiliation': 'Department of Medicine, University of Turku and Division of Medicine, Turku University Hospital, Finland.'}, {'ForeName': 'Harri', 'Initials': 'H', 'LastName': 'Niinikoski', 'Affiliation': 'Institute of Biomedicine, University of Turku, Department of Pediatrics and AdolescentMedicine, Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Olli', 'Initials': 'O', 'LastName': 'Simell', 'Affiliation': 'Department of Medicine, University of Turku and Division of Medicine, Turku University Hospital, Finland.'}, {'ForeName': 'Olli T', 'Initials': 'OT', 'LastName': 'Raitakari', 'Affiliation': 'Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Finland; Centre for Population Health Research, University of Turku and Turku University Hospital, Finland; Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Finland.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Pahkala', 'Affiliation': 'Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Finland; Paavo Nurmi Centre, Sports & Exercise Medicine Unit, Department of Health and Physical Activity, University of Turku, Finland.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Pulkki-Råback', 'Affiliation': 'Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Finland; Research Centre for Child Psychiatry, Faculty of Medicine, University of Turku, Finland. Electronic address: laura.pulkki-raback@helsinki.fi.'}]",Appetite,['10.1016/j.appet.2020.104681'] 125,30896452,Sympathectomy versus conventional treatment for refractory coronary artery spasm.,"BACKGROUND There is no clear consensus on the potential efficacy and indications for sympathectomy to prevent recurrence of vasospasm in patients with refractory coronary artery spasm (CAS). OBJECTIVE To compare the clinical outcomes of sympathectomy with those of conventional treatment in patients with refractory CAS. PATIENTS AND METHODS Patients with refractory CAS were randomly assigned to sympathectomy group (n = 37) or conventional treatment group (n = 42). The primary end point was a composite of major adverse cardiac event (MACE) episodes (including cardiac death, nonfatal myocardial infarction, unstable angina, heart failure, and life-threatening arrhythmia), and the secondary end point was death from any cause within 24 months after randomization. RESULTS During the follow-up period of 24 months, the incidence of MACE in the sympathectomy and conventional treatment groups was 16.22 and 61.90%, respectively (P = 0.0001). All-cause death as the secondary end point occurred in zero and six (14.29%) patients, respectively (P = 0.0272). The Kaplan-Meier curve for MACE and all-cause death showed a significant between-group difference (log-rank test, P = 0.0013 and 0.0176, respectively). CONCLUSION Compared with conventional treatment, sympathectomy significantly reduced the composite end point of MACE episodes and death from any cause in patients with refractory CAS by effectively preventing recurrence of vasospasm.",2019,"Compared with conventional treatment, sympathectomy significantly reduced the composite end point of MACE episodes and death from any cause in patients with refractory CAS by effectively preventing recurrence of vasospasm.","['Patients with refractory CAS', 'refractory coronary artery spasm', 'patients with refractory CAS', 'patients with refractory coronary artery spasm (CAS']","['Sympathectomy versus conventional treatment', 'sympathectomy', 'conventional treatment']","['recurrence of vasospasm', 'composite of major adverse cardiac event (MACE) episodes (including cardiac death, nonfatal myocardial infarction, unstable angina, heart failure, and life-threatening arrhythmia), and the secondary end point was death', 'incidence of MACE']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0010073', 'cui_str': 'Coronary Artery Vasospasm'}]","[{'cui': 'C0039038', 'cui_str': 'Sympathetic Denervation'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0085616', 'cui_str': 'Vasospasm (finding)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0376297', 'cui_str': 'Cardiac Death'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0002965', 'cui_str': 'Angina at Rest'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0003811', 'cui_str': 'Arrhythmia'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0349381', 'cui_str': 'Mace (substance)'}]",,0.0455716,"Compared with conventional treatment, sympathectomy significantly reduced the composite end point of MACE episodes and death from any cause in patients with refractory CAS by effectively preventing recurrence of vasospasm.","[{'ForeName': 'Yaowang', 'Initials': 'Y', 'LastName': 'Lin', 'Affiliation': ""Department of Cardiology, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, First Affiliated Hospital of South University of Science and Technology, Shenzhen.""}, {'ForeName': 'Huadong', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': ""Department of Cardiology, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, First Affiliated Hospital of South University of Science and Technology, Shenzhen.""}, {'ForeName': 'Danqing', 'Initials': 'D', 'LastName': 'Yu', 'Affiliation': ""Department of Cardiology, Guangdong General Hospital, Guangdong Academy of Sciences, Guangzhou, People's Republic of China.""}, {'ForeName': 'Meishan', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': ""Department of Cardiology, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, First Affiliated Hospital of South University of Science and Technology, Shenzhen.""}, {'ForeName': 'Qiyun', 'Initials': 'Q', 'LastName': 'Liu', 'Affiliation': ""Department of Cardiology, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, First Affiliated Hospital of South University of Science and Technology, Shenzhen.""}, {'ForeName': 'Xinjian', 'Initials': 'X', 'LastName': 'Liang', 'Affiliation': ""Department of Cardiology, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, First Affiliated Hospital of South University of Science and Technology, Shenzhen.""}, {'ForeName': 'Xinli', 'Initials': 'X', 'LastName': 'Pang', 'Affiliation': ""Department of Cardiology, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, First Affiliated Hospital of South University of Science and Technology, Shenzhen.""}, {'ForeName': 'Keqi', 'Initials': 'K', 'LastName': 'Chen', 'Affiliation': ""Department of Cardiology, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, First Affiliated Hospital of South University of Science and Technology, Shenzhen.""}, {'ForeName': 'Linjie', 'Initials': 'L', 'LastName': 'Luo', 'Affiliation': ""Department of Cardiology, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, First Affiliated Hospital of South University of Science and Technology, Shenzhen.""}, {'ForeName': 'Shaohong', 'Initials': 'S', 'LastName': 'Dong', 'Affiliation': ''}]",Coronary artery disease,['10.1097/MCA.0000000000000732'] 126,31713297,Oral versus topical tamoxifen in cyclical mastalgia-A randomized controlled trial.,"Mastalgia affects premenopausal in which cyclical mastalgia affects up to 40% of women. In approximately 8% of these women, pain will be severe and interfere with their normal activities. oral tamoxifen widely used in the treatment of mastalgia is associated with a wide range of side effects. Topical tamoxifen has the potential to be a more efficacious and safer alternative with lower blood drug levels hence having lower systemic side effects. To compare reduction in the pain, nodularity and blood drug levels of tamoxifen using topical verus oral tamoxifen in cyclical mastalgia. Patients who presented to the surgery outpatient department with complaints of breast pain were provided with a breast pain evaluation questionnaire. Patients were randomized using a computer generated sequence into two groups with 75 participants in each group. In Group 1, the participants received topical tamoxifen gel and a placebo tablet for 3 months, and in Group 2, the participants received Oral Tab Tamoxifen 10 mg OD and a placebo gel for 3 months. They were provided with a Cardiff Breast Pain assessment chart and asked to mark the severity of their pain and response to treatment in the following month and asked to report to the investigator. Patients were called for review every month, and the pain chart was monitored and documented. The response to therapy (relief of pain) was assessed after 3 months of treatment and once more at the end of 6 months for recurrence. After completion of 1 month of treatment, blood sample was drawn to check for the blood drug levels. There is a significant difference of mean pain score between oral and topical tamoxifen groups (P < .001) at the end of 1 month, 3 months (P < .001), and 6 months (P < .001). There is a significant difference in the Nodularity found between oral and topical groups at presentation (P = .004), at 1 month (P = .003) and at 6 months (P < .001). There is a significant difference of mean blood tamoxifen level (ng/mL) in oral and topical tamoxifen groups (P < .001). From this study, we conclude that topical tamoxifen is more effective than oral tamoxifen treatment in reducing cyclical breast pain and decreasing breast nodularity with lesser side effects and lower recurrence rates.",2020,Topical tamoxifen has the potential to be a more efficacious and safer alternative with lower blood drug levels hence having lower systemic side effects.,"['cyclical mastalgia', 'Patients who presented to the surgery outpatient department with complaints of breast pain']","['Topical tamoxifen', 'tamoxifen using topical verus oral tamoxifen', 'oral tamoxifen', 'Oral Tab Tamoxifen 10\xa0mg OD and a placebo gel', 'topical tamoxifen', 'topical tamoxifen gel and a placebo', 'tamoxifen']","['response to therapy (relief of pain', 'pain, nodularity and blood drug levels', 'cyclical breast pain', 'mean blood tamoxifen level', 'mean pain score']","[{'cui': 'C0405472', 'cui_str': 'Cyclical mastalgia (finding)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0277786', 'cui_str': 'Presenting complaint'}, {'cui': 'C0024902', 'cui_str': 'Mammalgia'}]","[{'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0039286', 'cui_str': 'Tamoxifen'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1596572', 'cui_str': 'Tamoxifen 10 MG [Nolvadex]'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1301676', 'cui_str': 'Relieves (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449579', 'cui_str': 'Nodularity (attribute)'}, {'cui': 'C1287340', 'cui_str': 'Blood drug levels - finding'}, {'cui': 'C0439596', 'cui_str': 'Cyclic (qualifier value)'}, {'cui': 'C0024902', 'cui_str': 'Mammalgia'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0005768'}, {'cui': 'C0039286', 'cui_str': 'Tamoxifen'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}]",75.0,0.202149,Topical tamoxifen has the potential to be a more efficacious and safer alternative with lower blood drug levels hence having lower systemic side effects.,"[{'ForeName': 'Divya Dhananjay', 'Initials': 'DD', 'LastName': 'Singh', 'Affiliation': 'Department of General Surgery, Jawaharlal Institute of Post Graduate Medical Education & Research, Pondicherry, India.'}, {'ForeName': 'Kadambari', 'Initials': 'K', 'LastName': 'Dharanipragada', 'Affiliation': 'Department of General Surgery, Jawaharlal Institute of Post Graduate Medical Education & Research, Pondicherry, India.'}, {'ForeName': 'Shanmugam', 'Initials': 'S', 'LastName': 'D', 'Affiliation': 'Department of General Surgery, Jawaharlal Institute of Post Graduate Medical Education & Research, Pondicherry, India.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Manikandan', 'Affiliation': 'Department of Pharmacology, JIPMER, Pondicherry, India.'}]",The breast journal,['10.1111/tbj.13674'] 127,32333847,"Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study.","BACKGROUND Raxibacumab is a monoclonal antibody against protective antigen, which is the cell-binding part of Bacillus anthracis toxin, and is approved for treatment and postexposure prophylaxis of inhalational anthrax. Anthrax Vaccine Adsorbed (AVA), for anthrax prophylaxis, consists primarily of adsorbed protective antigen. We did a postapproval study to assess the effect of raxibacumab on immunogenicity of AVA. METHODS We did an open-label, parallel-group, randomised non-inferiority study at three centres in the USA. We enrolled healthy volunteers (aged 18-65 years) with no evidence of exposure to protective antigen. Participants were randomly allocated (1:1) according to a pregenerated balanced independent randomisation schedule to either subcutaneous 0·5 mL AVA on days 1, 15, and 29 or raxibacumab intravenous infusion (40 mg/kg) immediately before AVA on day 1, followed by AVA only on days 15 and 29. It was an open-label study to investigators and participants; however, the sponsor remained blinded during the study. The primary outcome was the ratio of geometric mean concentrations (GMCs) of anti-protective antigen antibodies (attributable to the immune response to AVA) between AVA and AVA plus raxibacumab 4 weeks after the first AVA dose in the per-protocol population. The per-protocol population comprised all individuals who received the allocated treatment within the protocol-specified visit window and completed the primary study outcome assessment, without a protocol deviation requiring exclusion. The non-inferiority margin for the ratio of GMCs was predefined (upper limit of 90% CI <1·5). This trial is registered with ClinicalTrials.gov, NCT02339155. FINDINGS Between Feb 24, 2015, and June 6, 2017, 873 participants were screened for eligibility, of whom 300 were excluded. 573 were randomly allocated either AVA (n=287) or AVA plus raxibacumab (n=286). The per-protocol population comprised 276 individuals assigned AVA and 269 allocated AVA plus raxibacumab. At week 4, the GMC of anti-protective antigen antibodies in participants allocated AVA was 26·5 μg/mL (95% CI 23·6-29·8) compared with 22·5 μg/mL (20·1-25·1) among individuals allocated AVA plus raxibacumab. The ratio between groups was 1·18 (90% CI 1·03-1·35; p=0·0019), which met the predefined non-inferiority margin. Adverse events in the safety population were similar across groups (87 [30%] of 286 in the AVA group vs 80 [29%] of 280 in the AVA plus raxibacumab group) and no treatment-related serious adverse events were reported. INTERPRETATION Co-administration of raxibacumab with AVA does not negatively affect AVA immunogenicity. This finding suggests that combining raxibacumab with AVA might provide added benefit in postexposure prophylaxis against inhalational anthrax. FUNDING US Biomedical Advanced Research and Development Authority, and GlaxoSmithKline.",2020,"Adverse events in the safety population were similar across groups (87 [30%] of 286 in the AVA group vs 80 [29%] of 280 in the AVA plus raxibacumab group) and no treatment-related serious adverse events were reported. ","['enrolled healthy volunteers (aged 18-65 years) with no evidence of exposure to protective antigen', '276 individuals assigned AVA and 269 allocated', '873 participants were screened for eligibility, of whom 300 were excluded', 'Between Feb 24, 2015, and June 6, 2017']","['AVA', 'AVA plus raxibacumab', 'raxibacumab intravenous infusion', 'Anthrax Vaccine Adsorbed (AVA', 'raxibacumab with AVA', 'subcutaneous 0·5 mL AVA', 'raxibacumab']","['AVA immunogenicity', 'ratio of geometric mean concentrations (GMCs) of anti-protective antigen antibodies', 'serious adverse events', 'Adverse events']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332125', 'cui_str': 'No evidence of'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C1443846', 'cui_str': 'Anthrax toxin protective antigen'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0358297', 'cui_str': 'Anthrax vaccine'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}]","[{'cui': 'C0358297', 'cui_str': 'Anthrax vaccine'}, {'cui': 'C1329979', 'cui_str': 'Anthrax Vaccine Adsorbed'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2717174', 'cui_str': 'raxibacumab'}, {'cui': 'C0021440', 'cui_str': 'Intravenous infusion'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}]","[{'cui': 'C1329979', 'cui_str': 'Anthrax Vaccine Adsorbed'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1443846', 'cui_str': 'Anthrax toxin protective antigen'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",873.0,0.343685,"Adverse events in the safety population were similar across groups (87 [30%] of 286 in the AVA group vs 80 [29%] of 280 in the AVA plus raxibacumab group) and no treatment-related serious adverse events were reported. ","[{'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Skoura', 'Affiliation': 'GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Wang-Jairaj', 'Affiliation': 'GlaxoSmithKline, Uxbridge, UK.'}, {'ForeName': 'Oscar', 'Initials': 'O', 'LastName': 'Della Pasqua', 'Affiliation': 'GlaxoSmithKline, Uxbridge, UK.'}, {'ForeName': 'Vijayalakshmi', 'Initials': 'V', 'LastName': 'Chandrasekaran', 'Affiliation': 'GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Billiard', 'Affiliation': 'GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Yeakey', 'Affiliation': 'GlaxoSmithKline, Rockville, MD, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Smith', 'Affiliation': 'Alliance for Multispecialty Research at University of Tennessee Medical Center, Knoxville, TN, USA; New Orleans Center for Clinical Research, New Orleans, LA, USA.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Steel', 'Affiliation': 'GlaxoSmithKline, Uxbridge, UK.'}, {'ForeName': 'Lionel K', 'Initials': 'LK', 'LastName': 'Tan', 'Affiliation': 'GlaxoSmithKline, Uxbridge, UK. Electronic address: lionel.x.tan@gsk.com.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(20)30069-4'] 128,32380138,Reduced tactile acuity in chronic low back pain is linked with structural neuroplasticity in primary somatosensory cortex and is modulated by acupuncture therapy.,"Prior studies have shown that patients suffering from chronic Low Back Pain (cLBP) have impaired somatosensory processing including reduced tactile acuity, i.e. reduced ability to resolve fine spatial details with the perception of touch. The central mechanism(s) underlying reduced tactile acuity are unknown but may include changes in specific brain circuitries (e.g. neuroplasticity in the primary somatosensory cortex, S1). Furthermore, little is known about the linkage between changes in tactile acuity and the amelioration of cLBP by somatically-directed therapeutic interventions, such as acupuncture. In this longitudinal neuroimaging study, we evaluated healthy control adults (HC, N ​= ​50) and a large sample of cLBP patients (N ​= ​102) with structural brain imaging (T1-weighted MRI for Voxel-Based Morphometry, VBM; Diffusion Tensor Imaging, DTI) and tactile acuity testing using two-point discrimination threshold (2PDT) over the lower back (site of pain) and finger (control) locations. Patients were evaluated at baseline and following a 4-week course of acupuncture, with patients randomized to either verum acupuncture, two different forms of sham acupuncture (designed with or without somatosensory afference), or no-intervention usual care control. At baseline, cLBP patients demonstrated reduced acuity (greater 2PDT, P ​= ​0.01) over the low back, but not finger (P ​= ​0.29) locations compared to HC, suggesting that chronic pain affects tactile acuity specifically at body regions encoding the experience of clinical pain. At baseline, Gray Matter Volume (GMV) was elevated and Fractional Anisotropy (FA) was reduced, respectively, in the S1-back region of cLBP patients compared to controls (P ​< ​0.05). GMV in cLBP correlated with greater 2PDT-back scores (ρ ​= ​0.27, P ​= ​0.02). Following verum acupuncture, tactile acuity over the back was improved (reduced 2PDT) and greater improvements were associated with reduced S1-back GMV (ρ ​= ​0.52, P ​= ​0.03) and increased S1-back adjacent white matter FA (ρ ​= ​-0.56, P ​= ​0.01). These associations were not seen for non-verum control interventions. Thus, S1 neuroplasticity in cLBP is linked with deficits in tactile acuity and, following acupuncture therapy, may represent early mechanistic changes in somatosensory processing that track with improved tactile acuity.",2020,"At baseline, Gray Matter Volume (GMV) was elevated and Fractional Anisotropy (FA) was reduced, respectively, in the S1-back region of cLBP patients compared to controls (P<0.05).","['patients suffering from chronic Low Back Pain (cLBP', 'healthy control adults (HC, N=50) and a large sample of cLBP patients (N=102) with']","['acupuncture', 'structural brain imaging (T1-weighted MRI for Voxel Based Morphometry, VBM; Diffusion Tensor Imaging, DTI) and tactile acuity testing using two-point discrimination threshold (2PDT', 'verum acupuncture', 'sham acupuncture (designed with or without somatosensory afference), or no-intervention usual care control']","['tactile acuity', 'S1-back adjacent white matter FA', '2PDT-back scores', 'Fractional Anisotropy (FA', 'tactile acuity over the back was improved (reduced 2PDT', 'reduced S1-back GMV', 'reduced acuity', 'Gray Matter Volume (GMV']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0203860', 'cui_str': 'Imaging of brain'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C4523852', 'cui_str': 'Voxel-based morphometry'}, {'cui': 'C0078140', 'cui_str': 'VBM protocol'}, {'cui': 'C1537007', 'cui_str': 'Diffusion Tensor MRI'}, {'cui': 'C0439815', 'cui_str': 'Tactile'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0012632', 'cui_str': 'Cognitive discrimination'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439815', 'cui_str': 'Tactile'}, {'cui': 'C0205117', 'cui_str': 'Juxta-posed'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0085406', 'cui_str': 'Anisotropy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",102.0,0.102659,"At baseline, Gray Matter Volume (GMV) was elevated and Fractional Anisotropy (FA) was reduced, respectively, in the S1-back region of cLBP patients compared to controls (P<0.05).","[{'ForeName': 'Hyungjun', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA; Division of Clinical Medicine, Korea Institute of Oriental Medicine, Daejeon, 34054, South Korea.'}, {'ForeName': 'Ishtiaq', 'Initials': 'I', 'LastName': 'Mawla', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Jeungchan', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Gerber', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Walker', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Jieun', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA; Division of Clinical Medicine, Korea Institute of Oriental Medicine, Daejeon, 34054, South Korea.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Ortiz', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Suk-Tak', 'Initials': 'ST', 'LastName': 'Chan', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Marco L', 'Initials': 'ML', 'LastName': 'Loggia', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Ajay D', 'Initials': 'AD', 'LastName': 'Wasan', 'Affiliation': 'Department of Anesthesiology, Center for Pain Research, University of Pittsburgh, Pittsburgh, PA, 15261, USA.'}, {'ForeName': 'Robert R', 'Initials': 'RR', 'LastName': 'Edwards', 'Affiliation': ""Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.""}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Kong', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA; Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02215, USA.'}, {'ForeName': 'Ted J', 'Initials': 'TJ', 'LastName': 'Kaptchuk', 'Affiliation': 'Program in Placebo Studies & Therapeutic Encounter (PiPS), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.'}, {'ForeName': 'Randy L', 'Initials': 'RL', 'LastName': 'Gollub', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA; Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02215, USA.'}, {'ForeName': 'Bruce R', 'Initials': 'BR', 'LastName': 'Rosen', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Vitaly', 'Initials': 'V', 'LastName': 'Napadow', 'Affiliation': ""Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA; Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. Electronic address: vitaly@mgh.harvard.edu.""}]",NeuroImage,['10.1016/j.neuroimage.2020.116899'] 129,32384056,Young People's Experience of a Long-Term Social Media-Based Intervention for First-Episode Psychosis: Qualitative Analysis.,"BACKGROUND Digital mental health interventions present a unique opportunity to address the lack of social connection and loneliness experienced by young people with first-episode psychosis (FEP). The first generation of digital interventions, however, is associated with high attrition rates. Social media presents an opportunity to target this issue. A new generation of digital intervention has harnessed the popularity of social media to both promote engagement and foster social connectedness in youth mental health interventions. Despite their potential, little is known about how young people engage with, and experience, social media-based interventions as well as the optimal design, implementation, and management needed to ensure young people with psychosis receive benefit. OBJECTIVE This study aimed to explore how young people engage with, and experience, a long-term social media-based mental health intervention designed to address social functioning in individuals with FEP. METHODS This qualitative study was based on 12 interviews with young people who used Horyzons, a long-term social media-based mental health intervention, as part of a previous randomized controlled trial. A semistructured phenomenological interview guide with open-ended questions was used to explore young people's subjective experience of the intervention. All interviews were recorded and transcribed verbatim. Data were analyzed using interpretative phenomenological analysis. RESULTS A total of 4 superordinate themes emerged during the analysis including (1) shared experience as the catalyst for a cocreated social space, (2) the power of peer support, (3) an upbeat environment, and (4) experiences that interrupt being in Horyzons. CONCLUSIONS We found that Horyzon's therapeutic social network fostered a connection and an understanding among young people. It also aided in the creation of an embodied experience that afforded young people with FEP a sense of self-recognition and belonging over the long term. However, although we found that most young people had strong positive experiences of a social connection on Horyzons, we also found that they experienced significant barriers that could substantively interrupt their ability to use the platform. We found that social anxiety, paranoia, internalized stigma, lack of autonomy, and social protocol confusion interfered with young people's usage of the platform. From a design perspective, digital interventions are flexible and thus equipped to begin addressing these implications by providing customizable and personalized treatment options that account for varying levels of social connection and psychological need that could otherwise interrupt young people's usage of social media-based interventions.",2020,It also aided in the creation of an embodied experience that afforded young people with FEP a sense of self-recognition and belonging over the long term.,"['young people', 'young people engage with, and experience, a long-term social media-based mental health intervention designed to address social functioning in individuals with', 'young people with first-episode psychosis (FEP', '12 interviews with young people who used Horyzons, a long-term social media-based mental health intervention, as part of a previous randomized controlled trial']",['digital intervention'],"['social anxiety, paranoia, internalized stigma, lack of autonomy, and social protocol confusion']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C3179065', 'cui_str': 'Social Medium'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0439615', 'cui_str': 'First episode'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C1456784', 'cui_str': 'Paranoid disorder'}, {'cui': 'C0277787', 'cui_str': 'Stigma'}, {'cui': 'C0332268', 'cui_str': 'Lacking'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0009676', 'cui_str': 'Confusional state'}]",12.0,0.0185373,It also aided in the creation of an embodied experience that afforded young people with FEP a sense of self-recognition and belonging over the long term.,"[{'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'Valentine', 'Affiliation': 'Orygen, Parkville, Australia.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'McEnery', 'Affiliation': 'Orygen, Parkville, Australia.'}, {'ForeName': 'Shaunagh', 'Initials': 'S', 'LastName': ""O'Sullivan"", 'Affiliation': 'Orygen, Parkville, Australia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Gleeson', 'Affiliation': 'School of Behavioural and Health Sciences, Australian Catholic University, Melbourne, Australia.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Bendall', 'Affiliation': 'Orygen, Parkville, Australia.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Alvarez-Jimenez', 'Affiliation': 'Orygen, Parkville, Australia.'}]",Journal of medical Internet research,['10.2196/17570'] 130,32386082,Long-term mortality in the Intermediate care after emergency abdominal surgery (InCare) trial-A post-hoc follow-up study.,"BACKGROUND Patients undergoing emergency abdominal surgery are at high risk of post-operative complications. Although post-operative treatment at an intermediate care unit may improve early outcome, there is a lack of studies on the long-term effects of such therapy. The aim of this study was to assess the long-term effect of intermediate care versus standard surgical ward care on mortality in the Intermediate Care After Emergency Abdominal Surgery (InCare) trial. METHODS We included adult patients undergoing emergency major laparoscopy or laparotomy with an Acute Physiology and Chronic Health Evaluation (APACHE) II score of 10 or more, who participated in the InCare trial from October 2010 to November 2012. In the InCare trial, patients were randomized to either post-operative intermediate care or standard surgical ward care. The primary outcome was time to death within 6 years after surgery. We assessed mortality with Coxregression analysis. RESULTS A total of 286 patients were included. The all-cause 6-year landmark mortality was 52.8% (76 of 144 patients) in the intermediate care group and 47.9% (68 of 142 patients) in the ward care group. There was no statistically significant difference in mortality risk between the two groups (hazard ratio 1.06 (95% confidence interval 0.76-1.47), P = .73). CONCLUSION We found no statistically significant difference in 6-year mortality between patients randomized to post-operative intermediate care or ward care after emergency abdominal surgery. However, we detected an absolute mortality risk reduction of 5% in favour of ward care, possibly due to random error.",2020,We found no statistically significant difference in six-year mortality between patients randomised to postoperative intermediate care or ward care afteremergency abdominal surgery.,"['A total of 286 patients were included', 'Patients undergoing emergency abdominal surgeryare at high risk of postoperative complications', 'After Emergency Abdominal Surgery (InCare) trial', 'adult patients undergoingemergency major laparoscopy or laparotomy with an Acute Physiology and Chronic Health Evaluation (APACHE) II score of 10 or more, who participated in the InCare trial from October 2010 to November 2012']","['postoperative intermediate care or standard surgical ward care', 'intermediate care versus standard surgical ward care']","['six-year mortality', 'cause six-year landmark mortality', 'mortality risk', 'time to death within six years after surgery']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0001758', 'cui_str': 'Aftercare'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0023038', 'cui_str': 'Laparotomy'}, {'cui': 'C0243030', 'cui_str': 'Acute physiology and chronic health evaluation'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C1305702', 'cui_str': 'Ward'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]",286.0,0.118646,We found no statistically significant difference in six-year mortality between patients randomised to postoperative intermediate care or ward care afteremergency abdominal surgery.,"[{'ForeName': 'Anna K', 'Initials': 'AK', 'LastName': 'Hansted', 'Affiliation': 'Herlev Anaesthesia Critical and Emergency Care Science Unit (ACES), Department of Anaesthesiology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.'}, {'ForeName': 'Morten H', 'Initials': 'MH', 'LastName': 'Møller', 'Affiliation': 'Department of Intensive Care 4131, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Ann M', 'Initials': 'AM', 'LastName': 'Møller', 'Affiliation': 'Herlev Anaesthesia Critical and Emergency Care Science Unit (ACES), Department of Anaesthesiology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.'}, {'ForeName': 'Jørn', 'Initials': 'J', 'LastName': 'Wetterslev', 'Affiliation': 'Copenhagen Trial Unit Dpt. 7812, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Rosenberg', 'Affiliation': 'Department of Surgery, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Lars N', 'Initials': 'LN', 'LastName': 'Jorgensen', 'Affiliation': 'Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Waldau', 'Affiliation': 'Department of Intensive Care, Herlev Hospital, University of Copenhagen, Herlev, Denmark.'}, {'ForeName': 'Morten', 'Initials': 'M', 'LastName': 'Vester-Andersen', 'Affiliation': 'Herlev Anaesthesia Critical and Emergency Care Science Unit (ACES), Department of Anaesthesiology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13613'] 131,32387055,Timing of Peak Vision Gains in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab.,"PURPOSE To investigate whether time to peak best-corrected visual acuity (BCVA) was predictive of magnitude of BCVA changes at study end in patients with neovascular age-related macular degeneration (nAMD) who received ranibizumab and assess whether patient baseline characteristics and on-study events were predictive of time to peak BCVA. DESIGN Exploratory analysis of data from HARBOR (ClinicalTrials.gov identifier, NCT00891735). PARTICIPANTS Treatment-naïve patients 50 years of age or older with subfoveal nAMD. METHODS Data by ranibizumab dose were pooled; data by dosing schedule (pro re nata [PRN] and monthly) were evaluated separately. Time to peak BCVA was the monthly evaluation at which the patient's greatest gain in Early Treatment Diabetic Retinopathy Study (ETDRS) letters from baseline was achieved. Early peakers achieved peak BCVA between day 7 and month 6; late peakers achieved peak BCVA between months 7 and 12, months 13 and 18, and months 19 and 24. Variables evaluated for effect of time to peak BCVA included baseline demographic and clinical characteristics, presence of persistent subretinal fluid (SRF) or intraretinal fluid (IRF), and on-study events (atrophy status, fibrosis, retinal pigment epithelium tears). MAIN OUTCOME MEASURES Time to peak BCVA and its predictive value for magnitude of BCVA changes and BCVA at month 24 (study end). RESULTS Most patients reached peak BCVA after more than 6 months of treatment: 64% in the PRN group (301/474) and 70% in the monthly groups (327/469). Thirty-six percent and 30% of patients, respectively, peaked early, and 64% and 70%, respectively, peaked late. At month 24, early peakers on average lost vision (PRN, -1.6 ETDRS letters; monthly, -1.9 ETDRS letters). By contrast, late peakers achieved significantly better vision gains from baseline (PRN, 8.5-17.7 ETDRS letters; monthly, 10.1-18.7 ETDRS letters). No differences were found in patient characteristics, persistent SRF or IRF, or on-study events to account for the observed different outcomes between early and late peakers. CONCLUSIONS In most treatment-naïve patients with nAMD, vision gains were achieved at a slower rate (>6 months), and a slower response was associated with better vision outcomes after 24 months of ranibizumab. These findings suggest that continued treatment may result in greater vision improvements when consistent anti-vascular endothelial growth factor therapy is maintained over a longer period.",2020,"In most treatment-naïve patients with nAMD, vision gains were achieved at a slower rate (>6 months), and a slower response was associated with better vision outcomes after 24 months of ranibizumab.","['Patients with Neovascular Age-Related Macular Degeneration Treated with', 'patients with neovascular age-related macular degeneration (nAMD) who received', 'Treatment-naïve patients 50 years of age or older with subfoveal nAMD']","['Ranibizumab', 'ranibizumab']","['baseline demographic and clinical characteristics, presence of persistent subretinal fluid (SRF) or intraretinal fluid (IRF), and on-study events (atrophy status, fibrosis, retinal pigment epithelium\xa0tears', 'time to peak best-corrected visual acuity (BCVA', 'peak BCVA', 'Time to peak BCVA and its predictive value for magnitude of BCVA changes and BCVA', 'average lost vision', 'vision outcomes', 'vision gains', 'patient characteristics, persistent SRF or IRF', 'vision improvements']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0271084', 'cui_str': 'Exudative age-related macular degeneration'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0442185', 'cui_str': 'Subfoveal'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C1720732', 'cui_str': 'Subretinal fluid'}, {'cui': 'C4531067', 'cui_str': 'Intraretinal fluid'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0026846', 'cui_str': 'Muscle atrophy'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0035322', 'cui_str': 'Structure of retinal pigment epithelium'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",,0.134321,"In most treatment-naïve patients with nAMD, vision gains were achieved at a slower rate (>6 months), and a slower response was associated with better vision outcomes after 24 months of ranibizumab.","[{'ForeName': 'Rahul N', 'Initials': 'RN', 'LastName': 'Khurana', 'Affiliation': 'Northern California Retina Vitreous Associates, Mountain View, California. Electronic address: rnkhurana@gmail.com.'}, {'ForeName': 'Louis', 'Initials': 'L', 'LastName': 'Chang', 'Affiliation': 'Northern California Retina Vitreous Associates, Mountain View, California.'}, {'ForeName': 'Bann-Mo', 'Initials': 'BM', 'LastName': 'Day', 'Affiliation': 'Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Avanti', 'Initials': 'A', 'LastName': 'Ghanekar', 'Affiliation': 'Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Ivaylo', 'Initials': 'I', 'LastName': 'Stoilov', 'Affiliation': 'Genentech, Inc., South San Francisco, California.'}]",Ophthalmology. Retina,['10.1016/j.oret.2020.02.011'] 132,32393158,Blending Traditional Vocational Services and Individualized Placement and Support for Formerly Incarcerated Veterans.,"OBJECTIVE This study compared two vocational programs: the About Face Vocational Program (AFVP), a traditional group-based vocational program created for formerly incarcerated veterans, and a hybrid program combining the AFVP with principles of individual placement and support-supported employment. METHODS The study evaluated 111 veterans with at least one felony conviction who had a mental illness, substance use disorder, or both. Veterans were randomly assigned to either vocational condition. RESULTS Veterans in the hybrid condition, compared with the AFVP alone, were more likely to find employment, had higher rates of full-time employment, and earned significantly more money over the course of the study. A comparison of only participants who found employment showed higher rates of full-time employment for veterans in the hybrid condition but similarities between the two groups in other measures of employment success. CONCLUSIONS Blended models of vocational services for veterans with mental illness, substance use disorders, or both are effective at returning formerly incarcerated veterans to competitive employment.",2020,"RESULTS Veterans in the hybrid condition, compared with the AFVP alone, were more likely to find employment, had higher rates of full-time employment, and earned significantly more money over the course of the study.","['Formerly Incarcerated Veterans', 'Veterans in the hybrid condition', '111 veterans with at least one felony conviction who had a mental illness, substance use disorder, or both', 'veterans with mental illness']","['Face Vocational Program (AFVP), a traditional group-based vocational program created for formerly incarcerated veterans, and a hybrid program combining the AFVP with principles of individual placement and support-supported employment', 'vocational condition', 'AFVP']",['rates of full-time employment'],"[{'cui': 'C0392751', 'cui_str': 'In prison'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0007597', 'cui_str': 'Cell hybridization'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0038586', 'cui_str': 'Substance use disorder'}]","[{'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0392751', 'cui_str': 'In prison'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0007597', 'cui_str': 'Cell hybridization'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C4750554', 'cui_str': 'Individual Placement and Support'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0682295', 'cui_str': 'Full-time employment'}]",111.0,0.0219773,"RESULTS Veterans in the hybrid condition, compared with the AFVP alone, were more likely to find employment, had higher rates of full-time employment, and earned significantly more money over the course of the study.","[{'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'LePage', 'Affiliation': 'U.S. Department of Veterans Affairs (VA) North Texas Health Care System, Dallas (LePage, Rock); Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas (LePage); Dallas VA Research Corporation, Dallas (Crawford, Parish Johnson, Washington); College of Nursing and Health Innovation, University of Texas at Arlington, Arlington (Cipher); Department of Psychology, Colorado State University, Fort Collins (Anderson); James A. Haley Veterans Hospital, and Department of Rehabilitation and Mental Health Counseling, University of South Florida, Tampa (Ottomanelli).'}, {'ForeName': 'April M', 'Initials': 'AM', 'LastName': 'Crawford', 'Affiliation': 'U.S. Department of Veterans Affairs (VA) North Texas Health Care System, Dallas (LePage, Rock); Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas (LePage); Dallas VA Research Corporation, Dallas (Crawford, Parish Johnson, Washington); College of Nursing and Health Innovation, University of Texas at Arlington, Arlington (Cipher); Department of Psychology, Colorado State University, Fort Collins (Anderson); James A. Haley Veterans Hospital, and Department of Rehabilitation and Mental Health Counseling, University of South Florida, Tampa (Ottomanelli).'}, {'ForeName': 'Daisha J', 'Initials': 'DJ', 'LastName': 'Cipher', 'Affiliation': 'U.S. Department of Veterans Affairs (VA) North Texas Health Care System, Dallas (LePage, Rock); Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas (LePage); Dallas VA Research Corporation, Dallas (Crawford, Parish Johnson, Washington); College of Nursing and Health Innovation, University of Texas at Arlington, Arlington (Cipher); Department of Psychology, Colorado State University, Fort Collins (Anderson); James A. Haley Veterans Hospital, and Department of Rehabilitation and Mental Health Counseling, University of South Florida, Tampa (Ottomanelli).'}, {'ForeName': 'Kemol', 'Initials': 'K', 'LastName': 'Anderson', 'Affiliation': 'U.S. Department of Veterans Affairs (VA) North Texas Health Care System, Dallas (LePage, Rock); Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas (LePage); Dallas VA Research Corporation, Dallas (Crawford, Parish Johnson, Washington); College of Nursing and Health Innovation, University of Texas at Arlington, Arlington (Cipher); Department of Psychology, Colorado State University, Fort Collins (Anderson); James A. Haley Veterans Hospital, and Department of Rehabilitation and Mental Health Counseling, University of South Florida, Tampa (Ottomanelli).'}, {'ForeName': 'Avery', 'Initials': 'A', 'LastName': 'Rock', 'Affiliation': 'U.S. Department of Veterans Affairs (VA) North Texas Health Care System, Dallas (LePage, Rock); Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas (LePage); Dallas VA Research Corporation, Dallas (Crawford, Parish Johnson, Washington); College of Nursing and Health Innovation, University of Texas at Arlington, Arlington (Cipher); Department of Psychology, Colorado State University, Fort Collins (Anderson); James A. Haley Veterans Hospital, and Department of Rehabilitation and Mental Health Counseling, University of South Florida, Tampa (Ottomanelli).'}, {'ForeName': 'Julie A Parish', 'Initials': 'JAP', 'LastName': 'Johnson', 'Affiliation': 'U.S. Department of Veterans Affairs (VA) North Texas Health Care System, Dallas (LePage, Rock); Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas (LePage); Dallas VA Research Corporation, Dallas (Crawford, Parish Johnson, Washington); College of Nursing and Health Innovation, University of Texas at Arlington, Arlington (Cipher); Department of Psychology, Colorado State University, Fort Collins (Anderson); James A. Haley Veterans Hospital, and Department of Rehabilitation and Mental Health Counseling, University of South Florida, Tampa (Ottomanelli).'}, {'ForeName': 'Edward L', 'Initials': 'EL', 'LastName': 'Washington', 'Affiliation': 'U.S. Department of Veterans Affairs (VA) North Texas Health Care System, Dallas (LePage, Rock); Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas (LePage); Dallas VA Research Corporation, Dallas (Crawford, Parish Johnson, Washington); College of Nursing and Health Innovation, University of Texas at Arlington, Arlington (Cipher); Department of Psychology, Colorado State University, Fort Collins (Anderson); James A. Haley Veterans Hospital, and Department of Rehabilitation and Mental Health Counseling, University of South Florida, Tampa (Ottomanelli).'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Ottomanelli', 'Affiliation': 'U.S. Department of Veterans Affairs (VA) North Texas Health Care System, Dallas (LePage, Rock); Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas (LePage); Dallas VA Research Corporation, Dallas (Crawford, Parish Johnson, Washington); College of Nursing and Health Innovation, University of Texas at Arlington, Arlington (Cipher); Department of Psychology, Colorado State University, Fort Collins (Anderson); James A. Haley Veterans Hospital, and Department of Rehabilitation and Mental Health Counseling, University of South Florida, Tampa (Ottomanelli).'}]","Psychiatric services (Washington, D.C.)",['10.1176/appi.ps.201900421'] 133,32394049,A Large-Scale Replication of the Effectiveness of the KiVa Antibullying Program: a Randomized Controlled Trial in the Netherlands.,"This study evaluates the effectiveness of the KiVa antibullying program in the Netherlands through a randomized controlled trial of students in grades 3-4 (Dutch grades 5-6). The sample involved 98 schools who volunteered to participate in the research, with 245 classes and 4383 students at the baseline (49% girls; M age = 8.7 years), who participated in five measurement waves, collected in three consecutive school years. After the baseline, two-thirds of the schools were assigned to the intervention condition (KiVa or KiVa+, the latter included an additional intervention component of network feedback to teachers) and one-third to the control condition (waiting list, care as usual) with a stratified randomization procedure. The effects of the intervention on self-reported victimization and bullying were tested using cross-classified ordered multinomial models and binomial logistic regression models. These longitudinal models showed that self-reported victimization and bullying reduced more strongly in KiVa-schools compared with control schools, with stronger effects after two school years than after one school year of implementation. The results showed that for students in control schools, the odds of being a victim were 1.29-1.63 higher, and the odds of being a bully were 1.19-1.66 higher than for KiVa students. No significant differences between KiVa and KiVa+ emerged. Overall, the findings provide evidence of the effectiveness of the KiVa program in the Netherlands.",2020,"These longitudinal models showed that self-reported victimization and bullying reduced more strongly in KiVa-schools compared with control schools, with stronger effects after two school years than after one school year of implementation.","['students in grades 3-4 (Dutch grades 5-6', '98 schools who volunteered to participate in the research, with 245 classes and 4383 students at the baseline (49% girls; M age\u2009=\u20098.7\xa0years), who participated in five measurement waves, collected in three consecutive school years']","['KiVa Antibullying Program', 'intervention condition (KiVa or KiVa+, the latter included an additional intervention component of network feedback to teachers) and one-third to the control condition (waiting list, care as usual) with a stratified randomization procedure', 'KiVa antibullying program']",['odds of being a victim'],"[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C1705232', 'cui_str': 'Common terminology criteria for adverse events grade 5'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C4517661', 'cui_str': '245'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517880', 'cui_str': '8.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C1278569', 'cui_str': 'WAS A'}]",98.0,0.0250472,"These longitudinal models showed that self-reported victimization and bullying reduced more strongly in KiVa-schools compared with control schools, with stronger effects after two school years than after one school year of implementation.","[{'ForeName': 'Gijs', 'Initials': 'G', 'LastName': 'Huitsing', 'Affiliation': 'Department of Sociology, University of Groningen, and Interuniversity Center for Social Science Theory and Methodology (ICS), Groningen, The Netherlands. g.e.huitsing@rug.nl.'}, {'ForeName': 'Gerine M A', 'Initials': 'GMA', 'LastName': 'Lodder', 'Affiliation': 'Department of Sociology, University of Groningen, and Interuniversity Center for Social Science Theory and Methodology (ICS), Groningen, The Netherlands.'}, {'ForeName': 'Wiliam J', 'Initials': 'WJ', 'LastName': 'Browne', 'Affiliation': 'School of Education, University of Bristol, Bristol, UK.'}, {'ForeName': 'Beau', 'Initials': 'B', 'LastName': 'Oldenburg', 'Affiliation': 'Department of Sociology, University of Groningen, and Interuniversity Center for Social Science Theory and Methodology (ICS), Groningen, The Netherlands.'}, {'ForeName': 'Rozemarijn', 'Initials': 'R', 'LastName': 'Van der Ploeg', 'Affiliation': 'Department of Pedagogy and Educational Science, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'René', 'Initials': 'R', 'LastName': 'Veenstra', 'Affiliation': 'Department of Sociology, University of Groningen, and Interuniversity Center for Social Science Theory and Methodology (ICS), Groningen, The Netherlands.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-020-01116-4'] 134,32336266,Study design factors influencing patients' willingness to participate in clinical research: a randomised vignette-based study.,"BACKGROUND High patient participation in clinical research reduces selection bias and ensures the generalizability of study findings. We explored study-related factors that may influence patients' willingness to participate in research. METHODS We submitted by mail two vignettes that described clinical research studies - a drug trial and a diagnostic study - to patients recently discharged from hospital and assessed their willingness to participate. We used a factorial design to randomly allocate three study attributes per vignette: in the drug trial, presumed superiority of new drug versus equipoise, public versus industry funding, and random versus non-random treatment allocation; in the diagnostic study, common versus rare disease, genetic versus protein analysis, and automatic reporting of results versus reporting on request. RESULTS Of 2600 patients contacted, 1140 (44%) participated. Globally, willingness to participate in a drug trial was lower than in a diagnostic study (44.8% vs. 76.2%; P < 0.001). In the drug trial, participation was significantly higher when the new drug was presented as presumably better than the old (vs. equipoise) and when the study was funded by public sources (vs. industry), but was not affected by the allocation method. None of the factors tested in the diagnostic study was associated with participation. CONCLUSIONS Patients were more likely to participate in a hypothetical observational diagnostic study than in a hypothetical drug trial. Participation in the trial was lower when clinical equipoise was expressed and when the trial was funded by industry. These results suggest that some features of study design can influence participation.",2020,"In the drug trial, participation was significantly higher when the new drug was presented as presumably better than the old (vs. equipoise) and when the study was funded by public sources (vs. industry), but was not affected by the allocation method.","[""patients' willingness to participate in clinical research"", 'We submitted by mail two vignettes that described clinical research studies - a drug trial and a diagnostic study - to patients recently discharged from hospital and assessed their willingness to participate', '2600 patients contacted, 1140 (44%) participated']",[],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205448', 'cui_str': '2'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0438953', 'cui_str': 'Discharged from hospital'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C4517539', 'cui_str': '1140'}]",[],[],,0.0869634,"In the drug trial, participation was significantly higher when the new drug was presented as presumably better than the old (vs. equipoise) and when the study was funded by public sources (vs. industry), but was not affected by the allocation method.","[{'ForeName': 'Angèle', 'Initials': 'A', 'LastName': 'Gayet-Ageron', 'Affiliation': 'Division of Clinical Epidemiology and Department of health and community medicine, Geneva University Hospitals and Faculty of Medicine, 6 Rue Gabrielle Perret-Gentil, 1211, 14, Geneva, Switzerland. angele.gayet-ageron@hcuge.ch.'}, {'ForeName': 'Sandrine', 'Initials': 'S', 'LastName': 'Rudaz', 'Affiliation': 'Division of Clinical Epidemiology and Department of health and community medicine, Geneva University Hospitals and Faculty of Medicine, 6 Rue Gabrielle Perret-Gentil, 1211, 14, Geneva, Switzerland.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Perneger', 'Affiliation': 'Division of Clinical Epidemiology and Department of health and community medicine, Geneva University Hospitals and Faculty of Medicine, 6 Rue Gabrielle Perret-Gentil, 1211, 14, Geneva, Switzerland.'}]",BMC medical research methodology,['10.1186/s12874-020-00979-z'] 135,32289325,Caloric compensation and appetite control in children of different weight status and predisposition to obesity.,"To prevent childhood obesity it is critical to identify behavioral phenotypes for overeating, especially among children who are predisposed to obesity. We examined caloric compensation and appetite control in 212 normal-weight (NW) and obese (OB) children, ages 7 to 9, who were at high risk (HR) or low risk (LR) for obesity based on maternal obesity. In a within-subjects crossover design, children ate breakfast, lunch, dinner, and snacks in the laboratory once a week for two weeks. Children's percentage compensation index (%COMPX) was computed at breakfast. Twenty-five minutes before breakfast, children received one of two compulsory preloads, which varied in energy density (ED) and caloric content [Low ED (LED): 1.00 kcal/g; 100 kcal; High ED (HED): 1.60 kcal/g; 160 kcal]. Children's appetite was measured hourly using Visual Analog Scales, which were used to compute 3-h post-prandial area under the curve (AUCs) after breakfast and the satiety quotient (SQ), which allows between-group comparisons of a fixed amount of a food's potency to reduce appetite sensations per unit of intake. There were no significant differences in %COMPX, SQ, or AUC among LR-NW, HR-NW, and HR-OB children (P > 0.10). SQs for Hunger and Prospective Consumption were higher and SQ for Fullness lower after consuming the LED compared to the HED preload (P < 0.009). Further, the SQ and AUC for Desire to Eat and AUC for Prospective Consumption significantly predicted energy intake during the remainder of the day (P < 0.03). In this study, HR-NW children did not differ from LR-NW or HR-OB children in their caloric compensation or appetite control. Foods with a high satiating effect may facilitate appetite control and help to moderate daily energy intake in all children, including at-risk children.",2020,SQs for Hunger and Prospective Consumption were higher and SQ for Fullness lower after consuming the LED compared to the HED preload (P < 0.009).,"['212 normal-weight (NW) and obese (OB) children, ages 7 to 9, who were at high risk (HR) or low risk (LR) for obesity based on maternal obesity', 'children who are predisposed to obesity', 'children of different weight status and predisposition to obesity']","['caloric content [Low ED (LED): 1.00\u202fkcal/g; 100\u202fkcal; High ED (HED', 'Caloric compensation and appetite control']","[""Children's percentage compensation index"", 'COMPX, SQ, or AUC among LR-NW, HR-NW, and HR-OB children', ""Children's appetite"", 'SQs for Hunger and Prospective Consumption', 'energy intake']","[{'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0746977', 'cui_str': 'Maternal Obesity'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0012655', 'cui_str': 'Diathesis'}]","[{'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0152057', 'cui_str': 'Compensation'}, {'cui': 'C0003622', 'cui_str': 'Appetite control'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0152057', 'cui_str': 'Compensation'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}]",212.0,0.0314051,SQs for Hunger and Prospective Consumption were higher and SQ for Fullness lower after consuming the LED compared to the HED preload (P < 0.009).,"[{'ForeName': 'Tanja V E', 'Initials': 'TVE', 'LastName': 'Kral', 'Affiliation': 'Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: tkral@nursing.upenn.edu.'}, {'ForeName': 'Reneé H', 'Initials': 'RH', 'LastName': 'Moore', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Jesse', 'Initials': 'J', 'LastName': 'Chittams', 'Affiliation': 'Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': ""O'Malley"", 'Affiliation': 'Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Jones', 'Affiliation': 'Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Ryan J', 'Initials': 'RJ', 'LastName': 'Quinn', 'Affiliation': 'Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Jennifer O', 'Initials': 'JO', 'LastName': 'Fisher', 'Affiliation': 'Department of Social and Behavioral Sciences, College of Public Health, Temple University, Philadelphia, PA, USA.'}]",Appetite,['10.1016/j.appet.2020.104701'] 136,32176666,"Training, detraining, and retraining: Two 12-week respiratory muscle training regimens in a child with infantile-onset Pompe disease.","BACKGROUND Respiratory muscle weakness is a primary cause of morbidity and mortality in patients with Pompe disease. We previously described the effects of our 12-week respiratory muscle training (RMT) regimen in 8 adults with late-onset Pompe disease [1] and 2 children with infantile-onset Pompe disease [2]. CASE REPORT Here we describe repeat enrollment by one of the pediatric participants who completed a second 12-week RMT regimen after 7 months of detraining. We investigated the effects of two 12-week RMT regimens (RMT #1, RMT #2) using a single-participant A-B-A experimental design. Primary outcome measures were maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP). Effect sizes for changes in MIP and MEP were determined using Cohen's d statistic. Exploratory outcomes targeted motor function. RELEVANCE From pretest to posttest, RMT #2 was associated with a 25% increase in MIP and a 22% increase in MEP, corresponding with very large effect sizes (d= 2.92 and d= 2.65, respectively). Following two 12-week RMT regimens over 16 months, MIP increased by 69% and MEP increased by 97%, corresponding with very large effect sizes (d= 3.57 and d= 5.10, respectively). MIP and MEP were largely stable over 7 months of detraining between regimens. Magnitude of change was greater for RMT #1 relative to RMT #2.",2020,"Following two 12-week RMT regimens over 16 months, MIP increased by 69% and MEP increased by 97%, corresponding with very large effect sizes (d= 3.57 and d= 5.10, respectively).","['patients with Pompe disease', 'pediatric participants who completed a second 12-week RMT regimen after 7 months of detraining', '8 adults with late-onset Pompe disease\xa0[1] and 2 children with infantile-onset Pompe disease\xa0[2']","['Training, detraining, and retraining: Two 12-week respiratory muscle training regimens', 'respiratory muscle training (RMT) regimen']","['MIP and MEP', 'MIP', 'MEP', 'maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0342751', 'cui_str': 'Acid Maltase Deficiency'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0342753', 'cui_str': 'Glycogen storage disease type II late onset'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C3888924', 'cui_str': 'Glycogenosis due to acid maltase deficiency, infantile onset'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0006155', 'cui_str': 'Respiratory Muscle Training'}]","[{'cui': 'C0232021', 'cui_str': 'Maximum inspiratory pressure (observable entity)'}, {'cui': 'C0232022', 'cui_str': 'Maximum expiratory pressure (observable entity)'}]",8.0,0.0314969,"Following two 12-week RMT regimens over 16 months, MIP increased by 69% and MEP increased by 97%, corresponding with very large effect sizes (d= 3.57 and d= 5.10, respectively).","[{'ForeName': 'Kelly D', 'Initials': 'KD', 'LastName': 'Crisp', 'Affiliation': 'Department of Head and Neck Surgery and Communication Sciences, Duke University, Durham, NC, USA.'}, {'ForeName': 'Laura E', 'Initials': 'LE', 'LastName': 'Case', 'Affiliation': 'Physical Therapy Division, Duke University, Durham, NC, USA.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Kravitz', 'Affiliation': 'Division of Pediatric Pulmonary and Sleep Medicine, Duke University, Durham, NC, USA.'}, {'ForeName': 'Priya S', 'Initials': 'PS', 'LastName': 'Kishnani', 'Affiliation': 'Department of Pediatrics, Division of Medical Genetics, Duke University, Durham, NC, USA.'}, {'ForeName': 'Harrison N', 'Initials': 'HN', 'LastName': 'Jones', 'Affiliation': 'Department of Head and Neck Surgery and Communication Sciences, Duke University, Durham, NC, USA.'}]",Journal of pediatric rehabilitation medicine,['10.3233/PRM-190601'] 137,32234531,Which strategies to manage problem foods were related to weight loss in a randomized clinical trial?,"Individuals managing their weight are often faced with problem foods that are difficult to resist eating. In the context of a weight-loss intervention, we characterized the most commonly reported problem foods and the behavioral strategies used to manage them, and examined which strategies were related to weight loss. Women with overweight and obesity (N = 186) participated in a one-year randomized trial of three interventions (NCT01474759): standard advice to eat less food, choosing portions based on energy density, and using pre-portioned foods. At Months 0, 6, and 12 of the trial, participants listed the foods they found most problematic and reported the frequency of using eight behavioral strategies to control intake of these foods, including three practices for avoiding exposure to problem foods and three for consuming them but limiting intake. The responses showed that 82% of the top three problem foods were in the categories of sweet baked items, salty snacks, starchy side dishes, chocolate and candy, and ice cream. After one year, women who reported more frequently using the strategy of limiting portions of problem foods had a greater rate of weight loss (kg/week), regardless of their intervention group (p < 0.0001). Among women who limited portions of problem foods less frequently, those using pre-portioned foods had greater initial weight loss compared to the other two groups, but then regained weight at a greater rate (p < 0.0001). The three avoidance strategies for problem foods were reported to be frequently used but were not found to be related to weight loss. These results suggest that adopting and maintaining strategies to manage portions of problem foods, rather than avoiding exposure to them, can be a more useful approach for weight loss.",2020,The three avoidance strategies for problem foods were reported to be frequently used but were not found to be related to weight loss.,['Women with overweight and obesity'],"['standard advice to eat less food, choosing portions based on energy density, and using pre-portioned foods']","['rate of weight loss', 'categories of sweet baked items, salty snacks, starchy side dishes, chocolate and candy, and ice cream', 'initial weight loss']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0449719', 'cui_str': 'Part'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0085077', 'cui_str': 'Acute febrile neutrophilic dermatosis'}, {'cui': 'C0453863', 'cui_str': 'Snack food'}, {'cui': 'C0020498', 'cui_str': 'Disseminated idiopathic skeletal hyperostosis'}, {'cui': 'C0006622', 'cui_str': 'Theobroma cacao'}, {'cui': 'C0006855', 'cui_str': 'Candy'}, {'cui': 'C0020747', 'cui_str': 'Ice cream'}, {'cui': 'C0205265', 'cui_str': 'Initial'}]",186.0,0.0213008,The three avoidance strategies for problem foods were reported to be frequently used but were not found to be related to weight loss.,"[{'ForeName': 'Liane S', 'Initials': 'LS', 'LastName': 'Roe', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA, USA. Electronic address: LSR7@psu.edu.'}, {'ForeName': 'Barbara J', 'Initials': 'BJ', 'LastName': 'Rolls', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA, USA.'}]",Appetite,['10.1016/j.appet.2020.104687'] 138,30971750,"Glycemic response to low sugar apple juice treated with invertase, glucose oxidase and catalase.","BACKGROUND/OBJECTIVES Investigating the effect on post-prandial glycemic and venous serum insulin response of an apple drink following the conversion of its glucose to gluconate. SUBJECTS/METHODS In a double-blind randomized placebo-controlled clinical trial with cross-over design, 30 male adults with impaired fasting glucose (IFG) received a drink of 500 ml: 1. Verum: Apple juice treated with invertase, glucose oxidase/catalase (glucose 0.05 g; gluconate 18.2 g); 2. CONTROL Untreated apple juice (free glucose 8.5 g; bound glucose 6.7 g; gluconate below detection limit). Postprandial fingerprick capillary blood glucose and venous serum insulin were measured twice at baseline and at times 0 (start of drink), 15, 30, 45, 60, 90 and 120 min. Gastrointestinal symptoms, stool consistency and satiety were also assessed. RESULTS The incremental area under the curve (iAUC 120 ) of glucose levels (primary parameter) was significantly lower after verum (mean ± SD: 63.6 ± 46.7 min × mmol/l) compared to control (mean ± SD: 198 ± 80.9 min × mmol/l) (ANOVA F = 137.4, p < 0.001; α = 0.05). Also, iAUC 120 of venous serum insulin levels (secondary parameter) was significantly lower after verum (mean ± SD: 2045 ± 991 min × mmol/l) compared to control (3864.3 ± 1941 min × mmol/l), (ANOVA F = 52.94, p < 0.001; α = 0.025). Further parameters of glucose metabolism and ISI = 2/[AUC venous serum insulin × AUC glucose +1] were also improved after verum compared to control. Verum increased stool frequency and decreased stool consistency, as assessed by Bristol stool form scale. CONCLUSIONS By enzymatic treatment of apple juice its sugar content could be reduced by 21% and postprandial glycemic and venous serum insulin response by 68 and 47%, respectively resulting in a reduction of glycemic load by 74.6% without any adverse gastrointestinal side-effects.",2019,"By enzymatic treatment of apple juice its sugar content could be reduced by 21% and postprandial glycemic and venous serum insulin response by 68 and 47%, respectively resulting in a reduction of glycemic load by 74.6% without any adverse gastrointestinal side-effects.",['30 male adults with impaired fasting glucose (IFG) received a drink of 500\u2009ml: 1'],"['Apple juice treated with invertase, glucose oxidase/catalase (glucose 0.05\u2009g; gluconate 18.2\u2009g); 2.\nCONTROL\n\n\nUntreated apple juice (free glucose 8.5\u2009g; bound glucose 6.7\u2009g; gluconate below detection limit', 'low sugar apple juice treated with invertase, glucose oxidase and catalase', 'Verum', 'placebo']","['Postprandial fingerprick capillary blood glucose and venous serum insulin', 'Glycemic response', 'Gastrointestinal symptoms, stool consistency and satiety', 'iAUC 120 of venous serum insulin levels', 'Bristol stool form scale', 'glucose metabolism and ISI\u2009=\u20092/[AUC venous serum insulin', 'postprandial glycemic and venous serum insulin response', 'incremental area under the curve (iAUC 120 ) of glucose levels', 'stool frequency and decreased stool consistency']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}]","[{'cui': 'C0452454', 'cui_str': 'Apple juice'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0053409', 'cui_str': 'beta-Fructofuranosidase'}, {'cui': 'C0017735', 'cui_str': 'GLUCOSE OXIDASE'}, {'cui': 'C0007367', 'cui_str': 'CATALASE'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C4517411', 'cui_str': '0.05'}, {'cui': 'C0220836', 'cui_str': 'gluconate'}, {'cui': 'C4517610', 'cui_str': '18.2'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4517877', 'cui_str': '8.5'}, {'cui': 'C1145667', 'cui_str': 'Binding - action (qualifier value)'}, {'cui': 'C2718050', 'cui_str': 'Limit of Detection'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0242209', 'cui_str': 'Sugars'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0229666', 'cui_str': 'Capillary blood (substance)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0348013', 'cui_str': 'Venous (qualifier value)'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0332529', 'cui_str': 'Consistency finding'}, {'cui': 'C0036239', 'cui_str': 'Satiations'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C1997606', 'cui_str': 'Bristol stool form scale'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0428548', 'cui_str': 'Glucose level - finding'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}]",30.0,0.0394735,"By enzymatic treatment of apple juice its sugar content could be reduced by 21% and postprandial glycemic and venous serum insulin response by 68 and 47%, respectively resulting in a reduction of glycemic load by 74.6% without any adverse gastrointestinal side-effects.","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Laue', 'Affiliation': 'CRC Clinical Research Center Kiel, Kiel Center of Innovation and Technology, Kiel, Germany.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Ballance', 'Affiliation': 'Nofima AS, Norwegian Institute of Food, Fisheries and Aquaculture Research, Ås, Norway. simon.ballance@nofima.no.'}, {'ForeName': 'S H', 'Initials': 'SH', 'LastName': 'Knutsen', 'Affiliation': 'Nofima AS, Norwegian Institute of Food, Fisheries and Aquaculture Research, Ås, Norway.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Papazova', 'Affiliation': 'Tecura GmbH, Kiel Center of Innovation and Technology, Kiel, Germany.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Soeth', 'Affiliation': 'CRC Clinical Research Center Kiel, Kiel Center of Innovation and Technology, Kiel, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Pannenbeckers', 'Affiliation': 'CRC Clinical Research Center Kiel, Kiel Center of Innovation and Technology, Kiel, Germany.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Schrezenmeir', 'Affiliation': 'CRC Clinical Research Center Kiel, Kiel Center of Innovation and Technology, Kiel, Germany.'}]",European journal of clinical nutrition,['10.1038/s41430-019-0421-1'] 139,31089253,Sesame oil and vitamin E co-administration may improve cardiometabolic risk factors in patients with metabolic syndrome: a randomized clinical trial.,"OBJECTIVES Metabolic syndrome (MetS) represents a clustering of metabolic abnormalities that are associated with an increased risk of type 2 diabetes and cardiovascular disease. We aimed to evaluate the effects of sesame oil enriched with vitamin E (vit E), sesame oil alone and sunflower oil on lipid profile, fasting blood glucose (FBG), malondialdehyde (MDA), high-sensitivity C-reactive protein (Hs-CRP), homeostatic model assessment (HOMA-IR), and blood pressure (BP) in patients with MetS. SUBJECTS Overall, 75 individuals with MetS (aged 30-70 years) participated in this randomized, single-blind controlled trial. Patients were randomly allocated to: (1) Group A (n = 25): sesame oil (30 ml/day) enriched with vit E (400 mg/day), (2) Group B (n = 25): sesame oil (30 ml/day), (3) Group C (n = 25): sunflower oil (30 ml/day). Anthropometric data, dietary intake, blood pressure, and biochemical markers, including fasting serum lipids, FBG, serum insulin, MDA, and hs-CRP were measured at baseline and at week 8. RESULTS In individuals in the sesame oil enriched with vit E group (Group A), there were significant reductions in serum total cholesterol (TC), triglycerides (TG), FBG, HOMA-IR, MDA, hs-CRP, high-density lipoprotein (HDL-C) systolic and diastolic BP (for all the comparison p < 0.02). Similarly, in Group B (taking sesame oil alone), TC, TG, FBG, HOMA-IR, MDA, systolic and diastolic BP were significantly improved (for all the comparison p < 0.025), while there were no significant changes in serum HDL (baseline = 35.9 ± 7.2 mg/dL vs. 36.4 ± 6.2 mg/dL, p = 0.432) and hs-CRP (baseline = 4.38 ± 1.34 mg/dL vs. week 8 = 3.96 ± 1.7 mg/dL, p = 0.057) in second group. No significant changes in any of the studied clinical and anthropometric data were found in Group C (on sunflower oil). CONCLUSION Sesame oil (±vit E) was shown to beneficially affect several cardiometabolic indices (including lipids, FBG, BP, HOMA-IR, and MDA) in patients with MetS.",2019,"No significant changes in any of the studied clinical and anthropometric data were found in Group C (on sunflower oil). ","['patients with MetS', 'patients with MetS.\nSUBJECTS\n\n\nOverall, 75 individuals with MetS (aged 30-70 years', 'patients with metabolic syndrome']","['vit E', 'Sesame oil (±vit E', 'sunflower oil', 'sesame oil enriched with vitamin E (vit E), sesame oil alone and sunflower oil', 'sesame oil (30\u2009ml/day) enriched with vit E', 'Sesame oil and vitamin E co-administration']","['cardiometabolic risk factors', 'several cardiometabolic indices (including lipids, FBG, BP, HOMA-IR, and MDA', 'TC, TG, FBG, HOMA-IR, MDA, systolic and diastolic BP', 'serum HDL', 'serum total cholesterol (TC), triglycerides (TG), FBG, HOMA-IR, MDA, hs-CRP, high-density lipoprotein (HDL-C) systolic and diastolic BP', 'Anthropometric data, dietary intake, blood pressure, and biochemical markers, including fasting serum lipids, FBG, serum insulin, MDA, and hs-CRP', 'lipid profile, fasting blood glucose (FBG), malondialdehyde (MDA), high-sensitivity C-reactive protein (Hs-CRP), homeostatic model assessment (HOMA-IR), and blood pressure (BP']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0524620', 'cui_str': 'Metabolic Syndrome X'}]","[{'cui': 'C0036845', 'cui_str': 'Sesame Oil'}, {'cui': 'C0028908', 'cui_str': 'Oils'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C0439446', 'cui_str': 'mL/day'}, {'cui': 'C1533734', 'cui_str': 'Administration'}]","[{'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0000379', 'cui_str': '1,3-Benzodioxole-5-ethanamine, alpha-methyl-'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Marker'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",,0.0977576,"No significant changes in any of the studied clinical and anthropometric data were found in Group C (on sunflower oil). ","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Farajbakhsh', 'Affiliation': 'Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Seyed Mohammad', 'Initials': 'SM', 'LastName': 'Mazloomi', 'Affiliation': 'Department of Food Hygiene and Quality Control, School and Research Center of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Mazidi', 'Affiliation': 'Department of Biology and Biological Engineering, Food and Nutrition Science, Chalmers University of Technology, SE-41296, Gothenburg, Sweden.'}, {'ForeName': 'Peyman', 'Initials': 'P', 'LastName': 'Rezaie', 'Affiliation': 'Adelaide Medical School, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Marzieh', 'Initials': 'M', 'LastName': 'Akbarzadeh', 'Affiliation': 'Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Saeedeh Poor', 'Initials': 'SP', 'LastName': 'Ahmad', 'Affiliation': 'Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'G A', 'Initials': 'GA', 'LastName': 'Ferns', 'Affiliation': 'Brighton and Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Ofori-Asenso', 'Affiliation': 'Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Siavash', 'Initials': 'S', 'LastName': 'Babajafari', 'Affiliation': 'Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran. Jafaris@sums.ac.ir.'}]",European journal of clinical nutrition,['10.1038/s41430-019-0438-5'] 140,31668965,A Phase II Randomized Controlled Trial of Renshen Yangrong Tang Herbal Extract Granules for Fatigue Reduction in Cancer Survivors.,"CONTEXT Based on the traditional Chinese medicine theory, Renshen Yangrong Tang (RSYRT), which is a mixture of 12 herbs, was commonly used as a pharmacological option in China for fatigue management by correcting Qi deficiency. OBJECTIVES This randomized controlled Phase II trial investigated the efficacy of RSYRT for reducing cancer-related fatigue. METHODS Cancer survivors with moderate or severe fatigue (rated ≥4 on a 0-10 scale) for more than two months were randomized to take herbal extract granules of RSYRT or a low dose of a single herb (huangqi) twice a day for six weeks. Patient-reported fatigue was measured using the MD Anderson Symptom Inventory. Efficacy of RSYRT was evaluated using mixed model to test the differences over time among groups. We also conducted responder analyses and examined time to effect of symptom reduction. RESULTS None of the 83 evaluable patients (control group 42; intervention group 41) had discomfort or Grade 3 or 4 toxicity. We observed a significantly greater MD Anderson Symptom Inventory-fatigue score reduction in the intervention group than that in the control group (time-by-group interaction: estimate = -0.61 [0.10]; P < 0.0001). More patients in the intervention group had a two-point reduction on fatigue than that of the control group (90.2% vs. 52.4%). By Week 4, between-group differences of fatigue reduction on mean severity reached large effect size (intervention group vs. control group: -2.66 vs. -1.36; Cohen's d = 1.0; P < 0.0001). CONCLUSION Compared with control therapy, RSYRT therapy elicits a statistical and clinical improvement of fatigue severity and functioning. The effectiveness of RSYRT in managing cancer-related fatigue warrants further study in the real world.",2020,"By week 4, between groups difference of fatigue reduction on mean severity reached large effect size (intervention group vs. control group: -2.66 vs. -1.36, Cohen's d=1.0, P<0.0001). ","['Cancer survivors with moderate or severe fatigue (rated ≥4 on a 0-10 scale) over 2 months', 'Cancer Survivors']","['traditional Chinese medicine (TCM) theory, Renshen Yangrong Tang (RSYRT', 'Renshen Yangrong Tang Herbal Extract Granules', 'herbal extract granules of RSYRT or a low dose of a single herb (huangqi']","['MD Anderson Symptom Inventory (MDASI', 'discomfort or grade 3 or 4 toxicity', 'MDASI-fatigue score reduction', 'fatigue reduction', 'fatigue']","[{'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0222045'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0025124', 'cui_str': 'Zhong Yi Xue'}, {'cui': 'C0086767', 'cui_str': 'Ginseng'}, {'cui': 'C0376667', 'cui_str': 'Herbal'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C3853573', 'cui_str': 'Granules'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0019240', 'cui_str': 'Herb (substance)'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]",,0.0727621,"By week 4, between groups difference of fatigue reduction on mean severity reached large effect size (intervention group vs. control group: -2.66 vs. -1.36, Cohen's d=1.0, P<0.0001). ","[{'ForeName': 'Yichen', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Department of Integration of Chinese and Western Medicine, Key Lab of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institution, Beijing, China.'}, {'ForeName': 'Xin Shelley', 'Initials': 'XS', 'LastName': 'Wang', 'Affiliation': 'Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Yanzhi', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Integration of Chinese and Western Medicine, Key Lab of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institution, Beijing, China.'}, {'ForeName': 'Qiuling', 'Initials': 'Q', 'LastName': 'Shi', 'Affiliation': 'Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Tsun Hsuan', 'Initials': 'TH', 'LastName': 'Chen', 'Affiliation': 'Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Pingping', 'Initials': 'P', 'LastName': 'Li', 'Affiliation': 'Department of Integration of Chinese and Western Medicine, Key Lab of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institution, Beijing, China. Electronic address: lppma123@sina.com.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2019.10.018'] 141,32006612,Openness Personality Trait Associated With Benefit From a Nonpharmacological Breathlessness Intervention in People With Intrathoracic Cancer: An Exploratory Analysis.,"CONTEXT Breathlessness is common in people with lung cancer. Nonpharmacological breathlessness interventions reduce distress because of and increase mastery over breathlessness. OBJECTIVES Identify patient characteristics associated with response to breathlessness interventions. METHODS Exploratory secondary trial data analysis. Response defined as a one-point improvement in 0-10 Numerical Rating Scale of worst breathlessness/last 24 hours (response-worst) or a 0.5-point improvement in the Chronic Respiratory Questionnaire (CRQ) mastery (response-mastery) at four weeks. Univariable regression explored relationships with plausible demographic, clinical, and psychological variables followed by multivariable regression for associated (P < 0.05) variables. RESULTS About 158 participants with intrathoracic cancer (mean age 69.4 [SD 9.35] years; 40% women) were randomized to one or three breathlessness training sessions. About 91 participants had evaluable data for response-worst and 107 for response-mastery. In the univariable analyses, the personality trait openness was associated with response-worst (odds ratio [OR] 1.99 [95% CI 1.08-3.67]; P = 0.028) and response-mastery (OR 1.84 [95% CI 1.04-3.23]; P = 0.035). Higher CRQ-fatigue (OR 0.61 [95% CI 0.41-0.91]; P = 0.015), CRQ-emotion (OR 0.68 [95% CI 0.47-0.96]; P = 0.030), and worse CRQ-mastery (OR 0.61 [95% CI 0.42-0.88]; P = 0.008), and the presence of metastases and fatigue were associated with reduced odds of response-mastery. In the adjusted response-mastery model, only openness remained (OR 1.73 [95% CI 0.95-3.15]; P = 0.072). CONCLUSION Worse baseline health, worse breathlessness mastery, but not severity, and openness were associated with a better odds of response. Breathlessness services must be easy to access, and patients should be encouraged and supported to attend.",2020,Higher CRQ-Fatigue (OR 0.61 [95% CI 0.41 to 0.91]:,"['people with intra-thoracic cancer', '158 participants with intrathoracic cancer (mean age 69.4 [SD: 9.35] years; 40% women', 'people with lung cancer']",['pharmacological breathlessness intervention'],"['Response-Mastery ', 'Chronic Respiratory Questionnaire (CRQ) Mastery (Response-Mastery', 'Worse baseline health, worse breathlessness mastery', 'Higher CRQ-Fatigue', 'personality trait ""openness', 'worse CRQ-Mastery', 'CRQ-Emotion']","[{'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1306460', 'cui_str': 'Primary malignant neoplasm of lung'}]","[{'cui': 'C0205464', 'cui_str': 'Pharmacologic (qualifier value)'}, {'cui': 'C0013404', 'cui_str': 'Breathlessness'}]","[{'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013404', 'cui_str': 'Breathlessness'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0233849', 'cui_str': 'Personality finding'}, {'cui': 'C0547049', 'cui_str': 'Openness (qualifier value)'}, {'cui': 'C0013987', 'cui_str': 'Emotions'}]",158.0,0.164625,Higher CRQ-Fatigue (OR 0.61 [95% CI 0.41 to 0.91]:,"[{'ForeName': 'Miriam J', 'Initials': 'MJ', 'LastName': 'Johnson', 'Affiliation': 'Palliative Medicine, Wolfson Palliative Care Research Centre, University of Hull, Hull, UK. Electronic address: miriam.johnson@hyms.ac.uk.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Nabb', 'Affiliation': 'Student Wellbeing Learning and Welfare Support, University of Hull, Hull, UK; Humber Teaching NHS Foundation Trust, Willerby Hill, Hull, UK.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Booth', 'Affiliation': 'Cicely Saunders Institute, University of Cambridge, Kings College London, London, UK.'}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Kanaan', 'Affiliation': 'Department of Health Sciences, Applied Health Research (Statistics), University of York, York, UK.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2020.01.006'] 142,32322324,The Value of Combined Radial Endobronchial Ultrasound-Guided Transbronchial Lung Biopsy and Metagenomic Next-Generation Sequencing for Peripheral Pulmonary Infectious Lesions.,"Background Metagenomic next-generation sequencing (mNGS) is a new technology that allows for unbiased detection of pathogens. However, there are few reports on mNGS of lung biopsy tissues for pulmonary infection diagnosis. In addition, radial endobronchial ultrasound (R-EBUS) is widely used to detect peripheral pulmonary lesions (PPLs), but it is rarely used in the diagnosis of peripheral lung infection. Objective The present study aims to evaluate the combined application of R-EBUS-guided transbronchial lung biopsy (TBLB) and mNGS for the diagnosis of peripheral pulmonary infectious lesions. Methods From July 2018 to April 2019, 121 patients from Tianjin Medical University General Hospital diagnosed with PPLs and lung infection were enrolled in this prospective randomized study . Once the lesion was located, either TBLB or R-EBUS-guided-TBLB was performed in randomly selected patients, and mNGS was applied for pathogen detection in lung biopsy tissues. The results of mNGS were compared between the TBLB group and R-EBUS-guided TBLB group. In addition, the clinical characteristics and EBUS images from 61 patients receiving bronchoscopy for peripheral lung infectious detection were analyzed and compared with the results of mNGS. Results The positivity rate of mNGS in R-EBUS-guided TBLB was (78.7%, 48/61) that was significantly higher than (60.0%, 36/60) in the TBLB group. Difference in the position of R-EBUS probe and image characteristics of peripheral lung infectious lesions affected the positivity rate of mNGS. Tissue collected by R-EBUS within the lesion produced higher positivity rate than samples collected adjacent to the lesion ( P =0.030, odds ratio 17.742; 95% confidence interval, from 1.325 to 237.645). Anechoic areas and luminant areas of ultrasonic image characteristics were correlated with lower positivity rate of mNGS (respectively, P =0.019, odds ratio 17.878; 95% confidence interval, from 1.595 to 200.399; P =0.042, odds ratio 16.745; 95% confidence interval, from 1.106 to 253.479). Conclusions R-EBUS-guided TBLB is a safe and effective technique in the diagnosis of peripheral lung infectious lesions. R-EBUS significantly facilitates the accurate insertion of bronchoscope into the lesions, which improves positivity rate of mNGS analysis in pathogen detection. The R-EBUS probe position within lesion produced a higher positivity rate of mNGS analysis. Nevertheless, the presence of anechoic and luminant areas on ultrasonic image was correlated with poor mNGS positivity rate.",2020,"Tissue collected by R-EBUS within the lesion produced higher positivity rate than samples collected adjacent to the lesion ( P =0.030, odds ratio 17.742; 95% confidence interval, from 1.325 to 237.645).","['Methods\n\n\nFrom July 2018 to April 2019, 121 patients from Tianjin Medical University General Hospital diagnosed with PPLs and lung infection', '61 patients receiving bronchoscopy for peripheral lung infectious detection', 'Peripheral Pulmonary Infectious Lesions']","['\n\n\nMetagenomic next-generation sequencing (mNGS', 'Combined Radial Endobronchial Ultrasound-Guided Transbronchial Lung Biopsy and Metagenomic Next-Generation Sequencing', 'TBLB', 'radial endobronchial ultrasound (R-EBUS', 'R-EBUS-guided transbronchial lung biopsy (TBLB) and mNGS']","['positivity rate', 'positivity rate of mNGS in R-EBUS-guided TBLB', 'positivity rate of mNGS']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0020008', 'cui_str': 'Hospitals, General'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0876973', 'cui_str': 'Infectious disease of lung'}, {'cui': 'C0006290', 'cui_str': 'Bronchoscopy'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}]","[{'cui': 'C2936621', 'cui_str': 'Next-Generation Sequencing'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C3160856', 'cui_str': 'Endobronchial ultrasound'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0863477', 'cui_str': 'Transbronchial lung biopsy'}]","[{'cui': 'C2936621', 'cui_str': 'Next-Generation Sequencing'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C3160856', 'cui_str': 'Endobronchial ultrasound'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0863477', 'cui_str': 'Transbronchial lung biopsy'}]",,0.0420122,"Tissue collected by R-EBUS within the lesion produced higher positivity rate than samples collected adjacent to the lesion ( P =0.030, odds ratio 17.742; 95% confidence interval, from 1.325 to 237.645).","[{'ForeName': 'Guangsheng', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, 154 Anshan Road, Tianjin 300052, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Graduate School, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Yuechuan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Tianjin Chest Hospital, 261 Taierzhuang South Road, Tianjin 300222, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Feng', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, 154 Anshan Road, Tianjin 300052, China.'}]",Canadian respiratory journal,['10.1155/2020/2367505'] 143,31982605,"A Randomized, Placebo-Controlled, Double-Blind Study of Minocycline for Reducing the Symptom Burden Experienced by Patients With Advanced Pancreatic Cancer.","CONTEXT Although it is well known that patients with advanced pancreatic cancer (PC) experience significant symptom burden, few strategies for effective symptom intervention are available for them. OBJECTIVES To investigate the efficacy of minocycline, an anti-inflammatory agent, for symptom reduction in patients with advanced PC. METHODS We conducted Phase II, randomized, and placebo-controlled trial to obtain preliminary estimates of the effects on symptom reduction with 100 mg of minocycline or placebo given twice a day. Eligible patients had diagnosed advanced PC and were scheduled for standard chemotherapy. Patient-reported symptoms were measured weekly during the eight-week trial using the MD Anderson Symptom Inventory (MDASI) module in patients with gastrointestinal cancer. The primary outcome measure was the area under the curve values of the five most severe symptoms in the two arms. RESULTS Of the 44 patients recruited, 31 (71%) were evaluable for the primary efficacy analysis, with 18 received minocycline and 13 placebo. Fatigue, pain, disturbed sleep, lack of appetite, and drowsiness were the most severe symptoms reported by both groups. No significant differences in area under the curve values over time between the study arms were found for the composite MDASI score or single-item scores of the five most severe MDASI items. No treatment-related deaths were reported, and no Grade 3-4 toxicities were observed. CONCLUSION Minocycline is safe for use in patients receiving treatment for PC. There is no observed symptom reduction with minocycline on the major symptom burden associated with advanced PC compared with placebo. Attrition because of rapid disease progression impacted the study significantly.",2020,No significant differences in AUC values over time between the study arms were found for the composite MDASI score or single-item scores of the 5 most-severe MDASI items.,"['patients receiving treatment for PC', 'Patients with Advanced Pancreatic Cancer', 'Eligible patients had diagnosed advanced PC and were scheduled for standard chemotherapy', 'advanced PC patients', '44 patients recruited, 31 (71', 'patients with gastrointestinal cancer (MDASI-GI', 'patients with advanced pancreatic cancer (PC']","['Placebo', 'minocycline', 'Minocycline', 'placebo', 'minocycline or placebo']","['AUC values', 'grade 3-4 toxicities', 'composite MDASI score or single-item scores', 'area under the curve (AUC) values of the 5 most-severe symptoms', 'Fatigue, pain, disturbed sleep, lack of appetite, and drowsiness']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0346647', 'cui_str': 'Cancer of Pancreas'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0685938', 'cui_str': 'Gastrointestinal Cancer'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0026187', 'cui_str': 'Minocycline'}]","[{'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0559741', 'cui_str': 'Item score (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332268', 'cui_str': 'Lacking (qualifier value)'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C0013144', 'cui_str': 'Drowsy (finding)'}]",44.0,0.329015,No significant differences in AUC values over time between the study arms were found for the composite MDASI score or single-item scores of the 5 most-severe MDASI items.,"[{'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Kamal', 'Affiliation': 'Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Xin Shelley', 'Initials': 'XS', 'LastName': 'Wang', 'Affiliation': 'Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: xswang@mdanderson.org.'}, {'ForeName': 'Qiuling', 'Initials': 'Q', 'LastName': 'Shi', 'Affiliation': 'Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Tito', 'Initials': 'T', 'LastName': 'Mendoza', 'Affiliation': 'Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Araceli', 'Initials': 'A', 'LastName': 'Garcia-Gonzalez', 'Affiliation': 'Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Raza H', 'Initials': 'RH', 'LastName': 'Bokhari', 'Affiliation': 'Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Charles S', 'Initials': 'CS', 'LastName': 'Cleeland', 'Affiliation': 'Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Fogelman', 'Affiliation': 'Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2020.01.007'] 144,32166681,"Application of Low Tube Voltage, Low-concentration Contrast Agent Using a 320-row CT in Coronary CT Angiography: Evaluation of Image Quality, Radiation Dose and Iodine Intake.","The effect of low voltage and low concentration contrast agent on image quality of coronary CT angiography, radiation dose and iodine intake was evaluated. A total of 121 patients with body mass index (BMI) <26 kg/m 2 and heart rate (HR) <70 beats/min were randomly divided into four groups: group A (n=31, 80 kVp, 270 mgI/mL); group B (n=33, 100 kVp, 270 mgI/mL); group C (n=30, 100 kVp, 320 mgI/mL); group D (n=27, 100 kVp, 400 mgI/mL). The automatic current modulation system and the iterative algorithm for reconstruction were adopted in each group. The CT values and SD values of the aortic root (AR), subcutaneous fat, left coronary artery opening (LCA), and right coronary artery opening (RCA) were measured in all groups, the signal-to-noise ratio (SNR) and contrast noise ratio (CNR) were calculated, and effective radiation dose and iodine intake were recorded. The subjective assessment for image quality was performed by two physicians using a 4-point scale. The results were compared using the one-way ANOVA and rank sum tests. The image quality of the four groups met the clinical diagnostic requirements. The CT values of AR in groups A, B, C, and D were 537.6±71.4, 447.2±81.9, 445.2±64.9 and 518.5±94.9 Hu, respectively, with no significant difference between group A and group D, or between group B and group C, while CT values in groups B and C were significantly lower than those in groups A and D (P<0.05). In groups A, B, C, and D, the LCA SNR values were 22.7±9.1, 23.3±9.1, 23.3±7.7 and 26.6±8.9, and the RCA CNR values were 26.9±9.8, 28.5±11.4, 27.7±8.8 and 32.1±10.6, respectively. The AR visual scores in groups A, B, C and D were 3.8±0.2, 3.9±0.3, 3.9±0.3 and 4.0±0.3, respectively. There were no significant differences in SNR, CNR and visual score among the four groups (P>0.05). The radiation doses in groups A, B, C and D were 2.6±1.4, 3.6±1.8, 4.9±3.5 and 4.9±2.8 mSv, respectively. The radiation dose in group A was significantly less than that in the rest three groups (P<0.05). The iodine intakes in groups A, B, C and D were 14.9±1.5, 15.0±1.5, 17.7±2.0 and 18.1±2.5 g, respectively. There was no significant difference in the intake of iodine between groups C and D, or between groups A and B, while iodine intake in groups A and B were significantly reduced as compared with that in groups C and D (P<0.05). It was concluded that for patients with low BMI and controlled HR, compared to 100 kVp tube voltage combined with multiple concentration contrast agents, 80 kVp combined with 270 mgI/mL contrast agent is enough to ensure the quality of the images, and can reduce the radiation dose significantly, while reducing the amount of iodine intake notably, thus reducing the incidence of adverse reaction.",2020,The radiation dose in group A was significantly less than that in the rest three groups (P<0.05).,['121 patients with body mass index (BMI) <26 kg/m 2 and heart rate (HR) <70 beats/min'],['low voltage and low concentration contrast agent'],"['signal-to-noise ratio (SNR) and contrast noise ratio (CNR', 'CT values', 'LCA SNR values', 'CT values and SD values of the aortic root (AR), subcutaneous fat, left coronary artery opening (LCA), and right coronary artery opening (RCA', 'CT values of AR', 'RCA CNR values', 'SNR, CNR and visual score', 'effective radiation dose and iodine intake', 'intake of iodine', 'image quality of coronary CT angiography, radiation dose and iodine intake', 'AR visual scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0439385', 'cui_str': 'beats per minute'}]","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0009924', 'cui_str': 'Contrast Agents'}]","[{'cui': 'C2986823', 'cui_str': 'Signal-To-Noise Ratio'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0549113', 'cui_str': 'Supraaortic valve area structure'}, {'cui': 'C0222331', 'cui_str': 'Subcutaneous Fat'}, {'cui': 'C1261082', 'cui_str': 'Left coronary artery structure'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C1261316', 'cui_str': 'Right coronary artery structure'}, {'cui': 'C0610301', 'cui_str': 'RCA II'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0021968', 'cui_str': 'molecular iodine'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C1536105', 'cui_str': 'Angiography, CT'}]",121.0,0.0131779,The radiation dose in group A was significantly less than that in the rest three groups (P<0.05).,"[{'ForeName': 'Yue-Ying', 'Initials': 'YY', 'LastName': 'Pan', 'Affiliation': 'Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. xpyy02@sina.com.'}, {'ForeName': 'Shu-Chang', 'Initials': 'SC', 'LastName': 'Zhou', 'Affiliation': 'Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Yu-Jin', 'Initials': 'YJ', 'LastName': 'Wang', 'Affiliation': 'Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Ting-Ting', 'Initials': 'TT', 'LastName': 'Zhu', 'Affiliation': 'Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Chun-Xia', 'Initials': 'CX', 'LastName': 'Liu', 'Affiliation': 'Department of Health Records, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Han-Xiong', 'Initials': 'HX', 'LastName': 'Guan', 'Affiliation': 'Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}]",Current medical science,['10.1007/s11596-020-2162-8'] 145,32145674,"A double-blind, randomized, sham-controlled study of cranial electrotherapy stimulation as an add-on treatment for tic disorders in children and adolescents.","AIM The aim of this study was to determine the efficacy and safety of cranial electrotherapy stimulation (CES) as an add-on treatment for TD. METHODS A randomized, double-blind, sham-controlled trial was conducted at an outpatient, single-center academic setting. A total of 62 patients aged 6-17 years with TD and lack of clinical response to 4 weeks' pharmacotherapy were enrolled. Patients were divided randomly into 2 groups and given 4 weeks' treatment, including 30 min sessions of active CES (500 μA-2 mA) or sham CES (lower than 100 μA) per day for 40 d on weekdays. Change in Yale Global Tic Severity Scale (YGTSS), Clinical Global Impression-severity of illness-severity (CGI-S) and Hamilton Anxiety Scale-14 items (HAMA-14) were performed at baseline, week 2, week 4. Adverse events (AEs) were also evaluated. RESULTS 53 patients (34 males and 9 females) completed the trial, including 29 in the active CES group and 24 in the sham CES group. Both groups showed clinical improvement in tic severities compared to baseline respectively at week 4. Participants receiving active CES showed a reduction of 31.66 % in YGTSS score, compared with 23.96 % in participants in sham CES group, resulting in no significant difference between the two groups (t = 1.54, p = 0.13). CONCLUSION Four-week's treatment of CES for children and adolescents with TD is effective and safe, but the improvement for tic severity may be related to placebo effect.",2020,"Participants receiving active CES showed a reduction of 31.66 % in YGTSS score, compared with 23.96 % in participants in sham CES group, resulting in no significant difference between the two groups (t = 1.54, p = 0.13). ","[""62 patients aged 6-17 years with TD and lack of clinical response to 4 weeks' pharmacotherapy were enrolled"", 'tic disorders in children and adolescents', '53 patients (34 males and 9 females) completed the trial, including 29 in the active CES group and 24 in the sham CES group']","['cranial electrotherapy stimulation', 'active CES', 'cranial electrotherapy stimulation (CES', 'active CES (500\u2009μA-2\u2009mA) or sham CES']","['clinical improvement in tic severities', 'Yale Global Tic Severity Scale (YGTSS), Clinical Global Impression-severity of illness-severity (CGI-S) and Hamilton Anxiety', 'efficacy and safety', 'Adverse events (AEs', 'YGTSS score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332268', 'cui_str': 'Lacking (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0040188', 'cui_str': 'Tic disorder (disorder)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C3163632', 'cui_str': 'Cranial'}, {'cui': 'C0013787', 'cui_str': 'Electrical Stimulation Therapy'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0278076', 'cui_str': 'Habit Chorea'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C4720888', 'cui_str': 'Yale global tic severity scale (assessment scale)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",62.0,0.38816,"Participants receiving active CES showed a reduction of 31.66 % in YGTSS score, compared with 23.96 % in participants in sham CES group, resulting in no significant difference between the two groups (t = 1.54, p = 0.13). ","[{'ForeName': 'Wen-Jun', 'Initials': 'WJ', 'LastName': 'Wu', 'Affiliation': ""Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, 127# West Changle Road, Xi'an, 710032, China. Electronic address: wenjun104@126.com.""}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ""Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, 127# West Changle Road, Xi'an, 710032, China. Electronic address: fgx995@163.com.""}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Cai', 'Affiliation': ""Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, 127# West Changle Road, Xi'an, 710032, China. Electronic address: caimin@fmmu.edu.cn.""}, {'ForeName': 'Yi-Huan', 'Initials': 'YH', 'LastName': 'Chen', 'Affiliation': ""Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, 127# West Changle Road, Xi'an, 710032, China. Electronic address: 182368179@qq.com.""}, {'ForeName': 'Cui-Hong', 'Initials': 'CH', 'LastName': 'Zhou', 'Affiliation': ""Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, 127# West Changle Road, Xi'an, 710032, China. Electronic address: zch4610@126.com.""}, {'ForeName': 'Hua-Ning', 'Initials': 'HN', 'LastName': 'Wang', 'Affiliation': ""Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, 127# West Changle Road, Xi'an, 710032, China. Electronic address: xskzhu@fmmu.edu.cn.""}, {'ForeName': 'Long-Biao', 'Initials': 'LB', 'LastName': 'Cui', 'Affiliation': ""Department of Clinical Psychology, School of Medical Psychology, Fourth Military Medical University, 169 # West Changle Road, Xi'an, 710032, China. Electronic address: lbcui@fmmu.edu.cn.""}]",Asian journal of psychiatry,['10.1016/j.ajp.2020.101992'] 146,32333010,Feasibility of manual white blood cell counts as a predictor of neonatal sepsis in a low-resource setting.,"BACKGROUND Manual white blood cell (WBC) differential counts as a predictor for neonatal sepsis development in a low-resource setting have not been thoroughly evaluated. We hypothesized that manual differentiation (specifically immature:total [I:T] neutrophil ratios) would be feasible and useful as an adjunct to predict early-onset neonatal sepsis (EONS). Secondarily, we hypothesized that vaccination with bacillus Calmette-Guérin (BCG) and oral polio vaccine (OPV) could alter WBC differential counts and thus might reduce its predictive performance. METHODS We performed a prospective cohort study within a randomized trial, randomizing healthy, high-risk newborns admitted to the nursery at the national hospital in Guinea-Bissau 1:1 to BCG+OPV at admission or at discharge (usual practice). Thin capillary blood films were prepared at 2 d of age in a subset of 268 neonates. WBC counts were assessed by microscopy and neonates were followed up for sepsis development within 2 weeks. RESULTS Ninety-eight percent (264/268) of smears provided interpretable reads. Of the 264 children, 136 had been randomized to receive BCG+OPV prior to sampling; the remaining 128 were vaccinated at discharge. The I:T ratio (average 0.017) was lower among children who did not develop clinical sepsis but did not predict sepsis (p=0.70). Only three children had an I:T ratio >0.2 (associated with a higher probability of clinical sepsis in previous studies) but did not develop sepsis. Immunization did not alter WBC composition. CONCLUSIONS Manual WBC differentials are feasible in low-resource settings. WBC differentials are not affected by standard newborn immunization. However, the I:T ratio had no value in predicting subsequent development of sepsis.",2020,The I:T ratio (average 0.017) was lower among children who did not develop clinical sepsis but did not predict sepsis (p=0.70).,"['randomizing healthy, high-risk newborns admitted to the nursery at the national hospital in Guinea-Bissau 1:1 to BCG+OPV at admission or at discharge (usual practice', 'Ninety-eight percent (264/268) of smears', '264 children, 136 had been randomized to receive']","['bacillus Calmette-Guérin (BCG) and oral polio vaccine (OPV', 'BCG+OPV']","['neonatal sepsis', 'WBC counts', 'WBC composition']","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0028659', 'cui_str': 'Nurseries'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0018387', 'cui_str': 'Guinea-Bissau'}, {'cui': 'C0004587', 'cui_str': 'Bacillus'}, {'cui': 'C0032371', 'cui_str': 'Acute poliomyelitis'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C3871203', 'cui_str': 'At discharge'}, {'cui': 'C4319627', 'cui_str': '98'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0444186', 'cui_str': 'Smear test'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4517568', 'cui_str': '136'}]","[{'cui': 'C0004587', 'cui_str': 'Bacillus'}, {'cui': 'C0032375', 'cui_str': 'Sabin Vaccine'}, {'cui': 'C0032371', 'cui_str': 'Acute poliomyelitis'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0456103', 'cui_str': 'Sepsis of the newborn'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}]",264.0,0.15553,The I:T ratio (average 0.017) was lower among children who did not develop clinical sepsis but did not predict sepsis (p=0.70).,"[{'ForeName': 'Christian N', 'Initials': 'CN', 'LastName': 'Golding', 'Affiliation': 'Bandim Health Project, Indepth Network, Apartado 861, Bissau 1004, Guinea-Bissau.'}, {'ForeName': 'Frederik', 'Initials': 'F', 'LastName': 'Schaltz-Buchholzer', 'Affiliation': 'Bandim Health Project, Indepth Network, Apartado 861, Bissau 1004, Guinea-Bissau.'}, {'ForeName': 'Lilica', 'Initials': 'L', 'LastName': 'Sanca', 'Affiliation': 'Bandim Health Project, Indepth Network, Apartado 861, Bissau 1004, Guinea-Bissau.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Clipet-Jensen', 'Affiliation': 'Research Center for Vitamins and Vaccines, Statens Serum Institut, Artillerivej 5, Copenhagen S 2300, Denmark.'}, {'ForeName': 'Christine S', 'Initials': 'CS', 'LastName': 'Benn', 'Affiliation': 'Bandim Health Project, Indepth Network, Apartado 861, Bissau 1004, Guinea-Bissau.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Au', 'Affiliation': 'Department of Pathology and Laboratory Medicine, University of British Columbia, Rm. G227-2211 Wesbrook Mall, Vancouver, BC Canada V6T 2B5.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Chipperfield', 'Affiliation': 'Department of Pathology and Laboratory Medicine, University of British Columbia, Rm. G227-2211 Wesbrook Mall, Vancouver, BC Canada V6T 2B5.'}, {'ForeName': 'Tobias R', 'Initials': 'TR', 'LastName': 'Kollmann', 'Affiliation': 'Department of Pediatrics, University of British Columbia, Rm 2D19, 4480 Oak Street, Vancouver, BC Canada V6H 3V4.'}, {'ForeName': 'Nelly A', 'Initials': 'NA', 'LastName': 'Amenyogbe', 'Affiliation': 'Department of Experimental Medicine, University of British Columbia, 2775 Laurel Street, Vancouver, BC Canada V5Z 1M9.'}]",Transactions of the Royal Society of Tropical Medicine and Hygiene,['10.1093/trstmh/traa023'] 147,31586170,Comment on: A trial of a mechanical device for the treatment of blepharospasm.,,2020,,[],['mechanical device'],[],[],"[{'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}, {'cui': 'C0220819', 'cui_str': 'devices'}]",[],,0.0269564,,"[{'ForeName': 'Jonathan A', 'Initials': 'JA', 'LastName': 'Go', 'Affiliation': 'Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.'}, {'ForeName': 'Ashley N', 'Initials': 'AN', 'LastName': 'Anderson', 'Affiliation': 'Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.'}, {'ForeName': 'Ashwini', 'Initials': 'A', 'LastName': 'Kini', 'Affiliation': 'Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, 6550 Fannin St, Houston, TX, 77030, USA.'}, {'ForeName': 'Bayan', 'Initials': 'B', 'LastName': 'Al Othman', 'Affiliation': 'Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, 6550 Fannin St, Houston, TX, 77030, USA.'}, {'ForeName': 'Andrew G', 'Initials': 'AG', 'LastName': 'Lee', 'Affiliation': 'Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA. aglee@houstonmethodist.org.'}]","Eye (London, England)",['10.1038/s41433-019-0621-x'] 148,31485039,Posterior capsule opacification and Nd:YAG laser rates with two hydrophobic acrylic single-piece IOLs.,"OBJECTIVES To evaluate the development of posterior capsule opacification (PCO) and Nd:YAG capsulotomy rates following implantation of two hydrophobic acrylic IOLs. METHODS In a randomized, controlled trial, 80 patients with bilateral senile cataract were implanted with the hydrophobic acrylic single-piece intraocular Lenses (IOLs) EyeCee One in one eye and iMics1 in the other. Outcomes of 39 patients (78 eyes) were evaluated after 3 years. Automated Quantification of After-Cataract (AQUA; for PCO occurrence), visual acuity, anterior fibrosis, capsule-optic edge interaction and distance between anterior and posterior capsule IOL surface were analysed. RESULTS After a mean follow-up of 38 ± 1.95 months, Nd:YAG capsulotomy occurred at a rate of 15.4% and 46.2% in the EyeCee One and iMics1 groups, respectively (p < 0.01). Respective mean PCO scores measured by AQUA were 1.57 ± 1.63 and 2.45 ± 1.44 (p = 0.019). A distinct gap between the anterior capsule and the IOL optic was present in 89% of eyes implanted with EyeCee One and 13% of iMics1 eyes. A gap between the posterior capsule and the posterior surface of the lens was observed in 76% of EyeCee One eyes and 35% of iMics1 eyes. CONCLUSIONS Study findings suggest that PCO and Nd:YAG capsulotomy rates are significantly lower in eyes implanted with the EyeCee One IOL compared to the iMics1 IOL. Optic sharpness and lens material seem to be the decisive factors, while the stepped edge beneath the haptic junction appeared to be ineffective.",2020,A distinct gap between the anterior capsule and the IOL optic was present in 89% of eyes implanted with EyeCee One and 13% of iMics1 eyes.,"['80 patients with bilateral senile cataract', '39 patients (78 eyes) were evaluated after 3 years']","['hydrophobic acrylic single-piece intraocular Lenses (IOLs', 'hydrophobic acrylic single-piece IOLs', 'posterior capsule opacification (PCO) and Nd']","['PCO and Nd:YAG capsulotomy rates', 'Respective mean PCO scores', 'visual acuity, anterior fibrosis, capsule-optic edge interaction and distance between anterior and posterior capsule IOL surface', 'IOL optic', 'YAG capsulotomy rates', 'YAG capsulotomy']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2025430', 'cui_str': 'Senile cataract of both eyes'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0440181', 'cui_str': 'Acrylic dental material (substance)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0023319', 'cui_str': 'Lenses, Intraocular'}, {'cui': 'C1444680', 'cui_str': 'Posterior capsule opacification'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C0205154', 'cui_str': 'Along edge (qualifier value)'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0205148', 'cui_str': 'Surface (attribute)'}]",80.0,0.0689483,A distinct gap between the anterior capsule and the IOL optic was present in 89% of eyes implanted with EyeCee One and 13% of iMics1 eyes.,"[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Schartmüller', 'Affiliation': 'Department of Ophthalmology and Optometry of the Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Schriefl', 'Affiliation': 'Department of Ophthalmology and Optometry of the Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Schwarzenbacher', 'Affiliation': 'Department of Ophthalmology and Optometry of the Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Leydolt', 'Affiliation': 'Department of Ophthalmology and Optometry of the Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kundi', 'Affiliation': 'Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, 1090, Vienna, Austria.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Pieh', 'Affiliation': 'Department of Ophthalmology and Optometry of the Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Rupert', 'Initials': 'R', 'LastName': 'Menapace', 'Affiliation': 'Department of Ophthalmology and Optometry of the Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria. rupert.menapace@meduniwien.ac.at.'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Kriechbaum', 'Affiliation': 'Department of Ophthalmology and Optometry of the Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}]","Eye (London, England)",['10.1038/s41433-019-0569-x'] 149,32187464,A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.,"BACKGROUND No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. METHODS We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao 2 ) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao 2 ) to the fraction of inspired oxygen (Fio 2 ) of less than 300 mm Hg. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first. RESULTS A total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir-ritonavir group, and 100 to the standard-care group. Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.31; 95% confidence interval [CI], 0.95 to 1.80). Mortality at 28 days was similar in the lopinavir-ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, -5.8 percentage points; 95% CI, -17.3 to 5.7). The percentages of patients with detectable viral RNA at various time points were similar. In a modified intention-to-treat analysis, lopinavir-ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91). Gastrointestinal adverse events were more common in the lopinavir-ritonavir group, but serious adverse events were more common in the standard-care group. Lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events. CONCLUSIONS In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.).",2020,"Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.24; 95% confidence interval [CI], 0.90 to 1.72).","['Adults Hospitalized with Severe Covid-19', 'hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao 2 ) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao 2 ) to the fraction of inspired oxygen (Fio 2 ) of less than 300 mm Hg', '199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the', 'patients with severe illness']","['lopinavir-ritonavir', 'Lopinavir-ritonavir', 'Lopinavir-Ritonavir']","['Gastrointestinal adverse events', 'serious adverse events', 'time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first', 'Mortality']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'TS-COV19'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0030604', 'cui_str': 'Partial Pressure'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output (observable entity)'}, {'cui': 'C0428167', 'cui_str': 'FIO2'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}]","[{'cui': 'C0674432', 'cui_str': 'lopinavir'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0222045'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0960273', 'cui_str': 'CAME'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",199.0,0.162561,"Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.24; 95% confidence interval [CI], 0.90 to 1.72).","[{'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Cao', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Yeming', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Danning', 'Initials': 'D', 'LastName': 'Wen', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Jingli', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Guohui', 'Initials': 'G', 'LastName': 'Fan', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Lianguo', 'Initials': 'L', 'LastName': 'Ruan', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Song', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Cai', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Wei', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Xingwang', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Jiaan', 'Initials': 'J', 'LastName': 'Xia', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Nanshan', 'Initials': 'N', 'LastName': 'Chen', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Xiang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Yu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Bai', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Xuelei', 'Initials': 'X', 'LastName': 'Xie', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Caihong', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Yuan', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Huadong', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Hanping', 'Initials': 'H', 'LastName': 'Huang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Shengjing', 'Initials': 'S', 'LastName': 'Tu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Fengyun', 'Initials': 'F', 'LastName': 'Gong', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Wei', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Chongya', 'Initials': 'C', 'LastName': 'Dong', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Zhou', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Xiaoying', 'Initials': 'X', 'LastName': 'Gu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Jiuyang', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Zhibo', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Lianhan', 'Initials': 'L', 'LastName': 'Shang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Kunxia', 'Initials': 'K', 'LastName': 'Li', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Xuan', 'Initials': 'X', 'LastName': 'Dong', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Zhaohui', 'Initials': 'Z', 'LastName': 'Qu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Sixia', 'Initials': 'S', 'LastName': 'Lu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Xujuan', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Shunan', 'Initials': 'S', 'LastName': 'Ruan', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Shanshan', 'Initials': 'S', 'LastName': 'Luo', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Peng', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Cheng', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Lihong', 'Initials': 'L', 'LastName': 'Pan', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zou', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Chunmin', 'Initials': 'C', 'LastName': 'Jia', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Shuzhen', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Xudong', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Ge', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'He', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Haiyan', 'Initials': 'H', 'LastName': 'Zhan', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Qiu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Guo', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Chaolin', 'Initials': 'C', 'LastName': 'Huang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Jaki', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Frederick G', 'Initials': 'FG', 'LastName': 'Hayden', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Peter W', 'Initials': 'PW', 'LastName': 'Horby', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Dingyu', 'Initials': 'D', 'LastName': 'Zhang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}]",The New England journal of medicine,['10.1056/NEJMoa2001282'] 150,32305573,"Electroacupuncture trigeminal nerve stimulation plus body acupuncture for chemotherapy-induced cognitive impairment in breast cancer patients: An assessor-participant blinded, randomized controlled trial.","Chemotherapy causes various side effects, including cognitive impairment, known as 'chemobrain'. In this study, we determined whether a novel acupuncture mode called electroacupuncture trigeminal nerve stimulation plus body acupuncture (EA/TNS + BA) could produce better outcomes than minimum acupuncture stimulation (MAS) as controls in treating chemobrain and other symptoms in breast cancer patients. In this assessor- and participant-blinded, randomized controlled trial, 93 breast cancer patients under or post chemotherapy were randomly assigned to EA/TNS + BA (n = 46) and MAS (n = 47) for 2 sessions per week over 8 weeks. The Montreal Cognitive Assessment (MoCA) served as the primary outcome. Digit span test was the secondary outcomes for attentional function and working memory. The quality of life and multiple functional assessments were also evaluated. EA/TNS + BA treated group had much better performance than MAS-treated group on reverse digit span test at Week 2 and Week 8, with medium effect sizes of 0.53 and 0.48, respectively, although no significant differences were observed in MoCA score and prevalence of chemobrain between the two groups. EA/TNS + BA also markedly reduced incidences of diarrhoea, poor appetite, headache, anxiety, and irritation, and improved social/family and emotional wellbeing compared to MAS. These results suggest that EA/TNS + BA may have particular benefits in reducing chemotherapy-induced working memory impairment and the incidence of certain digestive, neurological, and distress-related symptoms. It could serve as an effective intervention for breast cancer patients under and post chemotherapy (trial registration: https://www.clinicaltrials.gov: NCT02457039).",2020,"EA/TNS+BA also markedly reduced incidences of diarrhoea, poor appetite, headache, anxiety, and irritation, and improved social/family and emotional wellbeing compared to MAS.","['breast cancer patients', '93 breast cancer patients under or post chemotherapy']","['minimum acupuncture stimulation (MAS', 'EA/TNS+BA', 'MAS', 'Chemotherapy', 'Electroacupuncture trigeminal nerve stimulation plus body acupuncture', 'acupuncture mode called electroacupuncture trigeminal nerve stimulation plus body acupuncture (EA/TNS+BA']","['quality of life and multiple functional assessments', 'MoCA score and prevalence of chemobrain', 'attentional function and working memory', 'diarrhoea, poor appetite, headache, anxiety, and irritation, and improved social/family and emotional wellbeing', 'reverse digit span test', 'Montreal Cognitive Assessment (MoCA']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439577', 'cui_str': 'Post-chemotherapy'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0040996', 'cui_str': 'Trigeminal nerve structure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1720420', 'cui_str': 'Call'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C4721272', 'cui_str': 'Montreal cognitive assessment score'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0232462', 'cui_str': 'Decrease in appetite'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0441723', 'cui_str': 'Irritation'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0025750', 'cui_str': ""3,3'-Dichloro-4,4'-Diaminodiphenylmethane""}]",93.0,0.224013,"EA/TNS+BA also markedly reduced incidences of diarrhoea, poor appetite, headache, anxiety, and irritation, and improved social/family and emotional wellbeing compared to MAS.","[{'ForeName': 'Zhang-Jin', 'Initials': 'ZJ', 'LastName': 'Zhang', 'Affiliation': 'Department of Chinese Medicine, The University of Hong Kong Shenzhen Hospital (HKU-SZH), Shenzhen, Guangdong 518053, China; School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. Electronic address: zhangzj@hku.hk.'}, {'ForeName': 'Sui-Cheung', 'Initials': 'SC', 'LastName': 'Man', 'Affiliation': 'School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Lo-Lo', 'Initials': 'LL', 'LastName': 'Yam', 'Affiliation': 'School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Chui Ying', 'Initials': 'CY', 'LastName': 'Yiu', 'Affiliation': 'School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Roland Ching-Yu', 'Initials': 'RC', 'LastName': 'Leung', 'Affiliation': 'Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Zong-Shi', 'Initials': 'ZS', 'LastName': 'Qin', 'Affiliation': 'School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Kit-Wa Sherry', 'Initials': 'KS', 'LastName': 'Chan', 'Affiliation': 'Department of Psychiatry, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Victor Ho Fun', 'Initials': 'VHF', 'LastName': 'Lee', 'Affiliation': 'Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Ava', 'Initials': 'A', 'LastName': 'Kwong', 'Affiliation': 'Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Wing-Fai', 'Initials': 'WF', 'LastName': 'Yeung', 'Affiliation': 'School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China.'}, {'ForeName': 'Winnie K W', 'Initials': 'WKW', 'LastName': 'So', 'Affiliation': 'The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, New Territory, Hong Kong.'}, {'ForeName': 'Lai Ming', 'Initials': 'LM', 'LastName': 'Ho', 'Affiliation': 'School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Ying-Ying', 'Initials': 'YY', 'LastName': 'Dong', 'Affiliation': 'Department of Psychosomatic Disorders, The Seventh People Hospital of Shaoxing, Shaoxing, Zhejiang 312000, China. Electronic address: 1941612959@qq.com.'}]","Brain, behavior, and immunity",['10.1016/j.bbi.2020.04.035'] 151,31199592,Cognitive Effects of Adding Caloric Restriction to Aerobic Exercise Training in Older Adults with Obesity.,"OBJECTIVE This study examined the short- and long-term effects of adding caloric restriction to 5 months of aerobic exercise training on executive function in sedentary older adults with obesity. METHODS Sedentary adults with obesity aged 65 to 79 years completed a randomized trial investigating the cardiorespiratory benefits of adding moderate (~ 250 kcal) or high (~ 600 kcal) caloric restriction to a 20-week aerobic exercise program. Approximately half (n = 88) completed a cognitive assessment battery at baseline, post intervention, and 18 to 24 months after intervention completion. The primary outcome was an executive function composite score. RESULTS In the overall sample, the executive function composite increased 0.114 from baseline to postintervention (P = 0.01). Randomization to caloric restriction did not significantly alter executive function over aerobic exercise alone, nor were there between-group differences on any individual executive function test following the intervention or at long-term follow-up. Adding caloric restriction to exercise was associated with a modest increase in Mini-Mental State Examination score (P = 0.04). In the overall sample, increases from baseline at long-term follow-up were noted in digit symbol and word list recall performance as well. CONCLUSIONS Adding caloric restriction to a 20-week aerobic exercise program does not worsen or improve executive function more than exercise alone assessed up to 24 months post randomization.",2019,"Randomization to caloric restriction did not significantly alter executive function over aerobic exercise alone, nor were there between-group differences on any individual executive function test following the intervention or at long-term follow-up.","['sedentary older adults with obesity', 'Older Adults with Obesity', 'Sedentary adults with obesity aged 65 to 79 years']","['cardiorespiratory benefits of adding moderate (~\u2009250 kcal) or high (~\u2009600 kcal) caloric restriction to a 20-week aerobic exercise program', 'aerobic exercise training', 'caloric restriction', 'Caloric Restriction to Aerobic Exercise Training', 'aerobic exercise program']","['Mini-Mental State Examination score', 'digit symbol and word list recall performance', 'executive function composite', 'individual executive function test', 'executive function composite score', 'executive function', 'cognitive assessment battery']","[{'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0439259', 'cui_str': 'kilocalorie'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C1135809', 'cui_str': 'Caloric Restriction'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C2960235', 'cui_str': 'Mini-mental state examination score (observable entity)'}, {'cui': 'C0582802', 'cui_str': 'Digit'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0542351', 'cui_str': 'Battery (event)'}]",,0.120639,"Randomization to caloric restriction did not significantly alter executive function over aerobic exercise alone, nor were there between-group differences on any individual executive function test following the intervention or at long-term follow-up.","[{'ForeName': 'Christina E', 'Initials': 'CE', 'LastName': 'Hugenschmidt', 'Affiliation': 'Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Leng', 'Affiliation': 'Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Lyles', 'Affiliation': 'Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Lemaat', 'Initials': 'L', 'LastName': 'Michael', 'Affiliation': 'Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Dougherty', 'Affiliation': 'Family Medicine, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Phyllis', 'Initials': 'P', 'LastName': 'Babcock', 'Affiliation': 'Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Laura D', 'Initials': 'LD', 'LastName': 'Baker', 'Affiliation': 'Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Tina E', 'Initials': 'TE', 'LastName': 'Brinkley', 'Affiliation': 'Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Barbara J', 'Initials': 'BJ', 'LastName': 'Nicklas', 'Affiliation': 'Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.'}]","Obesity (Silver Spring, Md.)",['10.1002/oby.22525'] 152,32297396,Effects of an intervention combining self-care and self-hypnosis on fatigue and associated symptoms in post-treatment cancer patients: A randomized-controlled trial.,"OBJECTIVE Cancer has a lot of consequences such as fatigue, sleep disturbances, emotional distress, cognitive impairment and reduced physical activity. Some hypnosis-based psychological interventions showed positive effects on fatigue, sleep and emotional distress, but generally focused on breast cancer patients. Our study aimed at assessing the effects of a group intervention combining self-care and self-hypnosis on quality of life of cancer patients. METHODS Our longitudinal randomized-controlled trial assessed the benefits of the intervention first on fatigue and secondly on associated symptoms (sleep, emotional distress, cognitive impairment and reduced physical activity) of post-treatment cancer patients, and investigated predictors of the evolution of fatigue. All variables were measured with questionnaires and an actigraph (for sleep and physical activity). RESULTS Ninety five women with different cancers were included in our study. Group-by-time effects were showed for fatigue, sleep, emotional distress and cognitive functioning: symptoms have improved in the intervention group compared to wait-list control group. Three predictors of the evolution of fatigue were revealed: depression, anxiety and worry. CONCLUSIONS Our group intervention had benefits for post-treatment cancer patients' quality of life. Impacting emotional distress could be important in order to decrease fatigue. Further studies are needed to replicate our results. This intervention could be easily implemented to improve quality of life of cancer patients. Registration: ClinicalTrials.gov (NCT03144154). Retrospectively registered on the 1st of May, 2017.",2020,"Group-by-time effects were showed for fatigue, sleep, emotional distress and cognitive functioning: symptoms have improved in the intervention group compared to wait-list control group.","['post-treatment cancer patients', '95 women with different cancers', 'breast cancer patients', 'cancer patients']","['intervention combining self-care and self-hypnosis', 'group intervention combining self-care and self-hypnosis']","['fatigue and associated symptoms', 'questionnaires and an actigraph (for sleep and physical activity', 'quality of life of cancer patients', 'associated symptoms (sleep, emotional distress, cognitive impairment and reduced physical activity', 'fatigue, sleep, emotional distress and cognitive functioning: symptoms', 'fatigue, sleep and emotional distress', 'quality of life', 'depression, anxiety, and worry']","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0020587', 'cui_str': 'Hypnotherapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0521989', 'cui_str': 'Associated symptom'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0700361', 'cui_str': 'Emotional distress'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0233481', 'cui_str': 'Worried'}]",95.0,0.0905398,"Group-by-time effects were showed for fatigue, sleep, emotional distress and cognitive functioning: symptoms have improved in the intervention group compared to wait-list control group.","[{'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Grégoire', 'Affiliation': 'Faculty of Psychology, Speech therapy and Educational Sciences, and Sensation and Perception Research Group, GIGA Research, University of Liège, Liège, Belgium.'}, {'ForeName': 'Marie-Elisabeth', 'Initials': 'ME', 'LastName': 'Faymonville', 'Affiliation': 'Interdisciplinary Algology Centre, CHU Liège, and Sensation and Perception Research Group, GIGA Research, University of Liège, Liège, Belgium.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Vanhaudenhuyse', 'Affiliation': 'Interdisciplinary Algology Centre, CHU Liège, and Sensation and Perception Research Group, GIGA Research, University of Liège, Liège, Belgium.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Charland-Verville', 'Affiliation': 'GIGA-Consciousness, Coma Science Group & Neurology Department, University and CHU of Liège, Liège, Belgium.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Jerusalem', 'Affiliation': 'Medical Oncology Department, CHU Liège and University of Liège, Liège, Belgium.'}, {'ForeName': 'Sylvie', 'Initials': 'S', 'LastName': 'Willems', 'Affiliation': 'Faculty of Psychology, Speech therapy and Educational Sciences, University of Liège, Liège, Belgium.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Bragard', 'Affiliation': 'Research and Continuing Education Departement, and CRIG Research Center, Haute Ecole Libre Mosane (HELMo), Liège, Belgium.'}]",Psycho-oncology,['10.1002/pon.5395'] 153,32330594,Pilot study of combined aerobic and resistance exercise on fatigue for patients with head and neck cancer: Inflammatory and epigenetic changes.,"This pilot study examined whether a combined aerobic resistance exercise program reduced fatigue and the potential inflammatory and epigenetic mechanisms in patients with head and neck cancer (HNC) receiving intensity-modulated radiotherapy. The exercise group (N = 12) received a 3-month supervised aerobic resistance exercise intervention that was initiated before a 6-week radiotherapy regimen; the control group (N = 14) received standard care. Fatigue was measured using Multidimensional Fatigue Inventory-20; physical function measures included a 6-minute walk distance (6MWD), chair stands, bicep curls, and hand grip strength. Inflammatory markers and DNA methylation data were acquired using standardized protocol. Patients were mostly white (93%) and male (81%) with a mean age of 57 years. At the end of the intervention, the exercise group had a marginal decrease in fatigue compared with the control (-5.0 vs. 4.9; P = 0.10). The exercise group had a significantly greater improvement in 6MWD (29.8 vs. -55.5 m; P = 0.04), and a marginally smaller decline in hand grip (-0.3 vs. -5.8 lbs; P = 0.05) at the end of the intervention than the control. No significant difference in inflammatory markers was observed between groups. Lower plasma interleukin (IL) 6, IL1 receptor antagonist, tumor necrosis factor α (TNFα), soluble TNF receptor II and C-reactive protein were significantly associated with increased 6MWD, chair stand, and bicep curl at the end of the intervention (p < 0.05). Among the 1152 differentially methylated sites (DMS) after intervention (p < 0.001), 163 DMS were located in gene promoter regions. Enrichment analysis suggested that the top 10 upstream regulators were associated with tumor (HNF4A, RPP38, HOXA9, SAHM1, CDK7, NDN, RPS15) and inflammation (IRF7, CRKL, ONECUT1). The top 5 diseases or functions annotations of the 62 hypermethylated DMS indicated anti-tumor and anti-inflammatory effects that might be linked to exercise. These findings suggest that exercise may improve physical performance and reduce fatigue, which could be further linked to decreased inflammation, during active radiotherapy for HNC patients. Larger studies are warranted.",2020,"Lower plasma interleukin (IL) 6, IL1 receptor antagonist, tumor necrosis factor α (TNFα), soluble TNF receptor II and C-reactive protein were significantly associated with increased 6MWD, chair stand, and bicep curl at the end of the intervention (p<0.05).","['Patients were mostly white (93%) and male (81%) with a mean age of 57 years', 'Patients with Head and Neck Cancer', 'patients with head and neck cancer (HNC) receiving intensity-modulated radiotherapy']","['supervised aerobic resistance exercise intervention', 'Combined Aerobic and Resistance Exercise', 'combined aerobic resistance exercise program', 'standard care']","['6MWD, chair stand, and bicep curl', '6-minute walk distance (6MWD), chair stands, bicep curls, and hand grip strength', 'inflammatory markers', 'Lower plasma interleukin (IL) 6, IL1 receptor antagonist, tumor necrosis factor α (TNFα), soluble TNF receptor II and C-reactive protein', 'fatigue and the potential inflammatory and epigenetic mechanisms', 'Fatigue', '6MWD', 'physical performance and reduce fatigue', 'fatigue', 'tumor (HNF4A, RPP38, HOXA9, SAHM1, CDK7, NDN, RPS15) and inflammation (IRF7, CRKL, ONECUT1']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0559499', 'cui_str': 'Biceps brachii muscle structure'}, {'cui': 'C0010474', 'cui_str': ""Curling's ulcers""}, {'cui': 'C1293900', 'cui_str': 'Hand grip'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0063710', 'cui_str': 'Interleukin 1 Receptor'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0077503', 'cui_str': 'Tumor Necrosis Factor Receptor'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C1516924', 'cui_str': 'Epigenetic Process'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0386322', 'cui_str': 'Hoxa9 protein'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C1530281', 'cui_str': 'IRF7 protein, human'}, {'cui': 'C0219488', 'cui_str': 'CRKL protein'}]",163.0,0.0291941,"Lower plasma interleukin (IL) 6, IL1 receptor antagonist, tumor necrosis factor α (TNFα), soluble TNF receptor II and C-reactive protein were significantly associated with increased 6MWD, chair stand, and bicep curl at the end of the intervention (p<0.05).","[{'ForeName': 'Canhua', 'Initials': 'C', 'LastName': 'Xiao', 'Affiliation': 'School of Nursing, Yale University, 400 West Campus Drive, Orange 06477, United States. Electronic address: canhua.xiao@yale.edu.'}, {'ForeName': 'Jonathan J', 'Initials': 'JJ', 'LastName': 'Beitler', 'Affiliation': 'Department of Radiation, School of Medicine, Emory University, 1520 Clifton Road NE, Atlanta 30322, United States.'}, {'ForeName': 'Kristin A', 'Initials': 'KA', 'LastName': 'Higgins', 'Affiliation': 'Department of Radiation, School of Medicine, Emory University, 1520 Clifton Road NE, Atlanta 30322, United States.'}, {'ForeName': 'Cynthia E', 'Initials': 'CE', 'LastName': 'Chico', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, School of Medicine, Emory University, 1365-B Clifton Road, Atlanta, GA 30322, United States.'}, {'ForeName': 'Janice S', 'Initials': 'JS', 'LastName': 'Withycombe', 'Affiliation': ""School of Nursing, Clemson University, 508 Edward's, Clemson, SC 29634, United States.""}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': 'State Key Laboratory of Medical Neurobiology and MOE Frontier Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200433, China.'}, {'ForeName': 'Hongyu', 'Initials': 'H', 'LastName': 'Zhao', 'Affiliation': 'Department of Epidemiology and Public Health, School of Medicine, Yale University, 300 George Street, New Haven, CT 06510, United States.'}, {'ForeName': 'I-Hsin', 'Initials': 'IH', 'LastName': 'Lin', 'Affiliation': 'Yale Center for Analytical Sciences, School of Public Health, Yale University, 300 George Street, New Haven, CT 06510, United States.'}, {'ForeName': 'Fangyong', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'School of Public Health, Yale University, 60 College St, New Haven, CT 06510, United States.'}, {'ForeName': 'Sangchoon', 'Initials': 'S', 'LastName': 'Jeon', 'Affiliation': 'School of Nursing, Yale University, 400 West Campus Drive, Orange 06477, United States.'}, {'ForeName': 'Melinda', 'Initials': 'M', 'LastName': 'Irwin', 'Affiliation': 'School of Public Health, Yale University, 60 College St, New Haven, CT 06510, United States.'}, {'ForeName': 'Deborah W', 'Initials': 'DW', 'LastName': 'Bruner', 'Affiliation': 'School of Nursing, Emory University, 1520 Clifton Road NE, Atlanta 30322, United States.'}, {'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Miller', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, School of Medicine, Emory University, 1365-B Clifton Road, Atlanta, GA 30322, United States.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Gary', 'Affiliation': 'School of Nursing, Emory University, 1520 Clifton Road NE, Atlanta 30322, United States.'}]","Brain, behavior, and immunity",['10.1016/j.bbi.2020.04.044'] 154,31899509,Transcranial Random Noise Stimulation for the Acute Treatment of Depression: A Randomized Controlled Trial.,"BACKGROUND Transcranial electrical stimulation has broad potential as a treatment for depression. Transcranial random noise stimulation, which delivers randomly fluctuating current intensities, may have greater cortical excitatory effects compared with other forms of transcranial electrical stimulation. We therefore aimed to investigate the antidepressant efficacy of transcranial random noise stimulation. METHODS Depressed participants were randomly assigned by computer number generator to receive 20 sessions of either active or sham transcranial random noise stimulation over 4 weeks in a double-blinded, parallel group randomized-controlled trial. Transcranial random noise stimulation was delivered for 30 minutes with a direct current offset of 2 mA and a random noise range of 2 mA. Primary analyses assessed changes in depression severity using the Montgomery-Asperg Depression Rating Scale. Neuroplasticity, neuropsychological, and safety outcomes were analyzed as secondary measures. RESULTS Sixty-nine participants were randomized, of which 3 discontinued treatment early, leaving 66 (sham n = 34, active n = 32) for per-protocol analysis. Depression severity scores reduced in both groups (Montgomery-Asperg Depression Rating Scale reduction in sham = 7.0 [95% CI = 5.0-8.9]; and active = 5.2 [95% CI = 3.2-7.3]). However, there were no differences between active and sham groups in the reduction of depressive symptoms or the number of participants meeting response (sham = 14.7%; active = 3.1%) and remission criteria (sham = 5.9%; active = 0%). Erythema, paresthesia, fatigue, and dizziness/light-headedness occurred more frequently in the active transcranial random noise stimulation group. Neuroplasticity, neuropsychological, and acute cognitive effects were comparable between groups. CONCLUSION Our results do not support the use of transcranial random noise stimulation with the current stimulation parameters as a therapeutic intervention for the treatment of depression. CLINICAL TRIAL REGISTRATION AT CLINICALTRIALS gov/NCT01792414.",2020,"However, there were no differences between active and sham groups in the reduction of depressive symptoms, or the number of participants meeting response (sham = 14.7%; active = 3.1%) and remission criteria (sham = 5.9%; active = 0%).","['69 participants', 'Depressed participants', 'depression']","['Transcranial electrical stimulation', 'Transcranial random noise stimulation', 'Transcranial random noise stimulation (tRNS', 'computer number generator to receive 20 sessions of either active or sham tRNS']","['Neuroplasticity, neuropsychological and acute cognitive effects', 'Neuroplasticity, neuropsychological, and safety outcomes', 'Erythema, paraesthesia, fatigue, and dizziness/light-headedness', 'depressive symptoms', 'Depression severity scores', 'depression severity using the Montgomery-Asperg Depression Rating Scale (MADRS']","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]","[{'cui': 'C0455803', 'cui_str': 'Transcranial Electrical Stimulation'}, {'cui': 'C3852967', 'cui_str': 'Transcranial Random Noise Stimulation'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0237638', 'cui_str': 'Generator'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C0027880', 'cui_str': 'Neural Plasticity'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0030554', 'cui_str': 'Paresthesia'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0220870', 'cui_str': 'Lightheadedness'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0457451', 'cui_str': 'Severity score (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0222045'}]",69.0,0.574411,"However, there were no differences between active and sham groups in the reduction of depressive symptoms, or the number of participants meeting response (sham = 14.7%; active = 3.1%) and remission criteria (sham = 5.9%; active = 0%).","[{'ForeName': 'Stevan', 'Initials': 'S', 'LastName': 'Nikolin', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Angelo', 'Initials': 'A', 'LastName': 'Alonzo', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Donel', 'Initials': 'D', 'LastName': 'Martin', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Gálvez', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Buten', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Rohan', 'Initials': 'R', 'LastName': 'Taylor', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Goldstein', 'Affiliation': 'Currumbin Clinic, Currumbin, Australia.'}, {'ForeName': 'Cristal', 'Initials': 'C', 'LastName': 'Oxley', 'Affiliation': 'Department of Child and Adolescent Psychiatry, Michael Rutter Centre - South London and Maudsley NHS Foundation Trust, UK.'}, {'ForeName': 'Dusan', 'Initials': 'D', 'LastName': 'Hadzi-Pavlovic', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Colleen K', 'Initials': 'CK', 'LastName': 'Loo', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, Australia.'}]",The international journal of neuropsychopharmacology,['10.1093/ijnp/pyz072'] 155,32145405,Age-related emotional bias in associative memory consolidation: The role of sleep.,"Sleep plays a crucial role in memory consolidation. However, the influence of sleep on emotional memory consolidation in older adults, especially in the context of associative memory, which is more cognitively demanding than item memory, remains elusive. For this study we recruited young and older adults, and randomly assigned them into the sleep or wake condition. They were administrated a visual-spatial associative memory task, which required them to remember a picture and its location. We measured memory performance for positive, neutral, and negative stimuli before and after a 12-h interval of being awake or asleep. An accuracy analysis indicated a beneficial effect of sleep on location memory regardless of age and valence. In addition, in a more fine-grained analysis, the drift rate from diffusion modeling showed that sleep facilitated the consolidation of negative stimuli in young adults, while this emotion bias shifted to positive stimuli in older adults. Moreover, negative correlations were observed between the change of memory performance and sleep characteristics in older adults, indicating that more sleep results in fewer negative memories. Our results provide a relatively weak support for an age-related emotional bias in the context of associative memory, manifested in the absence of an age-by-valence interaction in accuracy, whilst a modeling parameter in consideration of both accuracy and response time yielded evidence consistent with the predictions of the socioemotional selectivity theory.",2020,An accuracy analysis indicated a beneficial effect of sleep on location memory regardless of age and valence.,"['recruited young and older adults', 'older adults']",[],"['memory performance and sleep characteristics', 'memory performance for positive, neutral, and negative stimuli']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]",[],"[{'cui': 'C1285654', 'cui_str': 'Ability to remember'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0234402', 'cui_str': 'Stimulus, function (observable entity)'}]",,0.0344915,An accuracy analysis indicated a beneficial effect of sleep on location memory regardless of age and valence.,"[{'ForeName': 'Sheng-Yin', 'Initials': 'SY', 'LastName': 'Huan', 'Affiliation': 'Faculty of Psychology, Southwest University, Chongqing, China.'}, {'ForeName': 'Kun-Peng', 'Initials': 'KP', 'LastName': 'Liu', 'Affiliation': 'Faculty of Psychology, Southwest University, Chongqing, China.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Lei', 'Affiliation': 'Faculty of Psychology, Southwest University, Chongqing, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Faculty of Psychology, Southwest University, Chongqing, China; Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China. Electronic address: helen12@swu.edu.cn.'}]",Neurobiology of learning and memory,['10.1016/j.nlm.2020.107204'] 156,32324888,"A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.","Acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell transplantation (HCT) is a primary cause of nonrelapse mortality and a major barrier to successful transplant outcomes. Itacitinib is a Janus kinase (JAK)1-selective inhibitor that has demonstrated efficacy in preclinical models of aGVHD. We report results from the first registered study of a JAK inhibitor in patients with aGVHD. This was an open-label phase 1 study enrolling patients aged ≥18 years with first HCT from any source who developed grade IIB to IVD aGVHD. Patients with steroid-naive or steroid-refractory aGVHD were randomized 1:1 to itacitinib 200 mg or 300 mg once daily plus corticosteroids. The primary endpoint was safety and tolerability; day 28 overall response rate (ORR) was the main secondary endpoint. Twenty-nine patients (200 mg, n = 14; 300 mg, n = 15) received ≥1 dose of itacitinib and were included in safety and efficacy assessments. One dose-limiting toxicity was reported (grade 3 thrombocytopenia attributed to GVHD progression in a patient receiving 300 mg itacitinib with preexisting thrombocytopenia). The most common nonhematologic treatment-emergent adverse event was diarrhea (48.3%, n = 14); anemia occurred in 11 patients (38%). ORR on day 28 for all patients in the 200-mg and 300-mg groups was 78.6% and 66.7%, respectively. Day 28 ORR was 75.0% for patients with treatment-naive aGVHD and 70.6% in those with steroid-refractory aGVHD. All patients receiving itacitinib decreased corticosteroid use over time. In summary, itacitinib was well tolerated and demonstrated encouraging efficacy in patients with steroid-naive or steroid-refractory aGVHD, warranting continued clinical investigations. This trial was registered at www.clinicaltrials.gov as #NCT02614612.",2020,"ORR on day 28 for all patients in the 200-mg and 300-mg groups was 78.6% and 66.7%, respectively.","['patients with acute graft-versus-host disease', 'Patients with steroid-naive or steroid-refractory aGVHD', 'patients aged ≥18 years with first HCT from any source who developed grade IIB to IVD aGVHD', 'patients with aGVHD']","['JAK inhibitor', 'Acute graft-versus-host disease (aGVHD', 'itacitinib, a selective JAK1 inhibitor', 'allogeneic hematopoietic cell transplantation (HCT', 'itacitinib 200 mg or 300 mg once daily plus corticosteroids']","['anemia', 'diarrhea', 'safety and tolerability; day 28 overall response rate (ORR', 'ORR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0856825', 'cui_str': 'Acute graft-versus-host disease'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0449416', 'cui_str': 'Source'}, {'cui': 'C0441800', 'cui_str': 'Grade'}]","[{'cui': 'C3854325', 'cui_str': 'Janus kinase inhibitor'}, {'cui': 'C0856825', 'cui_str': 'Acute graft-versus-host disease'}, {'cui': 'C0169658', 'cui_str': 'JAK1 Protein Tyrosine Kinase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}]","[{'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.0808937,"ORR on day 28 for all patients in the 200-mg and 300-mg groups was 78.6% and 66.7%, respectively.","[{'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Schroeder', 'Affiliation': 'Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis, St. Louis, MO.'}, {'ForeName': 'H Jean', 'Initials': 'HJ', 'LastName': 'Khoury', 'Affiliation': 'Division of Hematology, Winship Cancer Institute of Emory School of Medicine, Atlanta, GA.'}, {'ForeName': 'Madan', 'Initials': 'M', 'LastName': 'Jagasia', 'Affiliation': 'Vanderbilt-Ingram Cancer Center, Nashville, TN.'}, {'ForeName': 'Haris', 'Initials': 'H', 'LastName': 'Ali', 'Affiliation': 'City of Hope National Medical Center, Duarte, CA.'}, {'ForeName': 'Gary J', 'Initials': 'GJ', 'LastName': 'Schiller', 'Affiliation': 'Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.'}, {'ForeName': 'Karl', 'Initials': 'K', 'LastName': 'Staser', 'Affiliation': 'Department of Dermatology, Washington University School of Medicine in St Louis, St Louis, MO.'}, {'ForeName': 'Jaebok', 'Initials': 'J', 'LastName': 'Choi', 'Affiliation': 'Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis, St. Louis, MO.'}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Gehrs', 'Affiliation': 'Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis, St. Louis, MO.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Arbushites', 'Affiliation': 'Incyte Corporation, Wilmington, DE.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': 'Incyte Corporation, Wilmington, DE.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Langmuir', 'Affiliation': 'Incyte Corporation, Wilmington, DE.'}, {'ForeName': 'Nithya', 'Initials': 'N', 'LastName': 'Srinivas', 'Affiliation': 'Incyte Corporation, Wilmington, DE.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Pratta', 'Affiliation': 'Incyte Corporation, Wilmington, DE.'}, {'ForeName': 'Miguel-Angel', 'Initials': 'MA', 'LastName': 'Perales', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Yi-Bin', 'Initials': 'YB', 'LastName': 'Chen', 'Affiliation': 'Massachusetts General Hospital, Boston, MA; and.'}, {'ForeName': 'Gabrielle', 'Initials': 'G', 'LastName': 'Meyers', 'Affiliation': 'Department of Medicine, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.'}, {'ForeName': 'John F', 'Initials': 'JF', 'LastName': 'DiPersio', 'Affiliation': 'Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis, St. Louis, MO.'}]",Blood advances,['10.1182/bloodadvances.2019001043'] 157,32324634,Interprofessional Improv: Using Theater Techniques to Teach Health Professions Students Empathy in Teams.,"PROBLEM Health professionals need to learn how to relate to one another to ensure high-quality patient care and to create collaborative and supportive teams in the clinical environment. One method for addressing both of these goals is teaching empathy during professional training to foster connection and commonality across differences. The authors describe a pilot improvisational theater (improv) course and present the preliminary outcomes showing its impact on interprofessional empathy. APPROACH In 2016-2017, the authors piloted a 15-hour course to teach interprofessional empathy to health professions students at the University of Wisconsin-Madison using improv techniques. The authors used a convergent mixed-methods design to evaluate the course's impact on interprofessional empathy. Students enrolled in the course (intervention group, n = 45) and a comparison group (n = 41) completed 2 validated empathy questionnaires (Interpersonal Reactivity Index [IRI], Consultative and Relational Empathy [CARE] measure) and a facial expression recognition task to measure empathy in the pre- and postintervention periods. Differences were examined using paired t tests. Semistructured interviews were conducted with 8 course participants to gain a deeper understanding of the course's effects. OUTCOMES The intervention group's mean scores on 5 CARE items improved significantly: ease, care, explain, help, and plan. On the IRI, personal distress levels decreased significantly in both the intervention and comparison groups. In the interviews, students who took the class reported a positive impact on their interprofessional relationships and on their ability to think on their feet. They also reported improv influenced other areas of their lives, including patient care and interactions with people outside their work life. NEXT STEPS The authors have continued to offer the course. They aim to conduct a randomized controlled study with medical students and test durability by measuring empathy again 3-6 months following the intervention.",2020,"On the IRI, personal distress levels decreased significantly in both the intervention and comparison groups.","['medical students', 'In 2016-2017 the authors piloted a 15-hour course to teach interprofessional empathy to health professions students at the University of Wisconsin-Madison using improv techniques', 'Interprofessional Improv: Using Theater Techniques to Teach Health Professions Students Empathy in Teams', 'Students enrolled in the course (intervention group, n = 45) and a comparison group (n = 41) completed 2']",[],"['IRI, personal distress levels', 'validated empathy questionnaires (Interpersonal Reactivity Index [IRI], Consultative and Relational Empathy [CARE] measure) and a facial expression recognition task to measure empathy', 'mean scores on 5 CARE items improved significantly: ease, care, explain, help, and plan']","[{'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C3812881', 'cui_str': 'Author'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0018722', 'cui_str': 'Health Professions'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0043193', 'cui_str': 'Wisconsin'}, {'cui': 'C0475307', 'cui_str': 'Theatre'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0960740', 'cui_str': 'ImProv'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]",[],"[{'cui': 'C0022077', 'cui_str': 'Iris structure'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}]",,0.0187709,"On the IRI, personal distress levels decreased significantly in both the intervention and comparison groups.","[{'ForeName': 'Amy B', 'Initials': 'AB', 'LastName': 'Zelenski', 'Affiliation': 'A.B. Zelenski is assistant professor and director of medical education, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. N. Saldivar is chair, Department of Theatre, University of Nevada, Las Vegas, and executive director, Nevada Conservatory Theatre, Las Vegas, Nevada. L.S. Park is a clinical research coordinator, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. V. Schoenleber is a project manager, Internal Medicine Residency Program, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. F. Osman is a biostatistician, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. S. Kraemer is founder and owner, Blueprint for Education, Madison, Wisconsin.'}, {'ForeName': 'Norma', 'Initials': 'N', 'LastName': 'Saldivar', 'Affiliation': ''}, {'ForeName': 'Linda S', 'Initials': 'LS', 'LastName': 'Park', 'Affiliation': ''}, {'ForeName': 'Vonnie', 'Initials': 'V', 'LastName': 'Schoenleber', 'Affiliation': ''}, {'ForeName': 'Fauzia', 'Initials': 'F', 'LastName': 'Osman', 'Affiliation': ''}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Kraemer', 'Affiliation': ''}]",Academic medicine : journal of the Association of American Medical Colleges,['10.1097/ACM.0000000000003420'] 158,32325005,Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial.,"Rationale: Idiopathic pulmonary fibrosis (IPF) is a deadly disease with increasingly impaired health-related quality of life (HRQOL). eHealth technologies facilitate collection of physiological outcomes and patient-reported outcomes at home, but randomized controlled trials (RCTs) on the effects of eHealth are scarce. Objectives: To investigate whether a home monitoring program improves HRQOL and medication use for patients with IPF. Methods: We performed a multicenter RCT in newly treated patients with IPF. Patients were randomly assigned to standard care or a home monitoring program on top of standard care for 24 weeks. The home monitoring program included home spirometry, reporting of symptoms and side effects, patient-reported outcomes, information, a medication coach, and eConsultations. The primary endpoint was between-group difference in change in King's Brief Interstitial Lung Disease Questionnaire (K-BILD) score at 24 weeks. Measurements and Main Results: A total of 90 patients were randomized (46 assigned to the home monitoring group and 44 to the standard care group). After 24 weeks, no statistically significant difference was found in K-BILD total score, with a 2.70-point increase in the home monitoring group (SD = 9.5) and a 0.03-point increase in the standard care group (SD = 10.4); between-group difference was 2.67 points (95% confidence interval [CI], -1.85 to 7.17; P  = 0.24). Between-group difference in psychological domain score was 5.6 points (95% CI, -1.13 to 12.3; P  = 0.10), with an increase of 5.12 points in the home monitoring group (SD = 15.8) and a decline of 0.48 points in the standard care group (SD = 13.3). In the home monitoring group, medication was more often adjusted (1 vs. 0.3 adjustments per patient; 95% CI, 0.2 to 1.3; P  = 0.027). Patient satisfaction with the home monitoring program was high. Home-based spirometry was highly correlated with hospital-based spirometry over time. Conclusions: The results of this first-ever eHealth RCT in IPF showed that a comprehensive home monitoring program did not improve overall HRQOL measured with K-BILD but tended to improve psychological well-being. Home monitoring was greatly appreciated by patients and allowed for individually tailored medication adjustments.Clinical trial registered with www.clinicaltrials.gov (NCT03420235).",2020,"After 24 weeks, no statistically significant differences were found in K-BILD total score (home monitoring group:+2.7 points, standard care:+0.03, p=0.24) and psychological domain score (home monitoring group:+5.1, standard care:-0.5, p=0.1).","['IPF patients', '90 patients were randomized (46 patients home monitoring, 44 standard care', 'Patients with Idiopathic Pulmonary Fibrosis', 'Idiopathic pulmonary fibrosis (IPF', 'newly treated patients with IPF']",['standard care or a home monitoring program'],"['psychological domain score', 'change in Kings Brief Interstitial Lung disease (K-BILD) questionnaire score', 'psychological wellbeing', 'home spirometry, reporting of symptoms and side-effects, PROMs, information, a medication coach and eConsultations', 'overall HRQOL', 'K-BILD total score']","[{'cui': 'C1800706', 'cui_str': 'Idiopathic pulmonary fibrosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0206062', 'cui_str': 'Interstitial lung disease'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0037981', 'cui_str': 'Spirometry'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",90.0,0.0641793,"After 24 weeks, no statistically significant differences were found in K-BILD total score (home monitoring group:+2.7 points, standard care:+0.03, p=0.24) and psychological domain score (home monitoring group:+5.1, standard care:-0.5, p=0.1).","[{'ForeName': 'Catharina C', 'Initials': 'CC', 'LastName': 'Moor', 'Affiliation': 'Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Rémy L M', 'Initials': 'RLM', 'LastName': 'Mostard', 'Affiliation': 'Department of Respiratory Medicine, Zuyderland Medical, Heerlen, the Netherlands.'}, {'ForeName': 'Jan C', 'Initials': 'JC', 'LastName': 'Grutters', 'Affiliation': 'Department of Pulmonology, Interstitial Lung Diseases Centre of Excellence, St. Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Bresser', 'Affiliation': 'Department of Respiratory Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands; and.'}, {'ForeName': 'Joachim G J V', 'Initials': 'JGJV', 'LastName': 'Aerts', 'Affiliation': 'Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Niels H', 'Initials': 'NH', 'LastName': 'Chavannes', 'Affiliation': 'Department of Public Health and Primary Care, National eHealth Living Lab, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Marlies S', 'Initials': 'MS', 'LastName': 'Wijsenbeek', 'Affiliation': 'Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.'}]",American journal of respiratory and critical care medicine,['10.1164/rccm.202002-0328OC'] 159,32325958,Modifications to Infant Formula Instructions Improve the Accuracy of Formula Dispensing.,"Readability of infant formula preparation instructions is universally poor, which may result in inaccurate infant feeding. Given that inaccurate formula dispensing can lead to altered infant growth and increased adiposity, there is an increased need for easy to follow instructions for formula preparation. We hypothesize that altering infant formula instruction labels using feedback from iterative focus groups will improve the preparation accuracy of powdered infant formula in a randomized controlled trial. Participants were recruited from the community, 18 years of age or older, willing to disclose demographic information for focus group matching, and willing to participate freely in the first ( n = 21) or second ( n = 150) phase of the study. In the second phase, participants were randomized to use the standard manufacturer instructions or to use the modified instructions created in the first phase. Accuracy was defined as the percent error between manufacturer-intended powder formula quantity and the amount dispensed by the participant. Participants who were assigned to the modified instructions were able to dispense the powdered formula more accurately than participants who used the standard manufacturer instructions (-0.67 ± 0.76 vs. -4.66 ± 0.74% error; p < 0.0001). Accuracy in powdered formula dispensing was influenced by bottle size ( p = 0.02) but not by body mass index ( p = 0.17), education level ( p = 0.75), income ( p = 0.7), age ( p = 0.89) or caregiver status ( p = 0.18). Percent error of water measurement was not different between the groups (standard: -1.4 ± 0.6 vs. modified: 0.7 ± 0.6%; p = 0.38). Thus, caloric density was more accurate in the modified instructions group compared to the standard manufacturer instructions group (-0.3 ± 0.6 vs.-2.9 ± 0.9%; p = 0.03). Infant formula label modifications using focus group feedback increased infant formula preparation accuracy.",2020,Participants who were assigned to the modified instructions were able to dispense the powdered formula more accurately than participants who used the standard manufacturer instructions (-0.67 ± 0.76 vs. -4.66 ± 0.74% error; p < 0.0001).,"['Participants were recruited from the community, 18 years of age or older, willing to disclose demographic information for focus group matching, and willing to participate freely in the first ( n = 21) or second ( n = 150) phase of the study']",[],"['education level', 'Percent error of water measurement', 'caloric density']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0600109', 'cui_str': 'Willing'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0016400', 'cui_str': 'Focus Groups'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],"[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0178587', 'cui_str': 'Density'}]",,0.057273,Participants who were assigned to the modified instructions were able to dispense the powdered formula more accurately than participants who used the standard manufacturer instructions (-0.67 ± 0.76 vs. -4.66 ± 0.74% error; p < 0.0001).,"[{'ForeName': 'Linda A', 'Initials': 'LA', 'LastName': 'Gilmore', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.'}, {'ForeName': 'Abby D', 'Initials': 'AD', 'LastName': 'Altazan', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.'}, {'ForeName': 'Emily W', 'Initials': 'EW', 'LastName': 'Flanagan', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.'}, {'ForeName': 'Alexandra G', 'Initials': 'AG', 'LastName': 'Beyer', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.'}, {'ForeName': 'Kelsey N', 'Initials': 'KN', 'LastName': 'Olson', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.'}, {'ForeName': 'Alexis A', 'Initials': 'AA', 'LastName': ""O'Connell"", 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.'}, {'ForeName': 'Timothy H', 'Initials': 'TH', 'LastName': 'Nguyen', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.'}, {'ForeName': 'Robbie A', 'Initials': 'RA', 'LastName': 'Beyl', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.'}, {'ForeName': 'Leanne M', 'Initials': 'LM', 'LastName': 'Redman', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.'}]",Nutrients,['10.3390/nu12041150'] 160,31676898,Effects of a Community-to-Clinic Navigation Intervention on Colorectal Cancer Screening Among Underserved People.,"BACKGROUND Colorectal cancer screening remains suboptimal among poor and underserved people. PURPOSE We tested the effectiveness of a community-to-clinic navigator intervention to guide multicultural, underinsured individuals into primary care clinics to complete colorectal cancer screening. METHODS This two-phase behavioral intervention study was conducted in Phoenix, Arizona (2012-2018). Community sites were randomized to group education or group education plus tailored navigation to increase attendance at primary care clinics (Phase I). Individuals who completed a clinic appointment received the tailored navigation in person or via phone (Phase II). RESULTS In Phase I (N = 345), 37.9% of the intervention group scheduled a clinic appointment versus 19.4% of the comparison group. In Phase II, 26.5% of the original intervention group were screened versus only 10.4% of the original comparison group. Those in the intervention group were 3.84 times more likely to be screened than were those in the comparison group (odds ratio = 3.84; 95% confidence interval = 1.81-6.92). CONCLUSIONS Translation of an efficacious tailored navigation intervention for colorectal cancer screening to a community-to-clinic context is associated with significantly increased rates of colorectal cancer screening. Navigation assistance to address barriers to screening may serve as the most important component of any educational program to increase individual adherence to colorectal cancer screening.",2020,Community sites were randomized to group education or group education plus tailored navigation to increase attendance at primary care clinics (Phase I).,"['Phoenix, Arizona (2012-2018', 'Colorectal Cancer Screening Among Underserved People']","['Community-to-Clinic Navigation Intervention', 'group education or group education plus tailored navigation to increase attendance at primary care clinics (Phase I', 'tailored navigation in person or via phone (Phase II', 'community-to-clinic navigator intervention']",[],"[{'cui': 'C0003787', 'cui_str': 'Arizona'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0150375', 'cui_str': 'Group instruction'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic (environment)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}]",[],,0.0153092,Community sites were randomized to group education or group education plus tailored navigation to increase attendance at primary care clinics (Phase I).,"[{'ForeName': 'Usha', 'Initials': 'U', 'LastName': 'Menon', 'Affiliation': 'University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Szalacha', 'Affiliation': 'University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Kue', 'Affiliation': 'The Ohio State University, Columbus, OH, USA.'}, {'ForeName': 'Patricia M', 'Initials': 'PM', 'LastName': 'Herman', 'Affiliation': 'Rand Corporation, Santa Monica, CA, USA.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Bucho-Gonzalez', 'Affiliation': 'Arizona State University, Phoenix, AZ, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Lance', 'Affiliation': 'University of Arizona Cancer Center, Tucson, AZ, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Larkey', 'Affiliation': 'Arizona State University, Phoenix, AZ, USA.'}]",Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,['10.1093/abm/kaz049'] 161,32321115,Beneficial effect of fluid warming in elderly patients with bladder cancer undergoing Da Vinci robotic-assisted laparoscopic radical cystectomy.,"OBJECTIVES The enhanced recovery after surgery (ERAS) protocol recommends prevention of intraoperative hypothermia. However, the beneficial effect of maintaining normothermia after radical cystectomy has not been evaluated. This study aimed to investigate the efficacy of fluid warming nursing in elderly patients undergoing Da Vinci robotic-assisted laparoscopic radical cystectomy. METHODS A total of 108 patients with bladder cancer scheduled to undergo DaVinci robotic-assisted laparoscopic radical cystectomy were recruited and randomly divided into the control group (n=55), which received a warming blanket (43°C) during the intraoperative period and the warming group (n=53), in which all intraoperative fluids were administered via a fluid warmer (41°C). The surgical data, body temperature, coagulation function indexes, and postoperative complications were compared between the two groups. RESULTS Compared to the control group, the warming group had significantly less intraoperative transfusion (p=0.028) and shorter hospitalization days (p<0.05). During the entire intraoperative period (from 1 to 6h), body temperature was significantly higher in the warming group than in the control group. There were significant differences in preoperative fibrinogen level, white blood cell count, total bilirubin level, intraoperative lactose level, postoperative thrombin time (TT), and platelet count between the control and warming groups. Multivariate linear regression analysis demonstrated that TT was the only significant factor, suggesting that the warming group had a lower TT than the control group. CONCLUSION Fluid warming nursing can effectively reduce transfusion requirement and hospitalization days, maintain intraoperative normothermia, and promote postoperative coagulation function in elderly patients undergoing Da Vinci robotic-assisted laparoscopic radical cystectomy.",2020,"Compared to the control group, the warming group had significantly less intraoperative transfusion (p=0.028) and shorter hospitalization days (p<0.05).","['elderly patients undergoing', '108 patients with bladder cancer scheduled to undergo', 'elderly patients with bladder cancer undergoing']","['fluid warming', 'DaVinci robotic-assisted laparoscopic radical cystectomy', 'warming blanket', 'Da Vinci robotic-assisted laparoscopic radical cystectomy', 'fluid warming nursing']","['intraoperative transfusion', 'preoperative fibrinogen level, white blood cell count, total bilirubin level, intraoperative lactose level, postoperative thrombin time (TT), and platelet count', 'surgical data, body temperature, coagulation function indexes, and postoperative complications', 'body temperature']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0005684', 'cui_str': 'Malignant tumor of urinary bladder'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}]","[{'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0194401', 'cui_str': 'Complete cystectomy'}, {'cui': 'C0184351', 'cui_str': 'Warming blanket'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0337428', 'cui_str': 'Fibrinogen assay'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0201913', 'cui_str': 'Bilirubin, total measurement'}, {'cui': 'C0428594', 'cui_str': 'Lactose measurement, urine, quantitative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0677634', 'cui_str': 'Reptilase time'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}]",108.0,0.0656869,"Compared to the control group, the warming group had significantly less intraoperative transfusion (p=0.028) and shorter hospitalization days (p<0.05).","[{'ForeName': 'Jianwei', 'Initials': 'J', 'LastName': 'Luo', 'Affiliation': 'Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Zhou', 'Affiliation': 'Department of Intensive Care Unit, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.'}, {'ForeName': 'Shaoman', 'Initials': 'S', 'LastName': 'Lin', 'Affiliation': 'Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.'}, {'ForeName': 'Wenchan', 'Initials': 'W', 'LastName': 'Yan', 'Affiliation': 'Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.'}, {'ForeName': 'Lijuan', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Department of Emergency, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.'}, {'ForeName': 'Sihua', 'Initials': 'S', 'LastName': 'Liang', 'Affiliation': 'Operating Room, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.'}]","Clinics (Sao Paulo, Brazil)",['10.6061/clinics/2020/e1639'] 162,30898331,Mindfulness-based relapse prevention for alcohol dependence: Findings from a randomized controlled trial.,"OBJECTIVES To assess the effects of mindfulness-based relapse prevention for alcohol dependence (MBRP-A) intervention on drinking and related consequences. METHODS 123 alcohol-dependent adults in early recovery, recruited from outpatient treatment programs, were randomly assigned to MBRP-A (intervention plus usual-care; N = 64) or Control (usual-care-alone; N = 59) group. MBRP-A consisted of eight-weekly sessions and home practice. Outcomes were assessed at baseline, 8 weeks and 26 weeks (18 weeks post-intervention), and compared between groups using repeated measures analysis. RESULTS Outcome analysis included 112 participants (57 MBRP-A; 55 Control) who provided follow-up data. Participants were 41.0 ± 12.2 years old, 56.2% male, and 91% white. Prior to ""quit date,"" they reported drinking on 59.4 ± 34.8% (averaging 6.1 ± 5.0 drinks/day) and heavy drinking (HD) on 50.4 ± 35.5% of days. Their drinking reduced after the ""quit date"" (before enrollment) to 0.4 ± 1.7% (HD: 0.1 ± 0.7%) of days. At 26 weeks, the MBRP-A and control groups reported any drinking on 11.5 ± 22.5% and 5.9 ± 11.6% of days and HD on 4.5 ± 9.3% and 3.2 ± 8.7% of days, respectively, without between-group differences (ps ≥ 0.05) in drinking or related consequences during the follow-up period. Three MBRP-A participants reported ""relapse,"" defined as three-consecutive HD days, during the study. Subgroup analysis indicated that greater adherence to session attendance and weekly home practice minutes were associated with improved outcomes. CONCLUSIONS MBRP-A as an adjunct to usual-care did not show to improve outcomes in alcohol-dependent adults in early recovery compared to usual-care-alone; a return to drinking and relapse to HD were rare in both groups. However, greater adherence to MBRP-A intervention may improve long-term drinking-related outcomes.",2019,"CONCLUSIONS MBRP-A as an adjunct to usual-care did not show to improve outcomes in alcohol-dependent adults in early recovery compared to usual-care-alone; a return to drinking and relapse to HD were rare in both groups.","['112 participants (57 MBRP-A; 55 Control) who provided follow-up data', 'alcohol dependence', 'Participants were 41.0\u202f±\u202f12.2\u202fyears old, 56.2% male, and 91% white', '123 alcohol-dependent adults in early recovery, recruited from outpatient treatment programs']","['MBRP-A (intervention plus usual-care; N\u202f=\u202f64) or Control (usual-care-alone; N\u202f=\u202f59) group', 'Mindfulness-based relapse prevention', 'mindfulness-based relapse prevention for alcohol dependence (MBRP-A) intervention']","['relapse', 'adherence to session attendance and weekly home practice minutes']","[{'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0001973', 'cui_str': 'Alcohol Dependence'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0679867', 'cui_str': 'Relapse Prevention'}, {'cui': 'C0001973', 'cui_str': 'Alcohol Dependence'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}]",123.0,0.0485957,"CONCLUSIONS MBRP-A as an adjunct to usual-care did not show to improve outcomes in alcohol-dependent adults in early recovery compared to usual-care-alone; a return to drinking and relapse to HD were rare in both groups.","[{'ForeName': 'Aleksandra E', 'Initials': 'AE', 'LastName': 'Zgierska', 'Affiliation': 'University of Wisconsin-Madison, School of Medicine and Public Health, Department of Family Medicine and Community Health, 1100 Delaplaine Court, Madison, WI 53715, United States of America. Electronic address: Aleksandra.Zgierska@fammed.wisc.edu.'}, {'ForeName': 'Cindy A', 'Initials': 'CA', 'LastName': 'Burzinski', 'Affiliation': 'University of Wisconsin-Madison, School of Medicine and Public Health, Department of Family Medicine and Community Health, 1100 Delaplaine Court, Madison, WI 53715, United States of America. Electronic address: Cindy.Burzinski@fammed.wisc.edu.'}, {'ForeName': 'Marlon P', 'Initials': 'MP', 'LastName': 'Mundt', 'Affiliation': 'University of Wisconsin-Madison, School of Medicine and Public Health, Department of Family Medicine and Community Health, 1100 Delaplaine Court, Madison, WI 53715, United States of America. Electronic address: Marlon.Mundt@fammed.wisc.edu.'}, {'ForeName': 'Andrew S', 'Initials': 'AS', 'LastName': 'McClintock', 'Affiliation': 'University of Wisconsin-Madison, School of Medicine and Public Health, Department of Family Medicine and Community Health, 1100 Delaplaine Court, Madison, WI 53715, United States of America. Electronic address: asmcclintock@wisc.edu.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Cox', 'Affiliation': 'University of Wisconsin-Madison, School of Medicine and Public Health, Department of Family Medicine and Community Health, 1100 Delaplaine Court, Madison, WI 53715, United States of America. Electronic address: jcox@uwhealth.org.'}, {'ForeName': 'Christopher L', 'Initials': 'CL', 'LastName': 'Coe', 'Affiliation': 'University of Wisconsin-Madison, Harlow Center for Biological Psychology, 22 N Charter St, Madison, WI 53715, United States of America. Electronic address: ccoe@wisc.edu.'}, {'ForeName': 'Michael M', 'Initials': 'MM', 'LastName': 'Miller', 'Affiliation': 'University of Wisconsin-Madison, School of Medicine and Public Health, Department of Psychiatry, 6001 Research Park Boulevard, Madison, WI 53719, United States of America. Electronic address: michael.miller@uwmf.wisc.edu.'}, {'ForeName': 'Michael F', 'Initials': 'MF', 'LastName': 'Fleming', 'Affiliation': 'University of Wisconsin-Madison, School of Medicine and Public Health, Department of Family Medicine and Community Health, 1100 Delaplaine Court, Madison, WI 53715, United States of America; Northwestern University, Feinberg School of Medicine, Department of Psychiatry and Behavioral Sciences, Abbott Hall Suite 1320, 710 N Lake Shore Drive, Chicago, IL 60611, United States of America. Electronic address: m-fleming@northwestern.edu.'}]",Journal of substance abuse treatment,['10.1016/j.jsat.2019.01.013'] 163,30926955,"Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial.","BACKGROUND Some weight loss medications, including liraglutide 3.0 mg, are thought to facilitate weight loss by improving appetite control. However, no studies have evaluated their long-term appetitive effects. SUBJECTS/METHODS This study examined changes in appetite in a subsample of 113 adults with obesity (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m 2 ) who participated in a 52-week trial. Participants were randomized to intensive behavioral therapy alone (IBT-alone), IBT with liraglutide 3.0 mg/day (IBT-liraglutide), or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component). Participants rated their hunger, fullness after meals, liking of meals, and food preoccupation (all as experienced over the past week) using visual analogue scales (0-100 mm). Ratings were completed at baseline and eight subsequent visits over the year. RESULTS At week 52, participants treated by IBT-alone lost 6.2 ± 1.6% of baseline weight, compared with 11.8 ± 1.6% and 12.1 ± 1.5% in the IBT-liraglutide and Multi-component groups, respectively. Compared to IBT-alone, IBT-liraglutide participants reported larger reductions at week 6 in hunger (-0.3 ± 4.2 vs -16.8 ± 4.0 mm, p = .005) and food preoccupation (+0.2 ± 3.7 vs -16.3 ± 3.6 mm, p = .002) and larger increases in fullness (-5.1 ± 3.2 vs +9.8 ± 3.0 mm, p = .001). These significant differences persisted at all assessments through week 24. There were no differences between IBT-alone and IBT-liraglutide in meal liking. IBT-alone and Multi-component participants differed in hunger at week 6, and in food preoccupation at all assessments through week 24. Multi-component participants reported reduced liking of meals relative to the IBT-alone and IBT-liraglutide groups through weeks 40 and 52, respectively. There were no other differences among any groups at week 52. CONCLUSIONS Consistent with short-term studies, IBT-liraglutide participants reported greater improvements in hunger, fullness, and food preoccupation than those assigned to IBT-alone. Differences in appetite persisted for 24 weeks but were not maintained at week 52, despite the relatively greater weight losses in the liraglutide-treated participants at the trial's end.",2020,"Multi-component participants reported reduced liking of meals relative to the IBT-alone and IBT-liraglutide groups through weeks 40 and 52, respectively.","['113 adults with obesity (76.1% female, 55.8% white, BMI\u2009=\u200938.8\u2009±\u20094.8\u2009kg/m 2 ) who participated in a 52-week trial']","['intensive behavioral therapy alone (IBT-alone), IBT with liraglutide 3.0\u2009mg/day (IBT-liraglutide), or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component', 'IBT-alone, IBT-liraglutide', 'IBT-alone and Multi-component', 'IBT-liraglutide', 'liraglutide']","['hunger, fullness, and food preoccupation', 'liking of meals relative', 'hunger, fullness after meals, liking of meals, and food preoccupation', 'fullness', 'weight losses', 'food preoccupation', 'appetite', 'visual analogue scales', 'appetite, food preoccupation, and food liking']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C4517765', 'cui_str': '4.8 (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0004933', 'cui_str': 'Behavior Modification'}, {'cui': 'C1456408', 'cui_str': 'liraglutide'}, {'cui': 'C0439422', 'cui_str': 'mg/day'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}]","[{'cui': 'C0020175', 'cui_str': 'Hunger'}, {'cui': 'C0439650', 'cui_str': 'Fullness (qualifier value)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0549165', 'cui_str': 'Preoccupation with ideas'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",113.0,0.0597185,"Multi-component participants reported reduced liking of meals relative to the IBT-alone and IBT-liraglutide groups through weeks 40 and 52, respectively.","[{'ForeName': 'Jena Shaw', 'Initials': 'JS', 'LastName': 'Tronieri', 'Affiliation': 'Department of Psychiatry, Center for Weight and Eating Disorders, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. jena.tronieri@pennmedicine.upenn.edu.'}, {'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Wadden', 'Affiliation': 'Department of Psychiatry, Center for Weight and Eating Disorders, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Walsh', 'Affiliation': 'Department of Psychiatry, Center for Weight and Eating Disorders, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Robert I', 'Initials': 'RI', 'LastName': 'Berkowitz', 'Affiliation': 'Department of Psychiatry, Center for Weight and Eating Disorders, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Naji', 'Initials': 'N', 'LastName': 'Alamuddin', 'Affiliation': 'Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Gruber', 'Affiliation': 'Department of Psychiatry, Center for Weight and Eating Disorders, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Leonard', 'Affiliation': 'Department of Psychiatry, Center for Weight and Eating Disorders, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Zayna M', 'Initials': 'ZM', 'LastName': 'Bakizada', 'Affiliation': 'Department of Psychiatry, Center for Weight and Eating Disorders, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Ariana M', 'Initials': 'AM', 'LastName': 'Chao', 'Affiliation': 'Department of Psychiatry, Center for Weight and Eating Disorders, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}]",International journal of obesity (2005),['10.1038/s41366-019-0348-6'] 164,32279529,Influence of pre-treatment blood pressure levels on antihypertensive drug benefits in diabetics: the roadmap experience.,"Purpose: Most guidelines for treatment of hypertension in the setting of diabetes recommend a blood pressure (BP) target of <130/80 mmHg. However, uncertainty exists about the extent, effectiveness and safety of lowering BP in diabetics. To expand the evidence on this issue, we analysed data from the Randomised Olmesartan and Diabetes MicroAlbuminuria Prevention (ROADMAP) study population. Material: Substudy with blood pressure readings. Methods : The response after initiation of therapy and adequacy of BP control across patients with different BP levels at baseline were analysed. Results : BP at randomisation was 136.2(15.3)/80.6(9.5) [mean (SD)] mmHg with a range of 87-213/37-123 mmHg. At 1 year, mean BP was 127 (11.9)/75 (8.1) mmHg and the overall control rate (<130/80 mmHg) exceeded 61% in this population. The mean reductions in systolic [-9.4 (15.4) mmHg] and diastolic BP [-5.4 (9.5) mmHg] were highly dependent on the BP stage at Visit 1. At 1 year, treatment decreased the prevalence of patients with baseline BP levels of >160/100 from 9 to 2%[[mean BP change -31 (15.7)/ -14 (9.8) mmHg]] and of 140-159/90-99 mmHg from 32 to 11% [[mean BP change -16(12.7)/ -8.9 (8.7) mmHg]], with corresponding increases in the prevalence of patients with baseline BP levels of 120-139/80-99 from 48 to 65% [[mean BP change -4.1 (10.6)/ -3.1 (7.8) mmHg]]and of <120/80 from 11 to 22% [[mean BP change +5.9 (11.8)/+2.5 (8.6) mmHg]]. These effects did not change significantly thereafter and were maintained throughout follow-up. Conclusion : Blood pressure control is feasible in patients with diabetes without nephropathy, independent of baseline BP values. Asymmetric BP-lowering in the first year after starting therapy represents a true antihypertensive effect with sustainable shifts in BP severity.",2020,The mean reductions in systolic [-9.4 (15.4) mmHg] and diastolic BP [-5.4 (9.5),"['patients with diabetes without nephropathy', 'of 120-139/80-99 from 48 to 65% [[mean BP change -4.1 ', 'diabetics']","['blood pressure readings', 'Olmesartan']","['diastolic BP', 'baseline BP levels', 'overall control rate', 'Blood pressure control', 'mean (SD', 'mean BP', 'prevalence of patients with baseline BP levels', 'Asymmetric BP-lowering']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1268766', 'cui_str': 'Blood pressure alteration'}, {'cui': 'C4517756', 'cui_str': '4.1'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C1098320', 'cui_str': 'olmesartan'}]","[{'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332514', 'cui_str': 'Asymmetry'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}]",,0.0532583,The mean reductions in systolic [-9.4 (15.4) mmHg] and diastolic BP [-5.4 (9.5),"[{'ForeName': 'Christos', 'Initials': 'C', 'LastName': 'Chatzikyrkou', 'Affiliation': 'Clinic of Nephrology, Hypertension, Diabetes and Endocrinology, Health Campus Immunology, Infectiology and inflammation, Otto-von Guericke University, Magdeburg, Germany.'}, {'ForeName': 'Florian G', 'Initials': 'FG', 'LastName': 'Scurt', 'Affiliation': 'Clinic of Nephrology, Hypertension, Diabetes and Endocrinology, Health Campus Immunology, Infectiology and inflammation, Otto-von Guericke University, Magdeburg, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Menne', 'Affiliation': 'Nephrology Section, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Korda', 'Affiliation': 'LVR-Klinikum Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.'}, {'ForeName': 'Peter R', 'Initials': 'PR', 'LastName': 'Mertens', 'Affiliation': 'Clinic of Nephrology, Hypertension, Diabetes and Endocrinology, Health Campus Immunology, Infectiology and inflammation, Otto-von Guericke University, Magdeburg, Germany.'}, {'ForeName': 'Hermann', 'Initials': 'H', 'LastName': 'Haller', 'Affiliation': 'Nephrology Section, Hannover Medical School, Hannover, Germany.'}]",Blood pressure,['10.1080/08037051.2020.1750298'] 165,32318288,Risk Factors Associated with Cardiac Autonomic Modulation in Obese Individuals.,"Obesity leads to an imbalance in the autonomic nervous system, especially in increased sympathetic modulation and decreased vagal tone, and some anthropometric, metabolic, and lifestyle variables may increase the risk of developing cardiovascular disease. Objective . To analyze the association between cardiovascular autonomic modulation and biochemical and anthropometric markers, food intake, and physical activity level in severely obese individuals. Methodology . The present study is a cutout of a randomized clinical trial ""Effect of nutritional intervention and olive oil in severe obesity"" (DieTBra Trial), where the baseline data were analyzed. Anthropometric data, biochemical exams, heart rate variability (HRV), accelerometry, and 24 h recall (R24H) of obese patients (body mass index BMI ≥35 kg/m 2 ) were collected. Results . 64 obese patients were analyzed, with a mean age of 39.10 ± 7.74 years (27 to 58 years). By HRV analysis, in the frequency domain, the obese had a higher predominance of sympathetic autonomic modulation (low frequency (LF) 56.44 ± 20.31 nu) and lower parasympathetic modulation (high frequency (HF) 42.52 ± 19.18 nu). A negative association was observed between the variables Homeostasis Evaluation Model (HOMA-IR) and HF ( p = 0.049). In the physical activity analysis, there was a negative association between moderate to vigorous physical activity and the sympathetic component ( p = 0.043), and for sedentary time (ST), there was a negative association with HF ( p = 0.049) and LF/HF ( p = 0.036) and a positive association with LF ( p = 0.014). For multiple linear regression, waist circumference (WC) and HOMA-IR values were negatively associated with HF ( β  = -0.685, p = 0.010; β  = -14.989, p = 0.010; respectively). HOMA-IR ( β  = 0.141, p = 0.003) and the percentage of lipids ingested ( β  = -0.030, p = 0.043) were negatively associated with LF/HF. Conclusion . Among the cardiovascular risk variables studied, insulin resistance and central adiposity showed the greatest influence on cardiac autonomic modulation of obese, increasing the risk for cardiovascular disease.",2020,"HOMA-IR ( β  = 0.141, p = 0.003) and the percentage of lipids ingested ( β  = -0.030, p = 0.043) were negatively associated with LF/HF. ","['severely obese individuals', 'Obese Individuals', '64 obese patients were analyzed, with a mean age of 39.10\u2009±\u20097.74 years (27 to 58 years']",['nutritional intervention and olive oil'],"['vigorous physical activity and the sympathetic component', 'parasympathetic modulation', 'sympathetic autonomic modulation', 'insulin resistance and central adiposity', 'sedentary time (ST', 'HOMA-IR', 'percentage of lipids ingested', 'waist circumference (WC) and HOMA-IR values', 'Anthropometric data, biochemical exams, heart rate variability (HRV), accelerometry, and 24\u2009h recall (R24H', 'variables Homeostasis Evaluation Model (HOMA-IR) and HF', 'cardiovascular autonomic modulation and biochemical and anthropometric markers, food intake, and physical activity level']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C4551560', 'cui_str': 'Central obesity'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0582103', 'cui_str': 'Medical assessment'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0441677', 'cui_str': 'Accelerometry'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0013470', 'cui_str': 'Eating'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",64.0,0.0503632,"HOMA-IR ( β  = 0.141, p = 0.003) and the percentage of lipids ingested ( β  = -0.030, p = 0.043) were negatively associated with LF/HF. ","[{'ForeName': 'Camila', 'Initials': 'C', 'LastName': 'Oliveira', 'Affiliation': 'Medicine Faculty, Health Science Post-Graduation Program, Universidade Federal de Goiás, Goiânia, Goiás, Brazil.'}, {'ForeName': 'Erika Aparecida', 'Initials': 'EA', 'LastName': 'Silveira', 'Affiliation': 'Medicine Faculty, Coordinator of the Severe Obesity Study Group, Federal University of Goiás, Goiânia, Brazil.'}, {'ForeName': 'Lorena', 'Initials': 'L', 'LastName': 'Rosa', 'Affiliation': 'Medicine Faculty, Health Science Post-Graduation Program, Universidade Federal de Goiás, Goiânia, Goiás, Brazil.'}, {'ForeName': 'Annelisa', 'Initials': 'A', 'LastName': 'Santos', 'Affiliation': 'Medicine Faculty, Health Science Post-Graduation Program, Universidade Federal de Goiás, Goiânia, Goiás, Brazil.'}, {'ForeName': 'Ana Paula', 'Initials': 'AP', 'LastName': 'Rodrigues', 'Affiliation': 'Medicine Faculty, Health Science Post-Graduation Program, Universidade Federal de Goiás, Goiânia, Goiás, Brazil.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Mendonça', 'Affiliation': 'Medicine Faculty, Health Science Post-Graduation Program, Universidade Federal de Goiás, Goiânia, Goiás, Brazil.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Silva', 'Affiliation': 'Medicine Faculty, Health Science Post-Graduation Program, Universidade Federal de Goiás, Goiânia, Goiás, Brazil.'}, {'ForeName': 'Paulo', 'Initials': 'P', 'LastName': 'Gentil', 'Affiliation': 'College of Physical Education and Dance, Federal University of Goiás, Goiânia, Brazil.'}, {'ForeName': 'Ana Cristina', 'Initials': 'AC', 'LastName': 'Rebelo', 'Affiliation': 'Department of Morphology, Biological Sciences Institute, Federal University of Goiás, Goiânia, Goiás, Brazil.'}]",Journal of obesity,['10.1155/2020/7185249'] 166,32307828,"Efficacy of health coaching and a web-based program on physical activity, weight, and distress management among cancer survivors: A multi-centered randomised controlled trial.","OBJECTIVES To investigate the efficacy of health coaching and a web-based program on survivor physical activity (PA), weight, and distress management among stomach, colon, lung and breast cancer patients. METHODS This randomised, controlled, 1-year trial conducted in five hospitals recruited cancer survivors within 2 months of completing primary cancer treatment who had not met ≥1 of these behavioural goals: (i) conducting moderate PA for at least 150 minutes/week or strenuous exercise for over 75 minutes per week or, in the case of lung cancer patients, low or moderate intensity exercise for over 12.5 MET per week, (ii) maintaining normal weight, and (iii) attaining a score >72 in the Post Traumatic Growth Inventory (PTGI). Participants were randomly assigned to one of three groups: the control group, a web-only group, or a health coaching + web group. The primary endpoint was based on a composite of PA, weight, and PTGI score at 12 months. RESULTS Patients in the health coaching + web group (difference = 6.6%, P = .010) and the web-only group (difference = 5.9%, P = .031) had greater overall improvements across the three-outcome composite than the control group. The health coaching + web group had greater overall improvement in PTGI (difference = 12.6%; P < .001) than the control group, but not in PA and weight. CONCLUSION The web-based program, with or without health coaching, may improve health behaviours including PA, weight, and distress management among cancer survivors within 2 months of completing primary cancer treatment. The web-based program with health coaching was mainly effective for reducing psychological distress.",2020,"RESULTS Patients in the health coaching+web group (difference = 6·6%, P=0.010) and the Web-only group (difference = 5·9%, P=0.031) had greater overall improvements across the 3-outcome composite than the control group.","['cancer survivors', '5 hospitals recruited cancer survivors within 2 months of completing primary cancer treatment who had not met ≥1 of these behavioral goals: i) conducting moderate PA for at least 150 min/week or', 'stomach, colon, lung and breast cancer patients', 'cancer survivors within 2 months of completing primary cancer treatment']","['lung cancer patients, low or moderate intensity exercise for over 12·5 MET per week, ii) maintaining normal weight, and iii) attaining a score >72 in the Post Traumatic Growth Inventory (PTGI', 'health coaching and a Web-based program', 'strenuous exercise', 'control group, a Web-only group, or a health coaching + Web group']","['composite of PA, weight, and PTGI score', 'overall improvement in PTGI', 'survivor physical activity (PA), weight, and distress management', 'psychological distress', 'physical activity, weight, and distress management']","[{'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0009368', 'cui_str': 'Colonic'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}]",5.0,0.0411775,"RESULTS Patients in the health coaching+web group (difference = 6·6%, P=0.010) and the Web-only group (difference = 5·9%, P=0.031) had greater overall improvements across the 3-outcome composite than the control group.","[{'ForeName': 'Young Ho', 'Initials': 'YH', 'LastName': 'Yun', 'Affiliation': 'Department of Family Medicine, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Cheol Il', 'Initials': 'CI', 'LastName': 'Lim', 'Affiliation': 'Department of Education, Seoul National University College of Education, Seoul, South Korea.'}, {'ForeName': 'Eun Sook', 'Initials': 'ES', 'LastName': 'Lee', 'Affiliation': 'Research Institute and Hospital, National Cancer Center, Goyang, South Korea.'}, {'ForeName': 'Young Tae', 'Initials': 'YT', 'LastName': 'Kim', 'Affiliation': 'Department of Cardiovascular and Thoracic Surgery, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Kyung Hwan', 'Initials': 'KH', 'LastName': 'Shin', 'Affiliation': 'Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Young-Woo', 'Initials': 'YW', 'LastName': 'Kim', 'Affiliation': 'Research Institute and Hospital, National Cancer Center, Goyang, South Korea.'}, {'ForeName': 'Kyu Joo', 'Initials': 'KJ', 'LastName': 'Park', 'Affiliation': 'Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Seung-Yong', 'Initials': 'SY', 'LastName': 'Jeong', 'Affiliation': 'Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Keun Won', 'Initials': 'KW', 'LastName': 'Ryu', 'Affiliation': 'Research Institute and Hospital, National Cancer Center, Goyang, South Korea.'}, {'ForeName': 'Wonshik', 'Initials': 'W', 'LastName': 'Han', 'Affiliation': 'Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Kyung Hae', 'Initials': 'KH', 'LastName': 'Jung', 'Affiliation': 'Department of Oncology, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Sung Chan', 'Initials': 'SC', 'LastName': 'Park', 'Affiliation': 'Research Institute and Hospital, National Cancer Center, Goyang, South Korea.'}, {'ForeName': 'Moon Soo', 'Initials': 'MS', 'LastName': 'Kim', 'Affiliation': 'Research Institute and Hospital, National Cancer Center, Goyang, South Korea.'}, {'ForeName': 'Sung', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Department of Surgery, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Young Mog', 'Initials': 'YM', 'LastName': 'Shim', 'Affiliation': 'Department of Cardiovascular and Thoracic Surgery, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Jae Hwan', 'Initials': 'JH', 'LastName': 'Oh', 'Affiliation': 'Research Institute and Hospital, National Cancer Center, Goyang, South Korea.'}, {'ForeName': 'Jong Mog', 'Initials': 'JM', 'LastName': 'Lee', 'Affiliation': 'Research Institute and Hospital, National Cancer Center, Goyang, South Korea.'}, {'ForeName': 'Seung-Bum', 'Initials': 'SB', 'LastName': 'Ryoo', 'Affiliation': 'Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Joohyun', 'Initials': 'J', 'LastName': 'Woo', 'Affiliation': 'Department of Oncology, Ewha Womans University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Dong-Young', 'Initials': 'DY', 'LastName': 'Noh', 'Affiliation': 'Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Ji Won', 'Initials': 'JW', 'LastName': 'Park', 'Affiliation': 'Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Byung', 'Initials': 'B', 'LastName': 'In Moon', 'Affiliation': 'Department of Oncology, Ewha Womans University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Hak Jae', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Seok Jin', 'Initials': 'SJ', 'LastName': 'Nam', 'Affiliation': 'Department of Surgery, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Dae Ho', 'Initials': 'DH', 'LastName': 'Lee', 'Affiliation': 'Department of Oncology, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Jae Il', 'Initials': 'JI', 'LastName': 'Zo', 'Affiliation': 'Department of Cardiovascular and Thoracic Surgery, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Sang Min', 'Initials': 'SM', 'LastName': 'Park', 'Affiliation': 'Department of Family Medicine, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'EunKyo', 'Initials': 'E', 'LastName': 'Kang', 'Affiliation': 'Department of Family Medicine, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'YeEun', 'Initials': 'Y', 'LastName': 'Rhee', 'Affiliation': 'Department of Family Medicine, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Ju Youn', 'Initials': 'JY', 'LastName': 'Jung', 'Affiliation': 'Department of Family Medicine, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Jin Ah', 'Initials': 'JA', 'LastName': 'Sim', 'Affiliation': 'Department of Family Medicine, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Joonki', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Aesun', 'Initials': 'A', 'LastName': 'Shin', 'Affiliation': 'Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, South Korea.'}]",Psycho-oncology,['10.1002/pon.5394'] 167,31968207,Effects of the Carrier Phrase on Word Recognition Performances by Younger and Older Listeners Using Two Stimulus Paradigms.,"BACKGROUND In the 1950s, with monitored live voice testing, the vu meter time constant and the short durations and amplitude modulation characteristics of monosyllabic words necessitated the use of the carrier phrase amplitude to monitor (indirectly) the presentation level of the words. This practice continues with recorded materials. To relieve the carrier phrase of this function, first the influence that the carrier phrase has on word recognition performance needs clarification, which is the topic of this study. PURPOSE Recordings of Northwestern University Auditory Test No. 6 by two female speakers were used to compare word recognition performances with and without the carrier phrases when the carrier phrase and test word were (1) in the same utterance stream with the words excised digitally from the carrier (VA-1 speaker) and (2) independent of one another (VA-2 speaker). The 50-msec segment of the vowel in the target word with the largest root mean square amplitude was used to equate the target word amplitudes. RESEARCH DESIGN A quasi-experimental, repeated measures design was used. STUDY SAMPLE Twenty-four young normal-hearing adults (YNH; M  = 23.5 years; pure-tone average [PTA] = 1.3-dB HL) and 48 older hearing loss listeners (OHL; M  = 71.4 years; PTA = 21.8-dB HL) participated in two, one-hour sessions. DATA COLLECTION AND ANALYSES Each listener had 16 listening conditions (2 speakers × 2 carrier phrase conditions × 4 presentation levels) with 100 randomized words, 50 different words by each speaker. Each word was presented 8 times (2 carrier phrase conditions × 4 presentation levels [YNH, 0- to 24-dB SL; OHL, 6- to 30-dB SL]). The 200 recorded words for each condition were randomized as 8, 25-word tracks. In both test sessions, one practice track was followed by 16 tracks alternated between speakers and randomized by blocks of the four conditions. Central tendency and repeated measures analyses of variance statistics were used. RESULTS With the VA-1 speaker, the overall mean recognition performances were 6.0% (YNH) and 8.3% (OHL) significantly better with the carrier phrase than without the carrier phrase. These differences were in part attributed to the distortion of some words caused by the excision of the words from the carrier phrases. With the VA-2 speaker, recognition performances on the with and without carrier phrase conditions by both listener groups were not significantly different, except for one condition (YNH listeners at 8-dB SL). The slopes of the mean functions were steeper for the YNH listeners (3.9%/dB to 4.8%/dB) than for the OHL listeners (2.4%/dB to 3.4%/dB) and were <1%/dB steeper for the VA-1 speaker than for the VA-2 speaker. Although the mean results were clear, the variability in performance differences between the two carrier phrase conditions for the individual participants and for the individual words was striking and was considered in detail. CONCLUSION The current data indicate that word recognition performances with and without the carrier phrase (1) were different when the carrier phrase and target word were produced in the same utterance with poorer performances when the target words were excised from their respective carrier phrases (VA-1 speaker), and (2) were the same when the carrier phrase and target word were produced as independent utterances (VA-2 speaker).",2020,"With the VA-2 speaker, recognition performances on the with and without carrier phrase conditions by both listener groups were not significantly different, except for one condition (YNH listeners at 8-dB SL).","['SAMPLE\n\n\nTwenty-four young normal-hearing adults (YNH; M = 23.5 years; pure-tone average [PTA] = 1.3-dB HL) and 48 older hearing loss listeners (OHL; M = 71.4 years; PTA = 21.8-dB HL', 'Northwestern University Auditory Test No. 6 by two female speakers', 'Younger and Older Listeners']","['Carrier Phrase', 'VA-1 speaker']","['Word Recognition Performances', 'overall mean recognition performances']","[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C3715070', 'cui_str': '24 (qualifier value)'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517499', 'cui_str': '1.3 (qualifier value)'}, {'cui': 'C0439498', 'cui_str': 'decibel hearing level'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0015522', 'cui_str': 'Factor Eleven'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0560175', 'cui_str': 'Carrier State'}, {'cui': 'C0600665', 'cui_str': 'Phrase'}]","[{'cui': 'C0524637', 'cui_str': 'Recognition (Psychology)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",24.0,0.0220376,"With the VA-2 speaker, recognition performances on the with and without carrier phrase conditions by both listener groups were not significantly different, except for one condition (YNH listeners at 8-dB SL).","[{'ForeName': 'Richard H', 'Initials': 'RH', 'LastName': 'Wilson', 'Affiliation': 'Department of Speech and Hearing Sciences, Arizona State University, Tempe, AZ.'}, {'ForeName': 'Victoria A', 'Initials': 'VA', 'LastName': 'Sanchez', 'Affiliation': 'Department of Otolaryngology-Head & Neck Surgery, University of South Florida, Tampa, FL.'}]",Journal of the American Academy of Audiology,['10.3766/jaaa.19061'] 168,30786162,"A Phase 3, Randomized, Placebo-Controlled Evaluation of the Safety of Intravenous Meloxicam Following Major Surgery.","An intravenous (IV) formulation of meloxicam is being studied for moderate to severe pain management. This phase 3, randomized, multicenter, double-blind, placebo-controlled trial evaluated the safety of once-daily meloxicam IV 30 mg in subjects following major elective surgery. Eligible subjects were randomized (3:1) to receive meloxicam IV 30 mg or placebo administered once daily. Safety was evaluated via adverse events, clinical laboratory tests, vital signs, wound healing, and opioid consumption. The incidence of adverse events was similar between meloxicam IV- and placebo-treated subjects (63.0% versus 65.0%). Investigators assessed most adverse events as mild or moderate in intensity and unrelated to treatment. Adverse events of interest (injection-site reactions, bleeding, cardiovascular, hepatic, renal, thrombotic, and wound-healing events) were similar between groups. Over the treatment period, meloxicam IV was associated with a 23.6% (P = .0531) reduction in total opioid use (9.2 mg morphine equivalent) compared to placebo-treated subjects. The results suggest that meloxicam IV had a safety profile similar to that of placebo with respect to numbers and frequencies of adverse events and reduced opioid consumption in subjects with moderate to severe postoperative pain following major elective surgery.",2019,"Over the treatment period, meloxicam IV was associated with a 23.6% (P = .0531) reduction in total opioid use (9.2 mg morphine equivalent) compared to placebo-treated subjects.","['Eligible subjects', 'subjects following major elective surgery', 'subjects with moderate to severe postoperative pain following major elective surgery']","['placebo', 'meloxicam IV', 'Placebo', 'meloxicam', 'Meloxicam', 'meloxicam IV 30 mg or placebo']","['adverse events, clinical laboratory tests, vital signs, wound healing, and opioid consumption', 'Adverse events of interest (injection-site reactions, bleeding, cardiovascular, hepatic, renal, thrombotic, and wound-healing events', 'total opioid use', 'incidence of adverse events', 'numbers and frequencies of adverse events and reduced opioid consumption']","[{'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0206058', 'cui_str': 'Elective Surgical Procedures'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0083381', 'cui_str': 'meloxicam'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4505474', 'cui_str': 'Clinical Laboratory Tests'}, {'cui': 'C0518766'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0151735', 'cui_str': 'Injection Site Adverse Event'}, {'cui': 'C0043187', 'cui_str': 'Wind'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}]",,0.421191,"Over the treatment period, meloxicam IV was associated with a 23.6% (P = .0531) reduction in total opioid use (9.2 mg morphine equivalent) compared to placebo-treated subjects.","[{'ForeName': 'Sergio D', 'Initials': 'SD', 'LastName': 'Bergese', 'Affiliation': 'The Ohio State University, Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Timothy I', 'Initials': 'TI', 'LastName': 'Melson', 'Affiliation': 'Helen Keller Hospital, Shoals Medical Trials, Inc, Sheffield, AL, USA.'}, {'ForeName': 'Keith A', 'Initials': 'KA', 'LastName': 'Candiotti', 'Affiliation': 'University of Miami, Jackson Memorial Hospital, Miami, FL, USA.'}, {'ForeName': 'Sabry S', 'Initials': 'SS', 'LastName': 'Ayad', 'Affiliation': 'Cleveland Clinic Fairview Hospital, Anesthesiology Institute, Outcomes Research, Cleveland, OH, USA.'}, {'ForeName': 'Randall J', 'Initials': 'RJ', 'LastName': 'Mack', 'Affiliation': 'Recro Pharma, Inc, Malvern, PA, USA.'}, {'ForeName': 'Stewart W', 'Initials': 'SW', 'LastName': 'McCallum', 'Affiliation': 'Recro Pharma, Inc, Malvern, PA, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Du', 'Affiliation': 'Clinical Statistics Consulting, Blue Bell, PA, USA.'}, {'ForeName': 'Alexis', 'Initials': 'A', 'LastName': 'Gomez', 'Affiliation': 'Recro Pharma, Inc, Malvern, PA, USA.'}, {'ForeName': 'Jorge E', 'Initials': 'JE', 'LastName': 'Marcet', 'Affiliation': 'Tampa General Hospital, Tampa, FL, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.666'] 169,31248746,The Baltimore Community-Based Organizations Neighborhood Network: Enhancing Capacity Together (CONNECT) Cluster RCT.,"INTRODUCTION This cluster RCT aimed to reduce healthcare utilization and increase the referral of patients between an academic health center and local community-based organizations (CBOs) that address social determinants of health. STUDY DESIGN Cluster RCT. SETTINGS/PARTICIPANTS Twenty-two CBOs located in Baltimore, Maryland, were randomly assigned to the intervention or control group, and 5,255 patients were allocated to the intervention or control group based on whether they lived closer to an intervention or control CBO. Data were collected in 2014-2016; the analysis was conducted in 2016. INTERVENTION A multicomponent intervention included an online tool to help refer clients to community resources, meet-and-greet sessions between CBO staff and healthcare staff, and research assistants. MAIN OUTCOME MEASURES The primary outcomes were patient emergency department visits and days spent in the hospital. Additional outcomes for CBO clients included knowledge of other CBOs, number of referrals to CBOs by the healthcare system, and number of referrals to healthcare system by CBOs. Outcomes for CBO staff included the number of referrals made to and received from the healthcare system and the number of referrals made to and received from other CBOs. RESULTS There was no significant effect of the intervention on healthcare utilization outcomes, CBO client outcomes, or CBO staff outcomes. Ancillary analyses demonstrated a 2.9% increase in referrals by inpatient staff to intervention CBOs (p=0.051) and a 6.6% increase in referrals by outpatient staff to intervention CBOs between baseline and follow-up (p=0.027). Outpatient staff reported a significant reduction in barriers related to the lack of information about CBO services (-18.3%, p=0.004) and an increase in confidence in community resources (+14.4%, p=0.023) from baseline to follow-up. CONCLUSIONS The intervention did not improve healthcare utilization outcomes but was associated with increased healthcare staff knowledge of, and confidence in, local CBOs. TRIAL REGISTRATION This study is registered at www.clinicaltrials.gov NCT02222909.",2019,"The intervention did not improve healthcare utilization outcomes but was associated with increased healthcare staff knowledge of, and confidence in, local CBOs. ","['patients between an academic health center and local community-based organizations (CBOs', 'Data were collected in 2014-2016; the analysis was conducted in 2016', 'Twenty-two CBOs located in Baltimore, Maryland, were randomly assigned to the intervention or control group, and 5,255 patients']",['intervention or control group based on whether they lived closer to an intervention or control CBO'],"['lack of information about CBO services', 'patient emergency department visits and days spent in the hospital', 'healthcare staff knowledge of, and confidence in, local CBOs', 'healthcare utilization outcomes, CBO client outcomes, or CBO staff outcomes', 'knowledge of other CBOs, number of referrals to CBOs by the healthcare system, and number of referrals to healthcare system by CBOs', 'confidence in community resources', 'healthcare utilization outcomes', 'referrals by outpatient staff to intervention CBOs', 'referrals by inpatient staff to intervention CBOs']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0475309', 'cui_str': 'Health center (environment)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0220885', 'cui_str': 'organization'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C4284772', 'cui_str': '22 (qualifier value)'}, {'cui': 'C0332285', 'cui_str': 'In (attribute)'}, {'cui': 'C0004716', 'cui_str': 'Baltimore'}, {'cui': 'C0024858', 'cui_str': 'Maryland'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0332268', 'cui_str': 'Lacking (qualifier value)'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0237529', 'cui_str': 'Self Confidence'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0042153', 'cui_str': 'use'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C0018696', 'cui_str': 'Health Care Systems'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0034927', 'cui_str': 'Referral'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}]",5255.0,0.0942463,"The intervention did not improve healthcare utilization outcomes but was associated with increased healthcare staff knowledge of, and confidence in, local CBOs. ","[{'ForeName': 'Albert W', 'Initials': 'AW', 'LastName': 'Wu', 'Affiliation': 'Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. Electronic address: awu@jhu.edu.'}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Weston', 'Affiliation': 'Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Chidinma A', 'Initials': 'CA', 'LastName': 'Ibe', 'Affiliation': 'Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Claire F', 'Initials': 'CF', 'LastName': 'Ruberman', 'Affiliation': 'Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'Bone', 'Affiliation': 'Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Romsai T', 'Initials': 'RT', 'LastName': 'Boonyasai', 'Affiliation': 'Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Hwang', 'Affiliation': 'Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Janice', 'Initials': 'J', 'LastName': 'Gentry', 'Affiliation': 'Biddle Broadway, North Avenue, Chester Support Council, Baltimore, Maryland.'}, {'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Purnell', 'Affiliation': 'Men and Families Center, Baltimore, Maryland.'}, {'ForeName': 'Yanyan', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'Johns Hopkins HealthCare LLC, Glen Burnie, Maryland.'}, {'ForeName': 'Shuwen', 'Initials': 'S', 'LastName': 'Liang', 'Affiliation': 'Johns Hopkins HealthCare LLC, Glen Burnie, Maryland.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Rosenblum', 'Affiliation': 'Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}]",American journal of preventive medicine,['10.1016/j.amepre.2019.03.013'] 170,32309882,"The effect of repetitive transcranial magnetic stimulation on food choice-related self-control in patients with severe, enduring anorexia nervosa.","OBJECTIVE Individuals with anorexia nervosa (AN) pursue low-fat, low-calorie diets even when in a state of emaciation. These maladaptive food choices may involve fronto-limbic circuitry associated with cognitive control, habit, and reward. We assessed whether high-frequency repetitive transcranial magnetic stimulation (rTMS) to the left dorsolateral prefrontal cortex (DLPFC) influenced food-related choice behavior in patients with severe, enduring (SE)-AN. METHOD Thirty-four females with SE-AN completed a Food Choice Task before and after 20 sessions of real or sham rTMS treatment and at a 4-month follow-up. During the task, participants rated high- and low-fat food items for healthiness and tastiness and then made a series of choices between a neutral-rated food and high- and low-fat foods. Outcomes included the proportion of high-fat and self-controlled choices made. A comparison group of 30 healthy women completed the task at baseline only. RESULTS Baseline data were consistent with previous findings: relative to healthy controls, SE-AN participants showed a preference for low-fat foods and exercised self-control on a greater proportion of trials. There was no significant effect of rTMS treatment nor time on food choices related to fat content. However, among SE-AN participants who received real rTMS, there was a decrease in self-controlled food choices at post-treatment, relative to baseline. Specifically, there was an increase in the selection of tasty-unhealthy foods. DISCUSSION In SE-AN, rTMS may promote more flexibility in relation to food choice. This may result from neuroplastic changes in the DLPFC and/or in associated brain areas.",2020,"However, among SE-AN participants who received real rTMS, there was a decrease in self-controlled food choices at post-treatment, relative to baseline.","['30 healthy women completed the task at baseline only', 'patients with severe, enduring (SE)-AN.\nMETHOD\n\n\nThirty-four females with SE-AN completed a', 'patients with severe, enduring anorexia nervosa', 'Individuals with anorexia nervosa (AN']","['repetitive transcranial magnetic stimulation', 'high-frequency repetitive transcranial magnetic stimulation (rTMS', 'real rTMS', 'Food Choice Task before and after 20 sessions of real or sham rTMS', 'rTMS']","['self-controlled food choices', 'proportion of high-fat and self-controlled choices made']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0003125', 'cui_str': 'Anorexia nervosa'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0684274', 'cui_str': 'Self-control'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0015677', 'cui_str': 'Fat'}]",34.0,0.0323544,"However, among SE-AN participants who received real rTMS, there was a decrease in self-controlled food choices at post-treatment, relative to baseline.","[{'ForeName': 'Bethan', 'Initials': 'B', 'LastName': 'Dalton', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Foerde', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, New York City, New York, USA.'}, {'ForeName': 'Savani', 'Initials': 'S', 'LastName': 'Bartholdy', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'McClelland', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Kekic', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Luiza', 'Initials': 'L', 'LastName': 'Grycuk', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Iain C', 'Initials': 'IC', 'LastName': 'Campbell', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Schmidt', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Joanna E', 'Initials': 'JE', 'LastName': 'Steinglass', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, New York City, New York, USA.'}]",The International journal of eating disorders,['10.1002/eat.23267'] 171,32321387,Improved Glycemic Control in Adults With Serious Mental Illness and Diabetes With a Behavioral and Educational Intervention.,"OBJECTIVE The purpose of this study was to evaluate a 16-week, reverse-integrated care (bringing primary care interventions/services into the psychiatric setting) behavioral and educational group intervention for individuals with serious mental illness and diabetes. METHODS The primary outcome was change in glycated hemoglobin (HbA1c). Secondary outcomes included body mass index (BMI), blood pressure, lipid levels, physical activity, diabetes knowledge, and self-care. RESULTS Thirty-five participants attended at least one group and were included in a modified intent-to-treat analysis. From baseline to week 16, HbA1c improved, from 7.5±1.6 to 7.1±1.4, p=0.01, and BMI improved, from 33.3±3.8 to 32.9±4.1, p<0.001, as did measures of diabetes knowledge and self-care. One-year follow-up in a subset of participants showed no evidence of rebound in HbA1c. CONCLUSIONS This 16-week behavioral and educational group intervention resulted in improvements in glycemic control, BMI, diabetes knowledge, and self-care. The results warrant larger-scale, controlled trial testing of this intervention to improve diabetes-related health outcomes in those with serious mental illness.",2020,"From baseline to week 16, HbA1c improved, from 7.5±1.6 to 7.1±1.4, p=0.01, and BMI improved, from 33.3±3.8 to 32.9±4.1, p<0.001, as did measures of diabetes knowledge and self-care.","['Adults With Serious Mental Illness and Diabetes With a Behavioral and Educational Intervention', 'individuals with serious mental illness and diabetes']","['behavioral and educational group intervention', 'reverse-integrated care (bringing primary care interventions/services into the psychiatric setting) behavioral and educational group intervention']","['diabetes knowledge and self-care', 'glycated hemoglobin (HbA1c', 'BMI', 'body mass index (BMI), blood pressure, lipid levels, physical activity, diabetes knowledge, and self-care', 'glycemic control, BMI, diabetes knowledge, and self-care']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332302', 'cui_str': 'Brought on by'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}]","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0428460', 'cui_str': 'Lipid level - finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",35.0,0.0533,"From baseline to week 16, HbA1c improved, from 7.5±1.6 to 7.1±1.4, p=0.01, and BMI improved, from 33.3±3.8 to 32.9±4.1, p<0.001, as did measures of diabetes knowledge and self-care.","[{'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Schnitzer', 'Affiliation': 'Center for Addiction Medicine, Department of Psychiatry (Schnitzer, Cather, Vilme, Dechert, Evins), Schizophrenia Research Program (Schnitzer, Cather, Freudenreich, MacLaurin, Vilme, Dechert, Evins), Diabetes Center, Department of Medicine (Wexler) and General Medicine Division, Department of Medicine (Thorndike), Department of Biostatistics (Potter), all at Massachusetts General Hospital (MGH), Boston; Erich Lindemann Mental Health Center, Freedom Trail Clinic, Boston (Freudenreich, MacLaurin).'}, {'ForeName': 'Corrine', 'Initials': 'C', 'LastName': 'Cather', 'Affiliation': 'Center for Addiction Medicine, Department of Psychiatry (Schnitzer, Cather, Vilme, Dechert, Evins), Schizophrenia Research Program (Schnitzer, Cather, Freudenreich, MacLaurin, Vilme, Dechert, Evins), Diabetes Center, Department of Medicine (Wexler) and General Medicine Division, Department of Medicine (Thorndike), Department of Biostatistics (Potter), all at Massachusetts General Hospital (MGH), Boston; Erich Lindemann Mental Health Center, Freedom Trail Clinic, Boston (Freudenreich, MacLaurin).'}, {'ForeName': 'Anne N', 'Initials': 'AN', 'LastName': 'Thorndike', 'Affiliation': 'Center for Addiction Medicine, Department of Psychiatry (Schnitzer, Cather, Vilme, Dechert, Evins), Schizophrenia Research Program (Schnitzer, Cather, Freudenreich, MacLaurin, Vilme, Dechert, Evins), Diabetes Center, Department of Medicine (Wexler) and General Medicine Division, Department of Medicine (Thorndike), Department of Biostatistics (Potter), all at Massachusetts General Hospital (MGH), Boston; Erich Lindemann Mental Health Center, Freedom Trail Clinic, Boston (Freudenreich, MacLaurin).'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Potter', 'Affiliation': 'Center for Addiction Medicine, Department of Psychiatry (Schnitzer, Cather, Vilme, Dechert, Evins), Schizophrenia Research Program (Schnitzer, Cather, Freudenreich, MacLaurin, Vilme, Dechert, Evins), Diabetes Center, Department of Medicine (Wexler) and General Medicine Division, Department of Medicine (Thorndike), Department of Biostatistics (Potter), all at Massachusetts General Hospital (MGH), Boston; Erich Lindemann Mental Health Center, Freedom Trail Clinic, Boston (Freudenreich, MacLaurin).'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Freudenreich', 'Affiliation': 'Center for Addiction Medicine, Department of Psychiatry (Schnitzer, Cather, Vilme, Dechert, Evins), Schizophrenia Research Program (Schnitzer, Cather, Freudenreich, MacLaurin, Vilme, Dechert, Evins), Diabetes Center, Department of Medicine (Wexler) and General Medicine Division, Department of Medicine (Thorndike), Department of Biostatistics (Potter), all at Massachusetts General Hospital (MGH), Boston; Erich Lindemann Mental Health Center, Freedom Trail Clinic, Boston (Freudenreich, MacLaurin).'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'MacLaurin', 'Affiliation': 'Center for Addiction Medicine, Department of Psychiatry (Schnitzer, Cather, Vilme, Dechert, Evins), Schizophrenia Research Program (Schnitzer, Cather, Freudenreich, MacLaurin, Vilme, Dechert, Evins), Diabetes Center, Department of Medicine (Wexler) and General Medicine Division, Department of Medicine (Thorndike), Department of Biostatistics (Potter), all at Massachusetts General Hospital (MGH), Boston; Erich Lindemann Mental Health Center, Freedom Trail Clinic, Boston (Freudenreich, MacLaurin).'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Vilme', 'Affiliation': 'Center for Addiction Medicine, Department of Psychiatry (Schnitzer, Cather, Vilme, Dechert, Evins), Schizophrenia Research Program (Schnitzer, Cather, Freudenreich, MacLaurin, Vilme, Dechert, Evins), Diabetes Center, Department of Medicine (Wexler) and General Medicine Division, Department of Medicine (Thorndike), Department of Biostatistics (Potter), all at Massachusetts General Hospital (MGH), Boston; Erich Lindemann Mental Health Center, Freedom Trail Clinic, Boston (Freudenreich, MacLaurin).'}, {'ForeName': 'Alyson', 'Initials': 'A', 'LastName': 'Dechert', 'Affiliation': 'Center for Addiction Medicine, Department of Psychiatry (Schnitzer, Cather, Vilme, Dechert, Evins), Schizophrenia Research Program (Schnitzer, Cather, Freudenreich, MacLaurin, Vilme, Dechert, Evins), Diabetes Center, Department of Medicine (Wexler) and General Medicine Division, Department of Medicine (Thorndike), Department of Biostatistics (Potter), all at Massachusetts General Hospital (MGH), Boston; Erich Lindemann Mental Health Center, Freedom Trail Clinic, Boston (Freudenreich, MacLaurin).'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Wexler', 'Affiliation': 'Center for Addiction Medicine, Department of Psychiatry (Schnitzer, Cather, Vilme, Dechert, Evins), Schizophrenia Research Program (Schnitzer, Cather, Freudenreich, MacLaurin, Vilme, Dechert, Evins), Diabetes Center, Department of Medicine (Wexler) and General Medicine Division, Department of Medicine (Thorndike), Department of Biostatistics (Potter), all at Massachusetts General Hospital (MGH), Boston; Erich Lindemann Mental Health Center, Freedom Trail Clinic, Boston (Freudenreich, MacLaurin).'}, {'ForeName': 'Anne Eden', 'Initials': 'AE', 'LastName': 'Evins', 'Affiliation': 'Center for Addiction Medicine, Department of Psychiatry (Schnitzer, Cather, Vilme, Dechert, Evins), Schizophrenia Research Program (Schnitzer, Cather, Freudenreich, MacLaurin, Vilme, Dechert, Evins), Diabetes Center, Department of Medicine (Wexler) and General Medicine Division, Department of Medicine (Thorndike), Department of Biostatistics (Potter), all at Massachusetts General Hospital (MGH), Boston; Erich Lindemann Mental Health Center, Freedom Trail Clinic, Boston (Freudenreich, MacLaurin).'}]","Psychiatric services (Washington, D.C.)",['10.1176/appi.ps.201900336'] 172,32321389,Evaluation of Proactive Community Case Detection to Increase Help Seeking for Mental Health Care: A Pragmatic Randomized Controlled Trial.,"OBJECTIVE The Community Informant Detection Tool (CIDT) is a vignette- and picture-based method of proactive case detection to promote help seeking for persons with depression, psychosis, alcohol use disorder, and epilepsy. The authors evaluated the effectiveness of the CIDT to increase help-seeking behavior in rural Nepal, where a district mental health care plan was being implemented. METHODS Twenty-four health facilities were randomly assigned to one of two methods for training their all-female cadre of community health volunteers: standard training or standard training that included the CIDT. The authors compared the number of patients with depression, psychosis, alcohol use disorder, and epilepsy who were registered in the routine health information system prior to and 6 months after the training. RESULTS At health facilities where volunteers received CIDT training, 309 patients were registered as having depression, psychosis, alcohol use disorder, or epilepsy, compared with 182 patients at facilities where volunteers received standard training. The median number of patients registered was 47% greater at facilities where CIDT training was included (24 patients) than at facilities with standard training (16 patients) (p=0.04, r=0.42). The difference in the number of registered patients remained significant when the analysis factored in the population catchment (N=18 patients [CIDT] versus N=14 [standard] per 10,000 population; p=0.05, r=0.40). CONCLUSIONS The median number of patients registered as having a mental illness was 47% greater at primary care facilities in which community health volunteers used the CIDT than at facilities where volunteers received standard training. Proactive case finding holds promise for increasing help seeking for mental health care.",2020,The median number of patients registered as having a mental illness was 47% greater at primary care facilities in which community health volunteers used the CIDT than at facilities where volunteers received standard training.,"['309 patients were registered as having depression, psychosis, alcohol use disorder, or epilepsy, compared with 182 patients at facilities where volunteers received', 'Twenty-four health facilities', 'Mental Health Care', 'patients with depression, psychosis, alcohol use disorder, and epilepsy who were registered in the routine health information system prior to and 6 months after the training']","['CIDT training', 'training their all-female cadre of community health volunteers: standard training or standard training that included the CIDT', 'standard training', 'CIDT', 'Proactive Community Case Detection', 'Community Informant Detection Tool (CIDT']","['median number of patients registered', 'median number of patients registered as having a mental illness']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0184643', 'cui_str': 'Mental health care'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0679918', 'cui_str': 'Health Information Systems'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0868928', 'cui_str': 'Case'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0585825', 'cui_str': 'Patient registered'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}]",309.0,0.0371716,The median number of patients registered as having a mental illness was 47% greater at primary care facilities in which community health volunteers used the CIDT than at facilities where volunteers received standard training.,"[{'ForeName': 'Mark J D', 'Initials': 'MJD', 'LastName': 'Jordans', 'Affiliation': ""Centre for Global Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London (Jordans, Lund); Transcultural Psychosocial Organization (TPO) Nepal, Kathmandu (Jordans, Luitel, Kohrt); Alan J. Flisher Centre for Public Mental Health, Department of Psychiatry and Mental Health, University of Cape Town, South Africa (Lund); Department of Psychiatry, George Washington University, Washington, D.C. (Kohrt).""}, {'ForeName': 'Nagendra P', 'Initials': 'NP', 'LastName': 'Luitel', 'Affiliation': ""Centre for Global Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London (Jordans, Lund); Transcultural Psychosocial Organization (TPO) Nepal, Kathmandu (Jordans, Luitel, Kohrt); Alan J. Flisher Centre for Public Mental Health, Department of Psychiatry and Mental Health, University of Cape Town, South Africa (Lund); Department of Psychiatry, George Washington University, Washington, D.C. (Kohrt).""}, {'ForeName': 'Crick', 'Initials': 'C', 'LastName': 'Lund', 'Affiliation': ""Centre for Global Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London (Jordans, Lund); Transcultural Psychosocial Organization (TPO) Nepal, Kathmandu (Jordans, Luitel, Kohrt); Alan J. Flisher Centre for Public Mental Health, Department of Psychiatry and Mental Health, University of Cape Town, South Africa (Lund); Department of Psychiatry, George Washington University, Washington, D.C. (Kohrt).""}, {'ForeName': 'Brandon A', 'Initials': 'BA', 'LastName': 'Kohrt', 'Affiliation': ""Centre for Global Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London (Jordans, Lund); Transcultural Psychosocial Organization (TPO) Nepal, Kathmandu (Jordans, Luitel, Kohrt); Alan J. Flisher Centre for Public Mental Health, Department of Psychiatry and Mental Health, University of Cape Town, South Africa (Lund); Department of Psychiatry, George Washington University, Washington, D.C. (Kohrt).""}]","Psychiatric services (Washington, D.C.)",['10.1176/appi.ps.201900377'] 173,32270474,"Ultrasound-guided transmuscular quadratus lumborum catheters for elective caesarean section: A protocol for a single-centre, double-blind randomised trial.","BACKGROUND Management of moderate-to-severe post-operative pain after elective caesarean section (ECS) is internationally primarily based on either epidural catheters or opioids. However, both techniques are associated with some undesirable adverse events. Bilateral transmuscular quadratus lumborum (TQL) block has proven to reduce opioid consumption significantly in the first 24 post-operative hours following ECS and prolong time to first opioid (TFO) (Hansen CKD, Steingrimsdottir M, Laier GE, et al. Reg Anesth Pain Med. 2019; 10.1136/rapm-2019-100540). We present a randomised controlled trial aiming to investigate whether continuous analgesia via bilateral TQL catheters can prolong TFO after ECS. METHODS This study is a double-blind, randomised, placebo-controlled trial. Patients should be 18 years or older and scheduled for ECS under spinal anaesthesia to be included. Main exclusion criteria are inability to cooperate, excessive daily intake of opioids and difficult ultrasound visualisation of muscular and fascial structures. Participants are randomised to receive ultrasound-guided injection of either 30 mL ropivacaine 0.2% bilaterally and an elastomeric pump containing 0.2% ropivacaine, or 30 mL saline bilaterally and an elastomeric pump containing saline, 2 hours after catheter placement. The primary endpoint is TFO. Secondary outcomes include pain intensity on a numeric rating scale (NRS), accumulated morphine consumption during 24 hours, displacement frequency of catheters and morphine-related adverse events. RECRUITMENT PERIOD Four patients were included from September 2018 to November 2018. Inclusion was resumed in June 2019 and will continue until 24 patients with useful data have been included in the trial. Expected inclusion period is 10-14 months. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT03663478. EudraCT: 2017-003625-15.",2020,Bilateral transmuscular quadratus lumborum (TQL) block has proven to reduce opioid consumption significantly in the first 24 postoperative hours following ECS and prolong time to first opioid (TFO).,"['Patients should be 18 years or older and scheduled for ECS under spinal anaesthesia to be included', 'PERIOD\n\n\nFour patients were included from September 2018 - November 2018', 'elective caesarean section', '24 patients with useful data have been included in the trial', 'moderate to severe postoperative pain after elective caesarean section (ECS']","['Bilateral transmuscular quadratus lumborum (TQL) block', 'placebo', 'continuous analgesia via bilateral TQL catheters', 'ultrasound-guided injection of either 30 ml ropivacaine 0.2% bilaterally and an elastomeric pump containing 0.2% ropivacaine, or 30 ml saline bilaterally and an elastomeric pump containing saline', 'Ultrasound-guided transmuscular quadratus lumborum catheters']","['pain intensity on a numeric rating scale (NRS), accumulated morphine consumption during 24 hours, displacement frequency of catheters and morphine-related adverse events', 'TFO', 'opioid consumption']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0224380', 'cui_str': 'Structure of quadratus lumborum muscle'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}]",4.0,0.736749,Bilateral transmuscular quadratus lumborum (TQL) block has proven to reduce opioid consumption significantly in the first 24 postoperative hours following ECS and prolong time to first opioid (TFO).,"[{'ForeName': 'Guðný E', 'Initials': 'GE', 'LastName': 'Steingrímsdóttir', 'Affiliation': 'Department of Anaesthesiology, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Christian K', 'Initials': 'CK', 'LastName': 'Hansen', 'Affiliation': 'Department of Anaesthesiology, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Børglum', 'Affiliation': 'Department of Anaesthesiology, Zealand University Hospital, Roskilde, Denmark.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13601'] 174,32312645,"Cemented vs Uncemented Femoral Components: A Randomized, Controlled Trial at 10 Years Minimum Follow-Up.","BACKGROUND The type of total knee arthroplasty (TKA) fixation (cemented or uncemented) is still subject to debate. The aim of this study is to assess the survival rate, clinical outcomes, and radiological results of TKA according to the fixation type. METHODS A total of 130 patients were randomly assigned to either the cement group (cemented femoral and tibial implants) or the hybrid group (cemented tibial implant, uncemented femoral implant). The inclusion criteria were patients between 50 and 90 years old who underwent primary TKA for osteoarthritis between 2004 and 2005 without a history of open knee surgery. Revisions and complications were reported, as well as clinical scores and radiological signs of loosening. RESULTS One hundred eighteen patients had complete data at 10 years of minimum follow-up (59 in each group). The mean age was 72 years old. The mean follow-up was 13 years. The survival rate was 98% at 13 years in both groups (1 aseptic loosening at 2 years in the cement group, 1 septic loosening in the hybrid group). The complication rate in the cement group was 8.5% (n = 5) vs 12.1% (n = 7) in the hybrid group (P = .8). The clinical results were not significantly different. In the cement group, 25% of patients (n = 15) had radiolucent lines at 10 years. In the hybrid group, 33% of patients had bone transparencies, not evolving or symptomatic. CONCLUSION At a minimum follow-up of 10 years, there were no significant differences between cemented TKA and hybrid TKA for the survivorship, the complication rate, the clinical scores, or the radiological signs of loosening. LEVEL OF EVIDENCE I.",2020,"At a minimum follow-up of 10 years, there were no significant differences between cemented TKA and hybrid TKA for the survivorship, the complication rate, the clinical scores, or the radiological signs of loosening. ","['The inclusion criteria were patients between 50 and 90 years old who underwent primary TKA for osteoarthritis between 2004 and 2005 without a history of open knee surgery', 'One hundred eighteen patients had complete data at 10 years of minimum follow-up (59 in each group', '130 patients', 'The mean age was 72 years old']","['cement group (cemented femoral and tibial implants) or the hybrid group (cemented tibial implant, uncemented femoral implant', 'total knee arthroplasty (TKA) fixation (cemented or uncemented', 'TKA', 'Cemented vs Uncemented Femoral Components']","['clinical scores and radiological signs of loosening', 'survival rate', 'bone transparencies, not evolving or symptomatic', 'complication rate, the clinical scores, or the radiological signs of loosening', 'complication rate']","[{'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0187769', 'cui_str': 'Operative procedure on knee'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0591126', 'cui_str': 'AT-10'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0011343', 'cui_str': 'Cementum structure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0040184', 'cui_str': 'Bone structure of tibia'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0007597', 'cui_str': 'Cell hybridization'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0449434', 'cui_str': 'Femoral component'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0333050', 'cui_str': 'Loosening'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0522503', 'cui_str': 'Translucent'}, {'cui': 'C0332253', 'cui_str': 'Evolving'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",130.0,0.0409115,"At a minimum follow-up of 10 years, there were no significant differences between cemented TKA and hybrid TKA for the survivorship, the complication rate, the clinical scores, or the radiological signs of loosening. ","[{'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Batailler', 'Affiliation': 'Orthopedic Surgery Department, Croix-Rousse Hospital, Lyon, France.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Malemo', 'Affiliation': 'Orthopedic Surgery Department, Croix-Rousse Hospital, Lyon, France.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Demey', 'Affiliation': 'Orthopedic Surgery Department, Croix-Rousse Hospital, Lyon, France; Lyon-Ortho-Clinic, Clinique de la Sauvegarde, Lyon, France.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Kenney', 'Affiliation': 'Orthopedic Surgery Department, Croix-Rousse Hospital, Lyon, France; Department of Orthopaedics, University of Rochester Medical Center, Rochester, NY.'}, {'ForeName': 'Sébastien', 'Initials': 'S', 'LastName': 'Lustig', 'Affiliation': 'Orthopedic Surgery Department, Croix-Rousse Hospital, Lyon, France; Univ Lyon, Université Claude Bernard Lyon 1, IFSTTAR, Villeurbanne, France.'}, {'ForeName': 'Elvire', 'Initials': 'E', 'LastName': 'Servien', 'Affiliation': 'Orthopedic Surgery Department, Croix-Rousse Hospital, Lyon, France; EA 7424, Interuniversity Laboratory of Human Movement Science, Université Lyon 1, Lyon, France.'}]",The Journal of arthroplasty,['10.1016/j.arth.2020.03.043'] 175,31974576,"Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.","BACKGROUND Different effectiveness profiles among antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to impact on long-term outcome. The aim of this study is to compare the clinical effectiveness of olanzapine, risperidone, haloperidol, aripiprazole, ziprasidone, and quetiapine in the treatment of first episode of psychosis at 3-year follow-up. METHOD From February 2001 to January 2011, 2 phases of a prospective, randomized, open-label study were undertaken. A total of 376 first-episode drug-naïve patients were randomly assigned to olanzapine (n = 55), risperidone (n = 63), haloperidol (n = 56), aripiprazole (n = 78), ziprasidone (n = 62), or quetiapine (n = 62) and followed up for 3 years. The primary effectiveness measure was all cause of treatment discontinuation. In addition, an analysis based on intention-to-treat principle was conducted in the analysis for clinical efficacy. RESULTS The overall dropout rate at 3 years reached 20.75%. Treatment discontinuation rates were significantly different among treatment groups (olanzapine = 69.09, risperidone = 71.43, aripiprazole = 73.08%, ziprasidone = 79.03%, haloperidol = 89.28%, and quetiapine = 95.53%) (χ2 = 79.86; P = .000). Statistically significant differences in terms of lack of efficacy, adherence, and tolerability were observed among treatment groups along the 3-year follow-up, determining significant differences in time to all-cause discontinuation (log-rank = 92.240; P = .000). Significant differences between treatments were found in the categories of sleepiness/sedation, increased sleep duration, akinesia, weight gain, ejaculatory dysfunction, extrapyramidal-symptoms, and amenorrhea. CONCLUSIONS Olanzapine, risperidone, and aripiprazole presented advantages for the first-line treatment of first episode of psychosis in terms of effectiveness. Identifying different discontinuation patterns may contribute to optimize treatment selection after first episode of psychosis.ClinicalTrials.gov Identifier: NCT02526030 https://clinicaltrials.gov/show/NCT02526030.",2020,"Statistically significant differences in terms of lack of efficacy, adherence and tolerability were observed among treatment groups along the 3-year follow-up determining significant differences in time to all-cause discontinuation (Log-Rank = 92.240; p =0.000).","['patients suffering a first episode of psychosis (FEP', 'Three hundred seventy-six first-episode drug-naïve patients']","['antipsychotics', 'olanzapine', 'haloperidol', 'haloperidol, olanzapine, risperidone, aripiprazole, quetiapine and ziprasidone', 'ziprasidone', 'quetiapine', 'aripiprazole', 'risperidone', 'Antipsychotic', 'olanzapine, risperidone, haloperidol, aripiprazole, ziprasidone and quetiapine', 'Olanzapine, risperidone and aripiprazole']","['cause of treatment discontinuation', 'categories of sleepiness/sedation, increased sleep duration, akinesia, weight gain, ejaculatory dysfunction, extrapyramidal-symptoms and amenorrhea', 'Treatment discontinuation rates', 'lack of efficacy, adherence and tolerability', 'overall dropout rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439615', 'cui_str': 'First episode (qualifier value)'}, {'cui': 'C0033975', 'cui_str': 'Psychoses'}, {'cui': 'C0032611', 'cui_str': 'Polytetrafluoroethylene'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C4319622', 'cui_str': 'Seventy-six'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}]","[{'cui': 'C0040615', 'cui_str': 'Antipsychotic Drugs'}, {'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C0018546', 'cui_str': 'Haloperidol'}, {'cui': 'C0073393', 'cui_str': 'Risperidone'}, {'cui': 'C0299792', 'cui_str': 'aripiprazole'}, {'cui': 'C0123091', 'cui_str': 'quetiapine'}, {'cui': 'C0380393', 'cui_str': 'ziprasidone'}]","[{'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2830004', 'cui_str': 'Somnolence'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0085623', 'cui_str': 'Akinesia (finding)'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}, {'cui': 'C0234133', 'cui_str': 'Extrapyramidal sign (finding)'}, {'cui': 'C0002453', 'cui_str': 'Amenorrhea'}, {'cui': 'C0332268', 'cui_str': 'Lacking (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.0175263,"Statistically significant differences in terms of lack of efficacy, adherence and tolerability were observed among treatment groups along the 3-year follow-up determining significant differences in time to all-cause discontinuation (Log-Rank = 92.240; p =0.000).","[{'ForeName': 'Marcos', 'Initials': 'M', 'LastName': 'Gómez-Revuelta', 'Affiliation': 'University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.'}, {'ForeName': 'José María', 'Initials': 'JM', 'LastName': 'Pelayo-Terán', 'Affiliation': 'University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Juncal-Ruiz', 'Affiliation': 'CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Vázquez-Bourgon', 'Affiliation': 'University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Suárez-Pinilla', 'Affiliation': 'University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Romero-Jiménez', 'Affiliation': 'University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Setién Suero', 'Affiliation': 'University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Ayesa-Arriola', 'Affiliation': 'University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.'}, {'ForeName': 'Benedicto', 'Initials': 'B', 'LastName': 'Crespo-Facorro', 'Affiliation': 'CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain.'}]",The international journal of neuropsychopharmacology,['10.1093/ijnp/pyaa004'] 176,32053828,Global connectivity and local excitability changes underlie antidepressant effects of repetitive transcranial magnetic stimulation.,"Repetitive transcranial magnetic stimulation (rTMS) is a commonly- used treatment for major depressive disorder (MDD). However, our understanding of the mechanism by which TMS exerts its antidepressant effect is minimal. Furthermore, we lack brain signals that can be used to predict and track clinical outcome. Such signals would allow for treatment stratification and optimization. Here, we performed a randomized, sham-controlled clinical trial and measured electrophysiological, neuroimaging, and clinical changes before and after rTMS. Patients (N = 36) were randomized to receive either active or sham rTMS to the left dorsolateral prefrontal cortex (dlPFC) for 20 consecutive weekdays. To capture the rTMS-driven changes in connectivity and causal excitability, resting fMRI and TMS/EEG were performed before and after the treatment. Baseline causal connectivity differences between depressed patients and healthy controls were also evaluated with concurrent TMS/fMRI. We found that active, but not sham rTMS elicited (1) an increase in dlPFC global connectivity, (2) induction of negative dlPFC-amygdala connectivity, and (3) local and distributed changes in TMS/EEG potentials. Global connectivity changes predicted clinical outcome, while both global connectivity and TMS/EEG changes tracked clinical outcome. In patients but not healthy participants, we observed a perturbed inhibitory effect of the dlPFC on the amygdala. Taken together, rTMS induced lasting connectivity and excitability changes from the site of stimulation, such that after active treatment, the dlPFC appeared better able to engage in top-down control of the amygdala. These measures of network functioning both predicted and tracked clinical outcome, potentially opening the door to treatment optimization.",2020,Patients (N = 36) were randomized to receive either active or sham rTMS to the left dorsolateral prefrontal cortex (dlPFC) for 20 consecutive weekdays.,"['Patients (N\u2009=\u200936', 'depressed patients and healthy controls', 'major depressive disorder (MDD']","['Repetitive transcranial magnetic stimulation (rTMS', 'active or sham rTMS to the left dorsolateral prefrontal cortex (dlPFC', 'TMS', 'repetitive transcranial magnetic stimulation', 'rTMS']","['connectivity and causal excitability, resting fMRI and TMS/EEG', 'global connectivity and TMS/EEG changes tracked clinical outcome', 'dlPFC global connectivity, (2) induction of negative dlPFC-amygdala connectivity, and (3) local and distributed changes in TMS/EEG potentials']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0450424', 'cui_str': 'To the left (qualifier value)'}, {'cui': 'C4019080', 'cui_str': 'Dorsolateral Prefrontal Cortex'}]","[{'cui': 'C0235169', 'cui_str': 'Excitability (finding)'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0013819', 'cui_str': 'EEG'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0040594', 'cui_str': 'Track'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0002708', 'cui_str': 'Amygdaloid Body'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}]",36.0,0.0327488,Patients (N = 36) were randomized to receive either active or sham rTMS to the left dorsolateral prefrontal cortex (dlPFC) for 20 consecutive weekdays.,"[{'ForeName': 'Neir', 'Initials': 'N', 'LastName': 'Eshel', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Corey J', 'Initials': 'CJ', 'LastName': 'Keller', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wu', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Colleen', 'Initials': 'C', 'LastName': 'Mills-Finnerty', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Huemer', 'Affiliation': 'Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Wright', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Fonzo', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Naho', 'Initials': 'N', 'LastName': 'Ichikawa', 'Affiliation': 'Department of Psychiatry and Neurosciences, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Carreon', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Melinda', 'Initials': 'M', 'LastName': 'Wong', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Yee', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Shpigel', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': ""Department of Neurology, Shenzhen People's Hospital, Shenzhen, China.""}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'McTeague', 'Affiliation': 'Department of Psychiatry, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Adi', 'Initials': 'A', 'LastName': 'Maron-Katz', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Etkin', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA. amitetkin@stanford.edu.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-020-0633-z'] 177,30940887,The effect of single periocular injection of methylprednisolone and drainage of suprachoroidal fluid in the treatment of rhegmatogenous retinal detachment combined with choroidal detachment.,"PURPOSE In this study we compared the anatomic and functional outcomes of two steroid treatments on rhegmatogenous retinal detachment (RRD) combined with choroidal detachment (CD), namely treatment with oral prednisolone (1 mg/kg daily) for 3-7 days before vitrectomy or a single periocular injection of methylprednisolone (40 mg) 1-3 days before vitrectomy. We also analyzed the outcomes of the eyes with subsided CD and the eyes with persistent CD that underwent drainage of suprachoroidal fluids during the vitrectomy. METHODS This was a prospective randomized study. Seventy five eyes with RRD combined with CD were divided into 2 groups based on the two different treatment regimens as above. The eyes in each group were further divided into 2 subgroups (A: CD subsided eyes; B: CD persistent eyes) according to the response of CD to the treatment of steroids. Retinal reattachment rates were measured at 6 months after the removal of silicone oil. RESULTS At 6 months after silicone oil removal, the retinal reattachment rate was similar (p = 0.666) in the oral prednisolone group (91.7%, 33/36) and the periocular injection group (94.9%, 37/39). Similar retinal reattachment rates (p = 0.364) were also found in the CD subsided eyes (97.1%, 34/35) and the CD persistent eyes (90.0%, 36/40). The retinal reattachment rate was comparable among the subgroups (p = 0.395; oral prednisolone A group: 95.2%, 20/21; oral prednisolone B group: 86.7%, 13/15; periocular injection A group: 100%, 14/14; periocular injection B group: 92.0%, 23/25). CONCLUSIONS For RRD combined with CD, eyes treated with a single periocular injection of methylprednisolone (40 mg, 1-3 days before pars plana vitrectomy) combined with the drainage of suprachoroidal fluids during the surgery had similar anatomic and functional outcomes compared to the eyes treated with oral prednisolone for 3-7 days before vitrectomy.",2019,"The retinal reattachment rate was comparable among the subgroups (p = 0.395; oral prednisolone A group: 95.2%, 20/21; oral prednisolone B group: 86.7%, 13/15; periocular injection A group: 100%, 14/14; periocular injection B group: 92.0%, 23/25). ","['rhegmatogenous retinal detachment combined with choroidal detachment', 'Seventy five eyes with RRD combined with CD']","['methylprednisolone and drainage of suprachoroidal fluid', 'oral prednisolone', 'methylprednisolone', 'rhegmatogenous retinal detachment (RRD) combined with choroidal detachment (CD', 'steroid treatments', 'silicone oil', 'prednisolone']","['retinal reattachment rate', 'Retinal reattachment rates', 'Similar retinal reattachment rates']","[{'cui': 'C0271055', 'cui_str': 'Rhegmatogenous retinal detachment (disorder)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0162279', 'cui_str': 'Choroidal detachment (disorder)'}, {'cui': 'C4319621', 'cui_str': 'Seventy-five'}, {'cui': 'C0015392', 'cui_str': 'Eye'}]","[{'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}, {'cui': 'C0395611', 'cui_str': 'Drainage of suprachoroidal fluid (procedure)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C0271055', 'cui_str': 'Rhegmatogenous retinal detachment (disorder)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0162279', 'cui_str': 'Choroidal detachment (disorder)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0037111', 'cui_str': 'Silicone Oils'}]","[{'cui': 'C0035331', 'cui_str': 'Retinal'}, {'cui': 'C0185042', 'cui_str': 'Refixation (procedure)'}]",75.0,0.0482548,"The retinal reattachment rate was comparable among the subgroups (p = 0.395; oral prednisolone A group: 95.2%, 20/21; oral prednisolone B group: 86.7%, 13/15; periocular injection A group: 100%, 14/14; periocular injection B group: 92.0%, 23/25). ","[{'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Wei', 'Affiliation': 'The Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China. weiyongdoctor@163.com.'}, {'ForeName': 'RongLe', 'Initials': 'R', 'LastName': 'Zhou', 'Affiliation': ""Shaanxi Ophthalmic Medical Center, Xi'an No.4 Hospital, Affiliated Guangren Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, 710004, China.""}, {'ForeName': 'Xiaobo', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Xiamen Eye Center Affiliated to Xiamen University, Xiamen, 361000, China.'}, {'ForeName': 'Xiuju', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Xiamen Eye Center Affiliated to Xiamen University, Xiamen, 361000, China.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'The Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China.'}]","Eye (London, England)",['10.1038/s41433-019-0420-4'] 178,32323609,"Phase I/II Study of Intrathecal Administration of Recombinant Human Hepatocyte Growth Factor in Patients with Acute Spinal Cord Injury: A Double-Blind, Randomized Clinical Trial of Safety and Efficacy.","Spinal cord injury (SCI) is an abrupt traumatic injury that leads to permanent functional loss, and no practical treatment is available. We have developed pharmaceutical recombinant human hepatocyte growth factor (KP-100), and its efficacy for SCI has been verified using animal models. The purpose of this study was to evaluate the safety and efficacy of intrathecal KP-100 administration for SCI patients in the acute phase. This investigation was a multi-center, randomized, double-blind study. Subjects with modified Frankel grade A/B1/B2 at 72 h after SCI were included. KP-100 was administered intrathecally. Subjects were followed up for 168 days after the first administration. Outcomes were evaluated using American Spinal Injury Association (ASIA) scores and subjected to analysis of covariance. Our results demonstrated that the subjects did not show any serious adverse events caused by KP-100. Forty-three subjects underwent neurological function testing (26 in KP-100 group; 17 in placebo group), which revealed that KP-100 contributed to motor improvement at Days 140 ( p  = 0.050) and 168 ( p  = 0.079). In the subset of subjects with Frankel grade A, the proportions of subjects who gained at least 1 point on their lower-extremity motor scores were 33.3% (5/15) and 6.3% (1/16) in the KP-100 and placebo groups, respectively ( p  = 0.083). Therefore, KP-100 has the potential to be useful and beneficial for SCI patients during the acute phase. However, this was a phase I/II trial and did not definitely address the question of efficacy; a larger phase III trial would be required to assess the efficacy.",2020,Our results demonstrated that the subjects did not show any serious adverse events caused by KP-100.,"['Subjects with modified Frankel grade', 'SCI patients in the acute phase', 'patients with acute spinal cord injury']","['KP-100', 'intrathecal KP-100', 'recombinant human hepatocyte growth factor', 'placebo']","['American Spinal Injury Association (ASIA) scores', 'neurological function testing', 'lower-extremity motor scores', 'safety and efficacy']","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439557', 'cui_str': 'Acute phase'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}]","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0677897', 'cui_str': 'Intrathecal route'}, {'cui': 'C1447107', 'cui_str': 'HGF protein, human'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0037937', 'cui_str': 'Spinal injury'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0027767', 'cui_str': 'Nervous system function'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.111947,Our results demonstrated that the subjects did not show any serious adverse events caused by KP-100.,"[{'ForeName': 'Narihito', 'Initials': 'N', 'LastName': 'Nagoshi', 'Affiliation': 'Department of Orthopedic Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Osahiko', 'Initials': 'O', 'LastName': 'Tsuji', 'Affiliation': 'Department of Orthopedic Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Kazuya', 'Initials': 'K', 'LastName': 'Kitamura', 'Affiliation': 'Department of Orthopedic Surgery, Saiseikai Yokohama-shi Tobu Hospital, Kanagawa, Japan.'}, {'ForeName': 'Kota', 'Initials': 'K', 'LastName': 'Suda', 'Affiliation': 'Department of Orthopedic Surgery, Hokkaido Spinal Cord Injury Center, Hokkaido, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Maeda', 'Affiliation': 'Department of Orthopedic Surgery, Spinal Injuries Center, Fukuoka, Japan.'}, {'ForeName': 'Yoshiyuki', 'Initials': 'Y', 'LastName': 'Yato', 'Affiliation': 'Department of Orthopedic Surgery, Murayama Medical Center, National Hospital Organization, Tokyo, Japan.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Abe', 'Affiliation': 'Faculty of Data Science, Yokohama City University School of Data Science, Kanagawaken, Japan.'}, {'ForeName': 'Daichika', 'Initials': 'D', 'LastName': 'Hayata', 'Affiliation': 'Kringle Pharma, Inc., Osaka, Japan.'}, {'ForeName': 'Morio', 'Initials': 'M', 'LastName': 'Matsumoto', 'Affiliation': 'Department of Orthopedic Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Okano', 'Affiliation': 'Department of Physiology, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Masaya', 'Initials': 'M', 'LastName': 'Nakamura', 'Affiliation': 'Department of Orthopedic Surgery, Keio University School of Medicine, Tokyo, Japan.'}]",Journal of neurotrauma,['10.1089/neu.2019.6854'] 179,32018252,Perinatal Probiotic Mixture and Development of Allergic Sensitization up to 13 Years of Age.,"BACKGROUND Probiotics have shown promising results in primary prevention of allergies in early years, but the long-term effects on allergic sensitization need more evaluation. OBJECTIVES We conducted a randomized double-blind placebo-controlled study to determine whether the use of a mixture of pre- and probiotics perinatally affects the prevalence of immunoglobulin E (IgE) sensitization up to 13 years in high-risk children. METHODS One thousand two hundred twenty-three pregnant women were randomized to receiving probiotics or placebo from 36 gestational weeks until delivery, and their infants received pre- and probiotics or placebo from birth until 6 months. At 2, 5, and 13 years, blood samples were taken to determine specific IgE levels against common foods, pollen, and animal antigens. RESULTS The prevalence of IgE sensitization to any allergen was high and increased with age. No significant difference in the prevalence of IgE sensitization to any particular one of the tested allergens was found between the groups. At 2, 5, and 13 years these prevalence rates of IgE sensitization to any allergen were 31.1 and 34.1%, 50.1 and 45.6%, and 61.4 and 56.8% in the probiotic and placebo groups, respectively. At 13 years, IgE sensitization to cat/dog dander was more frequent in the probiotic group compared to the placebo group (40.2 vs. 31.0%, p = 0.03). CONCLUSIONS In high-risk children, perinatal use of a mixture of probiotics did not affect the prevalence of sensitization to any one of the tested allergens, but it was associated with more frequent IgE sensitization to cat/dog dander at 13 years.",2020,"At 13 years, IgE sensitization to cat/dog dander was more frequent in the probiotic group compared to the placebo group (40.2 vs. 31.0%, p = 0.03). ","['13 years in high-risk children', 'Allergic Sensitization up to 13 Years of Age', 'One thousand two hundred twenty-three pregnant women']","['placebo', 'probiotics or placebo', 'pre- and probiotics or placebo']","['prevalence rates of IgE sensitization', 'prevalence of IgE sensitization', 'IgE sensitization to cat/dog dander', 'prevalence of immunoglobulin E (IgE) sensitization']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C3662483', 'cui_str': 'Allergic sensitization'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517548', 'cui_str': 'One thousand two hundred'}, {'cui': 'C0450348', 'cui_str': '23 (qualifier value)'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0525033', 'cui_str': 'Probiotics'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}]","[{'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0202086', 'cui_str': 'Immunoglobulin E measurement (procedure)'}, {'cui': 'C1325847', 'cui_str': 'Sensitization'}, {'cui': 'C0524517', 'cui_str': 'Felis'}, {'cui': 'C0440458', 'cui_str': 'Dog dander (substance)'}]",1223.0,0.136193,"At 13 years, IgE sensitization to cat/dog dander was more frequent in the probiotic group compared to the placebo group (40.2 vs. 31.0%, p = 0.03). ","[{'ForeName': 'Päivi Susanna', 'Initials': 'PS', 'LastName': 'Peldan', 'Affiliation': ""Pediatric Research Center, University of Helsinki and Helsinki University Hospital, New Children's Hospital, Helsinki, Finland, paivi.peldan@hus.fi.""}, {'ForeName': 'Anna Kaarina', 'Initials': 'AK', 'LastName': 'Kukkonen', 'Affiliation': 'Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Erkki', 'Initials': 'E', 'LastName': 'Savilahti', 'Affiliation': ""Pediatric Research Center, University of Helsinki and Helsinki University Hospital, New Children's Hospital, Helsinki, Finland.""}, {'ForeName': 'Mikael', 'Initials': 'M', 'LastName': 'Kuitunen', 'Affiliation': ""Pediatric Research Center, University of Helsinki and Helsinki University Hospital, New Children's Hospital, Helsinki, Finland.""}]",International archives of allergy and immunology,['10.1159/000504915'] 180,32022518,"Editorial Comment: Efficacy and Safety of Complete Intraureteral Stent Placement versus Conventional Stent Placement in Relieving Ureteral Stent Related Symptoms: A Randomized, Prospective, Single Blind, Multicenter Clinical Trial.",,2020,,['Relieving Ureteral Stent Related Symptoms'],['Complete Intraureteral Stent Placement versus Conventional Stent Placement'],[],"[{'cui': 'C1301771', 'cui_str': 'Relieved'}, {'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0522776', 'cui_str': 'Placement of stent (procedure)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]",[],,0.0832185,,"[{'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Danilovic', 'Affiliation': 'Serviço de Urologia, Hospital das Clínicas da Faculdade de Medicina da USP - HCFMUSP, São Paulo, SP, Brasil.'}]",International braz j urol : official journal of the Brazilian Society of Urology,['10.1590/S1677-5538.IBJU.2020.02.03'] 181,32203675,Comparison of Tendon Lengthening With Traditional Versus Accelerated Rehabilitation After Achilles Tendon Repair: A Prospective Randomized Controlled Trial.,"BACKGROUND Early weightbearing protocols after Achilles tendon repair promote mobilization, yet little is known about their effect on tendon lengthening. PURPOSE To evaluate tendon lengthening after Achilles tendon repair with accelerated rehabilitation. STUDY DESIGN Randomized controlled trial; Level of evidence, 1. METHODS Patients undergoing primary repair for acute Achilles tendon ruptures consented to have tantalum beads placed within the tendon. Patients were randomized into either a traditional (weightbearing at 6 weeks) or accelerated (graduated weightbearing at 2 weeks) rehabilitation group. The primary outcome of the study was postoperative tendon elongation as measured by radiostereometric beads. Secondary outcomes included Achilles Tendon Total Rupture Score (ATRS) and Patient-Reported Outcomes Measurement Information System Pain Interference Short Form (PROMIS PI-SF) score. RESULTS All 18 patients included in the final analysis were found to have significant tendon lengthening after surgery, with a mean lengthening of 15.9 mm. No significant differences were found in overall lengthening between the traditional and accelerated rehabilitation groups (15.3 ± 4.5 vs 16.4 ± 4.7 mm, respectively; P = .33) at final follow-up. The repair site in each group was found to lengthen more than the intratendinous site (traditional group, 13.2 vs 2.1 mm; accelerated group, 16.8 vs -0.4 mm); however, no difference in lengthening was seen between groups ( P = .82 and P = .31, respectively). The greatest amount of lengthening occurred between 2 and 6 weeks, and the least amount of lengthening occurred between 6 and 12 weeks, with no difference between the traditional and accelerated groups at these time points ( P = .84 and P = .38, respectively). No differences were noted in ankle range of motion (dorsiflexion, P = .16; plantarflexion, P = .08) or outcome scores (ATRS, P = .56; PROMIS PI-SF, P = .54). CONCLUSION This study's findings demonstrate that all patients undergoing operative repair of Achilles tendon ruptures had lengthening after surgery. No difference was found in tendon lengthening (repair site or intratendinous) at any time point between patients undergoing traditional versus accelerated rehabilitation postoperatively. The greatest amount of lengthening was found to occur between 2 and 6 weeks postoperatively, and tendon lengthening decreased significantly after 6 weeks. REGISTRATION NCT04050748 (ClinicalTrials.gov identifier).",2020,"No differences were noted in ankle range of motion (dorsiflexion, P = .16; plantarflexion, P = .08) or outcome scores (ATRS, P = .56; PROMIS PI-SF, P = .54). ","['Patients undergoing primary repair for acute Achilles tendon ruptures consented to have tantalum beads placed within the tendon', 'patients undergoing operative repair of Achilles tendon ruptures had lengthening after surgery', 'After Achilles Tendon Repair']","['Lengthening With Traditional Versus Accelerated Rehabilitation', 'traditional (weightbearing at 6 weeks) or accelerated (graduated weightbearing at 2 weeks) rehabilitation group', 'tendon lengthening after Achilles tendon repair with accelerated rehabilitation', 'Tendon']","['ankle range of motion (dorsiflexion', 'tendon lengthening (repair site or intratendinous', 'greatest amount of lengthening', 'least amount of lengthening', 'Achilles Tendon Total Rupture Score (ATRS) and Patient-Reported Outcomes Measurement Information System Pain Interference Short Form (PROMIS PI-SF) score', 'overall lengthening', 'postoperative tendon elongation', 'tendon lengthening']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C0263970', 'cui_str': 'Rupture of Achilles tendon'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C0039297', 'cui_str': 'Tantalum'}, {'cui': 'C1704765', 'cui_str': 'Place - dosing instruction imperative'}, {'cui': 'C0039508', 'cui_str': 'Tendons'}, {'cui': 'C0407029', 'cui_str': 'Repair of tendo achilles (procedure)'}, {'cui': 'C0443294', 'cui_str': 'Ruptured (qualifier value)'}, {'cui': 'C0392744', 'cui_str': 'Lengthened (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0565350', 'cui_str': 'Repair of tendon (procedure)'}]","[{'cui': 'C0392744', 'cui_str': 'Lengthened (qualifier value)'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0521110', 'cui_str': 'Accelerated (contextual qualifier) (qualifier value)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C1318107', 'cui_str': 'Loadbearing'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0588053', 'cui_str': 'Graduate (person)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0039508', 'cui_str': 'Tendons'}, {'cui': 'C0407029', 'cui_str': 'Repair of tendo achilles (procedure)'}]","[{'cui': 'C0576183', 'cui_str': 'Joint movement: ankle'}, {'cui': 'C0441593', 'cui_str': 'Tendon Lengthening'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0039508', 'cui_str': 'Tendons'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0443294', 'cui_str': 'Ruptured (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0021428', 'cui_str': 'Information Systems'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0392744', 'cui_str': 'Lengthened (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0856439', 'cui_str': 'Tendon elongation'}]",18.0,0.140827,"No differences were noted in ankle range of motion (dorsiflexion, P = .16; plantarflexion, P = .08) or outcome scores (ATRS, P = .56; PROMIS PI-SF, P = .54). ","[{'ForeName': 'Kelechi R', 'Initials': 'KR', 'LastName': 'Okoroha', 'Affiliation': 'Department of Orthopaedic Surgery, Henry Ford Hospital, Detroit, Michigan, USA.'}, {'ForeName': 'Najib', 'Initials': 'N', 'LastName': 'Ussef', 'Affiliation': 'Department of Orthopaedic Surgery, Henry Ford Hospital, Detroit, Michigan, USA.'}, {'ForeName': 'Toufic R', 'Initials': 'TR', 'LastName': 'Jildeh', 'Affiliation': 'Department of Orthopaedic Surgery, Henry Ford Hospital, Detroit, Michigan, USA.'}, {'ForeName': 'Lafi S', 'Initials': 'LS', 'LastName': 'Khalil', 'Affiliation': 'Department of Orthopaedic Surgery, Henry Ford Hospital, Detroit, Michigan, USA.'}, {'ForeName': 'Laith', 'Initials': 'L', 'LastName': 'Hasan', 'Affiliation': 'Tulane University Medical School, New Orleans, Louisiana, USA.'}, {'ForeName': 'Carter', 'Initials': 'C', 'LastName': 'Bench', 'Affiliation': 'Wayne State University School of Medicine, Detroit, Michigan, USA.'}, {'ForeName': 'Ferras', 'Initials': 'F', 'LastName': 'Zeni', 'Affiliation': 'Department of Orthopaedic Surgery, Henry Ford Hospital, Detroit, Michigan, USA.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Eller', 'Affiliation': 'Department of Orthopaedic Surgery, Henry Ford Hospital, Detroit, Michigan, USA.'}, {'ForeName': 'Vasilios', 'Initials': 'V', 'LastName': 'Moutzouros', 'Affiliation': 'Department of Orthopaedic Surgery, Henry Ford Hospital, Detroit, Michigan, USA.'}]",The American journal of sports medicine,['10.1177/0363546520909389'] 182,31357206,Pharmacological mechanisms of interhemispheric signal propagation: a TMS-EEG study.,"Interhemispheric connections across the corpus callosum have a predominantly inhibitory effect. Previous electrophysiology studies imply that local inhibitory circuits are responsible for inducing transcallosal inhibition, likely through inhibitory GABA B -mediated neurotransmission. We investigated the neurochemical mechanisms involved in interhemispheric connectivity by measuring transcranial magnetic stimulation (TMS)-induced interhemispheric signal propagation (ISP) in the motor cortex and dorsolateral prefrontal cortex (DLPFC) with electroencephalography (EEG) recordings under the pharmacological effects of baclofen, L-DOPA, dextromethorphan, and rivastigmine. We hypothesized that for both stimulated regions, GABA B receptor agonist baclofen would decrease ISP when compared against baseline while drugs that target other neurotransmitter systems (dopaminergic, acetylcholinergic, and glutamatergic systems) would have no effect on ISP. Twelve right-handed healthy volunteers completed this study and underwent TMS across five sessions in a randomized order. In the motor cortex, participants showed a significant decrease in ISP under baclofen, but not in the other drug conditions. There were no drug-induced changes in ISP in the DLPFC and baseline ISP did not differ across experimental sessions for both brain regions. Together, our results suggest that the inhibitory effects observed with interhemispheric signal transmission are mediated by a population of interneurons involving GABA B receptor neurotransmission. Inhibitory mechanisms of ISP may be more salient for motor-related functions in the motor cortex than for cognitive control in the DLPFC. These findings are a fundamental step in advancing our understanding of interhemispheric connectivity and may be used to identify treatments for disorders in which transcallosal transmission is dysfunctional.",2020,"In the motor cortex, participants showed a significant decrease in ISP under baclofen, but not in the other drug conditions.",['Twelve right-handed healthy volunteers'],"['baclofen, L-DOPA, dextromethorphan, and rivastigmine', 'TMS', 'transcranial magnetic stimulation (TMS)-induced interhemispheric signal propagation (ISP']","['ISP under baclofen', 'ISP']","[{'cui': 'C0344333', 'cui_str': 'Right handed (finding)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0004609', 'cui_str': 'Baclofen'}, {'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C0011816', 'cui_str': 'Dextromethorphan'}, {'cui': 'C0649350', 'cui_str': 'rivastigmine'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation (procedure)'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}]","[{'cui': 'C0004609', 'cui_str': 'Baclofen'}]",12.0,0.0545946,"In the motor cortex, participants showed a significant decrease in ISP under baclofen, but not in the other drug conditions.","[{'ForeName': 'Jeanette', 'Initials': 'J', 'LastName': 'Hui', 'Affiliation': 'Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Zomorrodi', 'Affiliation': 'Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.'}, {'ForeName': 'Pantelis', 'Initials': 'P', 'LastName': 'Lioumis', 'Affiliation': 'Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.'}, {'ForeName': 'Bahar', 'Initials': 'B', 'LastName': 'Salavati', 'Affiliation': 'Institute of Medical Science, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Tarek K', 'Initials': 'TK', 'LastName': 'Rajji', 'Affiliation': 'Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Chen', 'Affiliation': 'Institute of Medical Science, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Blumberger', 'Affiliation': 'Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.'}, {'ForeName': 'Zafiris J', 'Initials': 'ZJ', 'LastName': 'Daskalakis', 'Affiliation': 'Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada. Jeff.Daskalakis@camh.ca.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0468-7'] 183,32319087,The effect of rocuronium on ventilatory leak and sealing pressure using a supraglottic airway device: A randomized clinical trial.,"BACKGROUND The transition of ventilatory leak and sealing pressure in supraglottic airway devices after administration of neuromuscular blocking agents is unclear. We hypothesized that ventilatory leak would decrease due to the increase in sealing pressure after administration of 0.15 and 0.30 mg/kg rocuronium iv. METHODS Forty patients were randomly assigned to a control group or one of two rocuronium groups. After induction of general anaesthesia, an i-gel ® was inserted before rocuronium administration. The ventilatory leak and sealing pressure were measured immediately. Then, 0.15 mg/kg or 0.30 mg/kg rocuronium iv was administered and the ventilatory leak and sealing pressure were measured again. In the control group, measurements were obtained just after insertion of the supraglottic airway device and 5 minutes later, without any additional drug administration. RESULTS Similar decrements in ventilatory leak of approximately 3% were registered in all three groups. There were no changes in sealing pressure in any of the groups. However, multiple logistic regression analysis demonstrated that the reduced height of the first twitch response to train-of-four stimulation after administration of rocuronium was a determinant of a decrease in sealing pressure (odds ratio: 0.97, 95% confidence interval: 0.95-0.99, P = .04). CONCLUSIONS Our results suggest that ventilatory leak with a supraglottic airway device decreases independently of neuromuscular blockade, although the neuromuscular blockade may potentially decrease sealing pressure. Registration of Clinical trials: UMIN Clinical Trials Registry (registration ID: UMIN000027061, URL: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000031018).",2020,There were no changes in sealing pressure in any of the groups.,['Forty patients'],['rocuronium'],"['sealing pressure', 'ventilatory leak', 'ventilatory leak and sealing pressure', 'sealing pressure (odds ratio']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0209337', 'cui_str': 'Rocuronium'}]","[{'cui': 'C0036492', 'cui_str': 'Seal'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0332234', 'cui_str': 'Leaking'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}]",40.0,0.193245,There were no changes in sealing pressure in any of the groups.,"[{'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Fujimoto', 'Affiliation': 'Department of Anesthesiology, Nishinihon Hospital, Kumamoto-City, Kumamoto, Japan.'}, {'ForeName': 'Fumiyo', 'Initials': 'F', 'LastName': 'Kubota', 'Affiliation': 'Department of Anesthesiology, Nishinihon Hospital, Kumamoto-City, Kumamoto, Japan.'}, {'ForeName': 'Tatsuo', 'Initials': 'T', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Anesthesiology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto University Hospital, Kumamoto-City, Kumamoto, Japan.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13608'] 184,32304881,Omega-3 fatty acids ameliorate cognitive dysfunction in schizophrenia patients with metabolic syndrome.,"Our previous study showed that metabolic abnormalities reduced the levels of brain-derived neurotrophic factor (BDNF) and deteriorated cognitive performance in patients with schizophrenia. Inflammation may play a key role in this process. Omega-3 fatty acids have been documented to ameliorate inflammation. Therefore, we hypothesized that omega-3 fatty acids may be of value in enhancing BDNF levels and improving cognitive function in patients with schizophrenia with metabolic syndrome (MetS). We recruited 80 patients with both schizophrenia and MetS who received long-term olanzapine monotherapy. The enzyme-linked immunosorbent assay was used to measure the plasma levels of C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). The patients were randomly assigned to the OMG-3 group (n = 40) or the placebo group (n = 40). Of the 80 patients who consented to the study, 72 completed this 12-week RCT. The primary outcome was the changes from baseline to 12 weeks in clinical characteristics and the levels of BDNF, CRP, IL-6 and TNF-α. There was a significant correlation between omega-3 fatty acid treatment and enhanced delayed memory factor in the RBANS assessment (F group×time  = 6.82; df = 1, 66; P = 0.01) when the patients completed this study. Along with cognitive improvement, omega-3 fatty acids enhanced BDNF (F group×time  = 4.93; df = 1, 66; P = 0.03) and reduced CRP (F group×time  = 17.11; df = 1, 66; P < 0.01), IL-6 (F group×time  = 9.71; df = 1, 66; P < 0.004) and TNF-α (F group×time  = 6.71; df = 1, 66; P = 0.012) levels after 12 weeks of treatment. The changes in BDNF levels are negatively correlated with the changes in TNF-α levels (r = -0.37, P = 0.03) but not with the changes in CRP and IL-6 levels. Our findings provide suggestive evidence that omega-3 fatty acids have beneficial effects on cognitive function in patients with MetS, which is paralleled by enhanced BDNF levels.",2020,"Along with cognitive improvement, omega-3 fatty acids enhanced BDNF (F group×time =4.93;","['schizophrenia patients with metabolic syndrome', 'patients with MetS', 'patients with schizophrenia', '80 patients with both schizophrenia and MetS who received long-term', 'patients with schizophrenia with metabolic syndrome (MetS', '80 patients who consented to the study, 72 completed this 12-week RCT']","['OMG-3', 'omega-3 fatty acids enhanced BDNF', 'omega-3 fatty acids', 'placebo', 'olanzapine monotherapy', 'Omega-3 fatty acids']","['BDNF levels', 'CRP and IL-6 levels', 'TNF-α levels', 'levels of brain-derived neurotrophic factor (BDNF) and deteriorated cognitive performance', 'clinical characteristics and the levels of BDNF, CRP, IL-6 and TNF-α', 'IL-6', 'plasma levels of C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α', 'reduced CRP', 'cognitive function']","[{'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0171023', 'cui_str': 'olanzapine'}]","[{'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",80.0,0.0212196,"Along with cognitive improvement, omega-3 fatty acids enhanced BDNF (F group×time =4.93;","[{'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Tang', 'Affiliation': 'Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Department of Psychiatry, The Affiliated Kangning Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Yewei', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Feikang', 'Initials': 'F', 'LastName': 'Xu', 'Affiliation': 'Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Weixing', 'Initials': 'W', 'LastName': 'Fan', 'Affiliation': 'Department of Psychiatry, Jinhua Second Hospital, Jinhua, Zhejiang, China.'}, {'ForeName': 'Yaoyao', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Psychiatry, The Affiliated Kangning Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Kaili', 'Initials': 'K', 'LastName': 'Fan', 'Affiliation': 'Department of Psychiatry, The Affiliated Kangning Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Weiping', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Psychiatry, Jinhua Second Hospital, Jinhua, Zhejiang, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Zhang', 'Affiliation': 'Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: zhangchen645@gmail.com.'}]","Brain, behavior, and immunity",['10.1016/j.bbi.2020.04.034'] 185,31395900,Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.,"Polymorphisms contribute to inter-individual differences and show a promising predictive role for chemotherapy-related toxicity in colon cancer (CC). TOSCA is a multicentre, randomized, non-inferiority, phase III study conducted in high-risk stage II/stage III CC patients treated with 6 vs 3 months of FOLFOX-4 or XELOX adjuvant chemotherapy. During this post-hoc analysis, 218 women and 294 men were genotyped for 17 polymorphisms: TYMS (rs34743033, rs2853542, rs11280056), MTHFR (rs1801133, rs1801131), ERCC1 (rs11615), XRCC1 (rs25487), XRCC3 (rs861539), XPD (rs1799793, rs13181), GSTP1 (rs1695), GSTT1/GSTM1 (deletion +/-), ABCC1 (rs2074087), and ABCC2 (rs3740066, rs1885301, rs4148386). The aim was to assess the interaction between these polymorphisms and sex, on safety in terms of time to grade ≥3 haematological (TTH), grade ≥3 gastrointestinal (TTG) and grade ≥2 neurological (TTN) toxicity. Interactions were detected on TTH for rs1801133 and rs1799793, on TTG for rs13181 and on TTN for rs11615. Rs1799793 GA genotype (p = 0.006) and A allele (p = 0.009) shortened TTH in men. In women, the rs11615 CC genotype worsened TTN (co-dominant model p = 0.008, recessive model p = 0.003) and rs13181 G allele improved the TTG (p = 0.039). Differences between the two sexes in genotype distribution of rs1885301 (p = 0.020) and rs4148386 (p = 0.005) were found. We highlight that polymorphisms could be sex-specific biomarkers. These results, however, need to be confirmed in additional series.",2019,"In women, the rs11615 CC genotype worsened TTN (co-dominant model p = 0.008, recessive model p = 0.003) and rs13181 G allele improved the TTG (p = 0.039).","['218 women and 294 men', 'Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy']","['FOLFOX-4 or XELOX adjuvant chemotherapy', 'TOSCA']","['XRCC1 (rs25487), XRCC3 (rs861539), XPD (rs1799793, rs13181), GSTP1 (rs1695), GSTT1/GSTM1 (deletion\u2009', 'time to grade ≥3 haematological (TTH), grade ≥3 gastrointestinal (TTG) and grade ≥2 neurological (TTN) toxicity', ' ABCC1 (rs2074087), and ABCC2 (rs3740066, rs1885301, rs4148386']","[{'cui': 'C4517647', 'cui_str': 'Two hundred and eighteen'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0007102', 'cui_str': 'Cancer of Colon'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C1956962', 'cui_str': 'XELOX'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}]","[{'cui': 'C1956962', 'cui_str': 'XELOX'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}]","[{'cui': 'C1442161', 'cui_str': 'Deletion (morphologic abnormality)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}]",218.0,0.0590836,"In women, the rs11615 CC genotype worsened TTN (co-dominant model p = 0.008, recessive model p = 0.003) and rs13181 G allele improved the TTG (p = 0.039).","[{'ForeName': 'Annamaria', 'Initials': 'A', 'LastName': 'Ruzzo', 'Affiliation': 'Department of Biomolecular Sciences, Università degli Studi di Urbino ""Carlo Bo"", Urbino, Italy. annamaria.ruzzo@uniurb.it.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Graziano', 'Affiliation': 'Azienda Ospedaliera ""Ospedali Riuniti Marche Nord"", Pesaro, Italy. graziano.fda@yahoo.com.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Galli', 'Affiliation': 'Laboratory of Methodology for Clinical research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Galli', 'Affiliation': 'Laboratory of Methodology for Clinical research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.'}, {'ForeName': 'Eliana', 'Initials': 'E', 'LastName': 'Rulli', 'Affiliation': 'Laboratory of Methodology for Clinical research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Lonardi', 'Affiliation': 'Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Ronzoni', 'Affiliation': 'Ospedale San Raffaele, Milano, Italy.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Massidda', 'Affiliation': 'Azienda Ospedaliera Universitaria di Cagliari, P.O. Monserrato, Monserrato, Italy.'}, {'ForeName': 'Vittorina', 'Initials': 'V', 'LastName': 'Zagonel', 'Affiliation': 'Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.'}, {'ForeName': 'Nicoletta', 'Initials': 'N', 'LastName': 'Pella', 'Affiliation': 'Azienda Ospedaliera S. Maria della Misericordia, Udine, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Mucciarini', 'Affiliation': 'Ospedale ""B. Ramazzini"", Carpi, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Labianca', 'Affiliation': 'Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Maria Teresa', 'Initials': 'MT', 'LastName': 'Ionta', 'Affiliation': 'Azienda Ospedaliera Universitaria di Cagliari, P.O. Monserrato, Monserrato, Italy.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Bagaloni', 'Affiliation': 'Department of Biomolecular Sciences, Università degli Studi di Urbino ""Carlo Bo"", Urbino, Italy.'}, {'ForeName': 'Enzo', 'Initials': 'E', 'LastName': 'Veltri', 'Affiliation': 'Ospedale di Gaeta ASL Latina, Gaeta, Italy.'}, {'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Sozzi', 'Affiliation': 'Ospedale degli Infermi di Biella, Biella, Italy.'}, {'ForeName': 'Sandro', 'Initials': 'S', 'LastName': 'Barni', 'Affiliation': 'Ospedale ""Treviglio-Caravaggio"", Treviglio, Italy.'}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Ricci', 'Affiliation': 'Ospedale San Raffaele, Milano, Italy.'}, {'ForeName': 'Luisa', 'Initials': 'L', 'LastName': 'Foltran', 'Affiliation': 'Azienda Ospedaliera Santa Maria degli Angeli, Pordenone, Italy.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Nicolini', 'Affiliation': 'Azienda Ospedaliera Ospedale ""Cervesi"", Cattolica, Italy.'}, {'ForeName': 'Edoardo', 'Initials': 'E', 'LastName': 'Biondi', 'Affiliation': 'Ospedale ""F. Renzetti"", Lanciano, Italy.'}, {'ForeName': 'Annalisa', 'Initials': 'A', 'LastName': 'Bramati', 'Affiliation': 'Azienda Ospedaliera Fatebenefratelli, Milano, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Turci', 'Affiliation': 'AUSL Ospedale di Ravenna, Ravenna, Italy.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Lazzarelli', 'Affiliation': 'Azienda Ospedaliera di Cremona, Cremona, Italy.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Verusio', 'Affiliation': 'Ospedale di Saronno, Saronno, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Bergamo', 'Affiliation': 'Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Sobrero', 'Affiliation': 'Azienda Ospedaliera ""Ospedale San Martino"", Genova, Italy.'}, {'ForeName': 'Luciano', 'Initials': 'L', 'LastName': 'Frontini', 'Affiliation': 'Fondazione GISCAD, Vanzago, Italy.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Magnani', 'Affiliation': 'Department of Biomolecular Sciences, Università degli Studi di Urbino ""Carlo Bo"", Urbino, Italy.'}]",Scientific reports,['10.1038/s41598-019-47627-1'] 186,32315289,Neuroimaging of hypothalamic mechanisms related to glucose metabolism in anorexia nervosa and obesity.,"BACKGROUNDGiven the heightened tolerance to self-starvation in anorexia nervosa (AN), a hypothalamic dysregulation of energy and glucose homeostasis has been hypothesized. Therefore, we investigated whether hypothalamic reactivity to glucose metabolism is impaired in AN.METHODSTwenty-four participants with AN, 28 normal-weight participants, and 24 healthy participants with obesity underwent 2 MRI sessions in a single-blind, randomized, case-controlled crossover study. We used an intragastric infusion of glucose and water to bypass the cephalic phase of food intake. The responsivity of the hypothalamus and the crosstalk of the hypothalamus with reward-related brain regions were investigated using high-resolution MRI.RESULTSNormal-weight control participants displayed the expected glucose-induced deactivation of hypothalamic activation, whereas patients with AN and participants with obesity showed blunted hypothalamic reactivity. Furthermore, patients with AN displayed blunted reactivity in the nucleus accumbens and amygdala. Compared with the normal-weight participants and control participants with obesity, the patients with AN failed to show functional connectivity between the hypothalamus and the reward-related brain regions during water infusion relative to glucose infusion. Finally, the patients with AN displayed typical baseline levels of peripheral appetite hormones during a negative energy balance.CONCLUSIONThese results indicate that blunted hypothalamic glucose reactivity might be related to the pathophysiology of AN. This study provides insights for future research, as it is an extended perspective of the traditional primary nonhomeostatic understanding of the disease.FUNDINGThis study was supported by a grant from the DFG (SI 2087/2-1).",2020,"Compared to normal-weight and obese controls, patients with AN failed to show functional connectivity between the hypothalamus and reward-related brain regions during water relative to glucose.","['Twenty-four participants with AN, 28 normal-weight and 24 healthy participants with obesity underwent 2', 'anorexia nervosa', 'anorexia nervosa and obesity']","['intragastric infusion of glucose and water to bypass the cephalic phase of food intake', 'magnetic resonance imaging (MRI) sessions']","['peripheral appetite hormones', 'glucose-induced deactivation of hypothalamic activation', 'blunted hypothalamic reactivity']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0003125', 'cui_str': 'Anorexia nervosa'}]","[{'cui': 'C0442113', 'cui_str': 'Intragastric'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0741847', 'cui_str': 'Bypass'}, {'cui': 'C0205096', 'cui_str': 'Cephalic'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0013470', 'cui_str': 'Eating'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0020663', 'cui_str': 'Hypothalamic structure'}, {'cui': 'C1997138', 'cui_str': 'Blunted'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}]",24.0,0.0193325,"Compared to normal-weight and obese controls, patients with AN failed to show functional connectivity between the hypothalamus and reward-related brain regions during water relative to glucose.","[{'ForeName': 'Joe J', 'Initials': 'JJ', 'LastName': 'Simon', 'Affiliation': 'Centre for Psychosocial Medicine, Department of General Internal Medicine and Psychosomatics, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Marion A', 'Initials': 'MA', 'LastName': 'Stopyra', 'Affiliation': 'Centre for Psychosocial Medicine, Department of General Internal Medicine and Psychosomatics, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Mönning', 'Affiliation': 'Centre for Psychosocial Medicine, Department of General Internal Medicine and Psychosomatics, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Sailer', 'Affiliation': 'Centre for Psychosocial Medicine, Department of General Internal Medicine and Psychosomatics, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Lavandier', 'Affiliation': 'Centre for Psychosocial Medicine, Department of General Internal Medicine and Psychosomatics, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Lars P', 'Initials': 'LP', 'LastName': 'Kihm', 'Affiliation': 'Endocrinology and Nephrology, Department of Internal Medicine I, and.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Bendszus', 'Affiliation': 'Department of Neuroradiology, University Hospital of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Hubert', 'Initials': 'H', 'LastName': 'Preissl', 'Affiliation': 'fMEG Center, Helmholtz Center Munich, University of Tübingen, Tübingen, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Herzog', 'Affiliation': 'Centre for Psychosocial Medicine, Department of General Internal Medicine and Psychosomatics, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Hans-Christoph', 'Initials': 'HC', 'LastName': 'Friederich', 'Affiliation': 'Centre for Psychosocial Medicine, Department of General Internal Medicine and Psychosomatics, University Hospital Heidelberg, Heidelberg, Germany.'}]",The Journal of clinical investigation,['10.1172/JCI136782'] 187,32311162,Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction models.,"Venous thromboembolic events (VTE) are a frequent complication of lymphoma. We conducted a retrospective analysis to compare VTE risk in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Subjects were randomly assigned to training and validation sets to identify risk factors of VTE and evaluate risk model performance, including the Khorana score. A group of 790 patients were diagnosed from 2002 to 2014 (DLBCL = 542, FL = 248). Median follow- up was 49 months. We observed 106 VTE, with higher incidence in DLBCL (5-year cumulative incidence = 16.3% vs 3.8% in FL patients). Five-year OS for patients with VTE was 51.4% vs 73.1% in patients without VTE (P < .001). Baseline VTE risk factors identified in the training cohort included lymphoma subtype, previous VTE, ECOG performance status ≥2, decreased albumin, increased calcium, elevated WBC, absolute lymphocyte count or monocyte count, and presence of bulky disease. Addition of new variables to the Khorana score improved its performance measured by Akaike information criterion and Concordance index. A new risk model including lymphoma subtype, albumin, WBC count, and bulky disease was validated in time-based ROC analyses. These findings were confirmed in the validation cohort. Lymphoma subtypes have different VTE risk. The effect of lymphoma subtype was independent from disease burden and the use of systemic therapy. The Khorana risk-score was validated in time to event analyses, and a more robust lymphoma-specific VTE risk score is proposed. These findings suggest lymphoma patients with highest VTE risk can be identified with baseline parameters.",2020,Addition of new variables to the Khorana score improved its performance measured by Akaike information criterion and Concordance index.,['diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL'],[],"['Khorana risk-score', 'calcium, elevated WBC, absolute lymphocyte count or monocyte count, and presence of bulky disease', 'lymphoma subtype, albumin, WBC count, and bulky disease', 'Venous thromboembolic events (VTE']","[{'cui': 'C0079744', 'cui_str': 'Malignant lymphoma, large B-cell, diffuse'}, {'cui': 'C0024301', 'cui_str': 'Follicular lymphoma'}]",[],"[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C3544087', 'cui_str': 'Absolute lymphocyte count'}, {'cui': 'C0200637', 'cui_str': 'Monocyte count'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0024299', 'cui_str': 'Malignant lymphoma'}, {'cui': 'C0449560', 'cui_str': 'Subtype'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}]",,0.0310593,Addition of new variables to the Khorana score improved its performance measured by Akaike information criterion and Concordance index.,"[{'ForeName': 'Gouri', 'Initials': 'G', 'LastName': 'Dharmavaram', 'Affiliation': 'School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.'}, {'ForeName': 'Shufen', 'Initials': 'S', 'LastName': 'Cao', 'Affiliation': 'Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, USA.'}, {'ForeName': 'Suchitra', 'Initials': 'S', 'LastName': 'Sundaram', 'Affiliation': 'Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.'}, {'ForeName': 'Sabarish', 'Initials': 'S', 'LastName': 'Ayyappan', 'Affiliation': 'Division of Hematology, Oncology and Bone & Marrow Transplantation, University of Iowa, Iowa City, Iowa, USA.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Boughan', 'Affiliation': 'Hematologic Malignancies and Stem Cell Transplant Program, Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio and Case Comprehensive Cancer Center, Cleveland, Ohio, USA.'}, {'ForeName': 'Molly', 'Initials': 'M', 'LastName': 'Gallogly', 'Affiliation': 'Hematologic Malignancies and Stem Cell Transplant Program, Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio and Case Comprehensive Cancer Center, Cleveland, Ohio, USA.'}, {'ForeName': 'Ehsan', 'Initials': 'E', 'LastName': 'Malek', 'Affiliation': 'Hematologic Malignancies and Stem Cell Transplant Program, Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio and Case Comprehensive Cancer Center, Cleveland, Ohio, USA.'}, {'ForeName': 'Leland', 'Initials': 'L', 'LastName': 'Metheny', 'Affiliation': 'Hematologic Malignancies and Stem Cell Transplant Program, Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio and Case Comprehensive Cancer Center, Cleveland, Ohio, USA.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Tomlinson', 'Affiliation': 'Hematologic Malignancies and Stem Cell Transplant Program, Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio and Case Comprehensive Cancer Center, Cleveland, Ohio, USA.'}, {'ForeName': 'Folashade', 'Initials': 'F', 'LastName': 'Otegbeye', 'Affiliation': 'Hematologic Malignancies and Stem Cell Transplant Program, Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio and Case Comprehensive Cancer Center, Cleveland, Ohio, USA.'}, {'ForeName': 'Hillard M', 'Initials': 'HM', 'LastName': 'Lazarus', 'Affiliation': 'Hematologic Malignancies and Stem Cell Transplant Program, Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio and Case Comprehensive Cancer Center, Cleveland, Ohio, USA.'}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Cooper', 'Affiliation': 'Hematologic Malignancies and Stem Cell Transplant Program, Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio and Case Comprehensive Cancer Center, Cleveland, Ohio, USA.'}, {'ForeName': 'Pingfu', 'Initials': 'P', 'LastName': 'Fu', 'Affiliation': 'Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, USA.'}, {'ForeName': 'Marcos', 'Initials': 'M', 'LastName': 'de Lima', 'Affiliation': 'Hematologic Malignancies and Stem Cell Transplant Program, Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio and Case Comprehensive Cancer Center, Cleveland, Ohio, USA.'}, {'ForeName': 'Paolo F', 'Initials': 'PF', 'LastName': 'Caimi', 'Affiliation': 'Hematologic Malignancies and Stem Cell Transplant Program, Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio and Case Comprehensive Cancer Center, Cleveland, Ohio, USA.'}]",American journal of hematology,['10.1002/ajh.25837'] 188,32081767,"Calories, Caffeine and the Onset of Obesity in Young Children.","OBJECTIVE High calorie foods and beverages, which often contain caffeine, contribute to child overweight/obesity. We evaluated the results of an educational intervention to promote healthy growth in very young children. Secondarily, we used detailed diet data to explore the association of nutrient intake with the early development of overweight and obesity. METHODS Mothers were obese Latina women, enrolled prenatally, and their infants. Specially trained community health workers provided breastfeeding support and nutrition education during 10 home visits, birth to 24 months. At follow-up, age 18 to 36 months, we measured growth and completed detailed diet recalls (1-7 recall days/child). RESULTS Of 174 infants randomized, 106 children were followed for 24 to 36 months. The educational intervention did not prevent overweight/obesity. Forty-two percent of children became overweight or obese. Fifty-eight percent of children consumed caffeine on at least 1 recall day. Mean intake was 0.48 mg/kg/day. Caffeine correlated with higher consumption of calories, and added sugar and decreased intake of protein, fiber and dairy. Compared with days without caffeine, on days when caffeine was consumed, children ingested 121 more calories and 3.8 gm less protein. Children frequently consumed less than the recommended daily intake of key nutrients such as fiber, vegetables, whole fruit, and vitamins. CONCLUSIONS Caffeine was a marker for increased intake of calories and decreased intake of key nutrients. When discussing dietary intake in early childhood, practitioners should screen for nutrient deficiency in young children and recommend limiting the intake of caffeinated foods and beverages.",2020,"Children frequently consumed less than the recommended daily intake of key nutrients such as fiber, vegetables, whole fruit, and vitamins. ","['106 children were followed for 24-36 months', 'Mothers were obese Latina women, enrolled prenatally, and their infants', 'Young Children', '174 infants randomized', 'Forty-two percent of children became overweight or obese', 'very young children']","['Caffeine', 'Calories, Caffeine', 'educational intervention', 'caffeine']","['higher consumption of calories, and added sugar and decreased intake of protein, fiber and dairy', 'Mean intake', 'overweight/obesity']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0949335', 'cui_str': 'Latinas'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C4517604', 'cui_str': 'One hundred and seventy-four'}, {'cui': 'C4319566', 'cui_str': 'Forty-two'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}]","[{'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C1879985', 'cui_str': 'calorie'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0242209', 'cui_str': 'Sugars'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0225326', 'cui_str': 'Fiber'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]",174.0,0.0211932,"Children frequently consumed less than the recommended daily intake of key nutrients such as fiber, vegetables, whole fruit, and vitamins. ","[{'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'McCormick', 'Affiliation': 'University of Texas Medical Branch (DP McCormick), Galveston, Tex. Electronic address: david.mccormick@utmb.edu.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Reyna', 'Affiliation': 'College of Nursing and Health Innovation (L Reyna and E Reifsnider), Arizona State University, Phoenix, Ariz.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Reifsnider', 'Affiliation': 'College of Nursing and Health Innovation (L Reyna and E Reifsnider), Arizona State University, Phoenix, Ariz.'}]",Academic pediatrics,['10.1016/j.acap.2020.02.014'] 189,31352424,"Primary Palliative Care for Emergency Medicine (PRIM-ER): Protocol for a Pragmatic, Cluster-Randomised, Stepped Wedge Design to Test the Effectiveness of Primary Palliative Care Education, Training and Technical Support for Emergency Medicine.","INTRODUCTION Emergency departments (ED) care for society's most vulnerable older adults who present with exacerbations of chronic disease at the end of life, yet the clinical paradigm focuses on treatment of acute pathologies. Palliative care interventions in the ED capture high-risk patients at a time of crisis and can dramatically improve patient-centred outcomes. This study aims to implement and evaluate Primary Palliative Care for Emergency Medicine (PRIM-ER) on ED disposition, healthcare utilisation and survival in older adults with serious illness. METHODS AND ANALYSIS This is the protocol for a pragmatic, cluster-randomised stepped wedge trial to test the effectiveness of PRIM-ER in 35 EDs across the USA. The intervention includes four core components: (1) evidence-based, multidisciplinary primary palliative care education; (2) simulation-based workshops; (3) clinical decision support; and (4) audit and feedback. The study is divided into two phases: a pilot phase, to ensure feasibility in two sites, and an implementation and evaluation phase, where we implement the intervention and test the effectiveness in 33 EDs over 2 years. Using Centers for Medicare and Medicaid Services (CMS) data, we will assess the primary outcomes in approximately 300 000 patients: ED disposition to an acute care setting, healthcare utilisation in the 6 months following the ED visit and survival following the index ED visit. Analysis will also determine the site, provider and patient-level characteristics that are associated with variation in impact of PRIM-ER. ETHICS AND DISSEMINATION Institutional Review Board approval was obtained at New York University School of Medicine to evaluate the CMS data. Oversight will also be provided by the National Institutes of Health, an Independent Monitoring Committee and a Clinical Informatics Advisory Board. Trial results will be submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER NCT03424109; Pre-results.",2019,Palliative care interventions in the ED capture high-risk patients at a time of crisis and can dramatically improve patient-centred outcomes.,"['older adults with serious illness', 'approximately 300\u2009000 patients: ED disposition to an acute care setting, healthcare utilisation in the 6 months following the ED visit and survival following the index ED visit']","['PRIM-ER', 'Palliative care interventions', 'evidence-based, multidisciplinary primary palliative care education; (2) simulation-based workshops; (3) clinical decision support; and (4) audit and feedback', 'Emergency Medicine (PRIM-ER']",[],"[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0332232', 'cui_str': 'Approximate (qualifier value)'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0743223', 'cui_str': 'Disposition (disposition)'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]","[{'cui': 'C0700049', 'cui_str': 'Palliative care'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C3266593', 'cui_str': 'Palliative care education'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C4042765', 'cui_str': 'Clinical Decision Support'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0013964', 'cui_str': 'Emergency Medicine'}]",[],,0.159725,Palliative care interventions in the ED capture high-risk patients at a time of crisis and can dramatically improve patient-centred outcomes.,"[{'ForeName': 'Corita R', 'Initials': 'CR', 'LastName': 'Grudzen', 'Affiliation': 'Ronald O. Perelman Department of Emergency Medicine, New York University School of Medicine, New York City, New York, USA.'}, {'ForeName': 'Abraham A', 'Initials': 'AA', 'LastName': 'Brody', 'Affiliation': 'Hartford Institute for Geriatric Nursing, New York University Rory Meyers College of Nursing, New York City, New York, USA.'}, {'ForeName': 'Frank R', 'Initials': 'FR', 'LastName': 'Chung', 'Affiliation': 'Ronald O. Perelman Department of Emergency Medicine, New York University School of Medicine, New York City, New York, USA.'}, {'ForeName': 'Allison M', 'Initials': 'AM', 'LastName': 'Cuthel', 'Affiliation': 'Ronald O. Perelman Department of Emergency Medicine, New York University School of Medicine, New York City, New York, USA.'}, {'ForeName': 'Devin', 'Initials': 'D', 'LastName': 'Mann', 'Affiliation': 'Department of Population Health, New York University School of Medicine, New York City, New York, USA.'}, {'ForeName': 'Jordan A', 'Initials': 'JA', 'LastName': 'McQuilkin', 'Affiliation': 'Ronald O. Perelman Department of Emergency Medicine, New York University School of Medicine, New York City, New York, USA.'}, {'ForeName': 'Ada L', 'Initials': 'AL', 'LastName': 'Rubin', 'Affiliation': 'Ronald O. Perelman Department of Emergency Medicine, New York University School of Medicine, New York City, New York, USA.'}, {'ForeName': 'Jordan', 'Initials': 'J', 'LastName': 'Swartz', 'Affiliation': 'Ronald O. Perelman Department of Emergency Medicine, New York University School of Medicine, New York City, New York, USA.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Tan', 'Affiliation': 'Ronald O. Perelman Department of Emergency Medicine, New York University School of Medicine, New York City, New York, USA.'}, {'ForeName': 'Keith S', 'Initials': 'KS', 'LastName': 'Goldfeld', 'Affiliation': 'Department of Population Health, New York University School of Medicine, New York City, New York, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2019-030099'] 190,32156842,"The Effects of Nano-curcumin Supplementation on Serum Level of hs-CRP, Adhesion Molecules, and Lipid Profiles in Hemodialysis Patients, A Randomized Controlled Clinical Trial.","INTRODUCTION Hemodialysis (HD) patients are considered as a high-risk population for cardiovascular disease, within which morbidity and mortality have been determined to be associated with dyslipidemia, pro-inflammatory cytokines, increased levels of C-reactive protein (CRP), and adhesion molecules (ICAM-1, VCAM-1). Different markers have been investigated to detect inflammation in hemodialysis patients, as well as the prognostic values of these markers. METHODS The present study aimed to investigate the effect of nano-curcumin (120 mg) over 12 weeks on hs-CRP levels, adhesion molecules (ICAM-1, VCAM-1), and serum lipid profiles on hemodialysis patients in a randomized controlled clinical trial. RESULTS The results revealed that the mean serum hs-CRP level in the nano-curcumin group exhibited a decrease by the end of the study, when compared to mean serum hs-CRP level in the placebo group. However, this between-group trend was not found to be statistically significant (P > .05). Nevertheless, a significant difference was determined between the values in the group receiving nano-curcumin, in comparison with the placebo group, at the end of the study (P < .001). Based on the attained results, mean serum levels of VCAM-1 in the nano-curcumin group were significantly reduced at the end of the study, compared with the placebo group (P < .001). Furthermore, the between-group changes comparison showed significant reductions in serum levels of ICAM- 1 in patients treated with nano-curcumin at the end of the study (P < .05). Additionally, though decreases in mean triglycerides, total cholesterol, LDL-C were noted, there were no statistically significant between-group differences (P > .05). Moreover, between-group changes comparison of HDL-C levels and fasting blood sugar did not show any significant changes. CONCLUSION The current study indicates that nano-curcumin may show beneficial effects in lowering inflammation and hs-CRP levels, as well as adhesion molecules (ICAM-1, VCAM-1), in hemodialysis patients. However, the evidence is still insufficient.",2020,"Based on the attained results, mean serum levels of VCAM-1 in the nano-curcumin group were significantly reduced at the end of the study, compared with the placebo group (P < .001).","['Hemodialysis Patients', 'hemodialysis patients']","['placebo', 'nano-curcumin', 'Nano-curcumin Supplementation']","['mean serum hs-CRP level', 'CRP levels, adhesion molecules (ICAM-1, VCAM-1), and serum lipid profiles', 'serum levels of ICAM', 'HDL-C levels and fasting blood sugar', 'mean serum levels of VCAM-1', 'mean triglycerides, total cholesterol, LDL-C', 'Serum Level of hs-CRP, Adhesion Molecules, and Lipid Profiles']","[{'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0010467', 'cui_str': 'Curcumin'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0001511', 'cui_str': 'Tissue Adhesions'}, {'cui': 'C0567416', 'cui_str': 'Molecule (substance)'}, {'cui': 'C0063695', 'cui_str': 'CD54 Antigens'}, {'cui': 'C0078056', 'cui_str': 'CD106 Antigens'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}]",,0.0543771,"Based on the attained results, mean serum levels of VCAM-1 in the nano-curcumin group were significantly reduced at the end of the study, compared with the placebo group (P < .001).","[{'ForeName': 'Golchin', 'Initials': 'G', 'LastName': 'Vafadar Afshar', 'Affiliation': ''}, {'ForeName': 'Yousef', 'Initials': 'Y', 'LastName': 'Rasmi', 'Affiliation': '. yr1350@yahoo.com.'}, {'ForeName': 'Parichehreh', 'Initials': 'P', 'LastName': 'Yaghmaei', 'Affiliation': ''}, {'ForeName': 'Mohammad-Hasan', 'Initials': 'MH', 'LastName': 'Khadem-Ansari', 'Affiliation': ''}, {'ForeName': 'Khadijeh', 'Initials': 'K', 'LastName': 'Makhdomii', 'Affiliation': ''}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Rasooli', 'Affiliation': ''}]",Iranian journal of kidney diseases,[] 191,26333879,Development and Validation of a Portable Hearing Self-Testing System Based on a Notebook Personal Computer.,"BACKGROUND Hearing loss affects more than 27 million people in mainland China. It would be helpful to develop a portable and self-testing audiometer for the timely detection of hearing loss so that the optimal clinical therapeutic schedule can be determined. PURPOSE The objective of this study was to develop a software-based hearing self-testing system. RESEARCH DESIGN The software-based self-testing system consisted of a notebook computer, an external sound card, and a pair of 10-Ω insert earphones. The system could be used to test the hearing thresholds by individuals themselves in an interactive manner using software. The reliability and validity of the system at octave frequencies of 0.25 Hz to 8.0 kHz were analyzed in three series of experiments. STUDY SAMPLE Thirty-seven normal-hearing particpants (74 ears) were enrolled in experiment 1. Forty individuals (80 ears) with sensorineural hearing loss (SNHL) participated in experiment 2. Thirteen normal-hearing participants (26 ears) and 37 participants (74 ears) with SNHL were enrolled in experiment 3. Each participant was enrolled in only one of the three experiments. DATA COLLECTION AND ANALYSIS In all experiments, pure-tone audiometry in a sound insulation room (standard test) was regarded as the gold standard. SPSS for Windows, version 17.0, was used for statistical analysis. The paired t-test was used to compare the hearing thresholds between the standard test and software-based self-testing (self-test) in experiments 1 and 2. In experiment 3 (main study), one-way analysis of variance and post hoc comparisons were used to compare the hearing thresholds among the standard test and two rounds of the self-test. Linear correlation analysis was carried out for the self-tests performed twice. The concordance was analyzed between the standard test and the self-test using the kappa method. p < 0.05 was considered statistically significant. RESULTS Experiments 1 and 2: The hearing thresholds determined by the two methods were not significantly different at frequencies of 250, 500, or 8000 Hz (p > 0.05) but were significantly different at frequencies of 1000, 2000, and 4000 Hz (p < 0.05), except for 1000 Hz in the right ear in experiment 2. Experiment 3: The hearing thresholds determined by the standard test and self-tests repeated twice were not significantly different at any frequency (p > 0.05). The overall sensitivity of the self-test method was 97.6%, and the specificity was 98.3%. The sensitivity was 97.6% and the specificity was 97% for the patients with SNHL. The self-test had significant concordance with the standard test (kappa value = 0.848, p < 0.001). CONCLUSIONS This portable hearing self-testing system based on a notebook personal computer is a reliable and sensitive method for hearing threshold assessment and monitoring.",2015,"The hearing thresholds determined by the two methods were not significantly different at frequencies of 250, 500, or 8000 Hz (p > 0.05) but were significantly different at frequencies of 1000, 2000, and 4000 Hz (p < 0.05), except for 1000 Hz in the right ear in experiment 2.","['Experiments 1 and 2', 'SAMPLE\n\n\nThirty-seven normal-hearing particpants (74 ears', '27 million people in mainland China', 'Thirteen normal-hearing participants (26 ears) and 37 participants (74 ears) with SNHL were enrolled in experiment 3', 'Forty individuals (80 ears) with sensorineural hearing loss']",['Portable Hearing Self-Testing System'],"['overall sensitivity', 'sensitivity', 'hearing thresholds']","[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C4319569', 'cui_str': '37 (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0013443', 'cui_str': 'Vestibulocochlear Apparatus'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0018784', 'cui_str': 'Hearing Loss, Sensorineural'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}]",,0.0196753,"The hearing thresholds determined by the two methods were not significantly different at frequencies of 250, 500, or 8000 Hz (p > 0.05) but were significantly different at frequencies of 1000, 2000, and 4000 Hz (p < 0.05), except for 1000 Hz in the right ear in experiment 2.","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Fen', 'Initials': 'F', 'LastName': 'Xiong', 'Affiliation': ''}, {'ForeName': 'Lan', 'Initials': 'L', 'LastName': 'Yu', 'Affiliation': ''}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Ji', 'Affiliation': ''}, {'ForeName': 'Qiu-Ju', 'Initials': 'QJ', 'LastName': 'Wang', 'Affiliation': ''}]",Journal of the American Academy of Audiology,['10.3766/jaaa.14092'] 192,26333880,The Benefit of Remote Microphones Using Four Wireless Protocols.,"BACKGROUND Many studies have reported the speech recognition benefits of a personal remote microphone system when used by adult listeners with hearing loss. The advance of wireless technology has allowed for many wireless audio transmission protocols. Some of these protocols interface with commercially available hearing aids. As a result, commercial remote microphone systems use a variety of different protocols for wireless audio transmission. It is not known how these systems compare, with regard to adult speech recognition in noise. PURPOSE The primary goal of this investigation was to determine the speech recognition benefits of four different commercially available remote microphone systems, each with a different wireless audio transmission protocol. RESEARCH DESIGN A repeated-measures design was used in this study. STUDY SAMPLE Sixteen adults, ages 52 to 81 yr, with mild to severe sensorineural hearing loss participated in this study. INTERVENTION Participants were fit with three different sets of bilateral hearing aids and four commercially available remote microphone systems (FM, 900 MHz, 2.4 GHz, and Bluetooth(®) paired with near-field magnetic induction). DATA COLLECTION AND ANALYSIS Speech recognition scores were measured by an adaptive version of the Hearing in Noise Test (HINT). The participants were seated both 6 and 12' away from the talker loudspeaker. Participants repeated HINT sentences with and without hearing aids and with four commercially available remote microphone systems in both seated positions with and without contributions from the hearing aid or environmental microphone (24 total conditions). The HINT SNR-50, or the signal-to-noise ratio required for correct repetition of 50% of the sentences, was recorded for all conditions. A one-way repeated measures analysis of variance was used to determine statistical significance of microphone condition. RESULTS The results of this study revealed that use of the remote microphone systems statistically improved speech recognition in noise relative to unaided and hearing aid-only conditions across all four wireless transmission protocols at 6 and 12' away from the talker. CONCLUSIONS Participants showed a significant improvement in speech recognition in noise when comparing four remote microphone systems with different wireless transmission methods to hearing aids alone.",2015,"The results of this study revealed that use of the remote microphone systems statistically improved speech recognition in noise relative to unaided and hearing aid-only conditions across all four wireless transmission protocols at 6 and 12' away from the talker. ","['adult listeners with hearing loss', 'Sixteen adults, ages 52 to 81 yr, with mild to severe sensorineural hearing loss participated in this study']","['HINT sentences with and without hearing aids and with four commercially available remote microphone systems', 'hearing aid or environmental microphone', 'bilateral hearing aids and four commercially available remote microphone systems (FM, 900 MHz, 2.4 GHz, and Bluetooth(®) paired with near-field magnetic induction']","['speech recognition', 'speech recognition benefits']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0018784', 'cui_str': 'Hearing Loss, Sensorineural'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0018767', 'cui_str': 'Audition'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0205157', 'cui_str': 'Remote (qualifier value)'}, {'cui': 'C1709026', 'cui_str': 'Microphone'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0018768', 'cui_str': 'Hearing Aids'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C4517900', 'cui_str': '900 (qualifier value)'}, {'cui': 'C0556962', 'cui_str': 'MHz'}, {'cui': 'C4517631', 'cui_str': '2.4 (qualifier value)'}, {'cui': 'C0556961', 'cui_str': 'gigahertz'}, {'cui': 'C0475806', 'cui_str': 'Nr - Near'}, {'cui': 'C0440042', 'cui_str': ""Field's""}, {'cui': 'C0024488', 'cui_str': 'Magnetics'}]","[{'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0524637', 'cui_str': 'Recognition (Psychology)'}]",16.0,0.0215508,"The results of this study revealed that use of the remote microphone systems statistically improved speech recognition in noise relative to unaided and hearing aid-only conditions across all four wireless transmission protocols at 6 and 12' away from the talker. ","[{'ForeName': 'Krishna S', 'Initials': 'KS', 'LastName': 'Rodemerk', 'Affiliation': ''}, {'ForeName': 'Jason A', 'Initials': 'JA', 'LastName': 'Galster', 'Affiliation': ''}]",Journal of the American Academy of Audiology,['10.3766/jaaa.15008'] 193,31794974,One-year clinical outcomes following theta burst stimulation for post-traumatic stress disorder.,"Theta burst transcranial magnetic stimulation (TBS) is a potential new treatment for post-traumatic stress disorder (PTSD). We previously reported active intermittent TBS (iTBS) was associated with superior clinical outcomes for up to 1-month, in a sample of fifty veterans with PTSD, using a crossover design. In that study, participants randomized to the active group received a total of 4-weeks of active iTBS, or 2-weeks if randomized to sham. Results were superior with greater exposure to active iTBS, which raised the question of whether observed effects persisted over the longer-term. This study reviewed naturalistic outcomes up to 1-year from study endpoint, to test the hypothesis that greater exposure to active iTBS would be associated with superior outcomes. The primary outcome measure was clinical relapse, defined as any serious adverse event (e.g., suicide, psychiatric hospitalization, etc.,) or need for retreatment with repetitive transcranial magnetic stimulation (rTMS). Forty-six (92%) of the initial study's intent-to-treat participants were included. Mean age was 51.0 ± 12.3 years and seven (15.2%) were female. The group originally randomized to active iTBS (4-weeks active iTBS) demonstrated superior outcomes at one year compared to those originally randomized to sham (2-weeks active iTBS); log-rank ChiSq = 5.871, df = 1, p = 0.015; OR = 3.50, 95% CI = 1.04-11.79. Mean days to relapse were 296.0 ± 22.1 in the 4-week group, and 182.0 ± 31.9 in the 2-week group. When used, rTMS retreatment was generally effective. Exploratory neuroimaging revealed default mode network connectivity was predictive of 1-year outcomes (corrected p < 0.05). In summary, greater accumulated exposure to active iTBS demonstrated clinically meaningful improvements in the year following stimulation, and default mode connectivity could be used to predict longer-term outcomes.",2020,"The group originally randomized to active iTBS (4-weeks active iTBS) demonstrated superior outcomes at one year compared to those originally randomized to sham (2-weeks active iTBS); log-rank ChiSq = 5.871, df = 1, p = 0.015; OR = 3.50, 95% CI = 1.04-11.79.","['post-traumatic stress disorder (PTSD', 'Mean age was 51.0\u2009±\u200912.3 years and seven (15.2%) were female', 'fifty veterans with PTSD', ""Forty-six (92%) of the initial study's intent-to-treat participants were included""]","['total of 4-weeks of active iTBS', 'active iTBS (4-weeks active iTBS', 'theta burst stimulation', 'active intermittent TBS (iTBS', 'Theta burst transcranial magnetic stimulation (TBS', 'TMS']","['clinical relapse, defined as any serious adverse event (e.g., suicide, psychiatric hospitalization, etc.,) or need for retreatment with repetitive transcranial magnetic stimulation (rTMS', 'Mean days to relapse']","[{'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1283828', 'cui_str': 'Intentional'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation (procedure)'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0852733', 'cui_str': 'Suicide (accomplished)'}, {'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C0376495', 'cui_str': 'Retreatments'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]",50.0,0.149203,"The group originally randomized to active iTBS (4-weeks active iTBS) demonstrated superior outcomes at one year compared to those originally randomized to sham (2-weeks active iTBS); log-rank ChiSq = 5.871, df = 1, p = 0.015; OR = 3.50, 95% CI = 1.04-11.79.","[{'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'Petrosino', 'Affiliation': 'From the VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, and The Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, 02903, USA.'}, {'ForeName': ""Mascha van 't"", 'Initials': ""MV'"", 'LastName': 'Wout-Frank', 'Affiliation': 'From the VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, and The Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, 02903, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Aiken', 'Affiliation': 'From the VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, and The Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, 02903, USA.'}, {'ForeName': 'Hannah R', 'Initials': 'HR', 'LastName': 'Swearingen', 'Affiliation': 'From the VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, and The Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, 02903, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Barredo', 'Affiliation': 'From the VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, and The Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, 02903, USA.'}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Zandvakili', 'Affiliation': 'From the VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, and The Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, 02903, USA.'}, {'ForeName': 'Noah S', 'Initials': 'NS', 'LastName': 'Philip', 'Affiliation': 'From the VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, and The Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, 02903, USA. noah_philip@brown.edu.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0584-4'] 194,31995812,Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment.,"Major depressive disorder (MDD) is associated with altered global brain connectivity (GBC), as assessed via resting-state functional magnetic resonance imaging (rsfMRI). Previous studies found that antidepressant treatment with ketamine normalized aberrant GBC changes in the prefrontal and cingulate cortices, warranting further investigations of GBC as a putative imaging marker. These results were obtained via global signal regression (GSR). This study is an independent replication of that analysis using a separate dataset. GBC was analyzed in 28 individuals with MDD and 22 healthy controls (HCs) at baseline, post-placebo, and post-ketamine. To investigate the effects of preprocessing, three distinct pipelines were used: (1) regression of white matter (WM)/cerebrospinal fluid (CSF) signals only (BASE); (2) WM/CSF + GSR (GSR); and (3) WM/CSF + physiological parameter regression (PHYSIO). Reduced GBC was observed in individuals with MDD only at baseline in the anterior and medial cingulate cortices, as well as in the prefrontal cortex only after regressing the global signal. Ketamine had no effect compared to baseline or placebo in either group in any pipeline. PHYSIO did not resemble GBC preprocessed with GSR. These results concur with several studies that used GSR to study GBC. Further investigations are warranted into disease-specific components of global fMRI signals that may drive these results and of GBCr as a potential imaging marker in MDD.",2020,"Reduced GBC was observed in individuals with MDD only at baseline in the anterior and medial cingulate cortices, as well as in the prefrontal cortex only after regressing the global signal.","['Major depressive disorder (MDD', '28 individuals with MDD and 22 healthy controls (HCs) at baseline, post']","['placebo', 'Ketamine', 'placebo-controlled ketamine', 'ketamine', 'white matter (WM)/cerebrospinal fluid (CSF) signals only (BASE); (2) WM/CSF\u2009+\u2009GSR (GSR); and (3) WM/CSF\u2009+\u2009physiological parameter regression (PHYSIO']","['GBC', 'Reduced GBC']","[{'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0682708'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C0205463', 'cui_str': 'Physiologic (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0684321', 'cui_str': 'Regression'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}]",28.0,0.0521611,"Reduced GBC was observed in individuals with MDD only at baseline in the anterior and medial cingulate cortices, as well as in the prefrontal cortex only after regressing the global signal.","[{'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Kraus', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. christoph.kraus@nih.gov.'}, {'ForeName': 'Anahit', 'Initials': 'A', 'LastName': 'Mkrtchian', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Bashkim', 'Initials': 'B', 'LastName': 'Kadriu', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Allison C', 'Initials': 'AC', 'LastName': 'Nugent', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Carlos A', 'Initials': 'CA', 'LastName': 'Zarate', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Jennifer W', 'Initials': 'JW', 'LastName': 'Evans', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-020-0624-0'] 195,31995813,"Modafinil enhances cognitive, but not emotional conflict processing via enhanced inferior frontal gyrus activation and its communication with the dorsomedial prefrontal cortex.","Cognitive control regulates cognitive and emotional systems to facilitate goal-directed behavior in the context of task-irrelevant distractors. Cognitive control deficits contribute to residual functional impairments across psychiatric disorders and represent a promising novel treatment target. Translational evidence suggests that modafinil may enhance performance in executive functions; however, differential effects on regulatory control in cognitive and emotional domains have not been examined. The present pre-registered randomized-controlled pharmacological fMRI trial examined differential effects of modafinil (single-dose, 200 mg) on cognitive and emotional conflict processing. To further separate objective cognitive enhancing effects from subjective performance perception, a metacognitive paradigm was employed. Results indicated that modafinil specifically enhanced cognitive conflict performance and concomitantly increased activation in the inferior frontal gyrus and its functional communication with the dorsomedial prefrontal cortex. Exploratory analysis further revealed modafinil-enhanced basolateral amygdala reactivity to cognitive conflict, with stronger reactivity being associated with higher cognitive conflict performance. Whereas modafinil enhanced cognitive performance in the metacognitive paradigm, confidence indices remained unaffected. Overall, the present results suggest that modafinil has the potential to enhance cognitive conflict processing while leaving emotional conflict processing unaffected. On the neural level modafinil enhanced the recruitment of a network engaged in general conflict and regulatory control processes, whereas effects on the amygdala may reflect improved arousal-mediated attention processes for conflicting information. The pattern of cognitive enhancing effects in the absence of effects on affective processing suggests a promising potential to enhance cognitive control in clinical populations.",2020,"On the neural level modafinil enhanced the recruitment of a network engaged in general conflict and regulatory control processes, whereas effects on the amygdala may reflect improved arousal-mediated attention processes for conflicting information.",[],"['Modafinil', 'modafinil']","['cognitive performance', 'cognitive and emotional conflict processing', 'cognitive conflict performance']",[],"[{'cui': 'C0066677', 'cui_str': 'modafinil'}]","[{'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0009671', 'cui_str': 'Conflict'}]",,0.0288783,"On the neural level modafinil enhanced the recruitment of a network engaged in general conflict and regulatory control processes, whereas effects on the amygdala may reflect improved arousal-mediated attention processes for conflicting information.","[{'ForeName': 'Jialin', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'The Clinical Hospital of the Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'The Clinical Hospital of the Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Zhou', 'Affiliation': 'The Clinical Hospital of the Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Congcong', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'The Clinical Hospital of the Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Zhenyu', 'Initials': 'Z', 'LastName': 'Wei', 'Affiliation': 'The Clinical Hospital of the Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Xin', 'Affiliation': 'The Clinical Hospital of the Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Bianca', 'Initials': 'B', 'LastName': 'Daumann', 'Affiliation': 'LVR Clinics of Cologne, Cologne, Germany.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Daumann', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Keith M', 'Initials': 'KM', 'LastName': 'Kendrick', 'Affiliation': 'The Clinical Hospital of the Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Becker', 'Affiliation': 'The Clinical Hospital of the Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China. ben_becker@gmx.de.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-020-0625-z'] 196,32092760,Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin.,"Twenty-four hours after administration, ketamine exerts rapid and robust antidepressant effects that are thought to be mediated by activation of the mechanistic target of rapamycin complex 1 (mTORC1). To test this hypothesis, depressed patients were pretreated with rapamycin, an mTORC1 inhibitor, prior to receiving ketamine. Twenty patients suffering a major depressive episode were randomized to pretreatment with oral rapamycin (6 mg) or placebo 2 h prior to the intravenous administration of ketamine 0.5 mg/kg in a double-blind cross-over design with treatment days separated by at least 2 weeks. Depression severity was assessed using Montgomery-Åsberg Depression Rating Scale (MADRS). Rapamycin pretreatment did not alter the antidepressant effects of ketamine at the 24-h timepoint. Over the subsequent 2-weeks, we found a significant treatment by time interaction (F (8,245)  = 2.02, p = 0.04), suggesting a prolongation of the antidepressant effects of ketamine by rapamycin. Two weeks following ketamine administration, we found higher response (41%) and remission rates (29%) following rapamycin + ketamine compared to placebo + ketamine (13%, p = 0.04, and 7%, p = 0.003, respectively). In summary, single dose rapamycin pretreatment failed to block the antidepressant effects of ketamine, but it prolonged ketamine's antidepressant effects. This observation raises questions about the role of systemic vs. local blockade of mTORC1 in the antidepressant effects of ketamine, provides preliminary evidence that rapamycin may extend the benefits of ketamine, and thereby potentially sheds light on mechanisms that contribute to depression relapse after ketamine administration.",2020,"Two weeks following ketamine administration, we found higher response (41%) and remission rates (29%) following rapamycin + ketamine compared to placebo + ketamine (13%, p = 0.04, and 7%, p = 0.003, respectively).",['Twenty patients suffering a major depressive episode'],"['rapamycin\u2009+\u2009ketamine', 'placebo', 'ketamine', 'Rapamycin', 'rapamycin', 'placebo\u2009+\u2009ketamine', 'rapamycin, an mTORC1 inhibitor, prior to receiving ketamine', 'oral rapamycin']","['remission rates', 'Montgomery-Åsberg Depression Rating Scale (MADRS', 'Depression severity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0349217', 'cui_str': 'Depressive episode'}]","[{'cui': 'C0072980', 'cui_str': 'Sirolimus'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3888046', 'cui_str': 'mTORC1 Complex'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C2960593', 'cui_str': 'Montgomery-Åsberg depression rating scale'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",,0.0810233,"Two weeks following ketamine administration, we found higher response (41%) and remission rates (29%) following rapamycin + ketamine compared to placebo + ketamine (13%, p = 0.04, and 7%, p = 0.003, respectively).","[{'ForeName': 'Chadi G', 'Initials': 'CG', 'LastName': 'Abdallah', 'Affiliation': 'National Center for PTSD - Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA. chadi.abdallah@yale.edu.'}, {'ForeName': 'Lynnette A', 'Initials': 'LA', 'LastName': 'Averill', 'Affiliation': 'National Center for PTSD - Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA.'}, {'ForeName': 'Ralitza', 'Initials': 'R', 'LastName': 'Gueorguieva', 'Affiliation': 'Department of Biostatistics, Yale University School of Public Health, New Haven, CT, USA.'}, {'ForeName': 'Selin', 'Initials': 'S', 'LastName': 'Goktas', 'Affiliation': 'National Center for PTSD - Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA.'}, {'ForeName': 'Prerana', 'Initials': 'P', 'LastName': 'Purohit', 'Affiliation': 'National Center for PTSD - Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA.'}, {'ForeName': 'Mohini', 'Initials': 'M', 'LastName': 'Ranganathan', 'Affiliation': 'Departments of Psychiatry, Neuroscience, and Psychology Yale University, New Haven, CT, USA.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Sherif', 'Affiliation': 'Departments of Psychiatry, Neuroscience, and Psychology Yale University, New Haven, CT, USA.'}, {'ForeName': 'Kyung-Heup', 'Initials': 'KH', 'LastName': 'Ahn', 'Affiliation': 'Departments of Psychiatry, Neuroscience, and Psychology Yale University, New Haven, CT, USA.'}, {'ForeName': 'Deepak Cyril', 'Initials': 'DC', 'LastName': ""D'Souza"", 'Affiliation': 'Departments of Psychiatry, Neuroscience, and Psychology Yale University, New Haven, CT, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Formica', 'Affiliation': 'Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'Southwick', 'Affiliation': 'National Center for PTSD - Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA.'}, {'ForeName': 'Ronald S', 'Initials': 'RS', 'LastName': 'Duman', 'Affiliation': 'National Center for PTSD - Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Sanacora', 'Affiliation': 'National Center for PTSD - Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Krystal', 'Affiliation': 'National Center for PTSD - Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-020-0644-9'] 197,31238798,"A multi-centre, prospective, randomised controlled feasibility study of plantar resistance exercise therapy for venous leg ulcers - Results of the PREVUE study.",,2020,,[],['plantar resistance exercise therapy'],[],[],"[{'cui': 'C0442036', 'cui_str': 'Plantar (qualifier value)'}, {'cui': 'C0452240', 'cui_str': 'Rehabilitation Exercise'}]",[],,0.0218464,,"[{'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Jonker', 'Affiliation': 'Cumbria Partnership NHS Foundation Trust, Carlisle, UK.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Todhunter', 'Affiliation': 'North Cumbria University Hospitals NHS Trust, Carlisle, UK.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Schutter', 'Affiliation': 'Cumbria Partnership NHS Foundation Trust, Carlisle, UK.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Halliday', 'Affiliation': 'Cumbria Partnership NHS Foundation Trust, Carlisle, UK.'}, {'ForeName': 'Stacey', 'Initials': 'S', 'LastName': 'Fisher', 'Affiliation': 'Cumbria Partnership NHS Foundation Trust, Carlisle, UK.'}]",Phlebology,['10.1177/0268355519858889'] 198,32320006,Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans.,"BACKGROUND Nicotinamide riboside (NR) is an NAD+ precursor that boosts cellular NAD+ concentrations. Preclinical studies have shown profound metabolic health effects after NR supplementation. OBJECTIVES We aimed to investigate the effects of 6 wk NR supplementation on insulin sensitivity, mitochondrial function, and other metabolic health parameters in overweight and obese volunteers. METHODS A randomized, double-blinded, placebo-controlled, crossover intervention study was conducted in 13 healthy overweight or obese men and women. Participants received 6 wk NR (1000 mg/d) and placebo supplementation, followed by broad metabolic phenotyping, including hyperinsulinemic-euglycemic clamps, magnetic resonance spectroscopy, muscle biopsies, and assessment of ex vivo mitochondrial function and in vivo energy metabolism. RESULTS Markers of increased NAD+ synthesis-nicotinic acid adenine dinucleotide and methyl nicotinamide-were elevated in skeletal muscle after NR compared with placebo. NR increased body fat-free mass (62.65% ± 2.49% compared with 61.32% ± 2.58% in NR and placebo, respectively; change: 1.34% ± 0.50%, P = 0.02) and increased sleeping metabolic rate. Interestingly, acetylcarnitine concentrations in skeletal muscle were increased upon NR (4558 ± 749 compared with 3025 ± 316 pmol/mg dry weight in NR and placebo, respectively; change: 1533 ± 683 pmol/mg dry weight, P = 0.04) and the capacity to form acetylcarnitine upon exercise was higher in NR than in placebo (2.99 ± 0.30 compared with 2.40 ± 0.33 mmol/kg wet weight; change: 0.53 ± 0.21 mmol/kg wet weight, P = 0.01). However, no effects of NR were found on insulin sensitivity, mitochondrial function, hepatic and intramyocellular lipid accumulation, cardiac energy status, cardiac ejection fraction, ambulatory blood pressure, plasma markers of inflammation, or energy metabolism. CONCLUSIONS NR supplementation of 1000 mg/d for 6 wk in healthy overweight or obese men and women increased skeletal muscle NAD+ metabolites, affected skeletal muscle acetylcarnitine metabolism, and induced minor changes in body composition and sleeping metabolic rate. However, no other metabolic health effects were observed.This trial was registered at clinicaltrials.gov as NCT02835664.",2020,"However, no effects of NR were found on insulin sensitivity, mitochondrial function, hepatic and intramyocellular lipid accumulation, cardiac energy status, cardiac ejection fraction, ambulatory blood pressure, plasma markers of inflammation, or energy metabolism. ","['overweight and obese volunteers', 'healthy obese humans', '13 healthy overweight or obese men and women', 'healthy overweight or obese men']","['placebo supplementation, followed by broad metabolic phenotyping, including hyperinsulinemic-euglycemic clamps, magnetic resonance spectroscopy, muscle biopsies, and assessment of ex vivo mitochondrial function and in vivo energy metabolism', 'placebo', '6 wk NR supplementation', 'Nicotinamide riboside supplementation']","['NAD+ synthesis-nicotinic acid adenine dinucleotide and methyl nicotinamide', 'insulin sensitivity, mitochondrial function, and other metabolic health parameters', 'body composition and sleeping metabolic rate', 'insulin sensitivity, mitochondrial function, hepatic and intramyocellular lipid accumulation, cardiac energy status, cardiac ejection fraction, ambulatory blood pressure, plasma markers of inflammation, or energy metabolism', 'body fat-free mass', 'sleeping metabolic rate', 'metabolic health effects', 'capacity to form acetylcarnitine upon exercise', 'skeletal muscle NAD+ metabolites', 'acetylcarnitine concentrations in skeletal muscle']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0079318', 'cui_str': 'Euglycaemic Clamp'}, {'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}, {'cui': 'C0185283', 'cui_str': 'Biopsy of muscle'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0068711', 'cui_str': 'nicotinamide-beta-riboside'}]","[{'cui': 'C0027270', 'cui_str': 'Nicotinamide adenine dinucleotide (NAD)'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0068723', 'cui_str': 'nicotinic acid adenine dinucleotide'}, {'cui': 'C0028027', 'cui_str': 'Niacinamide'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0333574', 'cui_str': 'Fatty deposition'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0232174', 'cui_str': 'Cardiac ejection fraction'}, {'cui': 'C0855316', 'cui_str': 'Blood pressure ambulatory'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0001040', 'cui_str': 'Acetylcarnitine'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",13.0,0.485712,"However, no effects of NR were found on insulin sensitivity, mitochondrial function, hepatic and intramyocellular lipid accumulation, cardiac energy status, cardiac ejection fraction, ambulatory blood pressure, plasma markers of inflammation, or energy metabolism. ","[{'ForeName': 'Carlijn M E', 'Initials': 'CME', 'LastName': 'Remie', 'Affiliation': 'Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Kay H M', 'Initials': 'KHM', 'LastName': 'Roumans', 'Affiliation': 'Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Michiel P B', 'Initials': 'MPB', 'LastName': 'Moonen', 'Affiliation': 'Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Niels J', 'Initials': 'NJ', 'LastName': 'Connell', 'Affiliation': 'Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Bas', 'Initials': 'B', 'LastName': 'Havekes', 'Affiliation': 'Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Mevenkamp', 'Affiliation': 'Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Lindeboom', 'Affiliation': 'Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Vera H W', 'Initials': 'VHW', 'LastName': 'de Wit', 'Affiliation': 'Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Tineke', 'Initials': 'T', 'LastName': 'van de Weijer', 'Affiliation': 'Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Suzanne A B M', 'Initials': 'SABM', 'LastName': 'Aarts', 'Affiliation': 'Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Lutgens', 'Affiliation': 'Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Bauke V', 'Initials': 'BV', 'LastName': 'Schomakers', 'Affiliation': 'Laboratory Genetic Metabolic Diseases, Amsterdam Gastroenterology and Metabolism, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Hyung L', 'Initials': 'HL', 'LastName': 'Elfrink', 'Affiliation': 'Laboratory Genetic Metabolic Diseases, Amsterdam Gastroenterology and Metabolism, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Rubén', 'Initials': 'R', 'LastName': 'Zapata-Pérez', 'Affiliation': 'Laboratory Genetic Metabolic Diseases, Amsterdam Gastroenterology and Metabolism, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Riekelt H', 'Initials': 'RH', 'LastName': 'Houtkooper', 'Affiliation': 'Laboratory Genetic Metabolic Diseases, Amsterdam Gastroenterology and Metabolism, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Auwerx', 'Affiliation': 'Laboratory of Integrative and Systems Physiology, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Joris', 'Initials': 'J', 'LastName': 'Hoeks', 'Affiliation': 'Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Vera B', 'Initials': 'VB', 'LastName': 'Schrauwen-Hinderling', 'Affiliation': 'Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Phielix', 'Affiliation': 'Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Schrauwen', 'Affiliation': 'Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqaa072'] 199,32311349,Pneumonia and Exposure to Household Air Pollution in Children Under the Age of 5 Years in Rural Malawi: Findings From the Cooking and Pneumonia Study.,"BACKGROUND Exposure to household air pollution is associated with an increased risk of pneumonia in children in low- and middle-income countries; however, exposure-response data are limited, and there are uncertainties around the extent to which biomass-fueled cookstoves can reduce these exposures. RESEARCH QUESTION What is the association between exposure to household air pollution and pneumonia in children under the age of 5 years in rural Malawi and what are the effects of a biomass-fueled cookstove intervention on personal exposure to household air pollution? STUDY DESIGN AND METHODS We measured personal exposure to carbon monoxide (CO; 48 hours of continuous measurement and transcutaneous carboxyhemoglobin) every 6 months in children who participated in a cluster-randomized controlled trial of a cleaner burning biomass-fueled cookstove intervention to prevent pneumonia in children under the age of 5 years in rural Malawi (the Cooking And Pneumonia Study). Exposure-response and multivariable analyses were done. RESULTS We recruited 1805 (928 intervention; 877 control) children (mean age, 25.6 months; 50.6% female). We found no evidence of an association between exposure to CO (incident rate ratio, 1.0; 95% CI, 0.967 to 1.014; P = .53) or carboxyhemoglobin (incident rate ratio, 1.00; 95% CI, 0.993 to 1.003; P = .41) in children who experienced pneumonia vs those who did not. Median exposure to CO in the intervention and control groups was was 0.34 (interquartile range, 0.15 to 0.81) and 0.37 parts per million (interquartile range, 0.15 toa 0.97), respectively. The group difference in means was 0.46 (95% CI, -0.95 to 0.012; P = .06). INTERPRETATION Exposure to CO in our population was low with no association seen between exposure to CO and pneumonia incidence and no effect of the Cooking And Pneumonia Study intervention on these exposures. These findings suggest that CO may not be an appropriate measure of household air pollution exposure in settings such as rural Malawi and that there is a need to develop ways to measure particulate matter exposures directly in young children instead. CLINICAL TRIAL REGISTRATION ISRCTN59448623.",2020,"The group difference in means was 0.46 (95% CI:-0.95-0.012; p=0.06). ","['children under the age of 5 years in rural Malawi', 'children under the age of 5 years in rural Malawi - the Cooking And Pneumonia Study (CAPS', 'children participating in a cluster-randomised controlled trial of a', 'young children instead', 'We recruited 1805 (928 intervention; 877 control) children (mean age 25.6 months, 50.6% female', 'children under the age of 5 in rural Malawi']","['COHb ', 'CAPS intervention', 'personal exposure to carbon monoxide (CO', 'transcutaneous carboxyhemoglobin (COHb', 'cleaner-burning biomass-fueled cookstove intervention']",['Median exposure to CO'],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0024548', 'cui_str': 'Malawi'}, {'cui': 'C0335326', 'cui_str': 'Cookery'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0007061', 'cui_str': 'Carboxyhemoglobin'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0238889', 'cui_str': 'Exposure to carbon monoxide'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C0000912', 'cui_str': 'Accident caused by unspecified fire'}, {'cui': 'C0005535', 'cui_str': 'Biomass'}, {'cui': 'C0556991', 'cui_str': 'Fuel'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0238889', 'cui_str': 'Exposure to carbon monoxide'}]",,0.0927706,"The group difference in means was 0.46 (95% CI:-0.95-0.012; p=0.06). ","[{'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Mortimer', 'Affiliation': 'Liverpool School of Tropical Medicine, Liverpool, UK. Electronic address: Kevin.mortimer@lstmed.ac.uk.'}, {'ForeName': 'Maia', 'Initials': 'M', 'LastName': 'Lesosky', 'Affiliation': 'University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Semple', 'Affiliation': 'Stirling University, Stirling, UK.'}, {'ForeName': 'Jullita', 'Initials': 'J', 'LastName': 'Malava', 'Affiliation': 'Malawi Epidemiology and Intervention Research Unit, Chilumba, Malawi.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Katundu', 'Affiliation': 'Malawi Epidemiology and Intervention Research Unit, Chilumba, Malawi.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'Crampin', 'Affiliation': 'Malawi Epidemiology and Intervention Research Unit, Chilumba, Malawi; London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Duolao', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': 'Liverpool School of Tropical Medicine, Liverpool, UK.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Weston', 'Affiliation': 'Liverpool School of Tropical Medicine, Liverpool, UK.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Pope', 'Affiliation': 'University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Havens', 'Affiliation': 'Liverpool School of Tropical Medicine, Liverpool, UK.'}, {'ForeName': 'Stephen B', 'Initials': 'SB', 'LastName': 'Gordon', 'Affiliation': 'Liverpool School of Tropical Medicine, Liverpool, UK; Malawi Liverpool Wellcome Trust Programme, Blantyre, Malawi.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Balmes', 'Affiliation': 'University of California, Berkeley, CA; University of California, San Francisco, San Francisco, CA.'}]",Chest,['10.1016/j.chest.2020.03.064'] 200,32314327,[Liver transplantation optional treatment of liver metastases from colorectal cancer].,"Surgical treatment of liver metastases from colorectal cancer (CLM) is the only treatment option with curative potential; however, only about 15% to 20% of the patients seen at major hospitals are candidates for surgical resection. In a prospective study of liver transplantation (Ltx) for non-resectable CLM a 5-year overall survival rate of 60 % has been shown. We now plan to evaluate if the addition of Ltx to conventional treatment of non-resectable, non-ablatable CLM increases overall survival compared to best established treatment.  This will be done in a randomized study, primarily utilizing liver grafts from extended criteria donors not utilized for approved indications.",2020,In a prospective study of liver transplantation (Ltx) for non-resectable CLM a 5-year overall survival rate of 60 % has been shown.,"['liver metastases from colorectal cancer (CLM', 'liver metastases from colorectal cancer']",['liver transplantation (Ltx'],['overall survival'],"[{'cui': 'C0494165', 'cui_str': 'Secondary malignant neoplasm of liver'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}]","[{'cui': 'C0023911', 'cui_str': 'Transplantation of liver'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.020182,In a prospective study of liver transplantation (Ltx) for non-resectable CLM a 5-year overall survival rate of 60 % has been shown.,"[{'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Lindnér', 'Affiliation': '.'}, {'ForeName': 'Helga', 'Initials': 'H', 'LastName': 'Hagman', 'Affiliation': 'med dr, överläkare, , Skånes onkologiska klinik, Skånes universitetssjukhus Lund/Malmö.'}, {'ForeName': 'Gunnar', 'Initials': 'G', 'LastName': 'Söderdahl', 'Affiliation': 'med dr, verksamhetschef, , Karolinska institutet; PO transplantation, Karolinska universitetssjukhuset, Huddinge.'}]",Lakartidningen,[] 201,31199595,Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.,"Acne-like skin reactions frequently occur in patients undergoing treatment with drugs inhibiting the epidermal growth factor receptor. Recently, the effects of vitamin K1 containing cream (Reconval K1) as prophylactic skin treatment in addition to doxycycline were explored in a double-blind randomized phase II trial (EVITA) in patients with metastatic colorectal cancer receiving cetuximab. EVITA demonstrated a trend towards less severe skin rash in Reconval K1-treated patients using the tripartite WoMo skin reaction grading score as a thorough tool for quantification of drug related skin reactions. This gender-specific analysis of the EVITA trial evaluated the application of the WoMo score for assessment of epidermal growth factor receptor (EGFR)-related skin toxicities according to treatment arm and gender. To show the robustness of results parametric and non-parametric statistical analyses were conducted. All three parts of the WoMo score independently demonstrated the superiority of the treatment arm (Reconval K1) regarding a significant reduction in acneiform skin reactions in women. Men did not benefit from Reconval K1 cream at any time point in none of the WoMo score analyses. The treatment effect in women was confirmed by the use of skin rash categories based on the final WoMo overall score and mixed effect longitudinal multiple linear regression analysis. The WoMo score represents a sensitive tool for studies exploiting treatments against EGFR mediated acne-like skin rash. Part C of the WoMo score seems to be sufficient for quantification of drug related skin toxicities in further studies. Standard WoMo skin reaction score values for future studies are provided.",2019,All three parts of the WoMo score independently demonstrated the superiority of the treatment arm (Reconval K1) regarding a significant reduction in acneiform skin reactions in women.,"['patients with metastatic colorectal cancer receiving cetuximab', 'patients undergoing treatment with drugs inhibiting the epidermal growth factor receptor']","['Reconval K1 cream', 'doxycycline', 'vitamin K1 containing cream (Reconval K1']","['severe skin rash', 'epidermal growth factor receptor (EGFR)-related skin toxicities', 'acneiform skin toxicity', 'acneiform skin reactions']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0346973', 'cui_str': 'Secondary malignant neoplasm of large intestine'}, {'cui': 'C0995188', 'cui_str': 'cetuximab'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0034802', 'cui_str': 'c-erbB-1 Protein'}]","[{'cui': 'C1378128', 'cui_str': 'Cream'}, {'cui': 'C0013090', 'cui_str': 'Doxycycline'}, {'cui': 'C0031862', 'cui_str': 'phytonadione'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0015230', 'cui_str': 'Skin Rash'}, {'cui': 'C0034802', 'cui_str': 'c-erbB-1 Protein'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C1167791', 'cui_str': 'Skin toxicity'}, {'cui': 'C0221743', 'cui_str': 'Skin reaction (observable entity)'}]",,0.0360502,All three parts of the WoMo score independently demonstrated the superiority of the treatment arm (Reconval K1) regarding a significant reduction in acneiform skin reactions in women.,"[{'ForeName': 'Maria R', 'Initials': 'MR', 'LastName': 'Gaiser', 'Affiliation': 'Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Sylvie', 'Initials': 'S', 'LastName': 'Lorenzen', 'Affiliation': 'Medical Clinic III, University of Munich, Munich, Germany.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Merx', 'Affiliation': 'Interdisciplinary Tumor Center Mannheim, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Trojan', 'Affiliation': 'Medical Clinic I, University Hospital Frankfurt, Frankfurt, Germany.'}, {'ForeName': 'Janja', 'Initials': 'J', 'LastName': 'Ocvirk', 'Affiliation': 'Institute of Oncology, Ljubljana, Slovenia.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Ettrich', 'Affiliation': 'Medical Clinic I, University Hospital Ulm, Ulm, Germany.'}, {'ForeName': 'Salah-Eddin', 'Initials': 'SE', 'LastName': 'Al-Batran', 'Affiliation': 'Institute of Clinical Cancer Research (IKF) at Nordwest Hospital, UCT-University Cancer Center, Frankfurt, Germany.'}, {'ForeName': 'Holger', 'Initials': 'H', 'LastName': 'Schulz', 'Affiliation': 'Oncological Practice, Frechen, Germany.'}, {'ForeName': 'Nils', 'Initials': 'N', 'LastName': 'Homann', 'Affiliation': 'Medical Clinic II Wolfsburg, Wolfsburg, Germany.'}, {'ForeName': 'Hans-Peter', 'Initials': 'HP', 'LastName': 'Feustel', 'Affiliation': 'Hämatologisch-Onkologische Praxis, Speyer, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Schatz', 'Affiliation': 'Medizinische Klinik II, ViDia Christliche Kliniken Karlsruhe, Karlsruhe, Germany.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Kripp', 'Affiliation': 'Interdisciplinary Tumor Center Mannheim, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Schulte', 'Affiliation': 'Interdisciplinary Tumor Center Mannheim, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Heeger', 'Affiliation': 'Mannheim, Germany.'}, {'ForeName': 'Soetkin', 'Initials': 'S', 'LastName': 'Vlassak', 'Affiliation': 'Neervelp, Belgium.'}, {'ForeName': 'Winfried', 'Initials': 'W', 'LastName': 'Koch', 'Affiliation': 'BDS Koch, Schwetzingen, Germany.'}, {'ForeName': 'Ralf-Dieter', 'Initials': 'RD', 'LastName': 'Hofheinz', 'Affiliation': 'Interdisciplinary Tumor Center Mannheim, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.'}]",Cancer medicine,['10.1002/cam4.2132'] 202,30996338,"Visual Function Questionnaire as an outcome measure for homonymous hemianopia: subscales and supplementary questions, analysis from the VISION trial.","BACKGROUND We conduct supplementary analyses of the NEI VFQ-25 data to evaluate where changes occurred within subscales of the NEI VFQ-25 leading to change in the composite scores between the three treatment arms, and evaluate the NEI VFQ-25 with and without the Neuro 10 supplement. METHODS A prospective, multicentre, parallel, single-blind, three-arm RCT of fourteen UK acute stroke units was conducted. Stroke survivors with homonymous hemianopia were recruited. Interventions included: Fresnel prisms for minimum 2 h, 5 days/week over 6-weeks (Arm a), Visual search training for minimum 30 min, 5 days/week over 6-weeks (Arm b) and standard care-information only (Arm c). Primary and secondary outcomes (including NEI VFQ-25 data) were measured at baseline, 6, 12 and 26 weeks after randomisation. RESULTS Eighty seven patients were recruited (69% male; mean age (SD) equal to 69 (12) years). At 26 weeks, outcomes for 24, 24 and 22 patients, respectively, were compared to baseline. NEI VFQ-25 (with and without Neuro 10) responses improved from baseline to 26 weeks with visual search training compared to Fresnel prisms and standard care. In subscale analysis, the most impacted across all treatment arms was 'driving' whilst the least impacted were 'colour vision' and 'ocular pain'. CONCLUSIONS Composite scores differed systematically for the NEI VFQ-25 (Neuro 10) versus NEI VFQ-25 at all time points. For subscale scores, descriptive statistics suggest clinically relevant improvement in distance activities and vision-specific dependency subscales for NEI VFQ-25 scores in the visual search treatment arm. TRIAL REGISTRATION Current Controlled Trials ISRCTN05956042.",2019,"In subscale analysis, the most impacted across all treatment arms was 'driving' whilst the least impacted were 'colour vision' and 'ocular pain'. ","['Stroke survivors with homonymous hemianopia', 'fourteen UK acute stroke units', 'seven patients were recruited (69% male; mean age (SD) equal to 69 (12) years', 'Eighty']","['visual search training', 'Visual search training', 'NEI VFQ-25']","[""colour vision' and 'ocular pain"", 'Visual Function Questionnaire', 'distance activities and vision-specific dependency subscales for NEI VFQ-25 scores', 'NEI VFQ-25 data']","[{'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0271202', 'cui_str': 'Hemianopsia, Homonymous'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0751956', 'cui_str': 'Stroke, Acute'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}]","[{'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1955969', 'cui_str': 'NEI (US)'}]","[{'cui': 'C0086032', 'cui_str': 'Daylight Vision'}, {'cui': 'C0151827', 'cui_str': 'Eye pain'}, {'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0011546', 'cui_str': 'Dependency'}, {'cui': 'C1955969', 'cui_str': 'NEI (US)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",87.0,0.249442,"In subscale analysis, the most impacted across all treatment arms was 'driving' whilst the least impacted were 'colour vision' and 'ocular pain'. ","[{'ForeName': 'Fiona J', 'Initials': 'FJ', 'LastName': 'Rowe', 'Affiliation': 'Department of Health Services Research, University of Liverpool, Liverpool, L69 3GB, UK. rowef@liverpool.ac.uk.'}, {'ForeName': 'Lauren R', 'Initials': 'LR', 'LastName': 'Hepworth', 'Affiliation': 'Department of Health Services Research, University of Liverpool, Liverpool, L69 3GB, UK.'}, {'ForeName': 'Elizabeth J', 'Initials': 'EJ', 'LastName': 'Conroy', 'Affiliation': 'Department of Biostatistics, University of Liverpool, Liverpool, L69 3GA, UK.'}, {'ForeName': 'Naomi E A', 'Initials': 'NEA', 'LastName': 'Rainford', 'Affiliation': 'Department of Biostatistics, University of Liverpool, Liverpool, L69 3GA, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Bedson', 'Affiliation': 'Clinical Trials Research Unit, University of Liverpool, Liverpool, L69 3GL, UK.'}, {'ForeName': 'Avril', 'Initials': 'A', 'LastName': 'Drummond', 'Affiliation': 'School of Health Sciences, University of Nottingham, Nottingham, NG7 2UH, UK.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'García-Fiñana', 'Affiliation': 'Department of Biostatistics, University of Liverpool, Liverpool, L69 3GA, UK.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Howard', 'Affiliation': 'Department of Orthoptics, Salford Royal NHS Foundation Trust, Manchester, M6 8HD, UK.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Pollock', 'Affiliation': 'Nursing, Midwifery and Allied Health Professions Research Unit, Glasgow Caledonian University, Glasgow, G4 0BA, UK.'}, {'ForeName': 'Tracey', 'Initials': 'T', 'LastName': 'Shipman', 'Affiliation': 'Department of Orthoptics, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2JF, UK.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Dodridge', 'Affiliation': 'Department of Orthoptics, Oxford University Hospitals NHS Trust, Oxford, OX3 9DU, UK.'}, {'ForeName': 'Stevie', 'Initials': 'S', 'LastName': 'Johnson', 'Affiliation': 'Eye Clinic Support Service, Royal National Institute of Blind People, Birmingham, B29 6NA, UK.'}, {'ForeName': 'Carmel', 'Initials': 'C', 'LastName': 'Noonan', 'Affiliation': 'Department of Ophthalmology, Aintree University Hospital NHS Foundation Trust, Liverpool, L9 7AL, UK.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Sackley', 'Affiliation': ""Division of Health and Social Care, King's College, London, WC2B 5RL, UK.""}]","Eye (London, England)",['10.1038/s41433-019-0441-z'] 203,32003413,Transition to a More even Distribution of Daily Protein intake Is Associated with Enhanced Fat Loss during a Hypocaloric and Physical Activity Intervention in Obese Older Adults.,"BACKGROUND Optimization of intentional weight loss in obese older adults, through preferential fat mass reduction, is challenging, as the concomitant lean mass loss may exacerbate sarcopenia. Recent studies have suggested within-day distribution of protein intake plays a role in determining body composition remodeling. Here, we assessed whether changes in within-day protein intake distribution are related to improvements in body composition in overweight/obese older adults during a hypocaloric and exercise intervention. METHODS Thirty-six community-dwelling, overweight-to-obese (BMI 28.0-39.9 kg/m2), sedentary older adults (aged 70.6±6.1 years) were randomized into either physical activity plus successful aging health education (PA+SA; n=15) or physical activity plus weight loss (PA+WL; n=21) programs. Body composition (by CT and DXA) and dietary intake (by three-day food records) were determined at baseline, 6-month, and 12-month follow-up visits. Within-day protein distribution was calculated as the coefficient of variation (CV) of protein ingested per defined time periods (breakfast [5:00-10:59], lunch [11:00-16:59] and dinner [17:00-1:00]). Secondary analysis was performed to determine associations between changes in protein intake distribution and body composition. RESULTS In both groups, baseline protein intake was skewed towards dinner (PA+SA: 49.1%; PA+WL: 54.1%). The pattern of protein intake changed towards a more even within-day distribution in PA+WL during the intervention period, but it remained unchanged in PA+SA. Transition towards a more even pattern of protein intake was independently associated with a greater decline in BMI (P<0.05) and abdominal subcutaneous fat (P<0.05) in PA+WL. However, changes in protein CV were not associated with changes in body weight in PA+SA. CONCLUSION Our results show that mealtime distribution of protein intake throughout the day was associated with improved weight and fat loss under hypocaloric diet combined with physical activity. This finding provides a novel insight into the potential role of within-day protein intake on weight management in obese older people.",2020,Transition towards a more even pattern of protein intake was independently associated with a greater decline in BMI (P<0.05) and abdominal subcutaneous fat (P<0.05) in PA+WL.,"['obese older people', 'Obese Older Adults', 'Thirty-six', 'obese older adults', 'overweight/obese older adults', 'community-dwelling, overweight-to-obese (BMI 28.0-39.9 kg/m2), sedentary older adults (aged 70.6±6.1 years']","['hypocaloric and exercise intervention', 'Hypocaloric and Hhysical Activity Intervention', 'physical activity plus successful aging health education (PA+SA; n=15) or physical activity plus weight loss (PA+WL; n=21) programs']","['body composition', 'Body composition (by CT and DXA) and dietary intake', 'protein intake distribution and body composition', 'weight and fat loss', 'body weight', 'baseline protein intake']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4319606', 'cui_str': 'Thirty-six'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C4045975', 'cui_str': 'Community Dwelling'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0018701'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}]",36.0,0.0218255,Transition towards a more even pattern of protein intake was independently associated with a greater decline in BMI (P<0.05) and abdominal subcutaneous fat (P<0.05) in PA+WL.,"[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Farsijani', 'Affiliation': 'Anne B. Newman, 5126 Public Health, 130 DeSoto Street, Pittsburgh, PA 15261, Office (412) 624-3056 Fax (412) 624-3737, Email: newmana@edc.pitt.edu.'}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Cauley', 'Affiliation': ''}, {'ForeName': 'A J', 'Initials': 'AJ', 'LastName': 'Santanasto', 'Affiliation': ''}, {'ForeName': 'N W', 'Initials': 'NW', 'LastName': 'Glynn', 'Affiliation': ''}, {'ForeName': 'R M', 'Initials': 'RM', 'LastName': 'Boudreau', 'Affiliation': ''}, {'ForeName': 'A B', 'Initials': 'AB', 'LastName': 'Newman', 'Affiliation': ''}]","The journal of nutrition, health & aging",['10.1007/s12603-020-1313-8'] 204,31374218,Preliminary examination of the orexin system on relapse-related factors in cocaine use disorder.,"RATIONALE Current evidence and literature reviews provide a strong justification for examining the orexin receptor (OXR) system as a therapeutic target in substance use disorders, including cocaine and other psychostimulants. OBJECTIVES In this preliminary, proof-of-concept examination of orexin modulation in humans with cocaine use disorder, we measured changes in domains tied to relapse: stress, sleep, cue reactivity, and inhibitory control. Additionally, mood symptoms (anxiety, depression), medication compliance, and side effects were assessed. METHODS Twenty non-treatment seeking subjects with cocaine use disorder (CUD) received either the OX 1 R / OX 2 R antagonist suvorexant PO or placebo at 10 PM daily for two weeks (10 mg week 1, 20 mg week 2). Using psychometrics, smart-watch actigraphy, a cold-pressor stress challenge, and eye-tracking technology, the following domains were examined: sleep, stress/anxiety, cue-reactivity (attentional bias, craving), and inhibitory control. Psychometric data were collected every M/W/F (7 time points). Laboratory data were collected weekly (3 time points). RESULTS Bayesian and frequentist generalized linear models were employed in parallel to examine the effects of suvorexant compared to placebo, with a Bayesian posterior probability threshold >80% as evidence of a signal for suvorexant. Notable results favoring suvorexant over placebo included fewer total anti-saccade errors, improved sleep actigraphy (sleep/awake periods), pre/post cold-pressor change in heart rate and salivary cortisol (all posterior probabilities >94%), and craving (posterior probability >87%). CONCLUSIONS Initial but restricted evidence is provided supporting the orexin system as a modulator of relapse-related processes in cocaine use disorder. Baseline differences in the main outcome variables were not experimentally controlled and differences in craving were observed at baseline. This, in combination with a limited sample size, constrain the nature of the project. The results may serve to inform more comprehensive future research.",2020,"Notable results favoring suvorexant over placebo included fewer total anti-saccade errors, improved sleep actigraphy (sleep/awake periods), pre/post cold-pressor change in heart rate and salivary cortisol","['Twenty non-treatment seeking subjects with cocaine use disorder (CUD', 'humans with cocaine use disorder']","['OX 1 R / OX 2 R antagonist suvorexant PO or placebo', 'placebo']","['craving', 'total anti-saccade errors, improved sleep actigraphy (sleep/awake periods), pre/post cold-pressor change in heart rate and salivary cortisol', 'sleep, stress/anxiety, cue-reactivity (attentional bias, craving), and inhibitory control', 'mood symptoms (anxiety, depression), medication compliance, and side effects']","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0243076', 'cui_str': 'antagonists'}, {'cui': 'C3179535', 'cui_str': 'suvorexant'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0036019', 'cui_str': 'Saccadic Eye Movements'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C0234422', 'cui_str': 'Awake (finding)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0444689', 'cui_str': 'Cold pressor test (procedure)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0442040', 'cui_str': 'Salivary (qualifier value)'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C4277667', 'cui_str': 'Attentional Bias'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C3489773', 'cui_str': 'Medication Non-Compliance'}, {'cui': 'C0001688', 'cui_str': 'side effects'}]",,0.113466,"Notable results favoring suvorexant over placebo included fewer total anti-saccade errors, improved sleep actigraphy (sleep/awake periods), pre/post cold-pressor change in heart rate and salivary cortisol","[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Suchting', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, UTHealth McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA. Electronic address: Robert.Suchting@uth.tmc.edu.'}, {'ForeName': 'Jin H', 'Initials': 'JH', 'LastName': 'Yoon', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, UTHealth McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Guadalupe G San', 'Initials': 'GGS', 'LastName': 'Miguel', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, UTHealth McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Charles E', 'Initials': 'CE', 'LastName': 'Green', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, UTHealth McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA; Department of Pediatrics - Center for Evidence Based Medicine, UTHealth McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Michael F', 'Initials': 'MF', 'LastName': 'Weaver', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, UTHealth McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Jessica N', 'Initials': 'JN', 'LastName': 'Vincent', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, UTHealth McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Gabriel R', 'Initials': 'GR', 'LastName': 'Fries', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, UTHealth McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Joy M', 'Initials': 'JM', 'LastName': 'Schmitz', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, UTHealth McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Lane', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, UTHealth McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA; MD Anderson - UTHealth Graduate School of Biomedical Sciences, Program in Neuroscience, University of Texas Health Science Center at Houston, Houston, TX, USA.'}]",Brain research,['10.1016/j.brainres.2019.146359'] 205,32298381,The implementation of a nutrition protocol in a surgical intensive care unit; a randomized controlled trial at a tertiary care hospital.,"BACKGROUND Malnutrition in critically ill patients is linked with significant mortality and morbidity. However, it remains controversial whether nutrition therapy protocols are effective in improving clinical outcomes. The present study aimed to evaluate the effectiveness of a surgical ICU nutrition protocol, and to compare the hospital mortality, hospital LOS, and ICU LOS of protocol and non-protocol groups. METHODS A randomized controlled trial was conducted at the Surgical ICU, Siriraj Hospital. The nutrition administration of the control group was at the discretion of the attending physicians, whereas that of the intervention group followed the ""Siriraj Surgical ICU Nutrition Protocol"". Details of the demographic data, nutritional data, and clinical outcomes were collected. RESULTS In all, 170 patients underwent randomization, with 85 individuals each in the protocol and non-protocol groups. More than 90% of the patients in both groups were at risk of malnutrition, indicated by a score of ≥ 3 on the Nutritional Risk Screening 2002 tool. The average daily calories of the 2 groups were very similar (protocol group, 775.4±342.2 kcal vs. control group, 773.0±391.9 kcal; p = 0.972). However, the median time to commence enteral nutrition was shorter for the protocol group (1.94 days) than the control group (2.25 days; p = 0.503). Enteral nutrition was provided within the first 48 hours to 53.7% of the protocol patients vs. 47.4% of the control patients (p = 0.589). In addition, a higher proportion of the protocol patients (36.5%) reached the 60% calorie-target on Day 4 after admission than that for the non-protocol group (25.9%; p = 0.136). All other clinical outcomes and nutrition-related complications were not significantly different. CONCLUSIONS The implementation of the nutrition protocol did not improve the feeding effectiveness or clinical outcomes as compared to usual nutrition management practices of the Surgical ICU.",2020,The implementation of the nutrition protocol did not improve the feeding effectiveness or clinical outcomes as compared to usual nutrition management practices of the Surgical ICU.,"['critically ill patients', '170 patients underwent randomization, with 85 individuals each in the protocol and non-protocol groups']",['surgical ICU nutrition protocol'],"['average daily calories', 'Enteral nutrition', 'median time to commence enteral nutrition', 'hospital mortality, hospital LOS, and ICU LOS']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}]",170.0,0.0673065,The implementation of the nutrition protocol did not improve the feeding effectiveness or clinical outcomes as compared to usual nutrition management practices of the Surgical ICU.,"[{'ForeName': 'Pornrat', 'Initials': 'P', 'LastName': 'Chinda', 'Affiliation': 'Division of Critical Care Medicine, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Pulyamon', 'Initials': 'P', 'LastName': 'Poomthong', 'Affiliation': 'Division of Critical Care Medicine, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Puriwat', 'Initials': 'P', 'LastName': 'Toadithep', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Chayanan', 'Initials': 'C', 'LastName': 'Thanakiattiwibun', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Onuma', 'Initials': 'O', 'LastName': 'Chaiwat', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}]",PloS one,['10.1371/journal.pone.0231777'] 206,31427292,Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children.,"Piperacillin-tazobactam (TZP) is frequently used to treat severe hospital-acquired infections in children. We performed a single-center, pharmacokinetic (PK) trial of TZP in children ranging in age from 2 months to 6 years from various clinical subpopulations. Children who were on TZP per the standard of care were prospectively included and assigned to receive a dose of 80 mg/kg of body weight every 6 h infused over 2 h (ages 2 to 5 months) or a dose of 90 mg/kg every 8 h infused over 4 h (ages 6 months to 6 years). Separate population PK models were developed for piperacillin and tazobactam using nonlinear mixed-effects modeling. Optimal dosing was judged based on the ability to maintain free piperacillin concentrations above the piperacillin MIC for enterobacteria and Pseudomonas aeruginosa for ≥50% of the dosing interval. Any untoward event occurring during treatment was collected as an adverse event. A total of 79 children contributed 174 PK samples. The median (range) age and weight were 1.7 years (2 months to 6 years) and 11.4 kg (3.8 to 27.6 kg), respectively. A 2-compartment model with first-order elimination best described the piperacillin and tazobactam data. Both final population PK models included weight and concomitant furosemide administration on clearance and weight on the volume of distribution of the central compartment. The optimal dosing regimens in children with normal renal function, based on the piperacillin component, were 75 mg/kg/dose every 4 h infused over 0.5 h in infants ages 2 to ≤6 months and 130 mg/kg/dose every 8 h infused over 4 h in children ages >6 months to 6 years against bacteria with MICs up to 16 mg/liter. A total of 44 children (49%) had ≥1 adverse event, with 3 of these (site infiltrations) considered definitely associated with the extended infusions.",2019,"L. A total of 44 children (49%) had ≥ 1 adverse event, with 3 of these (site infiltrations) considered definitely associated with extended infusions.","['Children who were on TZP per standard of care', 'children with normal renal function', 'children 2m-6y from various clinical subpopulations', 'severe hospital-acquired infections in children', 'Infants and Children', '79 children contributed 174 PK samples']","['Piperacillin-Tazobactam', 'Piperacillin-tazobactam (TZP', 'piperacillin and tazobactam', 'TZP', 'piperacillin and tazobactam data']","['median (range) age and weight', 'clearance and weight on volume of the central compartment']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}, {'cui': 'C0232805', 'cui_str': 'Normal renal function (finding)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205721', 'cui_str': 'Infections, Hospital'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C4517604', 'cui_str': 'One hundred and seventy-four'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}]","[{'cui': 'C0250480', 'cui_str': 'Piperacillin / tazobactam'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]",79.0,0.0479806,"L. A total of 44 children (49%) had ≥ 1 adverse event, with 3 of these (site infiltrations) considered definitely associated with extended infusions.","[{'ForeName': 'Céline', 'Initials': 'C', 'LastName': 'Thibault', 'Affiliation': 'Department of Pediatrics, CHU Sainte-Justine, Montreal, Canada thibaultc@email.chop.edu julie.autmizguine@umontreal.ca.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Lavigne', 'Affiliation': 'Certara Strategic Consulting, Montreal, Canada.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Litalien', 'Affiliation': 'Department of Pediatrics, CHU Sainte-Justine, Montreal, Canada.'}, {'ForeName': 'Nastya', 'Initials': 'N', 'LastName': 'Kassir', 'Affiliation': 'Certara Strategic Consulting, Montreal, Canada.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Théorêt', 'Affiliation': 'Clinical Pharmacology Unit, CHU Sainte-Justine, Montreal, Canada.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Autmizguine', 'Affiliation': 'Department of Pediatrics, CHU Sainte-Justine, Montreal, Canada thibaultc@email.chop.edu julie.autmizguine@umontreal.ca.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.01260-19'] 207,31427299,"First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults.","VL-2397 is an antifungal drug with a novel mechanism of action, rapid fungicidal in vitro activity, and potent in vivo activity against Aspergillus fumigatus , including azole-resistant strains. VL2397-101, a phase 1 first-in-human, randomized, double-blind, placebo-controlled dose-escalation study, was conducted in healthy adults to determine the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending intravenous (i.v.) doses of VL-2397. All dosing cohorts were fully enrolled; all subjects completed the safety follow-up. A safety committee reviewed the safety data for each dosing cohort prior to recommending the initiation of each subsequent cohort. No serious adverse events (SAEs) occurred; the majority of treatment-emergent adverse events (TEAEs) were mild and self-limited. The most common drug-related TEAEs were infusion site reactions. No clinically concerning trends were noted in vital signs, electrocardiograms, physical examinations, or safety laboratory results. Following single infusions of VL-2397, the overall and maximum exposures rose less than proportionally with increasing doses from 3 mg to 1,200 mg as indicated by area under the concentration-time curve over 24 h (AUC 24 ) and maximum concentration ( C max ). No signs of VL-2397 accumulation were observed following i.v. infusions of 300, 600, and 1,200 mg every 24 h (q24h) for 7 days. Renal elimination played a major role in total body clearance, with up to 47% of unmetabolized drug in urine 24 h after administration at single doses of >30 mg. Overall, VL-2397 dosing in the study appeared to be safe and well tolerated in the healthy subjects. The safety profile, consistent PK, and lack of drug accumulation support further development of VL-2397 in patients with invasive aspergillosis.",2019,"No signs of VL-2397 accumulation were observed following IV infusions of 300, 600 and 1200 mg Q24H for 7 days.","['Healthy Adults', 'patients with invasive aspergillosis', 'healthy adults', 'healthy subjects']","['VL-2397', 'placebo']","['Safety, Tolerability and Pharmacokinetics', 'safety, tolerability, and pharmacokinetics (PK', 'total body clearance', 'safe and well tolerated', 'vital signs, electrocardiograms, physical examinations or safety laboratory results', 'VL-2397 accumulation']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0238013', 'cui_str': 'Invasive aspergillosis'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0518766'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0031809', 'cui_str': 'Physical Examination'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0569922,"No signs of VL-2397 accumulation were observed following IV infusions of 300, 600 and 1200 mg Q24H for 7 days.","[{'ForeName': 'Mammen P', 'Initials': 'MP', 'LastName': 'Mammen', 'Affiliation': 'Vical Incorporated, San Diego, California, USA.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Armas', 'Affiliation': 'Celerion, Tempe, Arizona, USA.'}, {'ForeName': 'Frank H', 'Initials': 'FH', 'LastName': 'Hughes', 'Affiliation': 'Vical Incorporated, San Diego, California, USA.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Hopkins', 'Affiliation': 'Vical Incorporated, San Diego, California, USA.'}, {'ForeName': 'Cindy L', 'Initials': 'CL', 'LastName': 'Fisher', 'Affiliation': 'Vical Incorporated, San Diego, California, USA.'}, {'ForeName': 'Pamela A', 'Initials': 'PA', 'LastName': 'Resch', 'Affiliation': 'Vical Incorporated, San Diego, California, USA.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Rusalov', 'Affiliation': 'Vical Incorporated, San Diego, California, USA.'}, {'ForeName': 'Sean M', 'Initials': 'SM', 'LastName': 'Sullivan', 'Affiliation': 'Vical Incorporated, San Diego, California, USA.'}, {'ForeName': 'Larry R', 'Initials': 'LR', 'LastName': 'Smith', 'Affiliation': 'Vical Incorporated, San Diego, California, USA molecularry@outlook.com.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.00969-19'] 208,32316070,"Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).","BACKGROUND Plaque psoriasis affects children and adults, but treatment options for paediatric psoriasis are limited. OBJECTIVES To evaluate the efficacy and safety of ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-17A, for moderate-to-severe paediatric psoriasis. METHODS In a randomized, double-blind, placebo-controlled, phase III study (IXORA-PEDS), patients aged 6 to < 18 years with moderate-to-severe plaque psoriasis were randomized 2 : 1 to weight-based dosing of IXE every 4 weeks (IXE Q4W, n = 115) or placebo (n = 56) through week 12, followed by open-label IXE Q4W. Coprimary endpoints were the proportions of patients at week 12 achieving ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) and those achieving a static Physician's Global Assessment score of 0 or 1 (sPGA 0,1). RESULTS IXE was superior (P < 0·001) to placebo for both coprimary endpoints of PASI 75 (IXE Q4W, 89%; placebo, 25%) and sPGA (0,1) (IXE Q4W, 81%; placebo, 11%). IXE was also superior for all gated secondary endpoints, including PASI 75 and sPGA (0,1) at week 4, improvement in itch, and complete skin clearance. IXE Q4W provided significant (P < 0·001) improvements vs. placebo in quality of life and clearance of scalp and genital psoriasis. Responses at week 12 were sustained or further improved through week 48. Through week 12, 45% (placebo) and 56% (IXE) of patients reported treatment-emergent adverse events. One serious adverse event was reported (IXE), one patient discontinued due to an adverse event (placebo) and no deaths were reported. CONCLUSIONS IXE was superior to placebo in the treatment of moderate-to-severe paediatric psoriasis, and the safety profile was generally consistent with that observed in adults. What is already known about this topic? Paediatric psoriasis affects approximately 1% of children and can negatively impact health-related quality of life. Treatment options for paediatric psoriasis are typically limited to off-label treatments and approved systemic biologics. Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for moderate-to-severe plaque psoriasis in adults and was recently approved by the US Food and Drug Administration for moderate-to-severe paediatric psoriasis. What does this study add? Ixekizumab resulted in rapid and statistically significant improvements over placebo in skin involvement, itch and health-related quality of life, which persisted through 48 weeks of treatment in paediatric patients with moderate-to-severe plaque psoriasis. The safety profile of ixekizumab was generally consistent with that seen in adults. Ixekizumab may be an additional potential therapeutic option and an additional class of biologic therapy (interleukin-17A antagonist) for the treatment of moderate-to-severe paediatric psoriasis. Plain language summary available online.",2020,IXE Q4W provided significant (p<0·001) improvements versus placebo in quality of life and clearance of scalp and genital psoriasis.,"['patients (age 6 to <18 years) with moderate-to-severe plaque psoriasis', 'Paediatric Patients with Moderate-to-Severe Plaque Psoriasis (IXORA-PEDS']","['IXE', 'IXE every four weeks (IXE Q4W, N=115) or placebo', 'placebo', 'ixekizumab (IXE', 'Ixekizumab', 'Placebo']","['quality of life and clearance of scalp and genital psoriasis', 'safety profile', 'Efficacy and Safety', 'PASI 75 and sPGA (0,1) at Week 4, improvement in itch, and complete skin clearance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0406317', 'cui_str': 'Chronic small plaque psoriasis'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}]","[{'cui': 'C3489764', 'cui_str': 'ixekizumab'}, {'cui': 'C1275555', 'cui_str': 'Every four weeks'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0036270', 'cui_str': 'Scalp structure'}, {'cui': 'C0017420', 'cui_str': 'Reproductive System'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}]",,0.383156,IXE Q4W provided significant (p<0·001) improvements versus placebo in quality of life and clearance of scalp and genital psoriasis.,"[{'ForeName': 'A S', 'Initials': 'AS', 'LastName': 'Paller', 'Affiliation': 'Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'M M B', 'Initials': 'MMB', 'LastName': 'Seyger', 'Affiliation': 'Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Alejandro Magariños', 'Affiliation': 'Psoriahue, Buenos Aires, Argentina.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Bagel', 'Affiliation': 'Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Pinter', 'Affiliation': 'Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt am Main, Germany.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Cather', 'Affiliation': 'Mindful Dermatology and Modern Research Associates, Dallas, TX, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Keller', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Rodriguez Capriles', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Gontijo Lima', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Gallo', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'C A', 'Initials': 'CA', 'LastName': 'Little', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Edson-Heredia', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Xu', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Papp', 'Affiliation': 'K Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The British journal of dermatology,['10.1111/bjd.19147'] 209,30772283,"Routine monitoring with pleural manometry during therapeutic large-volume thoracentesis to prevent pleural-pressure-related complications: a multicentre, single-blind randomised controlled trial.","BACKGROUND In patients with non-expandable lung, removal of pleural fluid can result in excessively negative pleural pressure, which is associated with chest discomfort, pneumothorax, and re-expansion pulmonary oedema. Pleural manometry is widely used to safeguard against pressure-related complications during thoracentesis despite little evidence to support the approach. We investigated whether monitoring of pleural pressure with manometry during thoracentesis could protect against complications compared with assessment of symptoms alone. METHODS We did a prospective randomised single-blind trial involving patients with large pleural effusions at two academic medical centres in, Nashville, TN, and Baltimore, MD, USA. Eligible patients were adults with free-flowing effusions estimated to be at least 0·5 L who could remain seated throughout the procedure. Patients were randomly assigned 1:1 to receive thoracentesis guided by symptoms only (control) or by symptoms plus manometry at timepoints based on volume drained. The randomisation schedule was computer generated, used permuted blocks of four and six, and was stratified by participating institution. Patients, who were masked to study-group assignment, were asked to rate chest discomfort on 100 mm visual analogue scales before, during, and after drainage. In both groups drainage was discontinued before complete evacuation of pleural fluid if patients developed persistent chest discomfort, intractable cough, or other complications. In the manometry group, an additional criterion for stopping was if end-expiratory pleural pressure was lower than -20 cm H 2 O or declined by more than 10 cm H 2 O between two measurements to a value less than or equal to -10 cm H 2 O. The primary outcome was overall chest discomfort from before the start to after the procedure measured by patients 5 min after the end of drainage. Analysis was by modified intention to treat (ie, included all patients with any procedure or outcome data). This trial is registered with ClinicalTrials.gov, number NCT02677883. FINDINGS Between March 4, 2016, and Sept 8, 2017, 191 patients were screened, of whom 128 were randomly assigned treatment and 124 were included in the final analysis (62 in each group). Four patients were excluded because of manometer malfunction (n=2), inability to access effusion due to pleural tumour burden (n=1), and inability to remain seated (n=1). Groups did not differ for the primary outcome (mean difference in chest discomfort score 2·4 mm, 95% CI -5·7 to 10·5, p=0·56). Six (10%) of 62 patients in the control group had asymptomatic pneumothorax ex vacuo compared with none in the manometry group (p=0·01). No serious complications occurred in either group. INTERPRETATION Measurement of pleural pressure by manometry during large-volume thoracentesis does not alter procedure-related chest discomfort. Our findings do not support the routine use of this approach. FUNDING Centurion Medical Products.",2019,"Groups did not differ for the primary outcome (mean difference in chest discomfort score 2·4 mm, 95% CI -5·7 to 10·5, p=0·56).","['Between March 4, 2016, and Sept 8, 2017, 191 patients were screened, of whom 128 were randomly assigned treatment and 124 were included in the final analysis (62 in each group', 'Four patients were excluded because of manometer malfunction (n=2), inability to access effusion due to pleural tumour burden (n=1), and inability to remain seated (n=1', 'Eligible patients were adults with free-flowing effusions estimated to be at least 0·5 L who could remain seated throughout the procedure', 'patients with large pleural effusions at two academic medical centres in, Nashville, TN, and Baltimore, MD, USA']","['thoracentesis guided by symptoms only (control) or by symptoms plus manometry at timepoints based on volume drained', 'Routine monitoring with pleural manometry']","['serious complications', 'asymptomatic pneumothorax ex vacuo', 'overall chest discomfort', 'chest discomfort score', 'persistent chest discomfort, intractable cough, or other complications']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C2720530', 'cui_str': 'Manometer (physical object)'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0013687', 'cui_str': 'Effusion (morphologic abnormality)'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C1522720', 'cui_str': 'Pleural (qualifier value)'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0032227', 'cui_str': 'Pleural Effusion'}, {'cui': 'C0000872', 'cui_str': 'University Medical Centers'}, {'cui': 'C0004716', 'cui_str': 'Baltimore'}]","[{'cui': 'C0189477', 'cui_str': 'Thoracocentesis'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0024751', 'cui_str': 'Manometry'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0180499', 'cui_str': 'Drain, device (physical object)'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C1522720', 'cui_str': 'Pleural (qualifier value)'}]","[{'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic (finding)'}, {'cui': 'C1960446', 'cui_str': 'Pneumothorax ex vacuo (disorder)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0235710', 'cui_str': 'Chest discomfort (finding)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}]",4.0,0.396658,"Groups did not differ for the primary outcome (mean difference in chest discomfort score 2·4 mm, 95% CI -5·7 to 10·5, p=0·56).","[{'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Lentz', 'Affiliation': 'Departments of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA; Department of Thoracic Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Andrew D', 'Initials': 'AD', 'LastName': 'Lerner', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Jasleen K', 'Initials': 'JK', 'LastName': 'Pannu', 'Affiliation': 'Departments of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Merrick', 'Affiliation': 'Departments of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Lance', 'Initials': 'L', 'LastName': 'Roller', 'Affiliation': 'Departments of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Charla', 'Initials': 'C', 'LastName': 'Walston', 'Affiliation': 'Departments of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA; Department of Thoracic Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Valenti', 'Affiliation': 'Department of Radiology, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Tracey', 'Initials': 'T', 'LastName': 'Goddard', 'Affiliation': 'Department of Radiology, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'John T', 'Initials': 'JT', 'LastName': 'Huggins', 'Affiliation': 'Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Otis B', 'Initials': 'OB', 'LastName': 'Rickman', 'Affiliation': 'Departments of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA; Department of Thoracic Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Lonny', 'Initials': 'L', 'LastName': 'Yarmus', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Psallidas', 'Affiliation': 'Oxford Centre for Respiratory Medicine, Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK.'}, {'ForeName': 'Najib M', 'Initials': 'NM', 'LastName': 'Rahman', 'Affiliation': 'Oxford Centre for Respiratory Medicine, Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK; Oxford NIHR Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Richard W', 'Initials': 'RW', 'LastName': 'Light', 'Affiliation': 'Departments of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Fabien', 'Initials': 'F', 'LastName': 'Maldonado', 'Affiliation': 'Departments of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA; Department of Thoracic Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA. Electronic address: fabien.maldonado@vanderbilt.edu.'}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(18)30421-1'] 210,31053766,Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).,"BACKGROUND Multiple androgens drive prostate cancer progression and higher pre-treatment levels of androgens, even within the castrate range, have been previously shown to be associated with an improved overall survival (OS) in mCRPC. Docetaxel impairs microtubules, has androgen receptor (AR) inhibitory effects and is used in both the castration resistant and sensitive settings, where androgen dynamics may impact outcome. The present analysis evaluates the association of decline in serum androgen levels (Testosterone (T), Androstenedione (A) and DHEA in docetaxel-treated mCRPC patients with OS. METHODS Data from 1050 men treated on CALGB 90401 with docetaxel, prednisone and either bevacizumab or placebo were evaluated. Eligibility required progressive mCRPC and no prior chemotherapy. Pre-treatment, 6 week and progression serum assays for T, A and DHEA were performed via tandem Liquid Chromatography-Mass Spectrometry (LC-MS/MS). Changes in T, A and DHEA levels from baseline to 6 weeks were calculated as the ratio of 6-week over baseline. The proportional hazards model was used to assess the prognostic significance of changes in T, A, and DHEA from baseline to 6 weeks in predicting OS adjusting for known prognostic factors. RESULTS Median baseline values for T, A, and, DHEA were 1.0, 13.5, and 8.1 ng/dL respectively while 6 week levels were 0.64, 7.0, and 6.8 ng/dL respectively. Median OS for low testosterone decline is 20.9 months vs 26.3 months for high testosterone decline. In multivariable analysis including known prognostic variables, change in testosterone levels was independently associated with greater OS; the hazard ratio for death with each unit increase in the 6-week/baseline ratio is 1.02 (95% CI = 1.01-1.03, p = 0.001). Decline in A and DHEA were not significant predictors of OS. In multivariable analysis change in the serum changes did not predict PFS however the ratio of T at 6-weeks over baseline was prognostic of ≥50% decline in PSA with an odds ratio of 0.93 (95% CI = 0.85-0.98, p-value = 0.039). CONCLUSIONS Declines in testosterone during docetaxel treatment is associated with a longer survival, consistent with a favorable prognostic significance of higher serum androgens in the CRPC.",2020,"In multivariable analysis including known prognostic variables, change in testosterone levels was independently associated with greater OS; the hazard ratio for death with each unit increase in the 6-week/baseline ratio is 1.02 (95% CI = 1.01-1.03, p = 0.001).","['Data from 1050 men treated on CALGB 90401 with', 'metastatic castration resistant prostate cancer (mCRPC']","['Docetaxel', 'Androstenedione (A) and DHEA in docetaxel-treated mCRPC', 'docetaxel therapy', 'docetaxel, prednisone and either bevacizumab or placebo']","['testosterone levels', 'Median OS for low testosterone decline', 'serum androgen levels (Testosterone (T', 'overall survival (OS', 'hazard ratio for death', 'Androgen decline and survival', 'Changes in T, A and DHEA levels']","[{'cui': 'C4517528', 'cui_str': '1050'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}]","[{'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0002860', 'cui_str': 'androstanedione'}, {'cui': 'C0011185', 'cui_str': 'prasterone'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0523912', 'cui_str': 'Testosterone measurement (procedure)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1295654', 'cui_str': 'Decreased testosterone level'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0919646', 'cui_str': 'Androgen level'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0002844', 'cui_str': 'Androgenic Compounds'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0011185', 'cui_str': 'prasterone'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",,0.188418,"In multivariable analysis including known prognostic variables, change in testosterone levels was independently associated with greater OS; the hazard ratio for death with each unit increase in the 6-week/baseline ratio is 1.02 (95% CI = 1.01-1.03, p = 0.001).","[{'ForeName': 'Charles J', 'Initials': 'CJ', 'LastName': 'Ryan', 'Affiliation': 'University of Minnesota and Masonic Cancer Center, Minneapolis, MN, USA. ryanc@umn.edu.'}, {'ForeName': 'Sandipan', 'Initials': 'S', 'LastName': 'Dutta', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'William K', 'Initials': 'WK', 'LastName': 'Kelly', 'Affiliation': 'Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Carly', 'Initials': 'C', 'LastName': 'Russell', 'Affiliation': 'University of California-San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA.'}, {'ForeName': 'Eric J', 'Initials': 'EJ', 'LastName': 'Small', 'Affiliation': 'University of California-San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Morris', 'Affiliation': 'Memorial Sloan Kettering Cancer, New York, NY, USA.'}, {'ForeName': 'Mary-Ellen', 'Initials': 'ME', 'LastName': 'Taplin', 'Affiliation': 'Dana-Farber/Partners Cancer Care, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Halabi', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Prostate cancer and prostatic diseases,['10.1038/s41391-019-0152-3'] 211,31391479,Association between dynamic resting-state functional connectivity and ketamine plasma levels in visual processing networks.,"Numerous studies demonstrate ketamine's influence on resting-state functional connectivity (rsFC). Seed-based and static rsFC estimation methods may oversimplify FC. These limitations can be addressed with whole-brain, dynamic rsFC estimation methods. We assessed data from 27 healthy subjects who underwent two 3 T resting-state fMRI scans, once under subanesthetic, intravenous esketamine and once under placebo, in a randomized, cross-over manner. We aimed to isolate only highly robust effects of esketamine on dynamic rsFC by using eight complementary methodologies derived from two dynamic rsFC estimation methods, two functionally defined atlases and two statistical measures. All combinations revealed a negative influence of esketamine on dynamic rsFC within the left visual network and inter-hemispherically between visual networks (p < 0.05, corrected), hereby suggesting that esketamine's influence on dynamic rsFC is highly stable in visual processing networks. Our findings may be reflective of ketamine's role as a model for psychosis, a disorder associated with alterations to visual processing and impaired inter-hemispheric connectivity. Ketamine is a highly effective antidepressant and studies have shown changes to sensory processing in depression. Dynamic rsFC in sensory processing networks might be a promising target for future investigations of ketamine's antidepressant properties. Mechanistically, sensitivity of visual networks for esketamine's effects may result from their high expression of NMDA-receptors.",2019,"All combinations revealed a negative influence of esketamine on dynamic rsFC within the left visual network and inter-hemispherically between visual networks (p < 0.05, corrected), hereby suggesting that esketamine's influence on dynamic rsFC is highly stable in visual processing networks.","['27 healthy subjects who underwent two 3\u2009T resting-state fMRI scans, once under subanesthetic, intravenous', 'visual processing networks']","['esketamine', 'esketamine and once under placebo', 'Ketamine']",['resting-state functional connectivity (rsFC'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C1097281', 'cui_str': '3-(DMP)-T'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0441633'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0589087', 'cui_str': 'Visual processing, function (observable entity)'}]","[{'cui': 'C2825616'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}]","[{'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}]",27.0,0.0647747,"All combinations revealed a negative influence of esketamine on dynamic rsFC within the left visual network and inter-hemispherically between visual networks (p < 0.05, corrected), hereby suggesting that esketamine's influence on dynamic rsFC is highly stable in visual processing networks.","[{'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Spies', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Manfred', 'Initials': 'M', 'LastName': 'Klöbl', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Höflich', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Allan', 'Initials': 'A', 'LastName': 'Hummer', 'Affiliation': 'MR Center of Excellence, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Vanicek', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Michenthaler', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Georg S', 'Initials': 'GS', 'LastName': 'Kranz', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Hahn', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Dietmar', 'Initials': 'D', 'LastName': 'Winkler', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Windischberger', 'Affiliation': 'MR Center of Excellence, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Siegfried', 'Initials': 'S', 'LastName': 'Kasper', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Rupert', 'Initials': 'R', 'LastName': 'Lanzenberger', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria. rupert.lanzenberger@meduniwien.ac.at.'}]",Scientific reports,['10.1038/s41598-019-46702-x'] 212,31565955,Project ImPACT for Toddlers : Pilot outcomes of a community adaptation of an intervention for autism risk.,"This study reports child and family outcomes from a community-based, quasi-experimental pilot trial of Project ImPACT for Toddlers that is a parent-mediated, naturalistic, developmental behavioral intervention for children with or at-risk for autism spectrum disorder developed through a research-community partnership. Community early interventionists delivered either Project ImPACT for Toddlers ( n  = 10) or Usual Care ( n  = 9) to families based on Part C assigned provider. Twenty-five families participated, with children averaging 22.76 months old ( SD  = 5.06). Family and child measures were collected at intake, after 3 months of service, and after a 3-month follow-up. Results indicate significantly greater improvements in positive parent-child interactions for Project ImPACT for Toddlers than usual care families, as well as large, but non-significant, effect sizes for Project ImPACT for Toddlers families in children's social and communication skills.",2020,"Results indicate significantly greater improvements in positive parent-child interactions for Project ImPACT for Toddlers than usual care families, as well as large, but non-significant, effect sizes for Project ImPACT for Toddlers families in children's social and communication skills.","['autism risk', 'Twenty-five families participated, with children averaging 22.76\u2009months old ( SD \u2009=\u20095.06', 'Toddlers ', 'children with or at-risk for autism spectrum disorder']",['Community early interventionists delivered either Project ImPACT for Toddlers ( n \u2009=\u200910) or Usual Care ( n \u2009=\u20099) to families based on Part C assigned provider'],['positive parent-child interactions'],"[{'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0682053', 'cui_str': 'Toddler (qualifier value)'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0682053', 'cui_str': 'Toddler (qualifier value)'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}]","[{'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}]",25.0,0.0298937,"Results indicate significantly greater improvements in positive parent-child interactions for Project ImPACT for Toddlers than usual care families, as well as large, but non-significant, effect sizes for Project ImPACT for Toddlers families in children's social and communication skills.","[{'ForeName': 'Aubyn C', 'Initials': 'AC', 'LastName': 'Stahmer', 'Affiliation': 'University of California, Davis, USA.'}, {'ForeName': 'Sarah R', 'Initials': 'SR', 'LastName': 'Rieth', 'Affiliation': 'Child and Adolescent Services Research Center (CASRC), USA.'}, {'ForeName': 'Kelsey S', 'Initials': 'KS', 'LastName': 'Dickson', 'Affiliation': 'Child and Adolescent Services Research Center (CASRC), USA.'}, {'ForeName': 'Josh', 'Initials': 'J', 'LastName': 'Feder', 'Affiliation': 'Fielding Graduate University, USA.'}, {'ForeName': 'Marilee', 'Initials': 'M', 'LastName': 'Burgeson', 'Affiliation': 'MB Speech Therapy, USA.'}, {'ForeName': 'Karyn', 'Initials': 'K', 'LastName': 'Searcy', 'Affiliation': 'San Diego State University, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Brookman-Frazee', 'Affiliation': 'Child and Adolescent Services Research Center (CASRC), USA.'}]",Autism : the international journal of research and practice,['10.1177/1362361319878080'] 213,31190442,Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group.,"INTRODUCTION Objectives were used to describe guardian proxy-report and child self-report quality of life (QoL) during chemotherapy for pediatric acute myeloid leukemia (AML) patients. METHODS Patients enrolled on the phase 3 AML trial AAML1031 who were 2-18 years of age with English-speaking guardians were eligible. Instruments used were the PedsQL Generic Core Scales, Acute Cancer Module, and Multidimensional Fatigue Scale. Assessments were obtained at the beginning of Induction 1 and following completion of cycles 2-4. Potential predictors of QoL included the total number of nonhematological grade 3-4 Common Terminology Criteria for Adverse Event (CTCAE) submissions. RESULTS There were 505 eligible guardians who consented to participate and 348 of their children provided at least one self-report assessment. The number of submitted CTCAE toxicities was significantly associated with worse physical health summary scores (β ± standard error (SE) -3.00 ± 0.69; P < 0.001) and general fatigue (β ± SE -2.50 ± 0.66; P < 0.001). Older age was significantly associated with more fatigue (β ± SE -0.58 ± 0.25; P = 0.022). Gender, white race, Hispanic ethnicity, private insurance status, risk status, bortezomib assignment, and duration of neutropenia were not significantly associated with QoL. DISCUSSION The number of CTCAE toxicities was the primary factor influencing QoL among children with AML. Reducing toxicities should improve QoL; identifying approaches to ameliorate them should be a priority.",2019,Older age was significantly associated with more fatigue (β ± SE -0.58 ± 0.25; P = 0.022).,"['505 eligible guardians who consented to participate and 348 of their children provided at least one self-report assessment', 'pediatric acute myeloid leukemia (AML) patients', 'Patients enrolled on the phase 3 AML trial AAML1031 who were 2-18\xa0years of age with English-speaking guardians were eligible', 'pediatric acute myeloid leukemia']",[],"['Gender, white race, Hispanic ethnicity, private insurance status, risk status, bortezomib assignment, and duration of neutropenia', 'number of submitted CTCAE toxicities', 'Quality of life', 'physical health summary scores (β\xa0±\xa0standard error (SE) -3.00', 'general fatigue', 'PedsQL Generic Core Scales, Acute Cancer Module, and Multidimensional Fatigue Scale', 'number of CTCAE toxicities']","[{'cui': 'C1274041', 'cui_str': 'Guardian'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C4517733', 'cui_str': '348'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0023467', 'cui_str': 'Nonlymphoblastic Leukemia, Acute'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439561', 'cui_str': 'Phase 3 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}]",[],"[{'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C3853635', 'cui_str': 'Race (observable entity)'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0243103', 'cui_str': 'ethnicity'}, {'cui': 'C4521534', 'cui_str': 'US Military enlisted E1'}, {'cui': 'C0376629', 'cui_str': 'Insurance Status'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0034380'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}]",505.0,0.034718,Older age was significantly associated with more fatigue (β ± SE -0.58 ± 0.25; P = 0.022).,"[{'ForeName': 'Rajaram', 'Initials': 'R', 'LastName': 'Nagarajan', 'Affiliation': ""Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Gerbing', 'Affiliation': ""The Children's Oncology Group, Monrovia, California.""}, {'ForeName': 'Todd', 'Initials': 'T', 'LastName': 'Alonzo', 'Affiliation': ""The Children's Oncology Group, Monrovia, California.""}, {'ForeName': 'Donna L', 'Initials': 'DL', 'LastName': 'Johnston', 'Affiliation': ""Division of Oncology, Children's Hospital of Eastern Ontario, Ottawa, Ontario.""}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Aplenc', 'Affiliation': ""Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.""}, {'ForeName': 'Edward A', 'Initials': 'EA', 'LastName': 'Kolb', 'Affiliation': 'Division of Oncology, AI Dupont, Wilmington, Delaware.'}, {'ForeName': 'Soheil', 'Initials': 'S', 'LastName': 'Meshinchi', 'Affiliation': ""Division of Oncology, Seattle Children's Hospital, Seattle, Washington.""}, {'ForeName': 'Lamia P', 'Initials': 'LP', 'LastName': 'Barakat', 'Affiliation': ""Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.""}, {'ForeName': 'Lillian', 'Initials': 'L', 'LastName': 'Sung', 'Affiliation': 'Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario.'}]",Cancer medicine,['10.1002/cam4.2337'] 214,32223044,"Monomeric Flavanols Are More Efficient Substrates for Gut Microbiota Conversion to Hydroxyphenyl-γ-Valerolactone Metabolites Than Oligomeric Procyanidins: A Randomized, Placebo-Controlled Human Intervention Trial.","SCOPE The majority of ingested flavanols reach the colon where they are catabolized by the microbiota to form hydroxyphenyl-γ-valerolactones (HGVLs). It is not known if the HGVLs are catabolic products of monomeric (epi)catechins (EPC), oligomeric procyanidins (OPCs), or both. Using data from a randomized, double-blind, placebo-controlled crossover trial the relative contributions of catechins and OPC to the bioavailable pool of HGVLs are estimated. METHODS AND RESULTS Participants ingested an apple extract once daily for 28 days that delivered the following: i) 70 mg EPC and 65 mg OPC (low dose EPC), ii) 140 mg EPC and 130 mg OPC (high dose EPC), iii) 6 mg EPC and 130 mg OPC (OPC), and iv) a placebo control. Urine is collected over a 24-h period before and after treatments. The median urinary excretion of HGVLs after ingestion of the high dose EPC is tenfold higher than that excreted after ingestion of the OPC that provided an equivalent dose of PC. Approximately 22% of catechins are converted to HGVLs in contrast to PC, for which there is limited conversion. CONCLUSION Monomeric catechins are efficiently converted to derived HGVLs that are absorbed and excreted in human urine, whereas oligomeric PCs are much less efficiently converted.",2020,The median urinary excretion of HGVL metabolites after ingestion of the high dose EPC was 10-fold higher than that excreted after ingestion of the OPC that provided an equivalent dose of PC.,['Participants ingested an apple extract once daily for 28-d that delivered the following: (i) 70\xa0mg'],"['catechins and 65\xa0mg PC (Low dose EPC', 'Placebo', 'placebo']",['median urinary excretion of HGVL metabolites'],"[{'cui': 'C3257517', 'cui_str': 'Apple extract'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}]","[{'cui': 'C0007404', 'cui_str': 'Catechin'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0169014', 'cui_str': 'erucylphosphocholine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}]",,0.455696,The median urinary excretion of HGVL metabolites after ingestion of the high dose EPC was 10-fold higher than that excreted after ingestion of the OPC that provided an equivalent dose of PC.,"[{'ForeName': 'Wendy J', 'Initials': 'WJ', 'LastName': 'Hollands', 'Affiliation': 'Food Innovation and Health Programme, Quadram Institute Bioscience, Norwich, NR4 7UQ, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Philo', 'Affiliation': 'Food Innovation and Health Programme, Quadram Institute Bioscience, Norwich, NR4 7UQ, UK.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Perez-Moral', 'Affiliation': 'Food Innovation and Health Programme, Quadram Institute Bioscience, Norwich, NR4 7UQ, UK.'}, {'ForeName': 'Paul W', 'Initials': 'PW', 'LastName': 'Needs', 'Affiliation': 'Food Innovation and Health Programme, Quadram Institute Bioscience, Norwich, NR4 7UQ, UK.'}, {'ForeName': 'George M', 'Initials': 'GM', 'LastName': 'Savva', 'Affiliation': 'Core Research Services, Quadram Institute Bioscience, Norwich, NR4 7UQ, UK.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Kroon', 'Affiliation': 'Food Innovation and Health Programme, Quadram Institute Bioscience, Norwich, NR4 7UQ, UK.'}]",Molecular nutrition & food research,['10.1002/mnfr.201901135'] 215,31279324,Effects of hydrocortisone on autobiographical memory retrieval in patients with posttraumatic stress disorder and borderline personality disorder: the role of childhood trauma.,"In a previous study, we found that patients with posttraumatic stress disorder (PTSD) and borderline personality disorder (BPD) showed better autobiographical memory (AM) retrieval after hydrocortisone administration than after placebo administration. Here we investigate the neural correlates of AM retrieval after hydrocortisone administration in patients with PTSD or BPD. We recruited 78 female participants for this placebo-controlled crossover study: 40 healthy controls, 20 patients with PTSD, and 18 patients with BPD (all without medication). All participants received an oral placebo or 10 mg hydrocortisone in a randomized order before performing an AM task. Neural activity was monitored during the task by functional magnetic resonance imaging. Neural activation did not differ between the three groups during AM retrieval, neither in the placebo condition nor after hydrocortisone intake. Multiple regression analysis revealed that Childhood Trauma Questionnaire scores correlated positively with hydrocortisone effects on activation in the anterior medial prefrontal cortex (amPFC), ventrolateral prefrontal cortex (vlPFC), posterior cingulate cortex (PCC), angular gyrus, and cerebellum. These results suggest that hydrocortisone-induced neural activation pattern during AM retrieval is related to childhood trauma. Previously described effects in the hippocampus, which were absent in the current study, might be related to PTSD caused by trauma in adulthood. The effects of hydrocortisone on brain activation and how these effects are influenced by childhood trauma, trauma in adulthood, and PTSD symptoms should be determined in future studies.",2019,"Neural activation did not differ between the three groups during AM retrieval, neither in the placebo condition nor after hydrocortisone intake.","['patients with PTSD or BPD', 'patients with posttraumatic stress disorder (PTSD) and borderline personality disorder (BPD', '78 female participants for this placebo-controlled crossover study: 40 healthy controls, 20 patients with PTSD, and 18 patients with BPD (all without medication', 'patients with posttraumatic stress disorder and borderline personality disorder']","['oral placebo', 'hydrocortisone']","['Neural activation', 'autobiographical memory retrieval', 'Childhood Trauma Questionnaire scores', 'autobiographical memory (AM) retrieval', 'anterior medial prefrontal cortex (amPFC), ventrolateral prefrontal cortex (vlPFC), posterior cingulate cortex (PCC), angular gyrus, and cerebellum', 'brain activation', 'Neural activity', 'neural activation pattern']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0006012', 'cui_str': 'Borderline Personality Disorder'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}]","[{'cui': 'C0561843', 'cui_str': 'Autobiographical Memory'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0205098', 'cui_str': 'Medial (qualifier value)'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C3266730', 'cui_str': 'Ventrolateral'}, {'cui': 'C0175191', 'cui_str': 'Posterior Cingulate'}, {'cui': 'C0152305', 'cui_str': 'Prelunate Gyrus'}, {'cui': 'C0007765', 'cui_str': 'Parencephalon'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}]",78.0,0.0472001,"Neural activation did not differ between the three groups during AM retrieval, neither in the placebo condition nor after hydrocortisone intake.","[{'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Metz', 'Affiliation': 'Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany. sophie.metz@charite.de.'}, {'ForeName': 'Juliane', 'Initials': 'J', 'LastName': 'Fleischer', 'Affiliation': 'Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany.'}, {'ForeName': 'Matti', 'Initials': 'M', 'LastName': 'Gärnter', 'Affiliation': 'Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Golde', 'Affiliation': 'Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany.'}, {'ForeName': 'Moritz', 'Initials': 'M', 'LastName': 'Duesenberg', 'Affiliation': 'Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Roepke', 'Affiliation': 'Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany.'}, {'ForeName': 'Oliver T', 'Initials': 'OT', 'LastName': 'Wolf', 'Affiliation': 'Department of Cognitive Psychology, Institute of Cognitive Neuroscience, Ruhr University Bochum, Bochum, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Otte', 'Affiliation': 'Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Wingenfeld', 'Affiliation': 'Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0459-8'] 216,31416333,Beta -adrenergic antagonism alters functional connectivity during associative processing in a preliminary study of individuals with and without autism.,"Beta- adrenergic antagonism (e.g. propranolol) has been associated with cognitive/behavioral benefits following stress-induced impairments and for some cognitive/behavioral domains in individuals with autism spectrum disorder. In this preliminary investigation, we examined whether the benefits of propranolol are associated with functional properties in the brain. Adolescents/adults (mean age = 22.54 years) with (n = 13) and without autism spectrum disorder (n = 13) attended three sessions in which propranolol, nadolol ( beta- adrenergic antagonist that does not cross the blood-brain barrier), or placebo was administered before a semantic fluency task during functional magnetic resonance imaging. Autonomic nervous system measures and functional connectivity between language/associative processing regions and within the fronto-parietal control, dorsal attention, and default mode networks were examined. Propranolol was associated with improved semantic fluency performance, which was correlated with the baseline resting heart rate. Propranolol also altered network efficiency of regions associated with semantic processing and in an exploratory analysis reduced functional differences in the fronto-parietal control network in individuals with autism spectrum disorder. Thus, the cognitive benefits from beta- adrenergic antagonism may be generally associated with improved information processing in the brain in domain-specific networks, but individuals with autism spectrum disorder may also benefit from additional improvements in domain-general networks. The benefits from propranolol may also be able to be predicted from baseline autonomic nervous system measures, which warrants further investigation.",2020,Propranolol also altered network efficiency of regions associated with semantic processing and in an exploratory analysis reduced functional differences in the fronto-parietal control network in individuals with autism spectrum disorder.,"['individuals with autism spectrum disorder', 'individuals with and without autism', 'Adolescents/adults (mean age\u2009=\u200922.54\u2009years) with (n\u2009=\u200913) and without autism spectrum disorder (n\u2009=\u200913) attended three sessions in which']","['propranolol, nadolol ( beta- adrenergic antagonist that does not cross the blood-brain barrier), or placebo', 'Beta- adrenergic antagonism (e.g. propranolol', 'Beta -adrenergic antagonism', 'propranolol', 'Propranolol']",['semantic fluency performance'],"[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1456498', 'cui_str': 'Attended'}]","[{'cui': 'C0033497', 'cui_str': 'Propranolol'}, {'cui': 'C0027302', 'cui_str': 'Nadolol'}, {'cui': 'C0001645', 'cui_str': 'beta-Adrenoceptor Antagonists'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0005854', 'cui_str': 'Hemato-Encephalic Barrier'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0001637', 'cui_str': 'Adrenergic Drugs'}]","[{'cui': 'C0036612', 'cui_str': 'Semantics'}]",,0.0504023,Propranolol also altered network efficiency of regions associated with semantic processing and in an exploratory analysis reduced functional differences in the fronto-parietal control network in individuals with autism spectrum disorder.,"[{'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Hegarty', 'Affiliation': 'University of Missouri, USA.'}, {'ForeName': 'Rachel M', 'Initials': 'RM', 'LastName': 'Zamzow', 'Affiliation': 'University of Missouri, USA.'}, {'ForeName': 'Bradley J', 'Initials': 'BJ', 'LastName': 'Ferguson', 'Affiliation': 'University of Missouri, USA.'}, {'ForeName': 'Shawn E', 'Initials': 'SE', 'LastName': 'Christ', 'Affiliation': 'University of Missouri, USA.'}, {'ForeName': 'Eric C', 'Initials': 'EC', 'LastName': 'Porges', 'Affiliation': 'University of Florida, USA.'}, {'ForeName': 'Jeffrey D', 'Initials': 'JD', 'LastName': 'Johnson', 'Affiliation': 'University of Missouri, USA.'}, {'ForeName': 'David Q', 'Initials': 'DQ', 'LastName': 'Beversdorf', 'Affiliation': 'University of Missouri, USA.'}]",Autism : the international journal of research and practice,['10.1177/1362361319868633'] 217,31421635,Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study.,"Increasing evidence supports a rapid antidepressant and antisuicidal effect of a single subanesthetic dose of ketamine infusion for treatment-resistant depression (TRD). Maintaining the initial clinical response after ketamine infusion in TRD is a crucial next-step challenge. D-cycloserine (DCS), a partial agonist of the glycine co-agonist of the N-methyl-D-aspartate (NMDA) glutamate receptor, is potentially effective as a depression augmentation treatment. However, whether DCS maintains the antidepressant and antisuicidal effects of ketamine infusion remains unknown. In all, 32 patients with TRD (17 with major depression and 15 with bipolar depression) who responded to ketamine infusion with an average 17-item Hamilton Depression Rating Scale (HAMD) score of 9.47 ± 4.11 at baseline were randomly divided to 6-week DCS treatment (250 mg for 2 days, 500 mg for 2 days, 750 mg for 3 days, and 1000 mg for 5 weeks) and placebo groups. Depression symptoms were rated at timepoints of dose titration and weekly. During the 6-week treatment, the total scores of HAMD did not differ between the DCS and placebo groups. The results remained consistent when stratified by disorder. A mixed model analysis indicated that the DCS group exhibited lower scores of HAMD item 3 (suicide) compared with the placebo group throughout the follow-up period (p = 0.01). A superior maintenance of the antisuicidal effect of ketamine was observed in the DCS group than in the placebo group. DCS may be therapeutically beneficial for patients with TRD who responded to ketamine infusion but have a residual suicidal risk.",2019,A superior maintenance of the antisuicidal effect of ketamine was observed in the DCS group than in the placebo group.,"['32 patients with TRD (17 with major depression and 15 with bipolar depression', 'infusion with an average 17-item Hamilton Depression Rating Scale (HAMD) score of 9.47\u2009±\u20094.11 at baseline', 'patients with treatment-resistant depression who responded to low-dose ketamine infusion', 'patients with TRD']","['DCS treatment', 'placebo', 'DCS', 'ketamine', 'D-cycloserine (DCS', 'D-cycloserine']","['total scores of HAMD', 'Depression symptoms', 'HAMD item 3 (suicide']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0005587', 'cui_str': 'Depression, Bipolar'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C2063866', 'cui_str': 'Refractory Depression'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0010590', 'cui_str': 'Cycloserine'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0852733', 'cui_str': 'Suicide (accomplished)'}]",,0.143272,A superior maintenance of the antisuicidal effect of ketamine was observed in the DCS group than in the placebo group.,"[{'ForeName': 'Mu-Hong', 'Initials': 'MH', 'LastName': 'Chen', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Chih-Ming', 'Initials': 'CM', 'LastName': 'Cheng', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Ralitza', 'Initials': 'R', 'LastName': 'Gueorguieva', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Wei-Chen', 'Initials': 'WC', 'LastName': 'Lin', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Cheng-Ta', 'Initials': 'CT', 'LastName': 'Li', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Chen-Jee', 'Initials': 'CJ', 'LastName': 'Hong', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Pei-Chi', 'Initials': 'PC', 'LastName': 'Tu', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Ya-Mei', 'Initials': 'YM', 'LastName': 'Bai', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Shih-Jen', 'Initials': 'SJ', 'LastName': 'Tsai', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Krystal', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. john.krystal@yale.edu.'}, {'ForeName': 'Tung-Ping', 'Initials': 'TP', 'LastName': 'Su', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. tomsu0402@gmail.com.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0480-y'] 218,31611635,A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer.,"BACKGROUND Monotherapy with immune checkpoint inhibitors has generally been unsuccessful in men with advanced prostate cancer. Preclinical data support the notion that cryotherapy may improve immune-mediated and anti-tumor responses. The objective of this study was to assess the safety and feasibility of whole-prostate gland cryotherapy combined with pembrolizumab and androgen deprivation in men with oligometastatic hormone-sensitive prostate cancer. METHODS This single-institution, pilot trial recruited 12 patients with newly diagnosed oligometastatic prostate cancer between 2015 and 2016. Patients underwent whole-prostate cryoablation combined with short-term androgen deprivation (eight months) and pembrolizumab (6 doses). The primary clinical endpoints were the number of patients with a PSA level of <0.6 ng/mL at one year and the frequency of adverse events. Other outcome measures included progression-free survival and systemic therapy-free survival. Exploratory analyses included PD-L1 protein expression. RESULTS Forty two percent (5/12) of patients had a PSAs of <0.6 ng/mL at one year though only 2 of these patients had recovered their testosterone at this time point. Median progression-free survival was 14 months, and median systemic therapy-free survival was 17.5 months. PD-L1 expression was not detectable by IHC in patients with evaluable tissue. All adverse events were grade ≤2, and there were no apparent complications from cryotherapy. CONCLUSIONS Whole-prostate cryoablation combined with short-term androgen deprivation and pembrolizumab treatment was well tolerated and no safety concerns were observed in men with oligometastatic prostate cancer. Though local disease appeared effectively treated in the majority of men, the regimen only infrequency led to sustained disease control following testosterone recovery.",2020,"All adverse events were grade ≤2, and there were no apparent complications from cryotherapy. ","['12 patients with newly diagnosed oligometastatic prostate cancer between 2015 and 2016', 'men with oligometastatic hormone-sensitive prostate cancer', 'patients with evaluable tissue', 'men with newly diagnosed oligometastatic hormone-sensitive prostate cancer', 'men with advanced prostate cancer', 'men with oligometastatic prostate cancer']","['pembrolizumab plus prostatic cryotherapy', 'whole-prostate cryoablation combined with short-term androgen deprivation (eight months) and pembrolizumab', 'whole-prostate gland cryotherapy combined with pembrolizumab and androgen deprivation', 'Whole-prostate cryoablation combined with short-term androgen deprivation and pembrolizumab']","['frequency of adverse events', 'Median progression-free survival', 'tolerated and no safety concerns', 'safety and feasibility', 'progression-free survival and systemic therapy-free survival', 'number of patients with a PSA level', 'median systemic therapy-free survival', 'PD-L1 protein expression', 'PD-L1 expression']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0376358', 'cui_str': 'Prostate Cancer'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C4302896', 'cui_str': 'Hormone sensitive prostate cancer (disorder)'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}]","[{'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C4551716', 'cui_str': 'Cryotherapy'}, {'cui': 'C0843747', 'cui_str': 'Prostate cryoablation'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0002844', 'cui_str': 'Androgenic Compounds'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0201544', 'cui_str': 'Prostate specific antigen measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C3854321', 'cui_str': 'Expression'}]",,0.114774,"All adverse events were grade ≤2, and there were no apparent complications from cryotherapy. ","[{'ForeName': 'Ashley E', 'Initials': 'AE', 'LastName': 'Ross', 'Affiliation': 'Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA. ashley.ross@usoncology.com.'}, {'ForeName': 'Paula J', 'Initials': 'PJ', 'LastName': 'Hurley', 'Affiliation': 'Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Phuoc T', 'Initials': 'PT', 'LastName': 'Tran', 'Affiliation': 'The Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Steven P', 'Initials': 'SP', 'LastName': 'Rowe', 'Affiliation': 'The Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Benzon', 'Affiliation': 'Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.'}, {'ForeName': ""Tanya O'"", 'Initials': 'TO', 'LastName': 'Neal', 'Affiliation': 'The Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Chapman', 'Affiliation': 'The Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Rana', 'Initials': 'R', 'LastName': 'Harb', 'Affiliation': 'The Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Yelena', 'Initials': 'Y', 'LastName': 'Milman', 'Affiliation': 'The Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Bruce J', 'Initials': 'BJ', 'LastName': 'Trock', 'Affiliation': 'Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Charles G', 'Initials': 'CG', 'LastName': 'Drake', 'Affiliation': 'The Department of Medicine, Columbia University, New York, NY, USA.'}, {'ForeName': 'Emmanuel S', 'Initials': 'ES', 'LastName': 'Antonarakis', 'Affiliation': 'Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.'}]",Prostate cancer and prostatic diseases,['10.1038/s41391-019-0176-8'] 219,32305477,"Lower Ischemic Heart Disease Diagnostic Costs With Treadmill Stress CMR Versus SPECT: A Multicenter, Randomized Trial.",,2020,,[],['Treadmill Stress CMR vs. SPECT'],[],[],"[{'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0006802', 'cui_str': 'Cameroon'}, {'cui': 'C0040399', 'cui_str': 'Single photon emission computerized tomography'}]",[],,0.0703892,,"[{'ForeName': 'Subha V', 'Initials': 'SV', 'LastName': 'Raman', 'Affiliation': ''}, {'ForeName': 'Rory', 'Initials': 'R', 'LastName': 'Hachamovitch', 'Affiliation': ''}, {'ForeName': 'Debbie', 'Initials': 'D', 'LastName': 'Scandling', 'Affiliation': ''}, {'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Mazur', 'Affiliation': ''}, {'ForeName': 'Raymond Y', 'Initials': 'RY', 'LastName': 'Kwong', 'Affiliation': ''}, {'ForeName': 'Timothy C', 'Initials': 'TC', 'LastName': 'Wong', 'Affiliation': ''}, {'ForeName': 'Erik B', 'Initials': 'EB', 'LastName': 'Schelbert', 'Affiliation': ''}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Moore', 'Affiliation': ''}, {'ForeName': 'Vien', 'Initials': 'V', 'LastName': 'Truong', 'Affiliation': ''}, {'ForeName': 'Orlando P', 'Initials': 'OP', 'LastName': 'Simonetti', 'Affiliation': ''}]",JACC. Cardiovascular imaging,['10.1016/j.jcmg.2020.02.020'] 220,32305492,Probiotics and fructo-oligosaccharide intervention modulate the microbiota-gut brain axis to improve autism spectrum reducing also the hyper-serotonergic state and the dopamine metabolism disorder.,"The prevalence of autism spectrum disorders (ASD) is increasing, but its etiology remains elusive and hence an effective treatment is not available. Previous research conducted on animal models suggests that microbiota-gut-brain axis may contribute to ASD pathology and more human research is needed. This study was divided into two stages,.At the discovery stage, we compared the differences in gut microbiota profiles (using 16S rRNA sequencing), fecal SCFAs (using GC-MS) and plasma neurotransmitters (using UHPLC-MS/MS) of 26 children with ASD and 24 normal children. All 26 children with ASD participated in the intervention stage, and we measured the gut microbiota profiles, SCFAs and neurotransmitters before and after probiotics + FOS (n = 16) or placebo supplementation (n = 10). We found that gut microbiota was in a state of dysbiosis and significantly lower levels of Bifidobacteriales and Bifidobacterium longum were observed at the discovery stage in children with ASD. An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (Clostridium) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms. Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD. Interestingly, the above SCFAs in children with autism significantly elevated after probiotics + FOS intervention and approached those in the control group. In addition, our data demonstrated that decreased serotonin and increased homovanillic acid emerged after probiotics + FOS intervention. However, the above-mentioned changes did not appear in the placebo group for ASD children. Probiotics + FOS intervention can modulate gut microbiota, SCFAs and serotonin in association with improved ASD symptoms, including a hyper-serotonergic state and dopamine metabolism disorder.",2020,"Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.","['26 children with ASD', '26 children with ASD and 24 normal children', 'autism', 'autism spectrum disorders (ASD', 'children with ASD']","['Probiotics and fructo-oligosaccharide intervention', 'placebo supplementation', 'Probiotics\u2009+\u2009FOS intervention', 'placebo']","['gut microbiota profiles (using 16S rRNA sequencing), fecal SCFAs (using GC-MS) and plasma neurotransmitters', 'hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid', 'severity of autism and gastrointestinal symptoms', 'acetic acid, propionic acid and butyric acid', 'homovanillic acid', 'beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (Clostridium']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}]","[{'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0873033', 'cui_str': 'fructooligosaccharide'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0087140', 'cui_str': 'v-fos Oncogenes'}]","[{'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0035701', 'cui_str': 'Ribosomal RNA'}, {'cui': 'C0162801', 'cui_str': 'Analysis, Sequence'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0015691', 'cui_str': 'Short chain fatty acid'}, {'cui': 'C0024868', 'cui_str': 'Chromatography, Gas-Mass Spectrometry'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0027908', 'cui_str': 'Neurotransmitter'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0025517', 'cui_str': 'Metabolic disease'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0019903', 'cui_str': 'Homovanillic acid'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0000983', 'cui_str': 'Acetic Acid'}, {'cui': 'C0033482', 'cui_str': 'Propanoic Acids'}, {'cui': 'C0006523', 'cui_str': 'Butanoic Acids'}, {'cui': 'C0004611', 'cui_str': 'Bacterium'}, {'cui': 'C1037103', 'cui_str': 'Bifidobacteriales'}, {'cui': 'C1564227', 'cui_str': 'Longum'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0450254', 'cui_str': 'Pathogenic organism'}, {'cui': 'C0009054', 'cui_str': 'Clostridium'}]",26.0,0.0229384,"Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.","[{'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ""Shandong Children's Microbiome Center, Research Institute of Pediatrics, Qilu Children's Hospital of Shandong University, Jinan, Shandong, China; State Key Laboratory of Microbial Technology, Shandong University, Qingdao, Shandong, China. Electronic address: wangyingying67@163.com.""}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': ""Institute of Child Health Care, Qilu Children's Hospital of Shandong University, Jinan, Shandong, China. Electronic address: 754520623@qq.com.""}, {'ForeName': 'Jun-Jie', 'Initials': 'JJ', 'LastName': 'Yang', 'Affiliation': 'College of Life Science, Qilu Normal University, Jinan, Shandong, China. Electronic address: microbiota@foxmail.com.'}, {'ForeName': 'Dong-Mei', 'Initials': 'DM', 'LastName': 'Zhao', 'Affiliation': ""Institute of Child Health Care, Qilu Children's Hospital of Shandong University, Jinan, Shandong, China. Electronic address: jnzhaodongmei@163.com.""}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Chen', 'Affiliation': ""Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Key Laboratory of Big Data-Based Precision Medicine (Beihang University), the Ministry of Industry and Information Technology of the People's Republic of China, Beijing, China. Electronic address: binchen23@163.com.""}, {'ForeName': 'Guo-Qing', 'Initials': 'GQ', 'LastName': 'Zhang', 'Affiliation': 'Bio-Med Big Data Center, CAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institute of Nutrition and Health, Shanghai, China. Electronic address: gqzhang@picb.ac.cn.'}, {'ForeName': 'Shuo', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China; CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China. Electronic address: shuo.chen1@siat.ac.cn.'}, {'ForeName': 'Rui-Fang', 'Initials': 'RF', 'LastName': 'Cao', 'Affiliation': 'Bio-Med Big Data Center, CAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institute of Nutrition and Health, Shanghai, China. Electronic address: caoruifang@picb.ac.cn.'}, {'ForeName': 'Han', 'Initials': 'H', 'LastName': 'Yu', 'Affiliation': ""Shandong Children's Microbiome Center, Research Institute of Pediatrics, Qilu Children's Hospital of Shandong University, Jinan, Shandong, China. Electronic address: yuhan_1991@163.com.""}, {'ForeName': 'Chang-Ying', 'Initials': 'CY', 'LastName': 'Zhao', 'Affiliation': ""Shandong Children's Microbiome Center, Research Institute of Pediatrics, Qilu Children's Hospital of Shandong University, Jinan, Shandong, China. Electronic address: 1163310981@qq.com.""}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Zhao', 'Affiliation': ""Shandong Children's Microbiome Center, Research Institute of Pediatrics, Qilu Children's Hospital of Shandong University, Jinan, Shandong, China. Electronic address: 1295163749@qq.com.""}, {'ForeName': 'Yong-Sheng', 'Initials': 'YS', 'LastName': 'Ge', 'Affiliation': ""Shandong Children's Microbiome Center, Research Institute of Pediatrics, Qilu Children's Hospital of Shandong University, Jinan, Shandong, China. Electronic address: 1305358934@qq.com.""}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': ""Shandong Children's Microbiome Center, Research Institute of Pediatrics, Qilu Children's Hospital of Shandong University, Jinan, Shandong, China. Electronic address: liuyi-ly@126.com.""}, {'ForeName': 'Le-Hai', 'Initials': 'LH', 'LastName': 'Zhang', 'Affiliation': ""Shandong Children's Microbiome Center, Research Institute of Pediatrics, Qilu Children's Hospital of Shandong University, Jinan, Shandong, China. Electronic address: zlh6813@126.com.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Hu', 'Affiliation': 'State Key Laboratory of Microbial Technology, Shandong University, Qingdao, Shandong, China. Electronic address: hw_1@sdu.edu.cn.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': ""Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Key Laboratory of Big Data-Based Precision Medicine (Beihang University), the Ministry of Industry and Information Technology of the People's Republic of China, Beijing, China; Microbiome Research Center, Shandong Institutes for Food and Drug Control, Shandong Institute of Industrial Technology for Health Sciences and Precision Medicine, Jinan, Shandong, China. Electronic address: microbiome@foxmail.com.""}, {'ForeName': 'Zhong-Tao', 'Initials': 'ZT', 'LastName': 'Gai', 'Affiliation': ""Shandong Children's Microbiome Center, Research Institute of Pediatrics, Qilu Children's Hospital of Shandong University, Jinan, Shandong, China. Electronic address: gzt@etyy.com.""}]",Pharmacological research,['10.1016/j.phrs.2020.104784'] 221,32305572,"Challenging the challenge: A randomized controlled trial evaluating the inflammatory response and pain perception of healthy volunteers after single-dose LPS administration, as a potential model for inflammatory pain in early-phase drug development.","BACKGROUND AND AIMS Following an infection, cytokines not only regulate the acute immune response, but also contribute to symptoms such as inflammatory hyperalgesia. We aimed to characterize the acute inflammatory response induced by a human endotoxemia model, and its effect on pain perception using evoked pain tests in two different dose levels. We also attempted to determine whether combining a human endotoxemia challenge with measurement of pain thresholds in healthy subjects could serve as a model to study drug effects on inflammatory pain. METHODS AND RESULTS This was a placebo-controlled, randomized, cross-over study in 24 healthy males. Twelve subjects were administered a bolus of 1 ng/kg LPS intravenously, and twelve 2 ng/kg LPS. Before days of placebo/LPS administration, subjects completed a full study day without study drug administration, but with identical pain threshold testing. Blood sampling and evoked pain tests (electrical burst and -stair, heat, pressure, and cold pressor test) were performed pre-dose and at frequent intervals up to 10hr post-dose. Data were analysed with a repeated-measures ANCOVA. For both dose levels, LPS induced an evident acute inflammatory response, but did not significantly affect any of the pain modalities. In a post-hoc analysis, lowering of pain thresholds was observed in the first 3 h after dosing, corresponding with the peak of the acute inflammatory response around 1-3 h post-dose. CONCLUSION Mild acute systemic inflammation, as induced by 1 ng/kg and 2 ng/kg LPS intravenous administration, did not significantly change pain thresholds in this study. The endotoxemia model in combination with evoked pain tests is not suitable to study acute inflammatory hyperalgesia in healthy males.",2020,"For both dose levels, LPS induced an evident acute inflammatory response, but did not significantly affect any of the pain modalities.","['healthy volunteers', '24 healthy males', 'healthy males', 'healthy subjects']","['placebo/LPS', 'placebo']","['change pain thresholds', 'Blood sampling and evoked pain tests (electrical burst and -stair, heat, pressure, and cold pressor test', 'lowering of pain thresholds', 'pain modalities', 'acute inflammatory response']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0005834', 'cui_str': 'Collection of blood specimen for laboratory'}, {'cui': 'C1444748', 'cui_str': 'Evoked'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0444689', 'cui_str': 'Cold pressor test'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}]",24.0,0.300045,"For both dose levels, LPS induced an evident acute inflammatory response, but did not significantly affect any of the pain modalities.","[{'ForeName': 'H J', 'Initials': 'HJ', 'LastName': 'Hijma', 'Affiliation': 'Centre for Human Drug Research, 2333 CL Leiden, The Netherlands; Leiden University Medical Centre, 2333 ZA Leiden, The Netherlands. Electronic address: hhijma@chdr.nl.'}, {'ForeName': 'L M', 'Initials': 'LM', 'LastName': 'Moss', 'Affiliation': 'Centre for Human Drug Research, 2333 CL Leiden, The Netherlands; Leiden University Medical Centre, 2333 ZA Leiden, The Netherlands. Electronic address: lmoss@chdr.nl.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Gal', 'Affiliation': 'Centre for Human Drug Research, 2333 CL Leiden, The Netherlands; Leiden University Medical Centre, 2333 ZA Leiden, The Netherlands. Electronic address: pgal@chdr.nl.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Ziagkos', 'Affiliation': 'Centre for Human Drug Research, 2333 CL Leiden, The Netherlands. Electronic address: dziagkos@chdr.nl.'}, {'ForeName': 'M L', 'Initials': 'ML', 'LastName': 'de Kam', 'Affiliation': 'Centre for Human Drug Research, 2333 CL Leiden, The Netherlands. Electronic address: mdekam@chdr.nl.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Moerland', 'Affiliation': 'Centre for Human Drug Research, 2333 CL Leiden, The Netherlands; Leiden University Medical Centre, 2333 ZA Leiden, The Netherlands. Electronic address: mmoerland@chdr.nl.'}, {'ForeName': 'G J', 'Initials': 'GJ', 'LastName': 'Groeneveld', 'Affiliation': 'Centre for Human Drug Research, 2333 CL Leiden, The Netherlands; Leiden University Medical Centre, 2333 ZA Leiden, The Netherlands. Electronic address: GGroeneveld@chdr.nl.'}]","Brain, behavior, and immunity",['10.1016/j.bbi.2020.04.033'] 222,32302083,One-stage versus 2-stage bilateral total joint arthroplasty: a matched cohort study.,"Background Patients with bilateral end-stage hip or knee arthritis want to know if it is safe to have bilateral surgery under a single anesthetic, to restore their quality of life as quickly as possible. The purpose of this study was to assess if there is an increase in the rate of postoperative medical adverse events, length of stay (LOS), blood transfusion rate and 30-day readmission rate among patients who undergo 1-stage bilateral total hip arthroplasty (BTHA) and 1-stage bilateral total knee arthroplasty (BTKA) compared with patients who undergo 2-stage BTHA and BTKA. Methods Our study cohorts included patients who underwent BTHA and BTKA between Apr. 1, 2009, and Jan. 31, 2016, in Alberta, Canada. To minimize selection bias associated with our retrospective study design, we matched patients who underwent 1-stage BTHA and BTKA with patients with patients who underwent 2-stage BTHA and BTKA, respectively, for age, sex and number of presurgical risk factors using propensity score in a matching ratio of 1:1. Results Our study included 1645 patients who underwent BTHA and 4125 patients who underwent BTKA. We matched 195 patients who underwent 1-stage BTHA and 302 patients who underwent 1-stage BTKA with patients who underwent 2-stage BTHA and BTKA, respectively. There was no significant difference in postoperative medical adverse events between the 1-stage and 2-stage matched cohort groups for both BTHA (adjusted odds ratio [OR] 1.3, 95% confidence interval [CI] 0.3-4.9) and BTKA (adjusted OR 0.9, 95% CI 0.3-2.6). There was no difference in inpatient, 30- or 90-day mortality between the 2 groups for BTHA or BTKA. Patients who underwent 1-stage BTHA and BTKA had a shorter acute length of stay but increased total length of stay (acute care and rehabilitation unit) and were less likely to be discharged home postoperatively. One-stage BTHA and BTKA were associated with higher odds of blood transfusion than 2-stage BTHA and BTKA. The 30-day readmission rate was significantly lower for 1-stage BTHA than for the 2-stage BTHA matched cohort (adjusted OR 0.3, 95% CI 0.1-0.8), whereas there was no difference in the 30-day readmission rate (adjusted OR 0.6, 95% CI 0.2-1.7) between the 1-stage and 2-stage BTKA matched cohorts. Finally, operating room time was significantly lower for 1-stage BTHA (49.6 min less) and 1-stage BTKA (66.7 min less) than for the 2-stage arthroplasty procedures. Conclusion Healthy patients who undergo 1-stage BTHA and BTKA have postoperative medical complication rates comparable to those of patients who undergo 2-stage procedures with the additional benefits of a shorter acute length of stay, but they do have a higher risk of blood transfusion and are less likely to be discharged directly home from the acute care hospital. A multicentre randomized controlled trial on this topic is currently being condcuted by the Canadian Arthroplasty Society.",2020,"There was no difference in inpatient, 30- or 90-day mortality between the 2 groups for BTHA or BTKA.","['\n\n\nPatients with bilateral end-stage hip or knee arthritis', 'patients who underwent BTHA and BTKA between Apr. 1, 2009, and Jan. 31, 2016, in Alberta, Canada', 'Canadian Arthroplasty Society', '195 patients who underwent 1-stage BTHA and 302 patients who underwent 1-stage BTKA with patients who underwent 2-stage BTHA and BTKA, respectively', 'matched patients who underwent 1-stage BTHA and BTKA with patients with patients who underwent 2-stage BTHA and BTKA, respectively, for age, sex and number of presurgical risk factors using propensity score in a matching ratio of 1:1', '1645 patients who underwent BTHA and 4125 patients who underwent BTKA', 'patients who undergo 1-stage bilateral total hip arthroplasty (BTHA) and 1-stage bilateral total knee arthroplasty (BTKA) compared with patients who undergo 2-stage BTHA and BTKA']","['2-stage bilateral total joint arthroplasty', '1-stage BTHA and BTKA']","['90-day mortality', 'shorter acute length of stay', '30-day readmission rate', 'postoperative medical adverse events', 'total length of stay (acute care and rehabilitation unit', 'rate of postoperative medical adverse events, length of stay (LOS), blood transfusion rate and 30-day readmission rate', 'operating room time', 'postoperative medical complication rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0240111', 'cui_str': 'Arthritis of knee'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C2004459', 'cui_str': 'Abdominoperineal resection'}, {'cui': 'C0001914', 'cui_str': 'Alberta'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0003893', 'cui_str': 'Arthroplasty'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C4517624', 'cui_str': '195'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C2718044', 'cui_str': 'Propensity Score'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]","[{'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003893', 'cui_str': 'Arthroplasty'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0030700', 'cui_str': 'Thirty Day Readmission'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0029064', 'cui_str': 'Operating theatre'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",1645.0,0.107084,"There was no difference in inpatient, 30- or 90-day mortality between the 2 groups for BTHA or BTKA.","[{'ForeName': 'Raghav', 'Initials': 'R', 'LastName': 'Saini', 'Affiliation': 'From the Cumming School of Medicine, University of Calgary, Calgary, Alta. (Saini, Powell, Sharma, Puloski, Mahdavi, Johnston); and the Alberta Bone and Joint Health Institute, Calgary, Alta. (Smith).'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Powell', 'Affiliation': 'From the Cumming School of Medicine, University of Calgary, Calgary, Alta. (Saini, Powell, Sharma, Puloski, Mahdavi, Johnston); and the Alberta Bone and Joint Health Institute, Calgary, Alta. (Smith).'}, {'ForeName': 'Rajrishi', 'Initials': 'R', 'LastName': 'Sharma', 'Affiliation': 'From the Cumming School of Medicine, University of Calgary, Calgary, Alta. (Saini, Powell, Sharma, Puloski, Mahdavi, Johnston); and the Alberta Bone and Joint Health Institute, Calgary, Alta. (Smith).'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Puloski', 'Affiliation': 'From the Cumming School of Medicine, University of Calgary, Calgary, Alta. (Saini, Powell, Sharma, Puloski, Mahdavi, Johnston); and the Alberta Bone and Joint Health Institute, Calgary, Alta. (Smith).'}, {'ForeName': 'Saboura', 'Initials': 'S', 'LastName': 'Mahdavi', 'Affiliation': 'From the Cumming School of Medicine, University of Calgary, Calgary, Alta. (Saini, Powell, Sharma, Puloski, Mahdavi, Johnston); and the Alberta Bone and Joint Health Institute, Calgary, Alta. (Smith).'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Smith', 'Affiliation': 'From the Cumming School of Medicine, University of Calgary, Calgary, Alta. (Saini, Powell, Sharma, Puloski, Mahdavi, Johnston); and the Alberta Bone and Joint Health Institute, Calgary, Alta. (Smith).'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Johnston', 'Affiliation': 'From the Cumming School of Medicine, University of Calgary, Calgary, Alta. (Saini, Powell, Sharma, Puloski, Mahdavi, Johnston); and the Alberta Bone and Joint Health Institute, Calgary, Alta. (Smith).'}]",Canadian journal of surgery. Journal canadien de chirurgie,['10.1503/cjs.001019'] 223,31201669,A randomized controlled trial and pragmatic analysis of the effects of volunteering on the health and well-being of older people.,"BACKGROUND Volunteering among older people has the potential to deliver health benefits to the individual, along with economic and social benefits to society. However, it is not clear whether healthier people are more likely to engage in volunteering, whether volunteering improves health, or the extent to which the relationship may be reciprocal. There is an identified need for longitudinal work, especially in the form of randomized controlled trials, to establish causality. AIMS To assess the effects of commencing volunteering among older non-volunteers utilizing a randomized controlled trial approach involving per-protocol and pragmatic analyses. METHODS Of the 445 Australians aged 60 + years who participated in the study, 201 were assigned to an intervention arm that required them to participate in a minimum of 1 h/week of formal volunteering in a position of their choice. The remaining participants were assigned to a control condition and asked to continue their lives as usual, but were not discouraged from commencing volunteering. RESULTS Across the assessed physical, psychological, and social variables, a significant difference in sit-to-stand scores was found in both the per-protocol and pragmatic analyses, and a further significant difference in the fast pace walk was identified in the pragmatic analyses. CONCLUSION The results provide some support for policies and programs designed to encourage older people to engage in volunteering to maintain or improve their health. TRIAL REGISTRATION Australian and New Zealand Clinical Trials Registry ACTRN12615000091505.",2020,"Across the assessed physical, psychological, and social variables, a significant difference in sit-to-stand scores was found in both the per-protocol and pragmatic analyses, and a further significant difference in the fast pace walk was identified in the pragmatic analyses. ","['older people', 'Of the 445 Australians aged 60\u2009+ years who participated in the study', 'older non-volunteers', 'Australian and New Zealand']",[],"['sit-to-stand scores', 'physical, psychological, and social variables']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}]",[],"[{'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C3888057', 'cui_str': 'Stand'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}]",445.0,0.1005,"Across the assessed physical, psychological, and social variables, a significant difference in sit-to-stand scores was found in both the per-protocol and pragmatic analyses, and a further significant difference in the fast pace walk was identified in the pragmatic analyses. ","[{'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Pettigrew', 'Affiliation': 'School of Psychology, Curtin University, Kent St, Bentley, WA, 6102, Australia. simone.pettigrew@curtin.edu.au.'}, {'ForeName': 'Michelle I', 'Initials': 'MI', 'LastName': 'Jongenelis', 'Affiliation': 'School of Psychology, Curtin University, Kent St, Bentley, WA, 6102, Australia.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Jackson', 'Affiliation': 'School of Human Sciences (Exercise and Sports Science), University of Western Australia, Perth, Australia.'}, {'ForeName': 'Jeni', 'Initials': 'J', 'LastName': 'Warburton', 'Affiliation': 'La Trobe Rural Health School, La Trobe University, Melbourne, Australia.'}, {'ForeName': 'Robert U', 'Initials': 'RU', 'LastName': 'Newton', 'Affiliation': 'School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.'}]",Aging clinical and experimental research,['10.1007/s40520-019-01241-3'] 224,31443102,Colonization by B. infantis EVC001 modulates enteric inflammation in exclusively breastfed infants.,"BACKGROUND Infant gut dysbiosis, often associated with low abundance of bifidobacteria, is linked to impaired immune development and inflammation-a risk factor for increased incidence of several childhood diseases. We investigated the impact of B. infantis EVC001 colonization on enteric inflammation in a subset of exclusively breastfed term infants from a larger clinical study. METHODS Stool samples (n = 120) were collected from infants randomly selected to receive either 1.8 × 10 10 CFU B. infantis EVC001 daily for 21 days (EVC001) or breast milk alone (controls), starting at day 7 postnatal. The fecal microbiome was analyzed using 16S ribosomal RNA, proinflammatory cytokines using multiplexed immunoassay, and fecal calprotectin using ELISA at three time points: days 6 (Baseline), 40, and 60 postnatal. RESULTS Fecal calprotectin concentration negatively correlated with Bifidobacterium abundance (P < 0.0001; ρ = -0.72), and proinflammatory cytokines correlated with Clostridiaceae and Enterobacteriaceae, yet negatively correlated with Bifidobacteriaceae abundance. Proinflammatory cytokines were significantly lower in EVC001-fed infants on days 40 and 60 postnatally compared to baseline and compared to control infants. CONCLUSION Our findings indicate that gut dysbiosis (absence of B. infantis) is associated with increased intestinal inflammation. Early addition of EVC001 to diet represents a novel strategy to prevent enteric inflammation during a critical developmental phase.",2019,"Proinflammatory cytokines were significantly lower in EVC001-fed infants on days 40 and 60 postnatally compared to baseline and compared to control infants. ","['exclusively breastfed infants', 'Stool samples (n\u2009=\u2009120']","['CFU B. infantis EVC001 daily for 21 days (EVC001) or breast milk alone (controls), starting at day 7 postnatal']","['Proinflammatory cytokines', 'intestinal inflammation', 'fecal microbiome', 'Fecal calprotectin concentration', 'enteric inflammation', 'proinflammatory cytokines']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1550661', 'cui_str': 'Feces specimen'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0026140', 'cui_str': 'Breast Milk'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0443281', 'cui_str': 'Postnatal (qualifier value)'}]","[{'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C3889047', 'cui_str': 'Intestinal inflammation'}, {'cui': 'C1956108', 'cui_str': 'Microbiome'}, {'cui': 'C1964053', 'cui_str': 'Faecal calprotectin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",1010.0,0.0603489,"Proinflammatory cytokines were significantly lower in EVC001-fed infants on days 40 and 60 postnatally compared to baseline and compared to control infants. ","[{'ForeName': 'Bethany M', 'Initials': 'BM', 'LastName': 'Henrick', 'Affiliation': 'Evolve Biosystems, Inc, Davis, CA, USA. bhenrick2@unl.edu.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Chew', 'Affiliation': 'Evolve Biosystems, Inc, Davis, CA, USA.'}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'Casaburi', 'Affiliation': 'Evolve Biosystems, Inc, Davis, CA, USA.'}, {'ForeName': 'Heather K', 'Initials': 'HK', 'LastName': 'Brown', 'Affiliation': 'Evolve Biosystems, Inc, Davis, CA, USA.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Frese', 'Affiliation': 'Evolve Biosystems, Inc, Davis, CA, USA.'}, {'ForeName': 'You', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Morrison Microscopy Core Research Facility, University of Nebraska, Lincoln, NE, USA.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Underwood', 'Affiliation': 'Foods for Health Institute, University of California Davis, Davis, CA, USA.'}, {'ForeName': 'Jennifer T', 'Initials': 'JT', 'LastName': 'Smilowitz', 'Affiliation': 'Foods for Health Institute, University of California Davis, Davis, CA, USA.'}]",Pediatric research,['10.1038/s41390-019-0533-2'] 225,31486777,Magnetic seizure therapy (MST) for major depressive disorder.,"Electroconvulsive therapy (ECT) is effective for major depressive disorder (MDD) but its effects on memory limit its widespread use. Magnetic seizure therapy (MST) is a potential alternative to ECT that may not adversely affect memory. In the current trial, consecutive patients with MDD consented to receive MST applied over the prefrontal cortex according to an open-label protocol. Depressive symptoms and cognition were assessed prior to, during and at the end of treatment. Patients were treated two to three times per week with high-frequency MST (i.e., 100 Hz) (N = 24), medium frequency MST (i.e., 60 or 50 Hz) (N = 26), or low-frequency MST (i.e., 25 Hz MST) (N = 36) using 100% stimulator output. One hundred and forty patients were screened; 86 patients with MDD received a minimum of eight treatments and were deemed to have an adequate course of MST; and 47 completed the trial per protocol, either achieving remission (i.e., 24-item Hamilton Rating Scale for Depression score <10 and a relative reduction of >60% at two consecutive assessments; n = 17) or received a maximum of 24 sessions (n = 30). High-frequency (100 Hz) MST produced the highest remission rate (33.3%). Performance on most cognitive measures remained stable, with the exception of significantly worsened recall consistency of autobiographical information and significantly improved brief visuospatial memory task performance. Under open conditions, MST led to clinically meaningful reduction in depressive symptoms in patients with MDD and produced minimal cognitive impairment. Future studies should compare MST and ECT under double-blind randomized condition.",2020,"Performance on most cognitive measures remained stable, with the exception of significantly worsened recall consistency of autobiographical information and significantly improved brief visuospatial memory task performance.","['consecutive patients with MDD consented to receive', 'major depressive disorder', 'One hundred and forty patients were screened; 86 patients with MDD received a minimum of eight treatments and were deemed to have an adequate course of MST; and 47 completed the trial per protocol, either achieving remission (i.e., 24-item Hamilton Rating Scale for Depression score <10 and a relative reduction of >60% at two consecutive assessments; n\u2009=\u200917) or received a maximum of 24 sessions (n\u2009=\u200930']","['Magnetic seizure therapy (MST', 'Electroconvulsive therapy (ECT', 'MST']","['depressive symptoms', 'High-frequency', 'Depressive symptoms and cognition', 'minimal cognitive impairment', 'highest remission rate', 'brief visuospatial memory task performance']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205411', 'cui_str': 'Adequate (qualifier value)'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C4545802', 'cui_str': 'HAM-D (Hamilton Rating Scale for Depression) score'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0024488', 'cui_str': 'Magnetics'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0013806', 'cui_str': 'Electroshock Therapy'}]","[{'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0205212', 'cui_str': 'High frequency (qualifier value)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C1291708', 'cui_str': 'Minimal cognitive impairment'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}]",140.0,0.0334955,"Performance on most cognitive measures remained stable, with the exception of significantly worsened recall consistency of autobiographical information and significantly improved brief visuospatial memory task performance.","[{'ForeName': 'Zafiris J', 'Initials': 'ZJ', 'LastName': 'Daskalakis', 'Affiliation': 'Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Jeff.Daskalakis@camh.ca.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Dimitrova', 'Affiliation': 'Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Shawn M', 'Initials': 'SM', 'LastName': 'McClintock', 'Affiliation': 'Neurocognitive Research Laboratory, Department of Psychiatry, University of Texas Southwestern Medical Center, and Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Yinming', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': 'Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Daphne', 'Initials': 'D', 'LastName': 'Voineskos', 'Affiliation': 'Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Tarek K', 'Initials': 'TK', 'LastName': 'Rajji', 'Affiliation': 'Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Goldbloom', 'Affiliation': 'Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Albert H C', 'Initials': 'AHC', 'LastName': 'Wong', 'Affiliation': 'Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Yuliya', 'Initials': 'Y', 'LastName': 'Knyahnytska', 'Affiliation': 'Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Benoit H', 'Initials': 'BH', 'LastName': 'Mulsant', 'Affiliation': 'Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Downar', 'Affiliation': 'Toronto General Hospital, University Health Network, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Paul B', 'Initials': 'PB', 'LastName': 'Fitzgerald', 'Affiliation': 'Epworth Centre for Innovation in Mental Health, Epworth Healthcare and Monash Alfred Psychiatry Research Centre, The Alfred and Monash University Central Clinical School, Commercial Rd Melbourne, VIC, Australia.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Blumberger', 'Affiliation': 'Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0515-4'] 226,32306694,[Intervention of Balint group on the emotional labor and job burnout of nurses in cardiology].,"Objective: To explore the effect of Balint group on the emotional labor and job burnout of nurses in cardiology, to provide a reference for improving the mental health of nurses in cardiology. Methods: A total of 78 pediatric nurses were randomly divided into observation group and control group by the random number table, 39 observation group nurses were received general nursing training and the intervention of 8- week Balint group, 39 control group nurses were not received anything intervention. Before and after the intervention of 8 weeks, The Emotional Labor Scale(ELS) and Maslach Burnout Inventory(MBI) were used to evaluate the emotional labor and job burnout of nurses. Results: The age of the nurses in the observation group was(26.3±2.7) years old, with 13 undergraduates and 26 specialists; the age of the nurses in the control group was (25.8±2.1) years old, with 14 undergraduates and 25 specialists. After 8 weeks intervention, the surface action score of ELS of observation group was significantly lower than the control group, the deep action and emotional display requirement scores of ELS of observation group were significantly higher than the control group, the differences were statistically significant ( P <0.05). The emotional exhaustion and depersonalization factor scores of MBI of observation group were significantly lower than the control group, the personal accomplishment factor score of MBI of observation group was significantly higher than the control group, the differences were statistically significant ( P <0.05). Conclusion: The use of Balint group may have contributed to improving emotional lab and job burnout of nurses in cardiology in a large degree.",2020,"The emotional exhaustion and depersonalization factor scores of MBI of observation group were significantly lower than the control group, the personal accomplishment factor score of MBI of observation group was significantly higher than the control group, the differences were statistically significant ( P <0.05). ","['The age of the nurses in the observation group was(26.3±2.7) years old, with 13 undergraduates and 26 specialists; the age of the nurses in the control group was (25.8±2.1) years old, with 14 undergraduates and 25 specialists', '78 pediatric nurses']","['observation group and control group by the random number table, 39 observation group nurses were received general nursing training and the intervention of 8- week Balint group, 39 control group nurses were not received anything intervention', 'emotional labor and job burnout of nurses in cardiology']","['emotional exhaustion and depersonalization factor scores of MBI', 'deep action and emotional display requirement scores of ELS', 'personal accomplishment factor score of MBI', 'surface action score of ELS']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030753', 'cui_str': 'Nursing, Pediatric'}]","[{'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0039224', 'cui_str': 'Table'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0022864', 'cui_str': 'Labor'}, {'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0011551', 'cui_str': 'Depersonalization'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2985547', 'cui_str': 'Scintimammography'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0205148', 'cui_str': 'Surface'}]",78.0,0.0167135,"The emotional exhaustion and depersonalization factor scores of MBI of observation group were significantly lower than the control group, the personal accomplishment factor score of MBI of observation group was significantly higher than the control group, the differences were statistically significant ( P <0.05). ","[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Lu', 'Affiliation': 'Tianjin Medical College, Tianjin 300222, China.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Lan', 'Affiliation': 'Tianjin Medical College, Tianjin 300222, China.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Zhang', 'Affiliation': 'Tianjin Chest Hospital, Tianjin 300222, China.'}]",Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases,['10.3760/cma.j.cn121094-20190403-00132'] 227,31634898,A multipredictor model to predict the conversion of mild cognitive impairment to Alzheimer's disease by using a predictive nomogram.,"Predicting the probability of converting from mild cognitive impairment (MCI) to Alzheimer's disease (AD) is still a challenging task. This study aims at providing a personalized MCI-to-AD conversion estimation by using a multipredictor nomogram that integrates neuroimaging features, cerebrospinal fluid (CSF) biomarker, and clinical assessments. To do so, 290 MCI patients were collected from the Alzheimer's Disease Neuroimaging Initiative (ADNI), of whom 76 has converted to AD and 214 remained with MCI. All subjects were randomly divided into a primary and validation cohort. Radiomics signature (Rad-sig) was obtained based on 17 cerebral cortex features selected by using Least Absolute Shrinkage and Selection Operator (LASSO) algorithm. Clinical factors and amyloid-beta peptide (Aβ) concentration were selected by using Spearman correlation between the converted and not-converted patients. Then, a nomogram that combines image features, clinical factor, and Aβ concentration was constructed and validated. Furthermore, we explored the associations between various predictors from the macro- to the microperspective by assessing gene expression patterns. Our results showed that the multipredictor nomogram (C-index 0.978 and 0.956 in both cohorts, respectively) outperformed the nomogram using either Rad-sig or Aβ concentration as individual predictors. Significant associations were found between neuropsychological scores, cerebral cortex features, Aβ levels, and underlying gene pathways. Our study may have a clinical impact as a powerful predictive tool for predicting the conversion probability of MCI and providing associations between cognitive impairment, structural changes, Aβ levels, and underlying biological patterns from the macro- to the microperspective.",2020,"Significant associations were found between neuropsychological scores, cerebral cortex features, Aβ levels, and underlying gene pathways.","[""290 MCI patients were collected from the Alzheimer's Disease Neuroimaging Initiative (ADNI), of whom 76 has converted to AD and 214 remained with MCI""]",[],"['neuropsychological scores, cerebral cortex features, Aβ levels, and underlying gene pathways', 'Clinical factors and amyloid-beta peptide (Aβ) concentration']","[{'cui': 'C0560005', 'cui_str': 'millicurie'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C0424093', 'cui_str': 'Initiative (observable entity)'}]",[],"[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0007776', 'cui_str': 'Cortical Plate'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0017337', 'cui_str': 'Genes'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0078939', 'cui_str': ""Alzheimer's ABP""}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",,0.0173736,"Significant associations were found between neuropsychological scores, cerebral cortex features, Aβ levels, and underlying gene pathways.","[{'ForeName': 'Kexin', 'Initials': 'K', 'LastName': 'Huang', 'Affiliation': ""School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, 710071, P. R. China.""}, {'ForeName': 'Yanyan', 'Initials': 'Y', 'LastName': 'Lin', 'Affiliation': ""School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, 710071, P. R. China.""}, {'ForeName': 'Lifeng', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': ""School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, 710071, P. R. China.""}, {'ForeName': 'Yubo', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ""School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, 710071, P. R. China.""}, {'ForeName': 'Suping', 'Initials': 'S', 'LastName': 'Cai', 'Affiliation': ""School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, 710071, P. R. China.""}, {'ForeName': 'Liaojun', 'Initials': 'L', 'LastName': 'Pang', 'Affiliation': ""School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, 710071, P. R. China.""}, {'ForeName': 'Xiaoming', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': ""The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Sciences and Technology, Xi'an Jiaotong University, Xi'an, 710049, P. R. China.""}, {'ForeName': 'Liyu', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': ""School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, 710071, P. R. China. huangly@mail.xidian.edu.cn.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0551-0'] 228,32011378,Does an Antimicrobial Incision Drape Prevent Intraoperative Contamination? A Randomized Controlled Trial of 1187 Patients.,"BACKGROUND The risk of periprosthetic joint infection (PJI), a serious complication after arthroplasty, has not changed for years. Interventions such as eradication of Staphylococcus aureus and antibiotic bone cement are used to diminish infection risk but despite these efforts, the percentage of infection in TKA remains constant. Antimicrobial drapes have a dual action, acting both as a physical and antimicrobial barrier to counter bacterial contamination of the surgical wound. To study the effect of antimicrobial drapes, we used intraoperative contamination as a proxy for infection in our investigation. QUESTIONS/PURPOSES (1) Do antimicrobial surgical drapes reduce the risk of intraoperative microbial contamination in patients undergoing primary knee arthroplasty? (2) Are other factors such as sex, season, age, type of arthroplasty and duration of surgery associated with an increased risk of contamination in patients undergoing primary knee arthroplasty? (3) Does loosening of the antimicrobial drape increase contamination risk? METHODS An investigator-initiated, two-arm, non-blinded, multicenter, randomized, controlled trial was performed at five different hospitals in the capital and central regions of Denmark. Twenty-four surgeons participated in the study. Participants were patients older than 18 years undergoing primary knee arthroplasty. We excluded patients with an iodine allergy, previous open knee surgery, previous septic arthritis, any antibiotics taken 4 weeks before surgery, and if they were unable to understand the implications of study participation. Patients were randomly assigned to operation with an antimicrobial drape (intervention group) or operation without (control group). We screened 1769 patients, of which 100 were ineligible and 10 declined to participate. In all, 94% (1659 of 1769) of patients consented and were randomized to the intervention group (51%, 838 of 1659) and control group (49%, 821 of 1659), respectively. In all, 36% (603 of 1659) of patients in the intervention group and 35% (584 of 1659) patients in the control group were available for final analysis. No crossover was performed, and analysis was done per-protocol. Patients were excluded due to logistic failures like lack of utensils, samples disappearing en route to the laboratory mainly caused by implementation of a new electronic patient chart (EPIC, Verona, WI, USA), and forgetful surgeons. Intraoperatively, we swabbed for bacteria at the surgical site and in a rinse from the surgeons' gloves. All samples were sent for cultivation, and colony forming units (CFUs) counts ≥ 1 were deemed contaminated. The primary outcome measure was the difference in the proportion of contaminated patients between the two randomized groups. Secondary outcome measures were the affiliation of sex, season, age, type of implant used, and duration of surgery on contamination risk. To investigate whether other factors were affiliated with contamination risk, we did a logistic regression to control for confounding variables, including sex, age, season, type of implant and duration of surgery. RESULTS Use of iodinated drapes reduced contamination, with contamination detected in 10% (60 of 603) procedures where iodinated drapes were used compared with 15% (90 of 584) when they were not (odds ratio 0.61 [95% CI 0.43 to 0.87]; p = 0.005), with a relative risk reduction of 35% (95% CI 12.3 to 52.5) and a number needed to treat of 18 patients. After controlling for confounding variables such as sex, age, type of implant, and duration of surgery, we found that not using an antimicrobial drape increased contamination risk by a factor of 1.6 (95% CI 1.08 to 2.35; p = 0.02). Female sex and undergoing surgery in the central region were associated with lower odds of contamination (OR 0.55 [95% CI 0.39 to 0.8]; p = 0.002 and OR 0.45 [95% CI 0.25 to 0.8]; p = 0.006, respectively). Patients with more than a 10-mm separation of the drape from the skin had higher odds of contamination (OR 3.54 [95% CI 1.64 to 11.05]; p = 0.0013). CONCLUSIONS The use of an antimicrobial drape resulted in lower contamination risk than operating without an antimicrobial drape. Our findings suggest that antimicrobial drapes are useful in infection prevention, but further studies are needed to investigate the effect of antimicrobial drapes on infection. LEVEL OF EVIDENCE Level I, therapeutic study.",2020,"RESULTS Use of iodinated drapes reduced contamination, with contamination detected in 10% (60 of 603) procedures where iodinated drapes were used compared with 15% (90 of 584) when they were not (odds ratio 0.61 [95% CI 0.43 to 0.87]; p = 0.005), with a relative risk reduction of 35% (95% CI 12.3 to 52.5) and a number needed to treat of 18 patients.","['Participants were patients older than 18 years undergoing primary knee arthroplasty', '1187 Patients', 'patients undergoing primary knee arthroplasty', 'Twenty-four surgeons participated in the study', 'Patients were excluded due to logistic failures like lack of utensils, samples disappearing en route to the laboratory mainly caused by implementation of a new electronic patient chart (EPIC, Verona, WI, USA), and forgetful surgeons', '1769 patients, of which 100 were ineligible and 10 declined to participate', 'patients with an iodine allergy, previous open knee surgery, previous septic arthritis, any antibiotics taken 4 weeks before surgery']","['antimicrobial drape (intervention group) or operation without (control group', 'antimicrobial surgical drapes']","['lower contamination risk', 'affiliation of sex, season, age, type of implant used, and duration of surgery on contamination risk']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C3715070', 'cui_str': '24 (qualifier value)'}, {'cui': 'C0582175', 'cui_str': 'Surgeon (occupation)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0242415', 'cui_str': 'Logistics'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0332268', 'cui_str': 'Lacking (qualifier value)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C1268547', 'cui_str': 'Patient chart'}, {'cui': 'C0542476', 'cui_str': 'Forgetful (finding)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0571818', 'cui_str': 'Iodine allergy'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0187769', 'cui_str': 'Operative procedure on knee'}, {'cui': 'C1692886', 'cui_str': 'Arthritis, Bacterial'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}]","[{'cui': 'C1136254', 'cui_str': 'Microbicides'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0180511', 'cui_str': 'Surgical Drapes'}]","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0449497', 'cui_str': 'Type of device (attribute)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]",24.0,0.133429,"RESULTS Use of iodinated drapes reduced contamination, with contamination detected in 10% (60 of 603) procedures where iodinated drapes were used compared with 15% (90 of 584) when they were not (odds ratio 0.61 [95% CI 0.43 to 0.87]; p = 0.005), with a relative risk reduction of 35% (95% CI 12.3 to 52.5) and a number needed to treat of 18 patients.","[{'ForeName': 'Anne Brun', 'Initials': 'AB', 'LastName': 'Hesselvig', 'Affiliation': 'A. B. Hesselvig, Department of Clinical Microbiology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark; Department of Orthopaedic Surgery, Herlev and Gentofte Hospital, University of Copenhagen, Gentofte, Denmark A. Odgaard, Department of Orthopaedic Surgery, Herlev and Gentofte Hospital, University of Copenhagen, Gentofte, Denmark T. Bjarnsholt, Costerton Biofilm Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark M. Arpi, Department of Clinical Microbiology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark F. Madsen, Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Arpi', 'Affiliation': ''}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Madsen', 'Affiliation': ''}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Bjarnsholt', 'Affiliation': ''}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Odgaard', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical orthopaedics and related research,['10.1097/CORR.0000000000001142'] 229,31514201,The effect of methylphenidate on social cognition and oxytocin in children with attention deficit hyperactivity disorder.,"The current study aimed to explore the possible effect of stimulants on oxytocin (OT), a neuropeptide which regulates social behavior, as a mediator of the pro-social effect of methylphenidate (MPH) in children with attention deficit hyperactivity disorder (ADHD) compared to healthy controls (HCs). Utilizing a double-blind placebo-controlled design, we compared the performance of 50 children with ADHD and 40 HCs in ""theory of mind"" (ToM) tasks and examined the effect of a single dose of MPH/placebo on ToM and salivary OT levels in children with ADHD at baseline and following an interpersonal interaction. Children with ADHD displayed significantly poorer ToM performance; however, following MPH administration, their performance normalized and differences between children with ADHD and HC were no longer found. Salivary OT levels at baseline did not differ between children with ADHD and HCs. However, after a parent-child interaction, OT levels were significantly higher in the HC group compared to children with ADHD. Administration of MPH attenuated this difference such that after parent-child interaction differences in OT levels between children with ADHD and HC were no longer found. In the ADHD group, OT levels decreased from administration of placebo to the parent-child interaction. However, the administration of MPH to children with ADHD was associated with an increase in OT levels after the parent-child interaction. We conclude that OT might play a role as a mediator of social deficits in children with ADHD and that the reactivity of the OT system to social interaction in children with ADHD might be impaired. Stimulants may improve ToM and social functions in children with ADHD via its impact on the OT system. PRS: OT and Social Cognition in Children with ADHD: Impact of MPH.",2020,"However, after a parent-child interaction, OT levels were significantly higher in the HC group compared to children with ADHD.","['Children with ADHD', 'children with attention deficit hyperactivity disorder (ADHD', '50 children with ADHD and 40 HCs in ""theory of mind"" (ToM) tasks', 'children with ADHD at baseline and following an interpersonal interaction', 'children with attention deficit hyperactivity disorder', 'children with ADHD']","['methylphenidate', 'HC', 'MPH', 'MPH/placebo', 'oxytocin (OT', 'placebo', 'methylphenidate (MPH']","['ToM and social functions', 'poorer ToM performance', 'Salivary OT levels', 'social cognition and oxytocin', 'ToM and salivary OT levels', 'OT levels']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1263846', 'cui_str': 'ADDH'}, {'cui': 'C0935573', 'cui_str': 'Mentalizing'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}]","[{'cui': 'C0025810', 'cui_str': 'Methylphenidate'}, {'cui': 'C0048853', 'cui_str': 'MPH'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}]","[{'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0442040', 'cui_str': 'Salivary (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}]",50.0,0.04804,"However, after a parent-child interaction, OT levels were significantly higher in the HC group compared to children with ADHD.","[{'ForeName': 'Orit', 'Initials': 'O', 'LastName': 'Levi-Shachar', 'Affiliation': 'Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Hila Z', 'Initials': 'HZ', 'LastName': 'Gvirts', 'Affiliation': 'Department of Behavioral Sciences and Psychology, Ariel University, Ariel, Israel.'}, {'ForeName': 'Yiftach', 'Initials': 'Y', 'LastName': 'Goldwin', 'Affiliation': 'Shalvata Mental Health Center, Hod-Hasharon, Israel.'}, {'ForeName': 'Yuval', 'Initials': 'Y', 'LastName': 'Bloch', 'Affiliation': 'Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Shamay-Tsoory', 'Affiliation': 'Department of Psychology, Haifa University, Haifa, Israel.'}, {'ForeName': 'Orna', 'Initials': 'O', 'LastName': 'Zagoory-Sharon', 'Affiliation': 'Baruch Ivcher School of Psychology, Interdisciplinary Center, Herzlia, Israel.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Feldman', 'Affiliation': 'Baruch Ivcher School of Psychology, Interdisciplinary Center, Herzlia, Israel.'}, {'ForeName': 'Hagai', 'Initials': 'H', 'LastName': 'Maoz', 'Affiliation': 'Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. hagaima@gmail.com.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0522-5'] 230,31590179,Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial.,"Glutamate and opioid systems play important roles in alcohol drinking behaviors. We examined if combined treatment with the NMDA antagonist memantine and the opioid antagonist naltrexone, when compared with naltrexone alone, would have a greater influence on alcohol drinking behaviors. Fifty-six, non-treatment-seeking heavy drinkers, with alcohol dependence and a positive family history (FHP) of alcoholism, participated in a randomized, double-blind, crossover trial, including two 6-8 days treatment periods, separated by a 6-day washout, and 3 alcohol drinking paradigm (ADP) sessions. After the first baseline (BAS) ADP1 session, participants were randomized to receive either naltrexone (NTX; 50 mg/day) + placebo memantine, or NTX (50 mg/day) + memantine (MEM; 20 mg/day), during the first treatment period, following which they completed ADP2. After a 6-day washout, participants were crossed over to the treatment they did not receive during the first treatment period, following which they completed ADP3. During each ADP, participants received a priming drink of alcohol followed by 3 1-hour, self-administration periods during which they had ad-lib access to 12 drinks. Individually, both NTX and NTX + MEM, when compared to BAS ADP1, significantly reduced the number of drinks consumed (p's < 0.001) and craving (p's < 0.001). When comparing NTX + MEM vs. NTX on number of drinks consumed, there was a significant treatment* sequence interaction (p = 0.004). Specifically, when NTX + MEM followed NTX alone, NTX + MEM resulted in a further reduction in drinking (mean: -1.94; 95% CI: -2.6, -0.8, p = 0.0005). However, when NTX alone followed NTX + MEM, NTX alone did not lead to further reduction in drinking (mean: 0.59; 95% CI: -0.67, 1.43, p = 0.47). Similar patterns were observed for alcohol craving; specifically, a significant reduction in craving was observed when NTX + MEM followed NTX alone (p = 0.009), but craving reduction was maintained when NTX + MEM was followed by NTX alone. Neither treatment condition significantly influenced alcohol-induced stimulation or sedation. Memantine (at a dose of 20 mg/day) enhances the efficacy of naltrexone (50 mg/day) in reducing alcohol drinking and craving among FHP drinkers with beneficial effects that appear to carryover after discontinuation of memantine treatment.",2020,"When comparing NTX + MEM vs. NTX on number of drinks consumed, there was a significant treatment* sequence interaction (p = 0.004).","['Fifty-six, non-treatment-seeking heavy drinkers, with alcohol dependence and a positive family history (FHP) of alcoholism']","['Memantine', 'naltrexone', 'NTX\u2009+\u2009MEM vs. NTX', 'NMDA antagonist memantine', 'NTX', 'alcohol drinking paradigm (ADP) sessions', 'naltrexone (NTX; 50\u2009mg/day)\u2009+\u2009placebo memantine, or NTX (50\u2009mg/day)\u2009+\u2009memantine (MEM', 'opioid antagonist naltrexone', 'naltrexone and memantine', 'priming drink of alcohol']","['craving', 'alcohol craving', 'alcohol drinking behaviors', 'craving reduction', 'number of drinks consumed', 'alcohol drinking and craving', 'alcohol-induced stimulation or sedation']","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0337678', 'cui_str': 'Heavy drinker (finding)'}, {'cui': 'C0001973', 'cui_str': 'Alcohol Dependence'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0559555', 'cui_str': 'FH - Alcoholism'}]","[{'cui': 'C0025242', 'cui_str': 'Memantine'}, {'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C1979923', 'cui_str': 'Micro-Electro-Mechanical Systems'}, {'cui': 'C0079883', 'cui_str': 'N-Methyl-D-aspartate'}, {'cui': 'C0243076', 'cui_str': 'antagonists'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0439422', 'cui_str': 'mg/day'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0027410', 'cui_str': 'Opioid Receptor Antagonists'}, {'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}]","[{'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0556385', 'cui_str': 'Craving for alcohol (finding)'}, {'cui': 'C0565662', 'cui_str': 'Finding relating to alcohol drinking behavior'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}]",12.0,0.0285429,"When comparing NTX + MEM vs. NTX on number of drinks consumed, there was a significant treatment* sequence interaction (p = 0.004).","[{'ForeName': 'Suchitra', 'Initials': 'S', 'LastName': 'Krishnan-Sarin', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, Office S-208, 34 Park Street, New Haven, CT, 06519, USA. suchitra.krishnan-sarin@yale.edu.'}, {'ForeName': 'Stephanie S', 'Initials': 'SS', 'LastName': ""O'Malley"", 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, Office S-208, 34 Park Street, New Haven, CT, 06519, USA.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Franco', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, Office S-208, 34 Park Street, New Haven, CT, 06519, USA.'}, {'ForeName': 'Dana A', 'Initials': 'DA', 'LastName': 'Cavallo', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, Office S-208, 34 Park Street, New Haven, CT, 06519, USA.'}, {'ForeName': 'Jeanette M', 'Initials': 'JM', 'LastName': 'Tetrault', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, Office S-208, 34 Park Street, New Haven, CT, 06519, USA.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, Office S-208, 34 Park Street, New Haven, CT, 06519, USA.'}, {'ForeName': 'Ralitza', 'Initials': 'R', 'LastName': 'Gueorguieva', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, Office S-208, 34 Park Street, New Haven, CT, 06519, USA.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Pittman', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, Office S-208, 34 Park Street, New Haven, CT, 06519, USA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Krystal', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, Office S-208, 34 Park Street, New Haven, CT, 06519, USA.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0536-z'] 231,31705526,"Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).","BACKGROUND Guselkumab, a fully human interleukin-23 antibody, is approved for systemic treatment of patients with moderate-to-severe plaque psoriasis. OBJECTIVES To compare the efficacy and safety of guselkumab with those of fumaric acid esters (FAE) in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment. METHODS Eligible patients were randomized to this multicentre, randomized, open-label, assessor-blinded, active-comparator-controlled phase IIIb study to receive guselkumab 100 mg by subcutaneous injection or oral FAE according to local label guidelines. RESULTS Through week 24, 56 of 60 patients completed guselkumab treatment and 36 of 59 completed FAE treatment. The primary endpoint (proportion of patients with ≥ 90% improvement from their baseline Psoriasis Area and Severity Index; PASI 90 response) was achieved by significantly more patients receiving guselkumab than FAE at week 24 (82% vs. 14%, P < 0·001). Analysis of the major secondary endpoints confirmed a statistically significant difference between the treatments with regards to PASI 75 response (90% vs. 27%, P < 0·001) and Dermatology Life Quality Index score of 0 or 1 (no effect at all on the patient's quality of life; 62% vs. 17%, P < 0·001). More patients in the guselkumab group achieved completely clear skin (PASI 100 response) than in the FAE group (32% vs. 3%, P < 0·001). The incidence of adverse events was lower with guselkumab than with FAE (73% vs. 98%). Overall, 28% of patients on FAE discontinued due to an adverse event, compared with none receiving guselkumab. No new safety findings were observed for guselkumab. CONCLUSIONS Guselkumab demonstrated superiority over FAE in systemic-treatment-naive patients with moderate-to-severe plaque psoriasis through 24 weeks.",2020,"Analysis of the major secondary endpoints confirmed a statistically significant difference between the treatments with regards to PASI 75 response (90.0% vs. 27.1%, p<0.001) and the Dermatology Life Quality Index (DLQI) response of 0/1 (no effect at all on patient's life; 61.7% vs. 16.9%, p<0.001).","['Eligible patients', 'patients with moderate-to-severe plaque psoriasis', 'systemic treatment-naïve patients with moderate-to-severe plaque psoriasis', 'patients with moderate-to-severe plaque psoriasis who are naïve to systemic treatment']","['FAE treatment', 'fumaric acid esters', 'Guselkumab', 'oral FAE', 'guselkumab with fumaric acid esters (FAE', 'guselkumab treatment', 'FAE']","['completely clear skin (PASI 100 response', 'PASI 75 response', 'incidence of adverse events (AE', 'baseline Psoriasis Area and Severity Index; PASI\xa090 response', 'Dermatology Life Quality Index (DLQI) response']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0406317', 'cui_str': 'Plaque psoriasis (disorder)'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1959568', 'cui_str': 'Fumarate Esters'}, {'cui': 'C3852217', 'cui_str': 'guselkumab'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C4554154', 'cui_str': 'Completely - dosing instruction fragment (qualifier value)'}, {'cui': 'C2963144', 'cui_str': 'Clear (qualifier value)'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0451112', 'cui_str': 'Dermatology life quality index (assessment scale)'}]",,0.088747,"Analysis of the major secondary endpoints confirmed a statistically significant difference between the treatments with regards to PASI 75 response (90.0% vs. 27.1%, p<0.001) and the Dermatology Life Quality Index (DLQI) response of 0/1 (no effect at all on patient's life; 61.7% vs. 16.9%, p<0.001).","[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Thaçi', 'Affiliation': 'Institute and Comprehensive Centre for Inflammation Medicine, University of Lübeck, Lübeck, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Pinter', 'Affiliation': 'Department of Dermatology, Venereology and Allergology, University Hospital of Frankfurt am Main, Frankfurt am Main, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Sebastian', 'Affiliation': 'Dermatological Practice Dr. med. Michael Sebastian, Mahlow, Germany.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Termeer', 'Affiliation': 'Dermatological Practice Prof. Dr. med. Christian Termeer, Stuttgart, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Sticherling', 'Affiliation': 'Department of Dermatology, University Hospital of Erlangen, Erlangen, Germany.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Gerdes', 'Affiliation': 'Psoriasis-Center, Department of Dermatology, Venerology and Allergology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Wegner', 'Affiliation': 'Janssen-Cilag GmbH, Neuss, Germany.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Krampe', 'Affiliation': 'Janssen-Cilag GmbH, Neuss, Germany.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Bartz', 'Affiliation': 'Janssen-Cilag GmbH, Neuss, Germany.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Rausch', 'Affiliation': 'Janssen-Cilag GmbH, Neuss, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Mensch', 'Affiliation': 'Janssen-Cilag GmbH, Neuss, Germany.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Eyerich', 'Affiliation': 'Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.'}]",The British journal of dermatology,['10.1111/bjd.18696'] 232,31514233,The efficacy and safety of thalidomide on the recurrence interval of continuous recurrent aphthous ulceration: A randomized controlled clinical trial.,"BACKGROUND Recurrent aphthous ulceration (RAU) is the most common oral mucosal disease. Some patients have almost continuous oral ulcers which influence the quality of life. The aim of this study was to observe the efficacy and safety of thalidomide on the recurrence interval of continuous RAU. METHODS A randomized controlled clinical trial was designed, and 60 continuous RAU patients were randomly assigned to the experimental group (n = 32, taking thalidomide before bed at a dose of 100 mg/d for 10 days, then 50 mg/d for 10 days, and 25 mg/d for 10 days) and the control group (n = 28, taking 0.4 mg/kg/d prednisone every morning for 15 days and then 0.2 mg/kg/d for 15 days). The clinical outcomes consisted of the primary outcome (recurrence interval) and the secondary outcomes (pain level, number of ulcers, and days for ulcer healing), and they were measured at every visit. Adverse reactions were recorded. RESULTS A total of 54 and 51 patients presented at the first and second return visit, respectively. After 1 month, the increase in the recurrence interval was not shown to differ between the two groups (P = .12). However, the improvement in the recurrence interval was significantly greater in the experimental group (P < .001) at the second return visit. The improvement in the secondary outcomes was identical between two groups at each return visit (P > .05). The incidence of adverse reactions was similar between two groups (P = .50). CONCLUSIONS Thalidomide had a long-term effect of extending the recurrence interval of continuous RAU.",2020,"However, the improvement in the recurrence interval was significantly greater in the experimental group (P < .001) at the second return visit.","['continuous recurrent aphthous ulceration', '60 continuous RAU patients']","['control group (n\xa0=\xa028, taking 0.4\xa0mg/kg/d prednisone', 'Thalidomide', 'thalidomide']","['recurrence interval', 'quality of life', 'incidence of adverse reactions', 'efficacy and safety', 'Adverse reactions', 'primary outcome (recurrence interval) and the secondary outcomes (pain level, number of ulcers, and days for ulcer healing']","[{'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C2937365', 'cui_str': 'Recurrent aphthous ulcer (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C4517457', 'cui_str': 'Zero point four'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0039736', 'cui_str': 'Thalidomide'}]","[{'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0034380'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0445135', 'cui_str': 'Number of ulcers (observable entity)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}]",,0.0919478,"However, the improvement in the recurrence interval was significantly greater in the experimental group (P < .001) at the second return visit.","[{'ForeName': 'Qingxiang', 'Initials': 'Q', 'LastName': 'Zeng', 'Affiliation': 'State Key Laboratory of Oral Diseases, Department of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.'}, {'ForeName': 'Xueke', 'Initials': 'X', 'LastName': 'Shi', 'Affiliation': 'State Key Laboratory of Oral Diseases, Department of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'State Key Laboratory of Oral Diseases, Department of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.'}, {'ForeName': 'Miao', 'Initials': 'M', 'LastName': 'Yang', 'Affiliation': 'State Key Laboratory of Oral Diseases, Department of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Zhao', 'Affiliation': 'State Key Laboratory of Oral Diseases, Department of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.'}, {'ForeName': 'Xiaoyi', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': 'Department of pharmacy, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.'}, {'ForeName': 'Jiahong', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': 'State Key Laboratory of Oral Diseases, Department of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.'}, {'ForeName': 'Hongmei', 'Initials': 'H', 'LastName': 'Zhou', 'Affiliation': 'State Key Laboratory of Oral Diseases, Department of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.'}]",Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology,['10.1111/jop.12960'] 233,31160244,Women's experiences of internet-delivered Cognitive Behaviour Therapy (iCBT) for Fear of Birth.,"BACKGROUND Fear of Birth is common in pregnant women and associated with negative physical and mental health. There is a clear comorbidity with anxiety and depression. Internet-delivered Cognitive Behaviour Therapy has been suggested as a treatment option for Fear of Birth and a randomized controlled trial comparing internet-delivered Cognitive Behaviour Therapy with midwifery led counselling as standard care has been conducted. OBJECTIVE The aim of this study was to describe women's experiences of guided internet-delivered Cognitive Behaviour Therapy for Fear of Birth and to describe the content of their fear. METHODS The present study is a qualitative, follow-up interview study following the randomized controlled trial, the U-CARE Pregnancy Trial. In total 19 women allocated to internet-delivered Cognitive Behaviour Therapy for Fear of Birth were interviewed by telephone. A semi-structured interview guide was used and the transcripts were analyzed with thematic analysis. RESULTS The women's descriptions of Fear of Birth differed, however their fear was most often associated with fear of losing control, fear for the baby's life or health or own life threatening events. The experiences of internet-delivered Cognitive Behaviour Therapy for Fear of Birth varied, some women were positive to its flexibility although most women preferred a face-to face meeting. The treatment did not pin-point their fears, it was challenging to maintain motivation and to work with the treatment in solitude. CONCLUSIONS Women's descriptions of Fear of Birth varied. Most women undergoing internet-delivered Cognitive Behaviour Therapy would have preferred a face-to-face meeting which they imagined would have soothed their fear. Internet-delivered Cognitive Behaviour Therapy for Fear of Birth may be an alternative for some women.",2020,"The experiences of internet-delivered Cognitive Behaviour Therapy for Fear of Birth varied, some women were positive to its flexibility although most women preferred a face-to face meeting.","['pregnant women and associated with negative physical and mental health', 'In total 19 women allocated to']","['Internet-delivered Cognitive Behaviour Therapy', 'guided internet-delivered Cognitive Behaviour Therapy', 'Cognitive Behaviour Therapy', 'internet-delivered Cognitive Behaviour Therapy', 'internet-delivered Cognitive Behaviour Therapy (iCBT']",[],"[{'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}]",[],19.0,0.0350531,"The experiences of internet-delivered Cognitive Behaviour Therapy for Fear of Birth varied, some women were positive to its flexibility although most women preferred a face-to face meeting.","[{'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Baylis', 'Affiliation': ""Department of Women's and Children's Health, Uppsala University Hospital, 751 85 Uppsala, Sweden. Electronic address: Rebecca.baylis@kbh.uu.se.""}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Ekdahl', 'Affiliation': 'Department of Psychology, Mid Sweden University, Östersund, Sweden. Electronic address: johanna.ekdahl@miun.se.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Haines', 'Affiliation': 'Department of Rural Health, University of Melbourne, Victoria, Australia. Electronic address: hhaines@unimelb.edu.au.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Rubertsson', 'Affiliation': ""Department of Women's and Children's Health, Uppsala University Hospital, 751 85 Uppsala, Sweden; Department of Health Science, Faculty of Medicine, Lund University, Box 188, 22100 Lund, Sweden. Electronic address: Christine.rubertsson@kbh.uu.se.""}]",Women and birth : journal of the Australian College of Midwives,['10.1016/j.wombi.2019.05.006'] 234,32302246,Effects of a 6-Week Straw Phonation in Water Exercise Program on the Aging Voice.,"Purpose Semi-occluded vocal tract (SOVT) exercises with tubes or straws have been widely used for a variety of voice disorders. Yet, the effects of longer periods of SOVT exercises (lasting for weeks) on the aging voice are not well understood. This study investigated the effects of a 6-week straw phonation in water (SPW) exercise program. Method Thirty-seven elderly subjects with self-perceived voice problems were assigned into two groups: (a) SPW exercises with six weekly sessions and home practice (experimental group) and (b) vocal hygiene education (control group). Before and after intervention (2 weeks after the completion of the exercise program), acoustic analysis, auditory-perceptual evaluation, and self-assessment of vocal impairment were conducted. Results Analysis of covariance revealed significant differences between the two groups in smoothed cepstral peak prominence measures, harmonics-to-noise ratio, the auditory-perceptual parameter of breathiness, and Voice Handicap Index-10 scores postintervention. No significant differences between the two groups were found for other measures. Conclusions Our results supported the positive effects of SOVT exercises for the aging voice, with a 6-week SPW exercise program being a clinical option. Future studies should involve long-term follow-up and additional outcome measures to better understand the efficacy of SOVT exercises, particularly SPW exercises, for the aging voice.",2020,"Results Analysis of covariance revealed significant differences between the two groups in smoothed cepstral peak prominence measures, harmonics-to-noise ratio, the auditory-perceptual parameter of breathiness, and Voice Handicap Index-10 scores postintervention.",['Method Thirty-seven elderly subjects with self-perceived voice problems'],"['6-Week Straw Phonation in Water Exercise Program', 'SOVT exercises', 'SPW exercise program', 'Semi-occluded vocal tract (SOVT) exercises with tubes or straws', '6-week straw phonation in water (SPW) exercise program', 'SPW exercises with six weekly sessions and home practice (experimental group) and (b) vocal hygiene education (control group']","['Aging Voice', 'smoothed cepstral peak prominence measures, harmonics-to-noise ratio, the auditory-perceptual parameter of breathiness, and Voice Handicap Index-10 scores postintervention']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319569', 'cui_str': '37'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0042940', 'cui_str': 'Voice Disorders'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4047917', 'cui_str': 'Cereal plant straw'}, {'cui': 'C0031577', 'cui_str': 'Laryngeal voice function'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0204945', 'cui_str': 'Hygiene education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0205357', 'cui_str': 'Smooth'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0559307', 'cui_str': 'Breathy voice quality'}, {'cui': 'C2985106', 'cui_str': 'Voice handicap index'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",37.0,0.0169641,"Results Analysis of covariance revealed significant differences between the two groups in smoothed cepstral peak prominence measures, harmonics-to-noise ratio, the auditory-perceptual parameter of breathiness, and Voice Handicap Index-10 scores postintervention.","[{'ForeName': 'Chia-Hsin', 'Initials': 'CH', 'LastName': 'Wu', 'Affiliation': 'Department of Speech Language Pathology and Audiology, National Taipei University of Nursing and Health Sciences, Taiwan.'}, {'ForeName': 'Roger W', 'Initials': 'RW', 'LastName': 'Chan', 'Affiliation': 'Department of Speech Language Pathology and Audiology, National Taipei University of Nursing and Health Sciences, Taiwan.'}]","Journal of speech, language, and hearing research : JSLHR",['10.1044/2020_JSLHR-19-00124'] 235,31115192,The effects of an integrated supportive care intervention on quality of life outcomes in outpatients with breast and gynecologic cancer undergoing chemotherapy: Results from a randomized controlled trial.,"The aim of the Complementary Nursing in Gynecologic Oncology study was to investigate the effects of a complex, nurse-led, supportive care intervention using Complementary and Integrative Medicine (CIM) on patients' quality of life (QoL) and associated patient-reported outcomes. In this prospective, pragmatic, bicentric, randomized controlled trial, women with breast or gynecologic cancer undergoing a new regimen of chemotherapy (CHT) were randomly assigned to routine supportive care plus intervention (intervention group, IG) or routine care alone (control group, CG). The intervention consisted of CIM applications and counseling for symptom management, as well as CIM information material. The primary endpoint was global QoL measured with the EORTC-QLQ-C30 before and after CHT. Mixed linear models considering fixed and random factors were used to analyze the data. In total, 126 patients were randomly assigned into the IG and 125 patients into the CG (median age 51 years). The patients' medical and socio-demographic characteristics were homogenous at baseline and at follow-up. No group effects on QoL were found upon completion of CHT (estimate -1.04 [-4.89; 2.81]; P = 0.596), but there was a significant group difference in favor of the IG 6 months later (estimate 6.643 [1.65; 11.64]; P = 0.010). IG patients did also experience significant better emotional functioning (P = 0.007) and less fatigue (P = 0.027). The tested supportive intervention did not improve patients' QoL outcomes directly after CHT (T3), but was associated with significant QoL improvements when considering the change from baseline to the time point T4, which could be assessed 6 months after patients' completion of CHT. This delayed effect may have resulted due to a strengthening of patients' self-management competencies.",2019,IG patients did also experience significant better emotional functioning (P = 0.007) and less fatigue (P = 0.027).,"['126 patients were randomly assigned into the IG and 125 patients into the CG (median age 51\xa0years', 'women with breast or gynecologic cancer undergoing a new regimen of chemotherapy (CHT', 'outpatients with breast and gynecologic cancer undergoing chemotherapy']","['routine supportive care plus intervention (intervention group, IG) or routine care alone (control group, CG', 'integrated supportive care intervention', 'complex, nurse-led, supportive care intervention using Complementary and Integrative Medicine (CIM']","['fatigue', 'emotional functioning', 'quality of life outcomes', 'global QoL measured with the EORTC-QLQ-C30', 'QoL', ""patients' quality of life (QoL""]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C4319551', 'cui_str': 'One hundred and twenty-five'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C0205480', 'cui_str': 'Gynecologic (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}]","[{'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C2350258', 'cui_str': 'Integrative Medicine'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]",126.0,0.0905502,IG patients did also experience significant better emotional functioning (P = 0.007) and less fatigue (P = 0.027).,"[{'ForeName': 'Nadja', 'Initials': 'N', 'LastName': 'Klafke', 'Affiliation': 'Department of General Practice and Health Services Research, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Cornelia', 'Initials': 'C', 'LastName': 'Mahler', 'Affiliation': 'Department of Nursing, Institute for Health Sciences, University Hospital Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Cornelia', 'Initials': 'C', 'LastName': 'von Hagens', 'Affiliation': ""Division of Naturopathy and Integrative Medicine, Department of Gynaecological Endocrinology and Reproductive Medicine, University Womens' Hospital Heidelberg, Heidelberg, Germany.""}, {'ForeName': 'Lorenz', 'Initials': 'L', 'LastName': 'Uhlmann', 'Affiliation': 'Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Bentner', 'Affiliation': 'Department of General Practice and Health Services Research, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Schneeweiss', 'Affiliation': 'Division Gynaecologic Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Mueller', 'Affiliation': ""Womens' Clinic, Community Hospital Karlsruhe, Karlsruhe, Germany.""}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Szecsenyi', 'Affiliation': 'Department of General Practice and Health Services Research, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Joos', 'Affiliation': 'Institute of General Practice and Interprofessional Care, University Hospital Tuebingen, Tuebingen, Germany.'}]",Cancer medicine,['10.1002/cam4.2196'] 236,32233095,Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study.,"We provide a long-term evaluation of patients enrolled in the EORTC/GIMEMA AML-10 trial which included a total of 2157 patients, 15-60 years old, randomized to receive either daunorubicin (DNR, 50 mg/m 2 ), mitoxantrone (MXR, 12 mg/m 2 ), or idarubicin (IDA, 10 mg/m 2 ) in addition to standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine for consolidation. Younger patients who reached complete remission with complete (CR) or incomplete (CRi) recovery were then scheduled to receive an allogeneic hematopoietic stem cell transplantation (HSCT). That was if they had a HLA-identical sibling donor; in all other cases, an autologous HSCT had to be administered. At an 11-year median follow-up, the 5-year, 10-year and 15-year overall survival (OS) rates were 33.2%, 30.1% and 28.0%, respectively. No significant difference between the three randomized groups regarding OS was observed (P = .38). In young patients, 15-45 years old, no treatment difference (P = .89) regarding OS was observed, while in patients 46-60 years old, MXR and IDA groups had a trend for a longer OS as compared to the DNR group (P = .029). Among younger patients without a favorable MRC cytogenetic risk subgroup who achieved a CR/CRi after induction chemotherapy, those with a HLA-identical sibling donor had higher 10-year and 15-year OS rates than those without. In older patients who reached CR/CRi, the long-term outcomes of those with or without a donor was similar. In conclusion, long-term outcomes of the study confirmed similar OS in the three randomized groups in the whole cohort of patients.",2020,"In young patients, 15-45 years old, no treatment difference (P=0.89) regarding OS was observed, while in patients 46-60 years old, MXR and IDA groups had a trend for a longer OS as compared to the DNR group (P=0.029).","['younger patients with acute myeloid leukaemia', 'Younger patients who reached complete remission with complete (CR) or incomplete (CRi) recovery', 'patients enrolled in the EORTC/GIMEMA AML-10 trial which included a total of 2157 patients, 15-60\u2009years old', 'younger patients without a favourable MRC cytogenetic risk subgroup']","['daunorubicin (DNR, 50 mg/m 2 ), mitoxantrone (MXR, 12 mg/m 2 ), or idarubicin (IDA, 10 mg/m 2 ) in addition to standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine', 'anthracycline and of stem cell transplantation', 'allogeneic hematopoietic stem cell transplantation (HSCT']","['15-year overall survival (OS) rates', 'OS']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0023467', 'cui_str': 'Nonlymphoblastic Leukemia, Acute'}, {'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0205257', 'cui_str': 'Incomplete (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0010802', 'cui_str': 'Cytogenetic'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]","[{'cui': 'C0011015', 'cui_str': 'Daunorubicin'}, {'cui': 'C0582114', 'cui_str': 'DNAR - Do not attempt resuscitation'}, {'cui': 'C0026259', 'cui_str': 'Mitoxantrone'}, {'cui': 'C0020789', 'cui_str': 'Idarubicin'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0010711', 'cui_str': 'Cytarabine'}, {'cui': 'C0015133', 'cui_str': 'Etoposide'}, {'cui': 'C3179010', 'cui_str': 'Induction Chemotherapy'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0282564', 'cui_str': 'Anthracyclines'}, {'cui': 'C1504389', 'cui_str': 'Stem Cell Transplantation'}, {'cui': 'C0472699', 'cui_str': 'Hematopoietic Stem Cell Transplantation'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",2157.0,0.159809,"In young patients, 15-45 years old, no treatment difference (P=0.89) regarding OS was observed, while in patients 46-60 years old, MXR and IDA groups had a trend for a longer OS as compared to the DNR group (P=0.029).","[{'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Baron', 'Affiliation': 'GIGA-I3 and CHU, University of Liège, Liège, Belgium.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Efficace', 'Affiliation': ""Gruppo Italiano Malattie Ematologiche Dell'Adulto GIMEMA, Rome, Italy.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Cannella', 'Affiliation': ""Gruppo Italiano Malattie Ematologiche Dell'Adulto GIMEMA, Rome, Italy.""}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Muus', 'Affiliation': 'Radboud University Medical Center, Nijmegen, Netherlands.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Trisolini', 'Affiliation': 'Sapienza University, Rome, Italy.'}, {'ForeName': 'Constantijn J M', 'Initials': 'CJM', 'LastName': 'Halkes', 'Affiliation': 'Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Fazi', 'Affiliation': ""Gruppo Italiano Malattie Ematologiche Dell'Adulto GIMEMA, Rome, Italy.""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Vignetti', 'Affiliation': ""Gruppo Italiano Malattie Ematologiche Dell'Adulto GIMEMA, Rome, Italy.""}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Marie', 'Affiliation': 'Saint-Antoine Hospital, Paris, France.'}, {'ForeName': 'Patrizia', 'Initials': 'P', 'LastName': 'Chiusolo', 'Affiliation': 'Gemelli Hospital, Rome, Italy.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'van der Velden', 'Affiliation': 'Radboud University Medical Center, Nijmegen, Netherlands.'}, {'ForeName': 'Edoardo', 'Initials': 'E', 'LastName': 'La Sala', 'Affiliation': ""Gruppo Italiano Malattie Ematologiche Dell'Adulto GIMEMA, Rome, Italy.""}, {'ForeName': 'Umberto', 'Initials': 'U', 'LastName': 'Vitolo', 'Affiliation': 'Candiolo Cancer Institute-IRCCS, Torino, Italy.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Thomas', 'Affiliation': 'Lyon-Sud University Hospital, Lyon, France.'}, {'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Lefrère', 'Affiliation': ""Assistance Publique-Hôpitaux de Paris, Necker Children's Hospital, Paris, France.""}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Di Raimondo', 'Affiliation': 'Universita di Catania, Catania, Italy.'}, {'ForeName': 'Jean-Henri', 'Initials': 'JH', 'LastName': 'Bourhis', 'Affiliation': 'Gustave Roussy cancer campus Grand Paris, Villejuif, France.'}, {'ForeName': 'Giorgina', 'Initials': 'G', 'LastName': 'Specchia', 'Affiliation': 'Giovanni XXIII- University Hospital, Bari, Italy.'}, {'ForeName': 'José E', 'Initials': 'JE', 'LastName': 'Guimarães', 'Affiliation': 'Hospital S. João, Porto, Portugal.'}, {'ForeName': 'Bernardino', 'Initials': 'B', 'LastName': 'Allione', 'Affiliation': 'Candiolo Cancer Institute-IRCCS, Torino, Italy.'}, {'ForeName': 'Radovan', 'Initials': 'R', 'LastName': 'Vrhovac', 'Affiliation': 'University Hospital Centre Zagreb, Zagreb, Croatia.'}, {'ForeName': 'Felicetto', 'Initials': 'F', 'LastName': 'Ferrara', 'Affiliation': 'Cardarelli Hospital, Naples, Italy.'}, {'ForeName': 'Marian', 'Initials': 'M', 'LastName': 'Stevens-Kroef', 'Affiliation': 'Radboud University Medical Center, Nijmegen, Netherlands.'}, {'ForeName': 'Liv', 'Initials': 'L', 'LastName': 'Meert', 'Affiliation': 'EORTC Headquarters, Brussels, Belgium.'}, {'ForeName': 'Theo', 'Initials': 'T', 'LastName': 'de Witte', 'Affiliation': 'Radboud University Medical Center, Nijmegen, Netherlands.'}, {'ForeName': 'Roelof', 'Initials': 'R', 'LastName': 'Willemze', 'Affiliation': 'Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Amadori', 'Affiliation': 'University Tor Vergata, Rome, Italy.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Suciu', 'Affiliation': 'EORTC Headquarters, Brussels, Belgium.'}]",American journal of hematology,['10.1002/ajh.25795'] 237,32298131,Bridge-Enhanced Anterior Cruciate Ligament Repair Is Not Inferior to Autograft Anterior Cruciate Ligament Reconstruction at 2 Years: Results of a Prospective Randomized Clinical Trial.,"BACKGROUND Preclinical studies suggest that for complete midsubstance anterior cruciate ligament (ACL) injuries, a suture repair of the ACL augmented with a protein implant placed in the gap between the torn ends (bridge-enhanced ACL repair [BEAR]) may be a viable alternative to ACL reconstruction (ACLR). HYPOTHESIS We hypothesized that patients treated with BEAR would have a noninferior patient-reported outcomes (International Knee Documentation Committee [IKDC] Subjective Score; prespecified noninferiority margin, -11.5 points) and instrumented anteroposterior (AP) knee laxity (prespecified noninferiority margin, +2-mm side-to-side difference) and superior muscle strength at 2 years after surgery when compared with patients who underwent ACLR with autograft. STUDY DESIGN Randomized controlled trial; Level of evidence, 1. METHODS One hundred patients (median age, 17 years; median preoperative Marx activity score, 16) with complete midsubstance ACL injuries were enrolled and underwent surgery within 45 days of injury. Patients were randomly assigned to receive either BEAR (n = 65) or autograft ACLR (n = 35 [33 with quadrupled semitendinosus-gracilis and 2 with bone-patellar tendon-bone]). Outcomes-including the IKDC Subjective Score, the side-to-side difference in instrumented AP knee laxity, and muscle strength-were assessed at 2 years by an independent examiner blinded to the procedure. Patients were unblinded after their 2-year visit. RESULTS In total, 96% of the patients returned for 2-year follow-up. Noninferiority criteria were met for both the IKDC Subjective Score (BEAR, 88.9 points; ACLR, 84.8 points; mean difference, 4.1 points [95% CI, -1.5 to 9.7]) and the side-to-side difference in AP knee laxity (BEAR, 1.61 mm; ACLR, 1.77 mm; mean difference, -0.15 mm [95% CI, -1.48 to 1.17]). The BEAR group had a significantly higher mean hamstring muscle strength index than the ACLR group at 2 years (98.2% vs 63.2%; P < .001). In addition, 14% of the BEAR group and 6% of the ACLR group had a reinjury that required a second ipsilateral ACL surgical procedure ( P = .32). Furthermore, the 8 patients who converted from BEAR to ACLR in the study period and returned for the 2-year postoperative visit had similar primary outcomes to patients who had a single ipsilateral ACL procedure. CONCLUSION BEAR resulted in noninferior patient-reported outcomes and AP knee laxity and superior hamstring muscle strength when compared with autograft ACLR at 2-year follow-up in a young and active cohort. These promising results suggest that longer-term studies of this technique are justified. REGISTRATION NCT02664545 (ClinicalTrials.gov identifier).",2020,The BEAR group had a significantly higher mean hamstring muscle strength index than the ACLR group at 2 years (98.2% vs 63.2%; P < .001).,"['One hundred patients (median age, 17 years; median preoperative Marx activity score, 16) with complete midsubstance ACL injuries were enrolled and underwent surgery within 45 days of injury', 'Autograft Anterior Cruciate Ligament Reconstruction at 2 Years', 'complete midsubstance anterior cruciate ligament (ACL) injuries']","['autograft ACLR', 'BEAR', 'ACLR', 'Bridge-Enhanced Anterior Cruciate Ligament Repair', 'ACLR with autograft']","['IKDC Subjective Score', 'AP knee laxity', 'IKDC Subjective Score, the side-to-side difference in instrumented AP knee laxity, and muscle strength', 'AP knee laxity and superior hamstring muscle strength', 'mean hamstring muscle strength index']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1456574', 'cui_str': 'Injury of anterior cruciate ligament'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0040736', 'cui_str': 'Autogenous transplantation'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C0078960', 'cui_str': 'Structure of anterior cruciate ligament of knee joint'}]","[{'cui': 'C0040736', 'cui_str': 'Autogenous transplantation'}, {'cui': 'C0162596', 'cui_str': 'Cardiolipin antibody'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0221821', 'cui_str': 'Dental bridge'}, {'cui': 'C0078960', 'cui_str': 'Structure of anterior cruciate ligament of knee joint'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0332536', 'cui_str': 'Laxity'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0584895', 'cui_str': 'Posterior muscle of thigh structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",100.0,0.170288,The BEAR group had a significantly higher mean hamstring muscle strength index than the ACLR group at 2 years (98.2% vs 63.2%; P < .001).,"[{'ForeName': 'Martha M', 'Initials': 'MM', 'LastName': 'Murray', 'Affiliation': ""Investigation performed at Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Braden C', 'Initials': 'BC', 'LastName': 'Fleming', 'Affiliation': ""Investigation performed at Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Gary J', 'Initials': 'GJ', 'LastName': 'Badger', 'Affiliation': ""Investigation performed at Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ""Investigation performed at Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Freiberger', 'Affiliation': ""Investigation performed at Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Henderson', 'Affiliation': ""Investigation performed at Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Barnett', 'Affiliation': ""Investigation performed at Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Ata', 'Initials': 'A', 'LastName': 'Kiapour', 'Affiliation': ""Investigation performed at Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Ecklund', 'Affiliation': ""Investigation performed at Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Benedikt', 'Initials': 'B', 'LastName': 'Proffen', 'Affiliation': ""Investigation performed at Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Sant', 'Affiliation': ""Investigation performed at Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Dennis E', 'Initials': 'DE', 'LastName': 'Kramer', 'Affiliation': ""Investigation performed at Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Lyle J', 'Initials': 'LJ', 'LastName': 'Micheli', 'Affiliation': ""Investigation performed at Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Yi-Meng', 'Initials': 'YM', 'LastName': 'Yen', 'Affiliation': ""Investigation performed at Boston Children's Hospital, Boston, Massachusetts, USA.""}]",The American journal of sports medicine,['10.1177/0363546520913532'] 238,30809967,"Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects.","Chiglitazar (CHI) is a potent and selective peroxisome proliferator-activated receptor potentially for the treatment of patients with type 2 diabetes mellitus (T2DM). An open-label, randomized, 3-period crossover and self-controlled study was conducted to investigate drug-drug interaction potential between CHI and metformin hydrochloride (MET). Eligible subjects received a single oral dose of CHI (48 mg), MET (1000 mg), or a combination in each period, followed by serial blood sampling collected for up to 48 hours postdose, and safety was assessed throughout the trial. The area under the plasma concentration-time curves from time 0 to 48 hours (AUC 0-48 h ) of CHI was similar following administration alone or with MET (AUC 0-48h , 12 540 ng·h/mL [9811-15 269 ng·h/mL] vs 12 130 ng·h/mL [9304-14 956 ng·h/mL]; 90% confidence interval [CI] of its geometric mean ratio [GMR], 89.7%-103.8%), whereas the maximum concentration (C max ) of CHI was reduced during coadministration, as its 90%CI of the GMR was slightly outside the acceptance range for bioequivalence (C max , 1620 ng/mL [1418-1822 ng/mL] vs 1420 ng/mL [1049-1791 ng/mL], 90%CI GMR, 77.%-94.1%). However, it was not considered clinically meaningful. The MET exposures remained consistent in the absence or presence of CHI (AUC 0-48 h , 12 570 ng·h/mL [10681-14 459 ng·h/mL] vs 13 190 [10973-15 407 ng·h/mL); 90%CI of GMR: 99.1%-110.5%; C max , 1790 ng/mL [1448-2132 ng/mL] vs 1820 ng/mL [1510-2130 ng/mL]; 90%CI of GMR, 94.2%-110.9%). No moderate to severe adverse events were reported. Our study indicated no clinically significant pharmacokinetic drug-drug interaction between CHI and MET and demonstrated good tolerance in subjects. These results support future application of CHI in combination with MET for treatment of T2DM.",2019,No moderate to severe adverse events were reported.,"['Healthy Subjects', 'patients with type 2 diabetes mellitus (T2DM']","['Metformin Hydrochloride', 'single oral dose of CHI', 'Chiglitazar (CHI', 'metformin hydrochloride (MET']","['severe adverse events', 'maximum concentration (C max ) of CHI']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]","[{'cui': 'C0770893', 'cui_str': 'Metformin hydrochloride'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1720589', 'cui_str': 'Greek letter chi'}, {'cui': 'C1873155', 'cui_str': 'chiglitazar'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C1720589', 'cui_str': 'Greek letter chi'}]",,0.1041,No moderate to severe adverse events were reported.,"[{'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Yi', 'Affiliation': 'Drug Clinical Trials Institution, The First Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, P.R.China.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Drug Clinical Trials Institution, The First Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, P.R.China.'}, {'ForeName': 'Jin-Wen', 'Initials': 'JW', 'LastName': 'Zhang', 'Affiliation': 'Exploratory Research Department, Shenzhen Chipscreen Biosciences Ltd., BIO-Incubator, Shenzhen Hi-Tech Industrial Park, Guangdong, Shenzhen, China.'}, {'ForeName': 'Xiao-Ming', 'Initials': 'XM', 'LastName': 'You', 'Affiliation': 'Drug Clinical Trials Institution, The First Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, P.R.China.'}, {'ForeName': 'Zhi-Qiang', 'Initials': 'ZQ', 'LastName': 'Ning', 'Affiliation': 'Exploratory Research Department, Shenzhen Chipscreen Biosciences Ltd., BIO-Incubator, Shenzhen Hi-Tech Industrial Park, Guangdong, Shenzhen, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Exploratory Research Department, Shenzhen Chipscreen Biosciences Ltd., BIO-Incubator, Shenzhen Hi-Tech Industrial Park, Guangdong, Shenzhen, China.'}, {'ForeName': 'Li-Fang', 'Initials': 'LF', 'LastName': 'Qian', 'Affiliation': 'Drug Clinical Trials Institution, The First Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, P.R.China.'}, {'ForeName': 'Li-Yan', 'Initials': 'LY', 'LastName': 'Miao', 'Affiliation': 'Drug Clinical Trials Institution, The First Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, P.R.China.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.668'] 239,32301412,"Exploring the impact of safety behaviour use on cognitive, psychophysiological, emotional and behavioural responses during a speech task.","BACKGROUND There is a debate among researchers and clinicians regarding whether the judicious use of safety behaviours (SBs) during exposure therapy is helpful or detrimental. Central to this debate is the premise that SBs may interfere with one's ability to gather disconfirmatory evidence. AIMS No study to date has assessed how SB use may impact cognitive mechanisms implicated during an exposure-like task. We investigated multiple cognitive, emotional, psychophysiological and behavioural underpinnings of exposure with and without SBs. METHOD Speech anxious participants (n = 111) were randomly assigned to deliver an evaluated speech with or without SBs. Self-reported anxiety ratings and psychophysiological arousal measures were recorded at baseline, in anticipation of the speech, and following the speech. Measures of working memory, ability to gather disconfirmatory evidence, speech duration, objective and subjective speech performance, and speech task acceptability were administered. RESULTS There were no differences between conditions on working memory, self-reported anxiety, psychophysiological arousal, ability to gather disconfirmatory evidence, speech duration, or objective and subjective speech performance. All participants were able to gather disconfirmatory evidence. However, condition did influence willingness to deliver future speeches. Our sample was largely female undergraduate students, and we offered only a small number of specific safety behaviours. CONCLUSIONS Judicious SB use may not necessarily be detrimental, but clients may believe them to be more helpful than they actually are.",2020,"There were no differences between conditions on working memory, self-reported anxiety, psychophysiological arousal, ability to gather disconfirmatory evidence, speech duration, or objective and subjective speech performance.","['Speech anxious participants (n = 111', 'Our sample was largely female undergraduate students']",['evaluated speech with or without SBs'],"['Self-reported anxiety ratings and psychophysiological arousal measures', 'working memory, self-reported anxiety, psychophysiological arousal, ability to gather disconfirmatory evidence, speech duration, or objective and subjective speech performance', 'working memory, ability to gather disconfirmatory evidence, speech duration, objective and subjective speech performance, and speech task acceptability', 'cognitive, psychophysiological, emotional and behavioural responses']","[{'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0003380', 'cui_str': 'Antimony'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}]",111.0,0.0677306,"There were no differences between conditions on working memory, self-reported anxiety, psychophysiological arousal, ability to gather disconfirmatory evidence, speech duration, or objective and subjective speech performance.","[{'ForeName': 'Jessica S', 'Initials': 'JS', 'LastName': 'Tutino', 'Affiliation': 'School of Psychology, University of Ottawa, OttawaCanada.'}, {'ForeName': 'Allison J', 'Initials': 'AJ', 'LastName': 'Ouimet', 'Affiliation': 'School of Psychology, University of Ottawa, OttawaCanada.'}, {'ForeName': 'Ryan J', 'Initials': 'RJ', 'LastName': 'Ferguson', 'Affiliation': 'School of Psychology, University of Ottawa, OttawaCanada.'}]",Behavioural and cognitive psychotherapy,['10.1017/S135246582000017X'] 240,32299120,Plantar stimulation alters brain connectivity in idiopathic Parkinson's disease.,"OBJECTIVE Individuals with Parkinson's disease (PD) and freezing of gait (FOG) present peripheral and central sensitivity disturbances that impair motor performance. This study aimed to investigate long-term effects of plantar sensory stimulation on brain activity, brain connectivity, and gait velocity of individuals with PD and FOG. METHODS Twenty-five participants were enrolled in this clinical trial (NCT02594540). Plantar sensory stimulation was delivered using the Automated Mechanical Peripheral Stimulation therapy (AMPS). Volunteers were randomly assigned to real or placebo AMPS groups and received eight sessions of treatment. The primary outcome was brain activity (task-based fMRI-active ankle dorsi-plantar flexion). Secondary outcomes were brain connectivity (resting state-RS fMRI) and gait velocity. fMRI was investigated on the left, right, and mid-sensory motor regions, left and right basal ganglia. RESULTS No changes in brain activity were observed when task-based fMRI was analyzed. After real AMPS, RS functional connectivity between basal ganglia and sensory-related brain areas increased (insular and somatosensory cortices). Gait velocity also increased after real AMPS. A positive correlation was found between gait velocity and the increased connectivity between sensory, motor and supplementary motor cortices. CONCLUSION Plantar sensory stimulation through AMPS was not able to modify brain activity. AMPS increased the RS brain connectivity mainly in areas related to sensory processing and sensorimotor integration. Plantar stimulation could be a way to improve plantar sensitivity and consequently ameliorate gait performance. However, the mechanisms behind the way AMPS influences brain pathways are still not completely known.",2020,"After real AMPS, RS functional connectivity between basal ganglia and sensory-related brain areas increased (insular and somatosensory cortices).","['subjects with PD and FOG.\nMETHODS\n\n\nTwenty-five subjects', ""Individuals with Parkinson's Disease (PD) and freezing of gait (FOG"", ""idiopathic Parkinson's Disease""]","['AMPS', 'plantar sensory stimulation', 'placebo AMPS', 'Plantar stimulation', 'Plantar sensory stimulation was delivered using the Automated Mechanical Peripheral Stimulation therapy (AMPS']","['connectivity between sensory, motor and supplementary motor cortices', 'RS brain connectivity', 'brain activity, brain connectivity and gait velocity', 'brain activity (task-based fMRI - active ankle dorsi-plantar flexion', 'fMRI', 'RS functional connectivity between basal ganglia and sensory-related brain areas increased (insular and somatosensory cortices', 'brain activity', 'Gait velocity', 'brain connectivity (resting-state - RS fMRI) and gait velocity', 'gait velocity', 'plantar sensitivity and consequently ameliorate gait performance']","[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0150763', 'cui_str': 'Sensory stimulation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C3496174', 'cui_str': 'Supplementary Motor Area'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0443158', 'cui_str': 'Brain activity'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0231784', 'cui_str': 'Plantar flexion'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0004781', 'cui_str': 'Basal ganglion structure'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0037658', 'cui_str': 'Somatosensory Cortex'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]",25.0,0.0374991,"After real AMPS, RS functional connectivity between basal ganglia and sensory-related brain areas increased (insular and somatosensory cortices).","[{'ForeName': 'Aline Souza', 'Initials': 'AS', 'LastName': 'Pagnussat', 'Affiliation': 'Graduate Program in Rehabilitation Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil.'}, {'ForeName': 'Ana Paula', 'Initials': 'AP', 'LastName': 'Salazar', 'Affiliation': 'Graduate Program in Rehabilitation Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil.'}, {'ForeName': 'Camila', 'Initials': 'C', 'LastName': 'Pinto', 'Affiliation': 'Graduate Program in Rehabilitation Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil.'}, {'ForeName': 'Ritchele', 'Initials': 'R', 'LastName': 'Redivo Marchese', 'Affiliation': 'Graduate Program in Rehabilitation Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil.'}, {'ForeName': 'Carlos R M', 'Initials': 'CRM', 'LastName': 'Rieder', 'Affiliation': 'Graduate Program in Rehabilitation Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil.'}, {'ForeName': 'José Osmar', 'Initials': 'JO', 'LastName': 'Alves Filho', 'Affiliation': 'Autism Center, Child Mind Institute, New York, NY, USA.'}, {'ForeName': 'Alexandre R', 'Initials': 'AR', 'LastName': 'Franco', 'Affiliation': 'Center for Biomedical Imaging and Neuromodulation, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA.'}, {'ForeName': 'Ana Francisca Rozin', 'Initials': 'AFR', 'LastName': 'Kleiner', 'Affiliation': 'Department of Physiotherapy, Universidade Federal de São Carlos (UFSCAR), São Carlos, Brazil.'}]",Acta neurologica Scandinavica,['10.1111/ane.13253'] 241,32303894,The Physiological Regulation of Emotion During Social Interactions: Vagal Flexibility Moderates the Effects of a Military Parenting Intervention on Father Involvement in a Randomized Trial.,"To make prevention programs more effective and understand ""what works for whom,"" evidence regarding what individual characteristics predict intervention responsiveness is needed. Previous studies have evaluated a military parent training program known as After Deployment Adaptive Parenting Tools/ADAPT, yet less is understood about the program's varying effects for fathers. We tested the physiological regulation of emotion during social interactions as a moderator predicting fathers' responsiveness in a randomized trial of ADAPT, in which emotion regulation was operationally measured through vagal flexibility (VF; dynamic changes in cardiac vagal tone). Families with a child aged between 4 and 13 years for whom physiological data were gathered (n = 145) were randomly assigned to ADAPT (14-week face-to-face group intervention) or a control group (services as usual). Fathers in these families were National Guard/Reserve members who had been deployed to war in Iraq and/or Afghanistan and recently returned. Prior to the intervention, cardiac data was collected in-home throughout a set of family interaction tasks and VF was operationalized as the changes in high frequency (HF) power of heart rate variability (HRV) from a reading task to a problem-solving task. Parenting behaviors were observed and coded based on theory-driven indicators pre-intervention and at 1-year follow-up. Results of structural equation modeling showed that VF significantly moderated fathers' intervention responsiveness, such that fathers with higher vs. lower VF exhibited more effective parenting at 1-year follow-up if they were randomized into ADAPT vs. the control group. This study is the first to demonstrate that parasympathetic vagal functioning may be a biomarker to predict response to a military parenting intervention to enhance parenting in combat deployed fathers. The implications for precision-based prevention are discussed.",2020,"Results of structural equation modeling showed that VF significantly moderated fathers' intervention responsiveness, such that fathers with higher vs. lower VF exhibited more effective parenting at 1-year follow-up if they were randomized into ADAPT vs. the control group.","['Emotion During Social Interactions', 'Families with a child aged between 4 and 13\xa0years for whom physiological data were gathered (n\u2009=\u2009145', 'Fathers in these families were National Guard/Reserve members who had been deployed to war in Iraq and/or Afghanistan and recently returned']","['Military Parenting Intervention', 'military parenting intervention', 'ADAPT (14-week face-to-face group intervention) or a control group (services as usual']","['Parenting behaviors', 'vagal flexibility (VF; dynamic changes in cardiac vagal tone']","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0037420', 'cui_str': 'Interaction with others'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C4517577', 'cui_str': '145'}, {'cui': 'C0015671', 'cui_str': 'Father'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0278253', 'cui_str': 'Guarded prognosis'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0043027', 'cui_str': 'War'}, {'cui': 'C0022066', 'cui_str': 'Iraq'}, {'cui': 'C0001732', 'cui_str': 'Afghanistan'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0332156', 'cui_str': 'Return to'}]","[{'cui': 'C0026126', 'cui_str': 'Military personnel'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0557854', 'cui_str': 'Services'}]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}]",145.0,0.0230976,"Results of structural equation modeling showed that VF significantly moderated fathers' intervention responsiveness, such that fathers with higher vs. lower VF exhibited more effective parenting at 1-year follow-up if they were randomized into ADAPT vs. the control group.","[{'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Zhang', 'Affiliation': 'REACH Institute, Department of Psychology, Arizona State University, 900 S. McAllister, Psychology North, Rm 212, Tempe, AZ, 85287, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Hoch', 'Affiliation': 'Department of Educational Psychology, University of Minnesota-Twin Cities, 250 Education Sciences Bldg, 56 East River Rd, Minneapolis, MN, 55455, USA.'}, {'ForeName': 'Abigail H', 'Initials': 'AH', 'LastName': 'Gewirtz', 'Affiliation': 'Department of Family Social Science and Institute of Child Development, University of Minnesota-Twin Cities, 290 McNeal Hall, 1985 Buford Ave, St. Paul, MN, 55108, USA. agewirtz@umn.edu.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-020-01122-6'] 242,30958141,Stress reduction intervention with mothers of children/adolescents with asthma: a randomized controlled study in Brazil.,"Brazil has a high prevalence of pediatric asthma, which can be a stressor to parents/caretakers. Researchers aimed to assesses the efficacy of a stress reduction intervention for mothers of children/adolescents with asthma through a randomized controlled study. Stress, anxiety, and depression were evaluated in three moments. The intervention group ( n  = 20), entailed 5-weekly sessions; the control group ( n  =34) had waiting list format. There was a significant decrease in stress, anxiety, and depression in the intervention group. This study indicates that the intervention directed to mothers of children/adolescents with asthma was efficient not only in reducing stress but also anxiety and depression reduction.",2020,"There was a significant decrease in stress, anxiety, and depression in the intervention group.",['mothers of children/adolescents with asthma'],"['Brazil', 'Stress reduction intervention', 'waiting list format', 'stress reduction intervention']","['Stress, anxiety, and depression', 'stress, anxiety, and depression']","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}]","[{'cui': 'C0006137', 'cui_str': 'Brazil'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C1301627', 'cui_str': 'Format'}]","[{'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]",,0.0193105,"There was a significant decrease in stress, anxiety, and depression in the intervention group.","[{'ForeName': 'Sandra Cairo de Oliveira', 'Initials': 'SCO', 'LastName': 'Amaral', 'Affiliation': 'Medical Clinic, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Filipa', 'Initials': 'F', 'LastName': 'Pimenta', 'Affiliation': 'ISPA - Instituto Universitário/WJCR - William James Center for Research, Lisbon, Portugal.'}, {'ForeName': 'João', 'Initials': 'J', 'LastName': 'Marôco', 'Affiliation': 'ISPA - Instituto Universitário/WJCR - William James Center for Research, Lisbon, Portugal.'}, {'ForeName': 'Clemax Couto', 'Initials': 'CC', 'LastName': ""Sant'Anna"", 'Affiliation': 'Medical Clinic, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}]",Health care for women international,['10.1080/07399332.2019.1570201'] 243,30977980,"Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers.","Glasdegib (PF-04449913) is an oral small-molecule inhibitor of the Hedgehog signaling pathway under development for treating myeloid malignancies. This was an open-label phase 1, randomized, 2-sequence, 2-treatment, 2-period, crossover study evaluating the absolute bioavailability of glasdegib in healthy volunteers under fasting condition (NCT03270878). In period 1, 12 eligible subjects received either a single oral dose of glasdegib 100 mg (tablet) or a single intravenous (IV) dose of glasdegib 50 mg. Following ≥6-day washout, subjects received the treatment that they did not receive in the first period. Blood samples were collected for up to 96 hours after dosing. Drug plasma concentrations were determined by high-performance liquid chromatography-tandem mass spectrometry. Glasdegib pharmacokinetic parameters were calculated using noncompartmental analysis. The mean terminal half-life was 14.3 hours for oral tablet treatment vs 13.8 hours for glasdegib IV treatment. The absolute oral bioavailability measured as the ratios (oral/IV) of adjusted geometric mean (90% confidence interval) of dose normalized area under the plasma concentration-time curve was 77.12% (71.83%-82.81%). Two adverse events (1 mild and 1 moderate in severity) were reported by 2 subjects following oral tablet administration; these were fully resolved by the end of the study.",2019,The mean terminal half-life was 14.3 hours for oral tablet treatment vs 13.8 hours for glasdegib IV treatment.,"['Randomized Healthy Volunteers', 'healthy volunteers under fasting condition (NCT03270878', '12 eligible subjects']","['glasdegib 100 mg (tablet) or a single intravenous (IV) dose of glasdegib 50 mg', 'Glasdegib (PF-04449913']","['absolute oral bioavailability', 'Absolute Oral Bioavailability', 'Blood samples', 'Drug plasma concentrations', 'plasma concentration-time curve', 'mean terminal half-life', 'Glasdegib pharmacokinetic parameters']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C3886640', 'cui_str': 'PF-04449913'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",,0.021152,The mean terminal half-life was 14.3 hours for oral tablet treatment vs 13.8 hours for glasdegib IV treatment.,"[{'ForeName': 'Naveed', 'Initials': 'N', 'LastName': 'Shaik', 'Affiliation': 'Pfizer Inc, San Diego, CA, USA.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Hee', 'Affiliation': 'Pfizer Inc, Groton, CT, USA.'}, {'ForeName': 'Yali', 'Initials': 'Y', 'LastName': 'Liang', 'Affiliation': 'Pfizer Inc, Groton, CT, USA.'}, {'ForeName': 'Robert Roland', 'Initials': 'RR', 'LastName': 'LaBadie', 'Affiliation': 'Pfizer Inc, Groton, CT, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.692'] 244,32301137,Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data.,"BACKGROUND Relamorelin, a pentapeptide ghrelin receptor agonist, accelerated gastric emptying significantly and improved symptoms in adults with diabetic gastroparesis in phase 2 trials. AIM To assess the safety and tolerability of relamorelin across phase 2 trials. METHODS Safety assessments in patients aged 18-75 years (weight, adverse events [AEs] and laboratory tests) from two randomised, double-blind phase 2 trials (NCT01571297, NCT02357420; results published previously) were reviewed descriptively. Analysis of covariance assessed treatment effect on glycated haemoglobin (HbA1c) and blood glucose post hoc. Phase 2a and 2b trial durations were, respectively, 4 weeks (relamorelin 10 µg once or twice daily [b.d.] or placebo b.d.) and 12 weeks (relamorelin 10, 30 or 100 µg or placebo b.d.) with 1- and 2-week, single-blind placebo run-ins. RESULTS Among 204 phase 2a and 393 phase 2b patients, respectively, 67% and 62% were female, and 88% and 89% had type 2 diabetes. Proportions of patients reporting serious AEs were similar across treatment groups, as were those with ≥1 treatment-emergent AE (TEAE). TEAE-related discontinuations were proportionally higher in relamorelin groups than placebo. Of 12 serious TEAEs in phase 2a, none occurred in >1 patient. In phase 2b, five serious TEAEs were reported in >1 patient, and one (100 µg) died (urosepsis), all unrelated to relamorelin. In phase 2b, increased HbA1c and fasting blood glucose levels were dose-related (P < 0.0001 and P = 0.0043, respectively). CONCLUSIONS Relamorelin showed acceptable safety and tolerability in phase 2 trials. Relamorelin may elevate blood glucose: this should be managed proactively in relamorelin-treated patients.",2020,"In phase 2b, increased HbA1c and fasting blood glucose levels were dose-related (P < 0.0001 and P = 0.0043, respectively). ","['adults with diabetic gastroparesis', '204 phase 2a and 393 phase 2b patients, respectively, 67% and 62% were female, and 88% and 89% had type 2 diabetes', 'adults with diabetic gastroparesis in phase\xa02 trials', 'patients aged 18-75\xa0years (weight, adverse events [AEs] and laboratory tests']","['Relamorelin', 'placebo', 'relamorelin', 'placebo b.d.) and 12\xa0weeks (relamorelin 10, 30 or 100\xa0µg or placebo b.d.) with 1- and 2-week, single-blind placebo run-ins']","['Overall safety', 'glycated haemoglobin (HbA1c) and blood glucose post hoc', 'TEAE-related discontinuations', 'blood glucose', 'safety and tolerability', 'acceptable safety and tolerability', 'HbA1c and fasting blood glucose levels']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0267176', 'cui_str': 'Gastroparesis with diabetes mellitus'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C4517754', 'cui_str': '393'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0282460', 'cui_str': 'Clinical Trials, Phase II as Topic'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0022885', 'cui_str': 'Laboratory procedure'}]","[{'cui': 'C4045486', 'cui_str': 'relamorelin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0242570', 'cui_str': 'Single-Masked Study'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}]",,0.432022,"In phase 2b, increased HbA1c and fasting blood glucose levels were dose-related (P < 0.0001 and P = 0.0043, respectively). ","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Camilleri', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Lembo', 'Affiliation': 'Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'McCallum', 'Affiliation': 'Division of Gastroenterology, Texas Tech University Health Sciences Center, El Paso, TX, USA.'}, {'ForeName': 'Stavros', 'Initials': 'S', 'LastName': 'Tourkodimitris', 'Affiliation': 'Biostatistics, Allergan plc, Madison, NJ, USA.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Kemps', 'Affiliation': 'Clinical Development, Allergan plc, Madison, NJ, USA.'}, {'ForeName': 'Matthew B', 'Initials': 'MB', 'LastName': 'Miller', 'Affiliation': 'Chemistry, Manufacturing and Controls, Allergan plc, Madison, NJ, USA.'}, {'ForeName': 'Kirk', 'Initials': 'K', 'LastName': 'Bertelsen', 'Affiliation': 'Clinical Pharmacology, Allergan plc, Madison, NJ, USA.'}, {'ForeName': 'Alexandru', 'Initials': 'A', 'LastName': 'Iacob', 'Affiliation': 'Medical Safety, Allergan plc, Madison, NJ, USA.'}]",Alimentary pharmacology & therapeutics,['10.1111/apt.15711'] 245,32299820,Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma.,"PURPOSE Treatment of multiple myeloma has evolved tremendously and optimal utilization of available therapies will ensure maximal patient benefits. PATIENTS AND METHODS We report the Southwest Oncology Group randomized phase II trial (S1304) comparing twice weekly low-dose (27 mg/m 2 ; arm 1) to high-dose carfilzomib (56 mg/m 2 ; arm 2), both with dexamethasone, administered for 12 cycles (11 months) for relapsed and/or refractory multiple myeloma with up to six prior lines of therapy (NCT01903811). The primary endpoint was progression-free survival (PFS), and patients on arm 1 could cross-over to arm 2 after progression on treatment. RESULTS Among 143 enrolled patients, of whom 121 were eligible and analyzable, the overall response rate was 42.8%, with no significant difference between the arms ( P = 0.113). Also, neither the median PFS [5 months and 8 months, respectively; HR, 1.061; 80% Wald confidence interval (CI), 0.821-1.370; P = 0.384] nor the median overall survival were significantly different (26 and 22 months, respectively; HR, 1.149, 80% Wald CI, 0.841-.571; P = 0.284). Sixteen patients crossed over to arm 2 with a median PFS benefit of 3 months. Certain adverse events (AE) were more frequent in arm 2, including fatigue, thrombocytopenia, and peripheral neuropathy, but there was no significant difference in cardiopulmonary AEs. CONCLUSIONS This randomized trial did not support a benefit of fixed duration, twice weekly 56 mg/m 2 dosing of carfilzomib over the 27 mg/m 2 dose for the treatment of relapsed and/or refractory multiple myeloma. However, treatment to progression in earlier patient populations with high-dose carfilzomib using different schedules should still be considered as part of the standard of care.",2020,"Certain adverse events (AE) were more frequent in Arm 2, including fatigue, thrombocytopenia and peripheral neuropathy, but there was no significant difference in cardiopulmonary AEs. ","['multiple myeloma (MM', '143 enrolled patients', 'Patients with Relapsed-Refractory Multiple Myeloma']","['dexamethasone', 'carfilzomib', 'Dexamethasone']","['fatigue, thrombocytopenia and peripheral neuropathy', 'cardiopulmonary AEs', 'median overall survival', 'Certain adverse events (AE', 'overall response rate', 'progression-free survival (PFS', 'median PFS']","[{'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}, {'cui': 'C4517573', 'cui_str': '143'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C4551538', 'cui_str': 'Plasma cell myeloma refractory'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C2001856', 'cui_str': 'carfilzomib'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0040034', 'cui_str': 'Thrombocytopenic disorder'}, {'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205423', 'cui_str': 'Certain'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",143.0,0.0870112,"Certain adverse events (AE) were more frequent in Arm 2, including fatigue, thrombocytopenia and peripheral neuropathy, but there was no significant difference in cardiopulmonary AEs. ","[{'ForeName': 'Sikander', 'Initials': 'S', 'LastName': 'Ailawadhi', 'Affiliation': 'Mayo Clinic, Jacksonville, Florida. ailawadhi.sikander@mayo.edu.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Sexton', 'Affiliation': 'Cancer Research and Biostatistics, Seattle, Washington.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Lentzsch', 'Affiliation': 'Columbia University Medical Center, New York, New York.'}, {'ForeName': 'Muneer H', 'Initials': 'MH', 'LastName': 'Abidi', 'Affiliation': 'Spectrum Health/Michigan State University, Grand Rapids, Michigan.'}, {'ForeName': 'Peter M', 'Initials': 'PM', 'LastName': 'Voorhees', 'Affiliation': 'Levine Cancer Institute, Charlotte, North Carolina.'}, {'ForeName': 'Adam D', 'Initials': 'AD', 'LastName': 'Cohen', 'Affiliation': 'Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Eric M', 'Initials': 'EM', 'LastName': 'Rohren', 'Affiliation': 'Baylor College of Medicine, Houston, Texas.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Heitner', 'Affiliation': 'Oregon Health & Science University, Portland, Oregon.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Kelly', 'Affiliation': 'Norris Comprehensive Cancer Center, Los Angeles, California.'}, {'ForeName': 'Niklas J', 'Initials': 'NJ', 'LastName': 'Mackler', 'Affiliation': 'IHA Hem/Onc, Ann Arbor, Michigan.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Baer', 'Affiliation': 'Kaiser Permanente, Oakland, California.'}, {'ForeName': 'Antje', 'Initials': 'A', 'LastName': 'Hoering', 'Affiliation': 'Cancer Research and Biostatistics, Seattle, Washington.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Durie', 'Affiliation': 'Cedars-Sinai Comprehensive Cancer Center, Los Angeles, California.'}, {'ForeName': 'Robert Z', 'Initials': 'RZ', 'LastName': 'Orlowski', 'Affiliation': 'The University of Texas MD Anderson Cancer Center, Houston, Texas.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-19-1997'] 246,30650257,A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet.,"Ezutromid (SMT C1100) is a small-molecule utrophin modulator that was developed to treat Duchenne muscular dystrophy (DMD). Previous clinical trials of this agent revealed lower exposure in DMD patients compared with healthy volunteers, which may reflect differences in diet. This study evaluated the pharmacokinetics of ezutromid in patients with DMD who followed a balanced diet. This was a multicenter, double-blind, placebo-controlled, ascending single and multiple oral dose study. Twelve pediatric patients were randomly allocated to 1 of 3 treatment sequences within which were 3 treatment periods of 2 weeks each. Each patient received, in a dose-escalating fashion, 1250 mg and 2500 mg twice daily (BID) of ezutromid administered orally as a microfluidized suspension (F3) with placebo in the other treatment period. Throughout the study, patients followed a balanced diet including recommended proportions of major food groups and administration of drug accompanied with 100 mL of full-fat milk. This approach improved the absorption of ezutromid, resulting in higher systemic exposure, with considerable variability in exposure between patients at each dose level. Single and multiple oral doses of 1250 mg and 2500 mg BID were considered safe and well tolerated. No severe or serious adverse events and no study discontinuations due to adverse events were reported. This study provides assurance that, with the formulation tested (F3) and instructions regarding food (balanced diet and whole-fat milk), 2500 mg BID of ezutromid achieves plasma concentrations that, based on preclinical studies, should be able to modulate utrophin expression in future clinical trials.",2019,No severe or serious adverse events and no study discontinuations due to adverse events were reported.,"['patients with DMD who followed a balanced diet', 'Twelve pediatric patients', 'Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet']","['placebo', 'balanced diet including recommended proportions of major food groups and administration of drug accompanied with 100 mL of full-fat milk', 'formulation tested (F3) and instructions regarding food (balanced diet and whole-fat milk', 'ezutromid administered orally as a microfluidized suspension (F3) with placebo', 'Ezutromid (SMT C1100']","['considered safe and well tolerated', 'severe or serious adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0013264', 'cui_str': 'Cardiomyopathy, Dilated, X-Linked'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C1382107', 'cui_str': 'Suspension'}, {'cui': 'C4308021', 'cui_str': 'SMT C1100'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",12.0,0.0714875,No severe or serious adverse events and no study discontinuations due to adverse events were reported.,"[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Muntoni', 'Affiliation': 'Dubowitz Neuromuscular Centre, University College London Institute of Child Health, London, UK.'}, {'ForeName': 'Bina', 'Initials': 'B', 'LastName': 'Tejura', 'Affiliation': 'Summit Therapeutics, Abingdon, UK.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Spinty', 'Affiliation': ""Alder Hey Children's NHS Foundation Trust, Liverpool, UK.""}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Roper', 'Affiliation': 'Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Imelda', 'Initials': 'I', 'LastName': 'Hughes', 'Affiliation': ""Royal Manchester Children's Hospital, Central Manchester University Hospitals NHS Foundation Trust, UK.""}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Layton', 'Affiliation': 'ParamStat Limited, Ash, UK.'}, {'ForeName': 'Kay E', 'Initials': 'KE', 'LastName': 'Davies', 'Affiliation': 'MRC Functional Genomics Unit, University of Oxford, Department of Physiology Anatomy and Genetics, Oxford, UK.'}, {'ForeName': 'Shawn', 'Initials': 'S', 'LastName': 'Harriman', 'Affiliation': 'Summit Therapeutics, Abingdon, UK.'}, {'ForeName': 'Jonathon', 'Initials': 'J', 'LastName': 'Tinsley', 'Affiliation': 'Summit Therapeutics, Abingdon, UK.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.642'] 247,32301812,The Influence of Speed During Stripping in Descemet Membrane Endothelial Keratoplasty Tissue Preparation.,"PURPOSE To evaluate whether the speed of stripping a Descemet membrane endothelial keratoplasty graft influences the graft scroll width. METHODS Human corneas suitable for research were selected for the study. Pairs of corneas were randomly divided into 2 groups: 1 cornea was stripped with a slow speed (group 1) and the contralateral with a fast speed (group 2). Slow speed was defined as the total time greater than 150 seconds or speed <0.057 mm/s. Fast peeling was defined as less than 75 seconds or speed >0.11 mm/s. The grafts acquired were evaluated by microscopy for the graft scroll width and endothelial cell density change pre- and post-preparation. RESULTS Twenty corneas of 10 donors were included in the analysis. The mean donor age was 68.6 ± 7.58 years. The mean total time of the tissue preparation in group 1 was 282.7 ± 28 seconds and in group 2 was 126 ± 50 seconds (P-value = 0.00000047). The mean speed of stripping in group 1 was 0.045 ± 0.006 mm/s and in group 2 was 0.266 ± 0.093 mm/s (P-value = 0.000027). The graft width in group 1 was 6.4 ± 0.92 mm and in group 2 was 2.87 ± 0.32 mm (P-value = 0.00000014). The mean endothelial cell loss in group 1 was 389 ± 149 cells/mm and in group 2 was 186 ± 63.44 cells/mm (P-value = 0.00134). CONCLUSION We found a correlation between the speed of stripping, scroll width, and endothelial cell loss. Slow-peeled Descemet membrane endothelial keratoplasty grafts result in a wider scroll width but were associated with a greater reduction in endothelial cell density.",2020,The mean total time of the tissue preparation in group 1 was 282.7 ± 28 seconds and in group 2 was 126 ± 50 seconds (P-value = 0.00000047).,"['The mean donor age was 68.6 ± 7.58 years', 'Twenty corneas of 10 donors were included in the analysis', 'Human corneas suitable for research were selected for the study']","['Slow-peeled Descemet membrane endothelial keratoplasty grafts', '1 cornea was stripped with a slow speed (group 1) and the contralateral with a fast speed']","['speed of stripping, scroll width, and endothelial cell loss', 'graft width', 'mean speed of stripping', 'endothelial cell density', 'Fast peeling', 'Slow speed', 'mean endothelial cell loss', 'mean total time of the tissue preparation']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517855', 'cui_str': '68.6'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0010031', 'cui_str': 'Corneal structure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0237849', 'cui_str': 'Peeling of skin'}, {'cui': 'C4302773', 'cui_str': ""Descemet's membrane endothelial keratoplasty""}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0010031', 'cui_str': 'Corneal structure'}, {'cui': 'C0185047', 'cui_str': 'Stripping'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441988', 'cui_str': 'Contralateral'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}]","[{'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0487742', 'cui_str': 'Width'}, {'cui': 'C0225336', 'cui_str': 'Endothelial cell'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0185047', 'cui_str': 'Stripping'}, {'cui': 'C0429518', 'cui_str': 'Endothelial cell density'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0200728', 'cui_str': 'Tissue processing technique'}]",,0.0244605,The mean total time of the tissue preparation in group 1 was 282.7 ± 28 seconds and in group 2 was 126 ± 50 seconds (P-value = 0.00000047).,"[{'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Borroni', 'Affiliation': ""Department of Corneal and External Eye Diseases, St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom.""}, {'ForeName': 'Kunal', 'Initials': 'K', 'LastName': 'Gadhvi', 'Affiliation': ""Department of Corneal and External Eye Diseases, St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom.""}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Wojcik', 'Affiliation': 'International Center for Ocular Physiopathology, The Veneto Eye Bank Foundation, Venice, Italy.'}, {'ForeName': 'Flavia', 'Initials': 'F', 'LastName': 'Pennisi', 'Affiliation': 'Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy.'}, {'ForeName': 'Neeru A', 'Initials': 'NA', 'LastName': 'Vallabh', 'Affiliation': ""Department of Corneal and External Eye Diseases, St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom.""}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Galeone', 'Affiliation': 'International Center for Ocular Physiopathology, The Veneto Eye Bank Foundation, Venice, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Ruzza', 'Affiliation': 'International Center for Ocular Physiopathology, The Veneto Eye Bank Foundation, Venice, Italy.'}, {'ForeName': 'Esmaeil', 'Initials': 'E', 'LastName': 'Arbabi', 'Affiliation': ""Department of Corneal and External Eye Diseases, St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom.""}, {'ForeName': 'Nardine', 'Initials': 'N', 'LastName': 'Menassa', 'Affiliation': ""Department of Corneal and External Eye Diseases, St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom.""}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Kaye', 'Affiliation': ""Department of Corneal and External Eye Diseases, St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom.""}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Ponzin', 'Affiliation': 'International Center for Ocular Physiopathology, The Veneto Eye Bank Foundation, Venice, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Ferrari', 'Affiliation': 'International Center for Ocular Physiopathology, The Veneto Eye Bank Foundation, Venice, Italy.'}, {'ForeName': 'Vito', 'Initials': 'V', 'LastName': 'Romano', 'Affiliation': ""Department of Corneal and External Eye Diseases, St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom.""}]",Cornea,['10.1097/ICO.0000000000002338'] 248,32304710,Presoaking of Semitendinosus Graft With Vancomycin Does Not Alter Its Biomechanical Properties: A Biomechanical In Vitro-Controlled Study Using Graft From Living Donors.,"PURPOSE To compare the biomechanical properties of human semitendinosus graft presoaked with or without vancomycin under a load to failure tensile test. METHODS Thirty semitendinosus grafts harvested during anterior cruciate ligament reconstruction were included. These were dissected equally into 2 halves and subsequently randomly allocated to a vancomycin group and to a control group. A digital caliper was used to precisely measure each samples thickness, length, and width. For the vancomycin group, samples were presoaked in a solution of 5 mg/mL vancomycin for a duration of 10 minutes and the control group samples were presoaked in a physiological serum equally for 10 minutes. Mechanical testing was performed on a universal testing machine (Instron 5566-A) after a preconditioning of 10 cycles of 1 mm extension and a progression of 10 mm/min to failure for each sample. The stress-strain curve was obtained to determine the elastic modulus (Young's modulus), the ultimate tensile stress, the ultimate tensile elongation (UTE) before failure and the elasticity limit. RESULTS For the control group, the average Young's modulus value was 4.8 ± 0.8, the average UTS was 25.2 ± 5.2 MPa, the average percentage of UTE was 78 ± 17%, and the average elasticity limit value was 17.3 ± 5.3 MPa. For the vancomycin group, the average Young's modulus value was 4.7 ± 0.9, the average ultimate tensile stress was 24.1 ± 6.1 MPa, the average percentage of UTE was 82 ± 14%, and the average elasticity limit value was 18.5 ± 5.9 MPa. No significant difference was observed between the 2 groups for all investigated parameters. CONCLUSIONS Presoaking of human semitendinosus graft with vancomycin does not alter its biomechanical properties. CLINICAL RELEVANCE This study demonstrates that vancomycin presoaking used to prevent post-anterior cruciate ligament reconstruction septic arthritis does not affect immediate biomechanical properties of semitendinosus tendons.",2020,"The stress-strain curve was obtained to determine the elastic modulus (Young's modulus), the Ultimate Tensile Stress (UTS), the Ultimate Tensile Elongation (UTE) before failure and the elasticity limit. ","['graft from living donors', 'Thirty semitendinosus grafts harvested during ACL reconstruction were included']","['vancomycin', 'human semitendinosus graft pre-soaked with or without vancomycin']","['stress-strain curve', 'Ultimate Tensile Stress (UTS), the Ultimate Tensile Elongation (UTE) before failure and the elasticity limit']","[{'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0348050', 'cui_str': 'Live donor'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0224453', 'cui_str': 'Semitendinosus muscle structure'}, {'cui': 'C0162596', 'cui_str': 'Cardiolipin antibody'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0042313', 'cui_str': 'Vancomycin'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0224453', 'cui_str': 'Semitendinosus muscle structure'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0204774', 'cui_str': 'Soak'}]","[{'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0439801', 'cui_str': 'Limited'}]",,0.0163028,"The stress-strain curve was obtained to determine the elastic modulus (Young's modulus), the Ultimate Tensile Stress (UTS), the Ultimate Tensile Elongation (UTE) before failure and the elasticity limit. ","[{'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Jacquet', 'Affiliation': 'Institute of Movement and Locomotion, Department of Orthopedics and Traumatology, St. Marguerite Hospital, Marseille, France.'}, {'ForeName': 'Maxime', 'Initials': 'M', 'LastName': 'Jaubert', 'Affiliation': 'Institute of Movement and Locomotion, Department of Orthopedics and Traumatology, St. Marguerite Hospital, Marseille, France.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Pioger', 'Affiliation': 'Institute of Movement and Locomotion, Department of Orthopedics and Traumatology, St. Marguerite Hospital, Marseille, France.'}, {'ForeName': 'Abderahmane', 'Initials': 'A', 'LastName': 'Sbihi', 'Affiliation': 'Institute of Movement and Locomotion, Department of Orthopedics and Traumatology, St. Marguerite Hospital, Marseille, France.'}, {'ForeName': 'Martine', 'Initials': 'M', 'LastName': 'Pithioux', 'Affiliation': 'Institute of Movement and Locomotion, Department of Orthopedics and Traumatology, St. Marguerite Hospital, Marseille, France.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Le Baron', 'Affiliation': 'Institute of Movement and Locomotion, Department of Orthopedics and Traumatology, St. Marguerite Hospital, Marseille, France.'}, {'ForeName': 'Akash', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Institute of Movement and Locomotion, Department of Orthopedics and Traumatology, St. Marguerite Hospital, Marseille, France; Institut de Chirurgie Orthopédique et Sportive, Marseille, France.'}, {'ForeName': 'Matthieu', 'Initials': 'M', 'LastName': 'Ollivier', 'Affiliation': 'Institute of Movement and Locomotion, Department of Orthopedics and Traumatology, St. Marguerite Hospital, Marseille, France. Electronic address: matthieu.ollivier@ap-hm.fr.'}]",Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association,['10.1016/j.arthro.2020.03.037'] 249,31175709,Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects.,"Assessing risk for QTc interval prolongation in a thorough QTc study is a standard recommendation when evaluating new chemical entities. As part of the clinical development program for odanacatib, an oral selective inhibitor of cathepsin K previously in development for the treatment of osteoporosis, 2 clinical studies in healthy subjects assessed pharmacokinetics and overall safety (including potential for delayed ventricular repolarization) of a supratherapeutic dose. In study 1, subjects received a supratherapeutic dose regimen of odanacatib (300 mg on day 1, then daily multiple doses of 25 mg to day 21) or placebo. In study 2 (days 1-4), subjects received the odanacatib supratherapeutic dose regimen or moxifloxacin (positive control, single 400-mg dose on day 4; matching placebo for odanacatib/moxifloxacin) or placebo. All doses were administered with a high-fat meal. In study 1 (N = 12), the supratherapeutic dosing regimen achieved exposure ∼3.5-fold of the proposed therapeutic dose (50 mg once weekly) and was sufficiently well tolerated to permit assessment in the thorough QTc study (study 2). In study 2 (N = 116), the primary objective was placebo-corrected change from baseline in QTcF interval (Fridericia's correction), assessed by replicate electrocardiograms (12-lead Holter recordings; days -1 through 7). Supratherapeutic odanacatib dosing was not associated with increased risk of prolonged QT interval, unlike moxifloxacin (confirming assay sensitivity). Pooled safety data across both studies suggested that the safety profile of odanacatib at high exposures was similar to placebo, with a small clustering of oral cavity adverse events. Odanacatib was not associated with increased risk of prolonged QT interval.",2019,"Supratherapeutic odanacatib dosing was not associated with increased risk of prolonged QT interval, unlike moxifloxacin (confirming assay sensitivity).",['Healthy Subjects'],"['moxifloxacin', 'odanacatib supratherapeutic dose regimen or moxifloxacin (positive control, single 400-mg dose on day 4; matching placebo for odanacatib/moxifloxacin) or placebo', 'placebo', 'supratherapeutic dose regimen of odanacatib']","['risk of prolonged QT interval', ""QTcF interval (Fridericia's correction""]","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C2351970', 'cui_str': 'odanacatib'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0151878', 'cui_str': 'Prolonged QT interval (finding)'}, {'cui': 'C1272706', 'cui_str': 'Interval'}]",,0.203675,"Supratherapeutic odanacatib dosing was not associated with increased risk of prolonged QT interval, unlike moxifloxacin (confirming assay sensitivity).","[{'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'McCrea', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Mostoller', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Chantal', 'Initials': 'C', 'LastName': 'Mahon', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Chengcheng', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Liu', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Zajic', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Panebianco', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Manu', 'Initials': 'M', 'LastName': 'Chakravarthy', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Brandquist', 'Affiliation': 'Celerion, Lincoln, NE, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Gutierrez', 'Affiliation': 'Comprehensive NeuroScience, Inc., Miramar, FL, USA.'}, {'ForeName': 'S Aubrey', 'Initials': 'SA', 'LastName': 'Stoch', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.698'] 250,32105341,"Pretreatment of Root Canal with Photodynamic Therapy Facilitates Adhesion, Viability and Differentiation of Stem Cells of the Apical Papilla.","This study was to test the hypothesis that root canal pretreated with photodynamic therapy (PDT) would promote stem cells from the apical papilla (SCAP) adhesion, proliferation and differentiation without affecting smear layer removal and microhardness of root canal. Standardized root canals were randomized into four groups (n = 30/group): (1) sodium hypochlorite(NaOCl) group, (2) NaOCl + ethylene diaminetetraacetic acid (EDTA) group, (3) NaOCl + PDT group, (4) NaOCl + EDTA + PDT group. After treatments, smear layer removal and microhardness of root canal were evaluated. SCAP with hydroxyapatite-based scaffolds were seeded into root canals for 7 days. SCAP adhesion was observed by scanning electron microscope (SEM), and viable cells were calculated by CellTiter-Glo Luminescent kit. Platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) expression of SCAP were evaluated by Quantitative Reverse Transcriptase-Polymerase Chain Reaction. There was no significant difference in the smear layer removal and microhardness of root dentin between the groups with and without PDT treatment (P > 0.05). SCAP with elongated cytoplasmic processes and cell-cell contact were observed on the dentin surfaces treated with PDT. Elevated cell viability, PDGF and VEGF expression were found in root canal treated with PDT (P < 0.05). Under the experimental conditions, PDT could provide positive microenvironment for SCAP growth.",2020,"Elevated cell viability, PDGF and VEGF expression were found in root canal treated with PDT (P<0.05).",[],"['root canal with photodynamic therapy', 'SCAP with hydroxyapatite-based scaffolds', 'sodium hypochlorite(NaOCl', 'photodynamic therapy (PDT', 'SCAP', 'NaOCl +EDTA+PDT', 'NaOCl + ethylene diaminetetraacetic acid (EDTA) group, 3) NaOCl +PDT group, 4']","['smear layer removal and microhardness of root canal', 'smear layer removal and microhardness of root dentin', 'Platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) expression of SCAP', 'SCAP adhesion', 'Elevated cell viability, PDGF and VEGF expression']",[],"[{'cui': 'C0086881', 'cui_str': 'Root Canal'}, {'cui': 'C0031740', 'cui_str': 'Photodynamic Therapy'}, {'cui': 'C0115137', 'cui_str': 'Durapatite'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0337143', 'cui_str': 'Scaffold, device (physical object)'}, {'cui': 'C3541959', 'cui_str': 'Sodium supplement (substance)'}, {'cui': 'C0044588', 'cui_str': 'PDT'}, {'cui': 'C0015075', 'cui_str': 'Ethylene'}, {'cui': 'C0001128', 'cui_str': 'Acids'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0085070', 'cui_str': 'Smear Layer'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0086881', 'cui_str': 'Root Canal'}, {'cui': 'C0563017', 'cui_str': 'Anal penetration using finger (finding)'}, {'cui': 'C0011429', 'cui_str': 'Dentin'}, {'cui': 'C0032200', 'cui_str': 'Platelet-Derived Growth Factor'}, {'cui': 'C0078058', 'cui_str': 'Vascular Endothelial Growth Factor A'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0001511', 'cui_str': 'Tissue Adhesions'}, {'cui': 'C0007620', 'cui_str': 'Cell Viability'}]",,0.0416994,"Elevated cell viability, PDGF and VEGF expression were found in root canal treated with PDT (P<0.05).","[{'ForeName': 'Yijun', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Fujian Key Laboratory of Oral Diseases & Fujian Provincial Engineering Research Center of Oral Biomaterial & Stomatological Key lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Huan', 'Initials': 'H', 'LastName': 'Ge', 'Affiliation': 'Fujian Key Laboratory of Oral Diseases & Fujian Provincial Engineering Research Center of Oral Biomaterial & Stomatological Key lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Lixuan', 'Initials': 'L', 'LastName': 'Wu', 'Affiliation': 'Fujian Key Laboratory of Oral Diseases & Fujian Provincial Engineering Research Center of Oral Biomaterial & Stomatological Key lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Lishan', 'Initials': 'L', 'LastName': 'Lei', 'Affiliation': 'Fujian Key Laboratory of Oral Diseases & Fujian Provincial Engineering Research Center of Oral Biomaterial & Stomatological Key lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Yanhuang', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Fujian Key Laboratory of Oral Diseases & Fujian Provincial Engineering Research Center of Oral Biomaterial & Stomatological Key lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Shan', 'Initials': 'S', 'LastName': 'Jiang', 'Affiliation': 'Restorative Dental Sciences, Faculty of Dentistry, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.'}, {'ForeName': 'Zhiyu', 'Initials': 'Z', 'LastName': 'Cai', 'Affiliation': 'Department of Stomatology, Fujian Medical University Union Hospital, Fuzhou, China.'}, {'ForeName': 'Xiaojing', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Fujian Key Laboratory of Oral Diseases & Fujian Provincial Engineering Research Center of Oral Biomaterial & Stomatological Key lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China.'}]",Photochemistry and photobiology,['10.1111/php.13240'] 251,32122147,Efficacy and safety of water-exchange enteroscopy compared to carbon dioxide insufflation during enteroscopy.,"INTRODUCTION carbon dioxide (CO2) insufflation during enteroscopy reduces procedure time and subsequent symptoms and increases the insertion depth compared with room air. In colonoscopy, the water-exchange (WE) technique is associated with less pain compared with CO2 insufflation. The WE technique is not well studied in enteroscopy. The aim of this study was to compare the efficacy and safety of enteroscopy with WE and CO2. METHODS a prospective, comparative and observational study was performed of double balloon enteroscopies (DBE) that were randomized in two groups. The first group used WE while the second group used CO2 insufflation. The data collected was evaluated via univariate analysis and multiple logistic regression (variables with p ≤ 0.10 according to the univariate analysis). RESULTS forty-six DBE were included; 23 in each arm. The median age of cases was 63.5 years and 37% were female. There were no statistical differences between the groups with regard to the access route, findings, therapy and complications. Four patients (20%) in the CO2 group had adverse events (abdominal distension and pain) and one in the WE group (nausea), which was not statistically significant. The median insertion depth was greater in the CO2 group; 260 cm vs 160 cm (p = 0.048). Multiple logistic regression showed a statistically significant difference in the insertion depth using CO2 insufflation (OR 1.009, 1.001-1.017; p = 0.034). CONCLUSIONS DBE with a CO2 insufflation technique and WE are safe with a greater insertion depth with CO2.",2020,The median insertion depth was greater in the CO2 group; 260 cm vs 160 cm (p = 0.048).,"['forty-six DBE were included; 23 in each arm', 'The median age of cases was 63.5 years and 37% were female']","['CO2 insufflation', 'carbon dioxide insufflation', 'water-exchange enteroscopy', 'carbon dioxide (CO2) insufflation during enteroscopy', 'double balloon enteroscopies (DBE']","['insertion depth using CO2 insufflation', 'efficacy and safety', 'Efficacy and safety', 'adverse events (abdominal distension and pain', 'median insertion depth', 'pain']","[{'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C1143776', 'cui_str': 'cobalt(II) bis(2,2,6,6-tetramethylheptane-3,5-dionate)'}, {'cui': 'C0021634', 'cui_str': 'Insufflation'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0399619', 'cui_str': 'Enteroscopy (procedure)'}, {'cui': 'C2936452', 'cui_str': 'Push-and-Pull Enteroscopy'}]","[{'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C1143776', 'cui_str': 'cobalt(II) bis(2,2,6,6-tetramethylheptane-3,5-dionate)'}, {'cui': 'C0021634', 'cui_str': 'Insufflation'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0000731', 'cui_str': 'Swollen abdomen (finding)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",46.0,0.0548185,The median insertion depth was greater in the CO2 group; 260 cm vs 160 cm (p = 0.048).,"[{'ForeName': 'Gerardo', 'Initials': 'G', 'LastName': 'Blanco Velasco', 'Affiliation': 'Endoscopia, Centro Medico Nacional Siglo XXI, IMSS, México.'}, {'ForeName': 'Raúl Antonio', 'Initials': 'RA', 'LastName': 'Zamarripa-Mottú', 'Affiliation': 'Endoscopia, Centro Medico Nacional Siglo XXI. IMSS.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Soria-Rodríguez', 'Affiliation': 'Endoscopia, Centro Medico Nacional Siglo XXI. IMSS.'}, {'ForeName': 'Omar Michel', 'Initials': 'OM', 'LastName': 'Solórzano-Pineda', 'Affiliation': 'Endoscopia, Centro Medico Nacional Siglo XXI. IMSS.'}, {'ForeName': 'Juan Manuel', 'Initials': 'JM', 'LastName': 'Blancas Valencia', 'Affiliation': 'Endoscopia, Centro Medico Nacional Siglo XXI. IMSS, México.'}, {'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'Murcio-Pérez', 'Affiliation': 'Endoscopia, Centro Medico Nacional Siglo XXI. IMSS.'}, {'ForeName': 'Óscar Víctor', 'Initials': 'ÓV', 'LastName': 'Hernandez Mondragón', 'Affiliation': 'Endoscopía, Centro Medico Nacional Siglo XXI. IMSS, Mexico.'}]",Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva,['10.17235/reed.2020.6788/2019'] 252,32304430,Comparative Evaluation of Central Corneal Thickness in Cross-Linked Keratoconic Eyes.,"PURPOSE To compare the central corneal thickness (CCT) measurements measured by using the Pentacam Scheimpflug system with the CCT measured using ultrasound pachymetry (UP) and to compare the compatibility between the methods in normal, keratoconic, and cross-linked keratoconic corneas. METHODS The study included 50 eyes of 50 patients with keratoconus (keratoconus group), 50 eyes of 50 patients with progressive keratoconus who underwent corneal cross-linking treatment (CCL group), and 50 eyes of 50 healthy subjects (control group). Patients in the keratoconus and CCL groups were further classified into mild (mean keratometry [Km] ≤ 47 D) and moderate keratoconus subgroups (47.0 < Km < 52.0 D). CCT values were noted from the Pentacam Scheimpflug and UP. RESULTS The difference between the Pentacam and UP values was largest in the CCL group (-20.9 0.21.5 μm), followed by the keratoconus and control groups (-10.6 0.20.3 and 0.4 0.6.8 μm). The Pentacam and UP measurements were not comparable in the keratoconus and CCL groups (P = 0.001 and P < 0.001), whereas they were comparable in the control group (P = 0.62). In subgroup analysis, the 2 methods were comparable in the mild keratoconus subgroup (P = 0.12) and not comparable in the moderate keratoconus subgroup and in both mild and moderate subgroups of the CCL group (P = 0.001, P < 0.001 and P < 0.001). CONCLUSIONS Pentacam Scheimpflug tomography and UP can be used interchangeably in normal and mild keratoconic eyes, but not in moderate keratoconic and cross-linked keratoconic eyes. Pachymetry measurements from Scheimpflug must be interpreted with extreme caution with different methods before planning an invasive procedure in these eyes.",2020,"In subgroup analysis, the 2 methods were comparable in the mild keratoconus subgroup (P = 0.12) and not comparable in the moderate keratoconus subgroup and in both mild and moderate subgroups of the CCL group (P = 0.001, P < 0.001 and P < 0.001). ","['Cross-Linked Keratoconic Eyes', '50 eyes of 50 patients with keratoconus (keratoconus group), 50 eyes of 50 patients with progressive keratoconus who underwent corneal cross-linking treatment (CCL group), and 50 eyes of 50 healthy subjects (control group']",['CCL'],"['central corneal thickness (CCT) measurements', 'CCT values', 'Pentacam and UP values']","[{'cui': 'C0332220', 'cui_str': 'Cross-linking'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022578', 'cui_str': 'Keratoconus'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0007537', 'cui_str': 'Cefaclor'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0007537', 'cui_str': 'Cefaclor'}]","[{'cui': 'C1720164', 'cui_str': 'Central corneal thickness'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C1444588', 'cui_str': 'Ultrasound pachymetry'}]",50.0,0.0343386,"In subgroup analysis, the 2 methods were comparable in the mild keratoconus subgroup (P = 0.12) and not comparable in the moderate keratoconus subgroup and in both mild and moderate subgroups of the CCL group (P = 0.001, P < 0.001 and P < 0.001). ","[{'ForeName': 'Pinar', 'Initials': 'P', 'LastName': 'Kosekahya', 'Affiliation': 'Department of Ophthalmology, Ulucanlar Eye Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Koc', 'Affiliation': 'Department of Ophthalmology, Special Kayseri Maya Eye Hospital, Kayseri, Turkey.'}, {'ForeName': 'Kubra Ozdemir', 'Initials': 'KO', 'LastName': 'Yalcinsoy', 'Affiliation': 'Department of Ophthalmology, Ulucanlar Eye Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Dilara Ozkoyuncu', 'Initials': 'DO', 'LastName': 'Kocabas', 'Affiliation': 'Department of Ophthalmology, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Mustafa Ilker', 'Initials': 'MI', 'LastName': 'Toker', 'Affiliation': 'Department of Ophthalmology, Ulucanlar Eye Training and Research Hospital, Ankara, Turkey.'}]",Cornea,['10.1097/ICO.0000000000002339'] 253,31777204,How individuals change during internet-based interventions for depression: A randomized controlled trial comparing standardized and individualized feedback.,"BACKGROUND Standardized and individualized Internet-based interventions (IBI) for depression yield significant symptom improvements. However, change patterns during standardized or individualized IBI are unknown. Identifying subgroups that experience different symptom courses during IBI and their characteristics is vital for improving response. METHODS Mildly to moderately depressed individuals according to self-report (N = 1,089) were randomized to receive module-wise feedback that was either standardized or individualized by a counselor within an otherwise identical cognitive-behavioral IBI for depression (seven modules over six weeks). Depressive symptoms were assessed at baseline and before each module (Patient Health Questionnaire; PHQ-9). Other individual characteristics (self-report) and the presence of an affective disorder (structured clinical interview) were assessed at baseline. Growth mixture modeling was used to identify and compare subgroups with discernable change patterns and associated client variables across conditions. RESULTS Model comparisons suggest equal change patterns in both conditions. Across conditions, a group of immediate (62.5%) and a group of delayed improvers (37.5%) were identified. Immediate improvers decreased their PHQ-9 score by 5.5 points from pre to post, with 33% of improvement occurring before treatment commenced. Delayed improvers were characterized by stable symptom severity during the first two modules and smaller overall symptom decrease (3.4 points). Higher treatment expectations, a current major depressive disorder (interview), and lower social support were associated with delayed improvement. CONCLUSION Internet-based interventions for depression with individualized and with standardized feedback lead to comparable patterns of change. Expectation management and bolstering of social support are promising strategies for individuals that are at risk for delayed improvement.",2020,"Immediate improvers decreased their PHQ-9 score by 5.5 points from pre to post, with 33% of improvement occurring before treatment commenced.","['Mildly to moderately depressed individuals according to self-report (N\xa0=\xa01,089']",['module-wise feedback that was either standardized or individualized by a counselor within an otherwise identical cognitive-behavioral IBI for depression (seven modules over six weeks'],"['stable symptom severity', 'Depressive symptoms', 'PHQ-9 score']","[{'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}]","[{'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C1571885', 'cui_str': 'Counselors'}, {'cui': 'C0205280', 'cui_str': 'Identical (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",1089.0,0.0919134,"Immediate improvers decreased their PHQ-9 score by 5.5 points from pre to post, with 33% of improvement occurring before treatment commenced.","[{'ForeName': 'Pavle', 'Initials': 'P', 'LastName': 'Zagorscak', 'Affiliation': 'Department of Clinical-Psychological Intervention, Freie Universität Berlin, Berlin, Germany.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Heinrich', 'Affiliation': 'Department of Clinical-Psychological Intervention, Freie Universität Berlin, Berlin, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Bohn', 'Affiliation': 'Department of Clinical-Psychological Intervention, Freie Universität Berlin, Berlin, Germany.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Stein', 'Affiliation': 'Department of Clinical-Psychological Intervention, Freie Universität Berlin, Berlin, Germany.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Knaevelsrud', 'Affiliation': 'Department of Clinical-Psychological Intervention, Freie Universität Berlin, Berlin, Germany.'}]",Brain and behavior,['10.1002/brb3.1484'] 254,31917897,Evidence for the contribution of COMT gene Val158/108Met polymorphism (rs4680) to working memory training-related prefrontal plasticity.,"BACKGROUND Genetic factors have been suggested to affect the efficacy of working memory training. However, few studies have attempted to identify the relevant genes. METHODS In this study, we first performed a randomized controlled trial (RCT) to identify brain regions that were specifically affected by working memory training. Sixty undergraduate students were randomly assigned to either the adaptive training group (N = 30) or the active control group (N = 30). Both groups were trained for 20 sessions during 4 weeks and received fMRI scans before and after the training. Afterward, we combined the data from the 30 participants in the RCT study who received adaptive training with data from 71 additional participants who also received the same adaptive training but were not part of the RCT study (total N = 101) to test the contribution of the COMT Val158/108Met polymorphism to the interindividual difference in the training effect within the identified brain regions. RESULTS In the RCT study, we found that the adaptive training significantly decreased brain activation in the left prefrontal cortex (TFCE-FWE corrected p = .030). In the genetic study, we found that compared with the Val allele homozygotes, the Met allele carriers' brain activation decreased more after the training at the left prefrontal cortex (TFCE-FWE corrected p = .025). CONCLUSIONS This study provided evidence for the neural effect of a visual-spatial span training and suggested that genetic factors such as the COMT Val158/108Met polymorphism may have to be considered in future studies of such training.",2020,"In the RCT study, we found that the adaptive training significantly decreased brain activation in the left prefrontal cortex (TFCE-FWE corrected p = .030).","['Sixty undergraduate students', '30 participants in the RCT study who received adaptive training with data from 71 additional participants who also received the']","['visual-spatial span training', 'same adaptive training', 'adaptive training group (N\xa0=\xa030) or the active control group']",['brain activation'],"[{'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0006104', 'cui_str': 'Encephalon'}]",,0.0432908,"In the RCT study, we found that the adaptive training significantly decreased brain activation in the left prefrontal cortex (TFCE-FWE corrected p = .030).","[{'ForeName': 'Wan', 'Initials': 'W', 'LastName': 'Zhao', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Qiumei', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Xiongying', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders & Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Wenjin', 'Initials': 'W', 'LastName': 'Fu', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Boqi', 'Initials': 'B', 'LastName': 'Du', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Xiaoxiang', 'Initials': 'X', 'LastName': 'Deng', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Ji', 'Affiliation': 'School of Mental Health, Jining Medical University, Jining, China.'}, {'ForeName': 'Yu-Tao', 'Initials': 'YT', 'LastName': 'Xiang', 'Affiliation': 'Faculty of Health Sciences, University of Macau, Taipa, China.'}, {'ForeName': 'Chuanyue', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders & Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Xiaohong', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders & Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Dong', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Chuansheng', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Department of Psychological Science, University of California, Irvine, CA, USA.'}, {'ForeName': 'Susanne M', 'Initials': 'SM', 'LastName': 'Jaeggi', 'Affiliation': 'School of Education & Department of Cognitive Sciences, University of California, Irvine, CA, USA.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}]",Brain and behavior,['10.1002/brb3.1523'] 255,31219248,Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.,"A fixed-dose combination (FDC) tablet of ertugliflozin, a selective inhibitor of sodium-glucose cotransporter 2, and sitagliptin, a dipeptidyl peptidase-4 inhibitor, was developed for the treatment of patients with type 2 diabetes mellitus. Four studies were conducted under fasted conditions to demonstrate bioequivalence of ertugliflozin/sitagliptin FDC tablets and individual components at respective strengths when coadministered in healthy subjects. All studies had open-label, randomized, 2-period, 2-sequence, single-dose crossover designs. In each study 18 or 19 subjects were enrolled and received an ertugliflozin/sitagliptin FDC tablet (5 mg/50 mg, 5 mg/100 mg, 15 mg/50 mg, or 15 mg/100 mg) and corresponding strengths of ertugliflozin and sitagliptin coadministered as individual components. For both ertugliflozin and sitagliptin, the 90%CIs for the ratio (FDC:coadministration) of geometric means for area under the plasma concentration-time profile from time 0 extrapolated to infinite time, and maximum observed plasma concentration, were within acceptance criteria for bioequivalence (80% to 125%). All adverse events were mild in intensity. The 4 studies demonstrated that each strength of FDC tablet is bioequivalent to the respective dose of coadministered individual components. This indicates that the known efficacy and tolerability of ertugliflozin and sitagliptin when coadministered can be translated to the use of a FDC formulation.",2019,All adverse events were mild in intensity.,"['In each study 18 or 19 subjects were enrolled and received an', 'patients with type 2 diabetes mellitus', 'healthy subjects']","['ertugliflozin/sitagliptin FDC tablets', 'ertugliflozin and sitagliptin coadministered as individual components', 'ertugliflozin, a selective inhibitor of sodium-glucose cotransporter\xa02, and sitagliptin, a dipeptidyl peptidase-4 inhibitor', 'ertugliflozin', 'Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets', 'ertugliflozin/sitagliptin FDC tablet']",[],"[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C4535697', 'cui_str': 'ertugliflozin / sitagliptin'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C4079805', 'cui_str': 'ertugliflozin'}, {'cui': 'C1565750', 'cui_str': 'sitagliptin'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0017739', 'cui_str': 'Sodium-Glucose Transport Proteins'}, {'cui': 'C1827106', 'cui_str': 'Dipeptidyl-Peptidase 4 Inhibitors'}, {'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]",[],,0.0262961,All adverse events were mild in intensity.,"[{'ForeName': 'Daryl J', 'Initials': 'DJ', 'LastName': 'Fediuk', 'Affiliation': 'Pfizer Inc, Groton, CT, USA.'}, {'ForeName': 'Kyle', 'Initials': 'K', 'LastName': 'Matschke', 'Affiliation': 'Pfizer Inc, Collegeville, PA, USA.'}, {'ForeName': 'Yali', 'Initials': 'Y', 'LastName': 'Liang', 'Affiliation': 'Pfizer Inc, Groton, CT, USA.'}, {'ForeName': 'Kathleen B', 'Initials': 'KB', 'LastName': 'Pelletier', 'Affiliation': 'Pfizer Inc, Groton, CT, USA.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Wei', 'Affiliation': 'Pfizer, Shanghai, China.'}, {'ForeName': 'Haihong', 'Initials': 'H', 'LastName': 'Shi', 'Affiliation': 'Pfizer Inc, Groton, CT, USA.'}, {'ForeName': 'Almasa', 'Initials': 'A', 'LastName': 'Bass', 'Affiliation': 'Pfizer Inc, Durham, NC, USA.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Hickman', 'Affiliation': 'Pfizer Inc, Groton, CT, USA.'}, {'ForeName': 'Steven G', 'Initials': 'SG', 'LastName': 'Terra', 'Affiliation': 'Pfizer Inc, Andover, MA, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Zhou', 'Affiliation': 'Merck & Co, Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Krishna', 'Affiliation': 'Merck & Co, Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'Vaishali', 'Initials': 'V', 'LastName': 'Sahasrabudhe', 'Affiliation': 'Pfizer Inc, Groton, CT, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.722'] 256,31268250,"A Randomized, Placebo-Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High-Density Lipoprotein Cholesterol in Subjects With Dyslipidemia.","GPR109A (HM74A), a G-protein-coupled receptor, is hypothesized to mediate lipid and lipoprotein changes and dermal flushing associated with niacin administration. GSK256073 (8-chloro-3-pentyl-1H-purine-2,6[3H,7H]-dione) is a selective GPR109A agonist shown to suppress fatty acid levels and produce mild flushing in short-term clinical studies. This study evaluated the effects of GSK256073 on lipids in subjects with low high-density lipoprotein cholesterol (HDLc). Subjects (n = 80) were randomized (1:1:1:1) to receive GSK256073 5, 50, or 150 mg/day or matching placebo for 8 weeks. The primary end point was determining the GSK256073 exposure-response relationship for change from baseline in HDLc. No significant exposure response was observed between GSK256073 and HDLc levels. GSK256073 did not significantly alter HDLc levels versus placebo, but rather revealed a trend at the 150-mg dose for a nonsignificant decrease in HDLc (-6.31%; P = .12) and an increase in triglycerides (median, 24.4%; 95% confidence interval, 7.3%-41.6%). Flushing was reported in 21%, 25%, and 60% of subjects (5, 50, and 150 mg, respectively) versus 24% for placebo. Results indicated that selective activation of the GPR109A receptor with GSK256073 did not produce niacin-like lipid effects. These findings add to the increasing evidence that niacin-mediated lipoprotein changes occur predominantly via GPR109A-independent pathways.",2019,Results indicated that selective activation of the GPR109A receptor with GSK256073 did not produce niacin-like lipid effects.,"['Subjects (n\xa0=\xa080', 'Subjects With Dyslipidemia', 'subjects with low high-density lipoprotein cholesterol (HDLc']","['GPR109A (HM74A', 'placebo', 'Placebo', 'GSK256073 5, 50, or 150\xa0mg/day or matching placebo', 'GSK256073, a Selective GPR109A Agonist', 'GSK256073', 'GSK256073 (8-chloro-3-pentyl-1H-purine-2,6[3H,7H]-dione']","['HDLc', 'triglycerides', 'HDLc levels', 'exposure response', 'Flushing', 'GSK256073 exposure-response relationship for change from baseline in HDLc']","[{'cui': 'C0242339', 'cui_str': 'Dyslipidemias'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0023822', 'cui_str': 'High Density Lipoprotein Cholesterol'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4079835', 'cui_str': 'GSK256073'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0439422', 'cui_str': 'mg/day'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0220903', 'cui_str': 'purine'}]","[{'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0016382', 'cui_str': 'Flushing'}, {'cui': 'C4079835', 'cui_str': 'GSK256073'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",80.0,0.396081,Results indicated that selective activation of the GPR109A receptor with GSK256073 did not produce niacin-like lipid effects.,"[{'ForeName': 'Eric J', 'Initials': 'EJ', 'LastName': 'Olson', 'Affiliation': 'Clinical Pharmacology and Experimental Medicine, GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Kelly M', 'Initials': 'KM', 'LastName': 'Mahar', 'Affiliation': 'Clinical Pharmacology, Modeling and Simulation, GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Thomas F', 'Initials': 'TF', 'LastName': 'Haws', 'Affiliation': 'Clinical Pharmacology and Experimental Medicine, GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Fossler', 'Affiliation': 'Clinical Pharmacology, Modeling and Simulation, GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Gao', 'Affiliation': 'Clinical Statistics, Metabolic Pathways and Cardiovascular Unit, GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Anne-Charlotte', 'Initials': 'AC', 'LastName': 'de Gouville', 'Affiliation': 'GlaxoSmithKline Laboratories, Centre de Recherche François Hyafil, Les Ulis Cedex, France.'}, {'ForeName': 'Dennis L', 'Initials': 'DL', 'LastName': 'Sprecher', 'Affiliation': 'Clinical Pharmacology and Experimental Medicine, GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'John J', 'Initials': 'JJ', 'LastName': 'Lepore', 'Affiliation': 'Clinical Pharmacology and Experimental Medicine, GlaxoSmithKline, Collegeville, PA, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.704'] 257,31930678,The role of oxytocin on self-serving lying.,"INTRODUCTION The effects of intranasal administration of the neuropeptide oxytocin on social cognition and behavior are highly specific. Potentially situational and personal variables influence these effects. The aim of the present study was to investigate effects of oxytocin administration on self-serving lying, including situational effects. METHODS A total of 161 adult males participated in a randomized double-blind placebo-controlled between-subject intranasal oxytocin administration (24 international units) study. Self-serving lying was assessed using three subsequent rounds of the die-in-a-cup paradigm, in which different degrees of lying can be implemented by the participants that can be determined on group level. RESULTS Oxytocin administration seemed to promote self-serving lying, particularly in the third (last) round and only to a certain degree (not to the maximum possible). CONCLUSIONS Our findings demonstrate that oxytocin administration can promote self-serving lying when given repeated opportunities to lie. Moreover, exploratory results presented in the Supplementary Material indicate that the sensitivity to the effects of intranasal oxytocin in this domain might be moderated by individual differences in the oxytocin receptor gene.",2020,A total of 161 adult males participated in a randomized double-blind placebo-controlled between-subject intranasal oxytocin administration (24 international units) study.,['161 adult males\xa0participated'],"['Oxytocin', 'neuropeptide oxytocin', 'oxytocin', 'placebo-controlled between-subject intranasal oxytocin', 'intranasal oxytocin']",['social cognition and behavior'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0027895', 'cui_str': 'Neuropeptides'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]",161.0,0.0789566,A total of 161 adult males participated in a randomized double-blind placebo-controlled between-subject intranasal oxytocin administration (24 international units) study.,"[{'ForeName': 'Cornelia', 'Initials': 'C', 'LastName': 'Sindermann', 'Affiliation': 'Department of Molecular Psychology, Institute of Psychology and Education, Ulm University, Ulm, Germany.'}, {'ForeName': 'Ruixue', 'Initials': 'R', 'LastName': 'Luo', 'Affiliation': 'The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Becker', 'Affiliation': 'The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Keith M', 'Initials': 'KM', 'LastName': 'Kendrick', 'Affiliation': 'The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Montag', 'Affiliation': 'Department of Molecular Psychology, Institute of Psychology and Education, Ulm University, Ulm, Germany.'}]",Brain and behavior,['10.1002/brb3.1518'] 258,31039663,Replacing Saturated Fat With Walnuts or Vegetable Oils Improves Central Blood Pressure and Serum Lipids in Adults at Risk for Cardiovascular Disease: A Randomized Controlled-Feeding Trial.,"Background Walnuts have beneficial effects on cardiovascular risk factors, but it is unclear whether these effects are attributable to the fatty acid ( FA ) content, including α-linolenic acid ( ALA ), and/or bioactives. Methods and Results A randomized, controlled, 3-period, crossover, feeding trial was conducted in individuals at risk for cardiovascular disease (n=45). Following a 2-week standard Western diet run-in (12% saturated FAs [ SFA ], 7% polyunsaturated FAs, 12% monounsaturated FAs), participants consumed 3 isocaloric weight-maintenance diets for 6 weeks each: a walnut diet ( WD ; 7% SFA , 16% polyunsaturated FAs, 3% ALA , 9% monounsaturated FAs); a walnut FA -matched diet; and an oleic acid-replaced- ALA diet (7% SFA , 14% polyunsaturated FAs, 0.5% ALA , 12% monounsaturated FAs), which substituted the amount of ALA from walnuts in the WD with oleic acid. This design enabled evaluation of the effects of whole walnuts versus constituent components. The primary end point, central systolic blood pressure, was unchanged, and there were no significant changes in arterial stiffness. There was a treatment effect ( P=0.04) for central diastolic blood pressure; there was a greater change following the WD versus the oleic acid-replaced-ALA diet (-1.78±1.0 versus 0.15±0.7 mm Hg, P=0.04). There were no differences between the WD and the walnut fatty acid-matched diet (-0.22±0.8 mm Hg, P=0.20) or the walnut FA-matched and oleic acid-replaced-ALA diets ( P=0.74). The WD significantly lowered brachial and central mean arterial pressure. All diets lowered total cholesterol, LDL (low-density lipoprotein) cholesterol, HDL (high-density lipoprotein) cholesterol, and non- HDL cholesterol. Conclusions Cardiovascular benefits occurred with all moderate-fat, high-unsaturated-fat diets. As part of a low- SFA diet, the greater improvement in central diastolic blood pressure following the WD versus the oleic acid-replaced-ALA diet indicates benefits of walnuts as a whole-food replacement for SFA . Clinical Trial Registration URL : https://www.clinicaltrials.gov . Unique identifier: NCT02210767.",2019,"All diets lowered total cholesterol, LDL (low-density lipoprotein) cholesterol, HDL (high-density lipoprotein) cholesterol, and non- HDL cholesterol.","['individuals at risk for cardiovascular disease (n=45', 'Adults at Risk for Cardiovascular Disease']","['walnut diet ( WD ; 7% SFA , 16% polyunsaturated FAs, 3% ALA , 9% monounsaturated FAs); a walnut FA -matched diet; and an oleic acid-replaced- ALA diet (7% SFA , 14% polyunsaturated FAs, 0.5% ALA , 12% monounsaturated FAs), which substituted the amount of ALA from walnuts in the WD with oleic acid', 'Replacing Saturated Fat With Walnuts or Vegetable Oils', 'oleic acid-replaced-ALA diet']","['brachial and central mean arterial pressure', 'central diastolic blood pressure', 'arterial stiffness', 'cardiovascular risk factors', 'central systolic blood pressure', 'Central Blood Pressure and Serum Lipids', 'total cholesterol, LDL (low-density lipoprotein) cholesterol, HDL (high-density lipoprotein) cholesterol, and non- HDL cholesterol']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0993635', 'cui_str': 'English walnut'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0028929', 'cui_str': 'Oleic Acids'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0597423', 'cui_str': 'Fatty Acids, Saturated'}, {'cui': 'C0042438', 'cui_str': 'Vegetable Oils'}]","[{'cui': 'C0445456', 'cui_str': 'Brachial (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0599949', 'cui_str': 'Arterial Stiffness'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0729627', 'cui_str': 'Non-HDL cholesterol'}]",,0.0564131,"All diets lowered total cholesterol, LDL (low-density lipoprotein) cholesterol, HDL (high-density lipoprotein) cholesterol, and non- HDL cholesterol.","[{'ForeName': 'Alyssa M', 'Initials': 'AM', 'LastName': 'Tindall', 'Affiliation': '1 Department of Nutritional Sciences The Pennsylvania State University University Park PA.'}, {'ForeName': 'Kristina S', 'Initials': 'KS', 'LastName': 'Petersen', 'Affiliation': '1 Department of Nutritional Sciences The Pennsylvania State University University Park PA.'}, {'ForeName': 'Ann C', 'Initials': 'AC', 'LastName': 'Skulas-Ray', 'Affiliation': '3 Department of Nutritional Sciences University of Arizona Tucson AZ.'}, {'ForeName': 'Chesney K', 'Initials': 'CK', 'LastName': 'Richter', 'Affiliation': '3 Department of Nutritional Sciences University of Arizona Tucson AZ.'}, {'ForeName': 'David N', 'Initials': 'DN', 'LastName': 'Proctor', 'Affiliation': '2 Department of Kinesiology The Pennsylvania State University University Park PA.'}, {'ForeName': 'Penny M', 'Initials': 'PM', 'LastName': 'Kris-Etherton', 'Affiliation': '1 Department of Nutritional Sciences The Pennsylvania State University University Park PA.'}]",Journal of the American Heart Association,['10.1161/JAHA.118.011512'] 259,31320735,Intravitreal dexamethasone implant as an alternative to systemic steroids as prophylaxis for uveitic cataract surgery: a randomized trial.,"PURPOSE To determine the utility of the dexamethasone implant (IVD) as an alternative to systemic steroids as prophylaxis against cystoid macular edema (CMO) in patients with chronic, recurrent CMO associated intermediate or posterior uveitis (IU/PU), and cataract undergoing cataract surgery. METHODS This was a randomized, parallel design, and clinical trial. Patients with IU/PU and cataract scheduled for cataract surgery were randomly assigned to receive the IVD concurrently with cataract surgery (Group 1: 20 patients) or systemic steroids (Group 2: 23 patients) tapered over 4-6 weeks along with uneventful cataract surgery and routine postoperative care. Patients with glaucoma/contraindications to steroids were excluded. All patients were followed up for 6 months. OUTCOME MEASURE Primary-incidence of postoperative CMO. Secondary-the change in BCVA (corrected distance visual acuity) and Central Subfield thickness (CST) and complications. Appropriate statistical analysis was done. RESULTS The median age was 47.3 ± 4.23 years (group 1) and 49.12 ± 5.32 years (Group 2). One patient (Group 1) and two (Group 2) developed CMO. The BCVA improved significantly in both groups (p = 0.013). The CST change was insignificant. Four patients (Group 1) required intraocular pressure (IOP) lowering medications. Three patients (Group 2) required early steroid taper. CONCLUSIONS IVD is a good alternative as prophylaxis in IU/PU and cataract in preventing postoperative CMO.",2020,The BCVA improved significantly in both groups (p = 0.013).,"['uveitic cataract surgery', 'Patients with IU/PU and cataract scheduled for cataract surgery', 'The median age was 47.3\u2009±\u20094.23 years (group 1) and 49.12\u2009±\u20095.32 years (Group 2', 'Patients with glaucoma/contraindications to steroids were excluded', 'patients with chronic, recurrent CMO associated intermediate or posterior uveitis (IU/PU), and cataract undergoing cataract surgery']","['dexamethasone implant (IVD', 'IVD concurrently with cataract surgery', 'systemic steroids (Group 2: 23 patients) tapered over 4-6 weeks along with uneventful cataract surgery and routine postoperative care', 'Intravitreal dexamethasone implant']","['CMO', 'BCVA', 'postoperative CMO', 'BCVA (corrected distance visual acuity) and Central Subfield thickness (CST) and complications', 'intraocular pressure (IOP) lowering medications']","[{'cui': 'C2004600', 'cui_str': 'Cataract surgery specialty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0856347', 'cui_str': 'Right cataract'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C2242746', 'cui_str': 'Glaucoma (SMQ)'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to (contextual qualifier) (qualifier value)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0042167', 'cui_str': 'Uveitis, Posterior'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C2004600', 'cui_str': 'Cataract surgery specialty'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0032786', 'cui_str': 'Postoperative Care'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0429537', 'cui_str': 'Distance visual acuity (observable entity)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0021888', 'cui_str': 'Ocular Tension'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}]",,0.0567074,The BCVA improved significantly in both groups (p = 0.013).,"[{'ForeName': 'Aditya', 'Initials': 'A', 'LastName': 'Sudhalkar', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India. adityasudhalkar@yahoo.com.'}, {'ForeName': 'Abhay', 'Initials': 'A', 'LastName': 'Vasavada', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}, {'ForeName': 'Deepak', 'Initials': 'D', 'LastName': 'Bhojwani', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}, {'ForeName': 'Viraj', 'Initials': 'V', 'LastName': 'Vasavada', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}, {'ForeName': 'Shail', 'Initials': 'S', 'LastName': 'Vasavada', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}, {'ForeName': 'Vaishali', 'Initials': 'V', 'LastName': 'Vasavada', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}, {'ForeName': 'Samaresh', 'Initials': 'S', 'LastName': 'Srivastava', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}]","Eye (London, England)",['10.1038/s41433-019-0534-8'] 260,31320738,Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data.,"BACKGROUND/OBJECTIVES This post hoc analysis explores the relationship between residual oedema exposure after ranibizumab treatment initiation and long-term visual acuity outcome in eyes with centre-involved diabetic macular oedema (DMO). SUBJECTS/METHODS Eyes randomised to the ranibizumab + prompt or deferred laser treatment arms in the Protocol I trial and with observed central retinal thickness (CRT) readings at baseline and ≥1 follow-up visits (n = 367) were stratified by 1) oedema duration (number of study visits with CRT ≥ 250 µm during the first 52 weeks of ranibizumab treatment); and 2) oedema extent (amount of excess CRT [≥ 250 µm] at each study visit, averaged over the first 52 weeks). Associations between measures of residual oedema and best-corrected visual acuity (BCVA) were assessed in multiple regression analyses. RESULTS Oedema duration and oedema extent during the first 52 weeks of ranibizumab treatment showed significant negative associations with BCVA improvement at weeks 52, 104 and 156. Eyes with the most persistent oedema gained (mean) 4.4 (95% CI 0.1─8.7) fewer Early Treatment Diabetic Retinopathy Study (ETDRS) letters at week 156 than eyes with the least persistent oedema (P = 0.044). Eyes with the greatest amount of oedema gained (mean) 9.3 (95% CI 4.0─14.5) fewer ETDRS letters at week 156 than eyes with the least amount of oedema (P < 0.001). CONCLUSIONS Macular oedema exposure over the first 52 weeks of ranibizumab treatment is a negative prognostic factor for long-term visual acuity improvement in centre-involved DMO.",2020,"Oedema duration and oedema extent during the first 52 weeks of ranibizumab treatment showed significant negative associations with BCVA improvement at weeks 52, 104 and 156.","['diabetic macular oedema', 'eyes with centre-involved diabetic macular oedema (DMO']","['ranibizumab + prompt or deferred laser treatment', 'ranibizumab']","['oedema and visual acuity outcome', 'residual oedema and best-corrected visual acuity (BCVA', 'Oedema duration and oedema extent', 'ETDRS letters']","[{'cui': 'C0730285', 'cui_str': 'Diabetic macular edema'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0013604', 'cui_str': 'Hydrops'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C1690532', 'cui_str': 'Best corrected visual acuity'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0439792', 'cui_str': 'Extents (qualifier value)'}, {'cui': 'C1096774', 'cui_str': 'Letter'}]",367.0,0.11728,"Oedema duration and oedema extent during the first 52 weeks of ranibizumab treatment showed significant negative associations with BCVA improvement at weeks 52, 104 and 156.","[{'ForeName': 'Srinivas R', 'Initials': 'SR', 'LastName': 'Sadda', 'Affiliation': 'Doheny Eye Institute, Los Angeles, CA, USA. SSadda@doheny.org.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Campbell', 'Affiliation': 'Allergan plc, Irvine, CA, USA.'}, {'ForeName': 'Pravin U', 'Initials': 'PU', 'LastName': 'Dugel', 'Affiliation': 'Retinal Consultants of Arizona, Phoenix, AZ, USA.'}, {'ForeName': 'Nancy M', 'Initials': 'NM', 'LastName': 'Holekamp', 'Affiliation': 'Pepose Vision Institute and Washington University School of Medicine, St. Louis, MO, USA.'}, {'ForeName': 'Szilárd', 'Initials': 'S', 'LastName': 'Kiss', 'Affiliation': 'Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Anat', 'Initials': 'A', 'LastName': 'Loewenstein', 'Affiliation': 'Department of Ophthalmology, Tel Aviv Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Albert J', 'Initials': 'AJ', 'LastName': 'Augustin', 'Affiliation': 'Department of Ophthalmology, Staedtisches Klinikum Karlsruhe, Karlsruhe, Germany.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Shih', 'Affiliation': 'Allergan plc, Irvine, CA, USA.'}, {'ForeName': 'Xiaoshu', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': 'Allergan plc, Irvine, CA, USA.'}, {'ForeName': 'Charles C', 'Initials': 'CC', 'LastName': 'Wykoff', 'Affiliation': 'Retina Consultants of Houston, Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, USA.'}, {'ForeName': 'Scott M', 'Initials': 'SM', 'LastName': 'Whitcup', 'Affiliation': 'Jules Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}]","Eye (London, England)",['10.1038/s41433-019-0522-z'] 261,32297539,Bayesian methods for pilot studies.,"BACKGROUND/AIMS The use of pilot studies to help inform the design of randomized controlled trials has increased significantly over the last couple of decades. A pilot study can provide estimates of feasibility parameters, such as the recruitment, compliance and follow-up probabilities. The use of frequentist confidence intervals of these estimates fails to provide a meaningful measure of the uncertainty as it pertains to the design of the associated randomized controlled trial. The objective of this article is to introduce Bayesian methods for the analysis of pilot studies for determining the feasibility of an associated randomized controlled trial. METHODS An example from the literature is used to illustrate the advantages of a Bayesian approach for accounting for the uncertainty in pilot study results when assessing the feasibility of an associated randomized controlled trial. Vague beta distribution priors for the feasibility parameters are used. Based on the results from a feasibility study, simulation methods are used to determine the expected power of specified recruitment strategies for an associated randomized controlled trial. RESULTS The vague priors used for the feasibility parameters are demonstrated to be considerably robust. Beta distribution posteriors for the feasibility parameters lead to beta-binomial predictive distributions for an associated randomized controlled trial regarding the number of patients randomized, the number of patients who are compliant and the number of patients who complete follow-up. Ignoring the uncertainty in pilot study results can lead to inadequate power for an associated randomized controlled trial. CONCLUSION Applying Bayesian methods to pilot studies' results provides direct inference about the feasibility parameters and quantifies the uncertainty regarding the feasibility of an associated randomized controlled trial in an intuitive and meaningful way. Furthermore, Bayesian methods can identify recruitment strategies that yield the desired power for an associated randomized controlled trial.",2020,Applying Bayesian methods to pilot studies' results provides direct inference about the feasibility parameters and quantifies the uncertainty regarding the feasibility of an associated randomized controlled trial in an intuitive and meaningful way.,[],[],[],[],[],[],,0.158836,Applying Bayesian methods to pilot studies' results provides direct inference about the feasibility parameters and quantifies the uncertainty regarding the feasibility of an associated randomized controlled trial in an intuitive and meaningful way.,"[{'ForeName': 'Andrew R', 'Initials': 'AR', 'LastName': 'Willan', 'Affiliation': 'Ontario Child Health Support Unit, SickKids Research Institute, Toronto, ON, Canada.'}, {'ForeName': 'Lehana', 'Initials': 'L', 'LastName': 'Thabane', 'Affiliation': 'Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.'}]","Clinical trials (London, England)",['10.1177/1740774520914306'] 262,31358922,Progression and new onset of macular retinoschisis in myopic choroidal neovascularization eyes after Conbercept therapy: a post-hoc analysis.,"OBJECTIVES The objective of this study is to evaluate the progression and new onset of macular retinoschisis (MRS) in the patients treated with intravitreal Conbercept injections for myopic choroidal neovascularization (mCNV). METHODS Post-hoc analysis of 160 mCNV patients included in SHINY study was performed to evaluate the impact of Conbercept injection on MRS in patients with mCNV undergoing intravitreal Conbercept injections. The patients were 3:1 randomized to the study group (three loading dose and thereafter pro re nata [PRN]) and the control group (3 months' sham injection, then one Conbercept injection at month 4 and thereafter PRN). MRS was assessed with optical coherence tomography by masked graders. RESULTS At baseline, 28 of 122 eyes in study group and 10 of 38 eyes in control group had MRS. At month 3, two patients showed MRS progression and one patient had new onset MRS in study group. No MRS progression nor new onset MRS was found in the control group. At final visit, the cumulative incidence of MRS was 1.3% (2/160). Both Spearman's correlation and multiple logistic regression demonstrated no association between the progression and new onset of MRS and intravitreal injection frequency (correlation coefficient = 0.017, P = 0.851 and odds ratio = 0.996, P = 0.982). In addition, baseline vitreoretinal adhesion was the most likely potential risk factor resulting in MRS progression (odds ratio = 4.566, P = 0.027). Furthermore, MRS progression was more likely to take place in outer retinal layers. CONCLUSIONS The progression and new onset of MRS was not associated with the frequency of intravitreal Conbercept injections.",2020,No MRS progression nor new onset MRS was found in the control group.,"['myopic choroidal neovascularization eyes after Conbercept therapy', '160 mCNV patients included in SHINY study', 'for myopic choroidal neovascularization (mCNV', 'patients with mCNV undergoing intravitreal Conbercept injections']","['Conbercept injection on MRS', 'intravitreal Conbercept injections']","['MRS', 'cumulative incidence of MRS', 'progression and new onset of MRS and intravitreal injection frequency', 'MRS progression nor new\xa0onset MRS', 'MRS progression', 'new onset MRS']","[{'cui': 'C3665926', 'cui_str': 'Myopic choroidal neovascularization'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C2352201', 'cui_str': 'KH902 fusion protein'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}]","[{'cui': 'C2352201', 'cui_str': 'KH902 fusion protein'}, {'cui': 'C1272883', 'cui_str': 'Injection'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0332162', 'cui_str': 'Onset of (contextual qualifier) (qualifier value)'}, {'cui': 'C1554888', 'cui_str': 'Intravitreal Injections'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}]",,0.0474506,No MRS progression nor new onset MRS was found in the control group.,"[{'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Shiqi', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Yuanzhi', 'Initials': 'Y', 'LastName': 'Yuan', 'Affiliation': 'Department of Ophthalmology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Minlu', 'Initials': 'M', 'LastName': 'Song', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Fenglei', 'Initials': 'F', 'LastName': 'Kuang', 'Affiliation': 'R&D Center, Chengdu Kanghong Biotech Ltd., Sichuan, China.'}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Liu', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Zhang', 'Affiliation': 'Department of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Peking, China.'}, {'ForeName': 'Fenghua', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China. shretina@sjtu.edu.cn.""}, {'ForeName': 'Xiaodong', 'Initials': 'X', 'LastName': 'Sun', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China. xdsun@sjtu.edu.cn.""}]","Eye (London, England)",['10.1038/s41433-019-0516-x'] 263,31013550,Acute effects of cannabinoids on addiction endophenotypes are moderated by genes encoding the CB1 receptor and FAAH enzyme.,"Understanding genetic factors that contribute to cannabis use disorder (CUD) is important, but to date, findings have been equivocal. Single-nucleotide polymorphisms (SNPs) in the cannabinoid receptor 1 gene (CNR1; rs1049353 and rs806378) and fatty acid amide hydrolase (FAAH) gene (rs324420) have been implicated in CUD. Their relationship to addiction endophenotypes such as cannabis-related state satiety, the salience of appetitive cues, and craving after acute cannabinoid administration has not been investigated. Forty-eight cannabis users participated in a double-blind, placebo-controlled, four-way crossover experiment where they were administered treatments in a randomized order via vaporization: placebo, Δ 9 -tetrahydrocannabinol (THC) (8 mg), THC + cannabidiol (THC + CBD) (8 + 16 mg), and CBD (16 mg). Cannabis-related state satiety, appetitive cue salience (cannabis and food), and cannabis craving were assessed each day. Participants were genotyped for rs1049353, rs806378, and rs324420. Results indicated that CNR1 rs1049353 GG carriers showed increased state satiety after THC/THC + CBD administration in comparison with placebo and reduced the salience of appetitive cues after THC in comparison with CBD administration; A carriers did not vary on either of these measures indicative of a vulnerability to CUD. CNR1 rs806378 CC carriers showed greater salience to appetitive cues in comparison with T carriers, but there was no evidence for changes in state satiety. FAAH rs324420 A carriers showed greater bias to appetitive cues after THC, in comparison with CC carriers. FAAH CC carriers showed reduced bias after THC in comparison with CBD. No SNPs modulated craving. These findings identify candidate neurocognitive mechanisms through which endocannabinoid system genetics may influence vulnerability to CUD.",2020,"CNR1 rs806378 CC carriers showed greater salience to appetitive cues in comparison with T carriers, but there was no evidence for changes in state satiety.",['Forty-eight cannabis users'],"['placebo', 'vaporization: placebo, Δ 9 -tetrahydrocannabinol', 'FAAH CC', 'FAAH rs324420', 'THC\xa0+\xa0cannabidiol (THC\xa0+\xa0CBD']","['salience of appetitive cues', 'state satiety', 'Cannabis-related state satiety, appetitive cue salience (cannabis and food), and cannabis craving']","[{'cui': 'C4319608', 'cui_str': 'Forty-eight'}, {'cui': 'C0678449', 'cui_str': 'Cannabis'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0581699', 'cui_str': 'Vaporization'}, {'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C0006863', 'cui_str': '1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-'}]","[{'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0036239', 'cui_str': 'Satiations'}, {'cui': 'C0678449', 'cui_str': 'Cannabis'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0870371', 'cui_str': 'Craving'}]",48.0,0.184911,"CNR1 rs806378 CC carriers showed greater salience to appetitive cues in comparison with T carriers, but there was no evidence for changes in state satiety.","[{'ForeName': 'Chandni', 'Initials': 'C', 'LastName': 'Hindocha', 'Affiliation': 'Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.'}, {'ForeName': 'Tom P', 'Initials': 'TP', 'LastName': 'Freeman', 'Affiliation': 'Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.'}, {'ForeName': 'Grainne', 'Initials': 'G', 'LastName': 'Schafer', 'Affiliation': 'Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.'}, {'ForeName': 'Chelsea', 'Initials': 'C', 'LastName': 'Gardner', 'Affiliation': 'Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.'}, {'ForeName': 'Michael A P', 'Initials': 'MAP', 'LastName': 'Bloomfield', 'Affiliation': 'Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.'}, {'ForeName': 'Elvira', 'Initials': 'E', 'LastName': 'Bramon', 'Affiliation': 'Division of Psychiatry, University College London, London, UK.'}, {'ForeName': 'Celia J A', 'Initials': 'CJA', 'LastName': 'Morgan', 'Affiliation': 'Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.'}, {'ForeName': 'H Valerie', 'Initials': 'HV', 'LastName': 'Curran', 'Affiliation': 'Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.'}]",Addiction biology,['10.1111/adb.12762'] 264,31312016,Advanced weight-bearing mat exercises combined with functional electrical stimulation to improve the ability of wheelchair-dependent people with spinal cord injury to transfer and attain independence in activities of daily living: a randomized controlled trial.,"STUDY DESIGN Randomized controlled trial. OBJECTIVE To determine the effects of advanced weight-bearing mat exercises (AWMEs) with/without functional electrical stimulation (FES) of the quadriceps and gastrocnemius muscles on the ability of wheelchair-dependent people with spinal cord injury (SCI) to transfer and attain independence in activities of daily living (ADLs). SETTING An outpatient clinic, Iran. METHODS People with traumatic chronic paraplegia (N = 16) were randomly allocated to three groups. The exercise group (EX; N = 5) performed AWMEs of quadruped unilateral reaching and tall-kneeling for 24 weeks (3 days/week). Sessions were increased from 10 min to 54 min over the 24-week period. The exercise-FES group (EX + FES; N = 5) performed AWMEs simultaneously with FES of the quadriceps and gastrocnemius muscles. The control group performed no exercise and no FES (N = 6). The primary outcomes were the total Spinal Cord Independence Measure-III (SCIM-III) to reflect independence with ADL, and the sum of the four SCIM-III transfer items to reflect ability to transfer. There were six other outcomes. RESULTS The mean (95% CI) between-group differences of the four transfer items of the SCIM-III for the EX vs. control group was 1.8 points (0.2-3.4), and for the EX + FES vs. control group was 2 points (0.4-3.6). The equivalent differences for the total SCIM-III scores were 2.7 points (-0.6-6.0) and 4.1 points (0.8-7.4), respectively. There were no significant between-group differences for any other outcomes. CONCLUSIONS Advanced weight-bearing mat exercises improve the ability of wheelchair-dependent people with SCI to transfer and attain independence in ADL.",2020,"CONCLUSIONS Advanced weight-bearing mat exercises improve the ability of wheelchair-dependent people with SCI to transfer and attain independence in ADL.","['People with traumatic chronic paraplegia (N\u2009=\u200916', 'wheelchair-dependent people with spinal cord injury (SCI', 'An outpatient clinic, Iran']","['no exercise and no FES', 'advanced weight-bearing mat exercises (AWMEs) with/without functional electrical stimulation (FES', 'Advanced weight-bearing mat exercises combined with functional electrical stimulation', 'exercise group (EX; N\u2009=\u20095) performed AWMEs of quadruped unilateral reaching and tall-kneeling']","['total SCIM-III scores', 'total Spinal Cord Independence Measure-III (SCIM-III) to reflect independence with ADL, and the sum of the four SCIM-III transfer items to reflect ability to transfer']","[{'cui': 'C0332663', 'cui_str': 'Traumatic (qualifier value)'}, {'cui': 'C3698571', 'cui_str': 'Chronic paraplegia'}, {'cui': 'C0043143', 'cui_str': 'Wheel Chairs'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0674267', 'cui_str': 'greigite'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0085086', 'cui_str': 'Finding of weight-bearing'}, {'cui': 'C0066317', 'cui_str': 'trisulfide methyl 2-propenyl'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0013786', 'cui_str': 'Electrical Stimulation'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0456677', 'cui_str': 'Total spinal blockade (finding)'}, {'cui': 'C3698497', 'cui_str': 'Axillary web syndrome'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0558058', 'cui_str': 'Reflecting (finding)'}, {'cui': 'C0001288', 'cui_str': 'ADL'}, {'cui': 'C0040671', 'cui_str': 'Transfer'}, {'cui': 'C0085732', 'cui_str': 'Ability'}]",,0.0665244,"CONCLUSIONS Advanced weight-bearing mat exercises improve the ability of wheelchair-dependent people with SCI to transfer and attain independence in ADL.","[{'ForeName': 'Mostafa', 'Initials': 'M', 'LastName': 'Rahimi', 'Affiliation': 'Department of Physiotherapy, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.'}, {'ForeName': 'Giti', 'Initials': 'G', 'LastName': 'Torkaman', 'Affiliation': 'Department of Physiotherapy, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. torkamg@modares.ac.ir.'}, {'ForeName': 'Mojdeh', 'Initials': 'M', 'LastName': 'Ghabaee', 'Affiliation': 'Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ghasem-Zadeh', 'Affiliation': 'Departments of Medicine and Endocrinology, Austin Health, The University of Melbourne, Melbourne, VIC, Australia.'}]",Spinal cord,['10.1038/s41393-019-0328-7'] 265,30811093,Fetus morphology changes by second-trimester ultrasound in pregnant women drinking alcohol.,"Fetal alcohol spectrum disorders (FASDs) are a group of negative conditions occurring in children exposed to alcohol during gestation. The early discovery of FASD is crucial for mother and infant follow-ups. In this study, we investigated in pregnant women the association between urine ethylglucuronide (EtG-a biomarker of alcohol drinking) and indicators of the physical characteristics of FASD by prenatal ultrasound in the second trimester of gestation. We also correlated these data with the AUDIT-C, T-ACE/TACER-3, TWEAK, and food habit diary, screening questionnaires used to disclose alcohol drinking during pregnancy. Forty-four pregnant women were randomly enrolled and examined for ultrasound investigation during the second trimester of gestation. Urine samples were provided by pregnant women immediately after the routine interviews. EtG determinations were performed with a cutoff established at 100 ng/mL, a value indicating occasional alcohol drinking. Fifteen of the enrolled pregnant women overcame the EtG cutoff (34.09%). Analysis of variance (ANOVA) revealed that the fetuses of the positive EtG pregnant women had significantly longer interorbital distance and also significantly increased frontothalamic distance (P's < 0.02). Quite interestingly, no direct correlation was found between EtG data and both food diary and AUDIT-C. However, a significant correlation was observed between urinary EtG and T-ACE (r = 0.375; P = 0.012) and between urinary EtG and TWEAK (r = 0.512; P < 0.001) and a concordance with all questionnaire for EtG values higher than 500 ng/mL. This study provides clinical evidence that the diagnosis of maternal alcohol consumption during pregnancy by urine EtG may disclose FASD-related damage in the fetus.",2020,"However, a significant correlation was observed between urinary EtG and T-ACE","['pregnant women the association between urine ethylglucuronide (EtG-a biomarker of alcohol drinking) and indicators of the physical characteristics of FASD by prenatal ultrasound in the second trimester of gestation', 'pregnant women drinking alcohol', 'Fifteen of the enrolled pregnant women overcame the EtG cutoff (34.09', 'Forty-four pregnant women']",[],"['urinary EtG and T-ACE', 'frontothalamic distance', 'interorbital distance']","[{'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0042037'}, {'cui': 'C0298229', 'cui_str': 'ethylglucuronide'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C2985290', 'cui_str': 'FASD'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0032980', 'cui_str': 'Midtrimester'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0556297', 'cui_str': 'Current drinker of alcohol (finding)'}, {'cui': 'C4319568', 'cui_str': '44'}]",[],"[{'cui': 'C0067453', 'cui_str': 'N-(2-acetamido)-2-aminoethanesulfonic acid'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}]",44.0,0.0258171,"However, a significant correlation was observed between urinary EtG and T-ACE","[{'ForeName': 'Giampiero', 'Initials': 'G', 'LastName': 'Ferraguti', 'Affiliation': 'Department of Experimental Medicine, Sapienza University Hospital of Rome, Rome, Italy.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Merlino', 'Affiliation': 'Department of Gynecological-Obstetric Sciences and Urological Sciences, Sapienza University Hospital of Rome, Rome, Italy.'}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Battagliese', 'Affiliation': 'Centro Riferimento Alcologico Regione Lazio, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Maria Grazia', 'Initials': 'MG', 'LastName': 'Piccioni', 'Affiliation': 'Department of Gynecological-Obstetric Sciences and Urological Sciences, Sapienza University Hospital of Rome, Rome, Italy.'}, {'ForeName': 'Greta', 'Initials': 'G', 'LastName': 'Barbaro', 'Affiliation': 'Department of Gynecological-Obstetric Sciences and Urological Sciences, Sapienza University Hospital of Rome, Rome, Italy.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Carito', 'Affiliation': 'Institute of Cell Biology and Neurobiology (IBCN), National Research Council (CNR), Rome, Italy.'}, {'ForeName': 'Marisa Patrizia', 'Initials': 'MP', 'LastName': 'Messina', 'Affiliation': 'Department of Experimental Medicine, Sapienza University Hospital of Rome, Rome, Italy.'}, {'ForeName': 'Bruna', 'Initials': 'B', 'LastName': 'Scalese', 'Affiliation': 'Centro Riferimento Alcologico Regione Lazio, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Coriale', 'Affiliation': 'Centro Riferimento Alcologico Regione Lazio, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Fiore', 'Affiliation': 'Institute of Cell Biology and Neurobiology (IBCN), National Research Council (CNR), Rome, Italy.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Ceccanti', 'Affiliation': 'Centro Riferimento Alcologico Regione Lazio, Sapienza University of Rome, Rome, Italy.'}]",Addiction biology,['10.1111/adb.12724'] 266,31535371,Parenting for Lifelong Health for Young Children: a randomized controlled trial of a parenting program in South Africa to prevent harsh parenting and child conduct problems.,"BACKGROUND Parenting programs suitable for delivery at scale in low-resource contexts are urgently needed. We conducted a randomized trial of Parenting for Lifelong Health (PLH) for Young Children, a low-cost 12-session program designed to increase positive parenting and reduce harsh parenting and conduct problems in children aged 2-9. METHODS Two hundred and ninety-six caregivers, whose children showed clinical levels of conduct problems (Eyberg Child Behavior Inventory Problem Score, >15), were randomly assigned using a 1:1 ratio to intervention or control groups. At t 0 , and at 4-5 months (t 1 ) and 17 months (t 2 ) after randomization, research assistants blind to group assignment assessed (through caregiver self-report and structured observation) 11 primary outcomes: positive parenting, harsh parenting, and child behavior; four secondary outcomes: parenting stress, caregiver depression, poor monitoring/supervision, and social support. TRIAL REGISTRATION ClinicalTrials.gov (NCT02165371); Pan African Clinical Trial Registry (PACTR201402000755243); Violence Prevention Trials Register (http://www.preventviolence.info/Trials?ID=24). RESULTS Caregivers attended on average 8.4 sessions. After adjustment for 30 comparisons, strongest results were as follows: at t 1 , frequency of self-reported positive parenting strategies (10% higher in the intervention group, p = .003), observed positive parenting (39% higher in the intervention group, p = .003), and observed positive child behavior (11% higher in the intervention group, p = .003); at t 2, both observed positive parenting and observed positive child behavior were higher in the intervention group (24%, p = .003; and 17%, p = .003, respectively). Results with p-values < .05 prior to adjustment were as follows: At t 1 , the intervention group self-reported 11% fewer child problem behaviors, 20% fewer problems with implementing positive parenting strategies, and less physical and psychological discipline (28% and 14% less, respectively). There were indications that caregivers reported 20% less depression but 7% more parenting stress at t 1 . Group differences were nonsignificant for observed negative child behavior, and caregiver-reported child behavior, poor monitoring or supervision, and caregiver social support. CONCLUSIONS PLH for Young Children shows promise for increasing positive parenting and reducing harsh parenting.",2020,"At t 1 , the intervention group self-reported 11% fewer child problem behaviors, 20% fewer problems with implementing positive parenting strategies, and less physical and psychological discipline (28% and 14% less, respectively).","['in South Africa to prevent harsh parenting and child conduct problems', 'Young Children', 'children aged 2-9', 'Two hundred and ninety-six caregivers, whose children showed clinical levels of conduct problems (Eyberg Child Behavior Inventory Problem Score, >15', 'young children']","['Parenting for Lifelong Health (PLH', 'parenting program']","['positive parenting, harsh parenting, and child behavior; four secondary outcomes: parenting stress, caregiver depression, poor monitoring/supervision, and social support', 'positive parenting and reducing harsh parenting', 'depression', 'parenting stress', 'observed negative child behavior, and caregiver-reported child behavior, poor monitoring or supervision, and caregiver social support', 'child problem behaviors', 'frequency of self-reported positive parenting strategies', 'positive child behavior', 'observed positive parenting', 'physical and psychological discipline']","[{'cui': 'C0037712', 'cui_str': 'Union of South Africa'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4319625', 'cui_str': '96'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0008065', 'cui_str': 'Child Behavior'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]","[{'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C4274169', 'cui_str': 'Entire period of life between birth and death'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0008065', 'cui_str': 'Child Behavior'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C0038842', 'cui_str': 'Supervision'}, {'cui': 'C0037438'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C3875135', 'cui_str': 'Observes (attribute)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0233514', 'cui_str': 'Behavioral Problem'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}]",296.0,0.159127,"At t 1 , the intervention group self-reported 11% fewer child problem behaviors, 20% fewer problems with implementing positive parenting strategies, and less physical and psychological discipline (28% and 14% less, respectively).","[{'ForeName': 'Catherine L', 'Initials': 'CL', 'LastName': 'Ward', 'Affiliation': 'Department of Psychology and Safety and Violence Initiative, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Inge M', 'Initials': 'IM', 'LastName': 'Wessels', 'Affiliation': 'Department of Psychology and Safety and Violence Initiative, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Jamie M', 'Initials': 'JM', 'LastName': 'Lachman', 'Affiliation': 'Department of Social Policy and Intervention, University of Oxford, Oxford, UK.'}, {'ForeName': 'Judy', 'Initials': 'J', 'LastName': 'Hutchings', 'Affiliation': 'Centre for Evidence-Based Early Intervention, Bangor University, Bangor, UK.'}, {'ForeName': 'Lucie D', 'Initials': 'LD', 'LastName': 'Cluver', 'Affiliation': 'Department of Social Policy and Intervention, University of Oxford, Oxford, UK.'}, {'ForeName': 'Reshma', 'Initials': 'R', 'LastName': 'Kassanjee', 'Affiliation': 'Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Nhapi', 'Affiliation': 'Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Little', 'Affiliation': 'Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Gardner', 'Affiliation': 'Department of Social Policy and Intervention, University of Oxford, Oxford, UK.'}]","Journal of child psychology and psychiatry, and allied disciplines",['10.1111/jcpp.13129'] 267,30452784,Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial.,"The chymase inhibitor fulacimstat is developed as a first-in-class treatment option for the inhibition of adverse cardiac remodeling in patients with left ventricular dysfunction (LVD) after acute myocardial infarction (MI). The aim of the study was to examine the safety and tolerability of fulacimstat in patients with LVD after remote MI. A multicenter, multinational randomized, placebo-controlled study was performed in clinically stable patients (40-79 years of age, left ventricular ejection fraction ≤ 45% because of MI in medical history) who were on stable evidence-based standard-of-care therapies for LVD post-MI including an angiotensin converting enzyme inhibitor or angiotensin receptor blocker at doses of at least half the recommended target dose. Patients were treated for 2 weeks with either placebo (n = 12) or 4 different doses of fulacimstat (5 mg twice daily, n = 9; 10 mg twice daily, n = 9; 25 mg twice daily, n = 10; 50 mg once daily, n = 9). Fulacimstat was safe and well tolerated at all examined doses. There were no clinically relevant effects on vital signs or potassium levels compared with placebo treatment. Mean plasma concentrations of fulacimstat increased with the administered dose and reached exposures predicted to be therapeutically active. The safety profile and the absence of effects on blood pressure or heart rate in a chronic patient population having similar comorbidities and receiving similar comedication as patients after acute MI support future clinical trials with fulacimstat in patients after acute MI.",2019,Mean plasma concentrations of fulacimstat increased with the administered dose and reached exposures predicted to be therapeutically active.,"['chronic patient population having similar comorbidities and receiving similar comedication as patients after acute MI', 'patients after acute MI', 'clinically stable patients (40-79 years of age, left ventricular ejection fraction ≤ 45% because of MI in medical history) who were on stable evidence-based standard-of-care therapies for LVD post-MI including an', 'at doses of at least half the recommended target dose', 'patients with left ventricular dysfunction (LVD) after acute myocardial infarction (MI', 'patients with LVD after remote MI', 'Patients With Left Ventricular Dysfunction']","['angiotensin converting enzyme inhibitor or angiotensin receptor blocker', 'Chymase Inhibitor Fulacimstat', 'placebo', 'fulacimstat (5\xa0mg twice daily, n\xa0']","['Mean plasma concentrations of fulacimstat', 'safe and well tolerated', 'Safety and Tolerability', 'safety and tolerability of fulacimstat', 'vital signs or potassium levels', 'blood pressure or heart rate']","[{'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction (observable entity)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0856742', 'cui_str': 'Post MI'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0242973', 'cui_str': 'Ventricular Dysfunction'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction (disorder)'}, {'cui': 'C0205157', 'cui_str': 'Remote (qualifier value)'}]","[{'cui': 'C0003015', 'cui_str': 'ACE Inhibitors'}, {'cui': 'C0815017', 'cui_str': 'Angiotensin Receptor Blockers'}, {'cui': 'C0055673', 'cui_str': 'Chymase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0518766'}, {'cui': 'C0428289', 'cui_str': 'Finding of potassium level (finding)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}]",,0.0995114,Mean plasma concentrations of fulacimstat increased with the administered dose and reached exposures predicted to be therapeutically active.,"[{'ForeName': 'Hans-Dirk', 'Initials': 'HD', 'LastName': 'Düngen', 'Affiliation': 'Department of Internal Medicine, Cardiology, Charité-Universitaetsmedizin, Berlin, Germany.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Kober', 'Affiliation': 'Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Savina', 'Initials': 'S', 'LastName': 'Nodari', 'Affiliation': 'Cardiology Section, Department of Clinical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Morten', 'Initials': 'M', 'LastName': 'Schou', 'Affiliation': 'Department of Cardiology, Cardiovascular Research Center, Gentofte and Herlev University Hospital, Herlev, Denmark.'}, {'ForeName': 'Christiane', 'Initials': 'C', 'LastName': 'Otto', 'Affiliation': 'Experimental Medicine Cardiovascular and Hematology, BAYER AG, Wuppertal, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Becka', 'Affiliation': 'Research and Clinical Sciences Statistics, BAYER AG, Wuppertal, Germany.'}, {'ForeName': 'Friederike', 'Initials': 'F', 'LastName': 'Kanefendt', 'Affiliation': 'Clinical Pharmacokinetics, BAYER AG, Wuppertal, Germany.'}, {'ForeName': 'Bernhard R', 'Initials': 'BR', 'LastName': 'Winkelmann', 'Affiliation': 'ClinPhenomics GmbH & Co KG, Frankfurt, Germany.'}, {'ForeName': 'Gunnar', 'Initials': 'G', 'LastName': 'Gislason', 'Affiliation': 'Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Richard', 'Affiliation': 'Private Praxis for Cardiology, Erfurt, Germany.'}, {'ForeName': 'Olav Wendelboe', 'Initials': 'OW', 'LastName': 'Nielsen', 'Affiliation': 'Department of Cardiology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.'}, {'ForeName': 'Mihai', 'Initials': 'M', 'LastName': 'Gheorghiade', 'Affiliation': 'Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Senni', 'Affiliation': 'Division of Cardiology 1, Papa Giovanni XXIII Hospital, Bergamo, Italy.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.633'] 268,32223057,Acute Effects of Three Different Meal Patterns on Postprandial Metabolism in Older Individuals with a Risk Phenotype for Cardiometabolic Diseases: A Randomized Controlled Crossover Trial.,"SCOPE The aim of this study is to investigate acute postprandial responses to intake of meals typical for Mediterranean and Western diets. METHODS In a randomized crossover design, overweight and obese participants with a risk phenotype for cardiometabolic diseases consumed three different isoenergetic meals: Western diet-like high-fat (WDHF), Western diet-like high-carbohydrate (WDHC), and Mediterranean diet (MED) meal. Blood samples are collected at fasting and 1, 2, 3, 4, 5 h postprandially and analyzed for parameters of lipid and glucose metabolism, inflammation, oxidation, and antioxidant status. RESULTS Compared to MED and WDHF meals, intake of a WDHC meal results in prolonged and elevated increases in glucose and insulin. Elevations for triglycerides are enhanced after the WDHF meal compared to the MED and the WDHC meal. Glucagon-like peptide-1 and interleukin-6 increase postprandially without meal differences. Apart from vitamin C showing an increase after the MED meal and a decrease after WDHF and WDHC meals, antioxidant markers decrease postprandially without meal differences. Plasma interleukin-1β is not affected by meal intake. CONCLUSIONS Energy-rich meals induce hyperglycemia, hyperlipemia, an inflammatory response, and a decrease in antioxidant markers. A meal typical for the Mediterranean diet results in favorable effects on glycemic, insulinemic, and lipemic responses.",2020,Glucagon-like peptide-1 and interleukin-6 increased postprandially without meal differences.,"['overweight and obese participants with a risk phenotype for cardiometabolic diseases consumed three different iso', 'Older Individuals with a Risk Phenotype for Cardiometabolic Diseases']","['energetic meals: Western diet high-fat (WDHF), Western diet high-carbohydrate (WDHC), and Mediterranean diet (MED) meal', 'vitamin C', 'Three Different Meal Patterns']","['WDHF and WDHC meals, antioxidant markers', 'Glucagon-like peptide-1 and interleukin-6', 'Plasma interleukin-1β', 'glucose and insulin', 'Postprandial Metabolism', 'antioxidant markers', 'hyperglycemia, hyperlipemia, an inflammatory response', 'glycemic, insulinemic and lipemic responses', 'lipid and glucose metabolism, inflammation, oxidation and antioxidant status', 'Elevations for triglycerides']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C1314763', 'cui_str': 'Phenotyping (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0911936', 'cui_str': 'iso(VL)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C3849996', 'cui_str': 'Western Dietary Pattern'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C1138412', 'cui_str': 'Diet, Mediterranean'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0392339', 'cui_str': 'Eating routine (observable entity)'}]","[{'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-Like Peptide 1'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0021764', 'cui_str': 'Interleukins'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0020473', 'cui_str': 'Hyperlipemia'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0030011', 'cui_str': 'Oxidation, function (observable entity)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}]",,0.0381607,Glucagon-like peptide-1 and interleukin-6 increased postprandially without meal differences.,"[{'ForeName': 'Yannik B', 'Initials': 'YB', 'LastName': 'Schönknecht', 'Affiliation': 'Department of Nutrition and Food Science, Nutritional Physiology, University of Bonn, Bonn, 53113, Germany.'}, {'ForeName': 'Silke', 'Initials': 'S', 'LastName': 'Crommen', 'Affiliation': 'Department of Nutrition and Food Science, Nutritional Physiology, University of Bonn, Bonn, 53113, Germany.'}, {'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Stoffel-Wagner', 'Affiliation': 'Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, 53127, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Coenen', 'Affiliation': 'Clinical Study Core Unit, Study Center Bonn, Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, 53127, Germany.'}, {'ForeName': 'Rolf', 'Initials': 'R', 'LastName': 'Fimmers', 'Affiliation': 'Institute of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, 53127, Germany.'}, {'ForeName': 'Jens J', 'Initials': 'JJ', 'LastName': 'Holst', 'Affiliation': 'Novo Nordisk Foundation Center for Basic Metabolic Research and Department for Biomedical Sciences, University of Copenhagen, Copenhagen, 2200, Denmark.'}, {'ForeName': 'Marie-Christine', 'Initials': 'MC', 'LastName': 'Simon', 'Affiliation': 'Department of Nutrition and Food Science, Nutritional Physiology, University of Bonn, Bonn, 53113, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Stehle', 'Affiliation': 'Department of Nutrition and Food Science, Nutritional Physiology, University of Bonn, Bonn, 53113, Germany.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Egert', 'Affiliation': 'Department of Nutrition and Food Science, Nutritional Physiology, University of Bonn, Bonn, 53113, Germany.'}]",Molecular nutrition & food research,['10.1002/mnfr.201901035'] 269,31016886,What Can Be Learned From Crowdsourced Population Asparagus Urinary Odor Kinetics?,"Asparagus consumption is associated with the production of malodorous urine. Interindividual variability was previously characterized by an American Society for Clinical Pharmacology and Therapeutics crowdsourced study. To further characterize urinary odor kinetics, we conducted a study with consenting participants from Takeda Pharmaceutical International Company. The participants were randomized to consume a specified number of asparagus spears and asked to record urine odor. A kinetic-pharmacodynamic model characterized the data from both the newly conducted Takeda study (N = 42) and the previously analyzed American Society for Clinical Pharmacology and Therapeutics studies (total N = 139). The updated model included the identification of an absorption process with a half-life of 25 minutes. We estimated the elimination half-life of the asparagus effect on malodorous urine to be 7.2 hours, which was 44% longer in our study. We built on previous experience using an improved R-Shiny app for conducting the crowdsourcing experiment, further demonstrating the utility of this population kinetics approach in organizational and educational settings.",2019,"We estimated the elimination half-life of the asparagus effect on malodorous urine to be 7.2 hours, which was 44% longer in our study.",['consenting participants from Takeda Pharmaceutical International Company'],[],[],"[{'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}]",[],[],,0.0562979,"We estimated the elimination half-life of the asparagus effect on malodorous urine to be 7.2 hours, which was 44% longer in our study.","[{'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Facius', 'Affiliation': 'thinkQ2 AG, Baar, Switzerland.'}, {'ForeName': 'Linda A', 'Initials': 'LA', 'LastName': 'Atkinson', 'Affiliation': 'Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Hanna', 'Affiliation': 'PRA Health Sciences, Deerfield, Illinois, USA.'}, {'ForeName': 'Mai Chi', 'Initials': 'MC', 'LastName': 'Coombes', 'Affiliation': 'PRA Health Sciences, Deerfield, Illinois, USA.'}, {'ForeName': 'Gezim', 'Initials': 'G', 'LastName': 'Lahu', 'Affiliation': 'thinkQ2 AG, Baar, Switzerland.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Wagner', 'Affiliation': 'Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.'}]",CPT: pharmacometrics & systems pharmacology,['10.1002/psp4.12401'] 270,31253849,Effects of a coping-oriented supportive programme for people with spinal cord injury during inpatient rehabilitation: a quasi-experimental study.,"STUDY DESIGN Parallel-group, quasi-experimental study. OBJECTIVES To evaluate the effectiveness of a coping-oriented supportive programme (COSP) for people with spinal cord injury (SCI) over a 12-week follow-up. SETTING SCI wards in two rehabilitation hospitals of Shaanxi, China. METHODS Ninety-nine participants (mean age = 41, 88% males and 74% paraplegia) joined the COSP intervention (n = 50) or attention control (n = 49) group. The COSP intervention was focussed on the facilitation of coping skills and consisted of 8 weekly sessions, whereas the attentional control group was provided with 8 weekly didactic education sessions. Effects of the COSP intervention were determined by primary outcomes (coping and self-efficacy) and secondary outcomes (depression, anxiety, social support, life satisfaction and pain). Data were collected at pre- and post-intervention, as well as 4- and 12-week follow-up. RESULTS Intention to treat analysis indicated statistically significant effects (with moderate to large effect sizes, all P-values < 0.01) on participants' maladaptive coping, adaptive coping, self-efficacy, depression, anxiety, satisfaction of social support and life satisfaction immediately post-COSP. Statistically significant effects were found for maladaptive coping, self-efficacy, anxiety, depression, satisfaction of social support and life satisfaction at 4-week follow-up. Maladaptive coping, anxiety, satisfaction of social support and life satisfaction were also significantly improved at 12-week follow-up. CONCLUSION The COSP intervention resulted in medium-term psychosocial benefits for people with SCI and has potential for integration into routine inpatient rehabilitation practice.",2020,"Maladaptive coping, anxiety, satisfaction of social support and life satisfaction were also significantly improved at 12-week follow-up. ","['people with spinal cord injury during inpatient rehabilitation', 'SCI wards in two rehabilitation hospitals of Shaanxi, China', 'people with spinal cord injury (SCI', 'Ninety-nine participants (mean age\u2009=\u200941, 88% males and 74% paraplegia) joined the', 'n\u2009=\u200950) or attention control (n\u2009=\u200949) group']","['coping-oriented supportive programme', 'coping-oriented supportive programme (COSP', 'COSP intervention']","['Maladaptive coping, anxiety, satisfaction of social support and life satisfaction', ""participants' maladaptive coping, adaptive coping, self-efficacy, depression, anxiety, satisfaction of social support and life satisfaction"", 'maladaptive coping, self-efficacy, anxiety, depression, satisfaction of social support and life satisfaction', 'primary outcomes (coping and self-efficacy) and secondary outcomes (depression, anxiety, social support, life satisfaction and pain']","[{'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}, {'cui': 'C0337962', 'cui_str': 'Rehabilitation hospital (environment)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C3828813', 'cui_str': 'Ninety-nine'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0030486', 'cui_str': 'Paralysis, Legs'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]",[],"[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0037438'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",99.0,0.0323196,"Maladaptive coping, anxiety, satisfaction of social support and life satisfaction were also significantly improved at 12-week follow-up. ","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ""The Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, UK. yan.li@kcl.ac.uk.""}, {'ForeName': 'Wai Tong', 'Initials': 'WT', 'LastName': 'Chien', 'Affiliation': 'The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Bressington', 'Affiliation': 'The School of Nursing, Faculty of Health and Social Science, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong.'}]",Spinal cord,['10.1038/s41393-019-0320-2'] 271,31462757,Sprint interval training versus moderate-intensity continuous training during inpatient rehabilitation after spinal cord injury: a randomized trial.,"STUDY DESIGN Randomized trial. OBJECTIVES To evaluate the effectiveness of a 5-week sprint interval training (SIT) protocol on an arm-crank ergometer in individuals with sub-acute spinal cord injury (SCI). SETTING Inpatient rehabilitation. METHODS Individuals with SCI (N = 20; 9 tetraplegia/11 paraplegia; time since injury, 14-182 days; age, 46 ± 16 years; 15 M/5 F) were randomized to SIT or moderate-intensity continuous training (MICT). SIT consisted of 3 × 20 s. 'all-out' cycle sprints (≥100% peak power output) interspersed with 2 min of active recovery (10% peak power output; total time commitment, 10 mins). MICT involved 20 min of cycling (45% peak power output; total time commitment, 25 mins). Both training interventions were delivered 3 times/week for 5 weeks. Heart rate and Borg's Rating of Perceived Exertion (RPE; 6-20) were monitored throughout training sessions. Maximal and sub-maximal power outputs were assessed on an arm-crank ergometer. Exercise enjoyment, exercise self-efficacy, and pain were assessed at the end of the intervention. RESULTS During training sessions, heart rate (135 bpm vs. 119 bpm; p = 0.05), peripheral RPE (16 vs. 12; p = 0.000), and central RPE (15 vs. 11; p = 0.004) responses were higher in the SIT group, yet total work performed was greater in MICT. Peak power output increased significantly with training (36%), with no difference between groups (39% vs. 33%; p = 0.524). Similarly, improvements in sub-maximal power output were not different across groups. There were no between-group differences in exercise enjoyment (p = 0.385), exercise self-efficacy (p = 0.930), or pain (p = 0780). CONCLUSIONS Five weeks of SIT improved physical capacity to the same extent as MICT in individuals with sub-acute SCI, despite a significantly lower time commitment with SIT.",2020,"Peak power output increased significantly with training (36%), with no difference between groups (39% vs. 33%; p = 0.524).","['inpatient rehabilitation after spinal cord injury', 'Individuals with SCI (N\u2009', 'Inpatient rehabilitation', '20; 9 tetraplegia/11 paraplegia; time since injury, 14-182 days; age, 46\u2009±\u200916 years; 15\u2009M/5\u2009F', 'individuals with sub-acute spinal cord injury (SCI']","['MICT', 'SIT or moderate-intensity continuous training (MICT', 'Sprint interval training versus moderate-intensity continuous training', '5-week sprint interval training (SIT) protocol']","['sub-maximal power output', 'Exercise enjoyment, exercise self-efficacy, and pain', ""Heart rate and Borg's Rating of Perceived Exertion"", 'Peak power output', 'heart rate', 'physical capacity', 'exercise enjoyment', 'peripheral RPE', 'exercise self-efficacy', 'central RPE']","[{'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0030486', 'cui_str': 'Paralysis, Legs'}, {'cui': 'C0449246', 'cui_str': 'Time since injury (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1264637', 'cui_str': 'Substance amount'}]","[{'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C4279979', 'cui_str': 'Sprint Interval Training'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}]","[{'cui': 'C1264637', 'cui_str': 'Substance amount'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0445194', 'cui_str': 'Power output (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0015264', 'cui_str': 'Exertion, function (observable entity)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0445208', 'cui_str': 'RPE'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]",780.0,0.0764155,"Peak power output increased significantly with training (36%), with no difference between groups (39% vs. 33%; p = 0.524).","[{'ForeName': 'Jonathan C', 'Initials': 'JC', 'LastName': 'Mcleod', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Herrington', 'Initials': 'H', 'LastName': 'Diana', 'Affiliation': 'Regional Rehabilitation Centre, Hamilton Health Sciences, Hamilton, ON, Canada.'}, {'ForeName': 'Audrey L', 'Initials': 'AL', 'LastName': 'Hicks', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, Canada. hicksal@mcmaster.ca.'}]",Spinal cord,['10.1038/s41393-019-0345-6'] 272,30329199,"Efficacy and safety of a triple active sore throat lozenge in the treatment of patients with acute pharyngitis: Results of a multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial (DoriPha).","OBJECTIVE The aim of this multi-centre, randomised, double-blind, placebo-controlled trial was to compare the efficacy and safety of the fixed combination of 0.5 mg tyrothricin, 1.0 mg benzalkonium chloride, and 1.5 mg benzocaine (study drug marketed as Dorithricin ® ) in repeat dosing for 3 days to match placebo lozenges in the treatment of acute pharyngitis in adults. METHODS Patients (pts, aged ≥18 years) with acute pharyngitis, ie, non-streptococcal sore throat and moderate-to-severe pain (intensity NRS ≥ 7; VAS ≥ 50) were assigned to study drug (n = 160) or matching placebo (n = 161). Efficacy was assessed by investigator for 2 hours post initial dose (p.i.d.), and 3 days later (Visit 2). Primary efficacy endpoint was the complete resolution of throat pain and difficulty in swallowing at Visit 2 (3 days p.i.d.). Safety and local tolerability were also assessed. RESULTS Seventy-two hours (p.i.d.), complete resolution of throat pain and difficulty in swallowing were achieved by 44.6% patients on study drug compared with 27.2% patients on placebo (difference 17.4% (CI [5.8%; 29.7%]; 64% improvement [GEE, P = 0.0022]). Until 2 hours p.i.d., reduction in symptoms was better with study drug (P < 0.005). Treatment satisfaction was higher with study drug (patients'/investigators' assessment (78.9%/78.9% vs 55.0%/55.6% for placebo) and was well tolerated, overall safety profile was comparable to placebo. CONCLUSION The strength of this randomised controlled trial lies in the endpoint of complete remission after 3 days p.i.d., especially in the light of other trials addressing acute pharyngitis. The results of this study show a significant benefit of the study drug over placebo in the treatment of acute pharyngitis. Local treatment with the fixed combination (0.5 mg tyrothricin, 1.0 mg benzalkonium chloride, and 1.5 mg benzocaine) provides a rapid analgesic effect and is effective in relieving both severe throat pain as well as difficulty in swallowing associated with acute pharyngitis leading to a 64% improved complete remission within 72 hours. The triple active combination is a suitable treatment option for patients in the self-management of acute pharyngitis and sore throat. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT03323528.",2018,"The triple active combination is a suitable treatment option for patients in the self-management of acute pharyngitis and sore throat. ","['acute pharyngitis in adults', 'patients in the self-management of acute pharyngitis and sore throat', 'Seventy-two hours', 'Patients (pts, aged ≥18\xa0years) with acute pharyngitis, ie, non-streptococcal sore throat and moderate-to-severe pain (intensity NRS\xa0≥\xa07; VAS\xa0≥\xa050', 'patients with acute pharyngitis', 'acute pharyngitis']","['matching placebo', 'triple active sore throat lozenge', 'placebo', 'fixed combination (0.5\xa0mg tyrothricin, 1.0\xa0mg benzalkonium chloride, and 1.5\xa0mg benzocaine', 'tyrothricin, 1.0\xa0mg benzalkonium chloride, and 1.5\xa0mg benzocaine', 'placebo lozenges']","['Efficacy', 'tolerated, overall safety profile', 'complete resolution of throat pain and difficulty in swallowing', 'Efficacy and safety', 'efficacy and safety', 'Treatment satisfaction', 'reduction in symptoms', 'Safety and local tolerability']","[{'cui': 'C0001344', 'cui_str': 'Acute pharyngitis (disorder)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0242429', 'cui_str': 'Sore Throat'}, {'cui': 'C4319632', 'cui_str': 'Seventy-two'}, {'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0036689', 'cui_str': 'Streptococcal sore throat (disorder)'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}]","[{'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0242429', 'cui_str': 'Sore Throat'}, {'cui': 'C4319836', 'cui_str': 'Lozenge'}, {'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0041499', 'cui_str': 'Tyrothricin'}, {'cui': 'C0005026', 'cui_str': 'Benzalkonium Chloride'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0005059', 'cui_str': 'Benzocaine'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0242429', 'cui_str': 'Sore Throat'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0326374', 'cui_str': 'Swallows'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}]",50.0,0.74929,"The triple active combination is a suitable treatment option for patients in the self-management of acute pharyngitis and sore throat. ","[{'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Palm', 'Affiliation': 'doc-hno, Röthenbach, Germany.'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Fuchs', 'Affiliation': 'Pharmalog Institut für klinische Forschung GmbH, Munich, Germany.'}, {'ForeName': 'Holger', 'Initials': 'H', 'LastName': 'Stammer', 'Affiliation': 'Pharmalog Institut für klinische Forschung GmbH, Munich, Germany.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Schumacher-Stimpfl', 'Affiliation': 'Medice Arzneimittel Pütter GmbH & Co.KG, Iserlohn, Germany.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Milde', 'Affiliation': 'Pharmalog Institut für klinische Forschung GmbH, Munich, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",International journal of clinical practice,['10.1111/ijcp.13272'] 273,32297653,Transmuscular quadratus lumborum block for percutaneous nephrolithotomy: Study protocol for a dose-finding trial.,"BACKGROUND The objective of this trial is to optimize the transmuscular quadratus lumborum (TQL) block, by investigating the minimal effective volume (MEV 90 ) of ropivacaine 0.75% for single-shot TQL block in percutaneous nephrolithotomy (PNL) patients. METHODS This double-blind, randomized and controlled dose-finding trial is based on a biased coin up-and-down sequential design, where the volume of local anaesthetic administered to each patient depends on the response from the previous one. Investigating the TQL block, the first patient recruited receives 20 ml ropivacaine 0.75% preoperatively. In case of block failure, the next patient will receive the same volume with an increment of 2 ml. Given a successful block for the first patient, the next patient will be randomized to either a lower volume (previous volume with a reduction of 2 ml), or the same volume as the previous patient. The respective probabilities being b = 0.11 for a reduced volume and 1-b = 0.89 for the same volume. Block success is defined as patient reported pain score numeric rated scale (NRS) ≤3 (0-10/10) 30 minutes after arrival in the post anaesthesia care unit (PACU). The NRS pain score is our primary and only outcome for block success. A minimum of 25 eligible patients are needed to achieve precise estimation of MEV 90 with narrow 95% confidence intervals derived by bootstrapping. DISCUSSION Recruiting will begin June 2020 and is expected to finish November 2020. Data analysis will be performed at interims during and after the study. Results will be published in an international peer-reviewed medical journal.",2020,The respective probabilities being b=0.11 for a reduced volume and 1-b=0.89 for the same volume.,"['25 eligible patients', 'percutaneous nephrolithotomy (PNL) patients']",['ropivacaine'],"['NRS pain score', 'pain score numeric rated scale (NRS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162428', 'cui_str': 'Removal of calculus of renal pelvis through percutaneous nephrostomy'}]","[{'cui': 'C0073571', 'cui_str': 'ropivacaine'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",,0.09871,The respective probabilities being b=0.11 for a reduced volume and 1-b=0.89 for the same volume.,"[{'ForeName': 'Christian H S', 'Initials': 'CHS', 'LastName': 'Andersen', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Gunnar H', 'Initials': 'GH', 'LastName': 'Laier', 'Affiliation': 'Production, Research and Innovation, Region Sjaelland, Soro, Denmark.'}, {'ForeName': 'Martin V', 'Initials': 'MV', 'LastName': 'Nielsen', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Mette', 'Initials': 'M', 'LastName': 'Dam', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Christian K', 'Initials': 'CK', 'LastName': 'Hansen', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Katrine', 'Initials': 'K', 'LastName': 'Tanggaard', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Børglum', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Zealand University Hospital, Roskilde, Denmark.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13605'] 274,32243609,The benefits of iron supplementation following blood donation vary with baseline iron status.,"Whole blood donation rapidly removes approximately 10% of a donor's blood volume and stimulates substantial changes in iron metabolism and erythropoiesis. We sought to identify donors who benefit from iron supplementation, describe the nature of the benefit, and define the time course for recovery from donation. Blood samples were collected over 24 weeks following whole blood donation from 193 participants, with 96 participants randomized to 37.5 mg daily oral iron. Changes in total body, red blood cell (RBC), and storage iron, hepcidin, erythropoietin, and reticulocyte count were modeled using semiparametric curves in a mixed model. and the changes were compared among six groups defined by baseline ferritin (<12; 12-50; ≥50 ng/mL) and iron supplementation. The effect of oral iron on storage and RBC iron recovery was minimal in donors with baseline ferritin ≥50 ng/mL, but sizeable when ferritin was <50 ng/mL. Iron initially absorbed went to RBC and storage iron pools when ferritin was <12 ng/mL but went mostly to RBCs when ferritin was ≥12 ng/mL. Donors with ferritin ≥12 ng/mL had a ""ripple"" increase in reticulocytes ~100 days after donation indicating physiological responses occur months following donation. Thus, iron supplements markedly enhance recovery from whole blood donation in donors with ferritin <50 ng/mL. However, full recovery from donation requires over 100 days when taking iron. The findings also highlight the value of the study of blood donors for understanding human hemoglobin and iron metabolism and their usefulness for future studies as additional biomarkers are discovered.",2020,"The effect of oral iron on storage and RBC iron recovery was minimal in donors with baseline ferritin ≥50 ng/mL, but sizeable when ferritin was <50 ng/mL. Iron initially absorbed went to RBC and storage iron pools when ferritin was <12 ng/mL but went mostly to RBCs when ferritin was ≥12 ng/mL. Donors with ferritin ≥12","['donors with baseline ferritin ≥50 ng/mL, but sizeable when ferritin was <50 ng/mL. Iron initially absorbed went to RBC and storage iron pools when ferritin was <12 ng/mL but went mostly to RBCs when ferritin was ≥12 ng/mL. Donors with ferritin ≥12', 'donors with ferritin <50 ng/mL']",['iron supplementation'],"['storage and RBC iron recovery', 'total body, RBC, and storage iron, hepcidin, erythropoietin, and reticulocyte count']","[{'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0015879', 'cui_str': 'Ferritin'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C1698986', 'cui_str': 'Storage'}, {'cui': 'C0337051', 'cui_str': 'Pool'}, {'cui': 'C0014792', 'cui_str': 'erythrocytes'}]","[{'cui': 'C3537005', 'cui_str': 'Iron supplement therapy'}]","[{'cui': 'C1698986', 'cui_str': 'Storage'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0966897', 'cui_str': 'Hepcidin'}, {'cui': 'C0014822', 'cui_str': 'erythropoietin'}, {'cui': 'C0206161', 'cui_str': 'Reticulocyte count'}]",96.0,0.117661,"The effect of oral iron on storage and RBC iron recovery was minimal in donors with baseline ferritin ≥50 ng/mL, but sizeable when ferritin was <50 ng/mL. Iron initially absorbed went to RBC and storage iron pools when ferritin was <12 ng/mL but went mostly to RBCs when ferritin was ≥12 ng/mL. Donors with ferritin ≥12","[{'ForeName': 'Alan E', 'Initials': 'AE', 'LastName': 'Mast', 'Affiliation': 'Blood Research Institute, Versiti, Milwaukee, Wisconsin, USA.'}, {'ForeName': 'Aniko', 'Initials': 'A', 'LastName': 'Szabo', 'Affiliation': 'Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.'}, {'ForeName': 'Mars', 'Initials': 'M', 'LastName': 'Stone', 'Affiliation': 'Vitalant Research Institute, San Francisco, California, USA.'}, {'ForeName': 'Ritchard G', 'Initials': 'RG', 'LastName': 'Cable', 'Affiliation': 'American Red Cross Scientific Affairs, Farmington, Connecticut, USA.'}, {'ForeName': 'Bryan R', 'Initials': 'BR', 'LastName': 'Spencer', 'Affiliation': 'American Red Cross Scientific Affairs, Dedham, Massachusetts, USA.'}, {'ForeName': 'Joseph E', 'Initials': 'JE', 'LastName': 'Kiss', 'Affiliation': 'Vitalant Northeast Division, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of hematology,['10.1002/ajh.25800'] 275,31066232,Sodium tanshinone IIA sulfonate prevents the adverse left ventricular remodelling: Focus on polymorphonuclear neutrophil-derived granule components.,"AIMS The aims of this study were to evaluate the effects of sodium tanshinone IIA sulfonate (STS) on left ventricular (LV) remodelling after for ST-elevated myocardial infarction (STEMI). METHODS AND RESULTS In this prospective, randomized clinical trial, 101 patients with the ST-elevated MI (STEMI) and a successful reperfusion were immediately randomized to receive STS (80 mg qd for 7 days) or saline control, along with standard therapy. The primary effectiveness endpoint is the % change in LV end diastolic volumes index (%∆ LVEDVi) as measured by echocardiography from baseline to 6 months. Secondary effectiveness endpoints include 6-month period for major adverse cardiac events (MACE), including the occurrence of recurrent myocardial infarction, death, hospitalization for heart failure and malignant arrhythmia. The 6-month changes in %∆ LVEDVi were significantly smaller in the STS group than in the control group [-5.05% vs 3.32%; P < 0.001]. With respect to MACE, there was a significant difference between those who received STS (8.16%) and those patients on control (26.00%) (P = 0.019). Meaningfully, results of parallel tests aimed at mechanistic explanation of the reported clinical effects, revealed a significantly reduced levels of neutrophils-derived granule components in the blood of STS treated patients. CONCLUSION We found that short-term treatment with STS reduced progressive left ventricular remodelling and subsequent better clinical outcome that could be mechanistically linked to the inhibition of the ultimate damage of infarcted myocardium by infiltrating neutrophils.",2019,LVEDVi were significantly smaller in the STS group than in the control group [-5.05% vs 3.32%; P < 0.001].,['101 patients with the ST-elevated MI (STEMI) and a successful reperfusion'],"['Sodium tanshinone IIA sulfonate', 'STS', 'saline control', 'sodium tanshinone IIA sulfonate (STS']","['6-month period for major adverse cardiac events (MACE), including the occurrence of recurrent myocardial infarction, death, hospitalization for heart failure and malignant arrhythmia', 'LVEDVi', 'LV end diastolic volumes index (%∆ LVEDVi', 'progressive left ventricular remodelling', 'left ventricular (LV) remodelling']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0520886', 'cui_str': 'ST segment elevation (finding)'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0035124', 'cui_str': 'Reperfusion'}]","[{'cui': 'C0075811', 'cui_str': 'sodium tanshinone IIA sulfonate'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0205282', 'cui_str': 'Malignant (qualifier value)'}, {'cui': 'C0003811', 'cui_str': 'Arrhythmia'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0205091', 'cui_str': 'Left (qualifier value)'}, {'cui': 'C0600519', 'cui_str': 'Myocardial Remodeling, Ventricular'}]",101.0,0.0487257,LVEDVi were significantly smaller in the STS group than in the control group [-5.05% vs 3.32%; P < 0.001].,"[{'ForeName': 'Shuai', 'Initials': 'S', 'LastName': 'Mao', 'Affiliation': 'Key Discipline of Integrated Chinese and Western Medicine, Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China.'}, {'ForeName': 'Shalina', 'Initials': 'S', 'LastName': 'Taylor', 'Affiliation': 'Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA.'}, {'ForeName': 'Qubo', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'Biological Resource Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.'}, {'ForeName': 'Minzhou', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Key Discipline of Integrated Chinese and Western Medicine, Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China.'}, {'ForeName': 'Aleksander', 'Initials': 'A', 'LastName': 'Hinek', 'Affiliation': 'Translational Medicine, Hospital for Sick Children, Toronto, Canada.'}]",Journal of cellular and molecular medicine,['10.1111/jcmm.14306'] 276,31099141,Methamphetamine acutely alters frontostriatal resting state functional connectivity in healthy young adults.,"Chronic use of methamphetamine impairs frontostriatal structure and function, which may result in increased incentive-motivational responses to drug cues and decreased regulation of drug-seeking behavior. However, less is known regarding how the drug affects these circuits after acute administration. The current study examined the effects of a single dose of methamphetamine on resting state frontostriatal functional connectivity in healthy volunteers. Participants (n = 22, 12 female) completed two sessions in which they received methamphetamine (20 mg) and placebo before a resting state scan during functional magnetic resonance imaging. Participants also provided self-report measures of euphoria and stimulation at regular intervals. We conducted seed-based voxelwise functional connectivity analyses using three bilateral striatal seed regions: nucleus accumbens (NAcc), caudate, and putamen and compared connectivity following methamphetamine versus placebo administration. Additionally, we conducted correlational analyses to assess if drug-induced changes in functional connectivity were related to changes in subjective response. Methamphetamine increased NAcc functional connectivity with medial frontal regions (ie, orbitofrontal cortex, medial frontal gyrus, and superior frontal gyrus) and decreased NAcc functional connectivity with subgenual anterior cingulate cortex (ACC). Methamphetamine also increased functional connectivity between putamen and left inferior frontal gyrus (IFG), and individuals who displayed greater drug-induced increase in connectivity reported less euphoria and stimulation. These findings provide important information regarding the effects of methamphetamine on brain function in nonaddicted individuals. Further studies will reveal whether such effects contribute to the abuse potential of the drug and whether they are related to the frontostriatal impairments observed after chronic methamphetamine use.",2020,"Methamphetamine also increased functional connectivity between putamen and left inferior frontal gyrus (IFG), and individuals who displayed greater drug-induced increase in connectivity reported less euphoria and stimulation.","['healthy volunteers', 'nonaddicted individuals', 'healthy young adults', 'Participants (n\xa0=\xa022, 12 female']","['Methamphetamine', 'methamphetamine versus placebo', 'methamphetamine', 'placebo']","['NAcc functional connectivity with medial frontal regions (ie, orbitofrontal cortex, medial frontal gyrus, and superior frontal gyrus) and decreased NAcc functional connectivity with subgenual anterior cingulate cortex (ACC', 'brain function', 'functional connectivity']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0025611', 'cui_str': 'metamfetamine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0205098', 'cui_str': 'Medial (qualifier value)'}, {'cui': 'C0549224', 'cui_str': 'Frontal region'}, {'cui': 'C2331062', 'cui_str': 'Orbital Area'}, {'cui': 'C0458310', 'cui_str': 'Medial Frontal Gyrus'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0205123', 'cui_str': 'Coronal (qualifier value)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0031843', 'cui_str': 'function'}]",,0.036196,"Methamphetamine also increased functional connectivity between putamen and left inferior frontal gyrus (IFG), and individuals who displayed greater drug-induced increase in connectivity reported less euphoria and stimulation.","[{'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Weafer', 'Affiliation': 'Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Kathryne', 'Initials': 'K', 'LastName': 'Van Hedger', 'Affiliation': 'Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada.'}, {'ForeName': 'Sarah K', 'Initials': 'SK', 'LastName': 'Keedy', 'Affiliation': 'Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Nkemdilim', 'Initials': 'N', 'LastName': 'Nwaokolo', 'Affiliation': 'Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Harriet', 'Initials': 'H', 'LastName': 'de Wit', 'Affiliation': 'Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois.'}]",Addiction biology,['10.1111/adb.12775'] 277,30772070,"Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial.","Aging is accompanied by a decline in immune function which can lead to decreased responses to vaccines. Attenuated recombinant Vibrio cholerae O1 vaccine strain CVD 103-HgR elicits a rapid serum vibriocidal antibody (SVA) response and protects against cholera diarrhea in volunteer challenge studies but has not been studied in older adults. We evaluated CVD 103-HgR (PXVX0200) in adults age 46-64, compared them to previously studied adults age 18-45, and studied age-related immunogenicity across adults 18-64 years of age. Volunteers were randomized to receive a single dose of 1 × 10 9  CFU of PXVX0200 or placebo. Immunogenicity endpoints included SVA and anti-cholera toxin (CT) antibody levels on days 1, 11, 29, 91 and 181 and lipopolysaccharide (LPS) and CT-specific IgA and IgG memory B cells on days 1, 91 and 181. Safety was assessed by comparing solicited signs and symptoms on days 1-8 and other adverse events through day 181. 2979 volunteers received vaccine, including 291 age 45-64. Day 11 seroconversion occurred in 90.4% of older adults vs 93.5%% of younger adults and met the endpoint of demonstrating non-inferiority between the two groups. Significant increases in LPS-specific IgG and IgA and CT-specific memory IgG memory B cells were seen at days 91 and 181. There appeared to be a continuous age-related decline in SVA seroconversion and geometric mean titers, but not memory B cell responses, across the 18-64 year age range. Most reactogenicity was mild and was more common in the placebo group. PXVX0200 appears safe and immunogenic in older adults. Clinical Trials Registration: clinicaltrials.gov NCT02100631.",2019,Significant increases in LPS-specific IgG and IgA and CT-specific memory IgG memory B cells were seen at days 91 and 181.,"['adults', '2979 volunteers received vaccine, including 291 age 45-64', 'age 46-64, compared them to previously studied adults age 18-45, and studied age-related immunogenicity across adults 18-64\u202fyears of age', 'older adults']","['PXVX0200 or placebo', 'placebo', 'PXVX0200', 'live oral cholera vaccine CVD 103-HgR', 'recombinant Vibrio cholerae O1 vaccine strain CVD']","['SVA seroconversion and geometric mean titers', 'SVA and anti-cholera toxin (CT) antibody levels on days 1, 11, 29, 91 and 181 and lipopolysaccharide (LPS) and CT-specific IgA and IgG memory B cells', 'LPS-specific IgG and IgA and CT-specific memory IgG memory B cells', 'CVD 103-HgR', '103-HgR elicits a rapid serum vibriocidal antibody ', 'Safety']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0961644', 'cui_str': 'cholera vaccine CVD 103-HgR'}, {'cui': 'C0318248', 'cui_str': 'Vibrio cholerae Serogroup O1'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0080194', 'cui_str': 'Strains'}]","[{'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0008356', 'cui_str': 'Choleragen'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0023810', 'cui_str': 'Lipoglycans'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0004561', 'cui_str': 'B-Cells'}, {'cui': 'C0961644', 'cui_str': 'cholera vaccine CVD 103-HgR'}, {'cui': 'C4517526', 'cui_str': 'One hundred and three'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",2979.0,0.506412,Significant increases in LPS-specific IgG and IgA and CT-specific memory IgG memory B cells were seen at days 91 and 181.,"[{'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'McCarty', 'Affiliation': 'Stanford University School of Medicine, 291 Campus Drive, Stanford, CA 94305 USA. Electronic address: jmccart2@stanford.edu.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Lock', 'Affiliation': 'PaxVax, Inc., 555 Twin Dolphin Drive, Ste. 360, Redwood City, CA 94065 USA.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Bennett', 'Affiliation': 'PaxVax, Inc., 555 Twin Dolphin Drive, Ste. 360, Redwood City, CA 94065 USA.'}, {'ForeName': 'Kristin M', 'Initials': 'KM', 'LastName': 'Hunt', 'Affiliation': 'PaxVax, Inc., 555 Twin Dolphin Drive, Ste. 360, Redwood City, CA 94065 USA.'}, {'ForeName': 'Jakub K', 'Initials': 'JK', 'LastName': 'Simon', 'Affiliation': 'PaxVax, Inc., 555 Twin Dolphin Drive, Ste. 360, Redwood City, CA 94065 USA.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Gurwith', 'Affiliation': 'PaxVax, Inc., 555 Twin Dolphin Drive, Ste. 360, Redwood City, CA 94065 USA.'}]",Vaccine,['10.1016/j.vaccine.2019.01.077'] 278,31240128,Comparison of abdominal compression devices in persons with abdominal paralysis due to spinal cord injury.,"Study Design Single subject design with five subjects. Objectives The objetive of this study is to compare the effectiveness and usability of alternative commercial abdominal compression garments with participants' usual medical binders. Setting Private residences in Pierce and King Counties, WA, USA. Methods Participants wore each garment for 5 days followed by a 2-day washout in personal binder. Week 1: Personal binder. Weeks 2 and 3: Randomly ordered test garments (tank, bodysuit). Physiologic measurements: blood pressure (SBP, DBP), blood oxygen saturation (SaO 2 ), forced expiratory volume in one second (FEV 1 ), and heart rate (HR). Participants completed logs twice daily for 5 days per garment regarding ease of use, comfort, respiration, and appearance. We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during the course of this research. Results The use of a personal binder results in significant increases in SBP and FEV 1 . Personal binders support FEV 1 significantly better than test garments. There is no difference in SBP between test garments and personal binders. There are no significant differences between DBP, SaO 2 , or HR between participants' personal binders and no binder. Participants reported that neither tank nor bodysuit felt adequately supportive or easy to use. Conclusions Abdominal compression improves respiratory function and supports SBP in individuals with chronic SCI. Further research is needed to guide the development of an easy-to-use and physiologically supportive abdominal compression garment.",2019,"There are no significant differences between DBP, SaO 2 , or HR between participants' personal binders and no binder.","['persons with abdominal paralysis due to spinal cord injury', 'human volunteers', 'five subjects', 'individuals with chronic SCI', 'Setting\n\n\nPrivate residences in Pierce and King Counties, WA, USA.\nMethods']","['abdominal compression devices', 'alternative commercial abdominal compression garments', ' Randomly ordered test garments (tank, bodysuit']","['SBP and FEV 1 ', 'DBP, SaO 2 , or HR', 'SBP', 'respiratory function', 'Physiologic measurements: blood pressure (SBP, DBP), blood oxygen saturation (SaO 2 ), forced expiratory volume in one second (FEV 1 ), and heart rate (HR']","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}, {'cui': 'C0522224', 'cui_str': 'Plegia'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0020155', 'cui_str': 'Human Volunteers'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C4521534', 'cui_str': 'US Military enlisted E1'}, {'cui': 'C0454792', 'cui_str': 'Offaly (geographic location)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}]","[{'cui': 'C0000726', 'cui_str': 'Abdomen'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C2985539', 'cui_str': 'Compression garment (physical object)'}, {'cui': 'C4284072', 'cui_str': 'Order (record artifact)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0009072', 'cui_str': 'Garments'}, {'cui': 'C0336821', 'cui_str': 'Tank - military vehicle (physical object)'}]","[{'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}, {'cui': 'C0199213', 'cui_str': 'Physiologic measurement'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0428174', 'cui_str': 'Hemoglobin saturation with oxygen (observable entity)'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}]",5.0,0.0276293,"There are no significant differences between DBP, SaO 2 , or HR between participants' personal binders and no binder.","[{'ForeName': 'Michaela de', 'Initials': 'M', 'LastName': 'Groot', 'Affiliation': '1University of Puget Sound, Tacoma, WA USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Swartz', 'Affiliation': '2University of Puget Sound, 1500 N Warner St. CMB 1030, 98416 Tacoma, WA USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Hastings', 'Affiliation': '2University of Puget Sound, 1500 N Warner St. CMB 1030, 98416 Tacoma, WA USA.'}]",Spinal cord series and cases,['10.1038/s41394-019-0176-x'] 279,32293943,Fundamental Frequency Variations Across the Menstrual Cycle and the Use of an Oral Contraceptive Pill.,"Purpose Concentrations of sex steroid hormones-estrogens, progesterone, and testosterone-have been associated with premenstrual and menstrual vocal symptoms. However, the extent to which these symptoms may be reflected on acoustical features of the voice is still debated. This study investigates variations in fundamental frequency ( f o ) and related parameters in connected speech across phases of the menstrual cycle and during the use of a combined oral contraceptive pill (OCP). Method Electrolaryngographic recordings were made, and blood samples were collected at three different phases of the menstrual cycle-menstrual, follicular, and luteal-for placebo and OCP use. These two conditions were blindly and randomly allocated in the study. Speaking f o (SFF), SFF standard deviation, SFF rate of change, SFF slope, maximum and minimum f o , and f o range were extracted for nine healthy females while reading a phrase from the Rainbow Passage. Concentrations of sex hormones were analyzed in serum. Nonparametric statistical tests were carried out to assess differences between phases and conditions. Results SFF, its standard deviation, and maximum f o were significantly different between phases of the menstrual cycle for placebo use only. Menstrual phase showed the lowest values. Maximum and minimum f o were significantly different between placebo and OCP use for menstrual and follicular phases, respectively. Conclusions Fluctuations in sex steroid hormones across the menstrual cycle alter f o in speech more than a particular hormonal concentration. OCP use seems to have a stabilizing effect on the voice relative to f o and related parameters in speech.",2020,OCP use seems to have a stabilizing effect on the voice relative to f ,[],"['placebo and OCP', 'combined oral contraceptive pill (OCP', 'OCP', 'placebo']","['Concentrations of sex hormones', 'f o (SFF), SFF standard deviation, SFF rate of change, SFF slope, maximum and minimum f o , and f o range', 'Results SFF, its standard deviation, and maximum f', 'Maximum and minimum f']",[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1282359', 'cui_str': 'Ocular cicatricial pemphigoid'}, {'cui': 'C0009906', 'cui_str': 'Oral Contraceptives, Combined'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0036884', 'cui_str': 'Sex hormone'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]",9.0,0.0456157,OCP use seems to have a stabilizing effect on the voice relative to f ,"[{'ForeName': 'Filipa M B', 'Initials': 'FMB', 'LastName': 'Lã', 'Affiliation': 'Faculty of Education, Department of Didactics, School Organization and Special Didactics, National Distance Education University, Madrid, Spain.'}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'Polo', 'Affiliation': 'Faculty of Philology, Department of Spanish Language and General Linguistics, National Distance Education University, Madrid, Spain.'}]","Journal of speech, language, and hearing research : JSLHR",['10.1044/2020_JSLHR-19-00277'] 280,32293967,Does a Systematic Vocal Exercise Program Enhance the Physiologic Range of Voice Production in Classical Singing Graduate-Level Students?,"Purpose The purpose of this study was to assess the effects of vocal function exercises (VFEs) on the physiologic range of the operatic voice. The primary outcome measure was total voice range profile (VRP) area. Method Forty graduate-level opera majors were randomly assigned to experimental (training with VFE + vocal hygiene) and control (vocal hygiene only) groups. All participants underwent an acoustic voice assessment (modified VRP) pre and post 10 weeks of the assigned intervention. VRP total area was calculated and compared between and within the two groups. The total VRP area was subsequently divided into three area thirds (low, medium, and high). Results A significant improvement (increase) was observed in the VFE group for the primary outcome measure of VRP area when pre- and postvoice conditions were compared for total area, upper third, and middle third. No significant improvement was found in the vocal hygiene-only group. Conclusion Vocal training with VFEs over a 10-week period demonstrated positive effects on physiologic voice range as evidenced by an increase in the total VRP area and therefore may enhance the potential of those who already have professional voice training.",2020,"A significant improvement (increase) was observed in the VFE group for the primary outcome measure of VRP area when pre- and postvoice conditions were compared for total area, upper third, and middle third.","['Classical Singing Graduate-Level Students', 'Method Forty graduate-level opera majors']","['Systematic Vocal Exercise Program', 'VFE', 'experimental (training with VFE + vocal hygiene) and control (vocal hygiene only) groups', 'acoustic voice assessment (modified VRP', 'vocal function exercises (VFEs']","['total VRP area', 'physiologic voice range', 'VRP total area', 'VRP area', 'total voice range profile (VRP) area', 'vocal hygiene']","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0588053', 'cui_str': 'Graduate'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]","[{'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0589289', 'cui_str': 'Voice exercises'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0020405', 'cui_str': 'Hygiene'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0001166', 'cui_str': 'Acoustics'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C1532868', 'cui_str': 'Vocal function'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0020405', 'cui_str': 'Hygiene'}]",40.0,0.0287027,"A significant improvement (increase) was observed in the VFE group for the primary outcome measure of VRP area when pre- and postvoice conditions were compared for total area, upper third, and middle third.","[{'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Guzman', 'Affiliation': 'Department of Communication Sciences and Disorders, Universidad de los Andes, Santiago, Chile.'}, {'ForeName': 'Vrushali', 'Initials': 'V', 'LastName': 'Angadi', 'Affiliation': 'Department of Communication Sciences and Disorders, University of Kentucky, Lexington.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Croake', 'Affiliation': 'The Blaine Block Institute for Voice Analysis and Rehabilitation, Dayton, OH.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Catalan', 'Affiliation': 'Servicio de Otorrinolaringología, Hospital Dr. Luis Calvo Mackena, Santiago, Chile.'}, {'ForeName': 'Constanza', 'Initials': 'C', 'LastName': 'Romero', 'Affiliation': 'Department of Communication Sciences and Disorders, University of Chile, Santiago.'}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Acuña', 'Affiliation': 'Department of Communication Sciences and Disorders, University of Chile, Santiago.'}, {'ForeName': 'Camilo', 'Initials': 'C', 'LastName': 'Quezada', 'Affiliation': 'Facultad de Medicina, Departamento de Fonoaudiología, Universidad de Chile, Santiago.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Andreatta', 'Affiliation': 'Department of Communication Sciences and Disorders, University of Kentucky, Lexington.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Stemple', 'Affiliation': 'Department of Communication Sciences and Disorders, University of Kentucky, Lexington.'}]","Journal of speech, language, and hearing research : JSLHR",['10.1044/2020_JSLHR-19-00362'] 281,31448513,Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.,"Palbociclib is a cyclin-dependent kinase 4/6 inhibitor indicated for treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in combination with endocrine therapy. We investigated the efficacy and safety of palbociclib in patients enrolled in North America during two-phase 3 trials: PALOMA-2 (n = 267, data cutoff: May 31, 2017) and PALOMA-3 (n = 240, data cutoffs: April 13, 2018, for overall survival, October 23, 2015, for all other outcomes). In PALOMA-2, treatment-naïve postmenopausal patients with advanced breast cancer were randomized 2:1 to palbociclib (125 mg/d; 3 weeks on/1 week off [3/1]) plus letrozole (2.5 mg/d, continuous) or placebo plus letrozole. In PALOMA-3, patients who progressed on prior endocrine therapy were randomized 2:1 to palbociclib (125 mg/d; 3/1) plus fulvestrant (500 mg, per standard of care) or placebo plus fulvestrant; pre/perimenopausal patients received ovarian suppression with goserelin. Palbociclib plus endocrine therapy prolonged median progression-free survival vs placebo plus endocrine therapy in North American patients (PALOMA-2: 25.4 vs 13.7 months, hazard ratio, 0.54 [95% CI, 0.40-0.74], P < .0001; PALOMA-3: 9.9 vs 3.5 months, hazard ratio, 0.52 [95% CI, 0.38-0.72], P < .0001). Objective response and clinical benefit response rates were greater with palbociclib vs placebo in North American patients in both trials. While overall survival data are not yet mature for PALOMA-2, median overall survival was increased in PALOMA-3 (32.0 vs 24.7 months, hazard ratio, 0.75 [95% CI, 0.53-1.04]), though this did not reach statistical significance (P = .0869). Safety profiles in North American patients were similar to those of the overall populations; neutropenia was the most common treatment-emergent adverse event. No new safety signals were observed. In summary, palbociclib plus endocrine therapy is an effective treatment option for North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.",2020,Objective response and clinical benefit response rates were greater with palbociclib vs placebo in North American patients in both trials.,"['North American patients', 'patients who progressed on prior endocrine therapy', 'North American patients in both trials', 'North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer', 'North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer', 'patients enrolled in North America during two-phase 3 trials: PALOMA-2 (n\xa0=\xa0267, data cutoff: May 31, 2017) and PALOMA-3 (n\xa0=\xa0240, data cutoffs: April 13, 2018, for overall survival, October 23, 2015, for all other outcomes', 'naïve postmenopausal patients with advanced breast cancer']","['palbociclib', 'placebo plus fulvestrant', 'palbociclib plus endocrine therapy', 'ovarian suppression with goserelin', 'placebo plus endocrine therapy', 'letrozole', 'placebo plus letrozole', 'palbociclib vs placebo', 'Palbociclib plus endocrine therapy', 'fulvestrant']","['overall survival data', 'Objective response and clinical benefit response rates', 'Efficacy and safety', 'efficacy and safety', 'median progression-free survival', 'median overall survival']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy (procedure)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C3496586', 'cui_str': 'epidermal growth factor receptor 2, human'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer metastatic'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C0439561', 'cui_str': 'Phase 3 (qualifier value)'}, {'cui': 'C4517672', 'cui_str': '267'}, {'cui': 'C4319600', 'cui_str': '240 (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}]","[{'cui': 'C3853822', 'cui_str': 'palbociclib'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0935916', 'cui_str': 'fulvestrant'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy (procedure)'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression (disorder)'}, {'cui': 'C0120107', 'cui_str': 'Goserelin'}, {'cui': 'C0246421', 'cui_str': 'letrozole'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",,0.456804,Objective response and clinical benefit response rates were greater with palbociclib vs placebo in North American patients in both trials.,"[{'ForeName': 'Karen A', 'Initials': 'KA', 'LastName': 'Gelmon', 'Affiliation': 'BC Cancer, Vancouver, BC, Canada.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Cristofanilli', 'Affiliation': 'Feinberg School of Medicine, Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL, USA.'}, {'ForeName': 'Hope S', 'Initials': 'HS', 'LastName': 'Rugo', 'Affiliation': 'Diller Family Comprehensive Cancer Center, University of California San Francisco Helen, San Francisco, CA, USA.'}, {'ForeName': 'Angela M', 'Initials': 'AM', 'LastName': 'DeMichele', 'Affiliation': 'Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Anil A', 'Initials': 'AA', 'LastName': 'Joy', 'Affiliation': 'Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Aurelio', 'Initials': 'A', 'LastName': 'Castrellon', 'Affiliation': 'Breast Cancer Center, Memorial Healthcare System, Hollywood, FL, USA.'}, {'ForeName': 'Bethany', 'Initials': 'B', 'LastName': 'Sleckman', 'Affiliation': 'Mercy Hospital St. Louis, St. Louis, MO, USA.'}, {'ForeName': 'Ave', 'Initials': 'A', 'LastName': 'Mori', 'Affiliation': 'Pfizer Oncology, Milan, Italy.'}, {'ForeName': 'Kathy Puyana', 'Initials': 'KP', 'LastName': 'Theall', 'Affiliation': 'Pfizer Oncology, Cambridge, MA, USA.'}, {'ForeName': 'Dongrui R', 'Initials': 'DR', 'LastName': 'Lu', 'Affiliation': 'Pfizer Inc, La Jolla, CA, USA.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Pfizer Oncology, New York, NY, USA.'}, {'ForeName': 'Eustratios', 'Initials': 'E', 'LastName': 'Bananis', 'Affiliation': 'Pfizer Oncology, New York, NY, USA.'}, {'ForeName': 'Richard S', 'Initials': 'RS', 'LastName': 'Finn', 'Affiliation': 'David Geffen School of Medicine, University of California Los Angeles, Santa Monica, CA, USA.'}, {'ForeName': 'Dennis J', 'Initials': 'DJ', 'LastName': 'Slamon', 'Affiliation': 'David Geffen School of Medicine, University of California Los Angeles, Santa Monica, CA, USA.'}]",The breast journal,['10.1111/tbj.13516'] 282,31651370,Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD).,"BACKGROUND Fibroblast growth factor 23 (FGF23) is associated with left ventricular hypertrophy (LVH) in patients with chronic kidney disease, and calcimimetic therapy reduces plasma concentrations of FGF23. It remains unknown whether treatment with the calcimimetic etelcalcetide (ETL) reduces LVH in patients on hemodialysis. METHODS/DESIGN This single-blinded randomized trial of 12 months duration will test the effects of ETL compared with alfacalcidol on LVH and cardiac fibrosis in maintenance hemodialysis patients with secondary hyperparathyroidism. Both treatment regimens will be titrated to equally suppress secondary hyperparathyroidism while alfacalcidol treatment causes an increase and ETL a decrease in FGF23, respectively. Patients treated thrice weekly with hemodialysis for ≥ 3 months and ≤ 3 years with parathyroid hormone levels ≥ 300 pg/ml and LVH will be enrolled in the study. The primary study endpoint is change from baseline to 12 months in left ventricular mass index (LVMI; g/m 2 ) measured by cardiac magnetic resonance imaging. Sample size calculations showed that 62 randomized patients will be necessary to detect a difference in LVMI of at least 20 g/m 2 between the two groups at 12 months. Due to the strong association of volume overload and LVH, randomization will be stratified by residual kidney function, and regular body composition monitoring will be performed to control the volume status of patients. Study medication will be administered intravenously by the dialysis nurses after every hemodialysis session, thus omitting adherence issues. Secondary study endpoints are cardiac parameters measured by echocardiography, biomarker concentrations of bone metabolism (FGF23, vitamin D, parathyroid hormone, calcium, phosphate, s-Klotho), cardiac markers (pro-brain natriuretic peptide, pre- and postdialysis troponin T) and metabolites of the renin-angiotensin-aldosterone cascade (angiotensin I (Ang I), Ang II, Ang-(1-7), Ang-(1-5), Ang-(1-9), and aldosterone). DISCUSSION The causal inference and pathophysiology of LVH regression by FGF23 reduction using calcimimetic treatment has not yet been shown. This intervention study has the potential to discover a new strategy for the treatment of cardiac hypertrophy and fibrosis in patients on maintenance hemodialysis. It might be speculated that successful treatment of cardiac morphology will also reduce the risk of cardiac death in this population. TRIAL REGISTRATION European Clinical Trials Database, EudraCT number 2017-000222-35; ClinicalTrials.gov, NCT03182699 . Registered on.",2019,This intervention study has the potential to discover a new strategy for the treatment of cardiac hypertrophy and fibrosis in patients on maintenance hemodialysis.,"['patients on maintenance hemodialysis', 'patients on hemodialysis', 'patients with chronic kidney disease', 'maintenance hemodialysis patients with secondary hyperparathyroidism', 'hemodialysis patients']","['calcimimetic etelcalcetide (ETL', 'etelcalcetide', 'hemodialysis for ≥\u20093\u2009months and\u2009≤\u20093\u2009years with parathyroid hormone levels ≥', 'alfacalcidol', 'ETL']","['cardiac magnetic resonance imaging', 'cardiac parameters measured by echocardiography, biomarker concentrations of bone metabolism (FGF23, vitamin D, parathyroid hormone, calcium, phosphate, s-Klotho), cardiac markers (pro-brain natriuretic peptide, pre- and postdialysis troponin T) and metabolites of the renin-angiotensin-aldosterone cascade (angiotensin I (Ang I), Ang II, Ang-(1-7), Ang-(1-5), Ang-(1-9), and aldosterone', 'change from baseline to 12\u2009months in left ventricular mass index (LVMI', 'LVMI', 'cardiac hypertrophy']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4040576', 'cui_str': 'Maintenance hemodialysis'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C0020503', 'cui_str': 'Hyperparathyroidism, Secondary'}]","[{'cui': 'C3713906', 'cui_str': 'velcalcetide'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0030520', 'cui_str': 'Parathyroid Hormone'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0044410', 'cui_str': 'Alfacalcidol'}]","[{'cui': 'C1552358', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0013516', 'cui_str': 'Transthoracic Echocardiography'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0030520', 'cui_str': 'Parathyroid Hormone'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C1601799', 'cui_str': 'phosphate ion'}, {'cui': 'C1271630', 'cui_str': 'Cardiac markers'}, {'cui': 'C0754710', 'cui_str': 'Amino-terminal pro-brain natriuretic peptide'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0077404', 'cui_str': 'Troponin T'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0035094', 'cui_str': 'Angiotensinogenase'}, {'cui': 'C0003018', 'cui_str': 'Angiotensins'}, {'cui': 'C0373535', 'cui_str': 'Aldosterone measurement (procedure)'}, {'cui': 'C0003006', 'cui_str': 'Angiotensin I'}, {'cui': 'C4548298', 'cui_str': 'angiotensin (1-5)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1383860', 'cui_str': 'Cardiac Hypertrophy'}]",,0.0791123,This intervention study has the potential to discover a new strategy for the treatment of cardiac hypertrophy and fibrosis in patients on maintenance hemodialysis.,"[{'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Dörr', 'Affiliation': 'Department of Nephrology, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kammer', 'Affiliation': 'Department of Nephrology, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Reindl-Schwaighofer', 'Affiliation': 'Department of Nephrology, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Lorenz', 'Affiliation': 'Vienna Dialysis Center, Kapellenweg 37, 1220, Vienna, Austria.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Loewe', 'Affiliation': 'Division of Cardiovascular and Interventional Radiology, Department of Bioimaging and Image-Guided Intervention, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Rodrig', 'Initials': 'R', 'LastName': 'Marculescu', 'Affiliation': 'Laboratory Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Reinhold', 'Initials': 'R', 'LastName': 'Erben', 'Affiliation': 'Physiology, Pathophysiology, and Experimental Endocrinology, VetMed Vienna, Veterinärplatz 1, Vienna, Austria.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Oberbauer', 'Affiliation': 'Department of Nephrology, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria. Rainer.oberbauer@meduniwien.ac.at.'}]",Trials,['10.1186/s13063-019-3707-7'] 283,32295808,Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial.,"OBJECTIVE To assess the efficacy and safety of a 1:1 fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) versus lixisenatide (Lixi) in insulin-naive Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drugs (OADs). RESEARCH DESIGN AND METHODS In this phase 3, open-label, multicenter trial, 321 patients with HbA 1c ≥7.5 to ≤10.0% (58-86 mmol/mol) and fasting plasma glucose (FPG) ≤13.8 mmol/L (250 mg/dL) were randomized 1:1 to iGlarLixi or Lixi for 52 weeks. The primary end point was change in HbA 1c at week 26. RESULTS Change in HbA 1c from baseline to week 26 was significantly greater with iGlarLixi (-1.58% [-17.3 mmol/mol]) than with Lixi (-0.51% [-5.6 mmol/mol]), confirming the superiority of iGlarLixi (least squares [LS] mean difference -1.07% [-11.7 mmol/mol], P < 0.0001). At week 26, significantly greater proportions of patients treated with iGlarLixi reached HbA 1c <7% (53 mmol/mol) (65.2% vs. 19.4%; P < 0.0001), and FPG reductions were greater with iGlarLixi than Lixi (LS mean difference -2.29 mmol/L [-41.23 mg/dL], P < 0.0001). Incidence of documented symptomatic hypoglycemia (≤3.9 mmol/L [70 mg/dL]) was higher with iGlarLixi (13.0% vs. 2.5%) through week 26, with no severe hypoglycemic events in either group. Incidence of gastrointestinal events through week 52 was lower with iGlarLixi (36.0% vs. 50.0%), and rates of treatment-emergent adverse events were similar. CONCLUSIONS This phase 3 study demonstrated superior glycemic control and fewer gastrointestinal adverse events with iGlarLixi than with Lixi, which may support it as a new treatment option for Japanese patients with T2DM that is inadequately controlled with OADs.",2020,"This phase 3 study demonstrated superior glycemic control and fewer gastrointestinal adverse events with iGlarLixi than with Lixi, which may support it as a new treatment option for Japanese patients with T2DM that is inadequately controlled with OADs.","['Japanese patients with T2DM', 'insulin-naïve Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drugs (OADs', 'Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs', '321 patients with HbA 1c ≥7.5 to ≤10.0% (58-86 mmol/mol) and fasting plasma glucose (FPG) ≤13.8 mmol/L (250 mg/dL']","['1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide', 'iGlarLixi or Lixi', 'insulin glargine and lixisenatide (iGlarLixi) versus lixisenatide (Lixi', 'iGlarLixi']","['Efficacy and Safety', 'FPG reductions', 'change in HbA 1c', 'rates of treatment-emergent adverse events', 'Incidence of documented symptomatic hypoglycemia', 'efficacy and safety', 'severe hypoglycemic events', 'Incidence of gastrointestinal events']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0935929', 'cui_str': 'Antidiabetic agent'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mol'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C1532563', 'cui_str': 'mmol/L'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}]","[{'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C4293375', 'cui_str': 'insulin glargine and lixisenatide'}, {'cui': 'C2973895', 'cui_str': 'Lixisenatide'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic agent'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",321.0,0.0516409,"This phase 3 study demonstrated superior glycemic control and fewer gastrointestinal adverse events with iGlarLixi than with Lixi, which may support it as a new treatment option for Japanese patients with T2DM that is inadequately controlled with OADs.","[{'ForeName': 'Hirotaka', 'Initials': 'H', 'LastName': 'Watada', 'Affiliation': 'Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan hwatada@juntendo.ac.jp.'}, {'ForeName': 'Akane', 'Initials': 'A', 'LastName': 'Takami', 'Affiliation': 'Research & Development, Sanofi K.K., Tokyo, Japan.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Spranger', 'Affiliation': 'Diabetes, Cardiovascular and Metabolics Development, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Amano', 'Affiliation': 'Research & Development, Sanofi K.K., Tokyo, Japan.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Hashimoto', 'Affiliation': 'Research & Development, Sanofi K.K., Tokyo, Japan.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Niemoeller', 'Affiliation': 'Diabetes, Cardiovascular and Metabolics Development, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.'}]",Diabetes care,['10.2337/dc19-2452'] 284,32275468,Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.,"PURPOSE Single-agent PD-1 blockade exhibits limited efficacy in epithelial ovarian cancer (EOC). We evaluated ipilimumab plus nivolumab compared with nivolumab alone in women with persistent or recurrent EOC. METHODS Eligibility criteria included measurable disease, 1-3 prior regimens, and platinum-free interval (PFI) < 12 months. Participants were randomly allocated to intravenous nivolumab (every 2 weeks) or induction with nivolumab plus ipilimumab for 4 doses (every 3 weeks), followed by every-2-week maintenance nivolumab for a maximum of 42 doses. The primary null hypothesis was equal probability of objective response within 6 months of random allocation in each arm. RESULTS One hundred patients were allocated to receive either nivolumab (n = 49), or nivolumab plus ipilimumab (n = 51), with PFI of < 6 months in 62%. Six (12.2%) responses occurred within 6 months in the nivolumab group and 16 (31.4%) in the nivolumab plus ipilimumab group (odds ratio, 3.28; 85% CI, 1.54 to infinity; P = .034). The median progression-free survival (PFS) was 2 and 3.9 months in the nivolumab and nivolumab plus ipilimumab groups, respectively, with a PFI-stratified hazard ratio of 0.53 (95% CI, 0.34 to 0.82); the respective hazard ratio for death was 0.79 (95% CI, 0.44 to 1.42). Grade ≥ 3 related adverse events occurred in 33% of patients in the nivolumab group and 49% in the combination group, with no treatment-related deaths. PD-L1 expression was not significantly associated with response in either treatment group. CONCLUSION Compared with nivolumab alone, the combination of nivolumab and ipilimumab in EOC resulted in superior response rate and longer, albeit limited, PFS, with toxicity of the combination regimen comparable to prior reports. Additional combination studies to enhance durability of the dual regimen are warranted.",2020,"3 related adverse events occurred in 33% of patients in the nivolumab group and 49% in the combination group, with no treatment-related deaths.","['Recurrent or Persistent Ovarian Cancer', 'One hundred patients', 'epithelial ovarian cancer (EOC', 'Eligibility criteria included measurable disease, 1-3 prior regimens, and platinum-free interval (PFI) < 12 months', 'women with persistent or recurrent EOC']","['nivolumab', 'nivolumab plus ipilimumab', 'intravenous nivolumab (every 2 weeks) or induction with nivolumab plus ipilimumab', 'nivolumab alone', 'Nivolumab Versus Nivolumab and Ipilimumab']","['adverse events', 'Grade ≥', 'PD-L1 expression', 'median progression-free survival (PFS', 'respective hazard ratio for death']","[{'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0919267', 'cui_str': 'Neoplasm of ovary'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4721610', 'cui_str': 'Epithelial Ovarian Carcinoma'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1367202', 'cui_str': 'ipilimumab'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0585332', 'cui_str': 'Biweekly'}, {'cui': 'C0205263', 'cui_str': 'Induced'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",100.0,0.189914,"3 related adverse events occurred in 33% of patients in the nivolumab group and 49% in the combination group, with no treatment-related deaths.","[{'ForeName': 'Dmitriy', 'Initials': 'D', 'LastName': 'Zamarin', 'Affiliation': 'Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Burger', 'Affiliation': 'Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Sill', 'Affiliation': 'Biostatistics and Bioinformatics, Clinical Trial Development Division, NRG Oncology, Roswell Park, Buffalo, NY.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Powell', 'Affiliation': 'Department of Pathology, University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Heather A', 'Initials': 'HA', 'LastName': 'Lankes', 'Affiliation': ""NRG Oncology Biospecimen Bank-Columbus, Biopathology Center, The Research Institute at Nationwide Children's Hospital, Columbus, OH.""}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Feldman', 'Affiliation': 'Department of Pathology, University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Zivanovic', 'Affiliation': 'Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Gunderson', 'Affiliation': 'Stephenson Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma; Oklahoma City, OK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Ko', 'Affiliation': 'Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Cara', 'Initials': 'C', 'LastName': 'Mathews', 'Affiliation': 'Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Providence, RI.'}, {'ForeName': 'Sudarshan', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'AMITA Health Physicians, Hinsdale, IL.'}, {'ForeName': 'Andrea R', 'Initials': 'AR', 'LastName': 'Hagemann', 'Affiliation': 'Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, Saint Louis, MO.'}, {'ForeName': 'Samir', 'Initials': 'S', 'LastName': 'Khleif', 'Affiliation': 'The Loop Immuno-oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington DC.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Aghajanian', 'Affiliation': 'Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.02059'] 285,32229173,Perioperative non-invasive haemodynamic optimisation using photoplethysmography: A randomised controlled trial and meta-analysis.,"BACKGROUND The present study aimed at evaluating the effect of a haemodynamic algorithm using SV maximisation by non-invasive photoplethysmography (interventional group) on the incidence of postoperative complications compared with a control group using intermittent mean arterial pressure. METHODS The non-blinded parallel-group trial randomised low-risk patients undergoing colorectal surgery into either interventional group or control group. The primary outcome was the incidence of patients with at least one complication during the 30 days following surgery. The secondary outcomes were the total number of complications, the length of hospital stay and postoperative mortality. A meta-analysis of randomised trials comparing perioperative haemodynamic optimisation (interventional group) using photoplethysmography with control group was performed to assess the external validity. RESULTS Among 160 randomised patients, 159 were analysed (80 and 79 in interventional and control groups, respectively). Demographic characteristics were similar in both groups. Postoperative complications occurred in 40 (50%) and 34 (43%) patients in the interventional and control groups, respectively (P=0.471). There were no significant differences between the two groups regarding the total number of complications (P=0.078), the hospital length of stay (P=0.960), or postoperative mortality (P=1.000). In the meta-analysis including 1089 patients in 7 randomised controlled studies, 203 (38%) and 221 (40%) patients suffered from at least one complication following surgery [risk ratio 0.89 (95% CI 0.68-1.17), P=0.407] in interventional and control groups, respectively. CONCLUSIONS Based on the findings of the present study and meta-analysis, a haemodynamic perioperative algorithm using SV maximisation by non-invasive photoplethysmography cannot reduce postoperative morbidity.",2020,"There were no significant differences between the two groups regarding the total number of complications (P = 0.078), the hospital length of stay (P = 0.960), or postoperative mortality (P = 1,000).","['160 patients randomised, 159 were analysed (80 and 79 in interventional and control groups, respectively', 'risk patients undergoing colorectal surgery into either interventional group or control group']","['Perioperative non-invasive haemodynamic optimisation using photoplethysmography', 'haemodynamic algorithm using SV maximisation by non-invasive photoplethysmography (interventional group']","['Postoperative complications', 'incidence of patients with at least one complication', 'Demographic characteristics', 'postoperative morbidity', 'postoperative complications', 'total number of complications', 'total number of complications, the length of hospital stay and postoperative mortality', 'hospital length of stay', 'postoperative mortality']","[{'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0009369', 'cui_str': 'Colon and Rectal Surgery Specialty'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0205303', 'cui_str': 'Non-invasive (qualifier value)'}, {'cui': 'C0162599', 'cui_str': 'Light Reflection Rheography'}, {'cui': 'C0002045'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0032787', 'cui_str': 'Postoperative Complications'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}]",,0.201676,"There were no significant differences between the two groups regarding the total number of complications (P = 0.078), the hospital length of stay (P = 0.960), or postoperative mortality (P = 1,000).","[{'ForeName': 'Marc-Olivier', 'Initials': 'MO', 'LastName': 'Fischer', 'Affiliation': ""UNICAEN, service d'anesthésie réanimation, Normandie université, CHU de Caen Normandie, 14000 Caen, France. Electronic address: marcolivierfischer@yahoo.fr.""}, {'ForeName': 'Anne-Lise', 'Initials': 'AL', 'LastName': 'Fiant', 'Affiliation': ""UNICAEN, service d'anesthésie réanimation, Normandie université, CHU de Caen Normandie, 14000 Caen, France.""}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Debroczi', 'Affiliation': ""UNICAEN, service d'anesthésie réanimation, Normandie université, CHU de Caen Normandie, 14000 Caen, France.""}, {'ForeName': 'Mariam', 'Initials': 'M', 'LastName': 'Boutros', 'Affiliation': ""UNICAEN, service d'anesthésie réanimation, Normandie université, CHU de Caen Normandie, 14000 Caen, France.""}, {'ForeName': 'Léa', 'Initials': 'L', 'LastName': 'Pasqualini', 'Affiliation': ""UNICAEN, service d'anesthésie réanimation, Normandie université, CHU de Caen Normandie, 14000 Caen, France.""}, {'ForeName': 'Marguerite', 'Initials': 'M', 'LastName': 'Demonchy', 'Affiliation': ""UNICAEN, service d'anesthésie réanimation, Normandie université, CHU de Caen Normandie, 14000 Caen, France.""}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Flais', 'Affiliation': ""UNICAEN, service d'anesthésie réanimation, Normandie université, CHU de Caen Normandie, 14000 Caen, France.""}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Alves', 'Affiliation': 'UNICAEN, service de chirurgie digestive, Normandie université, CHU de Caen Normandie, 14000 Caen, France.'}, {'ForeName': 'Jean-Louis', 'Initials': 'JL', 'LastName': 'Gérard', 'Affiliation': ""UNICAEN, service d'anesthésie réanimation, Normandie université, CHU de Caen Normandie, 14000 Caen, France.""}, {'ForeName': 'Clément', 'Initials': 'C', 'LastName': 'Buléon', 'Affiliation': ""UNICAEN, service d'anesthésie réanimation, Normandie université, CHU de Caen Normandie, 14000 Caen, France.""}, {'ForeName': 'Jean-Luc', 'Initials': 'JL', 'LastName': 'Hanouz', 'Affiliation': ""UNICAEN, service d'anesthésie réanimation, Normandie université, CHU de Caen Normandie, 14000 Caen, France.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Anaesthesia, critical care & pain medicine",['10.1016/j.accpm.2020.03.016'] 286,32285282,"Opioid Consumption Following Breast Surgery Decreases with a Brief Educational Intervention: A Randomized, Controlled Trial.","BACKGROUND Current rates of opioid prescribing and consumption in the United States have resulted in deleterious consequences for both patients and society. There has been a focus on opioid consumption and overprescribing, but the utility of patient education in reducing opioid consumption has only recently been explored. This randomized trial aimed to evaluate the effectiveness of a brief patient educational intervention in reducing pain and opioid consumption in patients undergoing mastectomy and breast reconstruction. METHODS A parallel, randomized, single-center trial of women undergoing mastectomy with immediate, implant-based breast reconstruction was completed to evaluate the utility of a patient educational instrument with information on multi-modal pain control. A questionnaire was administered postoperatively to collect data on pain control and opioid consumption. RESULTS Fifty participants were randomized to each group preoperatively; 46 control (92%) and 39 intervention (78%) participants completed the postoperative questionnaire. Active tobacco use was more common in the control group (p = 0.04). There was a trend towards lower pain scores in the intervention group (3.0/10, SD 1.8 vs 3.6/10, SD 1.6, p = 0.06). Both groups were prescribed a median of 32.0 5-mg oxycodone tablets postoperatively. Participants in the intervention group consumed 33% fewer opioids than the control group (16.2 tablets, SD 16.4 vs 24.3 tablets, SD 21.8, p = 0.05). CONCLUSIONS The use of a brief educational intervention provided at a preoperative appointment can reduce opioid consumption. We recommend the use of an educational intervention to decrease opioid consumption among breast surgery patients.",2020,"There was a trend towards lower pain scores in the intervention group (3.0/10, SD 1.8 vs 3.6/10, SD 1.6, p = 0.06).","['breast surgery patients', 'patients undergoing mastectomy and breast reconstruction', 'women undergoing', 'Fifty participants']","['patient educational instrument with information on multi-modal pain control', 'mastectomy with immediate, implant-based breast reconstruction', 'Opioid Consumption', 'educational intervention', 'patient educational intervention', 'Brief Educational Intervention']","['pain and opioid consumption', 'opioid consumption', 'postoperative questionnaire', 'lower pain scores']","[{'cui': 'C0851312', 'cui_str': 'Breast surgery'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024881', 'cui_str': 'Mastectomy'}, {'cui': 'C0085076', 'cui_str': 'Mammoplasty'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0024881', 'cui_str': 'Mastectomy'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0085076', 'cui_str': 'Mammoplasty'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",50.0,0.272624,"There was a trend towards lower pain scores in the intervention group (3.0/10, SD 1.8 vs 3.6/10, SD 1.6, p = 0.06).","[{'ForeName': 'Katie G', 'Initials': 'KG', 'LastName': 'Egan', 'Affiliation': 'Department of Plastic Surgery, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'De Souza', 'Affiliation': 'Department of Plastic Surgery, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Muenks', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Niaman', 'Initials': 'N', 'LastName': 'Nazir', 'Affiliation': 'Department of Population Health, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Korentager', 'Affiliation': 'Department of Plastic Surgery, University of Kansas Medical Center, Kansas City, KS, USA. rkorentager@kumc.edu.'}]",Annals of surgical oncology,['10.1245/s10434-020-08432-7'] 287,31400333,Impact of Aortic Atherosclerosis Burden on Outcomes of Surgical Aortic Valve Replacement.,"BACKGROUND Epiaortic ultrasound detects and localizes ascending aortic atherosclerosis. In this analysis we investigated the association between epiaortic ultrasound-based atheroma grade during surgical aortic valve replacement (SAVR) and perioperative adverse outcomes. METHODS SAVR patients in a randomized trial of 2 embolic protection devices underwent a protocol-defined 5-view epiaortic ultrasound read at a core laboratory. Aortic atherosclerosis was quantified with the Katz atheroma grade, and patients were categorized as mild (grade I-II) or moderate/severe (grade III-V). Multivariable logistic regression was used to estimate associations between atheroma grade and adverse outcomes, including death, clinically apparent stroke, cerebral infarction on diffusion-weighted magnetic resonance imaging, delirium, and acute kidney injury (AKI) by 7 and 30 days. RESULTS Precannulation epiaortic ultrasound data were available for 326 of 383 randomized patients (85.1%). Of these, 106 (32.5%) had moderate/severe Katz atheroma grade at any segment of the ascending aorta. Although differences in the composite of death, stroke, or cerebral infarction on diffusion-weighted magnetic resonance imaging by 7 days were not statistically significant, moderate/severe atheroma grade was associated with a greater risk of AKI by 7 days (adjusted odds ratio, 2.63; 95% confidence interval, 1.24-5.58; P = .01). At 30 days, patients with moderate/severe atheroma grade had a greater risk of death, stroke, or AKI (adjusted odds ratio, 1.97; 95% confidence interval, 1.04-3.71; P = .04). CONCLUSIONS Moderate/severe aortic atherosclerosis was associated with an increased risk of adverse events after SAVR. Epiaortic ultrasound may serve as a useful adjunct for identifying patients who may benefit from strategies to reduce atheroembolic complications during SAVR.",2020,"While there were no significant differences in the composite of death, stroke or cerebral infarction on DW-MRI by 7 days, moderate/severe atheroma grade was associated with a greater risk of AKI by 7 days (adjusted odds ratio [OR]: 2.63; 95% confidence interval [CI]: 1.24-5.58; p=0.01).","['SAVR patients', 'Of the 383 randomized patients, 326 (85.1%) had pre-cannulation epiaortic ultrasound data available']","['embolic protection devices underwent a protocol-defined 5-view epiaortic ultrasound read at a core-laboratory', 'Surgical Aortic Valve Replacement']","['risk of adverse events', 'severe aortic atherosclerosis', 'atheroma grade and adverse outcomes including death, clinically apparent stroke, cerebral infarction on diffusion-weighted magnetic resonance imaging (DW-MRI), delirium, and acute kidney injury (AKI', 'risk of death, stroke or AKI', 'composite of death, stroke or cerebral infarction on DW-MRI by 7 days, moderate/severe atheroma grade', 'Aortic atherosclerosis', 'moderate/severe Katz atheroma grade']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0917707', 'cui_str': 'Cannulation'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}]","[{'cui': 'C2936200', 'cui_str': 'Emboli Protection Devices'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0449911', 'cui_str': 'View (attribute)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve (procedure)'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0155733', 'cui_str': 'Atherosclerosis of aorta (disorder)'}, {'cui': 'C0264956', 'cui_str': 'Atheromatous Plaques'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0007785', 'cui_str': 'Cerebral Infarction'}, {'cui': 'C0598801', 'cui_str': 'Diffusion weighted magnetic resonance imaging'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C2609414', 'cui_str': 'Acute Renal Injury'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}]",383.0,0.312698,"While there were no significant differences in the composite of death, stroke or cerebral infarction on DW-MRI by 7 days, moderate/severe atheroma grade was associated with a greater risk of AKI by 7 days (adjusted odds ratio [OR]: 2.63; 95% confidence interval [CI]: 1.24-5.58; p=0.01).","[{'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Iribarne', 'Affiliation': 'Section of Cardiac Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Pan', 'Affiliation': 'Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Jock N', 'Initials': 'JN', 'LastName': 'McCullough', 'Affiliation': 'Section of Cardiac Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'Mathew', 'Affiliation': 'Division of Cardiothoracic Anesthesiology, Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Judy', 'Initials': 'J', 'LastName': 'Hung', 'Affiliation': 'Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Zeng', 'Affiliation': 'Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Voisine', 'Affiliation': 'Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec, Québec, Canada.'}, {'ForeName': 'Patrick T', 'Initials': 'PT', 'LastName': ""O'Gara"", 'Affiliation': ""Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Nancy M', 'Initials': 'NM', 'LastName': 'Sledz', 'Affiliation': 'Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Annetine C', 'Initials': 'AC', 'LastName': 'Gelijns', 'Affiliation': 'Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: annetine.gelijns@mssm.edu.'}, {'ForeName': 'Wendy C', 'Initials': 'WC', 'LastName': 'Taddei-Peters', 'Affiliation': 'Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland.'}, {'ForeName': 'Steven R', 'Initials': 'SR', 'LastName': 'Messé', 'Affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Alan J', 'Initials': 'AJ', 'LastName': 'Moskowitz', 'Affiliation': 'Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Vinod H', 'Initials': 'VH', 'LastName': 'Thourani', 'Affiliation': 'Department of Cardiac Surgery, MedStar Heart and Vascular Institute, Washington, DC.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Argenziano', 'Affiliation': 'Division of Cardiothoracic Surgery, Department of Surgery, New York-Presbyterian Hospital/Columbia University Medical Center, New York, New York.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Groh', 'Affiliation': 'Cardiovascular and Thoracic Surgery, Mission Health and Hospitals, Asheville, North Carolina.'}, {'ForeName': 'Gennaro', 'Initials': 'G', 'LastName': 'Giustino', 'Affiliation': 'Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Jessica R', 'Initials': 'JR', 'LastName': 'Overbey', 'Affiliation': 'Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'J Michael', 'Initials': 'JM', 'LastName': 'DiMaio', 'Affiliation': 'Department of Cardiothoracic Surgery, The Heart Hospital Baylor Plano, Baylor Scott & White Health, Plano, Texas.'}, {'ForeName': 'Peter K', 'Initials': 'PK', 'LastName': 'Smith', 'Affiliation': 'Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina.'}]",The Annals of thoracic surgery,['10.1016/j.athoracsur.2019.06.037'] 288,32285126,Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.,"This phase 2 study was designed to compare systemic decitabine exposure, demethylation activity, and safety in the first 2 cycles with cedazuridine 100 mg/decitabine 35 mg vs standard decitabine 20 mg/m2 IV. Adults with International Prognostic Scoring System intermediate-1/2- or high-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) were randomized 1:1 to receive oral cedazuridine/decitabine or IV decitabine in cycle 1, followed by crossover to the other treatment in cycle 2. All patients received oral cedazuridine/decitabine in subsequent cycles. Cedazuridine and decitabine were given initially as separate capsules in a dose-confirmation stage and then as a single fixed-dose combination (FDC) tablet. Primary end points: mean decitabine systemic exposure (geometric least-squares mean [LSM]) of oral/IV 5-day area under curve from time 0 to last measurable concentration (AUClast), percentage long interspersed nuclear element 1 (LINE-1) DNA demethylation for oral cedazuridine/decitabine vs IV decitabine, and clinical response. Eighty patients were randomized and treated. Oral/IV ratios of geometric LSM 5-day AUClast (80% confidence interval) were 93.5% (82.1-106.5) and 97.6% (80.5-118.3) for the dose-confirmation and FDC stages, respectively. Differences in mean %LINE-1 demethylation between oral and IV were ≤1%. Clinical responses were observed in 48 patients (60%), including 17 (21%) with complete response. The most common grade ≥3 adverse events regardless of causality were neutropenia (46%), thrombocytopenia (38%), and febrile neutropenia (29%). Oral cedazuridine/decitabine (100/35 mg) produced similar systemic decitabine exposure, DNA demethylation, and safety vs decitabine 20 mg/m2 IV in the first 2 cycles, with similar efficacy. This study is registered at www.clinicaltrials.gov as #NCT02103478.",2020,"Oral/IV ratios of geometric LSM 5-day AUClast (80% confidence interval) were 93.5% (82.1%, 106.5%) and 97.6% (80.5%, 118.3%) for the dose-confirmation and FDC stages, respectively.","['Eighty patients', 'Adults with International Prognostic Scoring System intermediate-1/2- or high-risk myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML']","['oral cedazuridine/decitabine', 'Cedazuridine and decitabine', 'cedazuridine 100 mg/decitabine 35 mg vs standard decitabine 20 mg', 'oral cedazuridine/decitabine or IV decitabine', 'Oral cedazuridine/decitabine', 'decitabine']","['febrile neutropenia', 'mean decitabine systemic exposure (geometric least-squares mean [LSM]) of oral/IV 5-day area under curve from time 0 to last measurable concentration (AUClast), % long interspersed nuclear element 1 (LINE-1) DNA demethylation for oral cedazuridine/decitabine vs IV decitabine, and clinical response', 'systemic decitabine exposure, DNA demethylation, and safety', 'systemic decitabine exposure, demethylation activity, and safety', 'geometric LSM 5-day AUClast', 'neutropenia', 'Clinical responses', 'thrombocytopenia']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0580272', 'cui_str': '1/2'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C2347761', 'cui_str': 'Childhood myelodysplastic syndrome'}, {'cui': 'C0023480', 'cui_str': 'Chronic myelomonocytic leukemia'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0049065', 'cui_str': 'decitabine'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0746883', 'cui_str': 'Febrile neutropenia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0049065', 'cui_str': 'decitabine'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0023189', 'cui_str': 'Analysis, Least-Squares'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0013879', 'cui_str': 'Chemical element'}, {'cui': 'C0600472', 'cui_str': 'L1 Elements'}, {'cui': 'C2755352', 'cui_str': 'DNA Demethylation'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0598864', 'cui_str': 'Demethylation'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0040034', 'cui_str': 'Thrombocytopenic disorder'}]",80.0,0.0957721,"Oral/IV ratios of geometric LSM 5-day AUClast (80% confidence interval) were 93.5% (82.1%, 106.5%) and 97.6% (80.5%, 118.3%) for the dose-confirmation and FDC stages, respectively.","[{'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Garcia-Manero', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Griffiths', 'Affiliation': 'Roswell Park Comprehensive Cancer Center, Buffalo, NY.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Steensma', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Gail J', 'Initials': 'GJ', 'LastName': 'Roboz', 'Affiliation': 'Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Wells', 'Affiliation': 'Sunnybrook Health Sciences Centre, Toronto, ON, Canada.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'McCloskey', 'Affiliation': 'Hackensack University Medical Center, Hackensack, NJ.'}, {'ForeName': 'Olatoyosi', 'Initials': 'O', 'LastName': 'Odenike', 'Affiliation': 'The University of Chicago Pritzker School of Medicine, Chicago, IL.'}, {'ForeName': 'Amy E', 'Initials': 'AE', 'LastName': 'DeZern', 'Affiliation': 'The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Yee', 'Affiliation': 'Princess Margaret Cancer Centre, Toronto, ON, Canada.'}, {'ForeName': 'Lambert', 'Initials': 'L', 'LastName': 'Busque', 'Affiliation': 'Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada.'}, {'ForeName': 'Casey', 'Initials': 'C', 'LastName': ""O'Connell"", 'Affiliation': 'USC Norris Comprehensive Cancer Center, Los Angeles, CA.'}, {'ForeName': 'Laura C', 'Initials': 'LC', 'LastName': 'Michaelis', 'Affiliation': 'Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Brandwein', 'Affiliation': 'University of Alberta Hospital, Edmonton, AB, Canada.'}, {'ForeName': 'Hagop', 'Initials': 'H', 'LastName': 'Kantarjian', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Aram', 'Initials': 'A', 'LastName': 'Oganesian', 'Affiliation': 'Astex Pharmaceuticals, Inc., Pleasanton, CA; and.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Azab', 'Affiliation': 'Astex Pharmaceuticals, Inc., Pleasanton, CA; and.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Savona', 'Affiliation': 'Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN.'}]",Blood,['10.1182/blood.2019004143'] 289,30496493,"Differential effects of endurance, interval, and resistance training on telomerase activity and telomere length in a randomized, controlled study.","Aims It is unknown whether different training modalities exert differential cellular effects. Telomeres and telomere-associated proteins play a major role in cellular aging with implications for global health. This prospective training study examines the effects of endurance training, interval training (IT), and resistance training (RT) on telomerase activity and telomere length (TL). Methods and results One hundred and twenty-four healthy previously inactive individuals completed the 6 months study. Participants were randomized to three different interventions or the control condition (no change in lifestyle): aerobic endurance training (AET, continuous running), high-intensive IT (4 × 4 method), or RT (circle training on 8 devices), each intervention consisting of three 45 min training sessions per week. Maximum oxygen uptake (VO2max) was increased by all three training modalities. Telomerase activity in blood mononuclear cells was up-regulated by two- to three-fold in both endurance exercise groups (AET, IT), but not with RT. In parallel, lymphocyte, granulocyte, and leucocyte TL increased in the endurance-trained groups but not in the RT group. Magnet-activated cell sorting with telomerase repeat-ampliflication protocol (MACS-TRAP) assays revealed that a single bout of endurance training-but not RT-acutely increased telomerase activity in CD14+ and in CD34+ leucocytes. Conclusion This randomized controlled trial shows that endurance training, IT, and RT protocols induce specific cellular pathways in circulating leucocytes. Endurance training and IT, but not RT, increased telomerase activity and TL which are important for cellular senescence, regenerative capacity, and thus, healthy aging.",2019,"Endurance training and IT, but not RT, increased telomerase activity and TL which are important for cellular senescence, regenerative capacity, and thus, healthy aging.",['One hundred and twenty-four healthy previously inactive individuals completed the 6\u2009months study'],"['endurance training, IT, and RT protocols', 'endurance, interval, and resistance training', 'control condition (no change in lifestyle): aerobic endurance training (AET, continuous running), high-intensive IT (4\u2009×\u20094 method), or RT (circle training', 'endurance training, interval training (IT), and resistance training (RT']","['lymphocyte, granulocyte, and leucocyte TL', 'Telomerase activity in blood mononuclear cells', 'telomerase activity and TL', 'telomerase activity and telomere length (TL', 'telomerase activity and telomere length', 'Maximum oxygen uptake (VO2max']","[{'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C4704697', 'cui_str': 'Endurance Training'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0518031', 'cui_str': 'Endurance capacity'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0442739', 'cui_str': 'Id status quo'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0629582', 'cui_str': 'AETS'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0035953', 'cui_str': 'Running'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C4018897', 'cui_str': 'Lymphocyte component of blood'}, {'cui': 'C0018183', 'cui_str': 'Granulocytic cell'}, {'cui': 'C0023516', 'cui_str': 'Blood Corpuscles, White'}, {'cui': 'C0087071', 'cui_str': 'Telomerase Reverse Transcriptase'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0005768'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0085187'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0429693', 'cui_str': 'Maximum oxygen uptake (observable entity)'}]",124.0,0.0185942,"Endurance training and IT, but not RT, increased telomerase activity and TL which are important for cellular senescence, regenerative capacity, and thus, healthy aging.","[{'ForeName': 'Christian M', 'Initials': 'CM', 'LastName': 'Werner', 'Affiliation': 'Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universität und Universitätsklinikum des Saarlandes, Geb. 41.1/IMED, Homburg/Saar, Germany.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Hecksteden', 'Affiliation': 'Institut für Sport und Präventivmedizin, Universität des Saarlandes, Campus, B8 2, Saarbrücken, Germany.'}, {'ForeName': 'Arne', 'Initials': 'A', 'LastName': 'Morsch', 'Affiliation': 'Deutsche Hochschule für Prävention und Gesundheitsmanagement, Hermann-Neuberger-Sportschule 3, Saarbrücken, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Zundler', 'Affiliation': 'Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universität und Universitätsklinikum des Saarlandes, Geb. 41.1/IMED, Homburg/Saar, Germany.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Wegmann', 'Affiliation': 'Institut für Sport und Präventivmedizin, Universität des Saarlandes, Campus, B8 2, Saarbrücken, Germany.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Kratzsch', 'Affiliation': 'Institut für Labormedizin, Klinische Chemie und Molekulare Diagnostik, Universitätsklinikum, Liebigstr. 20, Leipzig, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Thiery', 'Affiliation': 'Institut für Labormedizin, Klinische Chemie und Molekulare Diagnostik, Universitätsklinikum, Liebigstr. 20, Leipzig, Germany.'}, {'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Hohl', 'Affiliation': 'Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universität und Universitätsklinikum des Saarlandes, Geb. 41.1/IMED, Homburg/Saar, Germany.'}, {'ForeName': 'Jörg Thomas', 'Initials': 'JT', 'LastName': 'Bittenbring', 'Affiliation': 'Klinik für Innere Medizin I, Onkologie, Hämatologie, Klinische Immunologie und Rheumatologie, Universitätsklinikum des Saarlandes, Geb. 41.1/IMED, Homburg/Saar, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Neumann', 'Affiliation': 'Klinik für Innere Medizin I, Onkologie, Hämatologie, Klinische Immunologie und Rheumatologie, Universitätsklinikum des Saarlandes, Geb. 41.1/IMED, Homburg/Saar, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Böhm', 'Affiliation': 'Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universität und Universitätsklinikum des Saarlandes, Geb. 41.1/IMED, Homburg/Saar, Germany.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Meyer', 'Affiliation': 'Institut für Sport und Präventivmedizin, Universität des Saarlandes, Campus, B8 2, Saarbrücken, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Laufs', 'Affiliation': 'Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstr. 20, Leipzig, Germany.'}]",European heart journal,['10.1093/eurheartj/ehy585'] 290,32285582,A cluster randomized controlled trial of a simplified 5-step handwashing technique versus a conventional 7-step handwashing technique among Chinese students with intellectual disabilities.,"OBJECTIVE To compare the effects of the simplified 5-step and the conventional 7-Step hand hygiene programme in a cluster randomized controlled trial among students with intellectual disabilities. METHOD A total of 472 Chinese students with intellectual disabilities were randomized to either simplified 5-step or conventional 7-step hand hygiene programme. Assessments included handwashing technique, cleanliness and sick leave days. RESULTS Handwashing technique scores (g = 0.25, 95% CI [0.18, 0.32]) and hand cleanliness scores (g = 0.33, 95% CI [0.26, 0.4]) in intervention group were significantly higher than those scores in control group at 6th month post-intervention although there were significant increases in the scores within both groups. The mean number of sick leave days decreased between baseline and 10 month in both groups according to descriptive statistics. CONCLUSIONS It is feasible and effective to adopt the simplified 5-step intervention as a standardized handwashing technique for the population group with intellectual disabilities.",2020,"RESULTS Handwashing technique scores (g = 0.25, 95% CI [0.18, 0.32]) and hand cleanliness scores (g = 0.33, 95% CI [0.26, 0.4]) in intervention group were significantly higher than those scores in control group at 6th month post-intervention although there were significant increases in the scores within both groups.","['Chinese students with intellectual disabilities', 'population group with intellectual disabilities', '472 Chinese students with intellectual disabilities', 'students with intellectual disabilities']","['simplified 5-step handwashing technique versus a conventional 7-step handwashing technique', 'simplified 5-step and the conventional 7-Step hand hygiene programme', 'simplified 5-step or conventional 7-step hand hygiene programme']","['handwashing technique, cleanliness and sick leave days', 'hand cleanliness scores', 'mean number of sick leave days']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C3714756', 'cui_str': 'Intellectual disability'}, {'cui': 'C1257890', 'cui_str': 'Group'}]","[{'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C3494474', 'cui_str': 'Hand Hygiene'}]","[{'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0522513', 'cui_str': 'With cleanliness'}, {'cui': 'C0242807', 'cui_str': 'Sick Leave'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",472.0,0.0813514,"RESULTS Handwashing technique scores (g = 0.25, 95% CI [0.18, 0.32]) and hand cleanliness scores (g = 0.33, 95% CI [0.26, 0.4]) in intervention group were significantly higher than those scores in control group at 6th month post-intervention although there were significant increases in the scores within both groups.","[{'ForeName': 'Regina L T', 'Initials': 'RLT', 'LastName': 'Lee', 'Affiliation': 'Faculty of Health and Medicine, School of Nursing and Midwifery, The University of Newcastle, Callaghan, NSW, Australia.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Leung', 'Affiliation': 'Department of Applied Social Sciences, The Hong Kong Polytechnic University, Kowloon, Hong Kong.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Infection Control Branch, Centre for Health Protection, Hong Kong, Hong Kong.'}, {'ForeName': 'Paul H', 'Initials': 'PH', 'LastName': 'Lee', 'Affiliation': 'School of Nursing, The Hong Kong Polytechnic University, Kowloon, Hong Kong.'}, {'ForeName': 'Stephen W H', 'Initials': 'SWH', 'LastName': 'Kwok', 'Affiliation': 'School of Nursing, The Hong Kong Polytechnic University, Kowloon, Hong Kong.'}]",Journal of applied research in intellectual disabilities : JARID,['10.1111/jar.12731'] 291,32285242,"Tracking Time and Resources Associated with Systems Change and the Adoption of Evidence-Based Programs: The ""Hidden Costs"" of School-Based Coaching.","This study leveraged data from a 40-school randomized controlled trial to understand the cost of coaching to support implementation of evidence-based programs (EBPs) through a multi-tiered system of supports for behavior (MTSS-B) model. Coach activity log data were utilized to generate the annual average, per school, costs of coaching of $8198. The cost of school personnel time for coaching was estimated to be $3028. Data on coach-rated administrator buy-in, school MTSS-B engagement, and implementation infrastructure and capacity were also collected and found to be associated with coaching activities. Notably, coaches did not spend significantly different amounts of time in schools using few EBPs relative to more EBPs, indicating some inefficiency in the use of coaches' time. These findings highlight the often-overlooked resources needed to support EBP implementation in schools.",2020,"Notably, coaches did not spend significantly different amounts of time in schools using few EBPs relative to more EBPs, indicating some inefficiency in the use of coaches' time.",[],['coaching to support implementation of evidence-based programs (EBPs'],['cost of school personnel time for coaching'],[],"[{'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",,0.0297343,"Notably, coaches did not spend significantly different amounts of time in schools using few EBPs relative to more EBPs, indicating some inefficiency in the use of coaches' time.","[{'ForeName': 'Elise T', 'Initials': 'ET', 'LastName': 'Pas', 'Affiliation': 'Bloomberg School of Public Health, Johns Hopkins University, 415 N. Washington Street, Baltimore, MD, 21231, USA. epas@jhu.edu.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Lindstrom Johnson', 'Affiliation': 'T. Denny Sanford School of Social and Family Dynamics, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Y Natalia', 'Initials': 'YN', 'LastName': 'Alfonso', 'Affiliation': 'Bloomberg School of Public Health, Johns Hopkins University, 415 N. Washington Street, Baltimore, MD, 21231, USA.'}, {'ForeName': 'Catherine P', 'Initials': 'CP', 'LastName': 'Bradshaw', 'Affiliation': 'Curry School of Education and Human Development, University of Virginia, Charlottesville, VA, USA.'}]",Administration and policy in mental health,['10.1007/s10488-020-01039-w'] 292,31813636,"Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.","BACKGROUND Whole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence (IBTR), yielding comparable results to mastectomy. It is unknown whether accelerated partial breast irradiation (APBI) to only the tumour-bearing quadrant, which shortens treatment duration, is equally effective. In our trial, we investigated whether APBI provides equivalent local tumour control after lumpectomy compared with whole-breast irradiation. METHODS We did this randomised, phase 3, equivalence trial (NSABP B-39/RTOG 0413) in 154 clinical centres in the USA, Canada, Ireland, and Israel. Adult women (>18 years) with early-stage (0, I, or II; no evidence of distant metastases, but up to three axillary nodes could be positive) breast cancer (tumour size ≤3 cm; including all histologies and multifocal breast cancers), who had had lumpectomy with negative (ie, no detectable cancer cells) surgical margins, were randomly assigned (1:1) using a biased-coin-based minimisation algorithm to receive either whole-breast irradiation (whole-breast irradiation group) or APBI (APBI group). Whole-breast irradiation was delivered in 25 daily fractions of 50 Gy over 5 weeks, with or without a supplemental boost to the tumour bed, and APBI was delivered as 34 Gy of brachytherapy or 38·5 Gy of external bream radiation therapy in 10 fractions, over 5 treatment days within an 8-day period. Randomisation was stratified by disease stage, menopausal status, hormone-receptor status, and intention to receive chemotherapy. Patients, investigators, and statisticians could not be masked to treatment allocation. The primary outcome of invasive and non-invasive IBTR as a first recurrence was analysed in the intention-to-treat population, excluding those patients who were lost to follow-up, with an equivalency test on the basis of a 50% margin increase in the hazard ratio (90% CI for the observed HR between 0·667 and 1·5 for equivalence) and a Cox proportional hazard model. Survival was assessed by intention to treat, and sensitivity analyses were done in the per-protocol population. This trial is registered with ClinicalTrials.gov, NCT00103181. FINDINGS Between March 21, 2005, and April 16, 2013, 4216 women were enrolled. 2109 were assigned to the whole-breast irradiation group and 2107 were assigned to the APBI group. 70 patients from the whole-breast irradiation group and 14 from the APBI group withdrew consent or were lost to follow-up at this stage, so 2039 and 2093 patients respectively were available for survival analysis. Further, three and four patients respectively were lost to clinical follow-up (ie, survival status was assessed by phone but no physical examination was done), leaving 2036 patients in the whole-breast irradiation group and 2089 in the APBI group evaluable for the primary outcome. At a median follow-up of 10·2 years (IQR 7·5-11·5), 90 (4%) of 2089 women eligible for the primary outcome in the APBI group and 71 (3%) of 2036 women in the whole-breast irradiation group had an IBTR (HR 1·22, 90% CI 0·94-1·58). The 10-year cumulative incidence of IBTR was 4·6% (95% CI 3·7-5·7) in the APBI group versus 3·9% (3·1-5·0) in the whole-breast irradiation group. 44 (2%) of 2039 patients in the whole-breast irradiation group and 49 (2%) of 2093 patients in the APBI group died from recurring breast cancer. There were no treatment-related deaths. Second cancers and treatment-related toxicities were similar between the two groups. 2020 patients in the whole-breast irradiation group and 2089 in APBI group had available data on adverse events. The highest toxicity grade reported was: grade 1 in 845 (40%), grade 2 in 921 (44%), and grade 3 in 201 (10%) patients in the APBI group, compared with grade 1 in 626 (31%), grade 2 in 1193 (59%), and grade 3 in 143 (7%) in the whole-breast irradiation group. INTERPRETATION APBI did not meet the criteria for equivalence to whole-breast irradiation in controlling IBTR for breast-conserving therapy. Our trial had broad eligibility criteria, leading to a large, heterogeneous pool of patients and sufficient power to detect treatment equivalence, but was not designed to test equivalence in patient subgroups or outcomes from different APBI techniques. For patients with early-stage breast cancer, our findings support whole-breast irradiation following lumpectomy; however, with an absolute difference of less than 1% in the 10-year cumulative incidence of IBTR, APBI might be an acceptable alternative for some women. FUNDING National Cancer Institute, US Department of Health and Human Services.",2019,"INTERPRETATION APBI did not meet the criteria for equivalence to whole-breast irradiation in controlling IBTR for breast-conserving therapy.","['70 patients from the whole-breast irradiation group and 14 from the APBI group withdrew consent or were lost to follow-up at this stage, so 2039 and 2093 patients respectively were available for survival analysis', 'patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence (IBTR', 'Between March 21, 2005, and April 16, 2013, 4216 women were enrolled', 'early-stage breast cancer', '2020 patients in the whole-breast irradiation group and 2089 in APBI group had available data on', 'patients with early-stage breast cancer', '154 clinical centres in the USA, Canada, Ireland, and Israel', 'Adult women (>18 years) with early-stage (0, I, or II; no evidence of distant metastases, but up to three axillary nodes could be positive) breast cancer (tumour size ≤3 cm; including all histologies and multifocal breast cancers), who had had lumpectomy with negative (ie, no detectable cancer cells) surgical margins']","['brachytherapy or 38·5 Gy of external bream radiation therapy', 'biased-coin-based minimisation algorithm to receive either whole-breast irradiation (whole-breast irradiation group) or APBI (APBI group', 'APBI', 'Whole-breast irradiation after breast-conserving surgery', 'accelerated partial breast irradiation after breast-conserving surgery']","['hazard ratio', 'invasive and non-invasive IBTR as a first recurrence', 'adverse events', 'Survival', 'toxicities', '10-year cumulative incidence of IBTR', 'highest toxicity grade', 'survival status']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0457102', 'cui_str': 'Whole breast (qualifier value)'}, {'cui': 'C1282930', 'cui_str': 'Irradiation (physical force)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn (finding)'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C1302313', 'cui_str': 'Lost to Follow-Up'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0038953', 'cui_str': 'Survival Analysis'}, {'cui': 'C2363430', 'cui_str': 'Early stage (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0441989', 'cui_str': 'Ipsilateral (qualifier value)'}, {'cui': 'C1458155', 'cui_str': 'Breast Tumors'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0022067', 'cui_str': 'Ireland, Republic of'}, {'cui': 'C0022271', 'cui_str': 'Israel'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332125', 'cui_str': 'No evidence of (contextual qualifier) (qualifier value)'}, {'cui': 'C1269798', 'cui_str': 'pM category'}, {'cui': 'C0004454', 'cui_str': 'Axilla'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0475440', 'cui_str': 'Tumor size'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0344441', 'cui_str': 'Histologic test (procedure)'}, {'cui': 'C0205292', 'cui_str': 'Multifocal (qualifier value)'}, {'cui': 'C0024885', 'cui_str': 'Local Excision Mastectomy'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0229985', 'cui_str': 'Margins of Excision'}]","[{'cui': 'C0006098', 'cui_str': 'Radioisotope Brachytherapy'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0452965', 'cui_str': 'Bream (substance)'}, {'cui': 'C0034619', 'cui_str': 'radiation therapy'}, {'cui': 'C0524669', 'cui_str': 'Coins'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0002045'}, {'cui': 'C0457102', 'cui_str': 'Whole breast (qualifier value)'}, {'cui': 'C1282930', 'cui_str': 'Irradiation (physical force)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0917927', 'cui_str': 'Breast-Conserving Surgery'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0006141', 'cui_str': 'Breast'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive (qualifier value)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]",2039.0,0.272324,"INTERPRETATION APBI did not meet the criteria for equivalence to whole-breast irradiation in controlling IBTR for breast-conserving therapy.","[{'ForeName': 'Frank A', 'Initials': 'FA', 'LastName': 'Vicini', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; MHP Radiation Oncology Institute, St Joseph Mercy Hospital Campus, Pontiac, MI, USA. Electronic address: frank.vicini@21co.com.'}, {'ForeName': 'Reena S', 'Initials': 'RS', 'LastName': 'Cecchini', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Julia R', 'Initials': 'JR', 'LastName': 'White', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; Ohio State University Comprehensive Cancer Center-Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, OH, USA.'}, {'ForeName': 'Douglas W', 'Initials': 'DW', 'LastName': 'Arthur', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.'}, {'ForeName': 'Thomas B', 'Initials': 'TB', 'LastName': 'Julian', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.'}, {'ForeName': 'Rachel A', 'Initials': 'RA', 'LastName': 'Rabinovitch', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; University of Colorado Cancer Center, Aurora, CO, USA.'}, {'ForeName': 'Robert R', 'Initials': 'RR', 'LastName': 'Kuske', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; Arizona Breast Cancer Specialists, Arizona Center for Cancer Care, Scottsdale, AZ, USA.'}, {'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Ganz', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; University of California at Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Parda', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.'}, {'ForeName': 'Michael F', 'Initials': 'MF', 'LastName': 'Scheier', 'Affiliation': 'Carnegie Mellon University, Pittsburgh, PA, USA.'}, {'ForeName': 'Kathryn A', 'Initials': 'KA', 'LastName': 'Winter', 'Affiliation': 'NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, USA.'}, {'ForeName': 'Soonmyung', 'Initials': 'S', 'LastName': 'Paik', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Henry M', 'Initials': 'HM', 'LastName': 'Kuerer', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Vallow', 'Affiliation': 'Mayo Clinic Florida, Jacksonville, FL, USA.'}, {'ForeName': 'Lori J', 'Initials': 'LJ', 'LastName': 'Pierce', 'Affiliation': 'Southwest Oncology Group Cancer Research Network, Hope Foundation for Cancer Research, Portland, OR, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Eleftherios P', 'Initials': 'EP', 'LastName': 'Mamounas', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; Orlando Health, UF Health Cancer Center, Orlando, FL, USA.'}, {'ForeName': 'Beryl', 'Initials': 'B', 'LastName': 'McCormick', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'Costantino', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Harry D', 'Initials': 'HD', 'LastName': 'Bear', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Germain', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; Centre Hospitalier Universitaire de Québec-Université Laval, Pavillon Hôtel-Dieu de Québec, Québec City, QC, Canada.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Gustafson', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; Community Clinical Oncology Program, William Beaumont Hospital, Sterling Heights, MI, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Grossheim', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; Summit Cancer Center, Post Falls, ID, USA.'}, {'ForeName': 'Ivy A', 'Initials': 'IA', 'LastName': 'Petersen', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Richard S', 'Initials': 'RS', 'LastName': 'Hudes', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; Saint Agnes Hospital, Baltimore, MD, USA; Thomas Jefferson University, Baltimore, MD, USA.'}, {'ForeName': 'Walter J', 'Initials': 'WJ', 'LastName': 'Curran', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; Winship Cancer Institute of Emory University, Atlanta, GA, USA.'}, {'ForeName': 'John L', 'Initials': 'JL', 'LastName': 'Bryant', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Norman', 'Initials': 'N', 'LastName': 'Wolmark', 'Affiliation': 'NRG Oncology, Pittsburgh, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.'}]","Lancet (London, England)",['10.1016/S0140-6736(19)32514-0'] 293,30608273,No effect of test and treat on sexual behaviours at population level in rural South Africa.,"CONTEXT Within the community-randomized ANRS 12249 Treatment-as-Prevention trial conducted in rural South Africa, we analysed sexual behaviours stratified by sex over time, comparing immediate antiretroviral therapy irrespective of CD4+ cell count vs. CD4+-guided antiretroviral therapy (start at CD4+ cell count > 350 cells/μl then >500 cells/μl) arms. METHODS As part of the 6-monthly home-based trial rounds, a sexual behaviour individual questionnaire was administered to all residents at least 16 years. We considered seven indicators: sexual intercourse in the past month; at least one regular sexual partner in the past 6 months; at least one casual sexual partner in the past 6 months and more than one sexual partner in the past 6 months; condom use at last sex (CLS) with regular partner, CLS with casual partner, and point prevalence estimate of concurrency. We conducted repeated cross-sectional analyses, stratified by sex. Generalized Estimating Equations models were used, including trial arm, trial time, calendar time and interaction between trial arm and trial time. RESULTS CLS with regular partner varied between 29-51% and 23-46% for men and women, respectively, with significantly lower odds among women in the control vs. intervention arm by trial end (P < 0.001). CLS with casual partner among men showed a significant interaction between arm and trial round, with no consistent pattern. Women declared more than one partner in the past 6 months in less than 1% of individual questionnaires; among men, rates varied between 5-12%, and odds significantly and continuously declined between calendar rounds 1 and 7 [odds ratio = 4.2 (3.24-5.45)]. CONCLUSION Universal Test and Treat was not associated with increased sexual risk behaviours.",2019,Universal Test and Treat was not associated with increased sexual risk behaviours.,"['rural South Africa', 'seven indicators: sexual intercourse in the past month; at least one regular sexual partner in the past 6 months; at least one casual sexual partner in the past 6 months and more than one sexual partner in the past 6 months; condom use at last sex (CLS) with regular partner, CLS with casual partner, and point prevalence estimate of concurrency', 'sexual behaviours at population level in rural South Africa']",[],['sexual risk behaviours'],"[{'cui': 'C0037712', 'cui_str': 'Union of South Africa'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0009253', 'cui_str': 'Sexual Intercourse'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0036911', 'cui_str': 'Sexual Partners'}, {'cui': 'C0556473', 'cui_str': 'Casual sexual partner (finding)'}, {'cui': 'C0009653', 'cui_str': 'Condoms'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0036864', 'cui_str': 'Sexual Behavior'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",[],"[{'cui': 'C0035647', 'cui_str': 'Risk'}]",,0.0400376,Universal Test and Treat was not associated with increased sexual risk behaviours.,"[{'ForeName': 'Matthieu', 'Initials': 'M', 'LastName': 'Rolland', 'Affiliation': 'University Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France.'}, {'ForeName': 'Nuala', 'Initials': 'N', 'LastName': 'McGrath', 'Affiliation': 'Academic Unit of Primary Care and Population Sciences and Department of Social Statistics and Demography, University of Southampton, Southampton, UK.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Tiendrebeogo', 'Affiliation': 'University Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Larmarange', 'Affiliation': 'Africa Health Research Institute, Somkhele, Mtubatuba.'}, {'ForeName': 'Deenan', 'Initials': 'D', 'LastName': 'Pillay', 'Affiliation': 'Africa Health Research Institute, Somkhele, Mtubatuba.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Dabis', 'Affiliation': 'University Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Orne-Gliemann', 'Affiliation': 'University Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","AIDS (London, England)",['10.1097/QAD.0000000000002104'] 294,31677583,Ethnicity and health outcomes among people with epilepsy participating in an epilepsy self-management RCT.,"People with epilepsy (PWE) may experience negative health events (NHEs) such as seizures, emergency room visits, and hospitalizations, with ethnic and racial minorities disproportionately affected. Epilepsy self-management may reduce NHEs; however, few reports examine self-management outcomes in racial minorities. Using data from a longitudinal 6-month randomized controlled trial (RCT) of 120 PWE, this analysis compared African-American and Whites at baseline, 10 weeks and 24 weeks after receiving the ""Self-management for people with epilepsy (SMART) and a history of NHEs"" self-management program. The primary RCT outcome was number of NHEs. At baseline, compared to Whites, African-Americans had less education (p = 0.02) and greater depressive severity (p = 0.04). Both African-American and Whites generally improved with SMART, and there were no racial differences in NHE counts or other outcomes' responses. Given known racial disparities in epilepsy care, it may be particularly important to reach out to minority PWE with self-management programs.",2019,"Both African-American and Whites generally improved with SMART, and there were no racial differences in NHE counts or other outcomes' responses.","['African-American and Whites at baseline, 10\u202fweeks and 24\u202fweeks after receiving the ""Self-management for people with epilepsy (SMART) and a history of NHEs"" self-management program', 'People with epilepsy (PWE', 'people with epilepsy participating in an epilepsy self-management RCT']",[],"['number of NHEs', 'Ethnicity and health outcomes', 'depressive severity']","[{'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]",[],"[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0243103', 'cui_str': 'ethnicity'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",,0.0414492,"Both African-American and Whites generally improved with SMART, and there were no racial differences in NHE counts or other outcomes' responses.","[{'ForeName': 'Neha', 'Initials': 'N', 'LastName': 'Kumar', 'Affiliation': 'Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Aebi', 'Affiliation': 'Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'Lu', 'Affiliation': 'Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Burant', 'Affiliation': 'Case Western Reserve University, Frances Payne Bolton School of Nursing, Cleveland, Ohio, USA.'}, {'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Sajatovic', 'Affiliation': 'Department of Psychiatry and of Neurology, Neurological & Behavioral Outcomes Center, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. Electronic address: Martha.Sajatovic@uhhospitals.org.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2019.106469'] 295,31467447,"Parents of newborns in the NICU enrolled in genome sequencing research: hopeful, but not naïve.","PURPOSE In 2014, our institution launched a randomized controlled trial (RCT) comparing rapid genome sequencing (GS) to standard clinical evaluations of infants with suspected genetic disorders. This study aimed to understand parental response to the use of GS for their newborn babies. METHODS Twenty-three of 128 parents whose infant had enrolled in the RCT completed a retrospective survey and interview addressing attitudes about GS and responses to receiving diagnostic information. We also collected information about participants' genetic literacy, genetic knowledge, numeracy, and symptoms of anxiety and depression. RESULTS The majority reported positive (13; 56.5%) or neutral 4 (4; 17.4%) feelings when approached about GS for their infant and 100% felt that GS was generally beneficial. The 12 participants who had received a unifying diagnosis for their child's symptoms described personal utility of the information. Some reported the diagnosis led to changes in medical care. Participants showed understanding of some of the psychological risks of GS. For example, 21 (91.3%) agreed or strongly agreed that genetic testing could reveal disturbing results. CONCLUSIONS Parents who enrolled their newborn in a RCT of GS demonstrated awareness of a psychological risk, but generally held positive beliefs about GS and perceived the benefits outweighed the risk.",2020,The majority reported positive (13; 56.5%) or neutral 4 (4; 17.4%) feelings when approached about GS for their infant and 100% felt that GS was generally beneficial.,"['infants with suspected genetic disorders', 'Twenty-three of 128 parents whose infant had enrolled in the RCT completed a retrospective survey and interview addressing attitudes about GS and responses to receiving diagnostic information', 'Parents of newborns in the NICU enrolled in genome sequencing research', ""12 participants who had received a unifying diagnosis for their child's symptoms described personal utility of the information""]",[],['psychological risks of GS'],"[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}, {'cui': 'C0019247', 'cui_str': 'Hereditary Diseases'}, {'cui': 'C0450348', 'cui_str': '23 (qualifier value)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0376649', 'cui_str': 'Address'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0030551', 'cui_str': 'Parent of (observable entity)'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0021709', 'cui_str': 'Newborn ICU'}, {'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C0035168'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",[],"[{'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",128.0,0.0537586,The majority reported positive (13; 56.5%) or neutral 4 (4; 17.4%) feelings when approached about GS for their infant and 100% felt that GS was generally beneficial.,"[{'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Berrios', 'Affiliation': ""Center for Pediatric Genomic Medicine, Children's Mercy Kansas City, Kansas City, MO, USA. cdberrios@cmh.edu.""}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Koertje', 'Affiliation': ""Division of Developmental and Behavioral Sciences, Children's Mercy Kansas City, Kansas City, MO, USA.""}, {'ForeName': 'Janelle', 'Initials': 'J', 'LastName': 'Noel-MacDonnell', 'Affiliation': 'School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Soden', 'Affiliation': ""Center for Pediatric Genomic Medicine, Children's Mercy Kansas City, Kansas City, MO, USA.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Lantos', 'Affiliation': 'School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA.'}]",Genetics in medicine : official journal of the American College of Medical Genetics,['10.1038/s41436-019-0644-5'] 296,32282342,Comparative Evaluation of Participation and Diagnostic Yield of Colonoscopy vs Fecal Immunochemical Test vs Risk-Adapted Screening in Colorectal Cancer Screening: Interim Analysis of a Multicenter Randomized Controlled Trial (TARGET-C).,"INTRODUCTION In colorectal cancer screening, implementing risk-adapted screening might be more effective than traditional screening strategies. We aimed to compare the effectiveness of a risk-adapted screening strategy with colonoscopy and fecal immunochemical test (FIT) in colorectal cancer screening. METHODS A randomized controlled trial was conducted in 6 centers in China since May 2018. Nineteen thousand five hundred forty-six eligible participants aged 50-74 years were recruited and randomly allocated into 1 of the 3 screening groups in a 1:2:2 ratio: (i) one-time colonoscopy (n = 3,916), (ii) annual FIT (n = 7,854), and (iii) annual risk-adapted screening (n = 7,776). Based on the risk-stratification score, high-risk subjects were referred for colonoscopy and low-risk ones were referred for FIT. All subjects with positive FIT were referred for diagnostic colonoscopy. The detection rate of advanced neoplasm was the primary outcome. The study is registered with the China Clinical Trial Registry (www.chictr.org.cn Identifier: ChiCTR1800015506). RESULTS For baseline screening, the participation rates of the colonoscopy, FIT, and risk-adapted screening groups were 42.5% (1,665/3,916), 94.0% (7,386/7,854), and 85.2% (6,628/7,776), respectively. For the intention-to-screen analysis, the detection rates of advanced neoplasm were 2.40% (94/3,916), 1.13% (89/7,854), and 1.66% (129/7,776), with odds ratios (95% confidence intervals) of 2.16 (1.61-2.90; P < 0.001) for colonoscopy vs FIT, 1.45 (1.10-1.90; P < 0.001) for colonoscopy vs risk-adapted screening, and 1.49 (1.13-1.97; P < 0.001) for risk-adapted screening vs FIT, respectively. The numbers of subjects who required a colonoscopic examination to detect 1 advanced neoplasm were 18 in the colonoscopy group, 10 in the FIT group, and 11 in the risk-adapted screening group. DISCUSSION For baseline screening, the risk-adapted screening approach showed a high participation rate, and its diagnostic yield was superior to that of FIT at a similarly low load of colonoscopy.",2020,"DISCUSSION For baseline screening, the risk-adapted screening approach showed a high participation rate, and its diagnostic yield was superior to that of FIT at a similarly low load of colonoscopy.","['Colorectal Cancer Screening', 'colorectal cancer screening', 'Nineteen thousand five hundred forty-six eligible participants aged 50-74 years', '6 centers in China since May 2018', 'All subjects with positive FIT were referred for diagnostic colonoscopy']","['risk-adapted screening strategy with colonoscopy and fecal immunochemical test (FIT', 'Colonoscopy vs Fecal Immunochemical Test vs Risk-Adapted Screening']","['detection rate of advanced neoplasm', 'detection rates of advanced neoplasm']","[{'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0400018', 'cui_str': 'Diagnostic endoscopic examination on colon'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}]",19546.0,0.122397,"DISCUSSION For baseline screening, the risk-adapted screening approach showed a high participation rate, and its diagnostic yield was superior to that of FIT at a similarly low load of colonoscopy.","[{'ForeName': 'Hongda', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Lu', 'Affiliation': 'Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Chengcheng', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Shuangmei', 'Initials': 'S', 'LastName': 'Zou', 'Affiliation': 'Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Lingbin', 'Initials': 'L', 'LastName': 'Du', 'Affiliation': 'Department of Cancer Prevention, Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences/Cancer Hospital of University of Chinese Academy of Sciences/Zhejiang Cancer Hospital.'}, {'ForeName': 'Xianzhen', 'Initials': 'X', 'LastName': 'Liao', 'Affiliation': 'Department of Cancer Prevention, Hunan Cancer Hospital, Changsha, China.'}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Dong', 'Affiliation': 'Office of Cancer Prevention and Treatment, Xuzhou Cancer Hospital, Xuzhou, China.'}, {'ForeName': 'Donghua', 'Initials': 'D', 'LastName': 'Wei', 'Affiliation': 'Department of Cancer Prevention, Anhui Provincial Cancer Hospital, Hefei, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': 'Department of Colorectal Surgery, Tumor Hospital of Yunnan Province/Third Affiliated Hospital of Kunming Medical University, Kunming, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Zhu', 'Affiliation': 'Department of Cancer Prevention, Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences/Cancer Hospital of University of Chinese Academy of Sciences/Zhejiang Cancer Hospital.'}, {'ForeName': 'Liming', 'Initials': 'L', 'LastName': 'Zhu', 'Affiliation': 'Department of Medical Oncology, Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences/Cancer Hospital of University of Chinese Academy of Sciences/Zhejiang Cancer Hospital.'}, {'ForeName': 'Weifang', 'Initials': 'W', 'LastName': 'Zheng', 'Affiliation': 'Department of Proctology, Lanxi Red Cross Hospital, Jinhua, China.'}, {'ForeName': 'Haifan', 'Initials': 'H', 'LastName': 'Xiao', 'Affiliation': 'Department of Cancer Prevention, Hunan Cancer Hospital, Changsha, China.'}, {'ForeName': 'Yunxin', 'Initials': 'Y', 'LastName': 'Kong', 'Affiliation': 'Office of Cancer Prevention and Treatment, Xuzhou Cancer Hospital, Xuzhou, China.'}, {'ForeName': 'Huiping', 'Initials': 'H', 'LastName': 'Yin', 'Affiliation': 'Department of Cancer Prevention, Anhui Provincial Cancer Hospital, Hefei, China.'}, {'ForeName': 'Hai', 'Initials': 'H', 'LastName': 'Zhou', 'Affiliation': 'Administrative Management Office of Yunan Cancer Center, Yunnan Cancer Hospital/The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Center, Kunming, China.'}, {'ForeName': 'Rongbiao', 'Initials': 'R', 'LastName': 'Ying', 'Affiliation': 'Department of Surgical Oncology, Taizhou Cancer Hospital, Taizhou, China.'}, {'ForeName': 'Baoquan', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': 'Department of Public Health, Lanxi Red Cross Hospital, Jinhua, China.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Cancer Prevention, Anhui Provincial Cancer Hospital, Hefei, China.'}, {'ForeName': 'Xiaopeng', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of NCD Prevention and Heath Education, Hefei Center for Disease Control and Prevention, Hefei, China.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Department of Cancer Prevention, Tumor Hospital of Yunnan Province/Third Affiliated Hospital of Kunming Medical University, Kunming, China.'}, {'ForeName': 'Xuan', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Colorectal Surgery, Tumor Hospital of Yunnan Province/Third Affiliated Hospital of Kunming Medical University, Kunming, China.'}, {'ForeName': 'Yuhan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Lanwei', 'Initials': 'L', 'LastName': 'Guo', 'Affiliation': 'Henan Office for Cancer Control and Research, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Department of Epidemiology and Biostatistics, and the Ministry of Education Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Jiansong', 'Initials': 'J', 'LastName': 'Ren', 'Affiliation': 'Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Jufang', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': 'Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Ni', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Xiaoping', 'Initials': 'X', 'LastName': 'Miao', 'Affiliation': 'Department of Epidemiology and Biostatistics, and the Ministry of Education Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Hermann', 'Initials': 'H', 'LastName': 'Brenner', 'Affiliation': 'Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Dai', 'Affiliation': 'Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}]",The American journal of gastroenterology,['10.14309/ajg.0000000000000624'] 297,32171439,Effect of Physical Exercise Training in Patients With Chagas Heart Disease (from the PEACH STUDY).,"Chagas heart disease (HD) is a chronic fibrosing myocarditis with high mortality. The PEACH study aimed to evaluate if exercise training can improve the functional capacity of Chagas HD patients with left ventricular dysfunction and/or heart failure. The PEACH study was a single center, parallel-group, clinical trial that randomized 30 clinical stable Chagas HD patients with left ventricular ejection fraction <45% or heart failure symptoms to either supervised exercise training 3 times/week for 6 months or a control group. Both groups had the same monthly pharmaceutical and nutritional counseling and usual care. Primary end point was functional capacity assessed by peak exercise oxygen consumption (peak VO 2 ) obtained by cardiopulmonary exercise test. Secondary end points included other cardiopulmonary exercise test variables, cardiac function by echocardiography, body composition, muscle respiratory strength, and metabolic biomarkers. Peak VO 2 increased among patients in exercise group from 17.60 ± 4.65 mlO 2 kg -1 min -1 to 19.40 ± 5.51 mlO 2 kg -1 min -1 while decreased in controls from 15.40 ± 6.30 mlO 2 kg -1 min -1 to 12.96 ± 4.50 mlO 2 kg -1 min -1 , resulting in significant difference in change in peak VO 2 between groups after 6 months (β = +4.6, p = 0.004). There were significant differences between groups in changes in anaerobic threshold (β = 3.7, p = 0.05), peak oxygen pulse (β = +2.7, p = 0.032) and maximum minute ventilation (β = +13.9, p < 0.0001) after 6 months of intervention. In conclusion, exercise training improved functional capacity of chronic Chagas HD patients with left ventricular dysfunction and/or heart failure.",2020,"There were significant differences between groups in changes in anaerobic threshold (β = 3.7, p = 0.05), peak oxygen pulse (β = +2.7, p = 0.032) and maximum minute ventilation (β = +13.9, p < 0.0001) after 6 months of intervention.","['Chagas HD patients with left ventricular dysfunction and/or heart failure', 'chronic Chagas HD patients with left ventricular dysfunction and/or heart failure', '30 clinical stable Chagas HD patients with left ventricular ejection fraction <45% or heart failure symptoms to either', 'Patients With Chagas Heart Disease (from the PEACH STUDY']","['exercise training', 'supervised exercise training', 'Physical Exercise Training', '1 min -1']","['peak oxygen pulse', 'Peak VO 2', 'anaerobic threshold', 'functional capacity assessed by peak exercise oxygen consumption (peak VO 2 ) obtained by cardiopulmonary exercise test', 'functional capacity', 'cardiopulmonary exercise test variables, cardiac function by echocardiography, body composition, muscle respiratory strength, and metabolic biomarkers', 'maximum minute ventilation', 'peak VO']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0242973', 'cui_str': 'Ventricular Dysfunction'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0018799', 'cui_str': 'Cardiac Diseases'}, {'cui': 'C0949824', 'cui_str': 'Peach'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1301862', 'cui_str': 'Min 1'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0002749', 'cui_str': 'Anaerobic Threshold'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1305742', 'cui_str': 'Oxygen consumption'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary Exercise Test'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function (observable entity)'}, {'cui': 'C0013516', 'cui_str': 'Transthoracic Echocardiography'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1301655', 'cui_str': 'Minute ventilation'}]",30.0,0.0301918,"There were significant differences between groups in changes in anaerobic threshold (β = 3.7, p = 0.05), peak oxygen pulse (β = +2.7, p = 0.032) and maximum minute ventilation (β = +13.9, p < 0.0001) after 6 months of intervention.","[{'ForeName': 'Fernanda', 'Initials': 'F', 'LastName': 'de Souza Nogueira Sardinha Mendes', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil. Electronic address: fernanda.sardinha@ini.fiocruz.br.'}, {'ForeName': 'Mauro Felippe Felix', 'Initials': 'MFF', 'LastName': 'Mediano', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil; National Institute of Cardiology, Laranjeiras, Rio de Janeiro, Brazil.'}, {'ForeName': 'Fernando Cesar', 'Initials': 'FC', 'LastName': 'de Castro E Souza', 'Affiliation': 'National Institute of Cardiology, Laranjeiras, Rio de Janeiro, Brazil.'}, {'ForeName': 'Paula Simplício', 'Initials': 'PS', 'LastName': 'da Silva', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil.'}, {'ForeName': 'Fernanda Martins', 'Initials': 'FM', 'LastName': 'Carneiro', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil.'}, {'ForeName': 'Marcelo Teixeira', 'Initials': 'MT', 'LastName': 'de Holanda', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil.'}, {'ForeName': 'Roberto Magalhães', 'Initials': 'RM', 'LastName': 'Saraiva', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil.'}, {'ForeName': 'Sergio Salles', 'Initials': 'SS', 'LastName': 'Xavier', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil.'}, {'ForeName': 'Pedro Emmanuel Alvarenga', 'Initials': 'PEA', 'LastName': 'Americano do Brasil', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil.'}, {'ForeName': 'Andréa Silvestre', 'Initials': 'AS', 'LastName': 'de Sousa', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil.'}]",The American journal of cardiology,['10.1016/j.amjcard.2020.01.035'] 298,32282356,Corneal Haze After Transepithelial Collagen Cross-linking for Keratoconus: A Scheimpflug Densitometry Analysis.,"PURPOSE To quantitate corneal haze and analyze the postoperative time course of corneal haze after transepithelial corneal collagen cross-linking (TECXL) in patients with keratoconus. METHODS Patients underwent TECXL and were randomized into 2 groups. One group received intraoperative riboflavin 0.10% every minute, and the second group received riboflavin 0.10% every 2 minutes during ultraviolet exposure. Scheimpflug densitometry was measured preoperatively, and at 1, 3, 6, and 12 months to assess the postoperative time course. Densitometry measurements were also correlated with visual acuity, pachymetry, and topography outcomes. RESULTS Fifty-nine eyes of 43 patients with keratoconus were analyzed. Preoperative mean corneal densitometry was 20.45 ± 2.79. Mean densitometry increased at 1 month (22.58 ± 3.79; P < 0.001), did not significantly change between 1 and 3 months (22.64 ± 3.83; P = 0.8), and significantly improved between 3 and 12 months postoperatively (mean6 21.59 ± 3.39; P = 0.002, mean12 20.80 ± 3.27; P = 0.002). There was no difference between preoperative and 1-year densitometry measurements (P = 0.21). There was no significant difference between the 1-minute and 2-minute subgroups. In addition, corneal densitometry at either 3 months or 1 year did not correlate with uncorrected distance visual acuity (P = 0.4), corrected distance visual acuity (P = 0.1), or maximum keratometry (P = 0.5), 1 year after corneal collagen cross-linking (CXL). CONCLUSIONS After TECXL, corneal haze increased slightly at 1 month, plateaued between 1 and 3 months, and returned to baseline between 3 and 12 months. In general, corneal haze in this study was substantially less than the haze previously reported for the standard cross-linking procedure. CXL-associated corneal haze did not correlate with the postoperative visual or topographic outcomes 1 year after CXL.",2020,"Mean densitometry increased at 1 month (22.58 ± 3.79; P < 0.001), did not significantly change between 1 and 3 months (22.64 ± 3.83; P = 0.8), and significantly improved between 3 and 12 months postoperatively (mean6 21.59 ± 3.39; P = 0.002, mean12 20.80 ± 3.27; P = 0.002).","['patients with keratoconus', 'Fifty-nine eyes of 43 patients with keratoconus', 'Patients underwent', 'Keratoconus']","['transepithelial corneal collagen cross-linking (TECXL', 'intraoperative riboflavin', 'riboflavin', 'TECXL']","['Corneal Haze', 'corneal haze', 'CXL-associated corneal haze', 'visual acuity, pachymetry, and topography outcomes', 'postoperative time course', 'corrected distance visual acuity', 'Mean densitometry', 'preoperative and 1-year densitometry measurements', 'uncorrected distance visual acuity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022578', 'cui_str': 'Keratoconus'}, {'cui': 'C3830128', 'cui_str': '59'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}]","[{'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0332220', 'cui_str': 'Cross-linking'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0035527', 'cui_str': 'Riboflavin'}]","[{'cui': 'C0010038', 'cui_str': 'Corneal opacity'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0449247', 'cui_str': 'Time course'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0429537', 'cui_str': 'Distance visual acuity'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0011321', 'cui_str': 'Densitometry'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",43.0,0.0458156,"Mean densitometry increased at 1 month (22.58 ± 3.79; P < 0.001), did not significantly change between 1 and 3 months (22.64 ± 3.83; P = 0.8), and significantly improved between 3 and 12 months postoperatively (mean6 21.59 ± 3.39; P = 0.002, mean12 20.80 ± 3.27; P = 0.002).","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'J Lai', 'Affiliation': 'The Cornea and Laser Eye Institute-Hersh Vision Group, CLEI Center for Keratoconus, Teaneck, NJ.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Greenstein', 'Affiliation': 'The Cornea and Laser Eye Institute-Hersh Vision Group, CLEI Center for Keratoconus, Teaneck, NJ.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Gelles', 'Affiliation': 'The Cornea and Laser Eye Institute-Hersh Vision Group, CLEI Center for Keratoconus, Teaneck, NJ.'}, {'ForeName': 'Peter S', 'Initials': 'PS', 'LastName': 'Hersh', 'Affiliation': 'The Cornea and Laser Eye Institute-Hersh Vision Group, CLEI Center for Keratoconus, Teaneck, NJ.'}]",Cornea,['10.1097/ICO.0000000000002334'] 299,31707107,Neurofeedback impacts cognition and quality of life in pediatric focal epilepsy: An exploratory randomized double-blinded sham-controlled trial.,"OBJECTIVE Children with epilepsy experience cognitive deficits and well-being issues that have detrimental effects on their development. Pharmacotherapy is the standard of care in epilepsy; however, few interventions exist to promote cognitive development and to mitigate disease burden. We aimed to examine the impact of two different modalities of neurofeedback (NFB) on cognitive functioning and quality-of-life (QOL) measurements in children and adolescents with controlled focal epilepsy. The study also explored the effects of NFB on clinical outcomes and electroencephalography (EEG) quantitative analysis. METHODS Participants (n = 44) with controlled focal epilepsy were randomized to one of three arms: sensorimotor rhythm (SMR) NFB (n = 15), slow cortical potentials (SCP) NFB (n = 16), or sham NFB (n = 13). All participants received 25 sessions of intervention. The attention switching task (AST), Liverpool Seizure Severity Scale (LSSS), seizure frequency (SF), EEG power spectrum, and coherence were measured at baseline, postintervention, and at 3-month follow-up. RESULTS In children and adolescents with controlled focal epilepsy, SMR training significantly reduced reaction time in the AST (p = 0.006), and this was correlated with the difference of change for theta power on EEG (p = 0.03); only the SMR group showed a significant decrease in beta coherence (p = 0.03). All groups exhibited improvement in QOL (p = <0.05). CONCLUSIONS This study provides the first data on two NFB modalities (SMR and SCP) including cognitive, neurophysiological, and clinical outcomes in pediatric epilepsy. Sensorimotor rhythm NFB improved cognitive functioning, while all the interventions showed improvements in QOL, demonstrating a powerful placebo effect in the sham group.",2019,"All groups exhibited improvement in QOL (p = <0.05). ","['pediatric focal epilepsy', 'Participants (n\u202f=\u202f44) with controlled focal epilepsy', 'Children with epilepsy experience cognitive deficits', 'pediatric epilepsy', 'children and adolescents with controlled focal epilepsy']","['neurofeedback (NFB', 'Pharmacotherapy', 'NFB modalities (SMR and SCP', 'NFB', 'sensorimotor rhythm (SMR) NFB (n\u202f=\u202f15), slow cortical potentials (SCP) NFB (n\u202f=\u202f16), or sham NFB']","['reaction time', 'clinical outcomes and electroencephalography (EEG) quantitative analysis', 'Neurofeedback impacts cognition and quality of life', 'cognitive functioning', 'beta coherence', 'QOL', 'cognitive functioning and quality-of-life (QOL) measurements', 'attention switching task (AST), Liverpool Seizure Severity Scale (LSSS), seizure frequency (SF), EEG power spectrum, and coherence']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0014547', 'cui_str': 'Focal Seizure Disorder'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0338656', 'cui_str': 'Cognitive Dysfunction'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C2713543', 'cui_str': 'Neurofeedback'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1145610', 'cui_str': 'Cellulose sodium phosphate'}, {'cui': 'C0439834', 'cui_str': 'Slowly'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0013819', 'cui_str': 'EEG'}, {'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C2713543', 'cui_str': 'Neurofeedback'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0034380'}, {'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0222045'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]",,0.331688,"All groups exhibited improvement in QOL (p = <0.05). ","[{'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Morales-Quezada', 'Affiliation': 'Neuromodulation Center, Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Charlestown, MA, USA. Electronic address: jmorales-quezada@partners.org.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Martinez', 'Affiliation': 'Boston Neurodynamics, Brookline, MA, USA; Neocemod, Centro de Neuromodulacion, Aguascalientes, Mexico.'}, {'ForeName': 'Mirret M', 'Initials': 'MM', 'LastName': 'El-Hagrassy', 'Affiliation': 'Neuromodulation Center, Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Charlestown, MA, USA.'}, {'ForeName': 'Ted J', 'Initials': 'TJ', 'LastName': 'Kaptchuk', 'Affiliation': 'Program in Placebo Studies and Therapeutic Encounter, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA.'}, {'ForeName': 'M Barry', 'Initials': 'MB', 'LastName': 'Sterman', 'Affiliation': 'Department of Neurobiology, UCLA School of Medicine, USA; Department of Biobehavioral Psychiatry, UCLA School of Medicine, USA.'}, {'ForeName': 'Gloria Y', 'Initials': 'GY', 'LastName': 'Yeh', 'Affiliation': ""Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Osher Center for Integrative Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2019.106570'] 300,31591483,Role of appetitive phenotype trajectory groups on child body weight during a family-based treatment for children with overweight or obesity.,"OBJECTIVE Emerging evidence suggests that individual appetitive traits may usefully explain patterns of weight loss in behavioral weight loss treatments for children. The objective of this study was to identify trajectories of child appetitive traits and the impact on child weight changes over time. METHODS Secondary data analyses of a randomized noninferiority trial conducted between 2011 and 2015 evaluated children's appetitive traits and weight loss. Children with overweight and obesity (mean age = 10.4; mean BMI z = 2.0; 67% girls; 32% Hispanic) and their parent (mean age = 42.9; mean BMI = 31.9; 87% women; 31% Hispanic) participated in weight loss programs and completed assessments at baseline, 3, 6,12, and 24 months. Repeated assessments of child appetitive traits, including satiety responsiveness, food responsiveness and emotional eating, were used to identify parsimonious grouping of change trajectories. Linear mixed-effects models were used to identify the impact of group trajectory on child BMIz change over time. RESULTS One hundred fifty children and their parent enrolled in the study. The three-group trajectory model was the most parsimonious and included a high satiety responsive group (HighSR; 47.4%), a high food responsive group (HighFR; 34.6%), and a high emotional eating group (HighEE; 18.0%). Children in all trajectories lost weight at approximately the same rate during treatment, however, only the HighSR group maintained their weight loss during follow-ups, while the HighFR and HighEE groups regained weight (adjusted p-value < 0.05). CONCLUSIONS Distinct trajectories of child appetitive traits were associated with differential weight loss maintenance. Identified high-risk subgroups may suggest opportunities for targeted intervention and maintenance programs.",2019,"Repeated assessments of child appetitive traits, including satiety responsiveness, food responsiveness and emotional eating, were used to identify parsimonious grouping of change trajectories.","['children', 'children with overweight or obesity', 'Children with overweight and obesity (mean age\u2009', 'One hundred fifty children and their parent enrolled in the study', ""2011 and 2015 evaluated children's appetitive traits and weight loss""]",['appetitive phenotype trajectory'],"['child body weight', 'differential weight loss maintenance', 'child BMIz change over time', 'weight loss', 'child appetitive traits, including satiety responsiveness, food responsiveness and emotional eating']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}]","[{'cui': 'C1314763', 'cui_str': 'Phenotyping (qualifier value)'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0443199', 'cui_str': 'Differential (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0036239', 'cui_str': 'Satiations'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}]",150.0,0.0200187,"Repeated assessments of child appetitive traits, including satiety responsiveness, food responsiveness and emotional eating, were used to identify parsimonious grouping of change trajectories.","[{'ForeName': 'Kerri N', 'Initials': 'KN', 'LastName': 'Boutelle', 'Affiliation': 'Department of Pediatrics, UC San Diego, La Jolla, CA, USA. kboutelle@ucsd.edu.'}, {'ForeName': 'D Eastern', 'Initials': 'DE', 'LastName': 'Kang Sim', 'Affiliation': 'Department of Pediatrics, UC San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Manzano', 'Affiliation': 'Department of Pediatrics, UC San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Kyung E', 'Initials': 'KE', 'LastName': 'Rhee', 'Affiliation': 'Department of Pediatrics, UC San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Scott J', 'Initials': 'SJ', 'LastName': 'Crow', 'Affiliation': 'Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Strong', 'Affiliation': 'Department of Family Medicine and Public Health, UC San Diego, La Jolla, CA, USA.'}]",International journal of obesity (2005),['10.1038/s41366-019-0463-4'] 301,31005547,Thermoregulatory and perceptual responses of lean and obese fit and unfit girls exercising in the heat.,"OBJECTIVE To verify the thermoregulatory and perceptual responses of obese and lean girls, either fit or unfit, exercising in the heat at a similar rate of metabolic heat production per unit body mass. METHODS A total of 34 pubescent girls were allocated in four groups: 12 obese fit, 9 obese unfit, 5 lean fit, and 8 lean unfit. The obese groups (13.2±1.4 years, 40.5%±5.8% fat by DXA) differed in their aerobic fitness (V˙O 2peak 76.0±8.1 vs. 56.6±5.8mL.kgmusclemass -1 .min -1 ), as well as the lean groups (13.1±1.6 years, 24.0%±4.8% fat) (V˙O 2peak 74.5±2.9 vs. 56.2±5.0mL.kgmuscle mass -1 min -1 ). Girls cycled two bouts of 25min with a 10min rest in between, at ∼5.4W.kg -1 in the heat (36°C and 40% relative humidity) and they were kept euhydrated. Rectal and skin temperatures and heart rate were measured every 5min. Perceptual responses were evaluated throughout the exercise. RESULTS Initial rectal temperature was higher in the obese subjects compared to the lean subjects (37.5±0.3 and 37.2±0.3°C). No difference was observed among the girls whom were obese (eight fit or unfit) and lean (also fit or unfit) throughout the exercise in rectal temperature (37.6±0.2, 37.5±0.3, 37.5±0.3, 37.4±0.3°C, respectively), skin temperature (34.8±0.8, 35.1±1.0, 34.4±0.9, 35.2±0.9°C), and heart rate (128±18; 118±12, 130±16, 119±16beatsmin -1 ). No differences were observed in perceptual responses among groups. CONCLUSION Regardless of the adiposity or aerobic fitness, pubescent girls had similar thermoregulatory and perceptual responses while cycling in the heat at similar metabolic heat production.",2020,"RESULTS Initial rectal temperature was higher in the obese subjects compared to the lean subjects (37.5±0.3 and 37.2±0.3°C).","['obese and lean girls', 'lean and obese fit and unfit girls exercising in the heat', '34 pubescent girls were allocated in four groups: 12 obese fit, 9 obese unfit, 5 lean fit, and 8 lean unfit']",[],"['perceptual responses', 'Initial rectal temperature', 'Rectal and skin temperatures and heart rate', 'skin temperature', 'aerobic fitness', 'Perceptual responses']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]",[],"[{'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0489749', 'cui_str': 'Rectal temperature'}, {'cui': 'C0205052', 'cui_str': 'Rectal (qualifier value)'}, {'cui': 'C0037294', 'cui_str': 'Skin Temperature'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}]",34.0,0.0301948,"RESULTS Initial rectal temperature was higher in the obese subjects compared to the lean subjects (37.5±0.3 and 37.2±0.3°C).","[{'ForeName': 'Carolina de Ávila', 'Initials': 'CÁ', 'LastName': 'Rodrigues', 'Affiliation': 'Universidade Federal do Rio Grande do Sul (UFRGS), Escola de Educação Física, Fisioterapia e Dança, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Gabriela Tomedi', 'Initials': 'GT', 'LastName': 'Leites', 'Affiliation': 'Universidade Federal do Rio Grande do Sul (UFRGS), Escola de Educação Física, Fisioterapia e Dança, Porto Alegre, RS, Brazil. Electronic address: gabitomedi@yahoo.com.br.'}, {'ForeName': 'Flavia', 'Initials': 'F', 'LastName': 'Meyer', 'Affiliation': 'Universidade Federal do Rio Grande do Sul (UFRGS), Escola de Educação Física, Fisioterapia e Dança, Porto Alegre, RS, Brazil.'}]",Jornal de pediatria,['10.1016/j.jped.2018.12.011'] 302,31160237,"Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.","INTRODUCTION The phase III RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma (ENDEAVOR) trial showed significantly improved progression-free survival and overall survival (OS) with carfilzomib (56 mg/m 2 ) and dexamethasone (Kd56) versus bortezomib and Kd56 (Vd) in patients with relapsed or refractory multiple myeloma (RRMM). We report updated OS and safety data after 6 months of additional follow-up. PATIENTS AND METHODS Patients with RRMM (1-3 previous lines of therapy) were randomized 1:1 to Kd56 or Vd. Median OS was estimated using the Kaplan-Meier method; OS was compared between treatment groups using Cox proportional hazards models. RESULTS As of July 19, 2017, median follow-up was 44.3 months for Kd56 and 43.7 months for Vd. Median OS was 47.8 months (Kd56) versus 38.8 months (Vd; hazard ratio, 0.76; 95% confidence interval, 0.633-0.915). OS was longer with Kd56 versus Vd within age and cytogenetic subgroups, and according to number of previous lines of therapy, previous bortezomib exposure, previous lenalidomide exposure, and lenalidomide-refractory status. Exposure-adjusted incidences per 100 patient-years of adverse events (AEs) were 1352.07 for Kd56 and 1754.86 for Vd; for Grade ≥3 AEs, these values were 162.31 and 175.90. CONCLUSION With median follow-up of approximately 44 months, clinically meaningful improvements in OS were observed with Kd56 versus Vd, including in all subgroups examined. The Kd56 safety profile was consistent with previous analyses.",2019,"OS was longer with Kd56 versus Vd within age and cytogenetic subgroups, and according to number of previous lines of therapy, previous bortezomib exposure, previous lenalidomide exposure, and lenalidomide-refractory status.","['patients with relapsed or refractory multiple myeloma (RRMM', 'Patients with RRMM (1-3 previous lines of therapy', 'Relapsed or Refractory Multiple Myeloma', 'Patients']","['Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone', 'carfilzomib', 'Bortezomib Plus DexamethasOne', 'Carfilzomib Plus DExamethAsone', 'dexamethasone (Kd56) versus bortezomib and Kd56 (Vd']","['Median OS', 'progression-free survival and overall survival (OS', 'OS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0026764', 'cui_str': 'Myelomatosis'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C2001856', 'cui_str': 'carfilzomib'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",,0.0755891,"OS was longer with Kd56 versus Vd within age and cytogenetic subgroups, and according to number of previous lines of therapy, previous bortezomib exposure, previous lenalidomide exposure, and lenalidomide-refractory status.","[{'ForeName': 'Robert Z', 'Initials': 'RZ', 'LastName': 'Orlowski', 'Affiliation': 'Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address: ROrlowski@mdanderson.org.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Moreau', 'Affiliation': 'Department of Hematology, University Hospital Hotel-Dieu, Nantes, France.'}, {'ForeName': 'Ruben', 'Initials': 'R', 'LastName': 'Niesvizky', 'Affiliation': 'Department of Medical Oncology, Myeloma Center, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY.'}, {'ForeName': 'Heinz', 'Initials': 'H', 'LastName': 'Ludwig', 'Affiliation': 'Department of Medicine I, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Oriol', 'Affiliation': ""Department of Clinical Hematology, Institut Catala d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.""}, {'ForeName': 'Wee Joo', 'Initials': 'WJ', 'LastName': 'Chng', 'Affiliation': 'Department of Hematology Oncology, National University of Singapore, Singapore.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Goldschmidt', 'Affiliation': 'Department of Hematology Oncology, Heidelberg University Clinic and the National Center of Tumor Diseases, Heidelberg, Germany.'}, {'ForeName': 'Zhao', 'Initials': 'Z', 'LastName': 'Yang', 'Affiliation': 'Department of Biostatistics, Amgen, Inc, Thousand Oaks, CA.'}, {'ForeName': 'Amy S', 'Initials': 'AS', 'LastName': 'Kimball', 'Affiliation': 'Department of Clinical Research, Amgen, Inc, Thousand Oaks, CA.'}, {'ForeName': 'Meletios', 'Initials': 'M', 'LastName': 'Dimopoulos', 'Affiliation': 'Department of Clinical Therapeutics, University Athens School of Medicine, Athens, Greece.'}]","Clinical lymphoma, myeloma & leukemia",['10.1016/j.clml.2019.04.018'] 303,32087311,Ability influence on effort and associated cardiovascular responses: Nocebo-Placebo evidence that perception is key.,"Studies have documented the predictive utility of an integrative analysis of ability influence on effort and cardiovascular response. An assumption is that influence is driven by perception. We evaluated this altering ability perception through negative (nocebo) or positive (placebo) suggestion. Participants ingested a pill having been told it would reduce or enhance cognitive clarity. They then were presented a math task with the chance to earn an incentive if they met a low- or high performance standard. Analyses indicated higher reports of clarity during work among participants provided positive clarity instructions and a crossover clarity instruction x performance standard interaction for heart rate response. Responses were stronger for positive instruction participants when the standard was high, but stronger for negative instruction participants when it was low. Findings provide distinctive support for the assumption and suggest a fresh strategy for evaluating the impact of nocebo/placebo and other interventions on subjective experience.",2020,Analyses indicated higher reports of clarity during work among participants provided positive clarity instructions and a crossover clarity instruction x performance standard interaction for heart rate response.,[],"['negative (nocebo) or positive (placebo', 'Nocebo-Placebo']","['Ability Influence on Effort and Associated Cardiovascular Responses', 'heart rate response']",[],"[{'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3658218', 'cui_str': 'Nocebo'}]","[{'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C1997337', 'cui_str': 'Speed of heart rate response'}]",,0.266708,Analyses indicated higher reports of clarity during work among participants provided positive clarity instructions and a crossover clarity instruction x performance standard interaction for heart rate response.,"[{'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Mlynski', 'Affiliation': 'Technical University of Dresden, Germany. Electronic address: christophermlynski@gmail.com.'}, {'ForeName': 'Rex A', 'Initials': 'RA', 'LastName': 'Wright', 'Affiliation': 'University of North Texas, United States. Electronic address: Rex.Wright@unt.edu.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Kelly', 'Affiliation': 'University of North Texas, United States.'}]",Biological psychology,['10.1016/j.biopsycho.2020.107867'] 304,32278779,"Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life: A Secondary Analysis of the Long-Term Oxygen Treatment Trial.","BACKGROUND Although inhaled therapy reduces exacerbations among patients with COPD, the effectiveness of providing inhaled treatment per risk stratification models remains unclear. RESEARCH QUESTION Are inhaled regimens that align with the 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy associated with clinically important outcomes? STUDY DESIGN AND METHODS We conducted secondary analyses of Long-term Oxygen Treatment Trial (LOTT) data. The trial enrolled patients with COPD with moderate resting or exertional hypoxemia between 2009 and 2015. Our exposure was the patient-reported inhaled regimen at enrollment, categorized as either aligning with, undertreating, or potentially overtreating per the 2017 GOLD strategy. Our primary composite outcome was time to death or first hospitalization for COPD. Additional outcomes included individual components of the composite outcome and time to first exacerbation. We generated multivariable Cox proportional hazard models across strata of GOLD-predicted exacerbation risk (high vs low) to estimate between-group hazard ratios for time to event outcomes. We adjusted models a priori for potential confounders, clustered by site. RESULTS The trial enrolled 738 patients (73.4% men; mean age, 68.8 years). Of the patients, 571 (77.4%) were low risk for future exacerbations. Of the patients, 233 (31.6%) reported regimens aligning with GOLD recommendations; most regimens (54.1%) potentially overtreated. During a 2.3-year median follow-up, 332 patients (44.9%) experienced the composite outcome. We found no difference in time to composite outcome or death among patients reporting regimens aligning with recommendations compared with undertreated patients. Among patients at low risk, potential overtreatment was associated with higher exacerbation risk (hazard ratio, 1.42; 95% CI, 1.09-1.87), whereas inhaled corticosteroid treatment was associated with 64% higher risk of pneumonia (incidence rate ratio, 1.64; 95% CI, 1.01-2.66). INTERPRETATION Among patients with COPD with moderate hypoxemia, we found no difference in clinical outcomes between inhaled regimens aligning with the 2017 GOLD strategy compared with those that were undertreated. These findings suggest the need to reevaluate the effectiveness of risk stratification model-based inhaled treatment strategies.",2020,We found no difference in time-to composite outcome or death among patients reporting regimens aligning with recommendations compared to undertreated patients.,"['COPD patients with moderate hypoxemia', 'enrolled COPD patients with moderate resting or exertional hypoxemia between 2009-2015', 'and Methods', 'COPD patients', '571 patients (77.4%) were low-risk for future exacerbations', '738 patients; 73.4% were male with mean age 68.8 years']",[],"['individual components of the composite outcome and time-to first exacerbation', 'exacerbation risk', 'COPD Inhaler Regimenswith Mortality, Respiratory Exacerbations, and Quality of Life', 'risk of pneumonia', 'time-to composite outcome or death', 'time-to death or first hospitalization for COPD']","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0700292', 'cui_str': 'Hypoxemia'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0016884', 'cui_str': 'Future'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]",[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0021461', 'cui_str': 'Inhaler'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",738.0,0.234867,We found no difference in time-to composite outcome or death among patients reporting regimens aligning with recommendations compared to undertreated patients.,"[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Keller', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA. Electronic address: tlk33@uw.edu.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Spece', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA; Health Services Research & Development Center of Innovation for Veteran-centered and Value-driven Care, VA Puget Sound Healthcare System, Seattle, WA.'}, {'ForeName': 'Lucas M', 'Initials': 'LM', 'LastName': 'Donovan', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA; Health Services Research & Development Center of Innovation for Veteran-centered and Value-driven Care, VA Puget Sound Healthcare System, Seattle, WA.'}, {'ForeName': 'Edmunds', 'Initials': 'E', 'LastName': 'Udris', 'Affiliation': 'Health Services Research & Development Center of Innovation for Veteran-centered and Value-driven Care, VA Puget Sound Healthcare System, Seattle, WA.'}, {'ForeName': 'Scott S', 'Initials': 'SS', 'LastName': 'Coggeshall', 'Affiliation': 'Health Services Research & Development Center of Innovation for Veteran-centered and Value-driven Care, VA Puget Sound Healthcare System, Seattle, WA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Griffith', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA; Health Services Research & Development Center of Innovation for Veteran-centered and Value-driven Care, VA Puget Sound Healthcare System, Seattle, WA.'}, {'ForeName': 'Alexander D', 'Initials': 'AD', 'LastName': 'Bryant', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Casaburi', 'Affiliation': 'Los Angeles Biomedical Research Institute at Harbor - UCLA Medical Center, Torrance, CA.'}, {'ForeName': 'J Allen', 'Initials': 'JA', 'LastName': 'Cooper', 'Affiliation': 'Birmingham VA Medical Center and the Lung Health Center, University of Alabama Birmingham, Birmingham, AL.'}, {'ForeName': 'Gerard J', 'Initials': 'GJ', 'LastName': 'Criner', 'Affiliation': 'Temple University School of Medicine, Philadelphia, PA.'}, {'ForeName': 'Philip T', 'Initials': 'PT', 'LastName': 'Diaz', 'Affiliation': '201 Heart Lung Institute, Ohio State University School of Medicine, Columbus, OH.'}, {'ForeName': 'Anne L', 'Initials': 'AL', 'LastName': 'Fuhlbrigge', 'Affiliation': 'University of Colorado School of Medicine, Aurora, CO.'}, {'ForeName': 'Steven E', 'Initials': 'SE', 'LastName': 'Gay', 'Affiliation': 'University of Michigan School of Medicine, Ann Arbor, MI.'}, {'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Kanner', 'Affiliation': 'University of Utah Health Sciences Center, Salt Lake City, UT.'}, {'ForeName': 'Fernando J', 'Initials': 'FJ', 'LastName': 'Martinez', 'Affiliation': 'Weill Cornell Medical College, New York, NY.'}, {'ForeName': 'Ralph J', 'Initials': 'RJ', 'LastName': 'Panos', 'Affiliation': 'Cincinnati VA Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Shade', 'Affiliation': 'Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Sternberg', 'Affiliation': 'Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Stibolt', 'Affiliation': 'Kaiser Permanente Center for Health Research, Portland, OR.'}, {'ForeName': 'James K', 'Initials': 'JK', 'LastName': 'Stoller', 'Affiliation': 'Cleveland Clinic Foundation, Cleveland, OH.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Tonascia', 'Affiliation': 'Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Wise', 'Affiliation': 'Johns Hopkins University School of Medicine, Baltimore, MD.'}, {'ForeName': 'Roger D', 'Initials': 'RD', 'LastName': 'Yusen', 'Affiliation': 'Washington University School of Medicine, Saint Louis, MO.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Au', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA; Health Services Research & Development Center of Innovation for Veteran-centered and Value-driven Care, VA Puget Sound Healthcare System, Seattle, WA.'}, {'ForeName': 'Laura C', 'Initials': 'LC', 'LastName': 'Feemster', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA; Health Services Research & Development Center of Innovation for Veteran-centered and Value-driven Care, VA Puget Sound Healthcare System, Seattle, WA.'}]",Chest,['10.1016/j.chest.2020.02.073'] 305,32278781,"Effect of Venlafaxine on Apnea-Hypopnea Index in Patients With Sleep Apnea: A Randomized, Double-Blind Crossover Study.","BACKGROUND One of the key mechanisms underlying OSA is reduced pharyngeal muscle tone during sleep. Data suggest that pharmacologic augmentation of central serotonergic/adrenergic tone increases pharyngeal muscle tone. RESEARCH QUESTION We hypothesized that venlafaxine, a serotonin-norepinephrine reuptake inhibitor, would improve OSA severity. STUDY DESIGN AND METHODS In this mechanistic, randomized, double-blind, placebo-controlled crossover trial, 20 patients with OSA underwent two overnight polysomnograms ≥ 4 days apart, receiving either 50 mg of immediate-release venlafaxine or placebo before bedtime. Primary outcomes were the apnea-hypopnea index (AHI) and peripheral oxygen saturation (Spo 2 ) nadir, and secondary outcomes included sleep parameters and pathophysiologic traits with a view toward understanding the impact of venlafaxine on mechanisms underlying OSA. RESULTS Overall, there was no significant difference between venlafaxine and placebo regarding AHI (mean reduction, -5.6 events/h [95% CI, -12.0 to 0.9]; P = .09) or Spo 2 nadir (median increase, +1.0% [-0.5 to 5]; P = .11). Venlafaxine reduced total sleep time, sleep efficiency, and rapid eye movement (REM) sleep, while increasing non-REM stage 1 sleep (P all  < .05). On the basis of exploratory post hoc analyses venlafaxine decreased (""improved"") the ventilatory response to arousal (-30%; P = .049) and lowered (""worsened"") the predicted arousal threshold (-13%; [P = .02]; ie, more arousable), with no effects on other pathophysiologic traits (P all  ≥ .3). Post hoc analyses further suggested effect modification by arousal threshold (P = .002): AHI improved by 19% in patients with a high arousal threshold (-10.9 events/h [-3.9 to -17.9]) but tended to increase in patients with a low arousal threshold (+7 events/h [-2.0 to 16]). Other predictors of response were elevated AHI and less collapsible upper airway anatomy at baseline (|r| > 0.5, P ≤ .02). INTERPRETATION In unselected patients, venlafaxine simultaneously worsened and improved various pathophysiologic traits, resulting in a zero net effect. Careful patient selection based on pathophysiologic traits, or combination therapy with drugs countering its alerting effects, may produce a more robust response. TRIAL REGISTRY ClinicalTrials.gov; No.: NCT02714400; URL: www.clinicaltrials.gov.",2020,"Based on exploratory post hoc analyses venlafaxine decreased (""improved"") the ventilatory response to arousal (-30%, P=.049) and lowered (""worsened"") the predicted arousal threshold (-13%, P=.02; i.e. more arousable), with no effects on other pathophysiological traits (P all ≥.3).","['and Methods', 'obstructive sleep apnea (OSA', 'Patients with Sleep Apnea ', '20 OSA patients underwent two', 'patients with a high arousal threshold (-10.9/h']","['venlafaxine', 'Venlafaxine', 'overnight polysomnograms >4days apart receiving either 50mg immediate-release venlafaxine or placebo', 'placebo']","['Apnea Hypopnea Index', 'ventilatory response to arousal', 'total sleep time, sleep efficiency and rapid eye movement (REM) sleep', 'pathophysiological traits', 'apnea hypopnea index (AHI) and SpO 2 nadir; secondary outcomes included sleep parameters and pathophysiological traits with a view towards understanding its impact on mechanisms underlying OSA']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037315', 'cui_str': 'Sleep apnea'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}]","[{'cui': 'C0078569', 'cui_str': 'venlafaxine'}, {'cui': 'C0439583', 'cui_str': 'Overnight'}, {'cui': 'C0162701', 'cui_str': 'Polysomnography'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2111846', 'cui_str': 'Apnea Hypopnea Index'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0037322', 'cui_str': 'Rapid eye movement sleep'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}]",20.0,0.290939,"Based on exploratory post hoc analyses venlafaxine decreased (""improved"") the ventilatory response to arousal (-30%, P=.049) and lowered (""worsened"") the predicted arousal threshold (-13%, P=.02; i.e. more arousable), with no effects on other pathophysiological traits (P all ≥.3).","[{'ForeName': 'Christopher N', 'Initials': 'CN', 'LastName': 'Schmickl', 'Affiliation': 'Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, San Diego, CA.'}, {'ForeName': 'Yanru', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, San Diego, CA; Department of Otorhinolaryngology Head and Neck Surgery, Sleep Medicine Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Electronic address: liyanruru@aliyun.com.'}, {'ForeName': 'Jeremy E', 'Initials': 'JE', 'LastName': 'Orr', 'Affiliation': 'Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, San Diego, CA.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Jen', 'Affiliation': 'Division of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Scott A', 'Initials': 'SA', 'LastName': 'Sands', 'Affiliation': ""Division of Sleep and Circadian Disorders, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.""}, {'ForeName': 'Bradley A', 'Initials': 'BA', 'LastName': 'Edwards', 'Affiliation': 'Sleep and Circadian Medicine Laboratory, Department of Physiology, School of Biomedical Sciences and Biomedical Discovery Institute, Monash University, Melbourne, VIC, Australia; Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'DeYoung', 'Affiliation': 'Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, San Diego, CA.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Owens', 'Affiliation': 'Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, San Diego, CA.'}, {'ForeName': 'Atul', 'Initials': 'A', 'LastName': 'Malhotra', 'Affiliation': 'Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, San Diego, CA.'}]",Chest,['10.1016/j.chest.2020.02.074'] 306,32231295,A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.,"The National Institute of Mental Health (NIMH) 'fast-fail' approach seeks to improve too-often-misleading early-phase drug development methods by incorporating biomarker-based proof-of-mechanism (POM) testing in phase 2a. This first comprehensive application of the fast-fail approach evaluated the potential of κ-opioid receptor (KOR) antagonism for treating anhedonia with a POM study determining whether robust target engagement favorably impacts the brain circuitry hypothesized to mediate clinical effects. Here we report the results from a multicenter, 8-week, double-blind, placebo-controlled, randomized trial in patients with anhedonia and a mood or anxiety disorder (selective KOR antagonist (JNJ-67953964, 10 mg; n = 45) and placebo (n = 44)). JNJ-67953964 significantly increased functional magnetic resonance imaging (fMRI) ventral striatum activation during reward anticipation (primary outcome) as compared to placebo (baseline-adjusted mean: JNJ-67953964, 0.72 (s.d. = 0.67); placebo, 0.33 (s.d. = 0.68); F(1,86) = 5.58, P < 0.01; effect size = 0.58 (95% confidence interval, 0.13-0.99)). JNJ-67953964, generally well tolerated, was not associated with any serious adverse events. This study supports proceeding with assessment of the clinical impact of target engagement and serves as a model for implementing the 'fast-fail' approach.",2020,"significantly increased functional magnetic resonance imaging (fMRI) ventral striatum activation during reward anticipation (primary outcome) as compared to placebo (baseline-adjusted mean: JNJ-67953964, 0.72 (s.d. = 0.67); placebo, 0.33 (s.d. = 0.68); F(1,86) = 5.58, P < 0.01; effect size = 0.58 (95% confidence interval, 0.13-0.99)).","['patients with anhedonia and a mood or anxiety disorder (selective KOR antagonist (JNJ-67953964, 10\u2009mg; n\u2009=\u200945) and', 'n\u2009=\u200944']","['placebo', 'κ-opioid receptor (KOR) antagonism', 'JNJ-67953964']","['serious adverse events', 'functional magnetic resonance imaging (fMRI) ventral striatum activation']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0178417', 'cui_str': 'Anhedonia'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0003469', 'cui_str': 'Anxiety Disorders'}, {'cui': 'C0243076', 'cui_str': 'antagonists'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0034801', 'cui_str': 'Receptors, Opiate'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0917874', 'cui_str': 'Magnetic Resonance'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0750950', 'cui_str': 'Ventral Striatum'}]",,0.474631,"significantly increased functional magnetic resonance imaging (fMRI) ventral striatum activation during reward anticipation (primary outcome) as compared to placebo (baseline-adjusted mean: JNJ-67953964, 0.72 (s.d. = 0.67); placebo, 0.33 (s.d. = 0.68); F(1,86) = 5.58, P < 0.01; effect size = 0.58 (95% confidence interval, 0.13-0.99)).","[{'ForeName': 'Andrew D', 'Initials': 'AD', 'LastName': 'Krystal', 'Affiliation': 'Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA. andrew.krystal@ucsf.edu.'}, {'ForeName': 'Diego A', 'Initials': 'DA', 'LastName': 'Pizzagalli', 'Affiliation': 'McLean Hospital, Harvard Medical School, Belmont, MA, USA.'}, {'ForeName': 'Moria', 'Initials': 'M', 'LastName': 'Smoski', 'Affiliation': 'Departments of Psychiatry and Behavioral Sciences and Radiology, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Sanjay J', 'Initials': 'SJ', 'LastName': 'Mathew', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Nurnberger', 'Affiliation': 'Departments of Psychiatry and Neurobiology, Indiana University School of Medicine, Indianapolis, IN, USA.'}, {'ForeName': 'Sarah H', 'Initials': 'SH', 'LastName': 'Lisanby', 'Affiliation': 'National Institute of Mental Health, Bethesda, MD, USA.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Iosifescu', 'Affiliation': 'Department of Psychiatry, New York University School of Medicine, New York, NY, USA.'}, {'ForeName': 'James W', 'Initials': 'JW', 'LastName': 'Murrough', 'Affiliation': 'Department of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Hongqiu', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC, USA.'}, {'ForeName': 'Richard D', 'Initials': 'RD', 'LastName': 'Weiner', 'Affiliation': 'Departments of Psychiatry and Behavioral Sciences and Radiology, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Joseph R', 'Initials': 'JR', 'LastName': 'Calabrese', 'Affiliation': 'Department of Psychiatry, Case Western Reserve School of Medicine, Cleveland, OH, USA.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Sanacora', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Gretchen', 'Initials': 'G', 'LastName': 'Hermes', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Richard S E', 'Initials': 'RSE', 'LastName': 'Keefe', 'Affiliation': 'Departments of Psychiatry and Behavioral Sciences and Radiology, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Allen', 'Initials': 'A', 'LastName': 'Song', 'Affiliation': 'Departments of Psychiatry and Behavioral Sciences and Radiology, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Wayne', 'Initials': 'W', 'LastName': 'Goodman', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Steven T', 'Initials': 'ST', 'LastName': 'Szabo', 'Affiliation': 'Departments of Psychiatry and Behavioral Sciences and Radiology, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Alexis E', 'Initials': 'AE', 'LastName': 'Whitton', 'Affiliation': 'McLean Hospital, Harvard Medical School, Belmont, MA, USA.'}, {'ForeName': 'Keming', 'Initials': 'K', 'LastName': 'Gao', 'Affiliation': 'Department of Psychiatry, Case Western Reserve School of Medicine, Cleveland, OH, USA.'}, {'ForeName': 'William Z', 'Initials': 'WZ', 'LastName': 'Potter', 'Affiliation': 'National Institute of Mental Health, Bethesda, MD, USA.'}]",Nature medicine,['10.1038/s41591-020-0806-7'] 307,26366259,"Effect of Two Different Doses of Dexmedetomidine as Adjuvant in Bupivacaine Induced Subarachnoid Block for Elective Abdominal Hysterectomy Operations: A Prospective, Double-blind, Randomized Controlled Study.","OBJECTIVES Improvements in perioperative pain management for lower abdominal operations has been shown to reduce morbidity, induce early ambulation, and improve patients' long-term outcomes. Dexmedetomidine, a selective alpha-2 agonist, has recently been used intrathecally as adjuvant to spinal anesthesia to prolong its efficacy. We compared two different doses of dexmedetomidine added to hyperbaric bupivacaine for spinal anesthesia. The primary endpoints were the onset and duration of sensory and motor block, and duration of analgesia.  . METHODS A total of 100 patients, aged 35-60 years old, assigned to have elective abdominal hysterectomy under spinal anesthesia were divided into two equally sized groups (D5 and D10) in a randomized, double-blind fashion. The D5 group was intrathecally administered 3ml 0.5% hyperbaric bupivacaine with 5µg dexmedetomidine in 0.5ml of normal saline and the D10 group 3ml 0.5% bupivacaine with 10µg dexmedetomidine in 0.5ml of normal saline. For each patient, sensory and motor block onset times, block durations, time to first analgesic use, total analgesic need, postoperative visual analogue scale (VAS) scores, hemodynamics, and side effects were recorded.  . RESULTS Although both groups had a similar demographic profile, sensory and motor block in the D10 group (p<0.050) was earlier than the D5 group. Sensory and motor block duration and time to first analgesic use were significantly longer and the need for rescue analgesics was lower in the D10 group than the D5 group. The 24-hour VAS score was significantly lower in the D10 group (p<0.050). Intergroup hemodynamics were comparable (p>0.050) without any appreciable side effects.  . CONCLUSION Spinal dexmedetomidine increases the sensory and motor block duration and time to first analgesic use, and decreases analgesic consumption in a dose-dependent manner.",2015,Sensory and motor block duration and time to first analgesic use were significantly longer and the need for rescue analgesics was lower in the D10 group than the D5 group.,"['100 patients, aged 35-60 years old, assigned to have elective abdominal hysterectomy under spinal anesthesia', 'Elective Abdominal Hysterectomy Operations', 'spinal anesthesia']","['hyperbaric bupivacaine', 'Dexmedetomidine', 'Spinal dexmedetomidine', 'dexmedetomidine in 0.5ml of normal saline and the D10 group 3ml 0.5% bupivacaine', 'intrathecally administered 3ml 0.5% hyperbaric bupivacaine', 'Bupivacaine', 'dexmedetomidine']","['Intergroup hemodynamics', '24-hour VAS score', 'need for rescue analgesics', 'onset and duration of sensory and motor block, and duration of analgesia. \u2002', 'sensory and motor block onset times, block durations, time to first analgesic use, total analgesic need, postoperative visual analogue scale (VAS) scores, hemodynamics, and side effects', 'Sensory and motor block duration and time to first analgesic use', 'sensory and motor block duration and time to first analgesic use, and decreases analgesic consumption', 'demographic profile, sensory and motor block']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0404077', 'cui_str': 'Abdominal hysterectomy (procedure)'}, {'cui': 'C0002928', 'cui_str': 'Spinal Anesthesia'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}]","[{'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C1621583', 'cui_str': 'Administer'}]","[{'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0445254', 'cui_str': 'Sensory (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}]",100.0,0.225122,Sensory and motor block duration and time to first analgesic use were significantly longer and the need for rescue analgesics was lower in the D10 group than the D5 group.,"[{'ForeName': 'Anjan', 'Initials': 'A', 'LastName': 'Das', 'Affiliation': 'Department of Anesthesiology, College of Medicine and Sagore Dutta Hospital, Kolkata, India.'}, {'ForeName': 'Susanta', 'Initials': 'S', 'LastName': 'Halder', 'Affiliation': 'Department. of Anesthesiology, Radha Gobinda Kar Medical College and Hospital, Kolkata, India.'}, {'ForeName': 'Surajit', 'Initials': 'S', 'LastName': 'Chattopadhyay', 'Affiliation': 'Department of Anesthesiology, College of Medicine and Sagore Dutta Hospital, Kolkata, India.'}, {'ForeName': 'Parthajit', 'Initials': 'P', 'LastName': 'Mandal', 'Affiliation': 'Department of Gynecology and Obstetrics, College of Medicine & Sagore Dutta Hospital, Kolkata, India.'}, {'ForeName': 'Subinay', 'Initials': 'S', 'LastName': 'Chhaule', 'Affiliation': 'Department of Anesthesiology, College of Medicine and Sagore Dutta Hospital, Kolkata, India.'}, {'ForeName': 'Rezina', 'Initials': 'R', 'LastName': 'Banu', 'Affiliation': 'Department of Gynecology and Obstetrics, Murshidabad Medical College, Berhampur, India.'}]",Oman medical journal,['10.5001/omj.2015.52'] 308,30569083,Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms.,"BACKGROUND Pimavanserin is a 5-HT2A receptor inverse agonist/antagonist and is approved in the United States for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. OBJECTIVE Evaluate the efficacy of pimavanserin on symptoms of psychosis in patients with Alzheimer's disease (AD). DESIGN Randomized, double-blind, placebo-controlled trial. SETTING Nursing home residents. PARTICIPANTS Patients with AD psychosis. INTERVENTIONS Pimavanserin 34 mg or placebo daily for 12 weeks. MEASUREMENTS The primary endpoint was mean change from baseline at Week 6 on the Neuropsychiatric Inventory-Nursing Home Version psychosis score (NPI-NH-PS). In the prespecified subgroup analysis, the mean change in NPI-NH-PS and the responder rates among those with baseline NPI-NH-PS ≥12 were evaluated. RESULTS Of 181 patients randomized (n=90 pimavanserin; n=91 placebo), 57 had baseline NPI-NH-PS ≥12 (n=27 pimavanserin; n=30 placebo). In this severe subgroup, large treatment effects were observed (delta=-4.43, Cohen's d=-0.73, p=0.011), and ≥30% improvement was 88.9% vs. 43.3% (p<0.001) and ≥50% improvement was 77.8% vs. 43.3% (p=0.008) for pimavanserin and placebo, respectively. The rate of adverse events (AEs) in the severe subgroup was similar between treatment groups, and urinary tract infection, fall, and agitation were most frequent. Serious AEs was similar with pimavanserin (17.9%) and placebo (16.7%) with fewer discontinuations due to AEs with pimavanserin (7.1%) compared to placebo (10.0%). Minimal change from baseline occurred for the mean MMSE score over 12 weeks. CONCLUSIONS Pimavanserin demonstrated significant efficacy in AD psychosis in patients with higher baseline severity of psychotic symptoms (NPI-NH-PS ≥12). Treatment with pimavanserin showed an acceptable tolerability profile.",2019,Serious AEs was similar with pimavanserin (17.9%) and placebo (16.7%) with fewer discontinuations due to AEs with pimavanserin (7.1%) compared to placebo (10.0%).,"['Nursing home residents', ""patients with Alzheimer's disease (AD"", 'Patients with AD psychosis', ""Alzheimer's Disease Psychosis"", '181 patients randomized (n=90 pimavanserin; n=91', 'Patients with More Pronounced Psychotic Symptoms', '57 had baseline NPI-NH-PS ≥12 ']","['Pimavanserin', 'pimavanserin', 'placebo', 'Pimavanserin 34 mg or placebo']","['Neuropsychiatric Inventory-Nursing Home Version psychosis score (NPI-NH-PS', 'urinary tract infection, fall, and agitation', 'rate of adverse events (AEs', 'acceptable tolerability profile', 'mean change in NPI-NH-PS and the responder rates', 'mean MMSE score']","[{'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C0033975', 'cui_str': 'Psychoses'}, {'cui': 'C1722267', 'cui_str': 'pimavanserin'}, {'cui': 'C0871189', 'cui_str': 'Psychotic symptom'}]","[{'cui': 'C1722267', 'cui_str': 'pimavanserin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4704365', 'cui_str': 'pimavanserin 34 MG [Nuplazid]'}]","[{'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0028688', 'cui_str': 'Nursing Homes'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0033975', 'cui_str': 'Psychoses'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}, {'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated (finding)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}]",181.0,0.691774,Serious AEs was similar with pimavanserin (17.9%) and placebo (16.7%) with fewer discontinuations due to AEs with pimavanserin (7.1%) compared to placebo (10.0%).,"[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Ballard', 'Affiliation': 'Clive Ballard, MBChB, Institute of Health Research, University of Exeter Medical School, Exeter EX1 2LU, UK, C.Ballard@exeter.ac.uk.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Youakim', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Coate', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Stankovic', 'Affiliation': ''}]",The journal of prevention of Alzheimer's disease,['10.14283/jpad.2018.30'] 309,30569089,"Bifidobacterium Breve A1 Supplementation Improved Cognitive Decline in Older Adults with Mild Cognitive Impairment: An Open-Label, Single-Arm Study.","OBJECTIVES We previously reported the therapeutic potential of Bifidobacterium breve A1 (B. breve A1) for preventing cognitive impairment in Alzheimer's disease model mice, which suggested that supplementation of the probiotics could be an effective therapeutic strategy for managing cognitive function in mild cognitive impairment (MCI). DESIGN AND SETTINGS We conducted an open-label, single-arm study to examine the effects of 24-week supplementation of B. breve A1 on elderly with MCI in Aki Orthopedics Rehabilitation Clinic in Japan. PARTICIPANTS 27 participants were screened by their Mini Mental State Examination (MMSE) scores. MEASUREMENTS Cognitive function was assessed using MMSE and Digit Symbol Substitution Test (DSST) at baseline and every 8 weeks. Mental condition and quality of life for gastrointestinal symptoms were measured using the Profile of Mood States 2nd Edition (POMS2), and the Gastrointestinal Symptom Rating Scale (GSRS). RESULTS Of the 27 participants enrolled, 19 completed the study. MMSE scores were significantly increased during the intervention by mixed model Dunnett's test and Wilcoxon signed-rank tests (+1.7, P < 0.01). POMS2 and GSRS scores were significantly improved during intervention when analyzed by Wilcoxon signed-rank tests. CONCLUSION The present study showed that oral supplementation of B. breve A1 in participants with MCI improved cognitive function, thus suggesting the potential of B. breve A1 for improving cognitive function and maintaining quality of life of the elderly. Further randomized, double-blind placebo-controlled studies are worth conducting to examine the beneficial effect of B. breve A1.",2019,"MMSE scores were significantly increased during the intervention by mixed model Dunnett's test and Wilcoxon signed-rank tests (+1.7, P < 0.01).","['elderly with MCI in Aki Orthopedics Rehabilitation Clinic in Japan', ""Alzheimer's disease model mice"", '27 participants enrolled', 'mild cognitive impairment (MCI', '27 participants were screened by their Mini Mental State Examination (MMSE) scores', 'Older Adults with Mild Cognitive Impairment']","['Bifidobacterium Breve A1 Supplementation', 'Bifidobacterium breve A1 (B. breve A1', 'placebo']","['cognitive function', 'cognitive function and maintaining quality of life of the elderly', 'Mental condition and quality of life for gastrointestinal symptoms', 'POMS2 and GSRS scores', 'Cognitive function', 'MMSE and Digit Symbol Substitution Test (DSST', 'MMSE scores', 'Cognitive Decline', 'Profile of Mood States 2nd Edition (POMS2), and the Gastrointestinal Symptom Rating Scale (GSRS']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0560005', 'cui_str': 'millicurie'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C3839785', 'cui_str': 'Rehabilitation clinic (environment)'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C2960235', 'cui_str': 'Mini-mental state examination score (observable entity)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0314975', 'cui_str': 'Bifidobacterium breve'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C0034380'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}, {'cui': 'C0582802', 'cui_str': 'Digit'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0234985', 'cui_str': 'Cognitive Decline'}, {'cui': 'C0451394', 'cui_str': 'Profile of mood states (assessment scale)'}, {'cui': 'C0205436', 'cui_str': 'Second - ordinal'}, {'cui': 'C0441792', 'cui_str': 'Editions (qualifier value)'}, {'cui': 'C0222045'}]",27.0,0.0401814,"MMSE scores were significantly increased during the intervention by mixed model Dunnett's test and Wilcoxon signed-rank tests (+1.7, P < 0.01).","[{'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Kobayashi', 'Affiliation': 'Yodai Kobayashi, Morinaga Milk Industry Co., Ltd., Next Generation Science Institute, 5-1-83 Higashihara, Zama, Kanagawa 252-8583, Japan, Tel: 81-46-252-3068; Fax: 81-46-252-3077, E-mail: youd-kobayashi@morinagamilk.co.jp.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Kinoshita', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Matsumoto', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Yoshino', 'Affiliation': ''}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Saito', 'Affiliation': ''}, {'ForeName': 'J-Z', 'Initials': 'JZ', 'LastName': 'Xiao', 'Affiliation': ''}]",The journal of prevention of Alzheimer's disease,['10.14283/jpad.2018.32'] 310,31929405,Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.,"BACKGROUND In the Promoting Maternal and Infant Survival Everywhere (PROMISE) trial, tenofovir disoproxil fumarate (TDF) use was associated with moderate or severe adverse pregnancy/neonatal outcomes. This study characterized tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) concentrations in dried blood spots (DBS) and assessed association between severe adverse pregnancy/neonatal outcomes and TFV-DP concentration. METHODS Retrospective case-control study of PROMISE trial arm-C women randomized to receive TDF, FTC, and ritonavir-boosted lopinavir (LPV/r), who took at least 1 dose of TDF + FTC and had week-4 postrandomization DBS drawn before delivery. Cases, defined as severe adverse pregnancy/neonatal outcomes (very preterm delivery before 34 weeks of gestation, stillbirth ≥20 weeks of gestation, or infant death before 14 days-of-age), were matched to controls (1:2 ratio) by site and gestational age at entry. Week 4 and week 8 DBS samples were assayed for TFV-DP and FTC-TP by liquid chromatography and tandem mass spectrometry. Associations were tested using Wilcoxon rank test and conditional logistic regression. RESULTS Of 447 PROMISE arm-C women, 33 met case definitions, and overall, 22 cases and 44 controls were analyzed. Median (interquartile range) concentrations of TFV-DP at weeks 4 and 8 were 706 (375-1023) fmol/punch and 806 (414-1265) fmol/punch, respectively. Odds ratio (95% confidence interval) for severe adverse pregnancy/neonatal outcome with natural log of TFV-DP concentrations as the predictor were 1.27 (0.74 to 2.18) and 1.74 (0.66 to 4.60) at weeks 4 and 8, respectively. Median (interquartile range) concentrations of FTC-TP at weeks 4 and 8 were 0.27 (0.05-0.36) pmol/punch and 0.29 (0.05-0.40) pmol/punch, respectively. CONCLUSIONS TFV-DP concentrations in DBS appeared not to be associated with severe adverse pregnancy/neonatal outcomes, although sample size was limited.",2020,"Median (interquartile range) concentrations of FTC-TP at weeks 4 and 8 were 0.27 (0.05-0.36) pmol/punch and 0.29 (0.05-0.40) pmol/punch, respectively. ",['and Severe Adverse Pregnancy Outcomes'],"['tenofovir disoproxil fumarate (TDF', 'TDF, FTC, and ritonavir-boosted lopinavir (LPV/r), who took at least 1 dose of TDF + FTC', 'Tenofovir Diphosphate and Emtricitabine Triphosphate', 'tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP', 'Tenofovir Diphosphate']","['Median (interquartile range) concentrations of FTC-TP', 'severe adverse pregnancy/neonatal outcomes (very preterm delivery before 34 weeks of gestation, stillbirth ≥20 weeks of gestation, or infant death', 'Odds ratio', 'severe adverse pregnancy/neonatal outcome with natural log of TFV-DP concentrations', 'Median (interquartile range) concentrations of TFV-DP']","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0032972', 'cui_str': 'Pregnancy Outcome'}]","[{'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0674432', 'cui_str': 'lopinavir'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C3712637', 'cui_str': 'tenofovir diphosphate'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}, {'cui': 'C0146894', 'cui_str': 'triphosphate'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0151526', 'cui_str': 'Premature Birth'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0549159', 'cui_str': 'Infant Death'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C0205296', 'cui_str': 'Natural (qualifier value)'}]",447.0,0.220524,"Median (interquartile range) concentrations of FTC-TP at weeks 4 and 8 were 0.27 (0.05-0.36) pmol/punch and 0.29 (0.05-0.40) pmol/punch, respectively. ","[{'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Aizire', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.'}, {'ForeName': 'Kristina M', 'Initials': 'KM', 'LastName': 'Brooks', 'Affiliation': 'Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Mirochnick', 'Affiliation': 'Division of Neonatology, School of Medicine, Boston University, Boston, MA.'}, {'ForeName': 'Patricia M', 'Initials': 'PM', 'LastName': 'Flynn', 'Affiliation': ""Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN.""}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Butler', 'Affiliation': 'Harvard T. H. Chan School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA.'}, {'ForeName': 'Jennifer J', 'Initials': 'JJ', 'LastName': 'Kiser', 'Affiliation': 'Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO.'}, {'ForeName': 'George K', 'Initials': 'GK', 'LastName': 'Siberry', 'Affiliation': 'Division of Prevention, Care & Treatment, Office of HIV/AIDS, United States Agency for International Development (USAID), Arlington, VA.'}, {'ForeName': 'Terry', 'Initials': 'T', 'LastName': 'Fenton', 'Affiliation': 'Harvard T. H. Chan School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA.'}, {'ForeName': 'Mae', 'Initials': 'M', 'LastName': 'Cababasay', 'Affiliation': 'Harvard T. H. Chan School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA.'}, {'ForeName': 'Mary G', 'Initials': 'MG', 'LastName': 'Fowler', 'Affiliation': 'Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of acquired immune deficiency syndromes (1999),['10.1097/QAI.0000000000002247'] 311,30851501,"Ultrasound-guided erector spinae plane block versus oblique subcostal transversus abdominis plane block for postoperative analgesia of adult patients undergoing laparoscopic cholecystectomy: Randomized, controlled trial.","STUDY OBJECTIVE Laparoscopic cholecystectomy (LC) is a frequently applied minimally invasive surgery. Intraoperative access is provided with small keyhole entries on the abdominal wall. However, LC causes moderate to severe postoperative pain. The subcostal approach of TAP block was described by Hebbard et al. for postoperative analgesia especially for upper abdominal surgeries. Ultrasound-guided erector spinae plane (US-ESP) block is a novel technique targeting ventral rami, dorsal rami and rami communicantes of the spinal nerves. DESIGN Single-blinded, prospective, randomized study. SETTING Tertiary university hospital, postoperative recovery room and surgical ward. PATIENTS Seventy-six patients (ASA I-II) were divided into two equal groups. After applying the exclusion criteria, 68 patients were included in final analysis (34 patients in ESP group and 34 in OSTAP group). INTERVENTIONS Erector spinae plane block was performed in the ESP group and oblique subcostal transversus abdominis block was performed in the OSTAP group. MEASUREMENTS Postoperative tramadol consumption and pain scores between groups were compared. In addition, intraoperative fentanyl need was measured. MAIN RESULTS Postoperative tramadol consumption was 139.1 ± 21.9 mg in the ESP group and 199.4 ± 27.7 mg in the OSTAP group (mean difference 60.29 mg, 95% confidence interval - 72.40 to - 48.19; p < 0.001). NRS scores at almost all time-points were lower in the ESP group according to the repeated measures analysis. Integration of AUC and Mann Whitney U test results have revealed that there was no time wise difference between ESP and OSTAP groups even though NRS scores by itself and time-wise linear area under curve scores were higher in the OSTAP group compare to ESP group. There were no differences in intraoperative fentanyl need. CONCLUSION Ultrasound-guided ESP block reduced postoperative tramadol consumption and pain scores more effectively than OSTAP block after laparoscopic cholecystectomy surgery.",2019,NRS scores at almost all time-points were lower in the ESP group according to the repeated measures analysis.,"['Tertiary university hospital, postoperative recovery room and surgical ward', '68 patients were included in final analysis (34 patients in ESP group and 34 in OSTAP group', 'adult patients undergoing laparoscopic cholecystectomy', 'Seventy-six patients (ASA I-II']","['Laparoscopic cholecystectomy (LC', 'OSTAP', 'Ultrasound-guided erector spinae plane (US-ESP) block', 'Ultrasound-guided ESP block', 'Ultrasound-guided erector spinae plane block versus oblique subcostal transversus abdominis plane block', 'ESP group and oblique subcostal transversus abdominis block', 'ESP']","['severe postoperative pain', 'NRS scores by itself and time-wise linear area under curve scores', 'Postoperative tramadol consumption and pain scores', 'postoperative tramadol consumption and pain scores', 'intraoperative fentanyl need', 'NRS scores']","[{'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0034871', 'cui_str': 'Hospital Recovery Rooms'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0015373', 'cui_str': 'Extrasensory Perception'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0162522', 'cui_str': 'Cholecystectomy, Celioscopic'}, {'cui': 'C4319622', 'cui_str': 'Seventy-six'}]","[{'cui': 'C0162522', 'cui_str': 'Cholecystectomy, Celioscopic'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0015373', 'cui_str': 'Extrasensory Perception'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0205315', 'cui_str': 'Oblique (qualifier value)'}, {'cui': 'C0442184', 'cui_str': 'Subcostal (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0040610', 'cui_str': 'Tramadol'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0027552', 'cui_str': 'Needs'}]",68.0,0.110432,NRS scores at almost all time-points were lower in the ESP group according to the repeated measures analysis.,"[{'ForeName': 'Başak', 'Initials': 'B', 'LastName': 'Altıparmak', 'Affiliation': 'Muğla Sıtkı Koçman University, Department of Anesthesiology and Reanimation, Muğla, Turkey. Electronic address: basak_ugurlu@yahoo.com.'}, {'ForeName': 'Melike', 'Initials': 'M', 'LastName': 'Korkmaz Toker', 'Affiliation': 'Muğla Sıtkı Koçman University Training and Research Hospital, Department of Anesthesiology and Reanimation, Muğla, Turkey.'}, {'ForeName': 'Ali Ihsan', 'Initials': 'AI', 'LastName': 'Uysal', 'Affiliation': 'Muğla Sıtkı Koçman University Training and Research Hospital, Department of Anesthesiology and Reanimation, Muğla, Turkey.'}, {'ForeName': 'Yağmur', 'Initials': 'Y', 'LastName': 'Kuşçu', 'Affiliation': 'Muğla Sıtkı Koçman University, Department of Anesthesiology and Reanimation, Muğla, Turkey.'}, {'ForeName': 'Semra', 'Initials': 'S', 'LastName': 'Gümüş Demirbilek', 'Affiliation': 'Muğla Sıtkı Koçman University, Department of Anesthesiology and Reanimation, Muğla, Turkey.'}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2019.03.012'] 312,31939785,"Family Care Rituals in the ICU to Reduce Symptoms of Post-Traumatic Stress Disorder in Family Members-A Multicenter, Multinational, Before-and-After Intervention Trial.","OBJECTIVES To assess the feasibility and efficacy of implementing ""Family Care Rituals"" as a means of engaging family members in the care of patients admitted to the ICU with a high risk of ICU mortality on outcomes including stress-related symptoms in family members. DESIGN Prospective, before-and-after intervention evaluation. SETTING Two U.S. academic medical ICU's, and one Italian academic medical/surgical ICU. SUBJECTS Family members of patients who had an attending predicted ICU mortality of greater than 30% within the first 24 hours of admission. INTERVENTIONS A novel intervention titled ""Family Care Rituals"" during which, following a baseline observation period, family members enrolled in the intervention phase were given an informational booklet outlining opportunities for engagement in care of the patient during their ICU stay. MEASUREMENTS AND MAIN RESULTS Primary outcome was symptoms of post-traumatic stress disorder in family members 90 days after patient death or ICU discharge. Secondary outcomes included symptoms of depression, anxiety, and family satisfaction. At 90-day follow-up, 131 of 226 family members (58.0%) responded preintervention and 129 of 226 family members (57.1%) responded postintervention. Symptoms of post-traumatic stress disorder were significantly higher preintervention than postintervention (39.2% vs 27.1%; unadjusted odds ratio, 0.58; p = 0.046). There was no significant difference in symptoms of depression (26.5% vs 25.2%; unadjusted odds ratio, 0.93; p = 0.818), anxiety (41.0% vs 45.5%; unadjusted odds ratio, 1.20; p = 0.234), or mean satisfaction scores (85.1 vs 89.0; unadjusted odds ratio, 3.85; p = 0.052) preintervention versus postintervention 90 days after patient death or ICU discharge. CONCLUSIONS Offering opportunities such as family care rituals for family members to be involved with providing care for family members in the ICU was associated with reduced symptoms of post-traumatic stress disorder. This intervention may lessen the burden of stress-related symptoms in family members of ICU patients.",2020,"Symptoms of post-traumatic stress disorder were significantly higher preintervention than postintervention (39.2% vs 27.1%; unadjusted odds ratio, 0.58; p = 0.046).","[""Two U.S. academic medical ICU's, and one Italian academic medical/surgical ICU.\nSUBJECTS"", 'Family Members', 'family members of ICU patients', 'engaging family members in the care of patients admitted to the ICU with a high risk of ICU mortality on outcomes including stress-related symptoms in family members']","['implementing ""Family Care Rituals']","['symptoms of depression, anxiety, and family satisfaction', 'symptoms of depression', 'mean satisfaction scores', 'symptoms of post-traumatic stress disorder in family members 90 days after patient death or ICU discharge', 'ICU mortality', 'Symptoms of post-traumatic stress disorder', 'anxiety']","[{'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0337810', 'cui_str': 'Italians (ethnic group)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0086282', 'cui_str': 'Person in the family'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C2945764', 'cui_str': 'Ritual (qualifier value)'}]","[{'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0086282', 'cui_str': 'Person in the family'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",,0.0360186,"Symptoms of post-traumatic stress disorder were significantly higher preintervention than postintervention (39.2% vs 27.1%; unadjusted odds ratio, 0.58; p = 0.046).","[{'ForeName': 'Timothy H', 'Initials': 'TH', 'LastName': 'Amass', 'Affiliation': 'Department of Medicine, Division of Pulmonary, Critical Care & Sleep, Brown University, Providence, RI.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Villa', 'Affiliation': 'Department of Anesthesia and Intensive Care, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'OMahony', 'Affiliation': 'Department of Internal Medicine, Palliative Medicine Section, Rush University Medical Center, Chicago, IL.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Badger', 'Affiliation': 'Department of Psychiatry, Brown University, Providence, RI.'}, {'ForeName': 'Rory', 'Initials': 'R', 'LastName': 'McFadden', 'Affiliation': 'Department of Internal Medicine, Palliative Medicine Section, Rush University Medical Center, Chicago, IL.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Walsh', 'Affiliation': 'Rhode Island Hospital, Research Division of Pulmonary, Critical Care & Sleep, Providence, RI.'}, {'ForeName': 'Tanis', 'Initials': 'T', 'LastName': 'Caine', 'Affiliation': 'Rhode Island Hospital, Research Division of Pulmonary, Critical Care & Sleep, Providence, RI.'}, {'ForeName': 'Don', 'Initials': 'D', 'LastName': 'McGuirl', 'Affiliation': 'Rhode Island Hospital, Research Division of Pulmonary, Critical Care & Sleep, Providence, RI.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Palmisciano', 'Affiliation': 'Rhode Island Hospital, Research Division of Pulmonary, Critical Care & Sleep, Providence, RI.'}, {'ForeName': 'Mei-Ean', 'Initials': 'ME', 'LastName': 'Yeow', 'Affiliation': 'Center for Palliative Care, Mayo Clinic, Rochester, NY.'}, {'ForeName': 'Raffaele', 'Initials': 'R', 'LastName': 'De Gaudio', 'Affiliation': 'Department of Anesthesia and Intensive Care, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.'}, {'ForeName': 'J Randall', 'Initials': 'JR', 'LastName': 'Curtis', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA.'}, {'ForeName': 'Mitchell M', 'Initials': 'MM', 'LastName': 'Levy', 'Affiliation': 'Department of Medicine, Division of Pulmonary, Critical Care & Sleep, Brown University, Providence, RI.'}]",Critical care medicine,['10.1097/CCM.0000000000004113'] 313,32278783,Re-evaluation of the Uplift Clinical Trial Using Age-Appropriate Spirometric Criteria.,"BACKGROUND The clinical trial of tiotropium in COPD, UPLIFT, enrolled adults with a mean age of 65 years and moderate-to-severe airflow obstruction, based on criteria from the Global Initiative for Chronic Obstructive Lung Disease (GOLD). For the UPLIFT cohort, however, GOLD-based criteria are not age-appropriate. RESEARCH QUESTION Will the use of more age-appropriate criteria for airflow obstruction from the Global Lung Function Initiative (GLI) modify the spirometric classification of the UPLIFT cohort and, in turn, the mortality effect of tiotropium in COPD? STUDY DESIGN AND METHODS Baseline spirometric classifications were first cross-tabulated by GLI- and GOLD-based criteria. Next, in GLI- and GOLD-based airflow obstruction, modified intention-to-treat analyses evaluated differences in time to death over 4 years, comparing tiotropium vs placebo. Because treatment response may differ by COPD severity, the mortality effect also was evaluated within stratum defined by GLI- and GOLD-based moderate and severe airflow obstruction. RESULTS Of 5,898 participants with GOLD-based airflow-obstruction, staged as moderate in 2,739 (46.4%) and severe in 3,156 (53.5%), GLI-based criteria established airflow obstruction in 5,750 (97.5%), staged as moderate in 795 (13.5%) and severe in 4,947 (83.9%). Relative to placebo, tiotropium yielded statistically nonsignificant adjusted hazard ratios (adjHRs) (95% CI) for death of 0.91 (0.80-1.04) and 0.91 (0.79-1.03) in GLI- and GOLD-based airflow obstruction, respectively. However, statistically significant effect modification was observed, but only in GLI-based moderate and severe airflow-obstruction, with tiotropium yielding adjHRs for death of 0.53 (0.34-0.81) and 0.99 (0.86-1.13), respectively. The P value for interaction was .007. INTERPRETATION Mortality reduction by tiotropium was only statistically significant in GLI-based moderate airflow-obstruction, a group that was underrepresented in UPLIFT because of severity misclassification by the original GOLD-based enrollment criteria.",2020,"Relative to placebo, tiotropium yielded statistically non-significant adjusted hazard ratios (adjHRs) (95% confidence interval) for death of 0.91 (0.80, 1.04) and 0.91 (0.79, 1.03) in GLI- and GOLD-based airflow-obstruction, respectively.","['and Methods', 'chronic obstructive pulmonary disease (COPD), i.e. UPLIFT, enrolled adults with a mean age of 65 years and moderate-to-severe airflow-obstruction, based on criteria from the Global Initiative for Chronic Obstructive Lung Disease (GOLD', '5898 participants with GOLD-based']","['placebo, tiotropium', 'tiotropium', 'tiotropium vs. placebo']","['GLI-based moderate and severe airflow-obstruction', 'GLI-based criteria established airflow-obstruction', 'hazard ratios (adjHRs', 'mortality effect', 'Mortality reduction', 'airflow-obstruction']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0231999', 'cui_str': 'Airflow'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0213771', 'cui_str': 'tiotropium'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0231999', 'cui_str': 'Airflow'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",5898.0,0.179374,"Relative to placebo, tiotropium yielded statistically non-significant adjusted hazard ratios (adjHRs) (95% confidence interval) for death of 0.91 (0.80, 1.04) and 0.91 (0.79, 1.03) in GLI- and GOLD-based airflow-obstruction, respectively.","[{'ForeName': 'Carlos A', 'Initials': 'CA', 'LastName': 'Vaz Fragoso', 'Affiliation': 'Veterans Affairs (VA) Connecticut Healthcare System, West Haven; Yale University School of Medicine, Department of Internal Medicine, New Haven, CT. Electronic address: carlos.fragoso@yale.edu.'}, {'ForeName': 'Linda S', 'Initials': 'LS', 'LastName': 'Leo-Summers', 'Affiliation': 'Yale University School of Medicine, Department of Internal Medicine, New Haven, CT.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Gill', 'Affiliation': 'Yale University School of Medicine, Department of Internal Medicine, New Haven, CT.'}, {'ForeName': 'Gail J', 'Initials': 'GJ', 'LastName': 'McAvay', 'Affiliation': 'Yale University School of Medicine, Department of Internal Medicine, New Haven, CT.'}]",Chest,['10.1016/j.chest.2020.02.070'] 314,31826241,Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.,"Patients with acute myeloid leukemia (AML) harboring FLT3 internal tandem duplications (ITDs) have poor outcomes, in particular AML with a high (≥0.5) mutant/wild-type allelic ratio (AR). The 2017 European LeukemiaNet (ELN) recommendations defined 4 distinct FLT3-ITD genotypes based on the ITD AR and the NPM1 mutational status. In this retrospective exploratory study, we investigated the prognostic and predictive impact of the NPM1/FLT3-ITD genotypes categorized according to the 2017 ELN risk groups in patients randomized within the RATIFY trial, which evaluated the addition of midostaurin to standard chemotherapy. The 4 NPM1/FLT3-ITD genotypes differed significantly with regard to clinical and concurrent genetic features. Complete ELN risk categorization could be done in 318 of 549 trial patients with FLT3-ITD AML. Significant factors for response after 1 or 2 induction cycles were ELN risk group and white blood cell (WBC) counts; treatment with midostaurin had no influence. Overall survival (OS) differed significantly among ELN risk groups, with estimated 5-year OS probabilities of 0.63, 0.43, and 0.33 for favorable-, intermediate-, and adverse-risk groups, respectively (P < .001). A multivariate Cox model for OS using allogeneic hematopoietic cell transplantation (HCT) in first complete remission as a time-dependent variable revealed treatment with midostaurin, allogeneic HCT, ELN favorable-risk group, and lower WBC counts as significant favorable factors. In this model, there was a consistent beneficial effect of midostaurin across ELN risk groups.",2020,"Overall survival (OS) differed significantly between ELN risk groups with estimated 5-year OS probabilities of 0.63, 0.43, and 0.33 for favorable-, intermediate- and adverse-risk groups, respectively (P<0.001).","['318 of 549 trial patients with FLT3-ITD AML', '2017 European LeukemiaNet (ELN) recommendations defined four distinct FLT3-ITD genotypes based on the ITD-AR and the NPM1 mutational status', 'Patients with AML harboring FLT3 internal tandem duplications (ITD', 'patients with acute myeloid leukemia']","['allogeneic hematopoietic-cell transplantation (HCT', 'NPM1/FLT3-ITD', 'midostaurin to standard chemotherapy']","['5-year OS probabilities', 'Overall survival (OS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0239307', 'cui_str': 'European (ethnic group)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C1285573', 'cui_str': 'Genotype determination'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0475311', 'cui_str': 'Harbor (environment)'}, {'cui': 'C0205102', 'cui_str': 'Internal (qualifier value)'}, {'cui': 'C0075804', 'cui_str': 'TANDEM'}, {'cui': 'C0332597', 'cui_str': 'Duplication (finding)'}, {'cui': 'C0023467', 'cui_str': 'Nonlymphoblastic Leukemia, Acute'}]","[{'cui': 'C0206153', 'cui_str': 'Cell Transplantation'}, {'cui': 'C0526371', 'cui_str': 'midostaurin'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",,0.0364359,"Overall survival (OS) differed significantly between ELN risk groups with estimated 5-year OS probabilities of 0.63, 0.43, and 0.33 for favorable-, intermediate- and adverse-risk groups, respectively (P<0.001).","[{'ForeName': 'Konstanze', 'Initials': 'K', 'LastName': 'Döhner', 'Affiliation': 'Department of Internal Medicine III, University of Ulm, Ulm, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Thiede', 'Affiliation': 'Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.'}, {'ForeName': 'Nikolaus', 'Initials': 'N', 'LastName': 'Jahn', 'Affiliation': 'Department of Internal Medicine III, University of Ulm, Ulm, Germany.'}, {'ForeName': 'Ekaterina', 'Initials': 'E', 'LastName': 'Panina', 'Affiliation': 'Department of Internal Medicine III, University of Ulm, Ulm, Germany.'}, {'ForeName': 'Agnes', 'Initials': 'A', 'LastName': 'Gambietz', 'Affiliation': 'Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Larson', 'Affiliation': 'Department of Medicine and Comprehensive Cancer Research Center, University of Chicago, Chicago, IL.'}, {'ForeName': 'Thomas W', 'Initials': 'TW', 'LastName': 'Prior', 'Affiliation': 'The Ohio State University Comprehensive Cancer Center, Columbus, OH.'}, {'ForeName': 'Guido', 'Initials': 'G', 'LastName': 'Marcucci', 'Affiliation': 'The Ohio State University Comprehensive Cancer Center, Columbus, OH.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Jones', 'Affiliation': 'The Ohio State University Comprehensive Cancer Center, Columbus, OH.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Krauter', 'Affiliation': 'Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Heuser', 'Affiliation': 'Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Maria Teresa', 'Initials': 'MT', 'LastName': 'Voso', 'Affiliation': 'Department of Biomedicine and Prevention, Università di Roma ""Tor Vergata,"" Rome, Italy.'}, {'ForeName': 'Tiziana', 'Initials': 'T', 'LastName': 'Ottone', 'Affiliation': 'Department of Biomedicine and Prevention, Università di Roma ""Tor Vergata,"" Rome, Italy.'}, {'ForeName': 'Josep F', 'Initials': 'JF', 'LastName': 'Nomdedeu', 'Affiliation': 'Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Santpau and Jose Carreras Leukemia Research Institutes, Autonomus University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Sumithra J', 'Initials': 'SJ', 'LastName': 'Mandrekar', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Rebecca B', 'Initials': 'RB', 'LastName': 'Klisovic', 'Affiliation': 'The Ohio State University Comprehensive Cancer Center, Columbus, OH.'}, {'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Wei', 'Affiliation': 'Department of Clinical Hematology, The Alfred Hospital and Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Sierra', 'Affiliation': 'Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Santpau and Jose Carreras Leukemia Research Institutes, Autonomus University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Miguel A', 'Initials': 'MA', 'LastName': 'Sanz', 'Affiliation': 'Instituto de Investigación Sanitaria La Fe, University of Valencia, Valencia, Spain.'}, {'ForeName': 'Joseph M', 'Initials': 'JM', 'LastName': 'Brandwein', 'Affiliation': 'Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada.'}, {'ForeName': 'Theo', 'Initials': 'T', 'LastName': 'de Witte', 'Affiliation': 'Radboud University Medical Centre, Nijmegen, The Netherlands.'}, {'ForeName': 'Joop H', 'Initials': 'JH', 'LastName': 'Jansen', 'Affiliation': 'Laboratory Hematology, Deptartment of Laboratory Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.'}, {'ForeName': 'Dietger', 'Initials': 'D', 'LastName': 'Niederwieser', 'Affiliation': 'Department of Hematology, Oncology, and Hemostasis, University of Leipzig, Leipzig, Germany.'}, {'ForeName': 'Frederick R', 'Initials': 'FR', 'LastName': 'Appelbaum', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'Bruno C', 'Initials': 'BC', 'LastName': 'Medeiros', 'Affiliation': 'Division of Hematology, Stanford Comprehensive Cancer Center, Stanford University, Stanford, CA.'}, {'ForeName': 'Martin S', 'Initials': 'MS', 'LastName': 'Tallman', 'Affiliation': 'Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Richard F', 'Initials': 'RF', 'LastName': 'Schlenk', 'Affiliation': 'Department of Internal Medicine III, University of Ulm, Ulm, Germany.'}, {'ForeName': 'Arnold', 'Initials': 'A', 'LastName': 'Ganser', 'Affiliation': 'Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Hubert', 'Initials': 'H', 'LastName': 'Serve', 'Affiliation': 'Department of Medicine, Hematology/Oncology, Goethe University, Frankfurt, Germany.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Ehninger', 'Affiliation': 'Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Amadori', 'Affiliation': 'Department of Biomedicine and Prevention, Università di Roma ""Tor Vergata,"" Rome, Italy.'}, {'ForeName': 'Insa', 'Initials': 'I', 'LastName': 'Gathmann', 'Affiliation': 'Novartis Pharmaceuticals, Basel, Switzerland; and.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Benner', 'Affiliation': 'Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Celine', 'Initials': 'C', 'LastName': 'Pallaud', 'Affiliation': 'Novartis Pharmaceuticals, Basel, Switzerland; and.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Stone', 'Affiliation': 'Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Döhner', 'Affiliation': 'Department of Internal Medicine III, University of Ulm, Ulm, Germany.'}, {'ForeName': 'Clara D', 'Initials': 'CD', 'LastName': 'Bloomfield', 'Affiliation': 'The Ohio State University Comprehensive Cancer Center, Columbus, OH.'}]",Blood,['10.1182/blood.2019002697'] 315,32272030,Dry Needling Combined With Guideline-Based Physical Therapy Provides No Added Benefit in the Management of Chronic Neck Pain: A Randomized Controlled Trial.,"OBJECTIVE To determine the added benefit of combining dry needling with a guideline-based physical therapy treatment program consisting of exercise and manual therapy on pain and disability in people with chronic neck pain. DESIGN Randomized controlled trial. METHODS Participants were randomized to receive either guideline-based physical therapy or guideline-based physical therapy plus dry needling. The primary outcomes, measured at 1 month post randomization, were average pain intensity in the previous 24 hours and previous week, measured with a numeric pain-rating scale (0-10), and disability, measured with the Neck Disability Index (0-100). The secondary outcomes were pain and disability measured at 3 and 6 months post randomization and global perceived effect, quality of sleep, pain catastrophizing, and self-efficacy measured at 1, 3, and 6 months post randomization. RESULTS One hundred sixteen participants were recruited. At 1 month post randomization, people who received guideline-based physical therapy plus dry needling had a small reduction in average pain intensity in the previous 24 hours (mean difference, 1.56 points; 95% confidence interval [CI]: 1.11, 2.36) and in the previous week (mean difference, 1.20 points; 95% CI: 1.02, 2.21). There was no effect of adding dry needling to guideline-based physical therapy on disability at 1 month post randomization (mean difference, -2.08 points; 95% CI: -3.01, 5.07). There was no effect for any of the secondary outcomes. CONCLUSION When combined with guideline-based physical therapy for neck pain, dry needling resulted in small improvements in pain only at 1 month post randomization. There was no effect on disability. J Orthop Sports Phys Ther 2020;50(8):447-454. Epub 9 Apr 2020. doi:10.2519/jospt.2020.9389 .",2020,There was no effect of adding dry needling to guideline-based physical therapy on disability at 1-month post-randomization (mean difference: -2.08 points; 95% CI -1.16 to 5.07).,"['Participants', 'people with chronic neck pain', '116 participants were recruited', 'Chronic Neck Pain']","['Guideline-Based Physical Therapy', 'guideline-based physical therapy', 'guideline-based physical therapy or guideline-based physical therapy plus dry needling', 'exercise and manual therapy', 'Combining Dry Needling', 'dry needling plus guideline-based physical therapy']","['numerical pain rating scale (0-10), and disability measured with the Neck Disability Index', 'pain and disability measured at 3 and 6 months, and global perceived effect, quality of sleep, pain catastrophizing, and self-efficacy', 'average pain intensity', 'disability', 'pain', 'pain and disability']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0746815', 'cui_str': 'Chronic neck pain'}, {'cui': 'C4517541', 'cui_str': '116'}]","[{'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0394648', 'cui_str': 'Dry needle acupuncture'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0454525', 'cui_str': 'Manual therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",116.0,0.188397,There was no effect of adding dry needling to guideline-based physical therapy on disability at 1-month post-randomization (mean difference: -2.08 points; 95% CI -1.16 to 5.07).,"[{'ForeName': 'Fábio Franciscatto', 'Initials': 'FF', 'LastName': 'Stieven', 'Affiliation': ''}, {'ForeName': 'Giovanni Esteves', 'Initials': 'GE', 'LastName': 'Ferreira', 'Affiliation': ''}, {'ForeName': 'Matheus', 'Initials': 'M', 'LastName': 'Wiebusch', 'Affiliation': ''}, {'ForeName': 'Francisco Xavier', 'Initials': 'FX', 'LastName': 'de Araújo', 'Affiliation': ''}, {'ForeName': 'Luis Henrique Telles', 'Initials': 'LHT', 'LastName': 'da Rosa', 'Affiliation': ''}, {'ForeName': 'Marcelo Faria', 'Initials': 'MF', 'LastName': 'Silva', 'Affiliation': ''}]",The Journal of orthopaedic and sports physical therapy,['10.2519/jospt.2020.9389'] 316,32149391,Periodontal soft- and hard-tissue changes after augmented corticotomy in Chinese adult patients with skeletal Angle Class III malocclusion: A non-randomized controlled trial.,"BACKGROUND To investigate soft- and hard-tissue changes after augmented corticotomy in Chinese adult patients with skeletal Angle Class III malocclusion. METHODS This non-randomized controlled trial included 357 anterior teeth from 30 Chinese adult patients with skeletal Angle Class III malocclusion for whom the proposed treatment was augmented corticotomy. Jaws receiving surgery were allocated to a test group (S, surgical group, n = 47) and jaws not receiving surgery were allocated to a control group (NS, non-surgical group, n = 13). Changes in the periodontal biotype, width of the keratinized gingiva (WKG), and labial and lingual horizontal bone thicknesses (BTs) were compared 6 months after surgery by univariate and multivariate analyses. RESULTS After adjustment for confounding variables, average gains of 0.473 mm in the WKG and 0.649 mm in the labial BT were found in the S group relative to the NS group (P <0.05). The odds of transition from a thin periodontal biotype to a thick biotype in the S group were about 230 times those in the NS group, and the odds of the reverse biotype transition in the NS group were about 83 times those in the S group (P <0.05). CONCLUSIONS Within the limitations of the present study, augmented corticotomy is a promising approach to improve insufficient periodontal soft and hard tissues in Chinese adult patients with skeletal Angle Class III malocclusion.",2020,"After adjustment for confounding variables, average gains of 0.473 mm in the WKG and 0.649 mm in the labial BT were found in the S group relative to the NS group (p < 0.05).","['Jaws receiving surgery were allocated to a test group (S group, n = 47) and jaws not receiving surgery', '357 anterior teeth from 30 Chinese adult patients with skeletal Angle class III malocclusion for whom the proposed treatment was augmented corticotomy', 'Chinese adult patients with skeletal Angle class III malocclusion']",[],"['Periodontal soft- and hard-tissue changes', 'periodontal biotype, width of the keratinized gingiva (WKG), and labial and lingual horizontal bone thicknesses (BTs', 'reverse biotype transition', 'odds of transition from a thin periodontal biotype to a thick biotype']","[{'cui': 'C0022359', 'cui_str': 'Jaw'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0399526', 'cui_str': 'Habsburg Jaw'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}]",[],"[{'cui': 'C0205358', 'cui_str': 'Soft (qualifier value)'}, {'cui': 'C0018599', 'cui_str': 'Hardness'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0449562', 'cui_str': 'Biotype (attribute)'}, {'cui': 'C0487742', 'cui_str': 'Width (qualifier value)'}, {'cui': 'C0017562', 'cui_str': 'Gums'}, {'cui': 'C0023759', 'cui_str': 'Lip'}, {'cui': 'C2349948', 'cui_str': 'Lingual (qualifier value)'}, {'cui': 'C0205126', 'cui_str': 'Horizontal (qualifier value)'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0332528', 'cui_str': 'Decreased thickness (finding)'}, {'cui': 'C1280412', 'cui_str': 'Thick (qualifier value)'}]",357.0,0.0437276,"After adjustment for confounding variables, average gains of 0.473 mm in the WKG and 0.649 mm in the labial BT were found in the S group relative to the NS group (p < 0.05).","[{'ForeName': 'Wu-di', 'Initials': 'WD', 'LastName': 'Jing', 'Affiliation': 'Department of Stomatology, Chinese Academy of Medical Science & Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Jiao', 'Affiliation': 'Department of Periodontology, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': 'Department of Periodontology, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, China.'}, {'ForeName': 'Jian-Xia', 'Initials': 'JX', 'LastName': 'Hou', 'Affiliation': 'Department of Periodontology, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, China.'}, {'ForeName': 'Xiao-Tong', 'Initials': 'XT', 'LastName': 'Li', 'Affiliation': 'Department of Orthodontics, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, China.'}, {'ForeName': 'Xiao-Xia', 'Initials': 'XX', 'LastName': 'Wang', 'Affiliation': 'Department of Maxillofacial Surgery, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': 'Department of Periodontology, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, China.'}, {'ForeName': 'Ming-Xin', 'Initials': 'MX', 'LastName': 'Mao', 'Affiliation': 'Department of Periodontology, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, China.'}]",Journal of periodontology,['10.1002/JPER.19-0522'] 317,32271690,Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy.,"PURPOSE We evaluated health related quality of life following robotic and open radical cystectomy as a treatment for bladder cancer. MATERIALS AND METHODS Using the Randomized Open versus Robotic Cystectomy (RAZOR) trial population we assessed health related quality of life by using the Functional Assessment of Cancer Therapy (FACT)-Vanderbilt Cystectomy Index and the Short Form 8 Health Survey (SF-8) at baseline, 3 and 6 months postoperatively. The primary objective was to assess the impact of surgical approach on health related quality of life. As an exploratory analysis we assessed the impact of urinary diversion type on health related quality of life. RESULTS Analyses were performed in subsets of the per-protocol population of 302 patients. There was no statistically significant difference between the mean scores by surgical approach at any time point for any FACT-Vanderbilt Cystectomy Index subscale or composite score (p >0.05). The emotional well-being score increased over time in both surgical arms. Patients in the open arm showed significantly better SF-8 sores in the physical and mental summary scores at 6 months compared to baseline (p <0.05). Continent diversion (versus noncontinent) was associated with worse FACT-bladder-cystectomy score at 3 (p <0.01) but not at 6 months, and the SF-8 physical component was better in continent-diversion patients at 6 months (p=0.019). CONCLUSIONS Our data suggests lack of significant differences in the health related quality of life in robotic and open cystectomies. As robotic procedures become more widespread it is important to discuss this finding during counseling.",2020,There was no statistically significant difference between the mean scores by surgical approach at any time point for any FACT-VCI subscale or composite score (p>0.05).,['Patients with Bladder Cancer'],"['Robot versus Open Radical Cystectomy', 'Robotic Cystectomy (RAZOR', 'robotic and open radical cystectomy']","['worse FACT-BL-cys score', 'SF-8 physical component', 'Continent diversion', 'SF-8 sores', 'FACT-VCI subscale or composite score', 'Health-Related Quality of Life', 'health-related quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005684', 'cui_str': 'Malignant tumor of urinary bladder'}]","[{'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0194401', 'cui_str': 'Complete cystectomy'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0010651', 'cui_str': 'Bladder excision'}]","[{'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0010654', 'cui_str': 'Cysteine'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0429956', 'cui_str': 'Bowels: fully continent'}, {'cui': 'C0185033', 'cui_str': 'Diversion procedure'}, {'cui': 'C0234233', 'cui_str': 'Soreness'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",302.0,0.140481,There was no statistically significant difference between the mean scores by surgical approach at any time point for any FACT-VCI subscale or composite score (p>0.05).,"[{'ForeName': 'Maria F', 'Initials': 'MF', 'LastName': 'Becerra', 'Affiliation': 'Department of Urology, University of Miami Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Vivek', 'Initials': 'V', 'LastName': 'Venkatramani', 'Affiliation': 'Department of Urology, University of Miami Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Isildinha M', 'Initials': 'IM', 'LastName': 'Reis', 'Affiliation': 'Division of Biostatistics, Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, Florida.'}, {'ForeName': 'Nachiketh', 'Initials': 'N', 'LastName': 'Soodana-Prakash', 'Affiliation': 'Department of Urology, University of Miami Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Sanoj', 'Initials': 'S', 'LastName': 'Punnen', 'Affiliation': 'Department of Urology, University of Miami Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Mark L', 'Initials': 'ML', 'LastName': 'Gonzalgo', 'Affiliation': 'Department of Urology, University of Miami Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Shyamal', 'Initials': 'S', 'LastName': 'Raolji', 'Affiliation': 'Department of Urology, University of Miami Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Erik P', 'Initials': 'EP', 'LastName': 'Castle', 'Affiliation': 'Department of Urology, Mayo Clinic, Phoenix, Arizona.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Woods', 'Affiliation': 'Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Svatek', 'Affiliation': 'Department of Urology, Division of Urologic Oncology, University of Texas Health Science Center at San Antonio, San Antonio, Texas.'}, {'ForeName': 'Alon Z', 'Initials': 'AZ', 'LastName': 'Weizer', 'Affiliation': 'Department of Urology, University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'Badrinath R', 'Initials': 'BR', 'LastName': 'Konety', 'Affiliation': 'Department of Urology, University of Minnesota, Minneapolis, Minnesota.'}, {'ForeName': 'Mathew', 'Initials': 'M', 'LastName': 'Tollefson', 'Affiliation': 'Department of Urology, Mayo Clinic, Phoenix, Arizona.'}, {'ForeName': 'Tracey L', 'Initials': 'TL', 'LastName': 'Krupski', 'Affiliation': 'Department of Urology, University of Virginia Health Science Center, Charlottesville, Virginia.'}, {'ForeName': 'Norm D', 'Initials': 'ND', 'LastName': 'Smith', 'Affiliation': 'Department of Urology, University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Shabsigh', 'Affiliation': 'Department of Urology, Ohio State University, Columbus, Ohio.'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Barocas', 'Affiliation': 'Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.'}, {'ForeName': 'Marcus L', 'Initials': 'ML', 'LastName': 'Quek', 'Affiliation': 'Department of Urology, Loyola University Medical Center, Maywood, Illinois.'}, {'ForeName': 'Atreya', 'Initials': 'A', 'LastName': 'Dash', 'Affiliation': 'Department of Urology, University of Washington, Seattle, Washington.'}, {'ForeName': 'Dipen J', 'Initials': 'DJ', 'LastName': 'Parekh', 'Affiliation': 'Department of Urology, University of Miami Miller School of Medicine, Miami, Florida.'}]",The Journal of urology,['10.1097/JU.0000000000001029'] 318,31340979,High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.,"BACKGROUND AND OBJECTIVES Different rituximab protocols are used to treat membranous nephropathy. We compared two rituximab protocols in patients with membranous nephropathy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Twenty-eight participants from the NICE cohort received two infusions of 1-g rituximab at 2-week intervals, whereas 27 participants from the Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Membranous Nephropathy (GEMRITUX) cohort received two infusions of 375 mg/m 2 at 1-week interval. We measured serum rituximab levels and compared remission at month 6 and before any treatment modification and analyzed factors associated with remission and relapses. RESULTS Remissions occurred in 18 (64%) versus eight (30%) from the NICE and GEMRITUX cohort ( P =0.02) at month 6, respectively, and in 24 (86%) versus 18 (67%) participants ( P =0.12) before treatment modification, respectively. Median time to remission was 3 [interquartile range (IQR), 3-9] and 9 [IQR, 6-12] months for NICE and GEMRITUX cohorts respectively ( P =0.01). Participants from the NICE cohort had higher circulating level of rituximab and lower CD19 counts (3.3 µg/L [IQR, 0.0-10.8] versus 0.0 [IQR, 0.0-0.0] P <0.001 and 0.0 [IQR, 0.0-2.0] versus 16.5 [IQR, 2.5-31.0] P <0.001) at month 3, lower level of anti-PLA2R1 antibodies at month 6 (0.0 [IQR, 0.0-8.0] versus 8.3 [IQR, 0.0-73.5] P =0.03). In the combined study population, lower epitope spreading at diagnosis and higher rituximab levels at month 3 were associated with remissions at month 6 (13/26 (50%) versus 22/29 (76%) P =0.05 and 2.2 µg/ml [IQR, 0.0-10.9] versus 0.0 µg/ml [IQR, 0.0-0.0] P <0.001 respectively). All non-spreaders entered into remission whatever the protocol. Eight of the 41 participants who reached remission had relapses. Epitope spreading at diagnosis (8/8 (100%) versus 16/33 (48%) P =0.01) and incomplete depletion of anti-PLA2R1 antibodies at month 6 (4/8 (50%) versus 5/33 (9%) P =0.05) were associated with relapses. CONCLUSIONS Our work suggests that higher dose rituximab protocol is more effective on depletion of B-cells and lack of epitope spreading is associated with remission of membranous nephropathy.",2019,"Epitope spreading at diagnosis (8/8 (100%) versus 16/33 (48%) P =0.01) and incomplete depletion of anti-PLA2R1 antibodies at month 6 (4/8 (50%) versus 5/33 (9%) P =0.05) were associated with relapses. ","['PLA2R1-Related Membranous Nephropathy', 'patients with membranous nephropathy', 'Twenty-eight participants from the NICE cohort received two infusions of 1-g']","['High-Dose Rituximab', 'Rituximab', 'rituximab']","['Median time to remission', 'level of anti-PLA2R1 antibodies', 'lower epitope spreading at diagnosis and higher rituximab levels', 'circulating level of rituximab and lower CD19 counts', 'incomplete depletion of anti-PLA2R1 antibodies', 'Remissions', 'serum rituximab levels']","[{'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0017665', 'cui_str': 'Membranous Glomerulonephropathy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0721912', 'cui_str': ""N'ICE""}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}]","[{'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0003316', 'cui_str': 'Antigenic Determinants'}, {'cui': 'C0332261', 'cui_str': 'Spread (attribute)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0205257', 'cui_str': 'Incomplete (qualifier value)'}, {'cui': 'C0333668', 'cui_str': 'Depletion (morphologic abnormality)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",28.0,0.046324,"Epitope spreading at diagnosis (8/8 (100%) versus 16/33 (48%) P =0.01) and incomplete depletion of anti-PLA2R1 antibodies at month 6 (4/8 (50%) versus 5/33 (9%) P =0.05) were associated with relapses. ","[{'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Seitz-Polski', 'Affiliation': ""Department of Immunology, Hôpital l'Archet, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France; seitz-polski.b@chu-nice.fr.""}, {'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Dahan', 'Affiliation': 'Department of Nephrology and Dialysis, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Debiec', 'Affiliation': 'Unité Mixte de Recherche_S 1155, Institut National de la Santé et de la Recherche Médicale, Paris, France.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Rousseau', 'Affiliation': 'Department of Clinical Pharmacology and Clinical Research, Hôpital Saint Antoine, AP-HP, Paris, France.'}, {'ForeName': 'Marine', 'Initials': 'M', 'LastName': 'Andreani', 'Affiliation': ""Department of Nephrology-Dialysis-Transplantation, Hôpital Pasteur, CHU de Nice, Université Côte d'Azur, Nice, France.""}, {'ForeName': 'Christelle', 'Initials': 'C', 'LastName': 'Zaghrini', 'Affiliation': ""Institut de Pharmacologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Université Côte d'Azur, Nice, France.""}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Ticchioni', 'Affiliation': ""Department of Immunology, Hôpital l'Archet, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.""}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Rosenthal', 'Affiliation': ""Department of Immunology, Hôpital l'Archet, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.""}, {'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'Benzaken', 'Affiliation': ""Department of Immunology, Hôpital l'Archet, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.""}, {'ForeName': 'Ghislaine', 'Initials': 'G', 'LastName': 'Bernard', 'Affiliation': ""Department of Immunology, Hôpital l'Archet, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.""}, {'ForeName': 'Gérard', 'Initials': 'G', 'LastName': 'Lambeau', 'Affiliation': ""Institut de Pharmacologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Université Côte d'Azur, Nice, France.""}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Ronco', 'Affiliation': 'Department of Nephrology and Dialysis, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Vincent L M', 'Initials': 'VLM', 'LastName': 'Esnault', 'Affiliation': ""Department of Nephrology-Dialysis-Transplantation, Hôpital Pasteur, CHU de Nice, Université Côte d'Azur, Nice, France.""}]",Clinical journal of the American Society of Nephrology : CJASN,['10.2215/CJN.11791018'] 319,31408088,Viewing Pictures Triggers Rapid Morphological Enlargement in the Human Visual Cortex.,"Measuring brain morphology with non-invasive structural magnetic resonance imaging is common practice, and can be used to investigate neuroplasticity. Brain morphology changes have been reported over the course of weeks, days, and hours in both animals and humans. If such short-term changes occur even faster, rapid morphological changes while being scanned could have important implications. In a randomized within-subject study on 47 healthy individuals, two high-resolution T1-weighted anatomical images were acquired (á 263 s) per individual. The images were acquired during passive viewing of pictures or a fixation cross. Two common pipelines for analyzing brain images were used: voxel-based morphometry on gray matter (GM) volume and surface-based cortical thickness. We found that the measures of both GM volume and cortical thickness showed increases in the visual cortex while viewing pictures relative to a fixation cross. The increase was distributed across the two hemispheres and significant at a corrected level. Thus, brain morphology enlargements were detected in less than 263 s. Neuroplasticity is a far more dynamic process than previously shown, suggesting that individuals' current mental state affects indices of brain morphology. This needs to be taken into account in future morphology studies and in everyday clinical practice.",2020,We found that the measures of both GM volume and cortical thickness showed increases in the visual cortex while viewing pictures relative to a fixation cross.,"['47 healthy individuals, two high-resolution T1-weighted anatomical images were acquired (á 263\xa0s) per individual']",[],"['brain morphology enlargements', 'GM volume and cortical thickness', 'visual cortex']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0220784', 'cui_str': 'Anatomic (qualifier value)'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0439661', 'cui_str': 'Acquired (qualifier value)'}, {'cui': 'C4517671', 'cui_str': '263'}]",[],"[{'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0543482', 'cui_str': 'morphology'}, {'cui': 'C1293134', 'cui_str': 'Enlargement procedure'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0042817', 'cui_str': 'Visual Cortex'}]",47.0,0.0541673,We found that the measures of both GM volume and cortical thickness showed increases in the visual cortex while viewing pictures relative to a fixation cross.,"[{'ForeName': 'Kristoffer N T', 'Initials': 'KNT', 'LastName': 'Månsson', 'Affiliation': 'Department of Psychology, Stockholm University, SE-10691 Stockholm, Sweden.'}, {'ForeName': 'Diana S', 'Initials': 'DS', 'LastName': 'Cortes', 'Affiliation': 'Department of Psychology, Stockholm University, SE-10691 Stockholm, Sweden.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Manzouri', 'Affiliation': 'Department of Psychology, Stockholm University, SE-10691 Stockholm, Sweden.'}, {'ForeName': 'Tie-Qiang', 'Initials': 'TQ', 'LastName': 'Li', 'Affiliation': 'Department of Clinical Science, Intervention and Technology, Division of Functional Imaging and Technology, Karolinska Institutet, SE-141 86 Stockholm, Sweden.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Hau', 'Affiliation': 'Department of Psychology, Stockholm University, SE-10691 Stockholm, Sweden.'}, {'ForeName': 'Håkan', 'Initials': 'H', 'LastName': 'Fischer', 'Affiliation': 'Department of Psychology, Stockholm University, SE-10691 Stockholm, Sweden.'}]","Cerebral cortex (New York, N.Y. : 1991)",['10.1093/cercor/bhz131'] 320,32268161,Conventional Follow-up Versus Mobile Application Home Monitoring for Postoperative Anterior Cruciate Ligament Reconstruction Patients: A Randomized Controlled Trial.,"PURPOSE To determine whether a mobile app can reduce the need for in-person visits and examine the resulting societal cost differences between mobile and conventional follow-up for postoperative anterior cruciate ligament (ACL) reconstruction patients. METHODS Study design was a single-center, 2-arm parallel group randomized controlled trial. All patients undergoing ACL reconstruction aged 16 to 70 years were screened for inclusion in the study. Competent use of a mobile device and ability to communicate in English was required. Patients were randomly assigned to receive follow-up via a mobile app or conventional appointments. Analysis was intention-to-treat. The primary outcome was the number of in-person visits to any health care professional during the first 6 postoperative weeks. Secondary outcomes included analysis of costs incurred by the health care system and personal patient costs related to both methods of follow-up. Patient-reported satisfaction and convenience scores, rates of complications, and clinical outcomes were also analyzed. RESULTS Sixty patients were analyzed. Participants in the app group attended a mean of 0.36 in-person visits versus 2.44 in-person visits in the conventional group (95% confidence interval 0.08-0.28; P < .0001). On average, patients in the app group spent $211 (Canadian dollars) less than the conventional group over 6 weeks (P < .0001) on personal costs related to follow-up. Health care system costs were also significantly less in the app group ($157.5 vs CAD $202.2; P < .0001). There was no difference between groups in patient satisfaction, convenience, complication rates, or clinical outcome measures. CONCLUSIONS Mobile follow-up can eliminate a significant number of in-person visits during the first 6 postoperative weeks in patients undergoing ACL reconstruction with cost savings to both the patient and health care system. This method should be considered for dissemination among similar orthopaedic procedures during early postoperative care. LEVEL OF EVIDENCE I: Prospective randomized controlled trial.",2020,Healthcare system costs were also significantly less in the app group (CAD $157.5 versus CAD $202.2; p<0.0001).,"['Sixty patients were analyzed', 'All patients undergoing ACL reconstruction aged 16-70 were screened for inclusion in the study', 'for Post-Operative ACL Reconstruction Patients']","['Conventional Follow-up Versus Mobile App Home Monitoring', 'follow-up via a mobile app or through conventional appointments']","['patient satisfaction, convenience, complication rates, or clinical outcome measures', 'analysis of costs incurred by the healthcare system and personal patient costs related to both methods of follow-up', 'Healthcare system costs', 'number of in-person visits to any healthcare professional', 'satisfaction and convenience scores, rates of complications, and clinical outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162596', 'cui_str': 'Cardiolipin antibody'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}]","[{'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0018696', 'cui_str': 'Healthcare Systems'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",60.0,0.258303,Healthcare system costs were also significantly less in the app group (CAD $157.5 versus CAD $202.2; p<0.0001).,"[{'ForeName': 'James', 'Initials': 'J', 'LastName': 'Higgins', 'Affiliation': 'University of Toronto Orthopaedic Sports Medicine, Toronto, Ontario, Canada; Division of Orthopaedic Surgery, University of Toronto, Toronto, Ontario, Canada. Electronic address: james.higgins@one-mail.on.ca.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Chang', 'Affiliation': 'Division of Orthopaedic Surgery, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Graeme', 'Initials': 'G', 'LastName': 'Hoit', 'Affiliation': 'Division of Orthopaedic Surgery, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Jas', 'Initials': 'J', 'LastName': 'Chahal', 'Affiliation': ""University of Toronto Orthopaedic Sports Medicine, Toronto, Ontario, Canada; Division of Orthopaedic Surgery, University of Toronto, Toronto, Ontario, Canada; Division of Orthopaedic Surgery, Toronto Western Hospital, Toronto, Ontario, Canada; Division of Orthopaedic Surgery, Women's College Hospital, Toronto, Ontario, Canada.""}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Dwyer', 'Affiliation': ""University of Toronto Orthopaedic Sports Medicine, Toronto, Ontario, Canada; Division of Orthopaedic Surgery, University of Toronto, Toronto, Ontario, Canada; Division of Orthopaedic Surgery, Women's College Hospital, Toronto, Ontario, Canada; Division of Orthopaedic Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Theodoropoulos', 'Affiliation': ""University of Toronto Orthopaedic Sports Medicine, Toronto, Ontario, Canada; Division of Orthopaedic Surgery, University of Toronto, Toronto, Ontario, Canada; Division of Orthopaedic Surgery, Women's College Hospital, Toronto, Ontario, Canada; Division of Orthopaedic Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada.""}]",Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association,['10.1016/j.arthro.2020.02.045'] 321,31288829,Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience (EMPOWER) among Surrogate Decision-Makers of ICU Patients: study protocol for a randomized controlled trial.,"BACKGROUND Critical illness increases the risk for poor mental health outcomes among both patients and their informal caregivers, especially their surrogate decision-makers. Surrogates who must make life-and-death medical decisions on behalf of incapacitated patients may experience additional distress. EMPOWER (Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience) is a novel cognitive-behavioral, acceptance-based intervention delivered in the intensive care unit (ICU) setting to surrogate decision-makers designed to improve both patients' quality of life and death and dying as well as surrogates' mental health. METHODS Clinician stakeholder and surrogate participant feedback (n = 15), as well as results from an open trial (n = 10), will be used to refine the intervention, which will then be evaluated through a multisite randomized controlled trial (RCT) (n = 60) to examine clinical superiority to usual care. Feasibility, tolerability, and acceptability of the intervention will be evaluated through self-report assessments. Hierarchical linear modeling will be used to adjust for clustering within interventionists to determine the effect of EMPOWER on surrogate differences in the primary outcome, peritraumatic stress. Secondary outcomes will include symptoms of post-traumatic stress disorder, prolonged grief disorder, and experiential avoidance. Exploratory outcomes will include symptoms of anxiety, depression, and decision regret, all measured at 1 and 3 months from post-intervention assessment. Linear regression models will examine the effects of assignment to EMPOWER versus the enhanced usual care group on patient quality of life or quality of death and intensity of care the patient received during the indexed ICU stay assessed at the time of the post-intervention assessment. Participant exit interviews will be conducted at the 3-month assessment time point and will be analyzed using qualitative thematic data analysis methods. DISCUSSION The EMPOWER study is unique in its application of evidence-based psychotherapy targeting peritraumatic stress to improve patient and caregiver outcomes in the setting of critical illness. The experimental intervention will be strengthened through the input of a variety of ICU stakeholders, including behavioral health clinicians, physicians, bereaved informal caregivers, and open trial participants. Results of the RCT will be submitted for publication in a peer-reviewed journal and serve as preliminary data for a larger, multisite RCT grant application. TRIAL REGISTRATION ClinicalTrials.gov, NCT03276559 . Retrospectively registered on 8 September 2017.",2019,"Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience) is a novel cognitive-behavioral, acceptance-based intervention delivered in the intensive care unit (ICU) setting to surrogate decision-makers designed to improve both patients' quality of life and death and dying as well as surrogates' mental health. ","['Clinician stakeholder and surrogate participant feedback (n\u2009=\u200915), as well as results from an open trial (n\u2009=\u200910']",['RCT'],"['symptoms of anxiety, depression, and decision regret', 'symptoms of post-traumatic stress disorder, prolonged grief disorder, and experiential avoidance', 'Feasibility, tolerability, and acceptability', 'patient quality of life or quality of death and intensity of care']","[{'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}]",[],"[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0080101', 'cui_str': 'Regret'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C4511668', 'cui_str': 'Prolonged grief disorder (finding)'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0034380'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}]",,0.101242,"Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience) is a novel cognitive-behavioral, acceptance-based intervention delivered in the intensive care unit (ICU) setting to surrogate decision-makers designed to improve both patients' quality of life and death and dying as well as surrogates' mental health. ","[{'ForeName': 'Holly G', 'Initials': 'HG', 'LastName': 'Prigerson', 'Affiliation': 'Center for Research on End-of-Life Care, Weill Cornell Medicine, New York, NY, USA. hgp2001@med.cornell.edu.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Viola', 'Affiliation': 'Center for Research on End-of-Life Care, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Chris R', 'Initials': 'CR', 'LastName': 'Brewin', 'Affiliation': 'Department of Clinical, Educational and Health Psychology, University College London, London, UK.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Cox', 'Affiliation': 'Department of Medicine, Division of Pulmonary & Critical Care Medicine, Duke University, Durham, NC, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Ouyang', 'Affiliation': 'Center for Research on End-of-Life Care, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Madeline', 'Initials': 'M', 'LastName': 'Rogers', 'Affiliation': 'Center for Research on End-of-Life Care, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Cynthia X', 'Initials': 'CX', 'LastName': 'Pan', 'Affiliation': 'NewYork-Presbyterian Queens, New York, NY, USA.'}, {'ForeName': 'Shayna', 'Initials': 'S', 'LastName': 'Rabin', 'Affiliation': 'Center for Research on End-of-Life Care, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Jiehui', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Center for Research on End-of-Life Care, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Vaughan', 'Affiliation': 'Department of Psychiatry, Columbia College of Physicians and Surgeons, New York, NY, USA.'}, {'ForeName': 'Janna S', 'Initials': 'JS', 'LastName': 'Gordon-Elliot', 'Affiliation': 'Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Berlin', 'Affiliation': 'Department of Medicine, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Lief', 'Affiliation': 'Department of Medicine, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Wendy G', 'Initials': 'WG', 'LastName': 'Lichtenthal', 'Affiliation': 'Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA.'}]",Trials,['10.1186/s13063-019-3515-0'] 322,32241260,"A factorial cluster-randomised controlled trial combining home-environmental and early child development interventions to improve child health and development: rationale, trial design and baseline findings.","BACKGROUND Exposure to unhealthy environments and inadequate child stimulation are main risk factors that affect children's health and wellbeing in low- and middle-income countries. Interventions that simultaneously address several risk factors at the household level have great potential to reduce these negative effects. We present the design and baseline findings of a cluster-randomised controlled trial to evaluate the impact of an integrated home-environmental intervention package and an early child development programme to improve diarrhoea, acute respiratory infections and childhood developmental outcomes in children under 36 months of age living in resource-limited rural Andean Peru. METHODS We collected baseline data on children's developmental performance, health status and demography as well as microbial contamination in drinking water. In a sub-sample of households, we measured indoor kitchen 24-h air concentration levels of carbon monoxide (CO) and fine particulate matter (PM 2.5 ) and CO for personal exposure. RESULTS We recruited and randomised 317 children from 40 community-clusters to four study arms. At baseline, all arms had similar health and demographic characteristics, and the developmental status of children was comparable between arms. The analysis revealed that more than 25% of mothers completed primary education, a large proportion of children were stunted and diarrhoea prevalence was above 18%. Fifty-two percent of drinking water samples tested positive for thermo-tolerant coliforms and the occurrence of E.coli was evenly distributed between arms. The mean levels of kitchen PM 2.5 and CO concentrations were 213 μg/m 3 and 4.8 ppm, respectively. CONCLUSIONS The trial arms are balanced with respect to most baseline characteristics, such as household air and water pollution, and child development. These results ensure the possible estimation of the trial effectiveness. This trial will yield valuable information for assessing synergic, rational and cost-effective benefits of the combination of home-based interventions. TRIAL REGISTRY ISRCTN-26548981.",2020,Fifty-two percent of drinking water samples tested positive for thermo-tolerant coliforms and the occurrence of E.coli was evenly distributed between arms.,"['children under 36\u2009months of age living in resource-limited rural Andean Peru', '317 children from 40 community-clusters to four study arms']","['home-environmental and early child development interventions', 'integrated home-environmental intervention package and an early child development programme']","['mean levels of kitchen PM 2.5 and CO concentrations', 'diarrhoea prevalence', 'diarrhoea, acute respiratory infections and childhood developmental outcomes', 'indoor kitchen 24-h air concentration levels of carbon monoxide (CO) and fine particulate matter (PM 2.5 ) and CO for personal exposure']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0031238', 'cui_str': 'Peru'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0008071', 'cui_str': 'Child Development'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0026118', 'cui_str': 'Environmental intervention'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0557653', 'cui_str': 'Kitchen'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0238990', 'cui_str': 'Acute lower respiratory tract infection'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0458003', 'cui_str': 'Developmental'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0205232', 'cui_str': 'Fine'}, {'cui': 'C1720884', 'cui_str': 'Particulate Matter'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}]",317.0,0.197468,Fifty-two percent of drinking water samples tested positive for thermo-tolerant coliforms and the occurrence of E.coli was evenly distributed between arms.,"[{'ForeName': 'Stella M', 'Initials': 'SM', 'LastName': 'Hartinger', 'Affiliation': 'Department of Epidemiology & Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland. stella.hartinger.p@upch.pe.'}, {'ForeName': 'Nestor', 'Initials': 'N', 'LastName': 'Nuño', 'Affiliation': 'Department of Epidemiology & Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Hattendorf', 'Affiliation': 'Department of Epidemiology & Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland.'}, {'ForeName': 'Hector', 'Initials': 'H', 'LastName': 'Verastegui', 'Affiliation': 'School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima, Peru.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Karlen', 'Affiliation': 'Department of Health Sciences and Technology, ETH Zürich, Zürich, Switzerland.'}, {'ForeName': 'Mariela', 'Initials': 'M', 'LastName': 'Ortiz', 'Affiliation': 'Programa Nacional CUNA MAS, Lima, Peru.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Mäusezahl', 'Affiliation': 'Department of Epidemiology & Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland.'}]",BMC medical research methodology,['10.1186/s12874-020-00950-y'] 323,31674641,Bone Mineral Density Response With Denosumab in Combination With Standard or High-Dose Teriparatide: The DATA-HD RCT.,"CONTEXT In the Denosumab and High-Dose Teriparatide Administration (DATA-HD) study, we reported that 15 months of combined high-dose (HD) teriparatide and denosumab increased mean areal bone mineral density (aBMD) at the hip and spine more than combined denosumab and standard-dose (SD) teriparatide. OBJECTIVE In the current analysis, we compare the individual rates of aBMD response between the treatment groups. DESIGN Single-site, open-label, randomized controlled trial in which postmenopausal women received either teriparatide 20-μg daily (SD) or 40-μg daily (HD) given months 0 through 9, overlapped with denosumab 60 mg, given months 3 through 15 (15 months' total duration). The proportion of participants in the SD and HD groups experiencing total hip, femoral neck, and lumbar spine aBMD gains of >3%, >6%, and >9% were compared. PARTICIPANTS Postmenopausal women with osteoporosis completing all study visits (n = 60). MAIN OUTCOME MEASURE(S) aBMD (dual x-ray absorptiometry). RESULTS At the end of the 15-month treatment period, a higher proportion of women in the HD group had aBMD increases >3% (83% vs. 58%, P = .037) and >6% (45% vs. 19%, P = .034) at the total hip, and >3% at the femoral neck (86% vs. 63%, P = .044). At the lumbar spine, >3% response rates were similar, whereas the >6% and >9% response rates were greater in the HD group (100% vs. 79%, P = .012 and 93% vs. 59%, P = .003, respectively). CONCLUSION Compared with the SD regimen, more women treated with the HD regimen achieved clinically meaningful and rapid gains in hip and spine aBMD. These results suggest that this approach may provide unique benefits in the treatment of postmenopausal osteoporosis.",2020,"Compared with the SD regimen, more women treated with the HD regimen achieved clinically meaningful and rapid gains in hip and spine aBMD.","['postmenopausal women', 'Postmenopausal women with osteoporosis completing all study visits (n = 60']","['combined high-dose (HD) teriparatide and denosumab', 'teriparatide 20-μg daily (SD) or 40-μg daily (HD) given months 0-9, overlapped with denosumab 60-mg', 'denosumab in combination with\xa0standard or high-dose teriparatide']","['mean areal bone mineral density (aBMD', 'BMD', 'clinically meaningful and rapid gains in hip and spine aBMD', 'femoral neck', 'total hip, femoral neck, and lumbar spine aBMD gains', 'response rates', 'aBMD (dual x-ray absorptiometry', 'aBMD response', 'Bone mineral density response']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0070093', 'cui_str': 'Teriparatide'}, {'cui': 'C1690432', 'cui_str': 'denosumab'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0185027', 'cui_str': 'Imbrication (procedure)'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0037949', 'cui_str': 'Spinal Column'}, {'cui': 'C0015815', 'cui_str': 'Femoral Neck'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C3887615', 'cui_str': 'Lumbar spine structure (body structure)'}, {'cui': 'C1510486', 'cui_str': 'Dual X-Ray Absorptiometry'}]",,0.0653879,"Compared with the SD regimen, more women treated with the HD regimen achieved clinically meaningful and rapid gains in hip and spine aBMD.","[{'ForeName': 'Sabashini K', 'Initials': 'SK', 'LastName': 'Ramchand', 'Affiliation': 'Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA.'}, {'ForeName': 'Natalie L', 'Initials': 'NL', 'LastName': 'David', 'Affiliation': 'Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA.'}, {'ForeName': 'Benjamin Z', 'Initials': 'BZ', 'LastName': 'Leder', 'Affiliation': 'Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA.'}, {'ForeName': 'Joy N', 'Initials': 'JN', 'LastName': 'Tsai', 'Affiliation': 'Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgz163'] 324,32050782,"Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment.","OBJECTIVE To report efficacy and safety of galcanezumab in adults with chronic cluster headache. BACKGROUND Galcanezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide and inhibits its biological activity. METHODS This study comprised a prospective baseline period, a 12-week double-blind, placebo-controlled treatment period, and a 52-week open-label period. Up to six protocol-specified concomitant preventive medications were allowed if patients were on a stable dose for 2 months prior to the prospective baseline period. Patients were randomized 1:1 to monthly subcutaneous galcanezumab (300 mg) or placebo. The primary endpoint was overall mean change from baseline in weekly attack frequency with galcanezumab compared to placebo. Key secondary endpoints were ≥50% response rate and percentage of patients meeting sustained response. Results from the double-blind treatment period are reported. RESULTS A total of 237 patients were randomized and treated (120 placebo; 117 galcanezumab). At baseline, the mean age was 45 years and 63% were using ≥1 preventive drug. The primary endpoint was not met; mean change in weekly attack frequency was -4.6 placebo versus -5.4 galcanezumab ( p  = 0.334). Key secondary endpoints also were not met. Injection site-related treatment-emergent adverse events were more common in the galcanezumab than the placebo group, with significantly more injection site erythema. CONCLUSION Treatment with galcanezumab 300 mg did not achieve its primary and key secondary endpoints. This study underscores the potential distinct biology of cCH as well as the significant unmet need for safe, effective, and well-tolerated preventive treatment. The safety profile of galcanezumab in cCH is consistent with that observed in trials of episodic CH and migraine. TRIAL REGISTRATION NCT02438826; https://www.clinicaltrials.gov/ct2/show/NCT02438826.",2020,"Injection site-related treatment-emergent adverse events were more common in the galcanezumab than the placebo group, with significantly more injection site erythema. ","['237 patients were randomized and treated (120', 'adults with chronic cluster headache', 'patients with chronic cluster headache']","['subcutaneous galcanezumab', 'placebo', 'placebo; 117 galcanezumab', 'galcanezumab']","['overall mean change from baseline in weekly attack frequency', 'not met; mean change in weekly attack frequency', 'response rate and percentage of patients meeting sustained response']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0009088', 'cui_str': 'Neuralgic Migraine'}]","[{'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C1304680', 'cui_str': 'Attack (finding)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0443318', 'cui_str': 'Sustained (qualifier value)'}]",237.0,0.567527,"Injection site-related treatment-emergent adverse events were more common in the galcanezumab than the placebo group, with significantly more injection site erythema. ","[{'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Dodick', 'Affiliation': 'Department of Neurology, Mayo Clinic, Phoenix, AZ, USA.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Goadsby', 'Affiliation': ""NIHR-Wellcome Trust King's Clinical Research Facility, King's College London, London, UK.""}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Lucas', 'Affiliation': 'Pain Clinic, Department of Neurosurgery, Hôpital Salengro, CHU de Lille, Lille, France.'}, {'ForeName': 'Rigmor', 'Initials': 'R', 'LastName': 'Jensen', 'Affiliation': 'Danish Headache Center, Rigshospitalet-Glostrup, Glostrup, Denmark.'}, {'ForeName': 'Jennifer N', 'Initials': 'JN', 'LastName': 'Bardos', 'Affiliation': 'Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Martinez', 'Affiliation': 'Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.'}, {'ForeName': 'Chunmei', 'Initials': 'C', 'LastName': 'Zhou', 'Affiliation': 'Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.'}, {'ForeName': 'Sheena K', 'Initials': 'SK', 'LastName': 'Aurora', 'Affiliation': 'Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.'}, {'ForeName': 'Jyun Yan', 'Initials': 'JY', 'LastName': 'Yang', 'Affiliation': 'Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.'}, {'ForeName': 'Robert R', 'Initials': 'RR', 'LastName': 'Conley', 'Affiliation': 'Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Oakes', 'Affiliation': 'Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.'}]",Cephalalgia : an international journal of headache,['10.1177/0333102420905321'] 325,31279675,Aerobic Plus Resistance Exercise in Obese Older Adults Improves Muscle Protein Synthesis and Preserves Myocellular Quality Despite Weight Loss.,"Anabolic resistance and impaired myocellular quality contribute to age-related sarcopenia, which exacerbates with obesity. Diet-induced muscle mass loss is attenuated by resistance or aerobic plus resistance exercise compared to aerobic exercise in obese elderly. We assessed chronic effects of weight loss plus different exercise modalities on muscle protein synthesis response to feeding and myocellular quality. Obese older adults were randomized to a weight-management program plus aerobic, resistance, or combined aerobic and resistance exercise or to control. Participants underwent vastus lateralis biopsies at baseline and 6 months. Muscle protein synthesis rate increased more in resistance and combined than in control. Autophagy mediators' expression decreased more in combined than in aerobic, which experienced a higher increase in inflammation and mitochondrial regulators' expression. In obese elderly, combined aerobic and resistance exercise is superior to either mode independently for improving muscle protein synthesis and myocellular quality, thereby maintaining muscle mass during weight-loss therapy.",2019,"In obese elderly, combined aerobic and resistance exercise is superior to either mode independently for improving muscle protein synthesis and myocellular quality, thereby maintaining muscle mass during weight-loss therapy.","['Obese older adults', 'obese elderly', 'Obese Older Adults']","['Aerobic Plus Resistance Exercise', 'weight loss plus different exercise modalities', 'weight-management program plus aerobic, resistance, or combined aerobic and resistance exercise or to control', 'aerobic exercise', 'aerobic plus resistance exercise']","[""inflammation and mitochondrial regulators' expression"", 'Muscle protein synthesis rate', 'Muscle Protein Synthesis and Preserves Myocellular Quality', ""Autophagy mediators' expression"", 'Anabolic resistance']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C4273558', 'cui_str': 'Weight management program'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}]","[{'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0026832', 'cui_str': 'Muscle Proteins'}, {'cui': 'C0728887', 'cui_str': 'Preserving (attribute)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0004391', 'cui_str': 'Cellular Autophagies'}]",,0.0167948,"In obese elderly, combined aerobic and resistance exercise is superior to either mode independently for improving muscle protein synthesis and myocellular quality, thereby maintaining muscle mass during weight-loss therapy.","[{'ForeName': 'Georgia', 'Initials': 'G', 'LastName': 'Colleluori', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA; Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA.'}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Aguirre', 'Affiliation': 'Medical Care Line, New Mexico VA Health Care System and Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87108 USA.'}, {'ForeName': 'Uma', 'Initials': 'U', 'LastName': 'Phadnis', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA; Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Fowler', 'Affiliation': 'Medical Care Line, New Mexico VA Health Care System and Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87108 USA.'}, {'ForeName': 'Reina', 'Initials': 'R', 'LastName': 'Armamento-Villareal', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA; Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA.'}, {'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Sun', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Brunetti', 'Affiliation': 'Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Hyoung Park', 'Affiliation': 'Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.'}, {'ForeName': 'Benny Abraham', 'Initials': 'BA', 'LastName': 'Kaipparettu', 'Affiliation': 'Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.'}, {'ForeName': 'Nagireddy', 'Initials': 'N', 'LastName': 'Putluri', 'Affiliation': 'Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA; Advanced Technology Core, Baylor College of Medicine, Houston, TX 77030, USA.'}, {'ForeName': 'Vimlin', 'Initials': 'V', 'LastName': 'Auetumrongsawat', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA; Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Yarasheski', 'Affiliation': 'Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, Washington University School of Medicine, St. Louis, MO 63110, USA.'}, {'ForeName': 'Clifford', 'Initials': 'C', 'LastName': 'Qualls', 'Affiliation': 'Department of Mathematics and Statistics and School of Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87108 USA.'}, {'ForeName': 'Dennis T', 'Initials': 'DT', 'LastName': 'Villareal', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA; Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA. Electronic address: dennis.villareal@bcm.edu.'}]",Cell metabolism,['10.1016/j.cmet.2019.06.008'] 326,32271243,Clinical outcomes three-year after revascularization with biodegradable polymer stents: ultrathin-strut sirolimus-eluting stent versus biolimus-eluting stent: from the Scandinavian organization for randomized trials with clinical outcome VII trial.,"BACKGROUND Drug-eluting stents with biodegradable polymers have been designed to improve safety and efficacy. However, drug-eluting stents with biodegradable polymers may not be a class effect, as stent strut thickness, polymer coating, and drug resorption differ between these groups of stents. Twelve months results of Scandinavian Organization for Randomized Trials With Clinical Outcome VII showed that ultrathin-strut sirolimus-eluting Orsiro stent was noninferior to the biolimus-eluting Nobori stent. The sirolimus-eluting Orsiro stent was associated with a reduced risk of definite stent thrombosis. METHODS The Scandinavian Organization for Randomized Trials With Clinical Outcome VII trial is a prospective multicenter randomized clinical trial comparing sirolimus-eluting Orsiro stent and biolimus-eluting Nobori stent in all-comers patients. The endpoint target lesion failure was a composite of cardiac death, myocardial infarction (not related to other than index lesion) and target lesion revascularization. RESULTS A total of 1261 patients were randomized to treatment with sirolimus-eluting Orsiro stent and 1264 patients to biolimus-eluting Nobori stent and followed for 3 years. At 3-year the target lesion failure was comparable for sirolimus-eluting Orsiro stent (9.0%) and the biolimus-eluting Nobori stent (9.1%), (rate ratio, 0.99; 95% confidence interval, 0.77-1.29). Cardiac death (sirolimus-eluting Orsiro stent 3.0% vs. biolimus-eluting Nobori stent 2.6% [rate ratio, 1.16; 95% confidence interval, 0.73-1.86]), target lesion revascularization (sirolimus-eluting Orsiro stent 5.2% vs. biolimus-eluting Nobori stent 5.9% [rate ratio, 0.90; 95% confidence interval, 0.64-1.25]), myocardial infarction (sirolimus-eluting Orsiro stent 4.7% vs. biolimus-eluting Nobori stent 4.5% [rate ratio, 1.04; 95% confidence interval, 0.72-1.50]), and definite stent thrombosis (sirolimus-eluting Orsiro stent 1.0% vs. biolimus-eluting Nobori stent 1.7% [rate ratio, 0.59; 95% confidence interval, 0.30-1.18]) did not differ significantly between the two groups. CONCLUSION At 3-year follow-up, target lesion failure did not differ among ultrathin-strut sirolimus-eluting Orsiro stent and biolimus-eluting Nobori stent with biodegradable polymers.",2020,"The endpoint target lesion failure was a composite of cardiac death, myocardial infarction (not related to other than index lesion) and target lesion revascularization. ","['1261 patients', 'all-comers patients']","['biodegradable polymer stents: ultrathin-strut sirolimus-eluting stent versus biolimus-eluting stent', 'ultrathin-strut sirolimus-eluting Orsiro stent', 'sirolimus-eluting Orsiro stent and 1264 patients to biolimus-eluting Nobori stent', 'sirolimus-eluting Orsiro stent and biolimus-eluting Nobori stent']","['safety and efficacy', 'composite of cardiac death, myocardial infarction (not related to other than index lesion) and target lesion revascularization', 'myocardial infarction', 'Cardiac death', 'definite stent thrombosis', 'target lesion revascularization', 'target lesion failure']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0032521', 'cui_str': 'Polymer'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0441295', 'cui_str': 'Strut'}, {'cui': 'C0072980', 'cui_str': 'Sirolimus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0376297', 'cui_str': 'Cardiac death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0014742', 'cui_str': 'Erythema multiforme'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0439544', 'cui_str': 'Definite'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0231174', 'cui_str': 'Failure'}]",1261.0,0.160871,"The endpoint target lesion failure was a composite of cardiac death, myocardial infarction (not related to other than index lesion) and target lesion revascularization. ","[{'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Ellert', 'Affiliation': 'Department of Cardiology, Odense University Hospital, Odense.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Maeng', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Skejby Hospital, Aarhus.'}, {'ForeName': 'Bent', 'Initials': 'B', 'LastName': 'Raungaard', 'Affiliation': 'Department of Cardiology, Aalborg University Hospital, Aalborg.'}, {'ForeName': 'Knud Nørregaard', 'Initials': 'KN', 'LastName': 'Hansen', 'Affiliation': 'Department of Cardiology, Odense University Hospital, Odense.'}, {'ForeName': 'Johnny', 'Initials': 'J', 'LastName': 'Kahlert', 'Affiliation': 'Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Svend Eggert', 'Initials': 'SE', 'LastName': 'Jensen', 'Affiliation': 'Department of Cardiology, Aalborg University Hospital, Aalborg.'}, {'ForeName': 'Hans Erik', 'Initials': 'HE', 'LastName': 'Bøtker', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Skejby Hospital, Aarhus.'}, {'ForeName': 'Henrik Steen', 'Initials': 'HS', 'LastName': 'Hansen', 'Affiliation': 'Department of Cardiology, Odense University Hospital, Odense.'}, {'ForeName': 'Jens Flensted', 'Initials': 'JF', 'LastName': 'Lassen', 'Affiliation': 'Department of Cardiology, Odense University Hospital, Odense.'}, {'ForeName': 'Evald Høj', 'Initials': 'EH', 'LastName': 'Christiansen', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Skejby Hospital, Aarhus.'}, {'ForeName': 'Lisette Okkels', 'Initials': 'LO', 'LastName': 'Jensen', 'Affiliation': 'Department of Cardiology, Odense University Hospital, Odense.'}]",Coronary artery disease,['10.1097/MCA.0000000000000875'] 327,32270496,Noninterventional follow-up vs fluid bolus in RESPONSE to oliguria-The RESPONSE trial protocol and statistical analysis plan.,"BACKGROUND Oliguria is a frequent trigger for administering a fluid bolus, but the effect of fluid bolus in improving urine output is inadequately demonstrated. Here, we summarize the protocol and detailed statistical analysis plan of the randomized, controlled RESPONSE trial comparing follow-up as the experimental group and a 500 mL crystalloid fluid bolus as the control group for oliguria in critically ill oliguric patients. METHODS Our trial is an investigator-initiated, randomized, controlled, pilot trial conducted in three ICUs in two centers. We aim to randomize 1:1 altogether 130 hemodynamically stable oliguric patients either to a 2-hour follow-up without interventions or to receive a crystalloid bolus of 500 mL over 30 minutes. The primary outcome is the change in individual urine output during the 2-hour period compared to 2 hours preceding randomization. Doubling of the urine output is considered clinically significant. Additionally, we record the duration of oliguria, physiological and biochemical variables, adverse events, and the incidences of acute kidney injury and renal replacement therapy. CONCLUSIONS Oliguria is a frequent trigger for potentially harmful fluid loading. Therefore, the RESPONSE trial will give information of the potential effect of fluid bolus on oliguria in critically ill patients. TRIAL REGISTRATION clinical.trials.gov, NCT02860572.",2020,130 hemodynamically stable oliguric patients either to a 2-hour follow-up without interventions or to receive a crystalloid bolus of 500 mL over 30 minutes.,"['130 hemodynamically stable oliguric patients', 'critically ill patients', 'critically ill oliguric patients']",[],"['change in individual urine output', 'duration of oliguria, physiological and biochemical variables, adverse events, and the incidences of acute kidney injury and renal replacement therapy']","[{'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0578150', 'cui_str': 'Hemodynamically stable'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}]",[],"[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0028961', 'cui_str': 'Oliguria'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0206074', 'cui_str': 'Renal replacement therapy'}]",130.0,0.334481,130 hemodynamically stable oliguric patients either to a 2-hour follow-up without interventions or to receive a crystalloid bolus of 500 mL over 30 minutes.,"[{'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Inkinen', 'Affiliation': 'Department of Anesthesia and Intensive Care, Central Finland Central Hospital, Central Finland Health Care District, Jyväskylä, Finland.'}, {'ForeName': 'Tuomas', 'Initials': 'T', 'LastName': 'Selander', 'Affiliation': 'Science Service Center, Kuopio University Hospital, Kuopio, Finland.'}, {'ForeName': 'Ville', 'Initials': 'V', 'LastName': 'Pettilä', 'Affiliation': 'Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Miia', 'Initials': 'M', 'LastName': 'Valkonen', 'Affiliation': 'Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Minna', 'Initials': 'M', 'LastName': 'Bäcklund', 'Affiliation': 'Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Wennervirta', 'Affiliation': 'Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Anni', 'Initials': 'A', 'LastName': 'Pulkkinen', 'Affiliation': 'Department of Anesthesia and Intensive Care, Central Finland Central Hospital, Central Finland Health Care District, Jyväskylä, Finland.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Hästbacka', 'Affiliation': 'Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Suvi T', 'Initials': 'ST', 'LastName': 'Vaara', 'Affiliation': 'Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13599'] 328,31248950,"Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.","BACKGROUND AND OBJECTIVES The progression of kidney disease in some patients with type 2 diabetes mellitus may not be adequately suppressed by renin-angiotensin system inhibitors. Esaxerenone (CS-3150) is a nonsteroidal mineralocorticoid receptor blocker that has shown kidney protective effects in preclinical studies, and it is a potential add-on therapy to treat diabetic kidney disease. This phase 2 study evaluated the efficacy and safety of esaxerenone in Japanese patients with type 2 diabetes mellitus and microalbuminuria. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS This multicenter, randomized, double-blind, placebo-controlled trial enrolled 365 hypertensive or normotensive patients with type 2 diabetes mellitus and microalbuminuria (urinary albumin-to-creatinine ratio ≥45 to <300 mg/g creatinine) treated with renin-angiotensin system inhibitor who had eGFR≥30 ml/min per 1.73 m 2 . Participants were randomized to receive 0.625, 1.25, 2.5, or 5 mg/d esaxerenone or placebo for 12 weeks. The primary end point was the change in urinary albumin-to-creatinine ratio from baseline to week 12 (with last observation carried forward). RESULTS Esaxerenone treatment at 1.25, 2.5, and 5 mg/d significantly reduced urinary albumin-to-creatinine ratio by the end of treatment (38%, 50%, and 56%, respectively) compared with placebo (7%; all P <0.001). The urinary albumin-to-creatinine ratio remission rate (defined as urinary albumin-to-creatinine ratio <30 mg/g creatinine at the end of treatment and ≥30% decrease from baseline) was 21% in the 2.5- and 5-mg/d groups versus 3% for placebo (both P <0.05). Adverse events occurred slightly more frequently with esaxerenone versus placebo, but the frequencies of drug-related adverse events and discontinuation rates were similar in the placebo and the 0.625-, 1.25-, and 2.5-mg/d groups. Drug-related adverse events and treatment discontinuations were marginally higher in the 5-mg/d group. The most common drug-related adverse event was hyperkalemia, which was dose proportional. CONCLUSIONS Adding esaxerenone at 1.25, 2.5, and 5 mg/d for 12 weeks to an ongoing renin-angiotensin system inhibitor significantly reduces urinary albumin-to-creatinine ratio in patients with type 2 diabetes mellitus and microalbuminuria.",2019,"Adverse events occurred slightly more frequently with esaxerenone versus placebo, but the frequencies of drug-related adverse events and discontinuation rates were similar in the placebo and the 0.625-, 1.25-, and 2.5-mg/d groups.","['patients with type 2 diabetes mellitus and microalbuminuria', 'patients with type 2 diabetes mellitus', 'Type 2 Diabetes with Microalbuminuria', '365 hypertensive or normotensive patients with type 2 diabetes mellitus and microalbuminuria (urinary albumin-to-creatinine ratio ≥45 to <300 mg/g creatinine) treated with renin-angiotensin system inhibitor who had eGFR≥30 ml/min per 1.73 m 2 ', 'Japanese patients with type 2 diabetes mellitus and microalbuminuria']","['placebo', 'esaxerenone', 'Placebo', 'esaxerenone or placebo', 'Esaxerenone (CS-3150']","['Adverse events', 'change in urinary albumin-to-creatinine ratio', 'progression of kidney disease', 'urinary albumin-to-creatinine ratio', 'efficacy and safety', 'urinary albumin-to-creatinine ratio remission rate (defined as urinary albumin-to-creatinine ratio', 'frequencies of drug-related adverse events and discontinuation rates']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0730345', 'cui_str': 'Microalbuminuria (finding)'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C2712122', 'cui_str': 'Normal blood pressure (finding)'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C1300563', 'cui_str': 'ug/mg'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0035096'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0439445', 'cui_str': 'mL/min'}, {'cui': 'C1556094', 'cui_str': 'Japanese'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4278755', 'cui_str': 'CS-3150'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0022658', 'cui_str': 'Kidney Diseases'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}]",365.0,0.455259,"Adverse events occurred slightly more frequently with esaxerenone versus placebo, but the frequencies of drug-related adverse events and discontinuation rates were similar in the placebo and the 0.625-, 1.25-, and 2.5-mg/d groups.","[{'ForeName': 'Sadayoshi', 'Initials': 'S', 'LastName': 'Ito', 'Affiliation': 'Division of Nephrology, Endocrinology and Vascular Medicine, Department of Medicine, Tohoku University School of Medicine, Sendai, Japan; db554@med.tohoku.ac.jp.'}, {'ForeName': 'Kenichi', 'Initials': 'K', 'LastName': 'Shikata', 'Affiliation': 'Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.'}, {'ForeName': 'Masaomi', 'Initials': 'M', 'LastName': 'Nangaku', 'Affiliation': 'Division of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; and.'}, {'ForeName': 'Yasuyuki', 'Initials': 'Y', 'LastName': 'Okuda', 'Affiliation': 'Biostatistics and Data Management Department, and.'}, {'ForeName': 'Tomoko', 'Initials': 'T', 'LastName': 'Sawanobori', 'Affiliation': 'Clinical Development Department Daiichi-Sankyo Co., Ltd., Tokyo, Japan.'}]",Clinical journal of the American Society of Nephrology : CJASN,['10.2215/CJN.14751218'] 329,32264800,Trajectories of Homeless Shelter Utilization in the At Home/Chez Soi Trial of Housing First.,"OBJECTIVE Studies have shown that Housing First, a recovery-oriented housing intervention, is effective in reducing service utilization among homeless individuals with mental illness, but less is known about how Housing First affects patterns of service use over time and about characteristics associated with various utilization trajectories. This analysis aimed to explore latent class trajectories of shelter utilization in a randomized controlled trial of Housing First conducted across five Canadian cities. METHODS Data from the At Home/Chez Soi trial were analyzed (N=2,058). Latent class growth analysis was performed using days of shelter utilization to identify trajectories over 24 months. Multinomial logistic regression was used to determine which baseline variables, including treatment group, could predict class membership. RESULTS Four shelter use trajectories were identified: consistently low (N=1,631, 79%); mostly low (N=120, 6%); early temporary increase (N=179, 9%); and higher use, late temporary increase (N=128, 6%). Treatment group was a significant predictor of class membership. Those enrolled in Housing First had lower odds of experiencing higher shelter use trajectories (mostly low: odds ratio [OR]=0.50, 95% confidence interval [CI]=0.34-0.72; early temporary increase: OR=0.21, 95% CI=0.15-0.31; higher use, late temporary increase: OR=0.14, 95% CI=0.09-0.22). Other variables associated with trajectory classes included older age and longer time homeless, both of which were associated with higher shelter use. CONCLUSIONS Several participant characteristics were associated with different shelter use patterns. Knowledge of variables associated with more favorable trajectories may help to inform service planning and contribute to modeling efforts for homelessness.",2020,"OBJECTIVE Studies have shown that Housing First, a recovery-oriented housing intervention, is effective in reducing service utilization among homeless individuals with mental illness, but less is known about how Housing First affects patterns of service use over time and about characteristics associated with various utilization trajectories.","['Homeless Shelter Utilization in the At Home/Chez Soi Trial of Housing First', 'homeless individuals with mental illness', 'Housing First conducted across five Canadian cities', 'Data from the At Home/Chez Soi trial were analyzed (N=2,058']",[],['class membership'],"[{'cui': 'C0237154', 'cui_str': 'Homeless'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0676803', 'cui_str': 'Styrene-oxide isomerase'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0020056', 'cui_str': 'Housed'}, {'cui': 'C0425242', 'cui_str': 'Homeless single person'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0008848', 'cui_str': 'Cities'}]",[],"[{'cui': 'C0456387', 'cui_str': 'Class'}]",,0.0836163,"OBJECTIVE Studies have shown that Housing First, a recovery-oriented housing intervention, is effective in reducing service utilization among homeless individuals with mental illness, but less is known about how Housing First affects patterns of service use over time and about characteristics associated with various utilization trajectories.","[{'ForeName': 'Cherry M T', 'Initials': 'CMT', 'LastName': 'Chu', 'Affiliation': 'Department of Epidemiology, Biostatistics, and Occupational Health (Chu, Moodie), and Department of Psychiatry (Latimer), McGill University, Montreal; Douglas Mental Health University Institute, Montreal (Chu, Latimer); Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Canada (Streiner).'}, {'ForeName': 'Erica E M', 'Initials': 'EEM', 'LastName': 'Moodie', 'Affiliation': 'Department of Epidemiology, Biostatistics, and Occupational Health (Chu, Moodie), and Department of Psychiatry (Latimer), McGill University, Montreal; Douglas Mental Health University Institute, Montreal (Chu, Latimer); Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Canada (Streiner).'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Streiner', 'Affiliation': 'Department of Epidemiology, Biostatistics, and Occupational Health (Chu, Moodie), and Department of Psychiatry (Latimer), McGill University, Montreal; Douglas Mental Health University Institute, Montreal (Chu, Latimer); Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Canada (Streiner).'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Latimer', 'Affiliation': 'Department of Epidemiology, Biostatistics, and Occupational Health (Chu, Moodie), and Department of Psychiatry (Latimer), McGill University, Montreal; Douglas Mental Health University Institute, Montreal (Chu, Latimer); Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Canada (Streiner).'}]","Psychiatric services (Washington, D.C.)",['10.1176/appi.ps.201900260'] 330,32265129,A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806).,"Standard therapy for high-risk (HR) prostate cancer (PrCa) involves androgen deprivation therapy (ADT) and pelvic conventional fractionation (CF) external beam radiotherapy (EBRT) followed by boost CF-EBRT treatment to prostate for a total of 78 to 80 Gy in 39 to 40 fractions. This is a long and inconvenient treatment for patients. Brachytherapy boost treatment studies indicate that escalation of biological dose of radiotherapy (RT) can improve outcomes in HR-PrCa. However, brachytherapy is an invasive treatment associated with increased toxicity and requires specialized resources. Stereotactic body radiotherapy (SBRT) is a promising, non-invasive alternative to brachytherapy. However, its impact on patient quality of life (QoL) and RT-associated toxicity has not been investigated in a randomized setting. In this study, we investigate SBRT as a boost treatment, following pelvic CF-EBRT, in patients with HR-PrCa treated with ADT. One hundred patients with locally advanced PrCa will be randomized to receive daily CF-EBRT of 45 to 46 Gy in 23 to 25 fractions followed by either daily CF-EBRT of 32 to 33 Gy in 15 to 16 fractions (control arm) or SBRT boost treatment of 19.5 to 21 Gy in 3 fractions (1 fraction per week) (experimental arm). The primary objective of the PBS trial is early bowel and urinary QoL (expanded prostate index composite [EPIC], up to 6 months after RT). This phase II randomized study (PBS) provides an appropriate setting to investigate effectively the impact of SBRT boost on QoL and toxicity in patients with HR-PrCa, before this modality can be compared against the current standard of care in larger phase III protocols.",2020,Brachytherapy boost treatment studies indicate that escalation of biological dose of radiotherapy (RT) can improve outcomes in HR-PrCa.,"['patients with HR-PrCa', 'patients with HR-PrCa treated with ADT', 'patients', 'One hundred patients with locally advanced PrCa', 'Locally Advanced Prostate Cancer']","['brachytherapy', 'SBRT boost', 'radiotherapy (RT', 'daily CF-EBRT', 'SBRT', 'Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF', 'Prostate Boost Irradiation', 'External Beam Radiotherapy (EBRT', 'androgen deprivation therapy (ADT) and pelvic conventional fractionation (CF) external beam radiotherapy (EBRT', 'Stereotactic body radiotherapy (SBRT']","['early bowel and urinary QoL (expanded prostate index composite [EPIC', 'toxicity', 'patient quality of life (QoL) and RT-associated toxicity', 'QoL and toxicity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034902', 'cui_str': 'Pure red cell aplasia'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}]","[{'cui': 'C0006098', 'cui_str': 'Brachytherapy'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1720823', 'cui_str': 'Stereotactic Body Radiotherapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0524811', 'cui_str': 'Dose Fractionation, Radiotherapy'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0419095', 'cui_str': 'Teleradiotherapy procedure'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C0030797', 'cui_str': 'Pelvic'}]","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205229', 'cui_str': 'Expanding'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1273342', 'cui_str': 'Epithelial cell count'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}]",100.0,0.047573,Brachytherapy boost treatment studies indicate that escalation of biological dose of radiotherapy (RT) can improve outcomes in HR-PrCa.,"[{'ForeName': 'Naghmeh', 'Initials': 'N', 'LastName': 'Isfahanian', 'Affiliation': 'Radiation Oncology, Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada; Department of Oncology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Himanshu', 'Initials': 'H', 'LastName': 'Lukka', 'Affiliation': 'Radiation Oncology, Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada; Department of Oncology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Dayes', 'Affiliation': 'Radiation Oncology, Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada; Department of Oncology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Kimmen', 'Initials': 'K', 'LastName': 'Quan', 'Affiliation': 'Radiation Oncology, Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada; Department of Oncology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Kara Lynne', 'Initials': 'KL', 'LastName': 'Schnarr', 'Affiliation': 'Radiation Oncology, Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada; Department of Oncology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Georgia', 'Initials': 'G', 'LastName': 'Douvi', 'Affiliation': 'Department of Oncology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Mira', 'Initials': 'M', 'LastName': 'Goldberg', 'Affiliation': 'Radiation Oncology, Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Wright', 'Affiliation': 'Radiation Oncology, Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada; Department of Oncology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Swaminath', 'Affiliation': 'Radiation Oncology, Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada; Department of Oncology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Chow', 'Affiliation': 'Medical Physics, Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Diamond', 'Affiliation': 'Medical Physics, Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Jean Claude', 'Initials': 'JC', 'LastName': 'Cutz', 'Affiliation': 'Departments of Oncology, Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Kavsak', 'Affiliation': 'Departments of Oncology, Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Lehana', 'Initials': 'L', 'LastName': 'Thabane', 'Affiliation': ""Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada; Biostatistics Unit, St Joseph's Healthcare, Hamilton, ON, Canada.""}, {'ForeName': 'Theodoros', 'Initials': 'T', 'LastName': 'Tsakiridis', 'Affiliation': 'Radiation Oncology, Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada; Department of Oncology, McMaster University, Hamilton, ON, Canada; Departments of Oncology, Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. Electronic address: theos.tsakiridis@hhsc.ca.'}]",Clinical genitourinary cancer,['10.1016/j.clgc.2019.12.020'] 331,32267481,Comparison of Blood Pressure Variability Between Losartan and Amlodipine in Essential Hypertension (COMPAS-BPV).,"BACKGROUND Antihypertensive therapy using renin-angiotensin system blockers and calcium channel blockers to target blood pressure variability (BPV) has not yet been established. We aimed to compare the ability of losartan and amlodipine to lower BPV and systolic blood pressure (SBP) in essential hypertensive patients. METHODS Patients were randomly assigned either losartan 50 mg or amlodipine 5 mg. Medications were uptitrated and hydrochlorothiazide was added according to protocol for 6 months. The primary endpoint was the office visit-to-visit SD of SBP. The secondary endpoints included average real variability (ARV), office SBP, and home SBP. RESULTS The losartan group (n = 71) and amlodipine group (n = 73) finished the scheduled visits between April 2013 and May 2017. The office visit-to-visit SD of SBP was comparable between the losartan and amlodipine groups (11.0 ± 4.2 vs. 10.5 ± 3.8, P = 0.468). The office visit-to-visit ARV of SBP was significantly elevated in the losartan group (10.6 ± 4.3 vs. 9.1 ± 3.4, P = 0.02). The absolute SBP decrement from baseline to 6 months was similar between groups, although the office mean SBP at 6 months was higher in the losartan group (132.3 ± 12.9 vs. 127.5 ± 9.0 mm Hg, P = 0.011). In home blood pressure analysis, evening day-to-day BPV indexes (SD and ARV) were significantly higher in the losartan group at 6 months. CONCLUSIONS The lowering effect of the office visit-to-visit SD of SBP was similar between losartan and amlodipine. However, the losartan group showed a higher office visit-to-visit ARV of SBP and evening day-to-day home BPV indexes. Therefore, amlodipine may be better to lower BPV in essential hypertensive patients.",2020,The lowering effect of the office visit-to-visit SD of SBP was similar between losartan and amlodipine.,"['Patients', 'essential hypertensive patients', 'group (n=73) finished the scheduled visits between April 2013 and May 2017']","['hydrochlorothiazide', 'losartan and amlodipine', 'losartan 50 mg or amlodipine', 'amlodipine', 'losartan', 'calcium channel blockers']","['office visit-to-visit ARV of SBP', 'average real variability (ARV), office SBP and home SBP', 'office visit-to-visit standard deviation (SD) of SBP', 'office visit-to-visit SD of SBP', 'office mean SBP', 'blood pressure variability', 'higher office visit-to-visit ARV of SBP', 'absolute SBP decrement', 'BPV and systolic BP (SBP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205224', 'cui_str': 'Essential'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1706059', 'cui_str': 'Finish'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0020261', 'cui_str': 'Hydrochlorothiazide'}, {'cui': 'C3652748', 'cui_str': 'losartan and amlodipine'}, {'cui': 'C0126174', 'cui_str': 'Losartan'}, {'cui': 'C0051696', 'cui_str': 'Amlodipine'}, {'cui': 'C0006684', 'cui_str': 'Calcium channel blocker'}]","[{'cui': 'C0028900', 'cui_str': 'Office visit'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0006072', 'cui_str': 'Bovine papillomavirus'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",,0.0300826,The lowering effect of the office visit-to-visit SD of SBP was similar between losartan and amlodipine.,"[{'ForeName': 'Jun-Won', 'Initials': 'JW', 'LastName': 'Lee', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea.'}, {'ForeName': 'Eunhee', 'Initials': 'E', 'LastName': 'Choi', 'Affiliation': 'Department of Medicine, Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Jung-Woo', 'Initials': 'JW', 'LastName': 'Son', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea.'}, {'ForeName': 'Young Jin', 'Initials': 'YJ', 'LastName': 'Youn', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea.'}, {'ForeName': 'Sung-Gyun', 'Initials': 'SG', 'LastName': 'Ahn', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea.'}, {'ForeName': 'Min-Soo', 'Initials': 'MS', 'LastName': 'Ahn', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea.'}, {'ForeName': 'Jang-Young', 'Initials': 'JY', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea.'}, {'ForeName': 'Seung-Hwan', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea.'}, {'ForeName': 'Junghan', 'Initials': 'J', 'LastName': 'Yoon', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea.'}, {'ForeName': 'Dong Ryeol', 'Initials': 'DR', 'LastName': 'Ryu', 'Affiliation': 'Department of Internal Medicine, Kangwon National University College of Medicine, Chuncheon, Republic of Korea.'}, {'ForeName': 'Sang-Min', 'Initials': 'SM', 'LastName': 'Park', 'Affiliation': 'Division of Cardiology, Cardiovascular Center, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Republic of Korea.'}, {'ForeName': 'Kyung-Soon', 'Initials': 'KS', 'LastName': 'Hong', 'Affiliation': 'Division of Cardiology, Cardiovascular Center, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Republic of Korea.'}, {'ForeName': 'Byung-Su', 'Initials': 'BS', 'LastName': 'Yoo', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea.'}]",American journal of hypertension,['10.1093/ajh/hpaa060'] 332,32264985,iMAgery focused psychological therapy for persecutory delusions in PSychosis (iMAPS): a multiple baseline experimental case series.,"BACKGROUND Many people with psychosis experience persecutory delusions and report negative schematic beliefs and intrusive mental images which may be maintaining factors for psychotic symptoms. AIMS This study examined the feasibility and acceptability of a new psychological therapy targeting schemas and images (iMAPS therapy). METHOD The study used a randomised multiple baseline design. Participants with first episode psychosis were randomised using a multiple baseline design with 2-5 assessments. Six sessions of therapy, consisting of a combination of imagery techniques and imagery rescripting techniques, was used. In each session, participants completed a Mental Imagery in Psychosis Questionnaire (MIPQ) and imagery interview. Mood and delusional beliefs (PSYRATS) were also measured at each session. RESULTS Five participants with first episode psychosis completed the baseline visits and attended all therapy sessions. One participant declined the final assessment. Results demonstrated significant reductions in negative schematic beliefs, delusions, imagery distress and other measures of schema (YSQ, SMI). Although multiple baseline randomisation strengthens the study, it lacked a control arm and blind assessments. CONCLUSIONS iMAPS appears a feasible and acceptable treatment for psychosis, and further evaluation is indicated.",2020,"Results demonstrated significant reductions in negative schematic beliefs, delusions, imagery distress and other measures of schema (YSQ, SMI).","['Participants with first episode psychosis', 'persecutory delusions in PSychosis (iMAPS']","['new psychological therapy targeting schemas and images (iMAPS therapy', 'iMAPS', 'iMAgery focused psychological therapy']","['feasibility and acceptability', 'negative schematic beliefs, delusions, imagery distress and other measures of schema (YSQ, SMI', 'Mental Imagery in Psychosis Questionnaire (MIPQ) and imagery interview', 'Mood and delusional beliefs (PSYRATS']","[{'cui': 'C0439615', 'cui_str': 'First episode'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0349398', 'cui_str': 'Paranoid delusion'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0841584', 'cui_str': 'Psychological therapies'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0592034', 'cui_str': 'Redeptin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0011253', 'cui_str': 'Delusions'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0915075', 'cui_str': 'samarium diiodide'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0026516', 'cui_str': 'Mood'}]",5.0,0.0294871,"Results demonstrated significant reductions in negative schematic beliefs, delusions, imagery distress and other measures of schema (YSQ, SMI).","[{'ForeName': 'Christopher D J', 'Initials': 'CDJ', 'LastName': 'Taylor', 'Affiliation': 'Secondary Care Psychological Therapies Service, Pennine Care NHS Foundation Trust, Humphrey House, Angouleme Way, BuryML9 0EQ, UK.'}, {'ForeName': 'Penny E', 'Initials': 'PE', 'LastName': 'Bee', 'Affiliation': 'Division of Nursing, Midwifery and Social Work, School of Health Sciences, University of Manchester, Manchester, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Kelly', 'Affiliation': 'Greater Manchester Mental Health NHS Foundation Trust, Trust Headquarters, Bury New Road, Prestwich, ManchesterM25 3BL, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Emsley', 'Affiliation': ""Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, Denmark Hill, LondonSE5 8AF, UK.""}, {'ForeName': 'Gillian', 'Initials': 'G', 'LastName': 'Haddock', 'Affiliation': 'Division of Psychology and Mental Health, School of Health Sciences, University of Manchester, Zochonis Building, Brunswick Street, ManchesterM13 9PL, UK.'}]",Behavioural and cognitive psychotherapy,['10.1017/S1352465820000168'] 333,32267168,Self-guided mindfulness and cognitive behavioural practices reduce anxiety in autistic adults: A pilot 8-month waitlist-controlled trial of widely available online tools.,"LAY ABSTRACT Anxiety in autism is an important target for psychological therapies because it is very common and because it significantly impacts upon quality of life and well-being. Growing evidence suggests that cognitive behaviour therapies and mindfulness-based therapies can help autistic individuals learn to manage feelings of anxiety but access to such therapies remains problematic. In the current pilot study, we examined whether existing online cognitive behaviour therapy and mindfulness-based therapy self-help tools can help reduce anxiety in autistic adults. Specifically, 35 autistic adults were asked to try either an existing online cognitive behaviour therapy (n = 16) or mindfulness-based therapy (n = 19) programme while a further 19 autistic adults served as a waitlist comparison group. A first important finding was that 23 of the 35 (66%) participants who tried the online tools completed them, suggesting that such tools are, in principle, acceptable to many autistic adults. In addition, adults in the cognitive behaviour therapy and mindfulness-based therapy conditions reported significant decreases in anxiety over 3 and to some extent also 6 months that were less apparent in the waitlist group of participants. On broader measures of mental health and well-being, the benefits of the online tools were less apparent. Overall, the results suggest that online self-help cognitive behaviour therapy and mindfulness-based therapy tools should be explored further as a means of providing cost-effective mental health support to at least those autistic individuals who can engage effectively with such online tools.",2020,"On broader measures of mental health and well-being, the benefits of the online tools were less apparent.","['35 autistic adults', '19 autistic adults served as a waitlist comparison group', 'autistic adults']","['Self-guided mindfulness and cognitive behavioural practices', 'existing online cognitive behaviour therapy and mindfulness-based therapy self-help tools', 'existing online cognitive behaviour therapy (n = 16) or mindfulness-based therapy']",['anxiety'],"[{'cui': 'C0004352', 'cui_str': 'Autistic disorder'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0336791', 'cui_str': 'Tool'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}]",35.0,0.0145778,"On broader measures of mental health and well-being, the benefits of the online tools were less apparent.","[{'ForeName': 'Sebastian B', 'Initials': 'SB', 'LastName': 'Gaigg', 'Affiliation': 'City, University of London, London, UK.'}, {'ForeName': 'Paul E', 'Initials': 'PE', 'LastName': 'Flaxman', 'Affiliation': 'City, University of London, London, UK.'}, {'ForeName': 'Gracie', 'Initials': 'G', 'LastName': 'McLaven', 'Affiliation': 'City, University of London, London, UK.'}, {'ForeName': 'Ritika', 'Initials': 'R', 'LastName': 'Shah', 'Affiliation': 'City, University of London, London, UK.'}, {'ForeName': 'Dermot M', 'Initials': 'DM', 'LastName': 'Bowler', 'Affiliation': 'City, University of London, London, UK.'}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Meyer', 'Affiliation': 'University of Westminster, UK.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Roestorf', 'Affiliation': 'City, University of London, London, UK.'}, {'ForeName': 'Corinna', 'Initials': 'C', 'LastName': 'Haenschel', 'Affiliation': 'City, University of London, London, UK.'}, {'ForeName': 'Jacqui', 'Initials': 'J', 'LastName': 'Rodgers', 'Affiliation': 'Newcastle University, UK.'}, {'ForeName': 'Mikle', 'Initials': 'M', 'LastName': 'South', 'Affiliation': 'Brigham Young University, USA.'}]",Autism : the international journal of research and practice,['10.1177/1362361320909184'] 334,31454829,Acute kidney injury risk-based screening in pediatric inpatients: a pragmatic randomized trial.,"BACKGROUND Pediatric acute kidney injury (AKI) is common and associated with increased morbidity, mortality, and length of stay. We performed a pragmatic randomized trial testing the hypothesis that AKI risk alerts increase AKI screening. METHODS All intensive care and ward admissions of children aged 28 days through 21 years without chronic kidney disease from 12/6/2016 to 11/1/2017 were included. The intervention alert displayed if calculated AKI risk was > 50% and no serum creatinine (SCr) was ordered within 24 h. The primary outcome was SCr testing within 48 h of AKI risk > 50%. RESULTS Among intensive care admissions, 973/1909 (51%) were randomized to the intervention. Among those at risk, more SCr tests were ordered for the intervention group than for controls (418/606, 69% vs. 361/597, 60%, p = 0.002). AKI incidence and severity were the same in intervention and control groups. Among ward admissions, 5492/10997 (50%) were randomized to the intervention, and there were no differences between groups in SCr testing, AKI incidence, or severity of AKI. CONCLUSIONS Alerts based on real-time prediction of AKI risk increased screening rates in intensive care but not pediatric ward settings. Pragmatic clinical trials provide the opportunity to assess clinical decision support and potentially eliminate ineffective alerts.",2020,AKI incidence and severity were the same in intervention and control groups.,"['pediatric inpatients', 'All intensive care and ward admissions of children aged 28 days through 21 years without chronic kidney disease from 12/6/2016 to 11/1/2017 were included']",[],"['serum creatinine (SCr', 'SCr tests', 'AKI incidence and severity', 'morbidity, mortality, and length of stay', 'SCr testing within 48\u2009h of AKI risk', 'SCr testing, AKI incidence, or severity of AKI', 'calculated AKI risk']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0085559'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]",[],"[{'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",,0.192399,AKI incidence and severity were the same in intervention and control groups.,"[{'ForeName': 'Sara L', 'Initials': 'SL', 'LastName': 'Van Driest', 'Affiliation': 'Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA. sara.van.driest@vumc.org.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Michael F', 'Initials': 'MF', 'LastName': 'McLemore', 'Affiliation': 'Health Information Technology, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Brian C', 'Initials': 'BC', 'LastName': 'Bridges', 'Affiliation': 'Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Geoffrey M', 'Initials': 'GM', 'LastName': 'Fleming', 'Affiliation': 'Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Tracy L', 'Initials': 'TL', 'LastName': 'McGregor', 'Affiliation': 'Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Deborah P', 'Initials': 'DP', 'LastName': 'Jones', 'Affiliation': 'Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Shirey-Rice', 'Affiliation': 'Institute for Clinical and Translational Research, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Cheryl L', 'Initials': 'CL', 'LastName': 'Gatto', 'Affiliation': 'Institute for Clinical and Translational Research, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'James C', 'Initials': 'JC', 'LastName': 'Gay', 'Affiliation': 'Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Daniel W', 'Initials': 'DW', 'LastName': 'Byrne', 'Affiliation': 'Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Asli', 'Initials': 'A', 'LastName': 'Weitkamp', 'Affiliation': 'Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Dan M', 'Initials': 'DM', 'LastName': 'Roden', 'Affiliation': 'Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Bernard', 'Affiliation': 'Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.'}]",Pediatric research,['10.1038/s41390-019-0550-1'] 335,32252101,Addition of Caffeine to a Carbohydrate Feeding Strategy Prior to Intermittent Exercise.,"The ergogenic effect of caffeine is well established, although no investigations providing a high carbohydrate feeding strategy (pre-exercise meal=2 g/kg BM) co-ingested with caffeine exist for soccer. This investigation examines the effect of caffeine in addition to a pre-exercise carbohydrate meal and drink mid-way through a soccer simulation. Eight recreational soccer players completed an 85-minute soccer simulation followed by an exercise capacity test (Yo-yo Intermittent Endurance test level 2) on two occasions. Prior to exercise participants consumed a high carbohydrate meal, with placebo or 5 mg/kg BM -1 caffeine. No significant performance effect was identified (p=0.099) despite a 12.8% (109 m) improvement in exercise capacity following caffeine. Rates of carbohydrate and fat oxidation did not differ between conditions and nor were differences apparent for plasma glucose, fatty acids, glycerol, β-hydroxybutyrate (p>0.05). However, an increase in lactate was observed for caffeine (p=0.039). A significant condition effect on rating of perceived exertion was identified (p<0.001), with the overall mean for the protocol lowered to 11.7±0.9 au for caffeine compared to 12.8±1.3 au. Caffeine supplementation with a carbohydrate feeding strategy failed to affect metabolic and metabolite responses, although reductions in perception of exercise were observed. While a 12.8% increase in exercise capacity was noted the findings were not significant, possibly due to the small sample size.",2020,"Rates of carbohydrate and fat oxidation did not differ between conditions and nor were differences apparent for plasma glucose, fatty acids, glycerol, β-hydroxybutyrate (p>0.05).",['Eight recreational soccer players'],"['Caffeine', 'caffeine', '85-minute soccer simulation followed by an exercise capacity test (Yo-yo Intermittent Endurance test level 2', 'Caffeine supplementation', 'high carbohydrate meal, with placebo or 5\u2009mg/kg BM -1 caffeine']","['metabolic and metabolite responses', 'plasma glucose, fatty acids, glycerol, β-hydroxybutyrate (p>0.05', 'Rates of carbohydrate and fat oxidation', 'perception of exercise', 'performance effect', 'exercise capacity', 'lactate', 'rating of perceived exertion']","[{'cui': 'C0037393', 'cui_str': 'Soccer'}]","[{'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0456948', 'cui_str': 'Level 2'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}]","[{'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0017861', 'cui_str': 'Glycerin'}, {'cui': 'C0020332', 'cui_str': 'Hydroxybutyrates'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}]",,0.0329557,"Rates of carbohydrate and fat oxidation did not differ between conditions and nor were differences apparent for plasma glucose, fatty acids, glycerol, β-hydroxybutyrate (p>0.05).","[{'ForeName': 'Andrew T', 'Initials': 'AT', 'LastName': 'Hulton', 'Affiliation': 'Department of Nutritional Sciences, University of Surrey, Guildford, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Kaio', 'Initials': 'K', 'LastName': 'Vitzel', 'Affiliation': 'School of Heath Science, Massey University, Palmerston North, New Zealand.'}, {'ForeName': 'Dominic A', 'Initials': 'DA', 'LastName': 'Doran', 'Affiliation': 'Research Institute of Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Don P M', 'Initials': 'DPM', 'LastName': 'MacLaren', 'Affiliation': 'Research Institute of Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom of Great Britain and Northern Ireland.'}]",International journal of sports medicine,['10.1055/a-1121-7817'] 336,32255542,"Randomized, Double-Blind, Single-Dose, Placebo-Controlled Crossover Study to Evaluate the Effects of Esaxerenone on QTc Interval in Healthy Subjects.","This phase 1 single-center, single-dose, double-dummy, placebo-controlled, 4-period and 4-sequence crossover study assessed the potential of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker used to treat hypertension, to affect cardiac repolarization. In this double-blind study, 55 subjects were randomized to single doses of 10 mg esaxerenone (therapeutic dose), 40 mg esaxerenone (supratherapeutic dose), 400 mg moxifloxacin, or placebo. Serial electrocardiograms and pharmacokinetics (PK) were obtained over 24 and 168 hours, respectively. The primary end point was Fridericia-corrected QT interval (QTcF). Secondary end points included safety and PK. Assay sensitivity was confirmed as the lower limit of 90% confidence interval (90%CIs) for placebo-corrected change from baseline QTcF (∆∆QTcF) for moxifloxacin was >5 milliseconds at the prespecified times; mean ∆∆QTcF was 12.5 milliseconds at 3 and 4 hours postdose. The upper 90%CI limits of ∆∆QTcF were ≤0 milliseconds at all times for both doses of esaxerenone. No concentration-QTc relationship was identified. Therefore, esaxerenone had no potential to inhibit cardiac repolarization. No deaths or serious adverse events (AEs) occurred; 1 subject discontinued the study because of a treatment-emergent AE unrelated to esaxerenone. This clinical evaluation showed that esaxerenone has no QTc prolongation potential.",2020,The upper 90%CI limits of ∆∆QTcF were ≤0 milliseconds at all times for both doses of esaxerenone.,"['55 subjects', 'Healthy Subjects']","['esaxerenone', 'Placebo', 'esaxerenone (therapeutic dose), 40 mg esaxerenone (supratherapeutic dose), 400 mg moxifloxacin, or placebo', 'Esaxerenone', 'moxifloxacin']","['Assay sensitivity', 'concentration-QTc relationship', 'deaths or serious adverse events', 'Fridericia-corrected QT interval (QTcF', 'safety and PK', 'Serial electrocardiograms and pharmacokinetics (PK']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C5139864', 'cui_str': 'esaxerenone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}]","[{'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0860814', 'cui_str': 'QTc'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0429028', 'cui_str': 'QT interval feature'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}]",55.0,0.285919,The upper 90%CI limits of ∆∆QTcF were ≤0 milliseconds at all times for both doses of esaxerenone.,"[{'ForeName': 'Jeanne', 'Initials': 'J', 'LastName': 'Mendell', 'Affiliation': 'Daiichi Sankyo Pharma Development, Basking Ridge, New Jersey, USA.'}, {'ForeName': 'Fumiaki', 'Initials': 'F', 'LastName': 'Kobayashi', 'Affiliation': 'Daiichi Sankyo Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Takako', 'Initials': 'T', 'LastName': 'Shimizu', 'Affiliation': 'Daiichi Sankyo Co., Ltd., Tokyo, Japan.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.794'] 337,30911113,"Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.","Telomere length in chronic lymphocytic leukemia (CLL) has been shown to be of prognostic importance, but the analyses have largely been executed on heterogeneous patient cohorts outside of clinical trials. In the present study, we performed a comprehensive analysis of telomere length associations in the well characterized CLL8 trial (n = 620) of the German CLL study group, with validation in a representative cohort of the CLL4 trial (n = 293). Absolute telomere length was analyzed using quantitative-PCR. Apart from identifying associations of short telomere length with adverse prognostic factors and survival, the study identified cases with 17p- and 11q- associated with TP53 and ATM loss, respectively, to have the shortest telomeres, even when these aberrations were present in small subclones. Thus, telomere shortening may precede acquisition of the high-risk aberrations, contributing to disease evolution. In line with this, telomere shortening was associated with an increase in genomic complexity as well as clonal evolution, highlighting its importance as a biomarker especially in monitoring disease progression in non-high-risk CLL.",2019,"In line with this, telomere shortening was associated with an increase in genomic complexity as well as clonal evolution, highlighting its importance as a biomarker especially in monitoring disease progression in non-high-risk CLL.","['well characterized CLL8 trial (n\u2009=\u2009620) of the German CLL study group, with validation in a representative cohort of the CLL4 trial (n\u2009=\u2009293', 'chronic lymphocytic leukemia (CLL', 'chronic lymphocytic leukemia']",[],"['TP53 and ATM loss', 'Absolute telomere length', 'genomic complexity']","[{'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C4708788', 'cui_str': '620'}, {'cui': 'C1556085', 'cui_str': 'Germans (ethnic group)'}, {'cui': 'C0023434', 'cui_str': 'Lymphoma, Small Lymphocytic'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]",[],"[{'cui': 'C0678214', 'cui_str': 'atmosphere (qualifier value)'}, {'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0085187'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0887950', 'cui_str': 'Genomics'}]",,0.0234911,"In line with this, telomere shortening was associated with an increase in genomic complexity as well as clonal evolution, highlighting its importance as a biomarker especially in monitoring disease progression in non-high-risk CLL.","[{'ForeName': 'Billy Michael Chelliah', 'Initials': 'BMC', 'LastName': 'Jebaraj', 'Affiliation': 'Department of Internal Medicine III, Ulm University, Ulm, Germany.'}, {'ForeName': 'Eugen', 'Initials': 'E', 'LastName': 'Tausch', 'Affiliation': 'Department of Internal Medicine III, Ulm University, Ulm, Germany.'}, {'ForeName': 'Dan A', 'Initials': 'DA', 'LastName': 'Landau', 'Affiliation': 'Department of Medicine, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Jasmin', 'Initials': 'J', 'LastName': 'Bahlo', 'Affiliation': 'Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Robrecht', 'Affiliation': 'Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Amaro N', 'Initials': 'AN', 'LastName': 'Taylor-Weiner', 'Affiliation': 'Broad Institute, Cambridge, MA, USA.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Bloehdorn', 'Affiliation': 'Department of Internal Medicine III, Ulm University, Ulm, Germany.'}, {'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Scheffold', 'Affiliation': 'Department of Internal Medicine III, Ulm University, Ulm, Germany.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Mertens', 'Affiliation': 'Department of Internal Medicine III, Ulm University, Ulm, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Böttcher', 'Affiliation': 'Department II of Internal Medicine, University Hospital of Schleswig-Holstein, Kiel, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kneba', 'Affiliation': 'Department II of Internal Medicine, University Hospital of Schleswig-Holstein, Kiel, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Jäger', 'Affiliation': 'Department of Medicine I, Division of Hematology and Hemostaeology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Thorsten', 'Initials': 'T', 'LastName': 'Zenz', 'Affiliation': 'Department of Internal Medicine III, Ulm University, Ulm, Germany.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Wenger', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Guenter', 'Initials': 'G', 'LastName': 'Fingerle-Rowson', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Clemens', 'Initials': 'C', 'LastName': 'Wendtner', 'Affiliation': 'Klinikum Schwabing, Academic Teaching Hospital of University of Munich, Munich, Germany.'}, {'ForeName': 'Anna-Maria', 'Initials': 'AM', 'LastName': 'Fink', 'Affiliation': 'Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Catherine J', 'Initials': 'CJ', 'LastName': 'Wu', 'Affiliation': 'Broad Institute, Cambridge, MA, USA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Eichhorst', 'Affiliation': 'Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Fischer', 'Affiliation': 'Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hallek', 'Affiliation': 'Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Döhner', 'Affiliation': 'Department of Internal Medicine III, Ulm University, Ulm, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Stilgenbauer', 'Affiliation': 'Department of Internal Medicine III, Ulm University, Ulm, Germany. stephan.stilgenbauer@uniklinik-ulm.de.'}]",Leukemia,['10.1038/s41375-019-0446-4'] 338,32191366,How important are Phase 1 interventions for complex interpersonal trauma? A pilot randomized control trial of a group psychoeducational intervention.,"Although psychoeducational interventions are recommended as Phase 1 interventions for complex trauma, there is limited evidence on their efficacy. This pilot randomized control trial (RCT) investigated the efficacy of a pure psychoeducational intervention for complex trauma. A brief 10-session intervention was delivered to n = 44 female prisoners in a compressed format to accommodate short sentence lengths and was compared with usual care (n = 42). Results from an intent-to-treat (ITT) analysis indicated that there were no statistically significant differences between the two arms across the three assessment time points (including 1-month postintervention) for the main outcomes (Behavioural Assessment Checklist-Revised, β = 4.60, 95% CI [-1.60, 10.88], p = .148; posttraumatic stress disorder [PTSD] Checklist, β = -1.47, 95% CI [-4.30, 1.36], p = .303). Post hoc reliable change analyses suggested twice the number of adequate dose participants made progress in addressing PTSD symptoms compared with usual care (30.3% vs. 17.6%, OR 2.03, 95% CI [.64, 6.43]). Although further work in this area is required, initial results, overall, suggest that psychoeducational group-based treatment modalities achieve only small effect sizes in comparison with usual care.",2020,"Post hoc Reliable Change analyses suggested twice the number of AD participants made progress in addressing PTSD symptoms compared to usual care (30.3% vs 17.6%, OR 2.03 [95%CI, .64 to 6.43]).",['n=44 female prisoners in a compressed format to accommodate short sentence lengths and was compared to usual care (n=42'],['pure psychoeducational intervention'],['addressing PTSD symptoms'],"[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0033167', 'cui_str': 'Prisoners'}, {'cui': 'C0332260', 'cui_str': 'Compressing (qualifier value)'}, {'cui': 'C1301627', 'cui_str': 'Format'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}]",[],"[{'cui': 'C0376649', 'cui_str': 'Address'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.116649,"Post hoc Reliable Change analyses suggested twice the number of AD participants made progress in addressing PTSD symptoms compared to usual care (30.3% vs 17.6%, OR 2.03 [95%CI, .64 to 6.43]).","[{'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Mahoney', 'Affiliation': 'Psychology Department, Glasgow Caledonian University, Glasglow, UK.'}, {'ForeName': 'Thanos', 'Initials': 'T', 'LastName': 'Karatzias', 'Affiliation': 'School of Health & Social Science, Edinburgh Napier University, Edinburgh, UK.'}, {'ForeName': 'Kirsty', 'Initials': 'K', 'LastName': 'Halliday', 'Affiliation': 'Psychology Department, HMP & YOI Cornton Vale, Stirling, UK.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Dougal', 'Affiliation': 'School of Health & Social Science, Edinburgh Napier University, Edinburgh, UK.'}]",Clinical psychology & psychotherapy,['10.1002/cpp.2447'] 339,31431654,Lack of social support as measured by the Family Resource Scale screening tool is associated with early adverse cognitive outcome in extremely low birth weight children.,"OBJECTIVE Extremely low birth weight children are at high risk for cognitive impairment. STUDY DESIGN Cognitive outcome of extremely low birth weight children participating in a Neonatal Research Network, randomized trial was evaluated at 18 and 30 months corrected age using the Bayley Scales of Infant Development, 2nd ed. Family resources and social support were assessed using a Family Resource Scale parent questionnaire. Regression analysis was used to determine independent demographic, medical, and family resource factors influencing longitudinal cognitive outcome. RESULT Higher Family Resource Scale scores at 18 months were associated with greater improvement in cognitive scores between 18 and 30 months. Cognitive outcome was most adversely affected in children whose families had the least resources and social support. The adverse effect of poor social support was independent of family income. CONCLUSION Poor interpersonal social support has an independent, adverse impact on cognitive outcomes of extremely low birth weight infants.",2019,Cognitive outcome was most adversely affected in children whose families had the least resources and social support.,"['extremely low birth weight infants', 'extremely low birth weight children participating in a Neonatal Research Network, randomized trial was evaluated at 18 and 30 months corrected age using the Bayley Scales of Infant Development, 2nd ed', 'extremely low birth weight children']",[],"['Cognitive outcome', 'Higher Family Resource Scale scores', 'cognitive scores']","[{'cui': 'C0456065', 'cui_str': 'Infant, Extremely Low Birth Weight'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0035168'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0451021', 'cui_str': 'Bayley scale of infant development (assessment scale)'}, {'cui': 'C0205436', 'cui_str': 'Second - ordinal'}]",[],"[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0599714,Cognitive outcome was most adversely affected in children whose families had the least resources and social support.,"[{'ForeName': 'Martha G', 'Initials': 'MG', 'LastName': 'Fuller', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, University of California San Diego, San Diego, CA, USA. mfuller@sandiego.edu.'}, {'ForeName': 'Yvonne E', 'Initials': 'YE', 'LastName': 'Vaucher', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, University of California San Diego, San Diego, CA, USA.'}, {'ForeName': 'Carla M', 'Initials': 'CM', 'LastName': 'Bann', 'Affiliation': 'RTI International, Research Triangle Park, North Carolina, NC, USA.'}, {'ForeName': 'Abhik', 'Initials': 'A', 'LastName': 'Das', 'Affiliation': 'RTI International, Research Triangle Park, North Carolina, NC, USA.'}, {'ForeName': 'Betty R', 'Initials': 'BR', 'LastName': 'Vohr', 'Affiliation': 'Department of Pediatrics, Women, and Infants Hospital, Brown University, Providence, RI, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/s41372-019-0462-2'] 340,31050707,"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.","BACKGROUND Novel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall survival (OS) benefit of pembrolizumab, a programmed death 1 inhibitor, versus chemotherapy in patients with advanced UC that progressed on platinum-based chemotherapy. Here we report the long-term safety and efficacy outcomes of KEYNOTE-045. PATIENTS AND METHODS Adult patients with histologically/cytologically confirmed UC whose disease progressed after first-line, platinum-containing chemotherapy were enrolled. Patients were randomly assigned 1 : 1 to receive pembrolizumab [200 mg every 3 weeks (Q3W)] or investigator's choice of paclitaxel (175 mg/m2 Q3W), docetaxel (75 mg/m2 Q3W), or vinflunine (320 mg/m2 Q3W). Primary end points were OS and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) by blinded independent central radiology review (BICR). A key secondary end point was objective response rate per RECIST v1.1 by BICR. RESULTS A total of 542 patients were enrolled (pembrolizumab, n = 270; chemotherapy, n = 272). Median follow-up as of 26 October 2017 was 27.7 months. Median 1- and 2-year OS rates were higher with pembrolizumab (44.2% and 26.9%, respectively) than chemotherapy (29.8% and 14.3%, respectively). PFS rates did not differ between treatment arms; however, 1- and 2-year PFS rates were higher with pembrolizumab. The objective response rate was also higher with pembrolizumab (21.1% versus 11.0%). Median duration of response to pembrolizumab was not reached (range 1.6+ to 30.0+ months) versus chemotherapy (4.4 months; range 1.4+ to 29.9+ months). Pembrolizumab had lower rates of any grade (62.0% versus 90.6%) and grade ≥3 (16.5% versus 50.2%) treatment-related adverse events than chemotherapy. CONCLUSIONS Long-term results (>2 years' follow-up) were consistent with those of previously reported analyses, demonstrating continued clinical benefit of pembrolizumab over chemotherapy for efficacy and safety for treatment of locally advanced/metastatic, platinum-refractory UC. TRIAL REGISTRATION ClinicalTrials.gov: NCT02256436.",2019,"PFS rates did not differ between treatment arms; however, 1- and 2-year PFS rates were higher with pembrolizumab.","['Adult patients with histologically/cytologically confirmed UC whose disease progressed after first-line, platinum-containing chemotherapy were enrolled', 'patients with advanced urothelial cancer (UC', 'patients with advanced UC that progressed on platinum-based chemotherapy', 'recurrent advanced urothelial cancer', '542 patients were enrolled (pembrolizumab, n = 270; chemotherapy, n =272']","['docetaxel (75\u2009mg/m2 Q3W), or vinflunine', ""pembrolizumab (200\u2009mg every 3 weeks [Q3W]) or investigator's choice of paclitaxel"", 'Pembrolizumab', 'pembrolizumab', 'pembrolizumab versus paclitaxel, docetaxel, or vinflunine']","['1- and 2-year PFS rates', 'OS and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) by blinded independent central radiology review (BICR', 'rates of any-grade', 'objective response rate per RECIST v1.1 by BICR', 'objective response rate', 'PFS rates', 'Median duration of response to pembrolizumab', 'Median 1- and 2-year OS rates']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C1098768', 'cui_str': '(diethylenetriamine)-platinum(II)'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C4319603', 'cui_str': '270 (qualifier value)'}]","[{'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C1319266', 'cui_str': 'mg/sq.m'}, {'cui': 'C0672663', 'cui_str': 'vinflunine'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1709926', 'cui_str': 'RECIST'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C4517491', 'cui_str': 'One point one'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0034599', 'cui_str': 'Radiology'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}]",542.0,0.296657,"PFS rates did not differ between treatment arms; however, 1- and 2-year PFS rates were higher with pembrolizumab.","[{'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Fradet', 'Affiliation': 'Department of Surgery/Urology, CHU de Québec-Université Laval, Québec City, Canada. Electronic address: yves.fradet@crchudequebec.ulaval.ca.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Bellmunt', 'Affiliation': 'Department of Medical Oncology, PSMAR-IMIM Research Institute, Barcelona, Spain and Harvard Medical School University, Boston, USA.'}, {'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Vaughn', 'Affiliation': 'Department of Medical Oncology, Abramson Cancer Center, Perelman Center for Advanced Medicine, Philadelphia, USA.'}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Lee', 'Affiliation': 'Department of Oncology, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Fong', 'Affiliation': 'Department of Medicine and Urology, University of California San Francisco, San Francisco.'}, {'ForeName': 'N J', 'Initials': 'NJ', 'LastName': 'Vogelzang', 'Affiliation': 'Department of Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, USA.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Climent', 'Affiliation': 'Department of Medical Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.'}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Petrylak', 'Affiliation': 'Division of Medical Oncology, Smilow Cancer Hospital at Yale University, New Haven.'}, {'ForeName': 'T K', 'Initials': 'TK', 'LastName': 'Choueiri', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Necchi', 'Affiliation': 'Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Gerritsen', 'Affiliation': 'Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Gurney', 'Affiliation': 'Department of Medical Oncology, Westmead Hospital and Macquarie University, Sydney, NSW, Australia.'}, {'ForeName': 'D I', 'Initials': 'DI', 'LastName': 'Quinn', 'Affiliation': 'Department of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Culine', 'Affiliation': 'Department of Medical Oncology, Hôpital Saint-Louis, Paris, France.'}, {'ForeName': 'C N', 'Initials': 'CN', 'LastName': 'Sternberg', 'Affiliation': 'Department of Medical Oncology, Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian, New York.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Nam', 'Affiliation': 'Department of Medical Oncology, Merck & Co., Inc., Kenilworth, USA.'}, {'ForeName': 'T L', 'Initials': 'TL', 'LastName': 'Frenkl', 'Affiliation': 'Department of Medical Oncology, Merck & Co., Inc., Kenilworth, USA.'}, {'ForeName': 'R F', 'Initials': 'RF', 'LastName': 'Perini', 'Affiliation': 'Department of Medical Oncology, Merck & Co., Inc., Kenilworth, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'de Wit', 'Affiliation': 'Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.'}, {'ForeName': 'D F', 'Initials': 'DF', 'LastName': 'Bajorin', 'Affiliation': 'Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdz127'] 341,31368793,Facilitators and barriers to successful recruitment into a large comparative effectiveness trial: a qualitative study.,"Background: Recruitment of participants into research studies, especially individuals from minority groups, is challenging; lack of diversity may lead to biased findings. Aim: To explore beliefs about research participation among individuals who were approached and eligible for the GRADE study. Methods: In-depth qualitative telephone interviews with randomized participants (n = 25) and eligible individuals who declined to enroll (n = 26). Results: Refusers and consenters differed in trust and perceptions of risk, benefits and burden of participation. Few participants understood how comparative effectiveness research differed from other types of trials; however, some features of comparative effectiveness research were perceived as lower risk. Conclusion: We identified facilitators and addressable barriers to participation in research studies.",2019,"Results: Refusers and consenters differed in trust and perceptions of risk, benefits and burden of participation.","['randomized participants (n\xa0=\xa025) and eligible individuals who declined to enroll (n\xa0=\xa026', 'participants into research studies, especially individuals from minority groups', 'individuals who were approached and eligible for the GRADE study']",[],"['trust and perceptions of risk, benefits and burden of participation']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0035168'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0026192', 'cui_str': 'Minority Groups'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}]",[],"[{'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",,0.150427,"Results: Refusers and consenters differed in trust and perceptions of risk, benefits and burden of participation.","[{'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Behringer-Massera', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Diabetes and Bone Diseases, Icahn School of Medicine, 1 Gustave L Levy Place, NY 10029, USA.'}, {'ForeName': 'Terysia', 'Initials': 'T', 'LastName': 'Browne', 'Affiliation': 'Department of Family & Social Medicine, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA.'}, {'ForeName': 'Geny', 'Initials': 'G', 'LastName': 'George', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Duran', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Cherrington', 'Affiliation': 'Department of Medicine, University of Alabama, Birmingham, AL 35294, USA.'}, {'ForeName': 'M Diane', 'Initials': 'MD', 'LastName': 'McKee', 'Affiliation': 'Department of Family & Social Medicine, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of comparative effectiveness research,['10.2217/cer-2019-0010'] 342,32250730,Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial.,"PURPOSE Everolimus decreases tumor volume of renal angiomyolipomas in patients with tuberous sclerosis. No prospective data are available regarding the effect of everolimus on the growth kinetics in patients with sporadic angiomyolipomas. We sought to determine the safety and efficacy of everolimus in the volumetric reduction of sporadic angiomyolipomas. MATERIALS AND METHODS This multi-institutional, prospective, phase II trial, enrolled patients with 3 cm or larger sporadic angiomyolipomas who were candidates for surgical resection or percutaneous angioembolization. Patients received 10 mg everolimus daily for 4 planned 28-day cycles. Response was defined as a 25% or greater volumetric reduction of patient angiomyolipoma. Baseline, 4, 6 and 12-month volumetric analyses were performed using magnetic resonance imaging. Everolimus was discontinued in those with less than 25% volumetric reduction after 4 cycles. Those with 25% or greater volumetric reduction received 2 additional cycles. The primary outcomes were the efficacy of everolimus in the volumetric reduction of angiomyolipomas by 25% or more, and the safety and tolerability of everolimus. RESULTS Overall 20 patients were enrolled at 5 centers. Of these patients 11 (55%) completed 4 cycles and 7 (35%) completed 6 cycles. Efficacy was demonstrated, with 10 of 18 (55.6%) patients exhibiting a 25% or greater reduction in tumor volume at 4 months (median 58.5%) and 10 of 14 (71.4%) patients exhibiting a 25% or greater reduction in tumor volume at 6 months (median 58.2%). Four (20%) patients were withdrawn due to protocol defined toxicities and 8 (40%) self-withdrew from the study due to side effects. CONCLUSIONS Everolimus was effective in causing volumetric reduction of angiomyolipomas by 25% or greater in most patients but was associated with a high rate of treatment discontinuation.",2020,"The primary outcomes were the efficacy of everolimus in the volumetric reduction of angiomyolipomas by ≥25% and the safety and tolerability of everolimus. ","['Sporadic Angiomyolipomas (AMLs', 'patients with sporadic angiomyolipomas', '20 patients were enrolled at 5 centers', 'patients with tuberous sclerosis', 'enrolled patients with ≥3cm sporadic angiomyolipomas who were candidates for surgical resection or percutaneous angioembolization']","['Everolimus (SAGE', 'everolimus', 'Everolimus']","['safety and tolerability of everolimus', 'efficacy of everolimus in the volumetric reduction of angiomyolipomas', 'safety and efficacy', 'tumor volume', 'toxicities', 'volumetric reduction of angiomyolipomas', 'Efficacy', 'Growth Kinetics', 'renal angiomyolipomas']","[{'cui': 'C0205422', 'cui_str': 'Sporadic'}, {'cui': 'C0206633', 'cui_str': 'Angiomyolipoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0041341', 'cui_str': 'Tuberous sclerosis syndrome'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}]","[{'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C1122976', 'cui_str': 'Sage'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0445383', 'cui_str': 'Volumetric'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0206633', 'cui_str': 'Angiomyolipoma'}, {'cui': 'C0475276', 'cui_str': 'Tumor volume'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}]",20.0,0.03125,"The primary outcomes were the efficacy of everolimus in the volumetric reduction of angiomyolipomas by ≥25% and the safety and tolerability of everolimus. ","[{'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Geynisman', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Brian T', 'Initials': 'BT', 'LastName': 'Kadow', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Brian M', 'Initials': 'BM', 'LastName': 'Shuch', 'Affiliation': 'Yale University, New Haven, Connecticut.'}, {'ForeName': 'Stephen A', 'Initials': 'SA', 'LastName': 'Boorjian', 'Affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Surena F', 'Initials': 'SF', 'LastName': 'Matin', 'Affiliation': 'MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Rampersaud', 'Affiliation': 'Duke University, Durham, North Carolina.'}, {'ForeName': 'Barton N', 'Initials': 'BN', 'LastName': 'Milestone', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Elizabeth R', 'Initials': 'ER', 'LastName': 'Plimack', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Matthew R', 'Initials': 'MR', 'LastName': 'Zibelman', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Kutikov', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Marc C', 'Initials': 'MC', 'LastName': 'Smaldone', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'David Yt', 'Initials': 'DY', 'LastName': 'Chen', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Rosalia', 'Initials': 'R', 'LastName': 'Viterbo', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Shreyas', 'Initials': 'S', 'LastName': 'Joshi', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Greenberg', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Lois', 'Initials': 'L', 'LastName': 'Malizzia', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'McGowan', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Ross', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Uzzo', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}]",The Journal of urology,['10.1097/JU.0000000000001065'] 343,31501887,"Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.","BACKGROUND Treatment options are limited for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) following progression after first-line platinum-based therapy, particularly in Asian countries. PATIENTS AND METHODS In this randomised, open-label, phase III trial, we enrolled Asian patients aged ≥18 years, with histologically or cytologically confirmed recurrent/metastatic HNSCC following first-line platinum-based therapy who were not amenable for salvage surgery or radiotherapy, and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0/1. Patients were randomised (2 : 1) to receive oral afatinib (40 mg/day) or intravenous methotrexate (40 mg/m2/week), stratified by ECOG performance status and prior EGFR-targeted antibody therapy. The primary end point was progression-free survival (PFS) assessed by an independent central review committee blinded to treatment allocation. RESULTS A total of 340 patients were randomised (228 afatinib; 112 methotrexate). After a median follow-up of 6.4 months, afatinib significantly decreased the risk of progression/death by 37% versus methotrexate (hazard ratio 0.63; 95% confidence interval 0.48-0.82; P = 0.0005; median 2.9 versus 2.6 months; landmark analysis at 12 and 24 weeks, 58% versus 41%, 21% versus 9%). Improved PFS was complemented by quality of life benefits. Objective response rate was 28% with afatinib and 13% with methotrexate. There was no significant difference in overall survival. The most common grade ≥3 drug-related adverse events were rash/acne (4% with afatinib versus 0% with methotrexate), diarrhoea (4% versus 0%), fatigue (1% versus 5%), anaemia (<1% versus 5%) and leukopenia (0% versus 5%). CONCLUSIONS Consistent with the phase III LUX-Head & Neck 1 trial, afatinib significantly improved PFS versus methotrexate, with a manageable safety profile. These results demonstrate the efficacy and feasibility of afatinib as a second-line treatment option for certain patients with recurrent or metastatic HNSCC. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT01856478.",2019,"After a median follow-up of 6.4 months, afatinib significantly decreased the risk of progression/death by 37% versus methotrexate (hazard ratio 0.63; 95% confidence interval 0.48-0.82; P = 0.0005; median 2.9 versus 2.6 months; landmark analysis at 12 and 24 weeks, 58% versus 41%, 21% versus 9%).","['certain patients with recurrent or metastatic HNSCC', '340 patients', 'patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) following progression after first-line platinum-based therapy, particularly in Asian countries', 'enrolled Asian patients aged ≥18 years, with histologically or cytologically confirmed recurrent/metastatic HNSCC following first-line platinum-based therapy who were not amenable for salvage surgery or radiotherapy, and had an ECOG performance status of 0/1', 'Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3']","['oral afatinib', 'Afatinib versus methotrexate', 'intravenous methotrexate (40\u2009mg/m2/week), stratified by ECOG performance status and prior EGFR-targeted antibody therapy', 'methotrexate']","['leukopenia', 'diarrhoea', 'progression-free survival (PFS', 'anaemia', 'overall survival', 'Objective response rate', 'risk of progression/death', 'quality of life benefits', 'fatigue']","[{'cui': 'C0205423', 'cui_str': 'Certainty (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C4517730', 'cui_str': '340'}, {'cui': 'C0334246', 'cui_str': 'Squamous cell carcinoma, metastatic (morphologic abnormality)'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0027536', 'cui_str': 'Necking (finding)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C1098768', 'cui_str': '(diethylenetriamine)-platinum(II)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0454705', 'cui_str': 'Asian country (geographic location)'}, {'cui': 'C0078988', 'cui_str': 'Asians'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0442967', 'cui_str': 'Salvage procedure (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C1520224', 'cui_str': 'Eastern Cooperative Oncology Group performance status'}, {'cui': 'C0560137', 'cui_str': 'lux (qualifier value)'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C2987648', 'cui_str': 'Afatinib'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C1319266', 'cui_str': 'mg/sq.m'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C1520224', 'cui_str': 'Eastern Cooperative Oncology Group performance status'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0750394', 'cui_str': 'Decreased blood leukocyte number (finding)'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0034380'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}]",340.0,0.160933,"After a median follow-up of 6.4 months, afatinib significantly decreased the risk of progression/death by 37% versus methotrexate (hazard ratio 0.63; 95% confidence interval 0.48-0.82; P = 0.0005; median 2.9 versus 2.6 months; landmark analysis at 12 and 24 weeks, 58% versus 41%, 21% versus 9%).","[{'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'Department of Medical Oncology, Shanghai East Hospital, Tongji University, Shanghai, China. Electronic address: pattrickguo@gmail.com.'}, {'ForeName': 'M-J', 'Initials': 'MJ', 'LastName': 'Ahn', 'Affiliation': 'Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Chan', 'Affiliation': 'State Key Laboratory in Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'C-H', 'Initials': 'CH', 'LastName': 'Wang', 'Affiliation': 'Department of Medical Oncology, Chang Gung Memorial Hospital at Keelung, Keelung, Taiwan.'}, {'ForeName': 'J-H', 'Initials': 'JH', 'LastName': 'Kang', 'Affiliation': ""The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul.""}, {'ForeName': 'S-B', 'Initials': 'SB', 'LastName': 'Kim', 'Affiliation': 'Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Bello', 'Affiliation': ""Department of Oncology, St Luke's Medical Center, Quezon City, Philippines.""}, {'ForeName': 'R S', 'Initials': 'RS', 'LastName': 'Arora', 'Affiliation': 'Department Oncology, Sujan Surgical Cancer Hospital and Amravati Cancer Foundation, Amravati, India.'}, {'ForeName': 'Q', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.'}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'He', 'Affiliation': 'Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Science, Beijing.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Li', 'Affiliation': 'West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Dechaphunkul', 'Affiliation': 'Division of Medical Oncology, Prince of Songkla University, Songkhla, Thailand.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Kumar', 'Affiliation': ""Department of Surgical Oncology, King George's Medical University, Lucknow.""}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Kamble', 'Affiliation': 'Department of Medicine, Government Medical College and Hospital, Nagpur, India.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Department of Hematology and Oncology, First Hospital Affiliated to Jilin University, Jilin, China.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Kandil', 'Affiliation': 'Internal Medicine, Alexandria University Hospital, Alexandria, Egypt.'}, {'ForeName': 'E E W', 'Initials': 'EEW', 'LastName': 'Cohen', 'Affiliation': 'Department of Medicine, University of California, San Diego, USA.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Geng', 'Affiliation': 'Biostatistics, Boehringer Ingelheim (China) Investment Co., Ltd, China.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Zografos', 'Affiliation': 'Clinical Development and Medical Affairs, Boehringer Ingelheim Ltd, Bracknell, Berkshire, UK.'}, {'ForeName': 'P Z', 'Initials': 'PZ', 'LastName': 'Tang', 'Affiliation': 'Department of Oncology, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdz388'] 344,32248591,"In infants with sufficient vitamin D status at birth, vitamin D supplementation does not impact immune development.","BACKGROUND Low vitamin D levels have been associated with allergic diseases. Vitamin D has potent immunomodulatory properties, but the mechanisms remain unclear. We have investigated the effect of oral vitamin D supplementation on circulating immune cell phenotypes in infants. METHOD A double-blinded randomised controlled trial was conducted to investigate the effect of oral vitamin D supplementation (400 IU/d) on eczema and immune development. A subset of 78 infants was included in this analysis. Phenotypic analysis of immune cell subsets was performed using flow cytometry. RESULTS Vitamin D supplementation resulted in median 25(OH)D levels of 80.5 vs 59.5 nmol/L in the placebo group at 3 months of age (P = .002) and 87.5 vs 77 nmol/L at 6 months of age (P = .08). We observed significant changes in immune cell composition from birth (cord blood) to 6 months of age. Vitamin D supplementation did not impact these changes, nor did immune cell composition correlate with plasma 25(OH)D levels. Through exploratory analysis, we identified possible associations with eczema development and increased abundance of naïve CD4 - T cells at birth, as well as associations with basophils, iNKT and central memory CD4 + T cells, and altered expression patterns of IgE receptor (FcεR1) on monocytes and dendritic cells with eczema at 6 months. CONCLUSIONS Vitamin D supplementation in infants who were vitamin D sufficient at birth did not affect developmental changes in immune cells during the first 6 months of life. However, immune cell profiles at birth and at 6 months of age were associated with early life eczema.",2020,"Vitamin D supplementation did not impact these changes, nor did immune cell composition correlate with plasma 25(OH)D levels.",['78 infants'],"['vitamin D supplementation', 'placebo', 'Vitamin D', 'Vitamin D supplementation', 'oral vitamin D supplementation']","['immune cell composition from birth (cord blood', 'abundance of naïve CD4 - T cells at birth, as well as associations with basophils, iNKT and central memory CD4 + T cells and altered expression patterns of IgE receptor (FcεR1) on monocytes and dendritic cells with eczema', 'eczema and immune development', 'median 25(OH)D levels']","[{'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0162371', 'cui_str': 'Cord blood'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C1744681', 'cui_str': 'Congenital'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0004827', 'cui_str': 'Basophils'}, {'cui': 'C2350467', 'cui_str': 'iNKT Cells'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0020846', 'cui_str': 'Immunoglobulin E'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0026473', 'cui_str': 'Monocyte'}, {'cui': 'C0003315', 'cui_str': 'Immunologic Accessory Cells'}, {'cui': 'C0013595', 'cui_str': 'Eczema'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.446861,"Vitamin D supplementation did not impact these changes, nor did immune cell composition correlate with plasma 25(OH)D levels.","[{'ForeName': 'Jonatan', 'Initials': 'J', 'LastName': 'Leffler', 'Affiliation': 'Telethon Kids Institute, University of Western Australia, Nedlands, WA, Australia.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Gamez', 'Affiliation': 'Telethon Kids Institute, University of Western Australia, Nedlands, WA, Australia.'}, {'ForeName': 'Anderson P', 'Initials': 'AP', 'LastName': 'Jones', 'Affiliation': 'Telethon Kids Institute, University of Western Australia, Nedlands, WA, Australia.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Rueter', 'Affiliation': 'School of Medicine, The University of Western Australia, Crawley, WA, Australia.'}, {'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Read', 'Affiliation': 'Telethon Kids Institute, University of Western Australia, Nedlands, WA, Australia.'}, {'ForeName': 'Aris', 'Initials': 'A', 'LastName': 'Siafarikas', 'Affiliation': 'Telethon Kids Institute, University of Western Australia, Nedlands, WA, Australia.'}, {'ForeName': 'Ee-Mun', 'Initials': 'EM', 'LastName': 'Lim', 'Affiliation': 'Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.'}, {'ForeName': 'Paul S', 'Initials': 'PS', 'LastName': 'Noakes', 'Affiliation': 'Telethon Kids Institute, University of Western Australia, Nedlands, WA, Australia.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Prescott', 'Affiliation': 'Telethon Kids Institute, University of Western Australia, Nedlands, WA, Australia.'}, {'ForeName': 'Philip A', 'Initials': 'PA', 'LastName': 'Stumbles', 'Affiliation': 'Telethon Kids Institute, University of Western Australia, Nedlands, WA, Australia.'}, {'ForeName': 'Debra J', 'Initials': 'DJ', 'LastName': 'Palmer', 'Affiliation': 'Telethon Kids Institute, University of Western Australia, Nedlands, WA, Australia.'}, {'ForeName': 'Deborah H', 'Initials': 'DH', 'LastName': 'Strickland', 'Affiliation': 'Telethon Kids Institute, University of Western Australia, Nedlands, WA, Australia.'}]",Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,['10.1111/pai.13250'] 345,32246728,Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.,"BACKGROUND AND OBJECTIVE When patients seek to discontinue buprenorphine (BUP) treatment, monthly injectable extended-release naltrexone (XR-NTX) may help them avoid relapse. The efficacy of low ascending doses of oral NTX vs placebo for patients transitioning from BUP to XR-NTX is evaluated in this study. METHODS In a phase 3, hybrid residential/outpatient study, clinically stable participants with opioid use disorder (N = 101), receiving BUP for more than or equal to 3 months and seeking antagonist treatment, were randomized (1:1) to 7 residential days of descending doses of BUP and low ascending doses of oral NTX (NTX/BUP, n = 50) or placebo (PBO-N/BUP, n = 51). Both groups received standing ancillary medications and psychoeducational counseling. Following negative naloxone challenge, participants received XR-NTX (day 8). The primary endpoint was the proportion of participants who received and tolerated XR-NTX. RESULTS There was no statistical difference between groups for participants receiving a first dose of XR-NTX: 68.6% (NTX/BUP) vs 76.0% (PBO-N/BUP; P = .407). The mean number of days with peak Clinical Opiate Withdrawal Scale (COWS) score less than or equal to 12 during the treatment period (days 1-7) was similar for NTX/BUP and PBO-N/BUP groups (5.8 vs 6.3; P = .511). Opioid withdrawal symptoms during XR-NTX induction and post-XR-NTX observation period (days 8-11) were mild and similar between groups (mean peak COWS score: NTX/BUP, 5.1 vs PBO-N/BUP, 5.4; P = .464). Adverse events were mostly mild/moderate. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE Low ascending doses of oral NTX did not increase induction rates onto XR-NTX compared with placebo. The overall rate of successful induction across treatment groups supports a brief BUP taper with standing ancillary medications as a well-tolerated approach for patients seeking transition from BUP to XR-NTX. (Am J Addict 2020;00:00-00).",2020,There was no statistical difference between groups for participants receiving a first dose of XR-NTX: 68.6% (NTX/BUP) vs 76.0% (PBO-N/BUP; P = .407).,"['Patients with Opioid Use Disorder from', 'clinically stable participants with opioid use disorder (N\u2009=\u2009101), receiving BUP for more than or equal to 3 months and seeking antagonist treatment', 'patients transitioning from BUP to XR-NTX']","['naltrexone (XR-NTX', 'oral NTX', 'XR-NTX', 'Buprenorphine', 'discontinue buprenorphine (BUP', 'placebo', 'BUP and low ascending doses of oral NTX (NTX/BUP, n\u2009=\u200950) or placebo (PBO-N/BUP, n\u2009=\u200951', 'standing ancillary medications and psychoeducational counseling', 'Naltrexone', 'oral NTX vs placebo']","['overall rate of successful induction', 'proportion of participants who received and tolerated XR-NTX', 'Adverse events', 'mean number of days with peak Clinical Opiate Withdrawal Scale (COWS) score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4019079', 'cui_str': 'Care Transition'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}]","[{'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0031962', 'cui_str': 'Piperonyl Butoxide'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C4706547', 'cui_str': 'Clinical Opiate Withdrawal Scale score'}]",,0.0223737,There was no statistical difference between groups for participants receiving a first dose of XR-NTX: 68.6% (NTX/BUP) vs 76.0% (PBO-N/BUP; P = .407).,"[{'ForeName': 'Sandra D', 'Initials': 'SD', 'LastName': 'Comer', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center, New York, New York.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Mannelli', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Danesh', 'Initials': 'D', 'LastName': 'Alam', 'Affiliation': 'Northwestern Medicine Central DuPage Hospital, Winfield, Illinois.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Douaihy', 'Affiliation': 'Departments of Psychiatry and Medicine, Western Psychiatric Hospital, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Narinder', 'Initials': 'N', 'LastName': 'Nangia', 'Affiliation': 'Alkermes, Inc., Waltham, Massachusetts.'}, {'ForeName': 'Sarah C', 'Initials': 'SC', 'LastName': 'Akerman', 'Affiliation': 'Alkermes, Inc., Waltham, Massachusetts.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Zavod', 'Affiliation': 'Alkermes, Inc., Waltham, Massachusetts.'}, {'ForeName': 'Bernard L', 'Initials': 'BL', 'LastName': 'Silverman', 'Affiliation': 'Alkermes, Inc., Waltham, Massachusetts.'}, {'ForeName': 'Maria A', 'Initials': 'MA', 'LastName': 'Sullivan', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center, New York, New York.'}]",The American journal on addictions,['10.1111/ajad.13024'] 346,31485014,Goat lung surfactant for treatment of respiratory distress syndrome among preterm neonates: a multi-site randomized non-inferiority trial.,"OBJECTIVE To investigate the safety and efficacy of goat lung surfactant extract (GLSE) compared with bovine surfactant extract (beractant; Survanta®, AbbVie, USA) for the treatment of neonatal respiratory distress syndrome (RDS). STUDY DESIGN We conducted a double-blind, non-inferiority, randomized trial in seven Indian centers between June 22, 2016 and January 11, 2018. Preterm neonates of 26 to 32 weeks gestation with clinical diagnosis of RDS were randomized to receive either GLSE or beractant. Repeat dose, if required, was open-label beractant in both the groups. The primary outcome was a composite of death or bronchopulmonary dysplasia (BPD) at 36 weeks postmenstrual age (PMA). Interim analyses were done by an independent data and safety monitoring board (DSMB). RESULT After the first interim analyses on 5% enrolment, the ""need for repeat dose(s) of surfactant"" was added as an additional primary outcome and enrolment restricted to intramural births at five of the seven participating centers. Following second interim analysis after 98 (10% of 900 planned) neonates were enroled, DSMB recommended closure of study in view of inferior efficacy of GLSE in comparison to beractant. There was no significant difference in the primary outcome of death or BPD between GLSE group (n = 52) and beractant group (n = 46) (50.0 vs. 39.1%; OR 1.5; 95% CI 0.7-3.5; p = 0.28). The need for repeat dose of surfactant was significantly higher in GLSE group (65.4 vs. 17.4%; OR 9.0; 95% CI 3.5-23.3; p < 0.001). CONCLUSIONS Goat lung surfactant was less efficacious than beractant (Survanta®) for treatment of RDS in preterm infants. Reasons to ascertain inferior efficacy of goat lung surfactant requires investigation and possible mitigating strategies in order to develop a low-cost and effective surfactant.",2019,"The need for repeat dose of surfactant was significantly higher in GLSE group (65.4 vs. 17.4%; OR 9.0; 95% CI 3.5-23.3; p < 0.001). ","['seven Indian centers between June 22, 2016 and January 11, 2018', 'preterm neonates', 'Preterm neonates of 26 to 32 weeks gestation with clinical diagnosis of RDS', 'neonatal respiratory distress syndrome (RDS', 'preterm infants']","['GLSE or beractant', 'Goat lung surfactant', 'goat lung surfactant extract (GLSE', 'GLSE', 'beractant (Survanta®', 'bovine surfactant extract (beractant; Survanta®, AbbVie, USA']","['respiratory distress syndrome', 'death or BPD', 'composite of death or bronchopulmonary dysplasia (BPD']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C1524069', 'cui_str': 'Indian (racial group)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0332140', 'cui_str': 'Clinical diagnosis (contextual qualifier) (qualifier value)'}, {'cui': 'C0035220', 'cui_str': 'Respiratory Distress Syndrome, Newborn'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}]","[{'cui': 'C0105750', 'cui_str': 'beractant'}, {'cui': 'C1510458', 'cui_str': 'Capras'}, {'cui': 'C0034085', 'cui_str': 'Pulmonary Surfactants'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C0699934', 'cui_str': 'Survanta'}, {'cui': 'C1265545', 'cui_str': 'Family Bovidae'}, {'cui': 'C4543209', 'cui_str': 'Surfactant'}]","[{'cui': 'C0035220', 'cui_str': 'Respiratory Distress Syndrome, Newborn'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary Dysplasia'}]",900.0,0.399564,"The need for repeat dose of surfactant was significantly higher in GLSE group (65.4 vs. 17.4%; OR 9.0; 95% CI 3.5-23.3; p < 0.001). ","[{'ForeName': 'Kajal', 'Initials': 'K', 'LastName': 'Jain', 'Affiliation': 'All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Sushma', 'Initials': 'S', 'LastName': 'Nangia', 'Affiliation': 'Lady Hardinge Medical College (LHMC), New Delhi, India.'}, {'ForeName': 'Vishnu Bhat', 'Initials': 'VB', 'LastName': 'Ballambattu', 'Affiliation': 'Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.'}, {'ForeName': 'Venkataseshan', 'Initials': 'V', 'LastName': 'Sundaram', 'Affiliation': 'Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.'}, {'ForeName': 'M Jeeva', 'Initials': 'MJ', 'LastName': 'Sankar', 'Affiliation': 'All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Siddharth', 'Initials': 'S', 'LastName': 'Ramji', 'Affiliation': 'Maulana Azad Medical College (MAMC), New Delhi, India.'}, {'ForeName': 'Sreenivas', 'Initials': 'S', 'LastName': 'Vishnubhatla', 'Affiliation': 'All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Anu', 'Initials': 'A', 'LastName': 'Thukral', 'Affiliation': 'All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Yogendra Kumar', 'Initials': 'YK', 'LastName': 'Gupta', 'Affiliation': 'All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Nishad', 'Initials': 'N', 'LastName': 'Plakkal', 'Affiliation': 'Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.'}, {'ForeName': 'Mangalabharathi', 'Initials': 'M', 'LastName': 'Sundaram', 'Affiliation': 'Institute for Child Health (ICH), Chennai, India.'}, {'ForeName': 'Mamta', 'Initials': 'M', 'LastName': 'Jajoo', 'Affiliation': 'Chacha Nehru Bal Chikitsalaya (CNBC), New Delhi, India.'}, {'ForeName': 'Praveen', 'Initials': 'P', 'LastName': 'Kumar', 'Affiliation': 'Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.'}, {'ForeName': 'Kumutha', 'Initials': 'K', 'LastName': 'Jayaraman', 'Affiliation': 'Institute for Child Health (ICH), Chennai, India.'}, {'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Jain', 'Affiliation': 'Maulana Azad Medical College (MAMC), New Delhi, India.'}, {'ForeName': 'Arvind', 'Initials': 'A', 'LastName': 'Saili', 'Affiliation': 'Lady Hardinge Medical College (LHMC), New Delhi, India.'}, {'ForeName': 'Anitha', 'Initials': 'A', 'LastName': 'Murugesan', 'Affiliation': 'Institute for Child Health (ICH), Chennai, India.'}, {'ForeName': 'Deepak', 'Initials': 'D', 'LastName': 'Chawla', 'Affiliation': 'Government Medical College & Hospital, Chandigarh, India.'}, {'ForeName': 'Srinivas', 'Initials': 'S', 'LastName': 'Murki', 'Affiliation': 'Fernandez Hospital, Hyderabad, India.'}, {'ForeName': 'Ruchi', 'Initials': 'R', 'LastName': 'Nanavati', 'Affiliation': 'King Edward Memorial Hospital, Mumbai, India.'}, {'ForeName': 'Suman', 'Initials': 'S', 'LastName': 'Rao', 'Affiliation': ""St. John's Medical College, Bangalore, India.""}, {'ForeName': 'Umesh', 'Initials': 'U', 'LastName': 'Vaidya', 'Affiliation': 'King Edward Memorial Hospital, Pune, India.'}, {'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Mehta', 'Affiliation': 'Arpan Newborn Care center and Sterling NICU, Ahmedabad, India.'}, {'ForeName': 'Kamal', 'Initials': 'K', 'LastName': 'Arora', 'Affiliation': 'Dayanand Medical College and Hospital, Punjab, India.'}, {'ForeName': 'Jayashree', 'Initials': 'J', 'LastName': 'Mondkar', 'Affiliation': 'Lokmanya Tilak Municipal General Hospital (SION Hospital), Mumbai, India.'}, {'ForeName': 'Sugandha', 'Initials': 'S', 'LastName': 'Arya', 'Affiliation': 'Safdarjung Hospital, New Delhi, India.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Bahl', 'Affiliation': 'Clinical Development Services Agency, Faridabad, India.'}, {'ForeName': 'Alpana', 'Initials': 'A', 'LastName': 'Utture', 'Affiliation': 'King Edward Memorial Hospital, Mumbai, India.'}, {'ForeName': 'Swati', 'Initials': 'S', 'LastName': 'Manerkar', 'Affiliation': 'Lokmanya Tilak Municipal General Hospital (SION Hospital), Mumbai, India.'}, {'ForeName': 'Swarna Rekha', 'Initials': 'SR', 'LastName': 'Bhat', 'Affiliation': ""St. John's Medical College, Bangalore, India.""}, {'ForeName': 'Tushar', 'Initials': 'T', 'LastName': 'Parikh', 'Affiliation': 'King Edward Memorial Hospital, Pune, India.'}, {'ForeName': 'Manish', 'Initials': 'M', 'LastName': 'Kumar', 'Affiliation': 'Arpan Newborn Care center and Sterling NICU, Ahmedabad, India.'}, {'ForeName': 'Anurag', 'Initials': 'A', 'LastName': 'Bajpai', 'Affiliation': 'All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Sindhu', 'Initials': 'S', 'LastName': 'Sivanandan', 'Affiliation': 'Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.'}, {'ForeName': 'Pawandeep Kaur', 'Initials': 'PK', 'LastName': 'Dhawan', 'Affiliation': 'Clinical Development Services Agency, Faridabad, India.'}, {'ForeName': 'Gayatri', 'Initials': 'G', 'LastName': 'Vishwakarma', 'Affiliation': 'Clinical Development Services Agency, Faridabad, India.'}, {'ForeName': 'Sudhakar', 'Initials': 'S', 'LastName': 'Bangera', 'Affiliation': 'Clinical Development Services Agency, Faridabad, India.'}, {'ForeName': 'Sumit', 'Initials': 'S', 'LastName': 'Kumar', 'Affiliation': 'Clinical Development Services Agency, Faridabad, India.'}, {'ForeName': 'Shridhar', 'Initials': 'S', 'LastName': 'Gopalakrishnan', 'Affiliation': 'Command Hospital, Panchkula, India.'}, {'ForeName': 'Atul', 'Initials': 'A', 'LastName': 'Jindal', 'Affiliation': 'All India Institute of Medical Sciences (AIIMS), Raipur, India.'}, {'ForeName': 'Chandra Kumar', 'Initials': 'CK', 'LastName': 'Natarajan', 'Affiliation': 'Cloudnine Hospital, Chennai, India.'}, {'ForeName': 'Anumeet', 'Initials': 'A', 'LastName': 'Saini', 'Affiliation': 'Lady Hardinge Medical College (LHMC), New Delhi, India.'}, {'ForeName': 'Sukanya', 'Initials': 'S', 'LastName': 'Karunanidhi', 'Affiliation': 'Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.'}, {'ForeName': 'Meenakshi', 'Initials': 'M', 'LastName': 'Malik', 'Affiliation': 'Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.'}, {'ForeName': 'Parul', 'Initials': 'P', 'LastName': 'Narang', 'Affiliation': 'All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Gurkirat', 'Initials': 'G', 'LastName': 'Kaur', 'Affiliation': 'Maulana Azad Medical College (MAMC), New Delhi, India.'}, {'ForeName': 'Chander Prakash', 'Initials': 'CP', 'LastName': 'Yadav', 'Affiliation': 'National Institute of Malaria Research, New Delhi, India.'}, {'ForeName': 'Ashok', 'Initials': 'A', 'LastName': 'Deorari', 'Affiliation': 'All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Vinod K', 'Initials': 'VK', 'LastName': 'Paul', 'Affiliation': 'All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Ramesh', 'Initials': 'R', 'LastName': 'Agarwal', 'Affiliation': 'All India Institute of Medical Sciences (AIIMS), New Delhi, India. ra.aiims@gmail.com.'}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/s41372-019-0472-0'] 347,32064727,Randomized trial results of alerting primary clinicians to severe weight loss among older adults in the Low Indexes of Metabolism Intervention Trial part A.,"AIM To test whether alerting clinicians to severe weight loss in older patients leads to higher dietitian visit rates, to higher body mass index (BMI) levels and, mainly, to lower annual death risk. METHODS The randomized controlled trial included patients aged ≥75 years, with BMI ≤23 kg/m 2 that decreased ≥2 kg/m 2 during the previous 2 years. All participants received usual care. Additionally, an email alert was sent only to clinicians of participants assigned to the email alert group. The follow-up period was 12 months. RESULTS Among 706 participants (mean age 83 ± 6 years; mean baseline BMI 20.5 kg/m 2 ), the BMI record was updated in 541 (77%) participants, and 123 participants died. Dietitian visits were reported for 22 patients (6%) in the email group (n = 362) and 14 patients (4%) in the control group (n = 344; OR 1.5, 95% CI 0.8-2.9; P = 0.24). Measured BMI were raised by a mean of 0.69 (95% CI 0.43-0.95) kg/m 2 versus 0.79 (95% CI 0.48-1.1) kg/m 2 (P = 0.63). A total of 77 patients (21%) died in the intervention group versus 47 (14%) in the control group (P = 0.008; number needed to harm = 13; 95% CI 7-43). CONCLUSIONS In this trial, alerting clinical staff to severe weight loss in patients aged ≥75 years was not associated with higher visit rates to a dietitian or change in BMI, but was associated with a significantly higher death rate than usual clinical care. Geriatr Gerontol Int 2020; 20: 329-335.",2020,Measured BMI were raised by a mean of 0.69 (95% CI 0.43-0.95) kg/m 2 versus 0.79 (95% CI 0.48-1.1) kg/m 2 (P = 0.63).,"['older patients', '706 participants (mean age 83\u2009±\u20096\u2009years; mean baseline BMI 20.5\u2009kg/m 2 ), the BMI record was updated in 541 (77%) participants, and 123 participants died', 'patients aged ≥75\u2009years, with BMI ≤23', 'patients aged ≥75\u2009years', 'older adults in the Low Indexes of Metabolism Intervention Trial part\u2009A']",['usual care'],"['Dietitian visits', 'body mass index (BMI) levels', 'severe weight loss', 'death rate', 'Measured BMI']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}]",[],"[{'cui': 'C0334932', 'cui_str': 'Dietitian (general) (occupation)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}]",77.0,0.157863,Measured BMI were raised by a mean of 0.69 (95% CI 0.43-0.95) kg/m 2 versus 0.79 (95% CI 0.48-1.1) kg/m 2 (P = 0.63).,"[{'ForeName': 'Nir', 'Initials': 'N', 'LastName': 'Tsabar', 'Affiliation': 'Clalit Health Services (CHS) Northern District, Nazareth, Israel.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Press', 'Affiliation': 'Department of Family Medicine, Sial Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Rotman', 'Affiliation': 'Educational Programs, CHS Northern District, Nazareth, Israel.'}, {'ForeName': 'Bracha', 'Initials': 'B', 'LastName': 'Klein', 'Affiliation': 'Unit for Ambulatory Geriatric Services, CHS Northern District, Nazareth, Israel.'}, {'ForeName': 'Yonatan', 'Initials': 'Y', 'LastName': 'Grossman', 'Affiliation': 'The Azrieli Faculty of Medicine in Galilee, Bar-Ilan University, Safed, Israel.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Vainshtein-Tal', 'Affiliation': 'Unit for Clinical Nutrition and Dietetics, CHS Northern District, Nazareth, Israel.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Eilat-Tsanani', 'Affiliation': 'The Azrieli Faculty of Medicine in Galilee, Bar-Ilan University, Safed, Israel.'}]",Geriatrics & gerontology international,['10.1111/ggi.13888'] 348,31176727,Determining the biological associates of acute cold pressor post-encoding stress effects on human memory: The role of salivary interleukin-1β.,"Stress generally hurts many aspects of memory, but an interesting finding to emerge from the stress and memory literature is that stress that occurs shortly after learning (i.e., post-encoding stress) usually benefits memory. Although this effect is well established, the biological mechanisms underpinning this effect are not-especially in humans. We addressed this gap in the present study by collecting saliva samples from 80 participants who were randomized to a post-encoding stress (i.e., cold pressor for 3 min) or control task (i.e., warm water for 3 min) and 48 h later completed a recognition memory task. Saliva was collected both prior to and 15 min after the offset of (18 min after the onset of) the stress/control manipulation. Drawing on animal and human work, we examined how five stress-responsive biomarkers-cortisol, salivary α-amylase, progesterone, estradiol, and the proinflammatory cytokine interleukin (IL)-1β, all assessed in saliva-related to the effects of stress on memory. We found that stress enhanced recollection of negative images and that these effects were selectively related to salivary IL-1β. Moreover, we found that the beneficial effects of stress on memory were statistically mediated by salivary IL-1β. We found no robust associations-either linear or quadratic-between memory and any other biomarker, nor did we find significant interactions between biomarkers in predicting memory. These results suggest that immune system activity indexed by salivary IL-1β may play an important role in contributing to post-encoding stress effects on human memory.",2019,We found that stress enhanced recollection of negative images and that these effects were selectively related to salivary IL-1β.,"['80 participants who were randomized to a', 'human memory']","['post-encoding stress (i.e., cold pressor for 3\u202fmin) or control task (i.e., warm water for 3\u202fmin) and 48\u202fh later completed a recognition memory task', 'salivary interleukin-1β']",['salivary IL-1β'],"[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0025260', 'cui_str': 'Memory'}]","[{'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0444689', 'cui_str': 'Cold pressor test (procedure)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0184348', 'cui_str': 'Warmer'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0524637', 'cui_str': 'Recognition (Psychology)'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0442040', 'cui_str': 'Salivary (qualifier value)'}, {'cui': 'C0021764', 'cui_str': 'Interleukins'}]","[{'cui': 'C0442040', 'cui_str': 'Salivary (qualifier value)'}]",80.0,0.0340848,We found that stress enhanced recollection of negative images and that these effects were selectively related to salivary IL-1β.,"[{'ForeName': 'Grant S', 'Initials': 'GS', 'LastName': 'Shields', 'Affiliation': 'Center for Mind and Brain, University of California, Davis, United States. Electronic address: gsshields@ucdavis.edu.'}, {'ForeName': 'Tiffany M', 'Initials': 'TM', 'LastName': 'Dunn', 'Affiliation': 'Department of Psychology, University of California, Davis, United States.'}, {'ForeName': 'Brian C', 'Initials': 'BC', 'LastName': 'Trainor', 'Affiliation': 'Department of Psychology, University of California, Davis, United States.'}, {'ForeName': 'Andrew P', 'Initials': 'AP', 'LastName': 'Yonelinas', 'Affiliation': 'Department of Psychology, University of California, Davis, United States; Center for Neuroscience, University of California, Davis, United States.'}]","Brain, behavior, and immunity",['10.1016/j.bbi.2019.06.011'] 349,31504126,Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.,"BACKGROUND Extending the duration of adjuvant endocrine therapy reduces the risk of recurrence in a subset of women with early-stage hormone receptor-positive (HR+) breast cancer. Validated predictive biomarkers of endocrine response could significantly improve patient selection for extended therapy. Breast cancer index (BCI) [HOXB13/IL17BR ratio (H/I)] was evaluated for its ability to predict benefit from extended endocrine therapy in patients previously randomized in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. PATIENTS AND METHODS Trans-aTTom is a multi-institutional, prospective-retrospective study in patients with available formalin-fixed paraffin-embedded primary tumor blocks. BCI testing and central determination of estrogen receptor (ER) and progesterone receptor (PR) status by immunohistochemistry were carried out blinded to clinical outcome. Survival endpoints were evaluated using Kaplan-Meier analysis and Cox regression with recurrence-free interval (RFI) as the primary endpoint. Interaction between extended endocrine therapy and BCI (H/I) was assessed using the likelihood ratio test. RESULTS Of 583 HR+, N+ patients analyzed, 49% classified as BCI (H/I)-High derived a significant benefit from 10 versus 5 years of tamoxifen treatment [hazard ratio (HR): 0.35; 95% confidence interval (CI) 0.15-0.86; 10.2% absolute risk reduction based on RFI, P = 0.027]. BCI (H/I)-low patients showed no significant benefit from extended endocrine therapy (HR: 1.07; 95% CI 0.69-1.65; -0.2% absolute risk reduction; P = 0.768). Continuous BCI (H/I) levels predicted the magnitude of benefit from extended tamoxifen, whereas centralized ER and PR did not. Interaction between extended tamoxifen treatment and BCI (H/I) was statistically significant (P = 0.012), adjusting for clinicopathological factors. CONCLUSION BCI by high H/I expression was predictive of endocrine response and identified a subset of HR+, N+ patients with significant benefit from 10 versus 5 years of tamoxifen therapy. These data provide further validation, consistent with previous MA.17 data, establishing level 1B evidence for BCI as a predictive biomarker of benefit from extended endocrine therapy. TRIAL REGISTRATION ISRCTN17222211; NCT00003678.",2019,"Interaction between extended tamoxifen treatment and BCI (H/I) was statistically significant (P = 0.012), adjusting for clinicopathological factors. ","['patients with available formalin-fixed paraffin-embedded (FFPE) primary tumor blocks', 'Breast Cancer Patients Treated in the Adjuvant', 'women with early-stage hormone receptor-positive (HR+) breast cancer']","['tamoxifen therapy', 'adjuvant endocrine therapy', 'Tamoxifen', 'tamoxifen', 'Endocrine Therapy']","['BCI testing and central determination of estrogen receptor (ER) and progesterone receptor (PR) status by immunohistochemistry (IHC', 'Survival endpoints', 'risk of recurrence', 'BCI', 'Breast Cancer Index (BCI']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0949307', 'cui_str': 'Formalin'}, {'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0085185', 'cui_str': 'Paraffin Embedding'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C2363430', 'cui_str': 'Early stage (qualifier value)'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}]","[{'cui': 'C4510392', 'cui_str': 'Tamoxifen therapy'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy (procedure)'}, {'cui': 'C0039286', 'cui_str': 'Tamoxifen'}]","[{'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C1148554', 'cui_str': 'determination'}, {'cui': 'C0034804', 'cui_str': 'Estrogen Receptors'}, {'cui': 'C0034833', 'cui_str': 'Receptors, Progestin'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0021044', 'cui_str': 'Immunohistochemistry'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.13255,"Interaction between extended tamoxifen treatment and BCI (H/I) was statistically significant (P = 0.012), adjusting for clinicopathological factors. ","[{'ForeName': 'J M S', 'Initials': 'JMS', 'LastName': 'Bartlett', 'Affiliation': 'Ontario Institute for Cancer Research, Toronto, Canada; University of Edinburgh Cancer Research Centre, Edinburgh, UK. Electronic address: john.bartlett@oicr.on.ca.'}, {'ForeName': 'D C', 'Initials': 'DC', 'LastName': 'Sgroi', 'Affiliation': 'Department of Pathology, Massachusetts General Hospital, Boston, MA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Treuner', 'Affiliation': 'Biotheranostics Inc., San Diego, USA.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Biotheranostics Inc., San Diego, USA.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Ahmed', 'Affiliation': 'Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Piper', 'Affiliation': 'University of Edinburgh Cancer Research Centre, Edinburgh, UK.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Salunga', 'Affiliation': 'Biotheranostics Inc., San Diego, USA.'}, {'ForeName': 'E F', 'Initials': 'EF', 'LastName': 'Brachtel', 'Affiliation': 'Department of Pathology, Massachusetts General Hospital, Boston, MA.'}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Pirrie', 'Affiliation': 'Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'C A', 'Initials': 'CA', 'LastName': 'Schnabel', 'Affiliation': 'Biotheranostics Inc., San Diego, USA.'}, {'ForeName': 'D W', 'Initials': 'DW', 'LastName': 'Rea', 'Affiliation': 'Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdz289'] 350,31277077,Cardiorespiratory behavior of preterm infants receiving continuous positive airway pressure and high flow nasal cannula post extubation: randomized crossover study.,"BACKGROUND Nasal continuous positive airway pressure (NCPAP) and high flow nasal cannula (HFNC) are modes of non-invasive respiratory support commonly used after extubation in extremely preterm infants. However, the cardiorespiratory physiology of these infants on each mode is unknown. METHODS Prospective, randomized crossover study in infants with birth weight ≤1250 g undergoing their first extubation attempt. NCPAP and HFNC were applied randomly for 45 min each, while ribcage and abdominal movements, electrocardiogram, oxygen saturation, and fraction of inspired oxygen (FiO 2 ) were recorded. Respiratory signals were analyzed using an automated method, and differences between NCPAP and HFNC features and changes in FiO 2 were analyzed. RESULTS A total of 30 infants with median [interquartile range] gestational age of 27 weeks [25.7, 27.9] and birth weight of 930 g [780, 1090] were studied. Infants were extubated at 5 days [2, 13] of life with 973 g [880, 1170] and three failed (10%). No differences in cardiorespiratory behavior were noted, except for longer respiratory pauses (9.2 s [5.0, 11.5] vs. 7.3 s [4.6, 9.3]; p = 0.04) and higher FiO 2 levels (p = 0.02) during HFNC compared to NCPAP. CONCLUSIONS In extremely preterm infants studied shortly after extubation, the use of HFNC was associated with longer respiratory pauses and higher FiO 2 requirements.",2020,"No differences in cardiorespiratory behavior were noted, except for longer respiratory pauses (9.2 s [5.0, 11.5] vs. 7.3 s [4.6, 9.3]; p = 0.04) and higher FiO 2 levels (p = 0.02) during HFNC compared to NCPAP. ","['extremely preterm infants', 'infants with birth weight ≤1250', 'preterm infants receiving continuous positive airway pressure and high flow nasal cannula post extubation', '30 infants with median [interquartile range] gestational age of 27 weeks [25.7, 27.9] and birth weight of 930\u2009g [780, 1090']","['HFNC', 'NCPAP and HFNC', 'Nasal continuous positive airway pressure (NCPAP) and high flow nasal cannula (HFNC']","['longer respiratory pauses', 'ribcage and abdominal movements, electrocardiogram, oxygen saturation, and fraction of inspired oxygen (FiO 2 ', 'cardiorespiratory behavior']","[{'cui': 'C3494262', 'cui_str': 'Extremely Preterm Infants'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannula'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C1258045', 'cui_str': 'Nasal Continuous Positive Airway Pressure'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannula'}]","[{'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0222762', 'cui_str': 'Thoracic Cage'}, {'cui': 'C1286159', 'cui_str': 'Movement of abdomen'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C0428167', 'cui_str': 'FIO2'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]",30.0,0.118465,"No differences in cardiorespiratory behavior were noted, except for longer respiratory pauses (9.2 s [5.0, 11.5] vs. 7.3 s [4.6, 9.3]; p = 0.04) and higher FiO 2 levels (p = 0.02) during HFNC compared to NCPAP. ","[{'ForeName': 'Lara J', 'Initials': 'LJ', 'LastName': 'Kanbar', 'Affiliation': 'Department of Biomedical Engineering, Montreal, QC, Canada.'}, {'ForeName': 'Wissam', 'Initials': 'W', 'LastName': 'Shalish', 'Affiliation': 'Department of Pediatrics, Neonatal Division, Montreal, QC, Canada.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Latremouille', 'Affiliation': 'Department of Pediatrics, Neonatal Division, Montreal, QC, Canada.'}, {'ForeName': 'Smita', 'Initials': 'S', 'LastName': 'Rao', 'Affiliation': 'Department of Pediatrics, Neonatal Division, Montreal, QC, Canada.'}, {'ForeName': 'Karen A', 'Initials': 'KA', 'LastName': 'Brown', 'Affiliation': 'Department of Anesthesia, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Kearney', 'Affiliation': 'Department of Biomedical Engineering, Montreal, QC, Canada.'}, {'ForeName': 'Guilherme M', 'Initials': 'GM', 'LastName': ""Sant'Anna"", 'Affiliation': 'Department of Pediatrics, Neonatal Division, Montreal, QC, Canada. guilherme.santanna@mcgill.ca.'}]",Pediatric research,['10.1038/s41390-019-0494-5'] 351,31733631,"Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.","Lysergic acid diethylamide (LSD) is a classic psychedelic, 3,4-methylenedioxymethamphetamine (MDMA) is an empathogen, and D-amphetamine is a classic stimulant. All three substances are used recreationally. LSD and MDMA are being investigated as medications to assist psychotherapy, and D-amphetamine is used for the treatment of attention-deficit/hyperactivity disorder. All three substances induce distinct acute subjective effects. However, differences in acute responses to these prototypical psychoactive substances have not been characterized in a controlled study. We investigated the acute autonomic, subjective, and endocrine effects of single doses of LSD (0.1 mg), MDMA (125 mg), D-amphetamine (40 mg), and placebo in a randomized, double-blind, cross-over study in 28 healthy subjects. All of the substances produced comparable increases in hemodynamic effects, body temperature, and pupil size, indicating equivalent autonomic responses at the doses used. LSD and MDMA increased heart rate more than D-amphetamine, and D-amphetamine increased blood pressure more than LSD and MDMA. LSD induced significantly higher ratings on the 5 Dimensions of Altered States of Consciousness scale and Mystical Experience Questionnaire than MDMA and D-amphetamine. LSD also produced greater subjective drug effects, ego dissolution, introversion, emotional excitation, anxiety, and inactivity than MDMA and D-amphetamine. LSD also induced greater impairments in subjective ratings of concentration, sense of time, and speed of thinking compared with MDMA and D-amphetamine. MDMA produced greater ratings of good drug effects, liking, high, and ego dissolution compared with D-amphetamine. D-Amphetamine increased ratings of activity and concentration compared with LSD. MDMA but not LSD or D-amphetamine increased plasma concentrations of oxytocin. None of the substances altered plasma concentrations of brain-derived neurotrophic factor. These results indicate clearly distinct acute effects of LSD, MDMA, and D-amphetamine and may assist the dose-finding in substance-assisted psychotherapy research.",2020,LSD induced significantly higher ratings on the 5 Dimensions of Altered States of Consciousness scale and Mystical Experience Questionnaire than MDMA and D-amphetamine.,"['healthy subjects', '28 healthy subjects']","['3,4-methylenedioxymethamphetamine', 'LSD, MDMA, and D-amphetamine', 'LSD', 'MDMA', 'placebo', 'Lysergic acid diethylamide (LSD', 'D-amphetamine, and D-amphetamine', 'D-amphetamine']","['hemodynamic effects, body temperature, and pupil size, indicating equivalent autonomic responses', 'blood pressure', 'subjective ratings of concentration, sense of time, and speed of thinking', 'ratings of activity and concentration', 'plasma concentrations of oxytocin', 'subjective drug effects, ego dissolution, introversion, emotional excitation, anxiety, and inactivity than MDMA and D-amphetamine', 'LSD and MDMA increased heart rate', 'Consciousness scale and Mystical Experience Questionnaire', 'ratings of good drug effects, liking, high, and ego dissolution']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0115471', 'cui_str': 'MDMA'}, {'cui': 'C0024334', 'cui_str': 'LSD'}, {'cui': 'C0011812', 'cui_str': 'dexamfetamine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0886414', 'cui_str': 'Body temperature'}, {'cui': 'C0034121', 'cui_str': 'Pupil'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0728867', 'cui_str': 'Drug action (finding)'}, {'cui': 'C0013712', 'cui_str': 'Ego'}, {'cui': 'C0021924', 'cui_str': 'Introversion'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0115471', 'cui_str': 'MDMA'}, {'cui': 'C0011812', 'cui_str': 'dexamfetamine'}, {'cui': 'C0024334', 'cui_str': 'LSD'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}, {'cui': 'C0234421', 'cui_str': 'Consciousness'}, {'cui': 'C0222045'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]",28.0,0.0410698,LSD induced significantly higher ratings on the 5 Dimensions of Altered States of Consciousness scale and Mystical Experience Questionnaire than MDMA and D-amphetamine.,"[{'ForeName': 'Friederike', 'Initials': 'F', 'LastName': 'Holze', 'Affiliation': 'Department of Biomedicine and Department of Clinical Research, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, University of Basel, Basel, 4056, Switzerland.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Vizeli', 'Affiliation': 'Department of Biomedicine and Department of Clinical Research, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, University of Basel, Basel, 4056, Switzerland.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Müller', 'Affiliation': 'Psychiatric University Hospital (UPK), University of Basel, Basel, 4012, Switzerland.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Ley', 'Affiliation': 'Department of Biomedicine and Department of Clinical Research, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, University of Basel, Basel, 4056, Switzerland.'}, {'ForeName': 'Raoul', 'Initials': 'R', 'LastName': 'Duerig', 'Affiliation': 'Department of Biomedicine and Department of Clinical Research, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, University of Basel, Basel, 4056, Switzerland.'}, {'ForeName': 'Nimmy', 'Initials': 'N', 'LastName': 'Varghese', 'Affiliation': 'Psychiatric University Hospital (UPK), University of Basel, Basel, 4012, Switzerland.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Eckert', 'Affiliation': 'Psychiatric University Hospital (UPK), University of Basel, Basel, 4012, Switzerland.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Borgwardt', 'Affiliation': 'Psychiatric University Hospital (UPK), University of Basel, Basel, 4012, Switzerland.'}, {'ForeName': 'Matthias E', 'Initials': 'ME', 'LastName': 'Liechti', 'Affiliation': 'Department of Biomedicine and Department of Clinical Research, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, University of Basel, Basel, 4056, Switzerland. matthias.liechti@usb.ch.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0569-3'] 352,32247347,In Utero Restoration of Hindbrain Herniation in Fetal Myelomeningocele as Part of Prenatal Regenerative Therapy Program at Mayo Clinic.,"OBJECTIVE To assess our initial experience with prenatal restoration of hindbrain herniation following in utero repair of myelomeningocele (MMC). PATIENTS AND METHODS Three consecutive patients with prenatally diagnosed MMC (between January 1, 2018 and September 30, 2018) were managed with open in utero surgery. As per institutional review board approval and following a protocol designed at the Mayo Clinic Maternal & Fetal Center, fetal intervention was offered between 19 0/7 and 25 6/7 weeks of gestation. Prenatal improvement of hindbrain herniation was the declared restorative end point. Obstetrical and perinatal outcomes were also assessed. RESULTS Diagnosis of MMC was confirmed upon referral between 20 and 21 weeks' gestation by using fetal ultrasound and magnetic resonance imaging. In all cases reported here, the spinal defect was lumbosacral with evidence of hindbrain herniation. Open in utero MMC repair was performed between 24 and 25 weeks' gestation with no notable perioperative complications. Postprocedure fetal magnetic resonance imaging performed 6 weeks after in utero repair documented improvement of hindbrain herniation. Deliveries were at 37 weeks by cesarean section without complications. Most recent postnatal follow-ups were unremarkable at both 11 months (baby 1) and 3 months of age (baby 2), with mild ventriculomegaly. Antenatal and postnatal follow-up of baby 3 at 1 month of age was also unremarkable. CONCLUSION Our study highlights the prenatal restoration of hindbrain herniation following in utero MMC repair in all cases presented here as an example of a prenatal regenerative therapy program in our institution.",2020,Our study highlights the prenatal restoration of hindbrain herniation following in utero MMC repair in all cases presented here as an example of a prenatal regenerative therapy program in our institution.,"['Three consecutive patients with prenatally diagnosed MMC (between January 1, 2018 and September 30, 2018) were managed with open in utero surgery']",['hindbrain herniation following in utero repair of myelomeningocele (MMC'],['hindbrain herniation'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0002475', 'cui_str': 'Mitomycin'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0035507', 'cui_str': 'Hindbrain structure'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0196477', 'cui_str': 'Repair of myelomeningocele'}, {'cui': 'C0002475', 'cui_str': 'Mitomycin'}]","[{'cui': 'C0035507', 'cui_str': 'Hindbrain structure'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}]",3.0,0.0581863,Our study highlights the prenatal restoration of hindbrain herniation following in utero MMC repair in all cases presented here as an example of a prenatal regenerative therapy program in our institution.,"[{'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Ruano', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, Rochester, MN; Center for Regenerative Medicine, Mayo Clinic College of Medicine, Rochester, MN. Electronic address: ruano.rodrigo@mayo.edu.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Daniels', 'Affiliation': 'Division of Pediatric Neurosurgery, Department of Surgery, Mayo Clinic College of Medicine, Rochester, MN.'}, {'ForeName': 'Edward S', 'Initials': 'ES', 'LastName': 'Ahn', 'Affiliation': 'Division of Pediatric Neurosurgery, Department of Surgery, Mayo Clinic College of Medicine, Rochester, MN.'}, {'ForeName': 'Eniola R', 'Initials': 'ER', 'LastName': 'Ibirogba', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, Rochester, MN.'}, {'ForeName': 'Victor M', 'Initials': 'VM', 'LastName': 'Lu', 'Affiliation': 'Division of Pediatric Neurosurgery, Department of Surgery, Mayo Clinic College of Medicine, Rochester, MN.'}, {'ForeName': 'Kendall A', 'Initials': 'KA', 'LastName': 'Snyder', 'Affiliation': 'Division of Pediatric Neurosurgery, Department of Surgery, Mayo Clinic College of Medicine, Rochester, MN.'}, {'ForeName': 'Mari Charisse', 'Initials': 'MC', 'LastName': 'Trinidad', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, Rochester, MN.'}, {'ForeName': 'William A', 'Initials': 'WA', 'LastName': 'Carey', 'Affiliation': 'Division of Neonatal Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic College of Medicine, Rochester, MN.'}, {'ForeName': 'Christopher E', 'Initials': 'CE', 'LastName': 'Colby', 'Affiliation': 'Division of Neonatal Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic College of Medicine, Rochester, MN.'}, {'ForeName': 'Amy B', 'Initials': 'AB', 'LastName': 'Kolbe', 'Affiliation': 'Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN.'}, {'ForeName': 'Katherine W', 'Initials': 'KW', 'LastName': 'Arendt', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, Mayo Clinic College of Medicine, Rochester, MN.'}, {'ForeName': 'Leal', 'Initials': 'L', 'LastName': 'Segura', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, Mayo Clinic College of Medicine, Rochester, MN.'}, {'ForeName': 'Hans P', 'Initials': 'HP', 'LastName': 'Sviggum', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, Mayo Clinic College of Medicine, Rochester, MN.'}, {'ForeName': 'M Yasir', 'Initials': 'MY', 'LastName': 'Qureshi', 'Affiliation': 'Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic College of Medicine, Rochester, MN.'}, {'ForeName': 'Abimbola', 'Initials': 'A', 'LastName': 'Famuyide', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, Rochester, MN.'}, {'ForeName': 'Andre', 'Initials': 'A', 'LastName': 'Terzic', 'Affiliation': 'Center for Regenerative Medicine, Mayo Clinic College of Medicine, Rochester, MN; Department of Cardiovascular Medicine, Mayo Clinic College of Medicine, Rochester, MN.'}]",Mayo Clinic proceedings,['10.1016/j.mayocp.2019.10.039'] 353,32092321,"A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis.","BACKGROUND The interstitial lung diseases include a variety of disorders, many of which are characterized by fibrotic changes (fILD). Of the fILDs, Idiopathic pulmonary fibrosis is the most common. Pulmonary hypertension (PH) frequently complicates fILD and is associated with impaired functional capability, lower physical activity, and significantly reduced life expectancy. There is no proven treatment for patients with fILD-PH. We report results from the first cohort of a phase 2b/3 trial with pulsed inhaled nitric oxide (iNO) in patients with fILD-PH. METHODS Subjects in cohort 1 were randomized to iNO 30 μg/kg ideal body weight/h (iNO30) or placebo for 8 weeks of blinded treatment; subjects then transitioned to open-label extension (OLE) on iNO30 followed by dose escalation to iNO45 then iNO75. Activity monitoring was used to assess changes in daily activity. Safety and efficacy were evaluated. RESULTS Twenty-three patients were randomized to iNO30 and 18 to placebo. During blinded treatment, iNO30 subjects showed an average improvement in moderate/vigorous physical activity (MVPA) and remained stable in overall activity. Placebo subjects showed an average drop of 26% in MVPA and a 12% drop in overall activity. The iNO group had an improvement in oxygen saturation. During OLE, subjects maintained their activity levels including placebo subjects who transitioned from a decline to a maintenance in all activity parameters. Inhaled nitric oxide at all doses (30, 45, and 75) was safe and well tolerated. CONCLUSIONS Treatment with iNO30 demonstrated clinically and statistically significant benefit in MVPA and clinically significant benefit in overall activity. In the OLE, higher doses of iNO were also safe and well tolerated while showing maintenance in activity parameters.",2020,During blinded treatment iNO30 subjects showed an average improvement in moderate/vigorous physical activity (MVPA) and remained stable in overall activity.,"['subjects at risk of Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF) receiving Oxygen Therapy', 'patients with fILD-PH', 'patients with fILD-PH.\nMETHODS\n\n\nSubjects in Cohort 1']","['iNO 30 mcg/kg IBW/hr (iNO30) or placebo', 'placebo', 'pulsed, inhaled nitric oxide (iNO', 'pulsed iNO', 'Placebo']","['safety and efficacy', 'overall activity', 'activity levels', 'Safety and efficacy', 'oxygen saturation', 'safe and well tolerated', 'moderate/vigorous physical activity (MVPA']","[{'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C1963999', 'cui_str': 'Pulmonary hypertension (SMQ)'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0034069', 'cui_str': 'Pulmonary Fibrosis'}, {'cui': 'C0184633', 'cui_str': 'Oxygen Inhalation Therapy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1627892', 'cui_str': 'ng/g'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]",23.0,0.139946,During blinded treatment iNO30 subjects showed an average improvement in moderate/vigorous physical activity (MVPA) and remained stable in overall activity.,"[{'ForeName': 'Steven D', 'Initials': 'SD', 'LastName': 'Nathan', 'Affiliation': 'Advanced Lung Disease and Transplant Program, Inova Heart and Vascular Institute, Inova Fairfax Hospital, Richmond, VA; Virginia Commonwealth University, Richmond, VA. Electronic address: steven.nathan@inova.org.'}, {'ForeName': 'Kevin R', 'Initials': 'KR', 'LastName': 'Flaherty', 'Affiliation': 'University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Marilyn K', 'Initials': 'MK', 'LastName': 'Glassberg', 'Affiliation': 'University of Miami Miller School of Medicine, Miami, FL.'}, {'ForeName': 'Ganesh', 'Initials': 'G', 'LastName': 'Raghu', 'Affiliation': 'the University of Arizona College of Medicine - Phoenix and Banner; University of Washington Medical Center, Seattle, WA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Swigris', 'Affiliation': 'Department of Medicine, National Jewish, Denver, CO.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Alvarez', 'Affiliation': 'University of Miami Miller School of Medicine, Miami, FL.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Ettinger', 'Affiliation': 'The Lung Research Center-Missouri, Chesterfield, MO.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Loyd', 'Affiliation': 'Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Fernandes', 'Affiliation': 'Bellerophon Therapeutics, Warren, NJ.'}, {'ForeName': 'Hunter', 'Initials': 'H', 'LastName': 'Gillies', 'Affiliation': 'Bellerophon Therapeutics, Warren, NJ.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Kim', 'Affiliation': 'Bellerophon Therapeutics, Warren, NJ.'}, {'ForeName': 'Parag', 'Initials': 'P', 'LastName': 'Shah', 'Affiliation': 'Bellerophon Therapeutics, Warren, NJ.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Lancaster', 'Affiliation': 'Vanderbilt University Medical Center, Nashville, TN.'}]",Chest,['10.1016/j.chest.2020.02.016'] 354,32131365,Maternal pregnancy vitamin D supplementation increases offspring bone formation in response to mechanical loading: Findings from a MAVIDOS Trial sub-study.,"The Maternal Vitamin D Osteoporosis (MAVIDOS) trial reported higher total body bone mineral content in winter-born infants of mothers receiving vitamin D supplementation [1000 IU/day cholecalciferol] compared with placebo from 14 weeks gestation until delivery. This sub-study aimed to determine whether antenatal vitamin D supplementation altered postnatal bone formation in response to mechanical stimulation. Thirty-one children born to MAVIDOS participants randomised to either placebo (n=19) or cholecalciferol (n=12) were recruited at age 4-5 years. Children received whole body vibration (WBV) for 10 minutes on 5 consecutive days. Fasting blood samples for bone homeostasis, 25 hydroxyvitamin D (25OHD), parathyroid hormone (PTH), and bone turnover markers (Pro-collagen Type 1 N-terminal propeptide, P1NP; Cross-linked C-telopeptide of Type I Collagen, CTX) were collected pre-WBV and on day 8 (D8). Mean changes (D) in P1NP (ng/ml) between baseline and D8 in the vitamin-D intervention and placebo groups were 40.6 and -92.6 respectively and mean changes (Δ) in CTX (ng/ml) were 0.034 (intervention) and -0.084 (placebo) respectively. Between-group DP1NP difference was 133.2ng/ml [95% CI 0.4, 266.0; p=0.049] and ΔCTX 0.05ng/ml (95% CI -0.159, 0.26ng/mL; p=0.62). Antenatal vitamin-D supplementation resulted in increased P1NP in response to WBV, suggesting early life vitamin D supplementation increases the anabolic response of bone to mechanical loading in children.",2020,"Antenatal vitamin-D supplementation resulted in increased P1NP in response to WBV, suggesting early life vitamin D supplementation increases the anabolic response of bone to mechanical loading in children.","['winter-born infants of mothers receiving', 'n=12) were recruited at age 4-5 years', 'n=19) or', 'children']","['placebo', 'whole body vibration (WBV', 'vitamin D supplementation [1000 IU/day cholecalciferol', 'Antenatal vitamin-D supplementation', 'Maternal pregnancy vitamin D supplementation', 'antenatal vitamin D supplementation', 'cholecalciferol']","['Fasting blood samples for bone homeostasis, 25 hydroxyvitamin D (25OHD), parathyroid hormone (PTH), and bone turnover markers (Pro-collagen Type 1 N-terminal propeptide, P1NP; Cross-linked C-telopeptide of Type I Collagen, CTX', 'Mean changes (D) in P1NP', 'total body bone mineral content', 'anabolic response of bone to mechanical loading']","[{'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0444584', 'cui_str': 'Whole body (qualifier value)'}, {'cui': 'C0459800', 'cui_str': 'Vibration'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}, {'cui': 'C0439465', 'cui_str': 'IU/day'}, {'cui': 'C0242215', 'cui_str': 'Cholecalciferols'}, {'cui': 'C2828394', 'cui_str': 'Antenatal (qualifier value)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0019868', 'cui_str': 'Autoregulation'}, {'cui': 'C0535968', 'cui_str': '25-hydroxyvitamin D'}, {'cui': 'C0030520', 'cui_str': 'Parathyroid Hormone'}, {'cui': 'C0085268', 'cui_str': 'Bone Turnover'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0441729', 'cui_str': 'Type 1 (qualifier value)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0631180', 'cui_str': 'C-telopeptide'}, {'cui': 'C0041455', 'cui_str': 'Collagen Type I'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0005963', 'cui_str': 'Bone Mineral Content'}, {'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}]",31.0,0.468975,"Antenatal vitamin-D supplementation resulted in increased P1NP in response to WBV, suggesting early life vitamin D supplementation increases the anabolic response of bone to mechanical loading in children.","[{'ForeName': 'Jaya Sujatha', 'Initials': 'JS', 'LastName': 'Gopal-Kothandapani', 'Affiliation': 'Academic Unit of Child Health, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Alan S', 'Initials': 'AS', 'LastName': 'Rigby', 'Affiliation': 'Hull York Medical School, Faculty of Health, University of Hull, Hull, UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Harrison', 'Affiliation': ""Sheffield Children's NHS Foundation Trust.""}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Eastell', 'Affiliation': 'Academic Unit of Bone Metabolism, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Rebecca J', 'Initials': 'RJ', 'LastName': 'Moon', 'Affiliation': 'MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Curtis', 'Affiliation': 'MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Cyrus', 'Initials': 'C', 'LastName': 'Cooper', 'Affiliation': 'MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Nicholas C', 'Initials': 'NC', 'LastName': 'Harvey', 'Affiliation': 'MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Bishop', 'Affiliation': 'Academic Unit of Child Health, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.'}]",Journal of musculoskeletal & neuronal interactions,[] 355,32131366,Effect of calcium and vitamin D supplementation with and without collagen peptides on bone turnover in postmenopausal women with osteopenia.,"OBJECTIVES Collagen peptides (CPs) seem to exert beneficial effects on bone and may have a role as a treatment option. In the present randomized prospective study, we aimed to examine the efficacy, as expressed by changes in P1NP and CTX, and the tolerability of 3-month supplementation of calcium, vitamin D with or without bioactive CPs in postmenopausal women with osteopenia. METHODS Fifty-one female, postmenopausal women with osteopenia were allocated to two groups: Group A received a sachet containing 5 g CPs, 3.6 g calcium lactate (equivalent to 500 mg of elemental calcium) and 400 IU vitamin D3 and group B received a chewable tablet containing 1.25 g calcium carbonate (equivalent to 500 mg of elemental calcium) and 400 IU vitamin D3 daily. RESULTS In group A, the P1NP levels significantly decreased by 13.1% (p<0.001) and CTX levels decreased by 11.4% (p=0.058) within 3 months of supplementation. In group B, P1NP and CTX did not change. Group A presented better compliance in comparison to group B and no adverse events contrary to group B. CONCLUSIONS These findings may reflect the reduction of the increased bone turnover in postmenopausal women with the use of calcium, vitamin D and CPs supplements. The addition of CPs in a calcium and vitamin D supplement may enhance its already known positive effect on bone metabolism. Clinical Trial ID: NCT03999775.",2020,"In group A, the P1NP levels significantly decreased by 13.1% (p<0.001) and CTX levels decreased by 11.4% (p=0.058) within 3 months of supplementation.","['postmenopausal women', 'female, postmenopausal women with osteopenia', 'postmenopausal women with osteopenia', 'Fifty-one']","['P1NP and CTX', 'calcium, vitamin D with or without bioactive CPs', 'sachet containing 5 g CPs, 3.6 g calcium lactate (equivalent to 500 mg of elemental calcium) and 400 IU vitamin D3 and group B received a chewable tablet containing 1.25 g calcium carbonate (equivalent to 500 mg of elemental calcium) and 400 IU vitamin D3 daily', 'calcium and vitamin D supplementation with and without collagen peptides']","['CTX levels', 'P1NP levels', 'bone turnover']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}]","[{'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C4319662', 'cui_str': 'Sachet'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C4517694', 'cui_str': '3.6 (qualifier value)'}, {'cui': 'C0108121', 'cui_str': 'calcium 2-hydroxypropanoate'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C3265062', 'cui_str': 'vitamin D3'}, {'cui': 'C0441836', 'cui_str': 'Group B (qualifier value)'}, {'cui': 'C0304290', 'cui_str': 'Chewable Tablet'}, {'cui': 'C4517497', 'cui_str': '1.25 (qualifier value)'}, {'cui': 'C0006681', 'cui_str': 'Calcium Carbonate'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0030956', 'cui_str': 'Peptides'}]","[{'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0085268', 'cui_str': 'Bone Turnover'}]",,0.106847,"In group A, the P1NP levels significantly decreased by 13.1% (p<0.001) and CTX levels decreased by 11.4% (p=0.058) within 3 months of supplementation.","[{'ForeName': 'Chrysoula', 'Initials': 'C', 'LastName': 'Argyrou', 'Affiliation': 'Laboratory for Research of the Musculoskeletal System ""Th. Garofalidis"", Medical School, National and Kapodistrian University of Athens, KAT General Hospital of Athens, Greece.'}, {'ForeName': 'Efthymia', 'Initials': 'E', 'LastName': 'Karlafti', 'Affiliation': 'Laboratory for Research of the Musculoskeletal System ""Th. Garofalidis"", Medical School, National and Kapodistrian University of Athens, KAT General Hospital of Athens, Greece.'}, {'ForeName': 'Kalliopi', 'Initials': 'K', 'LastName': 'Lampropoulou-Adamidou', 'Affiliation': 'Laboratory for Research of the Musculoskeletal System ""Th. Garofalidis"", Medical School, National and Kapodistrian University of Athens, KAT General Hospital of Athens, Greece.'}, {'ForeName': 'Symeon', 'Initials': 'S', 'LastName': 'Tournis', 'Affiliation': 'Laboratory for Research of the Musculoskeletal System ""Th. Garofalidis"", Medical School, National and Kapodistrian University of Athens, KAT General Hospital of Athens, Greece.'}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Makris', 'Affiliation': 'Clinical Biochemistry Department, KAT General Hospital of Athens, Greece.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Trovas', 'Affiliation': 'Laboratory for Research of the Musculoskeletal System ""Th. Garofalidis"", Medical School, National and Kapodistrian University of Athens, KAT General Hospital of Athens, Greece.'}, {'ForeName': 'Ismene', 'Initials': 'I', 'LastName': 'Dontas', 'Affiliation': 'Laboratory for Research of the Musculoskeletal System ""Th. Garofalidis"", Medical School, National and Kapodistrian University of Athens, KAT General Hospital of Athens, Greece.'}, {'ForeName': 'Ioannis K', 'Initials': 'IK', 'LastName': 'Triantafyllopoulos', 'Affiliation': 'Laboratory for Research of the Musculoskeletal System ""Th. Garofalidis"", Medical School, National and Kapodistrian University of Athens, KAT General Hospital of Athens, Greece.'}]",Journal of musculoskeletal & neuronal interactions,[] 356,30860573,Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.,"BACKGROUND Dynamic changes in circulating tumour DNA (ctDNA) levels may predict long-term outcome. We utilised samples from a phase I/II randomised trial (BEECH) to assess ctDNA dynamics as a surrogate for progression-free survival (PFS) and early predictor of drug efficacy. PATIENTS AND METHODS Patients with estrogen receptor-positive advanced metastatic breast cancer (ER+ mBC) in the BEECH study, paclitaxel plus placebo versus paclitaxel plus AKT inhibitor capivasertib, had plasma samples collected for ctDNA analysis at baseline and at multiple time points in the development cohort (safety run-in, part A) and validation cohort (randomised, part B). Baseline sample ctDNA sequencing identified mutations for longitudinal analysis and mutation-specific digital droplet PCR (ddPCR) assays were utilised to assess change in ctDNA abundance (allele fraction) between baseline and 872 on-treatment samples. Primary objective was to assess whether early suppression of ctDNA, based on pre-defined criteria from the development cohort, independently predicted outcome in the validation cohort. RESULTS In the development cohort, suppression of ctDNA was apparent after 8 days of treatment (P = 0.014), with cycle 2 day 1 (4 weeks) identified as the optimal time point to predict PFS from early ctDNA dynamics. In the validation cohort, median PFS was 11.1 months in patients with suppressed ctDNA at 4 weeks and 6.4 months in patients with high ctDNA (hazard ratio = 0.20, 95% confidence interval 0.083-0.50, P < 0.0001). There was no difference in the level of ctDNA suppression between patients randomised to capivasertib or placebo overall (P = 0.904) nor in the PIK3CA mutant subpopulation (P = 0.071). Clonal haematopoiesis of indeterminate potential (CHIP) was evident in 30% (18/59) baseline samples, although CHIP had no effect on tolerance of chemotherapy nor on PFS. CONCLUSION Early on-treatment ctDNA dynamics are a surrogate for PFS. Dynamic ctDNA assessment has the potential to substantially enhance early drug development. CLINICAL REGISTRATION NUMBER NCT01625286.",2019,"In the development cohort, suppression of ctDNA was apparent after 8 days of treatment (p=0.014), with cycle 2 day 1 (4 weeks) identified as the optimal timepoint to predict PFS from early ctDNA dynamics.",['Patients with oestrogen receptor positive advanced metastatic breast cancer (ER+ mBC) in the BEECH study'],"['paclitaxel plus placebo versus paclitaxel plus AKT inhibitor capivasertib', 'placebo']","['ctDNA abundance (allele fraction', 'suppression of ctDNA', 'level of ctDNA suppression', 'Clonal haematopoiesis of indeterminate potential (CHIP', 'median PFS', 'mutation specific digital droplet PCR (ddPCR']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0202006', 'cui_str': 'Estrogen measurement (procedure)'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer metastatic'}, {'cui': 'C0950075', 'cui_str': 'Fagaceae'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0002085', 'cui_str': 'Allelomorphs'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression (disorder)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0018951', 'cui_str': 'Hematopoiesis'}, {'cui': 'C0205258', 'cui_str': 'Indeterminate (qualifier value)'}, {'cui': 'C1510451', 'cui_str': 'Fries'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray (qualifier value)'}, {'cui': 'C3853643', 'cui_str': 'Probe with target amplification technique (qualifier value)'}]",,0.431116,"In the development cohort, suppression of ctDNA was apparent after 8 days of treatment (p=0.014), with cycle 2 day 1 (4 weeks) identified as the optimal timepoint to predict PFS from early ctDNA dynamics.","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Hrebien', 'Affiliation': 'Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Citi', 'Affiliation': 'Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK; Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Garcia-Murillas', 'Affiliation': 'Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Cutts', 'Affiliation': 'Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Fenwick', 'Affiliation': 'Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Kozarewa', 'Affiliation': 'Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'McEwen', 'Affiliation': 'Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Ratnayake', 'Affiliation': 'Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Maudsley', 'Affiliation': 'Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK.'}, {'ForeName': 'T H', 'Initials': 'TH', 'LastName': 'Carr', 'Affiliation': 'Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK.'}, {'ForeName': 'E C', 'Initials': 'EC', 'LastName': 'de Bruin', 'Affiliation': 'Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Schiavon', 'Affiliation': 'Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Oliveira', 'Affiliation': ""Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.""}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Turner', 'Affiliation': 'Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK; Breast Unit, Royal Marsden Hospital, London, UK. Electronic address: Nick.Turner@icr.ac.uk.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdz085'] 357,31352467,Neural responses during extinction learning predict exposure therapy outcome in phobia: results from a randomized-controlled trial.,"Extinction learning is assumed to represent a core mechanism underlying exposure therapy. Empirical evaluations of this assumption, however, are largely lacking. The current study investigated whether neural activations and self-report outcomes during extinction learning and extinction recall could specifically predict exposure therapy response in specific phobia. In this double-blind randomized controlled trial, individuals with spider phobia (N = 45; female/male = 41/4) were on group basis randomly allocated to exposure therapy (n = 25; female/male = 24/1) or progressive muscle relaxation (PMR; n = 20; female/male = 17/3). Intervention effects were measured with the Fears of Spiders questionnaire. Participants also underwent a three-day fear conditioning, extinction learning, and extinction recall paradigm during functional magnetic resonance imaging at baseline. Extinction outcomes were self-reported fear and threat expectancy, and neural responses during conditioned stimulus processing and during extinction-related prediction errors (US omissions) in regions of interest (ventromedial prefrontal cortex (vmPFC) and nucleus accumbens). Results showed that exposure therapy resulted in stronger symptom reductions than PMR (Cohen's d = 0.90). Exposure therapy response was specifically predicted by prediction-error related vmPFC activation during early extinction. There were also indications vmPFC activations during conditioned safety stimulus processing at early extinction predicted therapy outcome. Neural activations during extinction recall and self-report data did however not predict therapy outcome. These findings indicate that exposure therapy may rely on neural extinction learning processes. Prediction errors are thought to drive the extinction learning process, and prediction error-related vmPFC activation specifically predicted therapy outcome. The extent to which vmPFC processes safety signals may additionally be predictive of exposure therapy response, but the specificity is less clear.",2020,Results showed that exposure therapy resulted in stronger symptom reductions than PMR (Cohen's d = 0.90).,"['specific phobia', 'n\u2009=\u200920; female/male\u2009=\u200917/3', 'individuals with spider phobia (N\u2009=\u200945; female/male\u2009=\u200941/4', 'phobia']","['exposure therapy (n\u2009=\u200925; female/male\u2009=\u200924/1) or progressive muscle relaxation (PMR', 'extinction learning and extinction recall', 'extinction learning']","['stronger symptom reductions', 'Fears of Spiders questionnaire', 'self-reported fear and threat expectancy, and neural responses during conditioned stimulus processing and during extinction-related prediction errors (US omissions) in regions of interest', 'Neural responses']","[{'cui': 'C0236801', 'cui_str': 'Phobia, Specific'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0037913', 'cui_str': 'Spiders'}, {'cui': 'C0349231', 'cui_str': 'Phobias'}]","[{'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0004361', 'cui_str': 'Progressive Relaxation'}, {'cui': 'C0015347', 'cui_str': 'Extinction (Psychology)'}]","[{'cui': 'C0442821', 'cui_str': 'Strong (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0392331', 'cui_str': 'Arachnophobia (finding)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0234404', 'cui_str': 'Conditioned stimulus, function (observable entity)'}, {'cui': 'C0015347', 'cui_str': 'Extinction (Psychology)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}]",,0.103046,Results showed that exposure therapy resulted in stronger symptom reductions than PMR (Cohen's d = 0.90).,"[{'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Lange', 'Affiliation': 'Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands. i.lange@maastrichtuniversity.nl.'}, {'ForeName': 'Liesbet', 'Initials': 'L', 'LastName': 'Goossens', 'Affiliation': 'Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Stijn', 'Initials': 'S', 'LastName': 'Michielse', 'Affiliation': 'Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Jindra', 'Initials': 'J', 'LastName': 'Bakker', 'Affiliation': 'Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Bram', 'Initials': 'B', 'LastName': 'Vervliet', 'Affiliation': 'Faculty of Psychology and Educational Sciences, Laboratory of Biological Psychology, University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Machteld', 'Initials': 'M', 'LastName': 'Marcelis', 'Affiliation': 'Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Marieke', 'Initials': 'M', 'LastName': 'Wichers', 'Affiliation': 'Department of Psychiatry, Interdisciplinary Center Psychopathology and Emotion Regulation (ICPE), University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'van Os', 'Affiliation': 'Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Therese', 'Initials': 'T', 'LastName': 'van Amelsvoort', 'Affiliation': 'Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Koen', 'Initials': 'K', 'LastName': 'Schruers', 'Affiliation': 'Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0467-8'] 358,31806413,"Continuous positive airway pressure versus standard care for the treatment of people with mild obstructive sleep apnoea (MERGE): a multicentre, randomised controlled trial.","BACKGROUND The evidence base for the treatment of mild obstructive sleep apnoea is limited and definitions of disease severity vary. The MERGE trial investigated the clinical effectiveness of continuous positive airway pressure in patients with mild obstructive sleep apnoea. METHODS MERGE, a multicentre, parallel, randomised controlled trial enrolled patients (≥18 years to ≤80 years) with mild obstructive sleep apnoea (apnoea-hypopnoea index [AHI] ≥5 to ≤15 events per h using either AASM 2007 or AASM 2012 scoring criteria) from 11 UK sleep centres. Participants were assigned (1:1) to either 3 months of continuous positive airway pressure plus standard care (sleep counselling), or standard care alone, by computer-generated randomisation; neither participants nor researchers were blinded. The primary outcome was a change in the score on the Short Form-36 questionnaire vitality scale in the intention-to-treat population of patients with mild obstructive sleep apnoea diagnosed using the American Academy of Sleep Medicine 2012 scoring criteria. The study is registered with ClinicalTrials.gov, NCT02699463. FINDINGS Between Nov 28, 2016 and Feb 12, 2019, 301 patients were recruited and randomised. 233 had mild obstructive sleep apnoea using AASM 2012 criteria and were included in the intention-to-treat analysis: 115 were allocated to receive continuous positive airway pressure and 118 to receive standard care. 209 (90%) of these participants completed the trial. The vitality score significantly increased with a treatment effect of a mean of 10·0 points (95% CI 7·2-12·8; p<0·0001) after 3 months of continuous positive airway pressure, compared with standard care alone (9·2 points [6·8 to 11·6] vs -0·8 points [-3·2 to 1·5]). Using the ANCOVA last-observation-carried-forward analysis, a more conservative estimate, the vitality score also significantly increased with a treatment effect of a mean of 7·5 points (95% CI 5·3 to 9·6; p<0·0001) after 3 months of continuous positive airway pressure, compared with standard care alone (7·5 points [6·0 to 9·0] vs 0·0 points [-1·5 to 1·5]). Three serious adverse events occurred (one allocated to the continuous positive airway pressure group) and all were unrelated to the intervention. INTERPRETATION 3 months of treatment with continuous positive airway pressure improved the quality of life in patients with mild obstructive sleep apnoea. These results highlight the need for health-care professionals and providers to consider treatment for patients with mild obstructive sleep apnoea. FUNDING ResMed Ltd.",2020,"Three serious adverse events occurred (one allocated to the continuous positive airway pressure group) and all were unrelated to the intervention. ","['Between Nov 28, 2016 and Feb 12, 2019, 301 patients were recruited and randomised', 'patients with mild obstructive sleep apnoea diagnosed using the American Academy of Sleep Medicine 2012 scoring criteria', 'enrolled patients (≥18 years to ≤80 years) with mild obstructive sleep apnoea (apnoea-hypopnoea index [AHI] ≥5 to ≤15 events per h using either AASM 2007 or AASM 2012 scoring criteria) from 11 UK sleep centres', 'mild obstructive sleep apnoea', 'patients with mild obstructive sleep apnoea', '233 had mild obstructive sleep apnoea using AASM 2012 criteria and were included in the intention-to-treat analysis: 115', 'people with mild obstructive sleep apnoea (MERGE']","['Continuous positive airway pressure versus standard care', 'continuous positive airway pressure', 'continuous positive airway pressure and 118 to receive standard care', 'continuous positive airway pressure plus standard care (sleep counselling), or standard care alone, by computer-generated randomisation']","['quality of life', 'serious adverse events', 'change in the score on the Short Form-36 questionnaire vitality scale', 'vitality score']","[{'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0000876', 'cui_str': 'Academies'}, {'cui': 'C4304028', 'cui_str': 'Sleep medicine specialist'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C2111846', 'cui_str': 'Apnea Hypopnea Index'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0009622', 'cui_str': 'Computer'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",301.0,0.136852,"Three serious adverse events occurred (one allocated to the continuous positive airway pressure group) and all were unrelated to the intervention. ","[{'ForeName': 'Alison J', 'Initials': 'AJ', 'LastName': 'Wimms', 'Affiliation': 'Department of Medicine, University of Sydney, Sydney, Australia; ResMed Science Center, ResMed Ltd, Sydney, Australia.'}, {'ForeName': 'Julia L', 'Initials': 'JL', 'LastName': 'Kelly', 'Affiliation': 'National Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield NHS Foundation Trust, London, UK. Electronic address: j.kelly@rbht.nhs.uk.'}, {'ForeName': 'Christopher D', 'Initials': 'CD', 'LastName': 'Turnbull', 'Affiliation': 'Oxford NIHR Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'McMillan', 'Affiliation': 'Lister Hospital, Stevenage, UK.'}, {'ForeName': 'Sonya E', 'Initials': 'SE', 'LastName': 'Craig', 'Affiliation': 'University Hospital Aintree, Liverpool, UK.'}, {'ForeName': 'John F', 'Initials': 'JF', 'LastName': ""O'Reilly"", 'Affiliation': 'University Hospital Aintree, Liverpool, UK.'}, {'ForeName': 'Annabel H', 'Initials': 'AH', 'LastName': 'Nickol', 'Affiliation': 'Oxford University Hospital NHS Foundation Trust, Hospital, Oxford, UK.'}, {'ForeName': 'Emma L', 'Initials': 'EL', 'LastName': 'Hedley', 'Affiliation': 'Oxford Respiratory Trials Unit, Oxford, UK.'}, {'ForeName': 'Meredith D', 'Initials': 'MD', 'LastName': 'Decker', 'Affiliation': 'Willes Consulting Group, Encinitas, CA, USA.'}, {'ForeName': 'Leslee A', 'Initials': 'LA', 'LastName': 'Willes', 'Affiliation': 'Willes Consulting Group, Encinitas, CA, USA.'}, {'ForeName': 'Peter M A', 'Initials': 'PMA', 'LastName': 'Calverley', 'Affiliation': 'Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Adam V', 'Initials': 'AV', 'LastName': 'Benjafield', 'Affiliation': 'ResMed Science Center, ResMed Ltd, Sydney, Australia.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Stradling', 'Affiliation': 'Oxford NIHR Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Mary J', 'Initials': 'MJ', 'LastName': 'Morrell', 'Affiliation': 'National Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield NHS Foundation Trust, London, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(19)30402-3'] 359,31837291,Increasing long-acting reversible contraceptives: the Australian Contraceptive ChOice pRoject (ACCORd) cluster randomized trial.,"BACKGROUND Long-active reversible contraceptives reduce unintended pregnancy and abortions, but uptake is low. Interventions to increase uptake in family medicine settings are untested. OBJECTIVE The Australian Contraceptive ChOice pRoject, which was adapted from the successful US Contraceptive CHOICE study, aimed to evaluate whether a complex intervention in family medicine practices resulted in increased long-active reversible contraceptive uptake. STUDY DESIGN This cluster randomized controlled trial was set in family practices in metropolitan Melbourne, Australia. From April 2016 to January 2017, we recruited 57 family physicians by mail invitation. Each family physician aimed to recruit at least 14 female patients. Eligible family physicians worked ≥3 sessions per week in computerized practices. Eligible women were English-speaking, sexually active, not pregnant, not planning a pregnancy in the next year, 16-45 years old, and interested in discussing contraception or in starting a new, reversible method. With the use of a randomization sequence with permuted blocks that were stratified by whether the family physician performed long-active reversible contraceptive insertion or not, family physicians were assigned randomly to a complex intervention that involved training to provide structured effectiveness-based contraceptive counselling and access to rapid referral to long-active reversible contraceptive insertion clinics. The 6-hour, online educational intervention was based on the US Contraceptive CHOICE Project and adapted for the Australian context. The control family physicians received neither the educational intervention nor access to the long-active reversible contraceptive rapid referral clinics and conducted their usual contraception counselling. We used the chi-square test, which was adjusted for clustering and stratification by whether the family physician inserted long-active reversible contraceptives, and binary regression models with generalized estimating equations and robust standard errors to compare, between the intervention and control groups, the proportions of women who had a long-active reversible contraceptive inserted. The primary outcome was the proportion of women with long-active reversible contraceptives that were inserted at 4 weeks. Secondary outcomes included women's choice of contraceptive method, quality of life, and long-active reversible contraceptive use at 6 and 12 months. Analyses were performed according to intention-to-treat. RESULTS A total of 25 intervention and 32 control family physicians recruited 307 and 433 women, respectively (N=740). Within 4 weeks, 19.3% of women in the intervention group and 12.9% of women in the control group had long-active reversible contraceptive inserted (relative risk, 2.0; 95% confidence interval, 1.1-3.9; P=.033). By 6 months, this number had risen to 44.4% and 29.3%, respectively (relative risk, 1.6; 95% confidence interval, 1.2-2.17; P=.001); by 12 months, it had risen to 46.6% and 32.8%, respectively (relative risk, 1.5; 95% confidence interval, 1.2-2.0; P=.0015). The levonorgestrel intrauterine system was the most commonly chosen long-active reversible contraceptive by women in the intervention group at all time points. Differences between intervention and control groups in mean quality-of-life scores across all domains at 6 and 12 months were small. CONCLUSION A complex intervention combination of family physician training on contraceptive effectiveness counselling and rapid access to long-active reversible contraceptive insertion clinics resulted in greater long-active reversible contraceptive uptake and has the potential to reduce unintended pregnancies.",2020,The levonorgestrel intra-uterine system was the most commonly chosen LARC by women in the intervention group at all time points.,"['Eligible women were English speaking, sexually active, not pregnant, not planning a pregnancy in the following year, aged 16-45 years and interested in discussing contraception or in starting a new, reversible method', 'From April 2016 to January 2017 we recruited 57 family physicians by mail invitation', '14 women patients', 'A total of 25 intervention and 32 control family physicians recruited 307 and 433 women respectively (N=740', 'family practices in metropolitan Melbourne, Australia']","['educational intervention nor access to the LARC rapid referral clinics and conducted their usual contraception counselling', 'Long-active reversible contraceptives (LARCs', 'complex intervention involving training to provide structured effectiveness-based contraceptive counselling, and access to rapid referral to LARC insertion clinics']","[""women's choice of contraceptive method, quality of life (QOL) and LARC use"", 'LARC', 'proportion of women with LARCs', 'mean QOL scores', 'LARC uptake']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0241028', 'cui_str': 'Sexually active (finding)'}, {'cui': 'C0232973', 'cui_str': 'Not pregnant (finding)'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0543488', 'cui_str': 'Interested (finding)'}, {'cui': 'C0700589', 'cui_str': 'Fertility Control'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0205343', 'cui_str': 'Reversible (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C1704221', 'cui_str': 'Physicians, Family'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0015607', 'cui_str': 'Family Practice'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0034927', 'cui_str': 'Referral'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C1443484', 'cui_str': 'Contraception care education (procedure)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0205343', 'cui_str': 'Reversible (qualifier value)'}, {'cui': 'C0009871', 'cui_str': 'Contraceptives'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}]","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0700589', 'cui_str': 'Fertility Control'}, {'cui': 'C0034380'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",433.0,0.307268,The levonorgestrel intra-uterine system was the most commonly chosen LARC by women in the intervention group at all time points.,"[{'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Mazza', 'Affiliation': 'Department of General Practice, Monash University, Melbourne, Australia; School of Primary Health Care, Monash University, Melbourne, Australia. Electronic address: Danielle.Mazza@monash.edu.'}, {'ForeName': 'Cathy J', 'Initials': 'CJ', 'LastName': 'Watson', 'Affiliation': 'Department of General Practice, Monash University, Melbourne, Australia.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Taft', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Melbourne, Australia.'}, {'ForeName': 'Jayne', 'Initials': 'J', 'LastName': 'Lucke', 'Affiliation': 'School of Psychology and Public Health, La Trobe University, Melbourne, Australia.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'McGeechan', 'Affiliation': 'University of Sydney, School of Public Health, and the University of Technology, Centre for Health Economics Research and Evaluation, Sydney, Australia.'}, {'ForeName': 'Marion', 'Initials': 'M', 'LastName': 'Haas', 'Affiliation': 'University of Sydney, School of Public Health, and the University of Technology, Centre for Health Economics Research and Evaluation, Sydney, Australia.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'McNamee', 'Affiliation': 'Family Planning Victoria, Melbourne, Australia.'}, {'ForeName': 'Jeffrey F', 'Initials': 'JF', 'LastName': 'Peipert', 'Affiliation': 'Department of Obstetrics & Gynecology, Indiana University School of Medicine, Indianapolis, IN.'}, {'ForeName': 'Kirsten I', 'Initials': 'KI', 'LastName': 'Black', 'Affiliation': 'Royal Prince Alfred Hospital, the University of Sydney, Sydney, Australia.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2019.11.1267'] 360,31839558,Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial.,"BACKGROUND Despite the improvement in the prognosis of acute coronary syndrome (ACS), substantial morbidity and mortality remain. We aimed to evaluate the effect of obstructive sleep apnoea (OSA) and its treatment with continuous positive airway pressure (CPAP) on the clinical evolution of patients with ACS. METHODS We designed a multicentre, open-label, parallel-group, randomised controlled trial of patients with ACS at 15 hospitals in Spain. Eligible non-sleepy patients were men and women aged 18 years and older, admitted to hospital for documented symptoms of ACS. All patients underwent respiratory polygraphy during the first 24-72 h after admission. OSA patients were randomly assigned (1:1) to CPAP treatment plus usual care (CPAP group) or usual care alone (UC group) by a computerised system available 24 h a day. A group of patients with ACS but without OSA was also included as a reference group. Because of the nature of the intervention, the trial intervention could not be masked to either investigators or patients. Patients were monitored and followed for a minimum of 1 year. Patients were examined at the time of inclusion; after 1 month, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months, and 36 months; and every 12 months thereafter, if applicable, during the follow-up period. The primary endpoint was the prevalence of a composite of cardiovascular events (cardiovascular death or non-fatal events [Acute myocardial infarction, non-fatal stroke, hospital admission for heart failure, and new hospitalisations for unstable angina or transient ischaemic attack]) in patients followed up for a minimum of 1 year. The primary analysis was done according to the intention-to-treat principle. This study is registered with Clinicaltrials.gov, NCT01335087 and is now closed. FINDINGS Between April 25, 2011, and Feb 2, 2018, a total of 2834 patients with ACS had respiratory polygraphy, of whom 2551 (90·01%) were recruited. 1264 (49·55%) patients had OSA and were randomly assigned to the CPAP group (n=633) or the UC group (n=631). 1287 (50·45%) patients did not have OSA, of whom 603 (46·85%) were randomly assigned to the reference group. Patients were followed up for a median of 3·35 years (IQR 1·50-5·31). The prevalence of cardiovascular events was similar in the CPAP and UC groups (98 events [16%] vs 108 events [17%]; hazard ratio [HR] 0·89 [95% CI 0·68-1·17]; p=0·40) during follow-up. Mean time of adherence to CPAP treatment was 2·78 h/night (SD 2·73). The prevalence of cardiovascular events was similar between patients in the reference group (90 [15%] events) and those in the UC group (102 (17%) events) during follow-up (1·01 [0·76-1·35]; p=0·93). The prevalence of cardiovascular events seem not to be related to CPAP compliance or OSA severity. 464 (74%) of 629 patients in the CPAP group had 1538 serious adverse events and 406 (65%) of 626 patients in the UC group had 1764 serious adverse events. INTERPRETATION Among non-sleepy patients with ACS, the presence of OSA was not associated with an increased prevalence of cardiovascular events and treatment with CPAP did not significantly reduce this prevalence. FUNDING ResMed (Australia), Fondo de Investigación Sanitaria (Fondo Europeo de Desarrollo Regional), the Spanish Respiratory Society, the Catalonian Cardiology Society, Esteve-Teijin, Oxigen Salud, and ALLER.",2020,"the presence of OSA was not associated with an increased prevalence of cardiovascular events and treatment with CPAP did not significantly reduce this prevalence. ","['0·89', '464', 'patients did not have OSA, of whom 603 (46·85', 'Eligible non-sleepy patients were men and women aged 18 years and older, admitted to hospital for documented symptoms of ACS', 'patients with ACS at 15 hospitals in Spain', 'OSA patients', 'Between April 25, 2011, and Feb 2, 2018, a total of 2834 patients with ACS had respiratory polygraphy, of whom 2551 (90·01%) were recruited', 'patients had OSA', 'patients with ACS', 'non-sleepy patients with ACS', 'patients with acute coronary syndrome (ISAACC study']","['continuous positive airway pressure (CPAP', 'CPAP', 'continuous positive airway pressure', 'obstructive sleep apnoea (OSA', 'CPAP treatment plus usual care (CPAP group) or usual care alone (UC group) by a computerised system available 24 h a day', 'obstructive sleep apnoea', 'UC']","['1764 serious adverse events', 'prevalence of cardiovascular events', 'cardiovascular events', '1538 serious adverse events', 'prevalence of a composite of cardiovascular events (cardiovascular death or non-fatal events [Acute myocardial infarction, non-fatal stroke, hospital admission for heart failure, and new hospitalisations for unstable angina or transient ischaemic attack', 'hazard ratio [HR', 'Mean time of adherence']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0013144', 'cui_str': 'Drowsy (finding)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0948089', 'cui_str': 'Acute Coronary Syndrome'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}, {'cui': 'C0520679', 'cui_str': 'Syndrome, Sleep Apnea, Obstructive'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction (disorder)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission (procedure)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0002965', 'cui_str': 'Angina at Rest'}, {'cui': 'C0007787', 'cui_str': 'Brain TIA'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",2834.0,0.0832191,"the presence of OSA was not associated with an increased prevalence of cardiovascular events and treatment with CPAP did not significantly reduce this prevalence. ","[{'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Sánchez-de-la-Torre', 'Affiliation': 'Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova-Santa Maria, IRB Lleida, Lleida, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Sánchez-de-la-Torre', 'Affiliation': 'Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova-Santa Maria, IRB Lleida, Lleida, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Bertran', 'Affiliation': 'Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova-Santa Maria, IRB Lleida, Lleida, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Abad', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain; Respiratory Department, Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain.'}, {'ForeName': 'Joaquín', 'Initials': 'J', 'LastName': 'Duran-Cantolla', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain; Servicio de Investigación OSI, Hospital Universitario Araba, IIS Bioaraba, Vitoria, Álava, Spain.'}, {'ForeName': 'Valentín', 'Initials': 'V', 'LastName': 'Cabriada', 'Affiliation': 'Respiratory Department, Hospital Universitario Cruces, Bizkaia, Spain.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Mediano', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain; Respiratory Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.'}, {'ForeName': 'María José', 'Initials': 'MJ', 'LastName': 'Masdeu', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain; Respiratory and Sleep Department, Hospital Universitari Parc Taulí, Institut Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain.'}, {'ForeName': 'Mari Luz', 'Initials': 'ML', 'LastName': 'Alonso', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain; Respiratory Department, Hospital Universitario de Burgos, Burgos, Spain.'}, {'ForeName': 'Juan Fernando', 'Initials': 'JF', 'LastName': 'Masa', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain; Respiratory Department, Hospital San Pedro Alcántara, Cáceres, Spain.'}, {'ForeName': 'Antonia', 'Initials': 'A', 'LastName': 'Barceló', 'Affiliation': 'Clinic Analysis and Respiratory Services, Hospital Universitari Son Espases, Institut de investigació sanitaria de Palma (IdisPa), Palma de Mallorca, Spain.'}, {'ForeName': 'Mónica', 'Initials': 'M', 'LastName': 'de la Peña', 'Affiliation': 'Clinic Analysis and Respiratory Services, Hospital Universitari Son Espases, Institut de investigació sanitaria de Palma (IdisPa), Palma de Mallorca, Spain.'}, {'ForeName': 'Mercè', 'Initials': 'M', 'LastName': 'Mayos', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain; Sleep Unit, Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.'}, {'ForeName': 'Ramón', 'Initials': 'R', 'LastName': 'Coloma', 'Affiliation': 'Respiratory Department, Hospital General Universitario de Albacete, Spain.'}, {'ForeName': 'Josep M', 'Initials': 'JM', 'LastName': 'Montserrat', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain; Respiratory Department, Hospital Clinic, Barcelona, Spain.'}, {'ForeName': 'Eusebi', 'Initials': 'E', 'LastName': 'Chiner', 'Affiliation': ""Respiratory Department, Hospital Universitari Sant Joan d'Alacant, Alicante, Spain.""}, {'ForeName': 'Salvador', 'Initials': 'S', 'LastName': 'Perelló', 'Affiliation': 'Respiratory Department, Hospital Joan XXIII, Tarragona, Spain.'}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Rubinós', 'Affiliation': 'Respiratory Department, Hospital Universitario Central de Asturias, Oviedo, Spain.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Mínguez', 'Affiliation': 'Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova-Santa Maria, IRB Lleida, Lleida, Spain.'}, {'ForeName': 'Lydia', 'Initials': 'L', 'LastName': 'Pascual', 'Affiliation': 'Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova-Santa Maria, IRB Lleida, Lleida, Spain.'}, {'ForeName': 'Anunciación', 'Initials': 'A', 'LastName': 'Cortijo', 'Affiliation': 'Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova-Santa Maria, IRB Lleida, Lleida, Spain.'}, {'ForeName': 'Dolores', 'Initials': 'D', 'LastName': 'Martínez', 'Affiliation': 'Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova-Santa Maria, IRB Lleida, Lleida, Spain.'}, {'ForeName': 'Albina', 'Initials': 'A', 'LastName': 'Aldomà', 'Affiliation': 'Cardiology Department, Hospital Universitari Arnau de Vilanova, IRBLleida, Lleida, Spain.'}, {'ForeName': 'Mireia', 'Initials': 'M', 'LastName': 'Dalmases', 'Affiliation': 'Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova-Santa Maria, IRB Lleida, Lleida, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain.'}, {'ForeName': 'R Doug', 'Initials': 'RD', 'LastName': 'McEvoy', 'Affiliation': 'Adelaide Institute for Sleep Health, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.'}, {'ForeName': 'Ferran', 'Initials': 'F', 'LastName': 'Barbé', 'Affiliation': 'Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova-Santa Maria, IRB Lleida, Lleida, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain. Electronic address: febarbe.lleida.ics@gencat.cat.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(19)30271-1'] 361,32012323,Mediating role of screen media use on adolescents' total sleep time: A cluster-randomized controlled trial for physical activity and sedentary behaviour.,"BACKGROUND The present study aimed to analyse the effect of an intervention for increasing physical activity (PA) and reducing sedentary time on adolescents' total sleep time (TST) and to examine whether the effect on adolescents' TST was mediated by the intervention changes on screen-based sedentary time. METHODS This study was a school-based cluster-randomized controlled trial conducted with Brazilian adolescents in Grades 7 to 9 (in 2017). Three schools participated in each of the intervention group (IG) and control group (CG). The intervention involved the following three strategies designed to increase PA and reduce sedentary time: (a) teacher training, (b) environmental improvements, and (c) health educational component. TST and screen-based sedentary time (television use, cell phone use, playing on computer/video game, and computer use that is not for gaming purposes) on weekdays and weekends were assessed using a standardized questionnaire. Generalized linear mixed models were conducted to verify the effect of the intervention on TST. Mediation analyses were used to examine the mediator role of changes in screen-based sedentary time in the relationship between the intervention and TST. RESULTS Overall, 597 students participated in this study (mean age: 13.0 ± 1.0 years; IG: n = 351; CG: n = 246). The intervention had no effect on TST on weekdays and weekends. Adolescents in the IG were more likely to report ≤2 hr of television viewing per day on weekdays at follow-up. Mediated effects by screen media use were not significant. CONCLUSIONS The school-based intervention for increasing PA and reducing sedentary time had no effect on adolescents' TST.",2020,The school-based intervention for increasing PA and reducing sedentary time had no effect on adolescents' TST.,"['597 students participated in this study (mean age: 13.0±1.0 years old; IG: n=351; CG: n=246', 'Brazilian adolescents in grades 7 th to 9 th (in 2017', ""adolescents' total sleep time""]","['television use, cell phone use, playing on computer/video game, and computer use that is not for gaming purposes', 'TST', 'control group (CG']","[""adolescents' total sleep time (TST"", 'TST and screen-based sedentary time', 'physical activity (PA) and reduce sedentary time: (I) teachers training, (II) environmental improvements, (III) health educational component']","[{'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C1632851', 'cui_str': 'Times'}]","[{'cui': 'C0039461', 'cui_str': 'Television'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C4505320', 'cui_str': 'Cell Phone Use'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0042649', 'cui_str': 'Video Games'}, {'cui': 'C1285529', 'cui_str': 'Purpose (attribute)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C4082803', 'cui_str': 'Teacher Training'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}]",3.0,0.0430397,The school-based intervention for increasing PA and reducing sedentary time had no effect on adolescents' TST.,"[{'ForeName': 'Margarethe Thaisi Garro', 'Initials': 'MTG', 'LastName': 'Knebel', 'Affiliation': 'Department of Physical Education, Research Centre in Physical Activity and Health, School of Sports, Federal University of Santa Catarina, Florianópolis, Brazil.'}, {'ForeName': 'Adriano Ferreti', 'Initials': 'AF', 'LastName': 'Borgatto', 'Affiliation': 'Department of Physical Education, Research Centre in Physical Activity and Health, School of Sports, Federal University of Santa Catarina, Florianópolis, Brazil.'}, {'ForeName': 'Marcus Vinicius Veber', 'Initials': 'MVV', 'LastName': 'Lopes', 'Affiliation': 'Department of Physical Education, Research Centre in Physical Activity and Health, School of Sports, Federal University of Santa Catarina, Florianópolis, Brazil.'}, {'ForeName': 'Priscila Cristina', 'Initials': 'PC', 'LastName': 'Dos Santos', 'Affiliation': 'Department of Physical Education, Research Centre in Physical Activity and Health, School of Sports, Federal University of Santa Catarina, Florianópolis, Brazil.'}, {'ForeName': 'Thiago Sousa', 'Initials': 'TS', 'LastName': 'Matias', 'Affiliation': 'Department of Physical Education, Research Centre in Physical Activity and Health, School of Sports, Federal University of Santa Catarina, Florianópolis, Brazil.'}, {'ForeName': 'Fernanda Veruska', 'Initials': 'FV', 'LastName': 'Narciso', 'Affiliation': 'Department of Sports, School of Physical Education, Physiotherapy, and Occupational Therapy, Federal University of Minas Gerais, Belo Horizonte, Brazil.'}, {'ForeName': 'Kelly Samara', 'Initials': 'KS', 'LastName': 'Silva', 'Affiliation': 'Department of Physical Education, Research Centre in Physical Activity and Health, School of Sports, Federal University of Santa Catarina, Florianópolis, Brazil.'}]","Child: care, health and development",['10.1111/cch.12755'] 362,31972765,Treatment Trajectories During and After a Medication Trial for Opioid Use Disorder: Moving from Research as Usual to Treatment as Usual.,"OBJECTIVES The effectiveness of treatment incorporating relapse prevention medications for opioid use disorder (OUD) is typically examined in research using rigidly predefined endpoints of success versus failure, usually over a single episode of care. But this perspective may not adequately portray the nonlinear trajectories typical of real-world treatment courses in this chronic, remitting, and relapsing disorder. METHODS This descriptive study examined 12-month treatment trajectories of n = 60 patients enrolled at a single site of a larger multisite randomized controlled trial examining the comparative effectiveness of buprenorphine versus extended-release naltrexone. While the parent study provided medication treatment through the research protocol for 6 months, this study documents treatment up to 12 months, including medications, provided through standard community resources (treatment as usual) outside of the protocol. RESULTS Some patients continued medications past the end of the study intervention, whereas others did not. Some patients initiated medications other than the one assigned by the study. Some patients switched from 1 medication to the other. Many patients returned to treatment after 1 or more periods of dropout and/or relapse. Patients utilized multiple episodes of bed-based care, including short-term acute residential and long-term residential treatment, and also recovery housing supports. Described trajectories are also depicted graphically. At 12 months, while rates of continuous treatment retention were low (8%), rates of cross-sectional treatment engagement including return to treatment after drop out were higher (35%). CONCLUSIONS This description of nonlinear treatment trajectories highlights the potential benefits of flexibility and optimism in the promotion of re-engagement, despite interim outcomes that might traditionally be considered ""failure"" endpoints.",2020,"At 12 months, while rates of continuous treatment retention were low (8%), rates of cross-sectional treatment engagement including return to treatment after drop out were higher (35%). ","['n\u200a=\u200a60 patients enrolled at a single site', 'Patients utilized multiple episodes of bed-based care, including short-term acute residential and long-term residential treatment, and also recovery housing supports']",['buprenorphine versus extended-release naltrexone'],"['rates of continuous treatment retention', 'rates of cross-sectional treatment engagement including return to treatment']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0565960', 'cui_str': 'Multiple episode (qualifier value)'}, {'cui': 'C0004916', 'cui_str': 'Beds'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0035189', 'cui_str': 'Residential Treatment'}, {'cui': 'C0020056', 'cui_str': 'Housing'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}]","[{'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C0231449', 'cui_str': 'Extended (qualifier value)'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}, {'cui': 'C0027360', 'cui_str': 'Naltrexone'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0205155', 'cui_str': 'Sectional (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0332156', 'cui_str': 'Return to (contextual qualifier) (qualifier value)'}]",60.0,0.0388449,"At 12 months, while rates of continuous treatment retention were low (8%), rates of cross-sectional treatment engagement including return to treatment after drop out were higher (35%). ","[{'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Fishman', 'Affiliation': 'Maryland Treatment Centers, Baltimore, MD (MF, RB, MR); Johns Hopkins University School of Medicine, Baltimore, MD (MF); University of Texas Southwestern Medical Center, Dallas, TX (HTV); New York University School of Medicine, New York, NY (JR, JL); New York State Psychiatric Institute, Columbia University Medical Center, New York, NY (EN).'}, {'ForeName': 'Hoa T', 'Initials': 'HT', 'LastName': 'Vo', 'Affiliation': ''}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Burgower', 'Affiliation': ''}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Ruggiero', 'Affiliation': ''}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Rotrosen', 'Affiliation': ''}, {'ForeName': 'Josh', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Nunes', 'Affiliation': ''}]",Journal of addiction medicine,['10.1097/ADM.0000000000000592'] 363,32236398,Effects of Rice Wine Lees on Cognitive Function in Community-Dwelling Physically Active Older Adults: A Pilot Randomized Controlled Trial.,"BACKGROUND Rice wine lees (RWL), a Japanese traditional fermented product, is a rich source of one-carbon metabolism-related nutrients, which may have beneficial effects on cognitive function. OBJECTIVES We aimed to examine the effect of the RWL on cognitive function in community-dwelling physically active older adults. DESIGN Double-blind, randomized, placebo-controlled study (clinical trial number: UMIN 000027158). SETTING Community-based intervention including assessments conducted at the University of Hyogo and a public liberal arts school in Himeji City, Japan. PARTICIPANTS A total of 35 community-dwelling older adults (68-80 years) who performed mild exercise before and during the trial were assigned to either the RWL (n=17) or the placebo group (n=18). INTERVENTION Daily consumption of 50 g RWL powder, which contained one-carbon metabolism-related nutrients, or the placebo powder (made from soy protein and dextrin) for 12 weeks. Both supplements included equivalent amounts of energy and protein. MEASUREMENTS Montreal Cognitive Assessment, computerized cognitive function test, and measurements of serum predictive biomarkers (transthyretin, apolipoprotein A1, and complement C3) were conducted at baseline and follow-up. RESULTS Visual selective attention and serum transthyretin significantly improved in the RWL group, whereas there was no significant change in the placebo group. No significant group difference was observed in the remaining cognitive performance tests. CONCLUSIONS RWL supplements seem to have a few effects on cognitive function in community-dwelling physically active older adults. However, the impact was limited; therefore, further studies with sufficient sample size are warranted to elucidate this issue.",2020,"RESULTS Visual selective attention and serum transthyretin significantly improved in the RWL group, whereas there was no significant change in the placebo group.","['A total of 35 community-dwelling older adults (68-80 years) who performed', 'community-dwelling physically active older adults', 'Community-Dwelling Physically Active Older Adults', 'Community-based intervention including assessments conducted at the University of Hyogo and a public liberal arts school in Himeji City, Japan']","['RWL', 'Rice Wine Lees', 'placebo', 'mild exercise']","['remaining cognitive performance tests', 'Montreal Cognitive Assessment, computerized cognitive function test, and measurements of serum predictive biomarkers (transthyretin, apolipoprotein A1, and complement C3', 'Cognitive Function', 'Visual selective attention and serum transthyretin', 'cognitive function']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0556453', 'cui_str': 'Physically active'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C0035567', 'cui_str': 'Rice'}, {'cui': 'C0043188', 'cui_str': 'Wine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C4707653', 'cui_str': 'Cognitive Performance Test'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0032923', 'cui_str': 'Prealbumin'}, {'cui': 'C0085201', 'cui_str': 'Apolipoprotein A-I'}, {'cui': 'C0009506', 'cui_str': 'Complement component C3'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0233421', 'cui_str': 'Selective inattention'}]",35.0,0.262895,"RESULTS Visual selective attention and serum transthyretin significantly improved in the RWL group, whereas there was no significant change in the placebo group.","[{'ForeName': 'N', 'Initials': 'N', 'LastName': 'Nagai', 'Affiliation': 'Narumi Nagai, Department of Food and Nutritional Science, School of Human Science and Environment, University of Hyogo, 1-1-12 Shinzaike-honcho, Himeji, Hyogo, 670-0092 Japan, Email: nagai.lab.uh@gmail.com, Tel.: +81792921515, Fax.: +81792935710.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Shindo', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Wada', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Izu', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Fujii', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Matsubara', 'Affiliation': ''}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Wada', 'Affiliation': ''}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Sakane', 'Affiliation': ''}]",The journal of prevention of Alzheimer's disease,['10.14283/jpad.2019.45'] 364,32236400,"Effects of a Group-Based 8-Week Multicomponent Cognitive Training on Cognition, Mood and Activities of Daily Living among Healthy Older Adults: A One-Year Follow-Up of a Randomized Controlled Trial.","BACKGROUND Cognitive interventions have the potential to enhance cognition among healthy older adults. However, little attention has been paid to the effect of cognitive training (CT) on mood and activities of daily living (ADL). OBJECTIVES To assess the effectiveness of a multicomponent CT using a training program of executive functions, attention, memory and visuospatial functions (TEAM-V Program) on cognition, mood and instrumental ADL. DESIGN A randomized, single-blinded, treatment-as-usual controlled trial. SETTING Geriatric clinic in Bangkok, Thailand. PARTICIPANTS 77 nondemented community-dwelling older adults (mean age 65.7±4.3 years). INTERVENTION The CT (TEAM-V) program or the treatment-as-usual controlled group. The TEAM-V intervention was conducted over 5 sessions, with a 2-week interval between each session. Of 77 participants randomized (n=40 the TEAM-V program; n=37 the control group). MEASUREMENTS The Thai version of Montreal Cognitive Assessment (MoCA), The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), Thai version of Hospital Anxiety and Depression Scale (HADS) and The Chula ADL were used to assess at baseline, 6 months and 1 year. RESULTS Compared with the control arm, the TEAM-V Program was associated with reducing anxiety (P = 0.004). Compared with the baseline, participants receiving the TEAM-V Program were associated with significantly improved general cognition (MoCA, P < 0.001), immediate recall (word recall task, P = 0.01), retrieval and retention of memory process (word recognition task, P = 0.01), attention (number cancellation part A, P < 0.001) and executive function (maze test, P = 0.02) at 1 year. No training effects on depression (P = 0.097) and IADL (P = 0.27) were detected. CONCLUSIONS The TEAM-V Program was effective in reducing anxiety. Even though, the program did not significantly improve cognition, depression and ADL compared with the control group, global cognition, memory, attention and executive function improved in the intervention group compared with baseline. Further studies incorporating a larger sample size, longitudinal follow-up and higher-intensity CT should be conducted.",2020,"Compared with the control arm, the TEAM-V Program was associated with reducing anxiety (P = 0.004).","['77 nondemented community-dwelling older adults (mean age 65.7±4.3 years', 'Geriatric clinic in Bangkok, Thailand', 'healthy older adults', 'Healthy Older Adults', '77 participants randomized (n=40 the TEAM-V program; n=37 the control group']","['Group-Based 8-Week Multicomponent Cognitive Training', 'multicomponent CT', 'cognitive training (CT']","['cognition, depression and ADL', 'global cognition, memory, attention and executive function', 'depression', 'Cognition, Mood and Activities of Daily Living', 'reducing anxiety', ""Montreal Cognitive Assessment (MoCA), The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), Thai version of Hospital Anxiety and Depression Scale (HADS) and The Chula ADL"", 'general cognition', 'immediate recall (word recall task, P = 0.01), retrieval and retention of memory process (word recognition task, P = 0.01), attention (number cancellation part A, P < 0.001) and executive function', 'anxiety', 'cognition, mood and instrumental ADL', 'IADL', 'mood and activities of daily living (ADL']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0555968', 'cui_str': 'Elderly assessment clinic'}, {'cui': 'C0039725', 'cui_str': 'Thailand'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0150135', 'cui_str': 'Alleviating anxiety'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0450989', 'cui_str': ""Alzheimer's Disease Assessment Scale""}, {'cui': 'C0009738', 'cui_str': 'Congo'}, {'cui': 'C0039724', 'cui_str': 'Thai language'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0331124', 'cui_str': 'Catharanthus roseus'}, {'cui': 'C0242393', 'cui_str': 'Immediate Recall'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C4517393', 'cui_str': '0.01'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C4517385', 'cui_str': '0.001'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0150641', 'cui_str': 'Instrumental activities of daily living'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}]",77.0,0.0641603,"Compared with the control arm, the TEAM-V Program was associated with reducing anxiety (P = 0.004).","[{'ForeName': 'P', 'Initials': 'P', 'LastName': 'Srisuwan', 'Affiliation': 'Patsri Srisuwan, Department of Outpatient and Family Medicine, Phramongkutklao Hospital, Bangkok, 10400, Thailand, Phone (662) 354-7660 ext. 93100, Fax (662) 354-9006, Email: patsri2004@yahoo.com.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Nakawiro', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Chansirikarnjana', 'Affiliation': ''}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Kuha', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Chaikongthong', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Suwannagoot', 'Affiliation': ''}]",The journal of prevention of Alzheimer's disease,['10.14283/jpad.2019.42'] 365,31634897,"Augmenting extinction learning with D-cycloserine reduces return of fear: a randomized, placebo-controlled fMRI study.","D-cycloserine (DCS), a partial NMDA-receptor agonist, seems to be a promising enhancer for exposure therapy in anxiety disorders. It has been tested successfully in animal models of fear extinction, where DCS enhanced extinction learning. Applied in clinical studies, results of DCS-augmented exposure therapy remain ambiguous, calling for a deeper understanding of the underlying mechanisms of DCS and its exact effect on extinction learning and return of fear (ROF) in humans. In the present study, we investigated the effect of DCS-augmented extinction learning on behavioral, psychophysiological, and neural indices of ROF during a 24-h delayed recall test. Thirty-seven participants entered a randomized, placebo-controlled, double-blind, 3-day fear conditioning and delayed extinction fMRI design. One hour before extinction training, participants received an oral dose of 50 mg of DCS or a placebo. Behavioral arousal ratings revealed a generalized ROF during extinction recall in the placebo but not DCS group. Furthermore, participants receiving DCS compared to placebo showed attenuated differential BOLD responses in left posterior hippocampus and amygdala from extinction learning to extinction recall, due to increased hippocampal recruitment in placebo and trendwise decreased amygdala responding in DCS subjects. Our finding that DCS reduces ROF in arousal ratings and neural structures subserving defensive reactions support a role for NMDA receptors in extinction memory consolidation and encourage further translational research.",2020,"Furthermore, participants receiving DCS compared to placebo showed attenuated differential BOLD responses in left posterior hippocampus and amygdala from extinction learning to extinction recall, due to increased hippocampal recruitment in placebo and trendwise decreased amygdala responding in DCS subjects.",['Thirty-seven participants'],"['placebo-controlled, double-blind, 3-day fear conditioning and delayed extinction fMRI design', 'DCS-augmented extinction learning', 'DCS', 'placebo', 'D-cycloserine (DCS']","['hippocampal recruitment', 'return of fear', 'behavioral, psychophysiological, and neural indices of ROF', 'extinction learning and return of fear (ROF', 'Behavioral arousal ratings', 'differential BOLD responses']","[{'cui': 'C4319569', 'cui_str': '37 (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0015347', 'cui_str': 'Extinction (Psychology)'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0010590', 'cui_str': 'Cycloserine'}]","[{'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0015347', 'cui_str': 'Extinction (Psychology)'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0443199', 'cui_str': 'Differential (qualifier value)'}]",37.0,0.340641,"Furthermore, participants receiving DCS compared to placebo showed attenuated differential BOLD responses in left posterior hippocampus and amygdala from extinction learning to extinction recall, due to increased hippocampal recruitment in placebo and trendwise decreased amygdala responding in DCS subjects.","[{'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Ebrahimi', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany. claudia.ebrahimi@charite.de.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Gechter', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Lueken', 'Affiliation': 'Department of Psychology, Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Schlagenhauf', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.'}, {'ForeName': 'Hans-Ulrich', 'Initials': 'HU', 'LastName': 'Wittchen', 'Affiliation': 'Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Alfons O', 'Initials': 'AO', 'LastName': 'Hamm', 'Affiliation': 'Department of Biological and Clinical Psychology/Psychotherapy, University of Greifswald, Greifswald, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Ströhle', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0552-z'] 366,31655485,Angiotensin involvement in trauma processing-exploring candidate neurocognitive mechanisms of preventing post-traumatic stress symptoms.,"The angiotensin-II antagonist losartan is a promising candidate that has enhanced extinction in a post-traumatic stress disorder (PTSD) animal model and was related to reducing PTSD symptom development in humans. Here, we investigate the neurocognitive mechanisms underlying these results, testing the effect of losartan on data-driven and contextual processing of traumatic material, mechanisms proposed to be relevant for PTSD development. In a double-blind between-subject design, 40 healthy participants were randomised to a single oral dose of losartan (50 mg) or placebo, 1 h before being exposed to distressing films as a trauma analogue while heart rate (HR) was measured. Peritraumatic processing was investigated using blurry picture stimuli from the films, which transformed into clear images. Data-driven processing was measured by the level of blurriness at which contents were recognised. Contextual processing was measured as the amount of context information retrieved when describing the pictures' contents. Negative-matched control images were used to test perceptual processing of peripheral trauma-cues. Post-traumatic stress symptoms were assessed via self-report questionnaires after analogue trauma and an intrusion diary completed over 4 days following the experiment. Compared to placebo, losartan facilitated contextual processing and enhanced detail perception in the negative-match pictures. During the films, the losartan group recorded lower HR and higher HR variability, reflecting lower autonomic stress responses. We discuss potential mechanisms of losartan in preventing PTSD symptomatology, including the role of reduced arousal and increased contextual processing during trauma exposure, as well as increased threat-safety differentiation when encountering peripheral trauma-cues in the aftermaths of traumatic events.",2020,"Compared to placebo, losartan facilitated contextual processing and enhanced detail perception in the negative-match pictures.",['40 healthy participants'],"['placebo', 'losartan', 'placebo, losartan', 'angiotensin-II antagonist losartan']","['contextual processing and enhanced detail perception', 'Contextual processing', 'lower HR and higher HR variability, reflecting lower autonomic stress responses']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0126174', 'cui_str': 'Losartan'}, {'cui': 'C0373546', 'cui_str': 'Angiotensin II measurement (procedure)'}, {'cui': 'C0243076', 'cui_str': 'antagonists'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0558058', 'cui_str': 'Reflecting (finding)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}]",40.0,0.0689031,"Compared to placebo, losartan facilitated contextual processing and enhanced detail perception in the negative-match pictures.","[{'ForeName': 'Lorika', 'Initials': 'L', 'LastName': 'Shkreli', 'Affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Marcella Lydia', 'Initials': 'ML', 'LastName': 'Woud', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum, Bochum, Germany.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Ramsbottom', 'Affiliation': 'Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK.'}, {'ForeName': 'Aleksandra Ewa', 'Initials': 'AE', 'LastName': 'Rupietta', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum, Bochum, Germany.'}, {'ForeName': 'Gerd Thomas', 'Initials': 'GT', 'LastName': 'Waldhauser', 'Affiliation': 'Department of Neuropsychology, Ruhr-Universität Bochum, Bochum, Germany.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Kumsta', 'Affiliation': 'Genetic Psychology, Ruhr-Universität Bochum, Bochum, Germany.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Reinecke', 'Affiliation': 'Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, OX37JX, UK. andrea.reinecke@psych.ox.ac.uk.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0553-y'] 367,32247649,Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users.,"INTRODUCTION The use and availability of oral and inhalable products containing cannabidiol (CBD) as the principal constituent has increased with expanded cannabis/hemp legalization. However, few controlled clinical laboratory studies have evaluated the pharmacodynamic effects of oral or vaporized CBD or CBD-dominant cannabis. METHODS Eighteen healthy adults (9 men; 9 women) completed four, double-blind, double-dummy, drug administration sessions. Sessions were separated by ≥1 week and included self-administration of 100 mg oral CBD, 100 mg vaporized CBD, vaporized CBD-dominant cannabis (100 mg CBD; 3.7 mg THC), and placebo. Study outcomes included: subjective drug effects, vital signs, cognitive/psychomotor performance, and whole blood THC and CBD concentrations. RESULTS Vaporized CBD and CBD-dominant cannabis increased ratings on several subjective items (e.g., Like Drug Effect) relative to placebo. Subjective effects did not differ between oral CBD and placebo and were generally higher for CBD-dominant cannabis compared to vaporized CBD. CBD did not increase ratings for several items typically associated with acute cannabis/THC exposure (e.g., Paranoid). Women reported qualitatively higher ratings for Pleasant Drug Effect than men after vaporized CBD and CBD-dominant cannabis use. CBD-dominant cannabis increased heart rate compared to placebo. Cognitive/psychomotor impairment was not observed in any drug condition. CONCLUSIONS Vaporized CBD and CBD-dominant cannabis produced discriminable subjective drug effects, which were sometimes stronger in women, but did not produce cognitive/psychomotor impairment. Subjective effects of oral CBD did not differ from placebo. Future research should further elucidate the subjective effects of various types of CBD products (e.g., inhaled, oral, topical), which appear to be distinct from THC-dominant products.",2020,Women reported qualitatively higher ratings for Pleasant Drug Effect than men after vaporized CBD and CBD-dominant cannabis use.,"['infrequent cannabis users', 'Eighteen healthy adults (9 men; 9 women']","['placebo', 'oral CBD', 'oral and inhalable products containing cannabidiol (CBD', 'CBD', 'vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis', 'oral CBD, 100 mg vaporized CBD, vaporized CBD-dominant cannabis (100 mg CBD; 3.7 mg THC), and placebo']","['several subjective items', 'Subjective effects', 'Cognitive/psychomotor impairment', 'subjective drug effects, vital signs, cognitive/psychomotor performance, and whole blood THC and CBD concentrations', 'CBD-dominant cannabis', 'heart rate']","[{'cui': 'C0521114', 'cui_str': 'Infrequent'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0006863', 'cui_str': 'Cannabidiol'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4517696', 'cui_str': '3.7'}, {'cui': 'C0039663', 'cui_str': 'dronabinol'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0424230', 'cui_str': 'Motor retardation'}, {'cui': 'C0728866', 'cui_str': 'drug effects'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0033923', 'cui_str': 'Psychomotor Performance'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C0006863', 'cui_str': 'Cannabidiol'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}]",18.0,0.0867755,Women reported qualitatively higher ratings for Pleasant Drug Effect than men after vaporized CBD and CBD-dominant cannabis use.,"[{'ForeName': 'Tory R', 'Initials': 'TR', 'LastName': 'Spindle', 'Affiliation': 'Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Dr., Baltimore, MD, 21224, USA. Electronic address: tspindle@jhmi.edu.'}, {'ForeName': 'Edward J', 'Initials': 'EJ', 'LastName': 'Cone', 'Affiliation': 'Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Dr., Baltimore, MD, 21224, USA.'}, {'ForeName': 'Elia', 'Initials': 'E', 'LastName': 'Goffi', 'Affiliation': 'Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Dr., Baltimore, MD, 21224, USA.'}, {'ForeName': 'Elise M', 'Initials': 'EM', 'LastName': 'Weerts', 'Affiliation': 'Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Dr., Baltimore, MD, 21224, USA.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Mitchell', 'Affiliation': 'RTI International, Research Triangle Park, 3040 East Cornwallis Rd., NC, 27709, USA.'}, {'ForeName': 'Ruth E', 'Initials': 'RE', 'LastName': 'Winecker', 'Affiliation': 'RTI International, Research Triangle Park, 3040 East Cornwallis Rd., NC, 27709, USA.'}, {'ForeName': 'George E', 'Initials': 'GE', 'LastName': 'Bigelow', 'Affiliation': 'Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Dr., Baltimore, MD, 21224, USA.'}, {'ForeName': 'Ronald R', 'Initials': 'RR', 'LastName': 'Flegel', 'Affiliation': 'Substance Abuse and Mental Health Services Administration (SAMHSA), Division of Workplace Programs (DWP), 5600Fishers Lane, Rockville, MD, 20857, USA.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Vandrey', 'Affiliation': 'Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Dr., Baltimore, MD, 21224, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.107937'] 368,31868905,Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.,"BACKGROUND FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. The consensus molecular subgroups (CMS) are grouping CRC samples according to their gene-signature in four different subtypes. Relevance of CMS for the treatment of mCRC has yet to be defined. PATIENTS AND METHODS In this exploratory analysis, patients were grouped according to the previously published tumor CRC-CMSs. Objective response rates (ORR) were compared using chi-square test. Overall survival (OS) and progression-free survival (PFS) times were compared using Kaplan-Meier estimation, log-rank tests. Hazard ratios (HR) were estimated according to the Cox proportional hazard method. RESULTS CMS classification could be determined in 438 out of 514 specimens available from the intent-to-treat (ITT) population (n = 592). Frequencies for the remaining 438 samples were as follows: CMS1 (14%), CMS2 (37%), CMS3 (15%), CMS4 (34%). For the 315 RAS wild-type tumors, frequencies were as follows: CMS1 (12%), CMS2 (41%), CMS3 (11%), CMS4 (34%). CMS distribution in right- versus (vs) left-sided primary tumors was as follows: CMS1 (27% versus 11%), CMS2 (28% versus 45%), CMS3 (10% versus 12%), CMS4 (35% versus 32%). Independent of the treatment, CMS was a strong prognostic factor for ORR (P = 0.051), PFS (P < 0.001), and OS (P < 0.001). Within the RAS wild-type population, OS observed in CMS4 significantly favored FOLFIRI cetuximab over FOLFIRI bevacizumab. In CMS3, OS showed a trend in favor of the cetuximab arm, while OS was comparable in CMS1 and CMS2, independent of targeted therapy. CONCLUSIONS CMS classification is prognostic for mCRC. Prolonged OS induced by FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab in the FIRE-3 study appears to be driven by CMS3 and CMS4. CMS classification provides deeper insights into the biology to CRC, but at present time has no direct impact on clinical decision-making.The FIRE-3 (AIO KRK-0306) study had been registered at ClinicalTrials.gov: NCT00433927.",2019,"Independent of the treatment, CMS was a strong prognostic factor for ORR (P = 0.051), PFS (P < 0.001), and OS (P < 0.001).",['592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients'],"['CMS', 'FOLFIRI cetuximab over FOLFIRI bevacizumab', 'cetuximab or bevacizumab', 'bevacizumab', 'FOLFIRI plus cetuximab or bevacizumab']","['Overall survival (OS) and progression-free survival ', 'CMS2', 'CMS distribution', 'PFS', 'CMS4', 'CMS1', 'CMS3', 'Hazard ratios (HR', 'Objective response rates (ORR']","[{'cui': 'C0015295', 'cui_str': 'Exons'}, {'cui': 'C0445392', 'cui_str': 'Wild (qualifier value)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0346973', 'cui_str': 'Secondary malignant neoplasm of large intestine'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0995188', 'cui_str': 'cetuximab'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}]",514.0,0.0379558,"Independent of the treatment, CMS was a strong prognostic factor for ORR (P = 0.051), PFS (P < 0.001), and OS (P < 0.001).","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Stintzing', 'Affiliation': 'Department of Medicine, Division of Hematology, Oncology, and Tumor Immunology (CCM), Charité Universitaetsmedizin Berlin, Berlin, Germany. Electronic address: sebastian.stintzing@charite.de.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Wirapati', 'Affiliation': 'SIB Swiss Institute of Bioinformatics, Bioinformatic Core Facility, Lausanne, Switzerland.'}, {'ForeName': 'H-J', 'Initials': 'HJ', 'LastName': 'Lenz', 'Affiliation': 'USC Norris Comprehensive Cancer Center, Los Angeles, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Neureiter', 'Affiliation': 'Institute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), Salzburg, Austria.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Fischer von Weikersthal', 'Affiliation': 'Gesundheitszentrum St. Marien, Amberg.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Decker', 'Affiliation': 'Oncological Practice, Ravensburg.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Kiani', 'Affiliation': 'Medizinische Klinik IV, Klinikum Bayreuth, Bayreuth.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Kaiser', 'Affiliation': 'VK&K Studien GbR, Landshut.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Al-Batran', 'Affiliation': 'Department of Hematology and Oncology, Krankenhaus Nordwest, Frankfurt/Main.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Heintges', 'Affiliation': 'Department of Medicine II, Städtisches Klinikum Neuss, Neuss.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Lerchenmüller', 'Affiliation': 'Oncological Practice, Münster.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Kahl', 'Affiliation': 'Haematology and Oncology, Staedtisches Klinikum Magdeburg, Magdeburg.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Seipelt', 'Affiliation': 'Oncological Practice, Bad Soden.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Kullmann', 'Affiliation': 'Department of Medicine I, Klinikum Weiden, Weiden.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Moehler', 'Affiliation': 'University Hospital Mainz, Mainz, Germany.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Scheithauer', 'Affiliation': 'Department of Internal Medicine I & Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Held', 'Affiliation': 'ClinAssess GmbH, Leverkusen.'}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Modest', 'Affiliation': 'Department of Medicine III, University Hospital, LMU Munich, Munich.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Jung', 'Affiliation': 'Institute of Pathology University of Munich, Munich, Germany.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Kirchner', 'Affiliation': 'Institute of Pathology University of Munich, Munich, Germany.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Aderka', 'Affiliation': 'Department of Gastrointestinal Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Tejpar', 'Affiliation': 'Molecular Digestive Oncology, UZ Leuven, Belgium.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Heinemann', 'Affiliation': 'Department of Medicine III, University Hospital, LMU Munich, Munich.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdz387'] 369,32249917,Relationships Between Measures of Malaria at Delivery and Adverse Birth Outcomes in a High-Transmission Area of Uganda.,"BACKGROUND Clinical trials of interventions for preventing malaria in pregnancy often use measures of malaria at delivery as their primary outcome. Although the objective of these interventions is to improve birth outcomes, data on associations between different measures of malaria at delivery and adverse birth outcomes are limited. METHODS Data came from 637 Ugandan women enrolled in a randomized controlled trial of intermittent preventive treatment of malaria in pregnancy. Malaria at delivery was detected using peripheral and placental blood microscopy, placental blood loop-mediated isothermal amplification (LAMP), and placental histopathology. Multivariate analyses were used to estimate associations between measures of malaria at delivery and risks of low birth weight (LBW), small for gestational age (SGA), and preterm birth (PTB). RESULTS Detection of malaria parasites by microscopy or LAMP was not associated with adverse birth outcomes. Presence of malaria pigment detected by histopathology in ≥30% of high-powered fields was strongly associated with LBW (adjusted risk ratio [aRR] = 3.42, P = .02) and SGA (aRR = 4.24, P < .001) but not PTB (aRR = 0.88, P = .87). CONCLUSIONS A semiquantitative classification system based on histopathologically detected malaria pigment provided the best surrogate measure of adverse birth outcomes in a high-transmission setting and should be considered for use in malaria in pregnancy intervention studies.",2020,"RESULTS Detection of malaria parasites by microscopy or LAMP was not associated with adverse birth outcomes.","['a high-transmission area of Uganda', 'Data came from 637 Ugandan women enrolled in a randomized controlled trial of intermittent preventive treatment of malaria in pregnancy']",[],"['malaria at delivery and risks of low birth weight (LBW), small-for-gestational age (SGA) and preterm birth (PTB']","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0040722', 'cui_str': 'transmission'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0041573', 'cui_str': 'Uganda'}, {'cui': 'C0960273', 'cui_str': 'CAME'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0282440', 'cui_str': 'Randomized Controlled Trials as Topic'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0747820', 'cui_str': 'Malaria, antepartum'}]",[],"[{'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}, {'cui': 'C0235991', 'cui_str': 'Small for gestational age'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}]",637.0,0.101558,"RESULTS Detection of malaria parasites by microscopy or LAMP was not associated with adverse birth outcomes.","[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'Ategeka', 'Affiliation': 'Infectious Diseases Research Collaboration, Kampala, Uganda.'}, {'ForeName': 'Abel', 'Initials': 'A', 'LastName': 'Kakuru', 'Affiliation': 'Infectious Diseases Research Collaboration, Kampala, Uganda.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Kajubi', 'Affiliation': 'Infectious Diseases Research Collaboration, Kampala, Uganda.'}, {'ForeName': 'Razack', 'Initials': 'R', 'LastName': 'Wasswa', 'Affiliation': 'Infectious Diseases Research Collaboration, Kampala, Uganda.'}, {'ForeName': 'Harriet', 'Initials': 'H', 'LastName': 'Ochokoru', 'Affiliation': 'Infectious Diseases Research Collaboration, Kampala, Uganda.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Arinaitwe', 'Affiliation': 'Infectious Diseases Research Collaboration, Kampala, Uganda.'}, {'ForeName': 'Adoke', 'Initials': 'A', 'LastName': 'Yeka', 'Affiliation': 'Infectious Diseases Research Collaboration, Kampala, Uganda.'}, {'ForeName': 'Prasanna', 'Initials': 'P', 'LastName': 'Jagannathan', 'Affiliation': 'Department of Medicine, Stanford University, Stanford, California, USA.'}, {'ForeName': 'Moses R', 'Initials': 'MR', 'LastName': 'Kamya', 'Affiliation': 'School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.'}, {'ForeName': 'Atis', 'Initials': 'A', 'LastName': 'Muehlenbachs', 'Affiliation': 'Centers for Disease Control and Prevention, Atlanta, Georgia, USA.'}, {'ForeName': 'R Matthew', 'Initials': 'RM', 'LastName': 'Chico', 'Affiliation': 'London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Grant', 'Initials': 'G', 'LastName': 'Dorsey', 'Affiliation': 'Department of Medicine, University of California San Francisco, San Francisco, California, USA.'}]",The Journal of infectious diseases,['10.1093/infdis/jiaa156'] 370,32017992,[Evolution of the cesarean delivery rate from 37 weeks of gestation among nulliparas or how to evaluate the external validity of a randomized North American trial about induction of labor].,"OBJECTIVE To determine the risk of caesarean delivery (CD) when an expectant management is considered for a nulliparous reaching≥37 weeks of gestation (wog). METHODS This is a prospective study, including all nulliparous women who delivered at≥37 wog a singleton fetus in a cephalic presentation between the first January 2017 and the 31st December 2017 in a French perinatal network (Mypa). For each week of gestation from 37 wog to 41 wog, the rate of CD was determined according the onset of labor (spontaneous or induced). The risk of CD when expectant management was considered at a specific gestational age was calculated by taking all the population who reached this gestational age, minus all women who had an induction of labor or underwent a caesarean delivery before labor. RESULTS In total, 16,085 women delivered at≥24 wog, and 5498 (34.1%) were nulliparous with a singleton fetus in a cephalic presentation reaching 37SA. The risk of CD increased from 40 wog, whatever the labor was spontaneous or induced (when labor was spontaneous, the risk of CD was stable till 39 wog around 11%, and increased from 14% at 40 wog to 20% at 41 wog; similarly, when labor was induced, the risk of CD was stable till 39 wog around 28%, and increased from 40% at 40 wog to 38% at 41 wog. The risk of CD for a nulliparous reaching>37 Wog when expectant management is considered was stable around 22.3%. CONCLUSION The risk of CD for a nulliparous reaching≥37SA when expectant management is considered is similar than the one in the United States of America.",2020,"The risk of CD increased from 40wog, whatever the labor was spontaneous or induced ( when labor was spontaneous, the risk of CD was stable till 39 wog around 11%, and increased from 14% at 40wog to 20% at 41wog; similarly, when labor was induced, the risk of CD was stable till 39","['16085 women delivered at ≥24 wog, and 5498 (34,1%) were nulliparous with a singleton fetus in a cephalic presentation reaching 37SA', 'all nulliparous women who delivered at ≥37 wog a singleton fetus in a cephalic presentation between the first January 2017 and the 31 st December 2017 in a French perinatal network (Mypa', 'population who reached this gestational age, minus all women who had an induction of labor or underwent a caesarean delivery before labor', 'labor']",['caesarean delivery (CD'],"['risk of CD', 'rate of CD']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0425979', 'cui_str': 'Nulliparous (finding)'}, {'cui': 'C0015965', 'cui_str': 'Fetus'}, {'cui': 'C2979973'}, {'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}, {'cui': 'C1556084', 'cui_str': 'French (ethnic group)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0332288', 'cui_str': 'Without (attribute)'}, {'cui': 'C0259787', 'cui_str': 'Labor Induction'}, {'cui': 'C1384674', 'cui_str': 'Deliveries by cesarean (finding)'}, {'cui': 'C0022864', 'cui_str': 'Labor, Obstetric'}]","[{'cui': 'C1384674', 'cui_str': 'Deliveries by cesarean (finding)'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}]",16085.0,0.0440481,"The risk of CD increased from 40wog, whatever the labor was spontaneous or induced ( when labor was spontaneous, the risk of CD was stable till 39 wog around 11%, and increased from 14% at 40wog to 20% at 41wog; similarly, when labor was induced, the risk of CD was stable till 39","[{'ForeName': 'T', 'Initials': 'T', 'LastName': 'Quibel', 'Affiliation': ""Département d'obstétrique et gynécologie, Hôpital Poissy-Saint-Germain, Poissy, France; Unité de recherche EA 7285, Université Versailles-Saint-Quentin, Montigny-le-Bretonneux, France. Electronic address: thibquib@chi-poissy-st-germain.fr.""}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Raynal', 'Affiliation': ""Département d'obstétrique et gynécologie, centre hospitalier de Versailles André-Mignot, Le-Chesnay, France; Réseau périnatal maternité en Yvelines et périnatalité active, Saint-Germain-en-Laye, France.""}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Bouyer', 'Affiliation': 'Réseau périnatal maternité en Yvelines et périnatalité active, Saint-Germain-en-Laye, France.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Rozenberg', 'Affiliation': ""Département d'obstétrique et gynécologie, Hôpital Poissy-Saint-Germain, Poissy, France; Unité de recherche EA 7285, Université Versailles-Saint-Quentin, Montigny-le-Bretonneux, France; Réseau périnatal maternité en Yvelines et périnatalité active, Saint-Germain-en-Laye, France.""}]","Gynecologie, obstetrique, fertilite & senologie",['10.1016/j.gofs.2020.01.026'] 371,31379301,Non-thrust cervical manipulations reduce short-term pain and decrease systolic blood pressure during intervention in mechanical neck pain: a randomized clinical trial.,"Objectives : To evaluate the association of resting blood pressure with pain response and evaluate the cardiovascular effects of anterior-to-posterior [AP] versus lateral [LAT] techniques of cervical spine non-thrust manipulation [NTM]. Methods : Forty-three (23 females) participants with non-chronic neck pain (mean age 29.00 ± SD 9.09 years) randomly received AP or LAT NTM to the cervical spine. Blood pressure and heart rate were measured before, during, and after the intervention. Disability and pain were measured pre- and post-intervention. Results : Resting systolic blood pressure (SBP) was significantly associated with average pain reduction two days later on univariate and multivariate analyses (coefficients -0.029 ± SD 0.013, p = 0.036; -0.026 ± 0.012, p = 0.032).No significant differences existed between AP and LAT NTM groups in disability, pain reduction, and cardiovascular variables. The decrease in 'worst neck pain' rating 2-days post-intervention was clinically significant within the AP (mean -2.43 ± SD 2.66) group. Mixed-effect model ANOVA revealed a significant change in SBP over time (estimate -1.94 ± SD 0.70, p = 0.007). Discussion : This spinal NTM study was the first to relate resting SBP with short-term pain reduction, demonstrating SBP-related hypoalgesia. In normotensive individuals with unilateral non-chronic neck pain, each 10 mmHg higher resting SBP was associated with a 0.29-unit decrease in average pain at follow-up when holding baseline pain constant.AP and LAT NTM equally reduced short-term pain and decreased SBP during-intervention, suggesting SBP-sympathoinhibition. These techniques have previously been shown to be sympatho-excitatory when delivered under different dosage parameters. SBP's mediating and moderating role should be investigated.""Level of Evidence: 1b.""",2020,The decrease in 'worst neck pain' rating 2-days post-intervention was clinically significant within the AP (mean -2.43 ± SD 2.66) group.,"['normotensive individuals with unilateral non-chronic neck pain', 'Methods : Forty-three (23 females) participants with non-chronic neck pain (mean age 29.00 ±\xa0SD 9.09\xa0years) randomly received', 'Discussion ', 'mechanical neck pain']","['anterior-to-posterior [AP] versus lateral [LAT', 'AP or LAT NTM']","['Resting systolic blood pressure (SBP', 'disability, pain reduction, and cardiovascular variables', 'average pain', 'systolic blood pressure', 'Disability and pain', 'Blood pressure and heart rate', ""worst neck pain' rating 2-days post-intervention"", 'short-term pain and decreased SBP', 'SBP']","[{'cui': 'C2712122', 'cui_str': 'Normal blood pressure (finding)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0746815', 'cui_str': 'Chronic neck pain'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0450368', 'cui_str': '43 (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0557061', 'cui_str': 'Discussion (procedure)'}, {'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}, {'cui': 'C0007859', 'cui_str': 'Neck Ache'}]","[{'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0205093', 'cui_str': 'Lateral (qualifier value)'}, {'cui': 'C0023979', 'cui_str': 'LATS'}, {'cui': 'C1265234', 'cui_str': 'Non-Tuberculous Mycobacteria'}]","[{'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0007859', 'cui_str': 'Neck Ache'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}]",,0.060293,The decrease in 'worst neck pain' rating 2-days post-intervention was clinically significant within the AP (mean -2.43 ± SD 2.66) group.,"[{'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Yung', 'Affiliation': 'Department of Physical Therapy, Sacred Heart University, Fairfield, CT, USA.'}, {'ForeName': 'Cheongeun', 'Initials': 'C', 'LastName': 'Oh', 'Affiliation': 'Division of Biostatistics, Department of Population Health, New York University School of Medicine, New York, NY, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Wong', 'Affiliation': 'Department of Physical Therapy, Azusa Pacific University, Azusa, CA, USA.'}, {'ForeName': 'Jason K', 'Initials': 'JK', 'LastName': 'Grimes', 'Affiliation': 'Department of Physical Therapy, Sacred Heart University, Fairfield, CT, USA.'}, {'ForeName': 'Erica Mae', 'Initials': 'EM', 'LastName': 'Barton', 'Affiliation': 'Department of Physical Therapy, Azusa Pacific University, Azusa, CA, USA.'}, {'ForeName': 'Muhammad I', 'Initials': 'MI', 'LastName': 'Ali', 'Affiliation': 'Department of Physical Therapy, Sacred Heart University, Fairfield, CT, USA.'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Breakey', 'Affiliation': 'Department of Physical Therapy, Sacred Heart University, Fairfield, CT, USA.'}]",The Journal of manual & manipulative therapy,['10.1080/10669817.2019.1646985'] 372,31560066,Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.,"BACKGROUND In the SPARTAN study, compared with placebo, apalutamide added to ongoing androgen deprivation therapy significantly prolonged metastasis-free survival (MFS) and time to symptomatic progression in patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). Overall survival (OS) results at the first interim analysis (IA1) were immature, with 104 of 427 (24%) events required for planned final OS analysis. Here, we report the results of a second pre-specified interim analysis (IA2). METHODS One thousand two hundred and seven patients with nmCRPC were randomized 2 : 1 to apalutamide (240 mg daily) or placebo. The primary end point of the study was MFS. Subsequent therapy for metastatic CRPC was permitted. When the primary end point was met, the study was unblinded. Patients receiving placebo who had not yet developed metastases were offered open-label apalutamide. At IA2, pre-specified analysis of OS was undertaken, using a group-sequential testing procedure with O'Brien-Fleming-type alpha spending function. Safety and second progression-free survival (PFS2) were assessed. RESULTS Median follow-up was 41 months. With 285 (67% of required) OS events, apalutamide was associated with an improved OS compared with placebo (HR 0.75; 95% CI 0.59-0.96; P = 0.0197), although the P-value did not cross the pre-specified O'Brien-Fleming boundary of 0.0121. Apalutamide improved PFS2 (HR 0.55; 95% CI 0.45-0.68). At IA2, 69% of placebo-treated and 40% of apalutamide-treated patients had received subsequent life-prolonging therapy for metastatic CRPC. No new safety signals were observed. CONCLUSION In patients with nmCRPC, apalutamide was associated with a 25% reduction in risk of death compared with placebo. This OS benefit was observed despite crossover of placebo-treated patients and higher rates of subsequent life-prolonging therapy for the placebo group.",2019,Apalutamide improved PFS2 (HR 0.55; 95% CI 0.45-0.68).,"['One thousand two hundred and seven patients with nmCRPC', 'non-metastatic castration-resistant prostate cancer', 'patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC']","['placebo', 'placebo, apalutamide added to ongoing androgen deprivation therapy', 'apalutamide']","['Apalutamide improved PFS2', 'Overall survival (OS', 'Safety and second progression-free survival (PFS2', 'risk of death', 'Apalutamide and overall survival']","[{'cui': 'C4517548', 'cui_str': 'One thousand two hundred'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4329353', 'cui_str': 'apalutamide'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy (procedure)'}]","[{'cui': 'C4329353', 'cui_str': 'apalutamide'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",1207.0,0.43351,Apalutamide improved PFS2 (HR 0.55; 95% CI 0.45-0.68).,"[{'ForeName': 'E J', 'Initials': 'EJ', 'LastName': 'Small', 'Affiliation': 'Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. Electronic address: Eric.Small@ucsf.edu.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Saad', 'Affiliation': ""Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, QC, Canada.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Chowdhury', 'Affiliation': ""Guy's, King's and St. Thomas' Hospitals, London; Sarah Cannon Research Institute, London, UK.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Oudard', 'Affiliation': 'Georges Pompidou Hospital, University René Descartes, Paris, France.'}, {'ForeName': 'B A', 'Initials': 'BA', 'LastName': 'Hadaschik', 'Affiliation': 'University of Duisburg-Essen, Essen; Ruprecht-Karls University Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'J N', 'Initials': 'JN', 'LastName': 'Graff', 'Affiliation': 'VA Portland Health Care System, Portland; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Olmos', 'Affiliation': 'Spanish National Cancer Research Centre (CNIO), Madrid; Hospitales Universitarios Virgen de la Victoria y Regional, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.'}, {'ForeName': 'P N', 'Initials': 'PN', 'LastName': 'Mainwaring', 'Affiliation': 'Centre for Personalized Nanomedicine, University of Queensland, Brisbane, Australia.'}, {'ForeName': 'J Y', 'Initials': 'JY', 'LastName': 'Lee', 'Affiliation': ""St. Mary's Hospital of Catholic University, Seoul, South Korea.""}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Uemura', 'Affiliation': 'Yokohama City University Medical Center, Yokohama, Japan.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'De Porre', 'Affiliation': 'Janssen Research & Development, Beerse, Belgium.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Smith', 'Affiliation': 'Janssen Research & Development, Spring House, PA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Zhang', 'Affiliation': 'Janssen Research & Development, San Diego, CA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Lopez-Gitlitz', 'Affiliation': 'Janssen Research & Development, Los Angeles, CA.'}, {'ForeName': 'M R', 'Initials': 'MR', 'LastName': 'Smith', 'Affiliation': 'Massachusetts General Hospital Cancer Center, Boston, MA; Harvard Medical School, Boston, MA, USA.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdz397'] 373,32036671,Optimizing future planning in Parkinson disease: suggestions for a comprehensive roadmap from patients and care partners.,"BACKGROUND Living with Parkinson disease (PD) is complicated by an unpredictable disease course which can delay planning for future needs. This study explores patient and care partner needs related to future planning using a palliative care framework with physical, psychological, social, cultural, end-of-life, and ethical aspects of care in PD to guide analysis. METHODS Secondary analysis of patient and care partner interviews from a randomized clinical trial comparing interdisciplinary outpatient palliative care versus standard care for individuals with PD and care partners in an academic setting. Sixty participants were interviewed (30 patients and 30 care partners) about needs related to future planning. Team-based thematic analysis was used to identify key themes. RESULTS Many care partners and patients living with PD described a desire for information about what to expect and how to plan for the future. Participants posed multiple questions about PD progression and devised the metaphor of a ""roadmap"" as a guide for decision making and planning. When exploring the concept of a PD roadmap, five themes emerged: (I) desire for a comprehensive tool for future planning, such as a roadmap, (II) care partner preferences for specific future planning, (III) PD-related life changes as opportunity for future planning and decision-making, (IV) cues from family, peers, and medical professionals about ""location"" on the roadmap, and (V) opportunities and challenges to integrating a PD roadmap into patient-centered care. CONCLUSIONS Patients and care partners described key needs related to future planning that can inform a comprehensive roadmap to assist with education, communication, and decision making. A roadmap tool can promote individualized anticipatory guidance and multidimensional shared decision-making discussions between patients, care partners, and the healthcare team related to PD progression.",2020,"Participants posed multiple questions about PD progression and devised the metaphor of a ""roadmap"" as a guide for decision making and planning.","['Living with Parkinson disease (PD', 'Parkinson disease', 'individuals with PD and care partners in an academic setting', 'patients and care partners', 'Secondary analysis of patient and care partner interviews', 'Sixty participants were interviewed (30 patients and 30 care partners) about needs related to future planning', 'Patients and care partners']",['interdisciplinary outpatient palliative care versus standard care'],[],"[{'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0016884', 'cui_str': 'Future'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning (observable entity)'}]","[{'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0700049', 'cui_str': 'Palliative care'}, {'cui': 'C0038137', 'cui_str': 'standards'}]",[],60.0,0.0233073,"Participants posed multiple questions about PD progression and devised the metaphor of a ""roadmap"" as a guide for decision making and planning.","[{'ForeName': 'Sarah R', 'Initials': 'SR', 'LastName': 'Jordan', 'Affiliation': 'Division of Geriatric Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Benzi', 'Initials': 'B', 'LastName': 'Kluger', 'Affiliation': 'Departments of Neurology and Medicine, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Ayele', 'Affiliation': 'Denver-Seattle Center of Innovation, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado, USA; College of Nursing, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Adreanne', 'Initials': 'A', 'LastName': 'Brungardt', 'Affiliation': 'Division of Geriatric Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Hall', 'Affiliation': 'Research Stakeholder, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Jones', 'Affiliation': 'College of Nursing, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Katz', 'Affiliation': 'Movement Disorders and Neuromodulation Center, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Janis M', 'Initials': 'JM', 'LastName': 'Miyasaki', 'Affiliation': 'Division of Neurology, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Hillary D', 'Initials': 'HD', 'LastName': 'Lum', 'Affiliation': 'Division of Geriatric Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA; VA Eastern Colorado Geriatric Research Education and Clinical Center, Aurora, Colorado, USA. Hillary.lum@cuanschutz.edu.'}]",Annals of palliative medicine,['10.21037/apm.2019.09.10'] 374,32240480,"The Effectiveness of the KiVa Bullying Prevention Program in Wales, UK: Results from a Pragmatic Cluster Randomized Controlled Trial.","The study evaluated the implementation fidelity and effectiveness of KiVa, an evidence-based program that aims to prevent and address bullying in schools, with a particular emphasis on changing the role of bystanders. The study was a two-arm waitlist control cluster randomized controlled trial in which 22 primary schools (clusters) (N = 3214 students aged 7-11) were allocated using a 1:1 ratio to intervention (KiVa; 11 clusters, n = 1588 students) and a waitlist control (usual school provision; 11 clusters, n = 1892 children)). The trial statistician (but not schools or researchers) remained blind to allocation status. The outcomes were as follows: student-reported victimization (primary outcome) and bullying perpetration; teacher-reported child behavior and emotional well-being; and school absenteeism (administrative records). Implementation fidelity was measured using teacher-completed online records (for class lessons) and independent researcher observations (for school-wide elements). Outcome analyses involved 11 intervention schools (n = 1578 children) and 10 control schools (n = 1636 children). There was no statistically significant effect on the primary outcome of child-reported victimization (adjusted intervention/control OR 0.76; 95% CI 0.55 to 1.06; p = 0.11) or on the secondary outcomes. The impact on victimization was not moderated by child gender, age, or victimization status at baseline. Lesson adherence was good but exposure (lesson length) was lower than the recommended amount, and there was considerable variability in the implementation of whole school elements. The trial found insufficient evidence to conclude that KiVa had an effect on the primary outcome. A larger trial of KiVa in the UK is warranted, however, with attention to issues regarding implementation fidelity. Trial registration: Current Controlled Trials ISRCTN23999021 Date 10-6-13.",2020,There was no statistically significant effect on the primary outcome of child-reported victimization (adjusted intervention/control OR 0.76; 95% CI 0.55 to 1.06; p = 0.11) or on the secondary outcomes.,"['22 primary schools (clusters) (N\u2009=\u20093214 students aged 7-11', '11 intervention schools (n\u2009=\u20091578 children) and 10 control schools (n\u2009=\u20091636 children', 'Wales, UK']","['KiVa', 'KiVa Bullying Prevention Program', 'waitlist control']","['Implementation fidelity', 'Lesson adherence', 'student-reported victimization (primary outcome) and bullying perpetration; teacher-reported child behavior and emotional well-being; and school absenteeism (administrative records']","[{'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0043015', 'cui_str': 'Wales'}]","[{'cui': 'C0424318', 'cui_str': 'Bullying'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0376695', 'cui_str': 'Victimization'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0424318', 'cui_str': 'Bullying'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0008065', 'cui_str': 'Behavior, Child'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0000849', 'cui_str': 'Absenteeism'}, {'cui': 'C1301664', 'cui_str': 'Administrative record'}]",3214.0,0.160181,There was no statistically significant effect on the primary outcome of child-reported victimization (adjusted intervention/control OR 0.76; 95% CI 0.55 to 1.06; p = 0.11) or on the secondary outcomes.,"[{'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Axford', 'Affiliation': 'NIHR ARC South West Peninsula (PenARC), University of Plymouth, Plymouth, UK.'}, {'ForeName': 'Gretchen', 'Initials': 'G', 'LastName': 'Bjornstad', 'Affiliation': 'University of Exeter Medical School, University of Exeter, Exeter, UK.'}, {'ForeName': 'Suzy', 'Initials': 'S', 'LastName': 'Clarkson', 'Affiliation': 'Bangor University, Bangor, UK.'}, {'ForeName': 'Obioha C', 'Initials': 'OC', 'LastName': 'Ukoumunne', 'Affiliation': 'PenARC, University of Exeter, Exeter, UK. o.c.ukoumunne@exeter.ac.uk.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Wrigley', 'Affiliation': 'University of Cardiff, Cardiff, UK.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Matthews', 'Affiliation': 'PenARC, University of Exeter, Exeter, UK.'}, {'ForeName': 'Vashti', 'Initials': 'V', 'LastName': 'Berry', 'Affiliation': 'PenARC, University of Exeter, Exeter, UK.'}, {'ForeName': 'Judy', 'Initials': 'J', 'LastName': 'Hutchings', 'Affiliation': 'Bangor University, Bangor, UK.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-020-01103-9'] 375,31685489,Effect of Surgical Versus Medical Therapy on Diabetic Kidney Disease Over 5 Years in Severely Obese Adolescents With Type 2 Diabetes.,"OBJECTIVE To compare diabetic kidney disease (DKD) rates over 5 years of follow-up in two cohorts of severely obese adolescents with type 2 diabetes (T2D) undergoing medical or surgical treatment for T2D. RESEARCH DESIGN AND METHODS A secondary analysis was performed of data collected from obese participants of similar age and racial distribution enrolled in the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) and the Treatment Options of Type 2 Diabetes in Adolescents and Youth (TODAY) studies. Teen-LABS participants underwent metabolic bariatric surgery (MBS). TODAY participants were randomized to metformin alone or in combination with rosiglitazone or intensive lifestyle intervention, with insulin therapy given for glycemic progression. Glycemic control, BMI, estimated glomerular filtration rate (eGFR), urinary albumin excretion (UAE), and prevalence of hyperfiltration (eGFR ≥135 mL/min/1.73 m 2 ) and elevated UAE (≥30 mg/g) were assessed annually. RESULTS Participants with T2D from Teen-LABS ( n = 30, mean ± SD age, 16.9 ± 1.3 years; 70% female; 60% white; BMI 54.4 ± 9.5 kg/m 2 ) and TODAY ( n = 63, age 15.3 ± 1.3 years; 56% female; 71% white; BMI 40.5 ± 4.9 kg/m 2 ) were compared. During 5 years of follow-up, hyperfiltration decreased from 21% to 18% in Teen-LABS and increased from 7% to 48% in TODAY. Elevated UAE decreased from 27% to 5% in Teen-LABS and increased from 21% to 43% in TODAY. Adjusting for baseline age, sex, BMI, and HbA 1c , TODAY participants had a greater odds of hyperfiltration (odds ratio 15.7 [95% CI 2.6, 94.3]) and elevated UAE (27.3 [4.9, 149.9]) at 5 years of follow-up. CONCLUSIONS Compared with MBS, medical treatment of obese youth with T2D was associated with a higher odds of DKD over 5 years.",2020,"Compared with MBS, medical treatment of obese youth with T2D was associated with a higher odds of DKD over 5 years.","['Participants with T2D from Teen-LABS ( n = 30, mean ± SD age, 16.9 ± 1.3 years; 70% female; 60% white; BMI 54.4 ± 9.5 kg/m 2 ) and TODAY ( n = 63, age 15.3 ± 1.3 years; 56% female; 71% white; BMI 40.5 ± 4.9 kg/m 2 ', 'Diabetic Kidney Disease Over 5 Years in Severely Obese Adolescents With Type 2 Diabetes', 'severely obese adolescents with type 2 diabetes ', 'T2D) undergoing medical or surgical treatment for T2D', 'obese participants of similar age and racial distribution enrolled in the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) and the Treatment Options of Type 2 Diabetes in Adolescents and Youth (TODAY) studies']","['Surgical Versus Medical Therapy', 'metabolic bariatric surgery (MBS', 'metformin alone or in combination with rosiglitazone or intensive lifestyle intervention, with insulin therapy']","['Elevated UAE', 'Glycemic control, BMI, estimated glomerular filtration rate (eGFR), urinary albumin excretion (UAE), and prevalence of hyperfiltration (eGFR ≥135 mL/min/1.73 m 2 ) and elevated UAE', 'diabetic kidney disease (DKD) rates']","[{'cui': 'C1521910', 'cui_str': 'Teens'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517499', 'cui_str': '1.3 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C4517899', 'cui_str': 'Nine point five'}, {'cui': 'C0310367', 'cui_str': 'Today'}, {'cui': 'C4517578', 'cui_str': '15.3'}, {'cui': 'C0011881', 'cui_str': 'Diabetic Nephropathy'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C1456587', 'cui_str': 'Bariatric Surgery'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy (procedure)'}, {'cui': 'C1456587', 'cui_str': 'Bariatric Surgery'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0289313', 'cui_str': 'rosiglitazone'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C3811844'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0011881', 'cui_str': 'Diabetic Nephropathy'}]",,0.0493397,"Compared with MBS, medical treatment of obese youth with T2D was associated with a higher odds of DKD over 5 years.","[{'ForeName': 'Petter', 'Initials': 'P', 'LastName': 'Bjornstad', 'Affiliation': ""University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO petter.bjornstad@childrenscolorado.org.""}, {'ForeName': 'Kara', 'Initials': 'K', 'LastName': 'Hughan', 'Affiliation': ""University of Pittsburgh and UPMC Children's Hospital Pittsburgh, Pittsburgh, PA.""}, {'ForeName': 'Megan M', 'Initials': 'MM', 'LastName': 'Kelsey', 'Affiliation': ""University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO.""}, {'ForeName': 'Amy S', 'Initials': 'AS', 'LastName': 'Shah', 'Affiliation': ""University of Cincinnati, Cincinnati Children's Medical Center, Cincinnati, OH.""}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Lynch', 'Affiliation': 'The University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Nehus', 'Affiliation': ""University of Cincinnati, Cincinnati Children's Medical Center, Cincinnati, OH.""}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Mitsnefes', 'Affiliation': ""University of Cincinnati, Cincinnati Children's Medical Center, Cincinnati, OH.""}, {'ForeName': 'Todd', 'Initials': 'T', 'LastName': 'Jenkins', 'Affiliation': ""University of Cincinnati, Cincinnati Children's Medical Center, Cincinnati, OH.""}, {'ForeName': 'Peixin', 'Initials': 'P', 'LastName': 'Xu', 'Affiliation': ""University of Cincinnati, Cincinnati Children's Medical Center, Cincinnati, OH.""}, {'ForeName': 'Changchun', 'Initials': 'C', 'LastName': 'Xie', 'Affiliation': ""University of Cincinnati, Cincinnati Children's Medical Center, Cincinnati, OH.""}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Inge', 'Affiliation': ""University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO.""}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Nadeau', 'Affiliation': ""University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO.""}]",Diabetes care,['10.2337/dc19-0708'] 376,32236402,Cortical β-Amyloid in Older Adults Is Associated with Multidomain Interventions with and without Omega 3 Polyunsaturated Fatty Acid Supplementation.,"Multidomain lifestyle interventions (including combinations of physical exercise, cognitive training and nutritional guidance) are attracting increasing research attention for reducing the risk of Alzheimer's disease (AD). Here we examined for the first time the cross-sectional relationship between cortical β-amyloid (Aβ) and multidomain lifestyle interventions (nutritional and exercise counselling and cognitive training), omega 3 polyunsaturated fatty acid (n-3 PUFA) supplementation or their combination in 269 participants of the Multidomain Alzheimer Preventive Trial (MAPT). In adjusted multiple linear regression models, compared to the control group (receiving placebo alone), cortical Aβ, measured once during follow-up (mean 512.7 ± 249.6 days post-baseline), was significantly lower in the groups receiving multidomain lifestyle intervention + placebo (mean difference, -0.088, 95 % CI, -0.148,-0.029, p = 0.004) or multidomain lifestyle intervention + n-3 PUFA (-0.100, 95 % CI, -0.160,-0.041, p = 0.001), but there was no difference in the n-3 PUFA supplementation alone group (-0.011, 95 % CI, -0.072,0.051, p = 0.729). Secondary analysis provided mixed results. Our findings suggest that multidomain interventions both with and without n-3 PUFA supplementation might be associated with lower cerebral Aβ. Future trials should investigate if such multidomain lifestyle interventions are causally associated with a reduction or the prevention of the accumulation of cerebral Aβ.",2020,"In adjusted multiple linear regression models, compared to the control group (receiving placebo alone), cortical Aβ, measured once during follow-up (mean 512.7 ± 249.6 days post-baseline), was significantly lower in the groups receiving multidomain lifestyle intervention + placebo (mean difference, -0.088, 95 % CI, -0.148,-0.029, p = 0.004) or multidomain lifestyle intervention + n-3 PUFA (","['269 participants of the Multidomain Alzheimer Preventive Trial (MAPT', 'Older Adults']","['multidomain lifestyle intervention + n-3 PUFA ', 'n-3 PUFA supplementation', 'Multidomain lifestyle interventions (including combinations of physical exercise, cognitive training and nutritional guidance', 'cortical β-amyloid (Aβ) and multidomain lifestyle interventions (nutritional and exercise counselling and cognitive training), omega 3 polyunsaturated fatty acid (n-3 PUFA) supplementation', 'multidomain lifestyle intervention + placebo']",[],"[{'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0204169', 'cui_str': 'Preventive dental procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0002716', 'cui_str': 'Amyloid Substance'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.0613644,"In adjusted multiple linear regression models, compared to the control group (receiving placebo alone), cortical Aβ, measured once during follow-up (mean 512.7 ± 249.6 days post-baseline), was significantly lower in the groups receiving multidomain lifestyle intervention + placebo (mean difference, -0.088, 95 % CI, -0.148,-0.029, p = 0.004) or multidomain lifestyle intervention + n-3 PUFA (","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Hooper', 'Affiliation': 'Claudie Hooper, Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France , Tel : +33 (5) 61 77 64 25, Fax : +33 (5) 61 77 64 75 claudie28@yahoo.com.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Coley', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'De Souto Barreto', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Payoux', 'Affiliation': ''}, {'ForeName': 'A S', 'Initials': 'AS', 'LastName': 'Salabert', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Andrieu', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Weiner', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Vellas', 'Affiliation': ''}]",The journal of prevention of Alzheimer's disease,['10.14283/jpad.2020.4'] 377,32223762,Using motivational interviewing to reduce parental risk related behaviors for early childhood caries: a pilot study.,"BACKGROUND Decades of epidemiological studies have documented high rates of early childhood caries (ECC) among American Indian and Alaska Native (AIAN) children. The aim of this pilot study was to investigate if a motivational interviewing (MI) intervention improved oral self-care behaviors of AIAN caregivers of infants, and determine if the MI intervention promoted positive changes in caregivers' ECC risk-related behaviors. METHODS Caregivers of infants presenting for well- child visits in a medical clinic were randomized to treatment and control groups. At the first visit, a caries risk test (CRT) for cariogenic bacteria was completed for both groups. The Parental Care of Child's Teeth (PCCT) was administered at the second visit and used to assess ECC risk-related behaviors. Over the course of four well-child visits, caregivers in the treatment group participated in a MI discussion focusing on behavior changes and desired outcomes for their personal oral health and their child's. The duration of the intervention was 1 year. The control group was given oral health information traditionally provided at well-child visits. At the fourth well-child visit, the CRT and PCCT questionnaire were administered again. RESULTS The mean bacterial load for mutans streptococcus (MS) was similar at both visits. A slight reduction in the mean bacterial levels of lactobacilli was observed in both the test and control groups after the last visit, although not at a level of statistical significance. The treatment group showed minimal improvement in child feeding practices and nighttime bottle habits. CONCLUSIONS Motivational Interviewing had little effect on oral self-care behaviors as measured by bacterial load, nor did MI reduce parental risk related behavior for early childhood caries. TRIAL REGISTRATION Clinicaltrials.gov# NCT04286256. Retrospectively registered, February 26, 2020.",2020,"A slight reduction in the mean bacterial levels of lactobacilli was observed in both the test and control groups after the last visit, although not at a level of statistical significance.","['Caregivers of infants presenting for well- child visits in a medical clinic', 'early childhood caries', 'American Indian and Alaska Native (AIAN) children', ""caregivers' ECC risk-related behaviors""]","['MI intervention', 'motivational interviewing (MI) intervention', 'motivational interviewing', 'Motivational Interviewing']","['mean bacterial load for mutans streptococcus (MS', 'child feeding practices and nighttime bottle habits', 'mean bacterial levels of lactobacilli', 'oral self-care behaviors']","[{'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C1444717', 'cui_str': 'Well child visit'}, {'cui': 'C0338037', 'cui_str': ""Private physicians' group office (environment)""}, {'cui': 'C3714731', 'cui_str': 'Early childhood caries'}, {'cui': 'C0002460', 'cui_str': 'American Indians'}, {'cui': 'C0682125', 'cui_str': 'Native Alaskians'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4077283', 'cui_str': '(67Ga)ECC'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]","[{'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0683474', 'cui_str': 'Motivational Interviewing'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C2936404', 'cui_str': 'Bacterial Load'}, {'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4319838', 'cui_str': 'Bottle'}, {'cui': 'C0018464', 'cui_str': 'Habits'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0474417', 'cui_str': 'Self-care behavior (finding)'}]",,0.0296306,"A slight reduction in the mean bacterial levels of lactobacilli was observed in both the test and control groups after the last visit, although not at a level of statistical significance.","[{'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Blue', 'Affiliation': 'Division of Dental Hygiene, University of Minnesota, 515 Delaware Street SE, 9-372 Moos Tower, Minneapolis, MN, 55455, USA. bluex005@umn.edu.'}, {'ForeName': 'Michelle C', 'Initials': 'MC', 'LastName': 'Arnett', 'Affiliation': 'Division of Dental Hygiene, University of Minnesota, 420 Delaware St SE, MMC 729, Minneapolis, MN, 55455, USA.'}, {'ForeName': 'Hiwet', 'Initials': 'H', 'LastName': 'Ephrem', 'Affiliation': 'Division of Dental Hygiene, University of Minnesota, 515 Delaware Street SE, 9-372 Moos Tower, Minneapolis, MN, 55455, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Lunos', 'Affiliation': 'University of Minnesota, 717 Delaware Street SE, 140-27, Minneapolis, MN, 55414, USA.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Ruoqiong', 'Affiliation': 'Department of Diagnostic and Biological Sciences, University of Minnesota, 515 Delaware Street SE, 17-237 Moos Tower, Minneapolis, MN, 55455, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Jones', 'Affiliation': 'Division of Pediatric Dentistry, University of Minnesota, 515 Delaware Street SE, 6-150 Moos Tower, Minneapolis, MN, 55455, USA.'}]",BMC oral health,['10.1186/s12903-020-1052-6'] 378,31321713,Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.,"BACKGROUND Population pharmacokinetic methods were used to characterize the pharmacokinetics of fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) in patients with chronic obstructive pulmonary disease (COPD) when administered as a fixed-dose combination via a single closed inhaler. METHODS Plasma concentration data from three studies were analyzed using non-linear mixed-effects modeling in NONMEM ® . RESULTS The pooled dataset consisted of 2948, 2589, and 3331 FF, UMEC, and VI observations from 714, 622, and 817 patients with COPD, respectively. There were 41%, 13%, and 21% of observations below the quantification limit for FF, UMEC, and VI, respectively. The pharmacokinetics of FF, UMEC, and VI were all adequately described by a two-compartment model with first-order absorption. The following covariates were statistically significant, but none were considered to be clinically relevant. For FF, Japanese heritage and FF/VI treatment on apparent inhaled clearance (CL/F) with FF CL/F 35% lower in patients of Japanese heritage across all treatments and FF CL/F 42% higher in patients with COPD following FF/VI administration. This is in line with the product label. For UMEC, weight, age, and smoking status on CL/F and weight on apparent volume of distribution (V2/F) with every 10% increase in age from 60 years of age leading to approximately a 6% decrease in UMEC CL/F and every 10% increase in weight from 70 kg leading to approximately a 6% increase in UMEC CL/F and approximately an 8% increase in UMEC V2/F. For a subject with COPD who smoked, UMEC CL/F was 28% higher. For VI, weight on CL/F and smoking status on V2/F with an approximately 4% increase in VI CL/F for every 10% increase in weight from 70 kg, and for a subject with COPD who smoked, VI V2/F was 46% higher. The majority of these covariates have been previously identified in historical analyses. None of these effects were clinically relevant in terms of systemic exposures and do not warrant dose adjustment. CONCLUSIONS All FF, UMEC, and VI plasma concentrations were well interspersed with historical data and were all adequately described by a two-compartment model with first-order absorption. There were no clinically relevant differences in FF, UMEC, or VI systemic exposures when administered as FF/UMEC/VI, FF/VI + UMEC, or the dual combinations FF/VI and/or UMEC/VI.",2020,"There were no clinically relevant differences in FF, UMEC, or VI systemic exposures when administered as FF/UMEC/VI, FF/VI + UMEC, or the dual combinations FF/VI and/or UMEC/VI.","['817 patients with COPD, respectively', 'patients with chronic obstructive pulmonary disease (COPD', 'Patients with Chronic Obstructive Pulmonary Disease']","['fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI', 'Fluticasone Furoate/Umeclidinium Bromide/Vilanterol']","['weight', 'FF, UMEC, or VI systemic exposures', 'For UMEC, weight, age, and smoking status on CL/F and weight on apparent volume of distribution (V2/F', 'All FF, UMEC, and VI plasma concentrations']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}]","[{'cui': 'C1948374', 'cui_str': 'fluticasone furoate'}, {'cui': 'C3661274', 'cui_str': 'umeclidinium'}, {'cui': 'C2935023', 'cui_str': 'vilanterol'}, {'cui': 'C3709474', 'cui_str': 'UMECLIDINIUM BROMIDE'}]","[{'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",817.0,0.333674,"There were no clinically relevant differences in FF, UMEC, or VI systemic exposures when administered as FF/UMEC/VI, FF/VI + UMEC, or the dual combinations FF/VI and/or UMEC/VI.","[{'ForeName': 'Rashmi', 'Initials': 'R', 'LastName': 'Mehta', 'Affiliation': 'GSK, Research Triangle Park, NC, USA. rashmi.s.mehta@gsk.com.'}, {'ForeName': 'Colm', 'Initials': 'C', 'LastName': 'Farrell', 'Affiliation': 'ICON Development Solutions, Marlow, UK.'}, {'ForeName': 'Siobhán', 'Initials': 'S', 'LastName': 'Hayes', 'Affiliation': 'ICON Development Solutions, Marlow, UK.'}, {'ForeName': 'Ruby', 'Initials': 'R', 'LastName': 'Birk', 'Affiliation': 'GSK, Uxbridge, UK.'}, {'ForeName': 'Malek', 'Initials': 'M', 'LastName': 'Okour', 'Affiliation': 'GSK, Collegeville, PA, USA.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Lipson', 'Affiliation': 'GSK, Collegeville, PA, USA.'}]",Clinical pharmacokinetics,['10.1007/s40262-019-00794-w'] 379,31495886,"Vitamin E absorption and kinetics in healthy women, as modulated by food and by fat, studied using 2 deuterium-labeled α-tocopherols in a 3-phase crossover design.","BACKGROUND Determining the human vitamin E [α-tocopherol (α-T)] requirement is difficult, and novel approaches to assess α-T absorption and trafficking are needed. OBJECTIVE We hypothesized that the dual-isotope technique, using 2 deuterium-labeled [intravenous (IV) d6- and oral d3-] α-T, would be effective in determining α-T fractional absorption. Further, defined liquid meal (DLM) fat or fasting would modulate α-T fractional absorption and lipoprotein transport. METHODS A 3-phase cr ossover design was used. At 0 h, participants received IV d6-α-T and consumed d3-α-T with a 600-kcal DLM (40% or 0% fat) followed by controlled meals or by the 0% fat DLM, a 12-h fast, and then controlled meals. Blood samples and fecal samples were collected at intervals and analyzed by LC-MS. Pharmacokinetic parameters were calculated from plasma tracer concentrations and enrichments. Fractional absorption was calculated from d3- to d6-α-T areas under the curve, from a novel mathematical model, and from the balance method (oral d3-α-T minus fecal d3-α-T excreted). RESULTS Estimated α-T fractional absorption during the 40% fat intervention was 55% ± 3% (mean ± SEM; n = 10), which was 9% less than during the 0% fat intervention (64% ± 3%, n = 10; P < 0.02). Fasting had no apparent effect (56% ± 3%, n = 7), except it slowed plasma oral d3-α-T appearance. Both balance data and model outcomes confirmed that the DLM fat did not potentiate d3-α-T absorption. During the IV emulsion clearance, HDL rapidly acquired d6-α-T (21 ± 2 nmol/L plasma per minute). During the first 8 h postdosing, triglyceride-rich lipoproteins (TRLs) were preferentially d3-α-T enriched relative to LDL or HDL, showing the TRL precursor role. CONCLUSIONS Quantitatively, α-T absorption is not limited by fat absence or by fasting. However, α-T leaves the intestine by a process that is prolonged during fasting and potentiated by eating, suggesting that α-T absorption is highly dependent on chylomicron assembly processes. This trial was registered at clinicaltrials.gov as NCT00862433.",2019,"Fasting had no apparent effect (56% ± 3%, n = 7), except it slowed plasma oral d3-α-T appearance.",['healthy women'],"['human vitamin E [α-tocopherol (α-T', 'IV d6-α-T and consumed d3-α-T with a 600-kcal DLM (40% or 0% fat) followed by controlled meals or by the 0% fat DLM', 'dual-isotope technique, using 2 deuterium-labeled [intravenous (IV) d6- and oral d3-] α-T']","['α-T fractional absorption', 'Fractional absorption', 'triglyceride-rich lipoproteins (TRLs', 'Blood samples and fecal samples', 'plasma oral d3-α-T appearance']","[{'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0439259', 'cui_str': 'kilocalorie'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0022262', 'cui_str': 'Isotopes'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0011744', 'cui_str': 'Hydrogen-2'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0700364', 'cui_str': 'Appearances (qualifier value)'}]",,0.0251946,"Fasting had no apparent effect (56% ± 3%, n = 7), except it slowed plasma oral d3-α-T appearance.","[{'ForeName': 'Maret G', 'Initials': 'MG', 'LastName': 'Traber', 'Affiliation': 'Linus Pauling Institute, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Scott W', 'Initials': 'SW', 'LastName': 'Leonard', 'Affiliation': 'Linus Pauling Institute, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Ifechukwude', 'Initials': 'I', 'LastName': 'Ebenuwa', 'Affiliation': 'Molecular and Clinical Nutrition Section, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Pierre-Christian', 'Initials': 'PC', 'LastName': 'Violet', 'Affiliation': 'Molecular and Clinical Nutrition Section, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Molecular and Clinical Nutrition Section, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Mahtab', 'Initials': 'M', 'LastName': 'Niyyati', 'Affiliation': 'Molecular and Clinical Nutrition Section, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Padayatty', 'Affiliation': 'Molecular and Clinical Nutrition Section, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Hongbin', 'Initials': 'H', 'LastName': 'Tu', 'Affiliation': 'Molecular and Clinical Nutrition Section, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Amber', 'Initials': 'A', 'LastName': 'Courville', 'Affiliation': 'Clinical Center Nutrition Department, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Shanna', 'Initials': 'S', 'LastName': 'Bernstein', 'Affiliation': 'Clinical Center Nutrition Department, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Jaewoo', 'Initials': 'J', 'LastName': 'Choi', 'Affiliation': 'Linus Pauling Institute, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Shamburek', 'Affiliation': 'Cardiovascular Branch, Intramural Research Program, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Sheila', 'Initials': 'S', 'LastName': 'Smith', 'Affiliation': 'Molecular and Clinical Nutrition Section, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Head', 'Affiliation': 'Linus Pauling Institute, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Gerd', 'Initials': 'G', 'LastName': 'Bobe', 'Affiliation': 'Linus Pauling Institute, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Rajasekhar', 'Initials': 'R', 'LastName': 'Ramakrishnan', 'Affiliation': 'Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Levine', 'Affiliation': 'Molecular and Clinical Nutrition Section, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqz172'] 380,32234462,"Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.","BACKGROUND People living with human immunodeficiency virus (PLHIV) are at increased risk of atherosclerotic cardiovascular disease (ASCVD) and are prone to statin-related adverse events from drug-drug interactions with certain antiretroviral regimens. OBJECTIVES This study sought to evaluate the efficacy and safety of evolocumab in dyslipidemic PLHIV. METHODS BEIJERINCK (EvolocumaB Effect on LDL-C Lowering in SubJEcts with Human Immunodeficiency VirRus and INcreased Cardiovascular RisK) is a randomized, double-blind, multinational trial comparing monthly subcutaneous evolocumab 420 mg with placebo in PLHIV with hypercholesterolemia/mixed dyslipidemia taking maximally-tolerated statin therapy. The primary endpoint was the percent change (baseline to week 24) in low-density lipoprotein cholesterol (LDL-C); secondary endpoints included achievement of LDL-C <70 mg/dl and percent change in other plasma lipid and lipoprotein levels. Treatment-emergent adverse events were also examined. RESULTS A total of 464 patients were analyzed (mean age of 56.4 years, 82.5% male, mean duration with HIV of 17.4 years). ASCVD was documented in 35.6% of patients, and statin intolerance/contraindications to statin use were present in 20.7% of patients. Evolocumab reduced LDL-C by 56.9% (95% confidence interval: 61.6% to 52.3%) from baseline to week 24 versus placebo. An LDL-C level of <70 mg/dl was achieved in 73.3% of patients in the evolocumab group versus 7.9% in the placebo group. Evolocumab also significantly reduced other atherogenic lipid levels, including non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) (all p < 0.0001). Evolocumab was well tolerated, and treatment-emergent adverse events patient incidence was similar among evolocumab and placebo groups. CONCLUSIONS Evolocumab was safe and significantly reduced lipid levels in dyslipidemic PLHIV on maximally-tolerated statin therapy. Evolocumab is an effective therapy for lowering atherogenic lipoproteins in PLHIV with high cardiovascular risk. (Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia; NCT02833844).",2020,"Evolocumab reduced LDL-C by 56.9% (95% CI: 61.6%, 52.3%) from baseline to week 24 versus placebo.","['A total of 464 patients were analyzed (mean age of 56.4 years, 82.5% male, mean duration with HIV of 17.4 years', 'HIV-Infected Patients With Dyslipidemia', 'People living with HIV (PLHIV', 'PLHIV with hypercholesterolemia/mixed dyslipidemia taking maximally-tolerated statin therapy']","['Evolocumab', 'evolocumab', 'placebo', 'subcutaneous evolocumab 420 mg with placebo']","['efficacy and safety', 'LDL-C level', 'low-density lipoprotein cholesterol (LDL-C); secondary endpoints included achievement of LDL-C <70 mg/dL and percent change in other plasma lipid and lipoprotein levels', 'lipid levels', 'atherogenic lipid levels, including non-HDL-C, ApoB, and Lp(a', 'ASCVD', 'tolerated, and TEAE patient incidence', 'Evolocumab reduced LDL-C']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517887', 'cui_str': '82.5'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemia'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0020443', 'cui_str': 'Hypercholesterolemia'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C1278454', 'cui_str': 'Statin prophylaxis'}]","[{'cui': 'C3529352', 'cui_str': 'evolocumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C4517774', 'cui_str': '420'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1278073', 'cui_str': 'Plasma lipid measurement'}, {'cui': 'C0523753', 'cui_str': 'Lipoproteins measurement'}, {'cui': 'C0428460', 'cui_str': 'Lipid level - finding'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0003593', 'cui_str': 'Apolipoprotein B'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C3529352', 'cui_str': 'evolocumab'}]",464.0,0.420886,"Evolocumab reduced LDL-C by 56.9% (95% CI: 61.6%, 52.3%) from baseline to week 24 versus placebo.","[{'ForeName': 'Franck', 'Initials': 'F', 'LastName': 'Boccara', 'Affiliation': ""AP-HP, Hôpitaux de l'Est Parisien, Hôpital Saint-Antoine, Department of Cardiology, Sorbonne Université-INSERM UMR S_938, Centre de Recherche Saint-Antoine, Paris, France. Electronic address: franck.boccara@aphp.fr.""}, {'ForeName': 'Princy N', 'Initials': 'PN', 'LastName': 'Kumar', 'Affiliation': 'Division of Infectious Diseases and Travel Medicine, Georgetown University School of Medicine, Washington, DC.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Caramelli', 'Affiliation': 'Interdisciplinary Medicine in Cardiology Unit, InCor, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Calmy', 'Affiliation': 'HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.'}, {'ForeName': 'J Antonio G', 'Initials': 'JAG', 'LastName': 'López', 'Affiliation': 'Global Development, Amgen Inc., Thousand Oaks, California.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Bray', 'Affiliation': 'Global Development, Amgen Inc., Thousand Oaks, California.'}, {'ForeName': 'Marcoli', 'Initials': 'M', 'LastName': 'Cyrille', 'Affiliation': 'Global Development, Amgen Inc., Thousand Oaks, California.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Rosenson', 'Affiliation': 'Cardiometabolics Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2020.03.025'] 381,32234702,Forecasting Mood in Bipolar Disorder From Smartphone Self-assessments: Hierarchical Bayesian Approach.,"BACKGROUND Bipolar disorder is a prevalent mental health condition that is imposing significant burden on society. Accurate forecasting of symptom scores can be used to improve disease monitoring, enable early intervention, and eventually help prevent costly hospitalizations. Although several studies have examined the use of smartphone data to detect mood, only few studies deal with forecasting mood for one or more days. OBJECTIVE This study aimed to examine the feasibility of forecasting daily subjective mood scores based on daily self-assessments collected from patients with bipolar disorder via a smartphone-based system in a randomized clinical trial. METHODS We applied hierarchical Bayesian regression models, a multi-task learning method, to account for individual differences and forecast mood for up to seven days based on 15,975 smartphone self-assessments from 84 patients with bipolar disorder participating in a randomized clinical trial. We reported the results of two time-series cross-validation 1-day forecast experiments corresponding to two different real-world scenarios and compared the outcomes with commonly used baseline methods. We then applied the best model to evaluate a 7-day forecast. RESULTS The best performing model used a history of 4 days of self-assessment to predict future mood scores with historical mood being the most important predictor variable. The proposed hierarchical Bayesian regression model outperformed pooled and separate models in a 1-day forecast time-series cross-validation experiment and achieved the predicted metrics, R 2 =0.51 and root mean squared error of 0.32, for mood scores on a scale of -3 to 3. When increasing the forecast horizon, forecast errors also increased and the forecast regressed toward the mean of data distribution. CONCLUSIONS Our proposed method can forecast mood for several days with low error compared with common baseline methods. The applicability of a mood forecast in the clinical treatment of bipolar disorder has also been discussed.",2020,"Accurate forecasting of symptom scores can be used to improve disease monitoring, enable early intervention, and eventually help prevent costly hospitalizations.","['84 patients with bipolar disorder participating in a randomized clinical trial', 'patients with bipolar disorder via a smartphone-based system in a randomized clinical trial']",[],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}, {'cui': 'C0206034', 'cui_str': 'Trials, Randomized Clinical'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]",[],[],84.0,0.0733923,"Accurate forecasting of symptom scores can be used to improve disease monitoring, enable early intervention, and eventually help prevent costly hospitalizations.","[{'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Busk', 'Affiliation': 'Department of Applied Mathematics and Computer Science, Technical University of Denmark, Lyngby, Denmark.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Faurholt-Jepsen', 'Affiliation': 'Copenhagen Affective Disorder Research Center, Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Mads', 'Initials': 'M', 'LastName': 'Frost', 'Affiliation': 'Monsenso ApS, Copenhagen, Denmark.'}, {'ForeName': 'Jakob E', 'Initials': 'JE', 'LastName': 'Bardram', 'Affiliation': 'Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Vedel Kessing', 'Affiliation': 'Copenhagen Affective Disorder Research Center, Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Ole', 'Initials': 'O', 'LastName': 'Winther', 'Affiliation': 'Department of Applied Mathematics and Computer Science, Technical University of Denmark, Lyngby, Denmark.'}]",JMIR mHealth and uHealth,['10.2196/15028'] 382,32239237,Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study.,"Community-based screening and treatment of women aged 70-85 years at high fracture risk reduced fractures; moreover, the screening programme was cost-saving. The results support a case for a screening programme of fracture risk in older women in the UK. INTRODUCTION The SCOOP (screening for prevention of fractures in older women) randomized controlled trial investigated whether community-based screening could reduce fractures in women aged 70-85 years. The objective of this study was to estimate the long-term cost-effectiveness of screening for fracture risk in a UK primary care setting compared with usual management, based on the SCOOP study. METHODS A health economic Markov model was used to predict the life-time consequences in terms of costs and quality of life of the screening programme compared with the control arm. The model was populated with costs related to drugs, administration and screening intervention derived from the SCOOP study. Fracture risk reduction in the screening arm compared with the usual management arm was derived from SCOOP. Modelled fracture risk corresponded to the risk observed in SCOOP. RESULTS Screening of 1000 patients saved 9 hip fractures and 20 non-hip fractures over the remaining lifetime (mean 14 years) compared with usual management. In total, the screening arm saved costs (£286) and gained 0.015 QALYs/patient in comparison with usual management arm. CONCLUSIONS This analysis suggests that a screening programme of fracture risk in older women in the UK would gain quality of life and life years, and reduce fracture costs to more than offset the cost of running the programme.",2020,"In total, the screening arm saved costs (£286) and gained 0.015 QALYs/patient in comparison with usual management arm. ","['older women in the UK', '1000 patients saved 9 hip fractures and 20 non-hip fractures', 'older women', 'women aged 70-85\xa0years at high fracture risk reduced fractures', 'women aged 70-85\xa0years']","['SCOOP (screening', 'community-based screening']","['Modelled fracture risk', 'costs and quality of life', 'fracture costs', 'Fracture risk reduction']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]","[{'cui': 'C0183177', 'cui_str': 'Scoop'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}]",,0.0413955,"In total, the screening arm saved costs (£286) and gained 0.015 QALYs/patient in comparison with usual management arm. ","[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Söreskog', 'Affiliation': 'Quantify Research, Stockholm, Sweden.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Borgström', 'Affiliation': 'Quantify Research, Stockholm, Sweden.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Shepstone', 'Affiliation': 'Norwich Medical School, University of East Anglia, Norwich, UK.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Clarke', 'Affiliation': 'Department of Rheumatology, University Hospitals Bristol, Bristol, UK.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Cooper', 'Affiliation': 'MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Harvey', 'Affiliation': 'Norwich Medical School, University of East Anglia, Norwich, UK.'}, {'ForeName': 'N C', 'Initials': 'NC', 'LastName': 'Harvey', 'Affiliation': 'MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Howe', 'Affiliation': 'Norwich Medical School, University of East Anglia, Norwich, UK.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Johansson', 'Affiliation': 'Centre for Metabolic Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Marshall', 'Affiliation': 'Norfolk and Norwich University Hospital, Norwich, UK.'}, {'ForeName': 'T W', 'Initials': 'TW', 'LastName': ""O'Neill"", 'Affiliation': 'NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.'}, {'ForeName': 'T J', 'Initials': 'TJ', 'LastName': 'Peters', 'Affiliation': 'Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'N M', 'Initials': 'NM', 'LastName': 'Redmond', 'Affiliation': 'Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Turner', 'Affiliation': 'Norwich Medical School, University of East Anglia, Norwich, UK.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Holland', 'Affiliation': 'Leicester Medical School, Centre for Medicine, University of Leicester, Leicester, UK.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'McCloskey', 'Affiliation': 'Centre for Metabolic Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK.'}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Kanis', 'Affiliation': 'Centre for Metabolic Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK. w.j.pontefract@shef.ac.uk.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,['10.1007/s00198-020-05372-6'] 383,31171257,Assessment of student pharmacist learning within an interprofessional simulation: A comparison of small group vs. large group debriefing.,"BACKGROUND Simulation debriefing is a critical component of interprofessional education (IPE). The purpose of this IPE report was to determine if there is a difference in a student pharmacist's ability to articulate areas for improvement and continued growth in interprofessional practice between those who participated in a large group debrief compared to a small group debrief after an interprofessional simulation. INTERPROFESSIONAL EDUCATION ACTIVITY One hundred pharmacy students participated in an interprofessional standardized patient simulation. Other participants included medicine or physician assistant, nursing, and physical therapy students. Students were randomly assigned to large or small group debriefing. Students completed a reflection to determine their ability to articulate areas for improvement and continued growth. DISCUSSION Forty-six students in the large group debrief and 49 students in the small group debrief completed a post-simulation reflection. Reflections were analyzed quantitatively and qualitatively. Quantitative analysis was based on a scoring rubric used to determine whether the student was able to successfully articulate areas for improvement or continued growth. Reflections were evaluated qualitatively to identify the areas for improvement. There was no difference in the ability to identify an area for improvement or continued growth between the large group debrief compared to the small group debrief. IMPLICATIONS There was no difference in students' post-simulation reflections based on participation in small group or large group debriefing following an interprofessional simulation. Students were able to effectively articulate areas for improvement and continued growth in interprofessional practice.",2019,There was no difference in students' post-simulation reflections based on participation in small group or large group debriefing following an interprofessional simulation.,"['One hundred pharmacy students participated in an interprofessional standardized patient simulation', 'participants included medicine or physician assistant, nursing, and physical therapy students', 'Forty-six students in the large group debrief and 49 students in the small group debrief completed a post-simulation reflection']",['student pharmacist learning'],[],"[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0038497', 'cui_str': 'Pharmacy Student'}, {'cui': 'C0085137', 'cui_str': 'Patient Simulation'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0031833', 'cui_str': ""Physicians' Extenders""}, {'cui': 'C0028678', 'cui_str': 'nursing care'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]","[{'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}]",[],100.0,0.0223367,There was no difference in students' post-simulation reflections based on participation in small group or large group debriefing following an interprofessional simulation.,"[{'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Meny', 'Affiliation': 'Ferris State University, College of Pharmacy, 25 Michigan St NE, Grand Rapids, MI 49503, United States. Electronic address: lisameny@ferris.edu.'}, {'ForeName': 'Margaret C', 'Initials': 'MC', 'LastName': 'de Voest', 'Affiliation': 'Ferris State University, College of Pharmacy, 25 Michigan St NE, Grand Rapids, MI 49503, United States. Electronic address: margaretdevoest@ferris.edu.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Salvati', 'Affiliation': 'Ferris State University, College of Pharmacy, 25 Michigan St NE, Grand Rapids, MI 49503, United States. Electronic address: lisasalvati@ferris.edu.'}]",Currents in pharmacy teaching & learning,['10.1016/j.cptl.2019.02.007'] 384,31430297,The effect of H1N1 vaccination on serum miRNA expression in children: A tale of caution for microRNA microarray studies.,"BACKGROUND MicroRNAs (miRNAs) are a class of small regulatory RNAs around 21-25 nucleotides in length which govern many aspects of immunity including the host innate and adaptive responses to infection. RT-qPCR studies of select microRNAs show that vaccination alters the expression circulating microRNAs but the effect of vaccination on the global microRNA population (i.e. micronome) has never been studied. AIM To describe vaccine associated changes in the expression of microRNAs 21 days after vaccination in children receiving a pandemic influenza (H1N1) vaccination. METHOD Serum samples were obtained from children aged 6 months to 12 years enrolled in an open label randomised control trial of two pandemic influenza (H1N1) vaccines, in which participants received either ASO3B adjuvanted split virion or a whole virion non-adjuvanted vaccine. MicroRNA expression was profiled in a discovery cohort of participants prior to, and 21 days after vaccination using an Agilent microarray platform. Findings were followed up by RT-qPCR in the original discovery cohort and then in a validation cohort of participants taken from the same study. RESULTS 44 samples from 22 children were assayed in a discovery cohort. The microarray results revealed 19 microRNAs were differentially expressed after vaccination after adjustment for multiple testing. The microarray detected ubiquitous expression of several microRNAs which could not be validated by RT-qPCR, many of which have little evidence of existence in publicly available RNA sequencing data. Real time PCR (RT-qPCR) confirmed downregulation of miR-142-3p in the discovery cohort. These findings were not replicated in the subsequent validation cohort (n = 22). CONCLUSION This study is the first study to profile microRNA expression after vaccination. An important feature of this study is many of the differentially expressed microRNAs could not be detected and validated by RT-qPCR. This study highlights the care that should be taken when interpreting omics biomarker discovery, highlighting the need for supplementary methods to validate microRNA microarray findings, and emphasises the importance of validation cohorts. Data from similar studies which do not meet these requirements should be interpreted with caution.",2019,Real time PCR (RT-qPCR) confirmed downregulation of miR-142-3p in the discovery cohort.,"['children', 'children receiving a pandemic influenza (H1N1) vaccination', 'Serum samples were obtained from children aged 6 months to 12 years enrolled in an open label randomised control trial of two']","['pandemic influenza (H1N1) vaccines', 'H1N1 vaccination', 'ASO3B adjuvanted split virion or a whole virion non-adjuvanted vaccine']","['Real time PCR (RT-qPCR', 'serum miRNA expression', 'MicroRNA expression']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1615608', 'cui_str': 'Pandemics'}, {'cui': 'C0042200', 'cui_str': 'Influenza vaccination (procedure)'}, {'cui': 'C1550100', 'cui_str': 'Serum specimen'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C1615608', 'cui_str': 'Pandemics'}, {'cui': 'C0021403', 'cui_str': 'Influenza Vaccines'}, {'cui': 'C0580264', 'cui_str': 'H1N1'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0042760', 'cui_str': 'Viral Particles'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}]","[{'cui': 'C1709846', 'cui_str': 'Real-Time PCR'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1101610', 'cui_str': 'miRNA'}, {'cui': 'C3854321', 'cui_str': 'Expression'}]",,0.0694924,Real time PCR (RT-qPCR) confirmed downregulation of miR-142-3p in the discovery cohort.,"[{'ForeName': 'Ruth Elizabeth', 'Initials': 'RE', 'LastName': 'Drury', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, Oxfordshire, United Kingdom.'}, {'ForeName': 'Andrew John', 'Initials': 'AJ', 'LastName': 'Pollard', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, Oxfordshire, United Kingdom.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': ""O'Connor"", 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, Oxfordshire, United Kingdom.'}]",PloS one,['10.1371/journal.pone.0221143'] 385,31575091,Significant Changes in Metabolic Profiles after Intervention with Selenium and Coenzyme Q10 in an Elderly Population.,"Selenium and coenzyme Q 10 (SeQ 10 ) are important for normal cellular function. Low selenium intake leads to increased cardiovascular mortality. Intervention with these substances with healthy elderly persons over a period of four years in a double-blind, randomised placebo-controlled prospective study showed reduced cardiovascular mortality, increased cardiac function, and a lower level of NT-proBNP. Therefore, we wanted to evaluate changes in biochemical pathways as a result of the intervention with SeQ10 using metabolic profiling. From a population of 443 healthy elderly individuals that were given 200 µg selenium and 200 mg coenzyme Q 10 , or placebo daily for four years, we selected nine males on active intervention and nine males on placebo for metabolic profiling in the main study. To confirm the results, two validation studies (study 1 n = 60 males, study 2 n = 37 males) were conducted. Principal component analyses were used on clinical and demographic data to select representative sets of samples for analysis and to divide the samples into batches for analysis. Gas chromatography time-of-flight mass spectrometry-based metabolomics was applied. The metabolite data were evaluated using univariate and multivariate approaches, mainly T-tests and orthogonal projections to latent structures (OPLS) analyses. Out of 95 identified metabolites, 19 were significantly decreased due to the intervention after 18 months of intervention. Significant changes could be seen in the pentose phosphate, the mevalonate, the beta-oxidation and the xanthine oxidase pathways. The intervention also resulted in changes in the urea cycle, and increases in the levels of the precursors to neurotransmitters of the brain. This adds information to previous published results reporting decreased oxidative stress and inflammation. This is the first-time metabolic profiling has been applied to elucidate the mechanisms behind an intervention with SeQ 10 . The study is small and should be regarded as hypothesis-generating; however, the results are interesting and, therefore, further research in the area is needed. This study was registered at Clinicaltrials.gov, with the identifier NCT01443780.",2019,"The intervention also resulted in changes in the urea cycle, and increases in the levels of the precursors to neurotransmitters of the brain.","['443 healthy elderly individuals', 'two validation studies (study 1 n = 60 males, study 2 n = 37 males', 'healthy elderly persons', 'Elderly Population', 'daily for four years, we selected nine males on active intervention and nine males on']","['200 µg selenium and 200 mg coenzyme Q 10 , or placebo', 'Selenium and coenzyme Q 10 (SeQ 10 ', 'placebo', 'Selenium and Coenzyme Q10', 'Low selenium intake']","['cardiovascular mortality, increased cardiac function, and a lower level of NT-proBNP', 'Metabolic Profiles', 'cardiovascular mortality']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0681836', 'cui_str': 'Validation Studies'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0966141', 'cui_str': '2-N-(APPDHP)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205455', 'cui_str': '9'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}]","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0036581', 'cui_str': 'Selenium'}, {'cui': 'C2242675', 'cui_str': 'Coenzyme Q'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0056077', 'cui_str': 'coenzyme Q10'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0564448', 'cui_str': 'Selenium intake (observable entity)'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0232165', 'cui_str': 'Increased cardiac function (finding)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1963813', 'cui_str': 'NT-proBNP'}]",443.0,0.0659959,"The intervention also resulted in changes in the urea cycle, and increases in the levels of the precursors to neurotransmitters of the brain.","[{'ForeName': 'Urban', 'Initials': 'U', 'LastName': 'Alehagen', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medical and Health Sciences, Linköping University, SE-581 85 Linköping, Sweden. urban.alehagen@liu.se.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Johansson', 'Affiliation': 'Department of Social and Welfare Studies, Linköping University, SE-581 83 Linköping, Sweden. peter.b.johansson@liu.se.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Aaseth', 'Affiliation': 'Research Department, Innlandet Hospital Trust, N-2380 Brumunddal, Norway. jaol-aas@online.no.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Alexander', 'Affiliation': 'Norwegian Institute of Public Health, N-0403 Oslo, Norway. Jan.Alexander@fhi.no.'}, {'ForeName': 'Izabella', 'Initials': 'I', 'LastName': 'Surowiec', 'Affiliation': 'AcureOmics AB, Tvistevägen 48, SE-907 36 Umeå, Sweden. izabella.surowiec@acureomics.com.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Lundstedt-Enkel', 'Affiliation': 'AcureOmics AB, Tvistevägen 48, SE-907 36 Umeå, Sweden. katrin.lundstedt-enkel@telia.com.'}, {'ForeName': 'Torbjörn', 'Initials': 'T', 'LastName': 'Lundstedt', 'Affiliation': 'AcureOmics AB, Tvistevägen 48, SE-907 36 Umeå, Sweden. torbjorn.Lundstedt@acureomics.com.'}]",Biomolecules,['10.3390/biom9100553'] 386,31338688,"SAGE-217, A Novel GABA A Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies.","BACKGROUND SAGE-217, a novel γ-aminobutyric acid A (GABA A ) receptor positive allosteric modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) studies to assess the safety and pharmacokinetics (PK) of SAGE-217 following administration as an oral solution. METHODS In the SAD study, subjects were randomized 6:2 to a single dose of SAGE-217 or placebo. Doses ranged from 0.25 to 66 mg across nine cohorts. In the MAD study, subjects were randomized 9:3 and received SAGE-217 (15, 30, or 35 mg) or placebo once daily for 7 days. In both studies, PK, maximum tolerated dose (MTD; against predetermined criteria), safety, and tolerability were assessed. RESULTS A total of 108 healthy volunteers enrolled in the studies-72 subjects in the SAD study and 36 subjects in the MAD study. SAGE-217 was orally bioavailable, with a terminal-phase half-life of 16-23 h and a t max of approximately 1 h. The MTDs for the oral solution of SAGE-217 in the SAD and MAD studies were determined to be 55 and 30 mg daily, respectively. In both studies, SAGE-217 was generally well tolerated, and no serious adverse events (SAEs) were reported. Most AEs were mild, dose-dependent, transient, occurred around the t max , and related to drug pharmacology. CONCLUSIONS SAGE-217 was generally well tolerated, and its PK profile was well characterized. Based on this profile, SAGE-217 has been advanced into multiple phase II clinical programs and pivotal studies of major depressive disorder and postpartum depression.",2020,"In both studies, SAGE-217 was generally well tolerated, and no serious adverse events (SAEs) were reported.",['108 healthy volunteers enrolled in the studies-72 subjects in the SAD study and 36 subjects in the MAD study'],"['Receptor Positive Allosteric Modulator', 'SAGE-217', 'placebo', 'SAGE-217 or placebo']","['safety, and tolerability', 'safety and pharmacokinetics (PK', 'tolerated, and no serious adverse events (SAEs']","[{'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0671759', 'cui_str': 'MAD'}]","[{'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C1122976', 'cui_str': 'Sage (substance)'}, {'cui': 'C4517646', 'cui_str': '217'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",108.0,0.184619,"In both studies, SAGE-217 was generally well tolerated, and no serious adverse events (SAEs) were reported.","[{'ForeName': 'Ethan', 'Initials': 'E', 'LastName': 'Hoffmann', 'Affiliation': 'Sage Therapeutics, Inc., 215 First Street, Cambridge, MA, 02412, USA. ethan@sagerx.com.'}, {'ForeName': 'George G', 'Initials': 'GG', 'LastName': 'Nomikos', 'Affiliation': 'Sage Therapeutics, Inc., 215 First Street, Cambridge, MA, 02412, USA.'}, {'ForeName': 'Inder', 'Initials': 'I', 'LastName': 'Kaul', 'Affiliation': 'Kaul Consulting, LLC, Concord, MA, USA.'}, {'ForeName': 'Shane', 'Initials': 'S', 'LastName': 'Raines', 'Affiliation': '2b Analytics, LLC, Wallingford, PA, USA.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Wald', 'Affiliation': 'qPharmetra, LLC, Cary, NC, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Bullock', 'Affiliation': 'Sage Therapeutics, Inc., 215 First Street, Cambridge, MA, 02412, USA.'}, {'ForeName': 'Abdul J', 'Initials': 'AJ', 'LastName': 'Sankoh', 'Affiliation': 'Sage Therapeutics, Inc., 215 First Street, Cambridge, MA, 02412, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Doherty', 'Affiliation': 'Sage Therapeutics, Inc., 215 First Street, Cambridge, MA, 02412, USA.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Kanes', 'Affiliation': 'Sage Therapeutics, Inc., 215 First Street, Cambridge, MA, 02412, USA.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Colquhoun', 'Affiliation': 'Sage Therapeutics, Inc., 215 First Street, Cambridge, MA, 02412, USA.'}]",Clinical pharmacokinetics,['10.1007/s40262-019-00801-0'] 387,32016310,Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.,"Importance Intravenous iron enables rapid correction of iron-deficiency anemia, but certain formulations induce fibroblast growth factor 23-mediated hypophosphatemia. Objective To compare risks of hypophosphatemia and effects on biomarkers of mineral and bone homeostasis of intravenous iron isomaltoside (now known as ferric derisomaltose) vs ferric carboxymaltose. Design, Setting, and Participants Between October 2017 and June 2018, 245 patients aged 18 years and older with iron-deficiency anemia (hemoglobin level ≤11 g/dL; serum ferritin level ≤100 ng/mL) and intolerance or unresponsiveness to 1 month or more of oral iron were recruited from 30 outpatient clinic sites in the United States into 2 identically designed, open-label, randomized clinical trials. Patients with reduced kidney function were excluded. Serum phosphate and 12 additional biomarkers of mineral and bone homeostasis were measured on days 0, 1, 7, 8, 14, 21, and 35. The date of final follow-up was June 19, 2018, for trial A and May 29, 2018, for trial B. Interventions Intravenous administration of iron isomaltoside, 1000 mg, on day 0 or ferric carboxymaltose, 750 mg, infused on days 0 and 7. Main Outcomes and Measures The primary end point was the incidence of hypophosphatemia (serum phosphate level <2.0 mg/dL) between baseline and day 35. Results In trial A, 123 patients were randomized (mean [SD] age, 45.1 [11.0] years; 95.9% women), including 62 to iron isomaltoside and 61 to ferric carboxymaltose; 95.1% completed the trial. In trial B, 122 patients were randomized (mean [SD] age, 42.6 [12.2] years; 94.1% women), including 61 to iron isomaltoside and 61 to ferric carboxymaltose; 93.4% completed the trial. The incidence of hypophosphatemia was significantly lower following iron isomaltoside vs ferric carboxymaltose (trial A: 7.9% vs 75.0% [adjusted rate difference, -67.0% {95% CI, -77.4% to -51.5%}], P < .001; trial B: 8.1% vs 73.7% [adjusted rate difference, -65.8% {95% CI, -76.6% to -49.8%}], P < .001). Beyond hypophosphatemia and increased parathyroid hormone, the most common adverse drug reactions (No./total No.) were nausea (iron isomaltoside: 1/125; ferric carboxymaltose: 8/117) and headache (iron isomaltoside: 4/125; ferric carboxymaltose: 5/117). Conclusions and Relevance In 2 randomized trials of patients with iron-deficiency anemia who were intolerant of or unresponsive to oral iron, iron isomaltoside (now called ferric derisomaltose), compared with ferric carboxymaltose, resulted in lower incidence of hypophosphatemia over 35 days. However, further research is needed to determine the clinical importance of this difference. Trial Registration ClinicalTrials.gov Identifiers: NCT03238911 and NCT03237065.",2020,"The incidence of hypophosphatemia was significantly lower following iron isomaltoside vs ferric carboxymaltose (trial A: 7.9% vs 75.0% [adjusted rate difference, -67.0% {95% CI, -77.4% to -51.5%}], P < .001; trial B: 8.1% vs 73.7% [adjusted rate difference, -65.8% {95% CI, -76.6% to -49.8%}], P < .001).","['Patients with reduced kidney function', 'patients with iron-deficiency anemia who were intolerant of or unresponsive to oral iron, iron isomaltoside (now called ferric derisomaltose', '123 patients were randomized (mean [SD] age, 45.1 [11.0] years; 95.9% women), including 62 to iron isomaltoside and 61 to ferric carboxymaltose; 95.1% completed the trial', 'Hypophosphatemia in Iron-Deficiency Anemia', 'Participants\n\n\nBetween October 2017 and June 2018, 245 patients aged 18 years and older with iron-deficiency anemia (hemoglobin level ≤11', '122 patients were randomized (mean [SD] age, 42.6 [12.2] years; 94.1% women), including 61 to iron isomaltoside and 61 to ferric carboxymaltose; 93.4% completed the trial']","['iron isomaltoside vs ferric carboxymaltose', 'ferric carboxymaltose', 'iron isomaltoside', 'intravenous iron isomaltoside', 'Iron Isomaltoside vs Ferric Carboxymaltose']","['Serum phosphate and 12 additional biomarkers of mineral and bone homeostasis', 'parathyroid hormone', 'nausea', 'headache', 'incidence of hypophosphatemia (serum phosphate level', 'incidence of hypophosphatemia']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia (disorder)'}, {'cui': 'C0237284', 'cui_str': 'Unresponsive'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C2001867', 'cui_str': 'ferric carboxymaltose'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0085682', 'cui_str': 'Hypophosphatemia'}, {'cui': 'C4517661', 'cui_str': '245'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]","[{'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C2001867', 'cui_str': 'ferric carboxymaltose'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}]","[{'cui': 'C0036820', 'cui_str': 'Serum phosphate'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0026162', 'cui_str': 'Minerals'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0019868', 'cui_str': 'Autoregulation'}, {'cui': 'C0030520', 'cui_str': 'Parathyroid Hormone'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0085682', 'cui_str': 'Hypophosphatemia'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",123.0,0.446537,"The incidence of hypophosphatemia was significantly lower following iron isomaltoside vs ferric carboxymaltose (trial A: 7.9% vs 75.0% [adjusted rate difference, -67.0% {95% CI, -77.4% to -51.5%}], P < .001; trial B: 8.1% vs 73.7% [adjusted rate difference, -65.8% {95% CI, -76.6% to -49.8%}], P < .001).","[{'ForeName': 'Myles', 'Initials': 'M', 'LastName': 'Wolf', 'Affiliation': 'Duke Clinical Research Institute, Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Rubin', 'Affiliation': 'Division of Endocrinology, Department of Medicine, University of North Carolina at Chapel Hill.'}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Achebe', 'Affiliation': 'Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Econs', 'Affiliation': 'Division of Endocrinology, Department of Medicine, Indiana University School of Medicine, Indianapolis.'}, {'ForeName': 'Munro', 'Initials': 'M', 'LastName': 'Peacock', 'Affiliation': 'Division of Endocrinology, Department of Medicine, Indiana University School of Medicine, Indianapolis.'}, {'ForeName': 'Erik A', 'Initials': 'EA', 'LastName': 'Imel', 'Affiliation': 'Division of Endocrinology, Department of Medicine, Indiana University School of Medicine, Indianapolis.'}, {'ForeName': 'Lars L', 'Initials': 'LL', 'LastName': 'Thomsen', 'Affiliation': 'Department of Clinical and Non-clinical Research, Pharmacosmos A/S, Holbæk, Denmark.'}, {'ForeName': 'Thomas O', 'Initials': 'TO', 'LastName': 'Carpenter', 'Affiliation': 'Department of Pediatrics (Endocrinology), Yale University School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Weber', 'Affiliation': 'Division of Endocrinology, Metabolism and Nutrition, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Brandenburg', 'Affiliation': 'Rhein-Maas Klinikum Würselen, Würselen, Germany.'}, {'ForeName': 'Heinz', 'Initials': 'H', 'LastName': 'Zoller', 'Affiliation': 'Department of Medicine I, Medical University of Innsbruck, Innsbruck, Austria.'}]",JAMA,['10.1001/jama.2019.22450'] 388,32228238,Reach Out Emergency Department: Partnering With an Economically Disadvantaged Community in the Development of a Text-Messaging Intervention to Address High Blood Pressure.,"Background. Hypertension affects nearly 30% of the U.S. adult population. Due to the ubiquitous nature of mobile phone usage, text messaging offers a promising platform for interventions to assist in the management of chronic diseases including hypertension, including among populations that are historically underserved. We present the intervention development of Reach Out, a health behavior theory-based, mobile health intervention to reduce blood pressure among hypertensive patients evaluated in a safety net emergency department primarily caring for African Americans. Aims. To describe the process of designing and refining text messages currently being implemented in the Reach Out randomized controlled trial. Method. We used a five-step framework to develop the text messages used in Reach Out. These steps included literature review and community formative research, conception of a community-centered behavioral theoretical framework, draft of evidence-based text messages, community review, and revision based on community feedback and finalization. Results . The Reach Out development process drew from pertinent evidence that, combined with community feedback, guided the development of a community-centered health behavior theory framework that led to development of text messages. A total of 333 generic and segmented messages were created. Messages address dietary choices, physical activity, hypertension medication adherence, and blood pressure monitoring. Discussion. Our five-step framework is intended to inform future text-messaging-based health promotion efforts to address health issues in vulnerable populations. Conclusion . Text message-based health promotion programs should be developed in partnership with the local community to ensure acceptability and relevance.",2020,"Due to the ubiquitous nature of mobile phone usage, text messaging offers a promising platform for interventions to assist in the management of chronic diseases including hypertension, including among populations that are historically underserved.","['Reach Out Emergency Department', 'hypertensive patients evaluated in a safety net emergency department primarily caring for African Americans']",[],"['physical activity, hypertension medication adherence, and blood pressure monitoring', 'blood pressure', 'Hypertension']","[{'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",[],"[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C2364172', 'cui_str': 'Medication Adherence'}, {'cui': 'C0026426', 'cui_str': 'Blood pressure monitoring'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}]",333.0,0.0398859,"Due to the ubiquitous nature of mobile phone usage, text messaging offers a promising platform for interventions to assist in the management of chronic diseases including hypertension, including among populations that are historically underserved.","[{'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Champoux', 'Affiliation': 'University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Rory', 'Initials': 'R', 'LastName': 'Price', 'Affiliation': 'University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Joan E', 'Initials': 'JE', 'LastName': 'Cowdery', 'Affiliation': 'Eastern Michigan University, Ypsilanti, MI, USA.'}, {'ForeName': 'Mackenzie', 'Initials': 'M', 'LastName': 'Dinh', 'Affiliation': 'University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Meurer', 'Affiliation': 'University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Narmeen', 'Initials': 'N', 'LastName': 'Rehman', 'Affiliation': 'University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Caitlin', 'Initials': 'C', 'LastName': 'Schille', 'Affiliation': 'University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Oliver', 'Affiliation': 'University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Devin L', 'Initials': 'DL', 'LastName': 'Brown', 'Affiliation': 'University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Jordan', 'Initials': 'J', 'LastName': 'Killingsworth', 'Affiliation': 'University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Lesli E', 'Initials': 'LE', 'LastName': 'Skolarus', 'Affiliation': 'University of Michigan, Ann Arbor, MI, USA.'}]",Health promotion practice,['10.1177/1524839920913550'] 389,32228789,"Effects of Individual and Combined Water, Sanitation, Handwashing, and Nutritional Interventions on Child Respiratory Infections in Rural Kenya: A Cluster-Randomized Controlled Trial.","Poor nutrition and hand hygiene are risk factors for acute respiratory infections (ARIs). Safe drinking water and sanitation can reduce exposure to pathogens and encourage healthy immune responses, reducing the risk of ARIs. Within a trial assessing impacts of water, sanitation, and handwashing (WASH), and nutritional interventions, we evaluated effects on ARIs. The WASH Benefits cluster-randomized trial enrolled pregnant women from Kenyan villages and evaluated health outcomes in children born to enrolled mothers 1 and 2 years after intervention delivery. Geographically adjacent clusters were block-randomized into a passive control (no promotional visits), a double-sized active control (monthly visits to measure mid-upper arm circumference), and six intervention groups: chlorinated drinking water (W), improved sanitation (S), handwashing with soap (H), combined WSH, improved nutrition (N) through counseling and lipid-based nutrient supplementation (LNS), and combined WSHN. The main outcome was the prevalence of ARI symptoms (cough, panting, wheezing, or difficulty breathing) in children younger than 3 years. Masking participants was not possible. Analyses were intention-to-treat. Between November 2012 and May 2014, 702 clusters were enrolled, including 6,960 (year 1) and 7,088 (year 2) children with ARI data. The cluster-level intra-cluster correlation coefficient for ARIs was 0.026 across both years. Water, sanitation, and handwashing interventions with behavior change messaging did not reduce ARIs. Nutrition counseling and LNS modestly reduced ARI symptoms compared with controls in year 1 [prevalence ratio (PR): 0.87, 95% confidence interval (CI): 0.77-0.99], but no effect in the combined WSHN group weakens this finding.",2020,"Safe drinking water and sanitation can reduce exposure to pathogens and encourage healthy immune responses, reducing the risk of ARIs.","['pregnant women from Kenyan villages and evaluated health outcomes in children born to enrolled mothers 1 and 2 years after intervention delivery', 'children younger than 3 years', 'Child Respiratory Infections in Rural Kenya', 'Between November 2012 and May 2014, 702 clusters were enrolled, including 6,960 (year 1) and 7,088 (year 2) children with ARI data']","['passive control (no promotional visits), a double-sized active control (monthly visits to measure mid-upper arm circumference), and six intervention groups: chlorinated drinking water (W), improved sanitation (S), handwashing with soap (H), combined WSH, improved nutrition (N) through counseling and lipid-based nutrient supplementation (LNS), and combined WSHN', 'water, sanitation, and handwashing (WASH), and nutritional interventions', 'Individual and Combined Water, Sanitation, Handwashing, and Nutritional Interventions', 'Nutrition counseling and LNS']","['prevalence of ARI symptoms (cough, panting, wheezing, or difficulty breathing', 'ARI symptoms']","[{'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0337839', 'cui_str': 'Kenyans (ethnic group)'}, {'cui': 'C0562518', 'cui_str': 'Village environment (environment)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0035243', 'cui_str': 'Infections, Respiratory'}, {'cui': 'C0022558', 'cui_str': 'Republic of Kenya'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0562351', 'cui_str': 'Mid upper arm circumference (observable entity)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0599638', 'cui_str': 'Drinking Water'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0036172', 'cui_str': 'Sanitation'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C0037392', 'cui_str': 'Soap'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0242295', 'cui_str': 'Dietary Supplementations'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C3714365', 'cui_str': 'Counseling about nutrition'}]","[{'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0453927', 'cui_str': 'Pants'}, {'cui': 'C0043144', 'cui_str': 'Wheezing'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}]",,0.102307,"Safe drinking water and sanitation can reduce exposure to pathogens and encourage healthy immune responses, reducing the risk of ARIs.","[{'ForeName': 'Jenna', 'Initials': 'J', 'LastName': 'Swarthout', 'Affiliation': 'Civil and Environmental Engineering, Tufts University, Medford, Massachusetts.'}, {'ForeName': 'Pavani K', 'Initials': 'PK', 'LastName': 'Ram', 'Affiliation': 'Epidemiology and Environmental Health, University at Buffalo, Buffalo, New York.'}, {'ForeName': 'Charles D', 'Initials': 'CD', 'LastName': 'Arnold', 'Affiliation': 'Department of Nutrition, University of California, Davis, Davis, California.'}, {'ForeName': 'Holly N', 'Initials': 'HN', 'LastName': 'Dentz', 'Affiliation': 'Department of Nutrition, University of California, Davis, Davis, California.'}, {'ForeName': 'Benjamin F', 'Initials': 'BF', 'LastName': 'Arnold', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco, California.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Kalungu', 'Affiliation': 'Innovations for Poverty Action, Nairobi, Kenya.'}, {'ForeName': 'Audrie', 'Initials': 'A', 'LastName': 'Lin', 'Affiliation': 'Department of Epidemiology and Biostatistics, University of California, Berkeley, Berkeley, California.'}, {'ForeName': 'Sammy M', 'Initials': 'SM', 'LastName': 'Njenga', 'Affiliation': 'Kenya Medical Research Institute, Nairobi, Kenya.'}, {'ForeName': 'Christine P', 'Initials': 'CP', 'LastName': 'Stewart', 'Affiliation': 'Department of Nutrition, University of California, Davis, Davis, California.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Colford', 'Affiliation': 'Department of Epidemiology and Biostatistics, University of California, Berkeley, Berkeley, California.'}, {'ForeName': 'Clair', 'Initials': 'C', 'LastName': 'Null', 'Affiliation': 'Center for International Policy Research and Evaluation, Mathematica Policy Research, Washington, District of Columbia.'}, {'ForeName': 'Amy J', 'Initials': 'AJ', 'LastName': 'Pickering', 'Affiliation': 'Civil and Environmental Engineering, Tufts University, Medford, Massachusetts.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.19-0779'] 390,31982494,Financial Incentives for Smoking Cessation in Hospitalized Patients: A Randomized Clinical Trial.,"BACKGROUND Financial incentives for smoking cessation and use of evidence-based therapy may increase quitting rates and reduce health and economic disparities. METHODS We randomized a low-income population of 182 hospitalized patients (mean age 58 years, 45% with high school education or less) to enhanced usual care, which included hospital-directed cessation care and Quitline referral or enhanced usual care plus financial incentives. All patients received enhanced usual care, while participants randomized to the financial incentives group were also eligible to receive up to $550 for participation in Quitline counseling ($50), participation in a community-based cessation program ($50), use of pharmacotherapy ($50), and biochemically confirmed smoking cessation at 2 months ($150) and 6 months ($250). Primary outcome was biochemically confirmed smoking cessation at 6 months after hospital discharge. RESULTS Total mean payment was $84 (standard deviation [SD] = $133) in the incentive group. The 6-month rate of biochemically confirmed smoking cessation was 19.6% in the incentive group and 8.9% in the enhanced usual care group (odds ratio [OR] 2.56; 95% confidence interval [CI] 0.84 to 7.83, P = 0.10). Participants in the incentive group had higher rates of nicotine replacement therapy use (57.3% vs 31.3%, P = 0.002). Financial incentives did not improve subjective social status but did increase financial stress. CONCLUSIONS Rates of bioconfirmed smoking cessation were higher among hospitalized patients randomized to financial incentives compared to usual care alone, but the difference was not significant. Considering the frequency of low payouts and the importance of assistance for successful quitting, future studies should explore the effectiveness of financial incentives sufficiently large to overcome barriers to evidence-based therapy.",2020,"Participants in the incentive group had higher rates of nicotine replacement therapy use (57.3% versus 31.3%, P=0.002).","['Hospitalized Patients', '182 hospitalized patients (mean age 58 years, 45% with high school education or less) to enhanced usual care, which included hospital-directed cessation care and Quitline referral, or enhanced usual care plus financial incentives']","['financial incentives group were also eligible to receive up to $550 for participation in Quitline counseling ($50), participation in a community-based cessation program ($50), use of pharmacotherapy ($50), and biochemically-confirmed smoking cessation']","['6-month rate of biochemically-confirmed smoking cessation', 'higher rates of nicotine replacement therapy use', 'subjective social status', 'financial stress', 'biochemically-confirmed smoking cessation at 6 months after hospital discharge']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0034927', 'cui_str': 'Referral'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}]","[{'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C3844103', 'cui_str': '550 (qualifier value)'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}]","[{'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1278444', 'cui_str': 'Nicotine replacement therapy'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0699806', 'cui_str': 'Social status'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}]",182.0,0.123893,"Participants in the incentive group had higher rates of nicotine replacement therapy use (57.3% versus 31.3%, P=0.002).","[{'ForeName': 'Joseph A', 'Initials': 'JA', 'LastName': 'Ladapo', 'Affiliation': 'Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at University of California, Los Angeles; Department of Population Health, New York University School of Medicine, New York. Electronic address: jladapo@mednet.ucla.edu.'}, {'ForeName': 'Chi-Hong', 'Initials': 'CH', 'LastName': 'Tseng', 'Affiliation': 'Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at University of California, Los Angeles.'}, {'ForeName': 'Scott E', 'Initials': 'SE', 'LastName': 'Sherman', 'Affiliation': 'Department of Population Health, New York University School of Medicine, New York; Department of Medicine, VA New York Harbor Healthcare System, New York; Department of Medicine, New York University School of Medicine, New York.'}]",The American journal of medicine,['10.1016/j.amjmed.2019.12.025'] 391,32149424,Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis.,"BACKGROUND APT-1011, a fluticasone propionate orally disintegrating tablet formulation, is under investigation for the treatment of eosinophilic oesophagitis (EoE). AIMS To evaluate the safety and tolerability of APT-1011 administered to patients with EoE and to assess the effect on clinical symptoms of EoE, endoscopic appearance and oesophageal eosinophilia. METHODS A randomised, double-blind, placebo-controlled, multicentre, phase 1b/2a study was conducted at seven medical centres in the US to evaluate the safety and tolerability of APT-1011 over 8 weeks in adults and adolescents with EoE. Participants were randomised to placebo (n = 8), 1.5 mg APT-1011 BID (n = 8) or 3.0 mg APT-1011 QD (n = 8). Safety and tolerability were assessed as the primary outcome; histologic and endoscopic measures were assessed as exploratory outcomes. RESULTS There were no deaths, serious treatment-emergent adverse events (TEAEs), severe TEAEs or discontinuations from the study related to a TEAE. In one participant randomised to 1.5 mg APT-1011 BID, a reduction in cortisol was observed, but without evidence of adrenal insufficiency. Compared with placebo, treatment with APT-1011 resulted in greater reductions in oesophageal eosinophil counts, EoE Endoscopic Reference Score, patient global assessment and symptom-based EoE activity index from baseline to end of treatment (Week 8). CONCLUSIONS APT-1011 was safe and well tolerated in adolescents and adults with EoE. Exploratory efficacy outcomes demonstrated improvement in histologic and endoscopic findings as well evidence of symptom improvement. The results of this study support the continued development of APT-1011 for the treatment of EoE (NCT-01386112).",2020,"There were no deaths, serious treatment-emergent adverse events (TEAEs), severe TEAEs or discontinuations from the study related to a TEAE.","['adults and adolescents with EoE. Participants', 'eosinophilic oesophagitis']","['fluticasone propionate orally disintegrating tablets versus placebo', 'mg APT-1011 QD ', 'placebo', 'fluticasone propionate', 'APT-1011', 'APT-1011 BID (n\xa0=\xa08) or 3.0']","['deaths, serious treatment-emergent adverse events (TEAEs), severe TEAEs or discontinuations', 'oesophageal eosinophil counts, EoE Endoscopic Reference Score, patient global assessment and symptom-based EoE activity index', 'safety and tolerability', 'Safety and tolerability', 'safe and well tolerated', 'clinical symptoms of EoE, endoscopic appearance and oesophageal eosinophilia']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0341106', 'cui_str': 'Chronic Esophagitis, Eosinophilic'}]","[{'cui': 'C0117996', 'cui_str': 'Fluticasone propionate'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0003645', 'cui_str': 'APT'}, {'cui': 'C0450317', 'cui_str': '1011'}, {'cui': 'C0048106', 'cui_str': 'BIDS'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil, segmented (cell)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0700364', 'cui_str': 'Appearances (qualifier value)'}, {'cui': 'C2240374', 'cui_str': 'Eosinophil count raised (finding)'}]",,0.392713,"There were no deaths, serious treatment-emergent adverse events (TEAEs), severe TEAEs or discontinuations from the study related to a TEAE.","[{'ForeName': 'Ikuo', 'Initials': 'I', 'LastName': 'Hirano', 'Affiliation': 'Department of Gastroenterology and Hepatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.'}, {'ForeName': 'Ekaterina', 'Initials': 'E', 'LastName': 'Safroneeva', 'Affiliation': 'Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Marie C', 'Initials': 'MC', 'LastName': 'Roumet', 'Affiliation': 'Clinical Trials Unit, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Gail M', 'Initials': 'GM', 'LastName': 'Comer', 'Affiliation': 'Adare Pharmaceuticals, Lawrenceville, NJ, USA.'}, {'ForeName': 'Gina', 'Initials': 'G', 'LastName': 'Eagle', 'Affiliation': 'Adare Pharmaceuticals, Lawrenceville, NJ, USA.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Schoepfer', 'Affiliation': 'Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Gary W', 'Initials': 'GW', 'LastName': 'Falk', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}]",Alimentary pharmacology & therapeutics,['10.1111/apt.15670'] 392,31455897,"Body weight, body composition and survival after 1 year: follow-up of a nutritional intervention trial in allo-HSCT recipients.","The role of body weight change in survival among recipients of hematopoietic stem-cell transplantation is controversial. We assessed the effect of optimizing energy and protein intake on 1-year survival, body weight and body composition, and the effect of body weight and body composition on 1-year survival in 117 patients (57 intervention, 60 control) in a randomized controlled trial. Cox regression was used to study effects of the intervention, weight and body composition on death, relapse, and nonrelapse mortality (NRM). We found no significant effect of intervention versus control on death hazard ratio (HR) 1.05, 95% confidence interval (CI) 0.54-2.04, p = 0.88), relapse (HR 1.15, 95% CI 0.48-2.27, p = 0.75), and NRM (HR 0.95, 95% CI 0.39-2.28, p = 0.90). Body weight, fat-free mass index, body fat mass index and total body water changed over time (p < 0.001), similarly in both groups (0.17 ≤ p ≤ 0.98). In multivariable analyses adjusted for group, gender and age, HRs and 95% CIs per one kilo increase in weight were 1.03 (1.01-1.06) and 1.04 (1.01-1.08) for death and NRM after 1 year (p ≤ 0.02), respectively, and 1.08 (1.01-1.15) for relapse after 3 months (p = 0.02). In conclusion, weight gain is possibly due to fluid retention and is an indicator of a complication in HSCT, rather than a marker of improved nutritional status.",2019,"We found no significant effect of intervention versus control on death hazard ratio (HR) 1.05, 95% confidence interval (CI) 0.54-2.04, p = 0.88), relapse (HR 1.15, 95% CI 0.48-2.27, p = 0.75), and NRM (HR 0.95, 95% CI 0.39-2.28, p = 0.90).","['allo-HSCT recipients', '117 patients (57 intervention, 60 control', 'recipients of hematopoietic stem-cell transplantation']",['optimizing energy and protein intake'],"['Body weight, body composition and survival', 'relapse', 'weight and body composition on death, relapse, and nonrelapse mortality (NRM', 'weight', 'Body weight, fat-free mass index, body fat mass index and total body water changed over time', 'weight gain', 'death and NRM', 'death hazard ratio', '1-year survival, body weight and body composition']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0472699', 'cui_str': 'Hematopoietic Stem Cell Transplantation'}]","[{'cui': 'C0033684', 'cui_str': 'Proteins'}]","[{'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass (observable entity)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0429632', 'cui_str': 'Total body water (observable entity)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",117.0,0.156154,"We found no significant effect of intervention versus control on death hazard ratio (HR) 1.05, 95% confidence interval (CI) 0.54-2.04, p = 0.88), relapse (HR 1.15, 95% CI 0.48-2.27, p = 0.75), and NRM (HR 0.95, 95% CI 0.39-2.28, p = 0.90).","[{'ForeName': 'K J', 'Initials': 'KJ', 'LastName': 'Skaarud', 'Affiliation': 'Department of Haematology, Oslo University Hospital, Oslo, Norway. kskaarud@ous-hf.no.'}, {'ForeName': 'M B', 'Initials': 'MB', 'LastName': 'Veierød', 'Affiliation': 'Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Lergenmuller', 'Affiliation': 'Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Bye', 'Affiliation': 'European Palliative Care Research Centre, Department of Oncology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.'}, {'ForeName': 'P O', 'Initials': 'PO', 'LastName': 'Iversen', 'Affiliation': 'Department of Haematology, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'G E', 'Initials': 'GE', 'LastName': 'Tjønnfjord', 'Affiliation': 'Department of Haematology, Oslo University Hospital, Oslo, Norway.'}]",Bone marrow transplantation,['10.1038/s41409-019-0638-6'] 393,31988481,Effectiveness and cost-effectiveness of The Daily Mile on childhood weight outcomes and wellbeing: a cluster randomised controlled trial.,"BACKGROUND The Daily Mile is designed to increase physical activity levels with children running or walking around school grounds for 15-min daily. It has been adopted by schools worldwide and endorsed as a solution to tackle obesity, despite no robust evidence of its benefits. We conducted a cluster randomised controlled trial to determine its clinical and cost-effectiveness. METHODS Forty schools were randomly assigned (1:1) to either the Daily Mile intervention or control group in which only the usual school health and wellbeing activities were implemented. The primary outcome was BMI z-score (BMIz) at 12 months follow-up from baseline, with planned subgroup analysis to examine differential effects. Primary economic analysis outcome was incremental cost per Quality-Adjusted-Life-Year (QALY) gained. RESULTS Using a constrained randomisation approach, balanced on school size, baseline BMIz and proportion of pupils eligible for free school meals, 20 schools were allocated to intervention (n = 1,153 participants) and 20 to control (n = 1,127); 3 schools withdrew (2 intervention, 1 control). At 12 months, BMIz data were available for 18 intervention schools (n = 850) and 19 control schools (n = 820 participants). Using intention-to-treat analysis the adjusted mean difference (MD) in BMIz (intervention - control) was -0.036 (95% CI: -0.085 to 0.013, p = 0.146). Pre-specified subgroup analysis showed a significant interaction with sex (p = 0.001) suggesting a moderate size benefit of The Daily Mile in girls (MD -0.097, 95% CI -0.156 to -0.037). This was consistent with the exploratory economic results that showed The Daily Mile to be highly cost-effective in girls (£2,492 per QALY), but not in boys, and overall to have a 76% chance of cost-effectiveness for the whole sample, at the commonly applied UK threshold of £20,000 per QALY. CONCLUSIONS Overall the Daily Mile had a small but non-significant effect on BMIz, however, it had a greater effect in girls suggesting that it might be considered as a cost-effective component of a system-wide approach to childhood obesity prevention.",2020,"Overall the Daily Mile had a small but non-significant effect on BMIz, however, it had a greater effect in girls suggesting that it might be considered as a cost-effective component of a system-wide approach to childhood obesity prevention.","['pupils eligible for free school meals, 20 schools', 'Forty schools']","['Daily Mile', 'Daily Mile intervention or control group in which only the usual school health and wellbeing activities were implemented']","['Effectiveness and cost-effectiveness', 'physical activity levels', 'childhood weight outcomes and wellbeing', 'BMI z-score (BMIz', 'BMIz', 'incremental cost per Quality-Adjusted-Life-Year (QALY) gained']","[{'cui': 'C0034121', 'cui_str': 'Pupil'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0331865', 'cui_str': 'Mile (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0080071', 'cui_str': 'QALY'}]",40.0,0.246083,"Overall the Daily Mile had a small but non-significant effect on BMIz, however, it had a greater effect in girls suggesting that it might be considered as a cost-effective component of a system-wide approach to childhood obesity prevention.","[{'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Breheny', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Passmore', 'Affiliation': 'Services for Education, Birmingham, B7 4AX, UK.'}, {'ForeName': 'Peymane', 'Initials': 'P', 'LastName': 'Adab', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK. p.adab@bham.ac.uk.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Martin', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK.'}, {'ForeName': 'Karla', 'Initials': 'K', 'LastName': 'Hemming', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK.'}, {'ForeName': 'Emma R', 'Initials': 'ER', 'LastName': 'Lancashire', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Frew', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK. e.frew@bham.ac.uk.'}]",International journal of obesity (2005),['10.1038/s41366-019-0511-0'] 394,32223601,One-Year Evaluation of a Targeted Medication Therapy Management Intervention for Older Adults.,"BACKGROUND Older adults are especially susceptible to adverse effects of inappropriate medication therapy, and anticholinergic medications are common culprits for cognitive dysfunction due to their action on the central nervous system. Medication therapy management (MTM) interventions can aid in deprescribing and reducing inappropriate medication use in older adults. However, there is sparse literature on the long-term sustainability of these interventions. OBJECTIVES To (a) investigate whether the deprescribing of anticholinergic medications during an 8-week randomized controlled trial (RCT) of a targeted MTM intervention is sustained at 1-year postintervention follow-up and (b) compare anticholinergic utilization trends in the study population with a large sample of similar individuals not exposed to the intervention. METHODS Participants in the targeted MTM (tMTM) RCT had normal cognition or mild cognitive impairment and were recruited from enrollees in a longitudinal study at the University of Kentucky Alzheimer's Disease Center (ADC) and thus have pertinent medical information gathered approximately annually. In this posttrial observational follow-up, sustainability of the anticholinergic deprescribing intervention was assessed in participants in the RCT, and anticholinergic medication use trends were described from the RCT baseline (which occurred immediately following an ADC visit) to the next annual visit in all participants. Mean change in anticholinergic burden from RCT baseline to the next annual visit was estimated using analysis of covariance, and participants were compared with 2 external samples. Anticholinergic burden was measured using the Anticholinergic Drug Scale (ADS). The odds of decreasing baseline anticholinergic burden and number of total and strong anticholinergic medications at the follow-up study time point was assessed using logistic regression. RESULTS Of the deprescribing changes made during the initial RCT, 50% were sustained after 1 year. Participants in the tMTM trial reported decreases in the use of anticholinergic antihistamines and bladder agents (-6.5 and -4.4%, respectively), but there was no change in the use of anticholinergic agents targeted at the central nervous system. While the anticholinergic burden of RCT participants decreased over 1 year (adjusted mean ADS change [95% CI] = -0.33 [-0.72, 0.07]), it was not different than the change observed in 2 external samples at the trial center (-0.20 [-0.42, 0.02]) and nationally (-0.33 [-0.39, -0.26]). There were no statistically significant differences between trial participants and external samples in the odds of decreasing anticholinergic burden nor in decreasing the number of total, or strongly anticholinergic, medications at the 1-year follow-up. CONCLUSIONS This study demonstrates that the sustainability of deprescribing is limited to the period of intervention, rather than affording lasting effects even over periods as short as 1 year, which was demonstrated not only in the small group of RCT participants but also by comparison with external groups. Future work should extend the duration of intervention and follow-up periods for MTM interventions to allow further insights regarding the sustainability of deprescribing efforts in older adults. DISCLOSURES The original trial was supported by a pilot study award from the University of Kentucky Center for Clinical and Translational Sciences (UL1TR000117). Additional support for this study was provided by the National Institutes of Health/National Institute on Aging (R01 AG054130). Jicha reports contract research for Esai, Biohaven, Alltech, Suven, Novartis, and Lilly. The other authors have nothing to disclose.",2020,Medication therapy management (MTM) interventions can aid in deprescribing and reducing inappropriate medication use in older adults.,"['Older adults', ""Participants in the targeted MTM (tMTM) RCT had normal cognition or mild cognitive impairment and were recruited from enrollees in a longitudinal study at the University of Kentucky Alzheimer's Disease Center (ADC) and thus have pertinent medical information gathered approximately annually"", 'older adults', 'Older Adults', 'study population with a large sample of similar individuals not exposed to the intervention']","['Targeted Medication Therapy Management Intervention', 'Medication therapy management (MTM) interventions', 'anticholinergic medications', 'MTM intervention']","['number of total, or strongly anticholinergic, medications', 'baseline anticholinergic burden and number of total and strong anticholinergic medications', 'Anticholinergic Drug Scale (ADS', 'anticholinergic antihistamines and bladder agents', 'Anticholinergic burden']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C2712133', 'cui_str': 'Normal cognition (finding)'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0022557', 'cui_str': 'Kentucky'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0332232', 'cui_str': 'Approximate (qualifier value)'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}]","[{'cui': 'C1611232', 'cui_str': 'Drug Therapy Management'}, {'cui': 'C0242896', 'cui_str': 'Anticholinergic Agents'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0242896', 'cui_str': 'Anticholinergic Agents'}, {'cui': 'C0442821', 'cui_str': 'Strong (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0222045'}, {'cui': 'C0019590', 'cui_str': 'Antihistamines'}, {'cui': 'C0005682', 'cui_str': 'Bladder'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}]",,0.0365253,Medication therapy management (MTM) interventions can aid in deprescribing and reducing inappropriate medication use in older adults.,"[{'ForeName': 'Ashley I', 'Initials': 'AI', 'LastName': 'Martinez', 'Affiliation': 'Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington.'}, {'ForeName': 'Erin L', 'Initials': 'EL', 'LastName': 'Abner', 'Affiliation': 'Department of Epidemiology, College of Public Health, University of Kentucky, and Sanders-Brown Center on Aging, Lexington, Kentucky.'}, {'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Jicha', 'Affiliation': 'Sanders-Brown Center on Aging, Lexington, Kentucky, and Department of Neurology, College of Medicine, University of Kentucky, Lexington.'}, {'ForeName': 'Dorinda N', 'Initials': 'DN', 'LastName': 'Rigsby', 'Affiliation': 'Medical Center, Lexington, Kentucky.'}, {'ForeName': 'Lynne C', 'Initials': 'LC', 'LastName': 'Eckmann', 'Affiliation': 'Pharmacy Consulting Services, Lexington, Kentucky.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Huffmyer', 'Affiliation': 'Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, and PRO2RX LLC Pharmacy Consulting Services, Lexington, Kentucky.'}, {'ForeName': 'Daniela C', 'Initials': 'DC', 'LastName': 'Moga', 'Affiliation': 'Department of Pharmacy Practice and Science, College of Pharmacy, and Department of Epidemiology, College of Public Health, University of Kentucky, and Sanders-Brown Center on Aging, Lexington, Kentucky.'}]",Journal of managed care & specialty pharmacy,['10.18553/jmcp.2020.26.4.520'] 395,32223645,Biceps Tenodesis Versus Tenotomy in the Treatment of Lesions of the Long Head of the Biceps Tendon in Patients Undergoing Arthroscopic Shoulder Surgery: A Prospective Double-Blinded Randomized Controlled Trial.,"BACKGROUND The biceps tendon is a known source of shoulder pain. Few high-level studies have attempted to determine whether biceps tenotomy or tenodesis is the optimal approach in the treatment of biceps pathology. Most available literature is of lesser scientific quality and shows varying results in the comparison of tenotomy and tenodesis. PURPOSE To compare patient-reported and objective clinical results between tenotomy and tenodesis for the treatment of lesions of the long head of the biceps brachii. STUDY DESIGN Randomized controlled trial; Level of evidence, 1. METHODS Patients aged ≥18 years undergoing arthroscopic surgery with intraoperative confirmation of a lesion of the long head of the biceps tendon were randomized. The primary outcome measure was the American Shoulder and Elbow Surgeons (ASES) score, while secondary outcomes included the Western Ontario Rotator Cuff Index (WORC) score, elbow and shoulder strength, operative time, complications, and the incidence of revision surgery with each procedure. Magnetic resonance imaging was performed at postoperative 1 year to evaluate the integrity of the procedure in the tenodesis group. RESULTS A total of 114 participants with a mean age of 57.7 years (range, 34 years to 86 years) were randomized to undergo either biceps tenodesis or tenotomy. ASES and WORC scores improved significantly from pre- to postoperative time points, with a mean difference of 32.3% ( P < .001) and 37.3% ( P < .001), respectively, with no difference between groups in either outcome from presurgery to postoperative 24 months. The relative risk of cosmetic deformity in the tenotomy group relative to the tenodesis group at 24 months was 3.5 (95% CI, 1.26-9.70; P = .016), with 4 (10%) occurrences in the tenodesis group and 15 (33%) in the tenotomy group. Pain improved from 3 to 24 months postoperatively ( P < .001) with no difference between groups. Cramping was not different between groups, nor was any improvement in cramping seen over time. There were no differences between groups in elbow flexion strength or supination strength. Follow-up magnetic resonance imaging at postoperative 12 months showed that the tenodesis was intact for all patients. CONCLUSION Tenotomy and tenodesis as treatment for lesions of the long head of biceps tendon both result in good subjective outcomes but there is a higher rate of Popeye deformity in the tenotomy group. REGISTRATION NCT01747902 ( ClinicalTrials.gov identifier).",2020,There were no differences between groups in elbow flexion strength or supination strength.,"['Patients Undergoing Arthroscopic Shoulder Surgery', 'Patients aged ≥18 years undergoing arthroscopic surgery with intraoperative confirmation of a lesion of the long head of the biceps tendon were randomized', '114 participants with a mean age of 57.7 years (range, 34 years to 86 years']","['Biceps Tenodesis Versus Tenotomy', 'Magnetic resonance imaging', 'biceps tenodesis or tenotomy']","['ASES and WORC scores', 'American Shoulder and Elbow Surgeons (ASES) score, while secondary outcomes included the Western Ontario Rotator Cuff Index (WORC) score, elbow and shoulder strength, operative time, complications, and the incidence of revision surgery with each procedure', 'Pain', 'relative risk of cosmetic deformity', 'elbow flexion strength or supination strength']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0037004', 'cui_str': 'Shoulder'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0750934', 'cui_str': 'Arthroscopic Surgical Procedures'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0521091', 'cui_str': 'Confirmation of (contextual qualifier) (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0039508', 'cui_str': 'Tendons'}, {'cui': 'C4708785', 'cui_str': 'One hundred and fourteen'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}]","[{'cui': 'C1260974', 'cui_str': 'Tenodesis'}, {'cui': 'C0856438', 'cui_str': 'Tenotomy (psoas)'}, {'cui': 'C1552358', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0037004', 'cui_str': 'Shoulder'}, {'cui': 'C0013769', 'cui_str': 'Elbow'}, {'cui': 'C0582175', 'cui_str': 'Surgeon (occupation)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C0085515', 'cui_str': 'Rotator Cuff'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0035110', 'cui_str': 'Revision Surgery'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0442965', 'cui_str': 'Cosmetic procedure (qualifier value)'}, {'cui': 'C0000768', 'cui_str': 'Birth Defects'}, {'cui': 'C0231452', 'cui_str': 'Flexion, function (observable entity)'}, {'cui': 'C0038845', 'cui_str': 'Supination'}]",114.0,0.295535,There were no differences between groups in elbow flexion strength or supination strength.,"[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'MacDonald', 'Affiliation': 'Pan Am Clinic and University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Fleur', 'Initials': 'F', 'LastName': 'Verhulst', 'Affiliation': 'Pan Am Clinic and University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Sheila', 'Initials': 'S', 'LastName': 'McRae', 'Affiliation': 'Pan Am Clinic and University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Old', 'Affiliation': 'Pan Am Clinic and University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Stranges', 'Affiliation': 'Pan Am Clinic and University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Dubberley', 'Affiliation': 'Pan Am Clinic and University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Randy', 'Initials': 'R', 'LastName': 'Mascarenhas', 'Affiliation': 'McGovern Medical School, University of Texas Health Sciences Center, Houston, Texas, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Koenig', 'Affiliation': 'Pan Am Clinic and University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Leiter', 'Affiliation': 'Pan Am Clinic and University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Nassar', 'Affiliation': 'Pan Am Clinic and University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Lapner', 'Affiliation': 'Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada.'}]",The American journal of sports medicine,['10.1177/0363546520912212'] 396,32216762,Group problem management plus (gPM+) in the treatment of common mental disorders in Syrian refugees in a Jordanian camp: study protocol for a randomized controlled trial.,"BACKGROUND Accessing quality mental health care poses significant challenges for persons affected by adversity, especially in low- and middle-income countries where resources are scarce. To mitigate this, the World Health Organization has developed group problem management plus (gPM+), a low-intensity psychological intervention for adults experiencing psychological distress. gPM+ is a group-based intervention consisting of five-sessions, and can be delivered by non-specialist providers. This paper outlines the study protocol for a trial of gPM+ in Jordan. METHODS We will conduct a single-blind, two-arm, randomized controlled trial in a Syrian refugee camp in Jordan. We aim to enrol 480 adults into the trial. Participants will be eligible for the trial if they screen positive for levels of psychological distress. Following screening, those eligible will be randomly assigned to receive the gPM+ intervention or enhanced treatment as usual. The primary outcome is reduction in levels of psychological distress at 3-months post-treatment. Secondary outcomes include anxiety, depression, prodromal psychotic symptoms, posttraumatic stress disorder, prolonged grief, daily functioning, economic effectiveness, and change in parenting behaviour. Secondary outcomes also include the reduction in psychological distress of the participant's child. DISCUSSION The trial aims to deliver a template for affordable and scalable psychosocial interventions that can readily be implemented in refugee settings, and that can benefit both the participant and their child. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry, ACTRN12619001386123. Registered prospectively on 10/10/2019.",2020,"gPM+ is a group-based intervention consisting of five-sessions, and can be delivered by non-specialist providers.","['Syrian refugee camp in Jordan', 'adults experiencing psychological distress', 'enrol 480 adults into the trial']","['gPM+ intervention or enhanced treatment as usual', 'gPM', 'Group problem management plus (gPM']","[""reduction in psychological distress of the participant's child"", 'anxiety, depression, prodromal psychotic symptoms, posttraumatic stress disorder, prolonged grief, daily functioning, economic effectiveness, and change in parenting behaviour', 'reduction in levels of psychological distress']","[{'cui': 'C0337819', 'cui_str': 'Syrians (ethnic group)'}, {'cui': 'C0242477', 'cui_str': 'Refugee Camps'}, {'cui': 'C0022418', 'cui_str': 'Jordan'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C4319609', 'cui_str': '480'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0871189', 'cui_str': 'Psychotic symptom'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C0018235', 'cui_str': 'Grief'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0013557', 'cui_str': 'economics'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",480.0,0.311792,"gPM+ is a group-based intervention consisting of five-sessions, and can be delivered by non-specialist providers.","[{'ForeName': 'Aemal', 'Initials': 'A', 'LastName': 'Akhtar', 'Affiliation': 'School of Psychology, University of New South Wales, Sydney, NSW, 2052, Australia.'}, {'ForeName': 'Luana', 'Initials': 'L', 'LastName': 'Giardinelli', 'Affiliation': 'Jordan Country Office, International Medical Corps, Amman, Jordan.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Bawaneh', 'Affiliation': 'Jordan Country Office, International Medical Corps, Amman, Jordan.'}, {'ForeName': 'Manar', 'Initials': 'M', 'LastName': 'Awwad', 'Affiliation': 'Jordan Country Office, International Medical Corps, Amman, Jordan.'}, {'ForeName': 'Hadeel', 'Initials': 'H', 'LastName': 'Naser', 'Affiliation': 'Jordan Country Office, International Medical Corps, Amman, Jordan.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Whitney', 'Affiliation': 'International Medical Corps, Beirut, Lebanon.'}, {'ForeName': 'Mark J D', 'Initials': 'MJD', 'LastName': 'Jordans', 'Affiliation': 'Research and Development Department, War Child Holland, Amsterdam, The Netherlands.'}, {'ForeName': 'Marit', 'Initials': 'M', 'LastName': 'Sijbrandij', 'Affiliation': 'Clinical, Neuro and Developmental Psychology, VU University, Amsterdam, The Netherlands.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Bryant', 'Affiliation': 'School of Psychology, University of New South Wales, Sydney, NSW, 2052, Australia. r.bryant@unsw.edu.au.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMC public health,['10.1186/s12889-020-08463-5'] 397,32216778,Gingivitis efficacy of a 0.454% w/w stannous fluoride dentifrice: a 24-week randomized controlled trial.,"BACKGROUND Plaque-induced gingivitis can be prevented and treated with regular effective oral hygiene, principally via mechanical cleaning with regular toothbrushing. To complement the mechanical plaque removal, antimicrobial ingredients can be incorporated into dentifrices to inhibit the growth of plaque. This study aimed to evaluate and compare gingivitis and the proportion of subjects moving between gingivitis severity (< 10, > 10 < 30, > 30% bleeding sites), and plaque reduction, following twice daily use of an experimental non-aqueous 0.454% weight/weight (w/w) stannous fluoride (SnF 2 ) dentifrice, compared to a negative control dentifrice over 12 and 24 weeks. METHOD This was a single-center, examiner-blinded, randomized, stratified, two-treatment arm, parallel group, 24-week clinical study in healthy adult volunteers with moderate gingivitis. At baseline, after abstaining from toothbrushing overnight, subjects underwent MGI (modified gingival index), BI (bleeding index) and PI (plaque index) assessments. Eligible subjects, who met the inclusion/exclusion criteria, were stratified based on gender and baseline mean MGI score (Low ≤2.00 /High > 2.00) and randomized to treatment. Following randomization, subjects underwent a thorough dental prophylaxis and flossing. After 12 and 24 weeks of twice daily brushing with their allocated treatment, subjects returned to the site (with overnight plaque, having abstained from oral hygiene procedures for 8 h prior to visit) for MGI, BI and PI assessments. Treatment effect was evaluated by comparing the MGI, BI and PI scores. RESULTS One hundred and twenty-nine subjects were screened; 98 subjects were randomized and 90 subjects completed the study. Statistically significant differences between treatments, in favour of the 0.454% stannous fluoride dentifrice were observed, compared to the negative control dentifrice, for all outcome measures (MGI, BI, bleeding sites and PI at weeks 12 and 24 p < 0.0001). At 24 weeks, 71% of subjects in the 0.453% SnF 2 treatment group demonstrated < 10% of bleeding sites. CONCLUSION A dentifrice containing 0.454% w/w SnF 2 was shown to be superior to a standard dentifrice in controlling gingivitis and supra-gingival plaque, over a 24-week period. Over two thirds of subjects in the 0.454% SnF 2 treatment group demonstrated a level of bleeding sites potentially representative of ""clinical periodontal health"" (< 10%) following a dental prophylaxis and 24 weeks of product use. TRIAL REGISTRATION This study was retrospectively registered at ClinicalTrials.gov, on 11th Oct. 2019 (NCT04123665).",2020,"Statistically significant differences between treatments, in favour of the 0.454% stannous fluoride dentifrice were observed, compared to the negative control dentifrice, for all outcome measures (MGI, BI, bleeding sites and PI at weeks 12 and 24 p < 0.0001).","['healthy adult volunteers with moderate gingivitis', 'One hundred and twenty-nine subjects were screened; 98 subjects were randomized and 90 subjects completed the study', 'subjects moving between gingivitis severity (<\u200910, >\u200910\u2009<\u200930, >\u200930% bleeding sites), and plaque reduction, following twice daily use of an experimental non-aqueous 0.454% weight/weight (w/w', 'Eligible subjects, who met the inclusion/exclusion criteria, were stratified based on gender and baseline mean MGI score (Low ≤2.00 /High']","['stannous fluoride (SnF 2 ) dentifrice, compared to a negative control dentifrice', 'stannous fluoride dentifrice']","['bleeding sites', 'level of bleeding sites potentially representative of ""clinical periodontal health', 'MGI (modified gingival index), BI (bleeding index) and PI (plaque index) assessments', 'MGI, BI and PI scores', 'outcome measures (MGI, BI, bleeding sites and PI', 'Gingivitis efficacy']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C4075412', 'cui_str': 'Moderate gingivitis (disorder)'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0578671', 'cui_str': 'Does move (finding)'}, {'cui': 'C0017574', 'cui_str': 'Gingivitis'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C2919747', 'cui_str': 'Weight/weight ratio'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}]","[{'cui': 'C0038143', 'cui_str': 'Stannous Fluoride'}, {'cui': 'C0040462', 'cui_str': 'Toothpaste'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0017569', 'cui_str': 'Gingival Index'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0017574', 'cui_str': 'Gingivitis'}]",98.0,0.0264049,"Statistically significant differences between treatments, in favour of the 0.454% stannous fluoride dentifrice were observed, compared to the negative control dentifrice, for all outcome measures (MGI, BI, bleeding sites and PI at weeks 12 and 24 p < 0.0001).","[{'ForeName': 'C R', 'Initials': 'CR', 'LastName': 'Parkinson', 'Affiliation': 'GlaxoSmithKline Consumer Healthcare, Weybridge, KT13 0DE, UK. charles.x.parkinson@gsk.com.'}, {'ForeName': 'K R', 'Initials': 'KR', 'LastName': 'Milleman', 'Affiliation': 'Salus Research, Inc., Fort Wayne, IN, USA.'}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Milleman', 'Affiliation': 'Salus Research, Inc., Fort Wayne, IN, USA.'}]",BMC oral health,['10.1186/s12903-020-01079-6'] 398,32232540,The effects of unilateral and bilateral cerebellar rTMS on human pharyngeal motor cortical activity and swallowing behavior.,"The cerebellum is recognised to bilaterally modulate sensorimotor function and has recently been shown to play a role in swallowing. Unilateral cerebellar repetitive trans-cranial magnetic stimulation (rTMS) excites corticobulbar motor pathways to the pharynx but the effects of bilateral versus unilateral cerebellar rTMS on these pathways are unknown. In this three-part cross-over study, healthy participants (n = 13) were randomly allocated to receive unilateral or bilateral 10 Hz cerebellar rTMS. Participants were intubated with pharyngeal electromyography and/or manometry catheters for motor evoked potentials (MEPs) and pressure recordings. In part 1 of the study, single pulse TMS was used to measure baseline motor cortical pharyngeal MEP (PMEP) and hemispheric cerebellar MEP (CMEP) amplitudes, before cerebellar rTMS was administered. Repeat measures of PMEP amplitude were performed at 15-min intervals for an hour post unilateral and bilateral rTMS. Thereafter, in two further studies, a cortical 'virtual lesion' (V/L) was applied prior to cerebellar rTMS with pre and post PMEPs (part 2) and measurements of swallowing accuracy (part 3) using a behavioural task. Compared to baseline, unilateral and bilateral cerebellar rTMS provoked increases in pharyngeal cortical excitation (P = 0.028, 0.0005, respectively). Bilateral rTMS was significantly more effective than unilateral in causing cortical excitation (P = 0.0005) and in reversing the suppressive neurological (P = 0.0005) and behavioural (P = 0.0005) effects of a cortical V/L. Our findings suggest bilateral cerebellar rTMS has greater facilitatory effects on corticobulbar motor pathways to the pharynx than unilateral stimulation with the potential to be a more effective clinical therapy if its effects are reproduced in populations with neurogenic dysphagia.",2020,Bilateral rTMS was significantly more effective than unilateral in causing cortical excitation (P = 0.0005) and in reversing the suppressive neurological (P = 0.0005) and behavioural (P = 0.0005) effects of a cortical V/L.,['healthy participants (n\u2009=\u200913'],"['unilateral and bilateral cerebellar rTMS', 'unilateral or bilateral 10\xa0Hz cerebellar rTMS', 'Unilateral cerebellar repetitive trans-cranial magnetic stimulation (rTMS', 'pharyngeal electromyography and/or manometry catheters for motor evoked potentials (MEPs) and pressure recordings']","['human pharyngeal motor cortical activity and swallowing behavior', 'PMEP amplitude', 'baseline motor cortical pharyngeal MEP (PMEP) and hemispheric cerebellar MEP (CMEP) amplitudes', 'pharyngeal cortical excitation', 'suppressive neurological']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C3163632', 'cui_str': 'Cranial'}, {'cui': 'C0024488', 'cui_str': 'Magnetics'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0941139', 'cui_str': 'Manometer catheter'}, {'cui': 'C0282617', 'cui_str': 'Evoked Potentials, Motor'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}]","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0326374', 'cui_str': 'Swallows'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0117061', 'cui_str': 'exopolysaccharide, Pseudomonas marginalis'}, {'cui': 'C0205139', 'cui_str': 'Hemispheric (qualifier value)'}, {'cui': 'C0205367', 'cui_str': 'Suppressive (qualifier value)'}, {'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}]",13.0,0.0286059,Bilateral rTMS was significantly more effective than unilateral in causing cortical excitation (P = 0.0005) and in reversing the suppressive neurological (P = 0.0005) and behavioural (P = 0.0005) effects of a cortical V/L.,"[{'ForeName': 'Ayodele', 'Initials': 'A', 'LastName': 'Sasegbon', 'Affiliation': 'Gastrointestinal (GI) Sciences, Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Salford Royal Hospital (part of the Manchester Academic Health Sciences Center (MAHSC)), Clinical Sciences Building, Eccles Old Road, Salford, M6 8HD, UK.'}, {'ForeName': 'Craig J', 'Initials': 'CJ', 'LastName': 'Smith', 'Affiliation': 'Division of Cardiovascular Sciences, Manchester Centre for Clinical Neurosciences, Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Salford Royal Hospital, Manchester Academic Health Sciences Centre (MAHSC), Salford, UK.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Bath', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Rothwell', 'Affiliation': 'Sobell Department of Motor Neuroscience and Movement Disorders, University College London, London, UK.'}, {'ForeName': 'Shaheen', 'Initials': 'S', 'LastName': 'Hamdy', 'Affiliation': 'Gastrointestinal (GI) Sciences, Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Salford Royal Hospital (part of the Manchester Academic Health Sciences Center (MAHSC)), Clinical Sciences Building, Eccles Old Road, Salford, M6 8HD, UK. shaheen.hamdy@manchester.ac.uk.'}]",Experimental brain research,['10.1007/s00221-020-05787-x'] 399,31144836,A preliminary test of a brief intervention to lessen young adults' cannabis use: Episode-level smartphone data highlights the role of protective behavioral strategies and exercise.,"Brief interventions are increasingly being used to help young adults to moderate their cannabis use. We conducted a randomized clinical trial of a brief (4 weekly sessions), in-person intervention that included a smartphone application that reinforced the use of protective behavioral strategies (PBSs) to lessen cannabis use. Young adults ( N = 37; 24 men) who regularly used cannabis were randomized to 2 intervention conditions rooted in cognitive-behavioral therapy (CBT) and motivational enhancement therapy (MET). Along with learning CBT + MET strategies, participants in 1 of the conditions were instructed to engage in exercise. All participants used smartphone-based ecological momentary assessment to provide episode-level reports about use of cannabis and PBSs. Two multilevel structural equation models were run to test the study hypotheses that (a) cannabis use would be reduced over the course of the 6-month study, (b) reductions would be moderated by intervention condition, and (c) episode-level PBS use would predict episode-level cannabis use. Participants reduced their cannabis use by approximately 1 half of a standard joint per time point. The MET + CBT + Exercise condition reduced cannabis use to a greater degree than did the MET + CBT condition. With episode-level PBS use in the model, reductions in cannabis use were independent of intervention condition. Our findings suggest that young adults will engage with a smartphone app that serves as a component of an in-person intervention to moderate their cannabis use. Intervention content that promotes the use of PBSs and exercise facilitates reductions in cannabis use. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,The MET + CBT + Exercise condition reduced cannabis use to a greater degree than did the MET + CBT condition.,"[""young adults' cannabis use"", 'Young adults ( N = 37; 24 men) who regularly used cannabis']","['protective behavioral strategies (PBSs', '2 intervention conditions rooted in cognitive-behavioral therapy (CBT) and motivational enhancement therapy (MET']",[],"[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C3160814', 'cui_str': 'Cannabis use'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0678449', 'cui_str': 'Cannabis'}]","[{'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0563017', 'cui_str': 'Anal penetration using finger (finding)'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",[],,0.031354,The MET + CBT + Exercise condition reduced cannabis use to a greater degree than did the MET + CBT condition.,"[{'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Prince', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'R Lorraine', 'Initials': 'RL', 'LastName': 'Collins', 'Affiliation': 'Department of Community Health and Health Behavior.'}, {'ForeName': 'Sandy D', 'Initials': 'SD', 'LastName': 'Wilson', 'Affiliation': 'Department of Community Health and Health Behavior.'}, {'ForeName': 'Paula C', 'Initials': 'PC', 'LastName': 'Vincent', 'Affiliation': 'Department of Cancer Prevention and Control.'}]",Experimental and clinical psychopharmacology,['10.1037/pha0000301'] 400,31978354,"Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study.","BACKGROUND Influenza is an important public health problem and existing vaccines are not completely protective. New vaccines that protect by alternative mechanisms are needed to improve efficacy of influenza vaccines. In 2015, we did a phase 1 trial of an oral influenza vaccine, VXA-A1.1. A favourable safety profile and robust immunogenicity results in that trial supported progression of the vaccine to the current phase 2 trial. The aim of this study was to evaluate efficacy of the vaccine in a human influenza challenge model. METHODS We did a single-site, placebo-controlled and active-controlled, phase 2 study at WCCT Global, Costa Mesa, CA, USA. Eligible individuals had an initial A/California/H1N1 haemagglutination inhibition titre of less than 20 and were aged 18-49 years and in good health. Individuals were randomly assigned (2:2:1) to receive a single immunisation of either 10 11 infectious units of VXA-A1.1 (a monovalent tablet vaccine) orally, a full human dose of quadrivalent inactivated influenza vaccine (IIV) via intramuscular injection, or matched placebo. Randomisation was done by computer-generated assignments with block size of five. An unmasked pharmacist provided the appropriate vaccines and placebos to the administrating nurse. Individuals receiving the treatments, investigators, and staff were all masked to group assignments. 90 days after immunisation, individuals without clinically significant symptoms or signs of influenza, an oral temperature of higher than 37·9°C, a positive result for respiratory viral shedding on a Biofire test, and any investigator-assessed contraindications were challenged intranasally with 0·5 mL wild-type A/CA/like(H1N1)pdm09 influenza virus. The primary outcomes were safety, which was assessed in all immunised participants through 365 days, and influenza-positive illness after viral challenge, which was assessed in individuals that received the viral challenge and the required number of assessments post viral challenge. This trial is registered with ClinicalTrials.gov, number NCT02918006. RESULTS Between Aug 31, 2016, and Jan 23, 2017, 374 individuals were assessed for eligibility, of whom 179 were randomly assigned to receive either VXA-A1.1 (n=71 [one individual did not provide a diary card, thus the solicited events were assessed in 70 individuals]), IIV (n=72), or placebo (n=36). Between Dec 2, 2016, and April 26, 2017, 143 eligible individuals (58 in the VXA-A1.1 group, 54 in the IIV group, and 31 in the placebo group) were challenged with influenza virus. VXA-A1.1 was well tolerated with no serious or medically significant adverse events. The most prevalent solicited adverse events for each of the treatment groups after immunisation were headache in the VXA-A1.1 (in five [7%] of 70 participants) and placebo (in seven [19%] of 36 participants) groups and tenderness at injection site in the IIV group (in 19 [26%] of 72 participants) Influenza-positive illness after challenge was detected in 17 (29%) of 58 individuals in the VXA-A1.1 group, 19 (35%) of 54 in the IIV group, and 15 (48%) of 31 in the placebo group. INTERPRETATION Orally administered VXA-A1.1 was well tolerated and generated protective immunity against virus shedding, similar to a licensed intramuscular IIV. These results represent a major step forward in developing a safe and effective oral influenza vaccine. FUNDING Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, and Biomedical Advanced Research and Development Authority.",2020,The most prevalent solicited adverse events for each of the treatment groups after immunisation were headache in the VXA-A1.1,"['143 eligible individuals (58 in the VXA-A1.1 group, 54 in the IIV group, and 31 in the placebo group) were challenged with influenza virus', 'Between Aug 31, 2016, and Jan 23, 2017, 374 individuals were assessed for eligibility, of whom 179', 'Eligible individuals had an initial A/California/H1N1 haemagglutination inhibition titre of less than 20 and were aged 18-49 years and in good health']","['oral influenza vaccine', 'vaccine', 'placebo', 'oral influenza vaccine, VXA-A1.1', 'VXA-A1.1 (a monovalent tablet vaccine) orally, a full human dose of quadrivalent inactivated influenza vaccine (IIV) via intramuscular injection, or matched placebo', 'VXA-A1.1']","['headache', 'Efficacy, immunogenicity, and safety', 'Influenza-positive illness', 'tenderness at injection site']","[{'cui': 'C4517573', 'cui_str': 'One hundred and forty-three'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4316910', 'cui_str': 'Influenzavirus'}, {'cui': 'C4517609', 'cui_str': '179 (qualifier value)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0580264', 'cui_str': 'H1N1'}, {'cui': 'C0018904', 'cui_str': 'Hemagglutination Inhibition Tests'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0021403', 'cui_str': 'Influenza Vaccines'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0021492', 'cui_str': 'Intramuscular injection (procedure)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]","[{'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0021400', 'cui_str': 'Influenza, Human'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0234233', 'cui_str': 'Tenderness (finding)'}, {'cui': 'C0221208', 'cui_str': 'Injection site (morphologic abnormality)'}]",374.0,0.340586,The most prevalent solicited adverse events for each of the treatment groups after immunisation were headache in the VXA-A1.1,"[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Liebowitz', 'Affiliation': 'Vaxart, South San Francisco, CA, USA.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Gottlieb', 'Affiliation': 'Vaxart, South San Francisco, CA, USA.'}, {'ForeName': 'Nikita S', 'Initials': 'NS', 'LastName': 'Kolhatkar', 'Affiliation': 'Vaxart, South San Francisco, CA, USA.'}, {'ForeName': 'Shaily J', 'Initials': 'SJ', 'LastName': 'Garg', 'Affiliation': 'Vaxart, South San Francisco, CA, USA.'}, {'ForeName': 'Jason M', 'Initials': 'JM', 'LastName': 'Asher', 'Affiliation': 'Biomedical Advanced Research and Development Authority, Washington, DC, USA.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Nazareno', 'Affiliation': 'Vaxart, South San Francisco, CA, USA.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Kim', 'Affiliation': 'Ark Clinical Research, Long Beach, CA, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'McIlwain', 'Affiliation': 'WCCT Global, Costa Mesa, CA, USA; Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Sean N', 'Initials': 'SN', 'LastName': 'Tucker', 'Affiliation': 'Vaxart, South San Francisco, CA, USA. Electronic address: sean_tucker@mac.com.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(19)30584-5'] 401,31990759,Metabolic Responses to Metformin in Inoperable Early-stage Non-Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial.,"BACKGROUND Metformin reduces glucose uptake in physiologic tissues and has been shown to affect non-small cell lung cancer (NSCLC) metabolism. We hypothesized that positron emission tomography (PET) scans could detect the impact of metformin on glucose uptake in NSCLC and we sought to test this hypothesis in a prospective clinical trial. MATERIALS AND METHODS A single-blinded phase II clinical trial was performed with subjects randomized 6:1 to 3 to 4 weeks of metformin versus placebo for inoperable early-stage NSCLC. PET scans were performed at baseline, mid-treatment (after 2 wk study medication), and 6 months postradiation. The primary endpoint of the trial was tumor metabolic response to metformin by PERCIST before definitive radiation. Stereotactic body radiotherapy to 50 Gy in 4 fractions was used for peripheral tumors and 70 Gy in 10 fractions for central tumors. RESULTS There were 14 subjects randomized to the metformin and 1 to placebo. Histologies were 60% adenocarcinoma, 33.3% squamous cell carcinoma, and 6.7% poorly differentiated carcinoma. At mid-treatment PET scan, 57% of subjects randomized to metformin met PERCIST criteria for metabolic response, of which 75% had progressive metabolic disease and 25% had partial metabolic response, whereas the placebo subject had stable metabolic disease. At 6 months, the metformin arm had 69% complete metabolic response, 23% partial metabolic response and 1 progressive metabolic disease, and the subject treated with placebo had a complete metabolic response. There were no CTCAE grade ≥3 toxicities. CONCLUSIONS Despite low accrual, majority of subjects treated with metformin had metabolic responses by PERCIST criteria on PET imaging. Contrary to the effect of metformin on most physiologic tissues, most tumors had increased metabolic activity in response to metformin.",2020,"There were no CTCAE grade ≥3 toxicities. ","['Inoperable Early-stage Non-Small Cell Lung Cancer', 'inoperable early-stage NSCLC']","['metformin', 'metformin versus placebo', 'Stereotactic Radiotherapy', 'Stereotactic body radiotherapy', 'placebo', 'Metformin', 'positron emission tomography (PET) scans']","['partial metabolic response', 'metabolic activity', 'Metabolic Responses', 'CTCAE grade ≥3 toxicities', 'tumor metabolic response', 'complete metabolic response', 'metabolic response, 23% partial metabolic response and 1 progressive metabolic disease', 'stable metabolic disease', 'progressive metabolic disease']","[{'cui': 'C0205187', 'cui_str': 'Inoperable (qualifier value)'}, {'cui': 'C2363430', 'cui_str': 'Early stage (qualifier value)'}, {'cui': 'C0007131', 'cui_str': 'Nonsmall Cell Lung Cancer'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4552093', 'cui_str': 'Stereotactic Radiation Therapy'}, {'cui': 'C1720823', 'cui_str': 'Stereotactic Body Radiotherapy'}, {'cui': 'C0032743', 'cui_str': 'Positron-Emission Tomography'}, {'cui': 'C0441633'}]","[{'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0025517', 'cui_str': 'Thesaurismosis'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}]",14.0,0.0959454,"There were no CTCAE grade ≥3 toxicities. ","[{'ForeName': 'Stephen G', 'Initials': 'SG', 'LastName': 'Chun', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}, {'ForeName': 'Zhongxing', 'Initials': 'Z', 'LastName': 'Liao', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}, {'ForeName': 'Melenda D', 'Initials': 'MD', 'LastName': 'Jeter', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}, {'ForeName': 'Joe Y', 'Initials': 'JY', 'LastName': 'Chang', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}, {'ForeName': 'Steven H', 'Initials': 'SH', 'LastName': 'Lin', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}, {'ForeName': 'Ritsuko U', 'Initials': 'RU', 'LastName': 'Komaki', 'Affiliation': 'Department of Radiation Oncology, Baylor College of Medicine, Houston, TX.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Guerrero', 'Affiliation': 'Department of Radiation Oncology, William Beaumont School of Medicine, Royal Oak, MI.'}, {'ForeName': 'Ray C', 'Initials': 'RC', 'LastName': 'Mayo', 'Affiliation': 'Departments of Diagnostic Radiology.'}, {'ForeName': 'Bobby M', 'Initials': 'BM', 'LastName': 'Korah', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}, {'ForeName': 'Suja M', 'Initials': 'SM', 'LastName': 'Koshy', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}, {'ForeName': 'John V', 'Initials': 'JV', 'LastName': 'Heymach', 'Affiliation': 'Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas, M.D. Anderson Cancer Center.'}, {'ForeName': 'Albert C', 'Initials': 'AC', 'LastName': 'Koong', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}, {'ForeName': 'Heath D', 'Initials': 'HD', 'LastName': 'Skinner', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}]",American journal of clinical oncology,['10.1097/COC.0000000000000632'] 402,30614823,Beneficial effect of ticagrelor on microvascular perfusion in patients with ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention.,"BACKGROUND Ticagrelor significantly reduced the incidence of death, myocardial infarction, and stent thrombosis in patients with ST-segment elevation myocardial infarction (STEMI) intended for reperfusion with a primary percutaneous coronary intervention (pPCI). However, the effects of this drug on microvascular perfusion in patients presenting with STEMI have not been evaluated completely. PATIENTS AND METHODS A total of 298 patients presenting with STEMI were randomized to either ticagrelor 180 mg loading, followed by 90 mg twice daily, or clopidogrel 600 mg loading, followed by 75 mg daily. The primary endpoint was ST-segment resolution at 90 min after pPCI. The secondary endpoints included myocardial blush grade and corrected thrombolysis in myocardial infarction frame count after the procedure. Left ventricular ejection fraction and major adverse cardiac events (MACE) at the 1- and 6-month follow-up time points were also recorded. RESULTS There were no significant differences between the two groups with respect to baseline characteristics. Ticagrelor administration resulted in a higher rate of completed ST-segment resolution (58.67 vs. 39.86%, P=0.001), higher myocardial blush grade (2.63±0.64 vs. 2.41±0.71, P=0.005), and lower corrected thrombolysis in myocardial infarction frame count (19.68±7.38 vs. 22.35±8.30, P=0.004). At 6 months, left ventricular ejection fraction was higher (55.01±8.44 vs. 52.34±9.05%, P=0.009) in the ticagrelor group. Kaplan-Meier analysis showed that MACE-free survival had also improved in the ticagrelor group during the 1- and 6-month follow-up time points. CONCLUSION Compared with clopidogrel, ticagrelor improves myocardial perfusion and left ventricular ejection fraction, and reduces the incidence of MACE for STEMI patients undergoing pPCI, with no significant increase in major bleeding.",2019,"Compared with clopidogrel, ticagrelor improves myocardial perfusion and left ventricular ejection fraction, and reduces the incidence of MACE for STEMI patients undergoing pPCI, with no significant increase in major bleeding.","['patients with ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention', 'patients with ST-segment elevation myocardial infarction (STEMI) intended for reperfusion with a primary percutaneous coronary intervention (pPCI', 'patients presenting with STEMI', '298 patients presenting with STEMI']","['Ticagrelor', 'clopidogrel, ticagrelor', 'ticagrelor 180\u2009mg loading, followed by 90\u2009mg twice daily, or clopidogrel 600\u2009mg loading, followed by 75\u2009mg daily', 'ticagrelor']","['ST-segment resolution', 'left ventricular ejection fraction', 'microvascular perfusion', 'higher rate of completed ST-segment resolution', 'myocardial infarction frame count', 'MACE-free survival', 'higher myocardial blush grade', 'myocardial perfusion and left ventricular ejection fraction', 'major bleeding', 'Left ventricular ejection fraction and major adverse cardiac events (MACE', 'myocardial blush grade and corrected thrombolysis in myocardial infarction frame count', 'incidence of death, myocardial infarction, and stent thrombosis']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1536220', 'cui_str': 'ST Elevated Myocardial Infarction'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C0035124', 'cui_str': 'Reperfusion'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}]","[{'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}]","[{'cui': 'C0429029', 'cui_str': 'ST segment (observable entity)'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0443258', 'cui_str': 'Microvascular (qualifier value)'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0180979', 'cui_str': 'Frame (physical object)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0349381', 'cui_str': 'Mace (substance)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0005874', 'cui_str': 'Blushings'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0428857', 'cui_str': 'Myocardial perfusion (observable entity)'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction (observable entity)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis, function (observable entity)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}]",298.0,0.0480864,"Compared with clopidogrel, ticagrelor improves myocardial perfusion and left ventricular ejection fraction, and reduces the incidence of MACE for STEMI patients undergoing pPCI, with no significant increase in major bleeding.","[{'ForeName': 'Xuechao', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ""Department of Cardiology, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China.""}, {'ForeName': 'Xinning', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Haibo', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Ruyi', 'Initials': 'R', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Huiliang', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Shiru', 'Initials': 'S', 'LastName': 'Bai', 'Affiliation': ''}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Tianlei', 'Initials': 'T', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Rongpin', 'Initials': 'R', 'LastName': 'Du', 'Affiliation': ''}]",Coronary artery disease,['10.1097/MCA.0000000000000707'] 403,32220520,Effect of Progressive Muscle Relaxation Exercise on Postoperative Pain Level in Patients Undergoing Open Renal Surgery: A Nonrandomized Evaluation.,"PURPOSE To investigate the effect of progressive muscle relaxation (PMR) exercise on pain and vital signs in patients undergoing open renal surgery. DESIGN Nonrandomized evaluation with intervention (n = 31) and control (n = 30) groups. METHODS In the intervention group, PMR exercise was performed twice daily on postoperative days 0, 1, 2, and 3. Pain severity and vital signs were evaluated 15 minutes after each exercise application. FINDINGS The study detected significant differences in the mean visual analog scale pain severity values in the intervention group, who received PMR exercise between 0 and 3 days. The repeated measurements 15 minutes after PMR exercise exhibited a statistically significant (P < .05) decrease in systolic blood pressure values as well as heart and respiratory rates. CONCLUSIONS It was determined that PMR decreased the mean postoperative visual analog scale pain scores and vital signs in patients of the intervention group compared with the control group.",2020,It was determined that PMR decreased the mean postoperative visual analog scale pain scores and vital signs in patients of the intervention group compared with the control group.,"['patients undergoing open renal surgery', 'Patients Undergoing Open Renal Surgery']","['progressive muscle relaxation (PMR) exercise', 'Progressive Muscle Relaxation Exercise', 'PMR exercise']","['Pain severity and vital signs', 'mean visual analog scale pain severity values', 'pain and vital signs', 'Postoperative Pain Level', 'systolic blood pressure values', 'heart and respiratory rates', 'mean postoperative visual analog scale pain scores and vital signs']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0194053', 'cui_str': 'Kidney operation (procedure)'}]","[{'cui': 'C0004361', 'cui_str': 'Progressive Relaxation'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0518766'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0231832', 'cui_str': 'Respiration Rate'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C2732809', 'cui_str': 'Visual analog scale pain score (observable entity)'}]",,0.0289078,It was determined that PMR decreased the mean postoperative visual analog scale pain scores and vital signs in patients of the intervention group compared with the control group.,"[{'ForeName': 'Mihriban', 'Initials': 'M', 'LastName': 'Kısaarslan', 'Affiliation': 'Department of Nursing, Akdeniz University Hospital, Antalya, Turkey.'}, {'ForeName': 'Nilgün', 'Initials': 'N', 'LastName': 'Aksoy', 'Affiliation': 'Faculty of Nursing, Akdeniz University, Antalya, Turkey. Electronic address: nilgunmutluaksoy@akdeniz.edu.tr.'}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2019.12.003'] 404,32027842,"Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study.","BACKGROUND The monoclonal antibody m102.4 is a potent, fully human antibody that neutralises Hendra and Nipah viruses in vitro and in vivo. We aimed to investigate the safety, tolerability, pharmacokinetics, and immunogenicity of m102.4 in healthy adults. METHODS In this double-blind, placebo-controlled, single-centre, dose-escalation, phase 1 trial of m102.4, we randomly assigned healthy adults aged 18-50 years with a body-mass index of 18·0-35·0 kg/m 2 to one of five cohorts. A sentinel pair for each cohort was randomly assigned to either m102.4 or placebo. The remaining participants in each cohort were randomly assigned (5:1) to receive m102.4 or placebo. Cohorts 1-4 received a single intravenous infusion of m102.4 at doses of 1 mg/kg (cohort 1), 3 mg/kg (cohort 2), 10 mg/kg (cohort 3), and 20 mg/kg (cohort 4), and were monitored for 113 days. Cohort 5 received two infusions of 20 mg/kg 72 h apart and were monitored for 123 days. The primary outcomes were safety and tolerability. Secondary outcomes were pharmacokinetics and immunogenicity. Analyses were completed according to protocol. The study was registered on the Australian New Zealand Clinical Trials Registry, ACTRN12615000395538. FINDINGS Between March 27, 2015, and June 16, 2016, 40 (52%) of 77 healthy screened adults were enrolled in the study. Eight participants were assigned to each cohort (six received m102.4 and two received placebo). 86 treatment-emergent adverse events were reported, with similar rates between placebo and treatment groups. The most common treatment-related event was headache (12 [40%] of 30 participants in the combined m102.4 group, and three [30%] of ten participants in the pooled placebo group). No deaths or severe adverse events leading to study discontinuation occurred. Pharmacokinetics based on those receiving m102.4 (n=30) were linear, with a median half-life of 663·3 h (range 474·3-735·1) for cohort 1, 466·3 h (382·8-522·3) for cohort 2, 397·0 h (333·9-491·8) for cohort 3, and 466·7 h (351·0-889·6) for cohort 4. The elimination kinetics of those receiving repeated dosing (cohort 5) were similar to those of single-dose recipients (median elimination half-time 472·0 [385·6-592·0]). Anti-m102.4 antibodies were not detected at any time-point during the study. INTERPRETATION Single and repeated dosing of m102.4 were well tolerated and safe, displayed linear pharmacokinetics, and showed no evidence of an immunogenic response. This study will inform future dosing regimens for m102.4 to achieve prolonged exposure for systemic efficacy to prevent and treat henipavirus infections. FUNDING Queensland Department of Health, the National Health and Medical Research Council, and the National Hendra Virus Research Program.",2020,"BACKGROUND The monoclonal antibody m102.4 is a potent, fully human antibody that neutralises Hendra and Nipah viruses in vitro and in vivo.","['Between March 27, 2015, and June 16, 2016, 40 (52%) of 77 healthy screened adults were enrolled in the study', 'healthy adults', 'healthy adults aged 18-50 years with a body-mass index of 18·0-35·0 kg/m 2 to one of five cohorts']","['human monoclonal antibody targeting the G glycoprotein', 'placebo']","['pharmacokinetics and immunogenicity', 'safety and tolerability', 'headache', 'tolerated and safe', 'Safety, tolerability, pharmacokinetics, and immunogenicity', 'elimination kinetics', 'safety, tolerability, pharmacokinetics, and immunogenicity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C3542957', 'cui_str': 'Antineoplastic MAbs'}, {'cui': 'C0017968', 'cui_str': 'Glycoproteins'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}]",8.0,0.485018,"BACKGROUND The monoclonal antibody m102.4 is a potent, fully human antibody that neutralises Hendra and Nipah viruses in vitro and in vivo.","[{'ForeName': 'Elliott Geoffrey', 'Initials': 'EG', 'LastName': 'Playford', 'Affiliation': 'Infection Management Services, Princess Alexandra Hospital, Brisbane, QLD, Australia; School of Medicine, University of Queensland Brisbane, QLD, Australia. Electronic address: geoffrey.Playford@health.qld.gov.au.'}, {'ForeName': 'Trent', 'Initials': 'T', 'LastName': 'Munro', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Stephen M', 'Initials': 'SM', 'LastName': 'Mahler', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia; ARC Training Centre for Biopharmaceutical Innovation, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Elliott', 'Affiliation': 'Q-Pharm, Clive Berghofer Cancer Research Centre, Herston, QLD, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Gerometta', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Kym L', 'Initials': 'KL', 'LastName': 'Hoger', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Martina L', 'Initials': 'ML', 'LastName': 'Jones', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia; ARC Training Centre for Biopharmaceutical Innovation, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Griffin', 'Affiliation': 'Q-Pharm, Clive Berghofer Cancer Research Centre, Herston, QLD, Australia; Clinical Tropical Medicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.'}, {'ForeName': 'Kathleen D', 'Initials': 'KD', 'LastName': 'Lynch', 'Affiliation': 'Child Health Research Centre, Faculty of Medicine, University of Queensland Brisbane, QLD, Australia; Communicable Disease Branch, Prevention Division, Queensland Health, Brisbane, QLD, Australia.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Carroll', 'Affiliation': 'Communicable Disease Branch, Prevention Division, Queensland Health, Brisbane, QLD, Australia.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'El Saadi', 'Affiliation': 'Communicable Disease Branch, Prevention Division, Queensland Health, Brisbane, QLD, Australia.'}, {'ForeName': 'Margaret E', 'Initials': 'ME', 'LastName': 'Gilmour', 'Affiliation': 'Q-Pharm, Clive Berghofer Cancer Research Centre, Herston, QLD, Australia.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Hughes', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Hughes', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Edwin', 'Initials': 'E', 'LastName': 'Huang', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'de Bakker', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Reuben', 'Initials': 'R', 'LastName': 'Klein', 'Affiliation': 'Health and Biosecurity Business Unit, CSIRO Australian Animal Health Laboratory, Geelong, VIC, Australia.'}, {'ForeName': 'Mark G', 'Initials': 'MG', 'LastName': 'Scher', 'Affiliation': 'Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.'}, {'ForeName': 'Ina L', 'Initials': 'IL', 'LastName': 'Smith', 'Affiliation': 'Health and Biosecurity Business Unit, CSIRO Australian Animal Health Laboratory, Geelong, VIC, Australia.'}, {'ForeName': 'Lin-Fa', 'Initials': 'LF', 'LastName': 'Wang', 'Affiliation': 'Health and Biosecurity Business Unit, CSIRO Australian Animal Health Laboratory, Geelong, VIC, Australia; Programme in Emerging Infectious Diseases, Duke-National University Medical School, Singapore.'}, {'ForeName': 'Stephen B', 'Initials': 'SB', 'LastName': 'Lambert', 'Affiliation': 'Child Health Research Centre, Faculty of Medicine, University of Queensland Brisbane, QLD, Australia; Communicable Disease Branch, Prevention Division, Queensland Health, Brisbane, QLD, Australia.'}, {'ForeName': 'Dimiter S', 'Initials': 'DS', 'LastName': 'Dimitrov', 'Affiliation': 'Center for Antibody Therapeutics, University of Pittsburgh Medical School, Pittsburgh, PA, USA.'}, {'ForeName': 'Peter P', 'Initials': 'PP', 'LastName': 'Gray', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia; ARC Training Centre for Biopharmaceutical Innovation, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Christopher C', 'Initials': 'CC', 'LastName': 'Broder', 'Affiliation': 'Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(19)30634-6'] 405,32220893,Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer.,"PURPOSE We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy. EXPERIMENTAL DESIGN The Sequencing Triplet With Avastin and Maintenance (STEAM) was a randomized, phase II trial investigating efficacy of bevacizumab (BEV) plus 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI), administered concurrently or sequentially, versus FOLFOX-BEV in first-line mCRC. Evaluation of biomarkers associated with treatment outcomes was an exploratory endpoint. Patients in the biomarker-evaluable population (BEP) had 1 tissue sample, 1 pre-induction plasma sample, and 1 post-induction plasma sample collected ≤60 days of induction from last drug date. RESULTS Among the 280 patients enrolled in STEAM, 183 had sequenced and evaluable tumor tissue, 118 had matched pre-induction plasma, and 54 (BEP) had ctDNA-evaluable sequencing data for pre- and post-induction plasma. The most common somatic variants in tumor tissue and pre-induction plasma were TP53, APC , and KRAS . Patients with lower-than-median versus higher-than-median post-induction mean allele fraction (mAF) levels had longer median PFS (17.7 vs. 7.5 months, HR, 0.33; 95% confidence interval, 0.17-0.63). Higher levels of post-induction mAF and post-induction mean mutant molecules per milliliter (mMMPM), and changes in ctDNA (stratified by a 10-fold or 100-fold reduction in mAF between pre- and post-induction plasma), were associated with shorter PFS. Post-induction mAF and mMMPM generally correlated with each other ( ρ = 0.987, P < 0.0001). CONCLUSIONS ctDNA quantification in post-induction plasma may serve as a prognostic biomarker for mCRC post-treatment outcomes.",2020,"Post-induction mAF and mMMPM generally correlated with each other ( r = 0.987, P < 0.0001). ","['280 patients enrolled in STEAM, 183 had sequenced and evaluable tumor tissue, 118 had matched pre-induction plasma, and 54 (BEP) had ctDNA-evaluable sequencing data for pre- and post-induction plasma', 'Patients in the biomarker evaluable population (BEP) had 1 tissue sample, 1 pre-induction plasma sample, and 1 post-induction plasma sample collected ≤60 days of induction from last drug date', 'Patients with Metastatic Colorectal Cancer']","['bevacizumab (BEV) plus 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI', 'Disease Monitoring Using Post-Induction Circulating Tumor DNA Analysis Following First-Line Therapy']","['median PFS', 'Higher levels of post-induction mAF and post-induction mean mutant molecules per milliliter (mMMPM), and changes in ctDNA', 'plasma circulating tumor DNA (ctDNA) level']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0038225', 'cui_str': 'Steam'}, {'cui': 'C4517615', 'cui_str': 'One hundred and eighty-three'}, {'cui': 'C0475358', 'cui_str': 'Tumor tissue sample (specimen)'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0444263', 'cui_str': 'Plasma specimen'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0011008', 'cui_str': 'Dates'}, {'cui': 'C0346973', 'cui_str': 'Secondary malignant neoplasm of large intestine'}]","[{'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C2721771', 'cui_str': 'levoleucovorin'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C3827014', 'cui_str': 'Cell-Free Tumor DNA'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0079786', 'cui_str': 'Macrophage-Activating Factors'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0567416', 'cui_str': 'Molecule (substance)'}, {'cui': 'C0439526', 'cui_str': 'per milliliter'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C3827014', 'cui_str': 'Cell-Free Tumor DNA'}]",280.0,0.0324867,"Post-induction mAF and mMMPM generally correlated with each other ( r = 0.987, P < 0.0001). ","[{'ForeName': 'Xiaoju', 'Initials': 'X', 'LastName': 'Max Ma', 'Affiliation': 'Medical Scientific Affairs, Roche Sequencing Solutions, Inc., Pleasanton, California. xiaoju.ma@gmail.com john.palma@roche.com.'}, {'ForeName': 'Johanna C', 'Initials': 'JC', 'LastName': 'Bendell', 'Affiliation': 'Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.'}, {'ForeName': 'Herbert I', 'Initials': 'HI', 'LastName': 'Hurwitz', 'Affiliation': 'Project Development Oncology, Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Ju', 'Affiliation': 'Clinical Operations and Biometrics, Roche Molecular Systems, Pleasanton, California.'}, {'ForeName': 'John J', 'Initials': 'JJ', 'LastName': 'Lee', 'Affiliation': 'Medical Scientific Affairs, Roche Sequencing Solutions, Inc., Pleasanton, California.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Lovejoy', 'Affiliation': 'Assay Development, Roche Sequencing Solutions, Inc., Pleasanton, California.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Mancao', 'Affiliation': 'Oncology Biomarker Development, Genentech, Inc., Basel, Switzerland.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Nicholas', 'Affiliation': 'US Medical Affairs and Biometrics, Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Price', 'Affiliation': 'Oncology Biomarker Development, Genentech, Inc., Basel, Switzerland.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Sommer', 'Affiliation': 'Medical Affairs BioOncology, Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Nalin', 'Initials': 'N', 'LastName': 'Tikoo', 'Affiliation': 'Clinical Operations and Biometrics, Roche Molecular Systems, Pleasanton, California.'}, {'ForeName': 'Lijing', 'Initials': 'L', 'LastName': 'Yao', 'Affiliation': 'Bioinformatics Research and Early Development, Roche Sequencing Solutions, Inc., Pleasanton, California.'}, {'ForeName': 'Stephanie J', 'Initials': 'SJ', 'LastName': 'Yaung', 'Affiliation': 'Medical and Scientific Affairs Bioinformatics, Roche Sequencing Solutions, Inc., Pleasanton, California.'}, {'ForeName': 'John F', 'Initials': 'JF', 'LastName': 'Palma', 'Affiliation': 'Medical Scientific Affairs, Roche Sequencing Solutions, Inc., Pleasanton, California. xiaoju.ma@gmail.com john.palma@roche.com.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-19-1209'] 406,31771942,A Calcium-Rich Multimineral Intervention to Modulate Colonic Microbial Communities and Metabolomic Profiles in Humans: Results from a 90-Day Trial.,"Aquamin is a calcium-, magnesium-, and multiple trace element-rich natural product with colon polyp prevention efficacy based on preclinical studies. The goal of this study was to determine the effects of Aquamin on colonic microbial community and attendant metabolomic profile. Thirty healthy human participants were enrolled in a 90-day trial in which Aquamin (delivering 800 mg of calcium per day) was compared with calcium alone or placebo. Before and after the intervention, colonic biopsies and stool specimens were obtained. All 30 participants completed the study without serious adverse event or change in liver and renal function markers. Compared with pretreatment values, intervention with Aquamin led to a reduction in total bacterial DNA ( P = 0.0001) and a shift in the microbial community measured by thetaYC (θ YC ; P = 0.0087). Treatment with calcium also produced a decline in total bacteria, but smaller than seen with Aquamin, whereas no reduction was observed with placebo in the colon. In parallel with microbial changes, a reduction in total bile acid levels ( P = 0.0375) and a slight increase in the level of the short-chain fatty acid (SCFA) acetate in stool specimens ( P < 0.0001) from Aquamin-treated participants were noted. No change in bile acids or SCFAs was observed with calcium or placebo. We conclude that Aquamin is safe and tolerable in healthy human participants and may produce beneficial alterations in the colonic microbial community and the attendant metabolomic profile. Because the number of participants was small, the findings should be considered preliminary.",2020,"Compared to pretreatment values, intervention with Aquamin® led to a reduction in total bacterial DNA (p=0.0001) and a shift in the microbial community measured by thetaYC (ΘYC) (p=0.0087).","['Humans', 'healthy human participants', 'Thirty healthy human participants']","['calcium alone or placebo', 'placebo', 'Calcium-Rich Multi-Mineral Intervention', 'Aquamin®', 'Aquamin® (delivering 800 mg of calcium']","['level of the short-chain fatty acid (SCFA) acetate', 'bile acids or SCFAs', 'total bacteria', 'total bacterial DNA', 'total bile acid levels', 'colonic microbial community and attendant metabolomic profile', 'serious adverse event or change in liver and renal function markers']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C3816446', 'cui_str': '30'}]","[{'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0026162', 'cui_str': 'Minerals'}, {'cui': 'C3492777', 'cui_str': 'Aquamin'}, {'cui': 'C3844106', 'cui_str': 'Eight hundred'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0015691', 'cui_str': 'Fatty Acids, Short-Chain'}, {'cui': 'C0000975', 'cui_str': 'Acetate'}, {'cui': 'C0005390', 'cui_str': 'Bile Acids'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1510439', 'cui_str': 'bacteria'}, {'cui': 'C0012924', 'cui_str': 'DNA, Bacterial'}, {'cui': 'C0201914', 'cui_str': 'Total bile acids measurement (procedure)'}, {'cui': 'C0009368', 'cui_str': 'Colon'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C1328813', 'cui_str': 'Metabolomic'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}]",30.0,0.0487427,"Compared to pretreatment values, intervention with Aquamin® led to a reduction in total bacterial DNA (p=0.0001) and a shift in the microbial community measured by thetaYC (ΘYC) (p=0.0087).","[{'ForeName': 'Muhammad N', 'Initials': 'MN', 'LastName': 'Aslam', 'Affiliation': 'Department of Pathology, The University of Michigan Medical School, Ann Arbor, Michigan. mnaslam@med.umich.edu.'}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Bassis', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, Michigan.'}, {'ForeName': 'Ingrid L', 'Initials': 'IL', 'LastName': 'Bergin', 'Affiliation': 'The Unit for Laboratory Animal Medicine, The University of Michigan Medical School, Ann Arbor, Michigan.'}, {'ForeName': 'Karsten', 'Initials': 'K', 'LastName': 'Knuver', 'Affiliation': 'Department of Pathology, The University of Michigan Medical School, Ann Arbor, Michigan.'}, {'ForeName': 'Suzanna M', 'Initials': 'SM', 'LastName': 'Zick', 'Affiliation': 'Department of Family Medicine, The University of Michigan Medical School, Ann Arbor, Michigan.'}, {'ForeName': 'Ananda', 'Initials': 'A', 'LastName': 'Sen', 'Affiliation': 'Department of Family Medicine, The University of Michigan Medical School, Ann Arbor, Michigan.'}, {'ForeName': 'D Kim', 'Initials': 'DK', 'LastName': 'Turgeon', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, Michigan.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Varani', 'Affiliation': 'Department of Pathology, The University of Michigan Medical School, Ann Arbor, Michigan.'}]","Cancer prevention research (Philadelphia, Pa.)",['10.1158/1940-6207.CAPR-19-0325'] 407,32221819,Voluntary Vs Nominated Peer Educators: a Randomized Trial within the NoTrap! Anti-Bullying Program.,"There is a debate in scientific literature about the effectiveness of a peer-led approach to anti-bullying interventions. In order to understand which circumstances and for whom these approaches work best, the present study was carried out within the NoTrap! anti-bullying program. Using a cluster design, classes were randomly assigned into two different peer educator recruitment strategies: volunteering (N = 500; 48% females; mean age = 13.5 years, ds = 1.3) vs peer nominated (N = 466; 38% females; mean age = 13.9 years, ds = 1.3). Results showed that voluntary peer educators suffered a higher level of victimization, while the nominated ones tended to be more popular and likable. Furthermore, a set of linear mixed-effect models showed that the program was effective in reducing bullying and victimization, and in increasing defending behaviour only in the voluntary recruitment condition. On the contrary, in classrooms under the peer nominated recruitment condition, bullying and victimization remained stable, and defending behaviour increased only for peer educators, but not for their classmates. This implies that the step of peer selection and recruitment must be kept into consideration in developing and validating an intervention, because of its possible impact on the effectiveness of the whole intervention.",2020,"Furthermore, a set of linear mixed-effect models showed that the program was effective in reducing bullying and victimization, and in increasing defending behaviour only in the voluntary recruitment condition.","['N\u2009=\u2009500; 48% females; mean age\u2009=\u200913.5\xa0years, ds\u2009=\u20091.3) vs peer nominated (N\u2009=\u2009466; 38% females; mean age\u2009=\u200913.9\xa0years, ds\u2009=\u20091.3']","['Voluntary Vs Nominated Peer Educators', 'peer educator recruitment strategies: volunteering']",['level of victimization'],"[{'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517559', 'cui_str': '13.5 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517499', 'cui_str': '1.3 (qualifier value)'}, {'cui': 'C4517562', 'cui_str': '13.9 (qualifier value)'}]","[{'cui': 'C0439656', 'cui_str': 'Voluntary (qualifier value)'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0376695', 'cui_str': 'Victimization'}]",,0.0193506,"Furthermore, a set of linear mixed-effect models showed that the program was effective in reducing bullying and victimization, and in increasing defending behaviour only in the voluntary recruitment condition.","[{'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Zambuto', 'Affiliation': 'Department of Education, Languages, Interculture, Literature and Psychology, University of Florence, Sede di via di San Salvi 12, Padiglione 26, 50135, Florence, Italy.'}, {'ForeName': 'Benedetta Emanuela', 'Initials': 'BE', 'LastName': 'Palladino', 'Affiliation': 'Department of Education, Languages, Interculture, Literature and Psychology, University of Florence, Sede di via di San Salvi 12, Padiglione 26, 50135, Florence, Italy. benedettaemanuela.palladino@unifi.it.'}, {'ForeName': 'Annalaura', 'Initials': 'A', 'LastName': 'Nocentini', 'Affiliation': 'Department of Education, Languages, Interculture, Literature and Psychology, University of Florence, Sede di via di San Salvi 12, Padiglione 26, 50135, Florence, Italy.'}, {'ForeName': 'Ersilia', 'Initials': 'E', 'LastName': 'Menesini', 'Affiliation': 'Department of Education, Languages, Interculture, Literature and Psychology, University of Florence, Sede di via di San Salvi 12, Padiglione 26, 50135, Florence, Italy.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-020-01108-4'] 408,31952923,"Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.","BACKGROUND The safety and immunogenicity of a highly attenuated recombinant vesicular stomatitis virus (rVSV) expressing HIV-1 gag (rVSVN4CT1-HIV-1gag1) was shown in previous phase 1 clinical studies. An rVSV vector expressing Ebola virus glycoprotein (EBOV-GP) in place of HIV-1 gag (rVSVN4CT1-EBOVGP1) showed single-dose protection from lethal challenge with low passage Ebola virus in non-human primates. We aimed to evaluate the safety and immunogenicity of the rVSVN4CT1-EBOVGP1 vaccine in healthy adults. METHODS We did a randomised double-blind, placebo-controlled, phase 1 dose-escalation study at a single clinical site (Optimal Research) in Melbourne, FL, USA. Eligible participants were healthy men and non-pregnant women aged 18-60 years, with a body-mass index (BMI) of less than 40 kg/m 2 , no history of filovirus infection, VSV infection, or receipt of rVSV in previous studies, and who had not visited regions where Ebola virus outbreaks have occurred. Three cohorts were enrolled to assess a low (2·5 × 10 4 plaque forming units [PFU]), intermediate (2 × 10 5 PFU), or high dose (1·8 × 10 6 PFU) of the vaccine. Participants within each cohort were randomly allocated (10:3) to receive vaccine or placebo by intramuscular injection in a homologous prime and boost regimen, with 4 weeks between doses. All syringes were masked with syringe sleeves; participants and study site staff were not blinded to dose level but were blinded to active vaccine and placebo. The primary outcomes were safety and tolerability; immunogenicity, assessed as GP-specific humoral immune response (at 2 weeks after each dose) and cellular immune response (at 1 and 2 weeks after each dose), was a secondary outcome. All randomised participants were included in primary and safety analyses. This trial is registered with ClinicalTrials.gov, NCT02718469. FINDINGS Between Dec 22, 2015, and Sept 15, 2016, 39 individuals (18 [46%] men and 21 [54%] women, mean age 51 years [SD 10]) were enrolled, with ten participants receiving the vaccine and three participants receiving placebo in each of three cohorts. One participant in the intermediate dose cohort was withdrawn from the study because of a diagnosis of invasive ductal breast carcinoma 24 days after the first vaccination, which was considered unrelated to the vaccine. No severe adverse events were observed. Solicited local adverse events occurred in ten (26%) of 39 participants after the first dose and nine (24%) of 38 participants after the second dose; the events lasted 3 days or less, were predominantly injection site tenderness (17 events) and injection site pain (ten events), and were either mild (19 events) or moderate (ten events) in intensity. Systemic adverse events occurred in 13 (33%) of 39 participants after the first dose and eight (21%) of 38 participants after the second dose; the events were mild (45 events) or moderate (11 events) in severity, and the most common events were malaise or fatigue (13 events) and headache (12 events). Arthritis and maculopapular, vesicular, or purpuric rash distal to the vaccination site(s) were not reported. A GP-specific IgG response was detected in all vaccine recipients after two doses (and IgG response frequency was 100% after a single high dose), and an Ebola virus neutralising response was detected in 100% of participants in the high-dose cohort. INTERPRETATION The rVSVN4CT1-EBOVGP1 vaccine was well tolerated at all dose levels tested and was immunogenic despite a high degree of attenuation. The combined safety and immunogenicity profile of the rVSVN4CT1-EBOVGP1 vaccine vector support phase 1-2 clinical evaluation. FUNDING US Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense: Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical.",2020,"A GP-specific IgG response was detected in all vaccine recipients after two doses (and IgG response frequency was 100% after a single high dose), and an Ebola virus neutralising response was detected in 100% of participants in the high-dose cohort. ","['Eligible participants were healthy men and non-pregnant women aged 18-60 years, with a body-mass index (BMI) of less than 40 kg/m 2 , no history of filovirus infection, VSV infection, or receipt of rVSV in previous studies, and who had not visited regions where Ebola virus outbreaks have occurred', 'Participants within each cohort', 'Between Dec 22, 2015, and Sept 15, 2016, 39 individuals (18 [46%] men and 21 [54%] women, mean age 51 years [SD 10]) were enrolled, with ten participants receiving the vaccine and three participants receiving', 'healthy adults', 'Three cohorts were enrolled to assess a low (2·5\u2008×\u200810 4 plaque forming units [PFU]), intermediate (2\u2008×\u200810 5 PFU), or high dose']","['placebo', 'rVSVN4CT1-EBOVGP1 Ebola virus vaccine', 'rVSVN4CT1-EBOVGP1 vaccine', 'rVSVN4CT1-EBOVGP1 vaccine vector', 'vaccine or placebo', 'vaccine', 'rVSV vector expressing Ebola virus glycoprotein (EBOV-GP', 'recombinant vesicular stomatitis virus (rVSV) expressing HIV-1 gag (rVSVN4CT1-HIV-1gag1']","['safety and immunogenicity', 'safety and tolerability; immunogenicity, assessed as GP-specific humoral immune response', 'injection site pain', 'severe adverse events', 'Ebola virus neutralising response', 'Systemic adverse events', 'Safety and immunogenicity', 'cellular immune response', 'Solicited local adverse events', 'malaise or fatigue (13 events) and headache']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0332122', 'cui_str': 'No history of (contextual qualifier) (qualifier value)'}, {'cui': 'C0242917', 'cui_str': 'Filovirus Infections'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0949892', 'cui_str': 'Ebola Virus'}, {'cui': 'C0220888', 'cui_str': 'outbreaks'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1449556', 'cui_str': 'Ebola Vaccines'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0442335', 'cui_str': 'Vectors (qualifier value)'}, {'cui': 'C0949892', 'cui_str': 'Ebola Virus'}, {'cui': 'C0017968', 'cui_str': 'Glycoproteins'}, {'cui': 'C1623048', 'cui_str': 'Vesicular stomatitis virus (organism)'}, {'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0328767', 'cui_str': 'Mycteroperca microlepis (organism)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C1155229'}, {'cui': 'C0151828', 'cui_str': 'Injection site pain (disorder)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0949892', 'cui_str': 'Ebola Virus'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C1817908', 'cui_str': 'Cellular Immune Response'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0231218', 'cui_str': 'Undifferentiated illness: Vague ill health'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}]",39.0,0.56335,"A GP-specific IgG response was detected in all vaccine recipients after two doses (and IgG response frequency was 100% after a single high dose), and an Ebola virus neutralising response was detected in 100% of participants in the high-dose cohort. ","[{'ForeName': 'David K', 'Initials': 'DK', 'LastName': 'Clarke', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA. Electronic address: dclarke@profectusbiosciences.com.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Xu', 'Affiliation': 'Department of Immunology, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Demetrius', 'Initials': 'D', 'LastName': 'Matassov', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Theresa E', 'Initials': 'TE', 'LastName': 'Latham', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Ayuko', 'Initials': 'A', 'LastName': 'Ota-Setlik', 'Affiliation': 'Department of Immunology, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Cheryl S', 'Initials': 'CS', 'LastName': 'Gerardi', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Amara', 'Initials': 'A', 'LastName': 'Luckay', 'Affiliation': 'Department of Immunology, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Susan E', 'Initials': 'SE', 'LastName': 'Witko', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Luz', 'Initials': 'L', 'LastName': 'Hermida', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Terry', 'Initials': 'T', 'LastName': 'Higgins', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Tremblay', 'Affiliation': 'Department of Quality Assurance, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Sciotto-Brown', 'Affiliation': 'Department of Regulatory Affairs, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Chen', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Egan', 'Affiliation': 'Bill and Melinda Gates Medical Research Institute, Cambridge, MA, USA.'}, {'ForeName': 'Janice M', 'Initials': 'JM', 'LastName': 'Rusnak', 'Affiliation': 'Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical, Fort Detrick, MD, USA.'}, {'ForeName': 'Lucy A', 'Initials': 'LA', 'LastName': 'Ward', 'Affiliation': 'Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical, Fort Detrick, MD, USA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Eldridge', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA; Department of Immunology, Profectus BioSciences, Pearl River, NY, USA.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(19)30614-0'] 409,31634286,Early Effects of the Trauma Collaborative Care Intervention: Results From a Prospective Multicenter Cluster Clinical Trial.,"OBJECTIVES To evaluate the impact of the Trauma Collaborative Care (TCC) program's early intervention components on 6-week outcomes. TCC was developed to improve psychosocial sequelae of orthopaedic trauma and includes the Trauma Survivors Network and additional collaborative care services. DESIGN Prospective, multicenter, cluster clinical trial. SETTING Level I Trauma Centers. PATIENTS Individuals with high-energy orthopaedic injuries requiring surgery and hospital admission: 413 patients at 6 trauma centers implementing the TCC program and 374 patients at 6 trauma centers receiving usual care. INTERVENTION TCC early intervention: patient education, peer visits, and coaching calls. MAIN OUTCOME MEASUREMENTS Pain rating scale, Patient Health Questionnaire-9 depression, Post-Traumatic Stress Disorder Checklist, and self-efficacy for return to work and managing finances. For each outcome, a hybrid Bayesian statistical procedure, accounting for clustering within sites and differences in baseline characteristics between sites, was used to estimate the intention-to-treat (ITT) effect and the effect under full receipt of early intervention components. RESULTS Sites varied substantially in utilization of intervention components. The posterior estimates of the ITT (full receipt) effect favor TCC for 4 (5) of the 5 endpoints. The posterior probabilities of a favorable (ITT; full receipt) TCC effect were as follows: depression (89%-93%), pain (84%-74%), post-traumatic stress disorder (68%-68%), self-efficacy for return to work (74%-76%), and self-efficacy for managing finances (47%-61%). CONCLUSIONS Results suggest TCC may have a small positive effect on early outcomes, but use of the services was highly variable among sites. LEVEL OF EVIDENCE Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.",2019,The posterior estimates of the ITT (full receipt) effect favor TCC for 4 (5) of the 5 endpoints.,"['Level I Trauma Centers', 'Individuals with high-energy orthopaedic injuries requiring surgery and hospital admission: 413 patients at 6 trauma centers implementing the TCC program and 374 patients at 6 trauma centers receiving usual care']","['TCC', 'Trauma Collaborative Care (TCC', 'Trauma Collaborative Care Intervention', 'TCC early intervention: patient education, peer visits, and coaching calls']","['TCC effect', 'posterior probabilities of a favorable (ITT; full receipt', 'psychosocial sequelae of orthopaedic trauma', 'intention-to-treat (ITT) effect', 'depression', 'Pain rating scale, Patient Health Questionnaire-9 depression, Post-Traumatic Stress Disorder Checklist, and self-efficacy for return to work and managing finances', 'pain', 'post-traumatic stress disorder', 'self-efficacy']","[{'cui': 'C0441925', 'cui_str': 'Level I (tumor staging)'}, {'cui': 'C0040786', 'cui_str': 'Trauma Centers'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission (procedure)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C1098189', 'cui_str': 'tetrakis(2-amino-5-ethyl-1,3,4-thiadiazole-N3)chlorocopper(II) chloride'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C1098189', 'cui_str': 'tetrakis(2-amino-5-ethyl-1,3,4-thiadiazole-N3)chlorocopper(II) chloride'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0242687', 'cui_str': 'Early Intervention'}, {'cui': 'C0030688', 'cui_str': 'Education of Patients'}, {'cui': 'C0557773', 'cui_str': 'Coach (physical object)'}, {'cui': 'C1720420', 'cui_str': 'Call'}]","[{'cui': 'C1098189', 'cui_str': 'tetrakis(2-amino-5-ethyl-1,3,4-thiadiazole-N3)chlorocopper(II) chloride'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0243088', 'cui_str': 'sequelae'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0222045'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0425105', 'cui_str': 'Back to Work'}, {'cui': 'C0376243', 'cui_str': 'finances'}]",413.0,0.137861,The posterior estimates of the ITT (full receipt) effect favor TCC for 4 (5) of the 5 endpoints.,"[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of orthopaedic trauma,['10.1097/BOT.0000000000001581'] 410,31107694,Traditional Chinese medicine training for cardiac rehabilitation: a randomized comparison with aerobic and resistance training.,"BACKGROUND The aim of this study was to investigate the efficacy and safety of different exercise regimens in the rehabilitation of patients with stable coronary heart disease. PATIENTS AND METHODS This study was a randomized controlled trial to screen 141 patients with stable coronary heart disease who were admitted to the General Administration of Sport of China Sports Medical Science Institute from January 2018 to September 2018. They were randomly divided into the aerobic and resistance training (ART) group for 12 weeks (36 cases), the traditional Chinese medicine training (TCMT) group 12 weeks (37 cases), and the control (CON) group (39 cases). We analyzed the baseline parameters of all participants and the 12-week exercise plate test parameters and related physical and body parameters. RESULT After 12 weeks of intervention, volume of oxygen (VO2), VO2/kg, metabolic equivalents, VO2/heart rate, stroke volume, and peaked grip strength and flexibility parameters of the ART group and the TCMT group were significantly higher than those of the control group (P<0.05). Resting heart rate of the TCMT group was significantly lower than the CON group, but there was no significant difference between the ART and CON groups (P>0.05). Ventilation/VO2 of the TCMT group was significantly higher than that of the CON group. BMI of the ART group was significantly lower than that of the TCMT group and the CON group, and body fat mass of the TCMT group was significantly smaller than that of the ART group, but there was no difference between the TCMT group and the CON group for BMI and body fat mass. CONCLUSION Both ART and TCMT can improve the cardiopulmonary aerobic exercise capacity and physical fitness of patients with stable coronary heart disease. Although the degree of improvement is different, they all have certain effects on the rehabilitation of patients with stable coronary heart disease and the application is safe.",2019,"BMI of the ART group was significantly lower than that of the TCMT group and the CON group, and body fat mass of the TCMT group was significantly smaller than that of the ART group, but there was no difference between the TCMT group and the CON group for BMI and body fat mass. ","['141 patients with stable coronary heart disease who were admitted to the General Administration of Sport of China Sports Medical Science Institute from January 2018 to September 2018', 'cardiac rehabilitation', 'patients with stable coronary heart disease']","['TCMT', 'Traditional Chinese medicine training', 'CON', 'aerobic and resistance training', 'exercise regimens', 'aerobic and resistance training (ART', 'traditional Chinese medicine training (TCMT']","['body fat mass', 'BMI', 'Ventilation/VO2', 'Resting heart rate', 'efficacy and safety', 'volume of oxygen (VO2), VO2/kg, metabolic equivalents, VO2/heart rate, stroke volume, and peaked grip strength and flexibility parameters', 'cardiopulmonary aerobic exercise capacity and physical fitness']","[{'cui': 'C4517572', 'cui_str': 'One hundred and forty-one'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0010068', 'cui_str': 'Coronary Disease'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0038039', 'cui_str': 'Sports'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0036397', 'cui_str': 'Science'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0700431', 'cui_str': 'Cardiovascular Rehabilitation'}]","[{'cui': 'C0025124', 'cui_str': 'Zhong Yi Xue'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0003826', 'cui_str': 'Arts'}]","[{'cui': 'C0344335', 'cui_str': 'Body Fat'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C1701256', 'cui_str': 'bis(acetylacetonato)oxovanadium(IV)'}, {'cui': 'C1821417', 'cui_str': 'Resting heart rate (observable entity)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C2355577', 'cui_str': 'Metabolic Equivalent'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0038455', 'cui_str': 'Stroke Volume'}, {'cui': 'C0429271', 'cui_str': 'Grip strength (observable entity)'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}]",141.0,0.0152263,"BMI of the ART group was significantly lower than that of the TCMT group and the CON group, and body fat mass of the TCMT group was significantly smaller than that of the ART group, but there was no difference between the TCMT group and the CON group for BMI and body fat mass. ","[{'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Liang', 'Affiliation': 'National Institute of Sports Medicine, Beijing, China.'}, {'ForeName': 'Can', 'Initials': 'C', 'LastName': 'Gao', 'Affiliation': ''}, {'ForeName': 'Jianhong', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Qun', 'Initials': 'Q', 'LastName': 'Ye', 'Affiliation': ''}, {'ForeName': 'Lindan', 'Initials': 'L', 'LastName': 'Zhai', 'Affiliation': ''}, {'ForeName': 'Fengrun', 'Initials': 'F', 'LastName': 'Zhao', 'Affiliation': ''}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': ''}]",Coronary artery disease,['10.1097/MCA.0000000000000734'] 411,32211084,High-Flow Nasal Cannula: A Promising Oxygen Therapy for Patients with Severe Bronchial Asthma Complicated with Respiratory Failure.,"Severe bronchial asthma complicated with respiratory failure, a common critical illness in respiratory medicine, may be life-threatening. High-flow nasal cannula (HFNC) is a novel oxygen therapy technique developed in recent years. HFNC was applied in this study for treating adult patients with severe bronchial asthma complicated with respiratory failure. Its efficacy was analyzed comparatively to conventional oxygen therapy (COT). HFNC and COT were randomly performed based on conventional treatment. The HFNC group was similar to COT-treated patients in terms of response rate, with no significant difference in efficacy between the two groups. In patients with bronchial asthma, effectively increased PO 2 and reduced PCO 2 were observed after treatment in both groups. However, HFNC was more efficient than COT in elevating PO 2 in patients with severe bronchial asthma complicated with respiratory failure, while no statistically significant difference in PCO 2 reduction was found between the two groups. Heart rate (HR) and respiratory rate (RR) between the two groups on admission (0 h) and at 2, 8, 24, and 48 h after admission were compared. Both indicators significantly decreased with time. No significant differences in HR and RR were found between the groups at 0, 2, and 8 h after admission. However, these indicators were significantly lower in the HFNC group compared with the COT group at 24 and 48 h after admission. HFNC could significantly elevate PO 2 and reduce HR and RR. Thus, it is a promising option for patients with severe bronchial asthma complicated with respiratory failure.",2020,"The HFNC group was similar to COT-treated patients in terms of response rate, with no significant difference in efficacy between the two groups.","['adult patients with severe bronchial asthma complicated with respiratory failure', 'patients with severe bronchial asthma complicated with respiratory failure', 'patients with bronchial asthma', 'Patients with Severe Bronchial Asthma Complicated with Respiratory Failure', 'patients with severe bronchial asthma']","['HFNC', 'High-Flow Nasal Cannula', 'HFNC and COT', 'conventional oxygen therapy (COT', 'Oxygen Therapy', 'COT', 'High-flow nasal cannula (HFNC']","['elevate PO 2 and reduce HR and RR', 'efficacy', 'PCO 2 reduction', 'PO 2 and reduced PCO 2', 'Heart rate (HR) and respiratory rate (RR', 'HR and RR']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0231242', 'cui_str': 'Complicated (qualifier value)'}, {'cui': 'C3889105', 'cui_str': 'Respiratory failure (SMQ)'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannula'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0184633', 'cui_str': 'Oxygen Inhalation Therapy'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0297199', 'cui_str': 'PO-2'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0231832', 'cui_str': 'Respiration Rate'}]",,0.0186214,"The HFNC group was similar to COT-treated patients in terms of response rate, with no significant difference in efficacy between the two groups.","[{'ForeName': 'Wanru', 'Initials': 'W', 'LastName': 'Geng', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100000, China.'}, {'ForeName': 'Wuliji', 'Initials': 'W', 'LastName': 'Batu', 'Affiliation': 'Department of Respiratory Medicine, The Hospital Affiliated to the Inner Mongolia University for Nationalities, Tongliao 028000, China.'}, {'ForeName': 'Shuhong', 'Initials': 'S', 'LastName': 'You', 'Affiliation': 'Department of Respiratory Medicine, The Hospital Affiliated to the Inner Mongolia University for Nationalities, Tongliao 028000, China.'}, {'ForeName': 'Zhaohui', 'Initials': 'Z', 'LastName': 'Tong', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100000, China.'}, {'ForeName': 'Hangyong', 'Initials': 'H', 'LastName': 'He', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100000, China.'}]",Canadian respiratory journal,['10.1155/2020/2301712'] 412,32115517,"Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.","Objective To examine the add-on effects, compared to the existing antidiabetes treatment, of the sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and the risk factors of cardiovascular disease (CVD) and chronic kidney disease (CKD) in patients with inadequately controlled type 2 diabetes. Methods This 12-week, randomized, open-label, active-controlled trial included 30 patients with type 2 diabetes who were randomized 1:1 to ipragliflozin and control groups (n=15 each). The ipragliflozin group received 50 mg of ipragliflozin once daily in addition to conventional therapy. The primary outcome was the change in hemoglobin A1c (HbA1c) from the baseline. Secondary outcomes were changes from the baseline in indices of glycemic control, uric acid (UA), renal function, and arterial stiffness. Results The patients' diminished estimated glomerular filtration rate (eGFR) was alleviated in the ipragliflozin group compared to the control group [difference between groups (Δ) =4.6 (95% confidence interval (CI): 1.5-7.7) mL/min/1.73 m 2 , p=0.006] prior to significant improvements in HbA1c and other parameters, including anthropometric indices and arterial stiffness. Furthermore, ipragliflozin add-on therapy resulted in a greater reduction in serum UA levels than control therapy [Δ=-52.3 (95% CI: -85.5-19.1) μmol/L, p=0.003]. The changes in the eGFR with ipragliflozin treatment were associated with ipragliflozin-mediated changes in the UA, even after adjusting for the age, sex, baseline HbA1c, baseline UA, and baseline eGFR (standardized regression coefficient=-0.535, p=0.010). Conclusion Ipragliflozin add-on therapy was associated with beneficial renal effects in parallel with reducing serum UA levels.",2020,"Furthermore, ipragliflozin add-on therapy resulted in a greater reduction in serum UA levels than control therapy [Δ=-52.3 (95% CI: -85.5-19.1) μmol/L, p=0.003].","['patients with inadequately controlled type 2 diabetes', '30 patients with type 2 diabetes', 'Japanese Patients with Type 2 Diabetes']","['sodium-glucose cotransporter 2 inhibitor ipragliflozin', 'Ipragliflozin', 'ipragliflozin']","['glomerular filtration rate (eGFR', 'glycemic control and the risk factors of cardiovascular disease (CVD) and chronic kidney disease (CKD', 'indices of glycemic control, uric acid (UA), renal function, and arterial stiffness', 'serum UA levels', 'anthropometric indices and arterial stiffness', 'change in hemoglobin A1c (HbA1c', 'Renal Function and Serum Uric Acid Levels']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1556094', 'cui_str': 'Japanese'}]","[{'cui': 'C0017739', 'cui_str': 'Sodium-Glucose Transport Proteins'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C3492889', 'cui_str': 'ipragliflozin'}]","[{'cui': 'C0017654', 'cui_str': 'Glomerular Filtration Rate'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0041980', 'cui_str': 'Uric Acid'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0599949', 'cui_str': 'Arterial Stiffness'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4521595', 'cui_str': 'Lcpl'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0455272', 'cui_str': 'Serum uric acid measurement'}]",30.0,0.0766758,"Furthermore, ipragliflozin add-on therapy resulted in a greater reduction in serum UA levels than control therapy [Δ=-52.3 (95% CI: -85.5-19.1) μmol/L, p=0.003].","[{'ForeName': 'Masashi', 'Initials': 'M', 'LastName': 'Tanaka', 'Affiliation': 'Department of Endocrinology, Metabolism, and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Japan.'}, {'ForeName': 'Hajime', 'Initials': 'H', 'LastName': 'Yamakage', 'Affiliation': 'Department of Endocrinology, Metabolism, and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Japan.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Inoue', 'Affiliation': 'Department of Endocrinology, Metabolism, and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Japan.'}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Odori', 'Affiliation': 'Department of Endocrinology, Metabolism, and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Japan.'}, {'ForeName': 'Toru', 'Initials': 'T', 'LastName': 'Kusakabe', 'Affiliation': 'Department of Endocrinology, Metabolism, and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Shimatsu', 'Affiliation': 'Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Japan.'}, {'ForeName': 'Noriko', 'Initials': 'N', 'LastName': 'Satoh-Asahara', 'Affiliation': 'Department of Endocrinology, Metabolism, and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Japan.'}]","Internal medicine (Tokyo, Japan)",['10.2169/internalmedicine.3473-19'] 413,32191142,Enrollment and transition challenges in the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) network's PROMISE trial for resource-limited regions.,"BACKGROUND We describe enrollment and accrual challenges in the ""Promoting Maternal and Infant Survival Everywhere"" (PROMISE) trial conducted in resource-limited countries, as well as the challenges in transitioning participants from the antepartum to the postpartum components of the study. METHODS PROMISE was a large multi-national randomized controlled trial of the safety and efficacy of interventions to reduce perinatal transmission of HIV-1 (HIV) during pregnancy and breastfeeding and of interventions to preserve maternal health after cessation of perinatal transmission risk. The PROMISE study included two protocols for HIV-infected pregnant women in resource-limited countries who intended to either breastfeed or formula-feed their infants and did not meet country criteria for antiretroviral treatment. The PROMISE breastfeeding protocol (1077BF) used a sequential randomization design with up to three randomizations (Antepartum, Postpartum, and Maternal Health). The PROMISE formula-feeding protocol (1077FF) had two randomizations (Antepartum and Maternal Health). Women presenting to the clinic during early or active labor or in the immediate postpartum period were registered as Late Presenters and screened to determine whether eligible to participate in the Postpartum randomization. RESULTS The study was conducted at 14 sites in seven countries and opened to enrollment in April 2011. A total of 3259 pregnant women intending to breastfeed and an additional 284 pregnant women intending to formula feed were randomized in the Antepartum component. A total of 204 Late Presenters were registered during labor or after delivery. Enrollment was high among breastfeeding women (representing 96% of the target of 3400 women) but was lower than expected among women intending to formula feed (28% of 1000 expected) and late-presenting women (8% of 2500 expected). The successful overall enrollment and final primary study analyses results were attributed to substantial preparation before the study opened, collaboration among all stakeholders, close study monitoring during implementation and the flexibility to change and streamline the protocol. CONCLUSIONS Experiences from the PROMISE study illustrate the challenges of enrolling in longer term studies in the setting of rapidly evolving prevention and treatment standards priorities. The lessons learned will help the community, site investigators, and study coordinators in the design and implementation of future clinical trials.",2020,Enrollment was high among breastfeeding women (representing 96% of the target of 3400 women) but was lower than expected among women intending to formula feed (28% of 1000 expected) and late-presenting women (8% of 2500 expected).,"['14 sites in seven countries and opened to enrollment in April 2011', 'Women presenting to the clinic during early or active labor or in the immediate postpartum period were registered as Late Presenters and screened to determine whether eligible to participate in the Postpartum randomization', 'HIV-infected pregnant women in resource-limited countries who intended to either breastfeed or formula-feed their infants and did not meet country criteria for antiretroviral treatment', '3259 pregnant women intending to breastfeed and an additional 284 pregnant women intending to formula feed']",[],['perinatal transmission of HIV-1 (HIV'],"[{'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0233081', 'cui_str': 'Normal labor (finding)'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0086839', 'cui_str': 'Postpartum Period'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C1623040', 'cui_str': 'Breastfeeding (mother)'}, {'cui': 'C2987508', 'cui_str': 'Feeding (observable entity)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",[],"[{'cui': 'C0040722', 'cui_str': 'transmission'}, {'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}]",3259.0,0.112228,Enrollment was high among breastfeeding women (representing 96% of the target of 3400 women) but was lower than expected among women intending to formula feed (28% of 1000 expected) and late-presenting women (8% of 2500 expected).,"[{'ForeName': 'Konstantia', 'Initials': 'K', 'LastName': 'Angelidou', 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Mary Glenn', 'Initials': 'MG', 'LastName': 'Fowler', 'Affiliation': 'Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Pat', 'Initials': 'P', 'LastName': 'Flynn', 'Affiliation': ""Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Coletti', 'Affiliation': 'IMPAACT Operations Center, FHI 360, Durham, NC, USA.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'McCarthy', 'Affiliation': 'IMPAACT Operations Center, FHI 360, Durham, NC, USA.'}, {'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Browning', 'Affiliation': 'Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'McIntyre', 'Affiliation': 'Anova Health Institute, Johannesburg, South Africa.'}, {'ForeName': 'Sean S', 'Initials': 'SS', 'LastName': 'Brummel', 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Shapiro', 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Camlin', 'Initials': 'C', 'LastName': 'Tierney', 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Clinical trials (London, England)",['10.1177/1740774520912428'] 414,32213342,"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.","BACKGROUND Intravenous daratumumab for treatment of patients with multiple myeloma involves a lengthy infusion that affects quality of life, and infusion-related reactions are common. Subcutaneous daratumumab is thought to be easier to administer and to cause fewer administration-related reactions. In this study (COLUMBA), we tested the non-inferiority of subcutaneous daratumumab to intravenous daratumumab. METHODS In this ongoing, multicentre (147 sites in 18 countries), open-label, non-inferiority, randomised, phase 3 trial, we recruited adult patients (age ≥18 years) if they had confirmed relapsed or refractory multiple myeloma according to International Myeloma Working Group criteria; received at least three previous lines of therapy, including a proteasome inhibitor and immunomodulatory drug, or were double refractory to both a proteasome inhibitor and immunomodulatory drug; and had an Eastern Cooperative Oncology Group performance status score of 2 or lower. Patients were randomly assigned (1:1) by a computer-generated randomisation schedule and balanced using randomly permuted blocks to receive daratumumab subcutaneously (subcutaneous group) or intravenously (intravenous group). Randomisation was stratified on the basis of baseline bodyweight (≤65 kg, 66-85 kg, >85 kg), previous therapy lines (≤four vs >four), and myeloma type (IgG vs non-IgG). Patients received 1800 mg of subcutaneous daratumumab co-formulated with 2000 U/mL recombinant human hyaluronidase PH20 or 16 mg/kg of intravenous daratumumab once weekly (cycles 1-2), every 2 weeks (cycles 3-6), and every 4 weeks thereafter (28-day cycles) until progressive disease or toxicity. The co-primary endpoints were overall response and maximum trough concentration (C trough ; cycle 3, day 1 pre-dose). The non-inferiority margin for overall response was defined using a 60% retention of the lower bound (20·8%) of the 95% CI of the SIRIUS trial. Efficacy analyses were done by intention-to-treat population. The pharmacokinetic-evaluable population included all patients who received all eight weekly daratumumab doses in cycles 1 and 2 and provided a pre-dose pharmacokinetics blood sample on day 1 of cycle 3. The safety population included all patients who received at least one daratumumab dose. This trial is registered with ClinicalTrials.gov, NCT03277105. FINDINGS Between Oct 31, 2017, and Dec 27, 2018, 655 patients were screened, of whom 522 were recruited and randomly assigned (subcutaneous group n=263; intravenous group n=259). Three patients in the subcutaneous group and one in the intravenous group did not receive treatment and were not evaluable for safety. At a median follow-up of 7·5 months (IQR 6·5-9·3), overall response and C trough met the predefined non-inferiority criteria. An overall response was seen in 108 (41%) of 263 patients in the subcutaneous group and 96 (37%) of 259 in the intravenous group (relative risk 1·11, 95% CI 0·89-1·37). The geometric means ratio for C trough was 107·93% (90% CI 95·74-121·67), and the maximum C trough was 593 μg/mL (SD 306) in the subcutaneous group and 522 μg/mL (226) in the intravenous group. The most common grade 3 and 4 adverse events were anaemia (34 [13%] of 260 patients evaluable for safety in the subcutaneous group and 36 [14%] of 258 patients in the intravenous group), neutropenia (34 [13%] and 20 [8%]), and thrombocytopenia (36 [14%] and 35 [14%]). Pneumonia was the only serious adverse event in more than 2% of patients (seven [3%] in the subcutaneous group and 11 [4%] in the intravenous group). There was one death resulting from a treatment-related adverse event in the subcutaneous daratumumab group (febrile neutropenia) and four in the intravenous group (sepsis [n=2], hepatitis B reactivation [n=1], and Pneumocystis jirovecii pneumonia [n=1]). INTERPRETATION Subcutaneous daratumumab was non-inferior to intravenous daratumumab in terms of efficacy and pharmacokinetics and had an improved safety profile in patients with relapsed or refractory multiple myeloma. These data could contribute to the approval of the subcutaneous daratumumab formulation by regulatory bodies. FUNDING Janssen Research & Development.",2020,"There was one death resulting from a treatment-related adverse event in the subcutaneous daratumumab group (febrile neutropenia) and four in the intravenous group (sepsis [n=2], hepatitis B reactivation [n=1], and Pneumocystis jirovecii pneumonia [n=1]). ","['adult patients (age ≥18 years) if they had confirmed relapsed or refractory multiple myeloma according to International Myeloma Working Group criteria', 'patients with relapsed or refractory multiple myeloma', 'patients with relapsed or refractory multiple myeloma (COLUMBA', 'patients with multiple myeloma', 'Between Oct 31, 2017, and Dec 27, 2018, 655 patients were screened, of whom 522 were recruited and randomly assigned (subcutaneous group n=263; intravenous group n=259']","['recombinant human hyaluronidase PH20 or 16 mg/kg of intravenous daratumumab', 'subcutaneous daratumumab co-formulated with 2000', 'U/mL', 'proteasome inhibitor and immunomodulatory drug, or were double refractory to both a proteasome inhibitor and immunomodulatory drug; and had an Eastern Cooperative Oncology Group performance status score of 2 or lower', 'daratumumab subcutaneously (subcutaneous group) or intravenously (intravenous group', 'Subcutaneous versus intravenous daratumumab']","['Pneumonia', 'anaemia', 'geometric means ratio for C trough', 'thrombocytopenia', 'neutropenia', 'overall response', 'overall response and maximum trough concentration']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0026764', 'cui_str': 'Myelomatosis'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0999231', 'cui_str': 'Genus Columba'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C4517804', 'cui_str': 'Five hundred and twenty-two'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}]","[{'cui': 'C1720035', 'cui_str': 'hyaluronidase, human recombinant'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C2346801', 'cui_str': 'daratumumab'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C2945590', 'cui_str': 'unit/mL'}, {'cui': 'C1443643', 'cui_str': 'Proteasome Endopeptidase Complex Inhibitors'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C1520224', 'cui_str': 'Eastern Cooperative Oncology Group performance status'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0444506', 'cui_str': 'Trough (qualifier value)'}, {'cui': 'C0040034', 'cui_str': 'Thrombopenia'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",655.0,0.267856,"There was one death resulting from a treatment-related adverse event in the subcutaneous daratumumab group (febrile neutropenia) and four in the intravenous group (sepsis [n=2], hepatitis B reactivation [n=1], and Pneumocystis jirovecii pneumonia [n=1]). ","[{'ForeName': 'Maria-Victoria', 'Initials': 'MV', 'LastName': 'Mateos', 'Affiliation': 'Cancer Research Unit, University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; Institute of Cancer Molecular and Cellular Biology (USAL-CSIC), Centre for Cancer Research (IBMCC), Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.'}, {'ForeName': 'Hareth', 'Initials': 'H', 'LastName': 'Nahi', 'Affiliation': 'Unit of Hematology, Department of Medicine, Karolinska University Hospital at Huddinge, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Legiec', 'Affiliation': 'Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Grosicki', 'Affiliation': 'Department of Hematology and Cancer Prevention, School of Public Health in Bytom, Medical University of Silesia in Katowice, Katowice, Poland.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Vorobyev', 'Affiliation': 'S P Botkin City Clinical Hospital, Moscow, Russia.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Spicka', 'Affiliation': '1st Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic; General University Hospital in Prague, Charles University, Prague, Czech Republic.'}, {'ForeName': 'Vania', 'Initials': 'V', 'LastName': 'Hungria', 'Affiliation': 'Clinica São Germano, São Paulo, Brazil.'}, {'ForeName': 'Sibirina', 'Initials': 'S', 'LastName': 'Korenkova', 'Affiliation': 'Kiev Bone Marrow Transplantation Center, Kiev, Ukraine.'}, {'ForeName': 'Nizar', 'Initials': 'N', 'LastName': 'Bahlis', 'Affiliation': 'Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Max', 'Initials': 'M', 'LastName': 'Flogegard', 'Affiliation': 'Department of Internal Medicine, Falun General Hospital, Falun, Sweden.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Bladé', 'Affiliation': ""Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.""}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Moreau', 'Affiliation': 'University Hospital of Nantes, Nantes, France.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Kaiser', 'Affiliation': 'Department of Haemato-Oncology, Royal Marsden Hospital, London, UK; Division of Molecular Pathology, Institute of Cancer Research, London, UK.'}, {'ForeName': 'Shinsuke', 'Initials': 'S', 'LastName': 'Iida', 'Affiliation': 'Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Laubach', 'Affiliation': 'Department of Hematology and Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Hila', 'Initials': 'H', 'LastName': 'Magen', 'Affiliation': 'Department of Hematology Chaim Sheba Medical Center, Ramat-Gan, Sackler Faculty of Medicine, Tel Aviv, Israel.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Cavo', 'Affiliation': 'Diagnostic and Specialty Medicine Department, Seràgnoli Institute of Hematology, University of Bologna, Bologna, Italy.'}, {'ForeName': 'Cyrille', 'Initials': 'C', 'LastName': 'Hulin', 'Affiliation': 'Centre Hospitalier Universitaire Bordeaux, Pessac, France.'}, {'ForeName': 'Darrell', 'Initials': 'D', 'LastName': 'White', 'Affiliation': 'Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada.'}, {'ForeName': 'Valerio', 'Initials': 'V', 'LastName': 'De Stefano', 'Affiliation': 'Institute of Hematology, Università Cattolica del Sacro Cuore, Rome, Italy; Fondazione Policlinico Universitario Agostino Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Rome, Italy.'}, {'ForeName': 'Pamela L', 'Initials': 'PL', 'LastName': 'Clemens', 'Affiliation': 'Janssen Research & Development, Spring House, PA, USA.'}, {'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'Masterson', 'Affiliation': 'Janssen Research & Development, Spring House, PA, USA.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Lantz', 'Affiliation': 'Janssen Research & Development, Spring House, PA, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': ""O'Rourke"", 'Affiliation': 'Janssen Research & Development, Spring House, PA, USA.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Heuck', 'Affiliation': 'Janssen Research & Development, Spring House, PA, USA.'}, {'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Qin', 'Affiliation': 'Janssen Research & Development, Raritan, NJ, USA.'}, {'ForeName': 'Dolly A', 'Initials': 'DA', 'LastName': 'Parasrampuria', 'Affiliation': 'Janssen Research & Development, Spring House, PA, USA.'}, {'ForeName': 'Zhilong', 'Initials': 'Z', 'LastName': 'Yuan', 'Affiliation': 'Janssen Research & Development, Raritan, NJ, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Xu', 'Affiliation': 'Janssen Research & Development, Spring House, PA, USA; Genmab US, Princeton, NJ, USA.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Qi', 'Affiliation': 'Janssen Research & Development, Spring House, PA, USA.'}, {'ForeName': 'Saad Z', 'Initials': 'SZ', 'LastName': 'Usmani', 'Affiliation': 'Levine Cancer Institute-Atrium Health, Charlotte, NC, USA. Electronic address: saad.usmani@atriumhealth.org.'}]",The Lancet. Haematology,['10.1016/S2352-3026(20)30070-3'] 415,32217888,Genetic predictors to acupuncture response for hot flashes: an exploratory study of breast cancer survivors.,"OBJECTIVE Because hot flashes are a common symptom experienced by women with breast cancer, we sought to explore genetic predictors associated with response to acupuncture for the treatment of hot flashes. METHODS Using data from our completed randomized controlled trial (Clinicaltrials.gov identifier: NCT01005108) on hot flashes among breast cancer survivors who provided biomarker collection (N = 108), we extracted and assayed DNA for single nucleotide polymorphisms in genes involved in neurotransmission, thermoregulation, and inflammation (ADORA1, COMT, TCL1A, and TRPV1). For our primary outcome we classified individuals with a 50% or more reduction in their hot flash composite score at the end of treatment as responders. We used Fisher exact test to identify individual and combined single nucleotide polymorphisms associated with treatment response. RESULTS Among women (N = 57) who received acupuncture treatment (electro or sham), we found that women who were carriers of at least one of these six genotypes (ADORA1 rs41264025-GA or rs16851029-GG or rs12744240-GT, COMT rs6269-GA, TCL1A rs2369049-GG, and TRPV1 rs8065080-TT) were more likely to respond to acupuncture for hot flashes than noncarriers (70.3% vs 37.5%, P = 0.035). These six genotypes were not associated with response in women (N = 51) who received pharmacological hot flash treatment (gabapentin or placebo pill; 37.5% vs 37.5%, P = 1.0). CONCLUSIONS In this exploratory, proof of concept study, we identified six genotypes that may predict response to acupuncture for hot flashes in breast cancer survivors. If confirmed by future studies, these findings may inform the development of personalized acupuncture for managing hot flashes.",2020,"These six genotypes were not associated with response in women (N = 51) who received pharmacological hot flash treatment (gabapentin or placebo pill; 37.5% vs 37.5%, P = 1.0). ","['women', 'breast cancer survivors who provided biomarker collection', 'women with breast cancer', 'breast cancer survivors']","['acupuncture', 'acupuncture treatment (electro or sham', 'pharmacological hot flash treatment (gabapentin or placebo pill', 'six genotypes (ADORA1 rs41264025-GA or rs16851029-GG or rs12744240-GT, COMT rs6269-GA, TCL1A rs2369049-GG, and TRPV1 rs8065080-TT']","['neurotransmission, thermoregulation, and inflammation (ADORA1, COMT, TCL1A, and TRPV1', 'hot flash composite score']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0600644', 'cui_str': 'Collection'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0394664', 'cui_str': 'Acupuncture Treatment'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0205464', 'cui_str': 'Pharmacologic (qualifier value)'}, {'cui': 'C0600142', 'cui_str': 'Hot Flashes'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0060926', 'cui_str': 'gabapentin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0994475', 'cui_str': 'Pill (basic dose form)'}, {'cui': 'C1285573', 'cui_str': 'Genotype determination'}]","[{'cui': 'C0027793', 'cui_str': 'Neural Transmission'}, {'cui': 'C0005905', 'cui_str': 'Thermoregulation'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0600142', 'cui_str': 'Hot Flashes'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.343199,"These six genotypes were not associated with response in women (N = 51) who received pharmacological hot flash treatment (gabapentin or placebo pill; 37.5% vs 37.5%, P = 1.0). ","[{'ForeName': 'Sally A D', 'Initials': 'SAD', 'LastName': 'Romero', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Qing Susan', 'Initials': 'QS', 'LastName': 'Li', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Orlow', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Mithat', 'Initials': 'M', 'LastName': 'Gonen', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Hui-Chun Irene', 'Initials': 'HI', 'LastName': 'Su', 'Affiliation': 'Moores Cancer Center, University of California San Diego, La Jolla, CA.'}, {'ForeName': 'Jun J', 'Initials': 'JJ', 'LastName': 'Mao', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}]","Menopause (New York, N.Y.)",['10.1097/GME.0000000000001545'] 416,32215767,"Evaluation of the clinical and biochemical efficacy of erbium, chromium:ytrium-scandium-gallium-garnet (ER,CR:YSGG) laser treatment in periodontitis.","The objective of this study was to evaluate the clinical and biochemical efficacy of erbium, chromium:ytrium-scandium-gallium-garnet (Er,Cr:YSGG) laser treatment, in addition to non-surgical periodontal treatment (NSPT), in periodontitis patients. This was a single-centre, split-mouth, randomized, controlled 6-month clinical trial. Twenty-seven patients with moderate to advanced periodontitis were included in the study. The patients were randomly assigned to a debridement and laser treatment group or control group (debridement alone). Clinical measurements were performed at baseline and 1, 3 and 6 months post-treatment. The following parameters were measured: plaque index (PI), gingival index (GI), probing depth (PD), clinical attachment level (CAL), bleeding on probing (BoP), gingival crevicular fluid (GCF) volume and IL-1β and MMP-8 levels in GCF. There were statistically significant clinical improvements in both groups, with no significant between-group differences in PD, CAL, PI and BoP clinical measurements (p < 0.05). As compared with the control group, the GI 1 and 3 months post-treatment and BoP 1 month post-treatment were significantly improved in the laser group (p < 0.05). There was also a significant reduction in IL-1 β levels in both groups at baseline versus those 1, 3 and 6 months later (p < 0.05) There was no statistically significant difference in IL-1β and MMP-8 levels between groups (p < 0.05). Both the treatment modalities resulted in significant improvements in clinical parameters. Within the limitations of this study, Er,Cr:YSGG laser treatment applied in addition to NSPT is indicated to reduce clinical inflammation.",2020,"There was also a significant reduction in IL-1 β levels in both groups at baseline versus those 1, 3 and 6 months later (p < 0.05)","['periodontitis', 'Twenty-seven patients with moderate to advanced periodontitis', 'periodontitis patients']","['debridement and laser treatment group or control group (debridement alone', 'erbium, chromium:ytrium-scandium-gallium-garnet', 'erbium, chromium:ytrium-scandium-gallium-garnet (ER,CR:YSGG) laser treatment', 'YSGG laser']","['PD, CAL, PI and BoP clinical measurements', 'plaque index (PI), gingival index (GI), probing depth (PD), clinical attachment level (CAL), bleeding on probing (BoP), gingival crevicular fluid (GCF) volume and IL-1β and MMP-8 levels in GCF', 'IL-1 β levels', 'IL-1β and MMP-8 levels', 'clinical parameters']","[{'cui': 'C0031099', 'cui_str': 'Periodontitis'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}]","[{'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0014688', 'cui_str': 'Erbium'}, {'cui': 'C0168430', 'cui_str': 'chromium hexavalent ion'}, {'cui': 'C0036274', 'cui_str': 'Scandium'}, {'cui': 'C0016980', 'cui_str': 'Gallium'}, {'cui': 'C0879167', 'cui_str': 'Yttrium-Scandium-Gallium Garnet Lasers'}]","[{'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0017569', 'cui_str': 'Gingival Index'}, {'cui': 'C3179165', 'cui_str': 'Probe (methazole)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0017564', 'cui_str': 'Gingival Exudate'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0623362', 'cui_str': 'MMPs'}, {'cui': 'C0021755', 'cui_str': 'T Helper Factor'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",27.0,0.0502073,"There was also a significant reduction in IL-1 β levels in both groups at baseline versus those 1, 3 and 6 months later (p < 0.05)","[{'ForeName': 'Dilara', 'Initials': 'D', 'LastName': 'Sezen', 'Affiliation': 'Department of Periodontology, Faculty of Dentistry, University of Akdeniz, Antalya, Turkey.'}, {'ForeName': 'Mükerrem', 'Initials': 'M', 'LastName': 'Hatipoğlu', 'Affiliation': 'Department of Periodontology, Faculty of Dentistry, University of Akdeniz, Antalya, Turkey. drmukerremhatipoglu@gmail.com.'}, {'ForeName': 'Kemal', 'Initials': 'K', 'LastName': 'Üstün', 'Affiliation': 'Department of Periodontology, Faculty of Dentistry, University of Akdeniz, Antalya, Turkey.'}]",Lasers in medical science,['10.1007/s10103-020-02990-8'] 417,31418989,A neurobiological correlate of stress-induced nicotine-seeking behavior among cigarette smokers.,"Stress is known to influence smoking relapse. Experimental studies indicate that acute stress increases nicotine-seeking behavior, yet neurobiological mechanisms remain poorly understood. Herein, we investigated disrupted excitatory neural activity in the dorsolateral prefrontal cortex (dlPFC) as a mechanism of stress-induced nicotine-seeking behavior. Non-treatment-seeking cigarette smokers were screened for psychiatric, medical, and neuroimaging contraindications. Using a double-blind, placebo-controlled, randomized crossover design, participants (N = 21) completed two oral-dosing sessions: stress (yohimbine 54 mg + hydrocortisone 10 mg) vs placebo (lactose 54 mg + lactose 10 mg). During each experimental session, working memory proficiency, dlPFC excitatory neural activity, nicotine-seeking behavior, and subjective effects were measured. dlPFC excitatory neural activity was quantified via glutamate modulation during working memory performance using functional proton magnetic resonance spectroscopy. Nicotine-seeking behavior was assayed using a cigarette puffs vs money choice progressive ratio task. Results indicated that yohimbine + hydrocortisone evoked a sustained physiological stress response (elevated heart rate, blood pressure, saliva cortisol, and saliva α-amylase levels; ps < .05). Relative to placebo levels, acute stress increased nicotine-seeking behavior (ps < .05), disrupted dlPFC glutamate modulation (p = .025), and impaired dlPFC function (working memory proficiency; ps < .05). The stress-induced increase in nicotine-seeking behavior was linearly related to the stress-induced disruption of dlPFC glutamate modulation (R 2  = 0.24-0.37; ps < .05). These findings suggest that disrupted dlPFC excitatory neural activity is a neurobiological correlate of acute stress-induced nicotine-seeking behavior. These findings further emphasize the central role of the dlPFC in regulating drug-seeking behavior. Future studies are needed to evaluate interventions to improve dlPFC resilience to acute stress effects, including neurostimulation, working memory training, and ""anti-stress"" medications.",2020,"Relative to placebo levels, acute stress increased nicotine-seeking behavior (ps < .05), disrupted dlPFC glutamate modulation (p = .025), and impaired dlPFC function (working memory proficiency; ps < .05).","['cigarette smokers', 'participants (N\xa0=\xa021) completed two', 'Non-treatment-seeking cigarette smokers']","['placebo', 'oral-dosing sessions: stress (yohimbine 54\xa0mg\xa0+\xa0hydrocortisone 10\xa0mg) vs placebo (lactose 54\xa0mg\xa0+\xa0lactose', 'yohimbine + hydrocortisone']","['working memory proficiency, dlPFC excitatory neural activity, nicotine-seeking behavior, and subjective effects', 'nicotine-seeking behavior', 'sustained physiological stress response (elevated heart rate, blood pressure, saliva cortisol, and saliva α-amylase levels', 'stress-induced disruption of dlPFC glutamate modulation', 'impaired dlPFC function', 'disrupted dlPFC glutamate modulation']","[{'cui': 'C0337667', 'cui_str': 'Cigarette smoker (finding)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0724441', 'cui_str': 'yohimbine'}, {'cui': 'C1603583', 'cui_str': 'Hydrocortisone 10 MG [Cortef]'}, {'cui': 'C0022949', 'cui_str': 'Lactose'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}]","[{'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C2350025', 'cui_str': 'Physiological Stress Reactivity'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0036087', 'cui_str': 'Saliva (substance)'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C0201883', 'cui_str': 'Amylase measurement (procedure)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0332453', 'cui_str': 'Disruption (morphologic abnormality)'}, {'cui': 'C0220839', 'cui_str': 'Glutamate'}, {'cui': 'C0031843', 'cui_str': 'function'}]",,0.0413021,"Relative to placebo levels, acute stress increased nicotine-seeking behavior (ps < .05), disrupted dlPFC glutamate modulation (p = .025), and impaired dlPFC function (working memory proficiency; ps < .05).","[{'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Woodcock', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.'}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Stanley', 'Affiliation': 'Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan, USA.'}, {'ForeName': 'Vaibhav A', 'Initials': 'VA', 'LastName': 'Diwadkar', 'Affiliation': 'Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan, USA.'}, {'ForeName': 'Dalal', 'Initials': 'D', 'LastName': 'Khatib', 'Affiliation': 'Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan, USA.'}, {'ForeName': 'Mark K', 'Initials': 'MK', 'LastName': 'Greenwald', 'Affiliation': 'Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan, USA.'}]",Addiction biology,['10.1111/adb.12819'] 418,31026419,Effect of Submucosal Injection of Tramadol on Postoperative Pain After Third Molar Surgery.,"PURPOSE This study aimed to evaluate the effectiveness of submucosal injection of tramadol in treating postoperative pain after surgical extraction of impacted mandibular third molars. MATERIALS AND METHODS We implemented a randomized controlled trial. The sample was divided into 30 cases (receiving tramadol injection) and 30 controls (receiving saline solution injection). Patients were asked to complete a visual analog pain scale (VAPS) at 0.5, 1, 2, 4, 6, 12, 24, and 48 hours. Patients also were asked to note the time at which rescue analgesics were taken, as well as the total number of analgesics taken. The VAPS data were analyzed using the unpaired Student t test. Other variables were analyzed using analysis of variance with the Bonferroni t test and Pearson χ 2 test. P < .05 was considered significant. RESULTS A total of 60 patients, 32 men and 28 women (mean age, 27.78 years; age range, 19 to 45 years), took part in this study. Postoperative pain scores, as recorded on the VAPS, were significantly lower in the tramadol group, with the differences being statistically significant at 0.5, 1, 2, 4, and 6 hours (P < 0.001, P = .006, P < 0.001, P < 0.001, and P < 0.001, respectively). The mean time at which the first tablet was taken and the total number of tablets taken by the tramadol group also were statistically significant (P = .001 for both). CONCLUSIONS The results suggest that submucosal injection of tramadol has a significant effect on postoperative pain control after surgical extraction of impacted third molars.",2019,"Postoperative pain scores, as recorded on the VAPS, were significantly lower in the tramadol group, with the differences being statistically significant at 0.5, 1, 2, 4, and 6 hours (P < 0.001, P = .006, P < 0.001, P < 0.001, and P < 0.001, respectively).","['postoperative pain after surgical extraction of impacted mandibular third molars', '60 patients, 32 men and 28 women (mean age, 27.78\xa0years; age range, 19 to 45\xa0years), took part in this study']","['Tramadol', 'tramadol', 'tramadol injection) and 30 controls (receiving saline solution injection']","['Postoperative Pain', 'total number of tablets taken', 'Postoperative pain scores', 'mean time', 'postoperative pain control', 'visual analog pain scale (VAPS']","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C1293139', 'cui_str': 'Surgical extraction'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0026369', 'cui_str': 'Tooth, Wisdom'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0040610', 'cui_str': 'Tramadol'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}]","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0042815', 'cui_str': 'Visual Analog Pain Scale'}]",60.0,0.130354,"Postoperative pain scores, as recorded on the VAPS, were significantly lower in the tramadol group, with the differences being statistically significant at 0.5, 1, 2, 4, and 6 hours (P < 0.001, P = .006, P < 0.001, P < 0.001, and P < 0.001, respectively).","[{'ForeName': 'Anas Mohammad', 'Initials': 'AM', 'LastName': 'Iqbal', 'Affiliation': 'Postgraduate Student, Department of Oral and Maxillofacial Surgery, Manipal College of Dental Sciences, Mangalore, Manipal Academy of Higher Education, Mangalore, India.'}, {'ForeName': 'Premalatha', 'Initials': 'P', 'LastName': 'Shetty', 'Affiliation': 'Associate Dean and Professor, Department of Oral and Maxillofacial Surgery, Manipal College of Dental Sciences, Mangalore, Manipal Academy of Higher Education, Mangalore, India. Electronic address: premalatha.shetty@manipal.edu.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.03.029'] 419,31112677,"Does Single-Dose Preemptive Intravenous Ibuprofen Reduce Postoperative Pain After Third Molar Surgery? A Prospective, Randomized, Double-Blind Clinical Study.","PURPOSE The aim of the present study was to identify the preemptive analgesic effect of intravenous (IV) ibuprofen before and after mandibular third molar surgery. MATERIALS AND METHODS We randomly divided 75 patients into 3 groups. Group 1 received IV ibuprofen 60 minutes before surgery and IV placebo (100 mL of saline) after surgery. Group 2 received IV placebo (100 mL of saline) before surgery and IV ibuprofen 60 minutes after surgery. Finally, group 3 received IV placebo (100 mL of saline) 60 minutes before and after surgery. Postoperative pain was recorded using a visual analog scale at 1, 2, 4, 6, 8, 12, and 24 hours within the postoperative period. The total dose of rescue acetaminophen intake was recorded during the first 24 hours of the postoperative period. RESULTS The efficacy of postoperative analgesia was greater within the preoperative IV ibuprofen group compared with the other groups (P < .001). The placebo group had required more rescue analgesia within the first hour compared with the other groups. The average dose of acetaminophen administered in group 1 was 640 mg compared with 1240 mg in group 2 and 1840 mg in group 3 within the first 24 hours after surgery (P < .001). CONCLUSIONS The present study has shown that the preemptive use of IV ibuprofen resulted in less pain and a decrease in the requirement for rescue analgesia during the first 24 hours after third molar surgery.",2019,The efficacy of postoperative analgesia was greater within the preoperative IV ibuprofen group compared with the other groups (P < .001).,['We randomly divided 75 patients into 3 groups'],"['IV placebo', 'ibuprofen', 'placebo', 'intravenous (IV) ibuprofen', 'IV ibuprofen 60\xa0minutes before surgery and IV placebo', 'acetaminophen', 'Ibuprofen', 'IV placebo (100\xa0mL of saline']","['Postoperative Pain', 'rescue analgesia', 'pain', 'efficacy of postoperative analgesia', 'Postoperative pain', 'total dose of rescue acetaminophen intake']","[{'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332286', 'cui_str': 'Into (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C3853333', 'cui_str': 'Sixty minutes'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}]","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}]",75.0,0.33039,The efficacy of postoperative analgesia was greater within the preoperative IV ibuprofen group compared with the other groups (P < .001).,"[{'ForeName': 'Ahmet Emin', 'Initials': 'AE', 'LastName': 'Demirbas', 'Affiliation': 'Assistant Professor, Department of Oral and Maxillofacial Surgery, Erciyes University Faculty of Dentistry, Kayseri, Turkey. Electronic address: aemindemirbas@hotmail.com.'}, {'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Karakaya', 'Affiliation': 'Resident, Department of Oral and Maxillofacial Surgery, Erciyes University Faculty of Dentistry, Kayseri, Turkey.'}, {'ForeName': 'Suheyb', 'Initials': 'S', 'LastName': 'Bilge', 'Affiliation': 'Assistant Professor, Department of Oral and Maxillofacial Surgery, Erciyes University Faculty of Dentistry, Kayseri, Turkey.'}, {'ForeName': 'Dilek Gunay', 'Initials': 'DG', 'LastName': 'Canpolat', 'Affiliation': 'Associate Professor, Anesthesiologist, Department of Oral and Maxillofacial Surgery, Erciyes University Faculty of Dentistry, Kayseri, Turkey.'}, {'ForeName': 'Nükhet', 'Initials': 'N', 'LastName': 'Kütük', 'Affiliation': 'Associate Professor, Department of Oral and Maxillofacial Surgery, Bezmialem Vakif University, Faculty of Dentistry, Istanbul, Turkey.'}, {'ForeName': 'Alper', 'Initials': 'A', 'LastName': 'Alkan', 'Affiliation': 'Professor, Department of Oral and Maxillofacial Surgery, Bezmialem Vakif University, Faculty of Dentistry, Istanbul, Turkey.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.04.019'] 420,30959006,Should Melatonin Be Used as an Alternative Sedative and Anxiolytic Agent in Mandibular Third Molar Surgery?,"PURPOSE Melatonin is a natural hormone that regulates circadian rhythms. The aim of this study was to compare the anxiolytic effects of oral melatonin and oral midazolam in patients undergoing third molar surgery. The study also sought to investigate the effects of these drugs on cognitive and psychomotor functions. MATERIALS AND METHODS This was a double-blinded, prospective, randomized clinical study. Patients scheduled for impacted third molar surgery were included in the study. Anxiety was evaluated with the visual analog scale (VAS). To measure psychomotor and cognitive functions before the procedure, all patients were asked to complete the digit symbol substitution test (DSST) and the trail making test (TMT parts A and B). Then, all patients were allocated to 1 of 3 groups to receive oral midazolam 0.2 mg/kg (group MD), oral melatonin 0.4 mg/kg (group M), or an oral multivitamin tablet as placebo (group P). After 60 minutes, patients were reassessed using the same 3 tests. The difference between the pre- and post-drug VAS values was calculated and the anxiolytic effects of the drugs were evaluated. RESULTS Ninety patients participated in the study. No relevant differences were observed among groups for age, gender, or duration of operation. The results suggested that anxiety decreased most in group MD (P < .001), but anxiety in group M also decreased significantly compared with group P (P = .016). Similarly, the greatest increase in TMT-A and -B score differences was in group MD compared with the other groups (P < .001), whereas there was no significant difference between groups M and P for TMT-A and -B scores (P = .913 and P = .964, respectively). CONCLUSION Melatonin showed sufficient anxiolytic effect in third molar surgery without affecting cognitive and psychomotor functions.",2019,"< .001), but anxiety in group M also decreased significantly compared with group P (P = .016).","['Ninety patients participated in the study', 'Patients scheduled for impacted third molar surgery were included in the study', 'patients undergoing third molar surgery']","['oral midazolam 0.2\xa0mg/kg (group MD), oral melatonin 0.4\xa0mg/kg (group M), or an oral multivitamin tablet as placebo', 'Melatonin', 'oral melatonin and oral midazolam']","['pre- and post-drug VAS values', 'anxiolytic effect', 'visual analog scale (VAS', 'TMT-A and -B scores', 'anxiolytic effects', 'TMT-A and -B score differences', 'anxiety', 'Anxiety']","[{'cui': 'C3816959', 'cui_str': 'Ninety'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0026369', 'cui_str': 'Tooth, Wisdom'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C4517457', 'cui_str': 'Zero point four'}, {'cui': 'C0441847', 'cui_str': 'Group M (qualifier value)'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C3179404', 'cui_str': 'Antianxiety Effects'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",90.0,0.106172,"< .001), but anxiety in group M also decreased significantly compared with group P (P = .016).","[{'ForeName': 'Aysun Caglar', 'Initials': 'AC', 'LastName': 'Torun', 'Affiliation': 'Assistant Professor, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ondokuz Mayis University, Samsun, Turkey. Electronic address: aysunct@hotmail.com.'}, {'ForeName': 'Ezgi', 'Initials': 'E', 'LastName': 'Yüceer', 'Affiliation': 'Research Assistant, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ondokuz Mayis University, Samsun, Turkey.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.02.045'] 421,31077671,Comparison Between Efficacy of Transdermal Ketoprofen and Diclofenac Patch in Patients Undergoing Therapeutic Extraction-A Randomized Prospective Split Mouth Study.,"PURPOSE Postoperative pain control is a significant aspect of patient treatment after an oral and maxillofacial surgical procedure. The use of a transdermal patch is one such method to provide postoperative analgesia. The present study was undertaken to investigate the efficacy of a single-dose transdermal patch of ketoprofen compared with that of diclofenac postoperatively after therapeutic extraction of first premolar teeth for patients undergoing orthodontic treatment. PATIENTS AND METHODS A split mouth randomized clinical trial was conducted of 40 patients aged 15 to 25 years who had required therapeutic extraction of both maxillary and mandibular first premolar teeth bilaterally. A single ketoprofen patch was applied for the first and fourth quadrant extraction, and diclofenac patch was applied for the second and third quadrant extraction after atraumatic therapeutic exodontia at 2 consecutive appointments with the patient under local anesthesia. The data were obtained and analyzed using the Student t test and Shapiro-Wilk test using SPSS software (IBM Corp, Armonk, NY). RESULTS All 40 patients who had received a single-dose ketoprofen patch had experienced less postoperative pain and did not require a rescue analgesic with a mean visual analog scale (VAS) score of 1.13 ± 0.335 (P < .00001). The patients who had received a diclofenac patch reported comparatively elevated pain scores in the initial 24 hours, with a mean VAS score of 2.0 ± 0.5064 postoperatively, and 20% of the diclofenac treatment arm had required a rescue analgesic. No complications were observed among the patients postoperatively in either treatment arm. CONCLUSIONS Both the ketoprofen and diclofenac transdermal patches were effective in achieving postoperative analgesia in patients after therapeutic extraction, with ketoprofen superior to diclofenac as a transdermal medicament.",2019,"Both the ketoprofen and diclofenac transdermal patches were effective in achieving postoperative analgesia in patients after therapeutic extraction, with ketoprofen superior to diclofenac as a transdermal medicament.","['patient treatment after an oral and maxillofacial surgical procedure', '40 patients aged 15 to 25\xa0years who had required therapeutic extraction of both maxillary and mandibular first premolar teeth bilaterally', 'patients undergoing orthodontic treatment', 'Patients Undergoing Therapeutic Extraction']","['ketoprofen', 'diclofenac patch', 'diclofenac transdermal patches', 'ketoprofen patch', 'diclofenac', 'Transdermal Ketoprofen and Diclofenac Patch']","['postoperative pain', 'rescue analgesic', 'rescue analgesic with a mean visual analog scale (VAS) score', 'elevated pain scores', 'postoperative analgesia']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C1704302', 'cui_str': 'Premolar'}, {'cui': 'C0029335', 'cui_str': 'Orthodontics'}]","[{'cui': 'C0022635', 'cui_str': 'Ketoprofen'}, {'cui': 'C0012091', 'cui_str': 'Diclofenac'}, {'cui': 'C0445403', 'cui_str': 'Human patch'}, {'cui': 'C0991556', 'cui_str': 'Transdermal System'}, {'cui': 'C4521342', 'cui_str': 'Transdermal (intended site)'}]","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}]",40.0,0.0349406,"Both the ketoprofen and diclofenac transdermal patches were effective in achieving postoperative analgesia in patients after therapeutic extraction, with ketoprofen superior to diclofenac as a transdermal medicament.","[{'ForeName': 'Darpan', 'Initials': 'D', 'LastName': 'Bhargava', 'Affiliation': ""Consultant, Department of Oral and Maxillofacial Surgery, People's College of Dental Sciences and Research Center, People's University, Bhopal, India. Electronic address: emaildarpan@gmail.com.""}, {'ForeName': 'Shaji', 'Initials': 'S', 'LastName': 'Thomas', 'Affiliation': ""Consultant and Head, Department of Oral and Maxillofacial Surgery, People's College of Dental Sciences and Research Center, People's University, Bhopal, India.""}, {'ForeName': 'Sivakumar', 'Initials': 'S', 'LastName': 'Beena', 'Affiliation': ""Resident, Department of Oral and Maxillofacial Surgery, People's College of Dental Sciences and Research Center, People's University, Bhopal, India.""}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.04.007'] 422,31125538,Inferior Alveolar Nerve Block Using the Anterior Technique to Anesthetize Buccal Nerve and Improve Anesthesia Success Rates for Third Molar Extraction: A Randomized Controlled Trial and Magnetic Resonance Imaging Evaluation.,"PURPOSE The lack of anesthesia to the buccal nerve and an insufficient volume of anesthetic have been reported to be responsible for failed inferior alveolar nerve blocks (IANBs) using the Halsted approach (conventional IANB). We aimed to determine the extent of anesthesia in the buccal nerve innervation area and evaluate the anesthetic efficacy of injecting a larger volume of anesthetic during IANB using the anterior approach (anterior technique) in the clinical setting and with magnetic resonance imaging (MRI) analysis. PATIENTS AND METHODS The prospective randomized controlled trial included patients scheduled for removal of a mandibular third molar. The primary predictor variables were the approach for IANB (anterior technique vs conventional IANB) and anesthetic dose (1.8 vs 2.7 mL). The primary outcome variables were the extent of anesthesia and the anesthesia success rate, defined as completion without additional anesthesia. The secondary outcome variable was the anesthetic drug distribution related to the pterygomandibular space measured on T2-weighted MRI scans. Statistical independence of the anesthesia success rate among the primary predictor variables was tested with statistical significance set at P ≤ .05. RESULTS A total of 108 patients and 10 volunteers were enrolled in the clinical and MRI studies, respectively. Anesthesia of the buccal nerve was evident in patients receiving the anterior technique with 2.7 mL of anesthetic. The success rate of the anterior technique with 2.7 mL of anesthetic (96%) was greater than that with 1.8 mL of anesthetic (67%; P = .0113), and increasing the dose had no effect on the efficacy of conventional IANB (78% vs 81%; P = 1.000). The MRI study showed that the anesthetic was distributed over the anterior surface of the temporalis tendon and in the pterygomandibular space after the anterior technique. CONCLUSIONS Anesthesia of the buccal nerve using the anterior technique with 2.7 mL of anesthetic solution might contribute to increasing the success rate of anesthesia for removal of mandibular third molars.",2019,"P = .0113), and increasing the dose had no effect on the efficacy of conventional IANB (78% vs 81%; P = 1.000).","['for Third Molar Extraction', 'patients scheduled for removal of a mandibular third molar', '108 patients and 10 volunteers were enrolled in the clinical and MRI studies, respectively']",['Magnetic Resonance Imaging Evaluation'],"['approach for IANB (anterior technique vs conventional IANB) and anesthetic dose', 'Anesthesia Success Rates', 'anesthetic drug distribution related to the pterygomandibular space measured on T2-weighted MRI scans', 'efficacy of conventional IANB', 'extent of anesthesia and the anesthesia success rate, defined as completion without additional anesthesia', 'success rate of the anterior technique']","[{'cui': 'C0026369', 'cui_str': 'Tooth, Wisdom'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C1552358', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0002930', 'cui_str': 'Anesthesiology'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C0002932', 'cui_str': 'Anesthetic Drugs'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0917711', 'cui_str': 'MRI Scans'}, {'cui': 'C0439792', 'cui_str': 'Extents (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}]",108.0,0.0577331,"P = .0113), and increasing the dose had no effect on the efficacy of conventional IANB (78% vs 81%; P = 1.000).","[{'ForeName': 'Shota', 'Initials': 'S', 'LastName': 'Tsukimoto', 'Affiliation': 'Research Associate, Department of Anesthesiology, Kindai University Faculty of Medicine, Osaka, Japan.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Takasugi', 'Affiliation': 'Assistant Professor, Department of Anesthesiology, Kindai University Faculty of Medicine, Osaka, Japan. Electronic address: dzc01654@nifty.com.'}, {'ForeName': 'Risa', 'Initials': 'R', 'LastName': 'Aoki', 'Affiliation': 'Research Associate, Department of Anesthesiology, Kindai University Faculty of Medicine, Osaka, Japan.'}, {'ForeName': 'Motoshi', 'Initials': 'M', 'LastName': 'Kimura', 'Affiliation': 'Assistant Professor, Department of Oral Surgery, Osaka Medical College, Osaka, Japan.'}, {'ForeName': 'Tatsuo', 'Initials': 'T', 'LastName': 'Konishi', 'Affiliation': 'Radiological Technologist, Department of Radiology, Kindai University Hospital, Osaka, Japan.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.04.021'] 423,31158346,"Assessment of Valeriana officinalis l. (Valerian) for Conscious Sedation of Patients During the Extraction of Impacted Mandibular Third Molars: A Randomized, Split-Mouth, Double-Blind, Crossover Study.","PURPOSE The objective of the present study was to evaluate the effectiveness of an herbal drug (valerian) to control anxiety during mandibular third molar extraction compared with a reference benzodiazepine drug commonly used in dental procedures (midazolam). MATERIALS AND METHODS Twenty anxious patients with an indication for bilateral extraction of mandibular third molars were selected. The patients received capsules containing valerian 100 mg or midazolam 15 mg orally 60 minutes before the procedures in a randomized, split-mouth, crossover design. Changes in the physiological parameters (eg, oxygen saturation, heart rate, blood pressure, respiratory rate) were assessed at specific times during surgery, and the patients completed a questionnaire postoperatively. The data were analyzed using the Wilcoxon and paired t tests, with a significance level of 5%. RESULTS No statistically significant differences in oxygen saturation were observed, regardless of the drug used. However, the other physiological parameters were significantly lower when the patients had taken midazolam compared with valerian. Somnolence was the most common side effect reported with both drugs. CONCLUSIONS Although midazolam was more effective in reducing the physiological parameters studied, valerian seemed to provide the comfort and relaxation required, with no sedation and less somnolence than midazolam, during third molar extraction. Further studies are necessary before valerian can be clinically recommended.",2019,"No statistically significant differences in oxygen saturation were observed, regardless of the drug used.","['Twenty anxious patients with an indication for bilateral extraction of mandibular third molars were selected', 'Conscious Sedation of Patients']","['capsules containing valerian 100\xa0mg or midazolam', 'midazolam', 'benzodiazepine drug commonly used in dental procedures (midazolam', 'Valeriana officinalis l. (Valerian', 'herbal drug (valerian']","['somnolence', 'physiological parameters (eg, oxygen saturation, heart rate, blood pressure, respiratory rate', 'oxygen saturation', 'Somnolence']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0392360', 'cui_str': 'Reason for (attribute)'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C0026369', 'cui_str': 'Tooth, Wisdom'}, {'cui': 'C0079159', 'cui_str': 'Sedation, Moderate'}]","[{'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0042281', 'cui_str': 'Valeriana'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0376667', 'cui_str': 'Herbal'}]","[{'cui': 'C2830004', 'cui_str': 'Somnolence'}, {'cui': 'C0205463', 'cui_str': 'Physiologic (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0231832', 'cui_str': 'Respiration Rate'}]",20.0,0.125999,"No statistically significant differences in oxygen saturation were observed, regardless of the drug used.","[{'ForeName': 'Gustavo Jacobucci', 'Initials': 'GJ', 'LastName': 'Farah', 'Affiliation': 'Professor, Division of Oral and Maxillofacial Surgery, Department of Dentistry, State University of Maringá, Maringá, Brazil.'}, {'ForeName': 'Gustavo Zanna', 'Initials': 'GZ', 'LastName': 'Ferreira', 'Affiliation': 'Professor, Division of Oral and Maxillofacial Surgery, Department of Dentistry, UniCesumar, Maringá, Brazil; and PhD Student, Bauru School of Dentistry, University of São Paulo, São Paulo, Brazil. Electronic address: gustavozanna@hotmail.com.'}, {'ForeName': 'Carolina Ferrairo', 'Initials': 'CF', 'LastName': 'Danieletto-Zanna', 'Affiliation': 'Professor, Division of Oral and Maxillofacial Surgery, Department of Dentistry, UniCesumar, Maringá, Brazil; and PhD Student, Bauru School of Dentistry, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Caroline Resquetti', 'Initials': 'CR', 'LastName': 'Luppi', 'Affiliation': 'Specialist, Private Practitioner, Maringá, Paraná, Brazil.'}, {'ForeName': 'Willian Pecin', 'Initials': 'WP', 'LastName': 'Jacomacci', 'Affiliation': 'Specialist, Private Practitioner Maringá, Paraná, Brazil.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.05.003'] 424,31260676,Is There a Benefit to the Use of Melatonin in Preoperative Zygomatic Fractures?,"PURPOSE We evaluated the effects of melatonin used in the preoperative period for patients who had undergone surgical treatment of a zygomatic fracture. PATIENTS AND METHODS A triple-blind, randomized clinical trial of 2 groups was conducted: the melatonin group (10 mg) and the placebo group. After allocation, 1 tablet of melatonin was used the night before and another tablet 2 hours before the start of surgery. Approximately 30 minutes before anesthetic induction, the following variables were evaluated: sleep quality, degree of sedation and anxiolysis using the Richmond Agitation-Sedation Scale, and the amount of opioid analgesic used intraoperatively. At the end of surgery, the time required for safe endotracheal extubation was evaluated. Next, a descriptive and inferential statistical analysis was performed. The margin of error considered was 5%. RESULTS Of the 68 analyzed patients, 36 had been allocated to the melatonin group and 32 to the placebo group. In the sleep quality evaluation for the night before surgery, 61.1% of the melatonin group reported better or much better sleep than usual, and 100% of the placebo group reported worse sleep or sleep as usual (P < .001). Melatonin was no better than placebo in relation to anxiolysis (P > .05). The average final dose of the opioid was lower, and the difference was statistically significant, in the melatonin group (0.296 ± 0.036 μg/kg/min vs 0.372 ± 0.037 μg/kg/min in the placebo group). The interval required for safe endotracheal extubation was longer, and the difference was statistically significant, in the melatonin group (14.84 ± 1.8 minutes vs 12.72 ± 0.99 minutes in the placebo group). CONCLUSIONS In the present study, melatonin was effective in improving sleep quality the night before surgery and in reducing intraoperative opioid consumption. An increase in the time required for safe endotracheal extubation was found in the melatonin group, and no improvement was seen in anxiolysis.",2019,"The average final dose of the opioid was lower, and the difference was statistically significant, in the melatonin group (0.296 ± 0.036 μg/kg/min vs 0.372 ± 0.037 μg/kg/min in the placebo group).","['68 analyzed patients', 'patients who had undergone surgical treatment of a zygomatic fracture']","['melatonin', 'Melatonin', 'placebo']","['sleep quality, degree of sedation and anxiolysis using the Richmond Agitation-Sedation Scale, and the amount of opioid analgesic used intraoperatively', 'time required for safe endotracheal extubation', 'interval required for safe endotracheal extubation', 'anxiolysis', 'sleep or sleep', 'sleep quality']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0043540', 'cui_str': 'Zygomatic Fractures'}]","[{'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C1961138', 'cui_str': 'Anxiolysis'}, {'cui': 'C4720839', 'cui_str': 'Richmond agitation-sedation scale'}, {'cui': 'C0002772', 'cui_str': 'Analgesics, Opioid'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C1272706', 'cui_str': 'Interval'}]",,0.170791,"The average final dose of the opioid was lower, and the difference was statistically significant, in the melatonin group (0.296 ± 0.036 μg/kg/min vs 0.372 ± 0.037 μg/kg/min in the placebo group).","[{'ForeName': 'Emerson Filipe', 'Initials': 'EF', 'LastName': 'de Carvalho Nogueira', 'Affiliation': 'Postgraduate Student, Department of Oral and Maxillofacial Surgery, University of Pernambuco; and Professor, Department of Oral Surgery, UNIBRA, Recife, Brazil. Electronic address: emerson_filipe@hotmail.com.'}, {'ForeName': 'Rafaela', 'Initials': 'R', 'LastName': 'de Oliveira Vasconcelos', 'Affiliation': 'Resident, Department of Oral and Maxillofacial Surgery, Hospital da Restauração, Recife, Brazil.'}, {'ForeName': 'Sheyla Simony', 'Initials': 'SS', 'LastName': 'Teixeira Correia', 'Affiliation': 'Resident, Department of Oral and Maxillofacial Surgery, Hospital da Restauração, Recife, Brazil.'}, {'ForeName': 'Ivson', 'Initials': 'I', 'LastName': 'Souza Catunda', 'Affiliation': 'Private Practitioner, Diface Clinical, Recife, Brazil.'}, {'ForeName': 'Jane Auxiliadora', 'Initials': 'JA', 'LastName': 'Amorim', 'Affiliation': 'Professor and Staff, Department of Anesthesiology, Hospital da Restauração, Recife, Brazil.'}, {'ForeName': 'Belmiro', 'Initials': 'B', 'LastName': 'do Egito Cavalcanti Vasconcelos', 'Affiliation': 'Professor and Head, Department of Oral and Maxillofacial Surgery, University of Pernambuco, Recife, Brazil.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.05.016'] 425,31319053,"Comparison of Three Anxiety Management Protocols for Extraction of Third Molars With the Use of Midazolam, Diazepam, and Nitrous Oxide: A Randomized Clinical Trial.","PURPOSE The objective of the present study was to compare 3 sedation protocols using diazepam, midazolam, and nitrous oxide. PATIENTS AND METHODS A total of 120 patients with an indication for extraction of third molars were selected. All 120 patients had had moderate to severe levels of anxiety according to the Corah Dental Anxiety Scale. The patients were randomly divided into 3 groups. The patients' vital signs were measured, and the results analyzed by descriptive statistical analysis and statistical tests of comparison. RESULTS No statistically significant differences were found in the patients' heart rate. However, the differences in the systolic and diastolic blood pressure were statistically significant after 15 minutes of nitrous oxide sedation. The oximetry data showed no differences among the 3 sedation protocols. We also found no statistically significant differences in the retrograde amnesia test. The differences in anxiety from preoperatively to postoperatively were statistically significant for all techniques, demonstrating their effectiveness in anxiety control. CONCLUSIONS All 3 preoperative sedation techniques for anxious patients undergoing extraction of third molars used in the present study were effective in controlling the anxiety, with little effect on the patients' vital signs and retrograde amnesia.",2019,"The differences in anxiety from preoperatively to postoperatively were statistically significant for all techniques, demonstrating their effectiveness in anxiety control. ","['anxious patients undergoing extraction of third molars', 'All 120 patients had had moderate to severe levels of anxiety according to the Corah Dental Anxiety Scale', '120 patients with an indication for extraction of third molars were selected']","['diazepam, midazolam, and nitrous oxide', 'Midazolam, Diazepam, and Nitrous Oxide']","['systolic and diastolic blood pressure', 'retrograde amnesia test', 'anxiety', ""patients' heart rate""]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C0026369', 'cui_str': 'Tooth, Wisdom'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety (observable entity)'}, {'cui': 'C0085380', 'cui_str': 'Fear, Dental'}, {'cui': 'C0222045'}, {'cui': 'C0392360', 'cui_str': 'Reason for (attribute)'}]","[{'cui': 'C0012010', 'cui_str': 'Diazepam'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0028215', 'cui_str': 'Nitrous Oxide'}]","[{'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0002624', 'cui_str': 'Retrograde amnesia (finding)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}]",120.0,0.0188975,"The differences in anxiety from preoperatively to postoperatively were statistically significant for all techniques, demonstrating their effectiveness in anxiety control. ","[{'ForeName': 'Michelle Bianchi', 'Initials': 'MB', 'LastName': 'de Moares', 'Affiliation': 'Assistant Professor, Oral and Maxillofacial Surgery Area, Department of Diagnosis and Surgery, College of Dentistry, State University of São Paulo, São José dos Campos, Brazil.'}, {'ForeName': 'Winnie Souza', 'Initials': 'WS', 'LastName': 'Barbier', 'Affiliation': 'DDS Student, Oral and Maxillofacial Surgery Area, Department of Diagnosis and Surgery, College of Dentistry, State University of São Paulo, São José dos Campos, Brazil.'}, {'ForeName': 'Fernando Vagner', 'Initials': 'FV', 'LastName': 'Raldi', 'Affiliation': 'Assistant Professor, Oral and Maxillofacial Surgery Area, Department of Diagnosis and Surgery, College of Dentistry, State University of São Paulo, São José dos Campos, Brazil.'}, {'ForeName': 'Rodrigo Dias', 'Initials': 'RD', 'LastName': 'Nascimento', 'Affiliation': 'Assistant Professor, Oral and Maxillofacial Surgery Area, Department of Diagnosis and Surgery, College of Dentistry, State University of São Paulo, São José dos Campos, Brazil.'}, {'ForeName': 'Lúcio Murilo', 'Initials': 'LM', 'LastName': 'Dos Santos', 'Affiliation': 'Assistant Professor, Department of Biosciences and Oral Diagnosis, College of Dentistry, State University of São Paulo, São José dos Campos, Brazil.'}, {'ForeName': 'Fábio Ricardo', 'Initials': 'FR', 'LastName': 'Loureiro Sato', 'Affiliation': 'Assistant Professor, Oral and Maxillofacial Surgery Area, Department of Diagnosis and Surgery, College of Dentistry, State University of São Paulo, São José dos Campos, Brazil. Electronic address: fabio.sato@ict.unesp.br.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.06.001'] 426,31028737,"Effectiveness of Articaine Buccal Infiltration Anesthesia for Mandibular Premolar Extraction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.","PURPOSE To evaluate the anesthetic adequacy of buccal versus buccal plus lingual infiltration of 4% articaine 1.8 mL for mandibular premolar teeth extraction. PATIENTS AND METHODS A randomized, double-blinded, placebo-controlled clinical trial was conducted in which patients presented with a mandibular premolar for extraction under local anesthesia. The sample population was randomly divided into 2 equal groups: the first group received infiltration of 4% articaine 1.8 mL buccally and 0.4 mL lingually and the second group received infiltration of 4% articaine 1.8 mL buccally plus lingual injection of normal saline 0.4 mL. Pain was measured during anesthetic injection, 8 minutes after injection, and during extraction using a visual analog scale. Initial lingual anesthesia and patients' satisfaction were measured using a 5-score verbal rating scale. Statistical analyses included descriptive statistics, t test, and Pearson χ 2 test. Significance was set at a P value less than.05. RESULTS Seventy-two patients were included in this study (37 men and 35 women; average age, 49.8 yr). Mean pain scores during injection and extraction and satisfaction scores were comparable between study groups (P = .432, .240, and .478, respectively). Success rates were 100 and 89% in groups A and B, respectively, with no significant difference (P = .1145). CONCLUSIONS The anesthetic parameters of 1 buccal infiltration of 4% articaine 1.8 mL with and without lingual supplementation were comparable. This result could justify the use of buccal articaine infiltration as an effective alternative to the standard inferior alveolar nerve block technique for extraction of lower premolar teeth.",2019,"Mean pain scores during injection and extraction and satisfaction scores were comparable between study groups (P = .432, .240, and .478, respectively).","['patients presented with a mandibular premolar for extraction under local anesthesia', 'Mandibular Premolar Extraction', 'mandibular premolar teeth extraction', 'Seventy-two patients were included in this study (37 men and 35 women; average age, 49.8\xa0yr']","['placebo', 'normal saline 0.4', 'Placebo', 'articaine 1.8\xa0mL', 'Articaine Buccal Infiltration Anesthesia', 'articaine 1.8']","['5-score verbal rating scale', 'Success rates', 'Mean pain scores during injection and extraction and satisfaction scores', 'mL. Pain']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C1704302', 'cui_str': 'Premolar'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C1720162', 'cui_str': 'Under local anesthesia'}, {'cui': 'C4319632', 'cui_str': 'Seventy-two'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C4517457', 'cui_str': 'Zero point four'}, {'cui': 'C1608295', 'cui_str': 'Articaine'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C0442010', 'cui_str': 'Buccal (qualifier value)'}, {'cui': 'C0234945', 'cui_str': 'Anesthesia, Infiltration'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0458261', 'cui_str': 'Verbal rating scale (assessment scale)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",72.0,0.315743,"Mean pain scores during injection and extraction and satisfaction scores were comparable between study groups (P = .432, .240, and .478, respectively).","[{'ForeName': 'Omer Waleed', 'Initials': 'OW', 'LastName': 'Majid', 'Affiliation': 'Assistant Professor, Department of Oral and Maxillofacial Surgery, College of Dentistry, University of Mosul, Mosul, Iraq. Electronic address: omerwaleedmajid@gmail.com.'}, {'ForeName': 'Zaid Abdulazeez', 'Initials': 'ZA', 'LastName': 'Muhammad', 'Affiliation': 'Assistant Lecturer, Department of Oral and Maxillofacial Surgery, College of Dentistry, University of Mosul, Mosul, Iraq.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.03.033'] 427,32209825,Community Health Workers Reduce Rehospitalizations and Emergency Department Visits for Low-Socioeconomic Urban Patients With Heart Failure.,"BACKGROUND Low-socioeconomic, urban, minority patients with heart failure (HF) often have unique barriers to care. Community health workers (CHWs) are specially trained laypeople who serve as liaisons between underserved communities and the health system. It is not known whether CHWs improve outcomes in low-socioeconomic, urban, minority patients with HF. HYPOTHESIS CHWs reduce rehospitalizations, emergency department (ED) visits, and healthcare costs for low-socioeconomic urban patients with HF. METHODS Patients admitted with acute decompensated HF were assigned to receive weekly visits by CHW after discharge. Patients were propensity score matched with controls who received usual care. HF-related rehospitalizations, ED visits, and inpatient costs were compared for 12 months following index admission versus the same period before. RESULTS Twenty-eight patients who received weekly visits from a CHW for 12 months after discharge were matched with 28 control patients who did not receive CHWs. Patients who received a CHW had a 75% decrease in HF-related ED visits (0.71 vs. 0.18 visits per patient, P < 0.001), an 89% decrease in HF-related readmissions (0.64 vs. 0.07 admissions per patient, P < 0.005), and a significant decrease in inpatient cost for HF-related visits. In controls receiving usual care, there was no significant change in hospitalizations, ED visits, or costs. CONCLUSIONS In conclusion, CHWs are associated with reduced rehospitalizations, ED visits, and inpatient costs in low-socioeconomic, urban, minority patients with HF. CHWs may be a cost-effective method to reduce health care utilization and improve outcomes for this population.",2020,"In controls receiving usual care, there was no significant change in hospitalizations, ED visits, or costs. ","['Community health workers (CHW) are specially trained lay-people who serve as liaisons between underserved communities and the health system', 'Patients were propensity-score matched with controls who received usual care', 'Low-Socioeconomic Urban Patients with Heart Failure', 'minority patients with heart failure (HF', 'low-socioeconomic, urban, minority patients with HF', 'Patients admitted with acute decompensated HF', 'low-socioeconomic urban patients with heart failure (HF', 'Twenty-eight patients who received weekly visits from a CHW for 12 months after discharge were matched with 28 control patients who did not receive CHWs']","['CHWs', 'CHW']","['rehospitalizations, emergency department (ED) visits, and healthcare costs', 'reduced rehospitalizations, ED visits, and inpatient costs', 'HF-related readmissions', 'hospitalizations, ED visits, or costs', 'inpatient cost for HF-related visits', 'HF-related rehospitalizations, ED visits, and inpatient costs', 'HF-related ED visits']","[{'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2718044', 'cui_str': 'Propensity Score'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}]",[],"[{'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0085552', 'cui_str': 'Healthcare Costs'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}]",28.0,0.0287021,"In controls receiving usual care, there was no significant change in hospitalizations, ED visits, or costs. ","[{'ForeName': 'Adam S', 'Initials': 'AS', 'LastName': 'Vohra', 'Affiliation': 'From the Department of Medicine, The University of Chicago, Chicago, IL.'}, {'ForeName': 'Rhys F M', 'Initials': 'RFM', 'LastName': 'Chua', 'Affiliation': 'Section of Cardiology, Department of Medicine, The University of Chicago, Chicago, IL, and.'}, {'ForeName': 'Stephanie A', 'Initials': 'SA', 'LastName': 'Besser', 'Affiliation': 'Section of Cardiology, Department of Medicine, The University of Chicago, Chicago, IL, and.'}, {'ForeName': 'Charina F', 'Initials': 'CF', 'LastName': 'Alcain', 'Affiliation': 'Section of Cardiology, Department of Medicine, The University of Chicago, Chicago, IL, and.'}, {'ForeName': 'Sweta', 'Initials': 'S', 'LastName': 'Basnet', 'Affiliation': 'Urban Health Initiative, The University of Chicago Medicine, Chicago, IL.'}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Battle', 'Affiliation': 'Urban Health Initiative, The University of Chicago Medicine, Chicago, IL.'}, {'ForeName': 'Mitchell J', 'Initials': 'MJ', 'LastName': 'Coplan', 'Affiliation': 'Section of Cardiology, Department of Medicine, The University of Chicago, Chicago, IL, and.'}, {'ForeName': 'James K', 'Initials': 'JK', 'LastName': 'Liao', 'Affiliation': 'Section of Cardiology, Department of Medicine, The University of Chicago, Chicago, IL, and.'}, {'ForeName': 'Corey E', 'Initials': 'CE', 'LastName': 'Tabit', 'Affiliation': 'Section of Cardiology, Department of Medicine, The University of Chicago, Chicago, IL, and.'}]",Critical pathways in cardiology,['10.1097/HPC.0000000000000220'] 428,32211998,Exercise for the intervertebral disc: a 6-month randomised controlled trial in chronic low back pain.,"BACKGROUND CONTEXT Muscle, bone and tendon respond anabolically to mechanical forces. Whether the intervertebral disc (IVD) can benefit from exercise is unclear. PURPOSE To examine whether exercise can beneficially affect IVD characteristics. STUDY DESIGN/SETTING This is a single-blinded 6-month randomised controlled trial (ACTRN12615001270505) in an exercise and physiotherapy clinic. PATIENT SAMPLE Forty patients with chronic non-specific low back pain (NSCLBP) are included in this study. OUTCOME MEASURES The primary outcome was lumbar IVD T2 time (MRI). Secondary outcomes included IVD diffusion coefficient and IVD expansion with short-duration lying. METHODS Twenty patients progressively loaded their lumbar IVDs (exercise) via an exercise programme involving progressive upright aerobic and resistance exercises targeting the trunk and major muscle groups and were compared to twenty patients who performed motor control training and manual therapy (control). Testing occurred at baseline, 3 months and 6 months. RESULTS Seventeen exercise and fifteen control patients completed the interventions. There were no group-by-time differences in T2 time of the entire IVD (exercise 94.1 ± 10.0 ms vs. control 96.5 ± 9.3 ms, p = 0.549). Exercise patients had shorter T2 time in the posterior annulus at 6 months (82.7 ± 6.8 ms vs. 85.1 ± 8.0 ms, p = 0.028). Exercise patients showed higher L5/S1 apparent diffusion coefficients and decreased IVD height at 3 months (both p ≤ 0.050). After adjustments for multiple comparisons, differences lost statistical significance. Per-protocol and intent-to-treat analyses yielded similar findings. CONCLUSIONS This trial found that 6 months of exercise did not benefit the IVD of people with NSCLBP. Based on this index study, future studies could investigate the effect of exercise on IVD in different populations, with different types, durations and/or intensities of exercise, and using different IVD markers. These slides can be retrieved under Electronic Supplementary Material.",2020,Exercise patients showed higher L5/S1 apparent diffusion coefficients and decreased IVD height at 3 months (both p ≤ 0.050).,"['Twenty patients progressively loaded their lumbar IVDs (exercise) via an', 'chronic low back pain', 'SAMPLE\n\n\nForty patients with chronic non-specific low back pain (NSCLBP']",['exercise programme involving progressive upright aerobic and resistance exercises targeting the trunk and major muscle groups and were compared to twenty patients who performed motor control training and manual therapy (control'],"['T2 time of the entire IVD', 'shorter T2 time', 'higher L5/S1 apparent diffusion coefficients and decreased IVD height', 'lumbar IVD T2 time (MRI', 'IVD diffusion coefficient and IVD expansion with short-duration lying']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain (finding)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0205370', 'cui_str': 'Non-specific (qualifier value)'}, {'cui': 'C0024031', 'cui_str': 'Low Back Ache'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0460005', 'cui_str': 'Torso'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0454525', 'cui_str': 'Manual Therapies'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439751', 'cui_str': 'Entire (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0024090', 'cui_str': 'Lumbar Region'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0439593', 'cui_str': 'Short duration (qualifier value)'}]",40.0,0.133116,Exercise patients showed higher L5/S1 apparent diffusion coefficients and decreased IVD height at 3 months (both p ≤ 0.050).,"[{'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Owen', 'Affiliation': 'Deakin University, Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Geelong, Australia. p.owen@deakin.edu.au.'}, {'ForeName': 'Clint T', 'Initials': 'CT', 'LastName': 'Miller', 'Affiliation': 'Deakin University, School of Exercise and Nutrition Sciences, Geelong, Australia.'}, {'ForeName': 'Timo', 'Initials': 'T', 'LastName': 'Rantalainen', 'Affiliation': 'Deakin University, Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Geelong, Australia.'}, {'ForeName': 'Katherine J', 'Initials': 'KJ', 'LastName': 'Simson', 'Affiliation': 'Deakin University, School of Exercise and Nutrition Sciences, Geelong, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Connell', 'Affiliation': 'Imaging@Olympic Park, Melbourne, Australia.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Hahne', 'Affiliation': 'Low Back Research Team, College of Science, Health & Engineering, La Trobe University, Bundoora, Australia.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Trudel', 'Affiliation': 'Bone and Joint Research Laboratory, Division of Physical Medicine and Rehabilitation, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.'}, {'ForeName': 'Jon J', 'Initials': 'JJ', 'LastName': 'Ford', 'Affiliation': 'Low Back Research Team, College of Science, Health & Engineering, La Trobe University, Bundoora, Australia.'}, {'ForeName': 'Daniel L', 'Initials': 'DL', 'LastName': 'Belavy', 'Affiliation': 'Deakin University, Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Geelong, Australia. d.belavy@deakin.edu.au.'}]","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society",['10.1007/s00586-020-06379-7'] 429,32209645,Continuous Glucose Monitoring in Pregnancy: Importance of Analyzing Temporal Profiles to Understand Clinical Outcomes.,"OBJECTIVE To determine if temporal glucose profiles differed between 1 ) women who were randomized to real-time continuous glucose monitoring (RT-CGM) or self-monitored blood glucose (SMBG), 2 ) women who used insulin pumps or multiple daily insulin injections (MDIs), and 3 ) women whose infants were born large for gestational age (LGA) or not, by assessing CGM data obtained from the Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT). RESEARCH DESIGN AND METHODS Standard summary metrics and functional data analysis (FDA) were applied to CGM data from the CONCEPTT trial (RT-CGM, n = 100; SMBG, n = 100) taken at baseline and at 24- and 34-weeks' gestation. Multivariable regression analysis determined if temporal differences in 24-h glucose profiles occurred between comparators in each of the three groups. RESULTS FDA revealed that women using RT-CGM had significantly lower glucose (0.4-0.8 mmol/L [7-14 mg/dL]) for 7 h/day (0800 h to 1200 h and 1600 h to 1900 h) compared with those with SMBG. Women using pumps had significantly higher glucose (0.4-0.9 mmol/L [7-16 mg/dL]) for 12 h/day (0300 h to 0600 h, 1300 h to 1800 h, and 2030 h to 0030 h) at 24 weeks with no difference at 34 weeks compared with MDI. Women who had an LGA infant ran a significantly higher glucose by 0.4-0.7 mmol/L (7-13 mg/dL) for 4.5 h/day at baseline, by 0.4-0.9 mmol/L (7-16 mg/dL) for 16 h/day at 24 weeks, and by 0.4-0.7 mmol/L (7-13 mg/dL) for 14 h/day at 34 weeks. CONCLUSIONS FDA of temporal glucose profiles gives important information about differences in glucose control and its timing, which are undetectable by standard summary metrics. Women using RT-CGM were able to achieve better daytime glucose control, reducing fetal exposure to maternal glucose.",2020,"Multivariable regression analysis determined if temporal differences in 24-h glucose profiles occurred between comparators in each of the three groups. ","['temporal glucose profiles differed between 1 ) women who were randomized to', 'Women who had an LGA infant ran a significantly', 'MDIs), and 3 ) women whose infants were born large for gestational age (LGA) or not, by assessing CGM data obtained from the Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT', 'Pregnancy']","['real-time continuous glucose monitoring (RT-CGM) or self-monitored blood glucose (SMBG), 2 ) women who used insulin pumps or multiple daily insulin injections']","['higher glucose', 'daytime glucose control, reducing fetal exposure to maternal glucose', '24-h glucose profiles']","[{'cui': 'C0442043', 'cui_str': 'Temporal (qualifier value)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C1848395', 'cui_str': 'Large for gestational age'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C4523945', 'cui_str': 'Continuous glucose monitoring'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1140609', 'cui_str': 'Insulin pump'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0586328', 'cui_str': 'Insulin injection'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0332169', 'cui_str': 'Daytime (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}]",2.0,0.024243,"Multivariable regression analysis determined if temporal differences in 24-h glucose profiles occurred between comparators in each of the three groups. ","[{'ForeName': 'Eleanor M', 'Initials': 'EM', 'LastName': 'Scott', 'Affiliation': 'Department of Clinical and Population Science, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K. e.m.scott@leeds.ac.uk.'}, {'ForeName': 'Denice S', 'Initials': 'DS', 'LastName': 'Feig', 'Affiliation': 'Department of Medicine, Sinai Health System, Toronto, Ontario, Canada.'}, {'ForeName': 'Helen R', 'Initials': 'HR', 'LastName': 'Murphy', 'Affiliation': ""Division of Maternal Health, St Thomas' Hospital, King's College London, London, U.K.""}, {'ForeName': 'Graham R', 'Initials': 'GR', 'LastName': 'Law', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes care,['10.2337/dc19-2527'] 430,31974142,PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid.,"The cardiovascular benefits of fibrates have been shown to be heterogeneous and to depend on the presence of atherogenic dyslipidemia. We investigated whether genetic variability in the PPARA gene, coding for the pharmacological target of fibrates (PPAR-α), could be used to improve the selection of patients with type 2 diabetes who may derive cardiovascular benefit from addition of this treatment to statins. We identified a common variant at the PPARA locus (rs6008845, C/T) displaying a study-wide significant influence on the effect of fenofibrate on major cardiovascular events (MACE) among 3,065 self-reported white subjects treated with simvastatin and randomized to fenofibrate or placebo in the ACCORD-Lipid trial. T/T homozygotes (36% of participants) experienced a 51% MACE reduction in response to fenofibrate (hazard ratio 0.49; 95% CI 0.34-0.72), whereas no benefit was observed for other genotypes ( P interaction = 3.7 × 10 -4 ). The rs6008845-by-fenofibrate interaction on MACE was replicated in African Americans from ACCORD ( N = 585, P = 0.02) and in external cohorts (ACCORD-BP, ORIGIN, and TRIUMPH, total N = 3059, P = 0.005). Remarkably, rs6008845 T/T homozygotes experienced a cardiovascular benefit from fibrate even in the absence of atherogenic dyslipidemia. Among these individuals, but not among carriers of other genotypes, fenofibrate treatment was associated with lower circulating levels of CCL11-a proinflammatory and atherogenic chemokine also known as eotaxin ( P for rs6008845-by-fenofibrate interaction = 0.003). The GTEx data set revealed regulatory functions of rs6008845 on PPARA expression in many tissues. In summary, we have found a common PPARA regulatory variant that influences the cardiovascular effects of fenofibrate and that could be used to identify patients with type 2 diabetes who would derive benefit from fenofibrate treatment, in addition to those with atherogenic dyslipidemia.",2020,T/T homozygotes (36% of participants) experienced a 51% MACE reduction in response to fenofibrate (HR=0.49; 95%C.I. 0.34-0.72) whereas no benefit was observed for other genotypes (p for interaction=3.7x10 -4 ).,"['Type 2 Diabetes', '3,065 self-reported White subjects treated with', 'patients with type 2 diabetes']","['Fenofibrate', 'simvastatin', 'fenofibrate', 'fenofibrate or placebo']","['circulating levels of CCL11 - a pro-inflammatory and atherogenic chemokine', 'major cardiovascular events (MACE']","[{'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0033228', 'cui_str': 'Fenofibrate'}, {'cui': 'C0074554', 'cui_str': 'Simvastatin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0282554', 'cui_str': 'Cytokines, Chemotactic'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0349381', 'cui_str': 'Mace (substance)'}]",,0.0503884,T/T homozygotes (36% of participants) experienced a 51% MACE reduction in response to fenofibrate (HR=0.49; 95%C.I. 0.34-0.72) whereas no benefit was observed for other genotypes (p for interaction=3.7x10 -4 ).,"[{'ForeName': 'Mario Luca', 'Initials': 'ML', 'LastName': 'Morieri', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA.'}, {'ForeName': 'Hetal S', 'Initials': 'HS', 'LastName': 'Shah', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Sjaarda', 'Affiliation': 'McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada.'}, {'ForeName': 'Petra A', 'Initials': 'PA', 'LastName': 'Lenzini', 'Affiliation': 'Department of Genetics, Washington University School of Medicine, St. Louis, MO.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Campbell', 'Affiliation': 'Department of Genetics, Washington University School of Medicine, St. Louis, MO.'}, {'ForeName': 'Alison A', 'Initials': 'AA', 'LastName': 'Motsinger-Reif', 'Affiliation': 'Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Durham, NC.'}, {'ForeName': 'He', 'Initials': 'H', 'LastName': 'Gao', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Lovato', 'Affiliation': 'Wake Forest School of Medicine, Winston Salem, NC.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Prudente', 'Affiliation': 'Research Unit of Metabolic and Cardiovascular Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.'}, {'ForeName': 'Assunta', 'Initials': 'A', 'LastName': 'Pandolfi', 'Affiliation': 'Department of Medical, Oral and Biotechnological Sciences, University ""G. d\'Annunzio,"" Chieti, Italy.'}, {'ForeName': 'Marcus G', 'Initials': 'MG', 'LastName': 'Pezzolesi', 'Affiliation': 'Division of Nephrology and Hypertension and Diabetes and Metabolism Center, University of Utah, Salt Lake City, UT.'}, {'ForeName': 'Ronald J', 'Initials': 'RJ', 'LastName': 'Sigal', 'Affiliation': 'Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Cumming School of Medicine, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Paré', 'Affiliation': 'McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada.'}, {'ForeName': 'Santica M', 'Initials': 'SM', 'LastName': 'Marcovina', 'Affiliation': 'Department of Medicine, University of Washington, and Northwest Lipid Metabolism and Diabetes Research Laboratories, Seattle, WA.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Rotroff', 'Affiliation': 'Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.'}, {'ForeName': 'Elisabetta', 'Initials': 'E', 'LastName': 'Patorno', 'Affiliation': ""Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.""}, {'ForeName': 'Luana', 'Initials': 'L', 'LastName': 'Mercuri', 'Affiliation': 'Research Unit of Metabolic and Cardiovascular Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.'}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Trischitta', 'Affiliation': 'Research Unit of Metabolic and Cardiovascular Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.'}, {'ForeName': 'Emily Y', 'Initials': 'EY', 'LastName': 'Chew', 'Affiliation': 'Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Kraft', 'Affiliation': 'Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA.'}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Buse', 'Affiliation': 'Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Wagner', 'Affiliation': 'Center for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Cresci', 'Affiliation': 'Department of Genetics, Washington University School of Medicine, St. Louis, MO.'}, {'ForeName': 'Hertzel C', 'Initials': 'HC', 'LastName': 'Gerstein', 'Affiliation': 'McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada.'}, {'ForeName': 'Henry N', 'Initials': 'HN', 'LastName': 'Ginsberg', 'Affiliation': 'Irving Institute for Clinical and Translational Research, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY.'}, {'ForeName': 'Josyf C', 'Initials': 'JC', 'LastName': 'Mychaleckyj', 'Affiliation': 'Center for Public Health Genomics, University of Virginia, Charlottesville, VA.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Doria', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA alessandro.doria@joslin.harvard.edu.'}]",Diabetes,['10.2337/db19-0973'] 431,31484786,Home initiation of chronic non-invasive ventilation in COPD patients with chronic hypercapnic respiratory failure: a randomised controlled trial.,"INTRODUCTION Chronic non-invasive ventilation (NIV) has become evidence-based care for stable hypercapnic COPD patients. While the number of patients increases, home initiation of NIV would greatly alleviate the healthcare burden. We hypothesise that home initiation of NIV with the use of telemedicine in stable hypercapnic COPD is non-inferior to in-hospital NIV initiation. METHODS Sixty-seven stable hypercapnic COPD patients were randomised to initiation of NIV in the hospital or at home using telemedicine. Primary outcome was daytime arterial carbon dioxide pressure (PaCO 2 ) reduction after 6 months NIV, with a non-inferiority margin of 0.4 kPa. Secondary outcomes were health-related quality of life (HRQoL) and costs. RESULTS Home NIV initiation was non-inferior to in-hospital initiation (adjusted mean difference in PaCO 2 change home vs in-hospital: 0.04 kPa (95% CI -0.31 to 0.38 kPa), with both groups showing a PaCO 2 reduction at 6 months compared with baseline (home: from 7.3±0.9 to 6.4±0.8 kPa (p<0.001) and in-hospital: from 7.4±1.0 to 6.4±0.6 kPa (p<0.001)). In both groups, HRQoL improved without a difference in change between groups (Clinical COPD Questionnaire total score-adjusted mean difference 0.0 (95% CI -0.4 to 0.5)). Furthermore, home NIV initiation was significantly cheaper (home: median €3768 (IQR €3546-€4163) vs in-hospital: median €8537 (IQR €7540-€9175); p<0.001). DISCUSSION This is the first study showing that home initiation of chronic NIV in stable hypercapnic COPD patients, with the use of telemedicine, is non-inferior to in-hospital initiation, safe and reduces costs by over 50%. TRIAL REGISTRATION NUMBER NCT02652559.",2020,"In both groups, HRQoL improved without a difference in change between groups (Clinical COPD Questionnaire total score-adjusted mean difference 0.0 (95% CI -0.4 to 0.5)).","['Sixty-seven stable hypercapnic COPD patients', 'stable hypercapnic COPD patients', 'COPD patients with chronic hypercapnic respiratory failure']","['telemedicine', 'chronic non-invasive ventilation', 'Chronic non-invasive ventilation (NIV']","['daytime arterial carbon dioxide pressure (PaCO 2 ) reduction', 'health-related quality of life (HRQoL) and costs', 'Clinical COPD Questionnaire total score']","[{'cui': 'C4517852', 'cui_str': '67'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0020440', 'cui_str': 'Hypercapnia'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1960052', 'cui_str': 'Chronic type II respiratory failure'}]","[{'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C1997883', 'cui_str': 'Non Invasive Ventilation'}]","[{'cui': 'C0332169', 'cui_str': 'Daytime (qualifier value)'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",67.0,0.274177,"In both groups, HRQoL improved without a difference in change between groups (Clinical COPD Questionnaire total score-adjusted mean difference 0.0 (95% CI -0.4 to 0.5)).","[{'ForeName': 'Marieke L', 'Initials': 'ML', 'LastName': 'Duiverman', 'Affiliation': 'Department of Pulmonary Diseases/Home Mechanical Ventilation, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands m.l.duiverman@umcg.nl.'}, {'ForeName': 'Judith M', 'Initials': 'JM', 'LastName': 'Vonk', 'Affiliation': 'Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Gerrie', 'Initials': 'G', 'LastName': 'Bladder', 'Affiliation': 'Department of Pulmonary Diseases/Home Mechanical Ventilation, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Joost P', 'Initials': 'JP', 'LastName': 'van Melle', 'Affiliation': 'Thoraxcenter, Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Jellie', 'Initials': 'J', 'LastName': 'Nieuwenhuis', 'Affiliation': 'Department of Pulmonary Diseases/Home Mechanical Ventilation, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Anda', 'Initials': 'A', 'LastName': 'Hazenberg', 'Affiliation': 'Department of Pulmonary Diseases/Home Mechanical Ventilation, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Huib A M', 'Initials': 'HAM', 'LastName': 'Kerstjens', 'Affiliation': 'Department of Pulmonary Diseases/Home Mechanical Ventilation, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Job F M', 'Initials': 'JFM', 'LastName': 'van Boven', 'Affiliation': 'Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Wijkstra', 'Affiliation': 'Department of Pulmonary Diseases/Home Mechanical Ventilation, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}]",Thorax,['10.1136/thoraxjnl-2019-213303'] 432,30796909,Hybrid Arch Bars Reduce Placement Time and Glove Perforations Compared With Erich Arch Bars During the Application of Intermaxillary Fixation: A Randomized Controlled Trial.,"PURPOSE The purpose of this study was to compare the time for placement and removal, the effect on the gingiva, and the operator safety of the Stryker Universal SMARTLock Hybrid MMF system (Stryker Craniomaxillofacial, Kalamazoo, MI) with traditional Erich arch bars. MATERIALS AND METHODS We designed a parallel-group, randomized controlled trial to compare the 2 types of arch bars. Patients with mandibular fractures presenting to our institution were enrolled in the study and randomized into 1 of 2 groups: the Erich arch bar group and the hybrid arch bar group. The primary outcome variable was arch bar placement time. Secondary outcomes were glove tears or penetrations during application, gingival appearance score at removal, loose hardware at removal, removal time, and glove tears or penetrations at removal. The groups were compared using t tests. RESULTS We enrolled 90 patients in the study, with 43 randomized to the Erich arch bar group and 47 randomized to the hybrid arch bar group. The mean application time was 31.3 ± 9.3 minutes for Erich arch bars and 6.9 ± 3.1 minutes for hybrid arch bars (P < .0001). Significantly more glove tears or penetrations occurred during application in the Erich Arch Bar group (0.56 ± 0.91 per application) than in the hybrid group (0.11 ± 0.32 per application) (P = .0025). At removal, no difference in overall gingival appearance or amount of loose hardware was noted. The time for removal was significantly less for the hybrid arch bar group (10.5 ± 5.1 minutes vs 17.9 ± 10.7 minutes, P = .0007). CONCLUSIONS Hybrid arch bars with bone-borne locking screws offer a number of advantages over traditional Erich arch bars and circumdental wires, including shorter placement and removal times and a greater margin of safety for the operating surgeon as shown by significantly fewer glove tears and penetrations.",2019,Significantly more glove tears or penetrations occurred during application in the Erich Arch Bar group (0.56 ± 0.91 per application) than in the hybrid group (0.11 ± 0.32 per application),"['enrolled 90 patients in the study, with 43 randomized to the Erich arch bar group and 47 randomized to the hybrid arch bar group', 'Patients with mandibular fractures presenting to our institution']","['Stryker Universal SMARTLock Hybrid MMF system (Stryker Craniomaxillofacial, Kalamazoo, MI) with traditional Erich arch bars', 'Intermaxillary Fixation']","['glove tears or penetrations', 'glove tears or penetrations during application, gingival appearance score at removal, loose hardware at removal, removal time, and glove tears or penetrations at removal', 'overall gingival appearance or amount of loose hardware', 'Placement Time and Glove Perforations', 'mean application time', 'arch bar placement time', 'time for removal']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0993613', 'cui_str': 'Bar (basic dose form)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0020205', 'cui_str': 'Hybrids'}, {'cui': 'C0024692', 'cui_str': 'Mandibular Fractures'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C1272753', 'cui_str': 'Institution'}]","[{'cui': 'C0175671', 'cui_str': 'Universal (qualifier value)'}, {'cui': 'C0020205', 'cui_str': 'Hybrids'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0993613', 'cui_str': 'Bar (basic dose form)'}, {'cui': 'C0185023', 'cui_str': 'pexy'}]","[{'cui': 'C0206069', 'cui_str': 'Glove'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C4521854', 'cui_str': 'Gingival (intended site)'}, {'cui': 'C0700364', 'cui_str': 'Appearances (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0205407', 'cui_str': 'Loose (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0549099', 'cui_str': 'Perforation (morphologic abnormality)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0993613', 'cui_str': 'Bar (basic dose form)'}]",90.0,0.055838,Significantly more glove tears or penetrations occurred during application in the Erich Arch Bar group (0.56 ± 0.91 per application) than in the hybrid group (0.11 ± 0.32 per application),"[{'ForeName': 'Brett J', 'Initials': 'BJ', 'LastName': 'King', 'Affiliation': 'Assistant Professor, Department of Oral & Maxillofacial Surgery, Louisiana State University Health Sciences Center, New Orleans, LA. Electronic address: bking6@lsuhsc.edu.'}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Christensen', 'Affiliation': 'Chief Resident, Department of Oral & Maxillofacial Surgery, Louisiana State University Health Sciences Center, New Orleans, LA.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.01.030'] 433,30902602,The Effects of Music Listening During Extraction of the Impacted Mandibular Third Molar on the Autonomic Nervous System and Psychological State.,"PURPOSE Pain, anxiety, and nervousness related to dental procedures can cause acute changes in the autonomic nervous system. Music is widely accepted as a relaxation method during dental treatment; however, its effects during dental treatment are unclear. The authors explored the effects of listening to music during extraction of the impacted mandibular third molar on the autonomic nervous system and the psychological state and hypothesized that listening to music would suppress sympathetic nervous activity and decrease anxiety. MATERIALS AND METHODS In this prospective study, 40 patients scheduled for extraction of an impacted mandibular third molar were randomized into 2 groups: extraction without music (control group) and extraction while listening to music (music group). Heart rate variability was recorded during the experiment, and Modified Dental Anxiety Scale and State-Trait Anxiety Inventory (STAI) scores were recorded before and after the procedure. Descriptive and bivariate statistics were computed and the P value was set at .05. RESULTS An increased low-to-high frequency ratio was observed in the control group during incision and flap reflection, bone removal, and separation of the tooth crown; the ratio was significantly decreased in the music group during these time points (P < .05). Compared with the control group, the music group had a significantly greater decrease in postoperative STAI State Anxiety scores from preoperative levels (P < .05). CONCLUSIONS This study suggested that listening to music while undergoing extraction of the impacted mandibular third molar suppresses activity of the sympathetic nerves during incision, flap reflection, bone removal, and separation of the tooth crown and relieves anxiety after treatment. Future studies will focus on the mechanisms involved and methods to prevent the onset of systemic incidents.",2019,"An increased low-to-high frequency ratio was observed in the control group during incision and flap reflection, bone removal, and separation of the tooth crown; the ratio was significantly decreased in the music group during these time points (P < .05).",['40 patients scheduled for extraction of an impacted mandibular third molar'],"['Music Listening', 'extraction without music (control group) and extraction while listening to music (music group']","['low-to-high frequency ratio', 'postoperative STAI State Anxiety scores', 'Heart rate variability', 'Modified Dental Anxiety Scale and State-Trait Anxiety Inventory (STAI) scores']","[{'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0026369', 'cui_str': 'Tooth, Wisdom'}]","[{'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0004339', 'cui_str': 'Auscultation'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205212', 'cui_str': 'High frequency (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0085380', 'cui_str': 'Fear, Dental'}, {'cui': 'C0222045'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",40.0,0.0570168,"An increased low-to-high frequency ratio was observed in the control group during incision and flap reflection, bone removal, and separation of the tooth crown; the ratio was significantly decreased in the music group during these time points (P < .05).","[{'ForeName': 'Kaoru', 'Initials': 'K', 'LastName': 'Yamashita', 'Affiliation': 'PhD Student, Department of Dental Anesthesiology, Field of Oral Maxillofacial Rehabilitation, Developmental Therapeutics Course, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.'}, {'ForeName': 'Toshiro', 'Initials': 'T', 'LastName': 'Kibe', 'Affiliation': 'Assistant Professor, Department of Oral and Maxillofacial Surgery, Field of Oral and Maxillofacial Surgery, Developmental Therapeutics Course, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. Electronic address: s2000@dent.kagoshima-u.ac.jp.'}, {'ForeName': 'Sachi', 'Initials': 'S', 'LastName': 'Ohno', 'Affiliation': 'Assistant Professor, Department of Dental Anesthesiology, Field of Oral Maxillofacial Rehabilitation, Developmental Therapeutics Course, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Kohjitani', 'Affiliation': 'Associate Professor, Department of Dental Anesthesiology, Field of Oral Maxillofacial Rehabilitation, Developmental Therapeutics Course, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.'}, {'ForeName': 'Mitsutaka', 'Initials': 'M', 'LastName': 'Sugimura', 'Affiliation': 'Professor, Department of Dental Anesthesiology, Field of Oral Maxillofacial Rehabilitation, Developmental Therapeutics Course, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.02.028'] 434,31801135,"Effect of Vitamin D Supplementation on Body Composition and Physical Fitness in Healthy Adults: A Double-Blind, Randomized Controlled Trial.","INTRODUCTION This study aimed to clarify whether 1 year of vitamin D3 supplementation has a direct effect on body composition and physical fitness in healthy adults. METHODS Ninety-five participants randomly received either 420 IU vitamin D3 per day (n = 48) or placebo (n = 47) in a double-blind manner for 1 year. Lean body mass and percentage body fat were determined. Physical fitness including hand grip strength, leg extension power and cardiorespiratory fitness (CRF) were assessed. Serum 25-hydroxyvitamin D (25[OH]D) and 1,25-dihydroxyvitamin D (1,25[OH]2D) concentrations were assessed using ELISA kits. RESULTS Serum 25(OH)D and (1,25[OH]2D) concentrations significantly increased by approximately 11.2 ± 9.2 ng/mL (pinteraction <0.001)and 7.0 ± 7.8 pg/mL (pinteraction <0.001) after 1 year of vitamin D3 supplementation respectively. Lean body mass significantly increased from 43.8 ± 9.6 to 44.3 ± 9.8 kg in vitamin D group, while no change was observed in placebo group (from 42.6 ± 8.9 to 42.4± 8.9 kg) after 1 year intervention. Furthermore, no treatment effects on other indicators of body composition and physical fitness were observed. CONCLUSIONS One year of vitamin D supplementation effectively improves lean body mass, but not muscle strength and CRF in healthy adults.",2019,"Serum 25(OH)D and (1,25[OH]2D) concentrations significantly increased by approximately 11.2 ± 9.2 ng/mL (pinteraction <0.001)and 7.0 ± 7.8 pg/mL (pinteraction <0.001) after 1 year of vitamin D3 supplementation respectively.","['Healthy Adults', 'healthy adults']","['420 IU vitamin D3', 'vitamin D supplementation', 'Vitamin D Supplementation', 'placebo', 'vitamin D3 supplementation']","['muscle strength and CRF', 'Physical fitness including hand grip strength, leg extension power and cardiorespiratory fitness (CRF', 'Body Composition and Physical Fitness', 'Serum 25(OH)D and (1,25[OH]2D) concentrations', 'Serum 25-hydroxyvitamin D (25[OH]D) and 1,25-dihydroxyvitamin D (1,25[OH]2D) concentrations', 'Lean body mass and percentage body fat', 'Lean body mass', 'lean body mass', 'body composition and physical fitness']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C4517774', 'cui_str': 'Four hundred and twenty'}, {'cui': 'C3265062', 'cui_str': 'vitamin D3'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0010132', 'cui_str': 'corticorelin'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1293900', 'cui_str': 'Hand grip'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0535968', 'cui_str': '25-hydroxyvitamin D'}, {'cui': 'C0370232', 'cui_str': '1,25-dihydroxyvitamin D'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass (observable entity)'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}]",95.0,0.533651,"Serum 25(OH)D and (1,25[OH]2D) concentrations significantly increased by approximately 11.2 ± 9.2 ng/mL (pinteraction <0.001)and 7.0 ± 7.8 pg/mL (pinteraction <0.001) after 1 year of vitamin D3 supplementation respectively.","[{'ForeName': 'Xiaomin', 'Initials': 'X', 'LastName': 'Sun', 'Affiliation': ""School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China.""}, {'ForeName': 'Kumpei', 'Initials': 'K', 'LastName': 'Tanisawa', 'Affiliation': 'Faculty of Sport Sciences, Waseda University, Tokorozawa, Saitama, Japan.'}, {'ForeName': 'Yuping', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Graduate School of Sport Sciences, Waseda University, Tokorozawa, Saitama, Japan.'}, {'ForeName': 'Tomoko', 'Initials': 'T', 'LastName': 'Ito', 'Affiliation': 'Faculty of Sport Sciences, Waseda University, Tokorozawa, Saitama, Japan.'}, {'ForeName': 'Satomi', 'Initials': 'S', 'LastName': 'Oshima', 'Affiliation': 'Faculty of Sport Sciences, Waseda University, Tokorozawa, Saitama, Japan.'}, {'ForeName': 'Mitsuru', 'Initials': 'M', 'LastName': 'Higuchi', 'Affiliation': 'Faculty of Sport Sciences, Waseda University, Tokorozawa, Saitama, Japan.'}, {'ForeName': 'Zhen-Bo', 'Initials': 'ZB', 'LastName': 'Cao', 'Affiliation': 'School of Kinesiology, Shanghai University of Sport, Shanghai, China, caozb_edu@yahoo.co.jp.'}]",Annals of nutrition & metabolism,['10.1159/000504873'] 435,30790529,Comparison of Intra-Socket Bupivacaine Administration Versus Oral Mefenamic Acid Capsule for Postoperative Pain Management Following Removal of Impacted Mandibular Third Molars.,"PURPOSE Surgical removal of impacted third molar teeth is one of the most common surgical procedures performed in oral and maxillofacial surgery. Postoperative pain is a common and predictable occurrence after maxillofacial surgery. MATERIALS AND METHODS This randomized double-blind clinical trial was conducted with a crossover design in which each patient served as his or her own control. Forty-six patients with similar bilateral impacted lower third molars were selected. In each patient, the intervention and control sides of the mandible were randomly determined at the end of surgery. If the removed tooth was in the intervention side, then the patient would receive bupivacaine and a placebo of mefenamic acid. If the impacted tooth was in the control side, then the patient would receive a mefenamic acid capsule and a placebo of bupivacaine. Pain severity was assessed using a visual analog scale. Data were analyzed using paired-sample t test and a P value less than .05 was considered statistically significant. RESULTS Of 46 participants originally recruited, 43 were included in the present study. The mean postoperative pain score in patients who received bupivacaine was increased to a maximum 4 hours, with marked improvements after this time. The mean intensity of pain after administration of bupivacaine was lower than that of mefenamic acid capsules at different time points. Statistical analysis showed a relevant difference in pain intensity between the 2 study groups. CONCLUSION The results of the present study showed that local administration of bupivacaine relieves postoperative pain after surgical removal of impacted third molar teeth.",2019,The mean intensity of pain after administration of bupivacaine was lower than that of mefenamic acid capsules at different time points.,"['Removal of Impacted Mandibular Third Molars', 'Forty-six patients with similar bilateral impacted lower third molars', '46 participants originally recruited']","['mefenamic acid', 'bupivacaine', 'placebo of mefenamic acid', 'mefenamic acid capsule and a placebo of bupivacaine', 'Intra-Socket Bupivacaine Administration Versus Oral Mefenamic Acid Capsule']","['postoperative pain', 'Pain severity', 'mean intensity of pain', 'mean postoperative pain score', 'Postoperative pain', 'pain intensity']","[{'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0026369', 'cui_str': 'Tooth, Wisdom'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0442051', 'cui_str': 'Lower third (qualifier value)'}, {'cui': 'C0026367', 'cui_str': 'Molar'}]","[{'cui': 'C0025152', 'cui_str': 'Mefenamic Acid'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",46.0,0.279366,The mean intensity of pain after administration of bupivacaine was lower than that of mefenamic acid capsules at different time points.,"[{'ForeName': 'Ideh', 'Initials': 'I', 'LastName': 'Talimkhani', 'Affiliation': 'Chief Resident of Oral and Maxillofacial Surgery, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Hamadan University of Medical Sciences, Hamadan, Iran.'}, {'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Jamalpour', 'Affiliation': 'Associate Professor, Department of Oral and Maxillofacial Surgery, Dental Implants Research Center, Faculty of Dentistry, Hamadan University of Medical Sciences, Hamadan, Iran. Electronic address: Jamalpour@umsha.ac.ir.'}, {'ForeName': 'Hamed', 'Initials': 'H', 'LastName': 'Babaei', 'Affiliation': 'Oral and Maxillofacial Surgeon, Dental Implants Research Center, Faculty of Dentistry, Hamadan University of Medical Sciences, Hamadan, Iran.'}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Faradmal', 'Affiliation': 'Associate Professor, Modeling of Noncommunicable Diseases Research Center and Department of Biostatistics and Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.01.021'] 436,32208898,The impact of mental health diagnoses on perceptions of risk of criminality.,"BACKGROUND Previous research has examined the relation between mental illness (MI) and perceptions of dangerousness, but less research has focused on its relation to perceived risk of criminality. Individuals with MI are perceived to be more dangerous than those without, and individuals with schizophrenia or substance abuse diagnoses are viewed as being more dangerous. Research also supports that race of individuals with MI plays an important role in the conceptualization and experience of stigma. AIMS The current study investigated the relation between MI, perceived criminality and race of diagnosed individuals. METHOD Two hundred ninety participants were randomly assigned to read one of the four vignettes and answer a series of questions. The first three vignettes depicted someone with MI (schizophrenia, depression or alcohol dependency), while the fourth vignette served as a control. Participants were asked to indicate likelihood of committing a future crime, severity of the future crime and the person's potential for rehabilitation. Levels of sympathy and trust, as well as perceived race of the person, were also measured. RESULTS Presence of MI was a significant predictor where MI elicited higher levels of perceived risk of criminality. The remaining predictor variables (type of MI, familiarity with MI and criminality and perceived race) were not significant predictors. Exploratory analyses revealed the schizophrenia and alcohol dependency conditions elicited higher levels of perceived severity of future crimes. Perceived MI severity and likelihood of rehabilitation were all significantly correlated with perceived risk of criminality. CONCLUSION Presence of MI appears to be the most important in influencing participant attitudes about perceived risk of criminality, though type of MI may influence beliefs about severity of future crimes. The impact of race could not be examined but should be examined in future studies.",2020,"The remaining predictor variables (type of MI, familiarity with MI and criminality and perceived race) were not significant predictors.","['Two hundred ninety participants', 'Individuals with MI']",[],"['Levels of sympathy and trust, as well as perceived race of the person', 'remaining predictor variables (type of MI, familiarity with MI and criminality and perceived race', 'Perceived MI severity and likelihood of rehabilitation']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3816959', 'cui_str': 'Ninety'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]",[],"[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C3853635', 'cui_str': 'Race (observable entity)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0600269', 'cui_str': 'Familiarity'}, {'cui': 'C0178573', 'cui_str': 'Illicit Behavior'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}]",290.0,0.0239088,"The remaining predictor variables (type of MI, familiarity with MI and criminality and perceived race) were not significant predictors.","[{'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Garcia', 'Affiliation': 'Department of Psychology, Loyola University Maryland, Baltimore, MD, USA.'}, {'ForeName': 'Adanna J', 'Initials': 'AJ', 'LastName': 'Johnson', 'Affiliation': 'Department of Psychology, Georgetown University, Washington, DC, USA.'}, {'ForeName': 'Marianna E', 'Initials': 'ME', 'LastName': 'Carlucci', 'Affiliation': 'Department of Psychology, Loyola University Maryland, Baltimore, MD, USA.'}, {'ForeName': 'Rachel L', 'Initials': 'RL', 'LastName': 'Grover', 'Affiliation': 'Department of Psychology, Loyola University Maryland, Baltimore, MD, USA.'}]",The International journal of social psychiatry,['10.1177/0020764020913322'] 437,32400903,Severe and enduring anorexia nervosa: No easy solutions.,"There is currently no evidence-based definition of severe and enduring anorexia nervosa (SE-AN) with which to reliably inform clinical practice and research. Indeed, data on the effect of AN severity and duration on treatment outcome are inconsistent. A large group of patients with SE-AN are repeatedly unsuccessfully managed with the available eating disorders treatments and have no access to adequate treatment for their illness. Cognitive behavioral therapy (CBT) adapted for SE-AN has been designed to enhance quality of life and reduce harm rather than promoting weight gain in such patients, and has had some success. However, a percentage of patients with SE-AN achieves remission, or at least returns to a normal weight range, with available evidence-based treatments for eating disorders, such as enhanced CBT (CBT-E). It would therefore be worth conducting a large-scale randomized controlled trial comparing CBT adapted for SE-AN with CBT-E to assess their relative acceptability; efficacy, including their effect on quality of life and medical stability; cost-effectiveness; and the treatment response moderators that might allow better matching of patients with SE-AN to a treatment oriented either to harm reduction or to change.",2020,"It would therefore be worth conducting a large-scale randomized controlled trial comparing CBT adapted for SE-AN with CBT-E to assess their relative acceptability; efficacy, including their effect on quality of life and medical stability; cost-effectiveness; and the treatment response moderators that might allow better matching of patients with SE-AN to a treatment oriented either to harm reduction or to change.",['Severe and enduring anorexia nervosa'],"['Cognitive behavioral therapy (CBT', 'CBT']",['quality of life and medical stability; cost-effectiveness'],"[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0003125', 'cui_str': 'Anorexia nervosa'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",,0.0280831,"It would therefore be worth conducting a large-scale randomized controlled trial comparing CBT adapted for SE-AN with CBT-E to assess their relative acceptability; efficacy, including their effect on quality of life and medical stability; cost-effectiveness; and the treatment response moderators that might allow better matching of patients with SE-AN to a treatment oriented either to harm reduction or to change.","[{'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Dalle Grave', 'Affiliation': 'Department of Eating and Weight Disorders, Villa Garda Hospital, Garda, Italy.'}]",The International journal of eating disorders,['10.1002/eat.23295'] 438,31733345,Principal results of the VITamin D and OmegA-3 TriaL (VITAL) and updated meta-analyses of relevant vitamin D trials.,"Whether supplemental vitamin D reduces risk of cancer or cardiovascular disease (CVD) is relatively unexplored in randomized trial settings. The VITamin D and OmegA-3 TriaL (VITAL) was a nationwide, randomized, placebo-controlled, 2 × 2 factorial trial of daily vitamin D 3 (2000 IU) and marine omega-3 fatty acids (1 g) in the primary prevention of cancer and CVD among 25,871 U.S. men aged ≥50 and women aged ≥55, including 5106 African Americans. Median treatment duration was 5.3 years. Vitamin D did not significantly reduce the primary endpoint of total invasive cancer incidence (hazard ratio [HR] = 0.96 [95% confidence interval 0.88-1.06]) but showed a promising signal for reduction in total cancer mortality (HR = 0.83 [0.67-1.02]), especially in analyses that accounted for latency by excluding the first year (HR = 0.79 [0.63-0.99]) or first 2 years (HR = 0.75 [0.59-0.96]) of follow-up. Vitamin D did not significantly reduce the co-primary endpoint of major CVD events (HR = 0.97 [0.85-1.12]), other cardiovascular endpoints, or all-cause mortality (HR = 0.99 [0.87-1.12]). Updated meta-analyses that include VITAL and other recent vitamin D trials indicate a significant reduction in cancer mortality but not in cancer incidence or CVD endpoints. Additional research is needed to determine which individuals may be most likely to derive a net benefit from vitamin D supplementation. (VITAL clinicaltrials.gov identifier: NCT01169259).",2020,"Vitamin D did not significantly reduce the co-primary endpoint of major CVD events (HR = 0.97 [0.85-1.12]), other cardiovascular endpoints, or all-cause mortality (HR = 0.99 [0.87-1.12]).","['25,871 U.S. men aged ≥50 and women aged ≥55, including 5,106 African Americans']","['placebo', 'daily vitamin D 3 (2000 IU) and marine omega-3 fatty acids', 'supplemental vitamin D', 'VITamin D and OmegA-3 TriaL', 'Vitamin D']","['total cancer mortality', 'total invasive cancer incidence', 'risk of cancer or cardiovascular disease (CVD', 'co-primary endpoint of major CVD events', 'cancer mortality']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0524645', 'cui_str': 'Marines'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C1719844', 'cui_str': 'Greek letter omega'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}]",,0.639178,"Vitamin D did not significantly reduce the co-primary endpoint of major CVD events (HR = 0.97 [0.85-1.12]), other cardiovascular endpoints, or all-cause mortality (HR = 0.99 [0.87-1.12]).","[{'ForeName': 'JoAnn E', 'Initials': 'JE', 'LastName': 'Manson', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States. Electronic address: jmanson@rics.bwh.harvard.edu.""}, {'ForeName': 'Shari S', 'Initials': 'SS', 'LastName': 'Bassuk', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.""}, {'ForeName': 'Julie E', 'Initials': 'JE', 'LastName': 'Buring', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Journal of steroid biochemistry and molecular biology,['10.1016/j.jsbmb.2019.105522'] 439,30902603,Tapered Versus Cylindrical Implant: Which Shape Inflicts Less Pain After Dental Implant Surgery? A Clinical Trial.,"PURPOSE Because no study has evaluated the postoperative pain caused by the shape of dental implants, this study compared the level of postoperative pain between tapered and cylindrical implants inserted in the posterior region of the maxilla. MATERIALS AND METHODS The study was designed as a double-blinded randomized clinical trial and conducted in 50 healthy patients 20 to 60 years old who were edentulous in the posterior maxilla and were candidates for single implantation. All patients had the same surgical difficulty with appropriate bone width and height. BioHorizons (Birmingham, AL) implants (tapered vs cylindrical) with 4.5-mm platform diameter were randomly selected for each group. The visual analog scale was used to evaluate the level of pain. Pain severity in each group was measured at 30-minute, 3-hour, 6-hour, 12-hour, 24-hour, 2-day, 3-day, and 1-week intervals. The predictor variable was implant shape and the outcome was postoperative pain severity. Data were statistically analyzed with SPPS 16 (SPSS, Inc, Chicago, IL) at the significance level of a P value less than .05. RESULTS Fifty patients (n = 25 per group) with the mean age of 43.7 ± 10.9 years were included in this study. The pain level in the 2 groups reached its maximum at the 6-hour postoperative interval. Pain severity decreased significantly over time in the 2 implant groups (P < .001). Severities of postoperative pain in the tapered group at 3-, 6-, 12-, and 24-hour intervals were statistically lower than those in the cylindrical group (P < .05). CONCLUSIONS Implant shape had an impact on postoperative pain. It can be concluded that tapered implants lead to less postoperative pain compared with cylindrical ones.",2019,Pain severity decreased significantly over time in the 2 implant groups (P < .001).,"['All patients had the same surgical difficulty with appropriate bone width and height', '25 per group) with the mean age of 43.7\xa0±', '50 healthy patients 20 to 60\xa0years old who were edentulous in the posterior maxilla and were candidates for single implantation', 'Fifty patients (n\xa0', '10.9\xa0years were included in this study']","['Tapered Versus Cylindrical Implant', 'BioHorizons (Birmingham, AL) implants (tapered vs cylindrical) with 4.5-mm platform diameter']","['postoperative pain', 'Severities of postoperative pain', 'Pain severity', 'visual analog scale', 'Pain', 'postoperative pain severity', 'level of pain', 'pain level']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0487742', 'cui_str': 'Width (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0026644', 'cui_str': 'Mouth, Toothless'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0024947', 'cui_str': 'Maxillary Bone'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0021107', 'cui_str': 'Insertion procedure'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0205114', 'cui_str': 'Cylindrical (qualifier value)'}, {'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C3844009', 'cui_str': 'Four point five'}, {'cui': 'C1301886', 'cui_str': 'Diameter (qualifier value)'}]","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}]",50.0,0.129444,Pain severity decreased significantly over time in the 2 implant groups (P < .001).,"[{'ForeName': 'Sahand', 'Initials': 'S', 'LastName': 'Samieirad', 'Affiliation': 'Assistant Professor, Dental Research Center, Mashhad University of Medical Sciences; Assistant Professor, Oral and Maxillofacial Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: samieerads@mums.ac.ir.'}, {'ForeName': 'Vajiheh', 'Initials': 'V', 'LastName': 'Mianbandi', 'Affiliation': 'Dentist, Student Research Committee, Mashhad Dental School, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Farid', 'Initials': 'F', 'LastName': 'Shiezadeh', 'Affiliation': 'Assistant Professor, Oral and Maxillofacial Surgery Department, Mashhad Dental School, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Hosseini-Abrishami', 'Affiliation': 'Assistant Professor, Dental Research Center, Mashhad University of Medical Sciences, Mashhad; Assistant Professor, Oral and Maxillofacial Surgery Department, Mashhad Dental School, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Elahe', 'Initials': 'E', 'LastName': 'Tohidi', 'Affiliation': 'Oral and Maxillofacial Radiologist, Dental Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.02.027'] 440,31915153,Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors.,"Sodium-glucose cotransport 2 inhibitors (SGLT2i) lower plasma glucose but stimulate endogenous glucose production (EGP). The current study examined the effect of dapagliflozin on EGP while clamping plasma glucose, insulin, and glucagon concentrations at their fasting level. Thirty-eight patients with type 2 diabetes received an 8-h measurement of EGP ([3- 3 H]-glucose) on three occasions. After a 3-h tracer equilibration, subjects received 1 ) dapagliflozin 10 mg ( n = 26) or placebo ( n = 12); 2 ) repeat EGP measurement with the plasma glucose concentration clamped at the fasting level; and 3 ) repeat EGP measurement with inhibition of insulin and glucagon secretion with somatostatin infusion and replacement of basal plasma insulin and glucagon concentrations. In study 1, the change in EGP (baseline to last hour of EGP measurement) in subjects receiving dapagliflozin was 22% greater (+0.66 ± 0.11 mg/kg/min, P < 0.05) than in subjects receiving placebo, and it was associated with a significant increase in plasma glucagon and a decrease in the plasma insulin concentration compared with placebo. Under glucose clamp conditions (study 2), the change in plasma insulin and glucagon concentrations was comparable in subjects receiving dapagliflozin and placebo, yet the difference in EGP between dapagliflozin and placebo persisted (+0.71 ± 0.13 mg/kg/min, P < 0.01). Under pancreatic clamp conditions (study 3), dapagliflozin produced an initial large decrease in EGP (8% below placebo), followed by a progressive increase in EGP that was 10.6% greater than placebo during the last hour. Collectively, these results indicate that 1 ) the changes in plasma insulin and glucagon concentration after SGLT2i administration are secondary to the decrease in plasma glucose concentration, and 2 ) the dapagliflozin-induced increase in EGP cannot be explained by the increase in plasma glucagon or decrease in plasma insulin or glucose concentrations.",2020,"Under glucose clamp conditions (Study 2), the change in plasma insulin and glucagon concentrations was comparable in subjects receiving dapagliflozin and placebo, yet the difference in EGP between dapagliflozin and placebo persisted (+0.71 ±0.13 mg/kg.min, p<0.01).",['38 T2DM patients'],"['dapagliflozin and placebo', 'dapagliflozin', 'placebo', '8-hour measurement of EGP', 'placebo (n=12); (ii) repeat EGP measurement with plasma glucose concentration clamped at the fasting level; (iii) repeat EGP measurement with inhibition of insulin and glucagon secretion with somatostatin infusion and replacement of basal plasma insulin and glucagon concentrations']","['plasma glucose concentration', 'EGP', 'change in EGP', 'progressive increase in EGP', 'change in plasma insulin and glucagon concentrations', 'plasma insulin and glucagon concentration', 'plasma insulin or glucose concentrations', 'EGP while clamping plasma glucose, insulin and glucagon concentrations', 'Plasma Insulin and Glucagon Concentrations', 'plasma insulin concentration', 'plasma glucagon']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1292429', 'cui_str': '8 hours (qualifier value)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C2584434', 'cui_str': 'Plasma glucose concentration'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0876232', 'cui_str': 'glucagon recombinant'}, {'cui': 'C0036537', 'cui_str': 'Secretions'}, {'cui': 'C0037659', 'cui_str': 'Somatostatin'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0205112', 'cui_str': 'Basal (qualifier value)'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]","[{'cui': 'C2584434', 'cui_str': 'Plasma glucose concentration'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0876232', 'cui_str': 'glucagon recombinant'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1287281', 'cui_str': 'Finding of glucose concentration, dipstick (finding)'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C1278023', 'cui_str': 'Plasma glucagon measurement'}]",38.0,0.0926784,"Under glucose clamp conditions (Study 2), the change in plasma insulin and glucagon concentrations was comparable in subjects receiving dapagliflozin and placebo, yet the difference in EGP between dapagliflozin and placebo persisted (+0.71 ±0.13 mg/kg.min, p<0.01).","[{'ForeName': 'Mariam', 'Initials': 'M', 'LastName': 'Alatrach', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Nitchakarn', 'Initials': 'N', 'LastName': 'Laichuthai', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Martinez', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Agyin', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Ali Muhammed', 'Initials': 'AM', 'LastName': 'Ali', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Hussein', 'Initials': 'H', 'LastName': 'Al-Jobori', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Lavynenko', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Adams', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Curtis', 'Initials': 'C', 'LastName': 'Triplitt', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Ralph', 'Initials': 'R', 'LastName': 'DeFronzo', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX albarado@uthscsa.edu.'}, {'ForeName': 'Eugenio', 'Initials': 'E', 'LastName': 'Cersosimo', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Muhammad', 'Initials': 'M', 'LastName': 'Abdul-Ghani', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}]",Diabetes,['10.2337/db19-0770'] 441,32196393,Immediate Effects of a Semi-Occluded Water Resistance Ventilation Mask on Objective and Subjective Vocal Outcomes in Musical Theater Students.,"Background Traditional semi-occluded vocal tract exercises (SOVTEs) are restricted to single-phoneme tasks due to the semi-occlusion at the mouth, which hinders full articulation, continuous speech, and singing. Innovative SOVTEs should overcome this limitation by creating the semi-occlusion outside the oral cavity. Purpose The purpose of this study was to investigate the immediate effects of a semi-occluded water resistance ventilation mask, which allows for continuous speech and singing, on objective (voice range, multiparametric voice quality indices) and subjective (auditory-perceptual, self-report) vocal outcomes in musical theater students. Method A pre-/posttest randomized controlled trial was used. Twenty-four musical theater students (16 women and eight men, with a mean age of 21 years) were randomly assigned into a study group and a control group. The study group received a vocal warm-up session with the innovative water resistance ventilation mask (tube attached to the mask ""outside"" the mouth), whereas the control group received the traditional water resistance approach (tube ""inside"" the mouth). Both sessions lasted 30 min and were similar with respect to vocal demand tasks. A multidimensional voice assessment including objective and subjective outcomes was performed pre- and posttraining by an assessor blinded to group allocation. Results The Dysphonia Severity Index significantly and similarly increased (improved) in both the study and control groups, whereas the Acoustic Voice Quality Index solely decreased (improved) in the control group. The intensity range significantly decreased (worsened) and the semitone range significantly increased (improved) in the study group, whereas no differences in voice range profile were found in the control group. Auditory-perceptually, a more strenuous speaking voice was noticed after the use of the traditional water resistance approach. The subjects perceived both SOVTEs as comfortable vocal warm-up exercises that decrease the amount of effort during speaking and singing, with a slight preference for the water resistance ventilation mask. Conclusions Both the innovative water resistance ventilation mask and the traditional water resistance exercise seem effective vocal warm-up exercises for musical theater students. The additional articulatory freedom of the mask might increase the phonatory comfort and the practical implementation of SOVTEs in the daily vocal warm-up of (future) elite vocal performers. The hypothesis of a higher transfer to continuous speech or singing in the mask condition has not been supported by the current study. Larger scale investigation and longer term follow-up studies are needed to confirm these preliminary results. Supplemental Material https://doi.org/10.23641/asha.11991549.",2020,"The intensity range significantly decreased (worsened) and the semitone range significantly increased (improved) in the study group, whereas no differences in voice range profile were found in the control group.","['Twenty-four musical theater students (16 women and eight men, with a mean age of 21 years', 'Musical Theater Students', 'musical theater students']","['Semi-Occluded Water Resistance Ventilation Mask', 'semi-occluded water resistance ventilation mask', 'Supplemental Material https://doi.org/10.23641/asha.11991549', ' Traditional semi-occluded vocal tract exercises (SOVTEs', 'vocal warm-up session with the innovative water resistance ventilation mask (tube attached to the mask ""outside"" the mouth), whereas the control group received the traditional water resistance approach (tube ""inside"" the mouth']","['intensity range', 'Dysphonia Severity Index', 'Objective and Subjective Vocal Outcomes', 'strenuous speaking voice', 'voice range profile', 'objective (voice range, multiparametric voice quality indices) and subjective (auditory-perceptual, self-report) vocal outcomes', 'Acoustic Voice Quality Index solely']","[{'cui': 'C3715070', 'cui_str': '24 (qualifier value)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C0024861', 'cui_str': 'Masks'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C1947917', 'cui_str': 'Occluded (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0184348', 'cui_str': 'Warmer'}, {'cui': 'C4318415', 'cui_str': 'Tube (unit of presentation)'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0230028', 'cui_str': 'Structure of oral region of face'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0205102', 'cui_str': 'Internal (qualifier value)'}]","[{'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C1527344', 'cui_str': 'Phonation Disorders'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0042943', 'cui_str': 'Voice Quality'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0001166', 'cui_str': 'Acoustics'}]",16.0,0.0281136,"The intensity range significantly decreased (worsened) and the semitone range significantly increased (improved) in the study group, whereas no differences in voice range profile were found in the control group.","[{'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Meerschman', 'Affiliation': 'Speech-Language Pathology Research Group, Department of Rehabilitation Sciences, Ghent University, Belgium.'}, {'ForeName': 'Kristiane', 'Initials': 'K', 'LastName': 'Van Lierde', 'Affiliation': 'Speech-Language Pathology Research Group, Department of Rehabilitation Sciences, Ghent University, Belgium.'}, {'ForeName': 'Yvonne Gonzales', 'Initials': 'YG', 'LastName': 'Redman', 'Affiliation': 'School of Music, University of Illinois at Urbana-Champaign.'}, {'ForeName': 'Lidia', 'Initials': 'L', 'LastName': 'Becker', 'Affiliation': 'Speech and Language and Audiology Department, Medicine School, Federal University of Rio de Janeiro, Brazil.'}, {'ForeName': 'Ayla', 'Initials': 'A', 'LastName': 'Benoy', 'Affiliation': 'Berlaar, Antwerp, Belgium.'}, {'ForeName': 'Imke', 'Initials': 'I', 'LastName': 'Kissel', 'Affiliation': 'Speech-Language Pathology Research Group, Department of Rehabilitation Sciences, Ghent University, Belgium.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Leyns', 'Affiliation': 'Speech-Language Pathology Research Group, Department of Rehabilitation Sciences, Ghent University, Belgium.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Daelman', 'Affiliation': 'Speech-Language Pathology Research Group, Department of Rehabilitation Sciences, Ghent University, Belgium.'}, {'ForeName': 'Evelien', 'Initials': 'E', 'LastName': ""D'haeseleer"", 'Affiliation': 'Speech-Language Pathology Research Group, Department of Rehabilitation Sciences, Ghent University, Belgium.'}]","Journal of speech, language, and hearing research : JSLHR",['10.1044/2019_JSLHR-19-00042'] 442,32203007,Effects of repleting organic phosphates in banked erythrocytes on plasma metabolites and vasoactive mediators after red cell exchange transfusion in sickle cell disease.,"BACKGROUND Red blood cell (RBC) exchange (RCE) transfusion therapy is indicated for certain patients with sickle cell disease (SCD). Although beneficial, this therapy is costly and inconvenient to patients, who may require it monthly or more often. Identification of blood and plasma biomarkers that could improve or help individualise RCE therapy is of interest. Here we examined relevant blood and plasma metabolites and biomarkers of vasoactivity and RBC fragility in a pilot study of SCD patients undergoing RCE using either standard RBC units or RBC units treated with a US Food and Drug Administration (FDA)-approved additive solution containing phosphate, inosine, pyruvate, and adenine (""PIPA""). MATERIALS AND METHODS In this prospective, single-blind, cross-over pilot clinical trial, patients were randomised to receive either standard RBC exchange or PIPA-treated RBC exchange transfusion with each RCE session over a 6-month treatment period. Pre- and post-transfusion blood samples were obtained and analysed for RBC O 2 affinity, ATP, purine metabolites, RBC microparticles, and cell free haemoglobin. RESULTS Red blood cell O 2 affinity was maintained after PIPA-RCE in contrast to standard RCE, after which P 5 0 fell (net O 2 affinity rose). Plasma ATP did not change significantly after RCE using either of the RBC unit types. Exchange transfusion with PIPA-treated RBC units led to modest increases in plasma inosine and hypoxanthine. Plasma cell free haemoglobin fell after either standard or PIPA-treated RBC exchange transfusion (novel findings), and to a similar extent. RBC-derived microparticles in the plasma fell significantly and similarly after both standard and PIPA-treated RCE transfusion. DISCUSSION In summary, treatment of RBCs with PIPA prior to RCE elicited favourable or neutral changes in key metabolic and vascular biomarkers. Further study of its efficacy and safety is recommended and could ultimately serve to improve outcomes in chronically transfused SCD patients.",2020,"RBC-derived microparticles in the plasma fell significantly and similarly after both standard and PIPA-treated RCE transfusion. ","['certain patients with sickle cell disease (SCD', 'SCD patients undergoing RCE using either standard RBC units or RBC units treated with a', 'chronically transfused SCD patients', 'sickle cell disease']","['US Food and Drug Administration (FDA)-approved additive solution containing phosphate, inosine, pyruvate, and adenine (""PIPA', 'repleting organic phosphates', 'Red blood cell (RBC) exchange (RCE) transfusion therapy', 'standard RBC exchange or PIPA-treated RBC exchange transfusion with each RCE session']","['Red blood cell O2 affinity', 'plasma metabolites and vasoactive mediators', 'plasma inosine and hypoxanthine', 'RBC O2 affinity, ATP, purine metabolites, RBC microparticles, and cell free haemoglobin', 'Plasma cell free haemoglobin fell', 'Plasma ATP']","[{'cui': 'C0205423', 'cui_str': 'Certainty (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0002895', 'cui_str': 'Sickle Cell Disease'}, {'cui': 'C0964695', 'cui_str': 's(7)(beta)CD'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0014792', 'cui_str': 'Blood Corpuscles, Red'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0041714', 'cui_str': 'Food and Drug Administration'}, {'cui': 'C0205540', 'cui_str': 'Approved (qualifier value)'}, {'cui': 'C0442796', 'cui_str': 'Additive (qualifier value)'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C1601799', 'cui_str': 'phosphate ion'}, {'cui': 'C0021528', 'cui_str': 'Inosine'}, {'cui': 'C0244104', 'cui_str': 'Pyruvate'}, {'cui': 'C0001407', 'cui_str': 'Adenine'}, {'cui': 'C0031701', 'cui_str': 'Phosphates, Organic'}, {'cui': 'C1277078', 'cui_str': 'Red blood cells, blood product'}, {'cui': 'C0015236', 'cui_str': 'Exchange Transfusion, Whole Blood'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0014792', 'cui_str': 'Blood Corpuscles, Red'}, {'cui': 'C1292734', 'cui_str': 'Treats'}]","[{'cui': 'C1277078', 'cui_str': 'Red blood cells, blood product'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0021528', 'cui_str': 'Inosine'}, {'cui': 'C0020684', 'cui_str': 'Hypoxanthine'}, {'cui': 'C0014792', 'cui_str': 'Blood Corpuscles, Red'}, {'cui': 'C0001480', 'cui_str': 'ATP'}, {'cui': 'C0220903', 'cui_str': 'purine'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C3854324', 'cui_str': 'Free hemoglobin'}, {'cui': 'C0032112', 'cui_str': 'Plasmacytes'}, {'cui': 'C0000921', 'cui_str': 'Falls'}]",,0.0236441,"RBC-derived microparticles in the plasma fell significantly and similarly after both standard and PIPA-treated RCE transfusion. ","[{'ForeName': 'Denise A', 'Initials': 'DA', 'LastName': 'Lopez Domowicz', 'Affiliation': 'Department of Pediatrics, Duke University Medical Center, Durham, NC, United States of America.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Welsby', 'Affiliation': 'Department of Anesthesiology, Duke University Medical Center, Durham, NC, United States of America.'}, {'ForeName': 'Charles R', 'Initials': 'CR', 'LastName': 'Esther', 'Affiliation': 'Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.'}, {'ForeName': 'Hongmei', 'Initials': 'H', 'LastName': 'Zhu', 'Affiliation': 'Department of Medicine, Duke University Medical Center, Durham, NC, United States of America.'}, {'ForeName': 'Robert D', 'Initials': 'RD', 'LastName': 'Marek', 'Affiliation': 'Department of Medicine, Duke University Medical Center, Durham, NC, United States of America.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Lee', 'Affiliation': 'Department of Medicine, Duke University Medical Center, Durham, NC, United States of America.'}, {'ForeName': 'Nirmish', 'Initials': 'N', 'LastName': 'Shah', 'Affiliation': 'Department of Pediatrics, Duke University Medical Center, Durham, NC, United States of America.'}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Poisson', 'Affiliation': 'Department of Pathology, Duke University Medical Center, Durham, NC, United States of America.'}, {'ForeName': 'Tim J', 'Initials': 'TJ', 'LastName': 'McMahon', 'Affiliation': 'Department of Medicine, Duke University Medical Center, Durham, NC, United States of America.'}]",Blood transfusion = Trasfusione del sangue,['10.2450/2020.0237-19'] 443,31671189,How Do I Help My Partner in Pain? Partners' Helping Behaviors Are Linked to Lower Pain and Greater Perceived Validation During an Experimental Pain Task.,"BACKGROUND Observers' responses to people with illness are important predictors of quality of life, yet findings are mixed regarding the types of responses that affect illness-related suffering. PURPOSE The purpose of this study was to examine whether perspective taking positively affects observers' responses to their romantic partner experiencing experimentally induced pain and whether responses based in Self-Determination Theory and communication models of illness are related to perceived validation and pain outcomes. METHODS Undergraduate romantic couples (N = 122) completed baseline questionnaires; then one partner was randomly assigned to complete the cold pressor task, whereas the other partner observed. Couples were randomly assigned to one of two groups: a perspective-taking group in which observers were privately instructed to take the perspective of the pain participant or a control group. Afterward, both partners completed surveys, and pain participants completed a video recall task in which they recalled partner behaviors that were coded by trained raters using a theoretically derived manual. RESULTS Pain participants in the perspective-taking group identified significantly less invalidating communication from their partners, fewer behaviors that thwarted their competence, and more behaviors that supported their autonomy. Across groups, pain participants who received more normalizing communication that supported their competence felt more validated by their partners, had lower pain intensity, and exhibited greater pain tolerance, whereas those who received more invalidation showed worse outcomes. CONCLUSIONS The results from this study suggest that attention to different types of partner behaviors is essential when developing behavioral medicine treatments for pain and illness.",2020,"Across groups, pain participants who received more normalizing communication that supported their competence felt more validated by their partners, had lower pain intensity, and exhibited greater pain tolerance, whereas those who received more invalidation showed worse outcomes. ",['Undergraduate romantic couples (N = 122) completed baseline questionnaires; then one partner'],['perspective-taking group in which observers were privately instructed to take the perspective of the pain participant or a control group'],"['lower pain intensity', 'invalidating communication', 'video recall task', 'pain tolerance']","[{'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0682323', 'cui_str': 'Companion'}]","[{'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0162703', 'cui_str': 'Pain Threshold'}]",,0.0976613,"Across groups, pain participants who received more normalizing communication that supported their competence felt more validated by their partners, had lower pain intensity, and exhibited greater pain tolerance, whereas those who received more invalidation showed worse outcomes. ","[{'ForeName': 'Bethany D', 'Initials': 'BD', 'LastName': 'Pester', 'Affiliation': 'Department of Psychology, Wayne State University, Detroit, MI, USA.'}, {'ForeName': 'Annmarie', 'Initials': 'A', 'LastName': 'Caño', 'Affiliation': 'Department of Psychology, Wayne State University, Detroit, MI, USA.'}, {'ForeName': 'Toni', 'Initials': 'T', 'LastName': 'Kostecki', 'Affiliation': 'Department of Psychology, Wayne State University, Detroit, MI, USA.'}, {'ForeName': 'Lee H', 'Initials': 'LH', 'LastName': 'Wurm', 'Affiliation': 'Department of Psychology, Wayne State University, Detroit, MI, USA.'}]",Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,['10.1093/abm/kaz047'] 444,31368770,Randomized controlled trial of d-cycloserine in cocaine dependence: Effects on contingency management and cue-induced cocaine craving in a naturalistic setting.,"Cocaine dependence constitutes a significant public health concern. This randomized, double-blind, placebo-controlled trial tested a novel approach to reducing cocaine use among cocaine-dependent individuals with d-cycloserine, a drug known to enhance learning and some learning-based therapies. Urine samples and cocaine craving were assessed across three phases: induction (Weeks 1-2), treatment (Weeks 3-5; urinalysis-based contingency management plus exposure therapy), and posttreatment (Weeks 6-7). During the treatment phase, either 50 mg of d-cycloserine or placebo was administered after delivery of urinalysis feedback with potential monetary reward and before exposure therapy sessions in naturalistic contexts individually associated with cocaine use. d-cycloserine significantly improved learning on an operant laboratory task. Contingency management significantly reduced cocaine use and craving. d-cycloserine did not significantly affect cocaine use or craving in the treatment phase. Craving significantly increased for the d-cycloserine group during the post treatment phase. Therefore, although the study showed that d-cycloserine was capable of improving learning, enhancement of learning-based therapy was not observed. Moreover, no differences in behavioral measures of cocaine demand (cocaine purchasing task) or monetary or sexual delay discounting were observed across phases or between groups in any phase. These results are somewhat consistent with previous findings suggesting that d-cycloserine administration increases cocaine craving, although they differ from other findings showing that d-cycloserine administration reduces alcohol or nicotine cravings. Methodological variables (e.g., guided vs. unguided exposure therapy sessions, length of extinction exposure) likely play a role in dissimilar findings observed across studies. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"Moreover, no differences in behavioral measures of cocaine demand (cocaine purchasing task) or monetary or sexual delay discounting were observed across phases or between groups in any phase.","['cocaine-dependent individuals with d-cycloserine, a drug known to enhance learning and some learning-based therapies', 'cocaine dependence']","['placebo', 'cycloserine or placebo', 'd-cycloserine']","['cocaine use or craving', 'Urine samples and cocaine craving', 'cocaine craving', 'cocaine use and craving', 'alcohol or nicotine cravings', 'behavioral measures of cocaine demand (cocaine purchasing task) or monetary or sexual delay discounting', 'Craving']","[{'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0010590', 'cui_str': 'Cycloserine'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0205309', 'cui_str': 'Known (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0600427', 'cui_str': 'Cocaine Dependence'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0010590', 'cui_str': 'Cycloserine'}]","[{'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C1610733', 'cui_str': 'Urine specimen'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0872355', 'cui_str': 'Nicotine craving'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C3850035', 'cui_str': 'Intertemporal Decision Making'}]",2019.0,0.0837616,"Moreover, no differences in behavioral measures of cocaine demand (cocaine purchasing task) or monetary or sexual delay discounting were observed across phases or between groups in any phase.","[{'ForeName': 'Matthew W', 'Initials': 'MW', 'LastName': 'Johnson', 'Affiliation': 'Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences.'}, {'ForeName': 'Natalie R', 'Initials': 'NR', 'LastName': 'Bruner', 'Affiliation': 'Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences.'}, {'ForeName': 'Patrick S', 'Initials': 'PS', 'LastName': 'Johnson', 'Affiliation': 'Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Silverman', 'Affiliation': 'Center for Learning and Health, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.'}, {'ForeName': 'Meredith S', 'Initials': 'MS', 'LastName': 'Berry', 'Affiliation': 'Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences.'}]",Experimental and clinical psychopharmacology,['10.1037/pha0000306'] 445,30904553,Influence of Timing on the Horizontal Stability of Connective Tissue Grafts for Buccal Soft Tissue Augmentation at Single Implants: A Prospective Controlled Pilot Study.,"PURPOSE The timing for soft tissue augmentation during implant therapy is still debated. Therefore, the present study clinically evaluated whether immediate versus delayed soft tissue augmentation procedures had an impact on the stability of peri-implant mucosal thickness (PMT). MATERIALS AND METHODS Patients requiring a single implant posterior to the canines in association with soft tissue augmentation procedures at the buccal aspect of single implants using a connective tissue graft (CTG) were enrolled. Patients were randomly allocated to 2 different timing protocols: simultaneous implant and CTG placement (test group) or implant placement and then CTG placement after 3 months (control group). PMT was measured clinically at the mid-buccal aspect of the implant site by bone sounding with an endodontic K-file using customized acrylic stents. PMT measurements were recorded before and after implant placement and at 1, 2, 3, 4, 6, 9, and 12 months after implant insertion. Parametric statistical tests were used to compare PMT between the test and control groups at each study period and to evaluate changes in PMT over time. The level of significance was set at a P value less than .05. RESULTS Fourteen implants placed in 14 patients were available for statistical comparison. At 12 months, the difference in PMT between the test and control groups was 0.12 ± 0.51 mm. This difference was not statistically significant (P = .54). A significant increase in PMT was observed from baseline to 12 months after implantation in the test (P = .004) and control (P < .001) groups. CONCLUSIONS The present study indicated that changes in PMT after CTG placement were not influenced by the timing of soft tissue augmentation and remained stable up to 1 year after implant insertion.",2019,"A significant increase in PMT was observed from baseline to 12 months after implantation in the test (P = .004) and control (P < .001) groups. ","['Buccal Soft Tissue Augmentation at Single Implants', 'Patients requiring a single implant posterior to the canines in association with soft tissue augmentation procedures at the buccal aspect of single implants using a connective tissue graft (CTG) were enrolled']","['Connective Tissue Grafts', 'immediate versus delayed soft tissue augmentation procedures', 'simultaneous implant and CTG placement (test group) or implant placement and then CTG placement']","['PMT', 'PMT measurements', 'stability of peri-implant mucosal thickness (PMT']","[{'cui': 'C0442010', 'cui_str': 'Buccal (qualifier value)'}, {'cui': 'C0225317', 'cui_str': 'Soft tissues (body structure)'}, {'cui': 'C1293122', 'cui_str': 'Augmentation procedure'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0009780', 'cui_str': 'Connective Tissue'}, {'cui': 'C1527362', 'cui_str': 'grafts'}]","[{'cui': 'C0009780', 'cui_str': 'Connective Tissue'}, {'cui': 'C1527362', 'cui_str': 'grafts'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0225317', 'cui_str': 'Soft tissues (body structure)'}, {'cui': 'C1293122', 'cui_str': 'Augmentation procedure'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0647195', 'cui_str': 'PMTS'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}, {'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C0026724', 'cui_str': 'Mucosal Tissue'}]",14.0,0.0312425,"A significant increase in PMT was observed from baseline to 12 months after implantation in the test (P = .004) and control (P < .001) groups. ","[{'ForeName': 'Pier Paolo', 'Initials': 'PP', 'LastName': 'Poli', 'Affiliation': 'PhD Student, Implant Center for Edentulism and Jawbone Atrophies, Maxillofacial Surgery and Odontostomatology Unit, Fondazione IRCCS Cà Granda Maggiore Policlinico Hospital, University of Milan, Milan, Italy. Electronic address: pierpaolo_poli@fastwebnet.it.'}, {'ForeName': 'Paolo Carlo', 'Initials': 'PC', 'LastName': 'Maridati', 'Affiliation': 'Attending Physician, Implant Center for Edentulism and Jawbone Atrophies, Maxillofacial Surgery and Odontostomatology Unit, Fondazione IRCCS Cà Granda Maggiore Policlinico Hospital, University of Milan, Milan, Italy.'}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Stoffella', 'Affiliation': 'Attending Physician, Implant Center for Edentulism and Jawbone Atrophies, Maxillofacial Surgery and Odontostomatology Unit, Fondazione IRCCS Cà Granda Maggiore Policlinico Hospital, University of Milan, Milan, Italy.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Beretta', 'Affiliation': 'Clinical Assistant Professor, Implant Center for Edentulism and Jawbone Atrophies, Maxillofacial Surgery and Odontostomatology Unit, Fondazione IRCCS Cà Granda Maggiore Policlinico Hospital, University of Milan, Milan, Italy.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Maiorana', 'Affiliation': 'Full Professor and Chairman, Implant Center for Edentulism and Jawbone Atrophies, Maxillofacial Surgery and Odontostomatology Unit, Fondazione IRCCS Cà Granda Maggiore Policlinico Hospital, University of Milan, Milan, Italy.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.02.030'] 446,31204824,On-line personalized feedback intervention for negative affect and cannabis: A pilot randomized controlled trial.,"Cannabis is the most commonly used illicit substance and many users report difficulty quitting. Situations involving stress and negative affect are the most difficult in which to abstain during quit/reduction attempts. Further, cannabis users with elevated social anxiety experience greater cannabis-related impairment than individuals with more normative levels of social anxiety. Yet, although most persons with cannabis-related problems are interested in quitting and endorse negative emotional symptoms, the vast majority do not seek in-person treatment. Thus, the current study tested the utility of an online personalized feedback intervention (PFI) that integrates feedback regarding cannabis with strategies to manage negative affect (PFI-NAC). Current (past month) cannabis using undergraduates (who used cannabis weekly, on average) were randomly assigned to the 1-session PFI-NAC (n = 37) or an assessment-only control (n = 26) and completed a 2-week follow-up assessment. After controlling for baseline negative affect and cannabis use frequency, social anxiety interacted with condition to predict follow-up cannabis use frequency. Specifically, among those with moderate or high levels of social anxiety, those in PFI-NAC reported less use at follow up than controls; this was not the case among those with lower social anxiety. Results of this pilot study indicate a 1-session intervention that teaches simultaneously teaching skills to manage negative affect and cannabis may benefit some cannabis users with moderate to high social anxiety. Future work with larger samples and a wider range of cannabis users, with longer follow-up assessments, are important next steps. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"After controlling for baseline negative affect and cannabis use frequency, social anxiety interacted with condition to predict follow-up cannabis use frequency.","['cannabis users with elevated social anxiety experience greater cannabis-related impairment than individuals with more normative levels of social anxiety', 'negative affect and cannabis', 'cannabis users with moderate to high social anxiety', 'undergraduates (who used cannabis weekly, on average']","['online personalized feedback intervention (PFI', 'line personalized feedback intervention', '1-session PFI-NAC (n = 37) or an assessment-only control']",['social anxiety'],"[{'cui': 'C0678449', 'cui_str': 'Cannabis'}, {'cui': 'C0424166', 'cui_str': 'Social Anxiety'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}]","[{'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0424166', 'cui_str': 'Social Anxiety'}]",,0.0332941,"After controlling for baseline negative affect and cannabis use frequency, social anxiety interacted with condition to predict follow-up cannabis use frequency.","[{'ForeName': 'Julia D', 'Initials': 'JD', 'LastName': 'Buckner', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Zvolensky', 'Affiliation': 'Department of Psychology, University of Houston.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Lewis', 'Affiliation': 'Department of Psychology, Louisiana State University.'}]",Experimental and clinical psychopharmacology,['10.1037/pha0000304'] 447,30851253,Capnography Detection Using Nasal Cannula Is Superior to Modified Nasal Hood in an Open Airway System: A Randomized Controlled Trial.,"PURPOSE The nasal cannula and modified nasal hood are methods used by oral and maxillofacial surgeons to detect expired carbon dioxide during procedural sedation in an open airway system. The purpose of this study was to compare the accuracy of the detection of expired carbon dioxide between the nasal cannula and modified nasal hood. MATERIALS AND METHODS The authors designed a parallel-group randomized controlled trial to compare the nasal cannula and modified nasal hood. Patients presenting to the authors' institution for outpatient oral and maxillofacial surgery (OMS) using intravenous deep sedation or general anesthesia were randomized to have capnography detection by the modified nasal hood or the nasal cannula. The primary outcome variable was the percentage of accurately captured breaths, as determined by the average number of capnography waveforms per auscultated breath using a precordial stethoscope. The 2 groups were compared using t test. RESULTS Fifty patients were screened for enrollment in the study. Twenty-five patients were randomized to the nasal cannula group and 25 patients were randomized to the modified nasal hood group. The proportion of accurate waveforms, recorded as a percentage of total breaths, was 95.7 ± 4.7% for the nasal cannula and 75.8 ± 14.1% for the modified nasal hood (P < .0001). CONCLUSIONS When used for capnography for procedural sedation in an open airway system for routine OMS, the nasal cannula accurately recorded more breaths than the modified nasal hood.",2019,The nasal cannula and modified nasal hood are methods used by oral and maxillofacial surgeons to detect expired carbon dioxide during procedural sedation in an open airway system.,"['Fifty patients were screened for enrollment in the study', 'Twenty-five patients were randomized to the nasal cannula group and 25 patients', ""Patients presenting to the authors' institution for outpatient oral and maxillofacial surgery (OMS) using intravenous deep sedation or general anesthesia"", 'Open Airway System']","['nasal cannula and modified nasal hood', 'capnography detection by the modified nasal hood or the nasal cannula', 'modified nasal hood group']","['percentage of total breaths', 'percentage of accurately captured breaths, as determined by the average number of capnography waveforms per auscultated breath using a precordial stethoscope']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannula'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C3812881', 'cui_str': 'Writer (occupation)'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0812928', 'cui_str': 'Oral and maxillofacial surgery'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C1956064', 'cui_str': 'Deep Sedation'}, {'cui': 'C0002915', 'cui_str': 'General Anesthesia'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0458827', 'cui_str': 'Airway structure (body structure)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}]","[{'cui': 'C0179574', 'cui_str': 'Nasal Cannula'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C4520890', 'cui_str': 'Nasal'}, {'cui': 'C0376529', 'cui_str': 'Capnography'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0225386', 'cui_str': 'Breath (substance)'}, {'cui': 'C0521095', 'cui_str': 'Determined by (contextual qualifier) (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0376529', 'cui_str': 'Capnography'}, {'cui': 'C0450448', 'cui_str': 'Waveforms (qualifier value)'}, {'cui': 'C2585391', 'cui_str': 'Precordial stethoscope (physical object)'}]",25.0,0.0287179,The nasal cannula and modified nasal hood are methods used by oral and maxillofacial surgeons to detect expired carbon dioxide during procedural sedation in an open airway system.,"[{'ForeName': 'Brett J', 'Initials': 'BJ', 'LastName': 'King', 'Affiliation': 'Assistant Professor, Department of Oral and Maxillofacial Surgery, Louisiana State University Health Sciences Center, New Orleans, LA. Electronic address: bking6@lsuhsc.edu.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Megison', 'Affiliation': 'Resident, Department of Oral and Maxillofacial Surgery, Louisiana State University Health Sciences Center, New Orleans, LA.'}, {'ForeName': 'Zach', 'Initials': 'Z', 'LastName': 'Scogin', 'Affiliation': 'Resident, Department of Oral and Maxillofacial Surgery, Louisiana State University Health Sciences Center, New Orleans, LA.'}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Christensen', 'Affiliation': 'Chief Resident, Department of Oral and Maxillofacial Surgery, Louisiana State University Health Sciences Center, New Orleans, LA.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.02.002'] 448,32192470,Methylphenidate improves executive functions in patients with traumatic brain injuries: a feasibility trial via the idiographic approach.,"BACKGROUND Road traffic accidents are known to be the main cause of traumatic brain injury (TBI). TBI is also a leading cause of death and disability. This study, by means of the idiographic approach (single-case experimental designs using multiple-baseline designs), has examined whether methylphenidate (MPH - trade name Ritalin) had a differential effect on cognitive measures among patients with TBI with the sequel of acute and chronic post-concussion syndromes. The effect on gender was also explored. METHODS In comparison with healthy controls, patients with TBI (acute and chronic) and accompanying mild cognitive impairment (MCI) were screened for their integrity of executive functioning. Twenty-four patients exhibiting executive dysfunction (ED) were then instituted with the pharmacological intervention methylphenidate (MPH). The methylphenidate was administered using an uncontrolled, open label design. RESULTS The administration of methylphenidate impacted ED in the TBI group but had no effect on mood. Attenuation of ED was more apparent in the chronic phases of TBI. The effect on gender was not statistically significant with regard to the observed changes. CONCLUSIONS To our knowledge, this is the first feasibility trial from the Arabian Gulf to report the performance of a TBI population with mild cognitive impairment according to the IQCODE Arabic version. This investigation confirms anecdotal observations of methylphenidate having the potential to attenuate cognitive impairment; particularly those functions that are critically involved in the integrity of executive functioning. The present feasibility trial should be followed by nomothetic studies such as those that adhere to the protocol of the randomized controlled trial. This evidence-based research is the foundation for intervention and future resource allocation by policy- or public health decision-makers.",2020,The administration of methylphenidate impacted ED in the TBI group but had no effect on mood.,"['patients with TBI with the sequel of acute and chronic post-concussion syndromes', 'patients with traumatic brain injuries', 'Twenty-four patients exhibiting executive dysfunction (ED', 'patients with TBI (acute and chronic) and accompanying mild cognitive impairment (MCI']","['methylphenidate', 'pharmacological intervention methylphenidate (MPH', 'methylphenidate (MPH - trade name Ritalin', 'Methylphenidate']",['executive functions'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0243089', 'cui_str': 'sequels'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0546983', 'cui_str': 'Post-Concussion Symptoms'}, {'cui': 'C0876926', 'cui_str': 'TBI (Traumatic Brain Injury)'}, {'cui': 'C3715070', 'cui_str': '24 (qualifier value)'}, {'cui': 'C0015272', 'cui_str': 'Exhibits'}, {'cui': 'C2748208', 'cui_str': 'Executive dysfunction'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C0560005', 'cui_str': 'millicurie'}]","[{'cui': 'C0025810', 'cui_str': 'Methylphenidate'}, {'cui': 'C0205464', 'cui_str': 'Pharmacologic (qualifier value)'}, {'cui': 'C0048853', 'cui_str': 'MPH'}, {'cui': 'C0728759', 'cui_str': 'Ritalin'}]","[{'cui': 'C0935584', 'cui_str': 'Executive Control'}]",24.0,0.0631699,The administration of methylphenidate impacted ED in the TBI group but had no effect on mood.,"[{'ForeName': 'Samir', 'Initials': 'S', 'LastName': 'Al-Adawi', 'Affiliation': 'Department of Behavioural Medicine, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman. samir-adawi@fulbrightmail.org.'}, {'ForeName': 'Aziz', 'Initials': 'A', 'LastName': 'Al-Naamani', 'Affiliation': 'Department of Behavioural Medicine, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.'}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Jaju', 'Affiliation': 'Department of Family Medicine and Public Health, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.'}, {'ForeName': 'Yahya M', 'Initials': 'YM', 'LastName': 'Al-Farsi', 'Affiliation': 'Department of Family Medicine and Public Health, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.'}, {'ForeName': 'Atsu S S', 'Initials': 'ASS', 'LastName': 'Dorvlo', 'Affiliation': 'Department of Mathematics and Statistics, College of Science, Sultan Qaboos University, Muscat, Oman.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Al-Maashani', 'Affiliation': 'Department of Neurosurgery, Khoula Hospital, Ministry of Health, Muscat, Oman.'}, {'ForeName': 'Sara S H', 'Initials': 'SSH', 'LastName': 'Al-Adawi', 'Affiliation': 'Oman Medical Specialty Board, Muscat, Oman.'}, {'ForeName': 'Ahmed A', 'Initials': 'AA', 'LastName': 'Moustafa', 'Affiliation': 'School of Social Sciences and Psychology, Marcs Institute of Brain and Behaviour, Western Sydney University, Penrith, NSW, Australia.'}, {'ForeName': 'Nasser', 'Initials': 'N', 'LastName': 'Al-Sibani', 'Affiliation': 'Department of Behavioural Medicine, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.'}, {'ForeName': 'Musthafa M', 'Initials': 'MM', 'LastName': 'Essa', 'Affiliation': 'Department of Food Science and Nutrition, College of Agricultural and Marine Sciences, Sultan Qaboos University, Muscat, Oman. drmdessa@gmail.com.'}, {'ForeName': 'David T', 'Initials': 'DT', 'LastName': 'Burke', 'Affiliation': 'Department of Rehabilitation Medicine, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'M Walid', 'Initials': 'MW', 'LastName': 'Qoronfleh', 'Affiliation': 'Research & Policy Department, World Innovation Summit for Health (WISH), Qatar Foundation, P.O. Box 5825, Doha, Qatar. wqoronfleh@qf.org.qa.'}]",BMC neurology,['10.1186/s12883-020-01663-x'] 449,32404355,Aerobic exercise improves cognition and cerebrovascular regulation in older adults.,"OBJECTIVE To test the hypothesis that aerobic exercise is associated with improvements in cognition and cerebrovascular regulation, we enrolled 206 healthy low-active middle-aged and older adults (mean ± SD age 65.9 ± 6.4 years) in a supervised 6-month aerobic exercise intervention and assessed them before and after the intervention. METHODS The study is a quasi-experimental single group pre/postintervention study. Neuropsychological tests were used to assess cognition before and after the intervention. Transcranial Doppler ultrasound was used to measure cerebral blood flow velocity. Cerebrovascular regulation was assessed at rest, during euoxic hypercapnia, and in response to submaximal exercise. Multiple linear regression was used to examine the association between changes in cognition and changes in cerebrovascular function. RESULTS The intervention was associated with improvements in some cognitive domains, cardiorespiratory fitness, and cerebrovascular regulation. Changes in executive functions were negatively associated with changes in cerebrovascular resistance index (CVRi) during submaximal exercise (β = -0.205, p = 0.013), while fluency improvements were positively associated with changes in CVRi during hypercapnia (β = 0.106, p = 0.03). CONCLUSION The 6-month aerobic exercise intervention was associated with improvements in some cognitive domains and cerebrovascular regulation. Secondary analyses showed a novel association between changes in cognition and changes in cerebrovascular regulation during euoxic hypercapnia and in response to submaximal exercise.",2020,"Changes in executive functions were negatively associated with changes in cerebrovascular resistance index (CVRi) during submaximal exercise (β = -0.205, p = 0.013), while fluency improvements were positively associated with changes in CVRi during hypercapnia (β = 0.106, p = 0.03). ","['older adults', '206 healthy low-active middle-aged and older adults (mean ± SD age 65.9 ± 6.4 years) in a']","['aerobic exercise intervention', 'Transcranial Doppler ultrasound', 'Aerobic exercise', 'supervised 6-month aerobic exercise intervention', 'aerobic exercise']","['Cerebrovascular regulation', 'executive functions', 'some cognitive domains and cerebrovascular regulation', 'cognition and cerebrovascular regulation', 'cerebral blood flow velocity', 'cognition and changes in cerebrovascular regulation', 'cerebrovascular resistance index (CVRi', 'some cognitive domains, cardiorespiratory fitness, and cerebrovascular regulation']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517822', 'cui_str': '6.4'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0206077', 'cui_str': 'Transcranial doppler ultrasonography'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}]",206.0,0.0187172,"Changes in executive functions were negatively associated with changes in cerebrovascular resistance index (CVRi) during submaximal exercise (β = -0.205, p = 0.013), while fluency improvements were positively associated with changes in CVRi during hypercapnia (β = 0.106, p = 0.03). ","[{'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Guadagni', 'Affiliation': ""From the Department of Physiology and Pharmacology (V.G., L.L.D., A.V.T., G.A.E., M.J.P.), Hotchkiss Brain Institute (V.G., L.L.D., A.V.T., R.S.L., M.D.H., D.B.H., M.J.P.), Division of Geriatric Medicine (D.B.H.), Department of Medicine, Department of Clinical Neurosciences (V.G., L.L.D., A.V.T., M.D.H., D.B.H., M.J.P.), Libin Cardiovascular Institute of Alberta (T.J.A., M.J.P.), O'Brien Institute for Public Health (V.G., D.B.H., M.J.P.), Department of Cardiac Sciences (T.J.A.), Libin Cardiovascular Institute of Alberta, and Department of Community Health Sciences (M.D.H.), Cumming School of Medicine, Faculty of Kinesiology (M.J.P.), and Department of Psychology (R.S.L.), University of Calgary; Psychology Service (R.S.L.), Alberta Health Service, Foothills Medical Centre, Calgary; Department of Psychiatry (G.A.E.), Faculty of Medicine, and Department of Psychology and Neuroscience (G.A.E.), Faculty of Science, Dalhousie University, Halifax, Nova Scotia; and Program for Pregnancy and Postpartum Health, Physical Activity and Diabetes Laboratory (M.H.D.), Faculty of Kinesiology, Sport, and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Edmonton, Canada.""}, {'ForeName': 'Lauren L', 'Initials': 'LL', 'LastName': 'Drogos', 'Affiliation': ""From the Department of Physiology and Pharmacology (V.G., L.L.D., A.V.T., G.A.E., M.J.P.), Hotchkiss Brain Institute (V.G., L.L.D., A.V.T., R.S.L., M.D.H., D.B.H., M.J.P.), Division of Geriatric Medicine (D.B.H.), Department of Medicine, Department of Clinical Neurosciences (V.G., L.L.D., A.V.T., M.D.H., D.B.H., M.J.P.), Libin Cardiovascular Institute of Alberta (T.J.A., M.J.P.), O'Brien Institute for Public Health (V.G., D.B.H., M.J.P.), Department of Cardiac Sciences (T.J.A.), Libin Cardiovascular Institute of Alberta, and Department of Community Health Sciences (M.D.H.), Cumming School of Medicine, Faculty of Kinesiology (M.J.P.), and Department of Psychology (R.S.L.), University of Calgary; Psychology Service (R.S.L.), Alberta Health Service, Foothills Medical Centre, Calgary; Department of Psychiatry (G.A.E.), Faculty of Medicine, and Department of Psychology and Neuroscience (G.A.E.), Faculty of Science, Dalhousie University, Halifax, Nova Scotia; and Program for Pregnancy and Postpartum Health, Physical Activity and Diabetes Laboratory (M.H.D.), Faculty of Kinesiology, Sport, and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Edmonton, Canada.""}, {'ForeName': 'Amanda V', 'Initials': 'AV', 'LastName': 'Tyndall', 'Affiliation': ""From the Department of Physiology and Pharmacology (V.G., L.L.D., A.V.T., G.A.E., M.J.P.), Hotchkiss Brain Institute (V.G., L.L.D., A.V.T., R.S.L., M.D.H., D.B.H., M.J.P.), Division of Geriatric Medicine (D.B.H.), Department of Medicine, Department of Clinical Neurosciences (V.G., L.L.D., A.V.T., M.D.H., D.B.H., M.J.P.), Libin Cardiovascular Institute of Alberta (T.J.A., M.J.P.), O'Brien Institute for Public Health (V.G., D.B.H., M.J.P.), Department of Cardiac Sciences (T.J.A.), Libin Cardiovascular Institute of Alberta, and Department of Community Health Sciences (M.D.H.), Cumming School of Medicine, Faculty of Kinesiology (M.J.P.), and Department of Psychology (R.S.L.), University of Calgary; Psychology Service (R.S.L.), Alberta Health Service, Foothills Medical Centre, Calgary; Department of Psychiatry (G.A.E.), Faculty of Medicine, and Department of Psychology and Neuroscience (G.A.E.), Faculty of Science, Dalhousie University, Halifax, Nova Scotia; and Program for Pregnancy and Postpartum Health, Physical Activity and Diabetes Laboratory (M.H.D.), Faculty of Kinesiology, Sport, and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Edmonton, Canada.""}, {'ForeName': 'Margie H', 'Initials': 'MH', 'LastName': 'Davenport', 'Affiliation': ""From the Department of Physiology and Pharmacology (V.G., L.L.D., A.V.T., G.A.E., M.J.P.), Hotchkiss Brain Institute (V.G., L.L.D., A.V.T., R.S.L., M.D.H., D.B.H., M.J.P.), Division of Geriatric Medicine (D.B.H.), Department of Medicine, Department of Clinical Neurosciences (V.G., L.L.D., A.V.T., M.D.H., D.B.H., M.J.P.), Libin Cardiovascular Institute of Alberta (T.J.A., M.J.P.), O'Brien Institute for Public Health (V.G., D.B.H., M.J.P.), Department of Cardiac Sciences (T.J.A.), Libin Cardiovascular Institute of Alberta, and Department of Community Health Sciences (M.D.H.), Cumming School of Medicine, Faculty of Kinesiology (M.J.P.), and Department of Psychology (R.S.L.), University of Calgary; Psychology Service (R.S.L.), Alberta Health Service, Foothills Medical Centre, Calgary; Department of Psychiatry (G.A.E.), Faculty of Medicine, and Department of Psychology and Neuroscience (G.A.E.), Faculty of Science, Dalhousie University, Halifax, Nova Scotia; and Program for Pregnancy and Postpartum Health, Physical Activity and Diabetes Laboratory (M.H.D.), Faculty of Kinesiology, Sport, and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Edmonton, Canada.""}, {'ForeName': 'Todd J', 'Initials': 'TJ', 'LastName': 'Anderson', 'Affiliation': ""From the Department of Physiology and Pharmacology (V.G., L.L.D., A.V.T., G.A.E., M.J.P.), Hotchkiss Brain Institute (V.G., L.L.D., A.V.T., R.S.L., M.D.H., D.B.H., M.J.P.), Division of Geriatric Medicine (D.B.H.), Department of Medicine, Department of Clinical Neurosciences (V.G., L.L.D., A.V.T., M.D.H., D.B.H., M.J.P.), Libin Cardiovascular Institute of Alberta (T.J.A., M.J.P.), O'Brien Institute for Public Health (V.G., D.B.H., M.J.P.), Department of Cardiac Sciences (T.J.A.), Libin Cardiovascular Institute of Alberta, and Department of Community Health Sciences (M.D.H.), Cumming School of Medicine, Faculty of Kinesiology (M.J.P.), and Department of Psychology (R.S.L.), University of Calgary; Psychology Service (R.S.L.), Alberta Health Service, Foothills Medical Centre, Calgary; Department of Psychiatry (G.A.E.), Faculty of Medicine, and Department of Psychology and Neuroscience (G.A.E.), Faculty of Science, Dalhousie University, Halifax, Nova Scotia; and Program for Pregnancy and Postpartum Health, Physical Activity and Diabetes Laboratory (M.H.D.), Faculty of Kinesiology, Sport, and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Edmonton, Canada.""}, {'ForeName': 'Gail A', 'Initials': 'GA', 'LastName': 'Eskes', 'Affiliation': ""From the Department of Physiology and Pharmacology (V.G., L.L.D., A.V.T., G.A.E., M.J.P.), Hotchkiss Brain Institute (V.G., L.L.D., A.V.T., R.S.L., M.D.H., D.B.H., M.J.P.), Division of Geriatric Medicine (D.B.H.), Department of Medicine, Department of Clinical Neurosciences (V.G., L.L.D., A.V.T., M.D.H., D.B.H., M.J.P.), Libin Cardiovascular Institute of Alberta (T.J.A., M.J.P.), O'Brien Institute for Public Health (V.G., D.B.H., M.J.P.), Department of Cardiac Sciences (T.J.A.), Libin Cardiovascular Institute of Alberta, and Department of Community Health Sciences (M.D.H.), Cumming School of Medicine, Faculty of Kinesiology (M.J.P.), and Department of Psychology (R.S.L.), University of Calgary; Psychology Service (R.S.L.), Alberta Health Service, Foothills Medical Centre, Calgary; Department of Psychiatry (G.A.E.), Faculty of Medicine, and Department of Psychology and Neuroscience (G.A.E.), Faculty of Science, Dalhousie University, Halifax, Nova Scotia; and Program for Pregnancy and Postpartum Health, Physical Activity and Diabetes Laboratory (M.H.D.), Faculty of Kinesiology, Sport, and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Edmonton, Canada.""}, {'ForeName': 'R Stewart', 'Initials': 'RS', 'LastName': 'Longman', 'Affiliation': ""From the Department of Physiology and Pharmacology (V.G., L.L.D., A.V.T., G.A.E., M.J.P.), Hotchkiss Brain Institute (V.G., L.L.D., A.V.T., R.S.L., M.D.H., D.B.H., M.J.P.), Division of Geriatric Medicine (D.B.H.), Department of Medicine, Department of Clinical Neurosciences (V.G., L.L.D., A.V.T., M.D.H., D.B.H., M.J.P.), Libin Cardiovascular Institute of Alberta (T.J.A., M.J.P.), O'Brien Institute for Public Health (V.G., D.B.H., M.J.P.), Department of Cardiac Sciences (T.J.A.), Libin Cardiovascular Institute of Alberta, and Department of Community Health Sciences (M.D.H.), Cumming School of Medicine, Faculty of Kinesiology (M.J.P.), and Department of Psychology (R.S.L.), University of Calgary; Psychology Service (R.S.L.), Alberta Health Service, Foothills Medical Centre, Calgary; Department of Psychiatry (G.A.E.), Faculty of Medicine, and Department of Psychology and Neuroscience (G.A.E.), Faculty of Science, Dalhousie University, Halifax, Nova Scotia; and Program for Pregnancy and Postpartum Health, Physical Activity and Diabetes Laboratory (M.H.D.), Faculty of Kinesiology, Sport, and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Edmonton, Canada.""}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Hill', 'Affiliation': ""From the Department of Physiology and Pharmacology (V.G., L.L.D., A.V.T., G.A.E., M.J.P.), Hotchkiss Brain Institute (V.G., L.L.D., A.V.T., R.S.L., M.D.H., D.B.H., M.J.P.), Division of Geriatric Medicine (D.B.H.), Department of Medicine, Department of Clinical Neurosciences (V.G., L.L.D., A.V.T., M.D.H., D.B.H., M.J.P.), Libin Cardiovascular Institute of Alberta (T.J.A., M.J.P.), O'Brien Institute for Public Health (V.G., D.B.H., M.J.P.), Department of Cardiac Sciences (T.J.A.), Libin Cardiovascular Institute of Alberta, and Department of Community Health Sciences (M.D.H.), Cumming School of Medicine, Faculty of Kinesiology (M.J.P.), and Department of Psychology (R.S.L.), University of Calgary; Psychology Service (R.S.L.), Alberta Health Service, Foothills Medical Centre, Calgary; Department of Psychiatry (G.A.E.), Faculty of Medicine, and Department of Psychology and Neuroscience (G.A.E.), Faculty of Science, Dalhousie University, Halifax, Nova Scotia; and Program for Pregnancy and Postpartum Health, Physical Activity and Diabetes Laboratory (M.H.D.), Faculty of Kinesiology, Sport, and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Edmonton, Canada.""}, {'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Hogan', 'Affiliation': ""From the Department of Physiology and Pharmacology (V.G., L.L.D., A.V.T., G.A.E., M.J.P.), Hotchkiss Brain Institute (V.G., L.L.D., A.V.T., R.S.L., M.D.H., D.B.H., M.J.P.), Division of Geriatric Medicine (D.B.H.), Department of Medicine, Department of Clinical Neurosciences (V.G., L.L.D., A.V.T., M.D.H., D.B.H., M.J.P.), Libin Cardiovascular Institute of Alberta (T.J.A., M.J.P.), O'Brien Institute for Public Health (V.G., D.B.H., M.J.P.), Department of Cardiac Sciences (T.J.A.), Libin Cardiovascular Institute of Alberta, and Department of Community Health Sciences (M.D.H.), Cumming School of Medicine, Faculty of Kinesiology (M.J.P.), and Department of Psychology (R.S.L.), University of Calgary; Psychology Service (R.S.L.), Alberta Health Service, Foothills Medical Centre, Calgary; Department of Psychiatry (G.A.E.), Faculty of Medicine, and Department of Psychology and Neuroscience (G.A.E.), Faculty of Science, Dalhousie University, Halifax, Nova Scotia; and Program for Pregnancy and Postpartum Health, Physical Activity and Diabetes Laboratory (M.H.D.), Faculty of Kinesiology, Sport, and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Edmonton, Canada.""}, {'ForeName': 'Marc J', 'Initials': 'MJ', 'LastName': 'Poulin', 'Affiliation': ""From the Department of Physiology and Pharmacology (V.G., L.L.D., A.V.T., G.A.E., M.J.P.), Hotchkiss Brain Institute (V.G., L.L.D., A.V.T., R.S.L., M.D.H., D.B.H., M.J.P.), Division of Geriatric Medicine (D.B.H.), Department of Medicine, Department of Clinical Neurosciences (V.G., L.L.D., A.V.T., M.D.H., D.B.H., M.J.P.), Libin Cardiovascular Institute of Alberta (T.J.A., M.J.P.), O'Brien Institute for Public Health (V.G., D.B.H., M.J.P.), Department of Cardiac Sciences (T.J.A.), Libin Cardiovascular Institute of Alberta, and Department of Community Health Sciences (M.D.H.), Cumming School of Medicine, Faculty of Kinesiology (M.J.P.), and Department of Psychology (R.S.L.), University of Calgary; Psychology Service (R.S.L.), Alberta Health Service, Foothills Medical Centre, Calgary; Department of Psychiatry (G.A.E.), Faculty of Medicine, and Department of Psychology and Neuroscience (G.A.E.), Faculty of Science, Dalhousie University, Halifax, Nova Scotia; and Program for Pregnancy and Postpartum Health, Physical Activity and Diabetes Laboratory (M.H.D.), Faculty of Kinesiology, Sport, and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Edmonton, Canada. poulin@ucalgary.ca.""}]",Neurology,['10.1212/WNL.0000000000009478'] 450,32406858,Web-Based Self-Management for Patients With Lymphoma: Assessment of the Reach of Intervention of a Randomized Controlled Trial.,"BACKGROUND Randomized controlled trials (RCTs) often provide accurate estimates of the internal validity of an intervention but lack information on external validity (generalizability). We conducted an RCT on the effectiveness of a self-management intervention among patients with lymphoma in a population-based setting. OBJECTIVE The objectives of the current study were to describe the proportion of RCT participants compared to all patients invited to participate, and compare sociodemographic and clinical characteristics of RCT participants with all respondents, all patients invited to participate, and all patients selected from the Netherlands Cancer Registry (NCR) to determine the reach of the intervention. An additional objective was to assess differences on RCT outcome variables between RCT and paper respondents. METHODS Patients with lymphoma or chronic lymphocytic leukemia ≥18 years old at diagnosis from 13 hospitals in the Netherlands were selected from the population-based NCR, which routinely collects data on sociodemographic and clinical characteristics. Eligible patients were invited to participate in an RCT and complete a questionnaire. Web-based completion determined RCT enrollment, whereas paper respondents were followed observationally. RESULTS A total of 1193 patients were selected from the NCR, 892 (74.77%) of whom were invited to participate in the trial by their hematologist after verifying eligibility. Among those invited, 25.4% (227/892) completed the web-based questionnaire and were enrolled in the RCT. The RCT participants were younger and there was a higher proportion of men than nonparticipants (P<.001). In addition, 25.7% (229/892) of those invited opted to participate in the paper-based observational follow-up study. Compared with paper respondents, RCT participants were younger (P<.001), with a higher proportion of men (P=.002), and had higher education levels (P=.02). RCT participants more often wanted to receive all available information on their disease (P<.001), whereas paper respondents reported higher levels of emotional distress (P=.009). CONCLUSIONS From a population-based sample of eligible patients, the participation rate in the RCT was approximately 25%. RCT participants may not be representative of the target population because of different sociodemographic and clinical characteristics. Since RCT participants represent a minority of the target population, RCT results should be interpreted with caution as patients in the RCT may be those least in need of a self-management intervention. TRIAL REGISTRATION Netherlands Trial Register NTR5953; https://www.trialregister.nl/trial/5790.",2020,The RCT participants were younger and there was a higher proportion of men than nonparticipants (P<.001).,"['Patients With Lymphoma', 'Patients with lymphoma or chronic lymphocytic leukemia ≥18 years old at diagnosis from 13 hospitals in the Netherlands were selected from the population-based NCR, which routinely collects data on sociodemographic and clinical characteristics', 'A total of 1193 patients were selected from the NCR, 892 (74.77%) of whom were invited to participate in the trial by their hematologist after verifying eligibility', 'Among those invited, 25.4% (227/892) completed the web-based questionnaire and were enrolled in the RCT', 'From a population-based sample of eligible patients', 'RCT participants with all respondents, all patients invited to participate, and all patients selected from the Netherlands Cancer Registry (NCR) to determine the reach of the intervention', 'patients with lymphoma in a population-based setting', 'Eligible patients were invited to participate in an RCT and complete a questionnaire']","['RCT', 'NTR5953', 'self-management intervention']","['higher education levels', 'emotional distress', 'participation rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024299', 'cui_str': 'Malignant lymphoma'}, {'cui': 'C0023434', 'cui_str': 'Chronic lymphocytic leukemia'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0424933', 'cui_str': 'Higher education'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0700361', 'cui_str': 'Emotional distress'}]",1193.0,0.125336,The RCT participants were younger and there was a higher proportion of men than nonparticipants (P<.001).,"[{'ForeName': 'Lindy P J', 'Initials': 'LPJ', 'LastName': 'Arts', 'Affiliation': 'Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Oerlemans', 'Affiliation': 'Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands.'}, {'ForeName': 'Eduardus F M', 'Initials': 'EFM', 'LastName': 'Posthuma', 'Affiliation': 'Department of Internal Medicine, Reinier de Graaf Hospital, Delft, Netherlands.'}, {'ForeName': 'Djamila E', 'Initials': 'DE', 'LastName': 'Issa', 'Affiliation': ""Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands.""}, {'ForeName': 'Margriet', 'Initials': 'M', 'LastName': 'Oosterveld', 'Affiliation': 'Department of Internal Medicine, Canisius-Wilhelmina Hospital, Nijmegen, Netherlands.'}, {'ForeName': 'René', 'Initials': 'R', 'LastName': 'van der Griend', 'Affiliation': 'Department of Internal Medicine, Diakonessenhuis, Utrecht/Zeist, Netherlands.'}, {'ForeName': 'Marten R', 'Initials': 'MR', 'LastName': 'Nijziel', 'Affiliation': 'Department of Internal Medicine, Catharina Hospital, Eindhoven, Netherlands.'}, {'ForeName': 'Lonneke V', 'Initials': 'LV', 'LastName': 'van de Poll-Franse', 'Affiliation': 'Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands.'}]",Journal of medical Internet research,['10.2196/17018'] 451,32406864,"Gratitude at Work: Prospective Cohort Study of a Web-Based, Single-Exposure Well-Being Intervention for Health Care Workers.","BACKGROUND Emotional exhaustion (EE) in health care workers is common and consequentially linked to lower quality of care. Effective interventions to address EE are urgently needed. OBJECTIVE This randomized single-exposure trial examined the efficacy of a gratitude letter-writing intervention for improving health care workers' well-being. METHODS A total of 1575 health care workers were randomly assigned to one of two gratitude letter-writing prompts (self- vs other focused) to assess differential efficacy. Assessments of EE, subjective happiness, work-life balance, and tool engagement were collected at baseline and 1-week post intervention. Participants received their EE score at baseline and quartile benchmarking scores. Paired-samples t tests, independent t tests, and correlations explored the efficacy of the intervention. Linguistic Inquiry and Word Count software assessed the linguistic content of the gratitude letters and associations with well-being. RESULTS Participants in both conditions showed significant improvements in EE, happiness, and work-life balance between the intervention and 1-week follow-up (P<.001). The self-focused (vs other) instruction conditions did not differentially predict improvement in any of the measures (P=.91). Tool engagement was high, and participants reporting higher motivation to improve their EE had higher EE at baseline (P<.001) and were more likely to improve EE a week later (P=.03). Linguistic analyses revealed that participants high on EE at baseline used more negative emotion words in their letters (P=.005). Reduction in EE at the 1-week follow-up was predicted at the level of a trend by using fewer first-person (P=.06) and positive emotion words (P=.09). No baseline differences were found between those who completed the follow-up assessment and those who did not (Ps>.05). CONCLUSIONS This single-exposure gratitude letter-writing intervention appears to be a promising low-cost, brief, and meaningful tool to improve the well-being of health care workers.",2020,"No baseline differences were found between those who completed the follow-up assessment and those who did not (Ps>.05). ","['Health Care Workers', '1575 health care workers', 'health care workers']","['gratitude letter-writing intervention', 'Single-Exposure Well-Being Intervention', 'gratitude letter-writing prompts (self- vs other focused']","['Assessments of EE, subjective happiness, work-life balance, and tool engagement', 'negative emotion words', 'EE, happiness, and work-life balance']","[{'cui': 'C0018724', 'cui_str': 'Health Care Providers'}]","[{'cui': 'C0282413', 'cui_str': 'Letters as Topic'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0018582', 'cui_str': 'Handwriting'}, {'cui': 'C0036588', 'cui_str': 'Self'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C4277700', 'cui_str': 'Work-Life Balance'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}]",,0.0319504,"No baseline differences were found between those who completed the follow-up assessment and those who did not (Ps>.05). ","[{'ForeName': 'Kathryn C', 'Initials': 'KC', 'LastName': 'Adair', 'Affiliation': 'Duke Center for Healthcare Safety and Quality, Duke University Health System, Durham, NC, United States.'}, {'ForeName': 'Larissa G', 'Initials': 'LG', 'LastName': 'Rodriguez-Homs', 'Affiliation': 'Duke University School of Medicine, Durham, NC, United States.'}, {'ForeName': 'Sabran', 'Initials': 'S', 'LastName': 'Masoud', 'Affiliation': 'Duke University School of Medicine, Durham, NC, United States.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Mosca', 'Affiliation': 'Duke Network Services Duke University Health System, Duke University Health System, Durham, NC, United States.'}, {'ForeName': 'J Bryan', 'Initials': 'JB', 'LastName': 'Sexton', 'Affiliation': 'Duke Center for Healthcare Safety and Quality, Duke University Health System, Durham, NC, United States.'}]",Journal of medical Internet research,['10.2196/15562'] 452,31282703,Automated assessment of alcohol-induced impairment of balance in male and female social drinkers.,"The acute administration of alcohol reliably impairs the ability to balance when standing. The standardized field sobriety test uses alcohol-induced impairment of body stability to indicate probable alcohol intoxication. Given that body sway is used in the detection of alcohol impairment and intoxication, it is surprising that little research with humans has incorporated new technology that provides automated neuromuscular control assessment. Therefore, the purpose of this study was to examine the dose response to the acute effects of alcohol below and at the legal limit for driving in the United States on balance impairments, as measured by the Biosway Portable Balance System (Biodex Medical Systems, Inc.). Fourteen social drinkers attended 3 separate sessions during which they received alcohol (0.0, 0.3, and 0.6 g/kg alcohol). Body sway with eyes open and eyes closed was assessed at 45 min after dose administration when breath alcohol concentration was peaking for both active alcohol doses (.04g% and .08g%). The results indicated that body sway was significantly increased in the 0.6 g/kg alcohol conditions when compared with the placebo and 0.3 g/kg alcohol conditions. Body sway was not significantly elevated in the 0.3 g/kg alcohol condition compared with placebo. The results from this study suggest that this new technology may be of interest to alcohol researchers and the police as a more precise assessment of balance. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,Body sway was not significantly elevated in the 0.3 g/kg alcohol condition compared with placebo.,"['male and female social drinkers', 'Fourteen social drinkers']",['placebo'],"['body sway', 'Body sway']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0337676', 'cui_str': 'Social drinker (finding)'}, {'cui': 'C3715152', 'cui_str': '14'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]",[],,0.0204312,Body sway was not significantly elevated in the 0.3 g/kg alcohol condition compared with placebo.,"[{'ForeName': 'Cecile A', 'Initials': 'CA', 'LastName': 'Marczinski', 'Affiliation': 'Department of Psychological Science.'}, {'ForeName': 'Clare L', 'Initials': 'CL', 'LastName': 'Mearns', 'Affiliation': 'Department of Psychological Science.'}]",Experimental and clinical psychopharmacology,['10.1037/pha0000309'] 453,32199723,Tailored Messages Addressing Human Papillomavirus Vaccination Concerns Improves Behavioral Intent Among Mothers: A Randomized Controlled Trial.,"PURPOSE The aim of the study was to determine whether supplementing a bundled recommendation (recommendation for all 11- to 12-year-old platform vaccines) with tailored messaging that addressed one versus all parental concerns improved human papillomavirus (HPV) vaccination intent among mothers. METHODS We conducted a Web-based randomized controlled trial, randomizing mothers who did not intend to vaccinate their 11- to 14-year-old child against HPV to (1) bundled recommendation video (""control""); (2) control + video addressing the top HPV vaccine concern; or (3) control + ≥1 videos addressing all concerns. Outcomes were HPV vaccination intent (1 = extremely unlikely and 10 = extremely likely) and strength of main concern (1 = a little concerned and 10 = very concerned). We assessed differences in intervention effects using generalized linear models for vaccine intent and mixed models for the strength of main concern. RESULTS Of the 762 mothers, 51% had a female child, 82% of children were white, and 90% were non-Hispanic. The mean intent to vaccinate postintervention ranged from 3.5 (95% confidence interval [CI] = 3.1-3.8) in the control group to 4.2 (95% CI = 3.9-4.6) in the all-concerns group (p = .01). The mean strength of the concerns declined pre- to postintervention by .1 (95% CI = -.1 to .3) in the control group (p = .42), .6 (95% CI = .4-.9) in the top concern group (p < .001), and .7 (95% CI = .5-1.0) in the all-concerns group (p < .001). However, the mean strength of the main concerns postintervention remained high (≥7.0 for each group). CONCLUSIONS Tailored messages addressing all concerns improved HPV vaccination intent and reduced the strength of the main concern more than bundled messages alone, but intent remained low and strength of the main concerns remained high in this vaccine-hesitant population.",2020,The mean intent to vaccinate postintervention ranged from 3.5 (95% confidence interval [CI] = 3.1-3.8) in the control group to 4.2 (95% CI = 3.9-4.6) in the all-concerns group (p = .01).,"['Mothers', 'among mothers', '762 mothers, 51% had a female child, 82% of children were white, and 90% were non-Hispanic', 'randomizing mothers who did not intend to vaccinate their 11- to 14-year-old child against HPV to (1']","['tailored messaging that addressed one versus all parental concerns improved human papillomavirus (HPV) vaccination intent', 'bundled recommendation video (""control""); (2) control\xa0+ video addressing the top HPV vaccine concern; or (3) control\xa0+ ≥1 videos addressing all concerns']","['strength of main concern', 'Behavioral Intent', 'mean strength']","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0870604', 'cui_str': 'Female child (person)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0521124', 'cui_str': 'Against (qualifier value)'}]","[{'cui': 'C0376649', 'cui_str': 'Address'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C1997921', 'cui_str': 'Vaccination for human papillomavirus (procedure)'}, {'cui': 'C1283828', 'cui_str': 'Intentional'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1512511', 'cui_str': 'HPV Vaccines'}]","[{'cui': 'C0205225', 'cui_str': 'Principal (qualifier value)'}, {'cui': 'C1283828', 'cui_str': 'Intentional'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",,0.172119,The mean intent to vaccinate postintervention ranged from 3.5 (95% confidence interval [CI] = 3.1-3.8) in the control group to 4.2 (95% CI = 3.9-4.6) in the all-concerns group (p = .01).,"[{'ForeName': 'Catherine A', 'Initials': 'CA', 'LastName': 'Panozzo', 'Affiliation': 'Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, Massachusetts. Electronic address: catherine_panozzo@harvardpilgrim.org.'}, {'ForeName': 'Katharine J', 'Initials': 'KJ', 'LastName': 'Head', 'Affiliation': 'Department of Communication Studies, Indiana University School of Liberal Arts, Indianapolis, Indiana.'}, {'ForeName': 'Melanie L', 'Initials': 'ML', 'LastName': 'Kornides', 'Affiliation': 'Department of Family & Community Health, University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania.'}, {'ForeName': 'Kristen A', 'Initials': 'KA', 'LastName': 'Feemster', 'Affiliation': ""Vaccine Education Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Disease Control, Philadelphia Department of Public Health, Philadelphia, Pennsylvania.""}, {'ForeName': 'Gregory D', 'Initials': 'GD', 'LastName': 'Zimet', 'Affiliation': 'Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana.'}]",The Journal of adolescent health : official publication of the Society for Adolescent Medicine,['10.1016/j.jadohealth.2020.01.024'] 454,32404782,"Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial.","BACKGROUND Vaccination against seasonal influenza is recommended for all children with a history of medical conditions placing them at increased risk of influenza-associated complications. The immunogenicity and efficacy of conventional influenza vaccines among young children are suboptimal; one strategy to enhance these is adjuvantation. We present immunogenicity and safety data for an MF59-adjuvanted quadrivalent influenza vaccine (aIIV4) in healthy children and those at a high risk of influenza-associated complications, based on the results of a recently completed phase III study. METHODS Children 6 months to 5 years of age (N = 10,644) were enrolled. The study was conducted across northern hemisphere seasons 2013-2014 and 2014-2015. Subjects received either aIIV4 or a nonadjuvanted comparator influenza vaccine. Antibody responses were assessed by hemagglutination inhibition assay against vaccine and heterologous strains. Long-term antibody persistence was assessed (ClinicalTrials.gov: NCT01964989). RESULTS aIIV4 induced significantly higher antibody titers than nonadjuvanted vaccine in high-risk subjects. aIIV4 antibody responses were of similar magnitude in high-risk and healthy subjects. Incidence of solicited local and systemic adverse events (AEs) was slightly higher in aIIV4 than nonadjuvanted vaccinees, in both the healthy and high-risk groups. Incidence of unsolicited AEs, serious AEs and AEs of special interest were similar for adjuvanted and nonadjuvanted vaccinees in the healthy and high-risk groups. CONCLUSION aIIV4 was more immunogenic than nonadjuvanted vaccine in both the healthy and high-risk study groups. The reactogenicity and safety profiles of aIIV4 and the nonadjuvanted vaccine were acceptable and similar in 6-month- to 5-year-old high-risk and healthy children.",2020,"Incidence of unsolicited AEs, serious AEs and AEs of special interest were similar for adjuvanted and nonadjuvanted vaccinees in the healthy and high-risk groups. ","['young children', 'Children 6 months to 5 years of age (N = 10,644) were enrolled', 'healthy children and those at a high risk of influenza-associated complications', 'northern hemisphere seasons 2013-2014 and 2014-2015', 'Young Children at High Risk of Influenza-associated Complications']","['MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine', 'MF59-adjuvanted quadrivalent influenza vaccine (aIIV4', 'conventional influenza vaccines', 'nonadjuvanted vaccine', 'aIIV4 or a nonadjuvanted comparator influenza vaccine']","['Antibody responses', 'immunogenicity and efficacy', 'antibody titers', 'Incidence of unsolicited AEs, serious AEs and AEs of special interest', 'Immunogenicity and Safety', 'Incidence of solicited local and systemic adverse events (AEs']","[{'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}]","[{'cui': 'C0289787', 'cui_str': 'MF59 oil emulsion'}, {'cui': 'C0439601', 'cui_str': 'Seasonal course'}, {'cui': 'C0021403', 'cui_str': 'Influenza virus vaccine'}, {'cui': 'C4318638', 'cui_str': 'Quadrivalent Influenza Vaccine'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0003261', 'cui_str': 'Antibody Production'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0474643', 'cui_str': 'Antibody titer measurement'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}]",10644.0,0.0497908,"Incidence of unsolicited AEs, serious AEs and AEs of special interest were similar for adjuvanted and nonadjuvanted vaccinees in the healthy and high-risk groups. ","[{'ForeName': 'Susanna', 'Initials': 'S', 'LastName': 'Esposito', 'Affiliation': 'From the Pediatric Clinic, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Perugia, Italy.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Fling', 'Affiliation': 'Department of Pediatrics, Health Science Center, University of North Texas, Fort Worth, TX.'}, {'ForeName': 'Kulkanya', 'Initials': 'K', 'LastName': 'Chokephaibulkit', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'de Bruijn', 'Affiliation': 'Seqirus Netherlands B.V., Amsterdam, The Netherlands.'}, {'ForeName': 'Janine', 'Initials': 'J', 'LastName': 'Oberye', 'Affiliation': 'Seqirus Netherlands B.V., Amsterdam, The Netherlands.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Zhang', 'Affiliation': 'Seqirus USA Inc., Cambridge, MA.'}, {'ForeName': 'Jeanique', 'Initials': 'J', 'LastName': 'Vossen', 'Affiliation': 'Seqirus Netherlands B.V., Amsterdam, The Netherlands.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Heijnen', 'Affiliation': 'Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Smolenov', 'Affiliation': 'Seqirus USA Inc., Cambridge, MA.'}]",The Pediatric infectious disease journal,['10.1097/INF.0000000000002727'] 455,31701308,Comparison of single minimum dose administration of dexmedetomidine and midazolam for prevention of emergence delirium in children: a randomized controlled trial.,"PURPOSE Emergence delirium (ED) is common in children after sevoflurane anesthesia and should be prevented for patient safety. A prospective, double-blind, randomized, controlled study was performed to compare the efficacy of minimal dosage of midazolam versus dexmedetomidine to prevent ED in children undergoing tonsillectomy. METHODS Seventy children aged 24 months to 12 years were allocated to receive midazolam (0.03 mg/kg) or dexmedetomidine (0.3 µg/kg) 5 min before the end of surgery. The incidence and severity of ED were assessed using a four-point scale and the pediatric anesthesia emergence delirium scale, respectively. The emergence time and postoperative pain scores were also evaluated. RESULTS The incidence of ED was 31.3% in the midazolam group and 26.5% in the dexmedetomidine group (P = 0.668). The severity of ED was similar in both groups (9.6 ± 5.8 in the midazolam group, vs. 8.1 ± 5.9 in the dexmedetomidine group, P = 0.299). The emergence time was comparable in the two groups [11.0 (8.3-13.8) min in midazolam group vs. 12.0 (10.0-13.5) min in dexmedetomidine group (P = 0.218)]. Postoperative pain score was higher in the midazolam group [0 (0-1)] than in the dexmedetomidine group [0 (0-0)] (P = 0.011). CONCLUSION Dexmedetomidine and midazolam at single minimum dosages had equal effectiveness to prevent ED in children without delaying emergence time, when administered at the end of surgery. With regards to postoperative analgesic efficacy, although dexmedetomidine showed statistically significant higher analgesic effect than midazolam, further clinical investigations are needed to validate our findings.",2020,"With regards to postoperative analgesic efficacy, although dexmedetomidine showed statistically significant higher analgesic effect than midazolam, further clinical investigations are needed to validate our findings.","['children', 'children undergoing tonsillectomy', 'Seventy children aged 24\xa0months to 12\xa0years', 'children after']","['dexmedetomidine', 'midazolam', 'Dexmedetomidine and midazolam', 'sevoflurane anesthesia', 'dexmedetomidine and midazolam']","['emergence time and postoperative pain scores', 'severity of ED', 'Postoperative pain score', 'incidence and severity of ED', 'incidence of ED', 'analgesic effect', 'emergence time', 'postoperative analgesic efficacy']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0040423', 'cui_str': 'Tonsillectomy'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}]",70.0,0.26482,"With regards to postoperative analgesic efficacy, although dexmedetomidine showed statistically significant higher analgesic effect than midazolam, further clinical investigations are needed to validate our findings.","[{'ForeName': 'Eun-Ah', 'Initials': 'EA', 'LastName': 'Cho', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul, 03181, Republic of Korea.'}, {'ForeName': 'Yun-Byeong', 'Initials': 'YB', 'LastName': 'Cha', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul, 03181, Republic of Korea.'}, {'ForeName': 'Jae-Geum', 'Initials': 'JG', 'LastName': 'Shim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul, 03181, Republic of Korea.'}, {'ForeName': 'Jin-Hee', 'Initials': 'JH', 'LastName': 'Ahn', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul, 03181, Republic of Korea.'}, {'ForeName': 'Sung Hyun', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul, 03181, Republic of Korea.'}, {'ForeName': 'Kyoung-Ho', 'Initials': 'KH', 'LastName': 'Ryu', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul, 03181, Republic of Korea. kh.ryu@skku.edu.'}]",Journal of anesthesia,['10.1007/s00540-019-02705-6'] 456,32403118,Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers.,"Glutamate neurotransmission is a prioritized target for antipsychotic drug development. Two metabotropic glutamate receptor 2/3 (mGluR2/3) agonists (pomaglumetad [POMA] and TS-134) were assessed in two Phase Ib proof of mechanism studies of comparable designs and using identical clinical assessments and pharmacoBOLD methodology. POMA was examined in a randomized controlled trial under double-blind conditions for 10-days at doses of 80 or 320 mg/d POMA versus placebo (1:1:1 ratio). The TS-134 trial was a randomized, single-blind, 6-day study of 20 or 60 mg/d TS-134 versus placebo (5:5:2 ratio). Primary outcomes were ketamine-induced changes in pharmacoBOLD in the dorsal anterior cingulate cortex (dACC) and symptoms reflected on the Brief Psychiatric Rating Scale (BPRS). Both trials were conducted contemporaneously. 95 healthy volunteers were randomized to POMA and 63 to TS-134. High-dose POMA significantly reduced ketamine-induced BPRS total symptoms within and between-groups (p < 0.01, d = -0.41; p = 0.04, d = -0.44, respectively), but neither POMA dose significantly suppressed ketamine-induced dACC pharmacoBOLD. In contrast, low-dose TS-134 led to moderate to large within and between group reductions in both BPRS positive symptoms (p = 0.02, d = -0.36; p = 0.008, d = -0.82, respectively) and dACC pharmacoBOLD (p = 0.004, d = -0.56; p = 0.079, d = -0.50, respectively) using pooled across-study placebo data. High-dose POMA exerted significant effects on clinical symptoms, but not on target engagement, suggesting a higher dose may yet be needed, while the low dose of TS-134 showed evidence of symptom reduction and target engagement. These results support further investigation of mGluR2/3 and other glutamate-targeted treatments for schizophrenia.",2020,"High-dose POMA significantly reduced ketamine-induced BPRS total symptoms within and between-groups (p < 0.01, d ","['healthy volunteers', '95 healthy volunteers']","['POMA versus placebo', 'TS-134 versus placebo', 'Two metabotropic glutamate receptor 2/3 (mGluR2/3) agonists (pomaglumetad [POMA] and TS-134', 'ketamine']","['BPRS positive symptoms', 'dACC pharmacoBOLD', 'BPRS total symptoms', 'clinical symptoms', 'ketamine-induced changes in pharmacoBOLD in the dorsal anterior cingulate cortex (dACC) and symptoms reflected on the Brief Psychiatric Rating Scale (BPRS']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C1098057', 'cui_str': 'poly(n-octyl methacrylate)'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0206529', 'cui_str': 'Metabotropic Glutamate Receptor'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}]","[{'cui': 'C0029941', 'cui_str': 'Brief psychiatric rating scale'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate Gyrus'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0558058', 'cui_str': 'Reflecting'}]",95.0,0.504117,"High-dose POMA significantly reduced ketamine-induced BPRS total symptoms within and between-groups (p < 0.01, d ","[{'ForeName': 'Joshua T', 'Initials': 'JT', 'LastName': 'Kantrowitz', 'Affiliation': 'Columbia University, New York, NY, USA.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Grinband', 'Affiliation': 'Columbia University, New York, NY, USA.'}, {'ForeName': 'Donald C', 'Initials': 'DC', 'LastName': 'Goff', 'Affiliation': 'Nathan Kline Institute, Orangeburg, NY, USA.'}, {'ForeName': 'Adrienne C', 'Initials': 'AC', 'LastName': 'Lahti', 'Affiliation': 'University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Stephen R', 'Initials': 'SR', 'LastName': 'Marder', 'Affiliation': 'UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Lawrence S', 'Initials': 'LS', 'LastName': 'Kegeles', 'Affiliation': 'Columbia University, New York, NY, USA.'}, {'ForeName': 'Ragy R', 'Initials': 'RR', 'LastName': 'Girgis', 'Affiliation': 'Columbia University, New York, NY, USA.'}, {'ForeName': 'Tarek', 'Initials': 'T', 'LastName': 'Sobeih', 'Affiliation': 'Nathan Kline Institute, Orangeburg, NY, USA.'}, {'ForeName': 'Melanie M', 'Initials': 'MM', 'LastName': 'Wall', 'Affiliation': 'Columbia University, New York, NY, USA.'}, {'ForeName': 'Tse-Hwei', 'Initials': 'TH', 'LastName': 'Choo', 'Affiliation': 'Columbia University, New York, NY, USA.'}, {'ForeName': 'Michael F', 'Initials': 'MF', 'LastName': 'Green', 'Affiliation': 'UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Yvonne S', 'Initials': 'YS', 'LastName': 'Yang', 'Affiliation': 'UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Junghee', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Horga', 'Affiliation': 'Columbia University, New York, NY, USA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Krystal', 'Affiliation': 'Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'William Z', 'Initials': 'WZ', 'LastName': 'Potter', 'Affiliation': 'National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Daniel C', 'Initials': 'DC', 'LastName': 'Javitt', 'Affiliation': 'Columbia University, New York, NY, USA.'}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Lieberman', 'Affiliation': 'Columbia University, New York, NY, USA. Jeffrey.Lieberman@nyspi.columbia.edu.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-020-0706-z'] 457,32406964,"Prospective cohort study of child mouthing of faeces and fomites in Dhaka, Bangladesh (CHoBI7 Program).","OBJECTIVE To characterise childhood mouthing and handling behaviours and to assess the association between hand-to-object and object-to-mouth contacts and diarrhoea prevalence in young children in urban Dhaka, Bangladesh. METHODS A prospective cohort study was conducted among 494 children under 5 years of age in Dhaka, Bangladesh. This study was nested within the randomised controlled trial of the Cholera Hospital-Based Intervention for 7 Days (CHoBI7) mobile health (mHealth) program. The CHoBI7 mHealth program focuses on promoting handwashing with soap and water treatment to diarrhoea patients and their household members through mobile messages and a single in person visit. Mouthing and handling of faeces and fomites among young children was measured by five-hour structured observation and caregiver reports. Diarrhoea surveillance data was collected monthly for 12 months. RESULTS Fifty five percent of caregivers reported that their child put a visibly dirty fomite (object or soil) in their mouth in the past week. Caregivers reported that 50% of children had mouthed visibly dirty objects, 26% had mouthed dirt, and 2% had mouthed faeces. Forty five percent of children were observed mouthing a visibly dirty fomite during structured observation, 40% of children were observed mouthing a visibly dirty object, 10% were observed mouthing soil, and one child (0.2%) was observed mouthing faeces. Mouthing of visibly dirty fomites was highest for children 12-18 months of age with 69% of these children having caregiver reports and 54% having observed events. Children with caregiver reports of mouthing faeces had a significantly higher odds of diarrhoea over the subsequent month (Odds Ratio: 4.54; 95% Confidence Interval: 1.06, 19.48). CONCLUSION These findings demonstrate that mouthing of contaminated fomites among young children is frequent in urban environments in Bangladesh, and that mouthing faeces is associated with a significantly higher odds of diarrhoea. Interventions are urgently needed to protect young children from faecal pathogens in their play spaces.",2020,"Children with caregiver reports of mouthing feces had significantly higher odds of diarrhea over the subsequent month (Odds Ratio: 4.54; 95% Confidence Interval: 1.06, 19.48). ","['young children in urban Dhaka', 'young children', 'Child Mouthing of Feces and Fomites in Urban Dhaka, Bangladesh (CHoBI7 Program', '494 children under 5 years of age in Dhaka, Bangladesh']",['Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) mobile health (mHealth) program'],"['diarrhea', 'visibly dirty objects', 'diarrhea prevalence', 'visibly dirty fomite (object or soil', 'Diarrhea surveillance data', 'visibly dirty fomite']","[{'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C1008855', 'cui_str': 'Fomites'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C0008354', 'cui_str': 'Cholera'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0008354', 'cui_str': 'Cholera'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0347997', 'cui_str': 'Physical object'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C1008855', 'cui_str': 'Fomites'}, {'cui': 'C0037592', 'cui_str': 'Soil'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}]",494.0,0.0478912,"Children with caregiver reports of mouthing feces had significantly higher odds of diarrhea over the subsequent month (Odds Ratio: 4.54; 95% Confidence Interval: 1.06, 19.48). ","[{'ForeName': 'Tahmina', 'Initials': 'T', 'LastName': 'Parvin', 'Affiliation': 'International Center for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Ismat', 'Initials': 'I', 'LastName': 'Minhaj Uddin', 'Affiliation': 'International Center for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Md Sazzadul', 'Initials': 'MS', 'LastName': 'Islam Bhuyian', 'Affiliation': 'International Center for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Saxton', 'Affiliation': 'Department of International Health, Johns Hopkins School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Fatema', 'Initials': 'F', 'LastName': 'Zohura', 'Affiliation': 'International Center for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Marzia', 'Initials': 'M', 'LastName': 'Sultana', 'Affiliation': 'International Center for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Fatema-Tuz', 'Initials': 'FT', 'LastName': 'Johura', 'Affiliation': 'International Center for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Shirajum', 'Initials': 'S', 'LastName': 'Monira', 'Affiliation': 'International Center for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Md Tasdik', 'Initials': 'MT', 'LastName': 'Hasan', 'Affiliation': 'International Center for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Nowshin', 'Initials': 'N', 'LastName': 'Papri', 'Affiliation': 'International Center for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Md Ahshanul', 'Initials': 'MA', 'LastName': 'Haque', 'Affiliation': 'International Center for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Shwapon K', 'Initials': 'SK', 'LastName': 'Biswas', 'Affiliation': 'International Center for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Sack', 'Affiliation': 'Department of International Health, Johns Hopkins School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Perin', 'Affiliation': 'Department of International Health, Johns Hopkins School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Munirul', 'Initials': 'M', 'LastName': 'Alam', 'Affiliation': 'International Center for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Christine Marie', 'Initials': 'CM', 'LastName': 'George', 'Affiliation': 'International Center for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}]",Tropical medicine & international health : TM & IH,['10.1111/tmi.13413'] 458,32406965,"Process evaluation for the delivery of a water, sanitation and hygiene mobile health program: findings from the randomised controlled trial of the CHoBI7 mobile health program.","OBJECTIVE The Cholera-Hospital-Based Intervention for 7-days (CHoBI7) mobile health (mHealth) program delivers mobile messages to diarrhoea patient households promoting water treatment and handwashing with soap. The randomised controlled trial (RCT) of the CHoBI7 mHealth program demonstrated this intervention was effective in significantly reducing diarrhoea and stunting amoung young children. The objective of this study was to assess the implementation of the CHoBI7 mHealth program in delivering mHealth messages during this RCT. METHODS 517 diarrhoea patient households with 1777 participants received weekly text, voice and interactive voice response (IVR) messages from the CHoBI7 mHealth program over the 12-month program period. The program process evaluation indicators were the following: the percentage of CHoBI7 mHealth messages received and fully listened to by program households (program fidelity and dose), and household members reporting receiving and sharing an mHealth message from the program in the past two weeks (program reach). RESULTS Ninety two percent of text messages were received by program households. Eighty three percent of voice and 86% of IVR messages sent were fully listened to by at least one household member. Eighty one percent of IVR quiz responses from households were answered correctly. Program households reported receiving a CHoBI7 mHealth message in the past two weeks at 79% of monthly household visits during the 12-month program. Seventy seven percent of participants reported sharing a program message with a spouse, 55% with a neighbour and 49% with a child during the program period. CONCLUSION There was high fidelity, dose and reach of mobile messages delivered for the CHoBI7 mHealth program. This study presents an approach for process evaluation that can be implemented to evaluate future mHealth programs.",2020,83% of voice and 86% of IVR messages sent were fully listened to by at least one household member.,"['young children', 'diarrhea patient households promoting water treatment and handwashing with soap', '517 diarrhea patient households received']","['CHoBI7 mHealth program', 'fully listened to by program households (program fidelity and dose), and beneficiaries reporting receiving and sharing a mHealth message from the program (program reach', 'Cholera-Hospital-Based-Intervention-for-7-days (CHoBI7) mobile health (mHealth) program', 'weekly text, voice, and interactive voice response (IVR) messages from the CHoBI7 mHealth program']",['diarrhea and stunting'],"[{'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0597684', 'cui_str': 'Water Treatment'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C0037392', 'cui_str': 'Soap'}]","[{'cui': 'C0008354', 'cui_str': 'Cholera'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0004309', 'cui_str': 'Auditory Perception'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0042939', 'cui_str': 'Voice'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0018273', 'cui_str': 'Growth disorder'}]",,0.0465095,83% of voice and 86% of IVR messages sent were fully listened to by at least one household member.,"[{'ForeName': 'Md Sazzadul', 'Initials': 'MS', 'LastName': 'Islam Bhuyian', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh(icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Saxton', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Khaled', 'Initials': 'K', 'LastName': 'Hasan', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Jahed', 'Initials': 'J', 'LastName': 'Masud', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh(icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Fatema', 'Initials': 'F', 'LastName': 'Zohura', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh(icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Shirajum', 'Initials': 'S', 'LastName': 'Monira', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh(icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Shwapon', 'Initials': 'S', 'LastName': 'Kumar Biswas', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh(icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Tasdik Hasan', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh(icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Tahmina', 'Initials': 'T', 'LastName': 'Parvin', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh(icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Ismat', 'Initials': 'I', 'LastName': 'Minhaj', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh(icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Kazi', 'Initials': 'K', 'LastName': 'Md Zillur Rahman', 'Affiliation': 'University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Nowshin', 'Initials': 'N', 'LastName': 'Papri', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh(icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Mahamud-Ur', 'Initials': 'MU', 'LastName': 'Rashid', 'Affiliation': 'University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'Lubaba', 'Initials': 'L', 'LastName': 'Sharin', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh(icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Alana', 'Initials': 'A', 'LastName': 'Teman', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Elizabeth D', 'Initials': 'ED', 'LastName': 'Thomas', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Alland', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Labrique', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Sack', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Perin', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Munirul', 'Initials': 'M', 'LastName': 'Alam', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh(icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Christine Marie', 'Initials': 'CM', 'LastName': 'George', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}]",Tropical medicine & international health : TM & IH,['10.1111/tmi.13414'] 459,32406989,Diarrhoeal disease knowledge among diarrhoea patient housholds: findings from the randomised controlled trial of the Cholera-Hospital-Based-Intervention-for-7-days (CHoBI7) mobile health program.,"OBJECTIVE The objective of this study was to evaluate the impact of the Cholera-Hospital-Based-Intervention-for-7-days (CHoBI7) handwashing with soap and water treatment mobile health (mHealth) program on diarrhoeal disease knowledge among diarrhoea patients and their household members in urban Dhaka, Bangladesh. METHODS A cluster-randomised controlled trial of the CHoBI7 mHealth program was conducted among diarrhoea patient households in Dhaka, Bangladesh. Patients were randomised to three arms: standard recommendation on oral rehydration solution use; health facility delivery of CHoBI7 plus mHealth (weekly voice and text messages) (no home visits); and health facility delivery of CHoBI7 plus two home visits and mHealth. An open-ended questionnaire was administered to 1468 participants 12 years of age or older on diarrhoeal disease transmission and prevention. These items were combined to form a diarrhoeal disease knowledge score measured at baseline and at a 1 week, 6 month and 12 month follow-up. RESULTS At baseline, when participants were asked to report three ways diarrhoeal diseases were spread 37% (546/1468) of participants reported by water, 13% (187/1468) by lack of handwashing and 4% (53/1468) by food not being covered properly. At baseline when asked to name three ways diarrhoeal diseases could be prevented, 35% (515/1468) of participants reported safe water, and 16% (228/1468) reported handwashing with soap. At the 12-month follow-up, the overall diarrhoeal disease knowledge score was significantly higher in the mHealth with no home visits arm (score coefficient: 0.69, 95% Confidence Interval: 0.36, 1.01, P < 0.0001) and the mHealth with two home visits arm (score coefficient: 1.18, 95% CI: 0.87, 1.49, P < 0.0001) compared with the standard recommendation arm. CONCLUSION The CHoBI7 mHealth program significantly increased knowledge of diarrhoeal disease transmission and prevention among diarrhoea patients and their household members 12 months after in-person visits for program delivery were conducted.",2020,"At the 12 month follow-up, the overall diarrhea knowledge score was significantly higher in mHealth with no home visits arm (score coefficient: 0.69, 95% Confidence Interval: 0.36, 1.01, p<0.0001) and the mHealth with two home visits arm (score coefficient:","['diarrhea patients and their household members in urban Dhaka', 'diarrhea patient households in Dhaka, Bangladesh', 'diarrhea patient households', 'Household Members of Diarrhea Patients', '1468 participants 12 years of age or older on diarrheal disease transmission and prevention']","['CHoBI7 mHealth program', 'Cholera-Hospital-Based-Intervention-for-7 Days (CHoBI7) Mobile Health Program', 'Cholera-Hospital-Based-Intervention-for-7-days (CHoBI7) handwashing with soap and water treatment mobile health (mHealth) program', 'standard recommendation on oral rehydration solution use; health facility delivery of CHoBI7 plus mHealth (no home visits); and health facility delivery of CHoBI7 plus two home visits and mHealth']","['diarrheal disease knowledge', 'overall diarrhea knowledge score', 'diarrheal disease knowledge score']","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1290807', 'cui_str': 'Diarrheal disorder'}, {'cui': 'C0040722', 'cui_str': 'transmission'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]","[{'cui': 'C0008354', 'cui_str': 'Cholera'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C0037392', 'cui_str': 'Soap'}, {'cui': 'C0597684', 'cui_str': 'Water Treatment'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0078516', 'cui_str': 'World Health Organization oral rehydration solution'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}]","[{'cui': 'C1290807', 'cui_str': 'Diarrheal disorder'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.131471,"At the 12 month follow-up, the overall diarrhea knowledge score was significantly higher in mHealth with no home visits arm (score coefficient: 0.69, 95% Confidence Interval: 0.36, 1.01, p<0.0001) and the mHealth with two home visits arm (score coefficient:","[{'ForeName': 'Jahed', 'Initials': 'J', 'LastName': 'Masud', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Md Sazzadul', 'Initials': 'MS', 'LastName': 'Islam Bhuyian', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Shwapon', 'Initials': 'S', 'LastName': 'Kumar Biswas', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Fatema', 'Initials': 'F', 'LastName': 'Zohura', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Perin', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Nowshin', 'Initials': 'N', 'LastName': 'Papri', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Fahmida', 'Initials': 'F', 'LastName': 'Dil Farzana', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Tahmina', 'Initials': 'T', 'LastName': 'Parvin', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Shirajum', 'Initials': 'S', 'LastName': 'Monira', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Munirul', 'Initials': 'M', 'LastName': 'Alam', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Christine Marie', 'Initials': 'CM', 'LastName': 'George', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}]",Tropical medicine & international health : TM & IH,['10.1111/tmi.13415'] 460,32164494,Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial.,"Review of: Rosenstock J, Perkovic V, Johansen, OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA . 2019;321:69-79. McGuire DK, Alexander JH, Johansen OE, et al. Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation . 2019;139:351-361. These two papers describe the findings from the CARMELINA trial (Cardiovascular and Renal Microvascular Outcome Study with Linagliptin): the first paper reported results for the primary cardiovascular composite outcome (cardiovascular [CV] death, nonfatal myocardial infarction [MI], or nonfatal stroke; 3-point major adverse cardiovascular event [3P-MACE]) and the key secondary renal composite outcome (renal death, end-stage kidney disease, or sustained ≥40% decrease in eGFR from baseline); the second paper reported secondary analyses of heart failure (HF) and related outcomes. The CARMELINA trial was a randomized, placebo-controlled, multicenter non-inferiority trial of adults with type 2 diabetes mellitus (T2DM) and elevated CV and renal risk. After a median 2.2-year follow-up of 6979 participants, patients allocated to linagliptin demonstrated no increase in the risk of 3P-MACE versus placebo: hazard ratio (HR) 1.02 [95% confidence interval (CI) 0.89-1.17]; P < 0.001 for non-inferiority. There was also no increase in the risk of hospitalization for HF for linagliptin versus placebo (HR 0.90 [0.74-1.08]). There was no increased risk of progression to end-stage kidney disease or death due to kidney disease (HR 0.87 [0.69-1.10]). Additionally, progression of albuminuria occurred less frequently in patients who received linagliptin versus placebo (HR 0.86 [0.78-0.95]). Overall, no new safety findings were identified for linagliptin, and no increased risk of hypoglycemia was observed for linagliptin versus placebo. Together, these findings from the CARMELINA trial reaffirm treatment guidelines for choosing additional therapies for patients with T2DM at elevated CV and/or renal risk, and provide new information on the role of linagliptin in the management of T2DM.",2020,"Overall, no new safety findings were identified for linagliptin, and no increased risk of hypoglycemia was observed for linagliptin versus placebo.","['patients with T2DM at elevated CV and/or renal risk', 'patients with type 2 diabetes and cardiovascular and/or renal disease', 'individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA', 'adults with type 2 diabetes and high cardiovascular and renal risk', 'adults with type 2 diabetes mellitus (T2DM) and elevated CV and renal risk']","['linagliptin', 'linagliptin vs placebo', 'Linagliptin', 'placebo']","['risk of progression to end-stage kidney disease or death due to kidney disease', 'heart failure', 'progression of albuminuria', 'major cardiovascular events', 'risk of 3P-MACE versus placebo: hazard ratio (HR', 'heart failure (HF) and related outcomes', 'risk of hospitalization for HF', 'primary cardiovascular composite outcome (cardiovascular [CV] death, nonfatal myocardial infarction [MI], or nonfatal stroke; 3-point major adverse cardiovascular event [3P-MACE]) and the key secondary renal composite outcome (renal death, end-stage kidney disease', 'risk of hypoglycemia']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0022658', 'cui_str': 'Kidney Diseases'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C2746078', 'cui_str': 'Linagliptin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0022661', 'cui_str': 'End-Stage Kidney Disease'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0022658', 'cui_str': 'Kidney Diseases'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0001925', 'cui_str': 'Albuminuria'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0349381', 'cui_str': 'Mace (substance)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}]",6979.0,0.215336,"Overall, no new safety findings were identified for linagliptin, and no increased risk of hypoglycemia was observed for linagliptin versus placebo.","[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Guthrie', 'Affiliation': 'The Department of Emergency Medicine, The Ohio State University , Dublin, OH, USA.'}]",Postgraduate medicine,['10.1080/00325481.2020.1742524'] 461,29741487,Regular drug-eluting stents versus dedicated bifurcation drug-eluting BiOSS stents for coronary bifurcation treatment: four-year results of the randomised POLBOS I and POLBOS II clinical trials.,,2020,"At 48-month there were no statistical differences in terms of MACE (rDES vs BiOSS: 18.8%vs19.8%,p=0.64), TLR (12.1%vs15.3%,p=0.34), MI (4.5%vs2.1%,p=0.72) or cardiac death (2.2%vs1.8%,p=0.81) between rDES and BiOSS groups.","['445 patients with 222 patients in BiOSS group and 223 patients in rDES group were analyzed', 'patients with stable CAD or NSTE-ACS']","['MACE', 'rDES', 'Regular drug-eluting stents versus dedicated bifurcation drug-eluting BiOSS® stents', 'regular DES (rDES']","['MI (4.5%vs2.1%,p=0.72) or cardiac death']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}]","[{'cui': 'C0349381', 'cui_str': 'Mace (substance)'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C0184906', 'cui_str': 'Bifurcation (procedure)'}]","[{'cui': 'C0376297', 'cui_str': 'Cardiac Death'}]",445.0,0.0244033,"At 48-month there were no statistical differences in terms of MACE (rDES vs BiOSS: 18.8%vs19.8%,p=0.64), TLR (12.1%vs15.3%,p=0.34), MI (4.5%vs2.1%,p=0.72) or cardiac death (2.2%vs1.8%,p=0.81) between rDES and BiOSS groups.","[{'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Gil', 'Affiliation': 'Department of Invasive Cardiology, Centre of Postgraduate Medical Education, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland.'}, {'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Bil', 'Affiliation': ''}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Kern', 'Affiliation': ''}, {'ForeName': 'Luis A', 'Initials': 'LA', 'LastName': 'Ingio Garcia', 'Affiliation': ''}, {'ForeName': 'Radoslaw', 'Initials': 'R', 'LastName': 'Formuszewicz', 'Affiliation': ''}, {'ForeName': 'Slawomir', 'Initials': 'S', 'LastName': 'Dobrzycki', 'Affiliation': ''}, {'ForeName': 'Dobrin', 'Initials': 'D', 'LastName': 'Vassilev', 'Affiliation': ''}, {'ForeName': 'Agnieszka', 'Initials': 'A', 'LastName': 'Segiet', 'Affiliation': ''}]",EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,['10.4244/EIJ-D-18-00172'] 462,31570179,Effects of L-DOPA on quadripulse magnetic stimulation-induced long-term potentiation in older adults.,"Reduced cortical plasticity has been previously reported in older adult as compared with young adults. However, the effects of dopamine on this plasticity reduction remain unknown. Here, we assessed the effects of high-dose (200 mg) and medium-dose (100 mg) L-3,4-dihydroxyphenylalanine (L-DOPA) intake on the long-term potentiation (LTP)-like effect induced by quadripulse magnetic stimulation (QPS) in older adults (aged ∼65 years). The subjects were 32 (200 mg) and 20 (100 mg) healthy older adult volunteers. This study was designed as a double-blind, crossover and placebo-controlled trial on one dose of L-dopa. Two hours after taking L-DOPA or placebo-drug, QPS was applied over the motor cortex. Motor evoked potentials were recorded to evaluate the motor cortical excitability changes. We found that both doses of L-DOPA enhanced LTP after QPS in older adults as one group. We classified subjects into QPS responders and QPS nonresponders. Both L-DOPA doses produced significant LTP enhancement in QPS nonresponders, whereas either of doses did not produce significant LTP enhancement in QPS responders. Collectively, our findings suggest that the neural plasticity reductions observed in older adults could be partly improved by dopamine.",2019,"L-3,4-dihydroxyphenylalanine (L-DOPA) intake on the long-term potentiation (LTP)-like effect induced by quadripulse magnetic stimulation (QPS) in older adults (aged ∼65 years).","['subjects were 32 (200\xa0mg) and 20 (100\xa0mg) healthy older adult volunteers', 'older adults', 'older adults (aged ∼65\xa0years']","['quadripulse magnetic stimulation (QPS', 'L-DOPA', 'L-3,4-dihydroxyphenylalanine (L-DOPA', 'placebo', 'L-DOPA enhanced LTP', 'placebo-drug, QPS', 'dopamine']","['motor cortical excitability changes', 'cortical plasticity', 'LTP enhancement']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0024488', 'cui_str': 'Magnetics'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0013030', 'cui_str': 'Dopamine'}]","[{'cui': 'C4277734', 'cui_str': 'Cortical Excitability'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0678558', 'cui_str': 'Plasticity'}, {'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}]",,0.17312,"L-3,4-dihydroxyphenylalanine (L-DOPA) intake on the long-term potentiation (LTP)-like effect induced by quadripulse magnetic stimulation (QPS) in older adults (aged ∼65 years).","[{'ForeName': 'Nobuyuki', 'Initials': 'N', 'LastName': 'Tanaka', 'Affiliation': 'Department of Neurology, University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Ryosuke', 'Initials': 'R', 'LastName': 'Tsutsumi', 'Affiliation': 'Department of Neurology, University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Yuichiro', 'Initials': 'Y', 'LastName': 'Shirota', 'Affiliation': 'Department of Neurology, University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Shimizu', 'Affiliation': 'Department of Neurology, University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Shinya', 'Initials': 'S', 'LastName': 'Ohminami', 'Affiliation': 'Department of Neurology, University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Yasuo', 'Initials': 'Y', 'LastName': 'Terao', 'Affiliation': 'Department of Neurology, University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Yoshikazu', 'Initials': 'Y', 'LastName': 'Ugawa', 'Affiliation': 'Department of Neurology, University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Shoji', 'Initials': 'S', 'LastName': 'Tsuji', 'Affiliation': 'Department of Neurology, University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Ritsuko', 'Initials': 'R', 'LastName': 'Hanajima', 'Affiliation': 'Department of Neurology, University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan. Electronic address: hanajima-tky@umin.ac.jp.'}]",Neurobiology of aging,['10.1016/j.neurobiolaging.2019.08.005'] 463,31802233,A single paravertebral injection via a needle vs. a catheter for the spreading to multiple intercostal levels: a randomized controlled trial.,"PURPOSE Thoracic paravertebral block (TPVB) provides a unilateral nerve block at multiple intercostal levels allowing injection of a local anesthetic into paravertebral space (PVS) via a needle or catheter. However, the most effective injection method remains unclear. This study compared the real-time spread of ropivacaine between two paravertebral injection methods using thoracoscopy. METHODS Thirty-four patients scheduled for thoracoscopic surgery were randomly allocated into the Needle or Catheter groups, and performed transverse in-plane ultrasound-guided TPVB. The Needle group received 20 ml of 0.5% ropivacaine via a needle placed into the lateral edge of PVS; the Catheter group received the same dose of ropivacaine via a catheter inserted 5 cm into PVS. The primary outcome was the spreading pattern of ropivacaine in each group. The secondary outcome was intraoperative vasopressor requirement after paravertebral injection. RESULTS In the Needle group, all cases showed ropivacaine spread to multiple intercostal levels, mainly across the ribs. Contrastingly, the Catheter group showed variable spreading patterns; multiple intercostal levels (n = 10) [across the ribs (n = 4), anterolateral aspect of the vertebral bodies (n = 6)] or unobservable spreading (no change; n = 7) (P = 0.007). Vasopressors were required in two and ten cases in the Needle and Catheter groups, respectively (P = 0.010). CONCLUSION Paravertebral injection via a needle typically resulted in spreading to multiple intercostal levels, especially across the ribs on the peripheral side of injection site, whereas injection via a catheter resulted in variable spreading patterns. Therefore, injections via needles are more stable.",2020,"Vasopressors were required in two and ten cases in the Needle and Catheter groups, respectively (P = 0.010). ",['Thirty-four patients scheduled for thoracoscopic surgery'],"['ropivacaine', 'Thoracic paravertebral block (TPVB', '20\xa0ml of 0.5% ropivacaine', 'ropivacaine via a catheter inserted 5\xa0cm into PVS', 'Needle or Catheter groups, and performed transverse in-plane ultrasound-guided TPVB']","['unobservable spreading', 'spreading pattern of ropivacaine', 'anterolateral aspect of the vertebral bodies', 'intraoperative vasopressor requirement after paravertebral injection', 'variable spreading patterns; multiple intercostal levels']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}, {'cui': 'C0751551', 'cui_str': 'Surgical Procedures, Thoracoscopic'}]","[{'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0442150', 'cui_str': 'Paravertebral (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C1881217', 'cui_str': 'Insert - unit of product usage'}, {'cui': 'C0398296', 'cui_str': 'Cannulation of vascular fistula, graft or prosthetic device (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0446380', 'cui_str': 'Transverse (qualifier value)'}, {'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}]","[{'cui': 'C0332261', 'cui_str': 'Spread (attribute)'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0332194', 'cui_str': 'Anterolateral (qualifier value)'}, {'cui': 'C0223084', 'cui_str': 'Structure of body of vertebra'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0442150', 'cui_str': 'Paravertebral (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",34.0,0.036128,"Vasopressors were required in two and ten cases in the Needle and Catheter groups, respectively (P = 0.010). ","[{'ForeName': 'Tasuku', 'Initials': 'T', 'LastName': 'Fujii', 'Affiliation': 'Department of Anesthesiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8560, Japan.'}, {'ForeName': 'Yasuyuki', 'Initials': 'Y', 'LastName': 'Shibata', 'Affiliation': 'Department of Surgical Center, Nagoya University Hospital, Nagoya, Japan.'}, {'ForeName': 'Yasutaka', 'Initials': 'Y', 'LastName': 'Ban', 'Affiliation': 'Department of Anesthesiology, Tosei General Hospital, Seto, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Shitaokoshi', 'Affiliation': 'Department of Anesthesiology, Tosei General Hospital, Seto, Japan.'}, {'ForeName': 'Kunihiko', 'Initials': 'K', 'LastName': 'Takahashi', 'Affiliation': 'Department of Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan.'}, {'ForeName': 'Shigeyuki', 'Initials': 'S', 'LastName': 'Matsui', 'Affiliation': 'Department of Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan.'}, {'ForeName': 'Kimitoshi', 'Initials': 'K', 'LastName': 'Nishiwaki', 'Affiliation': 'Department of Anesthesiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8560, Japan. nishi@med.nagoya-u.ac.jp.'}]",Journal of anesthesia,['10.1007/s00540-019-02713-6'] 464,32178648,Effect of a pedometer-based walking intervention on body composition in patients with ESRD: a randomized controlled trial.,"BACKGROUND A randomized trial of a pedometer-based intervention with weekly activity goals led to a modest increase in step count among dialysis patients. In a secondary analysis, we investigated the effect of this intervention on body composition. METHODS Sixty dialysis patients were randomized to standard care or a 6-month program consisting of 3 months of pedometers and weekly step count targets and 3 months of post-intervention follow-up. We obtained bioelectrical impedance spectroscopy (BIS) data on 54 of these patients (28 control, 26 intervention) and used linear mixed-modeling (adjusted for sex and dialysis modality) to estimate differences in change in total-body muscle mass (TBMM) adjusted for height 2 , fat mass (kg), and body mass index (BMI) (kg/m 2 ) between control and intervention groups. RESULTS The median age of participants was 57.5 years (53-66), and 76% were men. At baseline, there was no significant difference between groups in age, BMI, race, or body composition, but there were more men in the intervention group. After 3 months, patients in the intervention group increased their average daily steps by 2414 (95% CI 1047, 3782) more than controls (p < 0.001), but there were no significant differences in body composition. However, at 6 months, participants in the intervention had a significantly greater increase from baseline in TBMM of 0.7 kg/m 2 (95% CI 0.3, 1.13), decrease in fat mass (- 4.3 kg [95% CI -7.1, - 1.5]) and decrease in BMI (- 1.0 kg/m 2 [95% CI -1.8, - 0.2]) relative to controls. In post-hoc analysis, each increase of 1000 steps from 0 to 3 months was associated with a 0.3 kg decrease in fat mass (95% CI 0.05, 0.5) from 0 to 6 months, but there was no dose-response relationship with TBMM/ht 2 or BMI. CONCLUSION A pedometer-based intervention resulted in greater decreases in fat mass with relative preservation of muscle mass, leading to a greater decrease in BMI over time compared with patients not in the intervention. These differences were driven as much by worsening in the control group as by improvement in the intervention group. Step counts had a dose-response relationship with decrease in fat mass. TRIAL REGISTRATION ClinicalTrials.gov (NCT02623348). 02 December 2015.",2020,"At baseline, there was no significant difference between groups in age, BMI, race, or body composition, but there were more men in the intervention group.","['patients with ESRD', 'dialysis patients', 'The median age of participants was 57.5\u2009years (53-66), and 76% were men', '54 of these patients (28 control, 26 intervention) and used', 'Sixty dialysis patients']","['linear mixed-modeling (adjusted for sex and dialysis modality', 'pedometer-based walking intervention']","['TBMM', 'fat mass', 'average daily steps', 'BMI over time', 'total-body muscle mass (TBMM) adjusted for height 2 , fat mass (kg), and body mass index (BMI', 'body composition', 'BMI', 'age, BMI, race, or body composition']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0022661', 'cui_str': 'End-Stage Kidney Disease'}, {'cui': 'C4551529', 'cui_str': 'Renal Dialysis'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C1720722', 'cui_str': 'Mix'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C4551529', 'cui_str': 'Renal Dialysis'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]","[{'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C1261552', 'cui_str': 'Step'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle (finding)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3853635', 'cui_str': 'Race (observable entity)'}]",,0.155978,"At baseline, there was no significant difference between groups in age, BMI, race, or body composition, but there were more men in the intervention group.","[{'ForeName': 'Anoop', 'Initials': 'A', 'LastName': 'Sheshadri', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of California, San Francisco, USA. Anoop.Sheshadri@ucsf.edu.'}, {'ForeName': 'Piyawan', 'Initials': 'P', 'LastName': 'Kittiskulnam', 'Affiliation': 'Division of Internal Medicine-Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Jennifer C', 'Initials': 'JC', 'LastName': 'Lai', 'Affiliation': 'Division of Gastroenterology/Hepatology, Department of Medicine, University of California, San Francisco, USA.'}, {'ForeName': 'Kirsten L', 'Initials': 'KL', 'LastName': 'Johansen', 'Affiliation': 'Division of Nephrology, Hennepin County Medical Center, Minneapolis, MN, USA.'}]",BMC nephrology,['10.1186/s12882-020-01753-5'] 465,32164703,Children and parents' perspectives on the acceptability of three management strategies for dental caries in primary teeth within the 'Filling Children's Teeth: Indicated or Not' (FiCTION) randomised controlled trial - a qualitative study.,"BACKGROUND The Filling Children's Teeth: Indicated Or Not? (FiCTION) randomised controlled trial (RCT) aimed to explore the clinical- and cost-effectiveness of managing dental caries in children's primary teeth. The trial compared three management strategies: conventional caries management with best practice prevention (C + P), biological management with best practice prevention (B + P) and best practice prevention alone (PA)-based approaches. Recently, the concept of treatment acceptability has gained attention and attempts have been made to provide a conceptual definition, however this has mainly focused on adults. Recognising the importance of evaluating the acceptability of interventions in addition to their effectiveness, particularly for multi-component complex interventions, the trial design included a qualitative component. The aim of this component was to explore the acceptability of the three strategies from the perspectives of the child participants and their parents. METHODS Qualitative exploration, based on the concept of acceptability. Participants were children already taking part in the FiCTION trial and their parents. Children were identified through purposive maximum variation sampling. The sample included children from the three management strategy arms who had been treated and followed up; median (IQR) follow-up was at 33.8 (23.8, 36.7) months. Semi-structured interviews with thirteen child-parent dyads. Interviews were transcribed verbatim and analysed using a framework approach. RESULTS Data saturation was reached after thirteen interviews. Each child-parent dyad took part in one interview together. The participants were eight girls and five boys aged 5-11 years and their parents. The children's distribution across the trial arms was: C + P n = 4; B + P n = 5; PA n = 4. Three key factors influenced the acceptability of caries management in primary teeth to children and parents: i) experiences of specific procedures within management strategies; ii) experiences of anticipatory dental anxiety and; iii) perceptions of effectiveness (particularly whether pain was reduced). These factors were underpinned by a fourth key factor: the notion of trust in the dental professionals - this was pervasive across all arms. CONCLUSIONS Overall children and parents found each of the three strategies for the management of dental caries in primary teeth acceptable, with trust in the dental professional playing an important role.",2020,"CONCLUSIONS Overall children and parents found each of the three strategies for the management of dental caries in primary teeth acceptable, with trust in the dental professional playing an important role.","['child participants and their parents', 'sample included children from the three management strategy arms who had been treated and followed up; median (IQR) follow-up was at 33.8 (23.8, 36.7) months', 'Participants were children already taking part in the FiCTION trial and their parents', ""dental caries in primary teeth within the 'Filling Children's Teeth"", ""children's primary teeth"", ""Filling Children's Teeth"", 'participants were eight girls and five boys aged 5-11\u2009years and their parents']","['conventional caries management with best practice prevention (C\u2009+\u2009P), biological management with best practice prevention (B\u2009+\u2009P) and best practice prevention alone (PA)-based approaches']",['acceptability of caries management'],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0011334', 'cui_str': 'Dental Decay'}, {'cui': 'C3266841', 'cui_str': 'Baby Teeth'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}, {'cui': 'C3179154', 'cui_str': 'Best Practices'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C4553887', 'cui_str': 'Biologic Drugs'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}]",8.0,0.0496609,"CONCLUSIONS Overall children and parents found each of the three strategies for the management of dental caries in primary teeth acceptable, with trust in the dental professional playing an important role.","[{'ForeName': 'Sarab', 'Initials': 'S', 'LastName': 'El-Yousfi', 'Affiliation': 'School of Clinical Dentistry, Claremont Crescent, Sheffield, S10 2TA, UK.'}, {'ForeName': 'Nicola P T', 'Initials': 'NPT', 'LastName': 'Innes', 'Affiliation': 'School of Dentistry, University of Dundee, Park Place, Dundee, DD1 4HN, UK. n.p.Innes@dundee.ac.uk.'}, {'ForeName': 'Richard D', 'Initials': 'RD', 'LastName': 'Holmes', 'Affiliation': 'School of Dental Sciences, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Freeman', 'Affiliation': 'School of Dentistry, University of Dundee, Park Place, Dundee, DD1 4HN, UK.'}, {'ForeName': 'Kathryn B', 'Initials': 'KB', 'LastName': 'Cunningham', 'Affiliation': 'School of Medicine, University of St Andrews, North Haugh, St Andrews, KY16 9TF, UK.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'McColl', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Baddiley-Clark Building, Richardson Road, Newcastle upon Tyne, NE2 4AX, UK.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Maguire', 'Affiliation': 'School of Dental Sciences, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.'}, {'ForeName': 'Gail V A', 'Initials': 'GVA', 'LastName': 'Douglas', 'Affiliation': 'University of Leeds School of Dentistry, Clarendon Way, Leeds, LS2 9LU, UK.'}, {'ForeName': 'Janet E', 'Initials': 'JE', 'LastName': 'Clarkson', 'Affiliation': 'Dental Health Services Research Unit, School of Dentistry, Park Place, Dundee, DD1 4HN, UK.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Marshman', 'Affiliation': 'School of Clinical Dentistry, Claremont Crescent, Sheffield, S10 2TA, UK.'}]",BMC oral health,['10.1186/s12903-020-1060-6'] 466,32179001,Reducing the Burden of Complex Medication Regimens: SImplification of Medications Prescribed to Long-tErm care Residents (SIMPLER) Cluster Randomized Controlled Trial.,"OBJECTIVE To assess the application of a structured process to consolidate the number of medication administration times for residents of aged care facilities. DESIGN A nonblinded, matched-pair, cluster randomized controlled trial. SETTING AND PARTICIPANTS Permanent residents who were English-speaking and taking at least 1 regular medication, recruited from 8 South Australian residential aged care facilities (RACFs). METHODS The intervention involved a clinical pharmacist applying a validated 5-step tool to identify opportunities to reduce medication complexity (eg, by administering medications at the same time or through use of longer-acting or combination formulations). Residents in the comparison group received routine care. The primary outcome at 4-month follow-up was the number of administration times per day for medications charted regularly. Resident satisfaction and quality of life were secondary outcomes. Harms included falls, medication incidents, hospitalizations, and mortality. The association between the intervention and primary outcome was estimated using linear mixed models. RESULTS Overall, 99 residents participated in the intervention arm and 143 in the comparison arm. At baseline, the mean resident age was 86 years, 74% were female, and medications were taken an average of 4 times daily. Medication simplification was possible for 62 (65%) residents in the intervention arm, with 57 (62%) of 92 simplification recommendations implemented at follow-up. The mean number of administration times at follow-up was reduced in the intervention arm in comparison to usual care (-0.36, 95% confidence interval -0.63 to -0.09, P = .01). No significant changes in secondary outcomes or harms were observed. CONCLUSIONS AND IMPLICATIONS One-off application of a structured tool to reduce regimen complexity is a low-risk intervention to reduce the burden of medication administration in RACFs and may enable staff to shift time to other resident care activities.",2020,"The mean number of administration times at follow-up was reduced in the intervention arm in comparison to usual care (-0.36, 95% confidence interval -0.63 to -0.09, P = .01).","['Permanent residents who were English-speaking and taking at least 1 regular medication', 'residents of aged care facilities', 'recruited from 8 South Australian residential aged care facilities (RACFs', '99 residents participated in the intervention arm and 143 in the comparison arm']",['routine care'],"['Resident satisfaction and quality of life', 'number of administration times per day for medications charted regularly', 'falls, medication incidents, hospitalizations, and mortality', 'mean number of administration times']","[{'cui': 'C0205355', 'cui_str': 'Permanent (qualifier value)'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C4517573', 'cui_str': 'One hundred and forty-three'}]","[{'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}]","[{'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0034380'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C0684240', 'cui_str': 'Chart'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",,0.0978887,"The mean number of administration times at follow-up was reduced in the intervention arm in comparison to usual care (-0.36, 95% confidence interval -0.63 to -0.09, P = .01).","[{'ForeName': 'Janet K', 'Initials': 'JK', 'LastName': 'Sluggett', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia. Electronic address: janet.sluggett@monash.edu.'}, {'ForeName': 'Esa Y H', 'Initials': 'EYH', 'LastName': 'Chen', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia.'}, {'ForeName': 'Jenni', 'Initials': 'J', 'LastName': 'Ilomäki', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Corlis', 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia; Helping Hand Aged Care, North Adelaide, South Australia, Australia.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Van Emden', 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia; Helping Hand Aged Care, North Adelaide, South Australia, Australia.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Hogan', 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia; Helping Hand Aged Care, North Adelaide, South Australia, Australia.'}, {'ForeName': 'Tessa', 'Initials': 'T', 'LastName': 'Caporale', 'Affiliation': 'Helping Hand Aged Care, North Adelaide, South Australia, Australia.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Keen', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.'}, {'ForeName': 'Ria', 'Initials': 'R', 'LastName': 'Hopkins', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.'}, {'ForeName': 'Choon Ean', 'Initials': 'CE', 'LastName': 'Ooi', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia.'}, {'ForeName': 'Sarah N', 'Initials': 'SN', 'LastName': 'Hilmer', 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia; Kolling Institute of Medical Research, Royal North Shore Hospital, Northern Clinical School, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia.'}, {'ForeName': 'Georgina A', 'Initials': 'GA', 'LastName': 'Hughes', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Luu', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.'}, {'ForeName': 'Kim-Huong', 'Initials': 'KH', 'LastName': 'Nguyen', 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia; Centre for Health Services Research, The University of Queensland, Woolloogabba, Queensland, Australia.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Comans', 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia; Centre for Health Services Research, The University of Queensland, Woolloogabba, Queensland, Australia.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Edwards', 'Affiliation': 'Drug & Therapeutics Information Service, GP Plus Marion, South Australia, Australia.'}, {'ForeName': 'Lyntara', 'Initials': 'L', 'LastName': 'Quirke', 'Affiliation': 'Consumer Representative, Dementia Australia, Scullin, Australian Capital Territory, Australia.'}, {'ForeName': 'Allan', 'Initials': 'A', 'LastName': 'Patching', 'Affiliation': 'Helping Hand Consumer and Carer Reference Group, Helping Hand Aged Care, North Adelaide, South Australia, Australia.'}, {'ForeName': 'J Simon', 'Initials': 'JS', 'LastName': 'Bell', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}]",Journal of the American Medical Directors Association,['10.1016/j.jamda.2020.02.003'] 467,30338845,The effect of chest compression frequency on the quality of resuscitation by lifeguards. A prospective randomized crossover multicenter simulation trial.,"BACKGROUND The ability to perform high-quality cardiopulmonary resuscitation is one of the basic skills for lifeguards. The aim of the study was to assess the influence of chest compression frequency on the quality of the parameters of chest compressions performed by lifeguards. METHODS This prospective observational, randomized, crossover simulation study was performed with 40 lifeguards working in Warsaw, Wroclaw, and Poznan, Poland. The subjects then participated in a target study, in which they were asked to perform 2-min cycles of metronome-guided chest compressions at different rates: 80, 90, 100, 110, 120, 130, 140, and 150 compressions per minute (CPM). RESULTS The study involved 40 lifeguards. Optimal chest compression score calculated by manikin software was achieved for 110-120 CPM. Chest compression depth achieved 53 (interquartile range [IQR] 52-54) mm, 56 (IQR 54-57) mm, 52.5 (IQR 50-54) mm, 53 (IQR 52-53) mm, 50 (IQR 49-51) mm, 47 (IQR 44-51) mm, 41 (IQR 40-42) mm, 38 (IQR 38-43) mm for 80, 90, 100, 110, 120, 130, 140 and 150 CPM, respectively. The percentage of chest compressions with the correct depth was lower for rates exceeding 120 CPM. CONCLUSIONS The rate of 100-120 CPM, as recommended by international guidelines, is the optimal chest compression rate for cardiopulmonary resuscitation performed by lifeguards. A rate above 120 CPM was associated with a dramatic decrease in chest compression depth and overall chest compression quality. The role of full chest recoil should be emphasized in basic life support training.",2019,"The percentage of chest compressions with the correct depth was lower for rates exceeding 120 CPM. ","['40 lifeguards working in Warsaw, Wroclaw, and Poznan, Poland']",[],"['percentage of chest compressions', 'chest compression depth and overall chest compression quality', 'Chest compression depth']","[{'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0032356', 'cui_str': 'Republic of Poland'}]",[],"[{'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}]",40.0,0.0397757,"The percentage of chest compressions with the correct depth was lower for rates exceeding 120 CPM. ","[{'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Smereka', 'Affiliation': 'Department of Emergency Medical Service, Wroclaw Medical University, Wroclaw, Poland., Wroclaw, Poland.'}, {'ForeName': 'Łukasz', 'Initials': 'Ł', 'LastName': 'Iskrzycki', 'Affiliation': 'Department of Emergency Medical Service, Wroclaw Medical University, Wroclaw, Poland., Wroclaw, Poland.'}, {'ForeName': 'Elżbieta', 'Initials': 'E', 'LastName': 'Makomaska-Szaroszyk', 'Affiliation': 'Lazarski University, Warsaw, Poland.'}, {'ForeName': 'Karol', 'Initials': 'K', 'LastName': 'Bielski', 'Affiliation': 'Lazarski University, Warsaw, Poland.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Frass', 'Affiliation': 'Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Robak', 'Affiliation': 'Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Ruetzler', 'Affiliation': 'Departments of Outcomes Research and General Anesthesia, Cleveland Clinic, Cleveland, OH, USA., Cleveland, United States.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Czekajło', 'Affiliation': 'Hounter Holmes McGuire Center for Simulation and Healthcare, Virginia Commonwealth University, Richmond, VA, USA, Richmond, United States.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Rodríguez-Núnez', 'Affiliation': 'Paediatric Emergency and Critical Care Division, Paediatric Area Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain., Santiago de Compostela, Spain.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'López-Herce', 'Affiliation': 'Paediatric Intensive Care Department, Hospital General Universitario Gregorio Marannón, Medical School, Complutense University of Madrid, Madrid, Spain., Madrid, Spain.'}, {'ForeName': 'Łukasz', 'Initials': 'Ł', 'LastName': 'Szarpak', 'Affiliation': 'Lazarski University, Warsaw, Poland. lukasz.szarpak@gmail.com.'}]",Cardiology journal,['10.5603/CJ.a2018.0121'] 468,30484269,"The effect of acetylsalicylic acid dosed at bedtime on the anti-aggregation effect in patients with coronary heart disease and arterial hypertension: A randomized, controlled trial.","BACKGROUND Acetylsalicylic acid (ASA) is one of the basic drugs used in the secondary prevention of coronary artery disease (CAD), and in most cases it is taken in the morning in one daily dose. It is suggested that the morning peak of platelet aggregation is responsible for the occurrence of myocardial infarctions and strokes. Hence, the aim of the study was to observe the effect of ASA (morning vs. evening) dosing on the anti-aggregative effect of platelets in patients with CAD and arterial hypertension (AH). METHODS The study involved 175 patients with CAD and AH. Patients were randomly assigned to one of two study groups, taking ASA in the morning or in the evening. The patients had two visits, one baseline and another after 3 months from changing the time of ASA dosage. The platelet aggregation was determined using the VerifyNow analyzer. RESULTS In the ASA evening group, a significant reduction in platelet aggregation was obtained. In the ASA morning group, a significant difference in response to ASA was observed, depending on sex. In men, the reactivity of platelets decreased, but in women it increased. CONCLUSIONS In the group of patients with CAD and AH, bedtime ASA dosing is associated with a significant reduction in platelet aggregation. The response to ASA may differ between sexes. The benefit gained by changing the drug administration from the morning to the evening is greater in women.",2019,"In the group of patients with CAD and AH, bedtime ASA dosing is associated with a significant reduction in platelet aggregation.","['patients with coronary heart disease and arterial hypertension', 'patients with CAD and arterial hypertension (AH', '175 patients with CAD and AH']","['acetylsalicylic acid', 'Acetylsalicylic acid (ASA', 'ASA']","['response to ASA', 'platelet aggregation', 'reactivity of platelets']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0010068', 'cui_str': 'Coronary Disease'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C4517605', 'cui_str': '175'}]","[{'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}]","[{'cui': 'C0677599', 'cui_str': 'Platelet aggregation'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}]",175.0,0.0909861,"In the group of patients with CAD and AH, bedtime ASA dosing is associated with a significant reduction in platelet aggregation.","[{'ForeName': 'Beata', 'Initials': 'B', 'LastName': 'Krasińska', 'Affiliation': 'Department of Hypertension, Angiology and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland. beata.bkrasinska@gmail.com.'}, {'ForeName': 'Lech', 'Initials': 'L', 'LastName': 'Paluszkiewicz', 'Affiliation': 'Department of Thoracic And Cardiovascular Surgery/Perioperative diagnostics Bad Oeynhausen, Heart and Diabetes Center NRW, Ruhr-University of Bochum, Germany.'}, {'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Miciak-Lawicka', 'Affiliation': 'Department of Hypertension, Angiology and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Krasiński', 'Affiliation': 'Student, Imperial College London School of Medicine, United Kingdom.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Rzymski', 'Affiliation': 'Department of Environmental Medicine, Poznan University of Medical Sciences, Poznan, Poland.'}, {'ForeName': 'Andrzej', 'Initials': 'A', 'LastName': 'Tykarski', 'Affiliation': 'Department of Hypertension, Angiology and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland.'}, {'ForeName': 'Zbigniew', 'Initials': 'Z', 'LastName': 'Krasiński', 'Affiliation': 'Department of General and Vascular Surgery, Poznan University of Medical Sciences, Poznan, Poland.'}]",Cardiology journal,['10.5603/CJ.a2018.0142'] 469,32185802,Effects of sweet orange aromatherapy on pain and anxiety during needle insertion among patients undergoing hemodialysis: A quasi-experimental study.,"PURPOSE Patients undergoing hemodialysis experience pain and anxiety during needle insertion, and the scientific interest in aromatherapy in reducing pain and anxiety is increasing. Thus, this study aimed to determine the effects of sweet orange aromatherapy on pain and anxiety during needle insertion in hemodialysis. DESIGN Quasi-experimental, pretest, and posttest. METHODS This study was carried out among 50 patients with chronic kidney disease who were non-randomly assigned to either sweet orange aromatherapy or calm breathing in three outpatient hemodialysis centers in the Philippines between July and August 2015. The numeric rating scale and adapted state-trait anxiety inventory were utilized to measure pain and anxiety. RESULTS After the intervention, both the pain and anxiety scores were significantly lower for patients who received sweet orange aromatherapy than those who received calm breathing. The results obtained modest effect sizes that imply high practical significance. CONCLUSION The sweet orange aromatherapy can be effective in reducing pain and anxiety. Thus, this can be used by nurses as an alternative and complementary approach to reduce both pain and anxiety in painful procedures like needle insertion.",2020,"After the intervention, both the pain and anxiety scores were significantly lower for patients who received sweet orange aromatherapy than those who received calm breathing.","['Patients undergoing hemodialysis experience pain and anxiety during needle insertion', '50 patients with chronic kidney disease who were non-randomly assigned to either', 'hemodialysis', 'patients undergoing hemodialysis', 'in three outpatient hemodialysis centers in the Philippines between July and August 2015']","['sweet orange aromatherapy', 'sweet orange aromatherapy or calm breathing']","['pain and anxiety scores', 'numeric rating scale and adapted state-trait anxiety inventory', 'pain and anxiety']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0398296', 'cui_str': 'Cannulation of vascular fistula, graft or prosthetic device (procedure)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0522462', 'cui_str': 'Orange Tree'}, {'cui': 'C0376547', 'cui_str': 'Therapy, Aroma'}, {'cui': 'C0150157', 'cui_str': 'Calming'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",50.0,0.0191466,"After the intervention, both the pain and anxiety scores were significantly lower for patients who received sweet orange aromatherapy than those who received calm breathing.","[{'ForeName': 'Ma Catherine Grace Mendoza', 'Initials': 'MCGM', 'LastName': 'Reyes', 'Affiliation': 'College of Nursing, University of Santo Tomas, Manila, Philippines.'}, {'ForeName': 'Ma Corrine Grace Mendoza', 'Initials': 'MCGM', 'LastName': 'Reyes', 'Affiliation': 'College of Nursing, University of Santo Tomas, Manila, Philippines.'}, {'ForeName': 'Krystal Gale Lastrella', 'Initials': 'KGL', 'LastName': 'Ribay', 'Affiliation': 'College of Nursing, University of Santo Tomas, Manila, Philippines.'}, {'ForeName': 'Emmanuel Dayao', 'Initials': 'ED', 'LastName': 'Paragas', 'Affiliation': 'College of Nursing, University of Santo Tomas, Manila, Philippines.'}]",Nursing forum,['10.1111/nuf.12447'] 470,32184056,"Patient Navigation to Reduce Emergency Department (ED) Utilization Among Medicaid Insured, Frequent ED Users: A Randomized Controlled Trial.","BACKGROUND Some Medicaid enrollees frequently utilize the emergency department (ED) due to barriers accessing health care services in other settings. OBJECTIVES To determine whether an ED-initiated Patient Navigation program (ED-PN) designed to improve health care access for Medicaid-insured frequent ED users could decrease ED visits, hospitalizations, and costs. METHODS We conducted a prospective, randomized controlled trial comparing ED-PN with usual care (UC) among 100 Medicaid-enrolled frequent ED users (defined as 4-18 ED visits in the prior year), assessing ED utilization during the 12 months pre- and post-enrollment. Secondary outcomes included hospitalizations, outpatient utilization, hospital costs, and Medicaid costs. We also compared characteristics between ED-PN patients with and without reduced ED utilization. RESULTS Of 214 eligible patients approached, 100 (47%) consented to participate. Forty-nine were randomized to ED-PN and 51 to UC. Sociodemographic characteristics and prior utilization were similar between groups. ED-PN participants had a significant reduction in ED visits and hospitalizations during the 12-month evaluation period compared with UC, averaging 1.4 fewer ED visits per patient (p = 0.01) and 1.0 fewer hospitalizations per patient (p = 0.001). Both groups increased outpatient utilization. ED-PN patients showed a trend toward reduced per-patient hospital costs (-$10,201, p = 0.10); Medicaid costs were unchanged (-$5,765, p = 0.26). Patients who demonstrated a reduction in ED usage were older (mean age 42 vs. 33 years, p = 0.03) and had lower health literacy (78% low health literacy vs. 40%, p = 0.02). CONCLUSION An ED-PN program targeting Medicaid-insured high ED utilizers demonstrated significant reductions in ED visits and hospitalizations in the 12 months after enrollment.",2020,An ED-PN program targeting Medicaid-insured high ED utilizers demonstrated significant reductions in ED visits and hospitalizations in the 12 months after enrollment.,"['Forty-nine', '214 eligible patients approached, 100 (47%) consented to participate', '100 Medicaid-enrolled frequent ED users (defined as 4-18 ED visits in the prior year), assessing ED utilization during the 12\xa0months pre- and post-enrollment', 'Medicaid Insured, Frequent ED Users']","['ED-initiated Patient Navigation program (ED-PN', 'usual care (UC']","['Emergency Department (ED) Utilization', 'Medicaid costs', 'outpatient utilization', 'ED visits, hospitalizations, and costs', 'health literacy', 'hospitalizations, outpatient utilization, hospital costs, and Medicaid costs', 'reduced per-patient hospital costs', 'ED visits and hospitalizations', 'Sociodemographic characteristics and prior utilization']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C0025071', 'cui_str': 'Medicaid'}, {'cui': 'C0332183', 'cui_str': 'Frequent (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0042153', 'cui_str': 'use'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]","[{'cui': 'C3494323', 'cui_str': 'Navigations, Patient'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0042153', 'cui_str': 'use'}, {'cui': 'C0025071', 'cui_str': 'Medicaid'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C0206174', 'cui_str': 'Hospital Costs'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]",214.0,0.102574,An ED-PN program targeting Medicaid-insured high ED utilizers demonstrated significant reductions in ED visits and hospitalizations in the 12 months after enrollment.,"[{'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Kelley', 'Affiliation': 'Project Access-New Haven, New Haven, Connecticut.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Capp', 'Affiliation': 'Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Juan F', 'Initials': 'JF', 'LastName': 'Carmona', 'Affiliation': 'Project Access-New Haven, New Haven, Connecticut.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': ""D'Onofrio"", 'Affiliation': 'Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Mei', 'Affiliation': 'Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Darcey', 'Initials': 'D', 'LastName': 'Cobbs-Lomax', 'Affiliation': 'Project Access-New Haven, New Haven, Connecticut.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Ellis', 'Affiliation': 'Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.'}]",The Journal of emergency medicine,['10.1016/j.jemermed.2019.12.001'] 471,32182434,Auditory Training to Improve Speech Perception and Self-Efficacy in Aging Adults.,"Purpose Difficulty in understanding spoken speech is a common complaint among aging adults, even when hearing impairment is absent. Correlational studies point to a relationship between age, auditory temporal processing (ATP), and speech perception but cannot demonstrate causality unlike training studies. In the current study, we test (a) the causal relationship between a spatial-temporal ATP task (temporal order judgment [TOJ]) and speech perception among aging adults using a training design and (b) whether improvement in aging adult speech perception is accompanied by improved self-efficacy. Method Eighty-two participants aged 60-83 years were randomly assigned to a group receiving (a) ATP training (TOJ) over 14 days, (b) non-ATP training (intensity discrimination) over 14 days, or (c) no training. Results The data showed that TOJ training elicited improvement in all speech perception tests, which was accompanied by increased self-efficacy. Neither improvement in speech perception nor self-efficacy was evident following non-ATP training or no training. Conclusions There was no generalization of the improvement resulting from TOJ training to intensity discrimination or generalization of improvement resulting from intensity discrimination training to speech perception. These findings imply that the effect of TOJ training on speech perception is specific and such improvement is not simply the product of generally improved auditory perception. It provides support for the idea that temporal properties of speech are indeed crucial for speech perception. Clinically, the findings suggest that aging adults can be trained to improve their speech perception, specifically through computer-based auditory training, and this may improve perceived self-efficacy.",2020,"The data showed that TOJ training elicited improvement in all speech perception tests, which was accompanied by increased self-efficacy.","['Method Eighty-two participants aged 60-83 years', 'Aging Adults']","['Auditory Training', 'TOJ training', 'spatial-temporal ATP task (temporal order judgment [TOJ', 'ATP training (TOJ) over 14 days, (b) non-ATP training (intensity discrimination) over 14 days, or (c) no training', 'TOJ']","['speech perception nor self-efficacy', 'Speech Perception and Self-Efficacy', 'self-efficacy', 'speech perception tests']","[{'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0442043', 'cui_str': 'Temporal (qualifier value)'}, {'cui': 'C0001480', 'cui_str': 'ATP'}, {'cui': 'C4284072', 'cui_str': 'Order (record artifact)'}, {'cui': 'C0022423', 'cui_str': 'Judgment'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0234687', 'cui_str': 'Intensity discrimination, function (observable entity)'}]","[{'cui': 'C0037826', 'cui_str': 'Speech Perception'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",82.0,0.0106495,"The data showed that TOJ training elicited improvement in all speech perception tests, which was accompanied by increased self-efficacy.","[{'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Fostick', 'Affiliation': 'Department of Communication Disorders, Ariel University, Israel.'}, {'ForeName': 'Riki', 'Initials': 'R', 'LastName': 'Taitelbaum-Swead', 'Affiliation': 'Department of Communication Disorders, Ariel University, Israel.'}, {'ForeName': 'Shulamith', 'Initials': 'S', 'LastName': 'Kreitler', 'Affiliation': 'School of Psychological Sciences, Tel Aviv University, Israel.'}, {'ForeName': 'Shelly', 'Initials': 'S', 'LastName': 'Zokraut', 'Affiliation': 'Department of Health Systems Management, Ariel University, Israel.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Billig', 'Affiliation': 'Department of Sociology and Anthropology, Ariel University, Israel.'}]","Journal of speech, language, and hearing research : JSLHR",['10.1044/2019_JSLHR-19-00355'] 472,30155866,"Comparison of two infant chest compression techniques during simulated newborn cardiopulmonary resuscitation performed by a single rescuer: A randomized, crossover multicenter trial.","BACKGROUND In newborns, ventilation is a key resuscitation element but optimal chest compression (CC) improves resuscitation quality. The study compared two infant CC techniques during simulated newborn resuscitation performed by nurses. METHODS The randomized crossover manikin, multicenter trial involved 52 nurses. They underwent training with two CC techniques: standard two-finger technique (TFT) and novel two-thumb technique (NTTT; two thumbs at 90° to the chest, fingers in a fist). One week later, the participants performed resuscitation with the two techniques. A Tory® S2210 Tetherless and Wireless Full-term Neonatal Simulator was applied, with a 3:1 compression to ventilation ratio. CC quality in accordance with the 2015 American Heart Association guidelines was assessed during the 2-min resuscitation. RESULTS Median CC depth was 30 mm for TFT and 37 mm for NTTT (p = 0.002). Correct hand placement reached 98% in both techniques; full chest relaxation was obtained in 97% vs. 94% for TFT and NTTT, respectively. CC fraction was slightly better for NTTT (74% vs. 70% for TFT; p = 0.044), the ventilation volume was comparable for both techniques. On a 100-degree scale (1 - no fatigue; 100 - extreme fatigue), the participant tiredness achieved 72 points (IQR 61-77) for TFT vs. 47 points (IQR 40-63) for NTTT (p = 0.034). For real resuscitation, 86.5% would choose NTTT and 13.5% TFT. CONCLUSIONS The NTTT technique proved superior to TFT. Evidence suggests that NTTT offers better CC depth in various medical personnel groups. One-rescuer TFT quality is not consistent with resuscitation guidelines.",2019,"RESULTS Median CC depth was 30 mm for TFT and 37 mm for NTTT (p = 0.002).",['52 nurses'],"['training with two CC techniques: standard two-finger technique (TFT) and novel two-thumb technique (NTTT', 'infant chest compression techniques']","['CC quality', 'chest relaxation', 'resuscitation quality', 'Median CC depth', 'CC fraction', 'ventilation volume']","[{'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}]","[{'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0016129', 'cui_str': 'Fingers'}, {'cui': 'C0040067', 'cui_str': 'Thumb'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}]","[{'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0035273', 'cui_str': 'Resuscitation'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}]",52.0,0.0246247,"RESULTS Median CC depth was 30 mm for TFT and 37 mm for NTTT (p = 0.002).","[{'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Smereka', 'Affiliation': 'Department of Emergency Medical Service, Wroclaw Medical University, Wroclaw, Poland.'}, {'ForeName': 'Marcin', 'Initials': 'M', 'LastName': 'Madziala', 'Affiliation': 'Lazarski University, Warsaw, Poland.'}, {'ForeName': 'Lukasz', 'Initials': 'L', 'LastName': 'Szarpak', 'Affiliation': 'Lazarski University, Warsaw, Poland. lukasz.szarpak@gmail.com.'}]",Cardiology journal,['10.5603/CJ.a2018.0090'] 473,32127550,Intermittent Lactobacilli-containing Vaginal Probiotic or Metronidazole Use to Prevent Bacterial Vaginosis Recurrence: A Pilot Study Incorporating Microscopy and Sequencing.,"Bacterial vaginosis (BV) is associated with HIV acquisition and adverse pregnancy outcomes. Recurrence after metronidazole treatment is high. HIV-negative, non-pregnant Rwandan BV patients were randomized to four groups (n = 17/group) after seven-day oral metronidazole treatment: behavioral counseling only (control), or counseling plus intermittent use of oral metronidazole, Ecologic Femi+ vaginal capsule (containing multiple Lactobacillus and one Bifidobacterium species), or Gynophilus LP vaginal tablet (L. rhamnosus 35) for two months. Vaginal microbiota assessments at all visits included Gram stain Nugent scoring and 16S rRNA gene qPCR and HiSeq sequencing. All interventions were safe. BV (Nugent 7-10) incidence was 10.18 per person-year at risk in the control group, and lower in the metronidazole (1.41/person-year; p = 0.004), Ecologic Femi+ (3.58/person-year; p = 0.043), and Gynophilus LP groups (5.36/person-year; p = 0.220). In mixed effects models adjusted for hormonal contraception/pregnancy, sexual risk-taking, and age, metronidazole and Ecologic Femi+ users, each compared to controls, had higher Lactobacillus and lower BV-anaerobes estimated concentrations and/or relative abundances, and were less likely to have a dysbiotic vaginal microbiota type by sequencing. Inter-individual variability was high and effects disappeared soon after intervention cessation. Lactobacilli-based vaginal probiotics warrant further evaluation because, in contrast to antibiotics, they are not expected to negatively affect gut microbiota or cause antimicrobial resistance.",2020,"BV (Nugent 7-10) incidence was 10.18 per person-year at risk in the control group, and lower in the metronidazole (1.41/person-year; p = 0.004), Ecologic Femi+ (3.58/person-year; p = 0.043), and Gynophilus LP groups (5.36/person-year; p = 0.220).","['HIV-negative, non-pregnant Rwandan BV patients']","['Intermittent Lactobacilli-containing Vaginal Probiotic or Metronidazole', 'metronidazole treatment: behavioral counseling only (control), or counseling plus intermittent use of oral metronidazole, Ecologic Femi+ vaginal capsule (containing multiple Lactobacillus and one Bifidobacterium species), or Gynophilus LP vaginal tablet', 'metronidazole']","['Recurrence', 'Ecologic Femi', 'Vaginal microbiota assessments', 'Bacterial Vaginosis Recurrence', 'Bacterial vaginosis (BV', 'BV']","[{'cui': 'C0481430', 'cui_str': 'HTLV-3 antibody negative'}, {'cui': 'C0549206', 'cui_str': 'Pregnancy not delivered'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C0525033', 'cui_str': 'Probiotics'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4546207', 'cui_str': 'Behavioral counseling (procedure)'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1273011', 'cui_str': 'Vaginal capsule'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0022938', 'cui_str': 'Lactobacillus'}, {'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}, {'cui': 'C0042264', 'cui_str': 'Vaginal Tablet'}]","[{'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0085166', 'cui_str': 'Vaginitis, Nonspecific'}]",,0.0459912,"BV (Nugent 7-10) incidence was 10.18 per person-year at risk in the control group, and lower in the metronidazole (1.41/person-year; p = 0.004), Ecologic Femi+ (3.58/person-year; p = 0.043), and Gynophilus LP groups (5.36/person-year; p = 0.220).","[{'ForeName': 'Janneke H H M', 'Initials': 'JHHM', 'LastName': 'van de Wijgert', 'Affiliation': 'Institute of Infection and Global Health, University of Liverpool, Liverpool, UK. j.vandewijgert@liverpool.ac.uk.'}, {'ForeName': 'Marijn C', 'Initials': 'MC', 'LastName': 'Verwijs', 'Affiliation': 'Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Stephen K', 'Initials': 'SK', 'LastName': 'Agaba', 'Affiliation': 'Rinda Ubuzima, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Bronowski', 'Affiliation': 'Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Lambert', 'Initials': 'L', 'LastName': 'Mwambarangwe', 'Affiliation': 'Rinda Ubuzima, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.'}, {'ForeName': 'Mireille', 'Initials': 'M', 'LastName': 'Uwineza', 'Affiliation': 'Rinda Ubuzima, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.'}, {'ForeName': 'Elke', 'Initials': 'E', 'LastName': 'Lievens', 'Affiliation': 'Winclove Probiotics, Amsterdam, The Netherlands.'}, {'ForeName': 'Adrien', 'Initials': 'A', 'LastName': 'Nivoliez', 'Affiliation': 'Biose, Arpajon-sur-Cère, France.'}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Ravel', 'Affiliation': 'Institute of Genome Sciences, University of Maryland, Baltimore, USA.'}, {'ForeName': 'Alistair C', 'Initials': 'AC', 'LastName': 'Darby', 'Affiliation': 'Centre for Genomic Research, Institute of Integrative Biology, University of Liverpool, Liverpool, UK.'}]",Scientific reports,['10.1038/s41598-020-60671-6'] 474,32019428,Sleep for Stroke Management and Recovery Trial (Sleep SMART): Rationale and methods.,"RATIONALE Obstructive sleep apnea is common among patients with acute ischemic stroke and is associated with reduced functional recovery and an increased risk for recurrent vascular events. AIMS AND/OR HYPOTHESIS The Sleep for Stroke Management and Recovery Trial (Sleep SMART) aims to determine whether automatically adjusting continuous positive airway pressure (aCPAP) treatment for obstructive sleep apnea improves clinical outcomes after acute ischemic stroke or high-risk transient ischemic attack. SAMPLE SIZE ESTIMATE A total of 3062 randomized subjects for the prevention of recurrent serious vascular events, and among these, 1362 stroke survivors for the recovery outcome. METHODS AND DESIGN Sleep SMART is a phase III, multicenter, prospective randomized, open, blinded outcome event assessed controlled trial. Adults with recent acute ischemic stroke/transient ischemic attack and no contraindication to aCPAP are screened for obstructive sleep apnea with a portable sleep apnea test. Subjects with confirmed obstructive sleep apnea but without predominant central sleep apnea proceed to a run-in night of aCPAP. Subjects with use (≥4 h) of aCPAP and without development of significant central apneas are randomized to aCPAP plus usual care or care-as-usual for six months. Telemedicine is used to monitor and facilitate aCPAP adherence remotely. STUDY OUTCOMES Two separate primary outcomes: (1) the composite of recurrent acute ischemic stroke, acute coronary syndrome, and all-cause mortality (prevention) and (2) the modified Rankin scale scores (recovery) at six- and three-month post-randomization, respectively. DISCUSSION Sleep SMART represents the first large trial to test whether aCPAP for obstructive sleep apnea after stroke/transient ischemic attack reduces recurrent vascular events or death, and improves functional recovery.",2020,Subjects with use (≥4 h) of aCPAP and without development of significant central apneas are randomized to aCPAP plus usual care or care-as-usual for six months.,"['Subjects with use (≥4\u2009h) of aCPAP and without development of significant central apneas', 'Subjects with confirmed obstructive sleep apnea but without predominant central sleep apnea', 'Adults with recent acute ischemic stroke/transient ischemic attack and no contraindication to aCPAP are screened for obstructive sleep apnea with a portable sleep apnea test', '3062 randomized subjects for the prevention of recurrent serious vascular events, and among these, 1362 stroke survivors for the recovery outcome', 'patients with acute ischemic stroke', 'Sleep SMART']","['aCPAP', 'aCPAP plus usual care or care-as-usual for six months', 'Telemedicine', 'automatically adjusting continuous positive airway pressure (aCPAP) treatment']","['obstructive sleep apnea', 'composite of recurrent acute ischemic stroke, acute coronary syndrome, and all-cause mortality (prevention) and (2) the modified Rankin scale scores (recovery']","[{'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0520680', 'cui_str': 'Ondine Syndrome'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0520679', 'cui_str': 'Syndrome, Sleep Apnea, Obstructive'}, {'cui': 'C3887547', 'cui_str': 'Central sleep apnea syndrome (disorder)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0007787', 'cui_str': 'Brain TIA'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to (contextual qualifier) (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0037315', 'cui_str': 'Sleep Hypopnea'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}]","[{'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0520679', 'cui_str': 'Syndrome, Sleep Apnea, Obstructive'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0439589', 'cui_str': 'Recurrent acute (qualifier value)'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0948089', 'cui_str': 'Acute Coronary Syndrome'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",3062.0,0.0612725,Subjects with use (≥4 h) of aCPAP and without development of significant central apneas are randomized to aCPAP plus usual care or care-as-usual for six months.,"[{'ForeName': 'Devin L', 'Initials': 'DL', 'LastName': 'Brown', 'Affiliation': 'Division of Vascular Neurology and Division of Sleep Medicine, Department of Neurology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Durkalski', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Durmer', 'Affiliation': 'Nox Health, Johns Creek, GA, USA.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'Broderick', 'Affiliation': 'Department of Neurology and Rehabilitation Medicine, UC Gardner Neuroscience Institute, University of Cincinnati, Cincinnati, OH, USA.'}, {'ForeName': 'Darin B', 'Initials': 'DB', 'LastName': 'Zahuranec', 'Affiliation': 'Division of Vascular Neurology, Department of Neurology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Deborah A', 'Initials': 'DA', 'LastName': 'Levine', 'Affiliation': 'Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.'}, {'ForeName': 'Craig S', 'Initials': 'CS', 'LastName': 'Anderson', 'Affiliation': 'Faculty of Medicine, The George Institute for Global Health, UNSW, Sydney, Australia.'}, {'ForeName': 'Dawn M', 'Initials': 'DM', 'LastName': 'Bravata', 'Affiliation': 'Department of Internal Medicine and Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.'}, {'ForeName': 'H Klar', 'Initials': 'HK', 'LastName': 'Yaggi', 'Affiliation': 'Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Lewis B', 'Initials': 'LB', 'LastName': 'Morgenstern', 'Affiliation': 'Division of Vascular Neurology, Department of Neurology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Claudia S', 'Initials': 'CS', 'LastName': 'Moy', 'Affiliation': 'National Institutes of Neurological Disorders and Stroke, Bethesda, MD, USA.'}, {'ForeName': 'Ronald D', 'Initials': 'RD', 'LastName': 'Chervin', 'Affiliation': 'Department of Neurology and Sleep Disorders Center, University of Michigan, Ann Arbor, MI, USA.'}]",International journal of stroke : official journal of the International Stroke Society,['10.1177/1747493020903979'] 475,32178950,A Randomized Prospective Placebo-Controlled Study of the Effects of Lavender Aromatherapy on Preoperative Anxiety in Cataract Surgery Patients.,"PURPOSE To determine if lavender aromatherapy can reduce preoperative anxiety in cataract surgery patients. DESIGN Single-center prospective randomized placebo-controlled trial. METHODS Seventy-five patients awaiting cataract surgery were randomized to lavender essential oil or grape seed oil (control) and administered the State-Trait Anxiety Inventory. Vital signs were also recorded. FINDINGS Patients in the lavender group showed greater improvements in self-reported anxiety using the State-Trait Anxiety Inventory (P = .023, two-sample t test). Compared with the control group, the effects of lavender on the reduction of anxiety were statistically significant when adjusting for age, gender, and baseline scores (P = .012, analysis of covariance). CONCLUSIONS Lavender aromatherapy reduced anxiety in preoperative cataract surgery patients.",2020,"Compared with the control group, the effects of lavender on the reduction of anxiety were statistically significant when adjusting for age, gender, and baseline scores (P = .012, analysis of covariance). ","['preoperative cataract surgery patients', 'cataract surgery patients', 'Seventy-five patients awaiting cataract surgery', 'Cataract Surgery Patients']","['lavender essential oil or grape seed oil (control) and administered the State-Trait Anxiety Inventory', 'Lavender Aromatherapy', 'lavender aromatherapy', 'placebo', 'Lavender aromatherapy', 'Placebo']","['reduction of anxiety', 'anxiety', 'self-reported anxiety using the State-Trait Anxiety Inventory', 'Preoperative Anxiety', 'preoperative anxiety']","[{'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C2004600', 'cui_str': 'Cataract surgery specialty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319621', 'cui_str': 'Seventy-five'}]","[{'cui': 'C0028910', 'cui_str': 'Oils, Essential'}, {'cui': 'C0458160', 'cui_str': 'grape seed oil'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0524903', 'cui_str': 'Lavender'}, {'cui': 'C0376547', 'cui_str': 'Therapy, Aroma'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}]",75.0,0.0589282,"Compared with the control group, the effects of lavender on the reduction of anxiety were statistically significant when adjusting for age, gender, and baseline scores (P = .012, analysis of covariance). ","[{'ForeName': 'Philip Francis', 'Initials': 'PF', 'LastName': 'Stanley', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, Khoo Teck Puat Hospital, Singapore. Electronic address: philip.stanley@ktph.com.sg.'}, {'ForeName': 'Lai Foon', 'Initials': 'LF', 'LastName': 'Wan', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, Khoo Teck Puat Hospital, Singapore.'}, {'ForeName': 'Rostihar Abdul', 'Initials': 'RA', 'LastName': 'Karim', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, Khoo Teck Puat Hospital, Singapore.'}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2019.12.004'] 476,32178953,Extraluminal Placement of the Bronchial Blocker in Infants Undergoing Thoracoscopic Surgery: A Randomized Controlled Study.,"OBJECTIVE The purpose of the present study was to evaluate the efficacy of extraluminal use of the bronchial blocker (BB) for one-lung ventilation (OLV) in infants undergoing thoracoscopic surgery. DESIGN This was a prospective, randomized, controlled clinical study. SETTING University hospital. PARTICIPANTS The study comprised 60 infants undergoing thoracoscopic surgery. INTERVENTION The study included 2 groups. A BB was placed extraluminally for OLV in group A, and a single-lumen endobronchial tube was inserted into the desired mainstem bronchus for OLV in group C. MEASUREMENTS AND MAIN RESULTS The placement time (4.0 ± 0.6 min v 6.3 ± 4.1 min; p = 0.04) and the number of repositions (2 v 11; p = 0.005) were less in group A. There were significant differences in the heart rate and blood pressure after insertion between the 2 groups (p < 0.05). The tidal volumes and end-tidal pressure of carbon dioxide values 10 minutes after the initiation of OLV were similar between the 2 groups (p > 0.05). The incidence of intraoperative hypoxemia was reduced in group A compared with group C (0% v 20%; p = 0.024). No postoperative adverse events were observed in either group. CONCLUSIONS Extraluminal use of the BB may provide a solution for a rapid placement and excellent quality of lung isolation, and it may reduce the incidence of intraoperative hypoxemia in infants without increasing the incidence of hoarseness.",2020,There were significant differences in the heart rate and blood pressure after insertion between the 2 groups (p < 0.05).,"['University hospital', 'Infants Undergoing Thoracoscopic Surgery', '60 infants undergoing thoracoscopic surgery', 'infants undergoing thoracoscopic surgery']","['Bronchial Blocker', 'bronchial blocker (BB) for one-lung ventilation (OLV']","['tidal volumes and end-tidal pressure of carbon dioxide values', 'heart rate and blood pressure', 'incidence of intraoperative hypoxemia', 'number of repositions', 'postoperative adverse events']","[{'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0751551', 'cui_str': 'Surgical Procedures, Thoracoscopic'}]","[{'cui': 'C0205039', 'cui_str': 'Bronchial (qualifier value)'}, {'cui': 'C0559312', 'cui_str': 'Single-Lung Ventilation'}]","[{'cui': 'C0040210', 'cui_str': 'Tidal Volume'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0700292', 'cui_str': 'Hypoxemia'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0556030', 'cui_str': 'Repositioning (procedure)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",60.0,0.106799,There were significant differences in the heart rate and blood pressure after insertion between the 2 groups (p < 0.05).,"[{'ForeName': 'Jiang', 'Initials': 'J', 'LastName': 'Yan', 'Affiliation': ""Department of Anesthesiology, Shanghai Children's Hospital, Shanghai JiaoTong University, Shanghai, China.""}, {'ForeName': 'Zhang', 'Initials': 'Z', 'LastName': 'Rufang', 'Affiliation': ""Department of Cardiothoracic Surgery, Shanghai Children's Hospital, Shanghai JiaoTong University, Shanghai, China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Rong', 'Affiliation': ""Department of Anesthesiology, Shanghai Children's Hospital, Shanghai JiaoTong University, Shanghai, China. Electronic address: weirongej@163.com.""}, {'ForeName': 'Zhang', 'Initials': 'Z', 'LastName': 'Wangping', 'Affiliation': ""Department of Anesthesiology, Women and Children's Hospital of Jiaxing University, Jiaxing, China.""}]",Journal of cardiothoracic and vascular anesthesia,['10.1053/j.jvca.2020.02.006'] 477,31145045,Dietary Quality Assessed by the HEI-2010 and Biomarkers of Cardiometabolic Disease: An Exploratory Analysis.,"Objectives: This study explores relationships between cardiometabolic measures of antioxidant capacity or inflammation and diet quality assessed by the Healthy Eating Index (HEI)-2010 which measures conformity to Dietary Guidelines for Americans. This cross-sectional study was an ancillary analysis of baseline data for a randomized controlled trial with older adults at risk for cardiometabolic disease (ClinicalTrials.gov #NCT00955903). Methods: Community-dwelling older adults (n = 133, 49% male, 70.4 ± 4.8 years) with a body mass index of 30-40 kg/m 2 provided a fasted blood sample for measurement of antioxidant capacity, high-sensitivity C-reactive protein, tumor necrosis factor-alpha, and interleukin-6. Dietary data were generated from the mean of three 24-hour recalls. Results: After adjustment for potential confounders, HEI-2010 composite scores were not significantly associated with decreased inflammation or greater antioxidant capacity. In analysis of the 12 components composing the HEI-2010, significant positive association was observed between total dairy and total serum antioxidant capacity (0.043; 95% CI, 0.008-0.069). Significant associations observed in inflammatory markers were between total vegetable and tumor necrosis factor-alpha (-0.078; 95% CI, -0.151 to -0.005), sodium and interleukin-6 (0.091; 95% CI, 0.023-0.158), and scores for combined calories from solid fats, alcoholic beverages, and added sugars and interleukin-6 (0.139; 95% CI, 0.027-0.252). In models adjusting for HEI-2010 composite score when significant associations were observed between component scores and biomarkers, two of six associations were strengthened by adding the composite score as a potential confounder. Conclusions: Largely null findings along with those inconsistent with scientific expectations suggest caution in extrapolating adherence to the HEI-2010 with an individual's inflammatory or antioxidant status. Results merit additional investigation with other biomarkers of chronic disease and emphasis on dietary patterns given potential synergy within food combinations.",2019,Significant associations observed in inflammatory markers were between total vegetable and tumor necrosis factor-alpha,"['Americans', 'older adults at risk for cardiometabolic disease (ClinicalTrials.gov #NCT00955903', 'Community-dwelling older adults (n\u2009=\u2009133, 49% male, 70.4\u2009±\u20094.8\u2009years) with a body mass index of 30-40\u2009kg/m 2 provided a fasted blood sample for measurement of antioxidant capacity, high-sensitivity C-reactive protein, tumor necrosis factor-alpha, and interleukin-6']",[],"['inflammation or greater antioxidant capacity', 'Dietary Quality Assessed by the HEI-2010 and Biomarkers of Cardiometabolic Disease', 'total dairy and total serum antioxidant capacity', 'Healthy Eating Index', 'inflammatory markers']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C4517765', 'cui_str': '4.8 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}]",[],"[{'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C4280021', 'cui_str': 'Healthy Eating Index'}]",,0.372565,Significant associations observed in inflammatory markers were between total vegetable and tumor necrosis factor-alpha,"[{'ForeName': 'Kristi M', 'Initials': 'KM', 'LastName': 'Crowe-White', 'Affiliation': 'Department of Human Nutrition, University of Alabama , Tuscaloosa , Alabama , USA.'}, {'ForeName': 'Amy C', 'Initials': 'AC', 'LastName': 'Ellis', 'Affiliation': 'Department of Human Nutrition, University of Alabama , Tuscaloosa , Alabama , USA.'}, {'ForeName': 'Tapan', 'Initials': 'T', 'LastName': 'Mehta', 'Affiliation': 'Nutrition Obesity Research Center, University of Alabama at Birmingham , Birmingham , Alabama , USA.'}, {'ForeName': 'Julie L', 'Initials': 'JL', 'LastName': 'Locher', 'Affiliation': 'Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham , Birmingham , Alabama , USA.'}, {'ForeName': 'Jamy D', 'Initials': 'JD', 'LastName': 'Ard', 'Affiliation': 'Department of Epidemiology and Prevention, Wake Forest University School of Medicine , Winston-Salem , North Carolina , USA.'}]",Journal of the American College of Nutrition,['10.1080/07315724.2019.1580168'] 478,31326277,Evaluating a new objective grading software for conjunctival hyperaemia.,"BACKGROUND/ AIMS Standardised numeric grading scales are used in ophthalmic practice to improve consistency between clinicians in recording the severity of ocular conditions and to facilitate the monitoring of such changes. We investigated the intra- and inter-observer grading reliability and the agreement between subjective Cornea and Contact Lens Research Unit (CCLRU) and Efron grading scales as well as a new Advanced Ophthalmic Systems (AOS) software which uses an objective approach to grading conjunctival hyperaemia. METHODS One experienced observer graded n = 30 bulbar and n = 26 palpebral conjunctival hyperaemia images to 0.1 increments. Masked grading of randomised images was undertaken for all three methods, on two separate occasions. The agreement within and between the grading methods was assessed between sessions, and compared to the results of a novice observer. RESULTS There were no statistically significant differences (P > 0.05) between test and retest values. However, repeatability in the grading estimates of both bulbar and palpebral conjunctival hyperaemia was improved using the AOS grading method (R 2  = 0.998; Coefficient of Repeatability CoR 0.10-0.13), compared to Efron (R 2  = 0.926; CoR 0.62) and CCLRU (R 2  = 0.885-0.911; CoR 0.50-0.78). Intraclass coefficient correlations (ICC) improved inter-observer agreement using objective (> 0.995) versus subjective methods (0.853-0.959). CONCLUSION These subjective and objective grading methods are not interchangeable. Due to the excellent repeatability and improved agreement between experienced and novice observers, the objective grading method provides a more consistent approach when grading ocular abnormalities and may achieve greater reliability in record keeping and clinical monitoring in the future.",2020,"Intraclass coefficient correlations (ICC) improved inter-observer agreement using objective (> 0.995) versus subjective methods (0.853-0.959). ",['One experienced observer graded n\u202f=\u202f30 bulbar and n\u202f=\u202f26 palpebral conjunctival hyperaemia images to 0.1 increments'],[],"['Intraclass coefficient correlations (ICC', 'bulbar and palpebral conjunctival hyperaemia']","[{'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C1761613', 'cui_str': 'Conjunctival hyperemia (finding)'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C4517420', 'cui_str': 'Zero point one'}]",[],"[{'cui': 'C1761613', 'cui_str': 'Conjunctival hyperemia (finding)'}]",30.0,0.0296063,"Intraclass coefficient correlations (ICC) improved inter-observer agreement using objective (> 0.995) versus subjective methods (0.853-0.959). ","[{'ForeName': 'Byki', 'Initials': 'B', 'LastName': 'Huntjens', 'Affiliation': 'Centre for Applied Vision Research, Division of Optometry and Visual Science, City, University of London, United Kingdom. Electronic address: Byki.Huntjens.1@city.ac.uk.'}, {'ForeName': 'Mandeep', 'Initials': 'M', 'LastName': 'Basi', 'Affiliation': 'Centre for Applied Vision Research, Division of Optometry and Visual Science, City, University of London, United Kingdom.'}, {'ForeName': 'Manbir', 'Initials': 'M', 'LastName': 'Nagra', 'Affiliation': 'School of Health Sciences and Social Work, Faculty of Science, University of Portsmouth, United Kingdom.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2019.07.003'] 479,31495762,Effects of senofilcon A and lotrafilcon B bandage contact lenses on epithelial healing and pain management after bilateral photorefractive keratectomy.,"PURPOSE The purpose of this study was to compare postoperative epithelial healing time and ocular discomfort score in patients wearing two types of silicon hydrogel bandage contact lenses (BCLs) following bilateral photorefractive keratectomy (PRK). METHODS For the study's contralateral eye comparison, 43 patients who underwent bilateral PRK were randomized to be fitted for a senofilcon a lens in one eye and a lotrafilcon B lens in the other. The patients were masked to the specific BCL in each eye. On the first 3 days after PRK, the epithelial defect size was calculated, and patients reported their level of ocular discomfort, including pain, epiphora, and photophobia, on a visual analog scale (0 = no pain or discomfort, 10 = highest level of pain and discomfort). RESULTS Epithelial defect size (mm 2 ) did not differ significantly between the BCLs on Day 1 (senofilcon A vs. lotrafilcon B: 14.15 ± 5.59 vs. 14.93 ± 5.72, p = .327), Day 2 (senofilcon A vs. lotrafilcon B: 7.43 ± 4.67 vs. 7.04 ± 3.82, p = .586), or Day 3 (senofilcon A vs. lotrafilcon B: 0.59 ± 1.44 vs. 0.38 ± 1.08, p = .348) postoperation. By Day 3, re-epithelialization was complete in 35 eyes (81.3%) with senofilcon A lenses and 36 eyes (83.7%) with lotrafilcon B lenses. Patients reported less pain in eyes with senofilcon A lenses during the first 3 days postoperation (for all, p < .001) and less epiphora during the first 2 days postoperation (Day 1: p =  .008, Day 2: p <  .001, Day 3: p = .267) than in eyes with lotrafilcon B lenses. No significant difference in photophobia emerged between the BCLs postoperatively (for all, p > .05). CONCLUSIONS Although duration of corneal re-epithelialization after PRK between the two BCLs did not differ significantly, senofilcon A lenses caused significantly less pain and epiphora after PRK.",2020,"p <  .001, Day 3: p = .267) than in eyes with lotrafilcon B lenses.","['after bilateral photorefractive keratectomy', '43 patients who underwent bilateral PRK', 'patients wearing two types of silicon hydrogel bandage contact lenses (BCLs) following bilateral photorefractive keratectomy (PRK']","['senofilcon A and lotrafilcon B bandage contact lenses', 'senofilcon a lens in one eye and a lotrafilcon B lens']","['Epithelial defect size', 'photophobia', 'level of ocular discomfort, including pain, epiphora, and photophobia, on a visual analog scale', 're-epithelialization', 'epithelial defect size', 'pain', 'epithelial healing and pain management', 'postoperative epithelial healing time and ocular discomfort score']","[{'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0395416', 'cui_str': 'Photorefractive Keratectomy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0037107', 'cui_str': 'Silicon'}, {'cui': 'C1449669', 'cui_str': 'Bandages, Hydrogel'}, {'cui': 'C0009836', 'cui_str': 'Contact Lenses'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}]","[{'cui': 'C2002497', 'cui_str': 'senofilcon A'}, {'cui': 'C2001571', 'cui_str': 'lotrafilcon B'}, {'cui': 'C0150468', 'cui_str': 'Application of bandage (procedure)'}, {'cui': 'C0009836', 'cui_str': 'Contact Lenses'}, {'cui': 'C0023317', 'cui_str': 'Lens, Eye'}, {'cui': 'C0015392', 'cui_str': 'Eye'}]","[{'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0085636', 'cui_str': 'Light Sensitivity'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0948595', 'cui_str': 'Ocular discomfort'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0152227', 'cui_str': 'Epiphora'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0334221', 'cui_str': 'Re-Epithelialization'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0002766', 'cui_str': 'Pain management (procedure)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",43.0,0.0507538,"p <  .001, Day 3: p = .267) than in eyes with lotrafilcon B lenses.","[{'ForeName': 'Zeynep', 'Initials': 'Z', 'LastName': 'Duru', 'Affiliation': 'Kayseri City Education and Research Hospital, Department of Ophthalmology, Kayseri, Turkey. Electronic address: drzeynepduru@gmail.com.'}, {'ForeName': 'Necati', 'Initials': 'N', 'LastName': 'Duru', 'Affiliation': 'Kayseri City Education and Research Hospital, Department of Ophthalmology, Kayseri, Turkey.'}, {'ForeName': 'Döndü Melek', 'Initials': 'DM', 'LastName': 'Ulusoy', 'Affiliation': 'Kayseri City Education and Research Hospital, Department of Ophthalmology, Kayseri, Turkey.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2019.08.008'] 480,31578176,Therapeutic profile of a latent heat eyelid warming device with temperature setting variation.,"PURPOSE To compare the effects on ocular temperature and tear film parameters following a single application of a latent heat eyelid warming device at a range of temperature settings. METHODS Fifteen subjects were enrolled in a prospective, investigator-masked, randomised, cross-over trial. On separate days, participants were randomised to 10-minute application of a research latent heat device (Laboratoires Théa) at device temperature settings of 45 °C, 50 °C and 55 °C. Outer eyelid and corneal temperatures, tear film lipid layer grade, and non-invasive tear film breakup time (NIBUT) were measured at baseline and immediately after 10 min of device application. RESULTS Baseline measurements did not differ between treatment groups (all p > 0.05). Ocular temperatures, lipid layer grade and non-invasive tear film stability rose significantly following device application in all treatment groups (all p < 0.05). The 55 °C setting effected a mean ocular surface temperature rise in the order of +4 °C from baseline, which was 1.46 and 1.26 times greater than at the 45 °C and 50 °C temperature settings, respectively (all p < 0.05). Similarly, improvements in mean non-invasive tear film stability from baseline in the order of +7 s were observed, which were 2.43 and 1.66 times greater than those at the lower temperature settings of 45 °C and 50 °C, respectively (all p < 0.05). CONCLUSIONS At all temperature settings, the latent heat device resulted in clinically and statistically significant increases in ocular temperature, lipid layer grade, and non-invasive tear film stability. However, the 55 °C setting proved to be most effective at raising ocular temperature (in the order of +4 °C from baseline) and improving tear film stability.",2020,"Ocular temperatures, lipid layer grade and non-invasive tear film stability rose significantly following device application in all treatment groups (all p < 0.05).",['Fifteen subjects'],[],"['mean ocular surface temperature rise', 'mean non-invasive tear film stability', 'Outer eyelid and corneal temperatures, tear film lipid layer grade, and non-invasive tear film breakup time (NIBUT', 'ocular temperature, lipid layer grade, and non-invasive tear film stability', 'Ocular temperatures, lipid layer grade and non-invasive tear film stability', 'tear film stability']",[],[],"[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4521296', 'cui_str': 'Ocular (intended site)'}, {'cui': 'C0205148', 'cui_str': 'Surface (attribute)'}, {'cui': 'C0039476', 'cui_str': 'Temperature'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive (qualifier value)'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C4319646', 'cui_str': 'Film'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0015426', 'cui_str': 'Eyelids'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",15.0,0.0514213,"Ocular temperatures, lipid layer grade and non-invasive tear film stability rose significantly following device application in all treatment groups (all p < 0.05).","[{'ForeName': 'Michael T M', 'Initials': 'MTM', 'LastName': 'Wang', 'Affiliation': 'Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, New Zealand.'}, {'ForeName': 'Lucy J', 'Initials': 'LJ', 'LastName': 'Liu', 'Affiliation': ""Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, New Zealand; Neurodevelopmental Genomics Research Group, Murdoch Children's Research Institute, Melbourne, Australia; Department of Paediatrics, Melbourne Medical School, University of Melbourne, Melbourne, Australia.""}, {'ForeName': 'Robert D', 'Initials': 'RD', 'LastName': 'McPherson', 'Affiliation': 'Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, New Zealand.'}, {'ForeName': 'J Robert', 'Initials': 'JR', 'LastName': 'Fuller', 'Affiliation': 'Dorset General Hospital, Dorset, United Kingdom.'}, {'ForeName': 'Jennifer P', 'Initials': 'JP', 'LastName': 'Craig', 'Affiliation': 'Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, New Zealand. Electronic address: jp.craig@auckland.ac.nz.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2019.09.004'] 481,31548151,"The effect of lid hygiene on the tear film and ocular surface, and the prevalence of Demodex blepharitis in university students.","AIM To evaluate the effect blepharitis lid cleansers have on the tear film and ocular surface, and to examine the prevalence of Demodex folliculorum in a young population. METHODS Forty-eight university students completed a randomised, controlled, investigator-masked, eight-week clinical trial. Three eyelid hygiene products were investigated: blepharitis eyelid cleanser (OCuSOFT® Lid Scrub® PLUS foam), diluted baby shampoo (10% Johnson's® No More Tears ®) and a tea-tree based face wash (dr.organic®). Cooled boiled water was used as a control. Subjects attended for four visits: baseline, two weeks, four weeks and eight weeks. At each visit, subjective symptoms, non-invasive tear break up time, ocular surface staining and Demodex folliculorum investigation were assessed to evaluate any positive or negative effect on the tear film and ocular surface. Osmolarity was also measured at baseline and week eight only. RESULTS The overall prevalence of Demodex folliculorum found at baseline was 15%. Subjective symptoms improved in all groups, including control. There was no significant difference in mean osmolarity between the groups or within each group after eight weeks. There was a significant increase in osmolarity inter-eye variability in the baby shampoo group (5.5 ± 5.4 vs 15.2 ± 9.5; p = 0.03). There was no significant change in non-invasive tear break up time or ocular surface staining demonstrated after eight weeks of eyelid hygiene. CONCLUSION A low prevalence of Demodex folliculorum can be found in a young population. All blepharitis lid cleansers used demonstrated subjective improvement in symptoms, with no negative effects on tear break-up time or ocular surface staining. The blepharitis eyelid cleanser and tea-tree based face wash revealed no adverse effect on mean osmolarity or inter-eye variability. Similarly, baby shampoo did not cause a significant increase in mean osmolarity, however, a significant increase in inter-eye variability was found; suggesting a possible increase in ocular surface inflammation.",2020,"There was no significant change in non-invasive tear break up time or ocular surface staining demonstrated after eight weeks of eyelid hygiene. ","['young population', 'university students', 'Forty-eight university students']","['lid hygiene', ""blepharitis eyelid cleanser (OCuSOFT® Lid Scrub® PLUS foam), diluted baby shampoo (10% Johnson's® No More Tears ®) and a tea-tree based face wash (dr.organic®""]","['tear break-up time or ocular surface staining', 'ocular surface inflammation', 'mean osmolarity', 'overall prevalence of Demodex folliculorum', 'Osmolarity', 'inter-eye variability', 'non-invasive tear break up time or ocular surface staining', 'osmolarity inter-eye variability', 'Subjective symptoms']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C4319608', 'cui_str': 'Forty-eight'}]","[{'cui': 'C0020405', 'cui_str': 'Hygiene'}, {'cui': 'C0005741', 'cui_str': 'Blepharitis'}, {'cui': 'C0015426', 'cui_str': 'Eyelids'}, {'cui': 'C0722230', 'cui_str': 'Ocusoft'}, {'cui': 'C2946035', 'cui_str': 'Scrubs'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0991510', 'cui_str': 'Foam (basic dose form)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1554936', 'cui_str': 'Shampoo - dosing instruction imperative'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0039400', 'cui_str': 'Tea'}, {'cui': 'C0040811', 'cui_str': 'Trees'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C1547959', 'cui_str': 'Wash - dosing instruction imperative'}]","[{'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C4521296', 'cui_str': 'Ocular (intended site)'}, {'cui': 'C0205148', 'cui_str': 'Surface (attribute)'}, {'cui': 'C0487602', 'cui_str': 'Staining'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0029387', 'cui_str': 'Osmolarity'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0277431', 'cui_str': 'Demodex folliculorum (organism)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive (qualifier value)'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",48.0,0.0215289,"There was no significant change in non-invasive tear break up time or ocular surface staining demonstrated after eight weeks of eyelid hygiene. ","[{'ForeName': 'Orla', 'Initials': 'O', 'LastName': 'Murphy', 'Affiliation': 'Technological University Dublin, Ireland. Electronic address: orla.murphy@tudublin.ie.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': ""O' Dwyer"", 'Affiliation': 'Technological University Dublin, Ireland.'}, {'ForeName': 'Aoife', 'Initials': 'A', 'LastName': 'Lloyd-McKernan', 'Affiliation': 'Technological University Dublin, Ireland.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2019.09.003'] 482,30536713,Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials.,"An ASBMR Task Force recommends a drug holiday for certain women treated for ≥5 years with oral alendronate or ≥3 years with intravenous zoledronic acid, with reassessment 2 to 3 years later. It is not known whether changes in bone mineral density (BMD) or bone turnover markers differ after oral or intravenous therapy. Our goal was to compare changes in BMD and procollagen type I N propeptide (PINP) after oral or intravenous bisphosphonate use. In the Fracture Intervention Trial Long-term Extension (FLEX), women who received a mean 5 years of alendronate were randomized to placebo or continued treatment. In the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial Extension I (HORIZON-PFT E1), women who received 3 years of zoledronic acid were randomized to placebo or continued treatment. We examined the proportion of participants with BMD loss or PINP gain ≥ least significant change (LSC) and those whose values exceeded a threshold (T-score ≤-2.5 or PINP ≥36.0 ng/mL, a premenopausal median value). After 3 years of placebo, the FLEX group had greater mean total hip BMD decreases (-2.3% versus -1.2% in the HORIZON-PFT E1 group, p < 0.01) and greater rises in PINP (+11.6 ng/mL versus +6.7 ng/mL, p < 0.01). There was a greater proportion of individuals in FLEX with total hip BMD loss and PINP increases that exceeded LSC, and PINP values ≥36.0 ng/mL. In contrast, there were small changes in the proportion of women with femoral neck T-scores ≤-2.5 in both groups. In conclusion, 3 years after bisphosphonate discontinuation, a considerable proportion of former alendronate and zoledronic acid users had meaningful declines in total hip BMD and elevations in PINP. Despite a longer treatment course, alendronate may have a more rapid offset of drug effect than zoledronic acid. © 2018 American Society for Bone and Mineral Research.",2019,It is not known whether changes in bone mineral density (BMD) or bone turnover markers differ after oral or intravenous therapy.,"['3 Years', 'women who received a mean 5 years of', '© 2018 American Society for Bone and Mineral Research', 'women who received 3 years of', 'certain women treated for ≥5 years with oral alendronate or ≥3 years with intravenous', 'participants with BMD loss or PINP gain\u2009≥\u2009least significant change (LSC) and those whose values exceeded a threshold (T-score ≤-2.5 or PINP ≥36.0\u2009ng/mL, a premenopausal median value']","['FLEX', 'term Extension (FLEX', 'placebo', 'Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension', 'zoledronic acid', 'Zoledronic Acid', 'alendronate', 'bisphosphonate']","['BMD Changes and Bone Formation Marker Levels', 'total hip BMD and elevations in PINP', 'mean total hip BMD decreases', 'BMD and procollagen type', 'rises in PINP', 'bone mineral density (BMD) or bone turnover markers']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0026162', 'cui_str': 'Minerals'}, {'cui': 'C0035168'}, {'cui': 'C0205423', 'cui_str': 'Certainty (attribute)'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for (contextual qualifier) (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0102118', 'cui_str': 'Alendronate'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0449864', 'cui_str': 'Threshold (property) (qualifier value)'}, {'cui': 'C3854607', 'cui_str': 'T score'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]","[{'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0012544', 'cui_str': 'Bisphosphonates'}, {'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}, {'cui': 'C0257685', 'cui_str': 'zoledronic acid'}, {'cui': 'C0102118', 'cui_str': 'Alendronate'}]","[{'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0029433', 'cui_str': 'Ossification'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0033235', 'cui_str': 'Procollagen'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0085268', 'cui_str': 'Bone Turnover'}]",,0.129345,It is not known whether changes in bone mineral density (BMD) or bone turnover markers differ after oral or intravenous therapy.,"[{'ForeName': 'Tiffany Y', 'Initials': 'TY', 'LastName': 'Kim', 'Affiliation': 'Department of Medicine, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Douglas C', 'Initials': 'DC', 'LastName': 'Bauer', 'Affiliation': 'Department of Medicine, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Brian L', 'Initials': 'BL', 'LastName': 'McNabb', 'Affiliation': 'Department of Medicine, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Anne L', 'Initials': 'AL', 'LastName': 'Schafer', 'Affiliation': 'Department of Medicine, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Felicia', 'Initials': 'F', 'LastName': 'Cosman', 'Affiliation': 'Department of Clinical Medicine, Columbia University, New York, NY, USA.'}, {'ForeName': 'Dennis M', 'Initials': 'DM', 'LastName': 'Black', 'Affiliation': 'Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Eastell', 'Affiliation': 'Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.'}]",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,['10.1002/jbmr.3654'] 483,30890552,"Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma.","PURPOSE IL6 is important for the growth and survival of myeloma cells. This study evaluated blocking IL6 with siltuximab to delay the transition from high-risk smoldering multiple myeloma (SMM) to multiple myeloma. PATIENTS AND METHODS In a randomized, double-blind, placebo-controlled, multicenter study, 85 patients with high-risk SMM were randomized to 15 mg/kg siltuximab (43 patients) or placebo (42 patients). The primary endpoint was 1-year progression-free survival (PFS) rate, based on IMWG CRAB criteria. Secondary endpoints included progressive disease indicator rate, PFS, and safety. RESULTS Median age was 62 years (range: 21-84); 57% were male and 87% had a baseline Eastern Cooperative Oncology Group score of 0. The 1-year PFS rate was 84.5% (siltuximab) and 74.4% (placebo). After a median follow-up of 29.2 months, 32.6% of PFS events occurred with siltuximab and 42.9% with placebo. Median PFS was not reached with siltuximab but was 23.5 months with placebo [HR 0.50 (95% confidence interval, 0.24-1.04); P = 0.0597]. The safety profile of siltuximab was comparable with placebo. Most adverse events in the siltuximab group were grade 2/3; the most common serious adverse events were infections/infestations, and renal/urinary disorders. Mortality was low in both groups (3 deaths in the siltuximab group and 4 in the placebo group). CONCLUSIONS Although this study did not meet the prespecified protocol hypothesis criteria, data suggest that siltuximab may delay the progression of high-risk SMM.",2019,"Mortality was low in both groups (3 deaths in the siltuximab group and 4 in the placebo group). ","['Median age was 62 years (range: 21-84); 57% were male and 87% had a baseline Eastern Cooperative Oncology Group score of 0', '85 patients with high-risk SMM', 'High-Risk Smoldering Multiple Myeloma']","['Placebo', 'Siltuximab', 'placebo']","['Mortality', '1-year PFS rate', 'progressive disease indicator rate, PFS, and safety', 'safety profile of siltuximab', '1-year progression-free survival (PFS) rate, based on IMWG CRAB criteria', 'PFS events', 'Median PFS']","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C1531608', 'cui_str': 'Asymptomatic Multiple Myeloma'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1609931', 'cui_str': 'siltuximab'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1609931', 'cui_str': 'siltuximab'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0030759', 'cui_str': 'Pubic louse infestation'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",85.0,0.653868,"Mortality was low in both groups (3 deaths in the siltuximab group and 4 in the placebo group). ","[{'ForeName': 'Timothy A', 'Initials': 'TA', 'LastName': 'Brighton', 'Affiliation': 'Prince of Wales Hospital, Randwick, New South Wales, Australia.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Khot', 'Affiliation': 'Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.'}, {'ForeName': 'Simon J', 'Initials': 'SJ', 'LastName': 'Harrison', 'Affiliation': 'Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Ghez', 'Affiliation': ""Service d'Hématologie, Département de Médecine, Gustave Roussy Cancer Campus, Villejuif, France.""}, {'ForeName': 'Brendan M', 'Initials': 'BM', 'LastName': 'Weiss', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Andres', 'Initials': 'A', 'LastName': 'Kirsch', 'Affiliation': 'Medizinisches Versorgungszentrum Onkologischer Schwerpunkt am Oskar-Helene-Heim, Berlin, Germany.'}, {'ForeName': 'Hila', 'Initials': 'H', 'LastName': 'Magen', 'Affiliation': 'Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Mercedes', 'Initials': 'M', 'LastName': 'Gironella', 'Affiliation': ""Haematology Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Oriol', 'Affiliation': ""Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.""}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Streetly', 'Affiliation': ""Clinical Haematology, Guys Hospital, Guys and St. Thomas' NHS Foundation Trust, London, United Kingdom.""}, {'ForeName': 'Britte', 'Initials': 'B', 'LastName': 'Kranenburg', 'Affiliation': 'Janssen Biologics BV, Leiden, Netherlands.'}, {'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Qin', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, Pennsylvania.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Bandekar', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, Pennsylvania.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hu', 'Affiliation': 'Janssen Research & Development, LLC, Raritan, New Jersey.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Guilfoyle', 'Affiliation': 'Janssen Research & Development, LLC, Raritan, New Jersey.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Qi', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, Pennsylvania.'}, {'ForeName': 'Sepideh', 'Initials': 'S', 'LastName': 'Nemat', 'Affiliation': 'Janssen-Cilag Ltd, High Wycombe, United Kingdom.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Goldschmidt', 'Affiliation': 'University Hospital, Internal Medicine V and National Center for Tumor Diseases Heidelberg, Heidelberg, Germany. Hartmut.Goldschmidt@med.uni-heidelberg.de.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-18-3470'] 484,31821698,HIV self-testing intervention experiences and kit usability: results from a qualitative study among men who have sex with men in the SELPHI (Self-Testing Public Health Intervention) randomized controlled trial in England and Wales.,"OBJECTIVES SELPHI (HIV Self-Testing Public Health Intervention) is the largest randomized controlled trial (RCT) of HIV self-testing (HIVST) in a high-income setting to date, and has recruited 10 000 men who have sex with men (cis- and transgender) and transgender women who have sex with men. This qualitative substudy aimed to explore how those utilizing self-tests experience HIVST and the implications for further intervention development and scale-up. This is the first qualitative study in Europe investigating experiences of HIVST among intervention users, and the first globally examining the experience of using blood-based HIVST. METHODS Thirty-seven cisgender MSM SELPHI participants from across England and Wales were purposively recruited to the substudy, in which semi-structured interviews were used to explore testing history, HIVST experiences and intervention preferences. Interviews were audio-recorded, transcribed and analysed through a framework analysis. RESULTS Men accessed the intervention because HIVST reduced barriers related to convenience, stigma and privacy concerns. Emotional responses had direct links to acceptability. Supportive intervention components increased engagement with testing and addressed supportive concerns. HIVST facilitated more frequent testing, with the potential to reduce sexually transmitted infection (STI) screening frequency. Substudy participants with an HIV-positive result (n = 2) linked to care promptly and reported very high acceptability. Minor adverse outcomes (n = 2; relationship discord and fainting) did not reduce acceptability. Ease of use difficulties were with the lancet and the test processing stage. CONCLUSIONS Intervention components shaped acceptability, particularly in relation to overcoming a perceived lack of support. The intervention was broadly acceptable and usable; participants expressed an unexpected degree of enthusiasm for HIVST, including those with HIV-positive results and individuals with minor adverse outcomes.",2020,Minor adverse outcomes (n = 2; relationship discord and fainting) did not reduce acceptability.,"['participants from across England and Wales', 'Substudy participants with an HIV-positive result (n\xa0=\xa02) linked to care promptly and reported very high acceptability', 'Thirty-seven cisgender', '000 men who have sex with men (cis- and transgender) and transgender women who have sex with men', 'men who have sex with men in the\xa0SELPHI\xa0(Self-Testing Public Health Intervention) randomized controlled trial in England and Wales']","['HIVST', 'HIV self-testing intervention experiences and kit usability', 'MSM SELPHI', 'HIV self-testing (HIVST']",[],"[{'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0019699', 'cui_str': 'HTLV-III Seroconversion'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0442804', 'cui_str': 'Very high (qualifier value)'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C4319569', 'cui_str': '37 (qualifier value)'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0558141', 'cui_str': 'Transsexual (finding)'}, {'cui': 'C1319927', 'cui_str': 'Male-to-female transsexual'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C1690540', 'cui_str': 'Kit'}]",[],,0.0475477,Minor adverse outcomes (n = 2; relationship discord and fainting) did not reduce acceptability.,"[{'ForeName': 'T C', 'Initials': 'TC', 'LastName': 'Witzel', 'Affiliation': 'Department of Public Health, Environments and Society, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Bourne', 'Affiliation': 'Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne, VIC, Australia.'}, {'ForeName': 'F M', 'Initials': 'FM', 'LastName': 'Burns', 'Affiliation': 'Institute for Global Health, University College London, London, UK.'}, {'ForeName': 'A J', 'Initials': 'AJ', 'LastName': 'Rodger', 'Affiliation': 'Institute for Global Health, University College London, London, UK.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'McCabe', 'Affiliation': 'Medical Research Council Clinical Trials Unit, University College London, London, UK.'}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Gabriel', 'Affiliation': 'Medical Research Council Clinical Trials Unit, University College London, London, UK.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gafos', 'Affiliation': 'Medical Research Council Clinical Trials Unit, University College London, London, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Ward', 'Affiliation': 'Medical Research Council Clinical Trials Unit, University College London, London, UK.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Collaco-Moraes', 'Affiliation': 'Medical Research Council Clinical Trials Unit, University College London, London, UK.'}, {'ForeName': 'D T', 'Initials': 'DT', 'LastName': 'Dunn', 'Affiliation': 'Medical Research Council Clinical Trials Unit, University College London, London, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Speakman', 'Affiliation': 'Institute for Global Health, University College London, London, UK.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Bonell', 'Affiliation': 'Department of Public Health, Environments and Society, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Pebody', 'Affiliation': 'NAM Aidsmap, London, UK.'}, {'ForeName': 'F C', 'Initials': 'FC', 'LastName': 'Lampe', 'Affiliation': 'Institute for Global Health, University College London, London, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Harbottle', 'Affiliation': 'SH:24, London, UK.'}, {'ForeName': 'A N', 'Initials': 'AN', 'LastName': 'Phillips', 'Affiliation': 'Institute for Global Health, University College London, London, UK.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'McCormack', 'Affiliation': 'Medical Research Council Clinical Trials Unit, University College London, London, UK.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Weatherburn', 'Affiliation': 'Department of Public Health, Environments and Society, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.'}]",HIV medicine,['10.1111/hiv.12818'] 485,30987577,Neutrophil Gelatinase-associated Lipocalin as a Marker of Postoperative Acute Kidney Injury Following Cardiac Surgery in Patients with Preoperative Kidney Impairment.,"INTRODUCTION Acute kidney injury (AKI) is a serious complication of cardiac surgery. The current 'gold standard' for determining AKI is change in serum creatinine and urine output, however, this change occurs relatively late after the actual injury occurs. Identification of new biomarkers that detect early AKI is required. Recently, new biomarkers, such as the NephroCheck® Test and AKIRisk have also been tested and found to be good indicators of AKI. Neutrophil gelatinase-associated lipocalin (NGAL) has shown promise in paediatric patients but has displayed varied results in adult populations, particularly post cardiac surgery. The aim of this study was to assess the value of urinary NGAL as a biomarker of AKI in patients with pre-existing renal impairment (eGFR >15ml/min to eGFR<60ml/min). METHODS A post-hoc analysis of urinary NGAL concentrations from 125 patients with pre-existing kidney impairment, who participated in a randomised trial of haemofiltration during cardiac surgery, was undertaken. Urinary NGAL was measured using ELISA at baseline, post-operatively and 24 and 48 hours after surgery, and serum creatinine was measured pre and postoperatively and then at 24, 48, 72 and 96 hours as routine patient care. NGAL concentrations were compared in patients with and without AKI determined by changes in serum creatinine concentrations. A Kaplan-Meier plot compared survival for patients with or without AKI and a Cox proportional hazards analysis was performed to identify factors with the greatest influence on survival. RESULTS Following surgery, 43% of patients developed AKI (based on KDIGO definition). Baseline urinary NGAL was not found to be significantly different between patients that did and did not develop AKI. Urinary NGAL concentration was increased in all patients following surgery, regardless of whether they developed AKI and was also significant between groups at 24 (p=0.003) and 48 hours (p<0.0001). Urinary NGAL concentrations at 48 hours correlated with serum creatinine concentrations at 48 hours (r=0.477, p<0.0001), 72 hours (r=0.488, p<0.0001) and 96 hours (r=0.463, p<0.0001). Urinary NGAL at 48 hours after surgery strongly predicted AKI (AUC=0.76; P=0.0001). A Kaplan- Meier plot showed that patients with postoperative AKI had a significantly lower 7-year survival compared with those without AKI. Postoperative urinary NGAL at 48 hours >156ng/mL also strongly predicted 7-year survival. However, additive EuroSCORE, age, current smoking and post-operative antibiotics usage were distinctly significantly more predictive of 7-year survival as compared with postoperative urinary NGAL at 48 hours >156ng/mL. CONCLUSIONS Our study demonstrated that postoperative urinary NGAL levels at 48 hours postsurgery strongly predicts the onset or severity of postoperative AKI based on KDIGO classification in patients with preoperative kidney impairment and were also strongly related to 7-year survival.",2019,Urinary NGAL at 48 hours after surgery strongly predicted AKI (AUC=0.76; P=0.0001).,"['125 patients with pre-existing kidney impairment, who participated in a randomised trial of haemofiltration during cardiac surgery, was undertaken', 'patients with pre-existing renal impairment (eGFR >15ml/min to eGFR<60ml/min', 'paediatric patients', 'patients with pre-operative kidney impairment']","['Neutrophil gelatinase-associated lipocalin (NGAL', 'Neutrophil gelatinase-associated lipocalin']","['Urinary NGAL concentration', 'serum creatinine concentrations', 'Postoperative urinary NGAL', 'year survival', 'postoperative urinary NGAL levels', 'Baseline urinary NGAL', 'Urinary NGAL concentrations', 'NGAL concentrations', '7-year survival', 'Urinary NGAL']","[{'cui': 'C4319551', 'cui_str': 'One hundred and twenty-five'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0019014', 'cui_str': 'Hemofiltration'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C0041666', 'cui_str': 'Undertaking'}, {'cui': 'C1565489', 'cui_str': 'Renal Insufficiency'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}]","[{'cui': 'C0027950', 'cui_str': 'Polymorphonuclear Leukocytes'}, {'cui': 'C0206528', 'cui_str': 'Gelatinases'}, {'cui': 'C1956074', 'cui_str': 'Lipocalins'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",125.0,0.247377,Urinary NGAL at 48 hours after surgery strongly predicted AKI (AUC=0.76; P=0.0001).,"[{'ForeName': 'N', 'Initials': 'N', 'LastName': 'Tidbury', 'Affiliation': 'Liverpool Heart & Chest Hospital NHS Foundation Trust, University of Liverpool, Liverpool L14 3PE, United Kingdom.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Browning', 'Affiliation': 'Liverpool Heart & Chest Hospital NHS Foundation Trust, University of Liverpool, Liverpool L14 3PE, United Kingdom.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Shaw', 'Affiliation': 'Liverpool Heart & Chest Hospital NHS Foundation Trust, University of Liverpool, Liverpool L14 3PE, United Kingdom.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Morgan', 'Affiliation': 'Liverpool Heart & Chest Hospital NHS Foundation Trust, University of Liverpool, Liverpool L14 3PE, United Kingdom.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Kemp', 'Affiliation': 'Liverpool Heart & Chest Hospital NHS Foundation Trust, University of Liverpool, Liverpool L14 3PE, United Kingdom.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Matata', 'Affiliation': 'Liverpool Heart & Chest Hospital NHS Foundation Trust, University of Liverpool, Liverpool L14 3PE, United Kingdom.'}]",Cardiovascular & hematological disorders drug targets,['10.2174/1871529X19666190415115106'] 486,32170451,"Energy-dense, low-volume paediatric oral nutritional supplements improve total nutrient intake and increase growth in paediatric patients requiring nutritional support: results of a randomised controlled pilot trial.","Children with or at risk of faltering growth require nutritional support and are often prescribed oral nutritional supplements (ONS). This randomised controlled trial investigated the effects of energy-dense paediatric ONS (2.4 kcal/ml, 125 ml: cONS) versus 1.5 kcal/ml, 200 ml ONS (sONS) in community-based paediatric patients requiring oral nutritional support. Fifty-one patients (mean age 5.8 years (SD 3)) with faltering growth and/or requiring ONS to meet their nutritional requirements were randomised to cONS (n = 27) or sONS (n = 24) for 28 days. Nutrient intake, growth, ONS compliance and acceptability, appetite and gastro-intestinal tolerance were assessed. Use of the cONS resulted in significantly greater mean total daily energy (+ 531 kcal/day), protein (+ 10.1 g/day) and key micronutrient intakes compared with the sONS group at day 28 and over time, due to high ONS compliance (81% of patients ≥ 75%), maintained intake from diet alone and improved appetite in the cONS group, compared with the sONS group. Although growth increased in both intervention groups, results were significant in the cONS group (weight (p = 0.007), height (p < 0.001) and height z-score (p = 0.006)).Conclusions: This study shows that use of energy-dense (2.4 kcal/ml) low-volume paediatric-specific ONS leads to improved nutrient intakes, growth and appetite in paediatric patients requiring oral nutrition support compared with standard energy density ONS.Trial registration: The trial is registered at clinicaltrials.gov , identification number NCT02419599. What is Known: • Faltering growth is the failure of children to achieve adequate growth at a normal rate for their age and requires nutritional support, including the use of oral nutritional supplements (ONS). • Energy-dense, low-volume ONS have benefits over standard ONS in adults. What is New: • This is the first RCT to investigate the effects of energy-dense, low-volume ONS (2.4 kcal/ml, 125 ml) in children with faltering growth, showing significant improvements in total nutrient intake and increased growth. • Energy-dense, low-volume ONS can play a key role in the management of faltering growth.",2020,"Although growth increased in both intervention groups, results were significant in the cONS group (weight (p = 0.007), height (p < 0.001) and height z-score (p = 0.006)).Conclusions: This study shows that use of energy-dense (2.4 kcal/ml) low-volume paediatric-specific ONS leads to improved nutrient intakes, growth and appetite in paediatric patients requiring oral nutrition support compared with standard energy density ONS.Trial registration: The trial is registered at clinicaltrials.gov, identification number NCT02419599.What is Known:• Faltering growth is the failure of children to achieve adequate growth at a normal rate for their age and requires nutritional support, including the use of oral nutritional supplements (ONS).• Energy-dense, low-volume ONS have benefits over standard ONS in adults.","['paediatric patients requiring nutritional support', 'Fifty-one patients (mean age 5.8\xa0years (SD 3)) with faltering growth and/or requiring ONS to meet their nutritional requirements', 'Children with or at risk of faltering growth require nutritional support and are often prescribed oral nutritional supplements (ONS', 'community-based paediatric patients requiring oral nutritional support', 'paediatric patients requiring']","['oral nutrition support', 'cONS', '200\xa0ml ONS (sONS', 'sONS', 'energy-dense paediatric ONS']","['mean total daily energy', 'total nutrient intake', 'appetite', 'key micronutrient intakes', 'Nutrient intake, growth, ONS compliance and acceptability, appetite and gastro-intestinal tolerance', 'nutrient intakes, growth and appetite']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0242739', 'cui_str': 'Nutritional Support'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517796', 'cui_str': '5.8'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0028719', 'cui_str': 'Nutrition Requirements'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0242295', 'cui_str': 'Dietary Supplementations'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0846669', 'cui_str': 'Oral nutritional support (regime/therapy)'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0037683', 'cui_str': 'Sons'}, {'cui': 'C0439794', 'cui_str': 'Dense (qualifier value)'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0021853', 'cui_str': 'Intestines'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}]",,0.0502259,"Although growth increased in both intervention groups, results were significant in the cONS group (weight (p = 0.007), height (p < 0.001) and height z-score (p = 0.006)).Conclusions: This study shows that use of energy-dense (2.4 kcal/ml) low-volume paediatric-specific ONS leads to improved nutrient intakes, growth and appetite in paediatric patients requiring oral nutrition support compared with standard energy density ONS.Trial registration: The trial is registered at clinicaltrials.gov, identification number NCT02419599.What is Known:• Faltering growth is the failure of children to achieve adequate growth at a normal rate for their age and requires nutritional support, including the use of oral nutritional supplements (ONS).• Energy-dense, low-volume ONS have benefits over standard ONS in adults.","[{'ForeName': 'Gary P', 'Initials': 'GP', 'LastName': 'Hubbard', 'Affiliation': 'Nutricia Ltd, Medical Affairs, Trowbridge, UK.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Fry', 'Affiliation': 'Nutricia Ltd, Medical Affairs, Trowbridge, UK.'}, {'ForeName': 'Katy', 'Initials': 'K', 'LastName': 'Sorensen', 'Affiliation': 'Nutricia Ltd, Medical Affairs, Trowbridge, UK.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Casewell', 'Affiliation': ""Department of Nutrition and Dietetics, Ashford and St Peter's Hospitals NHS Foundation Trust, Chertsey, UK.""}, {'ForeName': 'Lydia', 'Initials': 'L', 'LastName': 'Collins', 'Affiliation': 'Department of Nutrition and Dietetics, Cumbria Partnership NHS Foundation Trust, Whitehaven, UK.'}, {'ForeName': 'Annaruby', 'Initials': 'A', 'LastName': 'Cunjamalay', 'Affiliation': 'Department of Nutrition and Dietetics, Hampshire Hospitals NHS Foundation Trust, Winchester, UK.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Simpson', 'Affiliation': 'Department of Nutrition and Dietetics, Hampshire Hospitals NHS Foundation Trust, Winchester, UK.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Wall', 'Affiliation': 'Department of Nutrition and Dietetics, East Lancashire Hospitals NHS Trust, Blackburn, UK.'}, {'ForeName': 'Elmarie', 'Initials': 'E', 'LastName': 'Van Wyk', 'Affiliation': 'Department of Nutrition and Dietetics, Great Western Hospitals NHS Foundation Trust, Swindon, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Ward', 'Affiliation': 'Department of Nutrition and Dietetics, Cwm Taf University Health Board, Prince Charles Hospital, Merthyr Tydfil, UK.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Hallowes', 'Affiliation': ""Department of Nutrition and Dietetics, Guy's and St Thomas' NHS Trust, London, UK.""}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Duggan', 'Affiliation': ""Department of Nutrition and Dietetics, Guy's and St Thomas' NHS Trust, London, UK.""}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Robison', 'Affiliation': 'Department of Nutrition and Dietetics, Lewisham and Greenwich NHS Trust, London, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Gane', 'Affiliation': 'Department of Nutrition and Dietetics, Western Sussex Hospitals NHS Foundation Trust, Chichester, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Pope', 'Affiliation': 'Department of Nutrition and Dietetics, Western Sussex Hospitals NHS Foundation Trust, Chichester, UK.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Clark', 'Affiliation': 'Department of Nutrition and Dietetics, Airedale NHS Foundation Trust, Keighley, UK.'}, {'ForeName': 'Rebecca J', 'Initials': 'RJ', 'LastName': 'Stratton', 'Affiliation': 'Nutricia Ltd, Medical Affairs, Trowbridge, UK. rjs@soton.ac.uk.'}]",European journal of pediatrics,['10.1007/s00431-020-03620-9'] 487,32175985,Transversus abdominis plane block versus quadratus lumborum block type 2 for analgesia in renal transplantation: A randomised trial.,"BACKGROUND Several studies have shown an analgesic efficacy of a transversus abdominis plane block (TAPB) in reducing opioid requirements during and after cadaveric renal transplantation surgery, but the effect of a quadratus lumborum block (QLB) in this type of surgery is unclear. OBJECTIVES The main objective of this prospective, randomised, double-centre clinical study was to compare the analgesic efficacy of a one-sided lateral approach TAPB with a unilateral QLB type 2 in cadaveric renal transplantation surgery. DESIGN Randomised, single-blinded trial. SETTING Two University-affiliated tertiary care hospitals between April 2016 and May 2017. PATIENTS A total of 101 patients aged more than 18 years, scheduled for cadaveric renal transplantation. INTERVENTIONS On receiving ethical board approval and individual informed consent, consecutive patients were allocated randomly to receive either an ultrasound-guided single-shot lateral TAPB or an ultrasound-guided single-shot QLB type 2 on the surgical side using 20 ml of bupivacaine 0.25% with adrenaline after a standardised induction of general anaesthesia. All patients on surgical completion and recovery from general anaesthesia were admitted to the postanaesthesia care unit for 24 h. They received standardised intravenous patient-controlled analgesia with fentanyl, and their pain scores were noted at regular intervals. MAIN OUTCOME MEASURES The primary endpoint was total cumulative fentanyl dose used per kg body mass in the first 24 h after surgery. Secondary outcomes were the need to start a continuous infusion of fentanyl in addition to patient-controlled analgesia boluses during the stay in post-anaesthesia care unit, postoperative pain severity measured using a numerical rating scale, patient satisfaction with analgesic treatment, evidence of postoperative nausea and vomiting, pruritus and sedation level. RESULTS The 49 patients allocated to the QLB type 2 group used significantly less fentanyl per kg in the first 24 h after surgery than the 52 patients who received a TAPB (median [IQR] 4.2 [2.3 to 8.0] μg kg versus 6.7 [3.5 to 10.7] μg kg, P = 0.042). No statistically significant differences were noted in the secondary endpoints within the study, including the frequency of adverse effects of opioids. CONCLUSION The reduction of fentanyl consumption in the first 24 h after renal transplantation with no difference in pain intensity and patient satisfaction shows a beneficial effect of one-sided QLB type 2 over a one-sided TAPB in regards to postoperative analgesia. However, the reduction in opioid consumption did not affect the frequency of opioid-related adverse effects. TRIAL REGISTRATION ClinicalTrials.gov ID: NCT02783586.",2020,The reduction of fentanyl consumption in the first 24 h after renal transplantation with no difference in pain intensity and patient satisfaction shows a beneficial effect of one-sided QLB type 2 over a one-sided TAPB in regards to postoperative analgesia.,"['All patients on surgical completion and recovery from general anaesthesia were admitted to the postanaesthesia care unit for 24\u200ah', 'renal transplantation', 'cadaveric renal transplantation surgery', 'Two University-affiliated tertiary care hospitals between April 2016 and May 2017', 'A total of 101 patients aged more than 18 years, scheduled for cadaveric renal transplantation']","['standardised intravenous patient-controlled analgesia with fentanyl', 'TAPB', 'transversus abdominis plane block (TAPB', 'ultrasound-guided single-shot lateral TAPB or an ultrasound-guided single-shot QLB type 2 on the surgical side using 20\u200aml of bupivacaine 0.25% with adrenaline', 'Transversus abdominis plane block versus quadratus lumborum block type 2 for analgesia']","['reduction of fentanyl consumption', 'need to start a continuous infusion of fentanyl in addition to patient-controlled analgesia boluses during the stay in post-anaesthesia care unit, postoperative pain severity measured using a numerical rating scale, patient satisfaction with analgesic treatment, evidence of postoperative nausea and vomiting, pruritus and sedation level', 'pain scores', 'analgesic efficacy', 'opioid consumption', 'frequency of adverse effects of opioids', 'total cumulative fentanyl dose used per kg body mass', 'pain intensity and patient satisfaction']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0002915', 'cui_str': 'General Anesthesia'}, {'cui': 'C0262723', 'cui_str': 'Postanesthesia care (regime/therapy)'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0022671', 'cui_str': 'Grafting, Kidney'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0337954', 'cui_str': 'Tertiary care hospital (environment)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0078944', 'cui_str': 'Patient-Controlled Analgesia'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0167914', 'cui_str': 'TAPB-H'}, {'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0205093', 'cui_str': 'Lateral (qualifier value)'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C4517443', 'cui_str': '0.25 (qualifier value)'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}]","[{'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0444889', 'cui_str': 'Continuous infusion (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0078944', 'cui_str': 'Patient-Controlled Analgesia'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0222045'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332120', 'cui_str': 'Evidence of (contextual qualifier) (qualifier value)'}, {'cui': 'C0520909', 'cui_str': 'PONV'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",101.0,0.286278,The reduction of fentanyl consumption in the first 24 h after renal transplantation with no difference in pain intensity and patient satisfaction shows a beneficial effect of one-sided QLB type 2 over a one-sided TAPB in regards to postoperative analgesia.,"[{'ForeName': 'Marcin', 'Initials': 'M', 'LastName': 'Kolacz', 'Affiliation': 'From the I Department of Anesthesiology and Intensive Care, Medical University of Warsaw, Warsaw (MK, MJ, KZ, BB, JT) and Department of Anesthesiology and Intensive Care, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland (MM, MW-D, DO).'}, {'ForeName': 'Marcin', 'Initials': 'M', 'LastName': 'Mieszkowski', 'Affiliation': ''}, {'ForeName': 'Marek', 'Initials': 'M', 'LastName': 'Janiak', 'Affiliation': ''}, {'ForeName': 'Krzysztof', 'Initials': 'K', 'LastName': 'Zagorski', 'Affiliation': ''}, {'ForeName': 'Beata', 'Initials': 'B', 'LastName': 'Byszewska', 'Affiliation': ''}, {'ForeName': 'Malgorzata', 'Initials': 'M', 'LastName': 'Weryk-Dysko', 'Affiliation': ''}, {'ForeName': 'Dariusz', 'Initials': 'D', 'LastName': 'Onichimowski', 'Affiliation': ''}, {'ForeName': 'Janusz', 'Initials': 'J', 'LastName': 'Trzebicki', 'Affiliation': ''}]",European journal of anaesthesiology,['10.1097/EJA.0000000000001193'] 488,31762400,Psychosocial mechanisms of a behavioral treatment for urinary incontinence of prostate cancer survivors.,"Purpose : We examined underlying psychosocial processes of a behavioral treatment for urinary incontinence (UI) of prostate cancer survivors. Design : Secondary analysis of data collected from a clinical trial. Sample : Two hundred forty-four prostate cancer survivors who participated in a clinical trial of behavioral intervention to UI as intervention or control subjects. Methods: The participants had a 3-month behavioral intervention or usual care and were followed up for an additional 3 months. They were assessed at baseline, 3, and 6 months. Latent growth curve models were performed to examine trajectories of each study variable and relationships among the variables. Findings : Increasing self-efficacy and social support were significantly and independently associated with more reduction of urinary leakage frequency over time. Implications for psychosocial oncology : Providing problem-solving skills and social support, including peer support, are essential for empowering patients to reduce UI.",2020,Increasing self-efficacy and social support were significantly and independently associated with more reduction of urinary leakage frequency over time.,"['Two hundred forty-four prostate cancer survivors who participated in a clinical trial of behavioral intervention to UI as intervention or control subjects', 'urinary incontinence of prostate cancer survivors', 'Findings ', 'Sample ', 'urinary incontinence (UI) of prostate cancer survivors', 'psychosocial oncology ']",['behavioral treatment'],"['urinary leakage frequency', 'Increasing self-efficacy and social support']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0376358', 'cui_str': 'Prostate Cancer'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0042024', 'cui_str': 'Urinary Incontinence'}, {'cui': 'C2607943', 'cui_str': 'findings'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C4505070', 'cui_str': 'Psychooncology'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0015376', 'cui_str': 'Extravasation (morphologic abnormality)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0037438'}]",,0.0278332,Increasing self-efficacy and social support were significantly and independently associated with more reduction of urinary leakage frequency over time.,"[{'ForeName': 'Amy Y', 'Initials': 'AY', 'LastName': 'Zhang', 'Affiliation': 'Case Western Reserve University School of Nursing, Cleveland, Ohio, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Burant', 'Affiliation': 'Case Western Reserve University School of Nursing, Cleveland, Ohio, USA.'}, {'ForeName': 'Alex Z', 'Initials': 'AZ', 'LastName': 'Fu', 'Affiliation': 'Cancer Prevention and Control Program, Georgetown University Medical Center, Washington, DC, USA.'}, {'ForeName': 'Gerald', 'Initials': 'G', 'LastName': 'Strauss', 'Affiliation': 'Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.'}, {'ForeName': 'Donald R', 'Initials': 'DR', 'LastName': 'Bodner', 'Affiliation': 'Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.'}, {'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'Ponsky', 'Affiliation': 'Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.'}]",Journal of psychosocial oncology,['10.1080/07347332.2019.1678547'] 489,32049831,Comparison of sugammadex and pyridostigmine bromide for reversal of rocuronium-induced neuromuscular blockade in short-term pediatric surgery: A prospective randomized study.,"BACKGROUND Sugammadex reverses rocuronium-induced neuromuscular blockade quickly and effectively. This study compared efficacy of sugammadex and pyridostigmine for reversal of rocuronium-induced light block or minimal block in children scheduled for elective entropion surgery. METHODS A prospective randomized study was conducted on 60 pediatric patients aged 1 to 11 years and scheduled for entropion surgery under sevoflurane anesthesia. Neuromuscular blockade was achieved by administration of 0.6 mg/kg rocuronium and assessed using train-of-four (TOF) ulnar nerve stimulation. Patients were randomly assigned to 2 groups receiving sugammadex 2 mg/kg or pyridostigmine 0.2 mg/kg plus glycopyrrolate 0.01 mg/kg. Primary outcomes were time from reversal agents administration to TOF ratio 0.9 and time from reversal agent administration to TOF ratio 1.0. Time from TOF ratio 0.9 to extubation, time from TOF ratio 1.0 to extubation, and postoperative adverse events were also recorded. RESULTS There were no substantial differences in demographic variables. Time from reversal agents administration to TOF ratio 0.9 and time from reversal agents to TOF ratio 1.0 were significantly faster in sugammadex group: 1.30 ± 0.84 versus 3.53 ± 2.73 minutes (P < .001) and 2.75 ± 1.00 versus 5.73 ± 2.83 minutes (P < .001). Extubation time was shorter in sugammadex group. Incidence of skin rash, nausea, vomiting, and postoperative residual neuromuscular blockade (airway obstruction) was not statistically different between groups. Incidence of patients agitation in recovery room was lower in sugammadex group. CONCLUSION Sugammadex provided more rapid reversal of rocuronium-induced neuromuscular blockade in pediatric patients undergoing surgery lasting 30 to 60 minutes than did pyridostigmine plus glycopyrrolate, with no differences in incidence of adverse events between groups.",2020,"Incidence of skin rash, nausea, vomiting, and postoperative residual neuromuscular blockade (airway obstruction) was not statistically different between groups.","['short-term pediatric surgery', 'children scheduled for elective entropion surgery', '60 pediatric patients aged 1 to 11 years and scheduled for entropion surgery under sevoflurane anesthesia', 'pediatric patients undergoing surgery lasting 30 to 60\u200aminutes than did']","['sugammadex and pyridostigmine bromide', 'sugammadex 2\u200amg/kg or pyridostigmine 0.2\u200amg/kg plus glycopyrrolate 0.01\u200amg/kg', 'sugammadex and pyridostigmine', 'rocuronium-induced light block', 'pyridostigmine plus glycopyrrolate']","['Incidence of patients agitation in recovery room', 'Extubation time', 'Incidence of skin rash, nausea, vomiting, and postoperative residual neuromuscular blockade (airway obstruction', 'Time from TOF ratio 0.9 to extubation, time from TOF ratio 1.0 to extubation, and postoperative adverse events', 'adverse events', 'Neuromuscular blockade', 'time from reversal agents administration to TOF ratio 0.9 and time from reversal agent administration to TOF ratio 1.0']","[{'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0279077', 'cui_str': 'Pediatric surgery'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0014390', 'cui_str': 'Entropion'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C3853333', 'cui_str': 'Sixty minutes'}]","[{'cui': 'C1700695', 'cui_str': 'Sugammadex'}, {'cui': 'C0034262', 'cui_str': 'Pyridostigmine Bromide'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0034261', 'cui_str': 'Pyridostigmine'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0017970', 'cui_str': 'Glycopyrrolate'}, {'cui': 'C4517393', 'cui_str': '0.01'}, {'cui': 'C0209337', 'cui_str': 'Rocuronium'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated (finding)'}, {'cui': 'C0034871', 'cui_str': 'Hospital Recovery Rooms'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0015230', 'cui_str': 'Skin Rash'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C4042763', 'cui_str': 'Postoperative Residual Curarization'}, {'cui': 'C0001883', 'cui_str': 'Airway Obstruction'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C4068881', 'cui_str': 'Zero point nine'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0235062', 'cui_str': 'Neuromuscular Block'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}]",60.0,0.323714,"Incidence of skin rash, nausea, vomiting, and postoperative residual neuromuscular blockade (airway obstruction) was not statistically different between groups.","[{'ForeName': 'Jihyun', 'Initials': 'J', 'LastName': 'An', 'Affiliation': ''}, {'ForeName': 'Ji-Hyang', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'Eunju', 'Initials': 'E', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Kyeongyoon', 'Initials': 'K', 'LastName': 'Woo', 'Affiliation': ''}, {'ForeName': 'Hyunkyum', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Donghwan', 'Initials': 'D', 'LastName': 'Lee', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000019130'] 490,32162741,The efficacy of topical red clover oil on knee osteoarthritis: A pilot prospective randomized triple-blind placebo-controlled clinical trial.,"A triple-blind placebo-controlled clinical trial was performed to evaluate the efficacy of topical red clover oil (containing standardized red clover extract in olive oil) on knee osteoarthritis (OA). A total of 80 patients, 50-80 years old, with primary knee OA were randomly allocated to two groups. The study group used topical red clover oil and the control group used olive oil for 4 weeks (20 drops twice a day). Both groups adhered to nonpharmacological American College of Rheumatology recommendations and took meloxicam tablets during the study (0-8 weeks), and were followed up from Week 4 to 8. Efficacy measures were evaluated using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale and Visual Analogue Scale (VAS). At baseline, both groups were homogeneous regarding demographic characteristics. In addition, they were asked about the side effects during the intervention. The results showed that the WOMAC score and its subscales of pain and stiffness and function scores and VAS significantly increased over time in both groups (p < .001). The study group showed a significant increase regarding pain (p = .001), function (p = .010), VAS (p < .001), and the WOMAC total score (p = .018). No serious drug side effects were observed. Red clover oil may have positive effects on symptoms of knee OA and can be considered as a complementary treatment.",2020,"The study group showed a significant increase regarding pain (p = .001), function (p = .010), VAS (p < .001), and the WOMAC total score (p = .018).","['knee osteoarthritis (OA', '80 patients, 50-80 years old, with primary knee OA', 'knee osteoarthritis']","['meloxicam tablets', 'topical red clover oil', 'topical red clover oil and the control group used olive oil', 'placebo', 'topical red clover oil (containing standardized red clover extract in olive oil']","['serious drug side effects', 'WOMAC score and its subscales of pain and stiffness and function scores and VAS', 'WOMAC total score', 'pain', 'Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale and Visual Analogue Scale (VAS', 'VAS']","[{'cui': 'C0409959', 'cui_str': 'Osteoarthritis, Knee'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}]","[{'cui': 'C0083381', 'cui_str': 'meloxicam'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0330783', 'cui_str': 'Clover, Red'}, {'cui': 'C0028908', 'cui_str': 'Oils'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0939844', 'cui_str': 'Red Clover Preparation'}]","[{'cui': 'C0041755', 'cui_str': 'Drug Side Effects'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3472647', 'cui_str': 'WOMAC index'}, {'cui': 'C0222045'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",80.0,0.0465415,"The study group showed a significant increase regarding pain (p = .001), function (p = .010), VAS (p < .001), and the WOMAC total score (p = .018).","[{'ForeName': 'Masoud', 'Initials': 'M', 'LastName': 'Mokhtari', 'Affiliation': 'Department of Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Yousefi', 'Affiliation': 'Department of Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mojtaba M', 'Initials': 'MM', 'LastName': 'Bazaz', 'Affiliation': 'Department of Community Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Rakhshandeh', 'Affiliation': 'Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Hamideh', 'Initials': 'H', 'LastName': 'Vahid', 'Affiliation': 'Department of Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Amir S', 'Initials': 'AS', 'LastName': 'Ariamanesh', 'Affiliation': 'Department of Orthopedics, Mashhad University of Medical Sciences, Mashhad, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.6650'] 491,31788985,"Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.","OBJECTIVE To report the efficacy and safety of blonanserin in patients with schizophrenia compared with risperidone in a Japanese multicenter, randomized, double-blind study based on post hoc sensitivity analysis in addition to the previous results reported by Miura and discuss the current approaches for schizophrenia treatment. METHODS Of 302 patients randomized, 156 received blonanserin (8-24 mg/d) and 145 received risperidone (2-6 mg/d) for 8 weeks. Efficacy variables included the Positive and Negative Syndrome Scale (PANSS) total score for the primary outcome, PANSS subscale, Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression-Improvement (CGI-I) for secondary outcomes. Safety variables included treatment-emergent adverse events, Drug Induced Extrapyramidal Symptoms Scale scores, laboratory data, vital signs, electrocardiogram, etc RESULTS: Blonanserin was not inferior to risperidone in the change in PANSS total score at a non-inferior margin of -7 (intergroup difference, -0.46; 95% CI, -4.40 to 3.48). Post hoc analyses wholly supported the primary result. No major difference was found in the changes in BPRS scores and the improvement rate on CGI-I between the drugs. The incidence of adverse events was similar in the two drugs. Blonanserin was associated with a lower risk of prolactin increase, weight gain, and orthostatic hypotension compared with risperidone. However, blonanserin was associated with a higher incidence of akathisia and excitability compared with risperidone. Most of the adverse events were mild to moderate in severity with no specific events of predominant high severity in the both drugs. CONCLUSIONS Blonanserin exerted the similar efficacy to risperidone in both positive and negative symptoms in schizophrenia with a lower risk of prolactin increase, weight gain, and orthostatic hypotension compared with risperidone. Blonanserin will serve as a favorable treatment option for schizophrenia in daily clinical practice.",2020,No major difference was found in the changes in BPRS scores and the improvement rate on CGI-I between the drugs.,"['patients with schizophrenia compared with', 'Of 302 patients randomized, 156 received', 'Japanese patients with schizophrenia']","['blonanserin', 'risperidone', 'Blonanserin']","['adverse events', 'Positive and Negative Syndrome Scale (PANSS) total score for the primary outcome, PANSS subscale, Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression-Improvement (CGI-I) for secondary outcomes', 'BPRS scores', 'efficacy and safety', 'akathisia and excitability', 'PANSS total score', 'lower risk of prolactin increase, weight gain, and orthostatic hypotension', 'treatment-emergent adverse events, Drug Induced Extrapyramidal Symptoms Scale scores, laboratory data, vital signs, electrocardiogram, etc RESULTS: Blonanserin', 'weight gain, and orthostatic hypotension']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C1556094', 'cui_str': 'Japanese'}]","[{'cui': 'C0287983', 'cui_str': 'blonanserin'}, {'cui': 'C0073393', 'cui_str': 'Risperidone'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0451383', 'cui_str': 'Positive and negative syndrome scale (assessment scale)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0029941', 'cui_str': 'Overall and Gorham Brief Psychiatric Rating Scale'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0392156', 'cui_str': 'Akathisia'}, {'cui': 'C0235169', 'cui_str': 'Excitability (finding)'}, {'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}, {'cui': 'C0553731', 'cui_str': 'PRL increased'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0020651', 'cui_str': 'Hypotension, Postural'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0458082', 'cui_str': 'Drug-induced (qualifier value)'}, {'cui': 'C0234133', 'cui_str': 'Extrapyramidal sign (finding)'}, {'cui': 'C0222045'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0518766'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0287983', 'cui_str': 'blonanserin'}]",302.0,0.159181,No major difference was found in the changes in BPRS scores and the improvement rate on CGI-I between the drugs.,"[{'ForeName': 'Philip D', 'Initials': 'PD', 'LastName': 'Harvey', 'Affiliation': 'Leonard M. Miller Professor of Psychiatry and Behavioral Sciences, University of Miami, Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Nakamura', 'Affiliation': 'Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd, Tokyo, Japan.'}, {'ForeName': 'Sadanori', 'Initials': 'S', 'LastName': 'Miura', 'Affiliation': 'Kitasato University School of Medicine, Kanagawa, Japan.'}]",Neuropsychopharmacology reports,['10.1002/npr2.12089'] 492,31542245,"Genetic susceptibility, lifestyle intervention and glycemic changes among women with prior gestational diabetes.","AIMS Women with prior gestational diabetes mellitus (GDM) or high genetic susceptibility are prone to development of type 2 diabetes. We examined whether a lifestyle intervention modified the genetic effect on changes in glycemic markers among women with prior GDM. RESEARCH DESIGN AND METHODS This study included 560 women with prior GDM from a randomized controlled trial, the Tianjin Gestational Diabetes Mellitus Prevention Program, who were assigned into an intervention arm (improved physical activity and healthy dietary intakes) or a control arm. We assessed associations of GDM related genetic variants in/near the CDKAL1 (rs7754840) and MTNR1B (rs10830962) genes with changes in fasting levels of glucose and insulin, β-cell function (HOMA-B) and insulin resistance (HOMA-IR) at 1 year and 2 years after the baseline. RESULTS We found significant interactions between CDKAL1 variant rs7754840 and lifestyle intervention on changes in fasting insulin and HOMA-IR at 1 year (P for interactions = 0.008 and 0.006, respectively). The GDM-increasing C allele was associated with a 0.07-unit greater increase in fasting insulin (P = 0.048) and HOMA-IR (P = 0.045) in the control group, while opposite-directional associations were observed in the intervention group; women with the C allele seemed to decrease more in these glycemic markers than the non-C-carriers (both P ≤ 0.06). The interactions between the CDKAL1 genetic variant and lifestyle intervention on changes in fasting insulin (P = 0.035) and HOMA-IR (P = 0.024) remained significant over the 2-year period, even though the effects of lifestyle intervention were attenuated at 2-year. The MTNR1B variant rs10830962 did not show interaction with lifestyle intervention on changes in the glycemic markers. CONCLUSIONS Healthy lifestyle intervention may be beneficial for women with the GDM predisposing CDKAL1 genetic variant in improvement of insulin resistance. TRIAL REGISTRATION NUMBER ClinicalTrials.gov NCT01554358. URL OF REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT01554358.",2020,"The MTNR1B variant rs10830962 did not show interaction with lifestyle intervention on changes in the glycemic markers. ","['560 women with prior GDM from a randomized controlled trial, the Tianjin Gestational Diabetes Mellitus Prevention Program', 'women with prior gestational diabetes', 'women with prior GDM', 'Women with prior gestational diabetes mellitus (GDM']","['intervention arm (improved physical activity and healthy dietary intakes) or a control arm', 'lifestyle intervention']","['fasting levels of glucose and insulin, β-cell function (HOMA-B) and insulin resistance (HOMA-IR', 'glycemic markers', 'fasting insulin', 'fasting insulin and HOMA-IR', 'HOMA-IR']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0085207', 'cui_str': 'Diabetes, Pregnancy-Induced'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0439671', 'cui_str': 'Gestational (qualifier value)'}]","[{'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}]",560.0,0.0338199,"The MTNR1B variant rs10830962 did not show interaction with lifestyle intervention on changes in the glycemic markers. ","[{'ForeName': 'Zhaoxia', 'Initials': 'Z', 'LastName': 'Liang', 'Affiliation': ""Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA; Department of Obstetrical, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.""}, {'ForeName': 'Leishen', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': ""Tianjin Women's and Children's Health Center, Tianjin, China.""}, {'ForeName': 'Huikun', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': ""Tianjin Women's and Children's Health Center, Tianjin, China.""}, {'ForeName': 'Yuhang', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA; Department of Public Health Laboratory Sciences, West China School of Public Health, Sichuan University, Chengdu, Sichuan Province, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Zhou', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.'}, {'ForeName': 'Yoriko', 'Initials': 'Y', 'LastName': 'Heianza', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.'}, {'ForeName': 'Junhong', 'Initials': 'J', 'LastName': 'Leng', 'Affiliation': ""Tianjin Women's and Children's Health Center, Tianjin, China.""}, {'ForeName': 'Weiqin', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': ""Tianjin Women's and Children's Health Center, Tianjin, China.""}, {'ForeName': 'Xilin', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Department of Epidemiology, School of Public Health, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Shen', 'Affiliation': ""Pennington Biomedical Research Center, Baton Rouge, LA, USA; Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, Shanghai, China.""}, {'ForeName': 'Ru', 'Initials': 'R', 'LastName': 'Gao', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA, USA.'}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Hu', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA, USA.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Qi', 'Affiliation': ""Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: lqi1@tulane.edu.""}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.08.032'] 493,30859478,Comparing the accuracy and speed of four data-checking methods.,"Double entry locates and corrects more data-entry errors than does visual checking or reading the data out loud with a partner. However, many researchers do not use double entry, because it is substantially slower. Therefore, in this study we examined the speed and accuracy of solo read aloud, which has never before been examined and might be faster than double entry. To compare these four methods, we deliberately introduced errors while entering 20 data sheets and then asked 412 randomly assigned undergraduates to locate and correct these errors. Double entry was significantly and substantially more accurate than the other data-checking methods. However, the double-entry participants still made some errors. Close examination revealed that whenever double-entry participants made errors, they made the two sets of entries match, sometimes by introducing new errors into the dataset. This suggests that double entry can be improved by focusing attention on making entries match the original data sheets (rather than each other), perhaps by using a new person for mismatch correction. Solo read aloud was faster than double entry, but not as accurate. Double entry remains the gold standard in data-checking methods. However, solo read aloud was often substantially more accurate than partner read aloud and was more accurate than visual checking for one type of data. Therefore, when double entry is not possible, we recommend that researchers use solo read aloud or visual checking.",2020,Double entry was significantly and substantially more accurate than the other data-checking methods.,[],[],[],[],[],[],412.0,0.293886,Double entry was significantly and substantially more accurate than the other data-checking methods.,"[{'ForeName': 'Kimberly A', 'Initials': 'KA', 'LastName': 'Barchard', 'Affiliation': 'University of Nevada Las Vegas, Las Vegas, NV, USA. kim.barchard@unlv.edu.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Freeman', 'Affiliation': 'University of Nevada Las Vegas, Las Vegas, NV, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Ochoa', 'Affiliation': 'University of Nevada Las Vegas, Las Vegas, NV, USA.'}, {'ForeName': 'Amber K', 'Initials': 'AK', 'LastName': 'Stephens', 'Affiliation': 'University of Nevada Las Vegas, Las Vegas, NV, USA.'}]",Behavior research methods,['10.3758/s13428-019-01207-3'] 494,31605923,A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.,"BACKGROUND Single inhaler triple therapies providing an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting β 2 -agonist (ICS/LAMA/LABAs) are an emerging treatment option for chronic obstructive pulmonary disease (COPD). Nevertheless, questions remain regarding the optimal patient population for triple therapy as well as the benefit:risk ratio of ICS treatment. METHODS ETHOS is an ongoing, randomized, double-blind, multicenter, parallel-group, 52-week study in symptomatic patients with moderate-to-very severe COPD and a history of exacerbation(s) in the previous year. Two doses of single inhaler triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI 320/18/9.6 μg and 160/18/9.6 μg) will be compared to glycopyrrolate/formoterol fumarate (GFF) MDI 18/9.6 μg and budesonide/formoterol fumarate (BFF) MDI 320/9.6 μg, all formulated using co-suspension delivery technology. Outcomes include the rate of moderate/severe (primary endpoint) and severe COPD exacerbations, symptoms, quality of life, and all-cause mortality. Sub-studies will assess lung function and cardiovascular safety. STUDY POPULATION From June 2015-July 2018, 16,044 patients were screened and 8572 were randomized. Preliminary baseline demographics show that 55.9% of patients had experienced ≥2 moderate/severe exacerbations in the previous year, 79.1% were receiving an ICS-containing treatment at study entry, and 59.9% had blood eosinophil counts ≥150 cells/mm 3 . CONCLUSIONS ETHOS will provide data on exacerbations, patient-reported outcomes, mortality, and safety in 8572 patients with moderate-to-very severe COPD receiving triple and dual fixed-dose combinations. For the first time, ICS/LAMA/LABA triple therapy with two different doses of ICS will be compared to dual ICS/LABA and LAMA/LABA therapies. CLINICAL TRIAL REGISTRATION NUMBER NCT02465567.",2019,"Outcomes include the rate of moderate/severe (primary endpoint) and severe COPD exacerbations, symptoms, quality of life, and all-cause mortality.","['From June 2015-July 2018, 16,044 patients were screened and 8572 were randomized', 'symptomatic patients with moderate-to-very severe COPD and a history of exacerbation(s) in the previous year', 'chronic obstructive pulmonary disease (COPD', 'moderate-to-very severe COPD', '8572 patients with moderate-to-very severe COPD receiving triple and dual fixed-dose combinations']","['glycopyrrolate/formoterol fumarate (GFF) MDI 18/9.6\u202fμg and budesonide/formoterol fumarate', 'ICS', 'budesonide/glycopyrrolate/formoterol fumarate']","['severe exacerbations', 'blood eosinophil counts', 'lung function and cardiovascular safety', 'rate of moderate/severe (primary endpoint) and severe COPD exacerbations, symptoms, quality of life, and all-cause mortality']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C3641272', 'cui_str': 'Extreme'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]","[{'cui': 'C0017970', 'cui_str': 'Glycopyrrolate'}, {'cui': 'C0771469', 'cui_str': 'formoterol fumarate'}, {'cui': 'C0993596', 'cui_str': 'Metered Dose Inhaler'}, {'cui': 'C1276807', 'cui_str': 'Budesonide / formoterol'}, {'cui': 'C0220833', 'cui_str': 'fumarate'}, {'cui': 'C0054201', 'cui_str': 'Budesonide'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil, segmented (cell)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0740304', 'cui_str': 'COPD exacerbation'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034380'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",,0.47029,"Outcomes include the rate of moderate/severe (primary endpoint) and severe COPD exacerbations, symptoms, quality of life, and all-cause mortality.","[{'ForeName': 'Klaus F', 'Initials': 'KF', 'LastName': 'Rabe', 'Affiliation': 'LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany. Electronic address: k.f.rabe@lungenclinic.de.'}, {'ForeName': 'Fernando J', 'Initials': 'FJ', 'LastName': 'Martinez', 'Affiliation': 'Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Gary T', 'Initials': 'GT', 'LastName': 'Ferguson', 'Affiliation': 'Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'National Clinical Research Centre for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Dave', 'Initials': 'D', 'LastName': 'Singh', 'Affiliation': 'Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester, UK.'}, {'ForeName': 'Jadwiga A', 'Initials': 'JA', 'LastName': 'Wedzicha', 'Affiliation': 'Respiratory Division, National Heart and Lung Institute, London, UK.'}, {'ForeName': 'Roopa', 'Initials': 'R', 'LastName': 'Trivedi', 'Affiliation': 'AstraZeneca, Durham, NC, USA.'}, {'ForeName': 'Earl', 'Initials': 'E', 'LastName': 'St Rose', 'Affiliation': 'AstraZeneca, Morristown, NJ, USA.'}, {'ForeName': 'Shaila', 'Initials': 'S', 'LastName': 'Ballal', 'Affiliation': 'AstraZeneca, Morristown, NJ, USA.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'McLaren', 'Affiliation': 'AstraZeneca, Gaithersburg, MD, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Darken', 'Affiliation': 'AstraZeneca, Morristown, NJ, USA.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Reisner', 'Affiliation': 'AstraZeneca, Morristown, NJ, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Dorinsky', 'Affiliation': 'AstraZeneca, Durham, NC, USA.'}]",Respiratory medicine,['10.1016/j.rmed.2019.08.010'] 495,31608930,Ghrelin Does Not Directly Stimulate Secretion of Glucagon-like Peptide-1.,"CONTEXT The gastrointestinal hormone ghrelin stimulates growth hormone secretion and appetite, but recent studies indicate that ghrelin also stimulates the secretion of the appetite-inhibiting and insulinotropic hormone glucagon-like peptide-1 (GLP-1). OBJECTIVE To investigate the putative effect of ghrelin on GLP-1 secretion in vivo and in vitro. SUBJECTS AND METHODS A randomized placebo-controlled crossover study was performed in eight hypopituitary subjects. Ghrelin or saline was infused intravenously (1 pmol/min × kg) after collection of baseline sample (0 min), and blood was subsequently collected at time 30, 60, 90, and 120 minutes. Mouse small intestine was perfused (n = 6) and GLP-1 output from perfused mouse small intestine was investigated in response to vascular ghrelin administration in the presence and absence of a simultaneous luminal glucose stimulus. Ghrelin receptor expression was quantified in human (n = 11) and mouse L-cells (n = 3) by RNA sequencing and RT-qPCR, respectively. RESULTS Ghrelin did not affect GLP-1 secretion in humans (area under the curve [AUC; 0-120 min]: ghrelin infusion = 1.37 ± 0.05 min × nmol vs. saline infusion = 1.40 ± 0.06 min × nmol [P = 0.63]), but induced peripheral insulin resistance. Likewise, ghrelin did not stimulate GLP-1 secretion from the perfused mouse small intestine model (mean outputs during baseline/ghrelin infusion = 19.3 ± 1.6/25.5 ± 2.0 fmol/min, n = 6, P = 0.16), whereas glucose-dependent insulinotropic polypeptide administration, used as a positive control, doubled GLP-1 secretion (P < 0.001). Intraluminal glucose increased GLP-1 secretion by 4-fold (P < 0.001), which was not potentiated by ghrelin. Finally, gene expression of the ghrelin receptor was undetectable in mouse L-cells and marginal in human L-cells. CONCLUSIONS Ghrelin does not interact directly with the L-cell and does not directly affect GLP-1 secretion.",2020,Intra-luminal glucose increased GLP-1 secretion by 4-fold (P<0.001) which was not potentiated by ghrelin.,['eight hypopituitary subjects'],"['placebo', 'Ghrelin or saline']","['Ghrelin receptor expression', 'GLP-1 secretion', 'peripheral insulin resistance']",[],"[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0911014', 'cui_str': 'Ghrelin (substance)'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}]","[{'cui': 'C0391690', 'cui_str': 'GHSR Protein'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-Like Peptide 1'}, {'cui': 'C0036537', 'cui_str': 'Secretions'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}]",,0.090868,Intra-luminal glucose increased GLP-1 secretion by 4-fold (P<0.001) which was not potentiated by ghrelin.,"[{'ForeName': 'Sara Lind', 'Initials': 'SL', 'LastName': 'Jepsen', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Esben Thyssen', 'Initials': 'ET', 'LastName': 'Vestergaard', 'Affiliation': 'Medical Research Laboratories Aarhus University, Aarhus N, Denmark.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Larraufie', 'Affiliation': ""Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, UK.""}, {'ForeName': 'Fiona Mary', 'Initials': 'FM', 'LastName': 'Gribble', 'Affiliation': ""Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, UK.""}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Reimann', 'Affiliation': ""Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, UK.""}, {'ForeName': 'Jens Otto Lunde', 'Initials': 'JOL', 'LastName': 'Jørgensen', 'Affiliation': 'Medical Research Laboratories Aarhus University, Aarhus N, Denmark.'}, {'ForeName': 'Jens Juul', 'Initials': 'JJ', 'LastName': 'Holst', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Rune Ehrenreich', 'Initials': 'RE', 'LastName': 'Kuhre', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgz046'] 496,32199095,"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.","BACKGROUND Pharmacological prevention against relapses in patients with neuromyelitis optica spectrum disorder (NMOSD) is developing rapidly. We aimed to investigate the safety and efficacy of rituximab, an anti-CD20 monoclonal antibody, against relapses in patients with NMOSD. METHODS We did a multicentre, randomised, double-blind, placebo-controlled clinical trial at eight hospitals in Japan. Patients aged 16-80 years with NMOSD who were seropositive for aquaporin 4 (AQP4) antibody, were taking 5-30 mg/day oral steroids, and had an Expanded Disability Status Scale (EDSS) score of 7·0 or less were eligible for the study. Individuals taking any other immunosuppressants were excluded. Participants were randomly allocated (1:1) either rituximab or placebo by a computer-aided dynamic random allocation system. The doses of concomitant steroid (converted to equivalent doses of prednisolone) and relapses in previous 2 years were set as stratification factors. Participants and those assessing outcomes were unaware of group assignments. Rituximab (375 mg/m 2 ) was administered intravenously every week for 4 weeks, then 6-month interval dosing was done (1000 mg every 2 weeks, at 24 weeks and 48 weeks after randomisation). A matching placebo was administered intravenously. Concomitant oral prednisolone was gradually reduced to 2-5 mg/day, according to the protocol. The primary outcome was time to first relapse within 72 weeks. Relapses were defined as patient-reported symptoms or any new signs consistent with CNS lesions and attributable objective changes in MRI or visual evoked potential. The primary analysis was done in the full analysis set (all randomly assigned patients) and safety analyses were done in the safety analysis set (all patients who received at least one infusion of assigned treatment). The primary analysis was by intention-to-treat principles. This trial is registered with the UMIN clinical trial registry, UMIN000013453. FINDINGS Between May 10, 2014, and Aug 15, 2017, 38 participants were recruited and randomly allocated either rituximab (n=19) or placebo (n=19). Three (16%) patients assigned rituximab discontinued the study and were analysed as censored cases. Seven (37%) relapses occurred in patients allocated placebo and none were recorded in patients assigned rituximab (group difference 36·8%, 95% CI 12·3-65·5; log-rank p=0·0058). Eight serious adverse events were recorded, four events in three (16%) patients assigned rituximab (lumbar compression fracture and infection around nail of right foot [n=1], diplopia [n=1], and uterine cancer [n=1]) and four events in two (11%) people allocated to placebo (exacerbation of glaucoma and bleeding in the right eye chamber after surgery [n=1], and visual impairment and asymptomatic white matter brain lesion on MRI [n=1]); all patients recovered. No deaths were reported. INTERPRETATION Rituximab prevented relapses for 72 weeks in patients with NMOSD who were AQP4 antibody-positive. This study is limited by its small sample size and inclusion of participants with mild disease activity. However, our results suggest that rituximab could be useful maintenance therapy for individuals with NMOSD who are AQP4 antibody-positive. FUNDING Japanese Ministry of Health, Labour and Welfare, Japan Agency for Medical Research and Development, and Zenyaku Kogyo.",2020,"No deaths were reported. ","['neuromyelitis optica spectrum disorders (RIN-1 study', 'Patients aged 16-80 years with NMOSD who were seropositive for aquaporin 4 (AQP4) antibody, were taking 5-30 mg/day oral steroids, and had an Expanded Disability Status Scale (EDSS) score of 7·0 or less were eligible for the study', 'patients with neuromyelitis optica spectrum disorder (NMOSD', 'individuals with NMOSD who are AQP4 antibody-positive', 'eight hospitals in Japan', 'Between May 10, 2014, and Aug 15, 2017, 38 participants', 'participants with mild disease activity', 'patients with NMOSD']","['concomitant steroid', 'Rituximab', 'rituximab or placebo', 'placebo', 'rituximab', 'prednisolone', 'Concomitant oral prednisolone']","['Safety and efficacy', 'Relapses', 'safety and efficacy', 'time to first relapse']","[{'cui': 'C0027873', 'cui_str': ""Devic's Neuromyelitis Optica""}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0521143', 'cui_str': 'Seropositive (qualifier value)'}, {'cui': 'C2919772', 'cui_str': 'Aquaporin-4 antibody'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0439422', 'cui_str': 'mg/day'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale (assessment scale)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0741132', 'cui_str': 'Antibody test positive'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]","[{'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",38.0,0.757995,"No deaths were reported. ","[{'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Tahara', 'Affiliation': 'Clinical Research Centre and Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto, Japan. Electronic address: tahara.masayuki.ne@mail.hosp.go.jp.'}, {'ForeName': 'Tomoko', 'Initials': 'T', 'LastName': 'Oeda', 'Affiliation': 'Clinical Research Centre and Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto, Japan.'}, {'ForeName': 'Kazumasa', 'Initials': 'K', 'LastName': 'Okada', 'Affiliation': 'Department of Neurology, University of Occupational and Environmental Health, Kitakyushu, Japan.'}, {'ForeName': 'Takao', 'Initials': 'T', 'LastName': 'Kiriyama', 'Affiliation': 'Department of Neurology, Nara Medical University School of Medicine, Nara, Japan.'}, {'ForeName': 'Kazuhide', 'Initials': 'K', 'LastName': 'Ochi', 'Affiliation': 'Department of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'Hirofumi', 'Initials': 'H', 'LastName': 'Maruyama', 'Affiliation': 'Department of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'Hikoaki', 'Initials': 'H', 'LastName': 'Fukaura', 'Affiliation': 'Department of Neurology, Saitama Medical University, Kawagoe, Japan.'}, {'ForeName': 'Kyoichi', 'Initials': 'K', 'LastName': 'Nomura', 'Affiliation': 'Department of Neurology, Saitama Medical University, Kawagoe, Japan.'}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Shimizu', 'Affiliation': ""Department of Neurology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.""}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Mori', 'Affiliation': 'Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.'}, {'ForeName': 'Ichiro', 'Initials': 'I', 'LastName': 'Nakashima', 'Affiliation': 'Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.'}, {'ForeName': 'Tatsuro', 'Initials': 'T', 'LastName': 'Misu', 'Affiliation': 'Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Umemura', 'Affiliation': 'Clinical Research Centre and Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto, Japan.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Yamamoto', 'Affiliation': 'Clinical Research Centre and Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto, Japan.'}, {'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Sawada', 'Affiliation': 'Clinical Research Centre and Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto, Japan.'}]",The Lancet. Neurology,['10.1016/S1474-4422(20)30066-1'] 497,31934845,Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT.,"BACKGROUND People with multiple sclerosis have problems with memory and attention. The effectiveness of cognitive rehabilitation has not been established. OBJECTIVES The objectives were to assess the clinical effectiveness and cost-effectiveness of a cognitive rehabilitation programme for people with multiple sclerosis. DESIGN This was a multicentre, randomised controlled trial in which participants were randomised in a ratio of 6 : 5 to receive cognitive rehabilitation plus usual care or usual care alone. Participants were assessed at 6 and 12 months after randomisation. SETTING The trial was set in hospital neurology clinics and community services. PARTICIPANTS Participants were people with multiple sclerosis who had cognitive problems, were aged 18-69 years, could travel to attend group sessions and gave informed consent. INTERVENTION The intervention was a group cognitive rehabilitation programme delivered weekly by an assistant psychologist to between four and six participants for 10 weeks. MAIN OUTCOME MEASURES The primary outcome was the Multiple Sclerosis Impact Scale - Psychological subscale at 12 months. Secondary outcomes included results from the Everyday Memory Questionnaire, the 30-Item General Health Questionnaire, the EuroQol-5 Dimensions, five-level version and a service use questionnaire from participants, and the Everyday Memory Questionnaire - relative version and the Modified Carer Strain Index from a relative or friend of the participant. RESULTS Of the 449 participants randomised, 245 were allocated to cognitive rehabilitation (intervention group) and 204 were allocated to usual care (control group). Of these, 214 in the intervention group and 173 in the control group were included in the primary analysis. There was no clinically important difference in the Multiple Sclerosis Impact Scale - Psychological subscale score between the two groups at the 12-month follow-up (adjusted difference in means -0.6, 95% confidence interval -1.5 to 0.3; p  = 0.20). There were no important differences between the groups in relation to cognitive abilities, fatigue, employment, or carer strain at follow-up. However, there were differences, although small, between the groups in the Multiple Sclerosis Impact Scale - Psychological subscale score at 6 months (adjusted difference in means -0.9, 95% confidence interval -1.7 to -0.1; p  = 0.03) and in everyday memory on the Everyday Memory Questionnaire as reported by participants at 6 (adjusted difference in means -5.3, 95% confidence interval -8.7 to -1.9) and 12 months (adjusted difference in means -4.4, 95% confidence interval -7.8 to -0.9) and by relatives at 6 (adjusted difference in means -5.4, 95% confidence interval -9.1 to -1.7) and 12 months (adjusted difference in means -5.5, 95% confidence interval -9.6 to -1.5) in favour of the cognitive rehabilitation group. There were also differences in mood on the 30-Item General Health Questionnaire at 6 (adjusted difference in means -3.4, 95% confidence interval -5.9 to -0.8) and 12 months (adjusted difference in means -3.4, 95% confidence interval -6.2 to -0.6) in favour of the cognitive rehabilitation group. A qualitative analysis indicated perceived benefits of the intervention. There was no evidence of a difference in costs (adjusted difference in means -£574.93, 95% confidence interval -£1878.93 to £729.07) or quality-adjusted life-year gain (adjusted difference in means 0.00, 95% confidence interval -0.02 to 0.02). No safety concerns were raised and no deaths were reported. LIMITATIONS The trial included a sample of participants who had relatively severe cognitive problems in daily life. The trial was not powered to perform subgroup analyses. Participants could not be blinded to treatment allocation. CONCLUSIONS This cognitive rehabilitation programme had no long-term benefits on quality of life for people with multiple sclerosis. FUTURE WORK Future research should evaluate the selection of those who may benefit from cognitive rehabilitation. TRIAL REGISTRATION Current Controlled Trials ISRCTN09697576. FUNDING This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 24, No. 4. See the National Institute for Health Research Journals Library website for further project information.",2020,"There was no clinically important difference in the Multiple Sclerosis Impact Scale - Psychological subscale score between the two groups at the 12-month follow-up (adjusted difference in means -0.6, 95% confidence interval -1.5 to 0.3; p  = 0.20).","['participants were randomised in a ratio of 6\u2009:\u20095 to receive', 'hospital neurology clinics and community services', 'people with multiple sclerosis', '449 participants randomised', 'participants who had relatively severe cognitive problems in daily life', 'Participants were people with multiple sclerosis who had cognitive problems, were aged 18-69 years, could travel to attend group sessions and gave informed consent', 'People with multiple sclerosis']","['CRAMMS RCT', 'cognitive rehabilitation programme', 'cognitive rehabilitation', 'cognitive rehabilitation (intervention group) and 204 were allocated to usual care (control group', 'cognitive rehabilitation plus usual care or usual care alone', 'cognitive rehabilitation programme delivered weekly by an assistant psychologist to between four and six participants for 10 weeks']","['clinical effectiveness and cost-effectiveness', 'everyday memory on the Everyday Memory Questionnaire', 'costs', 'quality of life', 'Everyday Memory Questionnaire, the 30-Item General Health Questionnaire, the EuroQol-5 Dimensions, five-level version and a service use questionnaire from participants, and the Everyday Memory Questionnaire - relative version and the Modified Carer Strain Index from a relative or friend of the participant', 'quality-adjusted life-year gain', 'cognitive abilities, fatigue, employment, or carer strain', '30-Item General Health Questionnaire', 'Multiple Sclerosis Impact Scale - Psychological subscale', 'Multiple Sclerosis Impact Scale - Psychological subscale score']","[{'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C3814532', 'cui_str': 'Neurology clinic (environment)'}, {'cui': 'C0009482', 'cui_str': 'Services, Community'}, {'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0040802', 'cui_str': 'Travel (event)'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}]","[{'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0557564', 'cui_str': 'Assistant psychologist (occupation)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C3850123', 'cui_str': 'Treatment Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0588977', 'cui_str': 'Everyday memory questionnaire (assessment scale)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0034380'}, {'cui': 'C4273686', 'cui_str': 'GHQ-30 (General Health Questionnaire 30)'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1305660', 'cui_str': 'Carer (occupation)'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0079382', 'cui_str': 'Friend (person)'}, {'cui': 'C0080071', 'cui_str': 'QALY'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0459443', 'cui_str': 'Subscale score (qualifier value)'}]",449.0,0.205448,"There was no clinically important difference in the Multiple Sclerosis Impact Scale - Psychological subscale score between the two groups at the 12-month follow-up (adjusted difference in means -0.6, 95% confidence interval -1.5 to 0.3; p  = 0.20).","[{'ForeName': 'Nadina B', 'Initials': 'NB', 'LastName': 'Lincoln', 'Affiliation': 'Division of Rehabilitation and Ageing, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Lucy E', 'Initials': 'LE', 'LastName': 'Bradshaw', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Cris S', 'Initials': 'CS', 'LastName': 'Constantinescu', 'Affiliation': 'Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Day', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Avril Er', 'Initials': 'AE', 'LastName': 'Drummond', 'Affiliation': 'School of Health Sciences, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Fitzsimmons', 'Affiliation': 'Swansea Centre for Health Economics, Swansea University, Swansea, UK.'}, {'ForeName': 'Shaun', 'Initials': 'S', 'LastName': 'Harris', 'Affiliation': 'Swansea Centre for Health Economics, Swansea University, Swansea, UK.'}, {'ForeName': 'Alan A', 'Initials': 'AA', 'LastName': 'Montgomery', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Roshan', 'Initials': 'R', 'LastName': 'das Nair', 'Affiliation': 'Institute of Mental Health, Nottingham, UK.'}]","Health technology assessment (Winchester, England)",['10.3310/hta24040'] 498,32037737,Examination of the influence of cedar fragrance on cognitive function and behavioral and psychological symptoms of dementia in Alzheimer type dementia.,"We examined whether symptoms of dementia are improved by olfactory nerve stimulation in Alzheimer type dementia patients. First, a stick-type olfactory identification ability test was performed in patients with Alzheimer type dementia, to select patients without olfactory dysfunctions. Then, these patients were randomly assigned into the intervention (n = 19) and the control groups (n = 17). To evaluate the effects of olfactory nerve stimulation, we exposed the intervention group to a disinfecting ethanol with added aroma extracts from ceder and the control group to the ethanol without the added aroma extracts. Each group underwent the intervention for 8 weeks, cognitive and behavioral functions were evaluated before and after treatments using the Neuropsychiatric Inventory (NPI), the Japanese version of Zarit Caregiver Burden interview (J-ZBI), and the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog). A significant improvement was observed in the NPI score and J-ZBI in the intervention group compared to the control group at 4 and 8 weeks. On the other hand, there was no significant difference in the score of ADAS-cog. Exposure to cedar fragrance improved behavioral and psychological symptoms of dementia (BPSD) in Alzheimer type dementia and may reduce the burden of nursing care. In addition to its effectiveness, the procedure is simple and minimally invasive and would be a valuable non-pharmaceutical treatment.",2020,A significant improvement was observed in the NPI score and J-ZBI in the intervention group compared to the control group at 4 and 8 weeks.,"['Alzheimer type dementia patients', 'dementia in Alzheimer type dementia', 'patients with Alzheimer type dementia, to select patients without olfactory dysfunctions']","['cedar fragrance', 'disinfecting ethanol with added aroma extracts from ceder and the control group to the ethanol without the added aroma extracts']","['cognitive function and behavioral and psychological symptoms', 'behavioral and psychological symptoms of dementia (BPSD', ""Neuropsychiatric Inventory (NPI), the Japanese version of Zarit Caregiver Burden interview (J-ZBI), and the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog"", 'NPI score and J-ZBI']","[{'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0439826', 'cui_str': 'Olfactory (qualifier value)'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}]","[{'cui': 'C2987717', 'cui_str': 'Aroma'}, {'cui': 'C0202304', 'cui_str': 'Alcohol measurement (procedure)'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0233397', 'cui_str': 'Psychological symptom'}, {'cui': 'C4285807', 'cui_str': 'Neuropsychiatric symptoms'}, {'cui': 'C1868717', 'cui_str': 'BPSD'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0450989', 'cui_str': ""Alzheimer's disease assessment scale (assessment scale)""}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",19.0,0.0454354,A significant improvement was observed in the NPI score and J-ZBI in the intervention group compared to the control group at 4 and 8 weeks.,"[{'ForeName': 'Yuya', 'Initials': 'Y', 'LastName': 'Takahashi', 'Affiliation': 'Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.'}, {'ForeName': 'Sho', 'Initials': 'S', 'LastName': 'Shindo', 'Affiliation': 'Akita Research Institute of Food and Brewing, Akita, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Kanbayashi', 'Affiliation': 'Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Takeshima', 'Affiliation': 'Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.'}, {'ForeName': 'Aya', 'Initials': 'A', 'LastName': 'Imanishi', 'Affiliation': 'Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Mishima', 'Affiliation': 'Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.'}]",Neuropsychopharmacology reports,['10.1002/npr2.12096'] 499,31492103,Glucose-insulin-potassium improves left ventricular performances after aortic valve replacement: a secondary analysis of a randomized controlled trial.,"BACKGROUND Patients with left ventricular (LV) hypertrophy may suffer ischemia-reperfusion injuries at the time of cardiac surgery with impairment in left ventricular function. Using transesophageal echocardiography (TEE), we evaluated the impact of glucose-insulin potassium (GIK) on LV performances in patients undergoing valve replacement for aortic stenosis. METHODS In this secondary analysis of a double-blind randomized trial, moderate-to-high risk patients were assigned to receive GIK (20 IU insulin with 10 mEq KCL in 50 ml glucose 40%) or saline over 60 min upon anesthetic induction. The primary outcomes were the early changes in 2-and 3-dimensional left ventricular ejection fraction (2D and 3D-LVEF), peak global longitudinal strain (PGLS) and transmitral flow propagation velocity (Vp). RESULTS At the end of GIK infusion, LV-FAC and 2D- and 3D-LVEF were unchanged whereas Vp (mean difference [MD + 7.9%, 95% confidence interval [CI] 3.2 to 12.5%; P <  0.001) increased compared with baseline values. After Placebo infusion, there was a decrease in LV-FAC (MD -2.9%, 95%CI - 4.8 to - 1.0%), 2D-LVEF (MD -2.0%, 95%CI - 2.8 to - 1.3%, 3D-LVEF (MD -3.0%, 95%CI - 4.0 to - 2.0%) and Vp (MD - 4.5 cm/s, 95%CI - 5.6 to - 3.3 cm/s). After cardiopulmonary bypass, GIK pretreatment was associated with preserved 2D and 3D-LVEF (+ 0.4%, 95% 95%CI - 0.8 to 1.7% and + 0.4%, 95%CI - 1.3 to 2.0%), and PGLS (- 0.9, 95%CI - 1.6 to - 0.2) as well as higher Vp (+ 5.1 cm/s, 95%CI 2.9 to 7.3), compared with baseline. In contrast, in the Placebo group, 2D-LVEF (- 2.2%, 95%CI - 3.4 to - 1.0), 3D-LVEF (- 6.0%, 95%CI - 7.8 to - 4.2), and Vp (- 7.6 cm/s, 95%CI - 9.4 to - 5.9), all decreased after bypass. CONCLUSIONS Administration of GIK before aortic cross-clamping resulted in better preservation of systolic and diastolic ventricular function in patients with LV hypertrophy undergoing aortic valve replacement. TRIAL REGISTRATION ClinicalTrials.gov: NCT00788242 , registered on November 10, 2008.",2019,"At the end of GIK infusion, LV-FAC and 2D- and 3D-LVEF were unchanged whereas Vp (mean difference [MD + 7.9%, 95% confidence interval [CI] 3.2 to 12.5%; P <  0.001) increased compared with baseline values.","['aortic valve replacement', 'patients with LV hypertrophy undergoing aortic valve replacement', 'patients undergoing valve replacement for aortic stenosis', 'moderate-to-high risk patients', 'Patients with left ventricular (LV) hypertrophy may suffer ischemia-reperfusion injuries at the time of cardiac surgery with impairment in left ventricular function']","['transesophageal echocardiography (TEE', 'Placebo', 'Glucose-insulin-potassium', 'glucose-insulin potassium (GIK', 'saline', 'GIK (20\u2009IU insulin with 10\u2009mEq KCL']","['PGLS', 'systolic and diastolic ventricular function', 'LV-FAC', 'early changes in 2-and 3-dimensional left ventricular ejection fraction (2D and 3D-LVEF), peak global longitudinal strain (PGLS) and transmitral flow propagation velocity (Vp', 'LV-FAC and 2D- and 3D-LVEF', 'preserved 2D and 3D-LVEF', '2D-LVEF']","[{'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve (procedure)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0149721', 'cui_str': 'Left Ventricular Hypertrophy'}, {'cui': 'C3888056', 'cui_str': 'Valve (physical object)'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0003507', 'cui_str': 'Aortic Stenosis'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0340279', 'cui_str': 'Ventricular hypertrophy (disorder)'}, {'cui': 'C0035126', 'cui_str': 'Ischemia-Reperfusion Injury'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0080309', 'cui_str': 'Ventricular Function'}]","[{'cui': 'C0206054', 'cui_str': 'Echocardiography, Transesophageal'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0304475', 'cui_str': 'Potassium supplement'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0439152', 'cui_str': 'milliequivalent'}]","[{'cui': 'C0136332', 'cui_str': 'PGL(a)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0080309', 'cui_str': 'Ventricular Function'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional (qualifier value)'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction (observable entity)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal (qualifier value)'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0728887', 'cui_str': 'Preserving (attribute)'}]",,0.631206,"At the end of GIK infusion, LV-FAC and 2D- and 3D-LVEF were unchanged whereas Vp (mean difference [MD + 7.9%, 95% confidence interval [CI] 3.2 to 12.5%; P <  0.001) increased compared with baseline values.","[{'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Licker', 'Affiliation': 'Department of Anesthesiology, Pharmacology and Intensive Care, University Hospital of Geneva, CH-1211, Geneva, Switzerland. marc-joseph.licker@hcuge.ch.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Diaper', 'Affiliation': 'Department of Anesthesiology, Pharmacology and Intensive Care, University Hospital of Geneva, CH-1211, Geneva, Switzerland.'}, {'ForeName': 'Tornike', 'Initials': 'T', 'LastName': 'Sologashvili', 'Affiliation': 'Division of Cardiovascular Surgery, University Hospital of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Ellenberger', 'Affiliation': 'Department of Anesthesiology, Pharmacology and Intensive Care, University Hospital of Geneva, CH-1211, Geneva, Switzerland.'}]",BMC anesthesiology,['10.1186/s12871-019-0845-0'] 500,30896990,Recurrence of Maltreatment After Newborn Home Visiting: A Randomized Controlled Trial.,"OBJECTIVES To investigate whether a newborn home visiting program for primiparous adolescent mothers (aged 16-20 years at childbirth) reduced recurrence of child maltreatment in child protective services (CPS) reports. METHODS We conducted a randomized controlled trial of Healthy Families Massachusetts, a statewide home visiting program for young parents. A total of 704 first-time young mothers were randomly assigned to a home visiting group, or to a control group who we referred to other services and who received child development and parenting information. The outcome variable was CPS reports (2008-2016) available for 688 families-specifically, rereports following an initial report (up to mean child age of 7 years). RESULTS Of the 52% of families who experienced initial CPS reports, 53% experienced additional CPS reports. Children of mothers in the home visiting group were less likely to receive a second report and had a longer period of time between initial and second reports. CONCLUSIONS The home visiting program reduced the recurrence of CPS maltreatment report by 32% and increased the length of time between initial and additional CPS reports. Home visiting parenting support and prevention programs may reduce the likelihood of recurrent maltreatment following completion of program services.",2019,"Children of mothers in the home visiting group were less likely to receive a second report and had a longer period of time between initial and second reports. ","['Of the 52% of families who experienced initial CPS reports', 'After Newborn Home Visiting', 'A total of 704 first-time young mothers', 'Healthy Families Massachusetts, a statewide home visiting program for young parents', 'primiparous adolescent mothers (aged 16-20 years at childbirth) reduced recurrence of child maltreatment in child protective services (CPS) reports']","['newborn home visiting program', 'home visiting group, or to a control group who we referred to other services and who received child development and parenting information']","['length of time', 'Recurrence of Maltreatment', 'recurrence of CPS maltreatment report']","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0020043', 'cui_str': 'Home Visits'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0033150', 'cui_str': 'Primiparity'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1148523', 'cui_str': 'Childbirth'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0008060', 'cui_str': 'Child Maltreatment'}, {'cui': 'C0681158', 'cui_str': 'Child Welfare Agencies'}]","[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0020043', 'cui_str': 'Home Visits'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0008071', 'cui_str': 'Child Development'}]","[{'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0684224', 'cui_str': 'Report'}]",,0.0388459,"Children of mothers in the home visiting group were less likely to receive a second report and had a longer period of time between initial and second reports. ","[{'ForeName': 'M Ann', 'Initials': 'MA', 'LastName': 'Easterbrooks', 'Affiliation': 'M. Ann Easterbrooks, Chie Kotake, and Rebecca Fauth are with Tufts Interdisciplinary Evaluation Research, Eliot-Pearson Department of Child Study and Human Development, Tufts University, Medford, MA.'}, {'ForeName': 'Chie', 'Initials': 'C', 'LastName': 'Kotake', 'Affiliation': 'M. Ann Easterbrooks, Chie Kotake, and Rebecca Fauth are with Tufts Interdisciplinary Evaluation Research, Eliot-Pearson Department of Child Study and Human Development, Tufts University, Medford, MA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Fauth', 'Affiliation': 'M. Ann Easterbrooks, Chie Kotake, and Rebecca Fauth are with Tufts Interdisciplinary Evaluation Research, Eliot-Pearson Department of Child Study and Human Development, Tufts University, Medford, MA.'}]",American journal of public health,['10.2105/AJPH.2019.304957'] 501,32154632,Language and stigmatization of individuals with mental health problems or substance addiction in the Netherlands: An experimental vignette study.,"Persons with mental health problems and/or substance addictions (MHPSA) are stigmatised more than persons with physical conditions. This includes stigmatisation by care professionals. Stigma is considered one of the most important barriers for recovery from these conditions. There is an ongoing debate that use of language can exacerbate or diminish stigmatisation. Therefore, we conducted an experiment examining how four different ways of referring to a person with (a) alcohol addiction, (b) drug addiction, (c) depression and (d) schizophrenia are related to stigmatising attitudes by care professionals in the Netherlands. We partially replicated two studies performed in the United States and used surveys with vignettes containing either 'disorder-first', 'person-first', 'victim' and 'recovery' language, which were randomly assigned to participants (n = 361). No significant differences between language conditions were found for any of the vignettes. Our findings suggest that subtle differences in language to refer to persons with mental health problems or substance addictions have no effect on stigmatising attitudes by care professionals in the Netherlands. However, more research is needed to determine the effect of language use on other groups, such as individuals with MHPSA.",2020,No significant differences between language conditions were found for any of the vignettes.,"['referring to a person with (a) alcohol addiction, (b) drug addiction, (c) depression and (d) schizophrenia are related to stigmatising attitudes by care professionals in the Netherlands', ""United States and used surveys with vignettes containing either 'disorder-first', 'person-first', 'victim' and 'recovery' language, which were randomly assigned to participants (n\xa0=\xa0361"", 'individuals with mental health problems or substance addiction in the Netherlands', 'Persons with mental health problems and/or substance addictions (MHPSA) are stigmatised more than persons with\xa0physical conditions', 'individuals with MHPSA']",[],[],"[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0001973', 'cui_str': 'Alcohol Dependence'}, {'cui': 'C1510472', 'cui_str': 'Drug Dependence'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0023008', 'cui_str': 'Languages'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1446377', 'cui_str': 'Mental health problem'}, {'cui': 'C0038580', 'cui_str': 'Substance Dependence'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]",[],[],,0.0307496,No significant differences between language conditions were found for any of the vignettes.,"[{'ForeName': 'Thomas F', 'Initials': 'TF', 'LastName': 'Martinelli', 'Affiliation': 'IVO Research Institute, The Hague, The Netherlands.'}, {'ForeName': 'Gert-Jan', 'Initials': 'GJ', 'LastName': 'Meerkerk', 'Affiliation': 'IVO Research Institute, The Hague, The Netherlands.'}, {'ForeName': 'Gera E', 'Initials': 'GE', 'LastName': 'Nagelhout', 'Affiliation': 'IVO Research Institute, The Hague, The Netherlands.'}, {'ForeName': 'Evelien P M', 'Initials': 'EPM', 'LastName': 'Brouwers', 'Affiliation': 'Tranzo Scientific Center for Care and Wellbeing, School of Social and Behavioural Sciences, Tilburg University, Tilburg, The Netherlands.'}, {'ForeName': 'Jaap', 'Initials': 'J', 'LastName': 'van Weeghel', 'Affiliation': 'Tranzo Scientific Center for Care and Wellbeing, School of Social and Behavioural Sciences, Tilburg University, Tilburg, The Netherlands.'}, {'ForeName': 'Gerdien', 'Initials': 'G', 'LastName': 'Rabbers', 'Affiliation': 'Samen Sterk Zonder Stigma, Amersfoort, The Netherlands.'}, {'ForeName': 'Dike', 'Initials': 'D', 'LastName': 'van de Mheen', 'Affiliation': 'Tranzo Scientific Center for Care and Wellbeing, School of Social and Behavioural Sciences, Tilburg University, Tilburg, The Netherlands.'}]",Health & social care in the community,['10.1111/hsc.12973'] 502,31948604,A randomized controlled trial of effectiveness of platelet-rich plasma gel and regular dressing on wound healing time in pilonidal sinus surgery: Role of different affecting factors.,"BACKGROUND The aim of this study was to assess the possible association between different factors such as age, sex, antibiotic consumption duration, angiogenesis and pain and ""acceleration of wound healing"" in pilonidal sinus patients after treating with platelet-rich plasma (PRP). METHODS In this clinical trial, 110 patients were randomly divided into treatment arm and control group. After surgery, control group underwent classic wound dressing and the treatment arm experienced PRP gel therapy. Before achieving complete healing, wound incisional biopsy was performed in order to evaluate angiogenesis. During the study, other data such as pain and antibiotic consumption duration were also collected. Wound healing time of pilonidal sinus disease was analyzed using Extended and Stratify Cox model. Data were analyzed using R and STATA software. p<0.05 were considered statistically significant. RESULTS The average wound volume was calculated 41.9 ± 8.01 cc in the controls and 42.35 ± 10.81 in the treatment arm group. The mean of healing time was 8.7 ± 1.18, 4.8 ± 0.87 weeks for control and treatment arm, respectively. There was a significant and strong negative association between healing time and wound volume (p<0.01). Moreover, a significant negative association was found between pain duration and angiogenesis (p<0.001), a strong positive significant association was found between healing time of the treatment arms (p<0.01), and the rate of wound healing for participants treated with PRP gel was 37.2 times more than that of controls. CONCLUSION Authors hope for these finding to help the future researches to more thoroughly focus on the mentioned factors in order to find a suitable strategy for wound healing using PRP.",2019,"Moreover, a significant negative association was found between pain duration and angiogenesis (p<0.001), a strong positive significant association was found between healing time of the treatment arms (p<0.01), and the rate of wound healing for participants treated with PRP gel was 37.2 times more than that of controls. ","['pilonidal sinus surgery', 'pilonidal sinus patients after treating with platelet-rich plasma (PRP', '110 patients']","['platelet-rich plasma gel and regular dressing', 'PRP gel', 'classic wound dressing and the treatment arm experienced PRP gel therapy']","['wound healing time', 'rate of wound healing', 'mean of healing time', 'average wound volume', 'pain duration and angiogenesis', 'healing time and wound volume', 'Wound healing time of pilonidal sinus disease', 'pain and antibiotic consumption duration', 'healing time']","[{'cui': 'C0031925', 'cui_str': 'Pilonidal Cyst'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0370220', 'cui_str': 'Platelet rich plasma (substance)'}, {'cui': 'C0242848', 'cui_str': 'PrP (GSS)'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma (substance)'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0013119', 'cui_str': 'Dressings'}, {'cui': 'C0242848', 'cui_str': 'PrP (GSS)'}, {'cui': 'C0439658', 'cui_str': 'Classic (qualifier value)'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}]","[{'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205249', 'cui_str': 'Healed (qualifier value)'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0031925', 'cui_str': 'Pilonidal Cyst'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]",110.0,0.0190802,"Moreover, a significant negative association was found between pain duration and angiogenesis (p<0.001), a strong positive significant association was found between healing time of the treatment arms (p<0.01), and the rate of wound healing for participants treated with PRP gel was 37.2 times more than that of controls. ","[{'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Mohamadi', 'Affiliation': 'Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Amir Hossein', 'Initials': 'AH', 'LastName': 'Norooznezhad', 'Affiliation': 'Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran; Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Shayan', 'Initials': 'S', 'LastName': 'Mostafaei', 'Affiliation': 'Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; Epidemiology and Biostatistics Unit, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Nikbakht', 'Affiliation': 'Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Shirzad', 'Initials': 'S', 'LastName': 'Nassiri', 'Affiliation': 'Surgery Ward, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hiva', 'Initials': 'H', 'LastName': 'Safar', 'Affiliation': 'Pathology Ward, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Kamran Ali', 'Initials': 'KA', 'LastName': 'Moghaddam', 'Affiliation': 'Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ardeshir', 'Initials': 'A', 'LastName': 'Ghavamzadeh', 'Affiliation': 'Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Anoshirvan', 'Initials': 'A', 'LastName': 'Kazemnejad', 'Affiliation': 'Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Electronic address: kazem_an@modares.ac.ir.'}]",Biomedical journal,['10.1016/j.bj.2019.05.002'] 503,31221280,"A normal sodium diet preserves serum sodium levels during treatment of acute decompensated heart failure: A prospective, blind and randomized trial.","BACKGROUND We tested the hypothesis that a normal sodium diet could be associated with preservation of serum sodium during treatment of acute decompensated heart failure (ADHF). METHODS AND RESULTS Forty-four patients hospitalized for ADHF were blindly randomized by using block method to a low sodium diet (LS: 3 g/day of dietary sodium chloride; n = 22, 59.5 ± 11.9 y.o., 50% males. LVEF = 30.0 ± 13.6%); and a normal sodium diet (NS: 7 g/day; n = 22, 56.4 ± 10.3 y.o., 68% males; LVEF = 27.8 ± 11.7%), and both groups were submitted to fluid restriction of 1.000 mL/day. At the 7th day of intervention 16 patients of LS group and 15 patients of NS group were assessed for difference in serum sodium. Both groups had equivalent decongestion, reflected by similar percent reduction of body weight (LS: -5.0 ± 4.7% vs NS: -4.5 ± 5.2%. p = 0.41). Reduction of the N terminal fragment of type B natriuretic peptide (NT-proBNP) was significant only in the NS (-1497.0 [-18843.0 - 1191.0]. p = 0.04). The LS group showed lower levels of serum sodium (135.4 ± 3.5 mmol/L) compared to the NS group (137.5 ± 1.9 mmol/L; p = 0.04). Four cases of hyponatremia were observed only in the LS group (22%). The NS group exhibited higher mean blood pressure values (79.4 ± 2.4 mmHg vs 75.5 ± 3.0 mmHg. p = 0.03), and lower heart rate (73.2 ± 1.6 bpm vs 75.5 ± 2.1 bpm. p = 0.02). CONCLUSIONS These results suggest that a normal sodium diet, when compared to a low sodium diet, is associated with similar degrees of decongestion, but with higher levels of natremia, blood pressure and lower neurohormonal activation during ADHF treatment. TRIAL REGISTRATION clinicaltrials.gov Identifier no. NCT03722069.",2019,Reduction of the N terminal fragment of type B natriuretic peptide (NT-proBNP) was significant only in the NS (-1497.0 [-18843.0 - 1191.0].,"['Forty-four patients hospitalized for ADHF', 'acute decompensated heart failure (ADHF', 'acute decompensated heart failure']","['normal sodium diet', 'low sodium diet (LS: 3\xa0g/day of dietary sodium chloride']","['mean blood pressure values', 'hyponatremia', 'levels of serum sodium', 'serum sodium', 'natremia, blood pressure and lower neurohormonal activation', 'lower heart rate', 'serum sodium levels', 'body weight']","[{'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1609524', 'cui_str': 'Acute decompensated heart failure'}, {'cui': 'C0581377', 'cui_str': 'Decompensated cardiac failure (disorder)'}]","[{'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0301592', 'cui_str': 'Sodium diet (finding)'}, {'cui': 'C0012169', 'cui_str': 'Diet, Low-Salt'}, {'cui': 'C0439417', 'cui_str': 'g/day'}, {'cui': 'C0206136', 'cui_str': 'Table Salt'}]","[{'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0020625', 'cui_str': 'Hyponatremia'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0523891', 'cui_str': 'Sodium measurement, serum (procedure)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}]",44.0,0.0700278,Reduction of the N terminal fragment of type B natriuretic peptide (NT-proBNP) was significant only in the NS (-1497.0 [-18843.0 - 1191.0].,"[{'ForeName': 'Camila Godoy', 'Initials': 'CG', 'LastName': 'Fabricio', 'Affiliation': 'Medical School of Ribeirao Preto, University of Sao Paulo, Avenida, Bandeirantes 3900, Monte Alegre 14049-900, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Denise Mayumi', 'Initials': 'DM', 'LastName': 'Tanaka', 'Affiliation': 'Medical School of Ribeirao Preto, University of Sao Paulo, Avenida, Bandeirantes 3900, Monte Alegre 14049-900, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Jaqueline Rodrigues de', 'Initials': 'JR', 'LastName': 'Souza Gentil', 'Affiliation': 'Medical School of Ribeirao Preto, University of Sao Paulo, Avenida, Bandeirantes 3900, Monte Alegre 14049-900, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Cristiana Alves', 'Initials': 'CA', 'LastName': 'Ferreira Amato', 'Affiliation': 'Medical School of Ribeirao Preto, University of Sao Paulo, Avenida, Bandeirantes 3900, Monte Alegre 14049-900, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Fabiana', 'Initials': 'F', 'LastName': 'Marques', 'Affiliation': 'Medical School of Ribeirao Preto, University of Sao Paulo, Avenida, Bandeirantes 3900, Monte Alegre 14049-900, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Pedro Vellosa', 'Initials': 'PV', 'LastName': 'Schwartzmann', 'Affiliation': 'Medical School of Ribeirao Preto, University of Sao Paulo, Avenida, Bandeirantes 3900, Monte Alegre 14049-900, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Schmidt', 'Affiliation': 'Medical School of Ribeirao Preto, University of Sao Paulo, Avenida, Bandeirantes 3900, Monte Alegre 14049-900, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Marcus Vinícius', 'Initials': 'MV', 'LastName': 'Simões', 'Affiliation': 'Medical School of Ribeirao Preto, University of Sao Paulo, Avenida, Bandeirantes 3900, Monte Alegre 14049-900, Ribeirão Preto, SP, Brazil. Electronic address: msimoes@fmrp.usp.br.'}]",Clinical nutrition ESPEN,['10.1016/j.clnesp.2019.03.009'] 504,31221297,"Effect of whey protein supplementation combined with resistance training on body composition, muscular strength, functional capacity, and plasma-metabolism biomarkers in older women with sarcopenic obesity: A randomized, double-blind, placebo-controlled trial.","BACKGROUNDS & AIMS Obesity and sarcopenia are independent illnesses associated with contemporary dietary and physical activity behaviors, aggravated by aging. Their coexistence is termed sarcopenic obesity (SO). Hence, increasing protein intake and resistance training (RT) are interventions that could counteract these illnesses. The objective of this investigation was to analyze the effects of whey protein (WP) supplementation associated with RT on body composition, muscular strength, functional capacity, and plasma-metabolism biomarkers in older women with SO. METHODS Twenty six sarcopenic (appendicular lean soft tissue ALST < 15.02 kg) obese (body fat mass ≥ 35%) older women were randomly assigned to receive daily, either 35 g of WP (WP group) or placebo (PLA group), combined with supervised RT (8 exercises, 3 × 8-12 rep, 3 times a week), during a 12-week protocol. Blood samples, blood pressure, dietary intake, functional capacity tests, the one repetition maximum (1RM) test, and body composition were assessed before and after the intervention period. Two-way analysis of variance for repeated measures was applied for comparisons. RESULTS The WP group presented greater (P < 0.05) increases in ALST (WP = 6.0% vs. PLA = 2.5%) and decreases in (P < 0.05) total (-3.3% vs. -0.3%) and trunk fat mass (WP = -5.1% vs. PLA = -1.1) and IL-6 (WP = -34.6% vs. PLA = 9.3%) compared with the PLA group. Both groups demonstrated improved (P < 0.05) scores for muscular strength, waist-hip ratio, functional capacity, and other plasma-metabolism biomarkers without significant differences between conditions. CONCLUSION Whey protein combined with RT increased ALST, and decreased total and trunk fat mass, improving sarcopenia and decreasing SO in older women, with a limited impact on inflammation. Registered under ClinicalTrials.gov Identifier n° NCT03752359.",2019,"Both groups demonstrated improved (P < 0.05) scores for muscular strength, waist-hip ratio, functional capacity, and other plasma-metabolism biomarkers without significant differences between conditions. ","['Twenty six sarcopenic (appendicular lean soft tissue', 'older women', 'older women with SO', 'older women with sarcopenic obesity']","['ALST', 'whey protein supplementation combined with resistance training', 'placebo', 'whey protein (WP) supplementation', 'WP (WP group) or placebo (PLA group), combined with supervised RT']","['ALST', 'body composition, muscular strength, functional capacity, and plasma-metabolism biomarkers', 'IL-6', 'total and trunk fat mass, improving sarcopenia and decreasing SO', 'muscular strength, waist-hip ratio, functional capacity, and other plasma-metabolism biomarkers', 'trunk fat mass', 'Blood samples, blood pressure, dietary intake, functional capacity tests, the one repetition maximum (1RM) test, and body composition']","[{'cui': 'C0450349', 'cui_str': '26 (qualifier value)'}, {'cui': 'C0225317', 'cui_str': 'Soft tissues (body structure)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0442025', 'cui_str': 'Muscular (qualifier value)'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0460005', 'cui_str': 'Torso'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0872084', 'cui_str': 'Sarcopenias'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0205682', 'cui_str': 'Waist-Hip Ratio'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",,0.261267,"Both groups demonstrated improved (P < 0.05) scores for muscular strength, waist-hip ratio, functional capacity, and other plasma-metabolism biomarkers without significant differences between conditions. ","[{'ForeName': 'Hellen C G', 'Initials': 'HCG', 'LastName': 'Nabuco', 'Affiliation': 'Federal Institute of Science and Technology of Mato Grosso, Highway BR-364, Km 329, Cuiabá, MT 78106-970, Brazil; Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Highway Celso Garcia Cid, Londrina, Paraná 86057-970, Brazil. Electronic address: hellen.nabuco@svc.ifmt.edu.br.'}, {'ForeName': 'Crisieli M', 'Initials': 'CM', 'LastName': 'Tomeleri', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Highway Celso Garcia Cid, Londrina, Paraná 86057-970, Brazil; Faculty of Physical Education, University of Campinas, Érico Veríssimo Avenue, Campinas, São Paulo 13083-970, Brazil. Electronic address: crisielitomeleri@gmail.com.'}, {'ForeName': 'Rodrigo R', 'Initials': 'RR', 'LastName': 'Fernandes', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Highway Celso Garcia Cid, Londrina, Paraná 86057-970, Brazil. Electronic address: rodrigo.r.fernandes@gmail.com.'}, {'ForeName': 'Paulo', 'Initials': 'P', 'LastName': 'Sugihara Junior', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Highway Celso Garcia Cid, Londrina, Paraná 86057-970, Brazil. Electronic address: juniornutricao@hotmail.com.'}, {'ForeName': 'Edilaine F', 'Initials': 'EF', 'LastName': 'Cavalcante', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Highway Celso Garcia Cid, Londrina, Paraná 86057-970, Brazil. Electronic address: edilainefungari@gmail.com.'}, {'ForeName': 'Paolo M', 'Initials': 'PM', 'LastName': 'Cunha', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Highway Celso Garcia Cid, Londrina, Paraná 86057-970, Brazil. Electronic address: pcunha88@hotmail.com.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Antunes', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Highway Celso Garcia Cid, Londrina, Paraná 86057-970, Brazil. Electronic address: melissa.antunes@hotmail.com.'}, {'ForeName': 'João Pedro', 'Initials': 'JP', 'LastName': 'Nunes', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Highway Celso Garcia Cid, Londrina, Paraná 86057-970, Brazil. Electronic address: joaonunes.jpn@hotmail.com.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Venturini', 'Affiliation': 'Clinical Analyses Laboratory, Londrina State University, Highway Celso Garcia Cid, Londrina, Paraná 86057-970, Brazil. Electronic address: danielle.venturini@bol.com.br.'}, {'ForeName': 'Décio S', 'Initials': 'DS', 'LastName': 'Barbosa', 'Affiliation': 'Clinical Analyses Laboratory, Londrina State University, Highway Celso Garcia Cid, Londrina, Paraná 86057-970, Brazil. Electronic address: sabbatini2011@hotmail.com.'}, {'ForeName': 'Roberto Carlos', 'Initials': 'RC', 'LastName': 'Burini', 'Affiliation': 'Exercise and Nutrition Metabolism Center, Department of Public Health, Botucatu School of Medicine, UNESP, Botucatu, São Paulo 18618-687, Brazil. Electronic address: burini@fmb.unesp.br.'}, {'ForeName': 'Analiza M', 'Initials': 'AM', 'LastName': 'Silva', 'Affiliation': 'Exercise and Health Laboratory, CIPER, Faculdade de Motricidade Humana, Universidade de Lisboa, Estrada da Costa, Cruz Quebrada, Dafundo 1499-002, Portugal. Electronic address: analiza@fmh.ulisboa.pt.'}, {'ForeName': 'Luís B', 'Initials': 'LB', 'LastName': 'Sardinha', 'Affiliation': 'Exercise and Health Laboratory, CIPER, Faculdade de Motricidade Humana, Universidade de Lisboa, Estrada da Costa, Cruz Quebrada, Dafundo 1499-002, Portugal. Electronic address: lbsardinha55@gmail.com.'}, {'ForeName': 'Edilson S', 'Initials': 'ES', 'LastName': 'Cyrino', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Highway Celso Garcia Cid, Londrina, Paraná 86057-970, Brazil. Electronic address: edilsoncyrino@gmail.com.'}]",Clinical nutrition ESPEN,['10.1016/j.clnesp.2019.04.007'] 505,31040007,Academic success plans in advanced pharmacy practice experiences to promote self-awareness and improve performance.,"INTRODUCTION Pharmacy schools should encourage self-awareness, provide exposure to the continuous professional development cycle, and intervene early when students exhibit performance deficiencies. Academic success plans (ASPs) have been shown in other disciplines to be successful intervention tools which encourage student reflection and self-awareness. This study evaluates the impact of ASPs used during the advanced pharmacy practice experience (APPE) curriculum at two schools. METHODS ASPs were assigned to students who had either a ""needs development"" or lower documented for the same learning outcome during more than one APPE, for poor overall performance during an APPE, or for documented professionalism issues. Average scores were calculated by assigning point values to each learning outcome assessment score (exceeds expectations = 1; competent = 0; needs development, needs significant development, remediation required = -1). RESULTS During AY2014-2015 and AY2015-2016, 104 ASPs were assigned to 75 students (13.5% of students). The majority (89.6%) were assigned due to repeated deficiencies in the same learning outcome(s), with the most frequent being ""Develop, Implement, and Monitor Drug Therapy Plans."" After completion of an ASP, average scores significantly improved (p < 0.05) in 9 out of 12 learning outcomes among all students who completed an ASP. Thirteen students completed 15 ASPs for professionalism reasons, most commonly punctuality. CONCLUSIONS Prior to 2015, Experiential Education Office interventions were primarily grades-based, not necessarily based on achievement of specific learning outcomes. ASPs were successfully used to allow students to practice self-awareness skills, to engage in the CPD process, and to improve APPE performance.",2019,"ASPs were successfully used to allow students to practice self-awareness skills, to engage in the CPD process, and to improve APPE performance.","['Thirteen students completed 15 ASPs for professionalism reasons, most commonly punctuality', 'ASPs were assigned to students who had either a ""needs development"" or lower documented for the same learning outcome during more than one APPE, for poor overall performance during an APPE, or for documented professionalism issues', 'advanced pharmacy practice experience (APPE) curriculum at two schools', 'During AY2014-2015 and AY2015-2016, 104 ASPs were assigned to 75 students (13.5% of students']",[],['APPE performance'],"[{'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0206298', 'cui_str': 'European Viper'}, {'cui': 'C0815219', 'cui_str': 'Professionalism'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0031322', 'cui_str': 'Pharmacies'}, {'cui': 'C0220815', 'cui_str': 'curriculum'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C4517559', 'cui_str': '13.5 (qualifier value)'}]",[],[],104.0,0.0183485,"ASPs were successfully used to allow students to practice self-awareness skills, to engage in the CPD process, and to improve APPE performance.","[{'ForeName': 'Lindsey H', 'Initials': 'LH', 'LastName': 'Welch', 'Affiliation': 'University of Georgia College of Pharmacy, 250 West Green Street, Athens, GA 30602, United States. Electronic address: lhwelch@uga.edu.'}, {'ForeName': 'C Lea', 'Initials': 'CL', 'LastName': 'Bonner', 'Affiliation': 'Mercer University College of Pharmacy, 3001 Mercer University Drive, Atlanta, GA 30341, United States. Electronic address: Bonner_cl@mercer.edu.'}, {'ForeName': 'Jill M', 'Initials': 'JM', 'LastName': 'Augustine', 'Affiliation': 'Mercer University College of Pharmacy, 3001 Mercer University Drive, Atlanta, GA 30341, United States. Electronic address: Augustine_jm@mercer.edu.'}, {'ForeName': 'Lori J', 'Initials': 'LJ', 'LastName': 'Duke', 'Affiliation': 'University of Georgia College of Pharmacy, 250 West Green Street, Athens, GA 30602, United States. Electronic address: ljduke@uga.edu.'}]",Currents in pharmacy teaching & learning,['10.1016/j.cptl.2019.01.012'] 506,31910028,"Effect of acute and short-term dietary fat ingestion on postprandial skeletal muscle protein synthesis rates in middle-aged, overweight, and obese men.","Muscle anabolic resistance to dietary protein is associated with obesity and insulin resistance. However, the contribution of excess consumption of fat to anabolic resistance is not well studied. The aim of these studies was to test the hypothesis that acute and short-term dietary fat overload will impair the skeletal muscle protein synthetic response to dietary protein ingestion. Eight overweight/obese men [46.4 ± 1.4 yr, body mass index (BMI) 32.3 ± 5.4 kg/m 2 ] participated in the acute feeding study, which consisted of two randomized crossover trials. On each occasion, subjects ingested an oral meal (with and without fat emulsion), 4 h before the coingestion of milk protein, intrinsically labeled with [1- 13 C]phenylalanine, and dextrose. Nine overweight/obese men (44.0 ± 1.7 yr, BMI 30.1 ± 1.1 kg/m 2 ) participated in the chronic study, which consisted of a baseline, 1-wk isocaloric diet, followed by a 2-wk high-fat diet (+25% energy excess). Acutely, incorporation of dietary amino acids into the skeletal muscle was twofold higher ( P < 0.05) in the lipid trial compared with control. There was no effect of prior lipid ingestion on indices of insulin sensitivity (muscle glucose uptake, pyruvate dehydrogenase complex activity, and Akt phosphorylation) in response to the protein/dextrose drink. Fat overfeeding had no effect on muscle protein synthesis or glucose disposal in response to whey protein ingestion, despite increased muscle diacylglycerol C16:0 ( P = 0.06) and ceramide C16:0 ( P < 0.01) levels. Neither acute nor short-term dietary fat overload has a detrimental effect on the skeletal muscle protein synthetic response to dietary protein ingestion in overweight/obese men, suggesting that dietary-induced accumulation of intramuscular lipids per se is not associated with anabolic resistance.",2020,"Acutely, incorporation of dietary amino acids into the skeletal muscle was 2-fold higher (P<0.05) in the lipid trial compared to control.","['overweight/obese men', 'Eight overweight/obese males [46.4±1.4 years, BMI 32.3±5.4 kg/m 2 ] participated in the acute feeding study', 'Nine overweight/obese males [44.0±1.7 years, BMI 30.1±1.1 kg/m 2 ] participated in the chronic study', 'middle-aged, overweight and obese men']","['lipid ingestion', 'oral meal (with and without fat emulsion) 4h before the coingestion of milk protein, intrinsically labelled with [1- 13 C]phenylalanine, and dextrose', 'acute and short-term dietary fat ingestion']","['muscle protein synthesis or glucose disposal', 'postprandial skeletal muscle protein synthesis rates', 'incorporation of dietary amino acids into the skeletal muscle', 'insulin sensitivity (muscle glucose uptake, PDC activity and Akt phosphorylation', 'muscle DAG C16:0']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0205847', 'cui_str': 'Middle Aged'}]","[{'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0304483', 'cui_str': 'Fat emulsion (substance)'}, {'cui': 'C0026138', 'cui_str': 'Milk Proteins'}, {'cui': 'C0017725', 'cui_str': 'dextrose'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0012171', 'cui_str': 'Dietary Fats'}]","[{'cui': 'C0026832', 'cui_str': 'Muscle Proteins'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0242692', 'cui_str': 'Muscle, Voluntary'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0243126', 'cui_str': 'incorporation'}, {'cui': 'C3539946', 'cui_str': 'Amino acids'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0031715', 'cui_str': 'Phosphorylation'}]",,0.0276175,"Acutely, incorporation of dietary amino acids into the skeletal muscle was 2-fold higher (P<0.05) in the lipid trial compared to control.","[{'ForeName': 'Kostas', 'Initials': 'K', 'LastName': 'Tsintzas', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Jones', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'Pardeep', 'Initials': 'P', 'LastName': 'Pabla', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Mallinson', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Barrett', 'Affiliation': 'Centre for Analytical Bioscience, Advanced Materials and Healthcare Technologies Division, School of Pharmacy, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Dong-Hyun', 'Initials': 'DH', 'LastName': 'Kim', 'Affiliation': 'Centre for Analytical Bioscience, Advanced Materials and Healthcare Technologies Division, School of Pharmacy, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Cooper', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Davies', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'Tariq', 'Initials': 'T', 'LastName': 'Taylor', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Chee', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Gaffney', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'Luc J C', 'Initials': 'LJC', 'LastName': 'van Loon', 'Affiliation': 'Department of Human Movement Sciences, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Francis B', 'Initials': 'FB', 'LastName': 'Stephens', 'Affiliation': 'School of Sport and Health Sciences, University of Exeter, Exeter, United Kingdom.'}]",American journal of physiology. Endocrinology and metabolism,['10.1152/ajpendo.00344.2019'] 507,30935324,"Effect of spinal manipulative therapy on mechanical pain sensitivity in patients with chronic nonspecific low back pain: a pilot randomized, controlled trial.","Objectives : The long-term goal of our study is to improve the understanding of the biological mechanisms associated with spinal manipulative therapy (SMT) in low back pain. Methods : This project involved a pilot randomized, blinded clinical trial (ClinicalTrials.gov registration number NCT03078114) of 3-week SMT in chronic nonspecific low back pain (CNSLBP) patients. We recruited 29 participants and randomly assigned them into either a SMT ( n = 14) or sham SMT ( n = 15) group. Pre- and postintervention, we quantified the effect of SMT on clinical outcomes (Numeric Pain Rating Scale and Oswestry Disability Index) and pressure pain threshold (PPT) at local (lumbar spine), regional (lower extremity), and remote (upper extremity) anatomical sites. Results : We observed a significant main effect for time signifying reduced hypersensitivity (increased PPT) at local ( p = .015) and regional ( p = .014) locations at 3 weeks. Furthermore, we found significant main effects of time indicating improvements in pain ( p < .001) and disability ( p = .02) from baseline among all participants regardless of intervention. However, no between-group differences were observed in PPT, clinical pain, or disability between the SMT and sham SMT groups over 3 weeks. Conclusions : After 3 weeks of SMT or sham SMT in CNSLBP patients, we found hypoalgesia at local and remote sites along with improved pain and low back-related disability. Level of Evidence : 1b.",2020,"However, no between-group differences were observed in PPT, clinical pain, or disability between the SMT and sham SMT groups over 3 weeks. ","['patients with chronic nonspecific low back pain', '29 participants', 'chronic nonspecific low back pain (CNSLBP) patients']","['SMT or sham SMT', 'SMT', 'spinal manipulative therapy (SMT', 'spinal manipulative therapy', 'sham SMT']","['pain', 'hypersensitivity', 'pain and low back-related disability', 'clinical outcomes (Numeric Pain Rating Scale and Oswestry Disability Index) and pressure pain threshold (PPT) at local (lumbar spine), regional (lower extremity), and remote (upper extremity) anatomical sites', 'disability', 'PPT, clinical pain, or disability', 'mechanical pain sensitivity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0024031', 'cui_str': 'Low Back Ache'}]","[{'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0949742', 'cui_str': 'Manipulation Therapy'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3544362', 'cui_str': 'Hypersensitivity (SMQ)'}, {'cui': 'C2939142', 'cui_str': 'Lower back (surface region)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index (assessment scale)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0162703', 'cui_str': 'Pain Threshold'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C3887615', 'cui_str': 'Lumbar spine structure (body structure)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0205157', 'cui_str': 'Remote (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0220784', 'cui_str': 'Anatomic (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0234252', 'cui_str': 'Mechanical pain (finding)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}]",29.0,0.425737,"However, no between-group differences were observed in PPT, clinical pain, or disability between the SMT and sham SMT groups over 3 weeks. ","[{'ForeName': 'Bryan M', 'Initials': 'BM', 'LastName': 'Bond', 'Affiliation': 'Department of Physical Therapy, University of Saint Mary, Leavenworth, KS, USA.'}, {'ForeName': 'Chris D', 'Initials': 'CD', 'LastName': 'Kinslow', 'Affiliation': 'Department of Physical Therapy, University of Saint Mary, Leavenworth, KS, USA.'}, {'ForeName': 'Adam W', 'Initials': 'AW', 'LastName': 'Yoder', 'Affiliation': 'Department of Physical Therapy, University of Saint Mary, Leavenworth, KS, USA.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': 'Department of Physical Therapy and Rehabilitation Science, University of Kansas Medical Center, Kansas City, KS, USA.'}]",The Journal of manual & manipulative therapy,['10.1080/10669817.2019.1572986'] 508,32171064,"Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial.","BACKGROUND Whether blood eosinophil counts and exhaled nitric oxide (FeNO) are associated with important outcomes in mild asthma is unclear. In this prespecified subgroup analysis of a previously published open-label clinical trial, we aimed to assess associations between blood eosinophil counts and FeNO with outcomes and response to asthma treatment. METHODS In the previously reported 52-week, open-label, randomised controlled trial, people with mild asthma receiving only β agonist reliever inhalers were enrolled at one of 16 clinical trials units in New Zealand, the UK, Italy, or Australia. Eligible participants were randomly assigned (1:1:1, stratified by country), to receive inhalers to take as-needed salbutamol (two inhalations of 100 μg in a pressurised metered dose inhaler), maintenance budesonide (200 μg twice per day by inhaler) plus as-needed salbutamol (two inhalations of 100 μg), or as-needed budesonide-formoterol (one inhalation of 200 μg budesonide and 6μg formoterol by inhaler). The primary outcome was the annual rates of asthma exacerbations per patient, and in this prespecified subgroup analysis, we assessed whether annual exacerbation rates in each treatment group were significantly different depending on levels of blood eosinophil count, FeNO, or a composite score of both. Analyses were done for patients with available biomarker measurements The study was registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12615000999538. FINDINGS 675 participants were enrolled between March 17, 2016, and Aug 29, 2017, of whom 656 had results for blood eosinophil analysis and 668 had results for FeNO. Of the patients who received as-needed salbutamol, the proportion of patients having a severe exacerbation increased progressively with increasing blood eosinophil count (two [4%] of 49 participants with <0·15 × 10 9 /L, six [6%] of 93 with 0·15 to <0·3 × 10 9 /L, and 15 [19%] of 77 with ≥0·3 × 10 9 /L; p=0·014). There were no significant interactions between blood eosinophil count or FeNO level and the effect of as-needed budesonide-formoterol compared with as-needed salbutamol for either exacerbations or severe exacerbations. However, there were significant interactions between blood eosinophil count subgroups and the effect of maintenance budesonide plus as-needed salbutamol compared with as-needed salbutamol, both for exacerbations (p=0·0006) and severe exacerbations (p=0·0007). Maintenance budesonide plus as-needed salbutamol was more effective than as-needed salbutamol in patients with blood eosinophil counts of 0·3 × 10 9 /L or more, both for exacerbations (rate ratio 0·13 [95% CI 0·05-0·33]) and severe exacerbations (risk odds ratio 0·11 [0·03-0·45]). This difference was not seen for blood eosinophil counts of less than 0·15 × 10 9 /L (1·15 [0·51-1·28] for exacerbations and 5·72 [0·97-33·60] for severe exacerbations). There was no consistent interaction between treatment response and FeNO or the composite score. INTERPRETATION In patients with mild asthma, the effects of as-needed budesonide-formoterol on exacerbations are independent of biomarker profile, whereas the benefits of maintenance inhaled budesonide are greater in patients with high blood eosinophil counts than in patients with low counts. FUNDING AstraZeneca, Health Research Council of New Zealand.",2020,This difference was not seen for blood eosinophil counts of less than 0·15 ,"['10', 'patients with blood eosinophil counts of 0·3', '675 participants were enrolled between March 17, 2016, and Aug 29, 2017, of whom 656 had results for blood eosinophil analysis and 668 had results for FeNO', 'people with mild asthma receiving only β agonist reliever inhalers were enrolled at one of 16 clinical trials units in New Zealand, the UK, Italy, or Australia', '0·13', 'patients with available biomarker measurements', '10 9', '49 participants with <0·15', 'patients with mild asthma', 'adults with mild asthma', 'Eligible participants']","['budesonide-formoterol', 'blood eosinophils and exhaled nitric oxide', 'salbutamol (two inhalations of 100 μg in a pressurised metered dose inhaler), maintenance budesonide (200 μg twice per day by inhaler) plus as-needed salbutamol (two inhalations of 100 μg), or as-needed budesonide-formoterol (one inhalation of 200 μg budesonide and 6μg formoterol by inhaler']","['blood eosinophil count', 'annual exacerbation rates', 'blood eosinophil counts', 'severe exacerbations', 'annual rates of asthma exacerbations', 'exacerbations (rate ratio', 'blood eosinophil count or FeNO level', 'levels of blood eosinophil count, FeNO, or a composite score of both']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil, segmented (cell)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C4517854', 'cui_str': '675 (qualifier value)'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C4523905', 'cui_str': 'Fractional exhaled nitric oxide'}, {'cui': 'C0581124', 'cui_str': 'Mild asthma'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0021461', 'cui_str': 'Inhalators'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C0060657', 'cui_str': 'formoterol'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil, segmented (cell)'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0001927', 'cui_str': 'Albuterol'}, {'cui': 'C1705211', 'cui_str': 'Inhalation - unit of product usage'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0475209', 'cui_str': 'm'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0021461', 'cui_str': 'Inhalators'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0027552', 'cui_str': 'Needs'}]","[{'cui': 'C0014467', 'cui_str': 'Eosinophil, segmented (cell)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C4523905', 'cui_str': 'Fractional exhaled nitric oxide'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",675.0,0.625881,This difference was not seen for blood eosinophil counts of less than 0·15 ,"[{'ForeName': 'Ian D', 'Initials': 'ID', 'LastName': 'Pavord', 'Affiliation': 'Oxford Respiratory National Institute for Health Research Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address: ian.pavord@ndm.ox.ac.uk.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Holliday', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': 'Helen K', 'Initials': 'HK', 'LastName': 'Reddel', 'Affiliation': 'Woolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Braithwaite', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Ebmeier', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Hancox', 'Affiliation': 'Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand; Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Harrison', 'Affiliation': 'Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Houghton', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Oldfield', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Papi', 'Affiliation': 'Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy.'}, {'ForeName': 'Mathew', 'Initials': 'M', 'LastName': 'Williams', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Weatherall', 'Affiliation': 'University of Otago Wellington, Wellington, New Zealand.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Beasley', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand; Capital and Coast District Health Board, Wellington, New Zealand.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(20)30053-9'] 509,32127584,Performance of single-use syringe versus multi-use MR contrast injectors: a prospective comparative study.,"The goal of this study was to compare performance parameters of a single-use syringe and a multi-use MR contrast injector. We compared preparation time, cost for disposables and volumes of contrast material used for a single-use (SI) and a multi-use (MI) MR contrast injector in a prospective cross-over trial. During the first study period all consecutive patients eligible for dynamic MR on two systems were included during a period of 20 working days. After 10 days, the injector was switched. Radiographer satisfaction was evaluated using a questionnaire. Contrast usage and waste on system MI was optimised by extra instructions for our radiographers and measured during the second study period of 10 consecutive working days. A total of 202 and 163 patients for systems SI and MI were included, respectively. Average preparation time was 4:55 min for SI and 2:24 min for MI (p < 0.05). Contrast waste for SI was 13% using 7.5 ml syringes. Contrast waste for MI was 5% for 7.5 ml containers. Costs for disposables were lower for MI if more than 5 patients per day were injected. Radiographer satisfaction was higher for MI (4.7 versus 2.8 on a 5-point scale; p < 0.05). The multi-use MR contrast injector led to higher radiographer satisfaction, shorter preparation time, and lower cost if more than 5 patients were injected per day. In addition, cheaper contrast containers of 15 or 30 ml could be used for the first patients if more than 2 or more than 4 injections are performed per day, potentially leading to lower contrast waste.",2020,Average preparation time was 4:55 min for SI and 2:24 min for MI (p < 0.05).,"['A total of 202 and 163 patients for systems SI and MI were included, respectively', 'consecutive patients eligible for dynamic MR on two systems were included during a period of 20 working days']","['single-use (SI) and a multi-use (MI) MR contrast injector', 'single-use syringe and a multi-use MR contrast injector', 'single-use syringe versus multi-use MR contrast injectors']","['Radiographer satisfaction', 'radiographer satisfaction, shorter preparation time, and lower cost', 'Average preparation time']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0181342', 'cui_str': 'Injector'}, {'cui': 'C0184957', 'cui_str': 'Irrigation with syringe (procedure)'}]","[{'cui': 'C0402007', 'cui_str': 'Medical radiographer (occupation)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",202.0,0.0169529,Average preparation time was 4:55 min for SI and 2:24 min for MI (p < 0.05).,"[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Struik', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands. struikfe@gmail.com.'}, {'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Futterer', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.'}, {'ForeName': 'W M', 'Initials': 'WM', 'LastName': 'Prokop', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.'}]",Scientific reports,['10.1038/s41598-020-60697-w'] 510,31981856,Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients.,"BACKGROUND While electroconvulsive therapy (ECT) is considered the gold standard for acute treatment of patients with otherwise treatment-resistant depression, ketamine has recently emerged as a fast-acting treatment alternative for these patients. Efficacy and onset of action are currently among the main factors that influence clinical decision making, however, the effect of these treatments on cognitive functions should also be a crucial point, given that cognitive impairment in depression is strongly related to disease burden and functional recovery. ECT is known to induce transient cognitive impairment, while little is known about ketamine's impact on cognition. This study therefore aims to compare ECT and serial ketamine administration not only with regard to their antidepressant efficacy but also to acute neurocognitive effects. METHODS Fifty patients suffering from depression were treated with either serial ketamine infusions or ECT. Depression severity and cognitive functions were assessed before, during, and after treatment. RESULTS ECT and ketamine administration were equally effective, however, the antidepressant effects of ketamine occurred faster. Ketamine improved neurocognitive functioning, especially attention and executive functions, whereas ECT was related to a small overall decrease in cognitive performance. CONCLUSIONS Due to its pro-cognitive effects and faster antidepressant effect, serial ketamine administration might be a more favorable short-term treatment option than ECT. LIMITATIONS As this research employed a naturalistic study design, patients were not systematically randomized, there was no control group and patients received concurrent and partially changing medications during treatment. CLINICAL TRIALS REGISTRATION Functional and Metabolic Changes in the Course of Antidepressive Treatment, https://clinicaltrials.gov/ct2/show/NCT02099630, NCT02099630.",2020,"Ketamine improved neurocognitive functioning, especially attention and executive functions, whereas ECT was related to a small overall decrease in cognitive performance. ","['patients with otherwise treatment-resistant depression', 'depressed patients', 'Fifty patients suffering from depression']","['electroconvulsive therapy (ECT', 'ECT and serial ketamine', 'serial ketamine administration versus ECT', 'serial ketamine infusions or ECT', 'Ketamine', 'ECT', 'ketamine']","['Antidepressant and neurocognitive effects', 'Depression severity and cognitive functions', 'neurocognitive functioning, especially attention and executive functions', 'cognitive performance']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2063866', 'cui_str': 'Refractory Depression'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]","[{'cui': 'C0013806', 'cui_str': 'Electroshock Therapy'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}]","[{'cui': 'C0003289', 'cui_str': 'Antidepressant Drugs'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}]",50.0,0.0408458,"Ketamine improved neurocognitive functioning, especially attention and executive functions, whereas ECT was related to a small overall decrease in cognitive performance. ","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Basso', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany; Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Lenggstrasse 31, 8032, Zurich, Switzerland.'}, {'ForeName': 'Luisa', 'Initials': 'L', 'LastName': 'Bönke', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany. Electronic address: luisa.boenke@charite.de.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Aust', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Matti', 'Initials': 'M', 'LastName': 'Gärtner', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Isabella', 'Initials': 'I', 'LastName': 'Heuser-Collier', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Otte', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Wingenfeld', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Malek', 'Initials': 'M', 'LastName': 'Bajbouj', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Grimm', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany; Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Lenggstrasse 31, 8032, Zurich, Switzerland; Department of Psychology, MSB Medical School Berlin, Calandrellistr. 1-9, 12247, Berlin, Germany.'}]",Journal of psychiatric research,['10.1016/j.jpsychires.2020.01.002'] 511,31292172,Randomised controlled trial to investigate the effectiveness of thoracic epidural and paravertebral blockade in reducing chronic post-thoracotomy pain (TOPIC): a pilot study to assess feasibility of a large multicentre trial.,"OBJECTIVES Thoracotomy is considered one of the most painful surgical procedures. The incidence of chronic post-thoracotomy pain (CPTP) is up to 50%. Paravertebral blockade (PVB) may be superior to thoracic epidural blockade (TEB) in preventing CPTP. The specific objective of this pilot study was to assess the feasibility of conducting a larger trial to determine whether PVB at thoracotomy is more effective in reducing CPTP compared with TEB. DESIGN A randomised, parallel, external pilot study was conducted to assess whether a large randomised trial of TEB and PVB with CPTP as the primary outcome is feasible. SETTING Two adult thoracic centres in the UK. PARTICIPANTS All adult patients admitted for elective open thoracotomy. Participants were excluded if they were American Society of Anesthesiologists physical status IV or V; or if there is contraindication to local anaesthetics; infection near the proposed puncture site; coagulation/thoracic spine disorders; required chest wall resection or emergency thoracic surgery or had a previous thoracotomy. RESULTS All patients presenting for thoracotomy were screened over a 12-month period with 194 found to be eligible. Of these, 69 (36%) were randomised (95% CI 29% to 42%). Discounting five participants who died, 54 of 64 participants (84%) returned questionnaire booklets at 6 months. The number of participants indicating at least a moderate level of chest pain at 6 months was lower with PVB but with high levels of uncertainty (RR: 0.7; 95% CI 0.3 to 1.7 for worst pain; RR: 0.3; 95% CI 0.0 to 2.8 for average pain). There were no safety concerns. CONCLUSIONS A large, multicentre randomised controlled trial of PVB versus TEB is feasible as it is possible to randomise and follow up participants with high fidelity. Pain scores were lower on average with PVB compared with TEB but a much larger trial is required to confirm this reliably. TRIAL REGISTRATION NUMBER ISRCTN45041624.",2019,"There were no safety concerns. ","['participants with high fidelity', 'Two adult thoracic centres in the UK', 'All adult patients admitted for elective open thoracotomy', 'Participants were excluded if they were American Society of Anesthesiologists physical status IV or V; or if there is contraindication to local anaesthetics; infection near the proposed puncture site; coagulation/thoracic spine disorders', 'All patients presenting for thoracotomy were screened over a 12-month period with 194 found to be eligible']","['TEB and PVB with CPTP', 'Paravertebral blockade (PVB', 'TEB', 'PVB', 'thoracic epidural and paravertebral blockade', 'chest wall resection or emergency thoracic surgery or had a previous thoracotomy']","['moderate level of chest pain', 'chronic post-thoracotomy pain', 'questionnaire booklets', 'incidence of chronic post-thoracotomy pain (CPTP', 'Pain scores']","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0039991', 'cui_str': 'Thoracotomy'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to (contextual qualifier) (qualifier value)'}, {'cui': 'C0002934', 'cui_str': 'Conduction-Blocking Anesthetics'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0475806', 'cui_str': 'Nr - Near'}, {'cui': 'C0033119', 'cui_str': 'Puncture wound - injury (disorder)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0441509', 'cui_str': 'Coagulation - action (qualifier value)'}, {'cui': 'C0581269', 'cui_str': 'Thoracic spine structure (body structure)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0442150', 'cui_str': 'Paravertebral (qualifier value)'}, {'cui': 'C3540676', 'cui_str': 'Blockade'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0039988', 'cui_str': 'Thoracoplasty'}, {'cui': 'C0175673', 'cui_str': 'Emergency (qualifier value)'}, {'cui': 'C0039986', 'cui_str': 'Thoracic Surgery'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0039991', 'cui_str': 'Thoracotomy'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0008031', 'cui_str': 'Chest Pain'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0039991', 'cui_str': 'Thoracotomy'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}]",64.0,0.256873,"There were no safety concerns. ","[{'ForeName': 'Joyce', 'Initials': 'J', 'LastName': 'Yeung', 'Affiliation': 'Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'Middleton', 'Affiliation': 'School of Health and Population Sciences, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Kostas', 'Initials': 'K', 'LastName': 'Tryposkiadis', 'Affiliation': 'Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Kerr', 'Affiliation': 'Department of Thoracic Surgery, Birmingham Heartlands Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Daniels', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Babu', 'Initials': 'B', 'LastName': 'Naidu', 'Affiliation': 'Department of Thoracic Surgery, Birmingham Heartlands Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Melody', 'Affiliation': 'Academic Department of Anaesthesia, Critical Care, Pain and Resuscitation, Birmingham Heartlands Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Goebel', 'Affiliation': 'University of Liverpool, Institute of Translational Medicine, Liverpool, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Wilson', 'Affiliation': 'Health Services Research, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Sajith', 'Initials': 'S', 'LastName': 'Kumar', 'Affiliation': 'Academic Department of Anaesthesia, Critical Care, Pain and Resuscitation, Birmingham Heartlands Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Lajos', 'Initials': 'L', 'LastName': 'Szentgyorgyi', 'Affiliation': 'Department of Anaesthesia, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Flanagan', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Shah', 'Affiliation': 'Department of Thoracic Surgery, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Antony', 'Initials': 'A', 'LastName': 'Worrall', 'Affiliation': 'Academic Department of Anaesthesia, Critical Care, Pain and Resuscitation, Birmingham Heartlands Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Gao', 'Affiliation': 'Academic Department of Anaesthesia, Critical Care, Pain and Resuscitation, Birmingham Heartlands Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.'}]",BMJ open,['10.1136/bmjopen-2018-023679'] 512,32150492,A Dose-Ranging Study of Epinephrine Hydrofluroalkane Metered-Dose Inhaler (Primatene ® MIST) in Subjects with Intermittent or Mild-to-Moderate Persistent Asthma.,"Background: Two sequential single-dose crossover dose-ranging studies were performed to evaluate the clinical efficacy and safety profile of epinephrine hydrofluroalkane (HFA) metered-dose inhaler (MDI) formulation at various doses in subjects with asthma. Methods: In these multicenter, multiarm, double-blinded, or evaluator-blinded studies, subjects were randomized to receive the epinephrine HFA (Primatene ® MIST HFA) MDI medication at doses ranging from 90 to 440 μg/dose, as well as to a placebo (PLA) control and an active control of epinephrine CFC (chlorofluorocarbon) MDI (Primatene ® MIST CFC) at 220 μg/inhalation. Results: Spirometry testing for FEV1 (Forced Expiratory Volume in one second) demonstrated statistically significant improvements over PLA for epinephrine HFA MDI at all doses above 125 μg, as the amount out of the actuator (i.e., mouthpiece). The efficacy results for epinephrine HFA MDI in the dose range of 125-250 μg were also comparable to epinephrine CFC MDI (220 μg/inh). Safety assessments demonstrated minimal safety concerns for all treatment groups. No notable safety differences were observed between the studied doses of epinephrine HFA MDI and the active control formulation of epinephrine CFC MDI. Conclusion: The findings indicate that epinephrine HFA MDI provided clinically significant bronchodilator efficacy with minimal safety concerns in a dose range of 125-250 μg. These findings confirmed the optimal treatment doses of 125-250 μg that were appropriate for use in longer term 12 and 26 week chronic dosing studies of epinephrine HFA MDI for patients with intermittent or mild to moderate persistent asthma. Clinical trials registration number: NCT01025648.",2020,No notable safety differences were observed between the studied doses of epinephrine HFA MDI and the active control formulation of epinephrine CFC MDI. ,"['subjects with asthma', 'Subjects with Intermittent or Mild-to-Moderate Persistent Asthma', 'patients with intermittent or mild to moderate persistent asthma']","['epinephrine CFC MDI', 'epinephrine HFA (Primatene ® MIST HFA', 'epinephrine CFC (chlorofluorocarbon) MDI (Primatene MIST CFC', 'Epinephrine Hydrofluroalkane Metered-Dose Inhaler (Primatene ® MIST', 'epinephrine HFA MDI', 'epinephrine hydrofluroalkane (HFA) metered-dose inhaler (MDI) formulation']","['bronchodilator efficacy', 'minimal safety concerns', 'FEV1 (Forced Expiratory Volume']","[{'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C3266628', 'cui_str': 'Persistent asthma'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0993596', 'cui_str': 'Metered Dose Inhaler'}, {'cui': 'C0722799', 'cui_str': 'Primatene'}, {'cui': 'C0475209', 'cui_str': 'm'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0021461', 'cui_str': 'Inhalators'}]","[{'cui': 'C0006280', 'cui_str': 'Bronchodilators'}, {'cui': 'C0547040', 'cui_str': 'Minimal (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}]",,0.109318,No notable safety differences were observed between the studied doses of epinephrine HFA MDI and the active control formulation of epinephrine CFC MDI. ,"[{'ForeName': 'Edward M', 'Initials': 'EM', 'LastName': 'Kerwin', 'Affiliation': 'Clinical Research Institute of Southern Oregon, Medford, Oregon.'}, {'ForeName': 'Donald P', 'Initials': 'DP', 'LastName': 'Tashkin', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.'}, {'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'Murphy', 'Affiliation': 'Charleston ENT and Allergy, Charleston, South Carolina.'}, {'ForeName': 'George W', 'Initials': 'GW', 'LastName': 'Bensch', 'Affiliation': 'Allergy, Immunology, and Asthma Medical Group, Inc., Stockton, California.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Marrs', 'Affiliation': 'Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California.'}, {'ForeName': 'Mary Z', 'Initials': 'MZ', 'LastName': 'Luo', 'Affiliation': 'Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California.'}, {'ForeName': 'Jack Y', 'Initials': 'JY', 'LastName': 'Zhang', 'Affiliation': 'Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California.'}]",Journal of aerosol medicine and pulmonary drug delivery,['10.1089/jamp.2019.1558'] 513,31850492,The Effect of a Priest-Led Intervention on the Choice and Preference of Soda Beverages: A Cluster-Randomized Controlled Trial in Catholic Parishes.,"BACKGROUND Latin America ranks among the regions with the highest level of intake of sugary beverages in the world. Innovative strategies to reduce the consumption of sugary drinks are necessary. PURPOSE Evaluate the effect of a one-off priest-led intervention on the choice and preference of soda beverages. METHODS We conducted a pragmatic cluster-randomized trial in Catholic parishes, paired by number of attendees, in Chimbote, Peru between March and June of 2017. The priest-led intervention, a short message about the importance of protecting one's health, was delivered during the mass. The primary outcome was the proportion of individuals that choose a bottle of soda instead of a bottle of water immediately after the service. Cluster-level estimates were used to compare primary and secondary outcomes between intervention and control groups utilizing nonparametric tests. RESULTS Six parishes were allocated to control and six to the intervention group. The proportion of soda selection at baseline was ~60% in the intervention and control groups, and ranged from 56.3% to 63.8% in Week 1, and from 62.7% to 68.2% in Week 3. The proportion of mass attendees choosing water over soda was better in the priest-led intervention group: 8.2% higher at Week 1 (95% confidence interval 1.7%-14.6%, p = .03), and 6.2% higher at 3 weeks after baseline (p = .15). CONCLUSIONS This study supports the proof-of-concept that a brief priest-led intervention can decrease sugary drink choice. CLINICAL TRIAL INFORMATION ISRCTN, ISRCTN24676734. Registered 25 April 2017, https://www.isrctn.com/ISRCTN24676734.",2020,"The proportion of mass attendees choosing water over soda was better in the priest-led intervention group: 8.2% higher at Week 1 (95% confidence interval 1.7%-14.6%, p = .03), and 6.2% higher at 3 weeks after baseline (p = .15). ","['Catholic parishes, paired by number of attendees, in Chimbote, Peru between March and June of 2017', 'Soda Beverages']","['one-off priest-led intervention', 'Priest-Led Intervention']","['proportion of soda selection', 'sugary drink choice', 'proportion of individuals that choose a bottle of soda instead of a bottle of water immediately after the service', 'proportion of mass attendees choosing water over soda']","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0031238', 'cui_str': 'Peru'}, {'cui': 'C0005329', 'cui_str': 'Beverages'}]","[{'cui': 'C0558272', 'cui_str': 'Priests'}, {'cui': 'C0023175', 'cui_str': 'Lead'}]","[{'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C4319838', 'cui_str': 'Bottle'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}]",,0.114264,"The proportion of mass attendees choosing water over soda was better in the priest-led intervention group: 8.2% higher at Week 1 (95% confidence interval 1.7%-14.6%, p = .03), and 6.2% higher at 3 weeks after baseline (p = .15). ","[{'ForeName': 'J Jaime', 'Initials': 'JJ', 'LastName': 'Miranda', 'Affiliation': 'CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Miraflores, Lima, Peru.'}, {'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Taype-Rondan', 'Affiliation': 'CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Miraflores, Lima, Peru.'}, {'ForeName': 'Janina', 'Initials': 'J', 'LastName': 'Bazalar-Palacios', 'Affiliation': 'Centro de Estudios de Población, Universidad Católica los Ángeles de Chimbote, Casco Urbano, Chimbote, Peru.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Bernabe-Ortiz', 'Affiliation': 'CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Miraflores, Lima, Peru.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Ariely', 'Affiliation': 'Center for Advanced Hindsight, Duke University, Durham, NC, USA.'}]",Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,['10.1093/abm/kaz060'] 514,32173255,Clinical observations of the effect of orthokeratology in children with myopic anisometropia.,"PURPOSE To evaluate the clinical effect of orthokeratology in controlling myopia and treating anisometropia among children with myopic anisometropia. METHODS A total of 108 myopic anisometropic children aged 8-16 years old who wore orthokeratology lenses in both eyes were enrolled in this study and followed up for over 1 year. The more severely myopic eye of each patient was assigned to the more myopic group (108 eyes), with a mean spherical equivalent refraction of -4.25 (-5.00, -3.38) D; the opposite eye of each patient was assigned to the less myopic group (108 eyes), with a refraction of -2.75 (-3.63, -1.88) D. This study observed and analyzed changes in ocular parameters after orthokeratology (Wilcoxon signed-rank test). RESULTS In children who wore orthokeratology lenses for approximately 1 year, the level of anisometropia significantly dropped from 1.38 (1.13, 1.75) D to 1.25 (1.13, 1.75) D (P = .005). The difference between the axial lengths of the two eyes significantly dropped from 0.54 (0.37, 0.74) mm to 0.46 (0.28, 0.67) mm (P< .0001). CONCLUSIONS Orthokeratology seemed to be more effective at delaying the progression of myopia in the more myopic eyes than in the less myopic eyes of myopic anisometropic children. Orthokeratology lenses are suitable for anisometropic children, although the effectiveness of orthokeratology against anisometropia requires additional follow-up time for further observation and study.",2020,"In children who wore orthokeratology lenses for approximately 1 year, the level of anisometropia significantly dropped from 1.38 (1.13, 1.75) D to 1.25 (1.13, 1.75) D (P = .005).","['108 myopic anisometropic children aged 8-16 years old who wore orthokeratology lenses in both eyes', 'anisometropic children', 'children with myopic anisometropia']",['Orthokeratology lenses'],"['level of anisometropia', 'axial lengths']","[{'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C1533088', 'cui_str': 'Orthokeratology'}, {'cui': 'C0023318', 'cui_str': 'Lenses'}, {'cui': 'C0229118', 'cui_str': 'OU - Both eyes'}, {'cui': 'C0003081', 'cui_str': 'Anisometropia'}]","[{'cui': 'C1533088', 'cui_str': 'Orthokeratology'}, {'cui': 'C0023318', 'cui_str': 'Lenses'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0003081', 'cui_str': 'Anisometropia'}, {'cui': 'C0205131', 'cui_str': 'Axial (qualifier value)'}]",108.0,0.0403991,"In children who wore orthokeratology lenses for approximately 1 year, the level of anisometropia significantly dropped from 1.38 (1.13, 1.75) D to 1.25 (1.13, 1.75) D (P = .005).","[{'ForeName': 'Weiwei', 'Initials': 'W', 'LastName': 'Lu', 'Affiliation': 'School of Ophthalmology and Eye Hospital, Wenzhou Medical University, 270 West Xueyuan Road, Wenzhou, Zhejiang, 325027, China.'}, {'ForeName': 'Wanqing', 'Initials': 'W', 'LastName': 'Jin', 'Affiliation': 'School of Ophthalmology and Eye Hospital, Wenzhou Medical University, 270 West Xueyuan Road, Wenzhou, Zhejiang, 325027, China. Electronic address: wcyjqw@163.com.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2020.03.002'] 515,32168290,Tablet-Based Decision Support Tool Improves Performance of Neonatal Resuscitation: A Randomized Trial in Simulation.,"INTRODUCTION Decision support tools (DST) may aid compliance of teams with the Neonatal Resuscitation Program (NRP) algorithm but have not been adequately tested in this population. Furthermore, the optimal team size for neonatal resuscitation is not known. Our aim was to determine whether use of a tablet-based DST or team size altered adherence to the NRP algorithm in teams of healthcare providers (HCPs) performing simulated neonatal resuscitation. METHOD One hundred nine HCPs were randomized into a team of 2 or 3 and into using a DST or memory alone while performing 2 simulation scenarios. The primary outcome was NRP compliance, assessed by the modified Neonatal Resuscitation Performance Evaluation (NRPE). Secondary outcomes were the subcomponents of the NRPE score, cumulative time error (the cumulative time in seconds to perform resuscitation tasks in error, early or late, from NRP guidelines), and the interaction between DST and team size. RESULTS Decision support tool use improved total NRPE score when compared with memory alone (p = 0.015). There was no difference in NRPE score within teams of 2 compared with 3 HCPs. Cumulative time error was decreased with DST use compared with memory alone but was not significant (p = 0.057). Team size did not affect time error. CONCLUSIONS Teams with the DST had improved NRP adherence compared with teams relying on memory alone in 1 of 2 scenarios. Two and 3 HCP teams performed similarly. Given the positive results observed in the simulated environment, further testing the DST in the clinical environment is warranted.",2020,"RESULTS Decision support tool use improved total NRPE score when compared with memory alone (p = 0.015).","['One hundred nine HCPs', 'Neonatal Resuscitation']","['DST or memory alone while performing 2 simulation scenarios', 'tablet-based DST', 'Decision support tools (DST']","['subcomponents of the NRPE score, cumulative time error (the cumulative time in seconds to perform resuscitation tasks in error, early or late, from NRP guidelines), and the interaction between DST and team size', 'NRP adherence', 'NRP compliance, assessed by the modified Neonatal Resuscitation Performance Evaluation (NRPE', 'total NRPE score', 'NRPE score', 'Cumulative time error']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0035273', 'cui_str': 'Resuscitation'}]","[{'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0870393', 'cui_str': 'Decision support tool'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0035273', 'cui_str': 'Resuscitation'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0220845', 'cui_str': 'guidelines'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",109.0,0.0853073,"RESULTS Decision support tool use improved total NRPE score when compared with memory alone (p = 0.015).","[{'ForeName': 'Charles M', 'Initials': 'CM', 'LastName': 'Roitsch', 'Affiliation': ""From the Section of Neonatology, Department of Pediatrics (C.M.R., K.E.P., J.L.H., N.C.S.), Baylor College of Medicine & Texas Children's Hospital, Houston, TX; and Center for Medical Simulation and Innovative Education (J.L.A.), Johns Hopkins All Children's Hospital, St. Petersburg, FL.""}, {'ForeName': 'Karen E', 'Initials': 'KE', 'LastName': 'Patricia', 'Affiliation': ''}, {'ForeName': 'Joseph L', 'Initials': 'JL', 'LastName': 'Hagan', 'Affiliation': ''}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Arnold', 'Affiliation': ''}, {'ForeName': 'Nathan C', 'Initials': 'NC', 'LastName': 'Sundgren', 'Affiliation': ''}]",Simulation in healthcare : journal of the Society for Simulation in Healthcare,['10.1097/SIH.0000000000000422'] 516,32103064,Physical fitness and physical activity association with cognitive function and quality of life: baseline cross-sectional analysis of the PREDIMED-Plus trial.,"Physical activity (PA) has been hypothesized to be effective to maintaining cognitive function and delay cognitive decline in the elderly, but physical fitness (PF) could be a better predictor of cognitive function. We aimed to study the association between PA and PF with cognitive function and quality of life using cross-sectional data from 6874 participants of the PREDIMED-Plus trial (64.9 ± 4.9 years, 48.5% female). PF and PA were measured with a Chair Stand Test, the REGICOR and Rapid Assessment Physical Activity questionnaires. Cognitive function was measured with Mini-mental State Examination, Control Oral Word Association Test, Trail Making Test and Digit Span tests; whereas health-related quality of life was assessed with the SF36-HRQL test. Cognitive and quality of life scores were compared among PF quartiles and PA levels (low, moderate and high) with ANCOVA and with Chair Stand repetitions and energy expenditure from total PA with multivariable linear regression adjusted for confounding factors. PF associated with higher scores in phonemic and semantic verbal fluency tests and with lower TMT A time. However, PA was not associated with the neurocognitive parameters evaluated. Both PF and PA levels were strongly associated with a better quality of life. We concluded that PF, but not PA, is associated with a better cognitive function. This trial was retrospectively registered at the International Standard Randomized Controlled Trial (ISRCTN89898870, https://www.isrctn.com/ISRCTN89898870?q=ISRCTN89898870&filters=&sort=&offset=1&totalResults=1&page=1&pageSize=10&searchType=basic-search) on 07/24/2014.",2020,PF associated with higher scores in phonemic and semantic verbal fluency tests and with lower TMT A time.,"['6874 participants of the PREDIMED-Plus trial (64.9\u2009±\u20094.9 years, 48.5% female']",['Physical activity (PA'],"['Physical fitness and physical activity association with cognitive function and quality of life', 'Cognitive function', 'Cognitive and quality of life scores', 'phonemic and semantic verbal fluency tests', 'quality of life', 'PF and PA', 'Mini-mental State Examination, Control Oral Word Association Test, Trail Making Test and Digit Span tests; whereas health-related quality of life']","[{'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0034380'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0036612', 'cui_str': 'Semantics'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}, {'cui': 'C3827022', 'cui_str': 'Controlled Oral Word Association Test'}, {'cui': 'C0582802', 'cui_str': 'Digit'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}]",6874.0,0.0441536,PF associated with higher scores in phonemic and semantic verbal fluency tests and with lower TMT A time.,"[{'ForeName': 'Lidia', 'Initials': 'L', 'LastName': 'Daimiel', 'Affiliation': 'Nutritional Genomics and Epigenomics Group, IMDEA Food, CEI UAM + CSIC, Madrid, Spain. lidia.daimiel@imdea.org.'}, {'ForeName': 'Miguel A', 'Initials': 'MA', 'LastName': 'Martínez-González', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Dolores', 'Initials': 'D', 'LastName': 'Corella', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Salas-Salvadó', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Helmut', 'Initials': 'H', 'LastName': 'Schröder', 'Affiliation': 'CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Vioque', 'Affiliation': 'CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Dora', 'Initials': 'D', 'LastName': 'Romaguera', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'J Alfredo', 'Initials': 'JA', 'LastName': 'Martínez', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Wärnberg', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Lopez-Miranda', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Ramón', 'Initials': 'R', 'LastName': 'Estruch', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Cano-Ibáñez', 'Affiliation': 'CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Angel', 'Initials': 'A', 'LastName': 'Alonso-Gómez', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Josep A', 'Initials': 'JA', 'LastName': 'Tur', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Francisco J', 'Initials': 'FJ', 'LastName': 'Tinahones', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Lluis', 'Initials': 'L', 'LastName': 'Serra-Majem', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Rafael M', 'Initials': 'RM', 'LastName': 'Micó-Pérez', 'Affiliation': 'Cátedra cronicidad Universidad Miguel Hernández, Fundación, Semergen, Spain.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Lapetra', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Alba', 'Initials': 'A', 'LastName': 'Galdón', 'Affiliation': 'Department of Endocrinology, Fundación Jiménez-Díaz, Madrid, Spain.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Pintó', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Vidal', 'Affiliation': 'CIBER Diabetes y enfermedades metabólicas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Micó', 'Affiliation': 'Nutritional Genomics and Epigenomics Group, IMDEA Food, CEI UAM + CSIC, Madrid, Spain.'}, {'ForeName': 'Gonzalo', 'Initials': 'G', 'LastName': 'Colmenarejo', 'Affiliation': 'Biostatistics and Bioinformatics Unit, IMDEA Food, CEI UAM+CSIC, Madrid, Spain.'}, {'ForeName': 'José J', 'Initials': 'JJ', 'LastName': 'Gaforio', 'Affiliation': 'CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Matía', 'Affiliation': 'Department of Endocrinology and Nutrition, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain.'}, {'ForeName': 'Emilio', 'Initials': 'E', 'LastName': 'Ros', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Buil-Cosiales', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Zenaida', 'Initials': 'Z', 'LastName': 'Vázquez-Ruiz', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'José V', 'Initials': 'JV', 'LastName': 'Sorlí', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Indira Paz', 'Initials': 'IP', 'LastName': 'Graniel', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Aida', 'Initials': 'A', 'LastName': 'Cuenca-Royo', 'Affiliation': ""Integrative Pharmacology and Systems Neurosciences Institut Hospital del Mar de Investigaciones Médicas Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain.""}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Gisbert-Sellés', 'Affiliation': ""Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain.""}, {'ForeName': 'Aina M', 'Initials': 'AM', 'LastName': 'Galmes-Panades', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'M Angeles', 'Initials': 'MA', 'LastName': 'Zulet', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'García-Ríos', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Andrés', 'Initials': 'A', 'LastName': 'Díaz-López', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'de la Torre', 'Affiliation': 'CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Iñigo', 'Initials': 'I', 'LastName': 'Galilea-Zabalza', 'Affiliation': 'Primary Health Care. Servicio Navarro de Salud, Pamplona, Spain.'}, {'ForeName': 'José M', 'Initials': 'JM', 'LastName': 'Ordovás', 'Affiliation': 'Nutritional Genomics and Epigenomics Group, IMDEA Food, CEI UAM + CSIC, Madrid, Spain.'}]",Scientific reports,['10.1038/s41598-020-59458-6'] 517,31971506,A group intervention to improve quality of life for people with advanced dementia living in care homes: the Namaste feasibility cluster RCT.,"BACKGROUND People with advanced dementia who live and die in nursing homes experience variable quality of life, care and dying. There is a need to identify appropriate, cost-effective interventions that facilitate high-quality end-of-life care provision. OBJECTIVES To establish the feasibility and acceptability to staff and family of conducting a cluster randomised controlled trial of the Namaste Care intervention for people with advanced dementia in nursing homes. DESIGN The study had three phases: (1) realist review and (2) intervention refinement to inform the design of (3) a feasibility cluster randomised controlled trial with a process evaluation and economic analysis. Clusters (nursing homes) were randomised in a 3 : 1 ratio to intervention or control (usual care). The nature of the intervention meant that blinding was not possible. SETTING Nursing homes in England providing care for people with dementia. PARTICIPANTS Residents with advanced dementia (assessed as having a Functional Assessment Staging Test score of 6 or 7), their informal carers and nursing home staff. INTERVENTION Namaste Care is a complex group intervention that provides structured personalised care in a dedicated space, focusing on enhancements to the physical environment, comfort management and sensory engagement. MAIN OUTCOME MEASURES The two contender primary outcome measures were Comfort Assessment in Dying - End of Life Care in Dementia for quality of dying (dementia) and Quality of Life in Late Stage Dementia for quality of life. The secondary outcomes were as follows: person with dementia, sleep/activity (actigraphy), neuropsychiatric symptoms, agitation and pain; informal carers, satisfaction with care at the end of life; staff members, person-centred care assessment, satisfaction with care at the end of life and readiness for change; and other data - health economic outcomes, medication/service use and intervention activity. RESULTS Phase 1 (realist review; 86 papers) identified that a key intervention component was the activities enabling the development of moments of connection. In phase 2, refinement of the intervention enabled the production of a user-friendly 16-page A4 booklet. In phase 3, eight nursing homes were recruited. Two homes withdrew before the intervention commenced; four intervention and two control homes completed the study. Residents with advanced dementia ( n  = 32) were recruited in intervention ( n  = 18) and control ( n  = 14) homes. Informal carers (total, n  = 12: intervention, n  = 5; control, n  = 7) and 97 staff from eight sites (intervention, n  = 75; control, n  = 22) were recruited over a 6-month period. Recruitment is feasible. Completion rates of the primary outcome questionnaires were high at baseline (100%) and at 4 weeks (96.8%). The Quality of Life in Late Stage Dementia was more responsive to change over 24 weeks. Even where economic data were missing, these could be collected in a full trial. The intervention was acceptable; the dose varied depending on the staffing and physical environment of each care home. Staff and informal carers reported changes for the person with dementia in two ways: increased social engagement and greater calm. No adverse events related to the intervention were reported. CONCLUSIONS A subsequent definitive trial is feasible if there are amendments to the recruitment process, outcome measure choice and intervention specification. FUTURE WORK In a full trial, consideration is needed of the appropriate outcome measure that is sensitive to different participant responses, and of clear implementation principles for this person-centred intervention in a nursing home context. TRIAL REGISTRATION Current Controlled Trials ISRCTN14948133. FUNDING This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 24, No. 6. See the NIHR Journals Library website for further project information.",2020,Staff and informal carers reported changes for the person with dementia in two ways: increased social engagement and greater calm.,"['people with advanced dementia in nursing homes', 'people with advanced dementia living in care homes', 'People with advanced dementia who live and die in nursing homes', 'Residents with advanced dementia ( n \u2009=\u200932) were recruited in intervention ( n \u2009=\u200918) and control ( n \u2009=\u200914) homes', 'Residents with advanced dementia (assessed as having a Functional Assessment Staging Test score of 6 or 7), their informal carers and nursing home staff', 'Clusters (nursing homes', 'Informal carers (total, n \u2009=\u200912: intervention, n \u2009=\u20095; control, n \u2009=\u20097) and 97 staff from eight sites (intervention, n \u2009=\u200975; control, n \u2009=\u200922', 'Nursing homes in England providing care for people with dementia', 'eight nursing homes were recruited']",['Namaste Care intervention'],"['quality of life', 'social engagement and greater calm', 'Quality of Life', 'Completion rates', 'Comfort Assessment in Dying - End of Life Care in Dementia for quality of dying (dementia) and Quality of Life in Late Stage Dementia for quality of life', 'person with dementia, sleep/activity (actigraphy), neuropsychiatric symptoms, agitation and pain; informal carers, satisfaction with care at the end of life; staff members, person-centred care assessment, satisfaction with care at the end of life and readiness for change; and other data - health economic outcomes, medication/service use and intervention activity']","[{'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0028688', 'cui_str': 'Nursing Homes'}, {'cui': 'C0856538', 'cui_str': 'Living in care'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1319882', 'cui_str': 'Informal carer'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0014282', 'cui_str': 'England'}]",[],"[{'cui': 'C0034380'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0150157', 'cui_str': 'Calming'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0039548', 'cui_str': 'End of Life Care'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C1279941', 'cui_str': 'Late stage (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C4285807', 'cui_str': 'Neuropsychiatric symptoms'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated (finding)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1319882', 'cui_str': 'Informal carer'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013557', 'cui_str': 'economics'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}]",,0.101671,Staff and informal carers reported changes for the person with dementia in two ways: increased social engagement and greater calm.,"[{'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Froggatt', 'Affiliation': 'International Observatory on End of Life Care, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Best', 'Affiliation': 'Clinical Trials Research Centre, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Bunn', 'Affiliation': 'Department of Health and Human Sciences, University of Hertfordshire, Hatfield, UK.'}, {'ForeName': 'Girvan', 'Initials': 'G', 'LastName': 'Burnside', 'Affiliation': 'Clinical Trials Research Centre, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Coast', 'Affiliation': 'Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'Lesley', 'Initials': 'L', 'LastName': 'Dunleavy', 'Affiliation': 'International Observatory on End of Life Care, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Goodman', 'Affiliation': 'Department of Health and Human Sciences, University of Hertfordshire, Hatfield, UK.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Hardwick', 'Affiliation': 'Clinical Trials Research Centre, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Jackson', 'Affiliation': 'Clinical Trials Research Centre, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Kinley', 'Affiliation': 'Hospice UK, London, UK.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Davidson Lund', 'Affiliation': 'Patient and public involvement member, UK.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Lynch', 'Affiliation': 'Department of Health and Human Sciences, University of Hertfordshire, Hatfield, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Mitchell', 'Affiliation': 'Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'Gareth', 'Initials': 'G', 'LastName': 'Myring', 'Affiliation': 'Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'Shakil', 'Initials': 'S', 'LastName': 'Patel', 'Affiliation': 'Lancashire Clinical Trials Unit, University of Central Lancashire, Preston, UK.'}, {'ForeName': 'Guillermo Perez', 'Initials': 'GP', 'LastName': 'Algorta', 'Affiliation': 'International Observatory on End of Life Care, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Preston', 'Affiliation': 'International Observatory on End of Life Care, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Scott', 'Affiliation': 'Patient and public involvement member, UK.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Silvera', 'Affiliation': 'Clinical Trials Research Centre, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Walshe', 'Affiliation': 'International Observatory on End of Life Care, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}]","Health technology assessment (Winchester, England)",['10.3310/hta24060'] 518,31100534,"GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men.","BACKGROUND Glucagon-like peptide-2 (GLP-2) and glucose-dependent insulinotropic polypeptide (GIP) both inhibit bone resorption in humans but the underlying mechanisms are poorly understood. In vitro, GLP-2 activates the GIP-receptor (GIPR). OBJECTIVE Based on in vitro studies, we hypothesized that the antiresorptive effect of GLP-2 was mediated through the GIPR. This was tested using the selective GIPR-antagonist GIP(3-30)NH 2 . METHODS The study was a randomized, single-blinded, placebo-controlled, crossover study conducted at Hvidovre University Hospital, Denmark. Eight healthy young men were included and studied on four study days: GIP (200 μg), GLP-2 (800 μg), GIP(3-30)NH 2 (800 pmol/kg/min) + GLP-2 (800 μg), and placebo. The main outcomes were bone resorption measured as collagen type 1 C-terminal telopeptide (CTX) and bone formation measured as procollagen type 1 N-terminal propeptide (P1NP). RESULTS CTX (mean ± SEM) significantly decreased after both GIP (to 55.3 ± 6.3% of baseline at t = 90 min) and GLP-2 (to 60.5 ± 5.0% of baseline at t = 180 min). The maximal reduction in CTX after GIP(3-30)NH 2  + GLP-2 (to 63.2 ± 3.1% of baseline) did not differ from GLP-2 alone (p = 0.95) nor did net AUC 0-240 (-6801 ± 879%*min vs -6027 ± 648%*min, p = 0.56). At t = 30 min, GIP significantly (p < 0.0001) increased P1NP to 115.1 ± 2.2% of baseline compared with 103.1 ± 1.5% after placebo. Both GLP-2 and GIP(3-30)NH 2  + GLP-2 significantly (p < 0.0001) decreased P1NP to 91.3 ± 1.1% and 88.1 ± 3.0% of baseline, respectively (at t = 45 min) compared with placebo. CONCLUSIONS GIPR antagonism did not inhibit the GLP-2-induced reduction in bone resorption (CTX) in healthy young men. In contrast to GLP-2, GIP increased P1NP despite decreasing CTX indicating an uncoupling of bone resorption from formation. Thus, GLP-2 and GIP seem to exert separate effects on bone turnover in humans. CLINICAL TRIALS INFORMATION ClinicalTrials.gov (NCT03159741).",2019,"At t = 30 min, GIP significantly (p < 0.0001) increased P1NP to 115.1 ± 2.2% of baseline compared with 103.1 ± 1.5% after placebo.","['Hvidovre University Hospital, Denmark', 'healthy young men', 'Eight healthy young men']","['GLP-2 (800\u202fμg), GIP(3-30)NH 2 (800\u202fpmol/kg/min)\u202f+\u202fGLP-2', 'Glucagon-like peptide-2 (GLP-2) and glucose-dependent insulinotropic polypeptide (GIP', 'placebo', 'GLP-2 and GIP']","['maximal reduction in CTX', 'bone resorption measured as collagen type 1 C-terminal telopeptide (CTX) and bone formation measured as procollagen type 1 N-terminal propeptide (P1NP', 'bone turnover', 'bone resorption (CTX']","[{'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C1530889', 'cui_str': 'teduglutide'}, {'cui': 'C3844106', 'cui_str': 'Eight hundred'}, {'cui': 'C0439192', 'cui_str': 'pmol'}, {'cui': 'C1532757', 'cui_str': 'kg/min'}, {'cui': 'C0912332', 'cui_str': 'Proglucagon (126-158)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C1305923', 'cui_str': 'Polypeptides'}, {'cui': 'C1702020', 'cui_str': '37-epsilon-palmitoyl-Lys-GIP'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0005974', 'cui_str': 'Osteoclastic Bone Loss'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0441729', 'cui_str': 'Type 1 (qualifier value)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0029433', 'cui_str': 'Ossification'}, {'cui': 'C0033235', 'cui_str': 'Procollagen'}, {'cui': 'C0085268', 'cui_str': 'Bone Turnover'}]",8.0,0.24366,"At t = 30 min, GIP significantly (p < 0.0001) increased P1NP to 115.1 ± 2.2% of baseline compared with 103.1 ± 1.5% after placebo.","[{'ForeName': 'Kirsa', 'Initials': 'K', 'LastName': 'Skov-Jeppesen', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Maria S', 'Initials': 'MS', 'LastName': 'Svane', 'Affiliation': 'Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark; Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark.'}, {'ForeName': 'Christoffer', 'Initials': 'C', 'LastName': 'Martinussen', 'Affiliation': 'Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark; Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark.'}, {'ForeName': 'Maria B N', 'Initials': 'MBN', 'LastName': 'Gabe', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Lærke S', 'Initials': 'LS', 'LastName': 'Gasbjerg', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Veedfald', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Kirstine N', 'Initials': 'KN', 'LastName': 'Bojsen-Møller', 'Affiliation': 'Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark.'}, {'ForeName': 'Sten', 'Initials': 'S', 'LastName': 'Madsbad', 'Affiliation': 'Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark.'}, {'ForeName': 'Jens J', 'Initials': 'JJ', 'LastName': 'Holst', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Mette M', 'Initials': 'MM', 'LastName': 'Rosenkilde', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Bolette', 'Initials': 'B', 'LastName': 'Hartmann', 'Affiliation': 'Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark. Electronic address: bhartmann@sund.ku.dk.'}]",Bone,['10.1016/j.bone.2019.05.014'] 519,30845365,Effect of Alendronic Acid on Fracture Healing: A Multicenter Randomized Placebo-Controlled Trial.,"There is a concern that bisphosphonates may impair fracture healing because of their inhibitory effects on bone turnover. Here we evaluated the effects of early bisphosphonate therapy on fracture healing and functional outcome following a fracture of the distal radius. The fracture and bisphosphonates (FAB) trial was a double-blind, randomized, placebo-controlled trial involving 15 trauma centers in the United Kingdom. We enrolled 421 bisphosphonate-naive patients aged ≥50 years with a radiographically confirmed fracture of the distal radius and randomized them in a 1:1 ratio to receive alendronic acid 70 mg once weekly (n = 215) or placebo (n = 206) within 14 days of the fracture. The primary outcome measure was the proportion of fractures that had radiologically united at 4 weeks as assessed by an observer, blinded to treatment allocation. Secondary outcomes included the Disabilities of the Arm Shoulder and Hand (DASH) questionnaire, range of wrist movement and grip strength, pain and analgesia requirements, and the rate of malunion. The mean ± SD age of participants was 63 ± 8.5 years and 362 (86%) were female. At 4 weeks, 48 of 202 (23.8%) fractures had united in the alendronic acid group compared with 52 of 187 (27.8%) in the placebo group (observed absolute proportion difference 4.0%; 95% CI, -4.7% to 12.8%; p = 0.36). The absolute proportion difference between groups based on imputed data was 4.5% (95% CI, -4.7% to 13.8%; p = 0.30). There was no significant difference in the proportion of fractures that had united at any other time point and no differences in the DASH score, pain at the fracture site, grip strength, or any other clinical outcome. We conclude that among patients aged 50 years and above with a distal radius fracture, early administration of alendronic acid does not adversely affect fracture union or clinical outcome. These findings suggest bisphosphonate therapy can be safely commenced early after fracture if clinically indicated. © 2019 American Society for Bone and Mineral Research.",2019,"At 4 weeks, 48 of 202 (23.8%) fractures had united in the alendronic acid group compared with 52 of 187 (27.8%) in the placebo group (observed absolute proportion difference 4.0%; 95% CI, -4.7% to 12.8%; p = 0.36).","['421 bisphosphonate-naive patients aged ≥50 years with a radiographically confirmed fracture of the distal radius and randomized them in a 1:1 ratio to receive', 'patients aged 50 years and above with a distal radius fracture, early administration of', '15 trauma centers in the United Kingdom', '© 2019 American Society for Bone and Mineral Research', 'The mean\u2009±\u2009SD age of participants was 63\u2009±\u20098.5 years and 362 (86%) were female']","['placebo', 'Placebo', 'alendronic acid 70', 'alendronic acid', 'bisphosphonates', 'Alendronic Acid', 'bisphosphonate therapy']","['DASH score, pain at the fracture site, grip strength, or any other clinical outcome', 'fracture healing and functional outcome', 'proportion of fractures that had radiologically united', 'Fracture Healing', 'proportion of fractures', 'Disabilities of the Arm Shoulder and Hand (DASH) questionnaire, range of wrist movement and grip strength, pain and analgesia requirements, and the rate of malunion']","[{'cui': 'C0012544', 'cui_str': 'Bisphosphonates'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius (body structure)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0040786', 'cui_str': 'Trauma Centers'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0026162', 'cui_str': 'Minerals'}, {'cui': 'C0035168'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4517877', 'cui_str': '8.5'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0771311', 'cui_str': 'Alendronic acid'}, {'cui': 'C4510264', 'cui_str': 'Disphosphonate therapy'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0429271', 'cui_str': 'Grip strength (observable entity)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0162542', 'cui_str': 'Fracture Healing'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C2919270', 'cui_str': 'Disabilities of the arm, shoulder and hand outcome measurement'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0043262', 'cui_str': 'Wrist'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}]",421.0,0.680244,"At 4 weeks, 48 of 202 (23.8%) fractures had united in the alendronic acid group compared with 52 of 187 (27.8%) in the placebo group (observed absolute proportion difference 4.0%; 95% CI, -4.7% to 12.8%; p = 0.36).","[{'ForeName': 'Andrew D', 'Initials': 'AD', 'LastName': 'Duckworth', 'Affiliation': 'Edinburgh Clinical Trials Unit, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Margaret M', 'Initials': 'MM', 'LastName': 'McQueen', 'Affiliation': 'Edinburgh Orthopaedic Trauma, Royal Infirmary of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Christopher E', 'Initials': 'CE', 'LastName': 'Tuck', 'Affiliation': 'Edinburgh Clinical Trials Unit, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Jonathan H', 'Initials': 'JH', 'LastName': 'Tobias', 'Affiliation': 'Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'Jeremy Mark', 'Initials': 'JM', 'LastName': 'Wilkinson', 'Affiliation': 'Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Leela C', 'Initials': 'LC', 'LastName': 'Biant', 'Affiliation': 'Trauma & Orthopaedic Surgery, University of Manchester, Manchester, UK.'}, {'ForeName': 'Elizabeth Claire', 'Initials': 'EC', 'LastName': 'Pulford', 'Affiliation': 'Oxford University Hospitals National Health Service (NHS) Foundation Trust, Headington, Oxford, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Aldridge', 'Affiliation': 'The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Edwards', 'Affiliation': 'Norfolk and Norwich University Hospital Foundation Trust, Norwich, UK.'}, {'ForeName': 'Chris P', 'Initials': 'CP', 'LastName': 'Roberts', 'Affiliation': 'Ipswich Hospital NHS Trust, Ipswich, UK.'}, {'ForeName': 'Manoj', 'Initials': 'M', 'LastName': 'Ramachandran', 'Affiliation': 'Royal London Hospital, Barts Health NHS Trust, London, UK.'}, {'ForeName': 'Andrew Richard', 'Initials': 'AR', 'LastName': 'McAndrew', 'Affiliation': 'Royal Berkshire Hospital Foundation Trust, Reading, UK.'}, {'ForeName': 'Kenneth Ck', 'Initials': 'KC', 'LastName': 'Cheng', 'Affiliation': 'NHS Ayrshire & Arran, Ayr, UK.'}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'Johnston', 'Affiliation': 'Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Nasir H', 'Initials': 'NH', 'LastName': 'Shah', 'Affiliation': 'Warrington & Halton Hospitals NHS Foundation Trust, Warrington, UK.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Mathew', 'Affiliation': ""Queen's Hospital, Romford, UK.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Harvie', 'Affiliation': 'Raigmore Hospital, Inverness, UK.'}, {'ForeName': 'Birgit C', 'Initials': 'BC', 'LastName': 'Hanusch', 'Affiliation': 'South Tees, Hospitals NHS Foundation Trust, Middlesbrough, UK.'}, {'ForeName': 'Ronnie', 'Initials': 'R', 'LastName': 'Harkess', 'Affiliation': 'Edinburgh Clinical Trials Unit, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Aryelly', 'Initials': 'A', 'LastName': 'Rodriguez', 'Affiliation': 'Edinburgh Clinical Trials Unit, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Gordon D', 'Initials': 'GD', 'LastName': 'Murray', 'Affiliation': 'Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Stuart H', 'Initials': 'SH', 'LastName': 'Ralston', 'Affiliation': 'Edinburgh Clinical Trials Unit, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.'}]",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,['10.1002/jbmr.3679'] 520,32147925,Evaluation of pharmacokinetics and acute anti-inflammatory potential of two oral cannabidiol preparations in healthy adults.,"Cannabidiol (CBD) is a dietary supplement with numerous purported health benefits and an expanding commercial market. Commercially available CBD preparations range from tinctures, oils, and powders, to foods and beverages. Despite widespread use, information regarding bioavailability of these formulations is limited. The purpose of this study was to test the bioavailability of two oral formulations of CBD in humans and explore their potential acute anti-inflammatory activity. We conducted a pilot randomized, parallel arm, double-blind study in 10 healthy adults to determine differences in pharmacokinetics of commercially available water and lipid-soluble CBD powders. Participants consumed a single 30 mg dose, which is within the range of typical commercial supplement doses, and blood samples were collected over 6 hr and analyzed for CBD concentrations. Peripheral blood mononuclear cells (PBMCs) were collected at baseline and T = 90 min, cultured and stimulated with bacterial lipopolysaccharide (LPS) to induce an inflammatory response. Cell supernatants were assayed for IL-10 and TNF, markers of inflammation, using enzyme-linked immunosorbent assays. The water-soluble powder had C max = 2.82 ng/ml, T max = 90 min, and was approximately ×4.5 more bioavailable than the lipid-soluble form. TNF was decreased in LPS-stimulated PBMCs collected 90 min after CBD exposure relative to cells collected at baseline. This study provides pilot data for designing and powering future studies to establish the anti-inflammatory potential and bioavailability of a larger variety of commercial CBD products consumed by humans.",2020,TNF was decreased in LPS-stimulated PBMCs collected 90 min after CBD exposure relative to cells collected at baseline.,"['10 healthy adults', 'healthy adults']","['CBD', 'Cannabidiol (CBD']","['Peripheral blood mononuclear cells (PBMCs', 'TNF']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0006863', 'cui_str': '1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-'}]","[{'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}]",10.0,0.129903,TNF was decreased in LPS-stimulated PBMCs collected 90 min after CBD exposure relative to cells collected at baseline.,"[{'ForeName': 'Jack M', 'Initials': 'JM', 'LastName': 'Hobbs', 'Affiliation': 'Food and Nutrition Clinical Research Laboratory, Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, Colorado.'}, {'ForeName': 'Allegra R', 'Initials': 'AR', 'LastName': 'Vazquez', 'Affiliation': 'Food and Nutrition Clinical Research Laboratory, Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, Colorado.'}, {'ForeName': 'Nicholas D', 'Initials': 'ND', 'LastName': 'Remijan', 'Affiliation': 'Department of Horticulture and Landscape Architecture, Colorado State University, Fort Collins, Colorado.'}, {'ForeName': 'Roxanne E', 'Initials': 'RE', 'LastName': 'Trotter', 'Affiliation': 'Food and Nutrition Clinical Research Laboratory, Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, Colorado.'}, {'ForeName': 'Thomas V', 'Initials': 'TV', 'LastName': 'McMillan', 'Affiliation': 'Food and Nutrition Clinical Research Laboratory, Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, Colorado.'}, {'ForeName': 'Kimberly E', 'Initials': 'KE', 'LastName': 'Freedman', 'Affiliation': 'Food and Nutrition Clinical Research Laboratory, Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, Colorado.'}, {'ForeName': 'Yuren', 'Initials': 'Y', 'LastName': 'Wei', 'Affiliation': 'Food and Nutrition Clinical Research Laboratory, Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, Colorado.'}, {'ForeName': 'Keith A', 'Initials': 'KA', 'LastName': 'Woelfel', 'Affiliation': 'Caliper Foods, Commerce City, Colorado.'}, {'ForeName': 'Olivia R', 'Initials': 'OR', 'LastName': 'Arnold', 'Affiliation': 'Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, Colorado.'}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Wolfe', 'Affiliation': 'Proteomics and Metabolomics Facility, Office of the Vice President, Colorado State University, Fort Collins, Colorado.'}, {'ForeName': 'Sarah A', 'Initials': 'SA', 'LastName': 'Johnson', 'Affiliation': 'Food and Nutrition Clinical Research Laboratory, Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, Colorado.'}, {'ForeName': 'Tiffany L', 'Initials': 'TL', 'LastName': 'Weir', 'Affiliation': 'Food and Nutrition Clinical Research Laboratory, Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, Colorado.'}]",Phytotherapy research : PTR,['10.1002/ptr.6651'] 521,31948903,"Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.","Limited-stage (LS) small-cell lung cancer (SCLC) remains an area of high unmet medical need. The standard-of-care therapy comprises curative-intent platinum-based chemotherapy with concurrent radiotherapy (cCRT), which can be followed by prophylactic brain irradiation and then observation. However, most patients will relapse. Durvalumab (antiprogrammed cell death ligand-1) has enhanced the efficacy outcomes after cCRT for patients with unresectable, stage III non-small-cell lung cancer. Recently, durvalumab combined with platinum-etoposide demonstrated a significant survival benefit compared with platinum-etoposide as first-line treatment of patients with extensive-stage SCLC and has also shown antitumor activity as monotherapy and combined with tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4) in pretreated patients with extensive-stage SCLC. ADRIATIC, a phase III, randomized, double-blind, placebo-controlled, multicenter, global study (ClinicalTrials.gov identifier, NCT03703297), is designed to investigate the efficacy of durvalumab, with or without tremelimumab, as consolidation therapy for patients with LS-SCLC without disease progression after cCRT. Approximately 600 patients with documented histologic or cytologic LS-SCLC, World Health Organization/Eastern Cooperative Oncology Group performance status 0 or 1, and no progression after 4 cycles of cCRT will be randomized (1:1:1) to treatment (durvalumab 1500 mg plus placebo every 4 weeks [q4w] for 4 cycles, followed by durvalumab 1500 mg q4w; durvalumab 1500 mg plus tremelimumab 75 mg q4w for 4 cycles, followed by durvalumab 1500 mg q4w; or dual placebo q4w for 4 cycles, followed by single placebo q4w) within 1 to 42 days of completing cCRT, stratified by stage and receipt of prophylactic brain irradiation. The primary endpoints are progression-free survival and overall survival. The secondary endpoints are overall survival and progression-free survival rates, objective response rate, and safety and tolerability. Recruitment began in September 2018.",2020,"Durvalumab (antiprogrammed cell death ligand-1) has enhanced the efficacy outcomes after cCRT for patients with unresectable, stage III, non-SCLC.","['Patients With Limited-stage Small-cell Lung Cancer', 'pretreated patients with extensive-stage SCLC', 'patients with LS-SCLC without disease progression after cCRT', 'patients with unresectable, stage III, non-SCLC', 'Approximately 600 patients with documented histologic or cytologic LS-SCLC, World Health Organization']","['standard-of-care therapy comprises curative-intent platinum-based chemotherapy with concurrent radiotherapy (cCRT', 'placebo', 'durvalumab, with or without tremelimumab', 'Durvalumab With or Without Tremelimumab', 'Placebo', 'durvalumab 1500 mg q4w; durvalumab 1500 mg plus tremelimumab 75 mg q4w for 4 cycles, followed by durvalumab 1500 mg q4w; or dual placebo', 'Concurrent Chemoradiotherapy', 'durvalumab combined with platinum-etoposide', 'durvalumab 1500 mg plus placebo', 'platinum-etoposide']","['antitumor activity', 'overall survival and progression-free survival rates, objective response rate, safety, and tolerability', 'progression-free survival and overall survival', 'survival benefit']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0149925', 'cui_str': 'Oat Cell Lung Cancer'}, {'cui': 'C0205231', 'cui_str': 'Extensive (qualifier value)'}, {'cui': 'C0242656', 'cui_str': 'Disease Progression'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3 (qualifier value)'}, {'cui': 'C0332232', 'cui_str': 'Approximate (qualifier value)'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0205462', 'cui_str': 'Histologic (qualifier value)'}, {'cui': 'C0205471', 'cui_str': 'Cytologic (qualifier value)'}, {'cui': 'C0043237', 'cui_str': 'WHO'}]","[{'cui': 'C2936643', 'cui_str': 'Standard of Care'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1276305', 'cui_str': 'Curative procedure'}, {'cui': 'C1283828', 'cui_str': 'Intentional'}, {'cui': 'C1098768', 'cui_str': '(diethylenetriamine)-platinum(II)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0205420', 'cui_str': 'Concurrent (qualifier value)'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4055109', 'cui_str': 'durvalumab'}, {'cui': 'C2351038', 'cui_str': 'tremelimumab'}, {'cui': 'C4517582', 'cui_str': '1500'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C3178775', 'cui_str': 'Concomitant Radiochemotherapy'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0015133', 'cui_str': 'Etoposide'}]","[{'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",600.0,0.396906,"Durvalumab (antiprogrammed cell death ligand-1) has enhanced the efficacy outcomes after cCRT for patients with unresectable, stage III, non-SCLC.","[{'ForeName': 'Suresh', 'Initials': 'S', 'LastName': 'Senan', 'Affiliation': 'Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands. Electronic address: s.senan@amsterdamumc.nl.'}, {'ForeName': 'Isamu', 'Initials': 'I', 'LastName': 'Okamoto', 'Affiliation': 'Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.'}, {'ForeName': 'Gyeong-Won', 'Initials': 'GW', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Gyeongsang, Republic of Korea.'}, {'ForeName': 'Yuanbin', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI.'}, {'ForeName': 'Seiji', 'Initials': 'S', 'LastName': 'Niho', 'Affiliation': 'Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Mak', 'Affiliation': 'AstraZeneca, Gaithersburg, MD.'}, {'ForeName': 'Wenliang', 'Initials': 'W', 'LastName': 'Yao', 'Affiliation': 'AstraZeneca, Gaithersburg, MD.'}, {'ForeName': 'Norah', 'Initials': 'N', 'LastName': 'Shire', 'Affiliation': 'AstraZeneca, Gaithersburg, MD.'}, {'ForeName': 'Haiyi', 'Initials': 'H', 'LastName': 'Jiang', 'Affiliation': 'AstraZeneca, Gaithersburg, MD.'}, {'ForeName': 'Byoung Chul', 'Initials': 'BC', 'LastName': 'Cho', 'Affiliation': 'Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea.'}]",Clinical lung cancer,['10.1016/j.cllc.2019.12.006'] 522,31366659,Effectiveness of a mobile preconception lifestyle programme in couples undergoing in vitro fertilisation (IVF): the protocol for the PreLiFe randomised controlled trial (PreLiFe-RCT).,"INTRODUCTION Infertility and in vitro fertilisation (IVF; with or without intracytoplasmic sperm injection) result in considerable emotional and financial burden. Increasing evidence suggests that lifestyle factors, including diet, physical activity and personal well-being, are associated with IVF-success rates. Currently, IVF is not routinely combined with a lifestyle programme. The preconception lifestyle (PreLiFe) randomised controlled trial (RCT) assesses the effects of a new mobile PreLiFe programme in couples undergoing IVF. METHODS AND ANALYSIS A multicentre RCT including 460 heterosexual couples starting IVF in Belgian fertility clinics. IVF couples are randomised between an attention control group or the PreLiFe programme for a period of 12 months or until an ongoing pregnancy is confirmed by ultrasound. The attention control programme includes a mobile application with treatment information (ie, appointments and medication instructions) in addition to standard care. The PreLiFe programme includes a mobile application with the same treatment information in combination with a lifestyle programme. This new lifestyle programme includes tailored advice and skills training on diet, physical activity and mindfulness in combination with text messages and telephone interaction with a healthcare professional trained in motivational interviewing. The primary outcome of this RCT is the cumulative ongoing pregnancy rate within 12 months after randomisation. Secondary outcomes include changes in diet, physical activity, emotional distress, body mass index, waist circumference, quality of life and other reproductive outcomes including IVF discontinuation, clinical pregnancy rate and time to pregnancy. Additionally, partner support and the feasibility (use and acceptability) of the PreLiFe programme will be evaluated in the intervention group. Analysis will be according to intention to treat. ETHICS AND DISSEMINATION This study has been approved by the Medical Ethical Committee of the Leuven University Hospital (Belgium) and the other recruiting clinics. The findings of this RCT will be disseminated through presentations at international scientific meetings and peer-reviewed publications. TRIAL REGISTRATION NUMBER NCT03790449; Pre-results.",2019,"Secondary outcomes include changes in diet, physical activity, emotional distress, body mass index, waist circumference, quality of life and other reproductive outcomes including IVF discontinuation, clinical pregnancy rate and time to pregnancy.","['IVF couples', 'couples undergoing in vitro fertilisation (IVF', '460 heterosexual couples starting IVF in Belgian fertility clinics', 'couples undergoing IVF']","['RCT', 'mobile preconception lifestyle programme', 'vitro fertilisation (IVF; with or without intracytoplasmic sperm injection', 'skills training on diet, physical activity and mindfulness in combination with text messages and telephone interaction with a healthcare professional trained in motivational interviewing', 'PreLiFe programme', 'new mobile PreLiFe programme']","['changes in diet, physical activity, emotional distress, body mass index, waist circumference, quality of life and other reproductive outcomes including IVF discontinuation, clinical pregnancy rate and time to pregnancy', 'cumulative ongoing pregnancy rate', 'feasibility (use and acceptability']","[{'cui': 'C0015915', 'cui_str': 'Test-Tube Fertilization'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C1527360', 'cui_str': 'Heterosexuals'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0337797', 'cui_str': 'Belgians (ethnic group)'}, {'cui': 'C0015895', 'cui_str': 'Fecundity'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}]","[{'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0015914', 'cui_str': 'Fertilization'}, {'cui': 'C0015915', 'cui_str': 'Test-Tube Fertilization'}, {'cui': 'C0455164', 'cui_str': 'ICSI'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}, {'cui': 'C1704312', 'cui_str': 'Healthcare professional (occupation)'}, {'cui': 'C0683474', 'cui_str': 'Motivational Interviewing'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0700361', 'cui_str': 'Emotional distress'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0034380'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0015915', 'cui_str': 'Test-Tube Fertilization'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rate'}, {'cui': 'C3494204', 'cui_str': 'Time-to-Pregnancy'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",,0.187266,"Secondary outcomes include changes in diet, physical activity, emotional distress, body mass index, waist circumference, quality of life and other reproductive outcomes including IVF discontinuation, clinical pregnancy rate and time to pregnancy.","[{'ForeName': 'Tessy', 'Initials': 'T', 'LastName': 'Boedt', 'Affiliation': 'Department of Chronic Diseases Metabolism and Ageing, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Eline', 'Initials': 'E', 'LastName': 'Dancet', 'Affiliation': 'Leuven University Fertility Centre, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Lie Fong', 'Affiliation': 'Leuven University Fertility Centre, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Peeraer', 'Affiliation': 'Leuven University Fertility Centre, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'De Neubourg', 'Affiliation': 'Antwerp University Hospital, Centre for Reproductive Medicine, Edegem, Belgium.'}, {'ForeName': 'Sofie', 'Initials': 'S', 'LastName': 'Pelckmans', 'Affiliation': 'Department of Obstetrics and Gynaecology, Imelda Hospital Bonheiden, Bonheiden, Belgium.'}, {'ForeName': 'Arne', 'Initials': 'A', 'LastName': 'van de Vijver', 'Affiliation': 'Department of Obstetrics and Gynaecology, General Hospital Sint Jan Bruges-Ostend, Brugge, Belgium.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Seghers', 'Affiliation': 'Department of Movement Sciences, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Katleen', 'Initials': 'K', 'LastName': 'Van der Gucht', 'Affiliation': 'Leuven Mindfulness Centre, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Van Calster', 'Affiliation': 'Department of Development and Regeneration, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Spiessens', 'Affiliation': 'Leuven University Fertility Centre, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Matthys', 'Affiliation': 'Department of Chronic Diseases Metabolism and Ageing, KU Leuven, Leuven, Belgium.'}]",BMJ open,['10.1136/bmjopen-2019-029665'] 523,31366664,Protocol for a pilot randomised controlled trial of an educational programme for adults on chronic haemodialysis with fatigue (Fatigue-HD).,"INTRODUCTION Fatigue is a pervasive symptom of end-stage renal disease (ESRD) that is associated with low quality of life, disability and mortality, and has been identified as a top research priority by patients. We developed a personalised, web-supported educational programme (the Personal Energy Planning (PEP) programme) to teach people with ESRD to use energy management to manage fatigue. Preliminary studies have demonstrated positive effects on fatigue and life participation (ie, the ability to participate in valued day-to-day activities), which justifies the need for a randomised controlled trial (RCT) to better understand the efficacy of the programme. The objectives of the pilot RCT are to estimate RCT eligibility, recruitment and attrition rates, to inform the primary outcome measure and sample size for the RCT and to evaluate treatment fidelity among programme administrators. METHODS AND ANALYSIS A parallel-arm, 1:1 pilot RCT will be conducted at four in-centre haemodialysis units in Calgary, Alberta, Canada. People on haemodialysis who report moderate or severe fatigue on the Fatigue Severity Scale, and meet other study eligibility criteria, will be invited to participate. Consenting participants will be randomised to undergo the 7-9 week 'PEP' programme or an active control, and followed for 12 weeks after the programme concludes. Information on eligibility, recruitment and attrition rates will be collected, and questionnaires assessing fatigue and life participation will be administered preintervention, midintervention, immediately postintervention and 12 weeks postintervention. Analyses will include calculation of eligibility, recruitment and attrition rates; power considerations for the full-scale RCT and evaluation of treatment fidelity of programme administrators. ETHICS AND DISSEMINATION Risks associated with this study are minor. Patients may experience emotional discomfort while filling out study questionnaires. They will be advised to skip any questions that make them uncomfortable. Potential benefits of participating include any benefit derived from the study intervention, and contributing to research that may benefit people with kidney disease in the future. Trial results will be disseminated via publication in an academic journal and presentation at academic conferences. The study has been approved by the Conjoint Health Research Ethics Board at the University of Calgary (ID #18-1657).",2019,"We developed a personalised, web-supported educational programme (the Personal Energy Planning (PEP) programme) to teach people with ESRD to use energy management to manage fatigue.","['adults on chronic haemodialysis with fatigue (Fatigue-HD', 'People on haemodialysis who report moderate or severe fatigue on the Fatigue Severity Scale, and meet other study eligibility criteria', 'Consenting participants']","['educational programme', ""PEP' programme or an active control""]",['experience emotional discomfort'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1740835', 'cui_str': 'Chronic haemodialysis'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0222045'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}]","[{'cui': 'C0359587', 'cui_str': 'Peptamen'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}]",,0.154542,"We developed a personalised, web-supported educational programme (the Personal Energy Planning (PEP) programme) to teach people with ESRD to use energy management to manage fatigue.","[{'ForeName': 'Janine F', 'Initials': 'JF', 'LastName': 'Farragher', 'Affiliation': 'Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Chandra', 'Initials': 'C', 'LastName': 'Thomas', 'Affiliation': 'Medicine, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Ravani', 'Affiliation': 'Medicine, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Braden', 'Initials': 'B', 'LastName': 'Manns', 'Affiliation': 'Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Meghan J', 'Initials': 'MJ', 'LastName': 'Elliott', 'Affiliation': 'Medicine, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Brenda R', 'Initials': 'BR', 'LastName': 'Hemmelgarn', 'Affiliation': 'Community Health Sciences, University of Calgary, Calgary, Alberta, Canada Brenda.Hemmelgarn@ahs.ca.'}]",BMJ open,['10.1136/bmjopen-2019-030333'] 524,31289092,Multicentre endoscopist-blinded randomised clinical trial to compare two bowel preparations after a colonoscopy with inadequate cleansing: a study protocol.,"INTRODUCTION Inadequate bowel preparation is common and negatively impacts colonoscopy quality. The objective of this study is to compare two bowel preparation regimens in cleansing the colon after an index colonoscopy with failed bowel preparation. METHODS AND ANALYSIS This is a phase III, multicentre, randomised clinical trial comparing two bowel preparation regimens after failure to adequately cleanse at the index colonoscopy. Regimen A consists of 4 L split-dose polyethylene glycol electrolyte solution (PEG-ELS) and Regimen B consists of 6 L split-dose PEG-ELS, both preceded by 15 mg of bisacodyl the day before the procedure along with a low-fibre diet 3 and 2 days before the procedure followed by a clear fluid diet starting the day before the procedure. The primary outcome is adequate bowel preparation, defined as a Boston Bowel Preparation Scale (BBPS) score of ≥6 with each segment score ≥2. Secondary outcomes include mean BBPS score, bowel preparation adequacy using the US Multi-Society Task Force on Colorectal Cancer definition, detection rate by polyp subtype, caecal intubation rate, mean Validated Patient Tolerability Questionnaire for Bowel Preparation score, subject willingness to repeat the preparation and faecal incontinence rate. ETHICS AND DISSEMINATION The study will be conducted in accordance with Good Clinical Practice guidelines and local institutional standards. Study findings will be disseminated at an international gastroenterology conference and published in peer-reviewed journals. TRIAL REGISTRATION NUMBER NCT02976805; Pre-results.",2019,"Secondary outcomes include mean BBPS score, bowel preparation adequacy using the US Multi-Society Task Force on Colorectal Cancer definition, detection rate by polyp subtype, caecal intubation rate, mean Validated Patient Tolerability Questionnaire for Bowel Preparation score, subject willingness to repeat the preparation and faecal incontinence rate. ",[],"['colonoscopy with inadequate cleansing', 'polyethylene glycol electrolyte solution (PEG-ELS']","['mean BBPS score, bowel preparation adequacy using the US Multi-Society Task Force on Colorectal Cancer definition, detection rate by polyp subtype, caecal intubation rate, mean Validated Patient Tolerability Questionnaire for Bowel Preparation score, subject willingness to repeat the preparation and faecal incontinence rate', 'adequate bowel preparation, defined as a Boston Bowel Preparation Scale (BBPS) score of ≥6 with each segment score ≥2']",[],"[{'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}, {'cui': 'C0205412', 'cui_str': 'Inadequate (qualifier value)'}, {'cui': 'C0032483', 'cui_str': 'polyethylene oxide'}, {'cui': 'C3541941', 'cui_str': 'Electrolyte solutions'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0455052', 'cui_str': 'Preparation of bowel for procedure (procedure)'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0162458', 'cui_str': 'Task Forces'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C3539107', 'cui_str': 'Definition (core metadata concept)'}, {'cui': 'C0032584', 'cui_str': 'Polyp (morphologic abnormality)'}, {'cui': 'C0449560', 'cui_str': 'Subtype (attribute)'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C0015732', 'cui_str': 'Bowel Incontinence'}, {'cui': 'C0205411', 'cui_str': 'Adequate (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C4302285', 'cui_str': 'Boston bowel preparation scale (assessment scale)'}, {'cui': 'C0441635', 'cui_str': 'Segment (qualifier value)'}]",,0.31304,"Secondary outcomes include mean BBPS score, bowel preparation adequacy using the US Multi-Society Task Force on Colorectal Cancer definition, detection rate by polyp subtype, caecal intubation rate, mean Validated Patient Tolerability Questionnaire for Bowel Preparation score, subject willingness to repeat the preparation and faecal incontinence rate. ","[{'ForeName': 'Michael Sai Lai', 'Initials': 'MSL', 'LastName': 'Sey', 'Affiliation': 'Program for Experimental Medicine, Western University, London, Ontario, Canada.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'von Renteln', 'Affiliation': ""Division of Gastroenterology, Centre Hospitalier de L'Universite de Montreal, Montreal, Quebec, Canada.""}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Sultanian', 'Affiliation': 'Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Cassandra', 'Initials': 'C', 'LastName': 'McDonald', 'Affiliation': 'Division of Gastroenterology, London Health Sciences Centre, London, Ontario, Canada.'}, {'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Martel', 'Affiliation': 'Division of Gastroenterology, McGill University, Montreal, Quebec, Canada.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Barkun', 'Affiliation': 'Division of Gastroenterology, McGill University, Montreal, Quebec, Canada.'}]",BMJ open,['10.1136/bmjopen-2019-029573'] 525,31289056,Smartphone-supported Positive Adjustment Coping Intervention (PACI) for couples undergoing fertility treatment: a randomised controlled trial protocol.,"INTRODUCTION Infertility generally counts as a profound crisis in the lives of couples and as an emotionally stressful experience. For couples undergoing fertility treatment, this is especially true of the waiting period following embryo transfer, which couples say is the most stressful period during treatment. However, at this specific phase, psychosocial counselling is not always available on the spot. The aim of this randomised controlled trial (RCT) study was to test the Positive Adjustment Coping Intervention (PACI), a low-dose, smartphone-supported psychological intervention for women and men undergoing fertility treatment. METHODS AND ANALYSIS The effectiveness of PACI is tested by means of a prospective two-arm RCT. During the 14-day waiting period between oocyte puncture/oocyte thawing and pregnancy test, participants are randomly assigned to one of the two groups, and both women and men receive daily text messages on their smartphones. One group receives text messages with statements reflecting positive-adjustment coping attitudes, the other group messages containing cognitive distractions. The primary outcome of this study is the reduction of psychosocial burden during the waiting period of reproductive treatment. Furthermore, we want to assess whether there are differences between the interventions in a pre-post assessment. The secondary outcomes are information on perceived effectiveness and practicability of the intervention one month after the waiting period. ETHICS AND DISSEMINATION Ethical approval has been obtained from the Ethics Committee of Heidelberg University Faculty of Medicine (S-074/2017). Study findings are planned for dissemination via peer-reviewed journal articles and at national and international conferences. TRIAL REGISTRATION NUMBER NCT03118219; Pre-results. PROTOCOL VERSION Version 2.0 dated 18/02/2019.",2019,"For couples undergoing fertility treatment, this is especially true of the waiting period following embryo transfer, which couples say is the most stressful period during treatment.","['women and men undergoing fertility treatment', 'couples undergoing fertility treatment']","['Positive Adjustment Coping Intervention (PACI), a low-dose, smartphone-supported psychological intervention', 'PACI', 'Smartphone-supported Positive Adjustment Coping Intervention (PACI', 'text messages with statements reflecting positive-adjustment coping attitudes, the other group messages containing cognitive distractions']","['effectiveness and practicability of the intervention one\u2009month after the waiting period', 'reduction of psychosocial burden during the waiting period of reproductive treatment']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0015895', 'cui_str': 'Fecundity'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0010222', 'cui_str': 'Couples'}]","[{'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0456081', 'cui_str': 'Adjustment (procedure)'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0558058', 'cui_str': 'Reflecting (finding)'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C1369038', 'cui_str': 'Distraction (procedure)'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C4082115', 'cui_str': 'One month (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",,0.157721,"For couples undergoing fertility treatment, this is especially true of the waiting period following embryo transfer, which couples say is the most stressful period during treatment.","[{'ForeName': 'Maren', 'Initials': 'M', 'LastName': 'Schick', 'Affiliation': 'Institute of Medical Psychology, University Hospital Heidelberg, Center for Psychosocial Medicine, Heidelberg, Germany.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Roesner', 'Affiliation': ""Department of Gynecologic Endocrinology and Fertility Disorders, University Women's Hospital Heidelberg, Heidelberg, Germany.""}, {'ForeName': 'Ariane', 'Initials': 'A', 'LastName': 'Germeyer', 'Affiliation': ""Department of Gynecologic Endocrinology and Fertility Disorders, University Women's Hospital Heidelberg, Heidelberg, Germany.""}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Moessner', 'Affiliation': 'Center for Psychotherapy Research, University Hospital Heidelberg, Center for Psychosocial Medicine, Heidelberg, Germany.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Bauer', 'Affiliation': 'Center for Psychotherapy Research, University Hospital Heidelberg, Center for Psychosocial Medicine, Heidelberg, Germany.'}, {'ForeName': 'Beate', 'Initials': 'B', 'LastName': 'Ditzen', 'Affiliation': 'Institute of Medical Psychology, University Hospital Heidelberg, Center for Psychosocial Medicine, Heidelberg, Germany.'}, {'ForeName': 'Tewes', 'Initials': 'T', 'LastName': 'Wischmann', 'Affiliation': 'Institute of Medical Psychology, University Hospital Heidelberg, Center for Psychosocial Medicine, Heidelberg, Germany.'}]",BMJ open,['10.1136/bmjopen-2018-025288'] 526,31352029,Brain structure changes induced by attention bias modification training.,"Attention bias modification (ABM) therapy aims to reduce anxiety by changing threat-related attention patterns using computerized training tasks. We examined changes in brain microstructure following ABM training. Thirty-two participants were randomly assigned to one of two training conditions: active ABM training shifting attention away from threat or attention control training involving no attention modification. Participants completed six lab visits, including five training sessions and three diffusion tensor imaging scans: immediately before and after the first training session, and at the end of the training series. Indices of local and global changes in microstructure and connectivity were measured. Significant longitudinal differences in fractional anisotropy (FA) between the active and control training regimens occurred in inferior temporal cortex. Changes in FA occurred across groups within ventromedial prefrontal cortex and middle occipital gyrus. These results indicate specific effects of active ABM on brain structure. Such changes could relate to clinical effects of ABM.",2019,Significant longitudinal differences in fractional anisotropy (FA) between the active and control training regimens occurred in inferior temporal cortex.,['Thirty-two participants'],"['Attention bias modification (ABM) therapy', 'active ABM training shifting attention away from threat or attention control training involving no attention modification']","['Changes in FA', 'fractional anisotropy (FA']","[{'cui': 'C0450357', 'cui_str': '32 (qualifier value)'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005346', 'cui_str': 'Bias'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0333051', 'cui_str': 'Shift (morphologic abnormality)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0085406', 'cui_str': 'Anisotropy'}]",32.0,0.0166734,Significant longitudinal differences in fractional anisotropy (FA) between the active and control training regimens occurred in inferior temporal cortex.,"[{'ForeName': 'Rany', 'Initials': 'R', 'LastName': 'Abend', 'Affiliation': 'Section on Development and Affective Neuroscience, National Institute of Mental Health, 9000 Rockville Pike, Bethesda, MD 20892, USA. Electronic address: rany.abend@nih.gov.'}, {'ForeName': 'Ariel', 'Initials': 'A', 'LastName': 'Rosenfelder', 'Affiliation': 'School of Psychological Sciences, Tel Aviv University, P.O. Box 39040, Tel Aviv 69978, Israel.'}, {'ForeName': 'Dana', 'Initials': 'D', 'LastName': 'Shamai', 'Affiliation': 'School of Psychological Sciences, Tel Aviv University, P.O. Box 39040, Tel Aviv 69978, Israel; Sagol School of Neuroscience, Tel Aviv University, P.O. Box 39040, Tel Aviv 69978, Israel.'}, {'ForeName': 'Daniel S', 'Initials': 'DS', 'LastName': 'Pine', 'Affiliation': 'Section on Development and Affective Neuroscience, National Institute of Mental Health, 9000 Rockville Pike, Bethesda, MD 20892, USA.'}, {'ForeName': 'Ido', 'Initials': 'I', 'LastName': 'Tavor', 'Affiliation': 'Sagol School of Neuroscience, Tel Aviv University, P.O. Box 39040, Tel Aviv 69978, Israel; Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University, P.O. Box 39040, Tel Aviv 69978, Israel.'}, {'ForeName': 'Yaniv', 'Initials': 'Y', 'LastName': 'Assaf', 'Affiliation': 'Department of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, P.O. Box 39040, Tel Aviv 69978, Israel; Sagol School of Neuroscience, Tel Aviv University, P.O. Box 39040, Tel Aviv 69978, Israel.'}, {'ForeName': 'Yair', 'Initials': 'Y', 'LastName': 'Bar-Haim', 'Affiliation': 'School of Psychological Sciences, Tel Aviv University, P.O. Box 39040, Tel Aviv 69978, Israel; Sagol School of Neuroscience, Tel Aviv University, P.O. Box 39040, Tel Aviv 69978, Israel.'}]",Biological psychology,['10.1016/j.biopsycho.2019.107736'] 527,30262813,Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial.,"BACKGROUND The effects of probiotic Bifidobacterium animalis subsp. lactis CECT 8145 (Ba8145) and those of its heat-killed form (h-k Ba8145) on human anthropometric adiposity biomarkers are unknown. OBJECTIVE To assess the effect of Ba8145 and h-k Ba8145 ingestion on anthropometric adiposity biomarkers. DESIGN Randomized, parallel, double-blind, placebo-controlled trial with abdominally obese individuals. Participants (n = 135) consumed 1 capsule/day containing 10 10 colony forming unit (CFU) of Ba8145, 10 10 CFU of h-k Ba8145, or placebo (maltodextrin) for 3 months. RESULTS Ba8145 ingestion decreased waist circumference, waist circumference/height ratio, and Conicity index (P < 0.05) versus its baseline. Changes versus the placebo group reached significance (P < 0.05) after the h-k Ba8145 treatment. Ba8145 decreased the body mass index compared with baseline and placebo group (P < 0.05). The decrease in visceral fat area after Ba8145 treatments reached significance (P < 0.05) only after h-k Ba8145. When analyses by gender were performed, significance remained only for women. Diastolic blood pressure and HOMA index decreased (P < 0.05) after h-k Ba8145. Gut microbiome analyses showed an increase in Akkermansia spp. after Ba8145 treatment, particularly in the live form, which was inversely related to weight (P = 0.003). CONCLUSIONS In abdominally obese individuals, consumption of Ba8145, both as viable and mainly as heat-killed cells, improves anthropometric adiposity biomarkers, particularly in women. An increase in the gut Akkermansia genus appears as a possible mechanism involved. Our results support Ba8145 probiotic as a complementary strategy in obesity management.",2019,Changes versus the placebo group reached significance (P < 0.05) after the h-k Ba8145 treatment.,"['abdominally obese subjects', 'abdominally obese individuals']","['probiotic Bifidobacterium animalis subsp', 'lactis CECT', 'placebo (maltodextrin', 'placebo', 'Ba8145 and h-k Ba8145 ingestion']","['Diastolic blood pressure and HOMA index', 'visceral fat area', 'anthropometric adiposity biomarkers', 'waist circumference, waist circumference/height ratio, and Conicity index', 'body mass index', 'Akkermansia spp']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0525033', 'cui_str': 'Probiotics'}, {'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}]","[{'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1563740', 'cui_str': 'Visceral Fat'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1563743', 'cui_str': 'Adiposis'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1490589', 'cui_str': 'Genus Akkermansia (organism)'}, {'cui': 'C0075148', 'cui_str': 'stable plasma protein solution'}]",,0.269698,Changes versus the placebo group reached significance (P < 0.05) after the h-k Ba8145 treatment.,"[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Pedret', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Rosa M', 'Initials': 'RM', 'LastName': 'Valls', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain. rosamaria.valls@urv.cat.'}, {'ForeName': 'Lorena', 'Initials': 'L', 'LastName': 'Calderón-Pérez', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Elisabet', 'Initials': 'E', 'LastName': 'Llauradó', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Companys', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Pla-Pagà', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Moragas', 'Affiliation': 'Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Martín-Luján', 'Affiliation': 'Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain.'}, {'ForeName': 'Yolanda', 'Initials': 'Y', 'LastName': 'Ortega', 'Affiliation': 'Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain.'}, {'ForeName': 'Montse', 'Initials': 'M', 'LastName': 'Giralt', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Caimari', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Empar', 'Initials': 'E', 'LastName': 'Chenoll', 'Affiliation': 'Biopolis SL/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain.'}, {'ForeName': 'Salvador', 'Initials': 'S', 'LastName': 'Genovés', 'Affiliation': 'Biopolis SL/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Martorell', 'Affiliation': 'Biopolis SL/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain.'}, {'ForeName': 'Francisco M', 'Initials': 'FM', 'LastName': 'Codoñer', 'Affiliation': 'Lifesequencing/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Ramón', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Lluís', 'Initials': 'L', 'LastName': 'Arola', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Solà', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}]",International journal of obesity (2005),['10.1038/s41366-018-0220-0'] 528,32149480,Therapeutic Effects of Bilateral Anodal Transcranial Direct Current Stimulation on Prefrontal and Motor Cortical Areas in Children with Autism Spectrum Disorders: A Pilot Study.,"Dysfunctional frontal cortical areas associated with clinical features are observed in children with autism spectrum disorder (ASD). This study attempted to identify any potential therapeutic effects of bilateral anodal transcranial direct current stimulation (tDCS) applied over the left and right prefrontal and motor areas on the clinical characteristics of children with ASD. Fifty children with confirmed ASD medical diagnoses were divided equally and randomly into a tDCS treatment group and a control group. The tDCS treatment group underwent 10 sessions (20-min durations, five per week) of bilateral anodal tDCS stimulation applied simultaneously over the left and right prefrontal and motor areas, whereas the control group underwent the same procedures but with the use of sham tDCS stimulation. Total scores and sub-scores of autism treatment evaluation checklist (ATEC) (language and communication; sociability; sensory awareness; and behavioral, health, and physical conditions) were measured before and after the tDCS treatment sessions of both groups. There were significant decreases in total ATEC scores (P = 0.014), sociability sub-scores (P = 0.021), and behavioral, health, and physical condition sub-scores (P = 0.011) in the tDCS treatment group. No significant changes were observed in total ATEC scores and sub-scores in the control group. In conclusion, compared to the control group, bilateral anodal tDCS showed potential therapeutic effects on children with ASD in terms of improvements in sociability, behavior, health, and physical conditions with no reported side effects. Autism Res 2020, 13: 828-836. © 2020 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: Dysfunctional frontal cortical areas are associated with clinical features in children with autism spectrum disorder (ASD). Transcranial direct current stimulation (tDCS) is found to be a safe, noninvasive method to stimulate cortical regions and thus have therapeutic effects on children with ASD. © 2020 International Society for Autism Research, Wiley Periodicals, Inc.",2020,"There were significant decreases in total ATEC scores (P = 0.014), sociability sub-scores (P = 0.021), and behavioral, health, and physical condition sub-scores (P = 0.011) in the tDCS treatment group.","['children with autism spectrum disorder (ASD', 'Fifty children with confirmed ASD medical diagnoses', 'Children with Autism', 'Spectrum Disorders', 'children with ASD']","['tDCS', 'Transcranial direct current stimulation (tDCS', 'bilateral anodal transcranial direct current stimulation (tDCS', 'Bilateral Anodal Transcranial Direct Current Stimulation', 'bilateral anodal tDCS stimulation']","['sociability, behavior, health, and physical conditions with no reported side effects', 'Total scores and sub-scores of autism treatment evaluation checklist (ATEC) (language and communication; sociability; sensory awareness; and behavioral, health, and physical conditions', 'sociability sub-scores', 'total ATEC scores', 'total ATEC scores and sub-scores', 'behavioral, health, and physical condition sub-scores']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}]","[{'cui': 'C0558182', 'cui_str': 'Ability to interact with others (observable entity)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1264637', 'cui_str': 'Substance amount'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0023008', 'cui_str': 'Languages'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0445254', 'cui_str': 'Sensory (qualifier value)'}, {'cui': 'C0004448', 'cui_str': 'Situational Awareness'}]",50.0,0.0150227,"There were significant decreases in total ATEC scores (P = 0.014), sociability sub-scores (P = 0.021), and behavioral, health, and physical condition sub-scores (P = 0.011) in the tDCS treatment group.","[{'ForeName': 'Hikmat', 'Initials': 'H', 'LastName': 'Hadoush', 'Affiliation': 'Department of Rehabilitation Sciences, Faculty of Applied Medical Sciences at Jordan University of Science and Technology, Irbid, Jordan.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Nazzal', 'Affiliation': 'Department of Rehabilitation Sciences, Faculty of Applied Medical Sciences at Jordan University of Science and Technology, Irbid, Jordan.'}, {'ForeName': 'Nihad A', 'Initials': 'NA', 'LastName': 'Almasri', 'Affiliation': 'Department of Physiotherapy, School of Rehabilitation Sciences, The University of Jordan, Amman, Jordan.'}, {'ForeName': 'Hanan', 'Initials': 'H', 'LastName': 'Khalil', 'Affiliation': 'Department of Rehabilitation Sciences, Faculty of Applied Medical Sciences at Jordan University of Science and Technology, Irbid, Jordan.'}, {'ForeName': 'Maha', 'Initials': 'M', 'LastName': 'Alafeef', 'Affiliation': 'Department of Biomedical Engineering, Jordan University of Science and Technology, Irbid, Jordan.'}]",Autism research : official journal of the International Society for Autism Research,['10.1002/aur.2290'] 529,31712584,Modulation of brain activation during executive functioning in autism with citalopram.,"Adults with autism spectrum disorder (ASD) are frequently prescribed selective serotonin reuptake inhibitors (SSRIs). However, there is limited evidence to support this practice. Therefore, it is crucial to understand the impact of SSRIs on brain function abnormalities in ASD. It has been suggested that some core symptoms in ASD are underpinned by deficits in executive functioning (EF). Hence, we investigated the role of the SSRI citalopram on EF networks in 19 right-handed adult males with ASD and 19 controls who did not differ in gender, age, IQ or handedness. We performed pharmacological functional magnetic resonance imaging to compare brain activity during two EF tasks (of response inhibition and sustained attention) after an acute dose of 20 mg citalopram or placebo using a randomised, double-blind, crossover design. Under placebo condition, individuals with ASD had abnormal brain activation in response inhibition regions, including inferior frontal, precentral and postcentral cortices and cerebellum. During sustained attention, individuals with ASD had abnormal brain activation in middle temporal cortex and (pre)cuneus. After citalopram administration, abnormal brain activation in inferior frontal cortex was 'normalised' and most of the other brain functional differences were 'abolished'. Also, within ASD, the degree of responsivity in inferior frontal and postcentral cortices to SSRI challenge was related to plasma serotonin levels. These findings suggest that citalopram can 'normalise' atypical brain activation during EF in ASD. Future trials should investigate whether this shift in the biology of ASD is maintained after prolonged citalopram treatment, and if peripheral measures of serotonin predict treatment response.",2019,"After citalopram administration, abnormal brain activation in inferior frontal cortex was 'normalised' and most of the other brain functional differences were 'abolished'.","['Adults with autism spectrum disorder (ASD', '19 right-handed adult males with ASD and 19 controls who did not differ in gender, age, IQ or handedness', 'autism with citalopram']","['citalopram or placebo', 'pharmacological functional magnetic resonance imaging', 'SSRI citalopram', 'citalopram']","['brain activity', 'abnormal brain activation', 'EF networks']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0023114', 'cui_str': 'Handedness'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0008845', 'cui_str': 'Citalopram'}]","[{'cui': 'C0008845', 'cui_str': 'Citalopram'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205464', 'cui_str': 'Pharmacologic (qualifier value)'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}]","[{'cui': 'C0443158', 'cui_str': 'Brain activity (observable entity)'}, {'cui': 'C0205161', 'cui_str': 'Abnormal (qualifier value)'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}]",19.0,0.257811,"After citalopram administration, abnormal brain activation in inferior frontal cortex was 'normalised' and most of the other brain functional differences were 'abolished'.","[{'ForeName': 'Robert H', 'Initials': 'RH', 'LastName': 'Wichers', 'Affiliation': ""Department of Forensic and Neurodevelopmental Sciences, The Sackler Centre for Translational Neurodevelopment, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. rob.wichers@kcl.ac.uk.""}, {'ForeName': 'James L', 'Initials': 'JL', 'LastName': 'Findon', 'Affiliation': ""Department of Forensic and Neurodevelopmental Sciences, The Sackler Centre for Translational Neurodevelopment, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Auke', 'Initials': 'A', 'LastName': 'Jelsma', 'Affiliation': ""Department of Forensic and Neurodevelopmental Sciences, The Sackler Centre for Translational Neurodevelopment, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Giampietro', 'Affiliation': ""Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Vladimira', 'Initials': 'V', 'LastName': 'Stoencheva', 'Affiliation': 'Behavioural and Developmental Psychiatry Clinical Academic Group, South London and Maudsley NHS Trust, London, UK.'}, {'ForeName': 'Dene M', 'Initials': 'DM', 'LastName': 'Robertson', 'Affiliation': ""Department of Forensic and Neurodevelopmental Sciences, The Sackler Centre for Translational Neurodevelopment, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Clodagh M', 'Initials': 'CM', 'LastName': 'Murphy', 'Affiliation': ""Department of Forensic and Neurodevelopmental Sciences, The Sackler Centre for Translational Neurodevelopment, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Grainne', 'Initials': 'G', 'LastName': 'McAlonan', 'Affiliation': ""Department of Forensic and Neurodevelopmental Sciences, The Sackler Centre for Translational Neurodevelopment, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Ecker', 'Affiliation': 'Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt am Main, Goethe-University Frankfurt am Main, Frankfurt, Germany.'}, {'ForeName': 'Katya', 'Initials': 'K', 'LastName': 'Rubia', 'Affiliation': ""Department of Child & Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Declan G M', 'Initials': 'DGM', 'LastName': 'Murphy', 'Affiliation': ""Department of Forensic and Neurodevelopmental Sciences, The Sackler Centre for Translational Neurodevelopment, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Eileen M', 'Initials': 'EM', 'LastName': 'Daly', 'Affiliation': ""Department of Forensic and Neurodevelopmental Sciences, The Sackler Centre for Translational Neurodevelopment, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}]",Translational psychiatry,['10.1038/s41398-019-0641-0'] 530,31272982,Effectiveness of additional X-ray protection devices in reducing Scattered radiation in radial interventions: protocol of the ESPRESSO randomised trial.,"BACKGROUND A number of devices have been developed to minimise operator radiation exposure in the setting of cardiac catheterisation. The effectiveness of these devices has traditionally been explored in transfemoral coronary procedures; however, less is known for the transradial approach. We set out to examine the impact of three different radiation protection devices in a real-world setting. METHODS AND DESIGN Consecutive coronary diagnostic and intervention procedures are randomised in a 1:1:1 ratio to a shield-only protection (shield group), shield and overlapping 0.5 mm Pb panel curtain (curtain group) or shield, curtain and additional 75×40 cm, 0.5 mm Pb drape placed across the waist of the patient (drape group).The primary outcome is the difference in relative exposure of the primary operator among groups. Relative exposure is defined as the ratio between operator's exposure (E in μSv) and patient exposure (dose area product in cGy·cm 2 ). ETHICS AND DISSEMINATION The protocol complies with good clinical practice and the ethical principles described in the Declaration of Helsinki and is approved by the local ethics committee. The results of the trial will be published as original article(s) in medical journals and/or as presentation at congresses. TRIAL REGISTRATION NUMBER NCT03634657.",2019,"The effectiveness of these devices has traditionally been explored in transfemoral coronary procedures; however, less is known for the transradial approach.",[],"['shield-only protection (shield group), shield and overlapping 0.5\u2009mm Pb panel curtain (curtain group) or shield, curtain and additional 75×40\u2009cm, 0.5\u2009mm Pb drape placed', 'additional X-ray protection devices']",[],[],"[{'cui': 'C0183251', 'cui_str': 'Shield, device (physical object)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0185027', 'cui_str': 'Imbrication (procedure)'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0556652', 'cui_str': 'mm Pb'}, {'cui': 'C0180239', 'cui_str': 'Curtain (physical object)'}, {'cui': 'C1704765', 'cui_str': 'Place - dosing instruction imperative'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0220819', 'cui_str': 'devices'}]",[],,0.23636,"The effectiveness of these devices has traditionally been explored in transfemoral coronary procedures; however, less is known for the transradial approach.","[{'ForeName': 'Remzi', 'Initials': 'R', 'LastName': 'Anadol', 'Affiliation': 'Kardiologie I, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Moritz', 'Initials': 'M', 'LastName': 'Brandt', 'Affiliation': 'Kardiologie I, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Nico', 'Initials': 'N', 'LastName': 'Merz', 'Affiliation': 'Kardiologie I, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Maike', 'Initials': 'M', 'LastName': 'Knorr', 'Affiliation': 'Kardiologie I, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Ahoopai', 'Affiliation': 'Kardiologie I, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Geyer', 'Affiliation': 'Kardiologie I, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Damian', 'Initials': 'D', 'LastName': 'Krompiec', 'Affiliation': 'Kardiologie I, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'Wenzel', 'Affiliation': 'Kardiologie I, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Münzel', 'Affiliation': 'Kardiologie I, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Tommaso', 'Initials': 'T', 'LastName': 'Gori', 'Affiliation': 'Kardiologie I, University Medical Center Mainz, Mainz, Germany.'}]",BMJ open,['10.1136/bmjopen-2019-029509'] 531,31274484,The perioperative effect of magnesium sulfate in patients with concentric left ventricular hypertrophy undergoing cardiac surgery: A double-blinded randomized study.,"Objective The objective of this study was to assess the cardioprotective effect of magnesium sulfate in patients with left ventricular concentric hypertrophy undergoing cardiac surgery. Design The study was a double-blinded randomized study. Setting This study was conducted at a cardiac center. Patients The study included 250 patients. Intervention The study included two groups (each = 125): Group M - the patients who received magnesium sulfate infusion (15 mg/kg/h). The infusion was started 20 min before induction, during surgery, and the first postoperative 24 h. Group C - the patients who received an equal amount of normal saline. Measurements The variables included troponin I level, creatinine kinase-MB (CK-MB) level, electrocardiograph (ECG) with automatic ST-segment analysis (leads II and V), E/A peak ratio, end-diastolic volume, cardiac index (CI), heart rate, mean arterial blood pressure (MAP), mean arterial pulmonary pressure (mPAP), pulmonary and systemic vascular resistances, and pharmacological and mechanical support. Main Results The troponin I level, CK-MB, and ECG changes were lower in Group M than Group C (P < 0.05). The E/A peak ratio and end-diastolic volume increased in Group M than Group C (P < 0.05). There was a significant increase in the CI and a decrease in the heart rate, mPAP, pulmonary vascular resistances, and pharmacological and mechanical support in Group M compared to Group C (P < 0.05). There were minimal changes in the MAP and systemic vascular resistance in Group M compared to Group C (P < 0.05). Conclusion The magnesium sulfate provides a cardioprotective effect in patients with concentric ventricular hypertrophy undergoing cardiac surgery. It decreases the incidence of perioperative myocardial infarction and arrhythmia. Furthermore, it decreases the requirement of pharmacological and mechanical support.",2019,The E/A peak ratio and end-diastolic volume increased in Group M than Group C (P < 0.05).,"['patients with concentric left ventricular hypertrophy undergoing cardiac surgery', 'Patients', 'patients with concentric ventricular hypertrophy undergoing cardiac surgery', 'patients with left ventricular concentric hypertrophy undergoing cardiac surgery', '250 patients']","['magnesium sulfate infusion', 'normal saline', 'magnesium sulfate']","['MAP and systemic vascular resistance', 'perioperative myocardial infarction and arrhythmia', 'heart rate, mPAP, pulmonary vascular resistances, and pharmacological and mechanical support', 'CI', 'troponin I level, creatinine kinase-MB (CK-MB) level, electrocardiograph (ECG) with automatic ST-segment analysis (leads II and V), E/A peak ratio, end-diastolic volume, cardiac index (CI), heart rate, mean arterial blood pressure (MAP), mean arterial pulmonary pressure (mPAP), pulmonary and systemic vascular resistances, and pharmacological and mechanical support', 'troponin I level, CK-MB, and ECG changes', 'peak ratio and end-diastolic volume']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439744', 'cui_str': 'Concentric (qualifier value)'}, {'cui': 'C0149721', 'cui_str': 'Left Ventricular Hypertrophy'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C0340279', 'cui_str': 'Ventricular hypertrophy (disorder)'}, {'cui': 'C0333963', 'cui_str': 'Concentric hypertrophy (morphologic abnormality)'}, {'cui': 'C2348831', 'cui_str': '250'}]","[{'cui': 'C0024480', 'cui_str': 'Magnesium Sulfate'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}]","[{'cui': 'C0024779', 'cui_str': 'Map'}, {'cui': 'C1258192', 'cui_str': 'Total Peripheral Resistance'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0003811', 'cui_str': 'Arrhythmia'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0456261', 'cui_str': 'Pulmonary Vascular Resistance'}, {'cui': 'C0205464', 'cui_str': 'Pharmacologic (qualifier value)'}, {'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0920210', 'cui_str': 'Troponin I measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C4521566', 'cui_str': 'Kinase'}, {'cui': 'C0523584', 'cui_str': 'Creatine kinase MB measurement'}, {'cui': 'C0180600', 'cui_str': 'Electrocardiograph'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C0429029', 'cui_str': 'ST segment (observable entity)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0449213', 'cui_str': 'Lead II (body structure)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0428776', 'cui_str': 'Cardiac index (observable entity)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1272641', 'cui_str': 'Arterial Tension'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C4522268', 'cui_str': 'Pulmonary'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C1623258', 'cui_str': 'ECG'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",250.0,0.128077,The E/A peak ratio and end-diastolic volume increased in Group M than Group C (P < 0.05).,"[{'ForeName': 'Rabie', 'Initials': 'R', 'LastName': 'Soliman', 'Affiliation': 'Department of Anesthesia, Cairo University, Cairo, Egypt; Department of Cardiac Anesthesia, Cardiac Center, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia.'}, {'ForeName': 'Walid', 'Initials': 'W', 'LastName': 'Abukhudair', 'Affiliation': 'Department of Cardiac Surgery, Cardiac Center, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia.'}]",Annals of cardiac anaesthesia,['10.4103/aca.ACA_34_18'] 532,31274485,Furosemide: Would it help to improve the lungs as evaluated by sonography and compliance during aortic coarctation surgery.,"Background We evaluated furosemide on attenuating lung injury and/or edema during coarctation repair surgery. We evaluated dynamic lung compliance. We measured the degree of lung edema by means of lung ultrasound (LUS). We recorded the (PaO 2 /FiO 2 ratio) as an indicator for oxygenation. Materials and Methods A study was conducted on 56 patients. Patients were divided into two groups: control group (Group C) which did not receive furosemide and furosemide group (Group F) at a dose of 1 mg/kg at induction of anesthesia. Dynamic lung compliance was calculated at induction (Cdyn 1) and at the end of the surgery (Cdyn 2). The (PaO 2 /FiO 2 ratio) was calculated at start and end of surgery as (PF 1) and (PF 2), respectively. LUS was performed after induction (LUS 1) and at the end of the surgery. LUS 2 using the 12 regions method plotting the results on scale from 0 to 36. Mechanical ventilation days were recorded. Results Administering furosemide attenuated the lung injury/edema and other pulmonary complications. Furosemide administration improved the dynamic lung compliance in the F Group compared to the C Group. Furthermore, it increased the (PaO 2 /FiO 2 ratio) in the F Group compared to the C Group. LUS scale values were lower in the F Group compared to the C Group. There was also less postoperative mechanical ventilation days. Conclusions The use of furosemide was accompanied by improved lung injury/edema profile as indicated by a much less drop in dynamic lung compliance, better oxygenation, a more favorable LUS scale with less parenchymal lung affection.",2019,"Furthermore, it increased the (PaO 2 /FiO 2 ratio) in the F Group compared to the C Group.","['56 patients', 'lung injury and/or edema during coarctation repair surgery']","['control group (Group C) which did not receive furosemide and furosemide', 'LUS', 'Furosemide', 'furosemide']","['lung injury/edema and other pulmonary complications', 'degree of lung edema by means of lung ultrasound (LUS', 'LUS scale values', 'postoperative mechanical ventilation days', 'lung injury/edema profile', 'Dynamic lung compliance', 'dynamic lung compliance']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0273115', 'cui_str': 'Pulmonary Injury'}, {'cui': 'C0013604', 'cui_str': 'Hydrops'}, {'cui': 'C0003492', 'cui_str': 'Coarctation of the Aorta'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0441837', 'cui_str': 'Group C (qualifier value)'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0016860', 'cui_str': 'Furosemide'}]","[{'cui': 'C0273115', 'cui_str': 'Pulmonary Injury'}, {'cui': 'C0013604', 'cui_str': 'Hydrops'}, {'cui': 'C4522268', 'cui_str': 'Pulmonary'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0034063', 'cui_str': 'Wet Lung'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4286019', 'cui_str': 'Lung ultrasound'}, {'cui': 'C0222045'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0024112', 'cui_str': 'Lung Compliance'}]",56.0,0.0188043,"Furthermore, it increased the (PaO 2 /FiO 2 ratio) in the F Group compared to the C Group.","[{'ForeName': 'Ahmed Kareem', 'Initials': 'AK', 'LastName': 'Mohammed', 'Affiliation': 'Department of Anesthesia, Surgical Intensive Care and Pain Management, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Mai A', 'Initials': 'MA', 'LastName': 'Madkour', 'Affiliation': 'Department of Anesthesia, Surgical Intensive Care and Pain Management, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Hossam M', 'Initials': 'HM', 'LastName': 'Hassanien', 'Affiliation': 'Department of Cardiothoracic Surgery, Faculty of Medicine, Cairo University, Cairo, Egypt.'}]",Annals of cardiac anaesthesia,['10.4103/aca.ACA_55_18'] 533,31175564,The Family Check-up Intervention Moderates Polygenic Influences on Long-Term Alcohol Outcomes: Results from a Randomized Intervention Trial.,"Alcohol problems are influenced by both genetic and environmental factors. Evidence from twin models and measured gene-environment interaction studies has demonstrated that the importance of genetic influences changes as a function of the environment. Research has also shown that family-centered interventions may protect genetically susceptible youth from developing substance use problems. In this study, we brought large-scale gene identification findings into an intervention study to examine gene-by-intervention effects. Using genome-wide polygenic scores derived from an independent genome-wide association study of adult alcohol dependence, we examined whether an adolescent family-centered intervention would moderate the effect of genetic risk for alcohol dependence on lifetime alcohol dependence in young adulthood, approximately 15 years after the start of intervention, among European American (N = 271; 48.3% in the intervention condition) and African American individuals (N = 192; 51.6% in the intervention condition). We found that among European American individuals, the intervention moderated the association between alcohol dependence polygenic scores and lifetime alcohol dependence diagnosis in young adulthood. Among participants in the control condition, higher alcohol dependence polygenic scores were associated with a greater likelihood of receiving an alcohol dependence diagnosis; in contrast, among participants in the intervention condition, there was no association between alcohol dependence polygenic scores and alcohol dependence diagnosis. No moderation effect was found among African Americans. These results demonstrate that modifying environments of genetically vulnerable youth could reduce the likelihood of developing alcohol dependence and underscore the significance of environmentally focused prevention and intervention efforts.",2019,"Among participants in the control condition, higher alcohol dependence polygenic scores were associated with a greater likelihood of receiving an alcohol dependence diagnosis; in contrast, among participants in the intervention condition, there was no association between alcohol dependence polygenic scores and alcohol dependence diagnosis.","['African Americans', 'young adulthood, approximately 15\xa0years after the start of intervention, among European American (N\u2009=\u2009271; 48.3% in the intervention condition) and African American individuals (N\u2009=\u2009192; 51.6% in the intervention condition']",[],"['alcohol dependence polygenic scores and alcohol dependence diagnosis', 'alcohol dependence polygenic scores']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0700597', 'cui_str': 'Adulthood - period'}, {'cui': 'C0332232', 'cui_str': 'Approximate (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0239307', 'cui_str': 'European (ethnic group)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C4517623', 'cui_str': '192'}]",[],"[{'cui': 'C0001973', 'cui_str': 'Alcohol Dependence'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]",,0.0115744,"Among participants in the control condition, higher alcohol dependence polygenic scores were associated with a greater likelihood of receiving an alcohol dependence diagnosis; in contrast, among participants in the intervention condition, there was no association between alcohol dependence polygenic scores and alcohol dependence diagnosis.","[{'ForeName': 'Sally I-Chun', 'Initials': 'SI', 'LastName': 'Kuo', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University, Box 842018, 806 West Franklin Street, Richmond, VA, 23284-2008, USA. ickuo@vcu.edu.'}, {'ForeName': 'Jessica E', 'Initials': 'JE', 'LastName': 'Salvatore', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University, Box 842018, 806 West Franklin Street, Richmond, VA, 23284-2008, USA.'}, {'ForeName': 'Fazil', 'Initials': 'F', 'LastName': 'Aliev', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University, Box 842018, 806 West Franklin Street, Richmond, VA, 23284-2008, USA.'}, {'ForeName': 'Thao', 'Initials': 'T', 'LastName': 'Ha', 'Affiliation': 'Department of Psychology, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Dishion', 'Affiliation': 'Department of Psychology, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Danielle M', 'Initials': 'DM', 'LastName': 'Dick', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University, Box 842018, 806 West Franklin Street, Richmond, VA, 23284-2008, USA.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-019-01024-2'] 534,31674093,A bioengineered living cell construct activates metallothionein/zinc/MMP8 and inhibits TGFβ to stimulate remodeling of fibrotic venous leg ulcers.,"Venous leg ulcers (VLU) represent a major clinical unmet need, impairing quality of life for millions worldwide. The bioengineered bilayered living cell construct (BLCC) is the only FDA-approved therapy demonstrating efficacy in healing chronic VLU, yet its in vivo mechanisms of action are not well understood. Previously, we reported a BLCC-mediated acute wounding response at the ulcer edge; in this study we elucidated the BLCC-specific effects on the epidermis-free ulcer bed. We conducted a randomized controlled clinical trial (ClinicalTrials.gov NCT01327937) enrolling 30 subjects with nonhealing VLUs, and performed genotyping, genomic profiling, and functional analysis on wound bed biopsies obtained at baseline and 1 week after treatment with BLCC plus compression or compression therapy (control). The VLU bed transcriptome featured processes of chronic inflammation and was strikingly enriched for fibrotic/fibrogenic pathways and gene networks. BLCC application decreased expression of profibrotic TGFß1 gene targets and increased levels of TGFß inhibitor decorin. Surprisingly, BLCC upregulated metallothioneins and fibroblast-derived MMP8 collagenase, and promoted endogenous release of MMP-activating zinc to stimulate antifibrotic remodeling, a novel mechanism of cutaneous wound healing. By activating a remodeling program in the quiescent VLU bed, BLCC application shifts nonhealing to healing phenotype. As VLU bed fibrosis correlates with poor clinical healing, findings from this study identify the chronic VLU as a fibrotic skin disease and are first to support the development and application of antifibrotic therapies as a successful treatment approach.",2020,BLCC application decreased expression of pro-fibrotic TGFß1 gene targets and increased levels of TGFß inhibitor decorin.,"['30 subjects with non-healing VLUs, and performed genotyping, genomic profiling and functional analysis on wound bed biopsies obtained at baseline and one week after treatment with']","['Bioengineered Living Cell Construct Activates Metallothionein/Zinc/MMP8 and Inhibits TGFβ', 'BLCC plus compression or compression therapy (control']",[],"[{'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0887950', 'cui_str': 'Genomics'}, {'cui': 'C0558024', 'cui_str': 'Functional analysis'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0004916', 'cui_str': 'Beds'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C1442452', 'cui_str': 'One week'}, {'cui': 'C0001758', 'cui_str': 'Follow-Up Care'}]","[{'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0025545', 'cui_str': 'Metallothionein'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",[],30.0,0.0347319,BLCC application decreased expression of pro-fibrotic TGFß1 gene targets and increased levels of TGFß inhibitor decorin.,"[{'ForeName': 'Rivka C', 'Initials': 'RC', 'LastName': 'Stone', 'Affiliation': 'Wound Healing and Regenerative Medicine Research Program, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami-Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Olivera', 'Initials': 'O', 'LastName': 'Stojadinovic', 'Affiliation': 'Wound Healing and Regenerative Medicine Research Program, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami-Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Andrew P', 'Initials': 'AP', 'LastName': 'Sawaya', 'Affiliation': 'Wound Healing and Regenerative Medicine Research Program, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami-Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'George D', 'Initials': 'GD', 'LastName': 'Glinos', 'Affiliation': 'Wound Healing and Regenerative Medicine Research Program, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami-Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Linsey E', 'Initials': 'LE', 'LastName': 'Lindley', 'Affiliation': 'Wound Healing and Regenerative Medicine Research Program, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami-Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Irena', 'Initials': 'I', 'LastName': 'Pastar', 'Affiliation': 'Wound Healing and Regenerative Medicine Research Program, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami-Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Evangelos', 'Initials': 'E', 'LastName': 'Badiavas', 'Affiliation': 'Wound Healing and Regenerative Medicine Research Program, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami-Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Marjana', 'Initials': 'M', 'LastName': 'Tomic-Canic', 'Affiliation': 'Wound Healing and Regenerative Medicine Research Program, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami-Miller School of Medicine, Miami, Florida.'}]",Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society,['10.1111/wrr.12778'] 535,30733169,An integrated neurocognitive and social-cognitive treatment for youth at clinical high risk for psychosis: Cognition for Learning and for Understanding Everyday Social Situations (CLUES).,"BACKGROUND Cognitive deficits, a core feature contributing to disability in schizophrenia, are present in milder form in individuals at clinical high risk (CHR) for psychosis. This study investigated the feasibility of Cognition for Learning and Understanding Everyday Social Situations (CLUES), an integrated neurocognitive and social cognitive treatment for youth at CHR. METHOD This was an open, pilot feasibility trial. Seventeen individuals meeting CHR criteria were assessed prior to and following participation in CLUES for changes in symptoms, social and role functioning, and cognition. Participant attitudes towards CLUES were also examined. RESULTS Participants significantly improved in social functioning [t(16) = -4.20, p = .001, d = 1.02], and trended for improvement in reaction time [t(15) = 2.09, p = .054, d = 0.52] from baseline to end of treatment. No other measures significantly changed. No participants transitioned to full psychosis during the treatment and follow up period. Participants reported they generally liked CLUES and found it helpful. CONCLUSION While limited by the small sample size and the open label design, our preliminary results indicate that CLUES is feasible and shows promise in improving social functioning. However, further investigation is warranted in order to determine its efficacy. Future directions should include conducting a randomized controlled trial in order to compare the efficacy of CLUES to another intervention.",2019,"RESULTS Participants significantly improved in social functioning [t(16) = -4.20, p = .001, d = 1.02], and trended for improvement in reaction time [t(15) = 2.09, p = .054, d = 0.52] from baseline to end of treatment.","['youth at CHR', 'youth at clinical high risk for psychosis', 'Seventeen individuals meeting CHR criteria']",['CLUES'],"['full psychosis', 'social functioning']","[{'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0033975', 'cui_str': 'Psychoses'}, {'cui': 'C0450331', 'cui_str': '17 (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]",[],"[{'cui': 'C0033975', 'cui_str': 'Psychoses'}]",17.0,0.0261051,"RESULTS Participants significantly improved in social functioning [t(16) = -4.20, p = .001, d = 1.02], and trended for improvement in reaction time [t(15) = 2.09, p = .054, d = 0.52] from baseline to end of treatment.","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Friedman-Yakoobian', 'Affiliation': 'Public Psychiatry Division of Department of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center, 75 Fenwood Road, Boston, MA 02115, United States of America. Electronic address: mfriedm3@bidmc.harvard.edu.'}, {'ForeName': 'E M', 'Initials': 'EM', 'LastName': 'Parrish', 'Affiliation': 'Public Psychiatry Division of Department of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center, 75 Fenwood Road, Boston, MA 02115, United States of America.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Thomas', 'Affiliation': 'University of Alabama Health System, United States of America.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Lesser', 'Affiliation': 'Cedars Sinai Medical Center, United States of America.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Gnong-Granato', 'Affiliation': 'The Plymouth Center for Behavioral Health, United States of America.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Eack', 'Affiliation': 'University of Pittsburgh School of Social Work and Department of Psychiatry, United States of America.'}, {'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Keshavan', 'Affiliation': 'Public Psychiatry Division of Department of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center, 75 Fenwood Road, Boston, MA 02115, United States of America.'}]",Schizophrenia research,['10.1016/j.schres.2019.01.029'] 536,32153209,Using predictive analytics to improve pragmatic trial design.,"Clinical trials embedded in health systems can randomize large populations using automated data sources to determine trial eligibility and assess outcomes. The suicide prevention outreach trial used real-world data for trial design and randomized 18,868 individuals in four health systems using patient-reported thoughts of death or self-harm (Patient Health Questionnaire item 9). This took 3.5 years. We consider if using predictive analytics, that is, suicide risk estimates based on prediction models, could improve trial ""efficiency."" We used data on mental health outpatient visits between 1 January 2009 and 30 September 2017 in seven health systems (HealthPartners; Henry Ford Health System; and Colorado, Hawaii, Northwest, Southern California, and Washington Kaiser Permanente regions). We used a suicide risk prediction model developed in these same systems. We compared five trial designs with different eligibility criteria: a response of a 2 or 3 on Patient Health Questionnaire item 9, a response of a 3, suicide risk score above 90th, 95th, or 99th percentile. We compared the sample that met each criterion, 90-day suicide attempt rate following first eligible visit, and necessary sample sizes to detect a 15%, 25%, and 35% relative reduction in the suicide attempt rate, assuming 90% power, for each eligibility criterion. Our sample included 24,355,599 outpatient visits. Despite wide-spread use of Patient Health Questionnaire, 21,026,985 (86.3%) visits did not have a recorded Patient Health Questionnaire. Of the 2,928,927 individuals in our sample, 109,861 had a recorded Patient Health Questionnaire item 9 response of a 2 or 3 over the study years with a 1.40% 90-day suicide attempt rate and 50,047 had a response of a 3 (suicide attempt rate 1.98%). More patients met criteria requiring a certain risk score or higher: 331,273 had a 90th percentile risk score or higher (suicide attempt rate: 1.36%); 182,316 a 95th percentile or higher (suicide attempt rate 2.16%), and 78,655 a 99th percentile or higher (suicide attempt rate: 3.95%). Eligibility criterion of a Patient Health Questionnaire item 9 response of a 2 or 3 would require randomizing 44,081 individuals (40.2% of eligible population in our sample); eligibility criterion of a 3 would require 31,024 individuals (62.0% of eligible population). Eligibility criterion of a suicide risk score of 90th percentile or higher would require 45,675 individuals (13.8% of eligible population), 95th percentile 28,699 individuals (15.7% of eligible population), and 99th percentile 15,509 (19.7% of eligible population). A suicide risk prediction calculator could improve trial ""efficiency""; identifying more individuals at increased suicide risk than relying on patient-report. It is an open scientific question if individuals identified using predictive analytics would respond differently to interventions than those identified by more traditional means.",2020,"Despite wide-spread use of Patient Health Questionnaire, 21,026,985 (86.3%) visits did not have a recorded Patient Health Questionnaire.","['2,928,927 individuals in our sample, 109,861 had a recorded Patient Health Questionnaire item 9 response of a 2 or 3 over the study years with a 1.40% 90-day suicide attempt rate and 50,047 had a response of a 3 (suicide attempt rate 1.98', '18,868 individuals in four health systems using patient-reported thoughts of death or self-harm (Patient Health Questionnaire item 9', 'mental health outpatient visits between 1 January 2009 and 30 September 2017 in seven health systems (HealthPartners; Henry Ford Health System; and Colorado, Hawaii, Northwest, Southern California, and Washington Kaiser Permanente regions', 'Eligibility criterion of a suicide risk score of 90th percentile or higher would require 45,675 individuals (13.8% of eligible population), 95th percentile 28,699 individuals (15.7% of eligible population), and 99th percentile 15,509 (19.7% of eligible population', 'More patients met criteria requiring a certain risk score or higher: 331,273 had a 90th percentile risk score or higher (suicide attempt rate: 1.36%); 182,316 a 95th percentile or higher (suicide attempt rate 2.16%), and 78,655 a 99th percentile or higher (suicide attempt rate: 3.95', 'Eligibility criterion of a Patient Health Questionnaire item 9 response of a 2 or 3 would require randomizing 44,081 individuals (40.2% of eligible population in our sample); eligibility criterion of a 3 would require 31,024 individuals (62.0% of eligible population']",[],['90-day suicide attempt rate'],"[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1879301', 'cui_str': 'Patient Health Questionnaire'}, {'cui': 'C0205136', 'cui_str': 'Over (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0038663', 'cui_str': 'Suicide attempt (event)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C4319827', 'cui_str': 'Thought'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0085271', 'cui_str': 'Self-Injury'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0582517', 'cui_str': 'henry (qualifier value)'}, {'cui': 'C0009399', 'cui_str': 'Colorado'}, {'cui': 'C0018619', 'cui_str': 'Hawaii'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0043038', 'cui_str': 'Washington'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0563664', 'cui_str': 'Suicide risk'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C4517561', 'cui_str': '13.8 (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205423', 'cui_str': 'Certainty (attribute)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C4708912', 'cui_str': '1.36 (qualifier value)'}, {'cui': 'C4517627', 'cui_str': '2.16 (qualifier value)'}]",[],"[{'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0038663', 'cui_str': 'Suicide attempt (event)'}]",18868.0,0.0822878,"Despite wide-spread use of Patient Health Questionnaire, 21,026,985 (86.3%) visits did not have a recorded Patient Health Questionnaire.","[{'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Shortreed', 'Affiliation': 'Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.'}, {'ForeName': 'Gregory E', 'Initials': 'GE', 'LastName': 'Simon', 'Affiliation': 'Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.'}]","Clinical trials (London, England)",['10.1177/1740774520910367'] 537,32152513,Effects of substituting eggs for high-carbohydrate breakfast foods on the cardiometabolic risk-factor profile in adults at risk for type 2 diabetes mellitus.,"OBJECTIVES To assess effects of egg-based versus non-egg, higher-carbohydrate (CHO) breakfast meals on cardiometabolic health markers in overweight or obese adults with prediabetes and/or metabolic syndrome. METHODS This randomized, crossover study included two 4-week dietary interventions, separated by a ≥4-week washout. Subjects incorporated into their habitual diets breakfast meals containing either 2 eggs/day for 6 days/week (Egg condition), or energy-matched, non-egg, higher-CHO-based foods (Non-Egg condition). Dietary intakes, insulin sensitivity, and other CHO metabolism indices, lipid biomarkers, high-sensitivity C-reactive protein, and blood pressures were measured. RESULTS Thirty men and women with mean age 54.1 ± 1.9 years and body mass index 31.9 ± 0.7 kg/m 2 provided data. Neither diet condition significantly altered insulin sensitivity indices, but the homeostasis model assessment for insulin resistance was significantly (p = 0.028) higher after the Non-Egg vs. the Egg condition. Low-density lipoprotein cholesterol (LDL-C) was decreased from baseline (119 mg/dL) by 2.9 and 6.0% with Egg and Non-Egg breakfasts, respectively (p = 0.023). Systolic blood pressure was reduced from baseline (127 mm Hg) by 2.7 and 0.0% with Egg and Non-Egg, respectively (p = 0.018). Diet records indicated 149 kcal/day higher (p = 0.008) energy intake from non-study foods during the Egg condition; however, weight change from baseline did not differ between conditions. CONCLUSION Compared with the baseline diet, consumption of 12 eggs/week for 4 weeks at breakfast was associated with less reduction in LDL-C, and more lowering of systolic blood pressure, than observed with non-egg-based, energy-matched, control foods higher in CHO.",2020,"Diet records indicated 149 kcal/day higher (p = 0.008) energy intake from non-study foods during the Egg condition; however, weight change from baseline did not differ between conditions. ","['overweight or obese adults with prediabetes and/or metabolic syndrome', 'Thirty men and women with mean age 54.1\u2009±\u20091.9\u2009years and body mass index 31.9\u2009±\u20090.7\u2009kg/m 2 provided data', 'adults at risk for type 2 diabetes mellitus']","['egg-based versus non-egg, higher-carbohydrate (CHO) breakfast meals']","['lowering of systolic blood pressure', 'Systolic blood pressure', 'Low-density lipoprotein cholesterol (LDL-C', 'Dietary intakes, insulin sensitivity, and other CHO metabolism indices, lipid biomarkers, high-sensitivity C-reactive protein, and blood pressures', 'weight change', 'cardiometabolic risk-factor profile', 'insulin sensitivity indices', 'homeostasis model assessment for insulin resistance', 'cardiometabolic health markers']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0362046', 'cui_str': 'Prediabetes'}, {'cui': 'C0524620', 'cui_str': 'Metabolic Syndrome X'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517517', 'cui_str': '1.9 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517474', 'cui_str': '0.7 (qualifier value)'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0011860', 'cui_str': 'Diabetes Mellitus, Type 2'}]","[{'cui': 'C0029974', 'cui_str': 'Egg, Unfertilized'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C4553621', 'cui_str': 'With breakfast'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}]","[{'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0005911', 'cui_str': 'Body Weight Changes'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C1829779', 'cui_str': 'Homeostasis model assessment'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0018684', 'cui_str': 'Health'}]",,0.0693838,"Diet records indicated 149 kcal/day higher (p = 0.008) energy intake from non-study foods during the Egg condition; however, weight change from baseline did not differ between conditions. ","[{'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': 'Maki', 'Affiliation': 'Midwest Biomedical Research, Addison, IL, USA. kmaki@mbclinicalresearch.com.'}, {'ForeName': 'Orsolya M', 'Initials': 'OM', 'LastName': 'Palacios', 'Affiliation': 'Midwest Biomedical Research, Addison, IL, USA.'}, {'ForeName': 'Melvyn W', 'Initials': 'MW', 'LastName': 'Kramer', 'Affiliation': 'MB Clinical Research, Boca Raton, FL, USA.'}, {'ForeName': 'Rupal', 'Initials': 'R', 'LastName': 'Trivedi', 'Affiliation': 'Great Lakes Clinical Trials, Chicago, IL, USA.'}, {'ForeName': 'Mary R', 'Initials': 'MR', 'LastName': 'Dicklin', 'Affiliation': 'Midwest Biomedical Research, Addison, IL, USA.'}, {'ForeName': 'Meredith L', 'Initials': 'ML', 'LastName': 'Wilcox', 'Affiliation': 'MB Clinical Research, Boca Raton, FL, USA.'}, {'ForeName': 'Cathleen E', 'Initials': 'CE', 'LastName': 'Maki', 'Affiliation': 'Midwest Biomedical Research, Addison, IL, USA.'}]",European journal of clinical nutrition,['10.1038/s41430-020-0599-2'] 538,32152738,Preoperative ankle block for postoperative analgesia in foot surgery.,"BACKGROUND The use of a tourniquet and patients' preference for general anesthesia (GA) limit performing ankle blocks (AB) as a sole anesthetic technique for orthopedic foot surgery. The aim of this prospective and randomized study was to test the hypothesis that administration of an AB before GA could be effective for postoperative pain relief in patients undergoing outpatient hallux valgus surgery. Primary outcome measure was mean pain score and secondary outcome measures were time to mobilization of patients, time to hospital discharge, and complications. METHODS A total of 110 adult patients were randomly assigned into two groups: group GA (n = 55) and group GA + AB (n = 55). Group GA + AB received an AB using 100 mg lidocaine 2% and 75 mg bupivacaine 0.5% before the induction of GA. Pain intensity was evaluated using a visual analogue scale (VAS). RESULTS Mean VAS scores were higher and times to first rescue analgesic were shorter in group GA compared to group GA + AB (p = 0.001). More patients required rescue analgesic in group GA and pethidine consumption was higher (p = 0.001). Time to mobilization was shorter in GA + AB group (p = 0.001) but hospital discharge time was similar between groups (p = 0.269). The incidence of nausea and vomiting was higher in group GA (p = 0.002). CONCLUSION Ankle block is an effective and simple technique for reducing postoperative pain and opioid consumption. It reduced the time to mobilization without a delay in hospital discharge. It is concluded that the routine administration of AB before GA may be an effective and simple method for pain relief after foot surgery.",2020,"RESULTS Mean VAS scores were higher and times to first rescue analgesic were shorter in group GA compared to group GA + AB (p = 0.001).","['110 adult patients', 'foot\xa0surgery', 'patients undergoing outpatient hallux valgus surgery']","['general anesthesia (GA) limit performing ankle blocks (AB', 'AB before GA', 'bupivacaine', 'lidocaine']","['postoperative pain relief', 'postoperative pain and opioid consumption', 'Mean VAS scores', 'hospital discharge time', 'pethidine consumption', 'Time to mobilization', 'pain relief', 'Pain intensity', 'nausea and vomiting', 'mean pain score', 'time to mobilization of patients, time to hospital discharge, and complications', 'visual analogue scale (VAS']","[{'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0188413', 'cui_str': 'Operative procedure on foot'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0158458', 'cui_str': 'Acquired hallux valgus (disorder)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0002915', 'cui_str': 'General Anesthesia'}, {'cui': 'C0439801', 'cui_str': 'Limited (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0394745', 'cui_str': 'Local anesthetic ankle block (procedure)'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}]","[{'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0025376', 'cui_str': 'pethidine'}, {'cui': 'C0300926', 'cui_str': 'mobilization'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting (disorder)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",110.0,0.125225,"RESULTS Mean VAS scores were higher and times to first rescue analgesic were shorter in group GA compared to group GA + AB (p = 0.001).","[{'ForeName': 'Mehmet Özgür', 'Initials': 'MÖ', 'LastName': 'Özhan', 'Affiliation': 'Department of Anesthesiology and Reanimation, Private Çankaya Hospital, Barbaros Mah. Bülten Sok. No.\xa044, 06500, Çankaya/Ankara, Turkey. metozhan2003@yahoo.com.'}, {'ForeName': 'Altuğ', 'Initials': 'A', 'LastName': 'Tanrıöver', 'Affiliation': 'Department of Orthopedics and Traumatology, Private Çankaya Hospital, Ankara, Turkey.'}, {'ForeName': 'Bülent', 'Initials': 'B', 'LastName': 'Atik', 'Affiliation': 'Department of Anesthesiology and Reanimation, Balıkesir University Medical School, Balıkesir, Turkey.'}, {'ForeName': 'Ceyda', 'Initials': 'C', 'LastName': 'Özhan Çaparlar', 'Affiliation': 'Department of Anesthesiology and Reanimation, University of Medical Sciences, Yıldırım Beyazıt Education and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Burak Mehmet', 'Initials': 'BM', 'LastName': 'Eşkin', 'Affiliation': 'Department of Anesthesiology and Reanimation, University of Medical Sciences, Gülhane Education and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Anıl Mehmet', 'Initials': 'AM', 'LastName': 'Süzer', 'Affiliation': 'Department of Anesthesiology and Reanimation, Private Çankaya Hospital, Barbaros Mah. Bülten Sok. No.\xa044, 06500, Çankaya/Ankara, Turkey.'}]",Der Anaesthesist,['10.1007/s00101-020-00754-1'] 539,31839533,Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER).,"Despite increased focus on prevention as well as improved treatment possibilities, lung cancer remains among the most frequent and deadliest cancer diagnoses worldwide. Even lung cancer patients treated with curative intent have a high risk of relapse, leading to a dismal prognosis. More knowledge on the efficacy of surveillance with both current and new technologies as well as on the impact on patient treatment, quality of life, and survival are urgently needed. We therefore designed a randomized phase 3 trial. In one arm, every other computed tomography (CT) scan is replaced by positron emission tomography/CT, the other arm is the standard follow-up scheme with CT. The standard arm is identical to the current national Danish follow-up program. The primary endpoint is to compare the number of relapses treatable with curative intent in the 2 arms. We aim to include 750 patients over a 3-year period. Additionally, we will test the feasibility of noninvasive lung cancer diagnostics and surveillance in the form of circulating tumor DNA analysis. For this purpose, blood samples are collected before treatment and at each following control. The blood samples are stored in a biobank for later analysis and will not be used for guiding patient treatment decisions.",2020,The primary endpoint is to compare the number of relapses treatable with curative intent in the 2 arms.,"['I-III Lung Cancer Patients', '750 patients over a 3-year period']",['computed tomography (CT) scan'],['number of relapses treatable with curative intent'],"[{'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C1306460', 'cui_str': 'Primary malignant neoplasm of lung'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517868', 'cui_str': '750 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0040395', 'cui_str': 'Tomographic imaging'}, {'cui': 'C0441633'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C1276305', 'cui_str': 'Curative procedure'}, {'cui': 'C1283828', 'cui_str': 'Intentional'}]",750.0,0.0467824,The primary endpoint is to compare the number of relapses treatable with curative intent in the 2 arms.,"[{'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Skougaard', 'Affiliation': 'Department of Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Østrup', 'Affiliation': 'Department of Genomic Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Kasper', 'Initials': 'K', 'LastName': 'Guldbrandsen', 'Affiliation': 'Department of Nuclear Medicine, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.'}, {'ForeName': 'Boe', 'Initials': 'B', 'LastName': 'Sørensen', 'Affiliation': 'Department of Clinical Biochemistry, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Meldgaard', 'Affiliation': 'Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Zaigham', 'Initials': 'Z', 'LastName': 'Saghir', 'Affiliation': 'Department of Pulmonology, Copenhagen University Hospital Gentofte, Hellerup, Denmark.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Gørtz', 'Affiliation': 'Department of Nuclear Medicine, Copenhagen University Hospital Gentofte, Hellerup, Denmark.'}, {'ForeName': 'Markus Nowak', 'Initials': 'MN', 'LastName': 'Lonsdale', 'Affiliation': 'Department of Nuclear Medicine, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.'}, {'ForeName': 'Malene Støchkel', 'Initials': 'MS', 'LastName': 'Frank', 'Affiliation': 'Department of Oncology, Zealand University Hospital Næstved, Næstved, Denmark.'}, {'ForeName': 'Oke', 'Initials': 'O', 'LastName': 'Gerke', 'Affiliation': 'Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Beata Agnieszka', 'Initials': 'BA', 'LastName': 'Rychwicka-Kielek', 'Affiliation': 'Department of Pulmonology, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Gitte', 'Initials': 'G', 'LastName': 'Persson', 'Affiliation': 'Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.'}, {'ForeName': 'Lotte Holm', 'Initials': 'LH', 'LastName': 'Land', 'Affiliation': 'Department of Oncology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Tine', 'Initials': 'T', 'LastName': 'Schytte', 'Affiliation': 'Department of Oncology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Uffe', 'Initials': 'U', 'LastName': 'Bodtger', 'Affiliation': 'Department of Pulmonology, Zealand University Hospital Næstved, Næstved, Denmark.'}, {'ForeName': 'Halla', 'Initials': 'H', 'LastName': 'Skuladottir', 'Affiliation': 'Department of Oncology, Regional Hospital Herning, Herning, Denmark.'}, {'ForeName': 'Jes', 'Initials': 'J', 'LastName': 'Søgaard', 'Affiliation': 'Institute of Health Economics, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Søren Steen', 'Initials': 'SS', 'LastName': 'Nielsen', 'Affiliation': 'Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Torben Riis', 'Initials': 'TR', 'LastName': 'Rasmussen', 'Affiliation': 'Department of Pulmonology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Barbara Malene', 'Initials': 'BM', 'LastName': 'Fischer', 'Affiliation': ""Department of Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; PET Center, School of Biomedical Engineering and Imaging Sciences Kings College London, St Thomas' Hospital, London, UK. Electronic address: barbara.malene.fischer@regionh.dk.""}]",Clinical lung cancer,['10.1016/j.cllc.2019.11.002'] 540,32150258,Pain and Psychological Outcomes Among Iraq and Afghanistan Veterans with Chronic Pain and PTSD: ESCAPE Trial Longitudinal Results.,"OBJECTIVE To compare pain and psychological outcomes in veterans with chronic musculoskeletal pain and comorbid post-traumatic stress disorder (PTSD) or pain alone and to determine if veterans with comorbidity respond differently to a stepped-care intervention than those with pain alone. DESIGN Secondary analysis of data from the Evaluation of Stepped Care for Chronic Pain (ESCAPE) trial. SETTING Six Veterans Health Affairs clinics. SUBJECTS Iraq and Afghanistan veterans (N = 222) with chronic musculoskeletal pain. METHODS Longitudinal analysis of veterans with chronic musculoskeletal pain and PTSD or pain alone and available baseline and nine-month trial data. Participants randomized to either usual care or a stepped-care intervention were analyzed. The pain-PTSD comorbidity group screened positive for PTSD and had a PTSD Checklist-Civilian score ≥41 at baseline. RESULTS T tests demonstrated statistically significant differences and worse outcomes on pain severity, pain cognitions, and psychological outcomes in veterans with comorbid pain and PTSD compared with those with pain alone. Analysis of covariance (ANCOVA) modeling change scores from baseline to nine months indicated no statistically significant differences, controlling for PTSD, on pain severity, pain centrality, or pain self-efficacy. Significant differences emerged for pain catastrophizing (t = 3.10, P < 0.01), depression (t = 3.39, P < 0.001), and anxiety (t = 3.80, P < 0.001). The interaction between PTSD and the stepped-care intervention was not significant. CONCLUSIONS Veterans with the pain-PTSD comorbidity demonstrated worse pain and psychological outcomes than those with chronic pain alone. These findings indicate a more intense chronic pain experience for veterans when PTSD co-occurs with pain. PTSD did not lead to a differential response to a stepped-care intervention.",2020,"Significant differences emerged for pain catastrophizing (t = 3.10, P < 0.01), depression (t = 3.39, P < 0.001), and anxiety (t = 3.80, P < 0.001).","['Six Veterans Health Affairs clinics', 'veterans with chronic musculoskeletal pain and comorbid post-traumatic stress disorder (PTSD) or', 'Iraq and Afghanistan veterans (N\u2009=\u2009222) with chronic musculoskeletal pain', 'veterans with chronic musculoskeletal pain and PTSD or pain alone and available baseline and nine-month trial data', 'Iraq and Afghanistan Veterans with Chronic Pain and PTSD', 'veterans with comorbidity respond differently to a stepped-care intervention than those with pain alone', 'Veterans with the pain-PTSD comorbidity']","['usual care or a stepped-care intervention', 'pain alone']","['pain catastrophizing', 'anxiety', 'Pain and Psychological Outcomes', 'pain severity, pain cognitions, and psychological outcomes', 'pain severity, pain centrality, or pain self-efficacy', 'pain and psychological outcomes', 'depression']","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0746683', 'cui_str': 'Chronic musculoskeletal pain'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0022066', 'cui_str': 'Republic of Iraq'}, {'cui': 'C0001732', 'cui_str': 'Afghanistan'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C1261552', 'cui_str': 'Step'}]","[{'cui': 'C1261552', 'cui_str': 'Step'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]",222.0,0.0623471,"Significant differences emerged for pain catastrophizing (t = 3.10, P < 0.01), depression (t = 3.39, P < 0.001), and anxiety (t = 3.80, P < 0.001).","[{'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Bair', 'Affiliation': 'Center for Health Information and Communication, Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service, Indianapolis, Indiana.'}, {'ForeName': 'Samantha D', 'Initials': 'SD', 'LastName': 'Outcalt', 'Affiliation': 'Center for Health Information and Communication, Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service, Indianapolis, Indiana.'}, {'ForeName': 'Dennis', 'Initials': 'D', 'LastName': 'Ang', 'Affiliation': 'Division of Rheumatology, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Jingwei', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Department of Biostatistics, Temple University, Philadelphia, Pennsylvania.'}, {'ForeName': 'Zhangsheng', 'Initials': 'Z', 'LastName': 'Yu', 'Affiliation': 'Center of Statistics Research, Research Department, School of Statistics, Shanghai Jiaotong University, Shanghai, China.'}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pnaa007'] 541,32150297,"Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.","Rituximab-containing induction followed by autologous stem cell transplantation (ASCT) is the standard first-line treatment for young mantle cell lymphoma patients. However, most patients relapse after ASCT. We investigated in a randomised phase II study the outcome of a chemo-immuno regimen and ASCT with or without maintenance therapy with bortezomib. Induction consisted of three cycles R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), two cycles high-dose cytarabine, BEAM (carmustine, etoposide, cytarabine, melphalan) and ASCT. Patients responding were randomised between bortezomib maintenance (1·3 mg/m 2 intravenously once every 2 weeks, for 2 years) and observation. Of 135 eligible patients, 115 (85%) proceeded to ASCT, 60 (44%) were randomised. With a median follow-up of 77·5 months for patients still alive, 5-year event-free survival (EFS) was 51% (95% CI 42-59%); 5-year overall survival (OS) was 73% (95% CI 65-80%). The median follow-up of randomised patients still alive was 71·5 months. Patients with bortezomib maintenance had a 5-year EFS of 63% (95% CI 44-78%) and 5-year OS of 90% (95% CI 72-97%). The patients randomised to observation had 5-year PFS of 60% (95% CI, 40-75%) and OS of 90% (95% CI 72-97%). In conclusion, in this phase II study we found no indication of a positive effect of bortezomib maintenance after ASCT.",2020,"The patients randomised to observation had 5-year PFS of 60% (95% CI, 40-75%) and OS of 90% (95% CI 72-97%).","['135 eligible patients, 115 (85%) proceeded to ASCT, 60 (44%) were randomised', 'newly diagnosed patients with mantle cell lymphoma', '1·3', 'young mantle cell lymphoma patients']","['three cycles R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), two cycles high-dose cytarabine, BEAM (carmustine, etoposide, cytarabine, melphalan) and ASCT', 'chemo-immuno regimen and ASCT with or without maintenance therapy with bortezomib', 'bortezomib', 'Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation', 'bortezomib maintenance', 'bortezomib maintenance ', 'Rituximab-containing induction followed by autologous stem cell transplantation (ASCT']","['5-year EFS', '5-year event-free survival (EFS', '5-year OS', '5-year overall survival (OS', '5-year PFS']","[{'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517540', 'cui_str': '115 (qualifier value)'}, {'cui': 'C0334634', 'cui_str': 'Lymphoma, Small-Cell, Centrocytic'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}]","[{'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0042679', 'cui_str': 'Vincristine'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0010711', 'cui_str': 'Cytarabine'}, {'cui': 'C0007257', 'cui_str': 'Carmustine'}, {'cui': 'C0015133', 'cui_str': 'Etoposide'}, {'cui': 'C0025241', 'cui_str': 'Melphalan'}, {'cui': 'C0677908', 'cui_str': 'Maintenance therapy'}, {'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C1504389', 'cui_str': 'Stem Cell Transplantation'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",135.0,0.180746,"The patients randomised to observation had 5-year PFS of 60% (95% CI, 40-75%) and OS of 90% (95% CI 72-97%).","[{'ForeName': 'Jeanette K', 'Initials': 'JK', 'LastName': 'Doorduijn', 'Affiliation': 'Haematology, Erasmus MC Cancer Centre, Rotterdam, Netherlands.'}, {'ForeName': 'Josee M', 'Initials': 'JM', 'LastName': 'Zijlstra', 'Affiliation': 'Amsterdam UMC - Locatie VUMC, Amsterdam, Netherlands.'}, {'ForeName': 'Pieternella J', 'Initials': 'PJ', 'LastName': 'Lugtenburg', 'Affiliation': 'Erasmus MC Cancer Centre, Rotterdam, Netherlands.'}, {'ForeName': 'Marie Josee', 'Initials': 'MJ', 'LastName': 'Kersten', 'Affiliation': 'Haematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam and LYMMCARE (lymphoma and myeloma Center), Amsterdam, Netherlands.'}, {'ForeName': 'Lara H', 'Initials': 'LH', 'LastName': 'Böhmer', 'Affiliation': 'Haematology, Haga Teaching Hospital, The Hague, USA.'}, {'ForeName': 'Monique C', 'Initials': 'MC', 'LastName': 'Minnema', 'Affiliation': 'Haematology, UMC Utrecht Cancer Centre, Utrecht, Netherlands.'}, {'ForeName': 'Marius A', 'Initials': 'MA', 'LastName': 'MacKenzie', 'Affiliation': 'UMCN, Nijmegen, Netherlands.'}, {'ForeName': 'Rien', 'Initials': 'R', 'LastName': 'van Marwijk Kooij', 'Affiliation': 'Internal Medicine, Isala Clinic, Zwolle, Netherlands.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'de Jongh', 'Affiliation': 'Albert Schweitzer Hospital Location Dordwijk, Dordrecht, Netherlands.'}, {'ForeName': 'Tjeerd J F', 'Initials': 'TJF', 'LastName': 'Snijders', 'Affiliation': 'Medisch Spectrum Twente, Enschede, Netherlands.'}, {'ForeName': 'Okke', 'Initials': 'O', 'LastName': 'de Weerdt', 'Affiliation': 'Sint Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'van Gelder', 'Affiliation': 'Maastricht University Medical Centre+, Maastricht, Netherlands.'}, {'ForeName': 'Mels', 'Initials': 'M', 'LastName': 'Hoogendoorn', 'Affiliation': 'Medical Centre Leeuwarden, Leeuwarden, Netherlands.'}, {'ForeName': 'Rineke B L', 'Initials': 'RBL', 'LastName': 'Leys', 'Affiliation': 'Maasstad Ziekenhuis, Rotterdam, Netherlands.'}, {'ForeName': 'Robby E', 'Initials': 'RE', 'LastName': 'Kibbelaar', 'Affiliation': 'Department of Pathology, Pathology Friesland, Groningen, Netherlands.'}, {'ForeName': 'Daphne', 'Initials': 'D', 'LastName': 'de Jong', 'Affiliation': 'Amsterdam UMC - Locatie VUMC, Amsterdam, Netherlands.'}, {'ForeName': 'Dana A', 'Initials': 'DA', 'LastName': 'Chitu', 'Affiliation': 'Erasmus MC Cancer Center, Rotterdam, Netherlands.'}, {'ForeName': 'Mars B', 'Initials': 'MB', 'LastName': ""Van't Veer"", 'Affiliation': 'Erasmus MC Cancer Centre, Rotterdam, Netherlands.'}, {'ForeName': 'Hanneke C', 'Initials': 'HC', 'LastName': 'Kluin-Nelemans', 'Affiliation': 'Haematology, University Medical Center Groningen, Groningen, Netherlands.'}]",British journal of haematology,['10.1111/bjh.16567'] 542,32145830,"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.","BACKGROUND The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We aimed to establish the effects of nintedanib in subgroups based on ILD diagnosis. METHODS The INBUILD trial was a randomised, double-blind, placebo-controlled, parallel group trial done at 153 sites in 15 countries. Participants had an investigator-diagnosed fibrosing ILD other than IPF, with chest imaging features of fibrosis of more than 10% extent on high resolution CT (HRCT), forced vital capacity (FVC) of 45% or more predicted, and diffusing capacity of the lung for carbon monoxide (DLco) of at least 30% and less than 80% predicted. Participants fulfilled protocol-defined criteria for ILD progression in the 24 months before screening, despite management considered appropriate in clinical practice for the individual ILD. Participants were randomly assigned 1:1 by means of a pseudo-random number generator to receive nintedanib 150 mg twice daily or placebo for at least 52 weeks. Participants, investigators, and other personnel involved in the trial and analysis were masked to treatment assignment until after database lock. In this subgroup analysis, we assessed the rate of decline in FVC (mL/year) over 52 weeks in patients who received at least one dose of nintedanib or placebo in five prespecified subgroups based on the ILD diagnoses documented by the investigators: hypersensitivity pneumonitis, autoimmune ILDs, idiopathic non-specific interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, and other ILDs. The trial has been completed and is registered with ClinicalTrials.gov, number NCT02999178. FINDINGS Participants were recruited between Feb 23, 2017, and April 27, 2018. Of 663 participants who received at least one dose of nintedanib or placebo, 173 (26%) had chronic hypersensitivity pneumonitis, 170 (26%) an autoimmune ILD, 125 (19%) idiopathic non-specific interstitial pneumonia, 114 (17%) unclassifiable idiopathic interstitial pneumonia, and 81 (12%) other ILDs. The effect of nintedanib versus placebo on reducing the rate of FVC decline (mL/year) was consistent across the five subgroups by ILD diagnosis in the overall population (hypersensitivity pneumonitis 73·1 [95% CI -8·6 to 154·8]; autoimmune ILDs 104·0 [21·1 to 186·9]; idiopathic non-specific interstitial pneumonia 141·6 [46·0 to 237·2]; unclassifiable idiopathic interstitial pneumonia 68·3 [-31·4 to 168·1]; and other ILDs 197·1 [77·6 to 316·7]; p=0·41 for treatment by subgroup by time interaction). Adverse events reported in the subgroups were consistent with those reported in the overall population. INTERPRETATION The INBUILD trial was not designed or powered to provide evidence for a benefit of nintedanib in specific diagnostic subgroups. However, its results suggest that nintedanib reduces the rate of ILD progression, as measured by FVC decline, in patients who have a chronic fibrosing ILD and progressive phenotype, irrespective of the underlying ILD diagnosis. FUNDING Boehringer Ingelheim.",2020,"Participants fulfilled protocol-defined criteria for ILD progression in the 24 months before screening, despite management considered appropriate in clinical practice for the individual ILD.","['patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis', 'Participants were recruited between Feb 23, 2017, and April 27, 2018', ' 125 (19%) idiopathic non-specific interstitial pneumonia, 114 (17%) unclassifiable idiopathic interstitial pneumonia, and 81 (12%) other ILDs', '153 sites in 15 countries', '663 participants who received at least one dose of', 'patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF']","['nintedanib or placebo', 'Nintedanib', 'nintedanib 150 mg twice daily or placebo', 'placebo', 'nintedanib versus placebo']","['Adverse events', 'rate of decline in FVC', 'rate of FVC decline', 'rate of ILD progression', 'high resolution CT (HRCT), forced vital capacity (FVC', 'chronic hypersensitivity pneumonitis', 'autoimmune ILD']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C1869044', 'cui_str': 'Interstitial lung disease (SMQ)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C4319551', 'cui_str': 'One hundred and twenty-five'}, {'cui': 'C1608429', 'cui_str': 'Idiopathic (IPAH)'}, {'cui': 'C0205370', 'cui_str': 'Non-specific (qualifier value)'}, {'cui': 'C0206061', 'cui_str': 'Pneumonitis, Interstitial'}, {'cui': 'C4708785', 'cui_str': 'One hundred and fourteen'}, {'cui': 'C0085786', 'cui_str': 'Alveolitis, Fibrosing'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]","[{'cui': 'C2930789', 'cui_str': 'nintedanib'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3859350', 'cui_str': 'nintedanib 150 MG [Ofev]'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C3714541', 'cui_str': 'Forced Vital Capacity'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0002390', 'cui_str': 'Pneumonitis, Hypersensitivity'}]",,0.727131,"Participants fulfilled protocol-defined criteria for ILD progression in the 24 months before screening, despite management considered appropriate in clinical practice for the individual ILD.","[{'ForeName': 'Athol U', 'Initials': 'AU', 'LastName': 'Wells', 'Affiliation': 'National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK.'}, {'ForeName': 'Kevin R', 'Initials': 'KR', 'LastName': 'Flaherty', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Kevin K', 'Initials': 'KK', 'LastName': 'Brown', 'Affiliation': 'Department of Medicine, National Jewish Health, Denver, CO, USA.'}, {'ForeName': 'Yoshikazu', 'Initials': 'Y', 'LastName': 'Inoue', 'Affiliation': 'Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan.'}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Devaraj', 'Affiliation': 'Department of Radiology, Royal Brompton and Harefield NHS Foundation Trust, London, UK; National Heart and Lung Institute, Imperial College, London, UK.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Richeldi', 'Affiliation': 'Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.'}, {'ForeName': 'Teng', 'Initials': 'T', 'LastName': 'Moua', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, MN, USA.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Crestani', 'Affiliation': 'Université de Paris, Inserm U1152, APHP, Hôpital Bichat, Centre de reference constitutif pour les maladies pulmonaires rares, Paris, France.'}, {'ForeName': 'Wim A', 'Initials': 'WA', 'LastName': 'Wuyts', 'Affiliation': 'Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Stowasser', 'Affiliation': 'Boehringer Ingelheim International, Ingelheim am Rhein, Germany.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Quaresma', 'Affiliation': 'Boehringer Ingelheim International, Ingelheim am Rhein, Germany.'}, {'ForeName': 'Rainer-Georg', 'Initials': 'RG', 'LastName': 'Goeldner', 'Affiliation': 'Boehringer Ingelheim Pharma, Biberach, Germany.'}, {'ForeName': 'Rozsa', 'Initials': 'R', 'LastName': 'Schlenker-Herceg', 'Affiliation': 'Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Kolb', 'Affiliation': ""McMaster University and St Joseph's Healthcare, Hamilton, Ontario, Canada.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(20)30036-9'] 543,31296516,"ASSERT (Acute Sacral inSufficiEncy fractuRe augmenTation) randomised controlled, feasibility in older people trial: a study protocol.","INTRODUCTION Pelvic fragility fractures (PFF) are common in older people and associated with a significant burden of mortality and morbidity. This is related to the challenges of appropriate pain control and early mobilisation. The current standard for treatment of PFF is non-surgical management. Minimally invasive surgical techniques for sacral fracture stabilisation have been shown to improve outcomes in terms of pain control and mobility, and they are safe. Randomised controlled trials are required before recommendations can be made for surgical management of PFF to become the new standard of care. This feasibility study will explore several uncertainties around conducting such a trial. METHODS AND ANALYSIS ASSERT (Acute Sacral inSufficiEncy fractuRe augmenTation) is a single-site randomised controlled, parallel-arm, feasibility trial of surgical stabilisation versus non-surgical management of acute sacral fragility fractures in people aged 70 years and over. Patients will be randomised to either surgical or non-surgical group on a 1:1 ratio. Follow-up of participants will occur at 2, 4 and 12 weeks with safety data collected at 52 weeks. Primary objectives are to determine feasibility and design of a future trial, including outcomes on recruitment, adherence to randomisation and safety. This will be supplemented with a qualitative interview study of participants and clinicians. Secondary objectives will inform study design procedures to determine clinical and economic outcomes between groups, including scored questionnaires, analgesia requirements, resource use and quality of life data. Data analysis will be largely descriptive to inform outcomes and future sample size. ETHICS AND DISSEMINATION Ethical approval was granted by the North East Newcastle and North Tyneside 2 Research Ethics Committee (reference 18/NE/0212). ASSERT was approved and sponsored by Nottingham University Hospitals NHS Trust (reference 18HC001) and the Health Research Authority (reference IRAS 232791). Recruitment is ongoing. Results will be presented at relevant conferences and submitted to appropriate journals on study completion. TRIAL REGISTRATION NUMBER ISRCTN16719542; Pre-results.",2019,"Minimally invasive surgical techniques for sacral fracture stabilisation have been shown to improve outcomes in terms of pain control and mobility, and they are safe.","['older people trial', 'acute sacral fragility fractures in people aged 70 years and over']","['PFF', 'surgical stabilisation versus non-surgical management', 'surgical or non-surgical']","['scored questionnaires, analgesia requirements, resource use and quality of life data']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0302113', 'cui_str': 'Fragility, function (observable entity)'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0034380'}]",,0.202656,"Minimally invasive surgical techniques for sacral fracture stabilisation have been shown to improve outcomes in terms of pain control and mobility, and they are safe.","[{'ForeName': 'Dawn', 'Initials': 'D', 'LastName': 'van Berkel', 'Affiliation': 'Health Care of the Older People Division, Nottingham University Hospitals NHS Trust, Nottingham, UK.'}, {'ForeName': 'Terence', 'Initials': 'T', 'LastName': 'Ong', 'Affiliation': 'Health Care of the Older People Division, Nottingham University Hospitals NHS Trust, Nottingham, UK.'}, {'ForeName': 'Avril', 'Initials': 'A', 'LastName': 'Drummond', 'Affiliation': 'School of Health Sciences, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Hendrick', 'Affiliation': 'Division of Physiotherapy and Rehabilitation Sciences, School of Health Sciences, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Leighton', 'Affiliation': 'School of Health Sciences, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Jones', 'Affiliation': 'Division of Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Khalid', 'Initials': 'K', 'LastName': 'Salem', 'Affiliation': 'Centre for Spinal Studies and Surgery, Nottingham University Hospitals NHS Trust, Nottingham, UK.'}, {'ForeName': 'Nasir', 'Initials': 'N', 'LastName': 'Quraishi', 'Affiliation': 'Centre for Spinal Studies and Surgery, Nottingham University Hospitals NHS Trust, Nottingham, UK.'}, {'ForeName': 'Cassandra', 'Initials': 'C', 'LastName': 'Brookes', 'Affiliation': 'Leicester Clinical Trials Unit, University of Leicester, Leicester, UK.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Suazo Di Paola', 'Affiliation': 'Leicester Clinical Trials Unit, University of Leicester, Leicester, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Edwards', 'Affiliation': 'Leicester Clinical Trials Unit, University of Leicester, Leicester, UK.'}, {'ForeName': 'Opinder', 'Initials': 'O', 'LastName': 'Sahota', 'Affiliation': 'Health Care of the Older People Division, Nottingham University Hospitals NHS Trust, Nottingham, UK.'}]",BMJ open,['10.1136/bmjopen-2019-032111'] 544,31659411,Implementation of a Surgical Simulation Care Pathway Approach to Training in Emergency Abdominal Surgery.,"BACKGROUND Simulation-based care pathway approach (CPA) training is a novel approach in surgical education. The objective of the present study was to determine whether CPA was feasible for training surgical residents and could improve efficiency in patients' management. A common disease was chosen: acute appendicitis. METHODS All five junior residents of our department were trained in CPA: preoperative CPA consisted in virtual patients (VPs) presenting with acute right iliac fossa pain; intraoperative CPA involved a virtual competency-based curriculum for laparoscopic appendectomy (LAPP); finally, post-operative VP were reviewed after LAPP. Thirty-eight patients undergoing appendectomy were prospectively included before (n = 21) and after (n = 17) the training. All demographic and perioperative data were prospectively collected from their medical records, and time taken from admission to management was measured. RESULTS All residents had performed less than 10 LAPP as primary operator. Pre- and intraoperative data were comparable between pretraining and post-training patients. Times to liquid and solid diet were significantly reduced after training [7 h (2-20) vs. 4 (4-6); P = 0.004, and 17 h (4-48) vs. 6 (4-24); P = 0.005] without changing post-operative morbidity [4 (19%) vs. 0 (0); P = 0.11] and length of stay [48 h (30-264) vs. 44 (21-145); P = 0.22]. CONCLUSIONS CPA training is feasible in abdominal surgery. In the current study, it improved patients' management in terms of earlier oral intake.",2020,"All five junior residents of our department were trained in CPA: preoperative CPA consisted in virtual patients (VPs) presenting with acute right iliac fossa pain; intraoperative CPA involved a virtual competency-based curriculum for laparoscopic appendectomy (LAPP); finally, post-operative VP were reviewed after LAPP.","['Thirty-eight patients undergoing appendectomy were prospectively included before (n\u2009=\u200921) and after (n\u2009=\u200917) the training', 'All five junior residents of our department were trained in', 'Emergency Abdominal Surgery', ""patients' management""]","['Simulation-based care pathway approach (CPA) training', 'CPA', 'CPA training', 'CPA: preoperative CPA consisted in virtual patients (VPs) presenting with acute right iliac fossa pain; intraoperative CPA involved a virtual competency-based curriculum for laparoscopic appendectomy (LAPP']","['Pre- and intraoperative data', 'operative morbidity', 'length of stay', 'Times to liquid and solid diet']","[{'cui': 'C0450361', 'cui_str': '38 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0003611', 'cui_str': 'Appendectomy'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0175673', 'cui_str': 'Emergency (qualifier value)'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0476306', 'cui_str': 'Right iliac fossa pain (finding)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0220815', 'cui_str': 'curriculum'}, {'cui': 'C0372525', 'cui_str': 'Endoscopic appendectomy'}, {'cui': 'C0337904', 'cui_str': 'Lapps (ethnic group)'}]","[{'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1304698', 'cui_str': 'Liquid - descriptor'}, {'cui': 'C0302909', 'cui_str': 'Solid substance (substance)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}]",38.0,0.0240625,"All five junior residents of our department were trained in CPA: preoperative CPA consisted in virtual patients (VPs) presenting with acute right iliac fossa pain; intraoperative CPA involved a virtual competency-based curriculum for laparoscopic appendectomy (LAPP); finally, post-operative VP were reviewed after LAPP.","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Beyer-Berjot', 'Affiliation': ""Department of Surgery and Cancer, St. Mary's Campus, Imperial College Healthcare NHS Trust, London, UK. laura.beyer@ap-hm.fr.""}, {'ForeName': 'Vishal', 'Initials': 'V', 'LastName': 'Patel', 'Affiliation': ""Department of Surgery and Cancer, St. Mary's Campus, Imperial College Healthcare NHS Trust, London, UK.""}, {'ForeName': 'Pramudith', 'Initials': 'P', 'LastName': 'Sirimanna', 'Affiliation': ""Department of Surgery and Cancer, St. Mary's Campus, Imperial College Healthcare NHS Trust, London, UK.""}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Hashimoto', 'Affiliation': 'Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Berdah', 'Affiliation': 'Centre for Surgical Teaching and Research (CERC), Faculté de Médecine Secteur Nord, Aix-Marseille University, 51 Boulevard Pierre Dramard, 13015, Marseille, France.'}, {'ForeName': 'Ara', 'Initials': 'A', 'LastName': 'Darzi', 'Affiliation': ""Department of Surgery and Cancer, St. Mary's Campus, Imperial College Healthcare NHS Trust, London, UK.""}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Aggarwal', 'Affiliation': ""Department of Surgery and Cancer, St. Mary's Campus, Imperial College Healthcare NHS Trust, London, UK.""}]",World journal of surgery,['10.1007/s00268-019-05242-1'] 545,30959470,Advance Care Planning Improves Psychological Symptoms But Not Quality of Life and Preferred End-of-Life Care of Patients With Cancer.,"BACKGROUND This study was conducted to examine whether a longitudinal advance care planning (ACP) intervention facilitates concordance between the preferred and received life-sustaining treatments (LSTs) of terminally ill patients with cancer and improves quality of life (QoL), anxiety symptoms, and depressive symptoms during the dying process. PATIENTS AND METHODS Of 795 terminally ill patients with cancer from a medical center in Taiwan, 460 were recruited and randomly assigned 1:1 to the experimental and control arms. The experimental arm received an interactive ACP intervention tailored to participants' readiness to engage in this process. The control arm received symptom management education. Group allocation was concealed, data collectors were blinded, and treatment fidelity was monitored. Outcome measures included 6 preferred and received LSTs, QoL, anxiety symptoms, and depressive symptoms. Intervention effectiveness was evaluated by intention-to-treat analysis. RESULTS Participants providing data had died through December 2017. The 2 study arms did not differ significantly in concordance between the 6 preferred and received LSTs examined (odds ratios, 0.966 [95% CI, 0.653-1.428] and 1.107 [95% CI, 0.690-1.775]). Participants who received the ACP intervention had significantly fewer anxiety symptoms (β, -0.583; 95% CI, -0.977 to -0.189; P= .004) and depressive symptoms (β, -0.533; 95% CI, -1.036 to -0.030; P= .038) compared with those in the control arm, but QoL did not differ. CONCLUSIONS Our ACP intervention facilitated participants' psychological adjustment to the end-of-life (EoL) care decision-making process, but neither improved QoL nor facilitated EoL care honoring their wishes. The inability of our intervention to improve concordance may have been due to the family power to override patients' wishes in deeply Confucian doctrine-influenced societies such as Taiwan. Nevertheless, our findings reassure healthcare professionals that such an ACP intervention does not harm but improves the psychological well-being of terminally ill patients with cancer, thereby encouraging physicians to discuss EoL care preferences with patients and involve family caregivers in EoL care decision-making to eventually lead to patient value-concordant EoL cancer care.",2019,"Participants who received the ACP intervention had significantly fewer anxiety symptoms (β, -0.583; 95% CI, -0.977 to -0.189; P= .004) and depressive symptoms (β, -0.533; 95% CI, -1.036 to -0.030; P= .038) compared with those in the control arm, but QoL did not differ. ","['Of 795 terminally ill patients with cancer from a medical center in Taiwan, 460', 'terminally ill patients with cancer', 'Patients With Cancer']","['ACP intervention', 'longitudinal advance care planning (ACP) intervention', 'symptom management education', 'interactive ACP intervention', 'life-sustaining treatments (LSTs', 'Advance Care Planning']","['6 preferred and received LSTs, QoL, anxiety symptoms, and depressive symptoms', 'depressive symptoms', 'Intervention effectiveness', 'quality of life (QoL), anxiety symptoms, and depressive symptoms', 'Psychological Symptoms', 'anxiety symptoms']","[{'cui': 'C0039552', 'cui_str': 'Terminally Ill'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0565990', 'cui_str': 'Medical center (environment)'}, {'cui': 'C0039260', 'cui_str': 'Formosa'}]","[{'cui': 'C0205127', 'cui_str': 'Longitudinal (qualifier value)'}, {'cui': 'C0600371', 'cui_str': 'Advance Health Care Planning'}, {'cui': 'C1536570', 'cui_str': 'Symptom management (procedure)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C3543840', 'cui_str': 'Preferred'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0233397', 'cui_str': 'Psychological symptom'}]",460.0,0.0690705,"Participants who received the ACP intervention had significantly fewer anxiety symptoms (β, -0.583; 95% CI, -0.977 to -0.189; P= .004) and depressive symptoms (β, -0.533; 95% CI, -1.036 to -0.030; P= .038) compared with those in the control arm, but QoL did not differ. ","[{'ForeName': 'Siew Tzuh', 'Initials': 'ST', 'LastName': 'Tang', 'Affiliation': 'aSchool of Nursing, Medical College, Chang Gung University.'}, {'ForeName': 'Jen-Shi', 'Initials': 'JS', 'LastName': 'Chen', 'Affiliation': 'dDivision of Hematology-Oncology, Chang Gung Memorial Hospital; and.'}, {'ForeName': 'Fur-Hsing', 'Initials': 'FH', 'LastName': 'Wen', 'Affiliation': 'fDepartment of International Business, Soochow University, and.'}, {'ForeName': 'Wen-Chi', 'Initials': 'WC', 'LastName': 'Chou', 'Affiliation': 'dDivision of Hematology-Oncology, Chang Gung Memorial Hospital; and.'}, {'ForeName': 'John Wen-Cheng', 'Initials': 'JW', 'LastName': 'Chang', 'Affiliation': 'dDivision of Hematology-Oncology, Chang Gung Memorial Hospital; and.'}, {'ForeName': 'Chia-Hsun', 'Initials': 'CH', 'LastName': 'Hsieh', 'Affiliation': 'dDivision of Hematology-Oncology, Chang Gung Memorial Hospital; and.'}, {'ForeName': 'Chen Hsiu', 'Initials': 'CH', 'LastName': 'Chen', 'Affiliation': 'gCollege of Nursing, National Taipei University of Nursing and Health Science, Taipei, Taiwan.'}]",Journal of the National Comprehensive Cancer Network : JNCCN,['10.6004/jnccn.2018.7106'] 546,30929458,The effects of a short-term mindfulness meditation intervention on coping flexibility.,"Background and objectives: Mindfulness meditation (MM) training promotes health and well-being. One potential mechanistic link between MM and health may be coping flexibility, (e.g., the ability to monitor and modify coping strategies based on situational needs and strategy effectiveness). We hypothesized that MM training would increase coping flexibility and also explored whether gains in coping flexibility continued to increase after training, or whether they were maintained or lost with time. Methods and design: One hundred thirteen students (71 female, M age  = 18.97) were randomly assigned to a waitlist control or MM condition. Participants in the MM condition were trained by a certified MM instructor and given guided recordings for one-week of at-home practice. Participants provided reports of coping flexibility over a three-week span. Results: Results from multilevel modeling indicated that MM increased coping flexibility among those in the MM condition and among those who spent relatively more time meditating. Results further suggested that the gains in coping flexibility that were evident at post-test were not only maintained but increased in the two weeks after the intervention. Conclusions: This study provides preliminary support for the assertion that MM increases the ability to monitor and modify coping strategies during times of stress.",2019,This study provides preliminary support for the assertion that MM increases the ability to monitor and modify coping strategies during times of stress.,"['One hundred thirteen students (71 female, M age \u2009=\u200918.97']","['Mindfulness meditation (MM) training', 'waitlist control or MM condition', 'MM training', 'short-term mindfulness meditation intervention']",['coping flexibility'],"[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0150277'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}]","[{'cui': 'C0242808', 'cui_str': 'Flexibility'}]",113.0,0.0215618,This study provides preliminary support for the assertion that MM increases the ability to monitor and modify coping strategies during times of stress.,"[{'ForeName': 'Dusti R', 'Initials': 'DR', 'LastName': 'Jones', 'Affiliation': 'a Department of Psychology , Western Washington University , Bellingham , WA , USA.'}, {'ForeName': 'Barbara J', 'Initials': 'BJ', 'LastName': 'Lehman', 'Affiliation': 'a Department of Psychology , Western Washington University , Bellingham , WA , USA.'}, {'ForeName': 'Alysia', 'Initials': 'A', 'LastName': 'Noriega', 'Affiliation': 'a Department of Psychology , Western Washington University , Bellingham , WA , USA.'}, {'ForeName': 'Dale L', 'Initials': 'DL', 'LastName': 'Dinnel', 'Affiliation': 'a Department of Psychology , Western Washington University , Bellingham , WA , USA.'}]","Anxiety, stress, and coping",['10.1080/10615806.2019.1596672'] 547,30993350,Comparison of lateral and supine positions for tracheal extubation in children : A randomized clinical trial.,"BACKGROUND The lateral position is known to be advantageous for maintaining airway patency. This study compared the lateral and supine positions for tracheal extubation in pediatric patients when performing deep extubation. OBJECTIVE The hypothesis was that tracheal extubation in the lateral position would improve airway obstruction that often occurs immediately after extubation and can be a practical method. MATERIAL AND METHODS This prospective randomized trial was performed in operating rooms in a tertiary care hospital and included 92 patients (3-12 years old) undergoing elective strabismus surgery. The patients were randomly divided into two groups: deep extubation in the supine position (group S) and deep extubation in the lateral position (group L). Oxygen saturation (SpO 2 ) and the incidence of stridor, laryngospasm, and coughing after tracheal extubation were assessed. RESULTS The mean ± standard deviation of the lowest SpO 2 values within 5 min after extubation was significantly higher in group L (98.3 ± 2.1%) than in group S (96.8 ± 2.5%, mean difference 1.5, 95% confidence interval, CI 0.5-2.5, p = 0.003). The incidences of stridor and laryngospasm of group L were significantly lower than those of group S (1/45, 2% vs. 8/45, 18%, respectively; relative risk 1.9, 95% CI 1.4-2.7, p = 0.03). The incidence of desaturation and coughing were not significantly different between groups. CONCLUSION In pediatric patients deep extubation in the lateral position improved SpO 2 and reduced the incidence of stridor and laryngospasm in the early emergence period when compared to extubation in the supine position.",2019,In pediatric patients deep extubation in the lateral position improved SpO 2 and reduced the incidence of stridor and laryngospasm in the early emergence period when compared to extubation in the supine position.,"['operating rooms in a\xa0tertiary care hospital and included 92\xa0patients (3-12\xa0years old) undergoing elective strabismus surgery', 'pediatric patients when performing deep extubation', 'children ']","['lateral and supine positions', 'deep extubation in the supine position (group\xa0S) and deep extubation in the lateral position']","['Oxygen saturation (SpO 2 ) and the incidence of stridor, laryngospasm, and coughing after tracheal extubation', 'incidence of desaturation and coughing', 'airway obstruction', 'incidences of stridor and laryngospasm of group\xa0L', 'incidence of stridor and laryngospasm']","[{'cui': 'C0029064', 'cui_str': 'Operating Room'}, {'cui': 'C0337954', 'cui_str': 'Tertiary care hospital (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C1705868', 'cui_str': 'Strabismus surgery'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0205093', 'cui_str': 'Lateral (qualifier value)'}, {'cui': 'C0038846', 'cui_str': 'Dorsal Position'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C0441853', 'cui_str': 'Group S (qualifier value)'}, {'cui': 'C0444379', 'cui_str': 'Lateral decubitus position (finding)'}]","[{'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0038450', 'cui_str': 'Stridor'}, {'cui': 'C0023066', 'cui_str': 'Laryngospasm'}, {'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C0001883', 'cui_str': 'Airway Obstruction'}, {'cui': 'C0441846', 'cui_str': 'Group L (qualifier value)'}]",,0.059665,In pediatric patients deep extubation in the lateral position improved SpO 2 and reduced the incidence of stridor and laryngospasm in the early emergence period when compared to extubation in the supine position.,"[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Jung', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, School of Medicine, Kyungpook National University, 807\xa0Hoguk-ro, 41404, Buk-gu, Daegu, Korea (Republic of).'}, {'ForeName': 'H J', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Keimyung University Dongsan Medical center, Daegu, Korea (Republic of).'}, {'ForeName': 'Y-C', 'Initials': 'YC', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Keimyung University Dongsan Medical center, Daegu, Korea (Republic of).'}, {'ForeName': 'H J', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, School of Medicine, Kyungpook National University, 807\xa0Hoguk-ro, 41404, Buk-gu, Daegu, Korea (Republic of). hj_kim@knu.ac.kr.'}]",Der Anaesthesist,['10.1007/s00101-019-0590-2'] 548,30243810,"Optimal treatment for women with a persisting pregnancy of unknown location, a randomized controlled trial: The ACT-or-NOT trial.","OBJECTIVE Pregnancy of unknown location (PUL) is not a diagnosis but a transient state used to classify a woman when she has a positive pregnancy test without definitive evidence of an intra-uterine or extra-uterine pregnancy on transvaginal ultrasonography. Management of a persisting PUL varies substantially, including expectant or active management. Active management can include uterine cavity evacuation or systemic administration of methotrexate. To date, no consensus has been reached on whether either management strategy is superior or non-inferior to the other. DESIGN Randomized controlled trial. SETTING Academic medical centers. PATIENTS We plan to randomize 276 persisting PUL-diagnosed women who are 18 years or older from Reproductive Medicine Network clinics and additional interested sites, all patients will be followed for 2 years for fertility and patient satisfaction outcomes. INTERVENTIONS Randomization will be 1:1:1 ratio between expectant management, uterine evacuation and empiric use of methotrexate. After randomization to initial management plan, all patients will be followed by their clinicians until resolution of the PUL. The clinician will determine whether there is a change in management, based on clinical symptoms, and/or serial human chorionic gonadotropin (hCG) concentrations and/or additional ultrasonography. MAIN OUTCOME The primary outcome measure in each of the 3 treatment arms is the uneventful clinical resolution of a persistent PUL without change from the initial management strategy. Secondary outcome measures include: number of ruptured ectopic pregnancies, number and type of re-interventions (additional methotrexate injections or surgical procedures), treatment complications, adverse events, number of visits, time to resolution, patient satisfaction, and future fertility. CONCLUSION This multicenter randomized controlled trial will provide guidance for evidence-based management for women who have persisting pregnancy of unknown location.",2018,This multicenter randomized controlled trial will provide guidance for evidence-based management for women who have persisting pregnancy of unknown location.,"['women who have persisting pregnancy of unknown location', 'women with a persisting pregnancy of unknown location', 'Academic medical centers', '276 persisting PUL-diagnosed women who are 18\u202fyears or older from Reproductive Medicine Network clinics and additional interested sites, all patients will be followed for 2\u202fyears for fertility and patient satisfaction outcomes']",['methotrexate'],"[' number of ruptured ectopic pregnancies, number and type of re-interventions (additional methotrexate injections or surgical procedures), treatment complications, adverse events, number of visits, time to resolution, patient satisfaction, and future fertility', 'uneventful clinical resolution of a persistent PUL without change from the initial management strategy']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C3495853', 'cui_str': 'Pregnancy of unknown location'}, {'cui': 'C0000872', 'cui_str': 'University Medical Centers'}, {'cui': 'C0449197', 'cui_str': 'PUL (body structure)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0242668', 'cui_str': 'Reproductive Medicine'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0543488', 'cui_str': 'Interested (finding)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0015895', 'cui_str': 'Fecundity'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}]","[{'cui': 'C0025677', 'cui_str': 'Methotrexate'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0392534', 'cui_str': 'Ruptured ectopic pregnancy (disorder)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C4034144', 'cui_str': 'Methotrexate Injection'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0016884', 'cui_str': 'Future'}, {'cui': 'C0015895', 'cui_str': 'Fecundity'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0449197', 'cui_str': 'PUL (body structure)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}]",,0.229722,This multicenter randomized controlled trial will provide guidance for evidence-based management for women who have persisting pregnancy of unknown location.,"[{'ForeName': 'Kurt T', 'Initials': 'KT', 'LastName': 'Barnhart', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States; Department of Biostatistics and Epidemiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States. Electronic address: kbarnhart@obgyn.upenn.edu.'}, {'ForeName': 'Mary D', 'Initials': 'MD', 'LastName': 'Sammel', 'Affiliation': 'Department of Biostatistics and Epidemiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Stephenson', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Illinois at Chicago, Chicago, IL, United States.'}, {'ForeName': 'Jared', 'Initials': 'J', 'LastName': 'Robins', 'Affiliation': 'Division of Reproductive Endocrinology and Infertility, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.'}, {'ForeName': 'Karl R', 'Initials': 'KR', 'LastName': 'Hansen', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences, Oklahoma City, OK, United States.'}, {'ForeName': 'Wahid A', 'Initials': 'WA', 'LastName': 'Youssef', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States.'}, {'ForeName': 'Nanette', 'Initials': 'N', 'LastName': 'Santoro', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Colorado, Denver, United States.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Eisenberg', 'Affiliation': 'Reproductive Sciences Branch, Eunice Kennedy Shriver NICHD, Rockville, MD, United States.'}, {'ForeName': 'Heping', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Biostatistics, Yale University School of Public Health, New Haven, CT, United States.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Contemporary clinical trials,['10.1016/j.cct.2018.09.009'] 549,32147352,Results of the spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Update after 21 years of follow-up.,"INTRODUCTION AND OBJECTIVE The objective of the European Randomized Study of Screening for Prostate Cancer (ERSPC) is to assess whether prostate cancer (PCa) screening leads to an improvement of cancer-specific survival. This multicenter study (eight European countries) has recruited more than 180,000 asymptomatic men. After a follow-up period of 16 years, it has been shown that PSA screening reduces PCa mortality by 20%, and that it does not affect all-cause mortality. This article provides updated the results of the Spanish arm of the ERSPC after 21 years of follow-up. MATERIALS AND METHODS The study invited 18,612 men (aged 45 - 70) of the Spanish section (Getafe and Parla, Madrid) to participate. They were randomly assigned to the intervention arm (serum PSA-based screening) and to the control arm (follow-up without intervention). The diagnoses of PCa were recorded, as well as the PCa-specific and all-cause mortality rates. A comparison between the survival curves of both arms of the study and detailed analysis of the causes of death were performed. RESULTS The study finally included 4,276 men (2,415 intervention arm, 1,861 control arm). The median age, serum PSA and follow-up time were 57 years, 0.9 ng/ml and 21.1 years, respectively. There were 285 cases with PCa diagnosis, 188 (7.8%) from the intervention arm and 97 (5.2%) from the control arm (p<,001). A total of 216 (75.8%) presented organ-confined disease. There were 994 deaths were recorded; 544 (22.5%) in the intervention arm and 450 (24.2%) in the control arm. No significant differences were detected between the arms of the study in terms of cancer-specific (p=.768) or all-cause (p=.192) mortality rates. The main cause of death was malignant tumors (492 patients, 49.5% of overall mortality), and the most frequent sites were lung and bronchus (29.5%), colon and rectum (14.8%), and hematologic (9.8%). Only 20 patients (0.4% of the patients recruited) died from PCa, with no significant difference between study arms. CONCLUSIONS In this update of the results of the Spanish section of the ERSPC study after 21 years of follow-up, we have not detected a benefit of PCa screening in terms of overall and cancer-specific survival.",2020,No significant differences were detected between the arms of the study in terms of cancer-specific (p=.768) or all-cause (p=.192) mortality rates.,"['18,612 men (aged 45 - 70) of the Spanish section (Getafe and Parla, Madrid) to participate', '4,276 men (2,415 intervention arm, 1,861 control arm', '180,000 asymptomatic men', '285 cases with PCa diagnosis, 188 (7.8%) from the intervention arm and 97 (5.2%) from the control arm (p<,001']",['Screening for Prostate Cancer (ERSPC'],"['survival curves', 'colon and rectum', 'mortality rates', 'PCa mortality', 'cancer-specific']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3161473', 'cui_str': 'Spaniards (ethnic group)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic (finding)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0030625', 'cui_str': 'PCA'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C4517790', 'cui_str': '5.2 (qualifier value)'}]","[{'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0376358', 'cui_str': 'Prostate Cancer'}]","[{'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0009368', 'cui_str': 'Colon'}, {'cui': 'C0034896', 'cui_str': 'Rectum'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C0030625', 'cui_str': 'PCA'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205369', 'cui_str': 'Specified'}]",18612.0,0.0563443,No significant differences were detected between the arms of the study in terms of cancer-specific (p=.768) or all-cause (p=.192) mortality rates.,"[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Luján Galán', 'Affiliation': 'Unidad de Urología, Hospital Universitario Infanta Cristina, Parla, Madrid, España. Electronic address: mlujang@salud.madrid.org.'}, {'ForeName': 'Á', 'Initials': 'Á', 'LastName': 'Páez Borda', 'Affiliation': 'Servicio de Urología, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, España.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Llanes González', 'Affiliation': 'Servicio de Urología, Hospital Universitario de Getafe, Getafe, Madrid, España.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Romero Cajigal', 'Affiliation': 'Servicio de Urología, Hospital Universitario de Getafe, Getafe, Madrid, España.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Berenguer Sánchez', 'Affiliation': 'European Randomized Study of Screening for Prostate Cancer, Rama española.'}]",Actas urologicas espanolas,['10.1016/j.acuro.2020.01.005'] 550,31481362,Longitudinal Study of music Therapy's Effectiveness for Premature infants and their caregivers (LongSTEP): protocol for an international randomised trial.,"INTRODUCTION Preterm birth has major medical, psychological and socioeconomic consequences worldwide. Music therapy (MT) has positive effects on physiological measures of preterm infants and maternal anxiety, but rigorous studies including long-term follow-up are missing. Drawing on caregivers' inherent resources, this study emphasises caregiver involvement in MT to promote attuned, developmentally appropriate musical interactions that may be of mutual benefit to infant and parent. This study will determine whether MT, as delivered by a qualified music therapist during neonatal intensive care unit (NICU) hospitalisation and/or in home/municipal settings following discharge, is superior to standard care in improving bonding between primary caregivers and preterm infants, parent well-being and infant development. METHODS AND ANALYSIS: Design: international multicentre, assessor-blind, 2×2 factorial, pragmatic randomised controlled trial; informed by a completed feasibility study. Participants: 250 preterm infants and their parents. Intervention: MT focusing on parental singing specifically tailored to infant responses, will be delivered during NICU and/or during a postdischarge 6-month period. Primary outcome: changes in mother-infant bonding at 6-month corrected age (CA), as measured by the Postpartum Bonding Questionnaire. Secondary outcomes : mother-infant bonding at discharge and at 12-month CA; child development over 24 months; and parental depression, anxiety and stress, and infant rehospitalisation, all over 12 months. ETHICS AND DISSEMINATION The Regional Committees for Medical and Health Research Ethics approved the study (2018/994/REK Nord, 03 July 2018). Service users were involved in development of the study and will be involved in implementation and dissemination. Dissemination of findings will apply to local, national and international levels. TRIAL REGISTRATION NUMBER NCT03564184.",2019,"Music therapy (MT) has positive effects on physiological measures of preterm infants and maternal anxiety, but rigorous studies including long-term follow-up are missing.","['Participants: 250 preterm infants and their parents', 'Premature infants and their caregivers (LongSTEP']","['Music therapy (MT', 'music Therapy']","['infant bonding at discharge and at 12-month CA; child development over 24 months; and parental depression, anxiety and stress, and infant rehospitalisation, all over 12 months', 'changes in mother-infant bonding at 6-month corrected age (CA), as measured by the Postpartum Bonding Questionnaire']","[{'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}]","[{'cui': 'C0026868', 'cui_str': 'Music Therapy'}]","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0028758', 'cui_str': 'Object Relationship'}, {'cui': 'C3871203', 'cui_str': 'At discharge (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0008071', 'cui_str': 'Child Development'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0086839', 'cui_str': 'Postpartum Period'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",250.0,0.309897,"Music therapy (MT) has positive effects on physiological measures of preterm infants and maternal anxiety, but rigorous studies including long-term follow-up are missing.","[{'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Ghetti', 'Affiliation': 'GAMUT - The Grieg Academy Music Therapy Research Centre, The Grieg Academy - Department of Music, University of Bergen, Bergen, Norway Claire.Ghetti@uib.no.'}, {'ForeName': 'Łucja', 'Initials': 'Ł', 'LastName': 'Bieleninik', 'Affiliation': 'GAMUT - The Grieg Academy Music Therapy Research Centre, NORCE Norwegian Research Centre AS, Bergen, Norway.'}, {'ForeName': 'Mari', 'Initials': 'M', 'LastName': 'Hysing', 'Affiliation': 'Department of Psychosocial Science, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Kvestad', 'Affiliation': 'Regional Center for Child and Youth Mental Health and Child Welfare, NORCE Norwegian Research Centre AS, Bergen, Norway.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Assmus', 'Affiliation': 'GAMUT - The Grieg Academy Music Therapy Research Centre, NORCE Norwegian Research Centre AS, Bergen, Norway.'}, {'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Romeo', 'Affiliation': ""King's Health Economics, King's College London, London, UK.""}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Ettenberger', 'Affiliation': 'Department of Patient and Family Care, Hospital Universitario Fundacion Santa Fe de Bogotá, Bogotá, Colombia.'}, {'ForeName': 'Shmuel', 'Initials': 'S', 'LastName': 'Arnon', 'Affiliation': 'Neonatal Department, Meir Medical Center, Kfar Saba, Israel.'}, {'ForeName': 'Bente Johanne', 'Initials': 'BJ', 'LastName': 'Vederhus', 'Affiliation': 'Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.'}, {'ForeName': 'Tora', 'Initials': 'T', 'LastName': 'Söderström Gaden', 'Affiliation': 'GAMUT - The Grieg Academy Music Therapy Research Centre, NORCE Norwegian Research Centre AS, Bergen, Norway.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Gold', 'Affiliation': 'GAMUT - The Grieg Academy Music Therapy Research Centre, NORCE Norwegian Research Centre AS, Bergen, Norway.'}]",BMJ open,['10.1136/bmjopen-2018-025062'] 551,31380892,Effect of a Professional Coaching Intervention on the Well-being and Distress of Physicians: A Pilot Randomized Clinical Trial.,"Importance Burnout symptoms among physicians are common and have potentially serious ramifications for physicians and their patients. Randomized studies testing interventions to address burnout have been uncommon. Objective To explore the effect of individualized coaching on the well-being of physicians. Design, Setting, and Participants A pilot randomized clinical trial involving 88 practicing physicians in the departments of medicine, family medicine, and pediatrics who volunteered for coaching was conducted between October 9, 2017, and March 27, 2018, at Mayo Clinic sites in Arizona, Florida, Minnesota, and Wisconsin. Statistical analysis was conducted from August 24, 2018, to March 25, 2019. Interventions A total of 6 coaching sessions facilitated by a professional coach. Main Outcomes and Measures Burnout, quality of life, resilience, job satisfaction, engagement, and meaning at work using established metrics. Analysis was performed on an intent-to-treat basis. Results Among the 88 physicians in the study (48 women and 40 men), after 6 months of professional coaching, emotional exhaustion decreased by a mean (SD) of 5.2 (8.7) points in the intervention group compared with an increase of 1.5 (7.7) points in the control group by the end of the study (P < .001). Absolute rates of high emotional exhaustion at 5 months decreased by 19.5% in the intervention group and increased by 9.8% in the control group (-29.3% [95% CI, -34.0% to -24.6%]) (P < .001). Absolute rates of overall burnout at 5 months also decreased by 17.1% in the intervention group and increased by 4.9% in the control group (-22.0% [95% CI, -25.2% to -18.7%]) (P < .001). Quality of life improved by a mean (SD) of 1.2 (2.5) points in the intervention group compared with 0.1 (1.7) points in the control group (1.1 points [95% CI, 0.04-2.1 points]) (P = .005), and resilience scores improved by a mean (SD) of 1.3 (5.2) points in the intervention group compared with 0.6 (4.0) points in the control group (0.7 points [95% CI, 0.0-3.0 points]) (P = .04). No statistically significant differences in depersonalization, job satisfaction, engagement, or meaning in work were observed. Conclusions and Relevance Professional coaching may be an effective way to reduce emotional exhaustion and overall burnout as well as improve quality of life and resilience for some physicians. Trial Registration ClinicalTrials.gov identifier: NCT03207581.",2019,"Quality of life improved by a mean (SD) of 1.2 (2.5) points in the intervention group compared with 0.1 (1.7) points in the control group (1.1 points [95% CI, 0.04-2.1 points]) (P = .005), and resilience scores improved by a mean (SD) of 1.3 (5.2) points in the intervention group compared with 0.6 (4.0) points in the control group (0.7 points [95% CI, 0.0-3.0 points]) (P = .04).","['88 physicians in the study (48 women and 40 men', 'Well-being and Distress of Physicians', '88 practicing physicians in the departments of medicine, family medicine, and pediatrics who volunteered for coaching was conducted between October 9, 2017, and March 27, 2018, at Mayo Clinic sites in Arizona, Florida, Minnesota, and Wisconsin']","['Professional Coaching Intervention', 'individualized coaching']","['Quality of life', 'Absolute rates of high emotional exhaustion', 'Measures\n\n\nBurnout, quality of life, resilience, job satisfaction, engagement, and meaning at work using established metrics', 'professional coaching, emotional exhaustion', 'resilience scores', 'quality of life and resilience', 'depersonalization, job satisfaction, engagement, or meaning in work', 'Absolute rates of overall burnout']","[{'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0015607', 'cui_str': 'Family Practice'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0454788', 'cui_str': 'Mayo (geographic location)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0003787', 'cui_str': 'Arizona'}, {'cui': 'C0016253', 'cui_str': 'Florida'}, {'cui': 'C0026183', 'cui_str': 'Minnesota'}, {'cui': 'C0043193', 'cui_str': 'Wisconsin'}]",[],"[{'cui': 'C0034380'}, {'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion (finding)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state (disorder)'}, {'cui': 'C0022397', 'cui_str': 'Work Satisfaction'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}, {'cui': 'C0699680', 'cui_str': 'Metric'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0011551', 'cui_str': 'Depersonalization'}, {'cui': 'C0557351', 'cui_str': 'Employed (finding)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",48.0,0.185465,"Quality of life improved by a mean (SD) of 1.2 (2.5) points in the intervention group compared with 0.1 (1.7) points in the control group (1.1 points [95% CI, 0.04-2.1 points]) (P = .005), and resilience scores improved by a mean (SD) of 1.3 (5.2) points in the intervention group compared with 0.6 (4.0) points in the control group (0.7 points [95% CI, 0.0-3.0 points]) (P = .04).","[{'ForeName': 'Liselotte N', 'Initials': 'LN', 'LastName': 'Dyrbye', 'Affiliation': 'Department of Medicine, Program on Physician Well-Being, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Tait D', 'Initials': 'TD', 'LastName': 'Shanafelt', 'Affiliation': 'Department of Medicine, WellMD Center, Stanford School of Medicine, Stanford University, Palo Alto, California.'}, {'ForeName': 'Priscilla R', 'Initials': 'PR', 'LastName': 'Gill', 'Affiliation': 'Workforce Learning, Mayo Clinic, Jacksonville, Florida.'}, {'ForeName': 'Daniel V', 'Initials': 'DV', 'LastName': 'Satele', 'Affiliation': 'Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Colin P', 'Initials': 'CP', 'LastName': 'West', 'Affiliation': 'Department of Medicine, Program on Physician Well-Being, Mayo Clinic, Rochester, Minnesota.'}]",JAMA internal medicine,['10.1001/jamainternmed.2019.2425'] 552,31289097,Ageing as a mindset: a study protocol to rejuvenate older adults with a counterclockwise psychological intervention.,"INTRODUCTION Although ageing is generally perceived as a biologically determined process, the literature increasingly points to the importance of psychological factors in the ageing process, specifically age-related stereotypes or cognitive mindsets. Such stereotypes reflect self-perceptions and others' perceptions about the ageing process and can have a strong influence on health and life satisfaction, specifically through self-fulfilling prophecy mechanisms. This study aimed to investigate whether changes in mindsets can change the ageing process. METHODS AND ANALYSIS This study replicates in large part the original 1979 'Counterclockwise' experiment by Ellen Langer and will involve a group of older adults (aged 75+) taking part of a 1-week retreat outside of Milan, Italy. Participants will be instructed and helped to relive their younger selves, acting as i f they are living in the year 1989. The week-long residential programme is designed to prime this perception by incorporating a completely retrofitted physical environment, as well as providing opportunities to engage in social activities that would have been common in the late 1980s. This 'counterclockwise' intervention will be tested as a randomised control trial comprised of the experimental ('counterclockwise') group, an active control group (same activities, no time manipulation) and a no-treatment group. Ninety participants will be randomly allocated to one of these three conditions. Every participant will be assessed for medical, cognitive, psychological and age appearance at four time points: at the time of recruitment, after the intervention (ie, after a week for the no-treatment group) and again after 6 and 12 months. ETHICS AND DISSEMINATION The study has been approved by the Ethics Committees of the Department of Psychology of Università Cattolica del Sacro Cuore and Don Gnocchi Foundation. Results will be disseminated through peer-reviewed journals, scientific meetings and direct presentation to the general population. TRIAL REGISTRATION NUMBER NCT03552042; Pre-results.",2019,"This 'counterclockwise' intervention will be tested as a randomised control trial comprised of the experimental ('counterclockwise') group, an active control group (same activities, no time manipulation) and a no-treatment group.","['Ninety participants', 'rejuvenate older adults with a counterclockwise psychological intervention', ""large part the original 1979 'Counterclockwise' experiment by Ellen Langer and will involve a group of older adults (aged 75+) taking part of a 1-week retreat outside of Milan, Italy""]",[],[],"[{'cui': 'C3816959', 'cui_str': 'Ninety'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0205313', 'cui_str': 'Original (qualifier value)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C1292711', 'cui_str': 'Part of (attribute)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0022277', 'cui_str': 'Italy'}]",[],[],90.0,0.0292664,"This 'counterclockwise' intervention will be tested as a randomised control trial comprised of the experimental ('counterclockwise') group, an active control group (same activities, no time manipulation) and a no-treatment group.","[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Pagnini', 'Affiliation': 'Department of Psychology, Università Cattolica del Sacro Cuore, Milano, Italy.'}, {'ForeName': 'Cesare', 'Initials': 'C', 'LastName': 'Cavalera', 'Affiliation': 'Department of Psychology, Università Cattolica del Sacro Cuore, Milano, Italy.'}, {'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Volpato', 'Affiliation': 'Department of Psychology, Università Cattolica del Sacro Cuore, Milano, Italy.'}, {'ForeName': 'Benedetta', 'Initials': 'B', 'LastName': 'Comazzi', 'Affiliation': 'IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Vailati Riboni', 'Affiliation': 'Department of Psychology, Università Cattolica del Sacro Cuore, Milano, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Valota', 'Affiliation': 'IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Bercovitz', 'Affiliation': 'Department of Psychology, Harvard University, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Molinari', 'Affiliation': 'Department of Psychology, Università Cattolica del Sacro Cuore, Milano, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Banfi', 'Affiliation': 'IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Phillips', 'Affiliation': 'Department of Psychology, Harvard University, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Langer', 'Affiliation': 'Department of Psychology, Harvard University, Cambridge, Massachusetts, USA.'}]",BMJ open,['10.1136/bmjopen-2019-030411'] 553,30899972,[Catheterization of the subclavian vein and the risk of pneumothorax : Mechanical ventilation increases the risk of pneumothorax during infraclavicular landmark-guided subclavian vein puncture: a prospective randomized study].,"BACKGROUND Infraclavicular subclavian vein (SCV) catheterization is a standard procedure in anesthesia and intensive care. There is a lack of evidence on how mechanical ventilation during venipuncture of the SCV influences pneumothorax rates. OBJECTIVE Primary hypothesis: non-inferiority of continuing vs. discontinuing mechanical ventilation during infraclavicular puncture of the SCV with respect to the pneumothorax rate. MATERIAL AND METHODS This prospective, randomized and single-blinded study was approved by the local ethics committee. A total of 1021 eligible patients who underwent cranial neurosurgery in 2 different university hospitals were assessed between August 2014 and October 2017. Patients were randomly assigned to two groups directly before induction of anesthesia. Intervention groups for venipuncture of the SCV were mechanical ventilation: tidal volume 7 ml/kg ideal body weight, positive end expiratory pressure (PEEP) ideal body weight/10, n = 535, or apnea: manual/spontaneous, APL valve 0 mbar, n = 486. Patients and the physicians who assessed pneumothorax rates were blinded to the intervention group. Venipuncture was carried out by both inexperienced and experienced physicians. RESULTS The pneumothorax rate was significantly higher in the mechanical ventilation group (2.2% vs. 0.4%; p = 0.012) with an odds ratio (OR) of 5.63 (95% confidence interval, CI: 1.17-27.2; p = 0.031). A lower body mass index (BMI) was associated with a higher pneumothorax rate, OR 0.89 (95% CI: 0.70-0.96; p = 0.013). CONCLUSION In this study landmark-guided infraclavicular SCV catheterization was associated with a significantly higher rate of pneumothorax when venipuncture was performed during mechanical ventilation and not in apnea. If a short phase of apnea is justifiable in the patient, mechanical ventilation should be discontinued during the venipuncture procedure.",2019,In this study landmark-guided infraclavicular SCV catheterization was associated with a significantly higher rate of pneumothorax when venipuncture was performed during mechanical ventilation and not in apnea.,['1021 eligible patients who underwent cranial neurosurgery in 2 different university hospitals were assessed between August 2014 and October 2017'],"['discontinuing mechanical ventilation', 'pneumothorax : Mechanical ventilation', 'Infraclavicular subclavian vein (SCV) catheterization', 'infraclavicular landmark-guided subclavian vein puncture', 'mechanical ventilation', 'Venipuncture', 'venipuncture of the SCV were mechanical ventilation: tidal volume 7\u202fml/kg ideal body weight, positive end expiratory pressure (PEEP) ideal body weight/10, n\u202f=\u2009535, or apnea: manual/spontaneous, APL valve 0\u202fmbar, n\u202f=\u2009486']","['risk of pneumothorax', 'body mass index (BMI', 'pneumothorax rate', 'rate of pneumothorax', 'pneumothorax rates']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3163632', 'cui_str': 'Cranial'}, {'cui': 'C0027926', 'cui_str': 'Neurosurgery'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}]","[{'cui': 'C1706472', 'cui_str': 'Discontinue - dosing instruction imperative'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0032326', 'cui_str': 'Pneumothorax'}, {'cui': 'C0038532', 'cui_str': 'Subclavian Vein'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0033119', 'cui_str': 'Puncture wound - injury (disorder)'}, {'cui': 'C0600406', 'cui_str': 'Venipuncture (procedure)'}, {'cui': 'C0040210', 'cui_str': 'Tidal Volume'}, {'cui': 'C1300574', 'cui_str': 'microliter/g'}, {'cui': 'C0421272', 'cui_str': 'Normal Body Weight'}, {'cui': 'C3494516', 'cui_str': 'Positive end expiratory pressure (observable entity)'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}, {'cui': 'C3888056', 'cui_str': 'Valve (physical object)'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0032326', 'cui_str': 'Pneumothorax'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",1021.0,0.161266,In this study landmark-guided infraclavicular SCV catheterization was associated with a significantly higher rate of pneumothorax when venipuncture was performed during mechanical ventilation and not in apnea.,"[{'ForeName': 'T', 'Initials': 'T', 'LastName': 'Palmaers', 'Affiliation': 'Klinik für Anästhesiologie und Intensivmedizin (OE8050), Medizinische Hochschule Hannover, Carl-Neuberg-Straße\xa01, 30625, Hannover, Deutschland. palmaers.thomas@mh-hannover.de.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Frank', 'Affiliation': 'Klinik für Anästhesiologie und Intensivmedizin (OE8050), Medizinische Hochschule Hannover, Carl-Neuberg-Straße\xa01, 30625, Hannover, Deutschland.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Eismann', 'Affiliation': 'Klinik für Anästhesiologie und Intensivmedizin (OE8050), Medizinische Hochschule Hannover, Carl-Neuberg-Straße\xa01, 30625, Hannover, Deutschland.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Sieg', 'Affiliation': 'Klinik für Anästhesiologie und Intensivmedizin (OE8050), Medizinische Hochschule Hannover, Carl-Neuberg-Straße\xa01, 30625, Hannover, Deutschland.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Leffler', 'Affiliation': 'Klinik für Anästhesiologie und Intensivmedizin (OE8050), Medizinische Hochschule Hannover, Carl-Neuberg-Straße\xa01, 30625, Hannover, Deutschland.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Schmitt', 'Affiliation': 'Anästhesiologische Klinik, Universitätsklinikum Erlangen, Maximiliansplatz\xa01, 91054, Erlangen, Deutschland.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Scholler', 'Affiliation': 'Anästhesiologische Klinik, Universitätsklinikum Erlangen, Maximiliansplatz\xa01, 91054, Erlangen, Deutschland.'}]",Der Anaesthesist,['10.1007/s00101-019-0579-x'] 554,32151511,Efficacy of Bilateral Transversus Thoracis Muscle Plane Block in Pediatric Patients Undergoing Open Cardiac Surgery.,"OBJECTIVES Adequate pain management is crucial for pediatric patients undergoing open cardiac surgery. The aim of the present study was to investigate the effect of a bilateral transversus thoracis muscle plane (TTP) block on open cardiac surgery outcomes. SETTING First Affiliated Hospital of Nanchang University. PARTICIPANTS Patients ages 6 to 60 months undergoing cardiac surgical procedures were included. INTERVENTIONS A group of 100 children were randomly allocated to receive either bilateral TTP block (TTP group) or no nerve block. MEASUREMENTS AND MAIN RESULTS The primary endpoint was postoperative pain, which was measured with the Modified Objective Pain Score. The secondary outcome measures included intraoperative and postoperative fentanyl consumption; time to extubation; time to first feces; length of stay in the intensive care unit; length of hospital stay; and possible complications such as ropivacaine allergy, pneumothorax, hematomas, infections, and injuries to the internal mammary artery and vein. The TTP group had a significantly lower Modified Objective Pain Score until 24 hours after extubation than the no nerve block group. The TTP group reported significantly less fentanyl consumption. Time to extubation and lengths of stay in the intensive care unit and hospital were significantly decreased in the TTP group. CONCLUSION Bilateral TTP blocks provide effective analgesia and accelerate recovery in pediatric patients.",2020,The TTP group had a significantly lower Modified Objective Pain Score until 24 hours after extubation than the no nerve block group.,"['A group of 100 children', 'First Affiliated Hospital of Nanchang University', 'pediatric patients undergoing open cardiac surgery', 'pediatric patients', 'Undergoing Open Cardiac Surgery', 'Pediatric Patients', 'Patients ages 6 to 60 months undergoing cardiac surgical procedures were included']","['Bilateral Transversus Thoracis Muscle Plane Block', 'bilateral TTP block (TTP group) or no nerve block', 'Bilateral TTP blocks', 'bilateral transversus thoracis muscle plane (TTP) block', 'TTP']","['postoperative pain, which was measured with the Modified Objective Pain Score', 'fentanyl consumption', 'Time to extubation and lengths of stay in the intensive care unit and hospital', 'intraoperative and postoperative fentanyl consumption; time to extubation; time to first feces; length of stay in the intensive care unit; length of hospital stay; and possible complications such as ropivacaine allergy, pneumothorax, hematomas, infections, and injuries to the internal mammary artery and vein', 'Modified Objective Pain Score']","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0018821', 'cui_str': 'Surgical Procedures, Heart'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C1744608', 'cui_str': 'Structure of transverse thoracis muscle'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0034155', 'cui_str': 'Moschkowitz Disease'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0027741', 'cui_str': 'Nerve Blockade'}]","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0332149', 'cui_str': 'Possible (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0002111', 'cui_str': 'Allergy Specialty'}, {'cui': 'C0032326', 'cui_str': 'Pneumothorax'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0226276', 'cui_str': 'Internal Mammary Artery'}, {'cui': 'C0042449', 'cui_str': 'Veins'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",100.0,0.0855439,The TTP group had a significantly lower Modified Objective Pain Score until 24 hours after extubation than the no nerve block group.,"[{'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, First Affiliated Hospital of Nanchang University, Nanchang, China.'}, {'ForeName': 'Shibiao', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, First Affiliated Hospital of Nanchang University, Nanchang, China.'}, {'ForeName': 'Haixia', 'Initials': 'H', 'LastName': 'Gong', 'Affiliation': 'Department of Anesthesiology, First Affiliated Hospital of Nanchang University, Nanchang, China.'}, {'ForeName': 'Biming', 'Initials': 'B', 'LastName': 'Zhan', 'Affiliation': 'Department of Cardiology, The Second Affiliated Hospital of Nanchang University, Jiangxi, China. Electronic address: drzhanbiming@163.com.'}]",Journal of cardiothoracic and vascular anesthesia,['10.1053/j.jvca.2020.02.005'] 555,31483962,Five-Year Outcomes of a Randomized Trial of Treatments for Varicose Veins.,"BACKGROUND Endovenous laser ablation and ultrasound-guided foam sclerotherapy are recommended alternatives to surgery for the treatment of primary varicose veins, but their long-term comparative effectiveness remains uncertain. METHODS In a randomized, controlled trial involving 798 participants with primary varicose veins at 11 centers in the United Kingdom, we compared the outcomes of laser ablation, foam sclerotherapy, and surgery. Primary outcomes at 5 years were disease-specific quality of life and generic quality of life, as well as cost-effectiveness based on models of expected costs and quality-adjusted life-years (QALYs) gained that used data on participants' treatment costs and scores on the EuroQol EQ-5D questionnaire. RESULTS Quality-of-life questionnaires were completed by 595 (75%) of the 798 trial participants. After adjustment for baseline scores and other covariates, scores on the Aberdeen Varicose Vein Questionnaire (on which scores range from 0 to 100, with lower scores indicating a better quality of life) were lower among patients who underwent laser ablation or surgery than among those who underwent foam sclerotherapy (effect size [adjusted differences between groups] for laser ablation vs. foam sclerotherapy, -2.86; 95% confidence interval [CI], -4.49 to -1.22; P<0.001; and for surgery vs. foam sclerotherapy, -2.60; 95% CI, -3.99 to -1.22; P<0.001). Generic quality-of-life measures did not differ among treatment groups. At a threshold willingness-to-pay ratio of £20,000 ($28,433 in U.S. dollars) per QALY, 77.2% of the cost-effectiveness model iterations favored laser ablation. In a two-way comparison between foam sclerotherapy and surgery, 54.5% of the model iterations favored surgery. CONCLUSIONS In a randomized trial of treatments for varicose veins, disease-specific quality of life 5 years after treatment was better after laser ablation or surgery than after foam sclerotherapy. The majority of the probabilistic cost-effectiveness model iterations favored laser ablation at a willingness-to-pay ratio of £20,000 ($28,433) per QALY. (Funded by the National Institute for Health Research; CLASS Current Controlled Trials number, ISRCTN51995477.).",2019,"In a two-way comparison between foam sclerotherapy and surgery, 54.5% of the model iterations favored surgery. ",['798 participants with primary varicose veins at 11 centers in the United Kingdom'],"['Endovenous laser ablation and ultrasound-guided foam sclerotherapy', 'laser ablation vs. foam sclerotherapy', 'laser ablation, foam sclerotherapy, and surgery', 'laser ablation or surgery than after foam sclerotherapy', 'laser ablation']","['Aberdeen Varicose Vein Questionnaire', ""disease-specific quality of life and generic quality of life, as well as cost-effectiveness based on models of expected costs and quality-adjusted life-years (QALYs) gained that used data on participants' treatment costs and scores on the EuroQol EQ-5D questionnaire"", 'Generic quality-of-life measures', 'quality of life']","[{'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0042345', 'cui_str': 'Varices'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom'}]","[{'cui': 'C0348007', 'cui_str': 'Pulsed Laser Tissue Ablation'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0991510', 'cui_str': 'Foam (basic dose form)'}, {'cui': 'C0036435', 'cui_str': 'Sclerotherapy'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0042345', 'cui_str': 'Varices'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0034380'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0080071', 'cui_str': 'QALY'}, {'cui': 'C0087112', 'cui_str': 'Treatment Costs'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]",798.0,0.132827,"In a two-way comparison between foam sclerotherapy and surgery, 54.5% of the model iterations favored surgery. ","[{'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Brittenden', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cooper', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Dimitrova', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Scotland', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Seonaidh C', 'Initials': 'SC', 'LastName': 'Cotton', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Elders', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Graeme', 'Initials': 'G', 'LastName': 'MacLennan', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Craig R', 'Initials': 'CR', 'LastName': 'Ramsay', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Norrie', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Burr', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Campbell', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Bachoo', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Chetter', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Gough', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Jonothan', 'Initials': 'J', 'LastName': 'Earnshaw', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Lees', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Scott', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Sara A', 'Initials': 'SA', 'LastName': 'Baker', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Tassie', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Francis', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}, {'ForeName': 'Marion K', 'Initials': 'MK', 'LastName': 'Campbell', 'Affiliation': 'From the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) - all in the United Kingdom.'}]",The New England journal of medicine,['10.1056/NEJMoa1805186'] 556,31274487,"A randomized, double-blinded trial comparing the effectiveness of tranexamic acid and epsilon-aminocaproic acid in reducing bleeding and transfusion in cardiac surgery.","Objectives To compare the effectiveness of epsilon aminocaproic acid (EACA) to tranexamic acid (TA) in reducing blood loss and transfusion requirements in patients undergone cardiac surgery under cardiopulmonary bypass. Design Randomized, double blinded study. Outcome variables collected included; baseline demographic characteristics, type of surgery, amount of 24 hour chest tube drainage, amount of 24 hour blood products administered, 30 day mortality and morbidity and length of stay. We analyzed the data using parametric and non-parametric tests as appropriate. Setting Single center tertiary-care university hospital setting. Participants 114 patients who had undergone cardiac surgery under cardiopulmonary bypass. Interventions Standard dose of intra-operative EACA or TA was compared in patients undergone cardiac surgery under cardiopulmonary bypass. Results: There was no statistically significant difference between groups when analyzing chest tube drainage. However, there was a significant difference in the administration of any transfusion (PRBC's, FFP, platelets) intra-operatively to 24 hours postoperatively, with less transfusion in patients receiving EACA compared to TA (25% vs. 44.8%, respectively P = 0.027). Additionally, there was no significant difference in terms of adverse events during the one month follow up period. Conclusion The findings of this study suggest that EACA and TA have similar effects on chest tube drainage but EACA is associated with fewer transfusions in CABG alone surgeries. Our results suggest that EACA can be used in a similar fashion to TA which may result in a cost and morbidity advantage.",2019,"However, there was a significant difference in the administration of any transfusion (PRBC's, FFP, platelets) intra-operatively to 24 hours postoperatively, with less transfusion in patients receiving EACA compared to TA (25% vs. 44.8%, respectively P = 0.027).","['Setting\n\n\nSingle center tertiary-care university hospital setting', 'cardiac surgery', 'patients undergone cardiac surgery under cardiopulmonary bypass', 'Participants\n\n\n114 patients who had undergone cardiac surgery under cardiopulmonary bypass']","['EACA and TA', 'EACA', 'epsilon aminocaproic acid (EACA', 'tranexamic acid and epsilon-aminocaproic acid', 'tranexamic acid (TA', 'intra-operative EACA or TA']","['baseline demographic characteristics, type of surgery, amount of 24 hour chest tube drainage, amount of 24 hour blood products administered, 30 day mortality and morbidity and length of stay', ""administration of any transfusion (PRBC's, FFP, platelets) intra-operatively"", 'adverse events', 'blood loss and transfusion requirements', 'bleeding and transfusion']","[{'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0007202', 'cui_str': 'Heart-Lung Bypass'}, {'cui': 'C4708785', 'cui_str': 'One hundred and fourteen'}]","[{'cui': 'C0000608', 'cui_str': 'aminocaproic acid'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}]","[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0008034', 'cui_str': 'Chest Tubes'}, {'cui': 'C0013103', 'cui_str': 'Drainage'}, {'cui': 'C0456388', 'cui_str': 'Blood product (product)'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0199960', 'cui_str': 'Transfusion - action (qualifier value)'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}]",114.0,0.312698,"However, there was a significant difference in the administration of any transfusion (PRBC's, FFP, platelets) intra-operatively to 24 hours postoperatively, with less transfusion in patients receiving EACA compared to TA (25% vs. 44.8%, respectively P = 0.027).","[{'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Leff', 'Affiliation': 'Montefiore Medical Center, New York, USA.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Rhee', 'Affiliation': 'Department of Anesthesiology, Icahn School of Medicine at Mount Sinai, New York, USA.'}, {'ForeName': 'Singh', 'Initials': 'S', 'LastName': 'Nair', 'Affiliation': 'Department of Anesthesiology, Montefiore Hospital and Medical Center, New York, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Lazar', 'Affiliation': 'Department of Anesthesiology, North Shore Long Island Jewish Health System, New York, USA.'}, {'ForeName': 'Sudheera Kokkada', 'Initials': 'SK', 'LastName': 'Sathyanarayana', 'Affiliation': 'Department of Anesthesiology, Lincoln Medical Center, New York, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Shore-Lesserson', 'Affiliation': 'Department of Anesthesiology, Hofstra University, North Shore Long Island Jewish School of Medicine, New York, USA.'}]",Annals of cardiac anaesthesia,['10.4103/aca.ACA_137_18'] 557,31274491,Comparison of sedation between dexmedetomidine and propofol during transesophageal echocardiography: A randomized controlled trial.,"Background This study aimed to compare sedation characteristics of dexmedetomidine (Dex) and propofol during transesophageal echocardiography (TEE) in cardiac patients. Methods This clinical trial was conducted on 65 cardiac patients, who underwent TEE in a referral heart hospital. The patients were randomly divided into two groups: Dex (n = 34) and propofol (n = 31). The depth of sedation in the patients was assessed at 5-min intervals until the end of the TEE examination. The patient, physicians' satisfaction was recorded. Furthermore, blood pressure, heart and respiratory rates, peripheral oxygen saturation, and the bispectral index (BIS) of the patients were measured. The occurrence of apnea, hypotension or bradycardia was documented. Results Demographic variables were similar in both groups. Time from the beginning of sedation to the start of TEE was significantly longer in the Dex group (P = 0.01). Duration of the TEE examination was not different between the two groups. Interestingly, the recovery time was shorter in the Dex group than in the propofol group. There were no significant differences regarding patient and physician satisfaction with sedation quality. Hemodynamic profile was mainly similar in both groups. There was a significantly lower BIS level in the Dex group. There was no significant difference in the incidence of apnea or hypotension between the groups. Conclusions Time from the beginning of sedation with Dex was longer than that with propofol. However, Dex was able to provide satisfactory sedation levels, hemodynamic stability, short recovery time, and acceptable patient and practitioner satisfaction during TEE in our cardiac patients.",2019,"There was no significant difference in the incidence of apnea or hypotension between the groups. ","['transesophageal echocardiography', 'cardiac patients', '65 cardiac patients, who underwent TEE in a referral heart hospital']","['propofol', 'dexmedetomidine (Dex) and propofol during transesophageal echocardiography (TEE', 'Dex', 'dexmedetomidine and propofol']","['occurrence of apnea, hypotension or bradycardia', 'incidence of apnea or hypotension', 'depth of sedation', 'satisfactory sedation levels, hemodynamic stability, short recovery time, and acceptable patient and practitioner satisfaction', 'Furthermore, blood pressure, heart and respiratory rates, peripheral oxygen saturation, and the bispectral index (BIS', 'recovery time', 'Hemodynamic profile', 'BIS level', 'Duration of the TEE examination']","[{'cui': 'C0206054', 'cui_str': 'Echocardiography, Transesophageal'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0034927', 'cui_str': 'Referral'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}]","[{'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0206054', 'cui_str': 'Echocardiography, Transesophageal'}]","[{'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0020649', 'cui_str': 'Blood Pressure, Low'}, {'cui': 'C0428977', 'cui_str': 'Bradyarrhythmia'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0231832', 'cui_str': 'Respiration Rate'}, {'cui': 'C2317096', 'cui_str': 'Peripheral oxygen saturation'}, {'cui': 'C1301882', 'cui_str': 'Bispectral index'}, {'cui': 'C1872096', 'cui_str': 'bis(phenylacetylarginine)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}]",65.0,0.029461,"There was no significant difference in the incidence of apnea or hypotension between the groups. ","[{'ForeName': 'Azin', 'Initials': 'A', 'LastName': 'Alizadehasl', 'Affiliation': 'Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Sadeghpour', 'Affiliation': 'Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ziae', 'Initials': 'Z', 'LastName': 'Totonchi', 'Affiliation': 'Department of Cardiac Anesthesia, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Rasoul', 'Initials': 'R', 'LastName': 'Azarfarin', 'Affiliation': 'Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Saeid', 'Initials': 'S', 'LastName': 'Rahimi', 'Affiliation': 'Department of Anesthesia, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Hendiani', 'Affiliation': 'Department of Anesthesia, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.'}]",Annals of cardiac anaesthesia,['10.4103/aca.ACA_42_18'] 558,30964804,How Can Programs Better Support Female Sex Workers to Avoid HIV Infection in Zimbabwe? A Prevention Cascade Analysis.,"BACKGROUND ""HIV prevention cascades"" have been proposed to support programs by identifying gaps in demand for, access to, and capability to adhere to HIV prevention tools, but there are few empirical examples to guide development. We apply a prevention cascade framework to examine prevention coverage and factors associated with condoms and/or PrEP adherence among female sex workers. SETTING Seven sites across Zimbabwe. METHODS Seven respondent-driven sampling surveys from the intervention sites of a pragmatic cluster-randomized trial in Zimbabwe in 2016 were analyzed, and 611/1439 women testing HIV-negative included. We operationalized key components of an HIV prevention cascade including demand, supply, and capability to adhere to 2 tools for HIV prevention: condoms and pre-exposure prophylaxis (PrEP). We used adjusted logistic regression to identify determinants of adherence to condoms and PrEP in turn, examining the effect of adherence to one tool on adherence to the other. RESULTS There were 343/611, 54.7%, women reporting adherence to condoms and/or PrEP, leaving almost half uncovered. Although women were aware that condoms prevented HIV and reported good access to them, only 45·5% reported full adherence to condom use. For PrEP, a new technology, there were gaps along all 3 domains of demand, supply, and adherence. Alcohol use decreased adherence to PrEP and condoms. Younger and newer entrants to sex work were less likely to take PrEP every day. CONCLUSIONS HIV prevention programming among female sex workers in Zimbabwe could consider increasing awareness of PrEP alongside supply, alcohol use interventions, and approaches to engaging younger women.",2019,"There were 343/611, 54.7%, women reporting adherence to condoms and/or PrEP, leaving almost half uncovered.","['Seven respondent-driven sampling surveys from the intervention sites of a pragmatic cluster-randomized trial in Zimbabwe in 2016 were analyzed, and 611/1439 women testing HIV-negative included', 'female sex workers in Zimbabwe', 'female sex workers', 'Seven sites across Zimbabwe']",[],[],"[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C2945843', 'cui_str': 'Site of (attribute)'}, {'cui': 'C0043476', 'cui_str': 'Southern Rhodesia'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0481430', 'cui_str': 'HTLV-3 antibody negative'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0240816', 'cui_str': 'Prostitutes'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}]",[],[],,0.0362943,"There were 343/611, 54.7%, women reporting adherence to condoms and/or PrEP, leaving almost half uncovered.","[{'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Fearon', 'Affiliation': 'Department of Social and Environmental Health Research, Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Phillips', 'Affiliation': 'Institute for Global Health, Faculty of Population Health Sciences, University College London, London, United Kingdom.'}, {'ForeName': 'Sibongile', 'Initials': 'S', 'LastName': 'Mtetwa', 'Affiliation': 'Centre for Sexual Health and HIV AIDS Research (CeSHHAR) Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Sungai T', 'Initials': 'ST', 'LastName': 'Chabata', 'Affiliation': 'Centre for Sexual Health and HIV AIDS Research (CeSHHAR) Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Phillis', 'Initials': 'P', 'LastName': 'Mushati', 'Affiliation': 'Centre for Sexual Health and HIV AIDS Research (CeSHHAR) Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Cambiano', 'Affiliation': 'Institute for Global Health, Faculty of Population Health Sciences, University College London, London, United Kingdom.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Busza', 'Affiliation': 'Department of Social and Environmental Health Research, Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Napierala', 'Affiliation': ""Women's Global Health Imperative, RTI International, San Francisco, CA.""}, {'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'Hensen', 'Affiliation': 'Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Baral', 'Affiliation': 'Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD.'}, {'ForeName': 'Sharon S', 'Initials': 'SS', 'LastName': 'Weir', 'Affiliation': 'Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Rice', 'Affiliation': 'Department of Social and Environmental Health Research, Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Frances M', 'Initials': 'FM', 'LastName': 'Cowan', 'Affiliation': 'Centre for Sexual Health and HIV AIDS Research (CeSHHAR) Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Hargreaves', 'Affiliation': 'Department of Social and Environmental Health Research, Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}]",Journal of acquired immune deficiency syndromes (1999),['10.1097/QAI.0000000000001980'] 559,32146571,Urinary carbohydrate antigen 19-9 level as a biomarker in children with acute pyelonephritis.,"Early and prompt diagnosis of pyelonephritis is of great importance in children. The aim of this study is to evaluate the diagnostic accuracy of urinary carbohydrate antigen 19-9 (CA19-9) levels for predicting acute pyelonephritis (APN) in children with urinary tract infection (UTI). Patients were allocated into two groups of APN and acute cystitis according to their diagnosis. Urine samples of all patients were collected. Also, complete history was taken, and physical examination, kidney and bladder ultrasonography, 99m Tc-dimercaptosuccinic acid renal cortical scintigraphy, and urine analysis and culture were performed. Urinary CA19-9 was measured by an electrochemiluminescence enzyme immunometric kit. In addition, CA19-9 levels were measured in the APN group 2 weeks and 3 months later. A total of 100 children were included in this study (mean age 46 ± 31 months, 16 males and 84 females). CA19-9 levels were significantly greater in the APN group than acute cystitis group (510 ± 328 vs. 18.7 ± 18.6 U/ml, P < 0.001). During follow-up periods of the APN group, CA19-9 levels decreased to 180 ± 124 U/ml after 2 weeks (P < 0.001) and 30 ± 23 U/ml after 3 months (P < 0.001). Urinary CA-19-9 had 95.3% sensitivity and 80% specificity for the diagnosis of APN. The area under the curve value of CA19-9 was 0.904 (95% CI 0.831-0.977).Conclusion: Urinary CA19-9 level can be used as a reliable biomarker for early detection of APN prior to urine culture confirmation in children with UTI. What is known: • Early and prompt diagnosis of pyelonephritis is necessary in children to prevent renal damage. • Acute pyelonephritis can present with vague and nonspecific symptoms in infants and children. What is new: • Urinary carbohydrate antigen 19-9 is a reliable biomarker for early detection of acute pyelonephritis prior to urine culture confirmation. • Urinary carbohydrate antigen 19-9 has 95.3% sensitivity and 80% specificity for diagnosis of acute pyelonephritis.",2020,Urinary carbohydrate antigen 19-9 has 95.3% sensitivity and 80% specificity for diagnosis of acute pyelonephritis.,"['children with urinary tract infection (UTI', 'children with acute pyelonephritis', '100 children were included in this study (mean age 46\u2009±\u200931\xa0months, 16 males and 84 females', 'children']",['urinary carbohydrate antigen 19-9 (CA19-9) levels'],"['physical examination, kidney and bladder ultrasonography, 99m Tc-dimercaptosuccinic acid renal cortical scintigraphy, and urine analysis and culture', 'Urinary CA19-9', 'CA19-9 levels']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}, {'cui': 'C0520575', 'cui_str': 'Acute pyelonephritis (disorder)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0201551', 'cui_str': 'CA 199 measurement'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]","[{'cui': 'C0031809', 'cui_str': 'Physical Examination'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0005682', 'cui_str': 'Bladder'}, {'cui': 'C0041618', 'cui_str': 'Echotomography'}, {'cui': 'C0075928', 'cui_str': 'Technetium-99m-DMSA'}, {'cui': 'C0034606', 'cui_str': 'Gamma Camera Imaging'}, {'cui': 'C0042014', 'cui_str': 'Urinalysis'}, {'cui': 'C0220814', 'cui_str': 'culture'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",100.0,0.03699,Urinary carbohydrate antigen 19-9 has 95.3% sensitivity and 80% specificity for diagnosis of acute pyelonephritis.,"[{'ForeName': 'Abdol-Mohammad', 'Initials': 'AM', 'LastName': 'Kajbafzadeh', 'Affiliation': ""Pediatric Urology and Regenerative Medicine Research Center, Children's Medical Center, Tehran University of Medical Sciences, 62, Dr. Qarib's St, Keshavarz Blvd, Tehran, 14194 33151, Iran. kajbafzd@sina.tums.ac.ir.""}, {'ForeName': 'Seyedeh Sanam', 'Initials': 'SS', 'LastName': 'Ladi Seyedian', 'Affiliation': ""Pediatric Urology and Regenerative Medicine Research Center, Children's Medical Center, Tehran University of Medical Sciences, 62, Dr. Qarib's St, Keshavarz Blvd, Tehran, 14194 33151, Iran.""}, {'ForeName': 'Seyedeh Maryam', 'Initials': 'SM', 'LastName': 'Kameli', 'Affiliation': ""Pediatric Urology and Regenerative Medicine Research Center, Children's Medical Center, Tehran University of Medical Sciences, 62, Dr. Qarib's St, Keshavarz Blvd, Tehran, 14194 33151, Iran.""}, {'ForeName': 'Behnam', 'Initials': 'B', 'LastName': 'Nabavizadeh', 'Affiliation': ""Pediatric Urology and Regenerative Medicine Research Center, Children's Medical Center, Tehran University of Medical Sciences, 62, Dr. Qarib's St, Keshavarz Blvd, Tehran, 14194 33151, Iran.""}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Boroomand', 'Affiliation': ""Pediatric Nephrology Department, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.""}, {'ForeName': 'Mastaneh', 'Initials': 'M', 'LastName': 'Moghtaderi', 'Affiliation': ""Pediatric Nephrology Department, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.""}]",European journal of pediatrics,['10.1007/s00431-020-03626-3'] 560,31270217,Language boosting by transcranial stimulation in progressive supranuclear palsy.,"OBJECTIVE To explore whether transcranial direct current stimulation (tDCS) over the dorsolateral prefrontal cortex (DLPFC) can improve language capacities in patients with progressive supranuclear palsy (PSP). METHODS We used a sham-controlled double-blind crossover design to assess the efficiency of tDCS over the DLPFC in a cohort of 12 patients with PSP. In 3 separate sessions, we evaluated the ability to boost the left DLPFC via left-anodal (excitatory) and right-cathodal (inhibitory) tDCS, while comparing them to sham tDCS. Tasks assessing lexical access (letter fluency task) and semantic access (category judgment task) were applied immediately before and after the tDCS sessions to provide a marker of potential language modulation. RESULTS The comparison with healthy controls showed that patients with PSP were impaired on both tasks at baseline. Contrasting poststimulation vs prestimulation performance across tDCS conditions revealed language improvement in the category judgment task following right-cathodal tDCS, and in the letter fluency task following left-anodal tDCS. A computational finite element model of current distribution corroborated the intended effect of left-anodal and right-cathodal tDCS on the targeted DLPFC. CONCLUSIONS Our results demonstrate tDCS-driven language improvement in PSP. They provide proof-of-concept for the use of tDCS in PSP and set the stage for future multiday stimulation regimens, which might lead to longer-lasting therapeutic effects promoted by neuroplasticity. CLASSIFICATION OF EVIDENCE This study provides Class III evidence that for patients with PSP, tDCS over the DLPFC improves performance in some language tasks.",2019,"Tasks assessing lexical access (letter fluency task) and semantic access (category judgment task) were applied immediately before and after the tDCS sessions to provide a marker of potential language modulation. ","['progressive supranuclear palsy', 'patients with progressive supranuclear palsy (PSP', 'patients with PSP, tDCS over the', '12 patients with PSP']","['transcranial direct current stimulation (tDCS', 'dorsolateral prefrontal cortex (DLPFC', 'DLPFC', 'Language boosting by transcranial stimulation']","['Tasks assessing lexical access (letter fluency task) and semantic access (category judgment task', 'ability to boost the left DLPFC via left-anodal (excitatory) and right-cathodal (inhibitory) tDCS', 'efficiency of tDCS']","[{'cui': 'C0038868', 'cui_str': 'Steele-Richardson-Olszewski Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1868193', 'cui_str': 'PSP'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C4019080', 'cui_str': 'Dorsolateral Prefrontal Cortex'}, {'cui': 'C0023008', 'cui_str': 'Languages'}, {'cui': 'C0442348', 'cui_str': 'Transcranial approach (qualifier value)'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}]","[{'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C1096774', 'cui_str': 'Letter'}, {'cui': 'C0036612', 'cui_str': 'Semantics'}, {'cui': 'C0022423', 'cui_str': 'Judgment'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0205091', 'cui_str': 'Left (qualifier value)'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}]",12.0,0.074106,"Tasks assessing lexical access (letter fluency task) and semantic access (category judgment task) were applied immediately before and after the tDCS sessions to provide a marker of potential language modulation. ","[{'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Valero-Cabré', 'Affiliation': 'From Groupe de Dynamiques Cérébrales, Plasticité et Rééducation (A.V.-C., C.S., J.G., O.F.) and Frontlab Team (A.V.-C., C.S., J.G., O.F., B.D., R.L., M.T.), Institut du Cerveau et de la Moelle Epinière (ICM), INSERM 1127, CNRS, UMR 7225 and Sorbonne Université (SO), Paris, France; Laboratory for Cerebral Dynamics Plasticity and Rehabilitation (A.V.-C.), Boston University School of Medicine, MA; Cognitive Neuroscience and Information Technology Research Program (A.V.-C.), Open University of Catalonia (UOC), Barcelona, Spain; Department of Neurology (B.D., R.L., M.T.), National Reference Center for ""PPA and Rare Dementias,"" Pitié Salpêtrière Hospital, AP-HP, Paris, France; and Neural Engineering Laboratory, Department of Biomedical Engineering (D.Q.T., M.B.), the City College of City University of New York, NY. marc.teichmann@psl.aphp.fr antoni.valerocabre@icm-institute.org.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Sanches', 'Affiliation': 'From Groupe de Dynamiques Cérébrales, Plasticité et Rééducation (A.V.-C., C.S., J.G., O.F.) and Frontlab Team (A.V.-C., C.S., J.G., O.F., B.D., R.L., M.T.), Institut du Cerveau et de la Moelle Epinière (ICM), INSERM 1127, CNRS, UMR 7225 and Sorbonne Université (SO), Paris, France; Laboratory for Cerebral Dynamics Plasticity and Rehabilitation (A.V.-C.), Boston University School of Medicine, MA; Cognitive Neuroscience and Information Technology Research Program (A.V.-C.), Open University of Catalonia (UOC), Barcelona, Spain; Department of Neurology (B.D., R.L., M.T.), National Reference Center for ""PPA and Rare Dementias,"" Pitié Salpêtrière Hospital, AP-HP, Paris, France; and Neural Engineering Laboratory, Department of Biomedical Engineering (D.Q.T., M.B.), the City College of City University of New York, NY.'}, {'ForeName': 'Juliette', 'Initials': 'J', 'LastName': 'Godard', 'Affiliation': 'From Groupe de Dynamiques Cérébrales, Plasticité et Rééducation (A.V.-C., C.S., J.G., O.F.) and Frontlab Team (A.V.-C., C.S., J.G., O.F., B.D., R.L., M.T.), Institut du Cerveau et de la Moelle Epinière (ICM), INSERM 1127, CNRS, UMR 7225 and Sorbonne Université (SO), Paris, France; Laboratory for Cerebral Dynamics Plasticity and Rehabilitation (A.V.-C.), Boston University School of Medicine, MA; Cognitive Neuroscience and Information Technology Research Program (A.V.-C.), Open University of Catalonia (UOC), Barcelona, Spain; Department of Neurology (B.D., R.L., M.T.), National Reference Center for ""PPA and Rare Dementias,"" Pitié Salpêtrière Hospital, AP-HP, Paris, France; and Neural Engineering Laboratory, Department of Biomedical Engineering (D.Q.T., M.B.), the City College of City University of New York, NY.'}, {'ForeName': 'Oriane', 'Initials': 'O', 'LastName': 'Fracchia', 'Affiliation': 'From Groupe de Dynamiques Cérébrales, Plasticité et Rééducation (A.V.-C., C.S., J.G., O.F.) and Frontlab Team (A.V.-C., C.S., J.G., O.F., B.D., R.L., M.T.), Institut du Cerveau et de la Moelle Epinière (ICM), INSERM 1127, CNRS, UMR 7225 and Sorbonne Université (SO), Paris, France; Laboratory for Cerebral Dynamics Plasticity and Rehabilitation (A.V.-C.), Boston University School of Medicine, MA; Cognitive Neuroscience and Information Technology Research Program (A.V.-C.), Open University of Catalonia (UOC), Barcelona, Spain; Department of Neurology (B.D., R.L., M.T.), National Reference Center for ""PPA and Rare Dementias,"" Pitié Salpêtrière Hospital, AP-HP, Paris, France; and Neural Engineering Laboratory, Department of Biomedical Engineering (D.Q.T., M.B.), the City College of City University of New York, NY.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Dubois', 'Affiliation': 'From Groupe de Dynamiques Cérébrales, Plasticité et Rééducation (A.V.-C., C.S., J.G., O.F.) and Frontlab Team (A.V.-C., C.S., J.G., O.F., B.D., R.L., M.T.), Institut du Cerveau et de la Moelle Epinière (ICM), INSERM 1127, CNRS, UMR 7225 and Sorbonne Université (SO), Paris, France; Laboratory for Cerebral Dynamics Plasticity and Rehabilitation (A.V.-C.), Boston University School of Medicine, MA; Cognitive Neuroscience and Information Technology Research Program (A.V.-C.), Open University of Catalonia (UOC), Barcelona, Spain; Department of Neurology (B.D., R.L., M.T.), National Reference Center for ""PPA and Rare Dementias,"" Pitié Salpêtrière Hospital, AP-HP, Paris, France; and Neural Engineering Laboratory, Department of Biomedical Engineering (D.Q.T., M.B.), the City College of City University of New York, NY.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Levy', 'Affiliation': 'From Groupe de Dynamiques Cérébrales, Plasticité et Rééducation (A.V.-C., C.S., J.G., O.F.) and Frontlab Team (A.V.-C., C.S., J.G., O.F., B.D., R.L., M.T.), Institut du Cerveau et de la Moelle Epinière (ICM), INSERM 1127, CNRS, UMR 7225 and Sorbonne Université (SO), Paris, France; Laboratory for Cerebral Dynamics Plasticity and Rehabilitation (A.V.-C.), Boston University School of Medicine, MA; Cognitive Neuroscience and Information Technology Research Program (A.V.-C.), Open University of Catalonia (UOC), Barcelona, Spain; Department of Neurology (B.D., R.L., M.T.), National Reference Center for ""PPA and Rare Dementias,"" Pitié Salpêtrière Hospital, AP-HP, Paris, France; and Neural Engineering Laboratory, Department of Biomedical Engineering (D.Q.T., M.B.), the City College of City University of New York, NY.'}, {'ForeName': 'Dennis Q', 'Initials': 'DQ', 'LastName': 'Truong', 'Affiliation': 'From Groupe de Dynamiques Cérébrales, Plasticité et Rééducation (A.V.-C., C.S., J.G., O.F.) and Frontlab Team (A.V.-C., C.S., J.G., O.F., B.D., R.L., M.T.), Institut du Cerveau et de la Moelle Epinière (ICM), INSERM 1127, CNRS, UMR 7225 and Sorbonne Université (SO), Paris, France; Laboratory for Cerebral Dynamics Plasticity and Rehabilitation (A.V.-C.), Boston University School of Medicine, MA; Cognitive Neuroscience and Information Technology Research Program (A.V.-C.), Open University of Catalonia (UOC), Barcelona, Spain; Department of Neurology (B.D., R.L., M.T.), National Reference Center for ""PPA and Rare Dementias,"" Pitié Salpêtrière Hospital, AP-HP, Paris, France; and Neural Engineering Laboratory, Department of Biomedical Engineering (D.Q.T., M.B.), the City College of City University of New York, NY.'}, {'ForeName': 'Marom', 'Initials': 'M', 'LastName': 'Bikson', 'Affiliation': 'From Groupe de Dynamiques Cérébrales, Plasticité et Rééducation (A.V.-C., C.S., J.G., O.F.) and Frontlab Team (A.V.-C., C.S., J.G., O.F., B.D., R.L., M.T.), Institut du Cerveau et de la Moelle Epinière (ICM), INSERM 1127, CNRS, UMR 7225 and Sorbonne Université (SO), Paris, France; Laboratory for Cerebral Dynamics Plasticity and Rehabilitation (A.V.-C.), Boston University School of Medicine, MA; Cognitive Neuroscience and Information Technology Research Program (A.V.-C.), Open University of Catalonia (UOC), Barcelona, Spain; Department of Neurology (B.D., R.L., M.T.), National Reference Center for ""PPA and Rare Dementias,"" Pitié Salpêtrière Hospital, AP-HP, Paris, France; and Neural Engineering Laboratory, Department of Biomedical Engineering (D.Q.T., M.B.), the City College of City University of New York, NY.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Teichmann', 'Affiliation': 'From Groupe de Dynamiques Cérébrales, Plasticité et Rééducation (A.V.-C., C.S., J.G., O.F.) and Frontlab Team (A.V.-C., C.S., J.G., O.F., B.D., R.L., M.T.), Institut du Cerveau et de la Moelle Epinière (ICM), INSERM 1127, CNRS, UMR 7225 and Sorbonne Université (SO), Paris, France; Laboratory for Cerebral Dynamics Plasticity and Rehabilitation (A.V.-C.), Boston University School of Medicine, MA; Cognitive Neuroscience and Information Technology Research Program (A.V.-C.), Open University of Catalonia (UOC), Barcelona, Spain; Department of Neurology (B.D., R.L., M.T.), National Reference Center for ""PPA and Rare Dementias,"" Pitié Salpêtrière Hospital, AP-HP, Paris, France; and Neural Engineering Laboratory, Department of Biomedical Engineering (D.Q.T., M.B.), the City College of City University of New York, NY. marc.teichmann@psl.aphp.fr antoni.valerocabre@icm-institute.org.'}]",Neurology,['10.1212/WNL.0000000000007893'] 561,31264138,Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).,"OBJECTIVES To evaluate the cost-effectiveness of insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) in basal-bolus regimens for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk based on the DEVOTE CV outcomes trial. METHODS A microsimulation model, informed by clinical outcomes from the subgroup of patients using basal-bolus insulin therapy in DEVOTE (NCT01959529) and by the UKPDS Outcomes Model 2 risk equations, was used to model direct costs (2018 GBP) and effectiveness outcomes [quality-adjusted life years (QALYs)] with degludec versus glargine U100 over a 40-year time horizon. The model captured the development of eight diabetes-related complications, death, severe hypoglycemia and insulin dosing. This analysis was conducted from the perspective of National Health Service (NHS) England. RESULTS Treatment with degludec versus glargine U100 in basal-bolus regimens was associated with improved clinical outcomes at a higher cost per patient [incremental cost effectiveness ratio (ICER): £14,956 GBP/QALY]. Degludec remained cost effective versus glargine U100 in all exploratory sensitivity analyses, with ICERs below the widely accepted willingness-to-pay threshold, although the result was most sensitive to assumptions regarding the persistence of treatment effects. CONCLUSIONS Our long-term modeling analysis suggested that degludec was cost effective (from the perspective of NHS England) versus glargine U100 in basal-bolus regimens for patients with T2D at high CV risk. Our findings raise important questions regarding how to model the health economics of diabetes therapies.",2019,"Degludec remained cost effective versus glargine U100 in all exploratory sensitivity analyses, with ICERs below the widely accepted willingness-to-pay threshold, although the result was most sensitive to assumptions regarding the persistence of treatment effects. ","['patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk based on the DEVOTE CV outcomes trial', 'UK', 'patients with T2D at high CV risk']","['Insulin Degludec Versus Insulin Glargine', 'glargine', 'insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100']","['clinical outcomes', 'effectiveness outcomes [quality-adjusted life years (QALYs)] with degludec versus glargine U100 over a 40-year time horizon']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]","[{'cui': 'C3491971', 'cui_str': 'insulin degludec'}, {'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C2945590', 'cui_str': 'unit/mL'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0080071', 'cui_str': 'QALY'}, {'cui': 'C3491971', 'cui_str': 'insulin degludec'}, {'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",,0.0495679,"Degludec remained cost effective versus glargine U100 in all exploratory sensitivity analyses, with ICERs below the widely accepted willingness-to-pay threshold, although the result was most sensitive to assumptions regarding the persistence of treatment effects. ","[{'ForeName': 'Richard F', 'Initials': 'RF', 'LastName': 'Pollock', 'Affiliation': 'Ossian Health Economics and Communications GmbH, Basel, Switzerland. pollock@covalence-research.com.'}, {'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Valentine', 'Affiliation': 'Ossian Health Economics and Communications GmbH, Basel, Switzerland.'}, {'ForeName': 'Steven P', 'Initials': 'SP', 'LastName': 'Marso', 'Affiliation': 'HCA Midwest Health Heart and Vascular Institute, Kansas City, MO, USA.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Andersen', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Gundgaard', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Nino', 'Initials': 'N', 'LastName': 'Hallén', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Deniz', 'Initials': 'D', 'LastName': 'Tutkunkardas', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Magnuson', 'Affiliation': ""Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.""}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Buse', 'Affiliation': 'Medicine/Endocrinology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Applied health economics and health policy,['10.1007/s40258-019-00494-3'] 562,30772908,Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial.,"Importance Abnormal peripheral perfusion after septic shock resuscitation has been associated with organ dysfunction and mortality. The potential role of the clinical assessment of peripheral perfusion as a target during resuscitation in early septic shock has not been established. Objective To determine if a peripheral perfusion-targeted resuscitation during early septic shock in adults is more effective than a lactate level-targeted resuscitation for reducing mortality. Design, Setting, and Participants Multicenter, randomized trial conducted at 28 intensive care units in 5 countries. Four-hundred twenty-four patients with septic shock were included between March 2017 and March 2018. The last date of follow-up was June 12, 2018. Interventions Patients were randomized to a step-by-step resuscitation protocol aimed at either normalizing capillary refill time (n = 212) or normalizing or decreasing lactate levels at rates greater than 20% per 2 hours (n = 212), during an 8-hour intervention period. Main Outcomes and Measures The primary outcome was all-cause mortality at 28 days. Secondary outcomes were organ dysfunction at 72 hours after randomization, as assessed by Sequential Organ Failure Assessment (SOFA) score (range, 0 [best] to 24 [worst]); death within 90 days; mechanical ventilation-, renal replacement therapy-, and vasopressor-free days within 28 days; intensive care unit and hospital length of stay. Results Among 424 patients randomized (mean age, 63 years; 226 [53%] women), 416 (98%) completed the trial. By day 28, 74 patients (34.9%) in the peripheral perfusion group and 92 patients (43.4%) in the lactate group had died (hazard ratio, 0.75 [95% CI, 0.55 to 1.02]; P = .06; risk difference, -8.5% [95% CI, -18.2% to 1.2%]). Peripheral perfusion-targeted resuscitation was associated with less organ dysfunction at 72 hours (mean SOFA score, 5.6 [SD, 4.3] vs 6.6 [SD, 4.7]; mean difference, -1.00 [95% CI, -1.97 to -0.02]; P = .045). There were no significant differences in the other 6 secondary outcomes. No protocol-related serious adverse reactions were confirmed. Conclusions and Relevance Among patients with septic shock, a resuscitation strategy targeting normalization of capillary refill time, compared with a strategy targeting serum lactate levels, did not reduce all-cause 28-day mortality. Trial Registration ClinicalTrials.gov Identifier: NCT03078712.",2019,"Peripheral perfusion-targeted resuscitation was associated with less organ dysfunction at 72 hours (mean SOFA score, 5.6 [SD, 4.3] vs 6.6 [SD, 4.7]; mean difference, -1.00","['424 patients randomized (mean age, 63 years; 226 [53%] women), 416 (98%) completed the trial', 'Four-hundred twenty-four patients with septic shock were included between March 2017 and March 2018', 'patients with septic shock', '28 intensive care units in 5 countries', 'Patients With Septic Shock']","['peripheral perfusion-targeted resuscitation', 'Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels']","['cause mortality', 'Sequential Organ Failure Assessment (SOFA) score (range, 0 [best] to 24 [worst]); death within 90 days; mechanical ventilation-, renal replacement therapy-, and vasopressor-free days within 28 days; intensive care unit and hospital length of stay', 'organ dysfunction']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C3715070', 'cui_str': '24 (qualifier value)'}, {'cui': 'C0036983', 'cui_str': 'Septic Shock'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}]","[{'cui': 'C0425710', 'cui_str': 'Peripheral blood flow (observable entity)'}, {'cui': 'C0035273', 'cui_str': 'Resuscitation'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0428446', 'cui_str': 'Serum lactate measurement'}]","[{'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C3494459', 'cui_str': 'SOFAS Scores'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0206074', 'cui_str': 'Kidney Replacement Therapy'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}]",424.0,0.453197,"Peripheral perfusion-targeted resuscitation was associated with less organ dysfunction at 72 hours (mean SOFA score, 5.6 [SD, 4.3] vs 6.6 [SD, 4.7]; mean difference, -1.00","[{'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Hernández', 'Affiliation': 'Departmento de Medicina Intensiva, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago.'}, {'ForeName': 'Gustavo A', 'Initials': 'GA', 'LastName': 'Ospina-Tascón', 'Affiliation': 'Fundación Valle del Lili, Universidad ICESI, Department of Intensive Care Medicine, Cali, Colombia.'}, {'ForeName': 'Lucas Petri', 'Initials': 'LP', 'LastName': 'Damiani', 'Affiliation': 'HCor Research Institute-Hospital do Coração, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Estenssoro', 'Affiliation': 'Hospital Interzonal de Agudos San Martín de La Plata, La Plata, Argentina.'}, {'ForeName': 'Arnaldo', 'Initials': 'A', 'LastName': 'Dubin', 'Affiliation': 'Sanatorio Otamendi, Buenos Aires, Argentina.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Hurtado', 'Affiliation': 'Intensive Care Unit, Hospital Español-ASSE, Montevideo, Uruguay.'}, {'ForeName': 'Gilberto', 'Initials': 'G', 'LastName': 'Friedman', 'Affiliation': 'Post-Graduation Program in Pneumological Sciences, Department of Internal Medicine, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Castro', 'Affiliation': 'Departmento de Medicina Intensiva, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago.'}, {'ForeName': 'Leyla', 'Initials': 'L', 'LastName': 'Alegría', 'Affiliation': 'Departmento de Medicina Intensiva, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago.'}, {'ForeName': 'Jean-Louis', 'Initials': 'JL', 'LastName': 'Teboul', 'Affiliation': 'Service de Réanimation Médicale, Hopital Bicetre, Hopitaux Universitaires Paris-Sud, Paris, France.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Cecconi', 'Affiliation': 'Humanitas Clinical and Research Center, Department of Biomedical Sciences, Humanitas University, Milan, Italy.'}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'Ferri', 'Affiliation': 'Unidad de Cuidados Intensivos, Hospital Barros Luco Trudeau, Santiago, Chile.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Jibaja', 'Affiliation': 'Unidad de Cuidados Intensivos, Hospital Eugenio Espejo, Escuela de Medicina, Universidad Internacional del Ecuador, Quito.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Pairumani', 'Affiliation': 'Unidad de Cuidados Intensivos, Hospital Barros Luco Trudeau, Santiago, Chile.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Fernández', 'Affiliation': 'Unidad de Pacientes Críticos, Hospital Guillermo Grant Benavente, Concepción, Chile.'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Barahona', 'Affiliation': 'Unidad de Cuidados Intensivos, Hospital General Docente de Calderón, Universidad Central del Ecuador, Quito.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Granda-Luna', 'Affiliation': 'Unidad de Cuidados Intensivos, Hospital San Francisco, Pontificia Universidad Católica de Quito, Quito, Ecuador.'}, {'ForeName': 'Alexandre Biasi', 'Initials': 'AB', 'LastName': 'Cavalcanti', 'Affiliation': 'HCor Research Institute-Hospital do Coração, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Bakker', 'Affiliation': 'Departmento de Medicina Intensiva, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Hernández', 'Affiliation': ''}, {'ForeName': 'Gustavo', 'Initials': 'G', 'LastName': 'Ospina-Tascón', 'Affiliation': ''}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Petri Damiani', 'Affiliation': ''}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Estenssoro', 'Affiliation': ''}, {'ForeName': 'Arnaldo', 'Initials': 'A', 'LastName': 'Dubin', 'Affiliation': ''}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Hurtado', 'Affiliation': ''}, {'ForeName': 'Gilberto', 'Initials': 'G', 'LastName': 'Friedman', 'Affiliation': ''}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Castro', 'Affiliation': ''}, {'ForeName': 'Leyla', 'Initials': 'L', 'LastName': 'Alegría', 'Affiliation': ''}, {'ForeName': 'Jean-Louis', 'Initials': 'JL', 'LastName': 'Teboul', 'Affiliation': ''}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Cecconi', 'Affiliation': ''}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Cecconi', 'Affiliation': ''}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'Ferri', 'Affiliation': ''}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Jibaja', 'Affiliation': ''}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Pairumani', 'Affiliation': ''}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Fernández', 'Affiliation': ''}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Barahona', 'Affiliation': ''}, {'ForeName': 'Alexandre Biasi', 'Initials': 'AB', 'LastName': 'Cavalcanti', 'Affiliation': ''}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Bakker', 'Affiliation': ''}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Hernández', 'Affiliation': ''}, {'ForeName': 'Leyla', 'Initials': 'L', 'LastName': 'Alegría', 'Affiliation': ''}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'Ferri', 'Affiliation': ''}, {'ForeName': 'Nicolás', 'Initials': 'N', 'LastName': 'Rodriguez', 'Affiliation': ''}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Holger', 'Affiliation': ''}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Soto', 'Affiliation': ''}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Pozo', 'Affiliation': ''}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Bakker', 'Affiliation': ''}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Cook', 'Affiliation': ''}, {'ForeName': 'Jean-Louis', 'Initials': 'JL', 'LastName': 'Vincent', 'Affiliation': ''}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Rhodes', 'Affiliation': ''}, {'ForeName': 'Bryan P', 'Initials': 'BP', 'LastName': 'Kavanagh', 'Affiliation': ''}, {'ForeName': 'Phil', 'Initials': 'P', 'LastName': 'Dellinger', 'Affiliation': ''}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'Rietdijk', 'Affiliation': ''}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Carpio', 'Affiliation': ''}, {'ForeName': 'Nicolás', 'Initials': 'N', 'LastName': 'Pavéz', 'Affiliation': ''}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Henriquez', 'Affiliation': ''}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Bravo', 'Affiliation': ''}, {'ForeName': 'Emilio Daniel', 'Initials': 'ED', 'LastName': 'Valenzuela', 'Affiliation': ''}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Vera', 'Affiliation': ''}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Dreyse', 'Affiliation': ''}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Oviedo', 'Affiliation': ''}, {'ForeName': 'Maria Alicia', 'Initials': 'MA', 'LastName': 'Cid', 'Affiliation': ''}, {'ForeName': 'Macarena', 'Initials': 'M', 'LastName': 'Larroulet', 'Affiliation': ''}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Petruska', 'Affiliation': ''}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Sarabia', 'Affiliation': ''}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Gallardo', 'Affiliation': ''}, {'ForeName': 'Juan Eduardo', 'Initials': 'JE', 'LastName': 'Sanchez', 'Affiliation': ''}, {'ForeName': 'Hugo', 'Initials': 'H', 'LastName': 'González', 'Affiliation': ''}, {'ForeName': 'José Miguel', 'Initials': 'JM', 'LastName': 'Arancibia', 'Affiliation': ''}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Muñoz', 'Affiliation': ''}, {'ForeName': 'Germán', 'Initials': 'G', 'LastName': 'Ramirez', 'Affiliation': ''}, {'ForeName': 'Florencia', 'Initials': 'F', 'LastName': 'Aravena', 'Affiliation': ''}, {'ForeName': 'Andrés', 'Initials': 'A', 'LastName': 'Aquevedo', 'Affiliation': ''}, {'ForeName': 'Fabián', 'Initials': 'F', 'LastName': 'Zambrano', 'Affiliation': ''}, {'ForeName': 'Milan', 'Initials': 'M', 'LastName': 'Bozinovic', 'Affiliation': ''}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Valle', 'Affiliation': ''}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Ramirez', 'Affiliation': ''}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Rossel', 'Affiliation': ''}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Muñoz', 'Affiliation': ''}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Ceballos', 'Affiliation': ''}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Esveile', 'Affiliation': ''}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Carmona', 'Affiliation': ''}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Candia', 'Affiliation': ''}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Mendoza', 'Affiliation': ''}, {'ForeName': 'Aída', 'Initials': 'A', 'LastName': 'Sanchez', 'Affiliation': ''}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Ponce', 'Affiliation': ''}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Ponce', 'Affiliation': ''}, {'ForeName': 'Jaime', 'Initials': 'J', 'LastName': 'Lastra', 'Affiliation': ''}, {'ForeName': 'Bárbara', 'Initials': 'B', 'LastName': 'Nahuelpán', 'Affiliation': ''}, {'ForeName': 'Fabrizio', 'Initials': 'F', 'LastName': 'Fasce', 'Affiliation': ''}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Luengo', 'Affiliation': ''}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Medel', 'Affiliation': ''}, {'ForeName': 'Cesar', 'Initials': 'C', 'LastName': 'Cortés', 'Affiliation': ''}, {'ForeName': 'Luz', 'Initials': 'L', 'LastName': 'Campassi', 'Affiliation': ''}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Rubatto', 'Affiliation': ''}, {'ForeName': 'Nahime', 'Initials': 'N', 'LastName': 'Horna', 'Affiliation': ''}, {'ForeName': 'Mariano', 'Initials': 'M', 'LastName': 'Furche', 'Affiliation': ''}, {'ForeName': 'Juan Carlos', 'Initials': 'JC', 'LastName': 'Pendino', 'Affiliation': ''}, {'ForeName': 'Lisandro', 'Initials': 'L', 'LastName': 'Bettini', 'Affiliation': ''}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Lovesio', 'Affiliation': ''}, {'ForeName': 'María Cecilia', 'Initials': 'MC', 'LastName': 'González', 'Affiliation': ''}, {'ForeName': 'Jésica', 'Initials': 'J', 'LastName': 'Rodruguez', 'Affiliation': ''}, {'ForeName': 'Héctor', 'Initials': 'H', 'LastName': 'Canales', 'Affiliation': ''}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Caminos', 'Affiliation': ''}, {'ForeName': 'Cayetano', 'Initials': 'C', 'LastName': 'Galletti', 'Affiliation': ''}, {'ForeName': 'Estefanía', 'Initials': 'E', 'LastName': 'Minoldo', 'Affiliation': ''}, {'ForeName': 'Maria Jose', 'Initials': 'MJ', 'LastName': 'Aramburu', 'Affiliation': ''}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Olmos', 'Affiliation': ''}, {'ForeName': 'Nicolás', 'Initials': 'N', 'LastName': 'Nin', 'Affiliation': ''}, {'ForeName': 'Jordán', 'Initials': 'J', 'LastName': 'Tenzi', 'Affiliation': ''}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Quiroga', 'Affiliation': ''}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Lacuesta', 'Affiliation': ''}, {'ForeName': 'Agustín', 'Initials': 'A', 'LastName': 'Gaudín', 'Affiliation': ''}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Pais', 'Affiliation': ''}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Silvestre', 'Affiliation': ''}, {'ForeName': 'Germán', 'Initials': 'G', 'LastName': 'Olivera', 'Affiliation': ''}, {'ForeName': 'Gloria', 'Initials': 'G', 'LastName': 'Rieppi', 'Affiliation': ''}, {'ForeName': 'Dolores', 'Initials': 'D', 'LastName': 'Berrutti', 'Affiliation': ''}, {'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'Ochoa', 'Affiliation': ''}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Cobos', 'Affiliation': ''}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Vintimilla', 'Affiliation': ''}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Ramirez', 'Affiliation': ''}, {'ForeName': 'Milton', 'Initials': 'M', 'LastName': 'Tobar', 'Affiliation': ''}, {'ForeName': 'Fernanda', 'Initials': 'F', 'LastName': 'García', 'Affiliation': ''}, {'ForeName': 'Fabricio', 'Initials': 'F', 'LastName': 'Picoita', 'Affiliation': ''}, {'ForeName': 'Nelson', 'Initials': 'N', 'LastName': 'Remache', 'Affiliation': ''}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Granda', 'Affiliation': ''}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Paredes', 'Affiliation': ''}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Barzallo', 'Affiliation': ''}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Garcés', 'Affiliation': ''}, {'ForeName': 'Fausto', 'Initials': 'F', 'LastName': 'Guerrero', 'Affiliation': ''}, {'ForeName': 'Santiago', 'Initials': 'S', 'LastName': 'Salazar', 'Affiliation': ''}, {'ForeName': 'German', 'Initials': 'G', 'LastName': 'Torres', 'Affiliation': ''}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Tana', 'Affiliation': ''}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Calahorrano', 'Affiliation': ''}, {'ForeName': 'Freddy', 'Initials': 'F', 'LastName': 'Solis', 'Affiliation': ''}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Torres', 'Affiliation': ''}, {'ForeName': 'Luís', 'Initials': 'L', 'LastName': 'Herrera', 'Affiliation': ''}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Ornes', 'Affiliation': ''}, {'ForeName': 'Verónica', 'Initials': 'V', 'LastName': 'Peréz', 'Affiliation': ''}, {'ForeName': 'Glenda', 'Initials': 'G', 'LastName': 'Delgado', 'Affiliation': ''}, {'ForeName': 'Alexei', 'Initials': 'A', 'LastName': 'López', 'Affiliation': ''}, {'ForeName': 'Eliana', 'Initials': 'E', 'LastName': 'Espinosa', 'Affiliation': ''}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Moreira', 'Affiliation': ''}, {'ForeName': 'Blanca', 'Initials': 'B', 'LastName': 'Salcedo', 'Affiliation': ''}, {'ForeName': 'Ivonne', 'Initials': 'I', 'LastName': 'Villacres', 'Affiliation': ''}, {'ForeName': 'Jhonny', 'Initials': 'J', 'LastName': 'Suing', 'Affiliation': ''}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Lopez', 'Affiliation': ''}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Gomez', 'Affiliation': ''}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Toctaquiza', 'Affiliation': ''}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Cadena Zapata', 'Affiliation': ''}, {'ForeName': 'Milton Alonso', 'Initials': 'MA', 'LastName': 'Orazabal', 'Affiliation': ''}, {'ForeName': 'Ruben', 'Initials': 'R', 'LastName': 'Pardo Espejo', 'Affiliation': ''}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Jimenez', 'Affiliation': ''}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Calderón', 'Affiliation': ''}, {'ForeName': 'Gustavo', 'Initials': 'G', 'LastName': 'Paredes', 'Affiliation': ''}, {'ForeName': 'José Luis', 'Initials': 'JL', 'LastName': 'Barberán', 'Affiliation': ''}, {'ForeName': 'Tatiana', 'Initials': 'T', 'LastName': 'Moya', 'Affiliation': ''}, {'ForeName': 'Horacio', 'Initials': 'H', 'LastName': 'Atehortua', 'Affiliation': ''}, {'ForeName': 'Rodolfo', 'Initials': 'R', 'LastName': 'Sabogal', 'Affiliation': ''}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Ortiz', 'Affiliation': ''}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Lara', 'Affiliation': ''}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Sanchez', 'Affiliation': ''}, {'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Hernán Portilla', 'Affiliation': ''}, {'ForeName': 'Humberto', 'Initials': 'H', 'LastName': 'Dávila', 'Affiliation': ''}, {'ForeName': 'Jorge Antonio', 'Initials': 'JA', 'LastName': 'Mora', 'Affiliation': ''}, {'ForeName': 'Luis Eduardo', 'Initials': 'LE', 'LastName': 'Calderón', 'Affiliation': ''}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Alvarez', 'Affiliation': ''}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Escobar', 'Affiliation': ''}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Bejarano', 'Affiliation': ''}, {'ForeName': 'Luis Alfonso', 'Initials': 'LA', 'LastName': 'Bustamante', 'Affiliation': ''}, {'ForeName': 'José Luis', 'Initials': 'JL', 'LastName': 'Aldana', 'Affiliation': ''}]",JAMA,['10.1001/jama.2019.0071'] 563,31015261,IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKD.,"BACKGROUND AND OBJECTIVES Systemic inflammation modulates cardiovascular disease risk and functionality of HDL in the setting of CKD. Whether interventions that modify systemic inflammation can improve HDL function in CKD is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS We conducted a post hoc analysis of two randomized, clinical trials, IL-1 trap in participants with GFR 15-59 ml/min per 1.73 m 2 (study A) and IL-1 receptor antagonist in participants on maintenance hemodialysis (study B), to evaluate if IL-1 blockade had improved the anti-inflammatory activity (IL-6, TNF- α , and Nod-like receptor protein 3), antioxidant function (superoxide production), and net cholesterol efflux capacity of HDL. HDL function was measured using LPS-stimulated THP-1 macrophages or peritoneal macrophages of apoE-deficient mice exposed to the apoB-depleted, HDL-containing fraction obtained from the plasma of the study participants, collected before and after the interventions to block IL-1 effects. Analysis of covariance was used for between group comparisons. RESULTS The mean age of the participants was 60±13 years, 72% ( n =33) were men, and 39% ( n =18) were black. There were 32 CKD (16 IL-1 trap and 16 placebo) and 14 maintenance hemodialysis (7 IL-1 receptor antagonist and 7 placebo) participants. Compared with placebo, IL-1 inhibition, in study A and B reduced cellular expression of TNF- α by 15% ( P =0.05) and 64% ( P =0.02), IL-6 by 38% ( P =0.004) and 56% ( P =0.08), and Nod-like receptor protein 3 by 16% ( P =0.01) and 25% ( P =0.02), respectively. The intervention blunted superoxide production in the treated arm compared with placebo, with the values being higher by 17% in the placebo arm in study A ( P <0.001) and 12% in the placebo arm in study B ( P =0.004). Net cholesterol efflux capacity was not affected by either intervention. CONCLUSIONS IL-1 blockade improves the anti-inflammatory and antioxidative properties of the HDL-containing fraction of plasma in patients with stages 3-5 CKD, including those on maintenance hemodialysis.",2019,"Compared with placebo, IL-1 inhibition, in study A and B reduced cellular expression of TNF- α by 15% ( P =0.05) and 64% ( P =0.02), IL-6 by 38% ( P =0.004) and 56% ( P =0.08), and Nod-like receptor protein 3 by 16% ( P =0.01) and 25% ( P =0.02), respectively.","['participants with GFR 15-59 ml/min per 1.73 m 2 (study A) and', 'The mean age of the participants was 60±13 years, 72% ( n =33) were men, and 39% ( n =18) were black', 'Patients with Stages 3 to 5 CKD']","['IL-1 blockade', 'IL-1 receptor antagonist', 'placebo']","['Net cholesterol efflux capacity', 'HDL function', 'superoxide production', 'anti-inflammatory activity (IL-6, TNF- α , and Nod-like receptor protein 3), antioxidant function (superoxide production), and net cholesterol efflux capacity of HDL', 'IL-6', 'IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma', 'cellular expression of TNF- α']","[{'cui': 'C1318304', 'cui_str': 'With GFR'}, {'cui': 'C0439445', 'cui_str': 'mL/min'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3 (qualifier value)'}]","[{'cui': 'C0021755', 'cui_str': 'T Helper Factor'}, {'cui': 'C3540676', 'cui_str': 'Blockade'}, {'cui': 'C0063710', 'cui_str': 'Receptors, IL-1'}, {'cui': 'C0243076', 'cui_str': 'antagonists'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0038836', 'cui_str': 'Superoxide Anion'}, {'cui': 'C0033268'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C4277661', 'cui_str': 'Nucleotide-binding Domain Leucine-rich Repeat Proteins'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0021755', 'cui_str': 'T Helper Factor'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C3854321', 'cui_str': 'Expression'}]",33.0,0.272383,"Compared with placebo, IL-1 inhibition, in study A and B reduced cellular expression of TNF- α by 15% ( P =0.05) and 64% ( P =0.02), IL-6 by 38% ( P =0.004) and 56% ( P =0.08), and Nod-like receptor protein 3 by 16% ( P =0.01) and 25% ( P =0.02), respectively.","[{'ForeName': 'Adriana M', 'Initials': 'AM', 'LastName': 'Hung', 'Affiliation': 'Division of Nephrology, Tennessee Valley Healthcare System, Nashville, Tennessee; Valentina.Kon@vanderbilt.edu Adriana.Hung@vanderbilt.edu.'}, {'ForeName': 'Yohei', 'Initials': 'Y', 'LastName': 'Tsuchida', 'Affiliation': 'Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee; and.'}, {'ForeName': 'Kristen L', 'Initials': 'KL', 'LastName': 'Nowak', 'Affiliation': 'Department of Medicine, University of Colorado Denver, Aurora, Colorado.'}, {'ForeName': 'Sudipa', 'Initials': 'S', 'LastName': 'Sarkar', 'Affiliation': 'Department of Medicine and.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Chonchol', 'Affiliation': 'Department of Medicine, University of Colorado Denver, Aurora, Colorado.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Whitfield', 'Affiliation': 'Department of Medicine and.'}, {'ForeName': 'Natjalie', 'Initials': 'N', 'LastName': 'Salas', 'Affiliation': 'Department of Medicine and.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Dikalova', 'Affiliation': 'Department of Medicine and.'}, {'ForeName': 'Patricia G', 'Initials': 'PG', 'LastName': 'Yancey', 'Affiliation': 'Department of Medicine and.'}, {'ForeName': 'Jiansheng', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Department of Medicine and.'}, {'ForeName': 'MacRae F', 'Initials': 'MF', 'LastName': 'Linton', 'Affiliation': 'Department of Medicine and.'}, {'ForeName': 'T Alp', 'Initials': 'TA', 'LastName': 'Ikizler', 'Affiliation': 'Division of Nephrology, Tennessee Valley Healthcare System, Nashville, Tennessee.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Kon', 'Affiliation': 'Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee; and Valentina.Kon@vanderbilt.edu Adriana.Hung@vanderbilt.edu.'}]",Clinical journal of the American Society of Nephrology : CJASN,['10.2215/CJN.04360418'] 564,31125395,Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.,Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.,2020,No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.,['HIV-uninfected Individuals in HPTN 077'],['placebo'],"['weight and fasting metabolic parameters', 'weight gain', 'weight or fasting metabolic parameters', 'Weight Gain']","[{'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}]",,0.0633201,No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.,"[{'ForeName': 'Raphael J', 'Initials': 'RJ', 'LastName': 'Landovitz', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, Center for AIDS Research and Education & Center for HIV Prevention, David Geffen School of Medicine at University of California, Los Angeles.'}, {'ForeName': 'Sahar Z', 'Initials': 'SZ', 'LastName': 'Zangeneh', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Chau', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Grinsztejn', 'Affiliation': 'Laboratório de HIV, Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.'}, {'ForeName': 'Joseph J', 'Initials': 'JJ', 'LastName': 'Eron', 'Affiliation': 'Division of Infectious Diseases, University of North Carolina, Chapel Hill.'}, {'ForeName': 'Halima', 'Initials': 'H', 'LastName': 'Dawood', 'Affiliation': 'Department of Medicine, University of KwaZulu-Natal, Pietermaritzburg, Durban, South Africa.'}, {'ForeName': 'Manya', 'Initials': 'M', 'LastName': 'Magnus', 'Affiliation': 'Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, George Washington University, Washington, DC.'}, {'ForeName': 'Albert Y', 'Initials': 'AY', 'LastName': 'Liu', 'Affiliation': 'Bridge HIV, Population Health Division, San Francisco Department of Public Health, California.'}, {'ForeName': 'Ravindre', 'Initials': 'R', 'LastName': 'Panchia', 'Affiliation': 'Perinatal HIV Research Unit, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand, Soweto, South Africa.'}, {'ForeName': 'Mina C', 'Initials': 'MC', 'LastName': 'Hosseinipour', 'Affiliation': 'Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Kofron', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, Center for AIDS Research and Education & Center for HIV Prevention, David Geffen School of Medicine at University of California, Los Angeles.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Margolis', 'Affiliation': 'ViiV Healthcare, Research Triangle Park, Durham, North Carolina.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Rinehart', 'Affiliation': 'ViiV Healthcare, Research Triangle Park, Durham, North Carolina.'}, {'ForeName': 'Adeola', 'Initials': 'A', 'LastName': 'Adeyeye', 'Affiliation': 'Division of AIDS, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, Maryland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Burns', 'Affiliation': 'Division of AIDS, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, Maryland.'}, {'ForeName': 'Marybeth', 'Initials': 'M', 'LastName': 'McCauley', 'Affiliation': 'Science Facilitation Department, FHI 360, Washington DC.'}, {'ForeName': 'Myron S', 'Initials': 'MS', 'LastName': 'Cohen', 'Affiliation': 'Division of Infectious Diseases, University of North Carolina, Chapel Hill.'}, {'ForeName': 'Judith S', 'Initials': 'JS', 'LastName': 'Currier', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, Center for AIDS Research and Education & Center for HIV Prevention, David Geffen School of Medicine at University of California, Los Angeles.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciz439'] 565,30659257,The influence of 15-week exercise training on dietary patterns among young adults.,"BACKGROUND/OBJECTIVES Little is currently known about how exercise may influence dietary patterns and/or food preferences. The present study aimed to examine the effect of a 15-week exercise training program on overall dietary patterns among young adults. SUBJECTS/METHODS This study consisted of 2680 young adults drawn from the Training Intervention and Genetics of Exercise Response (TIGER) study. Subjects underwent 15 weeks of aerobic exercise training, and exercise duration, intensity, and dose were recorded for each session using computerized heart rate monitors. In total, 4355 dietary observations with 102 food items were collected using a self-administered food frequency questionnaire before and after exercise training (n = 2476 at baseline; n = 1859 at 15 weeks). Dietary patterns were identified using a Bayesian sparse latent factor model. Changes in dietary pattern preferences were evaluated based on the pre/post-training differences in dietary pattern scores, accounting for the effects of gender, race/ethnicity, and BMI. RESULTS Within each of the seven dietary patterns identified, most dietary pattern scores were decreased following exercise training, consistent with increased voluntary regulation of food intake. A longer duration of exercise was associated with decreased preferences for the western (β: -0.0793; 95% credible interval: -0.1568, -0.0017) and snacking (β: -0.1280; 95% credible interval: -0.1877, -0.0637) patterns, while a higher intensity of exercise was linked to an increased preference for the prudent pattern (β: 0.0623; 95% credible interval: 0.0159, 0.1111). Consequently, a higher dose of exercise was related to a decreased preference for the snacking pattern (β: -0.0023; 95% credible interval: -0.0042, -0.0004) and an increased preference for the prudent pattern (β: 0.0029; 95% credible interval: 0.0009, 0.0048). CONCLUSIONS The 15-week exercise training appeared to motivate young adults to pursue healthier dietary preferences and to regulate their food intake.",2019,"A longer duration of exercise was associated with decreased preferences for the western (β: -0.0793; 95% credible interval: -0.1568, -0.0017) and snacking (β:","['2680 young adults drawn from the Training Intervention and Genetics of Exercise Response (TIGER) study', 'young adults']","['15-week exercise training program', 'aerobic exercise training, and exercise duration, intensity, and dose were recorded for each session using computerized heart rate monitors', '15-week exercise training']","['voluntary regulation of food intake', 'dietary pattern preferences', 'overall dietary patterns', 'dietary pattern scores']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0013113', 'cui_str': 'Drawing'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0017399', 'cui_str': 'genetics'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}]","[{'cui': 'C0439656', 'cui_str': 'Voluntary (qualifier value)'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0558295', 'cui_str': 'Preferences (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",4355.0,0.0292461,"A longer duration of exercise was associated with decreased preferences for the western (β: -0.0793; 95% credible interval: -0.1568, -0.0017) and snacking (β:","[{'ForeName': 'Jaehyun', 'Initials': 'J', 'LastName': 'Joo', 'Affiliation': 'Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Sinead A', 'Initials': 'SA', 'LastName': 'Williamson', 'Affiliation': 'Departments of Information, Risk, & Operations Management and Statistics & Data Science, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Ana I', 'Initials': 'AI', 'LastName': 'Vazquez', 'Affiliation': 'Department of Epidemiology & Biostatistics and Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI, USA.'}, {'ForeName': 'Jose R', 'Initials': 'JR', 'LastName': 'Fernandez', 'Affiliation': 'Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Molly S', 'Initials': 'MS', 'LastName': 'Bray', 'Affiliation': 'Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX, USA. mbray@austin.utexas.edu.'}]",International journal of obesity (2005),['10.1038/s41366-018-0299-3'] 566,30187097,"Letter to the editor concerning the article: ""Intra-articular injection of autologous adipose-derived stromal vascular fractions for knee osteoarthritis: a double-blind randomized self-controlled trial"" (Hong et al. International Orthopaedics doi: 10.1007/s00264-018-4099-0).",,2019,,['knee osteoarthritis'],['autologous adipose-derived stromal vascular fractions'],[],"[{'cui': 'C0409959', 'cui_str': 'Osteoarthritis, Knee'}]","[{'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}]",[],,0.255063,,"[{'ForeName': 'Berardo', 'Initials': 'B', 'LastName': 'Di Matteo', 'Affiliation': 'Department of Biomedical Sciences, Humanitas University, Via Manzoni 113, Rozzano, 20089, Milan, Italy. berardo.dimatteo@gmail.com.'}, {'ForeName': 'Maurilio', 'Initials': 'M', 'LastName': 'Marcacci', 'Affiliation': 'Department of Biomedical Sciences, Humanitas University, Via Manzoni 113, Rozzano, 20089, Milan, Italy.'}, {'ForeName': 'Elizaveta', 'Initials': 'E', 'LastName': 'Kon', 'Affiliation': 'Department of Biomedical Sciences, Humanitas University, Via Manzoni 113, Rozzano, 20089, Milan, Italy.'}]",International orthopaedics,['10.1007/s00264-018-4134-1'] 567,31642145,"Associations between patient, treatment, or wound-level factors and venous leg ulcer healing: Wound characteristics are the key factors in determining healing outcomes.","Chronic venous leg ulcers are challenging to heal and often recur. This has a significant impact on older individual health and is a financial burden on health care resources. This study aimed to identify factors associated with the healing of venous leg ulcers via secondary examination of data from a previously published prospective randomized controlled trial of elastic and inelastic compression systems. The data from the 45 patients who finished the trial was reanalyzed for a hypothesis generating study. Larger ulcers, higher exudate levels, larger calf circumferences, and longer ulcer duration at baseline were associated with lack of healing at 12 weeks. There was some evidence that NSAID use was associated with an increased likelihood of nonhealing (unadjusted OR for healing, 0.13, 95% CI (0.02, 0.70)). There was no evidence that other variables, including gender and BMI, were associated with healing. The key risk factors for wound healing are largely wound based or inherent to wound development, as these were found to be the factors with the strongest associations in the analysis. Future research should address how and why these factors are associated with wound healing over a longer time frame and explore how NSAIDs may affect wound healing outcomes.",2020,"Larger ulcers, higher exudate levels, larger calf circumferences, and longer ulcer duration at baseline were associated with lack of healing at 12 weeks.",['45 patients who finished the trial was reanalysed for a hypothesis generating study'],[],"['Larger ulcers, higher exudate levels, larger calf circumferences, and longer ulcer duration', 'likelihood of non-healing']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1706059', 'cui_str': 'Finish - dosing instruction imperative'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]",[],"[{'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015388', 'cui_str': 'Exudate'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}]",,0.0285405,"Larger ulcers, higher exudate levels, larger calf circumferences, and longer ulcer duration at baseline were associated with lack of healing at 12 weeks.","[{'ForeName': 'Carolina D', 'Initials': 'CD', 'LastName': 'Weller', 'Affiliation': 'Monash Nursing and Midwifery, Level 5 Alfred Centre, 99 Commercial Road, Melbourne, Victoria, 3004, Australia.'}, {'ForeName': 'Ayoub', 'Initials': 'A', 'LastName': 'Bouguettaya', 'Affiliation': 'Monash Nursing and Midwifery, Level 5 Alfred Centre, 99 Commercial Road, Melbourne, Victoria, 3004, Australia.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Team', 'Affiliation': 'Monash Nursing and Midwifery, Level 5 Alfred Centre, 99 Commercial Road, Melbourne, Victoria, 3004, Australia.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Flegg', 'Affiliation': 'School of Mathematics and Statistics, University of Melbourne, Level 3, Old Geology South, Parkville, Victoria, 3010, Australia.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Kasza', 'Affiliation': 'Monash School of Public Health and Preventative Medicine, Monash University, 553 St Kilda Road, Melbourne, Victoria, 3004, Australia.'}, {'ForeName': 'Chathranee', 'Initials': 'C', 'LastName': 'Jayathilake', 'Affiliation': 'School of Mathematics and Statistics, University of Melbourne, Level 3, Old Geology South, Parkville, Victoria, 3010, Australia.'}]",Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society,['10.1111/wrr.12773'] 568,30885775,MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.,"PURPOSE Organ-confined muscle-invasive bladder cancer is treated with cystectomy or bladder preservation techniques, including radiation therapy. There are currently no biomarkers to inform management decisions and aid patient choice. Previously we showed high levels of MRE11 protein, assessed by immunohistochemistry (IHC), predicted outcome after radiation therapy, but not cystectomy. Therefore, we sought to develop the MRE11 IHC assay for clinical use and define its relationship to clinical outcome in samples from 2 major clinical trials. METHODS AND MATERIALS Samples from the BCON and BC2001 randomized controlled trials and a cystectomy cohort were stained using automated IHC methods and scored for MRE11 in 3 centers in the United Kingdom. RESULTS Despite step-wise creation of scoring cards and standard operating procedures for staining and interpretation, there was poor intercenter scoring agreement (kappa, 0.32; 95% confidence interval, 0.17-0.47). No significant associations between MRE11 scores and cause-specific survival were identified in BCON (n = 132) and BC2001 (n = 221) samples. Reoptimized staining improved agreement between scores from BCON tissue microarrays (n = 116), but MRE11 expression was not prognostic for cause-specific survival. CONCLUSIONS Manual IHC scoring of MRE11 was not validated as a reproducible biomarker of radiation-based bladder preservation success. There is a need for automated quantitative methods or a reassessment of how DNA-damage response relates to clinical outcomes.",2019,No significant associations between MRE11 scores and cause-specific survival were identified in BCON (n = 132) and BC2001 (n = 221) samples.,"['Samples from the BCON and BC2001 randomized controlled trials and a cystectomy cohort were stained using automated IHC methods and scored for MRE11 in 3 centers in the United Kingdom', 'Bladder Cancer']","['MRE11', 'Radiation Therapy']","['MRE11 scores and cause-specific survival', 'high levels of MRE11 protein, assessed by immunohistochemistry (IHC']","[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C1096777', 'cui_str': 'Randomized Controlled Trial'}, {'cui': 'C0010651', 'cui_str': 'Cystectomy'}, {'cui': 'C0449895', 'cui_str': 'Stain used (attribute)'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom'}, {'cui': 'C0005684', 'cui_str': 'Malignant Tumor of Urinary Bladder'}]","[{'cui': 'C0034619', 'cui_str': 'radiation therapy'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0021044', 'cui_str': 'Immunohistochemistry'}]",,0.13996,No significant associations between MRE11 scores and cause-specific survival were identified in BCON (n = 132) and BC2001 (n = 221) samples.,"[{'ForeName': 'Alexandra K', 'Initials': 'AK', 'LastName': 'Walker', 'Affiliation': 'CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Katalin', 'Initials': 'K', 'LastName': 'Karaszi', 'Affiliation': 'CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Valentine', 'Affiliation': 'Translational Radiobiology Group, Division of Cancer Sciences, Christie Hospital NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Victoria Y', 'Initials': 'VY', 'LastName': 'Strauss', 'Affiliation': 'Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, Botnar Research Centre, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Ananya', 'Initials': 'A', 'LastName': 'Choudhury', 'Affiliation': 'Translational Radiobiology Group, Division of Cancer Sciences, Christie Hospital NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Shaun', 'Initials': 'S', 'LastName': 'McGill', 'Affiliation': 'CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Kaisheng', 'Initials': 'K', 'LastName': 'Wen', 'Affiliation': 'School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Brown', 'Affiliation': 'Genito Urinary Cancer Research Group, Division of Cancer Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Vijay', 'Initials': 'V', 'LastName': 'Ramani', 'Affiliation': 'Department of Urology, The Christie NHS Foundation Trust, Manchester, United Kingdom.'}, {'ForeName': 'Selina', 'Initials': 'S', 'LastName': 'Bhattarai', 'Affiliation': 'Department of Histopathology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.'}, {'ForeName': 'Mark T W', 'Initials': 'MTW', 'LastName': 'Teo', 'Affiliation': ""Leeds Cancer Centre, St James's University Hospital, Leeds, United Kingdom.""}, {'ForeName': 'Lingjian', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Translational Radiobiology Group, Division of Cancer Sciences, Christie Hospital NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Kevin A', 'Initials': 'KA', 'LastName': 'Myers', 'Affiliation': 'Experimental Cancer Medicine Centre, Department of Oncology, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Nayneeta', 'Initials': 'N', 'LastName': 'Deshmukh', 'Affiliation': 'School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Denley', 'Affiliation': 'Department of Cellular Pathology, Manchester University Foundation Trust, Manchester, United Kingdom.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Browning', 'Affiliation': 'Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.'}, {'ForeName': 'Sharon B', 'Initials': 'SB', 'LastName': 'Love', 'Affiliation': 'Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, Botnar Research Centre, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Gopa', 'Initials': 'G', 'LastName': 'Iyer', 'Affiliation': 'Weill Cornell Medical College, Cornell University, New York, New York.'}, {'ForeName': 'Noel W', 'Initials': 'NW', 'LastName': 'Clarke', 'Affiliation': 'Genito Urinary Cancer Research Group, Division of Cancer Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom; Department of Urology, The Christie NHS Foundation Trust, Manchester, United Kingdom.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Hall', 'Affiliation': 'Clinical Trials and Statistics Unit, Institute of Cancer Research, London, United Kingdom.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Huddart', 'Affiliation': 'Academic Uro-Oncology Unit, The Royal Marsden NHS Foundation Trust, Sutton, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom.'}, {'ForeName': 'Nicholas D', 'Initials': 'ND', 'LastName': 'James', 'Affiliation': 'School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Hoskin', 'Affiliation': 'Cancer Centre, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom; Manchester Cancer Research Centre, University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Catharine M L', 'Initials': 'CML', 'LastName': 'West', 'Affiliation': 'Translational Radiobiology Group, Division of Cancer Sciences, Christie Hospital NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Anne E', 'Initials': 'AE', 'LastName': 'Kiltie', 'Affiliation': 'CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom. Electronic address: anne.kiltie@oncology.ox.ac.uk.'}]","International journal of radiation oncology, biology, physics",['10.1016/j.ijrobp.2019.03.015'] 569,30679671,Comparing patterns of volatile organic compounds exhaled in breath after consumption of two infant formulae with a different lipid structure: a randomized trial.,"Infant formulae have been used since decades as an alternative to or a complement to human milk. Human milk, the ""gold standard"" of infant nutrition, has been studied for its properties in order to create infant formulae that bring similar benefits to the infant. One of the characteristics of milk is the size of the lipid droplets which is known to affect the digestion, gastric emptying and triglyceride metabolism. In the current study a concept infant milk formula with large, phospholipid coating of lipid droplets (mode diameter 3-5 μm; NUTURIS, further described as ""active""), was compared to a commercially available formula milk characterised by smaller lipid droplets, further described as ""control"" (both products derived from Nutricia). We investigated whether we could find an effect of lipid droplet size on volatile compounds in exhaled air upon ingestion of either product. For that purpose, exhaled breath was collected from a group of 29 healthy, non-smoking adult males before ingestion of a study product (baseline measurements, T0) and at the following time points after the test meal: 30, 60, 120, 180 and 240 min. Volatile organic compounds (VOCs) in breath were detected by gas chromatography-time-of-flight-mass spectrometry. Any differences in the time course of VOCs patterns upon intake of active and control products were investigated by regularised multivariate analysis of variance (rMANOVA). The rMANOVA analysis revealed statistically significant differences in the exhaled breath composition 240 min after ingestion of the active formula compared to control product (p-value < 0.0001), but did not show significant changes between active and control product at any earlier time points. A set of eight VOCs in exhaled breath had the highest contribution to the difference found at 240 minutes between the two formulas. A set of ten VOCs was different between baseline and the two formulae at T240 with p-value < 0.0001. To our knowledge this is the first study that shows the ability of VOCs in exhaled breath to monitor metabolic effects after ingestion of infant formulae with different lipid structure. The statistically significant differences in compound abundance found between active and control formula milk may be related to: (i) specific differences in the digestion, (ii) absorption of lipids and proteins and (iii) assimilation of the products in the gut.",2019,"The rMANOVA analysis revealed statistically significant differences in the exhaled breath composition 240 min after ingestion of the active formula compared to control product (p-value < 0.0001), but did not show significant changes between active and control product at any earlier time points.","['in breath after consumption of two infant formulae with a different lipid structure', '29 healthy, non-smoking adult males before ingestion of a study product (baseline measurements, T0) and at the following time points after the test meal: 30, 60, 120, 180 and 240\u2009min']","['volatile organic compounds exhaled', 'Volatile organic compounds (VOCs']","['exhaled breath composition', 'digestion, (ii) absorption of lipids and proteins and (iii) assimilation', 'digestion, gastric emptying and triglyceride metabolism']","[{'cui': 'C0225386', 'cui_str': 'Breath (substance)'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0150589', 'cui_str': 'Baby Formula'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C4319600', 'cui_str': '240 (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}]","[{'cui': 'C2350439', 'cui_str': 'Volatile Organic Compounds'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}]","[{'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0225386', 'cui_str': 'Breath (substance)'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0012238', 'cui_str': 'Digestion'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0017127', 'cui_str': 'Gastric Emptyings'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}]",,0.0390838,"The rMANOVA analysis revealed statistically significant differences in the exhaled breath composition 240 min after ingestion of the active formula compared to control product (p-value < 0.0001), but did not show significant changes between active and control product at any earlier time points.","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Smolinska', 'Affiliation': 'NUTRIM School of Nutrition and Translational Research in Metabolism, Department Pharmacology & Toxicology, Maastricht University, Maastricht, The Netherlands. A.Smolinska@maastrichtuniversity.nl.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Baranska', 'Affiliation': 'NUTRIM School of Nutrition and Translational Research in Metabolism, Department Pharmacology & Toxicology, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'J W', 'Initials': 'JW', 'LastName': 'Dallinga', 'Affiliation': 'NUTRIM School of Nutrition and Translational Research in Metabolism, Department Pharmacology & Toxicology, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'R P', 'Initials': 'RP', 'LastName': 'Mensink', 'Affiliation': 'NUTRIM School of Nutrition and Translational Research in Metabolism, Department of Human Biology, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Baumgartner', 'Affiliation': 'NUTRIM School of Nutrition and Translational Research in Metabolism, Department of Human Biology, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'B J M', 'Initials': 'BJM', 'LastName': 'van de Heijning', 'Affiliation': 'Nutricia Research, Utrecht, The Netherlands.'}, {'ForeName': 'F J', 'Initials': 'FJ', 'LastName': 'van Schooten', 'Affiliation': 'NUTRIM School of Nutrition and Translational Research in Metabolism, Department Pharmacology & Toxicology, Maastricht University, Maastricht, The Netherlands.'}]",Scientific reports,['10.1038/s41598-018-37210-5'] 570,31082285,Sleep quality and treatment of social anxiety disorder.,"Background and Objectives: Poor sleep is prevalent among individuals with social anxiety disorder (SAD) and may affect treatment outcome. We examined whether: (1) individuals with SAD differed from healthy controls (HCs) in sleep quality, (2) baseline sleep quality moderated the effects of treatment (Cognitive-behavioral group therapy [CBGT] vs. mindfulness-based stress reduction [MBSR] vs. waitlist [WL]) on social anxiety, (3) sleep quality changed over treatment, and (4) changes in sleep quality predicted anxiety 12-months post-treatment. Design: Participants were 108 adults with SAD from a randomized controlled trial of CBGT vs. MBSR vs. WL and 38 HCs. Methods: SAD and sleep quality were assessed pre-treatment and post-treatment; SAD was assessed again 12-months post-treatment. Results: Participants with SAD reported poorer sleep quality than HCs. The effect of treatment condition on post-treatment social anxiety did not differ as a function of baseline sleep quality. Sleep quality improved in MBSR, significantly more than WL, but not CBGT. Sleep quality change from pre- to post-treatment in CBGT or MBSR did not predict later social anxiety. Conclusions: MBSR, and not CBGT, improved sleep quality among participants. Other results were inconsistent with prior research; possible explanations, limitations, and implications for future research are discussed. ClinicalTrials.gov identifier: NCT02036658.",2019,The effect of treatment condition on post-treatment social anxiety did not differ as a function of baseline sleep quality.,"['individuals with social anxiety disorder (SAD', 'Participants were 108 adults with SAD', 'social anxiety disorder']","['treatment (Cognitive-behavioral group therapy [CBGT] vs. mindfulness-based stress reduction [MBSR] vs. waitlist [WL', 'CBGT or MBSR', 'CBGT vs. MBSR vs. WL and 38 HCs']","['SAD and sleep quality', 'social anxiety, (3) sleep quality changed over treatment, and (4) changes in sleep quality predicted anxiety 12-months post-treatment', 'sleep quality', 'Sleep quality change', 'Sleep quality']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0031572', 'cui_str': 'Social Anxiety Disorder'}, {'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1527374', 'cui_str': 'Group Therapy'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]","[{'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0424166', 'cui_str': 'Social Anxiety'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]",108.0,0.029064,The effect of treatment condition on post-treatment social anxiety did not differ as a function of baseline sleep quality.,"[{'ForeName': 'Arielle', 'Initials': 'A', 'LastName': 'Horenstein', 'Affiliation': 'a Adult Anxiety Clinic, Department of Psychology , Temple University , Philadelphia , PA , USA.'}, {'ForeName': 'Amanda S', 'Initials': 'AS', 'LastName': 'Morrison', 'Affiliation': 'b Department of Psychology , California State University , East Bay , CA , USA.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Goldin', 'Affiliation': 'c Betty Irene Moore School of Nursing , University of California , Davis , CA , USA.'}, {'ForeName': 'Maia', 'Initials': 'M', 'LastName': 'Ten Brink', 'Affiliation': 'd Department of Psychology , Stanford University , Stanford , CA , USA.'}, {'ForeName': 'James J', 'Initials': 'JJ', 'LastName': 'Gross', 'Affiliation': 'd Department of Psychology , Stanford University , Stanford , CA , USA.'}, {'ForeName': 'Richard G', 'Initials': 'RG', 'LastName': 'Heimberg', 'Affiliation': 'a Adult Anxiety Clinic, Department of Psychology , Temple University , Philadelphia , PA , USA.'}]","Anxiety, stress, and coping",['10.1080/10615806.2019.1617854'] 571,30939487,"A Novel, Duodenal-Release Formulation of a Combination of Caraway Oil and L-Menthol for the Treatment of Functional Dyspepsia: A Randomized Controlled Trial.","OBJECTIVES We conducted a randomized, placebo-controlled trial, which evaluated a novel formulation of caraway oil and L-menthol using microsphere-based site-specific targeting (COLM-SST) vs placebo in patients with functional dyspepsia (FD). METHODS Adult men and women with FD defined by Rome III criteria were recruited. Patients were randomized to COLM-SST (25 mg of caraway oil and 20.75 mg of L-menthol per capsule, at 2 capsules per dose, twice per day) or placebo. Efficacy was measured at 24 hours, 2 weeks, and 4 weeks. Patients were allowed to take concomitant medications for their FD throughout the trial, and rescue medicines were allowed, 48 hours after start of dosing. RESULTS Ninety-five patients were enrolled (mean age = 43.4 years; 75.8% women). At 24 hours, the active arm reported a statistically significant reduction in postprandial distress syndrome symptoms (P = 0.039), and a nonsignificant trend toward benefit of epigastric pain syndrome symptoms (P = 0.074). In patients with more severe symptoms, approximately 3 quarters of patients showed substantial global improvement (i.e., clinical global impressions), after 4 weeks of treatment, vs half in the control arm. These differences were statistically significant for patients with epigastric pain syndrome (P = 0.046), and trending toward significance for patients with postprandial distress syndrome (P = 0.091). There was no statistically significant difference between groups for Global Overall Symptom scores for the overall population at 2 and 4 weeks. Treatment emergent adverse events were mild to moderate, and no serious adverse events were reported. DISCUSSION In patients taking their usual medications for FD, COLM-SST provided rapid relief (within 24 hours) and relief of severe FD symptoms. It was safe and well tolerated.",2019,"At 24 hours, the active arm reported a statistically significant reduction in postprandial distress syndrome symptoms (P = 0.039), and a nonsignificant trend toward benefit of epigastric pain syndrome symptoms (P = 0.074).","['Ninety-five patients were enrolled (mean age = 43.4 years; 75.8% women', 'Adult men and women with FD defined by Rome III criteria were recruited', 'patients with functional dyspepsia (FD', 'Functional Dyspepsia']","['placebo', 'caraway oil and 20.75 mg of L-menthol', 'COLM-SST', 'Caraway Oil and L-Menthol', 'caraway oil and L-menthol using microsphere-based site-specific targeting (COLM-SST) vs placebo']","['Efficacy', 'safe and well tolerated', 'relief of severe FD symptoms', 'epigastric pain syndrome', 'postprandial distress syndrome symptoms', 'substantial global improvement', 'Global Overall Symptom scores', 'epigastric pain syndrome symptoms', 'postprandial distress syndrome']","[{'cui': 'C4517906', 'cui_str': '95'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0035831', 'cui_str': 'Rome'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0267167', 'cui_str': 'Nonulcer dyspepsia (disorder)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0304097', 'cui_str': 'caraway oil'}, {'cui': 'C0771655', 'cui_str': 'LEVOMENTHOL'}, {'cui': 'C0026032', 'cui_str': 'Microbeads'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}]","[{'cui': 'C1301676', 'cui_str': 'Relieves (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0232493', 'cui_str': 'Epigastric pain (finding)'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",95.0,0.195052,"At 24 hours, the active arm reported a statistically significant reduction in postprandial distress syndrome symptoms (P = 0.039), and a nonsignificant trend toward benefit of epigastric pain syndrome symptoms (P = 0.074).","[{'ForeName': 'William D', 'Initials': 'WD', 'LastName': 'Chey', 'Affiliation': 'Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Brian E', 'Initials': 'BE', 'LastName': 'Lacy', 'Affiliation': 'Division of Gastroenterology, Mayo Clinic, Jacksonville, Florida, USA.'}, {'ForeName': 'Brooks D', 'Initials': 'BD', 'LastName': 'Cash', 'Affiliation': 'Division of Gastroenterology, McGovern Medical School, University of Texas, Houston, Texas, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Epstein', 'Affiliation': 'Digestive Disorders Associates, Annapolis, Maryland, USA.'}, {'ForeName': 'Patrick E', 'Initials': 'PE', 'LastName': 'Corsino', 'Affiliation': 'IM Health Science, Boca Raton, Florida, USA.'}, {'ForeName': 'Syed M', 'Initials': 'SM', 'LastName': 'Shah', 'Affiliation': 'IM Health Science, Boca Raton, Florida, USA.'}]",Clinical and translational gastroenterology,['10.14309/ctg.0000000000000021'] 572,30524137,Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment.,"Background Both statins and PCSK9 inhibitors lower blood low-density lipoprotein cholesterol (LDL-C) levels to reduce risk of cardiovascular events. To assess potential differences between metabolic effects of these two lipid-lowering therapies, we performed detailed lipid and metabolite profiling of a large randomized statin trial and compared the results with the effects of genetic inhibition of PCSK9, acting as a naturally occurring trial. Methods 228 circulating metabolic measures were quantified by nuclear magnetic resonance spectroscopy, including lipoprotein subclass concentrations and their lipid composition, fatty acids, and amino acids, for 5,359 individuals (2,659 on treatment) in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) trial at 6-months post-randomization. The corresponding metabolic measures were analyzed in eight population cohorts (N=72,185) using PCSK9 rs11591147 as an unconfounded proxy to mimic the therapeutic effects of PCSK9 inhibitors. Results Scaled to an equivalent lowering of LDL-C, the effects of genetic inhibition of PCSK9 on 228 metabolic markers were generally consistent with those of statin therapy ( R 2 =0.88). Alterations in lipoprotein lipid composition and fatty acid distribution were similar. However, discrepancies were observed for very-low-density lipoprotein (VLDL) lipid measures. For instance, genetic inhibition of PCSK9 had weaker effects on lowering of VLDL-cholesterol compared with statin therapy (54% vs. 77% reduction, relative to the lowering effect on LDL-C; P =2x10 -7 for heterogeneity). Genetic inhibition of PCSK9 showed no significant effects on amino acids, ketones, or a marker of inflammation (GlycA) whereas statin treatment weakly lowered GlycA levels. Conclusions Genetic inhibition of PCSK9 had similar metabolic effects to statin therapy on detailed lipid and metabolite profiles. However, PCSK9 inhibitors are predicted to have weaker effects on VLDL lipids compared with statins for an equivalent lowering of LDL-C, which potentially translate into smaller reductions in cardiovascular disease risk.",2018,"Genetic inhibition of PCSK9 showed no significant effects on amino acids, ketones, or a marker of inflammation (GlycA) whereas statin treatment weakly lowered GlycA levels. ",[],['Pravastatin'],"['amino acids, ketones, or a marker of inflammation (GlycA', 'blood low-density lipoprotein cholesterol (LDL-C) levels', 'lowering of VLDL-cholesterol', 'lipoprotein lipid composition and fatty acid distribution', 'lipoprotein subclass concentrations and their lipid composition, fatty acids, and amino acids']",[],"[{'cui': 'C0085542', 'cui_str': 'Pravastatin'}]","[{'cui': 'C3539946', 'cui_str': 'Amino acids'}, {'cui': 'C0022634', 'cui_str': 'Ketones'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0005768'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0023826', 'cui_str': 'Pre-beta-Lipoprotein Cholesterol'}, {'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0015684', 'cui_str': 'Fatty Acids'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0445604', 'cui_str': 'Subclass (attribute)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}]",,0.0837646,"Genetic inhibition of PCSK9 showed no significant effects on amino acids, ketones, or a marker of inflammation (GlycA) whereas statin treatment weakly lowered GlycA levels. ","[{'ForeName': 'Eeva', 'Initials': 'E', 'LastName': 'Sliz', 'Affiliation': 'Center for Life Course Health Research, University of Oulu, Oulu, Finland.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Kettunen', 'Affiliation': 'Center for Life Course Health Research, University of Oulu, Oulu, Finland.'}, {'ForeName': 'Michael V', 'Initials': 'MV', 'LastName': 'Holmes', 'Affiliation': 'Medical Research Council Population Health Research Unit, University of Oxford, Oxford, UK.'}, {'ForeName': 'Clare Oliver', 'Initials': 'CO', 'LastName': 'Williams', 'Affiliation': 'MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Boachie', 'Affiliation': 'Robertson Centre for Biostatistics, Boyd Orr Building, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': 'Center for Life Course Health Research, University of Oulu, Oulu, Finland.'}, {'ForeName': 'Minna', 'Initials': 'M', 'LastName': 'Männikkö', 'Affiliation': 'Northern Finland Birth Cohorts, Faculty of Medicine, University of Oulu, Oulu, Finland.'}, {'ForeName': 'Sylvain', 'Initials': 'S', 'LastName': 'Sebert', 'Affiliation': 'Center for Life Course Health Research, University of Oulu, Oulu, Finland.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Walters', 'Affiliation': 'Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.'}, {'ForeName': 'Kuang', 'Initials': 'K', 'LastName': 'Lin', 'Affiliation': 'Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.'}, {'ForeName': 'Iona Y', 'Initials': 'IY', 'LastName': 'Millwood', 'Affiliation': 'Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Clarke', 'Affiliation': 'Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.'}, {'ForeName': 'Liming', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Chinese Academy of Medical Sciences, 9 Dongdan San Tiao, Beijing, China.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Rankin', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Welsh', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Delles', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK.'}, {'ForeName': 'J Wouter', 'Initials': 'JW', 'LastName': 'Jukema', 'Affiliation': 'Leiden University Medical Centre, Leiden, The Netherlands.'}, {'ForeName': 'Stella', 'Initials': 'S', 'LastName': 'Trompet', 'Affiliation': 'Leiden University Medical Centre, Leiden, The Netherlands.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Ford', 'Affiliation': 'Robertson Centre for Biostatistics, Boyd Orr Building, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Perola', 'Affiliation': 'National Institute for Health and Welfare, Helsinki, Finland.'}, {'ForeName': 'Veikko', 'Initials': 'V', 'LastName': 'Salomaa', 'Affiliation': 'National Institute for Health and Welfare, Helsinki, Finland.'}, {'ForeName': 'Marjo-Riitta', 'Initials': 'MR', 'LastName': 'Järvelin', 'Affiliation': 'Center for Life Course Health Research, University of Oulu, Oulu, Finland.'}, {'ForeName': 'Zhengming', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.'}, {'ForeName': 'Debbie A', 'Initials': 'DA', 'LastName': 'Lawlor', 'Affiliation': 'Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Ala-Korpela', 'Affiliation': 'Center for Life Course Health Research, University of Oulu, Oulu, Finland.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Danesh', 'Affiliation': 'MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Davey Smith', 'Affiliation': 'Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.'}, {'ForeName': 'Naveed', 'Initials': 'N', 'LastName': 'Sattar', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Butterworth', 'Affiliation': 'MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Würtz', 'Affiliation': 'Diabetes and Obesity Research Program, University of Helsinki, Helsinki, Finland.'}]",Circulation,['10.1161/CIRCULATIONAHA.118.034942'] 573,30283029,"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).","Numerous placebo-controlled studies have demonstrated the ability of ketamine, an NMDA receptor antagonist, to induce rapid (within hours), transient antidepressant effects when administered intravenously (IV) at subanesthetic doses (0.5 mg/kg over 40 min). However, the optimal antidepressant dose remains unknown. We aimed to compare to active placebo the rapid acting antidepressant properties of a broad range of subanesthetic doses of IV ketamine among outpatients with treatment-resistant depression (TRD). A range of IV ketamine doses were compared to active placebo in the treatment of adult TRD over a 3-day period following a single infusion over 40 min. This was an outpatient study conducted across six US academic sites. Outpatients were 18-70 years old with TRD, defined as failure to achieve a satisfactory response (e.g., less than 50% improvement of depression symptoms) to at least two adequate treatment courses during the current depressive episode. Following a washout period, 99 eligible subjects were randomly assigned to one of the five arms in a 1:1:1:1:1 fashion: a single intravenous dose of ketamine 0.1 mg/kg (n = 18), a single dose of ketamine 0.2 mg/kg (n = 20), a single dose of ketamine 0.5 mg/kg (n = 22), a single dose of ketamine 1.0 mg/kg (n = 20), and a single dose of midazolam 0.045 mg/kg (active placebo) (n = 19). The study assessments (HAM-D-6, MADRS, SDQ, PAS, CGI-S, and CGI-I) were performed at days 0, 1, 3 (endpoint), 5, 7, 14, and 30 to assess the safety and efficacy. The overall group × time interaction effect was significant for the primary outcome measure, the HAM-D-6. In post hoc pairwise comparisons controlling for multiple comparisons, standard dose (0.5 mg/kg) and high dose (1 mg/kg) of intravenous ketamine were superior to active placebo; a low dose (0.1 mg/kg) was significant only prior to adjustment (p = 0.02, p-adj = 0.14, d = -0.82 at day 1). Most of the interaction effect was due to differences at day 1, with no significant adjusted pairwise differences at day 3. This pattern generally held for secondary outcomes. The infusions of ketamine were relatively well tolerated compared to active placebo, except for greater dissociative symptoms and transient blood pressure elevations with the higher doses. Our results suggest that there is evidence for the efficacy of the 0.5 mg/kg and 1.0 mg/kg subanesthetic doses of IV ketamine and no clear or consistent evidence for clinically meaningful efficacy of lower doses of IV ketamine. Trial Registration: NCT01920555.",2020,"The infusions of ketamine were relatively well tolerated compared to active placebo, except for greater dissociative symptoms and transient blood pressure elevations with the higher doses.","['99 eligible subjects', 'Outpatients were 18-70 years old with TRD, defined as failure to achieve a satisfactory response (e.g., less than 50% improvement of depression symptoms) to at least two adequate treatment courses during the current depressive episode', 'treatment-resistant depression (TRD', 'outpatients with treatment-resistant depression (TRD']","['ketamine', 'IV ketamine', 'placebo', 'midazolam 0.045\u2009mg/kg (active placebo', 'ketamine 0.1\u2009mg/kg']","['safety and efficacy', 'HAM-D-6', 'dissociative symptoms and transient blood pressure elevations', 'study assessments (HAM-D-6, MADRS, SDQ, PAS, CGI-S, and CGI-I']","[{'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205411', 'cui_str': 'Adequate (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0349217', 'cui_str': 'Depressive episode'}, {'cui': 'C2063866', 'cui_str': 'Refractory Depression'}]","[{'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C4517410', 'cui_str': 'Zero point zero four five'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C4517420', 'cui_str': 'Zero point one'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3853311', 'cui_str': 'Ham'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205374', 'cui_str': 'Transitory (qualifier value)'}, {'cui': 'C0497247', 'cui_str': 'Finding of increased blood pressure (finding)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",99.0,0.456136,"The infusions of ketamine were relatively well tolerated compared to active placebo, except for greater dissociative symptoms and transient blood pressure elevations with the higher doses.","[{'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Fava', 'Affiliation': 'Massachusetts General Hospital, Boston, MA, USA. mfava@mgh.harvard.edu.'}, {'ForeName': 'Marlene P', 'Initials': 'MP', 'LastName': 'Freeman', 'Affiliation': 'Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Flynn', 'Affiliation': 'Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Judge', 'Affiliation': 'Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Bettina B', 'Initials': 'BB', 'LastName': 'Hoeppner', 'Affiliation': 'Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Cusin', 'Affiliation': 'Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Dawn F', 'Initials': 'DF', 'LastName': 'Ionescu', 'Affiliation': 'Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Sanjay J', 'Initials': 'SJ', 'LastName': 'Mathew', 'Affiliation': 'Baylor College of Medicine/Michael E. Debakey VA Medical Center, Houston, TX, USA.'}, {'ForeName': 'Lee C', 'Initials': 'LC', 'LastName': 'Chang', 'Affiliation': 'Baylor College of Medicine/Michael E. Debakey VA Medical Center, Houston, TX, USA.'}, {'ForeName': 'Dan V', 'Initials': 'DV', 'LastName': 'Iosifescu', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Murrough', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Debattista', 'Affiliation': 'Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Alan F', 'Initials': 'AF', 'LastName': 'Schatzberg', 'Affiliation': 'Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Madhukar H', 'Initials': 'MH', 'LastName': 'Trivedi', 'Affiliation': 'University of Texas Southwestern, Dallas, TX, USA.'}, {'ForeName': 'Manish K', 'Initials': 'MK', 'LastName': 'Jha', 'Affiliation': 'University of Texas Southwestern, Dallas, TX, USA.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Sanacora', 'Affiliation': 'Yale University, New Haven, CT, USA.'}, {'ForeName': 'Samuel T', 'Initials': 'ST', 'LastName': 'Wilkinson', 'Affiliation': 'Yale University, New Haven, CT, USA.'}, {'ForeName': 'George I', 'Initials': 'GI', 'LastName': 'Papakostas', 'Affiliation': 'Massachusetts General Hospital, Boston, MA, USA.'}]",Molecular psychiatry,['10.1038/s41380-018-0256-5'] 574,30085292,Effects of Intranasal Oxytocin on Stress-Induced Cigarette Craving in Daily Smokers.,"BACKGROUND Cigarette smoking is a well-known public health concern, and there is an urgent need to develop new treatments to reduce smoking or facilitate abstinence. One factor that is known to contribute to relapse is stress, making the stress response an important target for treatment. The neuropeptide oxytocin (OT) is believed to have stress-reducing effects, and in addition there is evidence that it reduces drug craving. The purpose of the present study was to examine the effects of intranasal OT on stress-induced cigarette craving in regular smokers after 12 h of abstinence. METHOD Daily smokers (n = 48) completed a stress induction task and a nonstressful control task at two different sessions, receiving intranasal OT (40 IU) or placebo (PBO) before or after the task. Subjects were randomly assigned to one of three groups: Group PP (n = 16) received PBO before and after the stress/control tasks, Group OP (n = 16) received OT before the tasks and PBO after, and Group PO (n = 16) received PBO before the tasks and OT shortly after completing the tasks. Cigarette craving as well as subjective and physiological responses to stress was assessed. RESULTS OT did not alter responses to stress, whether it was administered before or after the stressful task, on measures of cigarette craving, anxiety, heart rate, blood pressure, and cortisol levels. CONCLUSIONS The current study findings do not support several previous reports that OT reduced either stress or drug craving. IMPLICATIONS This study finds a null result of the neuropeptide oxytocin on stress-induced cigarette craving. Reporting null findings is part of the process of identifying potential treatments for addictive disorders.",2020,"Results OT did not alter responses to stress, whether it was administered before or after the stressful task, on measures of cigarette craving, anxiety, heart rate, blood pressure, and cortisol levels. ","['daily smokers', 'regular smokers after 12 hours of abstinence']","['neuropeptide oxytocin (OT', 'neuropeptide oxytocin', 'intranasal oxytocin', 'stress induction task and a non-stressful control task at two different sessions, receiving intranasal OT (40 IU) or placebo (PBO']","['stress-induced cigarette craving', 'Cigarette craving', 'cigarette craving, anxiety, heart rate, blood pressure, and cortisol levels']","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C1292430', 'cui_str': '12 hours'}]","[{'cui': 'C0027895', 'cui_str': 'Neuropeptides'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}]",,0.0220557,"Results OT did not alter responses to stress, whether it was administered before or after the stressful task, on measures of cigarette craving, anxiety, heart rate, blood pressure, and cortisol levels. ","[{'ForeName': 'Kathryne', 'Initials': 'K', 'LastName': 'Van Hedger', 'Affiliation': 'Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL.'}, {'ForeName': 'Anya K', 'Initials': 'AK', 'LastName': 'Bershad', 'Affiliation': 'Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL.'}, {'ForeName': 'Royce', 'Initials': 'R', 'LastName': 'Lee', 'Affiliation': 'Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL.'}, {'ForeName': 'Harriet', 'Initials': 'H', 'LastName': 'de Wit', 'Affiliation': 'Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/nty159'] 575,31978436,Perioperative prophylactic internal iliac artery balloon occlusion in the prevention of postpartum hemorrhage in placenta previa: a randomized controlled trial.,"BACKGROUND Placenta previa remains one of the major causes of massive postpartum hemorrhage and maternal mortality worldwide. OBJECTIVE To determine whether internal iliac artery balloon occlusion during cesarean delivery for placenta previa could reduce postpartum hemorrhage and other maternal complications. STUDY DESIGN This was a prospective randomized controlled trial conducted at a tertiary university obstetric unit in Hong Kong. Pregnant women who were diagnosed to have placenta previa at 34 weeks (defined as lower placenta edge within 2 cm from the internal os) and required cesarean delivery were invited to participate. Eligible pregnant women were randomized into internal iliac artery balloon occlusion (Occlusion) group or standard management (Control) group. Those randomized to the Occlusion group had internal iliac artery balloon catheter placement performed before cesarean delivery and then balloon inflation after delivery of the baby. The primary outcome was the reduction of postpartum hemorrhage in those with internal iliac artery balloon occlusion. Secondary outcome measures included hemoglobin drop after delivery; amount of blood product transfusion; incidence of hysterectomy; maternal complications including renal failure, ischemic liver, disseminated intravascular coagulation, and adult respiratory distress syndrome; length of stay in hospital; admission to intensive care unit; and maternal death. RESULTS Between May 2016 and September 2018, 40 women were randomized (20 in each group). Demographic and obstetric characteristics were similar between the 2 groups. In the Occlusion group, 3 women did not receive the scheduled procedure, as it was preceded by antepartum hemorrhage that required emergency cesarean delivery, and 1 woman had repeated scan at 36 weeks showing the placental edge was slightly more than 2 cm from the internal os. Intention-to-treat analysis found no significant differences between the Occlusion and the Control groups regarding to the median intraoperative blood loss (1451 [1024-2388] mL vs 1454 [888-2300] mL; P = .945), the median length of surgery (49 [30-62] min vs 37 [30-51] min; P = .204), or the need for blood transfusion during operation (57.9% vs 50.0%; P = .621). None of the patients had rebleeding after operation, complication related to internal iliac artery procedure, or any other maternal complications. Reanalyzing the data using on-treatment approach showed the same results. CONCLUSION The use of prophylactic internal iliac artery balloon occlusion in placenta previa patients undergoing cesarean delivery did not reduce postpartum hemorrhage or have any effect on maternal or neonatal morbidity.",2020,"None of the patients had rebleeding after operation, complication related to internal iliac artery procedure or any other maternal complications.","['ml vs 1454 (888-2300', 'tertiary university obstetric unit in Hong Kong', 'Eligible pregnant women', 'postpartum hemorrhage in placenta previa', 'Between May 2016 and Sep 2018, 40 women', 'placenta previa patients undergoing Cesarean delivery', 'Pregnant women who were diagnosed to have placenta previa at 34 weeks (defined as lower placenta edge within 2cm from the internal os) and required Cesarean delivery were invited to participate']","['Occlusion Group had internal iliac artery balloon catheter placement', 'internal iliac artery balloon occlusion (Occlusion) group or standard management (Control) group', 'internal iliac artery balloon occlusion', 'prophylactic internal iliac artery balloon occlusion', 'Perioperative prophylactic internal iliac artery balloon occlusion']","['hemoglobin drop after delivery, amount of blood product transfusion, incidence of hysterectomy, maternal complications including renal failure, ischemic liver, disseminated intravascular coagulation, adult respiratory distress syndrome, length of stay in hospital, admission to intensive care unit, and maternal death', 'median length of surgery', 'median intra-operative blood loss', 'reduction of postpartum hemorrhage in those with internal iliac artery balloon occlusion', 'postpartum hemorrhage', 'Demographic and obstetric characteristics', 'need for blood transfusion']","[{'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0019907', 'cui_str': 'Hongkong'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0032797', 'cui_str': 'Postpartum Hemorrhage'}, {'cui': 'C0032046', 'cui_str': 'Placenta Previa'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1384674', 'cui_str': 'Deliveries by cesarean (finding)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0032043', 'cui_str': 'Placentome'}, {'cui': 'C0205154', 'cui_str': 'Along edge (qualifier value)'}, {'cui': 'C0227842', 'cui_str': 'Structure of internal os'}]","[{'cui': 'C0441597', 'cui_str': 'Occlusion - action (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0226364', 'cui_str': 'Structure of internal iliac artery'}, {'cui': 'C0441127', 'cui_str': 'Balloon dilatation catheter (physical object)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0887842', 'cui_str': 'Balloon Occlusion'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0445202', 'cui_str': 'Prophylactic (qualifier value)'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4318619', 'cui_str': 'Drop (unit of presentation)'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0005841', 'cui_str': 'Blood Transfusion'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0035078', 'cui_str': 'Kidney Failure'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0012739', 'cui_str': 'Consumption Coagulopathy'}, {'cui': 'C0035222', 'cui_str': 'ARDS, Human'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0583239', 'cui_str': 'Admission to intensive care unit (procedure)'}, {'cui': 'C3494405', 'cui_str': 'Maternal Death'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0032797', 'cui_str': 'Postpartum Hemorrhage'}, {'cui': 'C0226364', 'cui_str': 'Structure of internal iliac artery'}, {'cui': 'C0887842', 'cui_str': 'Balloon Occlusion'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C1273858', 'cui_str': 'Transfusion Medicine'}]",40.0,0.221838,"None of the patients had rebleeding after operation, complication related to internal iliac artery procedure or any other maternal complications.","[{'ForeName': 'Simon Chun Ho', 'Initials': 'SCH', 'LastName': 'Yu', 'Affiliation': 'Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Yvonne Kwun Yue', 'Initials': 'YKY', 'LastName': 'Cheng', 'Affiliation': 'Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Wing Ting', 'Initials': 'WT', 'LastName': 'Tse', 'Affiliation': 'Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Daljit Singh', 'Initials': 'DS', 'LastName': 'Sahota', 'Affiliation': 'Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Man Yan', 'Initials': 'MY', 'LastName': 'Chung', 'Affiliation': 'Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Simon Sin Man', 'Initials': 'SSM', 'LastName': 'Wong', 'Affiliation': 'Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Oi Ka', 'Initials': 'OK', 'LastName': 'Chan', 'Affiliation': 'Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Tak Yeung', 'Initials': 'TY', 'LastName': 'Leung', 'Affiliation': 'Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Shatin, Hong Kong. Electronic address: tyleung@cuhk.edu.hk.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.01.024'] 576,32132845,"Isoinertial Eccentric-Overload Training in Young Soccer Players: Effects on Strength, Sprint, Change of Direction, Agility and Soccer Shooting Precision.","The isoinertial training method owes its efficacy to an accommodated resistance and optimal individualized eccentric overload. The aim of this study was to assess the effects of a 6-week isoinertial eccentric-overload training program - using a flywheel inertial device during the execution of specific soccer exercises - on explosive and reactive strength, sprint ability, change of direction (COD) performance and soccer shooting precision. Thirty-four junior soccer players were randomly assigned to a plyometric training group (PT) (n = 16, aged 13.36 ± 0.80), which underwent a six-week traditional soccer training program, and a flywheel eccentric overload group (FEO) (n = 18, aged 13.21 ± 1.21), which received additional training consisting of two inertial eccentric-overload training sessions per week. Pre and post intervention tests were carried out to assess explosive and reactive strength, sprint ability, COD ability, agility using the Y-agility test (YT) and soccer shooting precision. The FEO showed significantly higher values than the PT in squat jump height (SJh) (p = 0.01), drop jump height (DJh) (p = 0.003), 7 repeated hop test heights (p = 0.001), the Illinois test (ILL) (p = 0.001), and the Loughborough Soccer Shooting Test (SHOT) (p = 0.02). Finally, the FEO showed significant between-group differences in DJh (p = 0.007), ILL (p = 0.0002), YT (p = 0.002), a linear sprint test (SPRINT) (p = 0.001), and SHOT (p = 0.003). These results confirmed the positive effect of isoinertial training. The use of an isoinertial device to overload multidirectional movements in specific sport conditions leads to greater performance improvements than conventional soccer training. The absence of knowledge of the eccentric overload applied by the isoinertial device, which is different in any exercise repetition, may stimulate the athlete's neural adaptations, improving their soccer skills and in particular their soccer shooting precision.",2020,"The FEO showed significantly higher values than the PT in squat jump height (SJh) (p = 0.01), drop jump height (DJh) (p = 0.003), 7 repeated hop test heights (p = 0.001), the Illinois test (ILL) (p = 0.001), and the Loughborough Soccer Shooting Test (SHOT) (p = 0.02).","['Young Soccer Players', 'Thirty-four junior soccer players']","['Isoinertial Eccentric-Overload Training', 'six-week traditional soccer training program, and a flywheel eccentric overload group (FEO', 'plyometric training group (PT', 'isoinertial eccentric-overload training program', 'additional training consisting of two inertial eccentric-overload training sessions per week', 'conventional soccer training']","['explosive and reactive strength, sprint ability, change of direction (COD) performance and soccer shooting precision', 'linear sprint test (SPRINT', 'Strength, Sprint, Change of Direction, Agility and Soccer Shooting Precision', 'ILL', 'Illinois test (ILL', 'explosive and reactive strength, sprint ability, COD ability, agility using the Y-agility test (YT) and soccer shooting precision', 'Loughborough Soccer Shooting Test (SHOT']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0037393', 'cui_str': 'Soccers'}, {'cui': 'C3816446', 'cui_str': '30'}]","[{'cui': 'C0439740', 'cui_str': 'Eccentric (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0037393', 'cui_str': 'Soccers'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C3178799', 'cui_str': 'Plyometric Training'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]","[{'cui': 'C1721090', 'cui_str': 'Explosives'}, {'cui': 'C0205332', 'cui_str': 'Reactive (qualifier value)'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0439755', 'cui_str': 'Directions (qualifier value)'}, {'cui': 'C0037393', 'cui_str': 'Soccers'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0459207', 'cui_str': 'Cod'}]",34.0,0.0162557,"The FEO showed significantly higher values than the PT in squat jump height (SJh) (p = 0.01), drop jump height (DJh) (p = 0.003), 7 repeated hop test heights (p = 0.001), the Illinois test (ILL) (p = 0.001), and the Loughborough Soccer Shooting Test (SHOT) (p = 0.02).","[{'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Fiorilli', 'Affiliation': 'Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.'}, {'ForeName': 'Intrieri', 'Initials': 'I', 'LastName': 'Mariano', 'Affiliation': 'Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.'}, {'ForeName': 'Enzo', 'Initials': 'E', 'LastName': 'Iuliano', 'Affiliation': 'Faculty of Psychology, eCampus University, Novedrate, Italy.'}, {'ForeName': 'Arrigo', 'Initials': 'A', 'LastName': 'Giombini', 'Affiliation': 'Department of Movement, Human and Health Sciences, Italian University of Sport and Movement of Rome ""Foro Italico"", Rome, Italy.'}, {'ForeName': 'Antonello', 'Initials': 'A', 'LastName': 'Ciccarelli', 'Affiliation': 'Department of Movement, Human and Health Sciences, Italian University of Sport and Movement of Rome ""Foro Italico"", Rome, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Buonsenso', 'Affiliation': 'Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Calcagno', 'Affiliation': 'Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'di Cagno', 'Affiliation': 'Department of Movement, Human and Health Sciences, Italian University of Sport and Movement of Rome ""Foro Italico"", Rome, Italy.'}]",Journal of sports science & medicine,[] 577,31983281,"Effect of wheat bran derived prebiotic supplementation on gastrointestinal transit, gut microbiota, and metabolic health: a randomized controlled trial in healthy adults with a slow gut transit.","Acute intake of the wheat bran extract Arabinoxylan-Oligosaccharide (AXOS) modulates the gut microbiota, improves stool characteristics and postprandial glycemia in healthy humans. Yet, little is known on how long-term AXOS intake influences gastrointestinal (GI) functioning, gut microbiota, and metabolic health. In this randomized, placebo-controlled, double-blind study, we evaluated the effects of AXOS intake on GI function and metabolic health in adults with slow GI transit without constipation. Forty-eight normoglycemic adults were included with whole-gut transit time (WGTT) of >35 h receiving either 15 g/day AXOS or placebo (maltodextrin) for 12-wks. The primary outcome was WGTT, and secondary outcomes included stool parameters, gut permeability, short-chain fatty acids (SCFA), microbiota composition, energy expenditure, substrate oxidation, glucose, insulin, lipids, gut hormones, and adipose tissue (AT) function. WGTT was unchanged, but stool consistency softened after AXOS. 12-wks of AXOS intake significantly changed the microbiota by increasing Bifidobacterium and decreasing microbial alpha-diversity. With a good classification accuracy, overall microbiota composition classified responders with decreased WGTT after AXOS. The incretin hormone Glucagon-like protein 1 was reduced after AXOS compared to placebo. Energy expenditure, plasma metabolites, AT parameters, SCFA, and gut permeability were unchanged. In conclusion, intake of wheat bran extract increases fecal Bifidobacterium and softens stool consistency without major effects on energy metabolism in healthy humans with a slow GI transit. We show that overall gut microbiota classified responders with decreased WGTT after AXOS highlighting that GI transit and change thereof were associated with gut microbiota independent of Bifidobacterium . NCT02491125.",2020,12-wks of AXOS intake significantly changed the microbiota by increasing Bifidobacterium and decreasing microbial alpha-diversity.,"['adults with slow GI transit without constipation', 'healthy humans', 'healthy humans with a slow GI transit', 'Forty-eight normoglycemic adults', 'healthy adults with a slow gut transit']","['wheat bran extract Arabinoxylan-Oligosaccharide (AXOS', 'placebo', 'wheat bran derived prebiotic supplementation', 'wheat bran extract', 'whole-gut transit time (WGTT) of >35 h receiving either 15 g/day AXOS or placebo (maltodextrin', 'AXOS intake']","['gastrointestinal transit, gut microbiota, and metabolic health', 'Energy expenditure, plasma metabolites, AT parameters, SCFA, and gut permeability', 'stool characteristics and postprandial glycemia', 'incretin hormone Glucagon-like protein 1', 'stool parameters, gut permeability, short-chain fatty acids (SCFA), microbiota composition, energy expenditure, substrate oxidation, glucose, insulin, lipids, gut hormones, and adipose tissue (AT) function', 'GI function and metabolic health']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439834', 'cui_str': 'Slowly'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C4319608', 'cui_str': 'Forty-eight'}, {'cui': 'C0580545', 'cui_str': 'Blood glucose normal (finding)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C3257534', 'cui_str': 'Triticum vulgare extract'}, {'cui': 'C0250438', 'cui_str': 'arabinoxylan'}, {'cui': 'C0028959', 'cui_str': 'Oligosaccharides'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0043138', 'cui_str': 'Wheat Bran'}, {'cui': 'C2717875', 'cui_str': 'Prebiotics'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439417', 'cui_str': 'g/day'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}]","[{'cui': 'C0017191', 'cui_str': 'Gastrointestinal Transit'}, {'cui': 'C4018878', 'cui_str': 'Gastrointestinal Microbial Community'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0014272', 'cui_str': 'Energy Expenditure'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0031164', 'cui_str': 'Permeability'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C1562292', 'cui_str': 'Glucose-Dependent Insulin-Releasing Hormone'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0876232', 'cui_str': 'glucagon recombinant'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015691', 'cui_str': 'Fatty Acids, Short-Chain'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0030011', 'cui_str': 'Oxidation, function (observable entity)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0001527', 'cui_str': 'Fatty Tissue'}, {'cui': 'C0031843', 'cui_str': 'function'}]",48.0,0.211394,12-wks of AXOS intake significantly changed the microbiota by increasing Bifidobacterium and decreasing microbial alpha-diversity.,"[{'ForeName': 'Mattea', 'Initials': 'M', 'LastName': 'Müller', 'Affiliation': 'Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+ , Maastricht, The Netherlands.'}, {'ForeName': 'Gerben D A', 'Initials': 'GDA', 'LastName': 'Hermes', 'Affiliation': 'Laboratory of Microbiology, Wageningen University & Research , Wageningen, The Netherlands.'}, {'ForeName': 'Canfora', 'Initials': 'C', 'LastName': 'Emanuel E', 'Affiliation': 'Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+ , Maastricht, The Netherlands.'}, {'ForeName': 'Jens J', 'Initials': 'JJ', 'LastName': 'Holst', 'Affiliation': 'NNF Center for Basic Metabolic Research and Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen, Denmark.'}, {'ForeName': 'Erwin G', 'Initials': 'EG', 'LastName': 'Zoetendal', 'Affiliation': 'Laboratory of Microbiology, Wageningen University & Research , Wageningen, The Netherlands.'}, {'ForeName': 'Hauke', 'Initials': 'H', 'LastName': 'Smidt', 'Affiliation': 'Laboratory of Microbiology, Wageningen University & Research , Wageningen, The Netherlands.'}, {'ForeName': 'Freddy', 'Initials': 'F', 'LastName': 'Troost', 'Affiliation': 'Division of Gastroenterology-Hepatology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+ , Maastricht, The Netherlands.'}, {'ForeName': 'Frank G', 'Initials': 'FG', 'LastName': 'Schaap', 'Affiliation': 'Division of Gastroenterology-Hepatology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+ , Maastricht, The Netherlands.'}, {'ForeName': 'Steven Olde', 'Initials': 'SO', 'LastName': 'Damink', 'Affiliation': 'Division of Gastroenterology-Hepatology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+ , Maastricht, The Netherlands.'}, {'ForeName': 'Johan W E', 'Initials': 'JWE', 'LastName': 'Jocken', 'Affiliation': 'Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+ , Maastricht, The Netherlands.'}, {'ForeName': 'Kaatje', 'Initials': 'K', 'LastName': 'Lenaerts', 'Affiliation': 'Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+ , Maastricht, The Netherlands.'}, {'ForeName': 'Ad A M', 'Initials': 'AAM', 'LastName': 'Masclee', 'Affiliation': 'Department of Surgery, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+ , Maastricht, The Netherlands.'}, {'ForeName': 'Ellen E', 'Initials': 'EE', 'LastName': 'Blaak', 'Affiliation': 'Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+ , Maastricht, The Netherlands.'}]",Gut microbes,['10.1080/19490976.2019.1704141'] 578,31974753,"CO 2 Laser Moxibustion for Knee Osteoarthritis: Study Protocol for A Multicenter, Double-blind, Randomized Controlled Trial.","BACKGROUND Knee osteoarthritis (OA) is a major cause of disability among the older adults. Few treatments are safe and effective. Moxibustion is commonly used in treating knee OA in Chinese medicine (CM). CO 2 Laser moxibustion device is a substitute for traditional moxibustion, which mimics the effects of traditional moxibustion. More data are needed to support its application in knee OA. OBJECTIVE ObjectiveThe trial aims to assess the effect and safety of CO 2 laser moxibustion in patients with knee osteoarthritis compared with a sham control. METHODS This is a protocol for a multicenter, randomized, double-blind, placebo-controlled trial. A total of 392 participants were recruited and assigned to the CO 2 laser moxibustion group and sham laser moxibustion group with a 1:1 ratio at 6 outpatient clinics in Shanghai, China. Participants in both groups received treatment at the affected knee(s) at the acupuncture point Dubi (ST 35) and an Ashi point. There were 3 sessions per week for 4 weeks, and an additional 20-week follow-up. Primary outcomes were changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores at week 4. Secondary outcomes were WOMAC function score, stiffness score and overall score, VAS pain, Short-Form heath survey (SF-36), and patients' global assessment. The serum levels of cytokines involved in progress of knee OA were explored. Safety was assessed during the whole trial. Masking effectiveness was assessed by both participants and treatment providers.This is a protocol for a multicenter, randomized, double-blind, placebo-controlled trial. A total of 392 participants were recruited and assigned to the CO 2 laser moxibustion group and sham laser moxibustion group with a 1:1 ratio at 6 outpatient clinics in Shanghai, China. Participants in both groups received treatment at the affected knee(s) at the acupuncture point Dubi (ST 35) and an Ashi point. There were 3 sessions per week for 4 weeks, and an additional 20-week follow-up. Primary outcomes were changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores at week 4. Secondary outcomes were WOMAC function score, stiffness score and overall score, VAS pain, Short-Form heath survey (SF-36), and patients' global assessment. The serum levels of cytokines involved in progress of knee OA were explored. Safety was assessed during the whole trial. Masking effectiveness was assessed by both participants and treatment providers. DISCUSSION CO 2 laser moxibustion device, designed as a substitute for CM moxibustion, is easy to use and control with no choking smoke and smell, and is a plausible method for double-blind research. This study would provide rigorous evidence for the effect and safety of CO 2 laser moxibustion in treating knee OA (Trial registration No.: ISRCTN15030019).",2020,Participants in both groups received treatment at the affected knee(s) at the acupuncture point Dubi (ST 35) and an Ashi point.,"['Chinese medicine (CM', 'A total of 392 participants', 'patients with knee osteoarthritis compared with a sham control', 'Knee Osteoarthritis', 'group with a 1:1 ratio at 6 outpatient clinics in Shanghai, China', 'older adults']","['CO 2 Laser Moxibustion', 'CO 2 laser moxibustion', 'acupuncture point Dubi (ST 35) and an Ashi point', 'placebo', 'CO 2 laser moxibustion group and sham laser moxibustion', 'CO 2 Laser moxibustion device', 'Moxibustion']","[""WOMAC function score, stiffness score and overall score, VAS pain, Short-Form heath survey (SF-36), and patients' global assessment"", 'changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores', 'Masking effectiveness', 'Safety', 'serum levels of cytokines']","[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis, Knee'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C0026652', 'cui_str': 'Moxabustion'}, {'cui': 'C0001302', 'cui_str': 'Acupoints'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0220819', 'cui_str': 'devices'}]","[{'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0427008', 'cui_str': 'Stiffness (finding)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C3472647', 'cui_str': 'WOMAC index'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0024861', 'cui_str': 'Masks'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}]",392.0,0.490104,Participants in both groups received treatment at the affected knee(s) at the acupuncture point Dubi (ST 35) and an Ashi point.,"[{'ForeName': 'Meng-Hu', 'Initials': 'MH', 'LastName': 'Guo', 'Affiliation': 'School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Zhao', 'Affiliation': 'School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.'}, {'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Wu', 'Affiliation': 'School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.'}, {'ForeName': 'Jiong', 'Initials': 'J', 'LastName': 'Du', 'Affiliation': 'Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200021, China.'}, {'ForeName': 'Chen-Huan', 'Initials': 'CH', 'LastName': 'Ding', 'Affiliation': 'Renji Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 200127, China.'}, {'ForeName': 'Jing-Hua', 'Initials': 'JH', 'LastName': 'Ge', 'Affiliation': 'Shanghai Changning Tianshan Traditional Chinese Medicine Hospital, Shanghai, 200051, China.'}, {'ForeName': 'Ming T', 'Initials': 'MT', 'LastName': 'Tan', 'Affiliation': 'Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University Medical Center, Washington, D.C., 20057, USA.'}, {'ForeName': 'Li-Xing', 'Initials': 'LX', 'LastName': 'Lao', 'Affiliation': 'School of Chinese Medicine, University of Hong Kong, Hong Kong SAR, China.'}, {'ForeName': 'Xue-Yong', 'Initials': 'XY', 'LastName': 'Shen', 'Affiliation': 'School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.'}, {'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Cheng', 'Affiliation': 'School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. cheng_ker@hotmail.com.'}]",Chinese journal of integrative medicine,['10.1007/s11655-019-2714-6'] 579,32144049,Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial.,"BACKGROUND Limited evidence exists regarding the cost and health-related quality of life (HRQoL) effects of non-muscle-invasive bladder cancer (NMIBC) recurrence and progression to muscle-invasive bladder cancer (MIBC). We examined these effects using evidence from a recent randomized control trial. MATERIAL AND METHODS The costs and HRQoL associated with bladder cancer were assessed using data from the BOXIT trial (bladder COX-2 inhibition trial; n = 472). The cost and HRQoL effects from clinical events were estimated using generalized estimating equations. The costs were derived from the recorded resource usage and UK unit costs. HRQoL was assessed using the EQ-5D-3L and reported UK preference tariffs. The events were categorized using the TMN classification. RESULTS Cases of grade 3 recurrence and progression were associated with statistically significant HRQoL decrements (-0.08; 95% confidence interval [CI], -0.13 to -0.03; and -0.10; 95% CI, -0.17 to -0.03, respectively). The 3-year average cost per NMIBC patient was estimated at £8735 (95% CI, 8325-9145). Cases of grade 1, 2, and 3 recurrence were associated with annual cost effects of £1218 (95% CI, 403-2033), £1677 (95% CI, 920-2433), and £3957 (95% CI, 2332-5583), respectively. Progression to MIBC was associated with an average increase in costs of £5407 (95% CI, 2663-8152). CONCLUSION Evidence from the BOXIT trial suggests that patients with NMIBC will both experience decrements in HRQoL and incur significant costs, especially in the event of a grade 3 recurrence or a progression to MIBC.",2020,"Progression to MIBC was associated with an average increase in costs of £5407 (95% CI, 2663-8152). ",[],[],"['UK Healthcare Costs and Patient Health-Related Quality of Life', 'cost and HRQoL effects', 'annual cost effects', '3-year average cost per NMIBC patient', 'costs and HRQoL associated with bladder cancer', 'HRQoL', 'HRQoL decrements']",[],[],"[{'cui': 'C0085552', 'cui_str': 'Healthcare Costs'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0005684', 'cui_str': 'Malignant Tumor of Urinary Bladder'}]",,0.300627,"Progression to MIBC was associated with an average increase in costs of £5407 (95% CI, 2663-8152). ","[{'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Cox', 'Affiliation': 'Centre for Health Economics, University of York, York, United Kingdom. Electronic address: edward.cox@york.ac.uk.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Saramago', 'Affiliation': 'Centre for Health Economics, University of York, York, United Kingdom.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Kelly', 'Affiliation': 'Division of Surgery and Interventional Science, University College London, London, United Kingdom; Department of Urology, University College London Hospital, London, United Kingdom.'}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'Porta', 'Affiliation': 'Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Hall', 'Affiliation': 'Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.'}, {'ForeName': 'Wei Shen', 'Initials': 'WS', 'LastName': 'Tan', 'Affiliation': 'Division of Surgery and Interventional Science, University College London, London, United Kingdom; Department of Urology, Imperial College Healthcare, London, United Kingdom.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Sculpher', 'Affiliation': 'Centre for Health Economics, University of York, York, United Kingdom.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Soares', 'Affiliation': 'Centre for Health Economics, University of York, York, United Kingdom.'}]",Clinical genitourinary cancer,['10.1016/j.clgc.2019.12.004'] 580,30144630,"Competency Based Approach to Community Health (COACH): The methods of a family-centered, community-based, individually adaptive obesity randomized trial for pre-school child-parent pairs.","Competency-Based Approaches to Community Health (COACH) is a randomized controlled trial of a family-centered, community-based, and individually-tailored behavioral intervention for childhood obesity among Latino pre-school children. COACH focuses on improving personal agency for health behavior change by tailoring content to overcome contextual barriers. The intervention focuses on diet, physical activity, sleep, media use, and engaged parenting. The content is individually adapted based on routine assessments of competency in specific health behaviors using a mobile health platform and novel measurement tools developed by our team. In response to these regular assessments, health coaches provide tailored health behavior change strategies to help families focus on the areas where they decide to improve the most. The intervention consists of a 15-week group-based intensive phase, with weekly sessions delivered by health coaches in community centers. Following weekly sessions, a 3-month maintenance phase of the intervention consists of twice monthly coaching calls for participants to focus on individual health goals for their families. The primary outcome of the trial is child body mass index trajectory over 1 year. Secondary outcomes include parent body mass index change, child waist circumference, child diet, child physical activity, and other psychosocial mediators of child health behavior change. The control arm consists of a school readiness intervention, delivered by the Nashville Public Library. By applying a personalized approach to child behavior change, in the setting of both family and community, COACH aims to develop sustainable solutions for childhood obesity by supporting healthy childhood growth in low-income, minority preschool children.",2018,"Competency-Based Approaches to Community Health (COACH) is a randomized controlled trial of a family-centered, community-based, and individually-tailored behavioral intervention for childhood obesity among Latino pre-school children.","['childhood obesity among Latino pre-school children', 'pre-school child-parent pairs']","['behavioral intervention', 'school readiness intervention, delivered by the Nashville Public Library', 'Competency-Based Approaches to Community Health (COACH', 'Competency Based Approach to Community Health (COACH']","['child body mass index trajectory over 1\u202fyear', 'parent body mass index change, child waist circumference, child diet, child physical activity, and other psychosocial mediators of child health behavior change']","[{'cui': 'C2362324', 'cui_str': 'Childhood Onset Obesity'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0424930', 'cui_str': 'Pre-school (environment)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0023621', 'cui_str': 'Libraries'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0557773', 'cui_str': 'Coach (physical object)'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0008078', 'cui_str': 'Childrens Health'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]",,0.0218485,"Competency-Based Approaches to Community Health (COACH) is a randomized controlled trial of a family-centered, community-based, and individually-tailored behavioral intervention for childhood obesity among Latino pre-school children.","[{'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Heerman', 'Affiliation': 'Department of Pediatrics, Vanderbilt University Medical Center, USA. Electronic address: Bill.Heerman@vanderbilt.edu.'}, {'ForeName': 'Laura E', 'Initials': 'LE', 'LastName': 'Burgess', 'Affiliation': 'Department of Pediatrics, Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Escarfuller', 'Affiliation': 'Department of Pediatrics, Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Teeters', 'Affiliation': 'School of Education, University of Colorado Boulder, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Slesur', 'Affiliation': 'School of Medicine, Vanderbilt University, USA.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'School of Medicine, Vanderbilt University, USA.'}, {'ForeName': 'Ally', 'Initials': 'A', 'LastName': 'Qi', 'Affiliation': 'Department of Pediatrics, Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Lauren R', 'Initials': 'LR', 'LastName': 'Samuels', 'Affiliation': 'Department of Biostatistics, Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Marcy', 'Initials': 'M', 'LastName': 'Singer-Gabella', 'Affiliation': 'Peabody College of Education and Human Development, Vanderbilt University, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2018.08.006'] 581,31972848,Health Literacy and Outcomes of a Community-Based Self-Help Intervention: A Case of Korean Americans With Type 2 Diabetes.,"BACKGROUND Although scientific reports increasingly document the negative impact of inadequate health literacy on health-seeking behaviors, health literacy's effect on health outcomes in patients with diabetes is not entirely clear, owing to insufficient empirical studies, mixed findings, and insufficient longitudinal research. OBJECTIVE The aim of this study was to empirically examine underlying mechanisms of health literacy's role in diabetes management among a group of Korean Americans with Type 2 diabetes mellitus. METHODS Data from a randomized clinical trial of a health literacy-focused Type 2 diabetes self-management intervention conducted during 2012-2016 in the Korean American community were collected at baseline and at 3, 6, 9, and 12 months. A total of 250 Korean Americans with Type 2 diabetes participated (intervention, 120; control, 130). Participants were first-generation Korean American immigrants. Health literacy knowledge was measured with the original Rapid Estimate of Adult Literacy in Medicine and the diabetes mellitus-specific Rapid Estimate of Adult Literacy in Medicine. Functional health literacy was measured with the numeracy subscale of the Test of Functional Health Literacy in Adults and the Newest Vital Sign screening instrument, which also uses numeracy. Primary outcomes included glucose control and diabetes quality of life. Multivariate analyses included latent variable modeling. RESULTS A series of path analyses identified self-efficacy and self-care skills as significant mediators between health literacy and glucose control and quality of life. Education and acculturation were the most significant correlates of health literacy. DISCUSSION Despite inconsistent findings in the literature, this study indicates that health literacy may indirectly influence health outcomes through mediators such as self-care skills and self-efficacy. The study highlights the importance of health literacy, as well as underlying mechanisms with which health literacy influences processes and outcomes of diabetes self-management.",2020,A series of path analyses identified self-efficacy and self-care skills as significant mediators between health literacy and glucose control and quality of life.,"['Korean Americans with Type 2 Diabetes', 'patients with diabetes', '250 Korean Americans with type 2 diabetes participated (intervention, 120; control, 130', 'Korean Americans with type 2 diabetes mellitus', 'Participants were first-generation Korean American immigrants']","['health literacy-focused type 2 diabetes self-management intervention', 'Community-Based Self-Help Intervention']","['glucose control and diabetes quality of life', 'health literacy', 'Health literacy knowledge', 'Functional health literacy', 'health literacy and glucose control and quality of life']","[{'cui': 'C1556095', 'cui_str': 'Koreans'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0597921', 'cui_str': 'Korean Americans'}, {'cui': 'C0282163', 'cui_str': 'Immigrants'}]","[{'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0036588', 'cui_str': 'Self'}]","[{'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0034380'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}]",250.0,0.0347658,A series of path analyses identified self-efficacy and self-care skills as significant mediators between health literacy and glucose control and quality of life.,"[{'ForeName': 'Miyong T', 'Initials': 'MT', 'LastName': 'Kim', 'Affiliation': 'Miyong T. Kim, PhD, RN, FAAN, is Professor, School of Nursing, The University of Texas at Austin. Kim B. Kim, PhD, is President, Korean Resource Center, Ellicott City, Maryland. Jisook Ko, PhD, RN, is Assistant Professor, The University of Texas Health Science Center at San Antonio. Nicole Murry, RN, PhD, is Assistant Professor, School of Nursing, The University of Texas at Austin. Bo Xie, PhD, is Professor, School of Nursing, The University of Texas at Austin. Kavita Radhakrishnan, RN, PhD, is Associate Professor, School of Nursing, The University of Texas at Austin. Hae-Ra Han, PhD, RN, FAAN, is Professor, Johns Hopkins University School of Nursing, Baltimore, Maryland.'}, {'ForeName': 'Kim B', 'Initials': 'KB', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Jisook', 'Initials': 'J', 'LastName': 'Ko', 'Affiliation': ''}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Murry', 'Affiliation': ''}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Xie', 'Affiliation': ''}, {'ForeName': 'Kavita', 'Initials': 'K', 'LastName': 'Radhakrishnan', 'Affiliation': ''}, {'ForeName': 'Hae-Ra', 'Initials': 'HR', 'LastName': 'Han', 'Affiliation': ''}]",Nursing research,['10.1097/NNR.0000000000000409'] 582,32144056,Ultrasound-Guided Erector Spinae Plane Block Versus Intercostal Nerve Block for Post-Minithoracotomy Acute Pain Management: A Randomized Controlled Trial.,"OBJECTIVE Several nerve block procedures are available for post-thoracotomy pain management. DESIGN In this randomized trial, the authors aimed to determine whether the analgesic effect of preoperative ultrasound-guided erector spinae plane block (ESPB) might be superior to that of intraoperative intercostal nerve block (ICNB) in pain control in patients undergoing minithoracotomy. SETTING University hospital. PARTICIPANTS Sixty consecutive adult patients scheduled to undergo minithoracotomy for lung resection were enrolled. INTERVENTIONS Patients were allocated randomly in a 1:1 ratio to receive either single-shot ESPB or ICNB. MEASUREMENTS AND MAIN RESULTS The primary outcome was the intensity of postoperative pain at rest, assessed with the numeric rating scale (NRS). The secondary outcomes were (1) dynamic NRS values (during cough); (2) perioperative analgesic requirements; (3) patient satisfaction, on the basis of a verbal scale (Likert scale); and (4) respiratory muscle strength, considering the maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) variation from baseline. The ESPB group showed lower postoperative static and dynamic NRS values than the ICNB group (p < 0.05). Total remifentanil consumption and requirements for additional analgesics were lower in the ESPB group (p < 0.05). Patient satisfaction was higher in the ESPB group (p < 0.001). A significant overall time effect was found in MIP and MEP variation (p < 0.001); ESPB values were higher at all points, reaching a statistically significant level at the first and sixth hours for MIP, and at the first, 12th, 24th, and 48th hours for MEP (p < 0.05). CONCLUSIONS ESPB was demonstrated to provide superior analgesia, lower perioperative analgesic requirements, better patient satisfaction, and less respiratory muscle strength impairment than ICNB in patients undergoing minithoracotomy.",2020,Total remifentanil consumption and requirements for additional analgesics were lower in the ESPB group (p < 0.05).,"['patients undergoing minithoracotomy', 'Sixty consecutive adult patients scheduled to undergo minithoracotomy for lung resection were enrolled', 'University hospital']","['single-shot ESPB or ICNB', 'intraoperative intercostal nerve block (ICNB', 'ICNB', 'ESPB', 'preoperative ultrasound-guided erector spinae plane block (ESPB', 'Ultrasound-Guided Erector Spinae Plane Block Versus Intercostal Nerve Block']","['intensity of postoperative pain at rest, assessed with the numeric rating scale (NRS', 'ESPB values', 'postoperative static and dynamic NRS values', 'Total remifentanil consumption and requirements for additional analgesics', 'dynamic NRS values (during cough); (2) perioperative analgesic requirements; (3) patient satisfaction, on the basis of a verbal scale (Likert scale); and (4) respiratory muscle strength, considering the maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) variation', 'MIP and MEP variation', 'Patient satisfaction']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0405917', 'cui_str': 'Minithoracotomy (procedure)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0196716', 'cui_str': 'Local anesthetic intercostal nerve block (procedure)'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}]","[{'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0443144', 'cui_str': 'At rest (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0441463', 'cui_str': 'Static (qualifier value)'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C1626935', 'cui_str': 'Base'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0451267', 'cui_str': 'Likert scale (assessment scale)'}, {'cui': 'C0035231', 'cui_str': 'Ventilatory Muscles'}, {'cui': 'C0232021', 'cui_str': 'Maximum inspiratory pressure (observable entity)'}, {'cui': 'C0232022', 'cui_str': 'Maximum expiratory pressure (observable entity)'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}]",60.0,0.14122,Total remifentanil consumption and requirements for additional analgesics were lower in the ESPB group (p < 0.05).,"[{'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Fiorelli', 'Affiliation': ""Anesthesia and Intensive Care Medicine, Department of Clinical and Surgical Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy. Electronic address: silvia.fiorelli@uniroma1.it.""}, {'ForeName': 'Giulio', 'Initials': 'G', 'LastName': 'Leopizzi', 'Affiliation': ""Anesthesia and Intensive Care Medicine, Department of Clinical and Surgical Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.""}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Menna', 'Affiliation': ""Thoracic Surgery, Department of Clinical and Surgical Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.""}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Teodonio', 'Affiliation': ""Thoracic Surgery, Department of Clinical and Surgical Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.""}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Ibrahim', 'Affiliation': ""Thoracic Surgery, Department of Clinical and Surgical Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.""}, {'ForeName': 'Erino Angelo', 'Initials': 'EA', 'LastName': 'Rendina', 'Affiliation': ""Thoracic Surgery, Department of Clinical and Surgical Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.""}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Ricci', 'Affiliation': ""Department of Clinical and Molecular Medicine, Division of Respiratory Diseases, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.""}, {'ForeName': 'Roberto Alberto', 'Initials': 'RA', 'LastName': 'De Blasi', 'Affiliation': ""Anesthesia and Intensive Care Medicine, Department of Clinical and Surgical Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.""}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Rocco', 'Affiliation': ""Anesthesia and Intensive Care Medicine, Department of Clinical and Surgical Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.""}, {'ForeName': 'Domenico', 'Initials': 'D', 'LastName': 'Massullo', 'Affiliation': ""Anesthesia and Intensive Care Medicine, Department of Clinical and Surgical Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.""}]",Journal of cardiothoracic and vascular anesthesia,['10.1053/j.jvca.2020.01.026'] 583,29741576,Cluster-Randomized Test-Negative Design Trials: A Novel and Efficient Method to Assess the Efficacy of Community-Level Dengue Interventions.,"Cluster-randomized controlled trials are the gold standard for assessing efficacy of community-level interventions, such as vector-control strategies against dengue. We describe a novel cluster-randomized trial methodology with a test-negative design (CR-TND), which offers advantages over traditional approaches. This method uses outcome-based sampling of patients presenting with a syndrome consistent with the disease of interest, who are subsequently classified as test-positive cases or test-negative controls on the basis of diagnostic testing. We used simulations of a cluster trial to demonstrate validity of efficacy estimates under the test-negative approach. We demonstrated that, provided study arms are balanced for both test-negative and test-positive illness at baseline and that other test-negative design assumptions are met, the efficacy estimates closely match true efficacy. Analytical considerations for an odds ratio-based effect estimate arising from clustered data and potential approaches to analysis are also discussed briefly. We concluded that application of the test-negative design to certain cluster-randomized trials could increase their efficiency and ease of implementation.",2018,"Cluster-randomized controlled trials are the gold standard for assessing efficacy of community-level interventions, such as vector-control strategies against dengue.","['patients presenting with a syndrome consistent with the disease of interest, who are subsequently classified as test-positive cases or test-negative controls on the basis of diagnostic testing']",['test-negative design (CR-TND'],[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0332290', 'cui_str': 'Consistent with (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0008902', 'cui_str': 'Systematics'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1626935', 'cui_str': 'Base'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}]","[{'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}]",[],,0.0774177,"Cluster-randomized controlled trials are the gold standard for assessing efficacy of community-level interventions, such as vector-control strategies against dengue.","[{'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': 'Anders', 'Affiliation': 'Institute of Vector-Borne Disease, Monash University, Melbourne, Australia.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Cutcher', 'Affiliation': 'Institute of Vector-Borne Disease, Monash University, Melbourne, Australia.'}, {'ForeName': 'Immo', 'Initials': 'I', 'LastName': 'Kleinschmidt', 'Affiliation': 'MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Christl A', 'Initials': 'CA', 'LastName': 'Donnelly', 'Affiliation': 'MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, United Kingdom.'}, {'ForeName': 'Neil M', 'Initials': 'NM', 'LastName': 'Ferguson', 'Affiliation': 'MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, United Kingdom.'}, {'ForeName': 'Citra', 'Initials': 'C', 'LastName': 'Indriani', 'Affiliation': 'Centre for Tropical Medicine, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Ryan', 'Affiliation': 'Institute of Vector-Borne Disease, Monash University, Melbourne, Australia.'}, {'ForeName': 'Scott L', 'Initials': 'SL', 'LastName': ""O'Neill"", 'Affiliation': 'Institute of Vector-Borne Disease, Monash University, Melbourne, Australia.'}, {'ForeName': 'Nicholas P', 'Initials': 'NP', 'LastName': 'Jewell', 'Affiliation': 'Department of Statistics, School of Public Health, University of California, Berkeley, Berkeley, California.'}, {'ForeName': 'Cameron P', 'Initials': 'CP', 'LastName': 'Simmons', 'Affiliation': 'Institute of Vector-Borne Disease, Monash University, Melbourne, Australia.'}]",American journal of epidemiology,['10.1093/aje/kwy099'] 584,32406581,"Effect of a water, sanitation and hygiene program on handwashing with soap among household members of diarrhoea patients in healthcare facilities in Bangladesh: a cluster-randomised controlled trial of the CHoBI7 mobile health program.","OBJECTIVE The Cholera-Hospital-Based-Intervention-for-7-days (CHoBI7) is a water treatment and handwashing with soap intervention for diarrhoea patients and their household members which is initially delivered in a healthcare facility setting. This study evaluated the effectiveness of CHoBI7 program delivery in increasing handwashing with soap in a healthcare facility setting among diarrhoea patients and their household members. METHODS A randomised controlled trial of the CHoBI7 program was conducted among 404 diarrhoea patients and their accompanying household members in healthcare facilities in Dhaka, Bangladesh. The 'Standard Message' Arm received the standard message given in Bangladesh to diarrhoea patients on the use of oral rehydration solution. The 'Health Facility Visit + Soapy Water' Arm received the standard message, the CHoBI7 communication module delivered bedside to the patient; and a soapy water bottle in the healthcare facility. The 'Health Facility Visit + Handwashing Station' Arm received this same intervention plus a small plastic handwashing station. Within 24 h of intervention delivery, three-hour structured observation of handwashing practices at stool/vomit- and food-related events (key events) was conducted in healthcare facilities of diarrhoea patients and their accompanying household members. RESULTS Compared to the Standard Message Arm, there was significantly more handwashing with soap at key events in both the Health Facility Visit + Soapy Water Arm (51% vs. 25 %) (Odds Ratio: 3.02; (95% Confidence Interval (CI): 1.41, 6.45) and the Health Facility Visit + Handwashing Station Arm (58% vs. 25%) OR: 4.12; (95% CI: 1.86, 9.14). CONCLUSION These findings demonstrate that delivery of the CHoBI7 communication module and provision of a soapy water bottle to diarrhoea patients and their accompanying household members presents a promising approach to increase handwashing with soap among this high risk population in a healthcare facility setting in Bangladesh.",2020,"Compared to the Standard Message Arm, there was significantly more handwashing with soap at key events in both the Health Facility Visit + Handwashing Station Arm (58% vs. 25%)","['404 diarrhea patients and their accompanying household members in health facilities in Dhaka, Bangladesh', 'Handwashing with Soap among Household Members of Diarrhea Patients in Health Facilities in Bangladesh']","['CHoBI7 program delivery', 'Water, Sanitation, and Hygiene Program', 'Cholera-Hospital-Based-Intervention-for-7-days (CHoBI7', 'CHoBI7 program']",['Health Facility Visit + Soapy Water Arm'],"[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C0037392', 'cui_str': 'Soap'}]","[{'cui': 'C0008354', 'cui_str': 'Cholera'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0036172', 'cui_str': 'Sanitation'}, {'cui': 'C0020405', 'cui_str': 'Hygiene'}]","[{'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]",404.0,0.0475223,"Compared to the Standard Message Arm, there was significantly more handwashing with soap at key events in both the Health Facility Visit + Handwashing Station Arm (58% vs. 25%)","[{'ForeName': 'Fatema', 'Initials': 'F', 'LastName': 'Zohura', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Md Sazzadul Islam', 'Initials': 'MSI', 'LastName': 'Bhuyian', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Ronald E', 'Initials': 'RE', 'LastName': 'Saxton', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Tahmina', 'Initials': 'T', 'LastName': 'Parvin', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Shirajum', 'Initials': 'S', 'LastName': 'Monira', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Shwapon K', 'Initials': 'SK', 'LastName': 'Biswas', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Jahed', 'Initials': 'J', 'LastName': 'Masud', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Sharika', 'Initials': 'S', 'LastName': 'Nuzhat', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Nowshin', 'Initials': 'N', 'LastName': 'Papri', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'M Tasdik', 'Initials': 'MT', 'LastName': 'Hasan', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Elizabeth D', 'Initials': 'ED', 'LastName': 'Thomas', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Sack', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Perin', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Munirul', 'Initials': 'M', 'LastName': 'Alam', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Christine Marie', 'Initials': 'CM', 'LastName': 'George', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}]",Tropical medicine & international health : TM & IH,['10.1111/tmi.13416'] 585,32123242,Does resistance training have an effect on levels of ferritin and atherogenic lipids in postmenopausal women? - A pilot trial.,"The objective of this study was to determine if 15 weeks of resistance training (RT) can alter the levels of blood lipids, body iron status, and oxidative stress in postmenopausal women with vasomotor symptoms. Postmenopausal women enrolled in a randomised controlled trial were allocated to either a sedentary control group (n = 29) or a RT group (n = 26). Blood samples were taken at week-0 and week-15 for all participants. Blood lipids and iron status were measured via routine clinical analyses. Immunoassays were used to measure oxidative stress markers. The RT group, with good compliance, was associated with significant reductions in ferritin, total cholesterol, low-density lipoprotein, and non-high-density lipoprotein cholesterol. Moreover, ferritin was positively correlated with atherogenic lipids while negatively correlated with high-density lipoprotein in RT women. This occurred without alterations in serum iron, transferrin, transferrin-saturation, C-reactive protein and oxidative stress markers. No differences were found in control women. This study suggests that RT in postmenopausal women both reduces levels of ferritin and counteracts atherogenic lipid profiles independent of an apparent oxidative mechanism. RT may be a beneficial intervention in postmenopausal women via an interaction between ferritin and lipids; however, further investigation in a larger cohort is essential.",2020,"The RT group, with good compliance, was associated with significant reductions in ferritin, total cholesterol, low-density lipoprotein, and non-high-density lipoprotein cholesterol.","['postmenopausal women', 'postmenopausal women with vasomotor symptoms', 'Postmenopausal women']","['sedentary control group (n\u2009=\u200929) or a RT', 'resistance training (RT']","['levels of ferritin and atherogenic lipids', 'levels of blood lipids, body iron status, and oxidative stress', 'atherogenic lipids', 'oxidative stress markers', 'Blood lipids and iron status', 'serum iron, transferrin, transferrin-saturation, C-reactive protein and oxidative stress markers', 'ferritin, total cholesterol, low-density lipoprotein, and non-high-density lipoprotein\xa0cholesterol']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0373607', 'cui_str': 'Ferritin measurement (procedure)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0005768'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C1318312', 'cui_str': 'Serum iron measurement'}, {'cui': 'C0040679', 'cui_str': 'beta-1 Metal-Binding Globulin'}, {'cui': 'C1277709', 'cui_str': 'Transferrin saturation index (procedure)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0729627', 'cui_str': 'Non-HDL cholesterol'}]",,0.105155,"The RT group, with good compliance, was associated with significant reductions in ferritin, total cholesterol, low-density lipoprotein, and non-high-density lipoprotein cholesterol.","[{'ForeName': 'Liam J', 'Initials': 'LJ', 'LastName': 'Ward', 'Affiliation': 'Department of Obstetrics and Gynaecology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. liam.ward@liu.se.'}, {'ForeName': 'Mats', 'Initials': 'M', 'LastName': 'Hammar', 'Affiliation': 'Department of Obstetrics and Gynaecology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Lotta', 'Initials': 'L', 'LastName': 'Lindh-Åstrand', 'Affiliation': 'Department of Obstetrics and Gynaecology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Emilia', 'Initials': 'E', 'LastName': 'Berin', 'Affiliation': 'Department of Obstetrics and Gynaecology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Lindblom', 'Affiliation': 'Department of Health, Medicine and Caring Sciences, Unit of Physiotherapy, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Rubér', 'Affiliation': 'Department of Obstetrics and Gynaecology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Anna-Clara', 'Initials': 'AC', 'LastName': 'Spetz Holm', 'Affiliation': 'Department of Obstetrics and Gynaecology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Department of Obstetrics and Gynaecology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. wei.li@liu.se.'}]",Scientific reports,['10.1038/s41598-020-60759-z'] 586,32132832,Effects of Swimming with Added Respiratory Dead Space on Cardiorespiratory Fitness and Lipid Metabolism.,"The aim of this study was to investigate the circulatory, respiratory, and metabolic effects of induced hypercapnia via added respiratory dead space (ARDS) during moderate-intensity swimming in recreational swimmers. A mixed-sex sample of 22 individuals was divided into homogeneous experimental (E) and control (C) groups controlled for maximal oxygen uptake (VO 2 max). The intervention involved 50 min of front crawl swimming performed at 60% VO 2 max twice weekly for 6 consecutive weeks. ARDS was induced via tube breathing (1000 ml) in group E. An incremental exercise test was administered pre- and post-intervention to assess cardiorespiratory fitness (CRF) by measuring VO 2 max, carbon dioxide volume, respiratory minute ventilation, respiratory exchange ratio (RER), and heart rate at 50, 100, 150, 200 W and at maximal workload. Body mass index (BMI), fat mass (FM), and fat-free mass (FFM) were also measured. The mean difference in glycerol concentration (ΔGLY) was assessed after the first and last swimming session. No significant between-group differences were observed at post-intervention. No within-group differences were observed at post-intervention except for RER which increased in group E at maximal workload. A 6-week swimming intervention with ARDS did not enhance CRF. The RER increase in group E is not indicative of a substrate shift towards increased lipid utilization. No change in ΔGLY is evident of a lack of enhanced triglyceride hydrolyzation that was also confirmed by similar pre- and post-intervention BMI, FM, and FMM.",2020,No within-group differences were observed at post-intervention except for RER which increased in group E at maximal workload.,"['22 individuals', 'recreational swimmers']","['induced hypercapnia via added respiratory dead space (ARDS', 'Swimming with Added Respiratory Dead Space', 'ARDS was induced via tube breathing']","['Body mass index (BMI), fat mass (FM), and fat-free mass (FFM', 'glycerol concentration (ΔGLY', 'Cardiorespiratory Fitness and Lipid Metabolism', 'cardiorespiratory fitness (CRF) by measuring VO 2 max, carbon dioxide volume, respiratory minute ventilation, respiratory exchange ratio (RER), and heart rate', 'triglyceride hydrolyzation', 'RER', 'lipid utilization']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0450068', 'cui_str': 'Swimmer (person)'}]","[{'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0020440', 'cui_str': 'Hypercapnia'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0035218', 'cui_str': 'Respiratory Dead Space'}, {'cui': 'C0035222', 'cui_str': 'ARDS, Human'}, {'cui': 'C4318415', 'cui_str': 'Tube (unit of presentation)'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}]","[{'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass (observable entity)'}, {'cui': 'C0017861', 'cui_str': 'Glycerin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C1301655', 'cui_str': 'Minute ventilation'}, {'cui': 'C0429702', 'cui_str': 'Respiratory quotient (observable entity)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0042153', 'cui_str': 'use'}]",,0.0561001,No within-group differences were observed at post-intervention except for RER which increased in group E at maximal workload.,"[{'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Szczepan', 'Affiliation': 'Department of Swimming, University School of Physical Education in Wroclaw, Poland.'}, {'ForeName': 'Kamil', 'Initials': 'K', 'LastName': 'Michalik', 'Affiliation': 'Department of Physiology and Biochemistry, University School of Physical Education in Wroclaw, Poland.'}, {'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Borkowski', 'Affiliation': 'Department of Physiology and Biochemistry, University School of Physical Education in Wroclaw, Poland.'}, {'ForeName': 'Krystyna', 'Initials': 'K', 'LastName': 'Zatoń', 'Affiliation': 'Department of Swimming, University School of Physical Education in Wroclaw, Poland.'}]",Journal of sports science & medicine,[] 587,31926328,Long-term results of a randomized clinical trial comparing endoscopic versus conventional treatment of pilonidal sinus.,"BACKGROUND In the new era of minimally invasive surgery, recent studies encouraged the adoption of endoscopic approaches as the most effective way to treat (pilonidal sinus disease) PSD but little is known about long-term results of minimally invasive procedures. MATERIALS AND METHODS A total of 145 patients with chronic non recurrent pilonidal sinus were enrolled for this randomized controlled trial. The follow-up rate was 97% at 5 years for a total of 74 patients assigned to the minimally invasive treatment group and 67 patients assigned to the conventional Bascom cleft lift treatment group. We evaluated the following outcomes: long-term recurrence rate, patients' satisfaction, cosmetic outcome and cost-effectiveness results. RESULTS Long-term data confirm that the recurrence rate was similar in both groups and, in minimally invasive patients, there were a higher satisfaction and better cosmetic results. Costs analysis revealed improved outcome in favour of VAAPS with a much lower mean global cost. CONCLUSION Minimally invasive treatment has all the characteristics of an ideal approach to PSD with advantages including minimal patient inconveniences, high satisfaction and good aesthetics results. It was also more cost effective to carry out the treatment.",2020,The follow-up rate was 97% at 5 years for a total of 74 patients assigned to the minimally invasive treatment group and 67 patients assigned to the conventional Bascom cleft lift treatment group.,"['pilonidal sinus', '145 patients with chronic non recurrent pilonidal sinus']","['endoscopic', 'conventional Bascom cleft lift treatment group']","[""recurrence rate, patients' satisfaction, cosmetic outcome and cost-effectiveness results"", 'cost effective', 'mean global cost', 'recurrence rate']","[{'cui': 'C0031925', 'cui_str': 'Pilonidal Cyst'}, {'cui': 'C4517577', 'cui_str': '145'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0181620', 'cui_str': 'Lift'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0442965', 'cui_str': 'Cosmetic procedure (qualifier value)'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}]",145.0,0.0375773,The follow-up rate was 97% at 5 years for a total of 74 patients assigned to the minimally invasive treatment group and 67 patients assigned to the conventional Bascom cleft lift treatment group.,"[{'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Milone', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University of Naples, Via Sergio Pansini, 5, 80131, Naples, Italy. Electronic address: milone.marco.md@gmail.com.'}, {'ForeName': 'Nunzio', 'Initials': 'N', 'LastName': 'Velotti', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University of Naples, Via Sergio Pansini, 5, 80131, Naples, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Manigrasso', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University of Naples, Via Sergio Pansini, 5, 80131, Naples, Italy.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Vertaldi', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University of Naples, Via Sergio Pansini, 5, 80131, Naples, Italy.'}, {'ForeName': 'Katia', 'Initials': 'K', 'LastName': 'Di Lauro', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University of Naples, Via Sergio Pansini, 5, 80131, Naples, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'De Simone', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University of Naples, Via Sergio Pansini, 5, 80131, Naples, Italy.'}, {'ForeName': 'Vera', 'Initials': 'V', 'LastName': 'Cirillo', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University of Naples, Via Sergio Pansini, 5, 80131, Naples, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Maione', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University of Naples, Via Sergio Pansini, 5, 80131, Naples, Italy.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Gennarelli', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University of Naples, Via Sergio Pansini, 5, 80131, Naples, Italy.'}, {'ForeName': 'Loredana Maria', 'Initials': 'LM', 'LastName': 'Sosa Fernandez', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University of Naples, Via Sergio Pansini, 5, 80131, Naples, Italy.'}, {'ForeName': 'Giovanni Domenico', 'Initials': 'GD', 'LastName': 'De Palma', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University of Naples, Via Sergio Pansini, 5, 80131, Naples, Italy.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2019.12.033'] 588,31393518,Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.,"Importance Patients with estrogen receptor (ER)-positive breast cancer have a long-term risk for fatal disease. However, the tumor biological factors that influence the long-term risk and the benefit associated with endocrine therapy are not well understood. Objective To compare the long-term survival from tamoxifen therapy for patients with luminal A or luminal B tumor subtype. Design, Setting, and Participants Secondary analysis of patients from the Stockholm Tamoxifen (STO-3) trial conducted from 1976 to 1990, which randomized postmenopausal patients with lymph node-negative breast cancer to receive adjuvant tamoxifen or no endocrine therapy. Tumor tissue sections were assessed in 2014 using immunohistochemistry and Agilent microarrays. Only patients with luminal A or B subtype tumors were evaluated. Complete long-term follow-up data up to the end of the STO-3 trial on December 31, 2012, were obtained from the Swedish National registers. Data analysis for the secondary analysis was conducted in 2017 and 2018. Interventions Patients were randomized to receive at least 2 years of tamoxifen therapy or no endocrine therapy; patients without recurrence who reconsented were further randomized to 3 additional years of tamoxifen therapy or no endocrine therapy. Main Outcomes and Measures Distant recurrence-free interval (DRFI) by luminal A and luminal B subtype and trial arm was assessed by Kaplan-Meier analyses and time-dependent flexible parametric models to estimate time-varying hazard ratios (HRs) that were adjusted for patient and tumor characteristics. Results In the STO-3 treated trial arm, 183 patients had luminal A tumors and 64 patients had luminal B tumors. In the untreated arm, 153 patients had luminal A tumors and 62 had luminal B tumors. Age at diagnosis ranged from 45 to 73 years. A statistically significant difference in DRFI by trial arm was observed (log rank, P < .001 [luminal A subtype, n = 336], P = .04 [luminal B subtype, n = 126]): the 25-year DRFI for luminal A vs luminal B subtypes was 87% (95% CI, 82%-93%) vs 67% (95% CI, 56%-82%) for treated patients, and 70% (95 % CI, 62%-79%) vs 54% (95% CI, 42%-70%) for untreated patients, respectively. Patients with luminal A tumors significantly benefited from tamoxifen therapy for 15 years after diagnosis (HR, 0.57; 95% CI, 0.35-0.94), and those with luminal B tumors benefited from tamoxifen therapy for 5 years (HR, 0.38; 95% CI, 0.24-0.59). Conclusions and Relevance Patients with luminal A subtype tumors had a long-term risk of distant metastatic disease, which was reduced by tamoxifen treatment, whereas patients with luminal B tumors had an early risk of distant metastatic disease, and tamoxifen benefit attenuated over time.",2019,"A statistically significant difference in DRFI by trial arm was observed (log rank, P < .001","['Only patients with luminal A or B subtype tumors', 'Postmenopausal Patients', 'STO-3) trial conducted from 1976 to 1990, which randomized postmenopausal patients with lymph node-negative breast cancer to receive', 'patients without recurrence who reconsented', '183 patients had luminal A tumors and 64 patients had luminal B tumors', '153 patients had luminal A tumors and 62 had luminal B tumors', 'Importance\n\n\nPatients with estrogen receptor (ER)-positive breast cancer', 'patients with luminal A or luminal B tumor subtype', 'luminal B subtype, n\u2009=\u2009126']","['adjuvant tamoxifen or no endocrine therapy', 'tamoxifen therapy', 'tamoxifen', 'Tamoxifen Therapy', 'Stockholm Tamoxifen', 'tamoxifen therapy or no endocrine therapy']","['Tumor tissue sections', 'Measures\n\n\nDistant recurrence-free interval (DRFI) by luminal A and luminal B subtype and trial arm was assessed by Kaplan-Meier analyses and time-dependent flexible parametric models to estimate time-varying hazard ratios (HRs', 'DRFI']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0699493', 'cui_str': 'Luminal'}, {'cui': 'C0449560', 'cui_str': 'Subtype (attribute)'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0024204', 'cui_str': 'Lymphatic gland'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C4517615', 'cui_str': 'One hundred and eighty-three'}, {'cui': 'C2938924', 'cui_str': 'Oestrogen receptor positive breast cancer'}]","[{'cui': 'C0039286', 'cui_str': 'Tamoxifen'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy (procedure)'}, {'cui': 'C4510392', 'cui_str': 'Tamoxifen therapy'}]","[{'cui': 'C0475358', 'cui_str': 'Tumor tissue sample (specimen)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0443203', 'cui_str': 'Distant (qualifier value)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0699493', 'cui_str': 'Luminal'}, {'cui': 'C0449560', 'cui_str': 'Subtype (attribute)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0443220', 'cui_str': 'Flexible (qualifier value)'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",183.0,0.255489,"A statistically significant difference in DRFI by trial arm was observed (log rank, P < .001","[{'ForeName': 'Nancy Y', 'Initials': 'NY', 'LastName': 'Yu', 'Affiliation': 'Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Adina', 'Initials': 'A', 'LastName': 'Iftimi', 'Affiliation': 'Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Yau', 'Affiliation': 'Department of Surgery, University of California, San Francisco, San Francisco.'}, {'ForeName': 'Nicholas P', 'Initials': 'NP', 'LastName': 'Tobin', 'Affiliation': 'Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': ""van 't Veer"", 'Affiliation': 'Department of Laboratory Medicine, University of California, San Francisco, San Francisco.'}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Hoadley', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill.'}, {'ForeName': 'Christopher C', 'Initials': 'CC', 'LastName': 'Benz', 'Affiliation': 'Buck Institute for Research on Aging, Novato, California.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Nordenskjöld', 'Affiliation': 'Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Tommy', 'Initials': 'T', 'LastName': 'Fornander', 'Affiliation': 'Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Olle', 'Initials': 'O', 'LastName': 'Stål', 'Affiliation': 'Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Kamila', 'Initials': 'K', 'LastName': 'Czene', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Esserman', 'Affiliation': 'Department of Surgery, University of California, San Francisco, San Francisco.'}, {'ForeName': 'Linda S', 'Initials': 'LS', 'LastName': 'Lindström', 'Affiliation': 'Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.'}]",JAMA oncology,['10.1001/jamaoncol.2019.1856'] 589,31969343,Economic Evaluation of Tailored Web versus Tailored Telephone-Based Interventions to Increase Colorectal Cancer Screening among Women.,"Screening for colorectal cancer is cost-effective, but many U.S. women are nonadherent, and the cost-effectiveness of web-based tailored screening interventions is unknown. A randomized controlled trial, COBRA (Increasing Colorectal and Breast Cancer Screening), was the source of information for the economic evaluation. COBRA compared screening among a Usual Care group to: (i) tailored Phone Counseling intervention; (ii) tailored Web intervention; and (iii) tailored Web + Phone intervention groups. A sample of 1,196 women aged 50 to 75 who were nonadherent to colorectal cancer screening were recruited from Indiana primary care clinics during 2013 to 2015. Screening status was obtained through medical records at recruitment with verbal confirmation at consent, and at 6-month follow-up via medical record audit and participant self-report. A ""best sample"" analysis and microcosting from the patient and provider perspectives were applied to estimate the costs and effects of the interventions. Statistical uncertainty was analyzed with nonparametric bootstrapping and net benefit regression analysis. The per participant cost of implementing the Phone Counseling, Web-based, and Web + Phone Counseling interventions was $277, $314, and $336, respectively. The incremental cost per person screened for the Phone Counseling compared with no intervention was $995, while the additional cost of Web and the Web + Phone compared with Phone Counseling did not yield additonal persons screened. Tailored Phone Counseling significantly increased colorectal cancer screening rates compared with Usual Care. Tailored Web interventions did not improve the screening rate compared with the lower cost Phone Counseling intervention.",2020,Tailored Phone Counseling significantly increased CRC screening rates compared to Usual Care.,"['1196 women aged 50-75 who were non-adherent to CRC screening were recruited from Indiana primary care clinics during 2013-2015', 'colorectal cancer (CRC']","['Tailored Phone Counseling', 'Phone Counseling intervention, 2) tailored Web intervention, and 3) tailored Web + Phone intervention groups', 'COBRA']","['CRC screening rates', 'screening rate']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0170127', 'cui_str': 'Calcibiotic Root Canal Sealer'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0021206', 'cui_str': 'Indiana'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic (environment)'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}]","[{'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0206326', 'cui_str': 'Cobra'}]","[{'cui': 'C0170127', 'cui_str': 'Calcibiotic Root Canal Sealer'}, {'cui': 'C0220908', 'cui_str': 'Screening'}]",1196.0,0.0287479,Tailored Phone Counseling significantly increased CRC screening rates compared to Usual Care.,"[{'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Lairson', 'Affiliation': 'School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas. David.R.Lairson@uth.tmc.edu.'}, {'ForeName': 'Tong Han', 'Initials': 'TH', 'LastName': 'Chung', 'Affiliation': 'School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas.'}, {'ForeName': 'Danmeng', 'Initials': 'D', 'LastName': 'Huang', 'Affiliation': 'School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas.'}, {'ForeName': 'Timothy E', 'Initials': 'TE', 'LastName': 'Stump', 'Affiliation': 'Indiana University School of Medicine, Indianapolis, Indiana.'}, {'ForeName': 'Patrick O', 'Initials': 'PO', 'LastName': 'Monahan', 'Affiliation': 'Indiana University School of Medicine, Indianapolis, Indiana.'}, {'ForeName': 'Shannon M', 'Initials': 'SM', 'LastName': 'Christy', 'Affiliation': 'Division of Population Science, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.'}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Rawl', 'Affiliation': 'Indiana University Simon Cancer Center, Indianapolis, Indiana.'}, {'ForeName': 'Victoria L', 'Initials': 'VL', 'LastName': 'Champion', 'Affiliation': 'Indiana University Simon Cancer Center, Indianapolis, Indiana.'}]","Cancer prevention research (Philadelphia, Pa.)",['10.1158/1940-6207.CAPR-19-0376'] 590,32123197,"fMRI Revealed Reduced Amygdala Activation after Nx4 in Mildly to Moderately Stressed Healthy Volunteers in a Randomized, Placebo-Controlled, Cross-Over Trial.","Social stress contributes to major societal health burdens, such as anxiety disorders and nervousness. Nx4 has been found to modulate stress responses. We investigated whether dampening of such responses is associated with neuronal correlates in brain regions involved in stress and anxiety. In a randomized, placebo-controlled, double-blind, cross-over trial, 39 healthy males took a single dose (three tablets) of either placebo or Nx4, 40 to 60 minutes before an fMRI scan session. We here report on drug effects on amygdala responses during a face-matching task, which was performed during a complex test battery further including resting-state brain connectivity and a social stress experiment. The first of the Primary Outcomes, defined in a hierarchical order, concerned reduced amygdala effects after intake of verum compared to placebo. We found a statistically significant reduction in differential activations in the left amygdala for the contrast negative faces versus forms during verum versus placebo condition. Our results indicate that effects of Nx4 can be monitored in the brain. Previously noted effects on stress responses may thus be modulated by affective brain regions including the amygdala.",2020,We found a statistically significant reduction in differential activations in the left amygdala for the contrast negative faces versus forms during verum versus placebo condition.,['39 healthy males took a single dose (three tablets) of either'],"['placebo', 'fMRI', 'Placebo']","['differential activations', 'stress responses', 'Amygdala Activation']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}]","[{'cui': 'C0443199', 'cui_str': 'Differential (qualifier value)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0002708', 'cui_str': 'Amygdaloid Body'}]",39.0,0.242892,We found a statistically significant reduction in differential activations in the left amygdala for the contrast negative faces versus forms during verum versus placebo condition.,"[{'ForeName': 'Luisa', 'Initials': 'L', 'LastName': 'Herrmann', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, 72076, Germany.'}, {'ForeName': 'Petya', 'Initials': 'P', 'LastName': 'Vicheva', 'Affiliation': 'Clinical Affective Neuroimaging Laboratory (CANLAB), Magdeburg, 39120, Germany.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Kasties', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, 72076, Germany.'}, {'ForeName': 'Lena V', 'Initials': 'LV', 'LastName': 'Danyeli', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, 72076, Germany.'}, {'ForeName': 'Gregor R', 'Initials': 'GR', 'LastName': 'Szycik', 'Affiliation': 'Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hanover, 30625, Germany.'}, {'ForeName': 'Dominik', 'Initials': 'D', 'LastName': 'Denzel', 'Affiliation': 'Clinical Affective Neuroimaging Laboratory (CANLAB), Magdeburg, 39120, Germany.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Fan', 'Affiliation': 'Department of Psychiatry, Charité-CBF, Berlin, 12203, Germany.'}, {'ForeName': 'Johan Van der', 'Initials': 'JV', 'LastName': 'Meer', 'Affiliation': 'QIMR Berghofer Medical Research Institute, Brisbane, 4006, Australia.'}, {'ForeName': 'Johannes C', 'Initials': 'JC', 'LastName': 'Vester', 'Affiliation': 'idv Data Analysis and Study Planning, Krailling, 82152, Germany.'}, {'ForeName': 'Herbert', 'Initials': 'H', 'LastName': 'Eskoetter', 'Affiliation': 'Medical Consultant, Cologne, 50737, Germany.'}, {'ForeName': 'Myron', 'Initials': 'M', 'LastName': 'Schultz', 'Affiliation': 'Heel GmbH, Baden-Baden, 76532, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Walter', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, 72076, Germany. martin.walter@med.ovgu.de.'}]",Scientific reports,['10.1038/s41598-020-60392-w'] 591,32123205,Exercise training results in depot-specific adaptations to adipose tissue mitochondrial function.,"We assessed differences in mitochondrial function in gluteal (gSAT) and abdominal subcutaneous adipose tissue (aSAT) at baseline and in response to 12-weeks of exercise training; and examined depot-specific associations with body fat distribution and insulin sensitivity (S I ). Obese, black South African women (n = 45) were randomized into exercise (n = 23) or control (n = 22) groups. Exercise group completed 12-weeks of aerobic and resistance training (n = 20), while the control group (n = 15) continued usual behaviours. Mitochondrial function (high-resolution respirometry and fluorometry) in gSAT and aSAT, S I (frequently sampled intravenous glucose tolerance test), body composition (dual-energy X-ray absorptiometry), and ectopic fat (MRI) were assessed pre- and post-intervention. At baseline, gSAT had higher mitochondrial respiratory capacity and hydrogen peroxide (H 2 O 2 ) production than aSAT (p < 0.05). Higher gSAT respiration was associated with higher gynoid fat (p < 0.05). Higher gSAT H 2 O 2 production and lower aSAT mitochondrial respiration were independently associated with lower S I (p < 0.05). In response to training, S I improved and gynoid fat decreased (p < 0.05), while H 2 O 2 production reduced in both depots, and mtDNA decreased in gSAT (p < 0.05). Mitochondrial respiration increased in aSAT and correlated with a decrease in body fat and an increase in soleus and hepatic fat content (p < 0.05). This study highlights the importance of understanding the differences in mitochondrial function in multiple SAT depots when investigating the pathophysiology of insulin resistance and associated risk factors such as body fat distribution and ectopic lipid deposition. Furthermore, we highlight the benefits of exercise training in stimulating positive adaptations in mitochondrial function in gluteal and abdominal SAT depots.",2020,"At baseline, gSAT had higher mitochondrial respiratory capacity and hydrogen peroxide (H 2 O 2 ) production than aSAT (p < 0.05).","['Obese, black South African women (n\u2009=\u200945']","['Exercise group completed 12-weeks of aerobic and resistance training (n\u2009=\u200920), while the control group (n\u2009=\u200915) continued usual behaviours', 'Exercise training', 'exercise training']","['Mitochondrial function', 'body fat', 'Mitochondrial respiration', 'mitochondrial\xa0respiratory capacity and hydrogen peroxide (H 2 O 2 ) production', 'Higher gSAT respiration', 'gynoid fat', 'soleus and hepatic fat content', 'Higher gSAT H 2 O 2 production and lower aSAT mitochondrial respiration', 'body composition (dual-energy X-ray absorptiometry), and ectopic fat (MRI', 'mitochondrial function in gluteal (gSAT) and abdominal subcutaneous adipose tissue (aSAT']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}]","[{'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}, {'cui': 'C0020281', 'cui_str': 'Hydrogen Peroxide'}, {'cui': 'C0033268'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0201899', 'cui_str': 'Aspartate aminotransferase measurement (procedure)'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C1510486', 'cui_str': 'Dual X-Ray Absorptiometry'}, {'cui': 'C0340464', 'cui_str': 'Premature Cardiac Complex'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C1563741', 'cui_str': 'Subcutaneous Fat, Abdominal'}]",45.0,0.0203116,"At baseline, gSAT had higher mitochondrial respiratory capacity and hydrogen peroxide (H 2 O 2 ) production than aSAT (p < 0.05).","[{'ForeName': 'Amy E', 'Initials': 'AE', 'LastName': 'Mendham', 'Affiliation': 'Non-communicable Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa. amy.mendham@uct.ac.za.'}, {'ForeName': 'Steen', 'Initials': 'S', 'LastName': 'Larsen', 'Affiliation': 'Center for Healthy Aging, Department of Biomedical Sciences, Copenhagen University, Copenhagen, Denmark.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'George', 'Affiliation': 'Non-communicable Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Adams', 'Affiliation': 'Division of Exercise Science and Sports Medicine, Department of Human Biology, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Hauksson', 'Affiliation': 'Department of Radiation Sciences, Radiation Physics and Biomedical Engineering, Umeå University, Umeå, Sweden.'}, {'ForeName': 'Tommy', 'Initials': 'T', 'LastName': 'Olsson', 'Affiliation': 'Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.'}, {'ForeName': 'Melony C', 'Initials': 'MC', 'LastName': 'Fortuin-de Smidt', 'Affiliation': 'Non-communicable Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa.'}, {'ForeName': 'Pamela A', 'Initials': 'PA', 'LastName': 'Nono Nankam', 'Affiliation': 'Division of Exercise Science and Sports Medicine, Department of Human Biology, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Olah', 'Initials': 'O', 'LastName': 'Hakim', 'Affiliation': ""Department of Diabetes, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.""}, {'ForeName': 'Louise M', 'Initials': 'LM', 'LastName': 'Goff', 'Affiliation': ""Department of Diabetes, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.""}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Pheiffer', 'Affiliation': 'Biomedical Research and Innovation Platform, South African Medical Research Council, Cape Town, South Africa.'}, {'ForeName': 'Julia H', 'Initials': 'JH', 'LastName': 'Goedecke', 'Affiliation': 'Non-communicable Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa.'}]",Scientific reports,['10.1038/s41598-020-60286-x'] 592,31496381,Less painful ESWL with ultrasound-guided quadratus lumborum block: a prospective randomized controlled study.,"Objectives: Extracorporeal shock wave lithotripsy (ESWL) has been widely used for the treatment of urinary tract stones and is usually administered as an outpatient procedure, although the vast majority of patients do not tolerate it without sedoanalgesia. The quadratus lumborum block (QLB) is a newly-defined technique for abdominal surgery. The aim of this study was to evaluate the analgesic efficacy of ultrasound-guided QLB in ESWL. Materials and methods: Forty patients, aged 18-65, with ASA physical status I-II and scheduled for ESWL were randomly assigned to Group C (control group) and Group QLB (treatment group). Group QLB received single-shot USG-guided transmuscular QLB with 10 ml of 0.5% bupivacaine and 10 ml of 2% lidocaine before a 20-min ESWL procedure. No intervention was performed on Group C. Visual analogue scale (VAS) scores, opioid consumption, patient satisfaction, ESWL and stone details were recorded. Results: VAS scores were significantly lower in Group QLB at all time intervals ( p <  0.05). Fentanyl consumption during ESWL was significantly lower in Group QLB than in Group C ( p <  0.001). The fragmentation success rate was significantly higher in Group QLB than in Group C (19/20 vs 14/20, respectively, p =  0.046). Patient satisfaction was also higher in Group QLB ( p =  0.011). Conclusions: This study shows that QLB provided adequate analgesia for ESWL and that it reduced extra opioid consumption significantly compared to the control group.",2019,"The fragmentation success rate was significantly higher in Group QLB than in Group C (19/20 vs 14/20, respectively, p =  0.046).","['Forty patients, aged 18-65, with ASA physical status I-II and scheduled for ESWL']","['Group C (control group) and Group QLB', 'Extracorporeal shock wave lithotripsy (ESWL', 'single-shot USG-guided transmuscular QLB with 10\u2009ml of 0.5% bupivacaine and 10\u2009ml of 2% lidocaine', 'QLB', 'ultrasound-guided QLB', 'ultrasound-guided quadratus lumborum block']","['analgesic efficacy', 'Fentanyl consumption during ESWL', 'fragmentation success rate', 'Patient satisfaction', 'extra opioid consumption', 'VAS scores', 'Visual analogue scale (VAS) scores, opioid consumption, patient satisfaction, ESWL and stone details', 'quadratus lumborum block (QLB']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}]","[{'cui': 'C0441837', 'cui_str': 'Group C (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0015359', 'cui_str': 'Extracorporeal Shockwave Lithotripsy'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}]","[{'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0332472', 'cui_str': 'Fragmentation (morphologic abnormality)'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0006736', 'cui_str': 'Biliary or Urinary Stones'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}]",40.0,0.0512303,"The fragmentation success rate was significantly higher in Group QLB than in Group C (19/20 vs 14/20, respectively, p =  0.046).","[{'ForeName': 'Ahmet Murat', 'Initials': 'AM', 'LastName': 'Yayik', 'Affiliation': 'Department of Anesthesiology, Regional Training and Research Hospital, Erzurum, Turkey.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ahiskalioglu', 'Affiliation': 'Department of Anesthesiology and Reanimation, Ataturk University School of Medicine, Erzurum, Turkey.'}, {'ForeName': 'Haci Ahmet', 'Initials': 'HA', 'LastName': 'Alici', 'Affiliation': 'Department of Anesthesiology and Reanimation, Ataturk University School of Medicine, Erzurum, Turkey.'}, {'ForeName': 'Erkan Cem', 'Initials': 'EC', 'LastName': 'Celik', 'Affiliation': 'Department of Anesthesiology, Regional Training and Research Hospital, Erzurum, Turkey.'}, {'ForeName': 'Sevim', 'Initials': 'S', 'LastName': 'Cesur', 'Affiliation': 'Department of Anesthesiology, Regional Training and Research Hospital, Erzurum, Turkey.'}, {'ForeName': 'Elif Oral', 'Initials': 'EO', 'LastName': 'Ahiskalioglu', 'Affiliation': 'Department of Anesthesiology and Reanimation, Ataturk University School of Medicine, Erzurum, Turkey.'}, {'ForeName': 'Saban Oguz', 'Initials': 'SO', 'LastName': 'Demirdogen', 'Affiliation': 'Department of Urology, Ataturk University School of Medicine, Erzurum, Turkey.'}, {'ForeName': 'Omer', 'Initials': 'O', 'LastName': 'Karaca', 'Affiliation': 'Department of Anesthesiology and Reanimation, Baskent University, Konya, Turkey.'}, {'ForeName': 'Senol', 'Initials': 'S', 'LastName': 'Adanur', 'Affiliation': 'Department of Urology, Ataturk University School of Medicine, Erzurum, Turkey.'}]",Scandinavian journal of urology,['10.1080/21681805.2019.1658636'] 593,31970563,Efficacy of CO lasers in preventing dental caries in partially erupted first permanent molars: a randomized 18-month clinical trial.,"The aim of this controlled randomized double-blinded clinical trial was to evaluate the use of a CO 2 laser with or without topical application of acidulated fluorides in the prevention of dental caries in partially erupted first permanent molars. We selected 61 healthy children at high risk of caries, all between 6 and 8 (7.1 ± 0.8) years of age and with 4 partially erupted first permanent molars. A CO 2 laser device emitting at 10.6 μm was used (0.5 W, 0.05 mJ per pulse, 10 kHz). Each first molar in an individual was randomly assigned to one treatment: (L) CO 2 laser (0.066 J/cm 2 ); (FL) 1.23% acidulated fluoride gel and CO 2 laser (0.066 J/cm 2 ); (V) 5% fluoride varnish, or (S) sealant (control). Patients were followed-up at 3, 6, 12, and 18 months after treatment, through direct visual examination and by an operator blinded to the treatments (kappa ≥ 0.70). The International Caries Detection and Assessment System (ICDAS-II) index was used to assess the soundness of tooth structure or the presence of white spot lesions, cavitated enamel, and/or dentin lesions. The Yildiz Visual Index was used to evaluate sealant retention. Results were evaluated using Kaplan-Meier survival analysis, and the hazard ratio of the treatments was estimated using shared frailty models with a gamma distribution, which considered the patient as a cluster. There were no significant differences among treatments compared to sealants. After 18 months, the use of a CO 2 laser with or without acidulated fluorides was shown to be effective in preventing caries on the occlusal surface of partially erupted permanent first molars in children at high risk for caries.",2020,"After 18 months, the use of a CO 2 laser with or without acidulated fluorides was shown to be effective in preventing caries on the occlusal surface of partially erupted permanent first molars in children at high risk for caries.","['dental caries in partially erupted first permanent molars', '61 healthy children at high risk of caries, all between 6 and 8 (7.1\u2009±\u20090.8) years of age and with 4 partially erupted first permanent molars']","['CO lasers', 'CO 2 laser with or without acidulated fluorides', 'CO 2 laser with or without topical application of acidulated fluorides']",['Yildiz Visual Index'],"[{'cui': 'C0011334', 'cui_str': 'Dental Decay'}, {'cui': 'C0205355', 'cui_str': 'Permanent (qualifier value)'}, {'cui': 'C0026367', 'cui_str': 'Molar'}, {'cui': 'C0686744', 'cui_str': 'Well child (finding)'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}, {'cui': 'C4517481', 'cui_str': '0.8'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C0016327', 'cui_str': 'Fluorides'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}]","[{'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",61.0,0.106462,"After 18 months, the use of a CO 2 laser with or without acidulated fluorides was shown to be effective in preventing caries on the occlusal surface of partially erupted permanent first molars in children at high risk for caries.","[{'ForeName': 'Cristina Bueno', 'Initials': 'CB', 'LastName': 'Brandão', 'Affiliation': 'Department of Pediatric Dentistry, Ribeirão Preto School of Dentistry, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Silmara Aparecida Milori', 'Initials': 'SAM', 'LastName': 'Corona', 'Affiliation': 'Department of Restorative Dentistry, Ribeirão Preto School of Dentistry, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Carolina Paes', 'Initials': 'CP', 'LastName': 'Torres', 'Affiliation': 'Department of Pediatric Dentistry, Ribeirão Preto School of Dentistry, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Alessandra Afonso', 'Initials': 'AA', 'LastName': 'Côrrea-Marques', 'Affiliation': 'Department of Pediatric Dentistry, Ribeirão Preto School of Dentistry, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Maria Conceição Pereira', 'Initials': 'MCP', 'LastName': 'Saraiva', 'Affiliation': 'Department of Pediatric Dentistry, Ribeirão Preto School of Dentistry, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Maria Cristina', 'Initials': 'MC', 'LastName': 'Borsatto', 'Affiliation': 'Department of Pediatric Dentistry, Ribeirão Preto School of Dentistry, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. borsatto@forp.usp.br.'}]",Lasers in medical science,['10.1007/s10103-020-02967-7'] 594,31970564,Photobiomodulation as an adjunctive therapy for alveolar socket preservation: a preliminary study in humans.,"Bone remodeling results in loss of alveolar bone height and thickness. Photobiomodulation (PBM) based on photochemical stimulation by low-intensity lasers emerges as an adjunctive therapy for alveolar socket preservation. Our study aimed to evaluate the effects of PBM therapy on alveolar bone repair. Twenty healthy patients in need of bilateral extraction of lower molars were enrolled in this split-mouth randomized and blind clinical trial. The extraction sites were randomly selected to receive either the PBM therapy with a CW GaAIAs diode laser (808 nm; 0.028 mm 2 ; 0.1 W; 3.6 W/cm 2 ; 89 J/cm 2 ; 2.5 J/point) or no treatment (Control). Bone biopsies were harvested 45 days after the dental extraction and evaluated using micro-computerized tomography (μCT), morphometric, and histological analysis. Data were compared using the paired t test, and the level of significance was set at 5%. Bone surface (p = 0.029), bone surface/total volume (p = 0.028), trabecular number (p = 0.025), and connectivity density (p = 0.029) were higher at the PBM group compared with Control. The histological observations confirmed the μCT findings. PBM samples exhibited higher number of organized and connected bone trabeculae along with higher density of blood vessels than Control. Control samples displayed a dense and highly cellular connective tissue at the central area accompanied by the presence of immature bone trabeculae at the periphery. Our results indicated that the PBM therapy improved the newly bone trabeculae formation and their connectivity which increased bone surface, indicating the positive effect of the laser on alveolar human socket repair.",2020,Control samples displayed a dense and highly cellular connective tissue at the central area accompanied by the presence of immature bone trabeculae at the periphery.,"['Twenty healthy patients in need of bilateral extraction of lower molars', 'humans']","['PBM therapy', 'PBM therapy with a CW GaAIAs diode laser', 'Photobiomodulation', 'Photobiomodulation (PBM']","['connectivity density', 'Bone surface', 'alveolar bone height and thickness', 'alveolar bone repair', 'trabecular number', 'bone surface/total volume']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0026367', 'cui_str': 'Molar'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0071006', 'cui_str': 'phytobacteriomycin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0392254', 'cui_str': 'Semiconductor Diode Lasers'}]","[{'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0205148', 'cui_str': 'Surface (attribute)'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}]",20.0,0.0400744,Control samples displayed a dense and highly cellular connective tissue at the central area accompanied by the presence of immature bone trabeculae at the periphery.,"[{'ForeName': 'Kleber Arturo Vallejo', 'Initials': 'KAV', 'LastName': 'Rosero', 'Affiliation': 'School of Dentistry, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Rui Manuel Freire', 'Initials': 'RMF', 'LastName': 'Sampaio', 'Affiliation': 'School of Dentistry, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Maria Cristina Zindel', 'Initials': 'MCZ', 'LastName': 'Deboni', 'Affiliation': 'School of Dentistry, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Luciana', 'Initials': 'L', 'LastName': 'Corrêa', 'Affiliation': 'School of Dentistry, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Márcia Martins', 'Initials': 'MM', 'LastName': 'Marques', 'Affiliation': 'School of Dentistry, Ibirapuera University, São Paulo, Brazil.'}, {'ForeName': 'Emanuela Prado', 'Initials': 'EP', 'LastName': 'Ferraz', 'Affiliation': 'School of Dentistry, University of São Paulo, São Paulo, Brazil. emanuelaferraz@usp.br.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'da Graça Naclério-Homem', 'Affiliation': 'School of Dentistry, University of São Paulo, São Paulo, Brazil.'}]",Lasers in medical science,['10.1007/s10103-020-02962-y'] 595,31808408,Effects of perioperative pelvic floor muscle training on early recovery of urinary continence and erectile function in men undergoing radical prostatectomy: a randomized clinical trial.,"AIMS Radical prostatectomy (RP) can result in urinary incontinence (UI) and erectile dysfunction (ED), which negatively impact quality of life (QoL). This study aimed to evaluate the effects of a perioperative pelvic floor muscle training (PFMT) program versus usual care on early recovery of urinary continence and erectile function after RP. MATERIALS AND METHODS Of 59 eligible men, 31 were randomly allocated into 2 groups: Group 1 (Control, N=15) received usual post-RP care; and Group 2 (Physical therapy, N=16) received two pre-RP physical therapist-guided PFMT sessions, including exercises and electromyographic biofeedback, and verbal and written instructions to continue PFMT until RP, which was then resumed after urethral catheter removal. The International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF) and the 5-item version of the International Index of Erectile Function (IIEF-5) questionnaire were used to evaluate UI and ED, respectively. RESULTS Demographic characteristics were similar in both groups. Three months after RP, the UI rate was 72.7% and 70.0% in Groups 1 and 2, respectively (P >0.05). The severity and frequency of UI and its impact on QoL were evaluated by the ICIQ-Short Form, with scores of 6.9±6.26 in Group 1 and 7.0±5.12 in Group 2 (P >0.05). The IIEF-5 scores were similar in Groups 1 and 2 (5.73±7.43 vs. 6.70±6.68, respectively) (P >0.05). CONCLUSION Our pre-RP protocol of two physical therapist-assisted sessions of PFMT plus instructions did not signifi cantly improve urinary continence or erectile function at 3 months after RP.",2019,"Three months after RP, the UI rate was 72.7% and 70.0% in Groups 1 and 2, respectively (P >0.05).","['Of 59 eligible men', 'men undergoing radical prostatectomy']","['perioperative pelvic floor muscle training (PFMT) program versus usual care', 'Radical prostatectomy (RP', 'usual post-RP care; and Group 2 (Physical therapy, N=16) received two pre-RP physical therapist-guided PFMT sessions, including exercises and electromyographic biofeedback, and verbal and written instructions to continue PFMT until RP', 'perioperative pelvic floor muscle training']","['urinary continence and erectile function', 'urinary continence or erectile function', 'IIEF-5 scores', 'severity and frequency of UI and its impact on QoL', 'Incontinence Questionnaire - Short Form (ICIQ-SF) and the 5-item version of the International Index of Erectile Function (IIEF-5) questionnaire', 'UI rate', 'urinary incontinence (UI) and erectile dysfunction (ED']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy (procedure)'}]","[{'cui': 'C4087139', 'cui_str': 'Pelvic floor muscle training'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy (procedure)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapists'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0204624', 'cui_str': 'Electromyographic biofeedback (regime/therapy)'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}]","[{'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0021167', 'cui_str': 'Incontinence (finding)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C2960541', 'cui_str': 'International index of erectile function'}, {'cui': 'C0042024', 'cui_str': 'Urinary Incontinence'}, {'cui': 'C0242350', 'cui_str': 'Male Sexual Impotence'}]",59.0,0.0253155,"Three months after RP, the UI rate was 72.7% and 70.0% in Groups 1 and 2, respectively (P >0.05).","[{'ForeName': 'Gislano Heverton Soares', 'Initials': 'GHS', 'LastName': 'de Lira', 'Affiliation': 'Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brasil.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Fornari', 'Affiliation': 'Unidade de Disfunção Miccional, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brasil.'}, {'ForeName': 'Luiz Felipe', 'Initials': 'LF', 'LastName': 'Cardoso', 'Affiliation': 'Unidade de Disfunção Miccional, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brasil.'}, {'ForeName': 'Magda', 'Initials': 'M', 'LastName': 'Aranchipe', 'Affiliation': 'Unidade de Disfunção Miccional, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brasil.'}, {'ForeName': 'Carmem', 'Initials': 'C', 'LastName': 'Kretiska', 'Affiliation': 'Unidade de Disfunção Miccional, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brasil.'}, {'ForeName': 'Ernani Luis', 'Initials': 'EL', 'LastName': 'Rhoden', 'Affiliation': 'Departamento de Urologia, UFCSPA, Porto Alegre, RS, Brasil.'}]",International braz j urol : official journal of the Brazilian Society of Urology,['10.1590/S1677-5538.IBJU.2019.0238'] 596,31808410,Which of available selective serotonin reuptake inhibitors (SSRIs) is more effective in treatment of premature ejaculation? A randomized clinical trial.,"PURPOSE To compare the efficacy and safety of available selective serotonin reuptake inhibi-tors (SSRIs) in order to find the most effective drug with the least number of side effects in treatment of premature ejaculation (PE). MATERIALS AND METHODS This study was a randomized clinical trial. Four hundred and eighty pati-ents with PE in the 4 groups referred to Imam Reza hospital Tehran, Iran from July 2018 to Fe-bruary 2019 were enrolled in the study. The patients received sertraline 50mg, fluoxetine 20mg, paroxetine 20mg and citalopram 20mg, every 12 hours daily. The intravaginal ejaculatory laten-cy time (IELT) before treatment, fourth and eighth weeks after treatment was recorded by the patient's wife with a stopwatch. RESULTS Mean IELT before, 4 and 8 weeks after treatment in four groups were: sertraline 69.4±54.3, 353.5±190.4, 376.3±143.5; fluoxetine 75.5±64.3, 255.4±168.2, 314.8±190.4; paroxeti-ne 71.5±69.1, 320.7±198.3, 379.9±154.3; citalopram 90.39±79.3, 279.9±192.1, 282.5±171.1 seconds, respectively. The ejaculation time significantly increased in all groups (p <0.05), but there was no significant difference between the groups (P=0.75). Also, there was no significant difference in drugs side effects between groups (p >0.05). The most common side effects were drowsiness and dyspepsia, which were not severe enough to cause discontinuation of the drug. CONCLUSIONS All available SSRIs were effective and usually had no serious complications. In patients who did not respond to any of these drugs, other SSRI drugs could be used as a salvage therapy.",2019,"The ejaculation time significantly increased in all groups (p <0.05), but there was no significant difference between the groups (P=0.75).","['Four hundred and eighty pati-ents with PE in the 4 groups referred to Imam Reza hospital Tehran, Iran from July 2018 to Fe-bruary 2019 were enrolled in the study', 'premature ejaculation (PE']","['serotonin reuptake inhibitors (SSRIs', 'sertraline 50mg, fluoxetine 20mg, paroxetine 20mg and citalopram', 'available selective serotonin reuptake inhibi-tors (SSRIs', 'intravaginal ejaculatory laten-cy time (IELT', 'fluoxetine']","['ejaculation time', 'Mean IELT', 'drowsiness and dyspepsia', 'drugs side effects', 'efficacy and safety']","[{'cui': 'C4319609', 'cui_str': '480'}, {'cui': 'C1274038', 'cui_str': 'Ear, nose and throat surgery'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0521321', 'cui_str': 'Imam'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0033038', 'cui_str': 'Ejaculatio Praecox'}]","[{'cui': 'C0162758', 'cui_str': '5-HT Uptake Inhibitors'}, {'cui': 'C1603093', 'cui_str': 'Sertraline 50 MG [Zoloft]'}, {'cui': 'C0986112', 'cui_str': 'Fluoxetine 20 MG'}, {'cui': 'C0070122', 'cui_str': 'Paroxetine'}, {'cui': 'C0008845', 'cui_str': 'Citalopram'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0442122', 'cui_str': 'Intravaginal (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0016365', 'cui_str': 'Fluoxetine'}]","[{'cui': 'C0013746', 'cui_str': 'Ejaculation'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0013144', 'cui_str': 'Drowsy (finding)'}, {'cui': 'C0013395', 'cui_str': 'Indigestion'}, {'cui': 'C0041755', 'cui_str': 'Drug Side Effects'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",2019.0,0.0241384,"The ejaculation time significantly increased in all groups (p <0.05), but there was no significant difference between the groups (P=0.75).","[{'ForeName': 'Soheila', 'Initials': 'S', 'LastName': 'Siroosbakht', 'Affiliation': 'Faculty of Medicine, Imam Reza Hospital, AJA University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Sadra', 'Initials': 'S', 'LastName': 'Rezakhaniha', 'Affiliation': 'Department of Nutrition, Science and Research Islamic Azad University, Tehran, Iran.'}, {'ForeName': 'Bijan', 'Initials': 'B', 'LastName': 'Rezakhaniha', 'Affiliation': 'Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.'}]",International braz j urol : official journal of the Brazilian Society of Urology,['10.1590/S1677-5538.IBJU.2019.0121'] 597,31948461,Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin.,"BACKGROUND Inflammation contributes to the pathophysiology of major depressive disorder (MDD), and anti-inflammatory strategies might therefore have therapeutic potential. This trial aimed to determine whether adjunctive aspirin or rosuvastatin, compared with placebo, reduced depressive symptoms in young people (15-25 years). METHODS YoDA-A, Youth Depression Alleviation with Anti-inflammatory Agents, was a 12-week triple-blind, randomised, controlled trial. Participants were young people (aged 15-25 years) with moderate to severe MDD (MADRS mean at baseline 32.5 ± 6.0; N = 130; age 20.2 ± 2.6; 60% female), recruited between June 2013 and June 2017 across six sites in Victoria, Australia. In addition to treatment as usual, participants were randomised to receive aspirin (n = 40), rosuvastatin (n = 48), or placebo (n = 42), with assessments at baseline and weeks 4, 8, 12, and 26. The primary outcome was change in the Montgomery-Åsberg Depression Rating Scale (MADRS) from baseline to week 12. RESULTS At the a priori primary endpoint of MADRS differential change from baseline at week 12, there was no significant difference between aspirin and placebo (1.9, 95% CI (- 2.8, 6.6), p = 0.433), or rosuvastatin and placebo (- 4.2, 95% CI (- 9.1, 0.6), p = 0.089). For rosuvastatin, secondary outcomes on self-rated depression and global impression, quality of life, functioning, and mania were not significantly different from placebo. Aspirin was inferior to placebo on the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) at week 12. Statins were superior to aspirin on the MADRS, the Clinical Global Impressions Severity Scale (CGI-S), and the Negative Problem Orientation Questionnaire scale (NPOQ) at week 12. CONCLUSIONS The addition of either aspirin or rosuvastatin did not to confer any beneficial effect over and above routine treatment for depression in young people. Exploratory comparisons of secondary outcomes provide limited support for a potential therapeutic role for adjunctive rosuvastatin, but not for aspirin, in youth depression. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry, ACTRN12613000112763. Registered on 30/01/2013.",2020,Aspirin was inferior to placebo on the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) at week 12.,"['young people', 'young people (15-25\u2009years', 'Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A', 'Participants were young people (aged 15-25\u2009years) with moderate to severe MDD (MADRS mean at baseline 32.5\u2009±\u20096.0; N\xa0=\u2009130; age 20.2\u2009±\u20092.6; 60% female), recruited between June 2013 and June 2017 across six sites in Victoria, Australia', 'YoDA-A, Youth Depression Alleviation with Anti-inflammatory Agents']","['placebo', 'rosuvastatin', 'Aspirin', 'adjunctive aspirin or rosuvastatin', 'rosuvastatin and placebo', 'aspirin or rosuvastatin', 'aspirin', 'rosuvastatin and aspirin']","['depressive symptoms', 'self-rated depression and global impression, quality of life, functioning, and mania', 'Montgomery-Åsberg Depression Rating Scale (MADRS', 'MADRS, the Clinical Global Impressions Severity Scale (CGI-S), and the Negative Problem Orientation Questionnaire scale (NPOQ', 'MADRS differential change', 'Quality of Life Enjoyment and Satisfaction Questionnaire']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003209', 'cui_str': 'Antiinflammatories'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4517710', 'cui_str': '32.5 (qualifier value)'}, {'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C4517642', 'cui_str': '20.2 (qualifier value)'}, {'cui': 'C4517633', 'cui_str': 'Two point six'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0042645', 'cui_str': 'Victoria'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}]","[{'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0338831', 'cui_str': 'Manic State'}, {'cui': 'C2960593', 'cui_str': 'Montgomery-Åsberg depression rating scale'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0222045'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0029266', 'cui_str': 'Cognitive Orientation'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0443199', 'cui_str': 'Differential (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",,0.361743,Aspirin was inferior to placebo on the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) at week 12.,"[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Berk', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia. michael.berk@deakin.edu.au.'}, {'ForeName': 'Mohammadreza', 'Initials': 'M', 'LastName': 'Mohebbi', 'Affiliation': 'The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.'}, {'ForeName': 'Olivia M', 'Initials': 'OM', 'LastName': 'Dean', 'Affiliation': 'The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.'}, {'ForeName': 'Sue M', 'Initials': 'SM', 'LastName': 'Cotton', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Chanen', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}, {'ForeName': 'Seetal', 'Initials': 'S', 'LastName': 'Dodd', 'Affiliation': 'Centre for Youth Mental Health, University of Melbourne, Parkville, Australia.'}, {'ForeName': 'Aswin', 'Initials': 'A', 'LastName': 'Ratheesh', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}, {'ForeName': 'G Paul', 'Initials': 'GP', 'LastName': 'Amminger', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Phelan', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}, {'ForeName': 'Amber', 'Initials': 'A', 'LastName': 'Weller', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Mackinnon', 'Affiliation': 'Black Dog Institute, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Giorlando', 'Affiliation': 'Department of Psychiatry, University of Melbourne, Parkville, Australia.'}, {'ForeName': 'Shelley', 'Initials': 'S', 'LastName': 'Baird', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Incerti', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}, {'ForeName': 'Rachel E', 'Initials': 'RE', 'LastName': 'Brodie', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}, {'ForeName': 'Natalie O', 'Initials': 'NO', 'LastName': 'Ferguson', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Rice', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}, {'ForeName': 'Miriam R', 'Initials': 'MR', 'LastName': 'Schäfer', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Mullen', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Hetrick', 'Affiliation': 'Centre for Youth Mental Health, University of Melbourne, Parkville, Australia.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Kerr', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}, {'ForeName': 'Susy M', 'Initials': 'SM', 'LastName': 'Harrigan', 'Affiliation': 'Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Amelia L', 'Initials': 'AL', 'LastName': 'Quinn', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Mazza', 'Affiliation': 'The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'McGorry', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}, {'ForeName': 'Christopher G', 'Initials': 'CG', 'LastName': 'Davey', 'Affiliation': 'Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.'}]",BMC medicine,['10.1186/s12916-019-1475-6'] 598,31714598,The efficacy of a technology-based information and coaching/support program on pain and symptoms in Asian American survivors of breast cancer.,"BACKGROUND Pain is a common problem, especially in the first few years of breast cancer survivorship. Asian American survivors of breast cancer reportedly have inadequate cancer pain management, and subsequently report a lower quality of life compared with other racial/ethnic groups. Technology-based programs could improve the cancer pain management process. The purpose of the current study was to examine the efficacy of a technology-based information and coaching/support program on cancer pain and its accompanying symptoms among Asian American survivors of breast cancer. METHODS The current study adopted a randomized pretest/posttest group design. The sample included 115 Asian American survivors of breast cancer (49 in the control group and 66 in the intervention group). The participants' background features, pain (frequency and distress), accompanying symptom distress (global, physical, and psychological), and 4 theory-based mediators (attitude, self-efficacy, perceived barriers, and social influence) were measured using multiple instruments at 3 time points (pretest, after 1 month, and after 3 months). The current study used an intent-to-treat approach and conducted linear mixed model growth curve analyses. RESULTS There were significant decreases noted in all outcome variables, including pain and symptoms over time in both groups. There were greater decreases in physical symptom distress scores among the intervention group compared with the control group (P = .0229). The mediators as a whole significantly explained overall decreases in general, physical, and psychological symptom distress scores after 3 months in both groups and the intervention group's greater decreases in general, physical, and psychological symptom distress scores after 1 month. CONCLUSIONS The technology-based program described herein could help to reduce cancer pain and its accompanying symptoms among Asian American survivors of breast cancer.",2020,There were greater decreases in physical symptom distress scores among the intervention group compared with the control group (P = .0229).,"['Asian American survivors of breast cancer', '115 Asian American survivors of breast cancer (49 in the control group and 66 in the intervention group']",['technology-based information and coaching/support program'],"['pain and symptoms', 'pain and symptoms over time', 'general, physical, and psychological symptom distress scores', 'physical symptom distress scores', 'cancer pain', 'pain (frequency and distress), accompanying symptom distress (global, physical, and psychological), and 4 theory-based mediators (attitude, self-efficacy, perceived barriers, and social influence']","[{'cui': 'C0003988', 'cui_str': 'Asian Americans'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C4517540', 'cui_str': '115 (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0233397', 'cui_str': 'Psychological symptom'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0596240', 'cui_str': 'Tumor-Related Pain'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}]",115.0,0.0143995,There were greater decreases in physical symptom distress scores among the intervention group compared with the control group (P = .0229).,"[{'ForeName': 'Eun-Ok', 'Initials': 'EO', 'LastName': 'Im', 'Affiliation': 'School of Nursing, Duke University, Durham, North Carolina.'}, {'ForeName': 'Sangmi', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'School of Nursing, Duke University, Durham, North Carolina.'}, {'ForeName': 'You Lee', 'Initials': 'YL', 'LastName': 'Yang', 'Affiliation': 'School of Nursing, Duke University, Durham, North Carolina.'}, {'ForeName': 'Wonshik', 'Initials': 'W', 'LastName': 'Chee', 'Affiliation': 'School of Nursing, Duke University, Durham, North Carolina.'}]",Cancer,['10.1002/cncr.32579'] 599,31967283,Anesthesia upstream of the alcoholic lesion point alleviates the pain of alcohol neurolysis for intercostal neuralgia: a prospective randomized clinical trial.,"OBJECTIVES Alcohol for intercostal neuralgia may induce severe injection pain. Although nerve block provided partial pain relief, alcohol might be diluted, and the curative effect decreased when the local anesthetic and alcohol were given at the same point. Therefore, we observed the modified method for intercostal neuralgia, a Two-point method, in which the local anesthetic and alcohol were given at different sites. METHOD Thirty patients diagnosed with intercostal neuralgia were divided into 2 groups: Single-point group and Two-point group. In the Single-point group, alcohol and local anesthetic were injected at the same point, named the ""lesion point"", which was the lower edge of ribs and 5 cm away from the midline of the spinous process. In the Two-point group, alcohol was injected at the lesion point, whereas the local anesthetic was administered at the ""anesthesia point"", which was 3 cm away from the midline of spinous process. RESULTS After alcohol injection, visual analog scale (VAS) in the Two-point group was lower than the Single-point group, and the satisfaction ratio of patients in the Two-point group was higher (p<0.05). The degree of numbness in the Two-point group was greater than the Single-point group at 1 month and 3 months after operation (p<0.05). However, the long-term effects did not differ. CONCLUSIONS Local anesthetic was given upstream of the point where alcohol was administered, was a feasible and safe method to relieve pain during the operation, and improved the satisfaction of the patients and curative effect.",2020,The degree of numbness in the Two-point group was greater than the Single-point group at 1 month and 3 months after operation (p<0.05).,"['intercostal neuralgia', 'Thirty patients diagnosed with intercostal neuralgia']",[],"['degree of numbness', 'satisfaction ratio', 'visual analog scale (VAS', 'severe injection pain', 'pain of alcohol neurolysis']","[{'cui': 'C0344306', 'cui_str': 'Intercostal neuralgia (disorder)'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]",[],"[{'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0020580', 'cui_str': 'Reduced Sensation'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0196878', 'cui_str': 'Neurolysis (procedure)'}]",30.0,0.016268,The degree of numbness in the Two-point group was greater than the Single-point group at 1 month and 3 months after operation (p<0.05).,"[{'ForeName': 'Jiyu', 'Initials': 'J', 'LastName': 'Kang', 'Affiliation': 'Department of Anesthesiology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Niu', 'Affiliation': 'Department of Anesthesiology, the 211 Hospital of Chinese PLA, Harbin, China.'}, {'ForeName': 'Mengli', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Meng', 'Affiliation': 'Department of Pain Management, the Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Huacheng', 'Initials': 'H', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesiology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.'}]","Clinics (Sao Paulo, Brazil)",['10.6061/clinics/2020/e1296'] 600,31808404,Two-shift operation mode can improve the efficiency and comfort of flexible ureteroscopic holmium laser lithotripsy for the treatment of renal calculi larger than 1.5cm.,"PURPOSE To compare two-shift operation mode and single player mode different impact on surgical results and operator comfort in flexible ureteroscopic holmium laser lithotripsy for renal calculi larger than 1.5cm. MATERIALS AND METHODS From december 2017 to december 2018, 92 patients with renal calculi admitted to Qilu Hospital and were treated through fl exible ureteroscopy. They were randomized in two-shift group (n=50) and single player group (n=42). The operative time, blood loss, hospitalization stay after operation, residual fragments (≥4mm) rate, fragmentation speed, postoperative complications and operator's fatigue score were compared. RESULTS There was no significant difference between two groups regarding age, gender, illness side, stone size, blood loss, operative time, postoperative hospitalization stay, complications, etc (p >0.05). The fragmentation speed was 44.5±20.0mm3/min in two-shift group compared with 34.2±17.3mm3/min in single player group (p=0.037). Residual fragments (≥4mm) rate after fi rst surgery was 18% in two-shift group, while the residual fragments (≥4mm) rate was 40.5% after first surgery in single player group (p=0.017). The total fatigue score of two-shift group was 8.4 compared to 29.9 in single player group (p <0.001). CONCLUSION In flexible ureteroscopic holmium laser lithotripsy for the treatment of renal calculi larger than 1.5cm, two-shift operation mode can raise the fragmentation speed and stone clearance rate, as well as signifi cantly lower operator's fatigue level and improve operator's comfort.",2019,"There was no significant difference between two groups regarding age, gender, illness side, stone size, blood loss, operative time, postoperative hospitalization stay, complications, etc (p >0.05).","['From december 2017 to december 2018, 92 patients with renal calculi admitted to Qilu Hospital and were treated through fl exible ureteroscopy']",['flexible ureteroscopic holmium laser lithotripsy'],"['efficiency and comfort', 'Residual fragments (≥4mm) rate after fi rst surgery', 'fragmentation speed', 'total fatigue score', 'fragmentation speed and stone clearance rate', 'illness side, stone size, blood loss, operative time, postoperative hospitalization stay, complications, etc', ""operative time, blood loss, hospitalization stay after operation, residual fragments (≥4mm) rate, fragmentation speed, postoperative complications and operator's fatigue score""]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0022650', 'cui_str': 'Kidney Stones'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0194261', 'cui_str': 'Ureteroscopy'}]","[{'cui': 'C0443220', 'cui_str': 'Flexible (qualifier value)'}, {'cui': 'C1955839', 'cui_str': 'Holmium Lasers'}, {'cui': 'C0023878', 'cui_str': 'Litholapaxy'}]","[{'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0332472', 'cui_str': 'Fragmentation (morphologic abnormality)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0006736', 'cui_str': 'Biliary or Urinary Stones'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0449454', 'cui_str': 'Stone size'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C0032787', 'cui_str': 'Postoperative Complications'}]",92.0,0.0185283,"There was no significant difference between two groups regarding age, gender, illness side, stone size, blood loss, operative time, postoperative hospitalization stay, complications, etc (p >0.05).","[{'ForeName': 'Sun', 'Initials': 'S', 'LastName': 'Hui', 'Affiliation': 'Qilu Hospital of Shandong University, Qingdao, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Qingya', 'Affiliation': 'Qilu Hospital of Shandong University, Qingdao, China.'}, {'ForeName': 'Yin', 'Initials': 'Y', 'LastName': 'Xinbao', 'Affiliation': 'Qilu Hospital of Shandong University, Qingdao, China.'}, {'ForeName': 'Liu', 'Initials': 'L', 'LastName': 'Ming', 'Affiliation': 'Qilu Hospital of Shandong University, Qingdao, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Gonghui', 'Affiliation': 'Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Jun', 'Affiliation': 'Qilu Hospital of Shandong University, Qingdao, China.'}]",International braz j urol : official journal of the Brazilian Society of Urology,['10.1590/S1677-5538.IBJU.2019.0219'] 601,31872771,Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer.,"Aim: To determine the effectiveness of nivolumab compared with routine clinical practice (RCP) for patients with gastric or gastroesophageal cancer refractory to, or intolerant of, two or more previous regimens, using real-world electronic patient records from a US population, a single-arm trial (CheckMate 032) and a randomized controlled trial in an Asian setting (ATTRACTION-2). Materials & methods: A simulated treatment comparison was conducted to predict overall survival for patients treated with nivolumab compared with RCP in the USA. Results: Results of the indirect simulated treatment comparison suggest that nivolumab is associated with a 50% reduction in the risk of all-cause mortality relative to RCP (Hazard ratio: 0.50; 95% CI: 0.36, 0.68). Conclusion: The survival benefit of nivolumab may extend more generally to the USA.",2020,"suggest that nivolumab is associated with a 50% reduction in the risk of all-cause mortality relative to RCP (Hazard ratio: 0.50; 95% CI: 0.36, 0.68). ","['patients with gastric or gastroesophageal cancer refractory to, or intolerant of, two or more previous regimens, using real-world electronic patient records from a US population, a single-arm trial (CheckMate 032', 'advanced gastric or gastroesophageal junction cancer']","['routine clinical practice (RCP', 'nivolumab']","['overall survival', 'survival benefit of nivolumab']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C1112160', 'cui_str': 'Gastrooesophageal cancer'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0014871', 'cui_str': 'Gastroesophageal Junction'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}]","[{'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C3657270', 'cui_str': 'nivolumab'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C3657270', 'cui_str': 'nivolumab'}]",,0.239947,"suggest that nivolumab is associated with a 50% reduction in the risk of all-cause mortality relative to RCP (Hazard ratio: 0.50; 95% CI: 0.36, 0.68). ","[{'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Chau', 'Affiliation': 'Royal Marsden Hospital, London & Surrey, SM2 5PT, UK.'}, {'ForeName': 'Dieter', 'Initials': 'D', 'LastName': 'Ayers', 'Affiliation': 'Precision Xtract, Vancouver, B.C., V6H 3Y4, Canada.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Goring', 'Affiliation': 'Precision Xtract, Vancouver, B.C., V6H 3Y4, Canada.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Cope', 'Affiliation': 'Precision Xtract, Vancouver, B.C., V6H 3Y4, Canada.'}, {'ForeName': 'Beata', 'Initials': 'B', 'LastName': 'Korytowsky', 'Affiliation': 'Bristol-Myers Squibb, Princeton, NJ\xa008648, USA.'}, {'ForeName': 'Pranav', 'Initials': 'P', 'LastName': 'Abraham', 'Affiliation': 'Bristol-Myers Squibb, Princeton, NJ\xa008648, USA.'}]",Journal of comparative effectiveness research,['10.2217/cer-2019-0145'] 602,31813633,"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.","BACKGROUND Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. METHODS In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH, non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2-F3, or F1 with at least one accompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpoints for the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2-F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. FINDINGS Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1-F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2-F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1-F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). INTERPRETATION Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes. FUNDING Intercept Pharmaceuticals.",2019,"The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). ","['non-alcoholic steatohepatitis', '1968 patients with stage', 'adult patients with definite NASH, non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2-F3, or F1 with at least one accompanying comorbidity', 'F1-F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2-F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the', '1968 patients with fibrosis stages F1-F3', 'patients with NASH', 'Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present']","['obeticholic acid', 'placebo', 'oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily', 'Obeticholic acid', 'obeticholic acid 10 mg group, and 308 in the obeticholic acid']","['histological and biochemical markers of NASH and fibrosis, and safety', 'overall safety profile', 'serious adverse events', 'NASH resolution endpoint', 'fibrosis improvement endpoint', 'fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis']","[{'cui': 'C3241937', 'cui_str': 'Nonalcoholic Steatohepatitis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439544', 'cui_str': 'Definite (qualifier value)'}, {'cui': 'C0400966', 'cui_str': 'NAFLD'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517706', 'cui_str': '312 (qualifier value)'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C1623038', 'cui_str': 'Cirrhosis'}, {'cui': 'C0341439', 'cui_str': 'Chronic liver disease (disorder)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}]","[{'cui': 'C1143018', 'cui_str': 'obeticholic acid'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C4271802', 'cui_str': 'obeticholic acid 10 MG'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0205462', 'cui_str': 'Histologic (qualifier value)'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Marker'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}]",931.0,0.650406,"The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). ","[{'ForeName': 'Zobair M', 'Initials': 'ZM', 'LastName': 'Younossi', 'Affiliation': 'Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA.'}, {'ForeName': 'Vlad', 'Initials': 'V', 'LastName': 'Ratziu', 'Affiliation': 'Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Institute for Cardiometabolism and Nutrition, Paris, France.'}, {'ForeName': 'Rohit', 'Initials': 'R', 'LastName': 'Loomba', 'Affiliation': 'NAFLD Rsearch Center, University of California San Diego, San Diego, CA, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Rinella', 'Affiliation': 'Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.'}, {'ForeName': 'Quentin M', 'Initials': 'QM', 'LastName': 'Anstee', 'Affiliation': 'The Newcastle Liver Research Group, Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK; Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.'}, {'ForeName': 'Zachary', 'Initials': 'Z', 'LastName': 'Goodman', 'Affiliation': 'Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Bedossa', 'Affiliation': ""Service d'Anatomie Pathologique, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Paris, France.""}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Geier', 'Affiliation': 'Department of Hepatology, University of Wuerzburg, Wuerzburg, Germany.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Beckebaum', 'Affiliation': 'St Josef-Krankenhaus Kupferdreh, Essen, Germany.'}, {'ForeName': 'Philip N', 'Initials': 'PN', 'LastName': 'Newsome', 'Affiliation': 'National Institute for Health Research Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK; Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Sheridan', 'Affiliation': 'Institute of Translational & Stratified Medicine, University of Plymouth and University Hospitals Plymouth NHS Trust, Plymouth, UK.'}, {'ForeName': 'Muhammad Y', 'Initials': 'MY', 'LastName': 'Sheikh', 'Affiliation': 'Fresno Clinical Research Center, Fresno, CA, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Trotter', 'Affiliation': 'Baylor Health, Liver Consultants of Texas, Dallas, TX, USA.'}, {'ForeName': 'Whitfield', 'Initials': 'W', 'LastName': 'Knapple', 'Affiliation': 'Arkansas Gastroenterology, North Little Rock, AR, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Lawitz', 'Affiliation': 'Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX, USA.'}, {'ForeName': 'Manal F', 'Initials': 'MF', 'LastName': 'Abdelmalek', 'Affiliation': 'Division of Gastroenterology and Hepatology, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Kris V', 'Initials': 'KV', 'LastName': 'Kowdley', 'Affiliation': 'Swedish Liver Center, Seattle, WA, USA.'}, {'ForeName': 'Aldo J', 'Initials': 'AJ', 'LastName': 'Montano-Loza', 'Affiliation': 'Division of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Jerome', 'Initials': 'J', 'LastName': 'Boursier', 'Affiliation': 'HIFIH Laboratory, UPRES EA3859, SFR 4208, Angers University, Angers, France; Hepato-Gastroenterology Department, Angers University Hospital, Angers, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Mathurin', 'Affiliation': 'Hepato-gastroenterology, CHU Lille, Lille, France.'}, {'ForeName': 'Elisabetta', 'Initials': 'E', 'LastName': 'Bugianesi', 'Affiliation': 'Department of Medical Sciences, University of Turin, Turin, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Mazzella', 'Affiliation': 'Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna, Bologna, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Olveira', 'Affiliation': 'Department of Gastroenterology, Hospital Universitario La Paz, Madrid, Spain.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Cortez-Pinto', 'Affiliation': 'Clínica Universitária de Gastrenterologia, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Graupera', 'Affiliation': ""Liver Unit, Hospital Clínic de Barcelona, Barcelona, Spain; Institut D'investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Orr', 'Affiliation': 'New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.'}, {'ForeName': 'Lise Lotte', 'Initials': 'LL', 'LastName': 'Gluud', 'Affiliation': 'The Gastrounit, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.'}, {'ForeName': 'Jean-Francois', 'Initials': 'JF', 'LastName': 'Dufour', 'Affiliation': 'University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Shapiro', 'Affiliation': 'Intercept Pharmaceuticals, San Diego, CA, USA.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Campagna', 'Affiliation': 'Intercept Pharmaceuticals, San Diego, CA, USA.'}, {'ForeName': 'Luna', 'Initials': 'L', 'LastName': 'Zaru', 'Affiliation': 'Intercept Pharmaceuticals, San Diego, CA, USA.'}, {'ForeName': 'Leigh', 'Initials': 'L', 'LastName': 'MacConell', 'Affiliation': 'Intercept Pharmaceuticals, San Diego, CA, USA.'}, {'ForeName': 'Reshma', 'Initials': 'R', 'LastName': 'Shringarpure', 'Affiliation': 'Intercept Pharmaceuticals, San Diego, CA, USA.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Harrison', 'Affiliation': 'Pinnacle Clinical Research Center, San Antonio, TX, USA.'}, {'ForeName': 'Arun J', 'Initials': 'AJ', 'LastName': 'Sanyal', 'Affiliation': 'Department of Internal Medicine, Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA, USA. Electronic address: arun.sanyal@vcuhealth.org.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(19)33041-7'] 603,31954158,Patient-centered change in the day-to-day impact of postmenopausal vaginal symptoms: results from a multicenter randomized trial.,"BACKGROUND Vulvovaginal symptoms, which include dryness, irritation, and pain with intercourse, are common among postmenopausal women and are associated with impaired sexual functioning and quality of life. Previous assessment of treatment strategies for these symptoms has been limited by a lack of sensitive patient-centered outcome measures that assess symptom impact on functional and quality-of-life domains. OBJECTIVE We aimed to (1) examine change in the impact of postmenopausal vulvovaginal symptoms on multiple aspects of well-being and functioning in relation to vaginal estradiol and moisturizer treatment and (2) guide meaningful interpretation of scores on a structured-item questionnaire measure of condition-specific impact. STUDY DESIGN Data were drawn from postmenopausal women who were enrolled in the Menopause Strategies: Finding Lasting Answers for Symptoms and Health Vaginal Health Trial (a 12-week, double-blind, placebo-controlled randomized trial of treatment for vulvovaginal symptoms) who were assigned to vaginal 10-μg estradiol tablet plus placebo gel (n=98), vaginal moisturizer plus placebo tablet (n=97), or dual placebo (n=94). At baseline and 12-week follow up, participants completed the Day-to-Day Impact of Vaginal Aging questionnaire to assess the impact of vaginal symptoms on 4 domains (activities of daily living, emotional well-being, sexual functioning, and body image), each on a 0-4 point scale. Day-to-Day Impact of Vaginal Aging sensitivity to change was assessed by the examination of the associations between change in Day-to-Day Impact of Vaginal Aging domain scores and vulvovaginal symptom severity from baseline to 12 weeks with analysis of covariance. Within-woman and between-group minimal clinically important improvement was assessed with the use of an anchor-based approach that relates change in Day-to-Day Impact of Vaginal Aging domain scores with self-reported benefit from treatment. RESULTS Participants in all treatment arms (n=289) demonstrated reduced impact of vulvovaginal symptoms on all domains of well-being and functioning as assessed by Day-to-Day Impact of Vaginal Aging at 12-week follow up, with no significant differences in improvement between women who were assigned to either estradiol tablet or vaginal moisturizer compared with placebo. For all Day-to-Day Impact of Vaginal Aging domains, mean impact scores were reduced when participants reported symptom improvement (-0.3 to -0.8 point change in Day-to-Day Impact of Vaginal Aging scores for <2-point symptom severity change vs -0.4 to -1.6 point change in Day-to-Day Impact of Vaginal Aging scores for 2+ point symptom severity change; all P<.001). Minimal clinically important change in Day-to-Day Impact of Vaginal Aging domain scale scores, which are anchored to self-reported meaningful benefit from treatment at 12 weeks, ranged from -0.4 to -1.3 (within-woman) and -0.2 to -0.7 (between-group). Observed change and minimal clinically important difference were largest for the sexual functioning domain. CONCLUSION The impact of vulvovaginal symptoms on day-to-day activities, sexual function, emotional well-being, and body image may be improved with low-dose vaginal estradiol, moisturizer, or topical placebo. The Day-to-Day Impact of Vaginal Aging questionnaire demonstrates sensitivity to change with treatment of vulvovaginal symptoms, particularly Day-to-Day Impact of Vaginal Aging scales that focus on symptom impact on sexual functioning and body image. Minimal clinically important improvement in the impact of vulvovaginal symptoms as measured by the Day-to-Day Impact of Vaginal Aging can be defined with the use of these measures.",2020,,['Postmenopausal Vaginal Symptoms'],[],[],"[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",[],[],,0.0982499,,"[{'ForeName': 'Carolyn J', 'Initials': 'CJ', 'LastName': 'Gibson', 'Affiliation': 'San Francisco VA Health Care System, San Francisco, CA; Department of Psychiatry, University of California, San Francisco, CA. Electronic address: Carolyn.Gibson2@va.gov.'}, {'ForeName': 'Alison J', 'Initials': 'AJ', 'LastName': 'Huang', 'Affiliation': 'Department of Medicine, University of California, San Francisco, CA.'}, {'ForeName': 'Joseph C', 'Initials': 'JC', 'LastName': 'Larson', 'Affiliation': 'Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Mitchell', 'Affiliation': 'Vincent Obstetrics and Gynecology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Diem', 'Affiliation': 'Department of Medicine and Epidemiology and Community Health, University of Minnesota, Minneapolis, MN; Department of Medicine, Minneapolis VA Health Care System, Minneapolis, MN.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'LaCroix', 'Affiliation': 'Department of Family Medicine and Public Health, University of California, San Diego, CA.'}, {'ForeName': 'Katherine M', 'Initials': 'KM', 'LastName': 'Newton', 'Affiliation': 'Kaiser Permanente Washington Health Research Institute, Seattle, WA.'}, {'ForeName': 'Susan D', 'Initials': 'SD', 'LastName': 'Reed', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Washington, Seattle, WA.'}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Guthrie', 'Affiliation': 'Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2019.12.270'] 604,30843046,"Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial.","BACKGROUND The incidence of herpes zoster is up to 9 times higher in immunosuppressed solid organ transplant recipients than in the general population. We investigated the immunogenicity and safety of an adjuvanted recombinant zoster vaccine (RZV) in renal transplant (RT) recipients ≥18 years of age receiving daily immunosuppressive therapy. METHODS In this phase 3, randomized (1:1), observer-blind, multicenter trial, RT recipients were enrolled and received 2 doses of RZV or placebo 1-2 months (M) apart 4-18M posttransplant. Anti-glycoprotein E (gE) antibody concentrations, gE-specific CD4 T-cell frequencies, and vaccine response rates were assessed at 1M post-dose 1, and 1M and 12M post-dose 2. Solicited and unsolicited adverse events (AEs) were recorded for 7 and 30 days after each dose, respectively. Solicited general symptoms and unsolicited AEs were also collected 7 days before first vaccination. Serious AEs (including biopsy-proven allograft rejections) and potential immune-mediated diseases (pIMDs) were recorded up to 12M post-dose 2. RESULTS Two hundred sixty-four participants (RZV: 132; placebo: 132) were enrolled between March 2014 and April 2017. gE-specific humoral and cell-mediated immune responses were higher in RZV than placebo recipients across postvaccination time points and persisted above prevaccination baseline 12M post-dose 2. Local AEs were reported more frequently by RZV than placebo recipients. Overall occurrences of renal function changes, rejections, unsolicited AEs, serious AEs, and pIMDs were similar between groups. CONCLUSIONS RZV was immunogenic in chronically immunosuppressed RT recipients. Immunogenicity persisted through 12M postvaccination. No safety concerns arose. CLINICAL TRIALS REGISTRATION NCT02058589.",2020,gE-specific humoral and cell-mediated immune responses were higher in RZV than placebo recipients across post-vaccination time points and persisted above pre-vaccination baseline 12M post-dose 2.,"['chronically immunosuppressed RT recipients', 'Chronically Immunosuppressed Adults Following Renal Transplant', 'renal transplant (RT) recipients ≥18 years of age receiving daily immunosuppressive therapy', '264 participants (RZV: 132; Placebo: 132) were enrolled between March 2014 and April 2017']","['adjuvanted recombinant zoster vaccine (RZV', 'placebo', 'RZV or Placebo', 'RZV', 'Adjuvanted Recombinant Zoster Vaccine']","['Anti-glycoprotein E (gE) antibody concentrations, gE-specific CD4 T-cell frequencies, and vaccine response rates', 'Overall occurrences of renal function changes, rejections, unsolicited AEs, SAEs, and pIMDs', 'Solicited and unsolicited adverse events (AEs', 'Immunogenicity and Safety', 'immunogenicity and safety', 'Immunogenicity', 'gE-specific humoral and cell-mediated immune responses']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0022671', 'cui_str': 'Grafting, Kidney'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0021079', 'cui_str': 'Antirejection Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0019360', 'cui_str': 'Shingles'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0017968', 'cui_str': 'Glycoproteins'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0035015', 'cui_str': 'Rejection'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C0301872', 'cui_str': 'Immune response, function (observable entity)'}]",,0.592793,gE-specific humoral and cell-mediated immune responses were higher in RZV than placebo recipients across post-vaccination time points and persisted above pre-vaccination baseline 12M post-dose 2.,"[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Vink', 'Affiliation': 'GlaxoSmithKline (GSK), Rockville, Maryland.'}, {'ForeName': 'Josep Maria', 'Initials': 'JM', 'LastName': 'Ramon Torrell', 'Affiliation': 'Bellvitge University Hospital, Barcelona.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Sanchez Fructuoso', 'Affiliation': 'Hospital Clínico San Carlos, Madrid, Spain.'}, {'ForeName': 'Sung-Joo', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'Sungkyunkwan University, Canada.'}, {'ForeName': 'Sang-Il', 'Initials': 'SI', 'LastName': 'Kim', 'Affiliation': ""Seoul St Mary's Hospital, College of Medicine, Catholic University of Korea, Republic of Korea.""}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Zaltzman', 'Affiliation': ""St Michael's Hospital, University of Toronto, Ontario, Canada.""}, {'ForeName': 'Fernanda', 'Initials': 'F', 'LastName': 'Ortiz', 'Affiliation': 'Helsinki University Hospital, Finland.'}, {'ForeName': 'Josep Maria', 'Initials': 'JM', 'LastName': 'Campistol Plana', 'Affiliation': ""Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer.""}, {'ForeName': 'Ana Maria', 'Initials': 'AM', 'LastName': 'Fernandez Rodriguez', 'Affiliation': 'Hospital Ramón y Cajal, Madrid.'}, {'ForeName': 'Henar', 'Initials': 'H', 'LastName': 'Rebollo Rodrigo', 'Affiliation': 'University Hospital Valdecilla, Santander.'}, {'ForeName': 'Magda', 'Initials': 'M', 'LastName': 'Campins Marti', 'Affiliation': ""Hospital Universitario Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Perez', 'Affiliation': 'Social Security of Panama, Panama City.'}, {'ForeName': 'Francisco Manuel', 'Initials': 'FM', 'LastName': 'González Roncero', 'Affiliation': 'Hospital Universitario Virgen Rocio, Sevilla, Spain.'}, {'ForeName': 'Deepali', 'Initials': 'D', 'LastName': 'Kumar', 'Affiliation': 'University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Yang-Jen', 'Initials': 'YJ', 'LastName': 'Chiang', 'Affiliation': 'Chang Gung Memorial Hospital, Taoyuan, Taiwan.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Doucette', 'Affiliation': 'University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Lissa', 'Initials': 'L', 'LastName': 'Pipeleers', 'Affiliation': 'UZ Brussel, Belgium.'}, {'ForeName': 'Maria Luisa', 'Initials': 'ML', 'LastName': 'Agüera Morales', 'Affiliation': 'Hospital Universitario Reina Sofia, Córdoba.'}, {'ForeName': 'Maria Luisa', 'Initials': 'ML', 'LastName': 'Rodriguez-Ferrero', 'Affiliation': 'Hospital General Universitario Gregorio Marañón, Madrid, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Secchi', 'Affiliation': 'Vita Salute San Reffaele University, Milan, Italy.'}, {'ForeName': 'Shelly A', 'Initials': 'SA', 'LastName': 'McNeil', 'Affiliation': 'Canadian Center for Vaccinology, Izaak Walton Killam Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Canada.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Campora', 'Affiliation': 'GSK, Wavre, Belgium.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Di Paolo', 'Affiliation': 'GSK, Rixensart, Belgium.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'El Idrissi', 'Affiliation': 'GSK, Rixensart, Belgium.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'López-Fauqued', 'Affiliation': 'GSK, Wavre, Belgium.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Salaun', 'Affiliation': 'GSK, Rixensart, Belgium.'}, {'ForeName': 'Thomas C', 'Initials': 'TC', 'LastName': 'Heineman', 'Affiliation': 'GSK, King of Prussia, Pennsylvania.'}, {'ForeName': 'Lidia', 'Initials': 'L', 'LastName': 'Oostvogels', 'Affiliation': 'GSK, Wavre, Belgium.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciz177'] 605,31632709,Efficacy of water spray for evaporative cooling in athletes with spinal cord injury.,"Study design Interventional crossover study. Objective Spinal cord injury (SCI) disrupts afferent input to the hypothalamus and impairs efferent vaso- and sudomotor output, especially in lesions above the sympathetic chain (T1-L2). In consequence, persons with SCI under heat stress experience impairment in the ability to dissipate heat proportional to the lesion level. Thermoregulatory dysfunction places an individual at high risk of hyperthermia, which can be life threatening, especially for athletes with SCI during exercise. Current evidence on therapeutic cooling techniques in athletes with SCI is limited, but basic physiologic and research data suggest water spray (WS) might be efficacious, particularly in athletes with tetraplegia (TP), who are most impaired in thermoregulation. The aim of this study was to evaluate the effect of WS on core temperature (Tc) during exercise in athletes with SCI. Setting Texas, USA. Methods Eleven individuals with SCI: seven with TP, four with paraplegia (PP); and sixteen able-bodied (AB) controls underwent a wheelchair intermittent sprint exercise for 90 min under two conditions: (1) WS application every 15 min and (2) control (C), without WS. Tc was measured every 15 min and was analyzed for the effect of group (TP, PP, and AB) and time. Change in Tc (ΔTc) was also compared between groups. Results ΔTc was significantly higher in TP vs. PP ( p  < 0.0001) and TP vs. AB ( p  < 0.0001) groups under C treatment. WS significantly attenuated ΔTc in TP ( p  = 0.001), but did not change ΔTc in PP or AB. Conclusion WS effectively attenuated Tc elevation during exercise in athletes with TP. Sponsorship Texas chapter of the Paralyzed Veterans of America.",2019,"WS significantly attenuated ΔTc in TP ( p  = 0.001), but did not change ΔTc in PP or AB. Conclusion WS effectively attenuated Tc elevation during exercise in athletes with TP. ","['athletes with spinal cord injury', 'athletes with tetraplegia (TP', 'Sponsorship\n\n\nTexas chapter of the Paralyzed Veterans of America', 'Eleven individuals with SCI: seven with TP, four with paraplegia (PP); and sixteen able-bodied (AB) controls underwent a', 'athletes with SCI']","['water spray', 'wheelchair intermittent sprint exercise for 90\u2009min under two conditions: (1) WS application every 15\u2009min and (2) control (C), without WS']","['Change in Tc (ΔTc', 'Tc elevation', 'core temperature (Tc', 'TP vs. PP']","[{'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0034372', 'cui_str': 'Tetraplegia'}, {'cui': 'C0039711', 'cui_str': 'Texas'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0002454', 'cui_str': 'Americas'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0030486', 'cui_str': 'Paralysis, Legs'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C1299581', 'cui_str': 'Able'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C4521772', 'cui_str': 'Spray'}, {'cui': 'C0043143', 'cui_str': 'Wheel Chairs'}, {'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C0039476', 'cui_str': 'Temperature'}]",11.0,0.0318801,"WS significantly attenuated ΔTc in TP ( p  = 0.001), but did not change ΔTc in PP or AB. Conclusion WS effectively attenuated Tc elevation during exercise in athletes with TP. ","[{'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Trbovich', 'Affiliation': '1Department of Rehabilitation Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX USA.'}, {'ForeName': 'Wouter', 'Initials': 'W', 'LastName': 'Koek', 'Affiliation': '2Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX USA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Ortega', 'Affiliation': '3School of Health Professions, Physical Therapy Department, University of Texas Health Science Center at San Antonio, San Antonio, TX USA.'}]",Spinal cord series and cases,['10.1038/s41394-019-0194-8'] 606,31902690,A Randomized Cross-Over Trial Focused on Breast Core Needle Biopsy Skill Acquisition and Safety Using High Fidelity Versus Low Fidelity Simulation Models in Rwanda.,"OBJECTIVE Breast cancer is the most common cancer diagnosed in low and middle-income countries. Growing the number of health care personnel trained in diagnostic procedures like breast core needle biopsy (BCNB) is critical. We developed a BCNB simulation-training course that evaluated skill acquisition, confidence, and safety, comparing low-cost low fidelity (LF) models to expensive high fidelity (HF) models. DESIGN A single-center randomized education crossover trial was implemented. Participants were randomized to HF or LF groups. A preintervention baseline exam followed by lectures and training sessions with a HF or LF model was implemented. A postintervention simulation exam was conducted, and participants crossed over to the other simulation model. SETTING The study was implemented at the University Teaching Hospital, Kigali (CHUK) in Rwanda, Africa from October 2014 to March 2015. PARTICIPANTS Residents training in surgery or obstetrics and gynecology participated in a 1-day BCNB training course. RESULTS A total of 36 residents were analyzed, 19 in the HF arm and 17 in the LF arm. Mean difference in exam scores for HF and LF groups in the baseline exam (exam 1) (0.067, p = 0.94, standard error [SE] of 1.57) postintervention exam (exam 2) (1.85, SE 1.46, p = 0.33), and the crossover exam (exam 3) (4.39, SE = 1.90, p = 0.11) were not significantly different between HF and LF. Overall exam scores improved from pre- to postintervention. CONCLUSIONS Our results indicate that mean difference in exams scores were not significantly different between residents trained with HF versus LF models. In resources poor areas-LF models can be utilized as effective teaching tools for skill acquisition for diagnostic surgical procedures.",2020,"Mean difference in exam scores for HF and LF groups in the baseline exam (exam 1) (0.067, p = 0.94, standard error [SE] of 1.57) postintervention exam (exam 2) (1.85, SE 1.46, p = 0.33), and the crossover exam (exam 3) (4.39, SE = 1.90, p = 0.11) were not significantly different between HF and LF.","['The study was implemented at the University Teaching Hospital, Kigali (CHUK) in Rwanda, Africa from October 2014 to March 2015', 'A total of 36 residents were analyzed, 19 in the HF arm and 17 in the LF arm', 'Rwanda', 'Residents training in surgery or obstetrics and gynecology participated in a 1-day BCNB training course']",['Breast Core Needle Biopsy Skill Acquisition and Safety'],"['exams scores', 'Overall exam scores']","[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0020027', 'cui_str': 'Teaching Hospitals'}, {'cui': 'C0035978', 'cui_str': 'Ruanda'}, {'cui': 'C0001737', 'cui_str': 'Africa'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C1274104', 'cui_str': 'Obstetrics and gynecology'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}]","[{'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C1318309', 'cui_str': 'Biopsy, Large-Core Needle'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.0469817,"Mean difference in exam scores for HF and LF groups in the baseline exam (exam 1) (0.067, p = 0.94, standard error [SE] of 1.57) postintervention exam (exam 2) (1.85, SE 1.46, p = 0.33), and the crossover exam (exam 3) (4.39, SE = 1.90, p = 0.11) were not significantly different between HF and LF.","[{'ForeName': 'Shilpa S', 'Initials': 'SS', 'LastName': 'Murthy', 'Affiliation': ""Indiana University, Department of Surgery, Bloomington, Indiana; Center for Surgery and Public Health, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: shilpamurthy83@gmail.com.""}, {'ForeName': 'Faustin', 'Initials': 'F', 'LastName': 'Ntirenganya', 'Affiliation': 'University of Rwanda, Department of Surgery, Kigali, Rwanda.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Scott', 'Affiliation': ""Center for Surgery and Public Health, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts; University of Michigan, Department of Surgery, Ann Arbor, Michigan.""}, {'ForeName': 'Allen', 'Initials': 'A', 'LastName': 'Ingabire', 'Affiliation': 'University of Rwanda, Department of Surgery, Kigali, Rwanda.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Rosman', 'Affiliation': 'Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Sughra', 'Initials': 'S', 'LastName': 'Raza', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, Massachusetts.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Troyan', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, Massachusetts.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Dunnington', 'Affiliation': 'Indiana University, Department of Surgery, Bloomington, Indiana.'}, {'ForeName': 'Gally', 'Initials': 'G', 'LastName': 'Reznor', 'Affiliation': 'Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Stu', 'Initials': 'S', 'LastName': 'Lipitz', 'Affiliation': ""Center for Surgery and Public Health, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Georges', 'Initials': 'G', 'LastName': 'Ntakiyiruta', 'Affiliation': 'University of Rwanda, Department of Surgery, Kigali, Rwanda.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Riviello', 'Affiliation': ""Center for Surgery and Public Health, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts; University of Rwanda, Department of Surgery, Kigali, Rwanda.""}]",Journal of surgical education,['10.1016/j.jsurg.2019.11.014'] 607,31874652,[Clinical effect of white noise combined with glucose in reducing the pain of retinopathy screening in preterm infants].,"OBJECTIVE To study the clinical effect of white noise combined with glucose in reducing the procedural pain of retinopathy screening in preterm infants. METHODS A total of 396 preterm infants with a gestational age of 28-34 weeks and a birth weight of ≤2 000 g were randomly divided into 4 groups according to the intervention method for reducing pain in retinopathy screening: control group with 100 infants (no white noise or glucose intervention), white noise group with 96 infants, glucose group with 98 infants and white noise + glucose group with 102 infants. The Premature Infant Pain Profile (PIPP) was used to determine pain score during retinopathy screening, and the four groups were compared in terms of PIPP score before and after retinopathy screening. RESULTS There were no significant differences in PIPP score, heart rate and blood oxygen saturation between the four groups at 3 minutes before screening (P>0.05). At 1 and 5 minutes after screening, the white noise, glucose and white noise + glucose groups had significantly lower heart rate and PIPP score but significantly higher blood oxygen saturation than the control group (P<0.05).The white noise + glucose group had significantly lower heart rate and PIPP score but significantly higher blood oxygen saturation than the white noise and glucose groups (P<0.05). CONCLUSIONS White noise combined with glucose can reduce the procedural pain of retionopathy screening and keep vital signs stable in preterm infants.",2019,"There were no significant differences in PIPP score, heart rate and blood oxygen saturation between the four groups at 3 minutes before screening (P>0.05).","['396 preterm infants with a gestational age of 28-34 weeks and a birth weight of ≤2\u2009000\u2005g', 'group with 102 infants', 'preterm infants']","['white noise combined with glucose', 'intervention method for reducing pain in retinopathy screening: control group with 100 infants (no white noise or glucose intervention), white noise group with 96 infants, glucose group with 98 infants and white noise\u2009+\u2009glucose']","['heart rate and PIPP score', 'Premature Infant Pain Profile (PIPP', 'pain score', 'procedural pain of retinopathy screening', 'blood oxygen saturation', 'pain of retinopathy screening', 'PIPP score, heart rate and blood oxygen saturation']","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0035309', 'cui_str': 'Retinal Diseases'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C1619712', 'cui_str': 'Pain, Procedural'}, {'cui': 'C0035309', 'cui_str': 'Retinal Diseases'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0428174', 'cui_str': 'Hemoglobin saturation with oxygen (observable entity)'}]",396.0,0.0218232,"There were no significant differences in PIPP score, heart rate and blood oxygen saturation between the four groups at 3 minutes before screening (P>0.05).","[{'ForeName': 'Xiang-Fang', 'Initials': 'XF', 'LastName': 'Ren', 'Affiliation': ""Bayi Children's Hospital, Seventh Medical Center, General Hospital of the Chinese People's Liberation Army, Beijing 100700, China. sdkongxy@126.com.""}, {'ForeName': 'Zi-Zhen', 'Initials': 'ZZ', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Xiang-Yong', 'Initials': 'XY', 'LastName': 'Kong', 'Affiliation': ''}, {'ForeName': 'Zhi-Chun', 'Initials': 'ZC', 'LastName': 'Feng', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 608,32109176,A Randomized Controlled Trial Investigating Online Training for Prelinguistic Communication.,"Purpose This study explored the utility of online training as a platform for teaching early intervention speech-language pathologists to recognize potentially communicative, prelinguistic behaviors in young children with physical disabilities and complex communication needs. Method Using a randomized controlled trial, 45 early intervention speech-language pathologists were randomly assigned to one of three conditions within an online training: practice with implicit problem-solving (identification condition), practice with explicit problem-solving (reflection condition), or no practice (control condition). Knowledge about early communication, skill at recognizing prelinguistic behaviors, time taken to complete the training, and perceptions of the training experience were examined. Results Participants in the no-practice control condition took significantly less time to complete the training, achieved the same positive outcomes on the knowledge and skill assessments, and rated the training as appealing as compared with participants assigned to the more time-intensive identification and reflection practice conditions. Conclusions Results suggest the importance of considering efficiency and appeal when designing successful trainings for moving evidence into practice.",2020,"Results Participants in the no-practice control condition took significantly less time to complete the training, achieved the same positive outcomes on the knowledge and skill assessments, and rated the training as appealing as compared with participants assigned to the more time-intensive identification and reflection practice conditions.","['young children with physical disabilities and complex communication needs', '45 early intervention speech-language pathologists']","['online training: practice with implicit problem-solving (identification condition), practice with explicit problem-solving (reflection condition), or no practice (control condition', 'Online Training', 'online training']",[],"[{'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0520817', 'cui_str': 'Physical handicap (finding)'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0242687', 'cui_str': 'Early Intervention'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0023008', 'cui_str': 'Languages'}, {'cui': 'C0334866', 'cui_str': 'Pathologists'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C3669643', 'cui_str': 'Problem solving (qualifier value)'}, {'cui': 'C0020792', 'cui_str': 'Identification'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",[],45.0,0.033264,"Results Participants in the no-practice control condition took significantly less time to complete the training, achieved the same positive outcomes on the knowledge and skill assessments, and rated the training as appealing as compared with participants assigned to the more time-intensive identification and reflection practice conditions.","[{'ForeName': 'Julie L', 'Initials': 'JL', 'LastName': 'Feuerstein', 'Affiliation': 'School of Communication Sciences and Disorders, College of Health Professions and Sciences, University of Central Florida, Orlando.'}, {'ForeName': 'Lesley B', 'Initials': 'LB', 'LastName': 'Olswang', 'Affiliation': 'Department of Speech and Hearing Sciences, University of Washington, Seattle.'}]","Journal of speech, language, and hearing research : JSLHR",['10.1044/2019_JSLHR-19-00336'] 609,31315446,"Monthly Video-Consultation for Children With Type 1 Diabetes Using a Continuous Glucose Monitoring System: Design of ViDiKi, a Multimethod Intervention Study to Evaluate the Benefit of Telemedicine.","BACKGROUND The introduction of continuous glucose monitoring (CGM) implies new challenges for diabetes care. As CGM systems are often directly linked to a web-based software solution, structured telemedicine care using a video-consultation may be a new option for families who care for children with type 1 diabetes mellitus (T1DM). METHODS ""ViDiKi"" (Virtual Diabetes Outpatient Clinic for Children and Youth) is a multicenter controlled trial carried out in Northern Germany. ViDiKi will examine if monthly telemedical consultations, in addition to regular care, will improve glycemic control and psychosocial outcomes. The primary outcome is glycemic control as measured by a change in glycated hemoglobin (HbA1c). A total of 240 participants aged between one year and 16 years using a CGM with multiple daily injections (MDI) or insulin pump therapy were recruited and assigned to a starter group or a six-month waiting control group. The sample size is designed to detect a between-group difference of 0.5% in HbA1c change at six months. Secondary outcomes are variability of blood glucose, health-related quality of life, self-efficacy, and satisfaction with telemedicine. To gain deeper insight into the experience of using telemedicine, qualitative interviews will be conducted. In a health-economic analysis, the costs of telemedicine and a cost-of-care analysis will be calculated. CONCLUSIONS The results from the ViDiKi study shall give important information on the feasibility and putative benefits of telemedicine in children with T1DM and their caregivers. GERMAN CLINICAL TRAILS REGISTER (DRKS) DRKS00012645.",2020,"Secondary outcomes are variability of blood glucose, health-related quality of life, self-efficacy, and satisfaction with telemedicine.","['Northern Germany', 'children with T1DM and their caregivers', 'ViDiKi"" (Virtual Diabetes Outpatient Clinic for Children and Youth', '240 participants aged between one year and 16 years using a', 'families who care for children with type 1 diabetes mellitus (T1DM', 'Children']","['CGM with multiple daily injections (MDI) or insulin pump therapy', 'telemedicine', 'continuous glucose monitoring (CGM', 'starter group or a six-month waiting control group', 'Telemedicine']","['glycemic control as measured by a change in glycated hemoglobin (HbA1c', 'variability of blood glucose, health-related quality of life, self-efficacy, and satisfaction with telemedicine']","[{'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C4319600', 'cui_str': '240 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C1140609', 'cui_str': 'Insulin pump'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C4523945', 'cui_str': 'Continuous glucose monitoring'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0017853', 'cui_str': 'Hemoglobin, Glycosylated'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0162648', 'cui_str': 'Telemedicine'}]",240.0,0.0839175,"Secondary outcomes are variability of blood glucose, health-related quality of life, self-efficacy, and satisfaction with telemedicine.","[{'ForeName': 'Fabian-Simon', 'Initials': 'FS', 'LastName': 'Frielitz', 'Affiliation': 'Institute of Social Medicine and Epidemiology, University of Luebeck, Germany.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Müller-Godeffroy', 'Affiliation': 'Department of Pediatric Endocrinology and Diabetology, University Medical Center, Campus Luebeck, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Hübner', 'Affiliation': 'Institute of Social Medicine and Epidemiology, University of Luebeck, Germany.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Eisemann', 'Affiliation': 'Institute of Social Medicine and Epidemiology, University of Luebeck, Germany.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Dördelmann', 'Affiliation': 'Institute of Social Medicine and Epidemiology, University of Luebeck, Germany.'}, {'ForeName': 'Ingo', 'Initials': 'I', 'LastName': 'Menrath', 'Affiliation': 'Department of Pediatric Endocrinology and Diabetology, University Medical Center, Campus Luebeck, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Katalinic', 'Affiliation': 'Institute of Social Medicine and Epidemiology, University of Luebeck, Germany.'}, {'ForeName': 'Olaf', 'Initials': 'O', 'LastName': 'Hiort', 'Affiliation': 'Department of Pediatric Endocrinology and Diabetology, University Medical Center, Campus Luebeck, Germany.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'von Sengbusch', 'Affiliation': 'Department of Pediatric Endocrinology and Diabetology, University Medical Center, Campus Luebeck, Germany.'}]",Journal of diabetes science and technology,['10.1177/1932296819861991'] 610,31881241,Survival of composite restorations after selective or total caries removal in primary teeth and predictors of failures: A 36-months randomized controlled trial.,"OBJECTIVES The aim of this study was to assess the survival of composite restorations after selective (SCR) or total caries removal (TCR) and determine predictors of failures after 36 months. METHODS 120 teeth with deep occlusal or occlusal-proximal carious lesions were randomly divided into control (TCR; n = 54; 69% Class II) and test (SCR; n = 66; 63% Class II) groups. Clinical evaluation was applied using the USPHS criteria, and the presence of Charlie or Delta scores at the marginal integrity were considered as a failure. RESULTS The overall survival rate of restorations was 68% after 36 months, 81% for TCR and 57% for SCR (p = 0.004). The multivariable Cox Regression model demonstrated that restorations performed after SCR had 3.44 times greater probability of failure compared to TCR (p = 0.006). The other two predictors for failure of restorations were teeth with Class II cavities (hazard ratio = 3.3) and children with gingival bleeding over 20% (hazard ratio = 2.5). CONCLUSIONS Performing composite restorations after SCR in primary teeth had success rate significantly lower than restorations performed after TCR. Complex cavities and worst patient´s oral hygiene were found to be predictors of failure of restorations. CLINICAL SIGNIFICANCE Although SCR has been demonstrating high rates of pulp preservation, clinicians should consider that composite restorations fail in a higher frequency compared to TCR in primary teeth and, in some circumstances, may be preferable in terms of restoration longevity.",2020,"The overall survival rate of restorations was 68% after 36 months, 81% for TCR and 57% for SCR (p = 0.004).",['120 teeth with deep occlusal or occlusal-proximal carious lesions'],['selective (SCR) or total caries removal (TCR'],"['overall survival rate of restorations', 'probability of failure', 'survival of composite restorations', 'success rate', 'gingival bleeding']","[{'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C1947917', 'cui_str': 'Occluded (qualifier value)'}, {'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C0011334', 'cui_str': 'Dental Decay'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration (attribute)'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0017565', 'cui_str': 'Gingival Hemorrhage'}]",120.0,0.0391794,"The overall survival rate of restorations was 68% after 36 months, 81% for TCR and 57% for SCR (p = 0.004).","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Liberman', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, Universidad de la Republica, Montevideo, Uruguay.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Franzon', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil. Electronic address: renatafranzon@hotmail.com.'}, {'ForeName': 'L F', 'Initials': 'LF', 'LastName': 'Guimarães', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Casagrande', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'A N', 'Initials': 'AN', 'LastName': 'Haas', 'Affiliation': 'Periodontology, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'F B', 'Initials': 'FB', 'LastName': 'Araujo', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.'}]",Journal of dentistry,['10.1016/j.jdent.2019.103268'] 611,31948926,Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials.,"BACKGROUND Using latent class analysis (LCA) in five randomised controlled trial (RCT) cohorts, two distinct phenotypes of acute respiratory distress syndrome (ARDS) have been identified: hypoinflammatory and hyperinflammatory. The phenotypes are associated with differential outcomes and treatment response. The objective of this study was to develop parsimonious models for phenotype identification that could be accurate and feasible to use in the clinical setting. METHODS In this retrospective study, three RCT cohorts from the National Lung, Heart, and Blood Institute ARDS Network (ARMA, ALVEOLI, and FACTT) were used as the derivation dataset (n=2022), from which the machine learning and logistic regression classifer models were derived, and a fourth (SAILS; n=715) from the same network was used as the validation test set. LCA-derived phenotypes in all of these cohorts served as the reference standard. Machine-learning algorithms (random forest, bootstrapped aggregating, and least absolute shrinkage and selection operator) were used to select a maximum of six important classifier variables, which were then used to develop nested logistic regression models. Only cases with complete biomarker data in the derivation dataset were used for variable selection. The best logistic regression models based on parsimony and predictive accuracy were then evaluated in the validation test set. Finally, the models' prognostic validity was tested in two external ARDS clinical trial datasets (START and HARP-2) by assessing mortality at days 28, 60, and 90 and ventilator-free days to day 28. FINDINGS The six most important classifier variables were interleukin (IL)-8, IL-6, protein C, soluble tumour necrosis factor receptor 1, bicarbonate, and vasopressor use. From the nested models, three-variable (IL-8, bicarbonate, and protein C) and four-variable (3-variable plus vasopressor use) models were adjudicated to be the best performing. In the validation test set, both models showed good accuracy (AUC 0·94 [95% CI 0·92-0·95] for the three-variable model and 0·95 [95% CI 0·93-0·96] for the four-variable model) against LCA classifications. As with LCA-derived phenotypes, the hyperinflammatory phenotype as identified by the classifier model was associated with higher mortality at day 90 (87 [39%] of 223 patients vs 112 [23%] of 492 patients; p<0·0001) and fewer ventilator-free days (median 14 days [IQR 0-22] vs 22 days [0-25]; p<0·0001). In the external validation datasets, three-variable models developed in the derivation dataset identified two phenotypes with distinct clinical features and outcomes consistent with previous findings, including differential survival with simvastatin versus placebo in HARP-2 (p=0·023 for survival at 28 days). INTERPRETATION ARDS phenotypes can be accurately identified with parsimonious classifier models using three or four variables. Pending the development of real-time testing for key biomarkers and prospective validation, these models could facilitate identification of ARDS phenotypes to enable their application in clinical trials and practice. FUNDING National Institutes of Health.",2020,"In the validation test set, both models showed good accuracy (AUC 0·94 [95% CI 0·92-0·95] for the three-variable model and 0·95","['acute respiratory distress syndrome (ARDS', 'classify acute respiratory distress syndrome phenotypes']",['simvastatin versus placebo'],"['higher mortality', 'interleukin (IL)-8, IL-6, protein C, soluble tumour necrosis factor receptor 1, bicarbonate, and vasopressor use']","[{'cui': 'C0035222', 'cui_str': 'ARDS, Human'}, {'cui': 'C0008902', 'cui_str': 'Systematics'}, {'cui': 'C1314763', 'cui_str': 'Phenotyping (qualifier value)'}]","[{'cui': 'C0074554', 'cui_str': 'Simvastatin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0611128', 'cui_str': 'protein C (synaptosomal)'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C0005367', 'cui_str': 'Hydrogen Carbonates'}, {'cui': 'C1947944', 'cui_str': 'Use'}]",492.0,0.0742616,"In the validation test set, both models showed good accuracy (AUC 0·94 [95% CI 0·92-0·95] for the three-variable model and 0·95","[{'ForeName': 'Pratik', 'Initials': 'P', 'LastName': 'Sinha', 'Affiliation': 'Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Anesthesia, University of California, San Francisco, San Francisco, CA, USA. Electronic address: pratik.sinha@ucsf.edu.'}, {'ForeName': 'Kevin L', 'Initials': 'KL', 'LastName': 'Delucchi', 'Affiliation': 'Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Daniel F', 'Initials': 'DF', 'LastName': 'McAuley', 'Affiliation': ""The Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, Belfast, UK; Regional Intensive Care Unit, The Royal Hospitals, Belfast, UK.""}, {'ForeName': 'Cecilia M', 'Initials': 'CM', 'LastName': ""O'Kane"", 'Affiliation': ""The Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, Belfast, UK.""}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Matthay', 'Affiliation': 'Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Anesthesia, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Carolyn S', 'Initials': 'CS', 'LastName': 'Calfee', 'Affiliation': 'Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Anesthesia, University of California, San Francisco, San Francisco, CA, USA.'}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(19)30369-8'] 612,31948853,Effectiveness of a Diet and Resistance Exercise Intervention on Muscle Health in Older Adults: ProMuscle in Practice.,"OBJECTIVES Clinical studies show that resistance exercise and a protein-rich diet can counteract the age-related decline of muscle mass, strength, and physical performance. The aim of the ProMuscle in Practice study was to test effectiveness of a resistance exercise and dietary protein intervention for older adults implemented in a real-life setting. DESIGN A randomized controlled multicenter intervention study. SETTING AND PARTICIPANTS One hundred sixty-eight community-dwelling older adults were included (age 75 ± 6 years). A 12-week intensive support intervention including progressive resistance exercise supervised by a physiotherapist and dietitian guidance on increasing protein intake was followed by a voluntary 12-week moderate support intervention to continue the adapted lifestyle pattern. The control group received no intervention. METHODS Compliance was measured through attendance lists and 3-day food records. Physical functioning, leg strength (3-repetition maximum, knee extension strength), lean body mass [(LBM) dual-energy X-ray absorptiometry], and quality of life (5-level EQ-5D) were measured at baseline, and after 12 and 24 weeks. Differences in change between groups were assessed with linear mixed model analysis. RESULTS The intervention group increased protein intake and attended 83.6% of the training sessions. Short Physical Performance Battery score slightly increased in intervention participants [from 10.1 (95% confidence interval 9.7-10.5) to 10.4 (10.0-10.8) at week 12 and 10.6 (10.2-10.9) at week 24], where control participants decreased (time × treatment interactions, P < .05). Improvements in intervention group compared with controls were also observed for Timed Up-and-Go, strength and LBM at both time points (time × treatment interactions, P < .05). No difference between groups was found for the 6-Minute Walking Test, activities of daily living, and quality of life. CONCLUSIONS AND IMPLICATIONS ProMuscle in Practice was effective on improving muscle strength and LBM, with small changes in the composite function score in community-dwelling older adults in a real-life setting. Further research should explore feasibility of real-life implementation, as well as improving long-term compliance.",2020,"No difference between groups was found for the 6-Minute Walking Test, activities of daily living, and quality of life. ","['Older Adults', 'One hundred sixty-eight community-dwelling older adults were included (age 75\xa0±\xa06\xa0years', 'older adults implemented in a real-life setting', 'community-dwelling older adults']","['progressive resistance exercise supervised by a physiotherapist and dietitian guidance', 'Diet and Resistance Exercise Intervention', 'resistance exercise and a protein-rich diet', 'resistance exercise and dietary protein intervention', 'no intervention']","['Short Physical Performance Battery score', 'Physical functioning, leg strength (3-repetition maximum, knee extension strength), lean body mass [(LBM) dual-energy X-ray absorptiometry], and quality of life (5-level EQ-5D', 'protein intake', 'Muscle Health', '6-Minute Walking Test, activities of daily living, and quality of life']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0450387', 'cui_str': '68 (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0376558', 'cui_str': 'Life'}]","[{'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapists'}, {'cui': 'C0334932', 'cui_str': 'Dietitian (general) (occupation)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C0012177', 'cui_str': 'Dietary Proteins'}]","[{'cui': 'C4075289', 'cui_str': 'Short Physical Performance Battery score (observable entity)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass (observable entity)'}, {'cui': 'C1510486', 'cui_str': 'Dual X-Ray Absorptiometry'}, {'cui': 'C0034380'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0001288', 'cui_str': 'ADL'}]",168.0,0.0339392,"No difference between groups was found for the 6-Minute Walking Test, activities of daily living, and quality of life. ","[{'ForeName': 'Ellen J I', 'Initials': 'EJI', 'LastName': 'van Dongen', 'Affiliation': 'Food, Health and Consumer Research, Wageningen Food and Biobased Research, Wageningen, the Netherlands.'}, {'ForeName': 'Annemien', 'Initials': 'A', 'LastName': 'Haveman-Nies', 'Affiliation': 'Division of Strategic Communication, Wageningen University and Research, Wageningen, the Netherlands; Division of Human Nutrition and Health, Wageningen University and Research, the Netherlands; GGD Noord-en Oost-Gelderland, Academic Collaborative Center AGORA, Zutphen, the Netherlands.'}, {'ForeName': 'Esmée L', 'Initials': 'EL', 'LastName': 'Doets', 'Affiliation': 'Food, Health and Consumer Research, Wageningen Food and Biobased Research, Wageningen, the Netherlands.'}, {'ForeName': 'Berber G', 'Initials': 'BG', 'LastName': 'Dorhout', 'Affiliation': 'Division of Human Nutrition and Health, Wageningen University and Research, the Netherlands.'}, {'ForeName': 'Lisette C P G M', 'Initials': 'LCPGM', 'LastName': 'de Groot', 'Affiliation': 'Division of Human Nutrition and Health, Wageningen University and Research, the Netherlands. Electronic address: Lisette.degroot@wur.nl.'}]",Journal of the American Medical Directors Association,['10.1016/j.jamda.2019.11.026'] 613,31939036,A comparative study between intradermal botulinum toxin A and fractional microneedle radiofrequency (FMR) for the treatment of primary axillary hyperhidrosis.,"Microneedle radiofrequency (FMR) for the treatment of primary axillary hyperhidrosis radiofrequency (RF) technology is a new modality that applied deep heat energy directly affecting the epidermis and dermis. Limiting data about FMR for axillary hyperhidrosis is concerning. To compare clinical efficacy between fractional microneedle radiofrequency and intradermal botulinum toxin type A injection. This study was a randomized, intraindividual split-side comparative study. Twenty female subjects clinically diagnosed of primary axillary hyperhidrosis were enrolled. All subjects randomly assigned to receive either FMR device on one side of axilla or 50 units of intradermal botulinum toxin A on contralateral side of axilla. Treatment with FMR device was scheduled for 2 sessions for 4 weeks apart. After treatment, mean Hyperhidrosis Disease Severity Score (HDSS) of both groups revealed remarkably better reduction from the baseline (p < 000.1). By comparing between the two groups at the endpoint visit (12th week), the botulinum toxin A group had significantly better reduction of mean HDSS score than the microneedle RF group with 1.60 (0.59) versus 2.05 (0.68), respectively (p = 0.0332). At the week-12 visit, the botulinum toxin A group had significantly better participant's satisfaction score by quartile rating scale than the microneedle RF group (2.55 + 0.69 versus 1.70 + 1.03, respectively, p = 0.004). Therefore, the botulinum toxin A group also demonstrated with significantly better improvement for their quality of life by DLQI score at the 12th week than the microneedle RF group (p = 0.013). Intradermal botulinum toxin A had better efficacy than fractional microneedle radiofrequency for the treatment of primary axillary hyperhidrosis.",2020,Intradermal botulinum toxin A had better efficacy than fractional microneedle radiofrequency for the treatment of primary axillary hyperhidrosis.,"['primary axillary hyperhidrosis', 'Twenty female subjects clinically diagnosed of primary axillary hyperhidrosis were enrolled']","['Microneedle radiofrequency (FMR', 'microneedle RF', 'fractional microneedle radiofrequency and intradermal botulinum toxin type A injection', 'FMR device on one side of axilla or 50\xa0units of intradermal botulinum toxin A on contralateral side of axilla', 'FMR device', 'Intradermal botulinum toxin', 'intradermal botulinum toxin A and fractional microneedle radiofrequency (FMR', 'fractional microneedle radiofrequency']","['mean Hyperhidrosis Disease Severity Score (HDSS', ""participant's satisfaction score by quartile rating scale"", 'mean HDSS score', 'quality of life by DLQI score']","[{'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0004454', 'cui_str': 'Axilla'}, {'cui': 'C0020458', 'cui_str': 'Hyperhidrosis'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C4060200', 'cui_str': 'Botulinum Toxin Type A Injection [Botox]'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0004454', 'cui_str': 'Axilla'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0006055', 'cui_str': 'Botulin'}, {'cui': 'C0441988', 'cui_str': 'Contralateral (qualifier value)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0020458', 'cui_str': 'Hyperhidrosis'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0457451', 'cui_str': 'Severity score (qualifier value)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0034380'}]",20.0,0.0242862,Intradermal botulinum toxin A had better efficacy than fractional microneedle radiofrequency for the treatment of primary axillary hyperhidrosis.,"[{'ForeName': 'Paisal', 'Initials': 'P', 'LastName': 'Rummaneethorn', 'Affiliation': 'School of Antiaging and Regenerative Medicine, Mae Fah Luang University, 38/11-13 Asoke place building, Asoke road, Sukhumvit 21, Wattana, North Klongtoey, Bangkok, Thailand.'}, {'ForeName': 'Thep', 'Initials': 'T', 'LastName': 'Chalermchai', 'Affiliation': 'School of Antiaging and Regenerative Medicine, Mae Fah Luang University, 38/11-13 Asoke place building, Asoke road, Sukhumvit 21, Wattana, North Klongtoey, Bangkok, Thailand. thep_chalermchai@hotmail.com.'}]",Lasers in medical science,['10.1007/s10103-020-02958-8'] 614,31944472,Exploring the effectiveness of an 18-month weight management intervention in adults with Down syndrome using propensity score matching.,"BACKGROUND Down syndrome (DS) is one of the most common birth defects in the USA associated with high levels of overweight and obesity. Unique characteristics of adults with DS that may contribute to the high levels of obesity are high rates of hypothyroidism, poor muscle tone, altered gait and lower resting metabolic rate. Due to these factors, it is unknown if the same weight management interventions that are effective in adults with intellectual or developmental disability (IDD) without DS are as effective in those with DS. Therefore, the purpose of this secondary analysis was to compare changes in weight, diet and physical activity between participants with DS-related and non-DS-related IDD participating in an 18-month weight management trial. METHODS We used propensity score methods to adjust baseline variables of overweight/obese adults with and without DS participating in an 18-month effectiveness trial with 6 months weight loss and 12 months weight maintenance. Participants followed one of two reduced calorie diet plans, obtained 150 min of moderate-vigorous intensity physical activity (MVPA) per week, and logged dietary intake daily. A health educator held monthly at-home visits with participants and a caregiver to give feedback on intervention compliance. RESULTS Out of the 124 participants that met the criteria for inclusion, 21 were diagnosed with DS and 103 with non-DS-related IDD. Twenty out of 21 participants with DS were successfully matched. Clinically significant weight loss was seen at 18 months in participants with DS (-5.2%) and non-DS-related IDD (-6.8%), with no difference between groups (P = 0.53). Significant reductions in energy intake were seen across the 18-month intervention in both DS and non-DS-related IDD groups with between-group differences at 12 months only (1119 vs. 1492 kcal/day, respectively; P = 0.003). Although MVPA did not increase in either group across the intervention, those with non-DS-related IDD had higher levels of MVPA compared with those with DS across 18 months. CONCLUSION Participants with DS lost a clinically significant amount of weight across the 18-month intervention. Compared with those with non-DS-related IDD, those with DS lost similar amounts of weight, had similar decreases in energy intake and participated in less MVPA across the 18-month intervention. Although individuals with DS have physiological factors that may contribute to obesity, weight management interventions designed for individuals with IDD may be equally effective in this population.",2020,"Significant reductions in energy intake were seen across the 18-month intervention in both DS and non-DS-related IDD groups with between-group differences at 12 months only (1119 vs. 1492 kcal/day, respectively; P = 0.003).","['124 participants that met the criteria for inclusion, 21 were diagnosed with DS and 103 with non-DS-related IDD', 'adults with Down syndrome using propensity score matching', 'Twenty out of 21 participants with DS were successfully matched', 'participants with DS-related and non-DS-related IDD participating in an 18-month weight management trial', 'adults with intellectual or developmental disability (IDD) without DS', 'overweight/obese adults with and without DS participating in an 18-month effectiveness trial with 6\xa0months weight loss and 12\xa0months weight maintenance', 'adults with DS']","['weight management intervention', 'calorie diet plans, obtained 150\xa0min of moderate-vigorous intensity physical activity (MVPA) per week, and logged dietary intake daily']","['levels of MVPA', 'weight', 'energy intake', 'weight, diet and physical activity', 'weight loss']","[{'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C4517526', 'cui_str': 'One hundred and three'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0013080', 'cui_str': '47,XY,+21'}, {'cui': 'C2718044', 'cui_str': 'Propensity Score'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0008073', 'cui_str': 'Child Development Disorders'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}]","[{'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0301589', 'cui_str': 'Calorie diet (finding)'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}]",124.0,0.0405306,"Significant reductions in energy intake were seen across the 18-month intervention in both DS and non-DS-related IDD groups with between-group differences at 12 months only (1119 vs. 1492 kcal/day, respectively; P = 0.003).","[{'ForeName': 'L T', 'Initials': 'LT', 'LastName': 'Ptomey', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS.'}, {'ForeName': 'E A', 'Initials': 'EA', 'LastName': 'Willis', 'Affiliation': 'Center for Health Promotions and Disease Prevention, University of North Carolina at Chapel Hill, Chapel Hill, NC.'}, {'ForeName': 'J R', 'Initials': 'JR', 'LastName': 'Sherman', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS.'}, {'ForeName': 'D A', 'Initials': 'DA', 'LastName': 'White', 'Affiliation': ""Ward Family Heart Center, Children's Mercy Kansas City, Kansas City, MO.""}, {'ForeName': 'J E', 'Initials': 'JE', 'LastName': 'Donnelly', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS.'}]",Journal of intellectual disability research : JIDR,['10.1111/jir.12713'] 615,30969032,Combined nestorone-testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men.,"BACKGROUND Novel male-based contraceptives are needed to broaden family planning choices. A progestin, Nestorone ® (Nes) gel, plus a testosterone (T) gel suppresses sperm concentrations to levels associated with effective contraception in normal men. However, administration of two gels on different parts of the body daily is impractical. OBJECTIVE Compare the effectiveness of daily application of a single, combined 8.3 mg Nes-62.5 mg T gel (Nes-T) vs. 62.7 mg T gel to suppress serum FSH and LH concentrations to ≤1.0 IU/L (a threshold associated with suppression of sperm concentrations to ≤1 million and effective contraception) and to compare the pharmacokinetics of serum Nes and T concentrations between the gel groups. DESIGN We conducted a 28-day, double-blind, controlled trial of 44 healthy men randomized to daily Nes-T or T gel with measurement of hormones at baseline, treatment, and recovery and during 24-h pharmacokinetic studies on days 1 and 28 of treatment. RESULTS Of the subjects who met pre-defined inclusion criteria, 84% of the Nes-T group suppressed serum gonadotropin concentrations to ≤1.0 IU/L at days 21-28 vs. 16.7% in the T group (p < 0.001). On day 1, Nes concentrations rose significantly above baseline by 2 h and continued to rise up to 24 h after Nes-T gel application. Nes concentrations were not detectable in the T group. Serum total T concentrations rose and were significantly higher in the T gel group compared to the Nes-T group at 24 h on day 1 and days 11, 14, and 21 (p < 0.01). There were no serious adverse events in either group. About 80% of the subjects reported satisfaction with both gels. CONCLUSION Daily Nes-T gel effectively and safely suppresses serum gonadotropins and is acceptable to most men. It should be studied further in efficacy trials of hormonal male contraception.",2019,"Serum total T concentrations rose and were significantly higher in the T gel group compared to the Nes-T group at 24 h on day 1 and days 11, 14, and 21 (p < 0.01).","['men', '44 healthy men randomized to', 'normal men']","['progestin, Nestorone ® (Nes) gel, plus a testosterone (T) gel', 'Combined nestorone-testosterone gel', 'daily Nes-T or T gel']","['Nes and T concentrations', 'serum FSH and LH concentrations', 'Nes concentrations', 'Serum total T concentrations', 'serum gonadotropin concentrations', 'serious adverse events']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}]","[{'cui': 'C0033306', 'cui_str': 'Progestins'}, {'cui': 'C0283986', 'cui_str': 'Nestorone'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0523912', 'cui_str': 'Testosterone measurement (procedure)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0733758', 'cui_str': 'Follicle Stimulating Hormone'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4543260', 'cui_str': 'Gonadotropin'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",44.0,0.0605677,"Serum total T concentrations rose and were significantly higher in the T gel group compared to the Nes-T group at 24 h on day 1 and days 11, 14, and 21 (p < 0.01).","[{'ForeName': 'B D', 'Initials': 'BD', 'LastName': 'Anawalt', 'Affiliation': 'Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'M Y', 'Initials': 'MY', 'LastName': 'Roth', 'Affiliation': 'Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Ceponis', 'Affiliation': 'Institute of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Surampudi', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA, USA.'}, {'ForeName': 'J K', 'Initials': 'JK', 'LastName': 'Amory', 'Affiliation': 'Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'R S', 'Initials': 'RS', 'LastName': 'Swerdloff', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA, USA.'}, {'ForeName': 'P Y', 'Initials': 'PY', 'LastName': 'Liu', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Dart', 'Affiliation': 'Health Decisions, Durham, NC, USA.'}, {'ForeName': 'W J', 'Initials': 'WJ', 'LastName': 'Bremner', 'Affiliation': 'Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Sitruk-Ware', 'Affiliation': 'Center for Biomedical Research, Population Council, New York, NY, USA.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Kumar', 'Affiliation': 'Center for Biomedical Research, Population Council, New York, NY, USA.'}, {'ForeName': 'D L', 'Initials': 'DL', 'LastName': 'Blithe', 'Affiliation': 'Contraceptive Development Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'S T', 'Initials': 'ST', 'LastName': 'Page', 'Affiliation': 'Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA, USA.'}]",Andrology,['10.1111/andr.12603'] 616,31922707,"Glycated hemoglobin measurements at three, 12 and 24 months postpartum after gestational diabetes.","PURPOSE To determine the associations between glycated hemoglobin (A1C) values at three, 12 and 24 months postpartum taken during the Families Defeating Diabetes trial. METHODS The Families Defeating Diabetes trial was a randomized 12 month lifestyle intervention delivered in the first year postpartum. Women were reviewed at three, 6 12 and 24 months for body habitus, diet and lifestyle choices. Glycated hemoglobin levels were measured at three, 12 and 24 months. RESULTS There were 170 randomization participants: 89 interventional (INT); and 81 control (CON). Of these 170 participants, 50 INT and 47 CON completed 12-month follow-up and 26 INT and 24 CON completed 24-month follow-up. Study outcomes did not differ between the cohorts. Combined intraclass correlation coefficients for reliability of repeated results showed substantial reliability: 0.74 (95% CI 0.63, 0.83) between three and 12 month A1C; and 0.72 (95% CI 0.51, 0.85) for three and 24 month A1C. Pearson correlations for three month vs 12 month A1C were r=0.745 (p.",2019,Study outcomes did not differ between the cohorts.,"['170 participants, 50 INT and 47 CON completed 12-month follow-up and 26 INT and 24 CON completed 24-month follow-up', '170 randomization participants: 89 interventional (INT); and 81 control (CON']",[],"['Glycated hemoglobin measurements', 'Glycated hemoglobin levels', 'glycated hemoglobin (A1C) values']","[{'cui': 'C4517599', 'cui_str': 'One hundred and seventy'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",[],"[{'cui': 'C0017853', 'cui_str': 'Hemoglobin, Glycosylated'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",170.0,0.0221754,Study outcomes did not differ between the cohorts.,"[{'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Barton', 'Affiliation': 'Cumming School of Medicine, University of Calgary, Calgary, AB.'}, {'ForeName': 'Lois', 'Initials': 'L', 'LastName': 'Donovan', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Obstetrics and Gynecology, Cumming School of Medicine, University of Calgary, Calgary, AB.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Giroux', 'Affiliation': 'Faculty of Health Sciences, University of Ottawa, Ottawa, ON.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Miller', 'Affiliation': 'Division of Endocrinology, University of Victoria, BC.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Mottola', 'Affiliation': 'Faculty of Health Sciences, University of Western Ontario, London, ON.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'McManus', 'Affiliation': 'Division of Endocrinology and Metabolism, University of Western Ontario, London, ON Department of Medicine, University of Alberta, Edmonton, AB.'}]",Clinical and investigative medicine. Medecine clinique et experimentale,['10.25011/cim.v42i4.33343'] 617,31742670,Promoting colonoscopy screening among low-income Latinos at average risk of colorectal cancer: A randomized clinical trial.,"BACKGROUND Screening colonoscopy (SC) for colorectal cancer (CRC) is underused by Latino individuals. The current randomized clinical trial examined the impact of 3 interventions: 1) patient navigation; 2) patient navigation plus standard Centers for Disease Control and Prevention print materials; and 3) patient navigation plus culturally targeted print materials for Latinos referred for SC. Demographic, personal and health history, and psychometric factors associated with SC also were examined. METHODS A total of 344 urban Latino individuals aged 50 to 85 years with no personal and/or immediate family history of CRC diagnosed before age 60 years, no personal history of a gastrointestinal disorder, no colonoscopy within the past 5 years, with insurance coverage, and with a referral for SC were consented. Participants were randomized to patient navigation (20%), patient navigation plus standard Centers for Disease Control and Prevention print materials (40%), and patient navigation plus culturally targeted print materials (40%). The completion of SC was assessed at 12 months. RESULTS The interventions had an overall SC rate of 82%. Counterintuitively, patients with an average income of <$10,000 were found to have higher SC rates (87%) than those with a greater income (75%). CONCLUSIONS The addition of standard or culturally targeted print materials did not appear to increase SC rates above those for patient navigation. Indeed, after controlling for other variables, culturally targeted print materials were found to be associated with lower SC rates among Puerto Rican individuals.",2020,"Indeed, after controlling for other variables, culturally targeted print materials were found to be associated with lower SC rates among Puerto Rican individuals.","['Latino individuals', '344 urban Latino individuals aged 50 to 85\xa0years with no personal and/or immediate family history of CRC diagnosed before age 60\xa0years, no personal history of a gastrointestinal disorder, no colonoscopy within the past 5\xa0years, with insurance coverage, and with a referral for SC were consented', 'low-income Latinos at average risk of colorectal cancer']","['patient navigation plus standard Centers for Disease Control and Prevention print materials (40%), and patient navigation plus culturally targeted print materials', 'Screening colonoscopy (SC', 'patient navigation; 2) patient navigation plus standard Centers for Disease Control and Prevention print materials; and 3) patient navigation plus culturally targeted print materials for Latinos referred for SC']","['overall SC rate', 'SC rates']","[{'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0241889', 'cui_str': 'Family Medical History'}, {'cui': 'C0170127', 'cui_str': 'Calcibiotic Root Canal Sealer'}, {'cui': 'C0424945', 'cui_str': 'Social / personal history observable'}, {'cui': 'C0017178', 'cui_str': 'Gastrointestinal Diseases'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0376629', 'cui_str': 'Insurance Status'}, {'cui': 'C2585524', 'cui_str': 'Referral for'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}]","[{'cui': 'C3494323', 'cui_str': 'Navigations, Patient'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0007670', 'cui_str': 'CDC'}, {'cui': 'C0034036', 'cui_str': 'Publications'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.0568607,"Indeed, after controlling for other variables, culturally targeted print materials were found to be associated with lower SC rates among Puerto Rican individuals.","[{'ForeName': 'Katherine N', 'Initials': 'KN', 'LastName': 'DuHamel', 'Affiliation': 'Department of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, Icahn Medical Institute, New York, New York.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Schofield', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Villagra', 'Affiliation': 'Department of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, Icahn Medical Institute, New York, New York.'}, {'ForeName': 'Pathu', 'Initials': 'P', 'LastName': 'Sriphanlop', 'Affiliation': 'Department of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, Icahn Medical Institute, New York, New York.'}, {'ForeName': 'Steven H', 'Initials': 'SH', 'LastName': 'Itzkowitz', 'Affiliation': 'Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Gina', 'Initials': 'G', 'LastName': 'Cotter', 'Affiliation': 'Department of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, Icahn Medical Institute, New York, New York.'}, {'ForeName': 'Noah', 'Initials': 'N', 'LastName': 'Cohen', 'Affiliation': 'Department of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, Icahn Medical Institute, New York, New York.'}, {'ForeName': 'Deborah O', 'Initials': 'DO', 'LastName': 'Erwin', 'Affiliation': 'Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Winkel', 'Affiliation': 'Department of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, Icahn Medical Institute, New York, New York.'}, {'ForeName': 'Hayley S', 'Initials': 'HS', 'LastName': 'Thompson', 'Affiliation': 'Department of Community Outreach and Engagement, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.'}, {'ForeName': 'Ann G', 'Initials': 'AG', 'LastName': 'Zauber', 'Affiliation': 'Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.'}, {'ForeName': 'Lina H', 'Initials': 'LH', 'LastName': 'Jandorf', 'Affiliation': 'Department of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, Icahn Medical Institute, New York, New York.'}]",Cancer,['10.1002/cncr.32541'] 618,31866419,Effectiveness of Powerful Tools for Caregivers on Caregiver Burden and on Care Recipient Behavioral and Psychological Symptoms of Dementia: A Randomized Controlled Trial.,"OBJECTIVE The aim of this study was to evaluate the effectiveness of a psychoeducational intervention, Powerful Tools for Caregivers (PTC), for family caregivers of individuals with dementia. DESIGN A pragmatic, 2-arm randomized controlled trial compared the PTC intervention, as delivered in practice, to usual care. Participants randomized to usual care functioned as a control group and then received the PTC intervention. INTERVENTION PTC is a 6-week manualized program that includes weekly 2-hour classes in a group setting facilitated by 2 trained and certified leaders. The educational program helps caregivers to enhance self-care practices and manage emotional distress. SETTING AND PARTICIPANTS Two stakeholder organizations delivered the intervention in community settings. Participants were family caregivers of individuals with dementia recruited from the community in Florida. METHODS Primary outcomes were caregiver burden and behavioral and psychological symptoms of dementia of the care recipient. Secondary outcomes included caregiver depressive symptoms, self-efficacy, self-rated health, and life satisfaction. Measures were collected at baseline (n = 60 participants), postintervention (n = 55), and at 6-week follow-up (n = 44). RESULTS Intent-to-treat analyses found PTC reduced caregiver burden (d = -0.48) and depressive symptoms (d = -0.53), and increased self-confidence (d = 0.68), but found no significant benefit for behavioral and psychological symptoms of dementia in care recipients. PTC was rated highly by participants and program attrition was low, with 94% of caregivers completing at least 4 of the 6 classes. CONCLUSIONS AND IMPLICATIONS Although no significant effects were found for behavioral and psychological symptoms of dementia, this trial supports the effectiveness of PTC to improve caregiver outcomes as delivered in the community.",2020,"RESULTS Intent-to-treat analyses found PTC reduced caregiver burden (d = -0.48) and depressive symptoms (d = -0.53), and increased self-confidence (d = 0.68), but found no significant benefit for behavioral and psychological symptoms of dementia in care recipients.","['Participants were family caregivers of individuals with dementia recruited from the community in Florida', 'Caregivers (PTC), for family caregivers of individuals with dementia', 'Caregivers on Caregiver Burden and on Care Recipient Behavioral and Psychological Symptoms of Dementia']","['PTC intervention', 'PTC', 'psychoeducational intervention']","['caregiver burden and behavioral and psychological symptoms of dementia of the care recipient', 'self-confidence', 'caregiver depressive symptoms, self-efficacy, self-rated health, and life satisfaction', 'behavioral and psychological symptoms of dementia', 'depressive symptoms', 'PTC reduced caregiver burden']","[{'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0016253', 'cui_str': 'Florida'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C4285807', 'cui_str': 'Neuropsychiatric symptoms'}]","[{'cui': 'C0015491', 'cui_str': 'factor IX'}]","[{'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C4285807', 'cui_str': 'Neuropsychiatric symptoms'}, {'cui': 'C0237529', 'cui_str': 'Self Confidence'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0015491', 'cui_str': 'factor IX'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}]",60.0,0.178322,"RESULTS Intent-to-treat analyses found PTC reduced caregiver burden (d = -0.48) and depressive symptoms (d = -0.53), and increased self-confidence (d = 0.68), but found no significant benefit for behavioral and psychological symptoms of dementia in care recipients.","[{'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Terracciano', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL. Electronic address: antonio.terracciano@med.fsu.edu.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Artese', 'Affiliation': 'Health and Human Performance, Roanoke College, Salem, VA.'}, {'ForeName': 'Jenie', 'Initials': 'J', 'LastName': 'Yeh', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL.'}, {'ForeName': 'LaVon', 'Initials': 'L', 'LastName': 'Edgerton', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Granville', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL.'}, {'ForeName': 'Damaris', 'Initials': 'D', 'LastName': 'Aschwanden', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Luchetti', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Glueckauf', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL.'}, {'ForeName': 'Yannick', 'Initials': 'Y', 'LastName': 'Stephan', 'Affiliation': 'Euromov, University of Montpellier, Montpellier, France.'}, {'ForeName': 'Angelina R', 'Initials': 'AR', 'LastName': 'Sutin', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Katz', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL.'}]",Journal of the American Medical Directors Association,['10.1016/j.jamda.2019.11.011'] 619,31535359,The Therapeutic Effect of Intravesical Instillation of Platelet Rich Plasma on Recurrent Bacterial Cystitis in Women: A Randomized Clinical Trial.,"PURPOSE Recurrent bacterial cystitis is a common infection in women and there are concerns about its antibiotic therapy. Platelet rich plasma has antimicrobial and tissue repairing effects. We investigated the effect of platelet rich plasma as an intravesical therapy to prevent recurrence of bacterial cystitis. MATERIALS AND METHODS Thirty women with a history of recurrent bacterial cystitis were randomly assigned into two groups: 1) platelet rich plasma and 2) control groups. The first group received 10 mL of platelet rich plasma with intravesical instillation plus 40 mL of normal saline. The control group only received 50 mL of normal saline. We did the instillation once a week for four weeks in both groups. We followed up the participants two and 12 months after the last instillation with a questionnaire (the international consultation on incontinence questionnaire in overactive bladder) and result of their urine culture. RESULTS A significant decrease was observed in the number of bacterial cystitis recurrences in the platelet rich plasma group compared to the control group 12 months after the instillation (4 vs. 1, P = 0.004). Also, there was a significant improvement in the questionnaire's score two (3.6 ± 2.58 vs. 0.66 ± 1.63, P = 0.002) and 12 months (3.4 ± 2.77 vs. 0.006 ± 1.83, P < 0.001) after instillation in the platelet rich plasma group compared to control group. There was no adverse effect 12 months after instillation. CONCLUSION Platelet rich plasma can significantly decrease the recurrence of bacterial cystitis up to a year after instillation without any side effect.",2019,"A significant decrease was observed in the number of bacterial cystitis recurrences in the platelet rich plasma group compared to the control group 12 months after the instillation (4 vs. 1, P = 0.004).","['recurrent bacterial cystitis in women', 'Thirty women with a history of recurrent bacterial cystitis']","['platelet rich plasma and 2) control groups', '10 mL of platelet rich plasma with intravesical instillation plus 40 mL of normal saline', 'platelet rich plasma', '50 mL of normal saline', 'Materials and Methods']","[""questionnaire's score"", 'number of bacterial cystitis recurrences', 'recurrence of bacterial cystitis']","[{'cui': 'C1959870', 'cui_str': 'Recurrent bacterial cystitis (disorder)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma (substance)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021917', 'cui_str': 'Instillation, Bladder'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}]","[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0742964', 'cui_str': 'Bladder infection due bacteria'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}]",30.0,0.0435269,"A significant decrease was observed in the number of bacterial cystitis recurrences in the platelet rich plasma group compared to the control group 12 months after the instillation (4 vs. 1, P = 0.004).","[{'ForeName': 'Mahboubeh', 'Initials': 'M', 'LastName': 'Mirzaei', 'Affiliation': 'Department of Urology, Kerman University of Medical Sciences, Kerman, Iran. mirzaeimahboubeh@yahoo.com.'}, {'ForeName': 'Azar', 'Initials': 'A', 'LastName': 'Daneshpajooh', 'Affiliation': 'Department of Urology, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Farsinezhad', 'Affiliation': 'Cell Therapy and Regenerative Medicine Center, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Zeinab', 'Initials': 'Z', 'LastName': 'Jafarian', 'Affiliation': 'Department of Internal Medicine, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Ebadzadeh', 'Affiliation': 'Department of Urology, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Narjes', 'Initials': 'N', 'LastName': 'Saberi', 'Affiliation': 'Isfahan Kidney Transplantation Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Teimorian', 'Affiliation': 'Department of Urology, Kerman University of Medical Sciences, Kerman, Iran.'}]",Urology journal,['10.22037/uj.v0i0.5239'] 620,31862329,Computerized Advisory Decision Support for Cardiovascular Diseases in Primary Care: A Cluster Randomized Trial.,"PURPOSE The purpose of this research was to evaluate the impact of an outpatient computerized advisory clinical decision support system (CDSS) on adherence to guideline-recommended treatment for heart failure, atrial fibrillation, and hyperlipidemia. METHODS Twenty care teams (109 clinicians) in a primary care practice were cluster-randomized to either access or no access to an advisory CDSS integrated into the electronic medical record. For patients with an outpatient visit, the CDSS determined if they had heart failure with reduced ejection fraction, hyperlipidemia, or atrial fibrillation; and if so, was the patient receiving guideline-recommended treatment. In the intervention group, an alert was visible in the medical record if there was a discrepancy between current and guideline-recommended treatment. Clicking the alert displayed the treatment discrepancy and recommended treatment. Outcomes included prescribing patterns, self-reported use of decision aids, and self-reported efficiency. The trial was conducted between May 1 and November 15, 2016, and incorporated 16,310 patient visits. RESULTS The advisory CDSS increased adherence to guideline-recommended treatment for heart failure (odds ratio [OR] 7.6, 95% confidence interval [CI], 1.2, 47.5) but had no impact in atrial fibrillation (OR 0.94, 95% CI 0.15, 5.94) or hyperlipidemia (OR 1.1, 95% CI 0.6, 1.8). Clinicians with access to the CDSS self-reported greater use of risk assessment tools for heart failure (3.6 [1.1] vs 2.7 [1.0], mean [standard deviation] on a 5-point scale) but not for atrial fibrillation or hyperlipidemia. The CDSS did not impact self-assessed efficiency. The overall usage of the CDSS was low (19%). CONCLUSIONS A computerized advisory CDSS improved adherence to guideline-recommended treatment for heart failure but not for atrial fibrillation or hyperlipidemia.",2020,A computerized advisory CDSS improved adherence to guideline-recommended treatment for heart failure but not for atrial fibrillation or hyperlipidemia.,"['May 1 and November 15, 2016 and incorporated 16,310 patient visits', 'Twenty care teams (109 clinicians) in a primary care practice were cluster-randomized to either', 'Primary Care']","['outpatient computerized advisory clinical decision support system (CDSS', 'access or no access to an advisory CDSS integrated into the electronic medical record']","['hyperlipidemia', 'prescribing patterns, self-reported use of decision aids and self-reported efficiency', 'heart failure with reduced ejection fraction, hyperlipidemia, and/or atrial fibrillation', 'overall usage of the CDSS', 'atrial fibrillation or hyperlipidemia', 'atrial fibrillation', 'heart failure']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}]","[{'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0525070', 'cui_str': 'Decision Support Systems, Clinical'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C2362543', 'cui_str': 'Electronic Medical Record'}]","[{'cui': 'C0020473', 'cui_str': 'Hyperlipemia'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0457083', 'cui_str': 'Usage (attribute)'}]",,0.0365495,A computerized advisory CDSS improved adherence to guideline-recommended treatment for heart failure but not for atrial fibrillation or hyperlipidemia.,"[{'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'McKie', 'Affiliation': 'Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn. Electronic address: mckie.paul@mayo.edu.'}, {'ForeName': 'Daryl J', 'Initials': 'DJ', 'LastName': 'Kor', 'Affiliation': 'Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minn; Department of Anesthesiology, Mayo Clinic, Rochester, Minn.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Cook', 'Affiliation': 'Office of Information and Knowledge Management, Mayo Clinic, Rochester, Minn; Division of General Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minn.'}, {'ForeName': 'Maya E', 'Initials': 'ME', 'LastName': 'Kessler', 'Affiliation': 'Division of Primary Care Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minn.'}, {'ForeName': 'Rickey E', 'Initials': 'RE', 'LastName': 'Carter', 'Affiliation': 'Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minn; Department of Health Sciences Research, Mayo Clinic, Rochester, Minn.'}, {'ForeName': 'Patrick M', 'Initials': 'PM', 'LastName': 'Wilson', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, Minn.'}, {'ForeName': 'Laurie J', 'Initials': 'LJ', 'LastName': 'Pencille', 'Affiliation': 'Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minn; Office of Information and Knowledge Management, Mayo Clinic, Rochester, Minn.'}, {'ForeName': 'Branden C', 'Initials': 'BC', 'LastName': 'Hickey', 'Affiliation': 'Office of Information and Knowledge Management, Mayo Clinic, Rochester, Minn.'}, {'ForeName': 'Rajeev', 'Initials': 'R', 'LastName': 'Chaudhry', 'Affiliation': 'Office of Information and Knowledge Management, Mayo Clinic, Rochester, Minn; Division of Primary Care Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minn.'}]",The American journal of medicine,['10.1016/j.amjmed.2019.10.039'] 621,32197594,The effect of teaching puberty health concepts on the basis of a health belief model for improving perceived body image of female adolescents: a quasi-experimental study.,"BACKGROUND As children approach adolescence, they focus increasingly on their appearance and physical attraction due to teenage body-image. Teaching the concepts of adolescent health changes an individual's attitudes towards parts of the body. The health belief model (HBM) is one of the significant pedagogic models in health education. According to this model, the individual's decision and motivation for adopting healthy behaviors depends on three separate categories ""personal perception, adaptive behaviors, and probability of performing that action or behavior"". This study investigated the effect of teaching puberty health concepts on the basis of a HBM on perceived body image in female adolescents. METHODS A quasi-experimental research design was used in the study. This study was conducted with 60 sixth grade girls in state elementary schools in Yazd, Iran, that were selected with cluster sampling method and assigned randomly into experimental and control groups. The experimental group were educated in the school during eight 45-min sessions based on the HBM, whereas the control group were educated using the traditional lecturing method. The data were collected with demographic and self-body image questionnaires completed before and after intervention. The data were analyzed with SPSS16 using analysis of covariance (ANCOVA). RESULTS The mean age of the participants was 12.16 ± 0.74 years. The findings showed that ""perceived body image"" and ""students' self-attitude"" improved significantly after intervention; yet, no significant difference was found between the subscales ""attitudes towards weight"" and ""satisfaction with various parts of the body"". CONCLUSION The results of the study confirmed the efficacy and efficiency of teaching puberty health on the basis of the HBM on improving perceived body image in female adolescents.",2020,"The findings showed that ""perceived body image"" and ""students' self-attitude"" improved significantly after intervention; yet, no significant difference was found between the subscales ""attitudes towards weight"" and ""satisfaction with various parts of the body"". ","['female adolescents', '60 sixth grade girls in state elementary schools in Yazd, Iran, that were selected with cluster sampling method', 'The mean age of the participants was 12.16\u2009±\u20090.74\u2009years']",[],"['perceived body image"" and ""students\' self-attitude', 'subscales ""attitudes towards weight"" and ""satisfaction']","[{'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0205440', 'cui_str': 'Sixth (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517478', 'cui_str': '0.74 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",[],"[{'cui': 'C0005891', 'cui_str': 'Body Image'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",,0.0118675,"The findings showed that ""perceived body image"" and ""students' self-attitude"" improved significantly after intervention; yet, no significant difference was found between the subscales ""attitudes towards weight"" and ""satisfaction with various parts of the body"". ","[{'ForeName': 'Maasoumeh', 'Initials': 'M', 'LastName': 'Barkhordari-Sharifabad', 'Affiliation': 'Department of Nursing, School of Medical Sciences, Yazd Branch, Islamic Azad University, Shohadaye Gomnam Blvd., Safaiyeh, Yazd, Iran. barkhordary.m@gmail.com.'}, {'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Vaziri-Yazdi', 'Affiliation': 'Department of Educational Sciences, Yazd Branch, Islamic Azad University, Yazd, Iran.'}, {'ForeName': 'Mansoureh', 'Initials': 'M', 'LastName': 'Barkhordari-Sharifabad', 'Affiliation': 'Department of Educational Sciences, Yazd Branch, Islamic Azad University, Yazd, Iran.'}]",BMC public health,['10.1186/s12889-020-08482-2'] 622,31317460,"Apneic Oxygenation During Prolonged Laryngoscopy in Obese Patients: a Randomized, Double-Blinded, Controlled Trial of Nasal Cannula Oxygen Administration.","BACKGROUND Obese patients have a propensity to desaturate during induction of general anesthesia secondary to their reduced functional residual capacity and increased oxygen consumption. Apneic oxygenation can provide supplemental oxygen to the alveoli, even in the absence of ventilation, during attempts to secure the airway. In this study, we hypothesized that oxygen administration through a nasopharyngeal airway and standard nasal cannula during a simulated prolonged laryngoscopy would significantly prolong the safe apneic duration in obese patients. METHODS One hundred thirty-five obese patients undergoing non-emergent surgery requiring general anesthesia were randomized to either the control group or to receive apneic oxygenation with air versus oxygen. All patients underwent a standard intravenous induction. For patients randomized to receive apneic oxygenation, a nasopharyngeal airway and standard nasal cannula were inserted. A simulated prolonged laryngoscopy was performed to determine the duration of the safe apneic period, defined as the beginning of laryngoscopy until the peripheral oxygen saturation (SpO 2 ) reached 95%. RESULTS The oxygen group had a median safe apneic duration that was 103 s longer than the control group. The lowest mean SpO 2 value during the induction period was 3.8% higher in the oxygen group compared to the control group. Following intubation, patients in the oxygen group had a mean end tidal carbon dioxide (ETCO 2 ) level that was 3.0 mmHg higher than patients in the control group. CONCLUSIONS In obese patients, oxygen insufflation at 15 L/min through a nasopharyngeal airway and standard nasal cannula can significantly increase the safe apneic duration during induction of anesthesia.",2019,The lowest mean SpO 2 value during the induction period was 3.8% higher in the oxygen group compared to the control group.,"['Obese patients', 'Obese Patients', 'obese patients', 'One hundred thirty-five obese patients undergoing non-emergent surgery requiring general anesthesia']","['Nasal Cannula Oxygen Administration', 'apneic oxygenation, a nasopharyngeal airway and standard nasal cannula', 'control group or to receive apneic oxygenation with air versus oxygen']","['mean end tidal carbon dioxide (ETCO 2 ) level', 'Apneic Oxygenation', 'median safe apneic duration', 'safe apneic duration']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4319605', 'cui_str': 'Thirty-five'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0002915', 'cui_str': 'General Anesthesia'}]","[{'cui': 'C0179574', 'cui_str': 'Nasal Cannula'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0475745', 'cui_str': 'Apneic oxygenation (procedure)'}, {'cui': 'C0027442', 'cui_str': 'Rhinopharynx'}, {'cui': 'C0458827', 'cui_str': 'Airway structure (body structure)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001861', 'cui_str': 'Air'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0475745', 'cui_str': 'Apneic oxygenation (procedure)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C2926735', 'cui_str': 'Duration'}]",135.0,0.140261,The lowest mean SpO 2 value during the induction period was 3.8% higher in the oxygen group compared to the control group.,"[{'ForeName': 'Tiffany S', 'Initials': 'TS', 'LastName': 'Moon', 'Affiliation': 'University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9068, USA. Tiffany.Moon@UTSouthwestern.edu.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Tai', 'Affiliation': 'University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9068, USA.'}, {'ForeName': 'Agnes', 'Initials': 'A', 'LastName': 'Kim', 'Affiliation': 'University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9068, USA.'}, {'ForeName': 'Michael X', 'Initials': 'MX', 'LastName': 'Gonzales', 'Affiliation': 'University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9068, USA.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Lu', 'Affiliation': 'University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9068, USA.'}, {'ForeName': 'Taylor', 'Initials': 'T', 'LastName': 'Pak', 'Affiliation': 'University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9068, USA.'}, {'ForeName': 'Katelynn', 'Initials': 'K', 'LastName': 'Smith', 'Affiliation': 'University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9068, USA.'}, {'ForeName': 'Joy L', 'Initials': 'JL', 'LastName': 'Chen', 'Affiliation': 'University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9068, USA.'}, {'ForeName': 'Abu T', 'Initials': 'AT', 'LastName': 'Minhajuddin', 'Affiliation': 'University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9068, USA.'}, {'ForeName': 'Nwamaka', 'Initials': 'N', 'LastName': 'Nnamani', 'Affiliation': 'University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9068, USA.'}, {'ForeName': 'Pamela E', 'Initials': 'PE', 'LastName': 'Fox', 'Affiliation': 'University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9068, USA.'}, {'ForeName': 'Babatunde', 'Initials': 'B', 'LastName': 'Ogunnaike', 'Affiliation': 'University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9068, USA.'}]",Obesity surgery,['10.1007/s11695-019-04077-y'] 623,31298171,Who will benefit from computerized cognitive remediation therapy? Evidence from a multisite randomized controlled study in schizophrenia.,"BACKGROUND Computerized cognitive remediation therapy (CCRT) is generally effective for the cognitive deficits of schizophrenia. However, there is much uncertainty about what factors mediate or moderate effectiveness and are therefore important to personalize treatment and boost its effects. METHOD In total, 311 Chinese inpatients with Diagnostic and Statistical Manual of Mental Disorders-IV schizophrenia were randomized to receive CCRT or Active control for 12 weeks with four to five sessions per week. All participants were assessed at baseline, post-treatment and 3-month follow-up. The outcomes were cognition, clinical symptoms and functional outcomes. RESULTS There was a significant benefit in the MATRICS Consensus Cognitive Battery (MCCB) total score for CCRT (F1,258 = 5.62; p = 0.02; effect size was 0.27, 95% confidence interval 0.04-0.49). There were no specific moderators of CCRT improvements. However, across both groups, Wisconsin Card Sort Test improvement mediated a positive effect on functional capacity and Digit Span benefit mediated decreases in positive symptoms. In exploratory analyses younger and older participants showed cognitive improvements but on different tests (younger on Symbol Coding Test, while older on the Spatial Span Test). Only the older age group showed MSCEIT benefits at post-treatment. In addition, cognition at baseline negatively correlated with cognitive improvement and those whose MCCB baseline total score was around 31 seem to derive the most benefit. CONCLUSIONS CCRT can improve the cognitive function of patients with schizophrenia. Changes in cognitive outcomes also contributed to improvements in functional outcomes either directly or solely in the context of CCRT. Age and the basic cognitive level of the participants seem to affect the cognitive benefits from CCRT.",2020,"There was a significant benefit in the MATRICS Consensus Cognitive Battery (MCCB) total score for CCRT (F1,258 = 5.62; p = 0.02; effect size was 0.27, 95% confidence interval 0.04-0.49).","['311 Chinese inpatients with Diagnostic and Statistical Manual of Mental Disorders-IV schizophrenia', 'patients with schizophrenia']","['CCRT or Active control', 'Computerized cognitive remediation therapy (CCRT', 'CCRT']","['MSCEIT benefits', 'functional capacity and Digit Span benefit', 'cognitive improvements', 'cognition, clinical symptoms and functional outcomes', 'cognitive function', 'Consensus Cognitive Battery (MCCB) total score for CCRT', 'MCCB baseline total score']","[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C1136324', 'cui_str': 'Diagnostic and Statistical Manual of Mental Disorders'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4277695', 'cui_str': 'Cognitive Remediation'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0582802', 'cui_str': 'Digit'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0376298', 'cui_str': 'Consensus'}, {'cui': 'C0542351', 'cui_str': 'Battery (event)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",311.0,0.0451081,"There was a significant benefit in the MATRICS Consensus Cognitive Battery (MCCB) total score for CCRT (F1,258 = 5.62; p = 0.02; effect size was 0.27, 95% confidence interval 0.04-0.49).","[{'ForeName': 'Shuping', 'Initials': 'S', 'LastName': 'Tan', 'Affiliation': 'Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing100096, P.R. China.'}, {'ForeName': 'Xiaolin', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing100096, P.R. China.'}, {'ForeName': 'Hongzhen', 'Initials': 'H', 'LastName': 'Fan', 'Affiliation': 'Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing100096, P.R. China.'}, {'ForeName': 'Yunlong', 'Initials': 'Y', 'LastName': 'Tan', 'Affiliation': 'Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing100096, P.R. China.'}, {'ForeName': 'Fude', 'Initials': 'F', 'LastName': 'Yang', 'Affiliation': 'Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing100096, P.R. China.'}, {'ForeName': 'Zhiren', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing100096, P.R. China.'}, {'ForeName': 'Yanli', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing100096, P.R. China.'}, {'ForeName': 'Fengmei', 'Initials': 'F', 'LastName': 'Fan', 'Affiliation': 'Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing100096, P.R. China.'}, {'ForeName': 'Junhua', 'Initials': 'J', 'LastName': 'Guo', 'Affiliation': 'Beijing Anding Hospital of Capital Medical University, Beijing100088, P.R. China.'}, {'ForeName': 'Zhanjiang', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Beijing Anding Hospital of Capital Medical University, Beijing100088, P.R. China.'}, {'ForeName': 'Wenxiang', 'Initials': 'W', 'LastName': 'Quan', 'Affiliation': 'Institute of Mental Health, Peking University, Beijing100191, P.R. China.'}, {'ForeName': 'Xiangqun', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Institute of Mental Health, Peking University, Beijing100191, P.R. China.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Reeder', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, LondonSE5 8AF, UK.""}, {'ForeName': 'Dongfeng', 'Initials': 'D', 'LastName': 'Zhou', 'Affiliation': 'Institute of Mental Health, Peking University, Beijing100191, P.R. China.'}, {'ForeName': 'Yizhuang', 'Initials': 'Y', 'LastName': 'Zou', 'Affiliation': 'Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing100096, P.R. China.'}, {'ForeName': 'Til', 'Initials': 'T', 'LastName': 'Wykes', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, LondonSE5 8AF, UK.""}]",Psychological medicine,['10.1017/S0033291719001594'] 624,31286397,The Effect of Intraoperative Dexmedetomidine Versus Morphine on Postoperative Morphine Requirements After Laparoscopic Bariatric Surgery.,"BACKGROUND Dexmedetomidine is an α 2 receptor agonist with sedative and analgesic properties. During bariatric surgery, its use may reduce postoperative opioid requirements, reduce their side effects, and improve quality of recovery. The aim of this prospective randomized controlled trial was to compare the effect of dexmedetomidine bolus and infusion versus morphine bolus given prior to the end of laparoscopic bariatric surgery. METHODS Sixty morbidly obese patients (BMI > 40 kg m -2 ) aged 18 to 60 years, undergoing laparoscopic sleeve gastrectomy, received morphine sulfate (bolus 0.08 mg kg -1 followed by a saline infusion) (group M, n = 30) or dexmedetomidine (loading dose of 1 μg kg -1 followed by 0.5 μg kg -1  h -1 ) (group D, n = 30) 30 min before the end of surgery. Data collected included morphine consumption in the post-anesthesia care unit (PACU) (primary outcome) and at 24 h, pain intensity, nausea, heart rate, blood pressure, vomiting, sedation, and quality of recovery. RESULTS There was no significant difference in morphine consumption in the PACU (group D 12.2 ± 5.44 mg, group M 13.28 ± 6.64 mg, P = 0.54) or at 24 h (group D 40.67 ± 24.78 mg, group M 43.28 ± 27.79 mg, P = 0.75); when accounting for intraoperative morphine given group M had significantly higher morphine consumption when compared to group D (23.48 ± 6.22 mg vs. 12.22 ± 5.54 mg, respectively, P < 0.01). Group D patients had more cardiovascular stability. CONCLUSIONS Dexmedetomidine given prior to end of laparoscopic sleeve gastrectomy provides the same level of postoperative analgesia as morphine with better hemodynamic profile.",2019,"There was no significant difference in morphine consumption in the PACU (group D 12.2 ± 5.44 mg, group M 13.28 ± 6.64 mg, P = 0.54) or at 24 h (group D 40.67 ± 24.78 mg, group M 43.28 ± 27.79 mg, P = 0.75); when accounting for intraoperative morphine given group M had significantly higher morphine consumption when compared to group D (23.48 ± 6.22 mg vs. 12.22 ± 5.54 mg, respectively, P < 0.01).","['aged 18 to 60\xa0years, undergoing', 'Sixty morbidly obese patients (BMI\u2009>\u200940\xa0kg']","['Laparoscopic Bariatric Surgery', 'Dexmedetomidine', 'morphine sulfate (bolus 0.08', 'dexmedetomidine (loading dose of 1\xa0μg\xa0kg -1 followed by 0.5\xa0μg', 'PACU', 'laparoscopic sleeve gastrectomy', 'Intraoperative Dexmedetomidine Versus Morphine', 'dexmedetomidine bolus and infusion versus morphine']","['Postoperative Morphine Requirements', 'morphine consumption', '24\xa0h, pain intensity, nausea, heart rate, blood pressure, vomiting, sedation, and quality of recovery', 'cardiovascular stability']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1456587', 'cui_str': 'Bariatric Surgery'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0066814', 'cui_str': 'Morphine Sulfate'}, {'cui': 'C4517417', 'cui_str': 'Zero point zero eight'}, {'cui': 'C3714444', 'cui_str': 'Loading dose'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0034871', 'cui_str': 'Hospital Recovery Rooms'}, {'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}]",60.0,0.402263,"There was no significant difference in morphine consumption in the PACU (group D 12.2 ± 5.44 mg, group M 13.28 ± 6.64 mg, P = 0.54) or at 24 h (group D 40.67 ± 24.78 mg, group M 43.28 ± 27.79 mg, P = 0.75); when accounting for intraoperative morphine given group M had significantly higher morphine consumption when compared to group D (23.48 ± 6.22 mg vs. 12.22 ± 5.54 mg, respectively, P < 0.01).","[{'ForeName': 'Carine', 'Initials': 'C', 'LastName': 'Zeeni', 'Affiliation': 'Department of Anesthesiology, American University of Beirut Medical Center, Beirut, Lebanon.'}, {'ForeName': 'Marie T', 'Initials': 'MT', 'LastName': 'Aouad', 'Affiliation': 'Department of Anesthesiology, American University of Beirut Medical Center, Beirut, Lebanon.'}, {'ForeName': 'Dayane', 'Initials': 'D', 'LastName': 'Daou', 'Affiliation': 'Keserwan Medical Center, Keserwan, Jounieh, Lebanon.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Naji', 'Affiliation': 'Department of Anesthesiology, American University of Beirut Medical Center, Beirut, Lebanon.'}, {'ForeName': 'Samar', 'Initials': 'S', 'LastName': 'Jabbour-Khoury', 'Affiliation': 'Department of Anesthesiology, American University of Beirut Medical Center, Beirut, Lebanon.'}, {'ForeName': 'Ramzi S', 'Initials': 'RS', 'LastName': 'Alami', 'Affiliation': 'Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.'}, {'ForeName': 'Bassem Y', 'Initials': 'BY', 'LastName': 'Safadi', 'Affiliation': 'Department of Surgery, Lebanese American University, Beirut, Lebanon.'}, {'ForeName': 'Sahar M', 'Initials': 'SM', 'LastName': 'Siddik-Sayyid', 'Affiliation': 'Department of Anesthesiology, American University of Beirut Medical Center, Beirut, Lebanon. ss01@aub.edu.lb.'}]",Obesity surgery,['10.1007/s11695-019-04074-1'] 625,31117800,Effect of conscious sedation with midazolam and fentanyl on the overall quality of colonoscopy: a prospective and randomized study.,"INTRODUCTION a prospective, randomized study was performed to assess the influence of conscious sedation on the overall quality of colonoscopy, simultaneously quantifying its effect on the scientific quality, perceived quality and patient safety. METHODS patients referred for a colonoscopy were included in the study and were randomized to receive or not receive sedation. Demographic data, indication for colonoscopy, cecal intubation, introduction and withdrawal time, resected adenomas and complications during the exploration were collected. Thirty days later, a satisfaction questionnaire was performed (GHAA 9-me) and patients were asked about complications after the examination. RESULTS a total of 5,328 patients were included, the average age was 62 ± 15.22 years, 47% were male, 3,734 were sedated and 1,594 were not sedated. The sedated patients had a shorter endoscope insertion time (7'20 ± 2'15 min vs 6'15 ± 3'12 min, p < 0.019), a higher rate of cecal intubations (96% vs 88%, p < 0.05), longer withdrawal time (7'20 ± 2'15 min vs 6'15 ± 3'12 min, p < 0.01) and higher adenoma detection rates (22% vs 17%, p < 0.05). The use of sedation reduced discomfort during and after the exploration, without increasing the complications. The satisfaction questionnaire score was higher (23.6 ± 1.5 vs 16.6 ± 4.8, p < 0.001) in the sedated patients. CONCLUSIONS superficial sedation not only reduces patient discomfort but also improves the overall quality of the colonoscopy. Therefore, we must consider the use of sedation as an essential part of colonoscopy.",2019,"The satisfaction questionnaire score was higher (23.6 ± 1.5 vs 16.6 ± 4.8, p < 0.001) in the sedated patients. ","['a total of 5,328 patients were included, the average age was 62 ± 15.22 years, 47% were male, 3,734 were sedated and 1,594 were not sedated', 'patients referred for a colonoscopy were included in the study']","['midazolam and fentanyl', 'conscious sedation']","['Demographic data, indication for colonoscopy, cecal intubation, introduction and withdrawal time, resected adenomas and complications', 'satisfaction questionnaire score', 'overall quality of colonoscopy', 'shorter endoscope insertion time', 'longer withdrawal time', 'higher adenoma detection rates', 'higher rate of cecal intubations', 'scientific quality, perceived quality and patient safety', 'overall quality', 'satisfaction questionnaire', 'patient discomfort']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0079159', 'cui_str': 'Sedation, Moderate'}]","[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0392360', 'cui_str': 'Reason for (attribute)'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C1293116', 'cui_str': 'Introduction'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0001430', 'cui_str': 'Adenoma'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0014243', 'cui_str': 'Endoscopes'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1113679'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}]",5328.0,0.0765346,"The satisfaction questionnaire score was higher (23.6 ± 1.5 vs 16.6 ± 4.8, p < 0.001) in the sedated patients. ","[{'ForeName': 'Juan Salvador', 'Initials': 'JS', 'LastName': 'Baudet', 'Affiliation': 'Digestivo, Hospital San Juan de Dios Tenerife, España.'}, {'ForeName': 'Armando', 'Initials': 'A', 'LastName': 'Aguirre-Jaime', 'Affiliation': 'Unidad de Investigación, Hospital Universitario Ntra. Sra. de Candelaria, España.'}]",Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva,['10.17235/reed.2019.5735/2018'] 626,31958417,"Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.","BACKGROUND Previous trials testing prevention strategies for chronic graft versus host disease (GVHD) have measured its cumulative incidence. In this trial of anti-thymocyte globulin, we measured treatment-independence at a long-term timepoint as the primary endpoint. METHODS This was a randomised, open-label, multicentre, phase 3 trial done at ten centres in Canada and one in Australia. Eligible patients had a haematological malignancy (leukaemia, myelodysplastic syndrome, or lymphoma), were between 16 and 70 years of age, eligible for transplantation with a Karnofsky score of at least 60, and received an unrelated donor (fully matched or one-locus mismatched at HLA-A, HLA-B, HLA-C, or DRB1 loci) graft following myeloablative or non-myeloablative-reduced intensity conditioning. Patients were randomly assigned to receive anti-thymocyte globulin 4·5 mg/kg plus standard GVHD prophylaxis (cyclosporine or tacrolimus plus methotrexate or mycophenolate) or standard GVHD prophylaxis alone. The primary endpoint, freedom from immunosuppressive therapy without resumption at 12 months, was previously reported. Here we report on the prespecified 24-month analysis. Analyses were per-protocol, excluding those patients who did not proceed to transplantation. This trial is registered as ISRCTN 29899028 and NCT01217723, status completed. FINDINGS Between June 9, 2010, and July 8, 2013, we recruited and randomly assigned 203 eligible patients to receive anti-thymocyte globulin (n=101) or no additional treatment (n=102) along with standard GVHD prophylaxis. 7 (3%) patients did not receive a transplant and were excluded from the analysis. 38 (38%) of 99 evaluable patients in the anti-thymocyte globulin plus GVHD prophylaxis group were free from immunosuppressive therapy at 24 months compared with 18 (19%) of 97 patients in the standard GVHD prophylaxis group (adjusted odds ratio [OR] 3·49 [95% CI 1·60–7·60]; p=0·0016). At 24 months, the cumulative incidence of relapse was 16·3% (95% CI 8·9–23·7) in the anti-thymocyte globulin plus GVHD prophylaxis group compared with 17·5 (9·9–25·1) in the standard GVHD prophylaxis group (p=0·73) and non-relapse mortality was 21·2% (95% CI 13·2–29·2) versus 31·3% (21·9–40·7; p=0·15). The cumulative incidence of chronic GVHD at 24 months was 26·3% (95% CI 17·5–35·1) in the anti-thymocyte globulin group and 41·3% (31·3–51·3) in the standard GVHD prophylaxis group (p=0·032). Overall survival at 24 months was 70·6% (95% CI 60·6–78·6) in the anti-thymocyte globulin plus GVHD prophylaxis group compared with 53·3% (42·8–62·8) in the standard GVHD prophylaxis group (adjusted hazard ratio [HR] 0·56, 95% CI [0·35–0·90]; p=0·017). Symptoms of chronic GVHD by the Lee Scale were more prevalent in the standard GVHD prophylaxis group, with scores of 13·27 (SD 10·94) in the anti-thymocyte globulin plus GVHD prophylaxis group and 20·38 (SD 14·68) in the standard GVHD prophylaxis group (p=0·040). Depressive symptoms were more prominent in the standard GVHD prophylaxis group, the mean Center for Epidemiological Studies Depression scale (CES-D) scores were 10·40 (SD 9·88) in the anti-thymocyte globulin group and 14·62 (SD 12·26) in the standard GVHD prophylaxis group (p=0·034). Serious adverse events (CTCAE grade 4 or 5) occurred in 38 (38%) patients in the anti-thymocyte globulin group and in 49 (51%) in the standard GVHD prophylaxis group, the most common being infection and GVHD. One patient in the anti-thymocyte globulin plus GVHD prophylaxis group died of Epstein-Barr virus hepatitis, but no deaths were attributable to anti-thymocyte globulin. INTERPRETATION The results of this prespecified 24-month analysis suggest that pretreatment with anti-thymocyte globulin provides clinically meaningful benefits when added to standard GVHD prophylaxis in patients undergoing unrelated donor transplantation, including decreases in use of immunosuppressive therapy, chronic GVHD and its symptoms, depressive symptoms, and improved overall survival. Anti-thymocyte globulin should be included in the preparative regimens of patients with haematological malignancies selected for unrelated donor transplantation. FUNDING Canadian Institutes of Health Research and Sanofi.",2020,"Overall survival at 24 months was 53·3% (95% CI 42·8-62·7) in the anti-thymocyte globulin plus GVHD prophylaxis group compared with 70.6% (95% CI 60·6-78·6) in the standard GVHD prophylaxis group (adjusted hazard ratio [HR] 0·56, 95% CI [0·35-0·90]; p=0·017.","['3·49', 'patients with haematological malignancies selected for unrelated donor transplantation', 'patients with haematological malignancies undergoing transplantation from unrelated donors', 'ten centres in Canada and one in Australia', 'Between June 9, 2010, and July 8, 2013, we recruited and randomly assigned 203 eligible patients to', 'Eligible patients had a haematological malignancy (leukaemia, myelodysplastic syndrome, or lymphoma), were between 16 and 70 years of age, eligible for transplantation with a Karnofsky score of at least 60, and received an unrelated donor (fully matched or one-locus mismatched at HLA-A, HLA-B, HLA-C, or DRB1 loci) graft following myeloablative or non-myeloablative-reduced intensity conditioning', 'patients undergoing unrelated donor transplantation']","['anti-thymocyte globulin', 'Anti-thymocyte globulin', 'anti-thymocyte globulin 4·5 mg/kg plus standard GVHD prophylaxis (cyclosporine or tacrolimus plus methotrexate or mycophenolate) or standard GVHD prophylaxis alone', 'receive anti-thymocyte globulin (n=101) or no additional treatment (n=102) along with standard GVHD prophylaxis', 'anti-thymocyte globulin to standard graft-versus-host disease prophylaxis']","['mean Center for Epidemiological Studies Depression scale (CES-D) scores', 'Serious adverse events', 'freedom from immunosuppressive therapy without resumption', 'Overall survival', 'relapse mortality', 'cumulative incidence of relapse', 'Depressive symptoms', 'immunosuppressive therapy, chronic GVHD and its symptoms, depressive symptoms', 'overall survival', 'cumulative incidence of chronic GVHD']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0376545', 'cui_str': 'Hematological Neoplasms'}, {'cui': 'C3179133', 'cui_str': 'Unrelated Donors'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0023418', 'cui_str': 'Leucocythaemia'}, {'cui': 'C3666007', 'cui_str': 'Myelodysplastic syndrome (SMQ)'}, {'cui': 'C0024299', 'cui_str': 'Germinoblastoma'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0019728', 'cui_str': 'HLA-A'}, {'cui': 'C0019737', 'cui_str': 'HLA-B'}, {'cui': 'C0019751', 'cui_str': 'HLA-C'}, {'cui': 'C1527362', 'cui_str': 'grafts'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0359156', 'cui_str': 'Rabbit anti-human T-lymphocyte globulin'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0018133', 'cui_str': 'Homologous Wasting Disease'}, {'cui': 'C0033107', 'cui_str': 'prophylaxis'}, {'cui': 'C0010594', 'cui_str': 'Cyclosporins'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0883242', 'cui_str': 'MYCOPHENOLATE'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0002783', 'cui_str': 'Epidemiological Studies'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0021079', 'cui_str': 'Antirejection Therapy'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0018133', 'cui_str': 'Homologous Wasting Disease'}]",203.0,0.0916317,"Overall survival at 24 months was 53·3% (95% CI 42·8-62·7) in the anti-thymocyte globulin plus GVHD prophylaxis group compared with 70.6% (95% CI 60·6-78·6) in the standard GVHD prophylaxis group (adjusted hazard ratio [HR] 0·56, 95% CI [0·35-0·90]; p=0·017.","[{'ForeName': 'Irwin', 'Initials': 'I', 'LastName': 'Walker', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, ON, Canada; Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada. Electronic address: walkeri@mcmaster.ca.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Panzarella', 'Affiliation': 'Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto ON, Canada; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Couban', 'Affiliation': 'Dalhousie University and Capital District Health Authority Halifax, NS, Canada.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Couture', 'Affiliation': 'Centre Hospitalier Universitaire de Québec, Pavillon Hôtel-dieu de Québec, Québec City, QC, Canada.'}, {'ForeName': 'Gerald', 'Initials': 'G', 'LastName': 'Devins', 'Affiliation': 'Department of Psychiatry, University of Toronto, Toronto ON, Canada; Supportive Care Program, Princess Margaret Cancer Centre, Toronto, ON, Canada.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Elemary', 'Affiliation': 'Saskatoon Cancer Centre, Saskatoon, SK, Canada.'}, {'ForeName': 'Geneviève', 'Initials': 'G', 'LastName': 'Gallagher', 'Affiliation': 'Université Laval and CHU de Québec, Quebec city, QC, Canada.'}, {'ForeName': 'Holly', 'Initials': 'H', 'LastName': 'Kerr', 'Affiliation': 'Leukemia-Bone Marrow Transplant Program of British Columbia, Vancouver General Hospital, British Columbia Cancer, and University of British Columbia, BC, Canada.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Kuruvilla', 'Affiliation': 'Department of Medicine, University of Toronto, Toronto ON, Canada; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.'}, {'ForeName': 'Stephanie J', 'Initials': 'SJ', 'LastName': 'Lee', 'Affiliation': 'Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Moore', 'Affiliation': ""St Vincent's Hospital, Sydney, NSW, Australia.""}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Nevill', 'Affiliation': 'Leukemia-Bone Marrow Transplant Program of British Columbia, Vancouver General Hospital, British Columbia Cancer, and University of British Columbia, BC, Canada.'}, {'ForeName': 'Gizelle', 'Initials': 'G', 'LastName': 'Popradi', 'Affiliation': 'Royal Victoria Hospital, McGill University Health Center Montreal, QC, Canada.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Roy', 'Affiliation': 'Université de Montréal and Maisonneuve-Rosemont Hospital, Montreal, QC, Canada.'}, {'ForeName': 'Kirk R', 'Initials': 'KR', 'LastName': 'Schultz', 'Affiliation': ""Michael Cuccione Childhood Cancer Research Program and British Columbia Children's Hospital and Child & Family Research Institute, Vancouver, BC, Canada.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Szwajcer', 'Affiliation': 'CancerCare Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Toze', 'Affiliation': 'Leukemia-Bone Marrow Transplant Program of British Columbia, Vancouver General Hospital, British Columbia Cancer, and University of British Columbia, BC, Canada.'}, {'ForeName': 'Ronan', 'Initials': 'R', 'LastName': 'Foley', 'Affiliation': 'Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Haematology,['10.1016/S2352-3026(19)30220-0'] 627,31958540,Routine Interportal Capsular Repair Does Not Lead to Superior Clinical Outcome Following Arthroscopic Femoroacetabular Impingement Correction With Labral Repair.,"PURPOSE To evaluate the impact of routine capsular repair on clinical outcome in a consecutive series of patients undergoing arthroscopic correction of symptomatic femoroacetabular impingement. METHODS Between 2009 and 2015, patients were assigned to 1 of 2 groups based on whether a capsular repair was performed as part of their index hip arthroscopic procedure. Exclusion criteria included previous underlying hip conditions, Tönnis >1, age >45 years, and labrum not repaired. Patients were assessed preoperatively and 2-years postoperatively using patient-reported outcome measures (PROMs), including the modified Harris hip score (mHHS), UCLA activity scale, short form-36, Western Ontario and McMaster Universities Osteoarthritis Index score, and measures of range of hip movements. The incidence of any subsequent revision surgery within 2 years was recorded. Sex and age groups were specifically analyzed. RESULTS In total, 966 consecutive cases were included (96.4% follow-up rate): 508 in group A (no repair) and 458 in group B (repair). Average age for all cases was 28.1 ± 7.0 years (14.6-44.9). There were significant improvements in all PROMs following surgery for both groups (P < .001). Statistical significance between groups at 2 years was observed for Short Form-36 (P = .001) and WOMAC (P = .041), greater in group A. Both groups similarly met the minimal clinically important difference (mHHS P = .414 and .605; UCLA, P = .549 and .614; Short Form-36, P = .455 and .079; WOMAC, P = .425 and .750 for distribution and anchor-based methods, respectively). In total, 38 (7.8%) cases group A and 24 (5.4%) cases group B required repeat hip arthroscopy (HA) (P = .148); No (0%) cases in group A and 2 (0.45%) cases in group B required total hip replacement (P = .226). There was significantly lower rate of repeat HA among 25- to 34-year age group (8.6% vs 3.9%, P = .047) where capsular repair was performed. No significant difference in the rate of repeat HA between groups for male (P = .203) or female (P = .603) subjects. Adhesions were more common in the repair group (79.2%, 95% confidence interval [CI] 57.8-92.9 vs 55.3%, CI 38.3-71.4; P = .055), with further capsular repair/plication required more frequently in the unrepaired group (50%, CI 33.4-66.6 vs 25%, CI 10.8-44.3); however, differences between groups were not significant (P = .051). Internal rotation was larger in group A compared with group B at 2 years (36.2 vs 28.1, P = .000). Female patients with capsular repair had reduced PROM scores at 2 years compared with female patients without repair (WOMAC, P = .004, and mHHS, P = .037). CONCLUSIONS Arthroscopic correction of femoroacetabular impingement with labral repair results in significant improvements in patient-reported outcomes at 2-years postsurgery, irrespective of whether the capsule is repaired. Routine capsular repair in a consecutive series of patients did not lead to superior outcomes compared with a nonrepaired group; similar proportions of cases in both groups were able to achieve minimal clinically important difference. In female patients, routinely repairing the capsule may lead to statistically inferior clinical outcome at 2-years postsurgery, although this may not be clinically significant. Routine capsular repair, however, may be beneficial in the younger, active patient, where a significant reduction in repeat arthroscopy was observed. LEVEL OF EVIDENCE Level III, retrospective comparative study.",2020,Routine capsular repair in a consecutive series of patients did not lead to superior outcomes compared to a non-repaired group; Similar proportions of cases in both groups were able to achieve MCID.,"['patients undergoing arthroscopic correction of symptomatic femoro-acetabular impingement (FAI) METHODS', 'Exclusion criteria included prior underlying hip conditions, Tonnis >1, age >45 years, labrum not repaired', '966 consecutive cases were included (96.4% follow-up rate): 508 Group A(No Repair), 458 Group B(Repair', 'Female patients with capsular repair']","['routine capsular repair', 'Arthroscopic FAI Correction With Labral Repair']","['Internal rotation', 'Adhesions', 'PROM scores', 'modified Harris hip score (mHHS), UCLA activity scale, short form-36, WOMAC osteoarthritis index, and measures of range of hip movements', 'rate of repeat HA', 'repeat hip arthroscopy (HA', 'incidence of any subsequent revision surgery', 'total hip replacement', 'capsular repair/plication']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C2936290', 'cui_str': 'Femoroacetabular Impingement Syndrome'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C4280965', 'cui_str': '>1'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0205151', 'cui_str': 'Capsular (qualifier value)'}]","[{'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0205151', 'cui_str': 'Capsular (qualifier value)'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}]","[{'cui': 'C0231459', 'cui_str': 'Medial rotation - action (qualifier value)'}, {'cui': 'C0001511', 'cui_str': 'Tissue Adhesions'}, {'cui': 'C0015944', 'cui_str': 'Premature Rupture of Membrane (Pregnancy)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C2919875', 'cui_str': 'Harris hip score (observable entity)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0222045'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0029408', 'cui_str': 'Arthritis, Degenerative'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C0186190', 'cui_str': 'Arthroscopy of hip (procedure)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1277206', 'cui_str': 'Subsequent revision'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0040508', 'cui_str': 'Hip Replacement, Total'}, {'cui': 'C0205151', 'cui_str': 'Capsular (qualifier value)'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C0185026', 'cui_str': 'Plication - action (qualifier value)'}]",966.0,0.0930817,Routine capsular repair in a consecutive series of patients did not lead to superior outcomes compared to a non-repaired group; Similar proportions of cases in both groups were able to achieve MCID.,"[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Filan', 'Affiliation': 'Hip and Groin Clinic, UPMC Whitfield, Butlerstown North, Waterford, Co. Waterford, Ireland.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Carton', 'Affiliation': 'Hip and Groin Clinic, UPMC Whitfield, Butlerstown North, Waterford, Co. Waterford, Ireland. Electronic address: cartoni2k@hotmail.com.'}]",Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association,['10.1016/j.arthro.2019.12.002'] 628,31860172,Randomized controlled trial of a positive affect intervention to reduce HIV viral load among sexual minority men who use methamphetamine.,"INTRODUCTION In the era of HIV treatment as prevention (TasP), evidence-based interventions that optimize viral suppression among people who use stimulants such as methamphetamine are needed to improve health outcomes and reduce onward transmission risk. We tested the efficacy of positive affect intervention delivered during community-based contingency management (CM) for reducing viral load in sexual minority men living with HIV who use methamphetamine. METHODS Conducted in San Francisco, this Phase II randomized controlled trial tested the efficacy of a positive affect intervention for boosting and extending the effectiveness of community-based CM for stimulant abstinence to achieve more durable reductions in HIV viral load. From 2013 to 2017, 110 sexual minority men living with HIV who had biologically confirmed, recent methamphetamine use were randomized to receive a positive affect intervention (n = 55) or attention-control condition (n = 55). All individual positive affect intervention and attention-control sessions were delivered during three months of community-based CM where participants received financial incentives for stimulant abstinence. The 5-session positive affect intervention was designed to provide skills for managing stimulant withdrawal symptoms as well as sensitize individuals to natural sources of reward. The attention-control condition consisted of neutral writing exercises and self-report measures. RESULTS Men randomized to the positive affect intervention displayed significantly lower log 10 HIV viral load at six, twelve and fifteen months compared to those in the attention-control condition. Men in the positive affect intervention also had significantly lower risk of at least one unsuppressed HIV RNA (≥200 copies/mL) over the 15-month follow-up. There were concurrent, statistically significant intervention-related increases in positive affect as well as decreases in the self-reported frequency of stimulant use at six and twelve months. CONCLUSIONS Delivering a positive affect intervention during community-based CM with sexual minority men who use methamphetamine achieved durable and clinically meaningful reductions in HIV viral load that were paralleled by increases in positive affect and decreases in stimulant use. Further clinical research is needed to determine the effectiveness of integrative, behavioural interventions for optimizing the clinical and public health benefits of TasP in sexual minority men who use stimulants such as methamphetamine.",2019,"Men randomized to the positive affect intervention displayed significantly lower log 10 HIV viral load at six, twelve and fifteen months compared to those in the attention-control condition.","['sexual minority men living with HIV who use methamphetamine', 'sexual minority men who use', 'Conducted in San Francisco', 'sexual minority men who use stimulants such as methamphetamine', 'From 2013 to 2017, 110 sexual minority men living with HIV who had biologically confirmed, recent methamphetamine use']","['positive affect intervention (n\xa0=\xa055) or attention-control condition', 'methamphetamine', 'positive affect intervention', 'neutral writing exercises and self-report measures', 'community-based contingency management (CM']","['log 10 HIV viral load', 'HIV viral load']","[{'cui': 'C4277573', 'cui_str': 'Sexual and Gender Minorities'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0025611', 'cui_str': 'metamfetamine'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0036152', 'cui_str': 'San Francisco'}, {'cui': 'C0242977', 'cui_str': 'Stimulants, Historical'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}]","[{'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0025611', 'cui_str': 'metamfetamine'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C1168369', 'cui_str': 'HIV viral load'}]",,0.110968,"Men randomized to the positive affect intervention displayed significantly lower log 10 HIV viral load at six, twelve and fifteen months compared to those in the attention-control condition.","[{'ForeName': 'Adam W', 'Initials': 'AW', 'LastName': 'Carrico', 'Affiliation': 'University of Miami School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Torsten B', 'Initials': 'TB', 'LastName': 'Neilands', 'Affiliation': 'San Francisco School of Medicine, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Samantha E', 'Initials': 'SE', 'LastName': 'Dilworth', 'Affiliation': 'San Francisco School of Medicine, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Evans', 'Affiliation': 'San Francisco School of Medicine, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Gόmez', 'Affiliation': 'Berkeley School of Social Welfare, University of California, Berkeley, CA, USA.'}, {'ForeName': 'Jennifer P', 'Initials': 'JP', 'LastName': 'Jain', 'Affiliation': 'San Diego School of Medicine, University of California, La Jolla, CA, USA.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Gandhi', 'Affiliation': 'San Francisco School of Medicine, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Shoptaw', 'Affiliation': 'Departments of Family Medicine and Psychiatry, Los Angeles David Geffen School of Medicine, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Keith J', 'Initials': 'KJ', 'LastName': 'Horvath', 'Affiliation': 'Department of Psychology, San Diego State University, San Diego, CA, USA.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Coffin', 'Affiliation': 'San Francisco School of Medicine, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Michael V', 'Initials': 'MV', 'LastName': 'Discepola', 'Affiliation': 'San Francisco AIDS Foundation, San Francisco, CA, USA.'}, {'ForeName': 'Rick', 'Initials': 'R', 'LastName': 'Andrews', 'Affiliation': 'San Francisco AIDS Foundation, San Francisco, CA, USA.'}, {'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Woods', 'Affiliation': 'San Francisco School of Medicine, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Feaster', 'Affiliation': 'University of Miami School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Judith T', 'Initials': 'JT', 'LastName': 'Moskowitz', 'Affiliation': 'Department of Medical Social Sciences, Northwestern University, Chicago, CA, USA.'}]",Journal of the International AIDS Society,['10.1002/jia2.25436'] 629,31833184,Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.,"Peficitinib (ASP015K) is a novel Janus kinase inhibitor developed for the treatment of rheumatoid arthritis (RA). The impact of hepatic impairment on the peficitinib pharmacokinetic (PK) and safety profile was investigated in non-RA subjects (n = 24) in an open-label, parallel-group, multicenter comparative study in Japan. Subjects received a single, clinically relevant, oral dose of a peficitinib 150 mg tablet under fasting conditions. Plasma PK parameters were measured for peficitinib and its metabolites H1 (sulfate and methylated metabolite), H2 (sulfate metabolite), and H4 (methylated metabolite) in subjects with normal hepatic function, mild hepatic impairment, or moderate hepatic impairment. The peficitinib area under the plasma-concentration-time curve from time 0 to infinity (AUC inf ) and maximum observed concentration (C max ) were not markedly different in subjects with mild hepatic impairment versus normal hepatic function. In subjects with moderate hepatic impairment versus normal hepatic function, the geometric mean ratios for peficitinib AUC inf and C max , were 1.92 (90% CI: 1.39, 2.66) and 1.82 (90% CI: 1.24, 2.69), respectively. Five treatment-emergent adverse events (TEAEs) were experienced by 3 subjects, 1 in each group. There were no deaths, no serious TEAEs, and no TEAEs leading to withdrawal. In summary, the PK profile was unaltered in subjects with mild hepatic impairment after a single clinically relevant dose of peficitinib, but exposure almost doubled in subjects with moderate hepatic impairment. Peficitinib dose reduction may be considered in RA patients with moderate hepatic impairment.",2020,"There were no deaths, no serious TEAEs, and no TEAEs leading to withdrawal.","['Japanese Subjects With Normal and Impaired Hepatic Function', 'non-RA subjects (n\xa0=\xa024) in an open-label, parallel-group, multicenter comparative study in Japan', 'subjects with normal hepatic function, mild hepatic impairment, or moderate hepatic impairment', 'RA patients with moderate hepatic impairment']","['Peficitinib (ASP015K', 'Single Oral Dose of Peficitinib (ASP015K', 'peficitinib 150 mg tablet under fasting conditions']","['peficitinib and its metabolites H1 (sulfate and methylated metabolite), H2 (sulfate metabolite), and H4 (methylated metabolite', 'peficitinib pharmacokinetic (PK) and safety profile', 'geometric mean ratios for peficitinib AUC inf and C max', 'PK profile', 'Pharmacokinetics and Safety', 'Plasma PK parameters']","[{'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0232741', 'cui_str': 'Liver function (observable entity)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009491', 'cui_str': 'Comparative Study'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0948807', 'cui_str': 'Hepatic impairment'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C4505522', 'cui_str': '4-(((1R,2s,3S,5s,7s)-5-Hydroxyadamantan-2-yl)amino)-1H-pyrrolo(2,3-b)pyridine-5-carboxamide'}, {'cui': 'C4505523', 'cui_str': 'ASP015K'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C4505522', 'cui_str': '4-(((1R,2s,3S,5s,7s)-5-Hydroxyadamantan-2-yl)amino)-1H-pyrrolo(2,3-b)pyridine-5-carboxamide'}, {'cui': 'C0038720', 'cui_str': 'Sulfates, Inorganic'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",,0.0322615,"There were no deaths, no serious TEAEs, and no TEAEs leading to withdrawal.","[{'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Miyatake', 'Affiliation': 'Astellas Pharma Inc, Tokyo, Japan.'}, {'ForeName': 'Tomohisa', 'Initials': 'T', 'LastName': 'Shibata', 'Affiliation': 'Astellas Pharma Inc, Tokyo, Japan.'}, {'ForeName': 'Junko', 'Initials': 'J', 'LastName': 'Toyoshima', 'Affiliation': 'Astellas Pharma Inc, Tokyo, Japan.'}, {'ForeName': 'Yuichiro', 'Initials': 'Y', 'LastName': 'Kaneko', 'Affiliation': 'Astellas Pharma Inc, Tokyo, Japan.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Oda', 'Affiliation': 'Astellas Research Institute of America LLC, Northbrook, Illinois, USA.'}, {'ForeName': 'Tetsuya', 'Initials': 'T', 'LastName': 'Nishimura', 'Affiliation': 'Astellas Pharma Inc, Tokyo, Japan.'}, {'ForeName': 'Masataka', 'Initials': 'M', 'LastName': 'Katashima', 'Affiliation': 'Astellas Pharma Inc, Tokyo, Japan.'}, {'ForeName': 'Masashi', 'Initials': 'M', 'LastName': 'Sakaki', 'Affiliation': 'Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Kazuaki', 'Initials': 'K', 'LastName': 'Inoue', 'Affiliation': 'Showa University Fujigaoka Hospital, Yokohama, Japan.'}, {'ForeName': 'Takayoshi', 'Initials': 'T', 'LastName': 'Ito', 'Affiliation': 'Showa University Koto Toyosu Hospital, Tokyo, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Uchida', 'Affiliation': 'Clinical Research Institute of Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.'}, {'ForeName': 'Kenichi', 'Initials': 'K', 'LastName': 'Furihata', 'Affiliation': 'P-One Clinic, Keikokai Medical Corporation, Tokyo, Japan.'}, {'ForeName': 'Akinori', 'Initials': 'A', 'LastName': 'Urae', 'Affiliation': 'Mediscience Planning, Inc, Tokyo, Japan.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.751'] 630,31699709,"Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.","Given its ability to induce both humoral and cellular immune responses, NY-ESO-1 has been considered a suitable antigen for a cancer vaccine. Despite promising results from early-phase clinical studies in patients with melanoma, NY-ESO-1 vaccine immunotherapy has not been widely investigated in larger trials; consequently, many questions remain as to the optimal vaccine formulation, predictive biomarkers, and sequencing and timing of vaccines in melanoma treatment. We conducted an adjuvant phase I/II clinical trial in high-risk resected melanoma to optimize the delivery of poly-ICLC, a TLR-3/MDA-5 agonist, as a component of vaccine formulation. A phase I dose-escalation part was undertaken to identify the MTD of poly-ICLC administered in combination with NY-ESO-1 and montanide. This was followed by a randomized phase II part investigating the MTD of poly-ICLC with NY-ESO-1 with or without montanide. The vaccine regimens were generally well tolerated, with no treatment-related grade 3/4 adverse events. Both regimens induced integrated NY-ESO-1-specific CD4 + T-cell and humoral responses. CD8 + T-cell responses were mainly detected in patients receiving montanide. T-cell avidity toward NY-ESO-1 peptides was higher in patients vaccinated with montanide. In conclusion, NY-ESO-1 protein in combination with poly-ICLC is safe, well tolerated, and capable of inducing integrated antibody and CD4 + T-cell responses in most patients. Combination with montanide enhances antigen-specific T-cell avidity and CD8 + T-cell cross-priming in a fraction of patients, indicating that montanide contributes to the induction of specific CD8 + T-cell responses to NY-ESO-1.",2020,T-cell avidity towards NY-ESO-1 peptides was higher in patients vaccinated with montanide.,['high-risk melanoma patients'],"['poly-ICLC with NY-ESO-1 with or without montanide', 'Combined vaccination with NY-ESO-1 protein, poly-ICLC']","['T-cell avidity towards NY-ESO-1 peptides', 'humoral and cellular immune responses', 'CD8+ T-cell responses']","[{'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0071359', 'cui_str': 'polyriboinosinic-polyribocytidylic acid-polylysine carboxymethylcellulose'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}]","[{'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C0030956', 'cui_str': 'Peptides'}, {'cui': 'C1817908', 'cui_str': 'Cellular Immune Response'}]",,0.0441376,T-cell avidity towards NY-ESO-1 peptides was higher in patients vaccinated with montanide.,"[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Pavlick', 'Affiliation': 'Cancer Institute, New York University School of Medicine, New York, New York.'}, {'ForeName': 'Ana B', 'Initials': 'AB', 'LastName': 'Blazquez', 'Affiliation': 'Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Marcia', 'Initials': 'M', 'LastName': 'Meseck', 'Affiliation': 'Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lattanzi', 'Affiliation': 'Cancer Institute, New York University School of Medicine, New York, New York.'}, {'ForeName': 'Patrick A', 'Initials': 'PA', 'LastName': 'Ott', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, Massachusetts.'}, {'ForeName': 'Thomas U', 'Initials': 'TU', 'LastName': 'Marron', 'Affiliation': 'Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Rose Marie', 'Initials': 'RM', 'LastName': 'Holman', 'Affiliation': 'New York University School of Medicine, New York, New York.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Mandeli', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, New York.'}, {'ForeName': 'Andres M', 'Initials': 'AM', 'LastName': 'Salazar', 'Affiliation': 'Oncovir, Inc., Washington, D.C.'}, {'ForeName': 'Christopher B', 'Initials': 'CB', 'LastName': 'McClain', 'Affiliation': 'Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Gustavo', 'Initials': 'G', 'LastName': 'Gimenez', 'Affiliation': 'Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Sreekumar', 'Initials': 'S', 'LastName': 'Balan', 'Affiliation': 'Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Sacha', 'Initials': 'S', 'LastName': 'Gnjatic', 'Affiliation': 'Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Rachel Lubong', 'Initials': 'RL', 'LastName': 'Sabado', 'Affiliation': 'Genentech, San Francisco, California.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Bhardwaj', 'Affiliation': 'Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York. nina.bhardwaj@mssm.edu.'}]",Cancer immunology research,['10.1158/2326-6066.CIR-19-0545'] 631,31828492,Food Purchasing Behavior of Food Insecure Cancer Patients Receiving Supplemental Food Vouchers.,"PURPOSE Food insecure cancer patients experience worse health outcomes and poorer quality of life than food secure patients. There has been little research in programs to alleviate food insecurity in cancer patients. The objective of this paper is to report on the food purchasing behaviors of cancer patients enrolled in a supplemental food voucher program. METHODS This paper utilized data from a three-arm randomized controlled trial investigating the impact of food interventions on alleviating food insecurity in cancer patients receiving chemotherapy and/or radiation therapy. In one arm, patients received a monthly $230 voucher with which to purchase food. Receipts were collected for items purchased with the voucher and were coded to analyze purchasing behaviors. RESULTS Thirty-three patients provided receipts for more than 11,000 individual items. Patients spent 50% of voucher funds on animal protein, fruits, and vegetables. Patients spent, on average, 77% of voucher funds on items categorized as ""healthy."" CONCLUSIONS Patients who received a food voucher purchased more fruits and vegetables than national averages would suggest. They also spent less on sweetened beverages than national samples. Patients who were born outside of the United States or who were limited English proficient purchased significantly more healthy foods than English-speaking and American-born study patients. Supplemental food vouchers for food insecure cancer patients resulted in the purchase of healthy food items.",2020,Patients who were born outside of the United States or who were limited English proficient purchased significantly more healthy foods than English-speaking and American-born study patients.,"['cancer patients enrolled in a supplemental food voucher program', 'Food Insecure Cancer Patients Receiving Supplemental Food Vouchers', 'food insecure cancer patients', 'cancer patients receiving chemotherapy and/or radiation therapy', 'Patients who were born outside of the United States or who were limited English proficient purchased significantly more healthy foods than English-speaking and American-born study patients', 'cancer patients']","['food interventions', 'Supplemental food vouchers']","['quality of life', 'purchase of healthy food items']","[{'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0034619', 'cui_str': 'radiation therapy'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0016452', 'cui_str': 'Food'}]","[{'cui': 'C0034380'}, {'cui': 'C0016452', 'cui_str': 'Food'}]",33.0,0.0469702,Patients who were born outside of the United States or who were limited English proficient purchased significantly more healthy foods than English-speaking and American-born study patients.,"[{'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Paolantonio', 'Affiliation': 'Immigrant Health and Cancer Disparities Service, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, 2nd Floor, New York, NY, 10017, USA.'}, {'ForeName': 'Soo Young', 'Initials': 'SY', 'LastName': 'Kim', 'Affiliation': 'Immigrant Health and Cancer Disparities Service, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, 2nd Floor, New York, NY, 10017, USA.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Ramirez', 'Affiliation': 'Immigrant Health and Cancer Disparities Service, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, 2nd Floor, New York, NY, 10017, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Roberts-Eversley', 'Affiliation': 'Immigrant Health and Cancer Disparities Service, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, 2nd Floor, New York, NY, 10017, USA.'}, {'ForeName': 'Yuelin', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Immigrant Health and Cancer Disparities Service, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, 2nd Floor, New York, NY, 10017, USA.'}, {'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Melnic', 'Affiliation': 'Immigrant Health and Cancer Disparities Service, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, 2nd Floor, New York, NY, 10017, USA.'}, {'ForeName': 'Minlun', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'Immigrant Health and Cancer Disparities Service, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, 2nd Floor, New York, NY, 10017, USA.'}, {'ForeName': 'Devika R', 'Initials': 'DR', 'LastName': 'Jutagir', 'Affiliation': 'Immigrant Health and Cancer Disparities Service, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, 2nd Floor, New York, NY, 10017, USA.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Smith', 'Affiliation': 'Immigrant Health and Cancer Disparities Service, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, 2nd Floor, New York, NY, 10017, USA.'}, {'ForeName': 'Modupe', 'Initials': 'M', 'LastName': 'Oladele', 'Affiliation': 'Immigrant Health and Cancer Disparities Service, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, 2nd Floor, New York, NY, 10017, USA.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Gany', 'Affiliation': 'Immigrant Health and Cancer Disparities Service, Department of Psychiatry and Behavioral Sciences, Department of Medicine, and Department of Public Health, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. ganyf@mskcc.org.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-019-05183-4'] 632,31337877,Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.,"BACKGROUND Retrospective studies suggest that low molecular weight heparin may delay the development of metastasis in patients with resected NSCLC. METHODS Multicentre phase 3 study with patients with completely resected NSCLC who were randomised after surgery to receive chemotherapy with or without nadroparin. The main exclusion criteria were R1/2 and wedge/segmental resection. FDG-PET was required. The primary endpoint was recurrence-free survival (RFS). RESULTS Among 235 registered patients, 202 were randomised (nadroparin: n = 100; control n = 102). Slow accrual enabled a decrease in the number of patients needed from 600 to 202, providing 80% power to compare RFS with 94 events (α = 0.05; 2-sided). There were no differences in bleeding events between the two groups. The median RFS was 65.2 months (95% CI, 36-NA) in the nadroparin arm and 37.7 months (95% CI, 22.7-NA) in the control arm (HR 0.77 (95% CI, 0.53-1.13, P = 0.19). FDG-PET SUVmax ≥10 predicted a greater likelihood of recurrence in the first year (HR 0.48, 95% CI 0.22-0.9, P = 0.05). CONCLUSIONS Adjuvant nadroparin did not improve RFS in patients with resected NSCLC. In this study, a high SUVmax predicted a greater likelihood of recurrence in the first year. CLINICAL TRIAL REGISTRATION Netherlands Trial registry: NTR1250/1217.",2019,"FDG-PET SUVmax ≥10 predicted a greater likelihood of recurrence in the first year (HR 0.48, 95% CI 0.22-0.9, P = 0.05). ","['patients with completely resected non-small-cell lung cancer', '235 registered patients, 202 were randomised (nadroparin: n\u2009=\u2009100; control n\u2009=\u2009102', 'patients with resected NSCLC', 'patients with resected NSCLC.\nMETHODS\n\n\nMulticentre phase 3 study with patients with completely resected NSCLC who were randomised after surgery to receive']","['adjuvant chemotherapy with or without nadroparin', 'chemotherapy with or without nadroparin']","['median RFS', 'RFS', 'recurrence-free survival (RFS', 'bleeding events', 'likelihood of recurrence']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4554154', 'cui_str': 'Completely - dosing instruction fragment (qualifier value)'}, {'cui': 'C0007131', 'cui_str': 'Nonsmall Cell Lung Cancer'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0206232', 'cui_str': 'Nadroparin'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439561', 'cui_str': 'Phase 3 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}]","[{'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0206232', 'cui_str': 'Nadroparin'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease (finding)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}]",202.0,0.512985,"FDG-PET SUVmax ≥10 predicted a greater likelihood of recurrence in the first year (HR 0.48, 95% CI 0.22-0.9, P = 0.05). ","[{'ForeName': 'Harry J M', 'Initials': 'HJM', 'LastName': 'Groen', 'Affiliation': 'Department of Pulmonary Disease, University of Groningen and University Medical Center Groningen, Hanzeplein 1, Box 30.001, 9700 RB, Groningen, Netherlands. h.j.m.groen@umcg.nl.'}, {'ForeName': 'Erik H F M', 'Initials': 'EHFM', 'LastName': 'van der Heijden', 'Affiliation': 'Department of Pulmonary Diseases, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, Netherlands.'}, {'ForeName': 'Theo J', 'Initials': 'TJ', 'LastName': 'Klinkenberg', 'Affiliation': 'Department of Cardiothoracic Surgery, University of Groningen and University Medical Center Groningen, Hanzeplein 1, Box 30.001, 9700 RB, Groningen, Netherlands.'}, {'ForeName': 'Bonne', 'Initials': 'B', 'LastName': 'Biesma', 'Affiliation': ""Department of Pulmonary Diseases, Jeroen Bosch Hospital, Henri Dunantstraat 1, 5223 GZ, 's-Hertogenbosch, Netherlands.""}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Aerts', 'Affiliation': 'Department of Pulmonary Diseases, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD, Rotterdam, Netherlands.'}, {'ForeName': 'Ad', 'Initials': 'A', 'LastName': 'Verhagen', 'Affiliation': 'Department of Cardiothoracic Surgery, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, Netherlands.'}, {'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Kloosterziel', 'Affiliation': 'Department of Pulmonary Diseases, Isala Hospital, Dokter van Heesweg 2, 8025 AB, Zwolle, Netherlands.'}, {'ForeName': 'Remge', 'Initials': 'R', 'LastName': 'Pieterman', 'Affiliation': 'Department of Pulmonary Diseases, Ommelander Hospital Group, Pastorieweg 1, 9679 BJ, Scheemda, Netherlands.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'van den Borne', 'Affiliation': 'Department of Pulmonary Diseases, Catharina Hospital, Michelangelolaan 2, 5623 EJ, Eindhoven, Netherlands.'}, {'ForeName': 'Hans J M', 'Initials': 'HJM', 'LastName': 'Smit', 'Affiliation': 'Department of Pulmonary Diseases, Rijnstate Hospital, Wagnerlaan 55, 6815 AD, Arnhem, Netherlands.'}, {'ForeName': 'Otto', 'Initials': 'O', 'LastName': 'Hoekstra', 'Affiliation': 'Department of Nuclear Medicine, Amsterdam University Medical Center, De Boelelaan 1117, 1081, HVAmsterdam, Netherlands.'}, {'ForeName': 'Frans M N H', 'Initials': 'FMNH', 'LastName': 'Schramel', 'Affiliation': 'Department of Pulmonary Diseases, St Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, Netherlands.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'van der Noort', 'Affiliation': 'Department of Biometrics, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands.'}, {'ForeName': 'Harm', 'Initials': 'H', 'LastName': 'van Tinteren', 'Affiliation': 'Department of Biometrics, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands.'}, {'ForeName': 'Egbert F', 'Initials': 'EF', 'LastName': 'Smit', 'Affiliation': 'Department of Thoracic Oncology, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands.'}, {'ForeName': 'Anne-Marie C', 'Initials': 'AC', 'LastName': 'Dingemans', 'Affiliation': 'Department of Pulmonary Diseases, Maastricht University Medical Center, P. Debijelaan 25, 6229 HX, Maastricht, Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",British journal of cancer,['10.1038/s41416-019-0533-3'] 633,31330023,Pilot testing an app-based stress management intervention for cancer survivors.,"Psychosocial eHealth intervention programs for cancer survivors are still in their infancy, with inconsistent findings so far in the scientific literature. The aim of this study was to explore system use, usefulness, ease of use, and preliminary effects of Stress Proffen, an app-based cognitive-behavioral stress management intervention for patients with cancer. A feasibility pilot project tested the intervention with cancer survivors (N = 25). The intervention contained (a) one face-to-face introduction session, (b) 10 app-based modules with stress management educational material and exercises, and (c) one follow-up phone call. Post-intervention interviews were conducted and user log-data were extracted. Outcome measures-Perceived Stress Scale (PSS), Anxiety and Depression (Hospital Anxiety and Depression Scale [HADS]), Health-Related Quality of Life (HRQoL; SF-36), and Self-Regulatory Fatigue (SRF-18)-were completed at baseline and post-intervention. Participants were primarily women (84%), age 34-71 (mean 48) and represented a variety of cancer diagnoses (majority breast cancer: 40%). Twenty-two participants completed all (pre-post) questionnaires. Sixteen participants (67%) completed at least 7 of 10 modules within the 8-week study period. Post-intervention interviews described StressProffen as providing a new, appreciated, and easily accessible stress management tool for the cancer survivors. Dependent/paired t-tests showed significant pre-post intervention effects with significant decrease in stress (p = .008), anxiety (p = .019), and self-regulatory fatigue (p = .025), and improved HRQoL (Role Physical, General Health, Vitality, and Role Emotional, all p's <.01). App-based stress management interventions such as StressProffen can provide appreciated support for cancer survivors, should be easy to use, can provide significant stress reduction, and improve emotional well-being. Further testing in a randomized controlled trial is warranted and is in progress. Clinicaltrials.gov: NCT0293961.",2020,"Dependent/paired t-tests showed significant pre-post intervention effects with significant decrease in stress (p = .008), anxiety (p = .019), and self-regulatory fatigue (p = .025), and improved HRQoL (Role Physical, General Health, Vitality, and Role Emotional, all p's <.01).","['Sixteen participants (67%) completed at least 7 of 10 modules within the 8-week study period', 'cancer survivors', 'patients with cancer', 'cancer survivors (N = 25', 'Participants were primarily women (84%), age 34-71 (mean 48) and represented a variety of cancer diagnoses (majority breast cancer: 40']","['intervention contained (a) one face-to-face introduction session, (b) 10 app-based modules with stress management educational material and exercises, and (c) one follow-up phone call', 'StressProffen', 'app-based stress management intervention', 'Psychosocial eHealth intervention programs', 'Stress Proffen, an app-based cognitive-behavioral stress management intervention']","['stress', 'self-regulatory fatigue', 'HRQoL (Role Physical, General Health, Vitality, and Role Emotional', 'Outcome measures-Perceived Stress Scale (PSS), Anxiety and Depression (Hospital Anxiety and Depression Scale [HADS]), Health-Related Quality of Life (HRQoL; SF-36), and Self-Regulatory Fatigue (SRF-18)-were', 'anxiety']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}]","[{'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C1293116', 'cui_str': 'Introduction'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C0150788', 'cui_str': 'Manage stress control'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C1328956', 'cui_str': 'eHealth'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}]","[{'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0582653', 'cui_str': 'Perceived stress scale (assessment scale)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0037668', 'cui_str': 'Somatotropin-Releasing Factor 44'}]",22.0,0.051458,"Dependent/paired t-tests showed significant pre-post intervention effects with significant decrease in stress (p = .008), anxiety (p = .019), and self-regulatory fatigue (p = .025), and improved HRQoL (Role Physical, General Health, Vitality, and Role Emotional, all p's <.01).","[{'ForeName': 'Elin', 'Initials': 'E', 'LastName': 'Børøsund', 'Affiliation': 'Center for Shared Decision Making and Collaborative Care Research, Division of Medicine, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Cecilie', 'Initials': 'C', 'LastName': 'Varsi', 'Affiliation': 'Center for Shared Decision Making and Collaborative Care Research, Division of Medicine, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Matthew M', 'Initials': 'MM', 'LastName': 'Clark', 'Affiliation': 'Department of Psychiatry and Psychology, College of Medicine and Science, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Shawna L', 'Initials': 'SL', 'LastName': 'Ehlers', 'Affiliation': 'Department of Psychiatry and Psychology, College of Medicine and Science, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Andrykowski', 'Affiliation': 'Department of Behavioral Science, College of Medicine, University of Kentucky, Lexington, KY, USA.'}, {'ForeName': 'Hilde Renate Sætre', 'Initials': 'HRS', 'LastName': 'Sleveland', 'Affiliation': 'Center for Shared Decision Making and Collaborative Care Research, Division of Medicine, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Bergland', 'Affiliation': 'Center for Shared Decision Making and Collaborative Care Research, Division of Medicine, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Lise Solberg', 'Initials': 'LS', 'LastName': 'Nes', 'Affiliation': 'Center for Shared Decision Making and Collaborative Care Research, Division of Medicine, Oslo University Hospital, Oslo, Norway.'}]",Translational behavioral medicine,['10.1093/tbm/ibz062'] 634,31283481,Impact of different sensory stimuli on presence in credible virtual environments.,"Multiple factors can affect presence in virtual environments, such as the number of human senses engaged in a given experience or the extent to which the virtual experience is credible. The purpose of the present work is to study how the inclusion of credible multisensory stimuli affects the sense of presence, namely, through the use of wind, passive haptics, vibration, and scent. Our sample consisted of 37 participants (27 men and 10 women) whose ages ranged from 17 to 44 years old and were mostly students. The participants were divided randomly into 3 groups: Control Scenario (visual and auditory - N = 12), Passive Haptic Scenario (visual, auditory, and passive haptic - N = 13) and Multisensory Scenario (visual, auditory, wind, passive haptic, vibration, and scent - N = 12). The results indicated a significant increase in the involvement subscale when all multisensory stimuli were delivered. We found a trend where the use of passive haptics by itself has a positive impact on presence, which should be the subject of further work.",2019,"We found a trend where the use of passive haptics by itself has a positive impact on presence, which should be the subject of further work.","['37 participants (27 men and 10 women) whose ages ranged from 17 to 44 years old and were mostly students', 'credible virtual environments']","['sensory stimuli', 'Control Scenario (visual and auditory - N = 12), Passive Haptic Scenario (visual, auditory, and passive haptic - N = 13) and Multisensory Scenario (visual, auditory, wind, passive haptic, vibration, and scent - N = 12']",[],"[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0014406', 'cui_str': 'Environment'}]","[{'cui': 'C0445254', 'cui_str': 'Sensory (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C0043187', 'cui_str': 'Wind'}, {'cui': 'C0459800', 'cui_str': 'Vibration'}, {'cui': 'C2987717', 'cui_str': 'Aroma'}]",[],37.0,0.0134315,"We found a trend where the use of passive haptics by itself has a positive impact on presence, which should be the subject of further work.","[{'ForeName': 'Guilherme', 'Initials': 'G', 'LastName': 'Goncalves', 'Affiliation': ''}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Melo', 'Affiliation': ''}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Vasconcelos-Raposo', 'Affiliation': ''}, {'ForeName': 'Maximino Esteves', 'Initials': 'ME', 'LastName': 'Bessa', 'Affiliation': ''}]",IEEE transactions on visualization and computer graphics,['10.1109/TVCG.2019.2926978'] 635,30626911,"A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder.","NSI-189 is a novel neurogenic compound independent of monoamine reuptake pathways. This trial evaluated oral NSI-189 as monotherapy in major depressive disorder. To improve signal detection, the sequential-parallel comparison design (SPCD) was chosen. Two hundred and twenty subjects were randomized to NSI-189 40 mg daily, 80 mg daily, or placebo for 12 weeks. The primary outcome measure was the Montogmery Asberg Depression Rating Scale (MADRS). Secondary subject-rated measures included the Symptoms of Depression Questionnaire (SDQ), the Cognitive and Physical Functioning Scale (CPFQ), the patient-rated version of the Quick Inventory of Depressive Symptomatology Scale (QIDS-SR), and subtests from the CogScreen and Cogstate cognitive tests. MADRS score reduction versus placebo did not reach significance for either dose (40 mg pooled mean difference -1.8, p = 0.22, 80 mg pooled mean difference -1.4, p = 0.34, respectively). However, the 40 mg dose showed greater overall reduction in SDQ (pooled mean difference -8.2; Cohen's d for Stages 1 and 2 = -0.11 and -0.64, p = 0.04), and CPFQ scores (pooled mean difference -1.9; Cohen's d for Stages 1 and 2 = -0.28 and -0.47, p = 0.03) versus placebo, as well as QIDS-SR scores in Stage 2 of SPCD (-2.5; Cohen's d Stages 1 and 2 = -0.03 and -0.68, p = 0.04). The 40 mg dose also showed advantages on some objective cognitive measures of the CogScreen (absolute Cohen's d ranged between 0.12 and 1.12 in favor of NSI-189, p values between 0.002 and 0.048 for those with overall significance), but not the Cogstate test. Both doses were well tolerated. These findings replicate those of phase 1b study, and warrant further exploration of the antidepressant and pro-cognitive effects of NSI-189.",2020,"MADRS score reduction versus placebo did not reach significance for either dose (40 mg pooled mean difference -1.8, p = 0.22, 80 mg pooled mean difference -1.4, p = 0.34, respectively).","['major depressive disorder', 'Two hundred and twenty subjects were randomized to NSI-189 40', 'outpatients with major depressive disorder']","['NSI-189 phosphate', 'NSI-189', 'placebo']","['Montogmery Asberg Depression Rating Scale (MADRS', 'MADRS score reduction', 'Symptoms of Depression Questionnaire (SDQ), the Cognitive and Physical Functioning Scale (CPFQ), the patient-rated version of the Quick Inventory of Depressive Symptomatology Scale (QIDS-SR), and subtests from the CogScreen and Cogstate cognitive tests', 'QIDS-SR scores', 'tolerated', 'overall reduction in SDQ', 'objective cognitive measures of the CogScreen', 'CPFQ scores']","[{'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C4517650', 'cui_str': '220 (qualifier value)'}, {'cui': 'C4507670', 'cui_str': 'NSI-189'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}]","[{'cui': 'C4507671', 'cui_str': 'NSI-189 phosphate'}, {'cui': 'C4507670', 'cui_str': 'NSI-189'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C4720917', 'cui_str': 'Quick inventory of depressive symptomatology (assessment scale)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]",220.0,0.16936,"MADRS score reduction versus placebo did not reach significance for either dose (40 mg pooled mean difference -1.8, p = 0.22, 80 mg pooled mean difference -1.4, p = 0.34, respectively).","[{'ForeName': 'G I', 'Initials': 'GI', 'LastName': 'Papakostas', 'Affiliation': 'Massachusetts General Hospital Clinical Trials Network and Institute (MGH CTNI), Boston, MA, USA. gpapakostas@partners.org.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Johe', 'Affiliation': 'Neuralstem, Inc, Germantown, MD, USA.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Hand', 'Affiliation': 'Neuralstem, Inc, Germantown, MD, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Drouillard', 'Affiliation': 'Neuralstem, Inc, Germantown, MD, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Russo', 'Affiliation': 'Neuralstem, Inc, Germantown, MD, USA.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Kay', 'Affiliation': 'Cognitive Research Corp., Saint Petersburg, Florida, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Kashambwa', 'Affiliation': 'Massachusetts General Hospital Clinical Trials Network and Institute (MGH CTNI), Boston, MA, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Hoeppner', 'Affiliation': 'Massachusetts General Hospital Clinical Trials Network and Institute (MGH CTNI), Boston, MA, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Flynn', 'Affiliation': 'Massachusetts General Hospital Clinical Trials Network and Institute (MGH CTNI), Boston, MA, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Yeung', 'Affiliation': 'Massachusetts General Hospital Clinical Trials Network and Institute (MGH CTNI), Boston, MA, USA.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Martinson', 'Affiliation': 'Massachusetts General Hospital Clinical Trials Network and Institute (MGH CTNI), Boston, MA, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Fava', 'Affiliation': 'Massachusetts General Hospital Clinical Trials Network and Institute (MGH CTNI), Boston, MA, USA.'}]",Molecular psychiatry,['10.1038/s41380-018-0334-8'] 636,30965392,Improvement of hyponatremia in cirrhosis is associated with improved complex information processing.,"BACKGROUND AND AIM Hyponatremia, a cause of brain dysfunction and risk factor for hepatic encephalopathy, is frequent in patients with advanced cirrhosis and ascites. The interdependence of liver failure and hyponatremia makes it difficult to separate the effects of each on cognitive function. The objective was to assess whether an increase in plasma sodium in patients with cirrhosis and ascites leads to an improvement in cognitive function. METHODS This is a post-hoc analysis of 250 cirrhosis patients without overt hepatic encephalopathy randomized to receive either placebo or satavaptan, a vasopressin V 2 antagonist. The exposure was plasma sodium, and the outcome was the trail-making test (TMT) parts A and B, which assesses speed of information processing, performed before the study starts and after 14 days. The results were analyzed by initial and change to final sodium concentration. RESULTS At entry, the patients with normonatremia exhibited better results on both the TMT-A (median 56 vs 77.5 s for patients with sodium ≤ 130 mmol/L [P = 0.0059]) and the TMT-B (median 127 vs 170 s for patients with sodium ≤ 130 mmol/L [P = 0.0066]), unrelated to age. Improvement of hyponatremia was more common in patients who received satavaptan (59.7%) than placebo (18.5%). Correction of hyponatremia did not shorten the simple TMT-A but markedly improved the complex TMT-B by an average of 20 s compared with 6.5 s in those with continuing hyponatremia (P = 0.02). Liver status measures remained stable during the period reported. CONCLUSIONS These data suggest that improvement of hyponatremia in patients with cirrhosis leads to an increase in the speed of complex information processing.",2019,Correction of hyponatremia did not shorten the simple TMT-A but markedly improved the complex TMT-B by an average of 20 s compared with 6.5 s in those with continuing hyponatremia (P = 0.02).,"['250 cirrhosis patients without overt hepatic encephalopathy', 'patients with cirrhosis and ascites leads', 'patients with advanced cirrhosis and ascites', 'patients with cirrhosis']","['placebo', 'placebo or satavaptan, a vasopressin V 2 antagonist']","['hyponatremia', 'complex TMT-B', 'plasma sodium', 'Correction of hyponatremia']","[{'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C1623038', 'cui_str': 'Cirrhosis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019151', 'cui_str': 'Portal-Systemic Encephalopathy'}, {'cui': 'C0003962', 'cui_str': 'Ascites'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C1263666', 'cui_str': 'Advanced cirrhosis'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2607958', 'cui_str': 'satavaptan'}, {'cui': 'C0201849', 'cui_str': 'Antidiuretic hormone measurement (procedure)'}, {'cui': 'C0445362', 'cui_str': 'V 2'}, {'cui': 'C0243076', 'cui_str': 'antagonists'}]","[{'cui': 'C0020625', 'cui_str': 'Hyponatremia'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0858175', 'cui_str': 'Plasma sodium'}]",250.0,0.164424,Correction of hyponatremia did not shorten the simple TMT-A but markedly improved the complex TMT-B by an average of 20 s compared with 6.5 s in those with continuing hyponatremia (P = 0.02).,"[{'ForeName': 'Hugh', 'Initials': 'H', 'LastName': 'Watson', 'Affiliation': ""Infectious Diseases Research, Sanofi-Aventis R&D, Marcy l'Etoile, France.""}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Guevara', 'Affiliation': ""Liver Unit, Hospital Clinic of Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), and Centro de Investigaciones en Red Hepatologia y Digestivas (CIBEReHD), Barcelona, Spain.""}, {'ForeName': 'Hendrik', 'Initials': 'H', 'LastName': 'Vilstrup', 'Affiliation': 'Department of Gastroenterology and Hepatology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Pere', 'Initials': 'P', 'LastName': 'Ginès', 'Affiliation': ""Liver Unit, Hospital Clinic of Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), and Centro de Investigaciones en Red Hepatologia y Digestivas (CIBEReHD), Barcelona, Spain.""}]",Journal of gastroenterology and hepatology,['10.1111/jgh.14683'] 637,31914936,Online training and support program (iSupport) for informal dementia caregivers: protocol for an intervention study in Portugal.,"BACKGROUND Informal caregivers (IC) of people with dementia (PwD) are at greater risk of developing physical and mental health problems when compared to the general population and to IC of people with other chronic diseases. Internet-based interventions have been explored for their potential to minimize the negative effects of caring, accounting for their ubiquitous nature, convenient delivery, potential scalability and presumed (cost) effectiveness. iSupport is a self-help online program developed by the World Health Organization (WHO) to provide education, skills training and support to IC of PwD. This paper describes the design of an intervention study aimed at determining the effectiveness of a Portuguese culturally adapted version of iSupport on mental health and other well-being outcomes. METHODS The study follows an experimental parallel between-group design with two arms: access to the five modules and twenty-three lessons of ""iSupport"" for three months (intervention group); or access to an education-only e-book (comparison group). One hundred and eighty four participants will be recruited by referral from national associations. Inclusion criteria are: being 18 years or older and provide e-consent; being a self-reported non-paid caregiver for at least six months; of a person with a formal diagnosis of dementia; being skilled to use internet; and experience a clinically relevant level of burden (≥ 21 on Zarit Burden Interview) or depression or anxiety symptoms (≥ 8 on Hospital Anxiety and Depression Scale). Data is collected online, resorting to self-administered instruments, at baseline, 3 and 6 months after baseline. The primary outcome is caregiver burden, measured by the Zarit Burden Interview. Symptoms of depression and anxiety, quality of life, positive aspects of caregiving and general self-efficacy are secondary study outcomes. The data analysis will follow an Intention-to-treat (ITT) protocol. DISCUSSION This protocol is an important resource for the many organizations in several countries aiming to replicate iSupport. Findings from this intervention study will offer evidence to bolster an informed decision making on scaling up iSupport as a new intervention program with minimal costs aimed at minimizing the psychological distress of IC of PwD in Portugal and elsewhere. TRIAL REGISTRATION ClinicalTrials.gov, NCT04104568. Registered 26 September 2019.",2020,"This paper describes the design of an intervention study aimed at determining the effectiveness of a Portuguese culturally adapted version of iSupport on mental health and other well-being outcomes. ","['One hundred and eighty four participants will be recruited by referral from national associations', 'Inclusion criteria are: being 18\u2009years or older and provide e-consent; being a self-reported non-paid caregiver for at least six months; of a person with a formal diagnosis of dementia; being skilled to use internet; and experience a clinically relevant level of burden (≥ 21 on Zarit Burden Interview) or depression or anxiety symptoms (≥ 8 on Hospital Anxiety and Depression Scale', 'Informal caregivers (IC) of people with dementia (PwD', 'informal dementia caregivers']","['iSupport"" for three months (intervention group); or access to an education-only e-book (comparison group', 'Online training and support program (iSupport']","['Symptoms of depression and anxiety, quality of life, positive aspects of caregiving and general self-efficacy', 'caregiver burden, measured by the Zarit Burden Interview']","[{'cui': 'C4517616', 'cui_str': 'One hundred and eighty-four'}, {'cui': 'C0034927', 'cui_str': 'Referral'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C1292718', 'cui_str': 'Is a'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}]","[{'cui': 'C4082119', 'cui_str': 'Three months (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0006002', 'cui_str': 'Books'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0034380'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0935630', 'cui_str': 'Interview'}]",184.0,0.129054,"This paper describes the design of an intervention study aimed at determining the effectiveness of a Portuguese culturally adapted version of iSupport on mental health and other well-being outcomes. ","[{'ForeName': 'Soraia', 'Initials': 'S', 'LastName': 'Teles', 'Affiliation': 'Department of Behavioral Sciences, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua de Jorge Viterbo Ferreira, 228, 4050-313, Porto, Portugal. teles.s.soraia@gmail.com.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Ferreira', 'Affiliation': 'Center for Health Technology and Services Research (CINTESIS), Rua Dr. Plácido da Costa, 4200-450, Porto, Portugal.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Seeher', 'Affiliation': 'Department of Mental Health and Substance Use (MSD), World Health Organization, Avenue Appia 20, 1202, Geneva, Switzerland.'}, {'ForeName': 'Stéfanie', 'Initials': 'S', 'LastName': 'Fréel', 'Affiliation': 'Department of Mental Health and Substance Use (MSD), World Health Organization, Avenue Appia 20, 1202, Geneva, Switzerland.'}, {'ForeName': 'Constança', 'Initials': 'C', 'LastName': 'Paúl', 'Affiliation': 'Department of Behavioral Sciences, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua de Jorge Viterbo Ferreira, 228, 4050-313, Porto, Portugal.'}]",BMC geriatrics,['10.1186/s12877-019-1364-z'] 638,31704093,Refractive and corneal responses of young myopic children to short-term orthokeratology treatment with different compression factors.,"PURPOSE To evaluate changes in refractive and corneal responses in myopic children wearing orthokeratology (ortho-k) lenses with conventional compression factor (CCF, 0.75 D) and increased compression factor (ICF, 1.75 D). METHODS This was a double-blind self-controlled study. Subjects were randomly fitted with CCF in one eye and ICF in the fellow eye. Weekly monitoring of refraction, visual acuity (VA), external ocular health, and corneal responses were performed over one month of lens wear and after discontinuation of lens wear until stabilization was achieved. RESULTS Twenty-five subjects, aged 9.4 ± 1.0 years, completed one-month lens wear, of whom 23 completed the washout period. The first fit success rates for CCF and ICF were 93% and 96%, respectively. Myopia, unaided VA, central corneal thickness, anterior corneal curvatures (K), apical power (AP), and corneal resistance factor (CRF) all changed significantly during the study period (P <  0.003). Between-eye difference was significant only for myopia reduction (P =  0.001). About 4% and 8% of ICF and CCF eyes were under-corrected. The attempted target was achieved in about 80% of CCF and 60% of ICF eyes at week 4. At the end of the washout period (3 weeks), myopia, K, and AP were significantly different compared to baseline (P <  0.001). CONCLUSION Increasing the compression factor did not affect the first fit success rate and external ocular health, but did allow faster correction of refractive error within one month of lens wear. Further investigation is warranted to investigate the long-term effects of ICF on myopia control compared to CCF.",2020,"Increasing the compression factor did not affect the first fit success rate and external ocular health, but did allow faster correction of refractive error within one month of lens wear.","['Twenty-five subjects, aged 9.4\u202f±\u202f1.0 years, completed one-month lens wear, of whom 23 completed the washout period', 'young myopic children', 'myopic children wearing orthokeratology (ortho-k) lenses']","['CCF', 'ICF']","['Refractive and corneal responses', 'refractive and corneal responses', 'myopia reduction', 'Myopia, unaided VA, central corneal thickness, anterior corneal curvatures (K), apical power (AP), and corneal resistance factor (CRF', 'refraction, visual acuity (VA), external ocular health, and corneal responses']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C4082115', 'cui_str': 'One month (qualifier value)'}, {'cui': 'C0023317', 'cui_str': 'Lens, Eye'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1533088', 'cui_str': 'Orthokeratology'}, {'cui': 'C0023318', 'cui_str': 'Lenses'}]","[{'cui': 'C0444966', 'cui_str': 'ICF'}]","[{'cui': 'C0027092', 'cui_str': 'Nearsightedness'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C1720164', 'cui_str': 'Central corneal thickness'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0205111', 'cui_str': 'Apical (qualifier value)'}, {'cui': 'C0034471', 'cui_str': 'Resistance Factors'}, {'cui': 'C0010132', 'cui_str': 'corticorelin'}, {'cui': 'C0430943', 'cui_str': 'Refraction'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C4521296', 'cui_str': 'Ocular (intended site)'}, {'cui': 'C0018684', 'cui_str': 'Health'}]",25.0,0.0524115,"Increasing the compression factor did not affect the first fit success rate and external ocular health, but did allow faster correction of refractive error within one month of lens wear.","[{'ForeName': 'Kin', 'Initials': 'K', 'LastName': 'Wan', 'Affiliation': 'Centre for Myopia Research, School of Optometry, The Hong Kong Polytechnic University, Kowloon, Hong Kong, China. Electronic address: kkinwan@polyu.edu.hk.'}, {'ForeName': 'Jason Ki-Kit', 'Initials': 'JK', 'LastName': 'Lau', 'Affiliation': 'Centre for Myopia Research, School of Optometry, The Hong Kong Polytechnic University, Kowloon, Hong Kong, China.'}, {'ForeName': 'Sin Wan', 'Initials': 'SW', 'LastName': 'Cheung', 'Affiliation': 'Centre for Myopia Research, School of Optometry, The Hong Kong Polytechnic University, Kowloon, Hong Kong, China.'}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Cho', 'Affiliation': 'Centre for Myopia Research, School of Optometry, The Hong Kong Polytechnic University, Kowloon, Hong Kong, China.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2019.10.134'] 639,31325524,Natural American Spirit's pro-environment packaging and perceptions of reduced-harm cigarettes.,"Natural American Spirit (NAS) cigarettes feature a pro-environment marketing campaign on the packs. The NAS ""Respect for the Earth"" campaign is the first example of on-the-pack corporate social responsibility advertising. In a randomized survey design, we tested perceptions of NAS relative to other cigarette brands on harms to self, others, and the environment. Never (n = 421), former (n = 135), and current (n = 358) US adult smokers were recruited for an online survey from January through March 2018. All participants viewed packs of both NAS and Pall Mall. Participants were randomized to view NAS vs. Pall Mall and to pack color (blue, green, or yellow/orange), which was matched between brands. Survey items assessed perceptions of health risk of the cigarette brand to self, others, and the environment and corporate perceptions. Consistently on all measures, NAS cigarettes were rated as less harmful for oneself, others, and the environment relative to Pall Mall (p's < .001). Though Reynolds American owns both brands, participants rated the company behind NAS as more socially responsible than the company behind Pall Mall, F[1, 909] = 110.25, p < .001. The NAS advantage was significant irrespective of smoking status, pack color, and brand order, with findings stronger for current than never smokers. Pro-environmental marketing on NAS cigarette packs contributes to misperceptions that the product is safer for people and the environment than other cigarettes and made by a company that is more socially responsible. Stricter government regulations on the use of pro-environment terms in marketing that imply modified risk are needed.",2019,"The NAS advantage was significant irrespective of smoking status, pack color, and brand order, with findings stronger for current than never smokers.","['Never (n\u202f=\u202f421), former (n\u202f=\u202f135), and current (n\u202f=\u202f358) US adult smokers were recruited for an online survey from January through March 2018']","['view NAS vs. Pall Mall and to pack color (blue, green, or yellow/orange']","['perceptions of health risk of the cigarette brand to self, others, and the environment and corporate perceptions']","[{'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]","[{'cui': 'C0449911', 'cui_str': 'View (attribute)'}, {'cui': 'C1968515', 'cui_str': 'Pack (physical object)'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C1260957', 'cui_str': 'Blue color (qualifier value)'}, {'cui': 'C0332583', 'cui_str': 'Green color (qualifier value)'}, {'cui': 'C0221205', 'cui_str': 'Yellow color (qualifier value)'}, {'cui': 'C0440277', 'cui_str': 'Oranges'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0014406', 'cui_str': 'Environment'}]",,0.018191,"The NAS advantage was significant irrespective of smoking status, pack color, and brand order, with findings stronger for current than never smokers.","[{'ForeName': 'Anna E', 'Initials': 'AE', 'LastName': 'Epperson', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Eric F', 'Initials': 'EF', 'LastName': 'Lambin', 'Affiliation': 'School of Earth, Energy & Environmental Sciences, Woods Institute for the Environment, Stanford University, Stanford, CA, USA; Georges Lemaître Earth and Climate Research Centre, Earth and Life Institute, Université catholique de Louvain, Louvain-la-Neuve, Belgium.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Henriksen', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Baiocchi', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'June A', 'Initials': 'JA', 'LastName': 'Flora', 'Affiliation': 'Solutions Science Lab, Department of Pediatrics, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Judith J', 'Initials': 'JJ', 'LastName': 'Prochaska', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: jpro@stanford.edu.'}]",Preventive medicine,['10.1016/j.ypmed.2019.105782'] 640,31884945,Study protocol of coaching end-of-life palliative care for advanced heart failure patients and their family caregivers in rural appalachia: a randomized controlled trial.,"BACKGROUND Heart failure (HF) afflicts 6.5 million Americans with devastating consequences to patients and their family caregivers. Families are rarely prepared for worsening HF and are not informed about end-of-life and palliative care (EOLPC) conservative comfort options especially during the end stage. West Virginia (WV) has the highest rate of HF deaths in the U.S. where 14% of the population over 65 years have HF. Thus, there is a need to investigate a new family EOLPC intervention (FamPALcare), where nurses coach family-managed advanced HF care at home. METHODS This study uses a randomized controlled trial (RCT) design stratified by gender to determine any differences in the FamPALcare HF patients and their family caregiver outcomes versus standard care group outcomes (N = 72). Aim 1 is to test the FamPALcare nursing care intervention with patients and family members managing home supportive EOLPC for advanced HF. Aim 2 is to assess implementation of the FamPALcare intervention and research procedures for subsequent clinical trials. Intervention group will receive routine standard care, plus 5-weekly FamPALcare intervention delivered by community-based nurses. The intervention sessions involve coaching patients and family caregivers in advanced HF home care and supporting EOLPC discussions based on patients' preferences. Data are collected at baseline, 3, and 6 months. Recruitment is from sites affiliated with a large regional hospital in WV and community centers across the state. DISCUSSION The outcomes of this clinical trial will result in new knowledge on coaching techniques for EOLPC and approaches to palliative and end-of-life rural home care. The HF population in WV will benefit from a reduction in suffering from the most common advanced HF symptoms, selecting their preferred EOLPC care options, determining their advance directives, and increasing skills and resources for advanced HF home care. The study will provide a long-term collaboration with rural community leaders, and collection of data on the implementation and research procedures for a subsequent large multi-site clinical trial of the FamPALcare intervention. Multidisciplinary students have opportunity to engage in the research process. TRIAL REGISTRATION ClinicalTrials.gov NCT04153890, Registered on 4 November 2019.",2019,Aim 1 is to test the FamPALcare nursing care intervention with patients and family members managing home supportive EOLPC for advanced HF.,"['advanced heart failure patients and their family caregivers in rural appalachia', 'Heart failure (HF) afflicts 6.5 million Americans with devastating consequences to patients and their family caregivers', 'patients and family members managing home supportive EOLPC for advanced HF']","['intervention sessions involve coaching patients and family caregivers in advanced HF home care and supporting EOLPC discussions', 'coaching end-of-life palliative care', 'routine standard care, plus 5-weekly FamPALcare intervention delivered by community-based nurses', 'FamPALcare nursing care intervention', 'FamPALcare intervention']",[],"[{'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C0003609', 'cui_str': 'Appalachia'}, {'cui': 'C3844007', 'cui_str': '6.5'}, {'cui': 'C0086282', 'cui_str': 'Person in the family'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}]","[{'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0557773', 'cui_str': 'Coach (physical object)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0204977', 'cui_str': 'Home Care'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0557061', 'cui_str': 'Discussion (procedure)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0700049', 'cui_str': 'Palliative care'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0028682', 'cui_str': 'Nursing Care'}]",[],,0.100585,Aim 1 is to test the FamPALcare nursing care intervention with patients and family members managing home supportive EOLPC for advanced HF.,"[{'ForeName': 'Ubolrat', 'Initials': 'U', 'LastName': 'Piamjariyakul', 'Affiliation': 'West Virginia University, School of Nursing Health Sciences Center, Post Office Box 9600 - Office 6701, Morgantown, WV, 26506-9602, USA. ubolrat.piamjariyakul@hsc.wvu.edu.'}, {'ForeName': 'Trisha', 'Initials': 'T', 'LastName': 'Petitte', 'Affiliation': 'West Virginia University, School of Nursing Health Sciences Center, Post Office Box 9600 - Office 6701, Morgantown, WV, 26506-9602, USA.'}, {'ForeName': 'Angel', 'Initials': 'A', 'LastName': 'Smothers', 'Affiliation': 'West Virginia University, School of Nursing Health Sciences Center, Post Office Box 9600 - Office 6701, Morgantown, WV, 26506-9602, USA.'}, {'ForeName': 'Sijin', 'Initials': 'S', 'LastName': 'Wen', 'Affiliation': 'Department of Biostatistics School of Public Health, West Virginia University, Morgantown, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Morrissey', 'Affiliation': 'West Virginia University, School of Nursing Health Sciences Center, Post Office Box 9600 - Office 6701, Morgantown, WV, 26506-9602, USA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Young', 'Affiliation': 'West Virginia University, School of Nursing Health Sciences Center, Post Office Box 9600 - Office 6701, Morgantown, WV, 26506-9602, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Sokos', 'Affiliation': 'Advanced Heart Failure, West Virginia University Heart and Vascular Institute, J.W. Ruby Memorial Hospital, Morgantown, USA.'}, {'ForeName': 'Alvin H', 'Initials': 'AH', 'LastName': 'Moss', 'Affiliation': 'Sections of Nephrology and Supportive Care, West Virginia University Center for Health Ethics and Law, Morgantown, USA.'}, {'ForeName': 'Carol E', 'Initials': 'CE', 'LastName': 'Smith', 'Affiliation': 'University of Kansas Medical Center, School of Nursing and School of Preventive Medicine, Morgantown, USA.'}]",BMC palliative care,['10.1186/s12904-019-0500-z'] 641,31860366,A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder.,"BACKGROUND Extended-release (XR) naltrexone can prevent relapse to opioid use disorder following detoxification. However, one of the barriers to initiating XR-naltrexone is the recommendation for a 7-10-day period of abstinence from opioids prior to the first dose. OBJECTIVES The current study evaluated the feasibility of an XR-naltrexone induction protocol that can be implemented over 1 week in the outpatient clinic. METHODS Participants (N = 44) were seen in the clinic daily. On Day 1, after abstaining from opioids for at least 12 h, they received buprenorphine 6-8 mg. Adjunctive medications (clonidine, clonazepam, zolpidem, trazodone, and prochlorperazine) were dispensed on Days 2-5, while ascending oral doses of naltrexone were given on Days 3-5 starting with 1 mg dose. An injection of XR-naltrexone was given on Day 5, 1 h after receiving and tolerating naltrexone 24 mg. RESULTS Of the 44 participants (38 males), 35 (80%) were heroin users and 9 (20%) used prescription opioids. A total of 26 participants (59%) completed the induction and received their first injection of XR-naltrexone. XR-naltrexone was initiated in 54% (19/35) of heroin users and 78% (7/9) of prescription opioid users. CONCLUSION The results support the feasibility of a week-long outpatient induction onto XR-naltrexone with ascending doses of naltrexone and standing doses of adjunctive medications. By circumventing the need for a protracted period of abstinence and mitigating the severity of withdrawal symptoms experienced during naltrexone titration, this strategy has the potential to increase patient acceptability and access to relapse prevention treatment with XR-naltrexone.",2020,XR-naltrexone was initiated in 54% (19/35) of heroin users and 78% (7/9) of prescription opioid users.,"['patients with opioid use disorder', '44 participants (38 males), 35 (80%) were heroin users and 9 (20%) used prescription opioids']","['release (XR) naltrexone', 'XR-naltrexone induction protocol', 'XR-naltrexone', 'buprenorphine', 'Adjunctive medications (clonidine, clonazepam, zolpidem, trazodone, and prochlorperazine', 'naltrexone']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0011892', 'cui_str': 'diamorphine'}, {'cui': 'C0033080', 'cui_str': 'Prescriptions'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}]","[{'cui': 'C1963578', 'cui_str': 'Release (procedure)'}, {'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C0009014', 'cui_str': 'Clonidine'}, {'cui': 'C0009011', 'cui_str': 'Clonazepam'}, {'cui': 'C0078839', 'cui_str': 'zolpidem'}, {'cui': 'C0040805', 'cui_str': 'Trazodone'}, {'cui': 'C0033229', 'cui_str': 'Prochlorperazine'}]",[],26.0,0.0269508,XR-naltrexone was initiated in 54% (19/35) of heroin users and 78% (7/9) of prescription opioid users.,"[{'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Sibai', 'Affiliation': 'Department of Psychology, University of Detroit Mercy , Detroit, MI, USA.'}, {'ForeName': 'Kaitlyn', 'Initials': 'K', 'LastName': 'Mishlen', 'Affiliation': 'Division on Substance Use Disorders New York State Psychiatric Institute , New York, NY, USA.'}, {'ForeName': 'Edward V', 'Initials': 'EV', 'LastName': 'Nunes', 'Affiliation': 'Division on Substance Use Disorders New York State Psychiatric Institute , New York, NY, USA.'}, {'ForeName': 'Frances R', 'Initials': 'FR', 'LastName': 'Levin', 'Affiliation': 'Division on Substance Use Disorders New York State Psychiatric Institute , New York, NY, USA.'}, {'ForeName': 'John J', 'Initials': 'JJ', 'LastName': 'Mariani', 'Affiliation': 'Division on Substance Use Disorders New York State Psychiatric Institute , New York, NY, USA.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Bisaga', 'Affiliation': 'Division on Substance Use Disorders New York State Psychiatric Institute , New York, NY, USA.'}]",The American journal of drug and alcohol abuse,['10.1080/00952990.2019.1700265'] 642,30931723,Constructing Matched Groups in Dental Observational Health Disparity Studies for Causal Effects.,"INTRODUCTION Electronic health record (EHR) systems provide investigators with rich data from which to examine actual impacts of care delivery in real-world settings. However, confounding is a major concern when comparison groups are not randomized. OBJECTIVES This article introduced a step-by-step strategy to construct comparable matched groups in a dental study based on the EHR of the Willamette Dental Group. This strategy was employed in preparation for a longitudinal study evaluating the impact of a standardized risk-based caries prevention and management program across patients with public versus private dental insurance in Oregon. METHODS This study constructed comparable dental patient groups through a process of 1) evaluating the need for and feasibility of matching, 2) considering different matching methods, and 3) evaluating matching quality. The matched groups were then compared for their average ratio in the number of decayed, missing, and filled tooth surfaces (DMFS + dmfs) at baseline. RESULTS This systematic process resulted in comparably matched groups in baseline covariates but with a clear baseline disparity in caries experience between them. The weighted average ratio in our study showed that, at baseline, publicly insured patients had 1.21-times (95% CI: 1.08 to 1.32) and 1.21-times (95% CI: 1.08 to 1.37) greater number of DMFS + dmfs and number of decayed tooth surfaces (DS + ds) than privately insured patients, respectively. CONCLUSION Matching is a useful tool to create comparable groups with EHR data to resemble randomized studies, as demonstrated by our study where even with similar demographics, neighborhood and clinic characteristics, publicly insured pediatric patients had greater numbers of DMFS + dmfs and DS + ds than privately insured pediatric patients. KNOWLEDGE TRANSFER STATEMENT This article provides a systematic, step-by-step strategy for investigators to follow when matching groups in a study-in this case, a study based on electronic health record data. The results from this study will provide patients, clinicians, and policy makers with information to better understand the disparities in oral health between comparable publicly and privately insured pediatric patients who have similar values in individual, clinic, and community covariates. Such understanding will help clinicians and policy makers modify oral health care and relevant policies to improve oral health and reduce disparities between publicly and privately insured patients.",2020,"The matched groups were then compared for their average ratio in the number of decayed, missing, and filled tooth surfaces (DMFS + dmfs) at baseline. ","['pediatric patients had greater numbers of DMFS + dmfs and DS + ds than privately insured pediatric patients', 'patients with public versus private dental insurance in Oregon']",['standardized risk-based caries prevention and management program'],['number of DMFS + dmfs and number of decayed tooth surfaces'],"[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C4521534', 'cui_str': 'US Military enlisted E1'}, {'cui': 'C0021681', 'cui_str': 'Insurance, Dental'}, {'cui': 'C0029195', 'cui_str': 'Oregon'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1265875', 'cui_str': 'Disintegration'}, {'cui': 'C0447301', 'cui_str': 'Tooth surface (body structure)'}]",,0.0781924,"The matched groups were then compared for their average ratio in the number of decayed, missing, and filled tooth surfaces (DMFS + dmfs) at baseline. ","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Cheng', 'Affiliation': 'Department of Preventive and Restorative Dental Sciences, School of Dentistry, University of California-San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'S E', 'Initials': 'SE', 'LastName': 'Gregorich', 'Affiliation': 'Department of Preventive and Restorative Dental Sciences, School of Dentistry, University of California-San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'Gansky', 'Affiliation': 'Department of Preventive and Restorative Dental Sciences, School of Dentistry, University of California-San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'Fisher-Owens', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, School of Dentistry, University of California-San Francisco, San Francisco, CA, USA.""}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Kottek', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, School of Dentistry, University of California-San Francisco, San Francisco, CA, USA.""}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'White', 'Affiliation': 'Department of Preventive and Restorative Dental Sciences, School of Dentistry, University of California-San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'E A', 'Initials': 'EA', 'LastName': 'Mertz', 'Affiliation': 'Department of Preventive and Restorative Dental Sciences, School of Dentistry, University of California-San Francisco, San Francisco, CA, USA.'}]",JDR clinical and translational research,['10.1177/2380084419830655'] 643,31609072,Avocatin B Protects Against Lipotoxicity and Improves Insulin Sensitivity in Diet-Induced Obesity.,"SCOPE The effects of an avocado-derived fatty acid oxidation (FAO) inhibitor, avocatin B (AvoB), on glucose and lipid metabolism in models of diet-induced obesity (DIO) and in vitro models of lipotoxicity are evaluated. The safety of its oral consumption in humans is also determined. METHODS AND RESULTS Mice are given high-fat diets (HFD) for 8 weeks. Thereafter, AvoB or vehicle is administered orally twice weekly for 5 weeks. AvoB inhibits FAO which led to improved glucose tolerance, glucose utilization, and insulin sensitivity. AvoB's effects on metabolism under lipotoxic conditions are evaluated in vitro in pancreatic β-islet cells and C2C12 myotubes. AvoB inhibits FAO and increases glucose oxidation, resulting in lowering of mitochondrial reactive oxygen species that improves insulin responsiveness in C2C12 myotubes and insulin secretion in INS-1 (832/13) cells, respectively. A randomized, double-blind, placebo-controlled clinical trial in healthy human participants is conducted to assess the safety of AvoB consumption (50 mg or 200 mg per day for 60 days). AvoB is well-tolerated and not associated with any dose-limiting toxicity. CONCLUSION Therapeutic agents that are safe and effectively inhibit FAO and improve DIO-associated pathologies are currently not available. AvoB's mechanism of action and favorable safety profile highlight its nutritional and clinical importance.",2019,"AvoB inhibited FAO and increased glucose oxidation resulting in lowering of mitochondrial reactive oxygen species that improved insulin responsiveness in C2C12 myotubes and insulin secretion in INS-1 (832/13) cells, respectively.","['Mice were given high fat diets (HFD) for 8 weeks', 'healthy human participants']","['placebo', 'avocado-derived fatty acid oxidation (FAO) inhibitor, avocatin B (AvoB', 'AvoB consumption', 'Avocatin B Protects Against Lipotoxicity']","['Insulin Sensitivity', 'glucose oxidation', 'glucose tolerance, glucose utilization and insulin sensitivity']","[{'cui': 'C0026809', 'cui_str': 'Mice'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0521974', 'cui_str': 'Diet, High-Fat'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0330230', 'cui_str': 'Avocado'}, {'cui': 'C0015684', 'cui_str': 'Fatty Acids'}, {'cui': 'C0030011', 'cui_str': 'Oxidation, function (observable entity)'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0030011', 'cui_str': 'Oxidation, function (observable entity)'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0042153', 'cui_str': 'use'}]",,0.126763,"AvoB inhibited FAO and increased glucose oxidation resulting in lowering of mitochondrial reactive oxygen species that improved insulin responsiveness in C2C12 myotubes and insulin secretion in INS-1 (832/13) cells, respectively.","[{'ForeName': 'Nawaz', 'Initials': 'N', 'LastName': 'Ahmed', 'Affiliation': 'Department of Food Science, University of Guelph, Guelph, Ontario, Canada, N1G 2W1.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Tcheng', 'Affiliation': 'Department of Food Science, University of Guelph, Guelph, Ontario, Canada, N1G 2W1.'}, {'ForeName': 'Alessia', 'Initials': 'A', 'LastName': 'Roma', 'Affiliation': 'Department of Food Science, University of Guelph, Guelph, Ontario, Canada, N1G 2W1.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Buraczynski', 'Affiliation': 'Department of Food Science, University of Guelph, Guelph, Ontario, Canada, N1G 2W1.'}, {'ForeName': 'Preethi', 'Initials': 'P', 'LastName': 'Jayanth', 'Affiliation': 'Department of Food Science, University of Guelph, Guelph, Ontario, Canada, N1G 2W1.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Rea', 'Affiliation': 'Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada, N1G 2W1.'}, {'ForeName': 'Tariq A', 'Initials': 'TA', 'LastName': 'Akhtar', 'Affiliation': 'Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada, N1G 2W1.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Spagnuolo', 'Affiliation': 'Department of Food Science, University of Guelph, Guelph, Ontario, Canada, N1G 2W1.'}]",Molecular nutrition & food research,['10.1002/mnfr.201900688'] 644,31318603,Increasing Organ Donor Designation Rates in Adolescents: A Cluster Randomized Trial.,"Objectives. To evaluate the effectiveness of video messaging on adolescent organ donor designation rates. Methods. We randomized adolescent driver education classes in Massachusetts, between July 2015 and February 2018, to receive 1 of 3 organ donation video messaging interventions (informational, testimonial, or blended). Adolescents completed questionnaires before and after the intervention and at 1-week follow-up; we compared their registration status at time of obtaining driver's license with that of a regionally matched historical comparison group. Results. Donor designation rates were higher for those exposed to video messaging than for the historical comparison group (60% vs 50%; P  < .001). Testimonial (64%) and blended messaging (65%) yielded higher donor designation rates than informational messaging (51%; P  = .013). There was a statistically significant messaging × time interaction effect for donation knowledge ( P  = .03), with blended and informational messaging showing more gains in knowledge from before to after the intervention ( P  < .001; d  = 0.69 and P  < .001; d  = 0.45, respectively), compared with testimonial messaging ( d  = 0.09; P  = .22). Conclusions. Testimonial messaging is most effective in producing a verifiable and demonstrable impact on donor designation rates among adolescents, and driver education classes are an efficient venue for disseminating organ donation messaging to youths. Trial Registration. ClinicalTrials.gov; identifier: NCT03013816.",2019,Testimonial (64%) and blended messaging (65%) yielded higher donor designation rates than informational messaging (51%; P  = .013).,"['adolescent driver education classes in Massachusetts, between July 2015 and February 2018', 'Adolescents']","['3 organ donation video messaging interventions (informational, testimonial, or blended', 'video messaging', 'Testimonial messaging']","['higher donor designation rates', 'Donor designation rates', 'adolescent organ donor designation rates', 'donation knowledge']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}]","[{'cui': 'C0282366', 'cui_str': 'Organ Donation'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0029206', 'cui_str': 'Organ donor (person)'}, {'cui': 'C4049936', 'cui_str': 'Donation'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",,0.194283,Testimonial (64%) and blended messaging (65%) yielded higher donor designation rates than informational messaging (51%; P  = .013).,"[{'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Rodrigue', 'Affiliation': 'James R. Rodrigue is with the Department of Surgery, Beth Israel Deaconess Medical Center, and the Departments of Surgery and Psychiatry, Harvard Medical School, Boston, MA. Matthew Boger is with New England Donor Services, Waltham, MA. Derek DuBay is with the Transplant Integrated Center of Clinical Excellence and the Department of Surgery, Medical University of South Carolina, Charleston. Aaron Fleishman is with the FIRST Program, Department of Surgery, Beth Israel Deaconess Medical Center, Boston.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Boger', 'Affiliation': 'James R. Rodrigue is with the Department of Surgery, Beth Israel Deaconess Medical Center, and the Departments of Surgery and Psychiatry, Harvard Medical School, Boston, MA. Matthew Boger is with New England Donor Services, Waltham, MA. Derek DuBay is with the Transplant Integrated Center of Clinical Excellence and the Department of Surgery, Medical University of South Carolina, Charleston. Aaron Fleishman is with the FIRST Program, Department of Surgery, Beth Israel Deaconess Medical Center, Boston.'}, {'ForeName': 'Derek', 'Initials': 'D', 'LastName': 'DuBay', 'Affiliation': 'James R. Rodrigue is with the Department of Surgery, Beth Israel Deaconess Medical Center, and the Departments of Surgery and Psychiatry, Harvard Medical School, Boston, MA. Matthew Boger is with New England Donor Services, Waltham, MA. Derek DuBay is with the Transplant Integrated Center of Clinical Excellence and the Department of Surgery, Medical University of South Carolina, Charleston. Aaron Fleishman is with the FIRST Program, Department of Surgery, Beth Israel Deaconess Medical Center, Boston.'}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'Fleishman', 'Affiliation': 'James R. Rodrigue is with the Department of Surgery, Beth Israel Deaconess Medical Center, and the Departments of Surgery and Psychiatry, Harvard Medical School, Boston, MA. Matthew Boger is with New England Donor Services, Waltham, MA. Derek DuBay is with the Transplant Integrated Center of Clinical Excellence and the Department of Surgery, Medical University of South Carolina, Charleston. Aaron Fleishman is with the FIRST Program, Department of Surgery, Beth Israel Deaconess Medical Center, Boston.'}]",American journal of public health,['10.2105/AJPH.2019.305178'] 645,31318821,The Effect of Cognitive-Emotional Intervention on Growth and Posttraumatic Stress in Mothers of Children With Cancer: A Randomized Clinical Trial.,"BACKGROUND To diminish the negative impact and improve the positive outcomes on the parents of children with cancer, it is crucial to attend to their problems. This is especially significant in the case of mothers as the main caregivers. The present study aimed at evaluating the efficiency of cognitive-emotional intervention on growth and posttraumatic stress in mothers of children with cancer hospitalized in the chemotherapy ward. PROCEDURE This randomized clinical trial was conducted on 100 mothers of children with cancer who presented to the chemotherapy ward of a hospital located in southeastern Iran in 2018. The eligible mothers were chosen and randomly assigned to intervention and control groups. Mothers in the intervention group as a whole received 5 sessions of cognitive-emotional intervention. The sessions were held twice a week, each lasting 60 to 90 minutes. Sixteen weeks after the intervention, posttest data were collected through the Posttraumatic Stress Disorder Checklist and Posttraumatic Growth Inventory. The data were then analyzed using SPSS 21 utilizing statistical tests including independent and paired t tests, χ, and covariance analysis. RESULTS The results show that the mean value of posttraumatic stress in mothers of children with cancer after cognitive-emotional training in the intervention group (25.92±5.29) was significantly lower than that in the control group (44.94±11.92; P=0.0001). Moreover, in the posttest, the mean value of posttraumatic growth in the intervention group (92.06±5.50) was significantly more than that in the control group (62.98±15.08; P=0.0001). CONCLUSIONS Alleviating posttraumatic stress, the cognitive-emotional intervention proposed in this research had a significant and positive impact on posttraumatic growth in mothers of children diagnosed with cancer. Therefore, implementing this intervention in the chemotherapy department and throughout the course of the children's treatment is highly recommended for their caregivers, especially mothers of children diagnosed with cancer.",2020,"Sixteen weeks after the intervention, posttest data were collected through the Posttraumatic Stress Disorder Checklist and Posttraumatic Growth Inventory.","['mothers of children diagnosed with cancer', 'parents of children with cancer', 'Mothers of Children With Cancer', 'mothers of children with cancer hospitalized in the chemotherapy ward', '100 mothers of children with cancer who presented to the chemotherapy ward of a hospital located in southeastern Iran in 2018']","['cognitive-emotional intervention', 'Cognitive-Emotional Intervention']","['mean value of posttraumatic stress', 'growth and posttraumatic stress', 'Posttraumatic Stress Disorder Checklist and Posttraumatic Growth Inventory', 'Growth and Posttraumatic Stress', 'mean value of posttraumatic growth']","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0030551', 'cui_str': 'Parent of (observable entity)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0332285', 'cui_str': 'In (attribute)'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}]","[{'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C4704809', 'cui_str': 'Posttraumatic Growth'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",100.0,0.0381686,"Sixteen weeks after the intervention, posttest data were collected through the Posttraumatic Stress Disorder Checklist and Posttraumatic Growth Inventory.","[{'ForeName': 'Mansour', 'Initials': 'M', 'LastName': 'Shakiba', 'Affiliation': 'Departments of Psychiatry.'}, {'ForeName': 'Arsalan', 'Initials': 'A', 'LastName': 'Latifi', 'Affiliation': 'Nursing, Nursing and Midwifery School.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Navidian', 'Affiliation': 'Department of Counseling, Community Nursing Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.'}]",Journal of pediatric hematology/oncology,['10.1097/MPH.0000000000001558'] 646,32406770,Development of Quality-Controlled Low-Dose Protocols for Radiography in the Neonatal ICU Using a New Mobile Digital Radiography System.,"OBJECTIVE. The aim of this study was to develop a low-dose radiography protocol for the neonatal ICU (NICU) using a new mobile digital radiography system with advanced denoising image processing and to evaluate the noninferiority of that protocol. SUBJECTS AND METHODS. In this prospective randomized study, 40 neonates in the NICU underwent radiography of the thorax and abdomen with two different mobile radiography units: conventional technique on one unit (50 kV, 1.6 mAs, and no additional filtration) and a new technique on another unit (54 kV, 0.1-mm Cu filtration). Three low-dose protocols for the second unit were developed in a phantom study: protocol A (100% equivalent dose with conventional protocol), protocol B (80% equivalent dose), and protocol C (64% equivalent dose). The noninferiority of each low-dose protocol was assessed by three independent readers using image quality criteria. RESULTS. Forty patients each underwent three pairs of radiography examinations (protocol A and the conventional protocol, protocol B and the conventional protocol, and protocol C and the conventional protocol), except one pair that did not include one image of the conventional protocol. The interrater reliability among the three readers was 0.91 ( p < 0.001). Both of the low-dose protocols (B and C) were statistically noninferior to the conventional protocol with respect to overall image quality. Protocol B better depicted almost all anatomic landmarks and had better overall image quality than the conventional protocol. CONCLUSION. Using appropriate technique and acquisition factors, radiation dose can be lowered on a digital radiography system without significant effect on the image quality by adding filtrations and a new denoising technique.",2020,"Using appropriate technique and acquisition factors, radiation dose can be lowered on a digital radiography system without significant effect on the image quality by adding filtrations and a new denoising technique.","['40 neonates in the NICU underwent radiography of the thorax and abdomen with two different mobile radiography units: conventional technique on one unit (50 kV, 1.6 mAs, and no additional filtration) and a new technique on another unit (54 kV', 'Forty patients each underwent three pairs of']","['radiography examinations (protocol A and the conventional protocol, protocol B and the conventional protocol, and protocol C and the conventional protocol), except one pair that did not include one image of the conventional protocol']","['overall image quality', 'interrater reliability']","[{'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C4517508', 'cui_str': '1.6'}, {'cui': 'C0016107', 'cui_str': 'Filtration'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}]",,0.0597311,"Using appropriate technique and acquisition factors, radiation dose can be lowered on a digital radiography system without significant effect on the image quality by adding filtrations and a new denoising technique.","[{'ForeName': 'Gayoung', 'Initials': 'G', 'LastName': 'Choi', 'Affiliation': 'Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongo-gu, Seoul 03080, Korea.'}, {'ForeName': 'Jung-Eun', 'Initials': 'JE', 'LastName': 'Cheon', 'Affiliation': 'Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongo-gu, Seoul 03080, Korea.'}, {'ForeName': 'Seunghyun', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongo-gu, Seoul 03080, Korea.'}, {'ForeName': 'Young Hun', 'Initials': 'YH', 'LastName': 'Choi', 'Affiliation': 'Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongo-gu, Seoul 03080, Korea.'}, {'ForeName': 'Seung Han', 'Initials': 'SH', 'LastName': 'Shin', 'Affiliation': 'Department of Pediatrics, Seoul National University Hospital, Seoul, Korea.'}, {'ForeName': 'Yeon Jin', 'Initials': 'YJ', 'LastName': 'Cho', 'Affiliation': 'Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongo-gu, Seoul 03080, Korea.'}, {'ForeName': 'Sun Won', 'Initials': 'SW', 'LastName': 'Park', 'Affiliation': 'Department of Radiology, Seoul National University, Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea.'}]",AJR. American journal of roentgenology,['10.2214/AJR.19.22269'] 647,31220326,"Reach of a low-intensity, multicomponent childhood overweight and obesity intervention delivered in an integrated primary care setting.","Reach (i.e., proportion and representativeness of participants) of low-intensity, multicomponent childhood overweight/obesity interventions delivered in primary care settings with low-income and/or minority families is unknown. The purpose of this research is to describe the reach of a low-intensity, multicomponent childhood overweight/obesity intervention delivered in an integrated primary care setting in a federally qualified health center (FQHC). Eligibility criteria included children aged 4-10 years with a body mass index (BMI) ≥85th percentile, with a female caregiver. Using the electronic health record (EHR) and release forms, families were broadly categorized into groupings from recruitment flow, with differing proportions calculated from these groupings. Representativeness was determined using EHR data from families who were informed about the program (n = 963). Three calculated reach rates ranged from 54.9% to 3.9%. Lower reach rates were calculated using the number of families randomized (n = 73) as the numerator and the children from families who were informed about the program (n = 963) or all eligible children in the FQHC attending appointments (n = 1,864) as denominators. The first two steps in recruitment, informing families about the program and families initiating participation, were where the largest decreases in reach occurred. Children who were randomized were older, had a higher BMI, had a greater number of medical diagnoses indicating overweight or obesity, and were Hispanic. Reach of the intervention was low. Strategies that assist with reducing time for informing families of treatment and increasing families' awareness of their child's weight status should assist with enhancing reach.",2020,"Children who were randomized were older, had a higher BMI, had a greater number of medical diagnoses indicating overweight or obesity, and were Hispanic.","['Eligibility criteria included children aged 4-10 years with a body mass index (BMI) ≥85th percentile, with a female caregiver', 'Children who were randomized were older, had a higher BMI, had a greater number of medical diagnoses indicating overweight or obesity, and were Hispanic']",[],[],"[{'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}]",[],[],,0.0149515,"Children who were randomized were older, had a higher BMI, had a greater number of medical diagnoses indicating overweight or obesity, and were Hispanic.","[{'ForeName': 'Hollie A', 'Initials': 'HA', 'LastName': 'Raynor', 'Affiliation': 'Department of Nutrition, University of Tennessee Knoxville, Knoxville, TN, USA.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Barroso', 'Affiliation': 'Department of Public Health, University of Tennessee Knoxville, Knoxville, TN, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Propst', 'Affiliation': 'Cherokee Health Systems, Knoxville, TN, USA.'}, {'ForeName': 'Kristoffer', 'Initials': 'K', 'LastName': 'Berlin', 'Affiliation': 'Department of Psychology, University of Memphis, Memphis, TH, USA.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Robson', 'Affiliation': 'Department of Behavioral Health and Nutrition, University of Delaware, Newark, DE, USA.'}, {'ForeName': 'Parinda', 'Initials': 'P', 'LastName': 'Khatri', 'Affiliation': 'Cherokee Health Systems, Knoxville, TN, USA.'}]",Translational behavioral medicine,['10.1093/tbm/ibz055'] 648,31005588,Comparing bystander response to a sudden cardiac arrest using a virtual reality CPR training mobile app versus a standard CPR training mobile app.,"BACKGROUND Using a mobile virtual reality (VR) platform to heighten realism for cardiopulmonary resuscitation (CPR) training has the potential to improve bystander response. OBJECTIVES We examined whether using a VR mobile application (mApp) for CPR training would improve bystander response compared with a standard mApp CPR training. METHODS We randomized lay bystanders to either our intervention arm (VR mApp) or our control arm (mApp). During a post-intervention skills test, we collected bystander response data (call 911, perform CPR, ask for an automated external defibrillator (AED)), along with CPR quality (chest compression (CC) rate and depth). Wilcox rank sum was used to analyze CC rate and CC depth as they were not normally distributed; Pearson's Chi-square was used to analyze Chain of Survival variables. RESULTS Between 3/2018 and 9/2018, 105 subjects were enrolled: 52 VR mApp and 53 mApp. Mean age was 46 ± 16 years, 34% were female, 59% were Black, and 17% were currently CPR trained (≤2 years). Bystander response was significantly higher in the VR mApp arm: called 911 (82% vs 58%, p = 0.007) and asked for an AED (57% vs 28%, p = 0.003). However there was no difference in CPR performed (98% vs 98%, p = NS) and the application of the AED (90% vs 93%, p = NS). When comparing the VR mApp to the mApp, mean CC rate was 104 ± 42 cpm vs 112 ± 30 cpm (p = NS), and mean CC depth was 38 ± 15 mm vs 44 ± 13 mm (p = 0.05). CONCLUSION The use of the VR mApp significantly increased the likelihood of calling 911 and asking for an AED, however, CC depth was decreased.",2019,"The use of the VR mApp significantly increased the likelihood of calling 911 and asking for an AED, however, CC depth was decreased.","['Mean age was 46\u2009±\u200916\u2009years, 34% were female, 59% were Black, and 17% were currently CPR trained (≤2\u2009years', '105 subjects were enrolled']","['virtual reality CPR training mobile app versus a standard CPR training mobile app', 'VR mobile application (mApp) for CPR training', 'cardiopulmonary resuscitation (CPR) training']","['CPR quality (chest compression (CC) rate and depth', 'bystander response', 'mean CC depth', 'Bystander response', 'likelihood of calling 911 and asking for an AED, however, CC depth', 'mean CC rate', 'CPR']","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0007203', 'cui_str': 'Cardio-Pulmonary Resuscitation'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C4319547', 'cui_str': '105'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0007203', 'cui_str': 'Cardio-Pulmonary Resuscitation'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0007203', 'cui_str': 'Cardio-Pulmonary Resuscitation'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1720420', 'cui_str': 'Call'}]",105.0,0.0270381,"The use of the VR mApp significantly increased the likelihood of calling 911 and asking for an AED, however, CC depth was decreased.","[{'ForeName': 'Marion', 'Initials': 'M', 'LastName': 'Leary', 'Affiliation': 'Center for Resuscitation Science and Department of Emergency Medicine, Department of Emergency Medicine, University of Pennsylvania Perelman School of Medicine, United States; School of Nursing, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: mleary@nursing.upenn.edu.'}, {'ForeName': 'Shaun K', 'Initials': 'SK', 'LastName': 'McGovern', 'Affiliation': 'Center for Resuscitation Science and Department of Emergency Medicine, Department of Emergency Medicine, University of Pennsylvania Perelman School of Medicine, United States; School of Nursing, University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Zainab', 'Initials': 'Z', 'LastName': 'Chaudhary', 'Affiliation': 'Center for Resuscitation Science and Department of Emergency Medicine, Department of Emergency Medicine, University of Pennsylvania Perelman School of Medicine, United States; School of Nursing, University of Pennsylvania, Philadelphia, PA, United States; Department of Family Medicine and Community Health, Duke University, Durham, NC, United States.'}, {'ForeName': 'Jaldhi', 'Initials': 'J', 'LastName': 'Patel', 'Affiliation': 'Center for Resuscitation Science and Department of Emergency Medicine, Department of Emergency Medicine, University of Pennsylvania Perelman School of Medicine, United States; School of Nursing, University of Pennsylvania, Philadelphia, PA, United States; Department of Family Medicine and Community Health, Duke University, Durham, NC, United States.'}, {'ForeName': 'Benjamin S', 'Initials': 'BS', 'LastName': 'Abella', 'Affiliation': 'Center for Resuscitation Science and Department of Emergency Medicine, Department of Emergency Medicine, University of Pennsylvania Perelman School of Medicine, United States.'}, {'ForeName': 'Audrey L', 'Initials': 'AL', 'LastName': 'Blewer', 'Affiliation': 'Center for Resuscitation Science and Department of Emergency Medicine, Department of Emergency Medicine, University of Pennsylvania Perelman School of Medicine, United States; Department of Family Medicine and Community Health, Duke University, Durham, NC, United States.'}]",Resuscitation,['10.1016/j.resuscitation.2019.04.017'] 649,31937284,Teledentistry as a novel pathway to improve dental health in school children: a research protocol for a randomised controlled trial.,"BACKGROUND Despite great improvement in child oral health, some children subgroups still suffer from higher levels of dental caries. Geographic and socioeconomic barriers and the lack of access to dental care services are among common reasons for poor oral health in children. Historically in Australia, oral health therapists or dental therapists have been responsible for providing dental care for school children through the School Dental Services (SDS). The current SDS has been unable to provide sustainable dental care to all school children due to a reduction in workforce participation and limited resources. We propose a paradigm shift in the current service through the introduction of user-friendly technology to provide a foundation for sustainable dental care for school children. METHODS/DESIGN We describe an ongoing parallel, two-armed, non-inferiority randomised controlled trial that compares routine and teledental pathway of dental care in children aged 4-15 years (n = 250). Participating schools in Western Australia will be randomly assigned to the control or teledental group, approximately three schools in each group with a maximum of 45 children in each school. All participants will first receive a standard dental examination to identify those who require urgent referrals and then their teeth will be photographed using a smartphone camera. At the baseline, children in the control group will receive screening results and advice on the pathway of dental care based on the visual dental screening while children in the teledental group will receive screening results based on the assessment of dental images. At 9 months follow-up, all participants will undergo a final visual dental screening. The primary outcomes include decay experience and proportion of children become caries active. The secondary outcomes include the diagnostic performance of photographic dental assessment and costs comparison of two pathways of dental care. DISCUSSION The current project seeks to take advantage of mobile technology to acquire dental images from a child's mouth at school settings and forwarding images electronically to an offsite dental practitioner to assess and prepare dental recommendations remotely. Such an approach will help to prioritise high-risk children and provide them with a quick treatment pathway and avoid unnecessary referrals or travel. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry, ACTRN12619001233112. Registered 06 September 2019.",2020,"Historically in Australia, oral health therapists or dental therapists have been responsible for providing dental care for school children through the School Dental Services (SDS).","['children', 'school children through the School Dental Services (SDS', 'children aged 4-15\u2009years (n\u2009=\u2009250', 'school children', 'Participating schools in Western Australia']",['routine and teledental pathway of dental care'],"['dental health', 'diagnostic performance of photographic dental assessment and costs comparison of two pathways of dental care', 'decay experience and proportion of children become caries active']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0260267', 'cui_str': 'School child (occupation)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0043128', 'cui_str': 'Western Australia'}]","[{'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0011331', 'cui_str': 'Dental Care'}]","[{'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C3853050', 'cui_str': 'Cost Comparison'}, {'cui': 'C0011331', 'cui_str': 'Dental Care'}, {'cui': 'C1265875', 'cui_str': 'Disintegration'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0429170', 'cui_str': 'Caries active (finding)'}]",45.0,0.106929,"Historically in Australia, oral health therapists or dental therapists have been responsible for providing dental care for school children through the School Dental Services (SDS).","[{'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Estai', 'Affiliation': 'The Australian e-Health Research Centre, CSIRO, 147 Underwood Avenue, Floreat WA, Perth, 6014, Australia. abdalla177@gmail.com.'}, {'ForeName': 'Yogesan', 'Initials': 'Y', 'LastName': 'Kanagasingam', 'Affiliation': 'The Australian e-Health Research Centre, CSIRO, 147 Underwood Avenue, Floreat WA, Perth, 6014, Australia.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Mehdizadeh', 'Affiliation': 'The Australian e-Health Research Centre, CSIRO, 147 Underwood Avenue, Floreat WA, Perth, 6014, Australia.'}, {'ForeName': 'Janardhan', 'Initials': 'J', 'LastName': 'Vignarajan', 'Affiliation': 'The Australian e-Health Research Centre, CSIRO, 147 Underwood Avenue, Floreat WA, Perth, 6014, Australia.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Norman', 'Affiliation': 'School of Public Health, Curtin University, Perth, Australia.'}, {'ForeName': 'Boyen', 'Initials': 'B', 'LastName': 'Huang', 'Affiliation': 'School of Dentistry and Health Sciences, Charles Sturt University, Orange, Australia.'}, {'ForeName': 'Heiko', 'Initials': 'H', 'LastName': 'Spallek', 'Affiliation': 'Faculty of Medicine and Health, School of Dentistry, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Irving', 'Affiliation': 'Faculty of Medicine and Health, School of Dentistry, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Arora', 'Affiliation': 'Translational Health Research Institute, Western Sydney University, Campbelltown Campus, NSW, Australia.'}, {'ForeName': 'Estie', 'Initials': 'E', 'LastName': 'Kruger', 'Affiliation': 'School of Human Sciences, University of Western Australia, Perth, Australia.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Tennant', 'Affiliation': 'School of Human Sciences, University of Western Australia, Perth, Australia.'}]",BMC oral health,['10.1186/s12903-019-0992-1'] 650,31591940,Teprenone for the prevention of low-dose aspirin-induced gastric mucosal injury in Helicobacter pylori -negative patients.,"Objectives: Low-dose aspirin is the standard treatment for the prevention of cardiovascular events in at-risk patients. We performed a randomized, placebo-controlled study to determine the efficacy of teprenone for primary prevention of gastrointestinal injury in patients taking LDA for vascular protection. Methods: Patients were eligible for enrollment if they required aspirin 100 mg/day. Aspirin- naïve patients without gastroduodenal ulcer and Helicobacter pylori infection were randomized to receive teprenone 150 mg/day or placebo for 12 weeks. Primary outcome was assessed by the incidence rate of gastroduodenal ulcer. Secondary outcomes were assessed by the incidence rate of gastric mucosal injury, the improvement in modified Lanza score (MLS), gastrointestinal symptom rating scale (GSRS) and the change of gastric immunohistochemical expression for COX-1. Results: Total of 130 patients were randomized, 64 in teprenone group and 66 in placebo group. There was no incidence of ulcer after 12 weeks in both groups. Incidence of gastric mucosal injury was higher in placebo group than in teprenone group (40.0 vs. 13.38%, p  = .039). Mean change of MLS was higher in placebo group than in teprenone group (0.767 ± 0.467 vs. 0.271 ± 0.158, p  = .003). Scores of mucosal edema, hyperemia and hemorrhage and the change of GSRS were not different between the two groups. Change of COX-1 immunoreactive score was higher in placebo group than in teprenone group (2.433 ± 1.476 vs. 1.233 ± 0.955, p  = .001). There were no treatment-related adverse events. Conclusions: Teprenone is effective in preventing gastric mucosal injury in patients taking LDA. Preventive effects of teprenone on LDA-related gastroduodenal ulcers require further investigation.",2019,"Change of COX-1 immunoreactive score was higher in placebo group than in teprenone group (2.433 ± 1.476 vs. 1.233 ± 0.955, p  = .001).","['Patients were eligible for enrollment if they required aspirin 100\u2009mg/day', 'Helicobacter pylori -negative patients', 'at-risk patients', 'patients taking LDA', 'Total of 130 patients were randomized, 64 in teprenone group and 66 in', 'Aspirin- naïve patients without gastroduodenal ulcer and Helicobacter pylori infection', 'patients taking LDA for vascular protection']","['Low-dose aspirin', 'teprenone', 'Teprenone', 'placebo', 'teprenone 150\u2009mg/day or placebo']","['Scores of mucosal edema, hyperemia and hemorrhage and the change of GSRS', 'incidence rate of gastroduodenal ulcer', 'Change of COX-1 immunoreactive score', 'incidence rate of gastric mucosal injury, the improvement in modified Lanza score (MLS), gastrointestinal symptom rating scale (GSRS) and the change of gastric immunohistochemical expression for COX-1', 'Mean change of MLS', 'incidence of ulcer', 'cardiovascular events', 'Incidence of gastric mucosal injury', 'gastric mucosal injury']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1124475', 'cui_str': 'Aspirin 100 MG'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C0061231', 'cui_str': 'teprenone'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}, {'cui': 'C0030920', 'cui_str': 'Gastroduodenal Ulcer'}, {'cui': 'C0850666', 'cui_str': 'Infection caused by Helicobacter pylori'}]","[{'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}, {'cui': 'C0061231', 'cui_str': 'teprenone'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0439422', 'cui_str': 'mg/day'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0521481', 'cui_str': 'Mucous membrane edema (finding)'}, {'cui': 'C0020452', 'cui_str': 'Hyperemia'}, {'cui': 'C1869041', 'cui_str': 'Haemorrhages (SMQ)'}, {'cui': 'C0025320', 'cui_str': 'Change of Life, Female'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0030920', 'cui_str': 'Gastroduodenal Ulcer'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0442996', 'cui_str': 'Cox (qualifier value)'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C0026724', 'cui_str': 'Mucosal Tissue'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0222045'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",130.0,0.392181,"Change of COX-1 immunoreactive score was higher in placebo group than in teprenone group (2.433 ± 1.476 vs. 1.233 ± 0.955, p  = .001).","[{'ForeName': 'Taned', 'Initials': 'T', 'LastName': 'Chitapanarux', 'Affiliation': 'Gastrohepatology Unit, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Nirush', 'Initials': 'N', 'LastName': 'Lertprasertsuke', 'Affiliation': 'Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Acharaporn', 'Initials': 'A', 'LastName': 'Kongnak', 'Affiliation': 'Gastrohepatology Unit, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}]",Scandinavian journal of gastroenterology,['10.1080/00365521.2019.1672781'] 651,30919040,Comparison of parallel and crossed placement of antennas in microwave ablation of 3-5 cm hepatocellular carcinoma.,"PURPOSE To evaluate the effects of ablation strategies on local tumor progression (LTP) after microwave ablation (MWA) of hepatocellular carcinomas (HCCs) measuring 3-5 cm. MATERIALS AND METHODS Between December 2011 and May 2017, 71 HCC patients with 71 nodules treated by ultrasound(US)-guided percutaneous MWA were divided into parallel (group A) and crossed (group B) antenna placement groups. All patients underwent MWA using two antennas with four insertions. LTP and overall survival (OS) rates were compared between the two groups. RESULTS The median follow-up time was 16.8 months. There was no significant difference in the complete ablation rate and treatment sessions between the two groups. LTP was diagnosed in 8 of 48 nodules (16.7%) in group A and 1 of 23 nodules (4.3%) in group B, with no significant difference between two groups (P = 0.115). The 1-, 2-, and 3-year OS rates were 88.5%, 79%, and 71.8% in group A and 93.8%, 87.5%, and 87.5% in group B, respectively (P = 0.236). Multivariate analysis showed that the tumor diameter (P = 0.017), the distance between the antennas (P = 0.032), and the total emission time (P = 0.015) were associated with LTP. CONCLUSIONS There were trends with lower LTP and improved OS in group B, despite the lack of statistically significant differences between the two strategies at a level of P < 0.05. The increase of distance between antennas and total emission time will facilitate reductions in LTP rate.",2019,LTP and overall survival,"['microwave ablation of 3-5\xa0cm hepatocellular carcinoma', 'Between December 2011 and May 2017', '71 HCC patients with 71 nodules treated by ultrasound(US)-guided percutaneous MWA']",[],"['OS) rates', 'complete ablation rate', 'LTP and overall survival', 'distance between antennas and total emission time', 'total emission time', '3-year OS rates', 'local tumor progression (LTP', 'LTP']","[{'cui': 'C3854551', 'cui_str': 'Microwave ablation'}, {'cui': 'C2239176', 'cui_str': 'Liver Cell Carcinoma, Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0028259', 'cui_str': 'Nodule (morphologic abnormality)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach - access (qualifier value)'}]",[],"[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0233929', 'cui_str': 'Emission (finding)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0178874', 'cui_str': 'Tumor progression (finding)'}]",71.0,0.0291978,LTP and overall survival,"[{'ForeName': 'Li-Nan', 'Initials': 'LN', 'LastName': 'Dong', 'Affiliation': 'Department of Interventional Ultrasound, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China.'}, {'ForeName': 'Xiao-Ling', 'Initials': 'XL', 'LastName': 'Yu', 'Affiliation': 'Department of Interventional Ultrasound, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China.'}, {'ForeName': 'Zhi-Gang', 'Initials': 'ZG', 'LastName': 'Cheng', 'Affiliation': 'Department of Interventional Ultrasound, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China.'}, {'ForeName': 'Zhi-Yu', 'Initials': 'ZY', 'LastName': 'Han', 'Affiliation': 'Department of Interventional Ultrasound, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China.'}, {'ForeName': 'Fang-Yi', 'Initials': 'FY', 'LastName': 'Liu', 'Affiliation': 'Department of Interventional Ultrasound, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China.'}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': 'Department of Interventional Ultrasound, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China.'}, {'ForeName': 'Yan-Chun', 'Initials': 'YC', 'LastName': 'Luo', 'Affiliation': 'Department of Interventional Ultrasound, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Department of Interventional Ultrasound, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China. yu-jie301@hotmail.com.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Liang', 'Affiliation': 'Department of Interventional Ultrasound, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China. liangping301@hotmail.com.'}]",Abdominal radiology (New York),['10.1007/s00261-019-01959-8'] 652,31797570,"Pharmacokinetics, Bioequivalence, and Safety Studies of Prucalopride in Healthy Chinese Subjects.","The objectives of the present study were to evaluate the bioequivalence of 2 tablet formulations of prucalopride, generic and branded, and to investigate relevant pharmacokinetic and safety profiles. This study was designed as a randomized, open-label, fasting, single-dose, crossover, and dual-period trial. After overnight fasting, 12 subjects were given prucalopride tablets via oral administration, and blood specimens were obtained up to 96 hours after dosing. Prucalopride concentrations in plasma were measured using ultraprecision liquid chromatography-tandem mass spectrometry followed by calculation of pharmacokinetic parameters. The safety of prucalopride was assessed throughout the study. The pharmacokinetics of prucalopride can be defined as a 2-compartment model with a long elimination phase. No significant differences were observed between the pharmacokinetic profiles of the generic and branded prucalopride tablets. Bioequivalence was evaluated using 90%CIs for the ratio test/reference of log area under the concentration-time curve over 96 hours, log area under the concentration-time curve to infinity, and log peak concentration from generic and branded tablets, which were 100.06-109.94%, 100.63-110.32%, and 95.84-113.08%, respectively. During administration of the medication, there were 18 adverse events in 6 subjects in the test formulation group and 19 cases of adverse events in 6 subjects in the reference formulation group (P > .05). No severe adverse effects were detected. These results suggest that generic and branded prucalopride tablets are bioequivalent and show similar safety profiles.",2020,No significant differences were observed between the pharmacokinetic profiles of the generic and branded prucalopride tablets.,['Healthy Chinese Subjects'],['Prucalopride'],"['severe adverse effects', 'pharmacokinetic profiles of the generic and branded prucalopride tablets', 'adverse events']","[{'cui': 'C0152035', 'cui_str': 'Chinese'}]","[{'cui': 'C0913506', 'cui_str': '4-amino-5-chloro-N-(1-(3-methoxypropyl)-4-piperidinyl)-2,3-dihydro-1-benzofuran-7-carboxamide'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0913506', 'cui_str': '4-amino-5-chloro-N-(1-(3-methoxypropyl)-4-piperidinyl)-2,3-dihydro-1-benzofuran-7-carboxamide'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",12.0,0.044,No significant differences were observed between the pharmacokinetic profiles of the generic and branded prucalopride tablets.,"[{'ForeName': 'Ziye', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': 'Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Chenxiang', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Xuyong', 'Initials': 'X', 'LastName': 'Zheng', 'Affiliation': 'Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Xuben', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': 'Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Yu', 'Affiliation': 'Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Dongchuan', 'Initials': 'D', 'LastName': 'Zhang', 'Affiliation': 'Dikang Pharmaceutical Co, Ltd, Sichuan, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Xia', 'Affiliation': 'Leeway Biological Technology Co, Ltd, Jiangsu, China.'}, {'ForeName': 'Huafang', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Office of Drug Clinical Trial Institution, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Xiaoxiao', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Office of Drug Clinical Trial Institution, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.'}, {'ForeName': 'Xiuhua', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Office of Drug Clinical Trial Institution, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.754'] 653,31337697,Randomized Controlled Trial on Adjunctive Lavage for Severe Peritonitis.,"Background: In severe peritoneal dialysis (PD)-related peritonitis, patients' response to antibiotic can be poor. We postulated that adjunctive lavage may improve the outcome in severe cases by enhancing the removal of bacteria and inflammatory cells from the peritoneum. Methods: Severe PD peritonitis was defined as poor clinical response to empirical cefazolin/ceftazidime and a PD effluent (PDE) leukocyte count > 1,090/mm 3 on day 3. Enrolled patients were randomized into either the lavage group ( n = 20) or control group ( n = 20). In the lavage group, continuous lavage by an automated PD machine from day 3 to 5 or 6 was performed, whereas the usual PD schedule was maintained in the control group. The primary outcome was treatment success. Post hoc analysis was also performed to compare the outcome between subgroups with different severity. Results: Baseline parameters were similar in the lavage and control groups, including PDE leukocyte count on day 3 (4,871/mm 3 vs 4,143/mm 3 , p = 0.46). Treatment success rates were high in both groups (75% vs 70%, p = 0.72). C-reactive protein (CRP) on day 3 was found to be the only predictor of treatment failure and was used to stratify all patients into tertiles of severity. Whilst a significant decline in treatment success was evident across the tertiles of increasing CRP in the control group (100% vs 85.7% vs 28.6%, p = 0.005), treatment success was relatively maintained in the lavage group (85.7% vs 71.4% vs 66.7%, p = 0.43). Conclusions: Adjunctive lavage did not improve the overall outcome, although it may be beneficial for the more severe peritonitis patients who have high CRP.",2019,"Treatment success rates were high in both groups (75% vs 70%, p = 0.72).",['severe peritonitis patients who have high CRP'],"['C-reactive protein (CRP', 'cefazolin/ceftazidime']","['Treatment success rates', 'PDE leukocyte count', 'CRP', 'treatment success']","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0031154', 'cui_str': 'Peritonitis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]","[{'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0007546', 'cui_str': 'Cefazolin'}, {'cui': 'C0007559', 'cui_str': 'Ceftazidime'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0057968', 'cui_str': 'phosphate diethylstilbesterol'}, {'cui': 'C0023508', 'cui_str': 'Blood Cell Count, White'}]",,0.0384155,"Treatment success rates were high in both groups (75% vs 70%, p = 0.72).","[{'ForeName': 'Steve S', 'Initials': 'SS', 'LastName': 'Wong', 'Affiliation': 'Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong stevesmwong@gmail.com.'}, {'ForeName': 'Wai-Yan', 'Initials': 'WY', 'LastName': 'Lau', 'Affiliation': 'Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong.'}, {'ForeName': 'Yim-Yuk', 'Initials': 'YY', 'LastName': 'Tse', 'Affiliation': 'Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong.'}, {'ForeName': 'Ping-Kwan', 'Initials': 'PK', 'LastName': 'Chan', 'Affiliation': 'Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong.'}, {'ForeName': 'Ching-Kit', 'Initials': 'CK', 'LastName': 'Wan', 'Affiliation': 'Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong.'}, {'ForeName': 'Yuk-Lun', 'Initials': 'YL', 'LastName': 'Cheng', 'Affiliation': 'Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong.'}, {'ForeName': 'Alex W', 'Initials': 'AW', 'LastName': 'Yu', 'Affiliation': 'Central Administration Office, Hong Kong Baptist Hospital, Hong Kong.'}]",Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,['10.3747/pdi.2018.00111'] 654,31904578,"A Web- and Mobile App-Based Mental Health Promotion Intervention Comparing Email, Short Message Service, and Videoconferencing Support for a Healthy Cohort: Randomized Comparative Study.","BACKGROUND The rapid increase in mental health disorders has prompted a call for greater focus on mental health promotion and primary prevention. Web- and mobile app-based interventions present a scalable opportunity. Little is known about the influence of human support on the outcomes of these interventions. OBJECTIVE This study aimed to compare the influence of 3 modes of human support on the outcomes (ie, mental health, vitality, depression, anxiety, stress, life satisfaction, and flourishing) of a 10-week, Web- and mobile app-based, lifestyle-focused mental health promotion intervention among a healthy adult cohort. METHODS Participants were recruited voluntarily using a combination of online and offline advertising. They were randomized, unblinded into 3 groups differentiated by human support mode: Group 1 (n=201): standard-fully automated emails (S); Group 2 (n=202): standard plus personalized SMS (S+pSMS); and Group 3 (n=202): standard plus weekly videoconferencing support (S+VCS), hosted by 1 trained facilitator. Participants accessed the intervention, including the questionnaire, on a Web-based learning management system or through a mobile app. The questionnaire, administered at pre- and postintervention, contained self-reported measures of mental well-being, including the ""mental health"" and ""vitality"" subscales from the Short Form Health Survey-36, Depression Anxiety and Stress Scale-21, Diener Satisfaction With Life Scale (SWLS), and Diener Flourishing Scale. RESULTS Of 605 potential participants, 458 (S: n=157, S+pSMS: n=163, and S+VCS: n=138) entered the study by completing registration and the preintervention questionnaire. At post intervention, 320 out of 458 participants (69.9%; S: n=103, S+pSMS: n=114, and S+VCS: n=103) completed the questionnaire. Significant within-group improvements were recorded from pre- to postintervention in all groups and in every outcome measure (P≤.001). No significant between-group differences were observed for outcomes in any measure: mental health (P=.77), vitality (P=.65), depression (P=.93), anxiety (P=.25), stress (P.57), SWLS (P=.65), and Flourishing Scale (P=.99). Adherence was not significantly different between groups for mean videos watched (P=.42) and practical activity engagement (P=.71). Participation in videoconference support sessions (VCSSs) was low; 37 out of 103 (35.9%) participants did not attend any VCSSs, and only 19 out of 103 (18.4%) attended 7 or more out of 10 sessions. Stratification within the S+VCS group revealed that those who attended 7 or more VCSSs experienced significantly greater improvements in the domains of mental health (P=.006; d=0.71), vitality (P=.005; d=0.73), depression (P=.04; d=0.54), and life satisfaction (P=.046; d=0.50) compared with participants who attended less than 7. CONCLUSIONS A Web- and mobile app-based mental health promotion intervention enhanced domains of mental well-being among a healthy cohort, irrespective of human support. Low attendance at VCSSs hindered the ability to make meaningful between-group comparisons. Supplementing the intervention with VCSSs might improve outcomes when attendance is optimized. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry (ANZCTR): 12619001009101; http://www.anzctr.org.au/ACTRN12619001009101.aspx.",2020,Adherence was not significantly different between groups for mean videos watched (P=.42) and practical activity engagement (P=.71).,"['320 out of 458 participants (69.9%; S: n=103, S+pSMS: n=114, and S+VCS: n=103) completed the questionnaire', 'Healthy Cohort', 'mental health disorders', 'Of 605 potential participants, 458 (S: n=157, S+pSMS: n=163, and S+VCS: n=138) entered the study by completing registration and the preintervention questionnaire', 'healthy adult cohort', 'Participants were recruited voluntarily using a combination of online and offline advertising']","['ANZCTR', 'Web- and Mobile App-Based Mental Health Promotion Intervention', 'Web- and mobile app-based mental health promotion intervention', 'standard-fully automated emails (S); Group 2 (n=202): standard plus personalized SMS (S+pSMS); and Group 3 (n=202): standard plus weekly videoconferencing support (S+VCS), hosted by 1 trained facilitator', 'Web- and mobile app-based, lifestyle-focused mental health promotion intervention']","['vitality', 'practical activity engagement', 'depression', 'measure: mental health', 'Adherence', 'domains of mental health', 'vitality (P=.65), depression (P=.93), anxiety (P=.25), stress (P.57), SWLS (P=.65), and Flourishing Scale', 'outcomes (ie, mental health, vitality, depression, anxiety, stress, life satisfaction, and flourishing', 'life satisfaction', 'mental health"" and ""vitality"" subscales from the Short Form Health Survey-36, Depression Anxiety and Stress Scale-21, Diener Satisfaction With Life Scale (SWLS), and Diener Flourishing Scale']","[{'cui': 'C4517711', 'cui_str': '320 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder (disorder)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0184645', 'cui_str': 'Mental health promotion'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0441869', 'cui_str': 'Group 3 (qualifier value)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C1450048', 'cui_str': 'Videoconferencing'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}]","[{'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0222045'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0582668', 'cui_str': 'Satisfaction with life scale (assessment scale)'}]",458.0,0.0875452,Adherence was not significantly different between groups for mean videos watched (P=.42) and practical activity engagement (P=.71).,"[{'ForeName': 'Melanie Elise', 'Initials': 'ME', 'LastName': 'Renfrew', 'Affiliation': 'Lifestyle and Health Research Centre, Avondale University College, Cooranbong, New South Wales, Australia.'}, {'ForeName': 'Darren Peter', 'Initials': 'DP', 'LastName': 'Morton', 'Affiliation': 'Lifestyle and Health Research Centre, Avondale University College, Cooranbong, New South Wales, Australia.'}, {'ForeName': 'Jason Kyle', 'Initials': 'JK', 'LastName': 'Morton', 'Affiliation': 'Lifestyle and Health Research Centre, Avondale University College, Cooranbong, New South Wales, Australia.'}, {'ForeName': 'Jason Scott', 'Initials': 'JS', 'LastName': 'Hinze', 'Affiliation': 'Lifestyle and Health Research Centre, Avondale University College, Cooranbong, New South Wales, Australia.'}, {'ForeName': 'Peter James', 'Initials': 'PJ', 'LastName': 'Beamish', 'Affiliation': 'Lifestyle and Health Research Centre, Avondale University College, Cooranbong, New South Wales, Australia.'}, {'ForeName': 'Geraldine', 'Initials': 'G', 'LastName': 'Przybylko', 'Affiliation': 'Lifestyle and Health Research Centre, Avondale University College, Cooranbong, New South Wales, Australia.'}, {'ForeName': 'Bevan Adrian', 'Initials': 'BA', 'LastName': 'Craig', 'Affiliation': 'Lifestyle and Health Research Centre, Avondale University College, Cooranbong, New South Wales, Australia.'}]",Journal of medical Internet research,['10.2196/15592'] 655,31208499,[Intervention measures for maintenance of clinical control in the remission stage of childhood asthma].,"OBJECTIVE To explore the intervention measures to maintain clinical control in children with asthma in the remission stage when concomitant with acute upper respiratory infection (AURI). METHODS A total of 100 asthmatic children who had achieved clinical control were randomly divided into observation group and control group. The two groups were both treated with a combination of inhaled corticosteroids and long-acting β2 receptor agonist (ICS/LABA) at the lowest dose every night. Conventional therapies were used for the two groups when suffering from AURI. In addition to conventional therapies, the observation group was given early short-term upgrade therapy, i.e., on the basis of maintenance therapy, the same amount of ICS/LABA complex preparation was inhaled every morning, which lasted for 7-10 days. Both groups were treated following asthma guidelines according to the severity of the disease at the time of acute attacks. The control rate of asthma, severity of acute attacks, changes in pulmonary function indices, and occurrence of adverse events were evaluated after 3, 6, 9, and 12 months of treatment. RESULTS At each time point of follow-up, the rate of asthma control in the observation group was significantly higher than that in the control group (90% vs 80%; P<0.05). The severity of acute attacks in the observation group was significantly lower than that in the control group at all follow-up time points (P<0.05). Compared with the control group, the observation group had significantly improved pulmonary function indices of large and small airways (P<0.05) and significantly reduced mean amount of inhaled glucocorticoids and impact on family life (P<0.01). CONCLUSIONS Early short-term upgrade therapy for children with asthma in the remission stage when concomitant with AURI can prevent acute attacks of asthma, raise the rate of asthma control and improve pulmonary function.",2019,The severity of acute attacks in the observation group was significantly lower than that in the control group at all follow-up time points (P<0.05).,"['children with asthma in the remission stage when concomitant with acute upper respiratory infection (AURI', 'children with asthma', '100 asthmatic children who had achieved clinical control']",['inhaled corticosteroids and long-acting β2 receptor agonist (ICS/LABA'],"['control rate of asthma, severity of acute attacks, changes in pulmonary function indices, and occurrence of adverse events', 'rate of asthma control', 'pulmonary function indices of large and small airways', 'severity of acute attacks']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0264222', 'cui_str': 'Acute upper respiratory infection (disorder)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C4543206', 'cui_str': 'Receptor agonist (disposition)'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C1304680', 'cui_str': 'Attack (finding)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0458827', 'cui_str': 'Airway structure (body structure)'}]",100.0,0.0203942,The severity of acute attacks in the observation group was significantly lower than that in the control group at all follow-up time points (P<0.05).,"[{'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Pediatrics, First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China. panjiahua1960@163.com.'}, {'ForeName': 'Jia-Hua', 'Initials': 'JH', 'LastName': 'Pan', 'Affiliation': ''}, {'ForeName': 'Hao-Quan', 'Initials': 'HQ', 'LastName': 'Zhou', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 656,31208509,[Clinical effect and safety of different maintenance doses of caffeine citrate in treatment of apnea in very low birth weight preterm infants: a prospective randomized controlled trial].,"OBJECTIVE To study the clinical effect and safety of different maintenance doses of caffeine citrate in the treatment of apnea in very low birth weight preterm infants. METHODS A total of 78 very low birth weight preterm infants with primary apnea were enrolled who were admitted from January 2016 to January 2018. They were randomly divided into high-dose caffeine group with 38 children and low-dose caffeine group with 40 children. Both groups received a loading dose of 20 mg/kg caffeine citrate, and 24 hours later, the children in the high-dose caffeine group were given a maintenance dose of 10 mg/kg, and those in the low-dose caffeine group were given a maintenance dose of 5 mg/kg. The two groups were compared in terms of response rate and incidence rate of adverse events. RESULTS The high-dose caffeine group had a significantly higher response rate than the low-dose caffeine group (71% vs 48%; P<0.05). Compared with the low-dose caffeine group, the high-dose caffeine group had significantly shorter duration of apnea and time of caffeine treatment (P<0.05). There were no significant differences between the two groups in length of hospital stay and incidence rates of tachycardia, feeding intolerance, bronchopulmonary dysplasia, necrotizing enterocolitis, and intracranial hemorrhage (P>0.05). There was no significant difference in the mortality rate between the two groups (P>0.05). CONCLUSIONS Higher maintenance dose of caffeine citrate has a better clinical effect than lower maintenance dose of caffeine citrate in the treatment of apnea in very low birth weight preterm infants, without increasing the incidence rates of adverse drug reactions and serious complications in preterm infants.",2019,"There were no significant differences between the two groups in length of hospital stay and incidence rates of tachycardia, feeding intolerance, bronchopulmonary dysplasia, necrotizing enterocolitis, and intracranial hemorrhage (P>0.05).","['group with 40 children', 'very low birth weight preterm infants', '78 very low birth weight preterm infants with primary apnea were enrolled who were admitted from January 2016 to January 2018', 'apnea in very low birth weight preterm infants', 'preterm infants']","['caffeine citrate', 'loading dose of 20 mg/kg caffeine citrate', 'caffeine']","['length of hospital stay and incidence rates of tachycardia, feeding intolerance, bronchopulmonary dysplasia, necrotizing enterocolitis, and intracranial hemorrhage', 'mortality rate', 'response rate', 'duration of apnea and time', 'response rate and incidence rate of adverse events']","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0282666', 'cui_str': 'Very Low Birth Weight'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0232056', 'cui_str': 'Initial apnea (finding)'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}]","[{'cui': 'C0054436', 'cui_str': 'caffeine citrate'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}]","[{'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}, {'cui': 'C1820738', 'cui_str': 'Feeding intolerance'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary Dysplasia'}, {'cui': 'C0520459', 'cui_str': 'Necrotizing Enterocolitis'}, {'cui': 'C0151699', 'cui_str': 'Intracranial Hemorrhage'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",78.0,0.0285951,"There were no significant differences between the two groups in length of hospital stay and incidence rates of tachycardia, feeding intolerance, bronchopulmonary dysplasia, necrotizing enterocolitis, and intracranial hemorrhage (P>0.05).","[{'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ""Department of Neonatology, Tai'an Maternity and Child Care Hospital, Tai'an, Shandong 271000, China. victor2000y@163.com.""}, {'ForeName': 'Hai-Tao', 'Initials': 'HT', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Lyu', 'Affiliation': ''}, {'ForeName': 'Li-Feng', 'Initials': 'LF', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Zhen-Ying', 'Initials': 'ZY', 'LastName': 'Yang', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 657,31879945,"Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306).","PIX306 was a phase 3, randomised, single-blind, multicentre trial conducted in adult patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) grade 3 who relapsed after ≥1 rituximab-containing regimen and were not eligible for a stem cell transplant. Patients were randomised 1:1 to pixantrone 50 mg/m 2 or gemcitabine 1000 mg/m 2 on days 1, 8 and 15 of a 28-day cycle, combined with rituximab 375 mg/m 2 on day 1, for up to six cycles. Patients were followed for up to 96 weeks. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), complete response (CR) rate, overall response rate (ORR) and safety. Overall, 312 patients were randomised (median age 73·0 years). The study did not meet its primary endpoint. Median PFS [95% confidence interval (CI)] was 7·3 months (5·2-8·4) with pixantrone + rituximab (PIX + R) and 6·3 months (4·4-8·1) with gemcitabine + rituximab [GEM + R; hazard ratio (HR): 0·85; 95% CI 0·64-1·14; P = 0·28]. Median OS was 13·3 (10·1-19·8) months with PIX + R and 19·6 (12·4-31·9) months with GEM + R (HR: 1·13; 95% CI 0·83-1·53). ORR was 61·9% and 43·9% respectively and CR rate 35·5% and 21·7%. The incidence of adverse events, including cardiac events, was not statistically significant different between PIX + R and GEM + R.",2020,"The incidence of adverse events, including cardiac events, was not statistically significant different between PIX + R and GEM + R.","['adult patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) grade 3 who relapsed after ≥1 rituximab-containing regimen and were not eligible for a stem cell transplant', '1000', '312 patients were randomised (median age 73·0\xa0years', '1·13', 'patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation']","['gemcitabine\xa0+\xa0rituximab [GEM', 'pixantrone 50', 'GEM\xa0+\xa0R (HR', 'PIX306', 'Pixantrone plus rituximab versus gemcitabine plus rituximab', 'rituximab', 'gemcitabine']","['ORR', 'Median OS', 'incidence of adverse events, including cardiac events', 'progression-free survival (PFS', 'overall survival (OS), complete response (CR) rate, overall response rate (ORR) and safety', 'Median PFS']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0079744', 'cui_str': 'Diffuse Large-Cell Lymphoma'}, {'cui': 'C1264190', 'cui_str': ""Follicular non-Hodgkin's lymphoma, large cell (disorder)""}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C1504389', 'cui_str': 'Stem Cell Transplantation'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}, {'cui': 'C4517706', 'cui_str': '312 (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0004561', 'cui_str': 'B-Cells'}, {'cui': 'C0024305', 'cui_str': ""Lymphoma, Nonhodgkin's""}]","[{'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0445501', 'cui_str': 'Gem (qualifier value)'}, {'cui': 'C0253355', 'cui_str': 'pixantrone'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",312.0,0.218353,"The incidence of adverse events, including cardiac events, was not statistically significant different between PIX + R and GEM + R.","[{'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Pettengell', 'Affiliation': ""St. George's Hospital, London, UK.""}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Długosz-Danecka', 'Affiliation': 'Department of Haematology, Jagiellonian University, Krakow, Poland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Andorsky', 'Affiliation': 'Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Belada', 'Affiliation': 'Clinical Haematology, 4th Department of Internal Medicine, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.'}, {'ForeName': 'Pencho', 'Initials': 'P', 'LastName': 'Georgiev', 'Affiliation': 'Clinic of Oncology and Haematology, University Multiprofile Hospital for Active Treatment ""Sveti Georgi"" and Medical University, Plovdiv, Bulgaria.'}, {'ForeName': 'Donald', 'Initials': 'D', 'LastName': 'Quick', 'Affiliation': 'Joe Arrington Cancer Research Treatment Center, Lubbock, TX, USA.'}, {'ForeName': 'Jack W', 'Initials': 'JW', 'LastName': 'Singer', 'Affiliation': 'CTI Biopharma, Seattle, WA, USA.'}, {'ForeName': 'Simran B', 'Initials': 'SB', 'LastName': 'Singh', 'Affiliation': 'CTI Biopharma, Seattle, WA, USA.'}, {'ForeName': 'Athanasios', 'Initials': 'A', 'LastName': 'Pallis', 'Affiliation': 'Institut de Recherches Internationales Servier, Suresnes, France.'}, {'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Egorov', 'Affiliation': 'Institut de Recherches Internationales Servier, Suresnes, France.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Salles', 'Affiliation': 'Haematology Department, Hospices Civils de Lyon, Université Claude Bernard Lyon-1, Pierre-Bénite, France.'}]",British journal of haematology,['10.1111/bjh.16255'] 658,31308191,"First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants.","We present the preliminary data in an ongoing open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in treating patients with alcohol use disorder. At this stage, seven participants have completed the full 8-week MDMA-assisted psychotherapy course, including two therapy sessions each with MDMA. This paper focuses on the safety and tolerability of the therapeutic course for the first four participants to complete treatment. Longer-term outcomes of drinking behaviour will be presented later when the full project data are published. Results show all four participants have successfully tolerated the treatment. There have been no serious adverse events related to MDMA, no unexpected physiological responses to the MDMA sessions or changes to blood results or electrocardiograms, measured before and after the 8-week course. We conclude that the treatment is well- tolerated and are making plans to expand the project into a randomised placebo-controlled study.",2019,"There have been no serious adverse events related to MDMA, no unexpected physiological responses to the MDMA sessions or changes to blood results or electrocardiograms, measured before and after the 8-week course.",['patients with alcohol use disorder'],"['3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy', '3,4-methylenedioxymethamphetamine', 'MDMA)-assisted psychotherapy']",['safety and tolerability'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001956', 'cui_str': 'Alcohol Use Disorder'}]","[{'cui': 'C0115471', 'cui_str': 'MDMA'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C1273567', 'cui_str': 'Psychotherapy (specialty)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}]",7.0,0.012676,"There have been no serious adverse events related to MDMA, no unexpected physiological responses to the MDMA sessions or changes to blood results or electrocardiograms, measured before and after the 8-week course.","[{'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Sessa', 'Affiliation': 'Neuropsychopharmacology, Department of Medicine, Imperial College London, London, UK.'}, {'ForeName': 'Chloe', 'Initials': 'C', 'LastName': 'Sakal', 'Affiliation': 'Department of Medicine, Avon and Wiltshire Mental Health Partnership NHS Trust, Bath, UK.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': ""O'Brien"", 'Affiliation': 'Neuropsychopharmacology, Department of Medicine, Imperial College London, London, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Nutt', 'Affiliation': 'Neuropsychopharmacology, Department of Medicine, Imperial College London, London, UK.'}]",BMJ case reports,['10.1136/bcr-2019-230109'] 659,31364169,A randomised controlled trial of treatments of childhood anxiety disorder in the context of maternal anxiety disorder: clinical and cost-effectiveness outcomes.,"BACKGROUND This study evaluated whether clinical and economic outcomes from CBT for child anxiety disorders in the context of maternal anxiety disorders are improved by adding treatment focused on (a) maternal anxiety disorders or (b) mother-child interactions. METHODS Two hundred and eleven children (7-12 years, 85% White British, 52% female) with a primary anxiety disorder, whose mothers also had a current anxiety disorder, were randomised to receive (a) child-focused CBT with nonspecific control interventions (CCBT+Con), (b) CCBT with CBT for the maternal anxiety disorder (CCBT+MCBT), or (c) CCBT with an intervention targeting the mother-child interaction (CCBT+MCI). A cost-utility analysis from a societal perspective was conducted using mother/child combined quality-adjusted life years (QALYs). [Trial registration: https://doi.org/10.1186/isrctn19762288]. RESULTS MCBT was associated with immediate reductions in maternal anxiety compared to the nonspecific control; however, after children had also received CCBT, maternal outcomes in the CCBT+MCI and CCBT+Con arms improved and CCBT+MCBT was no longer superior. Neither CCBT+MCBT nor CCBT+MCI conferred a benefit over CCBT+Con in terms of child anxiety disorder diagnoses post-treatment [primary outcome] (adj RR: 1.22 (95% CI: 0.88, 1.67), p = .23; adj RR: 1.21 (95% CI: 0.88, 1.65), p = .24, respectively) or global improvement ratings (adj RR: 1.25 (95% CI: 0.99, 1.57), p = .06; adj RR: 1.18 (95% CI: 0.93, 1.50), p = .17) or six and 12 months later. No significant differences between the groups were found on the main economic outcome measures (child/mother combined QALY mean difference: CCBT+MCBT vs. CCBT+Con: -0.04 (95% CI: -0.12, 0.04), p = .29; CCBT+MCI vs. CCBT+Con: 0.02 (95% CI: -0.05, -0.09), p = .54). CCBT+MCI was associated with nonsignificantly higher costs than CCBT (mean difference: £154 (95% CI: -£1,239, £1,547), p = .83) but, when taking into account sampling uncertainty, it may be cost-effective compared with CCBT alone. CONCLUSIONS Good outcomes were achieved for children and their mothers across treatment arms. There was no evidence of significant clinical benefit from supplementing CCBT with either CBT for the maternal anxiety disorder or treatment focussed on mother-child interactions, but the addition of MCI (and not MCBT) may be cost-effective.",2020,"No significant differences between the groups were found on the main economic outcome measures (child/mother combined QALY mean difference: CCBT+MCBT vs. CCBT+Con: -0.04 (95% CI: -0.12, 0.04), p = .29; CCBT+MCI vs. CCBT+Con: 0.02","['Two hundred and eleven children (7-12\xa0years, 85% White British, 52% female) with a primary anxiety disorder, whose mothers also had a current anxiety disorder', 'childhood anxiety disorder in the context of maternal anxiety disorder']","['CCBT+Con', 'CBT with nonspecific control interventions (CCBT+Con), (b) CCBT with CBT for the maternal anxiety disorder (CCBT+MCBT), or (c) CCBT with an intervention targeting the mother-child interaction (CCBT+MCI', 'CBT', 'CCBT+MCBT']","['maternal anxiety', 'global improvement ratings', 'child anxiety disorder diagnoses']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1278523', 'cui_str': 'White British'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0003469', 'cui_str': 'Anxiety Disorders'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C0449255', 'cui_str': 'Context (attribute)'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0003469', 'cui_str': 'Anxiety Disorders'}, {'cui': 'C0026590', 'cui_str': 'Mother-Child Relationship'}]","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0003469', 'cui_str': 'Anxiety Disorders'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]",211.0,0.0783766,"No significant differences between the groups were found on the main economic outcome measures (child/mother combined QALY mean difference: CCBT+MCBT vs. CCBT+Con: -0.04 (95% CI: -0.12, 0.04), p = .29; CCBT+MCI vs. CCBT+Con: 0.02","[{'ForeName': 'Cathy', 'Initials': 'C', 'LastName': 'Creswell', 'Affiliation': 'Department of Psychiatry, University of Oxford, Oxford, UK.'}, {'ForeName': 'Mara', 'Initials': 'M', 'LastName': 'Violato', 'Affiliation': 'Nuffield Department of Population Health, University of Oxford, Oxford, UK.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Cruddace', 'Affiliation': 'School of Psychology and Clinical Language Sciences, University of Reading, Reading, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Gerry', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Science, University of Oxford, Oxford, UK.'}, {'ForeName': 'Lynne', 'Initials': 'L', 'LastName': 'Murray', 'Affiliation': 'School of Psychology and Clinical Language Sciences, University of Reading, Reading, UK.'}, {'ForeName': 'Roz', 'Initials': 'R', 'LastName': 'Shafran', 'Affiliation': 'Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health, London, UK.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Stein', 'Affiliation': 'Department of Psychiatry, University of Oxford, Oxford, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Willetts', 'Affiliation': 'Berkshire Healthcare NHS Foundation Trust, Berkshire, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'McIntosh', 'Affiliation': 'Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Cooper', 'Affiliation': 'School of Psychology and Clinical Language Sciences, University of Reading, Reading, UK.'}]","Journal of child psychology and psychiatry, and allied disciplines",['10.1111/jcpp.13089'] 660,32029415,A comparative study of video lecture versus video lecture and high fidelity simulation for training nurses on the delivery of targeted temperature management after cardiac arrest.,"INTRODUCTION Targeted temperature management (TTM) is recommended for cardiac arrest patients. Successful implementation of a TTM protocol depends on the nurses' knowledge and skills. The study's aim was to compare the level of knowledge, psychomotor skills, confidence and satisfaction before, immediately after and at 6 weeks after training nurses on the delivery of TTM with video lecture versus video lecture and high fidelity simulation. METHOD Demographic variables were compared across treatment groups using t-tests and Chi-square tests. Change over 6 weeks after intervention was tested with mixed effects model. RESULTS Fifty-two registered nurses were enrolled. Knowledge test scores, the primary outcome, did not differ between the groups immediately after the training (beta = 3.80, SE = 3.47, p = .27), but there was a strong trend 6 weeks after the training in favor of simulation (beta = 7.93, SE = 3.88, p = .04). Skills were significantly better immediately after the training in the simulation group, but no different 6 weeks later. No difference in confidence was found at either post-test point. Simulation-trained nurses were more satisfied with their training at both post-testing points. CONCLUSION In this study of training approaches to TTM after cardiac arrest, nurses trained with video lecture and high fidelity simulation benefitted from this approach by maintaining their TTM knowledge longer.",2020,"Knowledge test scores, the primary outcome, did not differ between the groups immediately after the training (beta = 3.80, SE = 3.47, p = .27), but there was a strong trend 6 weeks after the training in favor of simulation (beta = 7.93, SE = 3.88, p = .04).","['Fifty-two registered nurses were enrolled', 'cardiac arrest patients']","['TTM with video lecture versus video lecture and high fidelity simulation', 'video lecture versus video lecture and high fidelity simulation', 'Targeted temperature management (TTM']","['level of knowledge, psychomotor skills, confidence and satisfaction']","[{'cui': 'C4319570', 'cui_str': 'Fifty-two'}, {'cui': 'C0687673', 'cui_str': 'Registered nurse (occupation)'}, {'cui': 'C0018790', 'cui_str': 'Cardiac Arrest'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0376683', 'cui_str': 'Lecture'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0020674', 'cui_str': 'Targeted Temperature Management'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0237529', 'cui_str': 'Self Confidence'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",52.0,0.0258341,"Knowledge test scores, the primary outcome, did not differ between the groups immediately after the training (beta = 3.80, SE = 3.47, p = .27), but there was a strong trend 6 weeks after the training in favor of simulation (beta = 7.93, SE = 3.88, p = .04).","[{'ForeName': 'Roksolana', 'Initials': 'R', 'LastName': 'Starodub', 'Affiliation': 'University of Pennsylvania School of Nursing, 418 Curie Blvd, Philadelphia, PA 19104, USA. Electronic address: roksolana.starodub@kcl.ac.uk.'}, {'ForeName': 'Benjamin S', 'Initials': 'BS', 'LastName': 'Abella', 'Affiliation': 'University of Pennsylvania Center for Resuscitation Science, Ground Ravdin, 3400 Spruce Street, Philadelphia, PA 19104, USA.'}, {'ForeName': 'Ann Marie', 'Initials': 'AM', 'LastName': 'Hoyt-Brennan', 'Affiliation': 'University of Pennsylvania School of Nursing, 418 Curie Blvd, Philadelphia, PA 19104, USA.'}, {'ForeName': 'Marion', 'Initials': 'M', 'LastName': 'Leary', 'Affiliation': 'University of Pennsylvania School of Nursing, 418 Curie Blvd, Philadelphia, PA 19104, USA; University of Pennsylvania Center for Resuscitation Science, Ground Ravdin, 3400 Spruce Street, Philadelphia, PA 19104, USA.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Mancini', 'Affiliation': 'University of Texas at Arlington College of Nursing, 411 S Nedderman Dr, Arlington, TX 76010, USA.'}, {'ForeName': 'Jesse', 'Initials': 'J', 'LastName': 'Chittams', 'Affiliation': 'University of Pennsylvania School of Nursing, 418 Curie Blvd, Philadelphia, PA 19104, USA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Riegel', 'Affiliation': 'University of Pennsylvania School of Nursing, 418 Curie Blvd, Philadelphia, PA 19104, USA.'}]",International emergency nursing,['10.1016/j.ienj.2019.100829'] 661,31318392,Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.,"Importance New therapeutic options for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination therapy in patients with mPDAC. Objective To evaluate the safety and efficacy of the anti-PD-L1 (programmed death-ligand 1) antibody using either durvalumab monotherapy or in combination with the anticytotoxic T-lymphocyte antigen 4 antibody using durvalumab plus tremelimumab therapy in patients with mPDAC. Design, Setting, and Participants Part A of this multicenter, 2-part, phase 2 randomized clinical trial was a lead-in safety, open-label study with planned expansion to part B pending an efficacy signal from part A. Between November 26, 2015, and March 23, 2017, 65 patients with mPDAC who had previously received only 1 first-line fluorouracil-based or gemcitabine-based treatment were enrolled at 21 sites in 6 countries. Efficacy analysis included the intent-to-treat population; safety analysis included patients who received at least 1 dose of study treatment and for whom any postdose data were available. Interventions Patients received durvalumab (1500 mg every 4 weeks) plus tremelimumab (75 mg every 4 weeks) combination therapy for 4 cycles followed by durvalumab therapy (1500 mg every 4 weeks) or durvalumab monotherapy (1500 mg every 4 weeks) for up to 12 months or until the onset of progressive disease or unacceptable toxic effects. Main Outcomes and Measures Safety and efficacy were measured by objective response rate, which was used to determine study expansion to part B. The threshold for expansion was an objective response rate of 10% for either treatment arm. Results Among 65 randomized patients, 34 (52%) were men and median age was 61 (95% CI, 37-81) years. Grade 3 or higher treatment-related adverse events occurred in 7 of 32 patients (22%) receiving combination therapy and in 2 of 32 patients (6%) receiving monotherapy; 1 patient randomized to the monotherapy arm did not receive treatment owing to worsened disease. Fatigue, diarrhea, and pruritus were the most common adverse events in both arms. Overall, 4 of 64 patients (6%) discontinued treatment owing to treatment-related adverse events. Objective response rate was 3.1% (95% CI, 0.08-16.22) for patients receiving combination therapy and 0% (95% CI, 0.00-10.58) for patients receiving monotherapy. Low patient numbers limited observation of the associations between treatment response and PD-L1 expression or microsatellite instability status. Conclusion and Relevance Treatment was well tolerated, and the efficacy of durvalumab plus tremelimumab therapy and durvalumab monotherapy reflected a population of patients with mPDAC who had poor prognoses and rapidly progressing disease. Patients were not enrolled in part B because the threshold for efficacy was not met in part A. Trial Registration ClinicalTrials.gov identifier: NCT02558894.",2019,"Objective response rate was 3.1% (95% CI, 0.08-16.22) for patients receiving combination therapy and 0% (95% CI, 0.00-10.58) for patients receiving monotherapy.","['Patients With Metastatic Pancreatic Ductal Adenocarcinoma', 'patients who received at least 1 dose of study treatment and for whom any postdose data were available', '65 randomized patients, 34 (52%) were men and median age was 61 (95% CI, 37-81) years', 'Between November 26, 2015, and March 23, 2017, 65 patients with mPDAC who had previously received only 1 first-line fluorouracil-based or gemcitabine-based treatment were enrolled at 21 sites in 6 countries', 'patients with mPDAC who had poor prognoses and rapidly progressing disease', 'patients with metastatic pancreatic ductal adenocarcinoma (mPDAC', 'patients with mPDAC']","['tremelimumab', 'durvalumab', 'durvalumab monotherapy', 'durvalumab plus tremelimumab therapy', 'dual checkpoint combination therapy', 'durvalumab therapy', 'monotherapy', 'anti-PD-L1 (programmed death-ligand 1) antibody using either durvalumab monotherapy', 'Durvalumab With or Without Tremelimumab']","['adverse events', 'Objective response rate', 'objective response rate', 'Fatigue, diarrhea, and pruritus', 'Measures\n\n\nSafety and efficacy', 'safety and efficacy']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0001418', 'cui_str': 'Adenoma, Malignant'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0278252', 'cui_str': 'Prognosis bad (finding)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C2351038', 'cui_str': 'tremelimumab'}, {'cui': 'C4055109', 'cui_str': 'durvalumab'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0556895', 'cui_str': 'Combination therapy (regime/therapy)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0023688', 'cui_str': 'Ligands'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",65.0,0.0873355,"Objective response rate was 3.1% (95% CI, 0.08-16.22) for patients receiving combination therapy and 0% (95% CI, 0.00-10.58) for patients receiving monotherapy.","[{'ForeName': 'Eileen M', 'Initials': 'EM', 'LastName': ""O'Reilly"", 'Affiliation': 'Gastrointestinal Medical Oncology, David M. Rubenstein Center for Pancreatic Cancer, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.'}, {'ForeName': 'Do-Youn', 'Initials': 'DY', 'LastName': 'Oh', 'Affiliation': 'Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Neesha', 'Initials': 'N', 'LastName': 'Dhani', 'Affiliation': 'Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Renouf', 'Affiliation': 'Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Myung Ah', 'Initials': 'MA', 'LastName': 'Lee', 'Affiliation': ""Department of Oncology, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.""}, {'ForeName': 'Weijing', 'Initials': 'W', 'LastName': 'Sun', 'Affiliation': 'Division of Medical Oncology, University of Kansas Medical Center, Kansas City.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Fisher', 'Affiliation': 'Department of Medicine-Medical Oncology, Stanford University, Stanford, California.'}, {'ForeName': 'Aram', 'Initials': 'A', 'LastName': 'Hezel', 'Affiliation': 'Division of Hematology and Oncology, University of Rochester, Rochester, New York.'}, {'ForeName': 'Shao-Chun', 'Initials': 'SC', 'LastName': 'Chang', 'Affiliation': 'AstraZeneca, Gaithersburg, Maryland.'}, {'ForeName': 'Gordana', 'Initials': 'G', 'LastName': 'Vlahovic', 'Affiliation': 'AstraZeneca, Gaithersburg, Maryland.'}, {'ForeName': 'Osamu', 'Initials': 'O', 'LastName': 'Takahashi', 'Affiliation': 'AstraZeneca, Gaithersburg, Maryland.'}, {'ForeName': 'Yin', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'AstraZeneca, Gaithersburg, Maryland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Fitts', 'Affiliation': 'Independent Biostatistician, Durham, North Carolina.'}, {'ForeName': 'Philip Agop', 'Initials': 'PA', 'LastName': 'Philip', 'Affiliation': 'Department of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan.'}]",JAMA oncology,['10.1001/jamaoncol.2019.1588'] 662,31797750,A web-based training program for direct care workers in long-term care communities: Providing knowledge and skills to implement a music and memory intervention.,"As dementia increases and the availability of at-home caregivers decreases, the need grows for effective training for direct care workers. Direct care workers have demanding schedules with restrictive availability and lack professional incentives to pursue specialized training. This study explored the impact of the Mason Music & Memory Initiative ( M 3 I) , a web-based, micro-learning training for direct care workers, combined with the implementation of the Music & Memory intervention. The training provided a foundational understanding of dementia and the person-centered music intervention. Twenty-five direct care workers, across two long-term care communities, completed the training modules over four weeks. All participants completed a pre- and posttest, determining their knowledge and understanding of dementia and the Music & Memory intervention adopted by their facilities. Many workers found the training to be informative and inspiring, noting improved behaviors in residents during the implementation of the M 3 I .",2020,"All participants completed a pre- and posttest, determining their knowledge and understanding of dementia and the Music & Memory intervention adopted by their facilities.","['Twenty-five direct care workers, across two long-term care communities', 'direct care workers in long-term care communities']","['Mason Music & Memory Initiative ( M 3 I) , a web-based, micro-learning training']",[],"[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0023977'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0424093', 'cui_str': 'Initiative (observable entity)'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]",[],25.0,0.0217136,"All participants completed a pre- and posttest, determining their knowledge and understanding of dementia and the Music & Memory intervention adopted by their facilities.","[{'ForeName': 'Catherine J', 'Initials': 'CJ', 'LastName': 'Tompkins', 'Affiliation': 'College of Health and Human Services, Department of Social Work, George Mason University , Fairfax,Virginia, USA.'}, {'ForeName': 'Emily S', 'Initials': 'ES', 'LastName': 'Ihara', 'Affiliation': 'College of Health and Human Services, Department of Social Work, George Mason University , Fairfax,Virginia, USA.'}, {'ForeName': 'Megumi', 'Initials': 'M', 'LastName': 'Inoue', 'Affiliation': 'College of Health and Human Services, Department of Social Work, George Mason University , Fairfax,Virginia, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Ferenz', 'Affiliation': 'College of Health and Human Services, Department of Social Work, George Mason University , Fairfax,Virginia, USA.'}, {'ForeName': 'Shawn', 'Initials': 'S', 'LastName': 'Pham', 'Affiliation': 'College of Health and Human Services, Department of Social Work, George Mason University , Fairfax,Virginia, USA.'}]",Gerontology & geriatrics education,['10.1080/02701960.2019.1699074'] 663,31280620,Efficacy and Safety of Tolvaptan in Patients More Than 90 Years Old With Acute Heart Failure.,"BACKGROUND The oral vasopressin-2 receptor antagonist, tolvaptan, causes aquaresis and improves symptoms in patients with congestive heart failure. However, few studies have explored the effect of tolvaptan in acute heart failure (AHF) patients ≥90 years old. METHODS This study enrolled 106 AHF patients treated with tolvaptan added to standard therapy. The subjects were divided into 2 groups: ≥90-year-old patients (over-90 group, mean 92 ± 2 years, n = 45) and <90-year-old patients (under-90 group, mean 76 ± 11 years, n = 61). Patients' characteristics were assessed, and efficacy and safety were compared between the 2 groups. RESULTS The over-90 group had a lower proportion of male patients, lower body weight, and higher ejection fraction. The under-90 group had significantly higher prevalence of ischemic heart disease and diabetes mellitus. There were no significant differences between the 2 groups in total urine volume at 24 and 48 hours (1934 ± 983 mL vs 1816 ± 1028 mL, P = 0.58 and 3806 ± 1444 mL vs 4078 ± 1851 mL, P =0.47, respectively), the mean change in body weight (-3.0 ± 2.7 kg vs -2.6 ± 2.6 kg, P = 0.50), improvement of congestive symptoms, changes in serum sodium and creatinine levels, the incidences of hypernatremia (n = 0, 0% vs n = 1, 1.6%, P = 0.63), and worsening renal function (n = 9, 20% vs n = 17, 28%, P = 0.48). CONCLUSION The efficacy and safety of tolvaptan in AHF patients aged more than 90 years were comparable to those of <90 years old. Tolvaptan provides a complementary therapeutic option for AHF patients aged more than 90 years.",2020,"There were no significant differences between the 2 groups in total urine volume at 24 and 48 hours (1934 ± 983 mL vs 1816 ± 1028 mL, P = 0.58 and 3806 ± 1444 mL vs 4078 ± 1851 mL, P =0.47, respectively), the mean change in body weight (-3.0 ± 2.7 kg vs -2.6 ± 2.6 kg, P = 0.50), improvement of congestive symptoms, changes in serum sodium and creatinine levels, the incidences of hypernatremia (n = 0, 0% vs n = 1, 1.6%, P = 0.63), and worsening renal function (n = 9, 20% vs n = 17, 28%, P = 0.48). ","['patients with congestive heart failure', '90 Years Old With Acute Heart Failure', 'AHF patients aged more than 90 years were comparable to those of <90 years old', 'Patients', 'AHF patients aged more than 90 years', '106 AHF patients treated with', 'subjects were divided into 2 groups: ≥90-year-old patients (over-90 group, mean 92 ± 2 years, n = 45) and <90-year-old patients (under-90 group, mean 76 ± 11 years, n = 61', 'acute heart failure (AHF) patients ≥90 years old']","['tolvaptan', 'tolvaptan added to standard therapy', 'Tolvaptan']","['ischemic heart disease and diabetes mellitus', 'worsening renal function', 'congestive symptoms, changes in serum sodium and creatinine levels, the incidences of hypernatremia', 'total urine volume', 'mean change in body weight', 'efficacy and safety', 'Efficacy and Safety', 'lower body weight, and higher ejection fraction']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure (disorder)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0264714', 'cui_str': 'Acute heart failure (disorder)'}, {'cui': 'C0015506', 'cui_str': 'coagulation factor VIII'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439087', 'cui_str': '<90 (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]","[{'cui': 'C1176308', 'cui_str': 'tolvaptan'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0151744', 'cui_str': 'Ischemic Heart Disease'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0523891', 'cui_str': 'Sodium measurement, serum (procedure)'}, {'cui': 'C0428279', 'cui_str': 'Finding of creatinine level (finding)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0020488', 'cui_str': 'Hypernatremia'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1287298', 'cui_str': 'UO - Urine output'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1268088', 'cui_str': 'Lower body'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}]",106.0,0.0191389,"There were no significant differences between the 2 groups in total urine volume at 24 and 48 hours (1934 ± 983 mL vs 1816 ± 1028 mL, P = 0.58 and 3806 ± 1444 mL vs 4078 ± 1851 mL, P =0.47, respectively), the mean change in body weight (-3.0 ± 2.7 kg vs -2.6 ± 2.6 kg, P = 0.50), improvement of congestive symptoms, changes in serum sodium and creatinine levels, the incidences of hypernatremia (n = 0, 0% vs n = 1, 1.6%, P = 0.63), and worsening renal function (n = 9, 20% vs n = 17, 28%, P = 0.48). ","[{'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Sato', 'Affiliation': 'Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Hiroyasu', 'Initials': 'H', 'LastName': 'Uzui', 'Affiliation': 'Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Moe', 'Initials': 'M', 'LastName': 'Mukai', 'Affiliation': 'Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Yuichiro', 'Initials': 'Y', 'LastName': 'Shiomi', 'Affiliation': 'Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Kanae', 'Initials': 'K', 'LastName': 'Hasegawa', 'Affiliation': 'Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Ikeda', 'Affiliation': 'Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Naoto', 'Initials': 'N', 'LastName': 'Tama', 'Affiliation': 'Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Yoshitomo', 'Initials': 'Y', 'LastName': 'Fukuoka', 'Affiliation': 'Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Tetsuji', 'Initials': 'T', 'LastName': 'Morishita', 'Affiliation': 'Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Ishida', 'Affiliation': 'Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Kenichi', 'Initials': 'K', 'LastName': 'Kaseno', 'Affiliation': 'Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Shinsuke', 'Initials': 'S', 'LastName': 'Miyazaki', 'Affiliation': 'Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Nakano', 'Affiliation': 'Depatment of Cardiology, Hikone Municipal Hospital, Shiga, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Tada', 'Affiliation': 'Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.'}]",Journal of cardiovascular pharmacology and therapeutics,['10.1177/1074248419861962'] 664,31267818,Personality as a predictor of well-being in a randomized trial of a mindfulness-based stress reduction of Danish women with breast cancer.,"Purpose: Many clinical interventions have been designed to improve psychological well-being in women with breast cancer; however, there are individual differences in the extent of benefit across participants. Mindfulness-Based Stress Reduction (MBSR) is a structured 8-week intervention that has been shown to reduce depression and anxiety for patients with breast cancer. Personality factors may influence which participants benefit more from various psychological interventions, including MBSR. Design: In a secondary analysis, we examined whether personality factors accounted for variability in response to an MBSR intervention for women with breast cancer. Sample: Two hundred eighty Danish women with breast cancer who completed the Mindfulness and Cancer Mamma trial were included in this analysis. Methods: Using multiple regression analyses, we investigated whether personality factors, measured by the NEO-PI-R, contribute independently or interact with treatment to predict depressive symptoms at 2, 6, and 12-month follow-up. Findings: The interaction between low conscientiousness and MBSR, as well as high neuroticism and MBSR each predicted significantly lower levels of distress at 12-month follow-up compared to women who higher in conscientious or lower in neuroticism. Conclusions: Personality factors may contribute to the impact of psychosocial interventions, such as MBSR, on psychological well-being. Implications for Psychosocial Providers: Utilizing personality measures may assist providers in identifying which patients may benefit from mindfulness therapies.",2020,Mindfulness-Based Stress Reduction (MBSR) is a structured 8-week intervention that has been shown to reduce depression and anxiety for patients with breast cancer.,"['women with breast cancer', 'Danish women with breast cancer', 'patients with breast cancer', 'Two hundred eighty Danish women with breast cancer who completed the Mindfulness and Cancer Mamma trial']","['Mindfulness-Based Stress Reduction (MBSR', 'MBSR intervention']","['depression and anxiety', 'levels of distress']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}]","[{'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}]",280.0,0.030288,Mindfulness-Based Stress Reduction (MBSR) is a structured 8-week intervention that has been shown to reduce depression and anxiety for patients with breast cancer.,"[{'ForeName': 'Christina H', 'Initials': 'CH', 'LastName': 'Jagielski', 'Affiliation': 'Department of Internal Medicine/Division of Gastroenterology, Michigan Medicine, Ann Arbor, MI, USA.'}, {'ForeName': 'Diane C', 'Initials': 'DC', 'LastName': 'Tucker', 'Affiliation': 'Department of Psychology, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Susanne O', 'Initials': 'SO', 'LastName': 'Dalton', 'Affiliation': 'Survivorship Unit, Danish Cancer Society Research Center, Copenhagen, Denmark.'}, {'ForeName': 'Sylvie', 'Initials': 'S', 'LastName': 'Mrug', 'Affiliation': 'Department of Psychology, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Hanne', 'Initials': 'H', 'LastName': 'Würtzen', 'Affiliation': 'Copenhagen University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Christoffer', 'Initials': 'C', 'LastName': 'Johansen', 'Affiliation': 'Survivorship Unit, Danish Cancer Society Research Center, Copenhagen, Denmark.'}]",Journal of psychosocial oncology,['10.1080/07347332.2019.1626524'] 665,32298728,Palivizumab Following Extremely Premature Birth Does Not Affect Pulmonary Outcomes in Adolescence.,"BACKGROUND Prematurity is a risk factor for impaired lung function. We sought to assess the long-term effect of palivizumab immunization and extreme prematurity (<29 weeks gestation) on respiratory symptoms and pulmonary function in adolescence. RESEARCH QUESTION What is the long-term effect of palivizumab immunization and extreme prematurity (<29 weeks) on respiratory symptoms and pulmonary function in adolescence? STUDY DESIGN AND METHODS We examined survivors of extreme prematurity (<29 weeks gestation) at 13 to 18 years of age (study group). Study group babies who were born immediately before palivizumab immunization (nonpalivizumab group [NPG]) were compared with those babies who were born just after implementation (PG) and with a control group. For study group patients, lung function in adolescence was further compared longitudinally with that at primary school age. RESULTS Sixty-four adolescents aged 15.76 ± 1.52 years were included: 46 in the study group (17 PG and 29 NPG) and 18 in the control group. For the study group, wheezing episodes, inhaler use, and hospitalizations were uncommon. For the study group compared with the control group, FEV 1 percent predicted was 82.60% ± 13.54% vs 105.83% ± 13.12% (P < .001), and the lung clearance index was 7.67 ± 1.02 vs 7.46 ± 0.70 (P = .48), respectively. Study group adolescents with bronchopulmonary dysplasia had a higher lung clearance index than did adolescents with no bronchopulmonary dysplasia (7.94 ± 1.11 vs 7.20 ± 0.60; P = .002). PG and NPG adolescents were not significantly different. Comparing the study group in adolescence with primary school age, we found improvement in mean FEV 1 percent predicted bronchodilator response (0.37% ± 9.98% vs 5.67% ± 9.87%; P = .036) and mean provocative concentration causing 20% decline in FEV 1 (12.16 ± 4.71 mg/mL vs 4.14 ± 4.51 mg/mL, respectively; P < .001). INTERPRETATION Palivizumab did not provide any discernable long-term protective effect. Nevertheless, adolescent survivors of extreme prematurity showed good clinical and physiologic outcomes, except for mildly raised lung clearance index in patients with bronchopulmonary dysplasia. Airway hyperreactivity detected at primary school age, decreased by adolescence.",2020,"For the study group compared with the control group, FEV 1 percent predicted was 82.60% ± 13.54% vs 105.83% ± 13.12% (P < .001), and the lung clearance index was 7.67 ± 1.02 vs 7.46 ± 0.70","['Adolescents', 'patients with bronchopulmonary dysplasia', 'Sixty-four adolescents aged 15.76 ± 1.52 years were included: 46 in the study group (17 PG and 29 NPG) and 18 in the control group', 'Extremely Premature Birth', 'survivors of extreme prematurity (<29\xa0weeks gestation) at 13 to 18 years of age (study group']","['palivizumab immunization (nonpalivizumab group [NPG', 'palivizumab immunization and extreme prematurity (<29\xa0weeks gestation', 'Palivizumab']","['respiratory symptoms and pulmonary function at adolescence', 'lung clearance index', 'Airway hyperreactivity', 'bronchodilator response', 'mean provocative concentration', 'lung function at adolescence', 'wheezing episodes, inhaler use, and hospitalizations']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary dysplasia of newborn'}, {'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0068260', 'cui_str': 'N-palmitoylgalactosylsphingosine'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205403', 'cui_str': 'Extreme'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0672596', 'cui_str': 'palivizumab'}, {'cui': 'C0020971', 'cui_str': 'Immunization'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0068260', 'cui_str': 'N-palmitoylgalactosylsphingosine'}, {'cui': 'C0205403', 'cui_str': 'Extreme'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0037090', 'cui_str': 'Respiratory symptom'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0231990', 'cui_str': 'Lung clearance index'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0006280', 'cui_str': 'Bronchodilator agent'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0043144', 'cui_str': 'Wheezing'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0021461', 'cui_str': 'Inhaler'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",64.0,0.149305,"For the study group compared with the control group, FEV 1 percent predicted was 82.60% ± 13.54% vs 105.83% ± 13.12% (P < .001), and the lung clearance index was 7.67 ± 1.02 vs 7.46 ± 0.70","[{'ForeName': 'Nofar', 'Initials': 'N', 'LastName': 'Amitai', 'Affiliation': ""Pulmonary Institute, Schneider Children's Medical Center of Israel, Petah Tikva.""}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Stafler', 'Affiliation': ""Pulmonary Institute, Schneider Children's Medical Center of Israel, Petah Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.""}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Blau', 'Affiliation': ""Pulmonary Institute, Schneider Children's Medical Center of Israel, Petah Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.""}, {'ForeName': 'Eytan', 'Initials': 'E', 'LastName': 'Kaplan', 'Affiliation': ""Pediatric Intensive Care Unit, Schneider Children's Medical Center of Israel, Petah Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.""}, {'ForeName': 'Huda', 'Initials': 'H', 'LastName': 'Mussaffi', 'Affiliation': ""Pulmonary Institute, Schneider Children's Medical Center of Israel, Petah Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.""}, {'ForeName': 'Hagit', 'Initials': 'H', 'LastName': 'Levine', 'Affiliation': ""Pulmonary Institute, Schneider Children's Medical Center of Israel, Petah Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.""}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Steuer', 'Affiliation': ""Pulmonary Institute, Schneider Children's Medical Center of Israel, Petah Tikva.""}, {'ForeName': 'Ephraim', 'Initials': 'E', 'LastName': 'Bar-Yishay', 'Affiliation': 'Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheba, Israel.'}, {'ForeName': 'Gil', 'Initials': 'G', 'LastName': 'Klinger', 'Affiliation': ""Neonatal Intensive Care Unit, Schneider Children's Medical Center of Israel, Petah Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.""}, {'ForeName': 'Meir', 'Initials': 'M', 'LastName': 'Mei-Zahav', 'Affiliation': ""Pulmonary Institute, Schneider Children's Medical Center of Israel, Petah Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.""}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Prais', 'Affiliation': ""Pulmonary Institute, Schneider Children's Medical Center of Israel, Petah Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv. Electronic address: prais@tauex.tau.ac.il.""}]",Chest,['10.1016/j.chest.2020.02.075'] 666,32033532,Augmented exercise in hospital improves physical performance and reduces negative post hospitalization events: a randomized controlled trial.,"BACKGROUND To measure the effects of an augmented prescribed exercise programme versus usual care, on physical performance, quality of life and healthcare utilisation for frail older medical patients in the acute setting. METHODS This was a parallel single-blinded randomised controlled trial. Within 2 days of admission, older medical inpatients with an anticipated length of stay ≥3 days, needing assistance/aid to walk, were blindly randomly allocated to the intervention or control group. Until discharge, both groups received twice daily, Monday-to-Friday half-hour assisted exercises, assisted by a staff physiotherapist. The intervention group completed tailored strengthening and balance exercises; the control group performed stretching and relaxation exercises. Length of stay was the primary outcome measure. Blindly assessed secondary measures included readmissions within 3 months, and physical performance (Short Physical Performance Battery) and quality of life (EuroQOL-5D-5 L) at discharge and at 3 months. Time-to-event analysis was used to measure differences in length of stay, and regression models were used to measure differences in physical performance, quality of life, adverse events (falls, deaths) and negative events (prolonged hospitalisation, institutionalisation). RESULTS Of the 199 patients allocated, 190 patients' (aged 80 ± 7.5 years) data were analysed. Groups were comparable at baseline. In intention-to-treat analysis, length of stay did not differ between groups (HR 1.09 (95% CI, 0.77-1.56) p = 0.6). Physical performance was better in the intervention group at discharge (difference 0.88 (95% CI, 0.20-1.57) p = 0.01), but lost at follow-up (difference 0.45 (95% CI, - 0.43 - 1.33) p = 0.3). An improvement in quality of life was detected at follow-up in the intervention group (difference 0.28 (95% CI, 0.9-0.47) p = 0.004). Overall, fewer negative events occurred in the intervention group (OR 0.46 (95% CI 0.23-0.92) p = 0.03). CONCLUSION Improvements in physical performance, quality of life and fewer negative events suggest that this intervention is of value to frail medical inpatients. Its effect on length of stay remains unclear. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02463864, registered prospectively 26.05.2015.",2020,"Physical performance was better in the intervention group at discharge (difference 0.88 (95% CI, 0.20-1.57) p = 0.01), but lost at follow-up (difference 0.45 (95% CI, - 0.43 - 1.33) p = 0.3).","['frail older medical patients in the acute setting', 'older medical inpatients with an anticipated length of stay ≥3\u2009days, needing assistance/aid to walk', ""199 patients allocated, 190 patients' (aged 80\u2009±\u20097.5\u2009years) data were analysed"", 'frail medical inpatients']","['exercise programme versus usual care', 'tailored strengthening and balance exercises; the control group performed stretching and relaxation exercises']","['quality of life', 'negative events', 'physical performance, quality of life', 'length of stay', 'Physical performance', 'physical performance, quality of life, adverse events (falls, deaths) and negative events (prolonged hospitalisation, institutionalisation', 'physical performance and reduces negative post hospitalization events', 'readmissions within 3 months, and physical performance (Short Physical Performance Battery) and quality of life (EuroQOL-5D-5\u2009L', 'Length of stay', 'physical performance, quality of life and healthcare utilisation']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0449435', 'cui_str': 'Aid (attribute)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C4517622', 'cui_str': 'One hundred and ninety'}, {'cui': 'C4517859', 'cui_str': 'Seven point five'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0150219', 'cui_str': 'Balance exercises'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0203993', 'cui_str': 'Relaxation exercise (regime/therapy)'}]","[{'cui': 'C0034380'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C2607857'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C4075461', 'cui_str': 'Short Physical Performance Battery'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}]",,0.160564,"Physical performance was better in the intervention group at discharge (difference 0.88 (95% CI, 0.20-1.57) p = 0.01), but lost at follow-up (difference 0.45 (95% CI, - 0.43 - 1.33) p = 0.3).","[{'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'McCullagh', 'Affiliation': 'Centre for Gerontology & Rehabilitation, University College Cork, Cork, Ireland. r.mccullagh@ucc.ie.'}, {'ForeName': 'Eimear', 'Initials': 'E', 'LastName': ""O'Connell"", 'Affiliation': 'Physiotherapy Department, Mercy University Hospital, Cork, Ireland.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': ""O'Meara"", 'Affiliation': 'Clinical Research Facility, Mercy University Hospital, Cork, Ireland.'}, {'ForeName': 'Darren', 'Initials': 'D', 'LastName': 'Dahly', 'Affiliation': 'School of Public Health, University College Cork, Cork, Ireland.'}, {'ForeName': 'Eilis', 'Initials': 'E', 'LastName': ""O'Reilly"", 'Affiliation': 'School of Public Health, University College Cork, Cork, Ireland.'}, {'ForeName': 'Kieran', 'Initials': 'K', 'LastName': ""O'Connor"", 'Affiliation': 'Department of Geriatric Medicine, Mercy University Hospital, Cork, Ireland.'}, {'ForeName': 'N Frances', 'Initials': 'NF', 'LastName': 'Horgan', 'Affiliation': 'School of Physiotherapy, Royal College of Surgeons in Ireland, Dublin, Ireland.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Timmons', 'Affiliation': 'Centre for Gerontology & Rehabilitation, University College Cork, Cork, Ireland.'}]",BMC geriatrics,['10.1186/s12877-020-1436-0'] 667,31278109,Food and Agricultural Approaches to Reducing Malnutrition (FAARM): protocol for a cluster-randomised controlled trial to evaluate the impact of a Homestead Food Production programme on undernutrition in rural Bangladesh.,"INTRODUCTION Chronic undernutrition affects over 150 million children worldwide and has serious consequences. The causes are complex and include insufficient dietary diversity and poor hygiene practices. Systematic reviews of nutrition-sensitive agricultural interventions concluded that while these hold promise, there is insufficient evidence for their impact on child growth. The Food and Agricultural Approaches to Reducing Malnutrition (FAARM) project is a 1:1 cluster-randomised trial aiming to evaluate the impact of a Homestead Food Production (HFP) programme implemented by Helen Keller International on women's and children's undernutrition. METHODS AND ANALYSIS The HFP intervention comprises training of women's groups and asset distribution to support year-round home gardening, poultry rearing and improved nutrition and hygiene practices. Formal trainings are supplemented by behaviour change communication during household visits, and facilitated links between producer groups and market actors. The FAARM trial will examine if and how this complex intervention reduces undernutrition. In 2015, FAARM enrolled married women and their children (0-3 years) in 96 rural settlements of Habiganj district in Sylhet division, Bangladesh. Covariate-constrained randomisation was used to assign 48 settlements to receive a 3-year HFP intervention, with the other 48 acting as controls, targeting over 2700 women. To study impact pathways, a surveillance system collects data on all participants every 2 months. In late 2019, children 0-3 years of age (born during the intervention period) will be surveyed, thus capturing impact during the critical first 1000 days of life. Children's length/height-for-age z-scores will be compared between intervention and control arms using mixed-effects linear regression. Secondary outcomes include women's and children's micronutrient status, dietary intake, dietary diversity and other indicators of child growth, development and morbidity. ETHICS AND DISSEMINATION Ethical approval was received in Bangladesh and Germany. Results will be disseminated through peer-reviewed publications and presentations in Bangladesh and internationally. TRIAL REGISTRATION NUMBER NCT02505711; Pre-results.",2019,Children's length/height-for-age z-scores will be compared between intervention and control arms using mixed-effects linear regression.,"[""women's and children's undernutrition"", 'undernutrition in rural Bangladesh', 'In late 2019, children 0-3 years of age (born during the intervention period', '2015, FAARM enrolled married women and their children (0-3 years) in 96 rural settlements of Habiganj district in Sylhet division, Bangladesh']","['HFP intervention', 'Homestead Food Production programme', 'Homestead Food Production (HFP) programme']","[""Children's length/height-for-age z-scores"", ""women's and children's micronutrient status, dietary intake, dietary diversity and other indicators of child growth, development and morbidity""]","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0162429', 'cui_str': 'Malnutrition'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C1293097', 'cui_str': 'Division - action (qualifier value)'}]","[{'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0033268'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}]",2700.0,0.0985487,Children's length/height-for-age z-scores will be compared between intervention and control arms using mixed-effects linear regression.,"[{'ForeName': 'Amanda S', 'Initials': 'AS', 'LastName': 'Wendt', 'Affiliation': 'Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Thalia M', 'Initials': 'TM', 'LastName': 'Sparling', 'Affiliation': 'Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Jillian L', 'Initials': 'JL', 'LastName': 'Waid', 'Affiliation': 'Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Anna A', 'Initials': 'AA', 'LastName': 'Mueller', 'Affiliation': 'Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Gabrysch', 'Affiliation': 'Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany.'}]",BMJ open,['10.1136/bmjopen-2019-031037'] 668,29670295,Nested case-control study of telomere length and lung cancer risk among heavy smokers in the β-Carotene and Retinol Efficacy Trial.,"BACKGROUND Telomeres protect cells from genomic instability. We examined telomere length and lung cancer risk prospectively in heavy smokers. METHODS In a nested case-control study with 709 cases and 1313 controls, conditional logistic regression was used to evaluate associations between telomere length (global, chromosome 5p, and 13q) and lung cancer risk by histotype, controlling for detailed smoking history. RESULTS Risks of overall lung cancer and adenocarcinoma were suggestively elevated among individuals with telomere length in the longest tertile. No clear patterns were observed for other histotypes, or for chromosome 5p or 13q telomere length. Associations with adenocarcinoma were strongest among (OR, 95% CI for longest versus shortest tertile): former smokers (2.26, 1.03-4.96), individuals <65 years (2.22, 1.13-4.35), and women (2.21, 0.99-4.93). CONCLUSIONS Our large study of heavy smokers adds additional evidence that long telomere length prior to diagnosis is associated with risk of lung adenocarcinoma, but not other histotypes.",2018,"No clear patterns were observed for other histotypes, or for chromosome 5p or 13q telomere length.",['heavy smokers'],[],"['telomere length and lung cancer risk', 'Risks of overall lung cancer and adenocarcinoma']","[{'cui': 'C0857118', 'cui_str': 'Heavy smoker'}]",[],"[{'cui': 'C0085187'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C1306460', 'cui_str': 'Primary malignant neoplasm of lung'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0001418', 'cui_str': 'Adenoma, Malignant'}]",,0.0259382,"No clear patterns were observed for other histotypes, or for chromosome 5p or 13q telomere length.","[{'ForeName': 'Jennifer Anne', 'Initials': 'JA', 'LastName': 'Doherty', 'Affiliation': 'Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112-5550, USA. jen.doherty@hci.utah.edu.'}, {'ForeName': 'Laurie', 'Initials': 'L', 'LastName': 'Grieshober', 'Affiliation': 'Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112-5550, USA.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Houck', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109-1024, USA.'}, {'ForeName': 'Matt J', 'Initials': 'MJ', 'LastName': 'Barnett', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109-1024, USA.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'De Dieu Tapsoba', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109-1024, USA.'}, {'ForeName': 'Mark D', 'Initials': 'MD', 'LastName': 'Thornquist', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109-1024, USA.'}, {'ForeName': 'Ching-Yun', 'Initials': 'CY', 'LastName': 'Wang', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109-1024, USA.'}, {'ForeName': 'Gary E', 'Initials': 'GE', 'LastName': 'Goodman', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109-1024, USA.'}, {'ForeName': 'Chu', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109-1024, USA.'}]",British journal of cancer,['10.1038/s41416-018-0075-0'] 669,31004462,Sunscreen or simulated sweat minimizes the impact of acute ultraviolet radiation on cutaneous microvascular function in healthy humans.,"NEW FINDINGS What is the central question of this study? Are ultraviolet radiation (UVR)-induced increases in skin blood flow independent of skin erythema? Does broad-spectrum UVR exposure attenuate NO-mediated cutaneous vasodilatation, and does sunscreen or sweat modulate this response? What are the main findings and their importance? Erythema and vascular responses to UVR are temporally distinct, and sunscreen prevents both responses. Exposure to UVR attenuates NO-mediated vasodilatation in the cutaneous microvasculature; sunscreen or simulated sweat on the skin attenuates this response. Sun over-exposure may elicit deleterious effects on human skin that are separate from sunburn, and sunscreen or sweat on the skin may provide protection. ABSTRACT Exposure to ultraviolet radiation (UVR) may result in cutaneous vascular dysfunction independent of erythema (skin reddening). Two studies were designed to differentiate changes in erythema from skin vasodilatation throughout the 8 h after acute broad-spectrum UVR exposure with (+SS) or without SPF-50 sunscreen (study 1) and to examine NO-mediated cutaneous vasodilatation after acute broad-spectrum UVR exposure with or without +SS or simulated sweat (+SW) on the skin (study 2). In both studies, laser-Doppler flowmetry was used to measure red cell flux, and cutaneous vascular conductance (CVC) was calculated (CVC = flux/mean arterial pressure). In study 1, in 14 healthy adults (24 ± 4 years old; seven men and seven women), the skin erythema index and CVC were measured over two forearm sites (UVR only and UVR+SS) before, immediately after and every 2 h for 8 h post-exposure (750 mJ cm -2 ). The erythema index began to increase immediately post-UVR (P < 0.05 at 4, 6 and 8 h), but CVC did not increase above baseline for the first 4-6 h (P ≤ 0.01 at 6 and 8 h); +SS prevented both responses. In study 2, in 13 healthy adults (24 ± 4 years old; six men and seven women), three intradermal microdialysis fibres were placed in the ventral skin of the forearm [randomly assigned to UVR (450 mJ cm -2 ), UVR+SS or UVR+SW], and one fibre (non-exposed control; CON) was placed in the contralateral forearm. After UVR, a standardized local heating (42°C) protocol quantified the percentage of NO-mediated vasodilatation (%NO). The UVR attenuated %NO compared with CON (P = 0.01). The diminished %NO was prevented by +SS (P < 0.01) and +SW (P < 0.01). Acute broad-spectrum UVR attenuates NO-dependent dilatation in the cutaneous microvasculature, independent of erythema. Sunscreen protects against both inflammatory and heating-induced endothelial dysfunction, and sweat might prevent UVR-induced reductions in NO-dependent dilatation.",2019,The diminished %NO was prevented by +SS (P < 0.01) and +SW (P < 0.01).,"['healthy humans', 'cutaneous vascular dysfunction independent of erythema (skin reddening', '14 healthy adults (24\xa0±\xa04\xa0years old; seven men and seven women', '13 healthy adults (24\xa0±\xa04\xa0years old; six men and seven women']","['CON', 'Sunscreen or simulated sweat', 'spectrum UVR exposure with or without +SS or simulated sweat (+SW', 'intradermal microdialysis fibres were placed in the ventral skin of the forearm [randomly assigned to UVR (450\xa0mJ\xa0cm -2 ), UVR+SS or UVR+SW], and one fibre (non-exposed control; CON', 'acute ultraviolet radiation', 'ultraviolet radiation (UVR', 'laser-Doppler flowmetry', 'SPF-50 sunscreen']","['red cell flux, and cutaneous vascular conductance (CVC', 'Erythema and vascular responses', 'erythema index', 'skin erythema index and CVC']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C4521174', 'cui_str': 'Cutaneous'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}, {'cui': 'C0332291', 'cui_str': 'Independent of (attribute)'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0038818', 'cui_str': 'Sunscreens'}, {'cui': 'C0038990', 'cui_str': 'Sweating'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0206056', 'cui_str': 'Microdialysis'}, {'cui': 'C0225326', 'cui_str': 'Fiber'}, {'cui': 'C1704765', 'cui_str': 'Place - dosing instruction imperative'}, {'cui': 'C1704448', 'cui_str': 'Ventral'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0016536', 'cui_str': 'Antebrachiums'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C3844104', 'cui_str': 'Four hundred and fifty'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4319812', 'cui_str': 'Ultraviolet Radiation'}, {'cui': 'C0162520', 'cui_str': 'Laser-Doppler Flowmetry'}]","[{'cui': 'C0332575', 'cui_str': 'Red color (finding)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C4521174', 'cui_str': 'Cutaneous'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",14.0,0.0168513,The diminished %NO was prevented by +SS (P < 0.01) and +SW (P < 0.01).,"[{'ForeName': 'S Tony', 'Initials': 'ST', 'LastName': 'Wolf', 'Affiliation': 'Department of Kinesiology, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Craig W', 'Initials': 'CW', 'LastName': 'Berry', 'Affiliation': 'Department of Kinesiology, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Anna E', 'Initials': 'AE', 'LastName': 'Stanhewicz', 'Affiliation': 'Department of Kinesiology, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'Kenney', 'Affiliation': 'Department of Kinesiology, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Sara B', 'Initials': 'SB', 'LastName': 'Ferguson', 'Affiliation': 'Department of Kinesiology, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'W Larry', 'Initials': 'WL', 'LastName': 'Kenney', 'Affiliation': 'Department of Kinesiology, The Pennsylvania State University, University Park, PA, USA.'}]",Experimental physiology,['10.1113/EP087688'] 670,32409830,A phase III randomized controlled trial comparing surgery plus adjuvant chemotherapy with preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for locally recurrent rectal cancer: Japan Clinical Oncology Group study JCOG1801 (RC-SURVIVE study).,"A randomized phase III trial was initiated in Japan in August 2019 to confirm the superiority of preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy compared to the standard treatment, i.e. surgery plus adjuvant chemotherapy, for locally recurrent rectal cancer in local relapse-free survival. In all, 110 patients from 43 Japanese institutions will be recruited over a period of 6 years. Eligible patients would be registered and randomly assigned to each group with an allocation ratio of 1:1. The primary endpoint is local relapse-free survival. The secondary endpoints are overall survival, relapse-free survival, proportion of local relapse, proportion of distant relapse, proportion of patients with pathological R0 resection, response rate of preoperative chemoradiotherapy (preoperative chemoradiotherapy arm), pathological complete response rate (preoperative chemoradiotherapy arm), proportion of patients who completed the protocol treatment, incidence of adverse events (adverse reactions) and quality of life after surgery. This trial has been registered at the Japan Registry of Clinical Trial: jRCTs031190076 [https://jrct.niph.go.jp/latest-detail/jRCTs031190076] and ClinicalTrials.gov: NCT04288999 [https://clinicaltrials.gov/ct2/show/NCT04288999].",2020,"The secondary endpoints are overall survival, relapse-free survival, proportion of local relapse, proportion of distant relapse, proportion of patients with pathological R0 resection, response rate of preoperative chemoradiotherapy (preoperative chemoradiotherapy arm), pathological complete response rate (preoperative chemoradiotherapy arm), proportion of patients who completed the protocol treatment, incidence of adverse events (adverse reactions) and quality of life after surgery.","['locally recurrent rectal cancer', '110 patients from 43 Japanese institutions will be recruited over a period of 6\xa0years', 'Eligible patients']","['preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy', 'surgery plus adjuvant chemotherapy with preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy']","['local relapse-free survival', 'overall survival, relapse-free survival, proportion of local relapse, proportion of distant relapse, proportion of patients with pathological R0 resection, response rate of preoperative chemoradiotherapy (preoperative chemoradiotherapy arm), pathological complete response rate (preoperative chemoradiotherapy arm), proportion of patients who completed the protocol treatment, incidence of adverse events (adverse reactions) and quality of life after surgery']","[{'cui': 'C0278554', 'cui_str': 'Rectal cancer recurrent'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}]","[{'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0443203', 'cui_str': 'Distant'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]",110.0,0.319184,"The secondary endpoints are overall survival, relapse-free survival, proportion of local relapse, proportion of distant relapse, proportion of patients with pathological R0 resection, response rate of preoperative chemoradiotherapy (preoperative chemoradiotherapy arm), pathological complete response rate (preoperative chemoradiotherapy arm), proportion of patients who completed the protocol treatment, incidence of adverse events (adverse reactions) and quality of life after surgery.","[{'ForeName': 'Tomohiro', 'Initials': 'T', 'LastName': 'Kadota', 'Affiliation': 'JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Yuichiro', 'Initials': 'Y', 'LastName': 'Tsukada', 'Affiliation': 'Department of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Japan.'}, {'ForeName': 'Masaaki', 'Initials': 'M', 'LastName': 'Ito', 'Affiliation': 'Department of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Katayama', 'Affiliation': 'JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Junki', 'Initials': 'J', 'LastName': 'Mizusawa', 'Affiliation': 'JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Nakamura', 'Affiliation': 'Department of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan.'}, {'ForeName': 'Yoshinori', 'Initials': 'Y', 'LastName': 'Ito', 'Affiliation': 'Department of Radiation Oncology, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Bando', 'Affiliation': 'Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'Masahiko', 'Initials': 'M', 'LastName': 'Ando', 'Affiliation': 'Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Onaya', 'Affiliation': 'Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'Haruhiko', 'Initials': 'H', 'LastName': 'Fukuda', 'Affiliation': 'JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Yukihide', 'Initials': 'Y', 'LastName': 'Kanemitsu', 'Affiliation': 'Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.'}]",Japanese journal of clinical oncology,['10.1093/jjco/hyaa058'] 671,31250356,Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects-results from the POUDER pilot study.,"Pancreatic ductal adenocarcinoma is a highly aggressive malignancy with short survival and limited therapeutic options. Broccoli sulforaphane is a promising new treatment due to the results of recent epidemiological, experimental and patient studies. Upon approval from the ethics committee and registration at ClinicalTrials.gov, 40 patients with palliative chemotherapy were placed into a placebo and treatment group in an unblinded fashion. Fifteen capsules with pulverized broccoli sprouts containing 90 mg/508 μmol sulforaphane and 180 mg/411 μmol glucoraphanin or methylcellulose were administered daily for up to 1 year. Twenty-nine patients were included in the treatment group and 11 patients were in the placebo group; these patients were followed for up to 1 year. The patient characteristics, overall survival and feasibility were assessed. Compared to those of the placebo group, the mean death rate was lower in the treatment group during the first 6 months after intake (day 30: 0%/18%, day 90: 0%/25%, and day 180: 25%/43%), and Kaplan-Meier analysis revealed a higher survival rate. There was a high drop-out rate (72% in the treatment group and 55% in the placebo group) after 1 year. We concluded from the Karnofsky index that the broccoli sprouts did not impact patient's self-care and overall abilities severely. The intake of 15 capsules daily was difficult for some patients, and the broccoli sprouts sometimes increased digestive problems, nausea and emesis. We did not obtain statistically significant results (p = 0.291 for the endpoint at day 180), but the knowledge about the feasibility is the basis for the development of new sulforaphane drugs.",2020,There was a high drop-out rate (72% in the treatment group and 55% in the placebo group) after 1 year.,"['40 patients with palliative chemotherapy', 'Twenty-nine patients were included in the treatment group and 11 patients were in the', 'patients with advanced pancreatic cancer']","['Broccoli sprout supplementation', 'pulverized broccoli sprouts containing 90\xa0mg/508\xa0μmol sulforaphane and 180\xa0mg/411\xa0μmol glucoraphanin', 'Broccoli sulforaphane', 'placebo']","['mean death rate', 'digestive problems, nausea and emesis', 'survival rate', 'overall survival and feasibility']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1285530', 'cui_str': 'Palliative'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0450351', 'cui_str': '29 (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0346647', 'cui_str': 'Cancer of Pancreas'}]","[{'cui': 'C0330499', 'cui_str': 'Broccoli'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0163159', 'cui_str': '4-methylsulphinylbutyl glucosinolate'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0768176', 'cui_str': 'beta-D-glucopyranose, 1-thio-, 1-(5-(methylsulfinyl)-N-(sulfooxy)pentanimidate)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",40.0,0.469328,There was a high drop-out rate (72% in the treatment group and 55% in the placebo group) after 1 year.,"[{'ForeName': 'Vladimir J', 'Initials': 'VJ', 'LastName': 'Lozanovski', 'Affiliation': 'Department of General, Visceral, and Transplant Surgery, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany.'}, {'ForeName': 'Georgios', 'Initials': 'G', 'LastName': 'Polychronidis', 'Affiliation': 'Department of General, Visceral, and Transplant Surgery, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Gross', 'Affiliation': 'Department of General, Visceral, and Transplant Surgery, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany.'}, {'ForeName': 'Negin', 'Initials': 'N', 'LastName': 'Gharabaghi', 'Affiliation': 'Department of General, Visceral, and Transplant Surgery, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany.'}, {'ForeName': 'Arianeb', 'Initials': 'A', 'LastName': 'Mehrabi', 'Affiliation': 'Department of General, Visceral, and Transplant Surgery, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany.'}, {'ForeName': 'Thilo', 'Initials': 'T', 'LastName': 'Hackert', 'Affiliation': 'Department of General, Visceral, and Transplant Surgery, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Schemmer', 'Affiliation': 'Division of Transplant Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Herr', 'Affiliation': 'Department of General, Visceral, and Transplant Surgery, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany. i.herr@uni-heidelberg.de.'}]",Investigational new drugs,['10.1007/s10637-019-00826-z'] 672,31004378,Effects of acute nitric oxide precursor intake on peripheral and central fatigue during knee extensions in healthy men.,"NEW FINDINGS What is the central question of this study? What is the effect of acute NO precursor intake on vascular function, muscle and cerebral oxygenation and peripheral and central neuromuscular fatigue during knee-extension exercise? What is the main finding and its importance? Acute NO precursor ingestion increases the plasma concentrations of NO precursors (nitrate, arginine and citrulline) and enhances post-ischaemic vasodilatation, but has no significant effect on muscle and cerebral oxygenation, peripheral and central mechanisms of neuromuscular fatigue and, consequently, does not improve exercise performance. ABSTRACT Nitric oxide (NO) plays an important role in matching blood flow to oxygen demand in the brain and contracting muscles during exercise. Previous studies have shown that increasing NO bioavailability can improve muscle function. The aim of this study was to assess the effect of acute NO precursor intake on muscle and cerebral oxygenation and on peripheral and central neuromuscular fatigue during exercise. In four experimental sessions, 15 healthy men performed a thigh ischaemia-reperfusion test followed by submaximal isometric knee extensions (5 s on-4 s off; 45% of maximal voluntary contraction) until task failure. In each session, subjects drank a nitrate-rich beetroot juice containing 520 mg nitrate (N), N and citrulline (6 g; N+C), N and arginine (6 g; N+A) or a placebo (PLA). Prefrontal cortex and quadriceps near-infrared spectroscopy parameters were monitored continuously. Transcranial magnetic stimulation and femoral nerve electrical stimulation were used to assess central and peripheral determinants of fatigue. The post-ischaemic increase in thigh blood total haemoglobin concentration was larger in N (10.1 ± 3.7 mmol) and N+C (10.9 ± 3.3 mmol) compared with PLA (8.2 ± 2.7 mmol; P < 0.05). Nitric oxide precursors had no significant effect on muscle and cerebral oxygenation or on peripheral and central mechanisms of neuromuscular fatigue during exercise. The total number of knee extensions did not differ between sessions (N, 71.9 ± 33.2; N+A, 73.3 ± 39.4; N+C, 74.6 ± 34.0; PLA, 71.8 ± 39.9; P > 0.05). In contrast to the post-ischaemic hyperaemic response, NO bioavailability in healthy subjects might not be the limiting factor for tissue perfusion and oxygenation during submaximal knee extensions to task failure.",2019,Nitric oxide precursors had no significant effect on muscle and cerebral oxygenation or on peripheral and central mechanisms of neuromuscular fatigue during exercise.,"['healthy men', '15 healthy men performed a', 'healthy subjects']","['Transcranial magnetic stimulation and femoral nerve electrical stimulation', 'acute nitric oxide precursor intake', 'thigh ischaemia-reperfusion test followed by submaximal isometric knee extensions (5\xa0s on-4', 'nitrate-rich beetroot juice containing 520\xa0mg nitrate (N), N and citrulline (6', 'N and arginine (6\xa0g; N+A', 'placebo (PLA']","['muscle and cerebral oxygenation and on peripheral and central neuromuscular fatigue', 'muscle and cerebral oxygenation or on peripheral and central mechanisms of neuromuscular fatigue', 'peripheral and central fatigue', 'muscle and cerebral oxygenation, peripheral and central mechanisms of neuromuscular fatigue', 'total number of knee extensions', 'plasma concentrations of NO precursors (nitrate, arginine and citrulline) and enhances post-ischaemic vasodilatation', 'vascular function, muscle and cerebral oxygenation and peripheral and central neuromuscular fatigue', 'thigh blood total haemoglobin concentration']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation (procedure)'}, {'cui': 'C0015808', 'cui_str': 'Femoral Nerve'}, {'cui': 'C0013786', 'cui_str': 'Electrical Stimulation'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0039866', 'cui_str': 'Thigh'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0035124', 'cui_str': 'Reperfusion'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0028125', 'cui_str': 'Nitrates'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C0453112', 'cui_str': 'Beetroot (substance)'}, {'cui': 'C1268568', 'cui_str': 'Juice'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C4517803', 'cui_str': '520 (qualifier value)'}, {'cui': 'C0008864', 'cui_str': 'Citrulline'}, {'cui': 'C0968133', 'cui_str': 'alpha-(trifluoromethyl)arginine'}, {'cui': 'C1722869', 'cui_str': '(glycyl-prolyl-glycyl-glycyl-alanyl)6-glycine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0234116', 'cui_str': 'Neuromuscular fatigue, function (observable entity)'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0028125', 'cui_str': 'Nitrates'}, {'cui': 'C0968133', 'cui_str': 'alpha-(trifluoromethyl)arginine'}, {'cui': 'C0008864', 'cui_str': 'Citrulline'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C0042401', 'cui_str': 'Vasorelaxation'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0039866', 'cui_str': 'Thigh'}, {'cui': 'C0005768'}, {'cui': 'C1318517', 'cui_str': 'Hemoglobin concentration, dipstick - finding'}]",15.0,0.0342976,Nitric oxide precursors had no significant effect on muscle and cerebral oxygenation or on peripheral and central mechanisms of neuromuscular fatigue during exercise.,"[{'ForeName': 'Thibault', 'Initials': 'T', 'LastName': 'Le Roux-Mallouf', 'Affiliation': 'Laboratoire HP2 (U1042 INSERM), Université, Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Laurent', 'Affiliation': 'Laboratoire HP2 (U1042 INSERM), Université, Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Dimitri', 'Initials': 'D', 'LastName': 'Besset', 'Affiliation': 'Laboratoire HP2 (U1042 INSERM), Université, Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Marillier', 'Affiliation': 'Laboratoire HP2 (U1042 INSERM), Université, Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Larribaut', 'Affiliation': 'Laboratoire HP2 (U1042 INSERM), Université, Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Elise', 'Initials': 'E', 'LastName': 'Belaidi', 'Affiliation': 'Laboratoire HP2 (U1042 INSERM), Université, Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Christelle', 'Initials': 'C', 'LastName': 'Corne', 'Affiliation': 'Inherited Metabolic Disease Laboratory, Department of Biochemistry, Molecular and Environmental Toxicology Biology, Biology and Pathology Institute, Hôpital Michallon, Grenoble, France.'}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Doutreleau', 'Affiliation': 'Laboratoire HP2 (U1042 INSERM), Université, Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Verges', 'Affiliation': 'Laboratoire HP2 (U1042 INSERM), Université, Grenoble Alpes, Grenoble, France.'}]",Experimental physiology,['10.1113/EP087493'] 673,31280941,Comparison between new modified external rotation method and external rotation method for reduction of ASD.,"INTRODUCTION Dislocation of the shoulder joint is common and is mainly anterior. Several reduction methods have been described and the external reduction method (ERM) is one of the newest. We modified the ERM by making some additions in hopes to develop a less painful, quick and simple method. The aim of this study was to compare the new modified external rotation reduction method (MERM) with ERM in acute anterior shoulder dislocations (ASD). METHODS A total of 62 patients with ASD were classified randomly into 2 groups. The reduction was performed with MERM in one group and with ERM in the other group and the results were compared. Patients' pain scores, reduction time, success rate of the reduction methods, age, sex, dislocation side, dislocation time, previous dislocations history, injury mechanism, any complications, reduction time and neurovascular examination were collected. Parametric and nonparametric analyses were used to compare MERM and ERM. RESULTS The study cohort consisted of 62 patients (52 males, 10 females; mean age, 35 years; age range, 18-73 years) who were randomly assigned to treatment with the MERM (n = 32) or the ERM (n = 30). There was a statistically significant difference between the two methods in terms of time, and the MERM can be applied much faster than ERM (1.34 ± 1.41 min vs 3.05 ± 1.93 min; p < 0.001). The intra-reduction VAS pain score was not significantly in patients who were treated with MERM (85.31 ± 10.39 vs. 78.33 ± 16.54; p = 0.122). CONCLUSION MERM can be an alternate method compared to the ERM for the reduction of ASD.",2020,"There was a statistically significant difference between the two methods in terms of time, and the MERM can be applied much faster than ERM (1.34 ± 1.41 min vs 3.05 ± 1.93 min; p < 0.001).","['acute anterior shoulder dislocations (ASD', '62 patients with ASD', '62 patients (52 males, 10 females; mean age, 35\u202fyears; age range, 18-73\u202fyears']","['ERM', 'new modified external rotation reduction method (MERM) with ERM', 'new modified external rotation method and external rotation method', 'MERM']","['intra-reduction VAS pain score', 'pain scores, reduction time, success rate of the reduction methods, age, sex, dislocation side, dislocation time, previous dislocations history, injury mechanism, any complications, reduction time and neurovascular examination']","[{'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0037005', 'cui_str': 'Glenohumeral Dislocation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}]","[{'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0231462', 'cui_str': 'Lateral rotation - action (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0238395', 'cui_str': 'Male Pseudohermaphroditism'}]","[{'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0012691', 'cui_str': 'Joint Dislocations'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}]",62.0,0.020717,"There was a statistically significant difference between the two methods in terms of time, and the MERM can be applied much faster than ERM (1.34 ± 1.41 min vs 3.05 ± 1.93 min; p < 0.001).","[{'ForeName': 'Mehmet', 'Initials': 'M', 'LastName': 'Akcimen', 'Affiliation': 'Health Science University Antalya Training and Research Hospital, Department of Emergency Medicine, Antalya, Turkey.'}, {'ForeName': 'Cihan', 'Initials': 'C', 'LastName': 'Bedel', 'Affiliation': 'Health Science University Antalya Training and Research Hospital, Department of Emergency Medicine, Antalya, Turkey. Electronic address: cihanbedel@hotmail.com.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2019.07.001'] 674,31219721,Front-of-Pack Labeling and the Nutritional Quality of Students' Food Purchases: A 3-Arm Randomized Controlled Trial.,"Objectives. To assess the effects of the Nutri-Score label (relative to the Reference Intakes label or no label) on the nutritional quality of students' food purchases. Methods. A 3-arm randomized controlled trial was conducted in France in 2017; 2907 participants were randomized into 1 of the 3 study arms (Nutri-Score, Reference Intakes, no label) and invited to purchase groceries from an experimental Web-based supermarket. The main outcome was the overall nutritional quality of purchases, measured according to a modified version of the Food Standards Agency Nutrient Profiling System (FSAm-NPS/HCSP) score. Results. The mean (±SD) FSAm-NPS/HCSP score was lower in the Nutri-Score group (2.02 ±3.56) than in the Reference Intakes group (2.69 ±3.44), reflecting higher nutritional quality; however, there was no significant difference between the Nutri-Score and no-label (2.45 ±3.28) groups or between the Reference Intakes and no-label groups. Shopping cart content was lower in calories and saturated fatty acids and higher in fruits and vegetables in the Nutri-Score arm than in the other arms. Conclusions. The Nutri-Score label appeared to improve the nutritional composition of students' food purchases relative to the Reference Intakes label or no label.",2019,Shopping cart content was lower in calories and saturated fatty acids and higher in fruits and vegetables in the Nutri-Score arm than in the other arms. ,"['France in 2017; 2907 participants', ""students' food purchases"", ""Students' Food Purchases""]",['Nutri-Score label (relative to the Reference Intakes label or no label'],"['mean (±SD) FSAm-NPS/HCSP score', 'overall nutritional quality of purchases, measured according to a modified version of the Food Standards Agency Nutrient Profiling System (FSAm-NPS/HCSP) score']","[{'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0016452', 'cui_str': 'Food'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3875154', 'cui_str': 'Relative to (attribute)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C3489446', 'cui_str': 'Nutritional Quality'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}]",2907.0,0.0696289,Shopping cart content was lower in calories and saturated fatty acids and higher in fruits and vegetables in the Nutri-Score arm than in the other arms. ,"[{'ForeName': 'Manon', 'Initials': 'M', 'LastName': 'Egnell', 'Affiliation': ""Manon Egnell, Sandrine Péneau, Mathilde Touvier, Pilar Galan, Camille Buscail, Serge Hercberg, Emmanuelle Kesse-Guyot, and Chantal Julia are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Nutritional Epidemiology Research Team, Paris 13 University, Bobigny, France. Isabelle Boutron, Raphaël Porcher, and Philippe Ravaud are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Centre d'épidémiologie clinique, Hôtel-Dieu Hospital, Paris, France. Pauline Ducrot is with Santé Publique France, National Public Health Agency, Saint-Maurice, France.""}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Boutron', 'Affiliation': ""Manon Egnell, Sandrine Péneau, Mathilde Touvier, Pilar Galan, Camille Buscail, Serge Hercberg, Emmanuelle Kesse-Guyot, and Chantal Julia are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Nutritional Epidemiology Research Team, Paris 13 University, Bobigny, France. Isabelle Boutron, Raphaël Porcher, and Philippe Ravaud are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Centre d'épidémiologie clinique, Hôtel-Dieu Hospital, Paris, France. Pauline Ducrot is with Santé Publique France, National Public Health Agency, Saint-Maurice, France.""}, {'ForeName': 'Sandrine', 'Initials': 'S', 'LastName': 'Péneau', 'Affiliation': ""Manon Egnell, Sandrine Péneau, Mathilde Touvier, Pilar Galan, Camille Buscail, Serge Hercberg, Emmanuelle Kesse-Guyot, and Chantal Julia are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Nutritional Epidemiology Research Team, Paris 13 University, Bobigny, France. Isabelle Boutron, Raphaël Porcher, and Philippe Ravaud are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Centre d'épidémiologie clinique, Hôtel-Dieu Hospital, Paris, France. Pauline Ducrot is with Santé Publique France, National Public Health Agency, Saint-Maurice, France.""}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Ducrot', 'Affiliation': ""Manon Egnell, Sandrine Péneau, Mathilde Touvier, Pilar Galan, Camille Buscail, Serge Hercberg, Emmanuelle Kesse-Guyot, and Chantal Julia are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Nutritional Epidemiology Research Team, Paris 13 University, Bobigny, France. Isabelle Boutron, Raphaël Porcher, and Philippe Ravaud are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Centre d'épidémiologie clinique, Hôtel-Dieu Hospital, Paris, France. Pauline Ducrot is with Santé Publique France, National Public Health Agency, Saint-Maurice, France.""}, {'ForeName': 'Mathilde', 'Initials': 'M', 'LastName': 'Touvier', 'Affiliation': ""Manon Egnell, Sandrine Péneau, Mathilde Touvier, Pilar Galan, Camille Buscail, Serge Hercberg, Emmanuelle Kesse-Guyot, and Chantal Julia are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Nutritional Epidemiology Research Team, Paris 13 University, Bobigny, France. Isabelle Boutron, Raphaël Porcher, and Philippe Ravaud are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Centre d'épidémiologie clinique, Hôtel-Dieu Hospital, Paris, France. Pauline Ducrot is with Santé Publique France, National Public Health Agency, Saint-Maurice, France.""}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Galan', 'Affiliation': ""Manon Egnell, Sandrine Péneau, Mathilde Touvier, Pilar Galan, Camille Buscail, Serge Hercberg, Emmanuelle Kesse-Guyot, and Chantal Julia are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Nutritional Epidemiology Research Team, Paris 13 University, Bobigny, France. Isabelle Boutron, Raphaël Porcher, and Philippe Ravaud are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Centre d'épidémiologie clinique, Hôtel-Dieu Hospital, Paris, France. Pauline Ducrot is with Santé Publique France, National Public Health Agency, Saint-Maurice, France.""}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Buscail', 'Affiliation': ""Manon Egnell, Sandrine Péneau, Mathilde Touvier, Pilar Galan, Camille Buscail, Serge Hercberg, Emmanuelle Kesse-Guyot, and Chantal Julia are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Nutritional Epidemiology Research Team, Paris 13 University, Bobigny, France. Isabelle Boutron, Raphaël Porcher, and Philippe Ravaud are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Centre d'épidémiologie clinique, Hôtel-Dieu Hospital, Paris, France. Pauline Ducrot is with Santé Publique France, National Public Health Agency, Saint-Maurice, France.""}, {'ForeName': 'Raphaël', 'Initials': 'R', 'LastName': 'Porcher', 'Affiliation': ""Manon Egnell, Sandrine Péneau, Mathilde Touvier, Pilar Galan, Camille Buscail, Serge Hercberg, Emmanuelle Kesse-Guyot, and Chantal Julia are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Nutritional Epidemiology Research Team, Paris 13 University, Bobigny, France. Isabelle Boutron, Raphaël Porcher, and Philippe Ravaud are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Centre d'épidémiologie clinique, Hôtel-Dieu Hospital, Paris, France. Pauline Ducrot is with Santé Publique France, National Public Health Agency, Saint-Maurice, France.""}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Ravaud', 'Affiliation': ""Manon Egnell, Sandrine Péneau, Mathilde Touvier, Pilar Galan, Camille Buscail, Serge Hercberg, Emmanuelle Kesse-Guyot, and Chantal Julia are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Nutritional Epidemiology Research Team, Paris 13 University, Bobigny, France. Isabelle Boutron, Raphaël Porcher, and Philippe Ravaud are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Centre d'épidémiologie clinique, Hôtel-Dieu Hospital, Paris, France. Pauline Ducrot is with Santé Publique France, National Public Health Agency, Saint-Maurice, France.""}, {'ForeName': 'Serge', 'Initials': 'S', 'LastName': 'Hercberg', 'Affiliation': ""Manon Egnell, Sandrine Péneau, Mathilde Touvier, Pilar Galan, Camille Buscail, Serge Hercberg, Emmanuelle Kesse-Guyot, and Chantal Julia are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Nutritional Epidemiology Research Team, Paris 13 University, Bobigny, France. Isabelle Boutron, Raphaël Porcher, and Philippe Ravaud are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Centre d'épidémiologie clinique, Hôtel-Dieu Hospital, Paris, France. Pauline Ducrot is with Santé Publique France, National Public Health Agency, Saint-Maurice, France.""}, {'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Kesse-Guyot', 'Affiliation': ""Manon Egnell, Sandrine Péneau, Mathilde Touvier, Pilar Galan, Camille Buscail, Serge Hercberg, Emmanuelle Kesse-Guyot, and Chantal Julia are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Nutritional Epidemiology Research Team, Paris 13 University, Bobigny, France. Isabelle Boutron, Raphaël Porcher, and Philippe Ravaud are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Centre d'épidémiologie clinique, Hôtel-Dieu Hospital, Paris, France. Pauline Ducrot is with Santé Publique France, National Public Health Agency, Saint-Maurice, France.""}, {'ForeName': 'Chantal', 'Initials': 'C', 'LastName': 'Julia', 'Affiliation': ""Manon Egnell, Sandrine Péneau, Mathilde Touvier, Pilar Galan, Camille Buscail, Serge Hercberg, Emmanuelle Kesse-Guyot, and Chantal Julia are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Nutritional Epidemiology Research Team, Paris 13 University, Bobigny, France. Isabelle Boutron, Raphaël Porcher, and Philippe Ravaud are with the Sorbonne Paris Cité Epidemiology and Statistics Research Center and the Centre d'épidémiologie clinique, Hôtel-Dieu Hospital, Paris, France. Pauline Ducrot is with Santé Publique France, National Public Health Agency, Saint-Maurice, France.""}]",American journal of public health,['10.2105/AJPH.2019.305115'] 675,32409838,Study on the prevention of infection in terminal cancer patients applying epidural analgesia by adding cefazolin to anesthetics: a randomized controlled trial.,"OBJECTIVE To observe the antibacterial effect of adding cefazolin into anesthetics in patients with terminal cancer undergoing long-term epidural analgesia. METHODS Patients undergoing epidural analgesia with terminal cancer were randomly divided into two groups: the conventional drug group (group C) and the cefazolin group (group G). Both groups were given levobupivacaine and morphine, while cefazolin was added to group G. The mean arterial pressure (MAP), heart rate (HR), respiratory rates (R), visual analogue scale (VAS) scores, satisfaction and complications of patients in the two groups were observed. 3 ml of the used analgesic was taken for bacterial culture when replacing the new analgesic case. RESULTS HR, MAP, R, VAS scores, dosages of morphine, satisfaction of the analgesic and the complications were not significantly different between the two groups (P > 0.05). The overall satisfaction of patients in group G was significantly higher than that in group C (P < 0.05). One patient's anesthetics in group C were infected with colibacillus. Four patients in group C got infected in their epidural puncture sites. There was no infection in group G (P < 0.05). CONCLUSION Adding cefazolin to local anesthetics could effectively prevent bacterial infection and ensured the safety of epidural analgesia for patients with terminal cancer.",2020,"VAS scores, dosages of morphine, satisfaction of the analgesic and the complications were not significantly different between the two groups (P > 0.05).","['terminal cancer patients applying', 'Patients undergoing epidural analgesia with terminal cancer', 'patients with terminal cancer undergoing long-term epidural analgesia', 'patients with terminal cancer']","['cefazolin to anesthetics', 'cefazolin into anesthetics', 'epidural analgesia', 'cefazolin', 'levobupivacaine and morphine, while cefazolin']","['mean arterial pressure (MAP), heart rate (HR), respiratory rates (R), visual analogue scale (VAS) scores, satisfaction and complications', 'overall satisfaction', 'VAS scores, dosages of morphine, satisfaction of the analgesic and the complications']","[{'cui': 'C0741884', 'cui_str': 'End stage cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0002769', 'cui_str': 'Epidural analgesia'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]","[{'cui': 'C0007546', 'cui_str': 'Cefazolin'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0002769', 'cui_str': 'Epidural analgesia'}, {'cui': 'C0873118', 'cui_str': 'Levobupivacaine'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]","[{'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}]",4.0,0.0318469,"VAS scores, dosages of morphine, satisfaction of the analgesic and the complications were not significantly different between the two groups (P > 0.05).","[{'ForeName': 'Pengcheng', 'Initials': 'P', 'LastName': 'Xie', 'Affiliation': 'Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong, Shanghai, China.'}, {'ForeName': 'Zhanfang', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong, Shanghai, China.'}, {'ForeName': 'Jingli', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong, Shanghai, China.'}, {'ForeName': 'Yiming', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong, Shanghai, China.'}]",Japanese journal of clinical oncology,['10.1093/jjco/hyaa060'] 676,31220806,Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.,"BACKGROUND Patients with severe asthma can present with overlapping eosinophilic and allergic phenotypes, which makes it challenging when deciding which biologic therapy is most appropriate to reduce exacerbations and help achieve asthma control. OBJECTIVE This post hoc meta-analysis evaluated the efficacy of the licensed dose of mepolizumab (100 mg administered subcutaneously [SC]) versus placebo in patients with severe eosinophilic asthma (SEA), according to omalizumab eligibility and associated allergic characteristics. METHODS Data from two Phase 3 studies (MENSA [MEA115588/NCT01691521]; MUSCA [200862/NCT02281318]) were analyzed. Patients ≥12 years of age with SEA who experienced ≥2 exacerbations in the previous year received placebo, mepolizumab 100 mg SC or 75 mg intravenously, plus standard of care (high-dose inhaled corticosteroids and other controllers), every 4 weeks. Data from patients who received ≥1 dose placebo or mepolizumab 100 mg SC were used for this analysis. The primary endpoint was the rate of clinically significant exacerbations; other outcomes included forced expiratory volume in 1 s (FEV 1 ), Asthma Control Questionnaire (ACQ-5) score and quality of life measured using St George's Respiratory Questionnaire (SGRQ). RESULTS Rate reductions in clinically significant exacerbations with mepolizumab versus placebo were similar in omalizumab eligible and ineligible patients (57% vs 55%). FEV 1 , ACQ-5 and SGRQ scores improved with mepolizumab versus placebo regardless of omalizumab eligibility, Immunoglobulin E levels, or atopic status. CONCLUSION This analysis indicated that mepolizumab 100 mg SC has clinical benefit in patients with blood eosinophil counts ≥150 cells/μL (or history of ≥300 cells/μL), regardless of allergic characteristics or omalizumab eligibility.",2019,"FEV 1 , ACQ-5 and SGRQ scores improved with mepolizumab versus placebo regardless of omalizumab eligibility, Immunoglobulin E levels, or atopic status. ","['patients with blood eosinophil counts ≥150\u202fcells/μL (or history of ≥300\u202fcells/μL), regardless of allergic characteristics or omalizumab eligibility', 'Patients ≥12 years of age with SEA who experienced ≥2 exacerbations in the previous year received', 'Patients with severe asthma', 'severe eosinophilic asthma according to omalizumab eligibility', 'patients with severe eosinophilic asthma (SEA), according to omalizumab eligibility and associated allergic characteristics']","['mepolizumab', 'placebo', 'placebo, mepolizumab 100\u202fmg SC or 75\u202fmg intravenously, plus standard of care (high-dose inhaled corticosteroids and other controllers', 'placebo or mepolizumab 100\u202fmg SC', 'mepolizumab 100\u202fmg SC', 'mepolizumab (100\u202fmg administered subcutaneously [SC]) versus placebo']","['FEV 1 , ACQ-5 and SGRQ scores', 'Immunoglobulin E levels, or atopic status', ""rate of clinically significant exacerbations; other outcomes included forced expiratory volume in 1\u202fs (FEV 1 ), Asthma Control Questionnaire (ACQ-5) score and quality of life measured using St George's Respiratory Questionnaire (SGRQ""]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil, segmented (cell)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0966225', 'cui_str': 'omalizumab'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0036493', 'cui_str': 'Sea (environment)'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0581126', 'cui_str': 'Severe asthma'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0034068', 'cui_str': 'Pulmonary Eosinophilia'}]","[{'cui': 'C0969324', 'cui_str': 'mepolizumab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4058348', 'cui_str': 'mepolizumab 100 MG [Nucala]'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C1621583', 'cui_str': 'Administer'}]","[{'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0202086', 'cui_str': 'Immunoglobulin E measurement (procedure)'}, {'cui': 'C0392707', 'cui_str': 'Atopy (disorder)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C2919686', 'cui_str': 'Asthma control questionnaire'}, {'cui': 'C0034380'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.544759,"FEV 1 , ACQ-5 and SGRQ scores improved with mepolizumab versus placebo regardless of omalizumab eligibility, Immunoglobulin E levels, or atopic status. ","[{'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Humbert', 'Affiliation': 'Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, INSERM U 999, Le Kremlin-Bicêtre, France. Electronic address: mjc.humbert@gmail.com.'}, {'ForeName': 'Frank C', 'Initials': 'FC', 'LastName': 'Albers', 'Affiliation': 'Respiratory Medical Franchise, GSK, Research Triangle Park, NC, USA. Electronic address: frank.c.albers@gsk.com.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Bratton', 'Affiliation': 'Clinical Statistics, GSK, Stockley Park, Uxbridge, Middlesex, UK. Electronic address: daniel.x.bratton@gsk.com.'}, {'ForeName': 'Steven W', 'Initials': 'SW', 'LastName': 'Yancey', 'Affiliation': 'Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA. Electronic address: steve.w.yancey@gsk.com.'}, {'ForeName': 'Mark C', 'Initials': 'MC', 'LastName': 'Liu', 'Affiliation': 'Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA. Electronic address: mcl@jhmi.edu.'}, {'ForeName': 'Soichiro', 'Initials': 'S', 'LastName': 'Hozawa', 'Affiliation': 'Hiroshima Allergy and Respiratory Clinic, Hiroshima, Japan. Electronic address: hozawa@vesta.ocn.ne.jp.'}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Llanos', 'Affiliation': 'US Medical Affairs, GSK, Research Triangle Park, NC, USA. Electronic address: jean-pierre.r.llanos-ackert@gsk.com.'}, {'ForeName': 'Namhee', 'Initials': 'N', 'LastName': 'Kwon', 'Affiliation': 'Respiratory Medical Franchise, GSK, Brentford, Middlesex, UK. Electronic address: namhee.n.kwon@gsk.com.'}]",Respiratory medicine,['10.1016/j.rmed.2019.06.004'] 677,32409485,Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures.,"OBJECTIVE To evaluate the efficacy and safety of adjunctive cenobamate 200 mg/d in patients with uncontrolled focal (partial-onset) seizures despite treatment with 1 to 3 antiepileptic drugs. METHODS In this multicenter, double-blind, placebo-controlled study, adults 18 to 65 years of age with focal seizures were randomized 1:1 (cenobamate:placebo) after an 8-week baseline period. The 12-week double-blind treatment period consisted of a 6-week titration phase and a 6-week maintenance phase. The primary outcome was percent change in seizure frequency (from baseline) per 28 days during double-blind treatment. RESULTS Two hundred twenty-two patients were randomized; 113 received cenobamate and 109 received placebo; and 90.3% and 90.8% of patients, respectively, completed double-blind treatment. Median baseline seizure frequency was 6.5 in 28 days (range 0-237). Compared to placebo, cenobamate conferred a greater median percent seizure reduction (55.6% vs 21.5%; p < 0.0001) The responder rate (≥50% reduction in seizure frequency) was 50.4% for cenobamate and 22.2% for placebo ( p < 0.0001). Focal seizures with motor component, impaired awareness, and focal to bilateral tonic-clonic seizures were significantly reduced with cenobamate vs placebo. During maintenance, 28.3% of cenobamate-treated and 8.8% of placebo-treated patients were seizure-free. Treatment-emergent adverse events reported in >10% in either group (cenobamate vs placebo) were somnolence (22.1% vs 11.9%), dizziness (22.1% vs 16.5%), headache (12.4% vs 12.8%), nausea (11.5% vs 4.6%), and fatigue (10.6% vs 6.4%). CONCLUSION Adjunctive treatment with cenobamate 200 mg/d significantly improved seizure control in adults with uncontrolled focal seizures and was well tolerated. CLINICALTRIALSGOV IDENTIFIER NCT01397968. CLASSIFICATION OF EVIDENCE This study provides Class I evidence that, for patients with uncontrolled focal seizures, adjunctive cenobamate reduces seizures.",2020,The responder rate (≥50% reduction in seizure frequency) was 50.4% for cenobamate and 22.2% for placebo ( p < 0.0001).,"['patients with uncontrolled focal seizures', 'adults 18 to 65 years of age with focal seizures', 'Two hundred twenty-two patients were randomized; 113 received', 'patients with uncontrolled focal (partial-onset) seizures despite treatment with 1 to 3 antiepileptic drugs', 'patients with uncontrolled focal seizures, adjunctive cenobamate reduces seizures']","['adjunctive cenobamate', 'cenobamate vs placebo', 'cenobamate', 'placebo']","['headache', 'Median baseline seizure frequency', 'dizziness', 'responder rate', 'fatigue', 'seizure-free', 'efficacy and safety', 'somnolence', 'Focal seizures with motor component, impaired awareness, and focal to bilateral tonic-clonic seizures', 'nausea', 'percent change in seizure frequency', 'median percent seizure reduction', 'seizure control']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003299', 'cui_str': 'ANTIEPILEPTICS'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0149775', 'cui_str': 'Fit frequency'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C1299590', 'cui_str': 'Seizure free'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0494475', 'cui_str': 'Tonic-clonic seizure'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",222.0,0.791106,The responder rate (≥50% reduction in seizure frequency) was 50.4% for cenobamate and 22.2% for placebo ( p < 0.0001).,"[{'ForeName': 'Steve S', 'Initials': 'SS', 'LastName': 'Chung', 'Affiliation': 'From the Neuroscience Institute (S.S.C), Banner-University Medical Center, University of Arizona, Phoenix; NYU Langone Comprehensive Epilepsy Center (J.A.F.), New York; NZOZ Vito-Med (J.K.), Gliwice, Poland; Johns Hopkins University School of Medicine (G.L.K.), Baltimore, MD; Adult Comprehensive Epilepsy Center (S.K.L.), Seoul National University Hospital, Republic of Korea; NZOZ Diagnomed Clinical Research (M.M.), Katowice, Poland; Comprehensive Epilepsy Care Center for Children and Adults (W.E.R.), St. Louis, MO; Thomas Jefferson University (M.R.S.), Philadelphia, PA; MedVal Scientific Information Services (S.M.), Princeton, NJ; and SK Life Science, Inc (M.K.), Paramus, NJ. steve.chung@bannerhealth.com.'}, {'ForeName': 'Jacqueline A', 'Initials': 'JA', 'LastName': 'French', 'Affiliation': 'From the Neuroscience Institute (S.S.C), Banner-University Medical Center, University of Arizona, Phoenix; NYU Langone Comprehensive Epilepsy Center (J.A.F.), New York; NZOZ Vito-Med (J.K.), Gliwice, Poland; Johns Hopkins University School of Medicine (G.L.K.), Baltimore, MD; Adult Comprehensive Epilepsy Center (S.K.L.), Seoul National University Hospital, Republic of Korea; NZOZ Diagnomed Clinical Research (M.M.), Katowice, Poland; Comprehensive Epilepsy Care Center for Children and Adults (W.E.R.), St. Louis, MO; Thomas Jefferson University (M.R.S.), Philadelphia, PA; MedVal Scientific Information Services (S.M.), Princeton, NJ; and SK Life Science, Inc (M.K.), Paramus, NJ.'}, {'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Kowalski', 'Affiliation': 'From the Neuroscience Institute (S.S.C), Banner-University Medical Center, University of Arizona, Phoenix; NYU Langone Comprehensive Epilepsy Center (J.A.F.), New York; NZOZ Vito-Med (J.K.), Gliwice, Poland; Johns Hopkins University School of Medicine (G.L.K.), Baltimore, MD; Adult Comprehensive Epilepsy Center (S.K.L.), Seoul National University Hospital, Republic of Korea; NZOZ Diagnomed Clinical Research (M.M.), Katowice, Poland; Comprehensive Epilepsy Care Center for Children and Adults (W.E.R.), St. Louis, MO; Thomas Jefferson University (M.R.S.), Philadelphia, PA; MedVal Scientific Information Services (S.M.), Princeton, NJ; and SK Life Science, Inc (M.K.), Paramus, NJ.'}, {'ForeName': 'Gregory L', 'Initials': 'GL', 'LastName': 'Krauss', 'Affiliation': 'From the Neuroscience Institute (S.S.C), Banner-University Medical Center, University of Arizona, Phoenix; NYU Langone Comprehensive Epilepsy Center (J.A.F.), New York; NZOZ Vito-Med (J.K.), Gliwice, Poland; Johns Hopkins University School of Medicine (G.L.K.), Baltimore, MD; Adult Comprehensive Epilepsy Center (S.K.L.), Seoul National University Hospital, Republic of Korea; NZOZ Diagnomed Clinical Research (M.M.), Katowice, Poland; Comprehensive Epilepsy Care Center for Children and Adults (W.E.R.), St. Louis, MO; Thomas Jefferson University (M.R.S.), Philadelphia, PA; MedVal Scientific Information Services (S.M.), Princeton, NJ; and SK Life Science, Inc (M.K.), Paramus, NJ.'}, {'ForeName': 'Sang Kun', 'Initials': 'SK', 'LastName': 'Lee', 'Affiliation': 'From the Neuroscience Institute (S.S.C), Banner-University Medical Center, University of Arizona, Phoenix; NYU Langone Comprehensive Epilepsy Center (J.A.F.), New York; NZOZ Vito-Med (J.K.), Gliwice, Poland; Johns Hopkins University School of Medicine (G.L.K.), Baltimore, MD; Adult Comprehensive Epilepsy Center (S.K.L.), Seoul National University Hospital, Republic of Korea; NZOZ Diagnomed Clinical Research (M.M.), Katowice, Poland; Comprehensive Epilepsy Care Center for Children and Adults (W.E.R.), St. Louis, MO; Thomas Jefferson University (M.R.S.), Philadelphia, PA; MedVal Scientific Information Services (S.M.), Princeton, NJ; and SK Life Science, Inc (M.K.), Paramus, NJ.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Maciejowski', 'Affiliation': 'From the Neuroscience Institute (S.S.C), Banner-University Medical Center, University of Arizona, Phoenix; NYU Langone Comprehensive Epilepsy Center (J.A.F.), New York; NZOZ Vito-Med (J.K.), Gliwice, Poland; Johns Hopkins University School of Medicine (G.L.K.), Baltimore, MD; Adult Comprehensive Epilepsy Center (S.K.L.), Seoul National University Hospital, Republic of Korea; NZOZ Diagnomed Clinical Research (M.M.), Katowice, Poland; Comprehensive Epilepsy Care Center for Children and Adults (W.E.R.), St. Louis, MO; Thomas Jefferson University (M.R.S.), Philadelphia, PA; MedVal Scientific Information Services (S.M.), Princeton, NJ; and SK Life Science, Inc (M.K.), Paramus, NJ.'}, {'ForeName': 'William E', 'Initials': 'WE', 'LastName': 'Rosenfeld', 'Affiliation': 'From the Neuroscience Institute (S.S.C), Banner-University Medical Center, University of Arizona, Phoenix; NYU Langone Comprehensive Epilepsy Center (J.A.F.), New York; NZOZ Vito-Med (J.K.), Gliwice, Poland; Johns Hopkins University School of Medicine (G.L.K.), Baltimore, MD; Adult Comprehensive Epilepsy Center (S.K.L.), Seoul National University Hospital, Republic of Korea; NZOZ Diagnomed Clinical Research (M.M.), Katowice, Poland; Comprehensive Epilepsy Care Center for Children and Adults (W.E.R.), St. Louis, MO; Thomas Jefferson University (M.R.S.), Philadelphia, PA; MedVal Scientific Information Services (S.M.), Princeton, NJ; and SK Life Science, Inc (M.K.), Paramus, NJ.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Sperling', 'Affiliation': 'From the Neuroscience Institute (S.S.C), Banner-University Medical Center, University of Arizona, Phoenix; NYU Langone Comprehensive Epilepsy Center (J.A.F.), New York; NZOZ Vito-Med (J.K.), Gliwice, Poland; Johns Hopkins University School of Medicine (G.L.K.), Baltimore, MD; Adult Comprehensive Epilepsy Center (S.K.L.), Seoul National University Hospital, Republic of Korea; NZOZ Diagnomed Clinical Research (M.M.), Katowice, Poland; Comprehensive Epilepsy Care Center for Children and Adults (W.E.R.), St. Louis, MO; Thomas Jefferson University (M.R.S.), Philadelphia, PA; MedVal Scientific Information Services (S.M.), Princeton, NJ; and SK Life Science, Inc (M.K.), Paramus, NJ.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Mizne', 'Affiliation': 'From the Neuroscience Institute (S.S.C), Banner-University Medical Center, University of Arizona, Phoenix; NYU Langone Comprehensive Epilepsy Center (J.A.F.), New York; NZOZ Vito-Med (J.K.), Gliwice, Poland; Johns Hopkins University School of Medicine (G.L.K.), Baltimore, MD; Adult Comprehensive Epilepsy Center (S.K.L.), Seoul National University Hospital, Republic of Korea; NZOZ Diagnomed Clinical Research (M.M.), Katowice, Poland; Comprehensive Epilepsy Care Center for Children and Adults (W.E.R.), St. Louis, MO; Thomas Jefferson University (M.R.S.), Philadelphia, PA; MedVal Scientific Information Services (S.M.), Princeton, NJ; and SK Life Science, Inc (M.K.), Paramus, NJ.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Kamin', 'Affiliation': 'From the Neuroscience Institute (S.S.C), Banner-University Medical Center, University of Arizona, Phoenix; NYU Langone Comprehensive Epilepsy Center (J.A.F.), New York; NZOZ Vito-Med (J.K.), Gliwice, Poland; Johns Hopkins University School of Medicine (G.L.K.), Baltimore, MD; Adult Comprehensive Epilepsy Center (S.K.L.), Seoul National University Hospital, Republic of Korea; NZOZ Diagnomed Clinical Research (M.M.), Katowice, Poland; Comprehensive Epilepsy Care Center for Children and Adults (W.E.R.), St. Louis, MO; Thomas Jefferson University (M.R.S.), Philadelphia, PA; MedVal Scientific Information Services (S.M.), Princeton, NJ; and SK Life Science, Inc (M.K.), Paramus, NJ.'}]",Neurology,['10.1212/WNL.0000000000009530'] 678,31798892,Trimethylamine N-oxide and incident atherosclerotic events in high-risk individuals with diabetes: an ACCORD trial post hoc analysis.,"Introduction Type 2 diabetes mellitus (T2D) confers high atherosclerotic cardiovascular disease (ASCVD) risk. The metabolite trimethylamine N-oxide (TMAO) derived via gut flora has been linked to excess ASCVD. Research design and methods We analyzed data, biospecimens, and major adverse cardiovascular events (MACEs) from the prospective multicenter randomized Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial to assess its value in 330 high-risk individuals with T2D without evident atherosclerotic disease at enrollment. Results Incident cardiovascular events occurred in 165 cases; 165 controls matched by age, sex, and treatment arm experienced no incident events during follow-up. Cases and controls (mean age 64.5 years) had similar mean glycated hemoglobin (HbA1c) (8.2%) and mean 10-year ASCVD risk (23.5%); groups also had similar use of statins and antihypertensive medications at baseline and follow-up. Baseline plasma TMAO levels did not differ between groups after adjusting for ASCVD risk score, HbA1c, and estimated glomerular filtration rate, nor did TMAO distinguish patients suffering incident MACE from those who remained event-free. Conclusions TMAO's prognostic value for incident ASCVD events may be blunted when applied to individuals with T2D with poor glycemic control and high baseline ASCVD risk. These results behoove further translational investigations of unique mechanisms of ASCVD risk in T2D.",2019,"Baseline plasma TMAO levels did not differ between groups after adjusting for ASCVD risk score, HbA1c, and estimated glomerular filtration rate, nor did TMAO distinguish patients suffering incident MACE from those who remained event-free. ","['Introduction\n\n\nType 2 diabetes mellitus (T2D) confers high atherosclerotic cardiovascular disease (ASCVD) risk', 'high-risk individuals with diabetes', 'individuals with T2D with poor glycemic control and high baseline ASCVD risk', '330 high-risk individuals with T2D without evident atherosclerotic disease at enrollment']","['Trimethylamine N-oxide', 'metabolite trimethylamine N-oxide (TMAO']","['mean glycated hemoglobin (HbA1c', 'Incident cardiovascular events', 'mean 10-year ASCVD risk', 'Baseline plasma TMAO levels']","[{'cui': 'C1293116', 'cui_str': 'Introduction'}, {'cui': 'C0011860', 'cui_str': 'Diabetes Mellitus, Type 2'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0342299', 'cui_str': 'Poor glycemic control (disorder)'}, {'cui': 'C4517719', 'cui_str': '330 (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0077194', 'cui_str': 'trimethylammonium oxide'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0077194', 'cui_str': 'trimethylammonium oxide'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",330.0,0.0210106,"Baseline plasma TMAO levels did not differ between groups after adjusting for ASCVD risk score, HbA1c, and estimated glomerular filtration rate, nor did TMAO distinguish patients suffering incident MACE from those who remained event-free. ","[{'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Cardona', 'Affiliation': 'Department of Internal Medicine, Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': ""O'Brien"", 'Affiliation': 'Davis Heart and Lung Research Institute, Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Matthew C', 'Initials': 'MC', 'LastName': 'Bernier', 'Affiliation': 'Campus Chemical Instrument Center, Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Arpad', 'Initials': 'A', 'LastName': 'Somogyi', 'Affiliation': 'Campus Chemical Instrument Center, Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Vicki H', 'Initials': 'VH', 'LastName': 'Wysocki', 'Affiliation': 'Campus Chemical Instrument Center, Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Smart', 'Affiliation': 'Davis Heart and Lung Research Institute, Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'He', 'Affiliation': 'Department of Epidemiology and Biostatistics, University of Maryland at College Park, College Park, Maryland, USA.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Ambrosio', 'Affiliation': 'Division of Cardiology, University of Perugia School of Medicine and Surgery, Perugia, Italy.'}, {'ForeName': 'Willa Ann', 'Initials': 'WA', 'LastName': 'Hsueh', 'Affiliation': 'Department of Internal Medicine, Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Subha V', 'Initials': 'SV', 'LastName': 'Raman', 'Affiliation': 'Department of Internal Medicine, Ohio State University, Columbus, Ohio, USA.'}]",BMJ open diabetes research & care,['10.1136/bmjdrc-2019-000718'] 679,31222868,Effect of alcohol on the sense of agency in healthy humans.,"Even at low to moderate doses, ingestion of the widely used recreational drug alcohol (ethanol) can impact cognitive and emotional processing. Recent studies show that the sense of agency (SoA; ie, the subjective experience of voluntary control over actions) can be modulated by specific pharmacological manipulations. The SoA, as quantified by the intentional binding (IB) paradigm, is enhanced by direct or indirect dopaminergic agonists in patients with Parkinson's disease and by ketamine (an N-methyl-D-aspartate (NMDA) receptor antagonist) in healthy individuals. These findings implicate dopaminergic and glutamatergic neurotransmission in mechanisms underlying SoA. Alcohol has a complex set of actions, including disinhibition of dopaminergic neurotransmission and allosteric antagonism at NMDA receptors. Here, we tested the hypothesis that low to moderate doses of alcohol would enhance SoA, and impact impulsivity and subjective emotional state. We conducted two experiments in 59 healthy male and female social drinkers, who ingested either a placebo ""vehicle,"" or one of two doses of ethanol: 0.4 and 0.6 g/kg. In both experiments, we observed increased SoA/IB at both doses of alcohol exposure, relative to the placebo condition. We found no correlation between the effects of alcohol on IB and on impulsivity or subjective emotional state. Our findings might have implications for social and legal responsibility related to alcohol use, particularly in states prior to overt intoxication. Further studies are necessary to investigate the effects of alcohol and other addictive substances on the SoA.",2020,We found no correlation between the effects of alcohol on IB and on impulsivity or subjective emotional state.,"['healthy humans', ""patients with Parkinson's disease and by ketamine (an N-methyl-D-aspartate (NMDA) receptor antagonist) in healthy individuals"", '59 healthy male and female social drinkers, who ingested either a placebo ""vehicle,"" or one of two doses of ethanol: 0.4 and 0.6 g/kg']",['alcohol'],"['IB and on impulsivity or subjective emotional state', 'enhance SoA, and impact impulsivity and subjective emotional state']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C4521484', 'cui_str': 'N-methyl-D-aspartate receptor antagonist (disposition)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0337676', 'cui_str': 'Social drinker (finding)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle (substance)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0202304', 'cui_str': 'Alcohol measurement (procedure)'}, {'cui': 'C4517457', 'cui_str': 'Zero point four'}, {'cui': 'C4068883', 'cui_str': 'Zero point six'}, {'cui': 'C1300563', 'cui_str': 'ug/mg'}]","[{'cui': 'C0001975', 'cui_str': 'Alcohols'}]","[{'cui': 'C0021125', 'cui_str': 'Impulsivity'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0684322', 'cui_str': 'Emotional state finding'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}]",59.0,0.0145121,We found no correlation between the effects of alcohol on IB and on impulsivity or subjective emotional state.,"[{'ForeName': 'Silvana', 'Initials': 'S', 'LastName': 'De Pirro', 'Affiliation': 'Sussex Addiction Research and Intervention Centre (SARIC), School of Psychology, University of Sussex, Brighton, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Lush', 'Affiliation': 'Sussex Addiction Research and Intervention Centre (SARIC), School of Psychology, University of Sussex, Brighton, UK.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Parkinson', 'Affiliation': 'Sackler Centre for Consciousness Science, University of Sussex, Brighton, UK.'}, {'ForeName': 'Theodora', 'Initials': 'T', 'LastName': 'Duka', 'Affiliation': 'Sussex Addiction Research and Intervention Centre (SARIC), School of Psychology, University of Sussex, Brighton, UK.'}, {'ForeName': 'Hugo D', 'Initials': 'HD', 'LastName': 'Critchley', 'Affiliation': 'Sussex Addiction Research and Intervention Centre (SARIC), School of Psychology, University of Sussex, Brighton, UK.'}, {'ForeName': 'Aldo', 'Initials': 'A', 'LastName': 'Badiani', 'Affiliation': 'Sussex Addiction Research and Intervention Centre (SARIC), School of Psychology, University of Sussex, Brighton, UK.'}]",Addiction biology,['10.1111/adb.12796'] 680,20697842,Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib.,"A 70-year-old man with metastatic renal cell carcinoma developed progressive liver metastases after 8 weeks of treatment with the multitargeted tyrosine kinase inhibitor (TKI) sunitinib. He then participated in the phase III placebo-controlled clinical trial of the oral mammalian target of rapamycin (mTOR) inhibitor everolimus, initially randomized to placebo (but had disease progression after 3 months) and crossed over to everolimus at time of unblinding. The patient had stable disease after 8 weeks (two cycles) of everolimus that was maintained until 28 months of therapy, at which time the patient had achieved a partial response. This case illustrates the potential for patients with metastatic renal cell carcinoma, a malignancy with historically poor prognosis, to derive long-term benefit from everolimus when used in a manner consistent with its approved indication (after TKI therapy with sunitinib or sorafenib).",2011,A 70-year-old man with metastatic renal cell carcinoma developed progressive liver metastases after 8 weeks of treatment with the multitargeted tyrosine kinase inhibitor (TKI) sunitinib.,"['patients with metastatic renal cell carcinoma, a malignancy with historically poor prognosis', 'A 70-year-old man with metastatic renal cell carcinoma', 'metastatic renal cell carcinoma refractory to sunitinib']","['everolimus', 'placebo', 'rapamycin (mTOR) inhibitor everolimus', 'sunitinib or sorafenib', 'multitargeted tyrosine kinase inhibitor (TKI) sunitinib']","['partial response', 'progressive liver metastases']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0278678', 'cui_str': 'Metastatic renal cell carcinoma'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0278252', 'cui_str': 'Prognosis bad (finding)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C1176020', 'cui_str': 'sunitinib'}]","[{'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0072980', 'cui_str': 'Sirolimus'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C1176020', 'cui_str': 'sunitinib'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}, {'cui': 'C0033681', 'cui_str': 'Tyrosylprotein Kinase'}]","[{'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}]",,0.0572666,A 70-year-old man with metastatic renal cell carcinoma developed progressive liver metastases after 8 weeks of treatment with the multitargeted tyrosine kinase inhibitor (TKI) sunitinib.,"[{'ForeName': 'Ana M', 'Initials': 'AM', 'LastName': 'Molina', 'Affiliation': 'Genitourinary Service, Division of Medical Oncology and the Department of Medical Imaging, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Michelle S', 'Initials': 'MS', 'LastName': 'Ginsberg', 'Affiliation': ''}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Motzer', 'Affiliation': ''}]","Medical oncology (Northwood, London, England)",['10.1007/s12032-010-9640-y'] 681,31240842,"A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior.","Preclinical data indicate that selective kappa opioid receptor antagonists reduce nicotine self-administration and withdrawal symptoms. The aim of the current study was to determine whether treatment with CERC-501, an orally available, potent, and selective kappa opioid receptor antagonist, could alleviate nicotine withdrawal and craving and mitigate mood alterations associated with nicotine withdrawal in humans. Healthy, adult cigarette smokers were enrolled into this randomized, multisite, double-blind, placebo-controlled, crossover study. Participants completed two 8-day treatment phases during which they received either CERC-501 (15 mg, p.o., once daily) or placebo. On the seventh day of each dosing phase, participants were admitted as inpatients for an 18-hour cigarette abstinence period followed by experimental testing. The primary outcome measures were (a) performance on the McKee Smoking Lapse test (ie, latency to smoke in exchange for money) and (b) number of cigarettes self-administered during a 60-minute ad lib smoking period. Other outcomes included measures of craving, mood, anxiety, nicotine withdrawal, and subjective effects of cigarette smoking. A total of 71 participants who smoked an average of approximately 23 cigarettes per day were enrolled, and 56 subjects completed the study. CERC-501 was well tolerated, but it did not significantly alter the latency to start smoking (CERC-501: 16.5 min vs placebo: 17.7 min) or the number of cigarettes smoked (CERC-501: 3.3 cigarettes vs placebo: 3.1 cigarettes). Compared with placebo, CERC-501 also did not affect cigarette craving, mood, anxiety, nicotine withdrawal, or subjective effects of smoking. These findings do not support a role for CERC-501 in the treatment of nicotine use disorder.",2020,"Compared with placebo, CERC-501 also did not affect cigarette craving, mood, anxiety, nicotine withdrawal, or subjective effects of smoking.","['humans', 'Healthy, adult cigarette smokers', 'participants were admitted as inpatients for an 18-hour cigarette abstinence period followed by experimental testing', '71 participants who smoked an average of approximately 23 cigarettes per day were enrolled, and 56 subjects completed the study']","['CERC-501', 'placebo', 'placebo, CERC-501', 'kappa opioid receptor antagonist, CERC-501']","['tolerated', 'a) performance on the McKee Smoking Lapse test (ie, latency to smoke in exchange for money) and (b) number of cigarettes self-administered during a 60-minute ad lib smoking period', 'latency to start smoking', 'cigarette craving, mood, anxiety, nicotine withdrawal, or subjective effects of smoking', 'craving, mood, anxiety, nicotine withdrawal, and subjective effects of cigarette smoking']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337667', 'cui_str': 'Cigarette smoker (finding)'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0332232', 'cui_str': 'Approximate (qualifier value)'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0761929', 'cui_str': 'kappa1 opioid receptors'}, {'cui': 'C0243076', 'cui_str': 'antagonists'}]","[{'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C3853333', 'cui_str': 'Sixty minutes'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0028047', 'cui_str': 'Nicotine withdrawal (disorder)'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0700219', 'cui_str': 'Cigarette Smoking'}]",71.0,0.22683,"Compared with placebo, CERC-501 also did not affect cigarette craving, mood, anxiety, nicotine withdrawal, or subjective effects of smoking.","[{'ForeName': 'Jermaine D', 'Initials': 'JD', 'LastName': 'Jones', 'Affiliation': 'Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University Vagelos College of Physicians and Surgeons, New York City, New York, USA.'}, {'ForeName': 'Shanna', 'Initials': 'S', 'LastName': 'Babalonis', 'Affiliation': 'Department of Behavioral Science, Center on Drug and Alcohol Research, University of Kentucky, Lexington, Kentucky, USA.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Marcus', 'Affiliation': 'Supernus Pharmaceuticals, Rockville, Maryland, USA.'}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Vince', 'Affiliation': 'Vince and Associates, Overland Park, Kansas, USA.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Kelsh', 'Affiliation': 'Vince and Associates, Overland Park, Kansas, USA.'}, {'ForeName': 'Michelle R', 'Initials': 'MR', 'LastName': 'Lofwall', 'Affiliation': 'Department of Behavioral Science, Center on Drug and Alcohol Research, University of Kentucky, Lexington, Kentucky, USA.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Fraser', 'Affiliation': 'Cerecor Inc, Baltimore, Maryland, USA.'}, {'ForeName': 'Blake', 'Initials': 'B', 'LastName': 'Paterson', 'Affiliation': 'NRZ Consulting, Baltimore, Maryland, USA.'}, {'ForeName': 'Suky', 'Initials': 'S', 'LastName': 'Martinez', 'Affiliation': 'Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University Vagelos College of Physicians and Surgeons, New York City, New York, USA.'}, {'ForeName': 'Diana M', 'Initials': 'DM', 'LastName': 'Martinez', 'Affiliation': 'Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University Vagelos College of Physicians and Surgeons, New York City, New York, USA.'}, {'ForeName': 'Edward V', 'Initials': 'EV', 'LastName': 'Nunes', 'Affiliation': 'Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University Vagelos College of Physicians and Surgeons, New York City, New York, USA.'}, {'ForeName': 'Sharon L', 'Initials': 'SL', 'LastName': 'Walsh', 'Affiliation': 'Department of Behavioral Science, Center on Drug and Alcohol Research, University of Kentucky, Lexington, Kentucky, USA.'}, {'ForeName': 'Sandra D', 'Initials': 'SD', 'LastName': 'Comer', 'Affiliation': 'Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University Vagelos College of Physicians and Surgeons, New York City, New York, USA.'}]",Addiction biology,['10.1111/adb.12799'] 682,32068418,Mechanisms of change in female-specific and gender-neutral cognitive behavioral therapy for women with alcohol use disorder.,"OBJECTIVE In a randomized trial for women with alcohol use disorders (AUD), the efficacy of Female-Specific Cognitive Behavioral Therapy (FS-CBT) was compared with Gender-Neutral CBT (GN-CBT; Epstein et al., 2018). The current study examined whether putative mechanisms of change differed between treatment conditions, using a novel statistical approach. Both treatments were hypothesized to work by increasing use of alcohol-related coping skills (coping) and confidence to abstain from drinking (confidence), but FS-CBT additionally targeted female-salient mechanisms: anxiety, depression, sociotropy (i.e., overinvestment in others' opinion of oneself), autonomy, and social networks supportive of abstinence. METHOD Ninety-nine women with AUD (55 in GN-CBT, 44 in FS-CBT) completed self-report assessments at baseline and 0, 6, and 12 months posttreatment. Multilevel vector autoregression estimation was used to analyze associations between putative mechanisms of change, and network models of those associations were generated using network analysis. RESULTS Across conditions, higher confidence and coping were directly associated with less drinking; autonomy was directly and indirectly associated with drinking. Additionally, network analysis indicated that although variation in depression was associated with change in other variables specifically for GN-CBT, sociotropy was associated with change specifically in FS-CBT. CONCLUSIONS Women receiving CBT-AUD changed their drinking through increased confidence to abstain and greater use of coping skills. Autonomy played a central role in behavior change across treatment conditions. Participants receiving treatment tailored to women also changed through decreases in sociotropy and increases in social support for abstinence. For women who received standard CBT, changes in depression were important to clinical improvement. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"Both treatments were hypothesized to work by increasing use of alcohol-related coping skills (coping) and confidence to abstain from drinking (confidence), but FS-CBT additionally targeted female-salient mechanisms: anxiety, depression, sociotropy (i.e., overinvestment in others' opinion of oneself), autonomy, and social networks supportive of abstinence. ","['women with alcohol use disorders (AUD', 'women with alcohol use disorder', 'Ninety-nine women with AUD (55 in GN-CBT, 44 in FS-CBT) completed self-report assessments at baseline and 0, 6, and 12 months posttreatment']",['Female-Specific Cognitive Behavioral Therapy (FS-CBT'],['social support for abstinence'],"[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001956', 'cui_str': 'Alcohol Use Disorder'}, {'cui': 'C3828813', 'cui_str': 'Ninety-nine'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]",[{'cui': 'C0037438'}],99.0,0.0294468,"Both treatments were hypothesized to work by increasing use of alcohol-related coping skills (coping) and confidence to abstain from drinking (confidence), but FS-CBT additionally targeted female-salient mechanisms: anxiety, depression, sociotropy (i.e., overinvestment in others' opinion of oneself), autonomy, and social networks supportive of abstinence. ","[{'ForeName': 'Cathryn Glanton', 'Initials': 'CG', 'LastName': 'Holzhauer', 'Affiliation': 'Division of Addiction Psychiatry, Department of Psychiatry, University of Massachusetts Medical School.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Hildebrandt', 'Affiliation': 'Department of Psychiatry, Icahn School of Medicine at Mount Sinai.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Epstein', 'Affiliation': 'Division of Addiction Psychiatry, Department of Psychiatry, University of Massachusetts Medical School.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'McCrady', 'Affiliation': 'Center on Alcoholism, Substance Abuse, and Addictions, University of New Mexico.'}, {'ForeName': 'Kevin A', 'Initials': 'KA', 'LastName': 'Hallgren', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Washington.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Cook', 'Affiliation': 'Center of Alcohol Studies, Rutgers University.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000492'] 683,31229240,Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.,"BACKGROUND Tenosynovial giant cell tumour (TGCT), a rare, locally aggressive neoplasm, overexpresses colony-stimulating factor 1 (CSF1). Surgery is standard with no approved systemic therapy. We aimed to evaluate pexidartinib, a CSF1 receptor inhibitor, in patients with TGCT to provide them with a viable systemic treatment option, especially in cases that are not amenable to surgical resection. METHODS This phase 3 randomised trial had two parts. Part one was a double-blind study in which patients with symptomatic, advanced TGCT for whom surgery was not recommended were randomly assigned via an integrated web response system (1:1) to the pexidartinib or placebo group. Individuals in the pexidartinib group received a loading dose of 1000 mg pexidartinib per day orally (400 mg morning; 600 mg evening) for the first 2 weeks, followed by 800 mg per day (400 mg twice a day) for 22 weeks. Part two was an open-label study of pexidartinib for all patients. The primary endpoint, assessed in all intention-to-treat patients, was overall response at week 25, and was centrally reviewed by RECIST, version 1.1. Safety was analysed in all patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, number NCT02371369. FINDINGS Between May 11, 2015, and Sept 30, 2016, of 174 patients assessed for eligibility, 120 patients were randomly assigned to, and received, pexidartinib (n=61) or placebo (n=59). There were 11 dropouts in the placebo group and nine in the pexidartinib group. Emergence of mixed or cholestatic hepatotoxicity caused the data monitoring committee to stop enrolment six patients short of target. The proportion of patients who achieved overall response was higher for pexidartinib than placebo at week 25 by RECIST (24 [39%] of 61 vs none of 59; absolute difference 39% [95% CI 27-53]; p<0·0001). Serious adverse events occurred in eight (13%) of 61 patients in the pexidartinib group and one (2%) of 59 patients in the placebo group. Hair colour changes (67%), fatigue (54%), aspartate aminotransferase increase (39%), nausea (38%), alanine aminotransferase increase (28%), and dysgeusia (25%) were the most frequent pexidartinib-associated adverse events. Three patients given pexidartinib had aminotransferase elevations three or more times the upper limit of normal with total bilirubin and alkaline phosphatase two or more times the upper limit of normal indicative of mixed or cholestatic hepatotoxicity, one lasting 7 months and confirmed by biopsy. INTERPRETATION Pexidartinib is the first systemic therapy to show a robust tumour response in TGCT with improved patient symptoms and functional outcomes; mixed or cholestatic hepatotoxicity is an identified risk. Pexidartinib could be considered as a potential treatment for TGCT associated with severe morbidity or functional limitations in cases not amenable to improvement with surgery. FUNDING Daiichi Sankyo.",2019,The proportion of patients who achieved overall response was higher for pexidartinib than placebo at week 25 by RECIST (24 [39%] of 61 vs none of 59; absolute difference 39% [95% CI 27-53]; p<0·0001).,"['patients with', 'Between May 11, 2015, and Sept 30, 2016, of 174 patients assessed for eligibility, 120 patients', 'patients with symptomatic, advanced TGCT for whom surgery was not recommended were randomly assigned via an integrated web response system (1:1) to the pexidartinib or', 'advanced tenosynovial giant cell tumour (ENLIVEN']","['Pexidartinib versus placebo', 'placebo', 'TGCT']","['fatigue', 'aminotransferase elevations', 'Hair colour changes', 'nausea', 'alanine aminotransferase increase', 'Emergence of mixed or cholestatic hepatotoxicity', 'aspartate aminotransferase increase', 'overall response', 'Serious adverse events', 'Safety', 'dysgeusia']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517604', 'cui_str': 'One hundred and seventy-four'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C1318543', 'cui_str': 'Giant Cell Tumor of Tendon Sheath'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0002594', 'cui_str': 'Aminotransferases'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0474378', 'cui_str': 'Hair color change (finding)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0151905', 'cui_str': 'SGPT increased'}, {'cui': 'C0235378', 'cui_str': 'Hepatotoxicity'}, {'cui': 'C0151904', 'cui_str': 'Serum glutamic-oxaloacetic transaminase increased'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0013378', 'cui_str': 'Taste, Distorted'}]",120.0,0.679653,The proportion of patients who achieved overall response was higher for pexidartinib than placebo at week 25 by RECIST (24 [39%] of 61 vs none of 59; absolute difference 39% [95% CI 27-53]; p<0·0001).,"[{'ForeName': 'William D', 'Initials': 'WD', 'LastName': 'Tap', 'Affiliation': 'Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Electronic address: tapw@mskcc.org.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Gelderblom', 'Affiliation': 'Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Emanuela', 'Initials': 'E', 'LastName': 'Palmerini', 'Affiliation': 'IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.'}, {'ForeName': 'Jayesh', 'Initials': 'J', 'LastName': 'Desai', 'Affiliation': 'Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Bauer', 'Affiliation': 'Sarcoma Center, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Jean-Yves', 'Initials': 'JY', 'LastName': 'Blay', 'Affiliation': 'Centre Léon Bérard and Université Claude Bernard, Lyon, France.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Alcindor', 'Affiliation': 'McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Ganjoo', 'Affiliation': 'Stanford University Medical Center, Stanford, CA, USA.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Martín-Broto', 'Affiliation': 'Institute of Biomedicine of Sevilla, (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain.'}, {'ForeName': 'Christopher W', 'Initials': 'CW', 'LastName': 'Ryan', 'Affiliation': 'Oregon Health and Science University, Portland, OR, USA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Thomas', 'Affiliation': ""Chris O'Brien Lifehouse, Camperdown, NSW, Australia.""}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Peterfy', 'Affiliation': 'Spire Sciences, Boca Raton, FL, USA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Healey', 'Affiliation': 'Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Michiel', 'Initials': 'M', 'LastName': 'van de Sande', 'Affiliation': 'Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Heather L', 'Initials': 'HL', 'LastName': 'Gelhorn', 'Affiliation': 'Evidera, Bethesda, MD, USA.'}, {'ForeName': 'Dale E', 'Initials': 'DE', 'LastName': 'Shuster', 'Affiliation': 'Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': 'Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Yver', 'Affiliation': 'Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.'}, {'ForeName': 'Henry H', 'Initials': 'HH', 'LastName': 'Hsu', 'Affiliation': 'Plexxikon, Berkeley, CA, USA.'}, {'ForeName': 'Paul S', 'Initials': 'PS', 'LastName': 'Lin', 'Affiliation': 'Plexxikon, Berkeley, CA, USA.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Tong-Starksen', 'Affiliation': 'Plexxikon, Berkeley, CA, USA.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Stacchiotti', 'Affiliation': 'Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Wagner', 'Affiliation': 'Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(19)30764-0'] 684,31230925,Short versus long axis ultrasound guided approach for internal jugular vein cannulations: A prospective randomized controlled trial.,"OBJECTIVES Ultrasound-guided internal jugular vein cannulation is a standard procedure performed in ICUs worldwide. According to the guidelines, the short-axis approach is recommended over the long-axis approach for IJV cannulation. Double-operator cannulation is more convenient for the said procedure. However, the guidelines favor single-operator cannulation due to limited trials. We hypothesized that double-operator long-axis cannulation will be faster and have fewer complications than double-operator short-axis cannulation. METHODS This was a prospective, randomized trial of patients who needed central venous catheterization in the intensive care unit. The eligible patients were randomized into two groups. In one group, the short-axis view by two operators was used for cannulation, and the long-axis view by 2 operators was used in the other group. The time elapsed from skin puncture to guide-wire insertion. RESULTS The central venous catheter was placed by ultrasound guidance in all 100 patients. No significant differences were observed in the patient characteristics between the two groups. The mean time of insertion was 74.2 ± 110.1 s with the short-axis approach compared with 70.3 ± 97.3 s with the long-axis approach. The frequency of complications was also significantly lower with the long-axis approach. DISCUSSION The long-axis view for IJV cannulation has similar insertion and procedure timings to the short-axis view. However, the complication rate and number of needle punctures required were less with the long-axis view than with those with the short-axis view.",2020,"However, the complication rate and number of needle punctures required were less with the long-axis view than with those with the short-axis view.",['patients who needed central venous catheterization in the intensive care unit'],"['Ultrasound-guided internal jugular vein cannulation', 'Short versus long axis ultrasound guided approach for internal jugular vein cannulations', 'double-operator long-axis cannulation', 'Double-operator cannulation']","['frequency of complications', 'mean time of insertion', 'complication rate and number of needle punctures']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0007435', 'cui_str': 'Central Catheterization'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}]","[{'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0226550', 'cui_str': 'Internal jugular vein structure'}, {'cui': 'C0917707', 'cui_str': 'Cannulation'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0522487', 'cui_str': 'Long axis (qualifier value)'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}]","[{'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0398296', 'cui_str': 'Cannulation of vascular fistula, graft or prosthetic device (procedure)'}, {'cui': 'C0033119', 'cui_str': 'Puncture wound - injury (disorder)'}]",100.0,0.0343039,"However, the complication rate and number of needle punctures required were less with the long-axis view than with those with the short-axis view.","[{'ForeName': 'Arun', 'Initials': 'A', 'LastName': 'Rath', 'Affiliation': 'IMS and SUM Hospital, Bhubaneswar, Odisha 751014, India.'}, {'ForeName': 'Shakti Bedanta', 'Initials': 'SB', 'LastName': 'Mishra', 'Affiliation': 'Department of Anaesthesiology, IMS and SUM Hospital, Bhubaneswar, Odisha 751014, India. Electronic address: shaktibedantamishra@soauniversity.ac.in.'}, {'ForeName': 'Bhabani', 'Initials': 'B', 'LastName': 'Pati', 'Affiliation': 'IMS and SUM Hospital, Bhubaneswar, Odisha 751014, India.'}, {'ForeName': 'Sanjib Kumar', 'Initials': 'SK', 'LastName': 'Dhar', 'Affiliation': 'IMS and SUM Hospital, Bhubaneswar, Odisha 751014, India.'}, {'ForeName': 'Snigdha', 'Initials': 'S', 'LastName': 'Ipsita', 'Affiliation': 'IMS and SUM Hospital, Bhubaneswar, Odisha 751014, India.'}, {'ForeName': 'Samir', 'Initials': 'S', 'LastName': 'Samal', 'Affiliation': 'IMS and SUM Hospital, Bhubaneswar, Odisha 751014, India.'}, {'ForeName': 'Afzal', 'Initials': 'A', 'LastName': 'Azim', 'Affiliation': 'SGPGI, Lucknow 226014, India.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2019.06.010'] 685,31131617,"Prebiotic effect of two grams of lactulose in healthy Japanese women: a randomised, double-blind, placebo-controlled crossover trial.","Sixty healthy Japanese women with a defaecation frequency of 2-4 times/week participated in this randomised, double-blind crossover trial. Participants received 2 g/day lactulose for 2 weeks and placebo in a random order, separated by a washout period of 3 weeks. Eight participants were excluded who did not satisfy the conditions, and therefore data from 52 were analysed. The primary outcome was defaecation frequency and the secondary outcomes were the number of defaecation days, faecal consistency, faecal volume, and the number and percentage of Bifidobacterium in faeces. The defaecation frequency (times/week) was significantly higher during lactulose (4.28±0.23) than placebo (3.83±0.23) treatment (delta (Δ) 0.45 [95% confidence interval (CI) 0.10-0.80], P= 0.013). The defaecation days (days/week) was significantly higher during lactulose (3.77±0.17) than placebo (3.47±0.17) treatment (Δ0.30 [95% CI 0.04-0.56], P= 0.024). Faecal consistency using the Bristol Stool Scale (/defaecation) was significantly higher during lactulose (3.84±0.10) than placebo (3.68±0.10) treatment (Δ0.16 [95% CI 0.00-0.31], P= 0.044). Faecal volume (/week) was significantly higher during lactulose (21.73±3.07) than placebo (17.65±3.07) treatment (Δ4.08 [95% CI 0.57-7.60], P= 0.024). The number of Bifidobacterium in faeces (log colony forming units/g faeces) was significantly higher during lactulose (9.53±0.06) than placebo (9.16±0.06) treatment (Δ0.37 [95% CI 0.23-0.49], P <0.0001). The percentage of Bifidobacterium in faeces was also significantly higher during lactulose (25.3±1.4) than placebo (18.2±1.4) treatment (Δ7.1 [95% CI 2.9-11.4], P= 0.0014). Finally, straining at defaecation (/defaecation) during lactulose (3.62±0.24) treatment was significantly lower than during placebo (3.97±0.24) treatment (Δ0.35 [95% CI -0.69 - -0.02], P= 0.037). No significant difference was observed between lactulose and placebo with regard to flatulence. Severe adverse effects did not occur. Thus, oral ingestion of 2 g/day lactulose had a prebiotic effect, increasing the number and percentage of bifidobacteria in faeces, softening the faeces, and increasing defaecation frequency, but without increasing flatulence.",2019,"Faecal volume (/week) was significantly higher during lactulose (21.73±3.07) than placebo (17.65±3.07) treatment (Δ4.08 [95% CI 0.57-7.60], P= 0.024).","['healthy Japanese women', 'Sixty healthy Japanese women with a defaecation frequency of 2-4 times/week participated', 'Eight participants were excluded who did not satisfy the conditions, and therefore data from 52 were analysed']","['lactulose', 'placebo']","['Prebiotic effect', 'Severe adverse effects', 'number and percentage of bifidobacteria in faeces, softening the faeces, and increasing defaecation frequency', 'Faecal consistency using the Bristol Stool Scale (/defaecation', 'number of defaecation days, faecal consistency, faecal volume, and the number and percentage of Bifidobacterium in faeces', 'Faecal volume (/week', 'number of Bifidobacterium in faeces', 'percentage of Bifidobacterium in faeces', 'defaecation frequency']","[{'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0456698', 'cui_str': 'times/week (qualifier value)'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0022957', 'cui_str': 'Lactulose'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C2717875', 'cui_str': 'Prebiotics'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0024524', 'cui_str': 'Malacia (morphologic abnormality)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0332529', 'cui_str': 'Consistency finding'}, {'cui': 'C0222045'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C4552197', 'cui_str': 'Faecal volume'}, {'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}]",8.0,0.636511,"Faecal volume (/week) was significantly higher during lactulose (21.73±3.07) than placebo (17.65±3.07) treatment (Δ4.08 [95% CI 0.57-7.60], P= 0.024).","[{'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Sakai', 'Affiliation': 'Food Ingredients & Technology Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 5-1-83 Higashihara, Zama, Kanagawa 252-8583, Japan.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Seki', 'Affiliation': 'Food Ingredients & Technology Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 5-1-83 Higashihara, Zama, Kanagawa 252-8583, Japan.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Hamano', 'Affiliation': 'R&D Management Department, Morinaga Milk Industry Co., Ltd., 5-1-83 Higashihara, Zama, Kanagawa 252-8583, Japan.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Ochi', 'Affiliation': 'Food Ingredients & Technology Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 5-1-83 Higashihara, Zama, Kanagawa 252-8583, Japan.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Abe', 'Affiliation': 'Food Ingredients & Technology Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 5-1-83 Higashihara, Zama, Kanagawa 252-8583, Japan.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Masuda', 'Affiliation': ""Department of Food Science and Nutrition, Faculty of Life and Environmental Sciences, Showa Women's University, 1-7 Taishidou, Setagaya-ku, Tokyo 154-8533, Japan.""}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Iino', 'Affiliation': ""Life Sciences for Living Systems, Graduate School, Showa Women's University, 1-7 Taishidou, Setagaya-ku, Tokyo 154-8533, Japan.""}]",Beneficial microbes,['10.3920/BM2018.0174'] 686,31215805,Urine citrate excretion identifies changes in acid retention as eGFR declines in patients with chronic kidney disease.,"Previous studies have shown that acid (H + ) retention in patients with chronic kidney disease (CKD) but without metabolic acidosis increases as the estimated glomerular filtration rate (eGFR) decreases over time. The present study examined whether changes in urine excretion of the pH-sensitive metabolite citrate predicted changes in H + retention over time in similar patients with CKD that were followed for 10 yr. We randomized 120 CKD2 nondiabetic, hypertension-associated nephropathy patients with plasma total CO 2 of >24 mM to receive 0.5 meq·kg body wt -1 ·day -1 NaHCO 3 ([Formula: see text]; n = 40), 0.5 meq·kg body wt -1 ·day -1 NaCl (NaCl; n = 40), or usual care (UC; n = 40). We assessed eGFR (CKD-EPI) and H + retention by comparing the observed with expected plasma total CO 2 increase 2 h after an oral NaHCO 3 bolus (0.5 meq/kg body wt). Although 10 yr versus baseline eGFR was lower for each group, 10-yr eGFR was higher ( P < 0.01) in [Formula: see text] (59.6 ± 4.8 ml·min -1 ·1.73 m -2 ) than NaCl and UC (52.1 ± 5.9 and 52.3 ± 4.1 ml·min -1 ·1.73 m -2 , respectively) groups. Less eGFR preservation was associated with higher 10-yr versus baseline H + retention in the NaCl group (26.5 ± 13.1 vs. 18.2 ± 15.3 mmol, P < 0.01) and UC group (24.8 ± 11.3 vs. 17.7 ± 10.9 mmol, P < 0.01) and with lower 10-yr versus baseline 8-h urine citrate excretion (U citrate V) for the NaCl group (162 ± 47 vs. 196 ± 52 mg, respectively, P < 0.01) and UC group (153 ± 41 vs. 186 ± 42 mg, respectively, P < 0.01). Conversely, better eGFR preservation in the [Formula: see text] group was associated with no differences in 10-yr versus baseline H + retention (14.2 ±13.5 vs. 16.1 ± 15.1 mmol, P = 1.00) or U citrate V (212 ± 45 vs. 203 ± 49 mg, respectively, P = 0.74). An overall generalized linear model for repeated measures showed that U citrate V predicted H + retention ( P < 0.01). Less eGFR preservation in patients with CKD2 without metabolic acidosis was associated with increased H + retention that was predicted by decreased U citrate V.",2019,An overall generalized linear model for repeated measures showed that U citrate V predicted H + retention (p<0.01).,"['patients with chronic kidney disease (CKD) stage 2 eGFR (60-89 ml ', '120 CKD 2 non-diabetic, hypertension-associated nephropathy patients with plasma total CO 2 (PTCO 2 ) > 24 mM to receive 0.5 mEq/kg bw/day NaHCO 3 (HCO 3 - , n=40), 0.5 mEq/kg bw/day NaCl (NaCl, n=40), or Usual Care (UC, n=40', 'patients with chronic kidney disease']",['min-1.73m-2'],"['acid (H + ) retention', 'eGFR preservation', '10-year eGFR', 'eGFR (CKD-EPI) and H + retention']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2316786', 'cui_str': 'CKD stage 2'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0022658', 'cui_str': 'Kidney Diseases'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C1300572', 'cui_str': 'mEq/kg'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0037494', 'cui_str': 'Sodium Chloride'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}]","[{'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}]","[{'cui': 'C0001128', 'cui_str': 'Acids'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0267963', 'cui_str': 'Pancreatic Insufficiency'}]",120.0,0.0296586,An overall generalized linear model for repeated measures showed that U citrate V predicted H + retention (p<0.01).,"[{'ForeName': 'Nimrit', 'Initials': 'N', 'LastName': 'Goraya', 'Affiliation': 'Baylor Scott and White Health Department of Internal Medicine, Temple, Texas.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Simoni', 'Affiliation': 'Department of Surgery, Texas Tech University Health Sciences Center, Lubbock, Texas.'}, {'ForeName': 'Lauren N', 'Initials': 'LN', 'LastName': 'Sager', 'Affiliation': 'Baylor Scott and White Health Department of Biostatistics, Temple, Texas.'}, {'ForeName': 'Abdullah', 'Initials': 'A', 'LastName': 'Mamun', 'Affiliation': 'Baylor Scott and White Health and Wellness Center, Dallas, Texas.'}, {'ForeName': 'Nicolaos E', 'Initials': 'NE', 'LastName': 'Madias', 'Affiliation': ""School of Medicine, Department of Medicine, St. Elizabeth's Medical Center and Tufts University, Boston, Massachusetts.""}, {'ForeName': 'Donald E', 'Initials': 'DE', 'LastName': 'Wesson', 'Affiliation': 'Baylor Scott and White Health Department of Internal Medicine, Dallas, Texas.'}]",American journal of physiology. Renal physiology,['10.1152/ajprenal.00044.2019'] 687,31216126,Effects of a conscious sedation dressing on pain and anxiety in pediatric burn patients.,"AIM This study examined the effects of a conscious sedation dressing on pain and anxiety in pediatric patients with burns. METHODS This was a quasi-experimental study, using a nonequivalent control group. Using convenience sampling, the participants were assigned to two groups, an experimental group (n = 10), which comprised children who received a conscious sedation dressing, and a control group (n = 13), which comprised children who received general dressing care. To minimize the risk of contamination between the two groups, the sampling was sequentially performed. RESULTS The children in the experimental group showed significantly lower levels of pain (U = 3.29, d = 1.00, P = .003) and physiological responses, as evidenced by lower systolic blood pressures, diastolic blood pressures, pulse rates, and respiratory rates than the control group (systolic blood pressures: t = 5. 05, d = 1.22, P < .001; diastolic blood pressures: t = 2.12, d = 0.93, P = .046; pulse rates: t = 2.28, d = 1.00, P = .033; and respiratory rates: t = 2.47, d = 1.09, P = .022). CONCLUSION The application of a conscious sedation dressing may alleviate pain and anxiety for pediatric burn patients.",2020,"The children in the experimental group showed significantly lower levels of pain (U = 3.29, d = 1.00, P = .003) and physiological responses, as evidenced by lower systolic blood pressures, diastolic blood pressures, pulse rates, and respiratory rates than the control group (systolic blood pressures: t = 5. 05, d = 1.22, P < .001; diastolic blood pressures: t = 2.12, d = 0.93, P = .046; pulse rates: t = 2.28, d = 1.00, P = .033; and respiratory rates: t = 2.47, d = 1.09, P = .022). ","['pediatric burn patients', 'pediatric patients with burns']","['general dressing care', 'conscious sedation dressing']","['pain and anxiety', 'physiological responses', 'systolic blood pressures, diastolic blood pressures, pulse rates, and respiratory rates', 'levels of pain']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0006434', 'cui_str': 'Burns'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C4321376', 'cui_str': 'Dressing'}, {'cui': 'C0079159', 'cui_str': 'Sedation, Moderate'}, {'cui': 'C0013119', 'cui_str': 'Dressings'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0205463', 'cui_str': 'Physiologic (qualifier value)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0232117', 'cui_str': 'Pulse Rate'}, {'cui': 'C0231832', 'cui_str': 'Respiration Rate'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",,0.0327406,"The children in the experimental group showed significantly lower levels of pain (U = 3.29, d = 1.00, P = .003) and physiological responses, as evidenced by lower systolic blood pressures, diastolic blood pressures, pulse rates, and respiratory rates than the control group (systolic blood pressures: t = 5. 05, d = 1.22, P < .001; diastolic blood pressures: t = 2.12, d = 0.93, P = .046; pulse rates: t = 2.28, d = 1.00, P = .033; and respiratory rates: t = 2.47, d = 1.09, P = .022). ","[{'ForeName': 'Jung O', 'Initials': 'JO', 'LastName': 'Yang', 'Affiliation': 'Division of Nursing, Hallym University Hangang Sacred Heart Hospital, Seoul, South Korea.'}, {'ForeName': 'Shin-Jeong', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'Department of Nursing, Hallym University, Chuncheon, South Korea.'}, {'ForeName': 'Haeryun', 'Initials': 'H', 'LastName': 'Cho', 'Affiliation': 'Department of Nursing, Wonkwang University, Iksan, South Korea.'}, {'ForeName': 'Kyungeun', 'Initials': 'K', 'LastName': 'Lee', 'Affiliation': 'Department of Beauty stylist, Yeonsung University, Anyang, South Korea.'}]",Japan journal of nursing science : JJNS,['10.1111/jjns.12273'] 688,31131616,"The effect of a probiotic blend on gastrointestinal symptoms in constipated patients: a double blind, randomised, placebo controlled 2-week trial.","Selected strains of lactobacilli and bifidobacteria are known to ameliorate constipation-related symptoms and have previously shown efficacy on digestive health. In this clinical trial, the safety and effectiveness of a probiotic blend containing lactobacilli and bifidobacteria were evaluated in adults with self-reported bloating and functional constipation. Constipation was diagnosed by the Rome III criteria. A total of 156 adults were randomised into this double-blind and placebo-controlled trial. Participants consumed the combination of Lactobacillus acidophilus NCFM (10 10 cfu), Lactobacillus paracasei Lpc-37 (2.5×10 9 cfu), Bifidobacterium animalis subsp. lactis strains Bl-04 (2.5×10 9 cfu), Bi-07 (2.5×10 9 cfu) and HN019 (10 10 cfu) (n=78), or placebo (microcrystalline cellulose) (n=78) for two weeks. After treatment the following were measured: primary outcome of bloating and secondary outcomes of colonic transit time, bowel movement frequency, stool consistency, other gastrointestinal symptoms (flatulence, abdominal pain, and burbling), constipation-related questionnaires (PAC-SYM and PAC-QoL) and product satisfaction. Faecal recovery of consumed strains was determined. The enrolled population was defined as constipated, however, the initial bloating severity was lower than in previous similar studies. No clinically significant observations related to the safety of the product were reported. Product efficacy was not shown in the primary analysis for bloating nor for the secondary efficacy analyses. The placebo functioned similarly as the probiotic product. In post-hoc analysis, a statistically significant decrease in flatulence in favour of the probiotic group was observed; day 7 (intention-to-treat (ITT): P =0.0313; per-protocol (PP): 0.0253) and on day 14 (ITT: P =0.0116; PP: P =0.0102) as measured by area under the curve (AUC) analysis. The mean AUC of all symptoms decreased in favour of the probiotic group, indicating less digestive discomfort. The study was registered at the ISRCTN registry (ISRCTN41607808).",2019,"In post-hoc analysis, a statistically significant decrease in flatulence in favour of the probiotic group was observed; day 7 (intention-to-treat (ITT): P =0.0313; per-protocol (PP): 0.0253) and on day 14 (ITT: P =0.0116; PP: P =0.0102) as measured by area under the curve (AUC) analysis.","['constipated patients', 'A total of 156 adults', 'adults with self-reported bloating and functional constipation']","['placebo (microcrystalline cellulose', 'probiotic blend containing lactobacilli and bifidobacteria', 'placebo', 'probiotic blend']","['gastrointestinal symptoms', 'bloating', 'flatulence', 'bloating and secondary outcomes of colonic transit time, bowel movement frequency, stool consistency, other gastrointestinal symptoms (flatulence, abdominal pain, and burbling), constipation-related questionnaires (PAC-SYM and PAC-QoL) and product satisfaction', 'digestive discomfort', 'mean AUC of all symptoms', 'Constipation', 'initial bloating severity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0401146', 'cui_str': 'Constipation - functional (disorder)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0669247', 'cui_str': 'microcrystalline cellulose'}, {'cui': 'C0525033', 'cui_str': 'Probiotics'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}]","[{'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C1291077', 'cui_str': 'Abdomen feels bloated'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0009368', 'cui_str': 'Colon'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0332529', 'cui_str': 'Consistency finding'}, {'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0182281', 'cui_str': 'Picture Archiving and Communication Systems'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",156.0,0.26008,"In post-hoc analysis, a statistically significant decrease in flatulence in favour of the probiotic group was observed; day 7 (intention-to-treat (ITT): P =0.0313; per-protocol (PP): 0.0253) and on day 14 (ITT: P =0.0116; PP: P =0.0102) as measured by area under the curve (AUC) analysis.","[{'ForeName': 'K', 'Initials': 'K', 'LastName': 'Airaksinen', 'Affiliation': 'DuPont Nutrition and Health, Global Health & Nutrition Science, Sokeritehtaantie 20, 02460 Kantvik, Finland.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Yeung', 'Affiliation': 'DuPont Nutrition and Health, Global Health & Nutrition Science, Sokeritehtaantie 20, 02460 Kantvik, Finland.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Lyra', 'Affiliation': 'DuPont Nutrition and Health, Global Health & Nutrition Science, Sokeritehtaantie 20, 02460 Kantvik, Finland.'}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Lahtinen', 'Affiliation': 'DuPont Nutrition and Health, Global Health & Nutrition Science, Sokeritehtaantie 20, 02460 Kantvik, Finland.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Huttunen', 'Affiliation': '4Pharma Ltd, Tykistökatu 4, 20520 Turku, Finland.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Shanahan', 'Affiliation': 'Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland.'}, {'ForeName': 'A C', 'Initials': 'AC', 'LastName': 'Ouwehand', 'Affiliation': 'DuPont Nutrition and Health, Global Health & Nutrition Science, Sokeritehtaantie 20, 02460 Kantvik, Finland.'}]",Beneficial microbes,['10.3920/BM2018.0163'] 689,30107469,Endocrine-Metabolic Response in Patients Undergoing Multiple Body Contouring Surgeries After Massive Weight Loss.,"BACKGROUND The endocrine-metabolic response to trauma is directly related to its magnitude, but little is known about the adverse effects of combined surgical procedures on morbidity. OBJECTIVES The authors sought to evaluate risk factors by measuring the endocrine-metabolic response in patients who underwent multiple body-contouring surgeries after massive weight loss. METHODS This prospective, randomized, interventional study included 46 massive weight loss patients who experienced a weight loss >30% of their body mass index (BMI) and were referred for body contouring surgery. Patients were randomly allocated to the control group (n = 10) or intervention group (n = 36), which in turn was divided into 3 subgroups (n = 12, each) according to BMI, surgical time, and scar length values. Blood samples were collected from all patients at different time points to assess biological stress markers. RESULTS Levels of IL-6 in patients in the higher ranges of BMI and operating time and with more extensive scar length were significantly higher in the immediate postoperative period compared with baseline. Concentrations of noradrenaline were significantly higher 24 hours after surgery compared with baseline only in patients in the higher range of operating time. A higher level of IL-6 at 72 hours after surgery compared with baseline was associated with more extensive scar length. Levels of other biological stress markers did not significantly differ. CONCLUSIONS The combination of surgical procedures did not significantly affect the concentrations of most biological stress markers. The variable of operating time most influenced increase in plasma concentrations of stress markers. LEVEL OF EVIDENCE: 1 ",2019,Concentrations of noradrenaline were significantly higher 24 hours after surgery compared with baseline only in patients in the higher range of operating time.,"['46 massive weight loss patients who experienced a weight loss >30% of their body mass index (BMI) and were referred for body contouring surgery', 'patients who underwent multiple body-contouring surgeries after massive weight loss', 'Patients Undergoing Multiple Body Contouring Surgeries']",[],"['concentrations of most biological stress markers', 'Blood samples', 'Concentrations of noradrenaline', 'Levels of other biological stress markers', 'level of IL-6', 'extensive scar length', 'Endocrine-Metabolic Response', 'plasma concentrations of stress markers']","[{'cui': 'C0522501', 'cui_str': 'Massive (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C2224569', 'cui_str': 'Body Lift Surgery'}]",[],"[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C2350026', 'cui_str': 'Biological Stress'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0205231', 'cui_str': 'Extensive (qualifier value)'}, {'cui': 'C0008767', 'cui_str': 'Cicatrization'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}]",46.0,0.0442077,Concentrations of noradrenaline were significantly higher 24 hours after surgery compared with baseline only in patients in the higher range of operating time.,"[{'ForeName': 'Ana Claudia', 'Initials': 'AC', 'LastName': 'Roxo', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Pedro Ernesto University Hospital, Rio de Janeiro State University (UERJ), Rio de Janeiro, Brazil.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Del Pino Roxo', 'Affiliation': 'Chief of Plastic and Reconstructive Surgery Department at Andarai Federal Hospital, Rio de Janeiro, Brazil.'}, {'ForeName': 'Ruy Garcia', 'Initials': 'RG', 'LastName': 'Marques', 'Affiliation': 'Graduate Program in Physiopathology and Surgical Sciences, Department of General Surgery, UERJ, Rio de Janeiro, Brazil.'}, {'ForeName': 'Nadia Cristina Pinheiro', 'Initials': 'NCP', 'LastName': 'Rodrigues', 'Affiliation': 'Division of Statistics, Pedro Ernesto University Hospital, UERJ, Rio de Janeiro, Brazil.'}, {'ForeName': 'Diego Vigna', 'Initials': 'DV', 'LastName': 'Carneiro', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Federal Hospital at Andaraí, Rio de Janeiro, Brazil.'}, {'ForeName': 'Francisco Mateus Dantas Carneiro', 'Initials': 'FMDC', 'LastName': 'Souto', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Federal Hospital at Andaraí, Rio de Janeiro, Brazil.'}, {'ForeName': 'Fabio Xerfan', 'Initials': 'FX', 'LastName': 'Nahas', 'Affiliation': 'Division of Plastic Surgery, Federal University of São Paulo, São Paulo, Brazil.'}]",Aesthetic surgery journal,['10.1093/asj/sjy195'] 690,31787004,Implications of the Ankle Injury Management (AIM) trial: close contact casting or surgery for older adults with an unstable ankle fracture?,"The Ankle Injury Management (AIM) trial was a pragmatic equivalence randomized controlled trial conducted at 24 hospitals in the United Kingdom that recruited 620 patients aged more than 60 years with an unstable ankle fracture. The trial compared the usual care pathway of early management with open reduction and internal fixation with initially attempting non-surgical management using close contact casting (CCC). CCC is a minimally padded cast applied by an orthopaedic surgeon after closed reduction in the operating theatre. The intervention groups had equivalent functional outcomes at six months and longer-term follow-up. However, potential barriers to using CCC as an initial form of treatment for these patients have been identified. In this report, the results of the AIM trial are summarized and the key issues are discussed in order to further the debate about the role of CCC. Evidence from the AIM trial supports surgeons considering conservative management by CCC as a treatment option for these patients. The longer-term follow-up emphasized that patients treated with CCC need careful monitoring in the weeks after its application to monitor maintenance of reduction. Cite this article: Bone Joint J 2019;101-B:1472-1475.",2019,The intervention groups had equivalent functional outcomes at six months and longer-term follow-up.,['24 hospitals in the United Kingdom that recruited 620 patients aged more than 60 years with an unstable ankle fracture'],"['usual care pathway of early management with open reduction and internal fixation with initially attempting non-surgical management using close contact casting (CCC', 'CCC']",['equivalent functional outcomes'],"[{'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom'}, {'cui': 'C4708788', 'cui_str': '620'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0443343', 'cui_str': 'Unstable status (qualifier value)'}, {'cui': 'C0159877', 'cui_str': 'Ankle Fracture'}]","[{'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C2370853', 'cui_str': 'Open reduction (procedure)'}, {'cui': 'C0016642', 'cui_str': 'Osteosynthesis, Fracture'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0587267', 'cui_str': 'Closed (qualifier value)'}, {'cui': 'C0302143', 'cui_str': 'Casts (qualifier value)'}]","[{'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}]",620.0,0.0738175,The intervention groups had equivalent functional outcomes at six months and longer-term follow-up.,"[{'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Keene', 'Affiliation': 'Kadoorie Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences and Oxford NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Willett', 'Affiliation': 'Kadoorie Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences and Oxford NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.'}]",The bone & joint journal,['10.1302/0301-620X.101B12.BJJ-2019-0171.R2'] 691,31076187,Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging.,"Pharmacological imaging of the effects of selective serotonin reuptake inhibitors (SSRI) may aid the clarification of their mechanism of action and influence treatment of highly prevalent neuropsychiatric conditions if the detected effects could be related to patient outcomes. In a randomized double-blind design, 38 healthy participants received a constant infusion of 8 mg citalopram or saline during either their first or second of two PET/MR scans. Resting-state functional MRI (fMRI) was acquired simultaneously with PET data on the binding of serotonin transporters (5-HTT) using [ 11 C]DASB. Three different approaches for modeling of pharmacological fMRI response were tested separately. These relied on the use of regressors corresponding to (1) the drug infusion paradigm, (2) time courses of citalopram plasma concentrations and (3) changes in 5-HTT binding measured in each individual, respectively. Furthermore, the replication of results of a widely used model-free analysis method was attempted which assesses the deviation of signal in discrete time bins of fMRI data acquired after start of drug infusion. Following drug challenge, average 5-HTT occupancy was 69±7% and peak citalopram plasma levels were 111.8 ± 21.1 ng/ml. None of the applied methods could detect significant differences in the pharmacological response between SSRI and placebo scans. The failed replication of SSRI effects reported in the literature despite a threefold larger sample size highlights the importance of appropriate correction for family-wise error in order to avoid spurious results in pharmacological imaging. This calls for the development of analysis methods which take regional specialization and the dynamics of brain activity into account.",2019,"Following drug challenge, average 5-HTT occupancy was 69±7% and peak citalopram plasma levels were 111.8 ± 21.1 ng/ml.",['38 healthy participants'],"['constant infusion of 8\u202fmg citalopram or saline', 'selective serotonin reuptake inhibitors (SSRI']","['pharmacological response', '5-HTT binding', 'peak citalopram plasma levels', 'average 5-HTT occupancy']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0008845', 'cui_str': 'Citalopram'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C4552594', 'cui_str': 'SSRI - Selective serotonin reuptake inhibitor'}]","[{'cui': 'C0205464', 'cui_str': 'Pharmacologic (qualifier value)'}, {'cui': 'C1145667', 'cui_str': 'Binding - action (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0008845', 'cui_str': 'Citalopram'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",38.0,0.118893,"Following drug challenge, average 5-HTT occupancy was 69±7% and peak citalopram plasma levels were 111.8 ± 21.1 ng/ml.","[{'ForeName': 'Gregor', 'Initials': 'G', 'LastName': 'Gryglewski', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Manfred', 'Initials': 'M', 'LastName': 'Klöbl', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Neydher', 'Initials': 'N', 'LastName': 'Berroterán-Infante', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Austria.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Rischka', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Balber', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Austria.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Vanicek', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Verena', 'Initials': 'V', 'LastName': 'Pichler', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Austria.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Kautzky', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Eva-Maria', 'Initials': 'EM', 'LastName': 'Klebermass', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Austria.'}, {'ForeName': 'Murray Bruce', 'Initials': 'MB', 'LastName': 'Reed', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Chrysoula', 'Initials': 'C', 'LastName': 'Vraka', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Austria.'}, {'ForeName': 'Marius', 'Initials': 'M', 'LastName': 'Hienert', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Gregory Miles', 'Initials': 'GM', 'LastName': 'James', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Leo', 'Initials': 'L', 'LastName': 'Silberbauer', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Godber Mathis', 'Initials': 'GM', 'LastName': 'Godbersen', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Jakob', 'Initials': 'J', 'LastName': 'Unterholzner', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Michenthaler', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Hartenbach', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Austria.'}, {'ForeName': 'Edda', 'Initials': 'E', 'LastName': 'Winkler-Pjrek', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Wadsak', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Austria; Center for Biomarker Research in Medicine (CBmed), Graz, Austria.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Mitterhauser', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Austria; Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Austria.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Hahn', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Hacker', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Austria.'}, {'ForeName': 'Siegfried', 'Initials': 'S', 'LastName': 'Kasper', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Rupert', 'Initials': 'R', 'LastName': 'Lanzenberger', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. Electronic address: rupert.lanzenberger@meduniwien.ac.at.'}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2019.04.001'] 692,31157556,Effects of Lactobacillus reuteri -containing lozenges on healing after surgical removal of mandibular third molars: a randomised controlled trial.,"We investigated the effect of probiotic supplements on oral wound healing, swelling, pain and discomfort after surgical removal of mandibular third molars. A second aim was to evaluate if the intervention could influence the concentrations of oxytocin in saliva. Sixty-four consecutive volunteers (18-34 years) were enrolled to a double-blind randomised placebo-controlled trial with two parallel arms. Following surgery, the patients were asked to take three lozenges per day containing two strains of Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289) or placebo for two weeks. The clinical healing and extra-oral swelling were scored two weeks post-operatively. Samples of wound exudate were cultivated for the presence of Staphylococcus aureus and β-haemolytic streptococci. Salivary oxytocin concentrations were analysed from pre- and post-surgery samples using ELISA technique. Compliance and the subjective perception of swelling, pain and discomfort were reported daily through visual analogue scales in a logbook. All patients except three completed the protocol and the postoperative course was uneventful in most cases. Minor extra-oral swellings were noted in five patients, but none required antibiotic treatment. At the 2-week follow-up, there were no significant differences in clinical wound healing index, extra-oral swelling, bacterial growth or salivary oxytocin levels between the groups. The self-reported data unveiled, however, a significantly reduced sense of swelling, in particular during the second week after surgery in the probiotic test group ( P <0.05). Likewise, significantly fewer nights with disturbed sleep and fewer days with sick-leave from work were reported among the participants in the test group ( P <0.05). No differences were found in the post-operative use of analgesics. In conclusion, we found no significant influence of probiotic supplements on objective wound healing after surgical extraction of impacted mandibular third molars. However, since the patients' perceived significant post-operative ameliorations, further studies are needed to explore the patient's value of the intervention.",2019,"At the 2-week follow-up, there were no significant differences in clinical wound healing index, extra-oral swelling, bacterial growth or salivary oxytocin levels between the groups.","['Sixty-four consecutive volunteers (18-34 years', 'after surgical removal of mandibular third molars', 'healing after surgical removal of mandibular third molars']","['probiotic supplements', 'placebo', 'Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289) or placebo', 'Lactobacillus reuteri -containing lozenges']","['objective wound healing', 'Salivary oxytocin concentrations', 'subjective perception of swelling, pain and discomfort', 'clinical wound healing index, extra-oral swelling, bacterial growth or salivary oxytocin levels', 'oral wound healing, swelling, pain and discomfort', 'clinical healing and extra-oral swelling', 'post-operative use of analgesics', 'sense of swelling']","[{'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0026369', 'cui_str': 'Tooth, Wisdom'}, {'cui': 'C0205249', 'cui_str': 'Healed (qualifier value)'}]","[{'cui': 'C0525033', 'cui_str': 'Probiotics'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0317625', 'cui_str': 'Lactobacillus reuteri'}, {'cui': 'C0015522', 'cui_str': 'Factor Eleven'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C4319836', 'cui_str': 'Lozenge'}]","[{'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0442040', 'cui_str': 'Salivary (qualifier value)'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038999', 'cui_str': 'Bulging (morphologic abnormality)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0427944', 'cui_str': 'Finding of growth of bacteria'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}]",64.0,0.219493,"At the 2-week follow-up, there were no significant differences in clinical wound healing index, extra-oral swelling, bacterial growth or salivary oxytocin levels between the groups.","[{'ForeName': 'D-Å', 'Initials': 'DÅ', 'LastName': 'Wälivaara', 'Affiliation': 'Maxillofacial Unit, Halland Hospital, 30185 Halmstad, Sweden.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Sjögren', 'Affiliation': 'Department of Clinical Microbiology, Halland Hospital, 30185 Halmstad, Sweden.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Gerasimcik', 'Affiliation': 'Division of Periodontology, Department of Dental Medicine, Karolinska Institutet, P.O. Box 4064, 141 04 Huddinge, Sweden.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Yucel-Lindberg', 'Affiliation': 'Division of Periodontology, Department of Dental Medicine, Karolinska Institutet, P.O. Box 4064, 141 04 Huddinge, Sweden.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Twetman', 'Affiliation': 'Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Nørre Allé 20, 2200 Copenhagen N, Denmark.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Abrahamsson', 'Affiliation': 'Maxillofacial Unit, Halland Hospital, 30185 Halmstad, Sweden.'}]",Beneficial microbes,['10.3920/BM2018.0168'] 693,31787454,Comparative efficacy of epidural clonidine versus epidural fentanyl for treating breakthrough pain during labor: a randomized double-blind clinical trial.,"BACKGROUND Breakthrough pain during neuraxial labor analgesia is typically alleviated with additional administration of epidural local anesthetics, with or without adjuvants. Sometimes avoiding neuraxial opioids may be warranted and clonidine is an alternative. In a randomized double-blind trial we compared the efficacy of clonidine versus fentanyl, added to bupivacaine, for the management of breakthrough pain. METHODS Term parturients (n=98) receiving bupivacaine 0.0625% with fentanyl 2 μg/mL at 12 mL/h, a patient-administered bolus of 5 mL at lockout 6-10 min and a maximum of four boluses per hour, and experiencing breakthrough pain ≥5/10, were randomized to receive a 10 mL bolus containing 12.5 mg bupivacaine and either clonidine 100 μg or fentanyl 100 μg. The primary outcome was 'success' of study drug treatment, defined as a pain score reduction ≥4/10 within 15 min of administration. Maternal hemodynamics and fetal heart rate were documented for two hours after treatment. RESULTS There was no significant difference between groups in success rates (66.0% after clonidine (n=47) vs 74.5% after fentanyl (n=51), P=0.48) or in the incidence of hypotension (systolic blood pressure ≤80% of baseline or <90 mmHg) or sedation at 15 min, with 2/51 and 1/47 subjects in the fentanyl and clonidine groups, respectively, receiving phenylephrine. CONCLUSION Epidural clonidine 100 μg was not superior to fentanyl 100 μg for decreasing pain scores within 15 min of co-administration with bupivacaine 0.125% for intrapartum breakthrough pain. The analgesic efficacy and hemodynamic side effects did not significantly differ.",2020,Epidural clonidine 100 μg was not superior to fentanyl 100 μg for decreasing pain scores within 15 min of co-administration with bupivacaine 0.125% for intrapartum breakthrough pain.,"['Term parturients (n=98) receiving', 'during labor']","['Epidural clonidine', 'epidural fentanyl', 'epidural clonidine', 'clonidine 100\u202fμg or fentanyl 100\u202fμg', 'bupivacaine 0.0625% 12\u202fmL/h with fentanyl 2\u202fμg/mL, a patient-administered bolus of 5\u202fmL at lockout 6-10\u202fmin and a maximum of four boluses per hour, and experiencing breakthrough pain ≥5/10', 'bupivacaine', 'clonidine versus fentanyl', 'clonidine']","['pain scores', 'breakthrough pain', 'success rates', ""success' of study drug treatment, defined as a pain score reduction"", 'analgesic efficacy and hemodynamic side effects', 'hypotension (systolic blood pressure', 'Maternal hemodynamics and fetal heart rate']","[{'cui': 'C0022864', 'cui_str': 'Labor, Obstetric'}]","[{'cui': 'C0009014', 'cui_str': 'Clonidine'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0439391', 'cui_str': 'mL/h'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0564385', 'cui_str': 'per hour'}, {'cui': 'C1135120', 'cui_str': 'Breakthrough Pain'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C1135120', 'cui_str': 'Breakthrough Pain'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0020649', 'cui_str': 'Blood Pressure, Low'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0018811', 'cui_str': 'Heart Rate, Fetal'}]",,0.708028,Epidural clonidine 100 μg was not superior to fentanyl 100 μg for decreasing pain scores within 15 min of co-administration with bupivacaine 0.125% for intrapartum breakthrough pain.,"[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Lee', 'Affiliation': 'Columbia University Irving Medical Center, Department of Anesthesiology, New York, NY, USA. Electronic address: al3196@cumc.columbia.edu.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Landau', 'Affiliation': 'Columbia University Irving Medical Center, Department of Anesthesiology, New York, NY, USA.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Lavin', 'Affiliation': 'Columbia University Irving Medical Center, Department of Anesthesiology, New York, NY, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Goodman', 'Affiliation': 'Columbia University Irving Medical Center, Department of Anesthesiology, New York, NY, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Menon', 'Affiliation': 'Carlow University, Department of Mathematics, Pittsburgh, PA, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Smiley', 'Affiliation': 'Columbia University Irving Medical Center, Department of Anesthesiology, New York, NY, USA.'}]",International journal of obstetric anesthesia,['10.1016/j.ijoa.2019.11.003'] 694,31781755,Efficacy of JAK inhibitors in Crohn's Disease.,"Inhibition of Janus kinases [JAKs] in Crohn's disease [CD] patients has shown conflicting results in clinical trials. Tofacitinib, a pan-JAK inhibitor, showed efficacy in ulcerative colitis [UC] and has been approved for the treatment of patients with moderate to severe UC. In contrast, studies in CD patients were disappointing and the primary end point of clinical remission could not be met in the respective phase II induction and maintenance trials. Subsequently, the clinical development of tofacitinib was discontinued in CD. In contrast, efficacy of filgotinib, a selective JAK1 inhibitor, in CD patients was demonstrated in the randomized, double-blinded, placebo-controlled phase II FITZROY study. Upadacitinib also showed promising results in a phase II trial in moderate to severe CD. Subsequently, phase III programmes in CD have been initiated for both substances, which are still ongoing. Several newer molecules of this class of orally administrated immunosuppressants are being tested in clinical programmes. The concern of side effects of systemic JAK inhibition is addressed by either exclusively intestinal action or higher selectivity [Tyk2 inhibitors]. In general, JAK inhibitors constitute a new promising class of drugs for the treatment of CD.",2020,"Tofacitinib, a pan-JAK inhibitor showed efficacy in ulcerative colitis (UC) and has been approved for the treatment of patients with moderate to severe UC.","['CD patients', ""Crohn's disease (CD) patients"", 'patients with moderate to severe UC', ""Crohn's disease"", 'patients suffering from CD']","['placebo', 'filgotinib, a selective JAK1 inhibitor', 'Tofacitinib, a pan-JAK inhibitor']",['clinical remission'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0156147', 'cui_str': 'Colitis, Granulomatous'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4310256', 'cui_str': 'filgotinib'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C2930696', 'cui_str': 'tofacitinib'}, {'cui': 'C0085999', 'cui_str': 'Genus Pan (organism)'}, {'cui': 'C3854325', 'cui_str': 'JAK Inhibitors'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}]",,0.0812242,"Tofacitinib, a pan-JAK inhibitor showed efficacy in ulcerative colitis (UC) and has been approved for the treatment of patients with moderate to severe UC.","[{'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Rogler', 'Affiliation': 'Department of Gastroenterology & Hepatology, University Hospital of Zürich, Switzerland.'}]",Journal of Crohn's & colitis,['10.1093/ecco-jcc/jjz186'] 695,31843372,Contrast sensitivity and visual acuity in subjects wearing multifocal contact lenses with high additions designed for myopia progression control.,"OBJECTIVES To assess the visual performance of multifocal contact lenses (MFCLs) with high addition powers designed for myopia control. METHODS Twenty-four non-presbyopic adults (mean age 24 years, range 18-36 years) were fitted with soft MFCLs with add powers of +2.0 D (Add2) and +4.0 D (Add4) (RELAX, SwissLens) and single vision lenses (SVCL; Add0) in a counterbalanced order. In this double-masked study, half of the participants were randomly fitted with 3 mm-distance central zone MFCLs while the other half received 4.5 mm-distance central zone MFCLs. Visual acuity was measured at distance (3.0 m) and at near (0.4 m). Central and peripheral contrast sensitivity was evaluated at distance using the Gabor patch test. The area under the logarithmic contrast sensitivity function curve (ALCSF) was calculated and compared between the groups (i.e. different additions powers used). RESULTS Near and distance visual acuities were not affected by the lenses, neither Add2 nor Add4, when compared to Add0, however, CZ3 significantly reduced distance visual acuity with Add4 when compared to CZ4.5 (-0.08 logMAR vs. for CZ3 and -0.18 logMAR for CZ4.5, p = 0.013). MFCLs impaired central ALCSF only when Add2 was used (15.99 logCS for Add2 and 16.36 logCS for SVCLs, p = 0.021). Peripheral ALCSF was statistically lower for both addition powers of the MFCLs when compared to SVCLs (12.70 for Add2 and Add4, 13.73 for SVCLs, p = 0.009). The above effects were the same for both central zones used. CONCLUSIONS MFCLs with CZ3 diameter and high add power (Add4) slightly reduced distance visual acuity when compared to CZ4.5 but no reduction in this parameter was found with medium add power (Add2). Central contrast sensitivity was impaired only by MFCLs with the lower add power (Add2). Both add powers in the MFCLs reduced peripheral contrast sensitivity to a similar extent.",2020,"Near and distance visual acuities were not affected by the lenses, neither Add2 nor Add4, when compared to Add0, however, CZ3 significantly reduced distance visual acuity with Add4 when compared to CZ4.5 (-0.08 logMAR vs. for CZ3 and -0.18 logMAR for CZ4.5, p = 0.013).","['Twenty-four non-presbyopic adults (mean age 24 years, range 18-36 years', 'subjects wearing multifocal contact lenses']","['multifocal contact lenses (MFCLs', 'soft MFCLs with add powers of +2.0 D (Add2) and +4.0 D (Add4', 'RELAX, SwissLens) and single vision lenses (SVCL', '3 mm-distance central zone MFCLs while the other half received 4.5 mm-distance central zone MFCLs']","['Central and peripheral contrast sensitivity', 'Visual acuity', 'MFCLs impaired central ALCSF', 'Peripheral ALCSF', 'Central contrast sensitivity', 'distance visual acuity', 'Contrast sensitivity and visual acuity', 'Near and distance visual acuities', 'area under the logarithmic contrast sensitivity function curve (ALCSF']","[{'cui': 'C3715070', 'cui_str': '24 (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0205292', 'cui_str': 'Multifocal (qualifier value)'}, {'cui': 'C0009836', 'cui_str': 'Contact Lenses'}]","[{'cui': 'C0205292', 'cui_str': 'Multifocal (qualifier value)'}, {'cui': 'C0009836', 'cui_str': 'Contact Lenses'}, {'cui': 'C0205358', 'cui_str': 'Soft (qualifier value)'}, {'cui': 'C1275644', 'cui_str': 'Reading add'}, {'cui': 'C0542193', 'cui_str': 'Relaxed (qualifier value)'}, {'cui': 'C1275648', 'cui_str': 'Single vision spectacles'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C3844009', 'cui_str': 'Four point five'}]","[{'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0009928', 'cui_str': 'Visual Contrast Sensitivity'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}, {'cui': 'C0429537', 'cui_str': 'Distance visual acuity (observable entity)'}, {'cui': 'C0475806', 'cui_str': 'Nr - Near'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}]",,0.109819,"Near and distance visual acuities were not affected by the lenses, neither Add2 nor Add4, when compared to Add0, however, CZ3 significantly reduced distance visual acuity with Add4 when compared to CZ4.5 (-0.08 logMAR vs. for CZ3 and -0.18 logMAR for CZ4.5, p = 0.013).","[{'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Przekoracka', 'Affiliation': 'Laboratory of Bionics and Experimental Medical Biology, Department of Bionics and Bioimpendance, Poznań University of Medical Sciences, Parkowa 2, 60-775, Poznań, Poland; Laboratory of Vision and Neuroscience, NanoBioMedical Center, Adam Mickiewicz University of Poznań, Umultowska 85, 61-614 Poznań, Poland. Electronic address: katoptical@gmail.com.'}, {'ForeName': 'Krzysztof', 'Initials': 'K', 'LastName': 'Michalak', 'Affiliation': 'Laboratory of Vision and Neuroscience, NanoBioMedical Center, Adam Mickiewicz University of Poznań, Umultowska 85, 61-614 Poznań, Poland; Laboratory of Vision Science and Optometry, Faculty of Physics, Adam Mickiewicz University of Poznań, Umultowska 85, 61-614 Poznań, Poland. Electronic address: kmichalak@amu.edu.pl.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Olszewski', 'Affiliation': 'Laboratory of Bionics and Experimental Medical Biology, Department of Bionics and Bioimpendance, Poznań University of Medical Sciences, Parkowa 2, 60-775, Poznań, Poland. Electronic address: jolszewski@ump.edu.pl.'}, {'ForeName': 'Fabrizio', 'Initials': 'F', 'LastName': 'Zeri', 'Affiliation': 'University of Milano Bicocca, Department of Materials Science, R. Cozzi 55, I-20125 Milan, Italy; School of Life and Health Sciences, Aston University, Aston Triangle, B4 7ET, Birmingham, UK. Electronic address: fabrizio.zeri@unimib.it.'}, {'ForeName': 'Andrzej', 'Initials': 'A', 'LastName': 'Michalski', 'Affiliation': 'Department of Ophthalmology, Chair of Ophthalmology and Optometry, Poznan University of Medical Sciences, Rokietnicka 5D, 60-806 Poznań, Poznań, Poland. Electronic address: amichalski@home.pl.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Paluch', 'Affiliation': 'Laboratory of Vision Science and Optometry, Faculty of Physics, Adam Mickiewicz University of Poznań, Umultowska 85, 61-614 Poznań, Poland. Electronic address: asiaa0096@gmail.com.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Przekoracka-Krawczyk', 'Affiliation': 'Laboratory of Vision and Neuroscience, NanoBioMedical Center, Adam Mickiewicz University of Poznań, Umultowska 85, 61-614 Poznań, Poland; Laboratory of Vision Science and Optometry, Faculty of Physics, Adam Mickiewicz University of Poznań, Umultowska 85, 61-614 Poznań, Poland. Electronic address: ania_pk@amu.edu.pl.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2019.12.002'] 696,31771940,"Effects of 2-Phenethyl Isothiocyanate on Metabolism of 1,3-Butadiene in Smokers.","2-Phenethyl isothiocyanate (PEITC) is a natural product found as a conjugate in cruciferous vegetables. It has been reported to have preventative properties against lung cancer and to inhibit metabolic activation of tobacco carcinogens. In this study, we evaluated the ability of PEITC to influence the metabolism of the human carcinogen 1,3-butadiene in current smokers in a phase II clinical trial with a crossover design. Urinary mercapturic acids of 1,3-butadiene were quantified at baseline and during PEITC treatment. Seventy-nine smokers were randomly assigned to one of two arms: PEITC followed by placebo or placebo followed by PEITC. During the 1-week treatment period, each subject took PEITC (10 mg in 1 mL of olive oil, 4 times per day). There was a 1-week washout period between the PEITC and placebo periods. Oral ingestion of PEITC increased urinary levels of BD-mercapturic acids (MHBMA and DHBMA) by 11.1% and 3.7%, respectively, but these increases were not statistically significant ( P = 0.17 and 0.64, respectively). A much stronger effect was observed among subjects with the null genotype of both GSTM1 and GSTT1 : in these individuals, PEITC increased urinary levels of MHBMA by 58.7% ( P = 0.004) and 90.0% ( P = 0.001), respectively, but did not have a significant effect on urinary DHBMA. These results reveal a potentially protective effect of PEITC treatment with respect to the detoxification of 1,3-butadiene in cigarette smokers, specifically in those null for GSTT1 , and provide further evidence in support of stronger chemopreventive effects from consumption of dietary isothiocyanates in these individuals.",2020,"Oral ingestion of PEITC increased urinary levels of BD-mercapturic acids (MHBMA and DHBMA) by 11.13% and 3.65%, respectively, but these increases were not statistically significant (p = 0.17 and 0.64, respectively).","['Seventy-nine smokers', 'smokers', 'cigarette smokers']","['2-Phenethyl isothiocyanate (PEITC', 'placebo, or placebo followed by PEITC', '2-phenethyl isothiocyanate']","['urinary DHBMA', 'urinary levels of BD-mercapturic acids (MHBMA and DHBMA', 'Urinary mercapturic acids of 1,3-butadiene', 'urinary levels of MHBMA']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0337667', 'cui_str': 'Cigarette smoker (finding)'}]","[{'cui': 'C0070558', 'cui_str': 'beta-phenylethyl isothiocyanate'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}]","[{'cui': 'C0243173', 'cui_str': 'urinary levels'}, {'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}, {'cui': 'C0043902', 'cui_str': 'butadiene'}]",79.0,0.0338335,"Oral ingestion of PEITC increased urinary levels of BD-mercapturic acids (MHBMA and DHBMA) by 11.13% and 3.65%, respectively, but these increases were not statistically significant (p = 0.17 and 0.64, respectively).","[{'ForeName': 'Emily J', 'Initials': 'EJ', 'LastName': 'Boldry', 'Affiliation': 'University of Minnesota Department of Medicinal Chemistry, Minneapolis, Minnesota.'}, {'ForeName': 'Jian-Min', 'Initials': 'JM', 'LastName': 'Yuan', 'Affiliation': 'UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Steven G', 'Initials': 'SG', 'LastName': 'Carmella', 'Affiliation': 'University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota.'}, {'ForeName': 'Renwei', 'Initials': 'R', 'LastName': 'Wang', 'Affiliation': 'UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Katelyn', 'Initials': 'K', 'LastName': 'Tessier', 'Affiliation': 'University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota.'}, {'ForeName': 'Dorothy K', 'Initials': 'DK', 'LastName': 'Hatsukami', 'Affiliation': 'University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota.'}, {'ForeName': 'Stephen S', 'Initials': 'SS', 'LastName': 'Hecht', 'Affiliation': 'University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota.'}, {'ForeName': 'Natalia Y', 'Initials': 'NY', 'LastName': 'Tretyakova', 'Affiliation': 'University of Minnesota Department of Medicinal Chemistry, Minneapolis, Minnesota. trety001@umn.edu.'}]","Cancer prevention research (Philadelphia, Pa.)",['10.1158/1940-6207.CAPR-19-0296'] 697,31778249,Left bundle branch area pacing is superior to right ventricular septum pacing concerning depolarization-repolarization reserve.,"INTRODUCTION Left bundle branch area pacing (LBBAP) has recently been reported to be a new physiological pacing strategy with clinical feasibility and safety. The present study aims to investigate depolarization-repolarization measures including QT interval, QT dispersion (QTD), and T peak-end interval (T p T e ) in this novel LBBAP strategy. METHODS AND RESULTS A total of 131 pacing-indicated patients were prospectively enrolled and randomized to the LBBAP group (n = 66) and right ventricular septum pacing (RVSP) group (n = 65). LBBAP was successfully achieved in 61 subjects with stable lead performance and comparable complications (ie, pocket hematoma, lead perforation, and dislodgement) compared with RVSP. Of the 61 patients with successful LBBAP, the mean LV peak activation time was 67.89 ± 6.80 ms, with the LBB potential mapped in 46 cases (75.4%). Electrocardiogram (ECG) indices were compared between these two groups before and after implantation. As a result, LBBAP yielded a narrower paced QRS duration (121.49 ± 9.87 ms vs 145.62 ± 8.89 ms; P < .001), shorter QT interval (434.16 ± 32.70 ms vs 462.66 ± 32.04 ms; P < .001), and QT c interval (472.44 ± 33.30 ms vs 499.65 ± 31.35 ms; P < .001), lower QTD (40.10 ± 8.68 ms vs 46.11 ± 10.85 ms; P = .001), and QT c D (43.57 ± 8.78 ms vs 49.86 ± 11.98 ms; P = .001), and shorter T p T e (96.59 ± 10.76 ms vs 103.77 ± 10.16 ms; P < .001) than RVSP. However, T p T e /QT ratio did not differ between these two groups (0.223 ± 0.026 vs 0.225 ± 0.022; P = .733). Furthermore, LBBAP displayed less increased QRS duration, QT c interval, QTD, QT c D, and a more shortened QT interval compared with RVSP (all P < .05). CONCLUSION LBBAP proves to be a feasible and safe pacing procedure with better depolarization-repolarization reserve, which may predict lower risk of ventricular arrhythmia and sudden cardiac death.",2020,"T e (96.59±10.76ms vs. 103.77±10.16ms, P<0.001) than RVSP.","['61 patients with successful LBBAP', 'group (n=65', '131 pacing-indicated patients']","['right ventricular septum pacing (RVSP', 'RVSP', 'Left bundle branch area pacing (LBBAP', 'LBBAP', 'Left bundle branch area pacing']","['Electrocardiogram (ECG) indices', 'pocket hematoma, lead perforation and dislodgement', 'QT interval, QT dispersion (QTD) and T peak-end interval ', 'shorter QT interval', 'lower QTD', 'QRS duration, QT c interval, QTD, QT c D, and more shortened QT interval', 'T p T e /QT ratio', 'mean LV peak activation time', 'narrower paced QRS duration']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}]","[{'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0225870', 'cui_str': 'Interventricular septum structure'}, {'cui': 'C0205091', 'cui_str': 'Left (qualifier value)'}, {'cui': 'C0225920', 'cui_str': 'Structure of bundle branches'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0562458', 'cui_str': 'Pacing up and down (finding)'}]","[{'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0549099', 'cui_str': 'Perforation (morphologic abnormality)'}, {'cui': 'C0429028', 'cui_str': 'QT interval feature'}, {'cui': 'C0332624', 'cui_str': 'Dispersion'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0151879', 'cui_str': 'Shortened QT interval (finding)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",131.0,0.041933,"T e (96.59±10.76ms vs. 103.77±10.16ms, P<0.001) than RVSP.","[{'ForeName': 'Jingfeng', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China.'}, {'ForeName': 'Yixiu', 'Initials': 'Y', 'LastName': 'Liang', 'Affiliation': 'Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China.'}, {'ForeName': 'Xueying', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Bai', 'Affiliation': 'Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China.'}, {'ForeName': 'Haiyan', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Department of Echocardiography, Zhongshan Hospital, Shanghai Institute of Medical Imaging, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China.'}, {'ForeName': 'Yangang', 'Initials': 'Y', 'LastName': 'Su', 'Affiliation': 'Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China.'}, {'ForeName': 'Ruizhen', 'Initials': 'R', 'LastName': 'Chen', 'Affiliation': 'Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China.'}, {'ForeName': 'Junbo', 'Initials': 'J', 'LastName': 'Ge', 'Affiliation': 'Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China.'}]",Journal of cardiovascular electrophysiology,['10.1111/jce.14295'] 698,31770068,Lot-to-lot consistency study of an Escherichia coli -produced bivalent human papillomavirus vaccine in adult women: a randomized trial.,"An Escherichia. coli -produced HPV-16/18 bivalent vaccine has been proved to be well-tolerated and highly efficacious against diseases associated with vaccine HPV types. As a part of the multi-center, randomized, double-blind phase III clinical trial, this lot-to-lot consistency study aimed to assess the safety and immunogenicity consistency of this novel HPV vaccine, which is also one of the objectives of the phase III trial. A total of 3689 healthy women aged 18-45 years were enrolled and randomly assigned 1:1:1 to three lots of the HPV vaccine groups. The primary outcomes were the IgG antibody level at 1 month after the last dose (month 7). In the immunogenicity per-protocol set (PPS), almost all of the participants seroconverted at month 7 and remained seropositive at month 42. For each paired comparison of the three lot groups, the two-sides of 90% CIs of GMC ratios for both IgG and neutralizing antibodies for HPV-16 and HPV-18 at month 7 were within the equivalence interval [0.5, 2]. Lot consistency was also demonstrated at month 42. The majority of recorded solicited reactions were mild or moderate. The incidences of solicited reactions of Lot 2 and Lot 3 were slightly higher than Lot 1. However, the incidences of solicited reactions of ≥ grade 3 and solicited reactions by symptoms were all similar among the three lot groups. None of the SAEs was considered related to vaccination by the investigator. In conclusion, this study demonstrates lot-to-lot consistency of the 3 consecutive lots of the E. coli -produced HPV-16/18 bivalent vaccine.",2020,-produced HPV-16/18 bivalent vaccine has been proved to be well-tolerated and highly efficacious against diseases associated with vaccine HPV types.,"['adult women', '3689 healthy women aged 18-45 years']","['Escherichia coli -produced bivalent human papillomavirus vaccine', 'HPV vaccine', 'coli']","['IgG antibody level', 'solicited reactions']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0014834', 'cui_str': 'Escherichia coli'}, {'cui': 'C1512511', 'cui_str': 'HPV Vaccines'}]","[{'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}]",3689.0,0.0706711,-produced HPV-16/18 bivalent vaccine has been proved to be well-tolerated and highly efficacious against diseases associated with vaccine HPV types.,"[{'ForeName': 'Ying-Ying', 'Initials': 'YY', 'LastName': 'Su', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University , Xiamen, Fujian, China.'}, {'ForeName': 'Bi-Zhen', 'Initials': 'BZ', 'LastName': 'Lin', 'Affiliation': 'Vaccine R&D Department, Xiamen Innovax Biotech Company , Xiamen, Fujian, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zhao', 'Affiliation': 'National Institute for Food and Drug Control, Division of Respiratory Virus Vaccines , Beijing, China.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'National Institute for Food and Drug Control, Division of Respiratory Virus Vaccines , Beijing, China.'}, {'ForeName': 'Zhi-Jie', 'Initials': 'ZJ', 'LastName': 'Lin', 'Affiliation': 'Vaccine R&D Department, Xiamen Innovax Biotech Company , Xiamen, Fujian, China.'}, {'ForeName': 'You-Lin', 'Initials': 'YL', 'LastName': 'Qiao', 'Affiliation': 'National Cancer Center, National Center for Cancer Clinical Research, the Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College , Beijing, China.'}, {'ForeName': 'Li-Hui', 'Initials': 'LH', 'LastName': 'Wei', 'Affiliation': ""Department of Obstetrics and Gynecology, Peking University People's Hospital , Beijing, China.""}, {'ForeName': 'Yue-Mei', 'Initials': 'YM', 'LastName': 'Hu', 'Affiliation': 'Department of Vaccine Evaluation, Jiangsu Provincial Center for Disease Control and Prevention , Nanjing, Jiangsu, China.'}, {'ForeName': 'Rong-Cheng', 'Initials': 'RC', 'LastName': 'Li', 'Affiliation': 'Center for Vaccine Clinical Research, Guangxi Center for Disease Control and Prevention , Nanning, Guangxi, China.'}, {'ForeName': 'Si-Jie', 'Initials': 'SJ', 'LastName': 'Zhuang', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University , Xiamen, Fujian, China.'}, {'ForeName': 'Guang', 'Initials': 'G', 'LastName': 'Sun', 'Affiliation': 'Vaccine R&D Department, Xiamen Innovax Biotech Company , Xiamen, Fujian, China.'}, {'ForeName': 'Zi-Zheng', 'Initials': 'ZZ', 'LastName': 'Zheng', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University , Xiamen, Fujian, China.'}, {'ForeName': 'Shou-Jie', 'Initials': 'SJ', 'LastName': 'Huang', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University , Xiamen, Fujian, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Wu', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University , Xiamen, Fujian, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University , Xiamen, Fujian, China.'}, {'ForeName': 'Hui-Rong', 'Initials': 'HR', 'LastName': 'Pan', 'Affiliation': 'Vaccine R&D Department, Xiamen Innovax Biotech Company , Xiamen, Fujian, China.'}, {'ForeName': 'Chang-Gui', 'Initials': 'CG', 'LastName': 'Li', 'Affiliation': 'National Institute for Food and Drug Control, Division of Respiratory Virus Vaccines , Beijing, China.'}]",Human vaccines & immunotherapeutics,['10.1080/21645515.2019.1691413'] 699,31773444,"Changes in Days of Unhealthy Alcohol Use and Antiretroviral Therapy Adherence, HIV RNA Levels, and Condomless Sex: A Secondary Analysis of Clinical Trial Data.","In a sample of people with HIV (PWH) enrolled in an alcohol intervention trial and followed for 12 months, we examined the association of changes in days (i.e., decrease, increase, no change [reference]) of unhealthy drinking (consuming ≥ 4/≥ 5 drinks for women/men) with antiretroviral therapy adherence (≥ 95% adherent), viral suppression (HIV RNA < 75 copies/mL), condomless sex with HIV-negative/unknown status partners, and dual-risk outcome (HIV RNA ≥ 75 copies/mL plus condomless sex). The sample included 566 PWH (96.8% male; 63.1% White; 93.9% HIV RNA < 75 copies/mL) who completed baseline, 6-, and 12-month assessments. Decrease in days of unhealthy drinking was associated with increased likelihood of viral suppression (odds ratio [OR] 3.78; 95% confidence interval [CI] 1.06, 13.51, P = .04) versus no change. Increase in days of unhealthy drinking was associated with increased likelihood of condomless sex (OR 3.13; 95% CI 1.60, 6.12, P < .001). Neither increase nor decrease were associated with adherence or dual-risk outcome. On a continuous scale, for each increase by 1 day of unhealthy drinking in the prior month, the odds of being 95% adherent decreased by 6% (OR 0.94, 95% CI 0.88, 1.00, P = 0.04).",2020,"Increase in days of unhealthy drinking was associated with increased likelihood of condomless sex (OR 3.13; 95% CI 1.60, 6.12, P < .001).","['for women/men) with antiretroviral therapy adherence (≥\u200995% adherent), viral suppression (HIV RNA\u2009<\u200975 copies/mL), condomless sex with HIV-negative/unknown status partners, and dual-risk outcome (HIV RNA\u2009≥\u200975 copies/mL plus condomless sex', 'The sample included 566 PWH (96.8% male; 63.1% White; 93.9% HIV RNA\u2009<\u200975 copies/mL) who completed baseline, 6-, and 12-month assessments', 'people with HIV (PWH']",['unhealthy drinking (consuming\u2009≥\u20094/≥\u20095 drinks'],"['adherence or dual-risk outcome', 'likelihood of viral suppression', 'Changes in Days of Unhealthy Alcohol Use and Antiretroviral Therapy Adherence, HIV RNA Levels, and Condomless Sex', 'likelihood of condomless sex']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression (disorder)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0481430', 'cui_str': 'HTLV-3 antibody negative'}, {'cui': 'C0439673', 'cui_str': 'Unknown (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0684271', 'cui_str': 'Drinkings'}, {'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression (disorder)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}]",566.0,0.042416,"Increase in days of unhealthy drinking was associated with increased likelihood of condomless sex (OR 3.13; 95% CI 1.60, 6.12, P < .001).","[{'ForeName': 'Derek D', 'Initials': 'DD', 'LastName': 'Satre', 'Affiliation': 'Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. derek.satre@ucsf.edu.'}, {'ForeName': 'Varada', 'Initials': 'V', 'LastName': 'Sarovar', 'Affiliation': 'Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Leyden', 'Affiliation': 'Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.'}, {'ForeName': 'Charles B', 'Initials': 'CB', 'LastName': 'Hare', 'Affiliation': 'Department of Adult and Family Medicine, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.'}, {'ForeName': 'Sheryl L', 'Initials': 'SL', 'LastName': 'Catz', 'Affiliation': 'Betty Irene Moore School of Nursing, University of California at Davis, Sacramento, CA, USA.'}, {'ForeName': 'Kendall J', 'Initials': 'KJ', 'LastName': 'Bryant', 'Affiliation': 'National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA.'}, {'ForeName': 'Emily C', 'Initials': 'EC', 'LastName': 'Williams', 'Affiliation': 'Health Services Research & Development Center of Innovation for Veteran-Centered and Value-Driven Care, VA Puget Sound, Seattle, WA, USA.'}, {'ForeName': 'J Carlo', 'Initials': 'JC', 'LastName': 'Hojilla', 'Affiliation': 'Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Horberg', 'Affiliation': 'Mid-Atlantic Permanente Research Institute, Kaiser Permanente Mid-Atlantic States, Rockville, MD, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Silverberg', 'Affiliation': 'Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.'}]",AIDS and behavior,['10.1007/s10461-019-02742-y'] 700,31726081,Gait-synchronized oscillatory brain stimulation modulates common neural drives to ankle muscles in patients after stroke: A pilot study.,"The present study aimed to investigate the long-term effects of gait intervention with transcranial alternating current stimulation (tACS) synchronized with gait cycle frequency on the cortical control of muscle activity during gait, using coherence analyses, in patients after stroke. Eight chronic post-stroke patients participated in a single-blinded crossover study, and 7 patients completed the long-term intervention. Each patient received tACS over the primary motor cortex foot area on the affected side, which was synchronized with individual gait cycle frequency, and sham stimulation during treadmill gait in a random order. Electrical neuromuscular stimulation was used to assist the paretic ankle movement in both conditions. After gait intervention with tACS, beta band (15-35 Hz) coherence, which is considered to have a cortical origin, significantly increased in the paretic tibialis anterior (TA) muscle during 6-min of over-ground gait. The change in beta band coherence in the paretic TA muscle was positively correlated with the change in gait distance. These results indicate that gait intervention with tACS synchronized with gait cycle frequency may induce gait-specific plasticity that modulates the common neural drive to the TA motoneurons on the paretic side during gait and leads to changes in gait function in patients after stroke.",2020,The change in beta band coherence in the paretic TA muscle was positively correlated with the change in gait distance.,"['Eight chronic post-stroke patients', 'patients after stroke']","['tACS', 'Electrical neuromuscular stimulation', 'Gait-synchronized oscillatory brain stimulation', 'gait intervention with transcranial alternating current stimulation (tACS) synchronized with gait cycle frequency']","['gait distance', 'paretic tibialis anterior (TA) muscle', 'gait function', 'change in beta band coherence in the paretic TA muscle']","[{'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0442828', 'cui_str': 'Electrical (qualifier value)'}, {'cui': 'C0454448', 'cui_str': 'Neuromuscular stimulation (regime/therapy)'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0870227', 'cui_str': 'Brain stimulation'}, {'cui': 'C3852966', 'cui_str': 'Transcranial Alternating Current Stimulation'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0242690', 'cui_str': 'Anterior Tibial Muscle'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0185014', 'cui_str': 'Banding'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}]",8.0,0.0293107,The change in beta band coherence in the paretic TA muscle was positively correlated with the change in gait distance.,"[{'ForeName': 'Ryosuke', 'Initials': 'R', 'LastName': 'Kitatani', 'Affiliation': 'Department of Physical Therapy, Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Rehabilitation, Kansai Rehabilitation Hospital, Osaka, Japan. Electronic address: kitatani.ryosuke.88x@st.kyoto-u.ac.jp.'}, {'ForeName': 'Satoko', 'Initials': 'S', 'LastName': 'Koganemaru', 'Affiliation': 'Department of Physiology and Biological Information, Dokkyo Medical University, Tochigi, Japan.'}, {'ForeName': 'Ayaka', 'Initials': 'A', 'LastName': 'Maeda', 'Affiliation': 'Department of Physical Therapy, Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Mikami', 'Affiliation': 'Human Brain Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan.'}, {'ForeName': 'Masao', 'Initials': 'M', 'LastName': 'Matsuhashi', 'Affiliation': 'Department of Epilepsy, Movement Disorders and Physiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Tatsuya', 'Initials': 'T', 'LastName': 'Mima', 'Affiliation': 'Graduate School of Core Ethics and Frontier Sciences, Ritsumeikan University, Kyoto, Japan.'}, {'ForeName': 'Shigehito', 'Initials': 'S', 'LastName': 'Yamada', 'Affiliation': 'Department of Physical Therapy, Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}]",Neuroscience research,['10.1016/j.neures.2019.11.001'] 701,31770139,"Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study.","OBJECTIVES To assess the efficacy and safety of vonoprazan on heartburn symptoms in patients with nonerosive reflux disease (NERD) (ClinicalTrials.gov: NCT02954848). METHODS This phase 3, double-blind, placebo-controlled study included Japanese patients aged 20 years and older with grade N/M NERD and recurrent heartburn. Patients received placebo (n = 245) or vonoprazan 10 mg (n = 238) for 4 weeks. The primary efficacy outcome was frequency of heartburn experienced by patients during the treatment period (proportion of days without heartburn). Other outcomes included cumulative improvement rates of heartburn, proportion of patients with complete heartburn resolution in the fourth week of treatment, and safety. RESULTS Compared with placebo, the proportion of days without heartburn was not significantly higher in the vonoprazan group in the full analysis (primary end point, 72.55% vs 61.50%, vonoprazan vs placebo, P = 0.0643) but was significantly higher in the per-protocol-set sensitivity analysis (P = 0.0341). Early onset of response and significantly greater cumulative improvement rates of heartburn were observed in the vonoprazan group (P = 0.0003). In a post hoc analysis, a greater proportion of patients with complete heartburn resolution in the fourth week of treatment were reported in the vonoprazan group (P = 0.0023). Incidence of treatment-emergent adverse events was similar between treatment groups (23.5% vs 23.3%); most treatment-emergent adverse events were mild in severity. DISCUSSION Although vonoprazan 10 mg was not superior to placebo with respect to proportion of days without heartburn in Japanese patients with NERD, vonoprazan had a significantly higher cumulative rate of heartburn resolution and was well tolerated.",2019,"Incidence of treatment-emergent adverse events was similar between treatment groups (23.5% vs 23.3%); most treatment-emergent adverse events were mild in severity. ","['Patients With Nonerosive Gastroesophageal Reflux Disease', 'Japanese patients with NERD', 'patients with nonerosive reflux disease (NERD', 'Japanese patients aged 20 years and older with grade N/M NERD and recurrent heartburn']","['placebo', 'Placebo', 'Vonoprazan', 'vonoprazan']","['cumulative improvement rates of heartburn, proportion of patients with complete heartburn resolution', 'safety', 'tolerated', 'cumulative rate of heartburn resolution', 'Incidence of treatment-emergent adverse events', 'efficacy and safety', 'complete heartburn resolution', 'heartburn symptoms', 'cumulative improvement rates of heartburn', 'proportion of days without heartburn', 'Efficacy and Safety', 'frequency of heartburn experienced by patients during the treatment period (proportion of days without heartburn']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0017168', 'cui_str': 'Gastric Acid Reflux Disease'}, {'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0018834', 'cui_str': 'Pyrosis'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4080009', 'cui_str': 'Vonoprazan'}]","[{'cui': 'C0018834', 'cui_str': 'Pyrosis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]",,0.488409,"Incidence of treatment-emergent adverse events was similar between treatment groups (23.5% vs 23.3%); most treatment-emergent adverse events were mild in severity. ","[{'ForeName': 'Yoshikazu', 'Initials': 'Y', 'LastName': 'Kinoshita', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shimane University School of Medicine, Izumo, Japan.'}, {'ForeName': 'Yuuichi', 'Initials': 'Y', 'LastName': 'Sakurai', 'Affiliation': 'Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan.'}, {'ForeName': 'Nobuyoshi', 'Initials': 'N', 'LastName': 'Takabayashi', 'Affiliation': 'Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Kudou', 'Affiliation': 'Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Araki', 'Affiliation': 'Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan.'}, {'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Miyagi', 'Affiliation': 'Department of Internal Medicine, Fukuyama Daiichi Hospital, Hiroshima, Japan.'}, {'ForeName': 'Katsuhiko', 'Initials': 'K', 'LastName': 'Iwakiri', 'Affiliation': 'Department of Gastroenterology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Kiyoshi', 'Initials': 'K', 'LastName': 'Ashida', 'Affiliation': 'Department of Gastroenterology, Rakuwakai Otowa Hospital, Kyoto, Japan.'}]",Clinical and translational gastroenterology,['10.14309/ctg.0000000000000101'] 702,31776061,Reducing treatment zone diameter in orthokeratology and its effect on peripheral ocular refraction.,"PURPOSE To determine whether orthokeratology (OK) induced treatment zone (TZ) diameter can be reduced by altering OK lens design, and if so the impact of modifying TZ diameter on relative peripheral refraction (RPR). METHODS 16 subjects (mean age 23.4 ± 1.5 years; 8 female) completed the study. Standard (Control) OK lens design (PJ, Capricornia, Australia) or a modified version (Test) where the back optic zone diameter was reduced, and back optic zone asphericity and intermediate lens curves were altered, were worn overnight only for 7-nights in a randomised double masked order, with a minimum 1-week wash out (no lens wear) between lens designs. Full correction of refractive error was targeted. Refraction; best corrected visual acuity (BCVA); RPR (Shin-Nippon NVision-k 5001) along the horizontal and vertical meridians; and corneal topography (Medmont E300) were measured before starting lens wear and in the morning after lens removal after the seventh night of lens wear for both lens designs. TZ diameter and decentration was calculated from corneal topography. RESULTS After 7-nights of wear both lens designs created -2.00D refraction effect with no significant difference in refractive effect or change to BCVA between the designs. The Test design created a significantly smaller horizontal (4.78 ± 0.37 vs 5.70 ± 0.37 mm, p < 0.001) and vertical (5.09 ± 0.51 vs 5.92 ± 0.51 mm p < 0.001) TZ diameter. The TZ was decentered inferior temporal with no significant difference between designs. There was no significant difference between the lens designs in RPR along the horizontal and vertical meridians at any measurement period. CONCLUSIONS OK induced TZ diameter can be reliably reduced by altering OK lens design without detrimentally effecting lens centration or refractive effect. Reducing TZ diameter did not alter RPR, though measurement artifacts could be responsible for masking an effect. Longitudinal studies are needed to assess whether smaller TZ OK lens designs increase efficacy for slowing progression of myopia.",2020,"There was no significant difference between the lens designs in RPR along the horizontal and vertical meridians at any measurement period. ",['16 subjects (mean age 23.4\u202f±\u202f1.5 years; 8 female) completed the study'],"['smaller TZ OK lens', 'orthokeratology (OK']","['visual acuity (BCVA); RPR (Shin-Nippon NVision-k 5001) along the horizontal and vertical meridians; and corneal topography (Medmont E300', 'peripheral ocular refraction']","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517655', 'cui_str': '23.4 (qualifier value)'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0023317', 'cui_str': 'Lens, Eye'}, {'cui': 'C1533088', 'cui_str': 'Orthokeratology'}]","[{'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0201405', 'cui_str': 'Rapid plasma reagin test (procedure)'}, {'cui': 'C0230444', 'cui_str': 'Shin structure'}, {'cui': 'C0439790', 'cui_str': 'Horizontal and vertical (qualifier value)'}, {'cui': 'C0085282', 'cui_str': 'Ching Lo'}, {'cui': 'C0524957', 'cui_str': 'Corneal Topography'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C1261472', 'cui_str': 'Ocular Refraction'}]",16.0,0.0861399,"There was no significant difference between the lens designs in RPR along the horizontal and vertical meridians at any measurement period. ","[{'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Gifford', 'Affiliation': 'University of New South Wales, Sydney, 2052, Australia. Electronic address: p.gifford@unsw.edu.au.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Tran', 'Affiliation': 'University of New South Wales, Sydney, 2052, Australia.'}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Priestley', 'Affiliation': 'University of New South Wales, Sydney, 2052, Australia.'}, {'ForeName': 'Vinod', 'Initials': 'V', 'LastName': 'Maseedupally', 'Affiliation': 'University of New South Wales, Sydney, 2052, Australia.'}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Kang', 'Affiliation': 'University of New South Wales, Sydney, 2052, Australia.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2019.11.006'] 703,31712969,Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder.,"RATIONALE Depression is common among individuals with cannabis use disorder (CUD), particularly individuals who present to CUD treatment. Treatments that consider this comorbidity are essential. OBJECTIVES The goal of this secondary analysis was to examine whether N-acetylcysteine (NAC) reduced depressive symptoms among adults (age 18-50) with CUD (N = 302) and whether the effect of NAC on cannabis cessation varied as a result of baseline levels of depression. Bidirectional associations between cannabis use amount and depression were also examined. METHODS Data for this secondary analysis were from a National Drug Abuse Treatment Clinical Trials Network (NIDA CTN) multi-site clinical trial for CUD. Adults with CUD (N = 302) were randomized to receive 2400 mg of NAC daily or matched placebo for 12 weeks. All participants received abstinence-based contingency management. Cannabis quantity was measured by self-report, and weekly urinary cannabinoid levels (11-nor-9-carboxy-Δ9-tetrahydrocannabinol) confirmed abstinence. Depressive symptoms were measured by the Hospital Anxiety and Depression Scale. RESULTS Depressive symptoms did not differ between the NAC and placebo groups during treatment. There was no significant interaction between treatment and baseline depression predicting cannabis abstinence during treatment. Higher baseline depression was associated with decreased abstinence throughout treatment and a significant gender interaction suggested that this may be particularly true for females. Cross-lagged panel models suggested that depressive symptoms preceded increased cannabis use amounts (in grams) during the subsequent month. The reverse pathway was not significant (i.e., greater cannabis use preceding depressive symptoms). CONCLUSIONS Results from this study suggest that depression may be a risk factor for poor CUD treatment outcome and therefore should be addressed in the context of treatment. However, results do not support the use of NAC to concurrently treat co-occurring depressive symptoms and CUD in adults. TRIAL REGISTRATION Clinicaltrials.gov: NCT01675661.",2020,Depressive symptoms did not differ between the NAC and placebo groups during treatment.,"['individuals with cannabis use disorder (CUD), particularly individuals who present to CUD treatment', 'adults (age 18-50) with CUD (N\u2009=\u2009302', 'Adults with CUD (N\u2009=\u2009302', 'Data for this secondary analysis were from a National Drug Abuse Treatment Clinical Trials Network (NIDA CTN) multi-site clinical trial for CUD', 'adult cannabis use disorder']","['NAC', 'NAC daily or matched placebo', 'placebo', 'N-Acetylcysteine', 'N-acetylcysteine (NAC', 'abstinence-based contingency management']","['depressive symptoms', 'Hospital Anxiety and Depression Scale', 'Depressive symptoms', 'Cannabis quantity']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C3160814', 'cui_str': 'Cannabis use'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0013146', 'cui_str': 'Drug abuse (disorder)'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0068218', 'cui_str': 'NIDA'}, {'cui': 'C0917591', 'cui_str': 'CTN'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}, {'cui': 'C0678449', 'cui_str': 'Cannabis'}, {'cui': 'C1265611', 'cui_str': 'Quantity finding'}]",,0.539075,Depressive symptoms did not differ between the NAC and placebo groups during treatment.,"[{'ForeName': 'Rachel L', 'Initials': 'RL', 'LastName': 'Tomko', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, MSC 861, 67 President Street, Charleston, SC, 29425-8610, USA. tomko@musc.edu.'}, {'ForeName': 'Nathaniel L', 'Initials': 'NL', 'LastName': 'Baker', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina, MSC 861, 67 President Street, Charleston, SC, 29425-8610, USA.'}, {'ForeName': 'Caitlyn O', 'Initials': 'CO', 'LastName': 'Hood', 'Affiliation': 'Department of Psychology, University of Kentucky, Lexington, KY, 40506, USA.'}, {'ForeName': 'Amanda K', 'Initials': 'AK', 'LastName': 'Gilmore', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, MSC 861, 67 President Street, Charleston, SC, 29425-8610, USA.'}, {'ForeName': 'Erin A', 'Initials': 'EA', 'LastName': 'McClure', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, MSC 861, 67 President Street, Charleston, SC, 29425-8610, USA.'}, {'ForeName': 'Lindsay M', 'Initials': 'LM', 'LastName': 'Squeglia', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, MSC 861, 67 President Street, Charleston, SC, 29425-8610, USA.'}, {'ForeName': 'Aimee L', 'Initials': 'AL', 'LastName': 'McRae-Clark', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, MSC 861, 67 President Street, Charleston, SC, 29425-8610, USA.'}, {'ForeName': 'Susan C', 'Initials': 'SC', 'LastName': 'Sonne', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, MSC 861, 67 President Street, Charleston, SC, 29425-8610, USA.'}, {'ForeName': 'Kevin M', 'Initials': 'KM', 'LastName': 'Gray', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, MSC 861, 67 President Street, Charleston, SC, 29425-8610, USA.'}]",Psychopharmacology,['10.1007/s00213-019-05384-z'] 704,30243812,Rationale and development of a randomized pragmatic trial to improve diabetes outcomes in patient-centered medical homes serving rural patients.,"Proper diabetes self-care requires patients to have considerable knowledge, a range of skills, and to sustain multiple health behaviors. Self-management interventions are needed that can be readily implemented and sustained in rural clinics with limited resources that disproportionately care for patients with limited literacy. Researchers on our team developed an evidence-based, patient-centered, low literacy intervention promoting diabetes self-care that includes: 1) the American College of Physicians (ACP) Diabetes Guide that uses plain language and descriptive photographs to teach core diabetes concepts and empower patients to initiate behavior change; 2) a brief counseling strategy to assist patients in developing short-term, explicit and attainable goals for behavior change ('action plans'); and 3) a training module for health coaches that prepares them to assume educator/counselor roles with the Diabetes Guide as a teaching tool. While the intervention has previously been field tested and found to significantly improve patient knowledge, self-efficacy, and engagement in related health behaviors, its optimal implementation is not known. This project took advantage of a unique opportunity to modify and disseminate the ACP health literacy intervention among patients with type 2 diabetes cared for at rural clinics in Arkansas that are Patient-Centered Medical Homes (PCMH). These practices all had health coaches that could be leveraged to provide chronic disease self-management mostly via phone, but also at the point-of-care. Hence we conducted a patient-randomized, pragmatic clinical trial in 6 rural PCMHs in Arkansas, targeting individuals with uncontrolled type 2 diabetes.",2018,"While the intervention has previously been field tested and found to significantly improve patient knowledge, self-efficacy, and engagement in related health behaviors, its optimal implementation is not known.","['patient-centered medical homes serving rural patients', 'patients with type 2 diabetes cared for at rural clinics in Arkansas that are Patient-Centered Medical Homes (PCMH', 'rural clinics with limited resources that disproportionately care for patients with limited literacy', '6 rural PCMHs in Arkansas, targeting individuals with uncontrolled type 2 diabetes']",['ACP health literacy intervention'],[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C2713310', 'cui_str': 'Medical Home'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}]","[{'cui': 'C2362527', 'cui_str': 'Health Literacy'}]",[],6.0,0.025536,"While the intervention has previously been field tested and found to significantly improve patient knowledge, self-efficacy, and engagement in related health behaviors, its optimal implementation is not known.","[{'ForeName': 'Kristie B', 'Initials': 'KB', 'LastName': 'Hadden', 'Affiliation': 'University of Arkansas for Medical Sciences, 4301 W. Markham Street, Little Rock, AR 72205-7199, USA. Electronic address: khadden@uams.edu.'}, {'ForeName': 'Connie L', 'Initials': 'CL', 'LastName': 'Arnold', 'Affiliation': 'Louisiana State University Health Sciences Center - Shreveport, 1501 Kings Highway, Shreveport, LA 71130-3932, USA.'}, {'ForeName': 'Laura M', 'Initials': 'LM', 'LastName': 'Curtis', 'Affiliation': 'Northwestern University, Division of General Internal Medicine and Geriatrics, 750 N. Lake Shore Drive, 10th Floor, Chicago, IL 60611, USA.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Gan', 'Affiliation': 'University of Arkansas for Medical Sciences, 4301 W. Markham Street, Little Rock, AR 72205-7199, USA.'}, {'ForeName': 'Scott I', 'Initials': 'SI', 'LastName': 'Hur', 'Affiliation': 'Northwestern University, Division of General Internal Medicine and Geriatrics, 750 N. Lake Shore Drive, 10th Floor, Chicago, IL 60611, USA.'}, {'ForeName': 'Mary J', 'Initials': 'MJ', 'LastName': 'Kwasny', 'Affiliation': 'Northwestern University, Department of Preventive Medicine, 680 N. Lake Shore Drive, Suite 1400, Chicago, IL 60611, USA.'}, {'ForeName': 'Jean C', 'Initials': 'JC', 'LastName': 'McSweeney', 'Affiliation': 'University of Arkansas for Medical Sciences, 4301 W. Markham Street, Little Rock, AR 72205-7199, USA.'}, {'ForeName': 'Latrina Y', 'Initials': 'LY', 'LastName': 'Prince', 'Affiliation': 'University of Arkansas for Medical Sciences, 4301 W. Markham Street, Little Rock, AR 72205-7199, USA.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Wolf', 'Affiliation': 'Northwestern University, Division of General Internal Medicine and Geriatrics, 750 N. Lake Shore Drive, 10th Floor, Chicago, IL 60611, USA.'}, {'ForeName': 'Terry C', 'Initials': 'TC', 'LastName': 'Davis', 'Affiliation': 'Louisiana State University Health Sciences Center - Shreveport, 1501 Kings Highway, Shreveport, LA 71130-3932, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2018.09.007'] 705,31765759,Feasibility of Using Communication Coaching to Teach Palliative Care Clinicians Motivational Interviewing.,"CONTEXT Palliative care clinicians often have challenging conversations with patients or family caregivers who express ambivalence about goals or feel reluctant to discuss topics. Motivational Interviewing (MI) has tools to address ambivalence and reluctance. OBJECTIVE The aim of this pilot study was to test the feasibility, acceptability, and preliminary efficacy of an MI communication coaching intervention. METHODS We enrolled 22 palliative care clinicians and randomly assigned half to receive communication coaching versus wait-list control. The coaching entailed a lecture on MI, a 1:1 session to discuss applying MI, and audio recording and receiving feedback on four encounters (two separate times). Palliative care clinicians in the wait-list control arm audio-recorded four encounters. Coders blinded to study arm coded MI behaviors. We surveyed patients, caregivers, and clinicians after all audio-recorded encounters to assess perceptions of the encounter. The analyses were performed using a repeated-measures mixed model. RESULTS We found the intervention to be feasible and acceptable. Eighty-six percent of those enrolled completed all study activities including coaching sessions, audio-recording encounters, and completing surveys. Of those in the intervention arm, 88% rated the intervention as helpful and 100% would recommend it to a colleague. Compared to control clinicians, intervention clinicians had higher ratings of their MI skills after intervention, higher objectively rated communication skills, and slightly better burnout scores. We found no arm differences in patient, caregiver, or clinician ratings of satisfaction. CONCLUSION This pilot study indicates that coaching palliative care clinicians is feasible and shows promise that coaching can improve palliative care clinician communication.",2020,"Compared to control clinicians, intervention clinicians had higher ratings of their MI skills post-intervention, higher objectively rated communication skills, and slightly better burnout scores.",['22 palliative care clinicians'],"['communication coaching vs. waitlist control', 'Motivational Interviewing (MI', 'communication coaching', 'MI communication coaching intervention']","['objectively rated communication skills', 'patient, caregiver, or clinician ratings of satisfaction']","[{'cui': 'C0700049', 'cui_str': 'Palliative care'}]","[{'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0683474', 'cui_str': 'Motivational Interviewing'}, {'cui': 'C0557773', 'cui_str': 'Coach (physical object)'}]","[{'cui': 'C0870313', 'cui_str': 'Communication skills'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",22.0,0.027952,"Compared to control clinicians, intervention clinicians had higher ratings of their MI skills post-intervention, higher objectively rated communication skills, and slightly better burnout scores.","[{'ForeName': 'Kathryn I', 'Initials': 'KI', 'LastName': 'Pollak', 'Affiliation': 'Cancer Control and Populations Sciences, Duke Cancer Institute, Durham, North Carolina, USA; Department of Population Health Sciences, Duke School of Medicine, Durham, North Carolina, USA. Electronic address: kathryn.pollak@duke.edu.'}, {'ForeName': 'Xiaomei', 'Initials': 'X', 'LastName': 'Gao', 'Affiliation': 'Cancer Control and Populations Sciences, Duke Cancer Institute, Durham, North Carolina, USA.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Arnold', 'Affiliation': 'Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Arnett', 'Affiliation': 'Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Felton', 'Affiliation': 'Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.'}, {'ForeName': 'Diane L', 'Initials': 'DL', 'LastName': 'Fairclough', 'Affiliation': 'Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado, USA.'}, {'ForeName': 'Jean S', 'Initials': 'JS', 'LastName': 'Kutner', 'Affiliation': 'Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2019.11.010'] 706,30145268,Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomized controlled trial in military veterans.,"Posttraumatic stress disorder (PTSD) and alcohol use disorders (AUD) are two of the most common mental health disorders affecting civilians as well as military populations. If left untreated, individuals with co-occurring PTSD/AUD are at increased risk for developing other mental health problems (e.g., depression, anxiety), physical health problems, reduced resiliency and military readiness, and vocational and social impairment. Substantial gaps in the treatment of co-occurring PTSD/AUD exist and there is a critical need to develop more effective pharmacological treatments. The current study addresses this gap in the literature by testing the efficacy and safety of doxazosin, a long-acting and selective alpha-1 adrenergic antagonist, as compared to placebo in reducing PTSD and AUD severity among U.S. military veterans. Noradrenergic dysregulation has been implicated in the development and maintenance of PTSD and AUD, and pilot studies examining doxazosin in PTSD-only or AUD-only samples have shown promise. This is the first study, however, to evaluate doxazosin in a comorbid PTSD/AUD sample. This paper describes the rationale, design and methodology of a randomized, double-blind, placebo-controlled trial of doxazosin (16 mg/day) delivered over 12 weeks among military veterans with current PTSD and AUD. In addition, functional magnetic resonance imaging (fMRI) is applied at pre- and post-treatment to investigate the underlying pathophysiology of comorbid PTSD/AUD and identify prognostic indicators of treatment outcome. This study is designed to accelerate research on co-occurring PTSD/AUD and provide empirical evidence to inform clinical practice.",2018,Substantial gaps in the treatment of co-occurring PTSD/AUD exist and there is a critical need to develop more effective pharmacological treatments.,"['co-occurring PTSD and alcohol use disorder', 'U.S. military veterans', 'military veterans', 'military veterans with current PTSD and AUD']","['functional magnetic resonance imaging (fMRI', 'doxazosin', 'placebo', 'Doxazosin']",[],"[{'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0001956', 'cui_str': 'Alcohol Use Disorder'}, {'cui': 'C0026126', 'cui_str': 'Armed Forces Personnel'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}]","[{'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0114873', 'cui_str': 'Doxazosin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]",[],,0.0324595,Substantial gaps in the treatment of co-occurring PTSD/AUD exist and there is a critical need to develop more effective pharmacological treatments.,"[{'ForeName': 'Sudie E', 'Initials': 'SE', 'LastName': 'Back', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA; Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA. Electronic address: backs@musc.edu.'}, {'ForeName': 'Julianne C', 'Initials': 'JC', 'LastName': 'Flanagan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA. Electronic address: hellmuth@musc.edu.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Jones', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA. Electronic address: jonjen@musc.edu.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Augur', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA. Electronic address: augur@musc.edu.'}, {'ForeName': 'Alan L', 'Initials': 'AL', 'LastName': 'Peterson', 'Affiliation': 'Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA; Research and Development Service, South Texas Veterans Health Care System, South Texas Veterans Health Care System, San Antonio, TX, USA; Department of Psychology, University of Texas at San Antonio, San Antonio, TX, USA. Electronic address: petersona3@uthscsa.edu.'}, {'ForeName': 'Stacey', 'Initials': 'S', 'LastName': 'Young-McCaughan', 'Affiliation': 'Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. Electronic address: youngs1@uthscsa.edu.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Shirley', 'Affiliation': 'Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Aisling', 'Initials': 'A', 'LastName': 'Henschel', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Jane E', 'Initials': 'JE', 'LastName': 'Joseph', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA. Electronic address: josep@musc.edu.'}, {'ForeName': 'Brett T', 'Initials': 'BT', 'LastName': 'Litz', 'Affiliation': 'Massachusetts Veterans Epidemiological Research and Information Center, VA Boston Healthcare System, Boston, MA, USA; Department of Psychiatry, Boston University School of Medicine, Boston, MA, USA; Department of Psychological and Brain Sciences, Boston University, Boston, MA, USA. Electronic address: brett.litz@va.gov.'}, {'ForeName': 'Allison K', 'Initials': 'AK', 'LastName': 'Hancock', 'Affiliation': 'Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. Electronic address: hancocka@uthscsa.edu.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Roache', 'Affiliation': 'Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. Electronic address: roache@uthscsa.edu.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Mintz', 'Affiliation': 'Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA; Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. Electronic address: mintz@uthscsa.edu.'}, {'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Wachen', 'Affiliation': 'Department of Psychiatry, Boston University School of Medicine, Boston, MA, USA; National Center for PTSD, VA Boston Healthcare System, Boston, MA, USA. Electronic address: jennifer.wachen@va.gov.'}, {'ForeName': 'Terence M', 'Initials': 'TM', 'LastName': 'Keane', 'Affiliation': 'Department of Psychiatry, Boston University School of Medicine, Boston, MA, USA; National Center for PTSD, VA Boston Healthcare System, Boston, MA, USA. Electronic address: terence.keane@va.gov.'}, {'ForeName': 'Kathleen T', 'Initials': 'KT', 'LastName': 'Brady', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA; Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA. Electronic address: bradyk@musc.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Contemporary clinical trials,['10.1016/j.cct.2018.08.009'] 707,30776134,"Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ-61178104, a Novel Tumor Necrosis Factor-Alpha and Interleukin-17A Bispecific Antibody, in Healthy Subjects.","The safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of JNJ-61178104, a novel anti-tumor necrosis factor-alpha (TNFα) and anti-interleukin-17A (IL-17A) bispecific antibody, were investigated in a placebo-controlled, first-in-human study. Healthy subjects (n = 54) received a single dose of JNJ-61178104 by either intravenous infusion (0.1, 0.3, 1, 3, and 10 mg/kg) or subcutaneous injection (1 mg/kg). Blood samples for measurement of serum JNJ-61178104 concentrations, total IL-17A, total TNFα, and detection of antidrug antibodies were collected for up to 16 weeks after dosing and assessed using electrochemiluminescence immunoassays. PK parameters were calculated by noncompartmental analysis and estimated by nonlinear mixed-effects modeling. JNJ-61178104 was generally well tolerated in healthy subjects. For the intravenous cohorts, mean maximum concentration, and area under the concentration-time curve values increased in a dose-proportional manner. Mean clearance ranged from 6.73 to 9.99 mL/day/kg, mean volume of distribution at terminal phase after intravenous administration ranged from 51.0 to 91.9 mL/kg, and mean half-life ranged from 4.3 to 9.7 days following intravenous administration. After a single subcutaneous dose of 1 mg/kg, median time to maximum concentration was 4.0 days, mean bioavailability was 52.0% and mean half-life was 5.3 days. A linear 2-compartment population model with first-order elimination adequately characterized the pharmacokinetics with parameters consistent with noncompartmental analysis estimates. Body weight and antidrug antibodies were significant covariates on JNJ-61178104 clearance. The time to reach mean maximum serum total TNFα and total IL-17A concentrations appeared to be dose dependent across the 0.1 mg/kg to 10 mg/kg IV dose groups. All subjects who received active treatment were antidrug antibody positive after dosing with JNJ-61178104.",2019,The time to reach mean maximum serum total TNFα and total IL-17A concentrations appeared to be dose dependent across the 0.1 mg/kg to 10 mg/kg IV dose groups.,"['Healthy Subjects', 'Healthy subjects (n\xa0=\xa054', 'healthy subjects']",['subcutaneous injection'],"['Mean clearance', 'Blood samples for measurement of serum JNJ-61178104 concentrations, total IL-17A, total TNFα, and detection of antidrug antibodies', 'median time to maximum concentration', 'time to reach mean maximum serum total TNFα and total IL-17A concentrations', 'antidrug antibody positive', 'mean maximum concentration, and area under the concentration-time curve values', 'mean bioavailability', 'PK parameters', 'Body weight and antidrug antibodies', 'safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of JNJ-61178104, a novel anti-tumor necrosis factor-alpha (TNFα) and anti-interleukin-17A (IL-17A) bispecific antibody', 'Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0021499', 'cui_str': 'Subcutaneous Injections'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1705947', 'cui_str': 'CTLA8'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}, {'cui': 'C0741132', 'cui_str': 'Antibody test positive'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0206492', 'cui_str': 'Bifunctional Antibodies'}]",,0.0411094,The time to reach mean maximum serum total TNFα and total IL-17A concentrations appeared to be dose dependent across the 0.1 mg/kg to 10 mg/kg IV dose groups.,"[{'ForeName': 'Derrick E', 'Initials': 'DE', 'LastName': 'Akpalu', 'Affiliation': 'Clinical Pharmacology & Pharmacometrics, Janssen R&D, Spring House, PA, USA.'}, {'ForeName': 'Bart', 'Initials': 'B', 'LastName': 'Frederick', 'Affiliation': 'Immunology Translational Medicine, Janssen R&D, Spring House, PA, USA.'}, {'ForeName': 'Ivo P', 'Initials': 'IP', 'LastName': 'Nnane', 'Affiliation': 'Clinical Pharmacology & Pharmacometrics, Janssen R&D, Spring House, PA, USA.'}, {'ForeName': 'Zhenling', 'Initials': 'Z', 'LastName': 'Yao', 'Affiliation': 'Clinical Pharmacology & Pharmacometrics, Janssen R&D, Spring House, PA, USA.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Shen', 'Affiliation': 'Immunology Discovery, Janssen R&D, Spring House, PA, USA.'}, {'ForeName': 'Tatiana', 'Initials': 'T', 'LastName': 'Ort', 'Affiliation': 'Immunology Discovery, Janssen R&D, Spring House, PA, USA.'}, {'ForeName': 'Damien', 'Initials': 'D', 'LastName': 'Fink', 'Affiliation': 'Biologics Development Sciences, Janssen R&D, Spring House, PA, USA.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Dogmanits', 'Affiliation': 'Biologics Development Sciences, Janssen R&D, Spring House, PA, USA.'}, {'ForeName': 'Donald', 'Initials': 'D', 'LastName': 'Raible', 'Affiliation': 'Immunology Translational Medicine, Janssen R&D, Spring House, PA, USA.'}, {'ForeName': 'Amarnath', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Clinical Pharmacology & Pharmacometrics, Janssen R&D, Spring House, PA, USA.'}, {'ForeName': 'Zhenhua', 'Initials': 'Z', 'LastName': 'Xu', 'Affiliation': 'Clinical Pharmacology & Pharmacometrics, Janssen R&D, Spring House, PA, USA.'}]",Journal of clinical pharmacology,['10.1002/jcph.1393'] 708,30678744,Effectiveness of psychological treatments for depression and alcohol use disorder delivered by community-based counsellors: two pragmatic randomised controlled trials within primary healthcare in Nepal.,"BACKGROUND Evidence shows benefits of psychological treatments in low-resource countries, yet few government health systems include psychological services.AimEvaluating the clinical value of adding psychological treatments, delivered by community-based counsellors, to primary care-based mental health services for depression and alcohol use disorder (AUD), as recommended by the Mental Health Gap Action Programme (mhGAP). METHOD Two randomised controlled trials, separately for depression and AUD, were carried out. Participants were randomly allocated (1:1) to mental healthcare delivered by mhGAP-trained primary care workers (psychoeducation and psychotropic medicines when indicated), or the same services plus individual psychological treatments (Healthy Activity Program for depression and Counselling for Alcohol Problems). Primary outcomes were symptom severity, measured using the Patient Health Questionnaire - 9 item (PHQ-9) for depression and the Alcohol Use Disorder Identification Test for AUD, and functional impairment, measured using the World Health Organization Disability Assessment Schedule (WHODAS), at 12 months post-enrolment. RESULTS Participants with depression in the intervention arm (n = 60) had greater reduction in PHQ-9 and WHODAS scores compared with participants in the control (n = 60) (PHQ-9: M = -5.90, 95% CI -7.55 to -4.25, β = -3.68, 95% CI -5.68 to -1.67, P < 0.001, Cohen's d = 0.66; WHODAS: M = -12.21, 95% CI -19.58 to -4.84, β = -10.74, 95% CI -19.96 to -1.53, P= 0.022, Cohen's d = 0.42). For the AUD trial, no significant effect was found when comparing control (n = 80) and intervention participants (n = 82). CONCLUSION Adding a psychological treatment delivered by community-based counsellors increases treatment effects for depression compared with only mhGAP-based services by primary health workers 12 months post-treatment.Declaration of interestNone.",2019,"(PHQ-9: M = -5.90, 95% CI -7.55 to -4.25, β",['depression and alcohol use disorder delivered by community-based counsellors: two pragmatic randomised controlled trials within primary healthcare in Nepal'],"['mental healthcare delivered by mhGAP-trained primary care workers (psychoeducation and psychotropic medicines when indicated), or the same services plus individual psychological treatments (Healthy Activity Program for depression and Counselling for Alcohol Problems', 'psychological treatments']","['symptom severity, measured using the Patient Health Questionnaire - 9 item (PHQ-9) for depression and the Alcohol Use Disorder Identification Test for AUD, and functional impairment, measured using the World Health Organization Disability Assessment Schedule (WHODAS', 'PHQ-9 and WHODAS scores']","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0001956', 'cui_str': 'Alcohol Use Disorder'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0027689', 'cui_str': 'Federal Democratic Republic of Nepal'}]","[{'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0871175', 'cui_str': 'Psycho-education'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0549393', 'cui_str': 'Alcohol problem'}]","[{'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0450985', 'cui_str': 'Alcohol use disorders identification test (assessment scale)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0043237', 'cui_str': 'WHO'}, {'cui': 'C0451124', 'cui_str': 'Disability assessment schedule (assessment scale)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.138133,"(PHQ-9: M = -5.90, 95% CI -7.55 to -4.25, β","[{'ForeName': 'Mark J D', 'Initials': 'MJD', 'LastName': 'Jordans', 'Affiliation': ""Reader,Centre for Global Mental Health,Institute of Psychiatry, Psychology and Neuroscience, King's College London,UK;and Transcultural Psychosocial Organization,Nepal.""}, {'ForeName': 'Nagendra P', 'Initials': 'NP', 'LastName': 'Luitel', 'Affiliation': 'Researcher,Transcultural Psychosocial Organization,Nepal.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Garman', 'Affiliation': 'Researcher,Alan J Flisher Centre for Public Mental Health,Department of Psychiatry and Mental Health,University of Cape Town,South Africa.'}, {'ForeName': 'Brandon A', 'Initials': 'BA', 'LastName': 'Kohrt', 'Affiliation': 'Associate Professor,Department of Psychiatry,George Washington University;and Transcultural Psychosocial Organization,Nepal.'}, {'ForeName': 'Sujit D', 'Initials': 'SD', 'LastName': 'Rathod', 'Affiliation': 'Assistant Professor,Department of Population Health,London School of Hygiene and Tropical Medicine,UK.'}, {'ForeName': 'Pragya', 'Initials': 'P', 'LastName': 'Shrestha', 'Affiliation': 'Clinician,Transcultural Psychosocial Organization,Nepal.'}, {'ForeName': 'Ivan H', 'Initials': 'IH', 'LastName': 'Komproe', 'Affiliation': 'Professor,Research and Development Department,HealthNet TPO;and Faculty of Social and Behavioural Sciences,Utrecht University,The Netherlands.'}, {'ForeName': 'Crick', 'Initials': 'C', 'LastName': 'Lund', 'Affiliation': ""Professor,Alan J Flisher Centre for Public Mental Health,Department of Psychiatry and Mental Health,University of Cape Town,South Africa; and Centre for Global Mental Health,Institute of Psychiatry, Psychology and Neuroscience, King's College London,UK.""}, {'ForeName': 'Vikram', 'Initials': 'V', 'LastName': 'Patel', 'Affiliation': 'Professor,Department of Global Health and Social Medicine,Harvard Medical School;and Department of Global Health and Population,Harvard TH Chan School of Public Health,US.'}]",The British journal of psychiatry : the journal of mental science,['10.1192/bjp.2018.300'] 709,31101685,Potential protective effects of bilirubin following the treatment of neonatal hypoxic-ischemic encephalopathy with hypothermia therapy.,"Background : Therapeutic hypothermia (TH) is the standard therapy for hypoxic-ischemic encephalopathy (HIE) and is associated with a wide range of physiological changes. Objective : We re-evaluated the effects of HIE and TH on bilirubin measurements following HIE in a center involved in the China cooling randomized controlled trial (RCT). Methods : Serial serum bilirubin concentrations measured during the first week of life were compared among the HIE + NT (normothermia) group, HIE + TH treatment group and control group (without HIE). Survivors of HIE were followed and assessed at approximately 2 years of age, and the results were correlated with peak bilirubin levels during the first week of life. Results : One hundred and thirty-eight infants were available for analysis. Significantly lower bilirubin levels were recorded in the HIE + NT group than in the controls ( P <0.05). Significant differences were not observed among the patients in the HIE + NT group (mild to severe) or between the HIE + TH group and the HIE + NT group at any time point ( P >0.05). The peak serum bilirubin concentrations recorded at 96 h of age showed a good correlation with the results of the Bayley Scales of Infant and Toddler Development, third edition (BSID-III) ( P =0.02). Conclusion : Bilirubin potentially exerts a neuroprotective effect during the first week of life, and low temperature does not affect the possible antioxidant function of bilirubin during TH following HIE.",2019,Significantly lower bilirubin levels were recorded in the HIE + NT group than in the controls ( P <0.05).,"['One hundred and thirty-eight infants', 'neonatal hypoxic-ischemic encephalopathy with hypothermia therapy']","['bilirubin', 'Bilirubin', ' ', 'HIE + NT', 'Therapeutic hypothermia (TH', 'HIE and TH']","['peak serum bilirubin concentrations', 'bilirubin levels', 'bilirubin measurements', 'peak bilirubin levels', 'Serial serum bilirubin concentrations']","[{'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0752304', 'cui_str': 'Hypoxic-Ischemic Encephalopathy'}, {'cui': 'C0413252', 'cui_str': 'Hypothermia due to exposure'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0005437', 'cui_str': 'Bilirubin IX alpha'}, {'cui': 'C0020674', 'cui_str': 'Targeted Temperature Management'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0428441', 'cui_str': 'Serum bilirubin measurement'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0344395', 'cui_str': 'Bilirubin measurement'}]",138.0,0.0567274,Significantly lower bilirubin levels were recorded in the HIE + NT group than in the controls ( P <0.05).,"[{'ForeName': 'Liangyan', 'Initials': 'L', 'LastName': 'Zou', 'Affiliation': ""Department of Neonatology, Children's Hospital of Fudan University, Shanghai 201102, China.""}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Yuan', 'Affiliation': ""Department of Neonatology, Children's Hospital of Fudan University, Shanghai 201102, China.""}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Liu', 'Affiliation': ""Department of Neonatology, Children's Hospital of Fudan University, Shanghai 201102, China.""}, {'ForeName': 'Chunmei', 'Initials': 'C', 'LastName': 'Lu', 'Affiliation': ""Department of Neonatology, Children's Hospital of Fudan University, Shanghai 201102, China.""}, {'ForeName': 'Laishuan', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': ""Department of Neonatology, Children's Hospital of Fudan University, Shanghai 201102, China laishuanwang@yahoo.com.""}]",Bioscience reports,['10.1042/BSR20182332'] 710,31189497,Basic life support training: Demonstration versus lecture - A randomised controlled trial.,"INTRODUCTION Basic life support (BLS) and the use of an automated external defibrillator (AED) improve survival from cardiac arrest. The gold standard for teaching BLS/AED is yet to be identified. The aim of this study was to compare the learning outcome of an instructor-led demonstration with a formal lecture for introducing BLS/AED skills. We hypothesized that a demonstration was superior to a lecture. METHODS First year-medical students were randomised to either a demonstration or a lecture using PowerPoint® Presentation for skill introduction during European Resuscitation Council BLS/AED courses. Participants were skill-tested after training and required to perform all skills correctly to pass the test. Finally, all participants were asked to state their preferred teaching method. RESULTS Overall, 247 participants were included in the analysis (demonstration group: 124, lecture group: 123). Pass rate was 63% in both groups, p = 1.00. Both groups performed median compression rates within guidelines recommendations, p = 0.09. Mean compression depth was 55 mm (10 mm) in the demonstration group compared with 52 mm (10 mm) in the lecture group, p = 0.05. Median tidal volume was 265 (192, 447) ml and 405 (262, 578) ml, p < 0.001, respectively. The lecture group was 3 s faster at initiating BLS, p < 0.001. In total, 226 (91%) participants preferred demonstration on a manikin for introducing BLS/AED. CONCLUSION There was no statistically significant difference in pass rate when comparing a demonstration with a lecture for introducing BLS/AED. The lecture group was slightly faster at initiating BLS. Most participants preferred a demonstration as introduction.",2020,There was no statistically significant difference in pass rate when comparing a demonstration with a lecture for introducing BLS/AED.,"['First year-medical students', '247 participants were included in the analysis (demonstration group: 124, lecture group: 123']","['automated external defibrillator (AED', 'demonstration or a lecture using PowerPoint® Presentation']","['Pass rate', 'Median tidal volume', 'Mean compression depth', 'pass rate', 'median compression rates']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0038495', 'cui_str': 'Students, Medical'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C0376683', 'cui_str': 'Lecture'}]","[{'cui': 'C0180309', 'cui_str': 'Automated External Defibrillators'}, {'cui': 'C0376683', 'cui_str': 'Lecture'}, {'cui': 'C0449450', 'cui_str': 'Presentation (attribute)'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0040210', 'cui_str': 'Tidal Volume'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}]",247.0,0.0774313,There was no statistically significant difference in pass rate when comparing a demonstration with a lecture for introducing BLS/AED.,"[{'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Hansen', 'Affiliation': 'Research Center for Emergency Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 161, 8200 Aarhus, Denmark; Department of Internal Medicine, Randers Regional Hospital, Skovlyvej 15, 8930 Randers, Denmark; Clinical Research Unit, Randers Regional Hospital, Skovlyvej 15, 8930 Randers, Denmark.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Bang', 'Affiliation': 'Research Center for Emergency Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 161, 8200 Aarhus, Denmark; Department of Internal Medicine, Randers Regional Hospital, Skovlyvej 15, 8930 Randers, Denmark; Clinical Research Unit, Randers Regional Hospital, Skovlyvej 15, 8930 Randers, Denmark.'}, {'ForeName': 'Stinne Eika', 'Initials': 'SE', 'LastName': 'Rasmussen', 'Affiliation': 'Research Center for Emergency Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 161, 8200 Aarhus, Denmark.'}, {'ForeName': 'Mette Amalie', 'Initials': 'MA', 'LastName': 'Nebsbjerg', 'Affiliation': 'Research Center for Emergency Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 161, 8200 Aarhus, Denmark.'}, {'ForeName': 'Kasper G', 'Initials': 'KG', 'LastName': 'Lauridsen', 'Affiliation': 'Research Center for Emergency Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 161, 8200 Aarhus, Denmark; Department of Internal Medicine, Randers Regional Hospital, Skovlyvej 15, 8930 Randers, Denmark; Clinical Research Unit, Randers Regional Hospital, Skovlyvej 15, 8930 Randers, Denmark.'}, {'ForeName': 'Katrine', 'Initials': 'K', 'LastName': 'Bjørnshave Bomholt', 'Affiliation': 'Research Center for Emergency Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 161, 8200 Aarhus, Denmark.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Krogh', 'Affiliation': 'Department of Anesthesia and Intensive Care, Aarhus University Hospital, Palle Juul-Jensens Blvd. 99, 8200 Aarhus, Denmark; Centre for Health Sciences Education, Aarhus University, Palle Juul-Jensens Blvd. 82, INCUBA Skejby building B, 8200 Aarhus, Denmark.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Løfgren', 'Affiliation': 'Research Center for Emergency Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 161, 8200 Aarhus, Denmark; Department of Internal Medicine, Randers Regional Hospital, Skovlyvej 15, 8930 Randers, Denmark; Clinical Research Unit, Randers Regional Hospital, Skovlyvej 15, 8930 Randers, Denmark; Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Blvd. 82, INCUBA Skejby building 2, 8200 Aarhus, Denmark; Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Blvd. 69, 8200 Aarhus, Denmark. Electronic address: bo.loefgren@clin.au.dk.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2019.06.008'] 711,31172849,Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials.,"BACKGROUND In Phase 3 studies, teriflunomide reduced relapse rates and disability progression compared with placebo; however, decreases in lymphocyte counts were also observed. OBJECTIVE To describe the effect of long-term teriflunomide treatment on lymphocyte counts and infection rates among patients in pooled analyses of Phase 3 core and extension studies. METHODS Four randomized trials (TEMSO, TOWER, TENERE, and TOPIC) compared teriflunomide 7 mg or 14 mg treatment with either placebo and/or subcutaneous interferon (IFN) β-1a 44 µg in patients with relapsing forms of multiple sclerosis (MS) (or first clinical episode suggestive of MS in TOPIC). RESULTS In 1895, patients ever exposed to teriflunomide, mean (standard deviation) absolute lymphocyte counts declined from Week 0 (1.89 (0.59)) to Week 24 (1.67 (0.52)) and then remained stable thereafter. In the core plus extension studies (up to 10.7 years), 7.3% and 2.2% experienced Grade 1 and Grade 2 lymphopenia, respectively. Infections were reported in 56.9% of patients without lymphopenia, 60.9% with Grade 1 lymphopenia, and 54.8% with Grade 2 lymphopenia. Serious infections occurred in 3.7%, 4.3%, and 7.1%, respectively. CONCLUSION Long-term risk of lymphopenia and infections in patients who continue to receive teriflunomide is low, demonstrating a limited impact on adaptive and innate immunity.",2020,"Infections were reported in 56.9% of patients without lymphopenia, 60.9% with Grade 1 lymphopenia, and 54.8% with Grade 2 lymphopenia.","['patients in pooled analyses of Phase 3 core and extension studies', 'patients with relapsing forms of multiple sclerosis (MS) (or first clinical episode suggestive of MS in TOPIC']","['teriflunomide', 'placebo and/or subcutaneous interferon (IFN) β-1a 44\u2009µg', 'placebo', 'long-term teriflunomide']","['relapse rates and disability progression', 'Serious infections', 'lymphocyte counts', 'lymphocyte counts and infection rates', 'Characterizing lymphocyte counts and infection rates', 'Infections']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0337051', 'cui_str': 'Pool (environment)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0439561', 'cui_str': 'Phase 3 (qualifier value)'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0332299', 'cui_str': 'Suggestive of (attribute)'}]","[{'cui': 'C1718383', 'cui_str': 'teriflunomide'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C0021747', 'cui_str': 'Interferons'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0200635', 'cui_str': 'Lymphocyte Number'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}]",1895.0,0.111965,"Infections were reported in 56.9% of patients without lymphopenia, 60.9% with Grade 1 lymphopenia, and 54.8% with Grade 2 lymphopenia.","[{'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'Comi', 'Affiliation': 'Vita-Salute San Raffaele University, Milan, Italy.'}, {'ForeName': 'Aaron E', 'Initials': 'AE', 'LastName': 'Miller', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Benamor', 'Affiliation': 'Sanofi, Chilly-Mazarin, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Truffinet', 'Affiliation': 'Sanofi, Chilly-Mazarin, France.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Poole', 'Affiliation': 'Sanofi, Cambridge, MA, USA.'}, {'ForeName': 'Mark S', 'Initials': 'MS', 'LastName': 'Freedman', 'Affiliation': 'University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada.'}]","Multiple sclerosis (Houndmills, Basingstoke, England)",['10.1177/1352458519851981'] 712,31180608,Quality assessment of fetal middle cerebral and umbilical artery Doppler images using an objective scale within an international randomized controlled trial.,"OBJECTIVES To determine the quality of Doppler images of the fetal middle cerebral artery (MCA) and umbilical artery (UA) using an objective scale, and to determine the reliability of this scale, within a multicenter randomized controlled trial (Revealed versus concealed criteria for placental insufficiency in unselected obstetric population in late pregnancy (Ratio37)). METHODS The Ratio37 trial is an ongoing randomized, open-label, multicenter controlled study of women with a low-risk pregnancy recruited at 20 weeks. Doppler measurements of the fetal MCA and UA were performed at 37 weeks. Twenty patients from each of the six participating centers were selected randomly, with two images evaluated per patient (one each for the MCA and UA). The quality of a total of 240 images was evaluated by six experts, scored on an objective scale of six items. Inter- and intrarater reliability was assessed using the Fleiss-modified kappa statistic for ordinal scales. RESULTS On average, 89.2% of MCA images and 85.0% of UA images were rated as being of perfect (score of 6) or almost perfect (score of 5) quality. Kappa values for intrarater reliability of quality assessment were 0.90 (95% CI, 0.88-0.92) and 0.90 (95% CI, 0.88-0.93) for the MCA and UA, respectively. The corresponding inter-rater reliability values were 0.85 (95% CI, 0.81-0.89) and 0.84 (95% CI, 0.80-0.89), respectively. CONCLUSION The quality of MCA and UA Doppler ultrasound images can be evaluated reliably using an objective scale. Over 85% of images, which were obtained by operators from a broad range of clinical practices within a multicenter study, were rated as being of perfect or almost perfect quality. Intra- and inter-rater reliability of quality assessment was very good. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.",2020,"For MCA, 89.2% of the images were on average considered perfect (score of 6) or almost perfect (score of 5).","['unselected obstetric population in late pregnancy', ' 20 patients were randomly selected (2 images per patient, UA and MCA) from each of the 6 participating centres']","['middle cerebral artery and umbilical artery Doppler images', 'middle cerebral artery (MCA) and the umbilical artery (UA) Doppler evaluation']","['inter-rater reliabilities', 'inter- and intra-rater reliability']","[{'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0149566', 'cui_str': 'Middle Cerebral Artery'}, {'cui': 'C0041632', 'cui_str': 'Umbilical Arteries'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}, {'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}]",240.0,0.164292,"For MCA, 89.2% of the images were on average considered perfect (score of 6) or almost perfect (score of 5).","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Rial-Crestelo', 'Affiliation': 'Fetal Medicine Research Center, BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clinic and Hospital Sant Joan de Déu), Institut Clínic de Ginecología, Obstetricia y Neonatología, IDIBAPS, Obstetrics and Gynecology, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Morales-Roselló', 'Affiliation': 'Department of Obstetrics and Gynecology, Hospital Universitario y Politécnico la Fe, Valencia, Spain.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Hernández-Andrade', 'Affiliation': ""Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Wayne State University, Hutzel Women's Hospital, Perinatology Research Branch, NICHD/NIH/DHHS, Detroit, MI, USA.""}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Prefumo', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Brescia, Brescia, Italy.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Oros', 'Affiliation': 'Aragon Institute for Health Research (IIS Aragón), Obstetrics Department, Hospital Clínico Univeristario Zaragoza, Zaragoza, Spain.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Caffici', 'Affiliation': 'Sociedad Argentina de Ultrasonografía en Medicina y Biología, Buenos Aires, Argentina.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Sotiriadis', 'Affiliation': '2nd Department of Obstetrics and Gynecology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Zohav', 'Affiliation': ""Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Lis Maternity and Women's Hospital University, Tel Aviv University, Tel Aviv, Israel.""}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Cruz-Martinez', 'Affiliation': ""Department of Fetal Medicine and Surgery, Children's and Women's Specialty Hospital of Querétaro, Querétaro, Mexico.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Parra-Cordero', 'Affiliation': 'Fetal Medicine Unit, Obstetrics and Gynecology, University of Chile Hospital, Santiago de Chile, Chile.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Lubusky', 'Affiliation': 'Department of Obstetrics and Gynecology, Palacky University Olomouc, Faculty of Medicine and Dentistry, University Hospital Olomouc, Olomouc, Czech Republic.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kacerovsky', 'Affiliation': 'Charles University in Prague, Faculty of Medicine Hradec Kralove, Department of Obstetrics and Gynecology, University Hospital Hradec Kralove, Prague, Czech Republic.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Figueras', 'Affiliation': 'Fetal Medicine Research Center, BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clinic and Hospital Sant Joan de Déu), Institut Clínic de Ginecología, Obstetricia y Neonatología, IDIBAPS, Obstetrics and Gynecology, University of Barcelona, Barcelona, Spain.'}]",Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology,['10.1002/uog.20370'] 713,31563095,"The effects of a working memory load on drinking-related decisions: The role of incentives, disincentives, and lifetime alcohol problems.","BACKGROUND This study extends this literature on effects of working memory (WM) load on impulsive and disadvantageous decision-making by investigating the impact of WM load on drinking-related decisions in different incentive and disincentive contexts in a large sample (n = 821, 373 women) of young adults, 558 of whom had an alcohol use disorder (AUD). METHODS Decisions to attend and drink at hypothetical party events that varied in terms of alcohol party incentives (high vs low) and next day responsibility disincentives (high vs moderate vs low) were assessed. Subjects were randomly assigned to either a WM load (n = 387) or no load condition (n = 434). RESULTS Analyses revealed that the WM load reduced the degree to which a high disincentive deterred attendance decisions; attendance decisions were more likely under WM load in the high disincentive contexts. This effect was not found in the moderate or low disincentive contexts. Additionally, a WM load increased the effects of high alcohol party incentives on both decisions to attend and drink. The WM load also resulted in faster attendance decision reaction times, suggesting that subjects were more impulsive under load. CONCLUSIONS These results suggest that a WM load had a general effect of disrupting the decision-making process, reducing the inhibitory effects of high disincentives, amplifying the facilitating effects of high party incentives on alcohol-related decisions, and reducing decision deliberation times (reaction times). This suggests that individuals under significant cognitive load engage in more impulsive and riskier decisions when deciding to attend and drink at party events.",2019,"RESULTS Analyses revealed that the WM load reduced the degree to which a high disincentive deterred attendance decisions; attendance decisions were more likely under WM load in the high disincentive contexts.","['a large sample (n\u202f=\u202f821, 373 women) of young adults, 558 of whom had an alcohol use disorder (AUD']","['WM load (n\u202f=\u202f387) or no load condition', 'working memory (WM', 'working memory load']",['attendance decision reaction times'],"[{'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0001956', 'cui_str': 'Alcohol Use Disorder'}]","[{'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}]","[{'cui': 'C0034746', 'cui_str': 'Response Time'}]",373.0,0.0315715,"RESULTS Analyses revealed that the WM load reduced the degree to which a high disincentive deterred attendance decisions; attendance decisions were more likely under WM load in the high disincentive contexts.","[{'ForeName': 'Polly F', 'Initials': 'PF', 'LastName': 'Ingram', 'Affiliation': 'Department of Psychological and Brain Sciences, 1101 E 10th St, Indiana University, Bloomington, IN, 47405, United States.'}, {'ForeName': 'Peter R', 'Initials': 'PR', 'LastName': 'Finn', 'Affiliation': 'Department of Psychological and Brain Sciences, 1101 E 10th St, Indiana University, Bloomington, IN, 47405, United States. Electronic address: finnp@indiana.edu.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2019.107567'] 714,31062997,Reduced Reward Responsiveness Predicts Change in Depressive Symptoms in Anxious Children and Adolescents Following Treatment.,"Objectives: Reduced reward responsiveness, as measured by the event-related potential (ERP) component, the reward positivity (RewP), has been shown to play a role in the development of internalizing disorders, but implications for treatment remain unclear. In adult patients with anxiety and/or depression, reduced RewP has emerged as a predictor of greater change in symptoms following cognitive behavior therapy (CBT) or selective serotonin reuptake inhibitor (SSRI) treatment. The objectives of this preliminary study were to extend these findings to children and adolescents with anxiety disorders by evaluating RewP to reward as a predictor of change in anxiety severity or depressive symptoms following treatment with CBT or SSRI and to explore whether RewP differentially predicts response to one type of treatment. Methods: Patients (7-19 years old) with social and/or generalized anxiety disorder ( N  = 27) completed baseline measures of anxiety severity and depressive symptoms, as well as an ERP monetary reward anticipation and feedback task. RewP was measured in response to reward and breaking even feedback. Patients were then randomly assigned to CBT or SSRI treatment, and completed measures of anxiety and depressive symptom severity at the last treatment session. Results: Reduced reward responsiveness, as measured by RewP to rewards, predicted greater change in depressive symptoms following treatment, adjusting for baseline symptoms, age, and RewP to breaking even. RewP was not a significant predictor of change in anxiety symptoms. Although preliminary, exploratory analyses suggested that among anxious youth, RewP specifically predicted change in depressive symptoms following CBT, rather than SSRI. Conclusion: Results provide preliminary support for the utility of ERP measures of reward responsiveness in predicting treatment response in youth. With further research and standardization, ERP assessments could potentially be implemented in clinical settings to inform prognosis and treatment planning for youth with internalizing disorders.",2019,"Although preliminary, exploratory analyses suggested that among anxious youth, RewP specifically predicted change in depressive symptoms following CBT, rather than SSRI. ","['Anxious Children and Adolescents Following Treatment', 'children and adolescents with anxiety disorders', 'adult patients with anxiety and/or depression', 'Methods: Patients (7-19 years old) with social and/or generalized anxiety disorder ( N \u2009=\u200927', 'youth with internalizing disorders', 'youth']",['CBT or SSRI'],"['reward responsiveness, as measured by the event-related potential (ERP) component, the reward positivity (RewP', 'anxiety severity and depressive symptoms, as well as an ERP monetary reward anticipation and feedback task', 'depressive symptoms', 'anxiety and depressive symptom severity', 'anxiety symptoms', 'Reduced reward responsiveness']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0003469', 'cui_str': 'Anxiety Disorders'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",[],"[{'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0282171', 'cui_str': 'Potentials, Event-Related'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0337380', 'cui_str': 'Endoscopic retrograde pancreatography (procedure)'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}]",,0.0656652,"Although preliminary, exploratory analyses suggested that among anxious youth, RewP specifically predicted change in depressive symptoms following CBT, rather than SSRI. ","[{'ForeName': 'Autumn', 'Initials': 'A', 'LastName': 'Kujawa', 'Affiliation': '1 Department of Psychology and Human Development, Vanderbilt University, Nashville, Tennessee.'}, {'ForeName': 'Katie L', 'Initials': 'KL', 'LastName': 'Burkhouse', 'Affiliation': '2 Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois.'}, {'ForeName': 'Shannon R', 'Initials': 'SR', 'LastName': 'Karich', 'Affiliation': '2 Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois.'}, {'ForeName': 'Kate D', 'Initials': 'KD', 'LastName': 'Fitzgerald', 'Affiliation': '3 Department of Psychiatry, University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'Christopher S', 'Initials': 'CS', 'LastName': 'Monk', 'Affiliation': '3 Department of Psychiatry, University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'K Luan', 'Initials': 'KL', 'LastName': 'Phan', 'Affiliation': '2 Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois.'}]",Journal of child and adolescent psychopharmacology,['10.1089/cap.2018.0172'] 715,29520735,Neonatal outcomes among twins stratified by method of conception: secondary analysis of maternal fetal medicine (MFMU) network database.,"PURPOSE To investigate whether twin pregnancies conceived by different forms of fertility treatments are associated with adverse neonatal outcomes and to examine the difference in maternal and obstetrical characteristics between patients. METHODS Our study was a retrospective analysis of twin pregnancies conceived by fertility treatments from a prospectively collected database. Treatments were stratified into two groups: group 1 (ART) consisted of in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), and group 2 (non-ART) included intrauterine insemination (IUI) and ovulation induction (OI). Composite neonatal morbidity included respiratory distress syndrome, intraventricular hemorrhage, leukomalacia, chronic lung disease, and death prior to discharge. RESULTS There were 460 neonates in our study; among them, 67% (n = 310) were in group 1, and 33% (n = 150) in group 2. Group 1 patients were more likely to be older (p = 0.004), nulliparous (p = 0.01), delivered twins with lower birth weights (2278 g ± 605 vs. 2427 ± 519, p = 0.009), and had more deliveries < 32 weeks gestation (p = 0.001). In multivariable Poisson regression model, only neonatal intensive care unit admission rate was increased for group 1 twins (aRR = 1.27, 95% CI 1.003-1.60). CONCLUSIONS After adjusting for confounders, twins conceived via ART compared to non-ART had similar neonatal outcomes. These data can help when counseling this patient population and assist in planning larger prospective cohorts.",2018,"Group 1 patients were more likely to be older (p = 0.004), nulliparous (p = 0.01), delivered twins with lower birth weights (2278 g ± 605 vs. 2427 ± 519, p = 0.009), and had more deliveries < 32 weeks gestation (p = 0.001).","['twin pregnancies conceived by fertility treatments from a prospectively collected database', '460 neonates in our study; among them, 67% (n\u2009=\u2009310', 'twins stratified by method of conception: secondary analysis of maternal fetal medicine (MFMU) network database', 'twin pregnancies']","['group 1 (ART) consisted of in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), and group 2 (non-ART) included intrauterine insemination (IUI) and ovulation induction (OI']","['neonatal intensive care unit admission rate', 'delivered twins with lower birth weights', 'respiratory distress syndrome, intraventricular hemorrhage, leukomalacia, chronic lung disease, and death prior to discharge']","[{'cui': 'C0152150', 'cui_str': 'Pregnancy, Twin'}, {'cui': 'C0015895', 'cui_str': 'Fecundity'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0009637', 'cui_str': 'Conception'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}]","[{'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C0015915', 'cui_str': 'Test-Tube Fertilization'}, {'cui': 'C0455164', 'cui_str': 'ICSI'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0546824', 'cui_str': 'Intrauterine artificial insemination (procedure)'}, {'cui': 'C0029967', 'cui_str': 'Ovulation Induction'}]","[{'cui': 'C0021709', 'cui_str': 'Newborn ICU'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}, {'cui': 'C0035220', 'cui_str': 'Respiratory Distress Syndrome, Newborn'}, {'cui': 'C0240059', 'cui_str': 'Ventricular hemorrhage (disorder)'}, {'cui': 'C0746102', 'cui_str': 'Chronic lung disease'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}]",,0.242173,"Group 1 patients were more likely to be older (p = 0.004), nulliparous (p = 0.01), delivered twins with lower birth weights (2278 g ± 605 vs. 2427 ± 519, p = 0.009), and had more deliveries < 32 weeks gestation (p = 0.001).","[{'ForeName': 'Jaimin S', 'Initials': 'JS', 'LastName': 'Shah', 'Affiliation': 'Department of Obstetrics & Gynecology, McGovern Medical School at the University of Texas Health Science Center, 6431 Fannin St, Suite 3.214, Houston, TX, 77030, USA. Jaimin.Shah@uth.tmc.edu.'}, {'ForeName': 'Susan Hosseini', 'Initials': 'SH', 'LastName': 'Nasab', 'Affiliation': 'Department of Obstetrics & Gynecology, McGovern Medical School at the University of Texas Health Science Center, 6431 Fannin St, Suite 3.214, Houston, TX, 77030, USA.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Chappell', 'Affiliation': 'Department of Reproductive Endocrinology and Infertility, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Han-Yang', 'Initials': 'HY', 'LastName': 'Chen', 'Affiliation': 'Department of Obstetrics & Gynecology, McGovern Medical School at the University of Texas Health Science Center, 6431 Fannin St, Suite 3.214, Houston, TX, 77030, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Schutt', 'Affiliation': 'Department of Reproductive Endocrinology and Infertility, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Hector', 'Initials': 'H', 'LastName': 'Mendez-Figueroa', 'Affiliation': 'Department of Maternal & Fetal Medicine, McGovern Medical School at the University of Texas Health Science Center, Houston, TX, USA.'}]",Journal of assisted reproduction and genetics,['10.1007/s10815-018-1149-x'] 716,31867987,Individual and organizational characteristics predicting intervention use for children with autism in schools.,"LAY ABSTRACT Several interventions or treatment programs have been shown through research to improve social outcomes for children with autism, but they often are not used in schools. This study examined individual (school personnel) and organizational (school level) factors associated with the use of a research-informed social engagement intervention, Remaking Recess, for children with autism in elementary schools. A total of 28 school personnel from 12 schools in 5 districts in the northeastern United States participated. Schools were randomly assigned to (1) training in Remaking Recess only or (2) training in Remaking Recess with implementation support (tailored strategies to remove barriers to increase use of Remaking Recess). School personnel rated their attitudes about research-informed interventions, organizational readiness (school's readiness to use a research-informed intervention), and fidelity or the degree to which an intervention is used as it was originally designed. Observers rated school personnel's fidelity at baseline (pre-intervention training) and exit (post-intervention training). The results suggest that self-rated fidelity was lower when staff perceived the use of Remaking Recess was required; however, observer-rated fidelity was lower when staff rated Remaking Recess as appealing. In addition, self-rated fidelity was higher when there was a sufficient number of staff, positive individual growth, and organizational adaptability. The results also indicated higher observer-rated fidelity when staff perceived positive influence over their coworkers. The results suggest that both individual (attitudes) and organizational (influence, staffing, growth, adaptability) characteristics may affect implementation success in schools. A collaborative decision-making approach for evidence-based practice use is recommended.",2020,Observers rated school personnel's fidelity at baseline (pre-intervention training) and exit (post-intervention training).,"['children with autism', 'children with autism in elementary schools', '28 school personnel from 12 schools in 5 districts in the northeastern United States participated', 'children with autism in schools']",['training in Remaking Recess only or (2) training in Remaking Recess with implementation support (tailored strategies to remove barriers to increase use of Remaking Recess'],"['self-rated fidelity', ""Observers rated school personnel's fidelity""]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0036375', 'cui_str': 'School'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C1883720', 'cui_str': 'Removes'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0036375', 'cui_str': 'School'}]",,0.0181544,Observers rated school personnel's fidelity at baseline (pre-intervention training) and exit (post-intervention training).,"[{'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Locke', 'Affiliation': 'University of Washington, USA.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Kang-Yi', 'Affiliation': 'University of Pennsylvania, USA.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Frederick', 'Affiliation': 'University of Washington, USA.'}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Mandell', 'Affiliation': 'University of Pennsylvania, USA.'}]",Autism : the international journal of research and practice,['10.1177/1362361319895923'] 717,31764511,"Effect of High-dose Vitamin A Supplementation in Children With Sickle Cell Disease: A Randomized, Double-blind, Dose-finding Pilot Study.","Suboptimal vitamin A status (serum retinol <30 µg/dL) is associated with poor clinical outcomes in children with the hemoglobin-SS disease (HbSS), and supplementation with the recommended daily allowance of retinol is ineffective in improving vitamin A status. In a single-center randomized blinded dose-finding pilot study, we compared vitamin A and nutritional status in children with HbSS to healthy children and explored the impact of high-dose supplementation on the primary outcome serum vitamin A status. Exploratory outcomes included hematologic, nutritional, immunologic, and muscle function status in children with HbSS. A mixed-effects linear regression model evaluated associations between vitamin A dose, serum retinol, and exploratory outcomes. Twenty healthy children participated, and 22 subjects with HbSS were randomized to oral 3000 or 6000 IU/d retinol for 8 weeks; 21 subjects completed all evaluations. Serum retinol, growth, and nutritional status were all suboptimal in HbSS subjects at baseline, and supplementation did not change vitamin A status. Fetal hemoglobin (Δ=2.5, 95% confidence interval [CI], 0.5-4.3), mean corpuscular volume (Δ=2.7, 95% CI, 0.7-4.7), mean corpuscular hemoglobin (Δ=1.4, 95% CI, 0.5-2.3), and mean corpuscular hemoglobin concentration (Δ=0.5, 95% CI, 0.1-0.9) all improved with supplementation. Mild improvements in erythrocyte indices, growth status, and muscle function occurred independent of hydroxyurea use.",2020,"Serum retinol, growth, and nutritional status were all suboptimal in HbSS subjects at baseline, and supplementation did not change vitamin A status.","['children with the hemoglobin-SS disease (HbSS', 'Twenty healthy children participated, and 22 subjects with HbSS', 'children with HbSS', 'Children With Sickle Cell Disease', 'children with HbSS to healthy children']","['vitamin A and nutritional status', 'Suboptimal vitamin A status (serum retinol <30\u2009µg/dL', 'High-dose Vitamin A Supplementation']","['Fetal hemoglobin', 'Serum retinol, growth, and nutritional status', 'mean corpuscular hemoglobin', 'mean corpuscular volume', 'erythrocyte indices, growth status, and muscle function', 'hematologic, nutritional, immunologic, and muscle function status', 'mean corpuscular hemoglobin concentration']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0019035', 'cui_str': 'Hemoglobin SS'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0686744', 'cui_str': 'Well child (finding)'}, {'cui': 'C0002895', 'cui_str': 'Sickle Cell Disease'}]","[{'cui': 'C0042839', 'cui_str': 'Vitamin A'}, {'cui': 'C0392209', 'cui_str': 'Nutrition Status'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0087161', 'cui_str': 'All-Trans-Retinol'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C4524019', 'cui_str': 'Vitamin A supplementation'}]","[{'cui': 'C0015936', 'cui_str': 'Hemoglobin F'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0087161', 'cui_str': 'All-Trans-Retinol'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0392209', 'cui_str': 'Nutrition Status'}, {'cui': 'C0369183', 'cui_str': 'Mean corpuscular hemoglobin determination (procedure)'}, {'cui': 'C0863148', 'cui_str': 'Erythrocyte mean corpuscular volume determination (procedure)'}, {'cui': 'C0014792', 'cui_str': 'Blood Corpuscles, Red'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0231484', 'cui_str': 'Muscular activity'}, {'cui': 'C0205488', 'cui_str': 'Hematologic (qualifier value)'}, {'cui': 'C0205470', 'cui_str': 'Immunologic (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",20.0,0.171449,"Serum retinol, growth, and nutritional status were all suboptimal in HbSS subjects at baseline, and supplementation did not change vitamin A status.","[{'ForeName': 'Jefferson N', 'Initials': 'JN', 'LastName': 'Brownell', 'Affiliation': 'Division of Gastroenterology, Hepatology, and Nutrition.'}, {'ForeName': 'Joan I', 'Initials': 'JI', 'LastName': 'Schall', 'Affiliation': 'Division of Gastroenterology, Hepatology, and Nutrition.'}, {'ForeName': 'Carolyn R', 'Initials': 'CR', 'LastName': 'Mcanlis', 'Affiliation': 'Division of Gastroenterology, Hepatology, and Nutrition.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Smith-Whitley', 'Affiliation': 'Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.'}, {'ForeName': 'Cynthia F', 'Initials': 'CF', 'LastName': 'Norris', 'Affiliation': 'Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.'}, {'ForeName': 'Virginia A', 'Initials': 'VA', 'LastName': 'Stallings', 'Affiliation': 'Division of Gastroenterology, Hepatology, and Nutrition.'}]",Journal of pediatric hematology/oncology,['10.1097/MPH.0000000000001673'] 718,32410608,The role of text messaging intervention in Inner Mongolia among patients with type 2 diabetes mellitus: a randomized controlled trial.,"BACKGROUND Short messages service (SMS) provides a practical medium for delivering content to address patients to adherence to self-management. The aim of study was to design some patient-centered health education messages, evaluate the feasibility of messages, and explore the effect of this model. METHODS The messages were designed by a panel of experts, and SMS Quality Evaluation Questionnaire was used to evaluate their quality. A two-arm randomized controlled trial was conducted to evaluate the effectiveness of this management model. Participants were randomly divided into an intervention group (IG) who received evaluated messages and a control group (CG) who received regular education. The primary outcomes were changes in plasma glucose and control rates, and the secondary outcomes were improvements in diet control, physical activities, weight control, etc. RESULTS: A total of 42 messages covering five main domains: health awareness, diet control, physical activities, living habits and weight control were designed, and the average scores of the messages were 8.0 (SD 0.7), 8.5 (SD 0.6), 7.9 (SD 1.0), 8.0 (SD 0.7), and 8.4 (SD 0.9), respectively. In the SMS intervention, 171 patients with an average age of 55.1 years were involved, including 86 in the CG and 85 in the IG. At 12 months, compared with the control group (CG), the decrease of fasting plasma glucose (FPG) (1.5 vs. 0.4, P = 0.011) and control rate (49.4% vs. 33.3%, P = 0.034), the postprandial glucose (PPG) (5.8 vs. 4.2, P = 0.009) and control rate (57.8% vs. 33.7%, P = 0.002) were better in the intervention group (IG). In terms of self-management, improvements in weight control (49.3% vs. 28.2%, P = 0.031), vegetables consumption (87.3% vs. 29.0%, P < 0.001), fruits consumption (27.5% vs. 7.4%, P = 0.022), and physical activities (84.7% vs. 70.0%, P = 0.036) were better in the IG than in the CG. CONCLUSIONS The overall quality of the messages was high. It was effective and feasible to carry out an SMS intervention to improve the behavioral habits of patients with chronic diseases in remote and undeveloped areas. TRIAL REGISTRATION Clinicaltrials.gov, ChiCTR1900023445. Registered May 28, 2019--Retrospectively registered.",2020,"It was effective and feasible to carry out an SMS intervention to improve the behavioral habits of patients with chronic diseases in remote and undeveloped areas. ","['patients with type 2 diabetes mellitus', '171 patients with an average age of 55.1\u2009years were involved, including 86 in the CG and 85 in the IG', 'patients with chronic diseases in remote and undeveloped areas']","['intervention group (IG) who received evaluated messages and a control group (CG) who received regular education', 'Short messages service (SMS', 'SMS intervention', 'text messaging intervention']","['fruits consumption', 'fasting plasma glucose (FPG', 'weight control', 'physical activities', 'overall quality', 'diet control, physical activities, weight control, etc', 'postprandial glucose (PPG', 'vegetables consumption', 'behavioral habits', 'control rate', 'changes in plasma glucose and control rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C3178908', 'cui_str': 'Texting'}]","[{'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0743195', 'cui_str': 'Dietary control'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0018464', 'cui_str': 'Habits'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}]",171.0,0.0897911,"It was effective and feasible to carry out an SMS intervention to improve the behavioral habits of patients with chronic diseases in remote and undeveloped areas. ","[{'ForeName': 'Xuemei', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Health Statistics, School of Public Health, Inner Mongolia Medical University, Hohhot, China.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Liu', 'Affiliation': 'Department of Health Statistics, School of Public Health, Inner Mongolia Medical University, Hohhot, China.'}, {'ForeName': 'Maolin', 'Initials': 'M', 'LastName': 'Du', 'Affiliation': 'Department of Health Statistics, School of Public Health, Inner Mongolia Medical University, Hohhot, China. dumaolin2016@163.com.'}, {'ForeName': 'Ruiqi', 'Initials': 'R', 'LastName': 'Hao', 'Affiliation': 'Department of Health Statistics, School of Public Health, Inner Mongolia Medical University, Hohhot, China.'}, {'ForeName': 'Huiqiu', 'Initials': 'H', 'LastName': 'Zheng', 'Affiliation': 'Department of Health Statistics, School of Public Health, Inner Mongolia Medical University, Hohhot, China.'}, {'ForeName': 'Chaoli', 'Initials': 'C', 'LastName': 'Yan', 'Affiliation': 'Department of Endocrinology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.'}]",BMC medical informatics and decision making,['10.1186/s12911-020-01129-7'] 719,31712290,Effectiveness of Community-Links Practitioners in Areas of High Socioeconomic Deprivation.,"PURPOSE To assess the effect of a primary care-based community-links practitioner (CLP) intervention on patients' quality of life and well-being. METHODS Quasi-experimental cluster-randomized controlled trial in socioeconomically deprived areas of Glasgow, Scotland. Adult patients (aged 18 years or older) referred to CLPs in 7 intervention practices were compared with a random sample of adult patients from 8 comparison practices at baseline and 9 months. PRIMARY OUTCOME health-related quality of life (EQ-5D-5L, a standardized measure of self-reported health-related quality of life that assesses 5 dimensions at 5 levels of severity). SECONDARY OUTCOMES well-being (Investigating Choice Experiments for the Preferences of Older People Capability Measure for Adults [ICECAP-A]), depression (Hospital Anxiety and Depression Scale, Depression [HADS-D]), anxiety (Hospital Anxiety and Depression Scale, Anxiety [HADS-A]), and self-reported exercise. Multilevel, multiregression analyses adjusted for baseline differences. Patients were not blinded to the intervention, but outcome analysis was masked. RESULTS Data were collected on 288 and 214 (74.3%) patients in the intervention practices at baseline and follow-up, respectively, and on 612 and 561 (92%) patients in the comparison practices. Intention-to-treat analysis found no differences between the 2 groups for any outcome. In subgroup analyses, patients who saw the CLP on 3 or more occasions (45% of those referred) had significant improvements in EQ-5D-5L, HADS-D, HADS-A, and exercise levels. There was a high positive correlation between CLP consultation rates and patient uptake of suggested community resources. CONCLUSIONS We were unable to prove the effectiveness of referral to CLPs based in primary care in deprived areas for improving patient outcomes. Future efforts to boost uptake and engagement could improve overall outcomes, although the apparent improvements in those who regularly saw the CLPs may be due to reverse causality. Further research is needed before wide-scale deployment of this approach.",2019,We were unable to prove the effectiveness of referral to CLPs based in primary care in deprived areas for improving patient outcomes.,"['patients', 'Adult patients (aged 18 years or older', 'Quasi-experimental cluster-randomized controlled trial in socioeconomically deprived areas of Glasgow, Scotland', 'Community-Links Practitioners in Areas of High Socioeconomic Deprivation']",['primary care-based community-links practitioner (CLP) intervention'],"['Preferences of Older People Capability Measure for Adults [ICECAP-A]), depression (Hospital Anxiety and Depression Scale, Depression [HADS-D]), anxiety (Hospital Anxiety and Depression Scale, Anxiety [HADS-A]), and self-reported exercise', 'health-related quality of life (EQ-5D-5L, a standardized measure of self-reported health-related quality of life that assesses 5 dimensions at 5 levels of severity', 'EQ-5D-5L, HADS-D, HADS-A, and exercise levels', 'quality of life and well-being']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C1096777', 'cui_str': 'Randomized Controlled Trial'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0036453', 'cui_str': 'Scotland'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]","[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0558295', 'cui_str': 'Preferences (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}, {'cui': 'C0048008', 'cui_str': 'Benzenamine, 4-((4-aminophenyl)sulfonyl)-N-hydroxy-'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0439534', 'cui_str': 'Dimensions (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",,0.189547,We were unable to prove the effectiveness of referral to CLPs based in primary care in deprived areas for improving patient outcomes.,"[{'ForeName': 'Stewart W', 'Initials': 'SW', 'LastName': 'Mercer', 'Affiliation': 'Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom Stewart.Mercer@ed.ac.uk.'}, {'ForeName': 'Bridie', 'Initials': 'B', 'LastName': 'Fitzpatrick', 'Affiliation': 'Institute of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Lesley', 'Initials': 'L', 'LastName': 'Grant', 'Affiliation': 'Institute of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Nai Rui', 'Initials': 'NR', 'LastName': 'Chng', 'Affiliation': 'College of Social Sciences, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'McConnachie', 'Affiliation': 'Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Andisheh', 'Initials': 'A', 'LastName': 'Bakhshi', 'Affiliation': 'Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'James-Rae', 'Affiliation': 'Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Catherine A', 'Initials': 'CA', 'LastName': ""O'Donnell"", 'Affiliation': 'Institute of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Wyke', 'Affiliation': 'College of Social Sciences, University of Glasgow, Glasgow, United Kingdom.'}]",Annals of family medicine,['10.1370/afm.2429'] 720,31755321,Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.,"Ripretinib (DCC-2618) is a novel, type II tyrosine switch control inhibitor designed to broadly inhibit activating and drug-resistant mutations in KIT and PDGFRA . Ripretinib has emerged as a promising investigational agent for the treatment of gastrointestinal stromal tumor owing to targeted inhibition of secondary resistance mutations that may develop following treatment with prior line(s) of tyrosine kinase inhibitors. Here we describe the rationale and design of intrigue (NCT03673501), a global, randomized (1:1), open-label, Phase III study comparing the safety and efficacy of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor following imatinib. The primary end point is progression-free survival and key secondary objectives include objective response rate and overall survival. Clinical Trial Registration: NCT03673501.",2020,Ripretinib has emerged as a promising investigational agent for the treatment of gastrointestinal stromal tumor owing to targeted inhibition of secondary resistance mutations that may develop following treatment with prior line(s) of tyrosine kinase inhibitors.,"['patients with advanced gastrointestinal stromal tumor following imatinib', 'advanced gastrointestinal stromal tumor after imatinib']","['Ripretinib (DCC-2618', 'ripretinib versus sunitinib']","['progression-free survival', 'objective response rate and overall survival', 'safety and efficacy']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0238198', 'cui_str': 'Gastrointestinal Stromal Tumors'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0935989', 'cui_str': 'imatinib'}]","[{'cui': 'C1176020', 'cui_str': 'sunitinib'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0380732,Ripretinib has emerged as a promising investigational agent for the treatment of gastrointestinal stromal tumor owing to targeted inhibition of secondary resistance mutations that may develop following treatment with prior line(s) of tyrosine kinase inhibitors.,"[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'Nemunaitis', 'Affiliation': 'The University of Toledo College of Medicine & Life Sciences, Toledo, OH\xa043606, USA.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Bauer', 'Affiliation': 'West German Cancer Center, Deparment of Medical Oncology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Jean-Yves', 'Initials': 'JY', 'LastName': 'Blay', 'Affiliation': 'Centre Léon Bérard, Unicancer, LYRICAN and Université Claude Bernard Lyon 1, Lyon, France.'}, {'ForeName': 'Khalil', 'Initials': 'K', 'LastName': 'Choucair', 'Affiliation': 'The University of Toledo College of Medicine & Life Sciences, Toledo, OH\xa043606, USA.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Gelderblom', 'Affiliation': 'Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'George', 'Affiliation': 'Medical Oncology, Dana-Farber Cancer Institute, Boston, MA\xa002215, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Schöffski', 'Affiliation': 'University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, Leuven, Belgium.'}, {'ForeName': 'Margaret von', 'Initials': 'MV', 'LastName': 'Mehren', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, PA 19111, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Zalcberg', 'Affiliation': 'Department of Epidemiology & Preventive Medicine, School of Public Health & Preventive Medicine, Monash University & Department of Medical Oncology Alfred Health, Melbourne, Australia.'}, {'ForeName': 'Haroun', 'Initials': 'H', 'LastName': 'Achour', 'Affiliation': 'Deciphera Pharmaceuticals, LLC, Waltham, MA 02451, USA.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Ruiz-Soto', 'Affiliation': 'Deciphera Pharmaceuticals, LLC, Waltham, MA 02451, USA.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Heinrich', 'Affiliation': 'Portland VA Health Care System & OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.'}]","Future oncology (London, England)",['10.2217/fon-2019-0633'] 721,31104655,[A clinical follow-up study of children with well-controlled asthma after withdrawal of low-dose inhaled corticosteroids].,"OBJECTIVE To study the incidence of acute attacks of asthma and dynamic changes in laboratory markers in children with well-controlled asthma after the withdrawal of low-dose inhaled corticosteroids (ICS), and to provide a basis for optimal long-term control regimens for children with asthma. METHODS A total of 63 children with well-controlled asthma were enrolled as subjects. According to their parents' wishes, they were continuously administered with ICS (ICS treatment group; n=35) and without ICS (ICS withdrawal group; n=28). They were followed up for 18 months. The incidence of acute attacks of asthma was evaluated, dynamic monitoring was performed for pulmonary function and fractional exhaled nitric oxide (FeNO), and childhood asthma control test (C-ACT) was performed every three months. RESULTS At 3, 6, 9, and 12 months of follow-up, there was no significant difference in FeNO between the ICS treatment and withdrawal groups (P>0.05). However, at 15 and 18 months of follow-up, the withdrawal group had a significantly higher level of FeNO than the ICS treatment group (P<0.05). There was no significant difference in the C-ACT score between the two groups at all time points of follow-up (P>0.05). At 3, 6, 9, and 12 months of follow-up, there were no significant differences between the two groups in the percentage of forced expiratory volume in 1 second, the ratio of forced expiratory volume in 1 second to forced vital capacity, percentage of predicted maximum mid-expiratory flow (MMEF%), and maximal expiratory flow at 50% of vital capacity (MEF50) (P>0.05), while at 15 and 18 months of follow-up, the ICS treatment group had significantly higher MMEF% and MEF50 than the withdrawal group (P<0.05). During follow-up, 3 children (9%) in the ICS treatment group and 8 (29%) in the withdrawal group experienced acute attacks of asthma (P=0.0495). CONCLUSIONS Continuous inhalation of low-dose ICS can maintain the stability of pulmonary function and reduce acute attacks of asthma in children with well-controlled asthma.",2019,There was no significant difference in the C-ACT score between the two groups at all time points of follow-up (P>0.05).,"['children with well-controlled asthma', 'children with well-controlled asthma after withdrawal of low-dose inhaled', 'children with asthma', 'children with well-controlled asthma after the withdrawal of low-dose inhaled', '63 children with well-controlled asthma were enrolled as subjects']","['ICS (ICS treatment group; n=35) and without ICS (ICS withdrawal', 'ICS', 'corticosteroids (ICS', 'corticosteroids']","['level of FeNO', 'percentage of forced expiratory volume in 1 second, the ratio of forced expiratory volume in 1 second to forced vital capacity, percentage of predicted maximum mid-expiratory flow (MMEF%), and maximal expiratory flow at 50% of vital capacity (MEF50', 'MMEF% and MEF50', 'C-ACT score', 'acute attacks of asthma', 'FeNO', 'pulmonary function and fractional exhaled nitric oxide (FeNO), and childhood asthma control test (C-ACT']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C3853142', 'cui_str': 'Well controlled'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C4523905', 'cui_str': 'Fractional exhaled nitric oxide'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C3714541', 'cui_str': 'Forced Vital Capacity'}, {'cui': 'C0444598', 'cui_str': 'Mid (qualifier value)'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test (procedure)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1304680', 'cui_str': 'Attack (finding)'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0264408', 'cui_str': 'Childhood asthma (disorder)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",63.0,0.0431634,There was no significant difference in the C-ACT score between the two groups at all time points of follow-up (P>0.05).,"[{'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': ""Department of Pediatrics, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China. 497451128@qq.com.""}, {'ForeName': 'Zhi-Hong', 'Initials': 'ZH', 'LastName': 'Wen', 'Affiliation': ''}, {'ForeName': 'Cai-Qiong', 'Initials': 'CQ', 'LastName': 'Yang', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 722,29474306,THREE-YEAR OUTCOMES IN A RANDOMIZED SINGLE-BLIND CONTROLLED TRIAL OF INTRAVITREAL RANIBIZUMAB AND ORAL SUPPLEMENTATION WITH DOCOSAHEXAENOIC ACID AND ANTIOXIDANTS FOR DIABETIC MACULAR EDEMA.,"PURPOSE To report 3-year results of a randomized single-blind controlled trial of intravitreal ranibizumab combined with oral docosahexaenoic acid (DHA) supplementation versus ranibizumab alone in patients with diabetic macular edema. METHODS There were 26 patients (31 eyes) in the DHA group and 29 (38 eyes) in the control group. Ranibizumab (0.5 mg) was administered monthly for the first 4 months followed by a pro re nata (PRN) regimen. In the experimental group, patients received oral DHA supplementation (1,050 mg/day) (Brudyretina 1.5 g). RESULTS At 36 months, mean decrease of central subfield macular thickness was higher in the DHA-supplementation group than in controls (275 ± 50 μm vs. 310 ± 97 μm) with significant differences at Months 25, 30, 33, and 34. Between-group differences in best-corrected visual acuity were not found, but the percentages of ETRDS gains >5 and >10 letters were higher in the DHA-supplementation group. Differences serum HbA1c, plasma total antioxidant capacity values, erythrocyte DHA content, and serum IL-6 levels were all significant in favor of the DHA-supplementation group. CONCLUSION The addition of a high-rich DHA dietary supplement to intravitreal ranibizumab was effective to achieve better sustained improvement of central subfield macular thickness outcomes after 3 years of follow-up as compared with intravitreal ranibizumab alone.",2019,"At 36 months, mean decrease of central subfield macular thickness was higher in the DHA-supplementation group than in controls (275 ± 50 μm vs. 310 ± 97 μm) with significant differences at Months 25, 30, 33, and 34.","['patients with diabetic macular edema', '26 patients (31 eyes) in the DHA group and 29 (38 eyes) in the control group']","['intravitreal ranibizumab combined with oral docosahexaenoic acid (DHA) supplementation', 'Ranibizumab', 'ranibizumab alone', 'oral DHA supplementation', 'ranibizumab']","['Differences serum HbA1c, plasma total antioxidant capacity values, erythrocyte DHA content, and serum IL-6 levels', 'central subfield macular thickness', 'best-corrected visual acuity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0730285', 'cui_str': 'Diabetic macular edema'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0556102', 'cui_str': 'DHA - Docosahexaenoic acid supplementation'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0014792', 'cui_str': 'Blood Corpuscles, Red'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C1690532', 'cui_str': 'Best corrected visual acuity'}]",,0.112089,"At 36 months, mean decrease of central subfield macular thickness was higher in the DHA-supplementation group than in controls (275 ± 50 μm vs. 310 ± 97 μm) with significant differences at Months 25, 30, 33, and 34.","[{'ForeName': 'María', 'Initials': 'M', 'LastName': 'Lafuente', 'Affiliation': 'Department of Ophthalmology, Hospital Universitario Morales Meseguer, Murcia, Spain.'}, {'ForeName': 'Lourdes', 'Initials': 'L', 'LastName': 'Ortín', 'Affiliation': 'Department of Ophthalmology, Hospital Universitario Morales Meseguer, Murcia, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Argente', 'Affiliation': 'Department of Ophthalmology, Hospital Universitario Morales Meseguer, Murcia, Spain.'}, {'ForeName': 'José L', 'Initials': 'JL', 'LastName': 'Guindo', 'Affiliation': 'Department of Ophthalmology, Hospital Universitario Morales Meseguer, Murcia, Spain.'}, {'ForeName': 'María D', 'Initials': 'MD', 'LastName': 'López-Bernal', 'Affiliation': 'Department of Ophthalmology, Hospital Universitario Morales Meseguer, Murcia, Spain.'}, {'ForeName': 'Francisco J', 'Initials': 'FJ', 'LastName': 'López-Román', 'Affiliation': 'Faculty of Health Sciences, San Antonio Catholic University of Murcia, Murcia, Spain.'}, {'ForeName': 'Joan Carles', 'Initials': 'JC', 'LastName': 'Domingo', 'Affiliation': 'Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Jerónimo', 'Initials': 'J', 'LastName': 'Lajara', 'Affiliation': 'Department of Ophthalmology, Hospital Universitario Morales Meseguer, Murcia, Spain.'}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000002114'] 723,31146540,Traumatic imagery following glucocorticoid administration in earthquake-related post-traumatic stress disorder: A preliminary functional magnetic resonance imaging study.,"OBJECTIVE Post-traumatic stress disorder involves excessive retrieval of traumatic memories. Glucocorticoids impair declarative memory retrieval. This preliminary study examined the effect of acute hydrocortisone administration on brain activation in individuals with earthquake-related post-traumatic stress disorder compared with earthquake-exposed healthy individuals, during retrieval of traumatic memories. METHOD Participants exposed to earthquakes with ( n  = 11) and without post-traumatic stress disorder ( n  = 11) underwent two functional magnetic resonance imaging scans, 1-week apart, in a double-blind, placebo-controlled, counter-balanced design. On one occasion, they received oral hydrocortisone (20 mg), and on the other, placebo, 1 hour before scanning. Symptom provocation involved script-driven imagery (traumatic and neutral scripts) and measures of self-reported anxiety. RESULTS Arterial spin labelling showed that both post-traumatic stress disorder and trauma-exposed controls had significantly reduced cerebral blood flow in response to retrieval of traumatic versus neutral memories in the right hippocampus, parahippocampal gyrus, calcarine sulcus, middle and superior temporal gyrus, posterior cingulate, Heschl's gyrus, inferior parietal lobule, angular gyrus, middle occipital gyrus, supramarginal gyrus, lingual gyrus and cuneus, and the left prefrontal cortex. Hydrocortisone resulted in non-significant trends of increasing subjective distress and reduced regional cerebral blood flow in the left inferior frontal gyrus, left anterior cingulate gyrus, middle temporal gyrus, cerebellum, postcentral gyrus and right frontal pole, during the trauma script. CONCLUSION Findings do not fit with some aspects of the accepted neurocircuitry model of post-traumatic stress disorder, i.e., failure of the medial prefrontal cortex to quieten hyperresponsive amygdala activity, and the potential therapeutic benefits of hydrocortisone. They do, however, provide further evidence that exposure to earthquake trauma, regardless of whether post-traumatic stress disorder eventuates, impacts brain activity and highlights the importance of inclusion of trauma-exposed comparisons in studies of post-traumatic stress disorder.",2019,"Hydrocortisone resulted in non-significant trends of increasing subjective distress and reduced regional cerebral blood flow in the left inferior frontal gyrus, left anterior cingulate gyrus, middle temporal gyrus, cerebellum, postcentral gyrus and right frontal pole, during the trauma script. ","['individuals with earthquake-related post-traumatic stress disorder compared with earthquake-exposed healthy individuals', 'earthquake-related post-traumatic stress disorder', 'Participants exposed to earthquakes with ( n\u2009=\u200911) and without post-traumatic stress disorder ( n\u2009=\u200911) underwent two']","['glucocorticoid', 'placebo', 'functional magnetic resonance imaging scans', 'acute hydrocortisone', 'Glucocorticoids', 'placebo-controlled, counter-balanced design', 'oral hydrocortisone', 'Hydrocortisone', 'hydrocortisone']","['cerebral blood flow', 'Symptom provocation involved script-driven imagery (traumatic and neutral scripts) and measures of self-reported anxiety', ""parahippocampal gyrus, calcarine sulcus, middle and superior temporal gyrus, posterior cingulate, Heschl's gyrus, inferior parietal lobule, angular gyrus, middle occipital gyrus, supramarginal gyrus, lingual gyrus and cuneus, and the left prefrontal cortex"", 'subjective distress and reduced regional cerebral blood flow in the left inferior frontal gyrus, left anterior cingulate gyrus, middle temporal gyrus, cerebellum, postcentral gyrus and right frontal pole, during the trauma script', 'Traumatic imagery', 'brain activation']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0013463', 'cui_str': 'Earthquakes'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}]","[{'cui': 'C3540778', 'cui_str': 'Glucocorticoids'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0441633'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0677601', 'cui_str': 'Counter (physical object)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0428714', 'cui_str': 'Cerebral Blood Flow'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449428', 'cui_str': 'Provocation (attribute)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0150627', 'cui_str': 'Imagery'}, {'cui': 'C0332663', 'cui_str': 'Traumatic (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0228249', 'cui_str': 'Gyrus Hippocampi'}, {'cui': 'C0228224', 'cui_str': 'Sulcus Calcarinus'}, {'cui': 'C0444598', 'cui_str': 'Mid (qualifier value)'}, {'cui': 'C0152309', 'cui_str': 'Gyrus Temporalis Superior'}, {'cui': 'C0175191', 'cui_str': 'Posterior Cingulate'}, {'cui': 'C0152304', 'cui_str': 'Inferior parietal lobule structure'}, {'cui': 'C0152305', 'cui_str': 'Prelunate Gyrus'}, {'cui': 'C0228220', 'cui_str': 'Occipital gyrus'}, {'cui': 'C0228214', 'cui_str': 'Supramarginal Gyrus'}, {'cui': 'C0152308', 'cui_str': 'Medial Occipitotemporal Gyrus'}, {'cui': 'C0152307', 'cui_str': 'Cuneate Lobule'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0152298', 'cui_str': 'Gyrus Frontalis Inferior'}, {'cui': 'C0441998', 'cui_str': 'Left anterior (qualifier value)'}, {'cui': 'C0018427', 'cui_str': 'Cingulate Body'}, {'cui': 'C0152310', 'cui_str': 'Structure of middle temporal gyrus'}, {'cui': 'C0007765', 'cui_str': 'Parencephalon'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0149546', 'cui_str': 'Structure of frontal pole'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}]",,0.128357,"Hydrocortisone resulted in non-significant trends of increasing subjective distress and reduced regional cerebral blood flow in the left inferior frontal gyrus, left anterior cingulate gyrus, middle temporal gyrus, cerebellum, postcentral gyrus and right frontal pole, during the trauma script. ","[{'ForeName': 'Katie M', 'Initials': 'KM', 'LastName': 'Douglas', 'Affiliation': 'Department of Psychological Medicine, University of Otago, Christchurch, Christchurch, New Zealand.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Groves', 'Affiliation': 'Department of Psychological Medicine, University of Otago, Christchurch, Christchurch, New Zealand.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Porter', 'Affiliation': 'Department of Psychological Medicine, University of Otago, Christchurch, Christchurch, New Zealand.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Jordan', 'Affiliation': 'Department of Psychological Medicine, University of Otago, Christchurch, Christchurch, New Zealand.'}, {'ForeName': 'Lynere', 'Initials': 'L', 'LastName': 'Wilson', 'Affiliation': 'Department of Psychological Medicine, University of Otago, Christchurch, Christchurch, New Zealand.'}, {'ForeName': 'Tracy R', 'Initials': 'TR', 'LastName': 'Melzer', 'Affiliation': 'New Zealand Brain Research Institute, Christchurch, New Zealand.'}, {'ForeName': 'Richard G', 'Initials': 'RG', 'LastName': 'Wise', 'Affiliation': 'Brain Research Imaging Centre, School of Psychology, Cardiff University, Cardiff.'}, {'ForeName': 'Jonathan I', 'Initials': 'JI', 'LastName': 'Bisson', 'Affiliation': 'School of Medicine, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Caroline J', 'Initials': 'CJ', 'LastName': 'Bell', 'Affiliation': 'Department of Psychological Medicine, University of Otago, Christchurch, Christchurch, New Zealand.'}]",The Australian and New Zealand journal of psychiatry,['10.1177/0004867419851860'] 724,31121087,"Effect of citalopram on esophageal motility in healthy subjects-Implications for reflux episodes, dysphagia, and globus.","BACKGROUND Drugs such as citalopram, ""targeting"" the serotonin pathway, can alter esophageal mechano-chemical sensitivity and gastrointestinal motility. The aim of this study was to clarify the effect of citalopram on esophageal motility and sphincter function, transient lower esophageal sphincter relaxations (TLESRs), and reflux events. METHODS Sixteen healthy volunteers (HV) receiving 20 mg citalopram or placebo intravenously, in a randomized cross-over fashion, underwent two high-resolution impedance manometry studies involving liquid swallows and a high-fat, high-caloric meal. Manometric, reflux, and symptom-related parameters were studied. KEY RESULTS A lower distal contractile integral was recorded under citalopram, compared with placebo (P = 0.026). Upper esophageal sphincter (UES) resting pressure was significantly higher after citalopram administration throughout the study (P < 0.05, all periods). Similarly, the UES postswallow mean and maximum pressures were higher in the citalopram condition (P < 0.0001, in both cases) and this was also the case for the 0.2 s integrated relaxation pressure (P = 0.04). Esophagogastric junction resting pressures in the citalopram visit were significantly higher during swallow protocol, preprandial period, and the first postprandial hour (P < 0.05, in all cases). TLESRs and total reflux events were both reduced after citalopram infusion (P = 0.01, in both cases). During treatment with citalopram, five participants complained about globus sensation (P = 0.06). This citalopram-induced globus was associated with higher UES postswallow mean and maximum pressure values (P = 0.01 and P = 0.04, respectively). CONCLUSIONS AND INFERENCES Administration of citalopram exerts a diversified response on esophageal motility and sphincter function, linked to clinically relevant phenomena: a reduction in postprandial TLESRs and the induction of drug-induced globus.",2019,"TLESRs and total reflux events were both reduced after citalopram infusion (P = 0.01, in both cases).","['healthy subjects-Implications for reflux episodes, dysphagia, and globus', 'Sixteen healthy volunteers (HV) receiving 20\xa0mg']","['high-resolution impedance manometry studies involving liquid swallows and a high-fat, high-caloric meal', 'citalopram', 'citalopram or placebo', 'placebo']","['Esophagogastric junction resting pressures', 'UES postswallow mean and maximum pressures', 'esophageal motility', 'distal contractile integral', 'Manometric, reflux, and symptom-related parameters', 'esophageal motility and sphincter function, transient lower esophageal sphincter relaxations (TLESRs), and reflux events', 'esophageal motility and sphincter function', 'higher UES postswallow mean and maximum pressure values', 'relaxation pressure', 'Upper esophageal sphincter (UES) resting pressure', 'globus sensation', 'TLESRs and total reflux events']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C3715157', 'cui_str': '16'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0162537', 'cui_str': 'Electrical Impedance'}, {'cui': 'C0024751', 'cui_str': 'Manometry'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C1304698', 'cui_str': 'Liquid - descriptor'}, {'cui': 'C0326374', 'cui_str': 'Swallows'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0008845', 'cui_str': 'Citalopram'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0014871', 'cui_str': 'Gastroesophageal Junction'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1510470', 'cui_str': 'Motility (observable entity)'}, {'cui': 'C0205108', 'cui_str': 'Distal (qualifier value)'}, {'cui': 'C0443238', 'cui_str': 'Integral (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0205374', 'cui_str': 'Transitory (qualifier value)'}, {'cui': 'C0227192', 'cui_str': 'Esophageal Sphincter, Lower'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C1451819', 'cui_str': 'Upper Esophageal Sphincter'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0232534', 'cui_str': 'Globus sensation (finding)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",16.0,0.0463709,"TLESRs and total reflux events were both reduced after citalopram infusion (P = 0.01, in both cases).","[{'ForeName': 'Anastassios C', 'Initials': 'AC', 'LastName': 'Manolakis', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Broers', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Hannelore', 'Initials': 'H', 'LastName': 'Geysen', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Goelen', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Brecht', 'Initials': 'B', 'LastName': 'Van Houtte', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Rommel', 'Affiliation': 'Experimental Oto-Rhino-Laryngology, Department of Neurosciences, Deglutology, KU Leuven, Belgium.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Vanuytsel', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Tack', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Ans', 'Initials': 'A', 'LastName': 'Pauwels', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.'}]",Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,['10.1111/nmo.13632'] 725,31134608,Modified Mini-laparoscopic Surgery Optimized the Laparoscopic Decortication of Renal Cyst.,"PURPOSE This study was to introduce the modified mini-laparoscopic surgery for renal cyst and investigate itsadvantages on operative time, cosmetic effect and pain reduction by comparison with laparo-endoscopic single sitesurgery (LESS) and conventional laparoscopic surgery. METHODS AND PATIENTS Between May 2015 and October 2018, 140 consecutive patients with benign renal cystunderwent laparoscopic decortication of renal cyst. Of which, 48 cases were in mini-laparoscopic surgery group(M group), 56 cases in LESS group and 36 cases in conventional laparoscopic surgery group (C group). The operativetime, blood loss, visual analog scale (VAS) and Scar Cosmesis Assessment and Rating (SCAR) Scale wasrecorded. RESULTS The mean operative time in M group (26.08±7.70 min) and C group (28.56 ± 7.99 min). was significantlyless than that in LESS group (47.32 ±10.53 min) (P < 0.01). Mean blood loss did not differ between the 3 groups(P > 0.05). Mean VAS pain scores in M group were significantly lower than that of LESS group and C group onpostoperative day (POD) 1 and 3 (P < 0.01). The SCAR scale of POD 30 in C group (6.25 ± 1.0) was significantlyhigher than that in M group (0.77 ± 0.59) and LESS group (0.98 ± 0.70). The postoperative course was uneventfulwith no morbidity within 1to 6 months of follow-up. CONCLUSION Modified mini-laparoscopic decortication of renal cyst have more comprehensive advantages comparingwith LESS and conventional laparoscopic surgery. It is convenient and offered significant cosmetic benefitand reduced incisional pain.",2019,Mean blood loss did not differ between the 3 groups (P>0.05).,['140 consecutive patients with benign renal cyst underwent laparoscopic decortication of renal cyst'],"['modified mini-laparoscopic surgery', 'LESS', 'LESS and conventional laparoscopic surgery', 'conventional laparoscopic surgery', 'laparo-endoscopic single site surgery (LESS) and conventional laparoscopic surgery', 'Modified mini-laparoscopic decortication of renal cyst', 'Modified Mini-laparoscopic Surgery']","['Mean VAS pain scores', 'incisional pain', 'mean operative time', 'Mean blood loss', 'SCAR scale of POD', 'operative time, cosmetic effect and pain reduction', 'operative time, blood loss, visual analog scale (VAS) and Scar Cosmesis Assessment and Rating (SCAR']","[{'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205183', 'cui_str': 'Benign (qualifier value)'}, {'cui': 'C0268800', 'cui_str': 'Simple renal cyst (disorder)'}, {'cui': 'C2678502', 'cui_str': 'Decortication (procedure)'}]","[{'cui': 'C0445542', 'cui_str': 'Mini (qualifier value)'}, {'cui': 'C0751429', 'cui_str': 'Surgical Procedures, Laparoscopic'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C2678502', 'cui_str': 'Decortication (procedure)'}, {'cui': 'C0268800', 'cui_str': 'Simple renal cyst (disorder)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0008767', 'cui_str': 'Cicatrization'}, {'cui': 'C0222045'}, {'cui': 'C0442965', 'cui_str': 'Cosmetic procedure (qualifier value)'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",140.0,0.0358773,Mean blood loss did not differ between the 3 groups (P>0.05).,"[{'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': 'Urology Department of Zhongshan Hospital, Fudan University. chen.wei3@zs-hospital.sh.cn.'}, {'ForeName': 'Zhi-Bing', 'Initials': 'ZB', 'LastName': 'Xu', 'Affiliation': 'Urology Department of Zhongshan Hospital, Fudan University.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': 'Urology Department of Zhongshan Hospital, Fudan University.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Cang', 'Affiliation': 'Urology Department of Zhongshan Hospital, Fudan University.'}, {'ForeName': 'Jian-Ming', 'Initials': 'JM', 'LastName': 'Guo', 'Affiliation': 'Urology Department of Zhongshan Hospital, Fudan University.'}]",Urology journal,['10.22037/uj.v0i0.5029'] 726,31144577,A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis.,"BACKGROUND Stratified medicine methodologies based on subgroup analyses are often insufficiently powered. More powerful personalized medicine approaches are based on continuous scores. OBJECTIVE We deployed a patient-specific continuous score predicting treatment response in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS Data from two independent randomized controlled trials (RCTs) were used to build and validate an individual treatment response (ITR) score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. RESULTS The ITR score for the combined treatment groups versus placebo detected differential clinical response in both RCTs. High responders in one RCT had a cross-validated ARR ratio of 0.29 (95% confidence interval (CI) = 0.13-0.55) versus 0.62 (95% CI = 0.47-0.83) for all other responders (heterogeneity p  = 0.038) and were validated in the other RCT, with the corresponding ARR ratios of 0.31 (95% CI = 0.18-0.56) and 0.61 (95% CI = 0.47-0.79; heterogeneity p  = 0.036). The strongest treatment effect modifiers were the Short Form-36 Physical Component Summary, age, Visual Function Test 2.5%, prior MS treatment and Expanded Disability Status Scale. CONCLUSION Our modelling strategy detects and validates an ITR score and opens up avenues for building treatment response calculators that are also applicable in routine clinical practice.",2020,"The strongest treatment effect modifiers were the Short Form-36 Physical Component Summary, age, Visual Function Test 2.5%, prior MS treatment and Expanded Disability Status Scale. ","['multiple sclerosis', 'patients with relapsing-remitting multiple sclerosis (RRMS']",['placebo'],"['Short Form-36 Physical Component Summary, age, Visual Function Test 2.5%, prior MS treatment and Expanded Disability Status Scale', 'ITR score', 'individual treatment response (ITR) score, regressing annualized relapse rates (ARRs', 'cross-validated ARR ratio']","[{'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0751967', 'cui_str': 'Multiple Sclerosis, Relapsing-Remitting'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale (assessment scale)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",,0.193088,"The strongest treatment effect modifiers were the Short Form-36 Physical Component Summary, age, Visual Function Test 2.5%, prior MS treatment and Expanded Disability Status Scale. ","[{'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Pellegrini', 'Affiliation': 'Biogen International GmbH, Baar, Switzerland.'}, {'ForeName': 'Massimiliano', 'Initials': 'M', 'LastName': 'Copetti', 'Affiliation': 'Unit of Biostatistics, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Bovis', 'Affiliation': 'Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cheng', 'Affiliation': 'Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Hyde', 'Affiliation': 'Biogen International GmbH, Baar, Switzerland.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'de Moor', 'Affiliation': 'Biogen Inc., Cambridge, MA, USA.'}, {'ForeName': 'Bernd C', 'Initials': 'BC', 'LastName': 'Kieseier', 'Affiliation': 'Biogen Inc., Cambridge, MA, USA; Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.'}, {'ForeName': 'Maria Pia', 'Initials': 'MP', 'LastName': 'Sormani', 'Affiliation': 'Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.'}]","Multiple sclerosis (Houndmills, Basingstoke, England)",['10.1177/1352458519849513'] 727,31707732,Acute lower leg hot water immersion protects macrovascular dilator function following ischaemia-reperfusion injury in humans.,"NEW FINDINGS • What is the central question of this study? What is the effect of lower leg hot water immersion on vascular ischaemia-reperfusion injury induced in the arm of young healthy humans? • What is the main finding and its importance? Lower leg hot water immersion successfully protects against vascular ischaemia-reperfusion injury in humans. This raises the possibility that targeted heating of the lower legs may be an alternative therapeutic approach to whole-body heating that is equally efficacious at protecting against vascular ischaemia-reperfusion injury. ABSTRACT Reperfusion that follows a period of ischaemia paradoxically reduces vasodilator function in humans and contributes to the tissue damage associated with an ischaemic event. Acute whole-body hot water immersion protects against vascular ischaemia-reperfusion (I-R) injury in young healthy humans. However, the effect of acute lower leg heating on I-R injury is unclear. Therefore, the purpose of this study was to test the hypothesis that, compared with thermoneutral control immersion, acute lower leg hot water immersion would prevent the decrease in macro- and microvascular dilator functions following I-R injury in young healthy humans. Ten young healthy subjects (5 female) immersed their lower legs into a circulated water bath for 60 min under two randomized conditions: (1) thermoneutral control immersion (∼33°C) and (2) hot water immersion (∼42°C). Macrovascular (brachial artery flow-mediated dilatation) and microvascular (forearm reactive hyperaemia) dilator functions were assessed using Doppler ultrasound at three time points: (1) pre-immersion, (2) 60 min post-immersion, and (3) post-I/R (20 min of arm ischaemia followed by 20 min of reperfusion). Ischaemia-reperfusion injury reduced macrovascular dilator function following control immersion (pre-immersion 6.0 ± 2.1% vs. post-I/R 3.6 ± 2.1%; P < 0.05), but was well-maintained with prior hot water immersion (pre-immersion 5.8 ± 2.1% vs. post-I/R 5.3 ± 2.1%; P = 0.8). Microvascular dilator function did not differ between conditions or across time. Taken together, acute lower leg hot water immersion prevents the decrease in macrovascular dilator function that occurs following I-R injury in young healthy humans.",2020,Macrovascular (brachial artery flow-mediated dilatation) and microvascular (forearm reactive hyperaemia) dilator functions were assessed using Doppler ultrasound at three time points: 1) pre-immersion; 2) 60 min post-immersion; 3) post-I/R (20 min of arm ischaemia followed by 20 min of reperfusion).,"['Ten young healthy subjects (5 female', 'young healthy humans', 'Ischaemia-Reperfusion Injury in Humans']","['Leg Hot Water Immersion', 'thermoneutral control immersion (∼33°C); 2) hot water immersion (∼42°C', 'lower leg hot water immersion']","['Macrovascular (brachial artery flow-mediated dilatation) and microvascular (forearm reactive hyperaemia) dilator functions', 'macro- and microvascular dilator functions', 'Microvascular dilator function', 'macrovascular dilator function']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0035126', 'cui_str': 'Ischemia-Reperfusion Injury'}]","[{'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0337023', 'cui_str': 'Hot water (substance)'}, {'cui': 'C0020940', 'cui_str': 'Immersion'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1140621', 'cui_str': 'Leg'}]","[{'cui': 'C0006087', 'cui_str': 'Brachial Artery'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0443258', 'cui_str': 'Microvascular (qualifier value)'}, {'cui': 'C0016536', 'cui_str': 'Antebrachiums'}, {'cui': 'C0205332', 'cui_str': 'Reactive (qualifier value)'}, {'cui': 'C0020452', 'cui_str': 'Hyperemia'}, {'cui': 'C0180431', 'cui_str': 'Dilator, device (physical object)'}, {'cui': 'C0031843', 'cui_str': 'function'}]",10.0,0.0252533,Macrovascular (brachial artery flow-mediated dilatation) and microvascular (forearm reactive hyperaemia) dilator functions were assessed using Doppler ultrasound at three time points: 1) pre-immersion; 2) 60 min post-immersion; 3) post-I/R (20 min of arm ischaemia followed by 20 min of reperfusion).,"[{'ForeName': 'Rachel E', 'Initials': 'RE', 'LastName': 'Engelland', 'Affiliation': 'Human Vascular Physiology Laboratory, Department of Physiology and Anatomy, University of North Texas Health Science Center, Fort Worth, TX, USA.'}, {'ForeName': 'Holden W', 'Initials': 'HW', 'LastName': 'Hemingway', 'Affiliation': 'Human Vascular Physiology Laboratory, Department of Physiology and Anatomy, University of North Texas Health Science Center, Fort Worth, TX, USA.'}, {'ForeName': 'Olivia G', 'Initials': 'OG', 'LastName': 'Tomasco', 'Affiliation': 'Human Vascular Physiology Laboratory, Department of Physiology and Anatomy, University of North Texas Health Science Center, Fort Worth, TX, USA.'}, {'ForeName': 'Albert H', 'Initials': 'AH', 'LastName': 'Olivencia-Yurvati', 'Affiliation': 'Human Vascular Physiology Laboratory, Department of Physiology and Anatomy, University of North Texas Health Science Center, Fort Worth, TX, USA.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Romero', 'Affiliation': 'Human Vascular Physiology Laboratory, Department of Physiology and Anatomy, University of North Texas Health Science Center, Fort Worth, TX, USA.'}]",Experimental physiology,['10.1113/EP088154'] 728,31116017,Development of an audio and computer cognitive behavioral therapy for depression in older adults.,"Background: The purpose of this paper is to discuss the development of two novel technology-based interventions for depression in older adults while comparing older adults' preferences for audio-based and computer-based cognitive behavioral therapy for depressive symptoms. The audio program consisted of eight compact discs and a workbook while the computer program consisted of 11 modules of similar duration provided on a tablet PC. Both interventions consisted of the following topics: 1) introduction, 2) identifying and changing unhelpful thoughts, 3) addressing feelings, 4) relaxation, 5) engaging in pleasant events, 6) assertiveness, and 7) problem-solving. Methods : Fifty-one older adults were recruited from medical settings and rural communities and randomly assigned to an immediate treatment group (computer or audio) with minimal contact or a four-week minimal contact delayed treatment control condition. Results: Participants rated computer-based and audio-based cognitive behavioral therapy fairly equally, with 75% of those who received audio treatment and 85% of those who received computer-based treatment indicating benefits to their mood. Discussion : Computer-based or audio-based cognitive behavioral treatments may be valuable, low-cost modalities to deliver psychotherapy to older adults with depressive symptoms within a health care setting. Both modalities seem to be accepted by older adults.",2020,"Participants rated computer-based and audio-based cognitive behavioral therapy fairly equally, with 75% of those who received audio treatment and 85% of those who received computer-based treatment indicating benefits to their mood. ","['older adults with depressive symptoms within a health care setting', 'Methods : Fifty-one older adults were recruited from medical settings and rural communities', 'older adults']","['audio-based and computer-based cognitive behavioral therapy', 'audio and computer cognitive behavioral therapy', 'immediate treatment group (computer or audio) with minimal contact or a four-week minimal contact delayed treatment control condition', 'computer-based and audio-based cognitive behavioral therapy', 'introduction, 2) identifying and changing unhelpful thoughts, 3) addressing feelings, 4) relaxation, 5) engaging in pleasant events, 6) assertiveness, and 7) problem-solving', 'Computer-based or audio-based cognitive behavioral treatments', 'audio program consisted of eight compact discs and a workbook while the computer program consisted of 11 modules of similar duration provided on a tablet PC']",[],"[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0086944', 'cui_str': 'Rural Communities'}]","[{'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0547040', 'cui_str': 'Minimal (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C3693346', 'cui_str': 'Delayed Treatment'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C1293116', 'cui_str': 'Introduction'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C4319827', 'cui_str': 'Thought'}, {'cui': 'C0376649', 'cui_str': 'Address'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0004077', 'cui_str': 'Assertivenesses'}, {'cui': 'C3669643', 'cui_str': 'Problem solving (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0079141'}, {'cui': 'C0037585', 'cui_str': 'Computer Programs'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}]",[],51.0,0.0125774,"Participants rated computer-based and audio-based cognitive behavioral therapy fairly equally, with 75% of those who received audio treatment and 85% of those who received computer-based treatment indicating benefits to their mood. ","[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Morthland', 'Affiliation': 'VAMC Tuscaloosa, Tuscaloosa, Alabama, USA.'}, {'ForeName': 'Avani', 'Initials': 'A', 'LastName': 'Shah', 'Affiliation': 'School of Social Work, University of Alabama, Tuscaloosa, Alabama, USA.'}, {'ForeName': 'James T', 'Initials': 'JT', 'LastName': 'Meadows', 'Affiliation': 'School of Social Work, University of Alabama, Tuscaloosa, Alabama, USA.'}, {'ForeName': 'Forrest', 'Initials': 'F', 'LastName': 'Scogin', 'Affiliation': 'Psychology Department, University of Alabama, Tuscaloosa, Alabama, USA.'}]",Aging & mental health,['10.1080/13607863.2019.1609901'] 729,31141176,The efficacy of a single imaginal exposure-writing assignment in reducing posttraumatic stress and depressive symptoms: A pilot study.,"OBJECTIVE This online study examined the effects of a single imaginal exposure-writing assignment on posttraumatic stress (PTS) and comorbid depressive symptoms. METHOD Forty-six participants with PTS were allocated to either a single imaginal exposure-writing assignment, a nontrauma writing assignment, or to a nonwriting control condition, and were reassessed 2 and 5 weeks after baseline. Of the 49 participants, 36 were female, with an average age of 23. Participation was conducted through Qualtrics. Effects were assessed with the Posttraumatic Diagnostic Scale (PDS) and the Beck Depression Inventory-II (BDI-II). RESULTS PTS and depressive symptoms decreased over time regardless of the study condition. CONCLUSIONS We found no support for the efficacy of a single imaginal exposure-writing assignment in reducing PTS or comorbid depressive symptoms. Suggestions are given for future studies that attempt to identify a minimal dose of imaginal exposure writing for PTS.",2019,We found no support for the efficacy of a single imaginal exposure-writing assignment in reducing PTS or comorbid depressive symptoms.,"['49 participants, 36 were female, with an average age of 23', 'Forty-six participants with PTS']","['single imaginal exposure-writing assignment', 'single imaginal exposure-writing assignment, a nontrauma writing assignment, or to a nonwriting control condition']","['posttraumatic stress and depressive symptoms', 'depressive symptoms', 'Posttraumatic Diagnostic Scale (PDS) and the Beck Depression Inventory-II (BDI-II']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0222045'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory (assessment scale)'}]",46.0,0.0499802,We found no support for the efficacy of a single imaginal exposure-writing assignment in reducing PTS or comorbid depressive symptoms.,"[{'ForeName': 'Yvonne D', 'Initials': 'YD', 'LastName': 'Vinke', 'Affiliation': 'HSK, Mental Health Care Institution, Lelystad, The Netherlands.'}, {'ForeName': 'Femke', 'Initials': 'F', 'LastName': 'Truijens', 'Affiliation': 'Department of Psychology and Pedagogical Science, University of Ghent, Ghent, Belgium.'}, {'ForeName': 'Esmee', 'Initials': 'E', 'LastName': 'van Polanen Petel', 'Affiliation': 'PSYTREC, Mental Health Care Institution, Leusden, The Netherlands.'}, {'ForeName': 'Arnold A P', 'Initials': 'AAP', 'LastName': 'van Emmerik', 'Affiliation': 'Department of Clinical Psychology, University of Amsterdam, Amsterdam, The Netherlands.'}]",Journal of clinical psychology,['10.1002/jclp.22802'] 730,31113250,User Satisfaction and Insulin Pump Handling With a Prefilled Insulin Cartridge in Adults and Adolescents With Type 1 Diabetes.,"BACKGROUND This comparative handling study investigated user satisfaction and insulin pump handling with a prefilled insulin cartridge versus a self-filled insulin reservoir in insulin pump users with type 1 diabetes (T1D). METHODS Adult (n = 105) and adolescent (n = 25) participants performed insulin pump preparations using a prefilled insulin cartridge and self-filled insulin reservoir. User satisfaction, insulin pump preparation time, and residual air in infusion set tubing were assessed for each insulin filling method. Post hoc analysis evaluated training time. RESULTS User satisfaction scores were statistically significantly different in favor of the prefilled insulin cartridge versus the self-filled insulin reservoir (mean [SD]: overall, 4.0 [0.5] vs 3.3 [0.9]; burden on the user, 1.8 [0.6] vs 2.9 [1.0]; user inconvenience, 2.0 [0.7] vs 2.8 [1.1]; device effectiveness, 3.9 [0.7] vs 3.6 [0.9]; all P < .001). Insulin pump preparation time and residual air measurements were significantly different and numerically lower for the prefilled insulin cartridge versus the self-filled insulin reservoir (mean [SD]: preparation time, 124.4 [30.3] vs 237.8 [64.2] seconds, P < .001; residual air, 2.3 [26.3] vs 10.0 [63.3] mm, P = .007). Training time was shorter with the prefilled insulin cartridge versus the self-filled insulin reservoir (mean [min; max]: 193.1 [36; 453] vs 535.8 [124; 992] seconds). CONCLUSIONS Adult and adolescent insulin pump users were more satisfied with the prefilled insulin cartridge versus the self-filled insulin reservoir when preparing an insulin pump. The prefilled insulin cartridge was associated with reduced insulin pump preparation time and reduced training time versus the self-filled insulin reservoir.",2020,The prefilled insulin cartridge was associated with reduced insulin pump preparation time and reduced training time versus the self-filled insulin reservoir.,"['Adults and Adolescents With Type 1 Diabetes', 'insulin pump users with type 1 diabetes (T1D', 'Adult and adolescent insulin pump users', 'Adult (n = 105) and adolescent (n = 25) participants performed']","['Insulin Pump Handling With a Prefilled Insulin Cartridge', 'insulin pump preparations using a prefilled insulin cartridge and self-filled insulin reservoir']","['Insulin pump preparation time and residual air measurements', 'User satisfaction, insulin pump preparation time, and residual air in infusion set tubing', 'User satisfaction scores', 'Training time']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1140609', 'cui_str': 'Insulin pump'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C1140609', 'cui_str': 'Insulin pump'}, {'cui': 'C0018578', 'cui_str': 'Handling'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C4319642', 'cui_str': 'Cartridge (unit of presentation)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0442537', 'cui_str': 'Reservoir (environment)'}]","[{'cui': 'C1140609', 'cui_str': 'Insulin pump'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C4318415', 'cui_str': 'Tube (unit of presentation)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]",25.0,0.0436351,The prefilled insulin cartridge was associated with reduced insulin pump preparation time and reduced training time versus the self-filled insulin reservoir.,"[{'ForeName': 'Jitendra', 'Initials': 'J', 'LastName': 'Gupta', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Gitte Schøning', 'Initials': 'GS', 'LastName': 'Fuchs', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Jenkins', 'Affiliation': 'UL LLC, Concord, MA, USA.'}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'van Geel', 'Affiliation': 'UL International (Netherlands) BV, Utrecht, Netherlands.'}, {'ForeName': 'Morten Lind', 'Initials': 'ML', 'LastName': 'Jensen', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Sparre', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}]",Journal of diabetes science and technology,['10.1177/1932296819848700'] 731,31585686,Examining patterns of dose response for clients who do and do not complete cognitive processing therapy.,"Trauma-focused therapies, including Cognitive Processing Therapy (CPT; Resick et al., 2016), are effective at reducing clients' PTSD symptoms. A limitation to these treatments, however, is client completion of them. The current study examined temporal patterns of treatment non-completion and the relationships among non-completion, PTSD, and overall mental health functioning outcomes, among clients in a randomized controlled CPT implementation trial. Two models of symptom change were tested: 1) dose-effect model (i.e., clients uniformly improve with additional sessions at a negatively accelerating rate); and 2) the good-enough level model (i.e., clients remain in therapy until they have achieved sufficient improvement, thus clients who attend fewer sessions improve at quicker rates). Results indicated that 42% of clients did not complete treatment, with most discontinuing between sessions two and five. Data did not fit the dose-effect or good-enough level model. Rather, clients who improved at a greater rate in their PTSD symptoms and overall mental health functioning attended more sessions. The average client had the best outcomes when they completed all 12 sessions. Identifying clients who may be at risk for discontinuing treatment, and making a concerted effort toward retaining them, is imperative to reduce non-completion rates and ultimately improve client outcomes.",2019,"Rather, clients who improved at a greater rate in their PTSD symptoms and overall mental health functioning attended more sessions.",['clients who do and do not complete cognitive processing therapy'],[],['PTSD symptoms and overall mental health functioning'],"[{'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",[],"[{'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]",,0.0194681,"Rather, clients who improved at a greater rate in their PTSD symptoms and overall mental health functioning attended more sessions.","[{'ForeName': 'Samantha C', 'Initials': 'SC', 'LastName': 'Holmes', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, United States; University of Akron, Department of Psychology, United States.'}, {'ForeName': 'Clara M', 'Initials': 'CM', 'LastName': 'Johnson', 'Affiliation': 'National Center for PTSD, Dissemination and Training Division, United States.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Suvak', 'Affiliation': 'Suffolk University, Department of Psychology, United States.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Sijercic', 'Affiliation': 'Ryerson University, Department of Psychology, Canada.'}, {'ForeName': 'Candice M', 'Initials': 'CM', 'LastName': 'Monson', 'Affiliation': 'Ryerson University, Department of Psychology, Canada.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Wiltsey Stirman', 'Affiliation': 'National Center for PTSD, Dissemination and Training Division, United States; Stanford University, Department of Psychiatry and Behavioral Sciences, United States. Electronic address: sws1@stanford.edu.'}]",Journal of anxiety disorders,['10.1016/j.janxdis.2019.102120'] 732,31125296,Effectiveness of high intensity interval training supplemented with peripheral and inspiratory resistance training in chronic heart failure: a pilot study.,"Background: Cardiac rehabilitation (CR) is an evidence-based therapy in chronic heart failure (CHF). There is still debate about the optimal training protocol in CHF. The use of high intensity interval training (HIIT) supplemented with peripheral (PRT) and inspiratory resistance training (IRT) might be more beneficial because of the higher impact on the peripheral and inspiratory muscles, with less symptoms of dyspnoea and lower amount of dropouts as a result. We compared our standard exercise-based CR programme, mainly consisting of moderate intensity interval training to a programme combining HIIT, PRT and IRT (resistance training supplemented HIIT (RHIIT) programme). Design: Randomised controlled pilot study. Methods: Twenty patients with CHF were randomised on a 1:1 basis to the standard or RHIIT programme. At baseline and after 3 months, peak exercise capacity (VO 2 peak), peripheral (QF) and inspiratory respiratory muscle strength (MIP), quality of life (QOL) and physical activity were measured. Results: The RHIIT programme resulted in a significantly larger improvement in QF (ΔQF RHIIT programme: 19.3 ± 11.8 vs standard programme: -6.89 ± 19.0 Nm ( p  < .01)) and MIP (ΔMIP RHIIT programme: -44.9 ± 29.9 vs standard programme: 0.56 ± 19.4 cmH 2 O ( p  < .01)). Both programmes equally improved in VO 2 peak ( p  = .91), whereas ventilatory efficiency and physical activity remained stable. Conclusion: HIIT supplemented with PRT and IRT might be applicable as standard protocol in CHF. Larger studies are warranted to confirm our findings. The RHIIT programme resulted in similar training effects in VO 2 peak in a shorter training period. This might be beneficial in a chronic patient population such as CHF, where adherence is difficult.",2020,"Both programmes equally improved in VO 2 peak ( p  = .91), whereas ventilatory efficiency and physical activity remained stable. ","['Twenty patients with CHF', 'chronic heart failure', 'chronic heart failure (CHF']","[': Cardiac rehabilitation (CR', 'standard exercise-based CR programme, mainly consisting of moderate intensity interval training to a programme combining HIIT, PRT and IRT (resistance training supplemented HIIT (RHIIT) programme', 'PRT and IRT', 'high intensity interval training (HIIT) supplemented with peripheral (PRT) and inspiratory resistance training (IRT', 'high intensity interval training supplemented with peripheral and inspiratory resistance training']","['ventilatory efficiency and physical activity', 'QF', 'VO 2 peak', 'peak exercise capacity (VO 2 peak), peripheral (QF) and inspiratory respiratory muscle strength (MIP), quality of life (QOL) and physical activity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0264716', 'cui_str': 'Chronic heart failure (disorder)'}]","[{'cui': 'C0700431', 'cui_str': 'Cardiovascular Rehabilitation'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C4277545', 'cui_str': 'High-Intensity Intermittent Exercise'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}]","[{'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0035231', 'cui_str': 'Ventilatory Muscles'}, {'cui': 'C0034380'}]",20.0,0.0304073,"Both programmes equally improved in VO 2 peak ( p  = .91), whereas ventilatory efficiency and physical activity remained stable. ","[{'ForeName': 'Miek', 'Initials': 'M', 'LastName': 'Hornikx', 'Affiliation': 'Department of Rehabilitation Sciences, KU Leuven-University of Leuven, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Roselien', 'Initials': 'R', 'LastName': 'Buys', 'Affiliation': 'Department of Rehabilitation Sciences, KU Leuven-University of Leuven, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Veronique', 'Initials': 'V', 'LastName': 'Cornelissen', 'Affiliation': 'Department of Rehabilitation Sciences, KU Leuven-University of Leuven, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Deroma', 'Affiliation': 'Department of Rehabilitation Sciences, KU Leuven-University of Leuven, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Kaatje', 'Initials': 'K', 'LastName': 'Goetschalckx', 'Affiliation': 'Department of Cardiovascular Sciences, KU Leuven-University of Leuven, University Hospitals Leuven, Leuven, Belgium.'}]",Acta cardiologica,['10.1080/00015385.2019.1591676'] 733,31136456,Performance of Emergency Medical Service Providers in Pediatric and Adult Simulation of Unstable Supraventricular Tachycardia.,"OBJECTIVE The aim of the study was to compare emergency medical service resuscitation of pediatric and adult high-fidelity manikins in unstable supraventricular tachycardia. The primary objective was time to cardioversion. The secondary objective was to assess if the cardioversion was synchronized at the correct dosage for the manikin's weight. METHODS Emergency medical service providers were voluntarily enrolled as part of an emergency medical service training program. Participants were randomized to either a pediatric or adult resuscitation as their study scenario. They then completed the second resuscitation as part of the training program. Participants completed presurvey and postsurvey. Resuscitations were videotaped and analyzed by a blinded reviewer. The study was powered to detect a 60-second difference in performance between pediatric and adult scenarios with a β of 0.8 and 2-tailed α of 0.05 using an independent-samples t test. RESULTS A total of 37 participants were enrolled. Participants in the pediatric arm had a longer mean time to cardioversion, but the difference was not statistically significant. The mean delay to cardioversion in the pediatric scenario was 34 seconds (197 vs 163 seconds; difference 95% confidence interval [CI], -5 to 73 seconds; P = 0.09). There was no significant difference in the percentage of participants who administered a correct dose (32% vs 50%; difference 95% CI, -50% to 13%; P = 0.75) or regarding synchronization of cardioversion (74% vs 83%; difference 95% CI, -36% to 17%; P = 0.42). CONCLUSIONS Emergency medical service providers did not have a significant difference in time to cardioversion between pediatric and adult unstable supraventricular tachycardia simulations.",2020,"CONCLUSIONS Emergency medical service providers did not have a significant difference in time to cardioversion between pediatric and adult unstable supraventricular tachycardia simulations.","['Emergency medical service providers were voluntarily enrolled as part of an emergency medical service training program', 'Emergency Medical Service Providers in Pediatric and Adult Simulation of Unstable Supraventricular Tachycardia', 'emergency medical service resuscitation of pediatric and adult high-fidelity manikins in unstable supraventricular tachycardia', '37 participants were enrolled']",[],"['mean delay to cardioversion', 'time to cardioversion', 'synchronization of cardioversion', 'longer mean time to cardioversion']","[{'cui': 'C0013961', 'cui_str': 'Emergency medical services (qualifier value)'}, {'cui': 'C1292711', 'cui_str': 'Part of (attribute)'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0443343', 'cui_str': 'Unstable status (qualifier value)'}, {'cui': 'C0039240', 'cui_str': 'Supraventricular tachycardia (disorder)'}, {'cui': 'C0035273', 'cui_str': 'Resuscitation'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0024722', 'cui_str': 'Mannequins'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0013778', 'cui_str': 'Electrical Cardioversion'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",37.0,0.131994,"CONCLUSIONS Emergency medical service providers did not have a significant difference in time to cardioversion between pediatric and adult unstable supraventricular tachycardia simulations.","[{'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Khalil', 'Affiliation': ""From the Department of Emergency Medicine, Nicklaus Children's Hospital, Miami.""}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Berkovich', 'Affiliation': ""Department of Pediatric Hospital Medicine, Joe DiMaggio Children's Hospital, Hollywood.""}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Maniaci', 'Affiliation': ""From the Department of Emergency Medicine, Nicklaus Children's Hospital, Miami.""}, {'ForeName': 'Juan Manuel', 'Initials': 'JM', 'LastName': 'Lozano', 'Affiliation': 'Department of Medical and Population Health Sciences Research, Herbert Wertheim College of Medicine, Florida International University, Miami, FL.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Lowe', 'Affiliation': ""From the Department of Emergency Medicine, Nicklaus Children's Hospital, Miami.""}]",Pediatric emergency care,['10.1097/PEC.0000000000001845'] 734,30799167,Effects of a Multidisciplinary Intervention on the Presence of Neuropsychiatric Symptoms and Psychotropic Drug Use in Nursing Home Residents WithYoung-Onset Dementia: Behavior and Evolution of Young-Onset Dementia Part 2 (BEYOND-II) Study.,"OBJECTIVE The effect of an intervention on neuropsychiatric symptoms (NPS), particularly agitation and aggression, and psychotropic drug use (PDU) in institutionalized people with young-onset dementia (YOD) was evaluated. METHODS A randomized controlled trial was conducted using a stepped wedge design. Thirteen YOD special care units were randomly assigned to three groups, which received the intervention at different time points. Four assessments took place every 6 months during a period of 18 months. Two hundred seventy-four people with YOD who resided in YOD special care units participated, of whom 131 took part in all assessments. The intervention consisted of an educational program combined with a care program, which structured the multidisciplinary process of managing NPS. The care program included the following five steps: evaluation of psychotropic drug prescription, detection, analysis, treatment, and evaluation of treatment of NPS. The Cohen-Mansfield Agitation Inventory and the Neuropsychiatric Inventory-Nursing Home version were used to assess NPS. Data on PDU were retrieved from residents' medical files. Multilevel models were used to evaluate the effect of the intervention, which accounted for clustering of measurements in clients within units. RESULTS No significant differences were found in agitation, aggression, other NPS, or PDU after crossing over to the intervention condition. CONCLUSION We found no evidence that the intervention for management of NPS in nursing home residents with YOD was more effective in reducing agitation, aggression, other NPS, or PDU compared with care as usual.",2019,"No significant differences were found in agitation, aggression, other NPS, or PDU after crossing over to the intervention condition. ","['Nursing Home Residents WithYoung-Onset Dementia', 'Thirteen YOD special care units', 'institutionalized people with young-onset dementia (YOD', 'Young-Onset Dementia', 'clients within units', 'Two hundred seventy-four people with YOD who resided in YOD special care units participated, of whom 131 took part in all assessments']","['educational program combined with a care program, which structured the multidisciplinary process of managing NPS', 'Multidisciplinary Intervention']","['neuropsychiatric symptoms (NPS), particularly agitation and aggression, and psychotropic drug use (PDU', 'Neuropsychiatric Symptoms and Psychotropic Drug Use', 'agitation, aggression, other NPS, or PDU']","[{'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0558600', 'cui_str': 'Special care unit (environment)'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4517867', 'cui_str': 'Seventy-four'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C4521054', 'cui_str': 'Process (qualifier value)'}]","[{'cui': 'C4285807', 'cui_str': 'Neuropsychiatric symptoms'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated (finding)'}, {'cui': 'C0001807', 'cui_str': 'Aggression'}, {'cui': 'C0033978', 'cui_str': 'Psychoactive Drugs'}, {'cui': 'C1947944', 'cui_str': 'Use'}]",274.0,0.0529494,"No significant differences were found in agitation, aggression, other NPS, or PDU after crossing over to the intervention condition. ","[{'ForeName': 'Britt', 'Initials': 'B', 'LastName': 'Appelhof', 'Affiliation': 'Department of Primary and Community Care (BA, CB, JCLD, RTCMK), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; Knowledge Center for Specialized Care (BA), Landrijt Archipel, Eindhoven, The Netherlands; Radboudumc Alzheimer Center (BA, CB, JCLD, RTCMK), Nijmegen, The Netherlands; Send correspondence and reprint requests to Britt Appelhof, M.Sc., Department of Primary and Community Care, Radboud University Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.. Electronic address: britt.appelhof@radboudumc.nl.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Bakker', 'Affiliation': 'Department of Primary and Community Care (BA, CB, JCLD, RTCMK), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; Radboudumc Alzheimer Center (BA, CB, JCLD, RTCMK), Nijmegen, The Netherlands; Center for Specialized Care in Young-Onset Dementia (CB), Florence Mariahoeve, The Hague.'}, {'ForeName': 'Marjolein E', 'Initials': 'ME', 'LastName': 'de Vugt', 'Affiliation': 'Alzheimer Center Limburg (MEV, FRJV), School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Jeannette C L', 'Initials': 'JCL', 'LastName': 'van Duinen-van den IJssel', 'Affiliation': 'Department of Primary and Community Care (BA, CB, JCLD, RTCMK), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; Radboudumc Alzheimer Center (BA, CB, JCLD, RTCMK), Nijmegen, The Netherlands.'}, {'ForeName': 'Sandra A', 'Initials': 'SA', 'LastName': 'Zwijsen', 'Affiliation': 'Department of General Practice and Elderly Care Medicine/Amsterdam Public Health Research Institute (SAZ, MS), VU University Medical Center, Amsterdam.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Smalbrugge', 'Affiliation': 'Department of General Practice and Elderly Care Medicine/Amsterdam Public Health Research Institute (SAZ, MS), VU University Medical Center, Amsterdam.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Teerenstra', 'Affiliation': 'Department of Health Evidence (ST), Section Biostatistics, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'Frans R J', 'Initials': 'FRJ', 'LastName': 'Verhey', 'Affiliation': 'Alzheimer Center Limburg (MEV, FRJV), School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Sytse U', 'Initials': 'SU', 'LastName': 'Zuidema', 'Affiliation': 'Department of General Practice and Elderly Care Medicine (SUZ), University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Raymond T C M', 'Initials': 'RTCM', 'LastName': 'Koopmans', 'Affiliation': 'Department of Primary and Community Care (BA, CB, JCLD, RTCMK), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; Radboudumc Alzheimer Center (BA, CB, JCLD, RTCMK), Nijmegen, The Netherlands; De Waalboog ""Joachim en Anna"" Center for Specialized Geriatric Care (RTCMK), Nijmegen, The Netherlands.'}]",The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,['10.1016/j.jagp.2018.12.032'] 735,31740197,"Different metabolism of EPA, DPA and DHA in humans: A double-blind cross-over study.","This study aimed to compare eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA) incorporated into red blood cells (RBC) phospholipids (PL), plasma PL, plasma triglyceride (TAG), and plasma cholesteryl ester (CE) fractions, and the metabolomics profiles in a double-blind cross-over study. Twelve female healthy subjects randomly consumed 1 g per day for 6 days of pure EPA, DPA, or DHA. The placebo treatment was olive oil. The fasting venous blood was taken at days 0, 3 and 6, and the RBC PL and plasma lipid fractions were separated for fatty acid determination using thin layer chromatography followed by gas chromatography. Plasma metabolites were analyzed by UHPLC-Q-Exactive Orbitrap/MS. Supplemental EPA significantly increased the concentrations of EPA in RBC PL (days 3 and 6). For subjects consuming the DPA supplement, the concentrations of both DPA and EPA were significantly increased in RBC PL over a 6-day period, respectively. For plasma PL fraction, EPA and DPA supplementation significantly increased the concentrations of EPA and DPA at both days 3 and 6, respectively. Supplemental DHA significantly increased the concentrations of DHA in plasma PL at day 6. For plasma TAG fraction, supplementation with EPA and DPA significantly increased the concentrations of EPA and DPA at both days 3 and 6, respectively. After DHA supplementation, significant increases in the concentrations of DHA were found relative to baseline at both days 3 and 6. For plasma CE fraction, EPA supplementation significantly increased the concentrations of EPA (days 3 and 6) and DPA (days 6), respectively. Supplemental DPA significantly increased the concentrations of EPA at day 6. Meanwhile, the concentrations of DHA were significantly increased over a 6-day period of intervention after subjects consuming the DHA supplements. There were a total of 922 plasma metabolites identified using metabolomics analyses. Supplementation with DPA and DHA significantly increased the levels of sphingosine 1-phosphate (P for DPA  = 0.025, P for DHA  = 0.029) and 15-deoxy-Δ12,14-prostaglandin A1 (P for DPA  = 0.034; P for DHA  = 0.021) in comparison with olive oil group. Additionally, supplementation with EPA (P = 0.007) and DHA (P = 0.005) significantly reduced the levels of linoleyl carnitine, compared with olive oil group. This study shows that DPA might act as a reservoir of n-3 LCP incorporated into blood lipid fractions, metabolized into DHA, and retro-converted back to EPA. Metabolomics analyses indicate that supplemental EPA, DPA and DHA have shared and differentiated metabolites. The differences of these metabolic biomarkers should be investigated in additional studies.",2020,Supplementation with DPA and DHA significantly increased the levels of sphingosine 1-phosphate,"['Twelve female healthy subjects', 'humans']","['Supplemental EPA', 'randomly consumed 1\xa0g per day for 6 days of pure EPA, DPA, or DHA', 'EPA, DPA and DHA', 'placebo', 'eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA', 'Supplemental DPA']","['Plasma metabolites', 'concentrations of DHA', 'concentrations of DHA in plasma PL', 'red blood cells (RBC) phospholipids (PL), plasma PL, plasma triglyceride (TAG), and plasma cholesteryl ester (CE) fractions', 'RBC PL', 'concentrations of EPA', 'concentrations of EPA and DPA', 'levels of sphingosine 1-phosphate', 'concentrations of both DPA and EPA', 'concentrations of EPA in RBC PL', 'fasting venous blood', '15-deoxy-Δ12,14-prostaglandin A1', 'levels of linoleyl carnitine']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0059057', 'cui_str': 'EPA (prealbumin)'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic Acid'}, {'cui': 'C0058624', 'cui_str': 'docosapentaenoic acid (C22:5 N3)'}, {'cui': 'C0556150', 'cui_str': 'docosahexaenoic acid'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1277078', 'cui_str': 'Red blood cells, blood product'}, {'cui': 'C0031676', 'cui_str': 'Phospholipids'}, {'cui': 'C0583329', 'cui_str': 'Plasma triglyceride measurement'}, {'cui': 'C0008387', 'cui_str': 'Cholesteryl Esters'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}, {'cui': 'C0014792', 'cui_str': 'Blood Corpuscles, Red'}, {'cui': 'C0059057', 'cui_str': 'EPA (prealbumin)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0074992', 'cui_str': 'sphingosine 1-phosphate'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0229667', 'cui_str': 'VB - Venous blood'}, {'cui': 'C0072261', 'cui_str': 'prostaglandin A1'}, {'cui': 'C0696229', 'cui_str': 'Carnitine'}]",12.0,0.117066,Supplementation with DPA and DHA significantly increased the levels of sphingosine 1-phosphate,"[{'ForeName': 'Xiao-Fei', 'Initials': 'XF', 'LastName': 'Guo', 'Affiliation': 'Institute of Nutrition and Health, Qingdao University, Qingdao, China.'}, {'ForeName': 'Wen-Feng', 'Initials': 'WF', 'LastName': 'Tong', 'Affiliation': 'Department of Food Science and Nutrition, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Ruan', 'Affiliation': 'Department of Food Science and Nutrition, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Sinclair', 'Affiliation': 'Faculty of Health, Deakin University, Geelong, Australia; Department of Nutrition, Dietetics and Food, Monash University, Melbourne, Australia.'}, {'ForeName': 'Duo', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Institute of Nutrition and Health, Qingdao University, Qingdao, China; Department of Food Science and Nutrition, Zhejiang University, Hangzhou, China. Electronic address: duoli@qdu.edu.cn.'}]","Prostaglandins, leukotrienes, and essential fatty acids",['10.1016/j.plefa.2019.102033'] 736,30797651,Exercise for Depression: A Feasibility Trial Exploring Neural Mechanisms.,"OBJECTIVE The aim of this study was to test the feasibility of an exercise augmentation to pharmacotherapy in depressed younger and older adults while exploring neural mechanisms. METHODS A randomized, double-blind, controlled clinical trial was conducted in 15 inactive younger (20-39 years) and older (60-79 years) adults meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria for a major depressive episode (https://clinicaltrials.gov/ct2/show/NCT02407704). Participants were randomized to receive a 12-week regimen of venlafaxine XR or venlafaxine XR plus supervised exercise. Cardiorespiratory fitness was assessed using a submaximal Vo 2 test, and neuroimaging assessments were conducted using a Siemans MAGNETOM 7-Tesla magnetic resonance scanner at the University of Pittsburgh. RESULTS Attrition was 38% and 14% for the medication and exercise groups, respectively. Attendance was 91% for the exercise intervention. Exploratory analyses revealed an association between improvement in fitness and increased cortical thickness in the anterior cingulate cortex. CONCLUSION Exercise augmentation to pharmacotherapy is feasible for depressed younger and older adults and may have neural benefits in a core brain region implicated in depression.",2019,"Exploratory analyses revealed an association between improvement in fitness and increased cortical thickness in the anterior cingulate cortex. ","['depressed younger and older adults', '15 inactive younger (20-39 years) and older (60-79 years) adults meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria for a major depressive episode (https://clinicaltrials.gov/ct2/show/NCT02407704']","['venlafaxine XR or venlafaxine XR plus supervised exercise', 'exercise augmentation to pharmacotherapy']","['Cardiorespiratory fitness', 'Attendance', 'cortical thickness']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0556656', 'cui_str': 'Meetings (procedure)'}, {'cui': 'C1136324', 'cui_str': 'Diagnostic and Statistical Manual of Mental Disorders'}, {'cui': 'C0205439', 'cui_str': 'Fifth (qualifier value)'}, {'cui': 'C0441792', 'cui_str': 'Editions (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0349217', 'cui_str': 'Depressive episode'}]","[{'cui': 'C0078569', 'cui_str': 'venlafaxine'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1293122', 'cui_str': 'Augmentation procedure'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}]",,0.149387,"Exploratory analyses revealed an association between improvement in fitness and increased cortical thickness in the anterior cingulate cortex. ","[{'ForeName': 'Swathi', 'Initials': 'S', 'LastName': 'Gujral', 'Affiliation': 'VA VISN 4 Mental Illness Research, Education and Clinical Center of Excellence (SG), Pittsburgh; Department of Psychology (SG, GG, KIE), University of Pittsburgh, Pittsburgh; Department of Psychiatry (SG, HA, CFR, MAB, JFK), Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh. Electronic address: shemacha@gmail.com.'}, {'ForeName': 'Howard', 'Initials': 'H', 'LastName': 'Aizenstein', 'Affiliation': 'Department of Psychiatry (SG, HA, CFR, MAB, JFK), Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh.'}, {'ForeName': 'Charles F', 'Initials': 'CF', 'LastName': 'Reynolds', 'Affiliation': 'Department of Psychiatry (SG, HA, CFR, MAB, JFK), Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh.'}, {'ForeName': 'Meryl A', 'Initials': 'MA', 'LastName': 'Butters', 'Affiliation': 'Department of Psychiatry (SG, HA, CFR, MAB, JFK), Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Grove', 'Affiliation': 'Department of Psychology (SG, GG, KIE), University of Pittsburgh, Pittsburgh.'}, {'ForeName': 'Jordan F', 'Initials': 'JF', 'LastName': 'Karp', 'Affiliation': 'Department of Psychiatry (SG, HA, CFR, MAB, JFK), Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh.'}, {'ForeName': 'Kirk I', 'Initials': 'KI', 'LastName': 'Erickson', 'Affiliation': 'Department of Psychology (SG, GG, KIE), University of Pittsburgh, Pittsburgh.'}]",The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,['10.1016/j.jagp.2019.01.012'] 737,31093925,Seasonal fluctuations in weight and self-weighing behavior among adults in a behavioral weight loss intervention.,"PURPOSE The current study aimed to observe potential seasonal fluctuations in weight and self-weighing behavior among a diverse sample of adults engaged in a behavioral weight loss intervention. METHODS Active duty personnel (N = 248) were randomized to either a counselor-initiated or self-paced 12-month behavioral weight loss intervention promoting daily self-weighing. Body weight and self-weighing frequency were collected from electronic scales (e-scales) provided at baseline. RESULTS Overall, participants lost weight from winter to spring (p = 0.02) and gained weight from fall to winter (p < 0.001). No demographic differences in weight changes were observed. Participants self-weighed less frequently during summer compared to spring (p < 0.0001), less in fall compared to summer (p < 0.0001), and less in winter compared to fall (p < 0.0001). In multivariate models, weight change and self-weighing frequency during the previous season, as well as days since randomization and intervention intensity were associated with seasonal weight changes. CONCLUSIONS This study is the first to observe seasonal fluctuations of weight and self-weighing behavior among adults actively engaged in a weight loss intervention, consistent with research in the general population. Findings highlight the importance of acknowledging seasonal influence within weight loss programs and trials. LEVEL OF EVIDENCE Level I, randomized controlled trial.",2020,"Participants self-weighed less frequently during summer compared to spring (p < 0.0001), less in fall compared to summer (p < 0.0001), and less in winter compared to fall (p < 0.0001).","['adults in a behavioral weight loss intervention', 'Active duty personnel (N\u2009=\u2009248', 'adults engaged in a behavioral weight loss intervention']",['counselor-initiated or self-paced 12-month behavioral weight loss intervention promoting daily self-weighing'],"['weight change and self-weighing frequency', 'weight changes', 'gained weight', 'Body weight and self-weighing frequency']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}]","[{'cui': 'C1571885', 'cui_str': 'Counselors'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}]","[{'cui': 'C0005911', 'cui_str': 'Body Weight Changes'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}]",248.0,0.026921,"Participants self-weighed less frequently during summer compared to spring (p < 0.0001), less in fall compared to summer (p < 0.0001), and less in winter compared to fall (p < 0.0001).","[{'ForeName': 'Margaret C', 'Initials': 'MC', 'LastName': 'Fahey', 'Affiliation': 'Department of Psychology, The University of Memphis, 400 Innovation Drive, Memphis, TN, 38111, USA. mcfahey@memphis.edu.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Klesges', 'Affiliation': 'Department of Preventive Medicine, University of Tennessee Health Science Center, 66 N Pauline Street, Memphis, TN, 38105, USA.'}, {'ForeName': 'Mehmet', 'Initials': 'M', 'LastName': 'Kocak', 'Affiliation': 'Department of Preventive Medicine, University of Tennessee Health Science Center, 66 N Pauline Street, Memphis, TN, 38105, USA.'}, {'ForeName': 'Gerald W', 'Initials': 'GW', 'LastName': 'Talcott', 'Affiliation': 'Department of Preventive Medicine, University of Tennessee Health Science Center, 66 N Pauline Street, Memphis, TN, 38105, USA.'}, {'ForeName': 'Rebecca A', 'Initials': 'RA', 'LastName': 'Krukowski', 'Affiliation': 'Department of Preventive Medicine, University of Tennessee Health Science Center, 66 N Pauline Street, Memphis, TN, 38105, USA.'}]",Eating and weight disorders : EWD,['10.1007/s40519-019-00707-7'] 738,31744314,How does MobileMums work? Mediators of a physical activity intervention.,"Objectives: To establish which Social Cognitive Theory constructs mediated effects of the MobileMums (MMP) program on increased duration and frequency of moderate-vigorous physical activity (MVPA) in women with young children (<5 years). Methods: This secondary data analysis is from a community-based randomised controlled trial. Over 12 weeks, intervention participants received a minimum of 52 individually tailored text messages, one face-to-face and one telephone-delivered session with a trained behavioural counsellor. Participants identified a support person who also received 12 weeks of individually tailored text messages. Control participants received minimal intervention contact. Data were collected pre- and post-program. Five potential mediators were assessed: barrier self-efficacy, goal setting skills, outcome expectancies, perceived environmental opportunity for physical activity and social support for physical activity. Results: Improvements in MVPA frequency were mediated by improvements in barrier self-efficacy, goal setting skills, outcome expectancies and perceived social support. Improvements in MVPA duration resulting from the MMP were mediated by improvements in women's barrier self-efficacy and goal setting skills. Conclusions: MMP improved targeted theoretical constructs and this led to changes in women's MVPA. These findings are valuable for refinement and translation of the MMP and for further research to create theory- and evidence-based physical activity behaviour change programs for women with young children.",2020,"Improvements in MVPA frequency were mediated by improvements in barrier self-efficacy, goal setting skills, outcome expectancies and perceived social support.","['women with young children', 'women with young children (<5\u2009years']","['MobileMums (MMP) program', 'minimum of 52 individually tailored text messages, one face-to-face and one telephone-delivered session with a trained behavioural counsellor', 'physical activity intervention', 'minimal intervention contact']","['barrier self-efficacy, goal setting skills, outcome expectancies and perceived social support', 'MVPA frequency', 'duration and frequency of moderate-vigorous physical activity (MVPA', 'barrier self-efficacy, goal setting skills, outcome expectancies, perceived environmental opportunity for physical activity and social support for physical activity']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0547040', 'cui_str': 'Minimal (qualifier value)'}]","[{'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0150598', 'cui_str': 'Goal setting (qualifier value)'}, {'cui': 'C0037438'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]",52.0,0.054575,"Improvements in MVPA frequency were mediated by improvements in barrier self-efficacy, goal setting skills, outcome expectancies and perceived social support.","[{'ForeName': 'Brianna S', 'Initials': 'BS', 'LastName': 'Fjeldsoe', 'Affiliation': 'Faculty of Medicine, School of Public Health, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Yvette D', 'Initials': 'YD', 'LastName': 'Miller', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology, Brisbane, Australia.'}, {'ForeName': 'Samantha J', 'Initials': 'SJ', 'LastName': 'Prosser', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology, Brisbane, Australia.'}, {'ForeName': 'Alison L', 'Initials': 'AL', 'LastName': 'Marshall', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology, Brisbane, Australia.'}]",Psychology & health,['10.1080/08870446.2019.1687698'] 739,31092132,Full squat produces greater neuromuscular and functional adaptations and lower pain than partial squats after prolonged resistance training.,"The choice of the optimal squatting depth for resistance training (RT) has been a matter of debate for decades and is still controversial. In this study, fifty-three resistance-trained men were randomly assigned to one of four training groups: full squat (F-SQ), parallel squat (P-SQ), half squat (H-SQ), and Control (training cessation). Experimental groups completed a 10-week velocity-based RT programme using the same relative load (linear periodization from 60% to 80% 1RM), only differing in the depth of the squat trained. The individual range of motion and spinal curvatures for each squat variation were determined in the familiarization and subsequently replicated in every lift during the training and testing sessions. Neuromuscular adaptations were evaluated by one-repetition maximum strength (1RM) and mean propulsive velocity (MPV) at each squatting depth. Functional performance was assessed by countermovement jump, 20-m sprint and Wingate tests. Physical functional disability included pain and stiffness records. F-SQ was the only group that increased 1RM and MPV in the three squat variations (ES = 0.77-2.36), and achieved the highest functional performance (ES = 0.35-0.85). P-SQ group obtained the second best results (ES = 0.15-0.56). H-SQ produced no increments in neuromuscular and functional performance (ES = -0.11-0.28) and was the only group reporting significant increases in pain, stiffness and physical functional disability (ES = 1.21-0.87). Controls declined on all tests (ES = 0.02-1.32). We recommend using F-SQ or P-SQ exercises to improve strength and functional performance in well-trained athletes. In turn, the use of H-SQ is inadvisable due to the limited performance improvements and the increments in pain and discomfort after continued training.",2020,"H-SQ produced no increments in neuromuscular and functional performance (ES = -0.11-0.28) and was the only group reporting significant increases in pain, stiffness and physical functional disability (ES = 1.21-0.87).","['well-trained athletes', 'fifty-three resistance-trained men']","['Full squat', 'full squat (F-SQ), parallel squat (P-SQ), half squat (H-SQ), and Control (training cessation', 'resistance training (RT', 'F-SQ or P-SQ exercises', '10-week velocity-based RT programme']","['neuromuscular and functional performance', 'repetition maximum strength (1RM) and mean propulsive velocity (MPV', 'Functional performance', 'highest functional performance', 'neuromuscular and functional adaptations and lower pain', 'pain and discomfort', '1RM and MPV', 'pain, stiffness and physical functional disability', 'strength and functional performance']","[{'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0241236', 'cui_str': 'Does squat (finding)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C3853978'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3653283', 'cui_str': 'PROPULSIVES'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0392673', 'cui_str': 'Adaptation, function (observable entity)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0427008', 'cui_str': 'Stiffness (finding)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}]",,0.0291776,"H-SQ produced no increments in neuromuscular and functional performance (ES = -0.11-0.28) and was the only group reporting significant increases in pain, stiffness and physical functional disability (ES = 1.21-0.87).","[{'ForeName': 'Jesús G', 'Initials': 'JG', 'LastName': 'Pallarés', 'Affiliation': 'Faculty of Sport Sciences, Human Performance and Sports Science Laboratory, University of Murcia, Murcia, Spain.'}, {'ForeName': 'Alejandro M', 'Initials': 'AM', 'LastName': 'Cava', 'Affiliation': 'Faculty of Sport Sciences, Human Performance and Sports Science Laboratory, University of Murcia, Murcia, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Courel-Ibáñez', 'Affiliation': 'Faculty of Sport Sciences, Human Performance and Sports Science Laboratory, University of Murcia, Murcia, Spain.'}, {'ForeName': 'Juan José', 'Initials': 'JJ', 'LastName': 'González-Badillo', 'Affiliation': 'Faculty of Sport, Pablo de Olavide University, Seville, Spain.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Morán-Navarro', 'Affiliation': 'Faculty of Sport Sciences, Human Performance and Sports Science Laboratory, University of Murcia, Murcia, Spain.'}]",European journal of sport science,['10.1080/17461391.2019.1612952'] 740,31734098,"Comparison of nalbuphine, ondansetron and placebo for the prevention of shivering after spinal anaesthesia for urgent caesarean delivery: a randomised double-blind controlled clinical trial.","BACKGROUND Shivering is a common complication of caesarean delivery with neuraxial anaesthesia. The effective prevention and treatment of shivering, especially before delivery, is important and difficult. We tested the hypothesis that prophylactic nalbuphine and ondansetron can prevent post-spinal anaesthesia shivering in parturients undergoing urgent caesarean delivery. METHODS Sixty parturients scheduled for urgent caesarean delivery before spinal anaesthesia were selected and divided randomly into three groups. After peripheral venous catheterisation, parturients were given intravenous nalbuphine 0.08 mg/kg (group N), ondansetron 8 mg (group O), or normal saline (group C). RESULTS The incidence of shivering and of severe (grade ≥3) shivering was significantly lower in group N (15% and 15%, respectively) than in group C (80% and 65%) before delivery (P <0.001 and P=0.003); and significantly less shivering was observed in group N than in group C in the first 30 min after anaesthesia (P=0.001). Up to 60 min after anaesthesia, the incidence of grade ≥3 shivering remained lowest in group N (P=0.003). According to the data during the period from anaesthesia until delivery, the number needed-to-treat for nalbuphine was 1.54 (95%CI 1.13 to 2.41). No significant differences were found between groups O and N or groups O and C at any time. The incidence of dizziness in group N was significantly higher than that of groups O or C (P=0.009). CONCLUSION Nalbuphine 0.08 mg/kg can prevent post-spinal anaesthesia shivering in parturients undergoing urgent caesarean delivery but causes transient dizziness, while ondansetron 8 mg had no significant effect.",2020,"The incidence of shivering and of severe (grade ≥3) shivering was significantly lower in group N (15% and 15%, respectively) than in group C (80% and 65%) before delivery (P <0.001 and P=0.003); and significantly less shivering was observed in group N than in group C in the first 30 min after anaesthesia (P=0.001).","['Sixty parturients scheduled for urgent caesarean delivery before spinal anaesthesia', 'parturients undergoing urgent caesarean delivery', 'shivering after spinal anaesthesia for urgent caesarean delivery']","['ondansetron', 'prophylactic nalbuphine and ondansetron', 'Nalbuphine', 'intravenous nalbuphine', 'nalbuphine, ondansetron and placebo', 'ondansetron 8\u202fmg (group O), or normal saline']","['incidence of dizziness', 'incidence of shivering and of severe (grade ≥3) shivering', 'shivering', 'transient dizziness', 'grade ≥3 shivering']","[{'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0439609', 'cui_str': 'Urgency (qualifier value)'}, {'cui': 'C1384674', 'cui_str': 'Deliveries by cesarean (finding)'}, {'cui': 'C0002928', 'cui_str': 'Spinal Anesthesia'}, {'cui': 'C0036973', 'cui_str': 'Shiverings'}]","[{'cui': 'C0061851', 'cui_str': 'Ondansetron'}, {'cui': 'C0445202', 'cui_str': 'Prophylactic (qualifier value)'}, {'cui': 'C0027348', 'cui_str': 'Nalbuphine'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1596254', 'cui_str': 'Ondansetron 8 MG [Zofran]'}, {'cui': 'C0427626', 'cui_str': 'Group O (qualifier value)'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0036973', 'cui_str': 'Shiverings'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0205374', 'cui_str': 'Transitory (qualifier value)'}]",,0.24299,"The incidence of shivering and of severe (grade ≥3) shivering was significantly lower in group N (15% and 15%, respectively) than in group C (80% and 65%) before delivery (P <0.001 and P=0.003); and significantly less shivering was observed in group N than in group C in the first 30 min after anaesthesia (P=0.001).","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Department of Anaesthesiology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Huang', 'Affiliation': 'Department of Anaesthesiology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China. Electronic address: Drhuangsq@163.com.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Sun', 'Affiliation': 'Department of Anaesthesiology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.'}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Sun', 'Affiliation': 'Department of Anaesthesiology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Wang', 'Affiliation': 'Department of Anaesthesiology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.'}]",International journal of obstetric anesthesia,['10.1016/j.ijoa.2019.10.002'] 741,31567801,Decision Support Strategies for Hip and Knee Osteoarthritis: Less Is More: A Randomized Comparative Effectiveness Trial (DECIDE-OA Study).,"BACKGROUND As guidelines and payers increasingly recommend use of patient decision aids (DAs), evidence about the comparative effectiveness of available DAs is critical for organizations interested in implementing them. The primary purpose of this study was to compare 2 DAs with regard to their ability to help patients become informed and receive their preferred treatment (that is, make an informed patient-centered decision), shared decision-making, surgical rates, and surgeon satisfaction. METHODS We performed a multisite factorial randomized trial enrolling patients with hip or knee osteoarthritis. Patients were randomly assigned to use a long, detailed DA (long DA) or short, interactive DA (short DA). Eight surgeons were randomly assigned to receive a patient preference report detailing the patient's goals and treatment preferences or to administer usual care. RESULTS We distributed 1,636 pre-visit surveys, 1,220 of which were returned (75% response rate), and 1,124 post-visit surveys, 967 of which were returned (86% response rate). The patients in the sample had a mean age (and standard deviation) of 65 ± 10 years, 57% were female, 89% were white non-Hispanic, and 67% had knee osteoarthritis. The majority (67.2%) made informed patient-centered decisions, and the rate did not vary significantly between the DA groups (p = 0.97) or between the surgeon groups (p = 0.23). Knowledge scores were higher for the short-DA group (mean difference = 9%; p < 0.001). More than half of the sample (60.5%) had surgery within 6 months after the visit, and rates did not differ significantly by DA or surgeon group. Overall, the surgeons were highly satisfied and reported that the majority (88.7%) of the visits were of normal duration or shorter. CONCLUSIONS The DECIDE-OA study is, to our knowledge, the first randomized comparative effectiveness study of 2 orthopaedic DAs. The short DA outperformed the long DA with regard to knowledge scores and was comparable with respect to other outcomes. The surgeons reported high satisfaction and normal visit duration with both DAs. CLINICAL RELEVANCE Surgeons need to ensure that patients with osteoarthritis are well-informed and have a clear preference regarding whether to undergo hip or knee replacement surgery. The DAs used in this study may help surgeons involve patients in elective surgery decisions and meet the requirements of informed consent.",2019,Knowledge scores were higher for the short-DA group (mean difference = 9%; p < 0.001).,"['patients with hip or knee osteoarthritis', '2 orthopaedic DAs', 'Hip and Knee Osteoarthritis', 'patients in the sample had a mean age (and standard deviation) of 65 ± 10 years, 57% were female, 89% were white non-Hispanic, and 67% had knee osteoarthritis', 'patients with osteoarthritis', 'Eight surgeons']","[""patient preference report detailing the patient's goals and treatment preferences or to administer usual care"", 'detailed DA (long DA) or short, interactive DA (short DA']",['Knowledge scores'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis, Knee'}, {'cui': 'C0051767', 'cui_str': 'DASD'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0029408', 'cui_str': 'Arthritis, Degenerative'}, {'cui': 'C0582175', 'cui_str': 'Surgeon (occupation)'}]","[{'cui': 'C0376409', 'cui_str': 'Patient Preference'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018017', 'cui_str': 'Goals'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0558295', 'cui_str': 'Preferences (qualifier value)'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",1636.0,0.0516856,Knowledge scores were higher for the short-DA group (mean difference = 9%; p < 0.001).,"[{'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Sepucha', 'Affiliation': 'Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Hany', 'Initials': 'H', 'LastName': 'Bedair', 'Affiliation': 'Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Liyang', 'Initials': 'L', 'LastName': 'Yu', 'Affiliation': 'Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Janet M', 'Initials': 'JM', 'LastName': 'Dorrwachter', 'Affiliation': 'Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Dwyer', 'Affiliation': 'Newton Wellesley Hospital, Newton, Massachusetts.'}, {'ForeName': 'Carl T', 'Initials': 'CT', 'LastName': 'Talmo', 'Affiliation': 'New England Baptist Hospital, Boston, Massachusetts.'}, {'ForeName': 'Ha', 'Initials': 'H', 'LastName': 'Vo', 'Affiliation': 'Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Andrew A', 'Initials': 'AA', 'LastName': 'Freiberg', 'Affiliation': 'Massachusetts General Hospital, Boston, Massachusetts.'}]",The Journal of bone and joint surgery. American volume,['10.2106/JBJS.19.00004'] 742,31733809,Assessment of anesthesia machine redesign on cleaning of the anesthesia machine using surface disinfection wipes.,"BACKGROUND The use of surface disinfection wipes after induction of anesthesia improves anesthesia machine cleaning. We assessed whether anesthesia machine surface redesign improves disinfection wipe cleaning by anesthesia residents. METHODS Sixteen anesthesia residents were assigned to 2 cases in series. The first case was randomly assigned to regional knee or hip surgery, a brief or detailed checklist, and the Perseus A500 (redesigned) or GE Aespire 7900 (conventional) machine. The second case was assigned to the opposite for each condition. Setup checklists included cleaning instructions. Eight machine sites representing redesign were contaminated with fluorescent gel prior to setup and reassessed after setup to assess cleaning efficacy. Cleaning was compared by fluorescence quantification of before and after setup images. Our primary hypothesis was that, overall, more sites would be cleaned on the Perseus machine. Our secondary hypothesis was that redesign would affect some sites. RESULTS Overall, the number of sites cleaned did not differ between machines (median 0.74 more sites out of 8 for the Perseus A500; 25th and 75th percentiles, -0.34 and 1.04; P = .093). However, greater cleaning was observed for the work surface and manual bag arm/hose of the Perseus machine (0.58 more sites out of 2; 25th and 75th percentiles, 0.35 and 1.05; P = .0004). CONCLUSIONS The number of sites cleaned overall did not differ between the conventional and redesigned Perseus A500 machines. However, the redesigned work surface and smooth manual bag arm features improved resident cleaning with surface disinfection wipes.",2020,"Overall, the number of sites cleaned did not differ between machines (median 0.74 more sites out of 8 for the Perseus A500; 25th and 75th percentiles, -0.34 and 1.04; P = .093).",['Sixteen anesthesia residents'],"['regional knee or hip surgery, a brief or detailed checklist, and the Perseus A500 (redesigned) or GE Aespire 7900 (conventional) machine']","['number of sites cleaned overall', 'number of sites cleaned']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}]","[{'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0596706', 'cui_str': 'Hip surgery'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0336779', 'cui_str': 'Machine, device (physical object)'}]","[{'cui': 'C0445108', 'cui_str': 'Number of sites (qualifier value)'}, {'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",16.0,0.0172371,"Overall, the number of sites cleaned did not differ between machines (median 0.74 more sites out of 8 for the Perseus A500; 25th and 75th percentiles, -0.34 and 1.04; P = .093).","[{'ForeName': 'Eli', 'Initials': 'E', 'LastName': 'Schmidt', 'Affiliation': 'Department of Anesthesia, University of Iowa Healthcare, Iowa City, IA.'}, {'ForeName': 'Franklin', 'Initials': 'F', 'LastName': 'Dexter', 'Affiliation': 'Department of Anesthesia, University of Iowa Healthcare, Iowa City, IA.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Herrmann', 'Affiliation': 'Department of Biomedical Engineering, University of Iowa, Iowa City, IA.'}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Godding', 'Affiliation': 'Department of Anesthesia, University of Iowa Healthcare, Iowa City, IA.'}, {'ForeName': 'Brent', 'Initials': 'B', 'LastName': 'Hadder', 'Affiliation': 'Department of Anesthesia, University of Iowa Healthcare, Iowa City, IA.'}, {'ForeName': 'Randy W', 'Initials': 'RW', 'LastName': 'Loftus', 'Affiliation': 'Department of Anesthesia, University of Iowa Healthcare, Iowa City, IA. Electronic address: randy-loftus@uiowa.edu.'}]",American journal of infection control,['10.1016/j.ajic.2019.09.016'] 743,31734088,A contra-lateral comparison of the visual effects of a photochromic vs. non-photochromic contact lens.,"PURPOSE To compare the effects of a photochromic contact lens vs. a non-photochromic control lens on visual function. METHODS A subject-masked, prospective contralateral eye design was used. Sixty-one subjects were enroled based on age (using a 2:1 allocation ratio for ages 18-39 and 40-65 years, respectively). The study lenses were senofilcon A with photochromic additive (Test) that filtered over the entire lens, compared to a non-photochromic Control with no tint. The Test lens was partially activated during testing with a steady-state transmittance of approximately 62%. Eligible subjects were tested using both study lenses, with Test and Control lens randomized by eye. Five visual function outcomes were tested: photostress recovery (PSR), glare disability (GD), glare discomfort (GDC), chromatic contrast (CC) and vernier acuity (VA). Iris colour and macular pigment density were assessed as control variables. PSR was measured as the time needed to recover sight of a target after an intense xenon flash exposure; GD was evaluated as the energy needed to veil a central target by a surrounding xenon annulus; GDC was measured using bio-imaging of the squint response and by self-report using a 9-item Likert scale; CC was measured as thresholds for a yellow grating target superposed on a 460-nm background; VA was determined by measuring vernier offsets of light lines through apertures. RESULTS Based on our stimulus conditions, PSR was 43% faster using the Test vs. the Control. The eye wearing the Test had 38% less squint (GDC) compared to the Control. GD was improved by 36% in the Test vs. Control and CC was enhanced by 48% with the Test. There was no significant difference in VA. CONCLUSIONS There was a beneficial influence on visual function when comparing the photochromic with the non-photochromic contact lens. This benefit was seen specifically with respect to PRT, GDC, GD and CC thresholds.",2020,There was a beneficial influence on visual function when comparing the photochromic with the non-photochromic contact lens.,"['Eligible subjects', 'Sixty-one subjects were enroled based on age (using a 2:1 allocation ratio for ages 18-39 and 40-65 years, respectively']","['photochromic vs. non-photochromic contact lens', 'photochromic contact lens vs. a non-photochromic control lens']","['PSR', 'GD', 'Iris colour and macular pigment density', 'visual function', 'VA', 'photostress recovery (PSR), glare disability (GD), glare discomfort (GDC), chromatic contrast (CC) and vernier acuity (VA']","[{'cui': 'C4517832', 'cui_str': 'Sixty-one'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0009836', 'cui_str': 'Contact Lenses'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0023317', 'cui_str': 'Lens, Eye'}]","[{'cui': 'C0022077', 'cui_str': 'Iris'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C3850163', 'cui_str': 'Macular Pigment'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C1321306', 'cui_str': 'Glare disability'}, {'cui': 'C3887688', 'cui_str': 'Glare (finding)'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0392714', 'cui_str': 'Vernier acuity (observable entity)'}]",61.0,0.0328088,There was a beneficial influence on visual function when comparing the photochromic with the non-photochromic contact lens.,"[{'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Renzi-Hammond', 'Affiliation': 'Human Biofactors Laboratory, Institute of Gerontology, Department of Health Promotion and Behavior, University of Georgia, Athens, GA 30602, United States. Electronic address: lrenzi@uga.edu.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Buch', 'Affiliation': 'Johnson & Johnson Vision Care, Inc., United States. Electronic address: Jbuch@its.jnj.com.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Cannon', 'Affiliation': 'Johnson & Johnson Vision Care, Inc., United States. Electronic address: jcannon@its.jnj.com.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Hacker', 'Affiliation': 'Georgia Center for Sight, Greensboro, GA 30642, United States. Electronic address: hackerlauren@gmail.com.'}, {'ForeName': 'Youssef', 'Initials': 'Y', 'LastName': 'Toubouti', 'Affiliation': 'Johnson & Johnson Vision Care, Inc., United States. Electronic address: Ytoubouti@its.jnj.com.'}, {'ForeName': 'Billy R', 'Initials': 'BR', 'LastName': 'Hammond', 'Affiliation': 'Vision Sciences Laboratory, Behavioral and Brain Sciences Program, Department of Psychology, University of Georgia, Athens, GA, 30602, Greece. Electronic address: bhammond@uga.edu.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2019.10.138'] 744,31072217,Moderate-intensity exercise performed in the evening does not impair sleep in healthy males.,"The aim of this study was to examine the effect of single bouts of moderate-intensity aerobic exercise and moderate-intensity resistance exercise performed in the evening on the sleep of healthy young males. The study employed a repeated-measures, counterbalanced, crossover design with three conditions (control, evening aerobic exercise, evening resistance exercise). Twelve male participants (mean ± SD; age: 21.9 ± 2.7 yr) attended the laboratory on three occasions separated by one day between each visit. Between 20:45 h and 21:30 h, participants completed either no exercise, 30 min of aerobic exercise at 75%HRmax, or 30 min of resistance exercise corresponding to 75% of 10-repetition maximum. A 9-h sleep opportunity was provided between 23:00 h and 08:00 h. Core body temperature was measured using ingestible temperature capsules and sleep was measured using polysomnography. Core body temperature was higher during the aerobic exercise and resistance exercise compared to control ( p  = 0.001). There was no difference in core body temperature at bedtime between the conditions. Sleep onset latency, total sleep time, slow-wave sleep duration, REM sleep duration, wake after sleep onset and sleep efficiency were similar in each condition ( p  > 0.05). Single bouts of moderate-intensity aerobic exercise or moderate-intensity resistance exercise performed in the evening did not impact subsequent night-time sleep. Core body temperature increased during both forms of exercise, but returned to pre-exercise levels in the 90 min prior to bedtime. Healthy young males can engage in a single bout of moderate-intensity aerobic exercise or moderate-intensity resistance exercise ceasing 90 min before bed without compromising their subsequent sleep.",2020,Core body temperature was higher during the aerobic exercise and resistance exercise compared to control (p = 0.001).,"['healthy young males', 'Healthy young males', 'healthy males', 'Twelve male participants (mean\u2009±\u2009SD; age: 21.9\u2009±\u20092.7\u2005yr) attended the laboratory on three occasions separated by one day between each visit']","['no exercise, 30\u2005min of aerobic exercise at 75%HRmax, or 30\u2005min of resistance exercise corresponding to 75% of 10-repetition maximum', 'moderate-intensity aerobic exercise or moderate-intensity resistance exercise ceasing 90\u2005min before bed without compromising their subsequent sleep', 'moderate-intensity aerobic exercise and moderate-intensity resistance exercise', 'moderate-intensity aerobic exercise or moderate-intensity resistance exercise']","['core body temperature', 'Core body temperature', 'Sleep onset latency, total sleep time, slow-wave sleep duration, REM sleep duration, wake after sleep onset and sleep efficiency']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517635', 'cui_str': '2.7'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0443299', 'cui_str': 'Separate (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0587115', 'cui_str': 'Before sleeping (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}]","[{'cui': 'C0456240', 'cui_str': 'Core body temperature (observable entity)'}, {'cui': 'C4505222', 'cui_str': 'REM Sleep Latency'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0234451', 'cui_str': 'Sleep, Slow-Wave'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0037322', 'cui_str': 'Sleep, Fast-Wave'}, {'cui': 'C0442696', 'cui_str': 'Waking (observable entity)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}]",12.0,0.0665336,Core body temperature was higher during the aerobic exercise and resistance exercise compared to control (p = 0.001).,"[{'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Miller', 'Affiliation': 'Central Queensland University, The Appleton Institute for Behavioural Science, Adelaide, Australia.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Sargent', 'Affiliation': 'Central Queensland University, The Appleton Institute for Behavioural Science, Adelaide, Australia.'}, {'ForeName': 'G D', 'Initials': 'GD', 'LastName': 'Roach', 'Affiliation': 'Central Queensland University, The Appleton Institute for Behavioural Science, Adelaide, Australia.'}, {'ForeName': 'A T', 'Initials': 'AT', 'LastName': 'Scanlan', 'Affiliation': 'Human Exercise and Training Laboratory, School of Health, Medical and Applied Sciences, Central Queensland University, Rockhampton, Australia.'}, {'ForeName': 'G E', 'Initials': 'GE', 'LastName': 'Vincent', 'Affiliation': 'Central Queensland University, The Appleton Institute for Behavioural Science, Adelaide, Australia.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Lastella', 'Affiliation': 'Central Queensland University, The Appleton Institute for Behavioural Science, Adelaide, Australia.'}]",European journal of sport science,['10.1080/17461391.2019.1611934'] 745,29368994,Nurses' Intentions to Initiate an Antipsychotic or Behavioral Intervention with Nursing Home Residents: The Role of Norms and Being Evaluated.,"OBJECTIVES To examine whether exposure to a message to avoid antipsychotic medications and a salient sense of managerial oversight influenced nurses' treatment intentions. METHODS 158 nurses from 28 long-term care facilities were randomized to one of four conditions within a 2 × 2 between-participants design. The nurses responded to a case study depicting a resident with dementia-related behavioral problems with their intent to initiate an antipsychotic or a psychosocial intervention. Self-efficacy, descriptive norms, and attitudes were measured via self-report. RESULTS Perceived local antipsychotic prevalence was related to the nurses' treatment intentions. There were no main or interactive effects of the avoid antipsychotic or manager oversight conditions on the nurses' treatment intentions. However, there was a significant interaction of actual facility antipsychotic prevalence and the avoid antipsychotics message on intentions to initiate an antipsychotic. CONCLUSIONS Nurses' perceptions of local antipsychotic prevalence were positively associated with intentions to initiate an antipsychotic and negatively associated with intentions to initiate a psychosocial intervention. However, a salient message to avoid antipsychotics had limited influence on nurses' treatment intentions and was associated with increased intentions to initiate antipsychotics in facilities with higher rates of antipsychotic use. The oversight condition did not demonstrate adequate internal validity, which may have caused its lack of effect on treatment intentions. CLINICAL IMPLICATIONS Nurses' perceptions of the local prevalence of antipsychotic use is associated with their treatment intentions. However, increasing the visibility of a message discouraging antipsychotic use may have limited utility in influencing nurses' intentions to initiate an antipsychotic or psychosocial intervention.",2019,"However, a salient message to avoid antipsychotics had limited influence on nurses' treatment intentions and was associated with increased intentions to initiate antipsychotics in facilities with higher rates of antipsychotic use.","['with Nursing Home Residents', '158 nurses from 28 long-term care facilities']","['antipsychotic or a psychosocial intervention', 'Antipsychotic or Behavioral Intervention']","['Self-efficacy, descriptive norms, and attitudes', 'actual facility antipsychotic prevalence']","[{'cui': 'C0028688', 'cui_str': 'Nursing Homes'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}]","[{'cui': 'C0040615', 'cui_str': 'Antipsychotic Drugs'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0040615', 'cui_str': 'Antipsychotic Drugs'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}]",158.0,0.0158065,"However, a salient message to avoid antipsychotics had limited influence on nurses' treatment intentions and was associated with increased intentions to initiate antipsychotics in facilities with higher rates of antipsychotic use.","[{'ForeName': 'Brian M', 'Initials': 'BM', 'LastName': 'Ludwin', 'Affiliation': 'a Department of Psychological and Brain Sciences , University of Louisville , Louisville Kentucky , USA.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Meeks', 'Affiliation': ''}]",Clinical gerontologist,['10.1080/07317115.2018.1427643'] 746,31736342,Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.,"BACKGROUND While disease-modifying therapies exist for heart failure (HF) with reduced left ventricular ejection fraction (LVEF), few options are available for patients in the higher range of LVEF (>40%). Sacubitril/valsartan has been compared with a renin-angiotensin-aldosterone-system inhibitor alone in 2 similarly designed clinical trials of patients with reduced and preserved LVEF, permitting examination of its effects across the full spectrum of LVEF. METHODS We combined data from PARADIGM-HF (LVEF eligibility≤40%; n=8399) and PARAGON-HF (LVEF eligibility≥45%; n=4796) in a prespecified pooled analysis. We divided randomized patients into LVEF categories: ≤22.5% (n=1269), >22.5% to 32.5% (n=3987), >32.5% to 42.5% (n=3143), > 42.5% to 52.5% (n=1427), > 52.5% to 62.5% (n=2166), and >62.5% (n=1202). We assessed time to first cardiovascular death and HF hospitalization, its components, and total heart failure hospitlizations, all-cause mortality, and noncardiovascular mortality. Incidence rates and treatment effects were examined across categories of LVEF. RESULTS Among 13 195 randomized patients, we observed lower rates of cardiovascular death and HF hospitalization, but similar rates of noncardiovascular death, among patients in the highest versus the lowest groups. Overall sacubitril/valsartan was superior to renin-angiotensin-aldosterone-system inhibition for first cardiovascular death or heart failure hospitalization (Hazard Ratio [HR] 0.84 [95% CI, 0.78-0.90]), cardiovascular death (HR 0.84 [95% CI, 0.76-0.92]), heart failure hospitalization (HR 0.84 [95% CI, 0.77-0.91]), and all-cause mortality (HR 0.88 [95% CI, 0.81-0.96]). The effect of sacubitril/valsartan was modified by LVEF (treatment-by-continuous LVEF interaction P =0.02), and benefit appeared to be present for individuals with EF primarily below the normal range, although the treatment benefit for cardiovascular death diminished at a lower ejection fraction. We observed effect modification by LVEF on the efficacy of sacubitril/valsartan in both men and women with respect to composite total HF hospitalizations and cardiovascular death, although women derived benefit to higher ejection fractions. CONCLUSIONS The therapeutic effects of sacubitril/valsartan, compared with a renin-angiotensin-aldosterone-system inhibitor alone, vary by LVEF with treatment benefits, particularly for heart failure hospitalization, that appear to extend to patients with heart failure and mildly reduced ejection fraction. These therapeutic benefits appeared to extend to a higher LVEF range in women compared with men. CLINICAL TRIAL REGISTRATION https://www.clinicaltrials.gov. Unique identifiers: NCT01920711 (PARAGON-HF), NCT01035255 (PARADIGM-HF).",2020,"Overall sacubitril/valsartan was superior to RAS inhibition for first cardiovascular death or heart failure hospitalization (HR 0.84, 95% CI 0.78, 0.90), cardiovascular death (HR 0.84, 95% CI 0.76, 0.92), heart failure hospitalization (HR 0.84, 95% CI 0.77, 0.91), and all-cause mortality (HR 0.88, 95% CI 0.81, 0.96).","['patients with heart failure and mildly reduced ejection fraction', 'men and women with respect to composite total HF hospitalizations and cardiovascular death, although women derived benefit to higher ejection fractions', 'patients in the higher range of LVEF (>40', '13,195 randomized patients']","['Sacubitril/Valsartan', 'sacubitril/valsartan', 'Sacubitril/valsartan', 'LVEF']","['rates of non-cardiovascular death', 'cardiovascular death and HF hospitalization', 'time to first cardiovascular death and HF hospitalization, its components, and total heart failure hospitlizations, all-cause mortality and non-cardiovascular mortality', 'Incidence rates', 'heart failure hospitalization', 'RAS inhibition for first cardiovascular death or heart failure hospitalization', 'cardiovascular death']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0679133', 'cui_str': 'Respect'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}]","[{'cui': 'C4033631', 'cui_str': 'sacubitril / valsartan'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C3539085', 'cui_str': 'All'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}]",,0.115373,"Overall sacubitril/valsartan was superior to RAS inhibition for first cardiovascular death or heart failure hospitalization (HR 0.84, 95% CI 0.78, 0.90), cardiovascular death (HR 0.84, 95% CI 0.76, 0.92), heart failure hospitalization (HR 0.84, 95% CI 0.77, 0.91), and all-cause mortality (HR 0.88, 95% CI 0.81, 0.96).","[{'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Solomon', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D.S., M.V., B.L.C., M.A.P., A.D.).""}, {'ForeName': 'Muthiah', 'Initials': 'M', 'LastName': 'Vaduganathan', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D.S., M.V., B.L.C., M.A.P., A.D.).""}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'L Claggett', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D.S., M.V., B.L.C., M.A.P., A.D.).""}, {'ForeName': 'Milton', 'Initials': 'M', 'LastName': 'Packer', 'Affiliation': 'Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.).'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Zile', 'Affiliation': 'Medical University of South Carolina, Charleston (M.Z.).'}, {'ForeName': 'Karl', 'Initials': 'K', 'LastName': 'Swedberg', 'Affiliation': 'Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.).'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Rouleau', 'Affiliation': 'Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.R.).'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'A Pfeffer', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D.S., M.V., B.L.C., M.A.P., A.D.).""}, {'ForeName': 'Akshay', 'Initials': 'A', 'LastName': 'Desai', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D.S., M.V., B.L.C., M.A.P., A.D.).""}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'H Lund', 'Affiliation': 'Department of Medicine, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden (L.H.L.).'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Kober', 'Affiliation': 'Department of Cardiology, Heart Centre, Rigshospitalet, Copenhagen University Hospital, Denmark (L.K.).'}, {'ForeName': 'Inder', 'Initials': 'I', 'LastName': 'Anand', 'Affiliation': 'Department of Medicine, VA Medical Center and University of Minnesota, Minneapolis (I.A.).'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Sweitzer', 'Affiliation': 'Sarver Heart Center, University of Arizona College of Medicine, Tucson (N.S.).'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Linssen', 'Affiliation': 'Department of Cardiology, Hospital Group Twente, Almelo and Hengelo, The Netherlands (G.L.).'}, {'ForeName': 'Bela', 'Initials': 'B', 'LastName': 'Merkely', 'Affiliation': 'Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.).'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Luis Arango', 'Affiliation': 'Guatemalan Heart Institute (J.L.A.).'}, {'ForeName': 'Dragos', 'Initials': 'D', 'LastName': 'Vinereanu', 'Affiliation': 'University of Medicine and Pharmacy Carol Davila, University and Emergency Hospital of Bucharest, Romania (D.V.).'}, {'ForeName': 'Chen-Huan', 'Initials': 'CH', 'LastName': 'Chen', 'Affiliation': 'Department of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China (C.-H.C.).'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Senni', 'Affiliation': 'Cardiology Division, Cardiovascular Department, Hospital Papa Giovanni XXIII, Bergamo, Italy (M.S.).'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Sibulo', 'Affiliation': ""St Luke's Heart Institute, St. Luke's Medical Center, Taguig, Philippines (A.S.).""}, {'ForeName': 'Sergey', 'Initials': 'S', 'LastName': 'Boytsov', 'Affiliation': 'National Research Center for Cardiology of the Ministry of Health of the Russian Federation, Moscow (S.B.).'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Shi', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ (V.S, A.R., M.L.).'}, {'ForeName': 'Adel', 'Initials': 'A', 'LastName': 'Rizkala', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ (V.S, A.R., M.L.).'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Lefkowitz', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ (V.S, A.R., M.L.).'}, {'ForeName': 'John J V', 'Initials': 'JJV', 'LastName': 'McMurray', 'Affiliation': 'British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.V.M.).'}]",Circulation,['10.1161/CIRCULATIONAHA.119.044586'] 747,31060834,Postprandial glucose response after the consumption of three mixed meals based on the carbohydrate counting method in adults with type 1 diabetes. A randomized crossover trial.,"BACKGROUND & AIMS People on intensive insulin therapy usually calculate their premeal insulin dose based on the total amount of consumed carbohydrates. However, arguments have been expressed supporting that also the protein and fat content of the meals should be considered when estimating premeal insulin dose. We examined the effectiveness of the carbohydrate counting method after consumption of mixed meals, and we further explored the effects of added extra virgin olive oil in these mixed meals, in adults with type 1 diabetes. METHODS Twenty adults (35.0 ± 8.9 years, BMI 27 ± 5 kg/m 2 ) with diabetes duration 17 ± 11 years, on intensive insulin therapy with multiple injections, consumed 3 mixed meals (pasticcio, chicken with vegetables and baked giant beans), with and without the addition of 11 ml extra virgin olive oil (total of 6 meals), in random order, with the insulin dose determined by using the carbohydrate counting method. Capillary blood glucose was measured at premeal (baseline) and 30, 60, 90, 120, 150 and 180 min after meal consumption. At every visit, participants were assessed for anthropometric parameters and subjective stress. RESULTS Participants had mean HbA1c 7.5 ± 1.2%, mean carbohydrate to insulin ratio 9:1 IU and stable body weight, waist circumference and subjective stress throughout the study. The mean glucose concentration, for all 6 meals, 120 min postprandially was within target (<180 mg/dl) in nearly 80% of the sample. Addition of olive oil produced sustained increased postprandial glucose concentrations only to pasticcio meal, although within target, and no significant differences were noticed for the grilled chicken with vegetables or the baked giant beans (legume) meals. CONCLUSIONS The carbohydrate-counting method was effective for achieving postprandial glucose levels within target threshold up to 3 h postprandially. Moreover, adding small amounts of dietary fat (extra virgin olive oil) to low fat meals does not significantly alter the postprandial response within the first 3 h, whereas caused a sustained increase in postprandial blood glucose concentrations to the high energy density meal (i.e. the pasticcio meal).",2019,"The mean glucose concentration, for all 6 meals, 120 min postprandially was within target (<180 mg/dl) in nearly 80% of the sample.","['adults with type 1 diabetes', 'Twenty adults (35.0\xa0±\xa08.9 years, BMI 27\xa0±\xa05\xa0kg/m 2 ) with diabetes duration 17\xa0±\xa011 years, on']","['olive oil', 'added extra virgin olive oil', 'intensive insulin therapy with multiple injections, consumed 3 mixed meals (pasticcio, chicken with vegetables and baked giant beans), with and without the addition of 11\xa0ml extra virgin olive oil (total of 6 meals']","['mean carbohydrate to insulin ratio 9:1 IU and stable body weight, waist circumference and subjective stress', 'mean glucose concentration', 'Postprandial glucose response', 'anthropometric parameters and subjective stress', 'Capillary blood glucose', 'postprandial response', 'postprandial blood glucose concentrations', 'postprandial glucose levels', 'postprandial glucose concentrations']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}]","[{'cui': 'C0069449', 'cui_str': 'olive oil'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0555061', 'cui_str': 'Virgin (finding)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0008051', 'cui_str': 'Gallus gallus domesticus'}, {'cui': 'C0042440', 'cui_str': 'Vegetables'}, {'cui': 'C0017547', 'cui_str': 'Pituitary Gigantism'}, {'cui': 'C0004896', 'cui_str': 'Bean (substance)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C1287281', 'cui_str': 'Finding of glucose concentration, dipstick (finding)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0229666', 'cui_str': 'Capillary blood (substance)'}, {'cui': 'C2585282', 'cui_str': 'Blood glucose concentration'}, {'cui': 'C0428548', 'cui_str': 'Glucose level - finding'}]",20.0,0.044327,"The mean glucose concentration, for all 6 meals, 120 min postprandially was within target (<180 mg/dl) in nearly 80% of the sample.","[{'ForeName': 'Emilia', 'Initials': 'E', 'LastName': 'Papakonstantinou', 'Affiliation': 'Lab of Food Chemistry and Analysis, Department of Food Science and Human Nutrition, Agricultural University of Athens, Athens, Greece. Electronic address: emiliap@aua.gr.'}, {'ForeName': 'Kleopatra', 'Initials': 'K', 'LastName': 'Papavasiliou', 'Affiliation': 'Lab of Food Chemistry and Analysis, Department of Food Science and Human Nutrition, Agricultural University of Athens, Athens, Greece.'}, {'ForeName': 'Chrystalleni', 'Initials': 'C', 'LastName': 'Maouri', 'Affiliation': 'Department of Nutrition and Dietetics, Harokopio University, Athens, Greece.'}, {'ForeName': 'Emmanuella', 'Initials': 'E', 'LastName': 'Magriplis', 'Affiliation': 'Lab of Food Chemistry and Analysis, Department of Food Science and Human Nutrition, Agricultural University of Athens, Athens, Greece.'}, {'ForeName': 'Stavros', 'Initials': 'S', 'LastName': 'Pappas', 'Affiliation': 'Third Pathology Clinic, Diabetes Center, Nice General Hospital, Athens, Greece.'}, {'ForeName': 'Stavros', 'Initials': 'S', 'LastName': 'Bousboulas', 'Affiliation': 'Third Pathology Clinic, Diabetes Center, Nice General Hospital, Athens, Greece.'}, {'ForeName': 'Anastasios', 'Initials': 'A', 'LastName': 'Koutsovasilis', 'Affiliation': 'Third Pathology Clinic, Diabetes Center, Nice General Hospital, Athens, Greece.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Pappas', 'Affiliation': 'Third Pathology Clinic, Diabetes Center, Nice General Hospital, Athens, Greece.'}, {'ForeName': 'Alexis', 'Initials': 'A', 'LastName': 'Sotiropoulos', 'Affiliation': 'Third Pathology Clinic, Diabetes Center, Nice General Hospital, Athens, Greece.'}, {'ForeName': 'Meropi D', 'Initials': 'MD', 'LastName': 'Kontogianni', 'Affiliation': 'Department of Nutrition and Dietetics, Harokopio University, Athens, Greece.'}]",Clinical nutrition ESPEN,['10.1016/j.clnesp.2019.03.002'] 748,31610435,Combining oxytocin and cognitive bias modification training in a randomized controlled trial: Effects on trust in maternal support.,"BACKGROUND AND OBJECTIVES Research on the social effects of intranasal oxytocin in children is scarce. Oxytocin has been proposed to have clearer beneficial effects when added to social learning paradigms. The current study tested this proposition in middle childhood by assessing effects of cognitive bias modification (CBM) training and oxytocin on trust in maternal support. METHODS Children (N = 100, 8-12 years) were randomly assigned to one of two training conditions: CBM training aimed at increasing trust or neutral placebo training. Within each training condition, half the participants received oxytocin and half a placebo. Main and interaction effects were assessed on measures of trust-related interpretation bias and trust. We explored whether child characteristics moderated intervention effects. RESULTS Children in the CBM training were faster to interpret maternal behaviour securely versus insecurely. Effects did not generalize to interpretation bias measures or trust. There were no main or interaction effects of oxytocin. Exploratory moderation analyses indicated that combining CBM training with oxytocin had less positive effects on trust for children with more internalizing problems. LIMITATIONS As this was the first study combining CBM and oxytocin, replication of the results is needed. CONCLUSIONS This study combined a social learning paradigm with oxytocin in children. CBM training was effective at an automatic level of processing. Oxytocin did not enhance CBM effects or independently exert effects. Research in larger samples specifying when oxytocin might have beneficial effects is necessary before oxytocin can be used as intervention option in children.",2020,"Exploratory moderation analyses indicated that combining CBM training with oxytocin had less positive effects on trust for children with more internalizing problems. ","['children', 'Children (N\u202f=\u202f100, 8-12 years', 'children with more internalizing problems']","['CBM training', 'oxytocin and half a placebo', 'cognitive bias modification (CBM) training and oxytocin', 'CBM training with oxytocin', 'oxytocin', 'CBM training aimed at increasing trust or neutral placebo training', 'Oxytocin', 'intranasal oxytocin', 'oxytocin and cognitive bias modification training']","['maternal behaviour securely', 'CBM effects']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0005346', 'cui_str': 'Bias'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}]","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}]",,0.144225,"Exploratory moderation analyses indicated that combining CBM training with oxytocin had less positive effects on trust for children with more internalizing problems. ","[{'ForeName': 'Martine W F T', 'Initials': 'MWFT', 'LastName': 'Verhees', 'Affiliation': 'Parenting and Special Education Research Unit, KU Leuven, Leuven, Belgium. Electronic address: martine.verhees@kuleuven.be.'}, {'ForeName': 'Marinus H', 'Initials': 'MH', 'LastName': 'van IJzendoorn', 'Affiliation': 'Department of Psychology, Education and Child Studies, Erasmus University Rotterdam, the Netherlands; Primary Care Unit, School of Clinical Medicine, University of Cambridge, UK.'}, {'ForeName': 'Marian J', 'Initials': 'MJ', 'LastName': 'Bakermans-Kranenburg', 'Affiliation': 'Clinical Child and Family Studies, Vrije Universiteit Amsterdam, The Netherlands.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Ceulemans', 'Affiliation': 'Quantitative Psychology and Individual Differences Research Unit, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'de Winter', 'Affiliation': 'Parenting and Special Education Research Unit, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'Santens', 'Affiliation': 'Parenting and Special Education Research Unit, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Kaat', 'Initials': 'K', 'LastName': 'Alaerts', 'Affiliation': 'Research Group for Neuromotor Rehabilitation, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Casteels', 'Affiliation': 'Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium; Department of Development and Regeneration, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Elske', 'Initials': 'E', 'LastName': 'Salemink', 'Affiliation': 'Department of Developmental Psychology, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Verhaeghe', 'Affiliation': 'Department of Development and Regeneration, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Bosmans', 'Affiliation': 'Parenting and Special Education Research Unit, KU Leuven, Leuven, Belgium; Clinical Psychology Research Unit, KU Leuven, Leuven, Belgium.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2019.101514'] 749,31714582,Efficacy of α-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial.,"CONTEXT Pretreatment with α-adrenergic receptor blockers is recommended to prevent hemodynamic instability during resection of a pheochromocytoma or sympathetic paraganglioma (PPGL). OBJECTIVE To determine which type of α-adrenergic receptor blocker provides the best efficacy. DESIGN Randomized controlled open-label trial (PRESCRIPT; ClinicalTrials.gov NCT01379898). SETTING Multicenter study including 9 centers in The Netherlands. PATIENTS 134 patients with nonmetastatic PPGL. INTERVENTION Phenoxybenzamine or doxazosin starting 2 to 3 weeks before surgery using a blood pressure targeted titration schedule. Intraoperative hemodynamic management was standardized. MAIN OUTCOME MEASURES Primary efficacy endpoint was the cumulative intraoperative time outside the blood pressure target range (ie, SBP >160 mmHg or MAP <60 mmHg) expressed as a percentage of total surgical procedure time. Secondary efficacy endpoint was the value on a hemodynamic instability score. RESULTS Median cumulative time outside blood pressure targets was 11.1% (interquartile range [IQR]: 4.3-20.6] in the phenoxybenzamine group compared to 12.2% (5.3-20.2)] in the doxazosin group (P = .75, r = 0.03). The hemodynamic instability score was 38.0 (28.8-58.0) and 50.0 (35.3-63.8) in the phenoxybenzamine and doxazosin group, respectively (P = .02, r = 0.20). The 30-day cardiovascular complication rate was 8.8% and 6.9% in the phenoxybenzamine and doxazosin group, respectively (P = .68). There was no mortality after 30 days. CONCLUSIONS The duration of blood pressure outside the target range during resection of a PPGL was not different after preoperative treatment with either phenoxybenzamine or doxazosin. Phenoxybenzamine was more effective in preventing intraoperative hemodynamic instability, but it could not be established whether this was associated with a better clinical outcome.",2020,"The 30-day cardiovascular complication rate was 8.8% and 6.9% in the phenoxybenzamine and doxazosin group, respectively (P=0.68).","['134 patients with non-metastatic PPGL', 'Multicenter study including 9 centers in The Netherlands']","['phenoxybenzamine', 'Phenoxybenzamine', 'doxazosin', 'α-blockers', 'phenoxybenzamine or doxazosin', 'α-adrenergic receptor blockers', 'phenoxybenzamine and doxazosin']","['mortality', '30-day cardiovascular complication rate', 'cumulative intraoperative time outside the blood pressure target range (i.e., SBP >160 mmHg or MAP <60 mmHg) expressed as a percentage of total surgical procedure time', 'duration of blood pressure', 'hemodynamic instability score', 'intraoperative hemodynamic instability', 'Median cumulative time outside blood pressure targets']","[{'cui': 'C4517565', 'cui_str': 'One hundred and thirty-four'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1096776', 'cui_str': 'Multicenter Study'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0031441', 'cui_str': 'Phenoxybenzamine'}, {'cui': 'C0114873', 'cui_str': 'Doxazosin'}, {'cui': 'C0034783', 'cui_str': 'Adrenoceptors'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0439475', 'cui_str': 'torr (qualifier value)'}, {'cui': 'C0024779', 'cui_str': 'Map'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0948268', 'cui_str': 'Hemodynamic instability'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",134.0,0.097698,"The 30-day cardiovascular complication rate was 8.8% and 6.9% in the phenoxybenzamine and doxazosin group, respectively (P=0.68).","[{'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Buitenwerf', 'Affiliation': 'Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Thamara E', 'Initials': 'TE', 'LastName': 'Osinga', 'Affiliation': 'Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Henri J L M', 'Initials': 'HJLM', 'LastName': 'Timmers', 'Affiliation': 'Department of Internal Medicine, Section of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'Jacques W M', 'Initials': 'JWM', 'LastName': 'Lenders', 'Affiliation': 'Department of Internal Medicine, Section of Vascular Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Feelders', 'Affiliation': 'Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Elisabeth M W', 'Initials': 'EMW', 'LastName': 'Eekhoff', 'Affiliation': 'Department of Internal Medicine, Endocrinology Section, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Harm R', 'Initials': 'HR', 'LastName': 'Haak', 'Affiliation': 'Department of Internal Medicine, Máxima Medical Center, Eindhoven, The Netherlands.'}, {'ForeName': 'Eleonora P M', 'Initials': 'EPM', 'LastName': 'Corssmit', 'Affiliation': 'Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Peter H L T', 'Initials': 'PHLT', 'LastName': 'Bisschop', 'Affiliation': 'Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Gerlof D', 'Initials': 'GD', 'LastName': 'Valk', 'Affiliation': 'Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Ronald Groote', 'Initials': 'RG', 'LastName': 'Veldman', 'Affiliation': 'Department of Internal Medicine, Medical Spectrum Twente, Enschede, The Netherlands.'}, {'ForeName': 'Robin P F', 'Initials': 'RPF', 'LastName': 'Dullaart', 'Affiliation': 'Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Thera P', 'Initials': 'TP', 'LastName': 'Links', 'Affiliation': 'Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Magiel F', 'Initials': 'MF', 'LastName': 'Voogd', 'Affiliation': 'Department of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Götz J K G', 'Initials': 'GJKG', 'LastName': 'Wietasch', 'Affiliation': 'Department of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Michiel N', 'Initials': 'MN', 'LastName': 'Kerstens', 'Affiliation': 'Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgz188'] 750,31730369,Effects of attentional bias modification therapy on the cue reactivity and cognitive control networks in participants with cocaine use disorders.,"BACKGROUND While attentional bias modification therapy (ABMT) alters drug-related behaviors in some substance users, results have been mixed in individuals with cocaine use disorders (CUD). OBJECTIVES The current study examined whether ABMT affected brain functioning during independent measures of cue reactivity (i.e., cocaine versus food cues) and cognitive control (i.e., incongruent versus congruent trials), and whether brain activity was associated with baseline or post-intervention cocaine use. METHODS 37 participants (62% male) were randomly assigned to ABMT or control therapy. Clinical and neuroimaging assessments occurred at baseline and immediately post-intervention, with additional clinical testing at 2 weeks and 3 months following intervention. Cocaine use was assessed through self-report. RESULTS Slower reaction times and increased functional activation (prefrontal cortex, posterior parietal cortex) were observed for incongruent versus congruent stimuli and increased functional activation for cocaine relative to food videos (ventral striatum, dorsolateral prefrontal cortex and orbitofrontal cortex). The default-mode network (DMN) was not deactivated during exposure to cocaine videos. The degree of activation during cocaine relative to food cues was associated with baseline cocaine use (insula only) and reduction in use following treatment (insula and anterior DMN) above and beyond clinical variables. Cognitive control network activity was not associated with cocaine use at baseline or following treatment. ABMT therapy did not differentially affect cocaine use or functional activation during either task. CONCLUSION Current results suggest a relationship between cue reactivity network activation and cocaine use, but question the efficacy of ABMT in changing brain function during cue reactivity or cognitive control tasks.",2020,"Slower reaction times and increased functional activation (prefrontal cortex, posterior parietal cortex) were observed for incongruent versus congruent stimuli and increased functional activation for cocaine relative to food videos (ventral striatum, dorsolateral prefrontal cortex and orbitofrontal cortex).","['Methods : 37 participants (62% male', 'participants with cocaine use disorders', 'individuals with cocaine use disorders (CUD']","['Cocaine', 'ABMT therapy', ' ', 'ABMT', 'attentional bias modification therapy', 'ABMT or control therapy', 'attentional bias modification therapy (ABMT']","['brain activity', 'cue reactivity and cognitive control networks', 'Cognitive control network activity', 'brain functioning', 'functional activation for cocaine relative to food videos (ventral striatum, dorsolateral prefrontal cortex and orbitofrontal cortex', 'Slower reaction times and increased functional activation (prefrontal cortex, posterior parietal cortex']","[{'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4277667', 'cui_str': 'Attentional Bias'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0443158', 'cui_str': 'Brain activity (observable entity)'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C3875154', 'cui_str': 'Relative to (attribute)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0750950', 'cui_str': 'Ventral Striatum'}, {'cui': 'C4019080', 'cui_str': 'Dorsolateral Prefrontal Cortex'}, {'cui': 'C2331062', 'cui_str': 'Orbital Area'}, {'cui': 'C0439834', 'cui_str': 'Slowly'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C3853037', 'cui_str': 'Posterior Parietal Cortex'}]",37.0,0.0186149,"Slower reaction times and increased functional activation (prefrontal cortex, posterior parietal cortex) were observed for incongruent versus congruent stimuli and increased functional activation for cocaine relative to food videos (ventral striatum, dorsolateral prefrontal cortex and orbitofrontal cortex).","[{'ForeName': 'Andrew R', 'Initials': 'AR', 'LastName': 'Mayer', 'Affiliation': 'Nonprofit Research Organization/Lovelace Biomedical and Environmental Research Institute , Albuquerque, NM, USA.'}, {'ForeName': 'Andrew B', 'Initials': 'AB', 'LastName': 'Dodd', 'Affiliation': 'Nonprofit Research Organization/Lovelace Biomedical and Environmental Research Institute , Albuquerque, NM, USA.'}, {'ForeName': 'Claire E', 'Initials': 'CE', 'LastName': 'Wilcox', 'Affiliation': 'Department of Psychiatry, University of New Mexico, 1 University of New Mexico , Albuquerque, NM, USA.'}, {'ForeName': 'Stefan D', 'Initials': 'SD', 'LastName': 'Klimaj', 'Affiliation': 'Nonprofit Research Organization/Lovelace Biomedical and Environmental Research Institute , Albuquerque, NM, USA.'}, {'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Claus', 'Affiliation': 'Nonprofit Research Organization/Lovelace Biomedical and Environmental Research Institute , Albuquerque, NM, USA.'}, {'ForeName': 'Angela D', 'Initials': 'AD', 'LastName': 'Bryan', 'Affiliation': 'Nonprofit Research Organization/Lovelace Biomedical and Environmental Research Institute , Albuquerque, NM, USA.'}]",The American journal of drug and alcohol abuse,['10.1080/00952990.2019.1671437'] 751,31728673,Lower prednisone dosing for steroid-sensitive nephrotic syndrome relapse: a prospective randomized pilot study.,"Relapses of steroid-sensitive nephrotic syndrome are traditionally treated with prednisone 2 mg/kg/day or 60 mg/m 2 /day. Retrospective data support the use of lower doses. We designed a prospective randomized pilot study to investigate the efficacy of different doses in achieving remission of steroid sensitive nephrotic syndrome relapse. The cohort included 30 children with relapsed steroid sensitive nephrotic syndrome, mean age 6.3 ± 3 years and mean disease duration 2.2 ± 1.8 years. The children were randomized to receive 2, 1.5, or 1 mg/kg/day prednisone. The corresponding times to response, defined as the first of 3 consecutive days without proteinuria, were 7.2 ± 1.4, 10.2 ± 5.1, and 9 ± 3.3 days; the difference between the 1.5 and 2 mg/kg/day groups was statistically significant. One patient each in the 1 mg/kg/day and the 1.5 mg/kg/day groups failed to respond and were switched to 2 mg/kg/day, leading to a response after 3 and 10 days, respectively. Mean cumulative prednisone doses in the 3 groups were 45.5 ± 3.4, 42.7 ± 25.9, and 24.9 ± 7.4 mg/kg, respectively (P < 0.05).Conclusion: In the present study, treatment of childhood steroid sensitive nephrotic syndrome relapse with prednisone 1-1.5 mg/kg/day led to a significantly lower cumulative dose than the standard dose. Treatment with a lower dose may be equally safe and effective to the standard dose.What is Known:• Relapses of steroid-sensitive nephrotic syndrome are traditionally treated with standard-dose steroids.• Treatment with corticosteroids may have significant adverse effects mainly with long-term use.What is New:• Treatment of steroid sensitive nephrotic syndrome relapse with 1-1.5 mg/kg/day prednisone may lead to a significantly lower cumulative dose.• Treatment with a lower steroid dose may be as effective as the standard dose in achieving remission of steroid sensitive nephrotic syndrome relapse.",2020,We designed a prospective randomized pilot study to investigate the efficacy of different doses in achieving remission of steroid sensitive nephrotic syndrome relapse.,"['30 children with relapsed steroid sensitive nephrotic syndrome, mean age 6.3\u2009±\u20093\xa0years and mean disease duration 2.2\u2009±\u20091.8\xa0years', 'sensitive nephrotic syndrome relapse']","['steroid', 'prednisone']",['Mean cumulative prednisone doses'],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0403396', 'cui_str': 'Steroid-sensitive nephrotic syndrome (disorder)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4319697', 'cui_str': '6.3'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C4517629', 'cui_str': '2.2'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C0332324', 'cui_str': 'Sensitive (qualifier value)'}, {'cui': 'C0027726', 'cui_str': 'Nephrotic Syndrome'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}]","[{'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]",30.0,0.020056,We designed a prospective randomized pilot study to investigate the efficacy of different doses in achieving remission of steroid sensitive nephrotic syndrome relapse.,"[{'ForeName': 'Yael', 'Initials': 'Y', 'LastName': 'Borovitz', 'Affiliation': ""Institute of Nephrology, Schneider Children's Medical Center of Israel, 4920235, Petach Tikva, Israel.""}, {'ForeName': 'Hadas', 'Initials': 'H', 'LastName': 'Alfandary', 'Affiliation': ""Institute of Nephrology, Schneider Children's Medical Center of Israel, 4920235, Petach Tikva, Israel.""}, {'ForeName': 'Orly', 'Initials': 'O', 'LastName': 'Haskin', 'Affiliation': ""Institute of Nephrology, Schneider Children's Medical Center of Israel, 4920235, Petach Tikva, Israel.""}, {'ForeName': 'Shely', 'Initials': 'S', 'LastName': 'Levi', 'Affiliation': ""Institute of Nephrology, Schneider Children's Medical Center of Israel, 4920235, Petach Tikva, Israel.""}, {'ForeName': 'Shulamit', 'Initials': 'S', 'LastName': 'Kaz', 'Affiliation': ""Institute of Nephrology, Schneider Children's Medical Center of Israel, 4920235, Petach Tikva, Israel.""}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Davidovits', 'Affiliation': ""Institute of Nephrology, Schneider Children's Medical Center of Israel, 4920235, Petach Tikva, Israel.""}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Dagan', 'Affiliation': ""Institute of Nephrology, Schneider Children's Medical Center of Israel, 4920235, Petach Tikva, Israel. dagana@clalit.org.il.""}]",European journal of pediatrics,['10.1007/s00431-019-03506-5'] 752,31728675,Repeating a dose of sucrose for heel prick procedure in preterms is not effective in reducing pain: a randomised controlled trial.,"Oral sucrose is included in almost all recommendations for treatment of pain in newborns, but evidence if multiple doses might be more effective than a single standard dose is lacking. We designed a single-centre, double-blind, randomised, controlled trial. We enrolled preterm infants needing the heel prick procedure. Each enrolled infant was randomised to receive a single standard dose of sucrose 2 min before or a double dose of sucrose 2 min before, and 30 s after heel prick. Primary outcome was the efficacy of the two interventions tested by the premature infant pain profile-PIPP scale obtained at 30 s, 60 s, and 120 s after heel prick. Secondary outcome was the evaluation of the concordance between the PIPP scale and other pain scores more feasible in clinical practice. Seventy-two infants were randomised. No difference in pain perception as measured by the PIPP scale was found between the groups: median PIPP values 4.0(IQR 3.0-4.0) vs 3.0(IQR 3.0-4.0) at baseline; 6.0(IQR 5.0-10.0) vs 6.0(IQR 4.0-8.5) at 30 s; 6.0(IQR 4.0-7.0) vs 5.0(IQR 4.0-8.5) at 60 s and 5.0(IQR 4.0-7.0) vs 5.0(IQR 4.0-7.5) at 2 min, in the experimental and standard treatment groups, respectively (p = 0.9020). There was no correlation between PIPP scores and other pain scales.Conclusion: We do not recommend doubling the dose during heel prick.What is Known:• Oral sucrose is included in almost all international position papers and recommendations for the treatment of mild to moderate pain in newborns, associated with non-nutritive sucking and facilitated tucking• Premature infant pain profile (PIPP) scale is the gold standard for evaluation of pain in preterms but it is difficult to use in clinical practiceWhat is New:• Repeating a dose of 24% sucrose is not effective in reducing pain during the recovery phase of a skin breaking procedure• Other pain scales, easier to use in clinical practice, are not comparable with PIPP for the evaluation of procedural pain in preterms.",2020,No difference in pain perception as measured by the PIPP scale was found between the groups: median PIPP values 4.0(IQR 3.0-4.0) vs 3.0(IQR 3.0-4.0) at baseline;,"['enrolled preterm infants needing the heel prick procedure', 'Seventy-two infants were randomised']","['Oral sucrose', 'sucrose']","['PIPP scores and other pain scales', 'evaluation of the concordance between the PIPP scale and other pain scores more feasible in clinical practice', 'pain', 'pain perception', 'PIPP scale', 'premature infant pain profile-PIPP scale']","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0018870', 'cui_str': 'Heel'}, {'cui': 'C0033119', 'cui_str': 'Puncture wound - injury (disorder)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C4319632', 'cui_str': 'Seventy-two'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0038636', 'cui_str': 'Sucrose'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0222045'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3714605', 'cui_str': 'Pain Perception'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}]",72.0,0.483889,No difference in pain perception as measured by the PIPP scale was found between the groups: median PIPP values 4.0(IQR 3.0-4.0) vs 3.0(IQR 3.0-4.0) at baseline;,"[{'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Lago', 'Affiliation': 'Neonatal Intensive Care Unit, Department of Woman and Child Health, University of Padua, Via Giustiniani 3, 35128, Padua, Italy.'}, {'ForeName': 'Maria Elena', 'Initials': 'ME', 'LastName': 'Cavicchiolo', 'Affiliation': 'Neonatal Intensive Care Unit, Department of Woman and Child Health, University of Padua, Via Giustiniani 3, 35128, Padua, Italy. mecavicchiolo@gmail.com.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Mion', 'Affiliation': 'Neonatal Intensive Care Unit, Department of Woman and Child Health, University of Padua, Via Giustiniani 3, 35128, Padua, Italy.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Dal Cengio', 'Affiliation': 'Neonatal Intensive Care Unit, San Bortolo Hospital, Vicenza, Italy.'}, {'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Allegro', 'Affiliation': 'Neonatal Intensive Care Unit, Department of Woman and Child Health, University of Padua, Via Giustiniani 3, 35128, Padua, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Daverio', 'Affiliation': 'Paediatric Intensive Care Unit, Department of Woman and Child Health, University of Padua, Padua, Italy.'}, {'ForeName': 'Anna Chiara', 'Initials': 'AC', 'LastName': 'Frigo', 'Affiliation': 'Department of Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padua, Padua, Italy.'}]",European journal of pediatrics,['10.1007/s00431-019-03509-2'] 753,30982467,Cognitive training for children and adolescents with fragile X syndrome: a randomized controlled trial of Cogmed.,"BACKGROUND Individuals with fragile X syndrome (FXS) typically demonstrate profound executive function (EF) deficits that interfere with learning, socialization, and emotion regulation. We completed the first large, non-pharmacological controlled trial for FXS, designed to evaluate the efficacy of Cogmed, a computer/tablet-based working memory (WM) training program. METHODS The study was a randomized, blinded, parallel two-arm controlled trial in 100 children and adolescents with FXS (63 male, 37 female; 15.28 ± 3.36 yrs.). Participants were randomized equally to adaptive (difficulty level adjusted to performance) or non-adaptive (control) Cogmed training. Participants were assessed at home using objective measures of WM (primary outcome) and EF at baseline, following 20-25 caregiver-supported sessions over 5-6 weeks, and at follow-up 3 months after cessation of training. Parents and teachers provided ratings of WM, attention, and EF. RESULTS The WM composite and selective domains of EF (distractibility, cognitive flexibility), as well as parent- and teacher-reported attention and EF, significantly improved across the full study sample, with many changes maintained at follow-up. However, comparisons of improvement between adaptive and non-adaptive control conditions did not differ, showing that progressively challenging the WM system by expanding span length did not provide added benefit overall. CONCLUSIONS Further experimental comparisons are needed before Cogmed working memory training can be considered empirically validated for children with FXS, forming the basis of treatment recommendation. However, given that prior studies show no significant changes on these measures in FXS without treatment, that improvements were maintained for 3 months, and that blinded teachers reported improvements in the classroom, the modest benefits seen in both adaptive and non-adaptive groups overall are unlikely to be attributable to placebo or practice effects alone. Future analyses examining inter-individual differences (e.g., baseline capacity, training efficiency, co-morbidity, training environment, characteristics of training aide) may help to link this intervention to outcomes and potential transfer effects. TRIAL REGISTRATION US National Institutes of Health (ClinicalTrials.gov), NCT02747394 .",2019,"However, comparisons of improvement between adaptive and non-adaptive control conditions did not differ, showing that progressively challenging the WM system by expanding span length did not provide added benefit overall. ","['Individuals with fragile X syndrome (FXS', '100 children and adolescents with FXS (63 male, 37 female; 15.28\u2009±\u20093.36\u2009yrs', 'children and adolescents with fragile X syndrome', 'children with FXS']","['adaptive (difficulty level adjusted to performance) or non-adaptive (control)\xa0Cogmed training', 'placebo', 'Cognitive training']","['ratings of WM, attention, and EF', 'WM composite and selective domains of EF (distractibility, cognitive flexibility']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0016667', 'cui_str': 'X-Linked Mental Retardation and Macroorchidism'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0233415', 'cui_str': 'Distractibility (finding)'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}]",100.0,0.191163,"However, comparisons of improvement between adaptive and non-adaptive control conditions did not differ, showing that progressively challenging the WM system by expanding span length did not provide added benefit overall. ","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Hessl', 'Affiliation': 'MIND Institute, University of California Davis Medical Center, 2825 50th St, Sacramento, CA, 95817, USA. drhessl@ucdavis.edu.'}, {'ForeName': 'Julie B', 'Initials': 'JB', 'LastName': 'Schweitzer', 'Affiliation': 'MIND Institute, University of California Davis Medical Center, 2825 50th St, Sacramento, CA, 95817, USA.'}, {'ForeName': 'Danh V', 'Initials': 'DV', 'LastName': 'Nguyen', 'Affiliation': 'Department of Medicine, University of California Irvine, 333 City Blvd. West, Orange, CA, 92868, USA.'}, {'ForeName': 'Yingratana A', 'Initials': 'YA', 'LastName': 'McLennan', 'Affiliation': 'MIND Institute, University of California Davis Medical Center, 2825 50th St, Sacramento, CA, 95817, USA.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Johnston', 'Affiliation': 'MIND Institute, University of California Davis Medical Center, 2825 50th St, Sacramento, CA, 95817, USA.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Shickman', 'Affiliation': 'MIND Institute, University of California Davis Medical Center, 2825 50th St, Sacramento, CA, 95817, USA.'}, {'ForeName': 'Yanjun', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Institute for Clinical and Translational Science, Irvine, CA, 92697, USA.'}]",Journal of neurodevelopmental disorders,['10.1186/s11689-019-9264-2'] 754,30898329,Cost effectiveness of text messages to reduce methamphetamine use and HIV sexual risk behaviors among men who have sex with men.,"Methamphetamine use is highly prevalent among gay, bisexual, and other men who have sex with men (MSM) in the United States and has been associated with condomless anal intercourse (CAI), a common route of HIV infection. Text messaging is a very low-cost method of delivery for intervention content. This paper presents a cost-effectiveness analysis of a randomized controlled trial testing three nested methods of text message delivery designed to reduce methamphetamine use and HIV sexual risk behaviors among MSM (Project Tech Support2). From March 2014 to January 2016, 286 non-treatment seeking methamphetamine-using MSM were randomized into one of three study arms: 1) Interactive text message conversations with Peer Health Educators, plus five daily automated, unidirectional theory-based messages, plus a weekly self-monitoring text message assessment (TXT-PHE; n = 94); or, 2) Five daily automated, unidirectional theory-based messages plus a weekly self-monitoring text message assessment (TXT-Auto; n = 99); or, 3) The weekly self-monitoring text message assessment only (AO; n = 93). Methamphetamine use at nine months post-enrollment was lower than at baseline in all three arms. The addition of Peer Health Educators and/or theory-based text messages did not produce cost-effective reductions in methamphetamine use over the weekly AO text messages. However, both intervention arms outperformed the AO arm in reducing HIV risk behaviors, but the TXT-Auto arm dominated the TXT-PHE arm in achieving greater reductions in days of methamphetamine use and CAI at lower cost. The TXT-Auto arm achieved greater reductions in CAI than the attentional control at a cost in the base case of ~$37.50 per episode of CAI reduced per month. Sensitivity analyses showed that results were robust to a number of changes in assumptions. Interventions seeking to reduce methamphetamine use among non-treatment-seeking MSM may seek to add minimal attentional control-style text messages to their routines querying about recent methamphetamine use and/or high-risk sex. Interventions seeking to additionally reduce HIV sexual risk behaviors among non-treatment-seeking MSM, specifically engagement in CAI, may seek to additionally apply theory-based text messages.",2019,The addition of Peer Health Educators and/or theory-based text messages did not produce cost-effective reductions in methamphetamine use over the weekly AO text messages.,"['From March 2014 to January 2016, 286 non-treatment seeking methamphetamine-using MSM', 'men who have sex with men (MSM', 'men who have sex with men']","['Methamphetamine', 'Interactive text message conversations with Peer Health Educators, plus five daily automated, unidirectional theory-based messages, plus a weekly self-monitoring text message assessment (TXT-PHE; n\u202f=\u202f94); or, 2) Five daily automated, unidirectional theory-based messages plus a weekly self-monitoring text message assessment (TXT-Auto; n\u202f=\u202f99); or, 3) The weekly self-monitoring text message assessment']","['HIV sexual risk behaviors', 'methamphetamine use and HIV sexual risk behaviors', 'HIV risk behaviors']","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0025611', 'cui_str': 'metamfetamine'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}]","[{'cui': 'C0025611', 'cui_str': 'metamfetamine'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C1136362', 'cui_str': 'Health Educators'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0588436', 'cui_str': 'Self-monitoring (regime/therapy)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0047143', 'cui_str': 'tmdPHE'}]","[{'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0086931', 'cui_str': 'Risk Behavior'}, {'cui': 'C0025611', 'cui_str': 'metamfetamine'}, {'cui': 'C1947944', 'cui_str': 'Use'}]",,0.058227,The addition of Peer Health Educators and/or theory-based text messages did not produce cost-effective reductions in methamphetamine use over the weekly AO text messages.,"[{'ForeName': 'Cathy J', 'Initials': 'CJ', 'LastName': 'Reback', 'Affiliation': 'Friends Research Institute, Inc., 1419 N. La Brea Ave, Los Angeles, CA 90028, USA; David Geffen School of Medicine, Semel Institute of Neuroscience and Human Behavior, University of California, Los Angeles, USA; Center for HIV Identification, Prevention and Treatment Services, University of California, Los Angeles, 10880 Wilshire Blvd, Suite 1800, Los Angeles, CA 90024, USA. Electronic address: reback@friendsresearch.org.'}, {'ForeName': 'Jesse B', 'Initials': 'JB', 'LastName': 'Fletcher', 'Affiliation': 'Friends Research Institute, Inc., 1419 N. La Brea Ave, Los Angeles, CA 90028, USA.'}, {'ForeName': 'Arleen A', 'Initials': 'AA', 'LastName': 'Leibowitz', 'Affiliation': 'Center for HIV Identification, Prevention and Treatment Services, University of California, Los Angeles, 10880 Wilshire Blvd, Suite 1800, Los Angeles, CA 90024, USA; UCLA Luskin School of Public Affairs, University of California, Los Angeles, Los Angeles, CA, USA.'}]",Journal of substance abuse treatment,['10.1016/j.jsat.2019.02.006'] 755,30981585,Disparate effects of first and second generation antipsychotics on cognition in schizophrenia - Findings from the randomized NeSSy trial.,"Cognitive impairment represents a core feature of schizophrenia. Uncertainty about demonstrable benefits of available antipsychotics on cognition remains an important clinical question relevant to patients' quality of life. The aim of our multi-center, randomized, double-blind ""Neuroleptic Strategy Study"" (NeSSy) was to compare the effectiveness of selected antipsychotics, conventionally classified as second- (SGAs) (haloperidol, flupentixol) and first generation antipsychotics (FGAs) (aripiprazole, olanzapine, quetiapine), on quality of life in schizophrenia. The effects on cognitive deficits represented a secondary outcome. We used an innovative double randomization for assignment of treatment group, and followed the patients with a neurocognitive test-battery upon six and 24 weeks of treatment. Psychopathology and quality of life were assessed using CGI, PANSS and SF-36. Assessment of cognitive performance was conducted in 114 of the 136 randomized patients. The SGA group (N = 62) showed beneficial effects of small to moderate effect size on cognition during the initial six weeks of treatment (executive functions, verbal fluency) and at 24 weeks (executive functions, working memory). In contrast, the FGA group (N = 52) showed moderately improved executive function, but a decline in verbal fluency at six weeks, with significant declines of moderate to large effect size in executive function, verbal learning and memory, and verbal fluency at 24 weeks. Our study indicates that SGAs present an advantage over FGAs regarding cognitive function during a medium-term treatment for schizophrenia. The results further emphasize a distinction between progression to detrimental effects of FGAs with prolonged treatment in contrast to more persistent cognitive benefits with SGA treatment.",2019,"Psychopathology and quality of life were assessed using CGI, PANSS and SF-36",['114 of the 136 randomized patients'],"['first and second generation antipsychotics', 'selected antipsychotics, conventionally classified as second- (SGAs', 'SGA', 'FGA', 'haloperidol, flupentixol) and first generation antipsychotics (FGAs) (aripiprazole, olanzapine, quetiapine']","['quality of life in schizophrenia', 'verbal fluency', 'Psychopathology and quality of life', 'cognitive deficits', 'executive function', 'executive function, verbal learning and memory, and verbal fluency', 'cognitive performance']","[{'cui': 'C4708785', 'cui_str': 'One hundred and fourteen'}, {'cui': 'C4517568', 'cui_str': 'One hundred and thirty-six'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0040615', 'cui_str': 'Antipsychotic Drugs'}, {'cui': 'C0008902', 'cui_str': 'Systematics'}, {'cui': 'C0018546', 'cui_str': 'Haloperidol'}, {'cui': 'C0016367', 'cui_str': 'flupentixol'}, {'cui': 'C0299792', 'cui_str': 'aripiprazole'}, {'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C0123091', 'cui_str': 'quetiapine'}]","[{'cui': 'C0034380'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0338656', 'cui_str': 'Cognitive Dysfunction'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0042531', 'cui_str': 'Verbal Learning'}, {'cui': 'C0025260', 'cui_str': 'Memory'}]",136.0,0.0767002,"Psychopathology and quality of life were assessed using CGI, PANSS and SF-36","[{'ForeName': 'Tanja', 'Initials': 'T', 'LastName': 'Veselinović', 'Affiliation': 'Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany. Electronic address: tveselinovic@ukaachen.de.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Scharpenberg', 'Affiliation': 'Competence Center for Clinical Trials - Biometry, University of Bremen, Bremen, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Heinze', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Brandenburg Medical School, Immanuel Klinik, Rüdersdorf, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Cordes', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Mühlbauer', 'Affiliation': 'Competence Center for Clinical Trials - Biometry, University of Bremen, Bremen, Germany; Department of Pharmacology, Klinikum Bremen Mitte, Bremen, Germany.'}, {'ForeName': 'Georg', 'Initials': 'G', 'LastName': 'Juckel', 'Affiliation': 'Department of Psychiatry, LWL University Hospital, Ruhr University Bochum, Bochum, Germany.'}, {'ForeName': 'Ute', 'Initials': 'U', 'LastName': 'Habel', 'Affiliation': 'Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany.'}, {'ForeName': 'Eckart', 'Initials': 'E', 'LastName': 'Rüther', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Timm', 'Affiliation': 'Competence Center for Clinical Trials - Biometry, University of Bremen, Bremen, Germany.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Gründer', 'Affiliation': 'Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2019.03.014'] 756,30369351,[Preliminary application of Early Start Denver Model in children with autism spectrum disorder].,"OBJECTIVE To investigate the clinical effect of the Early Start Denver Model (ESDM) in children with autism spectrum disorder (ASD). METHODS Forty children aged 2-5 years who were diagnosed with ASD from September 2017 to January 2018 were enrolled in the study and were randomly divided into conventional intervention group and ESDM intervention group (n=20 each). Both groups were assessed by the Aberrant Behavior Checklist (ABC), Childhood Autism Rating Scale (CARS), and Clinical Global Impression-Severity (CGI-S) scale before intervention and by the ABC, CARS, CGI-S scale, and Clinical Global Impression-Improvement (CGI-I) scale after 3 months of intervention. RESULTS After 3 months of intervention, the total scores of ABC and CARS were both significantly decreased in the two groups (P<0.01); the scores on the social withdrawal and hyperactivity subscales of ABC were significantly decreased in the conventional intervention group (P<0.01), and the scores on the mood swings, social withdrawal, hyperactivity, and stereotyped behavior subscales of ABC were significantly decreased in the ESDM intervention group (P<0.01). Compared with the conventional intervention group, the ESDM intervention group had significantly greater changes in total score of ABC, scores on three subscales of ABC (mood swings, social withdrawal, and hyperactivity), and total score of CARS after intervention (P<0.05). After 3 months of intervention, the CGI-I scoring system showed that the disease improvement was significantly better in the ESDM intervention group than in the conventional intervention group (P<0.05). CONCLUSIONS Both conventional intervention and ESDM intervention can improve the social withdrawal and hyperactivity in children with ASD aged 2 to 5 years, but ESDM is more effective in improving the aberrant behavior of children with ASD.",2018,"Both conventional intervention and ESDM intervention can improve the social withdrawal and hyperactivity in children with ASD aged 2 to 5 years, but ESDM is more effective in improving the aberrant behavior of children with ASD.","['children with autism spectrum disorder (ASD', 'children with autism spectrum disorder', 'Forty children aged 2-5 years who were diagnosed with ASD from September 2017 to January 2018 were enrolled in the study', 'children with ASD aged 2 to 5 years']","['conventional intervention group and ESDM intervention', 'ESDM intervention', 'conventional intervention and ESDM intervention', 'Early Start Denver Model (ESDM']","['total scores of ABC and CARS', 'CGI-I scoring system', 'disease improvement', 'Aberrant Behavior Checklist (ABC), Childhood Autism Rating Scale (CARS), and Clinical Global Impression-Severity (CGI-S) scale before intervention and by the ABC, CARS, CGI-S scale, and Clinical Global Impression-Improvement (CGI-I) scale', 'social withdrawal and hyperactivity', 'total score of ABC, scores on three subscales of ABC (mood swings, social withdrawal, and hyperactivity), and total score of CARS', 'mood swings, social withdrawal, hyperactivity, and stereotyped behavior subscales of ABC', 'social withdrawal and hyperactivity subscales of ABC']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0443127', 'cui_str': 'Aberrant (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0222045'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0004381', 'cui_str': 'Automobiles'}, {'cui': 'C0424095', 'cui_str': 'Social withdrawal (finding)'}, {'cui': 'C0424295', 'cui_str': 'Increased purposeful goal-directed activity'}, {'cui': 'C0085633', 'cui_str': 'Mood swings (finding)'}, {'cui': 'C0038271', 'cui_str': 'Stereotyped Behavior'}]",40.0,0.0142349,"Both conventional intervention and ESDM intervention can improve the social withdrawal and hyperactivity in children with ASD aged 2 to 5 years, but ESDM is more effective in improving the aberrant behavior of children with ASD.","[{'ForeName': 'Hong-Hua', 'Initials': 'HH', 'LastName': 'Li', 'Affiliation': 'Department of Developmental-Behavioral Pediatrics, First Hospital of Jilin University, Changchun 130021, China. erkekangfujia@163.com.'}, {'ForeName': 'Chun-Li', 'Initials': 'CL', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Di', 'Initials': 'D', 'LastName': 'Gao', 'Affiliation': ''}, {'ForeName': 'Xiu-Yu', 'Initials': 'XY', 'LastName': 'Pan', 'Affiliation': ''}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'DU', 'Affiliation': ''}, {'ForeName': 'Fei-Yong', 'Initials': 'FY', 'LastName': 'Jia', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 757,30797634,Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge.,"BACKGROUND There is no licensed vaccine against enterotoxigenic Escherichia coli (ETEC), a major cause of diarrhea-associated morbidity and mortality among infants and children in low-income countries and travelers. The results of this vaccination/challenge study demonstrate strong protection by an attenuated ETEC vaccine candidate, ACE527, when co-administered with a mucosal adjuvant, the double-mutant heat-labile toxin (dmLT) of ETEC. METHODS Sixty healthy adults participated in a randomized, placebo-controlled, double-blind study with three doses of lyophilized ACE527 (∼3 × 10 9 of each strain per dose) administered orally with or without dmLT adjuvant (25 µg/dose). Six months later, 36 of these volunteers and a control group of 21 unvaccinated volunteers were challenged with virulent ETEC strain H10407. The primary outcome was severe diarrhea, defined as passing >800 g of unformed stools during the inpatient period following challenge. FINDINGS The vaccine was well tolerated and induced robust immune responses to key antigens. The protective efficacy (PE) against the primary outcome of severe diarrhea was 65.9% (95% confidence interval [CI] 5.4-87.7, p = 0.003). Among subjects receiving the adjuvanted vaccine, the attack rate of severe diarrhea was 23.1, while in unimmunized controls it was 67.7%. The PE against diarrhea of any severity was 58.5% (95% CI 3.8- 82.1, p = 0.016). There was a strong inverse correlation between shedding of the vaccine strain after either of the first two doses and absence of severe diarrhea upon challenge (RR = 0.29, 95% CI 0.08-1.05, p = 0.041). Challenge strain shedding was 10-fold lower in those receiving the adjuvant than in those receiving vaccine alone. The unadjuvanted vaccine was not protective (PE = 23.1%). INTERPRETATION The results of this study support further development of ACE527 + dmLT as a vaccine for children in endemic countries and travelers. This is the first clinical demonstration that dmLT can contribute significantly to vaccine efficacy and may warrant testing with other oral vaccines. (ClinicalTrials.gov registration: NCT01739231).",2019,"The PE against diarrhea of any severity was 58.5% (95% CI 3.8- 82.1, p = 0.016).",['Sixty healthy adults'],"['Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine', 'ACE527\u202f+\u202fdmLT', 'placebo', 'lyophilized ACE527 (∼3\u202f×\u202f10 9 of each strain per dose) administered orally with or without dmLT adjuvant']","['PE against diarrhea of any severity', 'Challenge strain shedding', 'attack rate of severe diarrhea', 'severe diarrhea', 'protective efficacy (PE', 'severe diarrhea, defined as passing >800\u202fg of unformed stools']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0580797', 'cui_str': 'E coli, Enterotoxigenic'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1621583', 'cui_str': 'Administer'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C1304680', 'cui_str': 'Attack (finding)'}, {'cui': 'C1443924', 'cui_str': 'Severe diarrhea'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C3844106', 'cui_str': 'Eight hundred'}, {'cui': 'C0015733', 'cui_str': 'Feces'}]",60.0,0.398969,"The PE against diarrhea of any severity was 58.5% (95% CI 3.8- 82.1, p = 0.016).","[{'ForeName': 'Clayton', 'Initials': 'C', 'LastName': 'Harro', 'Affiliation': 'Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Louis Bourgeois', 'Affiliation': 'PATH, Washington, DC, USA. Electronic address: lbourgeois@path.org.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Sack', 'Affiliation': 'Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Walker', 'Affiliation': 'PATH, Washington, DC, USA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'DeNearing', 'Affiliation': 'Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Brubaker', 'Affiliation': 'Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Maier', 'Affiliation': 'PATH, Washington, DC, USA.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Fix', 'Affiliation': 'PATH, Washington, DC, USA.'}, {'ForeName': 'Len', 'Initials': 'L', 'LastName': 'Dally', 'Affiliation': 'The Emmes Corporation, Rockville, MD, USA.'}, {'ForeName': 'Subhra', 'Initials': 'S', 'LastName': 'Chakraborty', 'Affiliation': 'Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Clements', 'Affiliation': 'Tulane University, School of Medicine, New Orleans, LA, USA.'}, {'ForeName': 'Ingelise', 'Initials': 'I', 'LastName': 'Saunders', 'Affiliation': 'TDVaccines, Odense, Denmark.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Darsley', 'Affiliation': 'MD Biologic Ltd., Cambridge, United Kingdom.'}]",Vaccine,['10.1016/j.vaccine.2019.02.025'] 758,31732552,Longterm Effect on Leisure Time Physical Activity Level in Individuals with Axial Spondyloarthritis: Secondary Analysis of a Randomized Controlled Trial.,"OBJECTIVE To explore the longterm effect of a 3-month exercise program on leisure time physical activity level in individuals with axial spondyloarthritis (axSpA). METHODS A secondary analysis was performed on data from 100 individuals with axSpA who were included in a randomized controlled trial. The exercise group (EG) participated in a 3-month exercise program while the control group (CG) received no intervention. Physical activity during leisure time was measured with a questionnaire (physically active: ≥ 1 h/week with moderate/vigorous intensity physical activity). Disease activity was measured with the Ankylosing Spondylitis Disease Activity Scale (ASDAS; higher score = worst). Statistical analyses were performed on an intention-to-treat basis using chi-square tests, logistic regression, and mixed models. RESULTS At the 12-month followup, significantly more individuals in the EG than in the CG were physically active [29 (67%) vs 13 (30%), p < 0.001] and exercised 2-3 times/week [25 (58%) vs 15 (34%), p = 0.02], and fewer exercised at light intensity [3 (8%) vs 14 (44%), p = 0.002]. ""Participation in the EG"" (OR 6.7, 95% CI 2.4-18.6, p < 0.001) and ""being physically active at baseline"" (OR 4.7, 95% CI 1.4-15.8, p = 0.01) were the factors most associated with being physically active. There were no differences between the groups in ASDAS (p = 0.79). CONCLUSION A 3-month exercise program had a beneficial longterm effect on leisure time physical activity in individuals with axSpA, thus indicating a more beneficial health profile. Still, few individuals continued the intensive program, and there was no difference between the groups in disease activity after 12 months. (ClinicalTrials.gov: NCT02356874).",2020,"A 3-month exercise programme had a beneficial long-term effect on leisure time physical activity in individuals with axSpA, thus indicating a more beneficial health profile.","['100 individuals with axSpA', 'individuals with axSpA', 'individuals with axial spondyloarthritis (axSpA', 'individuals with axial spondyloarthritis']","['exercise programme while the control group (CG) received no intervention', 'exercise programme']","['leisure time physical activity', 'Physical activity during leisure time', 'leisure time physical activity level', 'Ankylosing Spondylitis Disease Activity Scale (ASDAS', 'disease activity', 'Disease activity']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C3203547', 'cui_str': 'Axial spondyloarthritis (disorder)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0086542', 'cui_str': 'Leisure'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0038013', 'cui_str': 'Spondylarthritis Ankylopoietica'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0222045'}]",100.0,0.143508,"A 3-month exercise programme had a beneficial long-term effect on leisure time physical activity in individuals with axSpA, thus indicating a more beneficial health profile.","[{'ForeName': 'Silje Halvorsen', 'Initials': 'SH', 'LastName': 'Sveaas', 'Affiliation': 'From the National Advisory Unit on Rehabilitation in Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital, Oslo; Department of Physiotherapy, Martina Hansens Hospital, Bærum; Department of Physiotherapy, University Hospital of North Norway, Tromsø; Department of Coaching and Psychology, Norwegian School of Sport Sciences, Oslo; The Norwegian Rheumatology Association, Norway; Institute of Neuroscience and Physiology, Section of Health and Rehabilitation, Physiotherapy, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. s.h.sveaas@medisin.uio.no.'}, {'ForeName': 'Hanne', 'Initials': 'H', 'LastName': 'Dagfinrud', 'Affiliation': 'From the National Advisory Unit on Rehabilitation in Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital, Oslo; Department of Physiotherapy, Martina Hansens Hospital, Bærum; Department of Physiotherapy, University Hospital of North Norway, Tromsø; Department of Coaching and Psychology, Norwegian School of Sport Sciences, Oslo; The Norwegian Rheumatology Association, Norway; Institute of Neuroscience and Physiology, Section of Health and Rehabilitation, Physiotherapy, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Melissa Woll', 'Initials': 'MW', 'LastName': 'Johansen', 'Affiliation': 'From the National Advisory Unit on Rehabilitation in Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital, Oslo; Department of Physiotherapy, Martina Hansens Hospital, Bærum; Department of Physiotherapy, University Hospital of North Norway, Tromsø; Department of Coaching and Psychology, Norwegian School of Sport Sciences, Oslo; The Norwegian Rheumatology Association, Norway; Institute of Neuroscience and Physiology, Section of Health and Rehabilitation, Physiotherapy, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Pedersen', 'Affiliation': 'From the National Advisory Unit on Rehabilitation in Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital, Oslo; Department of Physiotherapy, Martina Hansens Hospital, Bærum; Department of Physiotherapy, University Hospital of North Norway, Tromsø; Department of Coaching and Psychology, Norwegian School of Sport Sciences, Oslo; The Norwegian Rheumatology Association, Norway; Institute of Neuroscience and Physiology, Section of Health and Rehabilitation, Physiotherapy, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Ole-Martin', 'Initials': 'OM', 'LastName': 'Wold', 'Affiliation': 'From the National Advisory Unit on Rehabilitation in Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital, Oslo; Department of Physiotherapy, Martina Hansens Hospital, Bærum; Department of Physiotherapy, University Hospital of North Norway, Tromsø; Department of Coaching and Psychology, Norwegian School of Sport Sciences, Oslo; The Norwegian Rheumatology Association, Norway; Institute of Neuroscience and Physiology, Section of Health and Rehabilitation, Physiotherapy, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Annelie', 'Initials': 'A', 'LastName': 'Bilberg', 'Affiliation': 'From the National Advisory Unit on Rehabilitation in Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital, Oslo; Department of Physiotherapy, Martina Hansens Hospital, Bærum; Department of Physiotherapy, University Hospital of North Norway, Tromsø; Department of Coaching and Psychology, Norwegian School of Sport Sciences, Oslo; The Norwegian Rheumatology Association, Norway; Institute of Neuroscience and Physiology, Section of Health and Rehabilitation, Physiotherapy, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}]",The Journal of rheumatology,['10.3899/jrheum.190317'] 759,31732558,Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study.,"OBJECTIVE To evaluate the development of radiological changes of the cervical spine in patients with rheumatoid arthritis (RA) in the NEO-RACo trial treated with an intensive, remission-targeted combination of conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and additional infliximab (IFX) or placebo (PLA) for the first 6 months. METHODS Ninety-nine patients with early, DMARD-naive RA were treated with a triple combination of csDMARD and prednisolone, and randomized to double-blindly receive either IFX (FIN-RACo+IFX) or PLA (FIN-RACo+PLA) infusions during the first 6 months. After 2 years the treatment strategies became unrestricted, but the treatment goal was strict NEO-RACo remission. At the 10-year visit, radiographs of the cervical spine were taken of 85 patients (38 in the FIN-RACo+IFX group and 47 in the FIN-RACo+PLA group). The study was registered at ClinicalTrials.gov (NCT00908089). RESULTS There were 4/85 patients (4.7%) with cervical spine involvement (CSI) by 10 years. Atlantoaxial subluxation was found in 2/85 patients (2.4%), both in the FIN-RACo+IFX group, and none in the FIN-RACo+PLA group. Atlantoaxial impaction was found in 1/85 patients (1.2%) in the FIN-RACo+IFX group. Subaxial subluxation was found in 1/85 patients (1.2%). CONCLUSION Early and intensive remission-targeted treatment has reduced the incidence of CSI and our results show that intensive treatment also prevents its development in the long run.",2020,Atlantoaxial impaction was found in 1/85 patients (1.2%) in the FIN-RACo+PLA group.,"['Ninety-nine patients with early, DMARD-naïve RA', 'patients with rheumatoid arthritis (RA) treated with intensive, remission-targeted combination of conventional synthetic (cs) disease modifying antirheumatic drugs (DMARDs) and additional', 'Patients with Rheumatoid Arthritis']","['FINRACo+ INFL', 'infliximab or placebo', 'triple combination of csDMARDs and prednisolone', 'infliximab (FIN-RACo+INFL) or placebo (FIN-RACo+PLA']","['Atlantoaxial subluxation', 'Subaxial subluxation', 'Atlantoaxial impaction']","[{'cui': 'C3828813', 'cui_str': 'Ninety-nine'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0242708', 'cui_str': 'Antirheumatic Drugs, Disease-Modifying'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid Arthritis'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]","[{'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}]","[{'cui': 'C0263905', 'cui_str': 'Subluxation of atlantoaxial joint (disorder)'}, {'cui': 'C0332768', 'cui_str': 'Joint Subluxations'}, {'cui': 'C0450192', 'cui_str': 'Atlantoaxial (qualifier value)'}, {'cui': 'C0333124', 'cui_str': 'Impaction (morphologic abnormality)'}]",99.0,0.0563874,Atlantoaxial impaction was found in 1/85 patients (1.2%) in the FIN-RACo+PLA group.,"[{'ForeName': 'Tia', 'Initials': 'T', 'LastName': 'Sandström', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. tia.sandstrom@hus.fi.'}, {'ForeName': 'Vappu', 'Initials': 'V', 'LastName': 'Rantalaiho', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'Timo', 'Initials': 'T', 'LastName': 'Yli-Kerttula', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'Hannu', 'Initials': 'H', 'LastName': 'Kautiainen', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'Timo', 'Initials': 'T', 'LastName': 'Malmi', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Karjalainen', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'Tea', 'Initials': 'T', 'LastName': 'Uusitalo', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'Heikki', 'Initials': 'H', 'LastName': 'Julkunen', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'Oili', 'Initials': 'O', 'LastName': 'Kaipiainen-Seppänen', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'Leena', 'Initials': 'L', 'LastName': 'Paimela', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Puolakka', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'Toini', 'Initials': 'T', 'LastName': 'Uutela', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'Timo', 'Initials': 'T', 'LastName': 'Möttönen', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'Pekka', 'Initials': 'P', 'LastName': 'Hannonen', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'Marjatta', 'Initials': 'M', 'LastName': 'Leirisalo-Repo', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'Leena', 'Initials': 'L', 'LastName': 'Laasonen', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'Markku', 'Initials': 'M', 'LastName': 'Kauppi', 'Affiliation': 'From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Journal of rheumatology,['10.3899/jrheum.190139'] 760,31014423,[Clinical effect of exogenous pulmonary surfactant in the treatment of severe neonatal infectious pneumonia: a multicenter prospective clinical trial].,"OBJECTIVE To study the clinical effect of calsurf, a domestic exogenous pulmonary surfactant, in the treatment of severe neonatal infectious pneumonia. METHODS A total of 208 neonates with severe infectious pneumonia who hospitalized in 5 hospitals of China were enrolled. According to their parents' wishes on admission, these neonates were administered with conventional treatment (control group; n=81) and calsurf  treatment + conventional treatment (calsurf treatment group, n=127). The two groups were compared in terms of the degree of oxygen dependence on admission, blood gas parameters before and after treatment, lung ultrasound results, duration of mechanical ventilation, length of hospital stay, hospital costs, complications and prognosis. RESULTS Compared with the control group on admission, the calsurf treatment group had significantly higher inhaled oxygen concentration and partial pressure of carbon dioxide and significantly lower arterial partial pressure of oxygen and oxygenation index (P<0.01). After 1 hour of treatment, both groups had significant improvements in the above indices (P<0.05), and the improvements were more significant in the calsurf treatment group (P<0.05). After 4-6 hours of calsurf administration, there was a significant reduction in the degree of pulmonary consolidation. The calsurf treatment group had significantly shorter duration of mechanical ventilation and length of hospital stay than the control group, while there was no significant difference in the incidence rate of complications between the two groups. The neonates of both groups had a good prognosis. CONCLUSIONS In neonates with severe infectious pneumonia, calsurf treatment can significantly improve oxygenation, reduce the degree of pulmonary consolidation, and shorten the duration of mechanical ventilation and length of hospital stay. Therefore, it should be considered in neonates with severe infectious pneumonia.",2019,"The calsurf treatment group had significantly shorter duration of mechanical ventilation and length of hospital stay than the control group, while there was no significant difference in the incidence rate of complications between the two groups.","['neonates with severe infectious pneumonia', 'severe neonatal infectious pneumonia', '208 neonates with severe infectious pneumonia who hospitalized in 5 hospitals of China were enrolled']","['domestic exogenous pulmonary surfactant', 'conventional treatment (control group; n=81) and calsurf\u2009 treatment\u2005+\u2005conventional treatment (calsurf treatment', 'exogenous pulmonary surfactant']","['incidence rate of complications', 'degree of pulmonary consolidation', 'duration of mechanical ventilation and length of hospital stay', 'arterial partial pressure of oxygen and oxygenation index', 'degree of oxygen dependence on admission, blood gas parameters before and after treatment, lung ultrasound results, duration of mechanical ventilation, length of hospital stay, hospital costs, complications and prognosis', 'shorter duration of mechanical ventilation and length of hospital stay', 'inhaled oxygen concentration and partial pressure of carbon dioxide']","[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0205228', 'cui_str': 'Exogenous (qualifier value)'}, {'cui': 'C0034085', 'cui_str': 'Pulmonary Surfactants'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C4522268', 'cui_str': 'Pulmonary'}, {'cui': 'C0702116', 'cui_str': 'Consolidation (morphologic abnormality)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0030604', 'cui_str': 'Partial Pressure'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C1278185', 'cui_str': 'Oxygenation index'}, {'cui': 'C0439857', 'cui_str': 'Patient dependence on (contextual qualifier) (qualifier value)'}, {'cui': 'C0005800', 'cui_str': 'Blood Gas Analysis'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0001758', 'cui_str': 'Follow-Up Care'}, {'cui': 'C4286019', 'cui_str': 'Lung ultrasound'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0206174', 'cui_str': 'Hospital Costs'}, {'cui': 'C0033325', 'cui_str': 'Prognosis'}, {'cui': 'C0439593', 'cui_str': 'Short duration (qualifier value)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0428646', 'cui_str': 'Oxygen concentration (observable entity)'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}]",208.0,0.029097,"The calsurf treatment group had significantly shorter duration of mechanical ventilation and length of hospital stay than the control group, while there was no significant difference in the incidence rate of complications between the two groups.","[{'ForeName': 'Ru-Xin', 'Initials': 'RX', 'LastName': 'Qiu', 'Affiliation': 'Department of Neonatology, Beijing Chaoyang District Maternal and Child Health Care Hospital, Beijing 100021, China. liujingbj@sina.com.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Jia-Li', 'Initials': 'JL', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Cai', 'Affiliation': ''}, {'ForeName': 'Jun-An', 'Initials': 'JA', 'LastName': 'Zeng', 'Affiliation': ''}, {'ForeName': 'Han-Chu', 'Initials': 'HC', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Cheng', 'Affiliation': ''}, {'ForeName': 'Zhan-Kui', 'Initials': 'ZK', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 761,31014426,[Clinical efficacy of interactive group sandplay versus individual sandplay in the treatment of preschool children with autism spectrum disorder].,"OBJECTIVE To study the clinical efficacy of interactive group sandplay versus individual sandplay in the treatment of preschool children with autism spectrum disorder (ASD). METHODS A total of 80 ASD children, aged 4-6 years, were enrolled and randomly divided into experimental and control groups, with 40 children in each group. The children in the experimental group joined group sandplay with normal children at a ratio of 1: 3, and those in the control group were treated with individual sandplay. The Aberrant Behavior Checklist (ABC) and Autism Treatment Evaluation Checklist (ATEC) were used to evaluate the treatment outcome after three months of intervention. RESULTS There were 33 children in the experimental group and 28 in the control group. After three months of intervention, the experimental group had significant reductions in the scores of irritability, social withdrawal, and stereotypic behavior and the total score of the ABC scale (P<0.05), and the control group had significant reductions in the scores of behavior and inappropriate speech and the total score of the ABC scale (P<0.05). Compared with the control group, the experimental group had significantly greater improvements in the score of social withdrawal and the total score of the ABC scale after three months of intervention (P<0.05). After three months of intervention, the experimental group had significant reductions in the scores of sociability, sensory and cognitive awareness, and physical/health behavior and the total score of the ATEC scale (P<0.05), and the control group had significant reductions in the scores of speech, sociability, and physical/health behavior and the total score of the ATEC scale (P<0.05). Compared with the control group, the experimental group had significantly greater improvements in the scores of speech, sociability, and sensory and cognitive awareness and the total score of the ATEC scale after intervention (P<0.01). Compared with the control group, the experimental group also had significantly greater improvements in eye contact and sand stereotyped arrangement (P<0.05). CONCLUSIONS Both interactive group sandplay and individual sandplay are effective in the treatment of ASD in preschool children. Interactive group sandplay is better than individual sandplay in the treatment of ASD, with significant improvements in sociability, emotion and stereotypic behavior.",2019,"After three months of intervention, the experimental group had significant reductions in the scores of sociability, sensory and cognitive awareness, and physical/health behavior and the total score of the ATEC scale (P<0.05), and the control group had significant reductions in the scores of speech, sociability, and physical/health behavior and the total score of the ATEC scale (P<0.05).","['preschool children with autism spectrum disorder', '80 ASD children, aged 4-6 years', 'preschool children', '33 children in the experimental group and 28 in the control group', 'preschool children with autism spectrum disorder (ASD']","['interactive group sandplay versus individual sandplay', 'individual sandplay']","['scores of speech, sociability, and sensory and cognitive awareness and the total score of the ATEC scale', 'scores of irritability, social withdrawal, and stereotypic behavior and the total score of the ABC scale', 'scores of sociability, sensory and cognitive awareness, and physical/health behavior and the total score of the ATEC scale', 'scores of speech, sociability, and physical/health behavior and the total score of the ATEC scale', 'sociability, emotion and stereotypic behavior', 'scores of behavior and inappropriate speech and the total score of the ABC scale', 'Aberrant Behavior Checklist (ABC) and Autism Treatment Evaluation Checklist (ATEC', 'eye contact and sand stereotyped arrangement', 'score of social withdrawal and the total score of the ABC scale']","[{'cui': 'C0008100', 'cui_str': 'Child, Preschool'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2350829', 'cui_str': 'Sandplay'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0558182', 'cui_str': 'Ability to interact with others (observable entity)'}, {'cui': 'C0445254', 'cui_str': 'Sensory (qualifier value)'}, {'cui': 'C0004448', 'cui_str': 'Situational Awareness'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0022107', 'cui_str': 'Irritable Mood'}, {'cui': 'C0424095', 'cui_str': 'Social withdrawal (finding)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0018687'}, {'cui': 'C0013987', 'cui_str': 'Emotions'}, {'cui': 'C1168248', 'cui_str': 'Inappropriate speech'}, {'cui': 'C0443127', 'cui_str': 'Aberrant (qualifier value)'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0037098', 'cui_str': 'Silicon Dioxide'}, {'cui': 'C0038272', 'cui_str': 'Stereotyping'}]",80.0,0.0177792,"After three months of intervention, the experimental group had significant reductions in the scores of sociability, sensory and cognitive awareness, and physical/health behavior and the total score of the ATEC scale (P<0.05), and the control group had significant reductions in the scores of speech, sociability, and physical/health behavior and the total score of the ATEC scale (P<0.05).","[{'ForeName': 'Yan-Xia', 'Initials': 'YX', 'LastName': 'Wang', 'Affiliation': ""Child Health Center, Fujian Provincial Maternity and Children's Hospital, Fuzhou 350001, China. gp8287@126.com.""}, {'ForeName': 'Guo-Bin', 'Initials': 'GB', 'LastName': 'Lu', 'Affiliation': ''}, {'ForeName': 'Pin', 'Initials': 'P', 'LastName': 'Ge', 'Affiliation': ''}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Ou', 'Affiliation': ''}, {'ForeName': 'Gui-Hua', 'Initials': 'GH', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Qin-Fang', 'Initials': 'QF', 'LastName': 'Qian', 'Affiliation': ''}, {'ForeName': 'Guo-Kai', 'Initials': 'GK', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Yan-Qin', 'Initials': 'YQ', 'LastName': 'Xie', 'Affiliation': ''}, {'ForeName': 'Zhang-Qiong', 'Initials': 'ZQ', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Qiu-Juan', 'Initials': 'QJ', 'LastName': 'Yu', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 762,31014435,"[Clinical effect of fluticasone propionate, montelukast sodium and ketotifen in treatment of cough variant asthma in children].","OBJECTIVE To study the clinical effect of different combinations of fluticasone propionate (Flu), montelukast sodium (Mon) and ketotifen (Ket) in the treatment of children with cough variant asthma (CVA). METHODS A total of 280 children with CVA who were admitted to the department of respiratory medicine from June 2015 to January 2018 were randomly divided into Flu+Mon+Ket, Flu+Mon, Flu+Ket, Mon+Ket, Flu, Mon and Ket groups, with 40 children in each group. The children in each group were given corresponding drug(s), and the course of treatment was 3 months for all groups. The condition of cough, cough symptom score, pulmonary function and adverse drug reactions were evaluated after 2 and 3 months of treatment. The children were followed up to observe recurrence. RESULTS After treatment, cough symptom score tended to decrease in all 7 groups, with increases in percentage of forced expiratory volume in 1 second (FEV1%) and percentage of predicted peak expiratory flow (PEF%). After 2 months of treatment, the Flu+Mon+Ket group had a significantly lower cough symptom score and significantly higher FEV1% and PEF% than the other groups (P<0.05). After 2 and 3 months of treatment, the Ket group had a significantly higher cough symptom score and significantly lower FEV1% and PEF% than the other groups (P<0.05). After 3 months of treatment, there were no significant differences in cough symptom score, FEV1% and PEF% among the other groups (P>0.05). There was a low incidence rate of adverse events in all 7 groups, and there was no significant difference among the 7 groups (P>0.05). The Ket group had a significantly higher recurrence rate of cough than the other groups (P<0.001), while there was no significant difference in this rate among the other groups (P>0.0024). CONCLUSIONS For children with CVA, a combination of Flu, Mon and Ket has a better clinical effect than a combination of two drugs and a single drug at 2 months of treatment and is safe. After 3 months of treatment, Flu or Mon alone has a similar effect to drug combination. Ket alone has a poor clinical effect and a high recurrence rate after drug withdrawal.",2019,"The Ket group had a significantly higher recurrence rate of cough than the other groups (P<0.001), while there was no significant difference in this rate among the other groups (P>0.0024). ","['cough variant asthma in children', '280 children with CVA who were admitted to the department of respiratory medicine from June 2015 to January 2018', 'children with cough variant asthma (CVA']","['Flu+Mon+Ket, Flu+Mon, Flu+Ket, Mon+Ket, Flu, Mon and Ket groups', 'fluticasone propionate, montelukast sodium and ketotifen', 'fluticasone propionate (Flu), montelukast sodium (Mon) and ketotifen (Ket', 'Flu+Mon+Ket']","['cough symptom score', 'low incidence rate of adverse events', 'recurrence rate of cough', 'cough symptom score, FEV1% and PEF', 'condition of cough, cough symptom score, pulmonary function and adverse drug reactions', 'percentage of forced expiratory volume in 1 second (FEV1%) and percentage of predicted peak expiratory flow (PEF']","[{'cui': 'C0694548', 'cui_str': 'Cough variant asthma (disorder)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0034060', 'cui_str': 'Pneumology'}]","[{'cui': 'C0021400', 'cui_str': 'Influenza, Human'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0117996', 'cui_str': 'Fluticasone propionate'}, {'cui': 'C0380447', 'cui_str': 'montelukast sodium'}, {'cui': 'C0022642', 'cui_str': 'Ketotifen'}]","[{'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0041755', 'cui_str': 'Drug Side Effects'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}]",280.0,0.0226145,"The Ket group had a significantly higher recurrence rate of cough than the other groups (P<0.001), while there was no significant difference in this rate among the other groups (P>0.0024). ","[{'ForeName': 'Xiao-Hong', 'Initials': 'XH', 'LastName': 'Zhu', 'Affiliation': ""Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University/Ministry of Education Key Laboratory of Child Development and Disorders/ China International Science and Technology Cooperation Base of Child Development and Critical Disorders/Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China. danieljh@163.com.""}, {'ForeName': 'Jin-Wei', 'Initials': 'JW', 'LastName': 'Tu', 'Affiliation': ''}, {'ForeName': 'Ji-Hong', 'Initials': 'JH', 'LastName': 'Dai', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 763,29447357,Analysis of cluster-randomized test-negative designs: cluster-level methods.,"Intervention trials of vector control methods often require community level randomization with appropriate inferential methods. For many interventions, the possibility of confounding due to the effects of health-care seeking behavior on disease ascertainment remains a concern. The test-negative design, a variant of the case-control method, was introduced to mitigate this issue in the assessment of the efficacy of influenza vaccination (measured at an individual level) on influenza infection. Here, we introduce a cluster-randomized test-negative design that includes randomization of the intervention at a group level. We propose several methods for estimation and inference regarding the relative risk (RR). The inferential methods considered are based on the randomization distribution induced by permuting intervention assignment across two sets of randomly selected clusters. The motivating example is a current study of the efficacy of randomized releases of Wolbachia-infected Aedes aegypti mosquitoes to reduce the incidence of dengue in Yogyakarta City, Indonesia. Estimation and inference techniques are assessed through a simulation study.",2019,"The motivating example is a current study of the efficacy of randomized releases of Wolbachia-infected Aedes aegypti mosquitoes to reduce the incidence of dengue in Yogyakarta City, Indonesia.",[],['Wolbachia-infected Aedes aegypti mosquitoes'],[],[],"[{'cui': 'C0752001', 'cui_str': 'Wolbachia'}, {'cui': 'C0322859', 'cui_str': 'Aedes aegypti (organism)'}, {'cui': 'C0026584', 'cui_str': 'Mosquitoes'}]",[],,0.0881931,"The motivating example is a current study of the efficacy of randomized releases of Wolbachia-infected Aedes aegypti mosquitoes to reduce the incidence of dengue in Yogyakarta City, Indonesia.","[{'ForeName': 'Nicholas P', 'Initials': 'NP', 'LastName': 'Jewell', 'Affiliation': 'Division of Biostatistics, School of Public Health, University of California, Berkeley, CA 94720, USA.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Dufault', 'Affiliation': 'Division of Biostatistics, School of Public Health, University of California, Berkeley, CA 94720, USA.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Cutcher', 'Affiliation': 'World Mosquito Program, Institute of Vector Borne Disease, Monash University, Level 1, 12 Innovation Walk, Clayton, Victoria 3800, Australia.'}, {'ForeName': 'Cameron P', 'Initials': 'CP', 'LastName': 'Simmons', 'Affiliation': 'World Mosquito Program, Institute of Vector Borne Disease, Monash University, Level 1, 12 Innovation Walk, Clayton, Victoria 3800, Australia.'}, {'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': 'Anders', 'Affiliation': 'World Mosquito Program, Institute of Vector Borne Disease, Monash University, Level 1, 12 Innovation Walk, Clayton, Victoria 3800, Australia.'}]","Biostatistics (Oxford, England)",['10.1093/biostatistics/kxy005'] 764,30457060,Evidence for oestrogen sensitivity in perinatal depression: pharmacological sex hormone manipulation study.,"BACKGROUND Enhanced sensitivity to oestrogen signalling may drive increased risk for depressive symptoms when exposed to peripartum sex-steroid hormone fluctuations. AIM Testing if 116 pre-identified sex steroid-responsive transcripts that predicted perinatal depression (PND) translates to a pharmacological model of hormone-induced mood changes. METHOD We generated longitudinal, genome-wide gene-expression and DNA-methylation data from 60 women exposed to a gonadotrophin-releasing hormone agonist (GnRHa) or placebo. We used linear mixed-effect models to assess differences between baseline and follow-up for gene expression and DNA methylation in the biphasic ovarian response to GnRHa. RESULTS Of the 116 PND-predictive transcripts, a significant (19%) overlap was observed with those differentially expressed post-GnRHa at both early and later follow-up, indicating sustained effects. Similarly, 49% of tested genes were differentially methylated post-GnRHa at the late follow-up. Within the GnRHa group, a large proportion of PND genes were significantly associated (gene expression; DNA methylation) with changes in depressive symptoms (28%; 66%), oestradiol levels (49%; 66%) and neocortex serotonin transporter binding (8%; 45%) between baseline and follow-up. CONCLUSIONS Our data bridge clinical PND biomarkers with a pharmacological model of sex hormone-induced mood changes and directly relate oestrogen-induced biological changes with depressive symptoms and associated serotonin-signalling changes. Our data highlight that individual variations in molecular sensitivity to oestrogen associate with susceptibility to hormone-induced mood changes and hold promise for candidate biomarkers. DECLARATION OF INTEREST V.G.F. received honorarium for being a speaker for H. Lundbeck A/S. E.B.B. receives research funding from Böhringer Ingelheim to investigate FKBP5 as a potential drug target for depression.",2019,"Within the GnRHa group, a large proportion of PND genes were significantly associated (gene expression; DNA methylation) with changes in depressive symptoms (28%; 66%), oestradiol levels (49%; 66%) and neocortex serotonin transporter binding (8%; 45%) between baseline and follow-up. ",['60 women exposed to a'],['gonadotrophin-releasing hormone agonist (GnRHa) or placebo'],"['neocortex serotonin transporter binding', 'depressive symptoms', 'oestradiol levels']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}]","[{'cui': 'C0023610', 'cui_str': 'Gonadorelin'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0175173', 'cui_str': 'Neopallium'}, {'cui': 'C0170657', 'cui_str': 'Serotonin Plasma Membrane Transport Proteins'}, {'cui': 'C1145667', 'cui_str': 'Binding - action (qualifier value)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0337434', 'cui_str': 'Estradiol measurement (procedure)'}]",,0.063197,"Within the GnRHa group, a large proportion of PND genes were significantly associated (gene expression; DNA methylation) with changes in depressive symptoms (28%; 66%), oestradiol levels (49%; 66%) and neocortex serotonin transporter binding (8%; 45%) between baseline and follow-up. ","[{'ForeName': 'Divya', 'Initials': 'D', 'LastName': 'Mehta', 'Affiliation': 'Senior Research Fellow, School of Psychology and Counselling, Faculty of Health and Institute of Health and Biomedical Innovation, Queensland University of Technology, Australia.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Rex-Haffner', 'Affiliation': 'Laboratory Manager, Department of Translational Psychiatry, Max Planck Institute of Psychiatry, Germany.'}, {'ForeName': 'Helle Bach', 'Initials': 'HB', 'LastName': 'Søndergaard', 'Affiliation': 'Senior Researcher, Molecular Biologist, Danish Multiple Sclerosis Center, Copenhagen University Hospital Rigshospitalet, Denmark.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Pinborg', 'Affiliation': 'Professor, Fertility Clinic, Copenhagen University Hospital Rigshospitalet and Gynecology and Obstetrics, Copenhagen University Hospital Hvidovre, Denmark.'}, {'ForeName': 'Elisabeth B', 'Initials': 'EB', 'LastName': 'Binder', 'Affiliation': 'Director, Department of Translational Psychiatry, Max Planck Institute of Psychiatry, Germany and Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, US.'}, {'ForeName': 'Vibe G', 'Initials': 'VG', 'LastName': 'Frokjaer', 'Affiliation': 'Senior Researcher, Neurobiology Research Unit, Center for Integrated Molecular Brain Imaging and Mental Health Services Copenhagen, Copenhagen University Hospital Rigshospitalet, Denmark.'}]",The British journal of psychiatry : the journal of mental science,['10.1192/bjp.2018.234'] 765,31719675,Longitudinal neovascular changes on optical coherence tomography angiography in proliferative diabetic retinopathy treated with panretinal photocoagulation alone versus with intravitreal conbercept plus panretinal photocoagulation: a pilot study.,"PURPOSE To investigate the longitudinal changes in neovascularization of the retinal elsewhere (NVE) size on optical coherence tomography angiography (OCTA) in proliferative diabetic retinopathy (PDR) treated by panretinal photocoagulation (PRP) alone or by single intravitreal conbercept injection plus PRP. METHODS A prospective pilot study. Forty-four PDR eyes with NVE confirmed by fundus fluorescein angiography (FFA) and OCTA were included. They were assigned to receive PRP alone (PRP group) or intravitreal conbercept injection plus PRP (combination group). Ophthalmic examinations, including BCVA and OCTA to measure the NVE size, were performed at baseline before each PRP session, and at 1, 3, and 6 months. RESULTS Twenty-nine eyes were included in the PRP group, and 15 eyes were included in the combination group. There was no significant difference between the two groups with respect to age, BCVA, and NVE area at baseline. In both groups, there was a significant (P < 0.05) NVE size reduction during the majority of study visits, with the reduction observed in the combination group significantly larger than that in the PRP group. No significant BCVA changes were observed in either groups, except that in the PRP group, the BCVA at 3 months was significantly improved (P < 0.05). No deaths or unexpected adverse events (AEs) were reported. CONCLUSIONS Intravitreal conbercept plus PRP was more effective than PRP monotherapy in NVE regression. Precise quantification of the NVE area by OCTA makes it a useful tool for monitoring the response of retinal neovascular lesions to the therapy.",2020,"There was no significant difference between the two groups with respect to age, BCVA, and NVE area at baseline.","['proliferative diabetic retinopathy treated with', 'Forty-four PDR eyes with NVE confirmed by fundus fluorescein angiography (FFA) and OCTA were included', 'proliferative diabetic retinopathy (PDR', 'Twenty-nine eyes were included in the PRP group, and 15 eyes were included in the combination group']","['optical coherence tomography angiography', 'intravitreal conbercept plus panretinal photocoagulation', 'PRP alone (PRP group) or intravitreal conbercept injection plus PRP', 'panretinal photocoagulation alone', 'panretinal photocoagulation (PRP) alone or by single intravitreal conbercept injection plus PRP', 'optical coherence tomography angiography (OCTA']","['No deaths or unexpected adverse events (AEs', 'NVE size reduction', 'BCVA changes', 'BCVA and OCTA to measure the NVE size', 'BCVA']","[{'cui': 'C0154830', 'cui_str': 'PDR - proliferative diabetic retinopathy'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by (contextual qualifier) (qualifier value)'}, {'cui': 'C0430878', 'cui_str': 'Retinal angiography'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0450351', 'cui_str': '29 (qualifier value)'}, {'cui': 'C0242848', 'cui_str': 'PrP (GSS)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0920367', 'cui_str': 'Tomography, Optical Coherence'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}, {'cui': 'C2352201', 'cui_str': 'KH902 fusion protein'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0730064', 'cui_str': 'Scatter retinal laser photocoagulation'}, {'cui': 'C0242848', 'cui_str': 'PrP (GSS)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]",44.0,0.0175467,"There was no significant difference between the two groups with respect to age, BCVA, and NVE area at baseline.","[{'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'He', 'Affiliation': 'Department of Ophthalmology, Peking Union Medical College Hospital, Key Lab of Ocular Fundus Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Weihong', 'Initials': 'W', 'LastName': 'Yu', 'Affiliation': 'Department of Ophthalmology, Peking Union Medical College Hospital, Key Lab of Ocular Fundus Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. yuweihongeye@foxmail.com.'}]","Eye (London, England)",['10.1038/s41433-019-0628-3'] 766,30856418,On the malleability of selective trust.,"Although much research has explored the cues that young children use to determine informant credibility, little research has examined whether credibility judgments can change over time as a function of children's language environment. This study explored whether changes in the syntactic complexity of adults' testimony shifts 4- and 5-year-old children's (N = 42) credibility and learning judgments. Children from lower-socioeconomic status (SES) backgrounds were randomly assigned to hear a high proportion of complex language (the passive voice) or simpler language (the active voice) during 10 days of book-reading interactions with adult experimenters. Before and after the book-reading sessions, children's learning preferences for informants who used passive versus active voice were measured. Exposure to the complex passive voice led children to use syntactic complexity as a cue to make inferences about who to learn from, whereas active voice exposure resulted in no such shift. Implications for the role of the language environment in children's selective trust are discussed.",2019,"Before and after the book-reading sessions, children's learning preferences for informants who used passive versus active voice were measured.","['young children', 'Children from lower-socioeconomic status (SES) backgrounds', ""adults' testimony shifts 4- and 5-year-old children's (N\u202f=\u202f42) credibility and learning judgments""]",['complex language (the passive voice) or simpler language (the active voice'],[],"[{'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0086996', 'cui_str': 'Socioeconomic Status'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0333051', 'cui_str': 'Shift (morphologic abnormality)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0022423', 'cui_str': 'Judgment'}]","[{'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0023008', 'cui_str': 'Languages'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0205352', 'cui_str': 'Simple (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}]",[],,0.0193102,"Before and after the book-reading sessions, children's learning preferences for informants who used passive versus active voice were measured.","[{'ForeName': 'Kathryn A', 'Initials': 'KA', 'LastName': 'Leech', 'Affiliation': 'Graduate School of Education, Harvard University, Cambridge, MA 02138, USA. Electronic address: kathryn_leech@gse.harvard.edu.'}, {'ForeName': 'Amanda S', 'Initials': 'AS', 'LastName': 'Haber', 'Affiliation': 'Wheelock College of Education and Human Development, Boston University, Boston, MA 02215, USA.'}, {'ForeName': 'Sudha', 'Initials': 'S', 'LastName': 'Arunachalam', 'Affiliation': 'Department of Communicative Sciences and Disorders, New York University, New York, NY 10012, USA.'}, {'ForeName': 'Katelyn', 'Initials': 'K', 'LastName': 'Kurkul', 'Affiliation': 'School of Education and Social Policy, Merrimack College, North Andover, MA 01845, USA.'}, {'ForeName': 'Kathleen H', 'Initials': 'KH', 'LastName': 'Corriveau', 'Affiliation': 'Wheelock College of Education and Human Development, Boston University, Boston, MA 02215, USA.'}]",Journal of experimental child psychology,['10.1016/j.jecp.2019.01.013'] 767,30926325,Mindfulness-based therapy modulates default-mode network connectivity in patients with opioid dependence.,"Recently, mindfulness-based programs have shown promising clinical effects in the treatment of substance-use disorders (SUD). While several studies linked mindfulness to decreased default mode network (DMN) connectivity in meditators, only a few studies investigated its effects in patients with SUD. This study aimed to detect changes in DMN connectivity in opiate dependent patients receiving mindfulness based therapy (MBT) during their first month of treatment. Data from 32 patients that were assigned to MBT or treatment as usual (TAU) groups was investigated using resting-state functional MRI at 1.5 T before and after four weeks of treatment. Independent Component Analysis was used to investigate distinct (anterior vs. posterior) DMN subsystems. Connectivity changes after treatment were related to measures of impulsivity, distress tolerance and mindfulness. Increased mindfulness scores after treatment were found in patients receiving MBT compared to TAU. Within the anterior DMN, decreased right inferior frontal cortical connectivity was detected in patients who received MBT compared to TAU. In addition, within the MBT-group decreased right superior frontal cortex connectivity was detected after treatment. Inferior frontal cortex function was significantly associated with mindfulness measures. The data suggest that MBT can be useful during abstinence from opiates. In opiate-dependent patients distinct functional connectivity changes within the DMN are associated with MBT.",2019,"Within the anterior DMN, decreased right inferior frontal cortical connectivity was detected in patients who received MBT compared to TAU.","['patients with opioid dependence', 'patients with SUD', '32 patients that were assigned to', 'opiate dependent patients receiving mindfulness based therapy (MBT) during their first month of treatment']","['Mindfulness-based therapy', 'MBT']","['right inferior frontal cortical connectivity', 'DMN connectivity', 'right superior frontal cortex connectivity', 'Inferior frontal cortex function', 'Increased mindfulness scores', 'impulsivity, distress tolerance and mindfulness', 'Connectivity changes']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0524662', 'cui_str': 'Opiate Dependence'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0242401', 'cui_str': 'Opiates'}, {'cui': 'C0581116', 'cui_str': 'Dependent patient (finding)'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0542339', 'cui_str': 'Below (qualifier value)'}, {'cui': 'C0205123', 'cui_str': 'Coronal (qualifier value)'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0016733', 'cui_str': 'Frontal Cortex'}, {'cui': 'C0582740', 'cui_str': 'Inferior frontal cortex (body structure)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0021125', 'cui_str': 'Impulsivity'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",32.0,0.01576,"Within the anterior DMN, decreased right inferior frontal cortical connectivity was detected in patients who received MBT compared to TAU.","[{'ForeName': 'Reham', 'Initials': 'R', 'LastName': 'Fahmy', 'Affiliation': 'Department of Psychiatry, Kasralainy Faculty of Medicine, Cairo University, Egypt.'}, {'ForeName': 'Maha', 'Initials': 'M', 'LastName': 'Wasfi', 'Affiliation': 'Department of Psychiatry, Kasralainy Faculty of Medicine, Cairo University, Egypt.'}, {'ForeName': 'Rania', 'Initials': 'R', 'LastName': 'Mamdouh', 'Affiliation': 'Department of Psychiatry, Kasralainy Faculty of Medicine, Cairo University, Egypt.'}, {'ForeName': 'Kareem', 'Initials': 'K', 'LastName': 'Moussa', 'Affiliation': 'Department of Radiology, Kasralainy Faculty of Medicine, Cairo University, Egypt.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Wahba', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Marburg University, Germany.'}, {'ForeName': 'Mike M', 'Initials': 'MM', 'LastName': 'Schmitgen', 'Affiliation': 'Center for Psychosocial Medicine, Department of General Psychiatry, Heidelberg University, Voßstraße 4, 69115 Heidelberg, Germany.'}, {'ForeName': 'Katharina M', 'Initials': 'KM', 'LastName': 'Kubera', 'Affiliation': 'Center for Psychosocial Medicine, Department of General Psychiatry, Heidelberg University, Voßstraße 4, 69115 Heidelberg, Germany.'}, {'ForeName': 'Nadine D', 'Initials': 'ND', 'LastName': 'Wolf', 'Affiliation': 'Center for Psychosocial Medicine, Department of General Psychiatry, Heidelberg University, Voßstraße 4, 69115 Heidelberg, Germany.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Sambataro', 'Affiliation': 'Department of Experimental and Clinical Medical Sciences (DISM), University of Udine, Udine, Italy.'}, {'ForeName': 'Robert Christian', 'Initials': 'RC', 'LastName': 'Wolf', 'Affiliation': 'Center for Psychosocial Medicine, Department of General Psychiatry, Heidelberg University, Voßstraße 4, 69115 Heidelberg, Germany. Electronic address: christian.wolf@med.uni-heidelberg.de.'}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2019.03.002'] 768,30928180,Neurochemical effects of oxytocin in people at clinical high risk for psychosis.,"Alterations in neurochemical metabolites are thought to play a role in the pathophysiology of psychosis onset. Oxytocin, a neuropeptide with prosocial and anxiolytic properties, modulates glutamate neurotransmission in preclinical models but its neurochemical effects in people at high risk for psychosis are unknown. We used proton magnetic resonance spectroscopy ( 1 H-MRS) to examine the effects of intranasal oxytocin on glutamate and other metabolites in people at Clinical High Risk for Psychosis (CHR-P) in a double-blind, placebo-controlled, crossover design. 30 CHR-P males were studied on two occasions, once after 40IU intranasal oxytocin and once after placebo. The effects of oxytocin on the concentration of glutamate, glutamate+glutamine and other metabolites (choline, N-acetylaspartate, myo-inositol) scaled to creatine were examined in the left thalamus, anterior cingulate cortex (ACC) and left hippocampus, starting approximately 75, 84 and 93 min post-dosing, respectively. Relative to placebo, administration of oxytocin was associated with an increase in choline levels in the ACC (p=.008, Cohen's d = 0.54). There were no other significant effects on metabolite concentrations (all p>.05). Our findings suggest that, at ∼75-99 min post-dosing, a single dose of intranasal oxytocin does not alter levels of neurochemical metabolites in the thalamus, ACC, or hippocampus in those at CHR-P, aside from potential effects on choline in the ACC.",2019,"Relative to placebo, administration of oxytocin was associated with an increase in choline levels in the ACC (p=.008, Cohen's d = 0.54).","['people at Clinical High Risk for Psychosis (CHR-P', 'people at clinical high risk for psychosis', '30 CHR-P males']","['placebo', 'proton magnetic resonance spectroscopy ( 1 H-MRS', 'intranasal oxytocin', 'Oxytocin', 'oxytocin']","['choline levels', 'metabolite concentrations', 'concentration of glutamate, glutamate+glutamine and other metabolites (choline, N-acetylaspartate, myo-inositol) scaled to creatine', 'levels of neurochemical metabolites']","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0033975', 'cui_str': 'Psychoses'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3850002', 'cui_str': '1H-MRS'}, {'cui': 'C0700308', 'cui_str': 'Protium (substance)'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}]","[{'cui': 'C0008405', 'cui_str': 'Choline'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0220839', 'cui_str': 'Glutamate'}, {'cui': 'C0067684', 'cui_str': 'N-acetyl aspartate'}, {'cui': 'C0021547', 'cui_str': 'Inositol'}, {'cui': 'C0222045'}, {'cui': 'C0010286', 'cui_str': 'Creatine'}]",,0.286814,"Relative to placebo, administration of oxytocin was associated with an increase in choline levels in the ACC (p=.008, Cohen's d = 0.54).","[{'ForeName': 'Cathy', 'Initials': 'C', 'LastName': 'Davies', 'Affiliation': ""Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, UK. Electronic address: cathy.davies@kcl.ac.uk.""}, {'ForeName': 'Grazia', 'Initials': 'G', 'LastName': 'Rutigliano', 'Affiliation': ""Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, UK.""}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'De Micheli', 'Affiliation': ""Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, UK; National Institute for Health Research (NIHR) Biomedical Research Centre (BRC), South London and Maudsley NHS Foundation Trust, London, UK.""}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Stone', 'Affiliation': ""National Institute for Health Research (NIHR) Biomedical Research Centre (BRC), South London and Maudsley NHS Foundation Trust, London, UK; Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Ramella-Cravaro', 'Affiliation': ""Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, UK.""}, {'ForeName': 'Umberto', 'Initials': 'U', 'LastName': 'Provenzani', 'Affiliation': ""Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, UK; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Cappucciati', 'Affiliation': ""Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, UK.""}, {'ForeName': 'Eleanor', 'Initials': 'E', 'LastName': 'Scutt', 'Affiliation': ""Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, UK.""}, {'ForeName': 'Yannis', 'Initials': 'Y', 'LastName': 'Paloyelis', 'Affiliation': ""Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Dominic', 'Initials': 'D', 'LastName': 'Oliver', 'Affiliation': ""Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, UK.""}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Murguia', 'Affiliation': 'Tower Hamlets Early Detection Service (THEDS), East London NHS Foundation Trust, London, UK.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Zelaya', 'Affiliation': ""Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Allen', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; Department of Psychology, University of Roehampton, London, UK.""}, {'ForeName': 'Sukhi', 'Initials': 'S', 'LastName': 'Shergill', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Morrison', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Williams', 'Affiliation': ""Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Taylor', 'Affiliation': ""Institute of Pharmaceutical Science, King's College London, London, UK.""}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Lythgoe', 'Affiliation': ""Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'McGuire', 'Affiliation': ""National Institute for Health Research (NIHR) Biomedical Research Centre (BRC), South London and Maudsley NHS Foundation Trust, London, UK; Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; Outreach and Support in South London (OASIS) Service, South London and Maudsley NHS Foundation Trust, London, UK.""}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Fusar-Poli', 'Affiliation': ""Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, UK; National Institute for Health Research (NIHR) Biomedical Research Centre (BRC), South London and Maudsley NHS Foundation Trust, London, UK; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; Outreach and Support in South London (OASIS) Service, South London and Maudsley NHS Foundation Trust, London, UK.""}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2019.03.008'] 769,31729550,Low dose fentanyl infusion versus 24% oral sucrose for pain management during laser treatment for retinopathy of prematurity-an open label randomized clinical trial.,"To compare the efficacy of low dose fentanyl infusion and 24% oral sucrose in providing optimal pain relief during laser for retinopathy of prematurity (ROP), we enrolled fifty-eight spontaneously breathing preterm infants undergoing laser. The preterm infants were randomized to either fentanyl infusion (1 mcg/kg/hr) or 24% oral sucrose (2 ml). We evaluated and compared the proportion of time spent crying during the procedure, salivary cortisol before and after the procedure, premature infant pain profile- revised (PIPP-R) scores during the procedure, apnoea during and after the procedure, need for mechanical ventilation, and feed intolerance and urinary retention 24 h after the procedure between the two groups. We found that the proportion of time spent crying during the procedure was significantly less in the fentanyl group [62.5% (50.7-74.2) vs 73.8% (55.6-83.4); P = 0.02]. Average PIPP-R score during the procedure was significantly less in the fentanyl group [7.2 vs 9.0; (mean difference of - 1.8; P = 0.01)]. There was no difference in other outcomes between the two groups.Conclusion: During laser for ROP, low dose fentanyl infusion was found to be efficacious in reducing pain as compared with 24% sucrose.What is Known:• Preterm infants undergoing laser photocoagulation for ROP suffer significant amount of pain.• Standard of care for pain relief in infants undergoing laser therapy in developed countries is general anesthesia (GA) or combination of sedation, analgesia, and paralysis (SAP).What is New:• During laser photocoagulation for ROP, fentanyl infusion at low dose (1 mcg/kg/hr) is efficacious in reducing pain as compared to 24% oral sucrose.",2020,Average PIPP-R score during the procedure was significantly less in the fentanyl group [7.2 vs 9.0; (mean difference of - 1.8; P = 0.01)].,"['infants undergoing', 'preterm infants', 'during laser for retinopathy of prematurity (ROP), we enrolled fifty-eight spontaneously breathing preterm infants undergoing laser', 'Known:• Preterm infants undergoing']","['fentanyl infusion versus 24% oral sucrose', 'fentanyl infusion (1 mcg/kg/hr) or 24% oral sucrose', 'laser therapy', 'fentanyl infusion and 24% oral sucrose', 'laser photocoagulation']","['premature infant pain profile- revised (PIPP-R) scores', 'optimal pain relief', 'pain', 'proportion of time spent crying', 'Average PIPP-R score', 'pain management']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C0035344', 'cui_str': 'Retrolental Fibroplasia'}, {'cui': 'C4517817', 'cui_str': '58'}]","[{'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0038636', 'cui_str': 'Sucrose'}, {'cui': 'C1320752', 'cui_str': 'mcg/kg/hr'}, {'cui': 'C1955835', 'cui_str': 'Laser Therapy'}, {'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C0023694', 'cui_str': 'Photocoagulation'}]","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0002766', 'cui_str': 'Pain management (procedure)'}]",58.0,0.0523975,Average PIPP-R score during the procedure was significantly less in the fentanyl group [7.2 vs 9.0; (mean difference of - 1.8; P = 0.01)].,"[{'ForeName': 'Amanpreet', 'Initials': 'A', 'LastName': 'Sethi', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, Room no.3058, Teaching block, Third floor, AIIMS, New Delhi, 110029, India.'}, {'ForeName': 'M Jeeva', 'Initials': 'MJ', 'LastName': 'Sankar', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, Room no.3058, Teaching block, Third floor, AIIMS, New Delhi, 110029, India. jeevasankar@gmail.com.'}, {'ForeName': 'Srikanth', 'Initials': 'S', 'LastName': 'Kulkarni', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, Room no.3058, Teaching block, Third floor, AIIMS, New Delhi, 110029, India.'}, {'ForeName': 'Anu', 'Initials': 'A', 'LastName': 'Thukral', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, Room no.3058, Teaching block, Third floor, AIIMS, New Delhi, 110029, India.'}, {'ForeName': 'Parijat', 'Initials': 'P', 'LastName': 'Chandra', 'Affiliation': 'Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, 110029, India.'}, {'ForeName': 'Ramesh', 'Initials': 'R', 'LastName': 'Agarwal', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, Room no.3058, Teaching block, Third floor, AIIMS, New Delhi, 110029, India.'}]",European journal of pediatrics,['10.1007/s00431-019-03514-5'] 770,31038430,"A randomized pilot study of music therapy in the form of patient-preferred live music on fatigue, energy and pain in hospitalized adult oncology patients on a blood and marrow transplant unit.","INTRODUCTION There is a lack of randomized research measuring how music therapy might influence fatigue in oncology patients. OBJECTIVE The purpose of this randomized pilot study was to evaluate the effects of music therapy in the form of patient-preferred live music (PPLM) on fatigue, energy and pain in adults hospitalized on a blood and marrow transplant (BMT) unit. METHOD Participants ( n  = 35) were randomly assigned to an experimental or wait-list control group and completed the Lee Fatigue Scale and a 10-point Likert-type pain scale at pre- and posttest. RESULTS Between-group posttest results were statistically significant for fatigue and pain, with the experimental group having less fatigue and pain than the control group. CONCLUSIONS PPLM can be a preferred and effective intervention to immediately lessen fatigue and pain without pharmacological intervention. Implications for clinical practice, limitations and suggestions for future research are provided.",2020,"RESULTS Between-group posttest results were statistically significant for fatigue and pain, with the experimental group having less fatigue and pain than the control group. ","['oncology patients', 'Participants (n\xa0=\xa035', 'hospitalized adult oncology patients on a blood and marrow transplant unit', 'adults hospitalized on a blood and marrow transplant (BMT) unit']","['music therapy', 'patient-preferred live music (PPLM']","['Lee Fatigue Scale and a 10-point Likert-type pain scale', 'fatigue and pain', 'fatigue, energy and pain']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0005768'}, {'cui': 'C0330477', 'cui_str': 'Cucurbita'}, {'cui': 'C0332835', 'cui_str': 'Grafts'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}]","[{'cui': 'C0026868', 'cui_str': 'Music Therapy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3543840', 'cui_str': 'Preferred'}, {'cui': 'C0026867', 'cui_str': 'Music'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0222045'}, {'cui': 'C0052080', 'cui_str': '3-((phenylacetyl)amino)-2,6-piperidinedione'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",35.0,0.0469403,"RESULTS Between-group posttest results were statistically significant for fatigue and pain, with the experimental group having less fatigue and pain than the control group. ","[{'ForeName': 'Lacey', 'Initials': 'L', 'LastName': 'Reimnitz', 'Affiliation': 'School of Music, University of Minnesota , Minneapolis, MN, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Silverman', 'Affiliation': 'School of Music, University of Minnesota , Minneapolis, MN, USA.'}]",Arts & health,['10.1080/17533015.2018.1534251'] 771,31695168,Intrinsic connectomes are a predictive biomarker of remission in major depressive disorder.,"Although major depressive disorder (MDD) is associated with altered functional coupling between disparate neural networks, the degree to which such measures are ameliorated by antidepressant treatment is unclear. It is also unclear whether functional connectivity can be used as a predictive biomarker of treatment response. Here, we used whole-brain functional connectivity analysis to identify neural signatures of remission following antidepressant treatment, and to identify connectomic predictors of treatment response. 163 MDD and 62 healthy individuals underwent functional MRI during pre-treatment baseline and 8-week follow-up sessions. Patients were randomized to escitalopram, sertraline or venlafaxine-XR antidepressants and assessed at follow-up for remission. Baseline measures of intrinsic functional connectivity between each pair of 333 regions were analyzed to identify pre-treatment connectomic features that distinguish remitters from non-remitters. We then interrogated these connectomic differences to determine if they changed post-treatment, distinguished patients from controls, and were modulated by medication type. Irrespective of medication type, remitters were distinguished from non-remitters by greater connectivity within the default mode network (DMN); specifically, between the DMN, fronto-parietal and somatomotor networks, the DMN and visual, limbic, auditory and ventral attention networks, and between the fronto-parietal and somatomotor networks with cingulo-opercular and dorsal attention networks. This baseline hypo-connectivity for non-remitters also distinguished them from controls and increased following treatment. In contrast, connectivity for remitters was higher than controls at baseline and also following remission, suggesting a trait-like connectomic characteristic. Increased functional connectivity within and between large-scale intrinsic brain networks may characterize acute recovery with antidepressants in depression.",2020,"Irrespective of medication type, remitters were distinguished from non-remitters by greater connectivity within the default mode network (DMN); specifically, between the DMN, fronto-parietal and somatomotor networks, the DMN and visual, limbic, auditory and ventral attention networks, and between the fronto-parietal and somatomotor networks with cingulo-opercular and dorsal attention networks.",['163 MDD and 62 healthy individuals underwent'],"['escitalopram, sertraline or venlafaxine-XR antidepressants', 'functional MRI']","['connectivity for remitters', 'intrinsic functional connectivity']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C1099456', 'cui_str': 'Escitalopram'}, {'cui': 'C0074393', 'cui_str': 'Sertraline'}, {'cui': 'C0078569', 'cui_str': 'venlafaxine'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant Drugs'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}]","[{'cui': 'C0439674', 'cui_str': 'Intrinsic (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}]",163.0,0.0349942,"Irrespective of medication type, remitters were distinguished from non-remitters by greater connectivity within the default mode network (DMN); specifically, between the DMN, fronto-parietal and somatomotor networks, the DMN and visual, limbic, auditory and ventral attention networks, and between the fronto-parietal and somatomotor networks with cingulo-opercular and dorsal attention networks.","[{'ForeName': 'Mayuresh S', 'Initials': 'MS', 'LastName': 'Korgaonkar', 'Affiliation': 'The Brain Dynamics Centre, Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia. m.korgaonkar@sydney.edu.au.'}, {'ForeName': 'Andrea N', 'Initials': 'AN', 'LastName': 'Goldstein-Piekarski', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, USA.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Fornito', 'Affiliation': 'Brain and Mental Health Research Hub, Turner Institute for Brain and Mental Health & Monash Biomedical Imaging, Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'Leanne M', 'Initials': 'LM', 'LastName': 'Williams', 'Affiliation': 'The Brain Dynamics Centre, Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia. leawilliams@stanford.edu.'}]",Molecular psychiatry,['10.1038/s41380-019-0574-2'] 772,29796932,"Low-phytate wholegrain bread instead of high-phytate wholegrain bread in a total diet context did not improve iron status of healthy Swedish females: a 12-week, randomized, parallel-design intervention study.","PURPOSE To investigate the effects of eating wholegrain rye bread with high or low amounts of phytate on iron status in women under free-living conditions. METHODS In this 12-week, randomized, parallel-design intervention study, 102 females were allocated into two groups, a high-phytate-bread group or a low-phytate-bread group. These two groups were administered: 200 g of blanched wholegrain rye bread/day, or 200 g dephytinized wholegrain rye bread/day. The bread was administered in addition to their habitual daily diet. Iron status biomarkers and plasma alkylresorcinols were analyzed at baseline and post-intervention. RESULTS Fifty-five females completed the study. In the high-phytate-bread group (n = 31) there was no change in any of the iron status biomarkers after 12 weeks of intervention (p > 0.05). In the low-phytate bread group (n = 24) there were significant decreases in both ferritin (mean = 12%; from 32 ± 7 to 27 ± 6 µg/L, geometric mean ± SEM, p < 0.018) and total body iron (mean = 12%; from 6.9 ± 1.4 to 5.4 ± 1.1 mg/kg, p < 0.035). Plasma alkylresorcinols indicated that most subjects complied with the intervention. CONCLUSIONS In Swedish females of reproductive age, 12 weeks of high-phytate wholegrain bread consumption had no effect on iron status. However, consumption of low-phytate wholegrain bread for 12 weeks resulted in a reduction of markers of iron status. Although single-meal studies clearly show an increase in iron bioavailability from dephytinization of cereals, medium-term consumption of reduced phytate bread under free-living conditions suggests that this strategy does not work to improve iron status in healthy women of reproductive age.",2019,In the high-phytate-bread group (n = 31) there was no change in any of the iron status biomarkers after 12 weeks of intervention (p > 0.05).,"['women under free-living conditions', '102 females', 'healthy Swedish females', 'Fifty-five females completed the study', 'healthy women of reproductive age']","['wholegrain bread', 'high-phytate-bread group or a low-phytate-bread group', 'blanched wholegrain rye bread/day, or 200', 'eating wholegrain rye bread with high or low amounts of phytate']","['iron status biomarkers', 'ferritin', 'iron bioavailability', 'total body iron', 'Iron status biomarkers and plasma alkylresorcinols', 'Plasma alkylresorcinols', 'reduction of markers of iron status']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0450382', 'cui_str': '55 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0006138', 'cui_str': 'Bread'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0086808', 'cui_str': 'Phytate'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0948786', 'cui_str': 'Blanching'}, {'cui': 'C0452545', 'cui_str': 'Rye bread (substance)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C1265611', 'cui_str': 'Quantity finding'}]","[{'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0373607', 'cui_str': 'Ferritin measurement (procedure)'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]",102.0,0.039502,In the high-phytate-bread group (n = 31) there was no change in any of the iron status biomarkers after 12 weeks of intervention (p > 0.05).,"[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hoppe', 'Affiliation': 'Department of Gastroenterology and Hepatology, Clinical Nutrition Unit, Sahlgrenska University Hospital, Gothenburg, Sweden. michael.hoppe@nutrition.gu.se.'}, {'ForeName': 'Alastair B', 'Initials': 'AB', 'LastName': 'Ross', 'Affiliation': 'Department of Biology and Biological Engineering, Food and Nutrition Science, Chalmers University of Technology, Gothenburg, Sweden.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Svelander', 'Affiliation': 'Department of Biology and Biological Engineering, Food and Nutrition Science, Chalmers University of Technology, Gothenburg, Sweden.'}, {'ForeName': 'Ann-Sofie', 'Initials': 'AS', 'LastName': 'Sandberg', 'Affiliation': 'Department of Biology and Biological Engineering, Food and Nutrition Science, Chalmers University of Technology, Gothenburg, Sweden.'}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Hulthén', 'Affiliation': 'Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.'}]",European journal of nutrition,['10.1007/s00394-018-1722-1'] 773,31728742,Encouraging Gamblers to Think Critically Using Generalised Analytical Priming is Ineffective at Reducing Gambling Biases.,"Gambling has been associated with an array of fallacious beliefs that foster risky gambling decisions. Research into other belief systems suggests that the endorsement of non-evidence based beliefs, such as the paranormal or conspiracy theories, can be reduced when people think more analytically. The purpose of this study was to explore whether an intervention designed to elicit analytical thinking was effective in altering the gambling beliefs and simulated gambling behaviour of 178 regular electronic gaming machine (EGM) gamblers (102 males, 76 female). Participants were randomly allocated to complete either an analytic or a neutral priming task, followed by completion of belief measures (erroneous and protective) and play on a simulated EGM game. Results failed to show that priming for analytical thinking changed betting on an EGM; including features of bet size, bet change, persistence and theoretical losses. Contrary to expectations, results suggest that priming analytical thinking using generalised interventions does not appear to be effective in altering peoples' simulated gambling involvement or gambling beliefs. In fact, priming people to think more critically might be counterproductive by contributing to greater positive expectations about gambling outcomes. The results further suggested that the number of times a player alters their bet is a good indicator of theoretical gambling losses and is associated with irrational gambling cognitions. Interventions designed to promote safer thinking in gamblers should be implemented with care, as results from our study suggest that encouraging critical thinking in at-risk or problem gamblers may not be effective in reducing risky gambling.",2020,"Contrary to expectations, results suggest that priming analytical thinking using generalised interventions does not appear to be effective in altering peoples' simulated gambling involvement or gambling beliefs.","['178 regular electronic gaming machine (EGM) gamblers (102 males, 76 female']","['analytic or a neutral priming task, followed by completion of belief measures (erroneous and protective) and play on a simulated EGM game']",['gambling beliefs and simulated gambling behaviour'],"[{'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0336779', 'cui_str': 'Machine, device (physical object)'}, {'cui': 'C0858352', 'cui_str': 'Gambler'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C3541364', 'cui_str': 'Erroneous component'}, {'cui': 'C0032214', 'cui_str': 'Play'}]","[{'cui': 'C0016995', 'cui_str': 'Gamblings'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}]",178.0,0.0422487,"Contrary to expectations, results suggest that priming analytical thinking using generalised interventions does not appear to be effective in altering peoples' simulated gambling involvement or gambling beliefs.","[{'ForeName': 'Tess', 'Initials': 'T', 'LastName': 'Armstrong', 'Affiliation': 'School of Human, Medical, and Applied Sciences, Central Queensland University, 44 Greenhill Road, Wayville, SA, 5034, Australia.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Rockloff', 'Affiliation': 'School of Human, Medical, and Applied Sciences, Central Queensland University, University Drive, Bundaberg, QLD, 4670, Australia.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Browne', 'Affiliation': 'School of Human, Medical, and Applied Sciences, Central Queensland University, University Drive, Bundaberg, QLD, 4670, Australia.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Blaszczynski', 'Affiliation': 'School of Psychology, The University of Sydney, M02F Mallett Street Campus, Sydney, NSW, 2006, Australia. alex.blaszczynski@sydney.edu.au.'}]",Journal of gambling studies,['10.1007/s10899-019-09910-8'] 774,31043129,Muscle damage responses to resistance exercise performed with high-load versus low-load associated with partial blood flow restriction in young women.,"The aim of this study was to compare if an acute exercise session of high-load resistance training (HL-RT, e.g. 70% of 1 repetition-maximum, 1 RM) induces a higher magnitude of muscle damage compared with a RT protocol with low-loads (e.g. 20% 1 RM) associated with partial blood flow restriction (LL-BFR), and investigate the recovery in the days after the protocols. We used an unilateral crossover research design in which 10 young women (22(2) y; 162(5) cm; 66(11) kg) performed HL-RT and LL-BFR in a randomized, counterbalanced manner with a minimum interval of 2 weeks between protocols. Indirect muscle damage markers were evaluated before and once a day for 4 days into recovery. Main results showed decreases of 8-12% at 24-48 h in maximal voluntary isometric and concentric contraction torques ( P  < 0.03), and changes in muscle architecture markers ( P  < 0.03) for HL-RT and LL-BFR, with no differences between protocols ( P  > 0.05). Moreover, delayed onset muscle soreness increased only after LL-BFR ( P  < 0.001). We conclude that an acute bout of low volume HL-RT or LL-BFR to failure resulted in edema-induced muscle swelling, but do not induce major or long-lasting decrements in muscle function and the level of soreness promoted from LL-BFR was mild.",2020,"Main results showed decreases of 8-12% at 24-48 h in maximal voluntary isometric and concentric contraction torques ( P  < 0.03), and changes in muscle architecture markers ( P  < 0.03) for HL-RT and LL-BFR, with no differences between protocols ( P  > 0.05).","['10 young women (22(2)\u2005y; 162(5)\u2005cm; 66(11)\u2005kg) performed', 'young women']","['HL-RT and LL-BFR', 'resistance exercise performed with high-load versus low-load associated with partial blood flow restriction', 'acute exercise session of high-load resistance training (HL-RT, e.g. 70% of 1 repetition-maximum, 1\u2005RM']","['Indirect muscle damage markers', 'delayed onset muscle soreness', 'maximal voluntary isometric and concentric contraction torques', 'partial blood flow restriction (LL-BFR', 'muscle architecture markers']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0042950', 'cui_str': 'Will'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}, {'cui': 'C4279937', 'cui_str': 'Acute Exercise'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0439852', 'cui_str': 'Indirect (qualifier value)'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0231528', 'cui_str': 'Muscle Pain'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0439656', 'cui_str': 'Voluntary (qualifier value)'}, {'cui': 'C0439744', 'cui_str': 'Concentric (qualifier value)'}, {'cui': 'C1140999', 'cui_str': 'Contraction (finding)'}, {'cui': 'C0376590', 'cui_str': 'Torque'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}, {'cui': 'C0042950', 'cui_str': 'Will'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0003737', 'cui_str': 'Architecture'}]",10.0,0.0559054,"Main results showed decreases of 8-12% at 24-48 h in maximal voluntary isometric and concentric contraction torques ( P  < 0.03), and changes in muscle architecture markers ( P  < 0.03) for HL-RT and LL-BFR, with no differences between protocols ( P  > 0.05).","[{'ForeName': 'Ieda Fernanda', 'Initials': 'IF', 'LastName': 'Alvarez', 'Affiliation': 'MUSCULAB - Laboratory of Neuromuscular Adaptations to Resistance Training, Department of Physical Education, Federal University of São Carlos, São Carlos, Brazil.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Damas', 'Affiliation': 'MUSCULAB - Laboratory of Neuromuscular Adaptations to Resistance Training, Department of Physical Education, Federal University of São Carlos, São Carlos, Brazil.'}, {'ForeName': 'Thaís Marina Pires de', 'Initials': 'TMP', 'LastName': 'Biazon', 'Affiliation': 'MUSCULAB - Laboratory of Neuromuscular Adaptations to Resistance Training, Department of Physical Education, Federal University of São Carlos, São Carlos, Brazil.'}, {'ForeName': 'Maiara', 'Initials': 'M', 'LastName': 'Miquelini', 'Affiliation': 'MUSCULAB - Laboratory of Neuromuscular Adaptations to Resistance Training, Department of Physical Education, Federal University of São Carlos, São Carlos, Brazil.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Doma', 'Affiliation': 'College of Healthcare Sciences, James Cook University, Townsville, Australia.'}, {'ForeName': 'Cleiton Augusto', 'Initials': 'CA', 'LastName': 'Libardi', 'Affiliation': 'MUSCULAB - Laboratory of Neuromuscular Adaptations to Resistance Training, Department of Physical Education, Federal University of São Carlos, São Carlos, Brazil.'}]",European journal of sport science,['10.1080/17461391.2019.1614680'] 775,31597536,"Improving Concussion Reporting across National College Athletic Association Divisions Using a Theory-Based, Data-Driven, Multimedia Concussion Education Intervention.","Although a base level of knowledge is needed to recognize a concussion, knowledge-focused concussion educational materials ignore multifaceted barriers to concussion reporting. We compared student-athlete concussion reporting intentions and behaviors prior to and 1 year after exposure to an intervention or control treatment. We randomly assigned 891 collegiate student-athletes from three universities (Divisions I, II, III) to either the control group (National College Athletic Association [NCAA] Concussion Fact Sheet) or intervention group (theory-based, data-driven, multimedia, simulated concussion reporting module). A final sample of 520 student-athletes (control = 253, intervention = 267, expired eligibility = 189, left university = 182) completed intentions and behaviors surveys immediately prior to and 1 year after the educational intervention, and a second survey to assess the intervention effect. We compared intentions using 2 x 2 mixed model analyses of variance (ANOVAs). Behaviors and educational intervention effect were assessed using logistic regression models (α = 0.05). The intervention group had significantly improved concussion reporting intentions at 1-year follow-up relative to the control group ( p  = 0.009), but had similar odds for behaviors. The intervention group had 2.42 times greater odds of rating the module as ""very effective,"" rather than ""not effective"" relative to the control group (95% confidence interval [CI]: 1.10,5.33). Relative to the control group, the intervention group had significantly greater odds of responding that the concussion education ""greatly improved"" rather than ""did not improve"" their knowledge (odds ratio [OR]: 2.49, 95% CI:1.25,4.96), attitudes (OR: 2.22, 95% CI: 1.23,4.03), self-efficacy (OR: 1.95,95% CI: 1.05,3.60), and intentions (OR: 1.86,95% CI: 1.03,3.35). The intervention was more effective at targeting elements of the overall sport culture in a way that substantively improved concussion reporting. We recommend use of this intervention in combination with other evidence-based educational materials.",2020,The intervention was more effective at targeting elements of the overall sport culture in a way that substantively improved concussion reporting.,"['520 student-athletes (control=253, intervention= 267, expired eligibility=189, left university=182) completed intentions and behaviors surveys immediately prior to and one year following the', '891 collegiate student-athletes from three universities (Division I, II, III) to either the']","['educational intervention', 'control group (NCAA Concussion Fact Sheet) or intervention group (theory-based, data-driven, multimedia, simulated concussion reporting module']","[' their knowledge (OR:2.49,95%CI:1.25,4.96), attitudes (OR:2.22,95%CI:1.23,4.03), self-efficacy', 'concussion reporting intentions', 'greater odds of responding that the concussion education ""greatly improved']","[{'cui': 'C4517803', 'cui_str': '520 (qualifier value)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C4517672', 'cui_str': '267'}, {'cui': 'C0205091', 'cui_str': 'Left (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C1293097', 'cui_str': 'Division - action (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0006107', 'cui_str': 'Cerebral Concussion'}, {'cui': 'C0439643', 'cui_str': 'Sheets (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0376478', 'cui_str': 'Multimedium'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}]","[{'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0006107', 'cui_str': 'Cerebral Concussion'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}]",891.0,0.0635521,The intervention was more effective at targeting elements of the overall sport culture in a way that substantively improved concussion reporting.,"[{'ForeName': 'Julianne D', 'Initials': 'JD', 'LastName': 'Schmidt', 'Affiliation': 'Department of Kinesiology, University of Georgia, Athens, Georgia.'}, {'ForeName': 'Michelle L', 'Initials': 'ML', 'LastName': 'Weber', 'Affiliation': 'Department of Kinesiology, University of Georgia, Athens, Georgia.'}, {'ForeName': 'David Welch', 'Initials': 'DW', 'LastName': 'Suggs', 'Affiliation': 'Department of Journalism, University of Georgia, Athens, Georgia.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Bierema', 'Affiliation': 'Department of Lifelong Education, Administration, & Policy, and University of Georgia, Athens, Georgia.'}, {'ForeName': 'L Stephen', 'Initials': 'LS', 'LastName': 'Miller', 'Affiliation': 'Department of Psychology, University of Georgia, Athens, Georgia.'}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Reifsteck', 'Affiliation': 'Department of University Health Center, University of Georgia, Athens, Georgia.'}, {'ForeName': 'Ron', 'Initials': 'R', 'LastName': 'Courson', 'Affiliation': 'University of Georgia Athletics Association, Sports Medicine, Athens, Georgia.'}, {'ForeName': 'Russel', 'Initials': 'R', 'LastName': 'Hoff', 'Affiliation': 'College of Nursing and Health Sciences, Valdosta State University, Valdosta, Georgia.'}, {'ForeName': 'Karli', 'Initials': 'K', 'LastName': 'Dill', 'Affiliation': 'Emory University Sports Medicine, Atlanta, Georgia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Dunham', 'Affiliation': 'Emory University Sports Medicine, Atlanta, Georgia.'}]",Journal of neurotrauma,['10.1089/neu.2019.6637'] 776,31642434,[Clinical effect of feeding with calorie-enriched formula in children with ventricular septal defect and severe pneumonia].,"OBJECTIVE To study the effect of different energy feeding patterns on the nutritional status, clinical course, and outcome of children with congenital heart disease (CHD) and severe pneumonia. METHODS A total of 43 malnourished infants, aged <6 months, who were diagnosed with ventricular septal defect and severe pneumonia and underwent surgical operation from January 1 to December 30, 2017 were enrolled. They were randomly divided into an observation group with 21 infants and a control group with 22 infants. The infants in the observation group were given calorie-enriched formula milk powder (100 kcal/100 mL) after surgery, and those in the control group were given formula milk powder with normal calories (67 kcal/100 mL). The two groups were observed for 3 months to record physical measurements, laboratory markers and nutritional risk screening results. Nutritional status was evaluated for all infants. The two groups were compared in terms of prognosis and adverse events. RESULTS There were no significant differences between the two groups in physical measurements, laboratory markers, nutritional assessment and nutritional risk screening results on admission (P>0.05). At discharge and 1 and 3 months after surgery, the control group had significantly higher degree of malnutrition and level of nutritional risk than the observation group (P<0.05). The analysis of variance with repeated measures showed significant differences in body weight, upper arm circumference, weight-for-age Z-score, height-for-age Z-score, weight-for-height Z-score, and albumin level at different time points and between different groups, and there was an interaction between group factors and time factors (P<0.05). Compared with the control group, the observation group had a significantly lower average daily intake of fluid, a significantly higher average daily intake of energy, and a significantly lower incidence rate of insufficient feeding during hospitalization (P<0.05). Compared with the control group, the observation group had significantly shorter length of hospital stay, duration of mechanical ventilation, and duration of postoperative pyrexia, as well as significantly lower hospital costs (P<0.05). No significant adverse reactions were observed in either group. CONCLUSIONS An appropriate increase in postoperative energy supply for children with CHD can improve the status of malnutrition and clinical outcome.",2019,"There were no significant differences between the two groups in physical measurements, laboratory markers, nutritional assessment and nutritional risk screening results on admission (P>0.05).","['children with ventricular septal defect and severe pneumonia', 'children with CHD', 'children with congenital heart disease (CHD) and severe pneumonia', '43 malnourished infants, aged <6 months, who were diagnosed with ventricular septal defect and severe pneumonia and underwent surgical operation from January 1 to December 30, 2017 were enrolled', '21 infants and a control group with 22 infants']","['feeding with calorie-enriched formula', 'energy feeding patterns', 'formula milk powder with normal calories', 'calorie-enriched formula milk powder']","['physical measurements, laboratory markers, nutritional assessment and nutritional risk screening results on admission (P>0.05', 'Nutritional status', 'degree of malnutrition and level of nutritional risk', 'shorter length of hospital stay, duration of mechanical ventilation, and duration of postoperative pyrexia, as well as significantly lower hospital costs', 'average daily intake of energy', 'adverse reactions', 'body weight, upper arm circumference, weight-for-age Z-score, height-for-age Z-score, weight-for-height Z-score, and albumin level', 'average daily intake of fluid']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0018818', 'cui_str': 'Intraventricular Septal Defects'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0152021', 'cui_str': 'Congenital heart disease (disorder)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C2987508', 'cui_str': 'Feeding (observable entity)'}, {'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C0015748', 'cui_str': 'Feeding Patterns'}, {'cui': 'C0452742', 'cui_str': 'Formula milk (substance)'}, {'cui': 'C0032861', 'cui_str': 'Powdered drug preparation'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}]","[{'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0162490', 'cui_str': 'Markers, Laboratory'}, {'cui': 'C0028708', 'cui_str': 'Nutritional Assessment'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0457453', 'cui_str': 'On admission (qualifier value)'}, {'cui': 'C0392209', 'cui_str': 'Nutrition Status'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0162429', 'cui_str': 'Malnutrition'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0206174', 'cui_str': 'Hospital Costs'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0446516', 'cui_str': 'Brachiums'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0424670', 'cui_str': 'Weight for height (observable entity)'}, {'cui': 'C0428519', 'cui_str': 'Albumin level - finding'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}]",2017.0,0.0262695,"There were no significant differences between the two groups in physical measurements, laboratory markers, nutritional assessment and nutritional risk screening results on admission (P>0.05).","[{'ForeName': 'Jiao-Tian', 'Initials': 'JT', 'LastName': 'Huang', 'Affiliation': ""Department of Critical Care Medicine, Children's Hospital of Hunan Province, Changsha 410007, China. 391118947@qq.com.""}, {'ForeName': 'Xiu-Lan', 'Initials': 'XL', 'LastName': 'Lu', 'Affiliation': ''}, {'ForeName': 'Zheng-Hui', 'Initials': 'ZH', 'LastName': 'Xiao', 'Affiliation': ''}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Zang', 'Affiliation': ''}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Gong', 'Affiliation': ''}, {'ForeName': 'Wu', 'Initials': 'W', 'LastName': 'Zhou', 'Affiliation': ''}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Huang', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 777,30782281,[Clinical effect of alanyl-glutamine-enriched nutritional support in the treatment of children with abdominal Henoch-Schönlein purpura].,"OBJECTIVE To study the clinical effect of alanyl-glutamine-enriched nutritional support in the treatment of children with abdominal Henoch-Schönlein purpura. METHODS Children with abdominal Henoch-Schönlein purpura who needed nutritional support were enrolled and stratified according to age, sex and the severity of disease, and were randomly divided into a control group (n=118) and an enriched nutritional support group (n=107). The control group was given nutritional support without using alanyl-glutamine, while the enriched nutritional support group was given alanyl-glutamine-enriched nutritional support. Intravenous steroids were used according to the severity of disease in both groups. Other therapies were the same in the two groups. The two groups were compared in terms of the length of hospital stay, the rate and duration of use of intravenous steroids, the recurrence rate of symptoms during hospitalization, the rate of total parenteral nutrition (TPN), the rate of weight loss and the rate of fasting for more than 5 days. All patients were followed up for 3 months after discharge to monitor the recurrence of symptoms. RESULTS There were no significant differences in the length of hospital stay, the rate of TPN and the rate of fasting for more than 5 days between the two groups (P>0.05). Compared with the enriched nutritional support group, the control group showed significant increases in the rate and duration of use of intravenous steroids, the recurrence rate of symptoms and the rate of weight loss (P<0.05). After the 3-month follow-up, all the children resumed normal diet, and the recurrence rate of digestive symptoms was less than 20% in each group. Abdominal pain was the most common symptom (83.33%, 30/36), followed by vomiting and abdominal distention. No digestive hemorrhage was observed. All the symptoms were relieved after symptomatic treatment. No significant difference was found between the two groups in the recurrence rate of digestive symptoms (P=0.693). CONCLUSIONS Alanyl-glutamine-enriched nutritional support in the treatment of children with abdominal Henoch-Schönlein purpura can reduce the use of intravenous steroids and weight loss, but without impact on the length of hospital stay and post-discharge recurrence.",2019,"No significant difference was found between the two groups in the recurrence rate of digestive symptoms (P=0.693). ","['children with abdominal Henoch-Schönlein purpura', 'Children with abdominal Henoch-Schönlein purpura who needed nutritional support were enrolled and stratified according to age, sex and the severity of disease']","['alanyl-glutamine-enriched nutritional support', 'Intravenous steroids', 'nutritional support without using alanyl-glutamine, while the enriched nutritional support group was given alanyl-glutamine-enriched nutritional support', 'control group (n=118) and an enriched nutritional support group', 'Alanyl-glutamine-enriched nutritional support']","['recurrence rate of digestive symptoms', 'Abdominal pain', 'recurrence of symptoms', 'length of hospital stay, the rate and duration of use of intravenous steroids, the recurrence rate of symptoms during hospitalization, the rate of total parenteral nutrition (TPN), the rate of weight loss and the rate of fasting for more than 5 days', 'rate and duration of use of intravenous steroids, the recurrence rate of symptoms and the rate of weight loss', 'vomiting and abdominal distention', 'length of hospital stay, the rate of TPN and the rate of fasting', 'digestive hemorrhage']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}, {'cui': 'C0034152', 'cui_str': 'Henoch Purpura'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0242739', 'cui_str': 'Nutritional Support'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0051080', 'cui_str': 'alanyl glutamine'}, {'cui': 'C0242739', 'cui_str': 'Nutritional Support'}, {'cui': 'C0563322', 'cui_str': 'Intravenous steroid injection (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0476288', 'cui_str': 'Digestive symptom (finding)'}, {'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0563322', 'cui_str': 'Intravenous steroid injection (procedure)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0030548', 'cui_str': 'Parenteral Hyperalimentation'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0000731', 'cui_str': 'Swollen abdomen (finding)'}, {'cui': 'C1869041', 'cui_str': 'Haemorrhages (SMQ)'}]",,0.0214073,"No significant difference was found between the two groups in the recurrence rate of digestive symptoms (P=0.693). ","[{'ForeName': 'Li-Jing', 'Initials': 'LJ', 'LastName': 'Xiong', 'Affiliation': ""Department of Pediatric Gastroenterology, Chengdu Women and Children's Central Hospital, Chengdu 610091, China. xxlilye@qq.com.""}, {'ForeName': 'Li-Hong', 'Initials': 'LH', 'LastName': 'Shang', 'Affiliation': ''}, {'ForeName': 'Xiao-Qin', 'Initials': 'XQ', 'LastName': 'Ou', 'Affiliation': ''}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Xiao-Li', 'Initials': 'XL', 'LastName': 'Xie', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 778,31058977,"A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection.","BACKGROUND Herpes simplex virus 2 (HSV2) causes genital herpes in >400 million persons worldwide. METHODS We conducted a randomized, double-blinded, placebo-controlled trial of a replication-defective HSV2 vaccine, HSV529. Twenty adults were enrolled in each of 3 serogroups of individuals: those negative for both HSV1 and HSV2 (HSV1-/HSV2-), those positive or negative for HSV1 and positive for HSV2 (HSV1±/HSV2+), and those positive for HSV1 and negative for HSV2 (HSV1+/HSV2-). Sixty participants received vaccine or placebo at 0, 1, and 6 months. The primary end point was the frequency of solicited local and systemic reactions to vaccination. RESULTS Eighty-nine percent of vaccinees experienced mild-to-moderate solicited injection site reactions, compared with 47% of placebo recipients (95% confidence interval [CI], 12.9%-67.6%; P = .006). Sixty-four percent of vaccinees experienced systemic reactions, compared with 53% of placebo recipients (95% CI, -17.9% to 40.2%; P = .44). Seventy-eight percent of HSV1-/HSV2- vaccine recipients had a ≥4-fold increase in neutralizing antibody titer after 3 doses of vaccine, whereas none of the participants in the other serogroups had such responses. HSV2-specific CD4+ T-cell responses were detected in 36%, 46%, and 27% of HSV1-/HSV2-, HSV1±/HSV2+, and HSV1+/HSV2- participants, respectively, 1 month after the third dose of vaccine, and CD8+ T-cell responses were detected in 14%, 8%, and 18% of participants, respectively. CONCLUSIONS HSV529 vaccine was safe and elicited neutralizing antibody and modest CD4+ T-cell responses in HSV-seronegative vaccinees. CLINICAL TRIALS REGISTRATION NCT01915212.",2019,"Sixty-four percent of vaccinees experienced systemic reactions compared with 53% of placebo recipients (p = 0.44, 95%CI -0.179, 0.402).","['Twenty adults each enrolled in three serogroups, HSV1 /HSV2 , HSV1 /HSV2 , and HSV1 /HSV2 , received', 'Adults With or Without HSV Infection', 'Herpes simplex virus 2 (HSV2) causes genital herpes in over 400 million persons worldwide']","['vaccine or placebo', 'placebo', 'HSV529 vaccine', 'HSV1 /HSV2 vaccine', 'Placebo', 'replication-defective HSV2 vaccine, HSV529']","['moderate solicited injection site reactions', 'HSV2-specific CD4+ T-cell responses', 'CD8+ T-cell responses', 'safe and elicited neutralizing antibody and modest CD4+ T-cell responses', 'systemic reactions', 'neutralizing antibody titer', 'frequency of solicited local and systemic reactions to vaccination']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0449543', 'cui_str': 'Serogroup'}, {'cui': 'C0019348', 'cui_str': 'Herpes Simplex Virus Infection'}, {'cui': 'C0042776', 'cui_str': 'Virus'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0019342', 'cui_str': 'Herpes Simplex Virus Genital Infection'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0027361', 'cui_str': 'Persons'}]","[{'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0151735', 'cui_str': 'Injection Site Adverse Event'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C1142254', 'cui_str': 'Neutralising antibodies'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]",20.0,0.700411,"Sixty-four percent of vaccinees experienced systemic reactions compared with 53% of placebo recipients (p = 0.44, 95%CI -0.179, 0.402).","[{'ForeName': 'Lesia K', 'Initials': 'LK', 'LastName': 'Dropulic', 'Affiliation': 'Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda.'}, {'ForeName': 'Makinna C', 'Initials': 'MC', 'LastName': 'Oestreich', 'Affiliation': 'Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda.'}, {'ForeName': 'Harlan L', 'Initials': 'HL', 'LastName': 'Pietz', 'Affiliation': 'Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda.'}, {'ForeName': 'Kerry J', 'Initials': 'KJ', 'LastName': 'Laing', 'Affiliation': 'Department of Medicine, School of Medicine, University of Washington.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Hunsberger', 'Affiliation': 'Biostatistics Research Branch, NIAID, NIH, Rockville.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Lumbard', 'Affiliation': 'Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, sponsored by the National Cancer Institute, NIH, Frederick, Maryland.'}, {'ForeName': 'Doreen', 'Initials': 'D', 'LastName': 'Garabedian', 'Affiliation': 'Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, sponsored by the National Cancer Institute, NIH, Frederick, Maryland.'}, {'ForeName': 'Siu Ping', 'Initials': 'SP', 'LastName': 'Turk', 'Affiliation': 'Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda.'}, {'ForeName': 'Aiying', 'Initials': 'A', 'LastName': 'Chen', 'Affiliation': 'Global Biostatistics and Programming, Pennsylvania.'}, {'ForeName': 'Ronald L', 'Initials': 'RL', 'LastName': 'Hornung', 'Affiliation': 'Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, sponsored by the National Cancer Institute, NIH, Frederick, Maryland.'}, {'ForeName': 'Chetan', 'Initials': 'C', 'LastName': 'Seshadri', 'Affiliation': 'Department of Medicine, School of Medicine, University of Washington.'}, {'ForeName': 'Malisa T', 'Initials': 'MT', 'LastName': 'Smith', 'Affiliation': 'Department of Medicine, School of Medicine, University of Washington.'}, {'ForeName': 'Nancy A', 'Initials': 'NA', 'LastName': 'Hosken', 'Affiliation': 'Department of Medicine, School of Medicine, University of Washington.'}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Phogat', 'Affiliation': 'New Vaccines Portfolio Strategy and Execution, Pennsylvania.'}, {'ForeName': 'Lee-Jah', 'Initials': 'LJ', 'LastName': 'Chang', 'Affiliation': 'Global Clinical Sciences, Sanofi Pasteur, Swiftwater, Pennsylvania.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Koelle', 'Affiliation': 'Department of Medicine, School of Medicine, University of Washington.'}, {'ForeName': 'Kening', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda.'}, {'ForeName': 'Jeffrey I', 'Initials': 'JI', 'LastName': 'Cohen', 'Affiliation': 'Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda.'}]",The Journal of infectious diseases,['10.1093/infdis/jiz225'] 779,31728715,"A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy.","Aim To compare the efficacy and safety of intermittent every other days 5-dose filgrastim with single pegfilgrastim in patients with breast cancer receiving adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy. Methods In this pilot study, Korean patients who had undergone complete resection for breast cancer and scheduled for adjuvant TAC chemotherapy were enrolled. Patients were randomized to receive either intermittent 5 doses of filgrastim (5 mcg/kg/day) or once-a-cycle pegfilgrastim (6 mg) as primary prophylaxis during the first three cycles of the TAC chemotherapy. Absolute neutrophil count (ANC) was analyzed as well. Results A total of 22 patients were randomly and equally divided into filgrastim or pegfilgrastim arms. Febrile neutropenia (FN) occurred in 1 patient in the pegfilgrastim arm (1 of 33 cycles) and none in the filgrastim arm. G3 neutropenia occurred in 1 patient (1 of 33 cycles) in the filgrastim arm and 2 patients (4 of 33 cycles) in the pegfilgrastim arm (P = 0.476). G4 neutropenia occurred in 11 patients (28 of 33 cycles) in the filgrastim arm and 9 patients (18 of 33 cycles) in the pegfilgrastim arm (P = 0.476). Except for on day 9 in cycle 3, there was no significant difference between the two groups in terms of ANC. Conclusion We observed no significant differences between the two methods of prophylaxis in terms of FN and G3/4 neutropenia incidence in patients receiving adjuvant TAC chemotherapy. Intermittent every other days 5-dose filgrastim may be available alternative to pegfilgrastim.",2020,"Except for on day 9 in cycle 3, there was no significant difference between the two groups in terms of ANC.","['patients with breast cancer receiving adjuvant', '22 patients', 'breast Cancer patients receiving', 'patients receiving adjuvant TAC chemotherapy', 'Korean patients who had undergone complete resection for breast cancer and scheduled for adjuvant TAC chemotherapy were enrolled']","['filgrastim or pegfilgrastim', 'single Pegfilgrastim', 'adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy', 'filgrastim with single pegfilgrastim', 'pegfilgrastim', 'TAC chemotherapy', 'filgrastim', 'Filgrastim', 'filgrastim (5 mcg/kg/day) or once-a-cycle pegfilgrastim', 'docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy']","['G3 neutropenia', 'efficacy and safety', 'Febrile neutropenia (FN', 'Absolute neutrophil count (ANC', 'G4 neutropenia']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C3489891', 'cui_str': 'TAC(a)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1556095', 'cui_str': 'Koreans'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}]","[{'cui': 'C0210630', 'cui_str': 'Filgrastim'}, {'cui': 'C1136535', 'cui_str': 'pegfilgrastim'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C3489891', 'cui_str': 'TAC(a)'}, {'cui': 'C1532561', 'cui_str': 'ug/kg/day'}]","[{'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0746883', 'cui_str': 'Febrile Neutropenia'}, {'cui': 'C0948762', 'cui_str': 'Absolute neutrophil count'}]",,0.0267571,"Except for on day 9 in cycle 3, there was no significant difference between the two groups in terms of ANC.","[{'ForeName': 'Byeong Seok', 'Initials': 'BS', 'LastName': 'Sohn', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.'}, {'ForeName': 'Jae Ho', 'Initials': 'JH', 'LastName': 'Jeong', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.'}, {'ForeName': 'Jin-Hee', 'Initials': 'JH', 'LastName': 'Ahn', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.'}, {'ForeName': 'Kyung Hae', 'Initials': 'KH', 'LastName': 'Jung', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.'}, {'ForeName': 'Jeong Eun', 'Initials': 'JE', 'LastName': 'Kim', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.'}, {'ForeName': 'Joo Hyuk', 'Initials': 'JH', 'LastName': 'Sohn', 'Affiliation': 'Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Su-Jin', 'Initials': 'SJ', 'LastName': 'Koh', 'Affiliation': 'Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.'}, {'ForeName': 'Jae Hong', 'Initials': 'JH', 'LastName': 'Seo', 'Affiliation': 'Division of Medical Oncology, Department of Internal Medicine, Korea University Guro Hospital, Korea University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Keun Seok', 'Initials': 'KS', 'LastName': 'Lee', 'Affiliation': 'Center for Breast Cancer, Research Institute and Hospital, National Cancer Center, Goyang, South Korea.'}, {'ForeName': 'Sung-Bae', 'Initials': 'SB', 'LastName': 'Kim', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. sbkim3@amc.seoul.kr.'}]",Investigational new drugs,['10.1007/s10637-019-00863-8'] 780,32117242,Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts.,"RituxiCAN-C4 combined an open-labeled randomized controlled trial (RCT) in 7 UK centers to assess whether rituximab could stabilize kidney function in patients with chronic rejection, with an exploratory analysis of how B cell-depletion influenced T cell anti-donor responses relative to outcome. Between January 2007 and March 2015, 59 recruits were enrolled after screening, 23 of whom consented to the embedded RCT. Recruitment was halted when in a pre-specified per protocol interim analysis, the RCT was discovered to be significantly underpowered. This report therefore focuses on the exploratory analysis, in which we confirmed that when B cells promoted CD4+ anti-donor IFNγ production assessed by ELISPOT, this associated with inferior clinical outcome; these patterns were inhibited by optimized immunosuppression but not rituximab. B cell suppression of IFNγ production, which associated with number of transitional B cells and correlated with slower declines in kidney function was abolished by rituximab, which depleted transitional B cells for prolonged periods. We conclude that in this patient population, optimized immunosuppression but not rituximab promotes anti-donor alloresponses associated with favorable outcomes. Clinical Trial Registration: Registered with EudraCT (2006-002330-38) and www.ClinicalTrials.gov, identifier: NCT00476164.",2020,"B cell suppression of IFNγ production, which associated with number of transitional B cells and correlated with slower declines in kidney function was abolished by rituximab, which depleted transitional B cells for prolonged periods.","['Between January 2007 and March 2015, 59 recruits were enrolled after screening, 23 of whom consented to the embedded RCT', 'Patients', 'patients with chronic rejection', '2006-002330-38) and www']","['Optimized Immunosuppression (Including Rituximab', 'rituximab', 'EudraCT', 'RituxiCAN-C4 combined']","['CD4+ anti-donor IFNγ production', 'kidney function', 'number of transitional B cells']","[{'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0035015', 'cui_str': 'Rejection'}]","[{'cui': 'C0021080', 'cui_str': 'Immunosuppression (Physiology)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0033268'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1512631', 'cui_str': 'Transitional B-Cells'}]",,0.0792756,"B cell suppression of IFNγ production, which associated with number of transitional B cells and correlated with slower declines in kidney function was abolished by rituximab, which depleted transitional B cells for prolonged periods.","[{'ForeName': 'Kin Yee', 'Initials': 'KY', 'LastName': 'Shiu', 'Affiliation': ""Department of Inflammation Biology, MRC Centre for Transplantation, Guy's Hospital, King's College London, London, United Kingdom.""}, {'ForeName': 'Dominic', 'Initials': 'D', 'LastName': 'Stringer', 'Affiliation': ""Biostatistics and Health Informatics, The Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'McLaughlin', 'Affiliation': ""Department of Inflammation Biology, MRC Centre for Transplantation, Guy's Hospital, King's College London, London, United Kingdom.""}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Shaw', 'Affiliation': 'Viapath Analytics LLP, London, United Kingdom.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Brookes', 'Affiliation': 'Histocompatibility and Immunogenetics, Imperial College Healthcare NHS Trust, London, United Kingdom.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Burton', 'Affiliation': ""Department of Inflammation Biology, MRC Centre for Transplantation, Guy's Hospital, King's College London, London, United Kingdom.""}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Wilkinson', 'Affiliation': ""Department of Inflammation Biology, MRC Centre for Transplantation, Guy's Hospital, King's College London, London, United Kingdom.""}, {'ForeName': 'Harriet', 'Initials': 'H', 'LastName': 'Douthwaite', 'Affiliation': ""Department of Inflammation Biology, MRC Centre for Transplantation, Guy's Hospital, King's College London, London, United Kingdom.""}, {'ForeName': 'Tjir-Li', 'Initials': 'TL', 'LastName': 'Tsui', 'Affiliation': ""Department of Inflammation Biology, MRC Centre for Transplantation, Guy's Hospital, King's College London, London, United Kingdom.""}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Mclean', 'Affiliation': 'Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, United Kingdom.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Hilton', 'Affiliation': ""Department of Nephrology and Transplantation, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom.""}, {'ForeName': 'Sian', 'Initials': 'S', 'LastName': 'Griffin', 'Affiliation': 'Department of Nephrology, University Hospital of Wales, Cardiff, United Kingdom.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Geddes', 'Affiliation': 'Renal Unit, Western Infirmary, NHS Greater Glasgow and Clyde Trust, Glasgow, United Kingdom.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Ball', 'Affiliation': 'Department of Nephrology, University Hospital Birmingham, Birmingham, United Kingdom.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Baker', 'Affiliation': ""Renal Unit, St. James's University Hospital, Leeds, United Kingdom.""}, {'ForeName': 'Candice', 'Initials': 'C', 'LastName': 'Roufosse', 'Affiliation': 'Histocompatibility and Immunogenetics, Imperial College Healthcare NHS Trust, London, United Kingdom.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Horsfield', 'Affiliation': ""Department of Histopathology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom.""}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Dorling', 'Affiliation': ""Department of Inflammation Biology, MRC Centre for Transplantation, Guy's Hospital, King's College London, London, United Kingdom.""}]",Frontiers in immunology,['10.3389/fimmu.2020.00079'] 781,31642426,[Clinical effect of double filtration plasmapheresis combined with glucocorticoid and immunosuppressant in treatment of children with severe Henoch-Schönlein purpura nephritis].,"OBJECTIVE To study the clinical effect and safety of double filtration plasmapheresis (DFPP) combined with double pulse therapy with methylprednisolone (MP) and cyclophosphamide (CTX) in the treatment of children with severe Henoch-Schönlein purpura nephritis (HSPN). METHODS A total of 60 children with severe HSPN who were admitted to the hospital from January 2014 to March 2018 were enrolled and were randomly divided into an observation group and a control group (n=30 each). In addition to routine treatment, the children in the control group were given MP+CTX pulse therapy. Those in the observation group were given DFPP treatment in addition to the treatment in the control group, with three courses of treatment in total. After three courses of treatment, the two groups were compared in terms of 24-hour urinary protein, urinary microproteins, renal function parameters, adverse reactions, and clinical outcome. RESULTS After three courses of treatment, the observation group had significantly greater reductions in 24-hour urinary protein, urinary albumin, urinary immunoglobulin G, urinary β2-microglobulin, serum creatinine, and blood urea nitrogen than the control group (P<0.05). After the treatment ended, the observation group had a significantly shorter time to achieve remission than the control group (P<0.05). No serious adverse reactions, such as hemorrhagic cystitis, thrombocytopenia, and hemolysis, were observed, and there was no significant difference in the overall incidence rate of adverse reactions between the two groups (P>0.05). CONCLUSIONS Compared with MP+CTX pulse therapy alone in the treatment of severe HSPN in children, DFPP combined with MP+CTX pulse therapy can further alleviate renal injury and improve clinical outcome and does not increase the incidence rate of adverse reactions.",2019,"No serious adverse reactions, such as hemorrhagic cystitis, thrombocytopenia, and hemolysis, were observed, and there was no significant difference in the overall incidence rate of adverse reactions between the two groups (P>0.05). ","['60 children with severe HSPN who were admitted to the hospital from January 2014 to March 2018 were enrolled', 'children with severe Henoch-Schönlein purpura nephritis', 'children with severe Henoch-Schönlein purpura nephritis (HSPN']","['double filtration plasmapheresis combined with glucocorticoid and immunosuppressant', 'DFPP', 'MP+CTX pulse therapy', 'double filtration plasmapheresis (DFPP) combined with double pulse therapy with methylprednisolone (MP) and cyclophosphamide (CTX']","['hemorrhagic cystitis, thrombocytopenia, and hemolysis', 'shorter time to achieve remission', '24-hour urinary protein, urinary albumin, urinary immunoglobulin G, urinary β2-microglobulin, serum creatinine, and blood urea nitrogen', '24-hour urinary protein, urinary microproteins, renal function parameters, adverse reactions, and clinical outcome', 'incidence rate of adverse reactions', 'overall incidence rate of adverse reactions', 'serious adverse reactions']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0034152', 'cui_str': 'Henoch Purpura'}, {'cui': 'C0027697', 'cui_str': 'Nephritis'}]","[{'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0016107', 'cui_str': 'Filtration - action'}, {'cui': 'C0032134', 'cui_str': 'Plasmapheresis'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C3540778', 'cui_str': 'Glucocorticoids'}, {'cui': 'C0021081', 'cui_str': 'Immunosuppressants'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0232120', 'cui_str': 'Double pulse (finding)'}, {'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}]","[{'cui': 'C0085692', 'cui_str': 'Hemorrhagic cystitis (disorder)'}, {'cui': 'C0040034', 'cui_str': 'Thrombopenia'}, {'cui': 'C2937287', 'cui_str': 'Hemolysis (observable entity)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0202087', 'cui_str': 'Immunoglobulin G measurement (procedure)'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0600137', 'cui_str': 'Blood urea nitrogen (substance)'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",60.0,0.0226708,"No serious adverse reactions, such as hemorrhagic cystitis, thrombocytopenia, and hemolysis, were observed, and there was no significant difference in the overall incidence rate of adverse reactions between the two groups (P>0.05). ","[{'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Liu', 'Affiliation': 'Department of Pediatrics, Harrison International Peace Hospital, Hengshui, Hebei 053000, China. kwlpsydbyly@163.com.'}, {'ForeName': 'Zhong-Zheng', 'Initials': 'ZZ', 'LastName': 'Ma', 'Affiliation': ''}, {'ForeName': 'Hui-Fang', 'Initials': 'HF', 'LastName': 'Yan', 'Affiliation': ''}, {'ForeName': 'Qiong', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Xiao-Qian', 'Initials': 'XQ', 'LastName': 'Lyu', 'Affiliation': ''}, {'ForeName': 'Wei-Li', 'Initials': 'WL', 'LastName': 'Kang', 'Affiliation': ''}, {'ForeName': 'Zhan-Ru', 'Initials': 'ZR', 'LastName': 'Yin', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 782,31437596,Reply to: Ultrasound-guided erector spinae plane block versus oblique subcostal transversus abdominis plane block for postoperative analgesia of adult patients undergoing laparoscopic cholecystectomy: Randomized controlled trial.,,2020,,['adult patients undergoing laparoscopic cholecystectomy'],['Ultrasound-guided erector spinae plane block versus oblique subcostal transversus abdominis plane block'],[],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0162522', 'cui_str': 'Cholecystectomy, Celioscopic'}]","[{'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0205315', 'cui_str': 'Oblique (qualifier value)'}, {'cui': 'C0442184', 'cui_str': 'Subcostal (qualifier value)'}]",[],,0.157027,,"[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kristensen', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Zealand University Hospital, University of Copenhagen, Sygehusvej 10, 4000 Roskilde, Denmark.'}, {'ForeName': 'Martin V', 'Initials': 'MV', 'LastName': 'Nielsen', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Zealand University Hospital, University of Copenhagen, Sygehusvej 10, 4000 Roskilde, Denmark.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Børglum', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Zealand University Hospital, University of Copenhagen, Sygehusvej 10, 4000 Roskilde, Denmark. Electronic address: jens.borglum@gmail.com.'}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2019.08.011'] 783,29718418,The Effectiveness of Dry Needling and Exercise Therapy in Patients with Dizziness Caused By Cervical Myofascial Pain Syndrome; Prospective Randomized Clinical Study.,"Objective The aim of this study is to compare the effectiveness of dry needling therapy combined with exercise and exercise treatment alone for alleviating the dizziness caused by cervical myofascial pain syndrome. Design This was a prospective randomized clinical study that included 61 women who had dizziness and myofascial trigger points on the neck muscles. The patients were randomized into a dry needling + exercise group (N = 31) and an exercise only group (N = 30). Results The mean age of the patients (±SD) was 38.4 ± 8.3 years. The intragroup comparisons of the severity of neck pain, algometric measurement, number of dizziness attacks per week, severity of the dizziness, fall index, and the Dizziness Handicap Inventory were improved in both groups at the first and fourth months (P < 0.05). The intergroup comparisons of the severity of neck pain, algometric measurement, number of dizziness attacks per week, the severity of the dizziness, and the Dizziness Handicap Inventory were more improved in the dry needling + exercise group at the first or fourth month compared with their inital assessments (P < 0.05). There was no diffence in fall index scores between the groups (P > 0.05). Conclusions Both dry needling + exercise therapy and exercise therapy alone were effective in treating dizziness caused by cervical myofascial pain syndrome. However, dry needling + exercise treatment was superior to exercise treatment alone.",2019,"There was no diffence in fall index scores between the groups (P > 0.05). ","['By Cervical Myofascial Pain Syndrome', '61 women who had dizziness and myofascial trigger points on the neck muscles', 'cervical myofascial pain syndrome', 'The mean age of the patients (±SD) was 38.4\u2009±\u20098.3\u2009years', 'Patients with Dizziness Caused']","['dry needling\u2009+\u2009exercise group (N\u2009=\u200931) and an exercise only group (N\u2009=\u200930', 'Dry Needling and Exercise Therapy', 'dry needling therapy combined with exercise and exercise treatment alone', 'dry needling\u2009+\u2009exercise therapy and exercise therapy alone']","['fall index scores', 'severity of neck pain, algometric measurement, number of dizziness attacks per week, the severity of the dizziness, and the Dizziness Handicap Inventory', 'dizziness', 'severity of neck pain, algometric measurement, number of dizziness attacks per week, severity of the dizziness, fall index, and the Dizziness Handicap Inventory']","[{'cui': 'C0205064', 'cui_str': 'Cervical (qualifier value)'}, {'cui': 'C0027073', 'cui_str': 'Myofascial Pain Syndromes'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0458343', 'cui_str': 'Trigger point (body structure)'}, {'cui': 'C0027532', 'cui_str': 'Neck Muscles'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}]","[{'cui': 'C0394648', 'cui_str': 'Dry needle acupuncture (procedure)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0452240', 'cui_str': 'Rehabilitation Exercise'}, {'cui': 'C0205222', 'cui_str': 'Dry (qualifier value)'}, {'cui': 'C0398296', 'cui_str': 'Cannulation of vascular fistula, graft or prosthetic device (procedure)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0007859', 'cui_str': 'Neck Ache'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C1304680', 'cui_str': 'Attack (finding)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0018576', 'cui_str': 'Handicapped'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",61.0,0.020923,"There was no diffence in fall index scores between the groups (P > 0.05). ","[{'ForeName': 'Tugba', 'Initials': 'T', 'LastName': 'Aydin', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Istanbul Medical Faculty, Istanbul, Turkey.'}, {'ForeName': 'Bahar', 'Initials': 'B', 'LastName': 'Dernek', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Istanbul Medical Faculty, Istanbul, Turkey.'}, {'ForeName': 'Tülin', 'Initials': 'T', 'LastName': 'Sentürk Ege', 'Affiliation': 'Department of Otolaryngology, Bagcilar Education and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Ayse', 'Initials': 'A', 'LastName': 'Karan', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Istanbul Medical Faculty, Istanbul, Turkey.'}, {'ForeName': 'Cihan', 'Initials': 'C', 'LastName': 'Aksoy', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Istanbul Medical Faculty, Istanbul, Turkey.'}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pny072'] 784,31714309,Prophylaxis of Wound Infections-antibiotics in Renal Donation (POWAR): A UK Multicentre Double Blind Placebo Controlled Randomised Trial.,"BACKGROUND Postoperative infection after hand-assisted laparoscopic donor nephrectomy (HALDN) confers significant morbidity to a healthy patient group. Current UK guidelines cite a lack of evidence for routine antibiotic prophylaxis. This trial assessed if a single preoperative antibiotic dose could reduce post HALDN infections. METHODS Eligible donors were randomly and blindly allocated to preoperative single-dose intravenous co-amoxiclav or saline. The primary composite endpoint was clinical evidence of any postoperative infection at 30 days, including surgical site infection (SSI), urinary tract infection (UTI), and lower respiratory tract infection (LRTI). FINDINGS In all, 293 participants underwent HALDN (148 antibiotic arm and 145 placebo arm). Among them, 99% (291/293) completed follow-up. The total infection rate was 40.7% (59/145) in the placebo group and 23% (34 of 148) in the antibiotic group (P = 0.001). Superficial SSIs were 20.7% (30/145 patients) in the placebo group versus 10.1% (15/148 patients) in the antibiotic group (P = 0.012). LRTIs were 9% (13/145) in the placebo group and 3.4% (5/148) in the antibiotic group (P = 0.046). UTIs were 4.1% (6/145) in the placebo group and 3.4% (5/148) in the antibiotic group (P = 0.72).Antibiotic prophylaxis conferred a 17.7% (95% confidence interval 7.2%-28.1%), absolute risk reduction in developing postoperative infection, with 6 donors requiring treatment to prevent 1 infection. INTERPRETATION Single-dose preoperative antibiotic prophylaxis dramatically reduces post-HALDN infection rates, mainly impacting SSIs and LRTIs.",2020,The total infection rate was 40.7% (59/145) in the placebo group and 23% (34 of 148) in the antibiotic group (P = 0.001).,"['healthy patient group', 'Eligible donors', '293 participants underwent HALDN (148 antibiotic arm and 145 placebo arm', 'Renal Donation (POWAR']","['hand-assisted laparoscopic donor nephrectomy (HALDN', 'Placebo', 'preoperative single-dose intravenous co-amoxiclav or saline', 'placebo']","['clinical evidence of any postoperative infection at 30 days, including surgical site infection (SSI), urinary tract infection (UTI), and lower respiratory tract infection (LRTI', 'LRTIs', 'Superficial SSIs', 'total infection rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C4517577', 'cui_str': '145'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4049936', 'cui_str': 'Donation'}]","[{'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0411257', 'cui_str': 'Donor nephrectomy (procedure)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0054066', 'cui_str': 'Amoxicillin / Clavulanate'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0332120', 'cui_str': 'Evidence of (contextual qualifier) (qualifier value)'}, {'cui': 'C0392618', 'cui_str': 'Postoperative infection (disorder)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0038941', 'cui_str': 'Postoperative Wound Infection'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0035243', 'cui_str': 'Infections, Respiratory'}, {'cui': 'C0149725', 'cui_str': 'Lower respiratory tract infection (disorder)'}, {'cui': 'C0205124', 'cui_str': 'Superficial (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}]",293.0,0.709113,The total infection rate was 40.7% (59/145) in the placebo group and 23% (34 of 148) in the antibiotic group (P = 0.001).,"[{'ForeName': 'Zubir', 'Initials': 'Z', 'LastName': 'Ahmed', 'Affiliation': ""Department of Transplantation, Guy's & St Thomas' NHS Foundation Trust, King's College, London, UK.""}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Uwechue', 'Affiliation': ""Department of Transplantation, Guy's & St Thomas' NHS Foundation Trust, King's College, London, UK.""}, {'ForeName': 'Pankaj', 'Initials': 'P', 'LastName': 'Chandak', 'Affiliation': ""Department of Transplantation, Guy's & St Thomas' NHS Foundation Trust, King's College, London, UK.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'van Dellen', 'Affiliation': 'Dept of Renal and Pancreas Transplantation, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Barwell', 'Affiliation': 'Renal Transplant Unit, Derriford Hospital, Plymouth Hospitals NHS Trust, Plymouth, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Heap', 'Affiliation': ""Renal Transplant Unit, St. George's Hospital, London, UK.""}, {'ForeName': 'Laszlo', 'Initials': 'L', 'LastName': 'Szabo', 'Affiliation': ""Department of Microbiology and Infection, Guy's & St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Hemsley', 'Affiliation': 'Department of Nephrology & Transplant Surgery, University Hospital of Wales, Cardiff & Vale University Health Board, Cardiff, UK.'}, {'ForeName': 'Jonathon', 'Initials': 'J', 'LastName': 'Olsburgh', 'Affiliation': ""Department of Transplantation, Guy's & St Thomas' NHS Foundation Trust, King's College, London, UK.""}, {'ForeName': 'Nicos', 'Initials': 'N', 'LastName': 'Kessaris', 'Affiliation': ""Department of Transplantation, Guy's & St Thomas' NHS Foundation Trust, King's College, London, UK.""}, {'ForeName': 'Nizam', 'Initials': 'N', 'LastName': 'Mamode', 'Affiliation': ""Department of Transplantation, Guy's & St Thomas' NHS Foundation Trust, King's College, London, UK.""}]",Annals of surgery,['10.1097/SLA.0000000000003666'] 785,30907345,[Clinical effect of psychological and behavioral intervention combined with biofeedback in the treatment of preschool children with attention deficit hyperactivity disorder].,"OBJECTIVE To study the clinical effect of psychological and behavioral intervention combined with biofeedback in the treatment of preschool children with attention deficit hyperactivity disorder (ADHD). METHODS Sixty children each with inattentive, hyperactive/impulsive or combined type ADHD were enrolled. According to the intervention measure, they were randomly divided into 4 groups: control, psychological and behavioral intervention, biofeedback treatment and comprehensive treatment (psychological and behavioral intervention + biofeedback). Attention concentration time and impulse/hyperactivity and hyperactivity index scores of the Conners Parent Symptom Questionnaire (PSQ) were evaluated after 4 months of treatment. RESULTS The attention concentration time increased in all types children with ADHD after psychological and behavioral intervention, biofeedback treatment or comprehensive treatment (P<0.05). In children with inattentive ADHD, hyperactive/impulsive ADHD or combined-type ADHD, biofeedback or comprehensive treatment reduced the impulse/hyperactivity index score (P<0.05). In children with inattentive or combined-type ADHD, psychological and behavioral intervention or comprehensive treatment reduced the hyperactivity index score (P<0.05). In children with hyperactive/impulsive ADHD, biofeedback treatment, psychological and behavioral intervention or comprehensive treatment reduced the hyperactivity index score (P<0.05). CONCLUSIONS In children with ADHD, psychological and behavioral intervention combined with biofeedback treatment can improve the attention concentration and impulsive/hyperactive and hyperactive symptoms. The treatment strategies are slightly different for children with different types of ADHD.",2019,"The attention concentration time increased in all types children with ADHD after psychological and behavioral intervention, biofeedback treatment or comprehensive treatment (P<0.05).","['preschool children with attention deficit hyperactivity disorder (ADHD', 'children with different types of ADHD', 'preschool children with attention deficit hyperactivity disorder', 'children with hyperactive/impulsive ADHD', 'Sixty children each with inattentive, hyperactive/impulsive or combined type ADHD were enrolled']","['control, psychological and behavioral intervention, biofeedback treatment and comprehensive treatment (psychological and behavioral intervention\u2009+\u2009biofeedback', 'psychological and behavioral intervention combined with biofeedback']","['attention concentration time', 'hyperactivity index score', 'attention concentration and impulsive/hyperactive and hyperactive symptoms', 'Attention concentration time and impulse/hyperactivity and hyperactivity index scores of the Conners Parent Symptom Questionnaire (PSQ', 'impulse/hyperactivity index score']","[{'cui': 'C0008100', 'cui_str': 'Child, Preschool'}, {'cui': 'C1263846', 'cui_str': 'ADDH'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0424295', 'cui_str': 'Increased purposeful goal-directed activity'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0678663', 'cui_str': 'Biofeedback, function (observable entity)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0424295', 'cui_str': 'Increased purposeful goal-directed activity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0443235', 'cui_str': 'Impulse (qualifier value)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",60.0,0.020021,"The attention concentration time increased in all types children with ADHD after psychological and behavioral intervention, biofeedback treatment or comprehensive treatment (P<0.05).","[{'ForeName': 'Xin-Xin', 'Initials': 'XX', 'LastName': 'Huang', 'Affiliation': ""Department of Health Care, Fujian Provincial Maternity and Children's Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou 350001, China. eve1019@126.com.""}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Ou', 'Affiliation': ''}, {'ForeName': 'Qin-Fang', 'Initials': 'QF', 'LastName': 'Qian', 'Affiliation': ''}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Shi-Wei', 'Initials': 'SW', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Yan-Xia', 'Initials': 'YX', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Shan', 'Initials': 'S', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Zhang-Qiong', 'Initials': 'ZQ', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Yan-Qin', 'Initials': 'YQ', 'LastName': 'Xie', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 786,30926451,Self-learning training versus instructor-led training for basic life support: A cluster randomised trial.,"AIM To compare the effectiveness of two basic life support (BLS) training interventions. METHODS This experimental trial enrolled 1301 lay people in BLS training. The participants were cluster randomised to either self-learning training or to traditional instructor-led training. Both groups used the Mini-Anne Kit (Laerdal Medical, Stavanger, Norway) and standardised film instructions. After training, the participants practical skills were measured on a Resusci Anne manikin and an AED trainer with the PC SkillReporting system (Laerdal Medical, Stavanger, Norway). The primary outcome was the total score from the modified Cardiff Test of basic life support with automated external defibrillation (19-70 points), six months after training. The secondary outcomes were total score directly after training and quality of individual variables, self-assessed knowledge, confidence and willingness to act, directly and six months after training. RESULTS For primary outcome six months after training there was no statistically significant difference (p = 0.44) between the total score for the self-learning group (n = 670; median 59, IQR 55-62) compared with the instructor-led group (n = 561; median 59, IQR 55-63). The instructor-led training resulted in a statistically significant higher total score (median 61 versus 59, p < 0.0001), self-assessed knowledge and willingness to act, directly after training (secondary outcomes) compared with the self-learning training. CONCLUSIONS There was no statistically significant difference in practical skills or willingness to act when comparing self-learning training with instructor-led training six months after training in BLS. However, directly after the intervention, practical skills were better when the training was led by an instructor.",2019,There was no statistically significant difference in practical skills or willingness to act when comparing self-learning training with instructor-led training six months after training in BLS.,['1301 lay people in BLS training'],"['Self-learning training versus instructor-led training', 'two basic life support (BLS) training interventions', 'Mini-Anne Kit (Laerdal Medical, Stavanger, Norway) and standardised film instructions', 'self-learning training or to traditional instructor-led training']","['total score directly after training and quality of individual variables, self-assessed knowledge, confidence and willingness to act, directly and six months after training', 'total score from the modified Cardiff Test of basic life support with automated external defibrillation', 'total score']","[{'cui': 'C0600261', 'cui_str': 'Lying'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0556993', 'cui_str': 'Instructor (occupation)'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0085873', 'cui_str': 'Basic life support (procedure)'}, {'cui': 'C0445542', 'cui_str': 'Mini (qualifier value)'}, {'cui': 'C1690540', 'cui_str': 'Kit'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0028423', 'cui_str': 'Kingdom of Norway'}, {'cui': 'C4319646', 'cui_str': 'Film'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0237529', 'cui_str': 'Self Confidence'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0085873', 'cui_str': 'Basic life support (procedure)'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0013778', 'cui_str': 'Electrical Cardioversion'}]",1301.0,0.0754113,There was no statistically significant difference in practical skills or willingness to act when comparing self-learning training with instructor-led training six months after training in BLS.,"[{'ForeName': 'Helene', 'Initials': 'H', 'LastName': 'Bylow', 'Affiliation': 'Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. Electronic address: helene.bylow@gu.se.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Karlsson', 'Affiliation': 'Health Metrics Unit, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Claesson', 'Affiliation': 'Department of Medicine, Centre for Resuscitation Science, Karolinska Institute, Stockholm, Sweden.'}, {'ForeName': 'Margret', 'Initials': 'M', 'LastName': 'Lepp', 'Affiliation': 'Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden; Østfold University College, Halden, Norway; School of Nursing and Midwifery, Griffith University, Australia.'}, {'ForeName': 'Jonny', 'Initials': 'J', 'LastName': 'Lindqvist', 'Affiliation': 'Centre of Registers Västra Götaland, Gothenburg, Sweden.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Herlitz', 'Affiliation': 'Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Centre of Registers Västra Götaland, Gothenburg, Sweden; Prehospen-Centre of Prehospital Research, Faculty of Caring Science, Work Life and Social Welfare, University of Borås, Sweden.'}]",Resuscitation,['10.1016/j.resuscitation.2019.03.026'] 787,29602956,Effects of vitamin D supplementation on FGF23: a randomized-controlled trial.,"PURPOSE Fibroblast growth factor-23 (FGF23) is critical for phosphate homeostasis. Considering the high prevalence of vitamin D deficiency and the association of FGF23 with adverse outcomes, we investigated effects of vitamin D3 supplementation on FGF23 concentrations. METHODS This is a post-hoc analysis of the Styrian Vitamin D Hypertension trial, a single-center, double-blind, randomized, placebo-controlled trial, conducted from 2011 to 2014 at the Medical University of Graz, Austria. Two hundred subjects with 25(OH)D concentrations < 30 ng/mL and arterial hypertension were randomized to receive either 2800 IU of vitamin D3 daily or placebo over 8 weeks. Primary outcome was the between-group difference in FGF23 levels at study end while adjusting for baseline values. RESULTS Overall, 181 participants (mean ± standard deviation age, 60.1 ± 11.3; 48% women) with available c-term FGF23 concentrations were considered for the present analysis. Mean treatment duration was 54 ± 10 days in the vitamin D3 group and 54 ± 9 days in the placebo group. At baseline, FGF23 was significantly correlated with serum phosphate (r = 0.135; p = 0.002). Vitamin D3 supplementation had no significant effect on FGF23 in the entire cohort (mean treatment effect 0.374 pmol/L; 95% confidence interval - 0.024 to 0.772 pmol/L; p = 0.065), but increased FGF23 concentrations in subgroups with baseline 25(OH)D concentrations below 20 ng/mL (n = 70; mean treatment effect 0.973 pmol/L; 95% confidence interval - 0.032 to 1.979 pmol/L; p = 0.019) and 16 ng/mL (n = 40; mean treatment effect 0.593 pmol/L; 95% confidence interval 0.076 to 1.109; p = 0.022). CONCLUSIONS Vitamin D3 supplementation had no significant effect on FGF23 in the entire study cohort. We did, however, observe an increase of FGF23 concentrations in subgroups with low baseline 25(OH)D.",2019,"Vitamin D3 supplementation had no significant effect on FGF23 in the entire cohort (mean treatment effect 0.374 pmol/L; 95% confidence interval - 0.024 to 0.772 pmol/L; p = 0.065), but increased FGF23 concentrations in subgroups with baseline 25(OH)D concentrations below 20 ","['Two hundred subjects with 25(OH)D concentrations\u2009<\u200930\xa0ng/mL and arterial hypertension', '181 participants (mean\u2009±\u2009standard deviation age, 60.1\u2009±\u200911.3; 48% women) with available c-term FGF23 concentrations', '2011 to 2014\xa0at the Medical University of Graz, Austria', 'subgroups with low baseline 25(OH)D']","['vitamin D supplementation', 'placebo', 'vitamin D3 daily or placebo', 'Vitamin D3 supplementation', 'vitamin D3 supplementation', 'vitamin D3']","['FGF23 concentrations', 'serum phosphate', 'FGF23 levels', 'FGF23']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0004348', 'cui_str': 'Austria'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}]","[{'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3265062', 'cui_str': 'vitamin D3'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0036820', 'cui_str': 'Serum phosphate'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",200.0,0.765831,"Vitamin D3 supplementation had no significant effect on FGF23 in the entire cohort (mean treatment effect 0.374 pmol/L; 95% confidence interval - 0.024 to 0.772 pmol/L; p = 0.065), but increased FGF23 concentrations in subgroups with baseline 25(OH)D concentrations below 20 ","[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Trummer', 'Affiliation': 'Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria. christian.trummer@medunigraz.at.'}, {'ForeName': 'Verena', 'Initials': 'V', 'LastName': 'Schwetz', 'Affiliation': 'Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.'}, {'ForeName': 'Marlene', 'Initials': 'M', 'LastName': 'Pandis', 'Affiliation': 'Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.'}, {'ForeName': 'Martin R', 'Initials': 'MR', 'LastName': 'Grübler', 'Affiliation': 'Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Verheyen', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Gaksch', 'Affiliation': 'Department of Laboratory Medicine, Paracelsus Medical University, Müllner Hauptstraße 48, 5020, Salzburg, Austria.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Zittermann', 'Affiliation': 'Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Georgstraße 11, 32545, Bad Oeynhausen, Germany.'}, {'ForeName': 'Winfried', 'Initials': 'W', 'LastName': 'März', 'Affiliation': 'Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Aberer', 'Affiliation': 'Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Steinkellner', 'Affiliation': 'Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Friedl', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 27, 8036, Graz, Austria.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Brandenburg', 'Affiliation': 'Department of Cardiology, University Hospital of the RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.'}, {'ForeName': 'Jakob', 'Initials': 'J', 'LastName': 'Voelkl', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.'}, {'ForeName': 'Ioana', 'Initials': 'I', 'LastName': 'Alesutan', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Obermayer-Pietsch', 'Affiliation': 'Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.'}, {'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'Pieber', 'Affiliation': 'Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Tomaschitz', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Pilz', 'Affiliation': 'Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.'}]",European journal of nutrition,['10.1007/s00394-018-1672-7'] 788,30111466,[Comparison of clinical efficacy of two noninvasive respiratory support therapies for respiratory distress syndrome in very low birth weight preterm infants].,"OBJECTIVE To compare the clinical efficacy of nasal intermittent positive pressure ventilation (NIPPV) and heated humidified high flow nasal cannula (HHHFNC) in the treatment of respiratory distress syndrome (RDS) among very low birth weight (VLBW) preterm infants. METHODS A total of 89 very low birth weight premature infants with respiratory distress syndrome (RDS) who were randomly administered with NIPPV (n=46) and HHHFNC (n=43) as an initial respiratory support. The incidence of initial treatment failure, the usage of pulmonary surfactant (PS), the parameters of respiratory support treatment and the incidence of complications were compared between the two groups. RESULTS There were no significant differences between the NIPPV and HHHFNC groups in the following items: the rate of intubation within 72 hours, rate of PS use, duration of invasive or non-invasive mechanical ventilation, duration of oxygen therapy, and incidence rates of severe apnea and pneumonia (P>0.05). There were also no significant differences in the incidence rates of bronchopulmonary dysplasia, necrotizing enterocolitis, retinopathy of prematurity, patent ductus arteriosus, intracranial hemorrhage, and air leak between the two group (P>0.05). The incidence rate of nose injury in the NIPPV group was higher than that in the HHHFNC group (P<0.05). CONCLUSIONS As an initial respiratory support for very low birth weight preterm infants with RDS, HHHFNC has a similar clinical effect as NIPPV, suggesting that HHHFNC is a safe and effective clinical option as a non-invasive ventilation treatment.",2018,"There were no significant differences between the NIPPV and HHHFNC groups in the following items: the rate of intubation within 72 hours, rate of PS use, duration of invasive or non-invasive mechanical ventilation, duration of oxygen therapy, and incidence rates of severe apnea and pneumonia (P>0.05).","['respiratory distress syndrome (RDS) among very low birth weight (VLBW) preterm infants', '89 very low birth weight premature infants with respiratory distress syndrome (RDS', 'very low birth weight preterm infants']","['nasal intermittent positive pressure ventilation (NIPPV) and heated humidified high flow nasal cannula (HHHFNC', 'NIPPV', 'HHHFNC', 'noninvasive respiratory support therapies']","['rate of intubation within 72 hours, rate of PS use, duration of invasive or non-invasive mechanical ventilation, duration of oxygen therapy, and incidence rates of severe apnea and pneumonia', 'incidence of complications', 'incidence rates of bronchopulmonary dysplasia, necrotizing enterocolitis, retinopathy of prematurity, patent ductus arteriosus, intracranial hemorrhage, and air leak', 'incidence of initial treatment failure, the usage of pulmonary surfactant (PS', 'incidence rate of nose injury', 'respiratory distress syndrome']","[{'cui': 'C0035220', 'cui_str': 'Respiratory Distress Syndrome, Newborn'}, {'cui': 'C0282666', 'cui_str': 'Very Low Birth Weight'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}]","[{'cui': 'C4520890', 'cui_str': 'Nasal'}, {'cui': 'C0021778', 'cui_str': 'IPPV'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannula'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C1292423', 'cui_str': '72 hours (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive (qualifier value)'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0184633', 'cui_str': 'Oxygen Inhalation Therapy'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary Dysplasia'}, {'cui': 'C0520459', 'cui_str': 'Necrotizing Enterocolitis'}, {'cui': 'C0035344', 'cui_str': 'Retrolental Fibroplasia'}, {'cui': 'C3495549', 'cui_str': 'Patent ductus arteriosus'}, {'cui': 'C0151699', 'cui_str': 'Intracranial Hemorrhage'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0332234', 'cui_str': 'Leaking (qualifier value)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0162643'}, {'cui': 'C0457083', 'cui_str': 'Usage (attribute)'}, {'cui': 'C0034085', 'cui_str': 'Pulmonary Surfactants'}, {'cui': 'C0272427', 'cui_str': 'Injury of nose (disorder)'}, {'cui': 'C0035220', 'cui_str': 'Respiratory Distress Syndrome, Newborn'}]",89.0,0.0513184,"There were no significant differences between the NIPPV and HHHFNC groups in the following items: the rate of intubation within 72 hours, rate of PS use, duration of invasive or non-invasive mechanical ventilation, duration of oxygen therapy, and incidence rates of severe apnea and pneumonia (P>0.05).","[{'ForeName': 'Zhu', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': ""Department of Neonatology, Guangdong Women and Children's Hospital, Guangzhou 511400, China. jasjie_yang@163.com.""}, {'ForeName': 'Jian-Wen', 'Initials': 'JW', 'LastName': 'Xiang', 'Affiliation': ''}, {'ForeName': 'Wei-Wei', 'Initials': 'WW', 'LastName': 'Gao', 'Affiliation': ''}, {'ForeName': 'Yong-Zhen', 'Initials': 'YZ', 'LastName': 'Shen', 'Affiliation': ''}, {'ForeName': 'Wen-Ji', 'Initials': 'WJ', 'LastName': 'Zhou', 'Affiliation': ''}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Xu', 'Affiliation': ''}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 789,30111467,[Effect of prone positioning on respiratory function in very preterm infants undergoing mechanical ventilation].,"OBJECTIVE To explore the effect of prone positioning on respiratory function in very preterm infants undergoing mechanical ventilation. METHODS A total of 83 very preterm infants treated with mechanical ventilation were enrolled in the study and were randomly assigned to supine group and prone group. Four infants withdrew from the study and 79 infants completed treatment and observation (37 in the supine group and 42 in the prone group). Infants in both groups were mechanically ventilated in a volume assist-control mode. Infants in the prone group were ventilated in the supine position for 4 hours and in the prone position for 2 hours. Ventilator parameters, arterial blood gas analysis, and vital signs were recorded before grouping, every 6 hours in the supine group, and every hour after conversion into the prone position in the prone group, respectively. RESULTS Fraction of inspired oxygen (FiO 2 ), peak inspiratory pressure, mean inspiratory pressure, and duration of ventilation were significantly lower in the prone group than in the supine group (P<0.05); there were no significant differences in tidal volume or positive end-expiratory pressure between the two groups (P>0.05). The prone group had a significantly higher PO 2 /FiO 2 ratio but significantly lower oxygenation index and respiratory rate than the supine group (P<0.05). There were no significant differences in arterial oxygen tension, pH, base excess, heart rate, or mean blood pressure between the two groups (P>0.05). CONCLUSIONS Alternating ventilation between the prone position and supine position can improve oxygenation function, decrease the fraction of inspired oxygen, and shorten the duration of mechanical ventilation in very preterm infants undergoing mechanical ventilation.",2018,The prone group had a significantly higher PO 2 /FiO 2 ratio but significantly lower oxygenation index and respiratory rate than the supine group (P<0.05).,"['83 very preterm infants treated with', 'Four infants withdrew from the study and 79 infants completed treatment and observation (37 in the supine group and 42 in the prone group', 'very preterm infants undergoing mechanical ventilation']","['mechanical ventilation', 'prone positioning', 'supine group and prone group']","['Ventilator parameters, arterial blood gas analysis, and vital signs', 'oxygenation index and respiratory rate', 'oxygenation function', 'respiratory function', 'arterial oxygen tension, pH, base excess, heart rate, or mean blood pressure', 'Fraction of inspired oxygen (FiO 2 ), peak inspiratory pressure, mean inspiratory pressure, and duration of ventilation', 'tidal volume or positive end-expiratory pressure']","[{'cui': 'C3897192', 'cui_str': 'Very preterm infant'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn (finding)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}]","[{'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0087153', 'cui_str': 'Ventilators'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0150411', 'cui_str': 'Blood gases, arterial measurement (procedure)'}, {'cui': 'C0518766'}, {'cui': 'C1278185', 'cui_str': 'Oxygenation index'}, {'cui': 'C0231832', 'cui_str': 'Respiration Rate'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}, {'cui': 'C0202155', 'cui_str': 'Oxygen measurement, partial pressure, arterial (procedure)'}, {'cui': 'C0201985', 'cui_str': 'Base excess - observation'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C0428167', 'cui_str': 'FIO2'}, {'cui': 'C0232021', 'cui_str': 'Maximum inspiratory pressure (observable entity)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C0040210', 'cui_str': 'Tidal Volume'}, {'cui': 'C3494516', 'cui_str': 'Positive end expiratory pressure (observable entity)'}]",83.0,0.0514257,The prone group had a significantly higher PO 2 /FiO 2 ratio but significantly lower oxygenation index and respiratory rate than the supine group (P<0.05).,"[{'ForeName': 'Qing-Hua', 'Initials': 'QH', 'LastName': 'Zhong', 'Affiliation': 'NICU, Department of Pediatrics, First Affiliated Hospital of Kunming Medical University, Kunming 650032, China. jetduan@126.com.'}, {'ForeName': 'Jiang', 'Initials': 'J', 'LastName': 'Duan', 'Affiliation': ''}, {'ForeName': 'Cai-Ying', 'Initials': 'CY', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Yan-Li', 'Initials': 'YL', 'LastName': 'Feng', 'Affiliation': ''}, {'ForeName': 'Zhi-Ye', 'Initials': 'ZY', 'LastName': 'Qi', 'Affiliation': ''}, {'ForeName': 'Xiang-Ying', 'Initials': 'XY', 'LastName': 'He', 'Affiliation': ''}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Liang', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 790,30111468,[Effect of golden-hour body temperature bundle management on admission temperature and clinical outcome in preterm infants after birth].,"OBJECTIVE To study the effect of golden-hour body temperature bundle management strategy on admission temperature and clinical outcome in preterm infants with a gestational age of <34 weeks after birth. METHODS The preterm infants who were born in the delivery room of the West China Second University Hospital of Sichuan University and admitted to the department of neonatology of this hospital within 1 hour after birth from December 2015 to June 2016 and from January to May, 2017 were enrolled. The 173 preterm infants who were admitted from January to May, 2017 were enrolled as the intervention group and were given golden-hour body temperature bundle management. The 164 preterm infants who were admitted from December 2015 to June 2016 were enrolled as the control group and were given conventional body temperature management. RESULTS The intervention group had a significantly higher mean admission temperature than the control group (36.4±0.4°C vs 35.3±0.6°C; P<0.001). The incidence rate of hypothermia on admission in the intervention group was significantly lower than that in the control group (56.6% vs 97.6%; P<0.001). The intervention group had a significantly lower incidence rate of intracranial hemorrhage within one week after admission than the control group (15.0% vs 31.7%; P<0.05). CONCLUSIONS Golden-hour body temperature bundle management for preterm infants within one hour after birth can reduce the incidence of hypothermia on admission and improve clinical outcome.",2018,The intervention group had a significantly higher mean admission temperature than the control group (36.4±0.4°C vs 35.3±0.6°C; P<0.001).,"['preterm infants after birth', '164 preterm infants who were admitted from December 2015 to June 2016', 'preterm infants who were born in the delivery room of the West China Second University Hospital of Sichuan University and admitted to the department of neonatology of this hospital within 1 hour after birth from December 2015 to June 2016 and from January to May, 2017 were enrolled', '173 preterm infants who were admitted from January to May, 2017 were enrolled as the intervention group and were given', 'preterm infants with a gestational age of <34 weeks after birth']","['golden-hour body temperature bundle management', 'golden-hour body temperature bundle management strategy', 'conventional body temperature management']","['incidence rate of hypothermia on admission', 'mean admission temperature', 'incidence rate of intracranial hemorrhage', 'admission temperature and clinical outcome']","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0011212', 'cui_str': 'Centers, Hospital Birth'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0027621', 'cui_str': 'Neonatology'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}, {'cui': 'C0886414', 'cui_str': 'Body temperature'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0413252', 'cui_str': 'Hypothermia due to exposure'}, {'cui': 'C0457453', 'cui_str': 'On admission (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0039476', 'cui_str': 'Temperature'}, {'cui': 'C0151699', 'cui_str': 'Intracranial Hemorrhage'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}]",2017.0,0.0283715,The intervention group had a significantly higher mean admission temperature than the control group (36.4±0.4°C vs 35.3±0.6°C; P<0.001).,"[{'ForeName': 'Xing-Li', 'Initials': 'XL', 'LastName': 'Wan', 'Affiliation': 'Department of Neonatology, West China Second University Hospital, Sichuan University/Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu 610041, China. 14023913@qq.com.'}, {'ForeName': 'Shao-Yu', 'Initials': 'SY', 'LastName': 'Su', 'Affiliation': ''}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': ''}, {'ForeName': 'Yan-Ling', 'Initials': 'YL', 'LastName': 'Hu', 'Affiliation': ''}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Cheng', 'Affiliation': ''}, {'ForeName': 'Wen-Tao', 'Initials': 'WT', 'LastName': 'Peng', 'Affiliation': ''}, {'ForeName': 'Qiong', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Xiao-Wen', 'Initials': 'XW', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Zheng-Dong', 'Initials': 'ZD', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'De-Zhi', 'Initials': 'DZ', 'LastName': 'Mu', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 791,30111472,[Effects of L-carnitine on serum levels of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide and cardiac function in children with severe hand-foot-mouth disease].,"OBJECTIVE To observe the effects of L-carnitine treatment on serum levels of brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) and cardiac function in children with heart dysfunction and severe hand-foot-mouth disease (HFMD). METHODS A total of 120 children with severe HFMD were enrolled and randomly and equally divided into routine treatment group and L-carnitine treatment group. Thirty healthy children served as the control group. HFMD patients were given anti-fever and antiviral treatment as the basic treatment, while the patients in the L-carnitine treatment group were given L-carnitine as an adjuvant treatment to the basic treatment. Treatment outcomes were observed in the two groups. For all the subjects, serum levels of BNP and NT-proBNP and cardiac function parameters including left ventricular ejection fraction (LVEF), fractional shortening (FS), and cardiac index (CI) were measured at different time points before and after treatment. RESULTS Before treatment, HFMD patients had significantly higher serum levels of BNP and NT-proBNP and heart rate but significantly lower LVEF, FS, and CI compared with the control group (P<0.05). After treatment, the L-carnitine treatment group had a significantly higher response rate than the routine treatment group (P<0.05). After 3 days of treatment, the serum levels of BNP and NT-proBNP, LVEF, FS, and CI were significantly reduced in the L-carnitine group (P<0.05); the L-carnitine group had significantly lower serum levels of BNP and NT-proBNP, LVEF, FS, and CI than the routine treatment group (P<0.05); there were no significant differences in the serum levels of BNP and NT-proBNP, LVEF, FS, or CI between the L-carnitine treatment and control groups (P>0.05). After 5 days of treatment, there were no significant differences in the serum levels of BNP and NT-proBNP, LVEF, FS, or CI between the L-carnitine treatment and routine treatment groups (P>0.05). Heart rate recovery was significantly slower in the routine treatment group than in the L-carnitine treatment group (P<0.05). CONCLUSIONS As an adjuvant therapy for severe HFMD, L-carnitine treatment has satisfactory short-term efficacy in reducing the serum levels of BNP and NT-proBNP and improving cardiac function, thus improving clinical outcomes.",2018,"After 5 days of treatment, there were no significant differences in the serum levels of BNP and NT-proBNP, LVEF, FS, or CI between the L-carnitine treatment and routine treatment groups (P>0.05).","['120 children with severe HFMD', 'children with severe hand-foot-mouth disease', 'Thirty healthy children', 'HFMD patients', 'children with heart dysfunction and severe hand-foot-mouth disease (HFMD']","['L-carnitine treatment group were given L-carnitine', 'L-carnitine', 'routine treatment group and L-carnitine treatment group']","['serum levels of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide and cardiac function', 'serum levels of BNP and NT-proBNP, LVEF, FS, or CI', 'serum levels of BNP and NT-proBNP and cardiac function parameters including left ventricular ejection fraction (LVEF), fractional shortening (FS), and cardiac index (CI', 'serum levels of BNP and NT-proBNP and heart rate', 'serum levels of brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) and cardiac function', 'LVEF, FS, and CI', 'response rate', 'Heart rate recovery', 'serum levels of BNP and NT-proBNP, LVEF, FS, and CI']","[{'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0016504', 'cui_str': 'Foot'}, {'cui': 'C0026636', 'cui_str': 'Mouth Diseases'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0686744', 'cui_str': 'Well child (finding)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}]","[{'cui': 'C0087163', 'cui_str': 'l-carnitine'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0054015', 'cui_str': 'Nesiritide'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0754710', 'cui_str': 'Amino-terminal pro-brain natriuretic peptide'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function (observable entity)'}, {'cui': 'C1095989', 'cui_str': 'Brain natriuretic peptide measurement (procedure)'}, {'cui': 'C1963813', 'cui_str': 'NT-proBNP'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction (observable entity)'}, {'cui': 'C0428776', 'cui_str': 'Cardiac index (observable entity)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0669479', 'cui_str': 'NT-BNP'}]",120.0,0.020863,"After 5 days of treatment, there were no significant differences in the serum levels of BNP and NT-proBNP, LVEF, FS, or CI between the L-carnitine treatment and routine treatment groups (P>0.05).","[{'ForeName': 'Yan-Zhu', 'Initials': 'YZ', 'LastName': 'Pan', 'Affiliation': ""Department of Emergency and Critical Medicine, Children's Hospital of Zhengzhou University/Children's Hospital of Henan Province/Zhengzhou Children's Hospital/Zhengzhou Children's Key Laboratory of Critical Care Medicine, Zhengzhou 450003, China. songchunlan0315@163.com.""}, {'ForeName': 'Chun-Lan', 'Initials': 'CL', 'LastName': 'Song', 'Affiliation': ''}, {'ForeName': 'Yan-Jun', 'Initials': 'YJ', 'LastName': 'Guo', 'Affiliation': ''}, {'ForeName': 'Ling-Ling', 'Initials': 'LL', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Ya-Jie', 'Initials': 'YJ', 'LastName': 'Cui', 'Affiliation': ''}, {'ForeName': 'Yi-Fan', 'Initials': 'YF', 'LastName': 'Ren', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 792,30898325,"Establishing the feasibility, acceptability and preliminary efficacy of a multi-component behavioral intervention to reduce pain and substance use and improve physical performance in older persons living with HIV.","Older persons living with HIV (PLWH), often defined as age 50 years and older, are a rapidly growing population, with high rates of chronic pain, substance use, and decreased physical functioning. No interventions currently exist that address all three of these health outcomes simultaneously. An 8-week behavioral intervention combining cognitive-behavioral therapy and tai chi reinforced with text messaging (CBT/TC/TXT) was developed and pilot tested in a community-based AIDS service organization with substance using PLWH aged 50 years and older who experienced chronic pain. Fifty-five participants were enrolled in a three arm randomized controlled trial that compared the CBT/TC/TXT intervention (N = 18) to routine Support Group (SG) (N = 19) and Assessment Only (AO) (N = 18) to assess the intervention's feasibility, acceptability and preliminary efficacy to reduce pain and substance use and improve physical performance. Participants were assessed at baseline, treatment-end (week 8) and week 12. Feasibility and acceptability indicators showed moderate levels of participant enrollment (62% of those eligible), excellent 12-week assessment completion (84%) and high attendance at CBT and tai chi sessions (>60% attended at least 6 of 8 sessions). Efficacy indicators showed within-group improvements from baseline to week 12 in the CBT/TC/TXT group, including all four substance use outcomes, percent pain relief in the past 24 h, and in two physical performance measures. Observed between-group changes included greater reductions in days of heavy drinking in the past 30 days for both CBT/TC/TXT (19%) and SG (13%) compared to the AO group. Percent pain relief in the past 24 h improved in the CBT/TC/TXT group relative to SG, and the CBT/TC/TXT's physical performance score improved relative to both the SG and AO groups. Findings demonstrate that the CBT/TC/TXT intervention is feasible to implement, acceptable and has preliminary efficacy for reducing substance use and pain and improving physical performance among a vulnerable population of older PLWH.",2019,"Percent pain relief in the past 24 h improved in the CBT/TC/TXT group relative to SG, and the CBT/TC/TXT's physical performance score improved relative to both the SG and AO groups.","['Older persons living with HIV (PLWH), often defined as age 50\u202fyears and older', 'community-based AIDS service organization with substance using PLWH aged 50\u202fyears and older who experienced chronic pain', 'older persons living with HIV', 'Fifty-five participants']","['behavioral intervention combining cognitive-behavioral therapy and tai chi reinforced with text messaging (CBT/TC/TXT', 'CBT/TC/TXT intervention', 'CBT/TC/TXT intervention (N\u202f=\u202f18) to routine Support Group (SG', 'multi-component behavioral intervention']","['pain and substance use and improve physical performance', 'Percent pain relief', 'Efficacy indicators', 'days of heavy drinking', ""CBT/TC/TXT's physical performance score"", 'pain relief']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0220885', 'cui_str': 'organization'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}, {'cui': 'C0450382', 'cui_str': '55 (qualifier value)'}]","[{'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0376403', 'cui_str': 'Taiji'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0036606', 'cui_str': 'Support Groups'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C2607857'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C0684271', 'cui_str': 'Drinkings'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",55.0,0.0426691,"Percent pain relief in the past 24 h improved in the CBT/TC/TXT group relative to SG, and the CBT/TC/TXT's physical performance score improved relative to both the SG and AO groups.","[{'ForeName': 'Alison A', 'Initials': 'AA', 'LastName': 'Moore', 'Affiliation': 'Division of Geriatrics, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States of America. Electronic address: alisonmoore@ucsd.edu.'}, {'ForeName': 'Jordan E', 'Initials': 'JE', 'LastName': 'Lake', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles, CA, United States of America.'}, {'ForeName': 'Suzette', 'Initials': 'S', 'LastName': 'Glasner', 'Affiliation': 'Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences and School of Nursing, University of California, Los Angeles, CA, United States of America.'}, {'ForeName': 'Arun', 'Initials': 'A', 'LastName': 'Karlamangla', 'Affiliation': 'Division of Geriatrics, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States of America.'}, {'ForeName': 'Alexis', 'Initials': 'A', 'LastName': 'Kuerbis', 'Affiliation': 'Silberman School of Social Work, Hunter College at City University of New York, New York, NY, United States of America.'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Preciado', 'Affiliation': 'Division of Geriatrics, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States of America.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Jenkins', 'Affiliation': 'Division of Geriatrics, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States of America.'}, {'ForeName': 'Blanca X', 'Initials': 'BX', 'LastName': 'Dominguez', 'Affiliation': 'Division of Geriatrics, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States of America.'}, {'ForeName': 'Jury', 'Initials': 'J', 'LastName': 'Candelario', 'Affiliation': 'APAIT, A Division of Special Services for Groups, Los Angeles, CA, United States of America.'}, {'ForeName': 'Diana H', 'Initials': 'DH', 'LastName': 'Liao', 'Affiliation': 'Division of Geriatrics, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States of America.'}, {'ForeName': 'Lingqi', 'Initials': 'L', 'LastName': 'Tang', 'Affiliation': 'Center for Health Services and Society, Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, United States of America; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles, United States of America.'}, {'ForeName': 'M Carrington', 'Initials': 'MC', 'LastName': 'Reid', 'Affiliation': 'Division of Geriatrics and Palliative Care, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, NY, United States of America.'}]",Journal of substance abuse treatment,['10.1016/j.jsat.2019.02.003'] 793,30907346,[Clinical effect of integrated sandplay therapy in children with Asperger syndrome].,"OBJECTIVE To study the clinical effect of integrated sandplay therapy in preschool children with Asperger syndrome (AS). METHODS A total of 44 preschool children with AS were randomly divided into an experimental group and a control group, with 22 children in each group. The children in the control group were given routine training, and those in the experimental group were given integrated sandplay therapy in addition to the routine training. The treatment response was assess by the Social Responsiveness Scale (SRS), emotional recognition tools and changes in sandplay theme characteristics after 6 months of treatment. RESULTS Before intervention, there were no significant differences between the two groups in the total score of SRS, the score of each factor of SRS, and correct rates of facial expression recognition of the upright position, inverted position, upper face and lower face (P>0.05). After 6 months of intervention, both groups had significant reductions in the total score of SRS and the score of each factor of SRS (P<0.01); the control group had significant increases in the correct rates of facial expression recognition of all positions except the upright position (P<0.05), while the experimental group had significant increases in the correct rates of facial expression recognition of all positions (P<0.05). Compared with the control group after intervention, the experimental group had significantly lower total score of SRS and scores of all factors of SRS except social perception (P<0.01) and significantly higher correct rates of facial expression recognition of all positions (P<0.01). The experimental group had a significant change in the number of sandplay theme characteristics after intervention (P<0.01). CONCLUSIONS Integrated sandplay therapy can improve social responsiveness and emotion recognition ability in preschool children with AS.",2019,"The experimental group had a significant change in the number of sandplay theme characteristics after intervention (P<0.01). ","['preschool children with Asperger syndrome (AS', 'children with Asperger syndrome', 'preschool children with AS', '44 preschool children with AS']","['routine training', 'integrated sandplay therapy', 'integrated sandplay therapy in addition to the routine training', 'Integrated sandplay therapy']","['total score of SRS and scores of all factors of SRS except social perception', 'total score of SRS, the score of each factor of SRS, and correct rates of facial expression recognition of the upright position, inverted position, upper face and lower face (P>0.05', 'number of sandplay theme characteristics', 'correct rates of facial expression recognition', 'Social Responsiveness Scale (SRS), emotional recognition tools and changes in sandplay theme characteristics', 'facial expression recognition', 'social responsiveness and emotion recognition ability', 'total score of SRS and the score of each factor of SRS']","[{'cui': 'C0008100', 'cui_str': 'Child, Preschool'}, {'cui': 'C0236792', 'cui_str': 'Asperger Disease'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C2350829', 'cui_str': 'Sandplay'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0037427', 'cui_str': 'Social Perception'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0015457', 'cui_str': 'Facial Expression'}, {'cui': 'C0524637', 'cui_str': 'Recognition (Psychology)'}, {'cui': 'C1561964', 'cui_str': 'Patient Positioning'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C2350829', 'cui_str': 'Sandplay'}, {'cui': 'C0222045'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0336791', 'cui_str': 'Tool, device (physical object)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0013987', 'cui_str': 'Emotions'}, {'cui': 'C0085732', 'cui_str': 'Ability'}]",44.0,0.0224377,"The experimental group had a significant change in the number of sandplay theme characteristics after intervention (P<0.01). ","[{'ForeName': 'Guo-Kai', 'Initials': 'GK', 'LastName': 'Li', 'Affiliation': ""Department of Child Healthcare Center, Fujian Provincial Maternity and Children's Hospital, Fujian Medical University, Fuzhou 350001, China. yyxu703@163.com.""}, {'ForeName': 'Pin', 'Initials': 'P', 'LastName': 'Ge', 'Affiliation': ''}, {'ForeName': 'Gui-Hua', 'Initials': 'GH', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Xin-Xin', 'Initials': 'XX', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Guo-Bin', 'Initials': 'GB', 'LastName': 'Lu', 'Affiliation': ''}, {'ForeName': 'Yan-Xia', 'Initials': 'YX', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Qin-Fang', 'Initials': 'QF', 'LastName': 'Qian', 'Affiliation': ''}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Ou', 'Affiliation': ''}, {'ForeName': 'Yu-Ying', 'Initials': 'YY', 'LastName': 'Xu', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 794,29589119,Dairy products intake and the risk of incident cataracts surgery in an elderly Mediterranean population: results from the PREDIMED study.,"PROPOSAL The aim of this study was to examine the association between the consumption of total and specific types of dairy products and the risk of incident cataracts in an elderly Mediterranean population at high cardiovascular risk. METHODS We prospectively analyzed 5860 subjects from the PREvención con DIeta MEDiterránea (PREDIMED) Study. The time to cataract surgery was calculated as the time between recruitment and the date of the surgery, last visit of the follow-up, date of death, or until the end of the study. Dairy products intake was assessed using validated food frequency questionnaires. We used Cox proportional hazard regression to assess the risk of cataract surgery according to average dietary energy-adjusted total dairy products, milk, yogurt and cheese consumption. RESULTS We documented a total of 768 new cataract events after a median of 5.6 years of follow-up. Subjects in the second [hazard ratio (HR) 0.62; 95% CI 0.52, 0.74] and third tertile (HR: 0.71; 95% CI 0.60, 0.85) of skimmed yogurt intake had a significantly lower risk of cataracts after adjusting for potential confounders. No significant associations were observed for total dairy products, whole and skimmed milk, whole yogurt and cheese consumption. CONCLUSION The intake of skimmed yogurt was associated with a reduced risk of cataracts in an elderly Mediterranean population with high cardiovascular risk. No significant associations were observed for other type of dairy product. CLINICAL TRIAL REGISTRATION International Standard Randomized Controlled Trial Number (ISRCTN): 35739639. Registration date: 5 October 2005.",2019,The intake of skimmed yogurt was associated with a reduced risk of cataracts in an elderly Mediterranean population with high cardiovascular risk.,"['elderly Mediterranean population with high cardiovascular risk', '768 new cataract events after a median of 5.6\xa0years of follow-up', '5860 subjects from the PREvención con DIeta MEDiterránea (PREDIMED) Study', 'elderly Mediterranean population', 'elderly Mediterranean population at high cardiovascular risk']",[],"['total dairy products, whole and skimmed milk, whole yogurt and cheese consumption', 'risk of cataracts', 'time to cataract surgery']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0856347', 'cui_str': 'Right cataract'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C4517794', 'cui_str': '5.6 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]",[],"[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0010947', 'cui_str': 'Dairy Products'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0043419', 'cui_str': 'Yogurt'}, {'cui': 'C0007968', 'cui_str': 'Cheese'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0856347', 'cui_str': 'Right cataract'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C2004600', 'cui_str': 'Cataract surgery specialty'}]",,0.108776,The intake of skimmed yogurt was associated with a reduced risk of cataracts in an elderly Mediterranean population with high cardiovascular risk.,"[{'ForeName': 'Lucía', 'Initials': 'L', 'LastName': 'Camacho-Barcia', 'Affiliation': 'Human Nutrition Unit, Biochemistry and Biotechnology Department, Faculty of Medicine and Health Sciences, University Hospital of Sant Joan de Reus, IISPV, Universitat Rovira i Virgili, St/Sant Llorenç 21, 43201, Reus, Spain.'}, {'ForeName': 'Mònica', 'Initials': 'M', 'LastName': 'Bulló', 'Affiliation': 'Human Nutrition Unit, Biochemistry and Biotechnology Department, Faculty of Medicine and Health Sciences, University Hospital of Sant Joan de Reus, IISPV, Universitat Rovira i Virgili, St/Sant Llorenç 21, 43201, Reus, Spain. monica.bullo@urv.cat.'}, {'ForeName': 'Jesús F', 'Initials': 'JF', 'LastName': 'García-Gavilán', 'Affiliation': 'Human Nutrition Unit, Biochemistry and Biotechnology Department, Faculty of Medicine and Health Sciences, University Hospital of Sant Joan de Reus, IISPV, Universitat Rovira i Virgili, St/Sant Llorenç 21, 43201, Reus, Spain.'}, {'ForeName': 'Miguel A', 'Initials': 'MA', 'LastName': 'Martínez-González', 'Affiliation': 'CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Dolores', 'Initials': 'D', 'LastName': 'Corella', 'Affiliation': 'CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Ramón', 'Initials': 'R', 'LastName': 'Estruch', 'Affiliation': 'CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Montse', 'Initials': 'M', 'LastName': 'Fitó', 'Affiliation': 'CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'Gómez-Gracia', 'Affiliation': 'CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Arós', 'Affiliation': 'CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Miquel', 'Initials': 'M', 'LastName': 'Fiol', 'Affiliation': 'CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'José M', 'Initials': 'JM', 'LastName': 'Santos-Lozano', 'Affiliation': 'CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Lluís', 'Initials': 'L', 'LastName': 'Serra-Majem', 'Affiliation': 'CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Pintó', 'Affiliation': 'CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Basora', 'Affiliation': 'Human Nutrition Unit, Biochemistry and Biotechnology Department, Faculty of Medicine and Health Sciences, University Hospital of Sant Joan de Reus, IISPV, Universitat Rovira i Virgili, St/Sant Llorenç 21, 43201, Reus, Spain.'}, {'ForeName': 'Estefanía', 'Initials': 'E', 'LastName': 'Toledo', 'Affiliation': 'CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Miguel A', 'Initials': 'MA', 'LastName': 'Muñoz', 'Affiliation': 'CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Vicente', 'Initials': 'V', 'LastName': 'Zanon-Moreno', 'Affiliation': 'Department of Preventive Medicine, University of Valencia, Valencia, Spain.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'García-Layana', 'Affiliation': 'CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Salas-Salvadó', 'Affiliation': 'Human Nutrition Unit, Biochemistry and Biotechnology Department, Faculty of Medicine and Health Sciences, University Hospital of Sant Joan de Reus, IISPV, Universitat Rovira i Virgili, St/Sant Llorenç 21, 43201, Reus, Spain. jordi.salas@urv.cat.'}]",European journal of nutrition,['10.1007/s00394-018-1647-8'] 795,30910277,Orthokeratology lens for management of myopia in anisometropic children: A contralateral study.,"PURPOSE To investigate the effect of overnight orthokeratology (OK) lens wear on axial growth in anisometropic children. METHODS The study involved 17 males and 12 females with an average age of 11.4 ± 2.9 years. Cycloplegic spherical equivalent error (SER) was -0.50D to -6.00D, and anisometropia ≥1.00D. The eyes with greater myopia were assigned to the G eye group and the fellow eyes with less myopia to the L eye group. All eyes were fitted with OK lenses. Axial length (AL) was measured at the beginning of the study and at 6-, 12-, 18-, and 24-month follow-up visits. Refractive error was measured at the beginning and at the 24-month visit. Linear mixed model analysis was used to evaluate the effect of time, group, and time*group on axial growth. Paired t test was used to compare the myopia increase over 24 months between the two groups. RESULTS The mean baseline AL was 25.06 ± 0.61 mm for the G eyes and 24.48 ± 0.61 mm for the L eyes. After 24 months, AL had increased by 0.31 ± 0.23 mm in the G eye group and by 0.41 ± 0.31 mm in the L eye group. Axial growth of the L eyes was significantly greater than that of the G eyes (p = 0.006). The mean baseline myopia of the G eye and the L eye was -3.62 ± 1.27D [-5.75D to -1.75D] and -1.93 ± 1.02D [-4.00D to -0.50D] respectively. At 24 months, the increase in myopia in the G eyes was significantly less than that in the L eyes (-0.84 ± 0.63D vs, -1.21 ± 0.89D, p < 0.001). CONCLUSIONS In anisometropic children who wore OK lenses, axial growth was greater in the eye with less baseline myopia than in the fellow eye with greater baseline myopia after 2 years.",2020,Axial growth of the L eyes was significantly greater than that of the G eyes (p = 0.006).,"['17 males and 12 females with an average age of 11.4\u2009±\u20092.9 years', 'eyes with greater myopia', 'anisometropic children']","['Orthokeratology lens', 'overnight orthokeratology (OK) lens wear']","['myopia increase', 'increase in myopia', 'Refractive error', 'Axial growth of the L eyes', 'Cycloplegic spherical equivalent error (SER', 'Axial length (AL', 'axial growth']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517533', 'cui_str': '11.4'}, {'cui': 'C4517641', 'cui_str': '2.9 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0027092', 'cui_str': 'Nearsightedness'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C1533088', 'cui_str': 'Orthokeratology'}, {'cui': 'C0023317', 'cui_str': 'Lens, Eye'}, {'cui': 'C0439583', 'cui_str': 'Overnight (qualifier value)'}]","[{'cui': 'C0027092', 'cui_str': 'Nearsightedness'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0034951', 'cui_str': 'Refractive Disorders'}, {'cui': 'C0205131', 'cui_str': 'Axial (qualifier value)'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0010586', 'cui_str': 'Cycloplegics'}, {'cui': 'C0332501', 'cui_str': 'Spherical shape (qualifier value)'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}]",17.0,0.0571607,Axial growth of the L eyes was significantly greater than that of the G eyes (p = 0.006).,"[{'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Zhong', 'Affiliation': 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China; Chongqing Key Laborary of Ophthalmology and Chongqing Eye Institute, Chongqing, PR China. Electronic address: towelface2017@163.com.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Ke', 'Affiliation': 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China; Chongqing Key Laborary of Ophthalmology and Chongqing Eye Institute, Chongqing, PR China.'}, {'ForeName': 'Wu', 'Initials': 'W', 'LastName': 'Qiong', 'Affiliation': 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China; Chongqing Key Laborary of Ophthalmology and Chongqing Eye Institute, Chongqing, PR China.'}, {'ForeName': 'Fengyang', 'Initials': 'F', 'LastName': 'Liu', 'Affiliation': 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China; Chongqing Key Laborary of Ophthalmology and Chongqing Eye Institute, Chongqing, PR China.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2019.03.003'] 796,31926340,"Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.","BACKGROUND & AIMS New oral therapeutic agents are needed for patients with ulcerative colitis (UC) who are unresponsive or intolerant to conventional therapy. METHODS We performed a double-blind, phase 2 trial of adults with active UC for 3 months or more who were naïve to biologic therapy or had been failed by, could not tolerate, or had contraindications to conventional therapies. The study was performed at 61 sites in 14 countries (screening from January 2015 through May 2017). Patients were randomly assigned to groups given apremilast 30 mg (n = 57), apremilast 40 mg (n = 55), or placebo (n = 58) twice daily for 12 weeks; patients were then randomly assigned to groups that received apremilast, 30 or 40 mg twice daily, for an additional 40 weeks. Endoscopies were performed and biopsies were collected during the screening phase, at week 12, and at week 52. Blood and fecal samples were also collected and analyzed throughout the study. The primary endpoint was clinical remission at week 12, defined as a total Mayo score of 2 or less, with no individual subscore above 1. RESULTS Clinical remission was achieved at week 12 by 31.6% of patients in the 30 mg apremilast group and 12.1% of patients in the placebo group (P = .01). However, only 21.8% of patients in the 40 mg apremilast group achieved clinical remission at week 12 (P = .27 compared with placebo). Differences in clinical remission between the 30 mg and 40 mg apremilast groups were associated with differences in endoscopic improvement. Both apremilast groups had similar improvements from baseline in Mayo score components (stool frequency score, rectal bleeding score, physician's global assessment). The 30 mg and 40 mg apremilast groups had greater median percent reductions in C-reactive protein (measured by a high-sensitivity blood test) and fecal calprotectin through week 12 than the placebo group. At week 52, clinical remission was achieved by 40.4% of patients initially assigned to the apremilast 30 mg group and 32.7% of patients initially assigned to the apremilast 40 mg group. The most frequent apremilast-associated adverse events were headache and nausea. CONCLUSIONS Although the primary endpoint of clinical remission was not met in this phase 2 trial, a greater proportion of patients with active UC who received apremilast (30 mg or 40 mg) had improvements in clinical and endoscopic features, and markers of inflammation, at 12 weeks. Clinical remission was maintained to week 52 in up to 40% of patients who continued apremilast until that time point. ClinicalTrials.gov no: NCT02289417.",2020,Clinical remission was maintained to week 52 in up to 40% of patients who continued apremilast until that time point.,"['61 sites in 14 countries (screening from January 2015 through May 2017', 'adults with active UC for 3 months or more who were naïve to biologic therapy or had been failed by, could not tolerate, or had contraindications to conventional therapies', 'patients with ulcerative colitis (UC) who are unresponsive or intolerant to conventional therapy', 'Patients With Active Ulcerative Colitis']",['placebo'],"['clinical and endoscopic features, and markers of inflammation', 'total Mayo score of 2 or less, with no individual subscore above 1', 'clinical remission', 'Clinical remission', 'median percent reductions in C-reactive protein', 'fecal calprotectin', ""Mayo score components (stool frequency score, rectal bleeding score, physician's global assessment"", 'Blood and fecal samples', 'headache and nausea', 'endoscopic improvement']","[{'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0005527', 'cui_str': 'Biologic Therapy'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to (contextual qualifier) (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009324', 'cui_str': 'Inflammatory Bowel Disease, Ulcerative Colitis Type'}, {'cui': 'C0237284', 'cui_str': 'Unresponsive'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0454788', 'cui_str': 'Mayo (geographic location)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C1964053', 'cui_str': 'Faecal calprotectin'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0205052', 'cui_str': 'Rectal (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0005768'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",,0.208769,Clinical remission was maintained to week 52 in up to 40% of patients who continued apremilast until that time point.,"[{'ForeName': 'Silvio', 'Initials': 'S', 'LastName': 'Danese', 'Affiliation': 'Humanitas Clinical and Research Center - IRCCS, Milan, Italy; Humanitas University, Department of Biomedical Sciences, Milan, Italy. Electronic address: silvio.danese@humanitasresearch.it.'}, {'ForeName': 'Markus F', 'Initials': 'MF', 'LastName': 'Neurath', 'Affiliation': 'Department of Internal Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Kopoń', 'Affiliation': 'Department of Gastroenterology, Toruńskie Centrum Gastrologiczne Gastromed, Toruń, Poland.'}, {'ForeName': 'Salam F', 'Initials': 'SF', 'LastName': 'Zakko', 'Affiliation': 'Connecticut Clinical Research Institute, Bristol Hospital, Bristol, Connecticut.'}, {'ForeName': 'Timothy C', 'Initials': 'TC', 'LastName': 'Simmons', 'Affiliation': 'West Gastroenterology Medical Group, Los Angeles, California.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Fogel', 'Affiliation': 'Clinical Research Institute of Michigan, Digestive Health Center of Michigan, Chesterfield, Michigan.'}, {'ForeName': 'Corey A', 'Initials': 'CA', 'LastName': 'Siegel', 'Affiliation': 'Department of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.'}, {'ForeName': 'Remo', 'Initials': 'R', 'LastName': 'Panaccione', 'Affiliation': 'Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Xiaojiang', 'Initials': 'X', 'LastName': 'Zhan', 'Affiliation': 'Clinical Research, Celgene Corporation, Summit, New Jersey.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Usiskin', 'Affiliation': 'Clinical Research, Celgene Corporation, Summit, New Jersey.'}, {'ForeName': 'Denesh', 'Initials': 'D', 'LastName': 'Chitkara', 'Affiliation': 'Clinical Research, Celgene Corporation, Summit, New Jersey.'}]",Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,['10.1016/j.cgh.2019.12.032'] 797,29546692,Vitamin D supplementation does not prevent the testosterone decline in males with advanced heart failure: the EVITA trial.,"PURPOSE Observational studies indicate a positive association between circulating 25-hydroxyvitamin D (25OHD) and testosterone (T) concentrations. Because low 25OHD concentrations and T deficiency are considered to be a generalized phenomenon in patients with advanced heart failure (HF), we aimed to investigate whether vitamin D supplementation has beneficial effects on T indices in these patients. METHODS In a pre-specified secondary analysis of the EVITA (effect of vitamin D on mortality in heart failure) randomized controlled trial, we analyzed in male subjects with 25OHD concentrations < 75 nmol/L the effect of a daily vitamin D 3 supplement of 4000 IU for 3 years (n = 71) vs. placebo (n = 62) on total T (TT), sex hormone-binding globulin (SHBG), free T (fT), and bioactive T (BAT). We assessed changes from baseline until study termination and between-group differences at study termination. RESULTS 25OHD increased in the placebo group from 36.6 nmol/L by 9.2 nmol/L (95% CI 3.2-15.1 nmol/L; P = 0.003) and in the vitamin D group from 36.5 nmol/L by 63.9 nmol/L (95% CI 52.6-75.3 nmol/L; P < 0.001), with a significant between-group difference at study termination (P < 0.001). TT and SHBG concentrations did not change significantly, neither in the placebo group nor in the vitamin D group (P = 0.845-0.082), but concentrations of fT and BAT declined significantly in both groups (P = 0.025-0.008). At study termination, there were no between-group differences in TT (P = 0.612), SHBG (P = 0.393), fT (P = 0.861), or BAT (P = 0.960). CONCLUSIONS In male patients with advanced HF and low 25OHD concentrations, a daily vitamin D 3 supplement of 4000 IU for 3 years did not prevent the decline in testosterone indices.",2019,"TT and SHBG concentrations did not change significantly, neither in the placebo group nor in the vitamin D group (P = 0.845-0.082), but concentrations of fT and BAT declined significantly in both groups (P = 0.025-0.008).","['males with advanced heart failure', 'patients with advanced heart failure (HF', 'male subjects with 25OHD concentrations\u2009<\u200975\xa0nmol/L the effect of a', 'male patients with advanced HF and low 25OHD concentrations']","['vitamin D', 'vitamin D supplementation', 'placebo', 'Vitamin D supplementation', 'daily vitamin D 3 supplement of 4000\xa0IU for 3\xa0years (n\u2009=\u200971) vs. placebo']","['SHBG', '25OHD', 'testosterone decline', 'concentrations of fT and BAT', 'testosterone indices', 'total T (TT), sex hormone-binding globulin (SHBG), free T (fT), and bioactive T (BAT', 'TT and SHBG concentrations', 'circulating 25-hydroxyvitamin D (25OHD) and testosterone (T) concentrations']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439282', 'cui_str': 'nM'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}]","[{'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C3842327', 'cui_str': '4000 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0312446', 'cui_str': 'Somatotropin binding globulin (substance)'}, {'cui': 'C0523912', 'cui_str': 'Testosterone measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0008139', 'cui_str': 'Bats'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0202218', 'cui_str': 'Sex hormone binding globulin measurement (procedure)'}, {'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0535968', 'cui_str': '25-hydroxyvitamin D'}]",,0.58248,"TT and SHBG concentrations did not change significantly, neither in the placebo group nor in the vitamin D group (P = 0.845-0.082), but concentrations of fT and BAT declined significantly in both groups (P = 0.025-0.008).","[{'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Zittermann', 'Affiliation': 'Clinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Georgstraße 11, 32545, Bad Oeynhausen, Germany. azittermann@hdz-nrw.de.'}, {'ForeName': 'Jana B', 'Initials': 'JB', 'LastName': 'Ernst', 'Affiliation': 'Clinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Georgstraße 11, 32545, Bad Oeynhausen, Germany.'}, {'ForeName': 'Sylvana', 'Initials': 'S', 'LastName': 'Prokop', 'Affiliation': 'Clinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Georgstraße 11, 32545, Bad Oeynhausen, Germany.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Fuchs', 'Affiliation': 'Clinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Georgstraße 11, 32545, Bad Oeynhausen, Germany.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Dreier', 'Affiliation': 'Institute for Laboratory and Transfusion Medicine, Herz- und Diabeteszentrum NRW, Ruhr University Bochum, Bad Oeynhausen, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Kuhn', 'Affiliation': 'Institute for Laboratory and Transfusion Medicine, Herz- und Diabeteszentrum NRW, Ruhr University Bochum, Bad Oeynhausen, Germany.'}, {'ForeName': 'Cornelius', 'Initials': 'C', 'LastName': 'Knabbe', 'Affiliation': 'Institute for Laboratory and Transfusion Medicine, Herz- und Diabeteszentrum NRW, Ruhr University Bochum, Bad Oeynhausen, Germany.'}, {'ForeName': 'Heiner K', 'Initials': 'HK', 'LastName': 'Berthold', 'Affiliation': 'Department of Internal Medicine and Geriatrics, Bethel Clinic (EvKB), Bielefeld, Germany.'}, {'ForeName': 'Ioanna', 'Initials': 'I', 'LastName': 'Gouni-Berthold', 'Affiliation': 'Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Cologne, Germany.'}, {'ForeName': 'Jan F', 'Initials': 'JF', 'LastName': 'Gummert', 'Affiliation': 'Clinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Georgstraße 11, 32545, Bad Oeynhausen, Germany.'}, {'ForeName': 'Jochen', 'Initials': 'J', 'LastName': 'Börgermann', 'Affiliation': 'Clinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Georgstraße 11, 32545, Bad Oeynhausen, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Pilz', 'Affiliation': 'Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.'}]",European journal of nutrition,['10.1007/s00394-018-1666-5'] 798,30882644,Effects of virtual reality immersive training with computerized cognitive training on cognitive function and activities of daily living performance in patients with acute stage stroke: A preliminary randomized controlled trial.,"OBJECTIVE The purpose of this study was to investigate the impact of virtual reality immersive training with computerized cognitive training on the cognitive function and activity of daily living in patients with acute stroke. METHOD We included 42 patients with acute stage stroke from C hospital in Sungnam from May, 2017 to September, 2017. The patients were randomly selected and divided into the experimental (n = 21) and control (n = 21) group. The experimental group performed virtual reality training, including Head Mount Display with computerized cognitive therapy, and the control group performed computerized cognitive therapy. Both groups trained for 30 minutes a day 5 times a week; the intervention lasted 4 weeks. To evaluate the improvement in each group, pre-post-test evaluation was conducted using the Loewenstein Occupational Therapy Cognitive Assessment and Computerized Neurocognitive Function Test for cognitive function, and Functional Independent Measure for activities of daily living. RESULTS Attention and memory in cognitive function and activity of daily living performance were improved in the both groups. CONCLUSION Virtual reality immersive training might be an affordable approach for cognitive function and activity of daily living performance recovery for patients with acute stroke.",2019,"RESULTS Attention and memory in cognitive function and activity of daily living performance were improved in the both groups. ","['42 patients with acute stage stroke from C hospital in Sungnam from May, 2017 to September, 2017', 'patients with acute stroke', 'patients with acute stage stroke']","['virtual reality training, including Head Mount Display with computerized cognitive therapy, and the control group performed computerized cognitive therapy', 'virtual reality immersive training with computerized cognitive training', 'Virtual reality immersive training']","['cognitive function and activity of daily living', 'Loewenstein Occupational Therapy Cognitive Assessment and Computerized Neurocognitive Function Test for cognitive function, and Functional Independent Measure for activities of daily living', 'Attention and memory in cognitive function and activity of daily living performance', 'cognitive function and activities of daily living performance']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0751956', 'cui_str': 'Stroke, Acute'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0181909', 'cui_str': 'Mount (physical object)'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]","[{'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0001288', 'cui_str': 'ADL'}, {'cui': 'C0451269', 'cui_str': 'Loewenstein OT Cognitive Assessment'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0025260', 'cui_str': 'Memory'}]",42.0,0.0406054,"RESULTS Attention and memory in cognitive function and activity of daily living performance were improved in the both groups. ","[{'ForeName': 'Dong-Rae', 'Initials': 'DR', 'LastName': 'Cho', 'Affiliation': 'Department of Occupational Therapy, CHA Bundang Medical Center, CHA University.'}, {'ForeName': 'Sang-Heon', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Department of Occupational Therapy, College of Medical Science, Soonchunhyang University, Republic of Korea.'}]",Medicine,['10.1097/MD.0000000000014752'] 799,30913926,Hospital Design with Nature Films Reduces Stress-Related Variables in Patients Undergoing Colonoscopy.,"PURPOSE To examine whether patients' experiences could be improved during colonoscopy by designing the examination room to include a digital screen showing calm nature films. BACKGROUND Colonoscopy is the gold standard for examination of the large intestine and the rectum. Around 50% of individuals invited for colorectal cancer screening choose to refrain from the screening due to fear and anxiety. It is therefore important to improve patients' comfort during the procedure. METHOD One of the four endoscopy rooms was rebuilt to include a large digital screen showing calm nature films. Patients were randomized to intervention (i.e., the room showing films) or control. During the colonoscopy, pulse and oxygen saturation were measured and the patients graded the intensity of pain and anxiety. Blood samples were taken regularly during the examination and were analyzed for glucose, cortisol, and prolactin. RESULTS The presence of calm nature films during colonoscopy decreased the release of cortisol, increased prolactin levels, and enhanced oxygen saturation. These effects were more apparent in patients who were unfamiliar with the procedure and the environment, patients who underwent the examination without analgesics or sedation, and patients whose examination procedure was relatively difficult and took a long time. CONCLUSIONS The intervention described in this study is easy to implement and might help improve the patient experience during colonoscopy. However, this study was performed in a single health institution, and more studies are needed to further explore the role of film interventions in endoscopic and other medical procedures.",2019,"The presence of calm nature films during colonoscopy decreased the release of cortisol, increased prolactin levels, and enhanced oxygen saturation.",['Patients Undergoing Colonoscopy'],[],"['release of cortisol, increased prolactin levels, and enhanced oxygen saturation', 'intensity of pain and anxiety', 'pulse and oxygen saturation']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}]",[],"[{'cui': 'C1963578', 'cui_str': 'Release (procedure)'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C0747979', 'cui_str': 'Increased prolactin level (finding)'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}]",,0.0181241,"The presence of calm nature films during colonoscopy decreased the release of cortisol, increased prolactin levels, and enhanced oxygen saturation.","[{'ForeName': 'Annica', 'Initials': 'A', 'LastName': 'Sjölander', 'Affiliation': 'Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Jakobsson Ung', 'Affiliation': 'Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Töres', 'Initials': 'T', 'LastName': 'Theorell', 'Affiliation': 'Stress Research Institute, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Åsa', 'Initials': 'Å', 'LastName': 'Nilsson', 'Affiliation': 'Department of Research and Development, Skaraborg Hospital, Skövde, Sweden.'}, {'ForeName': 'Kjell-Arne', 'Initials': 'KA', 'LastName': 'Ung', 'Affiliation': 'Department of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.'}]",HERD,['10.1177/1937586719837754'] 800,31698246,Ear block with general anaesthesia improves haemodynamics and surgical field in middle ear surgeries: A randomized double-blind trial.,,2020,,['middle ear surgeries'],['general anaesthesia'],['haemodynamics and surgical field'],"[{'cui': 'C0013455', 'cui_str': 'Middle ear structure (body structure)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0002915', 'cui_str': 'General Anesthesia'}]","[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0440042', 'cui_str': ""Field's""}]",,0.632849,,"[{'ForeName': 'Abd-Elazeem', 'Initials': 'AE', 'LastName': 'Elbakry', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Faculty of Medicine, Menoufia University, Menoufia, Egypt. Electronic address: abdelazeem.abd@med.menofia.edu.eg.'}, {'ForeName': 'Nagwa', 'Initials': 'N', 'LastName': 'Doha', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Faculty of Medicine, Menoufia University, Menoufia, Egypt.'}, {'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'El-Feky', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Faculty of Medicine, Menoufia University, Menoufia, Egypt.'}, {'ForeName': 'Ayman', 'Initials': 'A', 'LastName': 'Rady', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Faculty of Medicine, Menoufia University, Menoufia, Egypt.'}, {'ForeName': 'Yaser', 'Initials': 'Y', 'LastName': 'Khalil', 'Affiliation': 'Department of Otorhinolaryngology, Faculty of Medicine, Menoufia University, Menoufia, Egypt.'}, {'ForeName': 'Tarek', 'Initials': 'T', 'LastName': 'Abd-Elhafez', 'Affiliation': 'Department of Otorhinolaryngology, Faculty of Medicine, Menoufia University, Menoufia, Egypt.'}, {'ForeName': 'Ashraf', 'Initials': 'A', 'LastName': 'Mohammed', 'Affiliation': 'Department of Otorhinolaryngology, Faculty of Medicine, Menoufia University, Menoufia, Egypt.'}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2019.09.004'] 801,30827735,Influenza vaccination of pregnant women: Engaging clinicians to reduce missed opportunities for vaccination.,"BACKGROUND Antenatal influenza vaccination (AIV) is an effective intervention for protecting pregnant women and their newborns against influenza. Although the World Health Organization recommends AIV at any stage of pregnancy, in low- and middle-income countries, including India, it is rarely provided. Research suggests that antenatal care (ANC) provider practices explain much of this limited coverage. Our study in urban Pune, India, assessed the feasibility of a two-stage clinician-engagement strategy to reduce missed opportunities for AIV in urban private-practice ANC clinics. METHODS Clinicians were randomized to intervention and control groups in slum and middle-class study sites. Intervention-group clinicians (active clinicians) were assessed on vaccination-related views and practices, and were presented with authoritative AIV recommendations from global, academic and professional medical organizations. In a second meeting after a community survey, findings concerning vaccination-related views and experiences were explained to active clinicians. Assessments of community vaccination views were not provided to control-group clinicians. Both groups maintained logs of ANC clinic visit vaccination status throughout the 11-month study period to enable identification of missed and taken opportunities for vaccination. Analyses were restricted to visits of women in their third trimester without previous AIV in the current pregnancy. RESULTS Overall, 30 clinicians participated. After first and second interactions, active clinicians in middle-class communities vaccinated at 12.2% and 37.8%, respectively. Middle-class control clinicians vaccinated at <0.2% throughout the study. This difference in AIV taken opportunities between middle-class active and control clinics was statistically significant (p < 0.05) after first and second interactions. In slum-community sites, active clinicians' AIV activity was minimal throughout. CONCLUSIONS Our approach for engaging clinicians effectively reduced missed opportunities for AIV in urban middle-class settings of Pune. It may also improve maternal vaccination for other conditions. The absence of any similar effect in slum-based clinics likely reflects critical limitations of vaccine access.",2019,This difference in AIV taken opportunities between middle-class active and control clinics was statistically significant (p < 0.05) after first and second interactions.,"['protecting pregnant women and their newborns against influenza', 'pregnant women', 'urban private-practice ANC clinics', 'Clinicians']","['Antenatal influenza vaccination (AIV', 'Influenza vaccination']",['maternal vaccination'],"[{'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0521124', 'cui_str': 'Against (qualifier value)'}, {'cui': 'C0021400', 'cui_str': 'Influenza, Human'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0033174', 'cui_str': 'Private Practice'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}]","[{'cui': 'C2828394', 'cui_str': 'Antenatal (qualifier value)'}, {'cui': 'C0042200', 'cui_str': 'Influenza vaccination (procedure)'}]","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]",30.0,0.0406824,This difference in AIV taken opportunities between middle-class active and control clinics was statistically significant (p < 0.05) after first and second interactions.,"[{'ForeName': 'Joseph G', 'Initials': 'JG', 'LastName': 'Giduthuri', 'Affiliation': 'Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland. Electronic address: joseph.giduthuri@swisstph.ch.'}, {'ForeName': 'Vidula', 'Initials': 'V', 'LastName': 'Purohit', 'Affiliation': 'The Maharashtra Association of Anthropological Sciences, Centre for Health Research and Development, Pune, India; Savitribai Phule Pune University, Pune, India.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Maire', 'Affiliation': 'Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.'}, {'ForeName': 'Abhay', 'Initials': 'A', 'LastName': 'Kudale', 'Affiliation': 'The Maharashtra Association of Anthropological Sciences, Centre for Health Research and Development, Pune, India; Savitribai Phule Pune University, Pune, India.'}, {'ForeName': 'Jürg', 'Initials': 'J', 'LastName': 'Utzinger', 'Affiliation': 'Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Schindler', 'Affiliation': 'Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.'}, {'ForeName': 'Mitchell G', 'Initials': 'MG', 'LastName': 'Weiss', 'Affiliation': 'Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.'}]",Vaccine,['10.1016/j.vaccine.2019.02.035'] 802,30862193,TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.,"Objective: This study aimed to evaluate improvement of dyspareunia and associated vaginal dryness with a 17β-estradiol softgel vaginal insert (TX-004HR; TherapeuticsMD, Boca Raton, FL, USA) in women with postmenopausal vulvar and vaginal atrophy (VVA). Methods: Postmenopausal women with VVA and moderate to severe dyspareunia received TX-004HR (4, 10, or 25 μg) or placebo in the 12-week, randomized, double-blind, placebo-controlled, phase 3 REJOICE trial. Post hoc analyses examined improvement levels in dyspareunia and concurrent vaginal dryness with TX-004HR and assessed the effects of patient characteristics on vaginal dryness treatment. Results: Significantly more women treated with TX-004HR (all doses) than placebo had complete resolution or substantial improvement in dyspareunia or vaginal dryness (concurrent with dyspareunia) by 12 weeks, observed as early as week 2 with most doses. TX-004HR significantly improved both dyspareunia and vaginal dryness at least one level versus placebo by week 12 in women with both symptoms. Subgroup analyses showed TX-004HR improved vaginal dryness associated with dyspareunia regardless of age, body mass index, uterine status, prior pregnancy, and vaginal birth number. Conclusion: TX-004HR provided clinically meaningful improvements in dyspareunia and vaginal dryness associated with dyspareunia in postmenopausal women with VVA. Clinicians may be able to use this information when discussing patients' expectations regarding symptom improvement with the estradiol vaginal insert.",2019,TX-004HR significantly improved both dyspareunia and vaginal dryness at least one level versus placebo by week 12 in women with both symptoms.,"['postmenopausal women', 'postmenopausal women with VVA', 'Postmenopausal women with VVA and moderate to severe dyspareunia received TX-004HR (4, 10, or 25\u2009μg) or', 'women with postmenopausal vulvar and vaginal atrophy (VVA']","['17β-estradiol softgel vaginal insert (TX-004HR; TherapeuticsMD, Boca Raton, FL, USA', 'TX-004HR', 'placebo']","['dyspareunia and vaginal dryness', 'dyspareunia and concurrent vaginal dryness', 'dyspareunia and associated vaginal dryness', 'vaginal dryness treatment', 'TX-004HR improved vaginal dryness', 'dyspareunia or vaginal dryness', 'symptoms of vulvar and vaginal atrophy']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0013394', 'cui_str': 'Pain in female genitalia on intercourse (finding)'}, {'cui': 'C4705066', 'cui_str': 'TX-004HR'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C0333641', 'cui_str': 'Atrophy'}]","[{'cui': 'C1700235', 'cui_str': '(11BAPOP2) estradiol'}, {'cui': 'C1719963', 'cui_str': 'Conventional release vaginal insert'}, {'cui': 'C4705066', 'cui_str': 'TX-004HR'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0013394', 'cui_str': 'Pain in female genitalia on intercourse (finding)'}, {'cui': 'C0241633', 'cui_str': 'Vaginal dryness (disorder)'}, {'cui': 'C0205420', 'cui_str': 'Concurrent (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4705066', 'cui_str': 'TX-004HR'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C0333641', 'cui_str': 'Atrophy'}]",,0.2466,TX-004HR significantly improved both dyspareunia and vaginal dryness at least one level versus placebo by week 12 in women with both symptoms.,"[{'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Simon', 'Affiliation': 'a George Washington University School of Medicine , IntimMedicine Specialists , Washington , DC , USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Kagan', 'Affiliation': 'b Department of Gynecology and Reproductive Sciences , University of California, Sutter East Bay Medical Foundation , Berkeley , CA , USA.'}, {'ForeName': 'D F', 'Initials': 'DF', 'LastName': 'Archer', 'Affiliation': 'c Clinical Research Center, Department of Obstetrics and Gynecology , Eastern Virginia Medical School , Norfolk , VA , USA.'}, {'ForeName': 'G D', 'Initials': 'GD', 'LastName': 'Constantine', 'Affiliation': 'd EndoRheum Consultants , LLC , Malvern , PA , USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Bernick', 'Affiliation': 'e TherapeuticsMD , Boca Raton , FL , USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Graham', 'Affiliation': 'e TherapeuticsMD , Boca Raton , FL , USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Mirkin', 'Affiliation': 'e TherapeuticsMD , Boca Raton , FL , USA.'}]",Climacteric : the journal of the International Menopause Society,['10.1080/13697137.2019.1577379'] 803,30882604,"A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension.","OBJECTIVES We conducted a pilot multicenter double-blind randomized placebo-controlled crossover pharmacodynamic study to evaluate the blood pressure (BP) and the hormonal effects of firibastat, a first-in-class aminopeptidase A inhibitor prodrug, in patients with hypertension. METHODS Thirty-four patients with daytime ambulatory BP of at least 135/85 mmHg and less than 170/105 mmHg, after a 2-week run-in period were randomly assigned to receive either firibastat (250 mg b.i.d. for 1 week uptitrated to 500 mg b.i.d. for 3 weeks) and then placebo for 4 weeks each or vice versa, with a 2-week washout period on placebo. RESULTS At 4 weeks, daytime ambulatory systolic BP (SBP) decreased by 2.7 mmHg (95% confidence interval -6.5 to +1.1 mmHg) with firibastat versus placebo (P = 0.157). Office SBP decreased by 4.7 mmHg (95% confidence interval -11.1 to +1.8 mmHg) with firibastat versus placebo (P = 0.151). However, more the basal daytime ambulatory SBP was elevated, more the firibastat-induced BP decrease was marked. Firibastat did not influence 24h-ambulatory heart rate. Firibastat had no effect on plasma renin, aldosterone, apelin and copeptin concentrations. No major adverse events occurred. There was one episode of reversible skin allergy with facial edema. CONCLUSION In patients with hypertension, a 4-week treatment with firibastat, tended to decrease daytime SBP relative to placebo. Firibastat did not modify the activity of the systemic renin-angiotensin system These results have justified designing a larger, powered trial of longer duration to fully assess its safety and effectiveness. CLINICAL TRIAL REGISTRATION http://www.clinicaltrials.gov. NCT02322450.",2019,Office SBP decreased by 4.7 mmHg (95% confidence interval -11.1 to +1.8 mmHg) with firibastat versus placebo (P = 0.151).,"['patients with hypertension', 'Thirty-four patients with daytime ambulatory BP of at least 135/85\u200ammHg and less than 170/105']","['firibastat', 'placebo']","['firibastat-induced BP decrease', 'Office SBP', 'daytime SBP relative', 'blood pressure (BP', 'basal daytime ambulatory SBP', 'daytime ambulatory systolic BP (SBP', 'reversible skin allergy with facial edema', 'safety and effectiveness', 'plasma renin, aldosterone, apelin and copeptin concentrations']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0332169', 'cui_str': 'Daytime (qualifier value)'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0439475', 'cui_str': 'torr (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0442603', 'cui_str': 'Office (environment)'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C0332169', 'cui_str': 'Daytime (qualifier value)'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0205112', 'cui_str': 'Basal (qualifier value)'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0205343', 'cui_str': 'Reversible (qualifier value)'}, {'cui': 'C0585186', 'cui_str': 'Cutaneous hypersensitivity (disorder)'}, {'cui': 'C0013604', 'cui_str': 'Hydrops'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0035094', 'cui_str': 'Angiotensinogenase'}, {'cui': 'C0373535', 'cui_str': 'Aldosterone measurement (procedure)'}, {'cui': 'C3542402', 'cui_str': 'Apelin'}, {'cui': 'C0056279', 'cui_str': 'C-terminal provasopressin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",34.0,0.304107,Office SBP decreased by 4.7 mmHg (95% confidence interval -11.1 to +1.8 mmHg) with firibastat versus placebo (P = 0.151).,"[{'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Azizi', 'Affiliation': 'Université Paris-Descartes.'}, {'ForeName': 'Pierre-Yves', 'Initials': 'PY', 'LastName': 'Courand', 'Affiliation': 'University of Lyon.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Denolle', 'Affiliation': 'Cardiology Department, Hôpital Arthur Gardiner, Dinard.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Delsart', 'Affiliation': 'CHU Lille, Institut Cœur Poumon.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Zhygalina', 'Affiliation': 'Université Paris-Descartes.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Amar', 'Affiliation': 'Université Paris-Descartes.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Lantelme', 'Affiliation': 'University of Lyon.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Mounier-Vehier', 'Affiliation': 'CHU Lille, University of Lille, Lille.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'De Mota', 'Affiliation': 'Laboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, Center for Interdisciplinary Research in Biology, College de France, PSL Research University, INSERM U1050, CNRS UMR7241, Paris, France.'}, {'ForeName': 'Fabrice', 'Initials': 'F', 'LastName': 'Balavoine', 'Affiliation': 'Quantum Genomics SA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Llorens-Cortes', 'Affiliation': 'Laboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, Center for Interdisciplinary Research in Biology, College de France, PSL Research University, INSERM U1050, CNRS UMR7241, Paris, France.'}]",Journal of hypertension,['10.1097/HJH.0000000000002092'] 804,30850240,Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans.,"BACKGROUND Adjuvants like AS01 B increase the immunogenicity of vaccines and generally cause increased transient reactogenicity compared with Alum. A phase II randomized trial was conducted to characterize the response to AS01 B and Alum adjuvanted vaccines. A post-hoc analysis was performed to examine the associations between reactogenicity and innate immune parameters. METHODS The trial involved 60 hepatitis B-naïve adults aged 18-45 years randomized 1:1 to receive either two doses of HBsAg-AS01 B on Day (D)0 and D30, or three doses of HBsAg-Alum on D0, D30, D180. Prior to vaccination, all subjects received placebo injection in order to differentiate the impact of injection process and the vaccination. Main outcomes included reactogenicity symptoms, vital signs, blood cytokines, biochemical and hematological parameters after vaccination. Associations were explored using linear regression. FINDINGS The vaccine with AS01 B induced higher HBsAg-specific antibody levels than Alum. Local and systemic symptoms were more frequent in individuals who received HBsAg AS01 B /Alum vaccine or placebo, but were mild and short-lived. Blood levels of C-reactive protein (CRP), bilirubin, leukocyte, monocyte and neutrophil counts increased rapidly and transiently after AS01 B but not after Alum or placebo. Lymphocyte counts decreased in the AS01 B group and lactate dehydrogenase levels decreased after Alum. Modelling revealed associations between systemic symptoms and increased levels of CRP and IL-6 after the first HBsAg-AS01 B or HBsAg-Alum immunization. Following the second vaccine dose, CRP, IL-6, IP-10, IFN-γ, MIP-1β and MCP-2 were identified as key parameters associated with systemic symptoms. These observations were confirmed using an independent data set extracted from a previous study of the immune response to HBsAg-adjuvanted vaccines (NCT00805389). CONCLUSIONS IL-6 and IFN-γ signals were associated with systemic reactogenicity following administration of AS01 B -adjuvanted vaccine. These signals were similar to those previously associated with antibody and T-cell responses induced by HBsAg-adjuvanted vaccines, suggesting that similar innate immune signals may underlie adjuvant reactogenicity and immunogenicity. TRIAL REGISTRATION www.clinicaltrials.gov NCT01777295.",2019,"Following the second vaccine dose, CRP, IL-6, IP-10, IFN-γ, MIP-1β and MCP-2 were identified as key parameters associated with systemic symptoms.","['humans', '60 hepatitis B-naïve adults aged 18-45\u202fyears']","['HBsAg-AS01 B on Day (D)0 and D30, or three doses of HBsAg-Alum on D0, D30, D180', 'placebo', 'placebo injection', 'HBsAg AS01 B /Alum vaccine or placebo', 'vaccination with adjuvanted hepatitis B vaccines']","['Blood levels of C-reactive protein (CRP), bilirubin, leukocyte, monocyte and neutrophil counts', 'systemic reactogenicity', 'lactate dehydrogenase levels', 'levels of CRP and IL-6', 'CRP, IL-6, IP-10, IFN-γ, MIP-1β and MCP-2', 'reactogenicity and innate immune parameters', 'higher HBsAg-specific antibody levels', 'Lymphocyte counts', 'Local and systemic symptoms', 'reactogenicity symptoms, vital signs, blood cytokines, biochemical and hematological parameters']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0019163', 'cui_str': 'Hepatitis B Virus Infection'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0201477', 'cui_str': 'Hepatitis B surface antigen measurement (procedure)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0137988', 'cui_str': 'alum'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0062527', 'cui_str': 'Hepatitis B Surface Antigen Vaccine'}]","[{'cui': 'C0005768'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin IX alpha'}, {'cui': 'C0023516', 'cui_str': 'Blood Corpuscles, White'}, {'cui': 'C0026473', 'cui_str': 'Monocytes'}, {'cui': 'C0200633', 'cui_str': 'Neutrophil count (procedure)'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0202113', 'cui_str': 'Lactate dehydrogenase measurement (procedure)'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0439662', 'cui_str': 'Immune (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0201477', 'cui_str': 'Hepatitis B surface antigen measurement (procedure)'}, {'cui': 'C1277793', 'cui_str': 'Specific antibody measurement'}, {'cui': 'C0200635', 'cui_str': 'Lymphocyte Number'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0518766'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0205474', 'cui_str': 'Biochemical (qualifier value)'}]",60.0,0.277281,"Following the second vaccine dose, CRP, IL-6, IP-10, IFN-γ, MIP-1β and MCP-2 were identified as key parameters associated with systemic symptoms.","[{'ForeName': 'Wivine', 'Initials': 'W', 'LastName': 'Burny', 'Affiliation': 'GSK, Rixensart/Wavre, Belgium. Electronic address: Wivine.Burny@GSK.com.'}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Marchant', 'Affiliation': 'Institute for Medical Immunology, Université libre de Bruxelles, Charleroi, Belgium.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Hervé', 'Affiliation': 'GSK, Rixensart/Wavre, Belgium.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Callegaro', 'Affiliation': 'GSK, Rixensart/Wavre, Belgium.'}, {'ForeName': 'Magalie', 'Initials': 'M', 'LastName': 'Caubet', 'Affiliation': 'GSK, Rixensart/Wavre, Belgium.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Fissette', 'Affiliation': 'GSK, Rixensart/Wavre, Belgium.'}, {'ForeName': 'Lien', 'Initials': 'L', 'LastName': 'Gheyle', 'Affiliation': 'SGS Life Science Services, Antwerp, Belgium.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Legrand', 'Affiliation': 'Institute of Statistics, Biostatistics and Actuarial Sciences (ISBA), Université Catholique de Louvain, Louvain-la-Neuve, Belgium.'}, {'ForeName': 'Cheikh', 'Initials': 'C', 'LastName': 'Ndour', 'Affiliation': 'Institute of Statistics, Biostatistics and Actuarial Sciences (ISBA), Université Catholique de Louvain, Louvain-la-Neuve, Belgium.'}, {'ForeName': 'Fernanda', 'Initials': 'F', 'LastName': 'Tavares Da Silva', 'Affiliation': 'GSK, Rixensart/Wavre, Belgium.'}, {'ForeName': 'Robbert', 'Initials': 'R', 'LastName': 'van der Most', 'Affiliation': 'GSK, Rixensart/Wavre, Belgium.'}, {'ForeName': 'Fabienne', 'Initials': 'F', 'LastName': 'Willems', 'Affiliation': 'Institute for Medical Immunology, Université libre de Bruxelles, Charleroi, Belgium.'}, {'ForeName': 'Arnaud M', 'Initials': 'AM', 'LastName': 'Didierlaurent', 'Affiliation': 'GSK, Rixensart/Wavre, Belgium.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Yarzabal', 'Affiliation': 'GSK, Rixensart/Wavre, Belgium.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Vaccine,['10.1016/j.vaccine.2019.02.015'] 805,30795944,Depression Agency-Based Collaborative: Effect of Problem-Solving Therapy on Risk of Common Mental Disorders in Older Adults With Home Care Needs.,"BACKGROUND Interventions to prevent depression in older adults have mainly focused on young-old ambulatory adults, not on the old-old with disabilities who receive supportive services in their homes. OBJECTIVE The Depression Agency-Based Collaborative (Dep-ABC) is a single-blind pilot randomized controlled trial assessing the effect of an intervention-development strategy using problem-solving therapy (PST) on the risk of common mental health disorders in this vulnerable population. METHODS The intervention involved six to eight sessions of PST over 12 weeks. Participants were followed up to 12 months postintervention. RESULTS Dep-ABC randomized 104 participants-68.4% of eligible and 17.5% of all older adults screened. The proportion of participants with incident major depressive disorder or generalized anxiety disorder was 11.4% in PST and 14.3% in the enhanced usual care control arm. A test of the interaction between time and intervention for anxiety symptoms favored the PST arm (p = 0.04). CONCLUSION PST did not lower the risk of incident common mental illness but did lower anxiety symptom burden. Apart from low power, the effects of PST may have been blunted by referral for medical and aging services in the enhanced usual care group.",2019,"A test of the interaction between time and intervention for anxiety symptoms favored the PST arm (p = 0.04). ","['Older Adults With Home Care Needs', 'young-old ambulatory adults, not on the old-old with disabilities who receive supportive services in their homes', 'older adults']","['Problem-Solving Therapy', 'intervention-development strategy using problem-solving therapy (PST', 'PST', 'Depression Agency-Based Collaborative (Dep-ABC']","['risk of incident common mental illness', 'anxiety symptoms', 'generalized anxiety disorder']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0204977', 'cui_str': 'Home Care'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0001795', 'cui_str': 'Oldest Old'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}]","[{'cui': 'C1303140', 'cui_str': 'Problem solving therapy'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0057472', 'cui_str': '1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0205214', 'cui_str': 'Common (qualifier value)'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder (disorder)'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0270549', 'cui_str': 'Generalized anxiety disorder (disorder)'}]",104.0,0.0916943,"A test of the interaction between time and intervention for anxiety symptoms favored the PST arm (p = 0.04). ","[{'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'Albert', 'Affiliation': 'Department of Behavioral and Community Health Sciences (SMA, JK), Graduate School of Public Health, University of Pittsburgh, Pittsburgh. Electronic address: smalbert@pitt.edu.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'King', 'Affiliation': 'Department of Behavioral and Community Health Sciences (SMA, JK), Graduate School of Public Health, University of Pittsburgh, Pittsburgh.'}, {'ForeName': 'Stewart', 'Initials': 'S', 'LastName': 'Anderson', 'Affiliation': 'Department of Biostatistics (SA, MAD, JZ), University of Pittsburgh, Pittsburgh.'}, {'ForeName': 'Mary Amanda', 'Initials': 'MA', 'LastName': 'Dew', 'Affiliation': 'Department of Biostatistics (SA, MAD, JZ), University of Pittsburgh, Pittsburgh; Department of Psychiatry (MAD, STS, JFK, AGG, MAB, CFR), University of Pittsburgh, Pittsburgh.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Biostatistics (SA, MAD, JZ), University of Pittsburgh, Pittsburgh.'}, {'ForeName': 'Sarah T', 'Initials': 'ST', 'LastName': 'Stahl', 'Affiliation': 'Department of Psychiatry (MAD, STS, JFK, AGG, MAB, CFR), University of Pittsburgh, Pittsburgh.'}, {'ForeName': 'Jordan F', 'Initials': 'JF', 'LastName': 'Karp', 'Affiliation': 'Department of Psychiatry (MAD, STS, JFK, AGG, MAB, CFR), University of Pittsburgh, Pittsburgh.'}, {'ForeName': 'Ariel G', 'Initials': 'AG', 'LastName': 'Gildengers', 'Affiliation': 'Department of Psychiatry (MAD, STS, JFK, AGG, MAB, CFR), University of Pittsburgh, Pittsburgh.'}, {'ForeName': 'Meryl A', 'Initials': 'MA', 'LastName': 'Butters', 'Affiliation': 'Department of Psychiatry (MAD, STS, JFK, AGG, MAB, CFR), University of Pittsburgh, Pittsburgh.'}, {'ForeName': 'Charles F', 'Initials': 'CF', 'LastName': 'Reynolds Iii', 'Affiliation': 'Department of Psychiatry (MAD, STS, JFK, AGG, MAB, CFR), University of Pittsburgh, Pittsburgh.'}]",The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,['10.1016/j.jagp.2019.01.002'] 806,29855331,"The AWED trial (Applying Wolbachia to Eliminate Dengue) to assess the efficacy of Wolbachia-infected mosquito deployments to reduce dengue incidence in Yogyakarta, Indonesia: study protocol for a cluster randomised controlled trial.","BACKGROUND Dengue and other arboviruses transmitted by Aedes aegypti mosquitoes, including Zika and chikungunya, present an increasing public health challenge in tropical regions. Current vector control strategies have failed to curb disease transmission, but continue to be employed despite the absence of robust evidence for their effectiveness or optimal implementation. The World Mosquito Program has developed a novel approach to arbovirus control using Ae. aegypti stably transfected with Wolbachia bacterium, with a significantly reduced ability to transmit dengue, Zika and chikungunya in laboratory experiments. Modelling predicts this will translate to local elimination of dengue in most epidemiological settings. This study protocol describes the first trial to measure the efficacy of Wolbachia in reducing dengue virus transmission in the field. METHODS/DESIGN The study is a parallel, two-arm, non-blinded cluster randomised controlled trial conducted in a single site in Yogyakarta, Indonesia. The aim is to determine whether large-scale deployment of Wolbachia-infected Ae. aegypti mosquitoes leads to a measurable reduction in dengue incidence in treated versus untreated areas. The primary endpoint is symptomatic, virologically confirmed dengue virus infection of any severity. The 26 km 2 study area was subdivided into 24 contiguous clusters, allocated randomly 1:1 to receive Wolbachia deployments or no intervention. We use a novel epidemiological study design, the cluster-randomised test-negative design trial, in which dengue cases and arbovirus-negative controls are sampled concurrently from among febrile patients presenting to a network of primary care clinics, with case or control status classified retrospectively based on the results of laboratory diagnostic testing. Efficacy is estimated from the odds ratio of Wolbachia exposure distribution (probability of living in a Wolbachia-treated area) among virologically confirmed dengue cases compared to test-negative controls. A secondary per-protocol analysis allows for individual Wolbachia exposure levels to be assessed to account for movements outside the cluster and the heterogeneity in local Wolbachia prevalence among treated clusters. DISCUSSION The findings from this study will provide the first experimental evidence for the efficacy of Wolbachia in reducing dengue incidence. Together with observational evidence that is accumulating from pragmatic deployments of Wolbachia in other field sites, this will provide valuable data to estimate the effectiveness of this novel approach to arbovirus control, inform future cost-effectiveness estimates, and guide plans for large-scale deployments in other endemic settings. TRIAL REGISTRATION ClinicalTrials.gov, identifier: NCT03055585 . Registered on 14 February 2017.",2018,"aegypti stably transfected with Wolbachia bacterium, with a significantly reduced ability to transmit dengue, Zika and chikungunya in laboratory experiments.","['The 26 km 2 study area was subdivided into 24 contiguous clusters', 'febrile patients presenting to a network of primary care clinics, with case or control status classified retrospectively based on the results of laboratory diagnostic testing']","['Wolbachia deployments or no intervention', 'Wolbachia-infected Ae', 'Wolbachia']","['symptomatic, virologically confirmed dengue virus infection of any severity']","[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0205283', 'cui_str': 'Contiguous (qualifier value)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic (environment)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0008902', 'cui_str': 'Systematics'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}]","[{'cui': 'C0752001', 'cui_str': 'Wolbachia'}]","[{'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0011315', 'cui_str': 'Breakbone Fever Virus'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",,0.10741,"aegypti stably transfected with Wolbachia bacterium, with a significantly reduced ability to transmit dengue, Zika and chikungunya in laboratory experiments.","[{'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': 'Anders', 'Affiliation': 'World Mosquito Program, Institute of Vector Borne Disease, Monash University, Melbourne, Australia. katie.anders@worldmosquito.org.'}, {'ForeName': 'Citra', 'Initials': 'C', 'LastName': 'Indriani', 'Affiliation': 'Department of Biostatistics, Epidemiology and Population Health, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.'}, {'ForeName': 'Riris Andono', 'Initials': 'RA', 'LastName': 'Ahmad', 'Affiliation': 'Department of Biostatistics, Epidemiology and Population Health, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.'}, {'ForeName': 'Warsito', 'Initials': 'W', 'LastName': 'Tantowijoyo', 'Affiliation': 'Eliminate Dengue Project, Centre for Tropical Medicine, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.'}, {'ForeName': 'Eggi', 'Initials': 'E', 'LastName': 'Arguni', 'Affiliation': 'Eliminate Dengue Project, Centre for Tropical Medicine, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.'}, {'ForeName': 'Bekti', 'Initials': 'B', 'LastName': 'Andari', 'Affiliation': 'Eliminate Dengue Project, Centre for Tropical Medicine, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.'}, {'ForeName': 'Nicholas P', 'Initials': 'NP', 'LastName': 'Jewell', 'Affiliation': 'School of Public Health, University of California, Berkeley, USA.'}, {'ForeName': 'Edwige', 'Initials': 'E', 'LastName': 'Rances', 'Affiliation': 'World Mosquito Program, Institute of Vector Borne Disease, Monash University, Melbourne, Australia.'}, {'ForeName': 'Scott L', 'Initials': 'SL', 'LastName': ""O'Neill"", 'Affiliation': 'World Mosquito Program, Institute of Vector Borne Disease, Monash University, Melbourne, Australia.'}, {'ForeName': 'Cameron P', 'Initials': 'CP', 'LastName': 'Simmons', 'Affiliation': 'World Mosquito Program, Institute of Vector Borne Disease, Monash University, Melbourne, Australia.'}, {'ForeName': 'Adi', 'Initials': 'A', 'LastName': 'Utarini', 'Affiliation': 'Eliminate Dengue Project, Centre for Tropical Medicine, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.'}]",Trials,['10.1186/s13063-018-2670-z'] 807,30870102,Promoting mental health in traumatic brain injury using single-session Behavioural Activation and SMS messaging: A randomized controlled trial.,"We compared two treatments for depression and/ or anxiety in chronic moderate to severe traumatic brain injury (TBI) (Clinicaltrials.gov NCT02061553). Fifty-nine participants were randomized 2:1 to a single session of Behavioural Activation followed by 8 weeks of daily SMS (text) messages in the form of implementation intentions supporting individualized goals for increased rewarding/ meaningful activities (INT), or a single (attention control) session focused on the importance of motivation followed by 8 weeks of motivational SMS messages (MOT). Both conditions resulted in modestly improved emotional status. The INT condition led to more exposure to environmental reward and greater productivity. Gains in both conditions were of questionable clinical significance but suggested different mechanisms of action, which should be confirmed by further research. The delivery of frequent text messages proved to be a very feasible means of supporting treatment in this population.",2020,"Gains in both conditions were of questionable clinical significance but suggested different mechanisms of action, which should be confirmed by further research.",['Fifty-nine participants'],"['Behavioural Activation followed by 8 weeks of daily SMS (text) messages in the form of implementation intentions supporting individualized goals for increased rewarding/ meaningful activities (INT), or a single (attention control) session focused on the importance of motivation followed by 8 weeks of motivational SMS messages (MOT', 'single-session Behavioural Activation and SMS messaging']",['emotional status'],"[{'cui': 'C3830128', 'cui_str': '59 (qualifier value)'}]","[{'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0018017', 'cui_str': 'Goals'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}]","[{'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]",59.0,0.0707905,"Gains in both conditions were of questionable clinical significance but suggested different mechanisms of action, which should be confirmed by further research.","[{'ForeName': 'Tessa', 'Initials': 'T', 'LastName': 'Hart', 'Affiliation': 'Moss Rehabilitation Research Institute, Elkins Park, PA, USA.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Vaccaro', 'Affiliation': 'Moss Rehabilitation Research Institute, Elkins Park, PA, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Collier', 'Affiliation': 'Sixth Wave Technologies LLC, Asheville, NC, USA.'}, {'ForeName': 'Inna', 'Initials': 'I', 'LastName': 'Chervoneva', 'Affiliation': 'Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Jesse R', 'Initials': 'JR', 'LastName': 'Fann', 'Affiliation': 'University of Washington School of Medicine, Seattle, WA, USA.'}]",Neuropsychological rehabilitation,['10.1080/09602011.2019.1592761'] 808,30870245,Predictors of Exercise Training and Physical Activity Adherence in People Recently Hospitalized With Heart Failure: A BRIEF REPORT.,"PURPOSE For individuals with heart failure (HF), frequent attendance at exercise training programs and meeting physical activity (PA) guidelines are significantly associated with improvements in 6-min walk distance. Despite the evidence, adherence to exercise interventions remains poor. The aim of this study was to identify predictors of these 2 variables in patients recently hospitalized with HF. METHODS In this substudy of the Exercise Joins Education: Combined Therapy to Improve Outcomes in Newly-discharged Heart Failure (EJECTION-HF) trial, all participants were enrolled in a HF disease management program, including weekly review of a home exercise program for 12 wk. Intervention group participants additionally undertook twice weekly supervised exercise training. Primary outcomes were frequent exercise training program attendance (≥12 sessions) and attainment of PA guidelines (150 min/wk of moderate intensity exercise) at 12 wk. Participant and clinical characteristics were analyzed using a logistic regression model to identify significant predictors of each outcome. RESULTS A total of 278 participants provided PA data and 140 contributed attendance data. New diagnosis of HF was a significant predictor of frequent program attendance (OR = 2.3; 95% CI, 1.1-4.7; P = .03). Predictors of meeting PA guidelines at follow-up included new HF diagnosis (OR = 2.4; 95% CI, 1.2-4.8, P = .013), and being physically active at baseline (OR = 2.7; 95% CI, 1.3-5.6; P = .007). Gender, symptom severity, multimorbidity, and disability were not significantly associated with either outcome in multivariate analysis. CONCLUSION To improve adherence, specific strategies may be required for patients with decompensated HF and those physically inactive at time of referral.",2019,"New diagnosis of HF was a significant predictor of frequent program attendance (OR = 2.3; 95% CI, 1.1-4.7; P = .03).","['278 participants provided PA data and 140 contributed attendance data', 'Newly-discharged Heart Failure (EJECTION-HF) trial, all participants were enrolled in a HF disease management program, including weekly review of a home exercise program for 12 wk', 'individuals with heart failure (HF', 'patients with decompensated HF and those physically inactive at time of referral', 'People Recently Hospitalized With Heart Failure']","['Exercise Training and Physical Activity Adherence', 'supervised exercise training']","['Gender, symptom severity, multimorbidity, and disability', 'frequent exercise training program attendance (≥12 sessions) and attainment of PA guidelines', 'frequent program attendance']","[{'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0336969', 'cui_str': 'Ejection (qualifier value)'}, {'cui': 'C1303150', 'cui_str': 'Disease management program'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0699752', 'cui_str': 'Review of (contextual qualifier) (qualifier value)'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program (regime/therapy)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0034927', 'cui_str': 'Referral'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C1535889', 'cui_str': 'Multimorbidity'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0332183', 'cui_str': 'Frequent (qualifier value)'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C2728259', 'cui_str': 'Program'}]",278.0,0.0700865,"New diagnosis of HF was a significant predictor of frequent program attendance (OR = 2.3; 95% CI, 1.1-4.7; P = .03).","[{'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Adsett', 'Affiliation': ""Heart Support Service (Ms Adsett) and Departments of Physiotherapy (Ms Adsett) and Internal Medicine and Aged Care (Dr Mudge), Royal Brisbane and Women's Hospital, Brisbane, Australia; School of Allied Health Sciences, Griffith University, Gold Coast, Australia (Ms Adsett and Dr Morris); Menzies Health Institute, Queensland, Australia (Ms Adsett and Dr Morris); Metro North Hospital and Health Service, The Prince Charles Hospital, Allied Health Research Collaborative, Queensland, Australia (Dr Morris); and University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia (Dr Mudge).""}, {'ForeName': 'Norman R', 'Initials': 'NR', 'LastName': 'Morris', 'Affiliation': ''}, {'ForeName': 'Alison M', 'Initials': 'AM', 'LastName': 'Mudge', 'Affiliation': ''}]",Journal of cardiopulmonary rehabilitation and prevention,['10.1097/HCR.0000000000000407'] 809,30868305,Role of Spreader Flaps in Rhinoplasty: Analysis of Patients Undergoing Correction for Severe Septal Deviation with Long-Term Follow-Up.,"INTRODUCTION The aim of this randomized controlled study was to analyze the long-term results of patients undergoing rhinoplasty because of severe septal deviation and to evaluate the stability of results. MATERIALS AND METHODS The study was performed with a randomized design. Patients were randomly divided into four groups: group 1, spreader flaps were used in combination with spreader grafts; group 2, spreader flaps were used alone; group 3, spreader grafts were used alone; and group 4, neither spreader flaps nor grafts flaps were used. Patients answered the Italian version of the FACE-Q rhinoplasty module. Anthropometric measurements were performed by AutoCAD for MAC. We determined the angle of deviation, and we compared the pre- and postoperative angles and compared patient satisfaction in the four groups using the Chi-squared test for unpaired data. Two plastic surgeons reviewed all the postoperative photographs of the study patients and rated the photographs on a scale of 1 to 5. RESULTS A total of 264 patients who underwent primary rhinoplasty between January 2010 and September 2016 satisfied the inclusion criteria and were finally enrolled in this study. Anthropometric measurements revealed statistically significant differences (P < 0.01) between the preoperative and postoperative values for the angle of septal deviation in group 1 versus the other groups. Over the long-term follow-up, group 1 maintained an angle close to 180 degrees (P < 0.01). Group 1 and group 3 were more satisfied compared with groups 2 and 4 (P < 0.01). According to evaluations by the 2 reviewers, group 1 and group 3 were the most satisfactory outcomes (P < 0.01). CONCLUSIONS This was the first randomized study to show that the combined use of the spreader flap and spreader graft is the best choice for a good long-term outcome and durable correction of septal deviation. LEVEL OF EVIDENCE IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .",2019,Group 1 and group 3 were more satisfied compared with groups 2 and 4 (P < 0.01).,"['Patients Undergoing Correction for Severe Septal Deviation with Long-Term Follow-Up', 'Spreader Flaps in Rhinoplasty', '264 patients who underwent primary rhinoplasty between January 2010 and September 2016 satisfied the inclusion criteria and were finally enrolled in this study', 'patients undergoing rhinoplasty because of severe septal deviation']","['IV', 'spreader flap and spreader graft', 'spreader flaps were used in combination with spreader grafts; group 2, spreader flaps were used alone; group 3, spreader grafts were used alone; and group 4, neither spreader flaps nor grafts flaps']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0442004', 'cui_str': 'Septal (qualifier value)'}, {'cui': 'C0012727', 'cui_str': 'Displacement (morphologic abnormality)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0183479', 'cui_str': 'Spreader (physical object)'}, {'cui': 'C0038925', 'cui_str': 'Surgical Flaps'}, {'cui': 'C0035467', 'cui_str': 'Plastic operation on nose'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0183479', 'cui_str': 'Spreader (physical object)'}, {'cui': 'C0038925', 'cui_str': 'Surgical Flaps'}, {'cui': 'C1527362', 'cui_str': 'grafts'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C0441869', 'cui_str': 'Group 3 (qualifier value)'}, {'cui': 'C0441876', 'cui_str': 'Group 4 (qualifier value)'}]",[],264.0,0.0500869,Group 1 and group 3 were more satisfied compared with groups 2 and 4 (P < 0.01).,"[{'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Barone', 'Affiliation': 'Plastic and Reconstructive Surgery Unit, Campus Bio-Medico University of Rome, Via Alvaro Del Portillo 200, Rome, Italy. maurosabbarone@gmail.com.'}, {'ForeName': 'Annalisa', 'Initials': 'A', 'LastName': 'Cogliandro', 'Affiliation': 'Plastic and Reconstructive Surgery Unit, Campus Bio-Medico University of Rome, Via Alvaro Del Portillo 200, Rome, Italy.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Salzillo', 'Affiliation': 'Plastic and Reconstructive Surgery Unit, Campus Bio-Medico University of Rome, Via Alvaro Del Portillo 200, Rome, Italy.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Colapietra', 'Affiliation': 'Plastic and Reconstructive Surgery Unit, Campus Bio-Medico University of Rome, Via Alvaro Del Portillo 200, Rome, Italy.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Alessandri Bonetti', 'Affiliation': 'Plastic and Reconstructive Surgery Unit, Campus Bio-Medico University of Rome, Via Alvaro Del Portillo 200, Rome, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Morelli Coppola', 'Affiliation': 'Plastic and Reconstructive Surgery Unit, Campus Bio-Medico University of Rome, Via Alvaro Del Portillo 200, Rome, Italy.'}, {'ForeName': 'Emile', 'Initials': 'E', 'LastName': 'List', 'Affiliation': 'Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Ciarrocchi', 'Affiliation': 'Plastic and Reconstructive Surgery Unit, Campus Bio-Medico University of Rome, Via Alvaro Del Portillo 200, Rome, Italy.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Tenna', 'Affiliation': 'Plastic and Reconstructive Surgery Unit, Campus Bio-Medico University of Rome, Via Alvaro Del Portillo 200, Rome, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Persichetti', 'Affiliation': 'Plastic and Reconstructive Surgery Unit, Campus Bio-Medico University of Rome, Via Alvaro Del Portillo 200, Rome, Italy.'}]",Aesthetic plastic surgery,['10.1007/s00266-019-01343-3'] 810,30690785,"Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled Trial.","Mineral and bone disorders including osteoporosis are common in dialysis patients and contribute to increased morbimortality. However, whether denosumab and alendronate are effective and safe treatments in hemodialysis patients is not known. Thus, we conducted a prospective, three-center study of 48 hemodialysis patients who were diagnosed as having osteoporosis and had not received anti-osteoporotic agents previously. Participants were randomized to either denosumab or intravenous alendronate, and all subjects received elemental calcium and calcitriol during the initial 2 weeks. The primary endpoint was the percent change in lumbar spine bone mineral density (LSBMD) at 12 months of treatment. The secondary endpoints included the following: change in BMD at other sites; change of serum bone turnover markers (BTM), coronary artery calcium score (CACS), ankle-brachial pressure index (ABI), brachial-ankle pulse wave velocity (baPWV), flow mediated dilation (FMD), and intima-media thickness at the carotid artery (CA-IMT); change from day 0 to day 14 in serum levels of Ca and P; time course of serum calcium (Ca), phosphorus (P), and intact parathyroid hormone (i-PTH); new fractures; and adverse events. Initial supplementation with elemental calcium and calcitriol markedly ameliorated the decrease of serum corrected calcium (cCa) levels induced by denosumab during the first 2 weeks, whereas serum cCa levels in the alendronate group were increased. Denosumab and alendronate markedly decreased serum levels of BTM and increased LSBMD at 12 months compared with baseline. However, no significant differences were found in the changes in LSBMD between the two groups. The serum cCa, P, and i-PTH levels in the two groups were maintained within the appropriate range. In contrast to the anti-osteoporotic effects, no significant differences after 12 months of treatment were found in the CACS, CA-IMT, ABI, baPWV, and FMD compared with pretreatment in both groups. Denosumab and alendronate treatment improved LSBMD, reduced BTM, and appeared to be safe in hemodialysis patients with osteoporosis. © 2019 American Society for Bone and Mineral Research.",2019,Denosumab and alendronate markedly decreased serum levels of BTM and increased LSBMD at 12 months compared with baseline.,"['Hemodialysis Patients', '48 hemodialysis patients who were diagnosed as having osteoporosis and had not received anti-osteoporotic agents previously', 'hemodialysis patients with osteoporosis', 'hemodialysis patients', '© 2019 American Society for Bone and Mineral Research']","['elemental calcium and calcitriol', 'denosumab and alendronate', 'Denosumab and Alendronate', 'denosumab or intravenous alendronate', 'Denosumab and alendronate']","['Bone Health and Vascular Function', 'serum corrected calcium (cCa) levels', 'serum cCa levels', 'CACS, CA-IMT, ABI, baPWV, and FMD', 'LSBMD, reduced BTM', 'serum cCa, P, and i-PTH levels', 'serum levels of BTM and increased LSBMD', 'percent change in lumbar spine bone mineral density (LSBMD', 'LSBMD', 'change in BMD at other sites; change of serum bone turnover markers (BTM), coronary artery calcium score (CACS), ankle-brachial pressure index (ABI), brachial-ankle pulse wave velocity (baPWV), flow mediated dilation (FMD), and intima-media thickness at the carotid artery (CA-IMT); change from day 0 to day 14 in serum levels of Ca and P; time course of serum calcium (Ca), phosphorus (P), and intact parathyroid hormone (i-PTH); new fractures; and adverse events']","[{'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0026162', 'cui_str': 'Minerals'}, {'cui': 'C0035168'}]","[{'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0006674', 'cui_str': '1,25-dihydroxycholecalciferol'}, {'cui': 'C1690432', 'cui_str': 'denosumab'}, {'cui': 'C0102118', 'cui_str': 'Alendronate'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}]","[{'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C2732404', 'cui_str': 'Corrected measurement of calcium (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0202159', 'cui_str': 'Parathyroid hormone measurement (procedure)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C3887615', 'cui_str': 'Lumbar spine structure (body structure)'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0085268', 'cui_str': 'Bone Turnover'}, {'cui': 'C3484386', 'cui_str': 'Coronary artery calcium score'}, {'cui': 'C1276055', 'cui_str': 'ABPI - Ankle brachial pressure index'}, {'cui': 'C0445456', 'cui_str': 'Brachial (qualifier value)'}, {'cui': 'C0232154', 'cui_str': 'Ankle pulse'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0162864', 'cui_str': 'Vascular Intima'}, {'cui': 'C0007272', 'cui_str': 'Carotid Arteries'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0449247', 'cui_str': 'Time course (attribute)'}, {'cui': 'C0728876', 'cui_str': 'Serum calcium measurement'}, {'cui': 'C0031705', 'cui_str': 'Phosphorus'}, {'cui': 'C0030520', 'cui_str': 'Parathyroid Hormone'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",48.0,0.0219382,Denosumab and alendronate markedly decreased serum levels of BTM and increased LSBMD at 12 months compared with baseline.,"[{'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Iseri', 'Affiliation': 'Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Watanabe', 'Affiliation': 'Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hisako', 'Initials': 'H', 'LastName': 'Yoshikawa', 'Affiliation': 'Nephrology Center, Makita General Hospital, Tokyo, Japan.'}, {'ForeName': 'Hisao', 'Initials': 'H', 'LastName': 'Mitsui', 'Affiliation': 'Hanedaoozora Dialysis Clinic, Tokyo, Japan.'}, {'ForeName': 'Teruhiko', 'Initials': 'T', 'LastName': 'Endo', 'Affiliation': 'Adachimotoki Jin Dialysis Clinic, Tokyo, Japan.'}, {'ForeName': 'Yuichiro', 'Initials': 'Y', 'LastName': 'Yamamoto', 'Affiliation': 'Hanedaoozora Dialysis Clinic, Tokyo, Japan.'}, {'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Iyoda', 'Affiliation': 'Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Kakei', 'Initials': 'K', 'LastName': 'Ryu', 'Affiliation': 'Clinical Pharmacology, Pharmacology, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Taro', 'Initials': 'T', 'LastName': 'Inaba', 'Affiliation': 'Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Takanori', 'Initials': 'T', 'LastName': 'Shibata', 'Affiliation': 'Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}]",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,['10.1002/jbmr.3676'] 811,30773731,Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial.,"Neuropathy is a dose limiting side effect of taxanes which may impact the quality of life and treatment outcomes. This randomized placebo-controlled double-blinded clinical trial was carried out to assess the efficacy of gabapentin in preventing chemotherapy induced neuropathy. Women with breast cancer were randomized into two groups of paclitaxel chemotherapy with gabapentin 300 mg/three times a day orally or placebo for 2 weeks started at day 1 of each paclitaxel cycle. Two groups were compared based on the relative frequency of neuropathy and change in nerve conducting velocity (NCV). Twenty women were assigned to each study arm. The majority of the neuropathy in gabapentin group was grade 1 in all of the four cycles with no event of ≥grade 3 neuropathy in this group. Compared to the placebo, the rate of 2nd and 3rd grade neuropathy was significantly lower in the gabapentin group (P = 0.000). The change in NCV after four cycles of paclitaxel was significantly lower in the gabapentin group compared to the placebo group (17.7% vs 61.0% decline in NCV for sural and 21.9% vs 62.5% declines in NCV for peroneal nerve). Gabapentin given with paclitaxel is effective in the prevention of intermediate and high grade neuropathies both objectively and subjectively.",2019,Gabapentin given with paclitaxel is effective in the prevention of intermediate and high grade neuropathies both objectively and subjectively.,"['induced peripheral neuropathy', 'Women with breast cancer', 'Twenty women']","['placebo', 'taxanes', 'paclitaxel', 'Gabapentin', 'gabapentin', 'paclitaxel chemotherapy with gabapentin 300\xa0mg/three times a day orally or placebo']","['change in NCV', 'rate of 2nd and 3rd grade neuropathy', 'relative frequency of neuropathy and change in nerve conducting velocity (NCV']","[{'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0031117', 'cui_str': 'PNS (Peripheral Nervous System) Diseases'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0796419', 'cui_str': 'Taxanes'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0060926', 'cui_str': 'gabapentin'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C2978021', 'cui_str': 'gabapentin 300 MG [Gralise]'}, {'cui': 'C0556984', 'cui_str': 'Three times daily (qualifier value)'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0205436', 'cui_str': 'Second - ordinal'}, {'cui': 'C0205437', 'cui_str': 'Third (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0442874', 'cui_str': 'Neuropathy (disorder)'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0027740', 'cui_str': 'Nerve structure'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}]",20.0,0.200875,Gabapentin given with paclitaxel is effective in the prevention of intermediate and high grade neuropathies both objectively and subjectively.,"[{'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Aghili', 'Affiliation': 'Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mahkameh', 'Initials': 'M', 'LastName': 'Zare', 'Affiliation': 'Department of Radiation Oncology, Hafte-e-Tir Hospital, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Nima', 'Initials': 'N', 'LastName': 'Mousavi', 'Affiliation': 'Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Ghalehtaki', 'Affiliation': 'Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Sarvazad', 'Initials': 'S', 'LastName': 'Sotoudeh', 'Affiliation': 'Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Bita', 'Initials': 'B', 'LastName': 'Kalaghchi', 'Affiliation': 'Radiation Oncology Research Center (RORC), Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Shahram', 'Initials': 'S', 'LastName': 'Akrami', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Esmati', 'Affiliation': 'Radiation Oncology Research Center (RORC), Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.'}]",The breast journal,['10.1111/tbj.13196'] 812,30790008,"Weight-adapted ultra-low-dose pancreatic perfusion CT: radiation dose, image quality, and perfusion parameters.","PURPOSE We evaluate the reliability and feasibility of weight-adapted ultra-low-dose pancreatic perfusion CT. METHODS A total of 100 (47 men, 53 women) patients were enrolled prospectively and were assigned to five groups (A, B, C, D, and E) with different combination of tube voltage and tube current according to their body weight. Radiation dose parameters including volume CT dose index (CTDI) and dose-length product (DLP) were recorded. Image quality was evaluated both subjectively and objectively (noise, signal-to-noise ratio, contrast-to-noise ratio). Perfusion parameters including blood flow (BF), blood volume (BV), and permeability (PMB) were measured. The dose, image quality measurements, and perfusion parameters were compared between the five groups using one-way analysis of variance (ANOVA). RESULTS Radiation dose reached 8.7 mSv in patients under 50 kg and was 18.9 mSv in patients above 80 kg. The mean subjective image quality score was above 4.45 on a 5-point scale with good agreement between two radiologists. Groups A-D had equivalent performance on objective image quality (P > 0.05), while Group E performed even better (P < 0.05). No significant differences emerged in comparison with perfusion parameters (BF, BV, PMB) of normal pancreas parenchyma between the five groups. CONCLUSION Weight-adapted ultra-low-dose pancreatic perfusion CT can effectively reduce radiation dose without prejudice to image quality, and the perfusion parameters of normal parenchyma are accurate and reliable.",2019,The mean subjective image quality score was above 4.45 on a 5-point scale with good agreement between two radiologists.,"['A total of 100 (47 men, 53 women) patients']","['weight-adapted ultra-low-dose pancreatic perfusion CT', 'Weight-adapted ultra-low-dose pancreatic perfusion CT']","['volume CT dose index (CTDI) and dose-length product (DLP', 'objective image quality', 'mean subjective image quality score', 'blood flow (BF), blood volume (BV), and permeability (PMB', 'comparison with perfusion parameters (BF, BV, PMB) of normal pancreas parenchyma', 'Image quality']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}]","[{'cui': 'C1956110', 'cui_str': 'Cone-Beam Computerized Tomography'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}, {'cui': 'C0005850', 'cui_str': 'Blood Volume'}, {'cui': 'C0031164', 'cui_str': 'Permeability'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}]",,0.0180199,The mean subjective image quality score was above 4.45 on a 5-point scale with good agreement between two radiologists.,"[{'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Li', 'Affiliation': 'Department of Radiology, Peking Union Medical College Hospital, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China.'}, {'ForeName': 'Wanling', 'Initials': 'W', 'LastName': 'Deng', 'Affiliation': 'Peking Union Medical College, Chinese Academy of Medical Sciences, Dongcheng District, Beijing, 100730, China.'}, {'ForeName': 'Huadan', 'Initials': 'H', 'LastName': 'Xue', 'Affiliation': 'Department of Radiology, Peking Union Medical College Hospital, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China. bjdanna95@163.com.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Xu', 'Affiliation': 'Department of Radiology, Peking Union Medical College Hospital, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China.'}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Zhu', 'Affiliation': 'Department of Radiology, Peking Union Medical College Hospital, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Radiology, Peking Union Medical College Hospital, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China.'}, {'ForeName': 'Zhaoyong', 'Initials': 'Z', 'LastName': 'Sun', 'Affiliation': 'Department of Radiology, Peking Union Medical College Hospital, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China.'}, {'ForeName': 'Zhengyu', 'Initials': 'Z', 'LastName': 'Jin', 'Affiliation': 'Department of Radiology, Peking Union Medical College Hospital, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China.'}]",Abdominal radiology (New York),['10.1007/s00261-019-01938-z'] 813,30827757,Baseline effective connectivity predicts response to repetitive transcranial magnetic stimulation in patients with treatment-resistant depression.,"Repetitive transcranial magnetic stimulation (rTMS) has become a popular treatment option for treatment-resistant depression (TRD). However, suboptimal response rates highlight the need for improved efficacy through optimisation of treatment protocol and patient selection. We investigate whether the limbic salience network and its connectivity with prefrontal stimulation sites predict immediate and longer-term responsiveness to rTMS. Twenty-seven patients with TRD were randomly allocated to receive 16 sessions of either conventional rTMS or intermittent theta-burst (iTBS) over 4 weeks; delivered using connectivity profiling and neuronavigation to target person-specific dorsolateral prefrontal cortex (DLPFC). At baseline and 3-month follow-up, patients underwent clinical assessment and scanning session, and 1-month clinical follow-up. Resting-state fMRI data were entered into seed-based functional and effective connectivity analyses between right anterior insula (rAI) and DLPFC target, and independent components analysis to extract resting-state networks. Cerebral blood flow (CBF) was also assessed in the rAI. All brain measures were compared between baseline and follow-up, and related to treatment response at 1- and 3-months. Baseline fronto-insular effective connectivity and salience network connectivity were significantly positively correlated, while baseline rAI CBF was negatively correlated, with early (1-month) response to rTMS treatment but not sustained response (3-months), suggesting persistence of therapeutic response is not associated with baseline features. Connectivity or CBF measures did not change between the two time points. We demonstrate that fronto-insular and salience-network interactions can predict early response to rTMS in TRD, suggesting that these network nodes may be key regions toward developing rTMS response biomarkers.",2019,Connectivity or CBF measures did not change between the two time points.,"['Twenty-seven patients with TRD', 'patients with treatment-resistant depression']","['repetitive transcranial magnetic stimulation', 'conventional rTMS or intermittent theta-burst (iTBS) over 4 weeks; delivered using connectivity profiling and neuronavigation to target person-specific dorsolateral prefrontal cortex (DLPFC', 'rTMS', 'Repetitive transcranial magnetic stimulation (rTMS']","['Cerebral blood flow (CBF', 'baseline rAI', 'Connectivity or CBF measures', 'CBF', 'Baseline fronto-insular effective connectivity and salience network connectivity']","[{'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2063866', 'cui_str': 'Refractory Depression'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1136207', 'cui_str': 'Frameless Stereotaxy'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C4019080', 'cui_str': 'Dorsolateral Prefrontal Cortex'}]","[{'cui': 'C0428714', 'cui_str': 'Cerebral Blood Flow'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}]",27.0,0.0327343,Connectivity or CBF measures did not change between the two time points.,"[{'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Iwabuchi', 'Affiliation': ""NIHR Nottingham Biomedical Research Centre, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, United Kingdom; Sir Peter Mansfield Imaging Centre, School of Medicine, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom.""}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Auer', 'Affiliation': ""NIHR Nottingham Biomedical Research Centre, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, United Kingdom; Sir Peter Mansfield Imaging Centre, School of Medicine, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom.""}, {'ForeName': 'S T', 'Initials': 'ST', 'LastName': 'Lankappa', 'Affiliation': 'Nottinghamshire Healthcare NHS Foundation Trust, Nottingham NG7 2UH, UK.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Palaniyappan', 'Affiliation': 'Departments of Psychiatry and Medical Biophysics and Robarts Research Institute, Western University, London, ON, Canada; Lawson Health Research Institute, London, ON, Canada. Electronic address: lpalaniy@uwo.ca.'}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2019.02.012'] 814,30506431,Temporal bone trauma effects on auditory anatomical structures in mastoid obliteration.,"PURPOSE The risk of temporal bone fractures in head trauma is not negligible, as injuries also depend on the resistance and integrity of head structures. The capacity of mastoid cells to absorb part of the impact kinetic energy of the temporal bone is diminished after open cavity mastoidectomy, even if the surgical procedure is followed by mastoid obliteration. The aim of our study was to evaluate the severity of lesions in auditory anatomical structures after a lateral impact on cadaveric temporal bones in which open cavity mastoidectomy followed by mastoid obliteration was performed, compared to cadaveric temporal bones with preserved mastoids. METHODS The study was carried out on 20 cadaveric temporal bones, which were randomly assigned to two groups. In the study group, open cavity mastoidectomy followed by mastoid obliteration with heterologous materials was performed. All temporal bones were impacted laterally under the same conditions. Temporal bone fractures were evaluated by CT scan. RESULTS External auditory canal fractures were six times more seen in the study group. Tympanic bone fractures were present in 80% of the samples in the study group and 10% in the control group (p = .005). Middle ear fractures were found in 70% of the samples in the study group and 10% in the control group (p = .02). Otic capsule violating fractures of the temporal bone were present only in the study group. CONCLUSIONS Mastoid obliteration with heterologous materials after open cavity mastoidectomy increases the risk of fracture, with the involvement of auditory anatomical structures.",2019,Tympanic bone fractures were present in 80% of the samples in the study group and 10% in the control group (p = .005).,"['mastoid obliteration', '20 cadaveric temporal bones']",[],"['risk of fracture', 'Middle ear fractures', 'Temporal bone fractures', 'Tympanic bone fractures']","[{'cui': 'C0395708', 'cui_str': 'Obliteration of mastoid cavity (procedure)'}, {'cui': 'C0039484', 'cui_str': 'Temporal Bone'}]",[],"[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0013455', 'cui_str': 'Middle ear structure (body structure)'}, {'cui': 'C0039484', 'cui_str': 'Temporal Bone'}]",20.0,0.0208903,Tympanic bone fractures were present in 80% of the samples in the study group and 10% in the control group (p = .005).,"[{'ForeName': 'Aranka', 'Initials': 'A', 'LastName': 'Ilea', 'Affiliation': 'Department of Oral Rehabilitation, Oral Health and Dental Office Management, Faculty of Dentistry, ""Iuliu Hațieganu"" University of Medicine and Pharmacy Cluj-Napoca, Str.Victor Babeș, No 15, Cluj-Napoca, Romania.'}, {'ForeName': 'Anca', 'Initials': 'A', 'LastName': 'Butnaru', 'Affiliation': 'Department of Radiology, Faculty of Medicine, ""Iuliu Hațieganu"" University of Medicine and Pharmacy Cluj-Napoca, Str. Clinicilor, No 1-3, Cluj-Napoca, Romania.'}, {'ForeName': 'Silviu Andrei', 'Initials': 'SA', 'LastName': 'Sfrângeu', 'Affiliation': 'Department of Radiology, Faculty of Medicine, ""Iuliu Hațieganu"" University of Medicine and Pharmacy Cluj-Napoca, Str. Clinicilor, No 1-3, Cluj-Napoca, Romania.'}, {'ForeName': 'Mihaela', 'Initials': 'M', 'LastName': 'Hedeșiu', 'Affiliation': 'Department of Dental Radiology, Faculty of Dentistry, ""Iuliu Hațieganu"" University of Medicine and Pharmacy, Cluj-Napoca, Str. Clinicilor, No 32, Cluj-Napoca, Romania.'}, {'ForeName': 'Cristian Mircea', 'Initials': 'CM', 'LastName': 'Dudescu', 'Affiliation': 'Department of Mechanical Engineering, Faculty of Mechanics, Technical University Cluj-Napoca, B-dul Muncii, No 103-105, Cluj-Napoca, Romania.'}, {'ForeName': 'Bianca Adina', 'Initials': 'BA', 'LastName': 'Boșca', 'Affiliation': 'Department of Histology, Faculty of Medicine, ""Iuliu Hațieganu"" University of Medicine and Pharmacy Cluj-Napoca, Str. L. Pasteur, No. 4, 400349, Cluj-Napoca, Romania. biancabosca@yahoo.com.'}, {'ForeName': 'Veronica Elena', 'Initials': 'VE', 'LastName': 'Trombitaș', 'Affiliation': 'Department of Cervicofacial and ENT Surgery, Faculty of Dentistry, ""Iuliu Hațieganu"" University of Medicine and Pharmacy Cluj-Napoca, Str. Gheorghe Bilascu Nr. 16-20, Cluj-Napoca, Romania.'}, {'ForeName': 'Radu Septimiu', 'Initials': 'RS', 'LastName': 'Câmpian', 'Affiliation': 'Department of Oral Rehabilitation, Oral Health and Dental Office Management, Faculty of Dentistry, ""Iuliu Hațieganu"" University of Medicine and Pharmacy Cluj-Napoca, Str. Victor Babeș, No 15, Cluj-Napoca, Romania.'}, {'ForeName': 'Silviu', 'Initials': 'S', 'LastName': 'Albu', 'Affiliation': 'Department of Cervicofacial and ENT Surgery, Faculty of Dentistry, ""Iuliu Hațieganu"" University of Medicine and Pharmacy Cluj-Napoca, Str. Gheorghe Bilascu Nr. 16-20, Cluj-Napoca, Romania.'}]",European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,['10.1007/s00405-018-5227-6'] 815,30664549,TRPA1 Sensitization Produces Hyperalgesia to Heat but not to Cold Stimuli in Human Volunteers.,"BACKGROUND Transient receptor potential ion channels play a role in thermal hyperalgesia and are among targets of novel analgesics. However, a role of TRPA1 in either heat or cold hyperalgesia is controversial. In this study, changes in thermal sensitivity were assessed following topical application of a specific sensitizer of TRPA1 and compared with the effects of sensitizers of TRPV1 and TRPM8. METHODS Employing a randomized cross-over design, thermal thresholds were assessed in 16 pain-free volunteers before and at 20 minutes after topical application of cinnamaldehyde, capsaicin or menthol stimulating TRPA1, TRPV1, or TRPM8, respectively. Cold or warm detection thresholds and cold or heat pain thresholds were assessed according to the standardized quantitative sensory testing protocol proposed by the German Research Network on Neuropathic Pain. RESULTS The effects of different irritants displayed a cluster structure. Hyperalgesia was induced by capsaicin and cinnamaldehyde on heat pain thresholds and by menthol on cold pain thresholds (Cohen d=2.2035, 0.9932, and 1.256, respectively). A second cluster comprised large effects directed toward hyposensitization, such as cold hyposensitization induced by capsaicin and cinnamaldehyde, or small or absent hyposensitizing effects. CONCLUSIONS The observation that the TRPA1 irritant cinnamaldehyde induced heat hyperalgesia at an effect sizes comparable with that of capsaicin attributes TRPA1 a role in human heat-induced pain. Results suggest the inclusion of heat pain as a major efficacy measure in human experimental studies of the effects of TRPA1 antagonists and the development of TRPA1 antagonists for clinical pain settings involving heat hyperalgesia.",2019,", thermal thresholds were assessed in 16 pain-free volunteers before and at 20 minutes after topical application of cinnamaldehyde, capsaicin or menthol stimulating TRPA1, TRPV1, or TRPM8, respectively.",['Human Volunteers'],"['TRPV1 and TRPM8', 'capsaicin attributes', 'capsaicin', 'TRPA1']","['heat hyperalgesia', 'Hyperalgesia', 'heat pain thresholds', 'thermal sensitivity', 'cold pain thresholds']","[{'cui': 'C0020155', 'cui_str': 'Human Volunteers'}]","[{'cui': 'C0006931', 'cui_str': 'Capsaicin'}, {'cui': 'C0449234', 'cui_str': 'Attribute (attribute)'}]","[{'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0020429', 'cui_str': 'Hyperalgesic Sensations'}, {'cui': 'C0162703', 'cui_str': 'Pain Threshold'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0009443', 'cui_str': 'Common Cold'}]",,0.0339211,", thermal thresholds were assessed in 16 pain-free volunteers before and at 20 minutes after topical application of cinnamaldehyde, capsaicin or menthol stimulating TRPA1, TRPV1, or TRPM8, respectively.","[{'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Weyer-Menkhoff', 'Affiliation': 'Institute of Clinical Pharmacology, Goethe-University.'}, {'ForeName': 'Jörn', 'Initials': 'J', 'LastName': 'Lötsch', 'Affiliation': 'Institute of Clinical Pharmacology, Goethe-University.'}]",The Clinical journal of pain,['10.1097/AJP.0000000000000677'] 816,31705448,Efficacy of Acupuncture Combined with Local Anesthesia in Ischemic Stroke Patients with Carotid Artery Stenting: A Prospective Randomized Trial.,"OBJECTIVE To evaluate the efficacy of electro-acupuncture (EA) or transcutaneous electrical acupoint stimulation (TEAS) on perioperative cerebral blood flow (CBF) and neurological function in ischemic stroke (IS) patients undergoing carotid artery stenting (CAS). METHODS In total, 124 consecutive IS patients were randomly allocated to the EA, TEAS, and sham groups (groups A, T, and S; 41, 42, and 41 cases, respectively) by software-derived random-number sequence. Groups A and T received EA and TEAS, respectively, at the Shuigou (GV 26) and Baihui (GV 20), Hegu (LI4) and Waiguan (TE 5) acupoints. Group S received sham EA. The stimulation was started from 30 min before surgery until the end of the operation. The primary outcome was the CBF at 30 min after surgery, which was measured by transcranial Doppler sonography. The secondary outcomes included hyperperfusion incidence and neurological function. National Institutes of Health Stroke Scale (NIHSS) and General Evaluation Scale (GES) scores were recorded at 1 week, 1 month, and 3 months postoperatively. RESULTS Mean CBF velocity at 30 min after surgery in groups A and T was much lower than that in Group S (P < 0.05); the incidence of hyperperfusion in Groups A and T was also lower than that in group S (P <0.05). Acupuncture was an independent factor associated with reduced incidence of hyperperfusion (OR=0.042; 95% CI: 0.002-0.785; =0.034). NIHSS and GES scores improved significantly at 1 week postoperatively in Groups A and T than in Group S (P < 0.05). Relative to Group S, groups A and T exhibited significantly lower incidences of moderate pain, as well as higher incidences of satisfaction with anesthesia, at 1 day postoperatively (P < 0.05). CONCLUSIONS EA or TEAS administered in combination with local anesthesia during CAS can inhibit transient increases in CBF, reduce the incidence of postoperative hyperperfusion, and improve neurological function. (Registration No. ChiCTR-IOR-15007447).",2020,NIHSS and GES scores improved significantly at 1 week postoperatively in Groups A and T than in Group S (P < 0.05).,"['ischemic stroke (IS) patients undergoing carotid artery stenting (CAS', '124 consecutive IS patients', 'Ischemic Stroke Patients with Carotid Artery Stenting']","['EA, TEAS', 'Acupuncture Combined with Local Anesthesia', 'TEAS', 'electro-acupuncture (EA) or transcutaneous electrical acupoint stimulation (TEAS', 'Acupuncture', 'sham EA']","['incidence of hyperperfusion', 'moderate pain', 'perioperative cerebral blood flow (CBF) and neurological function', 'Mean CBF velocity', 'CBF', 'NIHSS and GES scores', 'Health Stroke Scale (NIHSS) and General Evaluation Scale (GES) scores', 'hyperperfusion incidence and neurological function', 'neurological function']","[{'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0007272', 'cui_str': 'Carotid Arteries'}, {'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}]","[{'cui': 'C0039400', 'cui_str': 'Tea'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia (procedure)'}, {'cui': 'C0442828', 'cui_str': 'Electrical (qualifier value)'}, {'cui': 'C0001302', 'cui_str': 'Acupoints'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0278139', 'cui_str': 'Moderate pain (finding)'}, {'cui': 'C0428714', 'cui_str': 'Cerebral Blood Flow'}, {'cui': 'C0027767', 'cui_str': 'Nervous System Physiology'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0222045'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",124.0,0.0827627,NIHSS and GES scores improved significantly at 1 week postoperatively in Groups A and T than in Group S (P < 0.05).,"[{'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Xiong', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100015, China.'}, {'ForeName': 'Chun-Mei', 'Initials': 'CM', 'LastName': 'Zhao', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100015, China.'}, {'ForeName': 'Li-Xin', 'Initials': 'LX', 'LastName': 'An', 'Affiliation': 'Department of Anesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China. anlixin8120@163.com.'}, {'ForeName': 'Si-Ning', 'Initials': 'SN', 'LastName': 'Xie', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100015, China.'}, {'ForeName': 'Chun-Rong', 'Initials': 'CR', 'LastName': 'Jia', 'Affiliation': 'Department of Traditional Chinese Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100015, China.'}]",Chinese journal of integrative medicine,['10.1007/s11655-019-3174-8'] 817,30791125,Absence of Drug-Drug Interaction of Anastrozole on Levonorgestrel Delivered Simultaneously by an Intravaginal Ring: Results of a Phase 2 Trial.,"Intravaginal rings (IVRs) are an established option for continuous administration of drugs in women. The combination of anastrozole (ATZ) and levonorgestrel (LNG) in an IVR with an intended 4-week wearing period has been considered for long-term treatment of endometriosis-associated pelvic pain. A randomized, parallel-group, multicenter phase 2b study to assess the efficacy and safety of different dose combinations in women with symptomatic endometriosis has recently been performed. This paper will focus on the investigation of pharmacokinetic (PK) effects of ATZ on LNG using data collected from this study. Two hundred sixteen patients were randomized to the treatment group with IVRs releasing LNG 40 μg/day alone or in combination with ATZ 300 μg/day, 600 μg/day, or 1050 μg/day for 12 weeks. PK blood samples were taken before dosing and before IVR replacement or removal (days 28, 56, and 84). The primary PK parameter was the plasma concentration in apparent steady state of ATZ and LNG at the end of each IVR wearing period. Results of PK analysis demonstrate that ATZ concentrations increased proportionally with increasing dose (geometric mean values of 7.85, 15.48, and 22.61 μg/L at 300, 600, and 1050 μg/day nominal release, respectively). All point estimates for LNG concentration in apparent steady state ratios between the mono and combination IVR groups were close to 1, and the 90% confidence interval limits were in the 0.80 to 1.25 range (1.01 [0.85-1.19], 1.03 [0.88-1.20], 0.94 [0.80-1.10]). In conclusion, our data indicate there is no evidence of drug-drug interaction of ATZ on LNG.",2019,"Results of PK analysis demonstrate that ATZ concentrations increased proportionally with increasing dose (geometric mean values of 7.85, 15.48, and 22.61 μg/L at 300, 600, and 1050 μg/day nominal release, respectively).","['Two hundred sixteen patients', 'women with symptomatic endometriosis', 'women']","['ATZ', 'Anastrozole', 'anastrozole (ATZ) and levonorgestrel (LNG', 'IVRs releasing LNG 40 μg/day alone or in combination with ATZ', 'Intravaginal rings (IVRs']","['ATZ concentrations', 'confidence interval limits', 'plasma concentration', 'efficacy and safety']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0014175', 'cui_str': 'Endometriosis'}]","[{'cui': 'C0290883', 'cui_str': 'anastrozole'}, {'cui': 'C0023566', 'cui_str': 'Levonorgestrel'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0442122', 'cui_str': 'Intravaginal (qualifier value)'}, {'cui': 'C1260969', 'cui_str': 'Ring, device (physical object)'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0009667', 'cui_str': 'Confidence Intervals'}, {'cui': 'C0439801', 'cui_str': 'Limited (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",216.0,0.129062,"Results of PK analysis demonstrate that ATZ concentrations increased proportionally with increasing dose (geometric mean values of 7.85, 15.48, and 22.61 μg/L at 300, 600, and 1050 μg/day nominal release, respectively).","[{'ForeName': 'Rüdiger', 'Initials': 'R', 'LastName': 'Nave', 'Affiliation': 'Clinical Sciences, Bayer AG, Berlin, Germany.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Mellinger', 'Affiliation': 'Development, Bayer AG, Berlin, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Klein', 'Affiliation': 'Clinical Sciences, Bayer AG, Berlin, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Höchel', 'Affiliation': 'Clinical Sciences, Bayer AG, Berlin, Germany.'}, {'ForeName': 'Heinz', 'Initials': 'H', 'LastName': 'Schmitz', 'Affiliation': 'Development, Bayer AG, Berlin, Germany.'}]",Journal of clinical pharmacology,['10.1002/jcph.1396'] 818,31704159,Using Electronic Health Records to Measure Quality Improvement Efforts: Findings from a Large Practice Facilitation Initiative.,"BACKGROUND Federal incentives for electronic health record (EHR) use typically require quality measure reporting over calendar year or 90-day periods. However, required reporting periods may not align with time frames of real-world quality improvement (QI) efforts. This study described primary care practices' ability to obtain measures with reporting periods aligning with a large QI initiative. METHODS Researchers conducted a substudy of a randomized trial testing practice facilitation strategies for preventive cardiovascular care. Three quality measures (aspirin for ischemic vascular disease; blood pressure control for hypertension; smoking screening/cessation) were collected quarterly over one year. The primary outcome was a binary indicator of whether a practice facilitator obtained all three measures with ""rolling 12-month"" reporting periods (that is, the year preceding each study quarter). RESULTS The study included 107 practices, 63 (58.9%) of which met the primary outcome of obtaining all measures with rolling 12-month reporting periods. Smaller practices were less likely to meet the primary outcome (p < 0.001). Practices used 11 different EHRs, 3 of which were unable to consistently produce rolling 12-month measures; at 33 practices (30.8%) using these 3 EHRs, facilitators met a secondary outcome of obtaining prior calendar year and rolling 3-month measures. Facilitators reported barriers to data collection such as practices lacking optional EHR features, and EHRs' inability to produce reporting periods across two calendar years. CONCLUSION EHR vendors' compliance with federal reporting requirements is not necessarily sufficient to support real-world QI work. Improvements are needed in the flexibility and usability of EHRs' quality measurement functions, particularly for smaller practices.",2020,Smaller practices were less likely to meet the primary outcome (p < 0.001).,"['107 practices, 63 (58.9%) of which met the primary outcome of obtaining all measures with rolling 12-month reporting periods']",[],"['binary indicator of whether a practice facilitator obtained all three measures with ""rolling 12-month"" reporting periods (that is, the year preceding each study quarter']","[{'cui': 'C4517529', 'cui_str': 'One hundred and seven'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]",[],"[{'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]",,0.0757072,Smaller practices were less likely to meet the primary outcome (p < 0.001).,"[{'ForeName': 'David T', 'Initials': 'DT', 'LastName': 'Liss', 'Affiliation': ''}, {'ForeName': 'Yaw A', 'Initials': 'YA', 'LastName': 'Peprah', 'Affiliation': ''}, {'ForeName': 'Tiffany', 'Initials': 'T', 'LastName': 'Brown', 'Affiliation': ''}, {'ForeName': 'Jody D', 'Initials': 'JD', 'LastName': 'Ciolino', 'Affiliation': ''}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Jackson', 'Affiliation': ''}, {'ForeName': 'Abel N', 'Initials': 'AN', 'LastName': 'Kho', 'Affiliation': ''}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Murakami', 'Affiliation': ''}, {'ForeName': 'Theresa L', 'Initials': 'TL', 'LastName': 'Walunas', 'Affiliation': ''}, {'ForeName': 'Stephen D', 'Initials': 'SD', 'LastName': 'Persell', 'Affiliation': ''}]",Joint Commission journal on quality and patient safety,['10.1016/j.jcjq.2019.09.006'] 819,28759333,Do Pattern-Focused Visuals Improve Skin Self-Examination Performance? Explicating the Visual Skill Acquisition Model.,"Skin self-examination (SSE) consists of routinely checking the body for atypical moles that might be cancerous. Identifying atypical moles is a visual task; thus, SSE training materials utilize pattern-focused visuals to cultivate this skill. Despite widespread use, researchers have yet to explicate how pattern-focused visuals cultivate visual skill. Using eye tracking to capture the visual scanpaths of a sample of laypersons (N = 92), the current study employed a 2 (pattern: ABCDE vs. ugly duckling sign [UDS]) × 2 (presentation: photorealistic images vs. illustrations) factorial design to assess whether and how pattern-focused visuals can increase layperson accuracy in identifying atypical moles. Overall, illustrations resulted in greater sensitivity, while photos resulted in greater specificity. The UDS × photorealistic condition showed greatest specificity. For those in the photo condition with high self-efficacy, UDS increased specificity directly. For those in the photo condition with self-efficacy levels at the mean or lower, there was a conditional indirect effect such that these individuals spent a larger amount of their viewing time observing the atypical moles, and time on target was positively related to specificity. Illustrations provided significant gains in specificity for those with low-to-moderate self-efficacy by increasing total fixation time on the atypical moles. Findings suggest that maximizing visual processing efficiency could enhance existing SSE training techniques.",2017,Illustrations provided significant gains in specificity for those with low-to-moderate self-efficacy by increasing total fixation time on the atypical moles.,[],"['ABCDE vs. ugly duckling sign [UDS', 'Skin self-examination (SSE']","['layperson accuracy', 'Skin Self-Examination Performance', 'total fixation time']",[],"[{'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C1444170', 'cui_str': 'Skin self-examination'}]","[{'cui': 'C1444170', 'cui_str': 'Skin self-examination'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",,0.0139209,Illustrations provided significant gains in specificity for those with low-to-moderate self-efficacy by increasing total fixation time on the atypical moles.,"[{'ForeName': 'Kevin K', 'Initials': 'KK', 'LastName': 'John', 'Affiliation': 'a School of Communication , Brigham Young University , Provo , Utah , USA.'}, {'ForeName': 'Jakob D', 'Initials': 'JD', 'LastName': 'Jensen', 'Affiliation': 'b Department of Communication , University of Utah , Salt Lake City , Utah , USA.'}, {'ForeName': 'Andy J', 'Initials': 'AJ', 'LastName': 'King', 'Affiliation': 'd Department of Public Relations , Texas Tech University , Lubbock , Texas , USA.'}, {'ForeName': 'Chelsea L', 'Initials': 'CL', 'LastName': 'Ratcliff', 'Affiliation': 'b Department of Communication , University of Utah , Salt Lake City , Utah , USA.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Grossman', 'Affiliation': 'e Departments of Dermatology and Oncological Sciences , University of Utah , Salt Lake City , Utah , USA.'}]",Journal of health communication,['10.1080/10810730.2017.1344750'] 820,30762404,"Predictive utility of subtyping women smokers on depression, eating, and weight-related symptoms.","OBJECTIVE Smoking and overweight or obesity are preventable causes of disease and death. Women are reluctant to quit smoking because of concerns about postcessation weight gain, underscoring the need to elucidate patterns of weight concerns and associated psychosocial factors that may affect smoking cessation outcomes. The present study aimed to subtype women smokers based on psychosocial and behavioral factors associated with smoking and weight, and examine the utility of these subtypes to predict abstinence and postcessation weight gain. METHOD Weight-concerned women (N = 343) were randomized to 1 of 2 smoking cessation counseling adjuncts and 1 of 2 cessation medication conditions. At baseline, women were weighed and completed measures of depression, weight or appearance concerns, and eating behaviors. At 3-, 6-, and 12-months after the target quit date, women were weighed and completed self-report and biochemical smoking assessments. RESULTS Latent profile (LP) analyses supported a 3-profile model. The groups had typical (53%, LP1), minimal (33%, LP2), and high (14%, LP3) levels of depressive symptoms and weight concerns. At 12-months posttarget quit date, women in LP3 were more likely to relapse than women in LP1 (odds ratio, OR = 2.93). Among abstinent women, those in LP2 and LP3 gained more postcessation weight than those in LP1. CONCLUSIONS Heterogeneity in symptoms of depression, weight or appearance concerns, and eating behaviors was captured by three groups of women smokers, with unique risks for relapse and postcessation weight gain. The distinct profiles identified may help personalize the delivery of care for smoking cessation and, ultimately, reduce disease risk. (PsycINFO Database Record (c) 2019 APA, all rights reserved).",2019,"Among abstinent women, those in LP2 and LP3 gained more postcessation weight than those in LP1. ","['subtype women smokers', 'subtyping women smokers', 'Weight-concerned women (N = 343']",['smoking cessation counseling adjuncts and 1 of 2 cessation medication conditions'],"['depression, weight or appearance concerns, and eating behaviors', 'depression, eating, and weight-related symptoms', 'postcessation weight', 'depressive symptoms and weight concerns']","[{'cui': 'C0449560', 'cui_str': 'Subtype (attribute)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}]","[{'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0700364', 'cui_str': 'Appearances (qualifier value)'}, {'cui': 'C0015745', 'cui_str': 'Eating Behavior'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}]",343.0,0.024646,"Among abstinent women, those in LP2 and LP3 gained more postcessation weight than those in LP1. ","[{'ForeName': 'Rachel H', 'Initials': 'RH', 'LastName': 'Salk', 'Affiliation': 'Department of Psychiatry.'}, {'ForeName': 'Lisa J', 'Initials': 'LJ', 'LastName': 'Germeroth', 'Affiliation': 'Department of Psychiatry.'}, {'ForeName': 'Rebecca L', 'Initials': 'RL', 'LastName': 'Emery', 'Affiliation': 'Department of Psychiatry.'}, {'ForeName': 'Rachel P Kolko', 'Initials': 'RPK', 'LastName': 'Conlon', 'Affiliation': 'Department of Psychiatry.'}, {'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Department of Statistics.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Cheng', 'Affiliation': 'Department of Statistics.'}, {'ForeName': 'Marsha D', 'Initials': 'MD', 'LastName': 'Marcus', 'Affiliation': 'Department of Psychiatry.'}, {'ForeName': 'Kenneth A', 'Initials': 'KA', 'LastName': 'Perkins', 'Affiliation': 'Department of Psychiatry.'}, {'ForeName': 'Michele D', 'Initials': 'MD', 'LastName': 'Levine', 'Affiliation': 'Department of Psychiatry.'}]","Health psychology : official journal of the Division of Health Psychology, American Psychological Association",['10.1037/hea0000702'] 821,24177001,Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression.,"We evaluated whether lysyl oxidase-like 2 (LOXL2), which promotes cross-linking of collagen in pathological stroma, was detectable in serum from idiopathic pulmonary fibrosis (IPF) patients, and assessed its relationship with IPF disease progression. Patients from the ARTEMIS-IPF (n=69) and the Genomic and Proteomic Analysis of Disease Progression in IPF (GAP) (n=104) studies were analysed. Baseline serum LOXL2 (sLOXL2) levels were compared with baseline clinical and physiological surrogates of disease severity, and the association with IPF disease progression was assessed using a classification and regression tree (CART) method. sLOXL2 correlated weakly with forced vital capacity and carbon monoxide diffusion capacity (r -0.24-0.05) in both cohorts. CART-determined thresholds were similar: ARTEMIS-IPF 800 pg·mL(-1) and GAP 700 pg·mL(-1). In ARTEMIS-IPF, higher sLOXL2 (>800 pg·mL(-1)) was associated with increased risk for disease progression (hazard ratio (HR) 5.41, 95% CI 1.65-17.73). Among GAP subjects with baseline spirometric data (n=70), higher sLOXL2 levels (>700 pg·mL(-1)) were associated with more disease progression events (HR 1.78, 95% CI 1.01-3.11). Among all GAP subjects, higher sLOXL2 levels were associated with increased risk for mortality (HR 2.28, 95% CI 1.18-4.38). These results suggest that higher sLOXL2 levels are associated with increased risk for IPF disease progression. However, due to multiple limitations, these results require validation.",2014,"In ARTEMIS-IPF, higher sLOXL2 (>800 pg·mL(-1)) was associated with increased risk for disease progression (hazard ratio (HR)",['Patients from the ARTEMIS-IPF (n=69) and the Genomic and Proteomic Analysis of Disease Progression in IPF (GAP) (n=104) studies were analysed'],['lysyl oxidase-like 2 (LOXL2'],"['forced vital capacity and carbon monoxide diffusion capacity', 'Baseline serum LOXL2 (sLOXL2) levels', 'sLOXL2 levels', 'risk for disease progression (hazard ratio (HR', 'disease progression events', 'risk for mortality', 'Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression', 'IPF disease progression']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0887950', 'cui_str': 'Genomics'}, {'cui': 'C0872252', 'cui_str': 'Proteomics'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0242656', 'cui_str': 'Disease Progression'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0024375', 'cui_str': 'Collagen Lysyl Oxidase'}]","[{'cui': 'C3714541', 'cui_str': 'Forced Vital Capacity'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0242656', 'cui_str': 'Disease Progression'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0024375', 'cui_str': 'Collagen Lysyl Oxidase'}, {'cui': 'C0085786', 'cui_str': 'Alveolitis, Fibrosing'}]",,0.031762,"In ARTEMIS-IPF, higher sLOXL2 (>800 pg·mL(-1)) was associated with increased risk for disease progression (hazard ratio (HR)","[{'ForeName': 'Jason W', 'Initials': 'JW', 'LastName': 'Chien', 'Affiliation': 'Inc., Seattle, WA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Richards', 'Affiliation': ''}, {'ForeName': 'Kevin F', 'Initials': 'KF', 'LastName': 'Gibson', 'Affiliation': ''}, {'ForeName': 'Yingze', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Kathleen O', 'Initials': 'KO', 'LastName': 'Lindell', 'Affiliation': ''}, {'ForeName': 'Lixin', 'Initials': 'L', 'LastName': 'Shao', 'Affiliation': ''}, {'ForeName': 'Susan K', 'Initials': 'SK', 'LastName': 'Lyman', 'Affiliation': ''}, {'ForeName': 'Joanne I', 'Initials': 'JI', 'LastName': 'Adamkewicz', 'Affiliation': ''}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Smith', 'Affiliation': ''}, {'ForeName': 'Naftali', 'Initials': 'N', 'LastName': 'Kaminski', 'Affiliation': ''}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': ""O'Riordan"", 'Affiliation': ''}]",The European respiratory journal,['10.1183/09031936.00141013'] 822,30767826,High- versus low-intensity interventions for perinatal depression delivered by non-specialist primary maternal care providers in Nigeria: cluster randomised controlled trial (the EXPONATE trial).,"BACKGROUND Contextually appropriate interventions delivered by primary maternal care providers (PMCPs) might be effective in reducing the treatment gap for perinatal depression. AIM To compare high-intensity treatment (HIT) with low-intensity treatment (LIT) for perinatal depression. METHOD Cluster randomised clinical trial, conducted in Ibadan, Nigeria between 18 June 2013 and 11 December 2015 in 29 maternal care clinics allocated by computed-generated random sequence (15 HIT; 14 LIT). Interventions were delivered individually to antenatal women with DSM-IV (1994) major depression by trained PMCPs. LIT consisted of the basic psychosocial treatment specifications in the World Health Organization Mental Health Gap Action Programme - Intervention Guide. HIT comprised LIT plus eight weekly problem-solving therapy sessions with possible additional sessions determined by scores on the Edinburgh Postnatal Depression Scale (EPDS). The primary outcome was remission of depression at 6 months postpartum (EPDS < 6). RESULTS There were 686 participants; 452 and 234 in HIT and LIT arms, respectively, with both groups similar at baseline. Follow-up assessments, completed on 85%, showed remission rates of 70% with HIT and 66% with LIT: risk difference 4% (95% CI -4.1%, 12.0%), adjusted odds ratio 1.12 (95% CI 0.73, 1.72). HIT was more effective for severe depression (odds ratio 2.29; 95% CI 1.01, 5.20; P = 0.047) and resulted in a higher rate of exclusive breastfeeding. Infant outcomes, cost-effectiveness and adverse events were similar. CONCLUSIONS Except among severely depressed perinatal women, we found no strong evidence to recommend high-intensity in preference to low-intensity psychological intervention in routine primary maternal care. DECLARATION OF INTERESTS None.",2019,"HIT was more effective for severe depression (odds ratio 2.29; 95% CI 1.01, 5.20; P = 0.047) and resulted in a higher rate of exclusive breastfeeding.","['There were 686 participants; 452 and 234 in HIT and LIT arms, respectively, with both groups similar at baseline', 'Ibadan, Nigeria between 18 June 2013 and 11 December 2015 in 29 maternal care clinics allocated by computed-generated random sequence (15 HIT; 14 LIT', 'severely depressed perinatal women', 'perinatal depression delivered by non-specialist primary maternal care providers in Nigeria', 'antenatal women with DSM-IV (1994) major depression by trained PMCPs']","['intensity treatment (HIT) with low-intensity treatment (LIT', 'High- versus low-intensity interventions']","['severe depression', 'remission of depression', 'Infant outcomes, cost-effectiveness and adverse events', 'Edinburgh Postnatal Depression Scale (EPDS', 'remission rates']","[{'cui': 'C0596020', 'cui_str': 'Does hit (finding)'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0028075', 'cui_str': 'Federal Republic of Nigeria'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4284586', 'cui_str': 'Perinatal depression'}, {'cui': 'C0087009', 'cui_str': 'Specialists'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C2828394', 'cui_str': 'Antenatal (qualifier value)'}, {'cui': 'C0220952', 'cui_str': 'DSM-IV'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}]","[{'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0596836', 'cui_str': 'Low intensity'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]","[{'cui': 'C0588008', 'cui_str': 'Severe depression (disorder)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0451144', 'cui_str': 'Edinburgh Postnatal Depression Scale'}]",,0.202362,"HIT was more effective for severe depression (odds ratio 2.29; 95% CI 1.01, 5.20; P = 0.047) and resulted in a higher rate of exclusive breastfeeding.","[{'ForeName': 'Oye', 'Initials': 'O', 'LastName': 'Gureje', 'Affiliation': 'Professor of Psychiatry, Director, World Health Organization Collaborating Center for Research and Training in Mental Health, Neuroscience and Substance Abuse, Department of Psychiatry, College of Medicine, University of Ibadan, Nigeria.'}, {'ForeName': 'Bibilola D', 'Initials': 'BD', 'LastName': 'Oladeji', 'Affiliation': 'Senior Lecturer, Consultant Psychiatrist, Department of Psychiatry, College of Medicine, University of Ibadan, Nigeria.'}, {'ForeName': 'Alan A', 'Initials': 'AA', 'LastName': 'Montgomery', 'Affiliation': ""Professor of Medical Statistics and Clinical Trials, Nottingham Clinical Trials Unit, University of Nottingham, Queen's Medical Centre, UK.""}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Araya', 'Affiliation': ""Director, Centre for Global Mental Health, Department of Health Services and Population Research, King's College London, UK.""}, {'ForeName': 'Toyin', 'Initials': 'T', 'LastName': 'Bello', 'Affiliation': 'Biostatistician, Department of Psychiatry, College of Medicine, University of Ibadan, Nigeria.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Chisholm', 'Affiliation': 'Programme Manager, Division of Noncommunicable Diseases, Department of Mental Health and Substance Abuse, World Health Organization, Switzerland.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Groleau', 'Affiliation': 'Associate Professor, Senior Investigator, Division of Social and Transcultural Psychiatry, McGill University; and Director, Department of Psychiatry, Jewish General Hospital, Canada.'}, {'ForeName': 'Laurence J', 'Initials': 'LJ', 'LastName': 'Kirmayer', 'Affiliation': 'Professor, Director, Division of Social and Transcultural Psychiatry, McGill University; and Department of Psychiatry, Jewish General Hospital, Canada.'}, {'ForeName': 'Lola', 'Initials': 'L', 'LastName': 'Kola', 'Affiliation': 'Medical Sociologist, Department of Psychiatry, College of Medicine, University of Ibadan, Nigeria.'}, {'ForeName': 'Lydia B', 'Initials': 'LB', 'LastName': 'Olley', 'Affiliation': 'Project Coordinator, Department of Psychiatry, College of Medicine, University of Ibadan, Nigeria.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Tan', 'Affiliation': ""Medical Statistician, Nottingham Clinical Trials Unit, University of Nottingham, Queen's Medical Centre, UK.""}, {'ForeName': 'Phyllis', 'Initials': 'P', 'LastName': 'Zelkowitz', 'Affiliation': 'Associate Professor, Division of Social and Transcultural Psychiatry, McGill University; and Research Director, Department of Psychiatry, Jewish General Hospital, Canada.'}]",The British journal of psychiatry : the journal of mental science,['10.1192/bjp.2019.4'] 823,31684903,Feasibility of a guided participation discharge program for very preterm infants in a neonatal intensive care unit: a randomized controlled trial.,"BACKGROUND Previous studies showed that parents of very preterm infants expressed feelings of incompetence and experienced high levels of stress upon the discharge of their infants. We conducted a systematic review of seven studies and observed potential benefits for parental outcomes when using discharge interventions that adopted guided participation (GP). More evidence is needed on the effective doses of discharge interventions underpinned by the principles of GP. AIM To investigate the feasibility and preliminarily estimate the effects on parental competence and stress outcomes of a newly developed, nurse-led, GP discharge program for mothers of very preterm infants. METHODS A two-arm randomized controlled trial was conducted in a neonatal intensive care unit (NICU). Mothers of infants with gestational ages of ≤32 weeks who had no congenital malformations and did not need to undergo major surgeries were recruited. All mothers were the primary caregivers to their infants. The intervention group received a nurse-led GP discharge intervention (three structured 30- to 60-min GP sessions and one follow-up phone call). The control group received usual care. The parental outcomes were measured using the Parenting Sense of Competence Scale (C-PSOC) and Perceived Stress Scale (C-PSS) at baseline (T0), on the day of discharge (T1), after the follow-up phone call (within 72 h after discharge) (T2), and 1 month after discharge (T3). The outcomes were analyzed using generalized estimating equations based on intention-to-treat principles. RESULTS Thirty infant-mother dyads were recruited. Greater improvements in the C-PSOC score were observed in the intervention group than in the control group at T1 and T2, although these differences were statistically insignificant. The intervention group exhibited greater improvements than the control group in the C-PSS scores at T1, T2, and T3, although these differences were also not statistically significant. CONCLUSIONS The findings suggest that a GP discharge intervention could improve parenting competence and stress among mothers with very preterm infants. The absence of adverse events suggests that the GP discharge intervention could be feasibly implemented in NICU settings. This feasibility study was not powered to determine the effectiveness of the intervention but is anticipated to lay the foundation for a future full-scale study. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT03668912. Date of registration: 13 September 2018 (retrospectively registered).",2019,"Greater improvements in the C-PSOC score were observed in the intervention group than in the control group at T1 and T2, although these differences were statistically insignificant.","['mothers with very preterm infants', 'mothers of very preterm infants', 'Thirty infant-mother dyads', 'neonatal intensive care unit (NICU', 'Mothers of infants with gestational ages of ≤32\u2009weeks who had no congenital malformations and did not need to undergo major surgeries were recruited', 'All mothers were the primary caregivers to their infants', 'very preterm infants in a neonatal intensive care unit']","['GP discharge intervention', 'nurse-led GP discharge intervention (three structured 30- to 60-min GP sessions and one follow-up phone call', 'GP discharge program', 'guided participation discharge program', 'usual care']","['Parenting Sense of Competence Scale (C-PSOC) and Perceived Stress Scale (C-PSS) at baseline (T0), on the day of discharge (T1', 'C-PSOC score', 'parenting competence and stress', 'C-PSS scores']","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C3897192', 'cui_str': 'Very preterm infant'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0021709', 'cui_str': 'Newborn ICU'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0000768', 'cui_str': 'Birth Defects'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}]","[{'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}]","[{'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0222045'}, {'cui': 'C0582653', 'cui_str': 'Perceived stress scale (assessment scale)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}]",30.0,0.157492,"Greater improvements in the C-PSOC score were observed in the intervention group than in the control group at T1 and T2, although these differences were statistically insignificant.","[{'ForeName': 'S Y', 'Initials': 'SY', 'LastName': 'Lee', 'Affiliation': 'Department of Pediatrics, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, N.T., Hong Kong SAR.'}, {'ForeName': 'J P C', 'Initials': 'JPC', 'LastName': 'Chau', 'Affiliation': 'The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong SAR. janitachau@cuhk.edu.hk.'}, {'ForeName': 'K C', 'Initials': 'KC', 'LastName': 'Choi', 'Affiliation': 'The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong SAR.'}, {'ForeName': 'S H S', 'Initials': 'SHS', 'LastName': 'Lo', 'Affiliation': 'The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong SAR.'}]",BMC pediatrics,['10.1186/s12887-019-1794-y'] 824,30773608,Birth choices for women in a 'Positive Birth after Caesarean' clinic: Randomised trial of alternative shared decision support strategies.,"BACKGROUND Systematic approaches to information giving and decision support for women with previous caesarean sections are needed. AIM To evaluate decision support within a 'real-world' shared decision-making model. METHODS A pragmatic comparative effectiveness randomised trial in the Positive Birth After Caesarean Clinic. Women with one previous caesarean and singleton pregnancy <25 weeks were randomly allocated to standard Positive Birth After Caesarean care, or standard Positive Birth After Caesarean care plus a decision aid booklet. Main outcome measure was mode of birth, with secondary measures of knowledge, decisional conflict, birth choice, adherence to birth choice, perception of decision support, and satisfaction. RESULTS Of 297 participants, rate of attempted vaginal birth after caesarean increased and was similar for both groups (61% vs 57%, P = 0.5). Knowledge scores increased more for women in the additional decision aid group (2.0 vs 1.6 points, P = 0.2). Decisional conflict score reduction was similar between groups (P = 0.5). Women initially unsure of their birth preference who received the additional decision aid had greater reduction in decisional conflict score (P = 0.04) and were more likely to plan vaginal birth after caesarean (49% vs 33%, P = 0.2). Adherence to birth choice and birth satisfaction was similar between groups. Women in the additional decision aid group rated their decision support tool higher (P < 0.01). CONCLUSIONS In a 'real world' shared decision-making model, an additional decision aid conferred some benefits in factors associated with preparation for shared decision-making. Decision aids may provide particular benefit for women who are initially unsure and need assistance in the deliberation phase.",2019,"Women in the additional decision aid group rated their decision support tool higher (P < 0.01). ","[""women in a 'Positive Birth after Caesarean' clinic"", 'women who are initially unsure and need assistance in the deliberation phase', 'Women with one previous caesarean and singleton pregnancy <25\xa0weeks', 'Positive Birth', 'women with previous caesarean sections']",['standard Positive Birth'],"['Knowledge scores', 'plan vaginal birth after caesarean', 'decisional conflict score', 'mode of birth, with secondary measures of knowledge, decisional conflict, birth choice, adherence to birth choice, perception of decision support, and satisfaction', 'Adherence to birth choice and birth satisfaction', 'Decisional conflict score reduction', 'rate of attempted vaginal birth after caesarean']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0269733', 'cui_str': 'Previous caesarean section'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0005615', 'cui_str': 'Birth'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0231394', 'cui_str': 'Decisional conflict (finding)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]",297.0,0.160695,"Women in the additional decision aid group rated their decision support tool higher (P < 0.01). ","[{'ForeName': 'Michelle R', 'Initials': 'MR', 'LastName': 'Wise', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Sadler', 'Affiliation': ""National Women's Health, Auckland District Health Board, Auckland, New Zealand.""}, {'ForeName': 'Brett', 'Initials': 'B', 'LastName': 'Shorten', 'Affiliation': 'Freelance Statistical Consultant, Vestavia, Alabama, USA.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'van der Westhuizen', 'Affiliation': ""National Women's Health, Auckland District Health Board, Auckland, New Zealand.""}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Shorten', 'Affiliation': 'School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}]",The Australian & New Zealand journal of obstetrics & gynaecology,['10.1111/ajo.12955'] 825,30210024,[A comparative study of two ventilation modes in the weaning phase of preterm infants with respiratory distress syndrome].,"OBJECTIVE To compare the efficacy between synchronized intermittent mandatory ventilation (SIMV) and pressure support ventilation with volume guarantee (PSV+VG) in the weaning phase of preterm infants with respiratory distress syndrome (RDS). METHODS Forty preterm infants with RDS who were admitted to the neonatal intensive care unit between March 2016 and May 2017 were enrolled as subjects. All infants were born at less than 32 weeks' gestation and received mechanical ventilation. These patients were randomly and equally divided into SIMV group and PSV+VG group in the weaning phase. Ventilator parameters, arterial blood gas, weaning duration (from onset of weaning to extubation), duration of nasal continuous positive airway pressure (NCPAP) after extubation, extubation failure rate, the incidence rates of pneumothorax, patent ductus arteriosus (PDA) and bronchopulmonary dysplasia (BPD), and the mortality rate were compared between the two groups. RESULTS The PSV+VG group had significantly decreased mean airway pressure, weaning duration, duration of NCPAP after extubation, and extubation failure rate compared with the SIMV group (P<0.05). There were no significant differences in arterial blood gas, mortality, or incidence rates of pneumothorax, PDA and BPD between the two groups (P>0.05). CONCLUSIONS For preterm infants with RDS, the PSV+VG mode may be a relatively safe and effective mode in the weaning phase. However, multi-center clinical trials with large sample sizes are needed to confirm the conclusion.",2018,"The PSV+VG group had significantly decreased mean airway pressure, weaning duration, duration of NCPAP after extubation, and extubation failure rate compared with the SIMV group (P<0.05).","['preterm infants with respiratory distress syndrome (RDS', 'preterm infants with respiratory distress syndrome', 'preterm infants with RDS', 'Forty preterm infants with RDS who were admitted to the neonatal intensive care unit between March 2016 and May 2017 were enrolled as subjects']","['mechanical ventilation', 'SIMV group and PSV+VG', 'PSV+VG', 'synchronized intermittent mandatory ventilation (SIMV) and pressure support ventilation with volume guarantee (PSV+VG']","['Ventilator parameters, arterial blood gas, weaning duration (from onset of weaning to extubation), duration of nasal continuous positive airway pressure (NCPAP) after extubation, extubation failure rate, the incidence rates of pneumothorax, patent ductus arteriosus (PDA) and bronchopulmonary dysplasia (BPD), and the mortality rate', 'arterial blood gas, mortality, or incidence rates of pneumothorax, PDA and BPD', 'mean airway pressure, weaning duration, duration of NCPAP after extubation, and extubation failure rate']","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0035220', 'cui_str': 'Respiratory Distress Syndrome, Newborn'}, {'cui': 'C0021709', 'cui_str': 'Newborn ICU'}]","[{'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0278335', 'cui_str': 'Synchronized intermittent mandatory ventilation (procedure)'}, {'cui': 'C0419008', 'cui_str': 'Pressure support'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}]","[{'cui': 'C0087153', 'cui_str': 'Ventilators'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0150411', 'cui_str': 'Blood gases, arterial measurement (procedure)'}, {'cui': 'C0043084', 'cui_str': 'Weaning'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0332162', 'cui_str': 'Onset of (contextual qualifier) (qualifier value)'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C1258045', 'cui_str': 'Nasal Continuous Positive Airway Pressure'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0032326', 'cui_str': 'Pneumothorax'}, {'cui': 'C3495549', 'cui_str': 'Patent ductus arteriosus'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary Dysplasia'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}]",40.0,0.0381701,"The PSV+VG group had significantly decreased mean airway pressure, weaning duration, duration of NCPAP after extubation, and extubation failure rate compared with the SIMV group (P<0.05).","[{'ForeName': 'Wen-Qiang', 'Initials': 'WQ', 'LastName': 'Liu', 'Affiliation': 'Department of Neonatology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, China. 664586331@qq.com.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': ''}, {'ForeName': 'Ai-Min', 'Initials': 'AM', 'LastName': 'Han', 'Affiliation': ''}, {'ForeName': 'Ling-Jian', 'Initials': 'LJ', 'LastName': 'Meng', 'Affiliation': ''}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 826,30776918,Autonomy deficits as vulnerability for anxiety: evidence from two laboratory-based studies.,"BACKGROUND Autonomous individuals are characterized by self-governance; awareness of and capacity to realize one's wishes and needs, while being connected with and sensitive towards others. In line with earlier research showing consistent associations between autonomy-connectedness deficits and anxiety, we tested in two studies whether autonomy deficits predict anxious responses to acute stressors. METHODS In Study 1, participants (N = 177) viewed an anxiety-inducing film fragment and reported anxiety before and after viewing the clip. In experimental Study 2, participants (N = 100) were randomly allocated to one of two conditions: giving a short presentation to an audience (impromptu speech task) or watching another person's presentation (control condition). Anxiety was measured at baseline, after a preparation period and directly after the presentation. RESULTS In Study 1, individuals' anxiety in reaction to watching the movie was positively associated with the autonomy-connectedness component sensitivity to others. In Study 2, individuals' anxiety in reaction to preparing the presentation was negatively associated with the autonomy-connectedness component self-awareness. CONCLUSIONS Specific autonomy components may be related to experiencing anxiety in differing situations (i.e., related to others' distress or presenting one's personal views). Collectively these results indicate that autonomy-connectedness deficits may form a vulnerability factor for experiencing anxiety.",2019,"In Study 2, individuals' anxiety in reaction to preparing the presentation was negatively associated with the autonomy-connectedness component self-awareness. ","['participants (N\u2009=\u2009100', 'participants (N\u2009=\u2009177) viewed an anxiety-inducing film fragment and reported anxiety before and after viewing the clip']","[""short presentation to an audience (impromptu speech task) or watching another person's presentation (control condition""]",['Anxiety'],"[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0449911', 'cui_str': 'View (attribute)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C4319646', 'cui_str': 'Film'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0175722', 'cui_str': 'Clip'}]","[{'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0449450', 'cui_str': 'Presentation (attribute)'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}]",177.0,0.0210746,"In Study 2, individuals' anxiety in reaction to preparing the presentation was negatively associated with the autonomy-connectedness component self-awareness. ","[{'ForeName': 'L E', 'Initials': 'LE', 'LastName': 'Kunst', 'Affiliation': 'a Department of Medical and Clinical Psychology , Tilburg University , Tilburg , Netherlands.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Maas', 'Affiliation': 'a Department of Medical and Clinical Psychology , Tilburg University , Tilburg , Netherlands.'}, {'ForeName': 'M A L M', 'Initials': 'MALM', 'LastName': 'Van Assen', 'Affiliation': 'c Department of Methodology and Statistics , Tilburg University , Tilburg , Netherlands.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Van der Heijden', 'Affiliation': 'a Department of Medical and Clinical Psychology , Tilburg University , Tilburg , Netherlands.'}, {'ForeName': 'M H J', 'Initials': 'MHJ', 'LastName': 'Bekker', 'Affiliation': 'a Department of Medical and Clinical Psychology , Tilburg University , Tilburg , Netherlands.'}]","Anxiety, stress, and coping",['10.1080/10615806.2019.1580697'] 827,31691019,Ergogenic effects of caffeine on peak aerobic cycling power during the menstrual cycle.,"PURPOSE Recent investigations have established that the ingestion of a moderate dose of caffeine (3-6 mg kg -1 ) can increase exercise and sports performance in women. However, it is unknown whether the ergogenicity of caffeine is similar during all phases of the menstrual cycle. The aim of this investigation was to determine the ergogenic effects of caffeine in three phases of the menstrual cycle. METHODS Thirteen well-trained eumenorrheic triathletes (age = 31 ± 6 years; body mass = 58.6 ± 7.8 kg) participated in a double-blind, cross-over, randomised experimental trial. In the (1) early follicular (EF); (2) preovulation (PO); (3) and mid luteal (ML) phases, participants either ingested a placebo (cellulose) or 3 mg kg -1 of caffeine in an opaque and unidentifiable capsule. After a 60-min wait for substance absorption, participants performed an incremental maximal cycle ergometer test until volitional fatigue (25 W/min) to assess peak aerobic cycling power (Wmax). RESULTS In comparison to the placebo, caffeine increased Wmax in the EF (4.13 ± 0.69 vs. 4.24 ± 0.71 W kg -1 , Δ = 2.7 ± 3.3%, P = 0.01), in the PO (4.14 ± 0.70 vs. 4.27 ± 0.73 W kg -1 , Δ = 3.3 ± 5.0%; P = 0.03) and in the ML (4.15 ± 0.69 vs. 4.29 ± 0.67 W kg -1 , Δ = 3.6 ± 5.1%; P = 0.01) phases. The magnitude of the caffeine ergogenic effect was similar during all of the menstrual cycle phases (P = 0.85). CONCLUSION Caffeine increased peak aerobic cycling power in the early follicular, preovulatory, and mid luteal phases. Thus, the ingestion of 3 mg of caffeine per kg of body mass might be considered an ergogenic aid for eumenorrheic women during all three phases of the menstrual cycle.",2020,"The magnitude of the caffeine ergogenic effect was similar during all of the menstrual cycle phases (P = 0.85). ","['Thirteen well-trained eumenorrheic triathletes (age\u2009=\u200931\u2009±\u20096\xa0years; body mass\u2009=\u200958.6\u2009±\u20097.8\xa0kg', 'women']","['Caffeine', 'placebo (cellulose) or 3\xa0mg\xa0kg -1 of caffeine', 'placebo, caffeine', 'caffeine']","['caffeine ergogenic effect', 'peak aerobic cycling power (Wmax', 'peak aerobic cycling power']","[{'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C3178747', 'cui_str': 'Ergogenic Effects'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}]",13.0,0.222593,"The magnitude of the caffeine ergogenic effect was similar during all of the menstrual cycle phases (P = 0.85). ","[{'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Lara', 'Affiliation': 'Exercise Physiology Laboratory, Camilo José Cela University, Madrid, Spain.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Gutiérrez-Hellín', 'Affiliation': 'Exercise Physiology Laboratory, Camilo José Cela University, Madrid, Spain.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'García-Bataller', 'Affiliation': 'Faculty of Physical Activity and Sport Sciences, Universidad Politécnica de Madrid, Madrid, Spain.'}, {'ForeName': 'Paloma', 'Initials': 'P', 'LastName': 'Rodríguez-Fernández', 'Affiliation': 'Centre for Sport Studies, Rey Juan Carlos University, Fuenlabrada, Spain.'}, {'ForeName': 'Blanca', 'Initials': 'B', 'LastName': 'Romero-Moraleda', 'Affiliation': 'Exercise Physiology Laboratory, Camilo José Cela University, Madrid, Spain.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Del Coso', 'Affiliation': 'Centre for Sport Studies, Rey Juan Carlos University, Fuenlabrada, Spain. juan.delcoso@urjc.es.'}]",European journal of nutrition,['10.1007/s00394-019-02100-7'] 828,30719926,"Exploring the Effects of Clinical Exam Room Design on Communication, Technology Interaction, and Satisfaction.","OBJECTIVE This article evaluates the effects of technology integration and design features in clinical exam rooms on examination experiences, communication, and satisfaction. BACKGROUND Exam room features can affect the delivery of patient-centered care and enhance the level of communication, which has been shown to directly impact clinical outcomes. Although there has been an increasing body of literature examining design and patient-centered care, little research has evaluated the extent to which information sharing and electronic health record (EHR) interaction are impacted. METHOD The research randomly allocated 22 patients, 28 caregivers, and 59 clinicians to simulated clinical encounters in four exam room mock-ups with semi-inclusive, exclusive, and inclusive layouts (128 sessions in 32 scenarios). Video recordings of the simulations were coded for clinician gazing, talking, and EHR-interaction behaviors. Participants also completed surveys and answered open-ended questions after experiencing each scenario ( N = 362). RESULTS Semi-inclusive rooms with a triangular arrangement of consultation table, sharable screens, exam table, and caregiver chair were highly preferred as they supported conversation, gazing, and information sharing. The inclusive layout had higher durations of EHR interactions and enhanced viewing and sharing of EHR information. However, this layout was criticized for the lack of clinician-shared information. The exclusive layouts impeded information sharing, eye contact, and constrained simultaneous data entry and eye contact for clinicians. The distance and orientation between chair, exam table, curtain, and door were important for protecting patient and family comfort and privacy. CONCLUSION Characteristics and configurations of design qualities and strategies have a key role on examination experiences, communication, and satisfaction.",2019,The inclusive layout had higher durations of EHR interactions and enhanced viewing and sharing of EHR information.,"['22 patients, 28 caregivers, and 59 clinicians to simulated clinical encounters in four exam room mock-ups with semi-inclusive, exclusive, and inclusive layouts (128 sessions in 32 scenarios', 'Participants also completed surveys and answered open-ended questions after experiencing each scenario ( N = 362']",[],"['Communication, Technology Interaction, and Satisfaction', 'durations of EHR interactions and enhanced viewing and sharing of EHR information']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0562577', 'cui_str': 'Mocking (finding)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}]",[],"[{'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C2926735', 'cui_str': 'Duration'}]",22.0,0.0311014,The inclusive layout had higher durations of EHR interactions and enhanced viewing and sharing of EHR information.,"[{'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Zamani', 'Affiliation': 'Design Researcher, EwingCole, Raleigh, NC, USA.'}, {'ForeName': 'Esperanza C', 'Initials': 'EC', 'LastName': 'Harper', 'Affiliation': 'Six Sigma Green Belt, Healthcare Planner, EwingCole, Raleigh, NC, USA.'}]",HERD,['10.1177/1937586719826055'] 829,31691579,A randomized controlled clinical trial of a hypothermically stored amniotic membrane for use in diabetic foot ulcers.,"Aim: Determine the effectiveness of hypothermically stored amniotic membrane (HSAM) versus standard of care (SOC) in diabetic foot ulcers (DFUs). Methods: A randomized controlled trial was conducted on 76 DFUs analyzed digitally. Results: Cox wound closure for HSAM (38 wounds) was significantly greater (p = 0.04) at weeks 12 (60 vs 38%), and 16 (63 vs 38%). The probability of wound closure increased by 75% (Hazard Ratio = 1.75; 95% CI: 1.16-2.70). HSAM showed >60% reductions in area (82 vs 58%; p = 0.02) and depth (65 vs 39%; p = 0.04) versus SOC. Conclusion: HSAM increased frequency and probability of wound closure in DFUs versus SOC.",2020,HSAM showed >60% reductions in area (82 vs 58%; p = 0.02) and depth (65 vs 39%; p = 0.04) versus SOC. ,"['diabetic foot ulcers', '76 DFUs analyzed digitally', 'diabetic foot ulcers (DFUs']","['hypothermically stored amniotic membrane', 'HSAM', 'hypothermically stored amniotic membrane (HSAM) versus standard of care (SOC']","['frequency and probability of wound closure', 'probability of wound closure', 'Cox wound closure for HSAM (38 wounds']","[{'cui': 'C1456868', 'cui_str': 'Diabetic foot ulcer (disorder)'}]","[{'cui': 'C0002630', 'cui_str': 'Amniotic Membrane'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}]","[{'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0450015', 'cui_str': 'Method of wound closure (attribute)'}, {'cui': 'C0442996', 'cui_str': 'Cox (qualifier value)'}, {'cui': 'C0021501', 'cui_str': 'wounds'}]",38.0,0.264049,HSAM showed >60% reductions in area (82 vs 58%; p = 0.02) and depth (65 vs 39%; p = 0.04) versus SOC. ,"[{'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Serena', 'Affiliation': 'SerenaGroup® Research Foundation, Cambridge, MA 02140, USA.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Yaakov', 'Affiliation': 'SerenaGroup Research Foundation, Cambridge, MA 02140, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Moore', 'Affiliation': 'SerenaGroup Research Foundation, Cambridge, MA 02140, USA.'}, {'ForeName': 'Windy', 'Initials': 'W', 'LastName': 'Cole', 'Affiliation': 'Kent State University College of Podiatric Medicine, Independence, OH 44131, USA.'}, {'ForeName': 'Stacey', 'Initials': 'S', 'LastName': 'Coe', 'Affiliation': 'Kent State University College of Podiatric Medicine, Independence, OH 44131, USA.'}, {'ForeName': 'Rob', 'Initials': 'R', 'LastName': 'Snyder', 'Affiliation': 'Barry University School of Podiatry Medicine, North Miami Beach, FL 33168, USA.'}, {'ForeName': 'Keyur', 'Initials': 'K', 'LastName': 'Patel', 'Affiliation': 'D & P Medical Group, Pittsburgh, PA 15237, USA.'}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Doner', 'Affiliation': 'D & P Medical Group, Pittsburgh, PA 15237, USA.'}, {'ForeName': 'Maria A', 'Initials': 'MA', 'LastName': 'Kasper', 'Affiliation': 'Martin Foot & Ankle, York, PA 17402, USA.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Hamil', 'Affiliation': 'SerenaGroup Research Foundation, Cambridge, MA 02140, USA.'}, {'ForeName': 'Santina', 'Initials': 'S', 'LastName': 'Wendling', 'Affiliation': 'Organogenenis, Inc, Canton, MA 02021, USA.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Sabolinski', 'Affiliation': 'Sabolinski LLC, Franklin, MA 02038, USA.'}]",Journal of comparative effectiveness research,['10.2217/cer-2019-0142'] 830,31654891,Tiotropium Respimat® add-on therapy to inhaled corticosteroids in patients with symptomatic asthma improves clinical outcomes regardless of baseline characteristics.,"BACKGROUND Despite currently available therapies and detailed treatment guidelines, many patients with asthma remain symptomatic. Tiotropium delivered by the soft mist inhaler Respimat®, as add-on therapy to medium-dose inhaled corticosteroids (ICS), has been shown to improve lung function and asthma control in patients with symptomatic moderate asthma. OBJECTIVE To determine whether the efficacy of tiotropium Respimat® in asthma differs by patients' study baseline characteristics. METHODS Two replicate Phase III, randomized, double-blind, placebo-controlled, parallel-group studies (MezzoTinA-asthma®; NCT01172808 and NCT01172821) of once-daily tiotropium Respimat 5 μg and 2.5 μg add-on to ICS were conducted in patients with symptomatic asthma despite treatment with medium-dose ICS with or without additional controllers. Subgroup analyses of peak forced expiratory volume in 1 s (FEV 1 ), trough FEV 1 , risk of severe asthma exacerbation and Asthma Control Questionnaire responder rate were performed to determine whether results were influenced by patients' baseline characteristics. RESULTS In this analysis, 523 patients received placebo while 517 and 519 patients received the 5 μg and 2.5 μg dose of tiotropium Respimat, respectively. The magnitude of the improvements in lung function and asthma control, as well as the reduced risk of severe exacerbation with both doses of tiotropium Respimat versus placebo, was independent of a broad range of baseline characteristics. CONCLUSIONS Once-daily tiotropium Respimat as add-on to ICS is a beneficial treatment option for patients with asthma who remain symptomatic despite at least medium-dose ICS, regardless of baseline characteristics.",2019,"Subgroup analyses of peak forced expiratory volume in 1 s (FEV 1 ), trough FEV 1 , risk of severe asthma exacerbation and Asthma Control Questionnaire responder rate were performed to determine whether results were influenced by patients' baseline characteristics. ","[""asthma differs by patients' study baseline characteristics"", 'patients with symptomatic asthma', '523 patients received', 'patients with asthma who remain symptomatic despite at least medium-dose ICS', 'patients with asthma remain symptomatic', 'patients with symptomatic asthma despite treatment with medium-dose ICS with or without additional controllers', 'patients with symptomatic moderate asthma']","['Tiotropium Respimat®', 'tiotropium Respimat', 'placebo-controlled, parallel-group studies (MezzoTinA-asthma®', 'tiotropium Respimat 5\u202fμg and 2.5\u202fμg add-on to ICS', 'Tiotropium', 'placebo', 'tiotropium Respimat versus placebo', 'tiotropium Respimat®', 'corticosteroids (ICS']","['peak forced expiratory volume in 1\u202fs (FEV 1 ), trough FEV 1 , risk of severe asthma exacerbation and Asthma Control Questionnaire responder rate', 'lung function and asthma control']","[{'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0439536', 'cui_str': 'Medium (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0581125', 'cui_str': 'Moderate asthma'}]","[{'cui': 'C0213771', 'cui_str': 'tiotropium'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0444506', 'cui_str': 'Trough (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0581126', 'cui_str': 'Severe asthma'}, {'cui': 'C2919686', 'cui_str': 'Asthma control questionnaire'}, {'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",523.0,0.634826,"Subgroup analyses of peak forced expiratory volume in 1 s (FEV 1 ), trough FEV 1 , risk of severe asthma exacerbation and Asthma Control Questionnaire responder rate were performed to determine whether results were influenced by patients' baseline characteristics. ","[{'ForeName': 'Thomas B', 'Initials': 'TB', 'LastName': 'Casale', 'Affiliation': 'Division of Allergy and Immunology, University of South Florida Morsani College of Medicine, Tampa, FL, USA. Electronic address: tbcasale@health.usf.edu.'}, {'ForeName': 'René', 'Initials': 'R', 'LastName': 'Aalbers', 'Affiliation': 'Martini Hospital, Groningen, Netherlands.'}, {'ForeName': 'Eugene R', 'Initials': 'ER', 'LastName': 'Bleecker', 'Affiliation': 'Center for Applied Genetics and Genomics Medicine, University of Arizona Health Sciences, Tucson, AZ, USA.'}, {'ForeName': 'Eli O', 'Initials': 'EO', 'LastName': 'Meltzer', 'Affiliation': 'Allergy & Asthma Medical Group & Research Center, San Diego, CA, USA.'}, {'ForeName': 'Liliana', 'Initials': 'L', 'LastName': 'Zaremba-Pechmann', 'Affiliation': 'Biostatistics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'de la Hoz', 'Affiliation': 'TA Respiratory/Biosimilars Medicine, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.'}, {'ForeName': 'Huib A M', 'Initials': 'HAM', 'LastName': 'Kerstjens', 'Affiliation': 'University of Groningen, University Medical Center Groningen, Department of Pulmonary Medicine and Tuberculosis and Groningen Research Institute for Asthma and COPD, Groningen, Netherlands.'}]",Respiratory medicine,['10.1016/j.rmed.2019.09.014'] 831,31685304,Gentle facemask ventilation during induction of anesthesia.,"BACKGROUND To determine the level of inspiratory pressure minimizing the risk of gastric insufflation while providing adequate pulmonary ventilation. METHODS In this prospective, randomized, double-blind study, patients were allocated to one of the two groups (P10, P15) defined by the inspiratory pressure applied during controlled-pressure ventilation: 10 and 15 cm H 2 O. Anesthesia was induced using propofol and sufentanil; no neuromuscular-blocking agent was administered. Once loss of eyelash reflex occurred, facemask ventilation was started for a 2-min period. The cross-sectional antral area was measured using ultrasonography before and after facemask ventilation. Respiratory parameters were recorded. RESULTS Forty patients were analyzed. Mean tidal volume was about 7 ml/kg in group P10, and was >11 ml/kg in group P15 in the same period. As indicated by ultrasonography test, the antral area in P15 group was markedly incresed compared with P10 group. CONCLUSION Inspiratory pressure of 10 cm H 2 O allowed for reduced occurrence of gastric insufflation with proper lung ventilation during induction of anesthesia with sufentanil and propofol in nonparalyzed and nonobese patients.",2020,"As indicated by ultrasonography test, the antral area in P15 group was markedly incresed compared with P10 group. ","['Forty patients were analyzed', 'nonparalyzed and nonobese patients']","['Gentle facemask ventilation', 'propofol and sufentanil; no neuromuscular-blocking agent', 'sufentanil and propofol']","['eyelash reflex', 'Inspiratory pressure', 'Mean tidal volume']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0027866', 'cui_str': 'Neuromuscular Blockers'}]","[{'cui': 'C0422906', 'cui_str': 'Eyelash reflex (observable entity)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0040210', 'cui_str': 'Tidal Volume'}]",40.0,0.0642312,"As indicated by ultrasonography test, the antral area in P15 group was markedly incresed compared with P10 group. ","[{'ForeName': 'Qingfu', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.""}, {'ForeName': 'Quanhong', 'Initials': 'Q', 'LastName': 'Zhou', 'Affiliation': ""Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.""}, {'ForeName': 'Junfeng', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China. Electronic address: zhangjunfeng16@126.com.""}, {'ForeName': 'Daqiang', 'Initials': 'D', 'LastName': 'Zhao', 'Affiliation': ""Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China. Electronic address: daqiangzhao23@yeah.net.""}]",The American journal of emergency medicine,['10.1016/j.ajem.2019.158399'] 832,32407710,"The effect of lactoferrin supplementation on death or major morbidity in very low birthweight infants (LIFT): a multicentre, double-blind, randomised controlled trial.","BACKGROUND Very low birthweight or preterm infants are at increased risk of adverse outcomes including sepsis, necrotising enterocolitis, and death. We assessed whether supplementing the enteral diet of very low-birthweight infants with lactoferrin, an antimicrobial protein, reduces all-cause mortality or major morbidity. METHODS We did a multicentre, double-blind, pragmatic, randomised superiority trial in 14 Australian and two New Zealand neonatal intensive care units. Infants born weighing less than 1500 g and aged less than 8 days, were eligible and randomly assigned (1:1) using minimising web-based randomisation to receive once daily 200 mg/kg pasteurised bovine lactoferrin supplements or no lactoferrin supplement added to breast or formula milk until 34 weeks' post-menstrual age (or for 2 weeks, if longer), or until discharge from the study hospital if that occurred first. Designated nurses preparing the daily feeds were not masked to group assignment, but other nurses, doctors, parents, caregivers, and investigators were unaware. The primary outcome was survival to hospital discharge or major morbidity (defined as brain injury, necrotising enterocolitis, late-onset sepsis at 36 weeks' post-menstrual age, or retinopathy treated before discharge) assessed in the intention-to-treat population. Safety analyses were by treatment received. We also did a prespecified, PRISMA-compliant meta-analysis, which included this study and other relevant randomised controlled trials, to estimate more precisely the effects of lactoferrin supplementation on late-onset sepsis, necrotising enterocolitis, and survival. This trial is registered with the Australian and New Zealand Clinical Trials Registry, ACTRN12611000247976. FINDINGS Between June 27, 2014, and Sept 1, 2017, we recruited 1542 infants; 771 were assigned to the intervention group and 771 to the control group. One infant who had consent withdrawn before beginning lactoferrin treatment was excluded from analysis. In-hospital death or major morbidity occurred in 162 (21%) of 770 infants in the intervention group and in 170 (22%) of 771 infants in the control group (relative risk [RR] 0·95, 95% CI 0·79-1·14; p=0·60). Three suspected unexpected serious adverse reactions occurred; two in the lactoferrin group, namely unexplained late jaundice and inspissated milk syndrome, but were not attributed to the intervention and one in the control group had fatal inspissated milk syndrome. Our meta-analysis identified 13 trials completed before Feb 18, 2020, including this Article, in 5609 preterm infants. Lactoferrin supplements significantly reduced late-onset sepsis (RR 0·79, 95% CI 0·71-0·88; p<0·0001; I 2 =58%), but not necrotising enterocolitis or all-cause mortality. INTERPRETATION Lactoferrin supplementation did not improve death or major morbidity in this trial, but might reduce late-onset sepsis, as found in our meta-analysis of over 5000 infants. Future collaborative studies should use products with demonstrated biological activity, be large enough to detect moderate and clinically important effects reliably, and assess greater doses of lactoferrin in infants at increased risk, such as those not exclusively receiving breastmilk or infants of extremely low birthweight. FUNDING Australian National Health and Medical Research Council.",2020,"Lactoferrin supplements significantly reduced late-onset sepsis (RR 0·79, 95% CI 0·71-0·88; p<0·0001; I 2 =58%), but not necrotising enterocolitis or all-cause mortality. INTERPRETATION Lactoferrin supplementation did not improve death or major morbidity in this trial, but might reduce late-onset sepsis, as found in our meta-analysis of over 5000 infants.","['Infants born weighing less than 1500 g and aged less than 8 days, were eligible and randomly assigned (1:1) using', '14 Australian and two New Zealand neonatal intensive care units', '5609 preterm infants', 'One infant who had consent withdrawn before beginning lactoferrin treatment was excluded from analysis', '1542 infants; 771 were assigned to the intervention group and 771 to the control group', 'very low birthweight infants (LIFT', 'Between June 27, 2014, and Sept 1, 2017']","['Lactoferrin supplements', 'lactoferrin supplementation', 'lactoferrin', ""minimising web-based randomisation to receive once daily 200 mg/kg pasteurised bovine lactoferrin supplements or no lactoferrin supplement added to breast or formula milk until 34 weeks' post-menstrual age""]","['death or major morbidity', 'hospital death or major morbidity', 'fatal inspissated milk syndrome', 'unexplained late jaundice and inspissated milk syndrome', ""survival to hospital discharge or major morbidity (defined as brain injury, necrotising enterocolitis, late-onset sepsis at 36 weeks' post-menstrual age, or retinopathy treated before discharge) assessed in the intention-to-treat population"", 'late-onset sepsis', 'late-onset sepsis, necrotising enterocolitis, and survival']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C4517582', 'cui_str': '1500'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0022942', 'cui_str': 'Lactoferrin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0442811', 'cui_str': 'Very low'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C0181620', 'cui_str': 'Hoist'}]","[{'cui': 'C0022942', 'cui_str': 'Lactoferrin'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C1440867', 'cui_str': 'Bovine lactoferrin'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0452742', 'cui_str': 'Formula milk'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0025344', 'cui_str': 'Menstruation'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0277608', 'cui_str': 'Death in hospital'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0022346', 'cui_str': 'Jaundice'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}, {'cui': 'C0014356', 'cui_str': 'Enterocolitis'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0025344', 'cui_str': 'Menstruation'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0035309', 'cui_str': 'Retinal disorder'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}]",5609.0,0.688179,"Lactoferrin supplements significantly reduced late-onset sepsis (RR 0·79, 95% CI 0·71-0·88; p<0·0001; I 2 =58%), but not necrotising enterocolitis or all-cause mortality. INTERPRETATION Lactoferrin supplementation did not improve death or major morbidity in this trial, but might reduce late-onset sepsis, as found in our meta-analysis of over 5000 infants.","[{'ForeName': 'William O', 'Initials': 'WO', 'LastName': 'Tarnow-Mordi', 'Affiliation': 'University of Sydney, Sydney, NSW, Australia. Electronic address: william.tarnow-mordi@ctc.usyd.edu.au.'}, {'ForeName': 'Mohamed E', 'Initials': 'ME', 'LastName': 'Abdel-Latif', 'Affiliation': 'Australian National University, Canberra, ACT, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Martin', 'Affiliation': 'University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Mohan', 'Initials': 'M', 'LastName': 'Pammi', 'Affiliation': 'Texas Medical Centre, Houston, TX, USA.'}, {'ForeName': 'Kristy', 'Initials': 'K', 'LastName': 'Robledo', 'Affiliation': 'University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Manzoni', 'Affiliation': 'Nuovo Ospedale Degli Infermi, Ponderano, Italy.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Osborn', 'Affiliation': 'University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Kei', 'Initials': 'K', 'LastName': 'Lui', 'Affiliation': 'University of New South Wales, Kensington, NSW, Australia.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Keech', 'Affiliation': 'University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Hague', 'Affiliation': 'University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Alpana', 'Initials': 'A', 'LastName': 'Ghadge', 'Affiliation': 'University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Javeed', 'Initials': 'J', 'LastName': 'Travadi', 'Affiliation': 'University of Newcastle, Newcastle, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Brown', 'Affiliation': 'University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Brian A', 'Initials': 'BA', 'LastName': 'Darlow', 'Affiliation': 'University of Otago, Otago, New Zealand.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Liley', 'Affiliation': 'University of Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'Margo', 'Initials': 'M', 'LastName': 'Pritchard', 'Affiliation': 'University of Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'Anu', 'Initials': 'A', 'LastName': 'Kochar', 'Affiliation': 'University of Adelaide, Adelaide, SA, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Isaacs', 'Affiliation': 'University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Adrienne', 'Initials': 'A', 'LastName': 'Gordon', 'Affiliation': 'University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Askie', 'Affiliation': 'University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Melinda', 'Initials': 'M', 'LastName': 'Cruz', 'Affiliation': 'Miracle Babies Foundation, Chipping Norton, NSW, Australia.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Schindler', 'Affiliation': 'University of New South Wales, Kensington, NSW, Australia.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Dixon', 'Affiliation': 'University of Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'Girish', 'Initials': 'G', 'LastName': 'Deshpande', 'Affiliation': 'University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Tracy', 'Affiliation': 'University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Schofield', 'Affiliation': 'Macquarie University, Sydney, NSW, Australia.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Austin', 'Affiliation': 'University of Otago, Otago, New Zealand.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Sinn', 'Affiliation': 'University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'R John', 'Initials': 'RJ', 'LastName': 'Simes', 'Affiliation': 'University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Child & adolescent health,['10.1016/S2352-4642(20)30093-6'] 833,31679186,Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.,"OBJECTIVES The aim of the study was to assess the effect of tenofovir alafenamide (TAF) on kidney and bone biomarkers in patients who developed proximal renal tubulopathy (PRT) while receiving tenofovir disoproxil fumarate (TDF). METHODS Individuals with a history of TDF-associated PRT and currently suppressed HIV infection on a tenofovir-sparing regimen were randomized 1:1 to continue current antiretroviral therapy or initiate emtricitabine (F)/TAF with discontinuation of nucleoside reverse transcriptase inhibitors (NRTIs) as appropriate. Renal and bone biomarkers were analysed at baseline, week 4 and week 12. The primary outcome was the mean difference between study arms in urine retinol-binding protein:creatinine ratio (RBPCR) change from baseline to week 12. Data were analysed using linear regression, with robust standard errors (primary outcome), and repeated measures mixed effects models (secondary outcomes). The trial was registered under European Union Drug Regulating Authorities Clinical Trials Database 2016-003345-29. RESULTS We randomized 31 individuals [mean age 52.4 (standard deviation 0.3) years; 97% male; 90% white); all completed the study. At 12 weeks, there was no difference in change in RBPCR (β 19.6; 95% confidence interval -35.3, 74.5; P = 0.47), and no difference in change in estimated glomerular filtration rate (eGFR) (based on creatinine or cystatin C), albuminuria, proteinuria, renal phosphate or urea handling, (fasting) urine osmolality, parathyroid hormone and bone turnover markers in the control versus the F/TAF exposed groups. No cases of PRT were observed. CONCLUSIONS In people with a history of proximal renal tubulopathy while on TDF, 12-week exposure to TAF did not adversely affect renal tubular function. These data support continued evaluation of the long-term safety of TAF in this group of patients.",2020,"At 12 weeks, there was no difference in change in RBPCR (β 19.6; 95% confidence interval -35.3, 74.5; P = 0.47), and no difference in change in estimated glomerular filtration rate (eGFR) (based on creatinine or cystatin C), albuminuria, proteinuria, renal phosphate or urea handling, (fasting) urine osmolality, parathyroid hormone and bone turnover markers in the control versus the F/TAF exposed groups.","['patients with a history of tubulopathy on', '31 individuals [mean age 52.4 (standard deviation 0.3) years; 97% male; 90% white); all completed the study', 'people with a history of proximal renal tubulopathy while on TDF, 12-week exposure to', 'Individuals with a history of TDF-associated PRT and currently suppressed HIV infection on a tenofovir-sparing regimen', 'patients who developed proximal renal tubulopathy (PRT) while receiving']","['tenofovir alafenamide (TAF', 'tenofovir alafenamide', 'tenofovir disoproxil fumarate (TDF', 'TAF', 'continue current antiretroviral therapy or initiate emtricitabine (F)/TAF with discontinuation of nucleoside reverse transcriptase inhibitors (NRTIs', 'tenofovir disoproxil fumarate']","['urine retinol-binding protein:creatinine ratio (RBPCR) change', 'change in RBPCR', 'Renal and bone biomarkers', 'kidney and bone biomarkers', 'renal tubular function', 'estimated glomerular filtration rate (eGFR) (based on creatinine or cystatin C), albuminuria, proteinuria, renal phosphate or urea handling, (fasting) urine osmolality, parathyroid hormone and bone turnover markers']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C4068885', 'cui_str': 'Zero point three'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C1260953', 'cui_str': 'Suppressed (qualifier value)'}, {'cui': 'C0019693', 'cui_str': 'T-Lymphotropic Virus Type III Infections, Human'}, {'cui': 'C0384228', 'cui_str': 'Tenofovir'}]","[{'cui': 'C3713958', 'cui_str': 'tenofovir alafenamide'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}, {'cui': 'C0028621', 'cui_str': 'Nucleosides'}, {'cui': 'C4521921', 'cui_str': 'Reverse transcriptase inhibitor'}]","[{'cui': 'C1262051', 'cui_str': 'Urine retinol binding protein'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0332208', 'cui_str': 'Tubular (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C3811844'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0071744', 'cui_str': 'Cystatin 3'}, {'cui': 'C0001925', 'cui_str': 'Albuminuria'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C1601799', 'cui_str': 'phosphate ion'}, {'cui': 'C0070525', 'cui_str': 'phenacemide'}, {'cui': 'C0018578', 'cui_str': 'Handling'}, {'cui': 'C0740085', 'cui_str': 'Osmolality measurement, urine (procedure)'}, {'cui': 'C0030520', 'cui_str': 'Parathyroid Hormone'}, {'cui': 'C0085268', 'cui_str': 'Bone Turnover'}]",31.0,0.271254,"At 12 weeks, there was no difference in change in RBPCR (β 19.6; 95% confidence interval -35.3, 74.5; P = 0.47), and no difference in change in estimated glomerular filtration rate (eGFR) (based on creatinine or cystatin C), albuminuria, proteinuria, renal phosphate or urea handling, (fasting) urine osmolality, parathyroid hormone and bone turnover markers in the control versus the F/TAF exposed groups.","[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Hamzah', 'Affiliation': ""St George's Healthcare NHS Trust, London, UK.""}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Williams', 'Affiliation': 'Brighton and Sussex University Hospitals, Brighton, UK.'}, {'ForeName': 'A C', 'Initials': 'AC', 'LastName': 'Bailey', 'Affiliation': 'Imperial College Healthcare NHS Trust, London, UK.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Jones', 'Affiliation': 'Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Ibrahim', 'Affiliation': ""King's College London, London, UK.""}, {'ForeName': 'C G', 'Initials': 'CG', 'LastName': 'Musso', 'Affiliation': 'Italian Hospital, Buenos Aires, Argentina.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Burling', 'Affiliation': 'Core Biochemical Assay Laboratory, NIHR Cambridge Biomedical Research Centre, Cambridge, UK.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Barbini', 'Affiliation': ""King's College Hospital NHS Foundation Trust, London, UK.""}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Campbell', 'Affiliation': ""King's College Hospital NHS Foundation Trust, London, UK.""}, {'ForeName': 'F A', 'Initials': 'FA', 'LastName': 'Post', 'Affiliation': ""King's College London, London, UK.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",HIV medicine,['10.1111/hiv.12819'] 834,30706746,"Group leader and participant perceptions of Balancing Everyday Life, a group-based lifestyle intervention for mental health service users.","Background: There exist few recovery and occupation-based interventions for mental health service users. Balancing Everyday Life (BEL) is a new occupation-based lifestyle intervention that was created to fill this need. Aim: To gain group leaders' and participants' perspectives of the BEL intervention content and format, including factors that helped, hindered, and could be improved. Methods: A constructivist grounded theory method guided data collection and analysis. Interviews took place with 12 BEL group leaders and 19 BEL participants from out-patient psychiatry settings and community-based day centers in Sweden. Results: BEL's structure and content were appreciated, yet flexibility was desired to adapt to participant needs. BEL could act as a bridge, helping participants connect with others, and to a more engaged and balanced everyday life. Facilitating factors included a person-focused (versus illness-focused) approach, physical and emotional environments, and connection. Barriers included room resources. More sessions were desired for the intervention. Conclusion: Group leaders and participants experienced BEL as a useful tool to instigate meaningful change and connection in the participants' lives. The combination of a positive person-focused approach and group support was appreciated. These results could inform future research, evaluation, and development of occupation-focused lifestyle interventions for mental health service users.",2020,"CONCLUSION Group leaders and participants experienced BEL as a useful tool to instigate meaningful change and connection in the participants' lives.","['Interviews took place with 12 BEL group leaders and 19 BEL participants from out-patient psychiatry settings and community-based day centers in Sweden', 'mental health service users']","['Balancing Everyday Life, a group-based lifestyle intervention']",[],"[{'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C1704765', 'cui_str': 'Place - dosing instruction imperative'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0025355', 'cui_str': 'Mental Hygiene Services'}]","[{'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}]",[],,0.110859,"CONCLUSION Group leaders and participants experienced BEL as a useful tool to instigate meaningful change and connection in the participants' lives.","[{'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Lund', 'Affiliation': 'Department of Health Sciences/Mental Health, Activity and Participation, Lund University, Lund, Sweden.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Hultqvist', 'Affiliation': 'Department of Health Sciences/Mental Health, Activity and Participation, Lund University, Lund, Sweden.'}, {'ForeName': 'Ulrika', 'Initials': 'U', 'LastName': 'Bejerholm', 'Affiliation': 'Department of Health Sciences/Mental Health, Activity and Participation, Lund University, Lund, Sweden.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Argentzell', 'Affiliation': 'Department of Health Sciences/Mental Health, Activity and Participation, Lund University, Lund, Sweden.'}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Eklund', 'Affiliation': 'Department of Health Sciences/Mental Health, Activity and Participation, Lund University, Lund, Sweden.'}]",Scandinavian journal of occupational therapy,['10.1080/11038128.2018.1551419'] 835,32407786,Study To Reduce Infection Prior to Elective Cesarean Deliveries (STRIPES): a randomized clinical trial of chlorhexidine.,"BACKGROUND Surgical site infections after cesarean delivery are a cause of maternal morbidity and are typically caused by skin microbial flora. Preadmission application of chlorhexidine gluconate using impregnated cloths may decrease surgical site infections by decreasing the abundance of microbial flora. OBJECTIVE To determine whether the application of chlorhexidine gluconate cloths the night before and the morning of scheduled cesarean delivery decreases the risk of surgical site infections by 6 weeks postoperatively compared with placebo. STUDY DESIGN In this single-center, double-blind, placebo-controlled trial, patients were randomized (1:1) to receive either Sage 2% chlorhexidine cloths or Sage Comfort Bath fragrance-free cloths (placebo) to apply to 6 skin sites on the body (neck, shoulders and chest, armpits, arm and hands, abdomen and groin, left leg and foot, right leg and foot, back and buttocks) the night before and after a shower the morning of scheduled cesarean delivery. Routine clinical and operative procedures were followed. The primary outcome was surgical site infections (superficial or deep incisional with or without organ space endometritis) by 6 weeks after cesarean delivery. The secondary outcomes were surgical site infections by 2 weeks and other wound-related complications by 2 and 6 weeks after cesarean delivery. RESULTS From April 2015 to August 2019, 1356 patients were enrolled: 682 were assigned to the chlorhexidine group and 674 to the placebo group. The groups were similar in demographic and medical characteristics. A total of 14 patients were lost to follow-up before cesarean delivery (10 in chlorhexidine and 4 in placebo) and 33 were lost to follow-up after cesarean delivery (10 in chlorhexidine and 23 in placebo). Among the remaining 1309 (97%), no difference was found in surgical site infections by 6 weeks between the 2 groups (2.6% in chlorhexidine vs 3.7% in placebo; P=.24). There were no differences in secondary outcomes at 2 or 6 weeks and no differences in primary outcome in a per-protocol analysis. CONCLUSION Preadmission use of chlorhexidine gluconate cloths compared with placebo does not reduce the risk of surgical site infection after scheduled cesarean deliveries. Following the standard of care guidelines results in a low risk of surgical site infections in this group of patients.",2020,Patients and physicians who follow the standard of care guidelines have a low risk of surgical site infections in this group of patients.,"['1,356 patients were enrolled: 682', 'From April 2015 through August 2019', 'Prior to Elective Cesarean Deliveries (STRIPES', 'Fourteen patients were lost to follow-up prior to cesarean delivery (10 in']","['chlorhexidine gluconate-impregnated cloths', 'chlorhexidine and 23 in placebo', 'chlorhexidine', 'Sage 2% chlorhexidine cloths or Sage Comfort Bath fragrance-free cloths (placebo', 'chlorhexidine gluconate', 'chlorhexidine and 4 in placebo', 'placebo']","['risk of surgical site infections', 'surgical site infection', 'surgical site infections (superficial or deep -incisional and/or organ space-endometritis', 'surgical site infections by 2 weeks and other wound-related complications', 'Infection', 'surgical site infections']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}, {'cui': 'C1532935', 'cui_str': 'Striped'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C1302313', 'cui_str': 'Lost to follow-up'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}]","[{'cui': 'C0055361', 'cui_str': 'Chlorhexidine gluconate'}, {'cui': 'C0039717', 'cui_str': 'Textiles'}, {'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1122976', 'cui_str': 'Sage'}, {'cui': 'C0031000', 'cui_str': 'Perfume'}, {'cui': 'C0332296', 'cui_str': 'Free of'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0014179', 'cui_str': 'Endometritis'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]",1356.0,0.327365,Patients and physicians who follow the standard of care guidelines have a low risk of surgical site infections in this group of patients.,"[{'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Stone', 'Affiliation': 'Department of Obstetrics, Gynecology and Reproductive Sciences, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: joanne.stone@mssm.edu.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Bianco', 'Affiliation': 'Department of Obstetrics, Gynecology and Reproductive Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Monro', 'Affiliation': 'Department of Obstetrics, Gynecology and Reproductive Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.'}, {'ForeName': 'Jessica R', 'Initials': 'JR', 'LastName': 'Overybey', 'Affiliation': 'Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Cadet', 'Affiliation': 'Department of Obstetrics, Gynecology and Reproductive Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.'}, {'ForeName': 'Katie Hyewon', 'Initials': 'KH', 'LastName': 'Choi', 'Affiliation': 'Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Pena', 'Affiliation': 'Department of Obstetrics, Gynecology and Reproductive Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.'}, {'ForeName': 'Brittany N', 'Initials': 'BN', 'LastName': 'Robles', 'Affiliation': 'Department of Obstetrics, Gynecology and Reproductive Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.'}, {'ForeName': 'Maria T', 'Initials': 'MT', 'LastName': 'Mella', 'Affiliation': 'Department of Obstetrics, Gynecology and Reproductive Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.'}, {'ForeName': 'Kathy C', 'Initials': 'KC', 'LastName': 'Matthews', 'Affiliation': 'Department of Obstetrics, Gynecology and Reproductive Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.'}, {'ForeName': 'Stephanie H', 'Initials': 'SH', 'LastName': 'Factor', 'Affiliation': 'Department of Obstetrics, Gynecology and Reproductive Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.05.021'] 836,31688064,"Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study.","OBJECTIVES To assess the efficacy and safety of vonoprazan on heartburn symptoms in patients with nonerosive reflux disease (NERD) (ClinicalTrials.gov: NCT02954848). METHODS This phase 3, double-blind, placebo-controlled study included Japanese patients aged 20 years and older with grade N/M NERD and recurrent heartburn. Patients received placebo (n = 245) or vonoprazan 10 mg (n = 238) for 4 weeks. The primary efficacy outcome was frequency of heartburn experienced by patients during the treatment period (proportion of days without heartburn). Other outcomes included cumulative improvement rates of heartburn, proportion of patients with complete heartburn resolution in the fourth week of treatment, and safety. RESULTS Compared with placebo, the proportion of days without heartburn was not significantly higher in the vonoprazan group in the full analysis (primary end point, 72.55% vs 61.50%, vonoprazan vs placebo, P = 0.0643) but was significantly higher in the per-protocol-set sensitivity analysis (P = 0.0341). Early onset of response and significantly greater cumulative improvement rates of heartburn were observed in the vonoprazan group (P = 0.0003). In a post hoc analysis, a greater proportion of patients with complete heartburn resolution in the fourth week of treatment were reported in the vonoprazan group (P = 0.0023). Incidence of treatment-emergent adverse events was similar between treatment groups (23.5% vs 23.3%); most treatment-emergent adverse events were mild in severity. DISCUSSION Although vonoprazan 10 mg was not superior to placebo with respect to proportion of days without heartburn in Japanese patients with NERD, vonoprazan had a significantly higher cumulative rate of heartburn resolution and was well tolerated.",2019,"Incidence of treatment-emergent adverse events was similar between treatment groups (23.5% vs 23.3%); most treatment-emergent adverse events were mild in severity. ","['Patients With Nonerosive Gastroesophageal Reflux Disease', 'Japanese patients with NERD', 'patients with nonerosive reflux disease (NERD', 'Japanese patients aged 20 years and older with grade N/M NERD and recurrent heartburn']","['placebo', 'Placebo', 'Vonoprazan', 'vonoprazan']","['cumulative improvement rates of heartburn, proportion of patients with complete heartburn resolution', 'safety', 'tolerated', 'cumulative rate of heartburn resolution', 'Incidence of treatment-emergent adverse events', 'efficacy and safety', 'complete heartburn resolution', 'heartburn symptoms', 'cumulative improvement rates of heartburn', 'proportion of days without heartburn', 'Efficacy and Safety', 'frequency of heartburn experienced by patients during the treatment period (proportion of days without heartburn']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0017168', 'cui_str': 'Gastric Acid Reflux Disease'}, {'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0018834', 'cui_str': 'Pyrosis'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4080009', 'cui_str': 'Vonoprazan'}]","[{'cui': 'C0018834', 'cui_str': 'Pyrosis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]",,0.488409,"Incidence of treatment-emergent adverse events was similar between treatment groups (23.5% vs 23.3%); most treatment-emergent adverse events were mild in severity. ","[{'ForeName': 'Yoshikazu', 'Initials': 'Y', 'LastName': 'Kinoshita', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shimane University School of Medicine, Izumo, Japan.'}, {'ForeName': 'Yuuichi', 'Initials': 'Y', 'LastName': 'Sakurai', 'Affiliation': 'Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan.'}, {'ForeName': 'Nobuyoshi', 'Initials': 'N', 'LastName': 'Takabayashi', 'Affiliation': 'Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Kudou', 'Affiliation': 'Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Araki', 'Affiliation': 'Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan.'}, {'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Miyagi', 'Affiliation': 'Department of Internal Medicine, Fukuyama Daiichi Hospital, Hiroshima, Japan.'}, {'ForeName': 'Katsuhiko', 'Initials': 'K', 'LastName': 'Iwakiri', 'Affiliation': 'Department of Gastroenterology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Kiyoshi', 'Initials': 'K', 'LastName': 'Ashida', 'Affiliation': 'Department of Gastroenterology, Rakuwakai Otowa Hospital, Kyoto, Japan.'}]",Clinical and translational gastroenterology,['10.14309/ctg.0000000000000101'] 837,30687808,Randomised trial of two embolic agents for uterine artery embolisation for fibroids: Gelfoam versus Embospheres (RAGE trial).,"Background Uterine artery embolisation (UAE) is an established treatment option for women with symptomatic uterine fibroids who wish to avoid surgery. However the most efficacious embolic agent remains uncertain. Methods We conducted a pilot double blind randomized controlled trial comparing Gelfoam with Embospheres in women undergoing UAE. Outcomes recorded at baseline, 24-h, 1 and 6 months included complications, inflammatory, haematological markers and ovarian function. Contrast enhanced MRI (CEMRI) was acquired at baseline, 24-h and 6 months. Pain score (visual analogue) was measured at 24-h, quality of life (UFS-Qol) at baseline, 1 and 6 months. All patients were followed to 6 months. Results Twenty patients were randomized 1:1 to receive either Gelfoam (G) or Embospheres (E). The UFS-Qol symptom score improved in both groups at 6 months mean of 64 ± 18 to 23 ± 16 and 54 ± 15 to 32 ± 26 in the E and G groups respectively. UFS-Qol HRQL also improved in both groups at 6 months, mean 41 ± 28 to 79 ± 20 and 53 ± 19 to 78 ± 21 in the E and G groups respectively.Uterine volume at 6 months reduced from 1018 ± 666mls to 622 ± 436 ( p  = 0.001) and from 1026 ± 756 to 908 ± 720 ( p  = 0.15) in the E and G groups respectively. There was a significant difference between groups for this parameter p  = 0.01. All uterine arteries were patent at 24-h and 6 months. Complete (100%) fibroid infarction rates were 5(50%) and 2(20%) in the E and G groups respectively. None of the other outcome measures showed any between group differences. There were no re-interventions in either group. Conclusion The only significant between group differences was for a greater reduction in uterine volume at 6 months in the E group. A larger trial (estimate 172 subjects) is required to determine whether other apparent differences are clinically and statistically significant. Trial registration ISRCTN67347987.",2019,"UFS-Qol HRQL also improved in both groups at 6 months, mean 41 ± 28 to 79 ± 20 and 53 ± 19 to 78 ± 21 in the E and G groups respectively.","['women with symptomatic uterine fibroids who wish to avoid surgery', 'uterine artery embolisation for fibroids', 'Twenty patients', 'women undergoing UAE']","['embolic agents', 'Gelfoam (G) or Embospheres (E', 'Gelfoam with Embospheres', '\n\n\nUterine artery embolisation (UAE']","['Uterine volume', 'complications, inflammatory, haematological markers and ovarian function', 'quality of life (UFS-Qol', 'Contrast enhanced MRI (CEMRI', 'UFS-Qol HRQL', 'UFS-Qol symptom score', 'uterine volume', 'Pain score (visual analogue', 'fibroid infarction rates']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0042133', 'cui_str': 'Fibroid Uterus'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0226378', 'cui_str': 'Uterine Artery'}, {'cui': 'C0013931', 'cui_str': 'Embolotherapy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}, {'cui': 'C0918040', 'cui_str': 'Gelfoam'}, {'cui': 'C1566002', 'cui_str': 'Embospheres'}, {'cui': 'C0226378', 'cui_str': 'Uterine Artery'}, {'cui': 'C0013931', 'cui_str': 'Embolotherapy'}]","[{'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0034380'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0042133', 'cui_str': 'Fibroid Uterus'}, {'cui': 'C0021308', 'cui_str': 'Infarction'}]",20.0,0.257914,"UFS-Qol HRQL also improved in both groups at 6 months, mean 41 ± 28 to 79 ± 20 and 53 ± 19 to 78 ± 21 in the E and G groups respectively.","[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Yadavali', 'Affiliation': '6Radiology department, Gartnavel General Hospital, 1053 Great Western Rd, Glasgow, G12 OYN UK.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Ananthakrishnan', 'Affiliation': '6Radiology department, Gartnavel General Hospital, 1053 Great Western Rd, Glasgow, G12 OYN UK.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Sim', 'Affiliation': '6Radiology department, Gartnavel General Hospital, 1053 Great Western Rd, Glasgow, G12 OYN UK.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Monaghan', 'Affiliation': '2School of Mathematics and Statistics, University of Glasgow, Glasgow, G12 8QW UK.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'McNaught', 'Affiliation': ""3Clinical Research Imaging Centre, University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ UK.""}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Hamoodi', 'Affiliation': 'University Department of Obstetrics and Gynaecology, Glasgow, New Lister Building, 10-16 Alexandra Parade, Glasgow, G31 2ER UK.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Bryden', 'Affiliation': 'Radiology department, Stobhill ACH Hospital, 133 Balornock Road, Glasgow, G21 3UW UK.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Lassman', 'Affiliation': 'Radiology department, Stobhill ACH Hospital, 133 Balornock Road, Glasgow, G21 3UW UK.'}, {'ForeName': 'J G', 'Initials': 'JG', 'LastName': 'Moss', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, 126 University Place, Glasgow, G12 8TA UK.'}]",CVIR endovascular,['10.1186/s42155-018-0044-y'] 838,30837170,"A randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with adjuvant LTh(αK): A phase I study.","BACKGROUND A nasal influenza vaccine has been available only in a live attenuated form, which limits the range of recipients to immune-competent individuals. The present study evaluated a newly developed intranasal inactivated influenza vaccine with a novel adjuvant, heat-labile enterotoxin (LT) derived from E. coli (LTh(αK)). METHODS The study was a randomized, double-blind, controlled phase I trial to evaluate the safety and immunogenicity of an intranasal vaccine containing the trivalent influenza HA antigen (7.5 µg each of A/California/7/09 (H1N1)-like virus, A/Victoria/210/2009 (H3N2) virus, and B/Brisbane/60/2008-like virus) in combination with 4 different doses of adjuvant LTh(αK) (7.5, 15, 30 or 45 μg) and 22.5 μg of influenza HA antigen alone (control vaccine). The vaccine was intranasally administered on Days 0 and 7. A safety evaluation commenced for 180 days, and hemagglutination inhibition (HI) antibody titers and nasal HA-specific IgA titers on Day 0 and Day 28 were assessed to determine whether an immunogenic response was elicited. RESULTS From November 2012 to September 2013, a total of 36 subjects were enrolled. Twenty-four subjects received an adjuvanted vaccine, and 12 subjects received a control vaccine. The most common adverse event (AE) was mild nasal discomfort, and systemic AEs were mild fatigue and headache. Only two subjects discontinued the study because of an AE (one had grade 3 fever, and one had nodal arrhythmia). In the group with 45 μg of LTh(αK), the seroprotection rates were 100%, 100% and 80%, and the nasal IgA conversion factors were 7.90, 7.46 and 12.27 for the A/H3N2, A/H1N1 and split B strains, respectively. Adjuvant LTh(αK) vaccine showed a significant enhancement in mucosal immunity in split B -specific IgA. CONCLUSION The intranasal inactivated influenza vaccine is generally safe, and the LTh(αK)-adjuvanted vaccine is more immunogenic than non-adjuvanted control vaccine. ClinicalTrials.gov Identifier: NCT03293732.",2019,"In the group with 45 μg of LTh(αK), the seroprotection rates were 100%, 100% and 80%, and the nasal IgA conversion factors were 7.90, 7.46 and 12.27 for the A/H3N2, A/H1N1 and split B strains, respectively.","['From November 2012 to September 2013, a total of 36 subjects were enrolled']","['intranasal inactivated influenza vaccine', 'intranasal vaccine containing the trivalent influenza HA antigen (7.5\u202fµg each of A/California/7/09 (H1N1)-like virus, A/Victoria/210/2009 (H3N2) virus, and B/Brisbane/60/2008-like virus) in combination with 4 different doses of adjuvant LTh(αK', 'control vaccine', 'vaccine', 'intranasally administered trivalent inactivated influenza vaccine with adjuvant LTh(αK', 'Adjuvant LTh(αK) vaccine', 'intranasal inactivated influenza vaccine with a novel adjuvant, heat-labile enterotoxin (LT) derived from E. coli (LTh(αK', 'adjuvanted vaccine', 'influenza HA antigen alone (control vaccine']","['mucosal immunity', 'nasal IgA conversion factors', 'nodal arrhythmia', 'seroprotection rates', 'hemagglutination inhibition (HI) antibody titers and nasal HA-specific IgA titers', 'safety and immunogenicity', 'mild nasal discomfort, and systemic AEs were mild fatigue and headache']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]","[{'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C0021403', 'cui_str': 'Influenza Vaccines'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0021400', 'cui_str': 'Influenza, Human'}, {'cui': 'C0003320', 'cui_str': 'Antigens'}, {'cui': 'C4517859', 'cui_str': 'Seven point five'}, {'cui': 'C0042776', 'cui_str': 'Virus'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0014372', 'cui_str': 'Enterotoxins'}, {'cui': 'C0014834', 'cui_str': 'Escherichia coli'}]","[{'cui': 'C0282558', 'cui_str': 'Immunity, Mucosal'}, {'cui': 'C4520890', 'cui_str': 'Nasal'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0439836', 'cui_str': 'Conversions (qualifier value)'}, {'cui': 'C0264893', 'cui_str': 'Nodal rhythm disorder (disorder)'}, {'cui': 'C0018904', 'cui_str': 'Hemagglutination Inhibition Tests'}, {'cui': 'C1287242', 'cui_str': 'Finding of antibody titer (finding)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0858259', 'cui_str': 'Nasal discomfort'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}]",36.0,0.450411,"In the group with 45 μg of LTh(αK), the seroprotection rates were 100%, 100% and 80%, and the nasal IgA conversion factors were 7.90, 7.46 and 12.27 for the A/H3N2, A/H1N1 and split B strains, respectively.","[{'ForeName': 'Sung-Ching', 'Initials': 'SC', 'LastName': 'Pan', 'Affiliation': 'Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Szu-Min', 'Initials': 'SM', 'LastName': 'Hsieh', 'Affiliation': 'Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Chih-Feng', 'Initials': 'CF', 'LastName': 'Lin', 'Affiliation': 'Department of Otolaryngology/Head and Neck Surgery, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Yu-Shen', 'Initials': 'YS', 'LastName': 'Hsu', 'Affiliation': 'Advagene Biopharma Co., Ltd., Taipei, Taiwan; Development Center for Biotechnology, New Taipei City, Taiwan.'}, {'ForeName': 'Mingi', 'Initials': 'M', 'LastName': 'Chang', 'Affiliation': 'Advagene Biopharma Co., Ltd., Taipei, Taiwan; Development Center for Biotechnology, New Taipei City, Taiwan.'}, {'ForeName': 'Shan-Chwen', 'Initials': 'SC', 'LastName': 'Chang', 'Affiliation': 'Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: changsc@ntu.edu.tw.'}]",Vaccine,['10.1016/j.vaccine.2019.02.006'] 839,30460402,The impact of platelet-rich plasma therapy on short-term postoperative outcomes of pediatric tonsillectomy patients.,"INTRODUCTION To compare the short-term outcomes of pediatric patients who underwent tonsillectomy alone vs. tonsillectomy plus platelet-rich plasma (PRP) therapy in terms of postoperative pain, appetite status, analgesia requirement, and bleeding complications. MATERIALS AND METHODS This study included a total of 80 pediatric tonsillectomy patients (53.8% female, 46.2% male, aged 4-16 years), who were randomly allocated into tonsillectomy alone (TA group; n = 40) and tonsillectomy plus PRP therapy (TPRP group, n = 40) groups. Patient demographic data (age, gender) and postoperative data of visual analog scale (VAS) pain scores (postoperative 2nd hour, 1-10 days), appetite scores (postoperative 1-7 days), and analgesia requirement (postoperative 1-10 days) and bleeding complications were recorded. RESULTS A significant gradual decrease was noted in pain scores starting from the 3rd postoperative day reaching 0.0 ± 0.0 and 0.50 ± 0.88 on Day 10 in the TPRP and TA groups, respectively (p < 0.001 for each). Compared to the TA group, the TPRP group was associated with significantly lower pain scores (Day 1 to Day 10), better appetite scores (Day 1 to Day 6), a lower requirement for analgesia (Day1 to Day 10) and fewer common bleeding complications (1 vs. 4 patients) in the postoperative period (p < 0.001 for each). CONCLUSION In conclusion, this study of pediatric tonsillectomy patients revealed the superiority of tonsillectomy with PRP over tonsillectomy alone in terms of effectiveness in reducing post-tonsillectomy pain and improving appetite status, together with a lower requirement for analgesia and a reduced risk of post-tonsillectomy bleeding during the first 10 postoperative days.",2019,"Compared to the TA group, the TPRP group was associated with significantly lower pain scores (Day 1 to Day 10), better appetite scores (Day 1 to Day 6), a lower requirement for analgesia (Day1 to Day 10) and fewer common bleeding complications (1 vs. 4 patients) in the postoperative period (p < 0.001 for each). ","['80 pediatric tonsillectomy patients (53.8% female, 46.2% male, aged 4-16\xa0years', 'pediatric patients who underwent', 'pediatric tonsillectomy patients']","['TPRP', 'tonsillectomy alone (TA group; n\u2009=\u200940) and tonsillectomy plus PRP therapy (TPRP', 'tonsillectomy alone vs. tonsillectomy plus platelet-rich plasma (PRP) therapy', 'platelet-rich plasma therapy']","['postoperative pain, appetite status, analgesia requirement, and bleeding complications', 'risk of post-tonsillectomy bleeding', 'bleeding complications', 'pain scores', 'appetite scores (postoperative 1-7\xa0days), and analgesia requirement (postoperative 1-10\xa0days) and bleeding complications', 'appetite scores', 'Patient demographic data (age, gender) and postoperative data of visual analog scale (VAS) pain scores']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0040423', 'cui_str': 'Tonsillectomy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0040423', 'cui_str': 'Tonsillectomy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0242848', 'cui_str': 'PrP (GSS)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0370220', 'cui_str': 'Platelet rich plasma (substance)'}]","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C1321022', 'cui_str': 'Appetite status'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0040423', 'cui_str': 'Tonsillectomy'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C2732809', 'cui_str': 'Visual analog scale pain score (observable entity)'}]",80.0,0.0586932,"Compared to the TA group, the TPRP group was associated with significantly lower pain scores (Day 1 to Day 10), better appetite scores (Day 1 to Day 6), a lower requirement for analgesia (Day1 to Day 10) and fewer common bleeding complications (1 vs. 4 patients) in the postoperative period (p < 0.001 for each). ","[{'ForeName': 'Sinem', 'Initials': 'S', 'LastName': 'Gökçe Kütük', 'Affiliation': 'Department of Otorhinolaryngology, Aydın State Hospital, Aydın, Turkey. drsinem2@gmail.com.'}, {'ForeName': 'Talih', 'Initials': 'T', 'LastName': 'Özdaş', 'Affiliation': 'Department of Otorhinolaryngology, University of Health Sciences Adana City Hospital, Adana, Turkey.'}]",European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,['10.1007/s00405-018-5211-1'] 840,31930949,Use of autologous platelet-rich plasma in healing skin graft donor sites.,"OBJECTIVE To demonstrate that the use of platelet-rich plasma (PRP) enhances both the quality of healing and the time required for wound healing at a skin graft donor site. METHODS Patients who had dermo-epidermal skin grafts taken from the thigh area were included in a prospective, randomised clinical study. PRP was applied to one donor site and then covered with Vaseline-impregnated, open-weave gauze and gauze, while the contralateral donor site on the other thigh served as a control and was covered with the open-weave gauze and gauze without PRP. RESULTS A total of 24 patients took part in the study, of which three developed infections and were thus removed from the study. Use of PRP reduced the wound healing time of the dermo-epidermal graft donor sites by a mean 17.8% and median 18 days. On average, the treated donor sites healed in 14.9 days compared with 18.4 days for the control group. The median was 14 days compared with 18 days in the control group (p=0.026). In one patient, healing was slower on the side where PRP was applied. In 20 patients, healing of the donor site was accelerated where PRP was applied. CONCLUSION The study demonstrated a beneficial effect of PRP, as healing time was shortened. Using PRP to heal wounds could be beneficial for patients for whom commonly available wound healing therapies have failed, as well as for high-risk patient groups for whom problematic wound healing may be expected.",2020,"On average, the treated donor sites healed in 14.9 days compared with 18.4 days for the control group.","['healing skin graft donor sites', 'Patients who had dermo-epidermal skin grafts taken from the thigh area', '24 patients took part in the study, of which three developed infections and were thus removed from the study']","['platelet-rich plasma (PRP', 'Vaseline-impregnated, open-weave gauze and gauze, while the contralateral donor site on the other thigh served as a control and was covered with the open-weave gauze and gauze without PRP', 'PRP', 'autologous platelet-rich plasma']","['healing', 'healing time', 'healing of the donor site', 'wound healing time', 'quality of healing and the time required for wound healing']","[{'cui': 'C0205249', 'cui_str': 'Healed (qualifier value)'}, {'cui': 'C0037297', 'cui_str': 'Grafting, Skin'}, {'cui': 'C1444716', 'cui_str': 'Donor site (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0039866', 'cui_str': 'Thigh'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C1292747', 'cui_str': 'Removes from'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma (substance)'}, {'cui': 'C0242848', 'cui_str': 'PrP (GSS)'}, {'cui': 'C0728774', 'cui_str': 'Vaseline'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0590323', 'cui_str': 'Gauzes (physical object)'}, {'cui': 'C0441988', 'cui_str': 'Contralateral (qualifier value)'}, {'cui': 'C1444716', 'cui_str': 'Donor site (attribute)'}, {'cui': 'C0039866', 'cui_str': 'Thigh'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439844', 'cui_str': 'Covered (qualifier value)'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}]","[{'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1444716', 'cui_str': 'Donor site (attribute)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}]",,0.0183254,"On average, the treated donor sites healed in 14.9 days compared with 18.4 days for the control group.","[{'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Slaninka', 'Affiliation': 'Department of Surgery, Faculty of Medicine of Charles University and University Hospital Hradec Králové, Czech Republic.'}, {'ForeName': 'Aleš', 'Initials': 'A', 'LastName': 'Fibír', 'Affiliation': 'Department of Surgery, Faculty of Medicine of Charles University and University Hospital Hradec Králové, Czech Republic.'}, {'ForeName': 'Milan', 'Initials': 'M', 'LastName': 'Kaška', 'Affiliation': 'Department of Surgery, Faculty of Medicine of Charles University and University Hospital Hradec Králové, Czech Republic.'}, {'ForeName': 'Jiří', 'Initials': 'J', 'LastName': 'Páral', 'Affiliation': 'Department of Surgery, Faculty of Medicine of Charles University and University Hospital Hradec Králové, Czech Republic.'}]",Journal of wound care,['10.12968/jowc.2020.29.1.36'] 841,30663324,Examining the impact of physical activity on sleep quality and executive functions in children with autism spectrum disorder: A randomized controlled trial.,"Sleep disturbance and executive dysfunction have been widely reported in children with autism spectrum disorder. While the positive impacts of physical activity on sleep quality and cognition are documented in children with typical development, similar studies in children with autism spectrum disorder are scarce. The objective of this study was to examine the impact of physical activity on sleep quality and cognition in children with autism spectrum disorder. A total of 40 children diagnosed with autism spectrum disorder (mean age = 9.95 years) were randomly assigned into two groups: physical activity intervention and control. Four sleep parameters (sleep efficiency, sleep onset latency, sleep duration, and wake after sleep onset) and two executive functions (inhibition control and working memory) were assessed. Results revealed a significant improvement in sleep efficiency, sleep onset latency, and sleep duration in the intervention group but not in the control group during weekdays. Moreover, a significant improvement in inhibitory control was shown in the intervention group but not in the control group. No significant improvement in working memory capacity was documented in either group ( p s > 0.05). Our findings highlight the value of physical activity in improving sleep quality and cognition among children with autism spectrum disorder, but specific physical activity may be required to benefit individual executive functions.",2019,No significant improvement in working memory capacity was documented in either group ( p s > 0.05).,"['children with autism spectrum disorder', '40 children diagnosed with autism spectrum disorder (mean age\u2009=\u20099.95\u2009years']","['physical activity', 'physical activity intervention and control']","['sleep efficiency, sleep onset latency, and sleep duration', 'Four sleep parameters (sleep efficiency, sleep onset latency, sleep duration, and wake after sleep onset) and two executive functions (inhibition control and working memory', 'Sleep disturbance and executive dysfunction', 'sleep quality and cognition', 'sleep quality and executive functions', 'inhibitory control', 'working memory capacity']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C4505222', 'cui_str': 'REM Sleep Latency'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0442696', 'cui_str': 'Waking (observable entity)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnias'}, {'cui': 'C2748208', 'cui_str': 'Executive dysfunction'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",40.0,0.0272284,No significant improvement in working memory capacity was documented in either group ( p s > 0.05).,"[{'ForeName': 'Choi Yeung Andy', 'Initials': 'CYA', 'LastName': 'Tse', 'Affiliation': '1 The Education University of Hong Kong, Hong Kong.'}, {'ForeName': 'Hong Paul', 'Initials': 'HP', 'LastName': 'Lee', 'Affiliation': '2 Hong Kong Polytechnic University, Hong Kong.'}, {'ForeName': 'Ka Shing Kevin', 'Initials': 'KSK', 'LastName': 'Chan', 'Affiliation': '1 The Education University of Hong Kong, Hong Kong.'}, {'ForeName': 'Veronica Bordes', 'Initials': 'VB', 'LastName': 'Edgar', 'Affiliation': '3 The University of Texas Southwestern Medical Center, USA.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Wilkinson-Smith', 'Affiliation': ""4 Children's Medical Center Dallas, USA.""}, {'ForeName': 'Wing Him Elvis', 'Initials': 'WHE', 'LastName': 'Lai', 'Affiliation': '5 Castle Peak Hospital, Hong Kong.'}]",Autism : the international journal of research and practice,['10.1177/1362361318823910'] 842,30674240,Extended Efficacy of Low-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients: Two-Year Follow-Up.,"OBJECTIVES In a previous study, we evaluated 1-year outcomes of using low-dose valganciclovir prophylaxis for cytomegalovirus infection in intermediate-risk kidney transplant recipients. Whether this effect persists in the long term is unknown. We aimed to evaluate the 2-year follow up of such adopted prophylaxis. MATERIALS AND METHODS We randomized 2 matched groups of kidney transplant recipients (1:1) to receive valganciclovir as 450 mg daily (group 1) or 900 mg daily (group 2) for the first 6 months after kidney transplant. The final analysis included 196 patients as intermediate-risk patients (98 in each treatment group) after exclusion of 5 high-risk patients. Serologically, all patients were at moderate risk for cytomegalovirus infection. Long-term outcomes including cytomegalovirus disease, acute rejection, new-onset diabetes after transplant, graft loss, and patient survival were assessed. RESULTS Through year 2 of follow-up, cytomegalovirus infection was reported in only 1 patient in group 1 (at month 13) and 1 patient in group 2 (at month 19) (not significant). Biopsy-proven acute rejection episodes were not statistically different between the groups (2 episodes in group 1 and 6 in group 2; P = .431). New-onset diabetes posttransplant was reported in 8.1% in group 1 and 13.2% in group 2 (P = .535). Graft failure was equal in both groups (1 in each group) at 2 years of follow up (not significant). Patient survival was comparable in both groups (100% in group 1 versus 97.9% in group 2; P = .661). The total number of cytomegalovirus infections at 2 years was numerically less in group 1 (P = .128). CONCLUSIONS Low-dose valganciclovir prophylaxis for 6 months was associated with sustained reduction of cytomegalovirus infection up to 2 years after kidney transplant without significant impact on the acute rejection, new-onset diabetes posttransplant, or patient and graft outcomes.",2019,"The total number of cytomegalovirus infections at 2 years was numerically less in group 1 (P = .128). ","['We randomized 2 matched groups of kidney transplant recipients (1:1) to receive', 'intermediate-risk kidney transplant recipients', 'Intermediate-Risk Kidney Transplant Recipients', '196 patients as intermediate-risk patients (98 in each treatment group) after exclusion of 5 high-risk patients']","['Low-Dose Valganciclovir', 'valganciclovir', 'low-dose valganciclovir prophylaxis']","['total number of cytomegalovirus infections', 'Graft failure', 'cytomegalovirus infection', 'Biopsy-proven acute rejection episodes', 'cytomegalovirus disease, acute rejection, new-onset diabetes after transplant, graft loss, and patient survival', 'New-onset diabetes posttransplant', 'Patient survival']","[{'cui': 'C0024908', 'cui_str': 'Matched Groups'}, {'cui': 'C0022671', 'cui_str': 'Grafting, Kidney'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C4517625', 'cui_str': '196'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}]","[{'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0909381', 'cui_str': 'valganciclovir'}, {'cui': 'C0033107', 'cui_str': 'prophylaxis'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0010823', 'cui_str': 'Salivary Gland Virus Disease'}, {'cui': 'C1262018', 'cui_str': 'Transplant failure'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0456369', 'cui_str': 'Proven (qualifier value)'}, {'cui': 'C0035015', 'cui_str': 'Rejection'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0332835', 'cui_str': 'Grafts'}, {'cui': 'C0877042', 'cui_str': 'Graft loss'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]",2.0,0.0212798,"The total number of cytomegalovirus infections at 2 years was numerically less in group 1 (P = .128). ","[{'ForeName': 'Medhat A', 'Initials': 'MA', 'LastName': 'Halim', 'Affiliation': 'The Department of Medicine, Hamed Al-Essa Organ Transplantation Centre, Ibn Sina Hospital, Kuwait.'}, {'ForeName': 'Osama A', 'Initials': 'OA', 'LastName': 'Gheith', 'Affiliation': ''}, {'ForeName': 'Yahya', 'Initials': 'Y', 'LastName': 'Makkeya', 'Affiliation': ''}, {'ForeName': 'Ayman M', 'Initials': 'AM', 'LastName': 'Nagib', 'Affiliation': ''}, {'ForeName': 'Ahmed F', 'Initials': 'AF', 'LastName': 'Atta', 'Affiliation': ''}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Emam', 'Affiliation': ''}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Yehia', 'Affiliation': ''}, {'ForeName': 'Tarek', 'Initials': 'T', 'LastName': 'Said', 'Affiliation': ''}, {'ForeName': 'Prasad', 'Initials': 'P', 'LastName': 'Nair', 'Affiliation': ''}, {'ForeName': 'Torki', 'Initials': 'T', 'LastName': 'Al-Otaibi', 'Affiliation': ''}]",Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation,['10.6002/ect.2018.0020'] 843,29365017,Association of Reperfusion With Brain Edema in Patients With Acute Ischemic Stroke: A Secondary Analysis of the MR CLEAN Trial.,"Importance It is uncertain whether therapeutic reperfusion with endovascular treatment yields more or less brain edema. Objective To elucidate the association between reperfusion and brain edema. The secondary objectives were to evaluate whether brain edema could partially be responsible for worse outcomes in patients with later reperfusion or lower Alberta Stroke Program Early Computed Tomography Score. Design, Setting, and Participants This was a post hoc analysis of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), which was a prospective, randomized, multicenter clinical trial of endovascular treatment compared with conventional care of patients with acute anterior circulation ischemic stroke. Of 502 patients enrolled from December 2010 to June 2014, 2 patients declined to participate. Additionally, exclusion criteria were absence of follow-up imaging or presence of parenchymal hematoma, resulting in 462 patients included in this study. Brain edema was assessed retrospectively, from December 10, 2016, to July 24, 2017, by measuring midline shift (MLS) in all available follow-up scans. Observers were blinded to clinical data. Main Outcomes and Measures Midline shift was assessed as present or absent and as a continuous variable. Reperfusion status was assessed by the modified thrombolysis in cerebral infarction score in the endovascular treatment arm. The modified arterial occlusive lesion score was used to evaluate the recanalization status in both arms. The modified Rankin scale score at 90 days was used for functional outcome. Results Of 462 patients, the mean (SD) age was 65 (11) years, and 41.8% (n = 193) were women. Successful reperfusion and recanalization were associated with a reduced likelihood of having MLS (adjusted common odds ratio, 0.25; 95% CI, 0.12-0.53; P < .001 and adjusted common odds ratio, 0.34; 95% CI, 0.21-0.55; P < .001, respectively). Midline shift was partially responsible for worse modified Rankin scale scores in patients without reperfusion or recanalization (MLS changed the logistic regression coefficients by 30.3% and 12.6%, respectively). In patients with delayed reperfusion or lower Alberta Stroke Program Early Computed Tomography Score, MLS mediated part of the worse modified Rankin scale scores, corresponding to a change in the regression coefficient of 33.3% and 64.2%, respectively. Conclusions and Relevance Successful reperfusion was associated with reduced MLS. This study identifies an additional benefit of reperfusion in relation to edema, as well as rescuing ischemic brain tissue at risk for infarction. Trial Registration Netherlands Trial Registry number: NTR1804 and Current Controlled Trials number: ISRCTN10888758.",2018,"Midline shift was partially responsible for worse modified Rankin scale scores in patients without reperfusion or recanalization (MLS changed the logistic regression coefficients by 30.3% and 12.6%, respectively).","['502 patients enrolled from December 2010 to June 2014, 2 patients declined to participate', 'Patients With Acute Ischemic Stroke', '462 patients included in this study', 'patients with acute anterior circulation ischemic stroke', 'Acute Ischemic Stroke in the Netherlands (MR CLEAN', '462 patients', 'the mean (SD) age was 65 (11) years, and 41.8% (n\u2009=\u2009193) were women']","['endovascular treatment', 'Endovascular Treatment', 'conventional care']","['cerebral infarction score', 'modified Rankin scale scores', 'brain edema', 'Brain edema', 'Measures\n\n\nMidline shift', 'modified arterial occlusive lesion score', 'modified Rankin scale score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]","[{'cui': 'C0007785', 'cui_str': 'Cerebral Infarction'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C1527311', 'cui_str': 'Intracranial Edema'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0333051', 'cui_str': 'Shift (morphologic abnormality)'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}]",502.0,0.0887985,"Midline shift was partially responsible for worse modified Rankin scale scores in patients without reperfusion or recanalization (MLS changed the logistic regression coefficients by 30.3% and 12.6%, respectively).","[{'ForeName': 'W Taylor', 'Initials': 'WT', 'LastName': 'Kimberly', 'Affiliation': 'Center for Genomic Medicine and Department of Neurology, Massachusetts General Hospital, Boston.'}, {'ForeName': 'Bruna Garbugio', 'Initials': 'BG', 'LastName': 'Dutra', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Academic Medical Center, Amsterdam, the Netherlands.'}, {'ForeName': 'Anna M M', 'Initials': 'AMM', 'LastName': 'Boers', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Academic Medical Center, Amsterdam, the Netherlands.'}, {'ForeName': 'Heitor C B R', 'Initials': 'HCBR', 'LastName': 'Alves', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Academic Medical Center, Amsterdam, the Netherlands.'}, {'ForeName': 'Olvert A', 'Initials': 'OA', 'LastName': 'Berkhemer', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Academic Medical Center, Amsterdam, the Netherlands.'}, {'ForeName': 'Lucie', 'Initials': 'L', 'LastName': 'van den Berg', 'Affiliation': 'Department of Neurology, Academic Medical Center, Amsterdam, the Netherlands.'}, {'ForeName': 'Kevin N', 'Initials': 'KN', 'LastName': 'Sheth', 'Affiliation': 'Department of Neurology, Yale New Haven Hospital, New Haven, Connecticut.'}, {'ForeName': 'Yvo B W E M', 'Initials': 'YBWEM', 'LastName': 'Roos', 'Affiliation': 'Department of Neurology, Academic Medical Center, Amsterdam, the Netherlands.'}, {'ForeName': 'Aad', 'Initials': 'A', 'LastName': 'van der Lugt', 'Affiliation': 'Department of Radiology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.'}, {'ForeName': 'Ludo F M', 'Initials': 'LFM', 'LastName': 'Beenen', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Academic Medical Center, Amsterdam, the Netherlands.'}, {'ForeName': 'Diederik W J', 'Initials': 'DWJ', 'LastName': 'Dippel', 'Affiliation': 'Department of Neurology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.'}, {'ForeName': 'Wim H', 'Initials': 'WH', 'LastName': 'van Zwam', 'Affiliation': 'Department of Radiology, Maastricht University Medical Center, Maastricht, the Netherlands.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'van Oostenbrugge', 'Affiliation': 'Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, the Netherlands.'}, {'ForeName': 'Hester F', 'Initials': 'HF', 'LastName': 'Lingsma', 'Affiliation': 'Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.'}, {'ForeName': 'Henk', 'Initials': 'H', 'LastName': 'Marquering', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Academic Medical Center, Amsterdam, the Netherlands.'}, {'ForeName': 'Charles B L M', 'Initials': 'CBLM', 'LastName': 'Majoie', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Academic Medical Center, Amsterdam, the Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA neurology,['10.1001/jamaneurol.2017.5162'] 844,30663474,Impact of a person-centred group intervention on life satisfaction and engagement in activities among persons aging in the context of migration ‡ .,"Background: There is a growing need to support the health and wellbeing of older persons aging in the context of migration. Objectives: We evaluated whether a group-based health promotion program with person-centred approach, maintained or improved life satisfaction and engagement in activities of older immigrants in Sweden. Methods: A randomised controlled trial with post-intervention follow-ups at 6 months and 1 year was conducted with 131 older independently living persons aged ≥70 years from Finland and the Balkan Peninsula. Participants were randomly allocated to an intervention group (4 weeks of group intervention and a follow-up home visit) and a control group (no intervention). Outcome measures were life satisfaction and engagement in activities. Chi-square and odds ratios were calculated. Results: The odds ratios for maintenance or improvement of life satisfaction (for social contact and psychological health) were higher in the person-centred intervention group. More participants in the intervention group maintained or improved their general participation in activities compared with the control group. However, no significant between-group differences were found. Conclusion: Person-centred interventions can support older person's capability to maintain their health in daily life when aging in migration. Further research is needed with a larger sample and longer intervention period to determine the effectiveness of the intervention.",2020,The odds ratios for maintenance or improvement of life satisfaction (for social contact and psychological health) were higher in the person-centred intervention group.,"['131 older independently living persons aged ≥70 years from Finland and the Balkan Peninsula', 'older immigrants in Sweden', 'persons aging in the context of migration ‡ ']","['person-centred group intervention', 'control group (no intervention', 'Person-centred interventions']","['general participation in activities', 'odds ratios for maintenance or improvement of life satisfaction (for social contact and psychological health', 'life satisfaction and engagement in activities']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0016132', 'cui_str': 'Finland'}, {'cui': 'C3494471', 'cui_str': 'Balkans'}, {'cui': 'C0282163', 'cui_str': 'Immigrants'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0449255', 'cui_str': 'Context (attribute)'}, {'cui': 'C1533574', 'cui_str': 'Migration, function (observable entity)'}]","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0237101', 'cui_str': 'Social interaction finding'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}]",131.0,0.0631823,The odds ratios for maintenance or improvement of life satisfaction (for social contact and psychological health) were higher in the person-centred intervention group.,"[{'ForeName': 'Annikki', 'Initials': 'A', 'LastName': 'Arola', 'Affiliation': 'Institute of Neuroscience and Physiology, Section for Health and Rehabilitation, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Synneve', 'Initials': 'S', 'LastName': 'Dahlin-Ivanoff', 'Affiliation': 'Institute of Neuroscience and Physiology, Section for Health and Rehabilitation, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Greta', 'Initials': 'G', 'LastName': 'Häggblom-Kronlöf', 'Affiliation': 'Institute of Neuroscience and Physiology, Section for Health and Rehabilitation, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}]",Scandinavian journal of occupational therapy,['10.1080/11038128.2018.1515245'] 845,30690550,The reach and effectiveness of SIPsmartER when implemented by rural public health departments: a pilot dissemination and implementation trial to reduce sugar-sweetened beverages.,"SIPsmartER is a theory-based, 6-month, multi-component health literacy intervention shown to improve sugar-sweetened beverages (SSB) behaviors among adults in rural, southwest Virginia. The objective of this pilot trial was to understand the reach and effectiveness of SIPsmartER when delivered by existing staff in public health practice settings. This pre-post research design was conducted in partnership with four medically underserved southwest Virginia Department of Health (VDH) districts. Validated measures and standardized data collection techniques were used. Analyses included descriptive statistics and multilevel mixed-effects linear regressions models. Of 928 individuals screened, 586 (63%) were eligible and 117 (20% of eligible) enrolled in SIPsmartER (79% retained). The sample was majority female (71%) and white (94%) and had ≤high school education (59%) and an annual income of approximately $12,500. Relative to the county population, the enrolled study sample was representative for age and race, yet underrepresented for men and overrepresented for low income and low educational attainment. Significant improvements from baseline to 6 months were observed for the primary SSB outcome (-403 [confidence interval [CI] = -528, -278] SSB kcals/day) (p < .001). SSB-related attitudes, perceived behavioral control, behavioral intentions, and media literacy also significantly improved (all p < .05). SIPsmartER appears to be promising for VDH and potentially other health departments in medically underserved areas. When compared to the previous effectiveness trial, existing VDH staff achieved similar reach and effectiveness for some, but not all, outcomes. Future work is needed on methods to support health departments in developing strategies to reach new participants and to integrate SIPsmartER into sustained practice.",2020,"When compared to the previous effectiveness trial, existing VDH staff achieved similar reach and effectiveness for some, but not all, outcomes.","['rural public health departments', 'The sample was majority female (71%) and white (94%) and had ≤high school education (59%) and an annual income of approximately $12,500', 'partnership with four medically underserved southwest Virginia Department of Health (VDH) districts', 'Of 928 individuals screened, 586 (63%) were eligible and 117 (20% of eligible) enrolled in SIPsmartER (79% retained', 'county population, the enrolled study sample was representative for age and race, yet underrepresented for men and overrepresented for low income and low educational attainment', 'adults in rural, southwest Virginia', 'public health practice settings']",[],"['SSB-related attitudes, perceived behavioral control, behavioral intentions, and media literacy']","[{'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0332232', 'cui_str': 'Approximate (qualifier value)'}, {'cui': 'C0042753', 'cui_str': 'Virginia'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3853635', 'cui_str': 'Race (observable entity)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0034024', 'cui_str': 'Public Health Practice'}]",[],"[{'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0439536', 'cui_str': 'Medium (qualifier value)'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}]",,0.066299,"When compared to the previous effectiveness trial, existing VDH staff achieved similar reach and effectiveness for some, but not all, outcomes.","[{'ForeName': 'Jamie M', 'Initials': 'JM', 'LastName': 'Zoellner', 'Affiliation': 'Department of Public Health Sciences, University of Virginia, Christiansburg, VA, USA.'}, {'ForeName': 'Kathleen J', 'Initials': 'KJ', 'LastName': 'Porter', 'Affiliation': 'Department of Public Health Sciences, University of Virginia, Christiansburg, VA, USA.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'You', 'Affiliation': 'Department of Agricultural and Applied Economics, Virginia Tech, Blacksburg, VA, USA.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Estabrooks', 'Affiliation': 'Department of Health Promotion, Social and Behavioral Health, University of Nebraska Medical Center, Omaha, NE, USA.'}, {'ForeName': 'Katelynn', 'Initials': 'K', 'LastName': 'Perzynski', 'Affiliation': 'Department of Public Health Sciences, University of Virginia, Christiansburg, VA, USA.'}, {'ForeName': 'Pamela A', 'Initials': 'PA', 'LastName': 'Ray', 'Affiliation': 'New River Health District, Virginia Department of Health, Christiansburg, VA, USA.'}, {'ForeName': 'Eleanor S', 'Initials': 'ES', 'LastName': 'Cantrell', 'Affiliation': 'LENOWISCO and Cumberland Plateau Health District, Virginia Department of Health, Wise, VA, USA.'}]",Translational behavioral medicine,['10.1093/tbm/ibz003'] 846,30675865,[Clinical effect of maternal voice stimulation in alleviating procedural pain in hospitalized neonates].,"OBJECTIVE To study the clinical effect of maternal voice stimulation in alleviating procedural pain in neonates during heel blood collection. METHODS A total of 72 neonates who were admitted to the neonate intensive care unit were randomly divided into an intervention group (n=35) and a control group (n=37). Heel blood collection was performed by the routine method in the control group. The intervention group listened to their mothers' voice from 1 minute before heel blood collection to the end of the procedure. Pain score, incidence of crying, and vital signs were recorded before and after heel blood collection. RESULTS Compared with the control group, the heart rate was significantly reduced, the blood oxygen saturation significantly increased, the incidence of crying and the pain score were significantly reduced in the intervention group during the procedure of heel blood collection (P<0.05). CONCLUSIONS Maternal voice stimulation helps to reduce procedural pain and maintain stable vital signs in neonates.",2019,"Compared with the control group, the heart rate was significantly reduced, the blood oxygen saturation significantly increased, the incidence of crying and the pain score were significantly reduced in the intervention group during the procedure of heel blood collection (P<0.05). ","['neonates during heel blood collection', 'hospitalized neonates', '72 neonates who were admitted to the neonate intensive care unit', 'neonates']","['maternal voice stimulation', 'Maternal voice stimulation']","['Pain score, incidence of crying, and vital signs', 'heart rate', 'blood oxygen saturation', 'Heel blood collection', 'procedural pain', 'incidence of crying and the pain score']","[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0018870', 'cui_str': 'Heel'}, {'cui': 'C0005768'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}]","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0518766'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0428174', 'cui_str': 'Hemoglobin saturation with oxygen (observable entity)'}, {'cui': 'C0018870', 'cui_str': 'Heel'}, {'cui': 'C0005768'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C1619712', 'cui_str': 'Pain, Procedural'}]",72.0,0.0250036,"Compared with the control group, the heart rate was significantly reduced, the blood oxygen saturation significantly increased, the incidence of crying and the pain score were significantly reduced in the intervention group during the procedure of heel blood collection (P<0.05). ","[{'ForeName': 'Yu-Shuang', 'Initials': 'YS', 'LastName': 'Chen', 'Affiliation': 'Central South University, Changsha 410013, China. tanyanjuan@yahoo.com.cn.'}, {'ForeName': 'Yan-Juan', 'Initials': 'YJ', 'LastName': 'Tan', 'Affiliation': ''}, {'ForeName': 'Le-Shan', 'Initials': 'LS', 'LastName': 'Zhou', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 847,31930944,Regenerated oxidised cellulose versus calcium alginate in controlling bleeding from malignant breast cancer wounds: randomised control trial study protocol.,"OBJECTIVE Malignant wounds due to breast cancer can present with recurrent episodes of bleeding in the tumour tissue. This study will compare the efficacy of a calcium alginate dressing (Biatain, Coloplast A/S, Denmark) and a regenerated oxidised cellulose dressing (Surgicel, Ethicon, LLC, Puerto Rico). PROTOCOL A total of 24 patients with breast cancer and bleeding, malignant wounds will be enrolled in the randomised, controlled, open study, conducted at a hospital specialising in breast cancer treatment and at another hospital specialising in palliative care. Patients over 18 years old, with bleeding and willing to undergo venipuncture for blood collection will be included. All enrolled patients will be randomised for allocation to an experimental group (regenerated oxidised cellulose dressing) or a control group (calcium alginate dressing). The main intervention will consist of the application of the haemostatic product, assessment of digital pressure and estimation of the time required for haemostasis. OUTCOMES Key outcome measures will be the percentage of patients with haemostasis within 20 minutes, observation of haemostasis after three, five and 10 minutes, in addition to recurrence of bleeding and the quantity of product used. DISCUSSION To our knowledge, this is the first study to evaluate the effectiveness of haemostatic products in malignant wounds. This type of wound is poorly explored in the literature and, among its signs and symptoms, bleeding is poorly studied. The completion of this study will provide a more robust rationale for clinical decision-making related to the control of bleeding in malignant breast cancer wounds in the context of evidence-based nursing practices.",2020,All enrolled patients will be randomised for allocation to an experimental group (regenerated oxidised cellulose dressing) or a control group (calcium alginate dressing).,"['malignant wounds', 'Patients over 18 years old, with bleeding and willing to undergo venipuncture for blood collection will be included', '24 patients with breast cancer and bleeding, malignant wounds', 'malignant breast cancer wounds']","['calcium alginate dressing (Biatain, Coloplast A/S, Denmark) and a regenerated oxidised cellulose dressing (Surgicel, Ethicon, LLC, Puerto Rico', 'Regenerated oxidised cellulose versus calcium alginate', 'experimental group (regenerated oxidised cellulose dressing) or a control group (calcium alginate dressing']","['percentage of patients with haemostasis within 20 minutes, observation of haemostasis', 'recurrence of bleeding and the quantity of product used']","[{'cui': 'C0205282', 'cui_str': 'Malignant (qualifier value)'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0600109', 'cui_str': 'Willing (finding)'}, {'cui': 'C0600406', 'cui_str': 'Venipuncture (procedure)'}, {'cui': 'C0005768'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}]","[{'cui': 'C0460767', 'cui_str': 'Calcium alginate dressing (physical object)'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C0007649', 'cui_str': 'Absorbable Cellulose'}, {'cui': 'C0013119', 'cui_str': 'Dressings'}, {'cui': 'C0075660', 'cui_str': 'Surgicel'}, {'cui': 'C0034044', 'cui_str': 'Puerto Rico'}, {'cui': 'C0108092', 'cui_str': 'CALCIUM ALGINATE'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0740166', 'cui_str': 'Haemostasis'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C1265611', 'cui_str': 'Quantity finding'}]",,0.0250714,All enrolled patients will be randomised for allocation to an experimental group (regenerated oxidised cellulose dressing) or a control group (calcium alginate dressing).,"[{'ForeName': 'Flávia', 'Initials': 'F', 'LastName': 'Firmino', 'Affiliation': 'School of Nursing of the University São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Juliano', 'Initials': 'J', 'LastName': 'Santos', 'Affiliation': 'School of Nursing of the University São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Karina Cardoso', 'Initials': 'KC', 'LastName': 'Meira', 'Affiliation': 'School of Health of the Federal University of Rio Grande do Norte, Rio Grande do Norte, Brazil.'}, {'ForeName': 'Janille Luciana', 'Initials': 'JL', 'LastName': 'de Araújo', 'Affiliation': 'National Cancer Institute José Alencar Gomes da Silva, Palliative Care Unit. Rio de Janeiro, Brazil.'}, {'ForeName': 'Valter Alvarenga', 'Initials': 'VA', 'LastName': 'Júnior', 'Affiliation': 'Post-Graduate Program in Surgical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Vera Lúcia Conceição', 'Initials': 'VLC', 'LastName': 'de Gouveia Santos', 'Affiliation': 'Department of Medical-Surgical Nursing, School of Nursing, University of São Paulo, São Paulo, Brazil.'}]",Journal of wound care,['10.12968/jowc.2020.29.1.52'] 848,32408253,Effect of amino acids on IGF1 gene expression in human myotubes and skeletal muscle.,"OBJECTIVE Insulin-like growth factor I (IGF1) is an important regulator of collagen and extracellular matrix protein expression. We aimed to evaluate the effect of amino acids (AAs) on expression of IGF1 and IGF1-dependent genes in human myotubes and skeletal muscle and supposed that AAs administration increases IGF1 levels in blood and expression of IGF1 and IGF1-dependent genes in trained skeletal muscle, thereby reducing training-induced muscle damage. DESIGN Human myotubes were incubated with Arg and Leu for 24 h. Then, the effects of long-term branched chain AAs administration (10 weeks, 0.1 g/kg body mass/day) to volunteers (six subjects per AAs and placebo groups) performing large training volumes regularly (cross country skiers, training twice a day) were examined. RESULTS Incubating the myotubes with AAs increases expression of IGF1 mRNA isoforms and IGF1 secretion by 2-3 times. In athletes, long-term AAs administration increased basal blood levels of IGF1 (~50%) and expression of IGF1Ea mRNA slightly in skeletal muscle. There is no marked increase in expression of COL1A1, COL3A1, COL5A1, and LOX genes in skeletal muscle after AAs administration. However, expression of these genes in the combined group (placebo + AAs; n = 12) significantly correlated with the expression of IGF1Ea mRNA in muscle and did not correlate with IGF1 levels in the blood. CONCLUSIONS AAs administration increases IGF1 expression in vitro and in vivo. To obtain more pronounced changes in expression of IGF1 and IGF1-dependent genes in skeletal muscle, it may be necessary to increase the dose and/or duration of AAs administration.",2020,"There is no marked increase in expression of COL1A1, COL3A1, COL5A1, and LOX genes in skeletal muscle after AAs administration.","['human myotubes and skeletal muscle', 'Human myotubes were incubated with Arg and Leu for 24\xa0h']","['Insulin-like growth factor', 'amino acids', 'amino acids (AAs']","['IGF1 gene expression', 'IGF1 expression', 'basal blood levels of IGF1', 'expression of IGF1 mRNA isoforms and IGF1 secretion', 'expression of IGF1Ea mRNA', 'expression of COL1A1, COL3A1, COL5A1, and LOX genes in skeletal muscle', 'IGF1 levels']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C1704336', 'cui_str': 'Skeletal muscle fiber'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0003761', 'cui_str': 'Argentina'}, {'cui': 'C0023401', 'cui_str': 'Leucine'}]","[{'cui': 'C0037657', 'cui_str': 'Somatomedin'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}]","[{'cui': 'C0202220', 'cui_str': 'Somatomedin-C measurement'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0597298', 'cui_str': 'Isoforms'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0972255', 'cui_str': 'type I collagen alpha 1'}, {'cui': 'C0024375', 'cui_str': 'Protein-lysine 6-oxidase'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}]",,0.0302591,"There is no marked increase in expression of COL1A1, COL3A1, COL5A1, and LOX genes in skeletal muscle after AAs administration.","[{'ForeName': 'Egor M', 'Initials': 'EM', 'LastName': 'Lednev', 'Affiliation': 'Institute of Biomedical Problems of the RAS, 76A Khoroshevskoye Shosse, Moscow 123007, Russian Federation. Electronic address: ledhauz@gmail.com.'}, {'ForeName': 'Irina V', 'Initials': 'IV', 'LastName': 'Kravchenko', 'Affiliation': 'Federal Research Centre «Fundamentals of Biotechnology» of the Russian Academy of Sciences, 33 build 2, Leninsky prospect, Moscow 119071, Russian Federation.'}, {'ForeName': 'Vladimir A', 'Initials': 'VA', 'LastName': 'Furalyov', 'Affiliation': 'Federal Research Centre «Fundamentals of Biotechnology» of the Russian Academy of Sciences, 33 build 2, Leninsky prospect, Moscow 119071, Russian Federation.'}, {'ForeName': 'Evgeny A', 'Initials': 'EA', 'LastName': 'Lysenko', 'Affiliation': 'Institute of Biomedical Problems of the RAS, 76A Khoroshevskoye Shosse, Moscow 123007, Russian Federation.'}, {'ForeName': 'Iulia S', 'Initials': 'IS', 'LastName': 'Lemesheva', 'Affiliation': 'Institute of Biomedical Problems of the RAS, 76A Khoroshevskoye Shosse, Moscow 123007, Russian Federation.'}, {'ForeName': 'Alexandr A', 'Initials': 'AA', 'LastName': 'Grushin', 'Affiliation': 'Russian Olympic Committee, Luzhnetskaya Embankment 8, Russia, Moscow 119991, Russian Federation.'}, {'ForeName': 'Vadim E', 'Initials': 'VE', 'LastName': 'Dubrov', 'Affiliation': 'Lomonosov Moscow State University, Faculty of Fundamental Medicine, 27 build. 1, Lomonosovsky Prospekt, Moscow 119991, Russian Federation.'}, {'ForeName': 'Olga L', 'Initials': 'OL', 'LastName': 'Vinogradova', 'Affiliation': 'Institute of Biomedical Problems of the RAS, 76A Khoroshevskoye Shosse, Moscow 123007, Russian Federation.'}, {'ForeName': 'Daniil V', 'Initials': 'DV', 'LastName': 'Popov', 'Affiliation': 'Institute of Biomedical Problems of the RAS, 76A Khoroshevskoye Shosse, Moscow 123007, Russian Federation.'}]",Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society,['10.1016/j.ghir.2020.101323'] 849,31668592,"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.","BACKGROUND Myeloma causes profound immunodeficiency and recurrent, serious infections. Around 5500 new cases of myeloma are diagnosed per year in the UK, and a quarter of patients will have a serious infection within 3 months of diagnosis. We aimed to assess whether patients newly diagnosed with myeloma benefit from antibiotic prophylaxis to prevent infection, and to investigate the effect on antibiotic-resistant organism carriage and health care-associated infections in patients with newly diagnosed myeloma. METHODS TEAMM was a prospective, multicentre, double-blind, placebo-controlled randomised trial in patients aged 21 years and older with newly diagnosed myeloma in 93 UK hospitals. All enrolled patients were within 14 days of starting active myeloma treatment. We randomly assigned patients (1:1) to levofloxacin or placebo with a computerised minimisation algorithm. Allocation was stratified by centre, estimated glomerular filtration rate, and intention to proceed to high-dose chemotherapy with autologous stem cell transplantation. All investigators, patients, laboratory, and trial co-ordination staff were masked to the treatment allocation. Patients were given 500 mg of levofloxacin (two 250 mg tablets), orally once daily for 12 weeks, or placebo tablets (two tablets, orally once daily for 12 weeks), with dose reduction according to estimated glomerular filtration rate every 4 weeks. Follow-up visits occurred every 4 weeks up to week 16, and at 1 year. The primary outcome was time to first febrile episode or death from all causes within the first 12 weeks of trial treatment. All randomised patients were included in an intention-to-treat analysis of the primary endpoint. This study is registered with the ISRCTN registry, number ISRCTN51731976, and the EU Clinical Trials Register, number 2011-000366-35. FINDINGS Between Aug 15, 2012, and April 29, 2016, we enrolled and randomly assigned 977 patients to receive levofloxacin prophylaxis (489 patients) or placebo (488 patients). Median follow-up was 12 months (IQR 8-13). 95 (19%) first febrile episodes or deaths occurred in 489 patients in the levofloxacin group versus 134 (27%) in 488 patients in the placebo group (hazard ratio 0·66, 95% CI 0·51-0·86; p=0·0018. 597 serious adverse events were reported up to 16 weeks from the start of trial treatment (308 [52%] of which were in the levofloxacin group and 289 [48%] of which were in the placebo group). Serious adverse events were similar between the two groups except for five episodes (1%) of mostly reversible tendonitis in the levofloxacin group. INTERPRETATION Addition of prophylactic levofloxacin to active myeloma treatment during the first 12 weeks of therapy significantly reduced febrile episodes and deaths compared with placebo without increasing health care-associated infections. These results suggest that prophylactic levofloxacin could be used for patients with newly diagnosed myeloma undergoing anti-myeloma therapy. FUNDING UK National Institute for Health Research.",2019,"Serious adverse events were similar between the two groups except for five episodes (1%) of mostly reversible tendonitis in the levofloxacin group. ","['patients with newly diagnosed myeloma undergoing anti-myeloma therapy', 'patients with newly diagnosed myeloma', 'patients aged 21 years and older with newly diagnosed myeloma in 93 UK hospitals', 'patients newly diagnosed with myeloma benefit from', '488 patients', 'patients with newly diagnosed myeloma (TEAMM', '489 patients) or', 'number 2011-000366-35.\nFINDINGS\n\n\nBetween Aug 15, 2012, and April 29, 2016, we enrolled and randomly assigned 977 patients to receive']","['levofloxacin prophylaxis', 'levofloxacin or placebo', 'levofloxacin', 'placebo tablets', 'placebo', 'prophylactic levofloxacin', 'chemotherapy with autologous stem cell transplantation', 'antibiotic prophylaxis', 'Levofloxacin prophylaxis']","['febrile episodes or deaths', '597 serious adverse events', 'time to first febrile episode or death', 'Serious adverse events', 'febrile episodes and deaths']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0026764', 'cui_str': 'Myelomatosis'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C2607943', 'cui_str': 'findings'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}]","[{'cui': 'C0282386', 'cui_str': 'Levofloxacin'}, {'cui': 'C0033107', 'cui_str': 'prophylaxis'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0445202', 'cui_str': 'Prophylactic (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C1504389', 'cui_str': 'Stem Cell Transplantation'}, {'cui': 'C0282638', 'cui_str': 'Premedication, Antibiotic'}]","[{'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",977.0,0.742669,"Serious adverse events were similar between the two groups except for five episodes (1%) of mostly reversible tendonitis in the levofloxacin group. ","[{'ForeName': 'Mark T', 'Initials': 'MT', 'LastName': 'Drayson', 'Affiliation': 'School of Immunity and Infection, University of Birmingham, Birmingham, UK. Electronic address: m.t.drayson@bham.ac.uk.'}, {'ForeName': 'Stella', 'Initials': 'S', 'LastName': 'Bowcock', 'Affiliation': ""King's College Hospital NHS Trust, London, UK.""}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Planche', 'Affiliation': ""Department of Medical Microbiology, St George's, University of London, London, UK.""}, {'ForeName': 'Gulnaz', 'Initials': 'G', 'LastName': 'Iqbal', 'Affiliation': 'Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Pratt', 'Affiliation': 'University Hospitals Birmingham NHS Trust, Birmingham, UK.'}, {'ForeName': 'Kwee', 'Initials': 'K', 'LastName': 'Yong', 'Affiliation': 'Department of Haematology, UCL Cancer Institute, London, UK.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Wood', 'Affiliation': 'Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': 'Kerry', 'Initials': 'K', 'LastName': 'Raynes', 'Affiliation': 'Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Higgins', 'Affiliation': 'Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': 'Bryony', 'Initials': 'B', 'LastName': 'Dawkins', 'Affiliation': 'Academic Unit of Health Economics, University of Leeds, Leeds, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Meads', 'Affiliation': 'Academic Unit of Health Economics, University of Leeds, Leeds, UK.'}, {'ForeName': 'Claire T', 'Initials': 'CT', 'LastName': 'Hulme', 'Affiliation': 'Academic Unit of Health Economics, University of Leeds, Leeds, UK.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Monahan', 'Affiliation': ""Department of Medical Microbiology, St George's, University of London, London, UK.""}, {'ForeName': 'Kamaraj', 'Initials': 'K', 'LastName': 'Karunanithi', 'Affiliation': 'University Hospitals North Midlands NHS Trust, Stoke On Trent, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Dignum', 'Affiliation': 'Portsmouth Hospitals NHS Trust, Portsmouth, UK.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Belsham', 'Affiliation': 'Portsmouth Hospitals NHS Trust, Portsmouth, UK.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Neilson', 'Affiliation': 'The Dudley Group NHS Foundation Trust, Russells Hall Hospital, Dudley, UK.'}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Harrison', 'Affiliation': 'University Hospitals Coventry and Warwickshire, Coventry, UK.'}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Lokare', 'Affiliation': 'University Hospitals Coventry and Warwickshire, Coventry, UK.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Campbell', 'Affiliation': 'East Suffolk and North Essex NHS Foundation Trust, Colchester, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hamblin', 'Affiliation': 'East Suffolk and North Essex NHS Foundation Trust, Colchester, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hawkey', 'Affiliation': 'West Midlands Public Health Laboratory, Heart of England NHS Trust, Birmingham, UK.'}, {'ForeName': 'Anna C', 'Initials': 'AC', 'LastName': 'Whittaker', 'Affiliation': 'School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Low', 'Affiliation': 'Patient Advocacy, Myeloma UK, Edinburgh UK.'}, {'ForeName': 'Janet A', 'Initials': 'JA', 'LastName': 'Dunn', 'Affiliation': 'Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Oncology,['10.1016/S1470-2045(19)30506-6'] 850,28987525,Subgroup Analysis of Antibiotic Treatment for Skin Abscesses.,"STUDY OBJECTIVE Two large randomized trials recently demonstrated efficacy of methicillin-resistant Staphylococcus aureus (MRSA)-active antibiotics for drained skin abscesses. We determine whether outcome advantages observed in one trial exist across lesion sizes and among subgroups with and without guideline-recommended antibiotic indications. METHODS We conducted a planned subgroup analysis of a double-blind, randomized trial at 5 US emergency departments, demonstrating superiority of trimethoprim-sulfamethoxazole (320/1,600 mg twice daily for 7 days) compared with placebo for patients older than 12 years with a drained skin abscess. We determined between-group differences in rates of clinical (no new antibiotics) and composite cure (no new antibiotics or drainage) through 7 to 14 and 42 to 56 days after treatment among subgroups with and without abscess cavity or erythema diameter greater than or equal to 5 cm, history of MRSA, fever, diabetes, and comorbidities. We also evaluated treatment effect by lesion size and culture result. RESULTS Among 1,057 mostly adult participants, median abscess cavity and erythema diameters were 2.5 cm (range 0.1 to 16.0 cm) and 6.5 cm (range 1.0 to 38.5), respectively; 44.3% grew MRSA. Overall, for trimethoprim-sulfamethoxazole and placebo groups, clinical cure rate at 7 to 14 days was 92.9% and 85.7%; composite cure rate at 7 to 14 days was 86.5% and 74.3%, and at 42 to 56 days, it was 82.4% and 70.2%. For all outcomes, across lesion sizes and among subgroups with and without guideline antibiotic criteria, trimethoprim-sulfamethoxazole was associated with improved outcomes. Treatment effect was greatest with history of MRSA infection, fever, and positive MRSA culture. CONCLUSION Treatment with trimethoprim-sulfamethoxazole was associated with improved outcomes regardless of lesion size or guideline antibiotic criteria.",2018,"CONCLUSION Treatment with trimethoprim-sulfamethoxazole was associated with improved outcomes regardless of lesion size or guideline antibiotic criteria.","['patients older than 12 years with a drained skin abscess', 'drained skin abscesses']","['methicillin-resistant Staphylococcus aureus (MRSA)-active antibiotics', 'placebo', 'trimethoprim-sulfamethoxazole', 'trimethoprim-sulfamethoxazole and placebo']","['median abscess cavity and erythema diameters', 'rates of clinical (no new antibiotics) and composite cure (no new antibiotics or drainage', 'composite cure rate', 'clinical cure rate', 'history of MRSA infection, fever, and positive MRSA culture']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0180499', 'cui_str': 'Drain, device (physical object)'}, {'cui': 'C0149777', 'cui_str': 'Skin abscess'}]","[{'cui': 'C1265292', 'cui_str': 'MRSA'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0041044', 'cui_str': 'Sulfamethoxazole / Trimethoprim'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0333372', 'cui_str': 'Abscess cavity (morphologic abnormality)'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C1301886', 'cui_str': 'Diameter (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0013103', 'cui_str': 'Drainage'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C1265292', 'cui_str': 'MRSA'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0220814', 'cui_str': 'culture'}]",1057.0,0.556834,"CONCLUSION Treatment with trimethoprim-sulfamethoxazole was associated with improved outcomes regardless of lesion size or guideline antibiotic criteria.","[{'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Talan', 'Affiliation': 'Department of Emergency Medicine, Olive View-UCLA Medical Center, Los Angeles, CA; Department of Medicine, Division of Infectious Diseases, Olive View-UCLA Medical Center, Los Angeles, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA. Electronic address: idnet@ucla.edu.'}, {'ForeName': 'Gregory J', 'Initials': 'GJ', 'LastName': 'Moran', 'Affiliation': 'Department of Emergency Medicine, Olive View-UCLA Medical Center, Los Angeles, CA; Department of Medicine, Division of Infectious Diseases, Olive View-UCLA Medical Center, Los Angeles, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA.'}, {'ForeName': 'Anusha', 'Initials': 'A', 'LastName': 'Krishnadasan', 'Affiliation': 'Department of Emergency Medicine, Olive View-UCLA Medical Center, Los Angeles, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA.'}, {'ForeName': 'Fredrick M', 'Initials': 'FM', 'LastName': 'Abrahamian', 'Affiliation': 'Department of Emergency Medicine, Olive View-UCLA Medical Center, Los Angeles, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Lovecchio', 'Affiliation': 'Department of Emergency Medicine, Maricopa Medical Center, University of Arizona, and Mayo Graduate School of Medicine, Phoenix, AZ.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Karras', 'Affiliation': 'Department of Emergency Medicine, Temple University Medical Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.'}, {'ForeName': 'Mark T', 'Initials': 'MT', 'LastName': 'Steele', 'Affiliation': 'Department of Emergency Medicine, Truman Medical Center, University of Missouri-Kansas City School of Medicine, Kansas City, MO.'}, {'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Rothman', 'Affiliation': 'Department of Emergency Medicine, Johns Hopkins Medical Center, Johns Hopkins School of Medicine, Baltimore, MD.'}, {'ForeName': 'William R', 'Initials': 'WR', 'LastName': 'Mower', 'Affiliation': 'Department of Emergency Medicine, Ronald Reagan Medical Center, Los Angeles, CA.'}]",Annals of emergency medicine,['10.1016/j.annemergmed.2017.07.483'] 851,31677046,The EffectiveNess of LIfestyle with Diet and Physical Activity Education ProGram Among Prehypertensives and Stage 1 HyperTENsives in an Urban Community Setting (ENLIGHTEN) Study.,"This study aims to determine the effectiveness of a monthly lifestyle education program, which included advice on nutritional changes and physical activity enhancement in the reduction of blood pressure and selected biochemical and anthropometric parameters among pre-hypertensive and stage 1 hypertensive participants in Manila, Philippines. Participants resided in two barangays (districts), in Manila, Philippines, and each barangay was assigned to either the intervention or attention-control group. The intervention group received monthly lectures on cardiovascular disease and organized classes on diet and exercise, while the attention-control group received monthly lectures on non-cardiovascular topics, with verbal advice that healthy diet and exercise are important. The primary outcome was systolic blood pressure, with secondary outcomes of BMI, waist circumference, and laboratory measures. Linear mixed effects models with an interaction between intervention group and time were used to estimate the 6-month change in each group. At 6 months, systolic blood pressure was lower in the intervention group compared to the attention-control group (- 12.7 mmHg (95% CI [- 14.5, - 10.9]) vs. - 0.24 mmHg (95% CI [- 1.87, 1.43]), p-value < 0.001). Waist circumference (p < 0.001), BMI (p < 0.001), and total cholesterol (p = 0.049) were also lower. However, no statistically significant difference in fasting glucose was observed between the two groups (p = 0.740). This study showed that participants receiving a non-pharmacological intervention, specifically a low-cost diet and active lifestyle education program, experienced a greater decrease in blood pressure, BMI, waist circumference, and total cholesterol than the attention-control group. Educational programs such as in ENLIGHTEN show promise for a developing country with limited resources to improve hypertension levels, and ultimately cardiovascular health. ENLIGHTEN deserves further study in randomized trials.",2020,"However, no statistically significant difference in fasting glucose was observed between the two groups (p = 0.740).","['pre-hypertensive and stage 1 hypertensive participants in Manila, Philippines', 'Prehypertensives and Stage 1 HyperTENsives in an Urban Community Setting (ENLIGHTEN) Study', 'participants receiving a non-pharmacological intervention, specifically a low-cost diet and active lifestyle education program']","['monthly lectures on cardiovascular disease and organized classes on diet and exercise, while the attention-control group received monthly lectures on non-cardiovascular topics, with verbal advice that healthy diet and exercise', 'LIfestyle with Diet and Physical Activity Education ProGram', 'intervention or attention-control group', 'monthly lifestyle education program']","['blood pressure, BMI, waist circumference, and total cholesterol', 'blood pressure and selected biochemical and anthropometric parameters', 'systolic blood pressure, with secondary outcomes of BMI, waist circumference, and laboratory measures', 'total cholesterol', 'Waist circumference', 'fasting glucose', 'BMI', 'systolic blood pressure']","[{'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1 (qualifier value)'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205464', 'cui_str': 'Pharmacologic (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0730543', 'cui_str': 'Lifestyle education'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C0376683', 'cui_str': 'Lecture'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0452415', 'cui_str': 'Healthy Diet'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0729314', 'cui_str': 'Education provision (procedure)'}, {'cui': 'C0730543', 'cui_str': 'Lifestyle education'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0205474', 'cui_str': 'Biochemical (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}]",,0.0292947,"However, no statistically significant difference in fasting glucose was observed between the two groups (p = 0.740).","[{'ForeName': 'Julieta', 'Initials': 'J', 'LastName': 'Gabiola', 'Affiliation': 'Division of Primary Care and Population Health, Stanford University School of Medicine, 1265 Welch Road, MC 5475, Stanford, CA, 94305, USA.'}, {'ForeName': 'Dante', 'Initials': 'D', 'LastName': 'Morales', 'Affiliation': 'Manila Doctors Hospital, Manila, Philippines.'}, {'ForeName': 'Olive', 'Initials': 'O', 'LastName': 'Quizon', 'Affiliation': 'Manila Doctors Hospital, Manila, Philippines.'}, {'ForeName': 'Ronald Ian', 'Initials': 'RI', 'LastName': 'Cadiz', 'Affiliation': 'Manila Doctors Hospital, Manila, Philippines.'}, {'ForeName': 'Kyle', 'Initials': 'K', 'LastName': 'Feliciano', 'Affiliation': 'Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Roberto L', 'Initials': 'RL', 'LastName': 'Ruiz', 'Affiliation': 'Manila Doctors Hospital, Manila, Philippines.'}, {'ForeName': 'Christine Joy', 'Initials': 'CJ', 'LastName': 'Aguatis', 'Affiliation': 'Manila Doctors Hospital, Manila, Philippines.'}, {'ForeName': 'Teresita', 'Initials': 'T', 'LastName': 'Mararac', 'Affiliation': 'Manila Doctors Hospital, Manila, Philippines.'}, {'ForeName': 'Jenssy', 'Initials': 'J', 'LastName': 'Rojina', 'Affiliation': 'Oregon Health and Science University School of Medicine, Portland, OR, USA.'}, {'ForeName': 'Ariadna', 'Initials': 'A', 'LastName': 'Garcia', 'Affiliation': 'Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Haley', 'Initials': 'H', 'LastName': 'Hedlin', 'Affiliation': 'Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Cullen', 'Affiliation': 'Center for Population Health Sciences, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Latha', 'Initials': 'L', 'LastName': 'Palaniappan', 'Affiliation': 'Division of Primary Care and Population Health, Stanford University School of Medicine, 1265 Welch Road, MC 5475, Stanford, CA, 94305, USA. lathap@stanford.edu.'}]",Journal of community health,['10.1007/s10900-019-00764-0'] 852,31634724,Effects of processing positive memories on posttrauma mental health: A preliminary study in a non-clinical student sample.,"BACKGROUND AND OBJECTIVES Although trauma research and therapy primarily focus on traumatic memories, recent evidence indicates positive memory processes play a role in the etiology/maintenance of posttraumatic stress disorder (PTSD) symptom severity. We examined the effects of a novel positive memory processing technique on PTSD symptom severity, depression symptom severity, affect, posttrauma cognitions, and self-esteem. METHODS Sixty-five trauma-exposed participants were randomly assigned to one of three conditions (narrating/processing vs. writing/processing two specific positive memories, or a time-matched control) and completed self-report measures pre- and post-task (T0). About one week later, participants repeated their assigned task condition and completed self-report measures pre- and post-task (T1). We conducted mixed ANOVAs to examine the impact of the technique on study variables over time. RESULTS The narrating condition had significant decreases in PTSD symptom severity, posttrauma cognitions, and negative affect from T0 pre-task to T1 post-task; and significant increases in positive affect from T0 pre-to-post-task and from T1 pre-to-post-task. The writing condition had significant increases in positive affect from T0 pre-to-post-task, but a significant decrease from T0 post-task to T1 post-task; and significant decreases in negative affect from T0 pre-to-post-task with an increase from T0 post-task to T1 post-task. LIMITATIONS Use of self-report measures, non-clinical convenience sample with less gender/ethnic/racial diversity, small sample size, methodological differences in time frames for measures, and no examination of follow-up effects. CONCLUSIONS Narrating and processing specific positive memories had a beneficial impact on PTSD symptom severity, posttrauma maladaptive cognitions, and affect; such results provide an impetus to examine positive memory interventions in trauma clinical work.",2020,"Narrating and processing specific positive memories had a beneficial impact on PTSD symptom severity, posttrauma maladaptive cognitions, and affect; such results provide an impetus to examine positive memory interventions in trauma clinical work.","['posttrauma mental health', 'Sixty-five trauma-exposed participants']","['three conditions (narrating/processing vs. writing/processing two specific positive memories, or a time-matched control) and completed self-report measures pre- and post-task (T0', 'processing positive memories', 'novel positive memory processing technique']","['PTSD symptom severity, posttrauma cognitions, and negative affect from T0 pre-task', 'PTSD symptom severity, depression symptom severity, affect, posttrauma cognitions, and self-esteem']","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0450385', 'cui_str': '65 (qualifier value)'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}]","[{'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C4521054', 'cui_str': 'Process (qualifier value)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0561841', 'cui_str': 'Pleasant memories (finding)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}]","[{'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0036597', 'cui_str': 'Self Esteem'}]",,0.0339626,"Narrating and processing specific positive memories had a beneficial impact on PTSD symptom severity, posttrauma maladaptive cognitions, and affect; such results provide an impetus to examine positive memory interventions in trauma clinical work.","[{'ForeName': 'Ateka A', 'Initials': 'AA', 'LastName': 'Contractor', 'Affiliation': 'Department of Psychology, University of North Texas, Denton, TX, USA. Electronic address: ateka.contractor@unt.edu.'}, {'ForeName': 'Anne N', 'Initials': 'AN', 'LastName': 'Banducci', 'Affiliation': 'The National Center for PTSD at VA Boston Healthcare System, Boston, MA, USA; Boston University School of Medicine, Boston, MA, USA.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Jin', 'Affiliation': 'Department of Psychology, University of North Texas, Denton, TX, USA.'}, {'ForeName': 'Fallon S', 'Initials': 'FS', 'LastName': 'Keegan', 'Affiliation': 'Department of Psychology, University of North Texas, Denton, TX, USA.'}, {'ForeName': 'Nicole H', 'Initials': 'NH', 'LastName': 'Weiss', 'Affiliation': 'Department of Psychology, University of Rhode Island, Kingston, RI, USA.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2019.101516'] 853,30635130,Central Histamine Boosts Perirhinal Cortex Activity and Restores Forgotten Object Memories.,"BACKGROUND A method that promotes the retrieval of lost long-term memories has not been well established. Histamine in the central nervous system is implicated in learning and memory, and treatment with antihistamines impairs learning and memory. Because histamine H 3 receptor inverse agonists upregulate histamine release, the inverse agonists may enhance learning and memory. However, whether the inverse agonists promote the retrieval of forgotten long-term memory has not yet been determined. METHODS Here, we employed multidisciplinary methods, including mouse behavior, calcium imaging, and chemogenetic manipulation, to examine whether and how the histamine H 3 receptor inverse agonists, thioperamide and betahistine, promote the retrieval of a forgotten long-term object memory in mice. In addition, we conducted a randomized double-blind, placebo-controlled crossover trial in healthy adult participants to investigate whether betahistine treatment promotes memory retrieval in humans. RESULTS The treatment of H 3 receptor inverse agonists induced the recall of forgotten memories even 1 week and 1 month after training in mice. The memory recovery was mediated by the disinhibition of histamine release in the perirhinal cortex, which activated the histamine H 2 receptor. Histamine depolarized perirhinal cortex neurons, enhanced their spontaneous activity, and facilitated the reactivation of behaviorally activated neuronal ensembles. A human clinical trial revealed that treatment of H 3 receptor inverse agonists is specifically more effective for items that are more difficult to remember and subjects with poorer performance. CONCLUSIONS These results highlight a novel interaction between the central histamine signaling and memory engrams.",2019,The treatment of H 3 receptor inverse agonists induced the recall of forgotten memories even 1 week and 1 month after training in mice.,"['humans', 'healthy adult participants']","['betahistine', 'Histamine', 'placebo', 'histamine H 3 receptor inverse agonists, thioperamide and betahistine']",['recall of forgotten memories'],"[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0005301', 'cui_str': 'BETAHISTINE'}, {'cui': 'C0019588', 'cui_str': 'Histamine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C0439850', 'cui_str': 'Inverse (qualifier value)'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0076502', 'cui_str': 'thioperamide'}]","[{'cui': 'C0025260', 'cui_str': 'Memory'}]",,0.0833973,The treatment of H 3 receptor inverse agonists induced the recall of forgotten memories even 1 week and 1 month after training in mice.,"[{'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Nomura', 'Affiliation': 'Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan; Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan. Electronic address: hnomura@pharm.hokudai.ac.jp.'}, {'ForeName': 'Hiroto', 'Initials': 'H', 'LastName': 'Mizuta', 'Affiliation': 'Department of Psychiatry, Kyoto University Graduate School of Medicine, Kyoto, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Norimoto', 'Affiliation': 'Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Fumitaka', 'Initials': 'F', 'LastName': 'Masuda', 'Affiliation': 'Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Miura', 'Affiliation': 'Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Ayame', 'Initials': 'A', 'LastName': 'Kubo', 'Affiliation': 'Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Hiroto', 'Initials': 'H', 'LastName': 'Kojima', 'Affiliation': 'Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Aoi', 'Initials': 'A', 'LastName': 'Ashizuka', 'Affiliation': 'Department of Psychiatry, Kyoto University Graduate School of Medicine, Kyoto, Japan.'}, {'ForeName': 'Noriko', 'Initials': 'N', 'LastName': 'Matsukawa', 'Affiliation': 'Department of Psychiatry, Kyoto University Graduate School of Medicine, Kyoto, Japan.'}, {'ForeName': 'Zohal', 'Initials': 'Z', 'LastName': 'Baraki', 'Affiliation': 'Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Natsuko', 'Initials': 'N', 'LastName': 'Hitora-Imamura', 'Affiliation': 'Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan; Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Nakayama', 'Affiliation': 'Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Tomoe', 'Initials': 'T', 'LastName': 'Ishikawa', 'Affiliation': 'Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Mami', 'Initials': 'M', 'LastName': 'Okada', 'Affiliation': 'Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Orita', 'Affiliation': 'Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Ryoki', 'Initials': 'R', 'LastName': 'Saito', 'Affiliation': 'Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Yamauchi', 'Affiliation': 'Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Yamato', 'Initials': 'Y', 'LastName': 'Sano', 'Affiliation': 'Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Kusuhara', 'Affiliation': 'Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Masabumi', 'Initials': 'M', 'LastName': 'Minami', 'Affiliation': 'Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.'}, {'ForeName': 'Hidehiko', 'Initials': 'H', 'LastName': 'Takahashi', 'Affiliation': 'Department of Psychiatry, Kyoto University Graduate School of Medicine, Kyoto, Japan. Electronic address: hidehiko@kuhp.kyoto-u.ac.jp.'}, {'ForeName': 'Yuji', 'Initials': 'Y', 'LastName': 'Ikegaya', 'Affiliation': 'Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan; Center for Information and Neural Networks, National Institute of Information and Communications Technology, Osaka, Japan.'}]",Biological psychiatry,['10.1016/j.biopsych.2018.11.009'] 854,30572991,[Protective effect of vitamin A on residual pancreatic β cell function in children with type 1 diabetes mellitus].,"OBJECTIVE To study the protective effect of vitamin A on residual pancreatic β cell function in children with type 1 diabetes mellitus (T1DM) and its mechanism. METHODS A total of 46 children with T1DM (with a course of disease of 0.5-1 year) were randomly divided into an intervention group and a non-intervention group (n=23 each). The children in both groups were given insulin treatment, and those in the intervention group were also given vitamin A at a daily dose of 1 500-2 000 IU. A total of 25 healthy children were enrolled as the control group. The daily dose of insulin was calculated for the children with T1DM, and the serum levels of glycosylated hemoglobin (HbA1C), stimulated C-peptide, vitamin A, and interleukin-17 (IL-17) were measured before intervention and 3 months after intervention. RESULTS Before vitamin A intervention, the intervention group and the non-intervention group had a significantly lower serum level of vitamin A and a significantly higher level of IL-17 than the control group (P<0.01). After 3 months of intervention, the intervention group had significantly lower serum IL-17 level and insulin dose and a significantly higher level of stimulated C-peptide than the non-intervention group (P<0.05). CONCLUSIONS Vitamin A may protect residual pancreatic β cell function, possibly by improving the abnormal secretion of IL-17 in children with T1DM.",2018,"After 3 months of intervention, the intervention group had significantly lower serum IL-17 level and insulin dose and a significantly higher level of stimulated C-peptide than the non-intervention group (P<0.05). ","['children with T1DM', 'children with type 1 diabetes mellitus', '25 healthy children', 'children with type 1 diabetes mellitus (T1DM', '46 children with T1DM (with a course of disease of 0.5-1 year']","['vitamin A', 'vitamin A intervention']","['serum IL-17 level and insulin dose', 'level of IL-17', 'serum levels of glycosylated hemoglobin (HbA1C), stimulated C-peptide, vitamin A, and interleukin-17 (IL-17', 'serum level of vitamin A']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0686744', 'cui_str': 'Well child (finding)'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0042839', 'cui_str': 'Vitamin A'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0384648', 'cui_str': 'IL-17'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0006558', 'cui_str': 'Proinsulin C-Peptide'}, {'cui': 'C0042839', 'cui_str': 'Vitamin A'}]",46.0,0.0300163,"After 3 months of intervention, the intervention group had significantly lower serum IL-17 level and insulin dose and a significantly higher level of stimulated C-peptide than the non-intervention group (P<0.05). ","[{'ForeName': 'Yong-Xing', 'Initials': 'YX', 'LastName': 'Chen', 'Affiliation': ""Department of Endocrinology and Inherited Metabolism, Children's Hospital Affiliated to Zhengzhou University/Henan Children's Hospital/Zhengzhou Children's Hospital, Zhengzhou 450000, China. haiyanwei2009@163.com.""}, {'ForeName': 'Qiong', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Ying-Xian', 'Initials': 'YX', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Hai-Hua', 'Initials': 'HH', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Sheng-Nan', 'Initials': 'SN', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Hai-Yan', 'Initials': 'HY', 'LastName': 'Wei', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 855,30593701,Effectiveness of a protocol for teaching dental tooth color in students with color vision impairment.,"OBJECTIVE In patients with color vision alterations (CVA), the correct determination of color is altered, but not the detection of changes in luminosity or value. There is no accepted training protocol for dental value selection in dental students with CVA. The objective of this pilot study was to determine the effectiveness of a dental color training protocol based on the dental value selection. MATERIALS AND METHODS An intervention study was carried out on dental students in a University setting, applying a specific dental color training protocol on two groups of students. Group 1:4 students with CVA, Group 2:4 healthy students. A third group of four students without intervention was used as a control group. An initial diagnostic test was applied, which was reapplied at the end of the training. RESULTS The number of errors in the selection of the dental color decreased after training in all three groups, P > .05. For the value parameter, there was a statistically significant decrease in the number of errors after training (P = .014). CONCLUSIONS The applied training protocol could be of help in students with CVA, but multicenter studies are needed. CLINICAL SIGNIFICANCE Level 3 evidence level.",2020,"The number of errors in the selection of the dental color decreased after training in all three groups, P > .05.","['dental students in a University setting, applying a specific dental color training protocol on two groups of students', 'patients with color vision alterations (CVA', 'dental students with CVA', 'students with color vision impairment', 'Group 1:4 students with CVA, Group 2:4 healthy students']",['dental color training protocol'],"['number of errors', 'number of errors in the selection of the dental color']","[{'cui': 'C0038493', 'cui_str': 'Students, Dental'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0522507', 'cui_str': 'With color (attribute)'}, {'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}]","[{'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0009393', 'cui_str': 'Color'}]",4.0,0.0170751,"The number of errors in the selection of the dental color decreased after training in all three groups, P > .05.","[{'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Wagner', 'Affiliation': 'School of Dentistry, Faculty of Medicine, Pontificia Universidad Católica de Chile, Macul, Santiago, Chile.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Rioseco', 'Affiliation': 'School of Dentistry, Faculty of Medicine, Pontificia Universidad Católica de Chile, Macul, Santiago, Chile.'}, {'ForeName': 'Duniel', 'Initials': 'D', 'LastName': 'Ortuño', 'Affiliation': 'School of Dentistry, Faculty of Medicine, Pontificia Universidad Católica de Chile, Macul, Santiago, Chile.'}, {'ForeName': 'María F', 'Initials': 'MF', 'LastName': 'Cortés', 'Affiliation': 'School of Dentistry, Faculty of Medicine, Pontificia Universidad Católica de Chile, Macul, Santiago, Chile.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Costa', 'Affiliation': 'School of Dentistry, Faculty of Medicine, Pontificia Universidad Católica de Chile, Macul, Santiago, Chile.'}]",Journal of esthetic and restorative dentistry : official publication of the American Academy of Esthetic Dentistry ... [et al.],['10.1111/jerd.12451'] 856,30466338,Behind the Wheel: Process Evaluation of a Safe-Transport Program for Older Drivers Delivered in a Randomized Controlled Trial.,"This process evaluation explores relationships between program outcomes and intervention implementation in a trial evaluating ""Behind the Wheel,"" an education-based safe-transport program for older drivers. Participants (intervention group) were 190 Sydney drivers aged ⩾75 years ( M = 80 ± 4years). Process measures included fidelity, dose delivered, and received. Outcomes were self-reported driving regulation and objectively measured driving exposure. Relationships were explored using regression models. Older drivers who took ownership of driving retirement and self-regulation by developing plans were more likely to reduce their weekly driving, (β = 38 km, 95% confidence interval (CI) = [7.5,68.7]), and night driving (β = 7 km, 95% CI = [3.5, 10.4]). Drivers of older age (odds ratio [ OR ] = 1.1/year older, 95% CI = [1.05, 1.3]) had greater odds of developing driving retirement plans. Female drivers ( OR = 2.7,95% CI = [1.1, 6.9]), drivers with poorer function ( OR = 1.2/5-point decrease on DriveSafe, 95% CI = [1.04, 1.4]), and worse health ( OR = 1.2/additional medication, 95% CI = [1.02, 1.5]) had greater odds of developing safe mobility plans. This program had greatest impact with older, lower functioning drivers. A stronger message was delivered and received, as intended, to older drivers with lower function and poorer health. Our logic model can help channel resources to drivers who benefit most.",2020,"Female drivers ( OR = 2.7,95% CI = [1.1, 6.9]), drivers with poorer function ( OR = 1.2/5-point decrease on DriveSafe, 95% CI = [1.04, 1.4]), and worse health ( OR = 1.2/additional medication, 95% CI = [1.02, 1.5]) had greater odds of developing safe mobility plans.","['Older Drivers', 'Participants (intervention group) were 190 Sydney drivers aged ⩾75 years ( M = 80 ± 4years', 'Older drivers', 'older drivers', 'Drivers of older age (odds ratio [ OR] = 1.1/year older, 95% CI = [1.05, 1.3]) had greater odds of developing driving retirement plans']",[],"['fidelity, dose delivered, and received', 'self-reported driving regulation and objectively measured driving exposure']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517622', 'cui_str': 'One hundred and ninety'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1999167', 'cui_str': 'Old-age (finding)'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C4517491', 'cui_str': 'One point one'}, {'cui': 'C4517499', 'cui_str': '1.3 (qualifier value)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0035345', 'cui_str': 'Retirement'}, {'cui': 'C1301732', 'cui_str': 'Planned'}]",[],"[{'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}]",,0.0681767,"Female drivers ( OR = 2.7,95% CI = [1.1, 6.9]), drivers with poorer function ( OR = 1.2/5-point decrease on DriveSafe, 95% CI = [1.04, 1.4]), and worse health ( OR = 1.2/additional medication, 95% CI = [1.02, 1.5]) had greater odds of developing safe mobility plans.","[{'ForeName': 'Kristy', 'Initials': 'K', 'LastName': 'Coxon', 'Affiliation': 'School of Science and Health, Western Sydney University, Penrith, New South Wales, Australia.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Hunter', 'Affiliation': 'The George Institute for Global Health, UNSW Sydney, New South Wales, Australia.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Chevalier', 'Affiliation': 'The George Institute for Global Health, UNSW Sydney, New South Wales, Australia.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Brown', 'Affiliation': 'Neuroscience Research Australia (NeuRA), UNSW Sydney, New South Wales, Australia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Clarke', 'Affiliation': 'Kolling Institute, University of Sydney, New South Wales, Australia.'}, {'ForeName': 'Kris', 'Initials': 'K', 'LastName': 'Rogers', 'Affiliation': 'The George Institute for Global Health, UNSW Sydney, New South Wales, Australia.'}, {'ForeName': 'Soufiane', 'Initials': 'S', 'LastName': 'Boufous', 'Affiliation': 'Transport and Road Safety (TARS) Research, UNSW Sydney, New South Wales, Australia.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Ivers', 'Affiliation': 'The George Institute for Global Health, UNSW Sydney, New South Wales, Australia.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Keay', 'Affiliation': 'The George Institute for Global Health, UNSW Sydney, New South Wales, Australia.'}]",Journal of applied gerontology : the official journal of the Southern Gerontological Society,['10.1177/0733464818811015'] 857,30022753,[Efficacy of recombinant human thrombopoietin combined with high-dose dexamethasone in the treatment of refractory immune thrombocytopenia in children].,"OBJECTIVE To explore the efficacy and safety of recombinant human thrombopoietin (rhTPO) combined with high-dose dexamethasone (DXM) in the treatment of children with refractory immune thrombocytopenic purpura (ITP). METHODS Fifty-eight ITP children who had failed first-line therapy were randomly divided into two groups: DXM treatment (n=27) and rhTPO + DXM treatment (n=31). The DXM treatment group received two continuous cycles of DXM treatment; in each cycle, patients received high-dose DXM (0.6 mg/kg daily) by intravenous drip for 4 days every 28 days. The rhTPO group received subcutaneous injection of rhTPO (300 U/kg daily) for 14 days additional to DXM treatment. The overall response rate (marked response rate + slight response rate) and adverse reactions were evaluated after 3, 7, and 14 days and 1, 2, and 3 months of treatment. RESULTS After 7 and 14 days and 1 month of treatment, the rhTPO + DXM treatment group had a significantly higher marked response rate and a significantly higher overall response rate than the DXM treatment group (P<0.05). After 2 months of treatment, the rhTPO + DXM treatment group had a significantly higher overall response rate than the DXM group (P<0.05). One patient in the DXM treatment group had liver damage during the first week of treatment. There was no hypertension, fever, rash, allergy, or weakness in the two groups. CONCLUSIONS rhTPO combined with high-dose DXM is an effective and safe approach for treating refractory ITP.",2018,"After 2 months of treatment, the rhTPO + DXM treatment group had a significantly higher overall response rate than the DXM group (P<0.05).","['children', 'children with refractory immune thrombocytopenic purpura (ITP', 'Fifty-eight ITP children who had failed first-line therapy']","['recombinant human thrombopoietin combined with high-dose dexamethasone', 'high-dose DXM', 'DXM treatment', 'subcutaneous injection of rhTPO', 'DXM', 'recombinant human thrombopoietin (rhTPO) combined with high-dose dexamethasone (DXM', 'rhTPO\u2009+\u2009DXM', 'rhTPO + DXM treatment', 'rhTPO combined with high-dose DXM']","['marked response rate', 'overall response rate (marked response rate\u2009+\u2009slight response rate) and adverse reactions', 'hypertension, fever, rash, allergy, or weakness', 'overall response rate', 'liver damage']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C3805225', 'cui_str': 'Refractory immune thrombocytopenic purpura'}, {'cui': 'C0021540', 'cui_str': 'ITP'}, {'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0040052', 'cui_str': 'Thrombocytopoiesis-Stimulating Factor'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0021499', 'cui_str': 'Subcutaneous Injections'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0522501', 'cui_str': 'Massive (qualifier value)'}, {'cui': 'C2937276', 'cui_str': 'Slight (qualifier value)'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0015230', 'cui_str': 'Skin Rash'}, {'cui': 'C0002111', 'cui_str': 'Allergy Specialty'}, {'cui': 'C3714552', 'cui_str': 'Weakness - general'}, {'cui': 'C0151763', 'cui_str': 'Liver damage (disorder)'}]",58.0,0.0323578,"After 2 months of treatment, the rhTPO + DXM treatment group had a significantly higher overall response rate than the DXM group (P<0.05).","[{'ForeName': 'Yuan-Yuan', 'Initials': 'YY', 'LastName': 'Lu', 'Affiliation': ""Department of Pediatrics, Weifang People's Hospital, Weifang, Shandong 261041, China. wangyingweifang@163.com.""}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Guan', 'Affiliation': ''}, {'ForeName': 'Qing-Hong', 'Initials': 'QH', 'LastName': 'Meng', 'Affiliation': ''}, {'ForeName': 'Ming-Lei', 'Initials': 'ML', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Yun-Yun', 'Initials': 'YY', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 858,30022759,[Clinical effect of pidotimod oral liquid as adjuvant therapy for infectious mononucleosis].,"OBJECTIVE To study the clinical effect of pidotimod oral liquid as adjuvant therapy for infectious mononucleosis and its effect on T lymphocyte subsets. METHODS A total of 76 children with infectious mononucleosis, who were admitted to the hospital between July 2016 and June 2017, were enrolled and randomly divided into two groups: conventional treatment and pidotimod treatment (n=38 each). The children in the conventional treatment group were given antiviral therapy with ganciclovir for injection and symptomatic treatment. Those in the pidotimod treatment group were given pidotimod oral liquid in addition to the treatment in the conventional treatment group. The course of treatment was two weeks for both groups. The two groups were compared in terms of the recovery of clinical indices and the changes in peripheral blood T lymphocyte subsets. RESULTS Compared with the conventional treatment group, the pidotimod treatment group had significantly shorter fever clearance time, time to the disappearance of isthmopyra, time to the relief of lymph node enlargement, time to the relief of hepatosplenomegaly, and length of hospital stay (P<0.05). After treatment, the pidotimod treatment group had significant reductions in the percentages of CD3 + and CD8 + T cells and had significantly lower percentages of CD3 + and CD8 + T cells than the conventional treatment group (P<0.001). The pidotimod treatment group had significant increases in the percentage of CD4 + T cells and CD4 + /CD8 + ratio after treatment, which was significantly higher than those in the conventional treatment group (P<0.001). The conventional treatment group had no significant changes in T lymphocyte subsets after treatment (P>0.05). CONCLUSIONS Pidotimod oral liquid has a good clinical effect as the adjuvant therapy for infectious mononucleosis and can improve cellular immune function, so it holds promise for clinical application.",2018,"The conventional treatment group had no significant changes in T lymphocyte subsets after treatment (P>0.05). ","['76 children with infectious mononucleosis, who were admitted to the hospital between July 2016 and June 2017', 'infectious mononucleosis']","['conventional treatment and pidotimod treatment', 'pidotimod oral liquid', 'antiviral therapy with ganciclovir']","['shorter fever clearance time, time to the disappearance of isthmopyra, time to the relief of lymph node enlargement, time to the relief of hepatosplenomegaly, and length of hospital stay', 'CD3 + and CD8 + T cells', 'T lymphocyte subsets', 'peripheral blood T lymphocyte subsets', 'percentage of CD4 + T cells and CD4 + /CD8 + ratio', 'percentages of CD3 + and CD8 + T cells']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0021345', 'cui_str': 'Glandular Fever'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0081002', 'cui_str': 'pidotimod'}, {'cui': 'C1273619', 'cui_str': 'Oral Liquid Product'}, {'cui': 'C0280274', 'cui_str': 'Antiviral therapy (procedure)'}, {'cui': 'C0017066', 'cui_str': 'Ganciclovir'}]","[{'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1301676', 'cui_str': 'Relieves (qualifier value)'}, {'cui': 'C0024204', 'cui_str': 'Lymphatic gland'}, {'cui': 'C1293134', 'cui_str': 'Enlargement procedure'}, {'cui': 'C0019214', 'cui_str': 'Hepatosplenomegaly (disorder)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C0080202', 'cui_str': 'T-Cell Subsets'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood (substance)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",76.0,0.0155165,"The conventional treatment group had no significant changes in T lymphocyte subsets after treatment (P>0.05). ","[{'ForeName': 'Hai-Tao', 'Initials': 'HT', 'LastName': 'Lyu', 'Affiliation': ""Department of Pediatrics, Ningbo Women and Children's Hospital, Ningbo, Zhejiang 315000, China. 857274858@qq.com.""}, {'ForeName': 'Teng-Teng', 'Initials': 'TT', 'LastName': 'Shen', 'Affiliation': ''}, {'ForeName': 'Ji-Shan', 'Initials': 'JS', 'LastName': 'Zheng', 'Affiliation': ''}, {'ForeName': 'Hui-Qing', 'Initials': 'HQ', 'LastName': 'Xu', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 859,30535100,Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial.,"BACKGROUND Gram-negative bacteremia is a major cause of morbidity and mortality in hospitalized patients. Data to guide the duration of antibiotic therapy are limited. METHODS This was a randomized, multicenter, open-label, noninferiority trial. Inpatients with gram-negative bacteremia, who were afebrile and hemodynamically stable for at least 48 hours, were randomized to receive 7 days (intervention) or 14 days (control) of covering antibiotic therapy. Patients with uncontrolled focus of infection were excluded. The primary outcome at 90 days was a composite of all-cause mortality; relapse, suppurative, or distant complications; and readmission or extended hospitalization (>14 days). The noninferiority margin was set at 10%. RESULTS We included 604 patients (306 intervention, 298 control) between January 2013 and August 2017 in 3 centers in Israel and Italy. The source of the infection was urinary in 411 of 604 patients (68%); causative pathogens were mainly Enterobacteriaceae (543/604 [90%]). A 7-day difference in the median duration of covering antibiotics was achieved. The primary outcome occurred in 140 of 306 patients (45.8%) in the 7-day group vs 144 of 298 (48.3%) in the 14-day group (risk difference, -2.6% [95% confidence interval, -10.5% to 5.3%]). No significant differences were observed in all other outcomes and adverse events, except for a shorter time to return to baseline functional status in the short-course therapy arm. CONCLUSIONS In patients hospitalized with gram-negative bacteremia achieving clinical stability before day 7, an antibiotic course of 7 days was noninferior to 14 days. Reducing antibiotic treatment for uncomplicated gram-negative bacteremia to 7 days is an important antibiotic stewardship intervention. CLINICAL TRIALS REGISTRATION NCT01737320.",2019,"The primary outcome at 90 days was a composite of all-cause mortality; relapse, suppurative or distant complications; and re-admission or extended hospitalization (>14 days).","['604 patients (306 intervention, 298 control) between January 2013 and August 2017 in three centers in Israel and Italy', 'hospitalized patients', 'Patients with uncontrolled focus of infection were excluded', 'Inpatients with Gram-negative bacteremia, afebrile and hemodynamically stable for at least 48 hours']","['antibiotic therapy', 'Antibiotic Therapy']","['composite of all-cause mortality; relapse, suppurative or distant complications; and re-admission or extended hospitalization', 'shorter time to return to baseline functional status', 'median duration of covering antibiotics']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0022271', 'cui_str': 'Israel'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0744471', 'cui_str': 'Gram-negative bacteremia'}, {'cui': 'C0277797', 'cui_str': 'Apyrexial'}, {'cui': 'C0578150', 'cui_str': 'Hemodynamically stable'}, {'cui': 'C0439586', 'cui_str': '48 hours (qualifier value)'}]","[{'cui': 'C0338237', 'cui_str': 'Antibiotic therapy (procedure)'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C3249881', 'cui_str': 'Infection - suppurative (disorder)'}, {'cui': 'C0443203', 'cui_str': 'Distant (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0332156', 'cui_str': 'Return to (contextual qualifier) (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0439844', 'cui_str': 'Covered (qualifier value)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}]",604.0,0.222348,"The primary outcome at 90 days was a composite of all-cause mortality; relapse, suppurative or distant complications; and re-admission or extended hospitalization (>14 days).","[{'ForeName': 'Dafna', 'Initials': 'D', 'LastName': 'Yahav', 'Affiliation': 'Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah-Tikva.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Franceschini', 'Affiliation': 'Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Italy.'}, {'ForeName': 'Fidi', 'Initials': 'F', 'LastName': 'Koppel', 'Affiliation': 'Infectious Diseases Institute, Rambam Health Care Campus, Haifa.'}, {'ForeName': 'Adi', 'Initials': 'A', 'LastName': 'Turjeman', 'Affiliation': 'Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.'}, {'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Babich', 'Affiliation': 'Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.'}, {'ForeName': 'Roni', 'Initials': 'R', 'LastName': 'Bitterman', 'Affiliation': 'Infectious Diseases Institute, Rambam Health Care Campus, Haifa.'}, {'ForeName': 'Ami', 'Initials': 'A', 'LastName': 'Neuberger', 'Affiliation': 'Infectious Diseases Institute, Rambam Health Care Campus, Haifa.'}, {'ForeName': 'Nesrin', 'Initials': 'N', 'LastName': 'Ghanem-Zoubi', 'Affiliation': 'Infectious Diseases Institute, Rambam Health Care Campus, Haifa.'}, {'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Santoro', 'Affiliation': 'Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Italy.'}, {'ForeName': 'Noa', 'Initials': 'N', 'LastName': 'Eliakim-Raz', 'Affiliation': 'Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah-Tikva.'}, {'ForeName': 'Barak', 'Initials': 'B', 'LastName': 'Pertzov', 'Affiliation': 'Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petah-Tikva.'}, {'ForeName': 'Tali', 'Initials': 'T', 'LastName': 'Steinmetz', 'Affiliation': 'Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petah-Tikva.'}, {'ForeName': 'Anat', 'Initials': 'A', 'LastName': 'Stern', 'Affiliation': 'Infectious Diseases Institute, Rambam Health Care Campus, Haifa.'}, {'ForeName': 'Yaakov', 'Initials': 'Y', 'LastName': 'Dickstein', 'Affiliation': 'Infectious Diseases Institute, Rambam Health Care Campus, Haifa.'}, {'ForeName': 'Elias', 'Initials': 'E', 'LastName': 'Maroun', 'Affiliation': 'Infectious Diseases Institute, Rambam Health Care Campus, Haifa.'}, {'ForeName': 'Hiba', 'Initials': 'H', 'LastName': 'Zayyad', 'Affiliation': 'Infectious Diseases Institute, Rambam Health Care Campus, Haifa.'}, {'ForeName': 'Jihad', 'Initials': 'J', 'LastName': 'Bishara', 'Affiliation': 'Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah-Tikva.'}, {'ForeName': 'Danny', 'Initials': 'D', 'LastName': 'Alon', 'Affiliation': 'Department of Medicine B, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel.'}, {'ForeName': 'Yonatan', 'Initials': 'Y', 'LastName': 'Edel', 'Affiliation': 'Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.'}, {'ForeName': 'Elad', 'Initials': 'E', 'LastName': 'Goldberg', 'Affiliation': 'Department of Medicine F, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Venturelli', 'Affiliation': 'Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Italy.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Mussini', 'Affiliation': 'Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Italy.'}, {'ForeName': 'Leonard', 'Initials': 'L', 'LastName': 'Leibovici', 'Affiliation': 'Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.'}, {'ForeName': 'Mical', 'Initials': 'M', 'LastName': 'Paul', 'Affiliation': 'Infectious Diseases Institute, Rambam Health Care Campus, Haifa.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciy1054'] 860,30396100,"Comparison of the effects of modified pectoral nerve block and erector spinae plane block on postoperative opioid consumption and pain scores of patients after radical mastectomy surgery: A prospective, randomized, controlled trial.","STUDY OBJECTIVE Breast cancer is the most common malignancy of women all over the world. In this study, we compared the effects of ultrasound-guided modified pectoral nerve (PECS) block and erector spinae plane (ESP) block on postoperative opioid consumption, pain scores, and intraoperative fentanyl need of patients undergoing unilateral modified radical mastectomy surgery. DESIGN Single-blinded, prospective, randomized, efficacy study. SETTING Tertiary university hospital, postoperative recovery room and surgical ward. PATIENTS Forty patients (ASA I-II) were allocated to two groups. After exclusion, 38 patients were included in the final analysis (18 patients in the PECS groups and 20 in the ESP group). INTERVENTIONS Modified pectoral nerve block was performed in the PECS group and erector spinae plane block was performed in the ESP group. MEASUREMENTS Postoperative tramadol consumption and pain scores were compared between the groups. Also, intraoperative fentanyl need was measured. MAIN RESULTS Postoperative tramadol consumption was 132.78 ± 22.44 mg in PECS group and 196 ± 27.03 mg in ESP group (p = 0.001). NRS scores at the 15th and 30th min were similar between the groups. However, median NRS scores were significantly lower in PECS group at the postoperative 60th min, 120th min, 12th hour and 24th hour (p = 0.024, p = 0.018, p = 0.021 and p = 0.011 respectively). Intraoperative fentanyl need was 75 mg in PECS group and 87.5 mg in ESP group. The difference was not statistically significant (p = 0.263). CONCLUSION Modified PECS block reduced postoperative tramadol consumption and pain scores more effectively than ESP block after radical mastectomy surgery.",2019,"However, median NRS scores were significantly lower in PECS group at the postoperative 60th min, 120th min, 12th hour and 24th ","['patients after radical mastectomy surgery', 'Forty patients (ASA I-II', 'patients undergoing unilateral modified radical mastectomy surgery', 'Tertiary university hospital, postoperative recovery room and surgical ward', '38 patients were included in the final analysis (18 patients in the PECS groups and 20 in the ESP group']","['Modified PECS block', 'ultrasound-guided modified pectoral nerve (PECS) block and erector spinae plane (ESP) block', 'modified pectoral nerve block and erector spinae plane block', 'PECS', 'ESP']","['median NRS scores', 'postoperative opioid consumption, pain scores', 'Postoperative tramadol consumption and pain scores', 'postoperative opioid consumption and pain scores', 'postoperative tramadol consumption and pain scores', 'NRS scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0024884', 'cui_str': 'Mastectomy, Radical'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0024883', 'cui_str': 'Modified Mastectomy'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0034871', 'cui_str': 'Hospital Recovery Rooms'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0015373', 'cui_str': 'Extrasensory Perception'}]","[{'cui': 'C4273496', 'cui_str': 'Modified PECS block'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0205967', 'cui_str': 'Pectoral Nerves'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0015373', 'cui_str': 'Extrasensory Perception'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0040610', 'cui_str': 'Tramadol'}]",38.0,0.114127,"However, median NRS scores were significantly lower in PECS group at the postoperative 60th min, 120th min, 12th hour and 24th ","[{'ForeName': 'Başak', 'Initials': 'B', 'LastName': 'Altıparmak', 'Affiliation': 'Muğla Sıtkı Koçman University, Department of Anesthesiology and Reanimation, Muğla, Turkey. Electronic address: basakugurlu@me.com.'}, {'ForeName': 'Melike', 'Initials': 'M', 'LastName': 'Korkmaz Toker', 'Affiliation': 'Muğla Sıtkı Koçman University Training and Research Hospital, Department of Anesthesiology and Reanimation, Muğla, Turkey.'}, {'ForeName': 'Ali İhsan', 'Initials': 'Aİ', 'LastName': 'Uysal', 'Affiliation': 'Muğla Sıtkı Koçman University Training and Research Hospital, Department of Anesthesiology and Reanimation, Muğla, Turkey.'}, {'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Turan', 'Affiliation': 'Muğla Sıtkı Koçman University, Department of Anesthesiology and Reanimation, Muğla, Turkey.'}, {'ForeName': 'Semra', 'Initials': 'S', 'LastName': 'Gümüş Demirbilek', 'Affiliation': 'Muğla Sıtkı Koçman University, Department of Anesthesiology and Reanimation, Muğla, Turkey.'}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2018.10.040'] 861,31663831,Direct Intra-arterial thrombectomy in order to Revascularize AIS patients with large vessel occlusion Efficiently in Chinese Tertiary hospitals: A Multicenter randomized clinical Trial (DIRECT-MT)-Protocol.,"RATIONALE Intravenous thrombolysis combined with mechanical thrombectomy (MT) has been proven safe and clinical effective in patients with acute ischemic stroke of anterior circulation large vessel occlusion. However, despite reperfusion, a considerable proportion of patients do not recover. Incidence of symptomatic intracerebral hemorrhage was similar between patients treated with the combination of intravenous thrombolysis and MT, as compared to intravenous thrombolysis alone, suggesting that this complication should be attributed to pre-treatment with intravenous thrombolysis. Conversely, intravenous thrombolysis may be beneficial in patients with small clots occluding intracranial arteries with underlying intracranial atherosclerotic disease, not accessible for MT. AIM To assess whether direct MT is non-inferior compared to combined intravenous thrombolysis plus MT in patients with AIS due to an anterior circulation large vessel occlusion, and to assess treatment effect modification by presence of intracranial atherosclerotic disease. SAMPLE SIZE Aim to randomize 636 patients 1:1 to receive direct MT (intervention) or combined intravenous thrombolysis plus MT (control). DESIGN This is a multicenter, prospective, open label parallel group trial with blinded outcome assessment (PROBE design) assessing non-inferiority of direct MT compared to combined intravenous thrombolysis plus MT. OUTCOMES The primary outcome is the score on the modified Rankin Scale assessed blindly at 90 (±14) days. An common odds ratio, adjusted for the prognostic factors (age, NIHSS, collateral score), representing the shift on the 6-category mRS scale measured at three months, estimated with ordinal logistic regression, will be the primary effect parameter. Non-inferiority is established if the lower boundary of the 95% confidence interval does not cross 0.8. DISCUSSION DIRECT-MT could result in improved therapeutic efficiency and cost reduction in treatment of anterior circulation large vessel occlusion stroke.",2020,"Incidence of symptomatic intracerebral hemorrhage was similar between patients treated with the combination of intravenous thrombolysis and MT, as compared to intravenous thrombolysis alone, suggesting that this complication should be attributed to pre-treatment with intravenous thrombolysis.","['Revascularize AIS patients with large vessel occlusion Efficiently in Chinese Tertiary hospitals', 'patients with acute ischemic stroke of anterior circulation large vessel occlusion', '636 patients 1:1 to receive', 'patients with small clots occluding intracranial arteries with underlying intracranial atherosclerotic disease', 'patients with AIS due to an anterior circulation large vessel occlusion']","['Direct Intra-arterial thrombectomy', 'direct MT (intervention) or combined intravenous thrombolysis plus MT (control', 'mechanical thrombectomy (MT', 'direct MT']","['therapeutic efficiency', '6-category mRS scale', 'score on the modified Rankin Scale assessed blindly at 90 (±14) days', 'symptomatic intracerebral hemorrhage']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0225990', 'cui_str': 'Large vessel'}, {'cui': 'C0441597', 'cui_str': 'Occlusion - action (qualifier value)'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0587437', 'cui_str': 'Tertiary Hospital'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0302148', 'cui_str': 'Blood coagulum'}, {'cui': 'C1947917', 'cui_str': 'Occluded (qualifier value)'}, {'cui': 'C0447028', 'cui_str': 'Structure of intracranial artery'}, {'cui': 'C0524466', 'cui_str': 'Intracranial (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}]","[{'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0694634', 'cui_str': 'Intra-arterial (qualifier value)'}, {'cui': 'C0162578', 'cui_str': 'Thrombectomy'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis, function (observable entity)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C2937358', 'cui_str': 'Intracerebral Hemorrhage'}]",636.0,0.161536,"Incidence of symptomatic intracerebral hemorrhage was similar between patients treated with the combination of intravenous thrombolysis and MT, as compared to intravenous thrombolysis alone, suggesting that this complication should be attributed to pre-treatment with intravenous thrombolysis.","[{'ForeName': 'Pengfei', 'Initials': 'P', 'LastName': 'Yang', 'Affiliation': 'Neurosurgery, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Kilian M', 'Initials': 'KM', 'LastName': 'Treurniet', 'Affiliation': 'Radiology & Nuclear Medicine, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Neurosurgery, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Yongwei', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Neurology, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Zifu', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Neurosurgery, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Pengfei', 'Initials': 'P', 'LastName': 'Xing', 'Affiliation': 'Neurology, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Yongxin', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Neurosurgery, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'Neurology, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Neurosurgery, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Hong', 'Affiliation': 'Neurosurgery, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Diederik Wj', 'Initials': 'DW', 'LastName': 'Dippel', 'Affiliation': 'Erasmus MC University Medical Center, Neurology and Stroke Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Yvo Bwem', 'Initials': 'YB', 'LastName': 'Roos', 'Affiliation': 'Neurology, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Charles Blm', 'Initials': 'CB', 'LastName': 'Majoie', 'Affiliation': 'Radiology & Nuclear Medicine, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Benqiang', 'Initials': 'B', 'LastName': 'Deng', 'Affiliation': 'Neurology, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Jianmin', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Neurosurgery, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",International journal of stroke : official journal of the International Stroke Society,['10.1177/1747493019882837'] 862,30150345,Unusual case of dasatinib-associated acute bilateral hyphemas leading to blindness in a patient with chronic myeloid leukaemia.,"Chronic myeloid leukaemia (CML) is a myeloproliferative disorder with an incidence of 1-2 cases per 100 000 adults per year. 1 Since the International Randomized Study of Interferon and STI571 trial (IRIS trial) in 2003, treatment with tyrosine kinase inhibitors (TKIs) has become the standard of care for patients with newly diagnosed CML in the chronic phase. 2 Dasatinib is a second-generation TKI and is generally well tolerated, with cytopenias, gastrointestinal (GI) symptoms and fluid retention being the most commonly observed side effects. 3-5 Bleeding complications, although unusual, have been reported with dasatinib, with an incidence ranging from 8% to 24%. 3-6 The most commonly reported site of bleeding is the GI tract. 3 5 We report an unusual case of dasatinib-associated bleeding presenting with acute bilateral hyphemas, which, to our knowledge, is the first report of its kind.",2018,"Since the International Randomized Study of Interferon and STI571 trial (IRIS trial) in 2003, treatment with tyrosine kinase inhibitors (TKIs) has become the standard of care for patients with newly diagnosed CML in the chronic phase.","['Chronic myeloid leukaemia (CML', 'patients with newly diagnosed CML in the chronic phase', 'patient with chronic myeloid leukaemia']","['Interferon and STI571', 'tyrosine kinase inhibitors (TKIs']",[],"[{'cui': 'C0023473', 'cui_str': 'Leukemia, Granulocytic, Chronic'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0457343', 'cui_str': 'Chronic phase (qualifier value)'}]","[{'cui': 'C0021747', 'cui_str': 'Interferons'}, {'cui': 'C0906802', 'cui_str': 'STI-571'}, {'cui': 'C0033681', 'cui_str': 'Tyrosylprotein Kinase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]",[],,0.0559164,"Since the International Randomized Study of Interferon and STI571 trial (IRIS trial) in 2003, treatment with tyrosine kinase inhibitors (TKIs) has become the standard of care for patients with newly diagnosed CML in the chronic phase.","[{'ForeName': 'Sandhya', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'Hematology/Medical Oncology, Monter Cancer Center, Lake Success, New York, USA.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Garg', 'Affiliation': 'Hematology/Medical Oncology, Monter Cancer Center, Lake Success, New York, USA.'}, {'ForeName': 'Cristina M', 'Initials': 'CM', 'LastName': 'Ghiuzeli', 'Affiliation': 'Hematology/Medical Oncology, Monter Cancer Center, Lake Success, New York, USA.'}]",BMJ case reports,['10.1136/bcr-2018-225705'] 863,30055883,Targeted cognitive training improves auditory and verbal outcomes among treatment refractory schizophrenia patients mandated to residential care.,"Computerized targeted cognitive training (TCT) of auditory processing has been shown to improve verbal learning in several clinical trials of schizophrenia outpatients. Less is known, however, about the effectiveness of this promising intervention in more chronic, treatment-refractory patients who are treated in non-academic settings. This study aimed to determine whether TCT improves auditory processing, verbal learning, and clinical symptoms in SZ patients mandated to receive care at a locked residential rehabilitation center. Secondarily, potential factors that moderate TCT's effectiveness including age, symptom severity, antipsychotic medication load, and duration of illness were examined. Schizophrenia patients were randomized to treatment as usual (TAU; n = 22) or TAU augmented with TCT (TAU + TCT; n = 24). Outcomes included a measure of auditory perception (Word-In-Noise test, WIN), verbal learning domain scores from the MATRICS Consensus Cognitive Battery (MCCB), and clinical symptoms (Scale for the Assessment of Positive Symptoms, SAPS; Scale for the Assessment of Negative Symptoms, SANS). TCT produced significant improvements in auditory perception (d = 0.67) and verbal learning (d = 0.65); exploratory analyses revealed a statistically significant reduction in auditory hallucinations (d = -0.64). TCT's effects were only weakly, and mostly non-significantly, moderated by age, clinical symptoms, medication, and illness duration. These findings indicate that even highly symptomatic, functionally disabled patients with chronic illness benefit from this emerging treatment. Ongoing studies will examine the predictive utility of neurophysiological biomarkers and other characteristics assessed at baseline.",2018,TCT produced significant improvements in auditory perception (d = 0.67) and verbal learning (d = 0.65); exploratory analyses revealed a statistically significant reduction in auditory hallucinations (d = -0.64).,"['schizophrenia outpatients', 'treatment refractory schizophrenia patients mandated to residential care', 'Schizophrenia patients', 'SZ patients mandated to receive care at a locked residential rehabilitation center']","['TAU augmented with TCT (TAU\u202f+\u202fTCT', 'Computerized targeted cognitive training (TCT) of auditory processing', 'cognitive training', 'TCT']","[""TCT's effects"", 'measure of auditory perception (Word-In-Noise test, WIN), verbal learning domain scores from the MATRICS Consensus Cognitive Battery (MCCB), and clinical symptoms (Scale for the Assessment of Positive Symptoms, SAPS; Scale for the Assessment of Negative Symptoms, SANS', 'verbal learning', 'auditory perception', 'auditory and verbal outcomes', 'auditory processing, verbal learning, and clinical symptoms', 'auditory hallucinations']","[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0034993', 'cui_str': 'Rehabilitation Centers'}]","[{'cui': 'C1720655', 'cui_str': 'Tau'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0677634', 'cui_str': 'Reptilase Time'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}]","[{'cui': 'C0677634', 'cui_str': 'Reptilase Time'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0004309', 'cui_str': 'Auditory Perception'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0042531', 'cui_str': 'Verbal Learning'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0376298', 'cui_str': 'Consensus'}, {'cui': 'C0542351', 'cui_str': 'Battery (event)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0222045'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0233762', 'cui_str': 'Hallucinations, Auditory'}]",,0.0298067,TCT produced significant improvements in auditory perception (d = 0.67) and verbal learning (d = 0.65); exploratory analyses revealed a statistically significant reduction in auditory hallucinations (d = -0.64).,"[{'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Thomas', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Andrew W', 'Initials': 'AW', 'LastName': 'Bismark', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Yash B', 'Initials': 'YB', 'LastName': 'Joshi', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Tarasenko', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Emily B H', 'Initials': 'EBH', 'LastName': 'Treichler', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Hochberger', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'San Diego State University/University of California, San Diego (SDSU/UCSD) Joint Doctoral Program (JDP) in Clinical Psychology, San Diego, CA, United States.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Nungaray', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Joyce', 'Initials': 'J', 'LastName': 'Sprock', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Cardoso', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; Alpine Special Treatment Center Inc., Alpine, CA, United States.'}, {'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Tiernan', 'Affiliation': 'Alpine Special Treatment Center Inc., Alpine, CA, United States.'}, {'ForeName': 'Mouna', 'Initials': 'M', 'LastName': 'Attarha', 'Affiliation': 'Posit Science Corporation, 160 Pine St Suite 200, San Francisco, CA 94111, United States.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Braff', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Vinogradov', 'Affiliation': 'Department of Psychiatry, University of Minnesota, Minneapolis, MN, United States.'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Swerdlow', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Light', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States; San Diego State University/University of California, San Diego (SDSU/UCSD) Joint Doctoral Program (JDP) in Clinical Psychology, San Diego, CA, United States. Electronic address: glight@ucsd.edu.'}]",Schizophrenia research,['10.1016/j.schres.2018.07.025'] 864,31668850,"Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.","BACKGROUND Endocrine treatment is recommended by clinical guidelines as the preferred treatment option for premenopausal as well as postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. In real-world clinical practice, however, a substantial number of patients are treated with chemotherapy. We aimed to compare the clinical antitumour activity and safety of palbociclib plus endocrine therapy with that of capecitabine chemotherapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. METHODS This multicentre, open-label, randomised, phase 2 study was done in 14 academic institutions in South Korea. Premenopausal women aged 19 years or older with hormone receptor-positive, HER2-negative breast cancer that had relapsed or progressed during previous tamoxifen therapy and with an Eastern Cooperative Oncology Group performance status of 0-2 were included. One line of previous chemotherapy for metastatic breast cancer was allowed. Patients were randomly assigned, using a random permuted block design (with a block size of two), to receive palbociclib plus combination endocrine therapy (oral exemestane 25 mg per day for 28 days and oral palbociclib 125 mg per day for 21 days every 4 weeks plus leuprolide 3·75 mg subcutaneously every 4 weeks) or chemotherapy (oral capecitabine 1250 mg/m 2 twice daily for 2 weeks every 3 weeks). Randomisation was stratified by previous chemotherapy for metastatic breast cancer and visceral metastasis. The primary endpoint was progression-free survival. All analyses were done in a modified intention-to-treat population that excluded patients who did not receive study medication. This study is registered with ClinicalTrials.gov, NCT02592746, and is ongoing for follow-up of overall survival. FINDINGS Between June 15, 2016, and Dec 10, 2018, 189 patients were enrolled, of whom 184 were randomly assigned to the palbociclib plus endocrine therapy group (n=92) or the capecitabine group (n=92). Six patients in the capecitabine group withdrew from the study before drug administration; therefore, 92 patients in the palbociclib plus endocrine therapy group and 86 patients in the capecitabine group were included in the modified intention-to-treat analyses. 46 (50%) of 92 patients in the palbociclib plus endocrine therapy group and 45 (51%) of 92 in the capecitabine group were treatment naive for metastatic breast cancer. During a median follow-up of 17 months (IQR 9-22), median progression-free survival was 20·1 months (95% CI 14·2-21·8) in the palbociclib plus endocrine therapy group versus 14·4 months (12·1-17·0) in the capecitabine group (hazard ratio 0·659 [95% CI 0·437-0·994], one-sided log-rank p=0·0235). Treatment-related grade 3 or worse neutropenia was more common in the palbociclib plus endocrine therapy group than in the capecitabine group (69 [75%] of 92 vs 14 [16%] of 86 patients). 2 (2%) patients in the palbociclib plus endocrine therapy group and 15 (17%) patients in the capecitabine group had treatment-related serious adverse events. No treatment-related deaths occurred. INTERPRETATION Exemestane plus palbociclib with ovarian function suppression showed clinical benefit compared with capecitabine in terms of improved progression-free survival in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Palbociclib plus exemestane with ovarian suppression is an active treatment option in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer who have been pretreated with tamoxifen. FUNDING Pfizer, Shinpoong, and Daewoong Korea and Takeda.",2019,Treatment-related grade 3 or worse neutropenia was more common in the palbociclib plus endocrine therapy group than in the capecitabine group (69 [75%] of 92 vs 14 [16%] of 86 patients).,"['premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10', 'premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer', 'postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer', 'Premenopausal women aged 19 years or older with hormone receptor-positive, HER2-negative breast cancer that had relapsed or progressed during previous tamoxifen therapy and with an Eastern Cooperative Oncology Group performance status of 0-2 were included', 'Six patients in the capecitabine group withdrew from the study before drug administration; therefore, 92 patients in the palbociclib plus endocrine therapy group and 86 patients in the', 'Between June 15, 2016, and Dec 10, 2018, 189 patients were enrolled, of whom 184', 'premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer', '14 academic institutions in South Korea', 'premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer who have been pretreated with']","['palbociclib plus endocrine therapy', 'capecitabine chemotherapy', 'Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine', 'leuprolide', 'chemotherapy (oral capecitabine 1250', 'Palbociclib plus exemestane with ovarian suppression', 'palbociclib plus combination endocrine therapy (oral exemestane', 'capecitabine', 'tamoxifen']","['progression-free survival', 'median progression-free survival', 'treatment-related serious adverse events', 'Treatment-related grade 3 or worse neutropenia']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C4087376', 'cui_str': 'HER2 negative'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer metastatic'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C4510392', 'cui_str': 'Tamoxifen therapy'}, {'cui': 'C1520224', 'cui_str': 'Eastern Cooperative Oncology Group performance status'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn (finding)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0150270', 'cui_str': 'Medication administration case management'}, {'cui': 'C3853822', 'cui_str': 'palbociclib'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy (procedure)'}, {'cui': 'C4517616', 'cui_str': 'One hundred and eighty-four'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0022773', 'cui_str': 'South Korea'}]","[{'cui': 'C3853822', 'cui_str': 'palbociclib'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy (procedure)'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0851344', 'cui_str': 'exemestane'}, {'cui': 'C4543260', 'cui_str': 'Gonadotropin'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0085272', 'cui_str': 'Leuprolide'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C4517554', 'cui_str': 'One thousand two hundred and fifty'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression (disorder)'}, {'cui': 'C0039286', 'cui_str': 'Tamoxifen'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}]",189.0,0.1161,Treatment-related grade 3 or worse neutropenia was more common in the palbociclib plus endocrine therapy group than in the capecitabine group (69 [75%] of 92 vs 14 [16%] of 86 patients).,"[{'ForeName': 'Yeon Hee', 'Initials': 'YH', 'LastName': 'Park', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address: yhparkhmo@skku.edu.'}, {'ForeName': 'Tae-Yong', 'Initials': 'TY', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Gun Min', 'Initials': 'GM', 'LastName': 'Kim', 'Affiliation': 'Division of Medical Oncology and Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Seok Yun', 'Initials': 'SY', 'LastName': 'Kang', 'Affiliation': 'Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, South Korea.'}, {'ForeName': 'In Hae', 'Initials': 'IH', 'LastName': 'Park', 'Affiliation': 'Center for Breast Cancer, National Cancer Center, Goyang, South Korea.'}, {'ForeName': 'Jee Hyun', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.'}, {'ForeName': 'Kyoung Eun', 'Initials': 'KE', 'LastName': 'Lee', 'Affiliation': 'Department of Hematology and Oncology, Ewha Womans University Hospital, Seoul, South Korea.'}, {'ForeName': 'Hee Kyung', 'Initials': 'HK', 'LastName': 'Ahn', 'Affiliation': 'Division of Medical Oncology and Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea.'}, {'ForeName': 'Moon Hee', 'Initials': 'MH', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Inha University School of Medicine, Incheon, South Korea.'}, {'ForeName': 'Hee-Jun', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Han Jo', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Hospital, Cheonan, South Korea.'}, {'ForeName': 'Jong In', 'Initials': 'JI', 'LastName': 'Lee', 'Affiliation': 'Division of Hematology-Oncology, Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, South Korea.'}, {'ForeName': 'Su-Jin', 'Initials': 'SJ', 'LastName': 'Koh', 'Affiliation': 'Department of Hematology and Oncology, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, South Korea.'}, {'ForeName': 'Ji-Yeon', 'Initials': 'JY', 'LastName': 'Kim', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Kyung-Hun', 'Initials': 'KH', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Joohyuk', 'Initials': 'J', 'LastName': 'Sohn', 'Affiliation': 'Division of Medical Oncology and Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Sung-Bae', 'Initials': 'SB', 'LastName': 'Kim', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Jin-Seok', 'Initials': 'JS', 'LastName': 'Ahn', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Young-Hyuck', 'Initials': 'YH', 'LastName': 'Im', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Kyung Hae', 'Initials': 'KH', 'LastName': 'Jung', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Seock-Ah', 'Initials': 'SA', 'LastName': 'Im', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Oncology,['10.1016/S1470-2045(19)30565-0'] 865,31659541,Low-level laser therapy improves pain in postcesarean section: a randomized clinical trial.,"This study aimed to evaluate the effect of low-level laser therapy (LLLT) on immediate postpartum pain relief during cesarean section. A randomized, parallel controlled trial was carried out. In total, 88 women with immediate postpartum were divided into 4 groups: control group (n = 22), placebo group (n = 22), experimental group I (n = 22, dose of 4 J/cm 2 ), and experimental group II (n = 22, dose of 2 J/cm 2 ). The pain measured by Numeric Rating Scale (NRS), algometry, and Global Change Perception Scale (GCPS) was assessed at 12, 20-24, and 44-48 h postpartum. Two LLLT sessions were performed at 12 and 24 h postpartum. A significant interaction was observed between time versus group for NRS F (2.40) = 36.80, p < 0.001 and algometry F (1.70) = 27.18, p < 0.001. GCPS revealed a significant difference between the groups during second (p = 0.04) and third evaluation (p = 0.04). The NRS and algometry presented a large effect size for the experimental groups. LLLT is an efficient method to reduce pain and enhance the GCP in postcesarean section. No significant clinical differences were found between the laser doses.",2020,GCPS revealed a significant difference between the groups during second (p = 0.04) and third evaluation (p = 0.04).,"['immediate postpartum pain relief during cesarean section', '88 women with immediate postpartum', 'postcesarean section']","['LLLT', 'GCPS', 'placebo', 'low-level laser therapy (LLLT', 'Low-level laser therapy']","['pain', 'pain measured by Numeric Rating Scale (NRS), algometry, and Global Change Perception Scale (GCPS']","[{'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0848200', 'cui_str': 'Afterbirth pain'}, {'cui': 'C1301676', 'cui_str': 'Relieves (qualifier value)'}, {'cui': 'C0007876', 'cui_str': 'C-Section (OB)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086839', 'cui_str': 'Postpartum Period'}, {'cui': 'C0032758', 'cui_str': 'Postcesarean Section'}]","[{'cui': 'C4019433', 'cui_str': 'LLLT'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0279027', 'cui_str': 'Low-Power Laser Therapy'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0222045'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]",88.0,0.126879,GCPS revealed a significant difference between the groups during second (p = 0.04) and third evaluation (p = 0.04).,"[{'ForeName': 'Alane Macatrao Pires', 'Initials': 'AMP', 'LastName': 'de Holanda Araujo', 'Affiliation': 'Health Science Center, Federal University of Rio Grande do Norte, Natal, RN, Brazil.'}, {'ForeName': 'Kassio Rafael Rocha', 'Initials': 'KRR', 'LastName': 'de Sena', 'Affiliation': 'Faculdade Estácio, Natal, RN, Brazil.'}, {'ForeName': 'Edson Meneses', 'Initials': 'EM', 'LastName': 'da Silva Filho', 'Affiliation': 'Faculty of Health Science of Trairí, Graduate Program in Rehabilitation Science, Federal University of Rio Grande do Norte, Santa Cruz, RN, Brazil. meneses.edson@yahoo.com.br.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Pegado', 'Affiliation': 'Faculty of Health Science of Trairí, Graduate Program in Rehabilitation Science, Federal University of Rio Grande do Norte, Santa Cruz, RN, Brazil.'}, {'ForeName': 'Maria Thereza Albuquerque Barbosa Cabral', 'Initials': 'MTABC', 'LastName': 'Micussi', 'Affiliation': 'Health Science Center, Federal University of Rio Grande do Norte, Natal, RN, Brazil.'}]",Lasers in medical science,['10.1007/s10103-019-02893-3'] 866,29972120,[Effect of suspension exercise training on motor and balance functions in children with spastic cerebral palsy].,"OBJECTIVE To study the effect of suspension exercise training on motor and balance functions in children with spastic cerebral palsy. METHODS A total of 97 children with spastic cerebral palsy were randomly divided into an observation group with 49 children and a control group with 48 children. Both groups were given routine rehabilitation training, and the children in the observation group were given suspension exercise training in addition. The scores of the D and E domains of the 88-item version of the Gross Motor Function Measure (GMFM-88) and Berg Balance Scale (BBS) were recorded before treatment and at 1, 3, and 6 months after treatment. Surface electromyography was performed to observe the changes in the root mean square (RMS) of surface electromyogram signals of the adductor muscle and the gastrocnemius muscle. RESULTS Over the time of treatment, both groups had varying degrees of improvement in the scores of the D and E domains of GMFM-88 and BBS. Compared with the control group, the observation group had significantly greater improvements in D and E functional areas and balance function (P<0.05). Both groups had reductions in the RMS of the surface electromyogram signals of the adductor muscle and the gastrocnemius muscle over the time of treatment, and the observation group had significantly greater reductions than the control group (P<0.05). CONCLUSIONS Suspension exercise training can effectively improve the motor and balance functions of children with spastic cerebral palsy.",2018,"Both groups had reductions in the RMS of the surface electromyogram signals of the adductor muscle and the gastrocnemius muscle over the time of treatment, and the observation group had significantly greater reductions than the control group (P<0.05). ","['49 children and a control group with 48 children', '97 children with spastic cerebral palsy', 'children with spastic cerebral palsy']","['Suspension exercise training', 'suspension exercise training', 'routine rehabilitation training']","['D and E functional areas and balance function', 'scores of the D and E domains of the 88-item version of the Gross Motor Function Measure (GMFM-88) and Berg Balance Scale (BBS', 'RMS of the surface electromyogram signals of the adductor muscle and the gastrocnemius muscle', 'mean square (RMS) of surface electromyogram signals of the adductor muscle and the gastrocnemius muscle', 'motor and balance functions']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0338596', 'cui_str': 'Spastic cerebral palsy (disorder)'}]","[{'cui': 'C1382107', 'cui_str': 'Suspension'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0677549', 'cui_str': 'Gross motor functions (observable entity)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C0205148', 'cui_str': 'Surface (attribute)'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0224435', 'cui_str': 'Structure of adductor muscle'}, {'cui': 'C0242691', 'cui_str': 'Gastrocnemius Muscle'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205120', 'cui_str': 'Square (qualifier value)'}]",97.0,0.0159533,"Both groups had reductions in the RMS of the surface electromyogram signals of the adductor muscle and the gastrocnemius muscle over the time of treatment, and the observation group had significantly greater reductions than the control group (P<0.05). ","[{'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Pediatric Rehabilitation, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. wj3028@163.com.'}, {'ForeName': 'Yong-Bin', 'Initials': 'YB', 'LastName': 'Lang', 'Affiliation': ''}, {'ForeName': 'Jiang-Hua', 'Initials': 'JH', 'LastName': 'DU', 'Affiliation': ''}, {'ForeName': 'Zhen', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Deng-Na', 'Initials': 'DN', 'LastName': 'Zhu', 'Affiliation': ''}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Meng-Yue', 'Initials': 'MY', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Pei', 'Initials': 'P', 'LastName': 'Tong', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 867,30536161,"Prospective, randomized, controlled, open-label study to compare efficacy of a mineral-rich solution vs normal saline after complete ethmoidectomy.","PURPOSES The purpose of this study was to compare the efficacy of a mineral-rich solution vs normal saline solution (0.9% NaCl) following endoscopic complete bilateral ethmoidectomy. METHODS This was a prospective, multicenter, randomized, controlled, open-label trial in subjects suffering from steroid-resistant sinonasal polyposis. Adults performed 4 nasal irrigations of mineral or saline solutions daily for 28 days. Evaluations included subject-reported RHINO quality of life (QoL) and NOSE scores, tolerability, and satisfaction, the Lund-Kennedy endoscopic score and assessments of crusting, secretions and mucociliary clearance (rhinoscintigraphy). RESULTS A total of 189 subjects were randomized. Clinically relevant improvements (> 20 points) in RhinoQOL and NOSE scores were measured in both groups without any significant inter-group difference. Among the subjects with impaired RhinoQOL at pre-inclusion, the change in Impact-RhinoQOL score was significantly superior in mineral-rich vs saline solution at day 21 (p = 0.028) and day 28 (p = 0.027). The Lund-Kennedy score continuously improved in both groups earlier with the mineral-rich solution. Crusts were significantly fewer in number and less severe/obstructive in patients receiving mineral-rich vs saline solution at day 7 (p = 0.026) and day 14 (p = 0.016). Furthermore, secretions disappeared significantly more quickly and were less thick/purulent with mineral-rich solution at day 14 (p = 0.002) and day 21 (p = 0.043). Less epistaxis was reported in the mineral vs saline solution (p = 0.008 at day 21). CONCLUSIONS Our findings indicate that the composition of a nasal irrigation solution influences endoscopic scores and QoL after sinus surgery for patients over 60, those with an initially poor QoL and higher symptom score, and smokers.",2019,Clinically relevant improvements (> 20 points) in RhinoQOL and NOSE scores were measured in both groups without any significant inter-group difference.,"['subjects suffering from steroid-resistant sinonasal polyposis', 'A total of 189 subjects were randomized']","['mineral-rich solution vs normal saline', 'nasal irrigations of mineral or saline solutions', 'mineral-rich solution vs normal saline solution (0.9% NaCl']","['Less epistaxis', 'RhinoQOL and NOSE scores', 'RHINO quality of life (QoL) and NOSE scores, tolerability, and satisfaction, the Lund-Kennedy endoscopic score and assessments of crusting, secretions and mucociliary clearance (rhinoscintigraphy', 'severe/obstructive', 'Impact-RhinoQOL score']","[{'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0334108', 'cui_str': 'Multiple polyps (morphologic abnormality)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]","[{'cui': 'C0026162', 'cui_str': 'Minerals'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C2350442', 'cui_str': 'Nasal Irrigation'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}]","[{'cui': 'C0014591', 'cui_str': 'Nosebleed'}, {'cui': 'C0028429', 'cui_str': 'Nose'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0036537', 'cui_str': 'Secretions'}, {'cui': 'C0026687', 'cui_str': 'Mucociliary Transport'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}]",189.0,0.184724,Clinically relevant improvements (> 20 points) in RhinoQOL and NOSE scores were measured in both groups without any significant inter-group difference.,"[{'ForeName': 'Ludovic', 'Initials': 'L', 'LastName': 'de Gabory', 'Affiliation': 'ENT Department, CHU Bordeaux, 33000, Bordeaux, France. ludovic.de-gabory@chu-bordeaux.fr.'}, {'ForeName': 'Virginie', 'Initials': 'V', 'LastName': 'Escabasse', 'Affiliation': 'ENT Department, Intercommunal Hospital of Créteil, Paris, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Boudard', 'Affiliation': 'ENT Department, Saint-Augustin Private Hospital, Bordeaux, France.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'de Bonnecaze', 'Affiliation': 'ENT Department, University Hospital of Toulouse, Toulouse, France.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Rumeau', 'Affiliation': 'ENT Department, University Hospital of Nancy, Nancy, France.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Jankowski', 'Affiliation': 'ENT Department, University Hospital of Nancy, Nancy, France.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Debry', 'Affiliation': 'ENT Department, University Hospital of Strasbourg, Strasbourg, France.'}, {'ForeName': 'Sylvain', 'Initials': 'S', 'LastName': 'Morinière', 'Affiliation': 'ENT Department, University Hospital of Tours, Tours, France.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Merino', 'Affiliation': 'Nuclear Medicine Department, Saint-Augustin Private Hospital, Bordeaux, France.'}, {'ForeName': 'Geoffrey', 'Initials': 'G', 'LastName': 'Mortuaire', 'Affiliation': 'ENT Department, University Hospital of Lille, Lille, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Malard', 'Affiliation': 'ENT Department, University Hospital of Nantes, Nantes, France.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Bordenave', 'Affiliation': 'CHU Bordeaux, CIC 14-01 IT, 33000, Bordeaux, France.'}]",European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,['10.1007/s00405-018-5232-9'] 868,30365408,Topical Ketoprofen Versus Placebo in Children Presenting With Ankle Sprain to the Emergency Department: A Randomized Controlled Study.,"OBJECTIVE Despite the favorable data concerning topical agents use in outpatient clinics, they are not commonly in emergency departments (EDs). The present study aimed to compare the effect of 2.5% topical ketoprofen (gel form) to placebo in children presenting with ankle sprain to the ED. STUDY DESIGN Children between 7 and 18 years old presenting with ankle sprain composed the study population. Study patients were randomized into 2 study arms: 2.5% ketoprofen gel and placebo administered in a 5-cm area locally. Pain improvements at 15 and 30 minutes were measured by visual analog scale. RESULTS Median pain reductions at 15 minutes for ketoprofen and placebo groups were 27.5 (16-39) and 5 (4-10), respectively. Median changes in pain intensity at 30 minutes for ketoprofen and placebo gel groups were 48 (43-52) and 9 (6-16), respectively. When compared 2 arms for the pain improvement at 15 and 30 minutes, the differences between 2 study drugs were 20 (13-28) and 35 (29-41), respectively. There were 7 (12.7%) rescue drug needs in the placebo group and 1 (1.7%) in the ketoprofen group (difference, 10.9%; 95% confidence interval, -6% to 7%; P = 0.83). There were no adverse effects in either group. CONCLUSIONS Ketoprofen gel is superior to placebo in ceasing pain in children presenting with ankle sprain to the ED with a high safety profile.",2020,"Median changes in pain intensity at 30 minutes for ketoprofen and placebo gel groups were 48 (43-52) and 9 (6-16), respectively.","['children presenting with ankle sprain to the ED.\nSTUDY DESIGN\n\n\nChildren between 7 and 18 years old presenting with ankle sprain composed the study population', 'Children Presenting With Ankle Sprain to the Emergency Department', 'children presenting with ankle sprain']","['ketoprofen', 'ketoprofen gel and placebo', 'placebo', 'topical ketoprofen (gel form) to placebo', 'Topical Ketoprofen Versus Placebo', 'placebo gel', 'Ketoprofen gel']","['pain improvement', 'visual analog scale', 'rescue drug needs', 'Median changes in pain intensity', 'Pain improvements', 'adverse effects', 'Median pain reductions']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0160087', 'cui_str': 'Ankle Sprains'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}]","[{'cui': 'C0022635', 'cui_str': 'Ketoprofen'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]",,0.396891,"Median changes in pain intensity at 30 minutes for ketoprofen and placebo gel groups were 48 (43-52) and 9 (6-16), respectively.","[{'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Serinken', 'Affiliation': 'From the Department of Emergency Medicine, Pamukkale University Medical Faculty, Denizli.'}, {'ForeName': 'Cenker', 'Initials': 'C', 'LastName': 'Eken', 'Affiliation': 'Department of Emergency Medicine, Akdeniz University Medical Faculty, Antalya.'}, {'ForeName': 'Kamil', 'Initials': 'K', 'LastName': 'Tünay', 'Affiliation': 'Department of Emergency Medicine, Kocatepe University Medical Faculty, Afyonkarahisar.'}, {'ForeName': 'Yalcin', 'Initials': 'Y', 'LastName': 'Gölcük', 'Affiliation': 'Department of Emergency Medicine, Manisa Celal Bayar University Medical Faculty, Manisa, Turkey.'}]",Pediatric emergency care,['10.1097/PEC.0000000000001595'] 869,30328708,Mechanical Noise Improves the Vibration Perception Threshold of the Foot in People With Diabetic Neuropathy.,"BACKGROUND Mechanical noise may improve somatosensation at the dorsal side of the foot, but the effect at the plantar side of the foot, the side most at risk for foot ulceration, is unknown. Moreover, techniques used in research so far have several problems that limit applicability in daily practice. Piezoelectric actuators may provide mechanical noise with better clinical applicability. We assessed the effects of piezoelectric actuators generating mechanical noise on the vibration perception threshold (VPT) at the plantar side of the foot in people with diabetic neuropathy. METHODS Double-blind within-subjects design in a controlled laboratory setting including participants with diabetic neuropathy (N = 40; 18 male; mean age 69.6 years; mean duration of diabetes 14.1 years; mean BMI 30.5). VPT was measured at three plantar foot locations with and without mechanical noise applied via piezoelectric actuators. RESULTS Mechanical noise improved VPT at metatarsophalangeal joint (MTP) 1 (left 39.3V vs 43.5V; right 39.0 vs 42.6 V), MTP5 (left 37.5V vs 41.7V; right 34.5V vs 40.8V) and the heel (left 40.0V vs 44.0V; right 39.3V vs 41.0V), all P < .001. CONCLUSIONS Mechanical noise improves VPT at the plantar side of the foot in people with diabetic neuropathy. This is an important step for further development of insoles using mechanical noise that may have the potential to improve VPT and decrease the risk of foot ulceration.",2020,"We assessed the effects of piezoelectric actuators generating mechanical noise on the vibration perception threshold (VPT) at the plantar side of the foot in people with diabetic neuropathy. ","['people with diabetic neuropathy', 'participants with diabetic neuropathy (N = 40; 18 male; mean age 69.6\u2009years; mean duration of diabetes 14.1\u2009years', 'People With Diabetic Neuropathy']","['piezoelectric actuators generating mechanical noise', 'Mechanical Noise', 'Mechanical noise']","['VPT', 'MTP5']","[{'cui': 'C0011882', 'cui_str': 'Diabetic Neuropathies'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}]","[{'cui': 'C1706706', 'cui_str': 'Actuator (physical object)'}, {'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}, {'cui': 'C0028263', 'cui_str': 'Noise'}]",[],40.0,0.0701352,"We assessed the effects of piezoelectric actuators generating mechanical noise on the vibration perception threshold (VPT) at the plantar side of the foot in people with diabetic neuropathy. ","[{'ForeName': 'Jennefer B J', 'Initials': 'JBJ', 'LastName': 'Zwaferink', 'Affiliation': 'Ziekenhuisgroep Twente, Almelo and Hengelo, The Netherlands.'}, {'ForeName': 'Juha M', 'Initials': 'JM', 'LastName': 'Hijmans', 'Affiliation': 'Department of Rehabilitation Medicine, University of Groningen, University Medical Center Groningen, The Netherlands.'}, {'ForeName': 'Claudia M', 'Initials': 'CM', 'LastName': 'Schrijver', 'Affiliation': 'Ziekenhuisgroep Twente, Almelo and Hengelo, The Netherlands.'}, {'ForeName': 'Laura K', 'Initials': 'LK', 'LastName': 'Schrijver', 'Affiliation': 'Ziekenhuisgroep Twente, Almelo and Hengelo, The Netherlands.'}, {'ForeName': 'Klaas', 'Initials': 'K', 'LastName': 'Postema', 'Affiliation': 'Department of Rehabilitation Medicine, University of Groningen, University Medical Center Groningen, The Netherlands.'}, {'ForeName': 'Jaap J', 'Initials': 'JJ', 'LastName': 'van Netten', 'Affiliation': 'Ziekenhuisgroep Twente, Almelo and Hengelo, The Netherlands.'}]",Journal of diabetes science and technology,['10.1177/1932296818804552'] 870,31931026,Seven-year-efficacy of proximal caries infiltration - Randomized clinical trial.,"OBJECTIVES We report efficacy of resin infiltration to arrest progression of caries lesions as compared with non-invasive measures and oral hygiene education alone after a mean observation time of seven years. MATERIALS AND METHODS This randomized split-mouth placebo-controlled clinical trial included 22 young adults having 29 pairs of interproximal non-cavitated caries lesions with radiographic extensions into inner half of enamel (E2) or outer third of dentin (D1). Lesion pairs were randomly allocated to two treatment groups: infiltration (Icon, pre-product; DMG) or mock (control) treatment. All subjects received risk-related instructions for diet, flossing and fluoridation. The primary outcome was radiographic (digital subtraction radiography) lesion progression after seven years. Secondly, Kaplan-Meier-analyses were applied to analyze time-to-failure additionally including patients followed up for less than 54 months as well. RESULTS Two lesion pairs were excluded due to invasive treatment decision by another dentist, five lesion pairs were lost to follow-up prior to 54 months but included in the survival analysis. No unwanted effects could be observed. For the primary outcome in 17 patients followed up in mean for 84 months 2/22 infiltrated lesions (9 %) compared with 10/22 control lesions (45 %) progressed (p = 0.018). The relative risk reduction for test in relation to control was 80 % (CI 95 % = 19-95 %). For the survival analysis within a mean (SD) observation time of 73 (25) months mean failure rates of 1.3 % and 7.8 % could be observed for test and controls, respectively. Hazard risk (95 % CI) for caries progression was 6.6 (2-22) for the control compared with the test lesions (p = 0.002). CONCLUSIONS We conclude that resin infiltration of proximal caries lesions extending radiographically around the enamel dentin junction is efficacious to reduce lesion progression after a mean observation time of seven years. CLINICAL SIGNIFICANCE This randomized clinical trial proves that caries infiltration is highly efficacious compared with non-invasive measures and oral hygiene education alone after a considerably longer observation time of 7 years than studied so far before.",2020,The relative risk reduction for test in relation to control was 80% (CI 95% = 19-95%).,"['22 young adults having 29 pairs of interproximal non-cavitated caries lesions with radiographic extensions into inner half of enamel (E2) or outer third of dentin (D1', 'Lesion pairs']","['placebo', 'resin infiltration', 'infiltration (Icon, pre-product; DMG) or mock (control) treatment']","['radiographic (digital subtraction radiography) lesion progression', 'Hazard risk', 'caries progression', 'relative risk reduction', 'failure rates']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C4039194', 'cui_str': 'Non-cavitated caries (morphologic abnormality)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C4041253', 'cui_str': 'Inner half of enamel'}, {'cui': 'C4038556', 'cui_str': 'Outer third of dentin (body structure)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3669041', 'cui_str': 'Spread by direct extension (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0562577', 'cui_str': 'Mocking (finding)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray (qualifier value)'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}]",22.0,0.208919,The relative risk reduction for test in relation to control was 80% (CI 95% = 19-95%).,"[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Paris', 'Affiliation': 'Department of Operative Dentistry and Preventive Dentistry, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Bitter', 'Affiliation': 'Department of Operative Dentistry and Preventive Dentistry, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Krois', 'Affiliation': 'Department of Operative Dentistry and Preventive Dentistry, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Meyer-Lueckel', 'Affiliation': 'Department of Restorative, Preventive & Pediatric Dentistry, University of Bern, Bern, Switzerland. Electronic address: hendrik.meyer-lueckel@zmk.unibe.ch.'}]",Journal of dentistry,['10.1016/j.jdent.2020.103277'] 871,31863582,Pilot Randomized Controlled Trial of a Digital Storytelling Intervention for Smoking Cessation in Women Living With HIV.,"BACKGROUND People living with HIV in the USA smoke at a rate nearly three times that of the general population, and Black women are disproportionately affected by HIV infection. PURPOSE This study was conducted to test the preliminary efficacy of a digital storytelling intervention for smoking cessation in U.S. women living with HIV. METHODS Participants in the treatment arm viewed a film in which women living with HIV talk about quitting smoking, and those in the control arm viewed an attention-control film in which women talk about living with HIV infection. Participants in both arms received eight weekly video-call counseling sessions focused on smoking cessation and nicotine patches or gum during the same period. Participants were followed on a monthly basis from quit day for 3 months. RESULTS Of the 53 participants randomized, four withdrew before receiving any intervention, one dropped out during the intervention, and 48 (90.6%) completed the study. No difference was found in the baseline characteristics between the two arms with the exception that the treatment arm had higher nicotine dependence scores [t(1.51) = 2.30, p = .03] than the control arm. Seven day point-prevalence abstinence rates at 3 month follow-up were not found to differ between the two arms. However, the odds of achieving 3 month prolonged abstinence were four times greater (odds ratio = 4.23, 95% confidence interval = 1.10, 16.23) in the treatment arm than the control arm when the analysis was performed with those (n = 49, 92.5%) who received any part of the allotted intervention. CONCLUSIONS A digital storytelling intervention seems to be a valuable strategy to enhance the effect of conventional tobacco dependence treatment for women living with HIV. However, the underlying mechanism of the effect of digital storytelling necessitates further investigations in a large RCT.Clinical Trials Registration No. NCT03289676.",2020,No difference was found in the baseline characteristics between the two arms with the exception that the treatment arm had higher nicotine dependence scores [t(1.51) =,"['Participants in the treatment arm viewed a film in which women living with HIV talk about quitting smoking, and those in the', '53 participants randomized', 'U.S. women living with HIV', 'Women Living With HIV', 'women living with HIV']","['video-call counseling sessions focused on smoking cessation and nicotine patches or gum', 'control arm viewed an attention-control film', 'digital storytelling intervention', 'Digital Storytelling Intervention']","['odds of achieving 3 month prolonged abstinence', 'prevalence abstinence rates']","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0449911', 'cui_str': 'View (attribute)'}, {'cui': 'C4319646', 'cui_str': 'Film'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}]","[{'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}, {'cui': 'C0358855', 'cui_str': 'Nicotine Transdermal Patch'}, {'cui': 'C1378701', 'cui_str': 'Gum (basic dose form)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0449911', 'cui_str': 'View (attribute)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C4319646', 'cui_str': 'Film'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray (qualifier value)'}]","[{'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}]",53.0,0.102643,No difference was found in the baseline characteristics between the two arms with the exception that the treatment arm had higher nicotine dependence scores [t(1.51) =,"[{'ForeName': 'Sun S', 'Initials': 'SS', 'LastName': 'Kim', 'Affiliation': 'Department of Nursing, College of Nursing and Health Sciences, University of Massachusetts Boston, Boston, MA, USA.'}, {'ForeName': 'Sang A', 'Initials': 'SA', 'LastName': 'Lee', 'Affiliation': 'Department of Nursing, College of Nursing and Health Sciences, University of Massachusetts Boston, Boston, MA, USA.'}, {'ForeName': 'Jeannette', 'Initials': 'J', 'LastName': 'Mejia', 'Affiliation': 'Department of Psychology, College of Liberal Arts and Sciences, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Cooley', 'Affiliation': 'Phyllis F. Cantor Center, Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, Boston, MA, USA.'}, {'ForeName': 'Rosanna F', 'Initials': 'RF', 'LastName': 'Demarco', 'Affiliation': 'Department of Nursing, College of Nursing and Health Sciences, University of Massachusetts Boston, Boston, MA, USA.'}]",Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,['10.1093/abm/kaz062'] 872,30253712,Automated blood pressure self-measurement station compared to office blood pressure measurement for first trimester screening of pre-eclampsia.,"BACKGROUND Preeclampsia is a serious medical disorder affecting pregnancy. Screening in early pregnancy can identify women at risk and enable effective prophylactic treatment. Accurate blood pressure (BP) measurement is an important element of the screening algorithm. Automated self-screening, while attending the first trimester ultra sound scan, using a BP self-measurement (BPSM) station, could be a low-cost alternative to office BP measurements (OBPM) on both arms performed by clinical staff, if the measurement quality can be ensured. OBJECTIVES The aim of this study was to compare automated BPSM using a self-measurement station on one arm, with OBPM performed by clinical staff on both arms. Primary outcome was the difference in mean arterial pressure (MAP) between the two methods and secondary outcomes were safety and practicality issues. METHODS Pregnant women attending ultrasound-examination at 12 weeks gestational age were recruited and randomized to start with having two OBPMs taken on both arms by staff, using two standard validated automatic upper arm BP devices, or self-measuring using an automated BPSM station following a crossover study design. The BPSM station consists of a validated blood pressure device, and an add-on sensor system capable of registering blood pressure values, rest-time, back-supported, legs-crossed, and ambient noise-levels respectively, and providing interactive guidance during the measurement process, for supporting the self-measurement process. RESULTS A total of 80 complete BP measurement sets were obtained, for a total of 240 BPSM measurements and 320 OBPM measurements. We found no significant difference between the OBPM and BPSM methods (p=0.86) for mean arterial pressure (MAP). However, erroneous measurements were observed frequently during the experiment, mainly during the first of the 3 BPSM measurements (6%), secondary during the second BPSM measurement (3%). Only one data set (1%) was excluded due to OBPM errors. CONCLUSION No significant difference in MAP between the two methods was found. Means for detecting and repeating erroneous BP measurements should be implemented. Measurement errors was found in 9 % of the measurement sets which is not acceptable for clinical use. Thus, several measures have been identified in order to properly identify and recover from such measurement errors in the future.",2019,We found no significant difference between the OBPM and BPSM methods (p=0.86) for mean arterial pressure (MAP).,['Pregnant women attending ultrasound-examination at 12 weeks gestational age'],"['standard validated automatic upper arm BP devices, or self-measuring using an automated BPSM station']","['Accurate blood pressure (BP) measurement', 'MAP', 'Measurement errors', 'mean arterial pressure (MAP', 'safety and practicality issues']","[{'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0948501', 'cui_str': 'Ultrasound examination'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C0446516', 'cui_str': 'Brachiums'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]","[{'cui': 'C0443131', 'cui_str': 'Accurate (qualifier value)'}, {'cui': 'C0005824', 'cui_str': 'Blood pressure taking (procedure)'}, {'cui': 'C0024779', 'cui_str': 'Map'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0726683,We found no significant difference between the OBPM and BPSM methods (p=0.86) for mean arterial pressure (MAP).,"[{'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Holm', 'Affiliation': ''}, {'ForeName': 'Tone', 'Initials': 'T', 'LastName': 'Stucke-Brander', 'Affiliation': ''}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Wagner', 'Affiliation': 'Aarhus University, Denmark.'}, {'ForeName': 'Puk', 'Initials': 'P', 'LastName': 'Sandager', 'Affiliation': ''}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Schlütter', 'Affiliation': ''}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Lindahl', 'Affiliation': ''}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Uldbjerg', 'Affiliation': 'Aarhus University Hospital, Denmark.'}]",Health informatics journal,['10.1177/1460458218799505'] 873,30274880,Adaptation of Proximal Femur to Mechanical Loading in Young Adults: Standard Vs Localized Regions Evaluated by DXA.,"Regions of the proximal femur with less adaptive protection by mechanical loading may be at increased risk of structural failure. Since the size and location of these regions diverge from those defined by the dual-energy X-ray absorptiometry manufacturers the purpose of this study was to compare areal bone mineral density (aBMD) of different regions of the proximal femur considering impact loads from physical activity (PA). The participants were 134 young adults divided into 2 groups according to the impact of PA performed in the last 12 mo: high-impact PA and low-impact PA. The aBMD of the proximal femur was assessed by dual-energy X-ray absorptiometry at the standard femoral neck, intertrochanter, and trochanter, and at specific locations of the superolateral femoral neck and intertrochanteric region. The bone-specific physical activity questionnaire was used to estimate the impact load of PA. Comparisons between groups were adjusted for body height and body lean mass. Interaction analysis between sex and PA groups were conducted with analysis of variance. Comparisons of aBMD between bone regions were analyzed separately for men and women with repeated measures analysis of variance. In the high-impact PA group, men benefit more than women at all bone regions, except the aBMD at intertrochanteric region. Analyses of repeated measures did not reveal any significant interaction effect between bone regions (standard vs specific) and PA groups (low vs high-impact). In conclusion, aBMD differences due to mechanical loading were more pronounced in men than in women; the magnitude of the aBMD differences as a result of different levels of PA was similar between standard and localized regions.",2020,"In the high-impact PA group, men benefit more than women at all bone regions, except the aBMD at intertrochanteric region.","['participants were 134 young adults', 'Young Adults']",[],"['bone-specific physical activity questionnaire', 'areal bone mineral density (aBMD', 'aBMD differences due to mechanical loading']","[{'cui': 'C4517565', 'cui_str': 'One hundred and thirty-four'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]",[],"[{'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}]",134.0,0.0301522,"In the high-impact PA group, men benefit more than women at all bone regions, except the aBMD at intertrochanteric region.","[{'ForeName': 'Fátima', 'Initials': 'F', 'LastName': 'Baptista', 'Affiliation': 'Exercise and Health Laboratory, CIPER, Faculdade de Motricidade Humana, Universidade de Lisboa, Lisboa, Portugal. Electronic address: fbaptista@fmh.ulisboa.pt.'}, {'ForeName': 'Edgar', 'Initials': 'E', 'LastName': 'Lopes', 'Affiliation': 'Exercise and Health Laboratory, CIPER, Faculdade de Motricidade Humana, Universidade de Lisboa, Lisboa, Portugal.'}, {'ForeName': 'Ángel', 'Initials': 'Á', 'LastName': 'Matute-Llorente', 'Affiliation': 'GENUD (Growth, Exercise, Nutrition and Development) Research Group, Department of Physiatry and Nursing, Faculty of Health and Sports Sciences, Universidad de Zaragoza, Zaragoza, Spain.'}, {'ForeName': 'Júlia', 'Initials': 'J', 'LastName': 'Teles', 'Affiliation': 'Mathematics Unit, CIPER, Faculdade de Motricidade Humana, Universidade de Lisboa, Lisboa, Portugal.'}, {'ForeName': 'Vera', 'Initials': 'V', 'LastName': 'Zymbal', 'Affiliation': 'Exercise and Health Laboratory, CIPER, Faculdade de Motricidade Humana, Universidade de Lisboa, Lisboa, Portugal.'}]",Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry,['10.1016/j.jocd.2018.07.012'] 874,30297988,"The Immediate Effect of Therapeutic Touch and Deep Touch Pressure on Range of Motion, Interoceptive Accuracy and Heart Rate Variability: A Randomized Controlled Trial With Moderation Analysis.","Background: There is paucity in the literature regarding the role of the interoceptive pathway through the insular cortex (IC), as well as heart rate variability (HRV) in relation to Osteopathic Manipulative Therapy (OMT) and deep-touch. Aims: The present study investigated whether both OMT treatment and deep-touch (a newly hypothesized treatment option) was effective at altering the interoceptive pathway and HRV, whilst OMT was only expected to be effective for increasing Range of Motion (ROM). Methods: Thirty-five healthy volunteers were randomly allocated into three conditions in a repeated measures crossover design; a control (laying supine on a plinth); deep-touch (head cradling); and an osteopathic mobilization therapeutic technique on the temporomandibular joint (TMJ). Interoceptive accuracy (IAc), HRV, as well as range of motion (ROM) for the TMJ area as well as the cervical spine (Csp) right and left measures were taken pre and post each condition setting. Results: Significant condition effects emerged from the deep-touch and mobilization interventions for IAc where increases were identified through planned comparisons. For the HRV measure (RMSSD), a significant effect emerged in the deep-touch condition (increase) but not in the mobilization or control conditions. ROM did not increase for any condition. IAc correlated with post-ROM outcomes in many cases and HRV moderated some of these relations. Conclusion: These results are discussed in the context of clinical practice, where cranial deep-touch maybe an effective treatment and modulator of the parasympathetic nervous systems, as well as the interoceptive system.",2018,"Interoceptive accuracy (IAc), HRV, as well as range of motion (ROM) for the TMJ area as well as the cervical spine (Csp",['Methods: Thirty-five healthy volunteers'],"['OMT', 'Therapeutic Touch and Deep Touch Pressure', 'control (laying supine on a plinth); deep-touch (head cradling); and an osteopathic mobilization therapeutic technique on the temporomandibular joint (TMJ']","['cervical spine (Csp', 'deep-touch and mobilization interventions for IAc', 'ROM', 'Interoceptive accuracy (IAc), HRV, as well as range of motion (ROM', 'Range of Motion, Interoceptive Accuracy and Heart Rate Variability']","[{'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C4319605', 'cui_str': 'Thirty-five'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0152054', 'cui_str': 'Therapeutic Touch'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0300926', 'cui_str': 'mobilization'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0039493', 'cui_str': 'TMJ'}]","[{'cui': 'C0728985', 'cui_str': 'Cervical spine'}, {'cui': 'C1145610', 'cui_str': 'Cellulose sodium phosphate'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0152054', 'cui_str': 'Therapeutic Touch'}, {'cui': 'C0300926', 'cui_str': 'mobilization'}, {'cui': 'C0080078', 'cui_str': 'Range of Motion'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}]",35.0,0.0270611,"Interoceptive accuracy (IAc), HRV, as well as range of motion (ROM) for the TMJ area as well as the cervical spine (Csp","[{'ForeName': 'Darren J', 'Initials': 'DJ', 'LastName': 'Edwards', 'Affiliation': 'Department of Interprofessional Health Studies, Swansea University, Swansea, United Kingdom.'}, {'ForeName': 'Hayley', 'Initials': 'H', 'LastName': 'Young', 'Affiliation': 'Department of Psychology, Swansea University, Swansea, United Kingdom.'}, {'ForeName': 'Annabel', 'Initials': 'A', 'LastName': 'Cutis', 'Affiliation': 'Department of Interprofessional Health Studies, Swansea University, Swansea, United Kingdom.'}, {'ForeName': 'Ross', 'Initials': 'R', 'LastName': 'Johnston', 'Affiliation': 'Department of Interprofessional Health Studies, Swansea University, Swansea, United Kingdom.'}]",Frontiers in integrative neuroscience,['10.3389/fnint.2018.00041'] 875,30290037,Testing the role of the posterior cingulate cortex in processing salient stimuli in cannabis users: an rTMS study.,"The posterior cingulate cortex (PCC) and precuneus are hubs in the default mode network and play a role in processing external salient stimuli. Accordingly, activation in these regions has been associated with response to salient stimuli using drug cue-reactivity paradigms in substance using populations. These studies suggest that the PCC and precuneus may underlie deficits in processing salient stimuli that contribute toward the development of substance use disorders. The goal of this study was to directly test this hypothesis using repetitive transcranial magnetic stimulation (rTMS). Using a double-blind, placebo-controlled design, we used rTMS to target the PCC and precuneus with a double-cone coil at 10 Hz (high frequency) and 1 Hz (low frequency) in 10 adult cannabis users and 10 age- and sex-matched non-using controls. Electroencephalography data were collected before and after rTMS during a modified oddball paradigm with neutral, oddball, self-relevant, and cannabis-related stimuli. Cannabis users exhibited increased amplitude in P3 and faster latencies in the P3, N2, and P2 components in response to self-relevant stimuli compared to controls during baseline that normalized after rTMS. These results suggest that cannabis users exhibited heightened salience to external self-relevant stimuli that were modulated after rTMS. PCC dysfunction in cannabis users may be related to abnormalities in processing salient stimuli, such those during cue-reactivity, and provides a potential target for cannabis use disorder intervention.",2019,"Cannabis users exhibited increased amplitude in P3 and faster latencies in the P3, N2, and P2 components in response to self-relevant stimuli compared to controls during baseline that normalized after rTMS.","['cannabis users', '10 adult cannabis users and 10 age- and sex-matched non-using controls']","['repetitive transcranial magnetic stimulation (rTMS', 'placebo', 'PCC and precuneus with a double-cone coil at 10\xa0Hz (high frequency) and 1\xa0Hz (low frequency']","['heightened salience to external self-relevant stimuli', 'Electroencephalography data', 'amplitude in P3 and faster latencies']","[{'cui': 'C0678449', 'cui_str': 'Cannabis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0044609', 'cui_str': '1-piperidinocyclohexanecarbonitrile'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0393983', 'cui_str': 'Cerebellar Herniation'}, {'cui': 'C0419518', 'cui_str': 'Contraceptive coil (physical object)'}, {'cui': 'C0591126', 'cui_str': 'AT 10'}, {'cui': 'C0205212', 'cui_str': 'High frequency (qualifier value)'}, {'cui': 'C0205213', 'cui_str': 'Low frequency (qualifier value)'}]","[{'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0234402', 'cui_str': 'Stimulus, function (observable entity)'}, {'cui': 'C0013819', 'cui_str': 'EEG'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}]",10.0,0.0708665,"Cannabis users exhibited increased amplitude in P3 and faster latencies in the P3, N2, and P2 components in response to self-relevant stimuli compared to controls during baseline that normalized after rTMS.","[{'ForeName': 'Shikha', 'Initials': 'S', 'LastName': 'Prashad', 'Affiliation': 'Center for BrainHealth, School of Behavioral and Brain Sciences, University of Texas at Dallas, 2200 West Mockingbird Lane, Dallas, TX, 75235, USA.'}, {'ForeName': 'Elizabeth S', 'Initials': 'ES', 'LastName': 'Dedrick', 'Affiliation': 'Center for BrainHealth, School of Behavioral and Brain Sciences, University of Texas at Dallas, 2200 West Mockingbird Lane, Dallas, TX, 75235, USA.'}, {'ForeName': 'Wing Ting', 'Initials': 'WT', 'LastName': 'To', 'Affiliation': 'Center for BrainHealth, School of Behavioral and Brain Sciences, University of Texas at Dallas, 2200 West Mockingbird Lane, Dallas, TX, 75235, USA.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Vanneste', 'Affiliation': 'Center for BrainHealth, School of Behavioral and Brain Sciences, University of Texas at Dallas, 2200 West Mockingbird Lane, Dallas, TX, 75235, USA.'}, {'ForeName': 'Francesca M', 'Initials': 'FM', 'LastName': 'Filbey', 'Affiliation': 'Center for BrainHealth, School of Behavioral and Brain Sciences, University of Texas at Dallas, 2200 West Mockingbird Lane, Dallas, TX, 75235, USA.'}]",The European journal of neuroscience,['10.1111/ejn.14194'] 876,31654345,Laparoscopic One-Anastomosis Gastric Bypass with Band-Separated Gastric Pouch (OAGB-BSGP): a Randomized Controlled Trial.,"BACKGROUND One-anastomosis gastric bypass with band-separated gastric pouch (OAGB-BSGP) is a novel ""staplerless"" version of OAGB. This randomized controlled trial (RCT) compared 2-year outcomes for OAGB-BSGP and standard OAGB. METHODS The parallel-group RCT randomly allocated patients to group A, staplerless OAGB-BSGP, or group B, stapled OAGB. RESULTS Respective mean values for groups A and B (n = 40 each): baseline body mass index (BMI, kg/m 2 ), 40.6 ± 5.6 vs 41.2 ± 6.4 (p = 0.64); abdominal bleeding (mL), 5.9 ± 8.0 vs 31.1 ± 30.5 (p < 0.0001). Two-year outcomes: BMI, 26.3 ± 3.2 vs 29.0 ± 4.7; %TWL, 34.1 ± 9.0 vs 29.3 ± 10.6, p < 0.03; %EBMIL, 94.3 ± 23.6 vs 77.9 ± 29.3, p < 0.007; bile reflux, n = 1 (2.5%) vs n = 7 (17.5%) (p = 0.05); revisions, n = 0 vs n = 4 (10.0%), p = 0.12. CONCLUSIONS At 2-year RCT follow-up, staplerless OAGB-BSGP patients had fewer complications, no revisions, and greater weight loss than stapled OAGB patients. TRIAL REGISTRATION ISRCTN56106651 (OSPAN-RCT).",2019,"At 2-year RCT follow-up, staplerless OAGB-BSGP patients had fewer complications, no revisions, and greater weight loss than stapled OAGB patients. ",[],"['staplerless OAGB-BSGP, or group B, stapled OAGB', 'Laparoscopic One-Anastomosis Gastric Bypass with Band-Separated Gastric Pouch (OAGB-BSGP', 'anastomosis gastric bypass with band-separated gastric pouch (OAGB-BSGP', 'OAGB-BSGP and standard OAGB']","['weight loss', 'abdominal bleeding']",[],"[{'cui': 'C0441836', 'cui_str': 'Group B (qualifier value)'}, {'cui': 'C1293124', 'cui_str': 'Stapling procedure'}, {'cui': 'C0332853', 'cui_str': 'Anastomosis (morphologic abnormality)'}, {'cui': 'C0017125', 'cui_str': 'Gastric Bypass'}, {'cui': 'C0185014', 'cui_str': 'Banding'}, {'cui': 'C0443299', 'cui_str': 'Separate (qualifier value)'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C4319584', 'cui_str': 'Pouch (unit of presentation)'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}]",,0.255256,"At 2-year RCT follow-up, staplerless OAGB-BSGP patients had fewer complications, no revisions, and greater weight loss than stapled OAGB patients. ","[{'ForeName': 'Oral', 'Initials': 'O', 'LastName': 'Ospanov', 'Affiliation': 'University Medical Center, Nur-Sultan, Kazakhstan. bariatric.kz@gmail.com.'}, {'ForeName': 'J N', 'Initials': 'JN', 'LastName': 'Buchwald', 'Affiliation': 'Division of Scientific Research Writing, Medwrite Medical Communications, Maiden Rock, WI, USA.'}, {'ForeName': 'Galymzhan', 'Initials': 'G', 'LastName': 'Yeleuov', 'Affiliation': 'University Medical Center, Nur-Sultan, Kazakhstan.'}, {'ForeName': 'Farida', 'Initials': 'F', 'LastName': 'Bekmurzinova', 'Affiliation': 'University Medical Center, Nur-Sultan, Kazakhstan.'}]",Obesity surgery,['10.1007/s11695-019-04236-1'] 877,31654154,"Acute effects of photobiomodulation therapy applied to respiratory muscles of chronic obstructive pulmonary disease patients: a double-blind, randomized, placebo-controlled crossover trial.","To investigate the effects of photobiomodulation applied to respiratory muscles on lung function, thoracoabdominal mobility, respiratory muscle strength, and functional capacity in COPD patients. This is a randomized double-blind crossover clinical trial. Twelve male COPD patients participated in the study. Participants were randomly allocated to receive two photobiomodulation sessions, 1 week apart: (1) an effective photobiomodulation session applied at the main respiratory muscles by means of a cluster with 69 light-emitting diodes (LEDs), containing 35 red (630 ± 10 nm; 10 mW; 0.2 cm 2 ) and 34 near-infrared (830 ± 20 nm; 10 mW; 0.2 cm 2 ) LEDs and (2) a sham photobiomodulation session, following the same procedures without emitting light. The primary outcomes were pulmonary function (spirometric indexes); thoracoabdominal mobility (cirtometry); respiratory muscle strength (maximal respiratory pressures), assessed at three moments: (1) baseline, (2) 1 h after intervention, and (3) 24 h after intervention; and the functional capacity, assessed by the 6-min walk test (6MWT) at baseline and 24 h after intervention. No significant interactions were found for spirometric variables, maximal respiratory pressures, and cirtometry. However, there was a Time × Condition interaction (F = 18.63; p = 0.001; η 2 p  = 0.62) in the walked distance on the 6MWT, with a significant increase after photobiomodulation intervention (p < 0.01) compared with the baseline. Photobiomodulation applied to respiratory muscles was effective in improving acute functional capacity in COPD patients. To the best of our knowledge, this is the first study assessing the effects of photobiomodulation applied to respiratory muscles in patients with COPD.",2020,"However, there was a Time × Condition interaction (F = 18.63; p = 0.001; η 2 p  = 0.62) in the walked distance on the 6MWT, with a significant increase after photobiomodulation intervention (p < 0.01) compared with the baseline.","['chronic obstructive pulmonary disease patients', 'patients with COPD', 'COPD patients', 'Twelve male COPD patients participated in the study']","['photobiomodulation therapy', 'placebo', 'photobiomodulation', 'photobiomodulation sessions, 1\xa0week apart: (1) an effective photobiomodulation session applied at the main respiratory muscles by means of a cluster with 69 light-emitting diodes (LEDs), containing 35 red (630\u2009±\u200910\xa0nm; 10\xa0mW; 0.2\xa0cm 2 ) and 34 near-infrared (830\u2009±\u200920\xa0nm; 10\xa0mW; 0.2\xa0cm 2 ) LEDs and (2) a sham photobiomodulation session']","['acute functional capacity', 'pulmonary function (spirometric indexes); thoracoabdominal mobility (cirtometry); respiratory muscle strength (maximal respiratory pressures), assessed at three moments: (1) baseline, (2) 1\xa0h after intervention, and (3) 24\xa0h after intervention; and the functional capacity, assessed by the 6-min walk test (6MWT', 'spirometric variables, maximal respiratory pressures, and cirtometry', 'lung function, thoracoabdominal mobility, respiratory muscle strength, and functional capacity']","[{'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C4019433', 'cui_str': 'LLLT'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0205225', 'cui_str': 'Principal (qualifier value)'}, {'cui': 'C0035231', 'cui_str': 'Ventilatory Muscles'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0332575', 'cui_str': 'Red color (finding)'}, {'cui': 'C4708165', 'cui_str': 'Six hundred and thirty'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0475806', 'cui_str': 'Nr - Near'}, {'cui': 'C4517889', 'cui_str': '830 (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0444467', 'cui_str': 'Thoracoabdominal (qualifier value)'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0035231', 'cui_str': 'Ventilatory Muscles'}, {'cui': 'C4277579', 'cui_str': 'Maximum Respiratory Pressures'}, {'cui': 'C0700308', 'cui_str': 'Protium (substance)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}]",12.0,0.0797867,"However, there was a Time × Condition interaction (F = 18.63; p = 0.001; η 2 p  = 0.62) in the walked distance on the 6MWT, with a significant increase after photobiomodulation intervention (p < 0.01) compared with the baseline.","[{'ForeName': 'Guilherme Henrique Martins', 'Initials': 'GHM', 'LastName': 'de Souza', 'Affiliation': 'Pró-Reitoria de Pesquisa e Pós-Graduação, Universidade do Sagrado Coração, São Paulo, SP, Brazil.'}, {'ForeName': 'Cleber', 'Initials': 'C', 'LastName': 'Ferraresi', 'Affiliation': 'Post-graduation Program in Biomedical Engineering, Universidade Brasil, São Paulo, Brazil.'}, {'ForeName': 'Marlene Aparecida', 'Initials': 'MA', 'LastName': 'Moreno', 'Affiliation': 'Post-graduation Program in Human Movement Sciences, Methodist University of Piracicaba (UNIMEP), Piracicaba, SP, Brazil.'}, {'ForeName': 'Bruna Varanda', 'Initials': 'BV', 'LastName': 'Pessoa', 'Affiliation': 'Pró-Reitoria de Pesquisa e Pós-Graduação, Universidade do Sagrado Coração, São Paulo, SP, Brazil.'}, {'ForeName': 'Ana Paula Moraes', 'Initials': 'APM', 'LastName': 'Damiani', 'Affiliation': 'Pró-Reitoria de Pesquisa e Pós-Graduação, Universidade do Sagrado Coração, São Paulo, SP, Brazil.'}, {'ForeName': 'Vinicius Gasparotto', 'Initials': 'VG', 'LastName': 'Filho', 'Affiliation': 'Pró-Reitoria de Pesquisa e Pós-Graduação, Universidade do Sagrado Coração, São Paulo, SP, Brazil.'}, {'ForeName': 'Giovanny Viegas', 'Initials': 'GV', 'LastName': 'Dos Santos', 'Affiliation': 'Pró-Reitoria de Pesquisa e Pós-Graduação, Universidade do Sagrado Coração, São Paulo, SP, Brazil.'}, {'ForeName': 'Antonio Roberto', 'Initials': 'AR', 'LastName': 'Zamunér', 'Affiliation': 'Departamento de Kinesiología, Laboratorio de Investigación Clínica en Kinesiología, Universidad Católica del Maule, Avenida San Miguel 3605, Talca, Maule, Chile. beto.zam@gmail.com.'}]",Lasers in medical science,['10.1007/s10103-019-02885-3'] 878,31642984,The lipid-lowering effect of once-daily soya drink fortified with phytosterols in normocholesterolaemic Chinese: a double-blind randomized controlled trial.,"PURPOSE Phytosterols reduce intestinal cholesterol absorption and help to lower LDL-cholesterol. Many Chinese adults are lactose-intolerant and cannot tolerate bovine milk enriched with phytosterol. Soya-milk is a common beverage in Asia and it has beneficial effects on general health. We therefore conducted a randomized double-blind controlled trial to assess the effectiveness of a phytosterols-enriched soya drink in lowering serum LDL-cholesterol level (primary outcome) and other cardiovascular parameters (secondary outcomes). METHODS One hundred and fifty-nine normocholesterolaemic participants (85 men and 74 women; aged 19-79) were randomized to daily intake of one serving of phytosterols-enriched soya drink (N = 82), equivalent to 2 g of phytosterol per day, or a matched soya drink without phytosterols (N = 77) for 3 weeks. Adverse events, withdrawal and compliance were documented. RESULTS Among the treatment group (N = 82), phytosterols-enriched soya drink significantly decreased LDL-cholesterol by 5.96% (SE 1.48, 95% CI - 8.91%, - 3.00%) with a median of 6.74% compared with baseline, resulting in a significant reduction of 4.70% (95% CI - 8.89%, - 0.51%; p = 0.028) with a median of 5.20% compared with placebo (N = 77). In contrast, there were no significant changes in other lipid parameters, blood glucose, blood pressure, body weight or waist circumference. Remarkably, 95% of the participants randomized to the fortified drink reported no adverse events at all. CONCLUSIONS Daily consumption of a phytosterols-enriched soya drink may be a simple and cost-neutral means of lowering LDL-cholesterol in individuals in China, with massive population and rising incidence of coronary heart disease (ClinicalTrials.gov identifier: NCT02881658; date of registration: 14 Aug 2016).",2020,"In contrast, there were no significant changes in other lipid parameters, blood glucose, blood pressure, body weight or waist circumference.","['normocholesterolaemic Chinese', 'One hundred and fifty-nine normocholesterolaemic participants (85 men and 74 women; aged 19-79']","['placebo', 'phytosterols-enriched soya drink', 'fortified drink', 'daily intake of one serving of phytosterols-enriched soya drink (N\u2009=\u200982), equivalent to 2\xa0g of phytosterol per day, or a matched soya drink without phytosterols']","['LDL-cholesterol', 'adverse events', 'Adverse events, withdrawal and compliance', 'lipid parameters, blood glucose, blood pressure, body weight or waist circumference', 'serum LDL-cholesterol level']","[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0031866', 'cui_str': 'Phytosterols'}, {'cui': 'C0037733', 'cui_str': 'Soy Beans'}, {'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]","[{'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0428474', 'cui_str': 'Serum LDL cholesterol measurement'}]",85.0,0.701151,"In contrast, there were no significant changes in other lipid parameters, blood glucose, blood pressure, body weight or waist circumference.","[{'ForeName': 'Yin-Pan', 'Initials': 'YP', 'LastName': 'Chau', 'Affiliation': 'Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Sassoon Road, Pokfulam, Hong Kong.'}, {'ForeName': 'Yu-Chun', 'Initials': 'YC', 'LastName': 'Cheng', 'Affiliation': 'Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Sassoon Road, Pokfulam, Hong Kong.'}, {'ForeName': 'Chor-Wing', 'Initials': 'CW', 'LastName': 'Sing', 'Affiliation': 'Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Sassoon Road, Pokfulam, Hong Kong.'}, {'ForeName': 'Man-Fung', 'Initials': 'MF', 'LastName': 'Tsoi', 'Affiliation': 'Department of Medicine, Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Pokfulam, Hong Kong.'}, {'ForeName': 'Vincent Ka-Fai', 'Initials': 'VK', 'LastName': 'Cheng', 'Affiliation': 'Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Sassoon Road, Pokfulam, Hong Kong.'}, {'ForeName': 'Grace Koon-Yee', 'Initials': 'GK', 'LastName': 'Lee', 'Affiliation': 'Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Sassoon Road, Pokfulam, Hong Kong.'}, {'ForeName': 'Ching-Lung', 'Initials': 'CL', 'LastName': 'Cheung', 'Affiliation': 'Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Sassoon Road, Pokfulam, Hong Kong. lung1212@hku.hk.'}, {'ForeName': 'Bernard M Y', 'Initials': 'BMY', 'LastName': 'Cheung', 'Affiliation': 'Department of Medicine, Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Pokfulam, Hong Kong. mycheung@hku.hk.'}]",European journal of nutrition,['10.1007/s00394-019-02119-w'] 879,30183453,Effects of integrating Neurac vibration into a side-lying bridge exercise on a sling in patients with chronic low back pain: a randomized controlled study.,"PURPOSE This study examined the effects of integrated Neurac vibration during side-lying bridge exercise using a sling system on pain, strength, and balance in patients with chronic low back pain (LBP). Subjects and Methods : A total of 30 patients were randomly assigned to experimental (EG; n =  15) or control groups (CG; n =  15). Both groups performed side-lying bridge exercise; however, the EG group also received Neurac vibration during exercise. Outcome measures included perceived pain level, asymmetry of weight distribution, asymmetry of hip abductor strength (AHAS), and static balance in one-leg standing. A 2 × 2 repeated-measures analysis of variance was used to determine main effects and interaction for each parameter. Results : Significant interaction effects were found between group and time factors for all parameters. Between-group comparisons revealed significant differences in observed changes for all parameters ( P <  0.05). In within-group comparisons, EG showed significant changes in all parameters after intervention ( P <  0.05); however, significant changes were only found for pain and AHAS in the CG ( P <  0.05). Pain score showed greatest effect size ( d  = 0.77) among all parameters, indicating a moderate effect of intervention. Conclusion : The side-lying bridge exercise on a sling system may alleviate pain and improve strength and balance in patients with chronic LBP, with more favorable effects when Neurac vibration is integrated into the exercise plan.",2020,"Pain score showed greatest effect size (d = 0.77) among all parameters, indicating a moderate effect of intervention. ","['patients with chronic low back pain (LBP', 'patients with chronic low back pain', '30 patients', 'patients with chronic LBP']","['integrating Neurac vibration into a side-lying bridge exercise', 'Neurac vibration during exercise', 'integrated Neurac vibration during side-lying bridge exercise']","['Pain score', 'pain level, asymmetry of weight distribution, asymmetry of hip abductor strength (AHAS), and static balance in one-leg standing', 'pain, strength, and balance', 'pain and AHAS', 'strength and balance']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain (finding)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}]","[{'cui': 'C0459800', 'cui_str': 'Vibration'}, {'cui': 'C0444379', 'cui_str': 'Lateral decubitus position (finding)'}, {'cui': 'C0456378', 'cui_str': 'Type of bridge (attribute)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0587107', 'cui_str': 'During exercise (qualifier value)'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0332514', 'cui_str': 'Asymmetry (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0441463', 'cui_str': 'Static (qualifier value)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",30.0,0.0199458,"Pain score showed greatest effect size (d = 0.77) among all parameters, indicating a moderate effect of intervention. ","[{'ForeName': 'Ae-Jeong', 'Initials': 'AJ', 'LastName': 'Gwon', 'Affiliation': 'Department of Physical Therapy, College of Health and Medical Science, Daejeon University , Daejeon, Republic of Korea.'}, {'ForeName': 'Suhn-Yeop', 'Initials': 'SY', 'LastName': 'Kim', 'Affiliation': 'Department of Physical Therapy, College of Health and Medical Science, Daejeon University , Daejeon, Republic of Korea.'}, {'ForeName': 'Duck-Won', 'Initials': 'DW', 'LastName': 'Oh', 'Affiliation': 'Department of Physical Therapy, College of Health Science, Cheongju University , Cheongju, Chungcheongbuk-do, Republic of Korea.'}]",Physiotherapy theory and practice,['10.1080/09593985.2018.1513616'] 880,30145269,Remote delivery of weight management for adults with intellectual and developmental disabilities: Rationale and design for a 24 month randomized trial.,"Adults with intellectual and developmental disabilities (IDD) represent an underserved segment of the US population with a high prevalence of obesity and limited options for weight management. Previous research has demonstrated clinically meaningful weight loss of 7% of total body weight in in adults with IDD using an enhanced Stop Light Diet (eSLD) in combination with monthly at-home face-to-face (FTF) behavioral sessions, and a recommendation for increased physical activity. However, the time and cost associated with FTF delivery (travel + sessions) limits the potential for scaling and implementation and suggests the need for the evaluation of less costly and burdensome strategies for intervention delivery. Therefore, we will conduct a 24-mo. randomized trial to compare a weight management intervention (6 mos. weight loss, 12 mos. maintenance, 6 mos. no-contact follow-up) delivered to 120 overweight/obese adults with IDD in their home, either remotely (RD) using video conferencing on a tablet computer, or during FTF visits. Our primary aim is whether RD is non-inferior to FTF for weight loss (0-6 mos.). Secondarily, we will compare the RD and FTF groups on mean weight loss, the proportion of participants who achieve clinically meaningful weight loss, and changes in quality of life across 24 months. We will also conduct cost analysis, cost-effectiveness, and contingent valuation analyses to compare the RD and FTF groups.",2018,"no-contact follow-up) delivered to 120 overweight/obese adults with IDD in their home, either remotely (RD) using video conferencing on a tablet computer, or during FTF visits.","['adults with intellectual and developmental disabilities', '120 overweight/obese adults with IDD in their home, either remotely (RD) using', 'Adults with intellectual and developmental disabilities (IDD']","['video conferencing', 'weight management', 'weight management intervention']","['quality of life', 'weight loss', 'mean weight loss']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008073', 'cui_str': 'Child Development Disorders'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1947944', 'cui_str': 'Use'}]","[{'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}]","[{'cui': 'C0034380'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",,0.022165,"no-contact follow-up) delivered to 120 overweight/obese adults with IDD in their home, either remotely (RD) using video conferencing on a tablet computer, or during FTF visits.","[{'ForeName': 'Lauren T', 'Initials': 'LT', 'LastName': 'Ptomey', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. Electronic address: lptomey@ku.edu.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Washburn', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. Electronic address: rwashburn@ku.edu.'}, {'ForeName': 'Matthew S', 'Initials': 'MS', 'LastName': 'Mayo', 'Affiliation': 'Department of Biostatistics, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. Electronic address: mmayo@kumc.edu.'}, {'ForeName': 'J Leon', 'Initials': 'JL', 'LastName': 'Greene', 'Affiliation': 'Department of Health, Sport, and Exercise Sciences, University of Kansas, Lawrence, KS 66045, USA. Electronic address: jlg@ku.edu.'}, {'ForeName': 'Robert H', 'Initials': 'RH', 'LastName': 'Lee', 'Affiliation': 'Department of Health Policy and Management, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. Electronic address: rlee2@kumc.edu.'}, {'ForeName': 'Amanda N', 'Initials': 'AN', 'LastName': 'Szabo-Reed', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. Electronic address: aszabo@kumc.edu.'}, {'ForeName': 'Jeffery J', 'Initials': 'JJ', 'LastName': 'Honas', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. Electronic address: jhonas@ku.edu.'}, {'ForeName': 'Joseph R', 'Initials': 'JR', 'LastName': 'Sherman', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. Electronic address: joesherman@ku.edu.'}, {'ForeName': 'Joseph E', 'Initials': 'JE', 'LastName': 'Donnelly', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. Electronic address: jdonnelly@ku.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2018.08.010'] 881,30088695,A bidirectional path analysis model of smoking cessation self-efficacy and concurrent smoking status: impact on abstinence outcomes.,"Self-efficacy is routinely associated with abstinence in the addictions literature, and is a major component relapse-prevention models. The magnitude of this relationship has been brought into question following equivocal results in studies controlling for concurrent smoking status. The aim of our study was to clarify the relationship between cessation self-efficacy, smoking status, and cessation outcomes in a cohort of treatment-seeking smokers. Smokers participating in the FLEX trial, a randomized trial investigating the efficacy of three pharmacologic treatments for smoking cessation, completed questionnaires assessing cessation self-efficacy at baseline and at weeks 1, 3, 5 and 10 post-target quit date; smoking status was verified using expired carbon monoxide. Structural models were fit in order to ascertain the relationship between cessation self-efficacy and concurrent smoking at each time-point, and to assess the association between cessation self-efficacy, smoking and seven-day point prevalence smoking status at week 10. A total of 737 treatment-seeking smokers participated. In our path model, self-efficacy and smoking status at all time points were associated with week 10 abstinence (except week 3 self-efficacy), after controlling these values' previous time-points. All direct pathways between cessation self-efficacy and smoking were also significant, supporting a bidirectional relationship. Our results support a bidirectional and reciprocal relationship between cessation self-efficacy and concurrent smoking behavior; participants with higher confidence were more likely to be smoke-free, and concurrent smoking status predicted levels of confidence over the ensuing weeks. Both measures were associated with week 10 abstinence. Our results indicate that while correlated, both cessation self-efficacy and current smoking behavior during a cessation attempt are important independent markers of ultimate cessation success.",2019,"Smokers participating in the FLEX trial, a randomized trial investigating the efficacy of three pharmacologic treatments for smoking cessation, completed questionnaires assessing cessation self-efficacy at baseline and at weeks 1, 3, 5 and 10 post-target quit date; smoking status was verified using expired carbon monoxide.","['Smokers participating in the FLEX trial', 'a cohort of treatment-seeking smokers', '737 treatment-seeking smokers participated']",[],"['self-efficacy and smoking status', 'cessation self-efficacy, smoking status, and cessation outcomes', 'cessation self-efficacy and current smoking behavior', 'Self-efficacy']","[{'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",[],"[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C1519383', 'cui_str': 'Smoking Behaviors'}]",737.0,0.0106728,"Smokers participating in the FLEX trial, a randomized trial investigating the efficacy of three pharmacologic treatments for smoking cessation, completed questionnaires assessing cessation self-efficacy at baseline and at weeks 1, 3, 5 and 10 post-target quit date; smoking status was verified using expired carbon monoxide.","[{'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Clyde', 'Affiliation': 'Prevention and Rehabilitation Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Pipe', 'Affiliation': 'Prevention and Rehabilitation Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Reid', 'Affiliation': 'Prevention and Rehabilitation Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.'}, {'ForeName': 'Charl', 'Initials': 'C', 'LastName': 'Els', 'Affiliation': 'Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Tulloch', 'Affiliation': 'Prevention and Rehabilitation Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.'}]",Addiction biology,['10.1111/adb.12647'] 882,29921538,Peer influence processes as mediators of effects of a middle school substance use prevention program.,"BACKGROUND Peer influence processes have been linked to escalation in substance use during the middle school years, particularly among at-risk youth. In this study, we report on an approach to prevention that attempts to counteract peer influence by interrupting the process of deviant peer clustering, in which socially marginalized youth self-aggregate and reinforce delinquent behavior, including substance use. We aimed to interrupt this process by implementing collaborative, group-based learning activities in school (i.e., cooperative learning). METHODS In a cluster randomized trial in the Pacific Northwest (N = 1460 7th-grade students in 15 schools), we tested whether cooperative learning can reduce alcohol and tobacco use, and whether these effects are mediated by reductions in the amount of alcohol and tobacco use among one's friends. Intervention schools were provided with training in cooperative learning, and data were collected in September/October 2016 (baseline) and March 2017 (follow-up). RESULTS Results indicated that cooperative learning significantly lowered rates of growth in alcohol (β = -0.60 [-0.36|-0.84]; p < .001) and tobacco use (β = -0.58 [-0.21|-0.94]; p = .01) between baseline and follow-up in intervention schools as compared to control schools. These effects were mediated by reductions in the prevalence of alcohol and tobacco use, respectively, among self-selected friends. CONCLUSIONS Cooperative learning was able to significantly reduce the prevalence of both alcohol and tobacco use in friendship networks during the school year. The lower prevalence of alcohol and tobacco use among friends, in turn, reduced individual use at follow-up. This study was registered as trial NCT03119415 in ClinicalTrials.gov.",2018,"CONCLUSIONS Cooperative learning was able to significantly reduce the prevalence of both alcohol and tobacco use in friendship networks during the school year.",['Pacific Northwest (N = 1460 7th-grade students in 15 schools'],['cooperative learning'],['rates of growth in alcohol'],"[{'cui': 'C0030170', 'cui_str': 'Pacific Northwest'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0036375', 'cui_str': 'School'}]",[],"[{'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}]",,0.0279829,"CONCLUSIONS Cooperative learning was able to significantly reduce the prevalence of both alcohol and tobacco use in friendship networks during the school year.","[{'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Van Ryzin', 'Affiliation': 'Oregon Research Institute, 1776 Millrace, Eugene, OR 97403, United States. Electronic address: markv@ori.org.'}, {'ForeName': 'Cary J', 'Initials': 'CJ', 'LastName': 'Roseth', 'Affiliation': 'Michigan State University, College of Education, East Lansing, MI, United States. Electronic address: croseth@msu.edu.'}]",Addictive behaviors,['10.1016/j.addbeh.2018.06.016'] 883,30152245,Near infrared spectroscopy-guided exercise training for claudication in peripheral arterial disease.,"RATIONALE Supervised treadmill exercise for claudication in peripheral arterial disease is effective but poorly tolerated because of ischemic leg pain. Near infrared spectroscopy allows non-invasive detection of muscle ischemia during exercise, allowing for characterization of tissue perfusion and oxygen utilization during training. OBJECTIVE We evaluated walking time, muscle blood flow, and muscle mitochondrial capacity in patients with peripheral artery disease after a traditional pain-based walking program and after a muscle oxygen-guided walking program. METHOD AND RESULTS Patients with peripheral artery disease trained thrice weekly in 40-minute-long sessions for 12 weeks, randomized to oxygen-guided training ( n = 8, age 72 ± 9.7 years, 25% female) versus traditional pain-based training ( n = 10, age 71.6 ± 8.8 years, 20% female). Oxygen-guided training intensity was determined by maintaining a 15% reduction in skeletal muscle oxygenation by near infrared spectroscopy rather than relying on symptoms of pain to determine exercise effort. Pain free and maximal walking times were measured with a 12-minute Gardner treadmill test. Gastrocnemius mitochondrial capacity and blood flow were measured using near infrared spectroscopy. Baseline pain-free walking time was similar on a Gardner treadmill test (2.5 ± 0.9 vs. 3.6 ± 1.0 min, p = 0.5). After training, oxygen-guided cohorts improved similar to pain-guided cohorts (pain-free walking time 6.7 ± 0.9 vs. 6.9 ± 1.1 min, p < 0.01 for change from baseline and p = 0.97 between cohorts). Mitochondrial capacity improved in both groups but more so in the pain-guided cohort than in the oxygen-guided cohort (38.8 ± 8.3 vs. 14.0 ± 9.3, p = 0.018). Resting muscle blood flow did not improve significantly in either group with training. CONCLUSIONS Oxygen-guided exercise training improves claudication comparable to pain-based training regimens. Adaptations in mitochondrial function rather than increases in limb perfusion may account for functional improvement. Increases in mitochondrial oxidative capacity may be proportional to the degree of tissue hypoxia during exercise.",2019,"Mitochondrial capacity improved in both groups but more so in the pain-guided cohort than in the oxygen-guided cohort (38.8 ± 8.3 vs. 14.0 ± 9.3, p = 0.018).","['patients with peripheral artery disease after a traditional pain-based walking program and after a muscle oxygen-guided walking program', ' n\u2009=\u200910, age 71.6\u2009±\u20098.8 years, 20% female', ' n\u2009=\u20098, age 72\u2009±\u20099.7 years, 25% female) versus', 'Patients with peripheral artery disease trained thrice weekly in 40-minute-long sessions for 12 weeks, randomized to']","['treadmill exercise', 'traditional pain-based training', 'Oxygen-guided exercise training', 'oxygen-guided training', 'Near infrared spectroscopy-guided exercise training']","['Mitochondrial capacity', 'mitochondrial oxidative capacity', 'Gastrocnemius mitochondrial capacity and blood flow', 'Resting muscle blood flow', 'Pain free and maximal walking times', 'Baseline pain-free walking time', 'walking time, muscle blood flow, and muscle mitochondrial capacity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Artery Disease'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517882', 'cui_str': '8.8 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0556987', 'cui_str': 'Three times weekly (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0184069', 'cui_str': 'Treadmill, device (physical object)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0376519', 'cui_str': 'Spectrometry, Near-Infrared'}]","[{'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0908489', 'cui_str': 'Pain-Free'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]",,0.0597121,"Mitochondrial capacity improved in both groups but more so in the pain-guided cohort than in the oxygen-guided cohort (38.8 ± 8.3 vs. 14.0 ± 9.3, p = 0.018).","[{'ForeName': 'Jonathan R', 'Initials': 'JR', 'LastName': 'Murrow', 'Affiliation': '1 Augusta University - University of Georgia Medical Partnership, USA.'}, {'ForeName': 'Jared T', 'Initials': 'JT', 'LastName': 'Brizendine', 'Affiliation': '2 University of Alabama Birmingham, USA.'}, {'ForeName': 'Bill', 'Initials': 'B', 'LastName': 'Djire', 'Affiliation': '3 Mercer University, Athens, Georgia, USA.'}, {'ForeName': 'Hui-Ju', 'Initials': 'HJ', 'LastName': 'Young', 'Affiliation': '2 University of Alabama Birmingham, USA.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Rathbun', 'Affiliation': '4 University of Georgia, Athens, Georgia, USA.'}, {'ForeName': 'Kent R', 'Initials': 'KR', 'LastName': 'Nilsson', 'Affiliation': '1 Augusta University - University of Georgia Medical Partnership, USA.'}, {'ForeName': 'Kevin K', 'Initials': 'KK', 'LastName': 'McCully', 'Affiliation': '4 University of Georgia, Athens, Georgia, USA.'}]",European journal of preventive cardiology,['10.1177/2047487318795192'] 884,30208343,Rationale and design of technology assisted stepped collaborative care intervention to improve patient-centered outcomes in hemodialysis patients (TĀCcare trial).,"Most hemodialysis (HD) patients experience symptoms of depression, pain and fatigue that impair their health-related quality of life (HRQOL) significantly. These symptoms are associated with increased hospitalization and mortality, mediated by behavioral factors (e.g. non-adherence to medication and dialysis) and biological factors (e.g. inflammatory cytokines). Prior interventions to alleviate symptoms and improve HRQOL showed limited effectiveness in HD patients and their effect on bio-behavioral mediators is lacking evidence. It is imperative to improve patient-centered dialysis care and to address call from Kidney Disease Improving Global Outcomes (KDIGO) guidelines for integration of symptom assessment and management in routine HD-care. Technology-Assisted stepped Collaborative Care (TĀCcare) is a multi-center randomized controlled trial (RCT) of 150 diverse HD patients from Pennsylvania and New Mexico, designed to compare the effectiveness of a 12-week stepped collaborative care intervention (cognitive behavioral therapy, CBT) with an attention control arm of technology-delivered health education. Collaborative care provides an integrated multi-disciplinary structured management plan. Furthermore, a stepped approach to pharmacotherapy and/or CBT allows for individualization of treatment according to patients' clinical status, preferences and treatment response. To simplify the delivery of CBT and to minimize patient and provider burden, we will use live video-conferencing with patients in dialysis units. We will examine the effect of these interventions on patient symptoms, HRQOL, treatment adherence and inflammatory biomarkers. This RCT tests a readily implementable intervention that can be integrated in routine HD-care and will generate novel and meaningful insights on strategies to alleviate common symptoms and improve HRQOL in HD.",2018,"Most hemodialysis (HD) patients experience symptoms of depression, pain and fatigue that impair their health-related quality of life (HRQOL) significantly.","['150 diverse HD patients from Pennsylvania and New Mexico', 'hemodialysis patients (TĀCcare trial']","['Technology-Assisted stepped Collaborative Care (TĀCcare', 'stepped collaborative care intervention (cognitive behavioral therapy, CBT) with an attention control arm of technology-delivered health education', 'technology assisted stepped collaborative care intervention']","['hospitalization and mortality', 'patient symptoms, HRQOL, treatment adherence and inflammatory biomarkers']","[{'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030853', 'cui_str': 'Pennsylvania'}, {'cui': 'C0027972', 'cui_str': 'New Mexico'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C1261552', 'cui_str': 'Step'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0018701'}]","[{'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C4505265', 'cui_str': 'Treatment Adherence'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",150.0,0.0453827,"Most hemodialysis (HD) patients experience symptoms of depression, pain and fatigue that impair their health-related quality of life (HRQOL) significantly.","[{'ForeName': 'Maria-Eleni', 'Initials': 'ME', 'LastName': 'Roumelioti', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, University of New Mexico School of Medicine Albuquerque, NM, United States.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Steel', 'Affiliation': 'Department of Surgery, Psychiatry and Psychology, University of Pittsburgh, Pittsburgh, PA, United States.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Yabes', 'Affiliation': 'Center for Research on Heath Care, Division of General Internal Medicine, Department of Medicine and Biostatistics, University of Pittsburgh, Pittsburgh, PA, United States.'}, {'ForeName': 'Kevin E', 'Initials': 'KE', 'LastName': 'Vowles', 'Affiliation': 'Department of Psychology, University of New Mexico & Division of Physical Medicine and Rehabilitation, University of New Mexico Health Sciences Center, Albuquerque, NM, United States.'}, {'ForeName': 'Yoram', 'Initials': 'Y', 'LastName': 'Vodovotz', 'Affiliation': 'Department of Immunology and Surgery, University of Pittsburgh, Pittsburgh, PA, United States.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Beach', 'Affiliation': 'Department of Psychology, University Center for Social and Urban Research, University of Pittsburgh, Pittsburgh, PA, United States.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Rollman', 'Affiliation': 'Department of Medicine, Psychiatry, Biomedical Informatics, and Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, United States.'}, {'ForeName': 'Steven D', 'Initials': 'SD', 'LastName': 'Weisbord', 'Affiliation': 'Renal and Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.'}, {'ForeName': 'Mark L', 'Initials': 'ML', 'LastName': 'Unruh', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, University of New Mexico School of Medicine Albuquerque, NM, United States.'}, {'ForeName': 'Manisha', 'Initials': 'M', 'LastName': 'Jhamb', 'Affiliation': 'Renal and Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States. Electronic address: jhambm@upmc.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2018.09.002'] 885,30149417,Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes.,"AIM To evaluate the effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes. METHODS A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 adults diagnosed with prediabetes and without pharmacological treatment. Patients were randomly assigned into two groups of 12 patients each to receive 10 mg of oral dapagliflozin or placebo once a day during 12 weeks. At baseline and at the end of the study, anthropometric and metabolic measurements were evaluated, including the first phase of insulin secretion, total insulin secretion, and insulin sensitivity. RESULTS After dapagliflozin administration, there were significant decreases in body weight (80.8±16.3 vs. 77.8±14.9 kg, p=0.019), body mass index (30.3±3.5 vs. 29.2±3.1 kg/m 2 , p=0.023), waist circumference (100.6±13.5 vs. 96.2±11.8 cm, p=0.003), fasting glucose (5.9±0.4 vs. 5.1±0.3 mmol/L, p<0.001) and uric acid (334.3±70.8 vs. 262.9±60.7 mmol/L, p=0.032), with a tendency to increase the insulin sensitivity (1.94±0.72 vs. 2.63±1.04, p=0.064). CONCLUSION Dapagliflozin administration in patients with prediabetes decreased body weight, body mass index, waist circumference, fasting glucose, and uric acid, with a tendency to increase the insulin sensitivity without changes in insulin secretion.",2020,"After dapagliflozin administration, there were significant decreases in body weight (80.8±16.3 vs. 77.8±14.9 kg, p=0.019), body mass index (30.3±3.5 vs. 29.2±3.1 kg/m 2 , p=0.023), waist circumference (100.6±13.5 vs. 96.2±11.8 cm, p=0.003), fasting glucose (5.9±0.4 vs. 5.1±0.3 mmol/L, p<0.001) and uric acid (334.3±70.8 vs. 262.9±60.7 mmol/L, p=0.032), with a tendency to increase the insulin sensitivity (1.94±0.72 vs. 2.63±1.04, p=0.064). CONCLUSION Dapagliflozin administration in patients with prediabetes decreased body weight, body mass index, waist circumference, fasting glucose, and uric acid, with a tendency to increase the insulin sensitivity without changes in insulin secretion.","['24 adults diagnosed with prediabetes and without pharmacological treatment', 'patients with prediabetes', 'Patients with Prediabetes']","['placebo', 'Dapagliflozin', 'dapagliflozin', 'oral dapagliflozin or placebo']","['insulin sensitivity', 'waist circumference', 'uric acid', 'fasting glucose', 'insulin secretion, total insulin secretion, and insulin sensitivity', 'body weight, body mass index, waist circumference, fasting glucose, and uric acid', 'body mass index', 'Insulin Secretion and Insulin Sensitivity', 'body weight', 'insulin secretion and insulin sensitivity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0362046', 'cui_str': 'Prediabetes'}, {'cui': 'C0205464', 'cui_str': 'Pharmacologic (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0041980', 'cui_str': 'Uric Acid'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C1256369', 'cui_str': 'Insulin Secretion'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",24.0,0.204756,"After dapagliflozin administration, there were significant decreases in body weight (80.8±16.3 vs. 77.8±14.9 kg, p=0.019), body mass index (30.3±3.5 vs. 29.2±3.1 kg/m 2 , p=0.023), waist circumference (100.6±13.5 vs. 96.2±11.8 cm, p=0.003), fasting glucose (5.9±0.4 vs. 5.1±0.3 mmol/L, p<0.001) and uric acid (334.3±70.8 vs. 262.9±60.7 mmol/L, p=0.032), with a tendency to increase the insulin sensitivity (1.94±0.72 vs. 2.63±1.04, p=0.064). CONCLUSION Dapagliflozin administration in patients with prediabetes decreased body weight, body mass index, waist circumference, fasting glucose, and uric acid, with a tendency to increase the insulin sensitivity without changes in insulin secretion.","[{'ForeName': 'Alejandra M', 'Initials': 'AM', 'LastName': 'Ramírez-Rodríguez', 'Affiliation': 'Institute of Experimental and Clinical Therapeutics, Department of Physiology, Health Sciences University Center, University of Guadalajara, Guadalajara, Jalisco, Mexico.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'González-Ortiz', 'Affiliation': 'Institute of Experimental and Clinical Therapeutics, Department of Physiology, Health Sciences University Center, University of Guadalajara, Guadalajara, Jalisco, Mexico.'}, {'ForeName': 'Esperanza', 'Initials': 'E', 'LastName': 'Martínez-Abundis', 'Affiliation': 'Institute of Experimental and Clinical Therapeutics, Department of Physiology, Health Sciences University Center, University of Guadalajara, Guadalajara, Jalisco, Mexico.'}]","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association",['10.1055/a-0664-7583'] 886,30114712,Bilateral Paravertebral Block versus Thoracic Epidural Analgesia for Pain Control Post-Cardiac Surgery: A Randomized Controlled Trial.,"BACKGROUND Adequate pain control after cardiac surgery is essential. Paravertebral block is a simple technique and avoids the potential complications of epidural catheters. The objective of this study is to compare the effect of ultrasound-guided bilateral thoracic paravertebral block with thoracic epidural block on pain control after cardiac surgery. MATERIALS AND METHODS Between March 2016 and 2017, 145 patients who had cardiac surgery through median sternotomy were randomized by stratified blocked randomization into two groups. Group I ( n  = 70 patients) had bilateral ultrasound-guided thoracic paravertebral block and Group II ( n  = 75 patients) had thoracic epidural analgesia. The primary end point was the postoperative visual analogue scale (VAS). The duration of mechanical ventilation, intensive care unit (ICU), and hospital stay were the secondary end points. The study design is a randomized parallel superiority clinical trial. RESULTS Both groups had similar preoperative and operative characteristics. No significant difference in VAS measured immediately after endotracheal extubation then after 12, 24, and 48 hours between groups ( p  = 0.45). Pain score significantly declined with the repeated measures ( p  < 0.001) and the decline was not related to the treatment group. Postoperative pain was significantly related to diabetes mellitus ( p  = 0.039). Six patients in group I (8.5%) required an additional dose of morphine versus three patients (4%) in group II ( p  = 0.30). Patients in group I had significantly shorter ICU stay ( p  = 0.005) and lower incidence of urinary retention ( p  = 0.04) and vomiting ( p  = 0.018). No difference was found in operative complications between groups. CONCLUSION This randomized parallel controlled trial demonstrates that ultrasound-guided paravertebral block is safe and effective method for relieving post-cardiac surgery sternotomy pain compared with thoracic epidural analgesia but not superior to it.",2020,Patients in group I had significantly shorter ICU stay ( p  = 0.005) and lower incidence of urinary retention ( p  = 0.04) and vomiting ( p  = 0.018).,"['Six patients in group', '145 patients who had cardiac surgery through median sternotomy', 'Between March 2016 and 2017', 'Pain Control Post-Cardiac Surgery']","['ultrasound-guided paravertebral block', 'bilateral ultrasound-guided thoracic paravertebral block and Group II', 'ultrasound-guided bilateral thoracic paravertebral block with thoracic epidural block', 'morphine', 'Bilateral Paravertebral Block versus Thoracic Epidural Analgesia', 'thoracic epidural analgesia']","['vomiting', 'operative complications', 'diabetes mellitus', 'postoperative visual analogue scale (VAS', 'shorter ICU stay', 'Postoperative pain', 'urinary retention', 'VAS', 'pain control', 'thoracic epidural analgesia', 'Pain score', 'duration of mechanical ventilation, intensive care unit (ICU), and hospital stay']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517577', 'cui_str': '145'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C1282959', 'cui_str': 'Median Sternotomy'}, {'cui': 'C1304888', 'cui_str': 'Pain control (procedure)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]","[{'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0442150', 'cui_str': 'Paravertebral (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0394835', 'cui_str': 'Local anesthetic thoracic epidural block (procedure)'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0002769', 'cui_str': 'Analgesia, Epidural'}]","[{'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0080274', 'cui_str': 'Urinary Retention'}, {'cui': 'C1304888', 'cui_str': 'Pain control (procedure)'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0002769', 'cui_str': 'Analgesia, Epidural'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",,0.112836,Patients in group I had significantly shorter ICU stay ( p  = 0.005) and lower incidence of urinary retention ( p  = 0.04) and vomiting ( p  = 0.018).,"[{'ForeName': 'Hatem A', 'Initials': 'HA', 'LastName': 'El Shora', 'Affiliation': 'Anesthesia and Surgical ICU Department, Faculty of Medicine-Tanta University, Tanta, Gharbeya, Egypt.'}, {'ForeName': 'Ahmed A', 'Initials': 'AA', 'LastName': 'El Beleehy', 'Affiliation': 'Anesthesia and Surgical ICU Department, Faculty of Medicine-Tanta University, Tanta, Gharbeya, Egypt.'}, {'ForeName': 'Amr A', 'Initials': 'AA', 'LastName': 'Abdelwahab', 'Affiliation': 'Department of Cardiothoracic Surgery, Faculty of Medicine-Tanta University, Tanta, Gharbeya, Egypt.'}, {'ForeName': 'Gaser A', 'Initials': 'GA', 'LastName': 'Ali', 'Affiliation': 'Department of Cardiothoracic Surgery, Faculty of Medicine- Zagazig University, Zagazig, Sharkia, Egypt.'}, {'ForeName': 'Tarek E', 'Initials': 'TE', 'LastName': 'Omran', 'Affiliation': 'Department of Cardiothoracic Surgery, Faculty of Medicine-Tanta University, Tanta, Gharbeya, Egypt.'}, {'ForeName': 'Essam A', 'Initials': 'EA', 'LastName': 'Hassan', 'Affiliation': 'Department of Cardiothoracic Surgery, Faculty of Medicine-Tanta University, Tanta, Gharbeya, Egypt.'}, {'ForeName': 'Amr A', 'Initials': 'AA', 'LastName': 'Arafat', 'Affiliation': 'Department of Cardiothoracic Surgery, Faculty of Medicine-Tanta University, Tanta, Gharbeya, Egypt.'}]",The Thoracic and cardiovascular surgeon,['10.1055/s-0038-1668496'] 887,31650328,Successful elevation of circulating acetate and propionate by dietary modulation does not alter T-regulatory cell or cytokine profiles in healthy humans: a pilot study.,"PURPOSE Increased circulating concentrations of short-chain fatty acids (SCFA) achieved by ingestion of high-fibre diets is associated with anti-inflammatory effects through promotion of FoxP3+ regulatory T(reg) cells in mouse models. This study aimed to determine whether similar increments in blood SCFA levels can be achieved in humans and whether these are associated with similar immune modulatory effects. METHODS In a pilot single-blinded, randomised, controlled cross-over study in ten healthy subjects, the effects were determined of high- (39 g/day) and low-fibre (18 g/day) intake (all food provided) on SCFA (gas chromatography), proportions of Treg cells (flow cytometry) and a panel of cytokines (multiplex methodology) measured in peripheral blood at day 5 of each diet. RESULTS Actual fibre intake differed between the diets by 19 [16-21] g/day (P< 0.001). Median [range] total plasma SCFA levels with high-fibre intake were 174.5 [104.8-249.5] µmol/L, which were greater than those associated with low-fibre intake at 59.0 [26.5-79.9] (P < 0.001). Differences were significantly different for both acetate and propionate. The frequencies of total CD4 T cells and T-regulatory cells, and concentrations of inflammatory and anti-inflammatory cytokines were not significantly different between the dietary interventions. CONCLUSIONS Plasma SCFA levels can be modulated by altering dietary fibre consumption in healthy individuals with increments similar to those achieved in murine studies. Five days of diet intervention did not result in changes in regulatory T-cell proportions and cytokine concentrations in peripheral blood, and may require longer duration of dietary change.",2020,"Five days of diet intervention did not result in changes in regulatory T-cell proportions and cytokine concentrations in peripheral blood, and may require longer duration of dietary change.","['healthy individuals', 'ten healthy subjects', 'healthy humans']",['short-chain fatty acids (SCFA'],"['regulatory T-cell proportions and cytokine concentrations', 'frequencies of total CD4 T cells and T-regulatory cells, and concentrations of inflammatory and anti-inflammatory cytokines', 'blood SCFA levels', 'SCFA (gas chromatography), proportions of Treg cells (flow cytometry', 'Median [range] total plasma SCFA levels', 'Actual fibre intake']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0015691', 'cui_str': 'Fatty Acids, Short-Chain'}]","[{'cui': 'C0039198', 'cui_str': 'T-Cells, Regulatory'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C1267822', 'cui_str': 'T lymphocyte positive for both CD4 antigen and CD25 antigen'}, {'cui': 'C0005768'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0008555', 'cui_str': 'Gas Chromatography'}, {'cui': 'C0016263', 'cui_str': 'Flow Microfluorimetry'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0225326', 'cui_str': 'Fiber'}]",10.0,0.128307,"Five days of diet intervention did not result in changes in regulatory T-cell proportions and cytokine concentrations in peripheral blood, and may require longer duration of dietary change.","[{'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Gill', 'Affiliation': 'Department of Gastroenterology, Central Clinical School, Monash University and Alfred Hospital, Melbourne, VIC, Australia.'}, {'ForeName': 'Menno C', 'Initials': 'MC', 'LastName': 'van Zelm', 'Affiliation': 'Department of Immunology and Pathology, Central Clinical School, Monash University and Alfred Hospital, Melbourne, VIC, Australia.'}, {'ForeName': 'Rosemary A', 'Initials': 'RA', 'LastName': 'Ffrench', 'Affiliation': 'Burnet Institute, Melbourne, VIC, Australia.'}, {'ForeName': 'Jane G', 'Initials': 'JG', 'LastName': 'Muir', 'Affiliation': 'Department of Gastroenterology, Central Clinical School, Monash University and Alfred Hospital, Melbourne, VIC, Australia.'}, {'ForeName': 'Peter R', 'Initials': 'PR', 'LastName': 'Gibson', 'Affiliation': 'Department of Gastroenterology, Central Clinical School, Monash University and Alfred Hospital, Melbourne, VIC, Australia. Peter.gibson@monash.edu.'}]",European journal of nutrition,['10.1007/s00394-019-02113-2'] 888,29985087,"Improbable, but plausible, research study: a randomised controlled trial of premature cord clamping vs. neonatal venesection to achieve routine prophylactic neonatal red cell reduction.",,2018,,[],['premature cord clamping vs. neonatal venesection'],[],[],"[{'cui': 'C0205252', 'cui_str': 'Immature (qualifier value)'}, {'cui': 'C3698497', 'cui_str': 'Axillary web syndrome'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0190979', 'cui_str': 'Venesection'}]",[],,0.0398055,,"[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Weeks', 'Affiliation': ""1 Sanyu Research Unit, Department of Women's and Children's Health, Liverpool Women's Hospital, University of Liverpool, Liverpool L8 7SS, UK.""}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Bewley', 'Affiliation': ""2 Department of Women and Children's Health, Faculty of Life Sciences and Medicine, Kings College London, St Thomas' Hospital, London SE1 7EH, UK.""}]",Journal of the Royal Society of Medicine,['10.1177/0141076818781406'] 889,29858625,"Moderate consumption of a soluble green/roasted coffee rich in caffeoylquinic acids reduces cardiovascular risk markers: results from a randomized, cross-over, controlled trial in healthy and hypercholesterolemic subjects.","PURPOSE Coffee is rich in bioactive compounds with health beneficial properties, with green coffee presenting higher phenol content than roasted. We evaluated the effects of regularly consuming realistic amounts of a green/roasted coffee blend on cardiovascular health-related biomarkers. METHODS A randomized, cross-over, controlled study was carried out in 25 normocholesterolemic [total cholesterol (TC) < 200 mg/dL] and 27 hypercholesterolemic (TC 200-240 mg/dL) subjects. During 8 weeks, volunteers consumed 6 g/day of soluble green/roasted (35:65) coffee or a control beverage (water or an isotonic drink). Blood pressure, heart rate and body weight were monitored at the end of each intervention, and serum lipids [TC, HDL-C, LDL-C, VLDL-C, triglycerides and phospholipids], cytokines and chemokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-17, G-CSF, GM-CSF, MCP-1, MIP-1β, TNF-α, INF-γ), adhesion molecules (ICAM-1, VCAM-1), and C-reactive protein were measured. Plasma antioxidant capacity (FRAP, ORAC and ABTS methods), and lipid (malondialdehyde, MDA) and protein (carbonyl groups, CG) oxidation were also determined. RESULTS Attending to the general lineal model of variance for repeated measures, after the green/roasted coffee intervention significant reductions in TC, LDL-C, VLDL-C and triglycerides levels (p = 0.006, 0.001, 0.003 and 0.017, respectively), and a significant group effect were observed (0.001, < 0.001, 0.019 and 0.027, respectively). Only within the hypercholesterolemic group, attending to the Bonferroni test, the aforementioned lipid parameters were significantly lower after regular green/roasted coffee intake compared to baseline values. Moreover, after the coffee stage, plasma antioxidant capacity improved, according to the increase in ORAC and FRAP values (p < 0.001 and p < 0.001, respectively) and decrease of MDA (p = 0.015) and CG (p < 0.001) levels, without differences between groups. Systolic (p = 0.001) and diastolic (p < 0.001) blood pressure, heart rate (p = 0.035), and body weight (p = 0.017) were reduced in both normo- and hypercholesterolemic groups. CONCLUSION Regular consumption of moderate amounts of a soluble green/roasted (35:65) coffee blend may contribute to improve cardiovascular health in moderately hypercholesterolemic people, as reducing serum lipids, blood pressure and body weight effects, as well as increasing plasma antioxidant capacity, have been observed. Moreover, positive influences on blood pressure, body weight, and plasma antioxidant capacity were obtained in the healthy group. Therefore, incorporation of green coffee beans into the coffee brew can be recommended as part of a dietary strategy to protect from cardiovascular disease.",2019,"Moreover, after the coffee stage, plasma antioxidant capacity improved, according to the increase in ORAC and FRAP values (p < 0.001 and p < 0.001, respectively) and decrease of MDA (p = 0.015) and CG (p < 0.001) levels, without differences between groups.","['25 normocholesterolemic [total cholesterol (TC)\u2009<\u2009200\xa0mg/dL] and 27 hypercholesterolemic (TC 200-240\xa0mg/dL) subjects', 'healthy and hypercholesterolemic subjects', 'moderately hypercholesterolemic people']","['soluble green/roasted (35:65) coffee blend', 'volunteers consumed 6\xa0g/day of soluble green/roasted (35:65) coffee or a control beverage (water or an isotonic drink']","['Plasma antioxidant capacity (FRAP, ORAC and ABTS methods), and lipid (malondialdehyde, MDA) and protein (carbonyl groups, CG) oxidation', 'plasma antioxidant capacity', 'cardiovascular health-related biomarkers', 'blood pressure, heart rate', 'diastolic', 'Blood pressure, heart rate and body weight', 'blood pressure, body weight, and plasma antioxidant capacity', 'serum lipids, blood pressure and body weight effects', 'body weight', 'Systolic', 'cardiovascular risk markers', 'ORAC and FRAP values', 'TC, LDL-C, VLDL-C and triglycerides levels', 'MDA', 'serum lipids [TC, HDL-C, LDL-C, VLDL-C, triglycerides and phospholipids], cytokines and chemokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-17, G-CSF, GM-CSF, MCP-1, MIP-1β, TNF-α, INF-γ), adhesion molecules (ICAM-1, VCAM-1), and C-reactive protein', 'cardiovascular health']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C4319600', 'cui_str': '240 (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}]","[{'cui': 'C0332583', 'cui_str': 'Green color (qualifier value)'}, {'cui': 'C0009237', 'cui_str': 'Coffee'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C1722869', 'cui_str': '(glycyl-prolyl-glycyl-glycyl-alanyl)6-glycine'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0005329', 'cui_str': 'Beverages'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0452461', 'cui_str': 'Sports drink (substance)'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0045246', 'cui_str': ""6-Benzothiazolesulfonic acid, 2,2'-azinobis(3-ethyl-2,3-dihydro), diammonium salt""}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0000379', 'cui_str': '1,3-Benzodioxole-5-ethanamine, alpha-methyl-'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0030011', 'cui_str': 'Oxidation, function (observable entity)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0523560', 'cui_str': 'VLDL cholesterol measurement'}, {'cui': 'C0428475', 'cui_str': 'Triglyceride level - finding'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0031676', 'cui_str': 'Phospholipids'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0021756', 'cui_str': 'TCGF'}, {'cui': 'C0021758', 'cui_str': 'Interleukin-4'}, {'cui': 'C0021759', 'cui_str': 'Interleukin-5'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0021761', 'cui_str': 'Interleukin-7'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0123759', 'cui_str': 'Interleukin-12'}, {'cui': 'C0214743', 'cui_str': 'IL13'}, {'cui': 'C0384648', 'cui_str': 'IL-17'}, {'cui': 'C0079459', 'cui_str': 'G-CSF'}, {'cui': 'C0079460', 'cui_str': 'Tumor-Cell Human GM Colony-Stimulating Factor'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0001511', 'cui_str': 'Tissue Adhesions'}, {'cui': 'C0567416', 'cui_str': 'Molecule (substance)'}, {'cui': 'C0063695', 'cui_str': 'CD54 Antigens'}, {'cui': 'C0078056', 'cui_str': 'CD106 Antigens'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}]",,0.0482129,"Moreover, after the coffee stage, plasma antioxidant capacity improved, according to the increase in ORAC and FRAP values (p < 0.001 and p < 0.001, respectively) and decrease of MDA (p = 0.015) and CG (p < 0.001) levels, without differences between groups.","[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Martínez-López', 'Affiliation': 'Department of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN), Spanish National Research Council (CSIC), C/José Antonio Nováis 10, 28040, Madrid, Spain.'}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Sarriá', 'Affiliation': 'Department of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN), Spanish National Research Council (CSIC), C/José Antonio Nováis 10, 28040, Madrid, Spain. beasarria@ictan.csic.es.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Mateos', 'Affiliation': 'Department of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN), Spanish National Research Council (CSIC), C/José Antonio Nováis 10, 28040, Madrid, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Bravo-Clemente', 'Affiliation': 'Department of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN), Spanish National Research Council (CSIC), C/José Antonio Nováis 10, 28040, Madrid, Spain. lbravo@ictan.csic.es.'}]",European journal of nutrition,['10.1007/s00394-018-1726-x'] 890,31641913,Effects of quadratus lumborum block regional anesthesia on postoperative pain after colorectal resection: a randomized controlled trial.,"INTRODUCTION Postoperative pain following colorectal surgery is associated with a significant use of opioids. Recently, regional anesthesia, such as the posterior quadratus lumborum block (QL2), has been proposed to improve pain relief and reduce opioid use. However, the benefit of the QL2 on postoperative pain control remains controversial. METHODS We conducted a randomized controlled trial of patients undergoing colorectal surgery at the CHU de Québec-Université Laval. Patients were randomized to regional QL2 anesthesia with 150 mg of ropivacaine combined with standard analgesia or to QL2 with a sham intervention and standard analgesia. Our primary outcome was postoperative opioid administration at 24 h. Secondary outcomes included opioid administration in the post-anesthesia care unit (PACU), at 48 h and at hospital discharge, postoperative pain scores, delay in resumption of intestinal transit, nausea and vomiting, and hospital length of stay. RESULTS A total of 62 patients were enrolled from November 2017 to February 2018. QL2 regional anesthesia compared with a sham intervention was not associated with a reduction in postoperative morphine dose equivalent (100.2 mg, 95% CI 68.9-131.5 versus 88.7 mg, 95% CI 59.3-118.0, p = 0.81, respectively). Compared to QL2 regional anesthesia, postoperative pain scores in the control group were lower although statistical significance was not consistent for all postoperative time points. Other secondary outcomes were comparable between both groups. CONCLUSION We did not observe a reduction in postoperative opioid administration at 24 h with a posterior quadratus lumborum block regional anesthesia in patients undergoing elective colorectal surgery.",2020,"Compared to QL2 regional anesthesia, postoperative pain scores in the control group were lower although statistical significance was not consistent for all postoperative time points.","['62 patients were enrolled from November 2017 to February 2018', 'patients undergoing colorectal surgery at the CHU de Québec-Université Laval', 'patients undergoing elective colorectal surgery', 'after colorectal resection']","['posterior quadratus lumborum block regional anesthesia', 'quadratus lumborum block regional anesthesia', 'regional QL2 anesthesia with 150\xa0mg of ropivacaine combined with standard analgesia or to QL2 with a sham intervention and standard analgesia', 'QL2']","['postoperative pain', 'QL2 regional anesthesia', 'postoperative opioid administration', 'QL2 regional anesthesia, postoperative pain scores', 'pain relief', 'opioid administration in the post-anesthesia care unit (PACU), at 48\xa0h and at hospital discharge, postoperative pain scores, delay in resumption of intestinal transit, nausea and vomiting, and hospital length of stay']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009369', 'cui_str': 'Colon and Rectal Surgery Specialty'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0555952', 'cui_str': 'Colorectal (qualifier value)'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}]","[{'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0002911', 'cui_str': 'Anesthesia, Regional'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0002911', 'cui_str': 'Anesthesia, Regional'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0021853', 'cui_str': 'Intestines'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting (disorder)'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}]",,0.245417,"Compared to QL2 regional anesthesia, postoperative pain scores in the control group were lower although statistical significance was not consistent for all postoperative time points.","[{'ForeName': 'Mélissa', 'Initials': 'M', 'LastName': 'Boulianne', 'Affiliation': 'Department of Surgery, Faculty of Medicine, Université Laval, Québec City, QC, Canada. melissa.boulianne.1@ulaval.ca.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Paquet', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine, Université Laval, Québec City, QC, Canada.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Veilleux', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine, Université Laval, Québec City, QC, Canada.'}, {'ForeName': 'Sébastien', 'Initials': 'S', 'LastName': 'Drolet', 'Affiliation': 'Department of Surgery, Faculty of Medicine, Université Laval, Québec City, QC, Canada.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Meunier', 'Affiliation': 'Department of Surgery, Faculty of Medicine, Université Laval, Québec City, QC, Canada.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Frigault', 'Affiliation': 'Department of Surgery, Faculty of Medicine, Université Laval, Québec City, QC, Canada.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Simonyan', 'Affiliation': 'CHU de Québec - Université Laval Research Centre, Clinical and Evaluative Research Platform, Québec City, QC, Canada.'}, {'ForeName': 'Alexis F', 'Initials': 'AF', 'LastName': 'Turgeon', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine, Université Laval, Québec City, QC, Canada.'}]",Surgical endoscopy,['10.1007/s00464-019-07184-0'] 891,30024796,Brief Standing Desk Intervention to Reduce Sedentary Behavior at a Physical Activity Conference in 2016.,"OBJECTIVES To examine the impact of environmental restructuring on attendees at a physical activity conference when provided with standing tables and given point-of-decision prompts (PODPs; e.g., health messages). METHODS This randomized controlled trial took place at the Health-Enhancing Physical Activity Europe 2016 conference in Belfast, United Kingdom, September 2016. We randomly allocated 14 oral sessions to either the intervention group (standing tables + PODPs; n = 7) or the control group (PODPs only; n = 7). Conference volunteers discreetly recorded the number of attendees standing and sitting and estimated the number of women and attendees aged 40 years or older. RESULTS There was a significant difference (P = .04) in the proportion of attendees standing during the intervention (mean = 16.8%; SD = 9.5%) than during control sessions (mean = 6.0%; SD = 5.8%). There was no differential response between gender and age groups in the proportion standing during intervention sessions (P > .05). CONCLUSIONS Providing standing tables may be a feasible and effective strategy to reduce sitting at physical activity conferences.",2018,"There was no differential response between gender and age groups in the proportion standing during intervention sessions (P > .05). ","['Health-Enhancing Physical Activity Europe 2016 conference in Belfast, United Kingdom, September 2016', 'women and attendees aged 40 years or older']","['Brief Standing Desk Intervention', 'intervention group (standing tables + PODPs; n\u2009=\u20097) or the control group (PODPs only; n\u2009=\u20097']",['proportion of attendees standing'],"[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0086047', 'cui_str': 'Conferences'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C3888057', 'cui_str': 'Stand'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1706074', 'cui_str': 'Table'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C3888057', 'cui_str': 'Stand'}]",,0.0503264,"There was no differential response between gender and age groups in the proportion standing during intervention sessions (P > .05). ","[{'ForeName': 'Jason J', 'Initials': 'JJ', 'LastName': 'Wilson', 'Affiliation': ""Jason J. Wilson, Conor Cunningham, Chris R. Cardwell, and Mark A. Tully are with the UK Clinical Research Collaboration Centre of Excellence for Public Health, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, United Kingdom. Deepti Adlakha is with the School of Natural and Built Environment, Queen's University Belfast. Paul Best is with the Centre for Evidence and Social Innovation, School of Social Sciences, Education and Social Work, Queen's University Belfast. Aoife Stephenson and Marie H. Murphy are with the Sport and Exercise Sciences Research Institute, School of Sport, Ulster University, Newtownabbey, United Kingdom.""}, {'ForeName': 'Deepti', 'Initials': 'D', 'LastName': 'Adlakha', 'Affiliation': ""Jason J. Wilson, Conor Cunningham, Chris R. Cardwell, and Mark A. Tully are with the UK Clinical Research Collaboration Centre of Excellence for Public Health, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, United Kingdom. Deepti Adlakha is with the School of Natural and Built Environment, Queen's University Belfast. Paul Best is with the Centre for Evidence and Social Innovation, School of Social Sciences, Education and Social Work, Queen's University Belfast. Aoife Stephenson and Marie H. Murphy are with the Sport and Exercise Sciences Research Institute, School of Sport, Ulster University, Newtownabbey, United Kingdom.""}, {'ForeName': 'Conor', 'Initials': 'C', 'LastName': 'Cunningham', 'Affiliation': ""Jason J. Wilson, Conor Cunningham, Chris R. Cardwell, and Mark A. Tully are with the UK Clinical Research Collaboration Centre of Excellence for Public Health, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, United Kingdom. Deepti Adlakha is with the School of Natural and Built Environment, Queen's University Belfast. Paul Best is with the Centre for Evidence and Social Innovation, School of Social Sciences, Education and Social Work, Queen's University Belfast. Aoife Stephenson and Marie H. Murphy are with the Sport and Exercise Sciences Research Institute, School of Sport, Ulster University, Newtownabbey, United Kingdom.""}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Best', 'Affiliation': ""Jason J. Wilson, Conor Cunningham, Chris R. Cardwell, and Mark A. Tully are with the UK Clinical Research Collaboration Centre of Excellence for Public Health, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, United Kingdom. Deepti Adlakha is with the School of Natural and Built Environment, Queen's University Belfast. Paul Best is with the Centre for Evidence and Social Innovation, School of Social Sciences, Education and Social Work, Queen's University Belfast. Aoife Stephenson and Marie H. Murphy are with the Sport and Exercise Sciences Research Institute, School of Sport, Ulster University, Newtownabbey, United Kingdom.""}, {'ForeName': 'Chris R', 'Initials': 'CR', 'LastName': 'Cardwell', 'Affiliation': ""Jason J. Wilson, Conor Cunningham, Chris R. Cardwell, and Mark A. Tully are with the UK Clinical Research Collaboration Centre of Excellence for Public Health, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, United Kingdom. Deepti Adlakha is with the School of Natural and Built Environment, Queen's University Belfast. Paul Best is with the Centre for Evidence and Social Innovation, School of Social Sciences, Education and Social Work, Queen's University Belfast. Aoife Stephenson and Marie H. Murphy are with the Sport and Exercise Sciences Research Institute, School of Sport, Ulster University, Newtownabbey, United Kingdom.""}, {'ForeName': 'Aoife', 'Initials': 'A', 'LastName': 'Stephenson', 'Affiliation': ""Jason J. Wilson, Conor Cunningham, Chris R. Cardwell, and Mark A. Tully are with the UK Clinical Research Collaboration Centre of Excellence for Public Health, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, United Kingdom. Deepti Adlakha is with the School of Natural and Built Environment, Queen's University Belfast. Paul Best is with the Centre for Evidence and Social Innovation, School of Social Sciences, Education and Social Work, Queen's University Belfast. Aoife Stephenson and Marie H. Murphy are with the Sport and Exercise Sciences Research Institute, School of Sport, Ulster University, Newtownabbey, United Kingdom.""}, {'ForeName': 'Marie H', 'Initials': 'MH', 'LastName': 'Murphy', 'Affiliation': ""Jason J. Wilson, Conor Cunningham, Chris R. Cardwell, and Mark A. Tully are with the UK Clinical Research Collaboration Centre of Excellence for Public Health, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, United Kingdom. Deepti Adlakha is with the School of Natural and Built Environment, Queen's University Belfast. Paul Best is with the Centre for Evidence and Social Innovation, School of Social Sciences, Education and Social Work, Queen's University Belfast. Aoife Stephenson and Marie H. Murphy are with the Sport and Exercise Sciences Research Institute, School of Sport, Ulster University, Newtownabbey, United Kingdom.""}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Tully', 'Affiliation': ""Jason J. Wilson, Conor Cunningham, Chris R. Cardwell, and Mark A. Tully are with the UK Clinical Research Collaboration Centre of Excellence for Public Health, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, United Kingdom. Deepti Adlakha is with the School of Natural and Built Environment, Queen's University Belfast. Paul Best is with the Centre for Evidence and Social Innovation, School of Social Sciences, Education and Social Work, Queen's University Belfast. Aoife Stephenson and Marie H. Murphy are with the Sport and Exercise Sciences Research Institute, School of Sport, Ulster University, Newtownabbey, United Kingdom.""}]",American journal of public health,['10.2105/AJPH.2018.304515'] 892,29804469,The effect of zinc and vitamin E cosupplementation on metabolic status and its related gene expression in patients with gestational diabetes.,"Objective: The aim of this study was to determine the effects of zinc and vitamin E cosupplementation on metabolic status and gene expression related to insulin and lipid metabolism in women with gestational diabetes mellitus (GDM). Methods: Fifty-four women, in the age range of 18-40 years, diagnosed with GDM were recruited for this randomized, double-blinded, placebo-controlled trial. Subjects were randomly allocated into two intervention groups to either taking 233 mg/day Zinc Gluconate plus 400-IU/day vitamin E supplements or placebo ( n  = 27 each group) for 6 weeks. Gene expression related to insulin and lipid metabolism was evaluated in peripheral blood mononuclear cells (PBMCs) of women with GDM using RT-PCR method. Results: Participants who received zinc plus vitamin E supplements had significantly lower serum insulin levels ( β  = -3.81; 95% CI, -5.90, -1.72; p  = .001), homeostasis model of assessment-insulin resistance ( β  = -0.96; 95% CI, -1.54, -0.38; p  = .002), serum total-cholesterol ( β  = -8.56; 95% CI, -16.69, -0.43; p  = .03) and low density lipoprotein-cholesterol (LDL)-cholesterol ( β  = -8.72; 95% CI, -15.27, -2.16; p  = .01), and higher quantitative insulin sensitivity check index ( β  = 0.01; 95% CI, 0.005, 0.02; p  = .007) compared with the placebo. Moreover, zinc and vitamin E cosupplementation upregulated gene expression of peroxisome proliferator-activated receptor gamma (PPAR-γ; p  = .03) and low-density lipoprotein receptor (LDLR; p  = .04) compared with the placebo. Though, zinc and vitamin E combination did not affect other metabolic parameters. Conclusions: Overall, zinc and vitamin E cosupplementation for 6 weeks in women with GDM significantly improved insulin metabolism, lipid profile, and the gene expression levels of PPAR-γ and LDLR.",2019,"RESULTS Participants who received zinc plus vitamin E supplements had significantly lower serum insulin levels (β = -3.81; 95% CI, -5.90, -1.72; p = .001), homeostasis model of assessment-insulin resistance (","['patients with gestational diabetes', 'Fifty-four women, in the age range of 18-40\xa0years, diagnosed with GDM', 'women with gestational diabetes mellitus (GDM']","['placebo', 'zinc and vitamin E cosupplementation', 'zinc and vitamin E combination', 'taking 233\u2009mg/day Zinc Gluconate\xa0plus 400-IU/day vitamin E supplements or placebo', 'zinc plus vitamin E supplements']","['insulin metabolism, lipid profile, and the gene expression levels of PPAR-γ and LDLR', 'low density lipoprotein-cholesterol (LDL)-cholesterol', 'serum insulin levels', 'low-density lipoprotein receptor', 'peripheral blood mononuclear cells (PBMCs', 'homeostasis model of assessment-insulin resistance ', 'higher quantitative insulin sensitivity check index', 'metabolic status and gene expression related to insulin and lipid metabolism', 'serum total-cholesterol (β\u2009']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439671', 'cui_str': 'Gestational (qualifier value)'}, {'cui': 'C4517807', 'cui_str': 'Fifty-four'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0085207', 'cui_str': 'Diabetes, Pregnancy-Induced'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0439422', 'cui_str': 'mg/day'}, {'cui': 'C0149381', 'cui_str': 'Zinc Gluconate'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0439465', 'cui_str': 'IU/day'}, {'cui': 'C3661607', 'cui_str': 'Vitamin E supplement'}]","[{'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0017262', 'cui_str': 'Gene Expression'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0166418', 'cui_str': 'Peroxisome Proliferator-Activated Receptors'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0034821', 'cui_str': 'Lipoprotein LDL Receptors'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0019868', 'cui_str': 'Autoregulation'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",54.0,0.734597,"RESULTS Participants who received zinc plus vitamin E supplements had significantly lower serum insulin levels (β = -3.81; 95% CI, -5.90, -1.72; p = .001), homeostasis model of assessment-insulin resistance (","[{'ForeName': 'Vahidreza', 'Initials': 'V', 'LastName': 'Ostadmohammadi', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Mansooreh', 'Initials': 'M', 'LastName': 'Samimi', 'Affiliation': 'Department of Gynecology and Obstetrics, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Moein', 'Initials': 'M', 'LastName': 'Mobini', 'Affiliation': 'Department of Kinesiology, University of Calgary, Calgary, Canada.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Zarezade Mehrizi', 'Affiliation': 'Department of Gynecology and Obstetrics, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Esmat', 'Initials': 'E', 'LastName': 'Aghadavod', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Chamani', 'Affiliation': 'Department of Gynecology and Obstetrics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Dastorani', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.'}]","The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians",['10.1080/14767058.2018.1481952'] 893,29804486,Subcuticular interrupted versus continuous skin suturing in elective cesarean section in obese women: a randomized controlled trial.,"Objective: To compare the interrupted subcuticular skin closure with continuous one in obese women undergoing cesarean delivery. Materials and methods: A randomized controlled study conducted on 169 obese women with term uncomplicated singleton pregnancy who underwent elective cesarean delivery. They were randomized to either skin closure through continuous subcuticular sutures using vicryl 3/0 or interrupted subcuticular suturing using vicryl 3/0. The primary outcome parameter was occurrence of wound infection. Secondary outcomes included other skin complications, postoperative pain, operative duration and hospital stay Results: There was a statistically higher number of cases with wound hematoma (20 vs. 10, p  = .04), infection (30 vs. 15, p  = .008) and those who needed reclosure of wound (8 vs. 0, p  = .004) in the continuous when compared to women in the interrupted subcuticular group, respectively. Healing with secondary intension was significantly higher in women in the continuous subcuticular group (52 vs. 26, respectively, p  < .001). The number of cases with wound seroma and keloid formation was not statistically different between the two groups (25 vs. 19, p  = .272 and 12 vs. 5, p  = .069 in the continuous vs. interrupted groups, respectively). The duration of CS was longer in those who underwent interrupted closure when compared to continuous ones. However, that was statistically insignificant (40.95 + 6.376 vs. 37.05 + 6.455, p  = 0.14). Conclusions: Most surgical wound complications were reduced if skin closure with continuous subcuticular sutures is replaced with interrupted one.",2019,"The number of cases with wound seroma and keloid formation was not statistically different between the two groups (25 vs. 19, p = .272 and 12 vs. 5, p = .069 in the continuous vs. interrupted groups, respectively).","['169 obese women with term uncomplicated singleton pregnancy who underwent elective cesarean delivery', 'obese women', 'obese women undergoing cesarean delivery']","['skin closure through continuous subcuticular sutures using vicryl 3/0 or interrupted subcuticular suturing using vicryl 3/0', 'Subcuticular interrupted versus continuous skin suturing', 'interrupted subcuticular skin closure', 'elective cesarean section']","['Healing with secondary intension', 'number of cases with wound hematoma', 'infection', 'occurrence of wound infection', 'duration of CS', 'number of cases with wound seroma and keloid formation', 'needed reclosure of wound', 'skin complications, postoperative pain, operative duration and hospital stay Results']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}, {'cui': 'C1384674', 'cui_str': 'Deliveries by cesarean (finding)'}]","[{'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0185003', 'cui_str': 'Reparative closure (procedure)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0563304', 'cui_str': 'Subcuticular (qualifier value)'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture (procedure)'}, {'cui': 'C0947694', 'cui_str': 'Vicryl'}, {'cui': 'C0443239', 'cui_str': 'Interrupted (qualifier value)'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}]","[{'cui': 'C0205249', 'cui_str': 'Healed (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0043241', 'cui_str': 'Wound Infection'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0406831', 'cui_str': 'Wound seroma (finding)'}, {'cui': 'C0022548', 'cui_str': 'Keloid'}, {'cui': 'C0439634', 'cui_str': 'Formations (qualifier value)'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",169.0,0.170396,"The number of cases with wound seroma and keloid formation was not statistically different between the two groups (25 vs. 19, p = .272 and 12 vs. 5, p = .069 in the continuous vs. interrupted groups, respectively).","[{'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'Maged', 'Affiliation': 'Department of Obstetrics and Gynecology, Cairo University, Giza, Egypt.'}, {'ForeName': 'Mohamed N', 'Initials': 'MN', 'LastName': 'Mohesen', 'Affiliation': 'Department of Obstetrics and Gynecology, Beni Suef University, Beni Suef, Egypt.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Elhalwagy', 'Affiliation': 'Department of Obstetrics and Gynecology, Cairo University, Giza, Egypt.'}, {'ForeName': 'Hoda', 'Initials': 'H', 'LastName': 'Abdelaal', 'Affiliation': 'Department of Obstetrics and Gynecology, Cairo University, Giza, Egypt.'}, {'ForeName': 'Maged', 'Initials': 'M', 'LastName': 'Almohamady', 'Affiliation': 'Department of Obstetrics and Gynecology, Cairo University, Giza, Egypt.'}, {'ForeName': 'Ali A', 'Initials': 'AA', 'LastName': 'Abdellatif', 'Affiliation': 'Department of Obstetrics and Gynecology, Cairo University, Giza, Egypt.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Alsawaf', 'Affiliation': 'Department of Obstetrics and Gynecology, Cairo University, Giza, Egypt.'}, {'ForeName': 'Khaled Abdel', 'Initials': 'KA', 'LastName': 'Malek', 'Affiliation': 'Department of Obstetrics and Gynecology, Cairo University, Giza, Egypt.'}, {'ForeName': 'Hala', 'Initials': 'H', 'LastName': 'Nabil', 'Affiliation': 'Department of Obstetrics and Gynecology, Cairo University, Giza, Egypt.'}, {'ForeName': 'Radwa M', 'Initials': 'RM', 'LastName': 'Fahmy', 'Affiliation': 'Department of Obstetrics and Gynecology, Cairo University, Giza, Egypt.'}, {'ForeName': 'Heba', 'Initials': 'H', 'LastName': 'Wageih', 'Affiliation': 'Department of Obstetrics and Gynecology, Cairo University, Giza, Egypt.'}]","The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians",['10.1080/14767058.2018.1481950'] 894,30117122,Both 50 and 30 Hz continuous theta burst transcranial magnetic stimulation depresses the cerebellum.,"The cerebellum is implicated in the pathophysiology of numerous movement disorders, which makes it an attractive target for noninvasive neurostimulation. Continuous theta burst stimulation (cTBS) can induce long lasting plastic changes in human brain; however, the efficacy of different simulation protocols has not been investigated at the cerebellum. Here, we compare a traditional 50-Hz and a modified 30-Hz cTBS protocols at modulating cerebellar activity in healthy subjects. Seventeen healthy adults participated in two testing sessions where they received either 50-Hz (cTBS 50 ) or 30-Hz (cTBS 30 ) cerebellar cTBS. Cerebellar brain inhibition (CBI), a measure of cerebello-thalamocortical pathway strength, and motor evoked potentials (MEP) were measured in the dominant first dorsal interosseous muscle before and after (up to ~ 40 min) cerebellar cTBS. Both cTBS protocols induced cerebellar depression, indicated by significant reductions in CBI (P < 0.001). No differences were found between protocols (cTBS 50 and cTBS 30 ) at any time point (P = 0.983). MEP amplitudes were not significantly different following either cTBS protocol (P = 0.130). The findings show cerebellar excitability to be equally depressed by 50-Hz and 30-Hz cTBS in heathy adults and support future work to explore the efficacy of different cerebellar cTBS protocols in movement disorder patients where cerebellar depression could provide therapeutic benefits.",2019,"Both cTBS protocols induced cerebellar depression, indicated by significant reductions in CBI (P < 0.001).","['human brain', 'healthy subjects', 'Seventeen healthy adults']","['50-Hz', 'traditional 50-Hz and a modified 30-Hz cTBS protocols', 'Continuous theta burst stimulation (cTBS']","['CBI', 'cerebellar depression', 'Cerebellar brain inhibition (CBI), a measure of cerebello-thalamocortical pathway strength, and motor evoked potentials (MEP', 'MEP amplitudes']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0450331', 'cui_str': '17 (qualifier value)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}]","[{'cui': 'C0259095', 'cui_str': 'C(2)BI'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0282617', 'cui_str': 'Evoked Potentials, Motor'}]",17.0,0.0268628,"Both cTBS protocols induced cerebellar depression, indicated by significant reductions in CBI (P < 0.001).","[{'ForeName': 'Nicholas D J', 'Initials': 'NDJ', 'LastName': 'Strzalkowski', 'Affiliation': 'Department of Clinical Neurosciences, Faculty of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, T2N4N1, Canada.'}, {'ForeName': 'Aaron D', 'Initials': 'AD', 'LastName': 'Chau', 'Affiliation': 'Department of Clinical Neurosciences, Faculty of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, T2N4N1, Canada.'}, {'ForeName': 'Liu Shi', 'Initials': 'LS', 'LastName': 'Gan', 'Affiliation': 'Department of Clinical Neurosciences, Faculty of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, T2N4N1, Canada.'}, {'ForeName': 'Zelma H T', 'Initials': 'ZHT', 'LastName': 'Kiss', 'Affiliation': 'Department of Clinical Neurosciences, Faculty of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, T2N4N1, Canada. zkiss@ucalgary.ca.'}]","Cerebellum (London, England)",['10.1007/s12311-018-0971-0'] 895,29962180,Effects of rosuvastatin in combination with nimodipine in patients with mild cognitive impairment caused by cerebral small vessel disease.,"BACKGROUND To investigate the clinical efficiency and safeness of the combination of rosuvastatin and nimodipine in treating mild cognitive impairment of cerebral small vessel disease (CSVD) patients. METHODS A total of 120 patients with mild cognitive impairment caused by CSVD were divided randomly into two groups: an observation group and a control group, each of which had 60 patients. In the observation group, patients were given rosuvastatin in combination with nimodipine, and other patients were given nimodipine in the control group. For the two groups, the course of treatment was six months. Before and after treatments, levels of total cholesterol (TC), triacylglycerol (TG), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), MMP-9 and high sensitivity C reactive protein (hs-CRP) were measured. Montreal Cognitive Assessment (MoCA) and activities of daily living (ADL) were also evaluated. Incidence of adverse reactions were compared between two groups. RESULTS The levels of TG, TC and LDL-C were decreased after treatment in the observation group (P<0.01), and these after-treatment levels were lower than the control group. Additionally, after treatment, the levels of MMP-9 and hs-CRP were significant lower in the observation group than the control group. The MoCA and ADL scores were higher in the observation group than the control group after treatment (P<0.05). Moreover, the overall effective rate were higher in the observation group (91.7%) than the control group (65.0%) (P<0.01), while there was no significant difference of the rate of adverse reactions between the observation group and the control one (10.0% vs. 8.3%) (P>0.05). CONCLUSIONS The combination of rosuvastatin and nimodipine was safe and effective in treating mild cognitive impairment of CSVD patients.",2019,"The levels of TG, TC and LDL-C were decreased after treatment in the observation group (P<0.01), and these after-treatment levels were lower than the control group.","['patients with mild cognitive impairment caused by CSVD', 'mild cognitive impairment of CSVD patients', '120 patients with mild cognitive impairment caused by CSVD']","['Nimodipine', 'Rosuvastatin', 'rosuvastatin', 'nimodipine', 'rosuvastatin and nimodipine']","['levels of TC (total cholesterol), TG (triacylglycerol), LDL-C (low density lipoprotein-cholesterol), HDL-C (high density lipoprotein-cholesterol), MMP-9 and hs-CRP (high sensitivity C reactive protein', 'Incidence of adverse reactions', 'MoCA and ADL scores', 'MoCA (Montreal Cognitive Assessment) and ADL (activities of daily living', 'overall effective rate', 'levels of TG, TC and LDL-C', 'levels of MMP-9 and hs-CRP', 'rate of adverse reactions']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}]","[{'cui': 'C0028094', 'cui_str': 'Nimodipine'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0023822', 'cui_str': 'High Density Lipoprotein Cholesterol'}, {'cui': 'C0623362', 'cui_str': 'MMPs'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}, {'cui': 'C0001288', 'cui_str': 'ADL'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3496286'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}]",120.0,0.0241155,"The levels of TG, TC and LDL-C were decreased after treatment in the observation group (P<0.01), and these after-treatment levels were lower than the control group.","[{'ForeName': 'Junling', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Department of Internal Medicine, Hanchuan People's Hospital of Hubei Province, Hanchuan, China.""}, {'ForeName': 'Nannuan', 'Initials': 'N', 'LastName': 'Liu', 'Affiliation': 'Department of Neurology, Renmin Hospital, Hubei University of Medicine, Shiyan, China.'}, {'ForeName': 'Chaoqun', 'Initials': 'C', 'LastName': 'Yang', 'Affiliation': ""Department of Neurology, Hanchuan People's Hospital of Hubei Province, Hanchuan, China - 1902763993@qq.com.""}]",Panminerva medica,['10.23736/S0031-0808.18.03475-4'] 896,29911893,Effects of an intensive long-term prevention programme after myocardial infarction - a randomized trial.,"BACKGROUND Long-term risk factor control after myocardial infarction (MI) is currently inadequate and there is an unmet need for effective secondary prevention programmes. DESIGN AND METHODS It was the aim of the study to compare a 12-month intensive prevention programme (IPP), coordinated by prevention assistants and including education sessions, telephone visits and telemetric risk factor control, with usual care after MI. Three hundred and ten patients were randomized to IPP vs. usual care one month after hospital discharge for MI in two German heart centres. Primary study endpoint was the IPP Prevention Score (0-15 points) quantifying global risk factor control. RESULTS Global risk factor control was strongly improved directly after MI before the beginning of the randomized study (30% increase IPP Prevention Score). During the 12-month course of the randomized trial the IPP Prevention Score was improved by a further 14.3% in the IPP group ( p < 0.001), while it decreased by 11.8% in the usual care group ( p < 0.001). IPP significantly reduced smoking, low-density lipoprotein cholesterol, systolic blood pressure and physical inactivity compared with usual care ( p < 0.05). Step counters with online documentation were used by the majority of patients (80%). Quality of life was significantly improved by IPP ( p < 0.05). The composite endpoint of adverse clinical events was slightly lower in the IPP group during 12 months (13.8% vs. 18.9%, p = 0.25). CONCLUSIONS A novel intensive prevention programme after MI, coordinated by prevention assistants and using personal teachings and telemetric strategies for 12 months, was significantly superior to usual care in providing sustainable risk factor control and better quality of life.",2019,"IPP significantly reduced smoking, low-density lipoprotein cholesterol, systolic blood pressure and physical inactivity compared with usual care ( p < 0.05).",['Three hundred and ten patients'],"['intensive prevention programme (IPP), coordinated by prevention assistants and including education sessions, telephone visits and telemetric risk factor control, with usual care after MI', 'intensive long-term prevention programme', 'IPP', 'IPP vs. usual care one month after hospital discharge for MI']","['Quality of life', 'IPP Prevention Score (0-15 points) quantifying global risk factor control', 'IPP Prevention Score', 'Global risk factor control', 'smoking, low-density lipoprotein cholesterol, systolic blood pressure and physical inactivity', 'quality of life', 'adverse clinical events']","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0427184', 'cui_str': 'No incoordination'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0063506', 'cui_str': 'IPP'}, {'cui': 'C4082115', 'cui_str': 'One month (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}]","[{'cui': 'C0034380'}, {'cui': 'C0063506', 'cui_str': 'IPP'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}]",310.0,0.0562838,"IPP significantly reduced smoking, low-density lipoprotein cholesterol, systolic blood pressure and physical inactivity compared with usual care ( p < 0.05).","[{'ForeName': 'Harm', 'Initials': 'H', 'LastName': 'Wienbergen', 'Affiliation': '1 Bremen Institute for Heart and Circulation Research (BIHKF) at the Klinikum Links der Weser, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Fach', 'Affiliation': '1 Bremen Institute for Heart and Circulation Research (BIHKF) at the Klinikum Links der Weser, Germany.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Meyer', 'Affiliation': '2 Klinikum Oldenburg, Department for Cardiology, European Medical School Oldenburg-Groningen, Germany.'}, {'ForeName': 'Jochen', 'Initials': 'J', 'LastName': 'Meyer', 'Affiliation': '3 OFFIS - Institute for Information Technology Oldenburg, Germany.'}, {'ForeName': 'Janina', 'Initials': 'J', 'LastName': 'Stehmeier', 'Affiliation': '1 Bremen Institute for Heart and Circulation Research (BIHKF) at the Klinikum Links der Weser, Germany.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Backhaus', 'Affiliation': '1 Bremen Institute for Heart and Circulation Research (BIHKF) at the Klinikum Links der Weser, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Michel', 'Affiliation': '1 Bremen Institute for Heart and Circulation Research (BIHKF) at the Klinikum Links der Weser, Germany.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Krämer', 'Affiliation': '1 Bremen Institute for Heart and Circulation Research (BIHKF) at the Klinikum Links der Weser, Germany.'}, {'ForeName': 'Rico', 'Initials': 'R', 'LastName': 'Osteresch', 'Affiliation': '1 Bremen Institute for Heart and Circulation Research (BIHKF) at the Klinikum Links der Weser, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Schmucker', 'Affiliation': '1 Bremen Institute for Heart and Circulation Research (BIHKF) at the Klinikum Links der Weser, Germany.'}, {'ForeName': 'Henning', 'Initials': 'H', 'LastName': 'Haase', 'Affiliation': '4 RehaZentrum Bremen, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Härle', 'Affiliation': '2 Klinikum Oldenburg, Department for Cardiology, European Medical School Oldenburg-Groningen, Germany.'}, {'ForeName': 'Albrecht', 'Initials': 'A', 'LastName': 'Elsässer', 'Affiliation': '2 Klinikum Oldenburg, Department for Cardiology, European Medical School Oldenburg-Groningen, Germany.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Hambrecht', 'Affiliation': '1 Bremen Institute for Heart and Circulation Research (BIHKF) at the Klinikum Links der Weser, Germany.'}]",European journal of preventive cardiology,['10.1177/2047487318781109'] 897,31642718,Effect of prophylactic endoscopic closure for an artificial ulceration after colorectal endoscopic submucosal dissection: a randomized controlled trial.,"Objective: Endoscopic submucosal dissection (ESD) is now commonly performed as a treatment for not only gastric tumor but also colorectal tumor. However, colorectal ESD has a substantial risk of complications, including post-ESD electrocoagulation syndrome, bowel perforation and bleeding. This study aimed to investigate whether prophylactic endoscopic closure can reduce the occurrence of complications after colorectal ESD. Materials and methods: Patients who underwent colorectal ESD in our unit were randomly assigned to either of two groups. Prophylactic endoscopic closure for an artificial ulceration after ESD was performed in group I but not in group II. After the procedure, the incidence of complications, visual analog scale (VAS) score for abdominal pain, and laboratory findings were investigated. Results: Of the 220 patients (110 per group) enrolled in this study, 137 were men. No significant differences were found in age, sex, comorbidity, medication history, tumor location, size of resected specimen, and pathologic result between the two groups. No significant difference was found in ESD outcomes, including hospitalization period, laboratory findings, VAS score for abdominal pain, incidence of surgical operation, and incidence of post-ESD complications, between the two groups. Conclusions: Contrary to popular belief, prophylactic endoscopic closure after colorectal ESD does not decrease the incidence of complications, and it does not ameliorate inflammatory response and abdominal pain. Clinical trial registration number: KCT0001666.",2019,"No significant difference was found in ESD outcomes, including hospitalization period, laboratory findings, VAS score for abdominal pain, incidence of surgical operation, and incidence of post-ESD complications, between the two groups. ","['artificial ulceration after colorectal endoscopic submucosal dissection', ' 137 were men', '220 patients (110 per group) enrolled in this study', 'Patients who underwent colorectal ESD in our unit']","['prophylactic endoscopic closure', 'Endoscopic submucosal dissection (ESD', 'Prophylactic endoscopic closure']","['incidence of complications, visual analog scale (VAS) score for abdominal pain, and laboratory findings', 'ESD outcomes, including hospitalization period, laboratory findings, VAS score for abdominal pain, incidence of surgical operation, and incidence of post-ESD complications', 'age, sex, comorbidity, medication history, tumor location, size of resected specimen, and pathologic result']","[{'cui': 'C2004457', 'cui_str': 'Artificial (qualifier value)'}, {'cui': 'C3887532', 'cui_str': 'Ulceration (qualifier value)'}, {'cui': 'C0555952', 'cui_str': 'Colorectal (qualifier value)'}, {'cui': 'C1700929', 'cui_str': 'Endoscopic Submucosal Dissection'}, {'cui': 'C4517569', 'cui_str': 'One hundred and thirty-seven'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C4517650', 'cui_str': '220 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}]","[{'cui': 'C0445202', 'cui_str': 'Prophylactic (qualifier value)'}, {'cui': 'C0185003', 'cui_str': 'Reparative closure (procedure)'}, {'cui': 'C1700929', 'cui_str': 'Endoscopic Submucosal Dissection'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C2607943', 'cui_str': 'findings'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0450429', 'cui_str': 'Location (attribute)'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C1521733', 'cui_str': 'Pathologic (qualifier value)'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",137.0,0.0513005,"No significant difference was found in ESD outcomes, including hospitalization period, laboratory findings, VAS score for abdominal pain, incidence of surgical operation, and incidence of post-ESD complications, between the two groups. ","[{'ForeName': 'Sang Pyo', 'Initials': 'SP', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea.'}, {'ForeName': 'In-Kyung', 'Initials': 'IK', 'LastName': 'Sung', 'Affiliation': 'Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Jeong Hwan', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Sun-Young', 'Initials': 'SY', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Hyung Seok', 'Initials': 'HS', 'LastName': 'Park', 'Affiliation': 'Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.'}]",Scandinavian journal of gastroenterology,['10.1080/00365521.2019.1674918'] 898,29843553,Efficacy of ferrous bis -glycinate versus ferrous glycine sulfate in the treatment of iron deficiency anemia with pregnancy: a randomized double-blind clinical trial.,"Objective: The aim of this study is to compare the efficacy and tolerability of oral ferrous bis -glycinate versus ferrous glycine sulfate in the treatment of iron deficiency anemia (IDA) with pregnancy. Methods: A randomized double-blind clinical trial (NCT02590224) conducted at a tertiary University Hospital in the period between 1 January 2016 and 31 July 2017 included pregnant women at 14-18 weeks of gestation with mild to moderate IDA. Patients were randomized into two groups: (Group I) received oral ferrous bis -glycinate tablets once daily for eight consecutive weeks and (Group II) received oral ferrous glycine sulfate capsules in the same dose and duration. The primary outcome of the study was the rate of increase of hemoglobin (HB) level after 8 weeks of iron treatment. Results: The study included 187 women in the final analysis. The mean increase in HB level after 8 weeks of treatment in ferrous bis -glycinate group was 2.48 ± 0.12 g/dL versus 1.32 ± 0.18 g/dL in ferrous glycine sulfate group ( p  ≤ .0001). The percentage of women with HB level more than 11 g/dL after 8 weeks of treatment was 89.2% in ferrous bis -glycinate group versus 71.3% in ferrous glycine sulfate group ( p  < .0001). The rate of adverse effects was significantly higher in ferrous glycine sulfate group ( p  = .001). Conclusions: Pregnant women with second trimester IDA could be supplied with ferrous bis -glycinate which is more efficient in increasing HB level. Moreover, it has tolerable adverse effects and high compliance than ferrous glycine sulfate.",2019,"The rate of adverse effects was significantly higher in ferrous glycine sulfate group (p = .001). ","['iron deficiency anemia (IDA) with pregnancy', 'iron deficiency anemia with pregnancy', 'Pregnant women with second trimester IDA', '187 women in the final analysis', 'tertiary University Hospital in the period between 1 January 2016 and 31 July 2017 included pregnant women at 14-18\u2009weeks of gestation with mild to moderate IDA']","['ferrous bis-glycinate versus ferrous glycine sulfate', 'oral ferrous glycine sulfate capsules', 'oral ferrous bis-glycinate tablets', 'ferrous glycine sulfate', 'oral ferrous bis-glycinate versus ferrous glycine sulfate']","['rate of adverse effects', 'efficacy and tolerability', 'percentage of women with HB level', 'rate of increase of hemoglobin (HB) level', 'HB level']","[{'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia (disorder)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0032980', 'cui_str': 'Midtrimester'}, {'cui': 'C4517618', 'cui_str': '187 (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}]","[{'cui': 'C1872096', 'cui_str': 'bis(phenylacetylarginine)'}, {'cui': 'C0357059', 'cui_str': 'Ferrous glycine sulfate'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}]","[{'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}]",187.0,0.397338,"The rate of adverse effects was significantly higher in ferrous glycine sulfate group (p = .001). ","[{'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'Abbas', 'Affiliation': 'Department of Obstetrics & Gynecology, Faculty of Medicine, Assiut University, Egypt.'}, {'ForeName': 'Safaa A', 'Initials': 'SA', 'LastName': 'Abdelbadee', 'Affiliation': 'Department of Obstetrics & Gynecology, Faculty of Medicine, Assiut University, Egypt.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Alanwar', 'Affiliation': 'Department of Obstetrics & Gynecology, Faculty of Medicine, Ain Shams University, Egypt.'}, {'ForeName': 'Sayed', 'Initials': 'S', 'LastName': 'Mostafa', 'Affiliation': 'Department of Obstetrics & Gynecology, Faculty of Medicine, Assiut University, Egypt.'}]","The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians",['10.1080/14767058.2018.1482871'] 899,31637467,A self-emulsifying Omega-3 ethyl ester formulation (AquaCelle) significantly improves eicosapentaenoic and docosahexaenoic acid bioavailability in healthy adults.,"PURPOSE Application of intelligent formulation design has the ability to address the poor bioavailability and improve the fasted state bioavailability of fish oils. In this study we assessed the ability of a self-emulsifying drug delivery system (SEDDS), AquaCelle ® , as an additive to enhance the oral absorption of Omega-3 ethyl esters (EE) in healthy subjects under low-fat diet conditions. METHODS Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) EE were formulated with AquaCelle ® . A single dose (680 mg dose of oil containing 272 mg of EPA EE and 204 mg of DHA EE), randomized, double-blind, study measured uptake of EPA and DHA over 24 h in healthy adults. Participants were randomized into two groups, receiving either the SEDDS AquaCelle ® fish oil formulation or the unformulated fish oil EE as control. RESULTS The AquaCelle ® fish oil EE formulation demonstrated instant and complete emulsification on addition to water to produce an emulsion with an average diameter of 43 μm, compared to the oil alone which did not emulsify. The study revealed a significant difference in absorption (C max and AUC 0-24h ) between the AquaCelle ® group and the control group. The AquaCelle ® group was capable of increasing maximum plasma concentrations and absorption (AUC 0-24h ) of total Omega-3 (EPA + DHA) 3.7- and 7.1-fold, respectively, compared to the control. CONCLUSION Formulating Omega-3 EE with a SEDSS concentrate (AquaCelle ® ) demonstrated a significant improvement in the oral absorption of Omega-3 fatty acids without requiring a high-fat meal.",2020,"The AquaCelle ® group was capable of increasing maximum plasma concentrations and absorption (AUC 0-24h ) of total Omega-3 (EPA + DHA) 3.7- and 7.1-fold, respectively, compared to the control. ","['healthy subjects under low-fat diet conditions', 'healthy adults']","['Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) EE', 'oil containing 272\xa0mg of EPA EE and 204\xa0mg of DHA EE', 'Formulating Omega-3 EE with a SEDSS concentrate (AquaCelle ® ', 'self-emulsifying drug delivery system (SEDDS), AquaCelle ®', 'Omega-3 ethyl esters (EE', 'self-emulsifying Omega-3 ethyl ester formulation (AquaCelle', 'SEDDS AquaCelle ® fish oil formulation or the unformulated fish oil EE']","['absorption (C max and AUC 0-24h ', 'eicosapentaenoic and docosahexaenoic acid bioavailability', 'oral absorption of Omega-3 fatty acids', 'maximum plasma concentrations and absorption (AUC 0-24h ) of total Omega-3 (EPA\u2009+\u2009DHA']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0242970', 'cui_str': 'Fat-Restricted Diet'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic Acid'}, {'cui': 'C0556150', 'cui_str': 'docosahexaenoic acid'}, {'cui': 'C0028908', 'cui_str': 'Oils'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0059057', 'cui_str': 'EPA (prealbumin)'}, {'cui': 'C1719844', 'cui_str': 'Greek letter omega'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C3884644', 'cui_str': '(trimethylsilyl)ethyl ester'}, {'cui': 'C0016157', 'cui_str': 'Fish Oils'}]","[{'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0556150', 'cui_str': 'docosahexaenoic acid'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1719844', 'cui_str': 'Greek letter omega'}, {'cui': 'C0059057', 'cui_str': 'EPA (prealbumin)'}]",,0.0520396,"The AquaCelle ® group was capable of increasing maximum plasma concentrations and absorption (AUC 0-24h ) of total Omega-3 (EPA + DHA) 3.7- and 7.1-fold, respectively, compared to the control. ","[{'ForeName': 'Kristen E', 'Initials': 'KE', 'LastName': 'Bremmell', 'Affiliation': 'School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, 5000, Australia. Kristen.bremmell@unisa.edu.au.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Briskey', 'Affiliation': 'RDC Clinical Pty Ltd, Brisbane, QLD, 4005, Australia.'}, {'ForeName': 'Tahlia R', 'Initials': 'TR', 'LastName': 'Meola', 'Affiliation': 'School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, 5000, Australia.'}, {'ForeName': 'Alistair', 'Initials': 'A', 'LastName': 'Mallard', 'Affiliation': 'School of Human Movement and Nutrition Sciences, University of Queensland, Brisbane, QLD, 4072, Australia.'}, {'ForeName': 'Clive A', 'Initials': 'CA', 'LastName': 'Prestidge', 'Affiliation': 'School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, 5000, Australia.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Rao', 'Affiliation': 'RDC Clinical Pty Ltd, Brisbane, QLD, 4005, Australia.'}]",European journal of nutrition,['10.1007/s00394-019-02118-x'] 900,29766292,Gut-derived lipopolysaccharides increase post-prandial oxidative stress via Nox2 activation in patients with impaired fasting glucose tolerance: effect of extra-virgin olive oil.,"PURPOSE Post-prandial phase is characterized by enhanced oxidative stress but the underlying mechanism is unclear. We investigated if gut-derived lipopolysaccharide (LPS) is implicated in this phenomenon and the effect of extra virgin olive oil (EVOO) in patients with impaired fasting glucose (IFG). METHODS This is a randomized cross-over interventional study including 30 IFG patients, to receive a lunch with or without 10 g of EVOO. Serum LPS, Apo-B48, markers of oxidative stress such as oxidized LDL (oxLDL) and soluble Nox2-derived peptide (sNox2-dp), a marker of nicotinamide-adenine-dinucleotide-phosphate oxidase isoform Nox2 activation, and plasma polyphenols were determined before, 60 and 120 min after lunch. RESULTS In patients not given EVOO oxidative stress as assessed by sNox2-dp and oxLDL significantly increased at 60 and 120 min concomitantly with an increase of LPS and Apo-B48. In these patients, changes of LPS were correlated with Apo-B48 (Rs = 0.542, p = 0.002) and oxLDL (Rs = 0.463, p = 0.010). At 120 min, LPS (β - 15.73, p < 0.001), Apo-B48 (β - 0.14, p = 0.004), sNox2-dp (β - 5.47, p = 0.030), and oxLDL (β - 42.80, p < 0.001) significantly differed between the two treatment groups. An inverse correlation was detected between polyphenols and oxLDL (R - 0.474, p < 0.005). In vitro study showed that LPS, at the same concentrations found in the human circulation, up-regulated Nox2-derived oxidative stress via interaction with Toll-like receptor 4. CONCLUSIONS Post-prandial phase is characterized by an oxidative stress-related inflammation potentially triggered by LPS, a phenomenon mitigated by EVOO administration.",2019,"At 120 min, LPS (β - 15.73, p < 0.001), Apo-B48 (β - 0.14, p = 0.004), sNox2-dp (β - 5.47, p = 0.030), and oxLDL (β - 42.80, p < 0.001) significantly differed between the two treatment groups.","['30 IFG patients', 'patients with impaired fasting glucose (IFG', 'patients with impaired fasting glucose tolerance']","['lunch with or without 10\xa0g of EVOO', 'gut-derived lipopolysaccharide (LPS', 'extra virgin olive oil (EVOO', 'extra-virgin olive oil']","['changes of LPS', 'Serum LPS, Apo-B48, markers of oxidative stress such as oxidized LDL (oxLDL) and soluble Nox2-derived peptide (sNox2-dp', 'sNox2-dp and oxLDL']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}]","[{'cui': 'C4552032', 'cui_str': 'With lunch'}, {'cui': 'C1318182', 'cui_str': '10G'}, {'cui': 'C0023810', 'cui_str': 'Lipoglycans'}, {'cui': 'C0555061', 'cui_str': 'Virgin (finding)'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}]","[{'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0348035', 'cui_str': 'oxidized low density lipoprotein'}, {'cui': 'C0030956', 'cui_str': 'Peptides'}]",30.0,0.0595437,"At 120 min, LPS (β - 15.73, p < 0.001), Apo-B48 (β - 0.14, p = 0.004), sNox2-dp (β - 5.47, p = 0.030), and oxLDL (β - 42.80, p < 0.001) significantly differed between the two treatment groups.","[{'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Carnevale', 'Affiliation': 'Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Pastori', 'Affiliation': 'I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Nocella', 'Affiliation': 'Department of AngioCardioNeurology, IRCCS NeuroMed, 86077, Pozzilli, IS, Italy.'}, {'ForeName': 'Vittoria', 'Initials': 'V', 'LastName': 'Cammisotto', 'Affiliation': 'I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Bartimoccia', 'Affiliation': 'I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Novo', 'Affiliation': 'I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Del Ben', 'Affiliation': 'I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.'}, {'ForeName': 'Alessio', 'Initials': 'A', 'LastName': 'Farcomeni', 'Affiliation': 'Department of Public Health and Infectious Diseases, ""Sapienza"" University of Rome, Rome, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Angelico', 'Affiliation': 'Department of Public Health and Infectious Diseases, ""Sapienza"" University of Rome, Rome, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Violi', 'Affiliation': 'I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. francesco.violi@uniroma1.it.'}]",European journal of nutrition,['10.1007/s00394-018-1718-x'] 901,29764568,[Effect of early application of recombinant human erythropoietin on white matter development in preterm infants].,"OBJECTIVE To evaluate the effect of early application of recombinant human erythropoietin (rhEPO) on white matter development in preterm infants using fractional anisotropy (FA) of magnetic resonance diffusion tensor imaging (DTI). METHODS A total of 81 preterm infants with gestational age ≤32 weeks, birth weight <1 500 g, and hospitalization within 24 hours after birth were randomly divided into rhEPO group (42 infants) and control group (39 infants). The infants in the rhEPO group were administered rhEPO, while those in the control group were given the same volume of normal saline. The preterm infants of both groups took examinations of head magnetic resonance imaging, diffusion-weighted imaging, and DTI at the corrected gestational age of 35-37 weeks. FA was calculated for the regions of interest in both groups. RESULTS There was no significant difference in the incidence of intracranial hemorrhage, periventricular leukomalacia, focal cerebral white matter damage (CWMD), and extensive CWMD between rhEPO and control groups (P>0.05). Compared with the control group, the rhEPO group showed higher FA values at the posterior limb of the internal capsule, the splenium of the corpus callosum, frontal white matter, and occipital white matter (P<0.05). There was no significant difference in FA values at the parietal white matter, thalamus, lenticular nucleus, and caudate nucleus between the two groups (P>0.05). CONCLUSIONS Early application of rhEPO has a neuroprotective effect on white matter development in preterm infants.",2018,"There was no significant difference in the incidence of intracranial hemorrhage, periventricular leukomalacia, focal cerebral white matter damage (CWMD), and extensive CWMD between rhEPO and control groups (P>0.05).","['preterm infants using fractional anisotropy (FA) of', 'preterm infants', 'group (42 infants) and control group (39 infants', '81 preterm infants with gestational age ≤32 weeks, birth weight <1\u2009500\u2005g, and hospitalization within 24 hours after birth']","['magnetic resonance diffusion tensor imaging (DTI', 'rhEPO', 'recombinant human erythropoietin', 'recombinant human erythropoietin (rhEPO']","['FA values at the parietal white matter, thalamus, lenticular nucleus, and caudate nucleus', 'FA values', 'FA', 'incidence of intracranial hemorrhage, periventricular leukomalacia, focal cerebral white matter damage (CWMD), and extensive CWMD']","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0085406', 'cui_str': 'Anisotropy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0005615', 'cui_str': 'Birth'}]","[{'cui': 'C0917874', 'cui_str': 'Magnetic Resonance'}, {'cui': 'C1537007', 'cui_str': 'Diffusion Tensor MRI'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0014822', 'cui_str': 'Erythropoietin'}]","[{'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0442030', 'cui_str': 'Parietal (qualifier value)'}, {'cui': 'C0682708'}, {'cui': 'C0039729', 'cui_str': 'Thalamencephalon'}, {'cui': 'C0162342', 'cui_str': 'Lenticular Nucleus'}, {'cui': 'C0007461', 'cui_str': 'Nucleus Caudatus'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0151699', 'cui_str': 'Intracranial Hemorrhage'}, {'cui': 'C0023529', 'cui_str': 'Encephalomalacia, Periventricular'}, {'cui': 'C0205234', 'cui_str': 'Focal (qualifier value)'}, {'cui': 'C0152295', 'cui_str': 'Cerebral white matter structure'}, {'cui': 'C0010957', 'cui_str': 'Damage (morphologic abnormality)'}, {'cui': 'C0205231', 'cui_str': 'Extensive (qualifier value)'}]",81.0,0.0251334,"There was no significant difference in the incidence of intracranial hemorrhage, periventricular leukomalacia, focal cerebral white matter damage (CWMD), and extensive CWMD between rhEPO and control groups (P>0.05).","[{'ForeName': 'Shu-Shuo', 'Initials': 'SS', 'LastName': 'Yang', 'Affiliation': 'Department of Neonatology, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. xufalin72@126.com.'}, {'ForeName': 'Fa-Lin', 'Initials': 'FL', 'LastName': 'Xu', 'Affiliation': ''}, {'ForeName': 'Hui-Qing', 'Initials': 'HQ', 'LastName': 'Cheng', 'Affiliation': ''}, {'ForeName': 'Hao-Ran', 'Initials': 'HR', 'LastName': 'Xu', 'Affiliation': ''}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Jing-Yue', 'Initials': 'JY', 'LastName': 'Xing', 'Affiliation': ''}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Cheng', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 902,29764571,[Efficiency of electrocardiogram monitor for positioning the catheter tip in peripherally inserted central catheter placement in neonates].,"OBJECTIVE To study the efficiency of electrocardiogram (ECG) monitor for positioning the catheter tip in the placement of peripherally inserted central catheter (PICC) in neonates. METHODS A total of 160 neonates who were admitted to the neonatal intensive care unit (NICU) from January 2015 to December 2017 and underwent the PICC placement via the veins of upper extremity were enrolled. They were randomly divided into an observation group and a control group, with 80 neonates in each group. The neonates in the control group were given body surface measurement and postoperative X-ray localization, while those in the observation group were given body surface measurement, ECG localization, and postoperative X-ray localization. The two groups were compared in terms of general information, one-time success rate of PICC placement, and time spent on PICC placement. RESULTS There were no significant differences between the two groups in sex composition, gestational age, age in days at the time of PICC placement, disease type, and site of puncture (P>0.05). Compared with the control group, the observation group had a significantly higher one-time success rate of PICC placement (95% vs 79%; P<0.05) and a significantly shorter time spent on PICC placement (P<0.05). Localization under an ECG monitor during PICC placement had a sensitivity of 97% and a specificity of 100%. CONCLUSIONS During the PICC placement in neonates, the use of ECG monitor to determine the position of catheter tip can improve the one-time success rate of placement and reduce the time spent on placement.",2018,"Compared with the control group, the observation group had a significantly higher one-time success rate of PICC placement (95% vs 79%; P<0.05) and a significantly shorter time spent on PICC placement (P<0.05).","['160 neonates who were admitted to the neonatal intensive care unit (NICU) from January 2015 to December 2017 and underwent the PICC placement via the veins of upper extremity were enrolled', 'neonates']",['electrocardiogram'],"['time spent on PICC placement', 'time success rate of PICC placement', 'time success rate of PICC placement, and time spent on PICC placement']","[{'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0021709', 'cui_str': 'Newborn ICU'}, {'cui': 'C2049629', 'cui_str': 'PICC Placement'}, {'cui': 'C0226792', 'cui_str': 'Venous system of upper extremity'}]","[{'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C2049629', 'cui_str': 'PICC Placement'}]",160.0,0.0521953,"Compared with the control group, the observation group had a significantly higher one-time success rate of PICC placement (95% vs 79%; P<0.05) and a significantly shorter time spent on PICC placement (P<0.05).","[{'ForeName': 'Qi-Ying', 'Initials': 'QY', 'LastName': 'Ling', 'Affiliation': 'Department of Pediatrics, Sichuan Academy of Medical Sciences & Sichuan Provincial People′s Hospital/University of Electronic Science and Technology of China, Chengdu 610072, China. tangbinzhi@med.uestc.edu.cn.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Tang', 'Affiliation': ''}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Qu', 'Affiliation': ''}, {'ForeName': 'Bin-Zhi', 'Initials': 'BZ', 'LastName': 'Tang', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 903,29764574,[Clinical effect and mechanism of hemoperfusion in treatment of children with severe abdominal Henoch-Schönlein purpura].,"OBJECTIVE To study the clinical effect and mechanism of hemoperfusion (HP) in the treatment of children with severe abdominal Henoch-Schönlein purpura (HSP). METHODS A total of 24 children with severe abdominal HSP were divided into two groups: conventional treatment and HP (n=12 each). Ten healthy children who underwent physical examination were enrolled as the control group. Before and after treatment, chemiluminescence was used to measure the serum levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α); thiobarbituric acid colorimetry was used to measure the plasma level of malondialdehyde (MDA); the hydroxylamine method was used to measure the plasma level of superoxide dismutase (SOD); chemical colorimetry was used to measure the plasma level of total anti-oxidant capability (T-AOC). RESULTS Compared with the control group, the conventional treatment and HP groups had significantly higher IL-6, TNF-α, and MDA levels and significantly lower SOD and T-AOC levels before treatment (P<0.05), but there were no significant differences between the conventional treatment and HP groups (P>0.05). After treatment, the conventional treatment and HP groups had significant reductions in IL-6, TNF-α, and MDA levels and significant increases in SOD and T-AOC levels (P<0.05). The HP group had significantly greater changes than the conventional treatment group; however, there were still significant differences in these indices between the HP and control groups (P<0.05). Compared with the HP group, the conventional treatment group had a significantly lower percentage of children with disappearance of digestive tract symptoms at 4 days after treatment and significantly longer time to disappearance of rash and digestive tract symptoms (P<0.05). Compared with the conventional treatment group, the HP group had a significantly lower amount of glucocorticoid used during treatment and a significantly lower percentage of children who experienced hematuria and/or proteinuria within 6 months of the disease course (P<0.05). There were no significant differences between the two groups in length of hospital stay and recurrence rates of rash and abdominal pain within 6 months of the disease course. CONCLUSIONS HP can reduce the amount of glucocorticoid used during treatment and the incidence rate of kidney injury in children with severe abdominal HSP, possibly by eliminating IL-6, TNF-α, and MDA.",2018,"There were no significant differences between the two groups in length of hospital stay and recurrence rates of rash and abdominal pain within 6 months of the disease course. ","['children with severe abdominal Henoch-Schönlein purpura', 'Ten healthy children who underwent physical examination were enrolled as the control group', 'children with severe abdominal Henoch-Schönlein purpura (HSP', '24 children with severe abdominal HSP']","['conventional treatment and HP', 'hemoperfusion', 'HP', 'hemoperfusion (HP']","['IL-6, TNF-α, and MDA levels', 'serum levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α); thiobarbituric acid colorimetry', 'hematuria and/or proteinuria', 'plasma level of total anti-oxidant capability (T-AOC', 'disappearance of rash and digestive tract symptoms', 'length of hospital stay and recurrence rates of rash and abdominal pain', 'plasma level of superoxide dismutase (SOD); chemical colorimetry', 'SOD and T-AOC levels', 'plasma level of malondialdehyde (MDA', 'children with disappearance of digestive tract symptoms']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}, {'cui': 'C0034152', 'cui_str': 'Henoch Purpura'}, {'cui': 'C0686744', 'cui_str': 'Well child (finding)'}, {'cui': 'C0031809', 'cui_str': 'Physical Examination'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0019063', 'cui_str': 'Hemosorption'}]","[{'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0000379', 'cui_str': '1,3-Benzodioxole-5-ethanamine, alpha-methyl-'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0041368', 'cui_str': 'Tumor Necrosis Factors'}, {'cui': 'C0076442', 'cui_str': 'thiobarbituric acid'}, {'cui': 'C0009407', 'cui_str': 'Colorimetry'}, {'cui': 'C0018965', 'cui_str': 'Hematuria'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0015230', 'cui_str': 'Skin Rash'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal Tract'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}, {'cui': 'C0069638', 'cui_str': 'orgotein'}, {'cui': 'C0220806', 'cui_str': 'Chemical (substance)'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0008059', 'cui_str': 'Child'}]",24.0,0.018998,"There were no significant differences between the two groups in length of hospital stay and recurrence rates of rash and abdominal pain within 6 months of the disease course. ","[{'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': 'Department of Nephrology, Anhui Provincial Children′s Hospital, Hefei 230051, China. 114931468@qq.com.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Dong', 'Affiliation': ''}, {'ForeName': 'Da-Liang', 'Initials': 'DL', 'LastName': 'Xu', 'Affiliation': ''}, {'ForeName': 'Jia-Yun', 'Initials': 'JY', 'LastName': 'Jiang', 'Affiliation': ''}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Rui-Juan', 'Initials': 'RJ', 'LastName': 'Ke', 'Affiliation': ''}, {'ForeName': 'Shao-Han', 'Initials': 'SH', 'LastName': 'Fang', 'Affiliation': ''}, {'ForeName': 'Yin', 'Initials': 'Y', 'LastName': 'Peng', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 904,30402987,Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and polysubstance-dependent individuals.,"Identifying key neural substrates in addiction disorders for targeted drug development remains a major challenge for clinical neuroscience. One emerging target is the opioid system, where substance-dependent populations demonstrate prefrontal opioid dysregulation that predicts impulsivity and relapse. This may suggest that disturbances to the prefrontal opioid system could confer a risk for relapse in addiction due to weakened 'top-down' control over impulsive behaviour. Naltrexone is currently licensed for alcohol dependence and is also used clinically for impulse control disorders. Using a go/no-go (GNG) task, we examined the effects of acute naltrexone on the neural correlates of successful motor impulse control in abstinent alcoholics (AUD), abstinent polysubstance-dependent (poly-SUD) individuals and controls during a randomised double blind placebo controlled fMRI study. In the absence of any differences on GNG task performance, the AUD group showed a significantly greater BOLD response compared to the control group in lateral and medial prefrontal regions during both placebo and naltrexone treatments; effects that were positively correlated with alcohol abstinence. There was also a dissociation in the positive modulating effects of naltrexone in the orbitofrontal cortex (OFC) and anterior insula cortex (AIC) of the AUD and poly-SUD groups respectively. Self-reported trait impulsivity in the poly-SUD group also predicted the effect of naltrexone in the AIC. These results suggest that acute naltrexone differentially amplifies neural responses within two distinct regions of a salience network during successful motor impulse control in abstinent AUD and poly-SUD groups, which are predicted by trait impulsivity in the poly-SUD group.",2019,"In the absence of any differences on GNG task performance, the AUD group showed a significantly greater BOLD response compared to the control group in lateral and medial prefrontal regions during both placebo and naltrexone treatments; effects that were positively correlated with alcohol abstinence.","['abstinent alcoholics (AUD), abstinent polysubstance-dependent (poly-SUD) individuals and controls', 'abstinent alcohol-dependent and polysubstance-dependent individuals']","['acute naltrexone', 'naltrexone', 'Naltrexone', 'placebo']","['neural correlates of motor impulse control', 'Self-reported trait impulsivity', 'GNG task performance', 'BOLD response', 'alcohol abstinence', 'orbitofrontal cortex (OFC) and anterior insula cortex (AIC']","[{'cui': 'C0577647', 'cui_str': 'Abstinent alcoholic (finding)'}, {'cui': 'C0457801', 'cui_str': 'Current non-drinker of alcohol (finding)'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}]","[{'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0443235', 'cui_str': 'Impulse (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0021125', 'cui_str': 'Impulsivity'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0678274', 'cui_str': 'Abstinences, Alcohol'}, {'cui': 'C2331062', 'cui_str': 'Orbital Area'}, {'cui': 'C0228259', 'cui_str': 'Anterior insula (body structure)'}]",,0.0384675,"In the absence of any differences on GNG task performance, the AUD group showed a significantly greater BOLD response compared to the control group in lateral and medial prefrontal regions during both placebo and naltrexone treatments; effects that were positively correlated with alcohol abstinence.","[{'ForeName': 'Liam J', 'Initials': 'LJ', 'LastName': 'Nestor', 'Affiliation': 'Neuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.'}, {'ForeName': 'Louise M', 'Initials': 'LM', 'LastName': 'Paterson', 'Affiliation': 'Neuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Murphy', 'Affiliation': 'Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'McGonigle', 'Affiliation': 'Neuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.'}, {'ForeName': 'Csaba', 'Initials': 'C', 'LastName': 'Orban', 'Affiliation': 'Neuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Reed', 'Affiliation': 'Neuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.'}, {'ForeName': 'Eleanor', 'Initials': 'E', 'LastName': 'Taylor', 'Affiliation': 'Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.'}, {'ForeName': 'Remy', 'Initials': 'R', 'LastName': 'Flechais', 'Affiliation': 'Neuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.'}, {'ForeName': 'Dana', 'Initials': 'D', 'LastName': 'Smith', 'Affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Edward T', 'Initials': 'ET', 'LastName': 'Bullmore', 'Affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Karen D', 'Initials': 'KD', 'LastName': 'Ersche', 'Affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Suckling', 'Affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Elliott', 'Affiliation': 'Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.'}, {'ForeName': 'Bill', 'Initials': 'B', 'LastName': 'Deakin', 'Affiliation': 'Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.'}, {'ForeName': 'Ilan', 'Initials': 'I', 'LastName': 'Rabiner', 'Affiliation': 'Imanova, Centre for Imaging Sciences, Invicro, London, UK.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Lingford Hughes', 'Affiliation': 'Neuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.'}, {'ForeName': 'Barbara J', 'Initials': 'BJ', 'LastName': 'Sahakian', 'Affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Trevor W', 'Initials': 'TW', 'LastName': 'Robbins', 'Affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Nutt', 'Affiliation': 'Neuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The European journal of neuroscience,['10.1111/ejn.14262'] 905,29658455,[Efficacy of early treatment via fiber bronchoscope in children with Mycoplasma pneumoniae pneumonia complicated by airway mucus obstruction].,"OBJECTIVE To study the efficacy of early treatment via fiber bronchoscope in children with Mycoplasma pneumoniae pneumonia (MPP) complicated by airway mucus obstruction. METHODS According to the time from admission to the treatment via fiber bronchoscope, the children with MPP who were found to have airway mucus obstruction under a fiber bronchoscope were randomly divided into early intervention group (≤3 days; n=40) and late intervention group (>3 days; n=56). The two groups were compared in terms of clinical data and imaging recovery.The children were followed for 1-3 months. RESULTS Of the 96 children, 38 were found to have the formation of plastic bronchial tree, among whom 10 were in the early intervention group and 28 were in the late intervention group (P=0.01). Compared with the late intervention group, the early intervention group had a shorter duration of fever, length of hospital stay, and time to the recovery of white blood cell count and C-reactive protein (P<0.05), as well as a higher atelectasis resolution rate (P<0.05). Compared with the late intervention group, the early intervention group had a higher percentage of children with a ≥ 60% absorbed area of pulmonary consolidation at discharge. After 3 months of follow-up, the early intervention group had a higher percentage of children with a ≥ 90% absorbed area of pulmonary consolidation than the late intervention group (80% vs 55%; P=0.01), and the early intervention group had a lower incidence rate of atelectasis than the late intervention group (P<0.05). CONCLUSIONS Early treatment via fiber bronchoscope can shorten the course of the disease and reduce complications and sequelae in MPP children with airway mucus obstruction.",2018,"Compared with the late intervention group, the early intervention group had a shorter duration of fever, length of hospital stay, and time to the recovery of white blood cell count and C-reactive protein (P<0.05), as well as a higher atelectasis resolution rate (P<0.05).","['children with Mycoplasma pneumoniae pneumonia complicated by airway mucus obstruction', 'children with MPP who were found to have airway mucus obstruction under a fiber bronchoscope', 'children with Mycoplasma pneumoniae pneumonia (MPP) complicated by airway mucus obstruction', 'MPP children with airway mucus obstruction', '96 children']",['early treatment via fiber bronchoscope'],"['shorter duration of fever, length of hospital stay, and time to the recovery of white blood cell count and C-reactive protein', 'incidence rate of atelectasis', 'formation of plastic bronchial tree', 'atelectasis resolution rate', 'higher percentage of children with a ≥\u200990% absorbed area of pulmonary consolidation']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0032302', 'cui_str': 'Pneumonia, Primary Atypical'}, {'cui': 'C0231242', 'cui_str': 'Complicated (qualifier value)'}, {'cui': 'C0458827', 'cui_str': 'Airway structure (body structure)'}, {'cui': 'C0026727', 'cui_str': 'Mucus'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0623363', 'cui_str': 'MPPS'}, {'cui': 'C0000696', 'cui_str': 'A Fibers'}, {'cui': 'C0179432', 'cui_str': 'Bronchoscopes'}]","[{'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0225326', 'cui_str': 'Fiber'}, {'cui': 'C0179432', 'cui_str': 'Bronchoscopes'}]","[{'cui': 'C0439593', 'cui_str': 'Short duration (qualifier value)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0023508', 'cui_str': 'Blood Cell Count, White'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0004144', 'cui_str': 'Lung Collapse'}, {'cui': 'C0439634', 'cui_str': 'Formations (qualifier value)'}, {'cui': 'C0032167', 'cui_str': 'Plastics'}, {'cui': 'C0205039', 'cui_str': 'Bronchial (qualifier value)'}, {'cui': 'C0040811', 'cui_str': 'Trees'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C4522268', 'cui_str': 'Pulmonary'}, {'cui': 'C0702116', 'cui_str': 'Consolidation (morphologic abnormality)'}]",96.0,0.0264042,"Compared with the late intervention group, the early intervention group had a shorter duration of fever, length of hospital stay, and time to the recovery of white blood cell count and C-reactive protein (P<0.05), as well as a higher atelectasis resolution rate (P<0.05).","[{'ForeName': 'Li-Jie', 'Initials': 'LJ', 'LastName': 'Cao', 'Affiliation': 'Second Department of Respiration, Children′s Hospital of Hebei Province, Shijiazhuang 050031, China. liuwjm@sina.com.'}, {'ForeName': 'Jian-Hua', 'Initials': 'JH', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Jin-Feng', 'Initials': 'JF', 'LastName': 'Shuai', 'Affiliation': ''}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Niu', 'Affiliation': ''}, {'ForeName': 'Su-Kun', 'Initials': 'SK', 'LastName': 'Lu', 'Affiliation': ''}, {'ForeName': 'Kun-Ling', 'Initials': 'KL', 'LastName': 'Huang', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 906,29696945,The effect of chewing-gum on dose rate of salivary gland in differentiated thyroid carcinoma patients treated with radioiodine.,"BACKGROUND Although, different methods have been suggested on reducing salivary gland radiation after radioiodine administration, an effective preventive or therapeutic measure is still debated. To the best of our knowledge this is the second study that aimed to evaluate the effect of chewing-gum as a sialagogue on the radioiodine content of salivary gland, and radioiodine-induced symptoms of salivary gland dysfunction. METHODS Twenty-two patients who were referred to radioiodine therapy were randomized into chewing-gum (group A) and control (group B) groups. Anterior and posterior planar images including both head and neck were obtained 2, 6, 12, 24 and 48 hours after the administration of radioiodine in all patients and round regions of interest (ROI) were drawn for both left and right parotid glands with a rectangular ROI in the region of cerebrum as the background. All patients were followed once, 6 months after radioiodine administration via a phone call for subjective evaluation of symptoms related to salivary gland damage. RESULTS There was no significant difference between the two groups regarding the mean age, gender and initial iodine activity. The geometric mean of background-corrected count per administrated dose and acquisition time was calculated for bilateral parotid glands. This normalized parotid count showed a significant reduction in net parotid count in both groups during the first 48 hours after the radioiodine administration. However, no significant difference was found between the groups according to the amount and pattern of dose reduction in this time period. CONCLUSIONS This study revealed that chewing-gum had no significant effect on the radioiodine content of parotid glands during the first 48 hours after radioiodine administration. Also, no significant difference was found in the incidence of relevant symptoms after 6 months comparing both groups.",2020,"However, no significant difference was found between the groups according to the amount and pattern of dose reduction in this time period. ","['Twenty two patients who were referred to', 'differentiated thyroid carcinoma patients treated with']","['radioiodine therapy', 'radioiodine', 'chewing-gum']","['geometric mean of background-corrected count per administrated dose and acquisition time', 'radioiodine content of parotid glands', 'incidence of relevant symptoms', 'net parotid count', 'mean age, gender and initial iodine activity']","[{'cui': 'C4284772', 'cui_str': '22 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0549473', 'cui_str': 'Thyroid Cancer'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4321298', 'cui_str': 'Chewing gum'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0030580', 'cui_str': 'Parotid Gland'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0021968', 'cui_str': 'molecular iodine'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]",22.0,0.0212463,"However, no significant difference was found between the groups according to the amount and pattern of dose reduction in this time period. ","[{'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Haghighatafshar', 'Affiliation': 'Nuclear Medicine and Molecular Imaging Research Center, Namazi Teaching Hospital, Shiraz University of Medical Sciences, Shiraz, Iran - afsharm@sums.ac.ir.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Nowshad', 'Affiliation': 'Nuclear Medicine and Molecular Imaging Research Center, Namazi Teaching Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Etemadi', 'Affiliation': 'Nuclear Medicine and Molecular Imaging Research Center, Namazi Teaching Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Tahereh', 'Initials': 'T', 'LastName': 'Ghaedian', 'Affiliation': 'Nuclear Medicine and Molecular Imaging Research Center, Namazi Teaching Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.'}]","The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...",['10.23736/S1824-4785.18.03078-9'] 907,29616235,"Effect of water quality, sanitation, hand washing, and nutritional interventions on child development in rural Bangladesh (WASH Benefits Bangladesh): a cluster-randomised controlled trial.","Background Poor nutrition and hygiene make children vulnerable to delays in growth and development. We aimed to assess the effects of water quality, sanitation, handwashing, and nutritional interventions individually or in combination on the cognitive, motor, and language development of children in rural Bangladesh. Methods In this cluster-randomised controlled trial, we enrolled pregnant women in their first or second trimester from rural villages of Gazipur, Kishoreganj, Mymensingh, and Tangail districts of central Bangladesh, with an average of eight women per cluster. Groups of eight geographically adjacent clusters were block-randomised, using a random number generator, into six intervention groups (all of which received weekly visits from a community health promoter for the first 6 months and every 2 weeks for the next 18 months) and a double-sized control group (no intervention or health promoter visit). The six intervention groups were: chlorinated drinking water; improved sanitation; handwashing with soap; combined water, sanitation, and handwashing; improved nutrition through counselling and provision of lipid-based nutrient supplements; and combined water, sanitation, handwashing, and nutrition. Here, we report on the prespecified secondary child development outcomes: gross motor milestone achievement assessed with the WHO module at age 1 year, and communication, gross motor, personal social, and combined scores measured by the Extended Ages and Stages Questionnaire (EASQ) at age 2 years. Masking of participants was not possible. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01590095. Findings Between May 31, 2012, and July 7, 2013, 5551 pregnant women residing in 720 clusters were enrolled. Index children of 928 (17%) enrolled women were lost to follow-up in year 1 and an additional 201 (3%) in year 2. 4757 children were assessed at 1 year and 4403 at 2 years. At year 1, compared with the control group, the combined water, sanitation, handwashing, and nutrition group had a higher rate of attaining the standing alone milestone (hazard ratio 1·19, 95% CI 1·01-1 ·40), and the nutrition group had a higher rate of attaining the walking alone milestone (1·32, 95% CI 1·07-1·62). The combined water, sanitation, handwashing, and nutrition group had a higher rate of attaining the walking alone milestone than those in the water, sanitation, and handwashing group (1·29, 1·01-1·65). At 2 years, we noted beneficial effects in the combined EASQ score in all intervention groups, with effect sizes smallest in the water treatment group (difference 0·15, 95% CI 0·04 to 0·26 vs control) and largest in the combined water, sanitation, handwashing, and nutrition treatment group (0·37, 0·27-0·46). Interpretation Improvements in water quality, handwashing, sanitation, or nutrition supported by intensive interpersonal communication, when delivered either individually or in combination, contributed to improvements in child development. A crucial next step is to establish whether similar effects can be achieved with reduced intensity of promoter contacts that could be supported in large-scale interventions. Funding Bill & Melinda Gates Foundation.",2018,"At 2 years, we noted beneficial effects in the combined EASQ score in all intervention groups, with effect sizes smallest in the water treatment group (difference 0·15, 95% CI 0·04 to 0·26 vs control) and largest in the combined water, sanitation, handwashing, and nutrition treatment group (0·37, 0·27-0·46). ","['Index children of 928 (17%) enrolled women were lost to follow-up in year 1 and an additional 201 (3%) in year 2', 'child development in rural Bangladesh (WASH Benefits Bangladesh', '5551 pregnant women residing in 720 clusters were enrolled', 'enrolled pregnant women in their first or second trimester from rural villages of Gazipur, Kishoreganj, Mymensingh, and Tangail districts of central Bangladesh, with an average of eight women per cluster', '4757 children were assessed at 1 year and 4403 at 2 years', 'children in rural Bangladesh']","['double-sized control group (no intervention or health promoter visit', 'water quality, sanitation, hand washing, and nutritional interventions', 'water quality, sanitation, handwashing, and nutritional interventions', 'chlorinated drinking water; improved sanitation; handwashing with soap; combined water, sanitation, and handwashing; improved nutrition through counselling and provision of lipid-based nutrient supplements; and combined water, sanitation, handwashing, and nutrition']","['higher rate of attaining the walking alone milestone', 'higher rate of attaining the standing alone milestone', 'rate of attaining the walking alone milestone', 'motor milestone achievement assessed with the WHO module at age 1 year, and communication, gross motor, personal social, and combined scores measured by the Extended Ages and Stages Questionnaire (EASQ', 'water quality, handwashing, sanitation, or nutrition supported by intensive interpersonal communication']","[{'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0680063', 'cui_str': 'Child of (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1302313', 'cui_str': 'Lost to Follow-Up'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0008071', 'cui_str': 'Child Development'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C1547959', 'cui_str': 'Wash - dosing instruction imperative'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C4517865', 'cui_str': 'Seven hundred and twenty'}, {'cui': 'C0032980', 'cui_str': 'Midtrimester'}, {'cui': 'C0562518', 'cui_str': 'Village environment (environment)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1704764', 'cui_str': 'Per'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0597680', 'cui_str': 'Water Quality'}, {'cui': 'C0036172', 'cui_str': 'Sanitation'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C0599638', 'cui_str': 'Drinking Water'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0037392', 'cui_str': 'Soap'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0439806', 'cui_str': 'Gross (qualifier value)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0597680', 'cui_str': 'Water Quality'}, {'cui': 'C0036172', 'cui_str': 'Sanitation'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}]",5551.0,0.142212,"At 2 years, we noted beneficial effects in the combined EASQ score in all intervention groups, with effect sizes smallest in the water treatment group (difference 0·15, 95% CI 0·04 to 0·26 vs control) and largest in the combined water, sanitation, handwashing, and nutrition treatment group (0·37, 0·27-0·46). ","[{'ForeName': 'Fahmida', 'Initials': 'F', 'LastName': 'Tofail', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh. Electronic address: ftofail@icddrb.org.'}, {'ForeName': 'Lia Ch', 'Initials': 'LC', 'LastName': 'Fernald', 'Affiliation': 'School of Public Health, University of California Berkeley, Berkeley, CA USA.'}, {'ForeName': 'Kishor K', 'Initials': 'KK', 'LastName': 'Das', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Mahbubur', 'Initials': 'M', 'LastName': 'Rahman', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Tahmeed', 'Initials': 'T', 'LastName': 'Ahmed', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Kaniz K', 'Initials': 'KK', 'LastName': 'Jannat', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Leanne', 'Initials': 'L', 'LastName': 'Unicomb', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Benjamin F', 'Initials': 'BF', 'LastName': 'Arnold', 'Affiliation': 'School of Public Health, University of California Berkeley, Berkeley, CA USA.'}, {'ForeName': 'Sania', 'Initials': 'S', 'LastName': 'Ashraf', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Winch', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Kariger', 'Affiliation': 'School of Public Health, University of California Berkeley, Berkeley, CA USA.'}, {'ForeName': 'Christine P', 'Initials': 'CP', 'LastName': 'Stewart', 'Affiliation': 'Department of Nutrition, University of California Davis, Davis, CA, USA.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Colford', 'Affiliation': 'School of Public Health, University of California Berkeley, Berkeley, CA USA.'}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Luby', 'Affiliation': 'Division of Infectious Diseases and Geographic Medicine, Stanford University Stanford, CA USA.'}]",The Lancet. Child & adolescent health,['10.1016/S2352-4642(18)30031-2'] 908,29765151,Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).,"BACKGROUND A randomised study to assess the addition of apatorsen, an antisense oligonucleotide that inhibits Hsp27 expression, to docetaxel in patients with metastatic urothelial carcinoma (mUC) relapsed after prior platinum-based chemotherapy. METHODS Multicentre, phase II study with 1:1 randomisation to apatorsen (three loading doses at 600 mg intravenous followed by weekly doses) plus docetaxel (75 mg/m 2 intravenous every 21 days) (A/D) or docetaxel alone. Overall survival (OS) was the primary end point with a P value <0.1 (one-sided) being positive. Progression-free survival (PFS), objective response rate (ORR), safety, and effect of Hsp27 levels on outcomes were secondary end points. RESULTS Patients randomised to A/D (n = 99) had improved OS compared to docetaxel alone (n = 101): HR: 0.80, 80% CI: 0.65-0.98, P = 0.0784, median 6.4 vs 5.9 months. PFS and ORR were similar in both arms. A/D had more incidence of sepsis and urinary tract infections. Patients with baseline Hsp27 levels <5.7 ng/mL had improved OS compared to those with levels ≥5.7 ng/mL. Patients with a decline or ≤20.5% increase in Hsp27 from baseline benefited more from A/D than those with >20.5% increase. CONCLUSIONS A/D met its predefined OS end point in patients with platinum-refractory mUC in this phase II trial. This trial is hypothesis generating requiring further study before informing practice.",2018,Overall survival (OS) was the primary end point with a P value <0.1 (one-sided) being positive.,"['Patients with baseline', 'platinum-resistant metastatic urothelial carcinoma (Borealis-2', 'patients with metastatic urothelial carcinoma (mUC) relapsed after prior platinum-based chemotherapy']","['docetaxel', 'docetaxel alone', 'Apatorsen plus docetaxel']","['Overall survival (OS', 'Progression-free survival (PFS), objective response rate (ORR), safety, and effect of Hsp27 levels', 'OS', 'PFS and ORR', 'incidence of sepsis and urinary tract infections', 'Hsp27 levels']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1098768', 'cui_str': '(diethylenetriamine)-platinum(II)'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C4288754', 'cui_str': 'Metastatic urothelial carcinoma'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}]",,0.146838,Overall survival (OS) was the primary end point with a P value <0.1 (one-sided) being positive.,"[{'ForeName': 'Jonathan E', 'Initials': 'JE', 'LastName': 'Rosenberg', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Noah M', 'Initials': 'NM', 'LastName': 'Hahn', 'Affiliation': 'Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Meredith M', 'Initials': 'MM', 'LastName': 'Regan', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA, USA.'}, {'ForeName': 'Lillian', 'Initials': 'L', 'LastName': 'Werner', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA, USA.'}, {'ForeName': 'Ajjai', 'Initials': 'A', 'LastName': 'Alva', 'Affiliation': 'University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.'}, {'ForeName': 'Saby', 'Initials': 'S', 'LastName': 'George', 'Affiliation': 'Roswell Park Cancer Institute, Buffalo, NY, USA.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Picus', 'Affiliation': 'Siteman Cancer Center, Washington University, St. Louis, MO, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Alter', 'Affiliation': 'John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.'}, {'ForeName': 'Arjun', 'Initials': 'A', 'LastName': 'Balar', 'Affiliation': 'New York University Perlmutter Cancer Center, New York, NY, USA.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Hoffman-Censits', 'Affiliation': 'Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA, USA.'}, {'ForeName': 'Petros', 'Initials': 'P', 'LastName': 'Grivas', 'Affiliation': 'Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Lauer', 'Affiliation': 'University of New Mexico Cancer Center, Albuquerque, NM, USA.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Guancial', 'Affiliation': 'University of Rochester Wilmot Cancer Institute, Rochester, NY, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Hoimes', 'Affiliation': 'University Hospitals Seidman Cancer Center, Cleveland, OH, USA.'}, {'ForeName': 'Guru', 'Initials': 'G', 'LastName': 'Sonpavde', 'Affiliation': 'University of Alabama Comprehensive Cancer Center, Birmingham, AL, USA.'}, {'ForeName': 'Constantine', 'Initials': 'C', 'LastName': 'Albany', 'Affiliation': 'Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.'}, {'ForeName': 'Mark N', 'Initials': 'MN', 'LastName': 'Stein', 'Affiliation': 'Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Breen', 'Affiliation': 'Hoosier Cancer Research Network, Indianapolis, IN, USA.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Jacobs', 'Affiliation': 'OncoGenex Pharmaceuticals, Inc., Bothell, WA, USA.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Anderson', 'Affiliation': 'OncoGenex Pharmaceuticals, Inc., Bothell, WA, USA.'}, {'ForeName': 'Joaquim', 'Initials': 'J', 'LastName': 'Bellmunt', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA, USA.'}, {'ForeName': 'Aly-Khan A', 'Initials': 'AA', 'LastName': 'Lalani', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA, USA.'}, {'ForeName': 'Sumanta', 'Initials': 'S', 'LastName': 'Pal', 'Affiliation': 'City of Hope Comprehensive Cancer Center, Duarte, CA, USA.'}, {'ForeName': 'Toni K', 'Initials': 'TK', 'LastName': 'Choueiri', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA, USA. Toni_Choueiri@DFCI.HARVARD.EDU.'}]",British journal of cancer,['10.1038/s41416-018-0087-9'] 909,29616236,"Effects of water quality, sanitation, handwashing, and nutritional interventions on child development in rural Kenya (WASH Benefits Kenya): a cluster-randomised controlled trial.","Background Poor nutrition and infectious diseases can prevent children from reaching their developmental potential. We aimed to assess the effects of improvements in water, sanitation, handwashing, and nutrition on early child development in rural Kenya. Methods In this cluster-randomised controlled trial, we enrolled pregnant women in their second or third trimester from three counties (Kakamega, Bungoma, and Vihiga) in Kenya's western region, with an average of 12 households per cluster. Groups of nine geographically adjacent clusters were block-randomised, using a random number generator, into the six intervention groups (including monthly visits to promote target behaviours), a passive control group (no visits), or a double-sized active control group (monthly household visits to measure child mid-upper arm circumference). The six intervention groups were: chlorinated drinking water; improved sanitation; handwashing with soap; combined water, sanitation, and handwashing; improved nutrition through counselling and provision of lipid-based nutrient supplements; and combined water, sanitation, handwashing, and nutrition. Here we report on the prespecified secondary child development outcomes: gross motor milestone achievement assessed with the WHO module at year 1, and communication, gross motor, personal social, and combined scores measured by the Extended Ages and Stages Questionnaire (EASQ) at year 2. Masking of participants was not possible, but data assessors were masked. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01704105. Findings Between Nov 27, 2012, and May 21, 2014, 8246 women residing in 702 clusters were enrolled. No clusters were lost to follow-up, but 2212 households with 2279 children were lost to follow-up by year 2. 5791 (69%) children were measured at year 1 and 6107 (73%) at year 2. At year 1, compared with the active control group, the combined water, sanitation, handwashing, and nutrition group had greater rates of attaining the standing with assistance milestone (hazard ratio 1·23, 95% CI 1·09-1·40) and the walking with assistance milestone (1·32, 1·17-1·50), and the handwashing group had a greater rate of attaining the standing alone milestone (1·15, 1·01-1·31). There were no differences when comparing the other intervention groups with the active control group on any of the motor milestone measures at year 1. At year 2, there were no differences among groups for the communication, gross motor, personal social, or combined EASQ scores. Interpretation The handwashing and combined water, sanitation, handwashing, and nutrition interventions might have improved child motor development after 1 year, although after 2 years there were no other differences between groups. Future research should examine ways to make community health and nutrition programmes more effective at supporting child development. Funding Bill & Melinda Gates Foundation.",2018,There were no differences when comparing the other intervention groups with the active control group on any of the motor milestone measures at year 1.,"[""enrolled pregnant women in their second or third trimester from three counties (Kakamega, Bungoma, and Vihiga) in Kenya's western region, with an average of 12 households per cluster"", '2212 households with 2279 children', 'rural Kenya', 'Findings\n\n\nBetween Nov 27, 2012, and May 21, 2014, 8246 women residing in 702 clusters were enrolled', 'child development in rural Kenya (WASH Benefits Kenya']","['passive control group (no visits), or a double-sized active control group', 'water quality, sanitation, handwashing, and nutritional interventions', 'chlorinated drinking water; improved sanitation; handwashing with soap; combined water, sanitation, and handwashing; improved nutrition through counselling and provision of lipid-based nutrient supplements; and combined water, sanitation, handwashing, and nutrition']","['rates of attaining the standing with assistance milestone', 'communication, gross motor, personal social, or combined EASQ scores', 'rate of attaining the standing alone milestone', 'motor milestone achievement assessed with the WHO module at year 1, and communication, gross motor, personal social, and combined scores measured by the Extended Ages and Stages Questionnaire (EASQ']","[{'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0032981', 'cui_str': 'Last Trimester'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C1704764', 'cui_str': 'Per'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0022558', 'cui_str': 'Republic of Kenya'}, {'cui': 'C2607943', 'cui_str': 'findings'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0008071', 'cui_str': 'Child Development'}, {'cui': 'C1547959', 'cui_str': 'Wash - dosing instruction imperative'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0597680', 'cui_str': 'Water Quality'}, {'cui': 'C0036172', 'cui_str': 'Sanitation'}, {'cui': 'C0599638', 'cui_str': 'Drinking Water'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C0037392', 'cui_str': 'Soap'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}]","[{'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0439806', 'cui_str': 'Gross (qualifier value)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",8246.0,0.135414,There were no differences when comparing the other intervention groups with the active control group on any of the motor milestone measures at year 1.,"[{'ForeName': 'Christine P', 'Initials': 'CP', 'LastName': 'Stewart', 'Affiliation': 'Department of Nutrition, University of California, Davis, CA, USA. Electronic address: cpstewart@ucdavis.edu.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Kariger', 'Affiliation': 'School of Public Health, University of California, Davis, CA, USA.'}, {'ForeName': 'Lia', 'Initials': 'L', 'LastName': 'Fernald', 'Affiliation': 'Community Health Sciences, University of California, Davis, CA, USA.'}, {'ForeName': 'Amy J', 'Initials': 'AJ', 'LastName': 'Pickering', 'Affiliation': 'Department of Civil and Environmental Engineering, Stanford University, Stanford, CA, USA; Department of Civil and Environmental Engineering, Tufts University, Medford, MA, USA.'}, {'ForeName': 'Charles D', 'Initials': 'CD', 'LastName': 'Arnold', 'Affiliation': 'Department of Nutrition, University of California, Davis, CA, USA.'}, {'ForeName': 'Benjamin F', 'Initials': 'BF', 'LastName': 'Arnold', 'Affiliation': 'Division of Epidemiology, University of California, Davis, CA, USA.'}, {'ForeName': 'Alan E', 'Initials': 'AE', 'LastName': 'Hubbard', 'Affiliation': 'Division of Biostatistics, University of California, Davis, CA, USA.'}, {'ForeName': 'Holly N', 'Initials': 'HN', 'LastName': 'Dentz', 'Affiliation': 'Department of Nutrition, University of California, Davis, CA, USA.'}, {'ForeName': 'Audrie', 'Initials': 'A', 'LastName': 'Lin', 'Affiliation': 'Division of Epidemiology, University of California, Davis, CA, USA.'}, {'ForeName': 'Theodora J', 'Initials': 'TJ', 'LastName': 'Meerkerk', 'Affiliation': 'Department of Nutrition and Health, Wageningen University, Wageningen, Netherlands.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Milner', 'Affiliation': 'Environmental Health Sciences, University of California, Davis, CA, USA.'}, {'ForeName': 'Jenna', 'Initials': 'J', 'LastName': 'Swarthout', 'Affiliation': 'Innovations for Poverty Action, New Haven, CT, USA.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Colford', 'Affiliation': 'Division of Epidemiology, University of California, Davis, CA, USA.'}, {'ForeName': 'Clair', 'Initials': 'C', 'LastName': 'Null', 'Affiliation': 'Innovations for Poverty Action, New Haven, CT, USA; Center for International Policy Research and Evaluation, Mathematica Policy Research, Washington DC, USA.'}]",The Lancet. Child & adolescent health,['10.1016/S2352-4642(18)30025-7'] 910,29626232,A pre-meal of whey proteins induces differential effects on glucose and lipid metabolism in subjects with the metabolic syndrome: a randomised cross-over trial.,"PURPOSE Postprandial lipaemia (PPL), an independent risk factor for cardiovascular disease, is affected by composition and timing of meals. We evaluated if whey proteins (WP) consumed as a pre-meal before a fat-rich meal reduce postprandial triglyceride (TG) and apolipoprotein B-48 (ApoB-48) responses in subjects with the metabolic syndrome (MeS). METHODS An acute, randomised, cross-over trial was conducted. 20 subjects with MeS consumed a pre-meal of 0, 10 or 20 g WP 15 min prior to a fat-rich meal. The responses of TG and ApoB-48 were assessed. We also analysed postprandial responses of free fatty acids (FFA), glucose, insulin, glucagon, glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) and paracetamol (reflecting gastric emptying rates). RESULTS WP pre-meal did not alter the TG or ApoB-48 responses. In contrast, the insulin response was more pronounced after a pre-meal of 20 g WP than with 10 g WP (P = 0.0005) and placebo (P < 0.0001). Likewise, the postprandial glucagon response was greater with a pre-meal of 20 g WP than with 10 g WP (P < 0.0001) and 0 g WP (P < 0.0001). A pre-meal with 20 g of WP generated lower glucose (P = 0.0148) and S-paracetamol responses (P = 0.0003) and a higher GLP-1 response (P = 0.0086) than placebo. However, the pre-meal did not influence responses of GIP, FFA or appetite assessed by a Visual Analog Scale. CONCLUSIONS Consumption of a WP pre-meal prior to a fat-rich meal did not affect TG and chylomicron responses. In contrast, the WP pre-meal stimulates insulin and glucagon secretion and reduces blood glucose as expected, and delays gastric emptying. Consequently, our study points to a differential impact of a WP pre-meal on lipid and glucose metabolism to a fat-rich meal in subjects with MeS.",2019,"However, the pre-meal did not influence responses of GIP, FFA or appetite assessed by a Visual Analog Scale. ","['subjects with the metabolic syndrome (MeS', 'subjects with MeS', 'subjects with the metabolic syndrome', '20 subjects with MeS consumed a pre-meal of 0, 10 or 20']","['whey proteins (WP', 'placebo']","['postprandial responses of free fatty acids (FFA), glucose, insulin, glucagon, glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) and paracetamol (reflecting gastric emptying rates', 'higher GLP-1 response', 'S-paracetamol responses', 'TG or ApoB-48 responses', 'WP pre-meal stimulates insulin and glucagon secretion and reduces blood glucose', 'postprandial triglyceride (TG) and apolipoprotein B-48 (ApoB-48) responses', 'GIP, FFA or appetite assessed by a Visual Analog Scale', 'insulin response', 'delays gastric emptying', 'glucose and lipid metabolism', 'postprandial glucagon response']","[{'cui': 'C0524620', 'cui_str': 'Metabolic Syndrome X'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}]","[{'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0373606', 'cui_str': 'Free fatty acids measurement (procedure)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0876232', 'cui_str': 'glucagon recombinant'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-Like Peptide 1'}, {'cui': 'C0017132', 'cui_str': 'Glucose-Dependent Insulin-Releasing Peptide'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0558058', 'cui_str': 'Reflecting (finding)'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0103839', 'cui_str': 'Chylomicron Apo B'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0036537', 'cui_str': 'Secretions'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C1702020', 'cui_str': '37-epsilon-palmitoyl-Lys-GIP'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0017127', 'cui_str': 'Gastric Emptyings'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}]",20.0,0.0497458,"However, the pre-meal did not influence responses of GIP, FFA or appetite assessed by a Visual Analog Scale. ","[{'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Bjørnshave', 'Affiliation': 'Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Tage-Hansens Gade 2, 8000, Aarhus C, Denmark. ann.bjoernshave@clin.au.dk.'}, {'ForeName': 'Jens Juul', 'Initials': 'JJ', 'LastName': 'Holst', 'Affiliation': 'NNF Centre for Basic Metabolic Research and The Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, 2200, København N, Denmark.'}, {'ForeName': 'Kjeld', 'Initials': 'K', 'LastName': 'Hermansen', 'Affiliation': 'Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Tage-Hansens Gade 2, 8000, Aarhus C, Denmark.'}]",European journal of nutrition,['10.1007/s00394-018-1684-3'] 911,31638477,Effects of a short workplace exercise program on body composition in women: A randomized controlled trial.,"Physical inactivity and poor diet cause alterations in body composition, which in turn increases risk factors for cardiovascular and metabolic diseases. Sixty-three women from different work environments were randomly assigned to an intervention ( n  = 34) or control ( n  = 29) group. The intervention was a short-term aerobic exercise program (12 weeks) at their workplace. Participants assigned to the control group did not perform any form of physical exercise. Body composition was measured by dual-energy X-ray absorptiometry (DXA). Diet was assessed using the Mediterranean Diet Quality Questionnaire (KIDMED) and nutrient balance by the Food Frequency Questionnaire. Researchers suggest that a short-term aerobic exercise program produces beneficial effects on body composition.",2020,Participants assigned to the control group did not perform any form of physical exercise.,"['women', 'Sixty-three women from different work environments']","['aerobic exercise program', 'control group did not perform any form of physical exercise', 'short workplace exercise program']","['Body composition', 'Mediterranean Diet Quality Questionnaire (KIDMED) and nutrient balance by the Food Frequency Questionnaire', 'body composition']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4319614', 'cui_str': '63 (qualifier value)'}, {'cui': 'C0162579', 'cui_str': 'Job Site'}]","[{'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0162579', 'cui_str': 'Job Site'}]","[{'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C1138412', 'cui_str': 'Diet, Mediterranean'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]",63.0,0.0346824,Participants assigned to the control group did not perform any form of physical exercise.,"[{'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Iturriaga', 'Affiliation': 'Faculty of Sport Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, Spain.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Barcelo', 'Affiliation': 'Faculty of Sport Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, Spain.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Diez-Vega', 'Affiliation': 'Faculty of Sport Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, Spain.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Cordero', 'Affiliation': 'Medical Service, Universidad Europea de Madrid, Villaviciosa de Odón, Spain.'}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Pulgar', 'Affiliation': 'Faculty of Sport Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, Spain.'}, {'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Fernandez-Luna', 'Affiliation': 'Faculty of Sport Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, Spain.'}, {'ForeName': 'Margarita', 'Initials': 'M', 'LastName': 'Perez-Ruiz', 'Affiliation': 'Faculty of Sport Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, Spain.'}]",Health care for women international,['10.1080/07399332.2019.1679813'] 912,31610436,A randomised controlled trial of computerised interpretation bias modification for health anxiety.,"BACKGROUND AND OBJECTIVES Health anxiety is characterised by a tendency to interpret benign bodily sensations as a sign of serious illness. This study aimed to examine whether computerised cognitive bias modification (CBM-I) training to facilitate benign interpretations of bodily symptoms could reduce these negative interpretations of bodily symptoms, health anxiety and comorbid symptoms. METHODS Participants (N = 89) with clinical levels of health anxiety (Short Health Anxiety Inventory [SHAI] scores ≥20) were randomised to receive two internet-delivered 30-min sessions of either CBM-I interpretation training (Intervention) or control CBM-I training over 1-week. Participants were assessed at pre-treatment, post-treatment and 2-weeks follow-up on self-reported health anxiety, cognitions and attributions of bodily symptoms, and comorbid symptoms (e.g., depression). RESULTS Results showed significantly reduced catastrophic attributions, health anxiety and related symptoms at post-treatment in both groups, which were maintained at 2-week follow-up. Although there were no significant group differences at post-treatment or follow-up, we found small non-significant effect sizes in favour of the CBM-I Intervention group on health anxiety and cognitions (Cohen's d's between-group effect sizes of 0.28 at post-treatment and d = 0.35 at follow-up on the 18-item Short Health Anxiety Inventory). LIMITATIONS The study was conducted online, limiting control over the setting in which participants completed training. Additionally, training was not tailored to the specific symptoms or diseases that participants feared. CONCLUSIONS This study is the first to evaluate the effect of internet-delivered CBM-I training targeting benign interpretations of bodily symptoms on health anxiety. Further research is needed before this intervention is disseminated.",2020,"RESULTS Results showed significantly reduced catastrophic attributions, health anxiety and related symptoms at post-treatment in both groups, which were maintained at 2-week follow-up.",['Participants (N\u202f=\u202f89) with clinical levels of health anxiety (Short Health Anxiety Inventory [SHAI] scores ≥20'],"['internet-delivered CBM-I training', 'CBM-I interpretation training (Intervention) or control CBM-I training over 1-week', 'computerised cognitive bias modification (CBM-I) training']","['catastrophic attributions, health anxiety and related symptoms', 'health anxiety and cognitions ', 'health anxiety, cognitions and attributions of bodily symptoms, and comorbid symptoms (e.g., depression']","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0018759', 'cui_str': 'Level of Health'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C2959402', 'cui_str': 'Short health anxiety inventory (assessment scale)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0459471', 'cui_str': 'Interpretation (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0005346', 'cui_str': 'Bias'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]",,0.0573474,"RESULTS Results showed significantly reduced catastrophic attributions, health anxiety and related symptoms at post-treatment in both groups, which were maintained at 2-week follow-up.","[{'ForeName': 'Sophie L', 'Initials': 'SL', 'LastName': 'Antognelli', 'Affiliation': 'School of Psychology, UNSW Sydney, Australia.'}, {'ForeName': 'Maria J', 'Initials': 'MJ', 'LastName': 'Sharrock', 'Affiliation': 'School of Psychology, UNSW Sydney, Australia.'}, {'ForeName': 'Jill M', 'Initials': 'JM', 'LastName': 'Newby', 'Affiliation': 'School of Psychology, UNSW Sydney, Australia. Electronic address: j.newby@unsw.edu.au.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2019.101518'] 913,31272988,"Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial.","INTRODUCTION Despite extensive prevention campaigns and scale-up of antiretroviral therapy, HIV incidence among young women in southern Africa remains high. While the development of an efficacious vaccine remains a challenge, the discovery of broadly neutralising monoclonal antibodies (mAbs) has created the opportunity to explore passive immunisation as a long-acting injectable HIV prevention strategy. The purpose of this trial is to provide safety, pharmacokinetic (PK) and functional activity data of VRC07-523LS and PGT121 when administered subcutaneously (SC) to young South African women. Going forward, the aim is to select the ideal dose and/or monoclonal antibody for co-formulation and testing with CAP256-VRC26.25LS, a potent monoclonal antibody against subtype C virus, in an efficacy trial. METHODS AND ANALYSIS CAPRISA 012A is a randomised, double blinded, placebo-controlled phase I trial to assess the safety and PK profile of two mAbs, VRC07-523LS and PGT121 administered SC to 35 young HIV negative women at low risk for HIV infection. Women will be randomised into seven groups of five participants each. In each group, women will be randomised (4:1) to the active intervention, VRC07-523LS and/or PGT121, or placebo. Participants will be followed up for 24 weeks after the administration of the last dose of study product with a total study duration of 72 weeks. Safety in the study will be assessed by the number and percentage of reactogenicity and adverse events experienced by participants and the relatedness to study product. The PK study design was based on preliminary PK data for VRC07-523LS and PGT121. ETHICS AND DISSEMINATION Ethical approval has been granted by the South African Health Products Regulatory Authority and by the University of KwaZulu-Natal Biomedical Research Ethics Committee. Results will be presented at international conferences and published in academic peer-reviewed journals. Trial results will be uploaded on the clinical trial registry. TRIAL REGISTRATION NUMBER PACTR201808919297244; Pre-results.",2019,"In each group, women will be randomised (4:1) to the active intervention, VRC07-523LS and/or PGT121, or placebo.","['HIV negative women in South Africa', 'young women in southern Africa remains high', '35 young HIV negative women at low risk for HIV infection', 'young South African women']","['VRC07-523LS and PGT121', 'placebo', 'VRC07-523LS and PGT121 administered SC', 'monoclonal antibodies, VRC07-523LS and PGT121', 'CAP256-VRC26.25LS', 'active intervention, VRC07-523LS and/or PGT121, or placebo']",[],"[{'cui': 'C0481430', 'cui_str': 'HTLV-3 antibody negative'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0037712', 'cui_str': 'Union of South Africa'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0001746', 'cui_str': 'Africa, Southern'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}, {'cui': 'C0019693', 'cui_str': 'T-Lymphotropic Virus Type III Infections, Human'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C3542957', 'cui_str': 'Antineoplastic MAbs'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}]",[],35.0,0.399446,"In each group, women will be randomised (4:1) to the active intervention, VRC07-523LS and/or PGT121, or placebo.","[{'ForeName': 'Sharana', 'Initials': 'S', 'LastName': 'Mahomed', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Garrett', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.'}, {'ForeName': 'Edmund', 'Initials': 'E', 'LastName': 'Capparelli', 'Affiliation': 'University of California San Diego, San Diego, California, USA.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Baxter', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.'}, {'ForeName': 'Nonhlanhla Yende', 'Initials': 'NY', 'LastName': 'Zuma', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.'}, {'ForeName': 'Tanuja', 'Initials': 'T', 'LastName': 'Gengiah', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.'}, {'ForeName': 'Derseree', 'Initials': 'D', 'LastName': 'Archary', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.'}, {'ForeName': 'Penny', 'Initials': 'P', 'LastName': 'Moore', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Samsunder', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.'}, {'ForeName': 'Dan H', 'Initials': 'DH', 'LastName': 'Barouch', 'Affiliation': 'Beth Israel Medical Center - Kings Highway Division, Brooklyn, New York, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Mascola', 'Affiliation': 'NIH, Bethesda, Maryland, USA.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Ledgerwood', 'Affiliation': 'NIH, Bethesda, Maryland, USA.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Morris', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.'}, {'ForeName': 'Salim', 'Initials': 'S', 'LastName': 'Abdool Karim', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.'}]",BMJ open,['10.1136/bmjopen-2019-030283'] 914,30786186,Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.,"BACKGROUND Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is uncertain. METHODS In this double-blind, randomized trial involving high-risk ambulatory patients with cancer (Khorana score of ≥2, on a scale from 0 to 6, with higher scores indicating a higher risk of venous thromboembolism), we randomly assigned patients without deep-vein thrombosis at screening to receive rivaroxaban (at a dose of 10 mg) or placebo daily for up to 180 days, with screening every 8 weeks. The primary efficacy end point was a composite of objectively confirmed proximal deep-vein thrombosis in a lower limb, pulmonary embolism, symptomatic deep-vein thrombosis in an upper limb or distal deep-vein thrombosis in a lower limb, and death from venous thromboembolism and was assessed up to day 180. In a prespecified supportive analysis involving the same population, the same end point was assessed during the intervention period (first receipt of trial agent to last dose plus 2 days). The primary safety end point was major bleeding. RESULTS Of 1080 enrolled patients, 49 (4.5%) had thrombosis at screening and did not undergo randomization. Of the 841 patients who underwent randomization, the primary end point occurred in 25 of 420 patients (6.0%) in the rivaroxaban group and in 37 of 421 (8.8%) in the placebo group (hazard ratio, 0.66; 95% confidence interval [CI], 0.40 to 1.09; P = 0.10) in the period up to day 180. In the prespecified intervention-period analysis, the primary end point occurred in 11 patients (2.6%) in the rivaroxaban group and in 27 (6.4%) in the placebo group (hazard ratio, 0.40; 95% CI, 0.20 to 0.80). Major bleeding occurred in 8 of 405 patients (2.0%) in the rivaroxaban group and in 4 of 404 (1.0%) in the placebo group (hazard ratio, 1.96; 95% CI, 0.59 to 6.49). CONCLUSIONS In high-risk ambulatory patients with cancer, treatment with rivaroxaban did not result in a significantly lower incidence of venous thromboembolism or death due to venous thromboembolism in the 180-day trial period. During the intervention period, rivaroxaban led to a substantially lower incidence of such events, with a low incidence of major bleeding. (Funded by Janssen and others; CASSINI ClinicalTrials.gov number, NCT02555878.).",2019,"The primary efficacy end point was a composite of objectively confirmed proximal deep-vein thrombosis in a lower limb, pulmonary embolism, symptomatic deep-vein thrombosis in an upper limb or distal deep-vein thrombosis in a lower limb, and death from venous thromboembolism and was assessed up to day 180.","['high-risk ambulatory patients with cancer (Khorana score of ≥2, on a scale from 0 to 6, with higher scores indicating a higher risk of venous thromboembolism', 'High-Risk Ambulatory Patients with Cancer', '1080 enrolled patients, 49 (4.5%) had thrombosis at screening and did not undergo randomization', 'high-risk ambulatory patients with cancer', 'Ambulatory patients receiving']","['rivaroxaban', 'systemic cancer therapy', 'placebo', 'Rivaroxaban']","['Major bleeding', 'major bleeding', 'composite of objectively confirmed proximal deep-vein thrombosis in a lower limb, pulmonary embolism, symptomatic deep-vein thrombosis in an upper limb or distal deep-vein thrombosis in a lower limb, and death from venous thromboembolism', 'venous thromboembolism or death']","[{'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C1861172', 'cui_str': 'Venous Thromboembolism'}, {'cui': 'C3844009', 'cui_str': 'Four point five'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]","[{'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C0149871', 'cui_str': 'Deep Vein Thrombosis'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary Embolism'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0205108', 'cui_str': 'Distal (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1861172', 'cui_str': 'Venous Thromboembolism'}]",1080.0,0.530441,"The primary efficacy end point was a composite of objectively confirmed proximal deep-vein thrombosis in a lower limb, pulmonary embolism, symptomatic deep-vein thrombosis in an upper limb or distal deep-vein thrombosis in a lower limb, and death from venous thromboembolism and was assessed up to day 180.","[{'ForeName': 'Alok A', 'Initials': 'AA', 'LastName': 'Khorana', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Gerald A', 'Initials': 'GA', 'LastName': 'Soff', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Ajay K', 'Initials': 'AK', 'LastName': 'Kakkar', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Saroj', 'Initials': 'S', 'LastName': 'Vadhan-Raj', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Hanno', 'Initials': 'H', 'LastName': 'Riess', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Ted', 'Initials': 'T', 'LastName': 'Wun', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Michael B', 'Initials': 'MB', 'LastName': 'Streiff', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Garcia', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Howard A', 'Initials': 'HA', 'LastName': 'Liebman', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Chandra P', 'Initials': 'CP', 'LastName': 'Belani', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Eileen M', 'Initials': 'EM', 'LastName': ""O'Reilly"", 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Jai N', 'Initials': 'JN', 'LastName': 'Patel', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Habte A', 'Initials': 'HA', 'LastName': 'Yimer', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Wildgoose', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Burton', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Ujjwala', 'Initials': 'U', 'LastName': 'Vijapurkar', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Simrati', 'Initials': 'S', 'LastName': 'Kaul', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Eikelboom', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'McBane', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Kenneth A', 'Initials': 'KA', 'LastName': 'Bauer', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Nicole M', 'Initials': 'NM', 'LastName': 'Kuderer', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': 'Gary H', 'Initials': 'GH', 'LastName': 'Lyman', 'Affiliation': 'From the Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland (A.A.K.); the Department of Medicine, Memorial Sloan Kettering Cancer Center (G.A.S., E.M.O.), and Weill Cornell Medical College (G.A.S., E.M.O.), New York; the Thrombosis Research Institute and University College London, London (A.K.K.); University of Texas M.D. Anderson Cancer Center, Houston (S.V.-R.), and U.S. Oncology Research-Texas Oncology, Tyler (H.A.Y.) - both in Texas; the Department of Medicine, Charité Universitätsmedizin Berlin, Berlin (H.R.); the Division of Hematology-Oncology, University of California Davis School of Medicine, Sacramento (T.W.), and the Keck School of Medicine, University of Southern California, Los Angeles (H.A.L.); the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (M.B.S.); the University of Washington School of Medicine (D.A.G., N.M.K., G.H.L.), Advanced Cancer Research Group (N.M.K.), and Fred Hutchinson Cancer Research Center (G.H.L.), Seattle; Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA (C.P.B.); the Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC (J.N.P.); Janssen Scientific Affairs, Titusville (P.W., P.B., S.K.), and Janssen Research and Development, Raritan (U.V.) - both in New Jersey; the Department of Medicine, McMaster University, Hamilton, ON, Canada (J.E.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (R.M.); and the Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston (K.A.B.).'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1814630'] 915,31876197,The role of progestogen supplementation (dydrogesterone) in the prevention of preeclampsia.,"Our goal was determine the effects of dydrogesterone supplementation to reduce the incidence of preeclampsia (PE) in early pregnancy (from 6 to 20 weeks of gestation). A total of 406 pregnant women were involved into the study. The Study group enrolled 169 women, supplemented with dydrogesterone at a dose of 30 mg/d 6-20 weeks of gestation compared with the control group (237 subjects) - without dydrogesterone supplementation. The women were randomized by age, race, obstetrics complications, and their somatic history. The use of dydrogesterone in early pregnancy - before 20 weeks of gestation (at a dose of 30 mg/d) with high-risk factors of PE contributed to a statistically significant reduction in the frequency of this complication (13.1% and 71.4%, p  < .001). It was seen, that women who took dydrogesterone developed significantly less such disorders like hypertension (3.2% and 71.2%, p  < .001), proteinuria (0.0% and 66.18%, p  < .001), fetal growth retardation syndrome (2.2% and 21.58%, p  < .001), destroy of uteri-placenta velocity (3.2% and 21.58%, p  < .001), preterm labor (8.6% and 53.95%, p  < .001). Dydrogesterone supplementation in the first and second period of pregnancy (from 6 to 20 weeks of gestation) significantly reduced the incidence of PE in women with higher risk pregnancy.",2020,"It was seen, that women who took dydrogesterone developed significantly less such disorders like hypertension (3.2% and 71.2%, p  < .001), proteinuria (0.0% and 66.18%, p  < .001), fetal growth retardation syndrome (2.2% and 21.58%, p  < .001), destroy of uteri-placenta velocity (3.2% and 21.58%, p  < .001), preterm labor (8.6% and 53.95%, p  < .001).","['406 pregnant women', '169 women, supplemented with', 'early pregnancy (from 6 to 20\xa0weeks of gestation', 'women with higher risk pregnancy']","['dydrogesterone', 'dydrogesterone at a dose of 30\u2009mg/d 6-20\xa0weeks of gestation compared with the control group (237 subjects) - without dydrogesterone supplementation', 'dydrogesterone supplementation', 'progestogen supplementation (dydrogesterone', 'Dydrogesterone supplementation']","['disorders like hypertension', 'preterm labor', 'frequency of this complication', 'fetal growth retardation syndrome', 'proteinuria', 'incidence of PE', 'destroy of uteri-placenta velocity', 'incidence of preeclampsia (PE']","[{'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0242786', 'cui_str': 'High-Risk Pregnancy'}]","[{'cui': 'C0013340', 'cui_str': 'Dydrogesterone'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0033306', 'cui_str': 'Progestins'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0022876', 'cui_str': 'Preterm Labor'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0015934', 'cui_str': 'Intrauterine Growth Restriction'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0042149', 'cui_str': 'Womb'}, {'cui': 'C0032043', 'cui_str': 'Placentome'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0032914', 'cui_str': 'EPH Toxemias'}]",169.0,0.0811062,"It was seen, that women who took dydrogesterone developed significantly less such disorders like hypertension (3.2% and 71.2%, p  < .001), proteinuria (0.0% and 66.18%, p  < .001), fetal growth retardation syndrome (2.2% and 21.58%, p  < .001), destroy of uteri-placenta velocity (3.2% and 21.58%, p  < .001), preterm labor (8.6% and 53.95%, p  < .001).","[{'ForeName': 'V', 'Initials': 'V', 'LastName': 'Tskhay', 'Affiliation': 'Perinatology, Obstetrics and Gynecology Department, Krasnoyarsk State Medical University named after Voino-Yasenetsky, Krasnoyarsk, Russia.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Schindler', 'Affiliation': 'Perinatology, Obstetrics and Gynecology Department, Krasnoyarsk State Medical University named after Voino-Yasenetsky, Krasnoyarsk, Russia.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Shestakova', 'Affiliation': 'Perinatology, Obstetrics and Gynecology Department, Krasnoyarsk State Medical University named after Voino-Yasenetsky, Krasnoyarsk, Russia.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Klimova', 'Affiliation': 'Perinatology, Obstetrics and Gynecology Department, Krasnoyarsk State Medical University named after Voino-Yasenetsky, Krasnoyarsk, Russia.'}, {'ForeName': 'А', 'Initials': 'А', 'LastName': 'Narkevich', 'Affiliation': 'Perinatology, Obstetrics and Gynecology Department, Krasnoyarsk State Medical University named after Voino-Yasenetsky, Krasnoyarsk, Russia.'}]",Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,['10.1080/09513590.2019.1706085'] 916,31628863,The effectiveness of two silicone dressings for sacral and heel pressure ulcer prevention compared with no dressings in high-risk intensive care unit patients: a randomized controlled parallel-group trial.,"BACKGROUND There is a high incidence of pressure ulcers in high-risk settings such as intensive care. There is emerging evidence that the application of dressings to pressure ulcer predilection areas (sacrum and heels) improves prevention strategies. OBJECTIVES To determine whether preventive dressings, applied to the sacrum and heels of high-risk patients in intensive care units, in addition to standard prevention, reduces the incidence of pressure ulcers. METHODS Between June 2015 and July 2018, a randomized, controlled, two-arm, superiority pragmatic study was performed with a concealed 1 : 1 allocation to the intervention and control group. Patients assigned to the intervention group had dressings applied to the sacrum and heels. RESULTS In total, 7575 patients were screened for eligibility and 475 patients were included and allocated to both groups. Finally, 212 patients in the intervention group and 210 in the control group were analysed. The mean age was 63·5 years and the majority of patients were male (65·4%). The cumulative pressure ulcer incidence category II and above was 2·8% in the intervention, and 10·5% in the control group (P = 0·001). Compared with the control group, the relative risk in the intervention group was 0·26 [95% confidence interval (CI) 0·11-0·62] and the absolute risk reduction was 0·08 (95% CI 0·03-0·13). CONCLUSIONS The results indicate that the application of dressings, in addition to standard prevention, in high-risk intensive care unit patients is effective in preventing pressure ulcers at the heels and sacrum. What's already known about this topic? Pressure ulcers are severe soft tissue injuries and wounds, which occur worldwide in all healthcare settings. Despite preventive interventions, pressure ulcers still develop. There is emerging evidence that dressings help to prevent pressure ulcers. What does this study add? The incidence of pressure ulcers in intensive care units among high-risk patients remains high. The application of dressings to the sacrum and heels, in addition to standard preventive measures, reduces the relative and absolute risks for the development of pressure ulcers. The application of preventive dressings at the heels and sacrum seems to be feasible in intensive care settings.",2020,"Compared to the control group, the relative risk in the intervention group was 0.26 (95% CI 0.11 to 0.62) and the absolute risk reduction was 0.08","['Finally, n = 212 patients in the intervention and n = 210 in the control groups were analyzed', 'In total, n = 7575 patients were screened for eligibilty, n = 475 patients', 'high risk intensive care unit patients', 'Between June 2015 and July 2018', 'Mean age was 63.5 years and the majority was male (65.4']","['silicone dressings', 'intervention group had dressings applied to sacrum and heels']","['pressure ulcers', 'absolute risk reduction', 'relative risk', 'cumulative pressure ulcer incidence category II and above']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C4517786', 'cui_str': '475 (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C1271483', 'cui_str': 'Silicone dressing'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0013119', 'cui_str': 'Dressings'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0036037', 'cui_str': 'Sacrum'}, {'cui': 'C0018870', 'cui_str': 'Heel'}]","[{'cui': 'C0011127', 'cui_str': 'Pressure Ulcer'}, {'cui': 'C3179139', 'cui_str': 'Absolute Risk Reduction'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0220856', 'cui_str': 'incidence'}]",475.0,0.0545794,"Compared to the control group, the relative risk in the intervention group was 0.26 (95% CI 0.11 to 0.62) and the absolute risk reduction was 0.08","[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Hahnel', 'Affiliation': 'Clinical Research Center for Hair and Skin Science, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'El Genedy', 'Affiliation': 'Clinical Research Center for Hair and Skin Science, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Tomova-Simitchieva', 'Affiliation': 'Clinical Research Center for Hair and Skin Science, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Hauß', 'Affiliation': 'Department of Clinical Quality and Risk Management, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Stroux', 'Affiliation': 'Department of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Lechner', 'Affiliation': 'Clinical Research Center for Hair and Skin Science, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Richter', 'Affiliation': 'Clinical Research Center for Hair and Skin Science, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Akdeniz', 'Affiliation': 'Clinical Research Center for Hair and Skin Science, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Blume-Peytavi', 'Affiliation': 'Clinical Research Center for Hair and Skin Science, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Löber', 'Affiliation': 'Department of Clinical Quality and Risk Management, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Kottner', 'Affiliation': 'Clinical Research Center for Hair and Skin Science, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}]",The British journal of dermatology,['10.1111/bjd.18621'] 917,30560738,Cognitive change in cognitive-behavioural therapy v. pharmacotherapy for adult depression: a longitudinal mediation analysis.,"BACKGROUND Although cognitive-behavioural therapy (CBT) is a well-established treatment for adult depression, its efficacy and efficiency may be enhanced by better understanding its mechanism(s) of action. According to the theoretical model of CBT, symptom improvement occurs via reductions in maladaptive cognition. However, previous research has not established clear evidence for this cognitive mediation model. METHODS The present study investigated the cognitive mediation model of CBT in the context of a randomized controlled trial of CBT v. antidepressant medication (ADM) for adult depression. Participants with major depressive disorder were randomized to receive 16 weeks of CBT (n = 54) or ADM (n = 50). Depression symptoms and three candidate cognitive mediators (dysfunctional attitudes, cognitive distortions and negative automatic thoughts) were assessed at week 0 (pre-treatment), week 4, week 8 and week 16 (post-treatment). Longitudinal associations between cognition and depression symptoms, and mediation of treatment outcome, were evaluated in structural equation models. RESULTS Both CBT and ADM produced significant reductions in maladaptive cognition and depression symptoms. Cognitive content and depression symptoms were moderately correlated within measurement waves, but cross-lagged associations between the variables and indirect (i.e. mediated) treatment effects were non-significant. CONCLUSIONS The results provide support for concurrent relationships between cognitive and symptom change, but not the longitudinal relationships hypothesized by the cognitive mediation model. Results may be indicative of an incongruence between the timing of measurement and the dynamics of cognitive and symptom change.",2019,Both CBT and ADM produced significant reductions in maladaptive cognition and depression symptoms.,"['adult depression', 'Participants with major depressive disorder']","['CBT v. antidepressant medication (ADM', 'ADM', 'CBT', 'cognitive-behavioural therapy v. pharmacotherapy', 'cognitive-behavioural therapy (CBT']","['maladaptive cognition and depression symptoms', 'Cognitive content and depression symptoms', 'Depression symptoms and three candidate cognitive mediators (dysfunctional attitudes, cognitive distortions and negative automatic thoughts', 'maladaptive cognition']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}]","[{'cui': 'C0003289', 'cui_str': 'Antidepressant Drugs'}, {'cui': 'C4521767', 'cui_str': 'US Military Commissioned Officer O10'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0332482', 'cui_str': 'Abnormal shape'}, {'cui': 'C0424004', 'cui_str': 'Negative automatic thoughts (finding)'}]",,0.0312751,Both CBT and ADM produced significant reductions in maladaptive cognition and depression symptoms.,"[{'ForeName': 'Leanne', 'Initials': 'L', 'LastName': 'Quigley', 'Affiliation': 'Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, USA.'}, {'ForeName': 'David J A', 'Initials': 'DJA', 'LastName': 'Dozois', 'Affiliation': 'Department of Psychology, Western University, London, Canada.'}, {'ForeName': 'R Michael', 'Initials': 'RM', 'LastName': 'Bagby', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Canada.'}, {'ForeName': 'Daniela S S', 'Initials': 'DSS', 'LastName': 'Lobo', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Canada.'}, {'ForeName': 'Lakshmi', 'Initials': 'L', 'LastName': 'Ravindran', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Canada.'}, {'ForeName': 'Lena C', 'Initials': 'LC', 'LastName': 'Quilty', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Canada.'}]",Psychological medicine,['10.1017/S0033291718003653'] 918,29397382,Effect of communication skills based group counseling on mothers' sex dialogue with their adolescent daughters.,"Background Sex dialogue is one of the most critical and challenging topics between mothers and adolescents. The knowledge and skills of mothers in sex dialogue with their daughters are essential. The purpose of this study is to determine the effect of group counseling based on communication skills on mothers through their sex dialogue with their daughters. Methods A randomized controlled field trial was conducted on 168 couples of mothers and their daughters selected by the stratified matching method and randomly divided into two control and intervention groups. The mothers in the intervention group participated in a communication-based consultation in groups consisting of 6-12 people for 6-7 weekly sessions, each one lasting 60 min. The data collection tool was a Persian-translated questionnaire by Jaccard for sex dialogue between mother and daughter. The data were analyzed using Chi-square (χ2), ANOVA with repeated measures and modified post hoc Bonferroni tests. Results There was a significant difference in the mean score of mother-daughter sex dialogue 1 week after intervention between the intervention (34.48 ± 8.74) and control (40.44 ± 9.49) groups (p = 0.001) and 1 month after the intervention between the intervention (30.41 ± 10.07) and control (42.47 ± 9.62) groups (p < 0.001). Conclusion Through applying communication skills, an increase in mother-daughter sex dialogue frequency was observed after group counseling. Therefore, it is suggested to promote mother-daughter communication skills by accessing the mothers via schools, health centers and with the aid of midwifery counselors, midwives and other trained caretakers.",2018,There was a significant difference in the mean score of mother-daughter sex dialogue 1 week after intervention between the intervention (34.48 ± 8.74) and control (40.44 ± 9.49) groups (p = 0.001) and 1 month after the intervention between the intervention (30.41 ± 10.07) and control (42.47 ± 9.62) groups (p < 0.001).,"[""mothers' sex dialogue with their adolescent daughters"", 'mothers and adolescents', 'mothers through their sex dialogue with their daughters', '168 couples of mothers and their daughters selected by the stratified matching method and randomly divided into two control and intervention groups']","['communication skills based group counseling', 'group counseling based on communication skills', 'communication-based consultation']","['mean score of mother-daughter sex dialogue', 'mother-daughter sex dialogue frequency']","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0011011', 'cui_str': 'Daughter'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C4319556', 'cui_str': 'One hundred and sixty-eight'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0332286', 'cui_str': 'Into (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0870313', 'cui_str': 'Communication skills'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0237547', 'cui_str': 'Group counseling (procedure)'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0011011', 'cui_str': 'Daughter'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]",168.0,0.021586,There was a significant difference in the mean score of mother-daughter sex dialogue 1 week after intervention between the intervention (34.48 ± 8.74) and control (40.44 ± 9.49) groups (p = 0.001) and 1 month after the intervention between the intervention (30.41 ± 10.07) and control (42.47 ± 9.62) groups (p < 0.001).,"[{'ForeName': 'Tayebe', 'Initials': 'T', 'LastName': 'Ziaei', 'Affiliation': 'Counseling and Reproductive Health Research Center, Golestan University of Medical Sciences, Gorgan, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Ghanbari Gorji', 'Affiliation': 'Counseling and Reproductive Health Research Center, Golestan University of Medical Sciences, Gorgan, Iran.'}, {'ForeName': 'Naser', 'Initials': 'N', 'LastName': 'Behnampour', 'Affiliation': 'Department of Biostatistics, Faculty of Health, Golestan University of Medical Sciences, Gorgan, Iran.'}, {'ForeName': 'Masumeh', 'Initials': 'M', 'LastName': 'Rezaei Aval', 'Affiliation': 'Counseling and Reproductive Health Research Center, Golestan University of Medical Sciences, Gorgan, Iran.'}]",International journal of adolescent medicine and health,['10.1515/ijamh-2017-0141'] 919,29445440,Comparison of Clinical and Radiological Outcome of Carotid Angioplasty and Stenting after Direct Navigation Versus Exchange Methods: A Randomized Clinical Trial.,"Background The purpose of this study was to compare the frequency of microembolic brain infarcts after direct navigation method versus exchange method in carotid artery stenting and vertebral artery origin angioplasty. Methods and Material This is a prospective study conducted at Shiraz University of Medical Sciences in southern Iran. Consecutive patients undergoing ""carotid angioplasty and stenting"" and ""vertebral artery origin stenting"" were randomly assigned into two groups with ""direct navigation method"" and ""exchange method."" Subsequently, postprocedural magnetic resonance imaging (MRI) including diffusion weighted imaging and apparent diffusion coefficient were obtained within the first 24 hours after completion of the procedure. Results In total, 89 patients were recruited (67% male, mean age: 72 years). Cases comprised of 38 left internal carotid arteries (ICAs), 38 right ICAs, 6 left vertebral artery origin, and 7 right vertebral artery origin. Forty patients underwent exchange method, while 49 underwent direct navigation method. There was only one clinical stroke that occurred in ""exchange method"" group. Fifteen patients (37.5%) in exchange group and 23 patients (46.9%) in direct navigation group developed diffusion restricted lesions. In exchange group, 13 patients (32.5%) had at least one diffusion restricted lesion ipsilateral to the target vessel, and three patients (7.5%) had at least one diffusion restricted lesion contralateral to the target vessel. In direct navigation group, these measures were 19 (38.8%) and 9 (18.4%). However, no statistically significant intergroup differences were observed. The only significant difference was bilateral infarct percentile, which was more common in the direct navigation method (0.032). Conclusion Diffusion restricted lesions were more common in the direct navigation method, both ipsilateral and contralateral to the target vessel, and in both carotid and vertebral artery study subgroups. However, differences were not statistically significant.",2017,"The only significant difference was bilateral infarct percentile, which was more common in the direct navigation method (0.032). ","['Consecutive patients undergoing ""carotid angioplasty and stenting"" and ""vertebral artery origin stenting', '89 patients were recruited (67% male, mean age: 72 years', 'Forty patients underwent exchange method, while 49 underwent direct navigation method', 'Shiraz University of Medical Sciences in southern Iran', 'Cases comprised of 38 left internal carotid arteries (ICAs), 38 right ICAs, 6 left vertebral artery origin, and 7 right vertebral artery origin']","['direct navigation method versus exchange method', 'direct navigation', 'Carotid Angioplasty and Stenting after Direct Navigation Versus Exchange Methods', 'direct navigation method"" and ""exchange method']","['clinical stroke', 'diffusion restricted lesions', 'bilateral infarct percentile']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3203476', 'cui_str': 'Carotid angioplasty'}, {'cui': 'C0042559', 'cui_str': 'Vertebral Artery'}, {'cui': 'C0439659', 'cui_str': 'Origins (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0226157', 'cui_str': 'Structure of left internal carotid artery'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0226231', 'cui_str': 'Structure of left vertebral artery'}, {'cui': 'C0226230', 'cui_str': 'Structure of right vertebral artery'}]","[{'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C3203476', 'cui_str': 'Carotid angioplasty'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C0443288', 'cui_str': 'Restricted (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0021308', 'cui_str': 'Infarction'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}]",89.0,0.0532954,"The only significant difference was bilateral infarct percentile, which was more common in the direct navigation method (0.032). ","[{'ForeName': 'Mojtaba', 'Initials': 'M', 'LastName': 'Rismanchi', 'Affiliation': 'Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Afshin', 'Initials': 'A', 'LastName': 'Borhani-Haghighi', 'Affiliation': 'Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",Journal of vascular and interventional neurology,[] 920,29504440,"Effects of a Community-Based Exercise Program on Older Adults' Physical Function, Activities of Daily Living, and Exercise Self-Efficacy: Feeling Fit Club.","Community-based exercise programs have demonstrated feasibility, yet many lack controlled studies examining their efficacy. This study examined the efficacy of a community-based exercise program, using a controlled design. Participants ( N = 262, M age = 74.0 years, SD = 8.4) were women (77%) and men recruited from senior centers served by the county Area Agency on Aging. Intervention participants ( n = 133) were newly enrolled in classes. Controls ( n = 129) were recruited from matched sites not offering classes. Validated measures of physical function, exercise self-efficacy, balance, and activities of daily living (ADL) confidence were administered at baseline and 3 months. Significant improvements in upper and lower body strength, aerobic endurance, mobility, exercise self-efficacy, and balance were found in the exercisers but not controls. No changes in ADL confidence occurred in exercisers, while significant decreases occurred in controls. Findings support the efficacy of the county-wide program. Building an evidence base for community-delivered programs should provide impetus for increased dissemination through state and national agencies thereby increasing program impact.",2020,"Significant improvements in upper and lower body strength, aerobic endurance, mobility, exercise self-efficacy, and balance were found in the exercisers but not controls.","['Participants ( N = 262, M age = 74.0 years, SD = 8.4) were women (77%) and men recruited from senior centers served by the county Area Agency on Aging', 'Intervention participants ( n = 133) were newly enrolled in classes', 'Controls ( n = 129) were recruited from matched sites not offering classes']","['community-based exercise program', 'Community-Based Exercise Program', 'Community-based exercise programs']","['ADL confidence', 'physical function, exercise self-efficacy, balance, and activities of daily living (ADL) confidence', ""Older Adults' Physical Function, Activities of Daily Living, and Exercise Self-Efficacy"", 'upper and lower body strength, aerobic endurance, mobility, exercise self-efficacy, and balance']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517876', 'cui_str': '8.4'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C3658240', 'cui_str': 'Centers for the Aged'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C1444651', 'cui_str': 'Not offered'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0001288', 'cui_str': 'ADL'}, {'cui': 'C0237529', 'cui_str': 'Self Confidence'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C1268088', 'cui_str': 'Lower body'}, {'cui': 'C0518031', 'cui_str': 'Endurance capacity'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}]",133.0,0.0227548,"Significant improvements in upper and lower body strength, aerobic endurance, mobility, exercise self-efficacy, and balance were found in the exercisers but not controls.","[{'ForeName': 'Susan S', 'Initials': 'SS', 'LastName': 'Levy', 'Affiliation': 'San Diego State University, CA, USA.'}, {'ForeName': 'Katie J', 'Initials': 'KJ', 'LastName': 'Thralls', 'Affiliation': 'San Diego State University, CA, USA.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Goble', 'Affiliation': 'San Diego State University, CA, USA.'}, {'ForeName': 'Taylor B', 'Initials': 'TB', 'LastName': 'Krippes', 'Affiliation': 'San Diego State University, CA, USA.'}]",Journal of applied gerontology : the official journal of the Southern Gerontological Society,['10.1177/0733464818760237'] 921,29470691,Even effect of milk protein and carbohydrate intake but no further effect of heavy resistance exercise on myofibrillar protein synthesis in older men.,"PURPOSE The responsiveness of older individuals' skeletal muscle to anabolic strategies may be impaired. However, direct comparisons within the same experimental setting are sparse. The aim of this study was to assess the resting and post-resistance exercise muscle protein synthesis rates in response to two types of milk protein and carbohydrate using a unilateral exercise leg model. METHODS Twenty-seven older (69 ± 1 year, mean ± SE) men were randomly assigned one of three groups: Whey hydrolysate (WH), caseinate (CAS), or carbohydrate (CHO). By applying stable isotope tracer techniques (L-[ 15 N]phenylalanine), the fasted-rested (basal) myofibrillar fractional synthesis rate (FSR) was measured. Hereafter, FSR was measured in the postprandial phase (0.45 g nutrient/kg LBM) in both legs, one rested (fed-rest) and one exercised (10 × 8 reps at 70% 1RM; fed-exercise). In addition, the activity of p70S6K and venous plasma insulin, phenylalanine, and leucine concentrations were measured. RESULTS Insulin, phenylalanine, and leucine concentrations differed markedly after intake of the different study drinks. The basal FSR in WH, CAS, and CHO were 0.027 ± 0.003, 0.030 ± 0.003, and 0.030 ± 0.004%/h, the fed-rested FSR were 0.043 ± 0.004, 0.045 ± 0.003, and 0.035 ± 0.004%/h, and the fed-exercised FSR were 0.041 ± 0.004, 0.043 ± 0.004, and 0.034 ± 0.004%/h, respectively. No significant differences were observed at any state between the groups. Fed-rested- and fed-exercised FSR were higher than basal (P < 0.001). 3 h after exercise and feeding, no significant group differences were detected in the activity of p70S6K. CONCLUSIONS Milk protein and carbohydrate supplementation stimulate myofibrillar protein synthesis in older men, with no further effect of heavy resistance exercise within 0-3 h post exercise.",2019,Fed-rested- and fed-exercised FSR were higher than basal (P < 0.001).,"['Twenty-seven older (69\u2009±\u20091\xa0year, mean\u2009±\u2009SE', 'older men']","['carbohydrate supplementation', 'heavy resistance exercise', 'stable isotope tracer techniques (L-[ 15 N]phenylalanine', 'milk protein and carbohydrate intake', 'Whey hydrolysate (WH), caseinate (CAS), or carbohydrate (CHO']","['myofibrillar protein synthesis', 'activity of p70S6K and venous plasma insulin, phenylalanine, and leucine concentrations', 'Insulin, phenylalanine, and leucine concentrations', 'heavy resistance exercise', 'basal FSR in WH, CAS, and CHO', 'fasted-rested (basal) myofibrillar fractional synthesis rate (FSR']","[{'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C3538953', 'cui_str': 'Carbohydrate supplementation'}, {'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0302918', 'cui_str': 'Stable isotope (substance)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0026138', 'cui_str': 'Milk Proteins'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0452720', 'cui_str': 'Whey'}, {'cui': 'C3535837', 'cui_str': 'caseinate'}]","[{'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C1136240', 'cui_str': 'Ribosomal Protein S6 Kinases, 70-kDa'}, {'cui': 'C3838734', 'cui_str': 'Venous plasma'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0031453', 'cui_str': 'L-phenylalanine'}, {'cui': 'C0023401', 'cui_str': 'L-leucine'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0205112', 'cui_str': 'Basal (qualifier value)'}, {'cui': 'C0035253', 'cui_str': 'Rest'}]",,0.0226173,Fed-rested- and fed-exercised FSR were higher than basal (P < 0.001).,"[{'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Reitelseder', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Bispebjerg Bakke 23, building 8, 1st floor, 2400, Copenhagen NV, Denmark. soeren.reitelseder@regionh.dk.'}, {'ForeName': 'Kasper', 'Initials': 'K', 'LastName': 'Dideriksen', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Bispebjerg Bakke 23, building 8, 1st floor, 2400, Copenhagen NV, Denmark.'}, {'ForeName': 'Jakob', 'Initials': 'J', 'LastName': 'Agergaard', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Bispebjerg Bakke 23, building 8, 1st floor, 2400, Copenhagen NV, Denmark.'}, {'ForeName': 'Nikolaj M', 'Initials': 'NM', 'LastName': 'Malmgaard-Clausen', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Bispebjerg Bakke 23, building 8, 1st floor, 2400, Copenhagen NV, Denmark.'}, {'ForeName': 'Rasmus L', 'Initials': 'RL', 'LastName': 'Bechshoeft', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Bispebjerg Bakke 23, building 8, 1st floor, 2400, Copenhagen NV, Denmark.'}, {'ForeName': 'Rasmus K', 'Initials': 'RK', 'LastName': 'Petersen', 'Affiliation': 'Department of Biology, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Serena', 'Affiliation': 'Arla Foods amba, Viby J, Denmark.'}, {'ForeName': 'Ulla R', 'Initials': 'UR', 'LastName': 'Mikkelsen', 'Affiliation': 'Arla Foods Ingredients Group P/S, Viby J, Denmark.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Holm', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Bispebjerg Bakke 23, building 8, 1st floor, 2400, Copenhagen NV, Denmark.'}]",European journal of nutrition,['10.1007/s00394-018-1641-1'] 922,29429455,[Early rehabilitation intervention reduces the incidence of extrauterine growth retardation in preterm infants].,"OBJECTIVE To investigate the effect of early rehabilitation intervention on the incidences of extrauterine growth retardation (EUGR) and early diseases in preterm infants. METHODS The appropriate-for-gestational-age preterm infants with a gestational age of <34 weeks and a birth weight of 1 000 to <2 000 g who were admitted to the neonatal intensive care unit (NICU) within 24 hours after birth were enrolled in a prospective randomized controlled trial. These infants were randomly divided into rehabilitation intervention group and control group. The infants in the rehabilitation intervention group were given early rehabilitation after their vital signs became stable, including oral sensory and muscle strength training and pressure touching of the head, chest, abdomen, extremities, hands, and feet. The primary outcome measures were the time to independent oral feeding, length of hospital stay, and incidence rate of EUGR. The secondary outcome measures were the incidence rates of related diseases in preterm infants, such as apnea, feeding intolerance, and sepsis. RESULTS A total of 97 preterm infants who met the inclusion criteria and had complete data were enrolled, with 48 in the control group and 49 in the rehabilitation intervention group. The rehabilitation intervention group had a shorter time to independent oral feeding than the control group (P<0.05). Compared with the control group, the rehabilitation intervention group had a shorter length of hospital stay and a lower corrected gestational age at discharge (P<0.05), as well as a lower incidence rate of EUGR (P<0.05). The rehabilitation intervention group ONCLUSIONS: Early rehabilitation intervention for preterm infants in the NICU may reduce the incidence rates of apnea, feeding intolerance, and EUGR and help them to achieve independent oral feeding early.",2018,The rehabilitation intervention group had a shorter time to independent oral feeding than the control group (P<0.05).,"['gestational-age preterm infants with a gestational age of <34 weeks and a birth weight of 1\u2009000 to <2\u2009000\u2005g who were admitted to the neonatal intensive care unit (NICU) within 24 hours after birth', 'preterm infants', '97 preterm infants who met the inclusion criteria and had complete data were enrolled, with 48 in the control group and 49 in the rehabilitation intervention group']","['early rehabilitation intervention', 'early rehabilitation after their vital signs became stable, including oral sensory and muscle strength training', 'rehabilitation intervention group and control group', 'Early rehabilitation intervention', 'rehabilitation intervention']","['incidence rates of related diseases in preterm infants, such as apnea, feeding intolerance, and sepsis', 'shorter length of hospital stay', 'incidence of extrauterine growth retardation', 'incidence rates of apnea, feeding intolerance, and EUGR', 'shorter time to independent oral feeding', 'time to independent oral feeding, length of hospital stay, and incidence rate of EUGR']","[{'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}, {'cui': 'C0021709', 'cui_str': 'Newborn ICU'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0518766'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0445254', 'cui_str': 'Sensory (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C1820738', 'cui_str': 'Feeding intolerance'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0151686', 'cui_str': 'Growth retardation (morphologic abnormality)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]",97.0,0.0353658,The rehabilitation intervention group had a shorter time to independent oral feeding than the control group (P<0.05).,"[{'ForeName': 'Wen-Si', 'Initials': 'WS', 'LastName': 'Ni', 'Affiliation': 'Department of Neonatology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China. xlj68115@sina.com.'}, {'ForeName': 'Yong-Hong', 'Initials': 'YH', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Dong-Ying', 'Initials': 'DY', 'LastName': 'Zhao', 'Affiliation': ''}, {'ForeName': 'Jin-Tong', 'Initials': 'JT', 'LastName': 'Tan', 'Affiliation': ''}, {'ForeName': 'Tian-Wen', 'Initials': 'TW', 'LastName': 'Zhu', 'Affiliation': ''}, {'ForeName': 'Li-Juan', 'Initials': 'LJ', 'LastName': 'Xie', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 923,29429459,[Clinical effect of Saccharomyces boulardii powder combined with azithromycin sequential therapy in treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia].,"OBJECTIVE To investigate the clinical effect of Saccharomyces boulardii powder combined with azithromycin sequential therapy in the treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia. METHODS A total of 88 children with diarrhea secondary to Mycoplasma pneumoniae pneumonia between June 2015 and March 2017 were divided into control group and study group using a random number table, with 44 children in each group. The children in the control group were given routine treatment combined with azithromycin sequential therapy, and those in the study group were given oral Saccharomyces boulardii powder in addition to the treatment in the control group until the end of azithromycin sequential therapy. After the treatment ended, the two groups were compared in terms of time to improvement of clinical symptoms, length of hospital stay, clinical outcome, defecation frequency before and after treatment, condition of intestinal dysbacteriosis, and incidence of adverse events. RESULTS Compared with the control group, the study group had significantly shorter time to improvement of clinical symptoms and length of hospital stay (P<0.05). The study group had a significantly higher response rate than the control group (P<0.05). On days 3 and 5 of treatment, the study group had a significant reduction in defecation frequency compared with the control group (P<0.05). The study group had a significantly lower rate of intestinal dysbacteriosis than the control group (P<0.05). There was no significant difference in the incidence of adverse events between the two groups (P>0.05). CONCLUSIONS In the treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia, Saccharomyces boulardii powder combined with azithromycin sequential therapy can improve clinical symptoms, shorten the length of hospital stay, reduce defecation frequency and the incidence of intestinal dysbacteriosis, and improve clinical outcomes, and does not increase the risk of adverse events.",2018,"Compared with the control group, the study group had significantly shorter time to improvement of clinical symptoms and length of hospital stay (P<0.05).","['children with diarrhea secondary to Mycoplasma pneumoniae pneumonia', '88 children with diarrhea secondary to Mycoplasma pneumoniae pneumonia between June 2015 and March 2017']","['oral Saccharomyces boulardii powder', 'azithromycin sequential therapy', 'routine treatment combined with azithromycin sequential therapy', 'Saccharomyces boulardii powder combined with azithromycin sequential therapy']","['risk of adverse events', 'defecation frequency', 'clinical symptoms, length of hospital stay, clinical outcome, defecation frequency before and after treatment, condition of intestinal dysbacteriosis, and incidence of adverse events', 'response rate', 'shorter time to improvement of clinical symptoms and length of hospital stay', 'length of hospital stay, reduce defecation frequency and the incidence of intestinal dysbacteriosis', 'rate of intestinal dysbacteriosis', 'incidence of adverse events']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0175668', 'cui_str': 'Secondary (qualifier value)'}, {'cui': 'C0032302', 'cui_str': 'Pneumonia, Primary Atypical'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0772093', 'cui_str': 'Saccharomyces boulardii'}, {'cui': 'C0032861', 'cui_str': 'Powdered drug preparation'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0001758', 'cui_str': 'Follow-Up Care'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0021853', 'cui_str': 'Intestines'}, {'cui': 'C1536021', 'cui_str': 'Disbacteriosis'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}]",88.0,0.0194437,"Compared with the control group, the study group had significantly shorter time to improvement of clinical symptoms and length of hospital stay (P<0.05).","[{'ForeName': 'Qi-Fen', 'Initials': 'QF', 'LastName': 'Chen', 'Affiliation': 'Department of Pediatrics, Central Hospital of Jiangjin District, Chongqing 402260, China. hm_4167@126.com.'}, {'ForeName': 'Yi-Wei', 'Initials': 'YW', 'LastName': 'Zhang', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 924,29386053,Routine versus on demand removal of the syndesmotic screw; a protocol for an international randomised controlled trial (RODEO-trial).,"BACKGROUND Syndesmotic injuries are common and their incidence is rising. In case of surgical fixation of the syndesmosis a metal syndesmotic screw is used most often. It is however unclear whether this screw needs to be removed routinely after the syndesmosis has healed. Traditionally the screw is removed after six to 12 weeks as it is thought to hamper ankle functional and to be a source of pain. Some studies however suggest this is only the case in a minority of patients. We therefore aim to investigate the effect of retaining the syndesmotic screw on functional outcome. DESIGN This is a pragmatic international multicentre randomised controlled trial in patients with an acute syndesmotic injury for which a metallic syndesmotic screw was placed. Patients will be randomised to either routine removal of the syndesmotic screw or removal on demand. Primary outcome is functional recovery at 12 months measured with the Olerud-Molander Score. Secondary outcomes are quality of life, pain and costs. In total 194 patients will be needed to demonstrate non-inferiority between the two interventions at 80% power and a significance level of 0.025 including 15% loss to follow-up. DISCUSSION If removal on demand of the syndesmotic screw is non-inferior to routine removal in terms of functional outcome, this will offer a strong argument to adopt this as standard practice of care. This means that patients will not have to undergo a secondary procedure, leading to less complications and subsequent lower costs. TRIAL REGISTRATION This study was registered at the Netherlands Trial Register (NTR5965), Clinicaltrials.gov ( NCT02896998 ) on July 15th 2016.",2018,"In total 194 patients will be needed to demonstrate non-inferiority between the two interventions at 80% power and a significance level of 0.025 including 15% loss to follow-up. ","['In total 194 patients', 'patients with an acute syndesmotic injury for which a metallic syndesmotic screw was placed']","['Routine versus on demand removal of the syndesmotic screw', 'syndesmotic screw', 'syndesmotic screw or removal on demand']","['functional recovery at 12\xa0months measured with the Olerud-Molander Score', 'quality of life, pain and costs']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3661498', 'cui_str': 'Syndesmotic Injuries'}, {'cui': 'C0301559', 'cui_str': 'Screw (physical object)'}, {'cui': 'C1704765', 'cui_str': 'Place - dosing instruction imperative'}]","[{'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0301559', 'cui_str': 'Screw (physical object)'}]","[{'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",194.0,0.255765,"In total 194 patients will be needed to demonstrate non-inferiority between the two interventions at 80% power and a significance level of 0.025 including 15% loss to follow-up. ","[{'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'Dingemans', 'Affiliation': 'Department of Surgery, Trauma Unit, Academic Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands.'}, {'ForeName': 'M F N', 'Initials': 'MFN', 'LastName': 'Birnie', 'Affiliation': 'Department of Surgery, Trauma Unit, Academic Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands.'}, {'ForeName': 'F R K', 'Initials': 'FRK', 'LastName': 'Sanders', 'Affiliation': 'Department of Surgery, Trauma Unit, Academic Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands.'}, {'ForeName': 'M P J', 'Initials': 'MPJ', 'LastName': 'van den Bekerom', 'Affiliation': 'Department of Orthopedic Surgery, OLVG, P.O. Box 95500, 1090 HM, Amsterdam, The Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Backes', 'Affiliation': 'Department of Surgery, Trauma Unit, Academic Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'van Beeck', 'Affiliation': 'Department of Public Health, Erasmus MC, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.'}, {'ForeName': 'F W', 'Initials': 'FW', 'LastName': 'Bloemers', 'Affiliation': 'Department of Surgery, Trauma Unit, VU University Medical Centre, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'van Dijkman', 'Affiliation': 'Department of Surgery, Flevo Hospital, P.O. Box 3005, 1300 EG, Almere, The Netherlands.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Flikweert', 'Affiliation': 'Department of Surgery, Deventer Hospital, P.O. Box 5001, 7400 GC, Deventer, The Netherlands.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Haverkamp', 'Affiliation': 'Department of Surgery, Slotervaart Hospital, P.O. Box 90440, 1006BK, Amsterdam, The Netherlands.'}, {'ForeName': 'H R', 'Initials': 'HR', 'LastName': 'Holtslag', 'Affiliation': 'Department of Surgery, Trauma Unit, Academic Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Hoogendoorn', 'Affiliation': 'Department of Surgery, Haaglanden MC, P.O. Box 432, 2501 CK, The Hague, The Netherlands.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Joosse', 'Affiliation': 'Department of Surgery, Noordwest Hospital Group, P.O. Box 501, 1815 JD, Alkmaar, The Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Parkkinen', 'Affiliation': 'Department of Orthopaedics and Traumatology, Helsinki University Hospital, Topeliuksenkatu 5, 00260, Helsinki, Finland.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Roukema', 'Affiliation': 'Department of Surgery, Maasstad Hospital, P.O. Box 9100, 3007 AC, Rotterdam, The Netherlands.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Sosef', 'Affiliation': 'Department of Surgery, Spaarne Hospital, P.O. Box 770, 2130 AT, Hoofddorp, The Netherlands.'}, {'ForeName': 'B A', 'Initials': 'BA', 'LastName': 'Twigt', 'Affiliation': 'Department of Surgery, BovenIJ Hospital, P.O. Box 37610, 1030 BD, Amsterdam, The Netherlands.'}, {'ForeName': 'R N', 'Initials': 'RN', 'LastName': 'van Veen', 'Affiliation': 'Department of Surgery, OLVG, P.O. Box 95500, 1090 HM, Amsterdam, The Netherlands.'}, {'ForeName': 'A H', 'Initials': 'AH', 'LastName': 'van der Veen', 'Affiliation': 'Department of Surgery, Catharina Hospital, P.O. Box 1350, 5602 ZA, Eindhoven, The Netherlands.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Vermeulen', 'Affiliation': 'Department of Surgery, Spaarne Hospital, P.O. Box 770, 2130 AT, Hoofddorp, The Netherlands.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Winkelhagen', 'Affiliation': 'Department of Surgery, Westfries Hospital, P.O. Box 600, 1620 AR, Hoorn, The Netherlands.'}, {'ForeName': 'B C', 'Initials': 'BC', 'LastName': 'van der Zwaard', 'Affiliation': ""Department of Orthopaedics, Jeroen Bosch Hospital, P.O. Box 90153, 5200 ME, 's-Hertogenbosch, The Netherlands.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'van Dieren', 'Affiliation': 'Department of Surgery, Trauma Unit, Academic Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands.'}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Goslings', 'Affiliation': 'Department of Orthopedic Surgery, OLVG, P.O. Box 95500, 1090 HM, Amsterdam, The Netherlands.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Schepers', 'Affiliation': 'Department of Surgery, Trauma Unit, Academic Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands. t.schepers@amc.nl.'}]",BMC musculoskeletal disorders,['10.1186/s12891-018-1946-5'] 925,29480399,"The effect of resistant dextrin as a prebiotic on metabolic parameters and androgen level in women with polycystic ovarian syndrome: a randomized, triple-blind, controlled, clinical trial.","INTRODUCTION Polycystic ovary syndrome (PCOS) is one of the most common abnormalities in women of reproductive age that can lead to a variety of metabolic and reproductive disorders. Studies reveal that a healthy diet is the most effective way for treating the risk factors associated with metabolic disorders and place greater emphasis on the consumption of prebiotic foods. The present study aims to determine the effect of resistant Dextrin on metabolic parameters, including lipid profile, fasting blood glucose (FBS) and high sensitivity C-reactive protein (hsCRP), and androgen levels, including serum levels of dehydroepiandrosterone sulfate (DHEA-S) and free testosterone, as the primary outcomes, and manifestations of PCOS including menstrual cycle irregularity and hirsutism, as the secondary outcomes. METHODS This randomized, controlled, triple-blind, clinical trial was conducted on 62 women aged 18-45 in Tabriz, Iran, in 2016-2017. The participants were divided into a prebiotic group and a placebo group using block randomization. The prebiotic group consumed 20 g of resistant dextrin dissolved in a glass of water and the placebo group 20 g of maltodextrin also dissolved in a glass of water on a daily basis for 3 months. To measure the serum lipid profile, FBS, hsCRP, DHEA-S and free testosterone before and 3 months after the intervention, 5-ml blood samples were collected from the participants and analyzed using the ELISA method. The Ferriman-Gallwey scale for assessing hirsutism and a checklist for assessing menstrual cycle characteristics were completed before and 3 months after the intervention. A general linear model was used to analyze the data. RESULTS No statistically significant differences were observed between the two groups in terms of sociodemographic characteristics and baseline values. 3 months after the intervention, based on the ANCOVA and after adjusting for the baseline values, the mean serum levels of LDL-C (adjusted mean difference = - 29.79; 95% CI = - 43.37 to - 16.21; P < 0.001), triglyceride (AMD = - 38.50; 95% CI = - 59.73 to - 17.28; P = 0.001), total cholesterol (AMD = - 29.98; 95% CI = - 40.14 to - 19.82; P < 0.001), FBS (AMD = - 11.24; 95% CI = - 15.43 to - 7.06; P < 0.001), hsCRP (AMD = - 1.75; 95% CI = - 2.92 to - 0.57; P = 0.004), DHEA-S (AMD = - 0.7; 95% CI = - 1.34 to - 0.13; P = 0.017) and free testosterone (AMD = - 0.32; 95% CI = - 0.56 to - 0.08; P = 0.010) revealed a statistically significant decrease in the intervention group compared to the placebo group, while the mean serum HDL-C showed a statistically significant increase in this group compared to the placebo group (AMD = 5.82; 95% CI = 2.27-9.37; P = 0.002). 3 months after the intervention, there was a significant difference between the two groups in terms of menstrual cycle intervals and hirsutism (P < 0.001). CONCLUSION Resistant dextrin consumption can regulate metabolic parameters and androgen levels and manifestations including hirsutism and menstrual cycle irregularity in women with PCOS.",2019,"3 months after the intervention, there was a significant difference between the two groups in terms of menstrual cycle intervals and hirsutism (P < 0.001). ","['women with PCOS', '62 women aged 18-45 in Tabriz, Iran, in 2016-2017', 'women with polycystic ovarian syndrome']","['prebiotic group consumed 20', 'placebo', 'maltodextrin', 'Resistant dextrin consumption', 'resistant dextrin']","['FBS', 'metabolic parameters, including lipid profile, fasting blood glucose (FBS) and high sensitivity C-reactive protein (hsCRP), and androgen levels, including serum levels of dehydroepiandrosterone sulfate (DHEA-S) and free testosterone, as the primary outcomes, and manifestations of PCOS including menstrual cycle irregularity and hirsutism, as the secondary outcomes', 'total cholesterol', 'menstrual cycle intervals and hirsutism', 'mean serum levels of LDL-C', 'free testosterone', 'triglyceride', 'mean serum HDL-C', 'hsCRP', 'serum lipid profile, FBS, hsCRP, DHEA-S and free testosterone']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}, {'cui': 'C0032460', 'cui_str': 'Sclerocystic Ovary Syndrome'}]","[{'cui': 'C2717875', 'cui_str': 'Prebiotics'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0054527', 'cui_str': 'caloreen'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0919646', 'cui_str': 'Androgen level'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0057277', 'cui_str': 'Prasterone Sulfate'}, {'cui': 'C0011185', 'cui_str': 'prasterone'}, {'cui': 'C0443483', 'cui_str': 'Free testosterone (substance)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1280464', 'cui_str': 'Manifestation of (qualifier value)'}, {'cui': 'C4553712', 'cui_str': 'Onset of menstrual cycle'}, {'cui': 'C0019572', 'cui_str': 'Hirsutism'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}]",62.0,0.254515,"3 months after the intervention, there was a significant difference between the two groups in terms of menstrual cycle intervals and hirsutism (P < 0.001). ","[{'ForeName': 'Sevda', 'Initials': 'S', 'LastName': 'Gholizadeh Shamasbi', 'Affiliation': 'Department of Midwifery, Faculty of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Parvin', 'Initials': 'P', 'LastName': 'Dehgan', 'Affiliation': 'Department of Food Science and Technology, School of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Sakineh', 'Initials': 'S', 'LastName': 'Mohammad-Alizadeh Charandabi', 'Affiliation': 'Department of Midwifery, Faculty of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Akbar', 'Initials': 'A', 'LastName': 'Aliasgarzadeh', 'Affiliation': 'Endocrine Research Center, Imam Reza Medical, Research and Training Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Mojgan', 'Initials': 'M', 'LastName': 'Mirghafourvand', 'Affiliation': 'Midwifery Department, Social Determinants of Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. mirghafourvandm@tbzmed.ac.ir.'}]",European journal of nutrition,['10.1007/s00394-018-1648-7'] 926,31610437,Effects of awareness material featuring individuals with experience of depression and suicidal thoughts on an audience with depressive symptoms: Randomized controlled trial.,"BACKGROUND AND OBJECTIVE Suicide prevention plans support individuals with personal experience of mental disorders and suicidality to provide their narratives of coping in the media. The evidence how such portrayals impact on individuals with similar symptoms is limited and there are concerns about unwanted side effects. METHODS This was a double-blinded randomized controlled online trial conducted from August to November 2018. N = 158 young adults aged 18-24 with current depressive symptoms and suicidal thoughts were randomized to watch a short film featuring a young individual with personal experience of depression and suicidality (n = 81), or a thematically unrelated control film (n = 77) with similar stylistic elements. Questionnaire data were collected before and immediately after exposure and analysed with ANOVA. The primary outcome was suicidal ideation; secondary outcomes were depressed mood and help-seeking intentions. We also tested the moderating effects of the degree of depressive symptoms on the effects. RESULTS Depressed mood was significantly lower, with small-to medium effect size, in the intervention group compared to the control group (F(1,111) = 4.13, P < .05, η p 2  = .036). There was no effect on suicidal ideation or help-seeking intentions in the total sample. Participants screening positive for moderately severe depression or higher experienced an increase in suicidal ideation in the control group. LIMITATIONS Self-reported variables in an online setting. CONCLUSIONS Videos featuring personal experience of coping with depression appear safe for young individuals with similar or higher symptoms of depression and suicidal ideation on the short run, and might have some benefits. TRIAL REGISTRATION German Clinical Trial Registry, DRKS00015095 (registration date: 2018-07-16).",2020,"RESULTS Depressed mood was significantly lower, with small-to medium effect size, in the intervention group compared to the control group (F(1,111) = 4.13, P < .05, η p 2  = .036).","['N\u202f=\u202f158 young adults aged 18-24 with current depressive symptoms and suicidal thoughts', 'awareness material featuring individuals with experience of depression and suicidal thoughts on an audience with depressive symptoms']","['short film featuring a young individual with personal experience of depression and suicidality (n\u202f=\u202f81), or a thematically unrelated control film (n\u202f=\u202f77) with similar stylistic elements']","['suicidal ideation or help-seeking intentions', 'suicidal ideation', 'suicidal ideation; secondary outcomes were depressed mood and help-seeking intentions', 'Questionnaire data']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0424000', 'cui_str': 'Suicidal Ideation'}, {'cui': 'C0004448', 'cui_str': 'Situational Awareness'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]","[{'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C4319646', 'cui_str': 'Film'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0445356', 'cui_str': 'Unrelated (finding)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0013879', 'cui_str': 'Elements'}]","[{'cui': 'C0424000', 'cui_str': 'Suicidal Ideation'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0344315', 'cui_str': 'Depressed'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",158.0,0.248972,"RESULTS Depressed mood was significantly lower, with small-to medium effect size, in the intervention group compared to the control group (F(1,111) = 4.13, P < .05, η p 2  = .036).","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Niederkrotenthaler', 'Affiliation': 'Unit Suicide Research & Mental Health Promotion, Department of Social and Preventive Medicine, Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, A-1090, Vienna, Austria. Electronic address: thomas.niederkrotenthaler@meduniwien.ac.at.'}, {'ForeName': 'Benedikt', 'Initials': 'B', 'LastName': 'Till', 'Affiliation': 'Unit Suicide Research & Mental Health Promotion, Department of Social and Preventive Medicine, Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, A-1090, Vienna, Austria.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2019.101515'] 927,31491535,"The effects of retrieval versus rehearsal of online problem-solving therapy sessions on recall, problem-solving skills and distress in distressed individuals: An experimental study.","BACKGROUND AND OBJECTIVES Improving memory for the content of therapy sessions might increase the effects of psychological interventions. Previous studies showed that healthy individuals who took a memory test (retrieval) of studied material showed better long-term memory retention than individuals who restudied (rehearsal) the material. The aim of the current study was to find out whether we can translate these findings to a subclinical setting. METHODS Individuals with moderate levels of distress were randomized into retrieving (n = 46) or rehearsing (n = 49) four weekly sessions of online Problem-Solving Therapy (PST). Session recall, problem-solving skills and distress were measured at baseline, three days after each session and at one-week follow-up. RESULTS Retrieval led to overall higher recall, but this difference disappeared when controlling for the time spent on retrieval versus rehearsal. Retrieval did not lead to better problem-solving skills or less distress, compared to rehearsal. Baseline working memory performance moderated the effect of condition on recall after controlling for the time spent on retrieval versus rehearsal: the effect of retrieval compared to rehearsal on recall was larger for individuals with lower working memory performance. LIMITATIONS The sample mostly consisted of university students with overall high working memory scores. CONCLUSIONS This study provided the first evidence that retrieval of the content of PST sessions may lead to better session recall compared to rehearsal of the PST sessions in individuals with a low working memory score. Implications for the use of cognitive support strategies within a therapeutic setting are discussed.",2020,"RESULTS Retrieval led to overall higher recall, but this difference disappeared when controlling for the time spent on retrieval versus rehearsal.","['university students with overall high working memory scores', 'Individuals with moderate levels of distress', 'distressed individuals', 'individuals with a low working memory score', 'individuals with lower working memory performance']","['retrieving (n\u202f=\u202f46) or rehearsing (n\u202f=\u202f49) four weekly sessions of online Problem-Solving Therapy (PST', 'retrieval versus rehearsal of online problem-solving therapy sessions']","['recall, problem-solving skills and distress', 'Session recall, problem-solving skills and distress', 'time spent on retrieval versus rehearsal']","[{'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}]","[{'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C1303140', 'cui_str': 'Problem solving therapy'}]","[{'cui': 'C3669643', 'cui_str': 'Problem solving (qualifier value)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",,0.0758784,"RESULTS Retrieval led to overall higher recall, but this difference disappeared when controlling for the time spent on retrieval versus rehearsal.","[{'ForeName': 'Sanne J E', 'Initials': 'SJE', 'LastName': 'Bruijniks', 'Affiliation': 'Department of Clinical, Neuro-, and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, the Netherlands. Electronic address: s.j.e.bruijniks@vu.nl.'}, {'ForeName': 'Marit', 'Initials': 'M', 'LastName': 'Sijbrandij', 'Affiliation': 'Department of Clinical, Neuro-, and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, the Netherlands.'}, {'ForeName': 'Marcus J H', 'Initials': 'MJH', 'LastName': 'Huibers', 'Affiliation': 'Department of Clinical, Neuro-, and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, the Netherlands; Department of Psychology, University of Pennsylvania, Philadelphia, United States.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2019.101485'] 928,29307094,Diet and exercise changes following bone densitometry in the Patient Activation After DXA Result Notification (PAADRN) study.,"Calcium and vitamin D intake and exercise are suboptimal among older adults. Following bone densitometry, a letter communicating individualized fracture risk accompanied by an educational brochure improved participants' lifestyle-but no more than existing communication strategies-over 52 weeks. Simple communication strategies are insufficient for achieving optimal levels of bone health behaviors. PURPOSE The Patient Activation After DXA Result Notification (PAADRN) study was designed to evaluate whether a letter with individualized fracture risk and an educational brochure mailed to patients soon after their DXA might improve bone health behaviors (daily calcium intake, vitamin D supplementation, and weekly exercise sessions) compared to slower, less individualized communication characterizing usual care. METHODS Participants ≥ 50 years were recruited, at three sites, following their DXA and randomized with 1:1 allocation to intervention and control (usual care only) groups. Data were collected at enrollment interview and by phone survey at 12 and 52 weeks thereafter. Intention-to-treat analyses were conducted on 7749 of the 20,397 eligible participants who enrolled. Changes in bone health behaviors were compared within and between study groups. Average treatment effects and heterogeneity of treatment effects were estimated with multivariable linear and logistic regression models. RESULTS In unadjusted analyses, calcium intake, vitamin D supplementation, and weekly exercise sessions increased significantly over 52 weeks within both the intervention and control groups (all p < 0.001). In unadjusted analyses and multivariable models, increases in each behavior did not significantly differ between the intervention and control groups. Intervention group participants with a > 20% 10-year fracture risk at enrollment did, however, have a significantly greater increase in calcium intake compared to other study participants (p = 0.031). CONCLUSIONS Bone health behaviors improved, on average, over 52 weeks among all participants following a DXA. Receipt of the PAADRN letter and educational brochure did not directly improve bone health behaviors compared to usual care. TRIAL REGISTRATION The Patient Activation after DXA Result Notification (PAADRN) Study is registered at ClinicalTrials.Gov: NCT01507662, https://clinicaltrials.gov/ct2/show/NCT01507662.",2018,"Receipt of the PAADRN letter and educational brochure did not directly improve bone health behaviors compared to usual care. ","['7749 of the 20,397 eligible participants who enrolled', '50\xa0years', 'Participants ≥', 'older adults']",['Calcium and vitamin D intake and exercise'],"['Patient Activation', 'bone health behaviors', 'calcium intake, vitamin D supplementation, and weekly exercise sessions', 'calcium intake', '10-year fracture risk', 'Patient Activation after DXA Result Notification (PAADRN']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0564439', 'cui_str': 'Vitamin D intake (observable entity)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C3853034', 'cui_str': 'Patient Activation'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0018687'}, {'cui': 'C0489458', 'cui_str': 'Calcium intake (observable entity)'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0422202', 'cui_str': 'Notifications (procedure)'}]",20397.0,0.111887,"Receipt of the PAADRN letter and educational brochure did not directly improve bone health behaviors compared to usual care. ","[{'ForeName': 'Douglas W', 'Initials': 'DW', 'LastName': 'Roblin', 'Affiliation': 'Mid-Atlantic Permanente Research Institute, 2101 East Jefferson St., 3 West, Rockville, MD, 20852, USA. Douglas.W.Roblin@KP.Org.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Cram', 'Affiliation': 'Division of General Internal Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.'}, {'ForeName': 'Yiyue', 'Initials': 'Y', 'LastName': 'Lou', 'Affiliation': 'Department of Biostatistics, University of Iowa College of Public Health, Iowa City, IA, USA.'}, {'ForeName': 'Stephanie W', 'Initials': 'SW', 'LastName': 'Edmonds', 'Affiliation': 'Division of General Internal Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.'}, {'ForeName': 'Sylvie F', 'Initials': 'SF', 'LastName': 'Hall', 'Affiliation': 'College of Nursing, University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Jones', 'Affiliation': 'Department of Biostatistics, University of Iowa College of Public Health, Iowa City, IA, USA.'}, {'ForeName': 'Kenneth G', 'Initials': 'KG', 'LastName': 'Saag', 'Affiliation': 'Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Nicole C', 'Initials': 'NC', 'LastName': 'Wright', 'Affiliation': 'Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Fredric D', 'Initials': 'FD', 'LastName': 'Wolinsky', 'Affiliation': 'Division of General Internal Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Archives of osteoporosis,['10.1007/s11657-017-0402-8'] 929,28774357,[Effect of extensively hydrolyzed formula on growth and development of infants with very/extremely low birth weight].,"OBJECTIVE To study the effect of extensively hydrolyzed formula on the growth and development in very low birth weight (VLBW) and extremely low birth weight (ELBW) infants. METHODS A total of 375 VLBW or ELBW infants were enrolled and divided into an observation group (187 infants) and a control group (188 infants) using a random number table. The infants in the observation group were given extensively hydrolyzed formula, and when the amount of extensively hydrolyzed formula reached 10 mL/time, it was changed to the standard formula for preterm infants. The infants in the control group were given standard formula for preterm infants. Both groups were fed for 4 consecutive weeks and were compared in terms of incidence rate of feeding intolerance, time to establish full enteral feeding, time to complete meconium excretion, number of spontaneous bowel movements, growth and development, motilin level at 4 and 10 days after feeding, and incidence rate of infection. RESULTS Compared with the control group, the observation group had a lower rate of feeding intolerance (P<0.05), a shorter duration to full enteral feeding and time to complete meconium excretion (P<0.05), a higher mean number of daily spontaneous bowel movements (P<0.05), higher body weight (1 793±317 g vs 1 621±138 g; P<0.05), head circumference (30.5±1.1 cm vs 30.0±1.6 cm; P<0.05), and body length (43.9±1.2 cm vs 42.1±2.0 cm; P<0.05), a higher motilin level at 4 and 10 days after feeding (P<0.05), and a significantly lower infection rate (P<0.05). CONCLUSIONS Extensively hydrolyzed formula can increase motilin level, improve gastrointestinal feeding tolerance, promote early growth and development, and reduce the incidence of infection in VLBW and ELBW infants.",2017,"Compared with the control group, the observation group had a lower rate of feeding intolerance (P<0.05), a shorter duration to full enteral feeding and time to complete meconium excretion (P<0.05), a higher mean number of daily spontaneous bowel movements (P<0.05), higher body weight (1 793±317 ","['very low birth weight (VLBW) and extremely low birth weight (ELBW) infants', 'infants with very/extremely low birth weight', 'A total of 375 VLBW or ELBW infants were enrolled and divided into an observation group (187 infants) and a control group (188 infants) using a random number table']",['extensively hydrolyzed formula'],"['shorter duration to full enteral feeding and time to complete meconium excretion', 'incidence rate of feeding intolerance, time to establish full enteral feeding, time to complete meconium excretion, number of spontaneous bowel movements, growth and development, motilin level at 4 and 10 days after feeding, and incidence rate of infection', 'motilin level, improve gastrointestinal feeding tolerance', 'rate of feeding intolerance', 'infection rate', 'higher motilin level', 'head circumference', 'body length', 'mean number of daily spontaneous bowel movements (P<0.05), higher body weight']","[{'cui': 'C0282666', 'cui_str': 'Very Low Birth Weight'}, {'cui': 'C0456065', 'cui_str': 'Infant, Extremely Low Birth Weight'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4517745', 'cui_str': '375 (qualifier value)'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517618', 'cui_str': '187 (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1706074', 'cui_str': 'Table'}]",[],"[{'cui': 'C0439593', 'cui_str': 'Short duration (qualifier value)'}, {'cui': 'C0086225', 'cui_str': 'Enteral Feeding'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0025047', 'cui_str': 'Meconium'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1820738', 'cui_str': 'Feeding intolerance'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C1457898', 'cui_str': 'growth & development'}, {'cui': 'C0026594', 'cui_str': 'Motilin (substance)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0262499', 'cui_str': 'Head circumference (observable entity)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}]",375.0,0.0375732,"Compared with the control group, the observation group had a lower rate of feeding intolerance (P<0.05), a shorter duration to full enteral feeding and time to complete meconium excretion (P<0.05), a higher mean number of daily spontaneous bowel movements (P<0.05), higher body weight (1 793±317 ","[{'ForeName': 'Chun-Yan', 'Initials': 'CY', 'LastName': 'Gu', 'Affiliation': 'Changzhou Maternal and Child Health Care Hospital, Changzhou, Jiangsu 213003, China. 1002451051@qq.com.'}, {'ForeName': 'Hui-Fen', 'Initials': 'HF', 'LastName': 'Jiang', 'Affiliation': ''}, {'ForeName': 'Jin-Xiu', 'Initials': 'JX', 'LastName': 'Wang', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 930,31619442,A Phase I Trial of Berberine in Chinese with Ulcerative Colitis.,"The Chinese natural product, berberine, has biological properties that support its potential efficacy as a colon cancer prevention agent. Its longstanding use in China to treat gastrointestinal tract and rheumatologic disorders is generally regarded as safe, supporting initial investigations in an at-risk population, such as individuals with ulcerative colitis. However, the safety of berberine in this population is not established. Individuals living in China with biopsy-proven ulcerative colitis, ≤grade 2 dysplasia, and with a ulcerative colitis disease activity index (UCDAI) score ≤1 on mesalamine, were randomized 3:1 in a double-blind phase I trial to berberine 900 mg/day or placebo for 3 months, with the primary objective of assessing safety. Blood samples and biopsies of the colorectum, from prespecified locations, were collected prior to and following therapy. Secondary endpoints included changes in UCDAI score, and in tissue and plasma markers of inflammation. Of toxicities at least possibly related, one episode of grade 3 elevation in transaminases and one episode of grade 1 nausea were observed among 12 individuals on berberine, and none were observed among 4 on placebo. The mean plasma berberine concentration was 3.5 nmol/L after berberine treatment, significantly higher than 0.5 nmol/L with placebo. Berberine significantly decreased the Geboes grade in colonic tissue, but had a nonsignificant effect on other tissue or blood biomarkers related to cell growth and inflammation. The combination of berberine and mesalamine is well tolerated in Chinese with ulcerative colitis and may enhance mesalamine's anti-inflammatory effects in colonic tissue.",2020,"Berberine significantly decreased the Geboes grade in colonic tissue, but had a nonsignificant effect on other tissue or blood biomarkers related to cell growth and inflammation.","['Chinese with Ulcerative Colitis', 'Individuals living in China with biopsy-proven UC, ≤ grade 2 dysplasia, and with a UC disease activity index (UCDAI) score ≤ 1 on', 'individuals with ulcerative colitis (UC']","['berberine 900 mg/day or placebo', 'berberine and mesalamine', 'placebo', 'Berberine', 'mesalamine']","['transaminases and one episode of grade 1 nausea', 'mean plasma berberine concentration', 'changes in UCDAI score, and in tissue and plasma markers of inflammation', 'Of toxicities']","[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0009324', 'cui_str': 'Inflammatory Bowel Disease, Ulcerative Colitis Type'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0334044', 'cui_str': 'Dysplasia (morphologic abnormality)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]","[{'cui': 'C0005117', 'cui_str': 'Berberine'}, {'cui': 'C4517900', 'cui_str': '900 (qualifier value)'}, {'cui': 'C0439422', 'cui_str': 'mg/day'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0127615', 'cui_str': 'mesalazine'}]","[{'cui': 'C0002594', 'cui_str': 'Aminotransferases'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0005117', 'cui_str': 'Berberine'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}]",12.0,0.116894,"Berberine significantly decreased the Geboes grade in colonic tissue, but had a nonsignificant effect on other tissue or blood biomarkers related to cell growth and inflammation.","[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': ""Department of Gastroenterology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Yujie', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ""Department of Gastroenterology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Xianmin', 'Initials': 'X', 'LastName': 'Xue', 'Affiliation': ""Department of Gastroenterology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': ""Department of Gastroenterology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Zeng-Shan', 'Initials': 'ZS', 'LastName': 'Li', 'Affiliation': ""Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Guang-Yu', 'Initials': 'GY', 'LastName': 'Yang', 'Affiliation': 'Department of Pathology, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': ""Department of Pharmacology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Pan', 'Affiliation': ""Department of Gastroenterology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Yueyun', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': ""Department of Clinical Laboratory Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Sijun', 'Initials': 'S', 'LastName': 'Hu', 'Affiliation': ""Department of Gastroenterology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Aidong', 'Initials': 'A', 'LastName': 'Wen', 'Affiliation': ""Department of Pharmacology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Yanyan', 'Initials': 'Y', 'LastName': 'Jia', 'Affiliation': ""Department of Pharmacology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Luz Maria', 'Initials': 'LM', 'LastName': 'Rodriguez', 'Affiliation': 'Division of Cancer Prevention, NCI, Bethesda, Maryland.'}, {'ForeName': 'Mary Beth', 'Initials': 'MB', 'LastName': 'Tull', 'Affiliation': 'Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Benante', 'Affiliation': 'Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Seema A', 'Initials': 'SA', 'LastName': 'Khan', 'Affiliation': 'Department of Surgery and Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Cao', 'Affiliation': ""Department of Gastroenterology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Borko', 'Initials': 'B', 'LastName': 'Jovanovic', 'Affiliation': 'Department of Preventive Medicine, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Richmond', 'Affiliation': 'Division of Cancer Prevention, NCI, Bethesda, Maryland.'}, {'ForeName': 'Asad', 'Initials': 'A', 'LastName': 'Umar', 'Affiliation': 'Division of Cancer Prevention, NCI, Bethesda, Maryland.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Bergan', 'Affiliation': 'Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon. kaicwu@fmmu.edu.cn bergan@ohsu.edu.'}, {'ForeName': 'Kaichun', 'Initials': 'K', 'LastName': 'Wu', 'Affiliation': ""Department of Gastroenterology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. kaicwu@fmmu.edu.cn bergan@ohsu.edu.""}]","Cancer prevention research (Philadelphia, Pa.)",['10.1158/1940-6207.CAPR-19-0258'] 931,31616932,"A Moderate-Fat Diet with One Avocado per Day Increases Plasma Antioxidants and Decreases the Oxidation of Small, Dense LDL in Adults with Overweight and Obesity: A Randomized Controlled Trial.","BACKGROUND Avocados are a nutrient-dense source of MUFAs and are rich in antioxidants. Avocados have an additional LDL cholesterol (LDL-C) lowering effect beyond that observed when their MUFAs are substituted for SFAs, especially on small, dense LDL (sdLDL) particles, which are susceptible to in vivo oxidation and associated with increased risk of cardiovascular disease (CVD). OBJECTIVES We investigated whether a healthy diet with 1 avocado daily decreased the following secondary outcomes: circulating oxidized LDL (oxLDL) and related oxidative stress markers. METHODS A randomized, crossover, controlled feeding trial was conducted with 45 men and women, aged 21-70 y, with overweight or obesity and elevated LDL-C (25th-90th percentile). Three cholesterol-lowering diets were provided (5 wk each) in random sequences: a lower-fat (LF) diet (24% calories from fat-7% SFAs, 11% MUFAs, 6% PUFAs) and 2 moderate-fat (MF) diets (34% calories from fat-6% SFAs, 17% MUFAs, 9% PUFAs): the avocado (AV) diet included 1 Hass avocado (∼136 g) per day, and the MF diet used high oleic acid oils to match the fatty acid profile of 1 avocado. A general linear mixed model was used to analyze the treatment effects. RESULTS Compared with baseline, the AV diet significantly decreased circulating oxLDL (-7.0 U/L, -8.8%, P = 0.0004) and increased plasma lutein concentration (19.6 nmol/L, 68.7%, P < 0.0001), and both changes differed significantly from that after the MF and LF diets (P ≤ 0.05). The change in oxLDL caused by the AV diet was significantly correlated with the changes in the number of sdLDL particles (r = 0.32, P = 0.0002) but not large, buoyant LDL particles. CONCLUSIONS One avocado a day in a heart-healthy diet decreased oxLDL in adults with overweight and obesity, and the effect was associated with the reduction in sdLDL. This trial was registered at http://www.clinicaltrials.gov as NCT01235832.",2020,"U/L, -8.8%, P = 0.0004) and increased plasma lutein concentration (19.6 nmol/L, 68.7%, P < 0.0001), and both changes differed significantly from that after the MF and LF diets (P ≤ 0.05).","['45 men and women, aged 21-70 y, with overweight or obesity and elevated LDL-C (25th-90th percentile', 'Adults with Overweight and Obesity']","['oxidized LDL (oxLDL', 'avocado (AV) diet included 1 Hass avocado (∼136 g) per day, and the MF diet used high oleic acid oils']","['plasma lutein concentration', 'number of sdLDL particles', 'circulating oxLDL', 'Oxidation of Small, Dense LDL']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0348035', 'cui_str': 'oxidized low density lipoprotein'}, {'cui': 'C0330230', 'cui_str': 'Avocado'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0028929', 'cui_str': 'Oleic Acids'}, {'cui': 'C0028908', 'cui_str': 'Oils'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0043328', 'cui_str': 'Lutein'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0348035', 'cui_str': 'oxidized low density lipoprotein'}, {'cui': 'C0030011', 'cui_str': 'Oxidation, function (observable entity)'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0439794', 'cui_str': 'Dense (qualifier value)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}]",,0.0615617,"U/L, -8.8%, P = 0.0004) and increased plasma lutein concentration (19.6 nmol/L, 68.7%, P < 0.0001), and both changes differed significantly from that after the MF and LF diets (P ≤ 0.05).","[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Nutritional Sciences, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Tao', 'Affiliation': 'Department of Food Science, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Hao', 'Affiliation': 'Department of Nutritional Sciences, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Todd H', 'Initials': 'TH', 'LastName': 'Stanley', 'Affiliation': 'Department of Food Science, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Kuan-Hsun', 'Initials': 'KH', 'LastName': 'Huang', 'Affiliation': 'Department of Nutritional Sciences, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Lambert', 'Affiliation': 'Department of Food Science, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Penny M', 'Initials': 'PM', 'LastName': 'Kris-Etherton', 'Affiliation': 'Department of Nutritional Sciences, Pennsylvania State University, University Park, PA, USA.'}]",The Journal of nutrition,['10.1093/jn/nxz231'] 932,31616933,A Community-Based Early Childhood Development Center Platform Promoting Diversified Diets and Food Production Increases the Mean Probability of Adequacy of Intake of Preschoolers in Malawi: A Cluster Randomized Trial.,"BACKGROUND Young children in Malawi consume low-quality diets lacking micronutrients critical for their development. OBJECTIVE To evaluate the impact of an agriculture and nutrition behavior change communication (BCC) intervention implemented through community-based childcare centers on the nutrient adequacy of diets of children living in food-insecure settings in Malawi. METHODS A cluster randomized trial was undertaken in 60 community-based childcare centers, including 1248 children aged 3-6 y. Nutrient intakes were estimated using interactive, multipass 24-h recall. Dietary adequacy was estimated through the probability of adequacy (PA) and mean probability of adequacy (MPA) of 11 micronutrients. Impacts were assessed by difference-in-difference (DID) estimates, adjusted for geographic clustering and child age and sex. RESULTS Intervention groups were similar for most baseline characteristics. Loss to follow-up was low (7% over a 12-mo period) and participation in the intervention was high (>90% enrollment and 80% attendance during the 5 d before the survey). Positive impacts were found for the PA of several individual micronutrient intakes: vitamin A [DID: 9 percentage points (pp), SE 3 pp], vitamin C (14 pp, SE 3 pp), riboflavin (11 pp, SE 3 pp), zinc (8 pp, SE 3 pp), and for the MPA for the 11 nutrients considered (5 pp, SE 1 pp). These impacts were driven by effects on younger children (aged 3-4 y). CONCLUSIONS Using a preschool platform to implement a nutrition-sensitive BCC intervention is an effective strategy to improve the adequacy of micronutrient intake of preschool children in food-insecure settings. The trial was registered at ISCRCTN as ISCRCTN96497560.",2020,"Positive impacts were found for the PA of several individual micronutrient intakes: vitamin A [DID: 9 percentage points (pp), SE 3 pp], vitamin C (14 pp, SE 3 pp), riboflavin (11 pp, SE 3 pp), zinc (8 pp, SE 3 pp), and for the MPA for the 11 nutrients considered (5 pp, SE 1 pp).","['Young children', '60 community-based childcare centers, including 1248 children aged 3-6 y. Nutrient intakes', 'younger children (aged 3-4 y', 'community-based childcare centers on the nutrient adequacy of diets of children living in food-insecure settings in Malawi', 'Preschoolers in Malawi', 'preschool children in food-insecure settings']","['agriculture and nutrition behavior change communication (BCC) intervention', 'vitamin C', 'nutrition-sensitive BCC intervention', 'riboflavin']",['probability of adequacy (PA) and mean probability of adequacy (MPA'],"[{'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0024548', 'cui_str': 'Republic of Malawi'}, {'cui': 'C0008100', 'cui_str': 'Child, Preschool'}]","[{'cui': 'C0001829', 'cui_str': 'Farming'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1274143', 'cui_str': 'Communication treatments and procedures'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0332324', 'cui_str': 'Sensitive (qualifier value)'}, {'cui': 'C0373720', 'cui_str': 'Vitamin B2'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",1248.0,0.214536,"Positive impacts were found for the PA of several individual micronutrient intakes: vitamin A [DID: 9 percentage points (pp), SE 3 pp], vitamin C (14 pp, SE 3 pp), riboflavin (11 pp, SE 3 pp), zinc (8 pp, SE 3 pp), and for the MPA for the 11 nutrients considered (5 pp, SE 1 pp).","[{'ForeName': 'Aulo', 'Initials': 'A', 'LastName': 'Gelli', 'Affiliation': 'International Food Policy Research Institute (IFPRI), Washington, DC, USA.'}, {'ForeName': 'Phuong Hong', 'Initials': 'PH', 'LastName': 'Nguyen', 'Affiliation': 'International Food Policy Research Institute (IFPRI), Washington, DC, USA.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Santacroce', 'Affiliation': 'International Food Policy Research Institute (IFPRI), Washington, DC, USA.'}, {'ForeName': 'Aisha', 'Initials': 'A', 'LastName': 'Twalibu', 'Affiliation': 'Save the Children, International/Malawi, Washington, DC, USA/Zomba, Malawi.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Margolies', 'Affiliation': 'Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Mangani', 'Initials': 'M', 'LastName': 'Katundu', 'Affiliation': 'Chancellor College, University of Malawi, Zomba, Malawi.'}]",The Journal of nutrition,['10.1093/jn/nxz245'] 933,31479863,Gaze entropy measures detect alcohol-induced driver impairment.,"Driving under the influence of alcohol is an ongoing cause of road traffic accidents. The biphasic nature of alcohol effects on subjective experience appears to contribute to the prevalence of drink-driving, as people perceive the declining phase of the BAC curve as recovery from intoxication and are more willing to drive despite significant impairments in objectively measured functions. The present study investigates whether alcohol-induced changes in gaze behaviour can be detected during engagement in a simulated driving task. In a repeated-measures and placebo-controlled design, this study examines the biphasic influence of moderate alcohol intake (0.6 g/kg) on measures of gaze behaviour and simulated driving performance. Twenty-two healthy young adults completed three driving sessions (baseline, ascending and descending) under two conditions (placebo, alcohol) while their eye movements were simultaneously recorded. The results revealed that gaze behaviour as measured by gaze transition entropy (GTE) and stationary gaze entropy (SGE) and driving performance measured by the standard deviation of lateral position (SDLP) of the vehicle, were significantly affected by alcohol across the ascending and descending sessions. The alcohol-induced reduction in GTE with an increase in SGE is discussed as alcohol's impact on top-down modulation of gaze resulting in more dispersed and erratic pattern of visual scanning. The observed changes in gaze behaviour also mediated the influence of alcohol upon driving performance. These results have significant implications for the development of driver monitoring systems that can detect alcohol-induced impairment.",2019,"The results revealed that gaze behaviour as measured by gaze transition entropy (GTE) and stationary gaze entropy (SGE) and driving performance measured by the standard deviation of lateral position (SDLP) of the vehicle, were significantly affected by alcohol across the ascending and descending sessions.",['Twenty-two healthy young adults'],"['placebo', 'driving sessions (baseline, ascending and descending) under two conditions (placebo, alcohol']","['gaze transition entropy (GTE) and stationary gaze entropy (SGE) and driving performance', 'Gaze entropy measures detect alcohol-induced driver impairment', 'gaze behaviour', 'gaze behaviour and simulated driving performance']","[{'cui': 'C4284772', 'cui_str': '22 (qualifier value)'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0205385', 'cui_str': 'Ascending (qualifier value)'}, {'cui': 'C0205386', 'cui_str': 'Descending (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}]","[{'cui': 'C0553544', 'cui_str': 'Gaze (finding)'}, {'cui': 'C0376522', 'cui_str': 'Entropy'}, {'cui': 'C0439835', 'cui_str': 'Stationary (qualifier value)'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0442726', 'cui_str': 'Detected (qualifier value)'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}]",22.0,0.0188674,"The results revealed that gaze behaviour as measured by gaze transition entropy (GTE) and stationary gaze entropy (SGE) and driving performance measured by the standard deviation of lateral position (SDLP) of the vehicle, were significantly affected by alcohol across the ascending and descending sessions.","[{'ForeName': 'Brook A', 'Initials': 'BA', 'LastName': 'Shiferaw', 'Affiliation': 'Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, VIC 3122, Australia. Electronic address: bshiferaw@swin.edu.au.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Crewther', 'Affiliation': 'Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, VIC 3122, Australia.'}, {'ForeName': 'Luke A', 'Initials': 'LA', 'LastName': 'Downey', 'Affiliation': 'Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, VIC 3122, Australia; Institute for Breathing and Sleep, Austin Hospital, Heidelberg, VIC 3084, Australia.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2019.06.021'] 934,31540791,"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.","BACKGROUND Localised prostate cancer is commonly treated with external-beam radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional fractionation. Ultra-hypofractionated stereotactic body radiotherapy would allow shorter treatment courses but could increase acute toxicity compared with conventionally fractionated or moderately hypofractionated radiotherapy. We report the acute toxicity findings from a randomised trial of standard-of-care conventionally fractionated or moderately hypofractionated radiotherapy versus five-fraction stereotactic body radiotherapy for low-risk to intermediate-risk localised prostate cancer. METHODS PACE is an international, phase 3, open-label, randomised, non-inferiority trial. In PACE-B, eligible men aged 18 years and older, with WHO performance status 0-2, low-risk or intermediate-risk prostate adenocarcinoma (Gleason 4 + 3 excluded), and scheduled to receive radiotherapy were recruited from 37 centres in three countries (UK, Ireland, and Canada). Participants were randomly allocated (1:1) by computerised central randomisation with permuted blocks (size four and six), stratified by centre and risk group, to conventionally fractionated or moderately hypofractionated radiotherapy (78 Gy in 39 fractions over 7·8 weeks or 62 Gy in 20 fractions over 4 weeks, respectively) or stereotactic body radiotherapy (36·25 Gy in five fractions over 1-2 weeks). Neither participants nor investigators were masked to allocation. Androgen deprivation was not permitted. The primary endpoint of PACE-B is freedom from biochemical or clinical failure. The coprimary outcomes for this acute toxicity substudy were worst grade 2 or more severe Radiation Therapy Oncology Group (RTOG) gastrointestinal or genitourinary toxic effects score up to 12 weeks after radiotherapy. Analysis was per protocol. This study is registered with ClinicalTrials.gov, NCT01584258. PACE-B recruitment is complete and follow-up is ongoing. FINDINGS Between Aug 7, 2012, and Jan 4, 2018, we randomly assigned 874 men to conventionally fractionated or moderately hypofractionated radiotherapy (n=441) or stereotactic body radiotherapy (n=433). 432 (98%) of 441 patients allocated to conventionally fractionated or moderately hypofractionated radiotherapy and 415 (96%) of 433 patients allocated to stereotactic body radiotherapy received at least one fraction of allocated treatment. Worst acute RTOG gastrointestinal toxic effect proportions were as follows: grade 2 or more severe toxic events in 53 (12%) of 432 patients in the conventionally fractionated or moderately hypofractionated radiotherapy group versus 43 (10%) of 415 patients in the stereotactic body radiotherapy group (difference -1·9 percentage points, 95% CI -6·2 to 2·4; p=0·38). Worst acute RTOG genitourinary toxicity proportions were as follows: grade 2 or worse toxicity in 118 (27%) of 432 patients in the conventionally fractionated or moderately hypofractionated radiotherapy group versus 96 (23%) of 415 patients in the stereotactic body radiotherapy group (difference -4·2 percentage points, 95% CI -10·0 to 1·7; p=0·16). No treatment-related deaths occurred. INTERPRETATION Previous evidence (from the HYPO-RT-PC trial) suggested higher patient-reported toxicity with ultrahypofractionation. By contrast, our results suggest that substantially shortening treatment courses with stereotactic body radiotherapy does not increase either gastrointestinal or genitourinary acute toxicity. FUNDING Accuray and National Institute of Health Research.",2019,"difference -4·2 percentage points, 95% CI -10·0 to 1·7; p=0·16).","['eligible men aged 18 years and older, with WHO performance status 0-2, low-risk or intermediate-risk prostate adenocarcinoma (Gleason 4\u2008+\u20083 excluded), and scheduled to receive radiotherapy were recruited from 37 centres in three countries (UK, Ireland, and Canada', '874 men to', '432 (98%) of 441 patients allocated to', 'Between Aug 7, 2012, and Jan 4, 2018', '433 patients allocated to']","['hypofractionated radiotherapy', 'stereotactic body radiotherapy', 'Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy', 'conventionally fractionated or moderately hypofractionated radiotherapy (n=441) or stereotactic body radiotherapy', 'conventionally fractionated or moderately hypofractionated radiotherapy', 'Ultra-hypofractionated stereotactic body radiotherapy', 'standard-of-care conventionally fractionated or moderately hypofractionated radiotherapy versus five-fraction stereotactic body radiotherapy', 'external-beam radiotherapy', 'conventionally fractionated or moderately hypofractionated', 'radiotherapy']","['acute toxicity substudy were worst grade 2 or more severe Radiation Therapy Oncology Group (RTOG) gastrointestinal or genitourinary toxic effects score', 'acute toxicity', 'toxicity', 'Androgen deprivation', 'PACE-B is freedom from biochemical or clinical failure', 'gastrointestinal or genitourinary acute toxicity', 'severe toxic events']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0001418', 'cui_str': 'Adenoma, Malignant'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0022067', 'cui_str': 'Ireland, Republic of'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C1720823', 'cui_str': 'Stereotactic Body Radiotherapy'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0443264', 'cui_str': 'Modulated (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}, {'cui': 'C0419095', 'cui_str': 'Teleradiotherapy procedure (procedure)'}]","[{'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0034619', 'cui_str': 'radiation therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0002844', 'cui_str': 'Androgenic Compounds'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0205474', 'cui_str': 'Biochemical (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}]",874.0,0.279497,"difference -4·2 percentage points, 95% CI -10·0 to 1·7; p=0·16).","[{'ForeName': 'Douglas H', 'Initials': 'DH', 'LastName': 'Brand', 'Affiliation': 'The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Alison C', 'Initials': 'AC', 'LastName': 'Tree', 'Affiliation': 'The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Ostler', 'Affiliation': 'Mount Vernon Cancer Centre, Northwood, UK.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'van der Voet', 'Affiliation': 'The James Cook University Hospital, Middlesbrough, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Loblaw', 'Affiliation': 'Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Chu', 'Affiliation': 'Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Ford', 'Affiliation': 'University Hospitals Birmingham, Birmingham, UK.'}, {'ForeName': 'Shaun', 'Initials': 'S', 'LastName': 'Tolan', 'Affiliation': 'The Clatterbridge Cancer Centre, Birkenhead, UK.'}, {'ForeName': 'Suneil', 'Initials': 'S', 'LastName': 'Jain', 'Affiliation': ""Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Martin', 'Affiliation': 'Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Staffurth', 'Affiliation': 'Cardiff University, Cardiff, UK.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Camilleri', 'Affiliation': 'Churchill Hospital, Oxford, UK.'}, {'ForeName': 'Kiran', 'Initials': 'K', 'LastName': 'Kancherla', 'Affiliation': 'University Hospitals of Leicester, Leicester, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Frew', 'Affiliation': 'Freeman Hospital, Newcastle, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Chan', 'Affiliation': 'University Hospitals Coventry & Warwickshire, Coventry, UK.'}, {'ForeName': 'Ian S', 'Initials': 'IS', 'LastName': 'Dayes', 'Affiliation': 'Department of Oncology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Henderson', 'Affiliation': 'University Hospitals Birmingham, Birmingham, UK.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Brown', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Cruickshank', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Burnett', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Aileen', 'Initials': 'A', 'LastName': 'Duffton', 'Affiliation': 'Beatson West of Scotland Cancer Centre, Glasgow, UK.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Griffin', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Hinder', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Kirsty', 'Initials': 'K', 'LastName': 'Morrison', 'Affiliation': 'The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Naismith', 'Affiliation': 'The Royal Marsden Hospital, London, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Hall', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'van As', 'Affiliation': 'The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK. Electronic address: nicholas.vanas@rmh.nhs.uk.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Oncology,['10.1016/S1470-2045(19)30569-8'] 935,31596774,Peer-Centered Versus Standard Physician-Centered Video Counseling for Midurethral Sling Surgery: A Randomized Controlled Trial.,"OBJECTIVES Peer counseling may improve upon provider counseling and enhance patient preparedness for midurethral sling (MUS) surgery. We aimed to compare the impact of peer-centered versus standard preoperative video counseling by assessing patient preparedness for MUS surgery. METHODS Women undergoing MUS were randomized to view either a peer-centered (PEER) or standard physician preoperative counseling video (PHYS). The PEER video featured a woman who had undergone MUS surgery and included the standard risks and benefits as well as additional information identified in prior work as important to patients. The PHYS video featured a surgeon discussing risks and benefits. Patients viewed either video at their preoperative visit and completed the Patient Preparedness Questionnaire (PPQ), Surgical Decision Satisfaction, Decisional Regret Scale, and the Urogenital Distress Inventory Short Form. Patients then underwent standard in-person surgeon counseling. Sessions were timed and compared with historical timed sessions. Our primary outcome was between-group differences in 6-week postoperative PPQ scores. RESULTS Patient Preparedness Questionnaire scores did not differ between groups (postoperative PPQ scores: median [interquartile range], 95 [84, 100] vs 92 [80, 100]; P=0.50). The PEER group reported higher decisional regret (15 [0, 28.75] vs 0 [0, 10], P=0.02) and less symptom improvement on Urogenital Distress Inventory Short Form change scores compared with the PHYS group (47.2 [37.2, 62.5] vs 36.1 [16.5, 50], P=0.03); secondary outcomes were not different between groups. In-person counseling times decreased after watching either video compared with the institution's historical standard (8:27 minutes [08:56, 17:14] vs 11:34 minutes [5:22, 13:07]; P < 0.005). CONCLUSION Patient preparedness did not differ between groups. Decision regret did not differ between groups once adjusted for urinary symptoms.",2020,"RESULTS Patient Preparedness Questionnaire scores did not differ between groups (postoperative PPQ scores: median [interquartile range], 95 [84, 100] vs 92 [80, 100]; P = 0.50).",['Women undergoing MUS'],"['Peer-Centered Versus Standard Physician-Centered Video Counseling for Midurethral Sling Surgery', 'peer-centered (PEER) or standard physician preoperative counseling video (PHYS', 'peer-centered versus standard preoperative video counseling', 'midurethral sling (MUS) surgery']","['Patient Preparedness Questionnaire scores', 'Decision regret', 'symptom improvement on Urogenital Distress Inventory Short Form change scores', 'Patient Preparedness Questionnaire (PPQ), Surgical Decision Satisfaction, Decisional Regret Scale, and the Urogenital Distress Inventory Short Form', '6-week postoperative PPQ scores', 'decisional regret']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0026809', 'cui_str': 'Mice'}]","[{'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C3179501', 'cui_str': 'Midurethral Slings'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0920638', 'cui_str': 'Preoperative counseling (procedure)'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C1141000', 'cui_str': 'Sled, device (physical object)'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0080101', 'cui_str': 'Regret'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0222045'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}]",,0.109692,"RESULTS Patient Preparedness Questionnaire scores did not differ between groups (postoperative PPQ scores: median [interquartile range], 95 [84, 100] vs 92 [80, 100]; P = 0.50).","[{'ForeName': 'Tessa E', 'Initials': 'TE', 'LastName': 'Krantz', 'Affiliation': 'From the Department of Obstetrics and Gynecology and Division of Urogynecology, University of New Mexico Health Science Center, Albuquerque, NM.'}, {'ForeName': 'Rebecca G', 'Initials': 'RG', 'LastName': 'Rogers', 'Affiliation': ""Department of Women's Health, University of Texas at Austin, Dell Medical School, Austin, TX.""}, {'ForeName': 'Timothy R', 'Initials': 'TR', 'LastName': 'Petersen', 'Affiliation': 'From the Department of Obstetrics and Gynecology and Division of Urogynecology, University of New Mexico Health Science Center, Albuquerque, NM.'}, {'ForeName': 'Gena C', 'Initials': 'GC', 'LastName': 'Dunivan', 'Affiliation': 'From the Department of Obstetrics and Gynecology and Division of Urogynecology, University of New Mexico Health Science Center, Albuquerque, NM.'}, {'ForeName': 'Amanda B', 'Initials': 'AB', 'LastName': 'White', 'Affiliation': ""Department of Women's Health, University of Texas at Austin, Dell Medical School, Austin, TX.""}, {'ForeName': 'Annetta M', 'Initials': 'AM', 'LastName': 'Madsen', 'Affiliation': 'Department of Obstetrics/Gynecology, St Paul, MN.'}, {'ForeName': 'Peter C', 'Initials': 'PC', 'LastName': 'Jeppson', 'Affiliation': 'From the Department of Obstetrics and Gynecology and Division of Urogynecology, University of New Mexico Health Science Center, Albuquerque, NM.'}, {'ForeName': 'Cara S', 'Initials': 'CS', 'LastName': 'Ninivaggio', 'Affiliation': 'From the Department of Obstetrics and Gynecology and Division of Urogynecology, University of New Mexico Health Science Center, Albuquerque, NM.'}, {'ForeName': 'Sara B', 'Initials': 'SB', 'LastName': 'Cichowski', 'Affiliation': 'From the Department of Obstetrics and Gynecology and Division of Urogynecology, University of New Mexico Health Science Center, Albuquerque, NM.'}, {'ForeName': 'Yuko M', 'Initials': 'YM', 'LastName': 'Komesu', 'Affiliation': 'From the Department of Obstetrics and Gynecology and Division of Urogynecology, University of New Mexico Health Science Center, Albuquerque, NM.'}]",Female pelvic medicine & reconstructive surgery,['10.1097/SPV.0000000000000784'] 936,30219823,Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.,"BACKGROUND Chronic inflammation in treated HIV infection is associated with mortality and atherosclerotic cardiovascular disease (ASCVD). We evaluated the safety and potential efficacy of low-dose methotrexate (LDMTX) in treated HIV. METHODS This was a phase 2 randomized, double-blind, multicenter trial in adults ≥40 years old with treated HIV, with CD4+ T-cell count ≥400 cells/μL and with/at increased risk for ASCVD. Participants received LDMTX (5-15 mg/week) or placebo (plus folic acid) for 24 weeks and were followed for an additional 12 weeks. Primary endpoints were safety and brachial artery flow-mediated dilation (FMD). RESULTS The 176 participants (90% male) had a median (Q1, Q3) age of 54 (49, 59) years. LDMTX was associated with decreases in CD4+ T cells at week 24 and CD8+ T cells at weeks 8, 12, and 24. Eleven participants (12.8%) experienced safety events in the LDMTX group vs 5 (5.6%) in placebo (Δ = 7.2%, upper 1-sided 90% CI, 13.4%; Pnoninferiority = .037). Week 24 change in FMD was 0.47% with LDMTX and 0.09% with placebo (P = .55). No inflammatory markers changed differentially with LDMTX compared to placebo. CONCLUSIONS Adults with HIV and increased ASCVD risk treated with LDMTX had more safety events than with placebo, but the prespecified noninferiority margin of 15% was not exceeded. LDMTX had no significant effect on endothelial function or inflammatory biomarkers but was associated with a significant decrease in CD8+ T cells. The balance of risks and potential benefits of LDMTX in this population will require additional investigation. CLINICAL TRIALS REGISTRATION NCT01949116.",2019,LDMTX had no significant effect on endothelial function or inflammatory biomarkers but was associated with a significant decrease in CD8+ T cells.,"['adults ≥40 years old with treated HIV, with CD4+ T-cell count ≥400 cells/μL and with/at increased risk for ASCVD', 'Individuals With Treated Human Immunodeficiency Virus', '176 participants (90% male) had a median (Q1, Q3) age of 54 (49, 59) years']","['placebo (plus folic acid', 'Low-dose Methotrexate', 'placebo', 'low-dose methotrexate (LDMTX', 'LDMTX']","['FMD', 'Endothelial Function and Inflammation', 'CD4+ T cells', 'safety and potential efficacy', 'safety and brachial artery flow-mediated dilation (FMD', 'safety events', 'endothelial function or inflammatory biomarkers', 'CD8+ T cells']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}]","[{'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0006087', 'cui_str': 'Brachial Artery'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",176.0,0.553697,LDMTX had no significant effect on endothelial function or inflammatory biomarkers but was associated with a significant decrease in CD8+ T cells.,"[{'ForeName': 'Priscilla Y', 'Initials': 'PY', 'LastName': 'Hsue', 'Affiliation': 'Department of Medicine, University of California, San Francisco School of Medicine, Boston, Massachusetts.'}, {'ForeName': 'Heather J', 'Initials': 'HJ', 'LastName': 'Ribaudo', 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Steven G', 'Initials': 'SG', 'LastName': 'Deeks', 'Affiliation': 'Department of Medicine, University of California, San Francisco School of Medicine, Boston, Massachusetts.'}, {'ForeName': 'Tanvir', 'Initials': 'T', 'LastName': 'Bell', 'Affiliation': 'McGovern Medical School, University of Texas Health Science Center at Houston, Boston, Massachusetts.'}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Ridker', 'Affiliation': ""Cardiology Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Fichtenbaum', 'Affiliation': 'University of Cincinnati College of Medicine, Ohio.'}, {'ForeName': 'Eric S', 'Initials': 'ES', 'LastName': 'Daar', 'Affiliation': 'David Geffen School of Medicine, University of California, Los Angeles, Boston.'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Havlir', 'Affiliation': 'Department of Medicine, University of California, San Francisco School of Medicine, Boston, Massachusetts.'}, {'ForeName': 'Eunice', 'Initials': 'E', 'LastName': 'Yeh', 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Tawakol', 'Affiliation': 'Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lederman', 'Affiliation': 'Case Western Reserve University School of Medicine, Cleveland, Ohio.'}, {'ForeName': 'Judith S', 'Initials': 'JS', 'LastName': 'Currier', 'Affiliation': 'David Geffen School of Medicine, University of California, Los Angeles, Boston.'}, {'ForeName': 'James H', 'Initials': 'JH', 'LastName': 'Stein', 'Affiliation': 'University of Wisconsin School of Medicine and Public Health, Madison.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciy781'] 937,28107221,Cash vs. food assistance to improve adherence to antiretroviral therapy among HIV-infected adults in Tanzania.,"OBJECTIVE We evaluated the effectiveness of short-term cash and food assistance to improve adherence to antiretroviral therapy (ART) and retention in care among people living with HIV in Tanzania. METHODS At three clinics, 805 participants were randomized to three groups in a 3 : 3 : 1 ratio, stratified by site : nutrition assessment and counseling (NAC) and cash transfers (∼$11/month, n = 347), NAC and food baskets (n = 345), and NAC-only (comparison group, n = 113, clinicaltrials.gov NCT01957917). Eligible people living with HIV were at least 18 years, initiated ART 90 days or less prior, and food insecure. Cash or food was provided for 6 or less consecutive months, conditional on visit attendance. The primary outcome was medication possession ratio (MPR ≥ 95%) at 6 months. Secondary outcomes were appointment attendance and loss to follow-up (LTFU) at 6 and 12 months. RESULTS The primary intent-to-treat analysis included 800 participants. Achievement of MPR ≥ 95% at 6 months was higher in the NAC + cash group compared with NAC-only (85.0 vs. 63.4%), a 21.6 percentage point difference [95% confidence interval (CI): 9.8, 33.4, P < 0.01]. MPR ≥ 95% was also significantly higher in the NAC + food group vs. NAC-only (difference = 15.8, 95% CI: 3.8, 27.9, P < 0.01). When directly compared, MPR ≥ 95% was similar in the NAC + cash and NAC + food groups (difference = 5.7, 95% CI: -1.2, 12.7, P = 0.15). Compared with NAC-only, appointment attendance and LTFU were significantly higher in both the NAC + cash and NAC + food groups at 6 months. At 12 months, the effect of NAC + cash, but not NAC + food, on MPR ≥ 95% and retention was sustained. CONCLUSION Short-term conditional cash and food assistance improves ART possession and appointment attendance and reduces LTFU among food-insecure ART initiates in Tanzania.",2017,"Achievement of MPR ≥ 95% at 6 months was higher in the NAC + cash group compared with NAC-only (85.0 vs. 63.4%), a 21.6 percentage point difference [95% confidence interval (CI): 9.8, 33.4,","['HIV-infected adults in Tanzania', 'Eligible people living with HIV were at least 18 years, initiated ART 90 days or less prior, and food insecure', 'people living with HIV in Tanzania', '805 participants', '800 participants']","['short-term cash and food assistance', 'Short-term conditional cash and food assistance', 'Cash vs. food assistance', 'antiretroviral therapy (ART', '3\u200a:\u200a3\u200a:\u200a1 ratio, stratified by site\u200a:\u200anutrition assessment and counseling (NAC) and cash transfers (∼$11/month, n\u200a=\u200a347), NAC and food baskets']","['ART possession and appointment attendance and reduces LTFU', 'MPR\u200a≥', 'medication possession ratio', 'appointment attendance and loss to follow-up (LTFU']","[{'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0039298', 'cui_str': 'United Republic of Tanzania'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C3844106', 'cui_str': 'Eight hundred'}]","[{'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C3494395', 'cui_str': 'Food Assistance'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0028708', 'cui_str': 'Nutritional Assessment'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0040671', 'cui_str': 'Transfer'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0016452', 'cui_str': 'Food'}]","[{'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C1701620', 'cui_str': 'mercaptopropionyl-phenylalanyl-cyclohexylalanyl-cyclohexylalanyl-arginyl-lysyl-prolyl-asparaginyl-aspartyl-lysinamide'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]",805.0,0.201934,"Achievement of MPR ≥ 95% at 6 months was higher in the NAC + cash group compared with NAC-only (85.0 vs. 63.4%), a 21.6 percentage point difference [95% confidence interval (CI): 9.8, 33.4,","[{'ForeName': 'Sandra I', 'Initials': 'SI', 'LastName': 'McCoy', 'Affiliation': 'aDivision of Epidemiology, University of California, Berkeley, California, USA bPrevention of Mother-to-Child HIV Transmission Programme, Ministry of Health, Community Development, Gender, Elderly, and Children, Dar es Salaam cRegional Medical Office, Ministry of Health, Community Development, Gender, Equity, and Children, Shinyanga, Tanzania dFaculty of Epidemiology and Population Health, Department of Population Health, London School of Hygiene & Tropical Medicine, London, UK eDivision of Biostatistics fDivision of Health Policy and Management, University of California, Berkeley, California, USA.'}, {'ForeName': 'Prosper F', 'Initials': 'PF', 'LastName': 'Njau', 'Affiliation': ''}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Fahey', 'Affiliation': ''}, {'ForeName': 'Ntuli', 'Initials': 'N', 'LastName': 'Kapologwe', 'Affiliation': ''}, {'ForeName': 'Suneetha', 'Initials': 'S', 'LastName': 'Kadiyala', 'Affiliation': ''}, {'ForeName': 'Nicholas P', 'Initials': 'NP', 'LastName': 'Jewell', 'Affiliation': ''}, {'ForeName': 'William H', 'Initials': 'WH', 'LastName': 'Dow', 'Affiliation': ''}, {'ForeName': 'Nancy S', 'Initials': 'NS', 'LastName': 'Padian', 'Affiliation': ''}]","AIDS (London, England)",['10.1097/QAD.0000000000001406'] 938,31620886,Daily intake of heat-killed Lactobacillus plantarum L-137 improves inflammation and lipid metabolism in overweight healthy adults: a randomized-controlled trial.,"PURPOSE The effects of heat-killed Lactobacillus plantarum L-137 (HK L-137) on inflammation and lipid metabolism were investigated in overweight volunteers. METHODS One hundred healthy subjects with a body mass index from 23.0 to 29.9 (51 men and 49 women; mean age: 41.4 years) were enrolled in this randomized, double-blind, placebo-controlled, parallel group study. Subjects were randomly assigned to daily administration of a tablet containing HK L-137 (10 mg) or a placebo tablet for 12 weeks. Blood samples were collected every 4 weeks to measure biomarkers of lipid metabolism and inflammatory mediators. RESULTS The percent change of concanavalin A-induced proliferation of peripheral blood mononuclear cells was significantly larger in the HK L-137 group than in the control group, similar to previous studies. The decreases of aspartate aminotransferase and alanine aminotransferase over time were significantly larger in the HK L-137 group than in the control group, as were the decreases of total cholesterol, low-density lipoprotein cholesterol, and the leukocyte count at one time point. These effects of HK L-137 were stronger in the subjects with higher C-reactive protein levels. CONCLUSIONS These findings suggest that daily intake of HK L-137 can improve inflammation and lipid metabolism in subjects at risk of inflammation.",2020,"The decreases of aspartate aminotransferase and alanine aminotransferase over time were significantly larger in the HK L-137 group than in the control group, as were the decreases of total cholesterol, low-density lipoprotein cholesterol, and the leukocyte count at one time point.","['overweight volunteers', 'subjects at risk of inflammation', 'One hundred healthy subjects with a body mass index from 23.0 to 29.9 (51 men and 49 women; mean age: 41.4\xa0years', 'overweight healthy adults']","['heat-killed Lactobacillus plantarum L-137 (HK L-137', 'HK L-137', 'tablet containing HK L-137', 'placebo', 'placebo tablet', 'heat-killed Lactobacillus plantarum L-137']","['peripheral blood mononuclear cells', 'aspartate aminotransferase and alanine aminotransferase over time', 'inflammation and lipid metabolism', 'total cholesterol, low-density lipoprotein cholesterol, and the leukocyte count']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C4521763', 'cui_str': 'Killed'}, {'cui': 'C0317608', 'cui_str': 'Lactobacillus plantarum'}, {'cui': 'C4517569', 'cui_str': 'One hundred and thirty-seven'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0004002', 'cui_str': 'L-Aspartate-2-Oxoglutarate Aminotransferase'}, {'cui': 'C0201836', 'cui_str': 'Alanine aminotransferase measurement (procedure)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0023508', 'cui_str': 'Blood Cell Count, White'}]",100.0,0.143037,"The decreases of aspartate aminotransferase and alanine aminotransferase over time were significantly larger in the HK L-137 group than in the control group, as were the decreases of total cholesterol, low-density lipoprotein cholesterol, and the leukocyte count at one time point.","[{'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Tanaka', 'Affiliation': 'Research Division, Research and Development Institute, House Wellness Foods Corp., Imoji 3-20, Itami, Hyogo, 664-0011, Japan. Tanaka_Yuusuke@house-wf.co.jp.'}, {'ForeName': 'Yoshitaka', 'Initials': 'Y', 'LastName': 'Hirose', 'Affiliation': 'Research Division, Research and Development Institute, House Wellness Foods Corp., Imoji 3-20, Itami, Hyogo, 664-0011, Japan.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Yamamoto', 'Affiliation': 'Research Division, Research and Development Institute, House Wellness Foods Corp., Imoji 3-20, Itami, Hyogo, 664-0011, Japan.'}, {'ForeName': 'Yasunobu', 'Initials': 'Y', 'LastName': 'Yoshikai', 'Affiliation': 'Division of Host Defense, Medical Institute of Bioregulation, Kyushu University, Fukuoka, 812-8582, Japan.'}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Murosaki', 'Affiliation': 'Research Division, Research and Development Institute, House Wellness Foods Corp., Imoji 3-20, Itami, Hyogo, 664-0011, Japan.'}]",European journal of nutrition,['10.1007/s00394-019-02112-3'] 939,31596648,A novel telehealth platform for alcohol use disorder treatment: preliminary evidence of reductions in drinking.,"BACKGROUND Alcohol use disorder (AUD) treatment remains greatly underutilized. Innovative strategies are needed to improve AUD treatment access and patient engagement. The Ria Treatment Platform (RTP) is a patient-centered telemedicine AUD treatment program accessed through a smartphone application (app) that includes a package of physician visits (with AUD prescriptions as appropriate), text- and phone-based support from a recovery coach, video monitoring of medication adherence, and Bluetooth-linked breathalyzer tracking of alcohol intake. OBJECTIVES The purpose of the current study is to examine changes in alcohol use among patients utilizing the RTP. METHODS This study examines daily breathalyzer blood alcohol content (BAC) readings collected from 77 adult patients (50.7% male) over the first 90 days in treatment with the RTP. Data were analyzed using dynamic structural equation modeling. RESULTS The treatment retention rate at 90 days was 55%. The best fit for the BAC data was given by a cubic curve, which showed that among patients who remained engaged for 90 days average BAC levels declined approximately 50% (from .091 to .045) from baseline to day 90. CONCLUSION This study provides preliminary evidence of substantial alcohol use reductions among patients utilizing the RTP, an innovative telemedicine program accessed via smartphone. Although other alcohol-reduction apps have shown promise from scientific evaluations, the RTP appears to be the only app that incorporates physician-prescribed medication and a recovery coach. Research incorporating random assignment and meaningful comparison groups is needed to further evaluate this promising strategy.",2020,"The Ria Treatment Platform (RTP) is a patient-centered telemedicine AUD treatment program accessed through a smartphone application (app) that includes a package of physician visits (with AUD prescriptions as appropriate), text- and phone-based support from a recovery coach, video monitoring of medication adherence, and Bluetooth-linked breathalyzer tracking of alcohol intake. ","['patients utilizing the RTP', '77 adult patients (50.7% male) over the first 90\xa0days in treatment with the RTP']",[' '],"['treatment retention rate', 'BAC levels', 'daily breathalyzer blood alcohol content (BAC) readings']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",[],"[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0887889', 'cui_str': 'BACs (Chromosomes)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0684262', 'cui_str': 'Blood Alcohol Level'}]",77.0,0.0171058,"The Ria Treatment Platform (RTP) is a patient-centered telemedicine AUD treatment program accessed through a smartphone application (app) that includes a package of physician visits (with AUD prescriptions as appropriate), text- and phone-based support from a recovery coach, video monitoring of medication adherence, and Bluetooth-linked breathalyzer tracking of alcohol intake. ","[{'ForeName': 'Mary M', 'Initials': 'MM', 'LastName': 'Mitchell', 'Affiliation': 'Friends Research Institute , Baltimore, MD, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Mendelson', 'Affiliation': 'Ria Health , San Francisco, CA, USA.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Gryczynski', 'Affiliation': 'Friends Research Institute , Baltimore, MD, USA.'}, {'ForeName': 'Steven B', 'Initials': 'SB', 'LastName': 'Carswell', 'Affiliation': 'Friends Research Institute , Baltimore, MD, USA.'}, {'ForeName': 'Robert P', 'Initials': 'RP', 'LastName': 'Schwartz', 'Affiliation': 'Friends Research Institute , Baltimore, MD, USA.'}]",The American journal of drug and alcohol abuse,['10.1080/00952990.2019.1658197'] 940,31599810,Reduction of Postoperative Wound Infections by Antiseptica (RECIPE)?: A Randomized Controlled Trial.,"OBJECTIVE To evaluate whether intraoperative subcutaneous wound irrigation with 0.04% polyhexanide can reduce surgical site infection (SSI) in elective laparotomies compared to saline. BACKGROUND SSI is a common complication after gastrointestinal surgery. To date, there is a lack of evidence whether subcutaneous wound irrigation is beneficial in terms of reduction of SSI. METHODS The RECIPE trial was an investigator initiated single-center, single-blind prospective, randomized controlled trial with 2 parallel treatment groups, comparing wound irrigation with 0.9% saline to antiseptic 0.04% polyhexanide solution in elective laparotomies. Primary endpoint was the rate of SSI within 30 days postoperatively according to Centers for Disease Control and Prevention criteria. RESULTS Between February 02, 2015, and May 23, 2018, 456 patients were randomly assigned to saline (n = 228) or polyhexanide (n = 228). Final cohort for analysis comprised 393 patients (202 in the saline and 191 in the polyhexanide group). Overall rate of SSI was 28.2%, n = 111. Simple analysis with cross tabulation revealed that significantly fewer SSIs occurred in the polyhexanide group: n = 70 (34.7%) versus n = 41 (21.5%); P = 0.004. In a multiple logistic regression model the factor wound irrigation with polyhexanide [odds ratio (OR) 0.44; 95% confidence interval (CI) 0.27-0.72; P = 0.001) was associated with risk reduction of SSI. Preoperative anemia (OR 2.08; 95% CI 1.27-3.40; P = 0.004) and more than 5 prior abdominal operations compared to none (OR 8.51; 95% CI 2.57-28.21; P < 0.001) were associated with SSI. CONCLUSIONS Intraoperative subcutaneous wound irrigation with antiseptic 0.04% polyhexanide solution is effective in reducing SSI after elective laparotomies.",2020,"Preoperative anemia (OR 2.08; 95% CI 1.27-3.40; P = 0.004) and more than 5 prior abdominal operations compared to none (OR 8.51; 95% CI 2.57-28.21; P < 0.001) were associated with SSI. ","['Between February 02, 2015, and May 23, 2018, 456 patients', '393 patients (202 in the saline and 191 in the polyhexanide group']","['Antiseptica (RECIPE', 'intraoperative subcutaneous wound irrigation with 0.04% polyhexanide', 'saline', 'antiseptic 0.04% polyhexanide solution', 'wound irrigation with 0.9% saline to antiseptic 0.04% polyhexanide solution', 'polyhexanide']","['Overall rate of SSI', 'SSIs', 'rate of SSI within 30 days postoperatively according to Centers for Disease Control and Prevention criteria', 'surgical site infection (SSI', 'risk reduction of SSI', 'Preoperative anemia']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517754', 'cui_str': 'Three hundred and ninety-three'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0376892', 'cui_str': 'polihexanide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0600194', 'cui_str': 'Recipes'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C0150410', 'cui_str': 'Irrigation of wound (procedure)'}, {'cui': 'C4517407', 'cui_str': 'Zero point zero four'}, {'cui': 'C0376892', 'cui_str': 'polihexanide'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C3540796', 'cui_str': 'Antiseptic throat preparations'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0007670', 'cui_str': 'CDC'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0038941', 'cui_str': 'Postoperative Wound Infection'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}]",456.0,0.287261,"Preoperative anemia (OR 2.08; 95% CI 1.27-3.40; P = 0.004) and more than 5 prior abdominal operations compared to none (OR 8.51; 95% CI 2.57-28.21; P < 0.001) were associated with SSI. ","[{'ForeName': 'Rahel M', 'Initials': 'RM', 'LastName': 'Strobel', 'Affiliation': 'Department of General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin, Hindenburgdamm, Berlin, Germany.'}, {'ForeName': 'Marja', 'Initials': 'M', 'LastName': 'Leonhardt', 'Affiliation': 'Innlandet Hospital Trust, Norwegian National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Brumunddal, Norway.'}, {'ForeName': 'Anika', 'Initials': 'A', 'LastName': 'Krochmann', 'Affiliation': 'Department of General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin, Hindenburgdamm, Berlin, Germany.'}, {'ForeName': 'Konrad', 'Initials': 'K', 'LastName': 'Neumann', 'Affiliation': 'Institute of Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Berlin and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Speichinger', 'Affiliation': 'Department of General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin, Hindenburgdamm, Berlin, Germany.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Hartmann', 'Affiliation': 'Department of General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin, Hindenburgdamm, Berlin, Germany.'}, {'ForeName': 'Lucas D', 'Initials': 'LD', 'LastName': 'Lee', 'Affiliation': 'Department of General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin, Hindenburgdamm, Berlin, Germany.'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Beyer', 'Affiliation': 'Department of General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin, Hindenburgdamm, Berlin, Germany.'}, {'ForeName': 'Severin', 'Initials': 'S', 'LastName': 'Daum', 'Affiliation': 'Department of Gastroenterology, Rheumatology and Infectious Diseases, Charité Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Martin E', 'Initials': 'ME', 'LastName': 'Kreis', 'Affiliation': 'Department of General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin, Hindenburgdamm, Berlin, Germany.'}, {'ForeName': 'Johannes C', 'Initials': 'JC', 'LastName': 'Lauscher', 'Affiliation': 'Department of General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin, Hindenburgdamm, Berlin, Germany.'}]",Annals of surgery,['10.1097/SLA.0000000000003645'] 941,29163743,Comparison of Endovascular Treatment with Intravenous Thrombolysis for Isolated M2 Segment of Middle Cerebral Artery Occlusion in Acute Ischemic Stroke.,"Background The benefit of endovascular treatment for distal large artery ischemic occlusions such as M2 segment of middle cerebral artery is not clear. Methods We retrospectively analyzed data from 51 subjects who had an isolated M2 segment occlusion on baseline computed tomographic (CT) angiogram who were randomized to either intravenous (IV) recombinant tissue plasminogen activator (rt-PA) followed by endovascular treatment or IV rt-PA alone in a multicenter trial. We determined the effect of endovascular treatment on occurrence of excellent [mRS (modified Rankin scale) scores of 0-1] functional outcomes at three months and any death within 3 and 12 months. We also performed proportional odds logistic regression analysis to compare the distribution of mRS scores between the two groups. Each of the analyses was adjusted for age, baseline Alberta stroke program early CT score strata, and baseline National Institutes of Health Stroke scale score strata. Results At three months, the rate of excellent functional outcome (38.2% versus 17.6%, unadjusted odds ratio 2.9; 95% confidence interval ; 0.7-12.1;  p  = 0.15) was non-significantly higher among subjects with M2 segment occlusion who were randomized to endovascular treatment. In multivariate analysis, the odds of excellent functional outcome at three months were non-significantly higher among subjects who were randomized to endovascular treatment at three months (OR 2.7; 95% CI; 0.6-13.6;  p = 0.22). There was a trend toward lower disability grades in subject randomized to endovascular treatment when distribution of the mRS score at three months were compared (common OR 2.6; p = 0.084), adjusting for potential confounders. The rates of any death within 3 (adjusted OR 0.1; 95% CI; 0.1-0.8; p = 0.031) and within 12 months (adjusted OR 0.1; 95% CI; 0.1-0.7; p = 0.022) were significantly lower among those who were randomized to endovascular treatment. Conclusion In this post-hoc analysis, acute ischemic stroke subjects who had isolated M2 segment occlusion randomized to endovascular treatment appeared to have lower mortality and a trend toward lower grades of disability.",2017,There was a trend toward lower disability grades in subject randomized to endovascular treatment when distribution of the mRS score at three months were compared (common OR 2.6; ,"['51 subjects who had an isolated M2 segment occlusion on baseline computed tomographic (CT) angiogram who were randomized to either', 'acute ischemic stroke subjects who had isolated M2 segment occlusion randomized to', 'Acute Ischemic Stroke']","['intravenous (IV) recombinant tissue plasminogen activator (rt-PA) followed by endovascular treatment or IV rt-PA alone', 'endovascular treatment', 'Endovascular Treatment with Intravenous Thrombolysis']","['occurrence of excellent [mRS (modified Rankin scale) scores of 0-1] functional outcomes', 'rate of excellent functional outcome', 'rates of any death', 'disability']","[{'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C0441635', 'cui_str': 'Segment (qualifier value)'}, {'cui': 'C0441597', 'cui_str': 'Occlusion - action (qualifier value)'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0032143', 'cui_str': 'alteplase'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis, function (observable entity)'}]","[{'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C1961136', 'cui_str': 'Excellent (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}]",,0.118363,There was a trend toward lower disability grades in subject randomized to endovascular treatment when distribution of the mRS score at three months were compared (common OR 2.6; ,"[{'ForeName': 'Adnan I', 'Initials': 'AI', 'LastName': 'Qureshi', 'Affiliation': 'Zeenat Qureshi Stroke Institute, St. Cloud, MN, USA.'}, {'ForeName': 'Muhammad A', 'Initials': 'MA', 'LastName': 'Saleem', 'Affiliation': 'Zeenat Qureshi Stroke Institute, St. Cloud, MN, USA.'}, {'ForeName': 'Emrah', 'Initials': 'E', 'LastName': 'Aytac', 'Affiliation': 'Zeenat Qureshi Stroke Institute, St. Cloud, MN, USA.'}]",Journal of vascular and interventional neurology,[] 942,29132458,[Efficacy of analgesic and sedative treatments in children with mechanical ventilation in the pediatric intensive care unit].,"OBJECTIVE To compare the efficacy and safety of different analgesic and sedative treatments in children with mechanical ventilation in the pediatric intensive care unit (PICU). METHODS Eighty children with mechanical ventilation in the PICU who needed analgesic and sedative treatments were equally and randomly divided into midazolam group and remifentanil+midazolam group. The sedative and analgesic effects were assessed using the Ramsay Scale and the Face, Legs, Activity, Cry and Consolability (FLACC) Scale. The following indices were recorded for the two groups: vital signs, ventilator parameters, organ function, total doses of remifentanil and midazolam, duration of mechanical ventilation, length of PICU stay, PICU cost, and incidence of adverse events. RESULTS Satisfactory sedation was achieved in the two groups, but the remifentanil+midazolam group had a significantly shorter time to analgesia and sedation than the midazolam group. The remifentanil+midazolam group had a significantly higher percentage of patients with grade 3-4 on the Ramsay Scale and a significantly lower dose of midazolam than the midazolam group (P<0.05). Both groups showed decreases in heart rate (HR), mean arterial pressure (MAP), and spontaneous breathing frequency (RRs) after treatment. However, the remifentanil+midazolam group had significantly greater decreases in HR at 3-24 hours after treatment and MAP and RRs at 3-12 hours after treatment than the midazolam group (P<0.05). Compared with the midazolam group, the remifentanil+midazolam group had significantly higher ventilator tidal volume and transcutaneous oxygen saturation at 6 and 12 hours after treatment and significantly lower end-tidal carbon dioxide partial pressure at 6 and 12 hours after treatment (P<0.05). The remifentanil+midazolam group had significantly shorter time to awake, extubation time, duration of mechanical ventilation, and length of PICU stay than the midazolam group (P<0.05). There were no significant differences in PICU cost, incidence of adverse events, and hepatic and renal functions before and after treatment between the two groups (P>0.05). Both groups showed a significant decrease in fasting blood glucose level after treatment (P<0.05). CONCLUSIONS For children with mechanical ventilation in the PICU, remifentanil+midazolam treatment can rapidly achieve analgesia and sedation, improve the effect of mechanical ventilation, and reduce the dose of sedative compared with midazolam alone, and is well tolerated.",2017,"There were no significant differences in PICU cost, incidence of adverse events, and hepatic and renal functions before and after treatment between the two groups (P>0.05).","['children with mechanical ventilation in the pediatric intensive care unit', 'children with mechanical ventilation in the pediatric intensive care unit (PICU', 'Eighty children with mechanical ventilation in the PICU who needed analgesic and sedative treatments']","['analgesic and sedative treatments', 'midazolam group and remifentanil+midazolam', 'remifentanil+midazolam', 'midazolam']","['Satisfactory sedation', 'ventilator tidal volume and transcutaneous oxygen saturation', 'sedative and analgesic effects', 'PICU cost, incidence of adverse events, and hepatic and renal functions', 'tidal carbon dioxide partial pressure', 'shorter time to analgesia and sedation', 'HR', 'shorter time to awake, extubation time, duration of mechanical ventilation, and length of PICU stay', 'Ramsay Scale and the Face, Legs, Activity, Cry and Consolability (FLACC) Scale', 'fasting blood glucose level', 'Ramsay Scale', 'vital signs, ventilator parameters, organ function, total doses of remifentanil and midazolam, duration of mechanical ventilation, length of PICU stay, PICU cost, and incidence of adverse events', 'efficacy and safety', 'heart rate (HR), mean arterial pressure (MAP), and spontaneous breathing frequency (RRs']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0021710', 'cui_str': 'PICU - Pediatric intensive care unit'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0036557', 'cui_str': 'Sedatives'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0036557', 'cui_str': 'Sedatives'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0087153', 'cui_str': 'Ventilators'}, {'cui': 'C0040210', 'cui_str': 'Tidal Volume'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C0036557', 'cui_str': 'Sedatives'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0030604', 'cui_str': 'Partial Pressure'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C0234422', 'cui_str': 'Awake (finding)'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0222045'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0010399', 'cui_str': 'Cryings'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0518766'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]",80.0,0.0323815,"There were no significant differences in PICU cost, incidence of adverse events, and hepatic and renal functions before and after treatment between the two groups (P>0.05).","[{'ForeName': 'Xiao-Fang', 'Initials': 'XF', 'LastName': 'Cai', 'Affiliation': ""Intensive Care Unit, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430016, China. lwb717299@163.com.""}, {'ForeName': 'Fu-Rong', 'Initials': 'FR', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Long', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Ji-Min', 'Initials': 'JM', 'LastName': 'Sun', 'Affiliation': ''}, {'ForeName': 'Wen-Bin', 'Initials': 'WB', 'LastName': 'Li', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 943,31603205,Supplementation with Small-Quantity Lipid-Based Nutrient Supplements Does Not Increase Child Morbidity in a Semiurban Setting in Ghana: A Secondary Outcome Noninferiority Analysis of the International Lipid-Based Nutrient Supplements (iLiNS)-DYAD Randomized Controlled Trial.,"BACKGROUND Adequate knowledge about the safety of consumption of small-quantity lipid-based nutrient supplements (SQ-LNSs) is needed. OBJECTIVE We aimed to test the hypothesis that SQ-LNS consumption is noninferior to control with respect to child morbidity. METHODS Women (n = 1320) ≤20 wk pregnant were assigned to iron and folic acid until delivery with no supplementation for offspring; or multiple micronutrient supplements until 6 mo postpartum with no supplementation for offspring; or SQ-LNSs until 6 mo postpartum, and SQ-LNSs for offspring (6 mg Fe/d) from 6 to 18 mo of age [the lipid-based nutrient supplement (LNS) group]. We assessed noninferiority (margin ≤20%) between any 2 groups during 0-6 mo of age, and between the non-LNS and LNS groups during 6-18 mo of age for caregiver-reported acute respiratory infection, diarrhea, gastroenteritis, fever/suspected malaria, poor appetite, and ""other illnesses."" RESULTS During 0-6 mo of age, 1197 infants contributed 190,503 infant-days. For all morbidity combined, overall mean incidence (per 100 infant-days) was 3.3 episodes, overall mean prevalence (percentage of infant-days) was 19.3%, and the 95% CIs of the incidence rate ratio (IRR) and longitudinal prevalence rate ratio (LPRR) between any 2 groups were ≤1.20. During 6-18 mo, there were 240,097 infant-days for the non-LNS group and 118,698 for the LNS group. For all morbidity combined, group mean incidences were 4.3 and 4.3, respectively (IRR: 1.0; 95% CI: 1.0, 1.1), and mean prevalences were 28.2% and 29.3%, respectively (LPRR: 1.0; 95% CI: 1.0, 1.1). Noninferiority was inconclusive for diarrhea, fever/suspected malaria, and poor appetite. CONCLUSIONS SQ-LNS consumption does not increase reported overall child morbidity in this population compared with the 2 other treatments.This trial was registered at clinicaltrials.gov as NCT00970866.",2020,"For all morbidity combined, group mean incidences were 4.3 and 4.3, respectively","['Semiurban Setting in Ghana', '1197 infants contributed 190,503 infant-days', '1320)\xa0≤20 wk pregnant', 'Women (n\xa0']","['iron and folic acid until delivery with no supplementation for offspring; or multiple micronutrient supplements until 6\xa0mo postpartum with no supplementation for offspring; or SQ-LNSs until 6\xa0mo postpartum, and SQ-LNSs for offspring (6\xa0mg Fe/d) from 6 to 18\xa0mo of age [the lipid-based nutrient supplement (LNS', 'Supplementation with Small-Quantity Lipid-Based Nutrient Supplements']","['diarrhea, fever/suspected malaria, and poor appetite', 'acute respiratory infection, diarrhea, gastroenteritis, fever/suspected malaria, poor appetite, and ""other illnesses', 'Child Morbidity', 'mean prevalences', 'incidence rate ratio (IRR) and longitudinal prevalence rate ratio (LPRR', 'overall child morbidity', 'overall mean incidence']","[{'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0017516', 'cui_str': 'Republic of Ghana'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0549206', 'cui_str': 'Pregnancy not delivered'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}, {'cui': 'C0086839', 'cui_str': 'Postpartum Period'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C1265611', 'cui_str': 'Quantity finding'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}, {'cui': 'C0024530', 'cui_str': 'Plasmodium Infections'}, {'cui': 'C0232462', 'cui_str': 'Decrease in appetite (finding)'}, {'cui': 'C0339901', 'cui_str': 'ARI - Acute respiratory infections'}, {'cui': 'C0017160', 'cui_str': 'Gastroenteritis'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",1197.0,0.445583,"For all morbidity combined, group mean incidences were 4.3 and 4.3, respectively","[{'ForeName': 'Seth', 'Initials': 'S', 'LastName': 'Adu-Afarwuah', 'Affiliation': 'Department of Nutrition and Food Science, University of Ghana, Legon, Accra, Ghana.'}, {'ForeName': 'Rebecca R', 'Initials': 'RR', 'LastName': 'Young', 'Affiliation': 'Program in International and Community Nutrition, Department of Nutrition, University of California, Davis, CA, USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Lartey', 'Affiliation': 'Department of Nutrition and Food Science, University of Ghana, Legon, Accra, Ghana.'}, {'ForeName': 'Harriet', 'Initials': 'H', 'LastName': 'Okronipa', 'Affiliation': 'Department of Nutrition and Food Science, University of Ghana, Legon, Accra, Ghana.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Ashorn', 'Affiliation': 'Centre for Child Health Research, Tampere University Faculty of Medicine and Health Sciences and Tampere University Hospital, Tampere, Finland.'}, {'ForeName': 'Ulla', 'Initials': 'U', 'LastName': 'Ashorn', 'Affiliation': 'Centre for Child Health Research, Tampere University Faculty of Medicine and Health Sciences and Tampere University Hospital, Tampere, Finland.'}, {'ForeName': 'Brietta M', 'Initials': 'BM', 'LastName': 'Oaks', 'Affiliation': 'Department of Nutrition and Food Sciences, University of Rhode Island, Kingston, RI, USA.'}, {'ForeName': 'Kathryn G', 'Initials': 'KG', 'LastName': 'Dewey', 'Affiliation': 'Program in International and Community Nutrition, Department of Nutrition, University of California, Davis, CA, USA.'}]",The Journal of nutrition,['10.1093/jn/nxz243'] 944,31605197,"The effect of inulin and resistant maltodextrin on weight loss during energy restriction: a randomised, placebo-controlled, double-blinded intervention.","PURPOSE The objective of this study was to investigate the additive effects of combining energy restriction with dietary fibres on change in body weight and gut microbiota composition. METHODS The study was a 12-week randomised, placebo-controlled, double-blinded, parallel intervention trial. A total of 116 overweight or obese participants were assigned randomly either to 10 g inulin plus 10 g resistant maltodextrin or to 20 g of placebo supplementation through 400 mL of milk a day, while on a - 500 kcal/day energy restricted diet. RESULTS Altogether, 86 participants completed the intervention. There were no significant differences in weight loss or body composition between the groups. The fibre supplement reduced systolic (5.35 ± 2.4 mmHg, p = 0.043) and diastolic (2.82 ± 1.3 mmHg, p = 0.047) blood pressure to a larger extent than placebo. Furthermore, a larger decrease in serum insulin was observed in the placebo group compared to the fibre group (- 26.0 ± 9.2 pmol/L, p = 0.006). The intake of fibre induced changes in the composition of gut microbiota resulting in higher abundances of Parabacteroides and Bifidobacteria, compared to placebo. The effects on blood pressure and glucose metabolism were mainly observed in women, and could be attributed to a higher gut microbiota diversity after intervention. Finally, the fibre group experienced a higher degree of gastrointestinal symptoms, which attenuated over time. CONCLUSIONS Supplementation of inulin and resistant maltodextrin did not provide an additional weight loss during an energy-restricted diet, but reduced both systolic and diastolic blood pressure. Furthermore, the fibre supplement did stimulate the growth of potentially beneficial bacteria genera. CLINICAL TRIAL REGISTRY The study was registered at http://www.clinicaltrials.gov , NCT03135041.",2020,"The fibre supplement reduced systolic (5.35 ± 2.4 mmHg, p = 0.043) and diastolic (2.82 ± 1.3 mmHg, p = 0.047) blood pressure to a larger extent than placebo.","['116 overweight or obese participants', '86 participants completed the intervention']","['placebo', 'inulin plus 10\xa0g resistant maltodextrin or to 20\xa0g of placebo supplementation through 400\xa0mL of milk a day, while on a -\u2009500\xa0kcal/day energy restricted diet', 'inulin and resistant maltodextrin']","['gastrointestinal symptoms', 'blood pressure', 'diastolic', 'body weight and gut microbiota composition', 'serum insulin', 'blood pressure and glucose metabolism', 'weight loss', 'weight loss or body composition', 'systolic and diastolic blood pressure', 'additional weight loss']","[{'cui': 'C4517541', 'cui_str': '116 (qualifier value)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0021936', 'cui_str': 'Inulin'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1318182', 'cui_str': '10G'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0450403', 'cui_str': '20G (qualifier value)'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0456649', 'cui_str': 'kcal/day'}, {'cui': 'C0443288', 'cui_str': 'Restricted (qualifier value)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}]","[{'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C4018878', 'cui_str': 'Gastrointestinal Microbial Community'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}]",86.0,0.439913,"The fibre supplement reduced systolic (5.35 ± 2.4 mmHg, p = 0.043) and diastolic (2.82 ± 1.3 mmHg, p = 0.047) blood pressure to a larger extent than placebo.","[{'ForeName': 'Anne Lundby', 'Initials': 'AL', 'LastName': 'Hess', 'Affiliation': 'The Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Rolighedsvej 26, 1958, Frederiksberg C, Denmark. lundbyhess@gmail.com.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Benítez-Páez', 'Affiliation': 'Microbial Ecology, Nutrition and Health Research Unit, Institute of Agrochemistry and Food Technology, Spanish National Research Council IATA-CSIC, C/Catedràtic Agustín Escardino Benlloch, 7, 46980, Paterna-Valencia, Spain. abenitez@iata.csic.es.'}, {'ForeName': 'Trine', 'Initials': 'T', 'LastName': 'Blædel', 'Affiliation': 'The Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Rolighedsvej 26, 1958, Frederiksberg C, Denmark.'}, {'ForeName': 'Lesli Hingstrup', 'Initials': 'LH', 'LastName': 'Larsen', 'Affiliation': 'The Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Rolighedsvej 26, 1958, Frederiksberg C, Denmark.'}, {'ForeName': 'Jose Ramón', 'Initials': 'JR', 'LastName': 'Iglesias', 'Affiliation': 'Corporación Alimentaria Peñasanta S.A., Asturias, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Madera', 'Affiliation': 'Corporación Alimentaria Peñasanta S.A., Asturias, Spain.'}, {'ForeName': 'Yolanda', 'Initials': 'Y', 'LastName': 'Sanz', 'Affiliation': 'Microbial Ecology, Nutrition and Health Research Unit, Institute of Agrochemistry and Food Technology, Spanish National Research Council IATA-CSIC, C/Catedràtic Agustín Escardino Benlloch, 7, 46980, Paterna-Valencia, Spain.'}, {'ForeName': 'Thomas Meinert', 'Initials': 'TM', 'LastName': 'Larsen', 'Affiliation': 'The Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Rolighedsvej 26, 1958, Frederiksberg C, Denmark.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of nutrition,['10.1007/s00394-019-02099-x'] 945,29046197,[Prospective study of ketogenic diet in treatment of children with global developmental delay].,"OBJECTIVE To study the effect of ketogenic diet (KD) on neurobehavioral development, emotional and social behaviors, and life ability in children with global developmental delay (GDD). METHODS A prospective case-control study was performed for hospitalized children with GDD, who were randomly divided into KD treatment group (n=40) and conventional treatment group (n=37). The children in both groups were given comprehensive rehabilitation training, and those in the KD treatment group were given modified Atkins diet in addition to the comprehensive rehabilitation training. The children in both groups were assessed with the Gesell Developmental Scale, Chinese version of Urban Infant-Toddler Social and Emotional Assessment (CITSEA)/Achenbach Child Behavior Checklist (CBCL), and Infants-Junior High School Students' Social Life Abilities Scale (S-M scale) before treatment and after 3, 6, and 9 months of treatment. The two groups were compared in terms of the improvements in neurobehavioral development, emotional and social behaviors, and social life ability. RESULTS After 3, 6, and 9 months of treatment, the KD treatment group had significantly greater improvements in the scores of the adaptive, fine motor, and language quotients of the Gesell Developmental Scale compared with the conventional treatment group (P<0.05); the KD treatment group had significantly greater improvements in CITSEA/CBCL scores than the conventional treatment group (P<0.05). The KD treatment group had a greater improvement in the score of the S-M scale after 9 months of treatment (P<0.05). During the KD treatment, 6 children experienced diarrhea and 1 experienced mild urinary stones. CONCLUSIONS KD can improve the neurobehavioral development and behavioral and emotional behaviors in children with GDD, and it has few adverse effects.",2017,"The two groups were compared in terms of the improvements in neurobehavioral development, emotional and social behaviors, and social life ability. ","['children with global developmental delay (GDD', 'hospitalized children with GDD', 'children with GDD', 'children with global developmental delay']","['ketogenic diet (KD', 'ketogenic diet', 'modified Atkins diet in addition to the comprehensive rehabilitation training', 'conventional treatment group', 'comprehensive rehabilitation training']","['neurobehavioral development, emotional and social behaviors, and social life ability', 'scores of the adaptive, fine motor, and language quotients of the Gesell Developmental Scale', 'score of the S-M scale', ""Gesell Developmental Scale, Chinese version of Urban Infant-Toddler Social and Emotional Assessment (CITSEA)/Achenbach Child Behavior Checklist (CBCL), and Infants-Junior High School Students' Social Life Abilities Scale (S-M scale"", 'CITSEA/CBCL scores', 'mild urinary stones', 'neurobehavioral development, emotional and social behaviors, and life ability', 'neurobehavioral development and behavioral and emotional behaviors', 'diarrhea']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0557874', 'cui_str': 'Global developmental delay (disorder)'}, {'cui': 'C0008098', 'cui_str': 'Child, Hospitalized'}]","[{'cui': 'C0259972', 'cui_str': 'Ketogenic Diet'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0037397', 'cui_str': 'Social Behavior'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205232', 'cui_str': 'Fine (qualifier value)'}, {'cui': 'C0023008', 'cui_str': 'Languages'}, {'cui': 'C0458003', 'cui_str': 'Developmental (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0682053', 'cui_str': 'Toddler (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0008065', 'cui_str': 'Child Behavior'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0042018', 'cui_str': 'Urinary Tract Stones'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",,0.0150556,"The two groups were compared in terms of the improvements in neurobehavioral development, emotional and social behaviors, and social life ability. ","[{'ForeName': 'Deng-Na', 'Initials': 'DN', 'LastName': 'Zhu', 'Affiliation': ""Department of Children's Rehabilitation, Third Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China. zhudengna@126.com.""}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Jun-Ying', 'Initials': 'JY', 'LastName': 'Yuan', 'Affiliation': ''}, {'ForeName': 'Guang-Yu', 'Initials': 'GY', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Jiang-Fang', 'Initials': 'JF', 'LastName': 'Liang', 'Affiliation': ''}, {'ForeName': 'Ming-Mei', 'Initials': 'MM', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Yun-Xia', 'Initials': 'YX', 'LastName': 'Zhao', 'Affiliation': ''}, {'ForeName': 'Shuang', 'Initials': 'S', 'LastName': 'An', 'Affiliation': ''}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Ma', 'Affiliation': ''}, {'ForeName': 'Dan-Dan', 'Initials': 'DD', 'LastName': 'Ma', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 946,28697827,[Effects of Huaiqihuang granules on immune function in children with severe Mycoplasma pneumoniae pneumonia].,"OBJECTIVE To observe the effects of Huaiqihuang granules on the immune function in children with severe Mycoplasma pneumoniae pneumonia. METHODS Pediatric inpatients with severe Mycoplasma pneumoniae pneumonia were randomly divided into Huaiqihuang granule treatment group (n=51) and conventional treatment group (n=47). The Huaiqihuang granule treatment group was orally administered Huaiqihuang granules in addition to the conventional treatment, while the conventional treatment group received conventional treatment only. Levels of serum IgA, IgG, and IgM, percentages of CD4 + and CD8 +  T lymphocyte subsets, and CD4 + /CD8 + ratio were examined in the two groups. The incidence rate of respiratory tract re-infection within three months following treatment was compared between the two groups. RESULTS The levels of serum IgA, IgG, and IgM, the percentage of CD4 +  T lymphocytes, and the CD4 + /CD8 + ratio were significantly higher in the Huaiqihuang granule treatment group than in the conventional treatment group three months after treatment (P<0.05). In contrast, the percentage of CD8 + T lymphocytes was significantly lower in the Huaiqihuang granule treatment group than in the conventional treatment group (P<0.05). In addition, the incidence rate of respiratory tract re-infection within three months following treatment was significantly lower in the Huaiqihuang granule treatment group than in the conventional treatment group (P<0.05). CONCLUSIONS Huaiqihuang granules can regulate immune functions and reduce the incidence of short-term respiratory tract re-infection in children with severe Mycoplasma pneumoniae pneumonia.",2017,"In contrast, the percentage of CD8 + T lymphocytes was significantly lower in the Huaiqihuang granule treatment group than in the conventional treatment group (P<0.05).","['children with severe Mycoplasma pneumoniae pneumonia', 'Pediatric inpatients with severe Mycoplasma pneumoniae pneumonia']","['Huaiqihuang granules', 'Huaiqihuang granule treatment group (n=51) and conventional treatment group', 'conventional treatment only']","['percentage of CD8 + T lymphocytes', 'incidence rate of respiratory tract re-infection', 'levels of serum IgA, IgG, and IgM, the percentage of CD4 + \u2005T lymphocytes, and the CD4 + /CD8 + ratio', 'Levels of serum IgA, IgG, and IgM, percentages of CD4 + and CD8 + \u2005T lymphocyte subsets, and CD4 + /CD8 + ratio', 'immune function']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0032302', 'cui_str': 'Pneumonia, Primary Atypical'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}]","[{'cui': 'C3883890', 'cui_str': 'huaiqihuang'}, {'cui': 'C3853573', 'cui_str': 'Granules'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]","[{'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0282335', 'cui_str': 'Respiratory Tract'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0020861', 'cui_str': 'IgM'}, {'cui': 'C0039215', 'cui_str': 'CD4-Positive Lymphocytes'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0080202', 'cui_str': 'T-Cell Subsets'}, {'cui': 'C0439662', 'cui_str': 'Immune (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}]",,0.0175814,"In contrast, the percentage of CD8 + T lymphocytes was significantly lower in the Huaiqihuang granule treatment group than in the conventional treatment group (P<0.05).","[{'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': ""The Second Department of Pediatrics, Shenyang Children's Hospital, Shenyang 110032, China. sysetyy8101@126.com.""}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Yan', 'Affiliation': ''}, {'ForeName': 'Xiao-Geng', 'Initials': 'XG', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Ya-Ping', 'Initials': 'YP', 'LastName': 'Mu', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 947,31526767,Dopamine replacement improves motor learning of an upper extremity task in people with Parkinson disease.,"BACKGROUND Dopamine replacement medication has positive effects on existing motor skills for people with Parkinson disease (PD), but may have detrimental effects on the learning of motor skills necessary for effective rehabilitation according to the dopamine overdose hypothesis. OBJECTIVES This study aimed to determine whether dopamine replacement medication (i.e. levodopa) affects: learning of a novel upper extremity task, decrements in skill following withdrawal of practice, the rate of learning, and the transfer of movement skill to untrained upper extremity tasks compared to training ""off"" medication, in people with PD. METHODS Participants with mild-moderate PD (Hoehn and Yahr stage 2) were randomized to train ""on"" (n = 12) or ""off"" (n = 11) levodopa medication. Participants practiced 10 blocks of five trials of a functional motor task with their non-dominant upper extremity over three consecutive days (acquisition period), followed by a single block of five trials two and nine days later. Participants were also assessed ""on"" levodopa with two transfer tasks (the nine-hole peg test and a functional dexterity task) prior to any practice and nine days after the end of the acquisition period. RESULTS Participants who practiced ""on"" levodopa medication learned the upper extremity task to a greater extent that those who practiced ""off"" medication, as determined by retained performance two days after practice. Skill decrement and skill transfer were not significantly different between groups. Rate of learning was unable to be modelled in this sample. CONCLUSIONS Levodopa medication improved the learning of an upper extremity task in people with mild-moderate PD.",2020,Skill decrement and skill transfer were not significantly different between groups.,"['people with mild-moderate PD', 'Participants who practiced ""on"" levodopa medication learned the', 'Participants with mild-moderate PD (Hoehn and Yahr stage 2', 'people with Parkinson disease', 'people with Parkinson disease (PD']","['Dopamine replacement', 'dopamine replacement medication (i.e. levodopa', 'Levodopa medication', 'Dopamine replacement medication', 'train ""on"" (n\u202f=\u202f12) or ""off"" (n\u202f=\u202f11) levodopa medication', 'functional motor task with their non-dominant upper extremity']","['Skill decrement and skill transfer', 'upper extremity task', 'learning of an upper extremity task', 'Rate of learning', 'motor learning of an upper extremity task']","[{'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2 (qualifier value)'}, {'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}]","[{'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}]","[{'cui': 'C0040671', 'cui_str': 'Transfer'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0023185', 'cui_str': 'Learning'}]",10.0,0.136439,Skill decrement and skill transfer were not significantly different between groups.,"[{'ForeName': 'Serene S', 'Initials': 'SS', 'LastName': 'Paul', 'Affiliation': 'Department of Physical Therapy and Athletic Training, University of Utah, 520 Wakara Way, Salt Lake City, UT, 84108, USA; Discipline of Physiotherapy, Faculty of Health Sciences, The University of Sydney, 75 East St, Lidcombe, NSW, 2141, Australia. Electronic address: serene.paul@sydney.edu.au.'}, {'ForeName': 'Leland E', 'Initials': 'LE', 'LastName': 'Dibble', 'Affiliation': 'Department of Physical Therapy and Athletic Training, University of Utah, 520 Wakara Way, Salt Lake City, UT, 84108, USA.'}, {'ForeName': 'Genevieve N', 'Initials': 'GN', 'LastName': 'Olivier', 'Affiliation': 'Department of Physical Therapy and Athletic Training, University of Utah, 520 Wakara Way, Salt Lake City, UT, 84108, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Walter', 'Affiliation': 'Department of Physical Therapy and Athletic Training, University of Utah, 520 Wakara Way, Salt Lake City, UT, 84108, USA; Department of Physical Therapy, University of Arkansas for Medical Sciences, 1125 N College Ave, Fayetteville, AR, 72703, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Duff', 'Affiliation': ""Center for Alzheimer's Care, Imaging & Research, Department of Neurology, University of Utah, 650 Komas Dr 106A, Salt Lake City, UT, 84108, USA.""}, {'ForeName': 'Sydney Y', 'Initials': 'SY', 'LastName': 'Schaefer', 'Affiliation': 'Department of Physical Therapy and Athletic Training, University of Utah, 520 Wakara Way, Salt Lake City, UT, 84108, USA; Department of Biological and Health Systems Engineering, Arizona State University, 501 E Tyler Mall, MC 9709, Tempe, AZ, 85287, USA.'}]",Behavioural brain research,['10.1016/j.bbr.2019.112213'] 948,31595300,Intervention Mediators in a Randomized Controlled Trial to Increase Physical Activity and Fatigue Self-management Behaviors Among Adults With Multiple Sclerosis.,"BACKGROUND People with multiple sclerosis (MS) often experience fatigue, which is aggravated by inactivity. Identifying mediators of changes in physical activity (PA) and fatigue self-management (FSM) behaviors could optimize future interventions that reduce the impact of MS fatigue. PURPOSE TO examine the effects of telephone-delivered interventions on Social Cognitive Theory constructs and test whether these constructs mediated secondary outcomes of PA and FSM behaviors. METHODS Participants with MS (n = 208; Mean age = 52.1; Female = 84.6%) were randomized into contact-control intervention (CC), PA-only intervention, and PA+FSM intervention. Step count (Actigraphy) and FSM behaviors as well as self-efficacy, outcome expectations, and goal setting for PA and FSM were measured at baseline, post-test (12 weeks), and follow-up (24 weeks). Path analyses using bias-corrected bootstrapped 95% confidence intervals (CI) determined whether constructs at post-test mediated behaviors at follow-up when adjusting for baseline measures. RESULTS Path analysis indicated that PA-only (β = 0.50, p < .001) and PA+FSM interventions (β = 0.42, p < .010) had an effect on goal setting for PA, and that PA + FSM intervention had an effect on self-efficacy for FSM (β = 0.48, p = .011) and outcome expectations for FSM (β = 0.42, p = .029). Goal setting for PA at post-test mediated the effects of PA-only (β = 159.45, CI = 5.399, 371.996) and PA + FSM interventions (β = 133.17, CI = 3.104, 355.349) on step count at follow-up. Outcome expectations for FSM at post-test mediated the effects of PA + FSM intervention on FSM behaviors at follow-up (β = 0.02, CI = 0.001, 0.058). CONCLUSIONS Goal setting for PA and outcome expectations for FSM may be important constructs to target in telephone-delivered interventions designed to reduce the impact of MS fatigue. TRIAL REGISTRATION Clinicaltrials.gov (NCT01572714).",2020,"Goal setting for PA at post-test mediated the effects of PA-only (β = 159.45, CI = 5.399, 371.996) and PA + FSM interventions (β = 133.17, CI = 3.104, 355.349) on step count at follow-up.","['People with multiple sclerosis (MS', 'Participants with MS (n = 208; Mean age = 52.1; Female = 84.6', 'Adults With Multiple Sclerosis']","['telephone-delivered interventions', 'PA + FSM intervention', 'contact-control intervention (CC), PA-only intervention, and PA+FSM intervention']","['Physical Activity and Fatigue Self-management Behaviors', 'FSM behaviors', 'Step count (Actigraphy) and FSM behaviors as well as self-efficacy, outcome expectations, and goal setting for PA and FSM', 'self-efficacy', 'PA+FSM interventions']","[{'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C1261552', 'cui_str': 'Step'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0018017', 'cui_str': 'Goals'}, {'cui': 'C0036849', 'cui_str': 'Set'}]",,0.0926462,"Goal setting for PA at post-test mediated the effects of PA-only (β = 159.45, CI = 5.399, 371.996) and PA + FSM interventions (β = 133.17, CI = 3.104, 355.349) on step count at follow-up.","[{'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Plow', 'Affiliation': 'Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, OH.'}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Motl', 'Affiliation': 'Department of Physical Therapy, The University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Marcia', 'Initials': 'M', 'LastName': 'Finlayson', 'Affiliation': ""School of Rehabilitation Therapy, Faculty of Health Sciences, Queen's University, Kingston, Ontario, Canada.""}, {'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Bethoux', 'Affiliation': 'Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, The Cleveland Clinic Foundation, Cleveland, OH.'}]",Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,['10.1093/abm/kaz033'] 949,31536941,Characteristics influencing expected cognitive performance during hypoglycaemia in type 2 diabetes.,"BACKGROUND Acute hypoglycaemia is associated with cognitive impairment in patients with type 2 diabetes. However, there is limited understanding of the relationship between patients' expected cognitive difficulties and their objectively-measured deficits during non-severe hypoglycaemia. OBJECTIVE This report investigates demographic and clinical factors associated with the discrepancy between expected (i.e., self-evaluated) and measurable (i.e., neuropsychological) cognitive functions in patients with type 2 diabetes during acute non-severe hypoglycaemia. METHODS We performed an analysis of factors associated with the relationship between expected and measurable cognitive performance for data collected from a cohort of patients with type 2 diabetes (N = 25). Patients attended two experimental visits during which we performed hyper-insulinaemic glucose clamping; (i) non-severe hypoglycaemic clamp (plasma glucose (PG): 3.1 ± 0.3 mmol/L) and (ii) normoglycaemic clamp (PG: 5.8 ± 0.3 mmol/L), as part of a double-blinded cross-over study. During hypoglycaemia, patients' expected cognitive performance was assessed with a visual analogue scale after which objective cognitive functions were assessed with a neuropsychological test battery. We computed a global 'cognitive discrepancy' composite variable with score values on a scale between -10 and +10 using a novel statistical formula that creates a discrepancy score between subjective and objective cognition. Positive values reflect more expected than objectively-measured difficulties, while negative values reflect disproportionately more objectively-measured than expected cognitive difficulties. We used paired samples t-tests to compare degree of cognitive discrepancy between conditions of hypo- and normoglycaemia, while multiple regression analysis was performed to identify factors associated with the degree and direction of the cognitive discrepancy. The significance level for the analyses was p ≤ 0.05 (two-tailed). RESULTS Patients generally underestimated their cognitive abilities (M = 1.6, SD = 3.3) during hypoglycaemia compared to normoglycaemia (M = -1.0, SD = 3.5) (p = 0.2), t(23) = 2.9, p < 0.01. Underestimation of cognitive capacity during hypoglycaemia was more pronounced for patients with younger age (β = 0.5, p = 0.02), higher verbal IQ (β = 0.5, p = 0.03), and more hypoglycaemia-related shakiness (β = 0.4, p = 0.03). LIMITATIONS The modest sample size limits the generalizability of the findings. CONCLUSIONS Patients with type 2 diabetes underestimated their cognitive abilities during non-severe hypoglycaemic states, especially those with younger age, higher IQ, and more hypoglycaemia-related shakiness. These patients may thus have excessive preoccupations with their cognitive difficulties in relation to cognitively challenging daily life situations.",2019,"Underestimation of cognitive capacity during hypoglycaemia was more pronounced for patients with younger age (β = 0.5, p = 0.02), higher verbal IQ (β = 0.5, p = 0.03), and more hypoglycaemia-related shakiness (β = 0.4, p = 0.03). ","['type 2 diabetes', 'patients with type 2 diabetes', 'patients with type 2 diabetes during acute non-severe hypoglycaemia', 'patients with type 2 diabetes (N\u202f=\u202f25']",['hyper-insulinaemic glucose clamping; (i) non-severe hypoglycaemic clamp (plasma glucose (PG): 3.1\u202f±\u202f0.3\u202fmmol/L) and (ii) normoglycaemic clamp (PG: 5.8\u202f±\u202f0.3\u202fmmol/L'],"['cognitive abilities', 'higher verbal IQ', 'Underestimation of cognitive capacity during hypoglycaemia', 'cognitive performance', 'hypoglycaemia-related shakiness']","[{'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}]","[{'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C4517683', 'cui_str': '3.1 (qualifier value)'}, {'cui': 'C4068885', 'cui_str': 'Zero point three'}, {'cui': 'C1532563', 'cui_str': 'umol/mL'}, {'cui': 'C0580545', 'cui_str': 'Blood glucose normal (finding)'}, {'cui': 'C4517796', 'cui_str': '5.8'}]","[{'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0392703', 'cui_str': 'Shakiness'}]",,0.0813642,"Underestimation of cognitive capacity during hypoglycaemia was more pronounced for patients with younger age (β = 0.5, p = 0.02), higher verbal IQ (β = 0.5, p = 0.03), and more hypoglycaemia-related shakiness (β = 0.4, p = 0.03). ","[{'ForeName': 'J Z', 'Initials': 'JZ', 'LastName': 'Petersen', 'Affiliation': 'Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet Dep. 6233, Blegdamsvej 9, DK-2100, Copenhagen, Denmark; Department of Psychology, University of Copenhagen, Øster Farimagsgade 2A, DK-1353, Copenhagen, Denmark. Electronic address: jeff.zarp.petersen@regionh.dk.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Nilsson', 'Affiliation': 'Bispebjerg University Hospital, Department of Endocrinology, Copenhagen, Denmark. Electronic address: malin.sofia.desiree.nilsson@regionh.dk.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Rungby', 'Affiliation': 'Bispebjerg University Hospital, Department of Endocrinology, Copenhagen, Denmark; Copenhagen Center for Translational Research, Bispebjerg University Hospital, Copenhagen, Denmark. Electronic address: jr@biomed.au.dk.'}, {'ForeName': 'K W', 'Initials': 'KW', 'LastName': 'Miskowiak', 'Affiliation': 'Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet Dep. 6233, Blegdamsvej 9, DK-2100, Copenhagen, Denmark; Department of Psychology, University of Copenhagen, Øster Farimagsgade 2A, DK-1353, Copenhagen, Denmark. Electronic address: kamilla.miskowiak@regionh.dk.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2019.104431'] 950,31370958,Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass: Randomized Controlled Trial.,"BACKGROUND The efficacy of intraoperative corticosteroids to improve outcomes following congenital cardiac operations remains controversial. OBJECTIVES The purpose of this study was to determine whether intraoperative methylprednisolone improves post-operative recovery in neonates undergoing cardiac surgery. METHODS Neonates undergoing cardiac surgery with cardiopulmonary bypass at 2 centers were enrolled in a double-blind randomized controlled trial of methylprednisolone (30 mg/kg) or placebo after the induction of anesthesia. The primary outcome was a previously validated morbidity-mortality composite that included any of the following events following surgery before discharge: death, mechanical circulatory support, cardiac arrest, hepatic injury, renal injury, or rising lactate level (>5 mmol/l). RESULTS Of the 190 subjects enrolled, 176 (n = 81 methylprednisolone, n = 95 placebo) were included in this analysis. A total of 27 (33%) subjects in the methylprednisolone group and 40 (42%) in the placebo group reached the primary study endpoint (odds ratio [OR]: 0.63; 95% confidence interval [CI]: 0.31 to 1.3; p = 0.21). Methylprednisolone was associated with reductions in vasoactive inotropic requirements and in the incidence of the composite endpoint in subjects undergoing palliative operations (OR: 0.38; 95% CI: 0.15 to 0.99; p = 0.048). There was a significant interaction between treatment effect and center. In this analysis, methylprednisolone was protective at 1 center, with an OR: 0.35 (95% CI: 0.15 to 0.84; p = 0.02), and not so at the other center, with OR: 5.13 (95% CI: 0.85 to 30.90; p = 0.07). CONCLUSIONS Intraoperative methylprednisolone failed to show an overall significant benefit on the incidence of the composite primary study endpoint. There was, however, a benefit in patients undergoing palliative procedures and a significant interaction between treatment effect and center, suggesting that there may be center or patient characteristics that make prophylactic methylprednisolone beneficial.",2019,Methylprednisolone was associated with reductions in vasoactive inotropic requirements and in the incidence of the composite endpoint in subjects undergoing palliative operations (OR: 0.38; 95% CI: 0.15 to 0.99; p = 0.048).,"['Neonates undergoing cardiac surgery with cardiopulmonary bypass at 2 centers', 'neonates undergoing cardiac surgery', 'Neonates Undergoing Cardiopulmonary Bypass', '190 subjects enrolled, 176 (n\xa0']","['intraoperative methylprednisolone', 'intraoperative corticosteroids', 'placebo', 'methylprednisolone', '81 methylprednisolone, n\xa0=\xa095 placebo', 'Corticosteroid Therapy', 'Methylprednisolone']","['morbidity-mortality composite that included any of the following events following surgery before discharge: death, mechanical circulatory support, cardiac arrest, hepatic injury, renal injury, or rising lactate level (>5\xa0mmol/l', 'vasoactive inotropic requirements']","[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C0007202', 'cui_str': 'Heart-Lung Bypass'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C4517622', 'cui_str': 'One hundred and ninety'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0018790', 'cui_str': 'Cardiac Arrest'}, {'cui': 'C0160390', 'cui_str': 'Injury of liver (disorder)'}, {'cui': 'C0160420', 'cui_str': 'Injury of kidney (disorder)'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439084', 'cui_str': '>5 (qualifier value)'}, {'cui': 'C1532563', 'cui_str': 'umol/mL'}]",190.0,0.752619,Methylprednisolone was associated with reductions in vasoactive inotropic requirements and in the incidence of the composite endpoint in subjects undergoing palliative operations (OR: 0.38; 95% CI: 0.15 to 0.99; p = 0.048).,"[{'ForeName': 'Eric M', 'Initials': 'EM', 'LastName': 'Graham', 'Affiliation': 'Medical University of South Carolina, Charleston, South Carolina. Electronic address: grahamem@musc.edu.'}, {'ForeName': 'Reneé H', 'Initials': 'RH', 'LastName': 'Martin', 'Affiliation': 'Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Jason R', 'Initials': 'JR', 'LastName': 'Buckley', 'Affiliation': 'Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Sinai C', 'Initials': 'SC', 'LastName': 'Zyblewski', 'Affiliation': 'Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Minoo N', 'Initials': 'MN', 'LastName': 'Kavarana', 'Affiliation': 'Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Scott M', 'Initials': 'SM', 'LastName': 'Bradley', 'Affiliation': 'Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Bahaaldin', 'Initials': 'B', 'LastName': 'Alsoufi', 'Affiliation': ""Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia.""}, {'ForeName': 'William T', 'Initials': 'WT', 'LastName': 'Mahle', 'Affiliation': ""Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia.""}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Hassid', 'Affiliation': 'Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Atz', 'Affiliation': 'Medical University of South Carolina, Charleston, South Carolina.'}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2019.05.060'] 951,32412417,A Mobile App Lifestyle Intervention to Improve Healthy Nutrition in Women Before and During Early Pregnancy: Single-Center Randomized Controlled Trial.,"BACKGROUND Unhealthy nutrition contributes to the worldwide rising prevalence of noncommunicable diseases. As most adverse reproductive outcomes originate during the periconception period, effective interventions targeting this period are needed. Therefore, we developed the lifestyle intervention Smarter Pregnancy to empower women to adapt a healthy diet prior to conception and during early pregnancy and performed a randomized controlled trial. OBJECTIVE The objectives of this trial were to investigate compliance and effectiveness in women using the Smarter Pregnancy program. METHODS Women aged between 18 and 45 years who were contemplating pregnancy or <13 weeks pregnant and their male partners living in the urban area of Rotterdam, the Netherlands, were eligible for participation. After baseline screening, the intervention group received personal online coaching based on identified inadequate intakes of vegetables, fruits, and folic acid supplements. The sum of these risk factors was used as a dietary risk score (DRS), ranging from 0 (healthy) to 9 (unhealthy). The control group did not receive coaching. We applied an intention-to-treat principle and used a multivariable linear regression model to evaluate the change in DRS after 24 weeks. Compliance was defined as the percentage of women who completed the screening questionnaire at 24 weeks. RESULTS Of women recruited, 81.2% (177/218) completed the program (intervention: 91/218, 83.5%; control: 86/218, 78.9%; P=.95). After 24 weeks, the reduction in DRS of women in the intervention group was significantly larger than in the control group (β=.75, 95% CI 0.18-1.34). This reduction was mainly due to increased vegetable intake (β=.55, 95% CI 0.25-0.86). CONCLUSIONS The high compliance and the larger improvements in nutritional behaviors, especially vegetable intake, in women in the intervention group emphasizes the effectiveness of empowering women by using the lifestyle change intervention Smarter Pregnancy. TRIAL REGISTRATION Netherlands Trial Register: NL3927; https://www.trialregister.nl/trial/3927. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR2-10.1186/s12884-017-1228-5.",2020,"This reduction was mainly due to increased vegetable intake (β=.55, 95% CI 0.25-0.86). ","['Women aged between 18 and 45 years who were contemplating pregnancy or <13 weeks pregnant and their male partners living in the urban area of Rotterdam, the Netherlands, were eligible for participation', 'Healthy Nutrition in Women Before and During Early Pregnancy', 'women using the Smarter Pregnancy program']","['control group did not receive coaching', 'personal online coaching based on identified inadequate intakes of vegetables, fruits, and folic acid supplements', 'Mobile App Lifestyle Intervention']","['reduction in DRS', 'vegetable intake', 'compliance and effectiveness', 'dietary risk score (DRS']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0460089', 'cui_str': 'Finding of length of gestation'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C5200690', 'cui_str': 'Healthy Nutrition'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0235048', 'cui_str': 'Smarting pain'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0556223', 'cui_str': 'Vegetable intake'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.112521,"This reduction was mainly due to increased vegetable intake (β=.55, 95% CI 0.25-0.86). ","[{'ForeName': 'Matthijs R', 'Initials': 'MR', 'LastName': 'van Dijk', 'Affiliation': 'Department of Obstetrics and Gynaecology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, Netherlands.'}, {'ForeName': 'Maria P H', 'Initials': 'MPH', 'LastName': 'Koster', 'Affiliation': 'Department of Obstetrics and Gynaecology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, Netherlands.'}, {'ForeName': 'Elsje C', 'Initials': 'EC', 'LastName': 'Oostingh', 'Affiliation': 'Department of Obstetrics and Gynaecology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, Netherlands.'}, {'ForeName': 'Sten P', 'Initials': 'SP', 'LastName': 'Willemsen', 'Affiliation': 'Department of Biostatistics, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, Netherlands.'}, {'ForeName': 'Eric A P', 'Initials': 'EAP', 'LastName': 'Steegers', 'Affiliation': 'Department of Obstetrics and Gynaecology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, Netherlands.'}, {'ForeName': 'Régine P M', 'Initials': 'RPM', 'LastName': 'Steegers-Theunissen', 'Affiliation': 'Department of Obstetrics and Gynaecology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, Netherlands.'}]",Journal of medical Internet research,['10.2196/15773'] 952,28771393,Single-Dose Testosterone Administration Impairs Cognitive Reflection in Men.,"In nonhumans, the sex steroid testosterone regulates reproductive behaviors such as fighting between males and mating. In humans, correlational studies have linked testosterone with aggression and disorders associated with poor impulse control, but the neuropsychological processes at work are poorly understood. Building on a dual-process framework, we propose a mechanism underlying testosterone's behavioral effects in humans: reduction in cognitive reflection. In the largest study of behavioral effects of testosterone administration to date, 243 men received either testosterone or placebo and took the Cognitive Reflection Test (CRT), which estimates the capacity to override incorrect intuitive judgments with deliberate correct responses. Testosterone administration reduced CRT scores. The effect remained after we controlled for age, mood, math skills, whether participants believed they had received the placebo or testosterone, and the effects of 14 additional hormones, and it held for each of the CRT questions in isolation. Our findings suggest a mechanism underlying testosterone's diverse effects on humans' judgments and decision making and provide novel, clear, and testable predictions.",2017,Testosterone administration reduced CRT scores.,"['humans', '243 men received either', 'Men']","['testosterone', 'placebo or testosterone', 'Testosterone', 'testosterone or placebo and took the Cognitive Reflection Test (CRT']",['CRT scores'],"[{'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0523912', 'cui_str': 'Testosterone measurement (procedure)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.308986,Testosterone administration reduced CRT scores.,"[{'ForeName': 'Gideon', 'Initials': 'G', 'LastName': 'Nave', 'Affiliation': '1 Department of Marketing, The Wharton School of the University of Pennsylvania.'}, {'ForeName': 'Amos', 'Initials': 'A', 'LastName': 'Nadler', 'Affiliation': '2 Department of Finance, Ivey School of Business, Western University.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Zava', 'Affiliation': '3 ZRT Laboratory, Beaverton, Oregon.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Camerer', 'Affiliation': '4 Department of Humanities and Social Sciences, California Institute of Technology.'}]",Psychological science,['10.1177/0956797617709592'] 953,31628558,"Pulsed Nd:YAG laser: effects on pain, postural stability, and weight-bearing pattern in children with hemophilic ankle arthropathy.","Hemophilic ankle arthropathy features joint pain, impaired postural control, and abnormal weight-bearing pattern. This study was designed to investigate the effects of pulsed Nd:YAG laser on pain, postural stability, and weight-bearing pattern in children with hemophilic ankle arthropathy. Forty children diagnosed with hemophilia type A (age, 8-16 years) were randomly allocated to either the treatment group (n = 20) who received a three-phase active therapy with pulsed Nd:YAG laser thrice/week (total energy was 1500 J) plus a physical exercise program for four consecutive weeks, or the placebo group (n = 20) who received placebo laser plus the physical exercise program. Pain, postural control (i.e., directional control [DC], endpoint excursion [EE], center-of-gravity movement velocity [CoG-MV], and maximum excursion [MXE]), and weight-bearing pattern (i.e., pressure peaks of the hindfoot [PP-HF] and forefoot [PP-FF], and the foot contact area [FCA]) were assessed pre- and post-treatment. The treatment group showed greater improvement in pain (P = .004), DC (P = .02), EE (P = .003), and CoG-MV (P = .003) compared to the placebo group. However, there was no statistically significant difference between both groups regarding the MXE (P = .15). In addition, the treatment group achieved favorable improvements in PP-HF (P = .003), PP-FF (P = .027), and FCA (P = .002) relative to the placebo group. Pulsed Nd:YAG laser is a potentially effective therapy for pain relief, postural control enhancement, and weight-bearing pattern adjustment in children with hemophilic ankle arthropathy.",2020,"The treatment group showed greater improvement in pain (P = .004), DC (P = .02), EE (P = .003), and CoG-MV (P = .003) compared to the placebo group.","['Forty children diagnosed with hemophilia type A (age, 8-16 years', 'children with hemophilic ankle arthropathy']","['placebo laser plus the physical exercise program', 'placebo', 'three-phase active therapy with pulsed Nd:YAG laser thrice/week (total energy was 1500 J) plus a physical exercise program', 'pulsed Nd:YAG laser', 'Pulsed Nd:YAG laser']","['CoG-MV', 'DC', 'Pain, postural control (i.e., directional control [DC], endpoint excursion [EE], center-of-gravity movement velocity [CoG-MV], and maximum excursion [MXE]), and weight-bearing pattern (i.e., pressure peaks of the hindfoot [PP-HF] and forefoot [PP-FF], and the foot contact area [FCA', 'pain', 'FCA', 'pain, postural stability, and weight-bearing pattern', 'PP-HF', 'PP-FF']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1321589', 'cui_str': 'Hemophilia - specialty'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0741040', 'cui_str': 'Ankle arthropathy'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0587723', 'cui_str': 'Lasers, Yttrium Aluminum Garnet'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4517582', 'cui_str': '1500'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205278', 'cui_str': 'Postural (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0282189', 'cui_str': 'Gravity'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0085086', 'cui_str': 'Finding of weight-bearing'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0230459', 'cui_str': 'Hindfoot (body structure)'}, {'cui': 'C1510667', 'cui_str': 'Forefoot region of foot'}, {'cui': 'C0016504', 'cui_str': 'Foot'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}]",40.0,0.0831787,"The treatment group showed greater improvement in pain (P = .004), DC (P = .02), EE (P = .003), and CoG-MV (P = .003) compared to the placebo group.","[{'ForeName': 'Ragab K', 'Initials': 'RK', 'LastName': 'Elnaggar', 'Affiliation': 'Department of Physical Therapy for Pediatrics, Faculty of Physical Therapy, Cairo University, Giza, Egypt. rke_pt2001@yahoo.com.'}]",Lasers in medical science,['10.1007/s10103-019-02889-z'] 954,31612263,Anatomic femoral tunnel placement is difficult by the transtibial technique: comparison of three different femoral tunnel drilling techniques in double-bundle anterior cruciate ligament reconstructions.,"PURPOSE To compare the position and direction of femoral and tibial tunnels for both the anteromedial bundle (AMB) and posterolateral bundle (PLB) among three different femoral tunnel drilling techniques, transtibial (TT), transportal (TP), and outside-in (OI) techniques, in anatomic double-bundle ACL reconstruction to clarify advantages and disadvantages of each technique. METHODS One-hundred and thirty-nine patients underwent primary ACL reconstruction with an autologous semitendinosus tendon in our institution between 2014 and 2016. Thirteen patients were excluded according to the exclusion criteria. Of the 126 patients, 98 patients agreed to be included in this study. Patients were then randomized into three groups according to the femoral tunnel drilling technique; the TT, TP, and OI groups. Femoral and tibial tunnel angles and positions were measured using three-dimensional computed tomography. RESULTS Of patients who agreed to be included in this study, eight patients (seven in TT and one in OI) were excluded since the femoral tunnel could not be created at the intended position. Eighty-six patients (29 in TT, 29 in TP, and 28 in OI) were included for the analyses. Tunnel angles, as well as tunnel lengths, had significant differences among different techniques depending on each technique's characteristics. In terms of tunnel position, femoral tunnel positions of both the AMB and PLB in the TT group were significantly higher than those in the TP group (AMB: p = 0.003, PLB: p = 0.001), and the PLB tunnel position in the TP group had significantly smaller vaciance than that in the TT group (p = 0.004) and OI group (0.002). CONCLUSIONS The femoral tunnel positions created by the TT technique were significantly higher, with larger variance, than the TP technique in double-bundle ACL reconstruction, although the positions seemed to be within anatomical footprint. In addition, there were several cases in which femoral tunnels could not be created at the intended position by the TT technique. LEVEL OF EVIDENCE I.",2020,"The femoral tunnel positions created by the TT technique were significantly higher, with larger variance, than the TP technique in double-bundle ACL reconstruction, although the positions seemed to be within anatomical footprint.","['Thirteen patients were excluded according to the exclusion criteria', 'Of patients who agreed to be included in this study', '126 patients, 98 patients agreed to be included in this study', 'in our institution between 2014 and 2016', 'Eighty-six patients (29 in TT, 29 in TP, and 28 in OI', 'One-hundred and thirty-nine patients underwent', 'eight patients (seven in TT and one in OI', 'double-bundle anterior cruciate ligament reconstructions']","['primary ACL reconstruction with an autologous semitendinosus tendon', 'femoral tunnel drilling techniques, transtibial (TT), transportal (TP), and outside-in (OI) techniques', 'Anatomic femoral tunnel placement', 'femoral tunnel drilling techniques', 'femoral tunnel drilling technique; the TT, TP']","['PLB tunnel position', 'tunnel position, femoral tunnel positions of both the AMB and PLB']","[{'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}]","[{'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0524865', 'cui_str': 'Reconstructive Surgery'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C0921292', 'cui_str': 'Semitendinosus Tendon'}, {'cui': 'C0015811', 'cui_str': 'Femur'}, {'cui': 'C3854183', 'cui_str': 'Tunneler (physical object)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0220784', 'cui_str': 'Anatomic (qualifier value)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}]","[{'cui': 'C3854183', 'cui_str': 'Tunneler (physical object)'}, {'cui': 'C1561964', 'cui_str': 'Patient Positioning'}, {'cui': 'C0015811', 'cui_str': 'Femur'}]",139.0,0.0240898,"The femoral tunnel positions created by the TT technique were significantly higher, with larger variance, than the TP technique in double-bundle ACL reconstruction, although the positions seemed to be within anatomical footprint.","[{'ForeName': 'Kaori', 'Initials': 'K', 'LastName': 'Nakamura', 'Affiliation': 'Department of Joint Surgery and Sports Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.'}, {'ForeName': 'Tomomasa', 'Initials': 'T', 'LastName': 'Nakamura', 'Affiliation': 'Department of Joint Surgery and Sports Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.'}, {'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Horie', 'Affiliation': 'Department of Joint Surgery and Sports Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Katagiri', 'Affiliation': 'Department of Joint Surgery and Sports Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Otabe', 'Affiliation': 'Department of Orthopaedic Surgery, Tokyo Medical and Dental University Hospital of Medicine, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Nakagawa', 'Affiliation': 'Department of Joint Surgery and Sports Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.'}, {'ForeName': 'Masaki', 'Initials': 'M', 'LastName': 'Amemiya', 'Affiliation': 'Department of Joint Surgery and Sports Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.'}, {'ForeName': 'Ichiro', 'Initials': 'I', 'LastName': 'Sekiya', 'Affiliation': 'Department of Orthopaedic Surgery, Tokyo Medical and Dental University Hospital of Medicine, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Muneta', 'Affiliation': 'Department of Joint Surgery and Sports Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.'}, {'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Koga', 'Affiliation': 'Department of Joint Surgery and Sports Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan. koga.orj@tmd.ac.jp.'}]","Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA",['10.1007/s00167-019-05740-8'] 955,31606753,Vitamin D-fortified cooking oil is an effective way to improve vitamin D status: an institutional efficacy trial.,"PURPOSE High prevalence of vitamin D deficiency (VDD) justifies a cost-effective and sustainable strategy to combat VDD in the community. This study was undertaken for the first time to evaluate the efficacy of daily consumption of vitamin D fortified sunflower oil with a meal. METHODS This single-blind trial was conducted in two separate institutions: one as intervention (D-fortified sunflower oil) group (DO, n 1  = 39) and the other as control (unfortified sunflower oil) group (SO, n 2  = 33). Participants consumed their lunches cooked either with D-fortified or unfortified cooking sunflower oil (500 IU/30 g) for 12 weeks. Dietary, anthropometric and biochemical assessments were done for all participants before and after the intervention. RESULTS A total of 65 subjects from both sexes aged 32.5 ± 4 years completed the intervention period. Serum 25(OH)D showed a significant increase in DO and a decrease in SO group (8.8 ± 9.3 vs. - 7.4 ± 6.4 ng/mL, p < 0.001). The rise in serum 25(OH)D in DO group was accompanied by a significant decrease in iPTH (DO: - 10.2 ± 29.4 vs. SO: + 9.2 ± 29.5 pg/mL; p = 0.009). A significant reduction in weight (p = 0.004), BMI (p = 0.029), waist girth (p < 0.001), serum total cholesterol (p = 0.0290) and LDL-C (p = 0.010) was observed in DO, as compared with SO group. CONCLUSIONS Cooking oil can be considered as an efficacious vehicle for mass fortification program to combat VDD. The improvement of vitamin D status may bring about betterment of certain cardiometabolic risk factors. REGISTRATION NUMBER Clinicaltrials.gov: NCT03826654.",2020,"A significant reduction in weight (p = 0.004), BMI (p = 0.029), waist girth (p < 0.001), serum total cholesterol (p = 0.0290) and LDL-C (p = 0.010) was observed in DO, as compared with SO group. ",['65 subjects from both sexes aged 32.5\u2009±\u20094\xa0years completed the intervention period'],"['vitamin D deficiency', 'unfortified cooking sunflower oil', 'intervention (D-fortified sunflower oil) group (DO, n 1 \u2009=\u200939) and the other as control (unfortified sunflower oil', 'Vitamin D-fortified cooking oil', 'vitamin D fortified sunflower oil with a meal', 'Cooking oil']","['serum total cholesterol', 'BMI', 'rise in serum 25(OH)D', 'iPTH', 'vitamin D status', 'waist girth', 'weight', 'DO']","[{'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517710', 'cui_str': '32.5 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0042870', 'cui_str': 'Vitamin D Deficiency'}, {'cui': 'C0335326', 'cui_str': 'Cookery'}, {'cui': 'C0028908', 'cui_str': 'Oils'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C1306756', 'cui_str': 'Cook (occupation)'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0047008', 'cui_str': 'IPTHS'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0230097', 'cui_str': 'Waist (surface region)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}]",65.0,0.147568,"A significant reduction in weight (p = 0.004), BMI (p = 0.029), waist girth (p < 0.001), serum total cholesterol (p = 0.0290) and LDL-C (p = 0.010) was observed in DO, as compared with SO group. ","[{'ForeName': 'Bahareh', 'Initials': 'B', 'LastName': 'Nikooyeh', 'Affiliation': 'Laboratory of Nutrition Research, National Nutrition and Food Technology Research Institute and Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Azizollaah', 'Initials': 'A', 'LastName': 'Zargaraan', 'Affiliation': 'Department of Food and Nutrition Policy and Planning Research, National Nutrition and Food Technology Research Institute and Faculty of Nutrition and Food Science, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Kalayi', 'Affiliation': 'Laboratory of Nutrition Research, National Nutrition and Food Technology Research Institute and Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Nastaran', 'Initials': 'N', 'LastName': 'Shariatzadeh', 'Affiliation': 'Laboratory of Nutrition Research, National Nutrition and Food Technology Research Institute and Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Maliheh', 'Initials': 'M', 'LastName': 'Zahedirad', 'Affiliation': 'Laboratory of Nutrition Research, National Nutrition and Food Technology Research Institute and Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Jamali', 'Affiliation': 'Laboratory of Quality Control, Kourosh Food Industry, Tehran, Iran.'}, {'ForeName': 'Marzieh', 'Initials': 'M', 'LastName': 'Khazraie', 'Affiliation': 'Quality Assurance Unit, Kourosh Food Industry, Tehran, Iran.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Hollis', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, Medical University of South Carolina, Charleston, SC, 29425, USA.'}, {'ForeName': 'Tirang R', 'Initials': 'TR', 'LastName': 'Neyestani', 'Affiliation': 'Laboratory of Nutrition Research, National Nutrition and Food Technology Research Institute and Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. tneyestani@sbmu.ac.ir.'}]",European journal of nutrition,['10.1007/s00394-019-02103-4'] 956,31605198,Efficacy of an intermittent energy restriction diet in a primary care setting.,"PURPOSE Intermittent energy restriction (IER) is a popular weight loss (WL) strategy; however, its efficacy in clinical practice remains unknown. The present study compared the effects of IER compared to continuous energy restriction (CER) on WL and cardiometabolic risk factors in primary care. METHODS A (self-selected) cohort study was conducted at the Rotherham Institute for Obesity (RIO), a primary care-based weight management service. 197(24% male) obese patients volunteered to participate and selected their diet group. IER participants (n = 99) consumed ~ 2600 kJ for two days/week. CER participants (n = 98) restricted their diet by ~ 2100 kJ/day below estimated requirements. Both interventions were delivered alongside RIO standard care. Changes in anthropometry and cardiometabolic disease risk markers (fasting biochemistry and blood pressure) were assessed after a 6-month intervention period and then participants were followed up again 6 months later (month 12). RESULTS 27 IER patients (27%) and 39 CER patients (40%) completed the 6-month weight loss phase. Among completers, mean (SEM) WL was greater in the IER group at 6 months (5.4 ± 1.1% versus 2.8 ± 0.6%; p = 0.01), as were reductions in fat mass (p < 0.001) and improvements in systolic blood pressure (p < 0.001). Fasting insulin (p = 0.873) and diastolic blood pressure (p = 0.701) were reduced similarly in both groups. However, in the IER group, changes in anthropometry and blood pressure in the IER group had reverted to baseline by 12-month follow-up, whilst the CER group maintained weight loss but showed an increase in blood pressure. CONCLUSIONS Among completers, IER resulted in superior short-term changes in anthropometry and some cardiometabolic risk factors. However, rates of attrition and weight regain were higher compared with standard care, providing important insights in the implementations of IER within a ""real-life"" NHS setting. TRIAL REGISTRATION NUMBER ISRCTN31465600.",2020,"Among completers, IER resulted in superior short-term changes in anthropometry and some cardiometabolic risk factors.","['197(24% male) obese patients volunteered to participate and selected their diet group', 'A (self-selected) cohort study was conducted at the Rotherham Institute for Obesity (RIO), a primary care-based weight management service', 'IER participants (n\u2009=\u200999) consumed\u2009']","['intermittent energy restriction diet', 'continuous energy restriction (CER', 'IER', 'Intermittent energy restriction (IER', 'CER']","['IER resulted in superior short-term changes in anthropometry and some cardiometabolic risk factors', 'systolic blood pressure', 'fat mass', 'blood pressure', 'diastolic blood pressure', 'rates of attrition and weight regain', 'anthropometry and cardiometabolic disease risk markers (fasting biochemistry and blood pressure', 'mean (SEM) WL', 'weight loss', 'anthropometry and blood pressure', 'Fasting insulin', 'WL and cardiometabolic risk factors', '6-month weight loss phase']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0237504', 'cui_str': 'CER (body structure)'}]","[{'cui': 'C0332294', 'cui_str': 'Resulting in (attribute)'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0005477', 'cui_str': 'Biochemistry'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}]",,0.024206,"Among completers, IER resulted in superior short-term changes in anthropometry and some cardiometabolic risk factors.","[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Antoni', 'Affiliation': 'Nutritional Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.'}, {'ForeName': 'K L', 'Initials': 'KL', 'LastName': 'Johnston', 'Affiliation': 'Lighterlife UK Ltd, Cavendish House, Parkway, Harlow Business Park, Essex, UK.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Steele', 'Affiliation': 'Clifton Medical Centre, The Health Village, Rotherham Institute for Obesity, Doncaster Gate, Rotherham, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Carter', 'Affiliation': 'Clifton Medical Centre, The Health Village, Rotherham Institute for Obesity, Doncaster Gate, Rotherham, UK.'}, {'ForeName': 'M D', 'Initials': 'MD', 'LastName': 'Robertson', 'Affiliation': 'Nutritional Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.'}, {'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Capehorn', 'Affiliation': 'Clifton Medical Centre, The Health Village, Rotherham Institute for Obesity, Doncaster Gate, Rotherham, UK. mcapehorn@yahoo.co.uk.'}]",European journal of nutrition,['10.1007/s00394-019-02098-y'] 957,29046201,[A clinical analysis of 101 infants with plagiocephaly].,"OBJECTIVE To investigate the possible causes of plagiocephaly in infants and the therapeutic effect of postural correction training on plagiocephaly. METHODS A total of 101 infants who were diagnosed with plagiocephaly were enrolled. According to the age at diagnosis, these infants were divided into 1-4 month group (31 infants), 5-8 month group (40 infants), and 9-12 month group (30 infants). The possible causes of plagiocephaly were analyzed in three groups. The cranial vault asymmetry index (CVAI) before and after postural correction training was compared in three groups. RESULTS Of the 101 infants, 89 (88.1%) had a sleeping posture in the supine position, and there was no significant difference in the percentage of infants with such posture between the three groups. Compared with the 5-8 month group and the 9-12 month group, the 1-4 month group had significantly higher rate of preterm birth, incidence rate of adverse perinatal factors, and incidence rate of congenital muscular torticollis. The three groups showed a significant decrease in CVAI 3 months after postural correction training (P<0.001). Compared with the 5-8 month group and the 9-12 month group, the 1-4 month group had a significantly greater change in CVAI after postural correction training (P<0.001). CONCLUSIONS The sleeping posture in the supine position may be associated with the development of plagiocephaly. Adverse perinatal factors, preterm birth, and congenital muscular torticollis as possible causes of plagiocephaly are commonly seen in early infancy. Postural correction training has a significant effect in improving plagiocephaly, especially in early infancy.",2017,The three groups showed a significant decrease in CVAI 3 months after postural correction training (P<0.001).,"['101 infants who were diagnosed with plagiocephaly were enrolled', '101 infants with plagiocephaly']","['Postural correction training', 'postural correction training']","['change in CVAI', 'CVAI', 'percentage of infants with such posture', 'sleeping posture', 'rate of preterm birth, incidence rate of adverse perinatal factors, and incidence rate of congenital muscular torticollis', 'Adverse perinatal factors, preterm birth, and congenital muscular torticollis', 'cranial vault asymmetry index (CVAI']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0265529', 'cui_str': 'Plagiocephaly'}]","[{'cui': 'C0205278', 'cui_str': 'Postural (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1262869', 'cui_str': 'Posture'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0151526', 'cui_str': 'Premature Birth'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0079352', 'cui_str': 'Congenital torticollis'}, {'cui': 'C3163632', 'cui_str': 'Cranial'}, {'cui': 'C0332514', 'cui_str': 'Asymmetry (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",101.0,0.029878,The three groups showed a significant decrease in CVAI 3 months after postural correction training (P<0.001).,"[{'ForeName': 'Wei-Wei', 'Initials': 'WW', 'LastName': 'Pan', 'Affiliation': 'Department of Pediatrics, Peking University Third Hospital, Beijing 100191, China. tongxm2007@126.com.'}, {'ForeName': 'Xiao-Mei', 'Initials': 'XM', 'LastName': 'Tong', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 958,32412419,A Lower Leg Physical Activity Intervention for Individuals With Chronic Venous Leg Ulcers: Randomized Controlled Trial.,"BACKGROUND Individuals with venous leg ulcers (VLUs) suffer disproportionately with multiple chronic conditions, are often physically deconditioned, and demonstrate high levels of physical inactivity. OBJECTIVE The primary objective of this randomized controlled trial was to establish the feasibility of a mobile health (mHealth) physical activity exercise app for individuals with VLUs to improve lower leg function. METHODS In a 6-week study, adults with VLUs were recruited from 2 wound centers in South Carolina, United States, and enrolled if they were aged 18 years or older with impaired functional mobility and an ankle-brachial index between 0.8 and 1.3. Participants were randomized 1:1 to receive evidence-based, phased, nonexertive physical conditioning activities for lower leg function (FOOTFIT) or FOOTFIT+ with an added patient-provider communication feature. The mHealth Conditioning Activities for Lower Leg Function app also provided automated educational and motivational messages and user reports. Foot movement on the VLU-affected leg was tracked by a Bluetooth-enabled triaxial accelerometer. The study was guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance framework to assess the feasibility of reach, adherence, acceptability, implementation, and maintenance. RESULTS A total of 24 patients were recruited, enrolled, and randomized in the study. Most patients reported difficulty following the protocol for exercising and using the accelerometer and mobile phone and did not use the provider contact feature. However, all patients were adherent to the 6-week exercise program more than 85% of the time for duration, whereas 33% (8/24) of patients adhered more than 85% for the frequency of performing the exercises. Across the three exercise levels, adherence did not differ between the two groups. Confidence limits around the difference in proportions ranged from -0.4 to 0.7. Providers in FOOTFIT+ were inconsistent in checking participant progress reports because of lack of time from competing work commitments. The technology became outdated quickly, making maintenance problematic. Participants said they would continue to exercise their foot and legs and liked being able to follow along with the demonstrations of each level of exercise provided through the app. CONCLUSIONS The findings of this study suggest that despite initial interest in using the app, several components of the program as originally designed had limited acceptability and feasibility. Future refinements should include the use of more modern technology including smaller wearable accelerometers, mobile phones or tablets with larger screens, an app designed with larger graphics, automated reporting for providers, and more engaging user features. TRIAL REGISTRATION ClinicalTrials.gov NTC02632695; https://clinicaltrials.gov/ct2/show/NCT02632695.",2020,"Across the three exercise levels, adherence did not differ between the two groups.","['Individuals With Chronic Venous Leg Ulcers', 'Individuals with venous leg ulcers (VLUs) suffer disproportionately with multiple chronic conditions', 'adults with VLUs were recruited from 2 wound centers in South Carolina, United States, and enrolled if they were aged 18 years or older with impaired functional mobility and an ankle-brachial index between 0.8 and 1.3', 'individuals with VLUs', 'A total of 24 patients']","['evidence-based, phased, nonexertive physical conditioning activities for lower leg function (FOOTFIT) or FOOTFIT+ with an added patient-provider communication feature', 'Leg Physical Activity Intervention', 'mobile health (mHealth) physical activity exercise']","['feasibility of reach, adherence, acceptability, implementation, and maintenance', 'Confidence limits']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0042344', 'cui_str': 'Stasis ulcer'}, {'cui': 'C3266262', 'cui_str': 'Multiple chronic diseases'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0037716', 'cui_str': 'South Carolina'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C1328319', 'cui_str': 'Ankle brachial pressure index'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C4517499', 'cui_str': '1.3'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0230446', 'cui_str': 'Both lower legs'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}]","[{'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0439801', 'cui_str': 'Limited'}]",24.0,0.0958684,"Across the three exercise levels, adherence did not differ between the two groups.","[{'ForeName': 'Teresa J', 'Initials': 'TJ', 'LastName': 'Kelechi', 'Affiliation': 'College of Nursing, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Margaret A', 'Initials': 'MA', 'LastName': 'Prentice', 'Affiliation': 'College of Nursing, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Mueller', 'Affiliation': 'College of Nursing, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Mohan', 'Initials': 'M', 'LastName': 'Madisetti', 'Affiliation': 'College of Nursing, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Alexey', 'Initials': 'A', 'LastName': 'Vertegel', 'Affiliation': 'Department of Bioengineering, Clemson University, Clemson, SC, United States.'}]",JMIR mHealth and uHealth,['10.2196/15015'] 959,28702120,Inpatient versus Outpatient Management of TIA or Minor Stroke: Clinical Outcome.,"BACKGROUND The management of patients with acute transient ischemic attack (TIA) or minor stroke is highly variable. Whether hospitalization of such patients significantly improves short-term clinical outcome is unknown. We assessed the short-term clinical outcome associated with inpatient versus outpatient management of patients with TIA or minor stroke. METHODS We evaluated a consecutive series of patients with acute TIA or minor ischemic stroke (NIH Stroke Scale score ≤ 3) presenting to a single emergency department (ED). We randomized patients to either hospital-based or outpatient-based management. All patients underwent interview and examination 7-10 days following the index event. RESULTS This study included 100 patients, 41 with TIA and 59 with minor stroke. Nineteen (46%) of the TIA patients and 29 (49%) of the minor stroke patients randomized to hospital management, and the remaining 22 TIA patients and 30 minor stroke patients randomized to outpatient-based management. In the patients with a minor stroke, neurologic worsening occurred in 6 out of 29 (21%) in the inpatient arm compared with 3 out of 30 (10%) in the outpatient arm ( p = 0.3). In none of these cases was acute interventional therapy or need for urgent admission considered medically appropriate. In the patients with a TIA, recurrence of a TIA occurred in 2 out of 19 (11%) in the inpatient arm compared with 2 out of 22 (9%) in the outpatient arm ( p = 1). None of the patients with a TIA randomized to the inpatient arm experienced a stroke compared with 1 out of 22 in the outpatient arm ( p = 1). There were no deaths in either group. CONCLUSION Routine hospitalization of all patients with TIA or minor ischemic stroke may not positively affect short-term clinical outcome.",2017,"There were no deaths in either group. ","['patients with acute transient ischemic attack (TIA) or minor stroke', 'patients with acute TIA or minor ischemic stroke (NIH Stroke Scale score ≤ 3) presenting to a single emergency department (ED', 'patients with TIA or minor stroke', '100 patients, 41 with TIA and 59 with minor stroke']",['hospital-based or outpatient-based management'],"['recurrence of a TIA', 'neurologic worsening']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0007787', 'cui_str': 'Brain TIA'}, {'cui': 'C0026193', 'cui_str': 'Minors'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C1697238', 'cui_str': 'NIH stroke scale'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}]","[{'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}]","[{'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0007787', 'cui_str': 'Brain TIA'}, {'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}]",100.0,0.0557728,"There were no deaths in either group. ","[{'ForeName': 'Shahram', 'Initials': 'S', 'LastName': 'Majidi', 'Affiliation': 'Department of Neurology, George Washington University School of Medicine, Washington, DC, USA.'}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Leon Guerrero', 'Affiliation': 'Department of Neurology, George Washington University School of Medicine, Washington, DC, USA.'}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Burger', 'Affiliation': 'Department of Neurology, George Washington University School of Medicine, Washington, DC, USA.'}, {'ForeName': 'John F', 'Initials': 'JF', 'LastName': 'Rothrock', 'Affiliation': 'Department of Neurology, George Washington University School of Medicine, Washington, DC, USA.'}]",Journal of vascular and interventional neurology,[] 960,28697832,[Efficacy of clonidine transdermal patch in treatment of moderate to severe tic disorders in children].,"OBJECTIVE To investigate the difference in the efficacy between clonidine transdermal patch and haloperidol tablets in the treatment of moderate to severe tic disorders in children. METHODS A total of 134 children with moderate to severe tic disorders were randomly divided into clonidine group (n=70) and haloperidol group (n=64). The clonidine and haloperidol groups were treated with clonidine transdermal patch and haloperidol tablets respectively, and the treatment lasted for 8 weeks in both groups. The Yale Global Tic Severity Scale (YGTSS) was used to evaluate the conditions of the children before and after treatment, and the adverse events during the treatment were recorded. RESULTS The haloperidol group had a significantly better treatment outcome than the clonidine group after one week of treatment (P<0.05); the treatment outcome showed no significant difference between the two groups after 3, 5, and 8 weeks of treatment (P>0.05). The clonidine group had significantly less reductions in the motor tics, vocal tics, and function impairment scores and total score of YGTSS than the haloperidol group after one week of treatment (P<0.05); there were no significant differences in YGTSS score reductions between the two groups after 3, 5, and 8 weeks of treatment (P>0.05). The clonidine group had a significantly lower overall incidence of adverse events than the haloperidol group (8% vs 37%; P<0.01). CONCLUSIONS Clonidine transdermal patch and haloperidol are both effective in the treatment of moderate to severe tic disorders in children. The clonidine transdermal patch, despite slow action, has comparable efficacy and fewer adverse effects compared with haloperidol.",2017,"The clonidine group had significantly less reductions in the motor tics, vocal tics, and function impairment scores and total score of YGTSS than the haloperidol group after one week of treatment (P<0.05); there were no significant differences in YGTSS score reductions between the two groups after 3, 5, and 8 weeks of treatment (P>0.05).","['134 children with moderate to severe tic disorders', 'moderate to severe tic disorders in children']","['Clonidine transdermal patch and haloperidol', 'clonidine transdermal patch and haloperidol tablets', 'clonidine and haloperidol', 'haloperidol', 'clonidine', 'clonidine transdermal patch']","['motor tics, vocal tics, and function impairment scores and total score of YGTSS', 'YGTSS score reductions', 'Yale Global Tic Severity Scale (YGTSS', 'adverse events', 'overall incidence of adverse events']","[{'cui': 'C4517565', 'cui_str': 'One hundred and thirty-four'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0040188', 'cui_str': 'Tic disorder (disorder)'}]","[{'cui': 'C0009014', 'cui_str': 'Clonidine'}, {'cui': 'C0991556', 'cui_str': 'Transdermal System'}, {'cui': 'C0018546', 'cui_str': 'Haloperidol'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}]","[{'cui': 'C0751901', 'cui_str': 'Tic, Vocal'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C4720888', 'cui_str': 'Yale global tic severity scale (assessment scale)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220856', 'cui_str': 'incidence'}]",134.0,0.0125777,"The clonidine group had significantly less reductions in the motor tics, vocal tics, and function impairment scores and total score of YGTSS than the haloperidol group after one week of treatment (P<0.05); there were no significant differences in YGTSS score reductions between the two groups after 3, 5, and 8 weeks of treatment (P>0.05).","[{'ForeName': 'Jing-Min', 'Initials': 'JM', 'LastName': 'Guo', 'Affiliation': ""Fujian Provincial Maternity and Children's Hospital of Fujian Medical University, Fuzhou, Fujian 350001, China. eve1019@126.com.""}, {'ForeName': 'Xiao-Xi', 'Initials': 'XX', 'LastName': 'Shi', 'Affiliation': ''}, {'ForeName': 'Shi-Wei', 'Initials': 'SW', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Qin-Fang', 'Initials': 'QF', 'LastName': 'Qian', 'Affiliation': ''}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Yan-Qin', 'Initials': 'YQ', 'LastName': 'Xie', 'Affiliation': ''}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Ou', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 961,28702113,"Cost-Effectiveness Analysis of the Unfractionated Heparin versus Low-Molecular-Weight Heparin in Hospitalized Patients with Stroke Due to Atrial Fibrillation in Shiraz, South of Iran.","BACKGROUND Patients with atrial fibrillation (AF) make a unique group of strokes. Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are among the medications used for preventing blood coagulation. This study was carried out aiming at analyzing the cost effectiveness of LMWH versus UFH in hospitalized patients with stroke due to AF with respect to the Iranian population. METHODS This randomized study was an economic evaluation of cost effectiveness with the help of the cross-sectional data of 2013-2015. In this study, 74 patients had undergone treatment in two groups, before being evaluated. Half of the patients were treated by LMWH, while the other half was treated by UFH. Effectiveness criterion was prevention of new stroke recurrence. RESULTS Average medical direct costs, non-medical direct costs, and indirect costs of UFH were 110375 ± 40411$, 15594 ± 11511$, and 21723 ± 19933$, respectively. Same average medical direct costs, non-medical direct costs, and indirect costs of LMWH were 99573 ± 59143$, 9016 ± 17156$, and 10385 ± 10598$, respectively. The number of prevention of new strokes due to AF in LMWH and UFH was 2 and 0, respectively. Expected effectiveness in LMWH and UFH groups was 0.56 and 0.51, respectively. Moreover, the expected costs were 26737.61$ and 30776.18$, respectively. The incremental cost-effectiveness ratio for stroke due to AF was -150, 201, 26$ per prevention of stroke recurrence ( p -values ≤ 0/05). CONCLUSION The results of the cost-effectiveness analysis of LMWH versus UFH showed that LMWH is a dominant strategy for patients with stroke due to AF in Iranian population.",2017,"The incremental cost-effectiveness ratio for stroke due to AF was -150, 201, 26$ per prevention of stroke recurrence ( p -values ≤ 0/05). ","['Patients with atrial fibrillation (AF', '74 patients had undergone treatment in two groups, before being evaluated', 'Hospitalized Patients with Stroke Due to Atrial Fibrillation in Shiraz, South of Iran', '2013-2015', 'patients with stroke due to AF in Iranian population', 'hospitalized patients with stroke due to AF with respect to the Iranian population']","['Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH', 'LMWH', 'LMWH versus UFH', 'Unfractionated Heparin versus Low-Molecular-Weight Heparin']","['Average medical direct costs, non-medical direct costs, and indirect costs of UFH', 'Same average medical direct costs, non-medical direct costs, and indirect costs of LMWH', 'incremental cost-effectiveness ratio']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}, {'cui': 'C0554962', 'cui_str': 'Iranian (NMO) (ethnic group)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0679133', 'cui_str': 'Respect'}]","[{'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0019139', 'cui_str': 'LMWH'}]","[{'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0439852', 'cui_str': 'Indirect (qualifier value)'}, {'cui': 'C0019139', 'cui_str': 'LMWH'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",74.0,0.0248135,"The incremental cost-effectiveness ratio for stroke due to AF was -150, 201, 26$ per prevention of stroke recurrence ( p -values ≤ 0/05). ","[{'ForeName': 'Nahid', 'Initials': 'N', 'LastName': 'Hatam', 'Affiliation': 'Professor of Health Administration, School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Jamshid', 'Initials': 'J', 'LastName': 'Bahmei', 'Affiliation': 'MSc in Health Care Services Management, Department of Health Economics, School of Management and Information \u200eSciences, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Khosro', 'Initials': 'K', 'LastName': 'Keshavarz', 'Affiliation': 'Assistant professor of Health Economics, Department of Health Economics, School of Management and Medical Information Sciences, Shiraz University of Medical Science, Shiraz, Iran.'}, {'ForeName': 'Farnia', 'Initials': 'F', 'LastName': 'Feiz', 'Affiliation': 'Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Reihaneh', 'Initials': 'R', 'LastName': 'Sedghi', 'Affiliation': 'Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Afshin', 'Initials': 'A', 'LastName': 'Borhani-Haghighi', 'Affiliation': 'Professor of Neurology, Clinical Neurology Research Center and Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",Journal of vascular and interventional neurology,[] 962,28774367,"[Myocardial protective effect of L-carnitine in children with hand, foot and mouth disease caused by Coxsackie A16 virus].","OBJECTIVE To investigate the myocardial protective effect of L-carnitine in children with hand, foot and mouth disease (HFMD) caused by Coxsackie A16 virus and possible mechanisms. METHODS A total of 60 HFMD children with abnormal myocardial enzyme after Coxsackie A16 virus infection were enrolled and randomly divided into L-carnitine group and fructose-1,6-diphosphate group (fructose group), with 30 children in each group. The two groups were given L-carnitine or fructose diphosphate in addition to antiviral and heat clearance treatment. Another 30 healthy children who underwent physical examination were enrolled as control group. The changes in myocardial zymogram, malondialdehyde (MDA), superoxide dismutase (SOD), and apoptosis factors sFas and sFasL after treatment were compared between groups. RESULTS There was no significant difference in treatment response between the L-carnitine group and the fructose group (P>0.05). One child in the fructose group progressed to critical HFMD, which was not observed in the L-carnitine group. Before treatment, the L-carnitine group and the fructose group had significantly higher indices of myocardial zymogram and levels of MDA, sFas, and sFasL and a significantly lower level of SOD than the control group (P<0.05), while there were no significant differences in these indices between the L-carnitine group and the fructose group (P>0.05). After treatment, the L-carnitine group and the fructose group had significant reductions in the indices of myocardial zymogram and levels of MDA, sFas, and sFasL and a significant increase in the level of SOD (P<0.05); the fructose group had a significantly higher level of creatine kinase (CK) than the control group and the L-carnitine group, and there were no significant differences in other myocardial enzyme indices, MDA, sFas, and sFasL between the L-carnitine group and the fructose group, as well as between the L-carnitine and fructose groups and the control group (P>0.05). SOD level was negatively correlated with aspartate aminotransferase, lactate dehydrogenase (LDH), CK, and creatine kinase-MB (CK-MB) (r=-0.437, -0.364, -0.397, and -0.519 respectively; P<0.05), and MDA level was positively correlated with LDH and CK-MB (r=0.382 and 0.411 respectively; P<0.05). CONCLUSIONS L-carnitine exerts a good myocardial protective effect in children with HFMD caused by Coxsackie A16 virus, possibly by clearing oxygen radicals and inhibiting cardiomyocyte apoptosis.",2017,"SOD level was negatively correlated with aspartate aminotransferase, lactate dehydrogenase (LDH), CK, and creatine kinase-MB (CK-MB)","['60 HFMD children with abnormal myocardial enzyme after Coxsackie A16 virus infection', 'children with hand, foot and mouth disease (HFMD', 'children with hand, foot and mouth disease caused by Coxsackie A16 virus', '30 healthy children who underwent physical examination were enrolled as control group', 'children with HFMD']","['L-carnitine or fructose diphosphate', 'L-carnitine', 'L-carnitine group and fructose-1,6-diphosphate group (fructose group']","['myocardial zymogram, malondialdehyde (MDA), superoxide dismutase (SOD), and apoptosis factors sFas and sFasL', 'myocardial zymogram and levels of MDA, sFas, and sFasL', 'level of SOD', 'myocardial enzyme indices, MDA, sFas, and sFasL', 'SOD level', 'MDA level', 'aspartate aminotransferase, lactate dehydrogenase (LDH), CK, and creatine kinase-MB (CK-MB', 'myocardial zymogram and levels of MDA, sFas, and sFasL and a significantly lower level of SOD', 'critical HFMD', 'level of creatine kinase (CK', 'treatment response']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205161', 'cui_str': 'Abnormal (qualifier value)'}, {'cui': 'C3541394', 'cui_str': 'Enzymes'}, {'cui': 'C0042769', 'cui_str': 'Viral Infections'}, {'cui': 'C0018572', 'cui_str': 'Hand, Foot and Mouth Disease'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0042776', 'cui_str': 'Virus'}, {'cui': 'C0686744', 'cui_str': 'Well child (finding)'}, {'cui': 'C0031809', 'cui_str': 'Physical Examination'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0087163', 'cui_str': 'l-carnitine'}, {'cui': 'C0391940', 'cui_str': 'Fructose measurement (procedure)'}, {'cui': 'C0034320', 'cui_str': 'Pyrophosphates'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0060771', 'cui_str': 'fructose-1,6-diphosphate'}]","[{'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0069638', 'cui_str': 'orgotein'}, {'cui': 'C0162638', 'cui_str': 'Programmed Cell Death, Type I'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0000379', 'cui_str': '1,3-Benzodioxole-5-ethanamine, alpha-methyl-'}, {'cui': 'C3541394', 'cui_str': 'Enzymes'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0004002', 'cui_str': 'L-Aspartate-2-Oxoglutarate Aminotransferase'}, {'cui': 'C0022917', 'cui_str': 'L-Lactate Dehydrogenase'}, {'cui': 'C0523584', 'cui_str': 'Creatine kinase MB measurement'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0201973', 'cui_str': 'Creatine kinase measurement (procedure)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",60.0,0.0198541,"SOD level was negatively correlated with aspartate aminotransferase, lactate dehydrogenase (LDH), CK, and creatine kinase-MB (CK-MB)","[{'ForeName': 'Ya-Jie', 'Initials': 'YJ', 'LastName': 'Cui', 'Affiliation': ""Zhengzhou Children's Hospital, Zhengzhou 450003, China. mlgbwxw@163.com.""}, {'ForeName': 'Chun-Lan', 'Initials': 'CL', 'LastName': 'Song', 'Affiliation': ''}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Yi-Bing', 'Initials': 'YB', 'LastName': 'Cheng', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 963,32412629,The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Responsive Parenting Intervention for Firstborns Affects Dietary Intake of Secondborn Infants.,"BACKGROUND Although previous work has shown that children with older siblings tend to have poorer diet quality, no study has directly compared diets of infant siblings. OBJECTIVE The goals of this analysis were to examine birth-order differences in dietary intake between firstborn (FB) and secondborn (SB) siblings, and to determine whether a responsive parenting (RP) intervention modified birth-order effects on diet. METHODS The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) study randomly assigned first-time mothers to an RP intervention, which included guidance on feeding, sleep, soothing, and interactive play, or control. INSIGHT mothers who delivered a second child enrolled in an observation-only study of their SB infant (SIBSIGHT). Mothers completed FFQs for both children at ages 6 (n = 97 sibling pairs) and 12 (n = 100) mo. FB compared with SB intake of food groups of interest were compared, and the moderating effect of the RP intervention on birth-order differences was tested using generalized linear mixed models. RESULTS Though FBs and SBs had similar diets, more FBs than SBs consumed 100% fruit juice at both 6 (13.8 compared with 3.2%, P = 0.006) and 12 mo (46.0 compared with 32.0%, P = 0.01). SBs consumed fruit more frequently (FB 2.8 compared with SB 3.2 times/d, P = 0.01), and were more likely to consume fried potatoes (FB 38.4 compared with SB 57.6%, P = 0.0009) and processed meats (FB 43.0 compared with SB 58.0%, P = 0.02) than FBs at 12 mo. There were no differences by birth order in intake of sweets, snacks, or sugar-sweetened beverages at 12 mo. At 12 mo, RP-group SBs ate vegetables more times per day (3.2) than control SBs (2.2, P = 0.01). RP-SBs also consumed a greater variety of vegetables (10.2) than control-SBs (7.9, P = 0.01). CONCLUSIONS Birth order is not consistently associated with healthy or unhealthy infant dietary intake. However, an RP intervention delivered to first-time mothers may benefit subsequent infants' vegetable intake. This trial was registered at clinicaltrials.gov as NCT01167270.",2020,"SBs consumed fruit more frequently (FB 2.8 compared with SB 3.2 times/d, P = 0.01), and were more likely to consume fried potatoes (FB 38.4 compared with SB 57.6%, P = 0.0009) and processed meats (FB 43.0 compared with SB 58.0%, P = 0.02) than FBs at 12 mo.","['Secondborn Infants', 'INSIGHT mothers who delivered a second child enrolled in an observation-only study of their SB infant (SIBSIGHT', 'children with older siblings', 'The Intervention Nurses Start Infants']","['RP intervention', 'RP intervention, which included guidance on feeding, sleep, soothing, and interactive play, or control', 'Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT']","['birth order in intake of sweets, snacks, or sugar-sweetened beverages']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0337511', 'cui_str': 'Older sibling'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0439659', 'cui_str': 'Origins'}]","[{'cui': 'C0205342', 'cui_str': 'Responsive'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0005607', 'cui_str': 'Place in family order'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0085077', 'cui_str': 'Acute febrile neutrophilic dermatosis'}, {'cui': 'C0453863', 'cui_str': 'Snack food'}, {'cui': 'C5197754', 'cui_str': 'Sugar-Added Beverages'}]",,0.0545827,"SBs consumed fruit more frequently (FB 2.8 compared with SB 3.2 times/d, P = 0.01), and were more likely to consume fried potatoes (FB 38.4 compared with SB 57.6%, P = 0.0009) and processed meats (FB 43.0 compared with SB 58.0%, P = 0.02) than FBs at 12 mo.","[{'ForeName': 'Emily E', 'Initials': 'EE', 'LastName': 'Hohman', 'Affiliation': 'Center for Childhood Obesity Research, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Savage', 'Affiliation': 'Center for Childhood Obesity Research, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Leann L', 'Initials': 'LL', 'LastName': 'Birch', 'Affiliation': 'Department of Foods and Nutrition, University of Georgia, Athens, GA, USA.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Paul', 'Affiliation': 'Departments of Pediatrics and Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.'}]",The Journal of nutrition,['10.1093/jn/nxaa135'] 964,19164441,The frequency and extent of mammillary body atrophy associated with surgical removal of a colloid cyst.,"BACKGROUND AND PURPOSE Patients who have had a colloid cyst removed from the third ventricle sometimes experience some difficulty with day-to-day memory. This study provided quantitative MR imaging volume measures of 1 structure potentially responsible for mnemonic problems, the mammillary bodies. Additional volume estimates in structures connected to the mammillary bodies sought to determine the specificity of any atrophy. MATERIALS AND METHODS Volume estimates of the mammillary bodies were performed on 38 patients after surgical removal of colloid cysts and 20 control subjects by the application of stereologic volume-estimation techniques. For the mammillary body measures, 2 groups of MR images were assessed (0.8- and 1.0-mm section thickness) to compare the sensitivity of each imaging sequence for detecting any atrophy. Other structures associated with memory processes, such as the hippocampus and fornix, were also assessed quantitatively to determine whether there was a correlation between mammillary body damage and atrophy in connecting structures. RESULTS Our investigations established the superiority of 0.8-mm-volume scans over standard isotropic 1.0-mm-thick-volume scans for mammillary body assessments. Comparisons with 20 age-matched controls revealed that patients with colloid cysts frequently showed significant mammillary body atrophy (mean volume of colloid cysts, 0.037 cm(3) right and 0.038 cm(3) left; control subjects, 0.069 cm(3) right and 0.067 cm(3) left). In fact, every patient had a mammillary body volume below the control mean, and the majority of patients had a volume decrease of >1 SD (82% right, 74% left). Mammillary body volumes correlated with fornix volumes in the same patient group. CONCLUSIONS Our results reveal the frequent presence of mammillary body atrophy in patients with surgical removal of colloid cysts and indicate that this atrophy is partly due to a loss of temporal lobe projections in the fornix.",2009,"Mammillary body volumes correlated with fornix volumes in the same patient group. ","['38 patients after surgical removal of colloid cysts and 20 control subjects by the application of stereologic volume-estimation techniques', 'Patients who have had a colloid cyst removed from the third ventricle sometimes experience some difficulty with day-to-day memory', 'patients with surgical removal of colloid cysts']",[],['mammillary body atrophy'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0333157', 'cui_str': 'Colloid Cysts'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0079305', 'cui_str': 'Estimation Technics'}, {'cui': 'C1292747', 'cui_str': 'Removes from'}, {'cui': 'C0149555', 'cui_str': '3rd Ventricle'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0025260', 'cui_str': 'Memory'}]",[],"[{'cui': 'C0024670', 'cui_str': 'Mammillary Bodies'}, {'cui': 'C0333641', 'cui_str': 'Atrophy'}]",38.0,0.0176209,"Mammillary body volumes correlated with fornix volumes in the same patient group. ","[{'ForeName': 'C E', 'Initials': 'CE', 'LastName': 'Denby', 'Affiliation': 'School of Psychological Sciences, Manchester, England. christinedenby@hotmail.com'}, {'ForeName': 'S D', 'Initials': 'SD', 'LastName': 'Vann', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Tsivilis', 'Affiliation': ''}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Aggleton', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Montaldi', 'Affiliation': ''}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Roberts', 'Affiliation': ''}, {'ForeName': 'A R', 'Initials': 'AR', 'LastName': 'Mayes', 'Affiliation': ''}]",AJNR. American journal of neuroradiology,['10.3174/ajnr.A1424'] 965,28606235,[Clinical effects of different therapeutic regimens for Helicobacter pylori infection in children].,"OBJECTIVE To investigate the clinical effects of sequential therapy, triple therapy, sequential therapy combined with Lactobacillus, and triple therapy combined with Lactobacillus in the eradication of Helicobacter pylori (H.pylori) infection in children. METHODS A total of 416 children with H.pylori infection were randomly assigned to sequential group (102 children), triple group (100 children), sequential-Lactobacillus group (109 children), and triple-Lactobacillus group (105 children). The clinical outcome, H.pylori eradication rate, cost-effect ratio, and incidence of adverse events were compared between the four groups. RESULTS The sequential-Lactobacillus and triple-Lactobacillus groups had significantly better clinical outcomes than the sequential group and the triple group (P<0.05). The sequential-Lactobacillus group had the highest marked response rate, followed by the triple-Lactobacillus group. The triple group had the lowest marked response rate. The sequential-Lactobacillus group also had the highest H.pylori eradication rate, followed by the triple-Lactobacillus group. The triple group had the lowest H.pylori eradication rate (P<0.05). The sequential group had the lowest cost-effect ratio, followed by the sequential-Lactobacillus group. The triple group had the highest cost-effect ratio (P<0.01). The sequential-Lactobacillus group had the lowest incidence rate of adverse events, followed by the triple-Lactobacillus group. The triple group had the highest incidence rate. CONCLUSIONS Sequential therapy combined with Lactobacillus seems to be the best regimen for the eradication of H.pylori infection in children.",2017,The triple group had the lowest H.pylori eradication rate (P<0.05).,"['children', 'group (105 children', '416 children with H.pylori infection']","['sequential therapy combined with Lactobacillus, and triple therapy combined with Lactobacillus', 'sequential-Lactobacillus group (109 children), and triple-Lactobacillus']","['clinical outcomes', 'lowest H.pylori eradication rate', 'lowest incidence rate of adverse events', 'H.pylori eradication rate, cost-effect ratio, and incidence of adverse events', 'highest incidence rate', 'Helicobacter pylori (H.pylori) infection', 'highest cost-effect ratio', 'highest H.pylori eradication rate']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C3714514', 'cui_str': 'Infection'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0022938', 'cui_str': 'Lactobacillus'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}, {'cui': 'C3714514', 'cui_str': 'Infection'}]",416.0,0.0147483,The triple group had the lowest H.pylori eradication rate (P<0.05).,"[{'ForeName': 'Xiang-Li', 'Initials': 'XL', 'LastName': 'Zhu', 'Affiliation': ""Department of Pediatrics, Tai'an Maternal and Child Health Care Hospital, Tai'an, Shandong 271000, China. 1850360706@qq.com.""}, {'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Zhong-Qiang', 'Initials': 'ZQ', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Ai-Ping', 'Initials': 'AP', 'LastName': 'Jiang', 'Affiliation': ''}, {'ForeName': 'Gui-Xia', 'Initials': 'GX', 'LastName': 'Yu', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 966,31591063,"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.","BACKGROUND Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the approach is not widely implemented. RELAY assessed erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untreated EGFR-mutated metastatic NSCLC. METHODS This is a worldwide, double-blind, phase 3 trial done in 100 hospitals, clinics, and medical centres in 13 countries. Eligible patients were aged 18 years or older (20 years or older in Japan and Taiwan) at the time of study entry, had stage IV NSCLC, with an EGFR exon 19 deletion (ex19del) or exon 21 substitution (Leu858Arg) mutation, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no CNS metastases. We randomly assigned eligible patients in a 1:1 ratio to receive oral erlotinib (150 mg/day) plus either intravenous ramucirumab (10 mg/kg) or matching placebo once every 2 weeks. Randomisation was done by an interactive web response system with a computer-generated sequence and stratified by sex, geographical region, EGFR mutation type, and EGFR testing method. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This trial is registered at ClinicalTrials.gov, NCT02411448, and is ongoing for long-term survival follow-up. FINDINGS Between Jan 28, 2016, and Feb 1, 2018, 449 eligible patients were enrolled and randomly assigned to treatment with ramucirumab plus erlotinib (n=224) or placebo plus erlotinib (n=225). Median duration of follow-up was 20·7 months (IQR 15·8-27·2). At the time of primary analysis, progression-free survival was significantly longer in the ramucirumab plus erlotinib group (19·4 months [95% CI 15·4-21·6]) than in the placebo plus erlotinib group (12·4 months [11·0-13·5]), with a stratified hazard ratio of 0·59 (95% CI 0·46-0·76; p<0·0001). Grade 3-4 treatment-emergent adverse events were reported in 159 (72%) of 221 patients in the ramucirumab plus erlotinib group versus 121 (54%) of 225 in the placebo plus erlotinib group. The most common grade 3-4 treatment-emergent adverse events in the ramucirumab plus erlotinib group were hypertension (52 [24%]; grade 3 only) and dermatitis acneiform (33 [15%]), and in the placebo plus erlotinib group were dermatitis acneiform (20 [9%]) and increased alanine aminotransferase (17 [8%]). Treatment-emergent serious adverse events were reported in 65 (29%) of 221 patients in the ramucirumab plus erlotinib group and 47 (21%) of 225 in the placebo plus erlotinib group. The most common serious adverse events of any grade in the ramucirumab plus erlotinib group were pneumonia (seven [3%]) and cellulitis and pneumothorax (four [2%], each); the most common in the placebo plus erlotinib group were pyrexia (four [2%]) and pneumothorax (three [1%]). One on-study treatment-related death due to an adverse event occurred (haemothorax after a thoracic drainage procedure for a pleural empyema) in the ramucirumab plus erlotinib group. INTERPRETATION Ramucirumab plus erlotinib demonstrated superior progression-free survival compared with placebo plus erlotinib in patients with untreated EGFR-mutated metastatic NSCLC. Safety was consistent with the safety profiles of the individual compounds in advanced lung cancer. The RELAY regimen is a viable new treatment option for the initial treatment of EGFR-mutated metastatic NSCLC. FUNDING Eli Lilly.",2019,Grade 3-4 treatment-emergent adverse events were reported in 159 (72%) of 221 patients in the ramucirumab plus erlotinib group versus 121 (54%) of 225 in the placebo plus erlotinib group.,"['Eligible patients were aged 18 years or older (20 years or older in Japan and Taiwan) at the time of study entry, had stage IV NSCLC, with an EGFR exon 19 deletion (ex19del) or exon 21 substitution (Leu858Arg) mutation, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no CNS metastases', 'patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY', 'Between Jan 28, 2016, and Feb 1, 2018, 449 eligible patients', '100 hospitals, clinics, and medical centres in 13 countries', 'advanced lung cancer', 'patients with untreated EGFR-mutated metastatic NSCLC']","['ramucirumab plus erlotinib', 'matching placebo', 'Ramucirumab plus erlotinib', 'placebo', 'placebo plus erlotinib', 'oral erlotinib', 'intravenous ramucirumab']","['pneumothorax', 'Grade 3-4 treatment-emergent adverse events', 'investigator-assessed progression-free survival', 'cellulitis and pneumothorax', 'Safety', 'progression-free survival', 'alanine aminotransferase', 'pyrexia', 'dermatitis acneiform', 'superior progression-free survival', 'hypertension', 'Median duration']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0039260', 'cui_str': 'Formosa'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0441772', 'cui_str': 'Stage level 4 (qualifier value)'}, {'cui': 'C3889117', 'cui_str': 'EGFR exon 19 deletion'}, {'cui': 'C0015295', 'cui_str': 'Exons'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C1520224', 'cui_str': 'Eastern Cooperative Oncology Group performance status'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0007131', 'cui_str': 'Nonsmall Cell Lung Cancer'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0565990', 'cui_str': 'Medical center (environment)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C4524268', 'cui_str': 'Advanced lung cancer'}, {'cui': 'C0278987', 'cui_str': 'Metastatic non-small cell lung cancer (disorder)'}]","[{'cui': 'C2742502', 'cui_str': 'ramucirumab'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1135135', 'cui_str': 'erlotinib'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}]","[{'cui': 'C0032326', 'cui_str': 'Pneumothorax'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0007642', 'cui_str': 'Cellulitis'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0201836', 'cui_str': 'Alanine aminotransferase measurement (procedure)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0234894', 'cui_str': 'Dermatitis acneiform'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}]",449.0,0.561056,Grade 3-4 treatment-emergent adverse events were reported in 159 (72%) of 221 patients in the ramucirumab plus erlotinib group versus 121 (54%) of 225 in the placebo plus erlotinib group.,"[{'ForeName': 'Kazuhiko', 'Initials': 'K', 'LastName': 'Nakagawa', 'Affiliation': 'Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan. Electronic address: nakagawa@med.kindai.ac.jp.'}, {'ForeName': 'Edward B', 'Initials': 'EB', 'LastName': 'Garon', 'Affiliation': 'David Geffen School of Medicine at University of California Los Angeles, Translational Research in Oncology US Network, Los Angeles, CA, USA.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Seto', 'Affiliation': 'National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.'}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Nishio', 'Affiliation': 'Department of Thoracic Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.'}, {'ForeName': 'Santiago', 'Initials': 'S', 'LastName': 'Ponce Aix', 'Affiliation': 'Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Clinical Research Unit, Universidad Complutense and Ciberonc, Madrid, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Paz-Ares', 'Affiliation': 'Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Clinical Research Unit, Universidad Complutense and Ciberonc, Madrid, Spain.'}, {'ForeName': 'Chao-Hua', 'Initials': 'CH', 'LastName': 'Chiu', 'Affiliation': 'Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Keunchil', 'Initials': 'K', 'LastName': 'Park', 'Affiliation': 'Samsung Medical Center, Division of Hematology and Oncology, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Novello', 'Affiliation': 'Department of Oncology, University of Turin, Azienda ospedaliero-universitaria San Luigi, Orbassano, Italy.'}, {'ForeName': 'Ernest', 'Initials': 'E', 'LastName': 'Nadal', 'Affiliation': ""Department of Medical Oncology, Catalan Institute of Oncology, and Clinical Research in Solid Tumors group, Oncobell, l'Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet, Barcelona, Spain.""}, {'ForeName': 'Fumio', 'Initials': 'F', 'LastName': 'Imamura', 'Affiliation': 'Osaka International Cancer Institute, Osaka, Japan.'}, {'ForeName': 'Kiyotaka', 'Initials': 'K', 'LastName': 'Yoh', 'Affiliation': 'National Cancer Center Hospital East, Kashiwa, Japan.'}, {'ForeName': 'Jin-Yuan', 'Initials': 'JY', 'LastName': 'Shih', 'Affiliation': 'Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Kwok Hung', 'Initials': 'KH', 'LastName': 'Au', 'Affiliation': 'Queen Elizabeth Hospital, Kowloon, Hong Kong.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Moro-Sibilot', 'Affiliation': 'Grenoble University Hospital, Grenoble, France.'}, {'ForeName': 'Sotaro', 'Initials': 'S', 'LastName': 'Enatsu', 'Affiliation': 'Eli Lilly Japan KK Kobe, Kobe, Japan.'}, {'ForeName': 'Annamaria', 'Initials': 'A', 'LastName': 'Zimmermann', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Bente', 'Initials': 'B', 'LastName': 'Frimodt-Moller', 'Affiliation': 'Eli Lilly and Company, Copenhagen, Denmark.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Visseren-Grul', 'Affiliation': 'Lilly Oncology, Utrecht, Netherlands.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Reck', 'Affiliation': 'LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Oncology,['10.1016/S1470-2045(19)30634-5'] 967,28606238,[Efficacy of sleep position correction for treating infants with positional plagiocephaly].,"OBJECTIVE To investigate the efficacy of 2-month course of sleeping position correction in the treatment of positional plagiocephaly in infants aged <8 months. METHODS A total of 73 infants with positional plagiocephaly between January 2015 and June 2016 were divided into treatment group (n=46) and control group (n=27) according to parents' wishes. The treatment group received sleeping position correction, while the control group received sleep curve mattress. The oblique diameters A and B in the two groups were measured and the cranial vault asymmetry (CVA) was calculated before and after treatment. The severity of positional plagiocephaly based on CVA was compared between the two groups before and after treatment. The Gesell Developmental Scale was used to determine the developmental quotients (DQs) in the motor, adaptive, language, and social domains in the two groups before and after treatment. RESULTS Before treatment, there were no significant differences in oblique diameters A and B, CVA, and DQs in the four specific domains between the two groups (P>0.05). After 2 months of treatment, the treatment group had a significantly greater oblique diameter B and a significantly smaller CVA than the control group (P<0.05); there were no significant differences in DQs in the four specific domains between the two groups (P>0.05). After treatment, both groups had significant improvements in oblique diameters A and B, CVA, and DQs in the motor and adaptive domains (P<0.01); moreover, the treatment group showed a significant improvement in the DQs in the social domain (P<0.01). There was no significant difference in the severity of positional plagiocephaly between the two groups before and after treatment (P>0.05). CONCLUSIONS For infants with positional plagiocephaly, sleeping position correction has better efficacy and is more convenient and economical than the sleep curve mattress, so it holds promise for clinical application.",2017,"There was no significant difference in the severity of positional plagiocephaly between the two groups before and after treatment (P>0.05). ","['73 infants with positional plagiocephaly between January 2015 and June 2016', 'infants aged <8 months', 'infants with positional plagiocephaly']","['sleep position correction', 'sleeping position correction, while the control group received sleep curve mattress', 'sleeping position correction']","['developmental quotients (DQs) in the motor, adaptive, language, and social domains', 'oblique diameters A and B, CVA, and DQs', 'cranial vault asymmetry (CVA', 'oblique diameters A and B, CVA, and DQs in the motor and adaptive domains', 'DQs', 'severity of positional plagiocephaly', 'oblique diameter B and a significantly smaller CVA', 'severity of positional plagiocephaly based on CVA']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1450010', 'cui_str': 'Plagiocephaly, Nonsynostotic'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C1561964', 'cui_str': 'Patient Positioning'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0024940', 'cui_str': 'Mattresses'}]","[{'cui': 'C0458003', 'cui_str': 'Developmental (qualifier value)'}, {'cui': 'C0023008', 'cui_str': 'Languages'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0205315', 'cui_str': 'Oblique (qualifier value)'}, {'cui': 'C1301886', 'cui_str': 'Diameter (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C3163632', 'cui_str': 'Cranial'}, {'cui': 'C0332514', 'cui_str': 'Asymmetry (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C1450010', 'cui_str': 'Plagiocephaly, Nonsynostotic'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}]",73.0,0.0158288,"There was no significant difference in the severity of positional plagiocephaly between the two groups before and after treatment (P>0.05). ","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Department of Pediatrics, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China. wuzhifengvip@ 126.com.'}, {'ForeName': 'Zhi-Feng', 'Initials': 'ZF', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Yu-Ping', 'Initials': 'YP', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Cong-Min', 'Initials': 'CM', 'LastName': 'Zhao', 'Affiliation': ''}, {'ForeName': 'Xiu-Mei', 'Initials': 'XM', 'LastName': 'Yu', 'Affiliation': ''}, {'ForeName': 'Wang', 'Initials': 'W', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Zai-Xin', 'Initials': 'ZX', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Qiu-Ming', 'Initials': 'QM', 'LastName': 'Pan', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 968,31586244,Comparison of pathological outcomes after transanal versus laparoscopic total mesorectal excision: a prospective study using data from randomized control trial.,"INTRODUCTION Total mesorectal excision (TME) is the standard procedure for middle lower rectal cancer, and transanal total mesorectal excision (taTME) was founded as a valid alternative to the open and laparoscopic TME. The quality of the procedure performed is important for prognosis of patients. This study was designed to compare the pathological results of taTME with those of laparoscopic TME (laTME), based on the data from a randomized control trial (RCT: NCT02966483). METHODS Between April 2016 and November 2018, all rectal cancer patients who underwent taTME or laTME in the Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) and enrolled in the RCT were included in this study. The data from all participants were prospectively input in a standardized database. RESULTS In total 128 patients were included in the taTME group and 133 patients were included in the laTME group. The demographics and tumor characteristics were not significantly different between the two group. T3 or N0 lesions were most common in both groups. The mesorectum specimen was complete or nearly complete in all patients. The positive distal resection margin (DRM) was detected in 2 (1.5%) cases in the laTME group versus no cases in the taTME group (P = 0.498), and the distance between the tumor and DRM in the taTME group (1.4 ± 1.1) may have the longer tendency than that in the laTME group (1.3 ± 0.9) (P = 0.745). The positive circumferential resection margin was detected in 2 cases in each group (P = 0.674). The median number of resected lymph nodes was 15.0 in taTME group versus 16.0 in the laTME group (P = 0.069). CONCLUSION The pathological outcomes between transanal and laparoscopic total mesorectal excision are similar. The rate of positive resection margin could not be significant decreased, nonetheless the decrease trend could be shown.",2020,"The positive distal resection margin (DRM) was detected in 2 (1.5%) cases in the laTME group versus no cases in the taTME group (P = 0.498), and the distance between the tumor and DRM in the taTME group (1.4 ± 1.1) may have the longer tendency than that in the laTME group (1.3 ± 0.9) (P = 0.745).","['In total 128 patients were included in the taTME group and 133 patients were included in the laTME group', 'Between April 2016 and November 2018, all rectal cancer patients who underwent taTME or laTME in the Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) and enrolled in the RCT were included in this study']","['Total mesorectal excision (TME', 'laTME', 'transanal versus laparoscopic total mesorectal excision', 'laparoscopic TME (laTME', 'transanal and laparoscopic total mesorectal excision']","['demographics and tumor characteristics', 'rate of positive resection margin', 'median number of resected lymph nodes', 'positive circumferential resection margin', 'positive distal resection margin (DRM']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0007113', 'cui_str': 'Cancer of Rectum'}, {'cui': 'C0205440', 'cui_str': 'Sixth (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0038817', 'cui_str': 'Sunshine'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C1273428', 'cui_str': 'Total mesorectal excision'}, {'cui': 'C0589371', 'cui_str': 'Transanal approach (qualifier value)'}]","[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0229985', 'cui_str': 'Margins of Excision'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0024204', 'cui_str': 'Lymphatic gland'}, {'cui': 'C1300632', 'cui_str': 'Surgical circumferential margin finding'}, {'cui': 'C0205108', 'cui_str': 'Distal (qualifier value)'}]",128.0,0.0585214,"The positive distal resection margin (DRM) was detected in 2 (1.5%) cases in the laTME group versus no cases in the taTME group (P = 0.498), and the distance between the tumor and DRM in the taTME group (1.4 ± 1.1) may have the longer tendency than that in the laTME group (1.3 ± 0.9) (P = 0.745).","[{'ForeName': 'Ziwei', 'Initials': 'Z', 'LastName': 'Zeng', 'Affiliation': ""Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510655, Guangdong, People's Republic of China.""}, {'ForeName': 'Shuangling', 'Initials': 'S', 'LastName': 'Luo', 'Affiliation': ""Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510655, Guangdong, People's Republic of China.""}, {'ForeName': 'Junji', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ""Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510655, Guangdong, People's Republic of China.""}, {'ForeName': 'Yonghua', 'Initials': 'Y', 'LastName': 'Cai', 'Affiliation': ""Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510655, Guangdong, People's Republic of China.""}, {'ForeName': 'Xingwei', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ""Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510655, Guangdong, People's Republic of China.""}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Kang', 'Affiliation': ""Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510655, Guangdong, People's Republic of China. kangl@mail.sysu.edu.cn.""}]",Surgical endoscopy,['10.1007/s00464-019-07167-1'] 969,31586420,"Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5.","OBJECTIVE To evaluate the effect of secukinumab on radiographic progression through 52 weeks in patients with PsA from the FUTURE 5 study. METHODS Patients with active PsA, stratified by prior anti-TNF use (naïve or inadequate response), were randomized to s.c. secukinumab 300 mg load (300 mg), 150 mg load (150 mg), 150 mg no load regimens or placebo at baseline, at weeks 1, 2 and 3 and every 4 weeks starting at week 4. Radiographic progression was assessed by change in van der Heijde-modified total Sharp score (vdH-mTSS; mean of two readers). Statistical analysis used a linear mixed-effects model (random slope) at weeks 24 and 52, and observed data at week 52. Assessments at week 52 included additional efficacy endpoints (non-responders imputation and mixed-effects models for repeated measures) and safety. RESULTS The majority (86.6%) of patients completed 52 weeks of treatment. The proportion of patients with no radiographic progression (change from baseline in vdH-mTSS ⩽0.5) was 91.8, 85.2 and 87.2% in 300, 150 and 150 mg no load groups, respectively, at week 52. The change in vdH-mTSS from baseline to week 52 using random slope [mean change (s.e.)] was -0.18 (0.17), 0.11 (0.18) and -0.20 (0.18) in 300, 150 and 150 mg no load groups, respectively; the corresponding observed data [mean change (s.d.)] was -0.09 (1.02), 0.13 (1.39) and 0.21 (1.15). Clinical efficacy endpoints were sustained, and no new or unexpected safety signals were reported through 52 weeks. CONCLUSION Secukinumab 300 and 150 mg with or without s.c. loading regimen provided sustained low rates of radiographic progression through 52 weeks of treatment. TRIAL REGISTRATION ClinicalTrials.gov, http://clinicaltrials.gov, NCT02404350.",2020,Radiographic progression was assessed by change in van der Heijde-modified total Sharp score (vdH-mTSS; mean of two readers).,"['Patients with active PsA, stratified by prior anti-TNF use (naïve or inadequate response', 'psoriatic arthritis', 'patients with PsA from the FUTURE 5 study']","['placebo', 'Secukinumab', 'secukinumab 300 mg load', 'secukinumab']","['radiographic progression', 'safety', 'Radiographic progression', 'change in vdH-mTSS', 'proportion of patients with no radiographic progression']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0201544', 'cui_str': 'Prostate specific antigen measurement (procedure)'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0205412', 'cui_str': 'Inadequate (qualifier value)'}, {'cui': 'C0003872', 'cui_str': 'Psoriatic Arthropathy'}, {'cui': 'C0016884', 'cui_str': 'Future'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3179547', 'cui_str': 'secukinumab'}, {'cui': 'C4319604', 'cui_str': '300'}]","[{'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]",,0.0869609,Radiographic progression was assessed by change in van der Heijde-modified total Sharp score (vdH-mTSS; mean of two readers).,"[{'ForeName': 'Désirée', 'Initials': 'D', 'LastName': 'van der Heijde', 'Affiliation': 'Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands.'}, {'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'Mease', 'Affiliation': 'Swedish Medical Center/Providence St Joseph Health and University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Robert B M', 'Initials': 'RBM', 'LastName': 'Landewé', 'Affiliation': 'Department of Rheumatology, University of Amsterdam and Atrium Medical Center, Amsterdam, The Netherlands.'}, {'ForeName': 'Proton', 'Initials': 'P', 'LastName': 'Rahman', 'Affiliation': 'Faculty of Medicine, Memorial University, St Johns, Newfoundland and Labrador, Canada.'}, {'ForeName': 'Hasan', 'Initials': 'H', 'LastName': 'Tahir', 'Affiliation': 'Rheumatology, Whipps Cross Hospital, London, UK.'}, {'ForeName': 'Atul', 'Initials': 'A', 'LastName': 'Singhal', 'Affiliation': 'Southwest Rheumatology, Dallas, TX, USA.'}, {'ForeName': 'Elke', 'Initials': 'E', 'LastName': 'Boettcher', 'Affiliation': 'Rheumazentrum Favoriten, Vienna, Austria.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Navarra', 'Affiliation': ""St Luke's Medical Center, University of Santo Tomas Hospital, Manila, Philippines.""}, {'ForeName': 'Xuan', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Ligozio', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Aimee', 'Initials': 'A', 'LastName': 'Readie', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Shephard', 'Initials': 'S', 'LastName': 'Mpofu', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Luminita', 'Initials': 'L', 'LastName': 'Pricop', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.'}]","Rheumatology (Oxford, England)",['10.1093/rheumatology/kez420'] 970,32413673,The effects of testosterone on the physiological response to social and somatic stressors.,"Higher testosterone levels in males have previously been linked to decreased stress reactivity, but in other cases, testosterone has been reported to increase the stress response. We addressed these inconsistencies in a placebo-controlled single-dose testosterone administration study, in which 120 male participants were randomly assigned to undergo a cold-pressor test (CPT, a non-social somatic stressor), a socially evaluated cold-pressor test (SECPT, a social-somatic stressor), or a lukewarm water test (LWT, a non-stressful control condition). Throughout the experiment, blood pressure and interbeat intervals were measured continuously, and saliva samples for hormonal analyses were taken repeatedly at predefined time points. When comparing the groups treated with placebo, the SECPT elicited a larger increase in the systolic blood pressure than CPT, in agreement with previous studies. However, testosterone administration altered this pattern. Compared to placebo, testosterone increased systolic blood pressure during the CPT, whereas the opposite effect was found during the SECPT. Cortisol reactivity was not affected by testosterone administration. The CAG repeat polymorphism of the androgen receptor gene was unrelated to the effects of testosterone on the stress response, but it was correlated with blood pressure across the whole sample. Our findings demonstrate that testosterone's effects on the stress response are dependent on the social context. Testosterone's ability to flexibly influence the response to stressors may be an important mechanism through which the hormone promotes adaptive behavior. Our results are also in line with research showing that testosterone decreases social anxiety and suggest it may help to modulate the effects of stress in socially challenging situations.",2020,"When comparing the groups treated with placebo, the SECPT elicited a larger increase in the systolic blood pressure than CPT, in agreement with previous studies.",['120 male participants'],"['SECPT', 'placebo, testosterone', 'testosterone', 'placebo-controlled single-dose testosterone', 'Testosterone', 'cold-pressor test (CPT, a non-social somatic stressor), a socially evaluated cold-pressor test (SECPT, a social-somatic stressor), or a lukewarm water test (LWT, a non-stressful control condition', 'placebo']","['blood pressure', 'blood pressure and interbeat intervals', 'systolic blood pressure', 'social anxiety', 'Cortisol reactivity']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0444689', 'cui_str': 'Cold pressor test'}, {'cui': 'C0006938', 'cui_str': 'Captopril'}, {'cui': 'C1257909', 'cui_str': 'Diploid Cell'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}]",120.0,0.036,"When comparing the groups treated with placebo, the SECPT elicited a larger increase in the systolic blood pressure than CPT, in agreement with previous studies.","[{'ForeName': 'Hana H', 'Initials': 'HH', 'LastName': 'Kutlikova', 'Affiliation': 'Neuropsychopharmacology and Biopsychology Unit, Department of Cognition, Emotion, and Methods in Psychology, Faculty of Psychology, University of Vienna, Liebiggasse 5, 1010 Vienna, Austria. Electronic address: hana.kutlikova@univie.ac.at.'}, {'ForeName': 'Jaroslava Babková', 'Initials': 'JB', 'LastName': 'Durdiaková', 'Affiliation': 'Institute of Physiology, Faculty of Medicine, Comenius University in Bratislava, Sasinkova 2, 813 72 Bratislava, Slovakia. Electronic address: durdiakova.jaroslava@fmed.uniba.sk.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Wagner', 'Affiliation': 'Institute of Biomedical Science, FH Joanneum University of Applied Sciences, Eggenberger Allee 13, 8020 Graz, Austria. Electronic address: bernhard.wagner@fh-joanneum.at.'}, {'ForeName': 'Miroslav', 'Initials': 'M', 'LastName': 'Vlček', 'Affiliation': 'Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Dúbravská cesta 9, 845 05 Bratislava, Slovakia. Electronic address: miroslav.vlcek@savba.sk.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Eisenegger', 'Affiliation': 'Neuropsychopharmacology and Biopsychology Unit, Department of Cognition, Emotion, and Methods in Psychology, Faculty of Psychology, University of Vienna, Liebiggasse 5, 1010 Vienna, Austria.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Lamm', 'Affiliation': 'Neuropsychopharmacology and Biopsychology Unit, Department of Cognition, Emotion, and Methods in Psychology, Faculty of Psychology, University of Vienna, Liebiggasse 5, 1010 Vienna, Austria; Social, Cognitive and Affective Neuroscience Unit, Department of Cognition, Emotion, and Methods in Psychology, Faculty of Psychology, University of Vienna, Liebiggasse 5, 1010 Vienna, Austria. Electronic address: claus.lamm@univie.ac.at.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Riečanský', 'Affiliation': 'Social, Cognitive and Affective Neuroscience Unit, Department of Cognition, Emotion, and Methods in Psychology, Faculty of Psychology, University of Vienna, Liebiggasse 5, 1010 Vienna, Austria; Department of Behavioural Neuroscience, Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Sienkiewiczova 1, 813 71 Bratislava, Slovakia. Electronic address: igor.riecansky@savba.sk.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2020.104693'] 971,28506339,[Effect of allergic rhinitis on disease condition and treatment in patients with juvenile-onset systemic lupus erythematosus].,"OBJECTIVE To investigate the effect of allergic rhinitis (AR) and its intervention on disease condition and medications in patients with juvenile-onset systemic lupus erythematosus (JSLE). METHODS The clinical data of 96 children diagnosed with JSLE were collected, and according to the presence or absence of AR or other allergic diseases, they were divided into AR group (n=44), non-AR group (n=20), and non-allergic group (n=32). The children in the AR group were randomly administered with or without intervention (n=22 each). All the children were given standard JSLE treatment. The systemic lupus erythematosus disease active index (SLEDAI) and application of hormones and immunosuppressants were compared between groups. RESULTS The AR and non-AR groups had significantly higher SLEDAI scores, daily cumulative doses of glucocorticoids, and number of types of immunosuppressants used than the non-allergic group before treatment (P<0.05), while there were no significant differences between the AR and non-AR groups (P>0.05). After one month of treatment, the AR group with intervention had significantly lower SLEDAI scores and daily cumulative doses of glucocorticoids than the AR group without intervention (P<0.05), while there was no significant difference in the application of immunosuppressants between these two groups (P>0.05). After 3 and 6 months of treatment, the AR group with intervention had significantly lower SLEDAI scores, daily cumulative doses of glucocorticoids, and number of types of immunosuppressants than the AR group without intervention (P<0.05). CONCLUSIONS JSLE combined with allergic diseases such as AR has an adverse effect on disease condition and treatment, and the intervention for AR helps with the control of JSLE.",2017,"The AR and non-AR groups had significantly higher SLEDAI scores, daily cumulative doses of glucocorticoids, and number of types of immunosuppressants used than the non-allergic group before treatment (P<0.05), while there were no significant differences between the AR and non-AR groups (P>0.05).","['patients with juvenile-onset systemic lupus erythematosus', 'patients with juvenile-onset systemic lupus erythematosus (JSLE', '96 children diagnosed with JSLE were collected, and according to the presence or absence of AR or other allergic diseases, they were divided into AR group (n=44), non-AR group (n=20), and non-allergic group (n=32']","['standard JSLE', 'JSLE', 'allergic rhinitis (AR', 'allergic rhinitis']","['SLEDAI scores, daily cumulative doses of glucocorticoids, and number of types of immunosuppressants', 'lower SLEDAI scores, daily cumulative doses of glucocorticoids, and number of types of immunosuppressants', 'SLEDAI scores and daily cumulative doses of glucocorticoids', 'systemic lupus erythematosus disease active index (SLEDAI', 'application of immunosuppressants']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3146221', 'cui_str': 'Juvenile (finding)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0024141', 'cui_str': 'Lupus Erythematosus Disseminatus'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C3854307', 'cui_str': 'Presence'}, {'cui': 'C0332197', 'cui_str': 'Absent (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332286', 'cui_str': 'Into (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2607914', 'cui_str': 'Rhinitis, Allergic'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C3540778', 'cui_str': 'Glucocorticoids'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0021081', 'cui_str': 'Immunosuppressants'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0024141', 'cui_str': 'Lupus Erythematosus Disseminatus'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}]",96.0,0.0183758,"The AR and non-AR groups had significantly higher SLEDAI scores, daily cumulative doses of glucocorticoids, and number of types of immunosuppressants used than the non-allergic group before treatment (P<0.05), while there were no significant differences between the AR and non-AR groups (P>0.05).","[{'ForeName': 'Yan-Qing', 'Initials': 'YQ', 'LastName': 'Zhou', 'Affiliation': 'Department of Pediatrics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200001, China. clf530417@126.com.'}, {'ForeName': 'Lan-Fang', 'Initials': 'LF', 'LastName': 'Cao', 'Affiliation': ''}, {'ForeName': 'Ru-Ru', 'Initials': 'RR', 'LastName': 'Guo', 'Affiliation': ''}, {'ForeName': 'Le-Ping', 'Initials': 'LP', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Hui-Fen', 'Initials': 'HF', 'LastName': 'Fang', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 972,32413812,Effects of a mindfulness based behavioral intervention for young adults with childhood maltreatment history on hippocampal morphometry: a pilot MRI study with voxel-based morphometry.,"Childhood maltreatment has long lasting impacts on neural development of the hippocampus, which is important for learning and memory. The present study aimed to assess the effects of a mindfulness based intervention on hippocampal morphometry and episodic memory in this population. We administered MRI, psychological questionnaires and an episodic memory task to 21 participants (5 males) before and after a mindfulness-based behavioral intervention, compared to 21 participants (7 males) on the waiting list. Changes in Gray Matter Volume (GMV) in bilateral hippocampi were analyzed with Voxel-Based Morphometry (VBM). One cluster was identified in the right hippocampus with a group by time interaction effect that consisted of 130 contiguous voxels but fell short of significance with full FDR correction (p = 0.077). GMV in this cluster increased by 0.76% in the mindfulness group and decreased by 0.78% in the control group. Within the mindfulness group, changes in hippocampal GMV were negatively associated with changes in perceived stress and depression severity and positively associated with enhancement in performance accuracy on the episodic memory task. Findings from this pilot study suggest that a mindfulness-based intervention may lead to an increase in partial hippocampal GMV with associated symptom reduction and improvement in episodic memory.",2020,GMV in this cluster increased by 0.76% in the mindfulness group and decreased by 0.78% in the control group.,"['21 participants (5 males) before and after a', 'young adults with childhood maltreatment history on hippocampal morphometry']","['mindfulness based intervention', 'mindfulness-based behavioral intervention', 'mindfulness based behavioral intervention']","['perceived stress and depression severity', 'GMV', 'hippocampal morphometry and episodic memory', 'episodic memory', 'hippocampal GMV', 'partial hippocampal GMV', 'Gray Matter Volume (GMV']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0200760', 'cui_str': 'Morphometric analysis'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0200760', 'cui_str': 'Morphometric analysis'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}, {'cui': 'C0728938', 'cui_str': 'Partial'}]",130.0,0.0170544,GMV in this cluster increased by 0.76% in the mindfulness group and decreased by 0.78% in the control group.,"[{'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Joss', 'Affiliation': 'Developmental Biopsychiatry Research Program, McLean Hospital, Belmont, MA, USA; Department of Psychiatry, Massachusetts General Hospital, USA; Department of Psychiatry, Harvard Medical School, Boston, USA. Electronic address: djoss@mclean.harvard.edu.'}, {'ForeName': 'Sara W', 'Initials': 'SW', 'LastName': 'Lazar', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, USA; Department of Psychiatry, Harvard Medical School, Boston, USA.'}, {'ForeName': 'Martin H', 'Initials': 'MH', 'LastName': 'Teicher', 'Affiliation': 'Developmental Biopsychiatry Research Program, McLean Hospital, Belmont, MA, USA; Department of Psychiatry, Harvard Medical School, Boston, USA.'}]",Psychiatry research. Neuroimaging,['10.1016/j.pscychresns.2020.111087'] 973,31347294,Effects of Fumanet exercise on Korean older adults with mild dementia.,"AIM This study aimed to examine the effects of Fumanet exercise on cognitive function, walking ability, and depression in older adults with mild dementia. METHODS A quasi-experimental pre- and post-test design with a non-equivalent control group was used. Participants were 45 patients with mild dementia (experimental group = 22, control group = 23). In the experimental group, Fumanet exercise was performed 60 minutes per day, once per week for 8 weeks. Data were analyzed using descriptive statistics, t test, Chi-square, Fisher's exact test, and two-way repeated measures analysis of variance. RESULTS Gait ability in the experimental group was significantly improved compared with the control group (F = 9.08, P = .004). There were no significant differences in cognitive function or depression between the experimental and control groups. Although the intervention did not show a reduction in depression, participants exhibited a high participation rate and brighter mood with increasing sessions. CONCLUSIONS It was confirmed that Fumanet exercise is an effective nursing intervention to improve gait ability among older adults with mild dementia.",2020,"RESULTS Gait ability in the experimental group was significantly improved compared with the control group (F = 9.08, P = .004).","['older adults with mild dementia', 'Participants were 45 patients with mild dementia (experimental group = 22, control group = 23', 'Korean older adults with mild dementia']",['Fumanet exercise'],"['cognitive function or depression', 'Gait ability', 'gait ability', 'cognitive function, walking ability, and depression']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3494623', 'cui_str': 'Mild dementia'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1556095', 'cui_str': 'Koreans'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0559964', 'cui_str': 'Ambulation ability'}]",,0.0404495,"RESULTS Gait ability in the experimental group was significantly improved compared with the control group (F = 9.08, P = .004).","[{'ForeName': 'Sun Mi', 'Initials': 'SM', 'LastName': 'Lee', 'Affiliation': 'Seongbuk Center for Dementia, Seoul, South Korea.'}, {'ForeName': 'Jaewon', 'Initials': 'J', 'LastName': 'Joung', 'Affiliation': 'Department of Nursing, Semyung University, Jecheon, South Korea.'}, {'ForeName': 'Sung Hee', 'Initials': 'SH', 'LastName': 'Shin', 'Affiliation': 'College of Nursing Science, Kyung Hee University, Seoul, South Korea.'}]",Japan journal of nursing science : JJNS,['10.1111/jjns.12286'] 974,28318835,Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.,"BACKGROUND Deficits in N-methyl-d-aspartate-type (NMDAR) function contribute to symptoms and cognitive dysfunction in schizophrenia. The efficacy of NMDAR agonists in the treatment of persistent symptoms of schizophrenia has been variable, potentially reflecting limitations in functional target engagement. We recently demonstrated significant improvement in auditory mismatch negativity (MMN) with once-weekly treatment with d-serine, a naturally occurring NMDAR glycine-site agonist. This study investigates effects of continuous (daily) NMDAR agonists in schizophrenia/schizoaffective disorder. METHODS Primary analysis was on MMN after double-blind crossover (60mg/kg/d, n=16, 6weeks) treatment with d-serine/placebo. Secondary measures included clinical symptoms, neurocognition, and the effects of open-label (30-120mg/kg/d, n=21) d-serine and bitopertin/placebo (10mg, n=29), a glycine transport inhibitor. RESULTS Double-blind d-serine treatment led to significant improvement in MMN frequency (p=0.001, d=2.3) generation and clinical symptoms (p=0.023, d=0.80). MMN frequency correlated significantly with change in symptoms (r=-0.63, p=0.002) following co-variation for treatment type. d-Serine treatment led to a significant, large effect size increase vs. placebo in evoked α-power in response to standards (p=0.036, d=0.81), appearing to normalize evoked α power relative to previous findings with controls. While similar results were seen with open-label d-serine, no significant effects of bitopertin were observed for symptoms or MMN. CONCLUSIONS These findings represent the first randomized double-blind placebo-controlled study with 60mg/kg d-serine in schizophrenia, and are consistent with meta-analyses showing significant effects of d-serine in schizophrenia. Results overall support suggest that MMN may have negative, as well as positive, predictive value in predicting efficacy of novel compounds. CLINICAL TRIALS REGISTRATION Clinicaltrials.gov: NCT00322023/NCT00817336 (d-serine); NCT01116830 (bitopertin).",2018,"RESULTS Double-blind d-serine treatment led to significant improvement in MMN frequency (p=0.001, d=2.3) generation and clinical symptoms (p=0.023, d=0.80).","['schizophrenia', 'schizophrenia/schizoaffective disorder']","['d-serine/placebo', 'placebo', 'continuous (daily) NMDAR agonists', 'NMDAR agonists', 'MMN']","['clinical symptoms, neurocognition, and the effects of open-label', 'glycine transport inhibitor', 'MMN frequency', 'generation and clinical symptoms', 'auditory mismatch negativity (MMN', 'mismatch negativity generation']","[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0036337', 'cui_str': 'Schizoaffective Disorder'}]","[{'cui': 'C1880218', 'cui_str': 'serine, D-'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0243192', 'cui_str': 'agonists'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0017890', 'cui_str': 'Glycine'}, {'cui': 'C1317949', 'cui_str': 'Transport (physical object)'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}]",,0.323989,"RESULTS Double-blind d-serine treatment led to significant improvement in MMN frequency (p=0.001, d=2.3) generation and clinical symptoms (p=0.023, d=0.80).","[{'ForeName': 'Joshua T', 'Initials': 'JT', 'LastName': 'Kantrowitz', 'Affiliation': 'Schizophrenia Research Center, Nathan Kline Institute, 140 Old Orangeburg Road, Orangeburg, NY 10962, United States; Department of Psychiatry, Columbia University, 1051 Riverside Drive, New York, NY 10032, United States. Electronic address: jk3380@cumc.columbia.edu.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Epstein', 'Affiliation': 'Schizophrenia Research Center, Nathan Kline Institute, 140 Old Orangeburg Road, Orangeburg, NY 10962, United States; Department of Psychiatry, Columbia University, 1051 Riverside Drive, New York, NY 10032, United States; Graduate Center, City University of New York, 365 5th Ave, New York, NY, United States.'}, {'ForeName': 'Migyung', 'Initials': 'M', 'LastName': 'Lee', 'Affiliation': 'Schizophrenia Research Center, Nathan Kline Institute, 140 Old Orangeburg Road, Orangeburg, NY 10962, United States; Department of Psychiatry, Columbia University, 1051 Riverside Drive, New York, NY 10032, United States.'}, {'ForeName': 'Nayla', 'Initials': 'N', 'LastName': 'Lehrfeld', 'Affiliation': 'Schizophrenia Research Center, Nathan Kline Institute, 140 Old Orangeburg Road, Orangeburg, NY 10962, United States.'}, {'ForeName': 'Karen A', 'Initials': 'KA', 'LastName': 'Nolan', 'Affiliation': 'Schizophrenia Research Center, Nathan Kline Institute, 140 Old Orangeburg Road, Orangeburg, NY 10962, United States; Department of Psychiatry, New York University School of Medicine, 1 Park Ave, New York, NY, United States.'}, {'ForeName': 'Constance', 'Initials': 'C', 'LastName': 'Shope', 'Affiliation': 'Schizophrenia Research Center, Nathan Kline Institute, 140 Old Orangeburg Road, Orangeburg, NY 10962, United States.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Petkova', 'Affiliation': 'Schizophrenia Research Center, Nathan Kline Institute, 140 Old Orangeburg Road, Orangeburg, NY 10962, United States; Department of Child and Adolescent Psychiatry, New York University School of Medicine, 1 Park Ave, New York, NY, United States.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Silipo', 'Affiliation': 'Schizophrenia Research Center, Nathan Kline Institute, 140 Old Orangeburg Road, Orangeburg, NY 10962, United States.'}, {'ForeName': 'Daniel C', 'Initials': 'DC', 'LastName': 'Javitt', 'Affiliation': 'Schizophrenia Research Center, Nathan Kline Institute, 140 Old Orangeburg Road, Orangeburg, NY 10962, United States; Department of Psychiatry, Columbia University, 1051 Riverside Drive, New York, NY 10032, United States.'}]",Schizophrenia research,['10.1016/j.schres.2017.02.027'] 975,30990093,Is prophylaxis for heterotopic ossification with radiation therapy after THR associated with early loosening or carcinogenesis?,"INTRODUCTION Heterotopic ossification may develop after major hip surgeries, thus preventive strategies including radiation therapy and non steroid anti-inflammatory drugs are commonly employed. There are certain concerns regarding the effects of radiation therapy on implant loosening and carcinogenesis. Our study aims to evaluate whether radiation therapy results in implant loosening or radiation-induced tumours in the long term. PATIENTS AND METHODS This was a prospective study including 97 high-risk patients for heterotopic ossification who underwent total hip arthroplasty. Patients were divided into 2 groups and received either a combination of radiation therapy and indomethacin (Group A), or indomethacin alone (Group B). Evaluated outcomes included implant loosening or development of radiation-induced tumours during the follow-up period. RESULTS The follow-up period of the study was 10 years. Group A consisted of 50 patients, while Group B consisted of 47 patients. 3 patients died during the follow-up. There were 2 cases of implant loosening, 1 from each of the 2 groups at 9 and 10 years after surgery respectively; thus, no statistically significant difference regarding implant loosening was found ( p < 0.05). During the follow-up period no cases of radiation-induced tumours were identified. CONCLUSION Our results are consistent with those of other studies supporting the safety of radiation therapy as a preventive strategy for heterotopic ossification following major surgeries in high risk patients. Further studies with even longer follow-up may be required to definitely exclude the possibility of adverse outcomes linked with radiation therapy.",2020,"There were 2 cases of implant loosening, 1 from each of the 2 groups at 9 and 10 years after surgery respectively; thus, no statistically significant difference regarding implant loosening was found ( p < 0.05).",['97 high-risk patients for heterotopic ossification who underwent total hip arthroplasty'],"['indomethacin alone', 'combination of radiation therapy and indomethacin', 'radiation therapy']","['implant loosening', 'implant loosening or development of radiation-induced tumours during the follow-up period']","[{'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0029396', 'cui_str': 'Ossification, Pathological'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0186193', 'cui_str': 'Arthroplasty of coxofemoral joint'}]","[{'cui': 'C0021246', 'cui_str': 'Indomethacin'}, {'cui': 'C0034619', 'cui_str': 'radiation therapy'}]","[{'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C0333050', 'cui_str': 'Loosening (morphologic abnormality)'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]",97.0,0.0132585,"There were 2 cases of implant loosening, 1 from each of the 2 groups at 9 and 10 years after surgery respectively; thus, no statistically significant difference regarding implant loosening was found ( p < 0.05).","[{'ForeName': 'Emilios E', 'Initials': 'EE', 'LastName': 'Pakos', 'Affiliation': 'Department of Orthopaedics, University Hospital of Ioannina, Ioannina, Greece.'}, {'ForeName': 'Dimitrios V', 'Initials': 'DV', 'LastName': 'Papadopoulos', 'Affiliation': 'Department of Orthopaedics, University Hospital of Ioannina, Ioannina, Greece.'}, {'ForeName': 'Ioannis D', 'Initials': 'ID', 'LastName': 'Gelalis', 'Affiliation': 'Department of Orthopaedics, University Hospital of Ioannina, Ioannina, Greece.'}, {'ForeName': 'Andreas G', 'Initials': 'AG', 'LastName': 'Tsantes', 'Affiliation': 'Department of Orthopaedics, University Hospital of Ioannina, Ioannina, Greece.'}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Gkiatas', 'Affiliation': 'Department of Orthopaedics, University Hospital of Ioannina, Ioannina, Greece.'}, {'ForeName': 'Dimitrios', 'Initials': 'D', 'LastName': 'Kosmas', 'Affiliation': 'Department of Orthopaedics, University Hospital of Ioannina, Ioannina, Greece.'}, {'ForeName': 'Pericles G', 'Initials': 'PG', 'LastName': 'Tsekeris', 'Affiliation': 'Department of Radiation Oncology, University of Ioannina, School of Medicine, Ioannina, Greece.'}, {'ForeName': 'Theodoros A', 'Initials': 'TA', 'LastName': 'Xenakis', 'Affiliation': 'Laboratory of Orthopedics and Biomechanics, University of Ioannina, School of Medicine, Ioannina, Greece.'}]",Hip international : the journal of clinical and experimental research on hip pathology and therapy,['10.1177/1120700019842724'] 976,28100321,"[Application of esmolol in severe hand, foot, and mouth disease].","OBJECTIVE To study the clinical effect and mechanism of action of esmolol in the treatment of severe hand, foot, and mouth disease (HFMD). METHODS A prospective randomized controlled trial was performed. A total of 102 children with severe HFMD were enrolled in the study and were randomly divided into conventional treatment and esmolol treatment groups (n=51 each). The children in the conventional treatment group were given conventional treatment according to the guidelines for the diagnosis and treatment of HFMD. Those in the esmolol treatment group were given esmolol in addition to the conventional treatment. The heart rate (HR), systolic blood pressure (SBP), and respiratory rate (RR) were continuously monitored for all children. Blood samples were collected from all children before treatment and 1, 3, and 5 days after treatment to measure the levels of norepinephrine (NE), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and nuclear factor-kappa B (NF-κB) p65 in mononuclear cells. Serum levels of myocardial enzymes and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured before treatment and after 5 days of treatment. RESULTS There were no significant differences in HR, SBP, RR, NE, TNF-α, IL-6, NF-κB p65, serum myocardial enzymes, and NT-proBNP before treatment between the conventional treatment and esmolol treatment groups. Both groups had significant reductions in these parameters at each time point (P<0.05). Compared with the conventional treatment group, the esmolol treatment group had significant improvements in the above parameters after 1 and 3 days of treatment (P<0.05). After 5 days of treatment, the esmolol treatment group had significant improvements in serum levels of myocardial enzymes and NT-proBNP compared with the conventional treatment group (P<0.05). CONCLUSIONS Early application of esmolol can effectively stabilize the vital signs of the children with severe HFMD. Its mechanism of action may be related to reducing serum catecholamine concentration, alleviating myocardial damage, improving cardiac function, and reducing inflammatory response.",2017,"There were no significant differences in HR, SBP, RR, NE, TNF-α, IL-6, NF-κB p65, serum myocardial enzymes, and NT-proBNP before treatment between the conventional treatment and esmolol treatment groups.","['children with severe HFMD', '102 children with severe HFMD']",['esmolol'],"['Serum levels of myocardial enzymes and N-terminal pro-brain natriuretic peptide (NT-proBNP', 'Blood samples', 'HR, SBP, RR, NE, TNF-α, IL-6, NF-κB p65, serum myocardial enzymes, and NT-proBNP', 'levels of norepinephrine (NE), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and nuclear factor-kappa B (NF-κB) p65 in mononuclear cells', 'serum levels of myocardial enzymes and NT-proBNP', 'heart rate (HR), systolic blood pressure (SBP), and respiratory rate (RR']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}]","[{'cui': 'C0116569', 'cui_str': 'esmolol'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C3541394', 'cui_str': 'Enzymes'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0754710', 'cui_str': 'Amino-terminal pro-brain natriuretic peptide'}, {'cui': 'C1963813', 'cui_str': 'NT-proBNP'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0299809', 'cui_str': 'p65(PAK)'}, {'cui': 'C0202145', 'cui_str': 'Norepinephrine measurement (procedure)'}, {'cui': 'C0041368', 'cui_str': 'Tumor Necrosis Factors'}, {'cui': 'C0079904', 'cui_str': 'Nuclear Factor-Kappab'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0231832', 'cui_str': 'Respiration Rate'}]",102.0,0.0229482,"There were no significant differences in HR, SBP, RR, NE, TNF-α, IL-6, NF-κB p65, serum myocardial enzymes, and NT-proBNP before treatment between the conventional treatment and esmolol treatment groups.","[{'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zhu', 'Affiliation': ""Department of Intensive Care Unit, Xuzhou Children's Hospital, Xuzhou, Jiangsu 221006, China. xuzhoupicu@163.com.""}, {'ForeName': 'Bo-Xiang', 'Initials': 'BX', 'LastName': 'Qi', 'Affiliation': ''}, {'ForeName': 'Dai-Hua', 'Initials': 'DH', 'LastName': 'Fang', 'Affiliation': ''}, {'ForeName': 'Gong-Jian', 'Initials': 'GJ', 'LastName': 'Qi', 'Affiliation': ''}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Gao', 'Affiliation': ''}, {'ForeName': 'Bao-Li', 'Initials': 'BL', 'LastName': 'Hu', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 977,28031424,The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.,"Purpose: Activin receptor-like kinase 1 (ALK1) is a novel target in angiogenesis. Concurrent targeting of ALK1 and VEGF signaling results in augmented inhibition of tumor growth in renal cell carcinoma (RCC) xenograft models. Dalantercept is an ALK1-receptor fusion protein that acts as a ligand trap for bone morphogenetic proteins 9 and 10. The DART Study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept plus axitinib in patients with advanced RCC and determined the optimal dose for further testing. Experimental Design: Patients received dalantercept 0.6, 0.9, or 1.2 mg/kg subcutaneously every 3 weeks plus axitinib 5 mg by mouth twice daily until disease progression or intolerance. Results: Twenty-nine patients were enrolled in the dose escalation ( n = 15) and expansion ( n = 14) cohorts. There were no dose-limiting toxicities or grade 4/5 treatment-related adverse events. In addition to common VEGFR tyrosine kinase inhibitor effects, such as fatigue and diarrhea, commonly seen treatment-related adverse events were peripheral edema, epistaxis, pericardial effusion, and telangiectasia. The objective response rate by RECIST v1.1 was 25% with responses seen at all dose levels. The overall median progression-free survival was 8.3 months. Conclusions: The combination of dalantercept plus axitinib is well tolerated and associated with clinical activity. On the basis of safety and efficacy results, the 0.9 mg/kg dose level was chosen for further study in a randomized phase II trial of dalantercept plus axitinib versus placebo plus axitinib. Clin Cancer Res; 23(14); 3557-65. ©2016 AACR .",2017,There were no dose-limiting toxicities or grade 4/5 treatment-related adverse events.,"['Advanced Renal Cell Carcinoma', 'Twenty-nine patients were enrolled in the dose escalation ( n = 15) and expansion ( n = 14) cohorts', 'Clin Cancer Res; 23(14); 3557-65', 'patients with advanced RCC and determined the optimal dose for further testing']","['axitinib 5 mg by mouth twice daily until disease progression or intolerance', 'Dalantercept plus Axitinib', 'dalantercept plus axitinib', 'ALK1 and VEGF', 'Activin receptor-like kinase 1 (ALK1', 'dalantercept plus axitinib versus placebo plus axitinib']","['objective response rate', 'fatigue and diarrhea', 'dose-limiting toxicities', 'safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept plus axitinib', 'overall median progression-free survival']","[{'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0007134', 'cui_str': 'Nephroid Carcinoma'}, {'cui': 'C0450351', 'cui_str': '29 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}]","[{'cui': 'C3265889', 'cui_str': 'axitinib 5 MG'}, {'cui': 'C1527415', 'cui_str': 'Per oral route'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C0242656', 'cui_str': 'Disease Progression'}, {'cui': 'C0231199', 'cui_str': 'Intolerance, function (observable entity)'}, {'cui': 'C2981815', 'cui_str': 'dalantercept'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1700874', 'cui_str': 'axitinib'}, {'cui': 'C0078058', 'cui_str': 'Vascular Endothelial Growth Factor A'}, {'cui': 'C0101389', 'cui_str': 'Activin Receptor'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C2981815', 'cui_str': 'dalantercept'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1700874', 'cui_str': 'axitinib'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",29.0,0.034345,There were no dose-limiting toxicities or grade 4/5 treatment-related adverse events.,"[{'ForeName': 'Martin H', 'Initials': 'MH', 'LastName': 'Voss', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York. vossm@mskcc.org.'}, {'ForeName': 'Rupal S', 'Initials': 'RS', 'LastName': 'Bhatt', 'Affiliation': 'Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Elizabeth R', 'Initials': 'ER', 'LastName': 'Plimack', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Brian I', 'Initials': 'BI', 'LastName': 'Rini', 'Affiliation': 'Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Alter', 'Affiliation': 'John Theurer Cancer Center Hackensack UMC, Hackensack, New Jersey.'}, {'ForeName': 'J Thaddeus', 'Initials': 'JT', 'LastName': 'Beck', 'Affiliation': 'Highlands Oncology Group, Fayetteville, Arkansas.'}, {'ForeName': 'Dawn', 'Initials': 'D', 'LastName': 'Wilson', 'Affiliation': 'Acceleron Pharma, Cambridge, Massachusetts.'}, {'ForeName': 'Xiaosha', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Acceleron Pharma, Cambridge, Massachusetts.'}, {'ForeName': 'Musa', 'Initials': 'M', 'LastName': 'Mutyaba', 'Affiliation': 'Acceleron Pharma, Cambridge, Massachusetts.'}, {'ForeName': 'Chad', 'Initials': 'C', 'LastName': 'Glasser', 'Affiliation': 'Acceleron Pharma, Cambridge, Massachusetts.'}, {'ForeName': 'Kenneth M', 'Initials': 'KM', 'LastName': 'Attie', 'Affiliation': 'Acceleron Pharma, Cambridge, Massachusetts.'}, {'ForeName': 'Matthew L', 'Initials': 'ML', 'LastName': 'Sherman', 'Affiliation': 'Acceleron Pharma, Cambridge, Massachusetts.'}, {'ForeName': 'Shuchi S', 'Initials': 'SS', 'LastName': 'Pandya', 'Affiliation': 'Acceleron Pharma, Cambridge, Massachusetts.'}, {'ForeName': 'Michael B', 'Initials': 'MB', 'LastName': 'Atkins', 'Affiliation': 'Georgetown University Medical Center, Washington, DC.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-16-2395'] 978,27974124,[Clinical efficacy of different doses of gamma globulin combined with glucocorticoid in treatment of moderate/severe acute Guillain-Barré syndrome in children: a comparative analysis].,"OBJECTIVE To investigate the clinical efficacy and safety of intravenous injection of low-dose versus high-dose gamma globulin combined with glucocorticoid pulse therapy in the treatment of children with moderate/severe acute Guillain-Barré syndrome (GBS). METHODS A total of 100 children with moderate/severe acute GBS were randomly assigned to low-dose group (n=48) and high-dose group (n=52). The children in the low-dose and high-dose groups were treated with 0.2 g/(kg · d) and 0.4 g/(kg · d) gamma globulin respectively combined with methylprednisolone. The two groups were compared in terms of the time to improvements of symptoms after treatment, serum levels of inflammatory factors, proportion of children undergoing invasive ventilation, treatment response rate, and adverse events. RESULTS After 5 days of treatment, the low- and high-dose groups had significant reductions in serum levels of tumor necrosis factor-α, interleukin-6, and C-reactive protein, and there were no significant differences in the reductions of these markers between the two groups. There were no significant differences between the two groups in the time to recovery of respiratory muscle paralysis, time to an improvement in muscle strength of one grade, time to recovery of sensory disturbance, and length of hospital stay. There was no significant difference in the treatment response rate between the low- and high-dose groups (90% vs 92%). There were also no significant differences in the incidence rates of pyrexia, headache, nausea, and palpitation between the two groups. CONCLUSIONS Low-dose versus high-dose gamma globulin combined with methylprednisolone pulse therapy have comparable clinical efficacy and safety in the treatment of children with moderate/severe acute GBS.",2016,"There were no significant differences between the two groups in the time to recovery of respiratory muscle paralysis, time to an improvement in muscle strength of one grade, time to recovery of sensory disturbance, and length of hospital stay.","['100 children with moderate/severe acute GBS', 'children with moderate/severe acute Guillain-Barré syndrome (GBS', 'moderate/severe acute Guillain-Barré syndrome in children', 'children with moderate/severe acute GBS']","['methylprednisolone pulse therapy', 'gamma globulin respectively combined with methylprednisolone', 'intravenous injection of low-dose versus high-dose gamma globulin combined with glucocorticoid pulse therapy', 'gamma globulin combined with glucocorticoid']","['treatment response rate', 'serum levels of tumor necrosis factor-α, interleukin-6, and C-reactive protein', 'serum levels of inflammatory factors, proportion of children undergoing invasive ventilation, treatment response rate, and adverse events', 'incidence rates of pyrexia, headache, nausea, and palpitation', 'clinical efficacy and safety', 'time to recovery of respiratory muscle paralysis, time to an improvement in muscle strength of one grade, time to recovery of sensory disturbance, and length of hospital stay']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0018378', 'cui_str': 'Landry-Guillain-Barre Syndrome'}]","[{'cui': 'C0587279', 'cui_str': 'Methylprednisolone pulse therapy (procedure)'}, {'cui': 'C0860681', 'cui_str': 'Immunogammaglobulin'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}, {'cui': 'C0021494', 'cui_str': 'Intravenous Injections'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C3540778', 'cui_str': 'Glucocorticoids'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0041368', 'cui_str': 'Tumor Necrosis Factors'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0030252', 'cui_str': 'Palpitations (finding)'}, {'cui': 'C0087113', 'cui_str': 'Treatment Efficacy'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0035232', 'cui_str': 'Diaphragmatic Paralysis'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0152027', 'cui_str': 'Sensory Disorders'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",100.0,0.0716371,"There were no significant differences between the two groups in the time to recovery of respiratory muscle paralysis, time to an improvement in muscle strength of one grade, time to recovery of sensory disturbance, and length of hospital stay.","[{'ForeName': 'Xiao-Yun', 'Initials': 'XY', 'LastName': 'Ma', 'Affiliation': ""Department of Pediatric Neurology, Women's and Children's Hospital of Qinghai, Xining 810000, China. mxyhzu@126.com.""}, {'ForeName': 'Zhao', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Xue-Jun', 'Initials': 'XJ', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Jian-Jun', 'Initials': 'JJ', 'LastName': 'Ye', 'Affiliation': ''}, {'ForeName': 'Yong-Ping', 'Initials': 'YP', 'LastName': 'Ma', 'Affiliation': ''}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 979,27817766,[Clinical effect and safety of somatostatin in treatment of postoperative gastrointestinal bleeding in neonates].,"OBJECTIVE To investigate the clinical effect and safety of somatostatin in the treatment of postoperative gastrointestinal bleeding in neonates. METHODS A prospective randomized study was performed, and 126 neonates who underwent surgery for congenital gastrointestinal anomalies were randomly divided into control group, treatment group A, and treatment group B. The neonates in the control group were given routine postoperative hemostasis, and those in the treatment groups were given somatostatin in addition to the treatment for the control group. The neonates in treatment group A were given intravenous injection of somatostatin 0.25 mg as the initial dose and 0.25 mg/h for maintenance, and those in treatment group B were given continuous intravenous pumping of somatostatin at a dose of 3.5 μg/(kg·h). The clinical outcome and complications were compared between the three groups. RESULTS Compared with the control group, the treatment groups had significantly shortened clearance time in occult blood test for gastrointestinal decompression drainage and a significantly lower degree of the reduction in 24-hour hemoglobin (P<0.05), while there were no significant differences between treatment groups A and B. Compared with the control group, treatment group A had significant reductions in heart rate (HR), respiratory rate (RR), blood pressure (BP), and SaO2 after one hour of treatment (P<0.05 ), but there were no significant differences at the other time points between the two groups (P>0.05). There were no significant differences in monitoring indices between the control group and treatment group B (P>0.05). No neonates in the control group experienced hypoglycemia reaction, and treatment group A had a significantly higher incidence rate of hypoglycemia (20%) than treatment group B (P<0.05). CONCLUSIONS Somatostatin has a marked clinical effect and good safety in the treatment of neonates with postoperative gastrointestinal bleeding, and the administration of somatostatin by continuous intravenous pumping leads to fewer side effects.",2016,There were no significant differences in monitoring indices between the control group and treatment group B (P>0.05).,"['neonates', 'postoperative gastrointestinal bleeding in neonates', 'neonates with postoperative gastrointestinal bleeding', '126 neonates who underwent surgery for congenital gastrointestinal anomalies']","['intravenous injection of somatostatin', 'somatostatin', 'Somatostatin']","['clearance time in occult blood test for gastrointestinal decompression drainage', 'heart rate (HR), respiratory rate (RR), blood pressure (BP), and SaO2', 'incidence rate of hypoglycemia', 'hypoglycemia reaction', '24-hour hemoglobin', 'monitoring indices']","[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0017181', 'cui_str': 'Gastrointestinal Hemorrhage'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C1744681', 'cui_str': 'Congenital (qualifier value)'}, {'cui': 'C0012241', 'cui_str': 'Congenital anomaly of gastrointestinal tract'}]","[{'cui': 'C0021494', 'cui_str': 'Intravenous Injections'}, {'cui': 'C0037659', 'cui_str': 'Somatostatin'}]","[{'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0028792', 'cui_str': 'Occult Blood'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0399613', 'cui_str': 'Gastrointestinal decompression (procedure)'}, {'cui': 'C0013103', 'cui_str': 'Drainage'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0231832', 'cui_str': 'Respiration Rate'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}, {'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.0193106,There were no significant differences in monitoring indices between the control group and treatment group B (P>0.05).,"[{'ForeName': 'Bo-Xiang', 'Initials': 'BX', 'LastName': 'Qi', 'Affiliation': ""Department of Surgical Intensive Care Unit, Xuzhou Children's Hospital, Xuzhou, Jiangsu 221006, China. xuzhoupicu@163.com.""}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zhu', 'Affiliation': ''}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Shang', 'Affiliation': ''}, {'ForeName': 'Li-Ping', 'Initials': 'LP', 'LastName': 'Sheng', 'Affiliation': ''}, {'ForeName': 'Bao-Li', 'Initials': 'BL', 'LastName': 'Hu', 'Affiliation': ''}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Gao', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 980,30690854,Predictors of mortality in patients with non-anterior ST-segment elevation myocardial infarction: Analysis from the HORIZONS-AMI trial.,"OBJECTIVES We sought to identify clinical, electrocardiographic (ECG), and angiographic characteristics that are predictive of 3-year mortality after primary percutaneous coronary intervention (PCI) in patients with non-anterior ST-elevation myocardial infarction (NA-STEMI) from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. BACKGROUND Which patients with NA-STEMI undergoing PCI have a poor prognosis is uncertain. METHODS NA-STEMI was defined as ST-segment elevation in lateral (V5, V6, I, aVL), inferior (II, III, aVF), or inferolateral (I, II, III, aVF, and V5-V6) ECG leads or posterior myocardial infarction with ST-segment depression of ≥1 mm in ≥2 contiguous anterior leads. Cox regression was used to identify independent predictors of 3-year mortality. Missing data were imputed using multiple imputation. RESULTS In HORIZONS-AMI, 2,578/3,602 patients had no prior coronary artery bypass grafting, underwent single-vessel PCI, and had baseline ECG data assessed in an independent core laboratory. Among them, 1,495 (58.0%) had NA-STEMI. Patients with NA-STEMI had lower 3-year mortality risk than those with anterior STEMI (4.5% versus 7.1%, P = 0.004). The independent predictors of increased 3-year mortality in NA-STEMI were older age (median > 59.0 years), diabetes, reduced LVEF (≤50%), Killip class ≥2, post-procedure TIMI flow 0-2 versus 3, renal insufficiency, and ST-resolution <30% at 60 min post-PCI. Patients with 0, 1, 2, 3, and ≥4 of these risk factors had 3-year mortality rates of 1.8%, 2.3%, 3.1%, 6.1%, and 36.3%, respectively (P < 0.0001). CONCLUSIONS Although NA-STEMI carries a better prognosis than anterior STEMI, high-risk patient cohorts with NA-STEMI may be identified who have substantial 3-year mortality.",2019,"Patients with NA-STEMI had lower 3-year mortality risk than those with anterior STEMI (4.5% versus 7.1%, P = 0.004).","['patients with non-anterior ST-segment elevation myocardial infarction', 'patients with non-anterior ST-elevation myocardial infarction (NA-STEMI', 'Acute Myocardial Infarction', '2,578/3,602 patients had no prior coronary artery bypass grafting, underwent single-vessel PCI, and had baseline ECG data assessed in an independent core laboratory']","['primary percutaneous coronary intervention (PCI', 'Revascularization and Stents']","['3-year mortality rates', 'ST-segment elevation in lateral (V5, V6, I, aVL), inferior (II, III, aVF), or inferolateral (I, II, III, aVF, and V5-V6) ECG leads or posterior myocardial infarction with ST-segment depression', '3-year mortality risk', '3-year mortality']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3874460', 'cui_str': 'Anterior ST segment elevation'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C1536220', 'cui_str': 'ST Elevated Myocardial Infarction'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction (disorder)'}, {'cui': 'C0010055', 'cui_str': 'Coronary Artery Bypass Grafting'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0148346', 'cui_str': 'Vessel'}, {'cui': 'C1623258', 'cui_str': 'ECG'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}]","[{'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0038257', 'cui_str': 'Stents'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C0520886', 'cui_str': 'ST segment elevation (finding)'}, {'cui': 'C0205093', 'cui_str': 'Lateral (qualifier value)'}, {'cui': 'C0449216', 'cui_str': 'aVL (body structure)'}, {'cui': 'C0542339', 'cui_str': 'Below (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0449215', 'cui_str': 'aVF (body structure)'}, {'cui': 'C0179504', 'cui_str': 'ECG lead'}, {'cui': 'C0340319', 'cui_str': 'Posterior myocardial infarction'}, {'cui': 'C0520887', 'cui_str': 'ST segment depression (finding)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",,0.0377035,"Patients with NA-STEMI had lower 3-year mortality risk than those with anterior STEMI (4.5% versus 7.1%, P = 0.004).","[{'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.'}, {'ForeName': 'Björn', 'Initials': 'B', 'LastName': 'Redfors', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.'}, {'ForeName': 'Shmuel', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.'}, {'ForeName': 'Bernard J', 'Initials': 'BJ', 'LastName': 'Gersh', 'Affiliation': 'Cardiovascular Division, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Roxana', 'Initials': 'R', 'LastName': 'Mehran', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.'}, {'ForeName': 'Yiran', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'McAndrew', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.'}, {'ForeName': 'Ori', 'Initials': 'O', 'LastName': 'Ben-Yehuda', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.'}, {'ForeName': 'Gary S', 'Initials': 'GS', 'LastName': 'Mintz', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.'}, {'ForeName': 'Gregg W', 'Initials': 'GW', 'LastName': 'Stone', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.'}]",Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,['10.1002/ccd.28096'] 981,32412952,Trends in Costs of Care and Utilization for Medicaid Patients With Diabetes in Accountable Care Communities.,"BACKGROUND/OBJECTIVES Medicaid beneficiaries with diabetes have complex care needs. The Accountable Care Communities (ACC) Program is a practice-level intervention implemented by UnitedHealthcare to improve care for Medicaid beneficiaries. We examined changes in costs and utilization for Medicaid beneficiaries with diabetes assigned to ACC versus usual care practices. RESEARCH DESIGN Interrupted time series with concurrent control group analysis, at the person-month level. The ACC was implemented in 14 states, and we selected comparison non-ACC practices from those states to control for state-level variation in Medicaid program. We adjusted the models for age, sex, race/ethnicity, comorbidities, seasonality, and state-by-year fixed effects. We examined the difference between ACC and non-ACC practices in changes in the time trends of expenditures and hospital and emergency room utilization, for the 4 largest categories of Medicaid eligibility [Temporary Assistance to Needy Families, Supplemental Security Income (without Medicare), Expansion, Dual-Eligible]. SUBJECTS/MEASURES Eligibility and claims data from Medicaid adults with diabetes from 14 states between 2010 and 2016, before and after ACC implementation. RESULTS Analyses included 1,200,460 person-months from 66,450 Medicaid patients with diabetes. ACC implementation was not associated with significant changes in outcome time trends, relative to comparators, for all Medicaid categories. CONCLUSIONS Medicaid patients assigned to ACC practices had no changes in cost or utilization over 3 years of follow-up, compared with patients assigned to non-ACC practices. The ACC program may not reduce costs or utilization for Medicaid patients with diabetes.",2020,"CONCLUSIONS Medicaid patients assigned to ACC practices had no changes in cost or utilization over 3 years of follow-up, compared with patients assigned to non-ACC practices.","['66,450 Medicaid patients with diabetes', 'Medicaid beneficiaries with diabetes', 'Medicaid adults with diabetes from 14 states between 2010 and 2016, before and after ACC implementation', 'Medicaid patients with diabetes', 'Medicaid Patients With Diabetes in Accountable Care Communities', 'Medicaid beneficiaries with diabetes assigned to ACC versus usual care practices']",[],"['Costs of Care and Utilization', 'cost or utilization', 'costs or utilization', 'costs and utilization']","[{'cui': 'C0025071', 'cui_str': 'Medicaid coverage'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]",[],"[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",66450.0,0.0160042,"CONCLUSIONS Medicaid patients assigned to ACC practices had no changes in cost or utilization over 3 years of follow-up, compared with patients assigned to non-ACC practices.","[{'ForeName': 'Tannaz', 'Initials': 'T', 'LastName': 'Moin', 'Affiliation': 'David Geffen School of Medicine at UCLA.'}, {'ForeName': 'Jessica M', 'Initials': 'JM', 'LastName': 'Harwood', 'Affiliation': 'David Geffen School of Medicine at UCLA.'}, {'ForeName': 'Carol M', 'Initials': 'CM', 'LastName': 'Mangione', 'Affiliation': 'David Geffen School of Medicine at UCLA.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Jackson', 'Affiliation': 'David Geffen School of Medicine at UCLA.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Ho', 'Affiliation': 'UnitedHealthcare, Minnetonka, MN.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Ettner', 'Affiliation': 'David Geffen School of Medicine at UCLA.'}, {'ForeName': 'O Kenrik', 'Initials': 'OK', 'LastName': 'Duru', 'Affiliation': 'David Geffen School of Medicine at UCLA.'}]",Medical care,['10.1097/MLR.0000000000001318'] 982,27974112,[Effect of early caffeine treatment on the need for respirator therapy in preterm infants with respiratory distress syndrome].,"OBJECTIVE To study the efficacy of early caffeine treatment in preterm infants with respiratory distress syndrome (RDS). METHODS A prospective controlled clinical trial was performed. A total of 59 preterm infants with RDS were enrolled and divided into a caffeine group (30 infants) and a control group (29 infants). Caffeine was administered in the caffeine group and control group at the same dosage at 12-24 hours after birth and before extubation respectively. The respirator parameters and the incidence rates of ventilator-associated pneumonia (VAP) and apnea were compared between the two groups. RESULTS Compared with the control group, the caffeine group had significantly lower peak inspiratory pressure, peak fraction of inspired oxygen, and incidence rate of VAP (p<0.05), as well as significantly shorter intubation time, NCPAP time, and total duration of oxygen supply (p<0.05). In addition, the caffeine group had a significantly longer time to first onset of apnea after extubation (p<0.05) and significantly fewer times of onset of apnea 1-2 days after extubation (p<0.01), as compared with the control group. CONCLUSIONS Early caffeine treatment can reduce the need for assisted ventilation in preterm infants with RDS, help with early extubation and ventilator weaning, reduce the oxygen time in the late stage, reduce the incidence of VAP, and prevent the development of apnea after extubation.",2016,"Compared with the control group, the caffeine group had significantly lower peak inspiratory pressure, peak fraction of inspired oxygen, and incidence rate of VAP (p<0.05), as well as significantly shorter intubation time, NCPAP time, and total duration of oxygen supply (p<0.05).","['preterm infants with respiratory distress syndrome (RDS', 'preterm infants with respiratory distress syndrome', 'group (30 infants) and a control group (29 infants', '59 preterm infants with RDS', 'preterm infants with RDS']","['caffeine', 'Caffeine']","['peak inspiratory pressure, peak fraction of inspired oxygen, and incidence rate of VAP (p<0.05), as well as significantly shorter intubation time, NCPAP time, and total duration of oxygen supply (p<0.05', 'incidence rates of ventilator-associated pneumonia (VAP) and apnea', 'longer time to first onset of apnea']","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0035220', 'cui_str': 'Respiratory Distress Syndrome, Newborn'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0006644', 'cui_str': 'Caffeine'}]","[{'cui': 'C0232021', 'cui_str': 'Maximum inspiratory pressure (observable entity)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0428167', 'cui_str': 'FIO2'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C1875802', 'cui_str': 'Healthcare supplies'}, {'cui': 'C0087153', 'cui_str': 'Ventilators'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0332162', 'cui_str': 'Onset of (contextual qualifier) (qualifier value)'}]",59.0,0.0271879,"Compared with the control group, the caffeine group had significantly lower peak inspiratory pressure, peak fraction of inspired oxygen, and incidence rate of VAP (p<0.05), as well as significantly shorter intubation time, NCPAP time, and total duration of oxygen supply (p<0.05).","[{'ForeName': 'Qiao-Zhen', 'Initials': 'QZ', 'LastName': 'Wei', 'Affiliation': ""Department of Neonatology, Yulin First People's Hospital/Sixth Hospital Affiliated to Guangxi Medical University, Yulin, Guangxi 537000, China. supin111@126.com.""}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Su', 'Affiliation': ''}, {'ForeName': 'Jin-Tian', 'Initials': 'JT', 'LastName': 'Han', 'Affiliation': ''}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Yu-Hui', 'Initials': 'YH', 'LastName': 'Duan', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 983,27974114,[Clinical efficacy of porcine pulmonary surfactant combined with budesonide suspension intratracheal instillation in the treatment of neonatal meconium aspiration syndrome].,"OBJECTIVE To study the clinical efficacy of porcine pulmonary surfactant (PS) combined with budesonide suspension intratracheal instillation in the treatment of neonatal meconium aspiration syndrome (MAS). METHODS Seventy neonates with MAS were enrolled for a prospective study. The neonates were randomly assigned to PS alone treatment group and PS+budesonide treatment group (n=35 each). The PS alone treatment group was given PS (100 mg/kg) by intratracheal instillation. The treatment group was given budesonide suspension (0.25 mg/kg) combined with PS (100 mg/kg). RESULTS The rate of repeated use of PS in the PS+ budesonide group was significantly lower than that in the PS alone group 12 hours after treatment (p<0.05). The improvement of PaO 2 /FiO 2 , TcSaO 2 , PaO 2 , and PaCO 2 in the PS+ budesonide group was significantly greater than that in the PS alone group 6, 12, and 24 hours after treatment (p<0.05). The chest X-ray examination showed that the pulmonary inflammation absorption in the PS+ budesonide group was significantly better than that in the PS alone group 48 hours after treatment (p<0.05). The incidence of complications in the PS+budesonide group was significantly lower than that in the PS alone group (p<0.05), and the average hospitalization duration was significantly shorter than that in the PS alone group (p<0.01). CONCLUSIONS PS combined with budesonide suspension intratracheal instillation for the treatment of neonatal MAS is effective and superior to PS alone treatment.",2016,"The incidence of complications in the PS+budesonide group was significantly lower than that in the PS alone group (p<0.05), and the average hospitalization duration was significantly shorter than that in the PS alone group (p<0.01). ","['Seventy neonates with MAS were enrolled for a prospective study', 'neonatal meconium aspiration syndrome (MAS', 'neonatal meconium aspiration syndrome']","['PS+ budesonide', 'PS alone treatment group and PS+budesonide treatment', 'budesonide suspension', 'budesonide suspension intratracheal instillation', 'porcine pulmonary surfactant (PS) combined with budesonide suspension intratracheal instillation', 'porcine pulmonary surfactant']","['average hospitalization duration', 'incidence of complications', 'rate of repeated use of PS', 'pulmonary inflammation absorption', 'improvement of PaO 2 /FiO 2 , TcSaO 2 , PaO 2 , and PaCO 2']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0033522', 'cui_str': 'Prospective Studies'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0025048', 'cui_str': 'Meconium Aspiration Syndrome'}]","[{'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1382107', 'cui_str': 'Suspension'}, {'cui': 'C1522653', 'cui_str': 'Intratracheal use'}, {'cui': 'C0184959', 'cui_str': 'Instillation - action (qualifier value)'}, {'cui': 'C0034085', 'cui_str': 'Pulmonary Surfactants'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C3714636', 'cui_str': 'Pulmonary Inflammation'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output (observable entity)'}]",70.0,0.0276657,"The incidence of complications in the PS+budesonide group was significantly lower than that in the PS alone group (p<0.05), and the average hospitalization duration was significantly shorter than that in the PS alone group (p<0.01). ","[{'ForeName': 'Xiu-Zhen', 'Initials': 'XZ', 'LastName': 'Tan', 'Affiliation': ""Department of Neonatology, The 6th People's Hospital of Foshan Nanhai District, Foshan, Guangdong 528248, China. 275828141@qq.com.""}, {'ForeName': 'Shi-Guang', 'Initials': 'SG', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Jian-Hua', 'Initials': 'JH', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Xiao-Fen', 'Initials': 'XF', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Ping-Ming', 'Initials': 'PM', 'LastName': 'Gao', 'Affiliation': ''}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 984,32412986,"Subarachnoid block and ultrasound-guided transversalis fascia plane block for caesarean section: A randomised, double-blind, placebo-controlled trial.","BACKGROUND After caesarean section, maternal postoperative comfort is critical to allow the new mother to care for her baby. Insufficient pain relief during the postoperative period may delay maternal/infant bonding and, in addition, such pain has been linked to subsequent depression and chronic pain. Caesarean section is commonly performed with a Pfannenstiel incision, and a transversalis fascia plane (TFP) block provides postoperative analgesia in the T12 and L1 dermatomes. OBJECTIVE The aim of this study was to investigate the effect of the TFP block on postoperative opioid consumption and pain scores in patients undergoing caesarean section under spinal anaesthesia. DESIGN A randomised controlled, double-blind study. SETTINGS Single-centre, academic hospital. PARTICIPANTS Sixty patients undergoing caesarean section. INTERVENTIONS The TFP group (n = 30) received an ultrasound-guided bilateral TFP block with 20 ml of 0.25% bupivacaine. The control group (n = 30) received 20 ml of saline bilaterally. Postoperative analgesia was given every 6 h with intravenous paracetamol 1 g and patient-controlled analgesia (PCA) with morphine. MAIN OUTCOME MEASURES Postoperative visual analogue pain scores, morphine consumption, rescue analgesia and opioid-related side effects were evaluated. RESULTS In the TFP group, the visual analogue pain scores were significantly lower at rest for 2 h after the operation (P = 0.011) and during active movement at 2, 4 and 8 h postoperatively (P = 0.014, <0.001 and 0.032, respectively). Morphine consumption in the first 24 h after surgery was significantly higher in the control group compared with the TFP group (38.5 ± 11.63 and 19.5 ± 8.33 mg, respectively; P < 0.001). The incidence of postoperative nausea and constipation were statistically higher in the control group than in the TFP group (P < 0.05). Patient satisfaction was significantly higher in the TFP group (P = 0.027). CONCLUSION A postoperative TFP block can reduce opioid consumption and relieve acute pain after a caesarean section under spinal anaesthesia. TRIAL REGISTRATION ClinicalTrials.gov, NCT04172727.",2020,The incidence of postoperative nausea and constipation were statistically higher in the control group than in the TFP group (P < 0.05).,"['Single-centre, academic hospital', 'patients undergoing caesarean section under spinal anaesthesia', 'caesarean section', 'Sixty patients undergoing caesarean section']","['transversalis fascia plane (TFP) block', 'ultrasound-guided bilateral TFP block with 20\u200aml of 0.25% bupivacaine', 'paracetamol 1 g and patient-controlled analgesia (PCA) with morphine', 'TFP', 'Subarachnoid block and ultrasound-guided transversalis fascia plane block', '20\u200aml of saline bilaterally', 'TFP block', 'placebo']","['Patient satisfaction', 'postoperative opioid consumption and pain scores', 'postoperative nausea and constipation', 'visual analogue pain scores', 'Morphine consumption', 'Postoperative visual analogue pain scores, morphine consumption, rescue analgesia and opioid-related side effects', 'acute pain']","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}]","[{'cui': 'C0015641', 'cui_str': 'Fascial'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0225232', 'cui_str': 'Transversalis fascia structure'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C4517443', 'cui_str': '0.25'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0078944', 'cui_str': 'Patient controlled analgesia'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0520904', 'cui_str': 'Postoperative nausea'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0184567', 'cui_str': 'Acute pain'}]",60.0,0.485841,The incidence of postoperative nausea and constipation were statistically higher in the control group than in the TFP group (P < 0.05).,"[{'ForeName': 'Muhammed E', 'Initials': 'ME', 'LastName': 'Aydin', 'Affiliation': 'From the Department of Anaesthesiology and Reanimation, Ataturk University Faculty of Medicine (MEA, AMY, ECC, IA, EOA, AA), Clinical Research, Development and Design Application and Research Center, Ataturk University School of Medicine (MEA, AMY, ECC, AA), and Nenehatun State Hospital, Erzurum, Turkey (ZB).'}, {'ForeName': 'Zehra', 'Initials': 'Z', 'LastName': 'Bedir', 'Affiliation': ''}, {'ForeName': 'Ahmet M', 'Initials': 'AM', 'LastName': 'Yayik', 'Affiliation': ''}, {'ForeName': 'Erkan C', 'Initials': 'EC', 'LastName': 'Celik', 'Affiliation': ''}, {'ForeName': 'İrem', 'Initials': 'İ', 'LastName': 'Ates', 'Affiliation': ''}, {'ForeName': 'Elif O', 'Initials': 'EO', 'LastName': 'Ahiskalioglu', 'Affiliation': ''}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ahiskalioglu', 'Affiliation': ''}]",European journal of anaesthesiology,['10.1097/EJA.0000000000001222'] 985,31905097,"Effectiveness of Cervical Spine High-Velocity, Low-Amplitude Thrust Added to Behavioral Education, Soft Tissue Mobilization, and Exercise for People With Temporomandibular Disorder With Myalgia: A Randomized Clinical Trial.","OBJECTIVE To determine the immediate and short-term effects of adding cervical spine high-velocity, low-amplitude thrust (HVLAT) to behavioral education, soft tissue mobilization, and a home exercise program on pain and dysfunction for people with a primary complaint of temporomandibular disorder (TMD) with myalgia. DESIGN Randomized clinical trial. METHODS Fifty individuals with TMD were randomly assigned to receive cervical HVLAT or sham manipulation for 4 visits over 4 weeks. Participants in both groups received other treatments, including standardized behavioral education, soft tissue mobilization, and a home exercise program. Primary outcomes included maximal mouth opening, the numeric pain-rating scale, the Jaw Functional Limitation Scale (JFLS), the Tampa Scale of Kinesiophobia for TMD (TSK-TMD), and a global rating of change (GROC). Self-report and objective measurements were taken at baseline, immediately after initial treatment, and follow-ups of 1 week and 4 weeks. A 2-by-4 mixed-model analysis of variance was used, with intervention group as the between-subjects factor and time as the within-subject factor. Separate analyses of variance were performed for dependent variables, and the hypothesis of interest was the group-by-time interaction. RESULTS There was no significant interaction for maximal mouth opening, the numeric pain-rating scale, or secondary measures. There were significant 2-way interactions for the JFLS ( d = 0.60) and TSK-TMD ( d = 0.80). The HVLAT group had lower fear at 4 weeks and improved jaw function earlier (1 week). The GROC favored the HVLAT group, with significant differences in successful outcomes noted immediately after baseline treatment (thrust, 6/25; sham, 0/25) and at 4 weeks (thrust, 17/25; sham, 10/25). CONCLUSION Both groups improved over time; however, differences between groups were small. There were significant differences between groups for the JFLS, TSK-TMD, and GROC. The additive clinical effect of cervical HVLAT to standard care remains unclear for treating TMD. J Orthop Sports Phys Ther 2020;50(8):455-465. Epub 6 Jan 2020. doi:10.2519/jospt.2020.9175 .",2020,Significant 2-way interactions were noted in JFLS (d=0.60) and TSK-TMD (d=0.80).,"['Individuals With Temporomandibular Disorder (TMD) With Myalgia', 'individuals with a primary complaint of temporomandibular disorder (TMD) with myalgia', 'Fifty individuals with TMD (n=50']","['cervical HVLAT or sham manipulation', 'Cervical Spine High Velocity Low Amplitude Thrust Added to Behavioral Education, Soft Tissue Mobilization, and Exercise', 'HVLAT', 'standardized behavioral education, soft tissue mobilization, and a HEP', 'cervical spine high velocity low amplitude thrust (HVLAT) added to behavioral education, soft tissue mobilization, and a home exercise program (HEP', 'JFLS']","['JFLS, TSK-TMD, and GROC', 'TSK-TMD), and Global Rating of Change (GROC', 'lower fear at 4-weeks and improved jaw function', 'pain and dysfunction', 'maximal mouth opening (MMO), Numeric Pain Rating Scale (NPRS), Jaw Functional Limitation Scale (JFLS), Tampa Scale of Kinesiophobia', 'successful outcomes', 'GROC']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0039494', 'cui_str': 'TMJ Diseases'}, {'cui': 'C0231528', 'cui_str': 'Muscle Pain'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0277786', 'cui_str': 'Presenting complaint'}]","[{'cui': 'C0205064', 'cui_str': 'Cervical (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0947647', 'cui_str': 'Manipulation - action (qualifier value)'}, {'cui': 'C0728985', 'cui_str': 'Cervical spine'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0686940', 'cui_str': 'Soft tissue mobilization'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0449198', 'cui_str': 'HEP (body structure)'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program (regime/therapy)'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0022359', 'cui_str': 'Jaw'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0230028', 'cui_str': 'Structure of oral region of face'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449295', 'cui_str': 'Limitation (attribute)'}, {'cui': 'C4285782', 'cui_str': 'Kinesiophobia'}, {'cui': 'C1272703', 'cui_str': 'Successful'}]",50.0,0.0853835,Significant 2-way interactions were noted in JFLS (d=0.60) and TSK-TMD (d=0.80).,"[{'ForeName': 'Breanna', 'Initials': 'B', 'LastName': 'Reynolds', 'Affiliation': ''}, {'ForeName': 'Emilio J', 'Initials': 'EJ', 'LastName': 'Puentedura', 'Affiliation': ''}, {'ForeName': 'Morey J', 'Initials': 'MJ', 'LastName': 'Kolber', 'Affiliation': ''}, {'ForeName': 'Joshua A', 'Initials': 'JA', 'LastName': 'Cleland', 'Affiliation': ''}]",The Journal of orthopaedic and sports physical therapy,['10.2519/jospt.2020.9175'] 986,32492148,"The Type and Amount of Dietary Fat Affect Plasma Factor VIIc, Fibrinogen, and PAI-1 in Healthy Individuals and Individuals at High Cardiovascular Disease Risk: 2 Randomized Controlled Trials.","BACKGROUND Factor VIIc, fibrinogen, and plasminogen activator inhibitor 1 (PAI-1) are cardiovascular disease (CVD) risk factors and are modulated, in part, by fat type and amount. OBJECTIVE We evaluated fat type and amount on the primary outcomes: factor VIIc, fibrinogen, and PAI-1. METHODS In the Dietary Effects on Lipoproteins and Thrombogenic Activity (DELTA) Trial, 2 controlled crossover feeding studies evaluated substituting carbohydrate or MUFAs for SFAs. Study 1: healthy participants (n = 103) were provided with (8 wk) an average American diet [AAD; designed to provide 37% of energy (%E) as fat, 16% SFA], a Step 1 diet (30%E fat, 9% SFA), and a diet low in SFA (Low-Sat; 26%E fat, 5% SFA). Study 2: participants (n = 85) at risk for CVD and metabolic syndrome (MetSyn) were provided with (7 wk) an AAD, a step 1 diet, and a high-MUFA diet (designed to provide 37%E fat, 8% SFA, 22% MUFA). RESULTS Study 1: compared with AAD, the Step 1 and Low-Sat diets decreased mean factor VIIc by 1.8% and 2.6% (overall P = 0.0001), increased mean fibrinogen by 1.2% and 2.8% (P = 0.0141), and increased mean square root PAI-1 by 0.0% and 6.0% (P = 0.0037), respectively. Study 2: compared with AAD, the Step 1 and high-MUFA diets decreased mean factor VIIc by 4.1% and 3.2% (overall P < 0.0001), increased mean fibrinogen by 3.9% and 1.5% (P = 0.0083), and increased mean square-root PAI-1 by 2.0% and 5.8% (P = 0.1319), respectively. CONCLUSIONS Replacing SFA with carbohydrate decreased factor VIIc and increased fibrinogen in healthy and metabolically unhealthy individuals and also increased PAI-1 in healthy subjects. Replacing SFA with MUFA decreased factor VIIc and increased fibrinogen but less than carbohydrate. Our results indicate an uncertain effect of replacing SFA with carbohydrate or MUFA on cardiometabolic risk because of small changes in hemostatic factors and directionally different responses to decreasing SFA. This trial was registered at https://clinicaltrials.gov/ct2/show/NCT00000538?term=NCT00000538&rank=1 as NCT00000538.",2020,"CONCLUSIONS Replacing SFA with carbohydrate decreased factor VIIc and increased fibrinogen in healthy and metabolically unhealthy individuals and also increased PAI-1 in healthy subjects.","['Healthy Individuals and Individuals at High Cardiovascular Disease Risk', 'Study 1: healthy participants (n\xa0=\xa0103', 'healthy subjects', 'Study 2: participants (n\xa0=\xa085) at risk for']",['carbohydrate or MUFAs'],"['mean square-root PAI-1', 'mean fibrinogen', 'factor\xa0VIIc and increased fibrinogen', 'CVD and metabolic syndrome (MetSyn', 'mean factor VIIc', 'mean square root PAI-1', 'factor VIIc, fibrinogen, and PAI-1', 'Lipoproteins and Thrombogenic Activity (DELTA']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C1444641', 'cui_str': 'At risk'}]","[{'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0015687', 'cui_str': 'Monounsaturated fatty acid'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0030190', 'cui_str': 'Plasminogen activator inhibitor-1'}, {'cui': 'C0016006', 'cui_str': 'Fibrinogen'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0023820', 'cui_str': 'Lipoprotein'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",103.0,0.0521474,"CONCLUSIONS Replacing SFA with carbohydrate decreased factor VIIc and increased fibrinogen in healthy and metabolically unhealthy individuals and also increased PAI-1 in healthy subjects.","[{'ForeName': 'Penny M', 'Initials': 'PM', 'LastName': 'Kris-Etherton', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Paul W', 'Initials': 'PW', 'LastName': 'Stewart', 'Affiliation': 'Department of Biostatistics, Collaborative Studies Coordinating Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Henry N', 'Initials': 'HN', 'LastName': 'Ginsberg', 'Affiliation': 'Department of Medicine, Irving Center for Clinical Research, Columbia University College of Physicians and Surgeons, New York, NY, USA.'}, {'ForeName': 'Russell P', 'Initials': 'RP', 'LastName': 'Tracy', 'Affiliation': 'Colchester Research Facility, University of Vermont, Colchester, VT, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lefevre', 'Affiliation': 'Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA.'}, {'ForeName': 'Patricia J', 'Initials': 'PJ', 'LastName': 'Elmer', 'Affiliation': 'Division of Epidemiology, University of Minnesota School of Public Health, Minneapolis, MN, USA.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Berglund', 'Affiliation': 'Department of Medicine, Irving Center for Clinical Research, Columbia University College of Physicians and Surgeons, New York, NY, USA.'}, {'ForeName': 'Abby G', 'Initials': 'AG', 'LastName': 'Ershow', 'Affiliation': 'Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Pearson', 'Affiliation': 'The Mary Imogene Bassett Research Institute, Cooperstown, NY, USA.'}, {'ForeName': 'Rajasekhar', 'Initials': 'R', 'LastName': 'Ramakrishnan', 'Affiliation': 'Department of Medicine, Irving Center for Clinical Research, Columbia University College of Physicians and Surgeons, New York, NY, USA.'}, {'ForeName': 'Stephen F', 'Initials': 'SF', 'LastName': 'Holleran', 'Affiliation': 'Department of Medicine, Irving Center for Clinical Research, Columbia University College of Physicians and Surgeons, New York, NY, USA.'}, {'ForeName': 'Barbara H', 'Initials': 'BH', 'LastName': 'Dennis', 'Affiliation': 'Department of Biostatistics, Collaborative Studies Coordinating Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Catherine M', 'Initials': 'CM', 'LastName': 'Champagne', 'Affiliation': 'Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA.'}, {'ForeName': 'Wahida', 'Initials': 'W', 'LastName': 'Karmally', 'Affiliation': 'Department of Medicine, Irving Center for Clinical Research, Columbia University College of Physicians and Surgeons, New York, NY, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Journal of nutrition,['10.1093/jn/nxaa137'] 987,27751217,[Clinical effect of gamma globulin pulse therapy for abdominal Henoch-Schönlein purpura in children].,"OBJECTIVE To study the clinical effect of high-dose gamma globulin pulse therapy for abdominal Henoch-Schönlein purpura (HSP). METHODS Thirty-three children with abdominal HSP were randomly assigned to dexamethasone group (15 children) and gamma globulin group (18 children). The children in the dexamethasone group were treated with dexamethasone and conventional treatment, and those in the gamma globulin group were treated with high-dose gamma globulin pulse therapy in addition to the conventional treatment. Clinical outcome and recurrence rate were observed in both groups. RESULTS Compared with the dexamethasone group, the gamma globulin group had a significantly shorter onset time of rash, a significantly shorter time to complete regression of rash, a significantly shorter time to abdominal pain remission, and a significantly shorter time to disappearance of bloody stool, as well as comparable time to vomiting remission and length of hospital stay. The gamma globulin group had a significantly higher response rate than the dexamethasone group (95% vs 65%; P<0.05) and a significantly lower recurrence rate within 6 months than the dexamethasone group (5.6% vs 33.3%; P<0.05). CONCLUSIONS High-dose gamma globulin pulse therapy has a marked clinical effect in the treatment of abdominal HSP. It is safe and reliable and has a low recurrence rate, and therefore, it holds promise for clinical application.",2016,"The gamma globulin group had a significantly higher response rate than the dexamethasone group (95% vs 65%; P<0.05) and a significantly lower recurrence rate within 6 months than the dexamethasone group (5.6% vs 33.3%; P<0.05). ","['group (18 children', 'Thirty-three children with abdominal HSP', 'abdominal Henoch-Schönlein purpura in children']","['High-dose gamma globulin pulse therapy', 'gamma globulin pulse therapy', 'dexamethasone', 'gamma globulin', 'high-dose gamma globulin pulse therapy']","['vomiting remission and length of hospital stay', 'recurrence rate', 'response rate', 'onset time of rash', 'shorter time to abdominal pain remission']","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0450358', 'cui_str': '33 (qualifier value)'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}, {'cui': 'C0034152', 'cui_str': 'Henoch Purpura'}]","[{'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0860681', 'cui_str': 'Immunogammaglobulin'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}]","[{'cui': 'C0042965', 'cui_str': 'Vomitus (substance)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0015230', 'cui_str': 'Skin Rash'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}]",33.0,0.074824,"The gamma globulin group had a significantly higher response rate than the dexamethasone group (95% vs 65%; P<0.05) and a significantly lower recurrence rate within 6 months than the dexamethasone group (5.6% vs 33.3%; P<0.05). ","[{'ForeName': 'Li-Ping', 'Initials': 'LP', 'LastName': 'Xia', 'Affiliation': 'Department of Pediatrics, Renmin Hospital of Wuhan University, Wuhan 430060, China. jiangyiwd@163.com.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 988,32412796,Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.,"INTRODUCTION Accumulating evidence supports the evaluation of glucagon-like peptide-1 (GLP-1) receptor (R) agonists for the treatment of the underlying pathology causing Parkinson's Disease (PD). Not only are these effects evident in models of PD and other neurodegenerative disorders but recently in a randomized, double-blind, placebo-controlled clinical trial, a GLP-1R agonist has provided improved cognition motor functions in humans with moderate PD. AREAS COVERED In this mini-review, we describe the development of GLP-1R agonists and their potential therapeutic value in treating PD. Many GLP-1R agonists are FDA approved for the treatment of metabolic disorders, and hence can be rapidly repositioned for PD. Furthermore, we present preclinical data offering insights into the use of monomeric dual- and tri-agonist incretin-based mimetics for neurodegenerative disorders. These drugs combine active regions of GLP-1 with those of glucose-dependent insulinotropic peptide (GIP) and/or glucagon (Gcg). EXPERT OPINION GLP-1Ragonists offer a complementary and enhanced therapeutic value to other drugs used to treat PD. Moreover, the use of the dual- or tri-agonist GLP-1-based mimetics may provide combinatory effects that are even more powerful than GLP-1R agonism alone. We advocate for further investigations into the repurposing of GLP-1R agonists and the development of classes of multi-agonists for PD treatment.",2020,"Many GLP-1R agonists are FDA approved for the treatment of metabolic disorders, and hence can be rapidly repositioned for PD.","[""Parkinson's disease"", 'humans with moderate PD']","['Glucagon-like peptide-1 (GLP-1)-based receptor agonists', 'placebo']",['cognition motor functions'],"[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}]","[{'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C2987634', 'cui_str': 'Receptor agonist'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}]",,0.0631103,"Many GLP-1R agonists are FDA approved for the treatment of metabolic disorders, and hence can be rapidly repositioned for PD.","[{'ForeName': 'Elliot J', 'Initials': 'EJ', 'LastName': 'Glotfelty', 'Affiliation': 'Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health , Baltimore, MD, USA.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Olson', 'Affiliation': 'Department of Neuroscience, Karolinska Institutet , Stockholm, Sweden.'}, {'ForeName': 'Tobias E', 'Initials': 'TE', 'LastName': 'Karlsson', 'Affiliation': 'Department of Neuroscience, Karolinska Institutet , Stockholm, Sweden.'}, {'ForeName': 'Yazhou', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health , Baltimore, MD, USA.'}, {'ForeName': 'Nigel H', 'Initials': 'NH', 'LastName': 'Greig', 'Affiliation': 'Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health , Baltimore, MD, USA.'}]",Expert opinion on investigational drugs,['10.1080/13543784.2020.1764534'] 989,28332246,Weight management in adults with intellectual and developmental disabilities: A randomized controlled trial of two dietary approaches.,"BACKGROUND The prevalence of obesity among individuals with intellectual and developmental disabilities (IDD) is equal to or greater than the general population. METHODS Overweight/obese adults (BMI ≥25 kg/m 2 ) with mild-to-moderate intellectual and developmental disabilities were randomized to an enhanced stop light diet (eSLD = SLD + portion-controlled meals, n = 78) or a conventional diet (CD, n = 72) for an 18 months trial (6 months weight loss, 12 months maintenance). Participants were asked to increase physical activity (150 min/week), self-monitor diet and physical activity and attend counselling/educational sessions during monthly home visits. RESULTS Weight loss (6 months) was significantly greater in the eSLD (-7.0% ± 5.0%) compared with the CD group (-3.8% ± 5.1%, p < .001). However, at 18 months, weight loss between groups did not differ significantly (eSLD = -6.7% ± 8.3%; CD = 6.4% ± 8.6%; p = .82). CONCLUSION The eSLD and CD provided clinically meaningful weight loss over 18 months in adults with intellectual and developmental disabilities.",2018,"However, at 18 months, weight loss between groups did not differ significantly (eSLD = -6.7% ± 8.3%; CD = 6.4% ± 8.6%; p = .82). ","['individuals with intellectual and developmental disabilities (IDD', 'adults with intellectual and developmental disabilities', 'Overweight/obese adults (BMI ≥25\xa0kg/m 2 ) with mild-to-moderate intellectual and developmental disabilities']","['self-monitor diet and physical activity and attend counselling/educational sessions during monthly home visits', 'conventional diet', 'SLD\xa0+\xa0portion-controlled meals, n\xa0', 'enhanced stop light diet (eSLD\xa0', 'Weight management']","['meaningful weight loss', 'physical activity', 'weight loss', 'Weight loss']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0008073', 'cui_str': 'Child Development Disorders'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0341618', 'cui_str': 'Counsel (occupation)'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C0020043', 'cui_str': 'Home Visits'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0450446', 'cui_str': 'Stops (attribute)'}, {'cui': 'C0419181', 'cui_str': 'Light diet (finding)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}]","[{'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]",,0.0319586,"However, at 18 months, weight loss between groups did not differ significantly (eSLD = -6.7% ± 8.3%; CD = 6.4% ± 8.6%; p = .82). ","[{'ForeName': 'Lauren T', 'Initials': 'LT', 'LastName': 'Ptomey', 'Affiliation': 'Cardiovascular Research Institute, Department of Internal Medicine, The\xa0University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Richard R', 'Initials': 'RR', 'LastName': 'Saunders', 'Affiliation': 'The Schiefelbusch Institute for Lifespan Studies, The University of Kansas-Lawrence, Lawrence, KS, USA.'}, {'ForeName': 'Muriel', 'Initials': 'M', 'LastName': 'Saunders', 'Affiliation': 'The Schiefelbusch Institute for Lifespan Studies, The University of Kansas-Lawrence, Lawrence, KS, USA.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Washburn', 'Affiliation': 'Cardiovascular Research Institute, Department of Internal Medicine, The\xa0University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Matthew S', 'Initials': 'MS', 'LastName': 'Mayo', 'Affiliation': 'Department of Biostatistics, The University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Debra K', 'Initials': 'DK', 'LastName': 'Sullivan', 'Affiliation': 'Department of Dietetics and Nutrition, The University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Cheryl A', 'Initials': 'CA', 'LastName': 'Gibson', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Jeannine R', 'Initials': 'JR', 'LastName': 'Goetz', 'Affiliation': 'Department of Dietetics and Nutrition, The University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Jeff J', 'Initials': 'JJ', 'LastName': 'Honas', 'Affiliation': 'Cardiovascular Research Institute, Department of Internal Medicine, The\xa0University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Erik A', 'Initials': 'EA', 'LastName': 'Willis', 'Affiliation': 'Cardiovascular Research Institute, Department of Internal Medicine, The\xa0University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Jessica C', 'Initials': 'JC', 'LastName': 'Danon', 'Affiliation': 'Cardiovascular Research Institute, Department of Internal Medicine, The\xa0University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Ron', 'Initials': 'R', 'LastName': 'Krebill', 'Affiliation': 'Department of Biostatistics, The University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Joseph E', 'Initials': 'JE', 'LastName': 'Donnelly', 'Affiliation': 'Cardiovascular Research Institute, Department of Internal Medicine, The\xa0University of Kansas Medical Center, Kansas City, KS, USA.'}]",Journal of applied research in intellectual disabilities : JARID,['10.1111/jar.12348'] 990,28202108,[Clinical efficacy of pulmonary surfactant combined with budesonide for preventing bronchopulmonary dysplasia in very low birth weight infants].,"OBJECTIVE To explore the clinical efficacy of intratracheal instillation of pulmonary surfactant (PS) combined with budesonide for preventing bronchopulmonary dysplasia (BPD) in very low birth weight (VLBW) infants. METHODS Thirty VLBW infants with gestational age <32 weeks who developed neonatal respiratory distress syndrome (NRDS) (grade III-IV) suffering from intrauterine infection were randomly assigned into a PS + budesonide group and a PS alone group. The changes were compared between the two groups in arterial blood gas indexes, oxygenation index (OI), duration of mechanical ventilation, duration of oxygen supplementation, incidence of BPD, mortality rate at 36 weeks corrected gestational age and incidences of other complications except BPD. RESULTS Compared with the PS alone group, the PS+budesonide group had a lower incidence of BPD, shorter duration of mechanical ventilation and oxygen supplementation (P<0.05). On the 2nd to 6th day after treatment, the PS+budesonide group had higher pH value of arterial blood gas and OI and lower carbon dioxide partial pressure compared with the PS alone group (P<0.05). There were no significant differences in the mortality rate at 36 weeks corrected gestational age and the incidences of other complications except BPD between the two groups (P>0.05). CONCLUSIONS Intratracheal instillation of PS combined with budesonide can effectively reduce the incidence of BPD in VLBW premature infants with severe NRDS.",2017,"There were no significant differences in the mortality rate at 36 weeks corrected gestational age and the incidences of other complications except BPD between the two groups (P>0.05). ","['very low birth weight infants', 'Thirty VLBW infants with gestational age <32 weeks who developed neonatal respiratory distress syndrome (NRDS) (grade III-IV) suffering from intrauterine infection', 'bronchopulmonary dysplasia (BPD) in very low birth weight (VLBW) infants', 'VLBW premature infants with severe NRDS']","['PS alone group', 'pulmonary surfactant combined with budesonide', 'PS + budesonide', 'budesonide', 'pulmonary surfactant (PS) combined with budesonide']","['higher pH value of arterial blood gas and OI and lower carbon dioxide partial pressure', 'arterial blood gas indexes, oxygenation index (OI), duration of mechanical ventilation, duration of oxygen supplementation, incidence of BPD, mortality rate', 'mortality rate', 'BPD, shorter duration of mechanical ventilation and oxygen supplementation', 'bronchopulmonary dysplasia', 'incidence of BPD']","[{'cui': 'C0282667', 'cui_str': 'Infant, Very Low Birth Weight'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0035220', 'cui_str': 'Respiratory Distress Syndrome, Newborn'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C1112157', 'cui_str': 'Intrauterine infection'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary Dysplasia'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0034085', 'cui_str': 'Pulmonary Surfactants'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0054201', 'cui_str': 'Budesonide'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0150411', 'cui_str': 'Blood gases, arterial measurement (procedure)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0030604', 'cui_str': 'Partial Pressure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1278185', 'cui_str': 'Oxygenation index'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0919655', 'cui_str': 'Oxygen supplementation'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C0439593', 'cui_str': 'Short duration (qualifier value)'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary Dysplasia'}]",30.0,0.0417484,"There were no significant differences in the mortality rate at 36 weeks corrected gestational age and the incidences of other complications except BPD between the two groups (P>0.05). ","[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Pan', 'Affiliation': 'Department of Pediatrics, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei 230001, China. chenmingwu01@163.com.'}, {'ForeName': 'Ming-Wu', 'Initials': 'MW', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Wen-Quan', 'Initials': 'WQ', 'LastName': 'Ni', 'Affiliation': ''}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Fang', 'Affiliation': ''}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Jia-Hua', 'Initials': 'JH', 'LastName': 'Pan', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 991,28202120,[Management of positional head deformity in 31 infants].,"OBJECTIVE To investigate the clinical effect of postural correction training and helmet therapy in the treatment of moderate-severe positional head deformity defined as asymmetric head shape in infants. METHODS A total of 31 infants who were diagnosed with moderate-severe plagiocephaly and/or brachiocephaly were enrolled. According to the different treatment methods, the infants were divided into helmet therapy group with 11 infants and postural correction training group with 20 infants. The cranial vault asymmetry index (CVAI), cephalic ratio (CR), and head circumference growth were compared between the two groups before and after treatment. RESULTS Compared with the postural correction training group, the helmet therapy group had significantly lower CVAI and CR after treatment. The helmet therapy group had significantly better improvements in CVAI and CR after treatment compared with the postural correction training group (CVAI difference: 6.0±1.9 vs 0.7±0.8, P=0.001; CR difference: 0.047±0.009 vs 0.008±0.005, P<0.001). There was no significant difference in head circumference growth between the two groups (P=0.55). CONCLUSIONS Helmet therapy has a significantly better effect in the treatment of moderate-severe positional head deformity than postural correction training in infants. Helmet therapy does not limit head circumference growth.",2017,"The helmet therapy group had significantly better improvements in CVAI and CR after treatment compared with the postural correction training group (CVAI difference: 6.0±1.9 vs 0.7±0.8, P=0.001;","['group with 20 infants', '31 infants', 'moderate-severe positional head deformity defined as asymmetric head shape in infants', '31 infants who were diagnosed with moderate-severe plagiocephaly and/or brachiocephaly were enrolled']","['helmet therapy group with 11 infants and postural correction training', 'postural correction training and helmet therapy', 'postural correction training', 'Helmet therapy']","['CVAI and CR', 'cranial vault asymmetry index (CVAI), cephalic ratio (CR), and head circumference growth', 'head circumference growth']","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0854297', 'cui_str': 'Head deformity'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0265529', 'cui_str': 'Plagiocephaly'}, {'cui': 'C0522512', 'cui_str': 'With shape (attribute)'}]","[{'cui': 'C0018884', 'cui_str': 'Helmets'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0205278', 'cui_str': 'Postural (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C3163632', 'cui_str': 'Cranial'}, {'cui': 'C0332514', 'cui_str': 'Asymmetry (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205096', 'cui_str': 'Cephalic (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0262499', 'cui_str': 'Head circumference (observable entity)'}, {'cui': 'C0018270', 'cui_str': 'Growth'}]",31.0,0.0235163,"The helmet therapy group had significantly better improvements in CVAI and CR after treatment compared with the postural correction training group (CVAI difference: 6.0±1.9 vs 0.7±0.8, P=0.001;","[{'ForeName': 'Wei-Wei', 'Initials': 'WW', 'LastName': 'Pan', 'Affiliation': 'Department of Pediatrics, Peking University Third Hospital, Beijing 100191, China. tongxm2007@126.com.'}, {'ForeName': 'Xiao-Mei', 'Initials': 'XM', 'LastName': 'Tong', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 992,27817767,[Clinical effects of different ways of mechanical ventilation combined with pulmonary surfactant in treatment of acute lung injury/acute respiratory distress syndrome in neonates: a comparative analysis].,"OBJECTIVE To compare the therapeutic effects of high-frequency oscillatory ventilation+pulmonary surfactant (HFOV+PS), conventional mechanical ventilation+pulmonary surfactant (CMV+PS), and conventional mechanical ventilation (CMV) alone for acute lung injury/acute respiratory distress syndrome (ALI/ARDS) in neonates. METHODS A total of 136 neonates with ALI/ARDS were enrolled, among whom 73 had ALI and 63 had ARDS. They were divided into HFOV+PS group (n=45), CMV+PS group (n=53), and CMV group (n=38). The neonates in the first two groups were given PS at a dose of 70-100 mg/kg. The partial pressure of oxygen (PaO 2 ), partial pressure of carbon dioxide (PaCO 2 ), PaO 2 /fraction of inspired oxygen (FiO 2 ), oxygenation index (OI), and respiratory index (RI) were measured at 0, 12, 24, 48, and 72 hours of mechanical ventilation. RESULTS At 12, 24, and 48 hours of mechanical ventilation, the HFOV+PS group had higher PaO 2 and lower PaCO 2 than the CMV+PS and CMV groups (P<0.05). At 12, 24, 48, and 72 hours of mechanical ventilation, the HFOV+PS group had higher PaO 2 /FiO 2 and lower OI and RI than the CMV+PS and CMV groups (P<0.05). The HFOV+PS group had shorter durations of mechanical ventilation and oxygen use than the CMV+PS and CMV groups (P<0.05). There were no significant differences in the incidence rates of air leakage and intracranial hemorrhage and cure rate between the three groups. CONCLUSIONS In neonates with ALI/ARDS, HFOV combined with PS can improve pulmonary function more effectively and shorten the durations of mechanical ventilation and oxygen use compared with CMV+PS and CMV alone. It does not increase the incidence of complications.",2016,The HFOV+PS group had shorter durations of mechanical ventilation and oxygen use than the CMV+PS and CMV groups (P<0.05).,"['136 neonates with ALI/ARDS were enrolled, among whom 73 had ALI and 63 had ARDS', 'acute lung injury/acute respiratory distress syndrome (ALI/ARDS) in neonates', 'acute lung injury/acute respiratory distress syndrome in neonates']","['HFOV+PS', 'mechanical ventilation combined with pulmonary surfactant', 'CMV', 'CMV+PS', 'high-frequency oscillatory ventilation+pulmonary surfactant (HFOV+PS), conventional mechanical ventilation+pulmonary surfactant (CMV+PS), and conventional mechanical ventilation (CMV) alone']","['shorter durations of mechanical ventilation and oxygen use', 'incidence of complications', 'incidence rates of air leakage and intracranial hemorrhage and cure rate', 'higher PaO 2 /FiO 2 and lower OI and RI', 'partial pressure of oxygen (PaO 2 ), partial pressure of carbon dioxide (PaCO 2 ), PaO 2 /fraction of inspired oxygen (FiO 2 ), oxygenation index (OI), and respiratory index (RI']","[{'cui': 'C4517568', 'cui_str': 'One hundred and thirty-six'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0035222', 'cui_str': 'ARDS, Human'}, {'cui': 'C0242488', 'cui_str': 'Acute Lung Injury'}]","[{'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0034085', 'cui_str': 'Pulmonary Surfactants'}, {'cui': 'C0205212', 'cui_str': 'High frequency (qualifier value)'}, {'cui': 'C4543209', 'cui_str': 'Surfactant'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}]","[{'cui': 'C0439593', 'cui_str': 'Short duration (qualifier value)'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0333257', 'cui_str': 'Air leakage (morphologic abnormality)'}, {'cui': 'C0151699', 'cui_str': 'Intracranial Hemorrhage'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output (observable entity)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0030604', 'cui_str': 'Partial Pressure'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C1278185', 'cui_str': 'Oxygenation index'}, {'cui': 'C0451423', 'cui_str': 'Respiratory index (assessment scale)'}]",136.0,0.113449,The HFOV+PS group had shorter durations of mechanical ventilation and oxygen use than the CMV+PS and CMV groups (P<0.05).,"[{'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Chang', 'Affiliation': 'Department of Neonatology, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, China. lhy5154@163.com.'}, {'ForeName': 'Hong-Yan', 'Initials': 'HY', 'LastName': 'Lu', 'Affiliation': ''}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Xiang', 'Affiliation': ''}, {'ForeName': 'Hou-Ping', 'Initials': 'HP', 'LastName': 'Lan', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 993,27817768,[Clinical effect of high-frequency oscillatory ventilation combined with pulmonary surfactant in treatment of neonatal severe meconium aspiration syndrome complicated by pulmonary hemorrhage].,"OBJECTIVE To study the clinical effect and safety of high-frequency oscillatory ventilation (HFOV) combined with pulmonary surfactant (PS) in the treatment of neonatal severe meconium aspiration syndrome (MAS) complicated by neonatal pulmonary hemorrhage (NPH). METHODS A total of 48 children with severe MAS complicated by NPH were enrolled, and a retrospective analysis was performed for the clinical effects of HFOV+PS (trial group, 25 children) and HFOV alone (control group, 23 children). The blood gas parameters, oxygenation index (OI), PaO 2 /FiO 2 (P/F) value, duration of pulmonary hemorrhage, ventilation time, length of hospital stay, incidence of complications, and outcome were compared between the two groups. RESULTS At 6, 12, 24, and 48 hours after treatment, the trial group had significantly better PaO 2 , OI, and P/F value than the control group (P<0.05). Compared with the control group, the trial group had significantly shortened ventilation time and duration of pulmonary hemorrhage (P<0.05). There were no significant differences in the length of hospital stay, the incidence of complications, and cure rate between the two groups (P>0.05). CONCLUSIONS HFOV combined with PS can better improve oxygenation function and shorten the duration of NPH and ventilation time. Meanwhile, it does not increase the incidence of adverse events. Therefore, it is a safe and effective therapy.",2016,"There were no significant differences in the length of hospital stay, the incidence of complications, and cure rate between the two groups (P>0.05). ","['group, 23 children', 'neonatal severe meconium aspiration syndrome complicated by pulmonary hemorrhage', '48 children with severe MAS complicated by NPH', 'neonatal severe meconium aspiration syndrome (MAS) complicated by neonatal pulmonary hemorrhage (NPH']","['HFOV+PS', 'HFOV alone (control', 'high-frequency oscillatory ventilation combined with pulmonary surfactant', 'high-frequency oscillatory ventilation (HFOV) combined with pulmonary surfactant (PS']","['duration of NPH and ventilation time', 'blood gas parameters, oxygenation index (OI), PaO 2 /FiO 2 (P/F) value, duration of pulmonary hemorrhage, ventilation time, length of hospital stay, incidence of complications, and outcome', 'length of hospital stay, the incidence of complications, and cure rate', 'incidence of adverse events', 'oxygenation function', 'shortened ventilation time and duration of pulmonary hemorrhage', 'PaO 2 , OI, and P/F value']","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0025048', 'cui_str': 'Meconium Aspiration Syndrome'}, {'cui': 'C0231242', 'cui_str': 'Complicated (qualifier value)'}, {'cui': 'C0151701', 'cui_str': 'Pulmonary hemorrhage (disorder)'}, {'cui': 'C1390281', 'cui_str': 'Pulmonary hemorrhage in newborn'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0419017', 'cui_str': 'High frequency oscillatory ventilation (procedure)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0034085', 'cui_str': 'Pulmonary Surfactants'}]","[{'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0005800', 'cui_str': 'Blood Gas Analysis'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1278185', 'cui_str': 'Oxygenation index'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output (observable entity)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0151701', 'cui_str': 'Pulmonary hemorrhage (disorder)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0031843', 'cui_str': 'function'}]",48.0,0.0316093,"There were no significant differences in the length of hospital stay, the incidence of complications, and cure rate between the two groups (P>0.05). ","[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Department of Neonatology, Maternal and Child Health Care Hospital of Xiamen, Xiamen, Fujian 361000, China. xinzhufj@163.com.'}, {'ForeName': 'Xin-Zhu', 'Initials': 'XZ', 'LastName': 'Lin', 'Affiliation': ''}, {'ForeName': 'Zhi', 'Initials': 'Z', 'LastName': 'Zheng', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 994,27751214,[Effects of virtual reality training on limb movement in children with spastic diplegia cerebral palsy].,"OBJECTIVE To study the effects of virtual reality (VR) training on the gross motor function of the lower limb and the fine motor function of the upper limb in children with spastic diplegia cerebral palsy. METHODS Thirty-five children with spastic diplegia cerebral palsy were randomly assigned to VR training group (n=19) and conventional training group (n=16). The conventional training group received conventional physical therapy and occupational therapy for three months. The VR training group received VR training and occupational therapy for three months. Grip and visual-motor integration subtests in Peabody Developmental Motor Scales-2 were used to evaluate the fine movement in patients before and after treatment. The D and E domains of the 88-item version of the Gross Motor Function Measure (GMFM-88), Modified Ashworth Scale (MAS), and Berg Balance Scale (BBS) were used to evaluate the gross movement in patients before and after treatment. RESULTS Before treatment, there were no significant differences in grip, visual-motor integration, fine motor development quotient, scores of D and E domains of GMFM-88, MAS score, or BBS score between the two groups (P>0.05). After treatment, all the indices were significantly improved in the VR training group compared with the conventional training group (P<0.05). CONCLUSIONS VR training can effectively improve the gross motor function of the lower limb and the fine motor function of the upper limb in children with spastic diplegia cerebral palsy.",2016,"Before treatment, there were no significant differences in grip, visual-motor integration, fine motor development quotient, scores of D and E domains of GMFM-88, MAS score, or BBS score between the two groups (P>0.05).","['Thirty-five children with spastic diplegia cerebral palsy', 'children with spastic diplegia cerebral palsy']","['VR training and occupational therapy', 'conventional training group received conventional physical therapy and occupational therapy', 'VR training', 'virtual reality (VR) training', 'conventional training group', 'virtual reality training']","['Gross Motor Function Measure (GMFM-88), Modified Ashworth Scale (MAS), and Berg Balance Scale (BBS', 'limb movement', 'grip, visual-motor integration, fine motor development quotient, scores of D and E domains of GMFM-88, MAS score, or BBS score']","[{'cui': 'C4319605', 'cui_str': 'Thirty-five'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0270804', 'cui_str': 'Cerebral palsy, spastic, diplegic'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1318464', 'cui_str': 'Occupational Therapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}]","[{'cui': 'C0677549', 'cui_str': 'Gross motor functions (observable entity)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C4707572', 'cui_str': 'Modified Ashworth Scale (assessment scale)'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C0015385', 'cui_str': 'Limbs'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0600117', 'cui_str': 'Does grip (finding)'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0205232', 'cui_str': 'Fine (qualifier value)'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3541951', 'cui_str': 'Domain'}]",35.0,0.00993484,"Before treatment, there were no significant differences in grip, visual-motor integration, fine motor development quotient, scores of D and E domains of GMFM-88, MAS score, or BBS score between the two groups (P>0.05).","[{'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Ren', 'Affiliation': 'Department of Rehabilitation, Sichuan Vocational College of Health and Rehabilitation, Zigong, Sichuan 643000, China. fensal@163.com.'}, {'ForeName': 'Xiao-Ming', 'Initials': 'XM', 'LastName': 'Gong', 'Affiliation': ''}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Xiu-Hui', 'Initials': 'XH', 'LastName': 'Chen', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 995,27324534,[Efficacy of heated humidified high-flow nasal cannula in preterm infants aged less than 32 weeks after ventilator weaning].,"OBJECTIVE To investigate the efficacy of heated humidified high-flow nasal cannula (HHHFNC) and nasal continuous positive airway pressure (nCPAP) in preterm infants aged 26-31(+6) weeks with respiratory distress syndrome after ventilator weaning. METHODS A total of 161 preterm infants were randomly divided into two groups after ventilator weaning: HHHFNC treatment (n=79) and nCPAP treatment (n=82). The two groups were subdivided into 26-28(+6) weeks and 29-31+6 weeks groups according to the gestational age. The treatment failure rate, reintubation rate within 7 days after extubation, incidence of complications, and mortality during hospitalization were compared between the two groups. RESULTS The treatment failure rate and reintubation rate showed no significant differences between the HHHFNC and nCPAP groups. The preterm infants aged 26-28(+6) weeks in the HHHFNC group had a significantly higher treatment failure rate than those in the nCPAP group (P<0.05), while the reintubation rate showed no significant difference. As for the preterm infants aged 29-31(+6) weeks, the treatment failure rate and reintubation rate showed no significant differences between the two groups. The incidence of complications and mortality showed no significant differences between the HHHFNC and nCPAP groups. CONCLUSIONS In preterm infants aged 29-31(+6) weeks, HHHFNC has a similar efficacy as nCPAP after ventilator weaning, while in those aged less than 29 weeks, HHHFNC should be used with great caution if selected as the first-line noninvasive respiratory support.",2016,"In preterm infants aged 29-31(+6) weeks, HHHFNC has a similar efficacy as nCPAP after ventilator weaning, while in those aged less than 29 weeks, HHHFNC should be used with great caution if selected as the first-line noninvasive respiratory support.","['161 preterm infants', 'preterm infants aged 26-31(+6) weeks with respiratory distress syndrome after ventilator weaning', 'preterm infants aged less than 32 weeks after ventilator weaning', 'preterm infants aged 29-31(+6']","['ventilator weaning: HHHFNC treatment', 'nCPAP treatment', 'heated humidified high-flow nasal cannula (HHHFNC) and nasal continuous positive airway pressure (nCPAP', 'nCPAP', 'HHHFNC', 'heated humidified high-flow nasal cannula']","['incidence of complications and mortality', 'treatment failure rate', 'treatment failure rate, reintubation rate within 7 days after extubation, incidence of complications, and mortality during hospitalization', 'failure rate and reintubation rate']","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0035220', 'cui_str': 'Respiratory Distress Syndrome, Newborn'}, {'cui': 'C1112479', 'cui_str': 'Respirator Weaning'}]","[{'cui': 'C1112479', 'cui_str': 'Respirator Weaning'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannula'}, {'cui': 'C1258045', 'cui_str': 'Nasal Continuous Positive Airway Pressure'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0162643'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}]",161.0,0.0377066,"In preterm infants aged 29-31(+6) weeks, HHHFNC has a similar efficacy as nCPAP after ventilator weaning, while in those aged less than 29 weeks, HHHFNC should be used with great caution if selected as the first-line noninvasive respiratory support.","[{'ForeName': 'Wen-Qing', 'Initials': 'WQ', 'LastName': 'Kang', 'Affiliation': ""Neonatal Intensive Care Unit, Zhengzhou Children's Hospital, Zhengzhou 450018, China. xionghong57@126.com.""}, {'ForeName': 'Bang-Li', 'Initials': 'BL', 'LastName': 'Xu', 'Affiliation': ''}, {'ForeName': 'Da-Peng', 'Initials': 'DP', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Yao-Dong', 'Initials': 'YD', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Guo', 'Affiliation': ''}, {'ForeName': 'Zhao-Hui', 'Initials': 'ZH', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Yan-Juan', 'Initials': 'YJ', 'LastName': 'Zhou', 'Affiliation': ''}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Xiong', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 996,27655538,[Therapeutic effects of zinc supplement as adjunctive therapy in infants and young children with rotavirus enteritis].,"OBJECTIVE To investigate the therapeutic effects of oral zinc supplement in infants and young children with rotavirus enteritis, and its preventive effects against diarrhea recurrence within 3 months after treatment. METHODS A total of 103 infants and young children with rotavirus enteritis were randomly divided into zinc supplement group (n=51) and conventional treatment group (n=52). Both groups were equally treated with a comprehensive therapy, besides which the zinc supplement group received zinc gluconate granules for 10 days. The treatment outcomes were examined at 72 hours after treatment, and the time required for the disappearance of positive symptoms and the recovery of injured extra-intestinal organs were determined. In addition, these patients were followed up for 3 months to determine the incidence of diarrhea recurrence after treatment. RESULTS The overall response rate in the zinc supplement group was significantly higher than that in the conventional treatment group (90% vs 75%; P<0.05). The durations of diarrhea, high fever, and vomiting in the zinc supplement group were significantly shorter than that in the conventional treatment group (P<0.05). In addition, the recurrence rate of diarrhea and the incidence of severe diarrhea within 3 months after treatment in the zinc supplement group were significantly lower than in the conventional treatment group (P<0.05). CONCLUSIONS Oral zinc supplement as adjunctive therapy is effective in treating infants and young children with rotavirus enteritis, and reducing the incidence and severity of diarrhea recurrence in the subsequent 3 months.",2016,"The durations of diarrhea, high fever, and vomiting in the zinc supplement group were significantly shorter than that in the conventional treatment group (P<0.05).","['infants and young children with rotavirus enteritis', '103 infants and young children with rotavirus enteritis']","['zinc supplement', 'oral zinc supplement', 'Oral zinc supplement', 'zinc supplement group (n=51) and conventional treatment', 'zinc supplement group received zinc gluconate granules']","['durations of diarrhea, high fever, and vomiting', 'recurrence rate of diarrhea and the incidence of severe diarrhea', 'time required for the disappearance of positive symptoms and the recovery of injured extra-intestinal organs', 'diarrhea recurrence', 'overall response rate']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0347854', 'cui_str': 'Enteritis due to rotavirus'}, {'cui': 'C4517526', 'cui_str': 'One hundred and three'}]","[{'cui': 'C3541396', 'cui_str': 'Zinc'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0149381', 'cui_str': 'Zinc Gluconate'}, {'cui': 'C3853573', 'cui_str': 'Granules'}]","[{'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1443924', 'cui_str': 'Severe diarrhea'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0021853', 'cui_str': 'Intestines'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",103.0,0.0292203,"The durations of diarrhea, high fever, and vomiting in the zinc supplement group were significantly shorter than that in the conventional treatment group (P<0.05).","[{'ForeName': 'Chao-Xiong', 'Initials': 'CX', 'LastName': 'Jiang', 'Affiliation': ""Department of Pediatrics, Second People's Hospital of Shanghai, Shanghai 200011, China. chundixu55@163.com.""}, {'ForeName': 'Chun-Di', 'Initials': 'CD', 'LastName': 'Xu', 'Affiliation': ''}, {'ForeName': 'Chang-Qing', 'Initials': 'CQ', 'LastName': 'Yang', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 997,27491778,"Beneficial effects of dark chocolate on exercise capacity in sedentary subjects: underlying mechanisms. A double blind, randomized, placebo controlled trial.","In heart failure patients the consumption of (-)-epicatechin ((-)-Epi)-rich cocoa can restore skeletal muscle (SkM) mitochondrial structure and decrease biomarkers of oxidative stress. However, nothing is known about its effects on exercise capacity and underlying mechanisms in normal, sedentary subjects. Twenty normal, sedentary subjects (∼50 years old) were randomized to placebo or dark chocolate (DC) groups and consumed 20 g of the products for 3 months. Subjects underwent before and after treatment, bicycle ergometry to assess VO2 max and work, SkM biopsy to assess changes in mitochondrial density, function and oxidative stress and blood sampling to assess metabolic endpoints. Seventeen subjects completed the trial. In the DC group (n = 9), VO2 max increased (17% increase, p = 0.056) as well as maximum work (watts) achieved (p = 0.026) with no changes with placebo (n = 8). The DC group evidenced increases in HDL levels (p = 0.005) and decreased triglycerides (p = 0.07). With DC, SkM evidenced significant increases in protein levels for LKB1, AMPK and PGC1α and in their active forms (phosphorylated AMPK and LKB1) as well as in citrate synthase activity while no changes were observed in mitochondrial density. With DC, significant increases in SkM reduced glutathione levels and decreases in protein carbonylation were observed. Improvements in maximum work achieved and VO2 max may be due to DC activation of upstream control systems and enhancement of SkM mitochondria efficiency. Larger clinical studies are warranted to confirm these observations.",2016,The DC group evidenced increases in HDL levels (p = 0.005) and decreased triglycerides (p = 0.07).,"['sedentary subjects', 'Seventeen subjects completed the trial', 'normal, sedentary subjects', 'Twenty normal, sedentary subjects (∼50 years old']","['placebo', 'dark chocolate', 'bicycle ergometry to assess VO2 max and work, SkM biopsy', 'placebo or dark chocolate (DC', 'epicatechin ((-)-Epi)-rich cocoa']","['mitochondrial density, function and oxidative stress and blood sampling to assess metabolic endpoints', 'decreased triglycerides', 'HDL levels', 'SkM reduced glutathione levels', 'VO2 max', 'protein levels for LKB1, AMPK and PGC1α and in their active forms (phosphorylated AMPK and LKB1', 'exercise capacity']","[{'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0450331', 'cui_str': '17 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3853217', 'cui_str': 'Dark chocolate (substance)'}, {'cui': 'C0857787', 'cui_str': 'Bicycle ergometry'}, {'cui': 'C1701256', 'cui_str': 'bis(acetylacetonato)oxovanadium(IV)'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0014485', 'cui_str': '(2R,3R)-2-(3,4-Dihydroxyphenyl)-3,5,7-chromanetriol'}, {'cui': 'C0267963', 'cui_str': 'Pancreatic Insufficiency'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C4521844', 'cui_str': 'Cocoa'}]","[{'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0005834', 'cui_str': 'Blood Specimen Collection'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0034917', 'cui_str': 'Reduced Glutathione'}, {'cui': 'C1701256', 'cui_str': 'bis(acetylacetonato)oxovanadium(IV)'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0428479', 'cui_str': 'Protein level - finding'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]",20.0,0.128552,The DC group evidenced increases in HDL levels (p = 0.005) and decreased triglycerides (p = 0.07).,"[{'ForeName': 'Pam R', 'Initials': 'PR', 'LastName': 'Taub', 'Affiliation': 'University of California, San Diego, School of Medicine, USA. fvillarr@ucsd.edu.'}, {'ForeName': 'Israel', 'Initials': 'I', 'LastName': 'Ramirez-Sanchez', 'Affiliation': ''}, {'ForeName': 'Minal', 'Initials': 'M', 'LastName': 'Patel', 'Affiliation': ''}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Higginbotham', 'Affiliation': ''}, {'ForeName': 'Aldo', 'Initials': 'A', 'LastName': 'Moreno-Ulloa', 'Affiliation': ''}, {'ForeName': 'Luis Miguel', 'Initials': 'LM', 'LastName': 'Román-Pintos', 'Affiliation': ''}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Phillips', 'Affiliation': ''}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Perkins', 'Affiliation': ''}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Ceballos', 'Affiliation': ''}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Villarreal', 'Affiliation': ''}]",Food & function,['10.1039/c6fo00611f'] 998,32492293,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.,"BACKGROUND Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the standard of care is observation and quarantine. Whether hydroxychloroquine can prevent symptomatic infection after SARS-CoV-2 exposure is unknown. METHODS We conducted a randomized, double-blind, placebo-controlled trial across the United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis. We enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure). Within 4 days after exposure, we randomly assigned participants to receive either placebo or hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days). The primary outcome was the incidence of either laboratory-confirmed Covid-19 or illness compatible with Covid-19 within 14 days. RESULTS We enrolled 821 asymptomatic participants. Overall, 87.6% of the participants (719 of 821) reported a high-risk exposure to a confirmed Covid-19 contact. The incidence of new illness compatible with Covid-19 did not differ significantly between participants receiving hydroxychloroquine (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]); the absolute difference was -2.4 percentage points (95% confidence interval, -7.0 to 2.2; P = 0.35). Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported. CONCLUSIONS After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. (Funded by David Baszucki and Jan Ellison Baszucki and others; ClinicalTrials.gov number, NCT04308668.).",2020,"Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported. ","['United States and parts of Canada testing', '821 asymptomatic participants', 'enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure']","['placebo', 'Hydroxychloroquine', 'placebo or hydroxychloroquine', 'hydroxychloroquine']","['Side effects', 'incidence of new illness compatible with Covid-19', 'incidence of either laboratory-confirmed Covid-19 or illness compatible with Covid-19 within 14 days', 'serious adverse reactions']","[{'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0454979', 'cui_str': 'Part of Canada'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0028798', 'cui_str': 'Exposure, Occupational'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0183251', 'cui_str': 'Shield'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}]",821.0,0.751633,"Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported. ","[{'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Boulware', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Matthew F', 'Initials': 'MF', 'LastName': 'Pullen', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Ananta S', 'Initials': 'AS', 'LastName': 'Bangdiwala', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Katelyn A', 'Initials': 'KA', 'LastName': 'Pastick', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Sarah M', 'Initials': 'SM', 'LastName': 'Lofgren', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Okafor', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Caleb P', 'Initials': 'CP', 'LastName': 'Skipper', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Alanna A', 'Initials': 'AA', 'LastName': 'Nascene', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Melanie R', 'Initials': 'MR', 'LastName': 'Nicol', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Abassi', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Nicole W', 'Initials': 'NW', 'LastName': 'Engen', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Cheng', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Derek', 'Initials': 'D', 'LastName': 'LaBar', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Sylvain A', 'Initials': 'SA', 'LastName': 'Lother', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Lauren J', 'Initials': 'LJ', 'LastName': 'MacKenzie', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Glen', 'Initials': 'G', 'LastName': 'Drobot', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Marten', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Zarychanski', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'Kelly', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Ilan S', 'Initials': 'IS', 'LastName': 'Schwartz', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Emily G', 'Initials': 'EG', 'LastName': 'McDonald', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Radha', 'Initials': 'R', 'LastName': 'Rajasingham', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Todd C', 'Initials': 'TC', 'LastName': 'Lee', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Kathy H', 'Initials': 'KH', 'LastName': 'Hullsiek', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}]",The New England journal of medicine,['10.1056/NEJMoa2016638'] 999,29169546,Telehealth electronic monitoring to reduce postdischarge complications and surgical site infections after arterial revascularization with groin incision.,"It is intuitive that postdischarge surgical complications are associated with increased patient dissatisfaction, and are directly associated with an increase in medical expenditures. It is also easy to make the connection that many post-hospital discharge surgical complications, including surgical site infections (SSIs), could be influenced or exacerbated by patient comorbidities. The authors of a recent study reported that female gender, obesity, diabetes, smoking, hypertension, coronary artery disease, critical limb ischemia, chronic obstructive pulmonary disease, dyspnea, and neurologic disease were significant predictors of SSIs after vascular reconstruction was performed. The main concern for optimal patient care, especially in geographically isolated areas of West Virginia, is to have early, expeditious, and prompt diagnosis of complications and SSI. This adjunct to existing approaches could lead to improved outcomes and patient satisfaction, minimizing third-party interventions and decreasing the total cost of care. It seems reasonable to believe that monitoring using telehealth technology and managing the general health care of patients after a hospital vascular intervention will improve overall health and reduce 30-day readmissions and SSIs.",2017,"This adjunct to existing approaches could lead to improved outcomes and patient satisfaction, minimizing third-party interventions and decreasing the total cost of care.",['surgical site infections after arterial revascularization with groin incision'],['Telehealth electronic monitoring'],['total cost of care'],"[{'cui': 'C0038941', 'cui_str': 'Postoperative Wound Infection'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0018246', 'cui_str': 'Groin'}, {'cui': 'C0184898', 'cui_str': 'Incision - attribute'}]","[{'cui': 'C1328956', 'cui_str': 'eHealth'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",,0.0261742,"This adjunct to existing approaches could lead to improved outcomes and patient satisfaction, minimizing third-party interventions and decreasing the total cost of care.","[{'ForeName': 'Albeir Y', 'Initials': 'AY', 'LastName': 'Mousa', 'Affiliation': 'Department of Surgery, Robert C. Byrd Health Sciences Center/West Virginia University, Charleston Area Medical Center, Vascular Center of Excellence, Charleston, WVa. Electronic address: amousa@hsc.wvu.edu.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Broce', 'Affiliation': 'Center for Health Services and Outcomes Research, Charleston Area Medical Center Health Education and Research Institute, Charleston, WVa.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'Davis', 'Affiliation': 'Center for Health Services and Outcomes Research, Charleston Area Medical Center Health Education and Research Institute, Charleston, WVa.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'McKee', 'Affiliation': 'Partners in Health Network Charleston, Charleston, WVa.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Yacoub', 'Affiliation': 'Department of Surgery, Robert C. Byrd Health Sciences Center/West Virginia University, Charleston Area Medical Center, Vascular Center of Excellence, Charleston, WVa.'}]",Journal of vascular surgery,['10.1016/j.jvs.2017.07.063'] 1000,27412548,[Influence of delayed cord clamping on preterm infants with a gestational age of <32 weeks].,"OBJECTIVE To investigate the influence of delayed cord clamping (DCC) on preterm infants with a gestational age of <32 weeks. METHODS Ninety preterm infants with a gestational age of <32 weeks delivered naturally from January to December, 2015 were enrolled and randomly divided into DCC group (46 infants) and immediate cord clamping (ICC) group (44 infants). The routine blood test results, total amount of red blood cell transfusion, blood gas parameters, mean arterial pressure, bilirubin peak, total time of phototherapy, and incidence rates of necrotizing enterocolitis, late-onset sepsis, intracranial hemorrhage, retinopathy, and bronchopulmonary dysplasia were compared between the two groups. RESULTS Compared with the ICC group, the DCC group had significantly higher levels of hemoglobin, hematocrit, mean arterial pressure, and standard base excess (P<0.05), as well as a significantly lower percentage of preterm infants who underwent volume expansion and dopamine treatment and a significantly lower amount of red blood cell transfusion (P<0.05). The body temperature, pH value, HCO3(-) concentration, serum bilirubin peak, total time of phototherapy, and incidence rates of late-onset sepsis, retinopathy, grade≥2 intracranial hemorrhage, and grade≥2 neonatal necrotizing enterocolitis showed no significant differences between the two groups (P>0.05). CONCLUSIONS DCC is a safe clinical intervention and can improve the prognosis of preterm infants with a gestational age of <32 weeks.",2016,"Compared with the ICC group, the DCC group had significantly higher levels of hemoglobin, hematocrit, mean arterial pressure, and standard base excess (P<0.05), as well as a significantly lower percentage of preterm infants who underwent volume expansion and dopamine treatment and a significantly lower amount of red blood cell transfusion (P<0.05).","['Ninety preterm infants with a gestational age of <32 weeks delivered naturally from January to December, 2015 were enrolled and randomly divided into DCC group (46 infants) and', 'preterm infants with a gestational age of <32 weeks', 'group (44 infants']","['ICC', 'DCC', 'delayed cord clamping', 'delayed cord clamping (DCC', 'immediate cord clamping (ICC']","['total amount of red blood cell transfusion, blood gas parameters, mean arterial pressure, bilirubin peak, total time of phototherapy, and incidence rates of necrotizing enterocolitis, late-onset sepsis, intracranial hemorrhage, retinopathy, and bronchopulmonary dysplasia', 'levels of hemoglobin, hematocrit, mean arterial pressure, and standard base excess (P<0.05', 'body temperature, pH value, HCO3(-) concentration, serum bilirubin peak, total time of phototherapy, and incidence rates of late-onset sepsis, retinopathy, grade≥2 intracranial hemorrhage, and grade≥2 neonatal necrotizing enterocolitis', 'red blood cell transfusion']","[{'cui': 'C3816959', 'cui_str': 'Ninety'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C3698497', 'cui_str': 'Axillary web syndrome'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0086252', 'cui_str': 'Red Blood Cell Transfusion'}, {'cui': 'C0005800', 'cui_str': 'Blood Gas Analysis'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin IX alpha'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0031765', 'cui_str': 'Photoradiation Therapy'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0520459', 'cui_str': 'Necrotizing Enterocolitis'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}, {'cui': 'C0151699', 'cui_str': 'Intracranial Hemorrhage'}, {'cui': 'C0035309', 'cui_str': 'Retinal Diseases'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary Dysplasia'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0518014', 'cui_str': 'Hematocrit - finding'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0201985', 'cui_str': 'Base excess - observation'}, {'cui': 'C0886414', 'cui_str': 'Body temperature'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0428441', 'cui_str': 'Serum bilirubin measurement'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}]",90.0,0.0260559,"Compared with the ICC group, the DCC group had significantly higher levels of hemoglobin, hematocrit, mean arterial pressure, and standard base excess (P<0.05), as well as a significantly lower percentage of preterm infants who underwent volume expansion and dopamine treatment and a significantly lower amount of red blood cell transfusion (P<0.05).","[{'ForeName': 'Xiao-Yue', 'Initials': 'XY', 'LastName': 'Dong', 'Affiliation': 'Department of Pediatrics, Nanjing Maternal and Child Health Hospital Affiliated to Nanjing Medical University, Nanjing 210004, China. shupinghan@njmu.edu.cn.'}, {'ForeName': 'Xiao-Fan', 'Initials': 'XF', 'LastName': 'Sun', 'Affiliation': ''}, {'ForeName': 'Meng-Meng', 'Initials': 'MM', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Zhang-Bing', 'Initials': 'ZB', 'LastName': 'Yu', 'Affiliation': ''}, {'ForeName': 'Shu-Ping', 'Initials': 'SP', 'LastName': 'Han', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1001,27412550,[Effect of motivational interviewing combined with peer participation on obesity management in adolescents].,"OBJECTIVE To investigate the effect of motivational interviewing combined with peer participation on obesity management in adolescents. METHODS A total of 100 adolescents with simple obesity were randomly divided into traditional management and peer participation groups (n=50 each). The traditional management group received traditional health management. The peer participation group received motivational interviewing performed by psychological consultants combined with peer participation through the entire process in addition to traditional health management. The physical exercise, dietary behavior, differences in body composition parameters, and effect of comprehensive intervention were compared between the two groups after intervention for half a year. RESULTS After the health management for six months, the peer participation group showed better improvements in the control of energy intake, adjustment of dietary structure, adherence to moderate/high intensity exercise, and increase in lean body mass compared with the traditional management group (P<0.05). The peer participation group had a significantly higher attendance rate for guidance and counseling performed by a multidisciplinary team once a week than the traditional management group (89% vs 57%; P<0.05), as well as a significantly higher response rate to health management than the traditional management group (83% vs 43%; P<0.05). CONCLUSIONS Motivational interviewing combined with peer participation for obesity management can improve the compliance and the effect of comprehensive intervention in losing weight in adolescents.",2016,"The peer participation group had a significantly higher attendance rate for guidance and counseling performed by a multidisciplinary team once a week than the traditional management group (89% vs 57%; P<0.05), as well as a significantly higher response rate to health management than the traditional management group (83% vs 43%; P<0.05). ","['adolescents', '100 adolescents with simple obesity']","['traditional management and peer participation groups ', 'traditional health management', 'motivational interviewing combined with peer participation', 'motivational interviewing performed by psychological consultants combined with peer participation through the entire process in addition to traditional health management']","['response rate to health management', 'lean body mass', 'control of energy intake, adjustment of dietary structure, adherence to moderate/high intensity exercise', 'attendance rate']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0451819', 'cui_str': 'Simple obesity (disorder)'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0683474', 'cui_str': 'Motivational Interviewing'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0009817', 'cui_str': 'Consultant'}, {'cui': 'C0439751', 'cui_str': 'Entire (qualifier value)'}, {'cui': 'C4521054', 'cui_str': 'Process (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass (observable entity)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0456081', 'cui_str': 'Adjustment (procedure)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]",100.0,0.017826,"The peer participation group had a significantly higher attendance rate for guidance and counseling performed by a multidisciplinary team once a week than the traditional management group (89% vs 57%; P<0.05), as well as a significantly higher response rate to health management than the traditional management group (83% vs 43%; P<0.05). ","[{'ForeName': 'Jian-Zhen', 'Initials': 'JZ', 'LastName': 'Wu', 'Affiliation': 'Department of Nursing, Third Xiangya Hospital, Central South University, Changsha 410008, China. 810835852@qq.com.'}, {'ForeName': 'Min-Hui', 'Initials': 'MH', 'LastName': 'Dai', 'Affiliation': ''}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Xiong', 'Affiliation': ''}, {'ForeName': 'Hai-Xia', 'Initials': 'HX', 'LastName': 'Liu', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1002,32416073,"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.","BACKGROUND Patients with advanced or metastatic oesophageal squamous cell carcinoma have poor prognosis and few treatment options after first-line therapy. We aimed to assess efficacy and safety of the anti-PD-1 antibody camrelizumab versus investigator's choice of chemotherapy in previously treated patients. METHODS ESCORT is a randomised, open-label, phase 3 study of patients aged 18 to 75 years with a histological or cytological diagnosis of advanced or metastatic oesophageal squamous cell carcinoma done at 43 hospitals in China. Eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and had progressed on, or were intolerant to, first-line standard therapy. Patients were randomly assigned (1:1) to camrelizumab (200 mg every 2 weeks) or chemotherapy with docetaxel (75 mg/m 2 every 3 weeks) or irinotecan (180 mg/m 2 every 2 weeks), all given intravenously. Central randomisation was done using the Randomization and Trial Supply Management system with block size randomly generated as four or six and stratified by disease and ECOG performance status. The primary endpoint was overall survival, assessed in randomised patients who had received at least one dose of treatment. Safety was assessed in all treated patients. The trial is registered with ClinicalTrials.gov, NCT03099382, and is closed to new participants. FINDINGS From May 10, 2017, to July 24, 2018, 457 (75%) of 607 screened patients were randomly assigned to treatment, of whom 228 received camrelizumab treatment and 220 received chemotherapy. As of data cutoff on May 6, 2019, with a median follow-up time of 8·3 months (IQR 4·1-12·8) in the camrelizumab group and 6·2 months (3·6-10·1) in the chemotherapy group, median overall survival was 8·3 months (95% CI 6·8-9·7) in the camrelizumab group and 6·2 months (5·7-6·9) in the chemotherapy group (hazard ratio 0·71 [95% CI 0·57-0·87]; two-sided p=0·0010). The most common treatment-related adverse events of grade 3 or worse were anaemia (camrelizumab vs chemotherapy: six [3%] vs 11 [5%]), abnormal hepatic function (four [2%] vs one [<1%]), and diarrhoea (three [1%] vs nine [4%]). Serious treatment-related adverse events occurred in 37 (16%) of 228 patients in the camrelizumab group, and in 32 (15%) of 220 patients in the chemotherapy group. Ten treatment-related deaths occurred, seven (3%) in the camrelizumab group (three deaths from unknown causes, one enterocolitis, one hepatic function abnormal, one pneumonitis, and one myocarditis) and three (1%) in the chemotherapy group (two deaths from unknown causes, and one gastrointestinal haemorrhage). INTERPRETATION Second-line camrelizumab significantly improved overall survival in patients with advanced or metastatic oesophageal squamous cell carcinoma compared with chemotherapy, with a manageable safety profile. It might represent a potential option of standard second-line treatment for patients with oesophageal squamous cell carcinoma in China. FUNDING Jiangsu Hengrui Medicine.",2020,"Serious treatment-related adverse events occurred in 37 (16%) of 228 patients in the camrelizumab group, and in 32 (15%) of 220 patients in the chemotherapy group.","['Patients with advanced or metastatic oesophageal squamous cell carcinoma', 'Eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and had progressed on, or were intolerant to, first-line standard therapy', 'From May 10, 2017, to July 24, 2018, 457 (75%) of 607 screened patients', 'advanced or metastatic oesophageal squamous cell carcinoma (ESCORT', 'patients with oesophageal squamous cell carcinoma in China', 'patients with advanced or metastatic oesophageal squamous cell carcinoma', 'patients aged 18 to 75 years with a histological or cytological diagnosis of advanced or metastatic oesophageal squamous cell carcinoma done at 43 hospitals in China', 'previously treated patients']","['anti-PD-1 antibody camrelizumab', 'camrelizumab', 'chemotherapy with docetaxel', 'Camrelizumab', 'camrelizumab treatment and 220 received chemotherapy', 'chemotherapy', 'irinotecan']","['Safety', 'overall survival', 'diarrhoea', 'efficacy and safety', 'median overall survival', 'adverse events', 'deaths', 'abnormal hepatic function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0279626', 'cui_str': 'Squamous cell carcinoma of esophagus'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0205471', 'cui_str': 'Cytologic'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C4682408', 'cui_str': 'camrelizumab'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0086565', 'cui_str': 'Abnormal liver function'}]",,0.242005,"Serious treatment-related adverse events occurred in 37 (16%) of 228 patients in the camrelizumab group, and in 32 (15%) of 220 patients in the chemotherapy group.","[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Jianming', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Department of Gastrointestinal Oncology, Cancer Center, Fifth Medical Center General Hospital of PLA, Beijing, China. Electronic address: jmxu2003@yahoo.com.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Radiation Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China.'}, {'ForeName': 'Wu', 'Initials': 'W', 'LastName': 'Zhuang', 'Affiliation': 'Department of Thoracic Medical Oncology, Fujian Province Cancer Hospital, Fuzhou, China.'}, {'ForeName': 'Yiping', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Zhendong', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Oncology Department, The Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Oncology, Jiangsu Cancer Hospital, Nanjing, China.'}, {'ForeName': 'Helong', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': ""Oncology Department, Tangdu Hospital of the Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Zuoxing', 'Initials': 'Z', 'LastName': 'Niu', 'Affiliation': 'Internal Medicine Ward 4, Shandong Cancer Hospital, Jinan, China.'}, {'ForeName': 'Qingxia', 'Initials': 'Q', 'LastName': 'Fan', 'Affiliation': 'Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.'}, {'ForeName': 'Lizhu', 'Initials': 'L', 'LastName': 'Lin', 'Affiliation': 'Oncology Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Kangsheng', 'Initials': 'K', 'LastName': 'Gu', 'Affiliation': 'Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Medical Oncology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Ba', 'Affiliation': 'Medical Oncology, Tianjin Cancer Hospital, Tianjin, China.'}, {'ForeName': 'Zhanhui', 'Initials': 'Z', 'LastName': 'Miao', 'Affiliation': 'Oncology Department, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.'}, {'ForeName': 'Xiaodong', 'Initials': 'X', 'LastName': 'Jiang', 'Affiliation': ""Oncology Department, The First People's Hospital of Lianyungang, Lianyungang, China.""}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Zeng', 'Affiliation': ""Oncology Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China.""}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Medical Oncology, Cancer Hospital of Central South University, Changsha, China.'}, {'ForeName': 'Zhichao', 'Initials': 'Z', 'LastName': 'Fu', 'Affiliation': 'Department of Radiotherapy, 900 Hospital of the Joint Logistics Team, Fuzhou, China.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Gan', 'Affiliation': 'The Oncology Department, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.'}, {'ForeName': 'Xianbao', 'Initials': 'X', 'LastName': 'Zhan', 'Affiliation': 'Department of Medical Oncology, Changhai Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Tianshu', 'Initials': 'T', 'LastName': 'Liu', 'Affiliation': 'Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Zhiping', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Integrated Chinese and Western Medical Oncology, Jiangxi Cancer Hospital, Nanchang, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Shen', 'Affiliation': 'Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China.'}, {'ForeName': 'Yongqian', 'Initials': 'Y', 'LastName': 'Shu', 'Affiliation': 'Medical Oncology, Jiangsu Province Hospital, Nanjing, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Jiangsu Hengrui Medicine, Shanghai, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Yang', 'Affiliation': 'Jiangsu Hengrui Medicine, Shanghai, China.'}, {'ForeName': 'Jianjun', 'Initials': 'J', 'LastName': 'Zou', 'Affiliation': 'Jiangsu Hengrui Medicine, Shanghai, China.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30110-8'] 1003,32414368,Preparing for an orthopedic consultation using an eHealth tool: a randomized controlled trial in patients with hip and knee osteoarthritis.,"BACKGROUND To evaluate the effect of a stand-alone mobile and web-based educational intervention (eHealth tool) compared to usual preparation of a first orthopedic consultation of patients with hip or knee osteoarthritis (OA) on patients' satisfaction. METHODS A two-armed randomized controlled trial involving 286 patients with (suspicion of) hip or knee OA, randomly allocated to either receiving an educational eHealth tool to prepare their upcoming consultation (n = 144) or usual care (n = 142). Satisfaction with the consultation on three subscales (range 1-4) of the Consumer Quality Index (CQI - primary outcome) and knowledge (assessed using 22 statements on OA, range 0-22), treatment beliefs (assessed by the Treatment beliefs in OsteoArthritis questionnaire, range 1-5), assessment of patient's involvement in consultation by the surgeon (assessed on a 5-point Likert scale) and patient satisfaction with the outcome of the consultation (numeric rating scale), were assessed. RESULTS No differences between groups were observed on the 3 subscales of the CQI (group difference (95% CI): communication 0.009 (- 0.10, 0.12), conduct - 0.02 (- 0.12, 0.07) and information provision 0.02 (- 0.18, 0.21)). Between group differences (95% CI) were in favor of the intervention group for knowledge (1.4 (0.6, 2.2)), negative beliefs regarding physical activities (- 0.19 (- 0.37, - 0.002) and pain medication (- 0.30 (- 0.49, - 0.01)). We found no differences on other secondary outcomes. CONCLUSIONS An educational eHealth tool to prepare a first orthopedic consultation for hip or knee OA does not result in higher patient satisfaction with the consultation, but it does influence cognitions about osteoarthritis. TRIAL REGISTRATION Dutch Trial Register (trial number NTR6262). Registered 30 January 2017.",2020,"An educational eHealth tool to prepare a first orthopedic consultation for hip or knee OA does not result in higher patient satisfaction with the consultation, but it does influence cognitions about osteoarthritis. ","['patients with hip and knee osteoarthritis', '286 patients with (suspicion of) hip or knee OA', ""patients with hip or knee osteoarthritis (OA) on patients' satisfaction""]","['educational eHealth tool to prepare their upcoming consultation (n\u2009=\u2009144) or usual care', 'stand-alone mobile and web-based educational intervention (eHealth tool']","[""Consumer Quality Index (CQI - primary outcome) and knowledge (assessed using 22 statements on OA, range 0-22), treatment beliefs (assessed by the Treatment beliefs in OsteoArthritis questionnaire, range 1-5), assessment of patient's involvement in consultation by the surgeon (assessed on a 5-point Likert scale) and patient satisfaction with the outcome of the consultation (numeric rating scale"", 'pain medication', 'negative beliefs regarding physical activities']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0242114', 'cui_str': 'Suspicion'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]","[{'cui': 'C1328956', 'cui_str': 'eHealth'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0560204', 'cui_str': 'Does stand alone'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0030699', 'cui_str': 'Client participation'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0451267', 'cui_str': 'Likert scale'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",286.0,0.118311,"An educational eHealth tool to prepare a first orthopedic consultation for hip or knee OA does not result in higher patient satisfaction with the consultation, but it does influence cognitions about osteoarthritis. ","[{'ForeName': 'Aniek A O M', 'Initials': 'AAOM', 'LastName': 'Claassen', 'Affiliation': 'Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, GM, 6500, The Netherlands. a.claassen@maartenskliniek.nl.'}, {'ForeName': 'Henk J', 'Initials': 'HJ', 'LastName': 'Schers', 'Affiliation': 'Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'Vincent J J F', 'Initials': 'VJJF', 'LastName': 'Busch', 'Affiliation': 'Department of Orthopaedic Surgery, Sint Maartenskliniek, Nijmegen, The Netherlands.'}, {'ForeName': 'Petra J C', 'Initials': 'PJC', 'LastName': 'Heesterbeek', 'Affiliation': 'Sint Maartenskliniek Research, Sint Maartenskliniek, Nijmegen, The Netherlands.'}, {'ForeName': 'Frank H J', 'Initials': 'FHJ', 'LastName': 'van den Hoogen', 'Affiliation': 'Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, GM, 6500, The Netherlands.'}, {'ForeName': 'Thea P M', 'Initials': 'TPM', 'LastName': 'Vliet Vlieland', 'Affiliation': 'Department of Orthopaedics, Rehabilitation and Physical Therapy, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Cornelia H M', 'Initials': 'CHM', 'LastName': 'van den Ende', 'Affiliation': 'Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, GM, 6500, The Netherlands.'}]",BMC medical informatics and decision making,['10.1186/s12911-020-01130-0'] 1004,32492168,A metabolomic study of red and processed meat intake and acylcarnitine concentrations in human urine and blood.,"BACKGROUND Acylcarnitines (ACs) play a major role in fatty acid metabolism and are potential markers of metabolic dysfunction with higher blood concentrations reported in obese and diabetic individuals. Diet, and in particular red and processed meat intake, has been shown to influence AC concentrations but data on the effect of meat consumption on AC concentrations is limited. OBJECTIVES To investigate the effect of red and processed meat intake on AC concentrations in plasma and urine using a randomized controlled trial with replication in an observational cohort. METHODS In the randomized crossover trial, 12 volunteers successively consumed 2 different diets containing either pork or tofu for 3 d each. A panel of 44 ACs including several oxidized ACs was analyzed by LC-MS in plasma and urine samples collected after the 3-d period. ACs that were associated with pork intake were then measured in urine (n = 474) and serum samples (n = 451) from the European Prospective Investigation into Cancer and nutrition (EPIC) study and tested for associations with habitual red and processed meat intake derived from dietary questionnaires. RESULTS In urine samples from the intervention study, pork intake was positively associated with concentrations of 18 short- and medium-chain ACs. Eleven of these were also positively associated with habitual red and processed meat intake in the EPIC cross-sectional study. In blood, C18:0 was positively associated with red meat intake in both the intervention study (q = 0.004, Student's t-test) and the cross-sectional study (q = 0.033, linear regression). CONCLUSIONS AC concentrations in urine and blood were associated with red meat intake in both a highly controlled intervention study and in subjects of a cross-sectional study. Our data on the role of meat intake on this important pathway of fatty acid and energy metabolism may help understanding the role of red meat consumption in the etiology of some chronic diseases. This trial was registered at Clinicaltrials.gov as NCT03354130.",2020,"In blood, C18:0 was positively associated with red meat intake in both the intervention study (q = 0.004, Student's t-test) and the cross-sectional study (q = 0.033, linear regression). ","['12 volunteers successively consumed 2 different diets containing either pork or tofu for 3 d each', 'obese and diabetic individuals', 'human urine and blood']",['red and processed meat intake'],"['red meat intake', 'habitual red and processed meat intake', 'several oxidized ACs']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0452867', 'cui_str': 'Pork'}, {'cui': 'C0453233', 'cui_str': 'Tofu'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0005767', 'cui_str': 'Blood'}]","[{'cui': 'C0332575', 'cui_str': 'Red color'}, {'cui': 'C0556213', 'cui_str': 'Processed meat intake'}]","[{'cui': 'C0556202', 'cui_str': 'Red meat intake'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0332575', 'cui_str': 'Red color'}, {'cui': 'C0556213', 'cui_str': 'Processed meat intake'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0368608', 'cui_str': 'Acylcarnitine'}]",12.0,0.0566447,"In blood, C18:0 was positively associated with red meat intake in both the intervention study (q = 0.004, Student's t-test) and the cross-sectional study (q = 0.033, linear regression). ","[{'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Wedekind', 'Affiliation': 'Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.'}, {'ForeName': 'Agneta', 'Initials': 'A', 'LastName': 'Kiss', 'Affiliation': 'Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.'}, {'ForeName': 'Pekka', 'Initials': 'P', 'LastName': 'Keski-Rahkonen', 'Affiliation': 'Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.'}, {'ForeName': 'Vivian', 'Initials': 'V', 'LastName': 'Viallon', 'Affiliation': 'Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.'}, {'ForeName': 'Joseph A', 'Initials': 'JA', 'LastName': 'Rothwell', 'Affiliation': 'Centre for Research into Epidemiology and Population Health (CESP), Faculté de Medicine, Université Paris-Saclay, Inserm, Villejuif, France.'}, {'ForeName': 'Amanda J', 'Initials': 'AJ', 'LastName': 'Cross', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.'}, {'ForeName': 'Agnetha Linn', 'Initials': 'AL', 'LastName': 'Rostgaard-Hansen', 'Affiliation': 'Danish Cancer Society Research Center, Copenhagen, Denmark.'}, {'ForeName': 'Torkjel M', 'Initials': 'TM', 'LastName': 'Sandanger', 'Affiliation': 'Department of Community Medicine, UiT the Arctic university of Norway, Tromsø, Norway.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Jakszyn', 'Affiliation': 'Unit of Nutrition and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology, Barcelona, Spain.'}, {'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Schmidt', 'Affiliation': 'Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Pala', 'Affiliation': 'Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,Italy.'}, {'ForeName': 'Roel', 'Initials': 'R', 'LastName': 'Vermeulen', 'Affiliation': 'Division of Environmental Epidemiology, \xa0Institute for Risk Assessment Sciences, Utrecht University, \xa0Utrecht, The Netherlands.'}, {'ForeName': 'Matthias B', 'Initials': 'MB', 'LastName': 'Schulze', 'Affiliation': 'Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.'}, {'ForeName': 'Tilman', 'Initials': 'T', 'LastName': 'Kühn', 'Affiliation': 'Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Theron', 'Initials': 'T', 'LastName': 'Johnson', 'Affiliation': 'Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Antonia', 'Initials': 'A', 'LastName': 'Trichopoulou', 'Affiliation': 'Hellenic Health Foundation, Athens, Greece.'}, {'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Peppa', 'Affiliation': 'Hellenic Health Foundation, Athens, Greece.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'La Vechia', 'Affiliation': 'Hellenic Health Foundation, Athens, Greece.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Masala', 'Affiliation': 'Cancer Risk Factors and Life-Style\xa0Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO) , Florence, Italy.'}, {'ForeName': 'Rosario', 'Initials': 'R', 'LastName': 'Tumino', 'Affiliation': 'Cancer Registry and Histopathology Department, Provincial Health Authority (ASP) Ragusa, Italy.'}, {'ForeName': 'Carlotta', 'Initials': 'C', 'LastName': 'Sacerdote', 'Affiliation': 'Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy.'}, {'ForeName': 'Clemens', 'Initials': 'C', 'LastName': 'Wittenbecher', 'Affiliation': 'Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.'}, {'ForeName': 'Maria Santucci', 'Initials': 'MS', 'LastName': 'de Magistris', 'Affiliation': 'Azienda Ospedialiera Universitaria (A.O.U.) Federico II, Naples, Italy.'}, {'ForeName': 'Christina C', 'Initials': 'CC', 'LastName': 'Dahm', 'Affiliation': 'Department of Public Health, Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Severi', 'Affiliation': 'Centre for Research into Epidemiology and Population Health (CESP), Faculté de Medicine, Université Paris-Saclay, Inserm, Villejuif, France.'}, {'ForeName': 'Francesca Romana', 'Initials': 'FR', 'LastName': 'Mancini', 'Affiliation': 'Centre for Research into Epidemiology and Population Health (CESP), Faculté de Medicine, Université Paris-Saclay, Inserm, Villejuif, France.'}, {'ForeName': 'Elisabete', 'Initials': 'E', 'LastName': 'Weiderpass', 'Affiliation': 'International Agency for Research on Cancer, WHO, Lyon, France.'}, {'ForeName': 'Marc J', 'Initials': 'MJ', 'LastName': 'Gunter', 'Affiliation': 'Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.'}, {'ForeName': 'Inge', 'Initials': 'I', 'LastName': 'Huybrechts', 'Affiliation': 'Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.'}, {'ForeName': 'Augustin', 'Initials': 'A', 'LastName': 'Scalbert', 'Affiliation': 'Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqaa140'] 1005,27403222,"Study of the Efficacy, Safety and Tolerability of Low-Molecular-Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation.","BACKGROUND Anticoagulation with adjusted dose warfarin is a well-accepted treatment for the prevention of recurrent stroke in patients with atrial fibrillation. Meanwhile, using bridging therapy with heparin or heparinoids before warfarin for initiation of anticoagulation is a matter of debate. We compared safety, efficacy, and tolerability of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) as a bridging method in patients with recent ischemic stroke due to atrial fibrillation. METHOD This study was a randomized single-blind controlled trial in patients with acute ischemic stroke due to atrial fibrillation who were eligible for receiving warfarin and were randomly treated with 60 milligrams (mg) of LMWH (enoxaparin) subcutaneously every 12 h, or 1000 units/h of continuous intravenous heparin. The primary efficacy endpoints were recurrence of new ischemic stroke, myocardial infarction and/or death. The primary safety endpoint was central nervous system and/or systemic bleeding. RESULTS Seventy-four subjects were recruited. Baseline demographic and clinical characteristics of two groups were matched. Composite endpoint outcome of new ischemic stroke, myocardial infarction, and/or death in follow-up period was seen in 10 subjects (27.03%) in UFH group and in four subjects (10.81%) in LMWH group (p value: 0.136). All hemorrhages and symptomatic central nervous system (CNS) hemorrhages in follow-up period were in 7 (18.9%) and 4 (10.8%) patients in UFH group, in 5 (13.5%), and 3 (8.1%) patients in LMWH group (p values: 0.754 and 0.751), respectively. Drop out and major adverse-effects such as heparin-induced thrombocytopenia and drug hypersensitivity were not seen in any patient. CONCLUSION Enoxaparin can be a safe and efficient alternative for UFH as bridging therapy.",2016,"Drop out and major adverse-effects such as heparin-induced thrombocytopenia and drug hypersensitivity were not seen in any patient. ","['Patients with Embolic Stroke due to Atrial Fibrillation', 'Seventy-four subjects were recruited', 'patients with recent ischemic stroke due to atrial fibrillation', 'patients with acute ischemic stroke due to atrial fibrillation who were eligible for receiving', 'patients with atrial fibrillation']","['LMWH', 'warfarin', 'heparin or heparinoids before warfarin', 'Enoxaparin', 'Low-Molecular-Weight Heparin vs. Unfractionated Heparin', 'LMWH (enoxaparin', 'heparin', 'low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH']","['safety, efficacy, and tolerability', 'Efficacy, Safety and Tolerability', 'recurrence of new ischemic stroke, myocardial infarction and/or death', 'central nervous system and/or systemic bleeding', 'thrombocytopenia and drug hypersensitivity', 'All hemorrhages and symptomatic central nervous system (CNS) hemorrhages', 'new ischemic stroke, myocardial infarction, and/or death in follow-up period']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0262469', 'cui_str': 'Embolic stroke (disorder)'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}, {'cui': 'C4517867', 'cui_str': 'Seventy-four'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}]","[{'cui': 'C0019139', 'cui_str': 'LMWH'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0019142', 'cui_str': 'Heparinoids'}, {'cui': 'C0206460', 'cui_str': 'Enoxaparin'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0040034', 'cui_str': 'Thrombopenia'}, {'cui': 'C0013182', 'cui_str': 'Drug Allergy'}, {'cui': 'C1869041', 'cui_str': 'Haemorrhages (SMQ)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C3267019', 'cui_str': 'Central nervous system haemorrhage'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]",74.0,0.050589,"Drop out and major adverse-effects such as heparin-induced thrombocytopenia and drug hypersensitivity were not seen in any patient. ","[{'ForeName': 'Farnia', 'Initials': 'F', 'LastName': 'Feiz', 'Affiliation': 'Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; These authors contributed equally to this work.'}, {'ForeName': 'Reyhane', 'Initials': 'R', 'LastName': 'Sedghi', 'Affiliation': 'Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; These authors contributed equally to this work.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Salehi', 'Affiliation': 'Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Nahid', 'Initials': 'N', 'LastName': 'Hatam', 'Affiliation': 'School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Jamshid', 'Initials': 'J', 'LastName': 'Bahmei', 'Affiliation': 'School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Afshin', 'Initials': 'A', 'LastName': 'Borhani-Haghighi', 'Affiliation': 'Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",Journal of vascular and interventional neurology,[] 1006,26903058,[Effect of botulinum toxin A injection in the treatment of gastrocnemius spasticity in children aged 9-36 months with cerebral palsy: a prospective study].,"OBJECTIVE To investigate the long-term clinical efficacy and adverse effects of botulinum toxin-A (BTX-A) injection in the treatment of gastrocnemius spasticity in children aged 9-36 months with cerebral palsy. METHODS Eighty children aged 9-36 months with cerebral palsy and gastrocnemius spasticity were selected and randomly divided into a BTX-A injection group and a conventional treatment group (n=40 each). The children in the BTX-A injection group received injections of BTX-A guided by color Doppler ultrasound and 4 courses of rehabilitation training after injection. Those in the conventional treatment group received 4 courses of the same rehabilitation training alone. Before treatment and at 1, 2, 3, and 6 months after treatment, the modified Tardieu scale (MTS) was applied to assess the degree of gastrocnemius spasticity, the values in the passive state measured by surface electromyography (sEMG) were applied to evaluate muscle tension, and the Gross Motor Function Measure (GMFM) was used to evaluate gross motor function. RESULTS Compared with the conventional treatment group, the BTX-A injection group had significantly greater reductions in MTS score and the values in the passive state measured by sEMG (P<0.05), as well as significantly greater increases in joint angles R1 and R2 in MTS and gross motor score in GMFM (P<0.05). No serious adverse reactions related to BTX-A injection were found. CONCLUSIONS BTX-A injection is effective and safe in the treatment of gastrocnemius spasticity in children aged 9-36 months with cerebral palsy.",2016,No serious adverse reactions related to BTX-,"['children aged 9-36 months with cerebral palsy', 'Eighty children aged 9-36 months with cerebral palsy and gastrocnemius spasticity']","['botulinum toxin-A (BTX-A) injection', 'BTX-A injection group and a conventional treatment group', 'BTX-A injection', 'rehabilitation training alone', 'BTX-A guided by color Doppler ultrasound and 4 courses of rehabilitation training', 'botulinum toxin A injection']","['degree of gastrocnemius spasticity, the values in the passive state measured by surface electromyography (sEMG', 'MTS score', 'joint angles R1 and R2 in MTS and gross motor score', 'modified Tardieu scale (MTS', 'gastrocnemius spasticity']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0007789', 'cui_str': 'CP (Cerebral Palsy)'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0026838', 'cui_str': 'Muscle Spasticity'}]","[{'cui': 'C0006055', 'cui_str': 'Botulin'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0474781', 'cui_str': 'Color doppler flow'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}]","[{'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0026838', 'cui_str': 'Muscle Spasticity'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0430815', 'cui_str': 'Surface Electromyography'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0022417', 'cui_str': 'Joints'}, {'cui': 'C0205143', 'cui_str': 'Angular (qualifier value)'}, {'cui': 'C0439806', 'cui_str': 'Gross (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0222045'}]",80.0,0.0159838,No serious adverse reactions related to BTX-,"[{'ForeName': 'Deng-Na', 'Initials': 'DN', 'LastName': 'Zhu', 'Affiliation': 'Department of Children′s Rehabilitation, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. zhudengna@126.com.'}, {'ForeName': 'Ming-Mei', 'Initials': 'MM', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'He-Zhou', 'Initials': 'HZ', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Po', 'Initials': 'P', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Hua-Chun', 'Initials': 'HC', 'LastName': 'Xiong', 'Affiliation': ''}, {'ForeName': 'Guo-Hui', 'Initials': 'GH', 'LastName': 'Niu', 'Affiliation': ''}, {'ForeName': 'San-Song', 'Initials': 'SS', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Yun-Xia', 'Initials': 'YX', 'LastName': 'Zhao', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1007,27165587,[Efficacy of different preparations of budesonide combined with pulmonary surfactant in the treatment of neonatal respiratory distress syndrome: a comparative analysis].,"OBJECTIVE To study the efficacy of different preparations of budesonide combined with pulmonary surfactant (PS) in improving blood gas levels and preventing bronchopulmonary dysplasia (BPD) in preterm infants with neonatal respiratory distress syndrome (NRDS). METHODS A total of 184 preterm infants who developed NRDS within 4 hours after birth were randomly administered with PS + continuous inhalation of budesonide aerosol (continuous aerosol group), PS+budesonide solution (solution group), PS + single inhalation of budesonide aerosol (single aerosol group), and PS alone, with 46 neonates in each group. The changes in arterial blood gas levels, rate of invasive mechanical ventilation after treatment, time of assisted ventilation, rate of repeated use of PS, and the incidence of BPD were compared between the four groups. RESULTS On the 2nd to 4th day after treatment, pH, PCO2, and oxygenation index (FiO2/PaO2) showed significant differences among the four groups, and the continuous aerosol group showed the most improvements of all indicators, followed by the solution group, single aerosol group, and PS alone group. The continuous aerosol group had a significantly shorter time of assisted ventilation than the other three groups (P<0.05). The solution group had a significantly shorter time of assisted ventilation than the single aerosol and PS alone groups (P<0.05). The rate of invasive mechanical ventilation after treatment, rate of repeated use of PS, and incidence of BPD showed significant differences among the four groups (P<0.05), and the continuous aerosol group had the lowest rates, followed by the solution group. CONCLUSIONS A combination of PS and continuous inhalation of budesonide aerosol has a better efficacy in the treatment of NRDS than a combination of PS and budesonide solution. The difference in reducing the incidence of BDP between the two administration methods awaits further investigation with a larger sample size.",2016,The continuous aerosol group had a significantly shorter time of assisted ventilation than the other three groups (P<0.05).,"['184 preterm infants who developed NRDS within 4 hours after birth', 'neonatal respiratory distress syndrome', 'preterm infants with neonatal respiratory distress syndrome (NRDS']","['budesonide combined with pulmonary surfactant', 'budesonide combined with pulmonary surfactant (PS', 'budesonide aerosol', 'PS\u2009+\u2009continuous inhalation of budesonide aerosol (continuous aerosol group), PS+budesonide solution (solution group), PS\u2009+\u2009single inhalation of budesonide aerosol (single aerosol group), and PS alone']","['rate of repeated use of PS, and incidence of BPD', 'bronchopulmonary dysplasia (BPD', 'blood gas levels', 'arterial blood gas levels, rate of invasive mechanical ventilation after treatment, time of assisted ventilation, rate of repeated use of PS, and the incidence of BPD', 'incidence of BDP', 'shorter time of assisted ventilation', 'pH, PCO2, and oxygenation index (FiO2/PaO2', 'rate of invasive mechanical ventilation']","[{'cui': 'C4517616', 'cui_str': 'One hundred and eighty-four'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C1292426', 'cui_str': '4 hours (qualifier value)'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0035220', 'cui_str': 'Respiratory Distress Syndrome, Newborn'}]","[{'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0034085', 'cui_str': 'Pulmonary Surfactants'}, {'cui': 'C0001712', 'cui_str': 'Aerosol (substance)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C1705211', 'cui_str': 'Inhalation - unit of product usage'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}]","[{'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary Dysplasia'}, {'cui': 'C0005800', 'cui_str': 'Blood Gas Analysis'}, {'cui': 'C0150411', 'cui_str': 'Blood gases, arterial measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1868981', 'cui_str': 'Invasive mechanical ventilation'}, {'cui': 'C0001758', 'cui_str': 'Follow-Up Care'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0391839', 'cui_str': 'PCO2'}, {'cui': 'C1278185', 'cui_str': 'Oxygenation index'}, {'cui': 'C0428167', 'cui_str': 'FIO2'}, {'cui': 'C1822073', 'cui_str': 'PaO2'}]",184.0,0.0581006,The continuous aerosol group had a significantly shorter time of assisted ventilation than the other three groups (P<0.05).,"[{'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Ke', 'Affiliation': ""Department of Neonatology, Northwest Women and Children's Hospital, Xi'an 710061, China. lzk5808@163.com.""}, {'ForeName': 'Zhan-Kui', 'Initials': 'ZK', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Xi-Ping', 'Initials': 'XP', 'LastName': 'Yu', 'Affiliation': ''}, {'ForeName': 'Jin-Zhen', 'Initials': 'JZ', 'LastName': 'Guo', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1008,32416251,Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.,"BACKGROUND Alpelisib (α-selective phosphatidylinositol 3-kinase inhibitor) plus fulvestrant is approved in multiple countries for men and postmenopausal women with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer following progression on or after endocrine therapy. A detailed understanding of alpelisib's safety profile should inform adverse event (AE) management and enhance patient care. PATIENTS AND METHODS AEs in the phase III SOLAR-1 trial were assessed in patients with and without PIK3CA mutations. The impact of protocol-specified AE-management recommendations was evaluated, including an amendment to optimize hyperglycemia and rash management. RESULTS Patients were randomly assigned to receive fulvestrant plus alpelisib (n = 284) or placebo (n = 287). The most common grade 3/4 AEs with alpelisib were hyperglycemia (grade 3, 32.7%; grade 4, 3.9%), rash (grade 3, 9.9%), and diarrhea (grade 3, 6.7%). Median time to onset of grade ≥3 toxicity was 15 days (hyperglycemia, based on fasting plasma glucose), 13 days (rash), and 139 days (diarrhea). Metformin alone or in combination with other antidiabetic agents was used by most patients (87.1%) with hyperglycemia. Preventive anti-rash medication resulted in lower incidence (any grade, 26.7% versus 64.1%) and severity of rash (grade 3, 11.6% versus 22.7%) versus no preventative medication. Discontinuations due to grade ≥3 AEs were lower following more-detailed AE management guidelines (7.9% versus 18.1% previously). Patients with PIK3CA mutations had a median alpelisib dose intensity of 248 mg/day. Median progression-free survival with alpelisib was 12.5 and 9.6 months for alpelisib dose intensities of ≥248 mg/day and <248 mg/day, respectively, compared with 5.8 months with placebo. CONCLUSIONS Hyperglycemia and rash occurred early during alpelisib treatment, while diarrhea occurred at a later time point. Early identification, prevention, and intervention, including concomitant medications and alpelisib dose modifications, resulted in less severe toxicities. Reductions in treatment discontinuations and improved progression-free survival at higher alpelisib dose intensities support the need for optimal AE management. CLINICALTRIALS. GOV ID NCT02437318.",2020,"Preventive anti-rash medication resulted in lower incidence (any grade, 26.7% vs 64.1%) and severity of rash (grade 3, 11.6% vs 22.7%) vs no preventative medication.","['Patients With HR-Positive Advanced Breast Cancer', 'AEs in the phase 3 SOLAR-1 trial were assessed in patients with and without PIK3CA mutations', 'multiple countries for men and post-menopausal women with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer following progression on or after endocrine therapy']","['Metformin', 'Alpelisib (α-selective PI3K inhibitor) plus fulvestrant', 'fulvestrant plus alpelisib', 'PI3K Inhibitor Alpelisib Plus Fulvestrant', 'placebo']","['diarrhea', 'median alpelisib dose intensity', 'PFS', 'Hyperglycemia and rash', 'Time Course and Management of Key Adverse Events', 'Median time to onset of grade ≥3 toxicity', 'Median progression-free survival (PFS', 'rash', 'severe toxicities', 'hyperglycemia', 'severity of rash']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1451005', 'cui_str': 'PIK3CA protein, human'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C4055478', 'cui_str': 'alpelisib'}, {'cui': 'C0044602', 'cui_str': '1-phosphatidylinositol 3-kinase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0935916', 'cui_str': 'fulvestrant'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C4055478', 'cui_str': 'alpelisib'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0449247', 'cui_str': 'Time course'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332162', 'cui_str': 'Onset of'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",,0.111823,"Preventive anti-rash medication resulted in lower incidence (any grade, 26.7% vs 64.1%) and severity of rash (grade 3, 11.6% vs 22.7%) vs no preventative medication.","[{'ForeName': 'H S', 'Initials': 'HS', 'LastName': 'Rugo', 'Affiliation': 'Department of Medicine, Division of Hematology and Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA. Electronic address: Hope.Rugo@ucsf.edu.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'André', 'Affiliation': 'Department of Medical Oncology, INSERM U981, Gustave Roussy, Université Paris-Sud, Villejuif, France.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Yamashita', 'Affiliation': 'Department of Breast and Endocrine Surgery, Kanagawa Cancer Center Hospital, Yokohama, Japan.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Cerda', 'Affiliation': 'Clinica RedSalud Vitacura, Santiago, Chile.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Toledano', 'Affiliation': 'Institut Curie, Paris, France.'}, {'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Stemmer', 'Affiliation': 'Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Jurado', 'Affiliation': 'Hospital Universitario Canarias, S/C Tenerife, Islas Canarias, Spain.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Juric', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, USA.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Mayer', 'Affiliation': 'Department of Medicine, Hematology and Oncology, Vanderbilt University, Nashville, USA.'}, {'ForeName': 'E M', 'Initials': 'EM', 'LastName': 'Ciruelos', 'Affiliation': 'Medical Oncology Department, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Madrid, Spain.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Iwata', 'Affiliation': 'Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Conte', 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology, University of Padua and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Campone', 'Affiliation': ""Department of Medical Oncology, Institut de Cancérologie de l'Ouest, St Herblain, France.""}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Wilke', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Mills', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Lteif', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Miller', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, USA.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Gaudenzi', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Loibl', 'Affiliation': 'Department of Medicine and Research, German Breast Group, Neu-Isenburg; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2020.05.001'] 1009,30427289,A controlled trial using a factorial design reported in 1946.,,2018,,[],[],[],[],[],[],,0.0847631,,"[{'ForeName': 'Jon I', 'Initials': 'JI', 'LastName': 'Pollock', 'Affiliation': 'Faculty of Health and Social Care, University of the West of England, Bristol, Blackberry Hill, Stapleton, Bristol BS16 1DD, UK.'}]",Journal of the Royal Society of Medicine,['10.1177/0141076818808491'] 1010,28448699,Challenges in Testing Intranasal Ketamine in Obsessive-Compulsive Disorder.,,2017,,['Obsessive-Compulsive Disorder'],['Ketamine'],[],"[{'cui': 'C0028768', 'cui_str': 'Anankastic Personality'}]","[{'cui': 'C0022614', 'cui_str': 'Ketamine'}]",[],,0.0272398,,"[{'ForeName': 'Carolyn I', 'Initials': 'CI', 'LastName': 'Rodriguez', 'Affiliation': 'cr2163@stanford.edu.'}, {'ForeName': 'Kyle A B', 'Initials': 'KAB', 'LastName': 'Lapidus', 'Affiliation': 'Department of Psychiatry, Northwell Health, New York, New York, USA.'}, {'ForeName': 'Jordana', 'Initials': 'J', 'LastName': 'Zwerling', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, USA.'}, {'ForeName': 'Amand', 'Initials': 'A', 'LastName': 'Levinson', 'Affiliation': 'Department of Psychology, Stony Brook University, Stony Brook, New York, USA.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Mahnke', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, USA.'}, {'ForeName': 'Shari A', 'Initials': 'SA', 'LastName': 'Steinman', 'Affiliation': 'Department of Psychology, West Virginia University, Morgantown, West Virginia, USA.'}, {'ForeName': 'Eyal', 'Initials': 'E', 'LastName': 'Kalanthroff', 'Affiliation': 'Department of Psychology, The Hebrew University of Jerusalem, Israel.'}, {'ForeName': 'Helen Blair', 'Initials': 'HB', 'LastName': 'Simpson', 'Affiliation': 'Columbia University, Department of Psychiatry, College of Physicians and Surgeons, New York, New York, USA.'}]",The Journal of clinical psychiatry,['10.4088/JCP.16cr11234'] 1011,32065769,Effects of Exercise Therapy Dosing Schedule on Impaired Cardiorespiratory Fitness in Patients With Primary Breast Cancer: A Randomized Controlled Trial.,"BACKGROUND Current exercise guidelines for clinical populations recommend an exercise therapy (ET) prescription of fixed intensity (moderate), duration (40-50 minutes per session), and volume (120-160 min/wk). A critical overarching element of exercise programming that has received minimal attention is dose scheduling. We investigated the tolerability and efficacy of 2 exercise training dose regimens on cardiorespiratory fitness and patient-reported outcomes in patients with posttreatment primary breast cancer. METHODS Using a parallel-group randomized trial, we randomly allocated 174 postmenopausal patients (2.8 years after adjuvant therapy) with impaired peak oxygen consumption (VO 2 peak) to 1 of 2 supervised exercise training interventions delivered with a standard linear (LET) (fixed dose intensity per session for 160 min/wk) or nonlinear (NLET) (variable dose intensity per session for ≈120 min/wk) schedule compared with a stretching attention control group for 16 consecutive weeks. Stretching was matched to exercise dosing arms on the basis of location, frequency, duration, and treatment length. The primary end point was change in VO 2 peak (mL O 2 ·kg -1 ·min -1 ) from baseline to after intervention. Secondary end points were patient-reported outcomes, tolerability, and safety. RESULTS No serious adverse events were observed. Mean attendance was 64%, 75%, and 80% for attention control, LET, and NLET, respectively. In intention-to-treat analysis, VO 2 peak increased 0.6±1.7 mL O 2 ·kg -1 ·min -1 ( P =0.05) and 0.8±1.8 mL O 2 ·kg -1 ·min -1 ( P =0.07) in LET and NLET, respectively, compared with attention control. Change in VO 2 peak ranged from -2.7 to 4.1 mL O 2 ·kg -1 ·min -1 and from -3.6 to 5.1 mL O 2 ·kg -1 ·min -1 in LET and NLET, respectively. Approximately 40% of patients in both exercise dosing regimens were classified as VO 2 peak responders (ie, Δ ≥1.32 mL O 2 ·kg -1 ·min -1 ). NLET improved all patient-reported outcomes compared with attention control. CONCLUSIONS Short-term exercise training, independently of dosing schedule, is associated with modest improvements in cardiorespiratory fitness in patients previously treated for early-stage breast cancer. CLINICAL TRIAL REGISTRATION URL: https://www.clinicaltrials.gov. Unique identifier: NCT01186367.",2020,"In intention-to-treat analysis, VO 2 peak increased 0.6±1.7","['patients with posttreatment primary breast cancer', 'Patients With Primary Breast Cancer', '174 postmenopausal patients (2.8 years after', 'patients previously treated for early-stage breast cancer']","['adjuvant therapy) with impaired peak oxygen consumption (VO 2 peak) to 1 of 2 supervised exercise training interventions delivered with a standard linear (LET) (fixed dose intensity per session for 160 min/wk) or nonlinear (NLET) (variable dose intensity per session for ≈120 min/wk) schedule compared with a stretching attention control', '2 exercise training', 'Short-term exercise training', 'Exercise Therapy', 'NLET']","['change in VO 2 peak', 'serious adverse events', 'tolerability, and safety', 'Cardiorespiratory Fitness', 'tolerability and efficacy', 'cardiorespiratory fitness', 'Mean attendance']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C4517604', 'cui_str': 'One hundred and seventy-four'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for (contextual qualifier) (qualifier value)'}, {'cui': 'C2363430', 'cui_str': 'Early stage (qualifier value)'}]","[{'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C1305742', 'cui_str': 'Oxygen consumption'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0600080', 'cui_str': 'Stretching procedure (procedure)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0452240', 'cui_str': 'Rehabilitation Exercise'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",174.0,0.279428,"In intention-to-treat analysis, VO 2 peak increased 0.6±1.7","[{'ForeName': 'Jessica M', 'Initials': 'JM', 'LastName': 'Scott', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY (J.M.S., C.T.D., A.F.Y., D.C., C.C., C.C., M.G.M., L.W.J.).'}, {'ForeName': 'Samantha M', 'Initials': 'SM', 'LastName': 'Thomas', 'Affiliation': 'Duke University Medical Center, Durham, NC (S.M.T., J.E.H., P.S.D., M.G.K.).'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Peppercorn', 'Affiliation': 'Weill Cornell Medical College, New York, NY (J.M.S., C.T.D., L.W.J.).'}, {'ForeName': 'James E', 'Initials': 'JE', 'LastName': 'Herndon', 'Affiliation': 'Duke University Medical Center, Durham, NC (S.M.T., J.E.H., P.S.D., M.G.K.).'}, {'ForeName': 'Pamela S', 'Initials': 'PS', 'LastName': 'Douglas', 'Affiliation': 'Duke University Medical Center, Durham, NC (S.M.T., J.E.H., P.S.D., M.G.K.).'}, {'ForeName': 'Michel G', 'Initials': 'MG', 'LastName': 'Khouri', 'Affiliation': 'Duke University Medical Center, Durham, NC (S.M.T., J.E.H., P.S.D., M.G.K.).'}, {'ForeName': 'Chau T', 'Initials': 'CT', 'LastName': 'Dang', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY (J.M.S., C.T.D., A.F.Y., D.C., C.C., C.C., M.G.M., L.W.J.).'}, {'ForeName': 'Anthony F', 'Initials': 'AF', 'LastName': 'Yu', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY (J.M.S., C.T.D., A.F.Y., D.C., C.C., C.C., M.G.M., L.W.J.).'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Catalina', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY (J.M.S., C.T.D., A.F.Y., D.C., C.C., C.C., M.G.M., L.W.J.).'}, {'ForeName': 'Cristi', 'Initials': 'C', 'LastName': 'Ciolino', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY (J.M.S., C.T.D., A.F.Y., D.C., C.C., C.C., M.G.M., L.W.J.).'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Capaci', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY (J.M.S., C.T.D., A.F.Y., D.C., C.C., C.C., M.G.M., L.W.J.).'}, {'ForeName': 'Meghan G', 'Initials': 'MG', 'LastName': 'Michalski', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY (J.M.S., C.T.D., A.F.Y., D.C., C.C., C.C., M.G.M., L.W.J.).'}, {'ForeName': 'Neil D', 'Initials': 'ND', 'LastName': 'Eves', 'Affiliation': 'University of British Columbia, Kelowna, British Columbia, Canada (N.D.E.).'}, {'ForeName': 'Lee W', 'Initials': 'LW', 'LastName': 'Jones', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY (J.M.S., C.T.D., A.F.Y., D.C., C.C., C.C., M.G.M., L.W.J.).'}]",Circulation,['10.1161/CIRCULATIONAHA.119.043483'] 1012,32419647,Worry as a Mechanism to Motivate Information Seeking about Protective End-of-Life Communication Behaviors.,"Making known one's end-of-life (EOL) care wishes via the processes of advance care planning (ACP) and advance directive (AD) completion is associated with many positive outcomes for patients including lower healthcare costs, greater patient-provider relationship satisfaction, increased quality of life, and more. Despite these benefits, fewer than 30% of patients in the United States engage in ACP or complete ADs. These low numbers are most likely due to several causes, including low self-efficacy and low motivation to engage in the process. Several researchers have examined the persuasive power of using worry to motivate patients to engage in preventive health behaviors. The present study expands upon this body of literature by examining patient intentions to seek information related to ACP and AD after being exposed to stimuli intended to arouse differing levels of worry regarding bad EOL outcomes. Participants ( N = 804) were randomly assigned to either the high worry, low worry, or control group and asked to complete a questionnaire examining beliefs and information seeking intentions regarding ACP and AD completion. Additionally, to control for participants' level of trait worry, each participant completed the Penn State Worry Questionnaire, which was treated as a covariate in the final analysis. A repeated measures MANCOVA found a statistically significant increase for the worrying conditions on the participants' intention to seek information about ACP and ADs from time 1 to time 2 for those in the worry experimental conditions. However, those in the control group did not show a statistically significant increase. Additionally, exposure to the high worry condition was predictive of engaging in actual information seeking behavior about EOL care. Results of the experiment indicate worry is associated with greater motivation to engage in information seeking about ACP and AD. This study contributes to the literature on worry as a persuasive mechanism to motivate patients to engage in important preventative health behaviors.",2020,A repeated measures MANCOVA found a statistically significant increase for the worrying conditions on the participants' intention to seek information about ACP and ADs from time 1 to time 2 for those in the worry experimental conditions.,['Participants ( N =\xa0804'],"['high worry, low worry, or control group and asked to complete a questionnaire examining beliefs and information seeking intentions regarding ACP and AD completion']",['Penn State Worry Questionnaire'],[],"[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0233481', 'cui_str': 'Worried'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1172410', 'cui_str': 'ASK protein, human'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0600371', 'cui_str': 'Advance care planning'}, {'cui': 'C0001683', 'cui_str': 'Advance Directives'}]","[{'cui': 'C2959752', 'cui_str': 'Penn State worry questionnaire'}]",804.0,0.0240796,A repeated measures MANCOVA found a statistically significant increase for the worrying conditions on the participants' intention to seek information about ACP and ADs from time 1 to time 2 for those in the worry experimental conditions.,"[{'ForeName': 'Christian R', 'Initials': 'CR', 'LastName': 'Seiter', 'Affiliation': 'Department of Communication, George Mason University , Fairfax, Virginia, USA.'}, {'ForeName': 'Nate S', 'Initials': 'NS', 'LastName': 'Brophy', 'Affiliation': 'Department of Communication, George Mason University , Fairfax, Virginia, USA.'}]",Journal of health communication,['10.1080/10810730.2020.1765222'] 1013,26781404,[Efficacy of volume-targeted ventilation for the treatment of neonatal respiratory distress syndrome].,"OBJECTIVE To investigate the efficacy of volume-targeted ventilation (VTV) for the treatment of neonatal respiratory distress syndrome (NRDS). METHODS Fifty-two neonates with NRDS between August 2013 and August 2015 were randomly divided into two groups: VTV and pressure-controlled ventilation (PCV) (n=26 each ). A/C+Vc+ ventilation model was applied in the VTV group, and A/C+PCV ventilation model was applied in the PCV group. Arterial blood gas analysis was performed at 6, 24, and 48 hours after ventilation. The following parameters were observed: time of invasive ventilation, duration of oxygen therapy, mortality, and the incidence rates of hypocapnia, pneumothorax, ventilator-associated pneumonia (VAP), grade III-IV periventricular-intraventricular hemorrhage (PVH-IVH), periventricular leukomalacia (PVL), bronchopulmonary dysplasia (BPD), and retinopathy of prematurity (ROP). RESULTS Compared with the PCV group, the VTV group had a significantly shorter time of invasive ventilation (P<0.05) and significantly lower incidence rates of hypocapnia, VAP, and PVL (P<0.05); however, there were no significant differences in the duration of oxygen therapy, mortality, and incidence rates of pneumothorax, grade III-IV PVH-IVH, BPD, and ROP. CONCLUSIONS VTV has a better efficacy than PCV in the treatment of NRDS, and is worthy of clinical promotion and application.",2016,"Compared with the PCV group, the VTV group had a significantly shorter time of invasive ventilation (P<0.05) and significantly lower incidence rates of hypocapnia, VAP, and PVL (P<0.05); however, there were no significant differences in the duration of oxygen therapy, mortality, and incidence rates of pneumothorax, grade III-IV PVH-IVH, BPD, and ROP. ","['neonatal respiratory distress syndrome', 'neonatal respiratory distress syndrome (NRDS', 'Fifty-two neonates with NRDS between August 2013 and August 2015']","['volume-targeted ventilation', 'VTV and pressure-controlled ventilation (PCV', 'VTV', 'volume-targeted ventilation (VTV', 'PCV']","['Arterial blood gas analysis', 'shorter time of invasive ventilation', 'duration of oxygen therapy, mortality, and incidence rates of pneumothorax, grade III-IV PVH-IVH, BPD, and ROP', 'time of invasive ventilation, duration of oxygen therapy, mortality, and the incidence rates of hypocapnia, pneumothorax, ventilator-associated pneumonia (VAP), grade III-IV periventricular-intraventricular hemorrhage (PVH-IVH), periventricular leukomalacia (PVL), bronchopulmonary dysplasia (BPD), and retinopathy of prematurity (ROP', 'incidence rates of hypocapnia, VAP, and PVL (P<0.05']","[{'cui': 'C0035220', 'cui_str': 'Respiratory Distress Syndrome, Newborn'}, {'cui': 'C4319570', 'cui_str': 'Fifty-two'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}]","[{'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C0564626', 'cui_str': 'Pressure controlled ventilation (procedure)'}, {'cui': 'C0018935', 'cui_str': 'Erythrocyte Volume, Packed'}]","[{'cui': 'C0150411', 'cui_str': 'Blood gases, arterial measurement (procedure)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0184633', 'cui_str': 'Oxygen Inhalation Therapy'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0032326', 'cui_str': 'Pneumothorax'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0085383', 'cui_str': 'Hypocapnia'}, {'cui': 'C0087153', 'cui_str': 'Ventilators'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0240059', 'cui_str': 'Ventricular hemorrhage (disorder)'}, {'cui': 'C0023529', 'cui_str': 'Encephalomalacia, Periventricular'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary Dysplasia'}, {'cui': 'C0035344', 'cui_str': 'Retrolental Fibroplasia'}]",52.0,0.0139461,"Compared with the PCV group, the VTV group had a significantly shorter time of invasive ventilation (P<0.05) and significantly lower incidence rates of hypocapnia, VAP, and PVL (P<0.05); however, there were no significant differences in the duration of oxygen therapy, mortality, and incidence rates of pneumothorax, grade III-IV PVH-IVH, BPD, and ROP. ","[{'ForeName': 'Chen-Zhou', 'Initials': 'CZ', 'LastName': 'Liu', 'Affiliation': 'Pediatric Intensive Care Unit, Jiangmen Central Hospital, Jiangmen, Guangdong 529030, China. chenzhou748190@163.com.'}, {'ForeName': 'Bi-Yin', 'Initials': 'BY', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Bao-Ying', 'Initials': 'BY', 'LastName': 'Tan', 'Affiliation': ''}, {'ForeName': 'Hao-Feng', 'Initials': 'HF', 'LastName': 'Guan', 'Affiliation': ''}, {'ForeName': 'Xiao-Hui', 'Initials': 'XH', 'LastName': 'Xu', 'Affiliation': ''}, {'ForeName': 'Qing-Yun', 'Initials': 'QY', 'LastName': 'Guo', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1014,26781417,[Resveratrol increases sirtuin 1 expression in peripheral blood mononuclear cells of premature infants and inhibits the oxidative stress induced by hyperoxia in vivo].,"OBJECTIVE To explore the effect of resveratrol on the levels of sirtuin 1 (SIRT1) and reactive oxygen species (ROS) in peripheral blood mononuclear cells (PBMCs) of premature infants exposed to hyperoxia. METHODS Peripheral blood and isolated PBMCs from premature infants (gestational age<32 weeks) without oxygen supplement were collected and were randomly assigned into four groups: control, air+resveratrol, hyperoxia, and hyperoxia+resveratrol. The PBMCs were cultured in vitro for 48 hours, then the ROS content in PBMCs was measured by laser scanning confocal microscopy. Malondialdehyde (MDA) content in the medium was measured by the whole spectrum spectrophotometer. SIRT1 positioning was assessed by immunofluorescence. SIRT1 expression levels in PBMCs were measured by Western bolt. RESULTS Compared with the control group, the level of SIRT1 in the air+resveratrol group increased significantly (P<0.05). The levels of ROS and MDA and the SIRT1 transposition rate in the hyperoxia group increased significantly, while the expression level of SIRT1 decreased significantly compared with the control group (P<0.05). The levels of ROS and MDA and the SIRT1 transposition rate decreased significantly (P<0.05), and the expression level of SIRT1 increased significantly in the hyperoxia+resveratrol group (P<0.05). CONCLUSIONS Resveratrol can increase SIRT1 expression in PBMCs and inhibit SIRT1 shuttle from nucleus to cytoplasm in order to increase the ability of antioxidative stress in premature infants exposed to hyperoxia, thereby reducing the oxidative stress injury in premature infants.",2016,"The levels of ROS and MDA and the SIRT1 transposition rate decreased significantly (P<0.05), and the expression level of SIRT1 increased significantly in the hyperoxia+resveratrol group (P<0.05). ","['Peripheral blood and isolated PBMCs from premature infants (gestational age<32 weeks) without oxygen supplement', 'premature infants', 'premature infants exposed to hyperoxia']","['hyperoxia+resveratrol', 'SIRT1', 'control, air+resveratrol, hyperoxia, and hyperoxia+resveratrol']","['Malondialdehyde (MDA) content', 'levels of ROS and MDA and the SIRT1 transposition rate', 'level of SIRT1', 'antioxidative stress', 'expression levels in PBMCs', 'ROS content in PBMCs', 'expression level of SIRT1']","[{'cui': 'C0229664', 'cui_str': 'Peripheral blood (substance)'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0439671', 'cui_str': 'Gestational (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0242706', 'cui_str': 'Hyperoxia'}]","[{'cui': 'C2720167', 'cui_str': 'Sirt1'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0242706', 'cui_str': 'Hyperoxia'}]","[{'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0000379', 'cui_str': '1,3-Benzodioxole-5-ethanamine, alpha-methyl-'}, {'cui': 'C2720167', 'cui_str': 'Sirt1'}, {'cui': 'C0040759', 'cui_str': 'Transposition (morphologic abnormality)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C3854321', 'cui_str': 'Expression'}]",,0.0206587,"The levels of ROS and MDA and the SIRT1 transposition rate decreased significantly (P<0.05), and the expression level of SIRT1 increased significantly in the hyperoxia+resveratrol group (P<0.05). ","[{'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Department of Neonatology, First Affiliated Hospital of Sichuan Medical University, Luzhou, Sichuan 646000, China. dongwenbin2000@163.com.'}, {'ForeName': 'Wen-Bin', 'Initials': 'WB', 'LastName': 'Dong', 'Affiliation': ''}, {'ForeName': 'Qing-Ping', 'Initials': 'QP', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Lan', 'Initials': 'L', 'LastName': 'Kang', 'Affiliation': ''}, {'ForeName': 'Xiao-Ping', 'Initials': 'XP', 'LastName': 'Lei', 'Affiliation': ''}, {'ForeName': 'Lian-Yu', 'Initials': 'LY', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'You-Ying', 'Initials': 'YY', 'LastName': 'Lu', 'Affiliation': ''}, {'ForeName': 'Xue-Song', 'Initials': 'XS', 'LastName': 'Zhai', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1015,31555976,EPA and DHA as markers of nutraceutical treatment response in major depressive disorder.,"PURPOSE Depression clinical trials are increasingly studying biomarkers to predict and monitor response to treatment. Assessment of biomarkers may reveal subsets of patients who are responsive to nutraceutical treatment, which may facilitate a personalized approach to treating depression. METHODS This is a post hoc analysis of an 8-week, double-blind, randomized, controlled trial (n = 158) investigating a combination nutraceutical comprising Omega-3 (EPA 1 g/DHA 656 mg), SAMe, zinc, 5-HTP, folinic acid, and co-factors versus placebo for the treatment of Major Depressive Disorder. The study explored levels of polyunsaturated fatty acids, folate, vitamin B12, zinc, homocysteine, and BDNF as possible predictors and correlates of response to nutraceutical supplementation. RESULTS Concentrations of EPA and DHA in red cell membranes increased in response to treatment and were significantly correlated with a decrease in depressive symptoms during active treatment (p = 0.003 and p = 0.029; respectively). Higher baseline levels of omega-6 fatty acid also correlated with depression reduction in the active treatment group ( p = 0.011). No other biomarkers were associated with a lessening of depressive symptoms. CONCLUSION Changes in fatty acid levels resulting from a nutraceutical combination containing EPA and DHA provide a response biomarker in treating depression.",2020,Higher baseline levels of omega-6 fatty acid also correlated with depression reduction in the active treatment group ( p = 0.011).,"['major depressive disorder', 'Major Depressive Disorder']","['combination nutraceutical comprising Omega-3 (EPA 1\xa0g/DHA 656\xa0mg), SAMe, zinc, 5-HTP, folinic acid, and co-factors versus placebo', 'EPA and DHA']","['polyunsaturated fatty acids, folate, vitamin B12, zinc, homocysteine, and BDNF', 'depression reduction', 'depressive symptoms', 'Concentrations of EPA and DHA in red cell membranes', 'omega-6 fatty acid']","[{'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}]","[{'cui': 'C1518478', 'cui_str': 'Nutraceuticals'}, {'cui': 'C1719844', 'cui_str': 'Greek letter omega'}, {'cui': 'C0635011', 'cui_str': 'Epa-1'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0000578', 'cui_str': '5-Hydroxytryptophan'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0059057', 'cui_str': 'EPA (prealbumin)'}]","[{'cui': 'C0015684', 'cui_str': 'Fatty Acids'}, {'cui': 'C0178638', 'cui_str': 'Folate'}, {'cui': 'C0042845', 'cui_str': 'cyanocobalamin'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0019878', 'cui_str': '2-amino-4-mercaptobutyric acid'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0059057', 'cui_str': 'EPA (prealbumin)'}, {'cui': 'C0332575', 'cui_str': 'Red color (finding)'}, {'cui': 'C0007603', 'cui_str': 'Cytoplasmic Membrane'}, {'cui': 'C0133860', 'cui_str': 'Fatty Acids, Omega-6'}]",,0.311991,Higher baseline levels of omega-6 fatty acid also correlated with depression reduction in the active treatment group ( p = 0.011).,"[{'ForeName': 'Kiki P', 'Initials': 'KP', 'LastName': 'van der Burg', 'Affiliation': 'MaSc Medicine at University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.'}, {'ForeName': 'Lachlan', 'Initials': 'L', 'LastName': 'Cribb', 'Affiliation': 'Professorial Unit, The Melbourne Clinic, Department of Psychiatry, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Firth', 'Affiliation': 'NICM Health Research Institute, Western Sydney University, Westmead, Australia.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Karmacoska', 'Affiliation': 'NICM Health Research Institute, Western Sydney University, Westmead, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Mischoulon', 'Affiliation': 'Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Gerard J', 'Initials': 'GJ', 'LastName': 'Byrne', 'Affiliation': ""Faculty of Medicine, Discipline of Psychiatry, Centre for Clinical Research, Royal Brisbane and Women's Hospital, The University of Queensland, Herston, Australia.""}, {'ForeName': 'Chad', 'Initials': 'C', 'LastName': 'Bousman', 'Affiliation': 'Departments of Medical Genetics, Psychiatry, and Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Con', 'Initials': 'C', 'LastName': 'Stough', 'Affiliation': 'Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, Australia.'}, {'ForeName': 'Jenifer', 'Initials': 'J', 'LastName': 'Murphy', 'Affiliation': 'Professorial Unit, The Melbourne Clinic, Department of Psychiatry, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Georgina', 'Initials': 'G', 'LastName': 'Oliver', 'Affiliation': 'Professorial Unit, The Melbourne Clinic, Department of Psychiatry, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Berk', 'Affiliation': 'Department of Psychiatry, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Chee H', 'Initials': 'CH', 'LastName': 'Ng', 'Affiliation': 'Professorial Unit, The Melbourne Clinic, Department of Psychiatry, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Jerome', 'Initials': 'J', 'LastName': 'Sarris', 'Affiliation': 'Professorial Unit, The Melbourne Clinic, Department of Psychiatry, The University of Melbourne, Melbourne, Australia. j.sarris@westernsydney.edu.au.'}]",European journal of nutrition,['10.1007/s00394-019-02090-6'] 1016,27097575,[Efficacy of fluticasone propionate aerosol versus budesonide suspension in treatment of recurrent wheezing caused by bronchiolitis].,"OBJECTIVE To investigate the efficacy of fluticasone propionate aerosol (flixotide) versus budesonide suspension in the treatment of recurrent wheezing caused by bronchiolitis. METHODS A total of 214 infants with newly diagnosed bronchiolitis were randomly divided into flixotide treatment (106 infants) and budesonide treatment groups (108 infants), and were given aerosol inhalation of flixotide or budesonide for 3 months after achieving remission of clinical symptoms. Another 136 infants with bronchiolitis who did not receive regular inhalation of corticosteroid after achieving remission of clinical symptoms were enrolled as the control group. The follow-up visits were performed for 1 year, and the effects of the two therapeutic methods on recurrent wheezing were evaluated. RESULTS Compared with the control group, both the flixotide and budesonide treatment groups had significantly fewer times of wheezing episodes within 1 year and a significantly lower recurrence rate of wheezing within the first 3 months after regular inhalation of corticosteroid, but no significant differences were observed between the two treatment groups. The amount of corticosteroid inhaled and hospital costs in the budesonide treatment group were significantly higher than in the flixotide treatment group (P<0.01). CONCLUSIONS Continuous inhalation of flixotide or budesonide after remission of clinical symptoms in children with bronchiolitis can reduce wheezing episodes and the recurrence of wheezing, and flixotide treatment is superior to budesonide treatment in the aspects of hospital costs and the amount of corticosteroid used.",2016,"The amount of corticosteroid inhaled and hospital costs in the budesonide treatment group were significantly higher than in the flixotide treatment group (P<0.01). ","['children with bronchiolitis', '214 infants with newly diagnosed bronchiolitis', 'recurrent wheezing caused by bronchiolitis', 'Another 136 infants with bronchiolitis who did not receive regular inhalation of corticosteroid after achieving remission of clinical symptoms were enrolled as the control group']","['aerosol inhalation of flixotide or budesonide', 'flixotide or budesonide', 'fluticasone propionate aerosol versus budesonide suspension', 'flixotide and budesonide', 'budesonide', 'flixotide treatment', 'budesonide suspension', 'fluticasone propionate aerosol (flixotide']","['times of wheezing episodes', 'amount of corticosteroid inhaled and hospital costs', 'recurrent wheezing', 'recurrence rate of wheezing']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0006271', 'cui_str': 'Bronchiolitis'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0043144', 'cui_str': 'Wheezing'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C4517568', 'cui_str': 'One hundred and thirty-six'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C1705211', 'cui_str': 'Inhalation - unit of product usage'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0001712', 'cui_str': 'Aerosol (substance)'}, {'cui': 'C1705211', 'cui_str': 'Inhalation - unit of product usage'}, {'cui': 'C0591521', 'cui_str': 'Flixotide'}, {'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C0117996', 'cui_str': 'Fluticasone propionate'}, {'cui': 'C1382107', 'cui_str': 'Suspension'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0043144', 'cui_str': 'Wheezing'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0206174', 'cui_str': 'Hospital Costs'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}]",214.0,0.0220082,"The amount of corticosteroid inhaled and hospital costs in the budesonide treatment group were significantly higher than in the flixotide treatment group (P<0.01). ","[{'ForeName': 'Wei-Ping', 'Initials': 'WP', 'LastName': 'Lan', 'Affiliation': 'Department of Pediatrics, Provincial Hospital Affiliated to Medical University of Anhui, Hefei 230001, China. panjiahua1960@163.com.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Chuan-Lin', 'Initials': 'CL', 'LastName': 'Dai', 'Affiliation': ''}, {'ForeName': 'Jia-Hua', 'Initials': 'JH', 'LastName': 'Pan', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1017,31552500,A comparison between whole grain and pearled oats: acute postprandial glycaemic responses and in vitro carbohydrate digestion in healthy subjects.,"PURPOSE To compare the glycaemic response of whole grain oat kernels and pearled oats cooked under normal pressure or higher pressure and examine whether replacing half of the rice in a given meal with either of the two oat grains could make a difference in acute glycaemic responses. METHODS In a randomised crossover trial, ten healthy subjects consumed two groups of test meals: (1) oat grain-only, including whole grain oats cooked under normal pressure (WONP) and higher pressure (WOHP) as well as their pearled oat counterparts, PONP and POHP; and (2) mixed meals of aforementioned oat grains and cooked rice (OG + R), including WONP + R, WOHP + R, PONP + R and POHP + R. A postprandial blood glucose test, texture profile analysis and in vitro carbohydrate digestion assay were carried out for each test meal. RESULTS Compared with the rice reference, oat grain-only meals induced lower glucose levels at all time points, lower peak values and smaller glucose excursions at 120 min (P < 0.05), but OG + Rs did not have the abovementioned effects. The oat grain-only meals had glycaemic indexes (GIs) ranging from 51 to 58, while those of OG + Rs ranged from 59 to 70. WONP + R had a 21% lower iAUC 0-60 and a 40% lower iAUC 60-120 value than those of rice (P < 0.05). Oat-rice mixed meals had lower iAUC 0-60 values compared with that of the rice control (P < 0.05), except for POHP + R. Excellent consistency between the hydrolysis index and the GI was observed (r = 0.969, P < 0.001) in oat grain-only meals. CONCLUSIONS All oat grain-only meals could be included in the glycaemic management diet, regardless of the oat grain type or cooking treatment. In oat-rice mixed meals, whole grain oats and normal pressure cooking ensured a favourable glycaemic effect.",2020,"Compared with the rice reference, oat grain-only meals induced lower glucose levels at all time points, lower peak values and smaller glucose excursions at 120 min (P < 0.05), but OG + Rs did not have the abovementioned effects.","['ten healthy subjects consumed two groups of test meals: (1', 'healthy subjects']","['whole grain and pearled oats: acute postprandial glycaemic responses and in vitro carbohydrate digestion', 'WONP', 'oat-rice mixed meals, whole grain oats and normal pressure cooking', 'oat grain-only, including whole grain oats cooked under normal pressure (WONP) and higher pressure (WOHP) as well as their pearled oat counterparts, PONP and POHP; and (2) mixed meals of aforementioned oat grains and cooked rice (OG\u2009+\u2009R), including WONP\u2009+\u2009R, WOHP\u2009+\u2009R, PONP\u2009+\u2009R and POHP\u2009+\u2009R. A postprandial blood glucose test, texture profile analysis and in vitro carbohydrate digestion assay were carried out for each test meal', 'whole grain oat kernels and pearled oats cooked under normal pressure']","['acute glycaemic responses', 'peak values and smaller glucose excursions', 'glycaemic response', 'glucose levels']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}]","[{'cui': 'C4042940', 'cui_str': 'Whole Grains'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0021135', 'cui_str': 'In Vitro'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0012238', 'cui_str': 'Digestion'}, {'cui': 'C0028753', 'cui_str': 'Oats (substance)'}, {'cui': 'C0035567', 'cui_str': 'Rice'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0335326', 'cui_str': 'Cookery'}, {'cui': 'C0086369', 'cui_str': 'Grain (substance)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1306756', 'cui_str': 'Cook (occupation)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0449582', 'cui_str': 'With texture (attribute)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C1510438', 'cui_str': 'Assay technique (qualifier value)'}, {'cui': 'C0439787', 'cui_str': 'Out (qualifier value)'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0428548', 'cui_str': 'Glucose level - finding'}]",10.0,0.0262235,"Compared with the rice reference, oat grain-only meals induced lower glucose levels at all time points, lower peak values and smaller glucose excursions at 120 min (P < 0.05), but OG + Rs did not have the abovementioned effects.","[{'ForeName': 'Ruixin', 'Initials': 'R', 'LastName': 'Zhu', 'Affiliation': 'Beijing Advanced Innovation Centre for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, 100083, China.'}, {'ForeName': 'Zhihong', 'Initials': 'Z', 'LastName': 'Fan', 'Affiliation': 'Beijing Advanced Innovation Centre for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, 100083, China. daisyfan@cau.edu.cn.'}, {'ForeName': 'Guojing', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'Beijing Advanced Innovation Centre for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, 100083, China.'}, {'ForeName': 'Yixue', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Beijing Advanced Innovation Centre for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, 100083, China.'}, {'ForeName': 'Wenqi', 'Initials': 'W', 'LastName': 'Zhao', 'Affiliation': 'Beijing Advanced Innovation Centre for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, 100083, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Ye', 'Affiliation': 'Beijing Advanced Innovation Centre for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, 100083, China.'}, {'ForeName': 'Linlin', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Beijing Advanced Innovation Centre for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, 100083, China.'}]",European journal of nutrition,['10.1007/s00394-019-02083-5'] 1018,26975813,[Effect and safety of intensive phototherapy in treatment of neonatal hyperbilirubinemia].,"OBJECTIVE To study the effect and safety of intensive phototherapy in the treatment of neonatal hyperbilirubinemia. METHODS A total of 144 neonates with neonatal hyperbilirubinemia were randomly and prospectively divided into intensive phototherapy group and conventional phototherapy group, with 72 neonates in each group. The therapeutic effect and incidence of complications were compared between the two groups. RESULTS Within 12 hours after phototherapy, the total serum bilirubin level in the intensive phototherapy group was significantly lower than in the conventional phototherapy group (P<0.05), and the intensive phototherapy group had a significantly greater reduction in serum bilirubin level than the conventional phototherapy group (P<0.05). The intensives phototherapy group had a significantly shorter time of phototherapy than the conventional phototherapy group (P<0.05). The incidence rates of fever, diarrhea, rash, and hypocalcemia and reductions in blood calcium and hemoglobin levels after phototherapy showed no significant differences between the two groups. CONCLUSIONS During the initial stage of phototherapy, intensive phototherapy can quickly and effectively reduce the serum level of bilirubin in neonates with neonatal hyperbilirubinemia. It can also shorten the total phototherapy time, and does not increase the incidence of adverse events. Therefore, it is superior to conventional phototherapy.",2016,The intensives phototherapy group had a significantly shorter time of phototherapy than the conventional phototherapy group (P<0.05).,"['neonates with neonatal hyperbilirubinemia', '144 neonates with neonatal hyperbilirubinemia', 'neonatal hyperbilirubinemia']","['intensive phototherapy group and conventional phototherapy', 'intensive phototherapy', 'conventional phototherapy']","['shorter time of phototherapy', 'total phototherapy time', 'incidence of adverse events', 'total serum bilirubin level', 'incidence rates of fever, diarrhea, rash, and hypocalcemia and reductions in blood calcium and hemoglobin levels', 'serum level of bilirubin', 'serum bilirubin level', 'therapeutic effect and incidence of complications']","[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0857007', 'cui_str': 'Hyperbilirubinemia, Neonatal'}]","[{'cui': 'C0031765', 'cui_str': 'Photoradiation Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]","[{'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0031765', 'cui_str': 'Photoradiation Therapy'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1287366', 'cui_str': 'Finding of serum bilirubin level (finding)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0015230', 'cui_str': 'Skin Rash'}, {'cui': 'C0020598', 'cui_str': 'Hypocalcemia'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0729820', 'cui_str': 'Blood calcium measurement'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin IX alpha'}, {'cui': 'C1527144'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}]",144.0,0.0299045,The intensives phototherapy group had a significantly shorter time of phototherapy than the conventional phototherapy group (P<0.05).,"[{'ForeName': 'Xiao-Rui', 'Initials': 'XR', 'LastName': 'Zhang', 'Affiliation': ""Department of Pediatrics, Peking University People's Hospital, Beijing 100044, China. zengcm@bjmu.edu.cn.""}, {'ForeName': 'Chao-Mei', 'Initials': 'CM', 'LastName': 'Zeng', 'Affiliation': ''}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1019,32419119,The Effectiveness and Cost-effectiveness of a Parenting Intervention Integrated with Primary Health Care on Early Childhood Development: a Cluster-Randomized Controlled Trial.,"Developing countries require interventions that can sustainably improve early childhood development (ECD) at scale because hundreds of millions of children are at risk of poor development. This study examined the effectiveness and cost-effectiveness of a parenting intervention integrated with primary health care in terms of ECD. A cluster-randomized controlled trial was conducted in 20 urban communities in China, with 82 and 86 children aged 1-2 months enrolled in the intervention and control groups, respectively, and 71 and 69 children, respectively, followed to 14 months of age. All children in both groups received routine primary health care services. Intervention caregivers received a parenting pamphlet and two parenting training sessions during well-child clinic visits; those with children with suspected developmental delay received additional parenting guidance by telephone. Compared with controls, children receiving the intervention had similar developmental outcomes, measured with the Chinese version of the Ages & Stages Questionnaires third edition (ASQ-C), at baseline, but had significantly higher communication (adjusted mean difference = 0.26; 95% CI 0.03, 0.51), fine motor (adjusted mean difference = 0.19; 95% CI 0.01, 0.37), and overall (adjusted mean difference = 0.25; 95% CI 0.10, 0.41) ASQ-C z-scores after 12 months of the intervention. The intervention cost per child was $50.87, and the costs for increasing the communication, fine motor, and overall ASQ-C scores by one SD were $195.65, $267.74, and $203.48, respectively. Our findings indicate that the integration of a parenting intervention with existing primary health care is a cost-effective way to improve ECD.",2020,"Compared with controls, children receiving the intervention had similar developmental outcomes, measured with the Chinese version of the Ages & Stages Questionnaires third edition (ASQ-C), at baseline, but had significantly higher communication (adjusted mean difference = 0.26; 95% CI 0.03, 0.51), fine motor (adjusted mean difference = 0.19; 95% CI 0.01, 0.37), and overall (adjusted mean difference = 0.25; 95% CI 0.10, 0.41) ASQ-C z-scores after 12 months of the intervention.","['20 urban communities in China, with 82 and 86 children aged 1-2\xa0months enrolled in the intervention and control groups, respectively, and 71 and 69 children, respectively, followed to 14\xa0months of age']","['parenting pamphlet and two parenting training sessions during well-child clinic visits; those with children with suspected developmental delay received additional parenting guidance by telephone', 'routine primary health care services', 'Parenting Intervention Integrated with Primary Health Care', 'parenting intervention integrated with primary health care']","['costs for increasing the communication, fine motor, and overall ASQ-C scores', 'Chinese version of the Ages & Stages Questionnaires third edition (ASQ-C', 'fine motor', 'effectiveness and cost-effectiveness', 'Effectiveness and Cost-effectiveness']","[{'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0008952', 'cui_str': 'Clinic Visits'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0424605', 'cui_str': 'Developmental delay'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0205232', 'cui_str': 'Fine'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0441796', 'cui_str': 'Third edition'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",,0.116487,"Compared with controls, children receiving the intervention had similar developmental outcomes, measured with the Chinese version of the Ages & Stages Questionnaires third edition (ASQ-C), at baseline, but had significantly higher communication (adjusted mean difference = 0.26; 95% CI 0.03, 0.51), fine motor (adjusted mean difference = 0.19; 95% CI 0.01, 0.37), and overall (adjusted mean difference = 0.25; 95% CI 0.10, 0.41) ASQ-C z-scores after 12 months of the intervention.","[{'ForeName': 'Huifeng', 'Initials': 'H', 'LastName': 'Shi', 'Affiliation': 'Department of Maternal and Child Health, School of Public Health, Peking University, Beijing, 38 Xueyuan Road, Haidian District, Beijing, 100191, China.'}, {'ForeName': 'Xuejun', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, 168 Litang Road, Changping District, Beijing, 102218, China. lixuejun0627@163.com.'}, {'ForeName': 'Hai', 'Initials': 'H', 'LastName': 'Fang', 'Affiliation': 'China Center for Health Development Studies (CCHDS), Peking University, 38 Xueyuan Road, Haidian District, Beijing, 100191, China.'}, {'ForeName': 'Jingxu', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Maternal and Child Health, School of Public Health, Peking University, Beijing, 38 Xueyuan Road, Haidian District, Beijing, 100191, China.'}, {'ForeName': 'Xiaoli', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Maternal and Child Health, School of Public Health, Peking University, Beijing, 38 Xueyuan Road, Haidian District, Beijing, 100191, China. xlwang@bjmu.edu.cn.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-020-01126-2'] 1020,26975815,[Effect of caffeine citrate on early pulmonary function in preterm infants with apnea].,"OBJECTIVE To investigate the effect of caffeine citrate treatment on early pulmonary function in preterm infants with apnea. METHODS Forty preterm infants with apnea were randomly divided into aminophylline treatment group (20 infants) and caffeine citrate treatment group (20 infants). When the preterm infants experienced apnea after birth, they were given aminophylline or caffeine citrate in addition to assisted ventilation with continuous positive airway pressure (NCPAP). After drug discontinuation, pulmonary function was measured and compared between the two groups. RESULTS After treatment, compared with the aminophylline treatment group, the caffeine citrate treatment group had significantly higher tidal volume, minute ventilation volume, ratio of time to peak tidal expiratory flow to total expiratory time, ratio of volume to peak tidal expiratory flow to total expiratory volume, peak expiratory flow, and breathing flow at 75%, 50%, and 25% of tidal volume (P<0.05). The caffeine citrate treatment group had a significantly shorter time of oxygen use and NCPAP support than the aminophylline treatment group (P<0.01). Compared with the aminophylline treatment group, the caffeine citrate treatment group had a significantly lower frequency of apnea attacks (P<0.01). CONCLUSIONS In the treatment of apnea in preterm infants, caffeine citrate can improve early pulmonary function and reduce the incidence of apnea.",2016,The caffeine citrate treatment group had a significantly shorter time of oxygen use and NCPAP support than the aminophylline treatment group (P<0.01).,"['preterm infants experienced apnea after birth', 'preterm infants with apnea', 'Forty preterm infants with apnea', 'group (20 infants']","['caffeine citrate treatment', 'caffeine citrate', 'aminophylline or caffeine citrate', 'aminophylline']","['shorter time of oxygen use and NCPAP support', 'frequency of apnea attacks', 'tidal volume, minute ventilation volume, ratio of time to peak tidal expiratory flow to total expiratory time, ratio of volume to peak tidal expiratory flow to total expiratory volume, peak expiratory flow, and breathing flow', 'pulmonary function', 'incidence of apnea', 'early pulmonary function']","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0054436', 'cui_str': 'caffeine citrate'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0002575', 'cui_str': 'Aminophylline'}]","[{'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0474454', 'cui_str': 'Apneic attack'}, {'cui': 'C0040210', 'cui_str': 'Tidal Volume'}, {'cui': 'C1301655', 'cui_str': 'Minute ventilation'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0428687', 'cui_str': 'Expiratory time (observable entity)'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}]",40.0,0.0141569,The caffeine citrate treatment group had a significantly shorter time of oxygen use and NCPAP support than the aminophylline treatment group (P<0.01).,"[{'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Yu', 'Affiliation': 'Department of Pediatrics, Binhu Hospital of Southern District, First Hospital of Hefei City, Hefei 230061, China. wenxiaohong2007@163.com.'}, {'ForeName': 'Jin-Hua', 'Initials': 'JH', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Zhu', 'Affiliation': ''}, {'ForeName': 'Xu-Zhong', 'Initials': 'XZ', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Wan-Yun', 'Initials': 'WY', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Xiao-Hong', 'Initials': 'XH', 'LastName': 'Wen', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1021,26975818,"[Effect of continuous hemofiltration on inflammatory mediators and hemodynamics in children with severe hand, foot and mouth disease].","OBJECTIVE To investigate the effect of continuous veno-venous hemofiltration (CVVH) on inflammatory mediators in children with severe hand, foot and mouth disease (HFMD), and to investigate its clinical efficacy. METHODS A total of 36 children with stage IV HFMD were enrolled and randomly divided into conventional treatment group and CVVH group (n=18 each). The children in the CVVH group were given CVVH for 48 hours in addition to the conventional treatment. The levels of interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α) and lactic acid in peripheral venous blood, heart rate, blood pressure, and left ventricular ejection fraction were measured before treatment and after 24 and 48 hours of treatment. RESULTS After 24 hours of treatment, the conventional treatment group had a significantly reduced serum IL-2 level (P<0.01), and the CVVH treatment group had significantly reduced serum levels of IL-2, IL-6, IL-10, and TNF-α (P<0.05). After 48 hours of treatment, both groups had significantly reduced serum levels of IL-2, IL-6, IL-10, and TNF-α (P<0.01), and the CVVH group had significantly lower levels of these inflammatory factors than the conventional treatment group (P<0.01). After 48 hours of treatment, heart rate, systolic pressure, and blood lactic acid level were significantly reduced, and left ventricular ejection fraction was significantly increased in both groups, and the CVVH group had significantly greater changes in these indices except systolic pressure than the conventional treatment group (P<0.01). CONCLUSIONS CVVH can effectively eliminate inflammatory factors, reduce heart rate and venous blood lactic acid, and improve heart function in children with severe HFMD.",2016,"After 48 hours of treatment, both groups had significantly reduced serum levels of IL-2, IL-6, IL-10, and TNF-α (P<0.01), and the CVVH group had significantly lower levels of these inflammatory factors than the conventional treatment group (P<0.01).","['children with severe HFMD', 'children with severe hand, foot and mouth disease (HFMD', '36 children with stage IV HFMD', 'children with severe hand, foot and mouth disease']","['CVVH', 'continuous veno-venous hemofiltration (CVVH', 'continuous hemofiltration', 'conventional treatment group and CVVH group ']","['heart rate, systolic pressure, and blood lactic acid level', 'inflammatory mediators and hemodynamics', 'systolic pressure', 'serum IL-2 level', 'serum levels of IL-2, IL-6, IL-10, and TNF-α', 'inflammatory factors', 'left ventricular ejection fraction', 'serum levels of IL-2, IL-6, IL-10, and TNF-α (P<0.05', 'heart rate and venous blood lactic acid', 'levels of interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α) and lactic acid in peripheral venous blood, heart rate, blood pressure, and left ventricular ejection fraction', 'heart function']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0018572', 'cui_str': 'Hand, Foot and Mouth Disease'}, {'cui': 'C0441772', 'cui_str': 'Stage level 4 (qualifier value)'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0348013', 'cui_str': 'Venous (qualifier value)'}, {'cui': 'C0019014', 'cui_str': 'Hemofiltration'}, {'cui': 'C0472683', 'cui_str': 'Continuous hemofiltration (procedure)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0853170', 'cui_str': 'Blood lactic acid'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0021756', 'cui_str': 'TCGF'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0229667', 'cui_str': 'VB - Venous blood'}, {'cui': 'C0064582', 'cui_str': 'Lactic acid'}, {'cui': 'C0041368', 'cui_str': 'Tumor Necrosis Factors'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction (observable entity)'}, {'cui': 'C4521692', 'cui_str': 'Cardiac physiological function (observable entity)'}]",36.0,0.0649103,"After 48 hours of treatment, both groups had significantly reduced serum levels of IL-2, IL-6, IL-10, and TNF-α (P<0.01), and the CVVH group had significantly lower levels of these inflammatory factors than the conventional treatment group (P<0.01).","[{'ForeName': 'Li-Jing', 'Initials': 'LJ', 'LastName': 'Cao', 'Affiliation': ""Intensive Care Unit One, Children's Hospital of Hebei Province, Shijiazhuang 050031, China. xmin17909@126.com.""}, {'ForeName': 'Wen-Jin', 'Initials': 'WJ', 'LastName': 'Geng', 'Affiliation': ''}, {'ForeName': 'Mei-Xian', 'Initials': 'MX', 'LastName': 'Xu', 'Affiliation': ''}, {'ForeName': 'Xi-Min', 'Initials': 'XM', 'LastName': 'Huo', 'Affiliation': ''}, {'ForeName': 'Xiao-Dong', 'Initials': 'XD', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Xiao-Na', 'Initials': 'XN', 'LastName': 'Shi', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1022,32063041,SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation: A Cluster-Randomized Study of Electronic Profiling and Messaging Combined With Academic Detailing for Providers Making Decisions About Anticoagulation in Patients With Atrial Fibrillation.,"BACKGROUND Previous provider-directed electronic messaging interventions have not by themselves improved anticoagulation use in patients with atrial fibrillation. Direct engagement with providers using academic detailing coupled with electronic messaging may overcome the limitations of the prior interventions. METHODS AND RESULTS We randomized outpatient providers affiliated with our health system in a 2.5:1 ratio to our electronic profiling/messaging combined with academic detailing intervention. In the intervention, we emailed providers monthly reports of their anticoagulation percentage relative to peers for atrial fibrillation patients with elevated stroke risk (CHA 2 DS 2 -VASc ≥2). We also sent electronic medical record-based messages shortly before an appointment with an anticoagulation-eligible but untreated atrial fibrillation patient. Providers had the option to send responses with explanations for prescribing decisions. We also offered to meet with intervention providers using an academic detailing approach developed based on knowledge gaps discussed in provider focus groups. To assess feasibility, we tracked provider review of our messages. To assess effectiveness, we measured the change in anticoagulation for patients of intervention providers relative to controls. We identified 85 intervention and 34 control providers taking care of 3591 and 1908 patients, respectively; 33 intervention providers participated in academic detailing. More than 80% of intervention providers read our emails, and 98% of the time a provider reviewed our in-basket messages. Replies to messages identified patient refusal as the most common reason for patients not being on anticoagulation (11.2%). For the group of patients not on anticoagulation at baseline assigned to an intervention versus control provider, the adjusted percent increase in the use of anticoagulation over 6 months was 5.2% versus 7.4%, respectively ( P =0.21). CONCLUSIONS Our electronic messaging and academic detailing intervention was feasible but did not increase anticoagulation use. Patient-directed interventions or provider interventions targeting patients declining anticoagulation may be necessary to raise the rate of anticoagulation. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT03583008.",2020,"We identified 85 intervention and 34 control providers taking care of 3591 and 1908 patients, respectively; 33 intervention providers participated in academic detailing.","['atrial fibrillation patients with elevated stroke risk (CHA 2 DS 2 -VASc ≥2', 'We randomized outpatient providers affiliated with our health system in a 2.5:1 ratio to our electronic profiling/messaging combined with academic detailing intervention', '34 control providers taking care of 3591 and 1908 patients, respectively; 33 intervention providers participated in academic detailing', 'Patients With Atrial Fibrillation', 'patients with atrial fibrillation', 'Atrial Fibrillation', 'patients of intervention providers relative to controls']","['SUPPORT-AF II', 'Electronic Profiling and Messaging Combined With Academic Detailing for Providers Making Decisions']",[],"[{'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1277291', 'cui_str': 'Stroke risk'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C3875154', 'cui_str': 'Relative to (attribute)'}]","[{'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]",[],,0.098147,"We identified 85 intervention and 34 control providers taking care of 3591 and 1908 patients, respectively; 33 intervention providers participated in academic detailing.","[{'ForeName': 'Alok', 'Initials': 'A', 'LastName': 'Kapoor', 'Affiliation': 'University of Massachusetts Memorial Health Care, Worcester (A.K., A.A, E.A., R.E., D.D.M.).'}, {'ForeName': 'Azraa', 'Initials': 'A', 'LastName': 'Amroze', 'Affiliation': 'University of Massachusetts Memorial Health Care, Worcester (A.K., A.A, E.A., R.E., D.D.M.).'}, {'ForeName': 'Fatima', 'Initials': 'F', 'LastName': 'Vakil', 'Affiliation': ""Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH (F.V.).""}, {'ForeName': 'Sybil', 'Initials': 'S', 'LastName': 'Crawford', 'Affiliation': 'University of Massachusetts Medical School, Worcester (A.K., S.C., J.M., E.A., S.J., R.E., A.L., S.N., A.N., K.M.M., J.S.S., D.D.M.).'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Der', 'Affiliation': 'Northeastern University, Boston, MA (J.D., J.S.S.).'}, {'ForeName': 'Jomol', 'Initials': 'J', 'LastName': 'Mathew', 'Affiliation': 'University of Massachusetts Medical School, Worcester (A.K., S.C., J.M., E.A., S.J., R.E., A.L., S.N., A.N., K.M.M., J.S.S., D.D.M.).'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Alper', 'Affiliation': 'University of Massachusetts Memorial Health Care, Worcester (A.K., A.A, E.A., R.E., D.D.M.).'}, {'ForeName': 'Dinesh', 'Initials': 'D', 'LastName': 'Yogaratnam', 'Affiliation': 'Mass College of Pharmacy and Health Sciences, Worcester, MA (D.Y., D.B.).'}, {'ForeName': 'Saud', 'Initials': 'S', 'LastName': 'Javed', 'Affiliation': 'University of Massachusetts Medical School, Worcester (A.K., S.C., J.M., E.A., S.J., R.E., A.L., S.N., A.N., K.M.M., J.S.S., D.D.M.).'}, {'ForeName': 'Rasha', 'Initials': 'R', 'LastName': 'Elhag', 'Affiliation': 'University of Massachusetts Memorial Health Care, Worcester (A.K., A.A, E.A., R.E., D.D.M.).'}, {'ForeName': 'Abraham', 'Initials': 'A', 'LastName': 'Lin', 'Affiliation': 'University of Massachusetts Medical School, Worcester (A.K., S.C., J.M., E.A., S.J., R.E., A.L., S.N., A.N., K.M.M., J.S.S., D.D.M.).'}, {'ForeName': 'Siddhartha', 'Initials': 'S', 'LastName': 'Narayanan', 'Affiliation': 'University of Massachusetts Medical School, Worcester (A.K., S.C., J.M., E.A., S.J., R.E., A.L., S.N., A.N., K.M.M., J.S.S., D.D.M.).'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Bartlett', 'Affiliation': 'Mass College of Pharmacy and Health Sciences, Worcester, MA (D.Y., D.B.).'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Nagy', 'Affiliation': 'University of Massachusetts Medical School, Worcester (A.K., S.C., J.M., E.A., S.J., R.E., A.L., S.N., A.N., K.M.M., J.S.S., D.D.M.).'}, {'ForeName': 'Bevin Kathleen', 'Initials': 'BK', 'LastName': 'Shagoury', 'Affiliation': ""The National Resource Center for Academic Detailing, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA (B.K.S., M.A.F.).""}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Fischer', 'Affiliation': ""The National Resource Center for Academic Detailing, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA (B.K.S., M.A.F.).""}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Mazor', 'Affiliation': 'University of Massachusetts Medical School, Worcester (A.K., S.C., J.M., E.A., S.J., R.E., A.L., S.N., A.N., K.M.M., J.S.S., D.D.M.).'}, {'ForeName': 'Jane S', 'Initials': 'JS', 'LastName': 'Saczynski', 'Affiliation': 'University of Massachusetts Medical School, Worcester (A.K., S.C., J.M., E.A., S.J., R.E., A.L., S.N., A.N., K.M.M., J.S.S., D.D.M.).'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Ashburner', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Boston (J.M.A.).'}, {'ForeName': 'Renato', 'Initials': 'R', 'LastName': 'Lopes', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC (R.L.).'}, {'ForeName': 'David D', 'Initials': 'DD', 'LastName': 'McManus', 'Affiliation': 'University of Massachusetts Memorial Health Care, Worcester (A.K., A.A, E.A., R.E., D.D.M.).'}]",Circulation. Cardiovascular quality and outcomes,['10.1161/CIRCOUTCOMES.119.005871'] 1023,26398741,Comparative Assessment of a Single Dose and a 2-dose Vaccination Series of a Quadrivalent Meningococcal CRM-conjugate Vaccine (MenACWY-CRM) in Children 2-10 Years of Age.,"BACKGROUND We compared the immunogenicity, safety and 1-year antibody persistence of a single-dose and a 2-dose series of a licensed meningococcal ACWY-CRM conjugate vaccine (MenACWY-CRM) in 2- to 10-year-old children. METHODS In this phase III, multicenter, observer-blind study, children aged 2-5 years (n = 359) and 6-10 years (n = 356) were randomized 1:1 to receive 2 doses of MenACWY-CRM (ACWY2) or 1 dose of placebo followed by 1 dose of MenACWY-CRM (ACWY1), 2 months apart. Immunogenicity was measured using serum bactericidal activity with human complement (hSBA). Primary outcomes were to assess the immunologic noninferiority and superiority of ACWY2 versus ACWY1. RESULTS One-month after the second dose, the hSBA seroresponse in ACWY2 was noninferior to ACWY1 for all 4 serogroups, in both age cohorts, and was superior for serogroups C and Y in the 2- to 5-year-old age cohort and for serogroup Y in the 6- to 10-year-old age cohort. Overall, 90%-99% of subjects in ACWY2 and 65%-96% in ACWY1 had hSBA titers ≥ 8; geometric mean titers were 1.8- to 6.4-fold higher in ACWY2 than ACWY1 across serogroups. At 1 year postvaccination, geometric mean titers declined, and the differences between ACWY2 and ACWY1 remained significant for serogroups A and C in the 2- to 5-year-old age cohort and for serogroups C and Y in the 6- to 10-year-old age cohort. The safety profile of MenACWY-CRM was similar in both groups. CONCLUSIONS The single dose and 2-dose MenACWY-CRM series were immunogenic and well tolerated. Although antibody responses were greater after 2 doses, especially in the 2- to 5-year-old age cohort, this difference was less pronounced at 1 year postvaccination.",2016,"One-month after the second dose, the hSBA seroresponse in ACWY2 was noninferior to ACWY1 for all 4 serogroups, in both age cohorts, and was superior for serogroups C and Y in the 2- to 5-year-old age cohort and for serogroup Y in the 6- to 10-year-old age cohort.","['children aged 2-5 years (n = 359) and 6-10 years (n = 356', 'Children 2-10 Years of Age', '2- to 10-year-old children']","['MenACWY-CRM (ACWY2) or 1 dose of placebo', 'Quadrivalent Meningococcal CRM-conjugate Vaccine (MenACWY-CRM', 'licensed meningococcal ACWY-CRM conjugate vaccine (MenACWY-CRM']","['immunogenic and well tolerated', 'hSBA titers ≥ 8; geometric mean titers', 'Immunogenicity', 'antibody responses', 'immunologic noninferiority and superiority of ACWY2 versus ACWY1', 'safety profile of MenACWY-CRM', 'immunogenicity, safety and 1-year antibody persistence', 'geometric mean titers']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C2003457', 'cui_str': 'MenACWY'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0206515', 'cui_str': 'Vaccines, Conjugate'}]","[{'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0003261', 'cui_str': 'Antibody Response'}, {'cui': 'C0205470', 'cui_str': 'Immunologic (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2003457', 'cui_str': 'MenACWY'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0546816', 'cui_str': 'Persistence (finding)'}]",356.0,0.104164,"One-month after the second dose, the hSBA seroresponse in ACWY2 was noninferior to ACWY1 for all 4 serogroups, in both age cohorts, and was superior for serogroups C and Y in the 2- to 5-year-old age cohort and for serogroup Y in the 6- to 10-year-old age cohort.","[{'ForeName': 'William', 'Initials': 'W', 'LastName': 'Johnston', 'Affiliation': 'From the *Alabama Clinical Therapeutics, Birmingham, Alabama; †Meridian Clinical Research, Omaha, Nebraska; ‡Advanced Clinical Research, West Jordan, Utah; §GlaxoSmithKline LLC, Cambridge, Massachusetts; and ¶GlaxoSmithKline BV, Amsterdam, The Netherlands.'}, {'ForeName': 'Brandon', 'Initials': 'B', 'LastName': 'Essink', 'Affiliation': ''}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Kirstein', 'Affiliation': ''}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Forleo-Neto', 'Affiliation': ''}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Percell', 'Affiliation': ''}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Han', 'Affiliation': ''}, {'ForeName': 'Pavitra', 'Initials': 'P', 'LastName': 'Keshavan', 'Affiliation': ''}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Smolenov', 'Affiliation': ''}]",The Pediatric infectious disease journal,['10.1097/INF.0000000000000931'] 1024,32417348,Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.,"BACKGROUND Concurrent chemoradiotherapy (CRT) is the standard of care (SoC) in locally advanced (LA) head and neck squamous cell carcinomas (HNSCC). This trial was designed to test whether dose-escalated IMRT and cisplatin could improve locoregional control without increasing complications over 3D-radiotherapy. METHODS Patients were randomized between 70 Gy/35F in 7 weeks with 3D-RT (Arm A) versus 75 Gy/35F with IMRT (Arm B). Both arms received 50 Gy in 25 fractions followed by a sequential boost of 20 Gy/10F in Arm A and 25 Gy/10F to gross tumor volume in Arm B, as well as 3 cycles of cisplatin at 100 mg/m2 during RT. The primary endpoint was locoregional progression (LRP). RESULTS 188 patients were randomized: 85% oropharynx and 73% stage IVa. P16 status was documented for 137 oropharyngeal tumors with P16+ in 53 (39%) patients; and 90% were smokers. Median follow-up was 60.5 months. Xerostomia was markedly decreased in arm B (p < 0.0001). The 1-year grade ≥2 xerostomia (RTOG criteria) was 63% vs 23% and 3-year 45% vs 11% in arms A and B, respectively. Xerostomia LENT-SOMA scale was also reduced in arm B. Dose-escalated IMRT did not reduce LRP with an adjusted HR of 1.13 [95%CI = 0.64-1.98] (p = 0.68). Survival was not different (adjusted HR: 1.19 [95%CI = 0.78-1.81], p = 0.42). No interaction between p16 and treatment effect was found. CONCLUSION Dose-escalated IMRT did not improve LRC in LA-HNSCC patients treated with concomitant CRT over standard 3D-RT. This trial reinforces the evidence showing IMRT reduces xerostomia in LA-HNSCC treated with radiotherapy. Clinicaltrial.gov: NCT00158678.",2020,"CONCLUSION Dose-escalated IMRT did not improve LRC in LA-HNSCC patients treated with concomitant CRT over standard 3D-RT.","['locally advanced (LA) head and neck squamous cell carcinomas (HNSCC', '188 patients were randomized: 85% oropharynx and 73% stage IVa', 'patients', 'locally advanced head and neck squamous cell carcinomas (HNSCC']","['Concurrent chemoradiotherapy (CRT', 'radiotherapy', 'Concurrent cisplatin and Dose escalation with Intensity-modulated radiotherapy (IMRT', 'cisplatin', 'conventional radiotherapy', 'IMRT and cisplatin', '75Gy/35F with IMRT']","['1-year grade ≥ 2 xerostomia (RTOG criteria', 'Xerostomia LENT-SOMA scale', 'Survival', 'P16 status', 'Xerostomia', 'locoregional progression (LRP', 'xerostomia']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1168401', 'cui_str': 'Squamous cell carcinoma of head and neck'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521367', 'cui_str': 'Oropharyngeal structure'}, {'cui': 'C0441773', 'cui_str': 'Stage IVa'}]","[{'cui': 'C3178775', 'cui_str': 'Concomitant Radiochemotherapy'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C1512814', 'cui_str': 'Intensity modulated radiation therapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0043352', 'cui_str': 'Xerostomia'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0702216', 'cui_str': 'Soma'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0249880', 'cui_str': 'Cdk4-Associated Protein p16'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}]",188.0,0.356655,"CONCLUSION Dose-escalated IMRT did not improve LRC in LA-HNSCC patients treated with concomitant CRT over standard 3D-RT.","[{'ForeName': 'Yungan', 'Initials': 'Y', 'LastName': 'Tao', 'Affiliation': 'Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France. Electronic address: yungan.tao@gustaveroussy.fr.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Auperin', 'Affiliation': 'Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France; INSERM 1018, Villefjuif, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Blanchard', 'Affiliation': 'Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Alfonsi', 'Affiliation': 'Institut Sainte Catherine, Avignon, France.'}, {'ForeName': 'Xu-Shan', 'Initials': 'XS', 'LastName': 'Sun', 'Affiliation': 'Hopital Nord Franche-Comté de Montbéliard & CHRU de Besançon, France.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Rives', 'Affiliation': 'Institut Claudius Regaud, Toulouse, France.'}, {'ForeName': 'Yoann', 'Initials': 'Y', 'LastName': 'Pointreau', 'Affiliation': 'Centre Jean Bernard, Le Mans, France.'}, {'ForeName': 'Joël', 'Initials': 'J', 'LastName': 'Castelli', 'Affiliation': 'Centre Eugène Marquis, Rennes, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Graff', 'Affiliation': 'Institut Claudius Regaud, Toulouse, France; Centre Alexis Vautrin, Nancy, France.'}, {'ForeName': 'Stéphanie', 'Initials': 'S', 'LastName': 'Wong Hee Kam', 'Affiliation': 'AP-HM Hôpital de la Timone, Marseille, France.'}, {'ForeName': 'Juliette', 'Initials': 'J', 'LastName': 'Thariat', 'Affiliation': 'Centre Antoine Lacassagne, Nice, France; Centre francois Baclesse, Caen, France.'}, {'ForeName': 'Ovidiu', 'Initials': 'O', 'LastName': 'Veresezan', 'Affiliation': 'Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Heymann', 'Affiliation': 'Clinique Sainte Anne, Strasbourg, France.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Renard-Oldrini', 'Affiliation': 'Centre Alexis Vautrin, Nancy, France.'}, {'ForeName': 'Cédrik', 'Initials': 'C', 'LastName': 'Lafond', 'Affiliation': 'Centre Jean Bernard, Le Mans, France.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Cornely', 'Affiliation': 'Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.'}, {'ForeName': 'Odile', 'Initials': 'O', 'LastName': 'Casiraghi', 'Affiliation': 'Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Boisselier', 'Affiliation': 'Centre Eugène Marquis, Rennes, France; Institut du Cancer de Montpellier, France.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Lapeyre', 'Affiliation': 'Centre Alexis Vautrin, Nancy, France; Centre Jean Perrin, Clermont-Ferrand, France.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Biau', 'Affiliation': 'Centre Jean Perrin, Clermont-Ferrand, France.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Bourhis', 'Affiliation': 'Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France; CHUV Lausanne, Switzerland. Electronic address: jean.bourhis@chuv.ch.'}]",Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,['10.1016/j.radonc.2020.05.021'] 1025,26321102,Recruitment challenges in a diabetes prevention trial in a low- and middle-income setting.,"AIM To describe recruitment challenges in a randomized controlled translational trial (RCTT) of diabetes prevention in India. METHODS The Diabetes Community Lifestyle Improvement Program (D-CLIP) is a RCTT, comparing standard of care to a step-wise model of diabetes prevention. Overweight adults with prediabetes were identified through a two-step screening process (1) field-based screening: minimal testing with a random capillary glucose measurement and (2) clinic-based screening including an Oral Glucose Tolerance Test (OGTT). RESULTS Individuals from the community (n=19377) were screened at residential locations, offices, educational institutions, places of worship, parks and beaches. Of these, 3535 (18.2%) 'high-risk' participants based on capillary glucose values were eligible for step 2 screening with OGTT. However, only 21.5% participated. An additional 521 participants directly entered step 2 via direct referrals from our clinical/research databases, study participant referrals and targeted advertisements. Of the 1285 individuals who underwent an OGTT, 710 (55.3%) were eligible for randomization, and 602 (84.8%) were randomized into the trial. The ratio of participants entering from step 1 to step 2 was 25:1 (3.9%) and from step 2 to randomization 2:1 (47%). Average staff time for recruitment was 350 h per week for an 11-person team. CONCLUSIONS Nearly 55 people needed to be screened with a questionnaire plus capillary glucose test to randomize one participant with prediabetes. Using a 2-step strategy requires additional staff time, but considerably reduces the need for OGTT's, thereby minimizing participant burden and study costs.",2015,"Using a 2-step strategy requires additional staff time, but considerably reduces the need for OGTT's, thereby minimizing participant burden and study costs.","['Nearly 55 people needed to be screened with a questionnaire plus capillary glucose test to randomize one participant with prediabetes', 'Overweight adults with prediabetes', '1285 individuals who underwent an OGTT, 710 (55.3%) were eligible for randomization, and 602 (84.8', '521 participants directly entered step 2 via direct referrals from our clinical/research databases, study participant referrals and targeted advertisements', 'Individuals from the community (n=19377) were screened at residential locations, offices, educational institutions, places of worship, parks and beaches']",['step screening process (1) field-based screening: minimal testing with a random capillary glucose measurement and (2) clinic-based screening including an Oral Glucose Tolerance Test (OGTT'],"['capillary glucose values', 'Average staff time']","[{'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0006901', 'cui_str': 'Capillaries'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0362046', 'cui_str': 'Prediabetes'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C1261552', 'cui_str': 'Step'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0034927', 'cui_str': 'Referral'}, {'cui': 'C0035168'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0949214', 'cui_str': 'Advertisements'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0450429', 'cui_str': 'Location (attribute)'}, {'cui': 'C0442603', 'cui_str': 'Office (environment)'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0442680', 'cui_str': 'Place of worship (environment)'}, {'cui': 'C0562547', 'cui_str': 'Park (environment)'}, {'cui': 'C0331781', 'cui_str': 'Beach (environment)'}]","[{'cui': 'C1261552', 'cui_str': 'Step'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C4521054', 'cui_str': 'Process (qualifier value)'}, {'cui': 'C0440042', 'cui_str': ""Field's""}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0547040', 'cui_str': 'Minimal (qualifier value)'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0006901', 'cui_str': 'Capillaries'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}]","[{'cui': 'C0006901', 'cui_str': 'Capillaries'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",19377.0,0.099527,"Using a 2-step strategy requires additional staff time, but considerably reduces the need for OGTT's, thereby minimizing participant burden and study costs.","[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Ranjani', 'Affiliation': ""Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, Chennai, India. Electronic address: ranjani@mdrf.in.""}, {'ForeName': 'M B', 'Initials': 'MB', 'LastName': 'Weber', 'Affiliation': 'Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'R M', 'Initials': 'RM', 'LastName': 'Anjana', 'Affiliation': ""Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, Chennai, India.""}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Lakshmi', 'Affiliation': ""Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, Chennai, India.""}, {'ForeName': 'K M Venkat', 'Initials': 'KMV', 'LastName': 'Narayan', 'Affiliation': 'Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Mohan', 'Affiliation': ""Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, Chennai, India.""}]",Diabetes research and clinical practice,['10.1016/j.diabres.2015.07.013'] 1026,26301034,Primary Stenting for Acute Ischemic Stroke Using the Enterprise Intracranial Stent: 2-Year Results of a Phase-I Trial.,"BACKGROUND The preliminary results of a prospective consecutive series of 20 patients who underwent Enterprise-assisted recanalization for acute ischemic stroke were recently reported. Recanalization to thrombolysis in myocardial infarction (TIMI) grade 2 (n = 6) or 3 (n = 12) flow was achieved in 18 patients (90% revascularization rate). Good outcome (modified Rankin Scale [mRS] score of ≤2) was obtained in 10 patients (50%) at 30 days. Here, we report the 2-year clinical follow-up data for patients enrolled in that prospective study. METHODS Study patients were scheduled for examinations 2 years postprocedure at which time mRS and Barthel indices were obtained. RESULTS Among 12 survivors at 2 years, 11 of the 20 (55%) study patients improved to mRS score ≤2 and 1 (5%) patient was disabled with an mRS 4. Of the 11 patients with mRS 0-2 scores, 10 patients had a Barthel index of 100, and the 11th had a Barthel index of 95. One patient improved from mRS 3 to 2 during the interval between the 6- and 12-month postintervention evaluations after intervention. Eight of 13 (62%) survivors underwent follow-up imaging at 6 months without evidence of instent stenosis or thrombosis. CONCLUSION At 2 years of follow-up, improvement in quality of life after acute stroke intervention was sustained; and 11 of 12 (92%) survivors had an excellent functional outcome. Improvement in functional status can occur even up to 1 year after stroke intervention. These results 2 years after acute stroke intervention demonstrate sustained benefit from acute intervention. ABBREVIATIONS AISacute ischemic strokeCTcomputed tomographicFDAFood and Drug AdministrationIVintravenousMCAmiddle cerebral arterymRSmodified Rankin ScaleNIHSSNational Institutes of Health Stroke Scale ScoreSWIFTSolitaire FR With the Intention For Thrombectomy (SWIFT)TIMIthrombolysis in myocardial infarctiontPAtissue plasminogen activatorTREVOThrombectomy REvascularization of large Vessel Occlusions.",2015,Good outcome (modified Rankin Scale [mRS] score of ≤2) was obtained in 10 patients (50%) at 30 days.,"['20 patients who underwent Enterprise-assisted recanalization for acute ischemic stroke', '11 patients with mRS 0-2 scores, 10 patients had a Barthel index of 100, and the 11th had a Barthel index of 95', 'Study patients were scheduled for examinations 2 years postprocedure at which time mRS and Barthel indices were obtained', 'patients enrolled in that prospective study']",['Primary Stenting'],"['mRS score', 'quality of life', 'Good outcome (modified Rankin Scale [mRS] score of ≤2']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0034771', 'cui_str': 'Recanalization (morphologic abnormality)'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451019', 'cui_str': 'Barthel index (assessment scale)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C0033522', 'cui_str': 'Prospective Studies'}]","[{'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}]",11.0,0.034473,Good outcome (modified Rankin Scale [mRS] score of ≤2) was obtained in 10 patients (50%) at 30 days.,"[{'ForeName': 'Sabareesh K', 'Initials': 'SK', 'LastName': 'Natarajan', 'Affiliation': 'Department of Neurosurgery, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA ; Department of Neurosurgery, Gates Vascular Institute/Kaleida Health, Buffalo, NY, USA.'}, {'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Sonig', 'Affiliation': 'Department of Neurosurgery, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA ; Department of Neurosurgery, Gates Vascular Institute/Kaleida Health, Buffalo, NY, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Mocco', 'Affiliation': 'Departments of Neurological Surgery and Radiology and Radiological Sciences, Mount Sinai Health System, New York City, NY, USA.'}, {'ForeName': 'Travis M', 'Initials': 'TM', 'LastName': 'Dumont', 'Affiliation': 'Division of Neurosurgery, Department of Surgery, The University of Arizona, Tucson, AZ, USA.'}, {'ForeName': 'Harjot', 'Initials': 'H', 'LastName': 'Thind', 'Affiliation': 'Department of Neurosurgery, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA ; Department of Neurosurgery, Gates Vascular Institute/Kaleida Health, Buffalo, NY, USA.'}, {'ForeName': 'Mary L', 'Initials': 'ML', 'LastName': 'Hartney', 'Affiliation': 'Department of Neurosurgery, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA ; Department of Neurosurgery, Gates Vascular Institute/Kaleida Health, Buffalo, NY, USA.'}, {'ForeName': 'Kenneth V', 'Initials': 'KV', 'LastName': 'Snyder', 'Affiliation': 'Department of Neurosurgery, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA ; Department of Neurosurgery, Gates Vascular Institute/Kaleida Health, Buffalo, NY, USA ; Department of Radiology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA ; Department of Radiology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA ; Toshiba Stroke and Vascular Research Center, University at Buffalo, State University of New York, Buffalo, NY, USA.'}, {'ForeName': 'L Nelson', 'Initials': 'LN', 'LastName': 'Hopkins', 'Affiliation': 'Department of Neurosurgery, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA ; Department of Neurosurgery, Gates Vascular Institute/Kaleida Health, Buffalo, NY, USA ; Department of Radiology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA ; Toshiba Stroke and Vascular Research Center, University at Buffalo, State University of New York, Buffalo, NY, USA ; Jacobs Institute, Buffalo, NY, USA.'}, {'ForeName': 'Adnan H', 'Initials': 'AH', 'LastName': 'Siddiqui', 'Affiliation': 'Department of Neurosurgery, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA ; Department of Neurosurgery, Gates Vascular Institute/Kaleida Health, Buffalo, NY, USA ; Department of Radiology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA ; Toshiba Stroke and Vascular Research Center, University at Buffalo, State University of New York, Buffalo, NY, USA ; Jacobs Institute, Buffalo, NY, USA.'}, {'ForeName': 'Elad I', 'Initials': 'EI', 'LastName': 'Levy', 'Affiliation': 'Department of Neurosurgery, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA ; Department of Neurosurgery, Gates Vascular Institute/Kaleida Health, Buffalo, NY, USA ; Department of Radiology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA ; Toshiba Stroke and Vascular Research Center, University at Buffalo, State University of New York, Buffalo, NY, USA.'}]",Journal of vascular and interventional neurology,[] 1027,32416978,"Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection.","OBJECTIVE To evaluate the efficacy and safety of highly purified human menotropin (HP-hMG) and recombinant follicle-stimulating hormone (rFSH) for controlled ovarian stimulation in a population of patients predicted to be high responders. DESIGN Randomized, open-label, assessor-blinded, parallel-group, noninferiority trial. SETTING Fertility centers. PATIENT(S) A total of 620 women with serum antimüllerian hormone (AMH) ≥5 ng/mL. INTERVENTION(S) Controlled ovarian stimulation with HP-hMG or rFSH in a GnRH antagonist assisted reproductive technology (ART) cycle. Fresh transfer of a single blastocyst was performed unless ovarian response was excessive, in which all embryos were cryopreserved. Subjects could undergo subsequent frozen blastocyst transfer within 6 months of randomization. MAIN OUTCOME MEASURE(S) Ongoing pregnancy rate (OPR) after fresh transfer (primary endpoint), as well as cumulative live birth, ovarian hyperstimulation syndrome (OHSS), and pregnancy loss rates. RESULTS OPR/cycle start after fresh transfer was 35.5% with HP-hMG and 30.7% with rFSH (difference: 4.7%, 95% CI -2.7%, 12.1%); noninferiority was established. Compared to rFSH, HP-hMG was associated with significantly lower OHSS (21.4% vs. 9.7% respectively; difference: -11.7%, 95% CI -17.3%, -6.1%) and cumulative early pregnancy loss rates (25.5% vs. 14.5% respectively; difference: -11.0%, 95% CI -18.8%, -3.14%). Despite 43 more transfers in the rFSH group, cumulative live birth rates were similar with HP-hMG and rFSH at 50.6% and 51.5% respectively (difference: -0.8%, 95% CI -8.7%, 7.1%). CONCLUSION(S) In high responders, HP-hMG provided comparable efficacy to rFSH with fewer adverse events, including pregnancy loss, suggesting its optimized risk/benefit profile in this population. CLINICAL TRIAL REGISTRATION NUMBER NCT02554279 (clinicaltrials.gov).",2020,"Despite 43 more transfers in the rFSH group, cumulative live birth rates were similar with HP-hMG and rFSH at 50.6% and 51.5% respectively (difference:","['high responders undergoing intracytoplasmic sperm injection', '620 women with serum antimüllerian hormone (AMH) ≥5', 'Fertility centers']","['HP-hMG or rFSH', 'highly purified human menotropin (HP-hMG) and recombinant follicle-stimulating hormone (rFSH', 'purified human menotropin and recombinant follicle-stimulating hormone', 'rFSH']","['cumulative early pregnancy loss rates', 'pregnancy loss', 'OHSS', 'Ongoing pregnancy rate (OPR', 'efficacy and safety', 'subsequent frozen blastocyst transfer', 'cumulative live birth rates', 'cumulative live birth, ovarian hyperstimulation syndrome (OHSS), and pregnancy loss rates']","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0455164', 'cui_str': 'IVF - In vitro fertilization with intracytoplasmic sperm injection (ICSI)'}, {'cui': 'C4708788', 'cui_str': '620'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0015895', 'cui_str': 'Ability to conceive'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0025326', 'cui_str': 'human menopausal gonadotrophin'}, {'cui': 'C0018120', 'cui_str': 'Ovarian follicle structure'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0202022', 'cui_str': 'Follicle stimulating hormone measurement'}]","[{'cui': 'C3830362', 'cui_str': 'Early Pregnancy Loss'}, {'cui': 'C0156543', 'cui_str': 'Pregnancy with abortive outcome'}, {'cui': 'C0085083', 'cui_str': 'Ovarian hyperstimulation syndrome'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rates'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0016701', 'cui_str': 'Freezing'}, {'cui': 'C0936221', 'cui_str': 'Blastocyst Transfer'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}]",620.0,0.661804,"Despite 43 more transfers in the rFSH group, cumulative live birth rates were similar with HP-hMG and rFSH at 50.6% and 51.5% respectively (difference:","[{'ForeName': 'Craig A', 'Initials': 'CA', 'LastName': 'Witz', 'Affiliation': 'Houston Fertility Institute, Houston, Texas.'}, {'ForeName': 'Gaurang S', 'Initials': 'GS', 'LastName': 'Daftary', 'Affiliation': 'Ferring Pharmaceuticals, Inc., Parsippany, New Jersey.'}, {'ForeName': 'Kevin J', 'Initials': 'KJ', 'LastName': 'Doody', 'Affiliation': 'Center for Assisted Reproduction, Bedford, Texas.'}, {'ForeName': 'John K', 'Initials': 'JK', 'LastName': 'Park', 'Affiliation': 'Carolina Conceptions, Raleigh, North Carolina.'}, {'ForeName': 'Yodit', 'Initials': 'Y', 'LastName': 'Seifu', 'Affiliation': 'Ferring Pharmaceuticals, Inc., Parsippany, New Jersey.'}, {'ForeName': 'Vladimir I', 'Initials': 'VI', 'LastName': 'Yankov', 'Affiliation': 'Ferring Pharmaceuticals, Inc., Parsippany, New Jersey.'}, {'ForeName': 'Patrick W', 'Initials': 'PW', 'LastName': 'Heiser', 'Affiliation': 'Ferring Pharmaceuticals, Inc., Parsippany, New Jersey. Electronic address: Patrick.Heiser@ferring.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Fertility and sterility,['10.1016/j.fertnstert.2020.03.029'] 1028,31955060,Toddlers imitate prosocial demonstrations in bystander but not transgressor contexts.,"Although prosocial abilities are associated with a wide range of healthy outcomes, few studies have experimentally examined socialization practices that may cause increased prosocial responding. The purpose of this study was to investigate conditions under which 2- and 3-year-old children can acquire prosocial behaviors through imitation. In Study 1 (N = 53), toddlers in the experimental condition watched a video of an adult comfort a woman in distress by performing a novel prosocial action without depicting how the woman was hurt. Parents then pretended they hurt their own finger and feigned distress. Children in the experimental condition were more likely to imitate the novel action relative to two control groups: (a) children who did not watch the video but witnessed a distressed parent, and (b) children who watched the video but witnessed parents engage in a neutral interaction. Thus, in a bystander context where children witnessed parent distress, toddlers imitated a general demonstration of how to respond prosocially to distress and applied this information to a specific distress scenario. In Study 2 (N = 54), the procedures were identical to those in the first study except that children were led to believe that they had transgressed to cause parent distress. In a transgressor context, children in the experimental condition were not more likely to imitate the prosocial behavior relative to children in either control group. These studies demonstrate that whether or not children have caused a victim's distress greatly affects their ability to apply a socially learned prosocial behavior, possibly due to self-conscious emotions such as guilt and shame.",2020,"Children in the experimental condition were more likely to imitate the novel action relative to two control groups: (a) children who did not watch the video but witnessed a distressed parent, and (b) children who watched the video but witnessed parents engage in a neutral interaction.",[],[],['prosocial behavior relative'],[],[],"[{'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}]",,0.0294409,"Children in the experimental condition were more likely to imitate the novel action relative to two control groups: (a) children who did not watch the video but witnessed a distressed parent, and (b) children who watched the video but witnessed parents engage in a neutral interaction.","[{'ForeName': 'Meghan Rose', 'Initials': 'MR', 'LastName': 'Donohue', 'Affiliation': 'Department of Psychology, Georgia State University, Atlanta, GA 30303, USA; Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: rdonohue@wustl.edu.'}, {'ForeName': 'Rebecca A', 'Initials': 'RA', 'LastName': 'Williamson', 'Affiliation': 'Department of Psychology, Georgia State University, Atlanta, GA 30303, USA.'}, {'ForeName': 'Erin C', 'Initials': 'EC', 'LastName': 'Tully', 'Affiliation': 'Department of Psychology, Georgia State University, Atlanta, GA 30303, USA.'}]",Journal of experimental child psychology,['10.1016/j.jecp.2019.104776'] 1029,31367742,Omadacycline for Acute Bacterial Skin and Skin Structure Infections.,"BACKGROUND Within the last decade, methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a frequent cause of purulent skin and soft tissue infections. New therapeutic options are being investigated for these infections. METHODS We report an integrated analysis of 2 randomized, controlled studies involving omadacycline, a novel aminomethylcycline, and linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Omadacycline in Acute Skin and Skin Structure Infections Study 1 (OASIS-1) initiated patients on intravenous omadacycline or linezolid, with the option to transition to an oral formulation after day 3. OASIS-2 was an oral-only study of omadacycline versus linezolid. RESULTS In total, 691 patients received omadacycline and 689 patients received linezolid. Infection types included wound infection in 46.8% of patients, cellulitis/erysipelas in 30.5%, and major abscess in 22.7%. Pathogens were identified in 73.2% of patients. S. aureus was detected in 74.7% and MRSA in 32.4% of patients in whom a pathogen was identified. Omadacycline was noninferior to linezolid using the Food and Drug Administration primary endpoint of early clinical response (86.2% vs 83.9%; difference 2.3, 95% confidence interval -1.5 to 6.2) and using the European Medicines Agency primary endpoint of investigator-assessed clinical response at the posttreatment evaluation. Clinical responses were similar across different infection types and infections caused by different pathogens. Treatment-emergent adverse events, mostly described as mild or moderate, were reported by 51.1% of patients receiving omadacycline and 41.2% of those receiving linezolid. CONCLUSIONS Omadacycline was effective and safe in ABSSSI. CLINICAL TRIALS REGISTRATION NCT02378480 and NCT02877927.",2019,S. aureus was detected in 74.7% and MRSA in 32.4% of patients in whom a pathogen was identified.,"['691 patients received', 'Acute Skin and Skin Structure Infections Study 1 (OASIS-1) initiated patients on intravenous', 'acute bacterial skin and skin structure infections (ABSSSI']","['omadacycline versus linezolid', 'Omadacycline', 'linezolid', 'omadacycline', 'omadacycline or linezolid', 'omadacycline, a novel aminomethylcycline, and linezolid']","['early clinical response', 'wound infection']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0766345', 'cui_str': 'OASIS'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C4552481', 'cui_str': 'Acute bacterial skin and skin structure infection'}, {'cui': 'C4552483', 'cui_str': 'ABSSSI'}]","[{'cui': 'C2983838', 'cui_str': 'omadacycline'}, {'cui': 'C0663241', 'cui_str': 'linezolid'}]","[{'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0043241', 'cui_str': 'Wound Infection'}]",691.0,0.0383841,S. aureus was detected in 74.7% and MRSA in 32.4% of patients in whom a pathogen was identified.,"[{'ForeName': 'Fredrick M', 'Initials': 'FM', 'LastName': 'Abrahamian', 'Affiliation': 'Department of Emergency Medicine, Olive View-UCLA Medical Center, Sylmar.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Sakoulas', 'Affiliation': 'Division of Host-Microbe Systems and Therapeutics, Center for Immunity, Infection and Inflammation, University of California San Diego School of Medicine, La Jolla.'}, {'ForeName': 'Evan', 'Initials': 'E', 'LastName': 'Tzanis', 'Affiliation': 'Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Manley', 'Affiliation': 'Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Steenbergen', 'Affiliation': 'Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania.'}, {'ForeName': 'Anita F', 'Initials': 'AF', 'LastName': 'Das', 'Affiliation': 'AD Stats Consulting, Guerneville, California.'}, {'ForeName': 'Paul B', 'Initials': 'PB', 'LastName': 'Eckburg', 'Affiliation': 'Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania.'}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'McGovern', 'Affiliation': 'Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciz396'] 1030,31543407,Fast versus gradual adaptation of soft daily disposable contact lenses in neophyte wearers.,"PURPOSE Despite the widespread practice of gradually adapting all new soft contact lens wearers (neophytes), there is little evidence-based research underpinning such practice. This work determined if a gradual adaptation period is necessary for neophytes when fitted with modern hydrogel or silicone-hydrogel daily disposable contact lenses. METHOD At four sites, neophytes (19-32 years) were randomly assigned to an adaptation schedule: fast (10 h wear from the first day) or gradual (4 h on the first day, increasing their wear-time by 2 h on each subsequent day until they had reached 10 h) with hydrogel (n = 24 fast; n = 21 gradual) or silicone-hydrogel (n = 10 fast; n = 10 gradual) contact lenses. Masked investigators graded ocular surface physiology and non-invasive tear breakup time (NIBUT). A range of subjective scores (using 0-100 visual analogue scales) were recorded at the initial visit and after 10 h of lens wear, 4-6 days and 12-14 days after initial fitting. Subjective scores were also repeated after 7 days. RESULTS There was no difference (p > 0.05) in ocular surface physiology between the fast and gradual adaptation groups at any time point in either lens type. NIBUT was similar at all time points for both adaptation groups in both lens types with the exception that the gradual adaptation silicone-hydrogel wearers had a slightly longer NIBUT (p = 0.007) than the fast adaptation group at 12-14 days. Subjective scores were also similar across the visits and lens types with the exception of 'lens awareness' and 'ease of lens removal' which were better (p < 0.05) in the fast compared with the gradual adaptation hydrogel lens group at day 7. Additionally, 'end-of-day discomfort' was better (p = 0.02) in the fast compared with the gradual adaptation hydrogel lens group at 12-14 days. CONCLUSION There appears to be no benefit in daily disposable soft contact lens adaptation for neophytes with modern contact lens materials.",2020,There was no difference (p > 0.05) in ocular surface physiology between the fast and gradual adaptation groups at any time point in either lens type.,"['soft contact lens wearers (neophytes', 'neophyte wearers', 'At four sites, neophytes (19-32 years']","['hydrogel (n\u202f=\u202f24 fast; n\u202f=\u202f21 gradual) or silicone-hydrogel (n\u202f=\u202f10 fast; n\u202f=\u202f10 gradual) contact lenses', 'Fast versus gradual adaptation of soft daily disposable contact lenses']","['Subjective scores', 'ocular surface physiology', ""lens awareness' and 'ease of lens removal""]","[{'cui': 'C0009838', 'cui_str': 'Soft Contact Lenses'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0063083', 'cui_str': 'Hydrogel, Polyethylene Glycol Dimethacrylate'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0439833', 'cui_str': 'Gradual (qualifier value)'}, {'cui': 'C0037114', 'cui_str': 'Silicones'}, {'cui': 'C0009836', 'cui_str': 'Contact Lenses'}, {'cui': 'C0392673', 'cui_str': 'Adaptation, function (observable entity)'}, {'cui': 'C0205358', 'cui_str': 'Soft (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4521296', 'cui_str': 'Ocular (intended site)'}, {'cui': 'C0205148', 'cui_str': 'Surface (attribute)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0023317', 'cui_str': 'Lens, Eye'}, {'cui': 'C0004448', 'cui_str': 'Situational Awareness'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}]",100.0,0.0218066,There was no difference (p > 0.05) in ocular surface physiology between the fast and gradual adaptation groups at any time point in either lens type.,"[{'ForeName': 'James S', 'Initials': 'JS', 'LastName': 'Wolffsohn', 'Affiliation': 'Ophthalmic Research Group, Aston University, Birmingham, UK. Electronic address: j.s.w.wolffsohn@aston.ac.uk.'}, {'ForeName': 'Harshali', 'Initials': 'H', 'LastName': 'Dhirajlal', 'Affiliation': 'Ophthalmic Research Group, Aston University, Birmingham, UK. Electronic address: dhirajlh@aston.ac.uk.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Vianya-Estopa', 'Affiliation': 'Vision and Hearing Sciences, Anglia Ruskin University, Cambridge, UK. Electronic address: marta.vianya@anglia.ac.uk.'}, {'ForeName': 'Manbir', 'Initials': 'M', 'LastName': 'Nagra', 'Affiliation': 'School of Health Sciences and Social Work, University of Portsmouth, Portsmouth, UK. Electronic address: manbir.nagra@port.ac.uk.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Madden', 'Affiliation': 'School of Health and Life Sciences, Glasgow Caledonian University, G4 0BA, UK. Electronic address: Louise.madedn@nes.scot.nhs.uk.'}, {'ForeName': 'Laura Elaine', 'Initials': 'LE', 'LastName': 'Sweeney', 'Affiliation': 'School of Health and Life Sciences, Glasgow Caledonian University, G4 0BA, UK. Electronic address: laura.sweeney@gcu.ac.uk.'}, {'ForeName': 'Anna Sarah', 'Initials': 'AS', 'LastName': 'Goodyear', 'Affiliation': 'School of Health and Life Sciences, Glasgow Caledonian University, G4 0BA, UK. Electronic address: agoody200@caledonian.ac.uk.'}, {'ForeName': 'Lauren Victoria', 'Initials': 'LV', 'LastName': 'Kerr', 'Affiliation': 'School of Health and Life Sciences, Glasgow Caledonian University, G4 0BA, UK. Electronic address: lkerr209@caledonian.ac.uk.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Terry', 'Affiliation': 'School of Optometry and Vision Sciences, Cardiff University, Cardiff, CF24 4HQ, UK. Electronic address: terryl1@cardiff.ac.uk.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Sheikh', 'Affiliation': 'School of Optometry and Vision Sciences, Cardiff University, Cardiff, CF24 4HQ, UK. Electronic address: sheikhsz@cardiff.ac.uk.'}, {'ForeName': 'Orla', 'Initials': 'O', 'LastName': 'Murphy', 'Affiliation': 'School of Physics & Clinical & Optometric Sciences, Technological University Dublin, Ireland. Electronic address: orla.murphy@dit.ie.'}, {'ForeName': 'Aoife', 'Initials': 'A', 'LastName': 'Lloyd', 'Affiliation': 'School of Physics & Clinical & Optometric Sciences, Technological University Dublin, Ireland. Electronic address: aoife.lloydmckernan@dit.ie.'}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Maldonado-Codina', 'Affiliation': 'Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. Electronic address: carole.m-codina@manchester.ac.uk.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2019.08.011'] 1031,25411293,"Effect of daily vitamin B-12 and folic acid supplementation on fracture incidence in elderly individuals with an elevated plasma homocysteine concentration: B-PROOF, a randomized controlled trial.","BACKGROUND Elevated plasma homocysteine concentrations are a risk factor for osteoporotic fractures. Lowering homocysteine with combined vitamin B-12 and folic acid supplementation may reduce fracture risk. OBJECTIVE This study [B-vitamins for the PRevention Of Osteoporotic Fractures (B-PROOF)] aimed to determine whether vitamin B-12 and folic acid supplementation reduces osteoporotic fracture incidence in hyperhomocysteinemic elderly individuals. DESIGN This was a double-blind, randomized, placebo-controlled trial in 2919 participants aged ≥65 y with elevated homocysteine concentrations (12-50 μmol/L). Participants were assigned to receive daily 500 μg vitamin B-12 plus 400 μg folic acid or placebo supplementation for 2 y. Both intervention and placebo tablets also contained 600 IU vitamin D3. The primary endpoint was time to first osteoporotic fracture. Exploratory prespecified subgroup analyses were performed in men and women and in individuals younger than and older than age 80 y. Data were analyzed according to intention-to-treat and per-protocol principles. RESULTS Osteoporotic fractures occurred in 61 persons (4.2%) in the intervention group and 75 persons (5.1%) in the placebo group. Osteoporotic fracture risk was not significantly different between groups in the intention-to-treat analyses (HR: 0.84; 95% CI: 0.58, 1.21) or per-protocol analyses (HR: 0.81; 95% CI: 0.54, 1.21). For persons aged >80 y, in per-protocol analyses, osteoporotic fracture risk was lower in the intervention group than in the placebo group (HR: 0.27; 95% CI: 0.10, 0.74). The total number of adverse events (including mortality) did not differ between groups. However, 63 and 42 participants in the intervention and placebo groups, respectively, reported incident cancer (HR: 1.56; 95% CI: 1.04, 2.31). CONCLUSIONS These data show that combined vitamin B-12 and folic acid supplementation had no effect on osteoporotic fracture incidence in this elderly population. Exploratory subgroup analyses suggest a beneficial effect on osteoporotic fracture prevention in compliant persons aged >80 y. However, treatment was also associated with increased incidence of cancer, although the study was not designed for assessing cancer outcomes. Therefore, vitamin B-12 plus folic acid supplementation cannot be recommended at present for fracture prevention in elderly people. The B-PROOF study was registered with the Netherlands Trial Register (trialregister.nl) as NTR1333 and at clinicaltrials.gov as NCT00696414.",2014,"For persons aged >80 y, in per-protocol analyses, osteoporotic fracture risk was lower in the intervention group than in the placebo group (HR: 0.27; 95% CI: 0.10, 0.74).","['compliant persons aged >80', 'men and women and in individuals younger than and older than age 80 y. Data were analyzed according to intention-to-treat and per-protocol principles', '2919 participants aged ≥65 y with elevated homocysteine concentrations (12-50 μmol/L', 'Osteoporotic Fractures (B-PROOF', 'elderly individuals with an elevated plasma homocysteine concentration', 'hyperhomocysteinemic elderly individuals', 'elderly people']","['daily vitamin B-12 and folic acid supplementation', 'placebo', 'vitamins', 'vitamin B-12 and folic acid supplementation', 'vitamin B-12 plus 400 μg folic acid or placebo supplementation', 'vitamin B-12 plus folic acid supplementation', 'vitamin D3']","['Osteoporotic fracture risk', 'Osteoporotic fractures', 'osteoporotic fracture prevention', 'osteoporotic fracture risk', 'time to first osteoporotic fracture', 'total number of adverse events (including mortality', 'fracture incidence', 'incidence of cancer', 'osteoporotic fracture incidence']","[{'cui': 'C0566588', 'cui_str': 'Compliant (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0019878', 'cui_str': '2-amino-4-mercaptobutyric acid'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0521170', 'cui_str': 'Osteoporotic Fractures'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0042845', 'cui_str': 'cyanocobalamin'}, {'cui': 'C0556110', 'cui_str': 'Folic acid supplementation (product)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0042890', 'cui_str': 'Vitamins'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C3265062', 'cui_str': 'vitamin D3'}]","[{'cui': 'C0521170', 'cui_str': 'Osteoporotic Fractures'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}]",2919.0,0.717797,"For persons aged >80 y, in per-protocol analyses, osteoporotic fracture risk was lower in the intervention group than in the placebo group (HR: 0.27; 95% CI: 0.10, 0.74).","[{'ForeName': 'Janneke P', 'Initials': 'JP', 'LastName': 'van Wijngaarden', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}, {'ForeName': 'Karin M A', 'Initials': 'KM', 'LastName': 'Swart', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}, {'ForeName': 'Anke W', 'Initials': 'AW', 'LastName': 'Enneman', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}, {'ForeName': 'Rosalie A M', 'Initials': 'RA', 'LastName': 'Dhonukshe-Rutten', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}, {'ForeName': 'Suzanne C', 'Initials': 'SC', 'LastName': 'van Dijk', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}, {'ForeName': 'Annelies C', 'Initials': 'AC', 'LastName': 'Ham', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}, {'ForeName': 'Elske M', 'Initials': 'EM', 'LastName': 'Brouwer-Brolsma', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}, {'ForeName': 'Nikita L', 'Initials': 'NL', 'LastName': 'van der Zwaluw', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}, {'ForeName': 'Evelien', 'Initials': 'E', 'LastName': 'Sohl', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}, {'ForeName': 'Joyce B J', 'Initials': 'JB', 'LastName': 'van Meurs', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}, {'ForeName': 'M Carola', 'Initials': 'MC', 'LastName': 'Zillikens', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}, {'ForeName': 'Natasja M', 'Initials': 'NM', 'LastName': 'van Schoor', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'van der Velde', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Brug', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}, {'ForeName': 'André G', 'Initials': 'AG', 'LastName': 'Uitterlinden', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Lips', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}, {'ForeName': 'Lisette C P G M', 'Initials': 'LC', 'LastName': 'de Groot', 'Affiliation': 'From the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (JPvW, RAMD-R, EMB-B, NLvdZ, and LCPGMdG); the Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (KMAS, ES, NMvS, JB, and PL) and the Department of Internal Medicine, Endocrine Section (PL), VU University Medical Center, Amsterdam, The Netherlands; the Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands (AWE, SCvD, ACH, JBJvM, MCZ, NvdV, and AGU); and the Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands (NvdV).'}]",The American journal of clinical nutrition,['10.3945/ajcn.114.090043'] 1032,31821750,"Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.","Itacitinib is a JAK1-selective inhibitor in phase 3 development in graft-versus-host disease. A post hoc electrocardiogram (ECG) analysis and a plasma concentration-QTc (C-QTc) analysis were performed to assess cardiac safety using data from the first-in-human itacitinib study. The study included 2 cohorts of 12 healthy participants each in an interleaving dosing design with single doses of 10-300 mg or placebo; 500 and 1000 mg doses were subsequently added with 12 participants randomized to itacitinib or placebo. Continuous Holter recordings were collected from 1 hour predose to 8 hours postdose on each dosing day, and ECG intervals were blindly extracted to match timed pharmacokinetic samples. Data showed no hysteresis, and a prespecified linear mixed-effects C-QTc model was used with change-from-baseline QTcF (QT interval corrected for heart rate by Fridericia's method) as the dependent variable, plasma itacitinib concentrations and centered baseline QTcF as continuous covariates, treatment and time as categorical factors, and a random intercept per participant. The estimated slope of the C-QTc relationship was not significantly different from zero: 0.0002 milliseconds per nM (90%CI, -0.00019 to 0.00054 milliseconds). No clinically meaningful effects on cardiac conduction (PR and QRS intervals) or any categorical PR or QRS outliers were observed. A QTc effect exceeding the threshold of concern (10 milliseconds) can be excluded for itacitinib plasma concentrations up to ∼13 000 nM (∼7200 ng/mL), which is well above the maximum concentration expected with the highest proposed therapeutic dose of itacitinib either with concomitant use of cytochrome P450 3A4 inhibitors or in patients with impaired hepatic function.",2020,No clinically meaningful effects on cardiac conduction (PR and QRS intervals) or any categorical PR or QRS outliers were observed.,"['patients with impaired hepatic function', '12 healthy participants each in an interleaving dosing design with single doses of 10-300 mg or', 'Healthy Participants']","['Itacitinib, a JAK1 Inhibitor', 'placebo', 'itacitinib or placebo']","['estimated slope of the C-QTc relationship', 'plasma concentration-QTc (C-QTc) analysis', 'cardiac conduction (PR and QRS intervals) or any categorical PR or QRS outliers']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0232741', 'cui_str': 'Liver function (observable entity)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C4319604', 'cui_str': '300'}]","[{'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0860814', 'cui_str': 'QTc'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0232217', 'cui_str': 'Cardiac conduction (observable entity)'}, {'cui': 'C0520880', 'cui_str': 'QRS interval'}]",,0.157254,No clinically meaningful effects on cardiac conduction (PR and QRS intervals) or any categorical PR or QRS outliers were observed.,"[{'ForeName': 'Xiaohua', 'Initials': 'X', 'LastName': 'Gong', 'Affiliation': 'Incyte Research Institute, Wilmington, Delaware, USA.'}, {'ForeName': 'Borje', 'Initials': 'B', 'LastName': 'Darpo', 'Affiliation': 'eRT/iCardiac Technologies, Rochester, New York, USA.'}, {'ForeName': 'Hongqi', 'Initials': 'H', 'LastName': 'Xue', 'Affiliation': 'eRT/iCardiac Technologies, Rochester, New York, USA.'}, {'ForeName': 'Naresh', 'Initials': 'N', 'LastName': 'Punwani', 'Affiliation': 'Incyte Research Institute, Wilmington, Delaware, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'He', 'Affiliation': 'Incyte Corporation, Wilmington, Delaware, USA.'}, {'ForeName': 'April M', 'Initials': 'AM', 'LastName': 'Barbour', 'Affiliation': 'Incyte Research Institute, Wilmington, Delaware, USA.'}, {'ForeName': 'Noam', 'Initials': 'N', 'LastName': 'Epstein', 'Affiliation': 'Incyte Research Institute, Wilmington, Delaware, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Landman', 'Affiliation': 'Incyte Research Institute, Wilmington, Delaware, USA.'}, {'ForeName': 'Xuejun', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Incyte Research Institute, Wilmington, Delaware, USA.'}, {'ForeName': 'Swamy', 'Initials': 'S', 'LastName': 'Yeleswaram', 'Affiliation': 'Incyte Research Institute, Wilmington, Delaware, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.758'] 1033,24742341,Rationale and design of the Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPiRED) trial.,"UNLABELLED The SYMPLICITY studies showed that renal denervation (RDN) is feasible as novel treatment for resistant hypertension. However, RDN is a costly and invasive procedure, the long-term efficacy and safety of which has not yet been proven. Therefore, we designed the INSPiRED trial to compare the blood pressure lowering efficacy and safety of RDN vs usual medical therapy. INSPiRED is a randomized controlled trial enrolling 240 treatment-resistant hypertensive patients at 16 expert hypertension centres in Belgium. Eligible patients, aged 20-69 years old, have a 24-h ambulatory blood pressure of 130 mmHg systolic or 80 mmHg diastolic or more, while taking at least three antihypertensive drugs. They are randomized to RDN (EnligHTN(TM), SJM system) plus usual care (intervention group) or usual care alone (control group) in a ratio of 1:1. The primary endpoints for efficacy and safety, measured after 6 months, are the baseline-adjusted between-group differences in 24h systolic blood pressure and in glomerular filtration rate as estimated by the Chronic Kidney Disease Epidemiology Collaboration equation. Follow-up will continue up to 36 months after randomization. INSPiRED is powered to demonstrate a 10-mmHg difference in systolic blood pressure between randomized groups with a two-sided p-value of 0.01 and 90% power. It will generate long-term efficacy and safety data, identify the subset of treatment-resistant hypertensive patients responsive to RDN, provide information on cost-effectiveness, and by doing so INSPiRED will inform guideline committees and health policy makers. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT 01505010.",2014,"They are randomized to RDN (EnligHTN(TM), SJM system) plus usual care (intervention group) or usual care alone (control group) in a ratio of 1:1.","['Eligible patients, aged 20-69 years old, have a 24-h ambulatory blood pressure of 130 mmHg systolic or 80 mmHg diastolic or more, while taking at least three antihypertensive drugs', '240 treatment-resistant hypertensive patients at 16 expert hypertension centres in Belgium']","['RDN vs usual medical therapy', 'RDN', 'RDN (EnligHTN(TM), SJM system) plus usual care (intervention group) or usual care alone (control group']","['efficacy and safety', '24h systolic blood pressure and in glomerular filtration rate', 'systolic blood pressure']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C0439475', 'cui_str': 'torr (qualifier value)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0003364', 'cui_str': 'Anti-Hypertensive Drugs'}, {'cui': 'C4319600', 'cui_str': '240 (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0004950', 'cui_str': 'Belgium'}]","[{'cui': 'C0418981', 'cui_str': 'Medical therapy (procedure)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0017654', 'cui_str': 'Glomerular Filtration Rate'}]",240.0,0.0967622,"They are randomized to RDN (EnligHTN(TM), SJM system) plus usual care (intervention group) or usual care alone (control group) in a ratio of 1:1.","[{'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Jin', 'Affiliation': 'Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, Department of Cardiovascular Sciences, University of Leuven , Leuven , Belgium.'}, {'ForeName': 'Lotte', 'Initials': 'L', 'LastName': 'Jacobs', 'Affiliation': ''}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Baelen', 'Affiliation': ''}, {'ForeName': 'Lutgarde', 'Initials': 'L', 'LastName': 'Thijs', 'Affiliation': ''}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Renkin', 'Affiliation': ''}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Hammer', 'Affiliation': ''}, {'ForeName': 'Joelle', 'Initials': 'J', 'LastName': 'Kefer', 'Affiliation': ''}, {'ForeName': 'Thibault', 'Initials': 'T', 'LastName': 'Petit', 'Affiliation': ''}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Verhamme', 'Affiliation': ''}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Janssens', 'Affiliation': ''}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Sinnaeve', 'Affiliation': ''}, {'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Lengelé', 'Affiliation': ''}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Persu', 'Affiliation': ''}, {'ForeName': 'Jan A', 'Initials': 'JA', 'LastName': 'Staessen', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Blood pressure,['10.3109/08037051.2014.899297'] 1034,25298858,Enrollment of research subjects through telemedicine networks in a multicenter acute intracerebral hemorrhage clinical trial: design and methods.,"BACKGROUND Enrollment of subjects in acute stroke trials is often hindered by narrow timeframes, because a large proportion of patients arrive via transfers from outside facilities rather than primary arrival at the enrolling hospital. RATIONALE Telemedicine networks have been increasingly used for provision of care for acute stroke patients at facilities outside of major academic centers. Treatment decisions made through telemedicine networks in patients with acute ischemic stroke have been shown to be safe, reliable, and effective. With the expanding use of this technology and the impediments to enrolling subjects into clinical trials, this approach can be applied successfully to the field of clinical research. METHODS AND CONCLUSIONS The Antihypertensive Treatment of Acute Cerebral Hemorrhage II trial is a phase III randomized multicenter trial that has developed a protocol in collaboration with participating sites to implement the use of telemedicine networks for the enrollment of research subjects. The protocol describes the operating procedures and legal and Institutional Review Board perspectives for its implementation.",2014,"Treatment decisions made through telemedicine networks in patients with acute ischemic stroke have been shown to be safe, reliable, and effective.","['acute stroke patients at facilities outside of major academic centers', 'patients with acute ischemic stroke']",[],[],"[{'cui': 'C0751956', 'cui_str': 'Stroke, Acute'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}]",[],[],,0.153349,"Treatment decisions made through telemedicine networks in patients with acute ischemic stroke have been shown to be safe, reliable, and effective.","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Alfredo Caceres', 'Affiliation': 'Zeenat Qureshi Stroke Institute, St Cloud MN, USA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Greer', 'Affiliation': 'Yale University School of Medicine, Department of Neurology, New Haven, CT, USA.'}, {'ForeName': 'Joshua N', 'Initials': 'JN', 'LastName': 'Goldstein', 'Affiliation': 'Harvard Medical School, Center for Neurologic Emergencies, Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Viswanathan', 'Affiliation': 'Harvard Medical School, Telestroke Services, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Jose I', 'Initials': 'JI', 'LastName': 'Suarez', 'Affiliation': 'Section of Vascular Neurology and Neurocritical Care, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Logan', 'Initials': 'L', 'LastName': 'Brau', 'Affiliation': 'Zeenat Qureshi Stroke Institute, St Cloud MN, USA.'}, {'ForeName': 'Joseph Christopher', 'Initials': 'JC', 'LastName': 'Zacko', 'Affiliation': 'Penn State Hershey Neurosurgery, Hershey, PA, USA.'}, {'ForeName': 'Theodore J', 'Initials': 'TJ', 'LastName': 'Lowenkopf', 'Affiliation': 'Oregon Health and Science University, Department of Neurology, Providence Stroke Center, Portland, OR, USA.'}, {'ForeName': 'Chad M', 'Initials': 'CM', 'LastName': 'Miller', 'Affiliation': 'Wexner Medical Center, The Ohio State University, Columbus, OH, USA.'}, {'ForeName': 'Qaisar A', 'Initials': 'QA', 'LastName': 'Shah', 'Affiliation': 'Neurointerventional and Neurocritical Care Services, Neurosciences Institute, Abington Memorial Hospital, Abington, PA, USA.'}, {'ForeName': 'Ira', 'Initials': 'I', 'LastName': 'Chang', 'Affiliation': 'Acute Neurological Services, Swedish Medical Center, Englewood, CO, USA.'}, {'ForeName': 'Souvik', 'Initials': 'S', 'LastName': 'Sen', 'Affiliation': 'Department of Neurology, University of South Carolina School of Medicine, Columbia, SC, USA.'}, {'ForeName': 'Steven R', 'Initials': 'SR', 'LastName': 'Messe', 'Affiliation': 'Hospital of the University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Sherry H', 'Initials': 'SH', 'LastName': 'Chou', 'Affiliation': 'Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Adnan I', 'Initials': 'AI', 'LastName': 'Qureshi', 'Affiliation': 'Zeenat Qureshi Stroke Institute, St Cloud MN, USA ; Zeenat Qureshi Stroke Institute, St Cloud, MN, USA.'}]",Journal of vascular and interventional neurology,[] 1035,32421353,Intrapleural Fibrinolytic Therapy versus Early Medical Thoracoscopy for Treatment of Pleural Infection. Randomized Controlled Clinical Trial.,"Rationale: Pleural infection is frequently encountered in clinical practice and is associated with high morbidity and mortality. Limited evidence exists regarding the optimal treatment. Although both early medical thoracoscopy (MT) and tube thoracostomy with intrapleural instillation of tissue plasminogen activator and human recombinant deoxyribonuclease are acceptable treatments for patients with complicated pleural infection, there is a lack of comparative data for these modes of management. Objectives: The aim of this study was to compare the safety and efficacy of early MT versus intrapleural fibrinolytic therapy (IPFT) in selected patients with multiloculated pleural infection and empyema. Methods: This was a prospective multicenter, randomized controlled trial involving patients who underwent MT or IPFT for pleural infection. The primary outcome was the length of hospital stay after either intervention. Secondary outcomes included the total length of hospital stay, treatment failure, 30-day mortality, and adverse events. Results: Thirty-two patients with pleural infection were included in the study. The median length of stay after an intervention was 4 days in the IPFT arm and 2 days in the MT arm ( P  = 0.026). The total length of hospital stay was 6 days in the IPFT arm and 3.5 days in MT arm ( P  = 0.12). There was no difference in treatment failure, mortality, or adverse events between the treatment groups, and no serious complications related to either intervention were recorded. Conclusions: When used early in the course of a complicated parapneumonic effusion or empyema, MT is safe and might shorten hospital stays for selected patients as compared with IPFT therapy. A multicenter trial with a larger sample size is needed to confirm these findings.Clinical trial registered with ClinicalTrials.gov (NCT02973139).",2020,"There was no difference in treatment failure, mortality or adverse events between treatment groups, and no serious complications related to either interventions were recorded. ","['patients with complicated pleural infection', 'selected patients with multiloculated pleural infection and empyema', 'Pleural Infection', '32 patients with pleural infection', 'patients who underwent MT or IPFT for pleural infection']","['Intrapleural Fibrinolytic Therapy versus Early Medical Thoracoscopy', 'IPFT therapy', 'Medical thoracoscopy', 'medical thoracoscopy (MT) and tube thoracostomy with intrapleural instillation of tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase', 'early MT versus intrapleural fibrinolytic therapy (IPFT']","['treatment failure, mortality or adverse events', 'median length of stay', 'total length of hospital stay, treatment failure, 30-day mortality and adverse events', 'length of hospital stay', 'safety and efficacy', 'total length of hospital stay']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C1522720', 'cui_str': 'Pleural'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0014009', 'cui_str': 'Empyema'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0039989', 'cui_str': 'Thoracoscopy'}, {'cui': 'C0595451', 'cui_str': 'Intrapleural route'}, {'cui': 'C0040044', 'cui_str': 'Thrombolytic therapy'}]","[{'cui': 'C0595451', 'cui_str': 'Intrapleural route'}, {'cui': 'C0040044', 'cui_str': 'Thrombolytic therapy'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0039989', 'cui_str': 'Thoracoscopy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0189476', 'cui_str': 'Insertion of pleural tube drain'}, {'cui': 'C0184959', 'cui_str': 'Instillation'}, {'cui': 'C0032143', 'cui_str': 'alteplase'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C1135662', 'cui_str': 'Dornase Alfa'}, {'cui': 'C0011522', 'cui_str': 'Deoxyribonucleases'}]","[{'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",32.0,0.0949974,"There was no difference in treatment failure, mortality or adverse events between treatment groups, and no serious complications related to either interventions were recorded. ","[{'ForeName': 'Fayez', 'Initials': 'F', 'LastName': 'Kheir', 'Affiliation': 'Division of Pulmonary Diseases, Critical Care and Environmental Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana.'}, {'ForeName': 'Sanket', 'Initials': 'S', 'LastName': 'Thakore', 'Affiliation': 'Division of Pulmonary Diseases, Critical Care and Environmental Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana.'}, {'ForeName': 'Hiren', 'Initials': 'H', 'LastName': 'Mehta', 'Affiliation': 'Division of Pulmonary Diseases and Critical Care, University of Florida Health, Gainesville, Florida; and.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Jantz', 'Affiliation': 'Division of Pulmonary Diseases and Critical Care, University of Florida Health, Gainesville, Florida; and.'}, {'ForeName': 'Mihir', 'Initials': 'M', 'LastName': 'Parikh', 'Affiliation': 'Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Chee', 'Affiliation': 'Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Upendra', 'Initials': 'U', 'LastName': 'Kaphle', 'Affiliation': 'Division of Pulmonary Diseases, Critical Care and Environmental Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Sisnega', 'Affiliation': 'Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Fernandez-Bussy', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Jacksonville, Florida.'}, {'ForeName': 'Adnan', 'Initials': 'A', 'LastName': 'Majid', 'Affiliation': 'Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.'}]",Annals of the American Thoracic Society,['10.1513/AnnalsATS.202001-076OC'] 1036,23649787,Community-partnered cluster-randomized comparative effectiveness trial of community engagement and planning or resources for services to address depression disparities.,"BACKGROUND Depression contributes to disability and there are ethnic/racial disparities in access and outcomes of care. Quality improvement (QI) programs for depression in primary care improve outcomes relative to usual care, but health, social and other community-based service sectors also support clients in under-resourced communities. Little is known about effects on client outcomes of strategies to implement depression QI across diverse sectors. OBJECTIVE To compare the effectiveness of Community Engagement and Planning (CEP) and Resources for Services (RS) to implement depression QI on clients' mental health-related quality of life (HRQL) and services use. DESIGN Matched programs from health, social and other service sectors were randomized to community engagement and planning (promoting inter-agency collaboration) or resources for services (individual program technical assistance plus outreach) to implement depression QI toolkits in Hollywood-Metro and South Los Angeles. PARTICIPANTS From 93 randomized programs, 4,440 clients were screened and of 1,322 depressed by the 8-item Patient Health Questionnaire (PHQ-8) and providing contact information, 1,246 enrolled and 1,018 in 90 programs completed baseline or 6-month follow-up. MEASURES Self-reported mental HRQL and probable depression (primary), physical activity, employment, homelessness risk factors (secondary) and services use. RESULTS CEP was more effective than RS at improving mental HRQL, increasing physical activity and reducing homelessness risk factors, rate of behavioral health hospitalization and medication visits among specialty care users (i.e. psychiatrists, mental health providers) while increasing depression visits among users of primary care/public health for depression and users of faith-based and park programs (each p < 0.05). Employment, use of antidepressants, and total contacts were not significantly affected (each p > 0.05). CONCLUSION Community engagement to build a collaborative approach to implementing depression QI across diverse programs was more effective than resources for services for individual programs in improving mental HRQL, physical activity and homelessness risk factors, and shifted utilization away from hospitalizations and specialty medication visits toward primary care and other sectors, offering an expanded health-home model to address multiple disparities for depressed safety-net clients.",2013,"RESULTS CEP was more effective than RS at improving mental HRQL, increasing physical activity and reducing homelessness risk factors, rate of behavioral health hospitalization and medication visits among specialty care users (i.e. psychiatrists, mental health providers) while increasing depression visits among users of primary care/public health for depression and users of faith-based and park programs (each p < 0.05).","['Matched programs from health, social and other service sectors', 'From 93 randomized programs, 4,440 clients were screened and of 1,322 depressed by the 8-item Patient Health Questionnaire (PHQ-8) and providing contact information, 1,246 enrolled and 1,018 in 90 programs completed baseline or 6-month follow-up']","['community engagement and planning or resources', 'Community Engagement and Planning (CEP) and Resources for Services (RS', 'community engagement and planning (promoting inter-agency collaboration) or resources for services (individual program technical assistance plus outreach) to implement depression QI toolkits in Hollywood-Metro and South Los Angeles']","['Employment, use of antidepressants, and total contacts', 'physical activity and reducing homelessness risk factors, rate of behavioral health hospitalization and medication visits', 'Self-reported mental HRQL and probable depression (primary), physical activity, employment, homelessness risk factors (secondary) and services use', 'outcomes relative to usual care, but health, social and other community-based service sectors']","[{'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0344315', 'cui_str': 'Depressed'}, {'cui': 'C1879301', 'cui_str': 'Patient Health Questionnaire'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning (observable entity)'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]","[{'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant Drugs'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0237154', 'cui_str': 'Homelessness'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0870196', 'cui_str': 'Behavioral health (qualifier value)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis (contextual qualifier) (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C3875154', 'cui_str': 'Relative to (attribute)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}]",4440.0,0.040556,"RESULTS CEP was more effective than RS at improving mental HRQL, increasing physical activity and reducing homelessness risk factors, rate of behavioral health hospitalization and medication visits among specialty care users (i.e. psychiatrists, mental health providers) while increasing depression visits among users of primary care/public health for depression and users of faith-based and park programs (each p < 0.05).","[{'ForeName': 'Kenneth B', 'Initials': 'KB', 'LastName': 'Wells', 'Affiliation': 'RAND Corporation, Santa Monica, CA, USA, kwells@mednet.ucla.edu.'}, {'ForeName': 'Loretta', 'Initials': 'L', 'LastName': 'Jones', 'Affiliation': ''}, {'ForeName': 'Bowen', 'Initials': 'B', 'LastName': 'Chung', 'Affiliation': ''}, {'ForeName': 'Elizabeth L', 'Initials': 'EL', 'LastName': 'Dixon', 'Affiliation': ''}, {'ForeName': 'Lingqi', 'Initials': 'L', 'LastName': 'Tang', 'Affiliation': ''}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Gilmore', 'Affiliation': ''}, {'ForeName': 'Cathy', 'Initials': 'C', 'LastName': 'Sherbourne', 'Affiliation': ''}, {'ForeName': 'Victoria K', 'Initials': 'VK', 'LastName': 'Ngo', 'Affiliation': ''}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Ong', 'Affiliation': ''}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Stockdale', 'Affiliation': ''}, {'ForeName': 'Esmeralda', 'Initials': 'E', 'LastName': 'Ramos', 'Affiliation': ''}, {'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'Belin', 'Affiliation': ''}, {'ForeName': 'Jeanne', 'Initials': 'J', 'LastName': 'Miranda', 'Affiliation': ''}]",Journal of general internal medicine,['10.1007/s11606-013-2484-3'] 1037,23826435,Enrollment of Research Subjects through Telemedicine Networks in a Multicenter Acute Intracerebral Hemorrhage Clinical Trial: Design and Methods.,"BACKGROUND Enrollment of subjects in acute stroke trials is often hindered by narrow timeframes, because a large proportion of patients arrive via transfers from outside facilities rather than primary arrival at the enrolling hospital. RATIONALE Telemedicine networks have been increasingly utilized for provision of care for acute stroke patients at facilities outside of major academic centers. Treatment decisions made through Telemedicine networks in patients with acute ischemic stroke have been shown to be safe, reliable, and effective. With the expanding use of this technology and the impediments to enrolling subjects into clinical trials, this approach can be applied successfully to the field of clinical research. METHODS AND CONCLUSIONS The antihypertensive treatment of acute cerebral hemorrhage II trial is a phase III randomized multicenter trial that has developed a protocol in collaboration with participating sites to implement the use of Telemedicine networks for the enrollment of research subjects. The protocol describes the operating procedures and legal and Institutional Review Board perspectives for its implementation.",2013,"Treatment decisions made through Telemedicine networks in patients with acute ischemic stroke have been shown to be safe, reliable, and effective.","['acute stroke patients at facilities outside of major academic centers', 'patients with acute ischemic stroke']",[],[],"[{'cui': 'C0751956', 'cui_str': 'Stroke, Acute'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}]",[],[],,0.160457,"Treatment decisions made through Telemedicine networks in patients with acute ischemic stroke have been shown to be safe, reliable, and effective.","[{'ForeName': 'Alfredo J', 'Initials': 'AJ', 'LastName': 'Caceres', 'Affiliation': 'Zeenat Qureshi Stroke Research Center, Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Greer', 'Affiliation': ''}, {'ForeName': 'Joshua N', 'Initials': 'JN', 'LastName': 'Goldstein', 'Affiliation': ''}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Viswanathan', 'Affiliation': ''}, {'ForeName': 'Jose I', 'Initials': 'JI', 'LastName': 'Suarez', 'Affiliation': ''}, {'ForeName': 'Logan', 'Initials': 'L', 'LastName': 'Brau', 'Affiliation': ''}, {'ForeName': 'Joseph Christopher', 'Initials': 'JC', 'LastName': 'Zacko', 'Affiliation': ''}, {'ForeName': 'Theodore J', 'Initials': 'TJ', 'LastName': 'Lowenkopf', 'Affiliation': ''}, {'ForeName': 'Chad M', 'Initials': 'CM', 'LastName': 'Miller', 'Affiliation': ''}, {'ForeName': 'Qaisar A', 'Initials': 'QA', 'LastName': 'Shah', 'Affiliation': ''}, {'ForeName': 'Ira', 'Initials': 'I', 'LastName': 'Chang', 'Affiliation': ''}, {'ForeName': 'Souvik', 'Initials': 'S', 'LastName': 'Sen', 'Affiliation': ''}, {'ForeName': 'Steven R', 'Initials': 'SR', 'LastName': 'Messe', 'Affiliation': ''}, {'ForeName': 'Sherry H-Y', 'Initials': 'SH', 'LastName': 'Chou', 'Affiliation': ''}, {'ForeName': 'Adnan I', 'Initials': 'AI', 'LastName': 'Qureshi', 'Affiliation': ''}]",Journal of vascular and interventional neurology,[] 1038,32066431,Influence of the implant-abutment connection on the ratio between height and thickness of tissues at the buccal zenith: a randomized controlled trial on 188 implants placed in 104 patients.,"BACKGROUND To compare tissue response to two implant systems, featuring internal hexed connections with different designs. METHODS Patients enrolled in this randomized controlled trial were assigned to two groups. In Group 1, patients were treated with implants with a 5° conical internal hexed connection (Anyridge®, MegaGen, South Korea). In Group 2, patients were treated with implants with an internal hexed connection (Core®, Kristal, Italy). After implant placement and a provisionalisation period of 12 months, impressions were taken, stone casts were poured and digitised with a desktop scanner (D700®, 3Shape, Copenhagen, Denmark). In a digital environment, for each fixture, two values were collected at the buccal zenith: the height of the peri-implant mucosa (mucosal height; MH), calculated from the vestibular shoulder of the implant analogue to the upper gingival margin of the supra-implant tissue; and the width of the peri-implant mucosa (mucosal thickness; MT), calculated from the vestibular shoulder of the analogue to the external mucosa point perpendicular to the implant major axis. The mean and standard deviation for MH and MT, as well as their ratios, were calculated for each group; the sectors in which the implants were placed were also considered. Finally, correlation between MH, MT, connection type and sector was assessed by Pearson's correlation coefficient, with significance level set at 0.05, and a confidence interval (CI) set at 95%. RESULTS Data deriving from 188 implants placed in 104 patients were evaluated. The mean MH values were 3.32 (± 0.12) and 2.70 (± 0.16) mm for Groups 1 and 2, respectively. The mean MT values were 4.37 (± 0.16) and 3.93 (± 0.18) mm for Groups 1 and 2, respectively. Group 1 showed higher MH and MT values and a better ratio (1.50 ± 0.88) than Group 2 (1.81 ± 1.20). The MH, MT and MH/MT ratio were significantly influenced both by sector (p = 0.015) and group (p = 0.047). CONCLUSIONS Within the limits of this study, the 5° connection implants supported a more extended tissue height and thickness at the buccal zenith, and a better ratio between them. TRIAL REGISTRATION This study was retrospectively registered in Clinicaltrials.gov, with number NCT04160689, dated 13/11/2019.",2020,"The MH, MT and MH/MT ratio were significantly influenced both by sector (p = 0.015) and group (p = 0.047). ","['188 implants placed in 104 patients', 'Data deriving from 188 implants placed in 104 patients were evaluated', 'Patients enrolled']","['implant-abutment connection', 'implants with a 5° conical internal hexed connection (Anyridge®, MegaGen, South Korea']","['MH and MT values', 'MH, MT and MH/MT ratio', 'mean MH values', 'MH, MT, connection type and sector', 'mean MT values']","[{'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C1704765', 'cui_str': 'Place - dosing instruction imperative'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C0449379', 'cui_str': 'Connection (attribute)'}, {'cui': 'C0205102', 'cui_str': 'Internal (qualifier value)'}, {'cui': 'C0022773', 'cui_str': 'South Korea'}]","[{'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449379', 'cui_str': 'Connection (attribute)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}]",104.0,0.0614897,"The MH, MT and MH/MT ratio were significantly influenced both by sector (p = 0.015) and group (p = 0.047). ","[{'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Farronato', 'Affiliation': 'Department of Medicine and Surgery, School of Dentistry, University of Insubria, Varese, Italy. davide@farronato.it.'}, {'ForeName': 'Pietro Mario', 'Initials': 'PM', 'LastName': 'Pasini', 'Affiliation': 'Department of Medicine and Surgery, School of Dentistry, University of Insubria, Varese, Italy.'}, {'ForeName': 'Mattia', 'Initials': 'M', 'LastName': 'Manfredini', 'Affiliation': 'Private Practice, corso Europa 10, 20122, Milan, Italy.'}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Scognamiglio', 'Affiliation': 'Private Practice, corso della Vittoria 744, 21042 Caronno Pertusella, Varese, Italy.'}, {'ForeName': 'Andrea Alain', 'Initials': 'AA', 'LastName': 'Orsina', 'Affiliation': 'Department of Medicine and Surgery, School of Dentistry, University of Insubria, Varese, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Farronato', 'Affiliation': 'Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Department of Orthodontics, School of Dentistry, Milan, Italy.'}]",BMC oral health,['10.1186/s12903-020-1037-5'] 1039,24358415,A randomized trial comparing primary angioplasty versus stent placement for symptomatic intracranial stenosis.,"BACKGROUND Both primary angioplasty alone and angioplasty with a self-expanding stent have been compared in non-randomized concurrent clinical studies that suggest equivalent results. However, there is no randomized trial that has compared the two procedures in patients with symptomatic high grade intracranial stenosis. OBJECTIVE The primary aim of the randomized trial was to compare the clinical and angiographic efficacy of primary angioplasty and angioplasty followed by stent placement in preventing restenosis, stroke, requirement for second treatment, and death in patients with symptomatic intracranial stenosis. METHODS The study prospectively evaluated efficacy and safety of the two existing neurointerventional techniques for treatment of moderate intracranial stenosis (stenosis ≥ 50%) with documented failure of medical treatment or severe stenosis (≥70%) with or without failure of medical treatment. RESULTS A total of 18 patients were recruited in the study (mean age [±SD] was 64.7 ± 15.1 years); out of these, 12 were men. Of these 18, 10 were treated with primary angioplasty and 8 were treated with angioplasty followed by self-expanding stent. The technical success rates of intracranial angioplasty and stent placements defined as ability to achieve <30% residual stenosis when assessed by immediate post-procedure angiography was 5 of 10 and 5 of 8 patients, respectively. The total fluoroscopic time (mean [±SD]) was lower in patients undergoing primary angioplasty 37 [±11] min versus those undergoing angioplasty followed by self-expanding stent 42 [±15] min, P = 0.4321. The stroke and death rate within 1 month was very low in both patient groups (1 of 10 versus 0 of 8 patients). One patient randomized to stent placement continued to have recurrent ischemic symptoms requiring another angioplasty in the vertebral artery on post-procedure Day 2. CONCLUSIONS The trial suggests that a randomized trial comparing primary angioplasty to angioplasty followed by stent placement is feasible. The immediate procedural outcomes with primary angioplasty are comparable to stent placement and warrant further studies.",2013,The stroke and death rate within 1 month was very low in both patient groups (1 of 10 versus 0 of 8 patients).,"['symptomatic intracranial stenosis', 'A total of 18 patients were recruited in the study (mean age [±SD] was 64.7 ± 15.1 years); out of these, 12 were men', 'patients with symptomatic intracranial stenosis', 'moderate intracranial stenosis (stenosis ≥ 50%) with documented failure of medical treatment or severe stenosis (≥70%) with or without failure of medical treatment', 'patients with symptomatic high grade intracranial stenosis']","['primary angioplasty to angioplasty followed by stent placement', 'existing neurointerventional techniques', 'primary angioplasty', 'primary angioplasty versus stent placement', 'stent placement', 'primary angioplasty alone and angioplasty with a self-expanding stent', 'angioplasty followed by self-expanding stent', 'primary angioplasty and angioplasty followed by stent placement']","['clinical and angiographic efficacy', 'recurrent ischemic symptoms', 'stroke and death rate', 'restenosis, stroke, requirement for second treatment, and death', 'total fluoroscopic time (mean [±SD']","[{'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0524466', 'cui_str': 'Intracranial (qualifier value)'}, {'cui': 'C1261287', 'cui_str': 'Stenosis'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1962917', 'cui_str': 'High grade (lymphoma)'}]","[{'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0162577', 'cui_str': 'Angioplasty'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0522776', 'cui_str': 'Placement of stent (procedure)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0441291', 'cui_str': 'Self-expanding stent (physical object)'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C0333186', 'cui_str': 'Restenosis'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",18.0,0.0740398,The stroke and death rate within 1 month was very low in both patient groups (1 of 10 versus 0 of 8 patients).,"[{'ForeName': 'Adnan I', 'Initials': 'AI', 'LastName': 'Qureshi', 'Affiliation': 'Zeenat Qureshi Stroke Research Center, Departments of Neurology and Neurosurgery, University of Minnesota, and Hennepin County Medical Center, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Saqib A', 'Initials': 'SA', 'LastName': 'Chaudhry', 'Affiliation': 'Zeenat Qureshi Stroke Research Center, Departments of Neurology and Neurosurgery, University of Minnesota, and Hennepin County Medical Center, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Farhan', 'Initials': 'F', 'LastName': 'Siddiq', 'Affiliation': 'Zeenat Qureshi Stroke Research Center, Departments of Neurology and Neurosurgery, University of Minnesota, and Hennepin County Medical Center, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Shahram', 'Initials': 'S', 'LastName': 'Majidi', 'Affiliation': 'Zeenat Qureshi Stroke Research Center, Departments of Neurology and Neurosurgery, University of Minnesota, and Hennepin County Medical Center, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Gustavo J', 'Initials': 'GJ', 'LastName': 'Rodriguez', 'Affiliation': 'Zeenat Qureshi Stroke Research Center, Departments of Neurology and Neurosurgery, University of Minnesota, and Hennepin County Medical Center, Minneapolis, MN 55455, USA.'}, {'ForeName': 'M Fareed K', 'Initials': 'MF', 'LastName': 'Suri', 'Affiliation': 'Zeenat Qureshi Stroke Research Center, Departments of Neurology and Neurosurgery, University of Minnesota, and Hennepin County Medical Center, Minneapolis, MN 55455, USA.'}]",Journal of vascular and interventional neurology,[] 1040,31399448,Glutathione infusion before primary percutaneous coronary intervention: a randomised controlled pilot study.,"OBJECTIVE In the setting of reperfused ST-elevation myocardial infarction (STEMI), increased production of reactive oxygen species (ROS) contributes to reperfusion injury. Among ROS, hydrogen peroxide (H 2 O 2 ) showed toxic effects on human cardiomyocytes and may induce microcirculatory impairment. Glutathione (GSH) is a water-soluble tripeptide with a potent oxidant scavenging activity. We hypothesised that the infusion of GSH before acute reoxygenation might counteract the deleterious effects of increased H 2 O 2 generation on myocardium. METHODS Fifty consecutive patients with STEMI, scheduled to undergo primary angioplasty, were randomly assigned, before intervention, to receive an infusion of GSH (2500 mg/25 mL over 10 min), followed by drug administration at the same doses at 24, 48 and 72 hours elapsing time or placebo. Peripheral blood samples were obtained before and at the end of the procedure, as well as after 5 days. H 2 O 2 production, 8-iso-prostaglandin F2α (PGF2α) formation, H 2 O 2 breakdown activity (HBA) and nitric oxide (NO) bioavailability were determined. Serum cardiactroponin T (cTpT) was measured at admission and up to 5 days. RESULTS Following acute reperfusion, a significant reduction of H 2 O 2 production (p=0.0015) and 8-iso-PGF2α levels (p=0.0003), as well as a significant increase in HBA (p<0.0001)and NO bioavailability (p=0.035), was found in the GSH group as compared with placebo. In treated patients, attenuated production of H 2 O 2 persisted up to 5 days from the index procedure (p=0.009) and these changes was linked to those of the cTpT levels (r=0.41, p=0.023). CONCLUSION The prophylactic and prolonged infusion of GSH seems to determine a rapid onset and persistent blunting of H 2 O 2 generation improving myocardial cell survival. Nevertheless, a larger trial, adequately powered for evaluation of clinical endpoints, is ongoing to confirm the current finding. TRIAL REGISTRATION NUMBER EUDRACT 2014-00448625; Pre-results.",2019,"Following acute reperfusion, a significant reduction of H 2 O 2 production (p=0.0015) and 8-iso-PGF2α levels (p=0.0003), as well as a significant increase in HBA (p<0.0001)and NO bioavailability (p=0.035), was found in the GSH group as compared with placebo.","['Fifty consecutive patients with STEMI, scheduled to undergo primary angioplasty', 'before primary percutaneous coronary intervention']","['Glutathione infusion', 'GSH', 'placebo', 'Glutathione (GSH', 'ROS, hydrogen peroxide']","['HBA (p<0.0001)and NO bioavailability', 'myocardial cell survival', 'microcirculatory impairment', 'Serum cardiactroponin T (cTpT', 'reduction of H 2 O 2 production (p=0.0015) and 8-iso-PGF2α levels', 'H 2 O 2 production, 8-iso-prostaglandin F2α (PGF2α) formation, H 2 O 2 breakdown activity (HBA) and nitric oxide (NO) bioavailability', 'Peripheral blood samples', 'attenuated production of H 2 O 2']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1536220', 'cui_str': 'ST Elevated Myocardial Infarction'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0162577', 'cui_str': 'Angioplasty'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}]","[{'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0020281', 'cui_str': 'Hydrogen Peroxide'}]","[{'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0225828', 'cui_str': 'Muscle Cells, Cardiac'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0033268'}, {'cui': 'C0911936', 'cui_str': 'iso(VL)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0356622', 'cui_str': 'Prostaglandins, oxytocics'}, {'cui': 'C0439634', 'cui_str': 'Formations (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood (substance)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}]",50.0,0.178928,"Following acute reperfusion, a significant reduction of H 2 O 2 production (p=0.0015) and 8-iso-PGF2α levels (p=0.0003), as well as a significant increase in HBA (p<0.0001)and NO bioavailability (p=0.035), was found in the GSH group as compared with placebo.","[{'ForeName': 'Gaetano', 'Initials': 'G', 'LastName': 'Tanzilli', 'Affiliation': 'Department of Heart and Great Vessels, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Truscelli', 'Affiliation': 'Department of Heart and Great Vessels, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Alessio', 'Initials': 'A', 'LastName': 'Arrivi', 'Affiliation': 'Department of Cardiology, ""Santa Maria"" Hospital, Terni, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Carnevale', 'Affiliation': 'Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy.'}, {'ForeName': 'Attilio', 'Initials': 'A', 'LastName': 'Placanica', 'Affiliation': 'Department of Cardiology, ""San Giovanni Evangelista"" Hospital, Tivoli, Italy.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Viceconte', 'Affiliation': 'Department of Heart and Great Vessels, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Raparelli', 'Affiliation': 'Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Mele', 'Affiliation': 'Department of Surgical Sciences, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Vittoria', 'Initials': 'V', 'LastName': 'Cammisotto', 'Affiliation': 'Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Nocella', 'Affiliation': 'Internal Medicine and Medical Specialties, Sapienza University of Rome.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Barillà', 'Affiliation': 'Department of Heart and Great Vessels, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Lucisano', 'Affiliation': 'Department of Cardiology, ""San Giovanni Evangelista"" Hospital, Tivoli, Italy.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Pennacchi', 'Affiliation': 'Department of Cardiology, ""San Giovanni Evangelista"" Hospital, Tivoli, Italy.'}, {'ForeName': 'Antonino', 'Initials': 'A', 'LastName': 'Granatelli', 'Affiliation': 'Department of Cardiology, ""San Giovanni Evangelista"" Hospital, Tivoli, Italy.'}, {'ForeName': 'Marcello', 'Initials': 'M', 'LastName': 'Dominici', 'Affiliation': 'Department of Cardiology, ""Santa Maria"" Hospital, Terni, Italy.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Basili', 'Affiliation': 'Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Gaudio', 'Affiliation': 'Department of Heart and Great Vessels, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Mangieri', 'Affiliation': 'Department of Heart and Great Vessels, Sapienza University of Rome, Rome, Italy.'}]",BMJ open,['10.1136/bmjopen-2018-025884'] 1041,32070302,The effect of intracanal medicaments used in Endodontics on the dislocation resistance of two calcium silicate-based filling materials.,"BACKGROUND Intracanal medicaments can be used in various endodontic conditions including multiple visit endodontics after trauma or in regenerative endodontics. These medicaments should be removed from the root canal before the placement of the filling or repair material. The aim of the present study was to evaluate the effect of prior calcium hydroxide (Ca(OH) 2 ) and modified triple antibiotic paste (mTAP) placement on the push-out bond strength of TotalFill BC fast set putty (BC fast set putty) to root dentin when compared to mineral trioxide aggregate (MTA). METHODS The root canals of 45 extracted mandibular premolars were prepared to a standardized internal diameter (1.5 mm). The specimens were randomly assigned to 3 groups according to the intracanal medicament used: mTAP (a mixture of metronidazole, ciprofloxacin, and cefaclor), Ca(OH) 2 , and no intracanal medicament. After 1 week, the medicaments were removed, and the middle third of the roots were cut into two transverse sections (2.0 ± 0.05) (n = 90 slices). Thereafter, the specimens were divided into two subgroups (n = 45 each): MTA or BC putty. After 1 week, the push-out test was performed and failure mode was evaluated. The data were statistically analyzed using two-way ANOVA and Tukey's post hoc. RESULTS The application of the intracanal medicament did not significantly affect the bond strength of BC putty (p > .05). For MTA, the prior application of Ca(OH) 2 or mTAP significantly decreased the dislocation resistance (p < .05). Specimens in the MTA subgroups showed an almost equal number of cohesive and mixed types of failure while the majority of the specimens in the BC putty subgroups revealed the cohesive type. CONCLUSIONS Ca(OH) 2 and mTAP promoted lower bond strength of MTA to root dentin compared to the control group. However, the BC fast set putty bond strength to dentin was not affected by prior medication with Ca(OH) 2 or mTAP.",2020,"CONCLUSIONS Ca(OH) 2 and mTAP promoted lower bond strength of MTA to root dentin compared to the control group.",['45 extracted mandibular premolars'],"['mTAP (a mixture of metronidazole, ciprofloxacin, and cefaclor), Ca(OH) 2 , and no intracanal medicament', 'calcium hydroxide (Ca(OH) 2 ) and modified triple antibiotic paste (mTAP) placement', 'intracanal medicaments']","['bond strength of BC putty', 'bond strength of MTA to root dentin', 'dislocation resistance']","[{'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C1704302', 'cui_str': 'Premolar'}]","[{'cui': 'C0439962', 'cui_str': 'Mixture (qualifier value)'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0007537', 'cui_str': 'Cefaclor'}, {'cui': 'C0456386', 'cui_str': 'Medicament (attribute)'}, {'cui': 'C0006701', 'cui_str': 'calcium hydroxide'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0030634', 'cui_str': 'Pastes'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}]","[{'cui': 'C0028758', 'cui_str': 'Object Relationship'}, {'cui': 'C0210657', 'cui_str': 'pemetrexed'}, {'cui': 'C0563017', 'cui_str': 'Anal penetration using finger (finding)'}, {'cui': 'C0011429', 'cui_str': 'Dentin'}, {'cui': 'C0012691', 'cui_str': 'Joint Dislocations'}]",,0.0181054,"CONCLUSIONS Ca(OH) 2 and mTAP promoted lower bond strength of MTA to root dentin compared to the control group.","[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Alsubait', 'Affiliation': 'Division of Endodontics, Department of Restorative Dental Science, College of Dentistry, King Saud University, Riyadh, Saudi Arabia. salsubait@ksu.edu.sa.'}, {'ForeName': 'Norah', 'Initials': 'N', 'LastName': 'Alsaad', 'Affiliation': 'Private Practice, Riyadh, Saudi Arabia.'}, {'ForeName': 'Sumayyah', 'Initials': 'S', 'LastName': 'Alahmari', 'Affiliation': 'Endodontic Residency Program, Saudi Commission for Health Specialist, Riyadh, Saudi Arabia.'}, {'ForeName': 'Fatimah', 'Initials': 'F', 'LastName': 'Alfaraj', 'Affiliation': 'Private Practice, Riyadh, Saudi Arabia.'}, {'ForeName': 'Hussam', 'Initials': 'H', 'LastName': 'Alfawaz', 'Affiliation': 'Division of Endodontics, Department of Restorative Dental Science, College of Dentistry, King Saud University, Riyadh, Saudi Arabia.'}, {'ForeName': 'Abdullah', 'Initials': 'A', 'LastName': 'Alqedairi', 'Affiliation': 'Division of Endodontics, Department of Restorative Dental Science, College of Dentistry, King Saud University, Riyadh, Saudi Arabia.'}]",BMC oral health,['10.1186/s12903-020-1044-6'] 1042,31996174,Study protocol of a randomised clinical trial testing whether metacognitive training can improve insight and clinical outcomes in schizophrenia.,"BACKGROUND Although insight in schizophrenia spectrum disorders (SSD) has been associated with positive outcomes, the effect size of previous treatments on insight has been relatively small to date. The metacognitive basis of insight suggests that metacognitive training (MCT) may improve insight and clinical outcomes in SSD, although this remains to be established. METHODS This single-center, assessor-blind, parallel-group, randomised clinical trial (RCT) aims to investigate the efficacy of MCT for improving insight (primary outcome), including clinical and cognitive insight, which will be measured by the Schedule for Assessment of Insight (Expanded version) (SAI-E) and the Beck Cognitive Scale (BCIS), respectively, in (at least) n = 126 outpatients with SSD at three points in time: i) at baseline (T0); ii) after treatment (T1) and iii) at 1-year follow-up (T2). SSD patients receiving MCT and controls attending a non-intervention support group will be compared on insight level changes and several clinical and cognitive secondary outcomes at T1 and T2, whilst adjusting for baseline data. Ecological momentary assessment (EMA) will be piloted to assess functioning in a subsample of participants. DISCUSSION To the best of our knowledge, this will be the first RCT testing the effect of group MCT on multiple insight dimensions (as primary outcome) in a sample of unselected patients with SSD, including several secondary outcomes of clinical relevance, namely symptom severity, functioning, which will also be evaluated with EMA, hospitalizations and suicidal behaviour. TRIAL REGISTRATION ClinicalTrials.gov: NCT04104347. Date of registration: 26/09/2019 (Retrospectively registered).",2020,"SSD patients receiving MCT and controls attending a non-intervention support group will be compared on insight level changes and several clinical and cognitive secondary outcomes at T1 and T2, whilst adjusting for baseline data.","['schizophrenia spectrum disorders (SSD', 'SSD patients receiving', 'schizophrenia', 'n\u2009=\u2009126 outpatients with SSD']","['MCT', 'Ecological momentary assessment (EMA', 'metacognitive training (MCT', 'metacognitive training']",['Assessment of Insight (Expanded version) (SAI-E) and the Beck Cognitive Scale (BCIS'],"[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0723179', 'cui_str': 'SSD'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}]","[{'cui': 'C1173173', 'cui_str': 'N-methanocarbathymidine'}, {'cui': 'C4277684', 'cui_str': 'Ecological Momentary Assessment'}, {'cui': 'C0268596', 'cui_str': 'Glutaric Acidemia, Type 2'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0233820', 'cui_str': 'Self-understanding'}, {'cui': 'C0205229', 'cui_str': 'Expanding (qualifier value)'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0222045'}]",126.0,0.244999,"SSD patients receiving MCT and controls attending a non-intervention support group will be compared on insight level changes and several clinical and cognitive secondary outcomes at T1 and T2, whilst adjusting for baseline data.","[{'ForeName': 'Javier-David', 'Initials': 'JD', 'LastName': 'Lopez-Morinigo', 'Affiliation': 'Departamento de Psiquiatría, IIS-Fundación Jiménez Díaz, Madrid, Spain. javierd.lopez@uam.es.'}, {'ForeName': 'Verónica González', 'Initials': 'VG', 'LastName': 'Ruiz-Ruano', 'Affiliation': 'Departamento de Psiquiatría, IIS-Fundación Jiménez Díaz, Madrid, Spain.'}, {'ForeName': 'Adela Sánchez Escribano', 'Initials': 'ASE', 'LastName': 'Martínez', 'Affiliation': 'Departamento de Psiquiatría, IIS-Fundación Jiménez Díaz, Madrid, Spain.'}, {'ForeName': 'María Luisa Barrigón', 'Initials': 'MLB', 'LastName': 'Estévez', 'Affiliation': 'Departamento de Psiquiatría, IIS-Fundación Jiménez Díaz, Madrid, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Mata-Iturralde', 'Affiliation': 'Departamento de Psiquiatría, IIS-Fundación Jiménez Díaz, Madrid, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Muñoz-Lorenzo', 'Affiliation': 'Departamento de Psiquiatría, IIS-Fundación Jiménez Díaz, Madrid, Spain.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Sánchez-Alonso', 'Affiliation': 'Departamento de Psiquiatría, IIS-Fundación Jiménez Díaz, Madrid, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Artés-Rodríguez', 'Affiliation': 'Departamento de Teoría de Señal y de la Comunicación, Universidad Carlos III, Madrid, Spain.'}, {'ForeName': 'Anthony S', 'Initials': 'AS', 'LastName': 'David', 'Affiliation': 'Institute of Mental Health, University College London, London, UK.'}, {'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'Baca-García', 'Affiliation': 'Departamento de Psiquiatría, IIS-Fundación Jiménez Díaz, Madrid, Spain.'}]",BMC psychiatry,['10.1186/s12888-020-2431-x'] 1043,31146028,An Efficient Single-session Spatial Skill Trainer for Robot-assisted Surgery: A Randomized Trial.,"STUDY OBJECTIVE To introduce and examine a single session of spatial skill training as an efficient means of improving surgical suturing performance in robot-assisted surgery. DESIGN A randomized, controlled trial. SETTING A tertiary university medical center in Israel. PARTICIPANTS A purposive sample composed of 41 residents with no robotic suturing skills. INTERVENTIONS A computer-based simulator training of spatial skills. MEASUREMENTS AND MAIN RESULTS Participants were randomly assigned to training (n = 21: mean age of 34 years [standard deviation (SD) = 1.92]) and control (n = 20: mean age of 32 years [SD = 3.17]) conditions. The training group underwent a session of spatial skills training, whereas the control group engaged in a neutral activity. After 1 participant was lost to the follow-up of the posttraining performance test, data of 40 participants were analyzed. Robotic suturing task performance with the da Vinci Skills Simulator (Intuitive Surgical, Sunnyvale, CA) was evaluated using the da Vinci Skills Simulator built-in measure of ""excess tissue piercing"" and an expert rating of ""tissue tearing."" The mean number of excess tissue piercing after training (but not after the neutral activity) was significantly lower than before training (3.25 [SD = 1.996] vs 6.75 [SD = 3.68], respectively; p <.001), reflecting an improvement of 52% (decreasing the mean number of excess tissue piercing in a single suture by 3.5 excess piercing trials). After the interventions, the extent of tissue tearing was rated lower in the training group (p = .01), and there was no change in the control group (p = .14). CONCLUSION We showed the efficiency of a training approach that focuses on spatial skills critical in robot-assisted surgery. We showed that surgeons who received a 1 session spatial skill training with a cognitive spatial skill trainer immediately improved the performance of a robotic suturing task compared with surgeons who did not receive such training.",2020,"After the interventions, the extent of tissue tearing was rated lower in the training group (p = .01), and there was no change in the control group (p = .14). ","['A tertiary university medical center in Israel', 'A purposive sample composed of 41 residents with no robotic suturing skills', 'Participants were randomly assigned to training (n\u202f=\u202f21: mean age of 34 years [standard deviation (SD)\u202f=\u202f1.92]) and control (n\u202f=\u202f20: mean age of 32 years [SD\u202f=\u202f3.17]) conditions']","['session spatial skill training with a cognitive spatial skill trainer', 'robotic suturing task compared with surgeons who did not receive such training', 'session of spatial skills training', 'spatial skill training', 'Robotic suturing task performance with the da Vinci Skills Simulator (Intuitive Surgical, Sunnyvale, CA', 'Single-session Spatial Skill Trainer for Robot-assisted Surgery']","['surgical suturing performance', 'mean number of excess tissue piercing', 'extent of tissue tearing']","[{'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0000872', 'cui_str': 'University Medical Centers'}, {'cui': 'C0022271', 'cui_str': 'Israel'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4517686', 'cui_str': '3.17'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0559197', 'cui_str': 'Skills training (procedure)'}, {'cui': 'C0453962', 'cui_str': 'Trainers (physical object)'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture (procedure)'}, {'cui': 'C0582175', 'cui_str': 'Surgeon (occupation)'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0183309', 'cui_str': 'Simulator (physical object)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0336537', 'cui_str': 'Robot, device (physical object)'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0038969', 'cui_str': 'Sutures'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0439792', 'cui_str': 'Extents (qualifier value)'}]",40.0,0.0758427,"After the interventions, the extent of tissue tearing was rated lower in the training group (p = .01), and there was no change in the control group (p = .14). ","[{'ForeName': 'Liel', 'Initials': 'L', 'LastName': 'Luko', 'Affiliation': 'Faculty of Industrial Engineering and Management, Israel Institute of Technology, Technion City, Haifa, Israel (Drs. Luko and Parush). Electronic address: liluko@campus.technion.ac.il.'}, {'ForeName': 'Avi', 'Initials': 'A', 'LastName': 'Parush', 'Affiliation': 'Faculty of Industrial Engineering and Management, Israel Institute of Technology, Technion City, Haifa, Israel (Drs. Luko and Parush).'}, {'ForeName': 'Emad', 'Initials': 'E', 'LastName': 'Matanes', 'Affiliation': 'Department of Obstetrics and Gynecology, Rambam Medical Center, Haifa, Israel (Drs. Matanes, Lauterbach, and Lowenstein).'}, {'ForeName': 'Roy', 'Initials': 'R', 'LastName': 'Lauterbach', 'Affiliation': 'Department of Obstetrics and Gynecology, Rambam Medical Center, Haifa, Israel (Drs. Matanes, Lauterbach, and Lowenstein).'}, {'ForeName': 'Ayal', 'Initials': 'A', 'LastName': 'Taitler', 'Affiliation': 'Technion Autonomous Systems Program, Israel Institute of Technology, Technion City, Haifa, Israel (Dr. Taitler).'}, {'ForeName': 'Lior', 'Initials': 'L', 'LastName': 'Lowenstein', 'Affiliation': 'Department of Obstetrics and Gynecology, Rambam Medical Center, Haifa, Israel (Drs. Matanes, Lauterbach, and Lowenstein).'}]",Journal of minimally invasive gynecology,['10.1016/j.jmig.2019.05.014'] 1044,22923917,Effect of exercise therapy on lipid parameters in patients with end-stage renal disease on hemodialysis.,"BACKGROUND Dyslipidemia has been established as a well-known traditional risk factor for cardiovascular disease in chronic kidney disease patients. AIM This study investigated the impact of Hatha yoga exercise on lipid parameters in patients with end-stage renal disease (ESRD) on hemodialysis. MATERIALS AND METHODS This prospective randomized study consisted of 33 ESRD patients in the Hatha yoga exercise group that was matched with 35 ESRD patients in the control group. Serum total cholesterol, triglycerides, low-density lipoprotein (LDL)-cholesterol, and high-density lipoprotein (HDL)-cholesterol were determined at baseline (0 month) and after 4 months. RESULTS Comparing values after 4 months versus baseline in the prehemodialysis Hatha yoga exercise group, there was found a significant decrease in total cholesterol from 5.126 ± 0.092 mmol/l to 4.891 ± 0.072 mmol/l (-4.58%; P = 0.0001), triglycerides from 2.699 ± 0.078 mmol/l to 2.530 ± 0.063 mmol/l (-6.26%; P = 0.0001), LDL-cholesterol from 2.729 ± 0.083 mmol/l to 2.420 ± 0.066 mmol/l (-11.32%; P = 0.0001), and total cholesterol/HDL-cholesterol ratio from 5.593 ± 0.119 mmol/l to 4.907 ± 0.116 mmol/l (-12.26%; P = 0.047). For patients in the Hatha yoga exercise group, 51.5% had normal total cholesterol at 0 month while 70.0% had normal total cholesterol (P < 0.05) after 4 four months and 54.5% of patients had normal LDL-cholesterol at 0 month while 84.9% had normal LDL-cholesterol after 4 months (P < 0.05). CONCLUSION These findings suggest that Hatha yoga exercise has preventive and beneficial effects and may be a safe therapeutic modality in ESRD patients.",2012,"Comparing values after 4 months versus baseline in the prehemodialysis Hatha yoga exercise group, there was found a significant decrease in total cholesterol from 5.126 ± 0.092 mmol/l to 4.891 ± 0.072 mmol/l (-4.58%; P = 0.0001), triglycerides from 2.699 ± 0.078 mmol/l to 2.530 ± 0.063 mmol/l (-6.26%; P = 0.0001), LDL-cholesterol from 2.729 ± 0.083 mmol/l to 2.420 ± 0.066 mmol/l (-11.32%; P = 0.0001), and total cholesterol/HDL-cholesterol ratio from 5.593 ± 0.119 mmol/l to 4.907 ± 0.116 mmol/l","['ESRD patients', 'chronic kidney disease patients', 'patients with end-stage renal disease on hemodialysis', '33 ESRD patients in the Hatha yoga exercise group that was matched with 35 ESRD patients in the control group', 'patients with end-stage renal disease (ESRD) on hemodialysis']","['exercise therapy', 'Hatha yoga exercise']","['normal LDL-cholesterol', 'normal total cholesterol', 'total cholesterol', 'LDL-cholesterol', 'lipid parameters', 'total cholesterol/HDL-cholesterol ratio', 'Serum total cholesterol, triglycerides, low-density lipoprotein (LDL)-cholesterol, and high-density lipoprotein (HDL)-cholesterol']","[{'cui': 'C0022661', 'cui_str': 'End-Stage Kidney Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0452240', 'cui_str': 'Rehabilitation Exercise'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol, HDL2'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023822', 'cui_str': 'High Density Lipoprotein Cholesterol'}]",33.0,0.0254069,"Comparing values after 4 months versus baseline in the prehemodialysis Hatha yoga exercise group, there was found a significant decrease in total cholesterol from 5.126 ± 0.092 mmol/l to 4.891 ± 0.072 mmol/l (-4.58%; P = 0.0001), triglycerides from 2.699 ± 0.078 mmol/l to 2.530 ± 0.063 mmol/l (-6.26%; P = 0.0001), LDL-cholesterol from 2.729 ± 0.083 mmol/l to 2.420 ± 0.066 mmol/l (-11.32%; P = 0.0001), and total cholesterol/HDL-cholesterol ratio from 5.593 ± 0.119 mmol/l to 4.907 ± 0.116 mmol/l","[{'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Gordon', 'Affiliation': 'Kingston Public Hospital, North Street, Kingston, Jamaica. lorenzogordon@yahoo.com'}, {'ForeName': 'Donovan A', 'Initials': 'DA', 'LastName': 'McGrowder', 'Affiliation': ''}, {'ForeName': 'Yeiny T', 'Initials': 'YT', 'LastName': 'Pena', 'Affiliation': ''}, {'ForeName': 'Elsa', 'Initials': 'E', 'LastName': 'Cabrera', 'Affiliation': ''}, {'ForeName': 'Marilyn', 'Initials': 'M', 'LastName': 'Lawrence-Wright', 'Affiliation': ''}]",Journal of laboratory physicians,['10.4103/0974-2727.98665'] 1045,22481421,Community-based treatment of serious bacterial infections in newborns and young infants: a randomized controlled trial assessing three antibiotic regimens.,"BACKGROUND Sepsis in the neonatal period is a major cause of child mortality in low-income countries. Hospitalization and parenteral penicillin/ampicillin and gentamicin therapy are recommended for management. Many families, however, are unable to access hospital care, and most home-delivered newborns who develop sepsis die without receiving antibiotic therapy. Appropriate community-based therapy in such situations is undefined. We compared failure rates of 3 clinic-based antibiotic regimens in 0- to 59-day-old infants with possible serious bacterial infection whose families refused hospitalization in Karachi communities with high neonatal mortality rates>45/1000 live births. METHODS Eligible infants were randomly assigned to 7 days of: (1) procaine penicillin [50,000 units/kg once daily (OD) by intramuscular injection (IM)] and gentamicin (5 mg/kg OD IM) reference arm, (2) ceftriaxone (50 mg/kg OD IM), or (3) oral trimethoprim-sulfamethoxazole (TMP-SMX) at 10 mg/kg/day divided twice daily and gentamicin IM OD. Primary outcome was treatment failure, defined as death, deterioration in clinical condition during therapy or no improvement after 2 days. RESULTS Possible serious bacterial infection was diagnosed in 704 infants, among 5766 screened. Among 434 (61.6%) randomized to clinic-based therapy, there were 13 of 145 failures with penicillin-gentamicin, 22 of 145 with ceftriaxone and 26 of 143 with TMP-SMX-gentamicin. Treatment failure was significantly higher with TMP-SMX-gentamicin compared with penicillin-gentamicin [relative risk 2.03, 95% confidence interval: 1.09-3.79] by intention-to-treat analysis. Differences were not significant in the ceftriaxone versus penicillin-gentamicin comparison [relative risk 1.69, 95% confidence interval 0.89-3.23). By 14 days, there were 2 deaths in the penicillin-gentamicin group, 3 in the ceftriaxone group and 11 in the TMP-SMX-gentamicin group [relative risk 5.58, 95% confidence interval: 1.26-24.72 (group 3 versus 1)]. CONCLUSION When hospitalization of sick infants is unfeasible, outpatient therapy with injectable antibiotics is an effective option. Procaine penicillin-gentamicin was superior to TMP-SMX-gentamicin. Ceftriaxone is a more expensive option, and may be less effective, although this requires further research.",2012,"Treatment failure was significantly higher with TMP-SMX-gentamicin compared with penicillin-gentamicin [relative risk 2.03, 95% confidence interval: 1.09-3.79] by intention-to-treat analysis.","['704 infants, among 5766 screened', '0- to 59-day-old infants with possible serious bacterial infection whose families refused hospitalization in Karachi communities with high neonatal mortality rates>45/1000 live births', 'newborns and young infants', 'Eligible infants']","['procaine penicillin [50,000 units/kg once daily (OD) by intramuscular injection (IM)] and gentamicin', 'gentamicin IM OD', 'Ceftriaxone', 'Procaine penicillin-gentamicin', 'penicillin-gentamicin', 'TMP-SMX-gentamicin', 'parenteral penicillin/ampicillin and gentamicin therapy', 'trimethoprim-sulfamethoxazole (TMP-SMX', 'ceftriaxone']","['Treatment failure', 'failure rates', 'treatment failure, defined as death, deterioration in clinical condition during therapy or no improvement after 2 days']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0332149', 'cui_str': 'Possible (qualifier value)'}, {'cui': 'C0004623', 'cui_str': 'Bacterial Infections'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C1705116', 'cui_str': 'Refused (qualifier value)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0027616', 'cui_str': 'Neonatal Mortality'}, {'cui': 'C0481667', 'cui_str': 'Live Birth'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}]","[{'cui': 'C0030830', 'cui_str': 'penicillin G procaine'}, {'cui': 'C1300561', 'cui_str': 'unit/kg'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C0021492', 'cui_str': 'Intramuscular injection (procedure)'}, {'cui': 'C0017436', 'cui_str': 'Gentamicins'}, {'cui': 'C0007561', 'cui_str': 'Ceftriaxone'}, {'cui': 'C0030842', 'cui_str': 'Antibiotics, Penicillin'}, {'cui': 'C0041044', 'cui_str': 'Sulfamethoxazole / Trimethoprim'}, {'cui': 'C4522267', 'cui_str': 'Parenteral (intended site)'}, {'cui': 'C0002680', 'cui_str': 'Ampicillin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0162643'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1444752', 'cui_str': 'Status during (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]",,0.188217,"Treatment failure was significantly higher with TMP-SMX-gentamicin compared with penicillin-gentamicin [relative risk 2.03, 95% confidence interval: 1.09-3.79] by intention-to-treat analysis.","[{'ForeName': 'Anita K M', 'Initials': 'AK', 'LastName': 'Zaidi', 'Affiliation': 'Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan. anita.zaidi@aku.edu'}, {'ForeName': 'Shiyam Sundar', 'Initials': 'SS', 'LastName': 'Tikmani', 'Affiliation': ''}, {'ForeName': 'Haider J', 'Initials': 'HJ', 'LastName': 'Warraich', 'Affiliation': ''}, {'ForeName': 'Gary L', 'Initials': 'GL', 'LastName': 'Darmstadt', 'Affiliation': ''}, {'ForeName': 'Zulfiqar A', 'Initials': 'ZA', 'LastName': 'Bhutta', 'Affiliation': ''}, {'ForeName': 'Shazia', 'Initials': 'S', 'LastName': 'Sultana', 'Affiliation': ''}, {'ForeName': 'Durrane', 'Initials': 'D', 'LastName': 'Thaver', 'Affiliation': ''}]",The Pediatric infectious disease journal,['10.1097/INF.0b013e318256f86c'] 1046,31395858,Impact of energy turnover on the regulation of glucose homeostasis in healthy subjects.,"OBJECTIVE Sedentary lifestyle increases the risk of type 2 diabetes. The aim of this study was to investigate the impact of different levels of energy turnover (ET; low, medium, and high level of physical activity and the corresponding energy intake) on glucose metabolism at zero energy balance, caloric restriction, and overfeeding. METHODS Sixteen healthy individuals (13 men, 3 women, 25.1 ± 3.9 years, BMI 24.0 ± 3.2 kg/m 2 ) participated in a randomized crossover intervention under metabolic ward conditions. Subjects passed 3 × 3 intervention days. Three levels of physical activity (PAL: low 1.3, medium 1.6, and high 1.8 achieved by walking at 4 km/h for 0, 3 × 55, or 3 × 110 min) were compared under three levels of energy balance (zero energy balance (EB): 100% of energy requirement (Ereq); caloric restriction (CR): 75% Ereq, and overfeeding (OF): 125% Ereq). Continuous interstitial glucose monitoring, C-peptide excretion, and HOMA-IR, as well as postprandial glucose and insulin were measured. RESULTS Daylong glycemia and insulin secretion did not increase with higher ET at all conditions of energy balance (EB, CR, and OF), despite a correspondingly higher CHO intake (Δ low vs. high ET: +86 to 135 g of CHO/d). At CR, daylong glycemia (p = 0.02) and insulin secretion (p = 0.04) were even reduced with high compared with low ET. HOMA-IR was impaired with OF and improved with CR, whereas ET had no effect on fasting insulin sensitivity. A higher ET led to lower postprandial glucose and insulin levels under conditions of CR and OF. CONCLUSION Low-intensity physical activity can significantly improve postprandial glycemic response of healthy individuals, independent of energy balance.",2019,"At CR, daylong glycemia (p = 0.02) and insulin secretion (p = 0.04) were even reduced with high compared with low ET.","['healthy individuals', 'healthy subjects', 'Sixteen healthy individuals (13 men, 3 women, 25.1\u2009±\u20093.9 years, BMI 24.0\u2009±\u20093.2\u2009kg/m 2 ']",['Low-intensity physical activity'],"['energy balance (EB, CR, and OF', 'Daylong glycemia and insulin secretion', 'CHO intake', 'daylong glycemia', 'glucose metabolism at zero energy balance, caloric restriction, and overfeeding', 'Continuous interstitial glucose monitoring, C-peptide excretion, and HOMA-IR, as well as postprandial glucose and insulin', 'energy turnover (ET', 'HOMA-IR', 'postprandial glucose and insulin levels', 'physical activity', 'insulin secretion', 'fasting insulin sensitivity', 'postprandial glycemic response']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4517698', 'cui_str': '3.9 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517687', 'cui_str': '3.2'}]","[{'cui': 'C0596836', 'cui_str': 'Low intensity'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C1256369', 'cui_str': 'Insulin Secretion'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0919414', 'cui_str': '0 (qualifier value)'}, {'cui': 'C1135809', 'cui_str': 'Caloric Restriction'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0006558', 'cui_str': 'Proinsulin C-Peptide'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0443331', 'cui_str': 'Turnover technique (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}]",16.0,0.0203393,"At CR, daylong glycemia (p = 0.02) and insulin secretion (p = 0.04) were even reduced with high compared with low ET.","[{'ForeName': 'Franziska', 'Initials': 'F', 'LastName': 'Büsing', 'Affiliation': 'Institute of Human Nutrition and Food Science, Christian-Albrechts University of Kiel, Kiel, Germany.'}, {'ForeName': 'Franziska Anna', 'Initials': 'FA', 'LastName': 'Hägele', 'Affiliation': 'Institute of Human Nutrition and Food Science, Christian-Albrechts University of Kiel, Kiel, Germany.'}, {'ForeName': 'Alessa', 'Initials': 'A', 'LastName': 'Nas', 'Affiliation': 'Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Hasler', 'Affiliation': 'Applied Statistics, Faculty of Agricultural and Nutritional Sciences, Christian-Albrechts University of Kiel, Kiel, Germany.'}, {'ForeName': 'Manfred James', 'Initials': 'MJ', 'LastName': 'Müller', 'Affiliation': 'Institute of Human Nutrition and Food Science, Christian-Albrechts University of Kiel, Kiel, Germany.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Bosy-Westphal', 'Affiliation': 'Institute of Human Nutrition and Food Science, Christian-Albrechts University of Kiel, Kiel, Germany. abosyw@nutrition.uni-kiel.de.'}]",Nutrition & diabetes,['10.1038/s41387-019-0089-6'] 1047,22401286,Human brain activity predicts individual differences in prior knowledge use during decisions.,"Studies by cognitive psychologists, psychophysicists, neuroscientists, and economists provide ample evidence that humans use prior knowledge to bias decisions adaptively. In this study, we sought to locate and investigate the brain areas mediating this behavior. Participants viewed ambiguous abstract shapes and decided whether a shape was of Category A (smoother) or B (bumpier). The decision was made in the context of one of two prior knowledge cues, 80/20 and 50/50. The 80/20 cue indicated that upcoming shapes had an 80% probability of being of one category, for example, B, and a 20% probability of being of the other. The 50/50 cue indicated that upcoming shapes had an equal probability of being of either category. The shift in bias produced by the 80/20 cue relative to the 50/50 cue was of the predicted sign for every subject but varied in magnitude. We searched for brain regions in which activity changes correlated with the extent of the bias shift; these were dorsolateral pFC (middle frontal gyrus), inferior frontal junction, anterior insula, inferior parietal lobule, intraparietal sulcus, head of the caudate, posterior cingulate cortex, and fusiform gyrus. The findings indicate that an individual's brain activity in these regions reflects the extent to which that individual makes use of prior knowledge to bias decisions. We also created within-ROI tuning curves by binning the shape curvature levels and plotting brain activity levels at each of the nine bins. In the fronto-parietal and anterior insula ROIs, the tuning curves peaked at targets contraindicated by the prior knowledge cue (e.g., Category B targets if the 80/20 cue meant 20% probability B). The increased activity in these regions likely indicates a no-go response when sufficient perceptual evidence favored the alternative contraindicated by the 80/20 cue.",2012,The shift in bias produced by the 80/20 cue relative to the 50/50 cue was of the predicted sign for every subject but varied in magnitude.,[],[],['brain activity levels'],[],[],"[{'cui': 'C0443158', 'cui_str': 'Brain activity (observable entity)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",,0.0187644,The shift in bias produced by the 80/20 cue relative to the 50/50 cue was of the predicted sign for every subject but varied in magnitude.,"[{'ForeName': 'Kathleen A', 'Initials': 'KA', 'LastName': 'Hansen', 'Affiliation': 'National Institutes of Health, Bethesda, MD, USA. hansenka@mail.nih.gov'}, {'ForeName': 'Sarah F', 'Initials': 'SF', 'LastName': 'Hillenbrand', 'Affiliation': ''}, {'ForeName': 'Leslie G', 'Initials': 'LG', 'LastName': 'Ungerleider', 'Affiliation': ''}]",Journal of cognitive neuroscience,['10.1162/jocn_a_00224'] 1048,22737262,Intravenous Thrombolysis in Expanded Time Window (3-4.5 hours) in General Practice with Concurrent Availability of Endovascular Treatment.,"INTRODUCTION A randomized double-blind trial (ECASS III) demonstrated that intravenous (IV) recombinant tissue plasminogen activator (rt-PA) administered between 3 and 4.5 hrs after the onset of symptoms significantly improved clinical outcomes in patients with acute ischemic stroke. In May 2009, the American Stroke Association guidelines recommended the use of IV rt-PA for patients presenting within 3 and 4.5 hrs after symptom onset. OBJECTIVE To determine the rate of patients treated with IV rt-PA within the 3- and 4.5-hr time window and associated comparative outcomes in general practice. METHODS We retrospectively reviewed all patients who were treated with IV rt-PA at two comprehensive stroke centers from September 1, 2008 to July 31, 2010 and identified a total of 98 patients. In addition, we identified patients who arrived to the ED of those centers within 2.5 to 4 hrs of symptom onset between January 1, 2007 and June 30, 2010 and received only endovascular treatment. We compared the rates of favorable outcome (determined by using modified Rankin scale 0-2 at discharge and 3-month follow-up), and National Institutes of Health Stroke Scale (NIHSS) score improvement by ≥ 4 points or 0 at discharge among patients treated with IV rt-PA within 3-4.5 hrs with those who received IV rt-PA within 0-3 hrs, and subsequently with patients presenting at similar time window treated only with endovascular treatment. RESULT Out of the total 98 IV rt-PA treated patients, 84 of them were treated within 0-3 hrs, and 14 within the 3--4.5 hrs. Twelve patients received endovascular treatment only for the specified time window. Mean admission NIHSS score ± standard deviation (SD) was 11.90 ± 6.72, 8.57 ± 5.40, and 11.75 ± 8.06, for the 0--3, 3--4.5 hrs, and endovascular only treatment groups, respectively. Favorable clinical outcome at discharge (50% vs. 56%, p=0.77), 3 months (64% vs. 64%, p=1.0), and NIHSS score improvement (43% vs. 58%, p=0.38) were not different between those treated within 3-4.5 and 0-3 hrs time windows. There appeared to be a non-significantly higher rate of favorable outcomes at discharge (25% vs. 50%, p=0.24), and at 3 months (42% vs. 64%, p=0.43) among patients treated with IV rt-PA within 3-4.5 hrs compared with those treated with primary endovascular treatment. CONCLUSION An additional 14% of patients received IV rt-PA because of treatment window expansion from 3 to 4.5 hrs. Outcomes were comparable to those treated within 3 hrs of symptom onset. The shift of those patients from primary endovascular treatment does not appear to adversely affect patient outcomes.",2012,"Favorable clinical outcome at discharge (50% vs. 56%, p=0.77), 3 months (64% vs. 64%, p=1.0), and NIHSS score improvement (43% vs. 58%, p=0.38) were not different between those treated within 3-4.5 and 0-3 hrs time windows.","['patients who were treated with IV rt-PA at two comprehensive stroke centers from September 1, 2008 to July 31, 2010 and identified a total of 98 patients', 'patients with acute ischemic stroke', 'patients who arrived to the ED of those centers within 2.5 to 4 hrs of symptom onset between January 1, 2007 and June 30, 2010 and received only endovascular treatment']","['Intravenous Thrombolysis', 'intravenous (IV) recombinant tissue plasminogen activator (rt-PA', 'IV rt-PA', 'endovascular treatment']","['NIHSS score improvement', 'National Institutes of Health Stroke Scale (NIHSS) score improvement', 'Mean admission NIHSS score ± standard deviation (SD']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis, function (observable entity)'}, {'cui': 'C0032143', 'cui_str': 'alteplase'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0222045'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}]",98.0,0.0969906,"Favorable clinical outcome at discharge (50% vs. 56%, p=0.77), 3 months (64% vs. 64%, p=1.0), and NIHSS score improvement (43% vs. 58%, p=0.38) were not different between those treated within 3-4.5 and 0-3 hrs time windows.","[{'ForeName': 'Wondwossen G', 'Initials': 'WG', 'LastName': 'Tekle', 'Affiliation': 'Zeenat Qureshi Stroke Research Center, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Saqib A', 'Initials': 'SA', 'LastName': 'Chaudhry', 'Affiliation': ''}, {'ForeName': 'Zara', 'Initials': 'Z', 'LastName': 'Fatima', 'Affiliation': ''}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Ahmed', 'Affiliation': ''}, {'ForeName': 'Shujaat', 'Initials': 'S', 'LastName': 'Khalil', 'Affiliation': ''}, {'ForeName': 'Ameer E', 'Initials': 'AE', 'LastName': 'Hassan', 'Affiliation': ''}, {'ForeName': 'Gustavo J', 'Initials': 'GJ', 'LastName': 'Rodriguez', 'Affiliation': ''}, {'ForeName': 'Fareed K', 'Initials': 'FK', 'LastName': 'Suri', 'Affiliation': ''}, {'ForeName': 'Adnan I', 'Initials': 'AI', 'LastName': 'Qureshi', 'Affiliation': ''}]",Journal of vascular and interventional neurology,[] 1049,31916704,Evaluation of Pharmacokinetics and Dose Proportionality of Diazepam After Intranasal Administration of NRL-1 to Healthy Volunteers.,"NRL-1 is a novel intranasal formulation of diazepam that is being evaluated as rescue medication in patients with epilepsy who experience bouts of increased seizure activity despite stable regimens of antiepileptic drugs. This phase 1, open-label, randomized, crossover study in healthy adult volunteers consisted of 3 single-dose periods (5, 10, and 20 mg) followed by a 2-dose period (2 × 10 mg) with a minimum 28-day washout between treatments. Blood samples were taken at prespecified time points after intranasal dosing, and bioanalytic analysis of diazepam and nordiazepam was conducted using a validated liquid chromatography-tandem mass spectrometry method. Plasma pharmacokinetic parameters were summarized using descriptive statistics, and dose proportionality (peak concentration [C max ] and area under the plasma concentration-time curve [AUC 0-∞ ]) was evaluated based on a power model within a 90%CI of 0.84 to 1.16. Comparisons were also conducted between single 10-mg dose and multidose (2 × 10 mg) treatments. NRL-1 administration resulted in rapid diazepam absorption (median time to peak concentration 1.4-1.5 hours). Plasma concentration-time profiles showed similar patterns of exposure that appeared to be dose dependent, with C max of 85.6, 133.6, and 235.3 ng/mL for the 5-, 10-, and 20-mg doses, respectively, although the lower 90%CI for C max and AUC 0-∞ exceeded dose proportionality criteria. The coefficient of variation ranged from 59% to 67% for C max and 48% to 56% for AUC parameters. Dose-normalized AUC 0-∞ values were comparable between the 2 × 10-mg and single 10-mg doses. Treatment-emergent adverse events were consistent with those expected for diazepam, with transient somnolence the most frequent adverse event (94.4%). These results support NRL-1 as a potential therapy for managing seizure emergencies.",2020,NRL-1 administration resulted in rapid diazepam absorption (median time to peak concentration 1.4-1.5 hours).,"['Healthy Volunteers', 'patients with epilepsy who experience bouts of increased seizure activity despite stable regimens of antiepileptic drugs', 'healthy adult volunteers']","['diazepam and nordiazepam', 'Diazepam', 'NRL-1', 'diazepam']","['rapid diazepam absorption', 'Plasma pharmacokinetic parameters', 'dose proportionality (peak concentration [C max ] and area under the plasma concentration-time curve [AUC 0-∞ ']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0003299', 'cui_str': 'Antiepileptic Agents'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0012010', 'cui_str': 'Diazepam'}, {'cui': 'C0011279', 'cui_str': 'Nordazepam'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0012010', 'cui_str': 'Diazepam'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}]",,0.0330675,NRL-1 administration resulted in rapid diazepam absorption (median time to peak concentration 1.4-1.5 hours).,"[{'ForeName': 'Sarina', 'Initials': 'S', 'LastName': 'Tanimoto', 'Affiliation': 'Pacific Link Consulting, San Diego, California, USA.'}, {'ForeName': 'Luana', 'Initials': 'L', 'LastName': 'Pesco Koplowitz', 'Affiliation': 'DUCK FLATS Pharma, Elbridge, New York, USA.'}, {'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Lowenthal', 'Affiliation': 'Pacific Link Consulting, San Diego, California, USA.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Koplowitz', 'Affiliation': 'DUCK FLATS Pharma, Elbridge, New York, USA.'}, {'ForeName': 'Adrian L', 'Initials': 'AL', 'LastName': 'Rabinowicz', 'Affiliation': 'Neurelis, Inc, San Diego, California, USA.'}, {'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'Carrazana', 'Affiliation': 'Neurelis, Inc, San Diego, California, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.767'] 1050,32070291,The integrated care pathway for managing post stroke patients (iCaPPS © ) in public primary care Healthcentres in Malaysia: impact on quality adjusted life years (QALYs) and cost effectiveness analysis.,"BACKGROUND The delivery of post stroke care is fragmented even in advanced public healthcare systems, globally. Primary care teams are entrusted to provide longer term care for stroke survivors in most developing countries. The integrated Care Pathway for Post Stroke patients (iCaPPS © ) was designed to guide primary care teams to incorporate further rehabilitation and regular screening for post stroke complications among patients residing at home in communities, using the shared-care approach, especially in areas with limited access to specialist stroke care services. The iCaPPS © addressed coordination of rehabilitation and screening for post stroke complications which were absent in the current conventional care of patients managed at public primary care healthcentres. This study aimed to evaluate the cost effectiveness and impact of iCaPPS © on quality-adjusted- life-years (QALY) compared with current conventional monitoring at public primary care healthcentres. METHODS A pragmatic healthcentre-based cluster randomised controlled trial-within trial on 151 post stroke patients from 10 public primary care facilities in Peninsular Malaysia was conducted to evaluate QALY of patients managed with iCaPPS © (n = 86) vs conventional care (n = 65) for 6 months. Costs from societal perspective were calculated, using combination of top down and activity-based costing methods. The 5-level EQ5D (EQ-5D-5 L) was used to calculate health state utility scores. Cost per QALY and incremental cost effectiveness ratio (ICER) were determined. Differences within groups were determined using Mann-Whitney tests. RESULTS Total costs for 6 months treatment with iCaPPS © was MYR790.34, while conventional care cost MYR527.22. Median QALY for iCaPPS © was 0.55 (0,1.65) compared to conventional care 0.32 (0, 0.73) (z = - 0.21, p = 0.84). Cost per QALY for iCaPPS © was MYR1436.98, conventional care was MYR1647.56. The ICER was MYR1144.00, equivalent to 3.7% of per capita GDP (2012 prices). CONCLUSIONS Management of post stroke patients in the community using iCaPPS © costs less per QALY compared to current conventional care and is very cost effective. TRIAL REGISTRATION Trial Registration number ACTRN12616001322426. Registered 21 September 2016. (Retrospectively registered).",2020,"Median QALY for iCaPPS © was 0.55 (0,1.65) compared to conventional care 0.32 (0, 0.73)","['post stroke patients (iCaPPS © ) in public primary care Healthcentres in Malaysia', '151 post stroke patients from 10 public primary care facilities in Peninsular Malaysia']","['iCaPPS © (n\u2009=\u200986) vs conventional care', 'iCaPPS']","['quality-adjusted- life-years (QALY', '5-level EQ5D (EQ-5D-5\u2009L', 'Cost per QALY and incremental cost effectiveness ratio (ICER', 'Median QALY for iCaPPS ©', 'Total costs']","[{'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0024552', 'cui_str': 'Federation of Malaya'}, {'cui': 'C0454750', 'cui_str': 'Peninsular Malaysia (geographic location)'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]","[{'cui': 'C0080071', 'cui_str': 'QALY'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",151.0,0.107047,"Median QALY for iCaPPS © was 0.55 (0,1.65) compared to conventional care 0.32 (0, 0.73)","[{'ForeName': 'Aznida Firzah', 'Initials': 'AF', 'LastName': 'Abdul Aziz', 'Affiliation': 'Department of Family Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Level 14, Preclinical Block, Jalan Yaacob Latiff, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia. draznida@ppukm.ukm.edu.my.'}, {'ForeName': 'Nor Azlin', 'Initials': 'NA', 'LastName': 'Mohd Nordin', 'Affiliation': 'Center for Rehabilitation and Special Needs, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Amrizal', 'Initials': 'A', 'LastName': 'Muhd Nur', 'Affiliation': 'International Centre for Casemix and Clinical Coding, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Saperi', 'Initials': 'S', 'LastName': 'Sulong', 'Affiliation': 'Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Syed Mohamed', 'Initials': 'SM', 'LastName': 'Aljunid', 'Affiliation': 'International Centre for Casemix and Clinical Coding, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.'}]",BMC geriatrics,['10.1186/s12877-020-1453-z'] 1051,22518212,Unruptured intracranial aneurysms and the Trial on Endovascular Aneurysm Management (TEAM): The principles behind the protocol.,"BACKGROUND With the widespread availability of non-invasive imaging of the brain in an aging population, we are increasingly confronted with the problem of the incidental discovery of unruptured aneurysms. The management of these patients remains controversial. Endovascular treatment can prevent rupture, but involves immediate risks. Furthermore, successful treatment does not eliminate all risk of rupture. The safety and efficacy of endovascular treatment of unruptured aneurysms remain undetermined. Hence the balance of the risks and benefits is uncertain. A randomized trial is needed to assess the potential benefits of endovascular management of unruptured aneurysms. THE TRIAL TEAM (Trial on Endovascular Aneurysm Management) is a randomized trial comparing endovascular treatment versus conservative management of unruptured aneurysms. TEAM aims to recruit 2002 patients in 60 centers throughout the world over a 3-year period and to follow all patients for 10 years. The primary outcome is to verify if the clinical outcome (morbidity/mortality (modified Rankin scale > 2) related to the aneurysm or its treatment) can be improved from 8% to 4%. The study is funded by the Canadian Institutes of Health Research.",2008,"THE TRIAL TEAM (Trial on Endovascular Aneurysm Management) is a randomized trial comparing endovascular treatment versus conservative management of unruptured aneurysms.",['2002 patients in 60 centers throughout the world over a 3-year period and to follow all patients for 10 years'],"['Endovascular Aneurysm Management (TEAM', 'endovascular treatment']","['safety and efficacy', 'clinical outcome (morbidity/mortality (modified Rankin scale > 2) related to the aneurysm or its treatment']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}]","[{'cui': 'C0002940', 'cui_str': 'Aneurysm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0002940', 'cui_str': 'Aneurysm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",,0.0524512,"THE TRIAL TEAM (Trial on Endovascular Aneurysm Management) is a randomized trial comparing endovascular treatment versus conservative management of unruptured aneurysms.","[{'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Raymond', 'Affiliation': 'Interventional Neuroradiology Research Unit, Université de Montréal, Canada.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Roy', 'Affiliation': ''}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Weill', 'Affiliation': ''}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Guilbert', 'Affiliation': ''}, {'ForeName': 'Thanh', 'Initials': 'T', 'LastName': 'Nguyen', 'Affiliation': ''}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Molyneux', 'Affiliation': ''}, {'ForeName': 'Allan J', 'Initials': 'AJ', 'LastName': 'Fox', 'Affiliation': ''}, {'ForeName': 'S Claiborne', 'Initials': 'SC', 'LastName': 'Johnston', 'Affiliation': ''}, {'ForeName': 'Jean-Paul', 'Initials': 'JP', 'LastName': 'Collet', 'Affiliation': ''}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Rouleau', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of vascular and interventional neurology,[] 1052,32421737,Predictors of change of health workers' knowledge and skills after the Helping Mothers Survive Bleeding after Birth (HMS BAB) in-facility training in Tanzania.,"BACKGROUND Our study aimed to assess the effect of Helping Mothers Survive Bleeding after Birth on knowledge and skills of health workers and whether such effect varies by health workers characteristics. METHODS Nested in a cluster-randomised trial to assess the effect of the training on health outcomes, we assessed changes in knowledge and simulated skills in 61 facilities. The assessments were done i) before, ii) immediately-after training session and iii) at 10-month follow-up for subset of health-workers of implementation facilities as defined by the trial. We used a self-administered questionnaire and Objective Structures Clinical Examinations to assess three skill sets: Active Management of Third Stage of Labour, removal of retained placenta and management of severe postpartum haemorrhage. We computed summary statistics and used the paired t-test to assess change of knowledge and skills immediately post-training and at 10-month follow-up. Linear regression was done to assess association of scores and health worker characteristics. RESULTS Of the 636 health workers included, 606 (96.7%) and 591 (91.4%) completed the knowledge and skills assessments, respectively. Majority of the participants (68%) were nurse-midwives. Knowledge scores increased by 15 percentage-points from 77.5% to 93% (95% CI 14.3, 16.3, p-value <0.000), and skills scores by 47 percentage-points (95% CI 46.5, 49.2, p-value <0.000) from 37.5% to 83%. There was a 4.0% decline of skills at 10-month follow-up. The decline was higher in auxiliary staff (-11.8%) and least in nurse-midwives (-2.1%) p-value <0.001. Health workers who assisted less than 5 deliveries in the last month, those who never attended postpartum haemorrhage in-service training and profession experience >8 years were associated with lower mean skill change immediately post-training. CONCLUSION Our study supports the potential of the Helping Mothers Survive Bleeding after Birth training to increase knowledge and skills of postpartum haemorrhage among all professional groups. Auxiliary staff benefited most from the training but also showed higher skill decline at 10-month. Our study highlights the importance to disaggregate knowledge and skills by health workers characteristics.",2020,"Knowledge scores increased by 15 percentage-points from 77.5% to 93% (95% CI 14.3, 16.3, p-value <0.000), and skills scores by 47 percentage-points (95% CI 46.5, 49.2, p-value <0.000) from 37.5% to 83%.","['61 facilities', 'Health workers who assisted less than 5 deliveries in the last month, those who never attended postpartum haemorrhage in-service training and profession experience >8 years', 'Of the 636 health workers', 'Mothers Survive Bleeding after Birth (HMS BAB) in-facility training in Tanzania']",[],"['knowledge and skills of postpartum haemorrhage', 'Knowledge scores', 'auxiliary staff', 'skills scores', 'skill decline']","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0557286', 'cui_str': 'No formal education'}, {'cui': 'C0032797', 'cui_str': 'Postpartum hemorrhage'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0262500', 'cui_str': 'Routine health maintenance'}, {'cui': 'C0039298', 'cui_str': 'Tanzania'}]",[],"[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0032797', 'cui_str': 'Postpartum hemorrhage'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}]",,0.0861455,"Knowledge scores increased by 15 percentage-points from 77.5% to 93% (95% CI 14.3, 16.3, p-value <0.000), and skills scores by 47 percentage-points (95% CI 46.5, 49.2, p-value <0.000) from 37.5% to 83%.","[{'ForeName': 'Fadhlun', 'Initials': 'F', 'LastName': 'Alwy Al-Beity', 'Affiliation': 'Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Andrea Barnabas', 'Initials': 'AB', 'LastName': 'Pembe', 'Affiliation': 'Department of Obstetrics and Gynaecology, Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania.'}, {'ForeName': 'Gaetano', 'Initials': 'G', 'LastName': 'Marrone', 'Affiliation': 'Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Ulrika', 'Initials': 'U', 'LastName': 'Baker', 'Affiliation': 'Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Hanson', 'Affiliation': 'Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.'}]",PloS one,['10.1371/journal.pone.0232983'] 1053,23230458,Expansion of recruitment time window in antihypertensive treatment of acute cerebral hemorrhage (ATACH) II trial.,"The Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II trial is an ongoing multi-center, randomized phase III trial to determine the efficacy of early, intensive, antihypertensive treatment using intravenous (IV) nicardipine initiated within 3 h of onset of intracerebral hemorrhage (ICH). On March 11th, 2012, the National Institutes of Neurological Disorders and Stroke approved recruitment of patients with ICH within 4.5 h of symptom onset. The expansion of recruitment window was based on the recent ATACH-I study analysis that suggests reduction of hematoma expansion and death, and disability in those subjects who were treated within 4.5 h after symptom onset. Another recent single center study further identified that hematoma expansion, the primary target for systolic blood pressure reduction, appeared to be equally prevalent in subjects who are presenting between 3 and 4.5 h. The expansion has the potential to evaluate the efficacy of the treatment intervention in a larger group of patients with ICH.",2012,"The Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II trial is an ongoing multi-center, randomized phase III trial to determine the efficacy of early, intensive, antihypertensive treatment using intravenous (IV) nicardipine initiated within 3 h of onset of intracerebral hemorrhage (ICH).","['patients with ICH', 'acute cerebral hemorrhage (ATACH', 'patients with ICH within 4.5 h of symptom onset', 'subjects who are presenting between 3 and 4.5 h']",['intravenous (IV) nicardipine'],"['systolic blood pressure reduction', 'hematoma expansion and death, and disability']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2937358', 'cui_str': 'Intracerebral Hemorrhage'}, {'cui': 'C3844009', 'cui_str': 'Four point five'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0028005', 'cui_str': 'Nicardipine'}]","[{'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}]",,0.030041,"The Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II trial is an ongoing multi-center, randomized phase III trial to determine the efficacy of early, intensive, antihypertensive treatment using intravenous (IV) nicardipine initiated within 3 h of onset of intracerebral hemorrhage (ICH).","[{'ForeName': 'Ai', 'Initials': 'A', 'LastName': 'Qureshi', 'Affiliation': 'Zeenat Qureshi Stroke Research Centre, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Yy', 'Initials': 'Y', 'LastName': 'Palesch', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of vascular and interventional neurology,[] 1054,31540869,Comparison of postoperative morbidity between conventional cold dissection and bipolar electrocautery tonsillectomy: which technique is better?,"INTRODUCTION Tonsillectomy is one of the most common surgeries in the head and neck worldwide. This operation is carried out by different methods, the most frequent of which are the cold dissection and bipolar electrocautery techniques. OBJECTIVE This study was conducted to assess and compare postoperative morbidity between cold dissection and bipolar electrocautery. METHODS This prospective randomized clinical trial was performed on 534 patients who underwent tonsillectomy in Vali-e-Asr Hospital of Birjand, east of Iran from October, 2013 to October, 2015. The patients were systematically selected for cold dissection technique or bipolar electrocautery technique groups. Time of surgery, amount of intraoperative blood loss, postoperative hemorrhage, the intensity of local pain 4 and 24hours after operation and nausea and/or vomiting were recorded and compared in the two groups to decide which technique is better. The data were analyzed in SPSS software (ver-22). The p-value less than 0.5 was considered significant. RESULTS In this study, 51.7% of the cold dissection technique patients and 50.6% of the bipolar electrocautery technique participants were male. Compared to the cold dissection technique, the average intraoperative blood loss was significantly lower (p<0.001) in the bipolar electrocautery technique group, while the intensity of local pain 4 and 24hours after the operation was significantly higher (p<0.001). Other variables showed no significant differences between the two groups. CONCLUSION Based on the findings of the present investigation, the bipolar electrocautery technique is suggested for tonsillectomy in children, while the cold dissection technique is preferred for adult patients.",2020,"Compared to the cold dissection technique, the average intraoperative blood loss was significantly lower (p<0.001) in the bipolar electrocautery technique group, while the intensity of local pain 4 and 24h after the operation was significantly higher (p<0.001).","['534 patients who underwent tonsillectomy in Vali-e-Asr Hospital of Birjand, east of Iran from October, 2013 to October, 2015']","['cold dissection technique', 'cold dissection and bipolar electrocautery', 'conventional cold dissection and bipolar electrocautery tonsillectomy', 'cold dissection technique or bipolar electrocautery technique groups']","['intensity of local pain', 'postoperative morbidity', 'average intraoperative blood loss', 'Time of surgery, amount of intraoperative blood loss, postoperative hemorrhage, the intensity of local pain 4 and 24h after operation and nausea and/or vomiting']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0040423', 'cui_str': 'Tonsillectomy'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}]","[{'cui': 'C0009443', 'cui_str': 'Common Cold'}, {'cui': 'C0012737', 'cui_str': 'Dissection'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0443156', 'cui_str': 'Bipolar (qualifier value)'}, {'cui': 'C0013804', 'cui_str': 'Surgical Diathermy'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0040423', 'cui_str': 'Tonsillectomy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0032788', 'cui_str': 'Blood Loss, Postoperative'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}]",534.0,0.0446586,"Compared to the cold dissection technique, the average intraoperative blood loss was significantly lower (p<0.001) in the bipolar electrocautery technique group, while the intensity of local pain 4 and 24h after the operation was significantly higher (p<0.001).","[{'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Mofatteh', 'Affiliation': 'Birjand University of Medical Sciences, Faculty of Medicine, Department of Ears, Nose and Throat, Birjand, Iran.'}, {'ForeName': 'Forod', 'Initials': 'F', 'LastName': 'Salehi', 'Affiliation': 'Birjand University of Medical Sciences, Faculty of Medicine, Department of Cardiology, Birjand, Iran.'}, {'ForeName': 'Mehran', 'Initials': 'M', 'LastName': 'Hosseini', 'Affiliation': 'Birjand University of Medical Sciences, Cellular and Molecular Research Center, Birjand, Iran.'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Hassanzadeh-Taheri', 'Affiliation': 'Birjand University of Medical Sciences, Faculty of Medicine, Birjand, Iran.'}, {'ForeName': 'Gholamreza', 'Initials': 'G', 'LastName': 'Sharifzadeh', 'Affiliation': 'Birjand University of Medical Sciences, Faculty of Health, Birjand, Iran.'}, {'ForeName': 'Mohammadmehdi', 'Initials': 'M', 'LastName': 'Hassanzadeh-Taheri', 'Affiliation': 'Birjand University of Medical Sciences, Faculty of Medicine, Department of Anatomy, Birjand, Iran. Electronic address: mmhtahery35@gmail.com.'}]",Brazilian journal of otorhinolaryngology,['10.1016/j.bjorl.2018.12.013'] 1055,31916906,Fathers' participation in the HPV vaccination decision-making process doesn't increase parents' intention to make daughters get the vaccine.,"INTRODUCTION The HPV vaccination rate in Japan has been dismally low. Our previous survey work found that mothers in Japan, who have a strong influence over their daughters, often are receptive to the fathers' participation in the family's decision-making process about getting their daughter HPV vaccinated. METHODS We conducted a survey to investigate the nature of the influence of fathers' participation on the mother's decision-making process. From an internet survey panel, we selected a pool of 1,499 eligible mothers who had 12-18 years old daughters. The mothers were randomized into three Groups. To the mothers in Group A, we gave an educational leaflet regarding HPV vaccination and a second leaflet which recommended that they talk with their husbands about the vaccination. To Group B, we gave only the educational leaflet. No leaflets were sent to Group C. A structured survey questionnaire was then distributed through the internet to the mothers. RESULTS In Groups A, B, and C, their intention to have their daughter receive the HPV vaccine was 21.6%, 20.7% and 8.2%, respectively. The percent of Group A mothers who thought their husband's opinion was important for when they made the decision was significantly higher (70%) than in Group B (56.6%) or Group C (47.1%). CONCLUSIONS The fathers' participation in the mothers' decision-making does not increase the likelihood of HPV vaccination for their daughters. On the other hand, the educational leaflet proved to be effective for this cause.",2020,The fathers' participation in the mothers' decision-making does not increase the likelihood of HPV vaccination for their daughters.,"['1,499 eligible mothers who had 12-18 years old daughters']",[],"['likelihood of HPV vaccination', 'HPV vaccination rate']","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0337559', 'cui_str': 'Oldest daughter (person)'}]",[],"[{'cui': 'C0042196', 'cui_str': 'Vaccination'}]",1499.0,0.0249593,The fathers' participation in the mothers' decision-making does not increase the likelihood of HPV vaccination for their daughters.,"[{'ForeName': 'Tomomi', 'Initials': 'T', 'LastName': 'Egawa-Takata', 'Affiliation': 'Department of Obstetrics and Gynecology, Osaka Police Hospital , Osaka, Japan.'}, {'ForeName': 'Ruriko', 'Initials': 'R', 'LastName': 'Nakae', 'Affiliation': 'Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine , Suita, Japan.'}, {'ForeName': 'Mariko', 'Initials': 'M', 'LastName': 'Shindo', 'Affiliation': 'Department of Obstetrics and Gynecology, Hannan Central Hospital , Matsubara, Japan.'}, {'ForeName': 'Ai', 'Initials': 'A', 'LastName': 'Miyoshi', 'Affiliation': 'Department of Obstetrics and Gynecology, Kaizuka City Hospital , Kaizuka, Japan.'}, {'ForeName': 'Tsuyoshi', 'Initials': 'T', 'LastName': 'Takiuchi', 'Affiliation': 'Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine , Suita, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Miyatake', 'Affiliation': 'Department of Obstetrics and Gynecology, Osaka Police Hospital , Osaka, Japan.'}, {'ForeName': 'Tadashi', 'Initials': 'T', 'LastName': 'Kimura', 'Affiliation': 'Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine , Suita, Japan.'}]",Human vaccines & immunotherapeutics,['10.1080/21645515.2019.1697107'] 1056,31937553,"Impact of respiratory muscle training on respiratory muscle strength, respiratory function and quality of life in individuals with tetraplegia: a randomised clinical trial.","BACKGROUND Respiratory complications remain a leading cause of morbidity and mortality in people with acute and chronic tetraplegia. Respiratory muscle weakness following spinal cord injury-induced tetraplegia impairs lung function and the ability to cough. In particular, inspiratory muscle strength has been identified as the best predictor of the likelihood of developing pneumonia in individuals with tetraplegia. We hypothesised that 6 weeks of progressive respiratory muscle training (RMT) increases respiratory muscle strength with improvements in lung function, quality of life and respiratory health. METHODS Sixty-two adults with tetraplegia participated in a double-blind randomised controlled trial. Active or sham RMT was performed twice daily for 6 weeks. Inspiratory muscle strength, measured as maximal inspiratory pressure (PImax) was the primary outcome. Secondary outcomes included lung function, quality of life and respiratory health. Between-group comparisons were obtained with linear models adjusting for baseline values of the outcomes. RESULTS After 6 weeks, there was a greater improvement in PImax in the active group than in the sham group (mean difference 11.5 cmH 2 O (95% CI 5.6 to 17.4), p<0.001) and respiratory symptoms were reduced (St George Respiratory Questionnaire mean difference 10.3 points (0.01-20.65), p=0.046). Significant improvements were observed in quality of life (EuroQol-Five Dimensional Visual Analogue Scale 14.9 points (1.9-27.9), p=0.023) and perceived breathlessness (Borg score 0.64 (0.11-1.17), p=0.021). There were no significant improvements in other measures of respiratory function (p=0.126-0.979). CONCLUSIONS Progressive RMT increases inspiratory muscle strength in people with tetraplegia, by a magnitude which is likely to be clinically significant. Measurement of baseline PImax and provision of RMT to at-risk individuals may reduce respiratory complications after tetraplegia. TRIAL REGISTRATION NUMBER Australian New Zealand Clinical Trials Registry (ACTRN 12612000929808).",2020,"There were no significant improvements in other measures of respiratory function (p=0.126-0.979). ","['Sixty-two adults with tetraplegia participated', 'individuals with tetraplegia', 'people with acute and chronic tetraplegia', 'people with tetraplegia']","['spinal cord injury-induced tetraplegia', 'progressive respiratory muscle training (RMT', 'respiratory muscle training', 'Active or sham RMT']","['respiratory symptoms', 'lung function, quality of life and respiratory health', 'Inspiratory muscle strength', 'respiratory muscle strength, respiratory function and quality of life', 'perceived breathlessness', 'maximal inspiratory pressure (PImax', 'inspiratory muscle strength', 'improvement in PImax', 'respiratory function', 'quality of life (EuroQol-Five Dimensional Visual Analogue Scale']","[{'cui': 'C4517835', 'cui_str': '62 (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0034372', 'cui_str': 'Tetraplegia'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}]","[{'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0034372', 'cui_str': 'Tetraplegia'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0006155', 'cui_str': 'Respiratory Muscle Training'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C0037090', 'cui_str': 'Signs and Symptoms, Respiratory'}, {'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}, {'cui': 'C0034380'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0035231', 'cui_str': 'Ventilatory Muscles'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}, {'cui': 'C0013404', 'cui_str': 'Breathlessness'}, {'cui': 'C4083126', 'cui_str': 'Maximum Inspiratory Pressure'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",62.0,0.362344,"There were no significant improvements in other measures of respiratory function (p=0.126-0.979). ","[{'ForeName': 'Claire L', 'Initials': 'CL', 'LastName': 'Boswell-Ruys', 'Affiliation': 'Neuroscience Research Australia, Sydney, New South Wales, Australia c.boswell-ruys@neura.edu.au.'}, {'ForeName': 'Chaminda R H', 'Initials': 'CRH', 'LastName': 'Lewis', 'Affiliation': 'Neuroscience Research Australia, Sydney, New South Wales, Australia.'}, {'ForeName': 'Nirupama S', 'Initials': 'NS', 'LastName': 'Wijeysuriya', 'Affiliation': 'Neuroscience Research Australia, Sydney, New South Wales, Australia.'}, {'ForeName': 'Rachel A', 'Initials': 'RA', 'LastName': 'McBain', 'Affiliation': 'Neuroscience Research Australia, Sydney, New South Wales, Australia.'}, {'ForeName': 'Bonsan Bonne', 'Initials': 'BB', 'LastName': 'Lee', 'Affiliation': 'Neuroscience Research Australia, Sydney, New South Wales, Australia.'}, {'ForeName': 'David K', 'Initials': 'DK', 'LastName': 'McKenzie', 'Affiliation': 'Prince of Wales Hospital and Community Health Services, Sydney, New South Wales, Australia.'}, {'ForeName': 'Simon C', 'Initials': 'SC', 'LastName': 'Gandevia', 'Affiliation': 'Neuroscience Research Australia, Sydney, New South Wales, Australia.'}, {'ForeName': 'Jane E', 'Initials': 'JE', 'LastName': 'Butler', 'Affiliation': 'Neuroscience Research Australia, Sydney, New South Wales, Australia.'}]",Thorax,['10.1136/thoraxjnl-2019-213917'] 1057,32051084,[Effect of parental training based on Early Start Denver Model combined with intensive training on children with autism spectrum disorder and its impact on parenting stress].,"OBJECTIVE To explore the effect of parental training based on the Early Start Denver Model (ESDM) combined with intensive training on the treatment outcome of children with autism spectrum disorder (ASD) and its impact on parenting stress. METHODS Seventy children aged 2-5 years who were diagnosed with ASD were enrolled in the study. They were divided into an ESDM group and a parental training group by the random number table method (n=35 each). The ESDM group received intensive training based on ESDM. In addition to intensive ESDM-based training, parents of the children in the parental training group received ESDM skills training. Both groups were assessed by Autism Behavior Checklist (ABC), Childhood Autism Rating Scale (CARS), Autism Treatment Evaluation Checklist (ATEC) and Parenting Stress Index-Short Form (PSI-SF) before and after the intervention of 3 months. RESULTS After 3 months of intervention, the total scores of ABC, CARS and ATEC were both significantly decreased in the two groups (P<0.05). There was no significant difference in the total scores of ABC, CARS and ATEC between the two groups before and after intervention (P>0.05). The change between ABC, CARS and ATEC total scores in the two groups had no significant difference (P>0.05). After 3 months of intervention, the total scores of PSI-SF were both significantly decreased in the two groups (P<0.05). The difficult child sub-scale scores in PSI-SF were significantly decreased in the ESDM group (P<0.05). While three sub-scale scores of parent distress, parent-child dysfunctional interaction and difficult child in PSI-SF were significantly decreased in the parental training group (P<0.05). Before and after intervention of 3 months, no significant difference was found in PSI-SF total scores between the two groups. Compared with the ESDM group, the change between PSI-SF total scores and two sub-scales of PSI-SF (parent distress and difficult child) were significantly bigger in the parental training group (P<0.05). CONCLUSIONS Both the combination of intensive training and parent training based on ESDM and ESDM intensive training alone can improve the core symptoms of children with ASD aged 2-5 years and relieve the parenting stress, however, the former is more effective in relieving parenting stress.",2020,"There was no significant difference in the total scores of ABC, CARS and ATEC between the two groups before and after intervention (P>0.05).","['children with autism spectrum disorder (ASD', 'children with ASD aged 2-5 years', 'children with autism spectrum disorder', 'Seventy children aged 2-5 years who were diagnosed with ASD were enrolled in the study']","['ESDM skills training', 'ESDM', 'parental training based on Early Start Denver Model combined with intensive training', 'parental training based on the Early Start Denver Model (ESDM) combined with intensive training', 'intensive training based on ESDM', 'intensive training and parent training based on ESDM and ESDM intensive training alone', 'parental training group by the random number table method']","['total scores of PSI-SF', 'PSI-SF total scores', 'ABC, CARS and ATEC total scores', 'PSI-SF', 'total scores of ABC, CARS and ATEC', 'PSI-SF total scores and two sub-scales of PSI-SF (parent distress and difficult child', 'Autism Behavior Checklist (ABC), Childhood Autism Rating Scale (CARS), Autism Treatment Evaluation Checklist (ATEC) and Parenting Stress Index-Short Form (PSI-SF', 'scale scores of parent distress, parent-child dysfunctional interaction and difficult child in PSI-SF']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0559197', 'cui_str': 'Skills training (procedure)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1706074', 'cui_str': 'Table'}, {'cui': 'C0025663', 'cui_str': 'Methods'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1706489', 'cui_str': 'Psi'}, {'cui': 'C0004381', 'cui_str': 'Automobiles'}, {'cui': 'C1264637', 'cui_str': 'Substance amount'}, {'cui': 'C0222045'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0332218', 'cui_str': 'With difficulty'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}]",70.0,0.0159923,"There was no significant difference in the total scores of ABC, CARS and ATEC between the two groups before and after intervention (P>0.05).","[{'ForeName': 'Di', 'Initials': 'D', 'LastName': 'Gao', 'Affiliation': 'Department of Developmental-Behavioral Pediatrics, First Hospital of Jilin University, Changchun 130021, China. honghua_li1986@jlu.edu.cn.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Yu', 'Affiliation': ''}, {'ForeName': 'Chun-Li', 'Initials': 'CL', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Fei-Yong', 'Initials': 'FY', 'LastName': 'Jia', 'Affiliation': ''}, {'ForeName': 'Hong-Hua', 'Initials': 'HH', 'LastName': 'Li', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1058,31685356,Effect of early restrictive fluid resuscitation on inflammatory and immune factors in patients with severe pelvic fracture.,"PURPOSE To study the effect of early restrictive fluid resuscitation (EFR) on inflammatory and immune factors in patients with severe pelvic fracture (SPF). METHODS A total of 174 SPF patients in the Department of Orthopaedics, the First Affiliated Hospital of Chengdu Medical College from July 2015 to June 2018 were involved in this study and divided into EFR group (n = 87) and control group (n = 87) using the random number table method. Conventional fluid resuscitation (CFR) was performed in control group, and EFR was performed in EFR group. The incidences of acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) during rescue, successful rescue rate, blood transfusion volume, fluid input, and resuscitation time were compared between the two groups. The parameters including prothrombin time (PT), hematocrit (HCT), platelet (PLT) and blood lactate (BL) at the 4th hour after fluid resuscitation were recorded. The levels of inflammatory factors (TNF-α, IL-6, CRP) and immune factors (CD3 + , CD4 + , CD8 + , CD4+/CD8+) were compared between the two groups before treatment and 7 days after treatment. The revised acute physiologic and chronic health evaluation system and the sequential organ failure assessment scores were adopted for evaluation before treatment and 7 days after treatment. RESULTS The incidences of ARDS and MODS during rescue in EFR group were significantly lower than those in control group (p=0.015 and 0.010 respectively), and the successful rescue rate in EFR group was significantly higher than that in control group (p = 0.011). The blood transfusion volume, fluid input, resuscitation time in EFR group were significantly lower than those in control group (p = 0.016, 0.002 and 0.001 respectively). At the 4th hour after fluid resuscitation, PT and BL in EFR group were significantly lower than those in control group (p = 0.021 and 0.003 respectively), while HCT and PLT in EFR group were significantly higher than those in control group (p = 0.016 and 0.021 respectively). On day 7 after treatment, TNF-α, IL-6, CRP and CD8 + in EFR group were significantly lower than those in control group (p = 0.003, 0.004, 0.007 and 0.003 respectively), while CD3 + , CD4 + and CD4+/CD8+ in EFR group were significantly higher than those in control group (p = 0.004, 0.000, 0.007 respectively). On day 7 after treatment, the revised acute physiologic and chronic health evaluation (APACHE) system and the sequential organ failure assessment (SOFA) scores in EFR group were significantly lower than those in control group. CONCLUSION EFR can effectively eliminate inflammatory factors, improve immune function, maintain the stability of blood components, reduce the incidences of ARDS and MODS, and elevate the successful rescue rate in patients with SPF.",2019,"The levels of inflammatory factors (TNF-α, IL-6, CRP) and immune factors (CD3 + , CD4 + , CD8 + , CD4+/CD8+) were compared between the two groups before treatment and 7 days after treatment.","['patients with severe pelvic fracture (SPF', 'patients with severe pelvic fracture', 'patients with SPF', '174 SPF patients in the Department of Orthopaedics, the First Affiliated Hospital of Chengdu Medical College from July 2015 to June 2018']","['Conventional fluid resuscitation (CFR', 'early restrictive fluid resuscitation (EFR', 'early restrictive fluid resuscitation']","['CD3 + , CD4 + and CD4+/CD8', 'incidences of ARDS and MODS', 'inflammatory and immune factors', 'revised acute physiologic and chronic health evaluation (APACHE) system and the sequential organ failure assessment (SOFA) scores', 'blood transfusion volume, fluid input, resuscitation time', 'prothrombin time (PT), hematocrit (HCT), platelet (PLT) and blood lactate (BL', 'TNF-α, IL-6, CRP and CD8 ', 'levels of inflammatory factors (TNF-α, IL-6, CRP) and immune factors (CD3 + , CD4 + , CD8 + , CD4+/CD8', 'successful rescue rate', 'acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) during rescue, successful rescue rate, blood transfusion volume, fluid input, and resuscitation time']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0149531', 'cui_str': 'Pelvic fracture'}, {'cui': 'C4517604', 'cui_str': 'One hundred and seventy-four'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0557806', 'cui_str': 'College (environment)'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C0035273', 'cui_str': 'Resuscitation'}, {'cui': 'C1305363', 'cui_str': 'Catalytic fraction'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0035222', 'cui_str': 'ARDS, Human'}, {'cui': 'C0026766', 'cui_str': 'Organ Dysfunction Syndrome, Multiple'}, {'cui': 'C0021054', 'cui_str': 'Immunological Factors'}, {'cui': 'C0205463', 'cui_str': 'Physiologic (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C3494459', 'cui_str': 'SOFAS Scores'}, {'cui': 'C1273858', 'cui_str': 'Transfusion Medicine'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0429646', 'cui_str': 'Fluid intake volume (observable entity)'}, {'cui': 'C0035273', 'cui_str': 'Resuscitation'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0033707', 'cui_str': 'Prothrombin Time'}, {'cui': 'C0518014', 'cui_str': 'Hematocrit - finding'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0005768'}, {'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1272703', 'cui_str': 'Successful'}]",2018.0,0.0154796,"The levels of inflammatory factors (TNF-α, IL-6, CRP) and immune factors (CD3 + , CD4 + , CD8 + , CD4+/CD8+) were compared between the two groups before treatment and 7 days after treatment.","[{'ForeName': 'La-Mei', 'Initials': 'LM', 'LastName': 'Jiang', 'Affiliation': 'Department of Emergency, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China. Electronic address: 513629159@qq.com.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'He', 'Affiliation': 'Department of Orthopaedics, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.'}, {'ForeName': 'Xiao-Yan', 'Initials': 'XY', 'LastName': 'Xi', 'Affiliation': 'Department of Orthopaedics, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.'}, {'ForeName': 'Chun-Mei', 'Initials': 'CM', 'LastName': 'Huang', 'Affiliation': 'Department of Emergency, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.'}]",Chinese journal of traumatology = Zhonghua chuang shang za zhi,['10.1016/j.cjtee.2019.07.008'] 1059,31455824,"Morphine compared to placebo for procedural pain in preterm infants: safety, efficacy and equipoise.",,2019,,['preterm infants'],"['placebo', 'Morphine']",[],"[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]",[],,0.11121,,"[{'ForeName': 'Omri David', 'Initials': 'OD', 'LastName': 'Soffer', 'Affiliation': ""Division of Newborn Medicine, Boston Children's Hospital, Boston, MA, USA. Omri.soffer@childrens.harvard.edu.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Cornelissen', 'Affiliation': ""Division of Pain Medicine, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA, USA.""}, {'ForeName': 'Christy', 'Initials': 'C', 'LastName': 'Cummings', 'Affiliation': ""Division of Newborn Medicine, Boston Children's Hospital, Boston, MA, USA.""}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Berde', 'Affiliation': ""Division of Pain Medicine, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA, USA.""}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/s41372-019-0476-9'] 1060,31434507,"Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial.","BACKGROUND Evidence regarding the primary prevention of coronary artery disease events by low-density lipoprotein cholesterol (LDL-C) lowering therapy in older individuals, aged ≥75 years, is insufficient. This trial tested whether LDL-C-lowering therapy with ezetimibe is useful for the primary prevention of cardiovascular events in older patients. METHODS This multicenter, prospective, randomized, open-label, blinded end-point evaluation conducted at 363 medical institutions in Japan examined the preventive efficacy of ezetimibe for patients aged ≥75 years, with elevated LDL-C without history of coronary artery disease. Patients, who all received dietary counseling, were randomly assigned (1:1) to receive ezetimibe (10 mg once daily) versus usual care with randomization stratified by site, age, sex, and baseline LDL-C. The primary outcome was a composite of sudden cardiac death, myocardial infarction, coronary revascularization, or stroke. RESULTS Overall, 3796 patients were enrolled between May 2009 and December 2014, and 1898 each were randomly assigned to ezetimibe versus control. Median follow-up was 4.1 years. After exclusion of 182 ezetimibe patients and 203 control patients because of lack of appropriate informed consent and other protocol violations, 1716 (90.4%) and 1695 (89.3%) patients were included in the primary analysis, respectively. Ezetimibe reduced the incidence of the primary outcome (hazard ratio [HR], 0.66; 95% CI, 0.50-0.86; P =0.002). Regarding the secondary outcomes, the incidences of composite cardiac events (HR, 0.60; 95% CI, 0.37-0.98; P =0.039) and coronary revascularization (HR, 0.38; 95% CI, 0.18-0.79; P =0.007) were lower in the ezetimibe group than in the control group; however, there was no difference in the incidence of stroke, all-cause mortality, or adverse events between trial groups. CONCLUSIONS LDL-C-lowering therapy with ezetimibe prevented cardiovascular events, suggesting the importance of LDL-C lowering for primary prevention in individuals aged ≥75 years with elevated LDL-C. Given the open-label nature of the trial, its premature termination and issues with follow-up, the magnitude of benefit observed should be interpreted with caution. Clinical Registration: URL: https://www.umin.ac.jp. Unique identifier: UMIN000001988.",2019,"Ezetimibe reduced the incidence of the primary outcome (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.50-0.86; P=0.002).","['older individuals aged ≥75 years', '363 medical institutions in Japan', '3,796 patients were enrolled between May 2009 and December 2014, and 1,898 each', '75 or Older (EWTOPIA 75', 'older patients', 'individuals aged ≥75 years with elevated LDL-C', 'patients aged ≥75 years with elevated LDL-C without history of coronary artery disease', 'https://www.umin.ac.jp Unique identifier']","['Ezetimibe', 'LDL-C-lowering therapy with ezetimibe', 'dietary counseling', 'Ezetimibe Lipid-Lowering Trial', 'ezetimibe', 'ezetimibe versus control', 'LDL-C-lowering therapy']","['coronary revascularization', 'incidences of composite cardiac events', 'incidence of stroke, all-cause mortality, or adverse events', 'cardiovascular events', 'composite of sudden cardiac death, myocardial infarction, coronary revascularization, or stroke']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C1956346', 'cui_str': 'Coronary Artery Disease'}]","[{'cui': 'C1142985', 'cui_str': 'ezetimibe'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0085298', 'cui_str': 'Sudden Cardiac Death'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}]",3796.0,0.28082,"Ezetimibe reduced the incidence of the primary outcome (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.50-0.86; P=0.002).","[{'ForeName': 'Yasuyoshi', 'Initials': 'Y', 'LastName': 'Ouchi', 'Affiliation': 'Toranomon Hospital, Tokyo, Japan (Y. Ouchi, M.K.).'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Sasaki', 'Affiliation': 'International University of Health and Welfare, Fukuoka, Japan (J.S.).'}, {'ForeName': 'Hidenori', 'Initials': 'H', 'LastName': 'Arai', 'Affiliation': 'National Center for Geriatrics and Gerontology, Obu, Japan (H.A.).'}, {'ForeName': 'Koutaro', 'Initials': 'K', 'LastName': 'Yokote', 'Affiliation': 'Chiba University, Chiba, Japan (K.Y.).'}, {'ForeName': 'Kazumasa', 'Initials': 'K', 'LastName': 'Harada', 'Affiliation': 'Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan (K.H., H.I.).'}, {'ForeName': 'Yasuo', 'Initials': 'Y', 'LastName': 'Katayama', 'Affiliation': 'General Tokyo Hospital, Tokyo, Japan (Y.K.).'}, {'ForeName': 'Takao', 'Initials': 'T', 'LastName': 'Urabe', 'Affiliation': 'Juntendo University Urayasu Hospital, Urayasu, Japan (T.U.).'}, {'ForeName': 'Yasufumi', 'Initials': 'Y', 'LastName': 'Uchida', 'Affiliation': 'Saga Memorial Hospital, Saga, Japan (Y.U.).'}, {'ForeName': 'Masaru', 'Initials': 'M', 'LastName': 'Hayashi', 'Affiliation': 'Nagahama City Hospital, Nagahama, Japan (M.H.).'}, {'ForeName': 'Naoto', 'Initials': 'N', 'LastName': 'Yokota', 'Affiliation': 'Yokota Clinic, Miyazaki, Japan (N.Y.).'}, {'ForeName': 'Hirokazu', 'Initials': 'H', 'LastName': 'Nishida', 'Affiliation': 'Nishida Clinic, Neyagawa, Japan (H.N.).'}, {'ForeName': 'Takatoshi', 'Initials': 'T', 'LastName': 'Otonari', 'Affiliation': 'Otonari Clinic, Chikushino, Japan (T.O.).'}, {'ForeName': 'Tadashi', 'Initials': 'T', 'LastName': 'Arai', 'Affiliation': 'Arai Clinic, Yamagata, Japan (T.A.).'}, {'ForeName': 'Ichiro', 'Initials': 'I', 'LastName': 'Sakuma', 'Affiliation': 'Caress Sapporo Hokko Memorial Clinic, Sapporo, Japan (I.S.).'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Sakabe', 'Affiliation': 'Sakabe Clinic, Kyoto, Japan (K.S.).'}, {'ForeName': 'Masayasu', 'Initials': 'M', 'LastName': 'Yamamoto', 'Affiliation': 'Yamamoto Clinic, Shimoniikawa, Japan (M.Y.).'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Kobayashi', 'Affiliation': 'Jyuzen General Hospital, Niihama, Japan (T.K.).'}, {'ForeName': 'Shinichi', 'Initials': 'S', 'LastName': 'Oikawa', 'Affiliation': 'Fukujuji Hospital, Tokyo, Japan (S.O.).'}, {'ForeName': 'Shizuya', 'Initials': 'S', 'LastName': 'Yamashita', 'Affiliation': 'Rinku General Medical Center, Izumisano, Japan (S.Y.).'}, {'ForeName': 'Hiromi', 'Initials': 'H', 'LastName': 'Rakugi', 'Affiliation': 'Osaka University, Suita, Japan (H.R.).'}, {'ForeName': 'Takumi', 'Initials': 'T', 'LastName': 'Imai', 'Affiliation': 'Kyoto University, Japan (T.I., S.T.).'}, {'ForeName': 'Shiro', 'Initials': 'S', 'LastName': 'Tanaka', 'Affiliation': 'Kyoto University, Japan (T.I., S.T.).'}, {'ForeName': 'Yasuo', 'Initials': 'Y', 'LastName': 'Ohashi', 'Affiliation': 'Chuo University, Tokyo, Japan (Y. Osachi).'}, {'ForeName': 'Masanari', 'Initials': 'M', 'LastName': 'Kuwabara', 'Affiliation': 'Toranomon Hospital, Tokyo, Japan (Y. Ouchi, M.K.).'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Ito', 'Affiliation': 'Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan (K.H., H.I.).'}]",Circulation,['10.1161/CIRCULATIONAHA.118.039415'] 1061,21322756,Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.,"Ovarian cancer remains the leading cause of death due to gynecologic malignancies. Most patients present with advanced disease at the time of diagnosis. Although many have a good initial response to surgical debulking and platinum-based chemotherapy, relapse is common, with the eventual development of chemotherapy resistance. Innovative treatments are needed in the remission setting to prolong the disease-free interval or prevent recurrence. Abagovomab is a murine monoclonal anti-idiotypic antibody (molecular weight: 165-175 kDa) that functionally imitates the tumor-associated antigen, CA-125. It has been shown to be well tolerated and to induce a sustained immune response in initial Phase I and II clinical trials. An ongoing, double-blind, placebo-controlled, multicenter, Phase III trial (MIMOSA) completed its double-blind period in December 2010 and will compare abagovomab maintenance therapy to placebo, which will definitively determine the efficacy of this immunotherapeutic approach in patients with ovarian cancer.",2011,It has been shown to be well tolerated and to induce a sustained immune response in initial Phase I and II clinical trials.,"['patients with ovarian cancer', 'ovarian cancer']","['Abagovomab', 'immunotherapeutic approach', 'placebo']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1140680', 'cui_str': 'Ovary Cancer'}]","[{'cui': 'C1832044', 'cui_str': 'abagovomab'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]",[],,0.205655,It has been shown to be well tolerated and to induce a sustained immune response in initial Phase I and II clinical trials.,"[{'ForeName': 'Rachel N', 'Initials': 'RN', 'LastName': 'Grisham', 'Affiliation': 'Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Berek', 'Affiliation': ''}, {'ForeName': 'Jacobus', 'Initials': 'J', 'LastName': 'Pfisterer', 'Affiliation': ''}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Sabbatini', 'Affiliation': ''}]",Immunotherapy,['10.2217/imt.10.100'] 1062,31535213,"Soy isoflavones interact with calcium and contribute to blood pressure homeostasis in women: a randomized, double-blind, placebo controlled trial.","BACKGROUND Estrogens and calcium regulate vascular health but caused adverse cardiovascular events in randomized trials. OBJECTIVES Whether phytoestrogenic soy isoflavones modulate the physiological effects of calcium on blood pressure was explored. DESIGN A double-blind, randomized study assigned 99 premenopausal women to 136.6 mg isoflavones (as aglycone equivalents) and 98 to placebo for 5 days per week for up to 2 years. Blood pressure, serum calcium and urinary excretion of daidzein (DE) and genistein (GE) were measured repeatedly before and during treatment. RESULTS Isoflavones did not affect blood pressure per intake dose assignment (i.e. intention-to-treat, n = 197), but significantly affected blood pressure per measured urinary excretion of isoflavones (i.e. per protocol analysis, n = 166). Isoflavones inversely moderated calcium effects on systolic blood pressure (SBP) (interaction term β-estimates: - 3.1 for DE, - 12.86 for GE, all P < 0.05), and decreased diastolic blood pressure (DBP) (β-estimates: - 0.84 for DE, - 2.82 for GE, all P < 0.05) after controlling for calcium. The net intervention effects between the maximum and no isoflavone excretion were - 17.7 and + 13.8 mmHg changes of SBP, respectively, at serum calcium of 10.61 and 8.0 mg/dL, and about 2.6 mmHg decrease of DBP. CONCLUSIONS Moderation by isoflavones of the physiological effect of calcium tends to normalize SBP, and this effect is most significant when calcium concentrations are at the upper and lower limits of the physiological norm. Isoflavones decrease DBP independent of calcium levels. Further studies are needed to assess the impact of this novel micronutrient effect on blood pressure homeostasis and cardiovascular health. TRIAL REGISTRATION www.clinicaltrials.gov identifier: NCT00204490.",2020,"Blood pressure, serum calcium and urinary excretion of daidzein (DE) and genistein (GE) were measured repeatedly before and during treatment. ","['99 premenopausal women to 136.6\xa0mg isoflavones (as aglycone equivalents) and 98 to', 'women']","['placebo', 'Soy isoflavones interact with calcium', 'Isoflavones', 'phytoestrogenic soy isoflavones']","['blood pressure', 'DBP', 'blood pressure homeostasis', 'systolic blood pressure (SBP', 'Blood pressure, serum calcium and urinary excretion of daidzein (DE) and genistein (GE', 'blood pressure per measured urinary excretion of isoflavones', 'diastolic blood pressure (DBP', 'isoflavone excretion']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0022179', 'cui_str': 'Isoflavone Derivatives'}, {'cui': 'C0304518', 'cui_str': 'Aglycone'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4076257', 'cui_str': 'Soy isoflavone (substance)'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0022179', 'cui_str': 'Isoflavone Derivatives'}]","[{'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0019868', 'cui_str': 'Autoregulation'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C0728876', 'cui_str': 'Serum calcium measurement'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0057090', 'cui_str': 'diadzein'}, {'cui': 'C0061202', 'cui_str': 'Genistein'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0022179', 'cui_str': 'Isoflavone Derivatives'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}]",,0.508317,"Blood pressure, serum calcium and urinary excretion of daidzein (DE) and genistein (GE) were measured repeatedly before and during treatment. ","[{'ForeName': 'Lee-Jane W', 'Initials': 'LW', 'LastName': 'Lu', 'Affiliation': 'Department of Preventive Medicine and Community Health, The University of Texas Medical Branch, 700 Harborside Dr., Galveston, TX, 77555-1109, USA. llu@utmb.edu.'}, {'ForeName': 'Nai-Wei', 'Initials': 'NW', 'LastName': 'Chen', 'Affiliation': 'Department of Preventive Medicine and Community Health, The University of Texas Medical Branch, 700 Harborside Dr., Galveston, TX, 77555-1109, USA.'}, {'ForeName': 'Fatima', 'Initials': 'F', 'LastName': 'Nayeem', 'Affiliation': 'Department of Preventive Medicine and Community Health, The University of Texas Medical Branch, 700 Harborside Dr., Galveston, TX, 77555-1109, USA.'}, {'ForeName': 'Manubai', 'Initials': 'M', 'LastName': 'Nagamani', 'Affiliation': 'Department of Obstetrics and Gynecology, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555, USA.'}, {'ForeName': 'Karl E', 'Initials': 'KE', 'LastName': 'Anderson', 'Affiliation': 'Department of Preventive Medicine and Community Health, The University of Texas Medical Branch, 700 Harborside Dr., Galveston, TX, 77555-1109, USA. kanderso@utmb.edu.'}]",European journal of nutrition,['10.1007/s00394-019-02085-3'] 1063,32430334,Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer.,"PD-1 and PD-L1 act to restrict T cell responses in cancer and contribute to self-tolerance. Consistent with this role, PD-1 checkpoint inhibitors have been associated with immune-related adverse events (irAEs), immune toxicities thought to be autoimmune in origin. Analyses of dermatological irAEs have identified an association with improved overall survival (OS) following anti-PD-(L)1 therapy, but the factors that contribute to this relationship are poorly understood. We collected germline whole-genome sequencing data from IMvigor211, a recent phase 3 randomized controlled trial comparing atezolizumab (anti-PD-L1) monotherapy to chemotherapy in bladder cancer. We found that high vitiligo, high psoriasis, and low atopic dermatitis polygenic risk scores (PRSs) were associated with longer OS under anti-PD-L1 monotherapy as compared to chemotherapy, reflecting the Th17 polarization of these diseases. PRSs were not correlated with tumor mutation burden, PD-L1 immunohistochemistry, nor T-effector gene signatures. Shared genetic factors impact risk for dermatological autoimmunity and anti-PD-L1 monotherapy in bladder cancer.",2020,"PRSs were not correlated with tumor mutation burden, PD-L1 immunohistochemistry, nor T-effector gene signatures.",['bladder cancer'],['atezolizumab (anti-PD-L1) monotherapy'],"['overall survival (OS', 'low atopic dermatitis polygenic risk scores (PRSs']","[{'cui': 'C0005684', 'cui_str': 'Malignant tumor of urinary bladder'}]","[{'cui': 'C4055433', 'cui_str': 'atezolizumab'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0526833,"PRSs were not correlated with tumor mutation burden, PD-L1 immunohistochemistry, nor T-effector gene signatures.","[{'ForeName': 'Zia', 'Initials': 'Z', 'LastName': 'Khan', 'Affiliation': 'Genentech, South San Francisco, CA 94080; khanz12@gene.com iram@gene.com albertm@insitro.com.'}, {'ForeName': 'Flavia', 'Initials': 'F', 'LastName': 'Di Nucci', 'Affiliation': 'Genentech, South San Francisco, CA 94080.'}, {'ForeName': 'Antonia', 'Initials': 'A', 'LastName': 'Kwan', 'Affiliation': 'Genentech, South San Francisco, CA 94080.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Hammer', 'Affiliation': 'Genentech, South San Francisco, CA 94080.'}, {'ForeName': 'Sanjeev', 'Initials': 'S', 'LastName': 'Mariathasan', 'Affiliation': 'Genentech, South San Francisco, CA 94080.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Rouilly', 'Affiliation': 'Genentech, South San Francisco, CA 94080.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Carroll', 'Affiliation': 'Genentech, South San Francisco, CA 94080.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Fontes', 'Affiliation': 'Genentech, South San Francisco, CA 94080.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Ley Acosta', 'Affiliation': 'Genentech, South San Francisco, CA 94080.'}, {'ForeName': 'Ellie', 'Initials': 'E', 'LastName': 'Guardino', 'Affiliation': 'Genentech, South San Francisco, CA 94080.'}, {'ForeName': 'Haiyin', 'Initials': 'H', 'LastName': 'Chen-Harris', 'Affiliation': 'Genentech, South San Francisco, CA 94080.'}, {'ForeName': 'Tushar', 'Initials': 'T', 'LastName': 'Bhangale', 'Affiliation': 'Genentech, South San Francisco, CA 94080.'}, {'ForeName': 'Ira', 'Initials': 'I', 'LastName': 'Mellman', 'Affiliation': 'Genentech, South San Francisco, CA 94080; khanz12@gene.com iram@gene.com albertm@insitro.com.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Rosenberg', 'Affiliation': 'Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Powles', 'Affiliation': 'Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, EC1M 6BQ London, United Kingdom.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Hunkapiller', 'Affiliation': 'Genentech, South San Francisco, CA 94080.'}, {'ForeName': 'G Scott', 'Initials': 'GS', 'LastName': 'Chandler', 'Affiliation': 'Genentech, South San Francisco, CA 94080.'}, {'ForeName': 'Matthew L', 'Initials': 'ML', 'LastName': 'Albert', 'Affiliation': 'Genentech, South San Francisco, CA 94080; khanz12@gene.com iram@gene.com albertm@insitro.com.'}]",Proceedings of the National Academy of Sciences of the United States of America,['10.1073/pnas.1922867117'] 1064,31586194,Developing a Psychological-Behavioral Intervention in Cardiac Patients Using the Multiphase Optimization Strategy: Lessons Learned From the Field.,"BACKGROUND The Multiphase Optimization Strategy (MOST) is an approach to systematically and efficiently developing a behavioral intervention using a sequence of experiments to prepare and optimize the intervention. PURPOSE Using a 6 year MOST-based behavioral intervention development project as an example, we outline the results-and resulting decision-making process-related to experiments at each step to display the practical challenges present at each stage. METHODS To develop a positive psychology (PP) based intervention to promote physical activity after an acute coronary syndrome (N = 255 across four phases), we utilized qualitative, proof-of-concept, factorial design, and randomized pilot experiments, with iterative modification of intervention content and delivery. RESULTS Through this multiphase approach, we ultimately developed a 12 week, phone-delivered, combined PP-motivational interviewing intervention to promote physical activity. Across stages, we learned several important lessons: (a) participant and interventionist feedback is important, even in later optimization stages; (b) a thoughtful and systematic approach using all information sources is required when conflicting results in experiments make next steps unclear; and (3) new approaches in the field over a multiyear project should be integrated into the development process. CONCLUSIONS A MOST-based behavioral intervention development program can be efficient and effective in developing optimized new interventions, and it may require complex and nuanced decision-making at each phase.",2020,"BACKGROUND The Multiphase Optimization Strategy (MOST) is an approach to systematically and efficiently developing a behavioral intervention using a sequence of experiments to prepare and optimize the intervention. ",[],"['positive psychology (PP) based intervention', 'combined PP-motivational interviewing intervention', 'Multiphase Optimization Strategy']",[],[],"[{'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0033909', 'cui_str': 'Psychology'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0935630', 'cui_str': 'Interview'}]",[],255.0,0.0166421,"BACKGROUND The Multiphase Optimization Strategy (MOST) is an approach to systematically and efficiently developing a behavioral intervention using a sequence of experiments to prepare and optimize the intervention. ","[{'ForeName': 'Jeff C', 'Initials': 'JC', 'LastName': 'Huffman', 'Affiliation': 'Department of Psychiatry, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Rachel A', 'Initials': 'RA', 'LastName': 'Millstein', 'Affiliation': 'Department of Psychiatry, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Celano', 'Affiliation': 'Department of Psychiatry, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Brian C', 'Initials': 'BC', 'LastName': 'Healy', 'Affiliation': 'Department of Psychiatry, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Elyse R', 'Initials': 'ER', 'LastName': 'Park', 'Affiliation': 'Department of Psychiatry, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Linda M', 'Initials': 'LM', 'LastName': 'Collins', 'Affiliation': 'The Methodology Center and Department of Human Development and Family Studies, Pennsylvania State University, University Park, PA, USA.'}]",Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,['10.1093/abm/kaz035'] 1065,21342036,Adjuvant therapy for pancreas adenocarcinoma: where are we going?,"Evaluation of: Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10), 1073-1081 (2010). Over the last decade, adjuvant therapy in the treatment of resected pancreas adenocarcinoma has had its value established. Such treatment incrementally increases 5-year survivorship and delays time to tumor recurrence. The backbone of adjuvant therapy is the single-agent gemcitabine, based primarily on results from the Charité Onkologie Clinical (CONKO)-001 study. Based on the combined results of the European Study Group for Pancreas Cancer (ESPAC)-1 and ESPAC-3 trials, Neoptolemos and colleagues have established both bolus 5-fluorouracil and leucovorin and gemcitabine as standard options for resected pancreatic cancer. Gemcitabine remains the main standard therapy based on its ease of administration and a more favorable toxicity profile; however, there is now a clearly validated alternate option of 5-fluororuacil and leucovorin based on the results of ESPAC-3. Moving forward, the integration of novel cytotoxic and targeted agents into adjuvant therapy, along with refining the role of neoadjuvant therapy for patients with resectable pancreas cancer, will hopefully accrue a more substantial improvement in outcome for patients with resected pancreas adenocarcinoma.",2011,Such treatment incrementally increases 5-year survivorship and delays time to tumor recurrence.,"['patients with resected pancreas adenocarcinoma', 'patients with resectable pancreas cancer', 'pancreas adenocarcinoma', 'pancreatic cancer resection', 'JAMA 304(10), 1073-1081']","['Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine', '5-fluorouracil and leucovorin and gemcitabine', 'Gemcitabine', 'leucovorin']",['5-year survivorship and delays time to tumor recurrence'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001418', 'cui_str': 'Adenoma, Malignant'}, {'cui': 'C0346647', 'cui_str': 'Cancer of Pancreas'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}]","[{'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C2721771', 'cui_str': 'levoleucovorin'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0038955'}, {'cui': 'C0522486', 'cui_str': 'Delay time (qualifier value)'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}]",,0.020615,Such treatment incrementally increases 5-year survivorship and delays time to tumor recurrence.,"[{'ForeName': 'Eileen M', 'Initials': 'EM', 'LastName': ""O'Reilly"", 'Affiliation': 'Department of Medicine, Gastrointestinal Oncology Service, 1275 York Avenue, Box 324, New York, NY 10065, USA. oreillye@mskcc.org'}]",Expert review of anticancer therapy,['10.1586/era.10.232'] 1066,32130065,Normal Gaze Patterns of the Face in Lateral View.,"Importance: Current efforts to quantify the attentional distraction of facial deformities have been limited to deformities that are best perceived when the face is in frontal view, and there remains a paucity of knowledge of societal perception of the face in lateral view. To date, no attempts have been made to characterize the fixation patterns of the face in lateral view. Objective: To characterize the fixation patterns and gaze patterns of the face in lateral view. Design, Setting, and Participants: This was a prospective randomized controlled trial at an academic tertiary medical center. Eighty participants (mean age 23.6 ± 1.7 years, 52.5% female) gazed freely at 11 images of faces in lateral view for 10 s each as an infrared eye-tracker recorded eye movements in real time. Main Outcomes and Measures: Recorded eye movements are superimposed on the images to visualize areas of interest (AOIs) that attract the most attention. Fixation duration targeted at each AOI is transformed into relative fixation of the entire face and neck. Hotelling's test of variance followed by post hoc t -testing assessed for the significance of fixation differences between the mouth and cheeks. Results: Participants spent an average of 6.0 (95% CI 5.8-6.2) s gazing at the face and neck areas of each image. Of this attention, 2.8 s or 49.8% (45.4-54.2%) was directed toward the eye, followed distantly by the nose (mean, 95% CI) (16.4%, 14.5-18.3%), cheek (12.0%, 11.4-14.5%), neck (4.6%, 3.8-5.4%), and mouth (4.0%, 3.4-4.6%). These differences were found to be significant by Hotelling's analysis and post hoc testing. A student's t -test also indicated observers directed significantly more attention within the eye-nose-cheek triangle [4.6 s or 79.5% (75.6-83.5)] compared with the eye-nose-mouth triangle [4.1 s or 71.2% (66.9-75.5)] ( p  < 0.001). Conclusions and Relevance: When perceiving novel faces in lateral view, casual observers preferentially directed attention toward the eye, nose, and cheek. These findings suggest that we draw from a slightly different collection of features to build a schema of the sagittal face, which may serve to complement the central triangle and build upon a three-dimensional model of the ""normal"" human face. Level of Evidence: NA.",2020,A student's t -test also indicated observers directed significantly more attention within the eye-nose-cheek triangle [4.6 s or 79.5% (75.6-83.5)] compared with the eye-nose-mouth triangle [4.1 s or 71.2% (66.9-75.5)] ( p  < 0.001). ,"['Eighty participants (mean age 23.6\u2009±\u20091.7 years, 52.5% female) gazed freely at 11 images of faces in lateral view for 10\u2009s each as an', 'academic tertiary medical center']",['infrared eye-tracker recorded eye movements in real time'],['attention within the eye-nose-cheek triangle'],"[{'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517512', 'cui_str': '1.7 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517802', 'cui_str': '52.5 (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0553544', 'cui_str': 'Gaze (finding)'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0205093', 'cui_str': 'Lateral (qualifier value)'}, {'cui': 'C0449911', 'cui_str': 'View (attribute)'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0565990', 'cui_str': 'Medical center (environment)'}]","[{'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0015413', 'cui_str': 'Eye Movements'}, {'cui': 'C1632851', 'cui_str': 'Times'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0028429', 'cui_str': 'Nose'}, {'cui': 'C0007966', 'cui_str': 'Bucca'}, {'cui': 'C0205119', 'cui_str': 'Triangular (qualifier value)'}]",,0.0487042,A student's t -test also indicated observers directed significantly more attention within the eye-nose-cheek triangle [4.6 s or 79.5% (75.6-83.5)] compared with the eye-nose-mouth triangle [4.1 s or 71.2% (66.9-75.5)] ( p  < 0.001). ,"[{'ForeName': 'Pauline P', 'Initials': 'PP', 'LastName': 'Huynh', 'Affiliation': 'Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Masaru', 'Initials': 'M', 'LastName': 'Ishii', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Juarez', 'Affiliation': 'Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Liao', 'Affiliation': 'Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Halley M', 'Initials': 'HM', 'LastName': 'Darrach', 'Affiliation': 'Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Fung', 'Affiliation': 'Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Jason C', 'Initials': 'JC', 'LastName': 'Nellis', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Byrne', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Kofi D O', 'Initials': 'KDO', 'LastName': 'Boahene', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Ira D', 'Initials': 'ID', 'LastName': 'Papel', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Theda C', 'Initials': 'TC', 'LastName': 'Kontis', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Lisa E', 'Initials': 'LE', 'LastName': 'Ishii', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}]",Facial plastic surgery & aesthetic medicine,['10.1089/fpsam.2019.29019.huy'] 1067,32066536,"Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.","BACKGROUND Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and increased blood eosinophils. The aim was to establish whether subcutaneous reslizumab 110 mg can reduce exacerbation rates in these patients (study 1) or reduce maintenance oral corticosteroid dose in patients with corticosteroid-dependent asthma (study 2). METHODS Both studies were randomised, double-blind, placebo-controlled, phase 3 studies. Entry criteria for study 1 were uncontrolled severe asthma, two or more asthma exacerbations in the previous year, a blood eosinophil count of 300 cells per μL or more (including no more than 30% patients with an eosinophil count <400 cells/μL), and at least a medium dose of inhaled corticosteroids with one or more additional asthma controllers. Patients in study 2 had severe asthma, a blood eosinophil count of 300 cells per μL or more, daily maintenance oral corticosteroid (prednisone 5-40 mg, or equivalent), and high-dose inhaled corticosteroids plus another controller. Patients were randomly assigned (1:1) to subcutaneous reslizumab (110 mg) or placebo once every 4 weeks for 52 weeks in study 1 and 24 weeks in study 2. Patients and investigators were masked to treatment assignment. Primary efficacy outcomes were frequency of exacerbations during 52 weeks in study 1 and categorised percentage reduction in daily oral corticosteroid dose from baseline to weeks 20-24 in study 2. Primary efficacy analyses were by intention to treat, and safety analyses included all patients who received at least one dose of study treatment. These studies are registered with ClinicalTrials.gov, NCT02452190 (study 1) and NCT02501629 (study 2). FINDINGS Between Aug 12, 2015, and Jan 31, 2018, 468 patients in study 1 were randomly assigned to placebo (n=232) or subcutaneous reslizumab (n=236), and 177 in study 2 to placebo (n=89) or subcutaneous reslizumab (n=88). In study 1, we found no significant difference in the exacerbation rate between reslizumab and placebo in the intention-to-treat population (rate ratio 0·79, 95% CI 0·56-1·12; p=0·19). Subcutaneous reslizumab reduced exacerbation frequency compared with placebo in the subgroup of patients with blood eosinophil counts of 400 cells per μL or more (0·64, 95% CI 0·43-0·95). Greater reductions in annual exacerbation risk (p=0·0035) and longer time to first exacerbation were observed for patients with higher trough serum reslizumab concentrations. In study 2, we found no difference between placebo and fixed-dose subcutaneous reslizumab in categorised percentage reduction in daily oral corticosteroid dose (odds ratio for a lower category of oral corticosteroid use in the reslizumab group vs the placebo group, 1·23, 95% CI 0·70-2·16; p=0·47). The frequency of adverse events and serious adverse events with reslizumab were similar to those with placebo in both studies. INTERPRETATION Fixed-dose (110 mg) subcutaneous reslizumab was not effective in reducing exacerbation frequency in patients with uncontrolled asthma and increased blood eosinophils (≥300 cells/μL), or in reducing the daily maintenance oral corticosteroid dose in patients with oral corticosteroid-dependent severe eosinophilic asthma. Higher exposures than those observed with 110 mg subcutaneous reslizumab are required to achieve maximal efficacy. FUNDING Teva Branded Pharmaceutical Products R&D.",2020,Greater reductions in annual exacerbation risk (p=0·0035) and longer time to first exacerbation were observed for patients with higher trough serum reslizumab concentrations.,"['468 patients in study 1', 'patients with uncontrolled asthma and increased blood eosinophils (≥300 cells/μL), or in reducing the daily maintenance oral corticosteroid dose in patients with oral corticosteroid-dependent severe eosinophilic asthma', 'severe eosinophilic asthma', 'patients with uncontrolled severe asthma and increased blood eosinophils', 'patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma', 'Patients in study 2 had severe asthma, a blood eosinophil count of 300 cells per μL or more, daily maintenance oral corticosteroid (prednisone 5-40 mg, or equivalent), and high-dose inhaled corticosteroids plus another controller', 'Between Aug 12, 2015, and Jan 31, 2018', 'Entry criteria for study 1 were uncontrolled severe asthma, two or more asthma exacerbations in the previous year, a blood eosinophil count of 300 cells per μL or more (including no more than 30% patients with an eosinophil count <400 cells/μL), and at least a medium dose of inhaled corticosteroids with one or more additional asthma controllers', 'patients with corticosteroid-dependent asthma (study 2']","['reslizumab and placebo', 'placebo', 'reslizumab', 'fixed-dose subcutaneous reslizumab', 'subcutaneous reslizumab']","['frequency of exacerbations', 'frequency of adverse events and serious adverse events', 'asthma exacerbations', 'exacerbation rates', 'safety and efficacy', 'exacerbation rate', 'maximal efficacy', 'annual exacerbation risk (p=0·0035) and longer time to first exacerbation', 'exacerbation frequency']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil, segmented (cell)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0034068', 'cui_str': 'Pulmonary Eosinophilia'}, {'cui': 'C0581126', 'cui_str': 'Severe asthma'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled (qualifier value)'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0200638', 'cui_str': 'Eosinophil count - observation'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0439536', 'cui_str': 'Medium (qualifier value)'}]","[{'cui': 'C1869620', 'cui_str': 'reslizumab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1522438', 'cui_str': 'SC use'}]","[{'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",,0.700246,Greater reductions in annual exacerbation risk (p=0·0035) and longer time to first exacerbation were observed for patients with higher trough serum reslizumab concentrations.,"[{'ForeName': 'Jonathan A', 'Initials': 'JA', 'LastName': 'Bernstein', 'Affiliation': 'Department of Internal Medicine, Division of Immunology/Allergy Section, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Bernstein Clinical Research Center, Cincinnati, OH, USA. Electronic address: bernstja@ucmail.uc.edu.'}, {'ForeName': 'J Christian', 'Initials': 'JC', 'LastName': 'Virchow', 'Affiliation': 'Departments of Pulmonary Medicine and Intensive Care Medicine, Universitätsmedizin Rostock, Rostock, Germany.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Murphy', 'Affiliation': 'Allergy, Asthma and Pulmonary Research, Boys Town National Research Hospital, Boys Town, NE, USA.'}, {'ForeName': 'Jorge Fernando', 'Initials': 'JF', 'LastName': 'Maspero', 'Affiliation': 'Allergy and Respiratory Research Unit, Fundación CIDEA, Buenos Aires, Argentina.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Jacobs', 'Affiliation': 'Allergy and Asthma Clinical Research, Walnut Creek, CA, USA.'}, {'ForeName': 'Yochai', 'Initials': 'Y', 'LastName': 'Adir', 'Affiliation': 'Pulmonary Division, Lady Davis Carmel Medical Center, Faculty of Medicine, The Technion, Institute of Technology, Haifa, Israel.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Humbert', 'Affiliation': 'Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Castro', 'Affiliation': 'Division of Pulmonary, Critical Care and Sleep Medicine, University of Kansas School of Medicine, Kansas City, KS, USA.'}, {'ForeName': 'Douglas A', 'Initials': 'DA', 'LastName': 'Marsteller', 'Affiliation': 'Teva Branded Pharmaceutical Products, West Chester, PA, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'McElhattan', 'Affiliation': 'Teva Branded Pharmaceutical Products, West Chester, PA, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Hickey', 'Affiliation': 'Teva Branded Pharmaceutical Products, West Chester, PA, USA.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Garin', 'Affiliation': 'Teva Branded Pharmaceutical Products, West Chester, PA, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Vanlandingham', 'Affiliation': 'Teva Branded Pharmaceutical Products, West Chester, PA, USA.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Brusselle', 'Affiliation': 'Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; Departments of Epidemiology and Respiratory Medicine, Erasmus MC-University Medical Center Rotterdam, Rotterdam, Netherlands.'}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(19)30372-8'] 1068,32128844,Effect of age and renal impairment on the pharmacokinetics and safety of trimetazidine: An open-label multiple-dose study.,"This study evaluated the effect of age and renal impairment on pharmacokinetics of trimetazidine (TMZ) in healthy elderly and renally impaired subjects and assess safety and tolerability. In this open-label, multi-dose study, 73 subjects were divided into six treatment groups: (1) 55-65 years; (2) 66-75 years; (3) >75 years (dosing for groups 1-3 [healthy]: B.D. for 4 days), (4) mild renally impaired (dosed B.D. for 8 days); (5) moderate renally impaired (dosed O.D. for 8 days); and (6) severe renally impaired-no dialysis (dosed once every 48 h for 8 days). Blood and urine samples were collected and analyzed. The geometric least squares mean ratios for; Group 2 and 1 of AUC (0-τ)ss was 112.2 (90% CI; 92.0-136.8) and C max,ss was 109.9 (89.6-134.8), Group 3 and 1 of AUC (0-τ),ss was 140.5 (115.9-170.3) and C max,ss was 137.8 (112.9-168.2), Group 4 and 1 of AUC (0-τ),ss was 114.2 (90.3-144.4) and C max,ss was 120.8 (92.5-157.8), Group 5 and 1 of; AUC (0-τ),ss was 213.0 (153.1-296.3) and C max,ss was 123.3 (92.2-164.7) and Group 6 and 1 of AUC (0-τ),ss was 247.4 (197.8-309.6) and C max,ss was 95.6 (73.0-125.1). Significant increase in systemic exposure of TMZ was observed in subjects; over 75 year's age and renally impaired compared to healthy subjects. TMZ was safe and well-tolerated.",2020,Significant increase in systemic exposure of TMZ was observed in subjects; over 75 year's age and renally impaired compared to healthy subjects.,"['73 subjects were divided into six treatment groups: (1) 55-65\u2009years; (2) 66-75\u2009years; (3) >75\u2009years (dosing for groups 1-3 [healthy', 'healthy elderly and renally impaired subjects']","['AUC', 'trimetazidine', 'trimetazidine (TMZ', 'TMZ']","['Blood and urine samples', 'systemic exposure of TMZ', 'safety and tolerability', 'severe renally impaired-no dialysis', 'safe and well-tolerated']","[{'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}]","[{'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0041037', 'cui_str': 'Trimetazidine'}]","[{'cui': 'C0005768'}, {'cui': 'C1610733', 'cui_str': 'Urine specimen'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}, {'cui': 'C4551529', 'cui_str': 'Renal Dialysis'}]",73.0,0.0174292,Significant increase in systemic exposure of TMZ was observed in subjects; over 75 year's age and renally impaired compared to healthy subjects.,"[{'ForeName': 'Nencho', 'Initials': 'N', 'LastName': 'Nenchev', 'Affiliation': 'Department of Medicine, Comac Medical, Sofia, Bulgaria.'}, {'ForeName': 'Jiri', 'Initials': 'J', 'LastName': 'Skopek', 'Affiliation': 'Department of Medicine, Thomayer Hospital, Prague, Czech Republic.'}, {'ForeName': 'Deepa', 'Initials': 'D', 'LastName': 'Arora', 'Affiliation': 'Department of Drug Safety and Risk Management, Lupin Limited (India), Mumbai, India.'}, {'ForeName': 'Abdus', 'Initials': 'A', 'LastName': 'Samad', 'Affiliation': 'Department of Drug Safety and Risk Management, Lupin Limited (India), Mumbai, India.'}, {'ForeName': 'Sigal', 'Initials': 'S', 'LastName': 'Kaplan', 'Affiliation': 'Department of Pharmacoepidemiology, Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel.'}, {'ForeName': 'Mónika', 'Initials': 'M', 'LastName': 'Domahidy', 'Affiliation': 'Department of Clinical Research, Gedeon Richter Plc., Budapest, Hungary.'}, {'ForeName': 'Hanka', 'Initials': 'H', 'LastName': 'de Voogd', 'Affiliation': 'Department of Global Clinical Sciences, Mylan, Amstelveen, The Netherlands.'}, {'ForeName': 'Stella', 'Initials': 'S', 'LastName': 'Böhmert', 'Affiliation': 'Global Postmarketing Studies and Clinical Operational Excellence, Sandoz International GmbH, Holzkirchen, Germany.'}, {'ForeName': 'Rita S', 'Initials': 'RS', 'LastName': 'Ramos', 'Affiliation': 'Department of Clinical Research, Generis Farmacêutica, S. A., Amadora, Portugal.'}, {'ForeName': 'Shashank', 'Initials': 'S', 'LastName': 'Jain', 'Affiliation': 'Department of Drug Safety and Risk Management, Lupin Limited (India), Mumbai, India.'}]",Drug development research,['10.1002/ddr.21654'] 1069,31537689,KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.,"In recent years, the outcome of mantle cell lymphoma (MCL) has improved, especially in younger patients, receiving cytarabine-containing chemoimmunotherapy and autologous stem cell transplantation. Nevertheless, a proportion of MCL patients still experience early failure. To identify biomarkers anticipating failure of intensive chemotherapy in MCL, we performed target resequencing and DNA profiling of purified tumor samples collected from patients enrolled in the prospective FIL-MCL0208 phase 3 trial (high-dose chemoimmunotherapy followed by autologous transplantation and randomized lenalidomide maintenance). Mutations of KMT2D and disruption of TP53 by deletion or mutation associated with an increased risk of progression and death, both in univariate and multivariate analysis. By adding KMT2D mutations and TP53 disruption to the MIPI-c backbone, we derived a new prognostic index, the ""MIPI-genetic"" (""MIPI- g""). The ""MIPI-g"" improved the model discrimination ability compared to the MIPI-c alone, defining three risk groups: i) low-risk patients (4-year progression free survival and overall survival of 72.0% and 94.5%); ii) inter-mediate-risk patients (4-year progression free survival and overall survival of 42.2% and 65.8%) and iii) high-risk patients (4-year progression free survival and overall survival of 11.5% and 44.9%). Our results: i) confirm that TP53 disruption identifies a high-risk population characterized by poor sensitivity to conventional or intensified chemotherapy; ii) provide the pivotal evidence that patients harboring KMT2D mutations share the same poor outcome as patients harboring TP53 disruption; and iii) allow to develop a tool for the identification of high-risk MCL patients for whom novel therapeutic strategies need to be investigated. ( Trial registered at clinicaltrials.gov identifier: NCT02354313 ).",2020,"The MIPI-g improved the model discrimination ability compared to the MIPI-c alone, defining three risk groups: i) low-risk patients (4-years progression free survival and overall survival of 72.0% and 94.5%); ii) intermediate-risk patients (4-years progression free survival and overall survival of 42.2% and 65.8%) and iii) high-risk patients (4-years progression free survival and overall survival of 11.5% and 44.9%).","['mantle cell lymphoma', 'patients enrolled in the prospective FIL-MCL0208 phase III trial (high-dose chemoimmunotherapy followed by autologous transplantation and randomized lenalidomide maintenance']",['cytarabine-containing chemoimmunotherapy and autologous stem cell transplantation'],"['progression free survival and overall survival', 'risk of progression and death', 'model discrimination ability']","[{'cui': 'C0334634', 'cui_str': 'Lymphoma, Small-Cell, Centrocytic'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0040736', 'cui_str': 'Autotransplantation'}, {'cui': 'C1144149', 'cui_str': 'lenalidomide'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}]","[{'cui': 'C0010711', 'cui_str': 'Cytarabine'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C1504389', 'cui_str': 'Stem Cell Transplantation'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C0012632', 'cui_str': 'Discrimination'}, {'cui': 'C0085732', 'cui_str': 'Ability'}]",,0.034178,"The MIPI-g improved the model discrimination ability compared to the MIPI-c alone, defining three risk groups: i) low-risk patients (4-years progression free survival and overall survival of 72.0% and 94.5%); ii) intermediate-risk patients (4-years progression free survival and overall survival of 42.2% and 65.8%) and iii) high-risk patients (4-years progression free survival and overall survival of 11.5% and 44.9%).","[{'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Ferrero', 'Affiliation': 'Department of Molecular Biotechnologies and Health Sciences - Hematology Division, Università di Torino, Torino, Italy simone.ferrero@unito.it.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Rossi', 'Affiliation': 'Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Rinaldi', 'Affiliation': ""Universita' della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.""}, {'ForeName': 'Alessio', 'Initials': 'A', 'LastName': 'Bruscaggin', 'Affiliation': ""Universita' della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.""}, {'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Spina', 'Affiliation': ""Universita' della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.""}, {'ForeName': 'Christian W', 'Initials': 'CW', 'LastName': 'Eskelund', 'Affiliation': 'Department of Hematology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Evangelista', 'Affiliation': 'Clinical Epidemiology, Città della Salute e della Scienza and CPO Piemonte, Torino, Italy.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Moia', 'Affiliation': 'Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.'}, {'ForeName': 'Ivo', 'Initials': 'I', 'LastName': 'Kwee', 'Affiliation': ""Universita' della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.""}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Dahl', 'Affiliation': 'Danish Cancer Society Research Center, Copenhagen, Denmark.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Di Rocco', 'Affiliation': 'Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, ""Sapienza"" University of Rome, Roma, Italy.'}, {'ForeName': 'Vittorio', 'Initials': 'V', 'LastName': 'Stefoni', 'Affiliation': 'Institute of Hematology ""L. e A. Seràgnoli"", University of Bologna, Bologna, Italy.'}, {'ForeName': 'Fary', 'Initials': 'F', 'LastName': 'Diop', 'Affiliation': 'Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Favini', 'Affiliation': 'Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Ghione', 'Affiliation': 'Department of Molecular Biotechnologies and Health Sciences - Hematology Division, Università di Torino, Torino, Italy.'}, {'ForeName': 'Abdurraouf Mokhtar', 'Initials': 'AM', 'LastName': 'Mahmoud', 'Affiliation': 'Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.'}, {'ForeName': 'Mattia', 'Initials': 'M', 'LastName': 'Schipani', 'Affiliation': 'Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.'}, {'ForeName': 'Arne', 'Initials': 'A', 'LastName': 'Kolstad', 'Affiliation': 'Department of Oncology, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Barbero', 'Affiliation': 'Department of Molecular Biotechnologies and Health Sciences - Hematology Division, Università di Torino, Torino, Italy.'}, {'ForeName': 'Domenico', 'Initials': 'D', 'LastName': 'Novero', 'Affiliation': 'First Unit of Pathology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Paulli', 'Affiliation': 'Unit of Anatomic Pathology, Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo and Università degli Studi di Pavia, Pavia, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Zamò', 'Affiliation': 'Department of Oncology, Università di Torino, Torino, Italy.'}, {'ForeName': 'Mats', 'Initials': 'M', 'LastName': 'Jerkeman', 'Affiliation': 'Department of Oncology, Lund University Hospital, Lund, Sweden.'}, {'ForeName': 'Maria Gomes', 'Initials': 'MG', 'LastName': 'da Silva', 'Affiliation': 'Department of Hematology, Instituto Português de Oncologia de Lisboa, Lisboa, Portugal.'}, {'ForeName': 'Armando', 'Initials': 'A', 'LastName': 'Santoro', 'Affiliation': 'Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.'}, {'ForeName': 'Annalia', 'Initials': 'A', 'LastName': 'Molinari', 'Affiliation': 'Hematology, Ospedale degli Infermi, Rimini, Italy.'}, {'ForeName': 'Andres', 'Initials': 'A', 'LastName': 'Ferreri', 'Affiliation': 'Lymphoma Unit, Department of Onco-Haematology, IRCCS San Raffaele Scientific Institute, Milano, Italy.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Grønbæk', 'Affiliation': 'Department of Hematology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Piccin', 'Affiliation': 'Department of Hematology, Ospedale Generale, Bolzano, Italy.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Cortelazzo', 'Affiliation': 'Oncology Unit, Humanitas/Gavazzeni Clinic, Bergamo, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Bertoni', 'Affiliation': ""Universita' della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Ladetto', 'Affiliation': 'SC Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Gaidano', 'Affiliation': 'Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.'}]",Haematologica,['10.3324/haematol.2018.214056'] 1070,31531707,Co-ingestion of whey protein hydrolysate with milk minerals rich in calcium potently stimulates glucagon-like peptide-1 secretion: an RCT in healthy adults.,"PURPOSE To examine whether calcium type and co-ingestion with protein alter gut hormone availability. METHODS Healthy adults aged 26 ± 7 years (mean ± SD) completed three randomized, double-blind, crossover studies. In all studies, arterialized blood was sampled postprandially over 120 min to determine GLP-1, GIP and PYY responses, alongside appetite ratings, energy expenditure and blood pressure. In study 1 (n = 20), three treatments matched for total calcium content (1058 mg) were compared: calcium citrate (CALCITR); milk minerals rich in calcium (MILK MINERALS); and milk minerals rich in calcium plus co-ingestion of 50 g whey protein hydrolysate (MILK MINERALS + PROTEIN). In study 2 (n = 6), 50 g whey protein hydrolysate (PROTEIN) was compared to MILK MINERALS + PROTEIN. In study 3 (n = 6), MILK MINERALS was compared to the vehicle of ingestion (water plus sucralose; CONTROL). RESULTS MILK MINERALS + PROTEIN increased GLP-1 incremental area under the curve (iAUC) by ~ ninefold (43.7 ± 11.1 pmol L -1  120 min; p < 0.001) versus both CALCITR and MILK MINERALS, with no difference detected between CALCITR (6.6 ± 3.7 pmol L -1  120 min) and MILK MINERALS (5.3 ± 3.5 pmol L -1  120 min; p > 0.999). MILK MINERALS + PROTEIN produced a GLP-1 iAUC ~ 25% greater than PROTEIN (p = 0.024; mean difference: 9.1 ± 6.9 pmol L -1  120 min), whereas the difference between MILK MINERALS versus CONTROL was small and non-significant (p = 0.098; mean difference: 4.2 ± 5.1 pmol L -1  120 min). CONCLUSIONS When ingested alone, milk minerals rich in calcium do not increase GLP-1 secretion compared to calcium citrate. Co-ingesting high-dose whey protein hydrolysate with milk minerals rich in calcium increases postprandial GLP-1 concentrations to some of the highest physiological levels ever reported. Registered at ClinicalTrials.gov: NCT03232034, NCT03370484, NCT03370497.",2020,"MILK MINERALS + PROTEIN produced a GLP-1 iAUC ~ 25% greater than PROTEIN (p = 0.024; mean difference: 9.1 ± 6.9 pmol L -1  120 min), whereas the difference between MILK MINERALS versus CONTROL was small and non-significant (p = 0.098; mean difference: 4.2 ± 5.1 pmol ","['Healthy adults aged 26\u2009±\u20097\xa0years (mean\u2009±\u2009SD', 'healthy adults', '50']","['calcium citrate (CALCITR); milk minerals rich in calcium (MILK MINERALS); and milk minerals rich in calcium plus', 'L -1', 'total calcium content', 'pmol\xa0L -1']","['increased GLP-1 incremental area under the curve (iAUC', 'GLP-1 secretion', 'GLP-1, GIP and PYY responses, alongside appetite ratings, energy expenditure and blood pressure']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]","[{'cui': 'C0108101', 'cui_str': 'Calcium Citrate'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0026162', 'cui_str': 'Minerals'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0673362', 'cui_str': 'L-1 (ester)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0439192', 'cui_str': 'pmol'}]","[{'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-Like Peptide 1'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0036537', 'cui_str': 'Secretions'}, {'cui': 'C1702020', 'cui_str': '37-epsilon-palmitoyl-Lys-GIP'}, {'cui': 'C0070358', 'cui_str': 'PYY Peptide'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C0014272', 'cui_str': 'Energy Expenditure'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}]",,0.024686,"MILK MINERALS + PROTEIN produced a GLP-1 iAUC ~ 25% greater than PROTEIN (p = 0.024; mean difference: 9.1 ± 6.9 pmol L -1  120 min), whereas the difference between MILK MINERALS versus CONTROL was small and non-significant (p = 0.098; mean difference: 4.2 ± 5.1 pmol ","[{'ForeName': 'Yung-Chih', 'Initials': 'YC', 'LastName': 'Chen', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'Harry A', 'Initials': 'HA', 'LastName': 'Smith', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'Hengist', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'Oliver J', 'Initials': 'OJ', 'LastName': 'Chrzanowski-Smith', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'Ulla Ramer', 'Initials': 'UR', 'LastName': 'Mikkelsen', 'Affiliation': 'Arla Foods Ingredients Group P/S, Viby J, Denmark.'}, {'ForeName': 'Harriet A', 'Initials': 'HA', 'LastName': 'Carroll', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Betts', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'Dylan', 'Initials': 'D', 'LastName': 'Thompson', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Saunders', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'Javier T', 'Initials': 'JT', 'LastName': 'Gonzalez', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK. J.T.Gonzalez@bath.ac.uk.'}]",European journal of nutrition,['10.1007/s00394-019-02092-4'] 1071,31960580,"Estimating the costs and cost-effectiveness of HIV self-testing among men who have sex with men, United States.","INTRODUCTION HIV testing is an essential prerequisite for accessing treatment with antiretroviral therapy or prevention using pre-exposure prophylaxis. Internet distribution of HIV self-tests is a novel approach, and data on the programmatic cost of this approach are limited. We analyse the costs and cost-effectiveness of a self-testing programme. METHODS Men who have sex with men (MSM) reporting unknown or negative HIV status were enrolled from March to August 2015 into a 12-month trial of HIV self-testing in the United States. Participants were randomly assigned either to the self-testing arm or the control arm. All participants received information on HIV testing services and locations in their community. Self-testing participants received up to four self-tests each quarter, which they could use themselves or distribute to their social network associates. Quarterly follow-up surveys collected testing outcomes, including number of tests used and new HIV diagnoses. Using trial expenditure data, we estimated the cost of implementing a self-testing programme. Primary outcomes of this analysis included total programme implementation costs, cost per self-test completed, cost per person tested, cost per new HIV diagnosis among those self-tested and cost per quality adjusted life year (QALY) saved. RESULTS A total of 2665 men were assigned either to the self-testing arm (n = 1325) or the control arm (n = 1340). HIV testing was reported by 971 self-testing participants who completed a total of 5368 tests. In the control arm, 619 participants completed 1463 HIV tests. The self-testing participants additionally distributed 2864 self-tests to 2152 social network associates. Testing during the trial identified 59 participants and social network associates with newly diagnosed HIV infection in the self-testing arm; 11 control participants were newly diagnosed with HIV. The implementation cost of the HIV self-testing programme was $449,510. The cost per self-test completed, cost per person tested at least once, and incremental cost per new HIV diagnosis was $61, $145 and $9365 respectively. We estimated that self-testing programme potentially averted 3.34 transmissions, saved 14.86 QALYs and nearly $1.6 million lifetime HIV treatment costs. CONCLUSIONS The HIV self-testing programme identified persons with newly diagnosed HIV infection at low cost, and the programme is cost saving.",2020,"The HIV self-testing programme identified persons with newly diagnosed HIV infection at low cost, and the programme is cost saving.","['971 self-testing participants who completed a total of 5368 tests', '619 participants completed 1463 HIV tests', 'Men who have sex with men (MSM) reporting unknown or negative HIV status were enrolled from March to August 2015 into a 12-month trial of HIV self-testing in the United States', '59 participants and social network associates with newly diagnosed HIV infection in the self-testing arm; 11 control participants were newly diagnosed with HIV', 'men who have sex with men, United States', 'A total of 2665 men']",['HIV self-testing'],"['number of tests used and new HIV diagnoses', 'total programme implementation costs, cost per self-test completed, cost per person tested, cost per new HIV diagnosis among those self-tested and cost per quality adjusted life year (QALY) saved', 'costs and cost-effectiveness', 'incremental cost per new HIV diagnosis']","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1321876', 'cui_str': 'Human immunodeficiency virus test (procedure)'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0439673', 'cui_str': 'Unknown (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0458074', 'cui_str': 'HIV status'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0019693', 'cui_str': 'T-Lymphotropic Virus Type III Infections, Human'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0036588', 'cui_str': 'Self'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0080071', 'cui_str': 'QALY'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",2665.0,0.0276086,"The HIV self-testing programme identified persons with newly diagnosed HIV infection at low cost, and the programme is cost saving.","[{'ForeName': 'Ram K', 'Initials': 'RK', 'LastName': 'Shrestha', 'Affiliation': 'Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Atlanta, GA, USA.'}, {'ForeName': 'Pollyanna R', 'Initials': 'PR', 'LastName': 'Chavez', 'Affiliation': 'Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Atlanta, GA, USA.'}, {'ForeName': 'Meredith', 'Initials': 'M', 'LastName': 'Noble', 'Affiliation': 'Evidence Solutions Group, Hayes Inc., Dallas, TX, USA.'}, {'ForeName': 'Stephanie L', 'Initials': 'SL', 'LastName': 'Sansom', 'Affiliation': 'Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Atlanta, GA, USA.'}, {'ForeName': 'Patrick S', 'Initials': 'PS', 'LastName': 'Sullivan', 'Affiliation': 'Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Jonathan H', 'Initials': 'JH', 'LastName': 'Mermin', 'Affiliation': 'Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Atlanta, GA, USA.'}, {'ForeName': 'Robin J', 'Initials': 'RJ', 'LastName': 'MacGowan', 'Affiliation': 'Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Atlanta, GA, USA.'}]",Journal of the International AIDS Society,['10.1002/jia2.25445'] 1072,30371826,Latent Structure of the Cigarette Purchase Task Among Treatment-Seeking Smokers With Depression and Its Predictive Validity on Smoking Abstinence.,"INTRODUCTION Research has recently shown that nicotine reinforcement is better characterized by a bifactorial latent structure: persistence (insensitivity to cigarette pricing) and amplitude (consumption at inexpensive prices). No study to date has examined its value as a predictor of abstinence. This study aimed to provide new evidence on the latent structure of the cigarette purchase task (CPT) in smokers with depressive symptoms and to examine whether the latent structure performs better as a predictor of continuous abstinence than do the individual indices. METHODS Participants (n = 205 smokers; 72% female: Beck Depression Inventory, Second Edition, M = 24.68, SD = 10.45) were randomized to two smoking cessation treatments for quitting smoking: cognitive behavioral treatment (CBT) or CBT + contingency management (CM). A principal-components analysis was conducted to examine the latent structure of the CPT and a set of regression models were performed to assess its predictive validity. RESULTS The principal-components analysis revealed a bifactorial solution, which was interpreted as persistence (breakpoint, Omax, Pmax, and elasticity) and psychological inertia (intensity and elasticity of demand). Evidence on the convergent validity was obtained through significant associations between the two latent factors and smoking variables (all r values ≥.17). Psychological inertia was negatively related to the number of days of continuous abstinence at the end of treatment regardless of the treatment condition [R2 = .038; F(2, 202) = 4.989, p = .008]. CONCLUSIONS Psychological inertia informs on which patients benefit less from smoking cessation treatments incorporating CM and CBT. Treatment components that affect individuals' excessive valuation of cigarettes might improve cessation outcomes. IMPLICATIONS This is the first attempt to examine the latent structure of the CPT in depressed smokers and to yield evidence on its predictive validity. A specific bifactorial solution exists for this population: persistence (breakpoint, Omax, Pmax, and elasticity) and psychological inertia (intensity and elasticity). Isolating demand indices and factors provides a high-resolution characterization of nicotine reinforcement for depressed smokers in that it informs on treatment response. Compared to the individual CPT indices, psychological inertia more effectively predicts which patients benefit most from either CM or CBT. Treatment components that affect individuals' excessive valuation of cigarettes (eg, episodic future thinking) should be integrated into smoking cessation treatments.",2020,"Psychological inertia was negatively related to the number of days of continuous abstinence at the end of treatment regardless of the treatment condition [R2 = .038; F(2, 202) =","['smokers with depressive symptoms', 'Methods\n\n\nParticipants [n = 205 smokers; 72% female: BDI-II M = 24.68, SD = 10.45']","['CPT', 'smoking cessation treatments for quitting smoking [Cognitive Behavioral Treatment (CBT) or CBT + Contingency Management (CM']","['Psychological inertia', 'number of days of continuous abstinence', 'Persistence (breakpoint, Omax, Pmax, elasticity) and Psychological inertia (intensity and elasticity of demand']","[{'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C4521399', 'cui_str': 'LT'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0546816', 'cui_str': 'Persistence (finding)'}, {'cui': 'C0013764'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}]",205.0,0.0248289,"Psychological inertia was negatively related to the number of days of continuous abstinence at the end of treatment regardless of the treatment condition [R2 = .038; F(2, 202) =","[{'ForeName': 'Alba', 'Initials': 'A', 'LastName': 'González-Roz', 'Affiliation': 'Department of Psychology, University of Oviedo, Oviedo, Spain.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Secades-Villa', 'Affiliation': 'Department of Psychology, University of Oviedo, Oviedo, Spain.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Weidberg', 'Affiliation': 'Department of Psychology, University of Oviedo, Oviedo, Spain.'}, {'ForeName': 'Ángel', 'Initials': 'Á', 'LastName': 'García-Pérez', 'Affiliation': 'Department of Psychology, University of Oviedo, Oviedo, Spain.'}, {'ForeName': 'Derek D', 'Initials': 'DD', 'LastName': 'Reed', 'Affiliation': 'Department of Applied Behavioral Science, University of Kansas, Lawrence, KS.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/nty236'] 1073,32428027,Effects of the Community Score Card approach on reproductive health service-related outcomes in Malawi.,"BACKGROUND Social accountability approaches are increasingly being employed in low-resource settings to improve government services. In line with the continuous quality improvement (CQI) philosophy that quality is the product of a linked chain, collaborative social accountability approaches like the Community Score Card (CSC) aim to empower clients and frontline service providers to transform their own lives and hold public officials to account for state obligations. Despite being a critical focus of collaborative social accountability approaches, to our knowledge, a quantitative survey of health workers to understand the impact of these approaches on their self-reported responsibilities and service provision has not been conducted. To fill this gap, we carried out a quantitative survey with health workers to assess the CSC's impact on health worker-reported service responsibilities and provision and complement women's self-reports. METHODS We evaluated the effect of the CSC on reproductive health-related outcomes using a cluster-randomized design in Ntcheu district, Malawi. We matched 10 pairs of health facilities and surrounding catchment communities; one from each pair was randomly assigned to the intervention and control arms. The intervention communities and health workers each completed 3-4 cycles of the CSC process by endline. We then surveyed all health workers in the 20 intervention and comparison sites at endline (n = 412) to estimate the intervention's impact. RESULTS Significantly (p < .05) more health workers in the CSC intervention areas compared to control areas reported responsibility for antenatal care, comprehensive antenatal care counseling, recording of the number of pregnant and postpartum women seen each month, and the average age of their last family planning client was younger. In addition, marginally significantly (p < .10) more health workers in treatment versus control areas report visiting women at their home at least once during their pregnancy. However, health worker-reported responsibility for HIV testing was significantly lower in intervention areas than in control. CONCLUSIONS The CSC aims to empower health workers to collaborate with the community and rest of the health system to identify and overcome the diverse and context-specific range of performance barriers they face. In doing so, it aims to support them to demand and ensure quality care for themselves from the health system so they can, in turn, deliver quality services to clients. Our results contribute to the evidence that the CSC may hold promise at improving service provision. While there is increasing evidence that collaborative social accountability approaches like the CSC are effective means to improving reproductive health-related service provision and outcomes in low-resource settings, additional research is needed.",2020,"Significantly (p < .05) more health workers in the CSC intervention areas compared to control areas reported responsibility for antenatal care, comprehensive antenatal care counseling, recording of the number of pregnant and postpartum women seen each month, and the average age of their last family planning client was younger.","['surveyed all health workers in the 20 intervention and comparison sites at endline (n = 412', 'reproductive health service-related outcomes in Malawi', 'We matched 10 pairs of health facilities and surrounding catchment communities']","['Community Score Card approach', 'CSC']",['health workers'],"[{'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C1136000', 'cui_str': 'Reproductive Health Services'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0024548', 'cui_str': 'Malawi'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1306056', 'cui_str': 'Worker'}]",,0.064098,"Significantly (p < .05) more health workers in the CSC intervention areas compared to control areas reported responsibility for antenatal care, comprehensive antenatal care counseling, recording of the number of pregnant and postpartum women seen each month, and the average age of their last family planning client was younger.","[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Gullo', 'Affiliation': 'CARE USA, Atlanta, Georgia, United States of America.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Galavotti', 'Affiliation': 'CARE USA, Atlanta, Georgia, United States of America.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Sebert Kuhlmann', 'Affiliation': 'College for Public Health & Social Justice, Saint Louis University, St. Louis, Missouri, United States of America.'}, {'ForeName': 'Thumbiko', 'Initials': 'T', 'LastName': 'Msiska', 'Affiliation': 'CARE Malawi, Lilongwe, Malawi.'}, {'ForeName': 'Phil', 'Initials': 'P', 'LastName': 'Hastings', 'Affiliation': 'Far Harbor, LLC, Austin, TX, United States of America.'}, {'ForeName': 'C Nathan', 'Initials': 'CN', 'LastName': 'Marti', 'Affiliation': 'Far Harbor, LLC, Austin, TX, United States of America.'}]",PloS one,['10.1371/journal.pone.0232868'] 1074,31568963,Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease.,"BACKGROUND AND AIMS In patients with cardiovascular disease, considerable residual risk remains despite evidence-based secondary prevention measures. Alkaline phosphatase (ALP) has been suggested as a modifiable cardiovascular risk factor. We sought to determine whether cardiovascular risk reduction by the bromodomain and extra-terminal (BET) protein inhibitor apabetalone is associated with the concomitant lowering of serum ALP. METHODS In a post-hoc analysis of 795 patients with established coronary heart disease and statin treatment, who participated in phase 2 placebo-controlled trials of apabetalone, we determined the effect of assigned treatment for up to 24 weeks on the incidence of major adverse cardiovascular events (MACE) and serum ALP. RESULTS Baseline ALP (median 72 U/L) predicted MACE (death, non-fatal myocardial infarction, coronary revascularization, or hospitalization for cardiovascular causes), independent of high-sensitivity C-reactive protein (hsCRP), sex, age, race, study, cardiovascular risk factors, chronic kidney disease (CKD), liver function markers and treatment allocation (hazard ratio [HR] per standard deviation [SD] 1.6, 95% CI 1.19-2.16, p = 0.002). Mean placebo-corrected decreases in ALP from baseline were 9.2% (p < 0.001) after 12-14 weeks and 7.7% (p < 0.001) after 24-26 weeks of apabetalone treatment. In the apabetalone group, a 1-SD reduction in ALP was associated with a HR for MACE of 0.64 (95% CI 0.46-0.90, p = 0.009). CONCLUSIONS Serum ALP predicts residual cardiovascular risk, independent of hsCRP, established cardiovascular risk factors and CKD, in patients with cardiovascular disease on statin treatment. Apabetalone lowers serum ALP, which was associated with a lower risk of cardiovascular events. Whether the beneficial cardiovascular effects of apabetalone are causally related to ALP reduction remains undetermined.",2019,"In the apabetalone group, a 1-SD reduction in ALP was associated with a HR for MACE of 0.64 (95% CI 0.46-0.90, p = 0.009). ","['patients with cardiovascular disease', '795 patients with established coronary heart disease and statin treatment, who participated in phase 2', 'patients with cardiovascular disease on statin treatment']","['placebo', 'Alkaline phosphatase (ALP']","['high-sensitivity C-reactive protein (hsCRP), sex, age, race, study, cardiovascular risk factors, chronic kidney disease (CKD), liver function markers and treatment allocation', '1-SD reduction in ALP', 'incidence of major adverse cardiovascular events (MACE) and serum ALP', 'cardiovascular risk', 'MACE (death, non-fatal myocardial infarction, coronary revascularization, or hospitalization for cardiovascular causes', 'cardiovascular risk reduction']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}, {'cui': 'C0010068', 'cui_str': 'Coronary Disease'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439560', 'cui_str': 'Phase 2 (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0002059', 'cui_str': 'Orthophosphoric-monoester phosphohydrolase (alkaline optimum)'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3853635', 'cui_str': 'Race (observable entity)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C0232741', 'cui_str': 'Liver function (observable entity)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0349381', 'cui_str': 'Mace (substance)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}]",795.0,0.170449,"In the apabetalone group, a 1-SD reduction in ALP was associated with a HR for MACE of 0.64 (95% CI 0.46-0.90, p = 0.009). ","[{'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Haarhaus', 'Affiliation': 'Division of Renal Medicine and Baxter Novum, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. Electronic address: mathias.loberg-haarhaus@sll.se.'}, {'ForeName': 'Kausik K', 'Initials': 'KK', 'LastName': 'Ray', 'Affiliation': 'Imperial Centre for Cardiovascular Disease Prevention, School of Public Health, Imperial College London, London, UK.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Nicholls', 'Affiliation': 'South Australian Health and Medical Research Institute, University of Adelaide, PO Box 11060, Adelaide, SA, 5001, Australia.'}, {'ForeName': 'Gregory G', 'Initials': 'GG', 'LastName': 'Schwartz', 'Affiliation': 'University of Colorado School of Medicine, Aurora, CO, USA.'}, {'ForeName': 'Ewelina', 'Initials': 'E', 'LastName': 'Kulikowski', 'Affiliation': 'Resverlogix Corp, Calgary, AB, Canada.'}, {'ForeName': 'Jan O', 'Initials': 'JO', 'LastName': 'Johansson', 'Affiliation': 'Resverlogix Inc, San Francisco, CA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Sweeney', 'Affiliation': 'Resverlogix Inc, San Francisco, CA, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Halliday', 'Affiliation': 'Resverlogix Corp, Calgary, AB, Canada.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Lebioda', 'Affiliation': 'Resverlogix Corp, Calgary, AB, Canada.'}, {'ForeName': 'Norman', 'Initials': 'N', 'LastName': 'Wong', 'Affiliation': 'Resverlogix Corp, Calgary, AB, Canada.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Brandenburg', 'Affiliation': 'Department of Cardiology and Nephrology, Rhein-Maas Klinikum Wuerselen, Wuerselen, Germany.'}, {'ForeName': 'Srinivasan', 'Initials': 'S', 'LastName': 'Beddhu', 'Affiliation': 'Division of Nephrology and Hypertension and Medical Service, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT, USA.'}, {'ForeName': 'Marcello', 'Initials': 'M', 'LastName': 'Tonelli', 'Affiliation': 'Department of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Carmine', 'Initials': 'C', 'LastName': 'Zoccali', 'Affiliation': 'CNR-IFC Clin Epid Renal Diseases and Hypertension, Reggio C. c/o Ospedali Riuniti, 89124, Reggio C. Italy.'}, {'ForeName': 'Kamyar', 'Initials': 'K', 'LastName': 'Kalantar-Zadeh', 'Affiliation': 'Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine Medical Center, Orange, CA, USA; Nephrology Section, Tibor Rubin Veterans Affairs Medical Center, Long Beach, CA, USA; Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA. Electronic address: kkz@uci.edu.'}]",Atherosclerosis,['10.1016/j.atherosclerosis.2019.09.002'] 1075,30457209,Genetic markers associated with long-term cardiovascular outcome in kidney transplant recipients.,"There is a clear genetic contribution to the risk of cardiovascular diseases, and a composite genetic risk score (GRS) based on 27 single nucleotide polymorphisms (SNPs) was reported to predict risk of cardiovascular events in the general population. We aimed to evaluate this risk score in renal transplant recipients, a population with heightened cardiovascular risk, with a yet unknown genetic contribution. A total of 1640 participants from the ALERT trial (Assessment of Lescol in Renal Transplantation), a study comparing fluvastatin with placebo in stable renal transplant recipients, were genotyped for all SNPs making up the GRS. Risk alleles were weighted by the log of odds ratios reported in genome wide association studies and summed. Associations between GRS and time from study inclusion to first major cardiovascular event (MACE) were analyzed by Cox regression. In analyses adjusted for cardiovascular risk factors, GRS was significantly associated with MACE (hazard ratio [HR] 1.81, P = .006) when comparing genetic high-risk patients (quartile 4) with genetic low-risk participants (quartile 1). A 27-SNP GRS, which predicted cardiovascular events in the nontransplant population, appears to have predictive value also in kidney allograft recipients. Refining the score to better fit the transplant population seems feasible.",2019,"A 27-SNP GRS, which predicted cardiovascular events in the nontransplant population, appears to have predictive value also in kidney allograft recipients.","['kidney allograft recipients', 'renal transplant recipients, a population with heightened cardiovascular risk', '1640 participants from the ALERT trial (Assessment of Lescol in Renal Transplantation', 'kidney transplant recipients', 'stable renal transplant recipients, were genotyped for all SNPs making up the GRS']",['fluvastatin with placebo'],"['cardiovascular risk factors, GRS']","[{'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0450127', 'cui_str': 'Allogeneic Grafts'}, {'cui': 'C0022671', 'cui_str': 'Grafting, Kidney'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0442803', 'cui_str': 'Heightened (qualifier value)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0591720', 'cui_str': 'Lescol'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C1285573', 'cui_str': 'Genotype determination'}, {'cui': 'C0752046', 'cui_str': 'Single Nucleotide Polymorphism'}]","[{'cui': 'C0082608', 'cui_str': 'fluvastatin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}]",1640.0,0.0288779,"A 27-SNP GRS, which predicted cardiovascular events in the nontransplant population, appears to have predictive value also in kidney allograft recipients.","[{'ForeName': 'Hege K', 'Initials': 'HK', 'LastName': 'Pihlstrøm', 'Affiliation': 'Section of Nephrology, Division of Surgery, Inflammatory Diseases and Transplantation, Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Geir', 'Initials': 'G', 'LastName': 'Mjøen', 'Affiliation': 'Section of Nephrology, Division of Surgery, Inflammatory Diseases and Transplantation, Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Sören', 'Initials': 'S', 'LastName': 'Mucha', 'Affiliation': 'Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, University Hospital Schleswig Holstein, Kiel, Germany.'}, {'ForeName': 'Andre', 'Initials': 'A', 'LastName': 'Franke', 'Affiliation': 'Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, University Hospital Schleswig Holstein, Kiel, Germany.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Jardine', 'Affiliation': 'British Heart Foundation, Glasgow Cardiovascular Research Centre, Glasgow, UK.'}, {'ForeName': 'Bengt', 'Initials': 'B', 'LastName': 'Fellström', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, Uppsala University Hospital, Uppsala, Sweden.'}, {'ForeName': 'Dag Olav', 'Initials': 'DO', 'LastName': 'Dahle', 'Affiliation': 'Section of Nephrology, Division of Surgery, Inflammatory Diseases and Transplantation, Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Hallvard', 'Initials': 'H', 'LastName': 'Holdaas', 'Affiliation': 'Section of Nephrology, Division of Surgery, Inflammatory Diseases and Transplantation, Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Espen', 'Initials': 'E', 'LastName': 'Melum', 'Affiliation': 'Norwegian PSC Research Center, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}]",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,['10.1111/ajt.15191'] 1076,19164438,Vertebral artery dissection with a normal-appearing lumen at multisection CT angiography: the importance of identifying wall hematoma.,"BACKGROUND AND PURPOSE CT angiography (CTA) is widely used and may be the only vascular imaging technique ordered for emergent evaluation of neurovascular disease. With thin-section multisection CTA, the resolution of vessel wall imaging has improved. We describe cases of acute vertebral artery dissection (VAD) in which the only abnormality on CTA was a characteristic thickening of the wall of the V3 portion of the vertebral artery (VA). The arterial lumen at the dissection site was normal in caliber. This type of dissection is easily overlooked if only lumen-opacifying studies such as contrast MR angiography (MRA) or conventional angiography are performed. We highlight the importance of recognizing this finding, the ""suboccipital rind"" sign, in the V3 portion, a segment commonly affected in VAD. The purpose of our study was to review the CTA imaging characteristics of patients with VAD in the V3 portion compared with normal controls. MATERIALS AND METHODS Our imaging data base was reviewed for cases of acute VAD and the presence of a ""suboccipital rind"" sign. A control group of 50 patients was randomly recruited from a group of patients undergoing CTA. The VA luminal diameter, the wall thickness (total diameter-luminal diameter), and the ratio of luminal diameter/total diameter were measured along 5 adjacent V3 segments and were compared between the 2 groups. RESULTS There was no evidence of luminal tapering or narrowing in the dissected VAs compared with controls (P = .1). The average wall thickness of the dissection group was 2.96 mm greater than that for the control group (P < .001; 95% confidence interval, 2.6-3.3). There was a significant difference in the ratio of lumen diameter/lumen+wall diameter in dissected segments compared with controls (P < .001). CONCLUSIONS Cross-sectional vascular imaging is often performed with multisection helical CTA for a variety of concerns, some without neurologic symptoms. Our study confirms that in cases of the ""suboccipital rind"" sign, the lumen appears normal in caliber, with wall thickening as the only imaging sign of VAD. In our center, this clinically occult VAD would influence management, with patients usually treated with antiplatelet agents. We caution against using only luminal-opacifying techniques such as contrast-enhanced MRA or conventional angiography to exclude VAD because they are limited in the evaluation of mural hematoma.",2009,There was no evidence of luminal tapering or narrowing in the dissected VAs compared with controls (P = .1).,"['patients with VAD in the V3 portion compared with normal controls', '50 patients was randomly recruited from a group of patients undergoing']","['Vertebral artery dissection with a normal-appearing lumen at multisection CT angiography', 'CTA', 'CT angiography (CTA']","['VA luminal diameter, the wall thickness (total diameter-luminal diameter), and the ratio of luminal diameter/total diameter', 'average wall thickness', 'luminal tapering or narrowing', 'ratio of lumen diameter/lumen+wall diameter']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0338586', 'cui_str': 'Dissecting Vertebral Artery Aneurysm'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C1536105', 'cui_str': 'Angiography, CT'}]","[{'cui': 'C0699493', 'cui_str': 'Luminal'}, {'cui': 'C1301886', 'cui_str': 'Diameter (qualifier value)'}, {'cui': 'C0205380', 'cui_str': 'Walled (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0441640', 'cui_str': 'Tapering - action (qualifier value)'}]",,0.0317208,There was no evidence of luminal tapering or narrowing in the dissected VAs compared with controls (P = .1).,"[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Lum', 'Affiliation': 'Department of Diagnostic Imaging-Diagnostic and Interventional Neuroradiology Section, Ottawa Hospital, Ottawa, Ontario, Canada. chlum@ottawahospital.on.ca'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Chakraborty', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Schlossmacher', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Santos', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Mohan', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Sinclair', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Sharma', 'Affiliation': ''}]",AJNR. American journal of neuroradiology,['10.3174/ajnr.A1455'] 1077,19001543,Effects of donepezil on cortical activation in mild cognitive impairment: a pilot double-blind placebo-controlled trial using functional MR imaging.,"BACKGROUND AND PURPOSE Cholinesterase-inhibitor therapy is approved for treatment of Alzheimer disease; however, application in patients with mild cognitive impairment (MCI) is still under active investigation. The purpose of this study was to determine the effect of such therapy on the neural substrates underlying memory processing in subjects with MCI by using functional MR imaging (fMRI). MATERIALS AND METHODS Thirteen subjects with MCI (mean age, 68 +/- 6.9 years) enrolled in a multicenter double-blind placebo-controlled trial testing the clinical efficacy of the cholinesterase-inhibitor, donepezil, were studied with fMRI at baseline and following 12 or 24 weeks of therapy (single-site pilot study). The cognitive paradigm was delayed-response visual memory for novel faces. Within-group 1-sample t tests were performed on the donepezil and placebo groups at baseline and at follow-up. A repeated-measures analysis of variance design was used to look for a Treatment Group x Time interaction showing a significant donepezil- but not placebo-related change in blood oxygen level-dependent response during the course of the study. RESULTS At baseline, both groups showed multiple areas of activation, including the bilateral dorsolateral prefrontal cortex, fusiform gyrus, and anterior cingulate cortex. On follow-up, the placebo group demonstrated a decreased extent of dorsolateral prefrontal activation, whereas the donepezil group demonstrated an increased extent of activation in the ventrolateral prefrontal cortex. Interaction demonstrated significant donepezil- but not placebo-related change in the left inferior frontal gyrus. CONCLUSIONS Despite the limitations inherent to a pilot study of a small sample, our results point to specific cortical substrates underlying the actions of donepezil, which can be tested in future studies.",2009,"At baseline, both groups showed multiple areas of activation, including the bilateral dorsolateral prefrontal cortex, fusiform gyrus, and anterior cingulate cortex.","['patients with mild cognitive impairment (MCI', 'subjects with MCI by using functional MR imaging (fMRI', 'mild cognitive impairment', 'Thirteen subjects with MCI (mean age, 68 ']","['placebo', 'donepezil', 'cholinesterase-inhibitor, donepezil', 'functional MR imaging', 'Cholinesterase-inhibitor therapy', 'donepezil and placebo']","['bilateral dorsolateral prefrontal cortex, fusiform gyrus, and anterior cingulate cortex', 'blood oxygen level', 'dorsolateral prefrontal activation', 'cortical activation']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C0560005', 'cui_str': 'millicurie'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0527316', 'cui_str': 'donepezil'}, {'cui': 'C4521309', 'cui_str': 'Cholinesterase inhibitor (disposition)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C4019080', 'cui_str': 'Dorsolateral Prefrontal Cortex'}, {'cui': 'C0228243', 'cui_str': 'Gyrus Fusiformis'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate'}, {'cui': 'C0005768'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C2983598', 'cui_str': 'Dorsolateral'}]",13.0,0.282773,"At baseline, both groups showed multiple areas of activation, including the bilateral dorsolateral prefrontal cortex, fusiform gyrus, and anterior cingulate cortex.","[{'ForeName': 'J R', 'Initials': 'JR', 'LastName': 'Petrella', 'Affiliation': ""Department of Radiology, Alzheimer's Disease Imaging Research Laboratory and Brain Imaging and Analysis Center, Duke University Medical Center, Duke University, Durham, NC 27710, USA. petre001@mc.duke.edu""}, {'ForeName': 'S E', 'Initials': 'SE', 'LastName': 'Prince', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Krishnan', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Husn', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Kelley', 'Affiliation': ''}, {'ForeName': 'P M', 'Initials': 'PM', 'LastName': 'Doraiswamy', 'Affiliation': ''}]",AJNR. American journal of neuroradiology,['10.3174/ajnr.A1359'] 1078,30506623,Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values.,"The purpose of this study was to determine the intrapatient (within the same patient) variability of tacrolimus in adherent patients. Daily tacrolimus trough levels were obtained at home using dried blood spot technology in kidney and liver transplant recipients. Patients were randomized to receive 3 formulations of tacrolimus, each for two 1-week periods. Adherence was monitored by patient diary, pill counts, and use of the Medication Event Monitoring System (MEMS). Variability was quantified as the coefficient of variation (CV). Comparison of CV between groups was by independent t test or one-way ANOVA as appropriate. The population was found to be adherent with a rate of 99.9% with a mean interval between the evening and morning dose of tacrolimus of 11.86 hours. The median CV for the entire population was 15.2% (range 4.8%-110%). There were no differences in CV by allograft type or tacrolimus formulation. The multivariate analysis did not identify any demographic characteristics associated with a CV > 30%. In a highly adherent population, tacrolimus did not display high intrapatient variability. Given the association between IPV and poor allograft outcomes, future studies are needed to quantitate the influence of adherence and establish target IPV goals.",2019,There were no differences in CV by allograft type or tacrolimus formulation.,"['adherent patients', 'stable adherent transplant recipients', 'kidney and liver transplant recipients']",['tacrolimus'],"['patient diary, pill counts, and use of the Medication Event Monitoring System (MEMS', 'Adherence', 'coefficient of variation (CV', 'median CV', 'Daily tacrolimus trough levels']","[{'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C1407119', 'cui_str': 'Transplant present'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C3811922', 'cui_str': 'Transplanted liver present (finding)'}]","[{'cui': 'C0085149', 'cui_str': 'Tacrolimus'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0376660', 'cui_str': 'Diary'}, {'cui': 'C0994475', 'cui_str': 'Pill (basic dose form)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C1979923', 'cui_str': 'Micro-Electro-Mechanical Systems'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0444506', 'cui_str': 'Trough (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",,0.0443996,There were no differences in CV by allograft type or tacrolimus formulation.,"[{'ForeName': 'Abbie D', 'Initials': 'AD', 'LastName': 'Leino', 'Affiliation': 'Division of Transplantation, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}, {'ForeName': 'Eileen C', 'Initials': 'EC', 'LastName': 'King', 'Affiliation': 'Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}, {'ForeName': 'Wenlei', 'Initials': 'W', 'LastName': 'Jiang', 'Affiliation': 'Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food & Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Alexander A', 'Initials': 'AA', 'LastName': 'Vinks', 'Affiliation': 'Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}, {'ForeName': 'Jost', 'Initials': 'J', 'LastName': 'Klawitter', 'Affiliation': 'iC42 Clinical Research and Development, University of Colorado, Aurora, Colorado.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Christians', 'Affiliation': 'iC42 Clinical Research and Development, University of Colorado, Aurora, Colorado.'}, {'ForeName': 'E Steve', 'Initials': 'ES', 'LastName': 'Woodle', 'Affiliation': 'Division of Transplantation, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}, {'ForeName': 'Rita R', 'Initials': 'RR', 'LastName': 'Alloway', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Rohan', 'Affiliation': ""Division of Hematology and Oncology, Children's Hospital of Richmond, Richmond, Virginia.""}]",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,['10.1111/ajt.15199'] 1079,31563038,Effects of acute psychosocial stress on the hypothalamic-pituitary-thyroid (HPT) axis in healthy women.,"OBJECTIVE The individual set point of the hypothalamic-pituitary-thyroid (HPT) axis is largely genetically determined. Apart from this genetic predisposition, the HPT axis may also be malleable to environmental demands such as psychosocial stress. Indeed, previous research has indicated that critical life events often precede the onset of autoimmune thyroid diseases, and subtle abnormalities in HPT functioning are present in some patients with stress-related disorders such as depression. However, no studies have investigated whether exposure to psychosocial stress leads to an immediate activation of the HPT axis. METHODS A total of N = 30 healthy women attended two laboratory appointments in a randomized order. An intravenous catheter was inserted at the beginning of each appointment. In the stress session, this was followed by the Trier Social Stress Test (TSST). Plasma samples to determine thyroid-stimulating hormone (TSH), triiodothyronine (T3), and thyroxine (T4) were taken at baseline and 20, 50, and 110 min after the TSST started. In the control session, participants rested and were instructed to read magazines, while the sampling schedule was maintained. RESULTS There was a significant rise in TSH concentrations in response to the TSST, with a peak observed 20 min after stressor onset, and a steady decline thereafter. No such response was observed in the control session. The TSST did not increase T3 or T4. CONCLUSION The finding that acute psychosocial stress is able to elicit a significant increase in TSH is relevant to our understanding of a number of stress-related illnesses presenting with abnormalities of the HPT axis.",2019,"There was a significant rise in TSH concentrations in response to the TSST, with a peak observed 20 min after stressor onset, and a steady decline thereafter.","['healthy women', 'A total of N\u202f=\u202f30 healthy women attended two laboratory appointments in a randomized order']","['acute psychosocial stress', 'TSST']","['TSH concentrations', 'Plasma samples to determine thyroid-stimulating hormone (TSH), triiodothyronine (T3), and thyroxine (T4']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C4284072', 'cui_str': 'Order (record artifact)'}]","[{'cui': 'C0038435', 'cui_str': 'Stress - value'}]","[{'cui': 'C0202230', 'cui_str': 'Thyroid stimulating hormone measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0444263', 'cui_str': 'Plasma specimen'}, {'cui': 'C0041014', 'cui_str': 'liothyronine'}, {'cui': 'C0202231', 'cui_str': 'Thyroxine measurement (procedure)'}]",30.0,0.0249151,"There was a significant rise in TSH concentrations in response to the TSST, with a peak observed 20 min after stressor onset, and a steady decline thereafter.","[{'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Fischer', 'Affiliation': 'University of Zurich, Institute of Psychology, Clinical Psychology and Psychotherapy, Switzerland. Electronic address: s.fischer@psychologie.uzh.ch.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Strahler', 'Affiliation': 'University of Giessen, Department of Psychology and Sport Science, Psychotherapy and Systems Neuroscience, Germany.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Markert', 'Affiliation': 'University of Giessen, Department of Psychology and Sport Science, Psychotherapy and Systems Neuroscience, Germany.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Skoluda', 'Affiliation': 'University of Vienna, Department of Psychology, Clinical Psychology, Austria.'}, {'ForeName': 'Johanna M', 'Initials': 'JM', 'LastName': 'Doerr', 'Affiliation': 'Department of Neurology, University Hospital Giessen and Marburg, Germany.'}, {'ForeName': 'Mattes', 'Initials': 'M', 'LastName': 'Kappert', 'Affiliation': 'University of Marburg, Department of Psychology, Clinical Biopsychology, Germany.'}, {'ForeName': 'Urs M', 'Initials': 'UM', 'LastName': 'Nater', 'Affiliation': 'University of Vienna, Department of Psychology, Clinical Psychology, Austria.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2019.104438'] 1080,32114513,Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study.,"INTRODUCTION To describe patient-reported outcomes and toxicities at time of treatment discontinuation secondary to progression or toxicities in advanced/recurrent cervical cancer patients receiving chemotherapy with bevacizumab. METHODS Summarize toxicity, grade, and health-related quality of life within 1 month of treatment discontinuation for women receiving chemotherapy with bevacizumab in GOG240. RESULTS Of the 227 patients who received chemotherapy with bevacizumab, 148 discontinued study protocol treatment (90 for disease progression and 58 for toxicity). The median survival time from treatment discontinuation to death was 7.9 months (95% CI 5.0 to 9.0) for those who progressed versus 12.1 months (95% CI 8.9 to 23.2) for those who discontinued therapy due to toxicities. The most common grade 3 or higher toxicities included hematologic, gastrointestinal, and pain. Some 57% (84/148) of patients completed quality of life assessment within 1 month of treatment discontinuation. Those patients who discontinued treatment due to progression had a mean decline in the FACT-Cx TOI of 3.2 points versus 2.2 in patients who discontinued therapy due to toxicity. This was a 9.9 point greater decline in the FACT-Cx TOI scores than those who discontinued treatment due to progression (95% CI 2.8 to 17.0, p=0.007). The decline in quality of life was due to worsening physical and functional well-being. Those who discontinued treatment due to toxicities had worse neurotoxicity and pain. DISCUSSION Patients who discontinued chemotherapy with bevacizumab for toxicity experienced longer post-protocol survival but significantly greater declination in quality of life than those with progression. Future trial design should include supportive care interventions that optimize physiologic function and performance status for salvage therapies.",2020,Those patients who discontinued treatment due to progression had a mean decline in the FACT-Cx TOI of 3.2 points versus 2.2 in patients who discontinued therapy due to toxicity.,"['advanced cervical cancer', '227 patients who received chemotherapy with bevacizumab, 148 discontinued study protocol treatment (90 for disease progression and 58 for toxicity', 'women receiving chemotherapy with bevacizumab in GOG240', 'advanced/recurrent cervical cancer patients receiving']","['chemotherapy with bevacizumab', 'bevacizumab']","['toxicities included hematologic, gastrointestinal, and pain', 'neurotoxicity and pain', 'quality of life assessment', 'toxicities', 'toxicity', 'quality of life', 'median survival time', 'FACT-Cx TOI scores']","[{'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C1706472', 'cui_str': 'Discontinue - dosing instruction imperative'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0242656', 'cui_str': 'Disease Progression'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}]","[{'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}]","[{'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205488', 'cui_str': 'Hematologic (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0235032', 'cui_str': 'Neurotoxin Diseases'}, {'cui': 'C0034380'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2919552', 'cui_str': 'Survival time'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",227.0,0.0254237,Those patients who discontinued treatment due to progression had a mean decline in the FACT-Cx TOI of 3.2 points versus 2.2 in patients who discontinued therapy due to toxicity.,"[{'ForeName': 'Dana', 'Initials': 'D', 'LastName': 'Chase', 'Affiliation': 'Arizona Oncology, Paradise Valley, California, USA dana.chase@usoncology.com.'}, {'ForeName': 'Helen Q', 'Initials': 'HQ', 'LastName': 'Huang', 'Affiliation': 'NRG Oncology Statistics and Data Management Center, Roswell Park Cancer Institute, Buffalo, New York, USA.'}, {'ForeName': 'Bradley J', 'Initials': 'BJ', 'LastName': 'Monk', 'Affiliation': 'Ob Gyn/Gyn Onc, Creighton University School of Medicine at St Josephs Hospital and Medical Center, Phoenix, Arizona, USA.'}, {'ForeName': 'Lois Michelle', 'Initials': 'LM', 'LastName': 'Ramondetta', 'Affiliation': 'Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Richard T', 'Initials': 'RT', 'LastName': 'Penson', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Gil', 'Affiliation': 'Psychology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.'}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Landrum', 'Affiliation': 'University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Leitao', 'Affiliation': 'Memorial Sloan-Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Oaknin', 'Affiliation': ""Vall d' Hebron Institute of Oncology, University Hospital, Barcelona, Spain.""}, {'ForeName': 'Warner K', 'Initials': 'WK', 'LastName': 'Huh', 'Affiliation': 'University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'Heather L', 'Initials': 'HL', 'LastName': 'Pulaski', 'Affiliation': 'Gynecological Oncology, University of Cincinnati, Cincinnati, Ohio, USA.'}, {'ForeName': 'Katina', 'Initials': 'K', 'LastName': 'Robison', 'Affiliation': 'Women and Infants Hospital of Rhode Island, Providence, Rhode Island, USA.'}, {'ForeName': 'Saketh R', 'Initials': 'SR', 'LastName': 'Guntupalli', 'Affiliation': 'Gynecologic Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Richardson', 'Affiliation': 'UT Southwestern Medical, Dallas, Texas, USA.'}, {'ForeName': 'Ritu', 'Initials': 'R', 'LastName': 'Salani', 'Affiliation': 'Ob/Gyn, Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Sill', 'Affiliation': 'NRG Oncology Statistics and Data Management Center, Roswell Park Cancer Institute, Buffalo, New York, USA.'}, {'ForeName': 'Lari B', 'Initials': 'LB', 'LastName': 'Wenzel', 'Affiliation': 'University of California Irvine School of Medicine, Irvine, California, USA.'}, {'ForeName': 'Krishnansu Sujata', 'Initials': 'KS', 'LastName': 'Tewari', 'Affiliation': 'University of California Irvine School of Medicine, Orange, California, USA.'}]",International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,['10.1136/ijgc-2019-000869'] 1081,32430771,Hypopharyngeal packing during adenotonsillectomy by cold dissection in children: a randomized controlled trial.,"PURPOSE Nausea and vomiting occur in up to 70% of children after adenotonsillectomy, ingested blood during procedure being one of the reasons for emesis. Hypopharyngeal packing (HP) is a common practice among otolaryngologists to prevent blood from being swallowed, but studies in nasal surgeries in adults failed to show efficacy of this technique in reducing postoperative nausea and vomiting (PONV). There are no studies evaluating the effect of HP in adenotonsillectomy in children. The aim of this study is to evaluate the efficacy HP during adenotonsillectomy in children in the prevention of PONV. METHODS This is a randomized, double-blinded, controlled trial. Children aged 4-16 years, scheduled for adenotonsillectomy due to sleep-disordered breathing were enrolled in Hospital da Criança Santo Antônio (Brazil). 192 participants were screened, while 129 were enrolled and completed follow-up for primary outcome. Patients were randomized in a consecutive manner to receive HP or not during adenotonsillectomy. PONV occurrence was assessed in the first 24 h after surgery in HP and control group and relative risk with 95% confidence interval was calculated. RESULTS There were 129 patients randomized, 64 in the HP and 65 in the control group. Female were 40.3% and mean ± SD age was 7.3 ± 2.9. Baseline characteristics and surgery variables were distributed similarly between the groups. Incidence of PONV was 20.3% in the HP and 23.1% in the control group. The relative risk for PONV was 0.88 (95% CI 0.46-1.70). CONCLUSION Our results suggest that there is no benefit of HP during adenotonsillectomy in children for the prevention of PONV. TRIAL REGISTRATION Brazilian Register of Randomized Trials (REBEC) identifier: RBR-3zjn27; Universal Trial Number U1111-1197-7461.",2020,The relative risk for PONV was 0.88,"['children', '129 patients randomized, 64 in the HP and 65 in the control group', 'children in the prevention of PONV', '192 participants were screened, while 129 were enrolled and completed follow-up for primary outcome', 'Female were 40.3% and mean\u2009±\u2009SD age was 7.3\u2009±\u20092.9', 'Children aged 4-16\xa0years, scheduled for adenotonsillectomy due to sleep-disordered breathing were enrolled in Hospital da Criança Santo Antônio (Brazil']","['HP or not during adenotonsillectomy', 'HP', 'Hypopharyngeal packing during adenotonsillectomy by cold dissection', 'adenotonsillectomy', 'Hypopharyngeal packing (HP']","['relative risk for PONV', 'PONV occurrence', 'postoperative nausea and vomiting (PONV', 'efficacy HP', 'Incidence of PONV']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1520439', 'cui_str': '129 Strain Mouse'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020629', 'cui_str': 'Hypopharyngeal structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517641', 'cui_str': '2.9'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0193959', 'cui_str': 'Tonsillectomy and adenoidectomy'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}]","[{'cui': 'C0020629', 'cui_str': 'Hypopharyngeal structure'}, {'cui': 'C0193959', 'cui_str': 'Tonsillectomy and adenoidectomy'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0012737', 'cui_str': 'Dissection - action'}]","[{'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0020629', 'cui_str': 'Hypopharyngeal structure'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",192.0,0.550873,The relative risk for PONV was 0.88,"[{'ForeName': 'Luciana Pimentel', 'Initials': 'LP', 'LastName': 'Oppermann', 'Affiliation': 'Department of Pediatric Otolaryngology of Hospital da Criança Santo Antônio/Postgraduate Program in Pediatrics, Irmandade da Santa Casa de Misericórdia de Porto Alegre/Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil. luopp24@hotmail.com.'}, {'ForeName': 'José Faibes', 'Initials': 'JF', 'LastName': 'Lubianca Neto', 'Affiliation': 'Department of Pediatric Otolaryngology of Hospital da Criança Santo Antônio/Postgraduate Program in Pediatrics, Irmandade da Santa Casa de Misericórdia de Porto Alegre/Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Renata Loss', 'Initials': 'RL', 'LastName': 'Drummond', 'Affiliation': 'Department of Pediatric Otolaryngology of Hospital da Criança Santo Antônio, Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Sérgio Luis', 'Initials': 'SL', 'LastName': 'Amantéa', 'Affiliation': 'Department of Pediatrics of Hospital da Criança Santo Antônio/Postgraduate Program in Pediatrics, Irmandade da Santa Casa de Misericórdia de Porto Alegre/Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Mariele', 'Initials': 'M', 'LastName': 'Bressan', 'Affiliation': 'Department of Otolaryngology, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Eduardo Esteves de Alcântara Marques', 'Initials': 'EEAM', 'LastName': 'Rodrigues', 'Affiliation': 'Department of Otolaryngology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Maira Isis Dos Santos', 'Initials': 'MIDS', 'LastName': 'Stangler', 'Affiliation': 'Department of Corporate Education in Nursing of Hospital da Criança Santo Antônio/Postgraduate Program in Pediatrics, Irmandade da Santa Casa de Misericórdia de Porto Alegre/Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.'}]",European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,['10.1007/s00405-020-06032-5'] 1082,32428983,Dietary interventions for multiple sclerosis-related outcomes.,"BACKGROUND Multiple sclerosis (MS) is a common demyelinating disease of the central nervous system. Although the exact pathogenesis remains unknown, the leading theory is that it results from immune system dysregulation. Approved disease-modifying therapy appears to modulate the immune system to improve MS-related outcomes. There is substantial interest in the ability of dietary interventions to influence MS-related outcomes. This is an update of the Cochrane Review 'Dietary interventions for multiple sclerosis' (Farinotti 2003; Farinotti 2007; Farinotti 2012). OBJECTIVES To assess the effects of dietary interventions (including dietary plans with recommendations for specific whole foods, macronutrients, and natural health products) compared to placebo or another intervention on health outcomes (including MS-related outcomes and serious adverse events) in people with MS. SEARCH METHODS On 30 May 2019, we searched CENTRAL, MEDLINE, Embase, and Web of Science. We also searched ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform (ICTRP), and Networked Digital Library of Theses and Dissertations (NDLTD). We checked reference lists in identified trials and requested information from trial authors to identify any additional published or unpublished data. SELECTION CRITERIA We included any randomized controlled trial (RCT) or controlled clinical trial (CCT) examining the effect of a dietary intervention versus placebo or another intervention among participants with MS on MS-related outcomes, including relapses, disability progression, and magnetic resonance imaging (MRI) measures. DATA COLLECTION AND ANALYSIS We used standard methodological procedures expected by Cochrane. Planned primary outcomes were number of participants experiencing relapse and change in disability progression, according to a validated disability scale at the last reported follow-up. Secondary outcomes included MRI activity, safety, and patient-reported outcomes. We entered and analysed data in Review Manager 5. MAIN RESULTS We found 41 full-text articles examining 30 trials following full-text review. Participants were adults with MS, defined by established criteria, presenting to MS clinics in Europe, North America, and the Middle East. Study design varied considerably, although all trials had at least one methodological issue leading to unknown or high risk of bias. Trials examined: supplementation to increase polyunsaturated fatty acids (PUFAs) (11 trials); a variety of antioxidant supplements (10 trials); dietary programmes (3 trials); and other dietary supplements (e.g. acetyl L-carnitine, biotin, creatine, palmitoylethanolamide, probiotic, riboflavin) (6 trials). In three trials comparing PUFAs with monounsaturated fatty acids (MUFAs), the evidence was very uncertain concerning difference in relapses (risk ratio (RR) 1.02, 95% confidence interval (CI) 0.88 to 1.20; 3 studies, 217 participants; 75% in the PUFA group versus 74% in the MUFA group; very low-certainty evidence). Among four trials comparing PUFAs with MUFAs, there may be little to no difference in global impression of deterioration (RR 0.85, 95% CI 0.71 to 1.03; 4 studies, 542 participants; 40% in the PUFA group versus 47% in the MUFA group; low-certainty evidence). In two trials comparing PUFAs with MUFAs (102 participants), there was very low-certainty evidence for change in disability progression. None of the PUFA versus MUFA trials examined MRI outcomes. In one trial comparing PUFAs with MUFAs (40 participants), there were no serious adverse events; based on low-certainty evidence. In two trials comparing different PUFAs (omega-3 versus omega-6), there may be little to no difference in relapses (RR 1.02, 95% CI 0.62 to 1.66; 2 studies, 129 participants; 30% in the omega-3 versus 29% in the omega-6 group; low-certainty evidence). Among three trials comparing omega-3 with omega-6, there may be little to no difference in change in disability progression, measured as mean change in Expanded Disability Status Scale (EDSS) (mean difference (MD) 0.00, 95% CI -0.30 to 0.30; 3 studies, 166 participants; low-certainty evidence). In one trial comparing omega-3 with omega-6, there was likely no difference in global impression of deterioration (RR 0.99, 95% CI 0.51 to 1.91; 1 study, 86 participants; 29% in omega-3 versus 29% in omega-6 group; moderate-certainty evidence). In one trial comparing omega-3 with omega-6 (86 participants), there was likely no difference in number of new T1- weighted gadolinium-enhancing lesions, based on moderate-certainty evidence. In four trials comparing omega-3 with omega-6, there may be little to no difference in serious adverse events (RR 1.12, 95% CI 0.38 to 3.31; 4 studies, 230 participants; 6% in omega-3 versus 5% in omega-6 group; low-certainty evidence). In four trials examining antioxidant supplementation with placebo, there may be little to no difference in relapses (RR 0.98, 95% CI 0.59 to 1.64; 4 studies, 345 participants; 17% in the antioxidant group versus 17% in the placebo group; low-certainty evidence). In six trials examining antioxidant supplementation with placebo, the evidence was very uncertain concerning change in disability progression, measured as mean change of EDSS (MD -0.19, 95% CI -0.49 to 0.11; 6 studies, 490 participants; very low-certainty evidence). In two trials examining antioxidant supplementation with placebo, there may be little to no difference in global impression of deterioration (RR 0.99, 95% 0.50 to 1.93; 2 studies, 190 participants; 15% in the antioxidant group versus 15% in the placebo group; low-certainty evidence). In two trials examining antioxidant supplementation with placebo, the evidence was very uncertain concerning difference in gadolinium-enhancing lesions (RR 0.67, 95% CI 0.09 to 4.88; 2 studies, 131 participants; 11% in the antioxidant group versus 16% in the placebo group; very low-certainty evidence). In three trials examining antioxidant supplementation versus placebo, there may be little to no difference in serious adverse events (RR. 0.72, 95% CI 0.17 to 3.08; 3 studies, 222 participants; 3% in the antioxidant group versus 4% in the placebo group; low-certainty evidence). AUTHORS' CONCLUSIONS There are a variety of controlled trials addressing the effects of dietary interventions for MS with substantial variation in active treatment, comparator, and outcomes of interest. PUFA administration may not differ when compared to alternatives with regards to relapse rate, disability worsening, or overall clinical status in people with MS, but evidence is uncertain. Similarly, at present, there is insufficient evidence to determine whether supplementation with antioxidants or other dietary interventions have any impact on MS-related outcomes.",2020,"PUFA administration may not differ when compared to alternatives with regards to relapse rate, disability worsening, or overall clinical status in people with MS, but evidence is uncertain.","['people with MS', 'Participants were adults with MS, defined by established criteria, presenting to MS clinics in Europe, North America, and the Middle East']","['PUFAs with monounsaturated fatty acids (MUFAs', 'antioxidant supplements (10 trials); dietary programmes (3 trials); and other dietary supplements (e.g. acetyl L-carnitine, biotin, creatine, palmitoylethanolamide, probiotic, riboflavin', 'supplementation to increase polyunsaturated fatty acids (PUFAs', 'dietary interventions', 'dietary intervention versus placebo', 'PUFA', 'PUFAs with MUFAs', 'omega-3 with omega-6', 'PUFAs (omega-3 versus omega-6', 'placebo']","['relapses, disability progression, and magnetic resonance imaging (MRI) measures', 'Expanded Disability Status Scale (EDSS) (mean difference (MD', 'global impression of deterioration', 'disability progression', 'serious adverse events', 'number of participants experiencing relapse and change in disability progression, according to a validated disability scale', 'health outcomes', 'relapses (risk ratio (RR', 'MRI activity, safety, and patient-reported outcomes', 'gadolinium-enhancing lesions']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C3839267', 'cui_str': 'Multiple sclerosis clinic'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C0026068', 'cui_str': 'Middle east country'}]","[{'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0001040', 'cui_str': 'Acetylcarnitine'}, {'cui': 'C0005575', 'cui_str': 'Biotin'}, {'cui': 'C0010286', 'cui_str': 'Creatine'}, {'cui': 'C0069964', 'cui_str': 'palmidrol'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0035527', 'cui_str': 'Riboflavin'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0032615', 'cui_str': 'Polyunsaturated fatty acid'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C1719844', 'cui_str': 'Omega'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0016911', 'cui_str': 'Gadolinium'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]",86.0,0.466002,"PUFA administration may not differ when compared to alternatives with regards to relapse rate, disability worsening, or overall clinical status in people with MS, but evidence is uncertain.","[{'ForeName': 'Natalie E', 'Initials': 'NE', 'LastName': 'Parks', 'Affiliation': 'Department of Medicine, Division of Neurology, Dalhousie University, Halifax, Canada.'}, {'ForeName': 'Caitlin S', 'Initials': 'CS', 'LastName': 'Jackson-Tarlton', 'Affiliation': 'Department of Medicine, Division of Neurology, Dalhousie University, Halifax, Canada.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Vacchi', 'Affiliation': 'Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.'}, {'ForeName': 'Roah', 'Initials': 'R', 'LastName': 'Merdad', 'Affiliation': 'Department of Community Health and Epidemiology, Dalhousie University, Halifax, Canada.'}, {'ForeName': 'Bradley C', 'Initials': 'BC', 'LastName': 'Johnston', 'Affiliation': 'Department of Nutrition, Texas A&M University, College Station, Texas, USA.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD004192.pub4'] 1083,31919898,"RE: Aliuskevicius M, Ostgaard SE, Hauge EM, et al. 2019. Influence of ibuprofen on bone healing after Colles' fracture: A randomized controlled clinical trial.",,2020,,"[""after Colles' fracture""]",['ibuprofen'],['bone healing'],"[{'cui': 'C0009353', 'cui_str': ""Colles' Fracture""}]","[{'cui': 'C0020740', 'cui_str': 'Ibuprofen'}]","[{'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}]",,0.051282,,"[{'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Starlinger', 'Affiliation': 'Department of Orthopedic Surgery, Mayo Clinic Rochester, Rochester, Minnesota.'}, {'ForeName': 'Joyce', 'Initials': 'J', 'LastName': 'Balls-Berry', 'Affiliation': 'Department of Education, Mayo Clinic Rochester, Rochester, Minnesota.'}, {'ForeName': 'Peter C', 'Initials': 'PC', 'LastName': 'Amadio', 'Affiliation': 'Department of Orthopedic Surgery, Mayo Clinic Rochester, Rochester, Minnesota.'}]",Journal of orthopaedic research : official publication of the Orthopaedic Research Society,['10.1002/jor.24582'] 1084,32035508,NELSON trial: reduced lung-cancer mortality with volume CT screening.,,2020,,[],['volume CT screening'],['lung-cancer mortality'],[],"[{'cui': 'C1956110', 'cui_str': 'Cone-Beam Computerized Tomography'}, {'cui': 'C0220908', 'cui_str': 'Screening'}]","[{'cui': 'C1306460', 'cui_str': 'Primary malignant neoplasm of lung'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",,0.0320646,,"[{'ForeName': 'Quintina', 'Initials': 'Q', 'LastName': 'Dawson', 'Affiliation': ''}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(20)30059-X'] 1085,32428840,Acute effects of time-restricted feeding in low-income women with obesity placed on hypoenergetic diets: Randomized trial.,"OBJECTIVE The aim of this study was to evaluate the acute effects of time-restricted feeding in obese women living in social vulnerability who were placed on diets with the same energy deficit. METHODS Fifty-eight obese women (19-44 y of age) were randomized to a group with a hypoenergetic diet and 12 h of fasting daily or to a group with only a hypoenergetic diet for 21 d, with body weight and waist circumference monitoring up to 81 d of intervention. The determination of the individual's energy content of the diets was based on their resting metabolic rate (by indirect calorimetry) and physical activity level (by triaxial accelerometers). Body composition, temperature, blood pressure, appetite, adhesion difficulty, thyroid axis hormones, leptin, glucose concentration, and insulin were measured before and after 21 d of intervention. A mixed analysis of variance test was performed. RESULTS The women had a mean age of 31 y and mean body mass index of 33 kg/m². Significant interaction between group × time was observed only in axillary temperature (0.44°C; 95% confidence interval [CI], 0.17-0.74°C; P < 0.01), which increased in the experimental group and in body fat (-0.75%; 95% CI, -1.43% to -0.07%; P = 0.02) decreased in the experimental group. Also, there was a significant decrease in waist circumference in the time-restricted feeding group after 81 d. There were no differences in hormonal profile, resting metabolic rate, reported appetite, or adherence difficulty. CONCLUSION Time-restricted feeding may be considered an alternative strategy for treating obesity in socially vulnerable women.",2020,"Significant interaction between group × time was observed only in axillary temperature (0.44°C; 95% confidence interval [CI], 0.17-0.74°C; P < 0.01), which increased in the experimental group and in body fat (-0.75%; 95% CI, -1.43% to -0.07%; P = 0.02) decreased in the experimental group.","['obese women living in social vulnerability who were placed on diets with the same energy deficit', 'low-income women with obesity placed on hypoenergetic diets', 'women had a mean age of 31 y and mean body mass index of 33 kg/m²', 'socially vulnerable women', 'Fifty-eight obese women (19-44 y of age']","['time-restricted feeding', 'hypoenergetic diet and 12 h of fasting daily or to a group with only a hypoenergetic diet']","['resting metabolic rate (by indirect calorimetry) and physical activity level', 'Body composition, temperature, blood pressure, appetite, adhesion difficulty, thyroid axis hormones, leptin, glucose concentration, and insulin', 'waist circumference', 'axillary temperature', 'hormonal profile, resting metabolic rate, reported appetite, or adherence difficulty', 'body fat']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0012655', 'cui_str': 'Diathesis'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517817', 'cui_str': '58'}]","[{'cui': 'C4704883', 'cui_str': 'Time Restricted Feeding'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0441835', 'cui_str': 'Group A'}]","[{'cui': 'C4082350', 'cui_str': 'Resting Metabolic Rate'}, {'cui': 'C0006781', 'cui_str': 'Indirect calorimetry'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0001511', 'cui_str': 'Adhesion'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0040132', 'cui_str': 'Thyroid structure'}, {'cui': 'C0004457', 'cui_str': 'Bone structure of axis'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0427743', 'cui_str': 'Glucose concentration, test strip measurement'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C1531924', 'cui_str': 'Axillary temperature'}, {'cui': 'C0458083', 'cui_str': 'Hormonal'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}]",58.0,0.0653357,"Significant interaction between group × time was observed only in axillary temperature (0.44°C; 95% confidence interval [CI], 0.17-0.74°C; P < 0.01), which increased in the experimental group and in body fat (-0.75%; 95% CI, -1.43% to -0.07%; P = 0.02) decreased in the experimental group.","[{'ForeName': 'Isabele R O M', 'Initials': 'IROM', 'LastName': 'Pureza', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, Cidade Universitária, Maceió, Alagoas, Brazil. Electronic address: isabelemaranhaonut@hotmail.com.'}, {'ForeName': 'Ingrid S V', 'Initials': 'ISV', 'LastName': 'Melo', 'Affiliation': 'Instituto Federal de Alagoas, Alagoas, Brazil. Electronic address: ingrid.melo@ifal.edu.br.'}, {'ForeName': 'Mateus L', 'Initials': 'ML', 'LastName': 'Macena', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, Cidade Universitária, Maceió, Alagoas, Brazil. Electronic address: m.l.macena@hotmail.com.'}, {'ForeName': 'Dafiny R S', 'Initials': 'DRS', 'LastName': 'Praxedes', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, Cidade Universitária, Maceió, Alagoas, Brazil. Electronic address: dafiny_rodrigues96@hotmail.com.'}, {'ForeName': 'Laís G L', 'Initials': 'LGL', 'LastName': 'Vasconcelos', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, Cidade Universitária, Maceió, Alagoas, Brazil. Electronic address: laisglv@gmail.com.'}, {'ForeName': 'André E', 'Initials': 'AE', 'LastName': 'Silva-Júnior', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, Cidade Universitária, Maceió, Alagoas, Brazil. Electronic address: andreeduardojr@hotmail.com.'}, {'ForeName': 'Telma M M T', 'Initials': 'TMMT', 'LastName': 'Florêncio', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, Cidade Universitária, Maceió, Alagoas, Brazil. Electronic address: telmatf_al@hotmail.com.'}, {'ForeName': 'Nassib B', 'Initials': 'NB', 'LastName': 'Bueno', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, Cidade Universitária, Maceió, Alagoas, Brazil. Electronic address: nassib.bueno@fanut.ufal.br.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110796'] 1086,31844967,"The effect of hesperidin supplementation on metabolic profiles in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial.","PURPOSE Hesperidin as an antioxidant flavonoid exerts anti-adipogenic, anti-inflammatory, anti-oxidant and anti-hypercholesterolemic effects. Besides, the increasing prevalence of metabolic syndrome (MetS) and its allied complications, on the one hand, and the willingness of individuals to use natural products for curing their diseases, on the other hand, led to the design of this study to evaluate the efficacy of hesperidin in normalizing the metabolic abnormalities in patients with MetS. METHODS In this clinical trial with a parallel-group design, 49 patients with MetS received either 500-mg hesperidin or placebo, twice daily, for 12 weeks. Number of participants with treated MetS was considered as a primary end point. Anthropometric parameters, dietary intake, physical activity, lipid profile, glucose homeostasis parameter, tumor necrosis factor alpha (TNF-α), high-sensitivity C-reactive protein (hs-CRP) were assessed at the beginning and at the end of the study. This trial is registered at clinicaltrials.gov as NCT03734874. RESULTS Compared with the placebo group, hesperidin decreased fasting glucose level (- 6.07 vs. - 13.32 mg/dL, P = 0.043), triglyceride (- 8.83 vs. - 49.09 mg/dL, P = 0.049), systolic blood pressure (- 0.58 vs. - 2.68 mmHg, P = 0.048) and TNF-α (- 1.29 vs. - 4.44 pg/mL, P = 0.009). Based on the within-group analysis, hesperidin led to significant decrease in serum levels of glucose, insulin, triglyceride, total cholesterol, low density lipoprotein cholesterol, TNF-α and hs-CRP, while in control group only glucose and insulin significantly decreased. CONCLUSIONS The results indicate that hesperidin supplementation can improve metabolic abnormalities and inflammatory status in patients with MetS.",2020,"Compared with the placebo group, hesperidin decreased fasting glucose level (- 6.07 vs. - 13.32 mg/dL, P = 0.043), triglyceride (- 8.83 vs. - 49.09 ","['patients with metabolic syndrome', '49 patients with MetS received either', 'patients with MetS']","['500-mg hesperidin or placebo', 'placebo', 'hesperidin supplementation']","['systolic blood pressure', 'Anthropometric parameters, dietary intake, physical activity, lipid profile, glucose homeostasis parameter, tumor necrosis factor alpha (TNF-α), high-sensitivity C-reactive protein (hs-CRP', 'triglyceride', 'TNF-α', 'serum levels of glucose, insulin, triglyceride, total cholesterol, low density lipoprotein cholesterol, TNF-α and hs-CRP', 'metabolic profiles', 'hesperidin decreased fasting glucose level', 'metabolic abnormalities and inflammatory status']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0524620', 'cui_str': 'Metabolic Syndrome X'}]","[{'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0019392', 'cui_str': 'Hesperidin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0019868', 'cui_str': 'Autoregulation'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0019392', 'cui_str': 'Hesperidin'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0428548', 'cui_str': 'Glucose level - finding'}, {'cui': 'C0000769', 'cui_str': 'anomalies'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]",49.0,0.167652,"Compared with the placebo group, hesperidin decreased fasting glucose level (- 6.07 vs. - 13.32 mg/dL, P = 0.043), triglyceride (- 8.83 vs. - 49.09 ","[{'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Yari', 'Affiliation': 'Student Research Committee, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mina', 'Initials': 'M', 'LastName': 'Movahedian', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology, Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Imani', 'Affiliation': 'Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran.'}, {'ForeName': 'Seyed Moayed', 'Initials': 'SM', 'LastName': 'Alavian', 'Affiliation': 'Middle East Liver Diseases (MELD) Center, Tehran, Iran.'}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Hedayati', 'Affiliation': 'Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Azita', 'Initials': 'A', 'LastName': 'Hekmatdoost', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology, Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Azita.Hekmatdoost@cw.bc.ca.'}]",European journal of nutrition,['10.1007/s00394-019-02105-2'] 1087,32061188,START: single-to-double arm transition design for phase II clinical trials.,"Phase II clinical trials designed for evaluating a drug's treatment effect can be either single-arm or double-arm. A single-arm design tests the null hypothesis that the response rate of a new drug is lower than a fixed threshold, whereas a double-arm scheme takes a more objective comparison of the response rate between the new treatment and the standard of care through randomization. Although the randomized design is the gold standard for efficacy assessment, various situations may arise where a single-arm pilot study prior to a randomized trial is necessary. To combine the single- and double-arm phases and pool the information together for better decision making, we propose a Single-To-double ARm Transition design (START) with switching hypotheses tests, where the first stage compares the new drug's response rate with a minimum required level and imposes a continuation criterion, and the second stage utilizes randomization to determine the treatment's superiority. We develop a software package in R to calibrate the frequentist error rates and perform simulation studies to assess the trial characteristics. Finally, a metastatic pancreatic cancer trial is used for illustrating the decision rules under the proposed START design.",2020,"A single-arm design tests the null hypothesis that the response rate of a new drug is lower than a fixed threshold, whereas a double-arm scheme takes a more objective comparison of the response rate between the new treatment and the standard of care through randomization.",[],[],[],[],[],[],,0.151021,"A single-arm design tests the null hypothesis that the response rate of a new drug is lower than a fixed threshold, whereas a double-arm scheme takes a more objective comparison of the response rate between the new treatment and the standard of care through randomization.","[{'ForeName': 'Haolun', 'Initials': 'H', 'LastName': 'Shi', 'Affiliation': 'Department of Statistics and Actuarial Science, Simon Fraser University, Burnaby, British Columbia, Canada.'}, {'ForeName': 'Teng', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Department of Statistics and Actuarial Science, The University of Hong Kong, Pok Fu Lam Road, Hong Kong.'}, {'ForeName': 'Guosheng', 'Initials': 'G', 'LastName': 'Yin', 'Affiliation': 'Department of Statistics and Actuarial Science, The University of Hong Kong, Pok Fu Lam Road, Hong Kong.'}]",Pharmaceutical statistics,['10.1002/pst.2005'] 1088,31981566,Change in Clinical Practice Associated With a Large Randomized Controlled Trial Comparing RBC Transfusion Strategies.,,2020,,[],[],[],[],[],[],,0.109654,,"[{'ForeName': 'Kevin M', 'Initials': 'KM', 'LastName': 'Trentino', 'Affiliation': 'School of Population and Global Health, University of Western Australia, Perth, Australia; Data and Digital Innovation, East Metropolitan Health Service, Perth, Australia. Electronic address: kevin.trentino@uwa.edu.au.'}, {'ForeName': 'Frank M', 'Initials': 'FM', 'LastName': 'Sanfilippo', 'Affiliation': 'School of Population and Global Health, University of Western Australia, Perth, Australia.'}, {'ForeName': 'Michael F', 'Initials': 'MF', 'LastName': 'Leahy', 'Affiliation': 'Department of Haematology, PathWest Laboratory Medicine, Royal Perth Hospital, Perth, Australia.'}, {'ForeName': 'Shannon L', 'Initials': 'SL', 'LastName': 'Farmer', 'Affiliation': 'Medical School and Division of Surgery, University of Western Australia, Perth, Australia; School of Health Sciences and Graduate Studies, Curtin University, Perth, Australia.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Gilfillan', 'Affiliation': 'Department of Cardiothoracic Surgery, Fiona Stanley Hospital, Perth, Australia.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Murray', 'Affiliation': 'School of Population and Global Health, University of Western Australia, Perth, Australia.'}]",Chest,['10.1016/j.chest.2020.01.004'] 1089,31986910,Understanding factors influencing antibiotic prescribing behaviour in rural China: a qualitative process evaluation of a cluster randomized controlled trial.,,2020,,['rural China'],[],[],"[{'cui': 'C0008115', 'cui_str': 'Mainland China'}]",[],[],,0.256765,,"[{'ForeName': 'Xiaolin', 'Initials': 'X', 'LastName': 'Wei', 'Affiliation': 'Dalla Lana Chair in Global Health Policy, Dalla Lana School of Public Health, University of Toronto, Canada.'}, {'ForeName': 'Simin', 'Initials': 'S', 'LastName': 'Deng', 'Affiliation': 'Research Associate, China Global Health Research and Development, China.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Haldane', 'Affiliation': 'Doctoral student, Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Canada.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Blacklock', 'Affiliation': 'Research Fellow, Nuffield Centre for International Health and Development, University of Leeds, UK.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Research Associate, China Global Health Research and Development, China.'}, {'ForeName': 'Zhitong', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Research Fellow, Dalla Lana School of Public Health, University of Toronto, Canada.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Walley', 'Affiliation': 'Professor of International Public Health, Nuffield Centre for International Health and Development, University of Leeds, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'King', 'Affiliation': 'Lecturer in International Health, Nuffield Centre for International Health and Development, University of Leeds, UK.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'Hicks', 'Affiliation': 'Lecturer in Medical Statistics, Nuffield Centre for International Health and Development, University of Leeds, UK.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Yin', 'Affiliation': 'Associate Professor, School of Health Care Management, Shandong University, China.'}, {'ForeName': 'Guanyang', 'Initials': 'G', 'LastName': 'Zou', 'Affiliation': 'Associate Professor, School of Economics and Management, Guangzhou University of Chinese Medicine, China.'}, {'ForeName': 'Yunayuan', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': 'Research Associate, China Global Health Research and Development, China.'}, {'ForeName': 'Mercy', 'Initials': 'M', 'LastName': 'Vergis', 'Affiliation': 'Research Fellow, Nuffield Centre for International Health and Development, University of Leeds, UK.'}, {'ForeName': 'Zeng', 'Initials': 'Z', 'LastName': 'Jun', 'Affiliation': 'Division Director, Guangxi Autonomous Region Centre for Disease Control and Prevention, China.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Sun', 'Affiliation': 'Professor and Dean, School of Health Care Management, Shandong University, China.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Lin', 'Affiliation': 'Director in General, Guangxi Autonomous Region Centre for Disease Control and Prevention, China.'}]",Journal of health services research & policy,['10.1177/1355819619896588'] 1090,32119790,Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Based on Total Daily Insulin in Adolescents with Type 1 Diabetes.,"Objective: To assess the safety and efficacy of a simplified initialization for the Tandem t:slim X2 Control-IQ hybrid closed-loop system, using parameters based on total daily insulin (""MyTDI"") in adolescents with type 1 diabetes under usual activity and during periods of increased exercise. Research Design and Methods: Adolescents with type 1 diabetes 12-18 years of age used Control-IQ for 5 days at home using their usual parameters. Upon arrival at a 60-h ski camp, participants were randomized to either continue Control-IQ using their home settings or to reinitialize Control-IQ with MyTDI parameters. Control-IQ use continued for 5 days following camp. The effect of MyTDI on continuous glucose monitoring outcomes were analyzed using repeated measures analysis of variance (ANOVA): baseline, camp, and at home. Results: Twenty participants were enrolled and completed the study; two participants were excluded from the analysis due to absence from ski camp (1) and illness (1). Time in range was similar between both groups at home and camp. A tendency to higher time <70 mg/dL in the MyTDI group was present but only during camp (median 3.8% vs. 1.4%, P  = 0.057). MyTDI users with bolus/TDI ratios >40% tended to show greater time in the euglycemic range improvements between baseline and home than users with ratios <40% (+16.3% vs. -9.0%, P  = 0.012). All participants maintained an average of 95% time in closed loop (84.1%-100%). Conclusions: MyTDI is a safe, effective, and easy way to determine insulin parameters for use in the Control-IQ artificial pancreas. Future modifications to account for the influence of carbohydrate intake on MyTDI calculations might further improve time in range.",2020,"MyTDI is a safe, effective, and easy way to determine insulin parameters for use in the Control-IQ artificial pancreas.","['Adolescents with Type 1 Diabetes', 'adolescents with type 1 diabetes under usual activity and during periods of increased exercise', 'Results: Twenty participants were enrolled and completed the study; two participants were excluded from the analysis due to absence from ski camp (1) and illness (1', 'Adolescents with type 1 diabetes 12-18 years of age used Control-IQ for 5 days at home using their usual parameters']","['Initializing the Control-IQ Artificial Pancreas System', 'simplified initialization for the Tandem t:slim X2 Control-IQ hybrid closed-loop system, using parameters based on total daily insulin (""MyTDI']","['euglycemic range improvements', 'continuous glucose monitoring outcomes', 'Safety and Efficacy', 'safety and efficacy']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C1689985', 'cui_str': 'Absence'}, {'cui': 'C0037262', 'cui_str': 'SKI (body structure)'}, {'cui': 'C0012054', 'cui_str': ""N',O'-Dibutyryl-cAMP""}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C2004457', 'cui_str': 'Artificial (qualifier value)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0075804', 'cui_str': 'TANDEM'}, {'cui': 'C0020205', 'cui_str': 'Hybrids'}, {'cui': 'C0443183', 'cui_str': 'Closed loop (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}]","[{'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C4523945', 'cui_str': 'Continuous glucose monitoring'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",2.0,0.0552424,"MyTDI is a safe, effective, and easy way to determine insulin parameters for use in the Control-IQ artificial pancreas.","[{'ForeName': 'Melissa J', 'Initials': 'MJ', 'LastName': 'Schoelwer', 'Affiliation': 'Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Robic', 'Affiliation': 'Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Thibault', 'Initials': 'T', 'LastName': 'Gautier', 'Affiliation': 'Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Fabris', 'Affiliation': 'Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Carr', 'Affiliation': 'Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Clancy-Oliveri', 'Affiliation': 'Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Sue A', 'Initials': 'SA', 'LastName': 'Brown', 'Affiliation': 'Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Stacey M', 'Initials': 'SM', 'LastName': 'Anderson', 'Affiliation': 'Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Mark D', 'Initials': 'MD', 'LastName': 'DeBoer', 'Affiliation': 'Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Daniel R', 'Initials': 'DR', 'LastName': 'Cherñavvsky', 'Affiliation': 'Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Marc D', 'Initials': 'MD', 'LastName': 'Breton', 'Affiliation': 'Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia.'}]",Diabetes technology & therapeutics,['10.1089/dia.2019.0471'] 1091,31523022,The effects of music therapy in patients undergoing septorhinoplasty surgery under general anesthesia.,"INTRODUCTION Music has been used for several years as a relaxation method to reduce stress and anxiety. It is a painless, safe, inexpensive and practical nonpharmacologic therapeutic modality, widely used all over the world. OBJECTIVES We aimed to evaluate the effect of music therapy on intraoperative awareness, patient satisfaction, awakening pain and waking quality in patients undergoing elective septorhinoplasty under general anesthesia. METHODS This randomized, controlled, prospective study was conducted with 120 patients undergoing septorhinoplasty within a 2 months period. The patients were randomly selected and divided into two groups: group music (music during surgery) and control group (without music during surgery). All patients underwent standard general anesthesia. Patients aged 18-70 years who would undergo a planned surgery under general anesthesia were included. Patients who had emergency surgery, hearing or cognitive impairment, were excluded from the study. RESULTS A total of 120 patients were enrolled, and separated into two groups. There were no statistically significant differences between the groups in terms of demographic characteristics, anesthesia and surgery durations (p>0.05). In the music group, sedation agitation scores were lower than those in the control group at the postoperative period (3.76±1.64 vs. 5.11±2.13; p<0.001). In addition; in patients of the music group, the pain level (2.73±1.28 vs. 3.61±1.40) was lower (p<0.001), requiring less analgesic drugs intake. CONCLUSION Music therapy, which is a nonpharmacologic intervention, is an effective method, without side effects, leading to positive effects in the awakening, hemodynamic parameters and analgesic requirements in the postoperative period. It is also effective in reducing the anxiety and intraoperative awareness episodes of surgical patients.",2020,"There were no statistically significant differences between the groups in terms of demographic characteristics, anesthesia and surgery durations (p>0.05).","['120 patients were enrolled, and separated into two groups', 'patients undergoing elective septorhinoplasty under general anesthesia', 'Patients aged 18-70 years who would undergo a planned surgery under general anesthesia were included', 'Patients who had emergency surgery, hearing or cognitive impairment, were excluded from the study', '120 patients undergoing septorhinoplasty within a 2 months period', 'patients undergoing septorhinoplasty surgery under general anesthesia']","['group music (music during surgery) and control group (without music during surgery', 'Music therapy', 'music therapy', 'standard general anesthesia']","['demographic characteristics, anesthesia and surgery durations', 'pain level', 'intraoperative awareness, patient satisfaction, awakening pain and waking quality', 'sedation agitation scores']","[{'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0443299', 'cui_str': 'Separate (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0189054', 'cui_str': 'Rhinoseptoplasty (procedure)'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0175673', 'cui_str': 'Emergency (qualifier value)'}, {'cui': 'C0338656', 'cui_str': 'Cognitive Dysfunction'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0026868', 'cui_str': 'Music Therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0002915', 'cui_str': 'General Anesthesia'}]","[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0919727', 'cui_str': 'Anesthesia Awareness'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0442696', 'cui_str': 'Waking (observable entity)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated (finding)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",120.0,0.0568432,"There were no statistically significant differences between the groups in terms of demographic characteristics, anesthesia and surgery durations (p>0.05).","[{'ForeName': 'Erhan', 'Initials': 'E', 'LastName': 'Gökçek', 'Affiliation': 'Diyarbakır Selahaddin Eyyübi State Hospital, Department of Anesthesiology and Reanimation, Diyarbakır, Turkey. Electronic address: gokcekerhan_44@hotmail.com.'}, {'ForeName': 'Ayhan', 'Initials': 'A', 'LastName': 'Kaydu', 'Affiliation': 'Diyarbakır Selahaddin Eyyübi State Hospital, Department of Anesthesiology and Reanimation, Diyarbakır, Turkey.'}]",Brazilian journal of otorhinolaryngology,['10.1016/j.bjorl.2019.01.008'] 1092,30327302,"PTEN Expression, Not Mutation Status in TSC1, TSC2 , or mTOR , Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial.","PURPOSE Genomic alterations in key components of PI3K/mTOR pathway have been proposed as candidate predictive markers for rapalog therapy in renal cell carcinoma (RCC). We tested this hypothesis in patients from a randomized phase II trial of everolimus versus sunitinib. PATIENTS AND METHODS Archival specimens collected at baseline were analyzed with targeted next-generation sequencing (NGS). Focus of interest were alterations in key PI3K pathway components. PTEN expression was assessed by IHC. Association between molecular findings and treatment outcomes was investigated; same associations were tested for 2 everolimus-treated trial cohorts in gastric and hepatocellular carcinoma (HCC). RESULTS Among 184 everolimus-treated patients with RCC with NGS data, mutation rates in genes of interest were 6% ( TSC1 ), 4.4% ( TSC2 ), and 8.2% ( mTOR ); 44% harbored alterations in ≥1 PI3K pathway component. For subjects with presence versus absence of mutations in TSC1, TSC2 , or mTOR progression-free survival (PFS) neither differed on univariate analysis (HR, 1.0; P = 0.895) nor on multivariate testing stratified by MSKCC risk group and other established prognostic factors (HR, 1.1; P = 0.806). Everolimus-treated patients with retained ( n = 50) versus lost ( n = 50) PTEN IHC expression had median PFS of 5.3 months versus 10.5 months (HR, 2.5; P < 0.001). Such differences were not seen with sunitinib (10.9 months vs. 10.3 months; HR, 0.8; P = 0.475). Molecular findings did not correlate with outcomes in gastric and HCC cohorts. CONCLUSIONS Association between mutation status for TSC1 / TSC2 / mTOR and therapeutic outcome on everolimus was not confirmed. Clinically meaningful differences in PFS were seen based on PTEN expression by IHC, lost in >50% of patients.",2019,"Such differences were not seen with sunitinib (10.9 months vs. 10.3 months; HR, 0.8; P = 0.475).","['Archival specimens collected at baseline were analyzed with targeted next-generation sequencing (NGS', 'Patients with Renal Cell Carcinoma', 'renal cell carcinoma (RCC']","['everolimus versus sunitinib', 'Everolimus']","['TSC1 / TSC2 / mTOR and therapeutic outcome on everolimus', 'median PFS', 'PTEN expression']","[{'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0007134', 'cui_str': 'Nephroid Carcinoma'}]","[{'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C1176020', 'cui_str': 'sunitinib'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3854321', 'cui_str': 'Expression'}]",,0.0535662,"Such differences were not seen with sunitinib (10.9 months vs. 10.3 months; HR, 0.8; P = 0.475).","[{'ForeName': 'Martin H', 'Initials': 'MH', 'LastName': 'Voss', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York City, New York. vossm@mskcc.org.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Chen', 'Affiliation': 'Novartis Oncology, East Hanover, New Jersey.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Reising', 'Affiliation': 'Novartis Oncology, East Hanover, New Jersey.'}, {'ForeName': 'Mahtab', 'Initials': 'M', 'LastName': 'Marker', 'Affiliation': 'Novartis Oncology, East Hanover, New Jersey.'}, {'ForeName': 'Jiayuan', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': 'Bristol-Myers Squibb Company, Hopewell township, New Jersey.'}, {'ForeName': 'Jianning', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York City, New York.'}, {'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Ostrovnaya', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York City, New York.'}, {'ForeName': 'Venkatraman E', 'Initials': 'VE', 'LastName': 'Seshan', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York City, New York.'}, {'ForeName': 'Almedina', 'Initials': 'A', 'LastName': 'Redzematovic', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York City, New York.'}, {'ForeName': 'Ying-Bei', 'Initials': 'YB', 'LastName': 'Chen', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York City, New York.'}, {'ForeName': 'Parul', 'Initials': 'P', 'LastName': 'Patel', 'Affiliation': 'Novartis Oncology, East Hanover, New Jersey.'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Han', 'Affiliation': 'Novartis Oncology, East Hanover, New Jersey.'}, {'ForeName': 'James J', 'Initials': 'JJ', 'LastName': 'Hsieh', 'Affiliation': 'Washington University, St. Louis, Missouri.'}, {'ForeName': 'A Ari', 'Initials': 'AA', 'LastName': 'Hakimi', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York City, New York.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Motzer', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York City, New York.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-18-1833'] 1093,32078037,"Incorrect design and analysis render conclusion unsubstantiated: comment on ""A digital movement in the world of inactive children: favourable outcomes of playing active video games in a pilot randomized trial"".",,2020,,[],[],[],[],[],[],,0.138104,,"[{'ForeName': 'Lilian', 'Initials': 'L', 'LastName': 'Golzarri-Arroyo', 'Affiliation': 'School of Public Health, Indiana University - Bloomington, Bloomington, IN, USA. lgolzarr@indiana.edu.'}, {'ForeName': 'Colby J', 'Initials': 'CJ', 'LastName': 'Vorland', 'Affiliation': 'School of Public Health, Indiana University - Bloomington, Bloomington, IN, USA.'}, {'ForeName': 'Lehana', 'Initials': 'L', 'LastName': 'Thabane', 'Affiliation': 'Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'J Michael', 'Initials': 'JM', 'LastName': 'Oakes', 'Affiliation': 'School of Public Health, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Ethan T', 'Initials': 'ET', 'LastName': 'Hunt', 'Affiliation': 'Department of Exercise Science, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.'}, {'ForeName': 'Andrew W', 'Initials': 'AW', 'LastName': 'Brown', 'Affiliation': 'School of Public Health, Indiana University - Bloomington, Bloomington, IN, USA.'}, {'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Allison', 'Affiliation': 'School of Public Health, Indiana University - Bloomington, Bloomington, IN, USA.'}]",European journal of pediatrics,['10.1007/s00431-020-03590-y'] 1094,32062872,Are People Sensitive to Problems in Communication?,"Recent research indicates that interpersonal communication is noisy, and that people exhibit considerable insensitivity to problems in communication. Using a dyadic referential communication task, the goal of which is accurate information transfer, this study examined the extent to which interlocutors are sensitive to problems in communication and use other-initiated repairs (OIRs) to address them. Participants were randomly assigned to dyads (N = 88 participants, or 44 dyads) and tried to communicate a series of recurring abstract geometric shapes to a partner across a text-chat interface. Participants alternated between directing (describing shapes) and matching (interpreting shape descriptions) roles across 72 trials of the task. Replicating prior research, over repeated social interactions communication success improved and the shape descriptions became increasingly efficient. In addition, confidence in having successfully communicated the different shapes increased over trials. Importantly, matchers were less confident on trials in which communication was unsuccessful, communication success was lower on trials that contained an OIR compared to those that did not contain an OIR, and OIR trials were associated with lower Director Confidence. This pattern of results demonstrates that (a) interlocutors exhibit (a degree of) sensitivity to problems in communication, (b) they appropriately use OIRs to address problems in communication, and (c) OIRs signal problems in communication.",2020,Participants alternated between directing (describing shapes) and matching (interpreting shape descriptions) roles across 72 trials of the task.,[],[],['communication success'],[],[],"[{'cui': 'C0009452', 'cui_str': 'Communication'}]",88.0,0.0499751,Participants alternated between directing (describing shapes) and matching (interpreting shape descriptions) roles across 72 trials of the task.,"[{'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Micklos', 'Affiliation': 'Language and Cognition Department, Max Planck Institute for Psycholinguistics.'}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Walker', 'Affiliation': 'School of Psychological Sciences, University of Western Australia.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Fay', 'Affiliation': 'School of Psychological Sciences, University of Western Australia.'}]",Cognitive science,['10.1111/cogs.12816'] 1095,31860756,Transition-Metal-Functionalized DNA Double-Crossover Tiles: Enhanced Stability and Chirality Transfer to Metal Centers.,"The double crossover junction (DX) is a fundamental building block for generating complex and varied structures from DNA. However, its implementation in functional devices is limited to the inherent properties of DNA itself. Here, we developed design strategies to generate the first metal-DX DNA tiles (DX M ) by site-specifically functionalizing the tile crossovers with tetrahedral binding pockets that coordinate Cu I . These DX junctions bind two Cu I ions independently at distinct sites, display greater thermal stability than native DX tiles upon metalation, and melt in a cooperative fashion. In addition, the right-handed helical chirality of DNA is transferred to the metal centers. Our tiles display high metal ion selectivity, such that Cu II is spontaneously reduced to Cu I in situ. By modifying our design over three generations of tiles, we elucidated the thermodynamic and geometric requirements for the successful assembly of DX M tiles, which have direct applicability in developing robust, stable DNA-based materials with electroactive, photoactive, and catalytic properties.",2020,"These DX junctions bind two Cu I ions independently at distinct sites, display greater thermal stability than native DX tiles upon metallation, and melt in a cooperative fashion.",[],['Transition Metal-Functionalized DNA'],[],[],"[{'cui': 'C1289927', 'cui_str': 'Metal (material)'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}]",[],,0.076231,"These DX junctions bind two Cu I ions independently at distinct sites, display greater thermal stability than native DX tiles upon metallation, and melt in a cooperative fashion.","[{'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Rousina-Webb', 'Affiliation': 'Department of Chemistry, McGill University, 801 Sherbrooke St W, Montreal, QC, H3A 0B8, Canada.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Lachance-Brais', 'Affiliation': 'Department of Chemistry, McGill University, 801 Sherbrooke St W, Montreal, QC, H3A 0B8, Canada.'}, {'ForeName': 'Felix J', 'Initials': 'FJ', 'LastName': 'Rizzuto', 'Affiliation': 'Department of Chemistry, McGill University, 801 Sherbrooke St W, Montreal, QC, H3A 0B8, Canada.'}, {'ForeName': 'Mohammad S', 'Initials': 'MS', 'LastName': 'Askari', 'Affiliation': 'Department of Chemistry, McGill University, 801 Sherbrooke St W, Montreal, QC, H3A 0B8, Canada.'}, {'ForeName': 'Hanadi F', 'Initials': 'HF', 'LastName': 'Sleiman', 'Affiliation': 'Department of Chemistry, McGill University, 801 Sherbrooke St W, Montreal, QC, H3A 0B8, Canada.'}]",Angewandte Chemie (International ed. in English),['10.1002/anie.201913956'] 1096,32102662,Effect of a polyphenol-rich dietary pattern on intestinal permeability and gut and blood microbiomics in older subjects: study protocol of the MaPLE randomised controlled trial.,"BACKGROUND During aging, alterations of the intestinal microbial ecosystem can occur contributing to immunosenescence, inflamm-aging and impairment of intestinal barrier function (increased intestinal permeability; IP). In the context of a diet-microbiota-IP axis in older subjects, food bioactives such as polyphenols may play a beneficial modulatory role. METHODS MaPLE is a project centered on a randomized, controlled cross-over dietary intervention trial [polyphenol-rich diet (PR-diet) versus control diet (C-diet)] targeted to older people (≥ 60 y) living in a well-controlled setting (i.e. nursing home). The 8-week interventions are separated by an 8-week wash-out period. Three small portions per day of selected polyphenol-rich foods are consumed during intervention in substitution of other comparable products within the C-diet. Biological samples are collected before and after each treatment period to evaluate markers related to IP, inflammation, vascular function, oxidative stress, gut and blood microbiomics, metabolomics. A sample size of 50 subjects was defined based on IP as primary outcome. DISCUSSION Evidence that increasing the consumption of polyphenol-rich food products can positively affect intestinal microbial ecosystem resulting in reduced IP and decreased translocation of inflammogenic bacterial factors into the bloodstream will be provided. The integration of data from gut and blood microbiomics, metabolomics and other IP-related markers will improve the understanding of the beneficial effect of the intervention in the context of polyphenols-microbiota-IP interactions. Finally, findings obtained will provide a proof of concept of the reliability of the dietary intervention, also contributing to future implementations of dietary guidelines directed to IP management in the older and other at risk subjects. TRIAL REGISTRATION The trial is registered at (ISRCTN10214981); April 28, 2017.",2020,"DISCUSSION Evidence that increasing the consumption of polyphenol-rich food products can positively affect intestinal microbial ecosystem resulting in reduced IP and decreased translocation of inflammogenic bacterial factors into the bloodstream will be provided.","['older subjects', 'older people (≥ 60 y) living in a well-controlled setting (i.e. nursing home']","['polyphenol-rich diet (PR-diet) versus control diet (C-diet', 'polyphenol-rich dietary pattern']","['IP, inflammation, vascular function, oxidative stress, gut and blood microbiomics, metabolomics', 'intestinal permeability and gut and blood microbiomics']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C3853142', 'cui_str': 'Well controlled'}, {'cui': 'C0028688', 'cui_str': 'Nursing Homes'}]","[{'cui': 'C0071649', 'cui_str': 'Polyphenol (substance)'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}]","[{'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0005768'}, {'cui': 'C1328813', 'cui_str': 'Metabolomic'}, {'cui': 'C0021853', 'cui_str': 'Intestines'}, {'cui': 'C0031164', 'cui_str': 'Permeability'}]",,0.0452674,"DISCUSSION Evidence that increasing the consumption of polyphenol-rich food products can positively affect intestinal microbial ecosystem resulting in reduced IP and decreased translocation of inflammogenic bacterial factors into the bloodstream will be provided.","[{'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Guglielmetti', 'Affiliation': 'Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, 20133, Milan, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Bernardi', 'Affiliation': 'Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, 20133, Milan, Italy.'}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': ""Del Bo'"", 'Affiliation': 'Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, 20133, Milan, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Cherubini', 'Affiliation': ""Geriatria, Accettazione Geriatrica e Centro di Ricerca per l'Invecchiamento, IRCCS INRCA, 60127, Ancona, Italy.""}, {'ForeName': 'Marisa', 'Initials': 'M', 'LastName': 'Porrini', 'Affiliation': 'Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, 20133, Milan, Italy.'}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'Gargari', 'Affiliation': 'Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, 20133, Milan, Italy.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Hidalgo-Liberona', 'Affiliation': 'Biomarkers and Nutrimetabolomics Laboratory, Department of Nutrition, Food Sciences and Gastronomy, Food Technology Reference Net (XaRTA), Nutrition and Food Safety Research Institute (INSA), Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028, Barcelona, Spain.'}, {'ForeName': 'Raul', 'Initials': 'R', 'LastName': 'Gonzalez-Dominguez', 'Affiliation': 'Biomarkers and Nutrimetabolomics Laboratory, Department of Nutrition, Food Sciences and Gastronomy, Food Technology Reference Net (XaRTA), Nutrition and Food Safety Research Institute (INSA), Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028, Barcelona, Spain.'}, {'ForeName': 'Gregorio', 'Initials': 'G', 'LastName': 'Peron', 'Affiliation': 'Biomarkers and Nutrimetabolomics Laboratory, Department of Nutrition, Food Sciences and Gastronomy, Food Technology Reference Net (XaRTA), Nutrition and Food Safety Research Institute (INSA), Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028, Barcelona, Spain.'}, {'ForeName': 'Raul', 'Initials': 'R', 'LastName': 'Zamora-Ros', 'Affiliation': 'Biomarkers and Nutrimetabolomics Laboratory, Department of Nutrition, Food Sciences and Gastronomy, Food Technology Reference Net (XaRTA), Nutrition and Food Safety Research Institute (INSA), Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028, Barcelona, Spain.'}, {'ForeName': 'Mark S', 'Initials': 'MS', 'LastName': 'Winterbone', 'Affiliation': 'Quadram Institute Bioscience, Norwich Research Park, Norwich, NR4 7UQ, UK.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Kirkup', 'Affiliation': 'Quadram Institute Bioscience, Norwich Research Park, Norwich, NR4 7UQ, UK.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Kroon', 'Affiliation': 'Quadram Institute Bioscience, Norwich Research Park, Norwich, NR4 7UQ, UK.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Andres-Lacueva', 'Affiliation': 'Biomarkers and Nutrimetabolomics Laboratory, Department of Nutrition, Food Sciences and Gastronomy, Food Technology Reference Net (XaRTA), Nutrition and Food Safety Research Institute (INSA), Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028, Barcelona, Spain.'}, {'ForeName': 'Patrizia', 'Initials': 'P', 'LastName': 'Riso', 'Affiliation': 'Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, 20133, Milan, Italy. patrizia.riso@unimi.it.'}]",BMC geriatrics,['10.1186/s12877-020-1472-9'] 1097,32427567,Mobile App for Symptom Management and Associated Quality of Life During Systemic Treatment in Early Stage Breast Cancer: Nonrandomized Controlled Prospective Cohort Study.,"BACKGROUND Providing patients with cancer who are undergoing systemic therapy with useful information about symptom management is essential to prevent unnecessary deterioration of quality of life. OBJECTIVE The aim was to evaluate whether use of an app for symptom management was associated with any change in patient quality of life or use of health resources. METHODS Outpatients with early stage breast cancer receiving systemic therapy were recruited at the Institute of Oncology in Ljubljana, Slovenia. Patients who received systemic therapy between December 2017 and March 2018 (control group) and between April 2018 and September 2018 (intervention group) were eligible. All patients received standard care, but only those in the intervention group were asked to use mPRO Mamma, an Android-based smartphone app, in addition. The app supported daily tracking of 50 symptoms, allowed users to grade their symptom severity (as mild, moderate, or severe), and also provided in-depth descriptions and recommendations based on reported symptom level. Patient-reported outcomes in both groups were assessed through the European Organisation for Research and Treatment of Cancer (EORTC) core (C-30) and breast cancer (BR-23) questionnaires, as well as a questionnaire about health resources use. The primary outcomes were the difference in the global quality of life between groups and the difference in summary score of the EORTC C-30 questionnaire between groups after 3 time periods (the first week of treatment, the first treatment cycle, and the entire treatment). The secondary outcome was the use of health resources (doctor visits and hospitalizations) in each time period. Other scales were used for exploratory analysis. RESULTS The mean difference between the intervention group (n=46) and the control group (n=45) in global quality of life (adjusted for baseline and type of surgery) after the first week was 10.1 (95% CI 1.8 to 18.5, P=.02). The intervention group summary scores were significantly higher than those of the control group after the first week (adjusted mean difference: 8.9, 95% CI 3.1 to 14.7, P=.003) and at the end of treatment (adjusted mean difference: 10.6, 95% CI 3.9 to 17.3, P=.002). Use of health resources was not statistically significant between the groups in either the first week (P=.12) or the first treatment cycle (P=.13). Exploratory analysis findings demonstrated clinically important improvements (indicated by EORTC C-30 or BR-23 scale scores)-social, physical, role, and cognitive function were improved while pain, appetite loss, and systemic therapy side effects were reduced. CONCLUSIONS Use of the app enabled patients undergoing systemic therapy for early stage breast cancer to better cope with symptoms which was demonstrated by a better global quality of life and summary score after the first week and by a better summary score at the end of treatment in the intervention group compared to those of the control group, but no change in the use of health resources was demonstrated.",2020,The difference in use of health resources (visits to the doctor and hospitalizations) between the groups was not statistically significant (in the first week: P=.12; in the first cycle: P=.13).,"['Early Breast Cancer', 'cancer patients undergoing', 'early breast cancer patients receiving systemic therapy in an outpatient setting at the Institute of Oncology Ljubljana, Slovenia']","['Mobile Application', 'mobile phone application', 'mobile application for Android smartphones and received the usual care, while the control group (n=45) received the usual care only', 'systemic therapy']","['Quality of Life', 'health resources (visits to the doctor and hospitalizations', 'social, physical, role and cognitive functioning', 'pain, appetite loss and systemic therapy side effects', 'global QoL and the summary score of the EORTC C-30 questionnaire', 'European Organisation for Research and Treatment of Cancer (EORTC) C-30 and BR-23 questionnaires, as well as Health Resource Usage Questionnaire', 'global QoL', 'use of health resources']","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0037334', 'cui_str': 'Slovenia'}]","[{'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0336541', 'cui_str': 'Android'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0018741', 'cui_str': 'Health Resources'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003123', 'cui_str': 'Anorexia'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0457083', 'cui_str': 'Usage'}, {'cui': 'C1524063', 'cui_str': 'Use of'}]",,0.071007,The difference in use of health resources (visits to the doctor and hospitalizations) between the groups was not statistically significant (in the first week: P=.12; in the first cycle: P=.13).,"[{'ForeName': 'Cvetka', 'Initials': 'C', 'LastName': 'Grašič Kuhar', 'Affiliation': 'Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Tjaša', 'Initials': 'T', 'LastName': 'Gortnar Cepeda', 'Affiliation': 'Faculty of Medicine Ljubljana, University of Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Timotej', 'Initials': 'T', 'LastName': 'Kovač', 'Affiliation': 'Faculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Matjaž', 'Initials': 'M', 'LastName': 'Kukar', 'Affiliation': 'Faculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Ružić Gorenjec', 'Affiliation': 'Institute for Biostatistics and Medical Informatics, Faculty of Medicine Ljubljana, University of Ljubljana, Ljubljana, Slovenia.'}]",JMIR mHealth and uHealth,['10.2196/17408'] 1098,31521520,Comparing effectiveness of polydeoxyribonucleotide injection and corticosteroid injection in plantar fasciitis treatment: A prospective randomized clinical study.,"BACKGROUND This study aimed to compare the efficacy and safety of polydeoxyribonucleotide (PDRN) injection and corticosteroid injection for plantar fasciitis. METHODS This study included 44 patients with plantar fasciitis, randomly allocated to the PDRN and corticosteroid groups. Evaluation using the visual analogue scale (VAS) pain score and Manchester-Oxford foot questionnaire (MOXFQ) was conducted at baseline, 1, 2, 6weeks and 6months. The thickness and echogenicity of the plantar fascia in ultrasonography and complications were recorded. RESULTS Corticosteroid injection elicited more pain relief than did PDRN injection at 2 (p=0.010) and 6weeks (p=0.016); however, it showed no superiority at 6months (p=0.523). MOXFQ showed similar outcomes. The thickness and echogenicity did not differ between groups and no complications were reported in either group. CONCLUSIONS We demonstrated that PDRN injection could be an effective and safe option for plantar fasciitis and was comparable to corticosteroid injection after 6months follow up. LEVEL OF EVIDENCE II, comparative study.",2020,"RESULTS Corticosteroid injection elicited more pain relief than did PDRN injection at 2 (p=0.010) and 6weeks (p=0.016); however, it showed no superiority at 6months (p=0.523).","['plantar fasciitis treatment', '44 patients with plantar fasciitis']","['polydeoxyribonucleotide (PDRN) injection and corticosteroid injection', 'polydeoxyribonucleotide injection and corticosteroid injection', 'MOXFQ', 'PDRN and corticosteroid', 'PDRN injection']","['effective and safe option for plantar fasciitis', 'pain relief', 'visual analogue scale (VAS) pain score and Manchester-Oxford foot questionnaire (MOXFQ', 'thickness and echogenicity', 'thickness and echogenicity of the plantar fascia in ultrasonography and complications']","[{'cui': 'C0149756', 'cui_str': ""Policeman's Heel""}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0032468', 'cui_str': 'Polydeoxyribonucleotides'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}]","[{'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0149756', 'cui_str': ""Policeman's Heel""}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C2732809', 'cui_str': 'Visual analog scale pain score (observable entity)'}, {'cui': 'C0016504', 'cui_str': 'Foot'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0549109', 'cui_str': 'Plantar fascia structure'}, {'cui': 'C0041618', 'cui_str': 'Echotomography'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}]",44.0,0.0362363,"RESULTS Corticosteroid injection elicited more pain relief than did PDRN injection at 2 (p=0.010) and 6weeks (p=0.016); however, it showed no superiority at 6months (p=0.523).","[{'ForeName': 'Dong-Oh', 'Initials': 'DO', 'LastName': 'Lee', 'Affiliation': 'Department of Orthopedic Surgery, Myongji Hospital, Hanyang University College of Medicine, 697-24 Hwajung-dong, Deokyang-gu, Goyang-si, Gyeonggi-do 10475, Republic of Korea. Electronic address: ronaki@naver.com.'}, {'ForeName': 'Jeong-Hyun', 'Initials': 'JH', 'LastName': 'Yoo', 'Affiliation': 'Department of Orthopedic Surgery, Myongji Hospital, Hanyang University College of Medicine, 697-24 Hwajung-dong, Deokyang-gu, Goyang-si, Gyeonggi-do 10475, Republic of Korea. Electronic address: yjh89331@mjh.or.kr.'}, {'ForeName': 'Hyung-In', 'Initials': 'HI', 'LastName': 'Cho', 'Affiliation': 'Department of Orthopedic Surgery, Myongji Hospital, Hanyang University College of Medicine, 697-24 Hwajung-dong, Deokyang-gu, Goyang-si, Gyeonggi-do 10475, Republic of Korea. Electronic address: 90candy-eye@hanmail.net.'}, {'ForeName': 'Soonghwan', 'Initials': 'S', 'LastName': 'Cho', 'Affiliation': 'Department of Orthopedic Surgery, Myongji Hospital, Hanyang University College of Medicine, 697-24 Hwajung-dong, Deokyang-gu, Goyang-si, Gyeonggi-do 10475, Republic of Korea. Electronic address: plushyy@naver.com.'}, {'ForeName': 'Hyung Rae', 'Initials': 'HR', 'LastName': 'Cho', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Myongji Hospital, Hanyang University College of Medicine, 697-24 Hwajung-dong, Deokyang-gu, Goyang-si, Gyeonggi-do 10475, Republic of Korea. Electronic address: callmex@hanmail.net.'}]",Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons,['10.1016/j.fas.2019.08.005'] 1099,32119742,Daily Preventive Zinc Supplementation Decreases Lymphocyte and Eosinophil Concentrations in Rural Laotian Children from Communities with a High Prevalence of Zinc Deficiency: Results of a Randomized Controlled Trial.,"BACKGROUND Zinc deficiency impairs immune function and is common among children in South-East Asia. OBJECTIVES The effect of zinc supplementation on immune function in young Laotian children was investigated. METHODS Children (n = 512) aged 6-23 mo received daily preventive zinc tablets (PZ; 7 mg Zn/d), daily multiple micronutrient powder (MNP; 10 mg Zn/d, 6 mg Fe/d, plus 13 other micronutrients), therapeutic dispersible zinc tablets only in association with diarrhea episodes (TZ; 20 mg Zn/d for 10 d after an episode), or daily placebo powder (control). These interventions continued for 9 mo. Cytokine production from whole blood cultures, the concentrations of T-cell populations, and a complete blood count with differential leukocyte count were measured at baseline and endline. Endline means were compared via ANCOVA, controlling for the baseline value of the outcome, child age and sex, district, month of enrollment, and baseline zinc status (below, or above or equal to, the median plasma zinc concentration). RESULTS T-cell cytokines (IL-2, IFN-γ, IL-13, IL-17), LPS-stimulated cytokines (IL-1β, IL-6, TNF-α, and IL-10), and T-cell concentrations at endline did not differ between intervention groups, nor was there an interaction with baseline zinc status. However, mean ± SE endline lymphocyte concentrations were significantly lower in the PZ than in the control group (5018 ± 158 compared with 5640 ± 160 cells/μL, P = 0.032). Interactions with baseline zinc status were seen for eosinophils (Pixn = 0.0036), basophils (Pixn = 0.023), and monocytes (P = 0.086) but a significant subgroup difference was seen only for eosinophils, where concentrations were significantly lower in the PZ than in the control group among children with baseline plasma zinc concentrations below the overall median (524 ± 44 compared with 600 ± 41 cells/μL, P = 0.012). CONCLUSIONS Zinc supplementation of rural Laotian children had no effect on cytokines or T-cell concentrations, although zinc supplementation affected lymphocyte and eosinophil concentrations. These cell subsets may be useful as indicators of response to zinc supplementation.This trial was registered at clinicaltrials.gov as NCT02428647.",2020,"RESULTS T-cell cytokines (IL-2, IFN-γ, IL-13, IL-17), LPS-stimulated cytokines (IL-1β, IL-6, TNF-α, and IL-10), and T-cell concentrations at endline did not differ between intervention groups, nor was there an interaction with baseline zinc status.","['Children (n\xa0=\xa0512) aged 6-23\xa0mo received', 'children in South-East Asia', 'rural Laotian children', 'young Laotian children', 'Rural Laotian Children from Communities with a High Prevalence of Zinc Deficiency']","['daily preventive zinc tablets (PZ; 7\xa0mg Zn/d), daily multiple micronutrient powder (MNP; 10\xa0mg Zn/d, 6\xa0mg', 'PZ', 'placebo powder (control', 'zinc supplementation', 'Daily Preventive Zinc Supplementation']","['T-cell cytokines (IL-2, IFN-γ, IL-13, IL-17), LPS-stimulated cytokines (IL-1β, IL-6, TNF-α, and IL-10), and T-cell concentrations', 'cytokines or T-cell concentrations', 'immune function', 'Lymphocyte and Eosinophil Concentrations', 'mean\xa0±\xa0SE endline lymphocyte concentrations', 'lymphocyte and eosinophil concentrations', 'complete blood count with differential leukocyte count']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0015631', 'cui_str': 'East Asia'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0235950', 'cui_str': 'Zinc deficiency (disorder)'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C1456501', 'cui_str': 'Preventive'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}, {'cui': 'C0032861', 'cui_str': 'Powdered drug preparation'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4524022', 'cui_str': 'Zinc supplementation'}]","[{'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C0021756', 'cui_str': 'TCGF'}, {'cui': 'C0214743', 'cui_str': 'IL13'}, {'cui': 'C0384648', 'cui_str': 'IL-17'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0439662', 'cui_str': 'Immune (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C4018897', 'cui_str': 'Lymphocyte component of blood'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil, segmented (cell)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0009555', 'cui_str': 'Complete Blood Count'}, {'cui': 'C0162401', 'cui_str': 'Leukocyte Count, Differential'}]",,0.450992,"RESULTS T-cell cytokines (IL-2, IFN-γ, IL-13, IL-17), LPS-stimulated cytokines (IL-1β, IL-6, TNF-α, and IL-10), and T-cell concentrations at endline did not differ between intervention groups, nor was there an interaction with baseline zinc status.","[{'ForeName': 'Chidchamai', 'Initials': 'C', 'LastName': 'Kewcharoenwong', 'Affiliation': 'The Centre for Research & Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Gertrud U', 'Initials': 'GU', 'LastName': 'Schuster', 'Affiliation': 'Institute for Global Nutrition, Department of Nutrition, University of California, Davis, CA, USA.'}, {'ForeName': 'K Ryan', 'Initials': 'KR', 'LastName': 'Wessells', 'Affiliation': 'Institute for Global Nutrition, Department of Nutrition, University of California, Davis, CA, USA.'}, {'ForeName': 'Guy-Marino', 'Initials': 'GM', 'LastName': 'Hinnouho', 'Affiliation': 'Institute for Global Nutrition, Department of Nutrition, University of California, Davis, CA, USA.'}, {'ForeName': 'Maxwell A', 'Initials': 'MA', 'LastName': 'Barffour', 'Affiliation': 'Institute for Global Nutrition, Department of Nutrition, University of California, Davis, CA, USA.'}, {'ForeName': 'Sengchanh', 'Initials': 'S', 'LastName': 'Kounnavong', 'Affiliation': ""Lao Tropical and Public Health Institute, Vientiane, Lao People's Democratic Republic.""}, {'ForeName': 'Kenneth H', 'Initials': 'KH', 'LastName': 'Brown', 'Affiliation': 'Institute for Global Nutrition, Department of Nutrition, University of California, Davis, CA, USA.'}, {'ForeName': 'Sonja Y', 'Initials': 'SY', 'LastName': 'Hess', 'Affiliation': 'Institute for Global Nutrition, Department of Nutrition, University of California, Davis, CA, USA.'}, {'ForeName': 'Waraporn', 'Initials': 'W', 'LastName': 'Samer', 'Affiliation': 'The Centre for Research & Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Inthira', 'Initials': 'I', 'LastName': 'Tussakhon', 'Affiliation': 'The Centre for Research & Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Janet M', 'Initials': 'JM', 'LastName': 'Peerson', 'Affiliation': 'Agricultural Research Service, Western Human Nutrition Research Center, USDA, Davis, CA, USA.'}, {'ForeName': 'Ganjana', 'Initials': 'G', 'LastName': 'Lertmemongkolchai', 'Affiliation': 'The Centre for Research & Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Charles B', 'Initials': 'CB', 'LastName': 'Stephensen', 'Affiliation': 'Institute for Global Nutrition, Department of Nutrition, University of California, Davis, CA, USA.'}]",The Journal of nutrition,['10.1093/jn/nxaa037'] 1100,32439823,Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials.,"We assessed whether oral insulin slowed metabolic decline after 1 year of treatment in individuals at high risk for type 1 diabetes. Two oral insulin trials that did not show efficacy overall and had type 1 diabetes as the primary end point were analyzed: the Diabetes Prevention Trial-Type 1 (DPT-1) and the TrialNet oral insulin trials. Oral glucose tolerance tests at baseline and after 1 year of treatment were analyzed. Among those at high risk (with a Diabetes Prevention Trial-Type 1 Risk Score [DPTRS] ≥6.75), the area under the curve (AUC) C-peptide increased significantly from baseline to 1 year in each oral insulin group, whereas the AUC glucose increased significantly in each placebo group. At 1 year, the AUC C-peptide/AUC glucose (AUC Ratio) was significantly higher in the oral insulin group than in the placebo group in each trial ( P < 0.05; P = 0.057 when adjusted for age in the TrialNet trial) and in both trials combined ( P < 0.01 with or without adjustment for age). For a DPTRS <6.75, oral insulin groups did not differ from placebo groups in the AUC Ratio. The findings suggest that 1 year of treatment with oral insulin slows metabolic deterioration in individuals at high risk for type 1 diabetes. Moreover, the findings further suggest that metabolic end points can be useful adjuncts to the diagnostic end point in assessments of preventive treatments for the disorder.",2020,AUC glucose was significantly higher (p<0.05) in the oral insulin group than in the placebo group in each trial,['individuals at high risk for type 1 diabetes'],"['oral insulin', 'placebo']","['AUC glucose', 'Slowed Metabolic Decline', 'AUC C-peptide', 'Oral glucose tolerance tests']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}]",,0.112215,AUC glucose was significantly higher (p<0.05) in the oral insulin group than in the placebo group in each trial,"[{'ForeName': 'Jay M', 'Initials': 'JM', 'LastName': 'Sosenko', 'Affiliation': 'University of Miami Miller School of Medicine, Miami, FL jsosenko@med.miami.edu.'}, {'ForeName': 'Jay S', 'Initials': 'JS', 'LastName': 'Skyler', 'Affiliation': 'University of Miami Miller School of Medicine, Miami, FL.'}, {'ForeName': 'Kevan C', 'Initials': 'KC', 'LastName': 'Herold', 'Affiliation': 'Yale University School of Medicine, New Haven, CT.'}, {'ForeName': 'Desmond A', 'Initials': 'DA', 'LastName': 'Schatz', 'Affiliation': 'University of Florida Diabetes Institute, Gainesville, FL.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Haller', 'Affiliation': 'University of Florida Diabetes Institute, Gainesville, FL.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Pugliese', 'Affiliation': 'University of Miami Miller School of Medicine, Miami, FL.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Cleves', 'Affiliation': 'University of South Florida, Tampa, FL.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Geyer', 'Affiliation': 'University of South Florida, Tampa, FL.'}, {'ForeName': 'Lisa E', 'Initials': 'LE', 'LastName': 'Rafkin', 'Affiliation': 'University of Miami Miller School of Medicine, Miami, FL.'}, {'ForeName': 'Della', 'Initials': 'D', 'LastName': 'Matheson', 'Affiliation': 'University of Miami Miller School of Medicine, Miami, FL.'}, {'ForeName': 'Jerry P', 'Initials': 'JP', 'LastName': 'Palmer', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes,['10.2337/db20-0166'] 1101,32435906,Evaluation of the effects of photobiomodulation therapy and ozone applications after gingivectomy and gingivoplasty on postoperative pain and patients' oral health-related quality of life.,"The aim of this study was to evaluate the effects of photobiomodulation therapy (PBM) and ozone applications on patients' quality of life after gingivectomy and gingivoplasty. In this study, 36 patients with chronic inflammatory gingival enlargement underwent gingivectomy and gingivoplasty. The groups were randomly divided into control (n = 12), PBM (n = 12) and ozone (n = 12) groups. GaAlAs diode laser 810 nm wavelength at a non-contact and continuous mode with a power of 0.3 W and a density of 4 J/cm 2 used for PBM for 1 min. Ozone was applied for 1 min for every 5 mm 2 in contact mode at power level 9 using probe number 3. PBM and ozone applications were performed immediately after the operation, on the 3rd and 7th days. Pain assessment was performed at 3rd, 7th, 14th and 28th days after gingivectomy and gingivoplasty by using visual analogue scale (VAS). Oral Health Impact Profile (OHIP-14) records were obtained from the patients before gingivectomy and gingivoplasty and postoperative 7th and 14th days. OHIP-14 questions were also evaluated individually. VAS pain levels of the control group measured on the 3rd day were higher than the PBM group and on the 7th day were found to be significantly higher than both groups (p < 0.05). The total OHIP-14 score of the control group on the 7th postoperative day was found to be higher than the PBM group (p < 0.05). The mean score obtained from the third question of OHIP-14 at 7th and 14th day of the PBM group was found to be lower than the control and ozone groups (p < 0.05). The PBM and ozone applications after gingivectomy and gingivoplasty reduce the pain levels of patients and have a positive effect on patients' quality of life.",2020,VAS pain levels of the control group measured on the 3rd day were higher than the PBM group and on the 7th day were found to be significantly higher than both groups (p < 0.05).,"[""patients' quality of life after gingivectomy and gingivoplasty"", '36 patients with chronic inflammatory gingival enlargement underwent gingivectomy and gingivoplasty']","['photobiomodulation therapy and ozone applications after gingivectomy and gingivoplasty', 'GaAlAs diode laser 810', 'photobiomodulation therapy (PBM) and ozone applications', 'PBM']","[""postoperative pain and patients' oral health-related quality of life"", 'pain levels', 'total OHIP-14 score', 'Pain assessment', 'VAS pain levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0017573', 'cui_str': 'Gingivectomy'}, {'cui': 'C0017576', 'cui_str': 'Gingivoplasty'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0017566', 'cui_str': 'Hyperplasia of gingiva'}]","[{'cui': 'C4019433', 'cui_str': 'Photobiomodulation Therapy'}, {'cui': 'C0030106', 'cui_str': 'Ozone'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0017573', 'cui_str': 'Gingivectomy'}, {'cui': 'C0017576', 'cui_str': 'Gingivoplasty'}, {'cui': 'C0392254', 'cui_str': 'Semiconductor laser device'}]","[{'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030198', 'cui_str': 'Pain assessment'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",36.0,0.014578,VAS pain levels of the control group measured on the 3rd day were higher than the PBM group and on the 7th day were found to be significantly higher than both groups (p < 0.05).,"[{'ForeName': 'Mustafa Özay', 'Initials': 'MÖ', 'LastName': 'Uslu', 'Affiliation': 'Faculty of Dentistry, Department of Periodontology, Inonu University, 44280, Malatya, Turkey. mustafaozayuslu@hotmail.com.'}, {'ForeName': 'Semih', 'Initials': 'S', 'LastName': 'Akgül', 'Affiliation': 'Malatya Şehit Mehmet Kılınç Oral And Dental Health Hospital, 44280, Malatya, Turkey.'}]",Lasers in medical science,['10.1007/s10103-020-03037-8'] 1102,31450175,"A randomized trial of the glottic views with the classic Miller, Wis-Hipple and C-MAC (videolaryngoscope and direct views) straight size 1 blades in young children.","STUDY OBJECTIVE The Miller and Wis-Hipple size 1 blades are widely used for laryngoscopy in children and the C-MAC straight blade is used increasingly in young children, although the glottic views with these blades have not been compared. To determine whether the glottic views with these blades are equivalent. DESIGN Equivalent study. SETTING Operating room. PATIENTS 96 children <2 years, ASA 1 or 2, elective surgery requiring orotracheal intubation. INTERVENTIONS Direct laryngoscopy with the Miller and Wis-Hipple or C-MAC (videolaryngoscope and direct view) straight blades size 1; photographs of the glottic opening. MEASUREMENTS Percent of glottic opening (POGO) was measured using a standardized scale by a blinded investigator. Heart rate, systolic blood pressure and hemoglobin oxygen saturation were measured before and after laryngoscopy. RESULTS The POGO scores with the four blades/views were equivalent (fewer than 20% of the views yielded POGO scores <80). However, a post hoc comparison of the POGO scores yielded significant differences (P = 0.0001); the C-MAC videolaryngoscope view yielded significantly better scores than the Miller, Wis-Hipple and direct C-MAC views (P = 0.0009, 0.0002 and 0.0001 respectively). The POGO score with the Miller blade was superior to that with the direct C-MAC view (P = 0.024). No adverse events or complications occurred. CONCLUSION The four blades/glottic views were equivalent, although a post hoc analysis demonstrated that the glottic view with the C-MAC videolaryngoscope was superior overall and the view with the Miller size 1 was superior to that with the direct C-MAC view.",2020,The POGO score with the Miller blade was superior to that with the direct C-MAC view (P = 0.024).,"['young children', '96 children <2 years, ASA 1 or 2, elective surgery requiring orotracheal intubation']","['Direct laryngoscopy with the Miller and Wis-Hipple or C-MAC (videolaryngoscope', 'classic Miller, Wis-Hipple and C-MAC (videolaryngoscope and direct views) straight size 1 blades']","['POGO score', 'Heart rate, systolic blood pressure and hemoglobin oxygen saturation', 'glottic opening (POGO', 'POGO scores']","[{'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0206058', 'cui_str': 'Elective Surgical Procedures'}, {'cui': 'C0396621', 'cui_str': 'Orotracheal intubation (procedure)'}]","[{'cui': 'C0392823', 'cui_str': 'Direct laryngoscopy (procedure)'}, {'cui': 'C0402830', 'cui_str': 'Miller (occupation)'}, {'cui': 'C0009545', 'cui_str': 'C5b-9'}, {'cui': 'C3164607', 'cui_str': 'Videolaryngoscope (physical object)'}, {'cui': 'C0439658', 'cui_str': 'Classic (qualifier value)'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0449911', 'cui_str': 'View (attribute)'}, {'cui': 'C1527360', 'cui_str': 'Heterosexuals'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C2948008', 'cui_str': 'Blade'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}]",96.0,0.0251883,The POGO score with the Miller blade was superior to that with the direct C-MAC view (P = 0.024).,"[{'ForeName': 'Hussein', 'Initials': 'H', 'LastName': 'Elattar', 'Affiliation': ""Department of Anesthesiology, Oishei Children's Outpatient Center, 1001 Main St. Suite K-3502, Buffalo 14203, United States of America; Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, New York, United States of America.""}, {'ForeName': 'Islam', 'Initials': 'I', 'LastName': 'Abdel-Rahman', 'Affiliation': ""Department of Anesthesiology, Oishei Children's Outpatient Center, 1001 Main St. Suite K-3502, Buffalo 14203, United States of America; Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, New York, United States of America.""}, {'ForeName': 'Muhammad', 'Initials': 'M', 'LastName': 'Ibrahim', 'Affiliation': ""Department of Anesthesiology, Oishei Children's Outpatient Center, 1001 Main St. Suite K-3502, Buffalo 14203, United States of America; Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, New York, United States of America.""}, {'ForeName': 'Remek', 'Initials': 'R', 'LastName': 'Kocz', 'Affiliation': ""Department of Anesthesiology, Oishei Children's Outpatient Center, 1001 Main St. Suite K-3502, Buffalo 14203, United States of America; Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, New York, United States of America.""}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Raczka', 'Affiliation': ""Department of Anesthesiology, Oishei Children's Outpatient Center, 1001 Main St. Suite K-3502, Buffalo 14203, United States of America; Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, New York, United States of America.""}, {'ForeName': 'Anuj', 'Initials': 'A', 'LastName': 'Kumar', 'Affiliation': ""Department of Anesthesiology, Oishei Children's Outpatient Center, 1001 Main St. Suite K-3502, Buffalo 14203, United States of America; Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, New York, United States of America.""}, {'ForeName': 'Baiba', 'Initials': 'B', 'LastName': 'Senbruna', 'Affiliation': ""Department of Anesthesiology, Oishei Children's Outpatient Center, 1001 Main St. Suite K-3502, Buffalo 14203, United States of America; Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, New York, United States of America.""}, {'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'Gensler', 'Affiliation': ""Department of Anesthesiology, Oishei Children's Outpatient Center, 1001 Main St. Suite K-3502, Buffalo 14203, United States of America; Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, New York, United States of America.""}, {'ForeName': 'Jerrold', 'Initials': 'J', 'LastName': 'Lerman', 'Affiliation': ""Department of Anesthesiology, Oishei Children's Outpatient Center, 1001 Main St. Suite K-3502, Buffalo 14203, United States of America; Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, New York, United States of America. Electronic address: Jerrold.lerman@gmail.com.""}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2019.08.009'] 1103,31507265,"Promoting vaccination in maternity wards ─ motivational interview technique reduces hesitancy and enhances intention to vaccinate, results from a multicentre non-controlled pre- and post-intervention RCT-nested study, Quebec, March 2014 to February 2015.","BackgroundMany countries are grappling with growing numbers of parents who delay or refuse recommended vaccinations for their children. This has created a need for strategies to address vaccine hesitancy (VH) and better support parental decision-making regarding vaccination.AimTo assess vaccination intention (VI) and VH among parents who received an individual motivational-interview (MI) based intervention on infant immunisation during post-partum stay at a maternity ward between March 2014 and February 2015.MethodsThis non-controlled pre-/post-intervention study was conducted using the results from parents enrolled in the intervention arm of the PromoVaQ randomised control trial (RCT), which was conducted in four maternity wards across the Province of Quebec. Participants (n = 1,223) completed pre- and post-intervention questionnaires on VI and VH using Opel's score. Pre-/post-intervention measures were compared using McNemar's test for categorical variables and Wilcoxon signed-rank test for continuous variables.ResultsPre-intervention: overall VI was 78% and significantly differed across maternity wards (74%, 77%, 84%, 79%, p = 0.02). Post-intervention: VI rose significantly across maternity wards (89%, 85%, 95%, 93%) and the overall increase in VI was 12% (78% vs 90%, p < 0.0001). VH corroborated these observations, pre- vs post-intervention, for each maternity ward (28% vs 16%, 29% vs 21%, 27% vs 17%, 24% vs 13%). Overall, VH was curbed post-intervention by 40% (27% vs 16%; p < 0.0001).ConclusionsCompared with pre-intervention status, participants who received the MI-based intervention on immunisation displayed lower hesitancy and greater intention to vaccinate their infant at 2 months of age.",2019,"Overall, VH was curbed post-intervention by 40% (27% vs 16%; p < 0.0001).ConclusionsCompared with pre-intervention status, participants who received the MI-based intervention on immunisation displayed lower hesitancy and greater intention to vaccinate their infant at 2 months of age.","['parents who received an', 'Participants (n\u2009=\u20091,223) completed', 'parents enrolled in the intervention arm of the PromoVaQ randomised control trial (RCT), which was conducted in four maternity wards across the Province of Quebec']","['Post-intervention', 'individual motivational-interview (MI) based intervention on infant immunisation during post-partum stay at a maternity ward between March 2014 and February 2015.MethodsThis non-controlled pre-/post-intervention', ""pre- and post-intervention questionnaires on VI and VH using Opel's score""]",[],"[{'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}, {'cui': 'C0034390', 'cui_str': 'Quebec'}]","[{'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0020971', 'cui_str': 'Sensitization, Immunologic'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",[],,0.133223,"Overall, VH was curbed post-intervention by 40% (27% vs 16%; p < 0.0001).ConclusionsCompared with pre-intervention status, participants who received the MI-based intervention on immunisation displayed lower hesitancy and greater intention to vaccinate their infant at 2 months of age.","[{'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Gagneur', 'Affiliation': 'Centre hospitalier universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.'}, {'ForeName': 'Marie-Claude', 'Initials': 'MC', 'LastName': 'Battista', 'Affiliation': 'Department of Medicine, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.'}, {'ForeName': 'François D', 'Initials': 'FD', 'LastName': 'Boucher', 'Affiliation': 'Centre de recherche du Centre Hospitalier Universitaire de Québec, Québec, Québec, Canada.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Tapiero', 'Affiliation': 'CHU Sainte Justine, Université de Montréal, Montréal, Québec, Canada.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Quach', 'Affiliation': 'McGill University Health Centre Research Institute - Vaccine Study Centre, Montréal, Québec, Canada.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'De Wals', 'Affiliation': 'Department of Social and Preventive Medicine, Laval University, Québec, Québec, Canada.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Lemaitre', 'Affiliation': 'Centre de recherche du CHUS, Sherbrooke, Québec, Canada.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Farrands', 'Affiliation': 'Centre de recherche du CHUS, Sherbrooke, Québec, Canada.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Boulianne', 'Affiliation': 'Institut national de santé publique du Québec, Québec, Québec, Canada.'}, {'ForeName': 'Chantal', 'Initials': 'C', 'LastName': 'Sauvageau', 'Affiliation': 'Institut national de santé publique du Québec, Québec, Québec, Canada.'}, {'ForeName': 'Manale', 'Initials': 'M', 'LastName': 'Ouakki', 'Affiliation': 'Institut national de santé publique du Québec, Québec, Québec, Canada.'}, {'ForeName': 'Virginie', 'Initials': 'V', 'LastName': 'Gosselin', 'Affiliation': 'Centre de recherche du CHUS, Sherbrooke, Québec, Canada.'}, {'ForeName': 'Geneviève', 'Initials': 'G', 'LastName': 'Petit', 'Affiliation': ""Direction de santé publique du CIUSSS de l'Estrie - CHUS, Département des sciences de la santé communautaire, Université de Sherbrooke, Sherbrooke, Québec, Canada.""}, {'ForeName': 'Marie-Claude', 'Initials': 'MC', 'LastName': 'Jacques', 'Affiliation': ""Institut universitaire de première ligne en santé et services sociaux du CIUSSS de l'Estrie - CHUS, Québec, Canada.""}, {'ForeName': 'Ève', 'Initials': 'È', 'LastName': 'Dubé', 'Affiliation': 'Institut national de santé publique du Québec, Québec, Québec, Canada.'}]",Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin,['10.2807/1560-7917.ES.2019.24.36.1800641'] 1104,31504982,Role of good oral hygiene on clinical evolution of rheumatoid arthritis: a randomized study nested in the ESPOIR cohort.,"OBJECTIVE There is a relationship between RA and periodontal disease. We aimed to investigate if a good oral hygiene could improve activity of RA. METHODS The patients with RA according to ACR/EULAR 2010 criteria and included in the French early arthritis ESPOIR cohort were included in a randomized nested study into: (i) intervention group: general recommendations of good oral hygiene including teeth brushing, daily antiseptic mouthwash and twice a year scaling; and (ii) control group: no intervention. The primary end point was the delta DAS28-ESR. RESULTS Four hundred and seventy-two patients were randomized (238 in intervention and 234 in control). 92/238 from the intervention group accepted the procedure and 81 had a first visit to the dentist. 56% of patients had periodontal disease at baseline. Duration of RA was 9.0±0.7 years. Baseline DAS28-ESR was 2.7±1.3. After a median duration of 24 months, delta DAS28-ESR was -0.17±1.29 and -0.09±1.28 in intervention and control groups, respectively (mean difference (complier average causal effect): -0.37 (95% CI -1.12, 0.37), P = 0.33). In the intervention group, there was a significant decrease of the bacteria involved in the red complex: Porphyromonas gingivalis (P = 0.002), Tannerella forsythia (P = 0.002) and Treponema denticola (P = 0.019). The patients with baseline periodontal disease and those who became negative for one red complex bacterium had a slightly more important decrease of DAS28-ESR. CONCLUSION Oral hygiene instruction together with regular scaling and polishing of the teeth significantly decreased the load of periodontal pathogens but did not decrease RA activity. This intervention should be tested in patients with earlier RA and more active disease. TRIAL REGISTRATION ClinicalTrials.gov, http://clinicaltrials.gov, NCT01831648.",2020,"In the intervention group, there was a significant decrease of the bacteria involved in the red complex: Porphyromonas gingivalis (P = 0.002), Tannerella forsythia (P = 0.002) and Treponema denticola (P = 0.019).","['patients with earlier RA and more active disease', 'rheumatoid arthritis', 'Four hundred and seventy-two patients were randomized (238 in intervention and 234 in control', 'patients with RA according to ACR/EULAR 2010 criteria and included in the French early arthritis ESPOIR cohort']","['good oral hygiene', 'intervention group: general recommendations of good oral hygiene including teeth brushing, daily antiseptic mouthwash and twice a year scaling; and (ii) control group: no intervention']","['DAS28-ESR', 'load of periodontal pathogens', 'bacteria involved in the red complex: Porphyromonas gingivalis', 'RA activity', 'Tannerella forsythia', 'Duration of RA', 'periodontal disease', 'delta DAS28-ESR', 'Treponema denticola']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid Arthritis'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C4319632', 'cui_str': 'Seventy-two'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1556084', 'cui_str': 'French (ethnic group)'}, {'cui': 'C3666006', 'cui_str': 'Arthritis (SMQ)'}]","[{'cui': 'C0457639', 'cui_str': 'Good oral hygiene (finding)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}, {'cui': 'C0443165', 'cui_str': 'Brushing, function (observable entity)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C3540796', 'cui_str': 'Antiseptic throat preparations'}, {'cui': 'C0026647', 'cui_str': 'Oral Rinse'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0450254', 'cui_str': 'Pathogen'}, {'cui': 'C1510439', 'cui_str': 'bacteria'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0332575', 'cui_str': 'Red color (finding)'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0206347', 'cui_str': 'Porphyromonas'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0314961', 'cui_str': 'Bacteroides forsythus'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0031090', 'cui_str': 'Parodontosis'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0318222', 'cui_str': 'Treponema denticola'}]",472.0,0.0855377,"In the intervention group, there was a significant decrease of the bacteria involved in the red complex: Porphyromonas gingivalis (P = 0.002), Tannerella forsythia (P = 0.002) and Treponema denticola (P = 0.019).","[{'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Mariette', 'Affiliation': 'Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Sud, INSERM UMR1184, Le Kremlin Bicêtre.'}, {'ForeName': 'Elodie', 'Initials': 'E', 'LastName': 'Perrodeau', 'Affiliation': 'Department of Epidemiology, Université Paris-Descartes, Paris.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Verner', 'Affiliation': 'Department of Periodontology, University of Nantes, Nantes.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Struillou', 'Affiliation': 'Department of Periodontology, University of Nantes, Nantes.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Picard', 'Affiliation': 'Private Practice, Rouen.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Schaeverbeke', 'Affiliation': 'Department of Rheumatology, Université de Bordeaux, Bordeaux.'}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Constantin', 'Affiliation': 'Department of Rheumatology, Hôpital Pierre-Paul Riquet and Université Toulouse III - Paul Sabatier, Toulouse.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Ravaud', 'Affiliation': 'Department of Epidemiology, Université Paris-Descartes, Paris.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Bouchard', 'Affiliation': 'Department of Periodontology, Service of Odontology, Rothschild Hospital, AP-HP, Denis Diderot University.'}]","Rheumatology (Oxford, England)",['10.1093/rheumatology/kez368'] 1105,31810829,Effects of Accessible Health Technology and Caregiver Support Posthospitalization on 30-Day Readmission Risk: A Randomized Trial.,"INTRODUCTION Patients with chronic illness often require ongoing support postdischarge. This study evaluated a simple-to-use, mobile health-based program designed to improve postdischarge follow-up via (1) tailored communication to patients using automated calls, (2) structured feedback to informal caregivers, and (3) automated alerts to clinicians about urgent problems. METHODS A total of 283 patients with common medical diagnoses, including chronic obstructive pulmonary disease, coronary artery disease, pneumonia, and diabetes, were recruited from a university hospital, a community hospital, and a US Department of Veterans Affairs hospital. All patients identified an informal caregiver or ""care partner"" (CP) to participate in their postdischarge support. Patient-CP dyads were randomized to the intervention or usual care. Intervention patients received weekly automated assessment and behavior change calls. CPs received structured e-mail feedback. Outpatient clinicians received fax alerts about serious problems. Primary outcomes were 30-day readmission rate and the combined outcome of readmission/emergency department (ED) use. Information about postdischarge outpatient visits, rehospitalizations, and ED encounters was obtained from medical records. RESULTS Overall, 11.4% of intervention patients and 17.9% of controls were rehospitalized within 30 days postdischarge (hazard ratio [HR]: 0.59; 95% confidence interval [CI]: 0.31-1.11; p = 0.102). Compared to intervention patients with other illnesses, those with pulmonary diagnoses generated the most clinical alerts (p = 0.004). Pulmonary patients in the intervention group showed significantly reduced 30-day risk of rehospitalization relative to controls (HR: 0.31; 95% CI: 0.11-0.87; p = 0.026). CONCLUSION The CP intervention did not improve 30-day readmission rates overall, although post hoc analyses suggested that it may be promising among patients with pulmonary diagnoses.",2020,"Compared to intervention patients with other illnesses, those with pulmonary diagnoses generated the most clinical alerts (p = 0.004).","['Patients with chronic illness', 'Patient-CP dyads', 'All patients identified an informal caregiver or ""care partner"" (CP) to participate in their postdischarge support', 'patients with pulmonary diagnoses', '283 patients with common medical diagnoses, including chronic obstructive pulmonary disease, coronary artery disease, pneumonia, and diabetes, were recruited from a university hospital, a community hospital, and a US Department of Veterans Affairs hospital']","['CP intervention', 'Accessible Health Technology and Caregiver Support Posthospitalization', 'mobile health-based program designed to improve postdischarge follow-up via (1) tailored communication to patients using automated calls, (2) structured feedback to informal caregivers, and (3) automated alerts to clinicians about urgent problems']","['30-day risk of rehospitalization relative', '30-Day Readmission Risk', '30-day readmission rates', '30-day readmission rate and the combined outcome of readmission/emergency department (ED) use']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C1319882', 'cui_str': 'Informal caregiver'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C4708786', 'cui_str': '283'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0020003', 'cui_str': 'Community hospital'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0752189', 'cui_str': 'Health Care Technology'}, {'cui': 'C0150162', 'cui_str': 'Caregiver support'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C1319882', 'cui_str': 'Informal caregiver'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0033213', 'cui_str': 'Problem'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0030700', 'cui_str': 'Thirty Day Readmission'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",283.0,0.0842126,"Compared to intervention patients with other illnesses, those with pulmonary diagnoses generated the most clinical alerts (p = 0.004).","[{'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Piette', 'Affiliation': ''}, {'ForeName': 'Dana', 'Initials': 'D', 'LastName': 'Striplin', 'Affiliation': ''}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Fisher', 'Affiliation': ''}, {'ForeName': 'James E', 'Initials': 'JE', 'LastName': 'Aikens', 'Affiliation': ''}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'Nicolle', 'Initials': 'N', 'LastName': 'Marinec', 'Affiliation': ''}, {'ForeName': 'Madhura', 'Initials': 'M', 'LastName': 'Mansabdar', 'Affiliation': ''}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Lynn A', 'Initials': 'LA', 'LastName': 'Gregory', 'Affiliation': ''}, {'ForeName': 'Christopher S', 'Initials': 'CS', 'LastName': 'Kim', 'Affiliation': ''}]",Joint Commission journal on quality and patient safety,['10.1016/j.jcjq.2019.10.009'] 1106,32093628,Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.,"BACKGROUND Migraine is recognized as the second leading cause of disability globally. Lasmiditan is a novel, selective serotonin 5-HT 1F receptor agonist developed for acute treatment of migraine. Here we analyzed effects of lasmiditan on migraine disability assessed with the Migraine Disability Assessment (MIDAS) scale for interim data from a long-term safety study. METHODS Completers of two single-attack parent studies were offered participation in the 1 year GLADIATOR study, that randomized participants to treatment with lasmiditan 100 mg or 200 mg taken as needed for migraine attacks of at least moderate severity. Changes in MIDAS were modeled using a mixed model repeated measures analysis. RESULTS The sample included 1978 patients who received ≥1 lasmiditan dose and were followed for a median of 288 days. Baseline mean MIDAS scores for the lasmiditan 100-mg and 200-mg groups were 29.4 and 28.9, respectively, indicating severe migraine-related disability. Relative to baseline, MIDAS total scores were significantly lower at 3, 6, 9, and 12 months for both dose groups. At 12 months, changes in MIDAS scores were - 12.5 and - 12.2 for lasmiditan 100 mg and 200 mg, respectively, with 49% and 53% of patients, respectively, achieving at least a 50% decrease in MIDAS total score. Statistically significant improvements were also seen for work and/or school absenteeism and presenteeism, monthly headache days, and mean headache pain intensity at all time points up to 1 year. Findings for patients who completed all visits versus those dropping out early were similar. Responses were generally similar for the lasmiditan 100 mg or 200 mg doses, between subgroups defined based on the number of baseline monthly migraine attacks (≤5 vs. >5), and also between subgroups defined by pain-free response (yes/no) during initial attacks. CONCLUSIONS Long-term treatment with lasmiditan was associated with significant reductions in migraine-related disability, including both work or school absenteeism and presenteeism. The similarity of responses in completers and those who dropped out suggests that selective attrition does not account for the improvements. Benefits were significant at 3 months and maintained through 12 months. TRIAL REGISTRATION clinicaltrials.govNCT02565186; first posted October 1, 2015.",2020,"Statistically significant improvements were also seen for work and/or school absenteeism and presenteeism, monthly headache days, and mean headache pain intensity at all time points up to 1 year.","['Completers of two single-attack parent studies were offered participation in the 1\u2009year', '1978 patients who received ≥1 lasmiditan dose and were followed for a median of 288\u2009days']","['lasmiditan', 'lasmiditan 100\u2009mg or 200\u2009mg taken']","['number of baseline monthly migraine attacks', 'Baseline mean MIDAS scores', 'MIDAS total score', 'MIDAS total scores', 'work and/or school absenteeism and presenteeism, monthly headache days, and mean headache pain intensity', 'severe migraine-related disability', 'migraine disability assessed with the Migraine Disability Assessment (MIDAS) scale', 'changes in MIDAS scores']","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1304680', 'cui_str': 'Attack (finding)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0456589', 'cui_str': '1978 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C1515187', 'cui_str': 'Take'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C1304680', 'cui_str': 'Attack (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0000849', 'cui_str': 'Absenteeism'}, {'cui': 'C4042785', 'cui_str': 'Sickness Presence'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C3854497', 'cui_str': 'Disability assessment scale'}, {'cui': 'C0443172', 'cui_str': 'State changes'}]",,0.0386271,"Statistically significant improvements were also seen for work and/or school absenteeism and presenteeism, monthly headache days, and mean headache pain intensity at all time points up to 1 year.","[{'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Lipton', 'Affiliation': 'Montefiore Medical Center, Bronx, NY, USA.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Lombard', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Dustin D', 'Initials': 'DD', 'LastName': 'Ruff', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Krege', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Li Shen', 'Initials': 'LS', 'LastName': 'Loo', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA. loo_li_shen@lilly.com.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Buchanan', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Melby', 'Affiliation': 'Syneos Health, Inc, Morrisville, NC, USA.'}, {'ForeName': 'Dawn C', 'Initials': 'DC', 'LastName': 'Buse', 'Affiliation': 'Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.'}]",The journal of headache and pain,['10.1186/s10194-020-01088-4'] 1107,32131801,Dental professionals' experiences of managing children with carious lesions in their primary teeth - a qualitative study within the FiCTION randomised controlled trial.,"BACKGROUND The lack of evidence for the effective management of carious lesions in children's primary teeth has caused uncertainty for the dental profession and patients. Possible approaches include conventional and biological management alongside best practice prevention, and best practice prevention alone. The FiCTION trial assessed the effectiveness of these options, and included a qualitative study exploring dental professionals' (DPs) experiences of delivering the different treatment arms. This paper reports on how DPs managed children with carious lesions within FiCTION and how this related to their everyday experiences of doing dentistry. METHODS Overall, 31 DPs from FiCTION-trained dental surgeries in four regions of the UK participated in semi-structured interviews about their experiences of the three treatment arms (conventional management of carious lesions and prevention (C + P), biological management of carious lesions and prevention (B + P) or prevention alone (PA)). A theoretical framework, drawing on social practice theory (SPT), was developed for analysis. RESULTS Participants discussed perceived effectiveness of, and familiarity with, the three techniques. The C + P arm was familiar, but some participants questioned the effectiveness of conventional restorations. Attitudes towards the B + P arm varied in terms of familiarity, but once DPs were introduced to the techniques, this was seen as effective. While prevention was familiar, PA was described as ineffective. DPs manage children with carious lesions day-to-day, drawing on previous experience and knowledge of the child to provide what they view as the most appropriate treatment in the best interests of each child. Randomisation undermined these normal choices. Several DPs reported deviating from the trial arms in order to treat a patient in a particular way. Participants valued evidence-based dentistry, and expect to use the results of FiCTION to inform future practice. They anticipate continuing to use the full range of treatment options, and to personally select appropriate strategies for individual children. CONCLUSIONS RCTs take place in the context of day-to-day practices of doing dentistry. DPs employ experiential and interpersonal knowledge to act in the best interests of their patients. Randomisation within a clinical trial can present a source of tension for DPs, which has implications for assuring individual equipoise in future trials.",2020,"Attitudes towards the B + P arm varied in terms of familiarity, but once DPs were introduced to the techniques, this was seen as effective.","[""Dental professionals' experiences of managing children with carious lesions in their primary teeth "", ""children's primary teeth"", 'DPs managed children with carious lesions']",[],[],"[{'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011334', 'cui_str': 'Dental Decay'}, {'cui': 'C3266841', 'cui_str': 'Baby Teeth'}]",[],[],,0.0399188,"Attitudes towards the B + P arm varied in terms of familiarity, but once DPs were introduced to the techniques, this was seen as effective.","[{'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Marshman', 'Affiliation': 'School of Clinical Dentistry, Claremont Crescent, Sheffield, S10 2TA, UK.'}, {'ForeName': 'Jennifer E', 'Initials': 'JE', 'LastName': 'Kettle', 'Affiliation': 'School of Clinical Dentistry, Claremont Crescent, Sheffield, S10 2TA, UK.'}, {'ForeName': 'Richard D', 'Initials': 'RD', 'LastName': 'Holmes', 'Affiliation': 'School of Dental Sciences, Faculty of Medical Sciences, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.'}, {'ForeName': 'Kathryn B', 'Initials': 'KB', 'LastName': 'Cunningham', 'Affiliation': 'School of Medicine, University of St Andrews, North Haugh, St Andrews, KY16 9TF, UK.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Freeman', 'Affiliation': 'Dental Health Services Research Unit, School of Dentistry, Park Place, Dundee, DD1 4HN, UK.'}, {'ForeName': 'Barry J', 'Initials': 'BJ', 'LastName': 'Gibson', 'Affiliation': 'School of Clinical Dentistry, Claremont Crescent, Sheffield, S10 2TA, UK.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'McColl', 'Affiliation': 'Newcastle Clinical Trials Unit, 4th Floor, William Leech Building, Framlington Place, Newcastle Upon Tyne, NE2 4HH, UK.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Maguire', 'Affiliation': 'School of Dental Sciences, Faculty of Medical Sciences, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.'}, {'ForeName': 'Gail V A', 'Initials': 'GVA', 'LastName': 'Douglas', 'Affiliation': 'Leeds Dental Institute, Clarendon Way, Leeds, LS2 9LU, UK.'}, {'ForeName': 'Janet E', 'Initials': 'JE', 'LastName': 'Clarkson', 'Affiliation': 'Dental Health Services Research Unit, School of Dentistry, Park Place, Dundee, DD1 4HN, UK.'}, {'ForeName': 'Nicola P T', 'Initials': 'NPT', 'LastName': 'Innes', 'Affiliation': 'School of Dentistry, University of Dundee, Park Place, Dundee, DD1 4HN, UK. n.p.Innes@dundee.ac.uk.'}]",BMC oral health,['10.1186/s12903-020-1051-7'] 1108,32127275,Heparin Dose and Point-of-Care Measurements of Hemostasis in Cardiac Surgery-Results of a Randomized Controlled Trial.,"OBJECTIVE High heparin doses during cardiopulmonary bypass (CPB) have been suggested to reduce thrombin activation and consumption coagulopathy and consequently bleeding complications. The authors investigated the effect of a high heparin dose during CPB on point-of-care measurements of coagulation. The authors hypothesized that during CPB a high heparin dose compared with a lower heparin dose would reduce thrombin generation and platelet activation and tested whether this would be reflected in the results of rotational thromboelastometry (TEM) and platelet aggregation, measured with multiple electrode aggregometry (MEA). DESIGN Prospective, randomized, controlled, open single-center study. SETTING University teaching hospital. PARTICIPANTS Sixty-three consecutive patients undergoing elective coronary artery bypass grafting with CPB were enrolled. INTERVENTIONS Patients were randomly assigned to receive either a high (600 IU/kg, n = 32) or a low (300 IU/kg, n = 31) initial dose of heparin. Target levels of activated clotting time during CPB were >600 seconds in the high heparin dose group and >400 seconds in the low heparin dose group. MEASUREMENTS AND MAIN RESULTS Blood samples were collected (1) preoperatively after induction of anesthesia, (2) 10 minutes after aortic declamping, (3) 30 minutes after protamine administration, and (4) 3 hours after protamine administration. TEM and MEA were then measured. There was no difference in blood loss up to 18 hours postoperatively (median 735 mL for high dose v 610 mL for low dose; p < 0.056) or transfusions between the groups. Total median heparin dose (54,300 IU v 27,000 IU; p = 0.001) and median antifactor Xa levels during CPB (9.38 U/mL v 5.04 U/mL; p = 0.001) were greater in the high than in the low heparin dose group. However, neither TEM nor MEA results differed significantly between the groups. CONCLUSIONS Compared with a lower dose of heparin during CPB, a high dose of heparin had little effect on the point-of-care measurements of hemostasis, TEM, and MEA. Based on the similarity of platelet and coagulation activity assessments, the higher heparin dose does not appear to offer benefit during CPB.",2020,There was no difference in blood loss up to 18 hours postoperatively (median 735 mL for high dose v 610 mL for low dose; p < 0.056) or transfusions between the groups.,"['Sixty-three consecutive patients undergoing elective coronary artery bypass grafting with CPB were enrolled', 'University teaching hospital']","['Heparin Dose and Point-of-Care Measurements of Hemostasis', 'heparin', 'CPB', 'cardiopulmonary bypass (CPB']","['TEM nor MEA results', 'thrombin generation and platelet activation', 'TEM and MEA', 'median antifactor Xa levels', 'blood loss', 'Target levels of activated clotting time']","[{'cui': 'C4319614', 'cui_str': '63 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0010055', 'cui_str': 'Coronary Artery Bypass Grafting'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0020027', 'cui_str': 'Teaching Hospitals'}]","[{'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0282664', 'cui_str': 'Point-of-Care'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0740166', 'cui_str': 'Haemostasis'}, {'cui': 'C0007202', 'cui_str': 'Heart-Lung Bypass'}]","[{'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0863178', 'cui_str': 'Thrombin'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0032173', 'cui_str': 'Platelet Activation'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",63.0,0.201492,There was no difference in blood loss up to 18 hours postoperatively (median 735 mL for high dose v 610 mL for low dose; p < 0.056) or transfusions between the groups.,"[{'ForeName': 'Mikko', 'Initials': 'M', 'LastName': 'Lax', 'Affiliation': 'Division of Anesthesiology, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: mikko.lax@hus.fi.'}, {'ForeName': 'Eero', 'Initials': 'E', 'LastName': 'Pesonen', 'Affiliation': 'Division of Anesthesiology, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Seppo', 'Initials': 'S', 'LastName': 'Hiippala', 'Affiliation': 'Division of Anesthesiology, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Alexey', 'Initials': 'A', 'LastName': 'Schramko', 'Affiliation': 'Division of Anesthesiology, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Riitta', 'Initials': 'R', 'LastName': 'Lassila', 'Affiliation': 'Coagulation Disorders Unit, Laboratory Services, Department of Hematology and Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Raivio', 'Affiliation': 'Department of Cardiac Surgery, Heart, and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}]",Journal of cardiothoracic and vascular anesthesia,['10.1053/j.jvca.2019.12.050'] 1109,31512050,"Effectiveness of a brief psychotherapeutic intervention compared with treatment as usual for adolescent nonsuicidal self-injury: a single-centre, randomised controlled trial.","Although nonsuicidal self-injury (NSSI) is a clinically significant behavior, evidence-based, specific, time-, and cost-effective treatment approaches are lacking. The aim of this study was to compare the efficacies of a brief cognitive-behavioral psychotherapy manual, the Cutting Down Programme (CDP), and treatment as usual (TAU) in the treatment of adolescent NSSI. We conducted a single-centre randomised controlled trial (RCT). Eligible participants were aged 12-17 years engaging in repetitive NSSI (at least 5 times within the past 6 months). We randomly allocated 74 participants to CDP (n = 37) or TAU (n = 37; in a 1:1 ratio). Outcome measures were administered before treatment (T0), directly after CDP or 4 months after baseline evaluation in the TAU group (T1), and another 6 months later (T2; primary endpoint). Primary outcome was a 50% reduction in NSSI frequency within the past 6 months at 10-month follow-up (T2). Regarding the primary outcome, there were no significant differences between the CDP (n = 26; 70.3%) and TAU group [n = 27; 73.0%; χ 2 (1) = 0.07; p = 0.797]; NSSI frequency within the past 6 months was significantly reduced at T2 [χ 2 (1) = 12.45; p < 0.001] with no between-group difference [χ 2 (1) = 0.14; p = 0.704]. However, we found a significant group x point of measurement interaction [χ 2 (2) = 7.78; p = 0.021] regarding NSSI within the last month indicating at T1. CDP was equally effective and achieved faster recovery compared to a significantly more intensive TAU in treating adolescent NSSI. The CDP could provide a brief and pragmatic first treatment within a stepped-care model for NSSI in routine clinical care.Clinical Trial Registration The trial was prospectively registered in the German Registry of Clinical Trials (https://www.drks.de; DRKS00003605) and is now complete.",2020,Primary outcome was a 50% reduction in NSSI frequency within the past 6 months at 10-month follow-up (T2).,"['adolescent NSSI', 'Eligible participants were aged 12-17\xa0years engaging in repetitive NSSI', 'adolescent nonsuicidal self-injury']","['CDP', 'TAU', 'cognitive-behavioral psychotherapy manual, the Cutting Down Programme (CDP', 'psychotherapeutic intervention']",['NSSI frequency'],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}, {'cui': 'C0085271', 'cui_str': 'Self-Injury'}]","[{'cui': 'C0010724', 'cui_str': 'CDP'}, {'cui': 'C1720655', 'cui_str': 'Tau'}, {'cui': 'C0004933', 'cui_str': 'Behavior Modification'}, {'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}]","[{'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]",74.0,0.188995,Primary outcome was a 50% reduction in NSSI frequency within the past 6 months at 10-month follow-up (T2).,"[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kaess', 'Affiliation': 'University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Stöckli, Bolligenstrasse 141c, 3000, Bern 60, Switzerland. michael.kaess@upd.ch.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Edinger', 'Affiliation': 'Section for Translational Psychobiology in Child and Adolescent Psychiatry, Clinic of Child and Adolescent Psychiatry, Centre for Psychosocial Medicine, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Gloria', 'Initials': 'G', 'LastName': 'Fischer-Waldschmidt', 'Affiliation': 'Clinic of Child and Adolescent Psychiatry, Centre for Psychosocial Medicine, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Parzer', 'Affiliation': 'Clinic of Child and Adolescent Psychiatry, Centre for Psychosocial Medicine, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Romuald', 'Initials': 'R', 'LastName': 'Brunner', 'Affiliation': 'Clinic and Policlinic of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Regensburg, Regensburg District Hospital, Regensburg, Germany.'}, {'ForeName': 'Franz', 'Initials': 'F', 'LastName': 'Resch', 'Affiliation': 'Clinic of Child and Adolescent Psychiatry, Centre for Psychosocial Medicine, University Hospital Heidelberg, Heidelberg, Germany.'}]",European child & adolescent psychiatry,['10.1007/s00787-019-01399-1'] 1110,15465502,"Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study.","PURPOSE To assess the comparative effectiveness of several medications on bone mineral density, biochemical bone markers, and the incidence of vertebral fractures in postmenopausal women with osteoporosis. METHODS A total of 396 postmenopausal women, aged 50 to 75 years, were allocated randomly to six equal-sized groups: hormone replacement therapy, etidronate, eel calcitonin, alfacalcidol, vitamin K (menatetrenone), or control (no treatment). Thoracic and lumbar spine radiographs, bone mineral density at the distal radius, and markers of bone turnover were assessed at baseline and every 3 months during the 2-year study. RESULTS Compared with baseline, the 2-year mean changes in bone mineral density were 2.0% for hormone replacement therapy, -0.5% for etidronate, 1.6% for calcitonin, -3.6% for alfacalcidol, -1.9% for vitamin K, and -3.3% for control. Seventeen (26%) of the 66 control patients developed new vertebral fractures. Compared with controls, the relative risks of vertebral fracture were 0.35 (95% confidence interval [CI]: 0.14 to 0.83) for hormone replacement therapy, 0.40 (95% CI: 0.17 to 0.92) for etidronate, 0.41 (95% CI: 0.17 to 0.93) for calcitonin, 0.56 (95% CI: 0.26 to 1.12) for alfacalcidol, and 0.44 (95% CI: 0.20 to 0.99) for vitamin K. CONCLUSION We observed significant reductions in the incidence of vertebral fractures with hormone replacement therapy, etidronate, and calcitonin, and significant improvements in bone mineral density with hormone replacement therapy and calcitonin.",2004,"Compared with baseline, the 2-year mean changes in bone mineral density were 2.0% for hormone replacement therapy, -0.5% for etidronate, 1.6% for calcitonin, -3.6% for alfacalcidol, -1.9% for vitamin K, and -3.3% for control.","['postmenopausal women with osteoporosis', '396 postmenopausal women, aged 50 to 75 years']","['hormone replacement therapy, etidronate, eel calcitonin, alfacalcidol, vitamin K (menatetrenone), or control (no treatment', 'hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K']","['bone mineral density, biochemical bone markers', 'new vertebral fractures', 'Thoracic and lumbar spine radiographs, bone mineral density at the distal radius, and markers of bone turnover', 'bone mineral density', 'vertebral fractures', 'relative risks of vertebral fracture']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0282402', 'cui_str': 'Hormone replacement therapy (procedure)'}, {'cui': 'C0086268', 'cui_str': 'Etidronate'}, {'cui': 'C0013668', 'cui_str': 'Eel Calcitonin'}, {'cui': 'C0044410', 'cui_str': 'Alfacalcidol'}, {'cui': 'C0042879', 'cui_str': 'Vitamin K measurement (procedure)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0073994', 'cui_str': 'calcitonin (salmon synthetic)'}]","[{'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0205474', 'cui_str': 'Biochemical (qualifier value)'}, {'cui': 'C0181734', 'cui_str': 'Bone marker'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0080179', 'cui_str': 'Spinal Fractures'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C3887615', 'cui_str': 'Lumbar spine structure (body structure)'}, {'cui': 'C1306645', 'cui_str': 'Plain x-ray'}, {'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius (body structure)'}, {'cui': 'C0085268', 'cui_str': 'Bone Turnover'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}]",396.0,0.0485534,"Compared with baseline, the 2-year mean changes in bone mineral density were 2.0% for hormone replacement therapy, -0.5% for etidronate, 1.6% for calcitonin, -3.6% for alfacalcidol, -1.9% for vitamin K, and -3.3% for control.","[{'ForeName': 'Yoichiro', 'Initials': 'Y', 'LastName': 'Ishida', 'Affiliation': 'Department of Orthopedic Surgery, Yamaguchi University School of Medicine, Ube-City, Japan. myishida@yamaguchi-u.ac.jp'}, {'ForeName': 'Shinya', 'Initials': 'S', 'LastName': 'Kawai', 'Affiliation': ''}]",The American journal of medicine,[] 1111,29929773,Computerized cognitive training is associated with improved psychosocial treatment engagement in schizophrenia.,"Poor treatment engagement is an enduring problem in the care of patients with schizophrenia. Evidence suggests that targeted cognitive training (TCT) improves cognition and functional outcomes, but this time-consuming intervention might reduce patients' engagement in other treatment activities when implemented in real-world settings. This is especially true of residential care programs which encourage patients to engage in group therapies, self-care, and a wide variety of structured social, work, and other rehabilitation activities. This study aimed to determine whether TCT negatively impacts engagement in other psychosocial treatments. Patients with schizophrenia were recruited from a community-based residential care program and randomized to one of two intervention arms: treatment as usual (TAU; n = 22) or TAU augmented with TCT (n = 24). Psychosocial treatment engagement was tracked over 20 weeks. Treatment groups did not significantly differ on baseline variables or psychosocial treatment engagement in the 5 weeks prior to randomization. TCT had a positive effect on engagement (β = 0.112, p = 0.003), but there was no treatment-by-time interaction (β = -0.029, p = 0.672). Participants in TCT engaged in an average of 1.34 additional group therapies, 0.58 additional activities of daily living, and 0.84 additional rehabilitation activities per week in comparison to TAU participants. Baseline cognition was also a significant predictor of psychosocial treatment engagement. Overall, results suggest that TCT can be implemented in real-world settings without negatively impacting engagement in other psychosocial treatments. Additional studies are needed to determine what role nonspecific factors play in the positive impact of TCT.",2018,"Participants in TCT engaged in an average of 1.34 additional group therapies, 0.58 additional activities of daily living, and 0.84 additional rehabilitation activities per week in comparison to TAU participants.","['patients with schizophrenia', 'Patients with schizophrenia were recruited from a community-based residential care program']","['TAU augmented with TCT', 'cognitive training (TCT', 'Computerized cognitive training', 'TCT']",['baseline variables or psychosocial treatment engagement'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C1720655', 'cui_str': 'Tau'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0677634', 'cui_str': 'Reptilase Time'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]","[{'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",,0.0351517,"Participants in TCT engaged in an average of 1.34 additional group therapies, 0.58 additional activities of daily living, and 0.84 additional rehabilitation activities per week in comparison to TAU participants.","[{'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Thomas', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States. Electronic address: mlthomas@ucsd.edu.'}, {'ForeName': 'Emily B H', 'Initials': 'EBH', 'LastName': 'Treichler', 'Affiliation': 'VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States; Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Bismark', 'Affiliation': 'VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States; Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Alexandra L', 'Initials': 'AL', 'LastName': 'Shiluk', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Tarasenko', 'Affiliation': 'VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States; Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Yash B', 'Initials': 'YB', 'LastName': 'Joshi', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Joyce', 'Initials': 'J', 'LastName': 'Sprock', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Cardoso', 'Affiliation': 'Alpine Special Treatment Center Inc., Alpine, CA, United States.'}, {'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Tiernan', 'Affiliation': 'Alpine Special Treatment Center Inc., Alpine, CA, United States.'}, {'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Light', 'Affiliation': 'VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States; Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}]",Schizophrenia research,['10.1016/j.schres.2018.06.024'] 1112,31846029,Nudging Emergency Care Providers to Reduce Opioid Prescribing Using Peer Norm Comparison Feedback: A Pilot Randomized Trial.,"OBJECTIVE To determine the feasibility, acceptability, and potential impact of using audit and feedback (A&F) with or without peer norm comparison on opioid prescribing by emergency medicine providers. METHODS A convenience sample of 37 emergency medicine providers were recruited from 16 emergency departments in Western Pennsylvania for a pilot randomized controlled trial. Participants completed a baseline survey, were randomly allocated to A&F (N = 17) or A&F with peer norm comparison (N = 20), and were asked to complete a postintervention survey. We matched each participant 1:1 to a control who was not exposed to either intervention. RESULTS At baseline, 57% of participants perceived that they prescribed opioids at the same frequency as their peers, whereas 32% perceived prescribing less than and 11% perceived prescribing more than their peers. Most participants rated the interventions as helpful, with no differences between conditions. For the A&F with peer norm comparison condition, from pre- to postintervention, there was a relative increase of 20% in the percentage of participants who perceived that they prescribed more opioids than their peers but no change in the A&F condition (P = 0.02). 56.8% of controls, 52.9% of A&F participants, and 75.5% of A&F with peer norm comparison participants reduced their opioid prescribing (P = 0.33). The mean reduction in opioid prescriptions (SD) was 3.3. (9.6) for controls, 3.9 (10.5) for A&F, and 7.3 (7.8) for A&F with peer norm comparison (P = 0.31). CONCLUSIONS Audit and feedback interventions with peer norm comparisons are helpful to providers, can alter perceptions about prescribing norms, and are a potentially effective way to alter ED providers' opioid prescribing behavior.",2020,A convenience sample of 37 emergency medicine providers were recruited from 16 emergency departments in Western Pennsylvania for a pilot randomized controlled trial.,['37 emergency medicine providers were recruited from 16 emergency departments in Western Pennsylvania'],"['Prescribing Using Peer Norm Comparison Feedback', 'audit and feedback (A&F) with or without peer norm comparison', 'A&F (N\u2009=\u200917) or A&F with peer norm comparison', 'Opioid']","['mean reduction in opioid prescriptions (SD', 'opioid prescribing']","[{'cui': 'C0013964', 'cui_str': 'Emergency Medicine'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0030853', 'cui_str': 'Pennsylvania'}]","[{'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0033080', 'cui_str': 'Prescriptions'}]",37.0,0.0640923,A convenience sample of 37 emergency medicine providers were recruited from 16 emergency departments in Western Pennsylvania for a pilot randomized controlled trial.,"[{'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Suffoletto', 'Affiliation': 'Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'Landau', 'Affiliation': 'School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.'}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pnz314'] 1113,31415193,Engaging Parents to Prevent Adolescent Substance Use: A Randomized Controlled Trial.,"Objectives. To test whether providing information to parents about their child's academic performance and behavior in school will lead to lower rates of adolescent substance use. Methods. We performed a randomized controlled trial in Los Angeles, California. We enrolled 318 seventh graders and their parents in 2014 and collected data through 2016. Half of the participants had parents with income less than $15 000, and 81% were Latino. During this intervention, Linking Information and Families Together, we sent parents weekly text messages, telephone calls, or e-mails about missed assignments, grades, and behavior. Parents reported their monitoring and parenting self-efficacy; students reported their use and intentions to use alcohol, marijuana, and other drugs. Results. By the end of eighth grade, lifetime use of alcohol or marijuana was 18.2% in the control group and 10.2% in the intervention group ( P  = .02). Parenting self-efficacy, parent-child relationship, and student's grades were similar between groups. Conclusions. The intervention successfully reduced adolescent alcohol and marijuana initiation between grades 7 and 8. The intervention cost $15 per student per year but could be automated, reducing the marginal cost toward zero. The intervention holds promise as a scalable and innovative approach to reducing substance use. Trial Registration. ClinicalTrials.gov Identifier: NCT02129153.",2019,"By the end of eighth grade, lifetime use of alcohol or marijuana was 18.2% in the control group and 10.2% in the intervention group ( P  = .02).","['We enrolled 318 seventh graders and their parents in 2014 and collected data through 2016', 'participants had parents with income less than $15\u2009000, and 81% were Latino', 'Los Angeles, California']",[],"['lifetime use of alcohol or marijuana', 'adolescent alcohol and marijuana initiation']","[{'cui': 'C0205441', 'cui_str': 'Seventh (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0332273', 'cui_str': 'Through (qualifier value)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0006754', 'cui_str': 'California'}]",[],"[{'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation (observable entity)'}]",318.0,0.101318,"By the end of eighth grade, lifetime use of alcohol or marijuana was 18.2% in the control group and 10.2% in the intervention group ( P  = .02).","[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Bergman', 'Affiliation': 'Peter Bergman is with Teachers College, Columbia University, New York, NY. Rebecca N. Dudovitz, Kulwant K. Dosanjh, and Mitchell D. Wong are with the David Geffen School of Medicine, University of California, Los Angeles.'}, {'ForeName': 'Rebecca N', 'Initials': 'RN', 'LastName': 'Dudovitz', 'Affiliation': 'Peter Bergman is with Teachers College, Columbia University, New York, NY. Rebecca N. Dudovitz, Kulwant K. Dosanjh, and Mitchell D. Wong are with the David Geffen School of Medicine, University of California, Los Angeles.'}, {'ForeName': 'Kulwant K', 'Initials': 'KK', 'LastName': 'Dosanjh', 'Affiliation': 'Peter Bergman is with Teachers College, Columbia University, New York, NY. Rebecca N. Dudovitz, Kulwant K. Dosanjh, and Mitchell D. Wong are with the David Geffen School of Medicine, University of California, Los Angeles.'}, {'ForeName': 'Mitchell D', 'Initials': 'MD', 'LastName': 'Wong', 'Affiliation': 'Peter Bergman is with Teachers College, Columbia University, New York, NY. Rebecca N. Dudovitz, Kulwant K. Dosanjh, and Mitchell D. Wong are with the David Geffen School of Medicine, University of California, Los Angeles.'}]",American journal of public health,['10.2105/AJPH.2019.305240'] 1114,31422858,A multicenter randomized controlled trial of a modified Valsalva maneuver for cardioversion of supraventricular tachycardias.,"CLINICAL QUESTION Valsalva maneuver is a recognized treatment for supraventricular tachycardia, but in clinical setting it has a low chance to achieve successful cardioversion. Studies suggested that the postural modification of valsalva maneuver may improve the rate of cardioversion. We further modified the maneuver and conduct a multicenter randomized controlled trial to test its efficacy. RESEARCH IN CONTEXT Appelboam A, Reuben A, Mann C, et al. Postural modification of the standard Valsalva maneuver for emergency treatment for supraventricular tachycardias (REVERT): a randomized controlled trial. Lancet 2015; 386 (10005):1747-53 [1]. Allison Michaud, PhD, Eddy Lang. Leg lift Valsalva maneuver for treatment of supraventricular tachycardias. CJEM 2017; 19(3):235-237 [2]. OBJECTIVE To verify the efficacy of the modified Valsalva maneuver in SVT in Chinese population and simplify the operation process further.",2020,Postural modification of the standard Valsalva maneuver for emergency treatment for supraventricular tachycardias (REVERT): a randomized controlled trial.,['supraventricular tachycardias (REVERT'],"['modified Valsalva maneuver', 'standard Valsalva maneuver', 'Leg lift Valsalva maneuver', 'modified Valsalva maneuver in SVT']",['rate of cardioversion'],"[{'cui': 'C0039240', 'cui_str': 'Supraventricular tachycardia (disorder)'}]","[{'cui': 'C0042293', 'cui_str': 'Valsalva Maneuver'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0181620', 'cui_str': 'Lift'}, {'cui': 'C0039240', 'cui_str': 'Supraventricular tachycardia (disorder)'}]","[{'cui': 'C0013778', 'cui_str': 'Electrical Cardioversion'}]",,0.0422851,Postural modification of the standard Valsalva maneuver for emergency treatment for supraventricular tachycardias (REVERT): a randomized controlled trial.,"[{'ForeName': 'Chaofeng', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': ""Cardiac Center, Beijing Chaoyang Hospital affiliated to Capital Medical University, China; Jiangsu People's Hospital of Xuzhou branch (Xuzhou Third People's Hospital), China. Electronic address: doctorchenchaofeng@163.com.""}, {'ForeName': 'Tsz Kin', 'Initials': 'TK', 'LastName': 'Tam', 'Affiliation': 'Prince of Wales Hospital, Hong Kong.'}, {'ForeName': 'Shuai', 'Initials': 'S', 'LastName': 'Sun', 'Affiliation': ""Shanxi provincial people's hospital, China.""}, {'ForeName': 'Yanyan', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': ""Jiangsu People's Hospital of Xuzhou branch (Xuzhou Third People's Hospital), China.""}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Teng', 'Affiliation': 'Xuzhou mine hospital, China.'}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Jin', 'Affiliation': 'Xuzhou mine hospital, China.'}, {'ForeName': 'Liujian', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': 'Shanghai prison general hospital, China.'}, {'ForeName': 'Xingpeng', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Cardiac Center, Beijing Chaoyang Hospital affiliated to Capital Medical University, China. Electronic address: xpliu71@vip.sina.com.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2019.158371'] 1115,32428523,A randomized clinical trial to arrest dentin caries in young children using silver diamine fluoride.,"OBJECTIVES The study aimed to compare the effectiveness of 38% silver diamine fluoride (SDF) solution, and 5% sodium fluoride (NaF) varnish applied semiannually in arresting dentin caries in young children with high caries risk. METHODS Children aged 1-3 years who had at least one active dentin carious lesion were randomly allocated into 2 groups as follows: Group 1 = 38% SDF (Topamine), and Group 2 = 5% NaF varnish (Duraphat). Both agents were applied every 6 months onto the carious surface. Lesion activity was assessed by the visual-tactile examination. Baseline and follow-up examinations were conducted by the same examiner. The children's demographic background, oral health-related habits, and oral hygiene practices, as well as parental satisfaction with children's dental appearance were collected at baseline and the 12-month follow-up. RESULTS At baseline, 153 and 149 children were recruited in Group 1 and Group 2, respectively. The mean dmfs scores in Groups 1 and 2 were 8.89 and 9.79, respectively. After 12 months, 87.1% remained in the study. The caries arrest rate of Group 1 (35.7%) was significantly higher than that of Group 2 (20.9%) (p < 0.001). The results of the multilevel logistic regression analysis confirmed that the treatment in Group 1 was more effective in arresting dentin carious lesions than that of Group 2 (OR = 2.04; 95% CI, 1.41-2.96). The presence of plaque on caries lesions, tooth type, tooth surface type, frequency of milk feeding, snack taking, and family income influenced on caries activity. Regardless of the intervention groups, there were no differences in parental satisfaction with on the child's dental appearance before and after receiving the intervention. CONCLUSION Based on the 12-month results, 38% SDF is more effective than 5% NaF varnish in arresting dentin carious lesions in young children. SDF has no negative impact on parental satisfaction with the child's dental appearance. CLINICAL SIGNIFICANCE To control dentin carious lesions in young children with high caries risk, 38% SDF is more effective than 5% NaF varnish.",2020,The caries arrest rate of Group 1 (35.7%) was significantly higher than that of Group 2 (20.9%) (p <  0.001).,"['young children using', 'young children', 'Children aged 1-3 years who had at least one active dentin carious lesion', 'young children with high caries risk']","['SDF', '38% silver diamine fluoride (SDF) solution, and 5% sodium fluoride (NaF) varnish', 'silver diamine fluoride', 'NaF varnish', 'SDF (Topamine), and Group 2\u2009=\u20095% NaF varnish (Duraphat']","['dentin carious lesions', 'mean dmfs scores', 'Lesion activity', 'caries arrest rate', 'dentin caries', 'effective in arresting dentin carious lesions', 'parental satisfaction', 'presence of plaque on caries lesions, tooth type, tooth surface type, frequency of milk feeding, snack taking, and family income influenced on caries activity']","[{'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0011429', 'cui_str': 'Dentin structure'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]","[{'cui': 'C0074538', 'cui_str': 'Silver diamine fluoride'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0037508', 'cui_str': 'Sodium Fluoride'}, {'cui': 'C0042359', 'cui_str': 'Varnish'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0058817', 'cui_str': 'Duraphat'}]","[{'cui': 'C0011429', 'cui_str': 'Dentin structure'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0266848', 'cui_str': 'Arrested dental caries'}, {'cui': 'C0266846', 'cui_str': 'Dental caries extending into dentin'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0447301', 'cui_str': 'Tooth surface'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0453863', 'cui_str': 'Snack food'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0021162', 'cui_str': 'Income'}]",,0.0269155,The caries arrest rate of Group 1 (35.7%) was significantly higher than that of Group 2 (20.9%) (p <  0.001).,"[{'ForeName': 'Sirinan', 'Initials': 'S', 'LastName': 'Mabangkhru', 'Affiliation': 'Faculty of Dentistry, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Duangporn', 'Initials': 'D', 'LastName': 'Duangthip', 'Affiliation': 'Faculty of Dentistry, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Chun Hung', 'Initials': 'CH', 'LastName': 'Chu', 'Affiliation': 'Faculty of Dentistry, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Araya', 'Initials': 'A', 'LastName': 'Phonghanyudh', 'Affiliation': 'Faculty of Dentistry, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Varangkanar', 'Initials': 'V', 'LastName': 'Jirarattanasopha', 'Affiliation': 'Faculty of Dentistry, Mahidol University, Bangkok, Thailand. Electronic address: Varangkanar.jir@mahidol.ac.th.'}]",Journal of dentistry,['10.1016/j.jdent.2020.103375'] 1116,32434637,[Application of vacuum stretcher combined with feeding in cranial magnetic resonance imaging examination for neonates: a prospective randomized controlled study].,"OBJECTIVE To study the effect and safety of vacuum stretcher combined with feeding in cranial magnetic resonance imaging (MRI) examination for neonates. METHODS A prospective study was performed for the neonates with hyperbilirubinemia, with a gestational age of >34 weeks and stable vital signs, who needed cranial MRI examination and did not need oxygen inhalation hospitalized in the Department of Neonatology, Children's Hospital of Zhejiang University School of Medicine, from September to November, 2019. The neonates were randomly divided into a vacuum stretcher combined with feeding group and a conventional sedation group. Vital signs were monitored before, during, and after MRI examination. The success rate of MRI procedure was recorded. RESULTS A total of 80 neonates were enrolled in the study, with 40 neonates in the vacuum stretcher combined with feeding group and 40 in the conventional sedation group. The vacuum stretcher combined with feeding group had a significantly higher success rate of MRI procedure than the conventional sedation group (P<0.05). As for the neonates who underwent successful MRI examination, the fastest heart rate after examination in the vacuum stretcher combined with feeding group was significantly lower than that in the conventional sedation group (P<0.05), while there were no significant differences between the two groups in transcutaneous oxygen saturation, respiratory rate, and body temperature before and after MRI examination (P>0.05). No complications, such as apnea, acute allergic reactions, and malignant fever, were observed. CONCLUSIONS Vacuum stretcher combined with feeding can improve the success rate of MRI procedure and reduce the use of sedatives, and meanwhile, it does not increase related risks.",2020,The vacuum stretcher combined with feeding group had a significantly higher success rate of MRI procedure than the conventional sedation group (P<0.05).,"['neonates', '80 neonates were enrolled in the study, with 40 neonates in the vacuum stretcher combined with feeding group and 40 in the conventional sedation group', ""neonates with hyperbilirubinemia, with a gestational age of >34 weeks and stable vital signs, who needed cranial MRI examination and did not need oxygen inhalation hospitalized in the Department of Neonatology, Children's Hospital of Zhejiang University School of Medicine, from September to November, 2019""]","['vacuum stretcher combined with feeding group and a conventional sedation group', 'cranial magnetic resonance imaging examination', 'vacuum stretcher combined with feeding in cranial magnetic resonance imaging (MRI) examination', 'vacuum stretcher combined with feeding']","['fastest heart rate', 'transcutaneous oxygen saturation, respiratory rate, and body temperature', 'No complications, such as apnea, acute allergic reactions, and malignant fever', 'success rate of MRI procedure']","[{'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0042221', 'cui_str': 'Vacuum'}, {'cui': 'C0150789', 'cui_str': 'Stretcher'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0020433', 'cui_str': 'Hyperbilirubinemia'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0037303', 'cui_str': 'Bone structure of cranium'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0027621', 'cui_str': 'Neonatology'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0042221', 'cui_str': 'Vacuum'}, {'cui': 'C0150789', 'cui_str': 'Stretcher'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0037303', 'cui_str': 'Bone structure of cranium'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}]","[{'cui': 'C0039231', 'cui_str': 'Tachycardia'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0413234', 'cui_str': 'Acute allergic reaction'}, {'cui': 'C0024591', 'cui_str': 'Malignant hyperthermia'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]",80.0,0.058861,The vacuum stretcher combined with feeding group had a significantly higher success rate of MRI procedure than the conventional sedation group (P<0.05).,"[{'ForeName': 'Xiao-Xia', 'Initials': 'XX', 'LastName': 'Shen', 'Affiliation': ""Department of Neonatal Intensive Care Unit, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310051, China. maxiaolu_zjuch@zju.edu.cn.""}, {'ForeName': 'Ting-Ting', 'Initials': 'TT', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Fu-Sheng', 'Initials': 'FS', 'LastName': 'Gao', 'Affiliation': ''}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Li-Zhong', 'Initials': 'LZ', 'LastName': 'DU', 'Affiliation': ''}, {'ForeName': 'Xiao-Lu', 'Initials': 'XL', 'LastName': 'Ma', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1117,31366999,The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial.,"BACKGROUND Breast cancer diagnosis may be a teachable moment for lifestyle behaviour change and to prevent adjuvant therapy associated weight gain. We assessed the acceptability and effectiveness of two weight control programmes initiated soon after breast cancer diagnosis to reduce weight amongst overweight or obese women and prevent gains in normal-weight women. METHODS Overweight or obese (n = 243) and normal weight (n = 166) women were randomised to a three-month unsupervised home (home), a supervised community weight control programme (community) or to standard written advice (control). Primary end points were change in weight and body fat at 12 months. Secondary end points included change in insulin, cardiovascular risk markers, quality of life and cost-effectiveness of the programmes. RESULTS Forty-three percent of eligible women were recruited. Both programmes reduced weight and body fat: home vs. control mean (95% CI); weight -2.3 (-3.5, -1.0) kg, body fat -1.6 (-2.6, -0.7) kg, community vs. control; weight -2.4 (-3.6, -1.1) kg, body fat -1.4 (-2.4, -0.5) kg (all p < 0.001). The community group increased physical activity, reduced insulin, cardiovascular disease risk markers, increased QOL and was cost-effective. CONCLUSIONS The programmes were equally effective for weight control, but the community programme had additional benefits. CLINICAL TRIAL REGISTRATION ISRCTN68576140.",2019,Both programmes reduced weight and body fat: home vs. control,"['overweight or obese women and prevent gains in normal-weight women', 'Forty-three percent of eligible women were recruited', 'Overweight or obese (n\u2009=\u2009243) and normal weight (n\u2009', '166) women', 'breast cancer diagnosis']","['home versus community-based weight control programmes', 'supervised community weight control programme (community) or to standard written advice (control']","['change in weight and body fat', 'acceptability and effectiveness', 'change in insulin, cardiovascular risk markers, quality of life and cost-effectiveness of the programmes', 'physical activity, reduced insulin, cardiovascular disease risk markers, increased QOL and was cost-effective', 'weight and body fat']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C2712185', 'cui_str': 'Normal weight (finding)'}, {'cui': 'C0450368', 'cui_str': '43 (qualifier value)'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen (regime/therapy)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0034380'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}]",,0.108066,Both programmes reduced weight and body fat: home vs. control,"[{'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Harvie', 'Affiliation': 'Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK. michelle.harvie@manchester.ac.uk.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Pegington', 'Affiliation': 'Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Debbie', 'Initials': 'D', 'LastName': 'McMullan', 'Affiliation': 'Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Bundred', 'Affiliation': 'Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Livingstone', 'Affiliation': 'The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Campbell', 'Affiliation': 'School of Applied Sciences, Edinburgh Napier University, Edinburgh, UK.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Wolstenholme', 'Affiliation': 'Nuffield Department of Population Health, Health Economics Research Centre, University of Oxford, Oxford, UK.'}, {'ForeName': 'Eleanora', 'Initials': 'E', 'LastName': 'Lovato', 'Affiliation': 'Nuffield Department of Population Health, Health Economics Research Centre, University of Oxford, Oxford, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Campbell', 'Affiliation': 'National Perinatal Epidemiology Unit, University of Oxford, Oxford, UK.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Adams', 'Affiliation': 'Clinical Radiology, Faculty of Medicine Biology and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Speed', 'Affiliation': 'The School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, UK.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Morris', 'Affiliation': 'Department of Medical Statistics, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Sacha', 'Initials': 'S', 'LastName': 'Howell', 'Affiliation': 'Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Howell', 'Affiliation': 'Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.'}]",British journal of cancer,['10.1038/s41416-019-0522-6'] 1118,31383985,Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.,"Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC) significantly increased non-progression rate in advanced ovarian cancer (OC) patients. We report final overall survival (OS) results to further strengthen the efficacy of DD-EPIC in the front-line therapy. In this phase 2 trial, 218 patients with FIGO IIIC-IV OC were randomly allocated to receive DD-EPIC followed by intravenous (IV) chemotherapy (DD-EPIC group), or IV chemotherapy alone (IV group). The study was prespecified to detect differences in progression-free survival (PFS) and OS. At a median follow-up period of 69.1 months, the median OS was 67.5 and 46.3 months in the DD-EPIC and IV group, respectively. The probability rate of OS at 5 years was 61.0% with DD-EPIC, and 38.2% with IV (hazard ratio [HR] for death from OC, 0.70; 95% confidence interval [CI], 0.49-1.00). DD-EPIC was associated with a prolonged PFS compared with the IV group (the estimated rate of PFS at 5 years, 26.0% vs. 8.5%; HR for disease progression, 0.64; 95% CI, 0.47-0.86). DD-EPIC was associated with a longer OS than IV chemotherapy alone. It may be considered as a valuable option of the front-line therapy for advanced ovarian cancer.Trial registration: ClinicalTrials.gov, NCT01669226 (date of registration: August 20, 2012).",2019,"DD-EPIC was associated with a prolonged PFS compared with the IV group (the estimated rate of PFS at 5 years, 26.0% vs. 8.5%; HR for disease progression, 0.64; 95% CI, 0.47-0.86).","['advanced ovarian cancer (OC) patients', 'advanced ovarian cancer', '218 patients with FIGO IIIC-IV OC']","['dose-dense early postoperative intraperitoneal chemotherapy', 'Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC', 'DD-EPIC followed by intravenous (IV) chemotherapy (DD-EPIC group), or IV chemotherapy alone']","['median OS', 'probability rate of OS', 'Survival benefits', 'progression-free survival (PFS) and OS']","[{'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C1140680', 'cui_str': 'Ovary Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517647', 'cui_str': 'Two hundred and eighteen'}]","[{'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439794', 'cui_str': 'Dense (qualifier value)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0442120', 'cui_str': 'Intraperitoneal (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0413365', 'cui_str': 'Intravenous chemotherapy (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",218.0,0.207204,"DD-EPIC was associated with a prolonged PFS compared with the IV group (the estimated rate of PFS at 5 years, 26.0% vs. 8.5%; HR for disease progression, 0.64; 95% CI, 0.47-0.86).","[{'ForeName': 'Tingyan', 'Initials': 'T', 'LastName': 'Shi', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Jiang', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Pu', 'Affiliation': 'Department of Obstetrics and Gynecology, Wuxi Caner Hospital, Jiangsu, China.'}, {'ForeName': 'Huijuan', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Dongsheng', 'Initials': 'D', 'LastName': 'Tu', 'Affiliation': ""Department of Mathematics and Statistics, Queen's University, Kingston, Canada.""}, {'ForeName': 'Zhiyuan', 'Initials': 'Z', 'LastName': 'Dai', 'Affiliation': 'Department of Obstetrics and Gynecology, Suzhou Municipal Hospital, Jiangsu, China.'}, {'ForeName': 'Yunlang', 'Initials': 'Y', 'LastName': 'Cai', 'Affiliation': 'Department of Obstetrics and Gynecology, Zhongda Hospital Southeast University, Jiangsu, China.'}, {'ForeName': 'Yuqin', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Cheng', 'Affiliation': 'Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Huixun', 'Initials': 'H', 'LastName': 'Jia', 'Affiliation': 'Clinical Statistics Center, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Ruiqin', 'Initials': 'R', 'LastName': 'Tu', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Huaying', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': 'Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Yuting', 'Initials': 'Y', 'LastName': 'Luan', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Shumo', 'Initials': 'S', 'LastName': 'Cai', 'Affiliation': 'Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Rongyu', 'Initials': 'R', 'LastName': 'Zang', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China. ryzang@yahoo.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",British journal of cancer,['10.1038/s41416-019-0543-1'] 1119,32072028,Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial.,"Background and purpose The penile bulb (PB) dose may be critical in development of post prostate radiotherapy erectile dysfunction (ED). This study aimed to generate PB dose constraints based on dose-volume histograms (DVHs) in patients treated with prostate radiotherapy, and to identify clinical and dosimetric parameters that predict the risk of ED post prostate radiotherapy. Materials and methods Penile bulb DVHs were generated for 276 patients treated within the randomised IGRT substudy of the multicentre randomised trial, CHHiP. Incidence of ED in relation to dose and randomised IGRT groups were evaluated using Wilcoxon rank sum, Chi-squared test and atlases of complication incidence. Youden index was used to find dose-volume constraints that discriminated for ED. Multivariate analysis (MVA) of effect of dosimetry, clinical and patient-related variables was performed. Results Reduced treatment margins using IGRT (IGRT-R) produced significantly reduced mean PB dose compared with standard margins (IGRT-S) (median: 25 Gy (IGRT-S) versus 11 Gy (IGRT-R); p < 0.0001). Significant difference in both mean (median: 23 Gy (ED) vs. 18 Gy (no ED); p = 0.011) and maximum (median: 59 Gy (ED) vs. 52 Gy (no ED); p = 0.018) PB doses between those with and without clinician reported ED were identified. Mean PB dose cut-point for ED was derived at around 20 Gy. On MVA, PB mean dose and age predicted for impotence. Conclusion PB dose appears predictive of post-radiotherapy ED with calculated threshold mean dose of around 20 Gy, substantially lower than published recommendations. IGRT-R enables favourable PB dosimetry and can be recommended provided prostate coverage is not compromised.",2020,Reduced treatment margins using IGRT (IGRT-R) produced significantly reduced mean PB dose compared with standard margins (IGRT-S),"['276 patients treated within the randomised IGRT substudy of the multicentre randomised trial', 'patients treated with']","['CHHiP', 'IGRT (IGRT-R', 'standard margins (IGRT-S', 'prostate radiotherapy']","['Wilcoxon rank sum, Chi-squared test and atlases of complication incidence', 'Mean PB dose cut-point for ED']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205284', 'cui_str': 'Marginal (qualifier value)'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}]","[{'cui': 'C0699794', 'cui_str': 'Rank (attribute)'}, {'cui': 'C1720589', 'cui_str': 'Greek letter chi'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0004171', 'cui_str': 'Atlases'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0000925', 'cui_str': 'Incised wound - morphology (morphologic abnormality)'}]",,0.115108,Reduced treatment margins using IGRT (IGRT-R) produced significantly reduced mean PB dose compared with standard margins (IGRT-S),"[{'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Murray', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Gulliford', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Griffin', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Wilkins', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Syndikus', 'Affiliation': 'Clatterbridge Cancer Centre, Wirral, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Staffurth', 'Affiliation': 'Cardiff University/Velindre Cancer Centre, Cardiff, UK.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Panades', 'Affiliation': 'Lincoln County Hospital, Lincoln, UK.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Scrase', 'Affiliation': 'Ipswich Hospital, Ipswich, UK.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Parker', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Khoo', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Dean', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Mayles', 'Affiliation': 'Clatterbridge Cancer Centre, Wirral, UK.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Mayles', 'Affiliation': 'Clatterbridge Cancer Centre, Wirral, UK.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Thomas', 'Affiliation': ""Addenbrooke's Hospital, Cambridge, UK.""}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Naismith', 'Affiliation': 'Royal Marsden NHS Foundation Trust, London, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Mossop', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Cruickshank', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Hall', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Dearnaley', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical and translational radiation oncology,['10.1016/j.ctro.2019.12.006'] 1120,31871115,Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.,"BACKGROUND There is a lack of data exploring the use and optimal timing of immunotherapy and chemoradiation therapy (CRT) in node-positive cervical cancer. Further translational research into mechanisms of response and resistance to immunotherapy in advanced cervical cancer is warranted. PRIMARY OBJECTIVES To determine if sequencing of atezolizumab and CRT result in differential immune activation, as determined by clonal expansion of T cell receptor beta (TCRB) repertoires in peripheral blood on day 21. STUDY HYPOTHESIS There is a difference for clonal expansion of T cell receptor beta repertoires in the peripheral blood at day 21 between the priming and concurrent atezolizumab and CRT in Arm A vs the concurrent atezolizumab and CRT in Arm B. TRIAL DESIGN Locally advanced cervical cancer patients with lymph node-positive disease will be randomized on this open-label, randomized trial with two experimental arms. Arm A will get one dose of atezolizumab prior to cisplatin CRT, and then two subsequent doses of atezolizumab during the CRT, and Arm B will get three doses during CRT. Patients will be followed for 2 years to assess outcomes. MAJOR INCLUSION/EXCLUSION CRITERIA Patients must have histologically confirmed, newly diagnosed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma): FIGO 2009 clinical stages IB2/IIA with positive para-aortic nodes, or FIGO 2009 clinical stages IIB/IIIB/IVA with positive pelvic or para-aortic lymph nodes. Exclusion criteria include those who had a prior hysterectomy or lymph node dissection. PRIMARY ENDPOINTS Clonal expansion of TCRB) repertoires in peripheral blood on day 21. SAMPLE SIZE The sample size will be 40 patients. ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS We estimate accrual to finish by the summer of 2020 with presentation of results to follow in 2021. TRIAL REGISTRATION NCT03738228.",2020,"There is a difference for clonal expansion of T cell receptor beta repertoires in the peripheral blood at day 21 between the priming and concurrent atezolizumab and CRT in Arm A vs the concurrent atezolizumab and CRT in Arm B. ","['Patients must have histologically confirmed, newly diagnosed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma): FIGO 2009 clinical stages IB2/IIA with positive para-aortic nodes, or FIGO 2009 clinical stages IIB/IIIB/IVA with positive pelvic or para-aortic lymph nodes', '40 patients', 'node-positive locally advanced cervical cancer', 'Exclusion criteria include those who had a prior hysterectomy or lymph node dissection', 'advanced cervical cancer', 'node-positive cervical cancer', 'Locally advanced cervical cancer patients with lymph node-positive disease']","['Anti-PD-L1 (atezolizumab', 'immunotherapy and chemoradiation therapy (CRT', 'atezolizumab and CRT', 'atezolizumab', 'atezolizumab prior to cisplatin CRT']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix (disorder)'}, {'cui': 'C0007137', 'cui_str': 'Carcinoma, Planocellular'}, {'cui': 'C0001418', 'cui_str': 'Adenoma, Malignant'}, {'cui': 'C0206623', 'cui_str': 'Adenosquamous cell carcinoma'}, {'cui': 'C0205563', 'cui_str': 'Clinical staging (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0740255', 'cui_str': 'Para-aortic lymph node group (body structure)'}, {'cui': 'C0030797', 'cui_str': 'Pelvic Region'}, {'cui': 'C0229789', 'cui_str': 'Para-aortic node (body structure)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C0242382', 'cui_str': 'Lymph Node Dissection'}, {'cui': 'C0024204', 'cui_str': 'Lymphatic gland'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C4055433', 'cui_str': 'atezolizumab'}, {'cui': 'C0021083', 'cui_str': 'Immunotherapy'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}]",[],,0.173007,"There is a difference for clonal expansion of T cell receptor beta repertoires in the peripheral blood at day 21 between the priming and concurrent atezolizumab and CRT in Arm A vs the concurrent atezolizumab and CRT in Arm B. ","[{'ForeName': 'Jyoti', 'Initials': 'J', 'LastName': 'Mayadev', 'Affiliation': 'Department of Radiation Medicine and Applied Sciences, University of California San Diego Medical Center, La Jolla, California, USA jmayadev@ucsd.edu.'}, {'ForeName': 'Dmitriy', 'Initials': 'D', 'LastName': 'Zamarin', 'Affiliation': 'Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Deng', 'Affiliation': 'Department of Biostatistics and Bioinformatics, NRG Oncology, Clinical Trial Development Division, Buffalo, New York, USA.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Lankes', 'Affiliation': ""Biopathology Center, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.""}, {'ForeName': 'Roisin', 'Initials': 'R', 'LastName': ""O'Cearbhaill"", 'Affiliation': 'Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.'}, {'ForeName': 'Carol A', 'Initials': 'CA', 'LastName': 'Aghajanian', 'Affiliation': 'Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.'}, {'ForeName': 'Russell', 'Initials': 'R', 'LastName': 'Schilder', 'Affiliation': 'Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.'}]",International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,['10.1136/ijgc-2019-001012'] 1121,32000753,Effect of air-polishing on surface roughness of composite dental restorative material - comparison of three different air-polishing powders.,"BACKGROUND Increased composite roughness enhances bacterial adhesion and discoloration, thus increasing the risk of gingival inflammation and secondary caries. Concerns about detrimental effects of sodium bicarbonate on surface roughness influenced the development of less abrasive powders: a glycine-based powder and an erythritol-based powder, additionally - sodium bicarbonate-based powder of reduced grain size. However, there is limited evidence on effects of these materials on the surface of dental fillings. The aim of the present study was to compare the effects of three air-polishing powders (of a reduced abrasiveness) on surface roughness of microhybrid restorative composite material. MATERIAL AND METHODS Microhybrid light-cure resin composite samples were placed on 64 plaster cubes and light-cured through polyester strips. Surface roughness was measured using laser confocal microscope (magnification 2160x). The specimens were randomly divided into three groups (n = 20, 20 and 24) and air-polished with: sodium bicarbonate (40 μm), glycine (25 μm) and erythritol (14 μm), respectively. Then surface roughness was remeasured, keeping the same field of observation. Specialized 3D analysis software was used for data processing. Parameters according to ISO 25178: Sa, Sq, Sku, Sp, Sv, Sz, Ssk were used to describe surface roughness. RESULTS Sa, Sq, Sp, Sv, Sz increased significantly following air polishing. Ssk was significantly higher, whereas Sku was significantly lower in sodium bicarbonate and erythritol groups than before air polishing. Comparison between the three powders revealed that Sa was significantly higher in sodium bicarbonate group than in glycine group. Sku was significantly higher in glycine and erythritol groups than in sodium bicarbonate group. CONCLUSIONS Sodium bicarbonate has a stronger detrimental effect on composite surface than glycine or erythritol. No advantage of erythritol comparing to glycine could be found.",2020,"Ssk was significantly higher, whereas Sku was significantly lower in sodium bicarbonate and erythritol groups than before air polishing.","['composite dental restorative material - comparison of three different air-polishing powders', 'Microhybrid light-cure resin composite samples were placed on 64 plaster cubes and light-cured through polyester strips']","['sodium bicarbonate', 'air-polishing', 'sodium bicarbonate (40\u2009μm), glycine', 'glycine', 'Sodium bicarbonate']","['Sa', 'Surface roughness', 'Sku']","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0182981', 'cui_str': 'Dental restorative material'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0032861', 'cui_str': 'Powdered drug preparation'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C1704765', 'cui_str': 'Place - dosing instruction imperative'}, {'cui': 'C0460977', 'cui_str': 'Plasters (physical object)'}, {'cui': 'C0032474', 'cui_str': 'Polyesters'}, {'cui': 'C1321564', 'cui_str': 'Strip'}]","[{'cui': 'C0074722', 'cui_str': 'Sodium Bicarbonate'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0017890', 'cui_str': 'Glycine'}]","[{'cui': 'C0205148', 'cui_str': 'Surface (attribute)'}]",,0.0193658,"Ssk was significantly higher, whereas Sku was significantly lower in sodium bicarbonate and erythritol groups than before air polishing.","[{'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Janiszewska-Olszowska', 'Affiliation': 'Department of Interdisciplinary Dentistry Pomeranian Medical, University in Szczecin, al. Powstancow Wlkp, 72, 70-111, Szczecin, Poland. jjo@pum.edu.pl.'}, {'ForeName': 'Agnieszka', 'Initials': 'A', 'LastName': 'Drozdzik', 'Affiliation': 'Department of Interdisciplinary Dentistry Pomeranian Medical, University in Szczecin, al. Powstancow Wlkp, 72, 70-111, Szczecin, Poland.'}, {'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Tandecka', 'Affiliation': 'Faculty of Mechanical Engineering Koszalin, University of Technology, ul, Raclawicka 15-17, 75-620, Koszalin, Poland.'}, {'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Grocholewicz', 'Affiliation': 'Department of Interdisciplinary Dentistry Pomeranian Medical, University in Szczecin, al. Powstancow Wlkp, 72, 70-111, Szczecin, Poland.'}]",BMC oral health,['10.1186/s12903-020-1007-y'] 1122,32048365,"The effect of saffron supplement on clinical outcomes and metabolic profiles in patients with active rheumatoid arthritis: A randomized, double-blind, placebo-controlled clinical trial.","Rheumatoid arthritis (RA) is a systemic autoimmune and inflammatory disease. Our study aimed to determine the effect of saffron supplement on clinical outcomes and metabolic profiles in patients with active RA. In this randomized, double-blind, placebo-controlled trial, 66 women older than 18 years old received 100 mg/day either saffron supplement in the intervention group (n = 33) or matched placebo in the placebo group (n = 33) for a period of 12 weeks. Sixty-one patients (30 in the control and 31 in the saffron group) remained for the final analysis. No adverse effects were reported by the patients. Saffron supplementation significantly decreased the number of tender (-1.38 ± 1.66 vs. 0.10 ± 0.40, p < .001) and swollen (-2.12 ± 2.34 vs. 0.63 ± 2.79, p < .001) joints, pain intensity based on visual analogue scale (-18.36 ± 15.07 vs. -2.33 ± 5.04), p < .001), and disease activity score (DAS28) (-0.75 ± 0.67 vs. 0.26 ± 0.77, p < .001) at the end of intervention between the two groups and in saffron group compared with baseline values. Physician Global Assessment (p = .002) and erythrocyte sedimentation rate were significantly improved after intervention (24.06 ± 12.66 vs. 32.00 ± 14.75, p = 0.028). High-sensitivity C-reactive protein reduced at the end of the intervention in the saffron group compared with baseline values (12.00 ± 7.40 vs. 8.82 ± 7.930, p = .004). Tumor necrosis factor alpha, interferon gamma, and malondialdehyde were decreased, and total antioxidant capacity were increased, but their differences between the two groups were not significant (p > .05). According to the results, saffron supplements could positively and significantly improve clinical outcomes in RA patients.",2020,"Physician Global Assessment (p = .002) and erythrocyte sedimentation rate were significantly improved after intervention (24.06 ± 12.66 vs. 32.00 ± 14.75, p = 0.028).","['66 women older than 18\u2009years old received', 'patients with active RA', 'patients with active rheumatoid arthritis']","['Saffron supplementation', 'placebo', '100\u2009mg/day either saffron supplement', 'saffron supplement']","['clinical outcomes', 'adverse effects', 'Tumor necrosis factor alpha, interferon gamma, and malondialdehyde', 'clinical outcomes and metabolic profiles', 'disease activity score (DAS28', 'total antioxidant capacity', 'High-sensitivity C-reactive protein', 'number of tender', 'erythrocyte sedimentation rate', 'Physician Global Assessment', 'pain intensity based on visual analogue scale']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid Arthritis'}]","[{'cui': 'C2348128', 'cui_str': 'Saffron'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0439422', 'cui_str': 'mg/day'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0021745', 'cui_str': 'interferon gamma'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C3853758', 'cui_str': 'Metabolic Profile'}, {'cui': 'C4706353', 'cui_str': 'Disease Activity Score'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0234234', 'cui_str': 'Tender (qualifier value)'}, {'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",66.0,0.472196,"Physician Global Assessment (p = .002) and erythrocyte sedimentation rate were significantly improved after intervention (24.06 ± 12.66 vs. 32.00 ± 14.75, p = 0.028).","[{'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Hamidi', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Naheed', 'Initials': 'N', 'LastName': 'Aryaeian', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Jamileh', 'Initials': 'J', 'LastName': 'Abolghasemi', 'Affiliation': 'Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Shirani', 'Affiliation': 'Department of Internal Medicine, Faculty of Medicine, Rasoul-e-Akram Hospital, Tehran, Iran.'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Hadidi', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Soudabeh', 'Initials': 'S', 'LastName': 'Fallah', 'Affiliation': 'Department of Clinical Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Nariman', 'Initials': 'N', 'LastName': 'Moradi', 'Affiliation': 'Department of Clinical Biochemistry, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.6633'] 1123,31707829,REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.,"BACKGROUND Some trials have found that patients from the United States derive less benefit than patients enrolled outside the United States. This prespecified REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl - Intervention Trial) subgroup analysis was conducted to determine the degree of benefit of icosapent ethyl in the United States. METHODS REDUCE-IT randomized 8179 statin-treated patients with qualifying triglycerides ≥135 and <500 mg/dL and low-density lipoprotein cholesterol >40 and ≤100 mg/dL and a history of atherosclerosis or diabetes mellitus to icosapent ethyl 4 g/d or placebo. The primary composite end point was cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina. The key secondary composite end point was cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. A hierarchy was prespecified for examination of individual and composite end points. RESULTS A total of 3146 US patients (38.5% of the trial) were randomized and followed for a median of 4.9 years; 32.3% were women and 9.7% were Hispanic. The primary composite end point occurred in 24.7% of placebo-treated patients versus 18.2% of icosapent ethyl-treated patients (hazard ratio [HR], 0.69 [95% CI, 0.59-0.80]; P =0.000001); the key secondary composite end point occurred in 16.6% versus 12.1% (HR, 0.69 [95% CI, 0.57-0.83]; P =0.00008). All prespecified hierarchical end points were meaningfully and significantly reduced, including cardiovascular death (6.7% to 4.7%; HR, 0.66 [95% CI, 0.49-0.90]; P =0.007), myocardial infarction (8.8% to 6.7%; HR, 0.72 [95% CI, 0.56-0.93]; P =0.01), stroke (4.1% to 2.6%; HR, 0.63 [95% CI, 0.43-0.93]; P =0.02), and all-cause mortality (9.8% to 7.2%; HR, 0.70 [95% CI, 0.55-0.90]; P =0.004); for all-cause mortality in the US versus non-US patients, P interaction =0.02. Safety and tolerability findings were consistent with the full study cohort. CONCLUSIONS Whereas the non-US subgroup showed significant reductions in the primary and key secondary end points, the US subgroup demonstrated particularly robust risk reductions across a variety of individual and composite end points, including all-cause mortality. CLINICAL TRIAL REGISTRATION URL: https://www.clinicaltrials.gov. Unique identifier: NCT01492361.",2020,"All prespecified hierarchy endpoints were meaningfully and significantly reduced, including cardiovascular death (6.7% to 4.7%, HR 0.66, 95% CI 0.49-0.90, p=0.007), myocardial infarction (8.8% to 6.7%, HR 0.72, 95% CI 0.56-0.93, p=0.01), stroke (4.1% to 2.6%, HR 0.63, 95% CI 0.43-0.93, p=0.02), and all-cause mortality (9.8% to 7.2%, HR 0.70, 95% CI 0.55-0.90, p=0.004); for all-cause mortality for the USA versus non-USA patients, p interaction =0.02.","['3,146 Patients Randomized in the United States', '8,179 statin-treated patients with qualifying triglycerides ≥135 and <500 mg/dL and low-density lipoprotein (LDL)-cholesterol >40 and ≤100 mg/dL and a history of atherosclerosis or diabetes to icosapent ethyl 4 grams/day or', '3,146 USA patients (38.5% of the trial) were randomized and followed for a median of 4.9 years; 32.3% were women, 9.7% Hispanic']",['placebo'],"['stroke', 'cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke', 'cause mortality', 'myocardial infarction', 'cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina', 'Safety and tolerability', 'cardiovascular death']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0058978', 'cui_str': 'icosapent ethyl'}, {'cui': 'C0439417', 'cui_str': 'g/day'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0002965', 'cui_str': 'Angina at Rest'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",3146.0,0.454731,"All prespecified hierarchy endpoints were meaningfully and significantly reduced, including cardiovascular death (6.7% to 4.7%, HR 0.66, 95% CI 0.49-0.90, p=0.007), myocardial infarction (8.8% to 6.7%, HR 0.72, 95% CI 0.56-0.93, p=0.01), stroke (4.1% to 2.6%, HR 0.63, 95% CI 0.43-0.93, p=0.02), and all-cause mortality (9.8% to 7.2%, HR 0.70, 95% CI 0.55-0.90, p=0.004); for all-cause mortality for the USA versus non-USA patients, p interaction =0.02.","[{'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': ""Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA (D.L.B.).""}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Miller', 'Affiliation': 'Department of Medicine, University of Maryland School of Medicine, Baltimore (M.M.).'}, {'ForeName': 'Eliot A', 'Initials': 'EA', 'LastName': 'Brinton', 'Affiliation': 'Utah Lipid Center, Salt Lake City (E.A.B.).'}, {'ForeName': 'Terry A', 'Initials': 'TA', 'LastName': 'Jacobson', 'Affiliation': 'Lipid Clinic and Cardiovascular Risk Reduction Program, Department of Medicine, Emory University School of Medicine, Atlanta, GA (T.A.J.).'}, {'ForeName': 'Ph Gabriel', 'Initials': 'PG', 'LastName': 'Steg', 'Affiliation': 'French Alliance for Cardiovascular Trials, Hôpital Bichat, Paris, France (P.G.S.).'}, {'ForeName': 'Steven B', 'Initials': 'SB', 'LastName': 'Ketchum', 'Affiliation': 'Amarin Pharma, Inc., Bridgewater, NJ (S.B.K., R.T.D., R.A.J., L.J., C.G.).'}, {'ForeName': 'Ralph T', 'Initials': 'RT', 'LastName': 'Doyle', 'Affiliation': 'Amarin Pharma, Inc., Bridgewater, NJ (S.B.K., R.T.D., R.A.J., L.J., C.G.).'}, {'ForeName': 'Rebecca A', 'Initials': 'RA', 'LastName': 'Juliano', 'Affiliation': 'Amarin Pharma, Inc., Bridgewater, NJ (S.B.K., R.T.D., R.A.J., L.J., C.G.).'}, {'ForeName': 'Lixia', 'Initials': 'L', 'LastName': 'Jiao', 'Affiliation': 'Amarin Pharma, Inc., Bridgewater, NJ (S.B.K., R.T.D., R.A.J., L.J., C.G.).'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Granowitz', 'Affiliation': 'Amarin Pharma, Inc., Bridgewater, NJ (S.B.K., R.T.D., R.A.J., L.J., C.G.).'}, {'ForeName': 'Jean-Claude', 'Initials': 'JC', 'LastName': 'Tardif', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Quebec, Canada (J.-C.T.).'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Olshansky', 'Affiliation': 'University of Iowa, Iowa City (B.O.).'}, {'ForeName': 'Mina K', 'Initials': 'MK', 'LastName': 'Chung', 'Affiliation': 'Cleveland Clinic, OH (M.K.C.).'}, {'ForeName': 'C Michael', 'Initials': 'CM', 'LastName': 'Gibson', 'Affiliation': 'Beth Israel Deaconess Hospital, Boston, MA (C.M.G.).'}, {'ForeName': 'Robert P', 'Initials': 'RP', 'LastName': 'Giugliano', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.P.G.).""}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Budoff', 'Affiliation': 'Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA (M.J.B.).'}, {'ForeName': 'Christie M', 'Initials': 'CM', 'LastName': 'Ballantyne', 'Affiliation': 'Department of Medicine, Baylor College of Medicine, Houston, TX (C.M.B.).'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Circulation,['10.1161/CIRCULATIONAHA.119.044440'] 1124,32428586,"Integrating an online weight management program with population health management in primary care: Design, methods, and baseline data from the PROPS randomized controlled trial (Partnerships for Reducing Overweight and Obesity with Patient-centered Strategies).","BACKGROUND Scalable, low-cost weight management strategies are needed in primary care. We conducted a pragmatic, cluster-randomized controlled trial to examine the effectiveness of an online weight management program integrated with population health management support. METHODS We adapted an online weight management program and integrated it with population health management support in 15 primary care practices (24 clinics). We randomized the 24 clinics to usual care (UC), online program alone (OP), or combined intervention (CI). Eligible participants had to be ages 20 to 70 and have a recent primary care visit, body mass index (BMI) ≥ 27 and < 40 kg/m 2 , and a diagnosis of hypertension or type 2 diabetes. Participants attended routine visits and completed surveys over 18 months. The primary outcome is absolute weight change at 12 months (± 90 days) after enrollment, calculated from weights measured at primary care visits and recorded in the electronic health record. RESULTS We enrolled 840 participants between July 2016 and August 2017 (326 UC, 216 OP, and 298 CI.) At enrollment, participants' mean age was 59.3 years, their mean weight was 203.1 pounds, and their mean BMI was 32.5 kg/m 2 ; 60% of participants were female, 76.8% were white, 96.4% had hypertension, and 24.4% had type 2 diabetes. CONCLUSION It is feasible to adapt an online weight management program and integrate it with population health management support in primary care. The results of this trial will provide valuable information about the effectiveness of these strategies in primary care settings. ClinicalTrials.govregistration number:NCT02656693.",2020,"We randomized the 24 clinics to usual care (UC), online program alone (OP), or combined intervention (CI).","['Eligible participants had to be ages 20 to 70 and have a recent primary care visit, body mass index (BMI)\u202f≥\u202f27 and\u202f<\u202f40\u202fkg/m 2 , and a diagnosis of hypertension or type 2 diabetes', '15 primary care practices (24 clinics', ""At enrollment, participants' mean age was 59.3\u202fyears, their mean weight was 203.1 pounds, and their mean BMI was 32.5\u202fkg/m 2 ; 60% of participants were female, 76% were white, 96.4% had hypertension, and 24.4% had type 2 diabetes"", 'We enrolled 840 participants between July 2016 and August 2017 (326 UC, 216 OP, and 298 CI']","['online weight management program with population health management', 'online weight management program and integrated it with population health management support', 'usual care (UC), online program alone (OP), or combined intervention (CI', 'online weight management program integrated with population health management support']","['absolute weight change at 12\u202fmonths (± 90\u202fdays) after enrollment, calculated from weights measured at primary care visits and recorded in the electronic health record']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0439219', 'cui_str': 'lb'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C4517710', 'cui_str': '32.5'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C4708913', 'cui_str': '840'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C5191353', 'cui_str': '326'}, {'cui': 'C4708905', 'cui_str': '216'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205171', 'cui_str': 'Singular'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C4273558', 'cui_str': 'Weight management program'}, {'cui': 'C4704688', 'cui_str': 'Population Health Management'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0043101', 'cui_str': 'Weights and Measures'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}]",840.0,0.0950447,"We randomized the 24 clinics to usual care (UC), online program alone (OP), or combined intervention (CI).","[{'ForeName': 'Heather J', 'Initials': 'HJ', 'LastName': 'Baer', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, United States of America; Harvard Medical School, Boston, MA, United States of America; Harvard T.H. Chan School of Public Health, Boston, MA, United States of America. Electronic address: hbaer@bwh.harvard.edu.""}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'De La Cruz', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, United States of America.""}, {'ForeName': 'Ronen', 'Initials': 'R', 'LastName': 'Rozenblum', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, United States of America; Harvard Medical School, Boston, MA, United States of America.""}, {'ForeName': 'Nyryan V', 'Initials': 'NV', 'LastName': 'Nolido', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, United States of America.""}, {'ForeName': 'E John', 'Initials': 'EJ', 'LastName': 'Orav', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, United States of America; Harvard Medical School, Boston, MA, United States of America; Harvard T.H. Chan School of Public Health, Boston, MA, United States of America.""}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Metzler', 'Affiliation': ""Department of Nutrition, Brigham and Women's Hospital, Boston, MA, United States of America.""}, {'ForeName': 'Jason P', 'Initials': 'JP', 'LastName': 'Block', 'Affiliation': ""Harvard Medical School, Boston, MA, United States of America; Department of Population Medicine, Harvard Pilgrim Healthcare Institute, Brigham and Women's Hospital, Boston, MA, United States of America.""}, {'ForeName': 'Florencia', 'Initials': 'F', 'LastName': 'Halperin', 'Affiliation': ""Harvard Medical School, Boston, MA, United States of America; Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Boston, MA, United States of America.""}, {'ForeName': 'Katherine D', 'Initials': 'KD', 'LastName': 'McManus', 'Affiliation': ""Department of Nutrition, Brigham and Women's Hospital, Boston, MA, United States of America.""}, {'ForeName': 'Louis J', 'Initials': 'LJ', 'LastName': 'Aronne', 'Affiliation': 'BMIQ Professionals Program, Intellihealth/BMIQ, United States of America; Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York, NY, United States of America.'}, {'ForeName': 'Guadalupe', 'Initials': 'G', 'LastName': 'Minero', 'Affiliation': 'BMIQ Professionals Program, Intellihealth/BMIQ, United States of America.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Bates', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, United States of America; Harvard Medical School, Boston, MA, United States of America; Harvard T.H. Chan School of Public Health, Boston, MA, United States of America.""}]",Contemporary clinical trials,['10.1016/j.cct.2020.106026'] 1125,31515173,"Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial.","BACKGROUND Combination nicotine replacement therapy shows additive cessation benefits. We aimed to find out the effectiveness of combining nicotine patches with an e-cigarette (with and without nicotine) on six-month smoking abstinence. METHODS We did a pragmatic, three-arm, parallel-group trial in New Zealand in adult smokers who were e-cigarette naive and motivated to quit smoking. Participants were recruited from the general population using national media advertising. Participants were randomly assigned (1:4:4), with the use of stratified block randomisation, to receive 14 weeks (2 weeks before the agreed quit date) of 21 mg, 24h nicotine patches, patches plus an 18 mg/L nicotine e-cigarette, or patches plus a nicotine-free e-cigarette. We advised participants to use one patch daily, with e-cigarette use as and when necessary or desired. Participants and researchers were masked to e-liquid nicotine content. We offered 6 weeks of telephone-delivered behavioural support. The primary outcome was exhaled carbon monoxide (CO)-verified continuous smoking abstinence 6 months after the agreed quit date. Primary analysis was by intention to treat, with sensitivity analysis by per protocol, treatment adherence, varying CO cutoffs, and complete case analysis. This paper presents the main analyses and is registered with ClinicalTrials.gov, NCT02521662. FINDINGS Between March 17, 2016 and Nov 30, 2017, 1124 people were assigned to nicotine patches (patches only group, n=125), patches plus a nicotine e-cigarette (patches plus nicotine e-cigarette group, n=500), or patches plus a nicotine-free e-cigarette (patches plus nicotine-free e-cigarette group, n=499). 62 (50%) of 125 participants in the patches only group withdrew or were lost to follow-up by 6 months compared with 161 (32%) of 500 in the patches plus nicotine e-cigarette group and 162 (33%) of 499 in the patches plus nicotine-free e-cigarette group. 35 (7%) participants in the patches plus nicotine e-cigarette group had CO-verified continuous abstinence at 6 months compared with 20 (4%) in the patches plus nicotine-free e-cigarette group (risk difference [RD] 2·99 [95% CI 0·17-5·81]), and three (2%) people in the patches only group (RD 4·60 [1·11-8·09]). 18 serious adverse events occurred in 16 people in the patches plus nicotine e-cigarette group compared with 27 events in 22 people in the patches plus nicotine-free e-cigarette group and four events in three people in the patches only group. In the patches plus nicotine e-cigarette group, two life-threatening serious adverse events were reported (two separate heart attacks in the one participant). In the patches plus nicotine-free e-cigarette group, one death occurred (accidental drug overdose) and one life-threatening serious adverse event (heart attack). No significant between-group differences were noted for serious adverse events, and none were treatment-related. INTERPRETATION Combining reduced-harm nicotine products, such as nicotine patches with a nicotine e-cigarette, can lead to a modest improvement in smoking cessation over and above that obtained from using patches plus a nicotine-free e-cigarette (or patches alone), with no indication of any serious harm in the short-term. Future e-cigarette trials should focus on their use alone or in combination with usual smoking cessation support, given issues with differential loss to follow-up and withdrawal if a usual care group is used as a comparator. FUNDING Health Research Council of New Zealand.",2020,18 serious adverse events occurred in 16 people in the patches plus nicotine e-cigarette group compared with 27 events in 22 people in the patches plus nicotine-free e-cigarette group and four events in three people in the patches only group.,"['adult smokers who were e-cigarette naive and motivated to quit smoking', 'Participants were recruited from the general population using national media advertising', '62 (50%) of 125 participants in the patches', 'Between March 17, 2016 and Nov 30, 2017, 1124 people were assigned to']","['nicotine e-cigarette', 'nicotine-free e-cigarette group', 'nicotine patches, patches plus an 18 mg/L nicotine e-cigarette, or patches plus a nicotine-free e-cigarette', 'nicotine patches with an e-cigarette (with and without nicotine', 'Nicotine patches used in combination with e-cigarettes (with and without nicotine', 'telephone-delivered behavioural support', 'nicotine replacement therapy', 'nicotine patches (patches only group, n=125), patches plus a nicotine e-cigarette (patches plus nicotine e-cigarette group, n=500), or patches plus a nicotine-free e-cigarette (patches plus nicotine-free e-cigarette']","['intention to treat, with sensitivity analysis by per protocol, treatment adherence, varying CO cutoffs, and complete case analysis', 'CO-verified continuous abstinence', '18 serious adverse events', 'smoking cessation', 'death occurred (accidental drug overdose) and one life-threatening serious adverse event (heart attack', 'serious adverse events', 'exhaled carbon monoxide (CO)-verified continuous smoking abstinence 6 months']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C3849993', 'cui_str': 'Electronic Cigarettes'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0439536', 'cui_str': 'Medium (qualifier value)'}, {'cui': 'C4319551', 'cui_str': 'One hundred and twenty-five'}, {'cui': 'C0445403', 'cui_str': 'Human patch'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}]","[{'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C3849993', 'cui_str': 'Electronic Cigarettes'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0358855', 'cui_str': 'Nicotine Transdermal Patch'}, {'cui': 'C0445403', 'cui_str': 'Human patch'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0439268', 'cui_str': 'microgram/mL'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C1278444', 'cui_str': 'Nicotine replacement therapy'}]","[{'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C4505265', 'cui_str': 'Treatment Adherence'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0520803', 'cui_str': 'Accidental drug overdose (disorder)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]",125.0,0.0725699,18 serious adverse events occurred in 16 people in the patches plus nicotine e-cigarette group compared with 27 events in 22 people in the patches plus nicotine-free e-cigarette group and four events in three people in the patches only group.,"[{'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Walker', 'Affiliation': 'National Institute for Health Innovation, School of Population Health, The University of Auckland, Auckland, New Zealand. Electronic address: n.walker@auckland.ac.nz.'}, {'ForeName': 'Varsha', 'Initials': 'V', 'LastName': 'Parag', 'Affiliation': 'National Institute for Health Innovation, School of Population Health, The University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Marjolein', 'Initials': 'M', 'LastName': 'Verbiest', 'Affiliation': 'Tranzo, Tilburg School of Social and Behavioral Sciences, Tilburg University, Tilburg, The Netherlands.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Laking', 'Affiliation': 'Department of Oncology, School of Medical Sciences, The University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Murray', 'Initials': 'M', 'LastName': 'Laugesen', 'Affiliation': 'Department of Psychology, University of Canterbury, Christchurch, New Zealand.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Bullen', 'Affiliation': 'National Institute for Health Innovation, School of Population Health, The University of Auckland, Auckland, New Zealand.'}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(19)30269-3'] 1126,31515355,"Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.","Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ineligible patients with multiple myeloma, comparing melphalan-prednisolone in combination with thalidomide or lenalidomide, followed by maintenance therapy until progression (MPT-T or MPR-R). The EORTC QLQ-C30 and MY20 questionnaires were completed at baseline, after three and nine induction cycles and six and 12 months of maintenance therapy. Linear mixed models and minimal important differences were used for evaluation. 596 patients participated in HRQoL reporting. Patients reported clinically relevant improvement in global quality of life (QoL), future perspective and role and emotional functioning, and less fatigue and pain in both arms. The latter being of large effect size. In general, improvement occurred after 6-12 months of maintenance only and was independent of the World Health Organisation performance at baseline. Patients treated with MPR-R reported clinically relevant worsening of diarrhea, and patients treated with MPT-T reported a higher incidence of neuropathy. Patients who remained on lenalidomide maintenance therapy for at least three months reported clinically meaningful improvement in global QoL and role functioning at six months, remaining stable thereafter. There were no clinically meaningful deteriorations, but patients on thalidomide reported clinically relevant worsening in neuropathy. In general, HRQoL improves both during induction and maintenance therapy with immunomodulatory drugs. The side effect profile of treatment did not negatively affect global QoL, but it was, however, clinically relevant for the patients. ( Clinicaltrials.gov identifier: NTR1630 ).",2020,"Patients reported clinically relevant improvement in global quality of life, future perspective and role and emotional functioning, and less fatigue and pain in both arms.","['596 patients participated in health-related quality of life reporting', 'newly diagnosed transplant ineligible patients with multiple myeloma, comparing', 'transplant ineligible newly diagnosed multiple myeloma patients treated with either']","['melphalan-prednisolone in combination with thalidomide or lenalidomide, followed by maintenance therapy until progression (MPT-T or MPR-R', 'thalidomide or lenalidomide', 'thalidomide']","['global quality of life', 'global QoL and role functioning', 'global quality of life, future perspective and role and emotional functioning, and less fatigue and pain', 'neuropathy', 'diarrhea', 'Health-related quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0332835', 'cui_str': 'Grafts'}, {'cui': 'C0026764', 'cui_str': 'Myelomatosis'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0025241', 'cui_str': 'Melphalan'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C0039736', 'cui_str': 'Thalidomide'}, {'cui': 'C1144149', 'cui_str': 'lenalidomide'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0677908', 'cui_str': 'Maintenance therapy'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C1701620', 'cui_str': 'mercaptopropionyl-phenylalanyl-cyclohexylalanyl-cyclohexylalanyl-arginyl-lysyl-prolyl-asparaginyl-aspartyl-lysinamide'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0016884', 'cui_str': 'Future'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0442874', 'cui_str': 'Neuropathy (disorder)'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}]",596.0,0.0684156,"Patients reported clinically relevant improvement in global quality of life, future perspective and role and emotional functioning, and less fatigue and pain in both arms.","[{'ForeName': 'Lene Kongsgaard', 'Initials': 'LK', 'LastName': 'Nielsen', 'Affiliation': 'Quality of Life Research Center, Department of Haematology, Odense University Hospital, Odense, Denmark lene.kongsgaard.nielsen@rsyd.dk.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Stege', 'Affiliation': 'Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Lissenberg-Witte', 'Affiliation': 'Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, Amsterdam, the Netherlands.'}, {'ForeName': 'Bronno', 'Initials': 'B', 'LastName': 'van der Holt', 'Affiliation': 'HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.'}, {'ForeName': 'Ulf-Henrik', 'Initials': 'UH', 'LastName': 'Mellqvist', 'Affiliation': 'Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gotheborg, Sweden.'}, {'ForeName': 'Morten', 'Initials': 'M', 'LastName': 'Salomo', 'Affiliation': 'Department of Haematology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Bos', 'Affiliation': 'Department of Haematology, Maastricht University Medical Center, Maastricht, the Netherlands.'}, {'ForeName': 'Mark-David', 'Initials': 'MD', 'LastName': 'Levin', 'Affiliation': 'Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.'}, {'ForeName': 'Heleen', 'Initials': 'H', 'LastName': 'Visser-Wisselaar', 'Affiliation': 'HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Hansson', 'Affiliation': 'Department of Haematology and Wallenberg Center for Molecular Medicine, Skåne University Hospital, Lund University, Lund, Sweden.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'van der Velden', 'Affiliation': 'Department of Internal Medicine, Martini Ziekenhuis, Groningen, the Netherlands.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Deenik', 'Affiliation': 'Department of Internal Medicine, Tergooi Ziekenhuis, Hilversum, the Netherlands.'}, {'ForeName': 'Juleon', 'Initials': 'J', 'LastName': 'Coenen', 'Affiliation': 'Department of Internal Medicine, Isala, Zwolle, the Netherlands.'}, {'ForeName': 'Maja', 'Initials': 'M', 'LastName': 'Hinge', 'Affiliation': 'Department of Internal Medicine, Division of Hematology, Vejle Hospital, Vejle, Denmark.'}, {'ForeName': 'Saskia', 'Initials': 'S', 'LastName': 'Klein', 'Affiliation': 'Department of Internal Medicine, Meander Medisch Centrum, Amersfoort, the Netherlands.'}, {'ForeName': 'Bea', 'Initials': 'B', 'LastName': 'Tanis', 'Affiliation': 'Department of Internal Medicine, Groene Hart Ziekenhuis, Gouda, the Netherlands.'}, {'ForeName': 'Damian', 'Initials': 'D', 'LastName': 'Szatkowski', 'Affiliation': 'Department of Oncology, Haematology and Palliative Care, Førde Central Hospital, Førde, Norway.'}, {'ForeName': 'Rolf', 'Initials': 'R', 'LastName': 'Brouwer', 'Affiliation': 'Department of Internal Medicine, Reinier de Graaf Ziekenhuis, Delft, the Netherlands.'}, {'ForeName': 'Matthijs', 'Initials': 'M', 'LastName': 'Westerman', 'Affiliation': 'Department of Internal Medicine, Northwest Clinics, Alkmaar, the Netherlands.'}, {'ForeName': 'Rineke', 'Initials': 'R', 'LastName': 'Leys', 'Affiliation': 'Department of Internal Medicine, Maasstad Ziekenhuis, Rotterdam, the Netherlands.'}, {'ForeName': 'Harm', 'Initials': 'H', 'LastName': 'Sinnige', 'Affiliation': 'Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, the Netherlands.'}, {'ForeName': 'Einar', 'Initials': 'E', 'LastName': 'Haukås', 'Affiliation': 'Department of Haematology, Stavanger University Hospital, Stavanger, Norway.'}, {'ForeName': 'Klaas', 'Initials': 'K', 'LastName': 'van der Hem', 'Affiliation': 'Department of Internal Medicine, Zaans Medisch Centrum, Zaandam, the Netherlands.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Durian', 'Affiliation': 'Department of Internal Medicine, Tweesteden Ziekenhuis, Tilburg, the Netherlands.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Gimsing', 'Affiliation': 'Department of Haematology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'van de Donk', 'Affiliation': 'Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Pieter', 'Initials': 'P', 'LastName': 'Sonneveld', 'Affiliation': 'Department of Haematology, Erasmus Medical Center Cancer Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Waage', 'Affiliation': 'Department of Haematology, St Olavs Hospital and Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Abildgaard', 'Affiliation': 'Quality of Life Research Center, Department of Haematology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Zweegman', 'Affiliation': 'Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands.'}]",Haematologica,['10.3324/haematol.2019.222299'] 1127,31707770,Individuals With Recurrent Low Back Pain Exhibit Significant Changes in Paraspinal Muscle Strength After Intramuscular Fine Wire Electrode Insertion.,"OBJECTIVE To examine how insertion and presence of intramuscular fine-wire electromyography electrodes (IFWEs) in lumbar multifidus affect paraspinal muscle strength, endurance, and activation in persons with and without recurrent lower back pain (RLBP) during activities that require high levels of muscle contraction. DESIGN Case-control with randomization of conditions. SETTING Clinical research laboratory. PARTICIPANTS Forty participants age 18 to 40 years were recruited (18 female; mean age = 25.5 years); 20 with a history of RLBP were compared to a matching control group of 20 without RLBP. INTERVENTIONS Each participant was tested under three conditions over three sessions. On Session 1, the baseline condition, we assessed muscle performance without IFWE insertion. On Sessions 2 and 3, participants were randomly alternated between two experimental conditions: (1) wire-in, in which the IFWE was inserted and remained within the muscle during testing; and (2) wire-out, in which the IFWE was inserted and immediately removed. MAIN OUTCOME MEASUREMENTS Lumbar spinal extensor peak strength, endurance, and normalized electromyography (EMG) amplitude during the endurance test. RESULTS Individuals with RLBP showed a significant decrease in peak strength during conditions that involved IFWE insertion and tend to experience more pain during muscle testing. Both groups exhibited similar levels of performance and muscle activation during the endurance test. CONCLUSION Our findings indicate that individuals with RLBP exhibited reduced lumbar extensor strength in response to IFWE insertion to the deep paraspinal muscles. This behavior is different from those without RLBP. Researchers should carefully consider the use of IFWE in individuals with RLBP during high exertion activities.",2020,"Both groups exhibited similar levels of performance and muscle activation during the endurance test. ","['persons with and without recurrent lower back pain (RLBP', 'individuals with RLBP during high exertion activities', 'Forty participants age 18-40 were recruited (18 female; mean age\u2009=\u200925.5\u2009yr); 20 with a history of RLBP']","['intramuscular fine-wire electromyography electrodes (IFWE', 'matching control group of 20 without RLBP']","['Paraspinal Muscle Strength', 'performance and muscle activation', 'peak strength', 'Lumbar spinal extensor peak strength, endurance, and normalized EMG amplitude during the endurance test', 'lumbar extensor strength']","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015264', 'cui_str': 'Exertion, function (observable entity)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4517663', 'cui_str': 'Twenty-five point five'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}]","[{'cui': 'C0442117', 'cui_str': 'Intramuscular (qualifier value)'}, {'cui': 'C0205232', 'cui_str': 'Fine (qualifier value)'}, {'cui': 'C0005978', 'cui_str': 'Bone Wires'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0013812', 'cui_str': 'Electrode, device (physical object)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0448353', 'cui_str': 'Deep Muscles of the Back'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0024090', 'cui_str': 'Lumbar Region'}, {'cui': 'C0518031', 'cui_str': 'Endurance capacity'}, {'cui': 'C0429340', 'cui_str': 'EMG amplitude'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",40.0,0.0413105,"Both groups exhibited similar levels of performance and muscle activation during the endurance test. ","[{'ForeName': 'Szu-Ping', 'Initials': 'SP', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Therapy, University of Nevada, Las Vegas, NV.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Dinglasan', 'Affiliation': 'Department of Physical Therapy, University of Nevada, Las Vegas, NV.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Duong', 'Affiliation': 'Department of Physical Therapy, University of Nevada, Las Vegas, NV.'}, {'ForeName': 'Russell', 'Initials': 'R', 'LastName': 'Totten', 'Affiliation': 'Department of Physical Therapy, University of Nevada, Las Vegas, NV.'}, {'ForeName': 'Jo A', 'Initials': 'JA', 'LastName': 'Smith', 'Affiliation': 'Department of Physical Therapy, Chapman University, Orange, CA.'}]","PM & R : the journal of injury, function, and rehabilitation",['10.1002/pmrj.12284'] 1128,31501293,Peritoneal Ultrafiltration for Heart Failure: Lessons from a Randomized Controlled Trial.,"Peritoneal ultrafiltration (PuF) has been employed for severe heart failure (HF), but evidence for its benefit is lacking. The Peritoneal Dialysis for Heart Failure (PDHF) study was a multicenter prospective randomized controlled trial which aimed to investigate this issue. The trial stopped early due to inadequate recruitment. We describe methods, trial activity, and lessons learned.The trial aimed to recruit 130 participants with severe diuretic-resistant HF (New York Heart Association [NYHA] 3/4) and chronic kidney disease (CKD) stage 3/4 on optimal medical treatment for ≥ 4 weeks from 6 UK centers. Participants were randomized to either continuation of conventional HF treatment or to additionally receiving PuF (1 overnight exchange using Icodextrin dialysate). Primary outcome was change in 6-minute walk test (6MWT) between baseline and 28 weeks (end of trial). Secondary outcomes were changes in patient reported quality of life as assessed by the Kansas City Cardiomyopathy Questionnaire, short form 36 (SF 36) health survey results, hospitalization, and mortality.Over a 2-year period, 290 patients were screened from which only 20 met inclusion criteria and 10 were recruited. Reasons for ineligibility were fluctuating estimated glomerular filtration rate (eGFR), suboptimal HF treatment, frailty, and patients being too unwell for randomization. Barriers to recruitment included patient frailty, with some participants considered only when they were at end of life, unwillingness to engage in an invasive therapy, and suboptimal coordination between cardiology and renal services. This is a challenging patient group in which to perform research, and lessons learned from the peritoneal dialysis (PD)-HF trial will be helpful in the planning of future studies in this area.",2019,"Secondary outcomes were changes in patient reported quality of life as assessed by the Kansas City Cardiomyopathy Questionnaire, short form 36 (SF 36) health survey results, hospitalization, and mortality.","['130 participants with severe diuretic-resistant HF (New York Heart Association [NYHA] 3/4) and chronic kidney disease (CKD) stage 3/4 on optimal medical treatment for ≥ 4 weeks from 6 UK centers', 'Heart Failure', '290 patients were screened from which only 20 met inclusion criteria and 10 were recruited']","['Peritoneal Ultrafiltration', 'conventional HF treatment or to additionally receiving PuF (1 overnight exchange using Icodextrin dialysate', 'Peritoneal ultrafiltration (PuF']","['quality of life as assessed by the Kansas City Cardiomyopathy Questionnaire, short form 36 (SF 36) health survey results, hospitalization, and mortality', 'change in 6-minute walk test (6MWT']","[{'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0012798', 'cui_str': 'Diuretics'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0442757', 'cui_str': '3/4'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0303135', 'cui_str': '10Be radioisotope'}]","[{'cui': 'C0442034', 'cui_str': 'Peritoneal (qualifier value)'}, {'cui': 'C0041612', 'cui_str': 'Ultrafiltration'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439583', 'cui_str': 'Overnight (qualifier value)'}, {'cui': 'C0538727', 'cui_str': 'icodextrin'}, {'cui': 'C0011947', 'cui_str': 'Dialyzates'}]","[{'cui': 'C0034380'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0878544', 'cui_str': 'Cardiomyopathies'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0430515', 'cui_str': '6-Minute Walk Test'}]",290.0,0.373672,"Secondary outcomes were changes in patient reported quality of life as assessed by the Kansas City Cardiomyopathy Questionnaire, short form 36 (SF 36) health survey results, hospitalization, and mortality.","[{'ForeName': 'Hari', 'Initials': 'H', 'LastName': 'Dukka', 'Affiliation': 'University Hospitals of Derby and Burton, Derby, UK hari.dukka@nhs.net.'}, {'ForeName': 'Philip A', 'Initials': 'PA', 'LastName': 'Kalra', 'Affiliation': 'University of Manchester, Manchester, UK.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Wilkie', 'Affiliation': 'Sheffield Kidney Institute, Sheffield, UK.'}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Bhandari', 'Affiliation': 'Hull and East Yorkshire NHS Trust, Hull, UK.'}, {'ForeName': 'Simon J', 'Initials': 'SJ', 'LastName': 'Davies', 'Affiliation': 'Faculty of Medicine and Health Sciences, Keele University, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Barratt', 'Affiliation': 'University of Leicester and NIHR Biomedical Research Centre, Leicester, UK.'}, {'ForeName': 'Iain', 'Initials': 'I', 'LastName': 'Squire', 'Affiliation': 'University of Leicester and NIHR Biomedical Research Centre, Leicester, UK.'}, {'ForeName': 'Aghogho', 'Initials': 'A', 'LastName': 'Odudu', 'Affiliation': 'University of Manchester, Manchester, UK.'}, {'ForeName': 'Nicholas M', 'Initials': 'NM', 'LastName': 'Selby', 'Affiliation': 'University Hospitals of Derby and Burton, Derby, UK.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'McIntyre', 'Affiliation': 'The University of Western Ontario, London, Canada.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Robertson', 'Affiliation': 'Centre for Kidney Research and Innovation, Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Maarten W', 'Initials': 'MW', 'LastName': 'Taal', 'Affiliation': 'University Hospitals of Derby and Burton, Derby, UK.'}]",Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,['10.3747/pdi.2018.00272'] 1129,31368233,Drainage tube hole suture improvement: Removal-free stitches.,"Surgical method improvements aim to optimize the patient experience. The problem of healing of the drainage tube hole has not received attention and is of concern because it can plague patient recovery. In this article we report on how we have improved the method of suturing the drainage tube hole and explore the safety and effectiveness of this method. Between December 2017 to August 2018, 102 patients underwent thoracoscopic lung resection (single port or single utility port) using different methods of suturing drainage tube holes. The intervention group received improved methods with subcuticular and intradermal suture and removal-free stitches, whilst the control group received a conventional mattress suture and fixed chest tube. A preset line was left to tie knots and close the hole after the removal of the chest tube. The stitches were removed 7-12 days after surgery. The baseline clinical features of the patients were subsequently analyzed. The objective and subjective conditions of scars were evaluated using the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS) at one month after surgery. The intervention group (n = 71) and control group (n = 31) had balanced baseline clinical characteristics. There were no significant differences between the two groups in terms of three-day postoperative pain and postoperative hospital stay. In the intervention group, three patients (4.23%) had wound splitting that required re-suturing, which was better than five patients (16.13%) in the control group (P < 0.05). The incidence of pleural fluid outflow, wound infection, post-removal pneumothorax, chest tube prolapse and incisional hernia were not different between the two groups. We conclude that the objective and subjective evaluation results of scars were significantly different between the two groups (P < 0.05), and the experimental group was superior to the control group. A balanced result between aesthetic appearance and safety as regards video-assisted thoracic surgery can be achieved through the chest tube hole improved suture method. This method also improves the patient's recovery experience.",2019,There were no significant differences between the two groups in terms of three-day postoperative pain and postoperative hospital stay.,"['Between December 2017 to August 2018, 102 patients underwent']","['methods with subcuticular and intradermal suture and removal-free stitches, whilst the control group received a conventional mattress suture and fixed chest tube', 'thoracoscopic lung resection (single port or single utility port) using different methods of suturing drainage tube holes', 'Drainage tube hole suture improvement: Removal-free stitches']","['postoperative pain and postoperative hospital stay', 'incidence of pleural fluid outflow, wound infection, post-removal pneumothorax, chest tube prolapse and incisional hernia', 'Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS', 'objective and subjective evaluation results of scars', 'wound splitting that required re-suturing']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0563304', 'cui_str': 'Subcuticular (qualifier value)'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture (procedure)'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0024940', 'cui_str': 'Mattresses'}, {'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0008034', 'cui_str': 'Chest Tubes'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0452253', 'cui_str': 'Port (substance)'}, {'cui': 'C0013103', 'cui_str': 'Drainage'}, {'cui': 'C4318415', 'cui_str': 'Tube (unit of presentation)'}]","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0225778', 'cui_str': 'Pleural fluid (substance)'}, {'cui': 'C0043241', 'cui_str': 'Wound Infection'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0032326', 'cui_str': 'Pneumothorax'}, {'cui': 'C0008034', 'cui_str': 'Chest Tubes'}, {'cui': 'C0033377', 'cui_str': 'Prolapse'}, {'cui': 'C0267716', 'cui_str': 'Postoperative Hernia'}, {'cui': 'C0008767', 'cui_str': 'Cicatrization'}, {'cui': 'C0222045'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales (assessment scale)'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture (procedure)'}]",102.0,0.0379996,There were no significant differences between the two groups in terms of three-day postoperative pain and postoperative hospital stay.,"[{'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Fu', 'Affiliation': ""Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.""}, {'ForeName': 'Jia-Tao', 'Initials': 'JT', 'LastName': 'Zhang', 'Affiliation': ""Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.""}, {'ForeName': 'Song', 'Initials': 'S', 'LastName': 'Dong', 'Affiliation': ""Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.""}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': ""Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.""}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Zhang', 'Affiliation': ""Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.""}, {'ForeName': 'Wen-Fang', 'Initials': 'WF', 'LastName': 'Tang', 'Affiliation': ""Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.""}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Xia', 'Affiliation': ""Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.""}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Nie', 'Affiliation': ""Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.""}, {'ForeName': 'Wen-Zhao', 'Initials': 'WZ', 'LastName': 'Zhong', 'Affiliation': ""Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.""}]",Thoracic cancer,['10.1111/1759-7714.13157'] 1130,31859347,Mindfulness Versus Distraction to Improve Affective Response and Promote Cardiovascular Exercise Behavior.,"BACKGROUND Variation in affective response to exercise partially explains high levels of inactivity. Examining ways to improve affective responses to physical activity is, therefore, an important direction for research aiming to promote exercise behavior. PURPOSE This study compares three strategies: mindfulness, distraction, and an associative focus comparison group as potential strategies to improve affective response to exercise and promote exercise behavior. METHODS Seventy-eight insufficiently active individuals (M age 26.82, 74% female) were randomly assigned to one of the following three conditions: (a) mindfulness, (b) distraction, or (c) associative attentional focus. The study was divided into two phases, a laboratory session in which participants learned their assigned strategy and completed a 30 min supervised exercise bout and an at-home intervention in which participants used their assigned strategy while exercising on their own for 2 weeks and filled out daily surveys. RESULTS Seventy-five participants completed the study. The central hypotheses were partially supported. Participants in the mindfulness and distraction conditions maintained more positive affective response to exercise over time compared to participants in the associative focus condition, whose affect became less positive over time (p = .04). Participants in the distraction condition experienced lower perceived exertion during exercise (p = .01). There were no condition differences in self-reported minutes exercised during follow-up, but participants in the mindfulness condition reported exercising for more days during the follow-up compared to the associative focus condition (p = .01). CONCLUSIONS These findings suggest individuals wishing to increase their cardiovascular exercise could engage in mindfulness or distraction in order to make exercise feel less difficult and/or more affectively pleasant.",2020,"Participants in the mindfulness and distraction conditions maintained more positive affective response to exercise over time compared to participants in the associative focus condition, whose affect became less positive over time (p = .04).","['Seventy-eight insufficiently active individuals (M age 26.82, 74% female', 'Seventy-five participants completed the study']","['mindfulness, (b) distraction, or (c) associative attentional focus', 'Mindfulness Versus Distraction', '30 min supervised exercise bout and an at-home intervention in which participants used their assigned strategy while exercising on their own for 2 weeks and filled out daily surveys']","['positive affective response', 'Affective Response and Promote Cardiovascular Exercise Behavior']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C4319621', 'cui_str': 'Seventy-five'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C1369038', 'cui_str': 'Distraction (procedure)'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]","[{'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]",78.0,0.020913,"Participants in the mindfulness and distraction conditions maintained more positive affective response to exercise over time compared to participants in the associative focus condition, whose affect became less positive over time (p = .04).","[{'ForeName': 'Arielle S', 'Initials': 'AS', 'LastName': 'Gillman', 'Affiliation': 'Department of Psychology and Neuroscience, University of Colorado Boulder, Boulder, CO, USA.'}, {'ForeName': 'Angela D', 'Initials': 'AD', 'LastName': 'Bryan', 'Affiliation': 'Department of Psychology and Neuroscience, University of Colorado Boulder, Boulder, CO, USA.'}]",Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,['10.1093/abm/kaz059'] 1131,32093657,The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial.,"BACKGROUND Emerging evidence showed promising effects of vitamin D on headaches characteristics. Thus, it seems there is still a need for more researches to clarify the mechanisms by which this vitamin exerts anti-migraine effects. METHODS The present study was conducted as a 16-week randomized double-blind placebo-controlled trial on 80 episodic migraine patients allocated in 2 parallel groups each consisted of 40 patients who received vitamin D 2000 IU/d or placebo. At baseline and after the intervention completion, headache diaries and migraine disability assessment questionnaire (MIDAS) were used to assess migraine related variables in patients. Also, interictal serum concentration of calcitonin gene-related peptide (CGRP) (as the dominant mediator of migraine pain pathogenesis) was evaluated using ELISA method. RESULTS The mean (SD) of age in the vitamin D and placebo groups was 37 (8) and 38 (12) years, respectively. ANCOVA test adjusted for baseline values, and confounders showed vitamin D supplementation resulted in a significant improvement in MIDAS score after 12 weeks in the intervention group (21.49 (16.22-26.77)) compared to placebo (31.16 (25.51-36.82) P value: 0.016). Moreover, after controlling for baseline levels, and other variables using ANCOVA, CGRP level was appeared to be significantly lower following vitamin D supplementation (153.26 (133.03-173.49) ng/L) than the patients in the placebo arm (188.35 (167.15-209.54) ng/L) (P value = 0.022). CONCLUSION According to the current findings, vitamin D supplementation in episodic migraineurs, particularly in those with migraine with aura, may potentially improve migraine headache characteristics and disability probably through attenuating CGRP levels. Therefore, these results could provide a new insight into anti-nociceptive effects of vitamin D; however, more studies are required to confirm our findings. TRIAL REGISTRATION The trial is registered in the Iranian registry of clinical trials (IRCT) at 11 July 2018, with IRCT code: IRCT20151128025267N6.",2020,"ANCOVA test adjusted for baseline values, and confounders showed vitamin D supplementation resulted in a significant improvement in MIDAS score after 12 weeks in the intervention group (21.49 (16.22-26.77)) compared to placebo (31.16 (25.51-36.82) P value: 0.016).","['episodic migraine patients', '80 episodic migraine patients allocated in 2 parallel groups each consisted of 40 patients who received']","['placebo', 'vitamin D 2000\u2009IU/d or placebo', 'vitamin D supplementation', 'vitamin D']","['headaches characteristics', 'CGRP level', 'interictal serum levels of calcitonin gene-related peptide (CGRP', 'interictal serum concentration of calcitonin gene-related peptide (CGRP', 'headache diaries and migraine disability assessment questionnaire (MIDAS', 'MIDAS score']","[{'cui': 'C1455761', 'cui_str': 'Episodic (qualifier value)'}, {'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}]","[{'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0006669', 'cui_str': 'Calcitonin Gene-Related Peptide'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0376660', 'cui_str': 'Diary'}, {'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",80.0,0.73152,"ANCOVA test adjusted for baseline values, and confounders showed vitamin D supplementation resulted in a significant improvement in MIDAS score after 12 weeks in the intervention group (21.49 (16.22-26.77)) compared to placebo (31.16 (25.51-36.82) P value: 0.016).","[{'ForeName': 'Zeinab', 'Initials': 'Z', 'LastName': 'Ghorbani', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Pegah', 'Initials': 'P', 'LastName': 'Rafiee', 'Affiliation': 'Student Research Committee, Department and Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Akbar', 'Initials': 'A', 'LastName': 'Fotouhi', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Samane', 'Initials': 'S', 'LastName': 'Haghighi', 'Affiliation': 'Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Reyhaneh', 'Initials': 'R', 'LastName': 'Rasekh Magham', 'Affiliation': 'Department of Nutrition, Faculty of Medical Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran.'}, {'ForeName': 'Zeynab Sadat', 'Initials': 'ZS', 'LastName': 'Ahmadi', 'Affiliation': 'Department of Nutrition, School of Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Djalali', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mahnaz', 'Initials': 'M', 'LastName': 'Zareei', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Soodeh', 'Initials': 'S', 'LastName': 'Razeghi Jahromi', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Sahar', 'Initials': 'S', 'LastName': 'Shahemi', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Mahmoudi', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. maryam.mahmoudi73@gmail.com.'}, {'ForeName': 'Mansoureh', 'Initials': 'M', 'LastName': 'Togha', 'Affiliation': 'Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. togha1961@gmail.com.'}]",The journal of headache and pain,['10.1186/s10194-020-01090-w'] 1132,31326225,Results from the United States cohort of the HORIZON trial of a Schlemm canal microstent to reduce intraocular pressure in primary open-angle glaucoma.,"PURPOSE To assess the safety and effectiveness of Schlemm canal stenting for reducing intraocular pressure (IOP) in combination with cataract surgery in the United States cohort of the HORIZON study. SETTING Twenty-six clinical sites in the U.S. DESIGN Prospective clinical trial. METHODS Eyes with mild to moderate primary open-angle glaucoma (POAG) on 1 to 4 medications, significant cataract, and an unmedicated diurnal IOP between 22 mm Hg and 34 mm Hg after medication washout were randomized 2:1 to receive the Hydrus microstent or no further treatment after successful cataract surgery. Patients were followed for 24 months. Medication washout and diurnal IOP measurements were repeated at 12 months and 24 months. RESULTS Two hundred nineteen eyes were randomized to microstent implantation and 112 patients to phacoemulsification only. At 24 months, the diurnal IOP was reduced by 20.0% or more in a greater proportion of eyes in the microstent group (78.5% versus 54.5%; P < .001). The mean change in the number of medications was -1.2 ± 0.9 (SD) in the microstent group and -0.8 ± 1.1 in the phaco-only group (P < .001), and 78.5% of eyes and 39.2% of eyes, respectively, were medication free (difference 38.8%; P < .001). CONCLUSIONS Implantation of a Schlemm canal microstent after phacoemulsification significantly reduced diurnal IOP and medication use compared with phacoemulsification only in patients with mild to moderately severe POAG. The combination procedure was equivalent to cataract surgery alone in terms of visual acuity outcomes and the rate of adverse ocular events.",2019,"At 24 months, the diurnal IOP was reduced by 20.0% or more in a greater proportion of eyes in the microstent group (78.5% versus 54.5%; P < .001).","['Eyes with mild to moderate primary open-angle glaucoma (POAG) on 1 to 4 medications, significant cataract, and\xa0an unmedicated diurnal IOP between 22\xa0mm Hg and 34\xa0mm Hg after medication washout', 'patients with mild to moderately severe POAG', 'Two hundred nineteen eyes', 'Twenty-six clinical sites in the U.S']","['cataract surgery', 'Hydrus microstent or no further treatment after successful cataract surgery', 'Schlemm canal stenting']","['intraocular pressure (IOP', 'intraocular pressure', 'visual acuity outcomes and the rate of adverse ocular events', 'safety and effectiveness', 'diurnal IOP and medication use', 'Medication washout and diurnal IOP measurements', 'diurnal IOP']","[{'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0339573', 'cui_str': 'Chronic Primary Open Angle Glaucoma'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0856347', 'cui_str': 'Right cataract'}, {'cui': 'C0332169', 'cui_str': 'Daytime (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0450337', 'cui_str': '19 (qualifier value)'}, {'cui': 'C0450349', 'cui_str': '26 (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}]","[{'cui': 'C2004600', 'cui_str': 'Cataract surgery specialty'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0229108', 'cui_str': 'Structure of sinus venosus of sclera'}]","[{'cui': 'C0021888', 'cui_str': 'Ocular Tension'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C4521296', 'cui_str': 'Ocular (intended site)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0332169', 'cui_str': 'Daytime (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}]",219.0,0.0907855,"At 24 months, the diurnal IOP was reduced by 20.0% or more in a greater proportion of eyes in the microstent group (78.5% versus 54.5%; P < .001).","[{'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Jones', 'Affiliation': 'Jones Eye Clinic, Sioux City, Iowa, USA. Electronic address: jasonjonesmd@mac.com.'}, {'ForeName': 'Douglas D', 'Initials': 'DD', 'LastName': 'Koch', 'Affiliation': 'Cullen Eye Institute, Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Vold', 'Affiliation': 'Vold Vision, Fayetteville, Arkansas, USA.'}, {'ForeName': 'Cathleen', 'Initials': 'C', 'LastName': 'McCabe', 'Affiliation': 'Eye Associates, Sarasota, Florida, USA.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Rhee', 'Affiliation': 'University Hospitals, Case Western Reserve University, Cleveland, Ohio, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Lewis', 'Affiliation': 'Sacramento Eye Consultants, California, USA.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Smith', 'Affiliation': 'Eye Associates of Fort Myers, Florida, USA.'}, {'ForeName': 'Quang H', 'Initials': 'QH', 'LastName': 'Nguyen', 'Affiliation': 'Scripps Clinic, La Jolla, California, USA.'}, {'ForeName': 'Thomas W', 'Initials': 'TW', 'LastName': 'Samuelson', 'Affiliation': 'Minnesota Eye Consultants, Minneapolis, Minnesota USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of cataract and refractive surgery,['10.1016/j.jcrs.2019.03.024'] 1133,32439248,Derivation and validation of a new nutritional index for predicting 90 days mortality after ICU admission in a Korean population.,"BACKGROUND/PURPOSE Predicting the mortality in patients admitted to the ICU is important for determining a treatment strategy and public health policy. Although many scores have been developed to predict the mortality, these scores were based on Caucasian population. We aimed to develop a new prognostic index, the New nutritional index (NNI), to predict 90-days mortality after ICU admission based on Korean population. METHODS Patients (1453) who admitted intensive care unit (ICU) of the Gangnam Severance hospital were analyzed. After exclusion, 984 patients were randomly divided into internal (n = 702) and external validation (n = 282) data set. The new nutritional index (NNI) was developed using univariate and multivariate logistic regression with backward selection of predictors. Receiver operating characteristic (ROC) curve analysis and comparison of the area under the curve (AUC) verified the better predictor of 90 days-mortality after ICU admission. RESULTS The NNI better predicted 90 days-mortality compared to modified NUTRIC score, APACHE II scores, SOFA scores, CRP, glucose, total protein, and albumin level in internal and external data sets, with AUC of 0.862 (SE: 0.017, 95% CI: 0.829-0.895) and 0.858 (SE: 0.015, 95% CI: 0.829-0.887), respectively. The calibration plots using external data set for validation showed a close approximation to the logistic calibration of each nomogram, and p-value of Hosmer and Lemeshow test was 0.1804. CONCLUSION The NNI has advantages as a predictor of 90 days mortality based on nutritional status in the Korean population.",2020,"The NNI better predicted 90 days-mortality compared to modified NUTRIC score, APACHE II scores, SOFA scores, CRP, glucose, total protein, and albumin level in internal and external data sets, with AUC of 0.862 (SE: 0.017, 95% CI: 0.829-0.895) and 0.858","['Patients (1453) who admitted intensive care unit (ICU) of the Gangnam Severance hospital were analyzed', '90 days mortality after ICU admission in a Korean population', '984 patients', 'patients admitted to the ICU']",[],"['modified NUTRIC score, APACHE II scores, SOFA scores, CRP, glucose, total protein, and albumin level in internal and external data sets', 'Receiver operating characteristic (ROC) curve analysis and comparison of the area under the curve (AUC']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0032659', 'cui_str': 'Population'}]",[],"[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0489438', 'cui_str': 'APACHE II score'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0555903', 'cui_str': 'Total protein measurement'}, {'cui': 'C0201838', 'cui_str': 'Albumin measurement'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0150098', 'cui_str': 'Data Set'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}]",984.0,0.0138512,"The NNI better predicted 90 days-mortality compared to modified NUTRIC score, APACHE II scores, SOFA scores, CRP, glucose, total protein, and albumin level in internal and external data sets, with AUC of 0.862 (SE: 0.017, 95% CI: 0.829-0.895) and 0.858","[{'ForeName': 'Da-Hye', 'Initials': 'DH', 'LastName': 'Son', 'Affiliation': 'Department of Family Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Kyung-Sub', 'Initials': 'KS', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Hye-Sun', 'Initials': 'HS', 'LastName': 'Lee', 'Affiliation': 'Biostatistics Collaboration Unit, Department of Research Affairs, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Ji-Won', 'Initials': 'JW', 'LastName': 'Lee', 'Affiliation': 'Department of Family Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: indi5645@yuhs.ac.'}, {'ForeName': 'Cheung-Soo', 'Initials': 'CS', 'LastName': 'Shin', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: cheung56@yuhs.ac.'}]",Journal of the Formosan Medical Association = Taiwan yi zhi,['10.1016/j.jfma.2020.05.007'] 1134,32434638,[Sedative effect of intranasal midazolam in neonates undergoing magnetic resonance imaging: a prospective single-blind randomized controlled study].,"OBJECTIVE To compare intranasal midazolam and intramuscular phenobarbital sodium for their sedative effect in neonates undergoing magnetic resonance imaging (MRI). METHODS A total of 70 neonates who underwent cranial MRI from September 2017 to March 2019 were randomized into an observation group and a control group, with 35 cases in each group. The observation group received intranasal drops of midazolam (0.3 mg/kg), and the control group received intramuscular injection of phenobarbital sodium (10 mg/kg). The sedation status of the neonates was evaluated using the Ramsay Sedation Scale. Meanwhile, the two groups were compared for the success rate of MRI procedure and incidence of adverse reactions. RESULTS In the observation group, the sedation score was the highest at 20 minutes post administration, then was gradually decreasing, and decreased to the lowest level at 70 minutes post administration. In the control group, the sedation score was the lowest at 10 minutes post administration, then was gradually increasing, and increased to the highest level at 40 minutes and 50 minutes post administration, followed by a gradual decrease. Comparison of the sedation score at each time period suggested that the sedation score was significantly higher in the observation group than in the control group within 40 minutes post administration (P<0.05), while there were no significant differences between the two groups in the sedation score after 40 minutes post administration (P>0.05). The success rate of MRI procedure was significantly higher in the observation group than in the control group (89% vs 69%, P<0.05). There was no significant difference between the two groups in the incidence of adverse reactions (P>0.05). CONCLUSIONS Intranasal midazolam is superior to intramuscular phenobarbital sodium in the sedative effect in neonates undergoing MRI, with the benefits of being fast, convenient, safe, and effective.",2020,"There was no significant difference between the two groups in the incidence of adverse reactions (P>0.05). ","['70 neonates who underwent cranial MRI from September 2017 to March 2019', 'neonates undergoing magnetic resonance imaging (MRI', 'neonates undergoing MRI', 'neonates undergoing magnetic resonance imaging']","['intramuscular injection of phenobarbital sodium', 'intranasal drops of midazolam', 'intranasal midazolam', 'midazolam and intramuscular phenobarbital sodium', 'midazolam']","['success rate of MRI procedure and incidence of adverse reactions', 'incidence of adverse reactions', 'sedation score', 'Ramsay Sedation Scale', 'success rate of MRI procedure']","[{'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0037303', 'cui_str': 'Bone structure of cranium'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C0021492', 'cui_str': 'Intramuscular injection'}, {'cui': 'C0282303', 'cui_str': 'Phenobarbital sodium'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}]","[{'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0559295', 'cui_str': 'Ramsay sedation scale'}]",70.0,0.0813785,"There was no significant difference between the two groups in the incidence of adverse reactions (P>0.05). ","[{'ForeName': 'Fang-Hui', 'Initials': 'FH', 'LastName': 'Wang', 'Affiliation': ""Department of Neonatology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. zhouxih@mail.xjtu.edu.cn.""}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Mi', 'Initials': 'M', 'LastName': 'Xiao', 'Affiliation': ''}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Xi-Hui', 'Initials': 'XH', 'LastName': 'Zhou', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1135,31790750,"Impact of a Nurse-Led Advance Care Planning Intervention on Satisfaction, Health-Related Quality of Life, and Health Care Utilization Among Patients With Severe Respiratory Disease: A Randomized Patient-Preference Trial.","CONTEXT Previous work has found that facilitated advance care planning (ACP) interventions are effective in increasing ACP uptake among patients with severe respiratory disease. OBJECTIVES The objective of this study was to investigate whether a nurse-led, facilitated ACP intervention among participants with severe respiratory disease impacts self-reported or clinical outcomes. METHODS A multicenter, open-label, patient-preference, randomized controlled trial of a nurse-led facilitated ACP intervention was performed. Outcome measures included self-report scales (health care satisfaction and EQ-5D-5L health-related quality of life at three- and six-month follow-up), 12-month mortality, and health care utilization during the final 90 days of life. RESULTS One hundred forty-nine participants were recruited across two study settings (metropolitan tertiary hospital respiratory department and rural sites) and 106 were allocated to receive the ACP intervention. There was no effect of the intervention on satisfaction with health care, health-related quality of life, or 12-month mortality rates. Among those participants who died during the follow-up period (N = 54), those allocated to the ACP intervention had significantly fewer outpatient consultations (7.51 vs. 13.6, P < 0.001). There were no changes in emergency department attendances, total hospital admissions or length of stay, or home nursing visits. Among those allocated to the ACP intervention, there was a reduced length of stay in acute hospital settings (7.76 vs. 11.5 nights, P < 0.001) and increased length of stay in palliative hospital settings (5.54 vs. 2.08, P < 0.001) during the final 90 days of life. CONCLUSION A facilitated ACP intervention among patients with severe respiratory disease did not have an impact on satisfaction, health-related quality of life, or 12-month mortality rate. Facilitated ACP may be associated with a different type of health care utilization during the end-of-life period.",2020,"There was no effect of the intervention on satisfaction with healthcare, health-related quality of life or 12-month mortality rates.","['participants with severe respiratory disease impacts self-reported or clinical outcomes', 'patients with severe respiratory disease', '149 participants were recruited across two study settings (metropolitan tertiary hospital respiratory department and rural sites) and 106 allocated to receive the']","['ACP intervention', 'nurse-led, facilitated ACP intervention', 'advance care planning (ACP) interventions', 'nurse-led facilitated ACP intervention', 'nurse-led advance care planning intervention']","['satisfaction, health-related quality of life or 12-month mortality rate', 'satisfaction, health related quality of life and health care utilization', 'satisfaction with healthcare, health-related quality of life or 12-month mortality rates', 'self-report scales (healthcare satisfaction and EQ-5D-5L health-related quality of life at 3- and 6-month follow up), 12-month mortality, and healthcare utilization during the final 90 days of life', 'reduced length of stay in acute hospital settings', 'emergency department attendances, total hospital admissions or length of stay, or home nursing visits', 'outpatient consultations', 'ACP uptake', 'length of stay in palliative hospital settings']","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0035204', 'cui_str': 'Respiration Disorders'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0587437', 'cui_str': 'Tertiary Hospital'}]","[{'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0600371', 'cui_str': 'Advance Health Care Planning'}]","[{'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C0030672', 'cui_str': 'Patient Acceptance of Healthcare'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0042153', 'cui_str': 'use'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission (procedure)'}, {'cui': 'C0019860', 'cui_str': 'Home Care, Nonprofessional'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C1285530', 'cui_str': 'Palliative'}]",149.0,0.0482788,"There was no effect of the intervention on satisfaction with healthcare, health-related quality of life or 12-month mortality rates.","[{'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Sinclair', 'Affiliation': 'University of New South Wales, Sydney, NSW, Australia. Electronic address: c.sinclair@unsw.edu.au.'}, {'ForeName': 'Kirsten Anne', 'Initials': 'KA', 'LastName': 'Auret', 'Affiliation': 'University of Western Australia, Perth, WA, Australia.'}, {'ForeName': 'Sharon Frances', 'Initials': 'SF', 'LastName': 'Evans', 'Affiliation': 'University of Western Australia, Perth, WA, Australia.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Jane', 'Affiliation': 'University of Western Australia, Perth, WA, Australia.'}, {'ForeName': 'Siobhan', 'Initials': 'S', 'LastName': 'Dormer', 'Affiliation': 'Sir Charles Gairdner Hospital, Perth, WA, Australia.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Wilkinson', 'Affiliation': 'Edith Cowan University, Perth, WA, Australia.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Greeve', 'Affiliation': 'Department of Health Western Australia, Perth, WA, Australia.'}, {'ForeName': 'M Audrey', 'Initials': 'MA', 'LastName': 'Koay', 'Affiliation': 'Department of Health Western Australia, Perth, WA, Australia.'}, {'ForeName': 'Fraser', 'Initials': 'F', 'LastName': 'Brims', 'Affiliation': 'Sir Charles Gairdner Hospital, Perth, WA, Australia.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2019.11.018'] 1136,30236776,Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial.,"BACKGROUND Although national guidelines for cancer genetic risk assessment (CGRA) for hereditary breast and ovarian cancer (HBOC) have been available for over two decades, less than half of high-risk women have accessed these services, especially underserved minority and rural populations. Identification of high-risk individuals is crucial for cancer survivors and their families to benefit from biomedical advances in cancer prevention, early detection, and treatment. METHODS This paper describes community-engaged formative research and the protocol of the ongoing randomized 3-arm controlled Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) trial. Ethnically and geographically diverse breast and ovarian cancer survivors at increased risk for hereditary cancer predisposition who have not had a CGRA are recruited through the three statewide cancer registries. The specific aims are to: 1) compare the effectiveness of a targeted intervention (TP) vs. a tailored counseling and navigation(TCN) intervention vs. usual care (UC) on CGRA utilization at 6 months post-diagnosis (primary outcome); compare the effectiveness of the interventions on genetic counseling uptake at 12 months after removal of cost barriers (secondary outcome); 2) examine potential underlying theoretical mediating and moderating mechanisms; and 3) conduct a cost evaluation to guide dissemination strategies. DISCUSSION The ongoing GRACE trial addresses an important translational gap by developing and implementing evidence-based strategies to promote guideline-based care and reduce disparities in CGRA utilization among ethnically and geographically diverse women. If effective, these interventions have the potential to reach a large number of high-risk families and reduce disparities through broad dissemination. TRIAL REGISTRATION NUMBER NCT03326713; clinicaltrials.gov.",2018,Ethnically and geographically diverse breast and ovarian cancer survivors at increased risk for hereditary cancer predisposition who have not had a CGRA are recruited through the three statewide cancer registries.,"['hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors', 'Ethnically and geographically diverse breast and ovarian cancer survivors at increased risk for hereditary cancer predisposition who have not had a CGRA are recruited through the three statewide cancer registries', 'hereditary breast and ovarian cancer (HBOC']","['targeted intervention (TP) vs. a tailored counseling and navigation(TCN) intervention vs. usual care (UC', 'guideline-based cancer genetic risk assessment']",['genetic counseling uptake'],"[{'cui': 'C0439660', 'cui_str': 'Hereditary (qualifier value)'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C1140680', 'cui_str': 'Ovary Cancer'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0012655', 'cui_str': 'Diathesis'}, {'cui': 'C0034975', 'cui_str': 'Registries'}]","[{'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0220845', 'cui_str': 'guidelines'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0017399', 'cui_str': 'genetics'}, {'cui': 'C0086930', 'cui_str': 'Risk assessment (procedure)'}]","[{'cui': 'C0017382', 'cui_str': 'Genetic Counseling'}]",,0.181131,Ethnically and geographically diverse breast and ovarian cancer survivors at increased risk for hereditary cancer predisposition who have not had a CGRA are recruited through the three statewide cancer registries.,"[{'ForeName': 'Anita Y', 'Initials': 'AY', 'LastName': 'Kinney', 'Affiliation': 'Department of Epidemiology, School of Public Health, Rutgers University, New Brunswick, Jersey; Cancer Institute of New Jersey, Rutgers University, New Brunswick, Jersey. Electronic address: anita.kinney@rutgers.edu.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Howell', 'Affiliation': 'Comprehensive Cancer Center, University of New Mexico, Albuquerque, Mexico.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Ruckman', 'Affiliation': 'Comprehensive Cancer Center, University of New Mexico, Albuquerque, Mexico.'}, {'ForeName': 'Jean A', 'Initials': 'JA', 'LastName': 'McDougall', 'Affiliation': 'Department of Internal Medicine, University of New Mexico, Albuquerque, Mexico; Comprehensive Cancer Center, University of New Mexico, Albuquerque, Mexico.'}, {'ForeName': 'Tawny W', 'Initials': 'TW', 'LastName': 'Boyce', 'Affiliation': 'Comprehensive Cancer Center, University of New Mexico, Albuquerque, Mexico.'}, {'ForeName': 'Belinda', 'Initials': 'B', 'LastName': 'Vicuña', 'Affiliation': 'Comprehensive Cancer Center, University of New Mexico, Albuquerque, Mexico; Department of Psychology, University of New Mexico, Albuquerque, Mexico.'}, {'ForeName': 'Ji-Hyun', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, University of New Mexico, Albuquerque, Mexico; Comprehensive Cancer Center, University of New Mexico, Albuquerque, Mexico.'}, {'ForeName': 'Dolores D', 'Initials': 'DD', 'LastName': 'Guest', 'Affiliation': 'Comprehensive Cancer Center, University of New Mexico, Albuquerque, Mexico.'}, {'ForeName': 'Randi', 'Initials': 'R', 'LastName': 'Rycroft', 'Affiliation': 'Colorado Central Cancer Registry, Colorado Department of Public Health and Environment, Denver, CO, United States.'}, {'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Valverde', 'Affiliation': 'Colorado School of Public Health, University of Colorado, Aurora, CO, United States.'}, {'ForeName': 'Kristina M', 'Initials': 'KM', 'LastName': 'Gallegos', 'Affiliation': 'Comprehensive Cancer Center, University of New Mexico, Albuquerque, Mexico.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Meisner', 'Affiliation': 'New Mexico Tumor Registry, University of New Mexico, Albuquerque, Mexico.'}, {'ForeName': 'Charles L', 'Initials': 'CL', 'LastName': 'Wiggins', 'Affiliation': 'Department of Internal Medicine, University of New Mexico, Albuquerque, Mexico; Comprehensive Cancer Center, University of New Mexico, Albuquerque, Mexico; New Mexico Tumor Registry, University of New Mexico, Albuquerque, Mexico.'}, {'ForeName': 'Antoinette', 'Initials': 'A', 'LastName': 'Stroup', 'Affiliation': 'Department of Epidemiology, School of Public Health, Rutgers University, New Brunswick, Jersey; Cancer Institute of New Jersey, Rutgers University, New Brunswick, Jersey.'}, {'ForeName': 'Lisa E', 'Initials': 'LE', 'LastName': 'Paddock', 'Affiliation': 'Department of Epidemiology, School of Public Health, Rutgers University, New Brunswick, Jersey; Cancer Institute of New Jersey, Rutgers University, New Brunswick, Jersey.'}, {'ForeName': 'Scott T', 'Initials': 'ST', 'LastName': 'Walters', 'Affiliation': 'Department of Health Behavior and Health Systems, University of North Texas Health Science Center, School of Public Health, Fort Worth, TX, United States.'}]",Contemporary clinical trials,['10.1016/j.cct.2018.09.005'] 1137,32433510,A trial comparing continuous positive airway pressure (CPAP) devices in preterm infants.,"OBJECTIVE To test the hypothesis that infants born <30 weeks' gestation supported by Seattle-PAP will have lower rates of continuous positive airway pressure (CPAP) failure than infants supported with conventional, Fisher&Paykel-CPAP (FP-CPAP). STUDY DESIGN Randomized trial (3/2017-01/2019) at 5 NICUs. The primary outcome was CPAP failure; subgroup analyses (gestational age, receipt antenatal corticosteroids) were performed. RESULTS A total of 232 infants were randomized. Infants in the Seattle-PAP and FP-CPAP groups had mean gestational ages of 27.0 and 27.2 weeks, respectively. We observed no differences in rates of treatment failure between Seattle-PAP (40/112, 35.7%) and FP-CPAP (38/120, 31.7%; risk difference, 4.1%; 95% CI, -8.1-16.2; P = 0.51). Subgroup analysis indicated no differences in rates of CPAP failure. We observed no differences between the two groups in frequencies of adverse events or duration of respiratory support. CONCLUSIONS Among infants born <30 weeks' gestation, rates of CPAP failure did not differ between Seattle-PAP and FP-CPAP.",2020,"Among infants born <30 weeks' gestation, rates of CPAP failure did not differ between Seattle-PAP and FP-CPAP.","['232 infants were randomized', ""infants born <30 weeks' gestation"", 'preterm infants']",['continuous positive airway pressure (CPAP) devices'],"['rates of treatment failure', 'rates of CPAP failure', 'CPAP failure; subgroup analyses (gestational age, receipt antenatal corticosteroids', 'FP-CPAP', 'continuous positive airway pressure (CPAP) failure']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C2828394', 'cui_str': 'Antenatal'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}]",232.0,0.309661,"Among infants born <30 weeks' gestation, rates of CPAP failure did not differ between Seattle-PAP and FP-CPAP.","[{'ForeName': 'Carl H', 'Initials': 'CH', 'LastName': 'Backes', 'Affiliation': ""Center for Perinatal Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. Carl.backesjr@nationwidechildrens.org.""}, {'ForeName': 'Jennifer N', 'Initials': 'JN', 'LastName': 'Cooper', 'Affiliation': 'Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Notestine', 'Affiliation': ""Center for Perinatal Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Crystal M', 'Initials': 'CM', 'LastName': 'Alfred', 'Affiliation': 'Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Molly K', 'Initials': 'MK', 'LastName': 'Ball', 'Affiliation': 'Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Brian K', 'Initials': 'BK', 'LastName': 'Rivera', 'Affiliation': ""Center for Perinatal Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Jane M', 'Initials': 'JM', 'LastName': 'Lamp', 'Affiliation': ""Center for Perinatal Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Marzec', 'Affiliation': ""Center for Perinatal Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Stenger', 'Affiliation': 'Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Mohannad', 'Initials': 'M', 'LastName': 'Moallem', 'Affiliation': 'Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Randy R', 'Initials': 'RR', 'LastName': 'Miller', 'Affiliation': 'Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Apurwa', 'Initials': 'A', 'LastName': 'Naik', 'Affiliation': 'OhioHealth Grant Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Lindsey J', 'Initials': 'LJ', 'LastName': 'Beer', 'Affiliation': 'Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Howard', 'Affiliation': ""Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, WA, USA.""}, {'ForeName': 'Stephen E', 'Initials': 'SE', 'LastName': 'Welty', 'Affiliation': ""Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, WA, USA.""}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Peter Richardson', 'Affiliation': ""Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, WA, USA.""}, {'ForeName': 'Noah H', 'Initials': 'NH', 'LastName': 'Hillman', 'Affiliation': ""SSM Health, Cardinal Glennon Children's Hospital, St. Louis University, St. Louis, MO, USA.""}, {'ForeName': 'John A F', 'Initials': 'JAF', 'LastName': 'Zupancic', 'Affiliation': 'Division of Newborn Medicine, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Larissa I', 'Initials': 'LI', 'LastName': 'Stanberry', 'Affiliation': 'Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.'}, {'ForeName': 'Thomas N', 'Initials': 'TN', 'LastName': 'Hansen', 'Affiliation': ""Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, WA, USA.""}, {'ForeName': 'Charles V', 'Initials': 'CV', 'LastName': 'Smith', 'Affiliation': ""Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, WA, USA.""}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/s41372-020-0690-5'] 1138,31462766,Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals.,"Medications to treat major depressive disorder (MDD) are not equally effective across patients. Given that neural response to rewards is altered in MDD and given that reward-related circuitry is modulated by dopamine and serotonin, we examined, for the first time, whether reward-related neural activity moderated response to sertraline, an antidepressant medication that targets these neurotransmitters. A total of 222 unmedicated adults with MDD randomized to receive sertraline (n = 110) or placebo (n = 112) in the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study completed demographic and clinical assessments, and pretreatment functional magnetic resonance imaging while performing a reward task. We tested whether an index of reward system function in the ventral striatum (VS), a key reward circuitry region, moderated differential response to sertraline versus placebo, assessed with the Hamilton Rating Scale for Depression (HSRD) over 8 weeks. We observed a significant moderation effect of the reward index, reflecting the temporal dynamics of VS activity, on week-8 depression levels (Fs ≥ 9.67, ps ≤ 0.002). Specifically, VS responses that were abnormal with respect to predictions from reinforcement learning theory were associated with lower week-8 depression symptoms in the sertraline versus placebo arms. Thus, a more abnormal pattern of pretreatment VS dynamic response to reward expectancy (expected outcome value) and prediction error (difference between expected and actual outcome), likely reflecting serotonergic and dopaminergic deficits, was associated with better response to sertraline than placebo. Pretreatment measures of reward-related VS activity may serve as objective neural markers to advance efforts to personalize interventions by guiding individual-level choice of antidepressant treatment.",2020,"Specifically, VS responses that were abnormal with respect to predictions from reinforcement learning theory were associated with lower week-8 depression symptoms in the sertraline versus placebo arms.","['depressed individuals', '222 unmedicated adults with MDD randomized to receive']","['placebo (n\u2009=\u2009112) in the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study completed demographic and clinical assessments, and pretreatment functional magnetic resonance imaging while performing a reward task', 'sertraline', 'placebo', 'sertraline versus placebo']","['Hamilton Rating Scale for Depression (HSRD', 'depression symptoms']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant Drugs'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0074393', 'cui_str': 'Sertraline'}]","[{'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression (assessment scale)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",222.0,0.129786,"Specifically, VS responses that were abnormal with respect to predictions from reinforcement learning theory were associated with lower week-8 depression symptoms in the sertraline versus placebo arms.","[{'ForeName': 'Tsafrir', 'Initials': 'T', 'LastName': 'Greenberg', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. greenbergt@upmc.edu.'}, {'ForeName': 'Jay C', 'Initials': 'JC', 'LastName': 'Fournier', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Richelle', 'Initials': 'R', 'LastName': 'Stiffler', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Henry W', 'Initials': 'HW', 'LastName': 'Chase', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Jorge R', 'Initials': 'JR', 'LastName': 'Almeida', 'Affiliation': 'Department of Psychiatry, Dell Medical School, University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Haris', 'Initials': 'H', 'LastName': 'Aslam', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Thilo', 'Initials': 'T', 'LastName': 'Deckersbach', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Crystal', 'Initials': 'C', 'LastName': 'Cooper', 'Affiliation': 'Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Marisa S', 'Initials': 'MS', 'LastName': 'Toups', 'Affiliation': 'Department of Psychiatry, Dell Medical School, University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Carmody', 'Affiliation': 'Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Benji', 'Initials': 'B', 'LastName': 'Kurian', 'Affiliation': 'Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Peltier', 'Affiliation': 'Functional MRI Laboratory, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'Adams', 'Affiliation': 'Department of Psychiatry, Columbia University College of Physicians and Surgeons and The New York State Psychiatric Institute, New York, NY, USA.'}, {'ForeName': 'Melvin G', 'Initials': 'MG', 'LastName': 'McInnis', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Maria A', 'Initials': 'MA', 'LastName': 'Oquendo', 'Affiliation': 'Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Fava', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Ramin', 'Initials': 'R', 'LastName': 'Parsey', 'Affiliation': 'Departments of Psychiatry and Behavioral Science & Radiology, Stony Brook University, Stony Brook, NY, USA.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'McGrath', 'Affiliation': 'Department of Psychiatry, Columbia University College of Physicians and Surgeons and The New York State Psychiatric Institute, New York, NY, USA.'}, {'ForeName': 'Myrna', 'Initials': 'M', 'LastName': 'Weissman', 'Affiliation': 'Department of Psychiatry, Columbia University College of Physicians and Surgeons and The New York State Psychiatric Institute, New York, NY, USA.'}, {'ForeName': 'Madhukar', 'Initials': 'M', 'LastName': 'Trivedi', 'Affiliation': 'Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Mary L', 'Initials': 'ML', 'LastName': 'Phillips', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.'}]",Molecular psychiatry,['10.1038/s41380-019-0490-5'] 1139,31201564,Cobb angle measurement with a conventional convex echography probe and a smartphone.,"BACKGROUND CONTEXT Serial X-rays are needed during the follow-up of adolescent idiopathic scoliosis. They are done every 6 or 3 months in cases of high risk of progression. Thanks to the advances in ultrasound techniques, deformity measurement systems free from ionizing radiations have been validated, although spinal surgeons did not use them routinely due to the need of special software. OBJECTIVE The aim of our work is to assess the reproducibility and correlation of an ultrasound measuring system based on the positioning of the transverse processes. STUDY DESIGN Prospective, single center, randomized, triple blinded. METHODS Two independent researchers trained in ultrasound examined the spinal deformities of 31 children. The measurements were compared against those performed with an X-ray by three scoliosis expert surgeons. Statistics were performed by an independent researcher. Parametric methods were used. RESULTS We found a 95% [(0.91-0.97) p < 2.2e -16 ] correlation between the degree of scoliosis measured with the proposed ultrasound system and the 30 cm × 90 cm X-rays in standing position. There was an intra-observer reliability of 97% [r-squared = 0.97; CI 95% (0.95-0.98) p < 2.2e -16 ] and an inter-observer reliability of 95% [r-squared = 0.95; CI 95% (0.90-0.97) p < 2.2e -16 ]. CONCLUSIONS An approximation of the Cobb angle measure is possible with ultrasound by using the transverse processes as reference. This is a very rapid and simple system for assessing the principal spinal deformity measure in young people, although it does not allow estimating the associated axial or sagittal rotation. These slides can be retrieved under Electronic Supplementary Material.",2019,We found a 95% [(0.91-0.97) p < 2.2e -16 ] correlation between the degree of scoliosis measured with the proposed ultrasound system and the 30 cm × 90 cm X-rays in standing position.,"['young people', 'Two independent researchers trained in ultrasound examined the spinal deformities of 31 children']",['conventional convex echography probe and a smartphone'],[],"[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0575157', 'cui_str': 'Deformity of spine (finding)'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0041618', 'cui_str': 'Echotomography'}, {'cui': 'C3179165', 'cui_str': 'Probe (methazole)'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}]",[],31.0,0.044673,We found a 95% [(0.91-0.97) p < 2.2e -16 ] correlation between the degree of scoliosis measured with the proposed ultrasound system and the 30 cm × 90 cm X-rays in standing position.,"[{'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Ferràs-Tarragó', 'Affiliation': 'La Fe Hospital, Valencia, Spain. cotferras@gmail.com.'}, {'ForeName': 'J M Morales', 'Initials': 'JMM', 'LastName': 'Valencia', 'Affiliation': 'La Fe Hospital, Valencia, Spain.'}, {'ForeName': 'P Rubio', 'Initials': 'PR', 'LastName': 'Belmar', 'Affiliation': 'La Fe Hospital, Valencia, Spain.'}, {'ForeName': 'S Pérez', 'Initials': 'SP', 'LastName': 'Vergara', 'Affiliation': 'La Fe Hospital, Valencia, Spain.'}, {'ForeName': 'P Jordà', 'Initials': 'PJ', 'LastName': 'Gómez', 'Affiliation': 'La Fe Hospital, Valencia, Spain.'}, {'ForeName': 'J L Bas', 'Initials': 'JLB', 'LastName': 'Hermida', 'Affiliation': 'La Fe Hospital, Valencia, Spain.'}, {'ForeName': 'P Bas', 'Initials': 'PB', 'LastName': 'Hermida', 'Affiliation': 'La Fe Hospital, Valencia, Spain.'}, {'ForeName': 'T Bas', 'Initials': 'TB', 'LastName': 'Hermida', 'Affiliation': 'La Fe Hospital, Valencia, Spain.'}]","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society",['10.1007/s00586-019-06030-0'] 1140,32433648,Pre-injury activity predicts outcomes following distal radius fractures in patients age 60 and older.,"INTRODUCTION One out of every 5 elderly patients will suffer a distal radius fracture and these injuries are often related to poor bone health. Several surgical subspecialties have demonstrated that pre-injury activity level can impact patient outcomes. To determine the importance of physical activity, we examined the relationship between pre-injury activity and patient-reported and functional outcomes among fracture patients. METHODS This is a retrospective analysis of prospectively collected data from participants enrolled in the Wrist and Radius Injury Surgical Trial (WRIST) from April 10, 2012 to December 31, 2016. This study included 304 adults, 60 years or older with isolated unstable distal radius fractures; 187 were randomized to one of three surgical treatments and 117 opted for casting. Participants opting for surgery were randomized to receive volar locking plate, percutaneous pinning, or external fixation. Participants who chose not to have surgery were treated with casting. All participants were stratified prior to analysis into highly and less-active groups based on pre-injury Rapid Assessment of Physical Activity Scores. RESULTS 280 patients had 12-month assessments of outcomes. Highly active participants scored 8 and 5 points greater on the Michigan Hand Questionnaire at 6 weeks and 3 months respectively, p<0.05. Highly active participants demonstrated greater grip strength at the 3-month (p = 0.017) and 6-month (p = 0.007) time-points. Highly active participants treated with volar locking plate scored 10+ points greater on the Michigan Hand Questionnaire compared to the less-active group at the 6-week (p = 0.032), 3-month (p = 0.009) and 12-month (0.004) time points, with an effect size larger than 0.50, suggesting pre-injury level of activity had a significant clinical impact. CONCLUSIONS Higher levels of pre-injury activity are predictive of patient-reported and functional outcomes following distal radius fracture. Because of the greater PROs, the early mobility and lower risk of hardware infection reported in the literature, volar plating is preferable to other treatments for highly active patients who request and meet indications for surgery. TRIAL REGISTRATION clinicaltrials.gov identifier: NCT01589692.",2020,"Highly active participants scored 8 and 5 points greater on the Michigan Hand Questionnaire at 6 weeks and 3 months respectively, p<0.05.","['Participants opting for surgery', '280 patients had 12-month assessments of outcomes', 'fracture patients', 'patients age 60 and older', 'Participants who chose not to have surgery were treated with casting', '304 adults, 60 years or older with isolated unstable distal radius fractures; 187', 'participants enrolled in the Wrist and Radius Injury Surgical Trial (WRIST) from April 10, 2012 to December 31, 2016']","['volar locking plate', 'volar locking plate, percutaneous pinning, or external fixation', 'distal radius fractures']","['Physical Activity Scores', 'grip strength', 'Michigan Hand Questionnaire']","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0179686', 'cui_str': 'Cast'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205409', 'cui_str': 'Isolated'}, {'cui': 'C0443343', 'cui_str': 'Unstable status'}, {'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius'}, {'cui': 'C4517618', 'cui_str': '187'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0034627', 'cui_str': 'Bone structure of radius'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0443349', 'cui_str': 'Volar'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0407333', 'cui_str': 'External skeletal fixation procedure'}, {'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0025939', 'cui_str': 'Michigan'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",304.0,0.0768138,"Highly active participants scored 8 and 5 points greater on the Michigan Hand Questionnaire at 6 weeks and 3 months respectively, p<0.05.","[{'ForeName': 'Rachel C', 'Initials': 'RC', 'LastName': 'Hooper', 'Affiliation': 'Hand Surgery Fellow, Section of Plastic Surgery, Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, United States of America.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Zhou', 'Affiliation': 'PhD Candidate, Department of Biostatistics, University of Michigan, Ann Arbor, MI, United States of America.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Associate Professor, Department of Biostatistics, University of Michigan, Ann Arbor, MI, United States of America.'}, {'ForeName': 'Melissa J', 'Initials': 'MJ', 'LastName': 'Shauver', 'Affiliation': 'Clinical Research Coordinator, Section of Plastic Surgery, Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, United States of America.'}, {'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': 'Chung', 'Affiliation': 'Charles B. G. de Nancrede Professor of Surgery, Section of Plastic Surgery, Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, United States of America.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",PloS one,['10.1371/journal.pone.0232684'] 1141,31801630,Effects of functional tasks exercise on cognitive functions of older adults with mild cognitive impairment: a randomized controlled pilot trial.,"BACKGROUND Dementia has been presenting an imminent public health challenge worldwide. Studies have shown a combination of cognitive and physical trainings may have synergistic value for improving cognitive functions. Daily functional tasks are innately cognitive demanding and involve components found in common exercise. Individuals with mild cognitive impairment may demonstrate difficulties with complex activities of daily living. Functional tasks could possibly be used as a means of combined cognitive and exercise training for improving cognitive functions. This pilot aims to validate the effects of functional tasks exercise on cognitive functions and functional status in older adults with mild cognitive impairment. METHODS A four-arm, rater-blinded randomized controlled trial. Participants (N = 59) were randomized to either a functional task exercise group, a cognitive training group, an exercise training group, or a waitlist control group for 8 weeks. All outcome measures were undertaken at baseline and post-intervention using Neurobehavioral Cognitive Status Examination, Trail Making Test A and B, Chinese Version Verbal Learning Test, Lawton Instrumental Activities of Daily Living Scale, and Zarit Burden Interview. RESULTS Results of the Kruskal-Wallis one-way ANOVA showed higher improvement in the functional task exercise group with significant between-group differences in memory (p = 0.009) compared to the exercise group and cognitive training group, functional status (p = 0.005) compared to the cognitive training group and waitlist control group, and caregiver burden (p = 0.037) compared to the exercise group and cognitive training group. CONCLUSION This pilot study showed that functional tasks exercise using simulated functional tasks as a means of combined cognitive and exercise program is feasible and beneficial in improving the memory and functional status of older adults with mild cognitive impairment as well as reducing the care-related burdens of their caregivers. The present findings warrant further well-designed longitudinal studies to examine the sustainability of effects and draw more definitive conclusions. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry, ACTRN 12616001635459. Registered on 25 November 2016.",2019,"RESULTS Results of the Kruskal-Wallis one-way ANOVA showed higher improvement in the functional task exercise group with significant between-group differences in memory (p = 0.009) compared to the exercise group and cognitive training group, functional status (p = 0.005) compared to the cognitive training group and waitlist control group, and caregiver burden (p = 0.037) compared to the exercise group and cognitive training group. ","['Individuals with mild cognitive impairment', 'Participants (N\u2009=\u200959', 'older adults with mild cognitive impairment']","['combined cognitive and exercise training', 'functional tasks exercise', 'combined cognitive and exercise program', 'functional task exercise group, a cognitive training group, an exercise training group, or a waitlist control group for 8\u2009weeks']","['cognitive functions and functional status', 'cognitive functions', 'caregiver burden', 'Neurobehavioral Cognitive Status Examination, Trail Making Test A and B, Chinese Version Verbal Learning Test, Lawton Instrumental Activities of Daily Living Scale, and Zarit Burden Interview']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0475497', 'cui_str': 'Neurobehavioral Cognitive Status Examination'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0042531', 'cui_str': 'Verbal Learning'}, {'cui': 'C4720843', 'cui_str': 'Lawton instrumental activities of daily living scale (assessment scale)'}, {'cui': 'C0935630', 'cui_str': 'Interview'}]",,0.0577172,"RESULTS Results of the Kruskal-Wallis one-way ANOVA showed higher improvement in the functional task exercise group with significant between-group differences in memory (p = 0.009) compared to the exercise group and cognitive training group, functional status (p = 0.005) compared to the cognitive training group and waitlist control group, and caregiver burden (p = 0.037) compared to the exercise group and cognitive training group. ","[{'ForeName': 'Lawla L F', 'Initials': 'LLF', 'LastName': 'Law', 'Affiliation': 'School of Medical and Health Sciences, Tung Wah College, Block A, 98 Shantung Street, Mongkok, Hong Kong SAR. lawlalaw@twc.edu.hk.'}, {'ForeName': 'Vincent C T', 'Initials': 'VCT', 'LastName': 'Mok', 'Affiliation': 'Therese Pei Fong Chow Research Centre for Prevention of Dementia, Gerald Choa Neuroscience Centre, Lui Che Woo Institute of Innovative Medicine, Division of Neurology, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong. Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong SAR.'}, {'ForeName': 'Matthew M K', 'Initials': 'MMK', 'LastName': 'Yau', 'Affiliation': 'School of Medical and Health Sciences, Tung Wah College, 31 Wylie Road, Homantin, Hong Kong SAR.'}]",Alzheimer's research & therapy,['10.1186/s13195-019-0548-2'] 1142,32087684,Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis.,"BACKGROUND Oral iron is recommended as first line treatment of anemia in non-dialysis chronic kidney disease (ND-CKD) patients. Sucrosomial® iron, a new generation oral iron with high absorption and bioavailability and a low incidence of side effects, has shown to be not inferior to intravenous (IV) iron in the replacement of iron deficiency anemia in patients with ND-CKD. Besides the clinical benefit, it is also important to determine the comparative total costs of oral versus IV iron administrations. The aim of this study was to perform a cost-minimization analysis of oral Sucrosomial iron, compared with IV iron gluconate from an Italian societal perspective. METHODS Cost analysis was performed on the 99 patients with ND-CKD and iron-deficiency anemia of the randomized trial by Pisani et al. Human and material resources utilization was recorded during each iron administration. According to study perspective, direct and indirect costs were considered. Costs for each resource unit were taken from official Italian sources. Probabilistic sensitivity analyses were carried out to test the robustness of the results. RESULTS The base case analysis showed an average cost/cycle per patient of € 111 for oral iron and € 1302 for IV iron. Thus, the potential saving was equal to € 1191 per patient/cycle. The sensitivity analysis showed that the most sensitive driver is the time loss by patient and caregivers for the therapy and related-care, followed by the minutes of nursing care and the number of kilometres travelled to reach the referral centre. DISCUSSION This study showed that oral Sucrosomial® iron could offer specific advantages in terms of potential savings, and allowed identifying some implications for future research. Such advantages still persist with the new single dose IV iron formulation available in the market, although to a lesser extent.",2020,"Sucrosomial® iron, a new generation oral iron with high absorption and bioavailability and a low incidence of side effects, has shown to be not inferior to intravenous (IV) iron in the replacement of iron deficiency anemia in patients with ND-CKD.","['ND-CKD patients', 'anemia in non-dialysis chronic kidney disease (ND-CKD) patients', '99 patients with ND-CKD and iron-deficiency anemia of the randomized trial by Pisani et al', 'patients with ND-CKD']","['Oral Sucrosomial® iron versus intravenous iron', 'oral Sucrosomial iron, compared with IV iron gluconate']",['potential saving'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C4551529', 'cui_str': 'Renal Dialysis'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia (disorder)'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0220836', 'cui_str': 'gluconate'}]","[{'cui': 'C0036245', 'cui_str': 'Savings'}]",99.0,0.0249461,"Sucrosomial® iron, a new generation oral iron with high absorption and bioavailability and a low incidence of side effects, has shown to be not inferior to intravenous (IV) iron in the replacement of iron deficiency anemia in patients with ND-CKD.","[{'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Riccio', 'Affiliation': 'Department of Nephrology, University of Campania ""Luigi Vanvitelli"", via S. Pansini 5, 80131, Naples, Italy. elyriccio@libero.it.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Sabbatini', 'Affiliation': 'Chair of Nephrology, Department of Public Health, University Federico II of Naples, Naples, Italy.'}, {'ForeName': 'Ivana', 'Initials': 'I', 'LastName': 'Capuano', 'Affiliation': 'Chair of Nephrology, Department of Public Health, University Federico II of Naples, Naples, Italy.'}, {'ForeName': 'Angela Maria', 'Initials': 'AM', 'LastName': 'Pellegrino', 'Affiliation': 'Chair of Nephrology, Department of Public Health, University Federico II of Naples, Naples, Italy.'}, {'ForeName': 'Luigi Annicchiarico', 'Initials': 'LA', 'LastName': 'Petruzzelli', 'Affiliation': 'Chair of Nephrology, Department of Public Health, University Federico II of Naples, Naples, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Pisani', 'Affiliation': 'Chair of Nephrology, Department of Public Health, University Federico II of Naples, Naples, Italy.'}]",BMC nephrology,['10.1186/s12882-020-01716-w'] 1143,31362969,Short-term weight gain among preschool children in rural Burkina Faso: a secondary analysis of a randomised controlled trial.,"OBJECTIVES Nutrition has profound effects on children's health outcomes and is linked to weight gain and cognitive development. We used data from a randomised controlled trial to evaluate the prospective associations between dietary, socioeconomic and demographic factors and short-term weight gain during the lean season in a rural area of Burkina Faso. DESIGN Prospective cohort data arising from a randomised controlled trial of the effect of antibiotic distribution on child growth and intestinal microbial diversity. SETTING Two rural communities in Nouna District, Burkina Faso. PARTICIPANTS 246 children aged 6-59 months living in the study communities were enrolled in the study. PRIMARY AND SECONDARY OUTCOME MEASURES Anthropometric measurements, including weight and height, were obtained at baseline and 1 month. RESULTS Of 246 children, the median weight for wasted children at baseline (weight-for-height z-score <-2) was 9.7 kg (IQR 8.65-10.8) and the weight of non-wasted children was 12.8 kg (IQR 10.9-14.75). Food insecurity was significantly associated with decreased weight gain velocity (mean difference -0.03 g/kg/day, 95% CI -0.06 to -0.006, p=0.04). CONCLUSION Experiences of household food insecurity before the beginning of the lean season were associated with decreased weight gain in children in rural Burkina Faso during the lean season, although the mean difference was small. Understanding the relationship between timing of food insecurity and anthropometric outcomes may help to develop policies and health programme that address both of these issues. TRIAL REGISTRATION NUMBER NCT03187834.",2019,"Food insecurity was significantly associated with decreased weight gain velocity (mean difference -0.03 g/kg/day, 95% CI -0.06 to -0.006, p=0.04). ","['246 children aged 6-59 months living in the study communities were enrolled in the study', '246 children', 'preschool children in rural Burkina Faso', 'Two rural communities in Nouna District, Burkina Faso']","['antibiotic distribution', 'Short-term weight gain']","['weight gain velocity', 'weight and height', 'weight gain', 'median weight']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0008100', 'cui_str': 'Child, Preschool'}, {'cui': 'C0006409', 'cui_str': 'Upper Volta'}, {'cui': 'C0086944', 'cui_str': 'Rural Communities'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}]","[{'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",246.0,0.192416,"Food insecurity was significantly associated with decreased weight gain velocity (mean difference -0.03 g/kg/day, 95% CI -0.06 to -0.006, p=0.04). ","[{'ForeName': 'Elena G', 'Initials': 'EG', 'LastName': 'Dennis', 'Affiliation': 'Francis I Proctor Foundation, University of California, San Francisco, California, USA.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Sie', 'Affiliation': 'Centre de Recherche en Sante de Nouna, Nouna, Burkina Faso.'}, {'ForeName': 'Lucienne', 'Initials': 'L', 'LastName': 'Ouermi', 'Affiliation': 'Centre de Recherche en Sante de Nouna, Nouna, Burkina Faso.'}, {'ForeName': 'Clarisse', 'Initials': 'C', 'LastName': 'Dah', 'Affiliation': 'Centre de Recherche en Sante de Nouna, Nouna, Burkina Faso.'}, {'ForeName': 'Charlemagne', 'Initials': 'C', 'LastName': 'Tapsoba', 'Affiliation': 'Centre de Recherche en Sante de Nouna, Nouna, Burkina Faso.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Zabre', 'Affiliation': 'Centre de Recherche en Sante de Nouna, Nouna, Burkina Faso.'}, {'ForeName': 'Till', 'Initials': 'T', 'LastName': 'Bärnighausen', 'Affiliation': 'Institute of Public Health, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Kieran S', 'Initials': 'KS', 'LastName': ""O'Brien"", 'Affiliation': 'Francis I Proctor Foundation, University of California, San Francisco, California, USA.'}, {'ForeName': 'Elodie', 'Initials': 'E', 'LastName': 'Lebas', 'Affiliation': 'Francis I Proctor Foundation, University of California, San Francisco, California, USA.'}, {'ForeName': 'Jeremy D', 'Initials': 'JD', 'LastName': 'Keenan', 'Affiliation': 'Francis I Proctor Foundation, University of California, San Francisco, California, USA.'}, {'ForeName': 'Catherine E', 'Initials': 'CE', 'LastName': 'Oldenburg', 'Affiliation': 'Francis I Proctor Foundation, University of California, San Francisco, California, USA catherine.oldenburg@ucsf.edu.'}]",BMJ open,['10.1136/bmjopen-2019-029634'] 1144,32439503,Pressure-Support Ventilation vs T-Piece During Spontaneous Breathing Trials Before Extubation Among Patients at High Risk of Extubation Failure: A Post-Hoc Analysis of a Clinical Trial.,"BACKGROUND Spontaneous breathing trial (SBT) using a T-piece remains the most frequently performed trial before extubation in ICUs. RESEARCH QUESTION We aimed at determining whether initial SBT using pressure-support ventilation (PSV) could increase successful extubation rates among patients at high risk of extubation failure. STUDY DESIGN AND METHODS Post hoc analysis of a multicenter trial focusing on reintubation in patients at high-risk of extubation failure. The initial SBT was performed using PSV or T-piece according to the physician/center decision. The primary outcome was the proportion of patients successfully extubated 72 hours after initial SBT, that is, extubated after initial SBT and not reintubated within the following 72 hours. RESULTS Among the 641 patients included in the original study, initial SBT was performed using PSV (7.0 cm H 2 O in median without positive end-expiratory pressure) in 243 patients (38%) and using a T-piece in 398 patients (62%). The proportion of patients successfully extubated 72 hours after initial SBT was 67% (162/243) using PSV and 56% (223/398) using T-piece (absolute difference 10.6%; 95% CI, 2.8 to 28.1; P = .0076). The proportion of patients extubated after initial SBT was 77% (186/283) using PSV and 63% (249/398) using T-piece (P = .0002), whereas reintubation rates within the following 72 hours did not significantly differ (13% vs 10%, respectively; P = .4259). Performing an initial SBT using PSV was independently associated with successful extubation (adjusted OR, 1.60; 95% CI, 1.30 to 2.18; P = .0061). INTERPRETATION In patients at high risk of extubation failure in the ICU, performing an initial SBT using PSV may hasten extubation without an increased risk of reintubation.",2020,"Performing an initial SBT using PSV was independently associated with successful extubation (adjusted odds ratio 1.60, 95% CI 1.30 to 2.18; p=0.0061). ","['641 patients included in the original study, initial SBT', 'patients at high-risk of extubation failure']","['Pressure-support ventilation versus T-piece', 'SBT using pressure-support ventilation (PSV']","['successful extubation', 'successful extubation rates', 'proportion of patients extubated after initial SBT', 'proportion of patients successfully extubated 72h after initial SBT', 'proportion of patients successfully extubated 72h after initial SBT, i.e. extubated after initial SBT', 'reintubation rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205313', 'cui_str': 'Original'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C1828139', 'cui_str': 'Trial for spontaneous breathing'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0231174', 'cui_str': 'Failure'}]","[{'cui': 'C0419008', 'cui_str': 'Pressure support'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C1828139', 'cui_str': 'Trial for spontaneous breathing'}]","[{'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C1828139', 'cui_str': 'Trial for spontaneous breathing'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C0860359', 'cui_str': 'Reintubate'}]",641.0,0.20449,"Performing an initial SBT using PSV was independently associated with successful extubation (adjusted odds ratio 1.60, 95% CI 1.30 to 2.18; p=0.0061). ","[{'ForeName': 'Arnaud W', 'Initials': 'AW', 'LastName': 'Thille', 'Affiliation': ""Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France; INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France. Electronic address: aw.thille@gmail.com.""}, {'ForeName': 'Rémi', 'Initials': 'R', 'LastName': 'Coudroy', 'Affiliation': ""Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France; INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.""}, {'ForeName': 'Mai-Anh', 'Initials': 'MA', 'LastName': 'Nay', 'Affiliation': ""Centre Hospitalier Régional d'Orléans, Médecine Intensive Réanimation, Orléans, France.""}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Gacouin', 'Affiliation': 'Centre Hospitalier Universitaire de Rennes, Hôpital Ponchaillou, Service des Maladies Infectieuses et Réanimation Médicale, Rennes, France.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Demoule', 'Affiliation': 'Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), UMRS1158 neurophysiologie respiratoire expérimentale et clinique, Sorbonne Université, Paris, France.'}, {'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Sonneville', 'Affiliation': 'Hôpital Bichat-Claude Bernard, Médecine Intensive Réanimation, Université Paris Diderot, Paris, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Beloncle', 'Affiliation': ""Centre Hospitalier Universitaire d'Angers, Département de Médecine Intensive Réanimation, Université d'Angers, Angers, France.""}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Girault', 'Affiliation': 'Centre Hospitalier Universitaire de Rouen, Hôpital Charles Nicolle, Département de Réanimation Médicale, Normandie Université, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Dangers', 'Affiliation': 'Centre Hospitalier Universitaire Félix Guyon, Service de Réanimation Polyvalente, Saint Denis de la Réunion, France.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Lautrette', 'Affiliation': 'Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Gabriel Montpied, Service de Réanimation Médicale, Clermont-Ferrand, France.'}, {'ForeName': 'Quentin', 'Initials': 'Q', 'LastName': 'Levrat', 'Affiliation': 'Centre Hospitalier de La Rochelle, Service de Réanimation, La Rochelle, France.'}, {'ForeName': 'Anahita', 'Initials': 'A', 'LastName': 'Rouzé', 'Affiliation': 'Centre Hospitalier Universitaire de Lille, Centre de Réanimation, Université de Lille, Lille, France.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Vivier', 'Affiliation': 'Hôpital Saint-Joseph Saint-Luc, Réanimation Polyvalente, Lyon, France.'}, {'ForeName': 'Jean-Baptiste', 'Initials': 'JB', 'LastName': 'Lascarrou', 'Affiliation': 'Centre Hospitalier Universitaire de Nantes, Médecine Intensive Réanimation, Nantes, France.'}, {'ForeName': 'Jean-Damien', 'Initials': 'JD', 'LastName': 'Ricard', 'Affiliation': 'Hôpital Louis Mourier, Réanimation Médico-Chirurgicale, Université Paris Diderot, Sorbonne Paris Cité, Colombes, France.'}, {'ForeName': 'Keyvan', 'Initials': 'K', 'LastName': 'Razazi', 'Affiliation': 'Hôpitaux universitaires Henri Mondor, Service de Réanimation Médicale DHU A-TVB, Créteil, France.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Barberet', 'Affiliation': 'Groupe Hospitalier Régional Mulhouse Sud Alsace, site Emile Muller, Service de Réanimation Médicale, Mulhouse, France.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Lebert', 'Affiliation': 'Centre Hospitalier Départemental de Vendée, Service de Médecine Intensive Réanimation, La Roche Sur Yon, France.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Ehrmann', 'Affiliation': ""Centre Hospitalier Régional Universitaire de Tours, Médecine Intensive Réanimation, Réseau CRICS-Trigger SEP, Centre d'étude des pathologies respiratoires, Université de Tours, Tours, France.""}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Massri', 'Affiliation': 'Centre Hospitalier de Pau, Service de Réanimation, Pau, France.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Bourenne', 'Affiliation': 'Centre Hospitalier Universitaire La Timone 2, Médecine Intensive Réanimation, Réanimation des Urgences, Aix-Marseille Université, Marseille, France.'}, {'ForeName': 'Gael', 'Initials': 'G', 'LastName': 'Pradel', 'Affiliation': ""Centre Hospitalier Henri Mondor d'Aurillac, Service de Réanimation, Aurillac, France.""}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Bailly', 'Affiliation': 'Centre Hospitalier Universitaire de Brest, Médecine Intensive Réanimation, Brest, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Terzi', 'Affiliation': 'Centre Hospitalier Universitaire Grenoble Alpes, Médecine Intensive Réanimation, INSERM, Université Grenoble-Alpes, Grenoble, France.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Dellamonica', 'Affiliation': ""Centre Hospitalier Universitaire de Nice, Médecine Intensive Réanimation, Archet 1, Université Cote d'Azur, Nice, France.""}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Lacave', 'Affiliation': 'Centre Hospitalier de Versailles, Service de Réanimation Médico-Chirurgicale, Le Chesnay, France.'}, {'ForeName': 'René', 'Initials': 'R', 'LastName': 'Robert', 'Affiliation': ""Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France; INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.""}, {'ForeName': 'Stéphanie', 'Initials': 'S', 'LastName': 'Ragot', 'Affiliation': ""INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.""}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Frat', 'Affiliation': ""Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France; INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Chest,['10.1016/j.chest.2020.04.053'] 1145,31462735,MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.,"We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance, or Benda induction alone. Patients with a clonal marker (t[14;18] translocation and/or immunoglobulin heavy or light chain rearrangement) detected at study screening were assessed for MRD at mid-induction (MI), end of induction (EOI), and every 6-24 months post-EOI/discontinuation by real-time quantitative PCR. At MI, 41/52 (79%) patients receiving G-Benda were MRD-negative vs. 17/36 (47%) patients receiving Benda alone (p = 0.0029). At EOI, 54/63 (86%) patients receiving G-Benda were MRD-negative vs. 30/55 (55%) receiving Benda alone (p = 0.0002). MRD-negative patients at EOI had improved progression-free survival (HR, 0.33, 95% CI, 0.19-0.56, p < 0.0001) and overall survival (HR, 0.39, 95% CI, 0.19-0.78, p = 0.008) vs. MRD-positive patients, and maintained their MRD-negative status for longer if they received G maintenance than if they did not. These results suggest that the addition of G to Benda-based treatment during induction can significantly contribute to the speed and depth of response, and G maintenance in MRD-negative patients potentially delays lymphoma regrowth.",2020,patients receiving Benda alone (p = 0.0029).,"['rituximab-refractory follicular lymphoma (FL', 'Patients with a clonal marker (t[14;18] translocation and/or immunoglobulin heavy or light chain rearrangement']","['obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance, or Benda induction alone', 'bendamustine']","['MRD response', 'progression-free survival', 'overall survival']","[{'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0024301', 'cui_str': 'Brill-Symmers Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0021027', 'cui_str': 'Immune Globulins'}, {'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C0337112', 'cui_str': 'Chain, device (physical object)'}]","[{'cui': 'C2742503', 'cui_str': 'obinutuzumab'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0525079', 'cui_str': 'bendamustine'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",,0.0473059,patients receiving Benda alone (p = 0.0029).,"[{'ForeName': 'Christiane', 'Initials': 'C', 'LastName': 'Pott', 'Affiliation': 'University Hospital Schleswig-Holstein, Kiel, Germany. c.pott@med2.uni-kiel.de.'}, {'ForeName': 'Laurie H', 'Initials': 'LH', 'LastName': 'Sehn', 'Affiliation': 'British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Belada', 'Affiliation': 'Department of Internal Medicine-Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Gribben', 'Affiliation': 'Queen Mary University of London, London, UK.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Hoster', 'Affiliation': 'Hospital of the Ludwig-Maximilians University, Munich, Germany.'}, {'ForeName': 'Brad', 'Initials': 'B', 'LastName': 'Kahl', 'Affiliation': 'Washington University School of Medicine, St Louis, MO, USA.'}, {'ForeName': 'Britta', 'Initials': 'B', 'LastName': 'Kehden', 'Affiliation': 'University Hospital Schleswig-Holstein, Kiel, Germany.'}, {'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Nicolas-Virelizier', 'Affiliation': 'University of Lyon, Lyon, France.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Spielewoy', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Guenter', 'Initials': 'G', 'LastName': 'Fingerle-Rowson', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Harbron', 'Affiliation': 'Roche, Welwyn Garden City, UK.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Mundt', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Wassner-Fritsch', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Bruce D', 'Initials': 'BD', 'LastName': 'Cheson', 'Affiliation': 'Georgetown University Hospital, Washington, DC, USA.'}]",Leukemia,['10.1038/s41375-019-0559-9'] 1146,30882166,Effect of Irrigation Solution Temperature on Complication of Percutaneous Nephrolithotomy: A Randomized Clinical Trial.,"PURPOSE Many factors affecthypothermia and shivering during percutaneous nephrolithotomy and in recovery.Hence this study was carried out to determine the effect of irrigation solution temperature on complications ofpercutaneous nephrolithotomy. MATERIALS AND METHODS In this randomized clinical trial, 60 patients undergoing PCNL in Sina University Hospitalwere enrolled. The patients were randomly assigned in three groups according to simple random manner. Thegroups included three groups of room temperature fluid (24 degree), warm solution (37 degree), and cold fluid (20degree) during nephroscopy. RESULTS Although the initial core temperature was alike across the groups (P > .05); the hypothermia rate occuredin all 20 patients in the cold fluid group (P = .012). There was significant difference between the groups interms of final temperature and alteration amount (P = .001). The mean VAS scores were significantly lower in thewarm fluid group compared with the others groups at recovery, and 8hrs post-operatively (P = .03). Assessmentof shivering rates revealed that 3(15%) patients in warm solution group shivered compared to8 (40%) patients incold fluid group (P = .018). CONCLUSION Warm irrigation solution during PCNL results in significantly decreased hypothermia, mean postoperativepain score and shivering. Hence use of warm irrigation fluid for this matter is recommended.",2019,"The mean VAS scores were significantly lower in warm fluid group compared with the others groups at the recovery, and 8 h postoperatively (P = 0.03).",['60 patients under PCNL in Sina University Hospital were enrolled'],"['percutaneous nephrolithotomy', 'irrigation solution temperature', 'Irrigation Solution Temperature']","['hypothermia rate', 'shivering rates', 'mean VAS scores', 'hypothermia, the mean postoperative pain score and shivering', 'Complication of Percutaneous Nephrolithotomy', 'final temperature and alteration amount']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}]","[{'cui': 'C0162428', 'cui_str': 'Nephrolithotomy, Percutaneous'}, {'cui': 'C2746010', 'cui_str': 'Irrigating solution'}, {'cui': 'C0039476', 'cui_str': 'Temperature'}]","[{'cui': 'C0413252', 'cui_str': 'Hypothermia due to exposure'}, {'cui': 'C0036973', 'cui_str': 'Shiverings'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0162428', 'cui_str': 'Nephrolithotomy, Percutaneous'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0039476', 'cui_str': 'Temperature'}]",60.0,0.0647947,"The mean VAS scores were significantly lower in warm fluid group compared with the others groups at the recovery, and 8 h postoperatively (P = 0.03).","[{'ForeName': 'Seyed Reza', 'Initials': 'SR', 'LastName': 'Hosseini', 'Affiliation': 'Department of Urology, Tehran University of Medical Sciences ,Tehran, Iran. rhosseinim@yahoo.com.'}, {'ForeName': 'Mohammad Ghasem', 'Initials': 'MG', 'LastName': 'Mohseni', 'Affiliation': 'Department of Urology, Tehran University of Medical Sciences ,Tehran, Iran. Email: mgmohseni@tums.ac.ir.'}, {'ForeName': 'Seyed Mohammad Kazem', 'Initials': 'SMK', 'LastName': 'Aghamir', 'Affiliation': 'Department of Urology, Tehran University of Medical Sciences, Tehran, Iran. Email: smkaghamir@yahoo.com.'}, {'ForeName': 'Hamed', 'Initials': 'H', 'LastName': 'Rezaei', 'Affiliation': 'Resident of Urology, Tehran University of Medical Sciences ,Tehran, Iran. hamed109@gmail.com.'}]",Urology journal,['10.22037/uj.v0i0.4399'] 1147,31340056,"Estimation of treatment allocation in a randomised, double-blinded, placebo-controlled trial.","  AIM OF THE STUDY: The internal validity of double blinding in randomised placebo-controlled trials (RCTs) has become a target of criticism. The goal of this study was to investigate (a) how accurately the patients and their treating physicians were able to guess their assigned treatment, and (b) predictors for an accurate guess. METHODS Data on treatment estimation from patients (n = 382) and their physicians (n = 358 guesses) in an RCT investigating the role of adjunct prednisone for community-acquired pneumonia in a tertiary care setting were analysed. At discharge, patients and their physicians had to guess whether they had been assigned to the prednisone or to the placebo group. The alternative possibility was “uncertain”. Percentages and confidence intervals (CIs) were calculated for the proportion of patients guessing correctly. Chance finding was defined as having 50% or less correct guesses. To test for predictors for prednisone treatment guess, a mixed effects logistic regression model was performed. RESULTS In the prednisone group, 28.9% (55/190; 95% CI 22.6–36.0%) of the patients made a correct guess and the majority (61.6%, 117/190) was uncertain. In the placebo group, 13.0% (25/192; 95% CI 8.8–18.8%) guessed correctly, with the majority being uncertain (69.8%, 134/192). Physicians guessed correctly in 48.3% (87/180, 95% CI 40.8–55.9%) of cases in the prednisone group and in 66.3% (118/178, 95% CI 58.8–73.2%) of cases in the placebo group, which was above chance for the placebo group. The physicians were uncertain in 21.7% (39/180) of cases in the prednisone group, and in 15.2% (27/178) of cases in the placebo group. Significant predictors for guessing prednisone were the occurrence of hyperglycaemia (odds ratio [OR] 3.77, 95% CI 2.39–5.95; p<0.001) and a shorter time to clinical stability (OR 0.95, 95% CI 0.91–0.99; p = 0.02). CONCLUSIONS We confirmed that patient blinding was achieved in this study. Physicians made correct guesses more often than patients. Treatment estimation by both patients and physicians was led not only by the expectations of treatment effects of the study drug but also by known side effects of prednisone. Trial registration no.: NCT00973154  .",2019,"Physicians guessed correctly in 48.3% (87/180, 95% CI 40.8–55.9%) of cases in the prednisone group and in 66.3% (118/178, 95% CI 58.8–73.2%) of cases in the placebo group, which was above chance for the placebo group.",['patients (n = 382) and their physicians (n = 358 guesses) in an RCT investigating the role of adjunct prednisone for community-acquired pneumonia in a tertiary care setting were analysed'],"['prednisone', 'placebo']","['occurrence of hyperglycaemia', 'shorter time to clinical stability']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517750', 'cui_str': 'Three hundred and eighty-two'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0694549', 'cui_str': 'Community acquired pneumonia (disorder)'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}]",382.0,0.566968,"Physicians guessed correctly in 48.3% (87/180, 95% CI 40.8–55.9%) of cases in the prednisone group and in 66.3% (118/178, 95% CI 58.8–73.2%) of cases in the placebo group, which was above chance for the placebo group.","[{'ForeName': 'Milica', 'Initials': 'M', 'LastName': 'Popovic', 'Affiliation': 'a Endocrinology, Diabetology and Metabolism, Department of Internal Medicine, University Hospital Basel, Switzerland / Department of Clinical Research, University of Basel, Switzerland.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Cesana-Nigro', 'Affiliation': 'a Endocrinology, Diabetology and Metabolism, Department of Internal Medicine, University Hospital Basel, Switzerland / Department of Clinical Research, University of Basel, Switzerland.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Winzeler', 'Affiliation': 'a Endocrinology, Diabetology and Metabolism, Department of Internal Medicine, University Hospital Basel, Switzerland / Department of Clinical Research, University of Basel, Switzerland.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Thomann', 'Affiliation': 'Bürgerspital Solothurn, Switzerland.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Schütz', 'Affiliation': 'Medical University Clinic, Department of General Internal and Emergency Medicine, and Department of Endocrinology, Diabetology and Clinical Nutrition, Kantonsspital Aarau, Switzerland.'}, {'ForeName': 'Beat', 'Initials': 'B', 'LastName': 'Müller', 'Affiliation': 'Medical University Clinic, Department of General Internal and Emergency Medicine, and Department of Endocrinology, Diabetology and Clinical Nutrition, Kantonsspital Aarau, Switzerland.'}, {'ForeName': 'Mirjam', 'Initials': 'M', 'LastName': 'Christ-Crain', 'Affiliation': 'Endocrinology, Diabetology and Metabolism, Department of Internal Medicine, University Hospital Basel, Switzerland / Medical University Clinic, Department of General Internal and Emergency Medicine, and Department of Endocrinology, Diabetology and Clinical Nutrition, Kantonsspital Aarau, Switzerland.'}, {'ForeName': 'Claudine A', 'Initials': 'CA', 'LastName': 'Blum', 'Affiliation': 'Endocrinology, Diabetology and Metabolism, Department of Internal Medicine, University Hospital Basel, Switzerland / Department of Clinical Research, University of Basel, Switzerland / Medical University Clinic, Department of General Internal and Emergency Medicine, and Department of Endocrinology, Diabetology and Clinical Nutrition, Kantonsspital Aarau, Switzerland.'}]",Swiss medical weekly,['10.4414/smw.2019.20114'] 1148,10543650,Contrast-enhanced spiral CT of the head and neck: comparison of contrast material injection rates.,"BACKGROUND AND PURPOSE Contrast-enhanced spiral CT studies of the head and neck are performed frequently using contrast material volumes of approximately 30 g iodine and a scan delay of 30-45 seconds. Because little is known about the effects of contrast material injection rates on tissue enhancement, this was prospectively investigated in our study. METHODS Ninety-seven patients underwent spiral CT of the head and neck. Each patient was assigned randomly to one of four groups who received 100 mL of nonionic contrast material (300 mg I/mL) at different monophasic injection flow rates with 1.5, 2, 3, and 4 mL/s. Scanning started after a constant delay of 35 seconds. The attenuation of the carotid artery, jugular vein, and sternocleidomastoid muscle was measured over time and the attenuation of the submandibular and thyroid gland was evaluated. Vascular attenuation of at least 150 HU was considered to be sufficient. RESULTS The mean scan time was 33+/-5 seconds. The study, using an injection rate of 2 mL/s, showed the longest time of sufficient overall (arterial and venous) vessel attenuation (27+/-4 seconds, P< or =.008). The injection flow rate did not influence significantly muscular attenuation (mean enhancement during scan time: 9+/-7 HU). The 1.5 mL/s protocol showed the lowest attenuation values of the submandibular gland (81+/-12 HU) and the highest attenuation values of the thyroid gland (164+/-22 HU), but the attenuation of the thyroid gland was not statistically different from that revealed by the 2 mL/s protocol. CONCLUSION Using 100 mL of intravenous contrast material with 300 mg I/mL for spiral CT studies of the entire head and neck, the optimal injection flow is 2 mL/s, whereas lower flow rates resulted in insufficient venous enhancement.",1999,The injection flow rate did not influence significantly muscular attenuation (mean enhancement during scan time: 9+/-7 HU).,['Ninety-seven patients underwent spiral CT of the head and neck'],['100 mL of nonionic contrast material'],"['attenuation of the carotid artery, jugular vein, and sternocleidomastoid muscle', 'longest time of sufficient overall (arterial and venous) vessel attenuation', 'mean scan time']","[{'cui': 'C0439073', 'cui_str': '97 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0860888', 'cui_str': 'CT Scan, Spiral'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0027536', 'cui_str': 'Necking (finding)'}]","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0009924', 'cui_str': 'Contrast Agents'}]","[{'cui': 'C0007272', 'cui_str': 'Carotid Arteries'}, {'cui': 'C0022427', 'cui_str': 'Jugular Veins'}, {'cui': 'C0224153', 'cui_str': 'Structure of sternocleidomastoid muscle'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205410', 'cui_str': 'Sufficient (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0348013', 'cui_str': 'Venous (qualifier value)'}, {'cui': 'C0148346', 'cui_str': 'Vessel'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0441633'}]",97.0,0.0384721,The injection flow rate did not influence significantly muscular attenuation (mean enhancement during scan time: 9+/-7 HU).,"[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Groell', 'Affiliation': 'Department of Radiology, University Hospital Graz, Austria.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Willfurth', 'Affiliation': ''}, {'ForeName': 'G J', 'Initials': 'GJ', 'LastName': 'Schaffler', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Mayer', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Schmidt', 'Affiliation': ''}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Uggowitzer', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Tillich', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Genser', 'Affiliation': ''}]",AJNR. American journal of neuroradiology,[] 1149,31060838,The effect of a low carbohydrate formula on glycaemia in critically ill enterally-fed adult patients with hyperglycaemia: A blinded randomised feasibility trial.,"BACKGROUND Enteral nutrition is a source of carbohydrate that may exacerbate hyperglycaemia. Its treatment, insulin, potentially exacerbates glycaemic variability. METHODS This was a prospective, parallel group, blinded, randomised feasibility trial. Patients were eligible if 18 years or over when admitted to the intensive care unit and receiving enteral nutrition (EN) exclusively with two consecutive blood glucose > 10 mmol/L. A standardized glucose management protocol determined administration of insulin. Key outcome measures were insulin administered and glycaemic variability (coefficient of variation) over the first 48 h. RESULTS 41 patients were randomized to either standard EN (14.1 g/100 mL carbohydrate; n = 20) or intervention EN (7.4 g/100 mL carbohydrate; n = 21). Overall 59% were male, mean (±SD) age of 62.3 years ± 10.4, APACHE II score of 16.5 ± 7.8 and a median (IQR) Body Mass Index 29.0 kg/m 2 (25.2-35.5). Most patients (73%) were mechanically ventilated. Approximately half (51%) were identified as having diabetes prior to ICU admission. Patients in the intervention arm received less insulin over the 48 h study period than those in the control group (mean insulin units over study period (95% CI) 45.0 (24.4-68.7) vs. 107 (56.1-157.9) units; p = 0.02) and had lower mean glycaemic variability (12.6 vs. 15.9%, p = 0.01). There was a small difference in the mean percentage of energy requirements met (intervention: 72.9 vs. control: 79.1%; p = 0.4) or protein delivered (78.2 vs. 85.4%; p = 0.3). CONCLUSIONS A low carbohydrate formula was associated with reduced insulin use and glycaemic variability in enterally-fed critically ill patients with hyperglycaemia. Further large trials are required to determine the impact of this formula on clinical outcomes. Registered under Australian and New Zealand Clinical Trials Registry, ANZCTR number: 12614000166673.",2019,A low carbohydrate formula was associated with reduced insulin use and glycaemic variability in enterally-fed critically ill patients with hyperglycaemia.,"['41 patients', 'Overall 59% were male, mean (±SD) age of 62.3 years\xa0±\xa010.4, APACHE II score of 16.5\xa0±\xa07.8 and a median (IQR) Body Mass Index 29.0\xa0kg', 'enterally-fed critically ill patients with hyperglycaemia', 'critically ill enterally-fed adult patients with hyperglycaemia', 'Patients were eligible if 18 years or over when admitted to the intensive care unit and receiving enteral nutrition (EN) exclusively with two consecutive blood glucose\xa0>\xa010\xa0mmol/L. A standardized glucose management protocol determined administration of insulin']","['standard EN (14.1\xa0g/100\xa0mL carbohydrate; n\xa0=\xa020) or intervention EN', 'low carbohydrate formula']","['mean glycaemic variability', 'glycaemia', 'insulin administered and glycaemic variability (coefficient of variation', 'insulin use and glycaemic variability']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0489438', 'cui_str': 'APACHE II score'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C2987508', 'cui_str': 'Feeding (observable entity)'}, {'cui': 'C0010340', 'cui_str': 'Critically Ill'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0086225', 'cui_str': 'Enteral Feeding'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C1532563', 'cui_str': 'umol/mL'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0199782', 'cui_str': 'Administration of insulin (procedure)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}, {'cui': 'C0240016', 'cui_str': 'Insulin used (attribute)'}]",41.0,0.287493,A low carbohydrate formula was associated with reduced insulin use and glycaemic variability in enterally-fed critically ill patients with hyperglycaemia.,"[{'ForeName': ""Ra'eesa"", 'Initials': 'R', 'LastName': 'Doola', 'Affiliation': 'Mater Health Services, Mater Research Institute, The University of Queensland, Australia. Electronic address: raeesa.doola@mater.uq.edu.au.'}, {'ForeName': 'Adam M', 'Initials': 'AM', 'LastName': 'Deane', 'Affiliation': 'The Royal Melbourne Hospital, The University of Melbourne, Mater Research Institute, The University of Queensland, Australia.'}, {'ForeName': 'Debbie M', 'Initials': 'DM', 'LastName': 'Tolcher', 'Affiliation': 'Mater Health Services, Australia.'}, {'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'Presneill', 'Affiliation': 'The Royal Melbourne Hospital, The University of Melbourne, Monash University, Australia.'}, {'ForeName': 'Helen L', 'Initials': 'HL', 'LastName': 'Barrett', 'Affiliation': 'Mater Health Services, Mater Research Institute, The University of Queensland, Australia.'}, {'ForeName': 'Josephine M', 'Initials': 'JM', 'LastName': 'Forbes', 'Affiliation': 'Mater Research Institute, The University of Queensland, Australia.'}, {'ForeName': 'Alwyn S', 'Initials': 'AS', 'LastName': 'Todd', 'Affiliation': 'Mater Research Institute, The University of Queensland, Menzies Health Institute Brisbane, Griffith University, Australia.'}, {'ForeName': 'Satomi', 'Initials': 'S', 'LastName': 'Okano', 'Affiliation': 'Mater Research Institute, Statistics Unit, QIMR Berghofer Medical Research Institute, Australia.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Sturgess', 'Affiliation': 'Mater Research Institute, The University of Queensland, Princess Alexandra Hospital, Australia.'}]",Clinical nutrition ESPEN,['10.1016/j.clnesp.2019.02.013'] 1150,32030723,A feasibility study of microwave therapy for precancerous actinic keratosis.,"BACKGROUND Actinic keratosis (AK) is a common premalignant skin lesion that can progress to cutaneous squamous cell carcinoma (cSCC). Microwave therapy is an established cancer treatment and has been used for plantar viral warts. OBJECTIVES To evaluate the efficacy and feasibility of microwave as a treatment for AK. METHODS Stage I was a dose-setting study, in which seven participants had the dielectric properties of 12 thick and 22 thin AKs assessed for optimization of the microwave dose used for treatment in Stage II. Stage II was a randomized, internally controlled trial evaluating 179 AKs in 11 patients (93 treated, 86 untreated controls) on the scalp/forehead or dorsal hand. Participants received one treatment initially and a repeat treatment to unresolved AKs at week 4. The response was assessed at six visits over 4 months. The primary outcome was partial or complete resolution of the treated AKs. RESULTS A significantly higher proportion of treated AK areas responded than untreated (90% vs. 15%; P < 0·001). Thin AKs were more responsive than thick AKs. The site did not affect efficacy. Pain was severe, but brief (80% reported pain lasting 'a few seconds only'). Adverse effects were minimal (erythema, n = 6; flaking, n = 3; itch, n = 3). All participants who would chose microwave therapy over their current treatment cited the shorter discomfort period. CONCLUSIONS Microwave therapy is a portable, safe and effective treatment for AK. An easy-to-deliver, acceptable therapy for AK is attractive as a prevention strategy. While these results are promising, a larger randomized controlled trial is needed against an effective comparator to confirm clinical efficacy and patient acceptability. What is already known about this topic? Actinic keratoses (AKs) are common precancerous skin lesions. Successful treatment of AK can prevent cutaneous squamous cell carcinoma (cSCC). Most topical therapies for AK require repeated application over weeks and drive local skin inflammation, leading to poor compliance. An easy-to-deliver and effective treatment for AK, suitable for use in primary care, could reduce cSCC. What does this study add? Microwave therapy is a feasible, effective treatment for AK. Ninety per cent of treated AKs showed full or partial resolution at 120 days post-treatment. Microwave therapy was painful, but the pain was short-lived (seconds) and this short discomfort period was cited as the main reason that microwave was preferred to their current treatment.",2020,"Adverse effects were minimal (redness n=6, flaking n=3, itching n=3).","['11 patients (93 treated, 86 untreated controls) on the scalp/forehead or dorsal hand', 'Stage 1 was a dose-setting study, where seven participants had the dielectric properties of 12 thick and 22 thin AK assessed for optimisation of the microwave dose used for treatment in Stage 2', 'cutaneous squamous cell carcinoma (cSCC', 'Actinic keratosis (AK', 'precancerous actinic keratoses']",['microwave therapy'],"['Pain', 'partial or complete resolution of the treated AK', 'Adverse effects']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0036270', 'cui_str': 'Scalp'}, {'cui': 'C0016540', 'cui_str': 'Forehead'}, {'cui': 'C0230372', 'cui_str': 'Structure of dorsum of hand'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1 (qualifier value)'}, {'cui': 'C1292718', 'cui_str': 'Is a'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0871161', 'cui_str': 'Property (attribute)'}, {'cui': 'C1280412', 'cui_str': 'Thick (qualifier value)'}, {'cui': 'C0332528', 'cui_str': 'Decreased thickness (finding)'}, {'cui': 'C0026051', 'cui_str': 'Microwaves'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2 (qualifier value)'}, {'cui': 'C0553723', 'cui_str': 'Squamous cell carcinoma of skin (disorder)'}, {'cui': 'C0022602', 'cui_str': 'Senile keratoma (disorder)'}]","[{'cui': 'C0438673', 'cui_str': 'Microwave diathermy (procedure)'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0001688', 'cui_str': 'side effects'}]",179.0,0.0432819,"Adverse effects were minimal (redness n=6, flaking n=3, itching n=3).","[{'ForeName': 'D N', 'Initials': 'DN', 'LastName': 'Jackson', 'Affiliation': 'Department of Dermatology, NHS Tayside, Ninewells Hospital, Dundee, DD1 9SY, Scotland, UK.'}, {'ForeName': 'F J', 'Initials': 'FJ', 'LastName': 'Hogarth', 'Affiliation': 'Tayside Clinical Trials Unit, University of Dundee, DD1 9SY, Scotland, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Sutherland', 'Affiliation': 'Clinical Research Centre, NHS Tayside, Ninewells Hospital, Dundee, DD1 9SY, Scotland, UK.'}, {'ForeName': 'E M', 'Initials': 'EM', 'LastName': 'Holmes', 'Affiliation': 'Dundee Epidemiology and Biostatistics Unit, Population Health and Genomics, School of Medicine, University of Dundee, DD1 9SY, Scotland, UK.'}, {'ForeName': 'P T', 'Initials': 'PT', 'LastName': 'Donnan', 'Affiliation': 'Dundee Epidemiology and Biostatistics Unit, Population Health and Genomics, School of Medicine, University of Dundee, DD1 9SY, Scotland, UK.'}, {'ForeName': 'C M', 'Initials': 'CM', 'LastName': 'Proby', 'Affiliation': 'Department of Dermatology, NHS Tayside, Ninewells Hospital, Dundee, DD1 9SY, Scotland, UK.'}]",The British journal of dermatology,['10.1111/bjd.18935'] 1151,31060839,Dietary and symptom assessment in adults with self-reported non-coeliac gluten sensitivity.,"BACKGROUND & AIMS The mechanisms behind non-coeliac gluten sensitivity (NCGS) are not fully understood although clinical symptoms have shown to subside after wheat withdrawal. Self-prescription of a gluten-free diet (GFD) without medical supervision is common in NCGS subjects, resulting in dietary restrictions that can cause macro- and micronutrient deficiencies. The primary aim was to describe dietary intake, including FODMAP, in subjects with self-reported gluten sensitivity on GFD in whom coeliac disease (CD) and wheat allergy were excluded. Secondary, clinical symptoms and health-related quality of life (HR-QoL) were examined. METHODS Baseline characteristics were obtained from 65 adults with self-reported NCGS on GFD recruited to a randomised placebo-controlled challenge trial at Oslo University Hospital. Dietary intake was obtained by a seven-day food record and symptoms recorded by questionnaires. RESULTS Mean proportions of energy were 43 E% from fat, 40 E% from carbohydrate and 17 E% from protein. Intakes of vitamin D, folic acid, calcium, iodine and iron were lower than recommended, mean (SD) 7.3 (5.8) μg, 235 (105) μg, 695 (309) mg, 81 (52) μg and 9.6 (7.5) mg, respectively. Mean (SD) intake of FODMAP was 11.6 g (8.7). Gastrointestinal symptoms as scored by 100 mm visual analogue scale (VAS) were all below 15 mm of which wind and bloating were the most expressed. Tiredness, concentration difficulties, fatigue and muscle/joint pain were scored highest among extra-intestinal symptoms. Gastrointestinal symptoms as scored by gastrointestinal symptom rating scale - irritable bowel syndrome version (GSRS-IBS) were correlated with mild depression (r = 0.43) and inversely correlated with five sub-domains of HR-QoL (-0.29 < r < -0.26). CONCLUSION Subjects with self-reported NCGS on GFD had high proportion of energy from fat and sub-optimal intakes of vitamin D, folic acid, calcium, iodine and iron. Despite GFD and moderate intake of FODMAP, the subjects reported various gastro- and extra-intestinal symptoms and reduced HR-QoL. The findings highlight the importance of dietary education and nutritional follow-up of subjects on GFD.",2019,Gastrointestinal symptoms as scored by gastrointestinal symptom rating scale - irritable bowel syndrome version (GSRS-IBS) were correlated with mild depression (r = 0.43) and inversely correlated with five sub-domains of HR-QoL (-0.29 ,"[' 695 (309) mg, 81 (52', 'adults with self-reported non-coeliac gluten sensitivity', '65 adults with self-reported NCGS on GFD recruited to a randomised placebo-controlled challenge trial at Oslo University Hospital', 'subjects with self-reported gluten sensitivity on GFD in whom coeliac disease (CD) and wheat allergy were excluded']","['gluten-free diet (GFD) without medical supervision', 'FODMAP', 'vitamin D, folic acid, calcium, iodine and iron']","['Dietary intake', 'Tiredness, concentration difficulties, fatigue and muscle/joint pain', 'various gastro- and extra-intestinal symptoms and reduced HR-QoL', 'Gastrointestinal symptoms', 'five sub-domains of HR-QoL', 'clinical symptoms and health-related quality of life (HR-QoL', 'gastrointestinal symptom rating scale - irritable bowel syndrome version (GSRS-IBS', 'mild depression', 'visual analogue scale (VAS', 'Mean (SD) intake of FODMAP']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C2711053', 'cui_str': 'Non-celiac gluten sensitivity (disorder)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0850024', 'cui_str': 'Gluten sensitivity (disorder)'}, {'cui': 'C0007570', 'cui_str': 'Sprue, Nontropical'}, {'cui': 'C0949570', 'cui_str': 'Allergy, Wheat'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}]","[{'cui': 'C0344351', 'cui_str': 'Gluten-Free Diet'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0038842', 'cui_str': 'Supervision'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0021968', 'cui_str': 'molecular iodine'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}]","[{'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0003862', 'cui_str': 'Joint Pain'}, {'cui': 'C0021853', 'cui_str': 'Intestines'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C1264637', 'cui_str': 'Substance amount'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0222045'}, {'cui': 'C0022104', 'cui_str': 'Irritable Bowel Syndrome'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0588006', 'cui_str': 'Mild depression (disorder)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",65.0,0.0455904,Gastrointestinal symptoms as scored by gastrointestinal symptom rating scale - irritable bowel syndrome version (GSRS-IBS) were correlated with mild depression (r = 0.43) and inversely correlated with five sub-domains of HR-QoL (-0.29 ,"[{'ForeName': 'Gry I', 'Initials': 'GI', 'LastName': 'Skodje', 'Affiliation': 'Department of Clinical Services, Oslo University Hospital Rikshospitalet, 0424, Oslo, Norway; K.G. Jebsen Coeliac Disease Research Centre, University of Oslo, 0424, Oslo, Norway. Electronic address: gry.irene.skodje@nes-ak.kommune.no.'}, {'ForeName': 'Ingunn H', 'Initials': 'IH', 'LastName': 'Minelle', 'Affiliation': 'Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, 0316, Oslo, Norway.'}, {'ForeName': 'Kjersti L', 'Initials': 'KL', 'LastName': 'Rolfsen', 'Affiliation': 'Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, 0316, Oslo, Norway.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Iacovou', 'Affiliation': 'Department of Gastroenterology, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Knut E A', 'Initials': 'KEA', 'LastName': 'Lundin', 'Affiliation': 'K.G. Jebsen Coeliac Disease Research Centre, University of Oslo, 0424, Oslo, Norway; Department of Gastroenterology, Oslo University Hospital Rikshospitalet, 0424, Oslo, Norway.'}, {'ForeName': 'Marit B', 'Initials': 'MB', 'LastName': 'Veierød', 'Affiliation': 'Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, 0317, Oslo, Norway.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Henriksen', 'Affiliation': 'Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, 0316, Oslo, Norway.'}]",Clinical nutrition ESPEN,['10.1016/j.clnesp.2019.02.012'] 1152,31149991,[Comparative results of using coronary drug-eluting stents 'NanoMed' and Orsiro].,"The purpose of the present study was to compare mid-term results of using drug-eluting stents 'NanoMed' and Orsiro. Within the framework of an ongoing randomized prospective study we carried out an intermediate analysis of clinical and angiographic data of 520 patients after coronary artery stenting. The duration of the follow-up period amounted to 6.8±0.2 months. The patients were randomly assigned to the study and control groups each consisting of 260 patients with implanted stents 'NanoMed' and Orsiro, respectively. The obtained findings demonstrated that the main baseline clinical, demographic, and angiographic parameters had no statistically significant differences. The primary endpoint was achieved in 6.1 and 5.3% of cases in the study and control group, respectively (p=0.7). One case of acute in-stent thrombosis was revealed in each group. Cardiac mortality amounted to 0.7% and 0.3% in the study and control group, respectively (p>0.9). Repeat interventions on the target lesion were performed in 2.7 versus 3.4% of cases in the study and control group, respectively (p=0.6). Hence, the comparative analysis of using 'NanoMed' and Orsiro stents in the mid-term period revealed no statistically significant differences.",2019,"Cardiac mortality amounted to 0.7% and 0.3% in the study and control group, respectively (p>0.9).","['520 patients after coronary artery stenting', '260 patients with']","[""coronary drug-eluting stents 'NanoMed' and Orsiro"", ""drug-eluting stents 'NanoMed' and Orsiro"", ""implanted stents 'NanoMed' and Orsiro, respectively""]",['Cardiac mortality'],"[{'cui': 'C4517803', 'cui_str': '520 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205042', 'cui_str': 'Coronary artery structure'}, {'cui': 'C4517669', 'cui_str': 'Two hundred and sixty'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C2828363', 'cui_str': 'Implant'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}]",520.0,0.0186782,"Cardiac mortality amounted to 0.7% and 0.3% in the study and control group, respectively (p>0.9).","[{'ForeName': 'V V', 'Initials': 'VV', 'LastName': 'Bazylev', 'Affiliation': 'Federal Centre of Cardiovascular Surgery under the RF Ministry of Public Health, Penza, Russia.'}, {'ForeName': 'M G', 'Initials': 'MG', 'LastName': 'Shmatkov', 'Affiliation': 'Federal Centre of Cardiovascular Surgery under the RF Ministry of Public Health, Penza, Russia.'}, {'ForeName': 'Z A', 'Initials': 'ZA', 'LastName': 'Morozov', 'Affiliation': 'Federal Centre of Cardiovascular Surgery under the RF Ministry of Public Health, Penza, Russia.'}]",Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery,['10.33529/angio2019208'] 1153,31381020,Association of High-Dose Vitamin D Supplementation During Pregnancy With the Risk of Enamel Defects in Offspring: A 6-Year Follow-up of a Randomized Clinical Trial.,"Importance Enamel defects of developmental origin affect up to 38% of schoolchildren and is recognized as a global public health challenge. The impaired enamel formation results in pain owing to hypersensitivity, posteruptive breakdowns, rapid caries progression, and extractions in some cases. The etiology is unknown; therefore, prevention is currently not possible. Objective To assess the association of a high-dose vitamin D supplementation in pregnant women with enamel defects and caries in their offspring. Design, Setting, and Participants Post hoc analysis of a double-blind, single-center, randomized clinical trial, the Copenhagen Prospective Studies on Asthma in Childhood 2010 cohort (COPSAC2010). Enrollment began March 2009 and included 623 women recruited at 24 weeks of pregnancy and 588 of their children. A dental examination was completed at age 6 years in 496 of 588 children (84%). Data were analyzed in 2018. Intervention High-dose vitamin D3 (2400 IU/d; N = 315) or matching placebo tablets (N = 308) from pregnancy week 24 to 1 week post partum. In addition, all women received 400 IU/d of vitamin D3 as part of standard care. Main Outcomes and Measures Enamel defect was defined as having at least 1 molar affected by demarcated opacity, enamel breakdown, and/or atypical restoration. Caries was defined as decayed, missing, or filled surfaces in both the deciduous and permanent dentitions (World Health Organization standard). Results The risk of enamel defects in the permanent dentition was lower in the offspring of mothers who received high-dose vitamin D supplementation during pregnancy compared with standard dose (15.1% [n = 26 of 172] vs 27.5% [n = 44 of 160]; odds ratio, 0.47; 95% CI, 0.27-0.81). A similar association was observed for the deciduous dentition (8.6% [n = 21 of 244] vs 15.9% [n = 40 of 252]; odds ratio, 0.50; 95% CI, 0.28-0.87). There was no association between supplementation and caries. Conclusions and Relevance High-dose vitamin D supplementation during pregnancy was associated with approximately 50% reduced odds of enamel defects in the offspring. This suggests prenatal vitamin D supplementation as a preventive intervention for enamel defects, with a clinically important association with dental health. Trial Registration ClinicalTrials.gov identifier: NCT00856947.",2019,"The risk of enamel defects in the permanent dentition was lower in the offspring of mothers who received high-dose vitamin D supplementation during pregnancy compared with standard dose (15.1% [n = 26 of 172] vs 27.5% [n = 44 of 160]; odds ratio, 0.47; 95% CI, 0.27-0.81).","['Offspring', 'A dental examination was completed at age 6 years in 496 of 588 children (84', 'Enrollment began March 2009 and included 623 women recruited at 24 weeks of pregnancy and 588 of their children', 'pregnant women with enamel defects and caries in their offspring']","['vitamin D supplementation', 'vitamin D3', 'High-Dose Vitamin D Supplementation', 'Intervention\n\n\nHigh-dose vitamin D3', 'matching placebo tablets', 'prenatal vitamin D supplementation']","['risk of enamel defects', 'deciduous dentition', 'Measures\n\n\nEnamel defect was defined as having at least 1 molar affected by demarcated opacity, enamel breakdown, and/or atypical restoration']","[{'cui': 'C0750862', 'cui_str': 'Dental examination'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0011350', 'cui_str': 'Enamel'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}]","[{'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C3265062', 'cui_str': 'vitamin D3'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0772413', 'cui_str': 'Prenatal vitamin'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0011350', 'cui_str': 'Enamel'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C3266841', 'cui_str': 'Baby Teeth'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0026367', 'cui_str': 'Molar'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C1265876', 'cui_str': 'Abnormally opaque structure (morphologic abnormality)'}, {'cui': 'C0205182', 'cui_str': 'Atypical (qualifier value)'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration (attribute)'}]",623.0,0.505528,"The risk of enamel defects in the permanent dentition was lower in the offspring of mothers who received high-dose vitamin D supplementation during pregnancy compared with standard dose (15.1% [n = 26 of 172] vs 27.5% [n = 44 of 160]; odds ratio, 0.47; 95% CI, 0.27-0.81).","[{'ForeName': 'Pia Elisabeth', 'Initials': 'PE', 'LastName': 'Nørrisgaard', 'Affiliation': 'Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Dorte', 'Initials': 'D', 'LastName': 'Haubek', 'Affiliation': 'Department of Dentistry and Oral Health, Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Kühnisch', 'Affiliation': 'Department of Operative Dentistry and Periodontology, University Hospital, Ludwig-Maximilians-Universität München, München, Germany.'}, {'ForeName': 'Bo Lund', 'Initials': 'BL', 'LastName': 'Chawes', 'Affiliation': 'Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Jakob', 'Initials': 'J', 'LastName': 'Stokholm', 'Affiliation': 'Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Bønnelykke', 'Affiliation': 'Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Bisgaard', 'Affiliation': 'Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Gentofte, Denmark.'}]",JAMA pediatrics,['10.1001/jamapediatrics.2019.2545'] 1154,31416496,[Curative effect of progressively integrated sandplay therapy on core symptoms and sleep management in preschool children with mild-to-moderate autism spectrum disorder].,"OBJECTIVE To explore the curative effect of progressively integrated sandplay therapy on core symptoms and sleep management in preschool children with mild-to-moderate autism spectrum disorder (ASD). METHODS A total of 50 mild-to-moderate ASD preschool children were randomly divided into an experimental group (n=25) and a control group (n=25). The control group was treated with structured teaching and auditory integration training (AIT). Based on these, the experimental group was treated with progressively integrated sandplay therapy. The Autism Behavior Checklist (ABC), Children Autism Rating Scale (CARS), Social Responsiveness Scale (SRS), Children's Sleep Habit Questionnaire (CSHQ) and emotion recognition tools were used to evaluate the overall curative effect before treatment and 3 months after treatment. RESULTS The experimental group had significantly lower scores of feeling, social interaction, somatic motor, language factor, total ABC and total CARS than the control group (P<0.05). The experimental group had also significantly lower scores of social cognition, social communication, social motivation, autistic behavior factor and total SRS than the control group (P<0.05). The experimental group had a significantly higher accurate rate of recognition of the upper facial expression and lower facial expression than the control group (P<0.05). The experimental group had significantly lower scores of bedtime resistance, sleep onset, sleep duration, night waking, daytime sleepiness, and total CSHQ than the control group (P<0.05). The experimental group had significantly reduced themes of wounding and significantly increased themes of healing after sandplay therapy (P<0.05). CONCLUSIONS Progressively integrated sandplay therapy can effectively improve the core symptoms and sleep quality of preschool children with mild-to-moderate ASD, which can be used as an early rehabilitation measure.",2019,The experimental group had a significantly higher accurate rate of recognition of the upper facial expression and lower facial expression than the control group (P<0.05).,"['preschool children with mild-to-moderate autism spectrum disorder (ASD', 'preschool children with mild-to-moderate autism spectrum disorder', 'preschool children with mild-to-moderate ASD', '50 mild-to-moderate ASD preschool children']","['structured teaching and auditory integration training (AIT', 'progressively integrated sandplay therapy']","['scores of feeling, social interaction, somatic motor, language factor, total ABC and total CARS', 'core symptoms and sleep quality', 'healing', 'accurate rate of recognition of the upper facial expression and lower facial expression', 'core symptoms and sleep management', 'scores of social cognition, social communication, social motivation, autistic behavior factor and total SRS', ""Autism Behavior Checklist (ABC), Children Autism Rating Scale (CARS), Social Responsiveness Scale (SRS), Children's Sleep Habit Questionnaire (CSHQ) and emotion recognition tools"", 'overall curative effect', 'scores of bedtime resistance, sleep onset, sleep duration, night waking, daytime sleepiness, and total CSHQ']","[{'cui': 'C0008100', 'cui_str': 'Child, Preschool'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}]","[{'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C2350829', 'cui_str': 'Sandplay'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0037420', 'cui_str': 'Social Interaction'}, {'cui': 'C0023008', 'cui_str': 'Languages'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0004381', 'cui_str': 'Automobiles'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0443131', 'cui_str': 'Accurate (qualifier value)'}, {'cui': 'C0524637', 'cui_str': 'Recognition (Psychology)'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0015457', 'cui_str': 'Facial Expression'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C1273382', 'cui_str': 'Sleep management'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0856975', 'cui_str': 'Autistic behavior'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0222045'}, {'cui': 'C0018464', 'cui_str': 'Habits'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0013987', 'cui_str': 'Emotions'}, {'cui': 'C0336791', 'cui_str': 'Tool, device (physical object)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1276305', 'cui_str': 'Curative procedure'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0521112', 'cui_str': 'Bedtime (qualifier value)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0393761', 'cui_str': 'Middle insomnia (disorder)'}, {'cui': 'C0541854', 'cui_str': 'Daytime sleepiness'}]",,0.0147311,The experimental group had a significantly higher accurate rate of recognition of the upper facial expression and lower facial expression than the control group (P<0.05).,"[{'ForeName': 'Gui-Hua', 'Initials': 'GH', 'LastName': 'Liu', 'Affiliation': ""Department of Child Healthcare Centre, Fujian Provincial Maternity and Children's Hospital/Affiliated Hospital of Fujian Medical University, Fuzhou 350001, China. gp8287@126.com.""}, {'ForeName': 'Long-Sheng', 'Initials': 'LS', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Qin-Fang', 'Initials': 'QF', 'LastName': 'Qian', 'Affiliation': ''}, {'ForeName': 'Yan-Xia', 'Initials': 'YX', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Pin', 'Initials': 'P', 'LastName': 'Ge', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1155,31416505,[Clinical effect of carvedilol in treatment of children with severe hand-foot-mouth disease caused by enterovirus 71 infection].,"OBJECTIVE To study the clinical effect of carvedilol in the treatment of children with severe hand-foot-mouth disease (HFMD) caused by enterovirus 71 (EV71) infection. METHODS A retrospective analysis was performed for the clinical data of 86 children with severe HFMD caused by EV71 infection who were admitted to the hospital from April 2016 to August 2017. According to whether carvedilol was used, the children were divided into conventional treatment group with 51 children and carvedilol treatment group with 35 children. A total of 56 healthy children who underwent physical examination at the outpatient service during the same period were enrolled as the control group. The two treatment groups were compared in terms of clinical features and levels of catecholamines (norepinephrine, adrenaline and dopamine), and the levels of catecholamines were compared between these two treatment groups and the control group. RESULTS Before treatment, the conventional treatment group and the carvedilol treatment group had significantly higher levels of norepinephrine and adrenaline than the control group (P<0.05). After treatment, both the conventional treatment group and the carvedilol treatment group had significant reductions in norepinephrine, adrenaline, blood glucose, systolic pressure, diastolic pressure, heart rate, body temperature and leukocyte count (P<0.05). Compared with the conventional treatment group, the carvedilol treatment group had significantly lower dopamine level, blood glucose, heart rate and respiratory rate after treatment (P<0.05). CONCLUSIONS Changes in norepinephrine and adrenaline might be involved in the pathogenesis of severe HFMD caused by EV71 infection. Carvedilol, in addition to the conventional treatment, can improve respiration, heart rate and blood glucose in children with severe HFMD caused by EV71 infection.",2019,"Carvedilol, in addition to the conventional treatment, can improve respiration, heart rate and blood glucose in children with severe HFMD caused by EV71 infection.","['children with severe hand-foot-mouth disease (HFMD) caused by enterovirus 71 (EV71) infection', 'children with severe HFMD caused by EV71 infection', '56 healthy children who underwent physical examination at the outpatient service during the same period were enrolled as the control group', 'group with 35 children', 'children with severe hand-foot-mouth disease caused by enterovirus 71 infection', '86 children with severe HFMD caused by EV71 infection who were admitted to the hospital from April 2016 to August 2017']","['carvedilol treatment', 'norepinephrine and adrenaline', 'carvedilol', 'Carvedilol']","['clinical features and levels of catecholamines (norepinephrine, adrenaline and dopamine), and the levels of catecholamines', 'respiration, heart rate and blood glucose', 'dopamine level, blood glucose, heart rate and respiratory rate', 'norepinephrine, adrenaline, blood glucose, systolic pressure, diastolic pressure, heart rate, body temperature and leukocyte count (P<0.05', 'levels of norepinephrine and adrenaline']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0016504', 'cui_str': 'Foot'}, {'cui': 'C0026636', 'cui_str': 'Mouth Diseases'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C3853962', 'cui_str': 'Infection caused by Human enterovirus 71 (disorder)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0686744', 'cui_str': 'Well child (finding)'}, {'cui': 'C0031809', 'cui_str': 'Physical Examination'}, {'cui': 'C0086751', 'cui_str': 'Outpatient Services'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}]","[{'cui': 'C0054836', 'cui_str': 'carvedilol'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0202145', 'cui_str': 'Norepinephrine measurement (procedure)'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0007412', 'cui_str': 'Sympathins'}, {'cui': 'C0202145', 'cui_str': 'Norepinephrine measurement (procedure)'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0231832', 'cui_str': 'Respiration Rate'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic Pressure'}, {'cui': 'C0886414', 'cui_str': 'Body temperature'}, {'cui': 'C0023508', 'cui_str': 'Blood Cell Count, White'}]",86.0,0.0143179,"Carvedilol, in addition to the conventional treatment, can improve respiration, heart rate and blood glucose in children with severe HFMD caused by EV71 infection.","[{'ForeName': 'Xiao-Yan', 'Initials': 'XY', 'LastName': 'Gong', 'Affiliation': 'Department of Pediatrics, Ganzhou Medical and Healthcare Center for Women and Children, Ganzhou, Jiangxi 341000, China. 1069286274@qq.com.'}, {'ForeName': 'Bing-Fei', 'Initials': 'BF', 'LastName': 'Li', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1156,31416506,[Clinical effect and safety of clopidogrel combined with aspirin in antithrombotic therapy for children with Kawasaki disease complicated by small/medium-sized coronary artery aneurysms].,"OBJECTIVE To study the clinical effect and safety of clopidogrel combined with aspirin in antithrombotic therapy for children with Kawasaki disease (KD) complicated by coronary artery aneurysm (CAA). METHODS A total of 77 KD children who were diagnosed with multiple small/medium-sized CAAs by echocardiography between January 2013 and June 2018 were enrolled. They were randomly divided into observation group with 38 children (treated with clopidogrel and aspirin) and control group with 39 children (treated with low-molecular-weight heparin and aspirin). All children were followed up regularly, and the first 3 months of the course of the disease was the observation period. The children were observed in terms of the change of the coronary artery and the incidence of complications. RESULTS At month 3 of follow-up, among the children in the observation group, 6 had normal coronary artery, 11 had coronary artery retraction, 19 had stable coronary artery, and 2 progressed to giant coronary aneurysm; among the children in the control group, 7 had normal coronary artery, 12 had coronary artery retraction, 19 had stable coronary artery, and 1 progressed to giant coronary aneurysm; there was no significant difference in the change of the coronary artery between the two groups (P>0.05). There were 2 cases of epistaxis and 6 cases of skin ecchymosis in the observation group, and 1 case of epistaxis and 7 cases of petechiae and ecchymosis at the injection site in the control group, and no other serious bleeding events were observed in either group. CONCLUSIONS Clopidogrel combined with low-dose aspirin is safe and effective in antithrombotic therapy for children with KD complicated by CAA.",2019,"The children were observed in terms of the change of the coronary artery and the incidence of complications. ","['children with KD complicated by CAA', '77 KD children who were diagnosed with multiple small/medium-sized CAAs by echocardiography between January 2013 and June 2018 were enrolled', 'children with Kawasaki disease (KD) complicated by coronary artery aneurysm (CAA', '38 children (treated with', 'children with Kawasaki disease complicated by small/medium-sized coronary artery aneurysms']","['Clopidogrel combined with low-dose aspirin', 'clopidogrel combined with aspirin', 'control group with 39 children (treated with low-molecular-weight heparin and aspirin', 'clopidogrel and aspirin']","['skin ecchymosis', 'serious bleeding events', 'petechiae and ecchymosis', 'coronary artery retraction']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0231242', 'cui_str': 'Complicated (qualifier value)'}, {'cui': 'C1842937', 'cui_str': 'Caa'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0439536', 'cui_str': 'Medium (qualifier value)'}, {'cui': 'C0013516', 'cui_str': 'Transthoracic Echocardiography'}, {'cui': 'C0026691', 'cui_str': 'Kawasaki Syndrome'}, {'cui': 'C0010051', 'cui_str': 'Coronary Aneurysm'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0019139', 'cui_str': 'LMWH'}]","[{'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0013491', 'cui_str': 'Ecchymosis'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0031256', 'cui_str': 'Petechia (morphologic abnormality)'}, {'cui': 'C0205042', 'cui_str': 'Coronary artery structure'}, {'cui': 'C0332523', 'cui_str': 'Retraction (finding)'}]",2018.0,0.0246929,"The children were observed in terms of the change of the coronary artery and the incidence of complications. ","[{'ForeName': 'Yi-Ling', 'Initials': 'YL', 'LastName': 'Liu', 'Affiliation': ""Department of Pediatric Cardiology, Chengdu Women's & Children's Central Hospital, Chengdu 610091, China. wxm6910@163.com.""}, {'ForeName': 'Xian-Min', 'Initials': 'XM', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Ting-Ting', 'Initials': 'TT', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Shi', 'Affiliation': ''}, {'ForeName': 'Ya-Heng', 'Initials': 'YH', 'LastName': 'Lu', 'Affiliation': ''}, {'ForeName': 'Yong-Hong', 'Initials': 'YH', 'LastName': 'Guo', 'Affiliation': ''}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1157,10094358,Risk of clot formation in femoral arterial sheaths maintained overnight for neuroangiographic procedures.,"BACKGROUND AND PURPOSE The purpose of this study was to evaluate the presence of blood clots in femoral arterial sheaths maintained after cerebral angiography and the effect of heparinized saline on clot formation. METHODS Twenty-three sheaths were evaluated in 18 patients. Sheaths were maintained for 14 to 80 hours (average, 33 hours; median, 24 hours). After the sheaths were removed, they were vigorously flushed with 60 mL of normal saline and the number and size of clots found in each sheath were recorded. Additionally, patients' age, catheter size, presence of heparin, amount of time the sheath was kept in the artery, and patients' coagulation status were recorded. RESULTS Clots were found in 17 (74%) of the 23 sheaths. Ten catheters had continuous heparin drip, of which seven (70%) sustained clots. Of the 13 sheaths without heparin, 10 sustained clots (77%). The difference was not statistically significant. The average number of clots was 2.2, and the maximal length of clots ranged from 0.5 to 105 mm. No thromboembolic complications associated with sheath placement were encountered in our patient population. CONCLUSION Blood clots are present in the vast majority of intraarterial sheaths maintained after cerebral angiography. These clots constitute a risk of thromboembolic complications in the event of repeat angiography. Sheath exchange should be considered before obtaining repeat cerebral angiograms.",1999,"No thromboembolic complications associated with sheath placement were encountered in our patient population. ","['Twenty-three sheaths were evaluated in 18 patients', 'femoral arterial sheaths maintained overnight for neuroangiographic procedures']","['heparinized saline', 'heparin']","['maximal length of clots', 'average number of clots', 'thromboembolic complications']","[{'cui': 'C0450348', 'cui_str': '23 (qualifier value)'}, {'cui': 'C0009653', 'cui_str': 'Condoms'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0015811', 'cui_str': 'Femur'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C0439583', 'cui_str': 'Overnight (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}]","[{'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0019134', 'cui_str': 'heparin'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0302148', 'cui_str': 'Blood coagulum'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}]",23.0,0.0647326,"No thromboembolic complications associated with sheath placement were encountered in our patient population. ","[{'ForeName': 'R A', 'Initials': 'RA', 'LastName': 'Koenigsberg', 'Affiliation': 'Department of Radiology, MCP/Hahnemann University, Philadelphia, PA 19129, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Wysoki', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Weiss', 'Affiliation': ''}, {'ForeName': 'S H', 'Initials': 'SH', 'LastName': 'Faro', 'Affiliation': ''}, {'ForeName': 'F Y', 'Initials': 'FY', 'LastName': 'Tsai', 'Affiliation': ''}]",AJNR. American journal of neuroradiology,[] 1158,31149999,[Prolonged paravertebral analgesia in therapy of chronic pain syndrome in critical lower-limb ischaemia].,"Chronic pain syndrome in patients presenting with lower-limb critical ischaemia may have considerable significance in progression of the degree of limb ischaemia, and quality of life of patients appears to be largely determined by adequate analgesia. Currently, there is no 'gold standard' of therapy for chronic pain syndrome in critical lower-limb ischaemia, which makes it necessary to search for new effective and safe methods of analgesia. The purpose of this study was to evaluate efficacy and safety of paravertebral analgesia compared with epidural analgesia in therapy of chronic pain syndrome in critical lower-limb ischaemia. Our prospective randomized double-centre study included a total of 40 patients suffering from atherosclerotic-genesis critical lower-limb ischaemia and pronounced unilateral pain syndrome. The patients were randomized into two equal groups comprising 20 patients each. They were comparable by the main clinical and demographic parameters, as well as by the scope of the comprehensive treatment performed. In the study group, therapy of chronic pain syndrome was provided by the method of paravertebral analgesia, with the comparison group patients receiving epidural analgesia. Paravertebral analgesia was performed with the use of ultrasound navigation, in the prolonged mode by means of using microinfusion elastomeric pumps, epidural analgesia - according to the standard technique. The use of various methods of analgesia was accompanied by a decrease in chronic pain syndrome according to the visual analogue scale by 60% within the first 24 hours, and by 65% at 72 hours thereafter, with the differences being statistically insignificant. The use of prolonged paravertebral analgesia was accompanied by neither considerable haemodynamic reactions nor the development of the motor block, however requiring significant expenditure of a local anaesthetic. The conclusion was drawn that paravertebral analgesia in lower-limb critical ischaemia turned out to be a safe and efficient method of comprehensive therapy of chronic pain syndrome.",2019,"The use of prolonged paravertebral analgesia was accompanied by neither considerable haemodynamic reactions nor the development of the motor block, however requiring significant expenditure of a local anaesthetic.","['chronic pain syndrome in critical lower-limb ischaemia', 'patients presenting with lower-limb critical ischaemia', '40 patients suffering from atherosclerotic-genesis critical lower-limb ischaemia and pronounced unilateral pain syndrome']","['paravertebral analgesia', 'epidural analgesia', 'Prolonged paravertebral analgesia']","['visual analogue scale', 'chronic pain syndrome', 'Chronic pain syndrome', 'efficacy and safety']","[{'cui': 'C1298685', 'cui_str': 'Chronic pain syndrome (disorder)'}, {'cui': 'C0340566', 'cui_str': 'Critical lower limb ischemia (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C4255166', 'cui_str': 'Genesis'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}]","[{'cui': 'C0442150', 'cui_str': 'Paravertebral (qualifier value)'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C0002769', 'cui_str': 'Analgesia, Epidural'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}]","[{'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C1298685', 'cui_str': 'Chronic pain syndrome (disorder)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",40.0,0.0235488,"The use of prolonged paravertebral analgesia was accompanied by neither considerable haemodynamic reactions nor the development of the motor block, however requiring significant expenditure of a local anaesthetic.","[{'ForeName': 'N B', 'Initials': 'NB', 'LastName': 'Priezzhev', 'Affiliation': 'Department of Faculty Surgery of Medical Institute, Sugrut State University of the Khanty-Mansi Autonomous Region-Yugra, Surgut, Russia.'}, {'ForeName': 'I I', 'Initials': 'II', 'LastName': ""Katel'nitskiĭ"", 'Affiliation': 'Department of Surgical Diseases #1, Rostov State Medical University of the RF Ministry of Public Health, Rostov-on-Don, Russia.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': ""Zor'kin"", 'Affiliation': 'Department of Faculty Surgery of Medical Institute, Sugrut State University of the Khanty-Mansi Autonomous Region-Yugra, Surgut, Russia.'}, {'ForeName': 'E V', 'Initials': 'EV', 'LastName': 'Drozhzhin', 'Affiliation': 'Department of Faculty Surgery of Medical Institute, Sugrut State University of the Khanty-Mansi Autonomous Region-Yugra, Surgut, Russia.'}, {'ForeName': 'K V', 'Initials': 'KV', 'LastName': 'Mazaĭshvili', 'Affiliation': 'Department of Faculty Surgery of Medical Institute, Sugrut State University of the Khanty-Mansi Autonomous Region-Yugra, Surgut, Russia.'}]",Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery,['10.33529/angio2019216'] 1159,31393548,Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.,"Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. Objective To determine whether adding bevacizumab to erlotinib treatment results in superior progression-free survival compared with erlotinib alone. Design, Setting, and Participants This phase 2 randomized clinical trial compared erlotinib plus bevacizumab with erlotinib alone in EGFR-mutant NSCLC. The trial was conducted in 17 US academic and community medical centers among 88 patients with EGFR exon 19 deletion or exon 21 L858R mutation based on local testing and stage 4 NSCLC who were eligible for bevacizumab. Patients were enrolled between November 2, 2012, and August 22, 2016, and followed up for a median (range) of 33 (0.7-62.5) months. Data were analyzed on August 28, 2018, and included data from November 2, 2012, to August 20, 2018. Interventions Patients were randomized with equal allocation to 150 mg of oral erlotinib daily alone or with 15 mg/kg of intravenous bevacizumab every 3 weeks. Study therapy continued until disease progression, unacceptable adverse event, or withdrawal of consent. Main Outcomes and Measures The primary outcome was PFS as assessed by the investigator; secondary outcomes were objective response rate (ORR), adverse events, and overall survival (OS). Analysis was designed to detect a hazard ratio (HR) of 0.667 for PFS (an improvement from a median PFS of 10 to 15 months). Results Among 88 patients enrolled, the median (range) age was 63 (31-84) years; 62 patients (70%) were female; 75 (85%) were white, 8 (9%) were African American, 3 (3%) were Asian, and for 2 (2%), data on race were not available. Forty-eight patients (55%) were never smokers, 45 patients (51%) were of Eastern Cooperative Oncology Group performance status 1, and 59 patients (67%) had EGFR exon 19 deletion. Compared with erlotinib, the combination did not result in a significant difference in PFS (HR, 0.81; 95% CI, 0.50-1.31; P = .39; median PFS 17.9 [combination] and 13.5 months [erlotinib]), ORR (81% vs 83%; P = .81), and OS (HR, 1.41; 95% CI, 0.71-2.81; P = .33; median OS, 32.4 months [combination] and 50.6 months [erlotinib]). Adverse events of grade 3 or higher observed in 5 or more patients in the combination and erlotinib arms were skin eruption in 11 (26%) vs 7 (16%) patients, diarrhea in 4 (9%) vs 6 (13%) patients, hypertension in 17 (40%) vs 9 (20%) patients, and proteinuria in 5 (12%) vs 0 (0%) patients. Conclusions and Relevance Erlotinib plus bevacizumab compared with erlotinib did not result in a significant improvement in PFS in EGFR-mutant NSCLC. Trial Registration ClinicalTrials.gov identifier: NCT01532089.",2019,"Compared with erlotinib, the combination did not result in a significant difference in PFS (HR, 0.81; 95% CI, 0.50-1.31; P = .39; median PFS 17.9 [combination] and 13.5 months [erlotinib]), ORR (81% vs 83%; P = .81), and OS (HR, 1.41; 95% CI, 0.71-2.81; P = .33; median OS, 32.4 months [combination] and 50.6 months [erlotinib]).","['patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC', '17 US academic and community medical centers among 88 patients with EGFR exon 19 deletion or exon 21 L858R mutation based on local testing and stage 4 NSCLC who were eligible for', '88 patients enrolled, the median (range) age was 63 (31-84) years; 62 patients (70%) were female; 75 (85%) were white, 8 (9%) were African American, 3 (3%) were Asian, and for 2 (2%), data on race were not available', 'Forty-eight patients (55%) were never smokers, 45 patients (51%) were of Eastern Cooperative Oncology Group performance status 1, and 59 patients (67%) had EGFR exon 19 deletion', 'Data were analyzed on August 28, 2018, and included data from November 2, 2012, to August 20, 2018', 'EGFR-mutant NSCLC', 'Patients were enrolled between November 2, 2012, and August 22, 2016, and followed up for a median (range) of 33 (0.7-62.5) months', 'Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer']","['erlotinib plus bevacizumab', 'bevacizumab', 'Erlotinib Plus Bevacizumab vs Erlotinib Alone', 'equal allocation to 150 mg of oral erlotinib daily alone or with 15 mg/kg of intravenous bevacizumab']","['ORR', 'PFS', 'objective response rate (ORR), adverse events, and overall survival (OS', 'Adverse events', 'superior progression-free survival', 'Progression-Free Survival', 'Median progression-free survival (PFS', 'hypertension', 'diarrhea', 'skin eruption']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0034802', 'cui_str': 'c-erbB-1 Protein'}, {'cui': 'C0007131', 'cui_str': 'Nonsmall Cell Lung Cancer'}, {'cui': 'C1562642', 'cui_str': 'Community medical center'}, {'cui': 'C3889117', 'cui_str': 'EGFR exon 19 deletion'}, {'cui': 'C0015295', 'cui_str': 'Exons'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0441772', 'cui_str': 'Stage level 4 (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0078988', 'cui_str': 'Asians'}, {'cui': 'C3853635', 'cui_str': 'Race (observable entity)'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C4319608', 'cui_str': 'Forty-eight'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C1520224', 'cui_str': 'Eastern Cooperative Oncology Group performance status'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C4517474', 'cui_str': '0.7 (qualifier value)'}, {'cui': 'C4517836', 'cui_str': '62.5'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}]","[{'cui': 'C1135135', 'cui_str': 'erlotinib'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}]","[{'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0015230', 'cui_str': 'Skin Rash'}]",88.0,0.19116,"Compared with erlotinib, the combination did not result in a significant difference in PFS (HR, 0.81; 95% CI, 0.50-1.31; P = .39; median PFS 17.9 [combination] and 13.5 months [erlotinib]), ORR (81% vs 83%; P = .81), and OS (HR, 1.41; 95% CI, 0.71-2.81; P = .33; median OS, 32.4 months [combination] and 50.6 months [erlotinib]).","[{'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Stinchcombe', 'Affiliation': 'Duke Cancer Institute, Durham, North Carolina.'}, {'ForeName': 'Pasi A', 'Initials': 'PA', 'LastName': 'Jänne', 'Affiliation': 'Dana Farber Cancer Institute, Boston, Massachusetts.'}, {'ForeName': 'Xiaofei', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Alliance Data and Statistical Center, Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.'}, {'ForeName': 'Erin M', 'Initials': 'EM', 'LastName': 'Bertino', 'Affiliation': 'The Ohio State University Comprehensive Cancer Center, Columbus.'}, {'ForeName': 'Jared', 'Initials': 'J', 'LastName': 'Weiss', 'Affiliation': 'University of North Carolina Lineberger Cancer Center at Chapel Hill.'}, {'ForeName': 'Lyudmila', 'Initials': 'L', 'LastName': 'Bazhenova', 'Affiliation': 'Moores Cancer Center, University of California, San Diego.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Gu', 'Affiliation': 'Alliance Data and Statistical Center, Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.'}, {'ForeName': 'Christie', 'Initials': 'C', 'LastName': 'Lau', 'Affiliation': 'Dana Farber Cancer Institute, Boston, Massachusetts.'}, {'ForeName': 'Cloud', 'Initials': 'C', 'LastName': 'Paweletz', 'Affiliation': 'Dana Farber Cancer Institute, Boston, Massachusetts.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Jaslowski', 'Affiliation': 'Saint Vincent Hospital Cancer Center, Green Bay, Wisconsin.'}, {'ForeName': 'Gregory J', 'Initials': 'GJ', 'LastName': 'Gerstner', 'Affiliation': 'Illinois Cancer Care-Peoria, Peoria, Illinois.'}, {'ForeName': 'Maria Q', 'Initials': 'MQ', 'LastName': 'Baggstrom', 'Affiliation': 'Division of Medical Oncology, Washington University School of Medicine in St Louis, Missouri.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Graziano', 'Affiliation': 'Division of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Bearden', 'Affiliation': 'Spartanburg Regional Health, Spartanburg, South Carolina.'}, {'ForeName': 'Everett E', 'Initials': 'EE', 'LastName': 'Vokes', 'Affiliation': 'Biological Sciences Division, University of Chicago Medicine, Chicago, Illinois.'}]",JAMA oncology,['10.1001/jamaoncol.2019.1847'] 1160,31931444,Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503.,"OBJECTIVE Adjuvant chemotherapy is standard of care for patients with completely resected stage IB, II and IIIA NSCLC. However, optimum chemotherapy regimen has not been determined. TORG0503 was undertaken to select a preferred platinum-based 3 rd generation regimen in this clinical setting. MATERIALS AND METHODS Patients with completely resected stage IB, IIA, IIB or stage IIIA NSCLC were stratified by stage (IB/IIA vs. IIB/IIIA) and institutions, and randomized to receive 3 cycles of docetaxel (60 mg/m 2 ) plus cisplatin (80 mg/m 2 ) (arm A) or paclitaxel (200 mg/m 2 ) plus carboplatin (AUC 6) (arm B) on day 1, every 3 weeks. The primary endpoint of the study was 2-year relapse free survival, and the key secondary endpoints included overall survival, feasibility and toxicity. RESULTS 111 patients were randomized, 58 patients to arm A and 53 to arm B. Patient demographics were balanced between the two arms. 93 % (54/58) of patients on the arm A and 92 % (49/53) patients on the arm B completed the planned 3 cycles of chemotherapy. There was no treatment-related death in both arms. The 2 and 5 year relapse free survival was 74.5 % (95 %CI: 68.6-80.4) and 61.6 % in the arm A, and 72.0 % (95 %CI: 65.7-78.3) and 46.0 % in the arm B. The overall 2, 5-year survival was 89.7 %, 73.9 % in the arm A and 86.9 %, 67.5 % in the arm B. CONCLUSION Both docetaxel plus cisplatin and paclitaxel plus carboplatin are safe and feasible regimens as adjuvant chemotherapy. We choose docetaxel plus cisplatin as the control regimen for the next clinical trial.",2020,"The 2 and 5 year relapse free survival was 74.5 % (95 %CI: 68.6-80.4) and 61.6 % in the arm A, and 72.0 % (95 %CI: 65.7-78.3) and 46.0 % in the arm","['111 patients', 'Patients with completely resected stage IB, IIA, IIB or stage', 'patients with completely resected non-small cell lung cancer: TORG 0503', 'patients with completely resected stage IB, II and IIIA NSCLC']","['adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin', 'chemotherapy', 'cisplatin', 'docetaxel', 'docetaxel plus cisplatin and paclitaxel plus carboplatin', 'carboplatin', 'paclitaxel', 'docetaxel plus cisplatin']","['5-year survival', 'death', '2-year relapse free survival', 'overall survival, feasibility and toxicity', 'relapse free survival']","[{'cui': 'C4517538', 'cui_str': '111 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4554154', 'cui_str': 'Completely - dosing instruction fragment (qualifier value)'}, {'cui': 'C0457152', 'cui_str': 'Stage Ib'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0007131', 'cui_str': 'Nonsmall Cell Lung Cancer'}]","[{'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}]",111.0,0.456634,"The 2 and 5 year relapse free survival was 74.5 % (95 %CI: 68.6-80.4) and 61.6 % in the arm A, and 72.0 % (95 %CI: 65.7-78.3) and 46.0 % in the arm","[{'ForeName': 'Kaoru', 'Initials': 'K', 'LastName': 'Kubota', 'Affiliation': 'Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: kkubota@nms.ac.jp.'}, {'ForeName': 'Hideo', 'Initials': 'H', 'LastName': 'Kunitoh', 'Affiliation': 'Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Internal Medicine, Japanese Red Cross Medical Center, Tokyo, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Seto', 'Affiliation': 'Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Shimada', 'Affiliation': 'Center for Medical Science, International University of Health and Welfare, Ohtawara, Japan.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Tsuboi', 'Affiliation': 'Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Surgery, Tokyo Medical University Hospital, Tokyo, Japan.'}, {'ForeName': 'Tatsuo', 'Initials': 'T', 'LastName': 'Ohhira', 'Affiliation': 'Department of Surgery, Tokyo Medical University Hospital, Tokyo, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Okamoto', 'Affiliation': ""Yokohama Municipal Citizen's Hospital, Yokohama, Japan.""}, {'ForeName': 'Noriyuki', 'Initials': 'N', 'LastName': 'Masuda', 'Affiliation': 'Kitazato University School of Medicine, Sagamihara, Japan.'}, {'ForeName': 'Riichiroh', 'Initials': 'R', 'LastName': 'Maruyama', 'Affiliation': 'Nippon Steel Yawata Memorial Hospital, Kitakyushu, Japan.'}, {'ForeName': 'Masahiko', 'Initials': 'M', 'LastName': 'Shibuya', 'Affiliation': 'Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.'}, {'ForeName': 'Koshiro', 'Initials': 'K', 'LastName': 'Watanabe', 'Affiliation': ""Yokohama Municipal Citizen's Hospital, Yokohama, Japan.""}]","Lung cancer (Amsterdam, Netherlands)",['10.1016/j.lungcan.2019.11.009'] 1161,31929697,Endothelial dysfunction and inflammatory biomarkers as a response factor of concurrent coenzyme Q10 add-on metformin in patients with type 2 diabetes mellitus.,"OBJECTIVES The objective of the study was to evaluate the effect of metformin alone or in combination with coenzyme Q10 (CoQ10) on inflammatory changes and endothelial dysfunction in patients with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS A total numbers of 54 patients with T2DM compared to 30 healthy subjects were divided into three groups: Group A ( n = 30): healthy subjects without any medications; Group B ( n = 24): T2DM patients treated with metformin 1 g/day; and Group C ( n = 30): T2DM patients treated with metformin 1 g/day plus CoQ10, 300 mg/day. The duration of the study was 8 weeks. Fasting blood glucose, glycated hemoglobin, lipid profile, blood pressure variables, fasting insulin, insulin resistance, homeostatic model assessment of insulin resistance, vascular cell adhesion molecule 1 (VCAM-1), and E-selectin were measured before and after therapy. RESULTS Metformin and/or CoQ10 therapy illustrated an insignificant effect on the fody mass index. This combination produced a significant improvement of metabolic changes in patients with T2DM ( P < 0.01). sVCAM-1 serum level was decreased significantly after the initiation of metformin and/or CoQ10 therapy compared to the baseline P < 0.05. E-selectin was declined significantly following metformin monotherapy and after metformin plus CoQ10 therapy ( P = 0.0001). CONCLUSION CoQ10 add-on metformin therapy improves endothelial dysfunction and inflammatory changes in patients with T2DM alongside with amelioration of metabolic profile.",2019,sVCAM-1 serum level was decreased significantly after the initiation of metformin and/or CoQ10 therapy compared to the baseline P < 0.05.,"['patients with type 2 diabetes mellitus', 'patients with type 2 diabetes mellitus (T2DM', 'patients with T2DM alongside with amelioration of metabolic profile', '54 patients with T2DM compared to 30 healthy subjects']","['healthy subjects without any medications', 'metformin therapy', 'metformin 1 g/day plus CoQ10', 'Metformin', 'metformin alone or in combination with coenzyme Q10 (CoQ10', 'metformin', 'T2DM patients treated with metformin']","['inflammatory changes and endothelial dysfunction', 'E-selectin', 'sVCAM-1 serum level', 'Fasting blood glucose, glycated hemoglobin, lipid profile, blood pressure variables, fasting insulin, insulin resistance, homeostatic model assessment of insulin resistance, vascular cell adhesion molecule 1 (VCAM-1), and E-selectin', 'metabolic changes', 'endothelial dysfunction and inflammatory changes']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C3853758', 'cui_str': 'Metabolic Profile'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439417', 'cui_str': 'g/day'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0056077', 'cui_str': 'coenzyme Q10'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0856169', 'cui_str': 'Endothelial dysfunction'}, {'cui': 'C0115305', 'cui_str': 'LECAM-2'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0078056', 'cui_str': 'CD106 Antigens'}]",30.0,0.0157873,sVCAM-1 serum level was decreased significantly after the initiation of metformin and/or CoQ10 therapy compared to the baseline P < 0.05.,"[{'ForeName': 'Hayder M', 'Initials': 'HM', 'LastName': 'Al-Kuraishy', 'Affiliation': 'Department of Pharmacology, Toxicology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq.'}, {'ForeName': 'Ali I', 'Initials': 'AI', 'LastName': 'Al-Gareeb', 'Affiliation': 'Department of Pharmacology, Toxicology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq.'}, {'ForeName': 'Hala A', 'Initials': 'HA', 'LastName': 'Shams', 'Affiliation': 'Department of Pharmacology, Toxicology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq.'}, {'ForeName': 'Farah', 'Initials': 'F', 'LastName': 'Al-Mamorri', 'Affiliation': 'Department of Pharmacology, Toxicology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq.'}]",Journal of laboratory physicians,['10.4103/JLP.JLP_123_19'] 1162,31022313,Group exposure and response prevention for college students with social anxiety: A randomized clinical trial.,"OBJECTIVE Social anxiety increases college student drop-out risk and stifles employment opportunities. Group cognitive-behavioral therapy with exposure (CBT ERP) has the potential to alleviate campus resource strain but remains under-researched with college students. The present study investigated the efficacy of group CBT ERP in a randomized clinical trial on a college campus. METHOD Thirty-one postsecondary students were randomly assigned to an exposure-only group or an active control. RESULTS Linear mixed-effects models indicated significant Group × Time interactions for general social anxiety (t = -2.02, g = 0.62) and depression (t = -2.77, g = 0.55); nonsignificant main effects were found for group and time variables. On a measure of fear of negative evaluation, only the main effect of time was significant (t = 2.15, p = 0.032). CONCLUSIONS When compared to an active control group, CBT ERP is an efficacious and time-effective treatment for college students experiencing social anxiety.",2019,"On a measure of fear of negative evaluation, only the main effect of time was significant (t = 2.15, p = 0.032). ","['Thirty-one postsecondary students', 'college students experiencing social anxiety', 'college students with social anxiety', 'Social anxiety increases college student drop-out risk and stifles employment opportunities']","['exposure-only group or an active control', 'CBT ERP', 'Group cognitive-behavioral therapy with exposure (CBT ERP']","['general social anxiety', 'depression']","[{'cui': 'C0450355', 'cui_str': '31 (qualifier value)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0424166', 'cui_str': 'Social Anxiety'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C4318619', 'cui_str': 'Drop (unit of presentation)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C1456798', 'cui_str': 'Stifle'}, {'cui': 'C0014003', 'cui_str': 'Employment'}]","[{'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0337380', 'cui_str': 'Endoscopic retrograde pancreatography (procedure)'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0424166', 'cui_str': 'Social Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]",31.0,0.0283219,"On a measure of fear of negative evaluation, only the main effect of time was significant (t = 2.15, p = 0.032). ","[{'ForeName': 'Brian A', 'Initials': 'BA', 'LastName': 'Zaboski', 'Affiliation': 'Department of Special Education, School Psychology, & Early Childhood Studies, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Joyce-Beaulieu', 'Affiliation': 'Department of Special Education, School Psychology, & Early Childhood Studies, University of Florida, Gainesville, Florida.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Kranzler', 'Affiliation': 'Department of Special Education, School Psychology, & Early Childhood Studies, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'McNamara', 'Affiliation': 'Department of Psychiatry, Division of Medical Psychology, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Cindi', 'Initials': 'C', 'LastName': 'Gayle', 'Affiliation': 'Independent Practice, Gainesville, Florida.'}, {'ForeName': 'Jann', 'Initials': 'J', 'LastName': 'MacInnes', 'Affiliation': 'Department of Human Development and Organization Studies, University of Florida, Gainesville, Florida.'}]",Journal of clinical psychology,['10.1002/jclp.22792'] 1163,31400765,Effects of isomaltulose ingestion on postexercise hydration state and heat loss responses in young men.,"NEW FINDINGS What is the central question of this study? What are the effects of isomaltulose, an ingredient in carbohydrate-electrolyte beverages to maintain glycaemia and attenuate the risk of dehydration during exercise heat stress, on postexercise rehydration and physiological heat loss responses? What is the main finding and its importance? Consumption of a 6.5% isomaltulose-electrolyte beverage following exercise heat stress restored hydration following a 2 h recovery as compared to a 2% solution or water only. While the 6.5% isomaltulose-electrolytes increased plasma volume and plasma osmolality, which are known to modulate postexercise heat loss, sweating and cutaneous vascular responses did not differ between conditions. Consequently, ingestion beverages containing 6.5% isomaltulose-electrolytes enhanced postexercise rehydration without affecting heat loss responses. ABSTRACT Isomaltulose is a disaccharide carbohydrate widely used during exercise to maintain glycaemia and hydration. We investigated the effects of ingesting a beverage containing isomaltulose and electrolytes on postexercise hydration state and physiological heat loss responses. In a randomized, single-blind cross-over design, 10 young healthy men were hypohydrated by performing up to three 30 min successive moderate-intensity (50% heart rate reserve) bouts of cycling, each separated by 10 min, while wearing a water-perfusion suit heated to 45°C. The protocol continued until a 2% reduction in body mass was achieved. Thereafter, participants performed a final 15 min moderate-intensity exercise bout followed by a 2 h recovery. Following cessation of exercise, participants ingested a beverage consisting of (i) water only (Water), (ii) 2% isomaltulose (CHO-2%), or (iii) 6.5% isomaltulose (CHO-6.5%) equal to the volume of 2% body mass loss within the first 30 min of the recovery. Changes in plasma volume (ΔPV) after fluid ingestion were greater for CHO-6.5% compared with CHO-2% (120 min postexercise) and Water (90 and 120 min) (all P ≤ 0.040). Plasma osmolality remained elevated with CHO-6.5% compared with consumption of the other beverages at 30 and 90 min postexercise (all P ≤ 0.050). Urine output tended to be reduced with CHO-6.5% compared to other fluid conditions (main effect, P = 0.069). Rectal and mean skin temperatures, chest sweat rate and cutaneous perfusion did not differ between conditions (all P > 0.05). In conclusion, compared with CHO-2% and Water, consuming a beverage consisting of CHO-6.5% and electrolytes during recovery under heat stress enhances PV recovery without modulating physiological heat loss responses.",2019,"Rectal and mean skin temperatures, chest sweat rate and cutaneous perfusion did not differ between conditions (all P > 0.05).","['young men', '10 young healthy men']","['ingesting a beverage containing isomaltulose and electrolytes', 'isomaltulose ingestion', 'hypohydrated by performing up to three 30\xa0min successive moderate-intensity (50% heart rate reserve) bouts of cycling, each separated by 10\xa0min, while wearing a water-perfusion suit heated to 45°C']","['Rectal and mean skin temperatures, chest sweat rate and cutaneous perfusion', 'Urine output', 'body mass', 'plasma volume and plasma osmolality', 'postexercise hydration state and heat loss responses', 'Plasma osmolality', 'plasma volume (ΔPV) after fluid ingestion', 'postexercise heat loss, sweating and cutaneous vascular responses']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0005329', 'cui_str': 'Beverages'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0064002', 'cui_str': 'isomaltulose anhydrous'}, {'cui': 'C0013832', 'cui_str': 'Electrolytes'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0443299', 'cui_str': 'Separate (qualifier value)'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0018837', 'cui_str': 'Heat'}]","[{'cui': 'C0205052', 'cui_str': 'Rectal (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0037294', 'cui_str': 'Skin Temperature'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0038990', 'cui_str': 'Sweating'}, {'cui': 'C4521174', 'cui_str': 'Cutaneous'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C1287298', 'cui_str': 'UO - Urine output'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0032127', 'cui_str': 'Blood Plasma Volume'}, {'cui': 'C0860721', 'cui_str': 'Plasma osmolality (observable entity)'}, {'cui': 'C1321013', 'cui_str': 'Hydration'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0018840', 'cui_str': 'Heat Loss'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}]",,0.0367423,"Rectal and mean skin temperatures, chest sweat rate and cutaneous perfusion did not differ between conditions (all P > 0.05).","[{'ForeName': 'Tatsuro', 'Initials': 'T', 'LastName': 'Amano', 'Affiliation': 'Laboratory for Exercise and Environmental Physiology, Faculty of Education, Niigata University, Niigata, Japan.'}, {'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Sugiyama', 'Affiliation': 'Laboratory for Exercise and Environmental Physiology, Faculty of Education, Niigata University, Niigata, Japan.'}, {'ForeName': 'Junya', 'Initials': 'J', 'LastName': 'Okumura', 'Affiliation': 'Laboratory for Exercise and Environmental Physiology, Faculty of Education, Niigata University, Niigata, Japan.'}, {'ForeName': 'Naoto', 'Initials': 'N', 'LastName': 'Fujii', 'Affiliation': 'Faculty of Health and Sport Sciences, University of Tsukuba, Tsukuba City, Japan.'}, {'ForeName': 'Glen P', 'Initials': 'GP', 'LastName': 'Kenny', 'Affiliation': 'Human and Environmental Physiology Research Unit, University of Ottawa, Ottawa, Canada.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Nishiyasu', 'Affiliation': 'Faculty of Health and Sport Sciences, University of Tsukuba, Tsukuba City, Japan.'}, {'ForeName': 'Yoshimitsu', 'Initials': 'Y', 'LastName': 'Inoue', 'Affiliation': 'Laboratory for Human Performance Research, Osaka International University, Osaka, Japan.'}, {'ForeName': 'Narihiko', 'Initials': 'N', 'LastName': 'Kondo', 'Affiliation': 'Laboratory for Applied Human Physiology, Graduate School of Human Development and Environment, Kobe University, Kobe, Japan.'}, {'ForeName': 'Katsumi', 'Initials': 'K', 'LastName': 'Sasagawa', 'Affiliation': 'Bourbon Institutes of Health Nutraceuticals Science Laboratory, Bourbon Corporation, Niigata, Japan.'}, {'ForeName': 'Yasuaki', 'Initials': 'Y', 'LastName': 'Enoki', 'Affiliation': 'Bourbon Institutes of Health Nutraceuticals Science Laboratory, Bourbon Corporation, Niigata, Japan.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Maejima', 'Affiliation': 'Bourbon Institutes of Health Nutraceuticals Science Laboratory, Bourbon Corporation, Niigata, Japan.'}]",Experimental physiology,['10.1113/EP087843'] 1164,31444252,FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults.,"On December 20, 2018, the Food and Drug Administration approved calaspargase pegol-mknl (CALASP), an asparagine-specific enzyme, as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years. Efficacy was determined on the basis of achievement and maintenance of steady-state nadir serum asparaginase activity (NSAA) above 0.1 U/mL when using CALASP, 2,500 U/m 2 intravenously, every 3 weeks. In a randomized comparison to pegaspargase (PEGASP) every 2 weeks, treatment with CALASP every 3 weeks had a similar safety profile and no substantial impairment in event-free survival. The pharmacokinetics of CALASP were studied when administered in combination with multiagent chemotherapy in 124 patients with B-cell ALL in Study AALL07P4 and Study DFCI 11-001. The results showed that 123 [99%, 95% confidence interval (CI), 96%-100%] of the 124 patients maintained NSAA >0.1 U/mL at weeks 6, 12, 18, 24, and 30 of post-induction phase. Maintaining adequate NSAA levels is critical to successful treatment of ALL. Herein, we describe the FDA review and approval of CALASP. See related commentary by Lew, p. 325 .",2020,"The results showed that 123 (99%, 95% confidence interval (CI): 96%-100%) of the 124 patients maintained NSAA > 0.1 U/mL at weeks 6, 12, 18, 24 and 30 of post-induction phase.","['124 patients with B-cell ALL in Study AALL07P4 and Study DFCI 11-001', 'acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years', 'Acute Lymphoblastic Leukemia in Children and Young Adults']","['multiagent chemotherapy', 'CALASP', ' Calaspargase Pegol-mknl', 'pegaspargase (PEGASP']","['Efficacy', 'achievement and maintenance of steady-state nadir serum asparaginase activity (NSAA']","[{'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0004561', 'cui_str': 'B-Cells'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1961102', 'cui_str': 'Lymphocytic Leukemia, Acute'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C2699709', 'cui_str': 'calaspargase pegol'}, {'cui': 'C0071568', 'cui_str': 'pegaspargase'}]","[{'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0003993', 'cui_str': 'ASPARAGINASE'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]",124.0,0.0357791,"The results showed that 123 (99%, 95% confidence interval (CI): 96%-100%) of the 124 patients maintained NSAA > 0.1 U/mL at weeks 6, 12, 18, 24 and 30 of post-induction phase.","[{'ForeName': 'Ruo-Jing', 'Initials': 'RJ', 'LastName': 'Li', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. ruojing.li@fda.hhs.gov.'}, {'ForeName': 'Runyan', 'Initials': 'R', 'LastName': 'Jin', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Xianhua', 'Initials': 'X', 'LastName': 'Cao', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Manning', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Xu Michael', 'Initials': 'XM', 'LastName': 'Di', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Przepiorka', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Namuswe', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Deisseroth', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Kirsten B', 'Initials': 'KB', 'LastName': 'Goldberg', 'Affiliation': 'Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Gideon M', 'Initials': 'GM', 'LastName': 'Blumenthal', 'Affiliation': 'Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Pazdur', 'Affiliation': 'Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-19-1255'] 1165,32441658,A Personalized eHealth Intervention for Lifestyle Changes in Patients With Cardiovascular Disease: Randomized Controlled Trial.,"BACKGROUND Behavior change methods involving new ambulatory technologies may improve lifestyle and cardiovascular disease outcomes. OBJECTIVE This study aimed to provide proof-of-concept analyses of an intervention aiming to increase (1) behavioral flexibility, (2) lifestyle change, and (3) quality of life. The feasibility and patient acceptance of the intervention were also evaluated. METHODS Patients with cardiovascular disease (N=149; mean age 63.57, SD 8.30 years; 50/149, 33.5% women) were recruited in the Do Cardiac Health Advanced New Generation Ecosystem (Do CHANGE) trial and randomized to the Do CHANGE intervention or care as usual (CAU). The intervention involved a 3-month behavioral program in combination with ecological momentary assessment and intervention technologies. RESULTS The intervention was perceived to be feasible and useful. A significant increase in lifestyle scores over time was found for both groups (F 2,146.6 =9.99; P<.001), which was similar for CAU and the intervention group (F 1,149.9 =0.09; P=.77). Quality of life improved more in the intervention group (mean 1.11, SD 0.11) than CAU (mean -1.47, SD 0.11) immediately following the intervention (3 months), but this benefit was not sustained at the 6-month follow-up (interaction: P=.02). No significant treatment effects were observed for behavioral flexibility (F 1,149.0 =0.48; P=.07). CONCLUSIONS The Do CHANGE 1 intervention was perceived as useful and easy to use. However, no long-term treatment effects were found on the outcome measures. More research is warranted to examine which components of behavioral interventions are effective in producing long-term behavior change. TRIAL REGISTRATION ClinicalTrials.gov NCT02946281; https://www.clinicaltrials.gov/ct2/show/NCT02946281.",2020,"Quality of life improved more in the intervention group (mean 1.11, SD 0.11) than CAU (mean -1.47, SD 0.11) immediately following the intervention (3 months), but this benefit was not sustained at the 6-month follow-up (interaction: P=.02).","['Patients With Cardiovascular Disease', 'Patients with cardiovascular disease (N=149; mean age 63.57, SD 8.30 years; 50/149, 33.5% women) were recruited in the Do Cardiac Health Advanced New Generation Ecosystem (Do CHANGE) trial and randomized to the']","['Personalized eHealth Intervention', 'Do CHANGE intervention or care as usual (CAU', 'behavioral program in combination with ecological momentary assessment and intervention technologies']","['increase (1) behavioral flexibility, (2) lifestyle change, and (3) quality of life', 'lifestyle scores', 'behavioral flexibility', 'Quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0162358', 'cui_str': 'Ecologic Systems'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C1328956', 'cui_str': 'eHealth'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0162358', 'cui_str': 'Ecologic Systems'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C4277684', 'cui_str': 'Ecological Momentary Assessment'}, {'cui': 'C0039421', 'cui_str': 'Technology'}]","[{'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.13002,"Quality of life improved more in the intervention group (mean 1.11, SD 0.11) than CAU (mean -1.47, SD 0.11) immediately following the intervention (3 months), but this benefit was not sustained at the 6-month follow-up (interaction: P=.02).","[{'ForeName': 'Eva Rosalinde', 'Initials': 'ER', 'LastName': 'Broers', 'Affiliation': 'Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg, Netherlands.'}, {'ForeName': 'Willem Johan', 'Initials': 'WJ', 'LastName': 'Kop', 'Affiliation': 'Department of Medical and Clinical Psychology, Tilburg University, Tilburg, Netherlands.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Denollet', 'Affiliation': 'Department of Medical and Clinical Psychology, Tilburg University, Tilburg, Netherlands.'}, {'ForeName': 'Jos', 'Initials': 'J', 'LastName': 'Widdershoven', 'Affiliation': 'Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg, Netherlands.'}, {'ForeName': 'Mart', 'Initials': 'M', 'LastName': 'Wetzels', 'Affiliation': 'University of Technology Eindhoven, Eindhoven, Netherlands.'}, {'ForeName': 'Idowu', 'Initials': 'I', 'LastName': 'Ayoola', 'Affiliation': 'University of Technology Eindhoven, Eindhoven, Netherlands.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Piera-Jimenez', 'Affiliation': 'Badalona Serveis Assistencials, Badalona, Spain.'}, {'ForeName': 'Mirela', 'Initials': 'M', 'LastName': 'Habibovic', 'Affiliation': 'Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg, Netherlands.'}]",Journal of medical Internet research,['10.2196/14570'] 1166,9311544,"Motor function, olfactory threshold, and hematological indices in manganese-exposed ferroalloy workers.","A cross-sectional study was conducted in 35 male subjects randomly selected from workers of a ferroalloy production plant and exposed to manganese (Mn) oxides; the objective was to detect early signs of neurologic impairment. The subjects' mean age was 39.4 years (SD, 8. 4); the average exposure duration was 14.5 years (range, 5-29 years). A control group of industrial workers not exposed to neurotoxic chemicals and comparable in age and confounding factors was recruited. The intensity of Mn exposure was moderate, as reflected by airborne Mn concentrations in total dust averaging 193 [corrected] micro g/m3. Mn levels in blood (MnB) and urine (MnU) were significantly higher in the Mn-exposed workers than in control workers. A relationship (not found with MnU) was found between MnB and a cumulative exposure index calculated on the basis of air concentration and exposure history for each subject (r = 0.52; r2 = 0.27; P = 0.002). Psychomotor function scores were lower among Mn-exposed subjects. The Aiming score was negatively correlated with MnB in the exposed group. The olfactory threshold did not differ between the two groups, although it was negatively associated with MnU in the exposed group. The white blood cell count results were significantly higher in Mn-exposed subjects than in controls. These findings show that an increase in Mn body burden is associated with an impairment of motor functions, whereas the increased excretion of Mn is related to an increased olfactory perception. Changes in numbers of leukocytes could indicate possible interferences of Mn with the immunological system.",1997,Mn levels in blood (MnB) and urine (MnU) were significantly higher in the Mn-exposed workers than in control workers.,"['manganese-exposed ferroalloy workers', '35 male subjects randomly selected from workers of a', ""subjects' mean age was 39.4 years (SD, 8. 4); the average exposure duration was 14.5 years (range, 5-29 years""]",['ferroalloy production plant and exposed to manganese (Mn) oxides'],"['Motor function, olfactory threshold, and hematological indices', 'intensity of Mn exposure', 'Mn levels in blood (MnB) and urine (MnU', 'white blood cell count results', 'Psychomotor function scores']","[{'cui': 'C0373677', 'cui_str': 'Manganese measurement (procedure)'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C3542016', 'cui_str': 'Range'}]","[{'cui': 'C0033268'}, {'cui': 'C0032098', 'cui_str': 'Plants'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0065646', 'cui_str': 'manganese oxide'}]","[{'cui': 'C0234130', 'cui_str': 'Motor function (observable entity)'}, {'cui': 'C0439826', 'cui_str': 'Olfactory (qualifier value)'}, {'cui': 'C0449864', 'cui_str': 'Threshold (property) (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0005768'}, {'cui': 'C0042037'}, {'cui': 'C0023508', 'cui_str': 'Blood Cell Count, White'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",35.0,0.0141496,Mn levels in blood (MnB) and urine (MnU) were significantly higher in the Mn-exposed workers than in control workers.,"[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Lucchini', 'Affiliation': 'Institute of Occupational Health, University of Brescia, Brescia, 25125, Italy.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Bergamaschi', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Smargiassi', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Festa', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Apostoli', 'Affiliation': ''}]",Environmental research,[] 1167,31811952,"Correction of Dyssynergic Defecation, but Not Fiber Supplementation, Reduces Symptoms of Functional Dyspepsia in Patients With Constipation in a Randomized Trial.","BACKGROUND & AIMS Patients with functional dyspepsia are believed to have increased sensitivity of the gastrointestinal tract, and some also have functional constipation. We investigated whether in patients with functional dyspepsia, correction of dyssynergic defecation can reduce postprandial fullness. METHODS We performed a parallel trial at 2 referral centers in Spain, from June 2016 through January 2018 of 50 patients who fulfilled the Rome IV criteria for functional dyspepsia with postprandial distress syndrome and functional constipation and dyssynergic defecation. After a 2-week pretreatment phase, the patients were randomly assigned to groups that learned to correct dyssynergic defecation (2-3 sessions of biofeedback combined with instructions for daily exercise; n = 25) or received dietary fiber supplementation (3.5 g plantago ovata per day; n = 25) for 4 weeks. The primary outcome was change in postprandial abdominal fullness, measured daily on a scale of 0-10, during the last 7 days treatment phase vs the last 7 days of the pretreatment phase. Anal gas evacuations were measured (by an event marker) during the last 2 days of the pretreatment vs treatment phases. RESULTS Biofeedback treatment corrected dyssynergic defecation in 19/25 patients; corrected dyssynergic defection reduced postprandial fullness by 22%±1% in these patients (P < .001), and reduced the number of anal evacuations by 21%±8% (P = .009). Fiber supplementation did not reduce postprandial fullness or anal evacuations (P ≤ .023 between groups for both parameters in the intent to treat analysis). CONCLUSIONS Diagnosis and correction of dyssynergic defecation reduces dyspeptic symptoms by more than 20% in patients with functional dyspepsia and associated constipation. Dietary fiber supplementation does not reduce symptoms in these patients. ClinicalTrials.gov no: NCT02956187.",2019,"Fiber supplementation did not reduce postprandial fullness or anal evacuations (P ≤ .023 between groups for both parameters in the intent to treat analysis). ","['patients with functional dyspepsia, correction of dyssynergic defecation can reduce postprandial fullness', 'Patients With Constipation', 'Patients with functional dyspepsia', '2 referral centers in Spain, from June 2016 through January 2018 of 50 patients who fulfilled the Rome IV criteria for functional dyspepsia with postprandial distress syndrome and functional constipation and dyssynergic defecation']","['Fiber supplementation', 'Dietary fiber supplementation', 'learned to correct dyssynergic defecation (2-3 sessions of biofeedback combined with instructions for daily exercise; n = 25) or received dietary fiber supplementation']","['constipation', 'postprandial abdominal fullness, measured daily on a scale of 0-10', 'dyssynergic defecation', 'number of anal evacuations', 'dyspeptic symptoms', 'Functional Dyspepsia', 'dyssynergic defection reduced postprandial fullness', 'Anal gas evacuations', 'postprandial fullness or anal evacuations']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0267167', 'cui_str': 'Nonulcer dyspepsia (disorder)'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0439650', 'cui_str': 'Fullness (qualifier value)'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0034927', 'cui_str': 'Referral'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0035831', 'cui_str': 'Rome'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0401146', 'cui_str': 'Constipation - functional (disorder)'}]","[{'cui': 'C0225326', 'cui_str': 'Fiber'}, {'cui': 'C0556106', 'cui_str': 'Dietary fiber supplementation (product)'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0678663', 'cui_str': 'Biofeedback, function (observable entity)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0235318', 'cui_str': 'Fullness abdominal'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C2939124', 'cui_str': 'Anal (qualifier value)'}, {'cui': 'C1282573', 'cui_str': 'Evacuation procedure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0267167', 'cui_str': 'Nonulcer dyspepsia (disorder)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0439650', 'cui_str': 'Fullness (qualifier value)'}, {'cui': 'C0596601', 'cui_str': 'Gas'}]",,0.234526,"Fiber supplementation did not reduce postprandial fullness or anal evacuations (P ≤ .023 between groups for both parameters in the intent to treat analysis). ","[{'ForeName': 'Jose-Walter', 'Initials': 'JW', 'LastName': 'Huaman', 'Affiliation': ""Digestive System Research Unit, University Hospital Vall d'Hebron, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain; Department of Gastroenterology, University Hospital General of Catalonia, San Cugat del Valles, Spain.""}, {'ForeName': 'Marianela', 'Initials': 'M', 'LastName': 'Mego', 'Affiliation': ""Digestive System Research Unit, University Hospital Vall d'Hebron, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain; Department of Gastroenterology, University Hospital General of Catalonia, San Cugat del Valles, Spain.""}, {'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Bendezú', 'Affiliation': ""Digestive System Research Unit, University Hospital Vall d'Hebron, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain; Department of Gastroenterology, University Hospital General of Catalonia, San Cugat del Valles, Spain.""}, {'ForeName': 'Hugo', 'Initials': 'H', 'LastName': 'Monrroy', 'Affiliation': ""Digestive System Research Unit, University Hospital Vall d'Hebron, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.""}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Samino', 'Affiliation': 'Metabolomics Platform, Campus Sescelades, Universitat Rovira i Virgili, Tarragona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas, Instituto Carlos III, Madrid, Spain.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Accarino', 'Affiliation': ""Digestive System Research Unit, University Hospital Vall d'Hebron, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.""}, {'ForeName': 'Esteban', 'Initials': 'E', 'LastName': 'Saperas', 'Affiliation': 'Department of Gastroenterology, University Hospital General of Catalonia, San Cugat del Valles, Spain.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Azpiroz', 'Affiliation': ""Digestive System Research Unit, University Hospital Vall d'Hebron, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Electronic address: azpiroz.fernando@gmail.com.""}]",Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,['10.1016/j.cgh.2019.11.048'] 1168,32438483,Telemonitoring versus standard care in heart failure: a randomised multicentre trial.,"AIMS The aim was to assess the effect of a telemonitoring programme vs. standard care (SC) in preventing all-cause deaths or unplanned hospitalisations in heart failure (HF) at 18 months. METHODS AND RESULTS OSICAT was a randomised, multicentre, open-label French study in 937 patients hospitalised for acute HF ≤12 months before inclusion. Patients were randomised to telemonitoring (daily body weight measurement, daily recording of HF symptoms, and personalised education) (n = 482) or to SC (n = 455). Mean ± standard deviation number of events for the primary outcome was 1.30 ± 1.85 for telemonitoring and 1.46 ± 1.98 for SC [rate ratio 0.97, 95% confidence interval (CI) 0.77-1.23; P = 0.80]. In New York Heart Association (NYHA) class III or IV HF, median time to all-cause death or first unplanned hospitalisation was 82 days in the telemonitoring group and 67 days in the SC group (P = 0.03). After adjustment for known predictive factors, telemonitoring was associated with a 21% relative risk reduction in first unplanned hospitalisation for HF [hazard ratio (HR) 0.79, 95% CI 0.62-0.99; P = 0.044); the relative risk reduction was 29% in patients with NYHA class III or IV HF (HR 0.71, 95% CI 0.53-0.95; P = 0.02), 38% in socially isolated patients (HR 0.62, 95% CI 0.39-0.98; P = 0.043), and 37% in patients who were ≥70% adherent to body weight measurement (HR 0.63, 95% CI 0.45-0.88; P = 0.006). CONCLUSION Telemonitoring did not result in a significantly lower rate of all-cause deaths or unplanned hospitalisations in HF patients. The pre-specified subgroup results suggest the telemonitoring approach improves clinical outcomes in selected populations but need further confirmation.",2020,Telemonitoring did not result in a significantly lower rate of all-cause deaths or unplanned hospitalisations in HF patients.,"['all-cause deaths or unplanned hospitalisations in heart failure (HF) at 18\u2009months', '937 patients hospitalised for acute HF ≤12\u2009months before inclusion', 'in heart failure']","['telemonitoring (daily body-weight measurement, daily recording of HF symptoms, and personalised education) (n\xa0=\xa0482) or to SC', 'telemonitoring programme versus standard care (SC', 'Telemonitoring versus standard of care']","['Mean\u2009±\u2009standard deviation number of events', 'median time to all-cause death or first unplanned hospitalisation', 'rate of all-cause deaths or unplanned hospitalisations', 'relative risk reduction']","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0264714', 'cui_str': 'Acute heart failure'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",937.0,0.224831,Telemonitoring did not result in a significantly lower rate of all-cause deaths or unplanned hospitalisations in HF patients.,"[{'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Galinier', 'Affiliation': 'Cardiology, Toulouse Rangueil University Hospital (CHU), Toulouse, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Roubille', 'Affiliation': 'PhyMedExp, Université de Montpellier, INSERM, CNRS, Cardiology Department, University Hospital of Montpellier, Montpellier, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Berdague', 'Affiliation': 'Beziers Hospital Centre, Beziers, France.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Brierre', 'Affiliation': ""Intercommunal Hospital Centre des Vallées de l'Ariege, Foix, France.""}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Cantie', 'Affiliation': 'Intercommunal Hospital Centre Castres-Mazamet, Castres, France.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Dary', 'Affiliation': 'Private Practice, Saint Yrieix La Perche, France.'}, {'ForeName': 'Jean-Marc', 'Initials': 'JM', 'LastName': 'Ferradou', 'Affiliation': 'Cardiology Aftercare and Rehabilitation Centre, Beaumont de Lomagne, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Fondard', 'Affiliation': 'Pasteur Clinic, Toulouse, France.'}, {'ForeName': 'Jean Philippe', 'Initials': 'JP', 'LastName': 'Labarre', 'Affiliation': 'Pont de Chaume Clinic, Montauban, France.'}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Mansourati', 'Affiliation': 'CHRU Brest, Brest, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Picard', 'Affiliation': ""Unité d'Insuffisance Cardiaque, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.""}, {'ForeName': 'Jean-Etienne', 'Initials': 'JE', 'LastName': 'Ricci', 'Affiliation': 'University Hospital of Nimes, Nimes, France.'}, {'ForeName': 'Muriel', 'Initials': 'M', 'LastName': 'Salvat', 'Affiliation': 'University Hospital of Grenoble, Grenoble, France.'}, {'ForeName': 'Lamia', 'Initials': 'L', 'LastName': 'Tartière', 'Affiliation': 'Leon Berard Hospital, Hyeres, France.'}, {'ForeName': 'Jean-Bernard', 'Initials': 'JB', 'LastName': 'Ruidavets', 'Affiliation': 'INSERM UMR - U1027, Toulouse, France.'}, {'ForeName': 'Vanina', 'Initials': 'V', 'LastName': 'Bongard', 'Affiliation': 'USMR - CHU Toulouse, Toulouse, France.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Delval', 'Affiliation': 'Air Liquide Santé International, Loges en Josas, France.'}, {'ForeName': 'Guila', 'Initials': 'G', 'LastName': 'Lancman', 'Affiliation': 'Air Liquide Santé International, Loges en Josas, France.'}, {'ForeName': 'Hélène', 'Initials': 'H', 'LastName': 'Pasche', 'Affiliation': 'Air Liquide Santé International, Loges en Josas, France.'}, {'ForeName': 'Juan Fernando', 'Initials': 'JF', 'LastName': 'Ramirez-Gil', 'Affiliation': 'Air Liquide Santé International, Loges en Josas, France.'}, {'ForeName': 'Atul', 'Initials': 'A', 'LastName': 'Pathak', 'Affiliation': 'Department of Cardiovascular Medicine, Princess Grace Hospital, Monaco, Monaco.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of heart failure,['10.1002/ejhf.1906'] 1169,31412790,Dynamic risk prediction for diabetes using biomarker change measurements.,"BACKGROUND Dynamic risk models, which incorporate disease-free survival and repeated measurements over time, might yield more accurate predictions of future health status compared to static models. The objective of this study was to develop and apply a dynamic prediction model to estimate the risk of developing type 2 diabetes mellitus. METHODS Both a static prediction model and a dynamic landmark model were used to provide predictions of a 2-year horizon time for diabetes-free survival, updated at 1, 2, and 3 years post-baseline i.e., predicting diabetes-free survival to 2 years and predicting diabetes-free survival to 3 years, 4 years, and 5 years post-baseline, given the patient already survived past 1 year, 2 years, and 3 years post-baseline, respectively. Prediction accuracy was evaluated at each time point using robust non-parametric procedures. Data from 2057 participants of the Diabetes Prevention Program (DPP) study (1027 in metformin arm, 1030 in placebo arm) were analyzed. RESULTS The dynamic landmark model demonstrated good prediction accuracy with area under curve (AUC) estimates ranging from 0.645 to 0.752 and Brier Score estimates ranging from 0.088 to 0.135. Relative to a static risk model, the dynamic landmark model did not significantly differ in terms of AUC but had significantly lower (i.e., better) Brier Score estimates for predictions at 1, 2, and 3 years (e.g. 0.167 versus 0.099; difference - 0.068 95% CI - 0.083 to - 0.053, at 3 years in placebo group) post-baseline. CONCLUSIONS Dynamic prediction models based on longitudinal, repeated risk factor measurements have the potential to improve the accuracy of future health status predictions.",2019,The dynamic landmark model demonstrated good prediction accuracy with area under curve (AUC) estimates ranging from 0.645 to 0.752 and Brier Score estimates ranging from 0.088 to 0.135.,"['2057 participants of the Diabetes Prevention Program (DPP) study (1027 in metformin arm, 1030 in placebo arm) were analyzed']",[],['Prediction accuracy'],"[{'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]",[],[],2057.0,0.0492703,The dynamic landmark model demonstrated good prediction accuracy with area under curve (AUC) estimates ranging from 0.645 to 0.752 and Brier Score estimates ranging from 0.088 to 0.135.,"[{'ForeName': 'Layla', 'Initials': 'L', 'LastName': 'Parast', 'Affiliation': 'RAND Corporation, 1776 Main St, Santa Monica, CA, 90401, USA. parast@rand.org.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Mathews', 'Affiliation': 'RAND Corporation, 1776 Main St, Santa Monica, CA, 90401, USA.'}, {'ForeName': 'Mark W', 'Initials': 'MW', 'LastName': 'Friedberg', 'Affiliation': 'RAND Corporation, 20 Park Plaza # 920, Boston, MA, 02116, USA.'}]",BMC medical research methodology,['10.1186/s12874-019-0812-y'] 1170,32133668,Home visits by occupational therapists improve adherence to recommendations: Process evaluation of a randomised controlled trial.,"INTRODUCTION As part of hospital discharge planning, occupational therapists often provide recommendations to improve the interaction between a person and their home environment. The aim of this study was to investigate the number and type of recommendations made by occupational therapists during a home assessment visit compared to hospital-based assessment for patients recovering from hip fracture. A secondary aim was to explore adherence rates to the different types of recommendations. METHODS Process evaluation of a randomised controlled trial of 65 participants recovering from hip fracture, returning to community living after hospital discharge. All participants received inpatient multidisciplinary rehabilitation and hospital-based assessment by an occupational therapist (usual care). In addition, the intervention group participated in a single home visit with an occupational therapist prior to hospital discharge. Analysis included the number and type of occupational therapy recommendations, adherence to recommendations at 30 days after discharge, and mediation analysis. RESULTS Participants in the home visit group received more recommendations than the usual care group (mean difference [MD] 2.8, 95% CI 1.6 to 3.9) and adhered to a greater proportion of recommendations for assistive technologies (MD 11.4%, 95% CI 2.6 to 20.2) and task modifications (MD 10.0%, 95% CI 0.7 to 19.3). Participants in both groups had lower rates of adherence to recommendations for home modifications compared with other types of recommendations. Adherence to recommendations was a mediator in the relationship between participants' involvement in a pre-discharge home visit and reduced hospital readmissions. CONCLUSION There was greater adherence to occupational therapy recommendations when patients recovering from hip fracture participated in a home visit compared to hospital-based assessment, contributing to reduced readmissions to hospital in the first 30 days. Home visits offer additional benefits to hospital-based assessment through the use of a collaborative approach to decision making in the home environment.",2020,"There was greater adherence to occupational therapy recommendations when patients recovering from hip fracture participated in a home visit compared to hospital-based assessment, contributing to reduced readmissions to hospital in the first 30 days.","['patients recovering from hip fracture', '65 participants recovering from hip fracture, returning to community living after hospital discharge']","['single home visit with an occupational therapist prior to hospital discharge', 'inpatient multidisciplinary rehabilitation and hospital-based assessment by an occupational therapist (usual care']","['adherence rates', 'number and type of occupational therapy recommendations, adherence to recommendations', 'proportion of recommendations for assistive technologies']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0521108', 'cui_str': 'Recovering from (contextual qualifier) (qualifier value)'}, {'cui': 'C0019557', 'cui_str': 'Hip Fractures'}, {'cui': 'C0332156', 'cui_str': 'Return to (contextual qualifier) (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0020043', 'cui_str': 'Home Visits'}, {'cui': 'C0028807', 'cui_str': 'Occupational therapist (occupation)'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C1318464', 'cui_str': 'Occupational Therapy'}, {'cui': 'C0036605', 'cui_str': 'Assistive Technology'}]",65.0,0.109519,"There was greater adherence to occupational therapy recommendations when patients recovering from hip fracture participated in a home visit compared to hospital-based assessment, contributing to reduced readmissions to hospital in the first 30 days.","[{'ForeName': 'Kylee J', 'Initials': 'KJ', 'LastName': 'Lockwood', 'Affiliation': 'School of Allied Health, Human Services & Sport, La Trobe University, Melbourne, Vic., Australia.'}, {'ForeName': 'Katherine E', 'Initials': 'KE', 'LastName': 'Harding', 'Affiliation': 'School of Allied Health, Human Services & Sport, La Trobe University, Melbourne, Vic., Australia.'}, {'ForeName': 'Jude N', 'Initials': 'JN', 'LastName': 'Boyd', 'Affiliation': 'Department of Occupational Therapy, Eastern Health, Melbourne, Vic., Australia.'}, {'ForeName': 'Nicholas F', 'Initials': 'NF', 'LastName': 'Taylor', 'Affiliation': 'School of Allied Health, Human Services & Sport, La Trobe University, Melbourne, Vic., Australia.'}]",Australian occupational therapy journal,['10.1111/1440-1630.12651'] 1171,30138718,Rationale and design of the Study To Understand Fall Reduction and Vitamin D in You (STURDY): A randomized clinical trial of Vitamin D supplement doses for the prevention of falls in older adults.,"Prior evidence suggests that vitamin D supplementation may reduce fall risk, but existing data are inconsistent and insufficient to guide policy. We designed a two-stage Bayesian response-adaptive dose-finding and seamless confirmatory randomized trial of vitamin D supplementation to prevent falls. Up to 1200 community-dwelling persons, aged ≥70 years, of predominantly white and African-American race, with serum 25(OH)D concentrations of 10-29 ng/mL and at elevated fall risk, will be randomized to one of four vitamin D3 (cholecalciferol) supplement doses: 200 (control), 1000, 2000, or 4000 IU/day and treated for up to 2 years. Stage 1 is designed to identify the best of the non-control doses for fall prevention. If a best dose is selected, Stage 2 will start seamlessly, with enrollees assigned to control or the best dose in Stage 1 continuing on that dose unchanged, enrollees assigned to the two non-control, non-best doses in Stage 1 switched to the best dose, and new enrollees randomly assigned 1:1 to control or the best dose. In Stage 2, we will compare the control dose group to the best dose group to potentially confirm the efficacy of that dose for fall prevention. The primary outcome measure in both stages is time to first fall or death, whichever comes first. Falls are ascertained from calendars, scheduled interviews, or interim self-reports. Secondary outcome measures include time to each component of the composite primary outcome and gait speed. Additional outcomes include the Short Physical Performance Battery score, physical activity level (assessed by accelerometry), and frailty score. CLINICAL TRIAL REGISTRATION NCT02166333.",2018,"Additional outcomes include the Short Physical Performance Battery score, physical activity level (assessed by accelerometry), and frailty score. ","['1200 community-dwelling persons, aged ≥70\u202fyears, of predominantly white and African-American race, with serum 25(OH)D concentrations of 10-29\u202fng/mL and at elevated fall risk', 'older adults']","['vitamin D3 (cholecalciferol', 'Vitamin D supplement', 'vitamin D supplementation']","['Fall Reduction and Vitamin D in You (STURDY', 'Short Physical Performance Battery score, physical activity level (assessed by accelerometry), and frailty score', 'time to each component of the composite primary outcome and gait speed', 'both stages is time to first fall or death, whichever comes first']","[{'cui': 'C4517548', 'cui_str': 'One thousand two hundred'}, {'cui': 'C4045975', 'cui_str': 'Community Dwelling'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C3853635', 'cui_str': 'Race (observable entity)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C1268740', 'cui_str': 'Fall risk'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C3265062', 'cui_str': 'vitamin D3'}, {'cui': 'C0242215', 'cui_str': 'Cholecalciferols'}, {'cui': 'C3541352', 'cui_str': 'Vitamin D supplement (substance)'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}]","[{'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C4075289', 'cui_str': 'Short Physical Performance Battery score (observable entity)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0441677', 'cui_str': 'Accelerometry'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C2009910', 'cui_str': 'Gait Speed'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0960273', 'cui_str': 'CAME'}]",,0.113765,"Additional outcomes include the Short Physical Performance Battery score, physical activity level (assessed by accelerometry), and frailty score. ","[{'ForeName': 'Erin D', 'Initials': 'ED', 'LastName': 'Michos', 'Affiliation': 'Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, United States; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, United States. Electronic address: edonnell@jhmi.edu.'}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Mitchell', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, United States.'}, {'ForeName': 'Edgar R', 'Initials': 'ER', 'LastName': 'Miller', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, United States; Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United States.'}, {'ForeName': 'Alice L', 'Initials': 'AL', 'LastName': 'Sternberg', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.'}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Juraschek', 'Affiliation': 'Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, United States; Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United States; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Jennifer A', 'Initials': 'JA', 'LastName': 'Schrack', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, United States; Center on Aging and Health, Johns Hopkins University, Baltimore, MD, United States.'}, {'ForeName': 'Sarah L', 'Initials': 'SL', 'LastName': 'Szanton', 'Affiliation': 'Center on Aging and Health, Johns Hopkins University, Baltimore, MD, United States; Johns Hopkins School of Nursing, Baltimore, MD, United States; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.'}, {'ForeName': 'Jeremy D', 'Initials': 'JD', 'LastName': 'Walston', 'Affiliation': 'Center on Aging and Health, Johns Hopkins University, Baltimore, MD, United States; Division of Geriatric Medicine and Gerontology, Johns Hopkins School of Medicine, Baltimore, MD, United States.'}, {'ForeName': 'Rita R', 'Initials': 'RR', 'LastName': 'Kalyani', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Center on Aging and Health, Johns Hopkins University, Baltimore, MD, United States; Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins School of Medicine, Baltimore, MD, United States.'}, {'ForeName': 'Timothy B', 'Initials': 'TB', 'LastName': 'Plante', 'Affiliation': 'Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States.'}, {'ForeName': 'Robert H', 'Initials': 'RH', 'LastName': 'Christenson', 'Affiliation': 'Department of Pathology, University of Maryland Medical Center, Baltimore, MD, United States.'}, {'ForeName': 'Dave', 'Initials': 'D', 'LastName': 'Shade', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Tonascia', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Roth', 'Affiliation': 'Center on Aging and Health, Johns Hopkins University, Baltimore, MD, United States; Division of Geriatric Medicine and Gerontology, Johns Hopkins School of Medicine, Baltimore, MD, United States.'}, {'ForeName': 'Lawrence J', 'Initials': 'LJ', 'LastName': 'Appel', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, United States; Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United States.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Contemporary clinical trials,['10.1016/j.cct.2018.08.004'] 1172,32437937,Causes of fever in primary care in Southeast Asia and the performance of C-reactive protein in discriminating bacterial from viral pathogens.,"OBJECTIVES This study investigated causes of fever in the primary levels of care in Southeast Asia, and evaluated whether C-reactive protein (CRP) could distinguish bacterial from viral pathogens. METHODS Blood and nasopharyngeal swab specimens were taken from children and adults with fever (>37.5 °C) or history of fever (<14 days) in Thailand and Myanmar. RESULTS Of 773 patients with at least one blood or nasopharyngeal swab specimen collected, 227 (29.4%) had a target organism detected. Influenza virus type A was detected in 85/227 cases (37.5%), followed by dengue virus (30 cases, 13.2%), respiratory syncytial virus (24 cases, 10.6%) and Leptospira spp. (nine cases, 4.0%). Clinical outcomes were similar between patients with a bacterial or a viral organism, regardless of antibiotic prescription. CRP was higher among patients with a bacterial organism compared with those with a viral organism (median 18 mg/L, interquartile range [10-49] versus 10 mg/L [≤8-22], p = 0.003), with an area under the curve of 0.65 (95% CI 0.55-0.75). CONCLUSIONS Serious bacterial infections requiring antibiotics are an exception rather than the rule in the first line of care. CRP testing could assist in ruling out such cases in settings where diagnostic uncertainty is high and routine antibiotic prescription is common. The original CRP randomised controlled trial was registered with ClinicalTrials.gov, number NCT02758821.",2020,"CRP was higher among patients with a bacterial organism compared to those with a viral organism (median 18mg/L, interquartile range [10-49] versus 10mg/L [≤8-22], p-value 0.003), with an area under the curve of 0.65, 95% confidence interval (0.55-0.75). ","['fever in the primary levels of care in Southeast Asia', '773 patients with at least one blood or nasopharyngeal swab specimen collected, 227 (29.4%) had a target organism detected', 'Blood and nasopharyngeal swab specimens were taken from children and adults with fever (>37.5˚C) or history of fever (<14 days) in Thailand and Myanmar']",[],"['respiratory syncytial virus', 'CRP']","[{'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003983', 'cui_str': 'South east Asian country'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0444192', 'cui_str': 'Nasopharyngeal swab'}, {'cui': 'C0029235', 'cui_str': 'Organism'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0039725', 'cui_str': 'Thailand'}, {'cui': 'C0006416', 'cui_str': 'Burma'}]",[],"[{'cui': 'C0035236', 'cui_str': 'Syncytial Virus, Respiratory'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}]",773.0,0.237316,"CRP was higher among patients with a bacterial organism compared to those with a viral organism (median 18mg/L, interquartile range [10-49] versus 10mg/L [≤8-22], p-value 0.003), with an area under the curve of 0.65, 95% confidence interval (0.55-0.75). ","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Althaus', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom. Electronic address: thomas.a@tropmedres.ac.'}, {'ForeName': 'Janjira', 'Initials': 'J', 'LastName': 'Thaipadungpanit', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Rachel C', 'Initials': 'RC', 'LastName': 'Greer', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Myo Maung Maung', 'Initials': 'MMM', 'LastName': 'Swe', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Myanmar-Oxford Clinical Research Unit (MOCRU), Medical Action Myanmar (MAM), Yangon, Myanmar.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Dittrich', 'Affiliation': 'Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.'}, {'ForeName': 'Pimnara', 'Initials': 'P', 'LastName': 'Peerawaranun', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Pieter W', 'Initials': 'PW', 'LastName': 'Smit', 'Affiliation': 'Maasstad Ziekenhuis Hospital, Department of Medical Microbiology, Rotterdam, The Netherlands; Public Health Laboratory (GGD), Amsterdam, The Netherlands.'}, {'ForeName': 'Tri', 'Initials': 'T', 'LastName': 'Wangrangsimakul', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Blacksell', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Jonas M', 'Initials': 'JM', 'LastName': 'Winchell', 'Affiliation': 'Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.'}, {'ForeName': 'Maureen H', 'Initials': 'MH', 'LastName': 'Diaz', 'Affiliation': 'Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.'}, {'ForeName': 'Nicholas P J', 'Initials': 'NPJ', 'LastName': 'Day', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Smithuis', 'Affiliation': 'Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom; Myanmar-Oxford Clinical Research Unit (MOCRU), Medical Action Myanmar (MAM), Yangon, Myanmar.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Turner', 'Affiliation': 'Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom; Cambodia-Oxford Medical Research Unit (COMRU), Angkor Hospital for Children, Siem Reap, Cambodia.'}, {'ForeName': 'Yoel', 'Initials': 'Y', 'LastName': 'Lubell', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.'}]",International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,['10.1016/j.ijid.2020.05.016'] 1173,32437857,"Is a two-step impression mandatory for complete denture fabrication on the severely resorbed mandible? A randomized trial on mastication, patient satisfaction and adjustments.","OBJECTIVES To compare one- vs two-step impression procedures for the provision of conventional complete dentures (CCDs) for edentulous individuals with severe mandibular resorption, in terms of (1) masticatory performance and ability; (2) satisfaction with mandibular CCDs; and (3) post-delivery adjustments. METHODS Fifty-two patients requiring maxillary + mandibular CCDs were randomly divided into two parallel arms according to the impression method of the mandibular ridge: (SI) single impression with stock trays (irreversible hydrocolloid); (TI) two-step impression in custom trays, with border molding (impression compound) followed by the impression itself (polyether). Mastication performance was evaluated by a colorimetric test, whereas patients answered questions on masticatory ability and satisfaction with mandibular CCDs (100-mm visual analogue scale). The number of post-delivery sessions for adjustments were also quantified. Outcomes were assessed at 3 and 6 months after delivery. RESULTS The masticatory performance was similar for both groups, regardless of time (3 months, P = 0.62; 6 months, P = 0.61). No significant difference was found for patient-reported (P > 0.05), i.e. masticatory ability (general ease of chewing and quality of grinding food; ability to chew specific foods), general satisfaction with the mandibular CCD (general satisfaction, comfort, aesthetics, ability to speak and to perform correct cleaning, retention and stability). Both methods resulted in a similar number of post-delivery adjustment sessions [SI: 3.8 (1.7); TI: 3.2 (1.4); P = 0.09]. CONCLUSIONS Compared to a traditional approach, CCDs obtained from a single impression achieve similar masticatory performance/ability and patient satisfaction, even in patients with severely reabsorbed mandibular ridge. Both methods demand the same amount of post-delivery adjustment. CLINICAL SIGNIFICANCE A simplified impression technique which eliminates the secondary impression can provide CCDs of good clinical quality, which influences the OHRQoL, and satisfaction in the same extent they would by a two-step procedure, even for patients with severely reabsorbed mandibular ridges (ClinicalTrials.gov: NCT02339194).",2020,"The masticatory performance was similar for both groups, regardless of time (3 months, P = 0.62; 6 months, P = 0.61).","['patients with severely reabsorbed mandibular ridge', 'Fifty-two patients requiring maxillary\u2009+\u2009mandibular CCDs', 'edentulous individuals with severe mandibular resorption, in terms of (1) masticatory performance and ability; (2) satisfaction with mandibular CCDs; and (3) post-delivery adjustments']","['impression method of the mandibular ridge: (SI) single impression with stock trays (irreversible hydrocolloid); (TI) two-step impression in custom trays, with border molding (impression compound) followed by the impression itself (polyether', 'conventional complete dentures (CCDs']","['masticatory performance', 'Mastication performance', 'masticatory ability (general ease of chewing and quality of grinding food; ability to chew specific foods), general satisfaction with the mandibular CCD (general satisfaction, comfort, aesthetics, ability to speak and to perform correct cleaning, retention and stability', 'masticatory ability and satisfaction with mandibular CCDs (100-mm visual analogue scale', 'masticatory performance/ability and patient satisfaction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0332243', 'cui_str': 'Ridging'}, {'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0026644', 'cui_str': 'Edentulous'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}]","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0332243', 'cui_str': 'Ridging'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0453908', 'cui_str': 'Stocking'}, {'cui': 'C0184054', 'cui_str': 'Tray'}, {'cui': 'C0020266', 'cui_str': 'Hydrocolloid'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0162343', 'cui_str': 'Customs'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0426103', 'cui_str': 'Fetal head molding'}, {'cui': 'C0205198', 'cui_str': 'Compound'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0011455', 'cui_str': 'Complete denture'}]","[{'cui': 'C0024888', 'cui_str': 'Mastication'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0185051', 'cui_str': 'Removal by grinding'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0566339', 'cui_str': 'Ability to chew'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0008928', 'cui_str': 'Cleidocranial dysostosis'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0564214', 'cui_str': 'Ability to speak'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0542277', 'cui_str': 'Cleans drug injection equipment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}]",52.0,0.0678577,"The masticatory performance was similar for both groups, regardless of time (3 months, P = 0.62; 6 months, P = 0.61).","[{'ForeName': 'Ivo S', 'Initials': 'IS', 'LastName': 'Albuquerque', 'Affiliation': 'Department of Restorative Dentistry, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceará (FFOE-UFC), Fortaleza, Brazil.'}, {'ForeName': 'Karina M', 'Initials': 'KM', 'LastName': 'Freitas-Pontes', 'Affiliation': 'Department of Restorative Dentistry, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceará (FFOE-UFC), Fortaleza, Brazil. Electronic address: kamatthes@yahoo.com.br.'}, {'ForeName': 'Raphael F', 'Initials': 'RF', 'LastName': 'de Souza', 'Affiliation': 'Oral Health and Society, Faculty of Dentistry, McGill University, 2001 McGill College Ave, Suite 500, Montreal, Quebec, Canada.'}, {'ForeName': 'Wagner A', 'Initials': 'WA', 'LastName': 'Negreiros', 'Affiliation': 'Department of Restorative Dentistry, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceará (FFOE-UFC), Fortaleza, Brazil.'}, {'ForeName': 'Marcelo B', 'Initials': 'MB', 'LastName': 'Ramos', 'Affiliation': 'Department of Restorative Dentistry, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceará (FFOE-UFC), Fortaleza, Brazil.'}, {'ForeName': 'Raniel F', 'Initials': 'RF', 'LastName': 'Peixoto', 'Affiliation': 'Department of Restorative Dentistry, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceará (FFOE-UFC), Fortaleza, Brazil.'}, {'ForeName': 'Rômulo R', 'Initials': 'RR', 'LastName': 'Regis', 'Affiliation': 'Department of Restorative Dentistry, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceará (FFOE-UFC), Fortaleza, Brazil.'}]",Journal of dentistry,['10.1016/j.jdent.2020.103357'] 1174,32437328,Physical Activity With Tailored mHealth Support for Individuals With Intellectual Disabilities: Protocol for a Randomized Controlled Trial.,"BACKGROUND Individuals with intellectual disabilities (IDs) have lower levels of physical activity (PA) and greater barriers for participation in fitness activities compared with members of the general population. As increased PA has positive effects on cardiovascular and psychosocial health, it is exceedingly important to identify effective interventions for use in everyday settings. Mobile health (mHealth) methods such as motion sensor games (exergames) and smartphone reminders for PA have been explored and found to be promising in individuals with IDs. OBJECTIVE The purpose of this study is to examine the effectiveness of an individually tailored PA program with motivational mHealth support on daily levels of PA in youth and adults with IDs. METHODS The trial uses a randomized controlled design comprising 30 intervention participants and 30 control group participants, aged 16 to 60 years, with sedentary lifestyles or low PA levels. While the controls will receive standard care, the intervention aims to increase the level of PA, measured as steps per day, as the primary outcome. Secondary outcome variables are body mass index, blood pressure, physical performance, social support for PA, self-efficacy in a PA setting, behavior problems, and goal attainment. The intervention involves the delivery of tailored mHealth support, using smartphones or tablets to create structure with focus on the communicative abilities of individual participants. Rewards and feedback are provided in order to motivate individuals to increase participation in PA. Participants in the intervention group, their close relatives, and care staff will be invited to participate in a preintervention goal-setting meeting, where goal attainment scaling will be used to select the participants' PA goals for the intervention period. All participants will be assessed at baseline, at 3 months, and at 6 months. RESULTS Enrollment was planned to start in April 2020 but will be delayed due to the pandemic situation. The main contribution of this paper is a detailed plan to run our study, which will produce new knowledge about tailored mHealth to support PA in individuals with intellectual disabilities. CONCLUSIONS We expect the new intervention to perform better than standard care in terms of improved PA, improved self-efficacy, and social support for activities. Technology offers new opportunities to promote healthy behaviors. The results of the study will determine the effectiveness and sustainability of a tailored mHealth support intervention to increase PA in youth and adults with IDs. TRIAL REGISTRATION ClinicalTrials.gov NCT04079439; https://clinicaltrials.gov/ct2/show/NCT04079439. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) PRR1-10.2196/19213.",2020,"We expect the new intervention to perform better than standard care in terms of improved PA, improved self-efficacy and social support for activities.","['30 intervention participants and 30 controls, aged 16 to 60 years, with a sedentary lifestyle or low PA level', 'individuals with IDs', 'youth and adults with IDs', 'individuals with intellectual disabilities', 'Individuals with intellectual disabilities (IDs']",[],"['Physical activity', 'blood pressure, physical performance, social support for PA, self-efficacy in PA setting, behavior problems and goal attainment']","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1532253', 'cui_str': 'Sedentary lifestyle'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3714756', 'cui_str': 'Intellectual disability'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]",[],"[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}]",30.0,0.0665167,"We expect the new intervention to perform better than standard care in terms of improved PA, improved self-efficacy and social support for activities.","[{'ForeName': 'Henriette', 'Initials': 'H', 'LastName': 'Michalsen', 'Affiliation': 'Department of Rehabilitation, University Hospital of North Norway, Tromsø, Norway.'}, {'ForeName': 'Silje Camilla', 'Initials': 'SC', 'LastName': 'Wangberg', 'Affiliation': 'Department of Health and Care Sciences, University of Tromsø - The Arctic University of Norway, Narvik, Norway.'}, {'ForeName': 'Gunnar', 'Initials': 'G', 'LastName': 'Hartvigsen', 'Affiliation': 'Department of Computer Science, University of Tromsø - The Artic University of Norway, Tromsø, Norway.'}, {'ForeName': 'Letizia', 'Initials': 'L', 'LastName': 'Jaccheri', 'Affiliation': 'Department of Computer Science, The Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Miroslav', 'Initials': 'M', 'LastName': 'Muzny', 'Affiliation': 'Department of Rehabilitation, University Hospital of North Norway, Tromsø, Norway.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Henriksen', 'Affiliation': 'Department of Community Medicine, University of Tromsø - The Arctic University of Norway, Tromsø, Norway.'}, {'ForeName': 'Monica Isabel', 'Initials': 'MI', 'LastName': 'Olsen', 'Affiliation': 'Department of Rehabilitation, University Hospital of North Norway, Tromsø, Norway.'}, {'ForeName': 'Gyrd', 'Initials': 'G', 'LastName': 'Thrane', 'Affiliation': 'Department of Health and Care Sciences, University of Tromsø - The Arctic University of Norway, Tromsø, Norway.'}, {'ForeName': 'Reidun Birgitta', 'Initials': 'RB', 'LastName': 'Jahnsen', 'Affiliation': 'Department of Neurosciences for Children, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Gunn', 'Initials': 'G', 'LastName': 'Pettersen', 'Affiliation': 'Department of Health and Care Sciences, University of Tromsø - The Arctic University of Norway, Tromsø, Norway.'}, {'ForeName': 'Cathrine', 'Initials': 'C', 'LastName': 'Arntzen', 'Affiliation': 'Department of Rehabilitation, University Hospital of North Norway, Tromsø, Norway.'}, {'ForeName': 'Audny', 'Initials': 'A', 'LastName': 'Anke', 'Affiliation': 'Department of Rehabilitation, University Hospital of North Norway, Tromsø, Norway.'}]",JMIR research protocols,['10.2196/19213'] 1175,31431343,Comparison of temporal muscle fascia and tragal cartilage perichondrium in endoscopic type 1 tympanoplasty with limited elevation of tympanomeatal flap.,"INTRODUCTION Elevation of tympanomeatal flap is one of the basic steps of tympanoplasty. A satisfactory level of anatomic and functional success can be achieved by using different grafts with limited tympanomeatal flap elevation. OBJECTIVES We aimed to compare the anatomic and functional success of tragal cartilage perichondrium and temporal muscle fascia in cases of endoscopic type 1 tympanoplasty performed with limited tympanomeatal flap elevation. METHODS In total, 81 cases (33 females, 48 males, mean age 22.1 ± 10.1 years, interval 18-49 years) which underwent transcanal endoscopic type 1 tympanoplasty with limited elevation of tympanomeatal flap were included the present study. All cases were divided into two groups as tragal cartilage perichondrium (group A) and temporal muscle fascia (group B). The comparison of the groups were made considering the pre- and postoperative air-bone gap and the tympanic membrane status. RESULTS There was no statistically significant difference between Group A and Group B in preoperative and in postoperative air-bone gap values (p = 0.608 and 0.529, respectively). In Group A and B, postoperative air-bone gap values demonstrated significant decrease compared to the preoperative values (p = 0.0001). Group A and group B did not demonstrate significant differences between postoperative improvements of air-bone gap values (p = 0.687). Graft retention success was 92.6% in group A while it was 90.0% in group B. There was no statistically significant difference between the groups in terms of graft retention success (p = 0.166). CONCLUSION In accordance with the results of this study, we believe that both tragal cartilage perichondrium and temporal muscle fascia, and also in limited tympanomeatal flap elevation in endoscopic tympanoplasty are all eligible for result in safe and successful surgery.",2020,Group A and Group B did not demonstrate significant differences between postoperative improvements of air-bone gap values (p = 0.687).,"['In total, 81 cases (33 females, 48 males, mean age 22.1\u202f±\u202f10.1 years, interval 18-49 years) who underwent transcanal endoscopic type 1 tympanoplasty with limited elevation of tympanomeatal flap were included the present study']","['tragal cartilage perichondrium and temporal muscle fascia', 'temporal muscle fascia and tragal cartilage perichondrium', 'tragal cartilage perichondrium (Group A) and temporal muscle fascia']","['postoperative improvements of air-bone gap values', 'graft retention success', 'postoperative air-bone gap values', 'Graft retention success']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0441729', 'cui_str': 'Type 1 (qualifier value)'}, {'cui': 'C0041447', 'cui_str': 'Tympanoplasty'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0038925', 'cui_str': 'Surgical Flaps'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0007301', 'cui_str': 'Cartilage'}, {'cui': 'C0225361', 'cui_str': 'Perichondrium (body structure)'}, {'cui': 'C0039487', 'cui_str': 'Temporal Muscle'}, {'cui': 'C0015641', 'cui_str': 'Fascia'}, {'cui': 'C0441835', 'cui_str': 'Group A (qualifier value)'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C1527362', 'cui_str': 'grafts'}, {'cui': 'C0035280', 'cui_str': 'Retention'}]",81.0,0.041576,Group A and Group B did not demonstrate significant differences between postoperative improvements of air-bone gap values (p = 0.687).,"[{'ForeName': 'Kadir', 'Initials': 'K', 'LastName': 'Özdamar', 'Affiliation': 'Private Lotus Hospital, Department of Otorhinolaryngology, Head and Neck Surgery, Şanlıurfa, Turkey. Electronic address: drkadirozdamar@hotmail.com.'}, {'ForeName': 'Alper', 'Initials': 'A', 'LastName': 'Sen', 'Affiliation': 'Harran University, Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, Şanlıurfa, Turkey.'}]",Brazilian journal of otorhinolaryngology,['10.1016/j.bjorl.2019.06.014'] 1176,31427751,"Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders.","Activation of the innate immune system is commonly associated with depression. Immunomodulatory drugs may have efficacy for depressive symptoms that are co-morbidly associated with inflammatory disorders. We report a large-scale re-analysis by standardized procedures (mega-analysis) of patient-level data combined from 18 randomized clinical trials conducted by Janssen or GlaxoSmithKline for one of nine disorders (N = 10,743 participants). Core depressive symptoms (low mood, anhedonia) were measured by the Short Form Survey (SF-36) or the Hospital Anxiety and Depression Scale (HADS), and participants were stratified into high (N = 1921) versus low-depressive strata based on baseline ratings. Placebo-controlled change from baseline after 4-16 weeks of treatment was estimated by the standardized mean difference (SMD) over all trials and for each subgroup of trials targeting one of 7 mechanisms (IL-6, TNF-α, IL-12/23, CD20, COX2, BLγS, p38/MAPK14). Patients in the high depressive stratum showed modest but significant effects on core depressive symptoms (SMD = 0.29, 95% CI [0.12-0.45]) and related SF-36 measures of mental health and vitality. Anti-IL-6 antibodies (SMD = 0.8, 95% CI [0.20-1.41]) and an anti-IL-12/23 antibody (SMD = 0.48, 95% CI [0.26-0.70]) had larger effects on depressive symptoms than other drug classes. Adjustments for physical health outcome marginally attenuated the average treatment effect on depressive symptoms (SMD = 0.20, 95% CI: 0.06-0.35), but more strongly attenuated effects on mental health and vitality. Effects of anti-IL-12/23 remained significant and anti-IL-6 antibodies became a trend after controlling for physical response to treatment. Novel immune-therapeutics can produce antidepressant effects in depressed patients with primary inflammatory disorders that are not entirely explained by treatment-related changes in physical health.",2020,Effects of anti-IL-12/23 remained significant and anti-IL-6 antibodies became a trend after controlling for physical response to treatment.,"['depressed patients with primary inflammatory disorders', 'for one of nine disorders (N\u2009=\u200910,743 participants']","['Placebo', 'placebo', 'immunomodulatory drugs', 'Janssen or GlaxoSmithKline']","['depressive symptoms', 'Anti-IL-6 antibodies', 'mental health and vitality', 'core depressive symptoms', 'related SF-36 measures of mental health and vitality', 'Core depressive symptoms (low mood, anhedonia', 'Hospital Anxiety and Depression Scale (HADS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1290884', 'cui_str': 'Inflammatory disorder'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}]","[{'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0344315', 'cui_str': 'Depressed'}, {'cui': 'C0178417', 'cui_str': 'Anhedonia'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}, {'cui': 'C0048008', 'cui_str': 'Benzenamine, 4-((4-aminophenyl)sulfonyl)-N-hydroxy-'}]",,0.398153,Effects of anti-IL-12/23 remained significant and anti-IL-6 antibodies became a trend after controlling for physical response to treatment.,"[{'ForeName': 'Gayle M', 'Initials': 'GM', 'LastName': 'Wittenberg', 'Affiliation': 'Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA. gwittenb@its.jnj.com.'}, {'ForeName': 'Annie', 'Initials': 'A', 'LastName': 'Stylianou', 'Affiliation': 'Clinical Statistics, GlaxoSmithKline R&D, Stevenage, UK.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': 'Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Ashutosh', 'Initials': 'A', 'LastName': 'Gupta', 'Affiliation': 'Clinical Statistics, GlaxoSmithKline R&D, Bangalore, India.'}, {'ForeName': 'P S', 'Initials': 'PS', 'LastName': 'Jagannatha', 'Affiliation': 'Clinical Statistics, GlaxoSmithKline R&D, Bangalore, India.'}, {'ForeName': 'Dai', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': 'Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Hsu', 'Affiliation': 'Immunology, Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Curran', 'Affiliation': 'Immunology, Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Shahid', 'Initials': 'S', 'LastName': 'Khan', 'Affiliation': 'ImmunoPsychiatry, Immuno-Inflammation Therapeutic Area Unit, GlaxoSmithKline R&D, Stevenage, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Guang', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': 'Neuroscience, Janssen Research & Development, LLC, La Jolla, CA, USA.'}, {'ForeName': 'Edward T', 'Initials': 'ET', 'LastName': 'Bullmore', 'Affiliation': 'ImmunoPsychiatry, Immuno-Inflammation Therapeutic Area Unit, GlaxoSmithKline R&D, Stevenage, UK.'}, {'ForeName': 'Wayne C', 'Initials': 'WC', 'LastName': 'Drevets', 'Affiliation': 'Neuroscience, Janssen Research & Development, LLC, La Jolla, CA, USA.'}]",Molecular psychiatry,['10.1038/s41380-019-0471-8'] 1177,31436843,"Attitudes, knowledge and sexual behavior among Finnish adolescents before and after an intervention.","Adolescents are an important target group for sexual health promotion, and there are numerous programs and interventions carried out in this field. The aim of this study is to describe adolescents' attitudes, knowledge and sexual behavior before and after a sexual health promotion intervention. The intervention was developed in the study and consisted of three elements: (i) class-room session, (ii) information materials and (iii) free condom distribution. The study was carried out in eight randomly selected vocational schools in Finland. The participants were first year students aged 15-19 years. The data were collected using an electronic questionnaire before intervention (intervention baseline n = 500, control baseline n = 183) and two times after the intervention (intervention first follow-up n = 173/second follow-up n = 202, control first follow-up n = 115/second follow-up n = 46). There were significant differences before and after the intervention concerning better knowledge and more frequent testing for sexually transmitted infections (STIs). Schools are an important environment to reach adolescents during the phase where their sexual health is developing and there is an increased risk of STI transmission. More school-based interventions are therefore needed, and the results of this study can be utilized when developing sexual health promotion interventions among adolescents.",2020,There were significant differences before and after the intervention concerning better knowledge and more frequent testing for sexually transmitted infections (STIs).,"['eight randomly selected vocational schools in Finland', 'adolescents', 'participants were first year students aged 15-19 years']","['electronic questionnaire before intervention (intervention baseline n\u2009=\u2009500, control baseline n\u2009=\u2009183) and two times after the intervention (intervention first follow-up n\u2009=\u2009173/second follow-up n\u2009=\u2009202, control first follow-up n\u2009=\u2009115/second follow-up']","['Attitudes, knowledge and sexual behavior']","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0016132', 'cui_str': 'Finland'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4517615', 'cui_str': 'One hundred and eighty-three'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C4517540', 'cui_str': '115 (qualifier value)'}]","[{'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0036864', 'cui_str': 'Sexual Behavior'}]",,0.0127669,There were significant differences before and after the intervention concerning better knowledge and more frequent testing for sexually transmitted infections (STIs).,"[{'ForeName': 'Marja', 'Initials': 'M', 'LastName': 'Pakarinen', 'Affiliation': 'Faculty of Social Sciences, Health Sciences.'}, {'ForeName': 'Jari', 'Initials': 'J', 'LastName': 'Kylmä', 'Affiliation': 'Faculty of Social Sciences, Health Sciences.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Helminen', 'Affiliation': 'Faculty of Social Sciences, Health Sciences, Science Center, Tampere University Hospital, Tampere University, PL 100, 33014 Tampereen yliopisto, Tampere, Finland.'}, {'ForeName': 'Tarja', 'Initials': 'T', 'LastName': 'Suominen', 'Affiliation': 'Faculty of Social Sciences, Health Sciences.'}]",Health promotion international,['10.1093/heapro/daz074'] 1178,32134279,Disrupting the path to craving: Acting without awareness mediates the link between negative affect and craving.,"Low treatment utilization, relapse, and chronicity are characteristic of substance use disorders (SUDs). Craving is an important predictor of relapse. Individuals with an SUD report using various coping strategies in response to negative affect, two of which are investigated in the current study: suppression and acting with awareness. Suppression is typically understood to be avoidance of unwanted experience through turning attention away from unwanted stimuli. Acting with awareness (AWA) is a facet of mindfulness, which includes turning toward experience with kindness and curiosity, even when the experience is unwanted. Evidence suggests mindfulness may reduce craving, while suppression has been associated with increased craving. In the current study, participants ( N = 210) had recently completed inpatient or intensive outpatient SUD treatment followed by a randomized controlled trial of aftercare. Participants completed measures within 2 weeks following the completion of the aftercare intervention. Negative affect and severity of dependence were both positively associated with craving. Structural equation modeling evaluated AWA and suppression as partial mediators of the link between negative affect and craving. Suppression was positively associated and AWA was negatively associated with craving. Mediation analyses revealed the indirect effect of negative affect on craving through AWA was significant, but the path through suppression was not. These findings suggest that AWA may inhibit the development of craving from negative affect, but further research is needed. Future research should investigate the path from negative affect to craving with greater temporal resolution to evaluate how these phenomena function with increased ecological validity. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,Suppression was positively associated and AWA was negatively associated with craving.,['participants ( N = 210) had recently completed inpatient or intensive outpatient SUD treatment followed by a randomized controlled trial of aftercare'],[],[],"[{'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0001758', 'cui_str': 'Follow-Up Care'}]",[],[],,0.0252668,Suppression was positively associated and AWA was negatively associated with craving.,"[{'ForeName': 'Matthew C', 'Initials': 'MC', 'LastName': 'Enkema', 'Affiliation': 'Department of Psychology, University of Washington.'}, {'ForeName': 'Kevin A', 'Initials': 'KA', 'LastName': 'Hallgren', 'Affiliation': 'Department of Psychiatry, University of Washington.'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Neilson', 'Affiliation': 'Department of Psychology, Morehead State University.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Bowen', 'Affiliation': 'Department of Psychology, Pacific University.'}, {'ForeName': 'Elizabeth R', 'Initials': 'ER', 'LastName': 'Bird', 'Affiliation': 'Department of Psychology, University of Washington.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Larimer', 'Affiliation': 'Department of Psychiatry, University of Washington.'}]",Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors,['10.1037/adb0000565'] 1179,32438639,"Safety, Tolerability and Efficacy of Dietary Supplementation with Concord Grape Juice in Gulf War Veterans with Gulf War Illness: A Phase I/IIA, Randomized, Double-Blind, Placebo-Controlled Trial.","Approximately 30 percent of U.S. veterans deployed during the Gulf War (1990-1991) have been diagnosed with Gulf War Illness (GWI), a chronic multi-symptom disorder without widely available specific treatments. We investigated whether the consumption of Concord grape juice (CGJ), rich in anti-inflammatory flavonoids, would be tolerated and safe in individuals with GWI and explored improvement in cognitive function and fatigue. Thirty-six veterans with GWI enrolled in a 24-week randomized, double-blind, Phase I/IIA clinical trial to explore safety, tolerability, and feasibility of 16 ounces daily of commercially available CGJ compared to placebo. Participants completed neurocognitive tests and self-reported surveys at baseline, 12 and 24 weeks. Thirty-one participants (86%) completed the study; no dropouts were related to side effects. Thirty participants (83%) documented ≥80% adherence. There were no statistically significant unadjusted differences between CGJ and placebo groups in change in efficacy measures from baseline to endpoint. We employed general linear regression models controlling for baseline differences between groups which indicated statistically significant improvement in the Halstead Category Test-Russell Revised Version (RCAT) at endpoint in the CGJ group compared to placebo (8.4 points, p = 0.04). Other measures of cognitive functioning did not indicate significant improvements in the adjusted analyses ( p -values: 0.09-0.32), nor did the fatigue variable ( p = 0.67). CGJ was safe and well-tolerated by veterans with GWI. Our data suggest high tolerability and potential benefit from CGJ in veterans with GWI and can be used to inform future studies of efficacy.",2020,"Other measures of cognitive functioning did not indicate significant improvements in the adjusted analyses ( p -values: 0.09-0.32), nor did the fatigue variable ( p = 0.67).","['Approximately 30 percent of U.S. veterans deployed during the Gulf War (1990-1991) have been diagnosed with Gulf War Illness (GWI), a chronic multi-symptom disorder without widely available specific treatments', 'Thirty-six veterans with GWI enrolled', 'Gulf War Veterans with Gulf War Illness', 'veterans with GWI']","['CGJ', 'Placebo', 'Dietary Supplementation with Concord Grape Juice', 'consumption of Concord grape juice (CGJ', 'placebo']","['Safety, Tolerability and Efficacy', 'cognitive functioning', 'safe and well-tolerated', 'tolerated and safe', 'Halstead Category Test-Russell Revised Version (RCAT']","[{'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C1449761', 'cui_str': 'Persian Gulf War, 1991'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4319606', 'cui_str': '36'}]","[{'cui': 'C4224777', 'cui_str': 'Concord grape juice'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C4505444', 'cui_str': 'Halstead Category Test'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C2607870', 'cui_str': 'Version'}]",,0.431748,"Other measures of cognitive functioning did not indicate significant improvements in the adjusted analyses ( p -values: 0.09-0.32), nor did the fatigue variable ( p = 0.67).","[{'ForeName': 'Drew A', 'Initials': 'DA', 'LastName': 'Helmer', 'Affiliation': 'War Related Illness and Injury Study Center, Veterans Affairs New Jersey Healthcare System, 385 Tremont Avenue, East Orange, NJ 07018, USA.'}, {'ForeName': 'William W', 'Initials': 'WW', 'LastName': 'Van Doren', 'Affiliation': 'War Related Illness and Injury Study Center, Veterans Affairs New Jersey Healthcare System, 385 Tremont Avenue, East Orange, NJ 07018, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Litke', 'Affiliation': 'War Related Illness and Injury Study Center, Veterans Affairs New Jersey Healthcare System, 385 Tremont Avenue, East Orange, NJ 07018, USA.'}, {'ForeName': 'Chin-Lin', 'Initials': 'CL', 'LastName': 'Tseng', 'Affiliation': 'War Related Illness and Injury Study Center, Veterans Affairs New Jersey Healthcare System, 385 Tremont Avenue, East Orange, NJ 07018, USA.'}, {'ForeName': 'Lap', 'Initials': 'L', 'LastName': 'Ho', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA.'}, {'ForeName': 'Omowunmi', 'Initials': 'O', 'LastName': 'Osinubi', 'Affiliation': 'War Related Illness and Injury Study Center, Veterans Affairs New Jersey Healthcare System, 385 Tremont Avenue, East Orange, NJ 07018, USA.'}, {'ForeName': 'Giulio Maria', 'Initials': 'GM', 'LastName': 'Pasinetti', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA.'}]",International journal of environmental research and public health,['10.3390/ijerph17103546'] 1180,31423922,"Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation (START): Methodology of a pragmatic, response-adaptive, prospective randomized clinical trial.","RATIONALE An estimated 15% of all strokes are associated with untreated atrial fibrillation. Long-term secondary stroke prevention in atrial fibrillation is anticoagulation, increasingly with non-vitamin K oral anticoagulants. The optimal time to initiate anticoagulation following an atrial fibrillation-related stroke that balances hemorrhagic conversion with recurrent stroke is not yet known. AIMS To determine if there is an optimal delay time to initiate anticoagulation after atrial fibrillation-related stroke that optimizes the composite outcome of hemorrhagic conversion and recurrent ischemic stroke. SAMPLE SIZE ESTIMATES The study will enroll 1500 total subjects split between a mild to moderate stroke cohort (1000) and a severe stroke cohort (500). METHODS AND DESIGN This study is a multi-center, prospective, randomized, pragmatic, adaptive trial that randomizes subjects to four arms of time to start of anticoagulation. The four arms for mild to moderate stroke are: Day 3, Day 6, Day 10, and Day 14. The time intervals for severe stroke are: Day 6, Day 10, Day 14, and Day 21. Allocation involves a response adaptive randomization via interim analyses to favor the arms that have a better risk-benefit profile. STUDY OUTCOMES The primary outcome event is the composite occurrence of an ischemic or hemorrhagic event within 30 days of the index stroke. Secondary outcomes are also collected at 30 and 90 days. DISCUSSION The optimal timing of direct oral anticoagulants post-ischemic stroke requires prospective randomized testing. A pragmatically designed trial with adaptive allocation and randomization to multiple time intervals such as the START trial is best suited to answer this question in order to directly inform current practice on this question.",2019,"To determine if there is an optimal delay time to initiate anticoagulation after atrial fibrillation-related stroke that optimizes the composite outcome of hemorrhagic conversion and recurrent ischemic stroke. ",['1500 total subjects split between a mild to moderate stroke cohort (1000) and a severe stroke cohort (500'],[],['composite occurrence of an ischemic or hemorrhagic event within 30 days of the index stroke'],"[{'cui': 'C4517582', 'cui_str': '1500'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}]",[],"[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C0333275', 'cui_str': 'Hemorrhagic (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}]",,0.18034,"To determine if there is an optimal delay time to initiate anticoagulation after atrial fibrillation-related stroke that optimizes the composite outcome of hemorrhagic conversion and recurrent ischemic stroke. ","[{'ForeName': 'Benjamin T', 'Initials': 'BT', 'LastName': 'King', 'Affiliation': 'Department of Neurology, University of Texas Dell Medical School, Austin, TX, USA.'}, {'ForeName': 'Patrick D', 'Initials': 'PD', 'LastName': 'Lawrence', 'Affiliation': 'Department of Neurology, University of Texas Dell Medical School, Austin, TX, USA.'}, {'ForeName': 'Truman J', 'Initials': 'TJ', 'LastName': 'Milling', 'Affiliation': 'Department of Neurology, University of Texas Dell Medical School, Austin, TX, USA.'}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Warach', 'Affiliation': 'Department of Neurology, University of Texas Dell Medical School, Austin, TX, USA.'}]",International journal of stroke : official journal of the International Stroke Society,['10.1177/1747493019870651'] 1181,32438600,Increasing Physical Activity in Empty Nest and Retired Populations Online: A Randomized Feasibility Trial Protocol.,"Despite the extensive evidence on the benefits of physical activity (PA) in older adults, including reduced risk of disease, mortality, falls, and cognitive and functional decline, most do not attain sufficient PA levels. Theoretical work suggests that behavioral change interventions are most effective during life transitions, and as such, a theory-based, online intervention tailored for recently retired and empty nest individuals could lend support for increasing levels of PA. The aim of this study is to examine the feasibility of the intervention and study procedures for a future controlled trial. This study has a randomized controlled trial design with an embedded qualitative and quantitative process evaluation. Participants are randomized at 1:1 between the intervention and waitlist controls. Potential participants are within six months of their final child leaving the familial home or within six months of retiring (self-defined), currently not meeting the Canadian PA guidelines, have no serious contraindications to exercise, and are residing in Victoria, British Columbia, Canada. Participants are recruited by online and print flyers as well as in-person at community events. The study aims to recruit 40 empty nest and 40 retired participants; half of each group received the intervention during the study period. The internet-delivered intervention is delivered over a 10-week period, comprising 10 modules addressing behavior change techniques associated with PA. Primary outcomes relate to recruitment, attrition, data collection, intervention delivery, and acceptability. Secondary behavioral outcomes are measured at baseline and post-treatment (10 weeks). Intervention-selected participants are invited to an optional qualitative exit interview. The results of this feasibility study will inform the planning of a randomized effectiveness trial, that will examine the behavior change, health-related fitness, and well-being outcomes by exploring how reflexive processes of habit and identity may bridge adoption and maintenance in behavioral adherence.",2020,"The results of this feasibility study will inform the planning of a randomized effectiveness trial, that will examine the behavior change, health-related fitness, and well-being outcomes by exploring how reflexive processes of habit and identity may bridge adoption and maintenance in behavioral adherence.","['older adults', 'Empty Nest and Retired Populations Online', 'Participants are recruited by online and print flyers as well as in-person at community events']",[],"['recruitment, attrition, data collection, intervention delivery, and acceptability', 'risk of disease, mortality, falls, and cognitive and functional decline']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0035345', 'cui_str': 'Retired'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0033161', 'cui_str': 'Printing'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",[],"[{'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0010995', 'cui_str': 'Data Collection'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]",,0.103504,"The results of this feasibility study will inform the planning of a randomized effectiveness trial, that will examine the behavior change, health-related fitness, and well-being outcomes by exploring how reflexive processes of habit and identity may bridge adoption and maintenance in behavioral adherence.","[{'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Cox', 'Affiliation': 'Behavioural Medicine Laboratory, Department of Education, University of Victoria, Victoria, BC V8W 3N4, Canada.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Rhodes', 'Affiliation': 'Behavioural Medicine Laboratory, Department of Education, University of Victoria, Victoria, BC V8W 3N4, Canada.'}]",International journal of environmental research and public health,['10.3390/ijerph17103544'] 1182,32438301,Preoperative fasting abbreviation (Enhanced Recovery After Surgery protocol) and its effects on the metabolism of patients undergoing gynecologic surgeries under spinal anesthesia: A randomized clinical trial.,"OBJECTIVES Recommended perioperative nutritional interventions may contribute to satisfactory surgical outcomes. Each moment in the course of a surgical pathologic condition may be a window of opportunity for an intervention with a positive impact on postoperative recovery. Based on the idea of accelerating postoperative recovery, the objective of this study was to evaluate the effectiveness of a nutritional intervention with preoperative fasting abbreviation (Enhanced Recovery After Surgery recommendations) on the metabolism of patients undergoing gynecologic surgeries under spinal anesthesia. METHODS This randomized clinical trial was performed at a hospital of medium complexity. After Human Research Ethics Committee approval on August 24, 2015, 80 women who had gynecologic surgery in the period from January to June 2016 and signed the consent form were randomly allocated into two groups: a control group (n = 42) and a juice group (n = 38). They received 200 mL of inert solution (control group) or liquid enriched with carbohydrate and protein (juice group) 4 h before surgery. The variables studied were serum glucose, insulin, insulin resistance evaluated by the homeostatic model assessment of insulin resistance (HOMA-IR), C-reactive protein, and albumin in the pre- and postoperative periods. The statistical analysis was performed with SPSS 20.0. RESULTS There was a statistically significant difference in the coefficient of variation for the HOMA-IR index in the control group (17.27%; P < 0.01) compared with the juice group (8.46%; P < 0.05), which remained stable from the pre- to the postoperative period. CONCLUSIONS Preoperative fasting abbreviation with liquid containing carbohydrate and protein before gynecologic surgeries may provide metabolic stability with lower variation in insulin resistance than inert solution.",2020,"There was a statistically significant difference in the coefficient of variation for the HOMA-IR index in the control group (17.27%; P < 0.01) compared with the juice group (8.46%; P < 0.05), which remained stable from the pre- to the postoperative period. ","['80 women who had gynecologic surgery in the period from January to June 2016 and signed the consent', 'patients undergoing gynecologic surgeries under spinal anesthesia']",['200 mL of inert solution (control group) or liquid enriched with carbohydrate and protein (juice group) 4 h before surgery'],"['serum glucose, insulin, insulin resistance evaluated by the homeostatic model assessment of insulin resistance (HOMA-IR), C-reactive protein, and albumin in the pre- and postoperative periods', 'Preoperative fasting abbreviation', 'HOMA-IR index']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038902', 'cui_str': 'Operation on female genital organs'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}]","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C1268568', 'cui_str': 'Juice'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}]","[{'cui': 'C0202041', 'cui_str': 'Glucose measurement, serum'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0000723', 'cui_str': 'Abbreviation'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.0703072,"There was a statistically significant difference in the coefficient of variation for the HOMA-IR index in the control group (17.27%; P < 0.01) compared with the juice group (8.46%; P < 0.05), which remained stable from the pre- to the postoperative period. ","[{'ForeName': 'Gisele Vissoci', 'Initials': 'GV', 'LastName': 'Marquini', 'Affiliation': 'Department of Gynecology, Federal University of São Paulo, São Paulo, Brazil. Electronic address: giselemarquini@gmail.com.'}, {'ForeName': 'Francisco Edes', 'Initials': 'FE', 'LastName': 'da Silva Pinheiro', 'Affiliation': 'Hospital and Municipal Maternity Dr. Odelmo Leão Carneiro, Uberlândia, Minas Gerais, Brazil.'}, {'ForeName': 'Alfredo Urbano', 'Initials': 'AU', 'LastName': 'da Costa Vieira', 'Affiliation': 'Hospital and Municipal Maternity Dr. Odelmo Leão Carneiro, Uberlândia, Minas Gerais, Brazil.'}, {'ForeName': 'Rogério Melo', 'Initials': 'RM', 'LastName': 'da Costa Pinto', 'Affiliation': 'Faculty of Maths, Nucleus of Statistical and Biometrical Studies, Federal University of Uberlândia, Minas Gerais, Brazil.'}, {'ForeName': 'Maria Gabriela Baumgarten', 'Initials': 'MGB', 'LastName': 'Kuster Uyeda', 'Affiliation': 'Department of Gynecology, Federal University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Manoel João Batista Castello', 'Initials': 'MJBC', 'LastName': 'Girão', 'Affiliation': 'Department of Gynecology, Federal University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Marair Gracio Ferreira', 'Initials': 'MGF', 'LastName': 'Sartori', 'Affiliation': 'Department of Gynecology, Federal University of São Paulo, São Paulo, Brazil.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110790'] 1183,32438716,Photobiomodulation Therapy on Orthodontic Movement: Analysis of Preliminary Studies with a New Protocol.,"This study aimed to investigate the effectiveness of photobiomodulation therapy (PBMT) on the acceleration of orthodontic movements, deriving from its biostimulating and regenerative capacity on soft tissues, consequent to the increase in differentiation, proliferation, and activity of cells that are involved with alveolar bone remodeling. The present randomized controlled trial was conducted on six patients who required extractive orthodontic therapy because their ectopic canines had erupted. A total of eight canines were analyzed, four of which received laser irradiation (i.e., experimental group). Two weeks after the extractions, all canines of the experimental and placebo groups were distalized simultaneously and symmetrically with the laceback retraction technique. The PBMT protocol consisted of four cycles of laser applications, one each on days 0, 3, 7, and 14 of the study, with session treatment durations of 2-4 min. The results of the descriptive analysis on the distal displacement speed of the canines after 1 month of follow-up indicate an average displacement of 1.35 mm for the non-irradiated group and 1.98 mm for the irradiated group. Through inferential analysis, a statistically significant difference ( p < 0.05) was found between the average speed of the irradiated canines and the control canines. The low energy density laser used in this study, with the parameters set, was found to be a tool capable of statistically significantly accelerating the distal displacement of canines.",2020,"Through inferential analysis, a statistically significant difference ( p < 0.05) was found between the average speed of the irradiated canines and the control canines.",['six patients who required extractive orthodontic therapy because their ectopic canines had erupted'],"['Photobiomodulation Therapy', 'photobiomodulation therapy (PBMT', 'laser irradiation', 'placebo']","['distal displacement of canines', 'distal displacement speed']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332276', 'cui_str': 'Orthodontic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0010482', 'cui_str': 'Structure of canine tooth'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}]","[{'cui': 'C4019433', 'cui_str': 'Photobiomodulation Therapy'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0010482', 'cui_str': 'Structure of canine tooth'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}]",8.0,0.0304746,"Through inferential analysis, a statistically significant difference ( p < 0.05) was found between the average speed of the irradiated canines and the control canines.","[{'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Impellizzeri', 'Affiliation': 'Department of Oral and Maxillofacial Sciences, ""Sapienza"" University of Rome, 00161 Rome, Italy.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Horodynski', 'Affiliation': 'Department of Oral and Maxillofacial Sciences, ""Sapienza"" University of Rome, 00161 Rome, Italy.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Fusco', 'Affiliation': 'Department of Oral and Maxillofacial Sciences, ""Sapienza"" University of Rome, 00161 Rome, Italy.'}, {'ForeName': 'Gaspare', 'Initials': 'G', 'LastName': 'Palaia', 'Affiliation': 'Department of Oral and Maxillofacial Sciences, ""Sapienza"" University of Rome, 00161 Rome, Italy.'}, {'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Polimeni', 'Affiliation': 'Department of Oral and Maxillofacial Sciences, ""Sapienza"" University of Rome, 00161 Rome, Italy.'}, {'ForeName': 'Umberto', 'Initials': 'U', 'LastName': 'Romeo', 'Affiliation': 'Department of Oral and Maxillofacial Sciences, ""Sapienza"" University of Rome, 00161 Rome, Italy.'}, {'ForeName': 'Ersilia', 'Initials': 'E', 'LastName': 'Barbato', 'Affiliation': 'Department of Oral and Maxillofacial Sciences, ""Sapienza"" University of Rome, 00161 Rome, Italy.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'Galluccio', 'Affiliation': 'Department of Oral and Maxillofacial Sciences, ""Sapienza"" University of Rome, 00161 Rome, Italy.'}]",International journal of environmental research and public health,['10.3390/ijerph17103547'] 1184,32438300,Efficacy of 4 wk of home enteral feeding supplementation after esophagectomy on immune function: A randomized controlled trial.,"OBJECTIVES In recent years, home enteral nutrition (HEN) has been adopted as a feasible and safe form of nutrition for patients undergoing esophagectomy. The aim of this study was to compare the effects of 4 wk of HEN with standard enteral nutrition (SEN) on immune function, nutritional status, and survival in patients undergoing esophagectomy. METHODS A parallel-group, randomized, single-blind, clinical trial was conducted between April 1 and August 1, 2017. Eighty patients were enrolled in the study and 62 were eligible for analysis. An enteral feeding pump was used to infuse enteral nutrition via jejunostomy tube postoperatively. Patients in HEN group were instructed to independently administer jejunostomy feeds at home. Immune parameters and nutritional indicators were measured at preoperative day 7 and at postoperative day 30. RESULTS There were no significant differences in baseline characteristics between the two groups. The levels of immunoglobulin (Ig)A and IgG, which can reflect a patient's immune function, significantly increased in the HEN group compared with those in the SEN group (P = 0.042 and P = 0.003, respectively). Comparing the two groups, 2-y progression-free survival and overall survival had no significant differences in survival curves (P = 0.36 and P = 0.29, respectively). CONCLUSION Four weeks of HEN is a safe and feasible nutritional strategy to improve immune function and nutritional status after esophagectomy. Although there was no significant difference in survival between the two groups, HEN could still be more effective and beneficial than SEN to patients with defective nutritional and immune status.",2020,"Although there was no significant difference in survival between the two groups, HEN could still be more effective and beneficial than SEN to patients with defective nutritional and immune status.","['Eighty patients were enrolled in the study and 62 were eligible for analysis', 'patients undergoing esophagectomy']","['home enteral nutrition (HEN', 'SEN', 'HEN', 'home enteral feeding supplementation', 'HEN with standard enteral nutrition (SEN']","['2-y progression-free survival and overall survival', 'levels of immunoglobulin (Ig)A and IgG', 'survival curves', 'immune function and nutritional status', 'survival', 'immune function, nutritional status, and survival', 'Immune parameters and nutritional indicators', 'immune function']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0085198', 'cui_str': 'Esophagectomy'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0086225', 'cui_str': 'Enteral feeding'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C1817756', 'cui_str': 'Immunologic function'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}]",80.0,0.113342,"Although there was no significant difference in survival between the two groups, HEN could still be more effective and beneficial than SEN to patients with defective nutritional and immune status.","[{'ForeName': 'Xiao-Kun', 'Initials': 'XK', 'LastName': 'Li', 'Affiliation': 'Department of Cardiothoracic Surgery, Jingling Hospital, School of Medicine, Southeast University, Nanjing, China.'}, {'ForeName': 'Zhuang-Zhuang', 'Initials': 'ZZ', 'LastName': 'Cong', 'Affiliation': 'Department of Cardiothoracic Surgery, Jingling Hospital, Medical School of Nanjing University, Nanjing, China.'}, {'ForeName': 'Wen-Jie', 'Initials': 'WJ', 'LastName': 'Wu', 'Affiliation': 'Department of Clinical Medicine, School of Medicine, Southeast University, Nanjing, China.'}, {'ForeName': 'Sai-Guang', 'Initials': 'SG', 'LastName': 'Ji', 'Affiliation': 'Department of Cardiothoracic Surgery, Jingling Hospital, Bengbu Medical College, Anhui, China.'}, {'ForeName': 'Hai', 'Initials': 'H', 'LastName': 'Zhou', 'Affiliation': 'Department of Cardiothoracic Surgery, Jingling Hospital, Jingling School of Clinical Medicine, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Kai-Chao', 'Initials': 'KC', 'LastName': 'Liu', 'Affiliation': 'Department of Clinical Medicine, School of Medicine, Southeast University, Nanjing, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Department of Cardiothoracic Surgery, Jingling Hospital, Jingling School of Clinical Medicine, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Shen', 'Affiliation': 'Department of Cardiothoracic Surgery, Jingling Hospital, School of Medicine, Southeast University, Nanjing, China; Department of Clinical Medicine, School of Medicine, Southeast University, Nanjing, China. Electronic address: dryishen@nju.edu.cn.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110787'] 1185,32688225,Gender and racial/ethnic differences in physiologic responses in the Stimulant Reduction Intervention using Dosed Exercise Study.,"Exercise may be beneficial for individuals in substance use disorder (SUD) treatment given the higher rates of both medical and psychiatric comorbidity, namely mood and anxiety disorders, compared to the general population. Gender and/or racial/ethnic differences in health benefits and response to prescribed exercise have been reported and may have implications for designing exercise interventions in SUD programs. METHOD Data are from the National Drug Abuse Treatment Clinical Trials Network (NIDA/CTN) Stimulant Reduction Intervention using Dosed Exercise (STRIDE) trial. Gender differences across racial/ethnic groups in physiological responses and stimulant withdrawal severity across time were analyzed using linear mixed effects models. RESULTS Males completed significantly more exercise sessions than females and were more adherent to the prescribed exercise dose of 12 Kcal/Kg/Week. Controlling for age, race/ethnicity, treatment group and stimulant withdrawal severity, there was a significant gender by time interaction for body mass index (BMI) (p < 0.001), waist circumference (p < 0.001) and heart rate measured prior to exercise sessions (p < 0.01). For females, body mass index (BMI) and waist circumference increased over time while for males BMI and waist circumference stayed unchanged or slightly decreased with time. Heart rate over time significantly increased for females at a higher rate than in males. Stimulant withdrawal severity was similar in males and females at baseline but males exhibited a significant decrease over time while females did not. Although baseline differences were observed, there were no time by race/ethnicity differences in physiologic responses. DISCUSSION Gender differences in response to exercise may have implications for developing gender specific exercise interventions in SUD programs.",2020,Stimulant withdrawal severity was similar in males and females at baseline but males exhibited a significant decrease over time while females did not.,['Data are from the National Drug Abuse Treatment Clinical Trials Network (NIDA/CTN'],['Stimulant Reduction Intervention'],"['waist circumference', 'heart rate', 'time interaction for body mass index (BMI', 'Heart rate over time', 'Stimulant withdrawal severity', 'body mass index (BMI) and waist circumference', 'exercise sessions']","[{'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0013146', 'cui_str': 'Drug abuse'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}]","[{'cui': 'C0002763', 'cui_str': 'Central stimulant'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1997739', 'cui_str': 'Psychostimulant withdrawal'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.0431347,Stimulant withdrawal severity was similar in males and females at baseline but males exhibited a significant decrease over time while females did not.,"[{'ForeName': 'T K', 'Initials': 'TK', 'LastName': 'Killeen', 'Affiliation': 'Medical University of South Carolina, Charleston, SC, USA. Electronic address: killeent@musc.edu.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Wolf', 'Affiliation': 'Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'T L', 'Initials': 'TL', 'LastName': 'Greer', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Carmody', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'C D', 'Initials': 'CD', 'LastName': 'Rethorst', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'M H', 'Initials': 'MH', 'LastName': 'Trivedi', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}]",Addictive behaviors,['10.1016/j.addbeh.2020.106546'] 1186,32438401,Mycoprotein ingestion stimulates protein synthesis rates to a greater extent than milk protein in rested and exercised skeletal muscle of healthy young men: a randomized controlled trial.,"BACKGROUND Mycoprotein is a fungal-derived sustainable protein-rich food source, and its ingestion results in systemic amino acid and leucine concentrations similar to that following milk protein ingestion. OBJECTIVE We assessed the mixed skeletal muscle protein synthetic response to the ingestion of a single bolus of mycoprotein compared with a leucine-matched bolus of milk protein, in rested and exercised muscle of resistance-trained young men. METHODS Twenty resistance-trained healthy young males (age: 22 ± 1 y, body mass: 82 ± 2 kg, BMI: 25 ± 1 kg·m-2) took part in a randomized, double-blind, parallel-group study. Participants received primed, continuous infusions of L-[ring-2H5]phenylalanine and ingested either 31 g (26.2 g protein: 2.5 g leucine) milk protein (MILK) or 70 g (31.5 g protein: 2.5 g leucine) mycoprotein (MYCO) following a bout of unilateral resistance-type exercise (contralateral leg acting as resting control). Blood and m. vastus lateralis muscle samples were collected before exercise and protein ingestion, and following a 4-h postprandial period to assess mixed muscle fractional protein synthetic rates (FSRs) and myocellular signaling in response to the protein beverages in resting and exercised muscle. RESULTS Mixed muscle FSRs increased following MILK ingestion (from 0.036 ± 0.008 to 0.052 ± 0.006%·h-1 in rested, and 0.035 ± 0.008 to 0.056 ± 0.005%·h-1 in exercised muscle; P <0.01) but to a greater extent following MYCO ingestion (from 0.025 ± 0.006 to 0.057 ± 0.004%·h-1 in rested, and 0.024 ± 0.007 to 0.072 ± 0.005%·h-1 in exercised muscle; P <0.0001) (treatment × time interaction effect; P <0.05). Postprandial FSRs trended to be greater in MYCO compared with MILK (0.065 ± 0.004 compared with 0.054 ± 0.004%·h-1, respectively; P = 0.093) and the postprandial rise in FSRs was greater in MYCO compared with MILK (Delta 0.040 ± 0.006 compared with Delta 0.018 ± 0.005%·h-1, respectively; P <0.01). CONCLUSIONS The ingestion of a single bolus of mycoprotein stimulates resting and postexercise muscle protein synthesis rates, and to a greater extent than a leucine-matched bolus of milk protein, in resistance-trained young men. This trial was registered at clinicaltrials.gov as 660065600.",2020,"Postprandial FSRs trended to be greater in MYCO compared with MILK (0.065 ± 0.004 compared with 0.054 ± 0.004%·h-1, respectively; P = 0.093) and the postprandial rise in FSRs was greater in MYCO compared with MILK (Delta 0.040 ± 0.006 compared with Delta 0.018 ± 0.005%·h-1, respectively; P <0.01). ","['resistance-trained young men', 'healthy young men', 'Twenty resistance-trained healthy young males (age: 22\xa0±\xa01 y, body mass: 82\xa0±\xa02 kg, BMI: 25\xa0±\xa01 kg·m-2']","['Mycoprotein ingestion', 'leucine) mycoprotein (MYCO) following a bout of unilateral resistance-type exercise (contralateral leg acting as resting control', 'L-[ring-2H5]phenylalanine and ingested either 31 g (26.2 g protein: 2.5 g leucine) milk protein (MILK) or 70 g', 'leucine-matched bolus of milk protein']","['MILK ingestion', 'postprandial rise in FSRs', 'Postprandial FSRs']","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C2347312', 'cui_str': 'Mycoprotein'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0023401', 'cui_str': 'Leucine'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441988', 'cui_str': 'Contralateral'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0521164', 'cui_str': 'Annular shape'}, {'cui': 'C0086376', 'cui_str': 'G protein'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0026138', 'cui_str': 'Milk protein'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]","[{'cui': 'C0026138', 'cui_str': 'Milk protein'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}]",,0.118269,"Postprandial FSRs trended to be greater in MYCO compared with MILK (0.065 ± 0.004 compared with 0.054 ± 0.004%·h-1, respectively; P = 0.093) and the postprandial rise in FSRs was greater in MYCO compared with MILK (Delta 0.040 ± 0.006 compared with Delta 0.018 ± 0.005%·h-1, respectively; P <0.01). ","[{'ForeName': 'Alistair J', 'Initials': 'AJ', 'LastName': 'Monteyne', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, Heavitree Road, University of Exeter, Exeter, UK.'}, {'ForeName': 'Mariana O C', 'Initials': 'MOC', 'LastName': 'Coelho', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, Heavitree Road, University of Exeter, Exeter, UK.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Porter', 'Affiliation': 'Department of Surgery, University of Texas Medical Branch & Shriners Hospital for Children, Galveston, TX, USA.'}, {'ForeName': 'Doaa R', 'Initials': 'DR', 'LastName': 'Abdelrahman', 'Affiliation': 'Department of Surgery, University of Texas Medical Branch & Shriners Hospital for Children, Galveston, TX, USA.'}, {'ForeName': 'Thomas S O', 'Initials': 'TSO', 'LastName': 'Jameson', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, Heavitree Road, University of Exeter, Exeter, UK.'}, {'ForeName': 'Sarah R', 'Initials': 'SR', 'LastName': 'Jackman', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, Heavitree Road, University of Exeter, Exeter, UK.'}, {'ForeName': 'Jamie R', 'Initials': 'JR', 'LastName': 'Blackwell', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, Heavitree Road, University of Exeter, Exeter, UK.'}, {'ForeName': 'Tim J A', 'Initials': 'TJA', 'LastName': 'Finnigan', 'Affiliation': 'Marlow Foods Ltd, Stokesly, North Yorkshire, UK.'}, {'ForeName': 'Francis B', 'Initials': 'FB', 'LastName': 'Stephens', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, Heavitree Road, University of Exeter, Exeter, UK.'}, {'ForeName': 'Marlou L', 'Initials': 'ML', 'LastName': 'Dirks', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, Heavitree Road, University of Exeter, Exeter, UK.'}, {'ForeName': 'Benjamin T', 'Initials': 'BT', 'LastName': 'Wall', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, Heavitree Road, University of Exeter, Exeter, UK.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqaa092'] 1187,31415003,Randomized Comparison of Gastric Tube Reconstruction With and Without Duodenal Diversion Plus Roux-en-Y Anastomosis After Esophagectomy.,"OBJECTIVE This prospective randomized phase-II trial examined whether gastric reconstruction with duodenal diversion plus Roux-en-Y anastomosis(RY) minimized gastroduodenal reflux and delayed gastric emptying compared with standard gastric reconstruction. SUMMARY BACKGROUND DATA There is no established standard surgical procedure to prevent both gastroduodenal reflux and delayed gastric emptying simultaneously. METHODS Sixty patients with thoracic esophageal cancer scheduled to undergo esophagectomy with retrosternal gastric tube reconstruction were randomly allocated to standard gastric reconstruction (non-RY, n = 31) or gastric reconstruction with duodenal diversion plus RY (n = 29) groups. Primary endpoint was quality of life assessed by DAUGS-32 score 1 year after surgery. Secondary endpoints were the extent of postoperative duodenal juice reflux into the gastric tube, postoperative morbidity, endoscopic findings, body weight changes, and nutritional status. RESULTS Preoperative clinicopathological characteristics and postoperative morbidity did not differ significantly between groups. However, operation time and blood loss volume were significantly higher in the RY group. Pancreatic amylase concentrations in the gastric conduit on postoperative days 2, 3, and 7 were higher in the non-RY group. Postoperative endoscopic examination showed residual gastric content in 7 of 17 patients in the non-RY group but in none in the RY group (P = 0.012). Quality of life was significantly favorable in the RY group with regard to reflux symptoms and food passage dysfunction. Postoperative body weight changes, serum albumin levels, and peripheral blood lymphocyte counts were not significantly different between groups. CONCLUSION Gastric reconstruction with duodenal diversion plus RY is effective in improving both gastroduodenal reflux and delayed gastric emptying.",2020,"Pancreatic amylase concentrations in the gastric conduit on postoperative days 2, 3, and 7 were higher in the non-RY group.",['Sixty patients with thoracic esophageal cancer scheduled to undergo esophagectomy with retrosternal gastric tube reconstruction'],"['Gastric Tube Reconstruction With and Without Duodenal Diversion Plus Roux-en-Y Anastomosis', 'standard gastric reconstruction', 'gastric reconstruction with duodenal diversion plus Roux-en-Y anastomosis(RY', 'standard gastric reconstruction (non-RY, n = 31) or gastric reconstruction with duodenal diversion plus RY']","['quality of life assessed by DAUGS-32 score 1 year after surgery', 'Quality of life', 'gastroduodenal reflux and delayed gastric emptying', 'operation time and blood loss volume', 'Preoperative clinicopathological characteristics and postoperative morbidity', 'extent of postoperative duodenal juice reflux into the gastric tube, postoperative morbidity, endoscopic findings, body weight changes, and nutritional status', 'gastroduodenal reflux and delayed gastric emptying simultaneously', 'Postoperative body weight changes, serum albumin levels, and peripheral blood lymphocyte counts', 'reflux symptoms and food passage dysfunction', 'Pancreatic amylase concentrations', 'residual gastric content']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0546837', 'cui_str': 'Cancer of Esophagus'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0085198', 'cui_str': 'Esophagectomy'}, {'cui': 'C0442179', 'cui_str': 'Retrosternal (qualifier value)'}, {'cui': 'C2242688', 'cui_str': 'Gastric tube reconstruction'}]","[{'cui': 'C2242688', 'cui_str': 'Gastric tube reconstruction'}, {'cui': 'C0013303', 'cui_str': 'Duodenum'}, {'cui': 'C0185033', 'cui_str': 'Diversion'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0002804', 'cui_str': 'Roux-en-Y Anastomosis'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C0524865', 'cui_str': 'Reconstructive Surgery'}]","[{'cui': 'C0034380'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0450199', 'cui_str': 'Gastroduodenal (qualifier value)'}, {'cui': 'C0740411', 'cui_str': 'Delayed gastric emptying (disorder)'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0439792', 'cui_str': 'Extents (qualifier value)'}, {'cui': 'C0227306', 'cui_str': 'Duodenal juice (substance)'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C4318415', 'cui_str': 'Tube (unit of presentation)'}, {'cui': 'C2607943', 'cui_str': 'findings'}, {'cui': 'C0005911', 'cui_str': 'Body Weight Changes'}, {'cui': 'C0392209', 'cui_str': 'Nutrition Status'}, {'cui': 'C0523465', 'cui_str': 'Albumin measurement, serum (procedure)'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood (substance)'}, {'cui': 'C0200635', 'cui_str': 'Lymphocyte Number'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}, {'cui': 'C0301812', 'cui_str': 'Pancreatic amylase (substance)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C0038352', 'cui_str': 'Stomach Contents'}]",60.0,0.0257535,"Pancreatic amylase concentrations in the gastric conduit on postoperative days 2, 3, and 7 were higher in the non-RY group.","[{'ForeName': 'Masahiko', 'Initials': 'M', 'LastName': 'Yano', 'Affiliation': 'Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.'}, {'ForeName': 'Keijiro', 'Initials': 'K', 'LastName': 'Sugimura', 'Affiliation': 'Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Miyata', 'Affiliation': 'Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.'}, {'ForeName': 'Masaaki', 'Initials': 'M', 'LastName': 'Motoori', 'Affiliation': 'Department of Surgery, Osaka General Medical Center, Osaka, Japan.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Tanaka', 'Affiliation': 'Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Omori', 'Affiliation': 'Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.'}, {'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Ohue', 'Affiliation': 'Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.'}, {'ForeName': 'Masato', 'Initials': 'M', 'LastName': 'Sakon', 'Affiliation': 'Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.'}]",Annals of surgery,['10.1097/SLA.0000000000003557'] 1188,32142170,"Effects of different doses of atorvastatin, rosuvastatin, and simvastatin on elderly patients with ST-elevation acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI).","OBJECTIVE To conduct a randomized double-blind prospective study to investigate effect of different doses of atorvastatin, rosuvastatin, and simvastatin on elderly patients with ST-elevation AMI after PCI. METHODS One hundred and ninety-two AMI patients over 60 years old who underwent PCI were randomly divided into six groups: the low atorvastatin group, high atorvastatin group; low rosuvastatin group; high rosuvastatin group; low simvastatin group; high simvastatin group. Demographic data and clinical information as well as coronary angiography parameters were recorded. Plasma levels of CK-MB, BNP, ALT, and TnI were measured at 12 hr, 24 hr, and 1 week after PCI. Major cardiovascular events (MACE) were recorded and analyzed using Kaplan-Meier (K-M) curve. RESULTS No significant differences were observed in angiographic and procedural characteristics. In all high dose groups, all levels of CK-MB, BNP, ALT, and TnI were significantly lower. However, after 1 week of PCI, only CK-MB, BNP, and TnI showed significant difference between high and low dose groups. Patients in high dose groups had significantly lower rates for surgical or percutaneous intervention, recurrence of angina, and rehospitalization. K-M curve analysis also showed cumulative incidence freedom time of overall MACE in high dose groups was significantly longer. No significant differences were found among different drugs with the same doses. CONCLUSION Patients with higher doses had lower level of CK-MB, BNP, ALT, and TnI and lower occurrence of MACE after PCI.",2020,"Patients in high dose groups had significantly lower rates for surgical or percutaneous intervention, recurrence of angina, and rehospitalization.","['elderly patients with ST-elevation acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI', 'One hundred and ninety-two AMI patients over 60\u2009years old who underwent PCI', 'elderly patients with ST-elevation AMI after PCI']","['simvastatin', 'low atorvastatin group, high atorvastatin group; low rosuvastatin group; high rosuvastatin group; low simvastatin', 'atorvastatin, rosuvastatin, and simvastatin']","['levels of CK-MB, BNP, ALT, and TnI', 'angiographic and procedural characteristics', 'rates for surgical or percutaneous intervention, recurrence of angina, and rehospitalization', 'cumulative incidence freedom time of overall MACE', 'Major cardiovascular events (MACE', 'level of CK-MB, BNP, ALT, and TnI and lower occurrence of MACE', 'Plasma levels of CK-MB, BNP, ALT, and TnI']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0520886', 'cui_str': 'ST segment elevation (finding)'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction (disorder)'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C0074554', 'cui_str': 'Simvastatin'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0286651', 'cui_str': 'atorvastatin'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0523584', 'cui_str': 'Creatine kinase MB measurement'}, {'cui': 'C1095989', 'cui_str': 'Brain natriuretic peptide measurement (procedure)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach - access (qualifier value)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0002962', 'cui_str': 'Stenocardia'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0349381', 'cui_str': 'Mace (substance)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}]",192.0,0.0184652,"Patients in high dose groups had significantly lower rates for surgical or percutaneous intervention, recurrence of angina, and rehospitalization.","[{'ForeName': 'Weifeng', 'Initials': 'W', 'LastName': 'He', 'Affiliation': 'Cardiovascular Medicine Department, Yongchuan Hospital Affiliated to Chongqing Medical University, Chongqing, China.'}, {'ForeName': 'Maolin', 'Initials': 'M', 'LastName': 'Cao', 'Affiliation': 'Cardiovascular Medicine Department, Yongchuan Hospital Affiliated to Chongqing Medical University, Chongqing, China.'}, {'ForeName': 'Zhifeng', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Cardiovascular Medicine Department, Yongchuan Hospital Affiliated to Chongqing Medical University, Chongqing, China.'}]",Drug development research,['10.1002/ddr.21651'] 1189,32187092,CORR Insights®: Does an Antimicrobial Incision Drape Prevent Intraoperative Contamination? A Randomized Controlled Trial of 1187 Patients.,,2020,,['1187 Patients'],['CORR Insights®'],[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}]",[],[],,0.206245,,"[{'ForeName': 'Matthew L', 'Initials': 'ML', 'LastName': 'Webb', 'Affiliation': 'M. L. Webb Hospital of the University of Pennsylvania, Department of Orthopaedic Surgery, Philadelphia, PA, USA.'}]",Clinical orthopaedics and related research,['10.1097/CORR.0000000000001220'] 1190,32111916,Transversus Abdominis Plane Block Reduced Early Postoperative Pain after Robot-assisted Prostatectomy: a Randomized Controlled Trial.,"Analgesic effect of transversus abdominis plane block (TAP block) in lower major abdominal laparoscopic surgery with about 5 cm of maximum surgical scar has been controversial. We hypothesized that TAP block has benefits, so the analgesic effect of TAP block after robot-assisted laparoscopic prostatectomy (RALP) was evaluated. One hundred patients were enrolled in this prospective, double-blinded, randomized study. Standardized general anesthesia with wound infiltration on camera port and fentanyl dose limit of 3 µg/kg was provided. Ultrasound-guided, single-shot subcostal TAP block with either 0.375% ropivacaine (Ropivacaine group, 48 patients) or normal saline (Control group, 52 patients) was performed by anesthesiologist in charge (34 anesthesiologists) after surgical procedure. Pain score using numerical rating scale (NRS) and postoperative intravenous fentanyl were evaluated for the first 24 postoperative hours. Median values (interquartile range) of NRS scores when the patients were transferred to post-anesthesia care unit (PACU) were 5 (2-7) in Ropivacaine group and 6 (4-8) in Control group at rest (P = 0.03), 5 (2-8) in Ropivacaine group and 7 (5-8) in Control group during movement (P < 0.01). These significant differences disappeared at the time of discharging PACU. Fentanyl doses for the first 24 postoperative hours were 210 µg (120-360) in Ropivacaine group and 200 µg (120-370) in Control group (P = 0.79). These results indicated that subcostal TAP block by anesthesiologists of varied level of training reduced postoperative pain immediate after RALP. TAP block had fundamental analgesic effect, but this benefit was too small to reduce postoperative 24-hour fentanyl consumption.",2020,Analgesic effect of transversus abdominis plane block (TAP block) in lower major abdominal laparoscopic surgery with about 5 cm of maximum surgical scar has been controversial.,['One hundred patients'],"['TAP block', 'Ropivacaine', 'Ultrasound-guided, single-shot subcostal TAP block with either 0.375% ropivacaine (Ropivacaine', 'transversus abdominis plane block (TAP block', 'Transversus Abdominis Plane Block Reduced Early Postoperative Pain after Robot-assisted Prostatectomy', 'Fentanyl', 'normal saline (Control group, 52 patients) was performed by anesthesiologist in charge']","['postoperative pain immediate', 'postoperative 24-hour fentanyl consumption', 'Pain score using numerical rating scale (NRS) and postoperative intravenous fentanyl', 'Median values (interquartile range) of NRS scores']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0034115', 'cui_str': 'Puncture and Drainage'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1444774', 'cui_str': 'Shooting'}, {'cui': 'C0442184', 'cui_str': 'Subcostal (qualifier value)'}, {'cui': 'C4517455', 'cui_str': '0.375 (qualifier value)'}, {'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0336537', 'cui_str': 'Robot, device (physical object)'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0033573', 'cui_str': 'Prostatectomy'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C0007961', 'cui_str': 'Charges'}]","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0222045'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",100.0,0.29246,Analgesic effect of transversus abdominis plane block (TAP block) in lower major abdominal laparoscopic surgery with about 5 cm of maximum surgical scar has been controversial.,"[{'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Taninishi', 'Affiliation': 'Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1, Shikata-Cho, Kitaku, Okayama City, 700-8558, Japan. tanini-h@okayama-u.ac.jp.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Matsusaki', 'Affiliation': 'Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1, Shikata-Cho, Kitaku, Okayama City, 700-8558, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Morimatsu', 'Affiliation': 'Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1, Shikata-Cho, Kitaku, Okayama City, 700-8558, Japan.'}]",Scientific reports,['10.1038/s41598-020-60687-y'] 1191,32168288,Impact of Simulation-Based Learning on National Ranking Medical Examination Results in France: A Randomized Trial (SimECNi Study).,"INTRODUCTION In France, the National Ranking Examination (ECNi) evaluates medical students based on their clinical reasoning. Simulation-based education on ECNi preparation has not been assessed. Our objective is to establish the added value of high-fidelity (HF) simulation-based learning in ECNi preparation compared with the current standard. METHODS We performed a controlled, prospective study. Fifth-year medical students from Nancy and Nice participated in a 3-phase process. In phase 1, students were tested on 6 themes (A-F) that were each presented as an ECNi clinical case and were randomized into 2 groups (#1 and #2). A 20-point grading scale was used. In phase 2, group #1 carried out HF simulation on themes A, B, and C, whereas group #2 did so on themes D, E, and F. Students were tested, in phase 3, with a new set of clinical cases on the same 6 themes. Progression in scores between phases 1 and 3 was analyzed. RESULTS One hundred sixty-six medical students randomized into 2 groups partook in the study. In phase 1, there was no significant difference in scores between groups. In phase 3, group #1 had significantly higher scores than group #2 for cases A, B, and C. Scores were significantly higher in group #2 for cases D, E, and F. Average scoring significantly improved between phases 1 and 3 with a 1.4-point gain for cases A, B, and C in group #1 and a 2.10-point gain for cases D, E, and F in group #2. CONCLUSIONS Our study shows that HF simulation learning significantly increases ECNi-like test results when compared with traditional forms.",2020,"In phase 3, group #1 had significantly higher scores than group #2 for cases A, B, and C. Scores were significantly higher in group #2 for cases D, E, and F. Average","['One hundred sixty-six medical students', 'France', 'Fifth-year medical students from Nancy and Nice participated in a 3-phase process']","['Simulation-Based Learning', 'HF simulation learning']",[],"[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4517841', 'cui_str': 'Sixty-six'}, {'cui': 'C0038495', 'cui_str': 'Students, Medical'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0205439', 'cui_str': 'Fifth (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0721912', 'cui_str': ""N'ICE""}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C4521054', 'cui_str': 'Process (qualifier value)'}]","[{'cui': 'C0178499', 'cui_str': 'Base'}]",[],166.0,0.018537,"In phase 3, group #1 had significantly higher scores than group #2 for cases A, B, and C. Scores were significantly higher in group #2 for cases D, E, and F. Average","[{'ForeName': 'Joris', 'Initials': 'J', 'LastName': 'Galland', 'Affiliation': ""From the Service de Médecine Interne (J.G.), Hôpital Lariboisière, Assistance Publique -Hôpitaux de Paris; Sorbonne Université Faculté de Médecine Diderot, Université de Paris Diderot (J.G.), faculté de médecine Sorbonne, F-75020 Paris; Service de Médecine Interne (N.M., M.L.), Hôpital Archet 1, CHU Nice; Université de Nice Sophia-Antipolis (M.L., J.-P.F.), Faculté de Médecine de Nice, Nice; Université de Lorraine (H.H., C.B., M.B.), faculté de médecine de Nancy, Vandœuvre-Lès-Nancy; Unité de méthodologie (C.B.), data management et statistique, DRCI, CHRU de Nancy, Nancy; Service de Médecine Générale d'Urgence (J.-P.F.), Hôpital Saint Roch, CHU, Nice; and Service de Neuroradiologie (M.B.), Hôpital Central, CHRU Nancy, Nancy, France.""}, {'ForeName': 'Nihal', 'Initials': 'N', 'LastName': 'Martis', 'Affiliation': ''}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Levraut', 'Affiliation': ''}, {'ForeName': 'Hind', 'Initials': 'H', 'LastName': 'Hani', 'Affiliation': ''}, {'ForeName': 'Cedric', 'Initials': 'C', 'LastName': 'Baumann', 'Affiliation': ''}, {'ForeName': 'Jean-Paul', 'Initials': 'JP', 'LastName': 'Fournier', 'Affiliation': ''}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Braun', 'Affiliation': ''}]",Simulation in healthcare : journal of the Society for Simulation in Healthcare,['10.1097/SIH.0000000000000431'] 1192,32139505,Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy.,"OBJECTIVE To report safety, pharmacokinetics, exon 53 skipping, and dystrophin expression in golodirsen-treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. METHODS Part 1 was a randomized, double-blind, placebo-controlled, 12-week dose titration of once-weekly golodirsen; part 2 is an ongoing, open-label evaluation. Safety and pharmacokinetics were primary and secondary objectives of part 1. Primary biological outcome measures of part 2 were blinded exon skipping and dystrophin protein production on muscle biopsies (baseline, week 48) evaluated, respectively, using reverse transcription PCR and Western blot and immunohistochemistry. RESULTS Twelve patients were randomized to receive golodirsen (n = 8) or placebo (n = 4) in part 1. All from part 1 plus 13 additional patients received 30 mg/kg golodirsen in part 2. Safety findings were consistent with those previously observed in pediatric patients with DMD. Most of the study drug was excreted within 4 hours following administration. A significant increase in exon 53 skipping was associated with ∼16-fold increase over baseline in dystrophin protein expression at week 48, with a mean percent normal dystrophin protein standard of 1.019% (range, 0.09%-4.30%). Sarcolemmal localization of dystrophin was demonstrated by significantly increased dystrophin-positive fibers (week 48, p < 0.001) and a positive correlation (Spearman r = 0.663; p < 0.001) with dystrophin protein change from baseline, measured by Western blot and immunohistochemistry. CONCLUSION Golodirsen was well-tolerated; muscle biopsies from golodirsen-treated patients showed increased exon 53 skipping, dystrophin production, and correct dystrophin sarcolemmal localization. CLINICALTRIALSGOV IDENTIFIER NCT02310906. CLASSIFICATION OF EVIDENCE This study provides Class I evidence that golodirsen is safe and Class IV evidence that it induces exon skipping and novel dystrophin as confirmed by 3 different assays.",2020,"A significant increase in exon 53 skipping was associated with ∼16-fold increase over baseline in dystrophin protein expression at week 48, with a mean percent normal dystrophin protein standard of 1.019% (range, 0.09%-4.30%).","['golodirsen-treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping', 'patients with Duchenne muscular dystrophy', 'pediatric patients with DMD', 'Twelve patients']","['placebo', 'golodirsen']","['blinded exon skipping and dystrophin protein production on muscle biopsies (baseline, week 48) evaluated, respectively, using reverse transcription PCR and Western blot and immunohistochemistry', 'dystrophin production', 'dystrophin-positive fibers', 'dystrophin protein expression', 'Safety and pharmacokinetics', 'tolerated; muscle biopsies']","[{'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0013264', 'cui_str': 'Cardiomyopathy, Dilated, X-Linked'}, {'cui': 'C0015295', 'cui_str': 'Exons'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0015295', 'cui_str': 'Exons'}, {'cui': 'C0079259', 'cui_str': 'Dystrophin'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0033268'}, {'cui': 'C0185283', 'cui_str': 'Biopsy of muscle (procedure)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0035380', 'cui_str': 'Reverse Transcription'}, {'cui': 'C3853643', 'cui_str': 'Probe with target amplification technique (qualifier value)'}, {'cui': 'C0949466', 'cui_str': 'Western Immunoblot'}, {'cui': 'C0021044', 'cui_str': 'Immunohistochemistry'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0225326', 'cui_str': 'Fiber'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}]",12.0,0.315679,"A significant increase in exon 53 skipping was associated with ∼16-fold increase over baseline in dystrophin protein expression at week 48, with a mean percent normal dystrophin protein standard of 1.019% (range, 0.09%-4.30%).","[{'ForeName': 'Diane E', 'Initials': 'DE', 'LastName': 'Frank', 'Affiliation': 'From Sarepta Therapeutics (D.E.F., F.J.S., C.A., S.H.E.-H., C.A.D., J.S.C.), Cambridge, MA; University College London (J.M., V.S., J.D., F.M.); Centre of Gene and Cell Therapy and Centre for Biomedical Sciences (G.D.), Royal Holloway, University of London, Egham, Surrey; Newcastle University John Walton Muscular Dystrophy Research Centre and the Newcastle Hospitals NHS Foundation Trust (V.S., M.G.), Newcastle upon Tyne, UK; Paediatric Neurology and Centro Clinico Nemo (E.M.), Catholic University and Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy; Institute I-Motion (L.S.), Hôpital Armand-Trousseau, Paris, France; Neuromuscular Reference Center (L.S.), CHU Liège, Belgium; Great Ormond Street Hospital (F.M.); and NIHR Great Ormond Street Hospital Biomedical Research Centre (F.M.), London, UK.'}, {'ForeName': 'Frederick J', 'Initials': 'FJ', 'LastName': 'Schnell', 'Affiliation': 'From Sarepta Therapeutics (D.E.F., F.J.S., C.A., S.H.E.-H., C.A.D., J.S.C.), Cambridge, MA; University College London (J.M., V.S., J.D., F.M.); Centre of Gene and Cell Therapy and Centre for Biomedical Sciences (G.D.), Royal Holloway, University of London, Egham, Surrey; Newcastle University John Walton Muscular Dystrophy Research Centre and the Newcastle Hospitals NHS Foundation Trust (V.S., M.G.), Newcastle upon Tyne, UK; Paediatric Neurology and Centro Clinico Nemo (E.M.), Catholic University and Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy; Institute I-Motion (L.S.), Hôpital Armand-Trousseau, Paris, France; Neuromuscular Reference Center (L.S.), CHU Liège, Belgium; Great Ormond Street Hospital (F.M.); and NIHR Great Ormond Street Hospital Biomedical Research Centre (F.M.), London, UK.'}, {'ForeName': 'Cody', 'Initials': 'C', 'LastName': 'Akana', 'Affiliation': 'From Sarepta Therapeutics (D.E.F., F.J.S., C.A., S.H.E.-H., C.A.D., J.S.C.), Cambridge, MA; University College London (J.M., V.S., J.D., F.M.); Centre of Gene and Cell Therapy and Centre for Biomedical Sciences (G.D.), Royal Holloway, University of London, Egham, Surrey; Newcastle University John Walton Muscular Dystrophy Research Centre and the Newcastle Hospitals NHS Foundation Trust (V.S., M.G.), Newcastle upon Tyne, UK; Paediatric Neurology and Centro Clinico Nemo (E.M.), Catholic University and Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy; Institute I-Motion (L.S.), Hôpital Armand-Trousseau, Paris, France; Neuromuscular Reference Center (L.S.), CHU Liège, Belgium; Great Ormond Street Hospital (F.M.); and NIHR Great Ormond Street Hospital Biomedical Research Centre (F.M.), London, UK.'}, {'ForeName': 'Saleh H', 'Initials': 'SH', 'LastName': 'El-Husayni', 'Affiliation': 'From Sarepta Therapeutics (D.E.F., F.J.S., C.A., S.H.E.-H., C.A.D., J.S.C.), Cambridge, MA; University College London (J.M., V.S., J.D., F.M.); Centre of Gene and Cell Therapy and Centre for Biomedical Sciences (G.D.), Royal Holloway, University of London, Egham, Surrey; Newcastle University John Walton Muscular Dystrophy Research Centre and the Newcastle Hospitals NHS Foundation Trust (V.S., M.G.), Newcastle upon Tyne, UK; Paediatric Neurology and Centro Clinico Nemo (E.M.), Catholic University and Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy; Institute I-Motion (L.S.), Hôpital Armand-Trousseau, Paris, France; Neuromuscular Reference Center (L.S.), CHU Liège, Belgium; Great Ormond Street Hospital (F.M.); and NIHR Great Ormond Street Hospital Biomedical Research Centre (F.M.), London, UK.'}, {'ForeName': 'Cody A', 'Initials': 'CA', 'LastName': 'Desjardins', 'Affiliation': 'From Sarepta Therapeutics (D.E.F., F.J.S., C.A., S.H.E.-H., C.A.D., J.S.C.), Cambridge, MA; University College London (J.M., V.S., J.D., F.M.); Centre of Gene and Cell Therapy and Centre for Biomedical Sciences (G.D.), Royal Holloway, University of London, Egham, Surrey; Newcastle University John Walton Muscular Dystrophy Research Centre and the Newcastle Hospitals NHS Foundation Trust (V.S., M.G.), Newcastle upon Tyne, UK; Paediatric Neurology and Centro Clinico Nemo (E.M.), Catholic University and Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy; Institute I-Motion (L.S.), Hôpital Armand-Trousseau, Paris, France; Neuromuscular Reference Center (L.S.), CHU Liège, Belgium; Great Ormond Street Hospital (F.M.); and NIHR Great Ormond Street Hospital Biomedical Research Centre (F.M.), London, UK.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Morgan', 'Affiliation': 'From Sarepta Therapeutics (D.E.F., F.J.S., C.A., S.H.E.-H., C.A.D., J.S.C.), Cambridge, MA; University College London (J.M., V.S., J.D., F.M.); Centre of Gene and Cell Therapy and Centre for Biomedical Sciences (G.D.), Royal Holloway, University of London, Egham, Surrey; Newcastle University John Walton Muscular Dystrophy Research Centre and the Newcastle Hospitals NHS Foundation Trust (V.S., M.G.), Newcastle upon Tyne, UK; Paediatric Neurology and Centro Clinico Nemo (E.M.), Catholic University and Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy; Institute I-Motion (L.S.), Hôpital Armand-Trousseau, Paris, France; Neuromuscular Reference Center (L.S.), CHU Liège, Belgium; Great Ormond Street Hospital (F.M.); and NIHR Great Ormond Street Hospital Biomedical Research Centre (F.M.), London, UK.'}, {'ForeName': 'Jay S', 'Initials': 'JS', 'LastName': 'Charleston', 'Affiliation': 'From Sarepta Therapeutics (D.E.F., F.J.S., C.A., S.H.E.-H., C.A.D., J.S.C.), Cambridge, MA; University College London (J.M., V.S., J.D., F.M.); Centre of Gene and Cell Therapy and Centre for Biomedical Sciences (G.D.), Royal Holloway, University of London, Egham, Surrey; Newcastle University John Walton Muscular Dystrophy Research Centre and the Newcastle Hospitals NHS Foundation Trust (V.S., M.G.), Newcastle upon Tyne, UK; Paediatric Neurology and Centro Clinico Nemo (E.M.), Catholic University and Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy; Institute I-Motion (L.S.), Hôpital Armand-Trousseau, Paris, France; Neuromuscular Reference Center (L.S.), CHU Liège, Belgium; Great Ormond Street Hospital (F.M.); and NIHR Great Ormond Street Hospital Biomedical Research Centre (F.M.), London, UK.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Sardone', 'Affiliation': 'From Sarepta Therapeutics (D.E.F., F.J.S., C.A., S.H.E.-H., C.A.D., J.S.C.), Cambridge, MA; University College London (J.M., V.S., J.D., F.M.); Centre of Gene and Cell Therapy and Centre for Biomedical Sciences (G.D.), Royal Holloway, University of London, Egham, Surrey; Newcastle University John Walton Muscular Dystrophy Research Centre and the Newcastle Hospitals NHS Foundation Trust (V.S., M.G.), Newcastle upon Tyne, UK; Paediatric Neurology and Centro Clinico Nemo (E.M.), Catholic University and Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy; Institute I-Motion (L.S.), Hôpital Armand-Trousseau, Paris, France; Neuromuscular Reference Center (L.S.), CHU Liège, Belgium; Great Ormond Street Hospital (F.M.); and NIHR Great Ormond Street Hospital Biomedical Research Centre (F.M.), London, UK.'}, {'ForeName': 'Joana', 'Initials': 'J', 'LastName': 'Domingos', 'Affiliation': 'From Sarepta Therapeutics (D.E.F., F.J.S., C.A., S.H.E.-H., C.A.D., J.S.C.), Cambridge, MA; University College London (J.M., V.S., J.D., F.M.); Centre of Gene and Cell Therapy and Centre for Biomedical Sciences (G.D.), Royal Holloway, University of London, Egham, Surrey; Newcastle University John Walton Muscular Dystrophy Research Centre and the Newcastle Hospitals NHS Foundation Trust (V.S., M.G.), Newcastle upon Tyne, UK; Paediatric Neurology and Centro Clinico Nemo (E.M.), Catholic University and Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy; Institute I-Motion (L.S.), Hôpital Armand-Trousseau, Paris, France; Neuromuscular Reference Center (L.S.), CHU Liège, Belgium; Great Ormond Street Hospital (F.M.); and NIHR Great Ormond Street Hospital Biomedical Research Centre (F.M.), London, UK.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Dickson', 'Affiliation': 'From Sarepta Therapeutics (D.E.F., F.J.S., C.A., S.H.E.-H., C.A.D., J.S.C.), Cambridge, MA; University College London (J.M., V.S., J.D., F.M.); Centre of Gene and Cell Therapy and Centre for Biomedical Sciences (G.D.), Royal Holloway, University of London, Egham, Surrey; Newcastle University John Walton Muscular Dystrophy Research Centre and the Newcastle Hospitals NHS Foundation Trust (V.S., M.G.), Newcastle upon Tyne, UK; Paediatric Neurology and Centro Clinico Nemo (E.M.), Catholic University and Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy; Institute I-Motion (L.S.), Hôpital Armand-Trousseau, Paris, France; Neuromuscular Reference Center (L.S.), CHU Liège, Belgium; Great Ormond Street Hospital (F.M.); and NIHR Great Ormond Street Hospital Biomedical Research Centre (F.M.), London, UK.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Straub', 'Affiliation': 'From Sarepta Therapeutics (D.E.F., F.J.S., C.A., S.H.E.-H., C.A.D., J.S.C.), Cambridge, MA; University College London (J.M., V.S., J.D., F.M.); Centre of Gene and Cell Therapy and Centre for Biomedical Sciences (G.D.), Royal Holloway, University of London, Egham, Surrey; Newcastle University John Walton Muscular Dystrophy Research Centre and the Newcastle Hospitals NHS Foundation Trust (V.S., M.G.), Newcastle upon Tyne, UK; Paediatric Neurology and Centro Clinico Nemo (E.M.), Catholic University and Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy; Institute I-Motion (L.S.), Hôpital Armand-Trousseau, Paris, France; Neuromuscular Reference Center (L.S.), CHU Liège, Belgium; Great Ormond Street Hospital (F.M.); and NIHR Great Ormond Street Hospital Biomedical Research Centre (F.M.), London, UK.'}, {'ForeName': 'Michela', 'Initials': 'M', 'LastName': 'Guglieri', 'Affiliation': 'From Sarepta Therapeutics (D.E.F., F.J.S., C.A., S.H.E.-H., C.A.D., J.S.C.), Cambridge, MA; University College London (J.M., V.S., J.D., F.M.); Centre of Gene and Cell Therapy and Centre for Biomedical Sciences (G.D.), Royal Holloway, University of London, Egham, Surrey; Newcastle University John Walton Muscular Dystrophy Research Centre and the Newcastle Hospitals NHS Foundation Trust (V.S., M.G.), Newcastle upon Tyne, UK; Paediatric Neurology and Centro Clinico Nemo (E.M.), Catholic University and Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy; Institute I-Motion (L.S.), Hôpital Armand-Trousseau, Paris, France; Neuromuscular Reference Center (L.S.), CHU Liège, Belgium; Great Ormond Street Hospital (F.M.); and NIHR Great Ormond Street Hospital Biomedical Research Centre (F.M.), London, UK.'}, {'ForeName': 'Eugenio', 'Initials': 'E', 'LastName': 'Mercuri', 'Affiliation': 'From Sarepta Therapeutics (D.E.F., F.J.S., C.A., S.H.E.-H., C.A.D., J.S.C.), Cambridge, MA; University College London (J.M., V.S., J.D., F.M.); Centre of Gene and Cell Therapy and Centre for Biomedical Sciences (G.D.), Royal Holloway, University of London, Egham, Surrey; Newcastle University John Walton Muscular Dystrophy Research Centre and the Newcastle Hospitals NHS Foundation Trust (V.S., M.G.), Newcastle upon Tyne, UK; Paediatric Neurology and Centro Clinico Nemo (E.M.), Catholic University and Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy; Institute I-Motion (L.S.), Hôpital Armand-Trousseau, Paris, France; Neuromuscular Reference Center (L.S.), CHU Liège, Belgium; Great Ormond Street Hospital (F.M.); and NIHR Great Ormond Street Hospital Biomedical Research Centre (F.M.), London, UK.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Servais', 'Affiliation': 'From Sarepta Therapeutics (D.E.F., F.J.S., C.A., S.H.E.-H., C.A.D., J.S.C.), Cambridge, MA; University College London (J.M., V.S., J.D., F.M.); Centre of Gene and Cell Therapy and Centre for Biomedical Sciences (G.D.), Royal Holloway, University of London, Egham, Surrey; Newcastle University John Walton Muscular Dystrophy Research Centre and the Newcastle Hospitals NHS Foundation Trust (V.S., M.G.), Newcastle upon Tyne, UK; Paediatric Neurology and Centro Clinico Nemo (E.M.), Catholic University and Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy; Institute I-Motion (L.S.), Hôpital Armand-Trousseau, Paris, France; Neuromuscular Reference Center (L.S.), CHU Liège, Belgium; Great Ormond Street Hospital (F.M.); and NIHR Great Ormond Street Hospital Biomedical Research Centre (F.M.), London, UK.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Muntoni', 'Affiliation': 'From Sarepta Therapeutics (D.E.F., F.J.S., C.A., S.H.E.-H., C.A.D., J.S.C.), Cambridge, MA; University College London (J.M., V.S., J.D., F.M.); Centre of Gene and Cell Therapy and Centre for Biomedical Sciences (G.D.), Royal Holloway, University of London, Egham, Surrey; Newcastle University John Walton Muscular Dystrophy Research Centre and the Newcastle Hospitals NHS Foundation Trust (V.S., M.G.), Newcastle upon Tyne, UK; Paediatric Neurology and Centro Clinico Nemo (E.M.), Catholic University and Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy; Institute I-Motion (L.S.), Hôpital Armand-Trousseau, Paris, France; Neuromuscular Reference Center (L.S.), CHU Liège, Belgium; Great Ormond Street Hospital (F.M.); and NIHR Great Ormond Street Hospital Biomedical Research Centre (F.M.), London, UK. f.muntoni@ucl.ac.uk.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Neurology,['10.1212/WNL.0000000000009233'] 1193,32175686,Application of erector spinae plane block guided by ultrasound for postoperative analgesia in breast cancer surgery: A randomized controlled trial.,,2020,,['breast cancer surgery'],['erector spinae plane block guided by ultrasound'],[],"[{'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}]",[],,0.154128,,"[{'ForeName': 'Wensheng', 'Initials': 'W', 'LastName': 'He', 'Affiliation': 'Department of Anesthesia, the First Hospital of Qinhuangdao, Qinhuangdao, Hebei, 066000, P. R. China.'}, {'ForeName': 'Zhenyu', 'Initials': 'Z', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesia, the First Hospital of Qinhuangdao, Qinhuangdao, Hebei, 066000, P. R. China.'}, {'ForeName': 'Lingjie', 'Initials': 'L', 'LastName': 'Zu', 'Affiliation': 'Department of Family Planning, Maternal and Child Health Care Hospital of Qinhuangdao, Qinhuangdao, Hebei, 066000, P. R. China.'}, {'ForeName': 'Haijun', 'Initials': 'H', 'LastName': 'Sun', 'Affiliation': 'Department of Anesthesia, the First Hospital of Qinhuangdao, Qinhuangdao, Hebei, 066000, P. R. China.'}, {'ForeName': 'Xiaochun', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesia, the First Hospital of Qinhuangdao, Qinhuangdao, Hebei, 066000, P. R. China.'}]","Cancer communications (London, England)",['10.1002/cac2.12013'] 1194,32195893,Early Effects of the Trauma Collaborative Care Intervention: Results from a Prospective Multicenter Cluster Clinical Trial: Erratum.,,2020,,[],['Trauma Collaborative Care Intervention'],[],[],"[{'cui': 'C0043251', 'cui_str': 'Trauma'}]",[],,0.0737869,,[],Journal of orthopaedic trauma,['10.1097/BOT.0000000000001740'] 1195,32134758,Randomized trial of intracoronary adenosine as adjunctive therapy for prevention of the no-reflow phenomenon.,"No-reflow phenomenon as a serious complication following percutaneous coronary intervention, deteriorates clinical outcomes. Intracoronary (IC) Adenosine, seems to be a way to deal with it. One hundred four consecutive patients with ST-segment elevation myocardial infarction were randomized into two groups. Each group consisted of 52 patients who managed with two bolus doses of IC Adenosine (Adenosine group) or two bolus doses of IC normal saline (placebo group) administered before and after stenting. Thrombolysis in myocardial infarction (TIMI) grade flow, ST-segment resolution (STR) and post-procedural clinical outcomes were used as endpoints. IC adenosine led to lower rates of no-reflow based on TIMI grade flow scaling (15.4% vs. 44.3%; P-value: 0.02). STR classified as complete, partial and no resolution was similar between two groups (P-value: 0.748). Also, post-interventional clinical outcomes, including arrhythmia, left ventricular ejection fraction, hospitalization time, and 30 days mortality were similar between Adenosine and placebo groups.",2020,"STR classified as complete, partial and no resolution was similar between two groups (P-value: 0.748).","['52 patients who managed with two bolus doses of', 'One hundred four consecutive patients with ST-segment elevation myocardial infarction']","['IC adenosine', 'IC Adenosine (Adenosine group) or two bolus doses of IC normal saline (placebo', 'Intracoronary (IC) Adenosine', 'intracoronary adenosine']","['arrhythmia, left ventricular ejection fraction, hospitalization time, and 30 days mortality', 'myocardial infarction (TIMI) grade flow, ST-segment resolution (STR) and post-procedural clinical outcomes', 'rates of no-reflow based on TIMI grade flow scaling']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C1536220', 'cui_str': 'ST Elevated Myocardial Infarction'}]","[{'cui': 'C0001443', 'cui_str': 'Adenosine'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0003811', 'cui_str': 'Arrhythmia'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction (observable entity)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0429029', 'cui_str': 'ST segment (observable entity)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0222045'}]",104.0,0.0789274,"STR classified as complete, partial and no resolution was similar between two groups (P-value: 0.748).","[{'ForeName': 'Nima', 'Initials': 'N', 'LastName': 'Naghshtabrizi', 'Affiliation': 'Department of Cardiology, Tehran University of Medical Science, Tehran.'}, {'ForeName': 'Manijeh', 'Initials': 'M', 'LastName': 'Sajedi', 'Affiliation': 'School of Medicine, Hamadan University of Medical Sciences.'}, {'ForeName': 'Behshad', 'Initials': 'B', 'LastName': 'Naghshtabrizi', 'Affiliation': 'Department of Cardiology, Hamadan University of Medical Science.'}, {'ForeName': 'Azadeh', 'Initials': 'A', 'LastName': 'Mozayanimonfared', 'Affiliation': 'Department of Cardiology, Hamadan University of Medical Science.'}, {'ForeName': 'Mohamad', 'Initials': 'M', 'LastName': 'Ali Seif Rabiei', 'Affiliation': 'Hamadan University of Medical Science, Hamadan.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Kanonisabet', 'Affiliation': 'Department of Cardiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}]",Coronary artery disease,['10.1097/MCA.0000000000000863'] 1196,31995838,Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.,"BACKGROUND Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids. OBJECTIVES To evaluate the efficacy and safety of baricitinib in patients with moderate-to-severe AD who had an inadequate response to topical therapies. METHODS In two independent, multicentre, double-blind, phase III monotherapy trials, BREEZE-AD1 and BREEZE-AD2, adults with moderate-to-severe AD were randomized 2 : 1 : 1 : 1 to once-daily placebo, baricitinib 1 mg, 2 mg, or 4 mg for 16 weeks. RESULTS At week 16, more patients achieved the primary end point of Validated Investigator's Global Assessment of AD (0, 1) on baricitinib 4 mg and 2 mg compared with placebo in BREEZE-AD1 [N = 624; baricitinib 4 mg 16·8% (P < 0·001), 2 mg 11·4% (P < 0·05), 1 mg 11·8% (P < 0·05), placebo 4·8%], and BREEZE-AD2 [N = 615; baricitinib 4 mg 13·8% (P = 0·001), 2 mg 10·6% (P < 0·05), 1 mg 8·8% (P = 0·085), placebo 4·5%]. Improvement in itch was achieved as early as week 1 for 4 mg and week 2 for 2 mg. Improvements in night-time awakenings, skin pain and quality-of-life measures were observed by week 1 for both 4 mg and 2 mg (P ≤ 0·05, all comparisons). The most common adverse events in patients treated with baricitinib were nasopharyngitis and headache. No cardiovascular events, venous thromboembolism, gastrointestinal perforation, significant haematological changes, or death were observed with any baricitinib dosage. CONCLUSIONS Baricitinib improved clinical signs and symptoms in patients with moderate-to-severe AD within 16 weeks of treatment and induced rapid reduction of itch. The safety profile remained consistent with prior findings from baricitinib clinical development in AD, with no new safety concerns.",2020,"Improvements in night-time awakenings, skin pain, and quality-of-life measures were observed by Week 1 for both 4-mg and 2-mg (P≤0.05, all comparisons).","['patients with moderate-to-severe AD', 'Patients with Moderate-to-Severe Atopic Dermatitis', 'adults with moderate-to-severe AD']","['placebo, baricitinib 1-mg, 2-mg or 4-mg for 16 weeks', 'baricitinib', 'Topical Corticosteroids']","['atopic dermatitis (AD) severity', 'efficacy and safety', 'night-time awakenings, skin pain, and quality-of-life measures', 'nasopharyngitis and headache', 'cardiovascular events, venous thromboembolism, gastrointestinal perforation, significant haematological changes, or death', 'clinical signs and symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0011615', 'cui_str': 'Neurodermatitis, Disseminated'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4044947', 'cui_str': 'baricitinib'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}]","[{'cui': 'C0011615', 'cui_str': 'Neurodermatitis, Disseminated'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0240526', 'cui_str': 'Night time (qualifier value)'}, {'cui': 'C1720052', 'cui_str': 'Awakening'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0034380'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C1861172', 'cui_str': 'Venous Thromboembolism'}, {'cui': 'C1963976', 'cui_str': 'Gastrointestinal perforation (SMQ)'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0037088', 'cui_str': 'Signs and Symptoms'}]",,0.136248,"Improvements in night-time awakenings, skin pain, and quality-of-life measures were observed by Week 1 for both 4-mg and 2-mg (P≤0.05, all comparisons).","[{'ForeName': 'E L', 'Initials': 'EL', 'LastName': 'Simpson', 'Affiliation': 'Department of Dermatology, Oregon Health and Science University, Portland, OR, USA.'}, {'ForeName': 'J-P', 'Initials': 'JP', 'LastName': 'Lacour', 'Affiliation': 'Department of Dermatology, University Hospital of Nice, Nice, France.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Spelman', 'Affiliation': 'Veracity Clinical Research, Brisbane, Australia.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Galimberti', 'Affiliation': 'Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.'}, {'ForeName': 'L F', 'Initials': 'LF', 'LastName': 'Eichenfield', 'Affiliation': ""University of California, San Diego and Rady Children's Hospital, San Diego, CA, USA.""}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Bissonnette', 'Affiliation': 'Innovaderm Research, Montreal, QC, Canada.'}, {'ForeName': 'B A', 'Initials': 'BA', 'LastName': 'King', 'Affiliation': 'Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Thyssen', 'Affiliation': 'Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'J I', 'Initials': 'JI', 'LastName': 'Silverberg', 'Affiliation': 'Department of Dermatology George Washington University School of Medicine, Washington, DC, USA.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Bieber', 'Affiliation': 'Department of Dermatology and Allergy, University of Bonn, Bonn, Germany.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Kabashima', 'Affiliation': 'Department of Dermatology, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Tsunemi', 'Affiliation': 'Department of Dermatology, Saitama Medical University, Saitama, Japan.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Costanzo', 'Affiliation': 'Humanitas University and Dermatology Unit, Humanitas Research Hospital, Milan, Italy.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Guttman-Yassky', 'Affiliation': 'Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'L A', 'Initials': 'LA', 'LastName': 'Beck', 'Affiliation': 'Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Janes', 'Affiliation': 'Lilly Research Laboratory, Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'DeLozier', 'Affiliation': 'Lilly Research Laboratory, Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gamalo', 'Affiliation': 'Lilly Research Laboratory, Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'D R', 'Initials': 'DR', 'LastName': 'Brinker', 'Affiliation': 'Lilly Research Laboratory, Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Cardillo', 'Affiliation': 'Lilly Research Laboratory, Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'F P', 'Initials': 'FP', 'LastName': 'Nunes', 'Affiliation': 'Lilly Research Laboratory, Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'A S', 'Initials': 'AS', 'LastName': 'Paller', 'Affiliation': 'Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Wollenberg', 'Affiliation': 'Department of Dermatology and Allergology, Ludwig Maximillian University, Munich, Germany.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Reich', 'Affiliation': 'Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Skinflammation® Center, Hamburg, Germany.'}]",The British journal of dermatology,['10.1111/bjd.18898'] 1197,32496902,Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131.,"PURPOSE The high-risk stratum of Children's Oncology Group Study AALL1131 was designed to test the hypothesis that postinduction CNS prophylaxis with intrathecal triple therapy (ITT) including methotrexate, hydrocortisone, and cytarabine would improve the postinduction 5-year disease-free survival (DFS) compared with intrathecal methotrexate (IT MTX), when given on a modified augmented Berlin-Frankfurt-Münster backbone. PATIENTS AND METHODS Children with newly diagnosed National Cancer Institute (NCI) high-risk B-cell acute lymphoblastic leukemia (HR B-ALL) or NCI standard-risk B-ALL with defined minimal residual disease thresholds during induction were randomly assigned to receive postinduction IT MTX or ITT. Patients with CNS3-status disease were not eligible. Postinduction IT therapy was given for a total of 21 to 26 doses. Neurocognitive assessments were performed during therapy and during 1 year off therapy. RESULTS Random assignment was closed to accrual in March 2018 after a futility boundary had been crossed, concluding that ITT could not be shown to be superior to IT MTX. The 5-year postinduction DFS and overall survival rates (± SE) of children randomly assigned to IT MTX versus ITT were 93.2% ± 2.1% v 90.6% ± 2.3% ( P = .85), and 96.3% ± 1.5% v 96.7% ± 1.4% ( P = .77), respectively. There were no differences in the cumulative incidence of isolated bone marrow relapse, isolated CNS relapse, or combined bone marrow and CNS relapse rates, or in toxicities observed for patients receiving IT MTX compared with ITT. There were no significant differences in neurocognitive outcomes for patients receiving IT MTX compared with ITT. CONCLUSION Postinduction CNS prophylaxis with ITT did not improve 5-year DFS for children with HR B-ALL. The standard of care for CNS prophylaxis for children with B-ALL and no overt CNS involvement remains IT MTX.",2020,"There were no differences in the cumulative incidence of isolated bone marrow relapse, isolated CNS relapse, or combined bone marrow and CNS relapse rates, or in toxicities observed for patients receiving IT MTX compared with ITT.","['children with B-ALL and no overt CNS involvement remains IT MTX', 'Patients with CNS3-status disease', 'Children with newly diagnosed National Cancer Institute (NCI) high-risk B-cell acute lymphoblastic leukemia (HR B-ALL) or NCI standard-risk B-ALL with defined minimal residual disease thresholds during induction']","['Intrathecal Methotrexate', 'postinduction IT MTX or ITT', 'IT MTX', 'Intrathecal Triple Therapy', 'intrathecal triple therapy (ITT) including methotrexate, hydrocortisone, and cytarabine', 'intrathecal methotrexate (IT MTX']","['cumulative incidence of isolated bone marrow relapse, isolated CNS relapse, or combined bone marrow and CNS relapse rates, or in toxicities', 'neurocognitive outcomes', '5-year DFS', 'postinduction 5-year disease-free survival (DFS', '5-year postinduction DFS and overall survival rates (± SE']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1292769', 'cui_str': 'Precursor B-cell lymphoblastic leukemia'}, {'cui': 'C0686377', 'cui_str': 'Secondary malignant neoplasm of central nervous system'}, {'cui': 'C0677897', 'cui_str': 'Intrathecal route'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C1513882', 'cui_str': 'National Cancer Institute'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0242596', 'cui_str': 'Minimal residual disease'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0205263', 'cui_str': 'Induced'}]","[{'cui': 'C0677897', 'cui_str': 'Intrathecal route'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0010711', 'cui_str': 'Cytarabine'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0005953', 'cui_str': 'Bone marrow structure'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0028654', 'cui_str': 'Clinical nurse specialist'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",,0.0503645,"There were no differences in the cumulative incidence of isolated bone marrow relapse, isolated CNS relapse, or combined bone marrow and CNS relapse rates, or in toxicities observed for patients receiving IT MTX compared with ITT.","[{'ForeName': 'Wanda L', 'Initials': 'WL', 'LastName': 'Salzer', 'Affiliation': 'Uniformed Services University, Bethesda, MD.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Burke', 'Affiliation': ""Department of Pediatrics, Children's Hospital of Wisconsin, Milwaukee, WI.""}, {'ForeName': 'Meenakshi', 'Initials': 'M', 'LastName': 'Devidas', 'Affiliation': ""Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN.""}, {'ForeName': 'Yunfeng', 'Initials': 'Y', 'LastName': 'Dai', 'Affiliation': 'Department of Biostatistics, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, FL.'}, {'ForeName': 'Kristina K', 'Initials': 'KK', 'LastName': 'Hardy', 'Affiliation': ""Children's National Medical Center, Washington, DC.""}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Kairalla', 'Affiliation': 'Department of Biostatistics, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, FL.'}, {'ForeName': 'Lia', 'Initials': 'L', 'LastName': 'Gore', 'Affiliation': ""Department of Pediatrics, Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO.""}, {'ForeName': 'Joanne M', 'Initials': 'JM', 'LastName': 'Hilden', 'Affiliation': ""Department of Pediatrics, Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO.""}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Larsen', 'Affiliation': ""Department of Pediatrics, Maine Children's Cancer Program, Scarborough, ME.""}, {'ForeName': 'Karen R', 'Initials': 'KR', 'LastName': 'Rabin', 'Affiliation': 'Department of Pediatrics, Baylor College of Medicine, Houston, TX.'}, {'ForeName': 'Patrick A', 'Initials': 'PA', 'LastName': 'Zweidler-McKay', 'Affiliation': 'ImmunoGen, Inc, Waltham, MA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Borowitz', 'Affiliation': 'Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD.'}, {'ForeName': 'Brent', 'Initials': 'B', 'LastName': 'Wood', 'Affiliation': 'Department of Laboratory Medicine, University of Washington, Seattle, WA.'}, {'ForeName': 'Nyla A', 'Initials': 'NA', 'LastName': 'Heerema', 'Affiliation': 'Department of Pathology, The Ohio State University School of Medicine, Columbus, OH.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Carroll', 'Affiliation': 'Department of Genetics, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Winick', 'Affiliation': 'Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'William L', 'Initials': 'WL', 'LastName': 'Carroll', 'Affiliation': 'Department of Pediatrics, Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Raetz', 'Affiliation': 'Department of Pediatrics, Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY.'}, {'ForeName': 'Mignon L', 'Initials': 'ML', 'LastName': 'Loh', 'Affiliation': ""Department of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.""}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Hunger', 'Affiliation': ""Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA.""}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.02892'] 1198,32243613,Patient-reported outcome measures in multiple myeloma: Real-time reporting to improve care (My-PROMPT) - a pilot randomized controlled trial.,,2020,,[],[],['multiple myeloma: real-time reporting to improve care (My-PROMPT'],[],[],"[{'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",,0.132905,,"[{'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Moore', 'Affiliation': 'School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Tracy A', 'Initials': 'TA', 'LastName': 'King', 'Affiliation': 'Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.'}, {'ForeName': 'Erica M', 'Initials': 'EM', 'LastName': 'Wood', 'Affiliation': 'School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Rasa', 'Initials': 'R', 'LastName': 'Ruseckaite', 'Affiliation': 'School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Klarica', 'Affiliation': 'Department of Malignant Haematology, The Alfred Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Spencer', 'Affiliation': 'Department of Malignant Haematology, The Alfred Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'P Joy', 'Initials': 'PJ', 'LastName': 'Ho', 'Affiliation': 'Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.'}, {'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Quach', 'Affiliation': ""University of Melbourne, St Vincent's Hospital, Melbourne, Victoria, Australia.""}, {'ForeName': 'H Miles', 'Initials': 'HM', 'LastName': 'Prince', 'Affiliation': 'Epworth Healthcare and University of Melbourne, Melbourne, Victoria, Australia.'}, {'ForeName': 'Zoe K', 'Initials': 'ZK', 'LastName': 'McQuilten', 'Affiliation': 'School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}]",American journal of hematology,['10.1002/ajh.25815'] 1199,32501109,Temporary Bridge Plating vs Primary Arthrodesis of the First Tarsometatarsal Joint in Lisfranc Injuries: Randomized Controlled Trial.,"BACKGROUND Unstable Lisfranc injuries are best treated with anatomic reduction and stable fixation. There are controversies regarding which type of stabilization is best. In the present study, we compared primary arthrodesis of the first tarsometatarsal (TMT) joint to temporary bridge plating in unstable Lisfranc injuries. METHODS Forty-eight patients with Lisfranc injuries were included and followed for 2 years. Twenty-four patients were randomized to primary arthrodesis (PA) of the medial 3 TMT joints, whereas 24 patients were randomized to temporary bridge plate (BP) over the first TMT joint and primary arthrodesis of the second and third TMT joints. The main outcome parameter was the American Orthopaedic Foot & Ankle Society (AOFAS) midfoot scale and the secondary outcome parameters were the 36-Item Short Form Health Survey (SF-36) and visual analog scale for pain (VAS pain). Computed tomography (CT) scans pre- and postoperatively were obtained. Radiographs were obtained at follow-ups. Pedobarographic examination was performed at the 2-year follow-up. Twenty-two of 24 patients in the PA and 23/24 in the BP group completed the 2-year follow-up. RESULTS The mean AOFAS midfoot score 2 years postoperatively was 89 (SD 9) in the PA group and 85 (SD 15) in the BP group ( P = .32). There were no significant differences between the groups with regard to SF-36 or VAS pain scores. The alignment of the first metatarsal was better in the BP group than in the PA group measured by the anteroposterior Meary angle ( P = .04). The PA group had a reduced peak pressure under the fifth metatarsal ( P = .047). In the BP group, 11/24 patients had radiologic signs of osteoarthritis in the first TMT joint. CONCLUSION Both treatment groups had good outcome scores. The first metatarsal was better aligned in the BP group; however, there was a high incidence of radiographic osteoarthritis in this group. LEVEL OF EVIDENCE Therapeutic level I, prospective randomized controlled study.",2020,There were no significant differences between the groups with regard to SF-36 or VAS pain scores.,"['Twenty-four patients were randomized to primary arthrodesis (PA) of the medial 3 TMT joints, whereas 24 patients', 'Twenty-two of 24 patients in the PA and 23/24 in the BP group completed the 2-year follow-up', 'Lisfranc Injuries', 'Forty-eight patients with Lisfranc injuries were included and followed for 2 years']","['primary arthrodesis of the first tarsometatarsal (TMT) joint to temporary bridge plating', 'temporary bridge plate (BP) over the first TMT joint and primary arthrodesis of the second and third TMT joints', 'Temporary Bridge Plating vs Primary Arthrodesis']","['peak pressure', 'Therapeutic level', 'mean AOFAS midfoot score', 'SF-36 or VAS pain scores', 'American Orthopaedic Foot & Ankle Society (AOFAS) midfoot scale', 'radiographic osteoarthritis', '36-Item Short Form Health Survey (SF-36) and visual analog scale for pain (VAS pain', 'radiologic signs of osteoarthritis']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0003881', 'cui_str': 'Arthrodesis'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0224724', 'cui_str': 'Structure of tarsometatarsal joint'}, {'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0221821', 'cui_str': 'Dental bridge'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C4523968', 'cui_str': 'Lisfranc injury'}, {'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0003881', 'cui_str': 'Arthrodesis'}, {'cui': 'C0447821', 'cui_str': 'First tarsometatarsal joint'}, {'cui': 'C0205374', 'cui_str': 'Transitory'}, {'cui': 'C0221821', 'cui_str': 'Dental bridge'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0447823', 'cui_str': 'Third tarsometatarsal joint'}]","[{'cui': 'C0445174', 'cui_str': 'Peak pressure'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0932074', 'cui_str': 'Midfoot region of foot'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0034599', 'cui_str': 'Radiology - specialty'}, {'cui': 'C0220912', 'cui_str': 'signs'}]",48.0,0.0430063,There were no significant differences between the groups with regard to SF-36 or VAS pain scores.,"[{'ForeName': 'Are H', 'Initials': 'AH', 'LastName': 'Stødle', 'Affiliation': 'Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Kjetil H', 'Initials': 'KH', 'LastName': 'Hvaal', 'Affiliation': 'Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Helga M', 'Initials': 'HM', 'LastName': 'Brøgger', 'Affiliation': 'Department of Radiology and Nuclear medicine, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Jan Erik', 'Initials': 'JE', 'LastName': 'Madsen', 'Affiliation': 'Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Elisabeth Ellingsen', 'Initials': 'EE', 'LastName': 'Husebye', 'Affiliation': 'Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.'}]",Foot & ankle international,['10.1177/1071100720925815'] 1200,32502164,Effect of practice exergames on the mood states and self-esteem of elementary school boys and girls during physical education classes: A cluster-randomized controlled natural experiment.,"Reduced physical exercise can impact children's mental health. Use of active electronic games can help promote psychological health. Physical education (PE class) uses different resources, methods, and contents to promote student health. We investigated the effect of exergames on the mood and self-esteem of children and compare it that of with traditional PE classes. From a sample of 213 children (7-11 years old), 140 from 10 classes of the fourth and fifth grades of elementary school (59 boys, 81 girls; mean age 9.41±0.48 years), allocated to an experimental group (EG; n = 68; five clusters) and a PE group (PE; n = 72; five clusters), participated in this experimental controlled study. The EG practiced exergames during three 40-minute classes, and the PE group held three routine curricular PE classes. Brunel's Mood Scale and Rosenberg's Self-Esteem Scale were applied. Repeated measures ANOVA identified differences between sexes and groups. The main results of the EG demonstrated reduced tension in girls (p <0.05; ES: 0.62; 95% CI: 0.17-1.05). Regarding sex comparisons, anger was lower in girls (F: 4.57; p <0.05; ES: 0.61; 95% CI: 0.11-1.11) in the EG. Vigor was higher in girls in the EG than in those in the PE group (F: 5.46; p <0.05; ES: 0.56; 95% CI: 0.12-1.01). The main results of the PE group indicated increased self-esteem in boys (p <0.05; ES: 0.58; 95% CI: 0.08-1.07) and reduction of girls' mental confusion (p <0.05; ES 0.58; 95% CI 0.15-1.06). Thus, exergames impact boys' and girls' self-esteem and mood, as well as traditional physical education classes. Further study on exergames in schools is essential, with long-term effects on physical and mental health. Exergames bring interesting, varied content, technology, and innovation that can increase the attractiveness of physical education.",2020,The main results of the EG demonstrated reduced tension in girls (p <0.05; ES: 0.62; 95% CI: 0.17-1.05).,"['213 children (7-11 years old), 140 from 10 classes of the fourth and fifth grades of elementary school (59 boys, 81 girls; mean age 9.41±0.48 years', 'elementary school boys and girls during physical education classes']","['physical exercise', 'Physical education (PE class', 'practice exergames', 'active electronic games']","[""Brunel's Mood Scale and Rosenberg's Self-Esteem Scale"", 'Vigor', ""reduction of girls' mental confusion"", 'mood states and self-esteem', 'self-esteem']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0205438', 'cui_str': 'Fourth'}, {'cui': 'C0205439', 'cui_str': 'Fifth'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0031805', 'cui_str': 'Education, Physical'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0031805', 'cui_str': 'Education, Physical'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}]","[{'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0582666', 'cui_str': 'Rosenberg self-esteem scale'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0009676', 'cui_str': 'Confusional state'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}]",213.0,0.0680954,The main results of the EG demonstrated reduced tension in girls (p <0.05; ES: 0.62; 95% CI: 0.17-1.05).,"[{'ForeName': 'Alexandro', 'Initials': 'A', 'LastName': 'Andrade', 'Affiliation': 'Laboratory of Sport and Exercise Psychology, Santa Catarina State University, Florianópolis, Brazil.'}, {'ForeName': 'Whyllerton Mayron da', 'Initials': 'WMD', 'LastName': 'Cruz', 'Affiliation': 'Laboratory of Sport and Exercise Psychology, Santa Catarina State University, Florianópolis, Brazil.'}, {'ForeName': 'Clara Knierim', 'Initials': 'CK', 'LastName': 'Correia', 'Affiliation': 'Laboratory of Aquatic Biomechanics, Santa Catarina State University, Florianópolis, Brazil.'}, {'ForeName': 'Ana Luiza Goya', 'Initials': 'ALG', 'LastName': 'Santos', 'Affiliation': 'Laboratory of Sport and Exercise Psychology, Santa Catarina State University, Florianópolis, Brazil.'}, {'ForeName': 'Guilherme Guimarães', 'Initials': 'GG', 'LastName': 'Bevilacqua', 'Affiliation': 'Laboratory of Sport and Exercise Psychology, Santa Catarina State University, Florianópolis, Brazil.'}]",PloS one,['10.1371/journal.pone.0232392'] 1201,32234533,Reducing an entrée portion size does not affect the amount of dessert consumed.,"BACKGROUND Increasing portion size has been shown to increase energy intake. However, little is known about the effect of reducing portion size on subsequent consumption and the consequent energy intake. OBJECTIVE The purpose of this study was to examine the effect of decreasing portion size of an entrée on the amount of dessert consumed as a following course. METHODS A total of 81 participants were instructed to consume a lunch entrée and dessert ad libitum. The participants were given the same entrée and dessert on the same day of the week for four consecutive weeks. However, the entrée was reduced to 90%, 85%, 80%, and 75% of the amount they consumed in the first week of the study. Participants were randomized into four groups and were served the reduced entrée according to a Latin square design. Dessert was consumed ad libitum. In addition, subjects' hunger and satiety levels were assessed before the entrée, after the entrée, and after dessert. RESULTS Reducing portion size had no effect on the amount of dessert consumed despite the finding that measures of hunger and satiety indicated that participants experienced increased hunger at 80% and 75% portion reductions. CONCLUSIONS Reduction in the portion size of an entrée by up to 25% did not increase the amount of dessert consumed, despite an increase in perceived hunger at lower portion sizes. Further investigation is needed to study how much further portion size could be reduced with a sustained decrease in energy intake without compensation, as well as to examine potential interventions for portion control that could reduce daily energy intake.",2020,"CONCLUSIONS Reduction in the portion size of an entrée by up to 25% did not increase the amount of dessert consumed, despite an increase in perceived hunger at lower portion sizes.",['81 participants'],[],"['perceived hunger', 'hunger', 'hunger and satiety levels', 'hunger and satiety']",[],[],"[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",81.0,0.0367898,"CONCLUSIONS Reduction in the portion size of an entrée by up to 25% did not increase the amount of dessert consumed, despite an increase in perceived hunger at lower portion sizes.","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Levitsky', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA; Department of Psychology, Cornell University, Ithaca, NY, USA. Electronic address: dal4@cornell.edu.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Agaronnik', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA.'}, {'ForeName': 'Wing', 'Initials': 'W', 'LastName': 'Zhong', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA.'}, {'ForeName': 'Colten', 'Initials': 'C', 'LastName': 'Morace', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Barre', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA.'}, {'ForeName': 'John Jeshurun', 'Initials': 'JJ', 'LastName': 'Michael', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA.'}]",Appetite,['10.1016/j.appet.2020.104684'] 1202,32499312,The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance).,"BACKGROUND Hyperinsulinemia is considered to be important in the development of colon cancer, but few studies have investigated the associations of hyperinsulinemia with colon cancer survival via dietary scores. METHODS Empirical dietary index for hyperinsulinemia (EDIH) was derived to assess the insulinemic potential of daily diets reflecting the long-term insulin exposure, with higher (more positive) scores indicating higher insulinemic diets. We prospectively estimated the HRs and 95% confidence intervals (CI) to investigate the association of EDIH with disease-free, recurrence-free, and overall survival among patients with stage III colon cancer (1999-2009) enrolled in a randomized adjuvant chemotherapy trial (CALGB 89803). RESULTS Of 1,024 patients (median follow-up: 7.3 years), 311 died, 350 had recurrences, and 394 had events for disease-free survival. Compared with patients in the lowest quintile of EDIH, the corresponding HRs of patients in the highest quintile for disease-free survival events, cancer recurrence, and overall mortality were 0.80 (95% CI, 0.56-1.15), 0.76 (95% CI, 0.51-1.11), and 0.77 (95% CI, 0.52-1.14). CONCLUSIONS Higher EDIH was not associated with the risk of colon cancer recurrence or mortality in this population of patients with stage III colon cancer. IMPACT EDIH, as a measure of dietary insulinemic potential, may be associated with colon cancer risk but not survival in patients with late-stage colon cancer.",2020,"CONCLUSIONS Higher EDIH was not associated with the risk of colon cancer recurrence or mortality in this population of stage III colon cancer patients. ","['late stage colon cancer patients', 'Patients with Stage III Colon Cancer (Alliance', 'patients with stage III colon cancer (1999-2009) enrolled in a randomized adjuvant chemotherapy trial (CALGB 89803', 'stage III colon cancer patients']",[],"['hazard ratios (HR', 'risk of colon cancer recurrence or mortality', 'EDIH with disease-free, recurrence-free, and overall survival', 'disease-free survival', 'disease-free survival events, cancer recurrence, and overall mortality']","[{'cui': 'C1279941', 'cui_str': 'Late stage'}, {'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0278480', 'cui_str': 'Carcinoma of colon, stage III'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],"[{'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0020459', 'cui_str': 'Hyperinsulinism'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]",,0.343602,"CONCLUSIONS Higher EDIH was not associated with the risk of colon cancer recurrence or mortality in this population of stage III colon cancer patients. ","[{'ForeName': 'En', 'Initials': 'E', 'LastName': 'Cheng', 'Affiliation': 'Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut.'}, {'ForeName': 'Sui', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': 'Division of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts.'}, {'ForeName': 'Fang-Shu', 'Initials': 'FS', 'LastName': 'Ou', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Mullen', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Kimmie', 'Initials': 'K', 'LastName': 'Ng', 'Affiliation': 'Division of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts.'}, {'ForeName': 'Leonard B', 'Initials': 'LB', 'LastName': 'Saltz', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Niedzwiecki', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Mayer', 'Affiliation': 'Division of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts.'}, {'ForeName': 'Rex B', 'Initials': 'RB', 'LastName': 'Mowat', 'Affiliation': 'Toledo Community Hospital Oncology Program, Toledo, Ohio.'}, {'ForeName': 'Renaud', 'Initials': 'R', 'LastName': 'Whittom', 'Affiliation': 'Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Hantel', 'Affiliation': 'Loyola University, Stritch School of Medicine, Naperville, Illinois.'}, {'ForeName': 'Al', 'Initials': 'A', 'LastName': 'Benson', 'Affiliation': 'Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Atienza', 'Affiliation': 'Virginia Oncology Associates, Norfolk, Virginia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Messino', 'Affiliation': 'Southeast Cancer Oncology Research Consortium, Mission Hospitals, Asheville, North Carolina.'}, {'ForeName': 'Hedy', 'Initials': 'H', 'LastName': 'Kindler', 'Affiliation': 'University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Edward L', 'Initials': 'EL', 'LastName': 'Giovannucci', 'Affiliation': 'Department of Epidemiology and Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Erin L', 'Initials': 'EL', 'LastName': 'Van Blarigan', 'Affiliation': 'Department of Epidemiology and Biostatistics and Department of Urology, University of California, San Francisco, California.'}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Meyerhardt', 'Affiliation': 'Division of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts.'}, {'ForeName': 'Charles S', 'Initials': 'CS', 'LastName': 'Fuchs', 'Affiliation': 'Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut. charles.fuchs@yale.edu.'}]","Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",['10.1158/1055-9965.EPI-19-1454'] 1203,32502908,Effects of 1 mA and 2 mA transcranial direct current stimulation on working memory performance in healthy participants.,"Anodal transcranial current stimulation (tDCS) to the left dorsolateral prefrontal cortex (DLPFC) has been shown to enhance working memory (WM) in neuropsychiatric patients. In healthy populations, however, tDCS obtains inconclusive results, mostly due to heterogeneous study and stimulation protocols. Here, we approached these issues by investigating effects of tDCS intensity on simultaneous WM performance with three cognitive loads by directly comparing findings of two double-blind, cross-over, sham-controlled experiments. TDCS was administrated to the left DLPFC at intensity of 1 mA (Experiment 1) or 2 mA (Experiment 2), while participants completed a verbal n-back paradigm (1-, 2-, 3-back). Analysis showed no overall effects of tDCS on WM, but a significant interaction with cognitive load. The present study suggests that cognitive load rather than tDCS intensity could be a decisive factor for effects on WM. Moreover, it emphasizes the need of thorough investigation on study parameters to develop more efficient stimulation protocols.",2020,"Analysis showed no overall effects of tDCS on WM, but a significant interaction with cognitive load.","['healthy participants', 'neuropsychiatric patients']","['1\xa0mA and 2\xa0mA transcranial direct current stimulation', 'TDCS', 'Anodal transcranial current stimulation (tDCS']",['working memory performance'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1172076', 'cui_str': '1-(1-phenylethyl)-2-methyleneaziridine'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0442348', 'cui_str': 'Transcranial approach'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0025265', 'cui_str': 'Immediate memory'}]",,0.0450811,"Analysis showed no overall effects of tDCS on WM, but a significant interaction with cognitive load.","[{'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Papazova', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany. Electronic address: Irina.papazova@med.uni-muenchen.de.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Strube', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany.'}, {'ForeName': 'Aida', 'Initials': 'A', 'LastName': 'Wienert', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Henning', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Schwippel', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Neurophysiology & Interventional Neuropsychiatry, University of Tübingen, Germany.'}, {'ForeName': 'Andreas J', 'Initials': 'AJ', 'LastName': 'Fallgatter', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Neurophysiology & Interventional Neuropsychiatry, University of Tübingen, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Padberg', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Falkai', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Plewnia', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Neurophysiology & Interventional Neuropsychiatry, University of Tübingen, Germany.'}, {'ForeName': 'Alkomiet', 'Initials': 'A', 'LastName': 'Hasan', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany; Department of Psychiatry, Psychotherapy and Psychosomatics, BKH Augsburg, Medical Faculty, University of Augsburg, Germany.'}]",Consciousness and cognition,['10.1016/j.concog.2020.102959'] 1204,32504611,Does Tweeting Improve Citations? One-Year Results from the TSSMN Prospective Randomized Trial.,"BACKGROUND The Thoracic Surgery Social Media Network (TSSMN) is a collaborative effort of leading journals in cardiothoracic surgery to highlight publications via social media. This study aims to evaluate the 1-year results of a prospective randomized social media trial to determine the effect of tweeting on subsequent citations and nontraditional bibliometrics. METHODS A total of 112 representative original articles were randomized 1:1 to be tweeted via TSSMN or a control (non-tweeted) group. Measured endpoints included citations at 1 year compared with baseline, as well as article-level metrics (Altmetric score) and Twitter analytics. Independent predictors of citations were identified through univariable and multivariable regression analyses. RESULTS When compared with control articles, tweeted articles achieved significantly greater increase in Altmetric scores (Tweeted 9.4 ± 5.8 vs Non-tweeted 1.0 ± 1.8, P < .001), Altmetric score percentiles relative to articles of similar age from each respective journal (Tweeted 76.0 ± 9.1 percentile vs Non-tweeted 13.8 ± 22.7 percentile, P < .001), with greater change in citations at 1 year (Tweeted +3.1 ± 2.4 vs Non-Tweeted +0.7 ± 1.3, P < .001). Multivariable analysis showed that independent predictors of citations were randomization to tweeting (odds ratio [OR] 9.50; 95% confidence interval [CI] 3.30-27.35, P < .001), Altmetric score (OR 1.32; 95% CI 1.15-1.50, P < .001), open-access status (OR 1.56; 95% CI 1.21-1.78, P < .001), and exposure to a larger number of Twitter followers as quantified by impressions (OR 1.30, 95% CI 1.10-1.49, P < .001). CONCLUSIONS One-year follow-up of this TSSMN prospective randomized trial importantly demonstrates that tweeting results in significantly more article citations over time, highlighting the durable scholarly impact of social media activity.",2020,"Multivariable analysis showed that independent predictors of citations were randomization to tweeting (OR 9.50; 95%CI 3.30-27.35, p<0.001), Altmetric score (OR 1.32; 95%CI 1.15-1.50, p<0.001), open-access status (OR 1.56; 95%CI 1.21-1.78, p<0.001), and exposure to a larger number of Twitter followers as quantified by impressions (OR 1.30, 95%CI 1.10-1.49, p<0.001). ",['A total of 112 representative original articles'],"['Thoracic Surgery Social Media Network (TSSMN', 'TSSMN']","['Altmetric scores', 'Altmetric score', 'article-level metrics (Altmetric score) and Twitter analytics']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0205313', 'cui_str': 'Original'}]","[{'cui': 'C0039986', 'cui_str': 'Thoracic surgery'}, {'cui': 'C3179065', 'cui_str': 'Social Medium'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0699680', 'cui_str': 'Metric'}]",112.0,0.101332,"Multivariable analysis showed that independent predictors of citations were randomization to tweeting (OR 9.50; 95%CI 3.30-27.35, p<0.001), Altmetric score (OR 1.32; 95%CI 1.15-1.50, p<0.001), open-access status (OR 1.56; 95%CI 1.21-1.78, p<0.001), and exposure to a larger number of Twitter followers as quantified by impressions (OR 1.30, 95%CI 1.10-1.49, p<0.001). ","[{'ForeName': 'Jessica G Y', 'Initials': 'JGY', 'LastName': 'Luc', 'Affiliation': 'Division of Cardiovascular Surgery, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Archer', 'Affiliation': 'Division of Thoracic Surgery, Department of Surgery, SUNY-Upstate Medical University, Syracuse, New York.'}, {'ForeName': 'Rakesh C', 'Initials': 'RC', 'LastName': 'Arora', 'Affiliation': 'Section of Cardiac Surgery, Department of Surgery, Max Rady College of Medicine, University of Manitoba, St Boniface Hospital, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Edward M', 'Initials': 'EM', 'LastName': 'Bender', 'Affiliation': 'Department of Cardiothoracic Surgery, Stanford University, Palo Alto, California.'}, {'ForeName': 'Arie', 'Initials': 'A', 'LastName': 'Blitz', 'Affiliation': 'Division of Cardiac Surgery, University of Cincinnati Medical Center, Cincinnati, Ohio.'}, {'ForeName': 'David T', 'Initials': 'DT', 'LastName': 'Cooke', 'Affiliation': 'Section of General Thoracic Surgery, UC Davis Health, Sacramento, California.'}, {'ForeName': 'Tamara Ni', 'Initials': 'TN', 'LastName': 'Hlci', 'Affiliation': 'Department of Cardiothoracic Surgery, Morriston Hospital, ABMU, Swansea, United Kingdom.'}, {'ForeName': 'Biniam', 'Initials': 'B', 'LastName': 'Kidane', 'Affiliation': 'Section of Thoracic Surgery, Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Maral', 'Initials': 'M', 'LastName': 'Ouzounian', 'Affiliation': 'Division of Cardiovascular Surgery, Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Thomas K', 'Initials': 'TK', 'LastName': 'Varghese', 'Affiliation': 'Division of Cardiothoracic Surgery, Department of Surgery, University of Utah, Salt Lake City, Utah.'}, {'ForeName': 'Mara B', 'Initials': 'MB', 'LastName': 'Antonoff', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, Houston, Texas. Electronic address: mbantonoff@mdanderson.org.'}]",The Annals of thoracic surgery,['10.1016/j.athoracsur.2020.04.065'] 1205,32500131,Oral caffeine intake amplifies the effect of isoproterenol in patients with frequent premature ventricular contractions.,"AIMS Infrequent appearance and failed induction of premature ventricular contractions (PVCs) at catheter ablation make their localization difficult and are associated with a poor procedural outcome. This study aimed to assess the effect of preprocedural oral caffeine intake on induction of PVCs during catheter ablation. METHODS AND RESULTS Seventy patients (age: 54 ± 14 years, 37 men) undergoing catheter ablation for monofocal PVCs were randomized to receive oral caffeine (5 mg/kg) or placebo. Before ablation, PVC counts for 5 min were performed at baseline and during isoproterenol infusion and the isoproterenol washout period. PVC count fluctuation was defined as the difference between the highest and lowest 5-min count among the three-time periods. The 5-min PVC counts during baseline and isoproterenol infusion were equivalent between the groups. However, those during the isoproterenol washout period and PVC count fluctuation were significantly higher in the caffeine group than the control group (73.1 ± 73.2 vs. 38.9 ± 28.9 beats/5 min, P = 0.012 and 69.3 ± 61.3 vs. 37.7 ± 30.9 beats/5 min, P = 0.008, respectively). The procedure and ablation times were significantly shorter in the caffeine group than the control group (105.0 ± 23.4 vs. 136.9 ± 43.2 min, P < 0.01 and 219.1 ± 104.7 vs. 283.5 ± 136.0 sec, P < 0.01, respectively). CONCLUSION  Oral caffeine intake amplified the effect of isoproterenol infusion on PVC induction during catheter ablation. The combined use of oral caffeine intake and isoproterenol infusion can be an option to increase intraprocedural PVCs.",2020,"The procedure and ablation times were significantly shorter in the caffeine group than the control group (105.0 ± 23.4 vs. 136.9 ± 43.2 min, P < 0.01 and 219.1 ± ","['Seventy patients (age: 54\u2009±\u200914\u2009years, 37 men) undergoing catheter ablation for monofocal PVCs', 'patients with frequent premature ventricular contractions']","['oral caffeine', 'Oral caffeine', 'caffeine', 'preprocedural oral caffeine', 'isoproterenol infusion', 'isoproterenol', 'oral caffeine intake and isoproterenol infusion', 'placebo']","['procedure and ablation times', '5-min PVC counts', 'PVC count fluctuation']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0162563', 'cui_str': 'Cardiac ablation'}, {'cui': 'C0151636', 'cui_str': 'Ventricular premature beats'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0022245', 'cui_str': 'Isoproterenol'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0032624', 'cui_str': 'Polyvinyl chloride'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0231239', 'cui_str': 'Fluctuation'}]",70.0,0.0199067,"The procedure and ablation times were significantly shorter in the caffeine group than the control group (105.0 ± 23.4 vs. 136.9 ± 43.2 min, P < 0.01 and 219.1 ± ","[{'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Hasebe', 'Affiliation': 'Department of Cardiology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Yoshida', 'Affiliation': 'Department of Cardiology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan.'}, {'ForeName': 'Yoshitaka', 'Initials': 'Y', 'LastName': 'Furuyashiki', 'Affiliation': 'Division of Arrhythmology, Shizuoka Saiseikai General Hospital, Shizuoka, Japan.'}, {'ForeName': 'Akihiko', 'Initials': 'A', 'LastName': 'Nogami', 'Affiliation': 'Department of Cardiology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan.'}, {'ForeName': 'Masaki', 'Initials': 'M', 'LastName': 'Ieda', 'Affiliation': 'Department of Cardiology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan.'}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euaa069'] 1206,32497023,l-Arginine supplementation in severe asthma.,"BACKGROUNDDysregulation of l-arginine metabolism has been proposed to occur in patients with severe asthma. The effects of l-arginine supplementation on l-arginine metabolite profiles in these patients are unknown. We hypothesized that individuals with severe asthma with low fractional exhaled nitric oxide (FeNO) would have fewer exacerbations with the addition of l-arginine to their standard asthma medications compared with placebo and would demonstrate the greatest changes in metabolite profiles.METHODSParticipants were enrolled in a single-center, crossover, double-blind l-arginine intervention trial at UCD. Subjects received placebo or l-arginine, dosed orally at 0.05 mg/kg (ideal body weight) twice daily. The primary end point was moderate asthma exacerbations. Longitudinal plasma metabolite levels were measured using mass spectrometry. A linear mixed-effect model with subject-specific intercepts was used for testing treatment effects.RESULTSA cohort of 50 subjects was included in the final analysis. l-Arginine did not significantly decrease asthma exacerbations in the overall cohort. Higher citrulline levels and a lower arginine availability index (AAI) were associated with higher FeNO (P = 0.005 and P = 2.51 × 10-9, respectively). Higher AAI was associated with lower exacerbation events. The eicosanoid prostaglandin H2 (PGH2) and Nα-acetyl-l-arginine were found to be good predictors for differentiating clinical responders and nonresponders.CONCLUSIONSThere was no statistically significant decrease in asthma exacerbations in the overall cohort with l-arginine intervention. PGH2, Nα-acetyl-l-arginine, and the AAI could serve as predictive biomarkers in future clinical trials that intervene in the arginine metabolome.TRIAL REGISTRATIONClinicalTrials.gov NCT01841281.FUNDINGThis study was supported by NIH grants R01HL105573, DK097154, UL1 TR001861, and K08HL114882. Metabolomics analysis was supported in part by a grant from the University of California Tobacco-Related Disease Research Program program (TRDRP).",2020,Higher citrulline levels and a lower arginine availability index (AAI) were associated with higher FeNO (P-value = 0.005 and 2.51 x 10-9 respectively).,"['severe asthma patients', 'Participants were enrolled in a single-center, cross-over, double-blinded, L-arginine intervention trial at the University of California-Davis (NCT01841281', 'severe asthma', '50 subjects was included in the final analysis']","['L-arginine supplementation', 'placebo or L-arginine', 'placebo']","['asthma exacerbations', 'Longitudinal plasma metabolite levels', 'Higher citrulline levels and a lower arginine availability index (AAI', 'moderate asthma exacerbations', 'L-arginine metabolite profiles', 'eicosanoid prostaglandin H2 (PGH2) and Nα-Acetyl-L-arginine']","[{'cui': 'C0581126', 'cui_str': 'Severe asthma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0010366', 'cui_str': 'Genetic crossing over'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0003765', 'cui_str': 'Arginine'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0003765', 'cui_str': 'Arginine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0349790', 'cui_str': 'Exacerbation of asthma'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0008864', 'cui_str': 'Citrulline'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0003765', 'cui_str': 'Arginine'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0581125', 'cui_str': 'Moderate asthma'}, {'cui': 'C0013725', 'cui_str': 'Eicosanoid'}, {'cui': 'C0072288', 'cui_str': 'Prostaglandin PGH2'}]",50.0,0.280177,Higher citrulline levels and a lower arginine availability index (AAI) were associated with higher FeNO (P-value = 0.005 and 2.51 x 10-9 respectively).,"[{'ForeName': 'Shu-Yi', 'Initials': 'SY', 'LastName': 'Liao', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, UCD, Sacramento, California, USA.'}, {'ForeName': 'Megan R', 'Initials': 'MR', 'LastName': 'Showalter', 'Affiliation': 'NIH West Coast Metabolomics Center.'}, {'ForeName': 'Angela L', 'Initials': 'AL', 'LastName': 'Linderholm', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, UCD, Sacramento, California, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Franzi', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, UCD, Sacramento, California, USA.'}, {'ForeName': 'Celeste', 'Initials': 'C', 'LastName': 'Kivler', 'Affiliation': 'Department of Respiratory Therapy, and.'}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Public Health Sciences, UCD, Davis, California, USA.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Sa', 'Affiliation': 'NIH West Coast Metabolomics Center.'}, {'ForeName': 'Zachary A', 'Initials': 'ZA', 'LastName': 'Kons', 'Affiliation': 'NIH West Coast Metabolomics Center.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Fiehn', 'Affiliation': 'NIH West Coast Metabolomics Center.'}, {'ForeName': 'Lihong', 'Initials': 'L', 'LastName': 'Qi', 'Affiliation': 'Department of Public Health Sciences, UCD, Davis, California, USA.'}, {'ForeName': 'Amir A', 'Initials': 'AA', 'LastName': 'Zeki', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, UCD, Sacramento, California, USA.'}, {'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'Kenyon', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, UCD, Sacramento, California, USA.'}]",JCI insight,['10.1172/jci.insight.137777'] 1207,31353364,Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma.,"Talimogene laherparepvec (T-VEC) has demonstrated efficacy for unresectable melanoma. We explored response patterns from a phase 2 study evaluating patients with unresectable stage IIIB-IVM1c malignant melanoma who received T-VEC plus ipilimumab or ipilimumab alone. Patients with objective response per modified irRC were evaluated for pseudo-progression (single ≥25% increase in tumour burden before response). Patients without pseudo-progression were classified by whether they responded within or after 6 months of treatment start; those with pseudo-progression were classified by whether pseudo-progression was due to increase in existing lesions or development of new lesions. Overall, 39% (n = 38/98) in the combination arm and 18% (n = 18/100) in the ipilimumab arm had an objective response. Eight responders (combination, n = 7 [18.4%]; ipilimumab, n = 1 [5.6%]) had pseudo-progression; most occurred by week 12 and were caused by an increase in existing lesions. These data reinforce use of T-VEC through initial progression when combined with checkpoint inhibitors.Trial Registration NCT01740297 (ClinicalTrials.gov; date of registration, December 4, 2012); 2012-000307-32 (ClinicalTrialsRegister.eu; date of registration, May 13, 2014).",2019,Patients with objective response per modified irRC were evaluated for pseudo-progression (single ≥25% increase in tumour burden before response).,"['metastatic unresectable melanoma', 'patients with unresectable stage IIIB-IVM1c malignant melanoma who received']","['ipilimumab or ipilimumab alone', 'Talimogene laherparepvec (T-VEC', 'T-VEC plus ipilimumab or ipilimumab alone']","['objective response', 'pseudo-progression']","[{'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0456599', 'cui_str': 'Stage 3B'}]","[{'cui': 'C1367202', 'cui_str': 'ipilimumab'}, {'cui': 'C1831828', 'cui_str': 'talimogene laherparepvec'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0205237', 'cui_str': 'False'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}]",,0.159882,Patients with objective response per modified irRC were evaluated for pseudo-progression (single ≥25% increase in tumour burden before response).,"[{'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Chesney', 'Affiliation': 'James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA. jason.chesney@louisville.edu.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Puzanov', 'Affiliation': 'Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Collichio', 'Affiliation': 'The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Mohammed M', 'Initials': 'MM', 'LastName': 'Milhem', 'Affiliation': 'University of Iowa Hospitals and Clinics, Iowa City, IA, USA.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Hauschild', 'Affiliation': 'University of Kiel, Kiel, Germany.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Anjali', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Garbe', 'Affiliation': 'University Hospital Tübingen, Tübingen, Germany.'}, {'ForeName': 'Parminder', 'Initials': 'P', 'LastName': 'Singh', 'Affiliation': 'Mayo Clinic, Phoenix, AZ, USA.'}, {'ForeName': 'Janice M', 'Initials': 'JM', 'LastName': 'Mehnert', 'Affiliation': 'Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.'}]",British journal of cancer,['10.1038/s41416-019-0530-6'] 1208,32506558,Telephone-based motivational interviewing enhanced with individualised personality-specific coping skills training for young people with alcohol-related injuries and illnesses accessing emergency or rest/recovery services: a randomized controlled trial (QuikFix).,"BACKGROUND AND AIMS Recent meta-analyses of motivational interviewing (MI) for reducing risky alcohol use in young people have reported modest effects. Few studies have targeted individual patient factors to increase MI effectiveness. This study determined if MI enhanced with individualised personality-specific coping skills training (QuikFix) was more efficacious than standard MI or an assessment feedback/information (AF/I) control among young people with alcohol-related injuries or illnesses. DESIGN AND SETTING Single-centre, single-blind, three-group superiority randomized controlled trial with 1-, 3-, 6- and 12-months follow-ups. Telephone intervention, Brisbane, Australia. PARTICIPANTS A total of 398 young people (16-25 years; M age = 20.30 years, SD = 2.12; 54% female) with alcohol-related injuries and/or illnesses were recruited from an emergency department (ED) or rest/recovery service (RRS). MEASURES The primary outcome was total standard (10 g ethanol) drinks in the past month (Timeline Follow back [TLFB]) at 12 months (primary time point). Secondary outcomes were total drinking days and standard drinks per drinking day (TLFB) in the past month and the frequency of alcohol-related problems in the past 3 months (Rutgers Alcohol Problem Index). INTERVENTIONS Young people were randomized to two sessions of QuikFix enhanced with individualised personality-specific coping skills training (n = 132), two sessions of MI (n = 136) or one session of AF/I (n = 130), all delivered by telehealth. FINDINGS QuikFix resulted in greater reductions (all P < 0.0017) in the primary outcome of total standard drinks (M = 19.50, CI 99.75% = [11.31, 27.68]) than both MI (M = 32.61, CI 99.75% = [24.82, 40.40]; Cohen's D = 0.40) and AF/I (M = 34.12, CI 99.75% = [26.59, 41.65]; D = 0.45) at 12 months (retention n = 324/398, 81%). QuikFix had greater reductions on drinking days (M = 3.16, CI 99.75% = [2.37, 3.96]) than both MI (M = 4.53, CI 99.75% = [3.57, 5.48];D = 0.38) and AF/I (M = 4.69, CI 99.75% = [3.73, 5.65];D = 0.42) and fewer drinks per drinking day (M = 5.02, CI 99.75% = [3.71, 6.33]) than AF/I (M = 7.15, CI 99.75% = [5.93, 8.38;D = 0.47) at 12 months. CONCLUSIONS Young people with alcohol-related injuries and/or illnesses who attended ED and rest/recovery services and received an individualised personality-specific coping skills training intervention (QuikFix) had greater reductions in the amount of alcohol consumed at 12 months compared with those who received motivational interviewing or an assessment feedback/information intervention.",2020,"FINDINGS QuikFix resulted in greater reductions (all p< 0.0017) in the primary outcome of total standard drinks (M=19.50, CI 99.75%=[11.31-27.68]) than both MI (M=32.61, CI 99.75%=[24.82-40.40];Cohen's D=0.40) and AF/I (M=34.12, CI 99.75%=[26.59-41.65];D=0.45) at 12 months (retention n=324/398, 81%).","['young people with alcohol-related injuries or illnesses', 'Young people with alcohol-related injuries and/or illnesses who attended emergency department and rest/recovery services', 'Young people', '398 young people (16-25 years; Mage=20.30 years, SD=2.12; 54% female) with alcohol-related injuries and/or illnesses were recruited from an emergency department (ED) or rest/recovery service (RRS', 'young people with alcohol-related injuries and illnesses accessing emergency or rest/recovery services']","['individualised personality-specific coping skills training intervention (QuikFix', 'motivational interviewing or an assessment feedback/information intervention', 'motivational interviewing (MI', 'Telephone-based motivational interviewing enhanced with individualised personality-specific coping skills training', 'MI enhanced with individualised personality-specific coping skills training (QuikFix', 'QuikFix enhanced with individualised personality-specific coping skills training']","['MI effectiveness', 'total standard drinks', 'total standard (10 grams ethanol) drinks in the past month (Timeline Followback, TLFB', 'total drinking days and standard drinks per drinking day (TLFB) in the past month and the frequency of alcohol-related problems in the past 3 months (Rutgers Alcohol Problem Index', 'drinking days']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}]","[{'cui': 'C0003944', 'cui_str': 'As If Personality'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0729375', 'cui_str': 'Coping skills training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0439208', 'cui_str': 'g'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0145943', 'cui_str': 'TimeLine'}, {'cui': 'C0556347', 'cui_str': 'Drinking day'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0549393', 'cui_str': 'Alcohol problem'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",398.0,0.107775,"FINDINGS QuikFix resulted in greater reductions (all p< 0.0017) in the primary outcome of total standard drinks (M=19.50, CI 99.75%=[11.31-27.68]) than both MI (M=32.61, CI 99.75%=[24.82-40.40];Cohen's D=0.40) and AF/I (M=34.12, CI 99.75%=[26.59-41.65];D=0.45) at 12 months (retention n=324/398, 81%).","[{'ForeName': 'Leanne', 'Initials': 'L', 'LastName': 'Hides', 'Affiliation': 'School of Psychology, National Centre for Youth Substance Use Research, The University of Queensland, St Lucia, Brisbane, Australia.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Quinn', 'Affiliation': 'School of Psychology, National Centre for Youth Substance Use Research, The University of Queensland, St Lucia, Brisbane, Australia.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Chan', 'Affiliation': 'National Centre for Youth Substance Use Research, The University of Queensland, St Lucia, Brisbane, Australia.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Cotton', 'Affiliation': 'Orygen The National Centre of Excellence in Youth Mental Health, University of Melbourne, Parkville, Melbourne, Australia.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Pocuca', 'Affiliation': 'School of Psychology, National Centre for Youth Substance Use Research, The University of Queensland, St Lucia, Brisbane, Australia.'}, {'ForeName': 'Jason P', 'Initials': 'JP', 'LastName': 'Connor', 'Affiliation': 'National Centre for Youth Substance Use Research, The University of Queensland, St Lucia, Brisbane, Australia.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Witkiewitz', 'Affiliation': 'Department of Psychology, Center on Alcoholism, Substance Abuse and Addictions (CASAA), University of New Mexico, Albuquerque, NM, USA.'}, {'ForeName': 'Mark R C', 'Initials': 'MRC', 'LastName': 'Daglish', 'Affiliation': 'Discipline of Psychiatry, Faculty of Medicine, The University of Queensland, Herston, Brisbane, Australia.'}, {'ForeName': 'Ross McD', 'Initials': 'RM', 'LastName': 'Young', 'Affiliation': 'School of Psychology and Counselling and Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Brisbane, Australia.'}, {'ForeName': 'Stoyan', 'Initials': 'S', 'LastName': 'Stoyanov', 'Affiliation': 'School of Psychology, National Centre for Youth Substance Use Research, The University of Queensland, St Lucia, Brisbane, Australia.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Kavanagh', 'Affiliation': 'School of Psychology and Counselling and Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Brisbane, Australia.'}]","Addiction (Abingdon, England)",['10.1111/add.15146'] 1209,32686435,Prophylactic HIPEC with oxaliplatin might be of benefit in T4 and perforated colon cancer: another possible interpretation of the COLOPEC results.,"The COLOPEC trial failed to show evidence for improved relapse-free survival (RFS) between the two study groups: 80,9% (95% CI 73.3-88.5) in the experimental group and 76.2 % (68.0-84.4) in the control group (one-sided log-rank p = 0.28). Nevertheless only 87 patients received the adjuvant HIPEC treatment in the experimental arm (n = 100). This group had a peritoneal relapse of 19 %, but only 10 % had a truly peritoneal relapse as 9 of them had stablished peritoneal carcinomatosis and 1 case was a peritoneal recurrence but did not receive adjuvant HIPEC. We conducted a per-protocol analysis comparing the 87 patients which truly received the adjuvant HIPEC to the 102 patients in the control arm and obtained an OR 0.396 (95 % CI 0.17-0.91) with a (Pearson Chi-Square p = 0.026, two-tailed Fisher exact test p = 0.032). This contradicts the COLOPEC reported conclusions and shows that adjuvant HIPEC could have an important protective role against peritoneal recurrence.",2020,"The COLOPEC trial failed to show evidence for improved relapse-free survival (RFS) between the two study groups: 80,9% (95% CI 73.3-88.5) in the experimental group and 76.2 % (68.0-84.4) in the control group (one-sided log-rank p = 0.28).","['T4 and perforated colon cancer', '87 patients which truly received the adjuvant HIPEC to the 102 patients in the control arm and obtained an OR 0.396', '87 patients received the']","['oxaliplatin', 'adjuvant HIPEC']","['peritoneal relapse', 'relapse-free survival (RFS', 'truly peritoneal relapse', 'peritoneal recurrence']","[{'cui': 'C0347646', 'cui_str': 'Perforation of colon'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C1868801', 'cui_str': 'Hyperthermic Intraperitoneal Chemotherapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}]","[{'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C1868801', 'cui_str': 'Hyperthermic Intraperitoneal Chemotherapy'}]","[{'cui': 'C0031153', 'cui_str': 'Peritoneum (serous membrane) structure'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",,0.173321,"The COLOPEC trial failed to show evidence for improved relapse-free survival (RFS) between the two study groups: 80,9% (95% CI 73.3-88.5) in the experimental group and 76.2 % (68.0-84.4) in the control group (one-sided log-rank p = 0.28).","[{'ForeName': 'Juan José', 'Initials': 'JJ', 'LastName': 'Segura-Sampedro', 'Affiliation': 'Cirugía General y del Aparato Digestivo, Hospital Universitario Son Espases, España.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Morales-Soriano', 'Affiliation': 'Cirugía General y del Aparato Digestivo, Hospital Universitario Son Espases.'}]",Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva,['10.17235/reed.2020.6755/2019'] 1210,32500650,Long-term health-related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer.,"BACKGROUND The long-term health-related quality of life (HRQOL) impacts of PCa screening have not been adequately evaluated. We aimed to compare the generic and disease-specific health-related quality of life (HRQOL) among men with prostate cancer in the screening arm with the control arm of the PSA-based prostate cancer screening trial in up to 15 years of follow-up. MATERIALS AND METHODS This study was conducted within population-based Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). During 1996-1999 80,458 men were randomized to the serum prostate-specific antigen (PSA) screening arm (SA, N = 32 000) and the control arm (CA, N = 48 458). Men in the screening arm were screened at 4-year intervals until 2007. HRQOL questionnaires were delivered to newly diagnosed prostate cancer patients in the screening and control arm 1996-2006 (N = 5128) at the time of diagnosis (baseline), at 3-month, 12-month and 5, 10, and 15-year follow-up. Validated UCLA Prostate Cancer Index (UCLA-PCI) and RAND 36-Item Health Survey were used for HRQOL assessment. The data were analyzed with a random effects model for repeated measures. RESULTS At baseline, men with prostate cancer in the screening arm reported better Sexual Function, as well as less Sexual and Urinary Bother. Long-term follow-up revealed slightly higher HRQOL scores in the screening arm in prostate cancer specific measures at 10-year post diagnosis, but the differences were statistically significant only in Urinary Bother (UCLA-PCI score 77.9; 95% CI 75.2 to 80.5 vs. 70.9; 95% CI 66.8 to 74.9 P = .005). The generic HRQOL scores were comparable between the trial arms. The overall differences in disease-specific or generic HRQOL scores by trial arm did not vary during the follow-up. CONCLUSION No major differences were observed in HRQOL in men with prostate cancer between the prostate cancer screening and control arms during five to 15-year follow-up.",2020,"Long-term follow-up revealed slightly higher HRQOL scores in the screening arm in prostate cancer specific measures at 10-year post diagnosis, but the differences were statistically significant only in Urinary Bother (UCLA-PCI score 77.9; 95% CI 75.2 to 80.5 vs. 70.9; 95% CI 66.8 to 74.9 P = .005).The generic HRQOL scores were comparable between the trial arms.","['Men in the screening arm were screened at 4-year intervals until 2007', 'newly diagnosed prostate cancer patients in the screening and control arm 1996-2006', 'population-based Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC', 'men with prostate cancer in the Finnish randomized study of screening for prostate cancer', 'men with prostate cancer in the screening arm with the control arm of the PSA-based prostate cancer screening trial in up to 15\xa0years of follow-up', 'During 1996-1999 80,458 men']",['serum prostate-specific antigen (PSA) screening'],"['HRQOL questionnaires', 'Validated UCLA Prostate Cancer Index (UCLA-PCI) and RAND 36-Item Health Survey', 'Urinary Bother (UCLA-PCI score', 'HRQOL', 'HRQOL scores', 'generic HRQOL scores', 'disease-specific or generic HRQOL scores', 'generic and disease-specific health-related quality of life (HRQOL', 'Sexual Function']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0016134', 'cui_str': 'Finnish language'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0278092', 'cui_str': 'Sexual function'}]",80458.0,0.0974762,"Long-term follow-up revealed slightly higher HRQOL scores in the screening arm in prostate cancer specific measures at 10-year post diagnosis, but the differences were statistically significant only in Urinary Bother (UCLA-PCI score 77.9; 95% CI 75.2 to 80.5 vs. 70.9; 95% CI 66.8 to 74.9 P = .005).The generic HRQOL scores were comparable between the trial arms.","[{'ForeName': 'Kirsi', 'Initials': 'K', 'LastName': 'Talala', 'Affiliation': 'Finnish Cancer Registry, Helsinki, Finland.'}, {'ForeName': 'Sirpa', 'Initials': 'S', 'LastName': 'Heinävaara', 'Affiliation': 'Finnish Cancer Registry, Helsinki, Finland.'}, {'ForeName': 'Kimmo', 'Initials': 'K', 'LastName': 'Taari', 'Affiliation': 'Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Teuvo L J', 'Initials': 'TLJ', 'LastName': 'Tammela', 'Affiliation': 'Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Kujala', 'Affiliation': 'Department of Pathology, Fimlab Laboratories, Tampere, Finland.'}, {'ForeName': 'Ulf-Håkan', 'Initials': 'UH', 'LastName': 'Stenman', 'Affiliation': 'Department of Clinical Chemistry and Hematology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Nea', 'Initials': 'N', 'LastName': 'Malila', 'Affiliation': 'Finnish Cancer Registry, Helsinki, Finland.'}, {'ForeName': 'Anssi', 'Initials': 'A', 'LastName': 'Auvinen', 'Affiliation': 'Faculty of Social Sciences/Health Sciences, Tampere University, Tampere, Finland.'}]",Cancer medicine,['10.1002/cam4.3181'] 1211,32497783,Study protocol: Using peer support to aid in prevention and treatment in prediabetes (UPSTART).,"BACKGROUND There is an urgent need to develop and evaluate effective and scalable interventions to prevent or delay the onset of type 2 diabetes mellitus (T2DM). METHODS In this randomized controlled pragmatic trial, 296 adults with prediabetes will be randomized to either a peer support arm or enhanced usual care. Participants in the peer support arm meet face-to-face initially with a trained peer coach who also is a patient at the same health center to receive information on locally available wellness and diabetes prevention programs, discuss behavioral goals related to diabetes prevention, and develop an action plan for the next week to meet their goals. Over six months, peer coaches call their assigned participants weekly to provide support for weekly action steps. In the final 6 months, coaches call participants at least once monthly. Participants in the enhanced usual care arm receive information on local resources and periodic updates on available diabetes prevention programs and resources. Changes in A1c, weight, waist circumference and other patient-centered outcomes and mediators and moderators of intervention effects will be assessed. RESULTS At least 296 participants and approximately 75 peer supporters will be enrolled. DISCUSSION Despite evidence that healthy lifestyle interventions can improve health behaviors and reduce risk for T2DM, engagement in recommended behavior change is low. This is especially true among racial and ethnic minority and low-income adults. Regular outreach and ongoing support from a peer coach may help participants to initiate and sustain healthy behavior changes to reduce their risk of diabetes. TRIAL REGISTRATION The ClinicalTrials.gov registration number is NCT03689530.",2020,"Changes in A1c, weight, waist circumference and other patient-centered outcomes and mediators and moderators of intervention effects will be assessed. ","['296 adults with prediabetes', 'At least 296 participants and approximately 75 peer supporters will be enrolled']","['peer support arm or enhanced usual care', 'peer support arm meet face-to-face initially with a trained peer coach who also is a patient at the same health center to receive information on locally available wellness and diabetes prevention programs, discuss behavioral goals related to diabetes prevention, and develop an action plan']","['Changes in A1c, weight, waist circumference', 'health behaviors']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}]","[{'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C1273866', 'cui_str': 'Action plan (community)'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",296.0,0.0609549,"Changes in A1c, weight, waist circumference and other patient-centered outcomes and mediators and moderators of intervention effects will be assessed. ","[{'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Heisler', 'Affiliation': 'Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States of America; VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, United States of America. Electronic address: mheisler@umich.edu.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Kullgren', 'Affiliation': 'Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States of America; VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, United States of America; Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, MI, United States of America; University of Michigan Institute for Healthcare Policy and Innovation, Ann Arbor, MI, United States of America. Electronic address: jkullgre@med.umich.edu.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Richardson', 'Affiliation': 'Department of Family Medicine, University of Michigan Medical School, Ann Arbor, MI, United States of America. Electronic address: caroli@umich.edu.'}, {'ForeName': 'Shelley', 'Initials': 'S', 'LastName': 'Stoll', 'Affiliation': 'Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States of America. Electronic address: scstoll@umich.edu.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Alvarado Nieves', 'Affiliation': 'University of Michigan, Department of Internal Medicine- Metabolism, Endocrinology and Diabetes, United States of America. Electronic address: alvaradc@med.umich.edu.'}, {'ForeName': 'Deanne', 'Initials': 'D', 'LastName': 'Wiley', 'Affiliation': 'Kaiser Permanente Northern California, United States of America. Electronic address: deanne.wiley@kp.org.'}, {'ForeName': 'Tali', 'Initials': 'T', 'LastName': 'Sedgwick', 'Affiliation': 'Kaiser Permanente Northern California Division of Research, United States of America. Electronic address: Tali.S.Sedgwick@kp.org.'}, {'ForeName': 'Alyce', 'Initials': 'A', 'LastName': 'Adams', 'Affiliation': 'Kaiser Permanente Northern California, United States of America. Electronic address: Alyce.S.Adams@kp.org.'}, {'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'Hedderson', 'Affiliation': 'Kaiser Permanente Northern California, United States of America. Electronic address: Monique.m.hedderson@kp.org.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Kim', 'Affiliation': 'The Permanente Medical Group (Kaiser Permanente, Northern California), United States of America. Electronic address: Eileen.Kim@kp.org.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Rao', 'Affiliation': 'The Permanente Medical Group (Kaiser Permanente, Northern California), United States of America. Electronic address: megan.rao@kp.org.'}, {'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Schmittdiel', 'Affiliation': 'Kaiser Permanente Northern California Division of Research, United States of America. Electronic address: Julie.A.Schmittdiel@kp.org.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106048'] 1212,32506498,Negative-pressure wound therapy does not reduce superficial SSI in pancreatectomy and hepatectomy procedures.,"INTRODUCTION Surgical site infections (SSIs) lead to increased morbidity and cost. Negative-pressure wound therapy (NPWT) removes wound exudate and improves local blood flow, but its effect on SSI is unproven following hepatectomy and pancreatectomy. The aim of this trial was to evaluate the effect of NPWT on SSI in this population. METHODS Patients were randomized to incisional NPWT or sterile island dressing following surgery. SSI predictive factors were recorded as well as patient comorbidities. Wound complications and type of SSI were recorded prospectively. RESULTS Forty patients received the standardized perioperative bundle. Twenty patients received sterile island: 11 hepatic and 9 pancreatic resections; 20 patients received NPWT: 11 hepatic and 9 pancreatic resections; 23 patients were male; mean age 60.8 years (SD ±10.3); mean BMI 31.7 (SD ±7.0). There were three incisional wound infections: two with sterile island, one with NPWT; six organ space infections: four sterile island and two NPWT. There were no significant differences in SSI rates between groups (P = .57). CONCLUSION NPWT does not improve SSI rates over simple sterile dressing following hepatectomy or pancreatectomy. Improvements in SSI must be directed toward organ-space infections, which are unaffected by NPWT.",2020,"There were no significant differences in SSI rates between groups (P = .57). ","['Twenty patients received sterile island: 11 hepatic and 9 pancreatic resections; 20 patients received NPWT: 11 hepatic and 9 pancreatic resections; 23 patients were male; mean age 60.8 years (SD ±10.3); mean BMI 31.7 (SD ±7.0', 'Forty patients received the standardized perioperative bundle', 'Patients']","['Negative-pressure wound therapy', 'NPWT', 'Negative-pressure wound therapy (NPWT', 'incisional NPWT or sterile island dressing following surgery']","['incisional wound infections', 'SSI rates', 'superficial SSI', 'Wound complications and type of SSI', 'local blood flow', 'SSI predictive factors']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021359', 'cui_str': 'Sterility'}, {'cui': 'C0022130', 'cui_str': 'Island'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0854522', 'cui_str': 'Pancreatic resection'}, {'cui': 'C1956078', 'cui_str': 'Topical Negative-Pressure Therapy'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4708784', 'cui_str': '31.7'}]","[{'cui': 'C1956078', 'cui_str': 'Topical Negative-Pressure Therapy'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0021359', 'cui_str': 'Sterility'}, {'cui': 'C0022130', 'cui_str': 'Island'}, {'cui': 'C0013119', 'cui_str': 'Medical dressing'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0043241', 'cui_str': 'Local infection of wound'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}]",23.0,0.083828,"There were no significant differences in SSI rates between groups (P = .57). ","[{'ForeName': 'Conor H', 'Initials': 'CH', 'LastName': ""O'Neill"", 'Affiliation': 'Hiram Polk Jr. MD, Department of Surgery, Division of Surgical Oncology, University of Louisville, Louisville, Kentucky.'}, {'ForeName': 'Robert C G', 'Initials': 'RCG', 'LastName': 'Martin', 'Affiliation': 'Hiram Polk Jr. MD, Department of Surgery, Division of Surgical Oncology, University of Louisville, Louisville, Kentucky.'}]",Journal of surgical oncology,['10.1002/jso.25980'] 1213,32505866,"Compared to Facebook, Instagram use causes more appearance comparison and lower body satisfaction in college women.","The current experiment tested the effect of social media use on college women's appearance comparisons, mood, and body satisfaction. We randomly assigned 308 undergraduate women (aged 18-26) to use Facebook, use Instagram, or play a matching game (the control condition) on an iPad for seven minutes. Compared to the Facebook condition, Instagram users retrospectively reported spending more time viewing images or videos containing people. Participants in both the Facebook and Instagram conditions also retrospectively reported engaging in more appearance comparisons relative to those in the control condition, but Instagram users reported significantly more appearance comparisons than those in the Facebook condition. Those who used Instagram, but not Facebook, showed decreased body satisfaction, decreased positive affect, and increased negative affect. Results are consistent with previous research suggesting social media use influences body satisfaction and social comparison, and that Instagram may be a particularly harmful platform when it comes to body image because of its focus on photos over text.",2020,"Those who used Instagram, but not Facebook, showed decreased body satisfaction, decreased positive affect, and increased negative affect.","[""college women's"", '308 undergraduate women (aged 18-26) to use', 'college women']","['Facebook, use Instagram, or play a matching game (the control condition']","['body satisfaction', 'appearance comparisons, mood, and body satisfaction']","[{'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0026516', 'cui_str': 'Mood'}]",308.0,0.0383295,"Those who used Instagram, but not Facebook, showed decreased body satisfaction, decreased positive affect, and increased negative affect.","[{'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Engeln', 'Affiliation': 'Department of Psychology, Northwestern University, United States. Electronic address: rengeln@northwestern.edu.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Loach', 'Affiliation': 'Department of Psychology, Northwestern University, United States.'}, {'ForeName': 'Megan N', 'Initials': 'MN', 'LastName': 'Imundo', 'Affiliation': 'Department of Psychology, University of California, Los Angeles, United States.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Zola', 'Affiliation': 'Oxford Internet Institute, University of Oxford, United Kingdom.'}]",Body image,['10.1016/j.bodyim.2020.04.007'] 1214,32418886,Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.,"BACKGROUND The ALEX study demonstrated significantly improved progression-free survival (PFS) with alectinib versus crizotinib in treatment-naive ALK-positive non-small-cell lung cancer (NSCLC) at the primary data cut-off (9 February 2017). We report mature PFS (cut-off: 30 November 2018) and overall survival (OS) data up to 5 years (cut-off: 29 November 2019). PATIENTS AND METHODS Patients with stage III/IV ALK-positive NSCLC were randomized to receive twice-daily alectinib 600 mg (n = 152) or crizotinib 250 mg (n = 151) until disease progression, toxicity, withdrawal or death. Primary end point: investigator-assessed PFS. Secondary end points included objective response rate, OS and safety. RESULTS Mature PFS data showed significantly prolonged investigator-assessed PFS with alectinib [hazard ratio (HR) 0.43, 95% confidence interval (CI) 0.32-0.58; median PFS 34.8 versus 10.9 months crizotinib]. Median duration of OS follow-up: 48.2 months alectinib, 23.3 months crizotinib. OS data remain immature (37% of events). Median OS was not reached with alectinib versus 57.4 months with crizotinib (stratified HR 0.67, 95% CI 0.46-0.98). The 5-year OS rate was 62.5% (95% CI 54.3-70.8) with alectinib and 45.5% (95% CI 33.6-57.4) with crizotinib, with 34.9% and 8.6% of patients still on study treatment, respectively. The OS benefit of alectinib was seen in patients with central nervous system metastases at baseline [HR 0.58 (95% CI 0.34-1.00)] and those without [HR 0.76 (95% CI 0.45-1.26)]. Median treatment duration was longer with alectinib (28.1 versus 10.8 months), and no new safety signals were observed. CONCLUSIONS Mature PFS data from ALEX confirmed significant improvement in PFS for alectinib over crizotinib in ALK-positive NSCLC. OS data remain immature, with a higher 5-year OS rate with alectinib versus crizotinib. This is the first global randomized study to show clinically meaningful improvement in OS for a next-generation tyrosine kinase inhibitor versus crizotinib in treatment-naive ALK-positive NSCLC. CLINICAL TRIALS NUMBER NCT02075840.",2020,"The 5-year OS rate was 62.5% (95% CI 54.3-70.8) with alectinib and 45.5% (95% CI 33.6-57.4) with crizotinib, with 34.9% and 9.3% of patients still on study treatment, respectively.","['patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study', 'patients with central nervous system metastases at baseline (HR 0.58', 'Patients with stage III/IV ALK-positive NSCLC']","['twice-daily alectinib 600 mg (n = 152) or crizotinib', 'alectinib versus crizotinib']","['overall survival (OS) data', 'Median duration of OS', 'Median OS', 'Updated overall survival and final progression-free survival data', 'Median treatment duration', 'objective response rate, OS and safety', '5-year OS rate', 'progression-free survival (PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1663627', 'cui_str': 'ALK protein, human'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0279130', 'cui_str': 'CNS metastases'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C4517463', 'cui_str': '0.58'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}]","[{'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C3853921', 'cui_str': 'alectinib'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C2974289', 'cui_str': 'crizotinib'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0444921', 'cui_str': 'Duration of treatment'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",,0.315613,"The 5-year OS rate was 62.5% (95% CI 54.3-70.8) with alectinib and 45.5% (95% CI 33.6-57.4) with crizotinib, with 34.9% and 9.3% of patients still on study treatment, respectively.","[{'ForeName': 'T', 'Initials': 'T', 'LastName': 'Mok', 'Affiliation': 'State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Shatin, NT, Hong Kong.'}, {'ForeName': 'D R', 'Initials': 'DR', 'LastName': 'Camidge', 'Affiliation': 'University of Colorado, Denver, USA.'}, {'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Gadgeel', 'Affiliation': 'Department of Internal Medicine, Rogel Cancer Center/University of Michigan, Ann Arbor, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Rosell', 'Affiliation': 'Catalan Institute of Oncology, Barcelona, Spain.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Dziadziuszko', 'Affiliation': 'Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.'}, {'ForeName': 'D-W', 'Initials': 'DW', 'LastName': 'Kim', 'Affiliation': 'Seoul National University Hospital, Seoul, South Korea.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Pérol', 'Affiliation': 'Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.'}, {'ForeName': 'S-H I', 'Initials': 'SI', 'LastName': 'Ou', 'Affiliation': 'Chao Family Comprehensive Cancer Center, University of California, Irvine, USA.'}, {'ForeName': 'J S', 'Initials': 'JS', 'LastName': 'Ahn', 'Affiliation': 'Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'A T', 'Initials': 'AT', 'LastName': 'Shaw', 'Affiliation': 'Massachusetts General Hospital, Boston, USA.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Bordogna', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Smoljanović', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Hilton', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Ruf', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Noé', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Peters', 'Affiliation': 'Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. Electronic address: solange.peters@chuv.ch.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2020.04.478'] 1215,32500675,Patient-controlled subcutaneous analgesia using sufentainil or morphine in home care treatment in patients with stage III-IV cancer: A multi-center randomized controlled clinical trial.,"PURPOSE Patient-controlled subcutaneous analgesia (PCSA) with sufentanil is an alternative analgesia strategy in patients with stage III-IV cancer; however, its efficacy and safety have not been fully investigated. METHODS From May 10, 2017 to November 10, 2017, 120 patients with stage III-IV cancer suffering from moderate to severe pain were prospectively enrolled from six hospitals and randomized to receive PCSA with morphine (control group) or sufentanil (intervention group). Before the PCSA and on days 1, 3, 7, 14, 28, and 56 after treatment, the numeric rating scale (NRS) and 36-item Short Form health survey (SF-36) were completed for each patient and the side effects were also recorded. RESULTS No significant differences (P > .05) were observed in the preoperative NRS score and the SF-36 parameters between the two groups. Patients in the intervention group achieved better pain relief, as indicated by lower NRS scores at days 14 (P = .040), 28 (P < .001), and 56 (P < .001) after PCSA device implantation (vs control group). Furthermore, the patients in the intervention group also achieved a better life quality, as indicated by the physical role, general health, social function body pain, and mental health scores. Finally, the patients receiving sufentanil showed lower levels of nausea and somnolence than those in the control group. CONCLUSION PCSA with sufentanil achieves better pain control and life quality as well as fewer adverse reactions in stage III-IV cancer patients with pain and may be a promising pain management in these patients. TRIAL REGISTRATION This study was registered at chictr.org.cn with the trial number: ChiCTR-IPR-17011280.",2020,No significant differences (P > .05) were observed in the preoperative NRS score and the SF-36 parameters between the two groups.,"['From May 10, 2017 to November 10, 2017, 120 patients with stage III-IV cancer suffering from moderate to severe pain', 'stage III-IV cancer patients with pain', 'patients with stage III-IV cancer']","['PCSA with sufentanil', 'sufentanil', 'sufentainil or morphine', 'PCSA with morphine (control group) or sufentanil']","['nausea and somnolence', 'preoperative NRS score and the SF-36 parameters', 'pain relief', 'numeric rating scale (NRS) and 36-item Short Form health survey (SF-36', 'physical role, general health, social function body pain, and mental health scores', 'adverse reactions', 'life quality', 'pain control and life quality', 'lower NRS scores']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]","[{'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0205251', 'cui_str': 'Low'}]",120.0,0.118879,No significant differences (P > .05) were observed in the preoperative NRS score and the SF-36 parameters between the two groups.,"[{'ForeName': 'Cheng-Fu', 'Initials': 'CF', 'LastName': 'Wan', 'Affiliation': 'Pain Department of the First Affiliated Hospital, China Medical University, Shenyang, China.'}, {'ForeName': 'Qing-Zhu', 'Initials': 'QZ', 'LastName': 'Meng', 'Affiliation': 'Pain Department of the Central Hospital of Haicheng city, Anshan, China.'}, {'ForeName': 'Yan-Wei', 'Initials': 'YW', 'LastName': 'Wang', 'Affiliation': ""Pain Department of the Third People's Hospital of Anshan city, Anshan, China.""}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Qi', 'Affiliation': 'Pain Department of the Central Hospital of Fuxin city, Fuxin, China.'}, {'ForeName': 'Chang-Liang', 'Initials': 'CL', 'LastName': 'Ai', 'Affiliation': ""Pain Department of the Women and Children's Hospital of Dandong city, Dandong, China.""}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Sui', 'Affiliation': 'Pain Department of the Central Hospital of Kuandian city, Dandong, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Song', 'Affiliation': 'Pain Department of the First Affiliated Hospital, China Medical University, Shenyang, China.'}]",Cancer medicine,['10.1002/cam4.3194'] 1216,32497520,"39·0°C versus 38·5°C ear temperature as fever limit in children with neutropenia undergoing chemotherapy for cancer: a multicentre, cluster-randomised, multiple-crossover, non-inferiority trial.","BACKGROUND Fever in neutropenia is the most frequent complication of chemotherapy for cancer. The temperature limit defining fever used clinically varies. A higher limit can avoid unnecessary diagnoses in patients spontaneously recovering from fever. This trial primarily aimed to determine if a limit of 39·0°C ear temperature is non-inferior to 38·5°C regarding safety. METHODS This cluster-randomised, multiple crossover, non-blinded, non-inferiority trial was done in six Swiss Paediatric Oncology Group centres (clusters) in Switzerland. Patients (aged 1 to <18 years) with any malignancy and treated with myelosuppressive chemotherapy expected to last 2 months or more were repeatedly randomly assigned (1:1), at the cluster level, to either monthly 39·0°C or 38·5°C ear temperature limits for diagnosis of fever in neutropenia. Diagnosis below the randomised limit was allowed for clinical reasons. Such a diagnosis implied emergency hospitalisation, examinations (including blood culture), as-needed antipyretics, and empirical intravenous broad-spectrum antibiotics. The primary outcome was the rate of fever in neutropenia with safety relevant events (SRE) per chemotherapy year; we also assessed efficacy in terms of rate of fever in neutropenia. The non-inferiority margin was 1·33 for safety, and for effiacy, the superiority margin was 1·00. This trial is registered at ClinicalTrials.gov, number NCT02324231. FINDINGS 269 patients were recruited between April 28, 2016, to Aug 27, 2018, until the trial was stopped for success after the second interim analysis. Patients were repeatedly randomly assigned, with 1210 (48%) of 2547 randomisation periods and 92 (47%) of 195 chemotherapy years randomised to 39·0°C. SREs were diagnosed in 72 (20%) of 360 fever in neutropenia episodes (zero deaths, 16 intensive care unit admissions, 22 cases of severe sepsis, and 56 cases of bacteraemia). In 92 chemotherapy years randomised to the 39·0°C fever limit, 151 episodes of fever with neutropenia were diagnosed (1·64 per year), including 22 (15%) with SRE (0·24 per year). In 103 chemotherapy years randomised to 38·5°C, 209 episodes were diagnosed (2·03 per year), including 50 (24%) with SRE (0·49 per year). The mixed Poisson regression rate ratio (RR) of fever in neutropenia with SRE in 39·0°C versus 38·5°C was 0·56 (95% upper confidence bound 0·72). The corresponding RR of fever in neutropenia was 0·83 (95% upper confidence bound 0·98). INTERPRETATION In children with neutropenia and chemotherapy for cancer, 39·0°C ear temperature was safe and seemed efficacious. For Switzerland and comparable settings, 39·0°C can be recommended as new evidence-based standard fever limit except for patients with acute myeloid leukaemia or haematopoietic stem cell transplantation. FUNDING Swiss Cancer League (KLS-3645-02-2015).",2020,The corresponding RR of fever in neutropenia was 0·83,"['patients spontaneously recovering from fever', 'children with neutropenia undergoing chemotherapy for cancer', '269 patients were recruited between April 28, 2016, to Aug 27, 2018, until the trial was stopped for success after the second interim analysis', '103 chemotherapy years randomised to 38·5', 'six Swiss Paediatric Oncology Group centres (clusters) in Switzerland', 'patients with acute myeloid leukaemia or haematopoietic stem cell transplantation', 'Patients (aged 1 to <18 years) with any malignancy and treated with myelosuppressive chemotherapy expected to last 2 months or more were repeatedly randomly assigned (1:1), at the cluster level, to either monthly 39·0°C or 38·5']",[],"['rate of fever in neutropenia', 'fever with neutropenia', 'mixed Poisson regression rate ratio (RR) of fever in neutropenia with SRE', 'SREs', 'corresponding RR of fever in neutropenia', 'rate of fever in neutropenia with safety relevant events (SRE']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521108', 'cui_str': 'Recovering from'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0450446', 'cui_str': 'Stops'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0241315', 'cui_str': 'Swiss'}, {'cui': 'C1518931', 'cui_str': 'Pediatric oncology'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}, {'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}, {'cui': 'C0018956', 'cui_str': 'Hematopoietic stem cell'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",[],"[{'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0684321', 'cui_str': 'Regression - mental defense mechanism'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",269.0,0.380971,The corresponding RR of fever in neutropenia was 0·83,"[{'ForeName': 'Christa', 'Initials': 'C', 'LastName': 'Koenig', 'Affiliation': 'Pediatric Hematology and Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Bodmer', 'Affiliation': ""Pediatric Oncology, University Children's Hospital of Zürich, University of Zürich, Zürich, Switzerland.""}, {'ForeName': 'Philipp K A', 'Initials': 'PKA', 'LastName': 'Agyeman', 'Affiliation': 'Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Niggli', 'Affiliation': ""Pediatric Oncology, University Children's Hospital of Zürich, University of Zürich, Zürich, Switzerland.""}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Adam', 'Affiliation': 'Unit of Pediatric Hematology-Oncology, Woman-Mother-Child Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Ansari', 'Affiliation': 'Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Hospital of Geneva, Geneva, Switzerland; Department of Paediatrics, CANSEARCH Research Laboratory, Faculty of Medicine, University of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Eisenreich', 'Affiliation': ""Department of Pediatric Oncology and Hematology, Children's Hospital Lucerne, Lucerne, Switzerland.""}, {'ForeName': 'Nanette', 'Initials': 'N', 'LastName': 'Keller', 'Affiliation': 'Pediatric Hematology and Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Leibundgut', 'Affiliation': 'Pediatric Hematology and Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Nadal', 'Affiliation': ""Pediatric Oncology, University Children's Hospital of Zürich, University of Zürich, Zürich, Switzerland.""}, {'ForeName': 'Jochen', 'Initials': 'J', 'LastName': 'Roessler', 'Affiliation': 'Pediatric Hematology and Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Scheinemann', 'Affiliation': ""Division of Pediatric Hematology and Oncology, Department of Pediatrics, Kantonsspital Aarau, Aarau, Switzerland; Division of Pediatric Hematology and Oncology, University Children's Hospital Basel, University of Basel, Basel, Switzerland; Department of Pediatrics, McMaster Children's Hospital and McMaster University, Hamilton, ON, Canada.""}, {'ForeName': 'Arne', 'Initials': 'A', 'LastName': 'Simon', 'Affiliation': ""Department of Pediatric Hematology and Oncology, Children's Hospital Medical Centre, University Hospital of Saarland, Homburg, Germany.""}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Teuffel', 'Affiliation': 'University of Tuebingen, Tuebingen, Germany; Division of Oncology, Medical Services of the Statutory Health Insurance, Baden-Wuerttemberg, Germany.'}, {'ForeName': 'Nicolas X', 'Initials': 'NX', 'LastName': 'von der Weid', 'Affiliation': ""Division of Pediatric Hematology and Oncology, University Children's Hospital Basel, University of Basel, Basel, Switzerland.""}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Zeller', 'Affiliation': 'Swiss Paediatric Oncology Group, Coordinating Centre, Bern, Switzerland.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Zimmermann', 'Affiliation': ""Children's Research Centre, University Children's Hospital of Zürich, University of Zürich, Zürich, Switzerland; Department Public Health-Nursing Science, Faculty of Medicine, University Basel, Basel, Switzerland.""}, {'ForeName': 'Roland A', 'Initials': 'RA', 'LastName': 'Ammann', 'Affiliation': 'Pediatric Hematology and Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address: roland.ammann@insel.ch.'}]",The Lancet. Child & adolescent health,['10.1016/S2352-4642(20)30092-4'] 1217,32506275,"Preoperative meloxicam versus postoperative meloxicam for pain control, patients' satisfaction and function recovery in hip osteoarthritis patients who receive total hip arthroplasty: a randomized, controlled study.","This study aimed to compare the analgesic effect, patients' satisfaction, tolerance and hip-joint function recovery by preoperative meloxicam versus postoperative meloxicam in treating hip osteoarthritis (OA) patients receiving total hip arthroplasty (THA). 132 hip OA patients who underwent THA surgery were allocated into postoperative analgesia (POST) and preoperative analgesia (PRE) groups at a 1:1 ratio. In the PRE group, patients took meloxicam 15 mg at 24 h pre-operation, 7.5 mg at 4 h, 24 h, 48 h and 72 h post-operation; in the POST group, patients received meloxicam 15 mg at 4 h post-operation, then 7.5 mg at 24 h, 48 h and 72 h post-operation. Furthermore, postoperative pain, consumption of patient-controlled analgesia (PCA), overall satisfaction and adverse events were evaluated within 96 h post-operation; meanwhile, Harris hip score was assessed within 6 months post-operation. Pain VAS at rest at 6 h, 12 h, 24 h, and pain VAS at passive movement at 6 h, 12 h were decreased in PRE group compared to POST group. In addition, additional consumption of PCA and the total consumption of PCA were both reduced in PRE group compared to POST group. Additionally, overall satisfaction in PRE group was higher at 24 h, 48 h and 72 h compared to POST group. While Harris hip score was of no difference between POST group and PRE group at M3 or M6. Besides, no difference in adverse events incidence was found between the two groups. In conclusion, preoperative meloxicam achieves better efficacy and similar tolerance compared to postoperative meloxicam in hip OA patients post THA.",2020,"In addition, additional consumption of PCA and the total consumption of PCA were both reduced in PRE group compared to POST group.","['hip osteoarthritis patients who receive total hip arthroplasty', '132 hip OA patients who underwent THA surgery', 'treating hip osteoarthritis (OA) patients receiving total hip arthroplasty (THA']","['postoperative analgesia (POST) and preoperative analgesia (PRE', 'meloxicam 15\xa0mg at 4\xa0h post-operation', 'meloxicam', 'Preoperative meloxicam versus postoperative meloxicam', 'meloxicam versus postoperative meloxicam']","['overall satisfaction', 'total consumption of PCA', 'Pain VAS', 'efficacy and similar tolerance', 'adverse events incidence', 'pain VAS at passive movement', ""analgesic effect, patients' satisfaction, tolerance and hip-joint function recovery"", 'Furthermore, postoperative pain, consumption of patient-controlled analgesia (PCA), overall satisfaction and adverse events']","[{'cui': 'C0029410', 'cui_str': 'Osteoarthritis of hip'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C1128682', 'cui_str': 'meloxicam 15 MG'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0083381', 'cui_str': 'meloxicam'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0078944', 'cui_str': 'Patient controlled analgesia'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0079991', 'cui_str': 'Passive movement'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019558', 'cui_str': 'Hip joint structure'}, {'cui': 'C0599766', 'cui_str': 'Recovery of Function'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}]",132.0,0.0274409,"In addition, additional consumption of PCA and the total consumption of PCA were both reduced in PRE group compared to POST group.","[{'ForeName': 'Lingyun', 'Initials': 'L', 'LastName': 'Ren', 'Affiliation': ""Department of Anesthesiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26, Shengli Street, Wuhan, 430014, People's Republic of China.""}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Meng', 'Affiliation': ""Department of Anesthesiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26, Shengli Street, Wuhan, 430014, People's Republic of China.""}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Yan', 'Affiliation': ""Department of Anesthesiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26, Shengli Street, Wuhan, 430014, People's Republic of China. haodunye9398649@163.com.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Sun', 'Affiliation': ""Department of Anesthesiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26, Shengli Street, Wuhan, 430014, People's Republic of China.""}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Yao', 'Affiliation': ""Department of Anesthesiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26, Shengli Street, Wuhan, 430014, People's Republic of China.""}]",Inflammopharmacology,['10.1007/s10787-020-00718-2'] 1218,32512184,"Accelerated iTBS treatment applied to the left DLPFC in depressed patients results in a rapid volume increase in the left hippocampal dentate gyrus, not driven by brain perfusion.","BACKGROUND Accelerated intermittent Theta Burst Stimulation (aiTBS) has been shown to be an effective antidepressant treatment. Although neurobiological changes shortly after this intervention have been reported, whether aiTBS results in structural brain changes must still be determined. Furthermore, it possible that rapid volumetric changes are driven by factors other than neurotrophic processes. OBJECTIVES We examined whether possible grey matter volumetric (GMV) increases after aiTBS treatment could be driven by increased brain perfusion, measured by Arterial Spin Labeling (ASL). METHODS 46 treatment-resistant depressed patients were randomized to receive 20 sessions of active or sham iTBS applied to the left dorsolateral prefrontal cortex. All sessions were delivered over 4 days at 5 sessions per day (trial registration: http://clinicaltrials.gov/show/NCT01832805). Patients were scanned the day before starting stimulation and three days after aiTBS. RESULTS There was a significant cluster of increased left hippocampal GMV in the dentate gyrus related to HRSD changes after active aiTBS, but not after sham stimulation. These GMV increases became more pronounced when accounting for changes in cerebral perfusion. CONCLUSIONS Active, but not sham, aiTBS, resulted in acute volumetric changes in parts of the left dentate gyrus, suggesting a connection with adult neurogenesis. Furthermore, taking cerebral perfusion measurements into account impacts on detection of the GMV changes. Whether these hippocampal volumetric changes produced by active aiTBS are necessary for long-term clinical improvement remains to be determined.",2020,"There was a significant cluster of increased left hippocampal GMV in the dentate gyrus related to HRSD changes after active aiTBS, but not after sham stimulation.",['46 treatment-resistant depressed patients'],"['Accelerated intermittent Theta Burst Stimulation (aiTBS', '20 sessions of active or sham iTBS']","['Arterial Spin Labeling (ASL', 'left hippocampal GMV']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0445383', 'cui_str': 'Volumetric'}]",46.0,0.102893,"There was a significant cluster of increased left hippocampal GMV in the dentate gyrus related to HRSD changes after active aiTBS, but not after sham stimulation.","[{'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Baeken', 'Affiliation': 'Ghent University, Department of Psychiatry and Medical Psychology, Ghent Experimental Psychiatry (GHEP) Lab, Ghent, Belgium; Vrije Universiteit Brussel (VUB), Department of Psychiatry, Universitair Ziekenhuis Brussel (UZBrussel), Laarbeeklaan 101, 1090, Brussels, Belgium; Eindhoven University of Technology, Department of Electrical Engineering, Eindhoven, the Netherlands.'}, {'ForeName': 'GuoRong', 'Initials': 'G', 'LastName': 'Wu', 'Affiliation': 'Key Laboratory of Cognition and Personality, Faculty of Psychology, Southwest University, Chongqing, China. Electronic address: guorongwu@swu.edu.cn.'}, {'ForeName': 'Harold A', 'Initials': 'HA', 'LastName': 'Sackeim', 'Affiliation': 'Columbia University, Department of Psychiatry, New York, NY, USA; Columbia University, Department of Radiology, New York, NY, USA.'}]",Brain stimulation,['10.1016/j.brs.2020.05.015'] 1219,32512234,Oxygen supplementation increases the total work and muscle damage markers but reduces the inflammatory response in COPD patients.,"INTRODUCTION Oxygen supplementation (O 2 -Suppl) is recommended for pulmonary rehabilitation with higher exercise intensities. However, high-intensity exercise tends toward muscle damage and a greater inflammatory response. We aimed to investigate the effect of O 2 -Suppl during exercise test (EET) on CRP level and muscle damage (CPK, LDH, lactate) in non-hypoxemic COPD patients. METHODS Eleven non-depleted patients with COPD (FEV 1 65.5 ± 4.3 %) performed two EET (room-air or O 2 -Suppl-100 %), through a blind, randomized, and placebo-controlled crossover design. CPK, LDH and CRP were measured before, immediately after and 24 h after EET. RESULTS Exercise time was higher with O 2 -Suppl (49.9 ± 37.3 %; p = 0.001) and increases in CPK and LDH were observed compared to basal values in the O 2 -Suppl (28.4UI/L and 28.3 UI/L). The O 2 -Suppl protocol resulted in a lower increase in CRP (92.1 ± 112.4 % vs. 400.1 ± 384.9 %; p = 0.003). CONCLUSIONS O 2 -Suppl increases exercise-tolerance, resulting in increased muscle injury markers in COPD. However, oxygen supplementation attenuates the inflammatory response, even upon increased physical exercise.",2020,"RESULTS Exercise time was higher with O 2 -Suppl (49.9 ± 37.3%; p = 0.001) and increases in CPK and LDH were observed compared to basal values in the O 2 -Suppl (28.4UI/L and 28.3 UI/L).","['Eleven non-depleted patients with COPD (FEV 1 65.5\u2009±\u20094.3%) performed two EET (room-air or O 2 -Suppl-100', 'COPD patients', 'non-hypoxemic COPD patients']","['oxygen supplementation', 'Oxygen supplementation (O 2 -Suppl', 'O 2 -Suppl during exercise test (EET', 'Oxygen supplementation', 'placebo']","['Exercise time', 'CRP', 'CPK and LDH', 'CPK, LDH and CRP', 'total work and muscle damage markers', 'physical exercise', 'exercise-tolerance', 'CRP level and muscle damage (CPK, LDH, lactate', 'inflammatory response']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C4517759', 'cui_str': '4.3'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C1704407', 'cui_str': '100'}]","[{'cui': 'C0919655', 'cui_str': 'Oxygen supplementation'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0587107', 'cui_str': 'During exercise'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439587', 'cui_str': 'Exercise time'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0022917', 'cui_str': 'Lactate dehydrogenase'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage NOS'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}]",11.0,0.185322,"RESULTS Exercise time was higher with O 2 -Suppl (49.9 ± 37.3%; p = 0.001) and increases in CPK and LDH were observed compared to basal values in the O 2 -Suppl (28.4UI/L and 28.3 UI/L).","[{'ForeName': 'Daniela Rodrigues', 'Initials': 'DR', 'LastName': 'Andrade', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Kelly Critine', 'Initials': 'KC', 'LastName': 'Pinto', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Julia Sampel', 'Initials': 'JS', 'LastName': 'de Castro', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Daniela Kuguimoto', 'Initials': 'DK', 'LastName': 'Andaku', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Viviani Aparecida', 'Initials': 'VA', 'LastName': 'Lara', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Fabio Augusto', 'Initials': 'FA', 'LastName': 'de Luca', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Gun', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Felipe Augusto Rodrigues', 'Initials': 'FAR', 'LastName': 'Mendes', 'Affiliation': 'Department of Physiotherapy, Ibirapuera University (UNIB), São Paulo, Brazil.'}, {'ForeName': 'Mayron F', 'Initials': 'MF', 'LastName': 'Oliveira', 'Affiliation': 'Pulmonary Function and Clinical Exercise Physiology Unit (SEFICE), Respiratory Division, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil; VO2Care Research Group, Research Physiotherapy Coordinator of Vila Nova Star Hospital, São Paulo, SP, Brazil.'}, {'ForeName': 'Wladimir Musetti', 'Initials': 'WM', 'LastName': 'Medeiros', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil; Department of Physiotherapy, Ibirapuera University (UNIB), São Paulo, Brazil; Pulmonary Function and Clinical Exercise Physiology Unit (SEFICE), Respiratory Division, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil; HEART - Institute of Cardiology, Department of Education and Research, São Paulo, Brazil. Electronic address: wmusettimedeiros@hotmail.com.'}]",Respiratory physiology & neurobiology,['10.1016/j.resp.2020.103475'] 1220,32513646,Development and Preliminary Evaluation of the Effects of an mHealth Web-Based Platform (HappyAir) on Adherence to a Maintenance Program After Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease: Randomized Controlled Trial.,"BACKGROUND Pulmonary rehabilitation is one of the main interventions to reduce the use of health resources, and it promotes a reduction in chronic obstructive pulmonary disease (COPD) costs. mHealth systems in COPD aim to improve adherence to maintenance programs after pulmonary rehabilitation by promoting the change in attitude and behavior necessary for patient involvement in the management of the disease. OBJECTIVE This study aimed to assess the effects of an integrated care plan based on an mHealth web-based platform (HappyAir) on adherence to a 1-year maintenance program applied after pulmonary rehabilitation in COPD patients. METHODS COPD patients from three hospitals were randomized to a control group or an intervention group (HappyAir group). Patients from both groups received an 8-week program of pulmonary rehabilitation and educational sessions about their illness. After completion of the process, only the HappyAir group completed an integrated care plan for 10 months, supervised by an mHealth system and therapeutic educator. The control group only underwent the scheduled check-ups. Adherence to the program was rated using a respiratory physiotherapy adherence self-report (CAP FISIO) questionnaire. Other variables analyzed were adherence to physical activity (Morisky-Green Test), quality of life (Chronic Obstructive Pulmonary Disease Assessment Test, St. George's Respiratory Questionnaire, and EuroQOL-5D), exercise capacity (6-Minute Walk Test), and lung function. RESULTS In total, 44 patients were recruited and randomized in the control group (n=24) and HappyAir group (n=20). Eight patients dropped out for various reasons. The CAP FISIO questionnaire results showed an improvement in adherence during follow-up period for the HappyAir group, which was statistically different compared with the control group at 12 months (56.1 [SD 4.0] vs 44.0 [SD 13.6]; P=.004) after pulmonary rehabilitation. CONCLUSIONS mHealth systems designed for COPD patients improve adherence to maintenance programs as long as they are accompanied by disease awareness and patient involvement in management. TRIAL REGISTRATION ClinicalTrials.gov NCT04479930; https://clinicaltrials.gov/ct2/show/NCT04479930.",2020,"The CAP FISIO questionnaire results showed an improvement in adherence during follow-up period for the HG, which was statistically different compared to the CG at 12 months (56.1±4 vs 44±13.6; P=.004) after PR. ","['44 patients were recruited and randomized in the CG (n=24) and HG (n=20', 'COPD patients from three hospitals', 'COPD patients', 'COPD Patients']","['control group (CG) or an intervention group (HappyAir™ group [HG', 'mHealth Web-based Platform (HappyAir™', 'integrated care plan based on an mHealth web-based platform (HappyAir™', 'Maintenance Program', 'Pulmonary rehabilitation (PR']","['adherence to physical activity (Morisky-Green Test), quality of life (CAT, SGRQ and EuroQOL-5D), exercise capacity (6MWT) and lung function', 'adherence', 'Adherence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0178916', 'cui_str': 'Care plan'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332583', 'cui_str': 'Green color'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0007366', 'cui_str': 'Catalan language'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}]",44.0,0.0421553,"The CAP FISIO questionnaire results showed an improvement in adherence during follow-up period for the HG, which was statistically different compared to the CG at 12 months (56.1±4 vs 44±13.6; P=.004) after PR. ","[{'ForeName': 'Begoña', 'Initials': 'B', 'LastName': 'Jiménez-Reguera', 'Affiliation': 'Departamento de Fisioterapia, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Maroto López', 'Affiliation': 'Lovexair Foundation, Madrid, Spain.'}, {'ForeName': 'Shane', 'Initials': 'S', 'LastName': 'Fitch', 'Affiliation': 'Lovexair Foundation, Madrid, Spain.'}, {'ForeName': 'Lourdes', 'Initials': 'L', 'LastName': 'Juarros', 'Affiliation': 'Hospital Universitario 12 de octubre, Madrid, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Sánchez Cortés', 'Affiliation': 'Hospital Universitario 12 de octubre, Madrid, Spain.'}, {'ForeName': 'Juan Luis', 'Initials': 'JL', 'LastName': 'Rodríguez Hermosa', 'Affiliation': 'Hospital Clínico San Carlos, Madrid, Spain.'}, {'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Calle Rubio', 'Affiliation': 'Hospital Clínico San Carlos, Madrid, Spain.'}, {'ForeName': 'María Teresa', 'Initials': 'MT', 'LastName': 'Hernández Criado', 'Affiliation': 'Hospital Universitario de La Princesa, Madrid, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'López', 'Affiliation': 'Hospital Universitario de La Princesa, Madrid, Spain.'}, {'ForeName': 'Santiago', 'Initials': 'S', 'LastName': 'Angulo-Díaz-Parreño', 'Affiliation': 'Departamento de Fisioterapia, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.'}, {'ForeName': 'Aitor', 'Initials': 'A', 'LastName': 'Martín-Pintado-Zugasti', 'Affiliation': 'Departamento de Fisioterapia, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Vilaró', 'Affiliation': 'Ramon Llull University, Barcelona, Spain.'}]",JMIR mHealth and uHealth,['10.2196/18465'] 1221,32516282,"Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2).","BACKGROUND Baloxavir marboxil (baloxavir) is a novel, cap-dependent endonuclease inhibitor that has previously demonstrated efficacy in the treatment of influenza in adults and adolescents. We assessed the safety and efficacy of baloxavir in otherwise healthy children with acute influenza. METHODS MiniSTONE-2 (Clinicaltrials.gov: NCT03629184) was a double-blind, randomized, active controlled trial enrolling children 1-<12 years old with a clinical diagnosis of influenza. Children were randomized 2:1 to receive either a single dose of oral baloxavir or oral oseltamivir twice daily for 5 days. The primary endpoint was incidence, severity and timing of adverse events (AEs); efficacy was a secondary endpoint. RESULTS In total, 173 children were randomized and dosed, 115 to the baloxavir group and 58 to the oseltamivir group. Characteristics of participants were similar between treatment groups. Overall, 122 AEs were reported in 84 (48.6%) children. Incidence of AEs was similar between baloxavir and oseltamivir groups (46.1% vs. 53.4%, respectively). The most common AEs were gastrointestinal (vomiting/diarrhea) in both groups [baloxavir: 12 children (10.4%); oseltamivir: 10 children (17.2%)]. No deaths, serious AEs or hospitalizations were reported. Median time (95% confidence interval) to alleviation of signs and symptoms of influenza was similar between groups: 138.1 (116.6-163.2) hours with baloxavir versus 150.0 (115.0-165.7) hours with oseltamivir. CONCLUSIONS Oral baloxavir is well tolerated and effective at alleviating symptoms in otherwise healthy children with acute influenza. Baloxavir provides a new therapeutic option with a simple oral dosing regimen.",2020,"Median time (95% confidence interval) to alleviation of signs and symptoms of influenza was similar between groups: 138.1 (116.6-163.2) hours with baloxavir versus 150.0 (115.0-165.7) hours with oseltamivir. ","['otherwise healthy children with acute influenza', 'children 1-<12 years old with a clinical diagnosis of influenza', 'adults and adolescents', '12 children (10.4', 'Influenza-infected Children', '10 children (17.2', '173 children were randomized and dosed, 115 to the baloxavir group and 58 to the oseltamivir group']","['oseltamivir', 'Baloxavir', 'baloxavir', 'Baloxavir Marboxil Single-dose Treatment', 'oral baloxavir or oral oseltamivir', 'Baloxavir marboxil (baloxavir']","['alleviation of signs and symptoms of influenza', 'incidence, severity and timing of adverse events (AEs); efficacy', 'No deaths, serious AEs or hospitalizations', 'safety and efficacy', 'Incidence of AEs', 'Median time', 'gastrointestinal (vomiting/diarrhea']","[{'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332140', 'cui_str': 'Clinical diagnosis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C5191376', 'cui_str': '10.4'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C4688747', 'cui_str': 'Baloxavir marboxil'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0874161', 'cui_str': 'Oseltamivir'}]","[{'cui': 'C0874161', 'cui_str': 'Oseltamivir'}, {'cui': 'C4734224', 'cui_str': 'baloxavir'}, {'cui': 'C4688747', 'cui_str': 'Baloxavir marboxil'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0449243', 'cui_str': 'Timing'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",173.0,0.517593,"Median time (95% confidence interval) to alleviation of signs and symptoms of influenza was similar between groups: 138.1 (116.6-163.2) hours with baloxavir versus 150.0 (115.0-165.7) hours with oseltamivir. ","[{'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Baker', 'Affiliation': 'From the Clinical Research Prime, Idaho Falls, Idaho.'}, {'ForeName': 'Stanley L', 'Initials': 'SL', 'LastName': 'Block', 'Affiliation': 'Kentucky Pediatric and Adult Research Inc., Bardstown, Kentucky.'}, {'ForeName': 'Balpreet', 'Initials': 'B', 'LastName': 'Matharu', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Welwyn Garden City, Hertfordshire, United Kingdom.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Burleigh Macutkiewicz', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Welwyn Garden City, Hertfordshire, United Kingdom.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Wildum', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Dimonaco', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Welwyn Garden City, Hertfordshire, United Kingdom.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Collinson', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Welwyn Garden City, Hertfordshire, United Kingdom.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Clinch', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Welwyn Garden City, Hertfordshire, United Kingdom.'}, {'ForeName': 'Pedro A', 'Initials': 'PA', 'LastName': 'Piedra', 'Affiliation': 'Baylor College of Medicine, Houston, Texas.'}]",The Pediatric infectious disease journal,['10.1097/INF.0000000000002747'] 1222,32516291,Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes.,"OBJECTIVES There is a bidirectional relationship between cardiovascular and renal disease. The drug-class of SGLT2 inhibitors improves outcomes at both ends of this so called cardiorenal axis. We assessed the effects of SGLT2 inhibition and sulfonylurea treatment on systemic hemodynamic function and investigated whether SGLT2 inhibitor-induced changes in systemic hemodynamics correlate with changes in renal hemodynamics. METHODS Forty-four people with type 2 diabetes were randomized to 12 weeks of dapagliflozin 10 mg/day or gliclazide 30 mg/day treatment. Systemic hemodynamic function, autonomic nervous system activity, and vascular stiffness were measured noninvasively, whereas renal hemodynamics, glomerular filtration rate (GFR) and effective renal plasma flow, were assessed with gold-standard urinary clearances of inulin or iohexol and para-aminohippuric acid, respectively. Correlation analyses were performed to assess relationships between dapagliflozin-induced changes in cardiovascular and renal variables. RESULTS Dapagliflozin reduced stroke volume by 4%, cardiac output by 5%, vascular stiffness by 11%, and mean arterial pressure by 5% from baseline, without increasing heart rate or sympathetic activity, while simultaneously lowering glomerular filtration rate by 8%. Despite similar improvements in glycemic control by dapagliflozin and gliclazide (-0.5 ± 0.5 versus-0.7 ± 0.5%; P = 0.12), gliclazide did not affect any of these measurements. There was no clear association between the dapagliflozin-induced changes in cardiovascular and renal physiology. CONCLUSION Dapagliflozin seemingly influences systemic and renal hemodynamics independently and beyond glucose lowering in people with type 2 diabetes.This clinical trial was registered at https://clinicalTrials.gov (ID: NCT02682563).",2020,"RESULTS Dapagliflozin reduced stroke volume by 4%, cardiac output by 5%, vascular stiffness by 11%, and mean arterial pressure by 5% from baseline, without increasing heart rate or sympathetic activity, while simultaneously lowering glomerular filtration rate by 8%.","['people with type 2 diabetes', 'Forty-four people with type 2 diabetes']","['gliclazide', 'dapagliflozin and gliclazide', 'dapagliflozin', 'SGLT2 inhibitors', 'SGLT2 inhibition and sulfonylurea', 'dapagliflozin 10\u200amg/day or gliclazide', 'Dapagliflozin']","['heart rate or sympathetic activity', 'cardiovascular and renal physiology', 'stroke volume', 'cardiac output', 'systemic and renal hemodynamics', 'vascular stiffness', 'mean arterial pressure', 'glomerular filtration rate', 'renal hemodynamics, glomerular filtration rate (GFR) and effective renal plasma flow', 'cardiovascular and renal variables', 'glycemic control', 'Systemic hemodynamic function, autonomic nervous system activity, and vascular stiffness']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C4319568', 'cui_str': '44'}]","[{'cui': 'C0017631', 'cui_str': 'Gliclazide'}, {'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C3273807', 'cui_str': 'SGLT2 Inhibitors'}, {'cui': 'C1505133', 'cui_str': 'SLC5A2 protein, human'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0038766', 'cui_str': 'Sulfonylurea'}, {'cui': 'C3709918', 'cui_str': 'dapagliflozin 10 MG'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0031842', 'cui_str': 'Physiology'}, {'cui': 'C0038455', 'cui_str': 'Stroke volume'}, {'cui': 'C0007165', 'cui_str': 'Cardiac output'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C3178781', 'cui_str': 'Vascular Stiffness'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0206088', 'cui_str': 'Effective renal plasma flow'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}]",44.0,0.164568,"RESULTS Dapagliflozin reduced stroke volume by 4%, cardiac output by 5%, vascular stiffness by 11%, and mean arterial pressure by 5% from baseline, without increasing heart rate or sympathetic activity, while simultaneously lowering glomerular filtration rate by 8%.","[{'ForeName': 'Erik J M', 'Initials': 'EJM', 'LastName': 'van Bommel', 'Affiliation': 'Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam.'}, {'ForeName': 'Mark M', 'Initials': 'MM', 'LastName': 'Smits', 'Affiliation': 'Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam.'}, {'ForeName': 'Danique', 'Initials': 'D', 'LastName': 'Ruiter', 'Affiliation': 'Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam.'}, {'ForeName': 'Marcel H A', 'Initials': 'MHA', 'LastName': 'Muskiet', 'Affiliation': 'Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam.'}, {'ForeName': 'Mark H H', 'Initials': 'MHH', 'LastName': 'Kramer', 'Affiliation': 'Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam.'}, {'ForeName': 'Max', 'Initials': 'M', 'LastName': 'Nieuwdorp', 'Affiliation': 'Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam.'}, {'ForeName': 'Daan J', 'Initials': 'DJ', 'LastName': 'Touw', 'Affiliation': 'Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen.'}, {'ForeName': 'Hiddo J L', 'Initials': 'HJL', 'LastName': 'Heerspink', 'Affiliation': 'Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen.'}, {'ForeName': 'Jaap A', 'Initials': 'JA', 'LastName': 'Joles', 'Affiliation': 'Department of Nephrology and Hypertension, University Medical Center, Utrecht, The Netherlands.'}, {'ForeName': 'Daniël H', 'Initials': 'DH', 'LastName': 'van Raalte', 'Affiliation': 'Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam.'}]",Journal of hypertension,['10.1097/HJH.0000000000002480'] 1223,32255568,Psychological and physiological impacts of a fast-track diagnostic workup for men with suspected prostate cancer: Preliminary report from a randomized clinical trial.,,2020,,['men with suspected prostate cancer'],['fast-track diagnostic workup'],[],"[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C1277615', 'cui_str': 'Suspected prostate cancer'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0040594', 'cui_str': 'Track'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]",[],,0.0407896,,"[{'ForeName': 'Jianwei', 'Initials': 'J', 'LastName': 'Zhu', 'Affiliation': 'Department of Orthopedic Surgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, 610000, P. R. China.'}, {'ForeName': 'Ruoqing', 'Initials': 'R', 'LastName': 'Chen', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, 171 77, Sweden.'}, {'ForeName': 'Sabina', 'Initials': 'S', 'LastName': 'Davidsson', 'Affiliation': 'Department of Urology, Faculty of Medicine and Health, Örebro University, Örebro, 701 85, Sweden.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Carlsson', 'Affiliation': 'Department of Urology, Faculty of Medicine and Health, Örebro University, Örebro, 701 85, Sweden.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Messing-Eriksson', 'Affiliation': 'Department of Urology, Faculty of Medicine and Health, Örebro University, Örebro, 701 85, Sweden.'}, {'ForeName': 'Jonna', 'Initials': 'J', 'LastName': 'Fridfeldt', 'Affiliation': 'Department of Urology, Faculty of Medicine and Health, Örebro University, Örebro, 701 85, Sweden.'}, {'ForeName': 'Ove', 'Initials': 'O', 'LastName': 'Andrén', 'Affiliation': 'Department of Urology, Faculty of Medicine and Health, Örebro University, Örebro, 701 85, Sweden.'}, {'ForeName': 'Sven-Olof', 'Initials': 'SO', 'LastName': 'Andersson', 'Affiliation': 'Department of Urology, Faculty of Medicine and Health, Örebro University, Örebro, 701 85, Sweden.'}, {'ForeName': 'Unnur', 'Initials': 'U', 'LastName': 'Valdimarsdóttir', 'Affiliation': 'Department of Orthopedic Surgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, 610000, P. R. China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Fang', 'Affiliation': 'Institute of Environmental Medicine, Karolinska Institutet, Stockholm, 171 77, Sweden.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Fall', 'Affiliation': 'Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, 701 85, Sweden.'}]","Cancer communications (London, England)",['10.1002/cac2.12021'] 1224,32499125,Effect of Acupuncture in Patients With Irritable Bowel Syndrome: A Randomized Controlled Trial.,"OBJECTIVE To evaluate the effect and safety of acupuncture for the treatment of irritable bowel syndrome (IBS) through comparisons with those of polyethylene glycol (PEG) 4000 and pinaverium bromide. PATIENTS AND METHODS This multicenter randomized controlled trial was conducted at 7 hospitals in China and enrolled participants who met the Rome III diagnostic criteria for IBS between May 3, 2015, and June 29, 2018. Participants were first stratified into constipation-predominant or diarrhea-predominant IBS group. Participants in each group were randomly assigned in a 2:1 ratio to receive acupuncture (18 sessions) or PEG 4000 (20 g/d, for IBS-C)/pinaverium bromide (150 mg/d, for IBS-D) over a 6-week period, followed by a 12-week follow-up. The primary outcome was change in total IBS-Symptom Severity Score from baseline to week 6. RESULTS Of 531 patients with IBS who were randomized, 519 (344 in the acupuncture group and 175 in the PEG 4000/ pinaverium bromide group) were included in the full analysis set. From baseline to 6 weeks, the total IBS-Symptom Severity Score decreased by 123.51 (95% CI, 116.61 to 130.42) in the acupuncture group and 94.73 (95% CI, 85.03 to 104.43) in the PEG 4000/pinaverium bromide group. The between-group difference was 28.78 (95% CI, 16.84 to 40.72; P<.001). No participant experienced severe adverse effects. CONCLUSION Acupuncture may be more effective than PEG 4000 or pinaverium bromide for the treatment of IBS, with effects lasting up to 12 weeks. TRIAL REGISTRATION Chinese Clinical Trials Register, ChiCTR-IOR-15006259.",2020,"From baseline to 6 weeks, the total IBS-Symptom Severity Score decreased by 123.51 (95% CI, 116.61 to 130.42) in the acupuncture group and 94.73 (95% CI, 85.03 to 104.43) in the PEG 4000/pinaverium bromide group.","['irritable bowel syndrome (IBS', 'Patients With Irritable Bowel Syndrome', 'Participants were first stratified into constipation-predominant or diarrhea-predominant IBS group', '7 hospitals in China and enrolled participants who met the Rome III diagnostic criteria for IBS between May 3, 2015, and June 29, 2018', '531 patients with IBS who were randomized, 519 (344 in the acupuncture group and 175 in the PEG 4000/ pinaverium bromide group) were included in the full analysis set']","['acupuncture', 'polyethylene glycol (PEG) 4000 and pinaverium bromide', 'Acupuncture', 'acupuncture (18 sessions) or PEG 4000 (20 g/d, for IBS-C)/pinaverium bromide']","['total IBS-Symptom Severity Score', 'severe adverse effects']","[{'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C1262211', 'cui_str': 'Diarrhoea predominant irritable bowel syndrome'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0035831', 'cui_str': 'Rome'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C0032483', 'cui_str': 'Polyethylene Glycols'}, {'cui': 'C0137073', 'cui_str': 'Pinaverium bromide'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0032483', 'cui_str': 'Polyethylene Glycols'}, {'cui': 'C3842327', 'cui_str': '4000'}, {'cui': 'C0137073', 'cui_str': 'Pinaverium bromide'}, {'cui': 'C0032479', 'cui_str': 'polyethylene glycol 4000'}, {'cui': 'C0450403', 'cui_str': '20G'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0006222', 'cui_str': 'bromides'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",531.0,0.308207,"From baseline to 6 weeks, the total IBS-Symptom Severity Score decreased by 123.51 (95% CI, 116.61 to 130.42) in the acupuncture group and 94.73 (95% CI, 85.03 to 104.43) in the PEG 4000/pinaverium bromide group.","[{'ForeName': 'Lixia', 'Initials': 'L', 'LastName': 'Pei', 'Affiliation': 'Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Geng', 'Affiliation': 'Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Guo', 'Affiliation': 'Nanjing University of Chinese Medicine, China.'}, {'ForeName': 'Guohui', 'Initials': 'G', 'LastName': 'Yang', 'Affiliation': 'Shuyang Hospital of Traditional Chinese Medicine, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Shuyang Hospital of Traditional Chinese Medicine, China.'}, {'ForeName': 'Rongrong', 'Initials': 'R', 'LastName': 'Shen', 'Affiliation': 'Nantong Hospital of Traditional Chinese Medicine, China.'}, {'ForeName': 'Shuyu', 'Initials': 'S', 'LastName': 'Xia', 'Affiliation': 'Nantong Hospital of Traditional Chinese Medicine, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Ding', 'Affiliation': 'Wuxi Hospital of Traditional Chinese Medicine, China.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Feng', 'Affiliation': 'Wuxi Hospital of Traditional Chinese Medicine, China.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Lu', 'Affiliation': 'Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, China.'}, {'ForeName': 'Lian', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Affiliated Hospital of Jiangsu University, Zhenjiang, China.'}, {'ForeName': 'Yanye', 'Initials': 'Y', 'LastName': 'Shu', 'Affiliation': 'Affiliated Hospital of Jiangsu University, Zhenjiang, China.'}, {'ForeName': 'Xiangdong', 'Initials': 'X', 'LastName': 'Fang', 'Affiliation': 'Affiliated Hospital of Jiangsu University, Zhenjiang, China; Kunshan Hospital of Traditional Chinese Medicine, China.'}, {'ForeName': 'Xiaoliang', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.'}, {'ForeName': 'Xiaoxiao', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.'}, {'ForeName': 'Shengjie', 'Initials': 'S', 'LastName': 'Weng', 'Affiliation': 'Nanjing University of Chinese Medicine, China.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Ju', 'Affiliation': 'Nanjing University of Chinese Medicine, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Nanjing University of Chinese Medicine, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Shen', 'Affiliation': 'Jiangsu Province Hospital of Chinese Medicine, Nanjing, China. Electronic address: shenghong999@163.com.'}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': 'Jiangsu Province Hospital of Chinese Medicine, Nanjing, China. Electronic address: 377201634@qq.com.'}]",Mayo Clinic proceedings,['10.1016/j.mayocp.2020.01.042'] 1225,32497736,Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study.,"BACKGROUND We designed an open-label, noncomparative phase II study to assess the safety and efficacy of first-line treatment with trifluridine/tipiracil plus bevacizumab (TT-B) and capecitabine plus bevacizumab (C-B) in untreated patients with unresectable metastatic colorectal cancer (mCRC) who were not candidates for combination with cytotoxic chemotherapies. PATIENTS AND METHODS From 29 April 2016 to 29 March 2017, 153 patients were randomly assigned (1:1) to either TT-B (N = 77) or C-B (N = 76). The primary end point was progression-free survival (PFS). The primary PFS analysis was performed after 100 events (radiological progression or death) were observed. Secondary end points included overall survival (OS), quality of life (QoL; QLQ-C30 and QLQ-CR29 questionnaires), and safety. RESULTS Median (range) duration of treatment was 7.8 (6.0-9.7) months and 6.2 (4.1-9.1) months in the TT-B and C-B groups, respectively. Median (range) PFS was 9.2 (7.6-11.6) and 7.8 (5.5-10.1) months, respectively. Median (range) OS was 18 (15.2 to NA) and 16.2 (12.5 to NA) months, respectively. QoL questionnaires showed no relevant changes over time for either treatment. Therapies were well tolerated. Patients receiving TT-B had more grade ≥3 neutropenia (47% versus 5% with C-B). Patients receiving C-B had more grade ≥3 hand-foot syndrome (12% versus 0% with TT-B) and grade ≥3 diarrhea (8% versus 1% with TT-B), consistent with the known safety profiles of these agents. CONCLUSION TT-B treatment showed promising clinical activity in untreated patients with unresectable mCRC ineligible for intensive therapy, with an acceptable safety profile and no clinically relevant changes in QoL. CLINICAL TRIAL INFORMATION NCT02743221 (ClinicalTrials.gov).",2020,Patients receiving TT-B had more grade ≥3 neutropenia (47% vs. 5% with C-B).,"['Patients with Untreated Metastatic Colorectal Cancer Ineligible for Intensive Therapy', 'From 29 April 2016 to 29 March 2017', 'untreated patients with unresectable metastatic colorectal cancer (mCRC) who were not candidates for combination with cytotoxic chemotherapies', '153 patients']","['Trifluridine/Tipiracil plus Bevacizumab', 'trifluridine/tipiracil plus bevacizumab (TT-B) and capecitabine plus bevacizumab (C-B']","['grade ≥3 hand-foot syndrome', 'Median PFS', 'Median OS', 'tolerated', 'overall survival (OS), quality of life (QoL; QLQ-C30 and QLQ-CR29 questionnaires) and safety', '100 events (radiological progression or death', 'clinical activity', 'grade ≥3 diarrhea', 'safety and efficacy', 'grade ≥3 neutropenia', 'progression-free survival (PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0304497', 'cui_str': 'Cytotoxic agent'}]","[{'cui': 'C4055631', 'cui_str': 'Tipiracil- and trifluridine-containing product'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}]","[{'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0549410', 'cui_str': 'Palmar-plantar erythrodysaesthesia syndrome'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}]",153.0,0.0974354,Patients receiving TT-B had more grade ≥3 neutropenia (47% vs. 5% with C-B).,"[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Van Cutsem', 'Affiliation': 'University Hospitals Leuven and KU Leuven, Leuven, Belgium. Electronic address: eric.vancutsem@uzleuven.be.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Danielewicz', 'Affiliation': 'Szpitale Wojewodzkie w Gdyni/Gdansk Medical University, Gdynia, Poland.'}, {'ForeName': 'M P', 'Initials': 'MP', 'LastName': 'Saunders', 'Affiliation': 'Christie Hospital NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Pfeiffer', 'Affiliation': 'Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Argilés', 'Affiliation': ""Vall d'Hebrón Institute of Oncology and Vall d'Hebrón University Hospital, Barcelona, Spain.""}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Borg', 'Affiliation': 'University Hospital Besançon, Besançon, France.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Glynne-Jones', 'Affiliation': 'Mount Vernon Hospital, Northwood, UK.'}, {'ForeName': 'C J A', 'Initials': 'CJA', 'LastName': 'Punt', 'Affiliation': 'Amsterdam University Medical Centers, Amsterdam.'}, {'ForeName': 'A J', 'Initials': 'AJ', 'LastName': 'Van de Wouw', 'Affiliation': 'VieCuri Medisch Centrum Noord-Limburg, Venlo, The Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Fedyanin', 'Affiliation': 'NN Blokhin National Medical Research Center of Oncology, Moscow, Russia.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Stroyakovskiy', 'Affiliation': 'Moscow City Oncology Hospital N62, Moscow, Russia.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Kroening', 'Affiliation': 'Schwerpunktpraxis für Haematologie und Onkologie Hasselbachplatz, Magdeburg, Germany.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Garcia-Alfonso', 'Affiliation': 'Hospital General Universitario Gregorio Marañón, Madrid, Spain.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Wasan', 'Affiliation': 'Hammersmith Hospital, Imperial College London, London, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Falcone', 'Affiliation': 'University Hospital of Pisa, Department of Oncology, Pisa, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Kanehisa', 'Affiliation': 'Institut de Recherches Internationales Servier, Suresnes, France.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Egorov', 'Affiliation': 'Institut de Recherches Internationales Servier, Suresnes, France.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Aubel', 'Affiliation': 'Institut de Recherches Internationales Servier, Suresnes, France.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Amellal', 'Affiliation': 'Institut de Recherches Internationales Servier, Suresnes, France.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Moiseenko', 'Affiliation': 'Saint-Petersburg Scientific Practical Center for Specialized Medical Care, St Petersburg, Russia.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2020.05.024'] 1226,32502443,"Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.","BACKGROUND Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through multiple mechanisms and augmented antitumour activity in multiple malignancies. We aimed to assess the efficacy and safety of atezolizumab (anti-PD-L1) alone and combined with bevacizumab (anti-VEGF) in patients with unresectable hepatocellular carcinoma. METHODS GO30140 is an open-label, multicentre, multiarm, phase 1b study that enrolled patients at 26 academic centres and community oncology practices in seven countries worldwide. The study included five cohorts, and the two hepatocellular carcinoma cohorts, groups A and F, are described here. Inclusion criteria for these two groups included age 18 years and older; histologically, cytologically, or clinically (per American Association for the Study of Liver Diseases criteria) confirmed unresectable hepatocellular carcinoma that was not amenable to curative treatment; no previous systemic treatment; and Eastern Cooperative Oncology Group performance status of 0 or 1. In group A, all patients received atezolizumab (1200 mg) and bevacizumab (15 mg/kg) intravenously every 3 weeks. In group F, patients were randomly assigned (1:1) to receive intravenous atezolizumab (1200 mg) plus intravenous bevacizumab (15 mg/kg) every 3 weeks or atezolizumab alone by interactive voice-web response system using permuted block randomisation (block size of two) and stratification factors of geographical region; macrovascular invasion, extrahepatic spread, or both; and baseline α-fetoprotein concentration. Primary endpoints were confirmed objective response rate in all patients who received the combination treatment for group A and progression-free survival in the intention-to-treat population in group F, both assessed by an independent review facility according to Response Evaluation Criteria in Solid Tumors version 1.1. In both groups, safety was assessed in all patients who received at least one dose of any study treatment. This study is registered with ClinicalTrials.gov, NCT02715531, and is closed to enrolment. FINDINGS In group A, 104 patients were enrolled between July 20, 2016, and July 31, 2018, and received atezolizumab plus bevacizumab. With a median follow-up of 12·4 months (IQR 8·0-16·2), 37 (36%; 95% CI 26-46) of 104 patients had a confirmed objective response. The most common grade 3-4 treatment-related adverse events were hypertension (13 [13%]) and proteinuria (seven [7%]). Treatment-related serious adverse events occurred in 25 (24%) patients and treatment-related deaths in three (3%) patients (abnormal hepatic function, hepatic cirrhosis, and pneumonitis). In group F, 119 patients were enrolled and randomly assigned (60 to atezolizumab plus bevacizumab; 59 to atezolizumab monotherapy) between May 18, 2018, and March 7, 2019. With a median follow-up of 6·6 months (IQR 5·5-8·5) for the atezolizumab plus bevacizumab group and 6·7 months (4·2-8·2) for the atezolizumab monotherapy group, median progression-free survival was 5·6 months (95% CI 3·6-7·4) versus 3·4 months (1·9-5·2; hazard ratio 0·55; 80% CI 0·40-0·74; p=0·011). The most common grade 3-4 treatment-related adverse events in group F were hypertension (in three [5%] patients in the atezolizumab plus bevacizumab group; none in the atezolizumab monotherapy group) and proteinuria (in two [3%] patients in the atezolizumab plus bevacizumab group; none in the atezolizumab monotherapy group). Treatment-related serious adverse events occurred in seven (12%) patients in the atezolizumab plus bevacizumab group and two (3%) patients in the atezolizumab monotherapy group. There were no treatment-related deaths. INTERPRETATION Our study shows longer progression-free survival with a combination of atezolizumab plus bevacizumab than with atezolizumab alone in patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy. Therefore, atezolizumab plus bevacizumab might become a promising treatment option for these patients. This combination is being compared with standard-of-care sorafenib in a phase 3 trial. FUNDING F Hoffmann-La Roche/Genentech.",2020,The most common grade 3-4 treatment-related adverse events in group F were hypertension,"['119 patients', 'patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy', 'unresectable hepatocellular carcinoma (GO30140', 'Inclusion criteria for these two groups included age 18 years and older; histologically, cytologically, or clinically (per American Association for the Study of Liver Diseases criteria) confirmed unresectable hepatocellular carcinoma that was not amenable to curative treatment; no previous systemic treatment; and Eastern Cooperative Oncology Group performance status of 0 or 1', 'enrolled patients at 26 academic centres and community oncology practices in seven countries worldwide', '104 patients were enrolled between July 20, 2016, and July 31, 2018, and received', 'patients with unresectable hepatocellular carcinoma']","['atezolizumab alone', 'intravenous atezolizumab (1200 mg) plus intravenous bevacizumab', 'atezolizumab (anti-PD-L1) alone and combined with bevacizumab (anti-VEGF', 'atezolizumab', 'atezolizumab alone by interactive voice-web response system', 'Atezolizumab with or without bevacizumab', 'standard-of-care sorafenib', 'atezolizumab monotherapy', 'bevacizumab', 'atezolizumab plus bevacizumab']","['median progression-free survival', 'progression-free survival', 'efficacy and safety', 'serious adverse events', 'proteinuria', 'objective response rate', 'hypertension']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1112459', 'cui_str': 'Liver cell carcinoma non-resectable'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0023895', 'cui_str': 'Disease of liver'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C4517527', 'cui_str': '104'}]","[{'cui': 'C4055433', 'cui_str': 'atezolizumab'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C4517548', 'cui_str': '1200'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]",104.0,0.146586,The most common grade 3-4 treatment-related adverse events in group F were hypertension,"[{'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Lee', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Baek-Yeol', 'Initials': 'BY', 'LastName': 'Ryoo', 'Affiliation': 'Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Chih-Hung', 'Initials': 'CH', 'LastName': 'Hsu', 'Affiliation': 'National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Kazushi', 'Initials': 'K', 'LastName': 'Numata', 'Affiliation': 'Yokohama City University Medical Center, Yokohama, Japan.'}, {'ForeName': 'Stacey', 'Initials': 'S', 'LastName': 'Stein', 'Affiliation': 'Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Verret', 'Affiliation': 'Genentech, South San Francisco, CA, USA.'}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Hack', 'Affiliation': 'Genentech, South San Francisco, CA, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Spahn', 'Affiliation': 'Genentech, South San Francisco, CA, USA.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Liu', 'Affiliation': 'Genentech, South San Francisco, CA, USA.'}, {'ForeName': 'Heba', 'Initials': 'H', 'LastName': 'Abdullah', 'Affiliation': 'Genentech, South San Francisco, CA, USA.'}, {'ForeName': 'Yulei', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Genentech, South San Francisco, CA, USA.'}, {'ForeName': 'Aiwu Ruth', 'Initials': 'AR', 'LastName': 'He', 'Affiliation': 'Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.'}, {'ForeName': 'Kyung-Hun', 'Initials': 'KH', 'LastName': 'Lee', 'Affiliation': 'Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Electronic address: kyunghunlee@snu.ac.kr.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30156-X'] 1227,32511981,"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.","BACKGROUND Resistance to approved inhibitors of KIT proto-oncogene, receptor tyrosine kinase (KIT), and platelet-derived growth factor receptor α (PDGFRA) is a clinical challenge for patients with advanced gastrointestinal stromal tumours. We compared the efficacy and safety of ripretinib, a switch-control tyrosine kinase inhibitor active against a broad spectrum of KIT and PDGFRA mutations, with placebo in patients with previously treated, advanced gastrointestinal stromal tumours. METHODS In this double-blind, randomised, placebo-controlled, phase 3 study, we enrolled adult patients in 29 specialised hospitals in 12 countries. We included patients aged 18 years or older who had advanced gastrointestinal stromal tumours with progression on at least imatinib, sunitinib, and regorafenib or documented intolerance to any of these treatments despite dose modifications, and who had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Eligible patients were randomly assigned (2:1) to receive either oral ripretinib 150 mg once daily (ripretenib group) or placebo once daily (placebo group). Randomisation was done via an interactive response system using randomly permuted block sizes of six and stratified according to number of previous therapies and ECOG performance status. Patients, investigators, research staff, and the sponsor study team were masked to a patient's treatment allocation until the blinded independent central review (BICR) showed progressive disease for the patient. The primary endpoint was progression-free survival, assessed by BICR. The primary analysis was done in the intention-to-treat population and safety was assessed in patients who received at least one dose of study drug. Patients randomly assigned to placebo were permitted to cross over to ripretinib 150 mg at the time of disease progression. The INVICTUS study is registered with ClinicalTrials.gov, number NCT03353753, and with WHO International Clinical Trials Registry Platform, number EUCTR2017-002446-76-ES; follow-up is ongoing. FINDINGS Between Feb 27, 2018, and Nov 16, 2018, 129 of 154 assessed patients were randomly assigned to receive either ripretinib (n=85) or placebo (n=44). At data cutoff (May 31, 2019), at a median follow-up of 6·3 months (IQR 3·2-8·2) in the ripretinib group and 1·6 months (1·1-2·7) in the placebo group, 51 patients in the ripretinib group and 37 in the placebo group had had progression-free survival events. In the double-blind period, median progression-free survival was 6·3 months (95% CI 4·6-6·9) with ripretinib compared with 1·0 months (0·9-1·7) with placebo (hazard ratio 0·15, 95% CI 0·09-0·25; p<0·0001). The most common (>2%) grade 3 or 4 treatment-related treatment-emergent adverse events in the ripretinib group (n=85) included lipase increase (four [5%]), hypertension (three [4%]), fatigue (two [2%]), and hypophosphataemia (two (2%]); in the placebo group (n=43), the most common (>2%) grade 3 or 4 treatment-related treatment-emergent adverse events were anaemia (three [7%]), fatigue (one [2%]), diarrhoea (one [2%]), decreased appetite (one [2%]), dehydration (one [2%]), hyperkalaemia (one [2%]), acute kidney injury (one [2%]), and pulmonary oedema (one [2%]). Treatment-related serious adverse events were reported in eight (9%) of 85 patients who received ripretinib and three (7%) of 43 patients who received placebo. Treatment-related deaths occurred in one patient in the placebo group (septic shock and pulmonary oedema) and one patient in the ripretinib group (cause of death unknown; the patient died during sleep). INTERPRETATION Ripretinib significantly improved median progression-free survival compared with placebo and had an acceptable safety profile in patients with advanced gastrointestinal stromal tumours who were resistant to approved treatments. FUNDING Deciphera Pharmaceuticals.",2020,"Ripretinib significantly improved median progression-free survival compared with placebo and had an acceptable safety profile in patients with advanced gastrointestinal stromal tumours who were resistant to approved treatments. ","['enrolled adult patients in 29 specialised hospitals in 12 countries', 'patients aged 18 years or older who had advanced gastrointestinal stromal tumours with progression on at least imatinib, sunitinib, and regorafenib or documented intolerance to any of these treatments despite dose modifications, and who had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2', 'patients with advanced gastrointestinal stromal tumours who were resistant to approved treatments', 'Between Feb 27, 2018, and Nov 16, 2018, 129 of 154 assessed patients', 'patients with previously treated, advanced gastrointestinal stromal tumours', 'patients with advanced gastrointestinal stromal tumours (INVICTUS', 'patients with advanced gastrointestinal stromal tumours', 'Eligible patients']","['ripretinib', 'oral ripretinib 150 mg once daily (ripretenib group) or placebo once daily (placebo', 'placebo']","['lipase increase', 'median progression-free survival', 'progression-free survival events', 'intention-to-treat population and safety', 'fatigue', 'hyperkalaemia', 'acute kidney injury', 'septic shock and pulmonary oedema', 'diarrhoea', 'dehydration', 'serious adverse events', 'pulmonary oedema', 'hypertension', 'deaths', 'decreased appetite', 'progression-free survival, assessed by BICR']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0238198', 'cui_str': 'Gastrointestinal stromal tumor'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0935989', 'cui_str': 'imatinib'}, {'cui': 'C1176020', 'cui_str': 'sunitinib'}, {'cui': 'C2980094', 'cui_str': 'regorafenib'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0231199', 'cui_str': 'Intolerance'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0205540', 'cui_str': 'Approved'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C1520439', 'cui_str': '129 Strain Mouse'}, {'cui': 'C5191279', 'cui_str': '154'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0549475', 'cui_str': 'Lipase increased'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0020461', 'cui_str': 'Hyperkalemia'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0036983', 'cui_str': 'Septic shock'}, {'cui': 'C0034063', 'cui_str': 'Pulmonary edema'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0011175', 'cui_str': 'Dehydration'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0232462', 'cui_str': 'Decrease in appetite'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0282443', 'cui_str': 'Review'}]",,0.788248,"Ripretinib significantly improved median progression-free survival compared with placebo and had an acceptable safety profile in patients with advanced gastrointestinal stromal tumours who were resistant to approved treatments. ","[{'ForeName': 'Jean-Yves', 'Initials': 'JY', 'LastName': 'Blay', 'Affiliation': 'Department of Medicine, Centre Léon Bérard, Lyon, France; Headquarters, Unicancer, Paris, France; LYRICAN, Lyon, France; Faculte Lyon Est, Université Claude Bernard, Lyon, France. Electronic address: jean-yves.blay@lyon.unicancer.fr.'}, {'ForeName': 'César', 'Initials': 'C', 'LastName': 'Serrano', 'Affiliation': ""Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain.""}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Heinrich', 'Affiliation': 'Department of Medicine, Portland VA Health Care System, Portland, OR, USA; OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Zalcberg', 'Affiliation': 'Department of Epidemiology and Preventative Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Department of Medical Oncology, Alfred Health, Melbourne, VIC, Australia.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Bauer', 'Affiliation': 'Department of Medical Oncology, West German Cancer Center, University of Duisburg-Essen, Essen, Germany; German Consortium for Translational Cancer Research (DKTK), Partner Site Essen, Germany.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Gelderblom', 'Affiliation': 'Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Schöffski', 'Affiliation': 'Leuven Cancer Institute and Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Robin L', 'Initials': 'RL', 'LastName': 'Jones', 'Affiliation': 'Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, UK; Division of Clinical Studies, The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Attia', 'Affiliation': 'Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.'}, {'ForeName': 'Gina', 'Initials': 'G', 'LastName': ""D'Amato"", 'Affiliation': 'Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Chi', 'Affiliation': 'Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Reichardt', 'Affiliation': 'Department of Oncology, Helios Klinikum Berlin-Buch, Berlin, Germany.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Meade', 'Affiliation': 'Deciphera Pharmaceuticals, Waltham, MA, USA.'}, {'ForeName': 'Kelvin', 'Initials': 'K', 'LastName': 'Shi', 'Affiliation': 'Deciphera Pharmaceuticals, Waltham, MA, USA.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Ruiz-Soto', 'Affiliation': 'Deciphera Pharmaceuticals, Waltham, MA, USA.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'George', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'von Mehren', 'Affiliation': 'Department of Hematology and Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.'}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30168-6'] 1228,32515703,[The Effects of Preventive Counseling Followed by Remote Support Via Telephone on the Motivation to Change Lifestyle in Patients With High and Very High Cardiovascular Risk].,"Aim To evaluate effectiveness of preventive telephone counseling with a nutritional component and distance support for three months with respect of motivation for lifestyle modification in patients with high and very high cardiovascular risk (CVR).Material and methods This prospective, controlled, randomized clinical study in two parallel groups included patients with high and very high CVR (5-9 % and ≥10 % according to the SCORE scale) who had at least two criteria of metabolic syndrome. Patients were randomized to the main and control groups in a 1:1 ratio with age and gender stratification. The main group received comprehensive preventive counseling with a nutritional component and distant support via telephone once in two weeks for three months (total 6 consultations). Patients of the control group received standard counseling by a health center physician. Patients' motivation for lifestyle changes was evaluated with a questionnaire at baseline and at 6 and 12 months.Results The study included a total of 100 patients (mean age, 59.85±4.47 years, 80 % females). At baseline, 81 % of patients had high and 19% of patients had very high CVR. Patients of the study groups did not differ in major demographic and clinical characteristics. At 6 month of follow-up, the main group showed a significantly more pronounced positive changes in motivation and healthier lifestyle (50 % in the main group vs. 12% in the control group, р<0.01). At 12 months of follow-up, the number of such patients somewhat decreased to 38%. In this process, a vast majority of patients in the control group (82 %) continued theoretically considering the expediency of lifestyle modification.Conclusions Preventive counseling with nutritional component and further distance support via telephone for three months for patients with high and very high CVR provided increased motivation for healthier lifestyle and positive behavioral changes.",2020,"At 6 month of follow-up, the main group showed a significantly more pronounced positive changes in motivation and healthier lifestyle (50 % in the main group vs. 12% in the control group, р<0.01).","['patients with high and very high cardiovascular risk (CVR).Material', 'Patients', '100 patients (mean age, 59.85±4.47 years, 80\u200a% females', 'two parallel groups included patients with high and very high CVR (5-9\u200a% and ≥10\u200a% according to the SCORE scale) who had at least two criteria of metabolic syndrome']","['standard counseling by a health center physician', 'Preventive Counseling Followed by Remote Support', 'preventive telephone counseling with a nutritional component and distance support', 'comprehensive preventive counseling with a nutritional component and distant support via telephone']",['motivation and healthier lifestyle'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0442804', 'cui_str': 'Very high'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0204169', 'cui_str': 'Preventive dental procedure'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0443203', 'cui_str': 'Distant'}]","[{'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C4277664', 'cui_str': 'Healthy Lifestyles'}]",100.0,0.0250074,"At 6 month of follow-up, the main group showed a significantly more pronounced positive changes in motivation and healthier lifestyle (50 % in the main group vs. 12% in the control group, р<0.01).","[{'ForeName': 'N V', 'Initials': 'NV', 'LastName': 'Pogosova', 'Affiliation': 'National Medical Research Center of Cardiology, Moscow, Russia.'}, {'ForeName': 'A I', 'Initials': 'AI', 'LastName': 'Yusubova', 'Affiliation': ""Children's Center for the diagnosis and treatment N. A. Semashko Russian Federation.""}, {'ForeName': 'Yu M', 'Initials': 'YM', 'LastName': 'Yufereva', 'Affiliation': 'National Medical Research Center of Cardiology, Moscow, Russia.'}, {'ForeName': 'A K', 'Initials': 'AK', 'LastName': 'Ausheva', 'Affiliation': 'National Medical Research Center of Cardiology, Moscow, Russia.'}, {'ForeName': 'A V', 'Initials': 'AV', 'LastName': 'Karpova', 'Affiliation': 'National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia.'}, {'ForeName': 'V A', 'Initials': 'VA', 'LastName': 'Vygodin', 'Affiliation': 'National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia.'}]",Kardiologiia,['10.18087/cardio.2020.5.n1009'] 1229,32321288,Low frequency activation of the sphenopalatine ganglion does not induce migraine-like attacks in migraine patients.,"INTRODUCTION Cephalic autonomic symptoms occur in 27‒73% of migraine patients during attacks. The role of parasympathetic activation in migraine attack initiation remains elusive. Low frequency stimulation of the sphenopalatine ganglion increases parasympathetic outflow. In this study, we hypothesized that low frequency stimulation of the sphenopalatine ganglion would provoke migraine-like attacks in migraine patients. METHODS In a double-blind randomized sham-controlled crossover study, 12 migraine patients with a sphenopalatine ganglion neurostimulator received low frequency or sham stimulation for 30 min on two separate days. We recorded headache characteristics, cephalic autonomic symptoms, ipsilateral mechanical perception and pain thresholds, mean blood flow velocity in the middle cerebral artery (V MCA ) and diameter of the superficial temporal artery during and after stimulation. RESULTS Five patients (42%) reported a migraine-like attack after low frequency stimulation compared to six patients (50%) after sham ( p  = 1.000). We found a significant increase in mechanical detection thresholds during low frequency stimulation compared to baseline ( p  = 0.007). Occurrence of cephalic autonomic symptoms and changes in mechanical perception thresholds, V MCA and diameter of the superficial temporal artery showed no difference between low frequency stimulation compared to sham ( p  = 0.533). CONCLUSION Low frequency stimulation of the sphenopalatine ganglion did not induce migraine-like attacks or autonomic symptoms in migraine patients. These data suggest that increased parasympathetic outflow by the sphenopalatine ganglion neurostimulator does not initiate migraine-like attacks. Study protocol: ClinicalTrials.gov registration number NCT02510742.",2020,We found a significant increase in mechanical detection thresholds during low frequency stimulation compared to baseline ( p  = 0.007).,"['12 migraine patients with a sphenopalatine ganglion neurostimulator received low frequency or sham stimulation for 30 min on two separate days', 'migraine patients']",['sphenopalatine ganglion'],"['migraine-like attacks or autonomic symptoms', 'migraine-like attacks', 'Occurrence of cephalic autonomic symptoms and changes in mechanical perception thresholds, V MCA and diameter of the superficial temporal artery', 'headache characteristics, cephalic autonomic symptoms, ipsilateral mechanical perception and pain thresholds, mean blood flow velocity in the middle cerebral artery (V MCA ) and diameter of the superficial temporal artery during and after stimulation', 'mechanical detection thresholds', 'migraine-like attack', 'parasympathetic outflow']","[{'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0229062', 'cui_str': 'Structure of sphenopalatine ganglion'}, {'cui': 'C0582124', 'cui_str': 'Neurostimulator'}, {'cui': 'C0205213', 'cui_str': 'Low frequency'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0229062', 'cui_str': 'Structure of sphenopalatine ganglion'}]","[{'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0004063', 'cui_str': 'Assault'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0205096', 'cui_str': 'Cephalic'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0149566', 'cui_str': 'Structure of middle cerebral artery'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0226130', 'cui_str': 'Structure of superficial temporal artery'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0441989', 'cui_str': 'Ipsilateral'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005798', 'cui_str': 'Blood Flow Velocity'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}]",12.0,0.0541007,We found a significant increase in mechanical detection thresholds during low frequency stimulation compared to baseline ( p  = 0.007).,"[{'ForeName': 'Song', 'Initials': 'S', 'LastName': 'Guo', 'Affiliation': 'Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark.'}, {'ForeName': 'Katrine', 'Initials': 'K', 'LastName': 'Falkenberg', 'Affiliation': 'Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark.'}, {'ForeName': 'Henrik Winther', 'Initials': 'HW', 'LastName': 'Schytz', 'Affiliation': 'Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Caparso', 'Affiliation': 'Aurea Medical, LLC, Cleveland, OH, USA.'}, {'ForeName': 'Rigmor Højland', 'Initials': 'RH', 'LastName': 'Jensen', 'Affiliation': 'Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark.'}, {'ForeName': 'Messoud', 'Initials': 'M', 'LastName': 'Ashina', 'Affiliation': 'Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark.'}]",Cephalalgia : an international journal of headache,['10.1177/0333102420921156'] 1230,32507672,"Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87.",,2020,,"['2020, Pages 79-87']","['istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine', 'placebo']",[],"[{'cui': 'C0013862', 'cui_str': 'Polyacrylamide gel electrophoresis'}]","[{'cui': 'C3641662', 'cui_str': 'MM-141'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.0987186,,"[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kundranda', 'Affiliation': 'Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, USA.'}, {'ForeName': 'A C', 'Initials': 'AC', 'LastName': 'Gracian', 'Affiliation': 'Medical Oncology, Centro Integral Oncologico Clara Campal, Universidad CEU San Pablo, Madrid, Spain; Departamento de Ciencias Médicas Clínicas, Universidad CEU San Pablo, Madrid, Spain.'}, {'ForeName': 'S F', 'Initials': 'SF', 'LastName': 'Zafar', 'Affiliation': 'Hematology and Oncology, Florida Cancer Specialists, Fort Myers, USA.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Meiri', 'Affiliation': 'Medical Oncology, Comprehensive Care and Research Center, Atlanta, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Bendell', 'Affiliation': 'GI Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Algül', 'Affiliation': 'TUM School of Medicine, Klinikum rechts der Isar, Medizinische Klinik II, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Rivera', 'Affiliation': 'Medical Oncology, Hospital Universitario Marques de Valdecilla, Santander, Spain.'}, {'ForeName': 'E R', 'Initials': 'ER', 'LastName': 'Ahn', 'Affiliation': 'Medical Oncology, Cancer Treatment Centers of America Chicago, Zion, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Watkins', 'Affiliation': 'Department of Medicine, Royal Marsden Hospital, Sutton, UK.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Pelzer', 'Affiliation': 'Charité - Universitätsmedizin, Berlin, Germany.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Charu', 'Affiliation': 'Hematology/Oncology, Pacific Cancer Medical Center, Anaheim, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Zalutskaya', 'Affiliation': 'Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Kuesters', 'Affiliation': 'Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Pipas', 'Affiliation': 'Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Santillana', 'Affiliation': 'Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Askoxylakis', 'Affiliation': 'Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA.'}, {'ForeName': 'A H', 'Initials': 'AH', 'LastName': 'Ko', 'Affiliation': 'Hematology/Oncology, University of California San Francisco Cancer Center, San Francisco, USA. Electronic address: andrew.ko@ucsf.edu.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2020.05.011'] 1231,32520346,Effect of dairy consumption and its fat content on glycemic control and cardiovascular disease risk factors in patients with type 2 diabetes: a randomized controlled study.,"BACKGROUND Dietary Guidelines for Americans recommend the consumption of 3 servings/d of low-fat/nonfat dairy. The effects of higher dairy consumption and its fat content are unknown in patients with type 2 diabetes. OBJECTIVE Evaluate the impact of higher consumption of high- compared with low-fat dairy on glycated hemoglobin (HbA1c), body weight, and cardiovascular disease risk factors in patients with type 2 diabetes. METHODS We enrolled 111 subjects with type 2 diabetes (aged 58.5 ± 8.9 y, 47% females, diabetes duration 13.2 ± 8.3 y, HbA1c 8.09 ± 0.96%) who consumed <3 servings of dairy/d. We randomly assigned them into 3 groups: control group maintained baseline dairy intake, low-fat (LF) group incorporated ≥3 servings/d of LF dairy, and the high-fat (HF) group incorporated ≥3 servings/d of HF dairy. We evaluated HbA1c, body weight, BMI, body composition parameters, blood pressure (BP), lipid parameters, homeostatic model assessment of insulin resistance (HOMA-IR), and total energy and macronutrient intake at baseline, and after 12 and 24 wk. RESULTS At 24 wk, percent energy from saturated fat increased from baseline in the HF group by 3.6%, (95% CI: 2.2, 5.1) and decreased in the LF group by -1.9% (95% CI: -3.3, -0.4). The LF group increased their percent energy from protein by 4.5% (95% CI: 2.6, 6.4), whereas the HF group decreased their percent energy from carbohydrates by -3.4% (95% CI: -0.2, -6.7). There were no differences in the mean changes in HbA1c, body weight, BMI, body composition or lipid parameters, or BP between the 3 groups at 24 wk. CONCLUSION In patients with type 2 diabetes, increased dairy consumption to ≥3 servings/d compared with <3 servings/d, irrespective of its fat content, while maintaining energy intake has no effect on HbA1c, body weight, body composition, lipid profile, or BP. This trial was registered at clinicaltrials.gov as NCT02895867.",2020,"There were no differences in the mean changes in HbA1c, body weight, BMI, body composition or lipid parameters, or BP between the 3 groups at 24 wk. CONCLUSION ","['111 subjects with type 2 diabetes (aged 58.5\xa0±\xa08.9 y, 47% females, diabetes duration 13.2\xa0±\xa08.3 y, HbA1c 8.09\xa0±\xa00.96%) who consumed\xa0<3 servings of dairy/d', 'patients with type 2 diabetes']","['dairy consumption and its fat content', 'control group maintained baseline dairy intake, low-fat (LF) group incorporated\xa0≥3 servings/d of LF dairy, and the high-fat (HF) group incorporated\xa0≥3 servings/d of HF dairy', 'high- compared with low-fat dairy']","['glycated hemoglobin (HbA1c), body weight, and cardiovascular disease risk factors', 'HbA1c, body weight, body composition, lipid profile, or BP', 'glycemic control and cardiovascular disease risk factors', 'percent energy from protein', 'mean changes in HbA1c, body weight, BMI, body composition or lipid parameters, or BP', 'dairy consumption', 'percent energy from saturated fat', 'HbA1c, body weight, BMI, body composition parameters, blood pressure (BP), lipid parameters, homeostatic model assessment of insulin resistance (HOMA-IR), and total energy and macronutrient intake']","[{'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0242970', 'cui_str': 'Low fat diet'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0015677', 'cui_str': 'Fat'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}]",111.0,0.0619029,"There were no differences in the mean changes in HbA1c, body weight, BMI, body composition or lipid parameters, or BP between the 3 groups at 24 wk. CONCLUSION ","[{'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Mitri', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA, USA.'}, {'ForeName': 'Shaheen', 'Initials': 'S', 'LastName': 'Tomah', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA, USA.'}, {'ForeName': 'Adham', 'Initials': 'A', 'LastName': 'Mottalib', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA, USA.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Salsberg', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA, USA.'}, {'ForeName': 'Sahar', 'Initials': 'S', 'LastName': 'Ashrafzadeh', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA, USA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Pober', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA, USA.'}, {'ForeName': 'Ahmed H', 'Initials': 'AH', 'LastName': 'Eldib', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA, USA.'}, {'ForeName': 'Mhd Wael', 'Initials': 'MW', 'LastName': 'Tasabehji', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA, USA.'}, {'ForeName': 'Osama', 'Initials': 'O', 'LastName': 'Hamdy', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA, USA.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqaa138'] 1232,32505701,Effect of Parent Training on Health-Related Quality of Life in Preschool Children With Attention-Deficit/Hyperactivity Disorder: A Secondary Analysis of Data From a Randomized Controlled Trial.,"OBJECTIVE School-age children with attention-deficit/hyperactivity disorder (ADHD) have reduced health-related quality of life (HRQoL), but it is unclear whether this is also true for preschool children. It is unknown whether parent training (PT) improves HRQoL. This study compared HRQoL in preschool children with ADHD with age-matched children from the general population; examined whether PT improves HRQoL; and tested if treatment-related changes in HRQoL were mediated by improvements in ADHD, parent efficacy, and family stress. METHOD Parents of 164 children age 3-7 years with an ADHD diagnosis participated in a randomized controlled trial comparing the New Forest Parenting Programme and treatment as usual. Measures of HRQoL, ADHD, parent efficacy, and family stress were completed at baseline, posttreatment, and 36-week follow-up. Child baseline HRQoL was compared with two general population-based reference groups. PT effects were analyzed using linear models and mediation analyses. RESULTS Preschoolers with ADHD had lower HRQoL than the reference groups. The New Forest Parenting Programme, but not treatment as usual, was associated with improvement in psychosocial HRQoL at posttreatment (change 2.28, 95% CI [0.78, 3.77]) and at 36-week follow-up (change 2.05, 95% CI [0.56, 3.54]). This difference between treatment arms was not statistically significant. Parent efficacy and family stress scores at posttreatment significantly mediated improvements in HRQoL at 36-week follow-up; ADHD scores at posttreatment did not. CONCLUSION ADHD negatively impacts HRQoL in early childhood. PT for ADHD has the potential to improve HRQoL independently of its effects on ADHD symptoms. CLINICAL TRIAL REGISTRATION INFORMATION A Controlled Study of Parent Training in the Treatment of ADHD in Young Children (D'SNAPP); http://clinicaltrial.gov/; NCT01684644.",2020,"NFPP, but not TAU, was associated with improvement in the psychosocial HRQoL at T2 (2.28, 95% CI [0.78; 3.77]) and at T3 (2.05, 95% CI [0.56; 3.54]).","['With Attention-Deficit/Hyperactivity Disorder', 'Preschool Children', 'School-aged children with attention-deficit/hyperactivity disorder (ADHD', 'Parents of 164 children, aged 3-7 years diagnosed with ADHD', 'Preschoolers with ADHD', 'preschool children with ADHD with age-matched children from the general population']","['Parent Training', 'New Forest Parenting Programme (NFPP) and Treatment', 'HRQoL', 'parent training (PT']","['psychosocial HRQoL', 'ADHD scores', 'HRQoL', 'PE and FS scores', 'Health-Related Quality of Life', 'PT effects', 'HRQoL, ADHD, PE and FS', 'efficacy (PE) and family stress (FS']","[{'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0086312', 'cui_str': 'Forest'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]","[{'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0577730', 'cui_str': 'Family tension'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",164.0,0.325556,"NFPP, but not TAU, was associated with improvement in the psychosocial HRQoL at T2 (2.28, 95% CI [0.78; 3.77]) and at T3 (2.05, 95% CI [0.56; 3.54]).","[{'ForeName': 'Liva Bundgaard', 'Initials': 'LB', 'LastName': 'Larsen', 'Affiliation': 'Aarhus University, Denmark. Electronic address: livlar@rm.dk.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Daley', 'Affiliation': 'University of Nottingham, UK.'}, {'ForeName': 'Anne-Mette', 'Initials': 'AM', 'LastName': 'Lange', 'Affiliation': 'Aarhus University Hospital, Denmark.'}, {'ForeName': 'Edmund', 'Initials': 'E', 'LastName': 'Sonuga-Barke', 'Affiliation': 'Aarhus University, Denmark; Kings College, London, UK.'}, {'ForeName': 'Per Hove', 'Initials': 'PH', 'LastName': 'Thomsen', 'Affiliation': 'Aarhus University Hospital, Denmark.'}, {'ForeName': 'Charlotte Ulrikka', 'Initials': 'CU', 'LastName': 'Rask', 'Affiliation': 'Aarhus University Hospital, Denmark.'}]",Journal of the American Academy of Child and Adolescent Psychiatry,['10.1016/j.jaac.2020.04.014'] 1233,32512477,"Effect of a maximal exercise test on serum and urinary concentrations of magnesium, phosphorous, rubidium and strontium in athletes.","AIM This study aims to determine the changes induced by a maximal exercise test until exhaustion on the serum and urinary concentrations of Magnesium (Mg), Phosphorous (P), Rubidium (Rb) and Strontium (Sr) in athletes (AG) and sedentary students (SG). METHODS Fifty subjects participated in the study divided into two groups. In AG there were twenty-five male athletes and in SG there were twenty-five male sedentary students. Both groups performed an exercise test until exhaustion, starting at 8 or 10 km/h respectively, and increasing the speed at 1 km/h every 400 m. Serum and urine samples were obtained from all participants before and after the test. RESULTS Regarding the basal status, AG showed lower values of Mg in serum (p < 0.05) and urine (p < 0.01), but higher concentrations of serum P (p < 0.05) in comparison to SG. Comparing the pre and post-test values, corrected or non-corrected for hemoconcentration in serum and for creatinine in urine, AG showed a decrease in serum Mg (p < 0.05), in serum P (p < 0.01) and in urinary Sr (p < 0.01) while an increase was observed in urinary P (p < 0.05) and in urinary Rb (p < 0.05). CONCLUSIONS It can be concluded that a treadmill test until exhaustion leads to changes in serum and urinary concentrations of minerals in both AG and SG males. This may reflect an adaptive response of the body to overcome the physical stress and, in some cases, to avoid loss of these elements.",2020,"Regarding the basal status, AG showed lower values of Mg in serum (p < 0.05) and urine (p < 0.01), but higher concentrations of serum P (p < 0.05) in comparison to SG.","['athletes', 'athletes (AG) and sedentary students (SG', 'In AG there were twenty-five male athletes and in SG there were twenty-five male sedentary students', 'Fifty subjects participated in the study divided into two groups']",['maximal exercise test'],"['urinary Rb', 'serum and urinary concentrations of Magnesium (Mg), Phosphorous (P), Rubidium (Rb) and Strontium (Sr', 'urinary Sr', 'serum and urinary concentrations of magnesium, phosphorous, rubidium and strontium']","[{'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}]","[{'cui': 'C0035930', 'cui_str': 'Rubidium'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0232827', 'cui_str': 'Urinary concentration'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0031705', 'cui_str': 'Phosphorus'}, {'cui': 'C0038467', 'cui_str': 'Strontium'}]",25.0,0.0207851,"Regarding the basal status, AG showed lower values of Mg in serum (p < 0.05) and urine (p < 0.01), but higher concentrations of serum P (p < 0.05) in comparison to SG.","[{'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Muñoz', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: diegomun@unex.es.'}, {'ForeName': 'Francisco J', 'Initials': 'FJ', 'LastName': 'Grijota', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: fgrijota@gmail.com.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Siquier-Coll', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: jsiquier@alumnos.unex.es.'}, {'ForeName': 'Víctor', 'Initials': 'V', 'LastName': 'Toro-Román', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: vtororom@alumnos.unex.es.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Bartolomé', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: ignbs.1991@gmail.com.'}, {'ForeName': 'Marcos', 'Initials': 'M', 'LastName': 'Maynar-Mariño', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: mmaynar@unex.es.'}]",Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS),['10.1016/j.jtemb.2020.126572'] 1234,32517492,Intraoperative Effect of 2D vs 3D Fluoroscopy on Quality of Reduction and Patient-Related Outcome in Calcaneal Fracture Surgery.,"BACKGROUND Three-dimensional (3D) fluoroscopy is thought to be advantageous in the open reduction and internal fixation (ORIF) of calcaneal fractures. The goal of this multicenter randomized controlled trial was to investigate the clinical effect of additional intraoperative 3D fluoroscopy on postoperative quality of reduction and fixation and patient-reported outcome as compared to conventional 2-dimensional (2D) fluoroscopy in patients with intra-articular fractures of the calcaneus. METHODS Patients were randomized to 3D or conventional 2D fluoroscopy during operative treatment of calcaneal fractures. Primary outcome was the difference in quality of fracture reduction and implant position on postoperative computed tomography (CT). Secondary endpoints included intraoperative corrections (prior to wound closure), complications, and revision surgery (after wound closure). Function and patient-reported outcome were evaluated after surgery and included range of motion, Foot and Ankle Outcome Score (FAOS), American Orthopaedic Foot & Ankle Society (AOFAS) score, Short-Form 36 (SF-36) questionnaires, and Kellgren-Lawrence posttraumatic osteoarthritis classification. A total of 102 calcaneal fractures were included in the study in 100 patients. Fifty fractures were randomized to the 3D group and 52 to the 2D group. RESULTS There was a statistically significant difference in duration of surgery between the groups (2D 125 min vs 3D 147 min; P < .001). After 3D fluoroscopy, a total of 57 intraoperative corrections were performed in 28 patients (56%). The postoperative CT scan revealed an indication for additional revision of reduction or implant position in 69% of the 3D group vs 60% in the 2D fluoroscopy group. At 2 years, there was no difference in number of revision surgery, complications, FAOS, AOFAS score, SF-36 score, or posttraumatic osteoarthritis. CONCLUSION The use of intraoperative 3D fluoroscopy in the treatment of intra-articular calcaneal fractures prolongs the operative procedures without improving the quality of reduction and fixation. There was no benefit of intraoperative 3D fluoroscopy with regard to postoperative complications, quality of life, functional outcome, or posttraumatic osteoarthritis. Level of Evidence: Level I, prospective randomized controlled study.",2020,"There was no benefit of intraoperative 3D fluoroscopy with regard to postoperative complications, quality of life, functional outcome, or posttraumatic osteoarthritis. ","['patients with intra-articular fractures of the calcaneus', 'Calcaneal Fracture Surgery', '102 calcaneal fractures were included in the study in 100 patients', 'Fifty fractures were randomized to the 3D group and 52 to the 2D group', 'Patients']","['conventional 2-dimensional (2D) fluoroscopy', 'conventional 2D fluoroscopy', 'intraoperative 3D fluoroscopy', '2D vs 3D Fluoroscopy', 'additional intraoperative 3D fluoroscopy']","['postoperative CT scan', 'number of revision surgery, complications, FAOS, AOFAS score, SF-36 score, or posttraumatic osteoarthritis', 'postoperative complications, quality of life, functional outcome, or posttraumatic osteoarthritis', 'additional revision of reduction or implant position', 'duration of surgery', 'quality of fracture reduction and implant position on postoperative computed tomography (CT', 'quality of reduction and fixation', 'range of motion, Foot and Ankle Outcome Score (FAOS), American Orthopaedic Foot & Ankle Society (AOFAS) score, Short-Form 36 (SF-36) questionnaires, and Kellgren-Lawrence posttraumatic osteoarthritis classification', 'intraoperative 3D fluoroscopy', 'Quality of Reduction and Patient-Related Outcome', 'intraoperative corrections (prior to wound closure), complications, and revision surgery (after wound closure']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332715', 'cui_str': 'Fracture, intra-articular'}, {'cui': 'C0006655', 'cui_str': 'Bone structure of calcaneum'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0439616', 'cui_str': 'Revisions'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0016641', 'cui_str': 'Fixation of fracture'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0450015', 'cui_str': 'Method of wound closure'}]",50.0,0.0919927,"There was no benefit of intraoperative 3D fluoroscopy with regard to postoperative complications, quality of life, functional outcome, or posttraumatic osteoarthritis. ","[{'ForeName': 'Jens A', 'Initials': 'JA', 'LastName': 'Halm', 'Affiliation': 'Trauma Unit, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'M Suzan H', 'Initials': 'MSH', 'LastName': 'Beerekamp', 'Affiliation': 'Trauma Unit, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Robert Jan', 'Initials': 'RJ', 'LastName': 'de Muinck-Keijzer', 'Affiliation': 'Trauma Unit, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Ludo F M', 'Initials': 'LFM', 'LastName': 'Beenen', 'Affiliation': 'Department of Radiology, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Maas', 'Affiliation': 'Department of Radiology, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'J Carel', 'Initials': 'JC', 'LastName': 'Goslings', 'Affiliation': 'Department of Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Schepers', 'Affiliation': 'Trauma Unit, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.'}]",Foot & ankle international,['10.1177/1071100720926111'] 1235,32522591,Mothers' DASH diet adherence and food purchases after week-long episodic future thinking intervention.,"Prospection has helped participants forego the temptation to buy and eat higher calorie nutrient poor foods in favor of buying and eating fewer calories and healthier macronutrient profiles in laboratory tasks and brief field studies. This pilot study examines whether episodic future thinking (EFT) improves mothers' dietary behavior and food purchasing over a longer 7-10-day period. The study utilized a 2 × 2 factorial design with mothers (N = 60) randomized to EFT or standardized episodic thinking (SET) crossed with dietary approaches to stop hypertension (DASH) diet education or a food safety education control. Participants listened to their cues (e.g., recordings of themselves imagining a future event or recalling a past episode) using a mobile ecological momentary intervention (EMI) tool and returned to complete a follow-up dietary recall and submit food receipts. Results showed diets of mothers in the EFT groups became more concordant with the DASH diet (η p 2  = 0.08, p < .05) than mothers in the SET group. When considering food purchases for the family, there was an EFT effect on milligrams of sodium purchased (η p 2  = 0.07, p < .05) and a trend towards a decrease in grams of fat purchased (η p 2  = 0.06, p = .06), however, these findings were no longer significant after correcting for multiple comparisons. There were no DASH education effects and no DASH by EFT interactions observed. The dietary intake and food purchasing results should be replicated in larger more representative samples.",2020,"Results showed diets of mothers in the EFT groups became more concordant with the DASH diet (η p 2  = 0.08, p < .05) than mothers in the SET group.",['2\u202f×\u202f2 factorial design with mothers (N\u202f=\u202f60) randomized to'],"['episodic future thinking (EFT', 'EFT or standardized episodic thinking (SET) crossed with dietary approaches to stop hypertension (DASH) diet education or a food safety education control', 'mobile ecological momentary intervention (EMI) tool and returned to complete a follow-up dietary recall and submit food receipts']","['DASH education effects', ""mothers' dietary behavior and food purchasing"", 'grams of fat purchased']","[{'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]","[{'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0016884', 'cui_str': 'Future'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C4053458', 'cui_str': 'Dietary Approaches to Stop Hypertension diet'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C1456535', 'cui_str': 'Food Safety'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0016452', 'cui_str': 'Foods'}]","[{'cui': 'C4053458', 'cui_str': 'Dietary Approaches to Stop Hypertension diet'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0439208', 'cui_str': 'g'}, {'cui': 'C0015677', 'cui_str': 'Fat'}]",60.0,0.0401892,"Results showed diets of mothers in the EFT groups became more concordant with the DASH diet (η p 2  = 0.08, p < .05) than mothers in the SET group.","[{'ForeName': 'Kelseanna', 'Initials': 'K', 'LastName': 'Hollis-Hansen', 'Affiliation': 'Department of Population Health, University of Texas at Austin, Dell Medical School, Austin, TX, USA; University of Texas at Austin, Steve Hicks School of Social Work, Austin, TX, USA. Electronic address: kelseanna.hollishansen@austin.utexas.edu.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Seidman', 'Affiliation': 'Department of Pediatrics, Division of Behavioral Medicine, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': ""O'Donnell"", 'Affiliation': 'Department of Pediatrics, Division of Behavioral Medicine, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.'}, {'ForeName': 'Leonard H', 'Initials': 'LH', 'LastName': 'Epstein', 'Affiliation': 'Department of Pediatrics, Division of Behavioral Medicine, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.'}]",Appetite,['10.1016/j.appet.2020.104757'] 1236,32682929,"Antioxidant supplementation, redox deficiencies and exercise performance: A falsification design.","The aim of the present study was to validate the idea of personalized redox supplementation by subjecting individuals to targeted and non-targeted antioxidant supplementation schemes. Seventy-three volunteers were screened for plasma vitamin C and erythrocyte glutathione levels. Three groups were formed: i) the ""low vitamin C″ group (12 individuals with the lowest vitamin C levels; Low VitC), ii) the ""low glutathione"" group (12 individuals with the lowest glutathione levels; Low GSH) and iii) a control group (12 individuals with moderate vitamin C and glutathione levels). The three groups received 1 g of vitamin C or 1.2 g of NAC daily for 30 days in a crossover design with a wash-out period of 30 days. Both antioxidant treatments reduced the increased resting systemic oxidative stress levels, assessed via urine F 2 -isoprostanes, in the Low VitC and Low GSH groups (P < .05). A significant group × time interaction (P < .05) was found for VO 2 max and isometric peak torque after both treatments, with the Low VitC and Low GSH groups exhibiting improved performance only after the targeted treatment (vitamin C and NAC, respectively). A significant group × time interaction (P < .05) was found for fatigue index after NAC treatment, but not after vitamin C treatment. No interaction was found for the Wingate test after both treatments. Most of the evidence verifies the idea that antioxidant supplementation increases performance when a particular deficiency is reversed. This indicates that the presence of oxidative stress per se does not rationalize the use of antioxidants and emphasizes the need to identify ""responsive"" phenotypes.",2020,"A significant group × time interaction (P<.05) was found for VO 2 max and isometric peak torque after both treatments, with the Low VitC and Low GSH groups exhibiting improved performance only after the targeted treatment (vitamin C and NAC, respectively).",[],"['low vitamin C"" group (12 individuals with the lowest vitamin C levels; Low VitC), ii) the ""low glutathione"" group (12 individuals with the lowest glutathione levels; Low GSH) and iii) a control group (12 individuals with moderate vitamin C and glutathione levels', 'antioxidant supplementation', 'personalized redox supplementation', 'vitamin C or 1.2g of NAC']","['Antioxidant supplementation, redox deficiencies and exercise performance', 'fatigue index', 'resting systemic oxidative stress levels', 'VO 2 max and isometric peak torque', 'plasma vitamin C and erythrocyte glutathione levels']",[],"[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0201898', 'cui_str': 'Ascorbic acid measurement'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0202053', 'cui_str': 'Glutathione measurement'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0030012', 'cui_str': 'Oxidation-reduction'}, {'cui': 'C4068880', 'cui_str': '1.2'}, {'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}]","[{'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0030012', 'cui_str': 'Oxidation-reduction'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0202053', 'cui_str': 'Glutathione measurement'}]",73.0,0.0729379,"A significant group × time interaction (P<.05) was found for VO 2 max and isometric peak torque after both treatments, with the Low VitC and Low GSH groups exhibiting improved performance only after the targeted treatment (vitamin C and NAC, respectively).","[{'ForeName': 'Nikos V', 'Initials': 'NV', 'LastName': 'Margaritelis', 'Affiliation': 'Department of Physical Education and Sport Science at Serres, Aristotle University of Thessaloniki, Serres, Greece; Dialysis Unit, 424 General Military Hospital of Thessaloniki, Thessaloniki, Greece. Electronic address: nvmargar@auth.gr.'}, {'ForeName': 'Vassilis', 'Initials': 'V', 'LastName': 'Paschalis', 'Affiliation': 'School of Physical Education and Sport Science, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: vpaschalis@phed.uoa.gr.'}, {'ForeName': 'Anastasios A', 'Initials': 'AA', 'LastName': 'Theodorou', 'Affiliation': 'Department of Health Sciences, School of Sciences, European University Cyprus, Nicosia, Cyprus. Electronic address: a.theodorou@euc.ac.cy.'}, {'ForeName': 'Antonios', 'Initials': 'A', 'LastName': 'Kyparos', 'Affiliation': 'Department of Physical Education and Sport Science at Serres, Aristotle University of Thessaloniki, Serres, Greece. Electronic address: akyparos@auth.gr.'}, {'ForeName': 'Michalis G', 'Initials': 'MG', 'LastName': 'Nikolaidis', 'Affiliation': 'Department of Physical Education and Sport Science at Serres, Aristotle University of Thessaloniki, Serres, Greece. Electronic address: nikolaidis@auth.gr.'}]",Free radical biology & medicine,['10.1016/j.freeradbiomed.2020.06.029'] 1237,32526448,Exploratory study of association between blood immune markers and cognitive symptom severity in major depressive disorder: Stratification by body mass index status.,"BACKGROUND A subset of patients with Major Depressive Disorder (MDD) have shown differences relative to healthy controls in blood inflammatory and immune markers. Meanwhile, MDD and comorbid obesity appear to present with distinct biological and symptom characteristics, categorised as ""atypical"" or ""immunometabolic"" depression, although the relevant underlying biological mechanisms are still uncertain. Therefore, this exploratory study aimed to better characterise the relationship between peripheral blood immune markers and symptoms of MDD, as well as the extent to which body mass index (BMI) may alter this relationship. METHODS Linear regression analyses were performed between selected baseline characteristics including clinical scales and blood inflammatory markers in participants with MDD (n = 119) enrolled in the PREDDICT randomised controlled trial (RCT), using age, sex and BMI as covariates, and then stratified by BMI status. Specifically, the Montgomery-Åsberg Depression Rating Scale (MADRS) for symptom severity, Clinical Global Impression scale (CGI) for functional impairment, Oxford Depression Questionnaire (ODQ) for emotional blunting, and THINC integrated tool (THINC-it) for cognitive function were considered as clinical measures. RESULTS There was a significant association between basophil count and THINC-it Codebreaker mean response time (associated with complex attention, perceptual motor, executive function, and learning and memory abilities) in overweight individuals and with THINC-it Trails total response time (associated with executive function ability) in moderately obese individuals, when controlling for age, sex, and years of education. No correlation was found between any tested blood markers and MADRS, CGI or ODQ clinical measures, regardless of BMI. DISCUSSION Although the present study is exploratory, the results suggest that targeting of the immune system and of metabolic parameters might confer benefits, specifically in patients with high BMI and experiencing cognitive impairment associated with MDD. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12617000527369p. Registered on 11 April 2017.",2020,"No correlation was found between any tested blood markers and MADRS, CGI or ODQ clinical measures, regardless of BMI. ","['moderately obese individuals', 'overweight individuals and with THINC-it', 'participants with MDD (n = 119) enrolled', 'patients with high BMI and experiencing cognitive impairment associated with MDD', 'major depressive disorder', 'patients with Major Depressive Disorder (MDD']",[],"['Trails total response time', 'basophil count and THINC', 'clinical scales and blood inflammatory markers', 'Montgomery-Åsberg Depression Rating Scale (MADRS) for symptom severity, Clinical Global Impression scale (CGI) for functional impairment, Oxford Depression Questionnaire (ODQ) for emotional blunting, and THINC integrated tool (THINC-it) for cognitive function', 'complex attention, perceptual motor, executive function, and learning and memory abilities', 'blood markers and MADRS, CGI or ODQ clinical measures, regardless of BMI']","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}]",[],"[{'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0200641', 'cui_str': 'Basophil count'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C2960593', 'cui_str': 'Montgomery-Åsberg depression rating scale'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C3639708', 'cui_str': 'Clinical global impression scale'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0233469', 'cui_str': 'Blunted affect'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",119.0,0.0202413,"No correlation was found between any tested blood markers and MADRS, CGI or ODQ clinical measures, regardless of BMI. ","[{'ForeName': 'Célia', 'Initials': 'C', 'LastName': 'Fourrier', 'Affiliation': 'Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, Australia; Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Sampson', 'Affiliation': 'Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Hikaru', 'Initials': 'H', 'LastName': 'Hori', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health, Kitakyushu City, Japan.'}, {'ForeName': 'K Oliver', 'Initials': 'KO', 'LastName': 'Schubert', 'Affiliation': 'Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, Australia; Northern Adelaide Mental Health Service, Salisbury, Australia.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Clark', 'Affiliation': 'Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Natalie T', 'Initials': 'NT', 'LastName': 'Mills', 'Affiliation': 'Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Bernhard T', 'Initials': 'BT', 'LastName': 'Baune', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital Münster, University of Münster, Münster, Germany; Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Australia; The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia. Electronic address: bernhard.baune@ukmuenster.de.'}]","Brain, behavior, and immunity",['10.1016/j.bbi.2020.06.007'] 1238,32527120,Using medical comics to explore challenging everyday topics in medicine: lessons learned from teaching medical humanities.,"BACKGROUND Studying medicine requires an extensive acquisition of knowledge, skills and attitudes. At the MedUni Vienna, this wide range of skills is strengthened by discussing aspects of medical humanities (MH) with medical students in their pre-clinical fifth study year. Medical comics (MCs), as a part of MH, offer the possibility to address challenging situations within medical settings through the use of graphic illustrations. Thus, patient stories as well as different perspectives of patients, caregivers, and medical staff can be addressed. METHODS A total of 506 medical students were randomly assigned to one of three MCs within a blended learning setting via the Moodle online learning platform. The medical students were instructed to reflect on the MC by answering three questions within one week. Depending on the MC assigned, the learning objectives were to (I) comprehend demands on a young doctor during a night shift, (II) reflect on a patient examination situation, or (III) recognize patients' physical and/or emotional needs. The word counts of the answers and the time spent online answering the questions in the learning platform were analyzed. This was followed by an analysis in which the answers and their content were rated on a three-point Likert scale (insufficient, sufficient, exceptional). Subsequently, an MH and MCs lecture was held that incorporated the medical students' reflections. After the lecture, a one-minute paper (OMP) survey comprising two questions was conducted on the learning platform. RESULTS Of the 506 medical students assigned the online task, 505 completed it. On average, each medical student wrote 110.87 words (SD: 78.54; range, 4.00-602.00) and spent 12.75 minutes (SD: 11.60) on the task. Of all the answers, 84% were rated as sufficient or exceptional. Two OMP questions: (I) ""What was the most important thing you learned today?"", and (II) ""What questions remain unanswered?"" were answered by the medical students. ""What was the most important thing you learned today?"" was answered by 78% (n=393) of the medical students with a profound statement. When asked ""What questions remain unanswered?"", 85% (n=429) of the medical students stated that nothing was left unanswered. All the answers included 154 positive and 28 negative comments on the lecture. CONCLUSIONS The study results indicate that medical students saw great potential in the use of MCs in medical teaching in terms of addressing challenging topics and reflecting on them deeply. This kind of blended learning (a form of learning in which the advantages of face-to-face events and e-learning are combined) successfully showed that medical students can gain a deeper understanding of MH and be inspired through the use of MCs.",2020,"On average, each medical student wrote 110.87 words (SD: 78.54; range, 4.00-602.00) and spent 12.75 minutes (SD: 11.60) on the task.","['506 medical students assigned the online task', '506 medical students', '78% (n=393) of the medical students with a profound statement']","['blended learning', 'MCs within a blended learning setting via the Moodle online learning platform']",[],"[{'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439808', 'cui_str': 'Profound'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C4505477', 'cui_str': 'Online Education'}]",[],506.0,0.014258,"On average, each medical student wrote 110.87 words (SD: 78.54; range, 4.00-602.00) and spent 12.75 minutes (SD: 11.60) on the task.","[{'ForeName': 'Eva Katharina', 'Initials': 'EK', 'LastName': 'Masel', 'Affiliation': 'Department of Internal Medicine I, Division of Palliative Care, Medical University of Vienna, Vienna, Austria. eva.masel@gmx.at.'}, {'ForeName': 'Feroniki', 'Initials': 'F', 'LastName': 'Adamidis', 'Affiliation': 'Department of Internal Medicine I, Division of Palliative Care, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Kitta', 'Affiliation': 'Department of Internal Medicine I, Division of Palliative Care, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Gruebl', 'Affiliation': 'Department of Internal Medicine I, Division of Palliative Care, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Unseld', 'Affiliation': 'Department of Internal Medicine I, Division of Palliative Care, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Pavelka', 'Affiliation': 'Teaching Center, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Herbert Hans', 'Initials': 'HH', 'LastName': 'Watzke', 'Affiliation': 'Department of Internal Medicine I, Division of Palliative Care, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Zlabinger', 'Affiliation': 'Teaching Center, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Praschinger', 'Affiliation': 'Teaching Center, Medical University of Vienna, Vienna, Austria.'}]",Annals of palliative medicine,['10.21037/apm-20-261'] 1239,32682992,Characterizing the analgesic effects of real and imagined acupuncture using functional and structure MRI.,"Acupuncture and imagery interventions for pain management have a long history. The present study comparatively investigated whether acupuncture and video-guided acupuncture imagery treatment (VGAIT, watching a video of acupuncture on the participant's own body while imagining it being applied) could modulate brain regional connectivity to produce analgesic effects. The study also examined whether pre-intervention brain functional and structural features could be used to predict the magnitude of analgesic effects. Twenty-four healthy participants were recruited and received four different interventions (real acupuncture, sham acupuncture, VGAIT, and VGAIT control) in random order using a cross-over design. Pain thresholds and magnetic resonance imaging (MRI) data were collected before and after each intervention. We first compared the modulatory effects of real acupuncture and VGAIT on intra- and inter-regional intrinsic brain connectivity and found that real acupuncture decreased regional homogeneity (ReHo) and functional connectivity (FC) in sensorimotor areas, whereas VGAIT increased ReHo in basal ganglia (BG) (i.e., putamen) and FC between the BG subcortical network and default mode network. The altered ReHo and FC were associated with changes in pain threshold after real acupuncture and VGAIT, respectively. A multimodality fusion approach with pre-intervention ReHo and gray matter volume (GMV) as features was used to explore the brain profiles underlying individual variability of pain threshold changes by real acupuncture and VGAIT. Variability in acupuncture responses was associated with ReHo and GMV in BG, whereas VGAIT responses were associated with ReHo and GMV in the anterior insula. These results suggest that, through different pathways, both real acupuncture and VGAIT can modulate brain systems to produce analgesic effects.",2020,"The altered ReHo and FC were associated with changes in pain threshold after real acupuncture and VGAIT, respectively.",['Twenty-four healthy participants'],"['real acupuncture and VGAIT', 'acupuncture and video-guided acupuncture imagery treatment (VGAIT, watching a video of acupuncture', 'pre-intervention ReHo and grey matter volume (GMV', 'interventions (real acupuncture, sham acupuncture, VGAIT, and VGAIT control', 'Acupuncture and imagery interventions']","['pain threshold', 'Pain thresholds and magnetic resonance imaging (MRI) data', 'regional homogeneity (ReHo) and functional connectivity (FC']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]",24.0,0.0799386,"The altered ReHo and FC were associated with changes in pain threshold after real acupuncture and VGAIT, respectively.","[{'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Cao', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States.'}, {'ForeName': 'Yiheng', 'Initials': 'Y', 'LastName': 'Tu', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States.'}, {'ForeName': 'Georgia', 'Initials': 'G', 'LastName': 'Wilson', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States.'}, {'ForeName': 'Scott P', 'Initials': 'SP', 'LastName': 'Orr', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Kong', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States; Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States. Electronic address: jkong2@mgh.harvard.edu.'}]",NeuroImage,['10.1016/j.neuroimage.2020.117176'] 1240,32512314,Women's unmet needs in early labour: Qualitative analysis of free-text survey responses in the M@NGO trial of caseload midwifery.,"OBJECTIVE to analyse women's experiences of early labour care in caseload midwifery in Australia. DESIGN this study sits within a multi-site randomised controlled trial of caseload midwifery versus standard care. Participant surveys were conducted at 6-weeks and 6-months after birth. Free-text responses about experiences of care were subject to critical thematic analysis in NVivo 11 software. SETTING two urban Australian hospitals in different states. PARTICIPANTS women 18 years and over, with a singleton pregnancy, less than 24 weeks' pregnant, not planning a caesarean section or already booked with a care provider; were eligible to participate in the trial. INTERVENTIONS participants were randomised to caseload midwifery or standard care for antenatal, labour and birth and postpartum care. MEASUREMENTS AND FINDINGS The 6-week survey response rate was 58% (n = 1,019). The survey included five open questions about women's experiences of pregnancy, labour and birth, and postnatal care. Nine-hundred and one respondents (88%) provided free text comments which were coded to generate 10 categories. The category of early labour contained data from 84 individual participants (caseload care n = 44; standard care n = 40). Descriptive themes were: (1) needing permission; (2) doing the 'wrong' thing; and (3) being dismissed. Analytic themes were: (1) Seeking: women wanting to be ""close to those who know what's going on""; and (2) Shielding: midwives defending resources and normal birth. KEY CONCLUSIONS Regardless of model of care, early labour care was primarily described in negative terms. This could be attributed to reporting bias, because women who were neutral about early labour care may not comment. Nevertheless, the findings demonstrate a gap in knowledge about early labour care in caseload midwifery models. IMPLICATIONS FOR PRACTICE Maternity services that offer caseload midwifery are ideally placed to evaluate how early labour home visiting impacts women's experiences of early labour.",2020,"IMPLICATIONS FOR PRACTICE Maternity services that offer caseload midwifery are ideally placed to evaluate how early labour home visiting impacts women's experiences of early labour.","['two urban Australian hospitals in different states', 'Nine-hundred and one respondents (88%) provided free text comments which were coded to generate 10 categories', '84 individual participants (caseload care n\xa0=\xa044; standard care n\xa0=\xa040', ""Women's unmet needs in early labour"", ""women's experiences of early labour care in caseload midwifery in Australia"", ""women 18 years and over, with a singleton pregnancy, less than 24 weeks' pregnant, not planning a caesarean section or already booked with a care provider; were eligible to participate in the trial""]","['caseload midwifery versus standard care', 'caseload midwifery or standard care for antenatal, labour and birth and postpartum care']","['pregnancy, labour and birth, and postnatal care']","[{'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C4517900', 'cui_str': '900'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0282411', 'cui_str': 'Editorial Comment'}, {'cui': 'C0007465', 'cui_str': 'Cause of death'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0022864', 'cui_str': 'Labor'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C1171200', 'cui_str': 'Labor care'}, {'cui': 'C0026082', 'cui_str': 'Midwifery'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0006002', 'cui_str': 'Book'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0026082', 'cui_str': 'Midwifery'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2828394', 'cui_str': 'Antenatal'}, {'cui': 'C0022864', 'cui_str': 'Labor'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0032782', 'cui_str': 'Postpartum care'}]","[{'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0022864', 'cui_str': 'Labor'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0032782', 'cui_str': 'Postpartum care'}]",,0.0808094,"IMPLICATIONS FOR PRACTICE Maternity services that offer caseload midwifery are ideally placed to evaluate how early labour home visiting impacts women's experiences of early labour.","[{'ForeName': 'Jyai', 'Initials': 'J', 'LastName': 'Allen', 'Affiliation': 'Mater Research Institute-The University of Queensland, Brisbane, Queensland, Australia; School of Nursing and Midwifery, Griffith University, Meadowbrook, Queensland, Australia. Electronic address: jyai.allen@griffith.edu.au.'}, {'ForeName': 'Bec', 'Initials': 'B', 'LastName': 'Jenkinson', 'Affiliation': 'Mater Research Institute-The University of Queensland, Brisbane, Queensland, Australia. Electronic address: bec.jenkinson@mater.uq.edu.au.'}, {'ForeName': 'Sally K', 'Initials': 'SK', 'LastName': 'Tracy', 'Affiliation': ""Midwifery and Women's Health Research Unit, University of Sydney, Royal Hospital for Women, Randwick, New South Wales, Australia. Electronic address: sally.tracy@sydney.edu.au.""}, {'ForeName': 'Donna L', 'Initials': 'DL', 'LastName': 'Hartz', 'Affiliation': ""Midwifery and Women's Health Research Unit, University of Sydney, Royal Hospital for Women, Randwick, New South Wales, Australia; College of Nursing and Midwifery, Charles Darwin University, Sydney Campus, New South Wales, Australia. Electronic address: donna.hartz@cdu.edu.au.""}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Tracy', 'Affiliation': ""Department of Paediatrics and Child health Westmead Children's Clinical School, The University of Sydney, Westmead, New South Wales, Australia; Westmead Neonatal Intensive Care Unit, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia. Electronic address: mark.tracy@sydney.edu.au.""}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Kildea', 'Affiliation': 'Mater Research Institute-The University of Queensland, Brisbane, Queensland, Australia; Molly Wardaguga Research Centre, College of Nursing and Midwifery, Charles Darwin University, Queensland, Australia. Electronic address: sue.kildea@cdu.edu.au.'}]",Midwifery,['10.1016/j.midw.2020.102751'] 1241,32520900,Associations of pituitary-ovarian hormones and white matter hyperintensities in recently menopausal women using hormone therapy.,"OBJECTIVE Little is known about how menopausal hormone treatment (HT) may influence the development of white matter hyperintensities (WMHs) in the brain. This study evaluated the associations of changes in levels of pituitary-ovarian hormones during HT and changes in WMH. METHODS Women (n = 78 adherent to treatment) enrolled in the Kronos Early Estrogen Prevention Study underwent brain magnetic resonance imaging, and blood collection before and after 48 months of randomization to 0.45 mg/d oral conjugated equine estrogen (oCEE) daily, 50 μg/d transdermal 17β estradiol (tE2), or placebo pills and patches. Women in the active treatment groups also received oral 200 mg/d micronized progesterone the first 12 days of the month. Estradiol (E2), estrone (E1), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were measured in serum by high sensitivity liquid chromatography/mass spectrometry at baseline and following 48 months of HT. Longitudinal change in WMH volume was determined from fluid-attenuated inversion recovery magnetic resonance imaging using a semiautomated image segmentation algorithm. RESULTS Serum levels of FSH, LH, E1, or E2 did not associate with WMH volume at baseline. After 48 months of treatment, smaller increases in WMH associated with decreases in FSH from baseline in the tE2 group and increases in E1 in both tE2 and oCEE groups. Changes in LH did not associate with changes in WMH in any group. CONCLUSIONS Circulating levels of pituitary-ovarian hormones associate with changes in WMH volume in recently menopausal women using HT. Whether these relationships would be influenced by different doses of tE2 or oCEE remains to be determined. : Video Summary:http://links.lww.com/MENO/A590.",2020,"RESULTS Serum levels of FSH, LH, E1, or E2 did not associate with WMH volume at baseline.","['Women (n\u200a=\u200a78 adherent to treatment) enrolled in the Kronos', '50']","['transdermal 17β estradiol (tE2), or placebo pills and patches', ' Video Summary:http://links.lww.com/MENO/A590', 'brain magnetic resonance imaging, and blood collection before and after 48 months of randomization to 0.45\u200amg/d oral conjugated equine estrogen (oCEE', 'hormone therapy', 'menopausal hormone treatment (HT', 'oral 200\u200amg/d micronized progesterone']","['Estradiol (E2), estrone (E1), follicle-stimulating hormone (FSH), and luteinizing hormone (LH', 'WMH', 'Serum levels of FSH, LH, E1, or E2', 'levels of pituitary-ovarian hormones', 'FSH', 'WMH volume']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0040652', 'cui_str': 'Transdermal route'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C4068884', 'cui_str': '0.45'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0019944', 'cui_str': 'Equus caballus'}, {'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0033308', 'cui_str': 'Progesterone'}]","[{'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0014942', 'cui_str': 'Estrone'}, {'cui': 'C0202022', 'cui_str': 'Follicle stimulating hormone measurement'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032002', 'cui_str': 'Disorder of pituitary gland'}, {'cui': 'C0729511', 'cui_str': 'Ovarian hormone'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",,0.216075,"RESULTS Serum levels of FSH, LH, E1, or E2 did not associate with WMH volume at baseline.","[{'ForeName': 'Juliana M', 'Initials': 'JM', 'LastName': 'Kling', 'Affiliation': ""Division of Women's Health Internal Medicine, Mayo Clinic, Scottsdale, AZ, 13737 North 92nd Street, Scottsdale, AZ 85260.""}, {'ForeName': 'Virginia M', 'Initials': 'VM', 'LastName': 'Miller', 'Affiliation': 'Departments of Surgery and Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Nirubol', 'Initials': 'N', 'LastName': 'Tosakulwong', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Lesnick', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Kejal', 'Initials': 'K', 'LastName': 'Kantarci', 'Affiliation': 'Department of Radiology, Mayo Clinic, Rochester, MN.'}]","Menopause (New York, N.Y.)",['10.1097/GME.0000000000001557'] 1242,32526688,Examining the effect of a brief psychoeducation intervention based on self-regulation model on sexual satisfaction for women with breast cancer: A randomized controlled trial.,"PURPOSE The main goal of this study was to investigate whether the Self-Regulation Model could improve sexual satisfaction for women diagnosed with breast cancer. METHODS Adult women diagnosed with breast cancer were recruited from a hospital in Qazvin, Iran. Participants were randomly assigned to either an intervention group (n = 40) or a control group (n = 40). All participants were administered a demographic questionnaire and an Index of Sexual Satisfaction (ISS) pre-intervention, immediately post-intervention, and 1, 2, and 3 months following the intervention. The control group completed the assessments along the same time line as the intervention group. Women in the experimental group were provided three sessions of a psychological individual intervention which included psychoeducation regarding their diagnosis and personalized intervention strategies to improve their overall sexual satisfaction with sexual intercourse. Each intervention took between 60 and 90 min to administer. RESULTS The experimental and control group participants were well balanced in terms of demographic characteristics and sexual satisfaction scores before the intervention. The intervention group showed a positive increasing trend in the sexual satisfaction scores over time while the control group participants had a negative trend (p < 0.05). There were also statistical differences in the sexual satisfaction scores at each follow-up month (p < 0.05) adjusted for the baseline score and relevant demographical variables, showing longer term effects with a significant increase in sexual satisfaction over time. CONCLUSION Providing a psychoeducational based intervention provided an increase of sexual satisfaction during intercourse for women diagnosed with breast cancer. The psychoeducation based intervention provided an opportunity for participants to dispel common myths regarding their disease and obtain new strategies and skills to improve their sexual satisfaction from intercourse with their partners.",2019,"There were also statistical differences in the sexual satisfaction scores at each follow-up month (p < 0.05) adjusted for the baseline score and relevant demographical variables, showing longer term effects with a significant increase in sexual satisfaction over time. ","['women diagnosed with breast cancer', 'Adult women diagnosed with breast cancer were recruited from a hospital in Qazvin, Iran', 'women with breast cancer']","['psychoeducational based intervention', 'Self-Regulation Model', 'psychological individual intervention which included psychoeducation regarding their diagnosis and personalized intervention strategies', 'psychoeducation intervention based on self-regulation model']","['demographic characteristics and sexual satisfaction scores', 'sexual satisfaction scores', 'sexual satisfaction']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022065', 'cui_str': 'Iran'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0684274', 'cui_str': 'Self-control'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0871356', 'cui_str': 'Sexual Gratification'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0482538,"There were also statistical differences in the sexual satisfaction scores at each follow-up month (p < 0.05) adjusted for the baseline score and relevant demographical variables, showing longer term effects with a significant increase in sexual satisfaction over time. ","[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Abedini', 'Affiliation': 'Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran.'}, {'ForeName': 'Frouzan', 'Initials': 'F', 'LastName': 'Olfati', 'Affiliation': 'Metabolic Diseases Research Center, School of Nursing and Midwifery, Qazvin University of Medical Sciences, Qazvin, Iran. Electronic address: folfati@qums.ac.ir.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Oveisi', 'Affiliation': 'Metabolic Disease Research Center, School of Medicine, Qazvin University of Medical Science, Qazvin, Iran. Electronic address: soveysi@qums.ac.ir.'}, {'ForeName': 'Nasim', 'Initials': 'N', 'LastName': 'Bahrami', 'Affiliation': 'Social Determinants of Health Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran. Electronic address: nbahrami@qums.ac.ir.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Astrologo', 'Affiliation': 'Interpersonal Relationships & Development Laboratory, Centre for Research in Human Development, Department of Psychology, Concordia University, Montréal, QC, Canada. Electronic address: lisa.astrologo@live.ca.'}, {'ForeName': 'Yiong Huak', 'Initials': 'YH', 'LastName': 'Chan', 'Affiliation': 'Biostatistics Unit, Yong Loo Lin School of Medicine, National University Health System, Singapore. Electronic address: yiong_huak_chan@nuhs.edu.sg.'}]",European journal of oncology nursing : the official journal of European Oncology Nursing Society,['10.1016/j.ejon.2019.101673'] 1243,32531428,Impact of acute inflammation on the extinction of aversive gut memories.,"Impaired extinction of pain-related fear memories can lead to persistent or resurging fear of pain, contributing to the development and maintenance of chronic pain conditions. The mechanisms underlying maladaptive pain-related learning and memory processes remain incompletely understood, particularly in the context of interoceptive, visceral pain. Inflammation is known to interfere with learning and memory, but its effects on the extinction of pain-related fear memories have never been tested. In a randomized, double-blind, placebo-controlled study, we assessed the impact of experimental acute inflammation on the extinction and reinstatement of conditioned visceral pain-related fear. Forty healthy male volunteers underwent differential fear conditioning with visceral pain as clinically relevant unconditioned stimulus (US). Participants then received an intravenous injection of either 0.8 ng/kg lipopolysaccharide (LPS) as inflammatory stimulus or physiological saline as placebo, and extinction training was conducted at the peak of the inflammatory response. Extinction recall and reinstatement test were performed after overnight consolidation. Results showed that visceral pain represents an effective US, eliciting pronounced conditioned pain-related fear responses. Repeated unreinforced presentation of the pain-predictive cue during extinction training resulted in full extinction of the conditioned behavioral response. However, unexpected re-exposure to the US during reinstatement test resulted in return of fear. Despite pronounced LPS-induced effects on inflammatory markers, cortisol, and negative affect, we did not find evidence that acute inflammation resulted in altered fear extinction. The findings support the notion that visceral pain-related fear learning establishes a robust aversive memory trace that remains preserved during inhibitory learning, leaving a latent vulnerability for the return of fear. Inflammation during inhibitory learning did neither weaken nor further amplify this aversive memory trace, suggesting that it is rather resistant to acute inflammation-induced effects, at least in healthy individuals with no additional vulnerability factors.",2020,"Inflammation during inhibitory learning did neither weaken nor further amplify this aversive memory trace, suggesting that it is rather resistant to acute inflammation-induced effects, at least in healthy individuals with no additional vulnerability factors.","['Forty healthy male volunteers', 'healthy individuals with no additional vulnerability factors']","['intravenous injection of either 0.8ng/kg lipopolysaccharide (LPS) as inflammatory stimulus or physiological saline as placebo, and extinction training', 'extinction training', 'differential fear conditioning with visceral pain as clinically relevant unconditioned stimulus (US', 'placebo']","['full extinction of the conditioned behavioral response', 'return of fear', 'conditioned pain-related fear responses', 'extinction of aversive gut memories']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}]","[{'cui': 'C0021494', 'cui_str': 'Intravenous injection'}, {'cui': 'C0023810', 'cui_str': 'Lipopolysaccharide'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0015347', 'cui_str': 'Psychological Extinction'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0443199', 'cui_str': 'Differential'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0234245', 'cui_str': 'Visceral pain'}, {'cui': 'C0234403', 'cui_str': 'Unconditioned stimulus'}]","[{'cui': 'C0015347', 'cui_str': 'Psychological Extinction'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}]",40.0,0.101091,"Inflammation during inhibitory learning did neither weaken nor further amplify this aversive memory trace, suggesting that it is rather resistant to acute inflammation-induced effects, at least in healthy individuals with no additional vulnerability factors.","[{'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Benson', 'Affiliation': 'Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Germany.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Rebernik', 'Affiliation': 'Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Germany.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Pastoors', 'Affiliation': 'Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Germany.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Brinkhoff', 'Affiliation': 'Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Wegner', 'Affiliation': 'Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Germany; Department of Orthopaedics, Trauma and Reconstructive Surgery, Marienhospital Mülheim an der Ruhr, Germany.'}, {'ForeName': 'Sigrid', 'Initials': 'S', 'LastName': 'Elsenbruch', 'Affiliation': 'Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Germany; Department of Medical Psychology and Medical Sociology, Ruhr University Bochum, Germany.'}, {'ForeName': 'Harald', 'Initials': 'H', 'LastName': 'Engler', 'Affiliation': 'Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Germany. Electronic address: harald.engler@uk-essen.de.'}]","Brain, behavior, and immunity",['10.1016/j.bbi.2020.06.009'] 1244,32534120,Effect of traditional Chinese medicine formula GeGen decoction on primary dysmenorrhea: A randomized controlled trial study.,"ETHNOPHARMACOLOGICAL RELEVANCE GeGen Decoction, a well-known Chinese herbal formula, is widely used in China and other Asian countries to treat gynecological diseases, including primary dysmenorrhea. Pharmacological studies have confirmed that GeGen Decoction is able to inhibit spasmodic contractions of the uterus in vivo and in vitro. AIM OF THE STUDY The objective of this study is to examine the efficacy and safety of GeGen Decoction on primary dysmenorrheic patients. METHODS This was a randomized, double-blinded, placebo-controlled trial. GeGen Decoction or placebo was administered a week before the expected start of each cycle for three consecutive menstrual periods. Between-group differences in pain intensity were detected by visual analogue scale (VAS). In addition, serum levels of arginine vasopressin (AVP) and estrogen (E) were examined by enzyme-linked immunosorbent assay. Metabolomic analysis was further used to evaluate the influence of GeGen Decoction on the metabolomics of primary dysmenorrheic patients. RESULTS A total of 71 primary dysmenorrheic women were recruited and 30 participants met the criteria were randomized into GeGen Decoction or placebo group. After three consecutive menstrual cycles' treatments, the VAS score of the GeGen Decoction group was significantly lower than that of the placebo group. Both serum levels of AVP and E decreased after GeGen Decoction administration, while the placebo seemed to have little effect on either of the index. Moreover, after GeGen Decoction treatment, seven important metabolites were identified by metabolomic analysis compared to the placebo group. No abnormalities in blood biochemical and routine physical examination pre and post GeGen Decoction intervention were observed. CONCLUSIONS GeGen Decoction can remarkably relieve the severity of menstrual pain without obvious adverse effects. Its therapeutic effect on primary dysmenorrhea might be related to the regulation of pituitary hypothalamic ovarian hormones, and interfering with the metabolic change.",2020,"After three consecutive menstrual cycles' treatment, the VAS score of the GeGen Decoction group was significantly lower than that of the placebo group.","['primary dysmenorrhea', 'primary dysmenorrheic patients', '71 primary dysmenorrheic women were recruited and 30 participants met the criteria']","['GeGen Decoction', 'traditional Chinese medicine formula GeGen decoction', 'GeGen Decoction or placebo', 'placebo']","['VAS score', 'pain intensity', 'blood biochemical and routine physical examination pre and post GeGen Decoction intervention', 'visual analogue scale (VAS', 'serum levels of arginine vasopressin (AVP) and estrogen (E', 'serum levels of AVP and E', 'efficacy and safety', 'severity of menstrual pain']","[{'cui': 'C0149875', 'cui_str': 'Primary dysmenorrhea'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003779', 'cui_str': 'Argipressin'}, {'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0013390', 'cui_str': 'Dysmenorrhea'}]",71.0,0.369829,"After three consecutive menstrual cycles' treatment, the VAS score of the GeGen Decoction group was significantly lower than that of the placebo group.","[{'ForeName': 'Chengzhi', 'Initials': 'C', 'LastName': 'Chai', 'Affiliation': 'Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Development, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, PR China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Hong', 'Affiliation': 'Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Development, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, PR China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': 'Shanxi University, Taiyuan, Shanxi Province, PR China.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Development, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, PR China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zong', 'Affiliation': 'Hospital Affiliated to Shanxi University of Traditional Chinese Medicine, Taiyuan, Shanxi Province, PR China.'}, {'ForeName': 'Changsong', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Traditional Chinese Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu Province, PR China.'}, {'ForeName': 'Zhigang', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Department of Traditional Chinese Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu Province, PR China. Electronic address: liuzhigang729@seu.edu.cn.'}, {'ForeName': 'Boyang', 'Initials': 'B', 'LastName': 'Yu', 'Affiliation': 'Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Development, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, PR China. Electronic address: boyangyu59@163.com.'}]",Journal of ethnopharmacology,['10.1016/j.jep.2020.113053'] 1245,32534221,The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.,"INTRODUCTION In women with postmenopausal osteoporosis denosumab discontinuation is associated with rapid bone loss that could be potentially prevented by a single zoledronate infusion for two years. The longer-term effects, however, of zoledronate treatment are unknown. We aimed to study the effect of a single zoledronate infusion during the third year following denosumab discontinuation, in initially treatment-naive postmenopausal women who became osteopenic after 2.4 ± 0.2 years of denosumab therapy. METHODS We report the 1-year follow-up results of a single arm observational extension of a previously reported 2-year multicenter prospective randomized clinical trial. The primary endpoint of this extension was the change in lumbar spine bone mineral density (LS-BMD); secondary endpoints were changes in femoral neck (FN)-BMD and markers of bone turnover (BTM) during the 3rd year from the zoledronate infusion. Changes are presented as mean and SEM. RESULTS LS-BMD did not change significantly at year 3 compared to year 2 (-1.35 ± 1.1%, p = 1.00) and compared to baseline (-1.96 ± 1.44%, p = 1.00). FN-BMD values did not change while serum P1NP values decreased and CTX values remained unchanged during the third-year of the follow-up. In 4 of the 23 studied women BMD values returned to the osteoporotic range at 3 years. CONCLUSIONS A single i.v. infusion of zoledronate 5 mg, given 6 months after the last injection of denosumab therapy maintains for three years BMD gains in the majority of patients previously treated with denosumab for an approximate period of 2.5 years. Follow-up of patients is, however, recommended because about one-fifth of treated women will require additional antiosteoporotic treatment.",2020,FN-BMD values did not change while serum P1NP values decreased and CTX values remained unchanged during the third-year of the follow-up.,"['women with postmenopausal osteoporosis', 'initially treatment-naive postmenopausal women who became osteopenic after 2.4\u202f±\u202f0.2\u202fyears of denosumab therapy']","['single zoledronate infusion', 'zoledronate infusion', 'denosumab', 'zoledronate', 'denosumab discontinuation']","['CTX values', 'femoral neck (FN)-BMD and markers of bone turnover (BTM', 'FN-BMD values', 'lumbar spine bone mineral density (LS-BMD', 'bone mineral density and bone turnover markers', 'LS-BMD']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0029458', 'cui_str': 'Postmenopausal osteoporosis'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C4517631', 'cui_str': '2.4'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3839270', 'cui_str': 'Denosumab therapy'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0392938', 'cui_str': 'Zoledronate'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C1690432', 'cui_str': 'denosumab'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}]","[{'cui': 'C0010377', 'cui_str': 'Crotoxin'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0015815', 'cui_str': 'Structure of neck of femur'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0085268', 'cui_str': 'Bone remodeling'}, {'cui': 'C0024091', 'cui_str': 'Bone structure of lumbar vertebra'}]",23.0,0.0926873,FN-BMD values did not change while serum P1NP values decreased and CTX values remained unchanged during the third-year of the follow-up.,"[{'ForeName': 'Polyzois', 'Initials': 'P', 'LastName': 'Makras', 'Affiliation': 'Department of Endocrinology and Diabetes and Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, Athens, Greece.'}, {'ForeName': 'Socrates E', 'Initials': 'SE', 'LastName': 'Papapoulos', 'Affiliation': 'Center for Bone Quality, Department of Internal Medicine, Section Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Stergios A', 'Initials': 'SA', 'LastName': 'Polyzos', 'Affiliation': 'First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Natasha M', 'Initials': 'NM', 'LastName': 'Appelman-Dijkstra', 'Affiliation': 'Center for Bone Quality, Department of Internal Medicine, Section Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Athanasios D', 'Initials': 'AD', 'LastName': 'Anastasilakis', 'Affiliation': 'Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece. Electronic address: a.anastasilakis@gmail.com.'}]",Bone,['10.1016/j.bone.2020.115478'] 1246,32539432,The Effects of an Online Training on Preservice Speech-Language Pathologists' Use of Family-Centered Skills.,"Purpose Despite the recognition that family-centered services are best practice in augmentative and alternative communication services, many speech-language pathologists (SLPs) are lacking in their acquisition and implementation of family-centered skills. The purpose of this study was to evaluate the effects of online instruction in a family-centered, relational skills strategy on preservice SLPs use of family-centered skills. Method A switching replications design was used to evaluate the effects of an online training on the use of family-centered behaviors by 15 preservice SLPs who were randomly assigned to two groups. The online training taught the students a four-step relational skills strategy (summarized by the acronym LAFF): (a) Listen, empathize, and communicate respect; (b) Ask questions; (c) Focus on the issues; and (d) Find a first step. Participants were videotaped during interactions with simulated parents before and after the training. Results After an average of 61 min of instruction via the online module, all of the preservice SLPs significantly improved their demonstration of relational skills. Additionally, one parent of a child who used augmentative and alternative communication viewed the video recordings and chose 14 of the 15 postinstruction role plays as more family-centered. Conclusion The findings from this study provide support for the use of an online environment to teach preservice SLPs family-centered relational skills. In order to prepare future SLPs and ensure the delivery of family-centered services, future research is necessary, including investigations to determine whether other family-centered skills can be effectively taught through an online environment. Supplemental Material https://doi.org/10.23641/asha.12462344.",2020,"After an average of 61 min of instruction via the online module, all of the preservice SLPs significantly improved their demonstration of relational skills.","[""Preservice Speech-Language Pathologists' Use of Family-Centered Skills"", 'family-centered behaviors by 15 preservice SLPs']","['online instruction', 'online training', 'Supplemental Material https://doi.org/10.23641/asha.12462344', 'Online Training', 'online training taught the students a four-step relational skills strategy (summarized by the acronym LAFF): (a) Listen, empathize, and communicate respect']",['demonstration of relational skills'],"[{'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0334866', 'cui_str': 'Medical pathologist'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]","[{'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C1956259', 'cui_str': 'Acronyms'}, {'cui': 'C0004309', 'cui_str': 'Auditory Perception'}, {'cui': 'C0205196', 'cui_str': 'Communicating'}, {'cui': 'C0679133', 'cui_str': 'Respect'}]",[],,0.0160661,"After an average of 61 min of instruction via the online module, all of the preservice SLPs significantly improved their demonstration of relational skills.","[{'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Mandak', 'Affiliation': 'Department of Communication Sciences and Disorders, The Pennsylvania State University, State College.'}, {'ForeName': 'Janice', 'Initials': 'J', 'LastName': 'Light', 'Affiliation': 'Department of Communication Sciences and Disorders, The Pennsylvania State University, State College.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'McNaughton', 'Affiliation': 'Department of Educational Psychology, Counseling, and Special Education, The Pennsylvania State University, State College.'}]",American journal of speech-language pathology,['10.1044/2020_AJSLP-19-00057'] 1247,32522263,ICT-based adherence monitoring in kidney transplant recipients: a randomized controlled trial.,"BACKGROUND Prior studies have explored the use of regular reminders to improve adherence among kidney transplant recipients (KTRs), but none have included real-time alarms about drug dosage, frequency, and interval. In the present study, we aimed to evaluate the efficacy and stability of an information and communication technology (ICT)-based centralized monitoring system for increasing medication adherence among Korean KTRs. METHODS In this prospective, multicenter, randomized controlled study, enrolled KTRs were randomized to either the ICT-based centralized monitoring group or control group. The ICT-based centralized monitoring system alerted both patients and medical staff with texts and pill box alarms if there was a missed dose or a dosage/time error. We compared the two groups in terms of medication adherence and transplant outcomes over 6 months, and evaluated patient satisfaction with the ICT-based monitoring system. RESULTS Among 114 enrolled KTRs, 57 were assigned to the ICT-based centralized monitoring group and 57 to the control group. The two groups did not significantly differ in mean adherence at each follow-up visit. The intrapatient variability of tacrolimus and mycophenolic acid levels, renal function, and adverse transplant outcomes did not differ between the intervention and control groups, or between the intervention group with feedback generation and the intervention group without feedback generation. Patients showed high overall satisfaction with the ICT-based centralized monitoring system, which significantly improved across the study period (p = 0.012). CONCLUSIONS Due to high baseline adherence, the ICT-based centralized monitoring system did not maximize medication adherence or enhance transplant outcomes among Korean KTRs. However, patients were highly satisfied with the system. Our results suggest that the ICT-based centralized monitoring system could be successfully applied in clinical trials. TRIAL REGISTRATION ClinicalTrials.gov, NCT03136588. Registered 20 April 2017 - Retrospectively registered.",2020,"CONCLUSIONS Due to high baseline adherence, the ICT-based centralized monitoring system did not maximize medication adherence or enhance transplant outcomes among Korean KTRs.","['kidney transplant recipients (KTRs', '114 enrolled KTRs', 'kidney transplant recipients', 'Registered 20 April 2017 - Retrospectively registered', 'Korean KTRs']","['ICT-based centralized monitoring system', 'ICT-based centralized monitoring', 'ICT-based centralized monitoring group or control group', 'ICT-based adherence monitoring', 'information and communication technology (ICT)-based centralized monitoring system']","['intrapatient variability of tacrolimus and mycophenolic acid levels, renal function, and adverse transplant outcomes', 'overall satisfaction', 'mean adherence', 'medication adherence and transplant outcomes']","[{'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}]","[{'cui': 'C0683867', 'cui_str': 'Information Technology'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]","[{'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0026933', 'cui_str': 'Mycophenolic Acid'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}]",,0.0490329,"CONCLUSIONS Due to high baseline adherence, the ICT-based centralized monitoring system did not maximize medication adherence or enhance transplant outcomes among Korean KTRs.","[{'ForeName': 'Hee-Yeon', 'Initials': 'HY', 'LastName': 'Jung', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, 41944, South Korea.'}, {'ForeName': 'Yena', 'Initials': 'Y', 'LastName': 'Jeon', 'Affiliation': 'Department of Statistics, Kyungpook National University, Daegu, South Korea.'}, {'ForeName': 'Sook Jin', 'Initials': 'SJ', 'LastName': 'Seong', 'Affiliation': 'Department of Biomedical Science and Clinical Trial Center, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea.'}, {'ForeName': 'Jung Ju', 'Initials': 'JJ', 'LastName': 'Seo', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, 41944, South Korea.'}, {'ForeName': 'Ji-Young', 'Initials': 'JY', 'LastName': 'Choi', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, 41944, South Korea.'}, {'ForeName': 'Jang-Hee', 'Initials': 'JH', 'LastName': 'Cho', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, 41944, South Korea.'}, {'ForeName': 'Sun-Hee', 'Initials': 'SH', 'LastName': 'Park', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, 41944, South Korea.'}, {'ForeName': 'Chan-Duck', 'Initials': 'CD', 'LastName': 'Kim', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, 41944, South Korea.'}, {'ForeName': 'Young-Ran', 'Initials': 'YR', 'LastName': 'Yoon', 'Affiliation': 'Department of Biomedical Science and Clinical Trial Center, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea.'}, {'ForeName': 'Se-Hee', 'Initials': 'SH', 'LastName': 'Yoon', 'Affiliation': 'Department of Internal Medicine, Konyang University College of Medicine, Daejeon, South Korea.'}, {'ForeName': 'Jong Soo', 'Initials': 'JS', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan, South Korea.'}, {'ForeName': 'Yong-Lim', 'Initials': 'YL', 'LastName': 'Kim', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, 41944, South Korea. ylkim@knu.ac.kr.'}]",BMC medical informatics and decision making,['10.1186/s12911-020-01146-6'] 1248,32524499,"PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta ® ): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers.","INTRODUCTION PF-06881894 is a proposed biosimilar to pegfilgrastim (Neulasta ® ). This study evaluated the pharmacodynamic/pharmacokinetic (PD/PK) equivalence, immunogenicity, and safety of PF-06881894 vs pegfilgrastim reference products (US- and EU-Neulasta ® ) in healthy volunteers. METHODS A phase 1, open-label, randomized, crossover study was conducted to assess the pharmacologic equivalence and safety of a single 6-mg dose of PF-06881894, pegfilgrastim-US, and pegfilgrastim-EU. The primary PD endpoints were area under the effect-versus-time curve for absolute neutrophil count (ANC) from dose administration to 288 h postdose, and maximum observed ANC value among subjects confirmed negative for anti-pegfilgrastim antibodies. Primary PK variables included area under the serum pegfilgrastim-versus-time curve from the time of dose administration to time infinity and maximum observed serum pegfilgrastim concentration. A second phase 1, open-label, randomized (1:1), parallel-group, non-inferiority study was conducted to assess the immunogenicity and safety of multiple 6-mg doses of PF-06881894 versus pegfilgrastim-US. The primary endpoint for the immunogenicity study was the proportion of subjects with both negative baseline and confirmed positive postdose anti-pegfilgrastim antibodies at any time during the study. RESULTS Across the single- and multiple-dose studies (N = 153 and N = 420 treated subjects, respectively), demographics for age (18-65 years), male gender (n = 264/573), and white race (n = 423/573) were similar. Three-way PD/PK equivalence of PF-06881894, pegfilgrastim-US, and pegfilgrastim-EU was demonstrated with the primary PD endpoints and primary PK variables being completely contained within the predefined 90% confidence interval acceptance limits (80-125%). The non-inferiority of PF-06881894 versus pegfilgrastim-US in terms of immunogenicity was established according to the prespecified non-inferiority margin (≤10%). Overall, there were no clinically meaningful differences in safety profiles among or between study groups. CONCLUSIONS Single-dose PF-06881894 demonstrated PD/PK equivalence and comparable safety with US- and EU-pegfilgrastim reference products. Multiple-dose PF-06881894 demonstrated immunogenicity non-inferiority to pegfilgrastim-US with comparable safety. Both studies contributed to the totality of evidence supporting biosimilarity. TRIAL REGISTRATION ClinicalTrials.gov identifiers: NCT02629289; NCT03273842 (C1221005).",2020,The non-inferiority of PF-06881894 versus pegfilgrastim-US in terms of immunogenicity was established according to the prespecified non-inferiority margin (≤10%).,"['Healthy Volunteers', '420 treated subjects, respectively), demographics for age (18-65\xa0years), male gender (n\u2009=\u2009264/573), and white race (n\u2009=\u2009423/573', 'healthy volunteers']","['PF-06881894 vs pegfilgrastim reference products (US- and EU-Neulasta ® ', 'pegfilgrastim-US', 'PF-06881894, pegfilgrastim-US, and pegfilgrastim-EU']","['area under the effect-versus-time curve for absolute neutrophil count (ANC', 'pharmacodynamic/pharmacokinetic (PD/PK) equivalence, immunogenicity, and safety', 'proportion of subjects with both negative baseline and confirmed positive postdose anti-pegfilgrastim antibodies', 'area under the serum pegfilgrastim-versus-time curve from the time of dose administration to time infinity and maximum observed serum pegfilgrastim concentration', 'pharmacologic equivalence and safety', 'PD/PK equivalence', 'immunogenicity and safety', 'confidence interval acceptance limits']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4517774', 'cui_str': '420'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}]","[{'cui': 'C1136535', 'cui_str': 'pegfilgrastim'}, {'cui': 'C1171279', 'cui_str': 'Neulasta'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0948762', 'cui_str': 'Absolute neutrophil count'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1136535', 'cui_str': 'pegfilgrastim'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0009667', 'cui_str': 'Confidence Intervals'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0439801', 'cui_str': 'Limited'}]",420.0,0.0810477,The non-inferiority of PF-06881894 versus pegfilgrastim-US in terms of immunogenicity was established according to the prespecified non-inferiority margin (≤10%).,"[{'ForeName': 'Shahrzad', 'Initials': 'S', 'LastName': 'Moosavi', 'Affiliation': 'Pfizer Inc, New York, NY, USA.'}, {'ForeName': 'Troy', 'Initials': 'T', 'LastName': 'Borema', 'Affiliation': 'Quotient Sciences, Miami, FL, USA.'}, {'ForeName': 'Reginald', 'Initials': 'R', 'LastName': 'Ewesuedo', 'Affiliation': 'Pfizer Inc, Cambridge, MA, USA.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Harris', 'Affiliation': 'Quotient Sciences, Miami, FL, USA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Levy', 'Affiliation': 'Quotient Sciences, Miami, FL, USA.'}, {'ForeName': 'Thomas B', 'Initials': 'TB', 'LastName': 'May', 'Affiliation': 'Pfizer Inc, Lake Forest, IL, USA.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Summers', 'Affiliation': 'Pfizer Inc, San Diego, CA, USA.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Thomas', 'Affiliation': 'Pfizer Inc, San Diego, CA, USA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Pfizer Inc, Lake Forest, IL, USA.'}, {'ForeName': 'Hsuan-Ming', 'Initials': 'HM', 'LastName': 'Yao', 'Affiliation': 'Pfizer Inc, Lake Forest, IL, USA. hsuan-ming.yao@pfizer.com.'}]",Advances in therapy,['10.1007/s12325-020-01387-x'] 1249,32530426,Pay-it-forward gonorrhoea and chlamydia testing among men who have sex with men in China: a randomised controlled trial.,"BACKGROUND WHO recommends that men who have sex with men (MSM) receive gonorrhoea and chlamydia testing, but many evidence-based preventive services are unaffordable. The pay-it-forward strategy offers an individual a gift (eg, a test for sexually transmitted diseases) and then asks whether they would like to give a gift (eg, a future test) to another person. This study examined the effectiveness of a pay-it-forward programme to increase gonorrhoea and chlamydia testing among MSM in China. METHODS We did a randomised controlled superiority trial at three HIV testing sites run by MSM community-based organisations in Guangzhou and Beijing, China. We included MSM aged 16 years or older who were seeking HIV testing and met indications for gonorrhoea and chlamydia testing. Restricted randomisation was done using computer-generated permuted blocks. 30 groups were randomised into three arms (1:1:1): a pay-it-forward arm in which men were offered free gonorrhoea and chlamydia testing and then asked whether they would like to donate for testing of prospective participants, a pay-what-you-want arm in which men were offered free testing and given the option to pay any desired amount for the test, and a standard-of-care arm in which testing was offered at ¥150 (US$22). There was no masking to arm assignment. The primary outcome was gonorrhoea and chlamydia test uptake ascertained by administrative records. We used generalised estimating equations to estimate intervention effects with one-sided 95% CIs and a prespecified superiority margin of 20%. The trial is registered with ClinicalTrials.gov, NCT03741725. FINDINGS Between Dec 8, 2018, and Jan 19, 2019, 301 men were recruited and included in the analysis. 101 were randomly assigned to the pay-it-forward group, 100 to the pay-what-you-want group, and 100 to the standard-of-care group. Test uptake for gonorrhoea and chlamydia was 56% (57 of 101 participants) in the pay-it-forward arm, 46% (46 of 100 participants) in the pay-what-you-want arm, and 18% (18 of 100 participants) in the standard-of-care arm. The estimated difference in test uptake between the pay-it-forward and standard-of-care group was 38·4% (95% CI lower bound 28·4%). Among men in the pay-it-forward arm, 54 of 57 (95%) chose to donate to support testing for others. INTERPRETATION The pay-it-forward strategy can increase gonorrhoea and chlamydia testing uptake among Chinese MSM and could be a useful tool for scaling up preventive services that carry a mandatory fee. FUNDING US National Institute of Health; Special Programme for Research and Training in Tropical Diseases, sponsored by UNICEF, UNDP, World Bank, and WHO; the National Key Research and Development Program of China; Doris Duke Charitable Foundation; and Social Entrepreneurship to Spur Health.",2020,"Test uptake for gonorrhoea and chlamydia was 56% (57 of 101 participants) in the pay-it-forward arm, 46% (46 of 100 participants) in the pay-what-you-want arm, and 18% (18 of 100 participants) in the standard-of-care arm.","['MSM aged 16 years or older who were seeking HIV testing and met indications for gonorrhoea and chlamydia testing', 'men who have sex with men in China', 'MSM in China', 'three HIV testing sites run by MSM community-based organisations in Guangzhou and Beijing, China', 'Between Dec 8, 2018, and Jan 19, 2019, 301 men were recruited and included in the analysis', 'men who have sex with men (MSM']","['pay-it-forward arm in which men were offered free gonorrhoea and chlamydia testing', 'pay-it-forward group, 100 to the pay-what-you-want group, and 100 to the standard-of-care group', 'Pay-it-forward gonorrhoea and chlamydia testing', 'pay-it-forward programme', 'pay-what-you-want arm in which men were offered free testing and given the option to pay any desired amount for the test, and a standard-of-care arm in which testing']",['gonorrhoea and chlamydia test uptake'],"[{'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0018081', 'cui_str': 'Gonorrhea'}, {'cui': 'C0008148', 'cui_str': 'Chlamydia'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0018081', 'cui_str': 'Gonorrhea'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}]","[{'cui': 'C0018081', 'cui_str': 'Gonorrhea'}, {'cui': 'C0008148', 'cui_str': 'Chlamydia'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",301.0,0.098425,"Test uptake for gonorrhoea and chlamydia was 56% (57 of 101 participants) in the pay-it-forward arm, 46% (46 of 100 participants) in the pay-what-you-want arm, and 18% (18 of 100 participants) in the standard-of-care arm.","[{'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Yang', 'Affiliation': 'Dermatology Hospital of Southern Medical University, Guangzhou, China; University of North Carolina at Chapel Hill, Project-China, Guangzhou, China.'}, {'ForeName': 'Tiange P', 'Initials': 'TP', 'LastName': 'Zhang', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China; Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA.'}, {'ForeName': 'Weiming', 'Initials': 'W', 'LastName': 'Tang', 'Affiliation': 'Dermatology Hospital of Southern Medical University, Guangzhou, China; University of North Carolina at Chapel Hill, Project-China, Guangzhou, China.'}, {'ForeName': 'Jason J', 'Initials': 'JJ', 'LastName': 'Ong', 'Affiliation': 'Central Clinical School, Monash University, Melbourne, VIC, Australia; London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Alexander', 'Affiliation': 'Yale Institute for Network Science, Yale University, New Haven, CT, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Forastiere', 'Affiliation': 'Yale Institute for Network Science, Yale University, New Haven, CT, USA; Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.'}, {'ForeName': 'Navin', 'Initials': 'N', 'LastName': 'Kumar', 'Affiliation': 'Yale Institute for Network Science, Yale University, New Haven, CT, USA.'}, {'ForeName': 'Katherine T', 'Initials': 'KT', 'LastName': 'Li', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China; Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Zou', 'Affiliation': 'Department of Biostatistics, University of North Carolina at Chapel Hill, NC, USA.'}, {'ForeName': 'Ligang', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Dermatology Hospital of Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Guodong', 'Initials': 'G', 'LastName': 'Mi', 'Affiliation': 'Blued, Beijing, China.'}, {'ForeName': 'Yehua', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China.'}, {'ForeName': 'Wenting', 'Initials': 'W', 'LastName': 'Huang', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Lee', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China.'}, {'ForeName': 'Weizan', 'Initials': 'W', 'LastName': 'Zhu', 'Affiliation': 'Zhitong Guangzhou LGBT Center, Guangzhou, China.'}, {'ForeName': 'Danyang', 'Initials': 'D', 'LastName': 'Luo', 'Affiliation': 'Zhitong Guangzhou LGBT Center, Guangzhou, China.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Vickerman', 'Affiliation': 'School of Social and Community Medicine, University of Bristol, Bristol, UK.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Wu', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China; London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Yang', 'Affiliation': 'Dermatology Hospital of Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Nicholas A', 'Initials': 'NA', 'LastName': 'Christakis', 'Affiliation': 'Yale Institute for Network Science, Yale University, New Haven, CT, USA.'}, {'ForeName': 'Joseph D', 'Initials': 'JD', 'LastName': 'Tucker', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China; London School of Hygiene and Tropical Medicine, London, UK. Electronic address: jdtucker@med.unc.edu.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(20)30172-9'] 1250,32538561,[Clinical study on reconstruction of posterior cruciate ligament with platelet rich plasma combined with 3-strand peroneus longus tendons].,"Objective To investigate the effectiveness of the reconstruction of posterior cruciate ligament (PCL) with platelet rich plasma (PRP) and 3-strand peroneal longus tendons under arthroscope. Methods Between June 2014 and December 2017, 58 patients with PCL rupture were randomly divided into two groups: the trial group (PRP assisted reconstruction of 3-strand peroneal longus tendons) and the control group (4-strand hamstring tendon reconstruction alone), 29 cases in each group. There was no significant difference in gender, age, injury side, Kellgren-Lawrence grade, time from injury to operation, and preoperative American Orthopaedic Foot and Ankle Society (AOFAS) ankle-hindfoot score, International Knee Documentation Committee (IKDC) score, Lysholm score between the two groups ( P >0.05). Before operation, at 3 months and 12 months after operation, the IKDC score and Lysholm score of the two groups were recorded to evaluate the knee joint function, AOFAS ankle-hindfoot score was used to evaluate ankle function; KT-2000 examination (knee flexion of 90°, 30 lbs) was used to evaluate the difference of bilateral knee joint posterior relaxation at 12 months after operation, and MRI was used to evaluate ligament reconstruction; CT was used to evaluate the bone tunnel expansion of femur and tibia at 3 months and 12 months after operation. Results The operation was completed successfully in both groups, there was no complication in the donor tendon area. All the incisions healed by first intention. All the patients were followed up for more than 1 year. The follow-up time of the trial group was 13-17 months, with an average of 15.0 months; that of the control group was 15-20 months, with an average of 15.4 months. At 3 and 12 months after operation, there was no significant difference in AOFAS ankle-hindfoot score when compared with preoperative score and between the two groups ( P >0.05). At 3 and 12 months after operation, the IKDC score and Lysholm score of the two groups were significantly improved, and further improvement was found at 12 months when compared with at 3 months ( P <0.05); the scores in the trial group were significantly better than those of the control group ( P <0.05). At 12 months after operation, the difference of the posterior relaxation of the bilateral knees in the trial group was less than 5 mm in 27 cases, 6-10 mm in 2 cases; in the control group was less than 5 mm in 20 cases, 6-10 mm in 6 cases, and >10 mm in 3 cases; the difference between the two groups was not significant ( Z =0.606, P =0.544). At 12 months after operation, MRI of knee joint showed that all patients had good PCL graft. The MRI score of the trial group was better than that of the control group ( t =2.425, P =0.019). CT examination at 3 and 12 months after operation showed that the bone tunnel expansion of femur and tibia in the trial group were significantly better than those in the control group ( P <0.05). Conclusion PRP combined with 3-stand peroneal longus tendons can significantly improve the function and stability of knee joint, effectively promote graft remodeling, and promote tendon bone healing, reduce the expansion of bone tunnel. The effectiveness is satisfactory.",2020,"At 3 and 12 months after operation, the IKDC score and Lysholm score of the two groups were significantly improved, and further improvement was found at 12 months when compared with at 3 months ( P <0.05); the scores in the trial group were significantly better than those of the control group ( P <0.05).","['Methods\n\n\nBetween June 2014 and December 2017, 58 patients with PCL rupture']","['posterior cruciate ligament with platelet rich plasma combined with 3-strand peroneus longus tendons', 'posterior cruciate ligament (PCL) with platelet rich plasma (PRP', 'trial group (PRP assisted reconstruction of 3-strand peroneal longus tendons) and the control group (4-strand hamstring tendon reconstruction alone']","['MRI of knee joint', 'AOFAS ankle-hindfoot score', 'IKDC score and Lysholm score', 'MRI score', 'knee joint function, AOFAS ankle-hindfoot score', 'bilateral knee joint posterior relaxation', 'posterior relaxation of the bilateral knees', 'CT examination', 'bone tunnel expansion of femur and tibia', 'gender, age, injury side, Kellgren-Lawrence grade, time from injury to operation, and preoperative American Orthopaedic Foot and Ankle Society (AOFAS) ankle-hindfoot score, International Knee Documentation Committee (IKDC) score, Lysholm score']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0080039', 'cui_str': 'Structure of posterior cruciate ligament of knee joint'}, {'cui': 'C0443294', 'cui_str': 'Ruptured'}]","[{'cui': 'C0080039', 'cui_str': 'Structure of posterior cruciate ligament of knee joint'}, {'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0224469', 'cui_str': 'Peroneus longus muscle structure'}, {'cui': 'C0039508', 'cui_str': 'Tendon structure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0442035', 'cui_str': 'Peroneal'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0559650', 'cui_str': 'Tendon reconstruction'}]","[{'cui': 'C0412714', 'cui_str': 'MRI of knee'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0230459', 'cui_str': 'Hindfoot'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0175636', 'cui_str': 'Documentation procedure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0022745', 'cui_str': 'Knee joint structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0582801', 'cui_str': 'Bilateral knee joints'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0337138', 'cui_str': 'Tunnel'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0040184', 'cui_str': 'Bone structure of tibia'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0037455', 'cui_str': 'Societies'}]",58.0,0.0176895,"At 3 and 12 months after operation, the IKDC score and Lysholm score of the two groups were significantly improved, and further improvement was found at 12 months when compared with at 3 months ( P <0.05); the scores in the trial group were significantly better than those of the control group ( P <0.05).","[{'ForeName': 'Shichun', 'Initials': 'S', 'LastName': 'Wu', 'Affiliation': 'Department of Orthopaedics, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou Fujian, 363000, P.R.China.'}, {'ForeName': 'Wenxiang', 'Initials': 'W', 'LastName': 'Lin', 'Affiliation': 'Department of Orthopaedics, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou Fujian, 363000, P.R.China.'}, {'ForeName': 'Weihua', 'Initials': 'W', 'LastName': 'Xu', 'Affiliation': 'Department of Orthopaedics, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou Fujian, 363000, P.R.China.'}, {'ForeName': 'Honghan', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Orthopaedics, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou Fujian, 363000, P.R.China.'}]",Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery,['10.7507/1002-1892.201910115'] 1251,32540779,Comparison of simple frenotomy with 4-flap Z-frenuloplasty in treatment for ankyloglossia with articulation difficulty: A prospective randomized study.,"OBJECTIVE To compare the surgical outcomes of simple frenotomy and the 4-flap Z-frenuloplasty according to the articulation test values and tongue-tie classification in patients with ankyloglossia with articulation difficulty. STUDY DESIGN prospective randomized study. SETTING Tertiary academic center. SUBJECTS and methods: Children with ankyloglossia with articulation difficulty were randomly divided into 2 groups for surgical treatment. Patients were evaluated for the tongue-tie classification and articulation test before surgery. Three months after the operation, the frenulum classification and articulation test were re-evaluated to compare the differences in surgical outcome between the two surgical methods. RESULTS Out of 37 patients, 19 underwent the 4-flap Z-frenuloplasty and 18, the simple frenotomy. No differences were observed in the baseline characteristics of the patients assigned to both groups. Changes in the tongue-tie classification and improvement in the articulation test results were observed with both the surgical methods. Both surgical groups had significant improvement in the speech articulation test (consonants) but there was no difference in the speech outcomes between the surgical groups. CONCLUSION Although there was no significant difference in the surgical outcome between the two surgical methods, ankyloglossia patients showed improvement in a Korean speech articulation test 3 months after undergoing surgery to release the lingual frenulum.",2020,"Both surgical groups had significant improvement in the speech articulation test (consonants) but there was no difference in the speech outcomes between the surgical groups. ","['patients with ankyloglossia with articulation difficulty', 'ankyloglossia with articulation difficulty', 'and methods', 'Children with ankyloglossia with articulation difficulty', 'Tertiary academic center', '37 patients, 19 underwent the 4-flap Z-frenuloplasty and 18, the simple frenotomy']","['simple frenotomy and the 4-flap Z-frenuloplasty', 'simple frenotomy with 4-flap Z-frenuloplasty']","['speech articulation test', 'speech outcomes', 'surgical outcome', 'Korean speech articulation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0152415', 'cui_str': 'Tongue tie'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0038925', 'cui_str': 'Flap'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0192139', 'cui_str': 'Incision of lingual frenum'}]","[{'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0192139', 'cui_str': 'Incision of lingual frenum'}, {'cui': 'C0038925', 'cui_str': 'Flap'}]","[{'cui': 'C0037819', 'cui_str': 'Speech Articulation Tests'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}]",37.0,0.0322658,"Both surgical groups had significant improvement in the speech articulation test (consonants) but there was no difference in the speech outcomes between the surgical groups. ","[{'ForeName': 'Tae Hoon', 'Initials': 'TH', 'LastName': 'Kim', 'Affiliation': 'Department of Otorhinolaryngology - Head & Neck Surgery, School of Medicine, Kyung Hee University, Seoul, Republic of Korea.'}, {'ForeName': 'Young Chan', 'Initials': 'YC', 'LastName': 'Lee', 'Affiliation': 'Department of Otorhinolaryngology - Head & Neck Surgery, School of Medicine, Kyung Hee University, Seoul, Republic of Korea.'}, {'ForeName': 'Seung Don', 'Initials': 'SD', 'LastName': 'Yoo', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.'}, {'ForeName': 'Seung Ah', 'Initials': 'SA', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.'}, {'ForeName': 'Young-Gyu', 'Initials': 'YG', 'LastName': 'Eun', 'Affiliation': 'Department of Otorhinolaryngology - Head & Neck Surgery, School of Medicine, Kyung Hee University, Seoul, Republic of Korea. Electronic address: ygeun@khu.ac.kr.'}]",International journal of pediatric otorhinolaryngology,['10.1016/j.ijporl.2020.110146'] 1252,32521448,Design cues for tobacco communication: Heuristic interpretations and usability of online health information about harmful chemicals.,"OBJECTIVE Many people have a poor understanding of the numerous chemicals in tobacco products that cause severe health harms. The US government must display a list of these harmful chemicals for the public. Online disclosures are one promising solution, but evidence is needed for effective design strategies to encourage interpretation and use of information as intended. METHOD To examine the impact of website designs for the activation of heuristics and usability perceptions, a national probability sample of US adolescents and adults (n = 1441) was randomized in a 3 (chemical format) × 2 (webpage layout) between-subjects online experiment. Chemicals were displayed as names only, with a visual risk indicator, or with numerical ranges. Layouts displayed health harms at the top of the webpage separate from chemicals or the chemicals grouped by associated health harms. Participants viewed a webpage and reported activated heuristics, usability (perceived ease of use and usefulness), and intentions to use the website. RESULTS Displaying risk indicators increased website usability by encouraging users to rely on colors to interpret the risk of the chemicals (all p < .01). Website designs that grouped chemicals with harms allowed users to link the chemicals to harms they cause and increased perceived usability and intentions to use the website (all p < .001). CONCLUSION Assessing heuristics gives insights for how US adolescents and adults interpret chemical information and the impact of design strategies on usability. Public disclosures of chemicals in tobacco products could be optimized with color-coded risk indicators and layouts placing chemicals near the harms they cause.",2020,"Website designs that grouped chemicals with harms allowed users to link the chemicals to harms they cause and increased perceived usability and intentions to use the website (all p < .001). ",['US adolescents and adults (n = 1441'],[],['website usability'],"[{'cui': 'C0002838', 'cui_str': 'Andorra'}]",[],[],1441.0,0.0625486,"Website designs that grouped chemicals with harms allowed users to link the chemicals to harms they cause and increased perceived usability and intentions to use the website (all p < .001). ","[{'ForeName': 'Allison J', 'Initials': 'AJ', 'LastName': 'Lazard', 'Affiliation': 'School of Media and Journalism, University of North Carolina at Chapel Hill, NC 27599-3365, United States; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27599-3365, United States. Electronic address: lazard@unc.edu.'}]",International journal of medical informatics,['10.1016/j.ijmedinf.2020.104177'] 1253,32525954,Gut carriage of antimicrobial resistance genes in women exposed to small-scale poultry farms in rural Uganda: A feasibility study.,"BACKGROUND Antibiotic use for livestock is presumed to be a contributor to the acquisition of antimicrobial resistance (AMR) genes in humans, yet studies do not capture AMR data before and after livestock introduction. METHODS We performed a feasibility study by recruiting a subset of women in a delayed-start randomized controlled trial of small-scale chicken farming to examine the prevalence of clinically-relevant AMR genes. Stool samples were obtained at baseline and one year post-randomization from five intervention women who received chickens at the start of the study, six control women who did not receive chickens until the end of the study, and from chickens provided to the control group at the end of the study. Stool was screened for 87 clinically significant AMR genes using a commercially available qPCR array (Qiagen). RESULTS Chickens harbored 23 AMR genes from classes found in humans as well as additional vancomycin and β-lactamase resistance genes. AMR patterns between intervention and control women appeared more similar at baseline than one year post randomization (PERMANOVA R2 = 0.081, p = 0.61 at baseline, R2 = 0.186, p = 0.09 at 12 months) Women in the control group who had direct contact with the chickens sampled in the study had greater similarities in AMR gene patterns to chickens than those in the intervention group who did not have direct contact with chickens sampled (p = 0.01). However, at one year there was a trend towards increased similarity in AMR patterns between humans in both groups and the chickens sampled (p = 0.06). CONCLUSIONS Studies designed to evaluate human AMR genes in the setting of animal exposure should account for high baseline AMR rates. Concomitant collection of animal, human, and environmental samples over time is recommended to determine the directionality and source of AMR genes. TRIAL REGISTRATION ClinicalTrials.gov Identifier NCT02619227.",2020,"AMR patterns between intervention and control women appeared more similar at baseline than one year post randomization (PERMANOVA R2 = 0.081, p = 0.61 at baseline, R2 = 0.186, p = 0.09 at 12 months)",['women exposed to small-scale poultry farms in rural Uganda'],[],"['similarity in AMR patterns', 'AMR patterns', 'AMR gene patterns']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0032850', 'cui_str': 'Fowls, Domestic'}, {'cui': 'C0557759', 'cui_str': 'Farming environment'}, {'cui': 'C0041573', 'cui_str': 'Uganda'}]",[],"[{'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0017337', 'cui_str': 'Gene'}]",87.0,0.104382,"AMR patterns between intervention and control women appeared more similar at baseline than one year post randomization (PERMANOVA R2 = 0.081, p = 0.61 at baseline, R2 = 0.186, p = 0.09 at 12 months)","[{'ForeName': 'Ana A', 'Initials': 'AA', 'LastName': 'Weil', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital Boston, Boston, Massachusetts, United States of America.'}, {'ForeName': 'Meti D', 'Initials': 'MD', 'LastName': 'Debela', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital Boston, Boston, Massachusetts, United States of America.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Muyanja', 'Affiliation': 'Mbarara University of Science and Technology, Mbarara, Uganda.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Kakuhikire', 'Affiliation': 'Mbarara University of Science and Technology, Mbarara, Uganda.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Baguma', 'Affiliation': 'Mbarara University of Science and Technology, Mbarara, Uganda.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Bangsberg', 'Affiliation': 'Mbarara University of Science and Technology, Mbarara, Uganda.'}, {'ForeName': 'Alexander C', 'Initials': 'AC', 'LastName': 'Tsai', 'Affiliation': 'Harvard Medical School, Boston, Massachusetts, United States of America.'}, {'ForeName': 'Peggy S', 'Initials': 'PS', 'LastName': 'Lai', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital Boston, Boston, Massachusetts, United States of America.'}]",PloS one,['10.1371/journal.pone.0229699'] 1254,32530760,Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.,"PURPOSE Three new therapies have been approved recently for the adjuvant treatment of stage III melanoma, substantially reducing the risk of tumor recurrences. This study evaluates 3 independent data sets to clarify the survival probabilities of patients with stage III melanoma. PATIENTS AND METHODS The Central Malignant Melanoma Registry (CMMR) evaluated 1,553 patients with a primary diagnosis of stage III melanoma from 2000 to 2012. Studies from the European Organisation for Research and Treatment of Cancer (EORTC), of 573 patients in the observation arm of the 18991 study and 445 patients in the placebo arm of the 18071 study, were evaluated as reference cohorts. The survival outcomes were compared with the published American Joint Committee on Cancer version 8 (AJCCv8) stage III survival data. RESULTS For the CMMR stage III cohort versus the AJCCv8 cohort, the melanoma-specific survival (MSS) rates at 5 years were 67% versus 77%, and at 10 years were 56% versus 69%, respectively. For stage IIIA, the MSS rates at 5 years were 80% versus 93%, and at 10 years were 71% versus 88%; for stage IIIB, the MSS rates at 5 years were 75% versus 83%, and at 10 years were 61% versus 77%. The MSS rates of the EORTC studies either overlapped with or were lower than, the CMMR data. CONCLUSION The MSS rates in the CMMR and EORTC cohorts over the entire stage III are less favorable than those published in AJCCv8. This is particularly true for substages IIIA and IIIB.",2020,"For stage IIIA, the MSS rates at 5 years were 80% versus 93%, and at 10 years were 71% versus 88%; for stage IIIB, the MSS rates at 5 years were 75% versus 83%, and at 10 years were 61% versus 77%.","['573 patients in the observation arm of the 18991 study and 445 patients in the placebo arm of the 18071 study, were evaluated as reference cohorts', 'Patients With Stage III Melanoma', 'patients with stage III melanoma', 'The Central Malignant Melanoma Registry (CMMR) evaluated 1,553 patients with a primary diagnosis of stage III melanoma from 2000 to 2012']",[],"['MSS rates', 'survival probabilities', 'melanoma-specific survival (MSS) rates', 'survival outcomes', 'Cancer version 8 (AJCCv8) stage III survival data']","[{'cui': 'C4708164', 'cui_str': '573'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0332137', 'cui_str': 'Principal diagnosis'}, {'cui': 'C0470277', 'cui_str': '2000'}]",[],"[{'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0441915', 'cui_str': 'AJCC'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}]",1553.0,0.101388,"For stage IIIA, the MSS rates at 5 years were 80% versus 93%, and at 10 years were 71% versus 88%; for stage IIIB, the MSS rates at 5 years were 75% versus 83%, and at 10 years were 61% versus 77%.","[{'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Garbe', 'Affiliation': 'Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Keim', 'Affiliation': 'Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Suciu', 'Affiliation': 'European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Amaral', 'Affiliation': 'Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Thomas K', 'Initials': 'TK', 'LastName': 'Eigentler', 'Affiliation': 'Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Gesierich', 'Affiliation': 'Department of Dermatology, University Hospital Wuerzburg, Wuerzburg, Germany.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Hauschild', 'Affiliation': 'Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.'}, {'ForeName': 'Lucie', 'Initials': 'L', 'LastName': 'Heinzerling', 'Affiliation': 'Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Kiecker', 'Affiliation': 'Skin Cancer Center, Department of Dermatology, Charité Berlin, Berlin, Germany.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Schadendorf', 'Affiliation': 'Department of Dermatology, University Hospital Essen, Essen, & German Cancer Consortium, Heidelberg, Germany.'}, {'ForeName': 'Rudolf', 'Initials': 'R', 'LastName': 'Stadler', 'Affiliation': 'Department of Dermatology, Johannes Wesling Hospital Minden, Ruhr-University of Bochum, Minden, Germany.'}, {'ForeName': 'Cord', 'Initials': 'C', 'LastName': 'Sunderkötter', 'Affiliation': 'Department of Dermatology and Venereology, University Hospital Halle, Halle, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Tüting', 'Affiliation': 'Department of Dermatology, University Hospital Magdeburg, Magdeburg, Germany.'}, {'ForeName': 'Jochen', 'Initials': 'J', 'LastName': 'Utikal', 'Affiliation': 'Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Wollina', 'Affiliation': 'Department of Dermatology and Allergology, Municipal Hospital of Dresden, Dresden, Germany.'}, {'ForeName': 'Christos C', 'Initials': 'CC', 'LastName': 'Zouboulis', 'Affiliation': 'Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Keilholz', 'Affiliation': 'Charité, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Testori', 'Affiliation': 'Department of Dermatology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Martus', 'Affiliation': 'Institute of Clinical Epidemiology and Applied Biostatistics, Eberhard-Karls-University of Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Leiter', 'Affiliation': 'Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Alexander M M', 'Initials': 'AMM', 'LastName': 'Eggermont', 'Affiliation': 'Princess Máxima Center, Utrecht, the Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.03034'] 1255,32530769,International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct.,"PURPOSE To compare cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel in chemotherapy-naïve advanced anal cancer to establish the optimal regimen. PATIENTS AND METHODS Patients who had not received systemic therapy for advanced anal cancer were randomly assigned 1:1 to intravenous cisplatin 60 mg/m 2 (day 1) plus FU 1,000 mg/m 2 (days 1-4) every 21 days or carboplatin (area under the curve, 5; day 1) plus paclitaxel 80 mg/m 2 (days 1, 8, and 15) every 28 days for 24 weeks, until disease progression, intolerable toxicity, or withdrawal of consent. Primary end point was objective response rate (ORR). Primary and secondary end points were assessed in a hierarchic model to compare the regimens and pick the winner. RESULTS We conducted an international multicenter randomized phase II study in 60 centers between December 2013 and November 2017. Median follow-up was 28.6 months. A total of 91 patients were randomly assigned: 46 to cisplatin plus FU and 45 to carboplatin plus paclitaxel. ORR was 57% (95% CI, 39.4% to 73.7%) for cisplatin plus FU versus 59% (95% CI, 42.1% to 74.4%) for carboplatin plus paclitaxel. More serious adverse events were noted in the cisplatin plus FU arm (62%) compared with the carboplatin plus paclitaxel arm (36%; P = .016). Median progression-free survival was 5.7 months (95% CI, 3.3 to 9.0 months) for cisplatin plus FU compared with 8.1 months (95% CI, 6.6 to 8.8 months) for carboplatin plus paclitaxel. Median overall survival was 12.3 months for cisplatin plus FU (95% CI, 9.2 to 17.7 months) compared with 20 months (95% CI, 12.7 months to not reached) for carboplatin plus paclitaxel (hazard ratio, 2.00; 95% CI, 1.15 to 3.47; P = .014). CONCLUSION This is the first international randomized trial to our knowledge conducted in chemotherapy-naïve advanced anal cancer. Although there was no difference in ORR, the association with clinically relevant reduced toxicity and a trend toward longer survival suggest that carboplatin plus paclitaxel should be considered as a new standard of care.",2020,Median overall survival was 12.3 months for cisplatin plus FU,"['60 centers between December 2013 and November 2017', 'Advanced Anal Cancer', 'International Rare Cancers Initiative', 'A total of 91 patients were randomly assigned: 46 to', 'chemotherapy-naïve advanced anal cancer', 'Patients who had not received systemic therapy for advanced anal cancer']","['paclitaxel', 'cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel', 'carboplatin', 'carboplatin plus paclitaxel', 'cisplatin plus FU', 'Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel', 'intravenous cisplatin 60 mg/m 2 (day 1) plus FU 1,000 mg/m 2', 'cisplatin plus FU and 45 to carboplatin plus paclitaxel']","['Median overall survival', 'Median progression-free survival', 'objective response rate (ORR', 'toxicity', 'ORR', 'hierarchic model to compare the regimens and pick the winner', 'serious adverse events']","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0153446', 'cui_str': 'Malignant tumor of anus'}, {'cui': 'C0521114', 'cui_str': 'Infrequent'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}]","[{'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",91.0,0.183791,Median overall survival was 12.3 months for cisplatin plus FU,"[{'ForeName': 'Sheela', 'Initials': 'S', 'LastName': 'Rao', 'Affiliation': 'Royal Marsden Hospital, London, United Kingdom.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Sclafani', 'Affiliation': 'Royal Marsden Hospital, London, United Kingdom.'}, {'ForeName': 'Cathy', 'Initials': 'C', 'LastName': 'Eng', 'Affiliation': 'MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Adams', 'Affiliation': 'Velindre Cancer Centre, Cardiff, Wales.'}, {'ForeName': 'Marianne G', 'Initials': 'MG', 'LastName': 'Guren', 'Affiliation': 'Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Sebag-Montefiore', 'Affiliation': 'Leeds Cancer Centre, Leeds, United Kingdom.'}, {'ForeName': 'Al', 'Initials': 'A', 'LastName': 'Benson', 'Affiliation': 'Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Bryant', 'Affiliation': 'Royal Marsden Hospital, London, United Kingdom.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Peckitt', 'Affiliation': 'Royal Marsden Hospital, London, United Kingdom.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Segelov', 'Affiliation': 'Monash Health and Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Amitesh', 'Initials': 'A', 'LastName': 'Roy', 'Affiliation': 'Flinders University and Flinders Medical Centre, Adelaide, SA, Australia.'}, {'ForeName': 'Matt T', 'Initials': 'MT', 'LastName': 'Seymour', 'Affiliation': 'Leeds Cancer Centre, Leeds, United Kingdom.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Welch', 'Affiliation': 'National Cancer Institute, Bethesda, MD.'}, {'ForeName': 'Mark P', 'Initials': 'MP', 'LastName': 'Saunders', 'Affiliation': 'Christie Cancer Centre, Manchester, United Kingdom.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Muirhead', 'Affiliation': 'University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': ""O'Dwyer"", 'Affiliation': 'Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Bridgewater', 'Affiliation': 'University College Hospital, London, United Kingdom.'}, {'ForeName': 'Shree', 'Initials': 'S', 'LastName': 'Bhide', 'Affiliation': 'Institute of Cancer Research, London, United Kingdom.'}, {'ForeName': 'Rob', 'Initials': 'R', 'LastName': 'Glynne-Jones', 'Affiliation': 'Hamburg University Medical Centre, Hamburg, Germany.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Arnold', 'Affiliation': 'Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cunningham', 'Affiliation': 'Royal Marsden Hospital, London, United Kingdom.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.03266'] 1256,32534250,External trigeminal nerve stimulation for drug resistant epilepsy: A randomized controlled trial.,"BACKGROUND External trigeminal nerve stimulation (ETNS) is an emergent, non-invasive neurostimulation therapy delivered bilaterally with adhesive skin electrodes. In previous studies, ETNS was associated to a decrease in seizure frequency in patients with focal drug-resistant epilepsy (DRE). OBJECTIVE To determine the long-term efficacy and tolerability of ETNS in patients with focal DRE. Moreover, to explore whether its efficacy depends on the epileptogenic zone (frontal or temporal), and its impact on mood, cognitive function, quality of life, and trigeminal nerve excitability. METHODS Forty consecutive patients with frontal or temporal DRE, unsuitable for surgery, were randomized to ETNS or usual medical treatment. Participants were evaluated at 3, 6 and 12 months for efficacy, side effects, mood scales, neuropsychological tests and trigeminal nerve excitability. RESULTS Subjects had a median of 15 seizures per month and had tried a median of 12.5 antiepileptic drugs. At 12 months, percentage of responders was 50% in ETNS group and 0% in control group. Seizure frequency in ETNS group decreased by -43.5% from baseline. Temporal epilepsy subgroup responded better than frontal epilepsy subgroup (55.56% vs. 45.45%, respectively). Median stimulation intensity was 6.2 mA. ETNS improved quality of life, but not anxiety or depression. Long-term ETNS affected neither neuropsychological function, nor trigeminal nerve excitability. No relevant adverse events were observed. CONCLUSIONS ETNS is an effective and well-tolerated therapy for focal DRE. Patients with temporal epilepsy showed a better response than those with frontal epilepsy. Future studies with larger populations may define its role compared to other neurostimulation techniques. CLASSIFICATION OF EVIDENCE This study provides Class II evidence that ETNS reduces seizure frequency in patients with focal DRE.",2020,"Temporal epilepsy subgroup responded better than frontal epilepsy subgroup (55.56% vs. 45.45%, respectively).","['Patients with temporal epilepsy', 'Subjects had a median of 15 seizures per month and had tried a median of 12.5 antiepileptic drugs', 'patients with focal drug-resistant epilepsy (DRE', 'drug resistant epilepsy', 'Forty consecutive patients with frontal or temporal DRE, unsuitable for surgery', 'patients with focal DRE']","['ETNS or usual medical treatment', 'External trigeminal nerve stimulation (ETNS', 'ETNS', 'External trigeminal nerve stimulation']","['quality of life', 'seizure frequency', 'neuropsychological function, nor trigeminal nerve excitability', 'efficacy, side effects, mood scales, neuropsychological tests and trigeminal nerve excitability', 'Seizure frequency', 'Median stimulation intensity', 'adverse events', 'anxiety or depression', 'mood, cognitive function, quality of life, and trigeminal nerve excitability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442043', 'cui_str': 'Temporal'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C4517544', 'cui_str': '12.5'}, {'cui': 'C0003299', 'cui_str': 'ANTIEPILEPTICS'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C1096063', 'cui_str': 'Refractory epilepsy'}, {'cui': 'C0205123', 'cui_str': 'Coronal'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0040996', 'cui_str': 'Trigeminal nerve structure'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0149775', 'cui_str': 'Fit frequency'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0040996', 'cui_str': 'Trigeminal nerve structure'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",40.0,0.130105,"Temporal epilepsy subgroup responded better than frontal epilepsy subgroup (55.56% vs. 45.45%, respectively).","[{'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Gil-López', 'Affiliation': ""Epilepsy Unit, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain, Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. Electronic address: fran.gil.lopez@gmail.com.""}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Boget', 'Affiliation': 'Epilepsy Unit, Department of Neuropsychology, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Manzanares', 'Affiliation': ""Epilepsy Unit, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain, Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.""}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Donaire', 'Affiliation': ""Epilepsy Unit, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain, Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.""}, {'ForeName': 'Estefanía', 'Initials': 'E', 'LastName': 'Conde-Blanco', 'Affiliation': ""Epilepsy Unit, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain, Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.""}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Baillés', 'Affiliation': 'Epilepsy Unit, Department of Psychiatry, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Pintor', 'Affiliation': 'Epilepsy Unit, Department of Psychiatry, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Setoaín', 'Affiliation': 'Epilepsy Unit, Department of Nuclear Medicine, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Núria', 'Initials': 'N', 'LastName': 'Bargalló', 'Affiliation': 'Epilepsy Unit, Department of Neurorradiology, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Navarro', 'Affiliation': 'Electromyography Unit, Neurophysiology, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Casanova', 'Affiliation': 'Electromyography Unit, Neurophysiology, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Valls', 'Affiliation': 'Electromyography Unit, Neurophysiology, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Roldán', 'Affiliation': 'Epilepsy Unit, Department of Neurosurgery, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Rumià', 'Affiliation': 'Epilepsy Unit, Department of Neurosurgery, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Georgina', 'Initials': 'G', 'LastName': 'Casanovas', 'Affiliation': 'Medical Statistics Core Facility, IDIBAPS-Hospital Clínic, Barcelona, Spain.'}, {'ForeName': 'Gema', 'Initials': 'G', 'LastName': 'Domenech', 'Affiliation': 'Medical Statistics Core Facility, IDIBAPS-Hospital Clínic, Barcelona, Spain.'}, {'ForeName': 'Ferrán', 'Initials': 'F', 'LastName': 'Torres', 'Affiliation': 'Medical Statistics Core Facility, IDIBAPS-Hospital Clínic, Barcelona, Spain.'}, {'ForeName': 'Mar', 'Initials': 'M', 'LastName': 'Carreño', 'Affiliation': ""Epilepsy Unit, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain, Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.""}]",Brain stimulation,['10.1016/j.brs.2020.06.005'] 1257,32534252,"Two weeks of image-guided left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation improves smoking cessation: A double-blind, sham-controlled, randomized clinical trial.","BACKGROUND Previous studies have found that repetitive transcranial magnetic stimulation (rTMS) to the left dorsal lateral prefrontal cortex (LDLPFC) transiently reduces smoking craving, decreases cigarette consumption, and increases abstinence rates. OBJECTIVE We investigated whether 10 daily MRI-guided rTMS sessions over two weeks to the LDLPFC paired with craving cues could reduce cigarette consumption and induce smoking cessation. METHODS We enrolled 42 treatment-seeking nicotine-dependent smokers (≥10 cigarettes per day) in a randomized, double-blind, sham-controlled trial. Participants received 10 daily sessions over 2 weeks of either active or sham MRI-guided rTMS (10Hz, 3000 pulses each session) to the LDLPFC concurrently with video smoking cues. The primary outcome was a reduction in biochemically confirmed cigarette consumption with a secondary outcome of abstinence on the target quit date. We also recorded cue-induced craving and withdrawal symptoms. RESULTS Compared to sham (n = 17), participants receiving active rTMS (n = 21) smoked significantly fewer cigarettes per day during the 2-week treatment (mean [SD], 13.73[9.18] vs. 11.06[9.29], P < .005) and at 1-month follow-up (12.78[9.53] vs. 7.93[7.24], P < .001). Active rTMS participants were also more likely to quit by their target quit rate (23.81%vs. 0%, OR 11.67, 90% CL, 0.96-141.32, x 2  = 4.66, P = .031). Furthermore, rTMS significantly reduced mean craving throughout the treatments and at follow-up (29.93[13.12] vs. 25.01[14.45], P < .001). Interestingly across the active treatment sample, more lateral coil location was associated with more success in quitting (-43.43[0.40] vs. -41.79[2.24], P < .013). CONCLUSIONS Daily MRI-guided rTMS to the LDLPFC for 10 days reduces cigarette consumption and cued craving for up to one month and also increases the likelihood of smoking cessation. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02401672.",2020,"Compared to sham (n=17), participants receiving active rTMS (n=21) smoked significantly fewer cigarettes per day during the 2-week treatment (mean [SD], 13.73[9.18] vs. 11.06[9.29], P<.005) and at 1-month follow-up (12.78[9.53] vs. 7.93[7.24], P<.001).",['enrolled 42 treatment-seeking nicotine-dependent smokers (≥10 cigarettes per day'],"['rTMS', 'Image-guided Left Dorsolateral Prefrontal Cortex Repetitive Transcranial Magnetic Stimulation Improves Smoking Cessation', 'active rTMS', 'repetitive transcranial magnetic stimulation (rTMS', 'LDLPFC paired with craving cues', 'active or sham MRI-guided rTMS (10Hz, 3000 pulses each session) to the LDLPFC concurrently with video smoking cues']","['abstinence on the target quit date', 'likelihood of smoking cessation', 'lateral coil location', 'cigarette consumption and cued craving', 'mean craving', 'likely to quit by their target quit rate']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0439505', 'cui_str': '/day'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0470279', 'cui_str': '3000'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0450424', 'cui_str': 'To the left'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}]","[{'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0011008', 'cui_str': 'Date'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0337671', 'cui_str': 'Ex-smoker'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0419518', 'cui_str': 'Contraceptive coil'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0459840', 'cui_str': 'Cigarette consumption'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}]",42.0,0.428626,"Compared to sham (n=17), participants receiving active rTMS (n=21) smoked significantly fewer cigarettes per day during the 2-week treatment (mean [SD], 13.73[9.18] vs. 11.06[9.29], P<.005) and at 1-month follow-up (12.78[9.53] vs. 7.93[7.24], P<.001).","[{'ForeName': 'Xingbao', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA; Center for Biomedical Imaging, Medical University of South Carolina, Charleston, SC, 29425, USA. Electronic address: lixi@musc.edu.'}, {'ForeName': 'Karen J', 'Initials': 'KJ', 'LastName': 'Hartwell', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, 29401, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Henderson', 'Affiliation': 'Center for Biomedical Imaging, Medical University of South Carolina, Charleston, SC, 29425, USA.'}, {'ForeName': 'Bashar W', 'Initials': 'BW', 'LastName': 'Badran', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA.'}, {'ForeName': 'Kathleen T', 'Initials': 'KT', 'LastName': 'Brady', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, 29401, USA.'}, {'ForeName': 'Mark S', 'Initials': 'MS', 'LastName': 'George', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, 29401, USA.'}]",Brain stimulation,['10.1016/j.brs.2020.06.007'] 1258,32534376,Fatty acid desaturation in red blood cell membranes of patients with type 2 diabetes is improved by zinc supplementation.,"BACKGROUND/OBJECTIVE Membrane flexibility can be a determining factor in pathophysiological mechanisms of type 2 diabetes (T2D). As a cofactor of delta-5 desaturase (D5D) and delta-6 desaturase (D6D), and gene expression regulator, zinc may play a role modulating membrane flexibility by increasing membrane polyunsaturated fatty acids (PUFA) abundance. The objective of this study was to evaluate the effect of a 24-month zinc supplementation (30 mg elemental zinc) on membrane fatty acid composition in patients with T2D. SUBJECTS/METHODS Sixty patients with T2D were evaluated. Thirty were randomly assigned to the zinc supplemented group and thirty to the placebo group. Fatty acid composition in red blood cell (RBC) membranes was determined by gas chromatography. Expression of gene encoding for D5D (FADS1), and D6D (FADS2) were evaluated in peripheral blood mononuclear cells by real-time polymerase chain reaction. RESULTS After 24 months of supplementation, a greater abundance of docosapentaenoic acid (C22:5 n-3), arachidonic acid (C20:4 n-6), adrenic acid (C22:4 n-6), and total n-6 PUFA was found (p = 0.001, p = 0.007, p = 0.033, p = 0.048, respectively). The unsaturated fatty acids/saturated fatty acids ratio, and unsaturation index was increased in the zinc supplemented group at month 24 (p = 0.003 and p  = 0.000, respectively). FADS1 gene was upregulated in the zinc group in relation to placebo at month 12 (p = 0.020). CONCLUSIONS Supplementation with 30 mg/d elemental zinc during 24 months in patients with T2D had an effect on the composition of RBC membranes increasing PUFA abundance and in turn, improving membrane flexibility. This effect may be mediated by induction of D5D gene expression.",2020,"FADS1 gene was upregulated in the zinc group in relation to placebo at month 12 (p = 0.020). ","['patients with T2D', 'Sixty patients with T2D were evaluated', 'patients with type 2 diabetes']","['Fatty acid desaturation', 'zinc supplementation (30\u202fmg elemental zinc', 'placebo']","['membrane flexibility', 'Expression of gene encoding for D5D (FADS1), and D6D (FADS2', 'Fatty acid composition in red blood cell (RBC) membranes', 'abundance of docosapentaenoic acid (C22:5 n-3), arachidonic acid (C20:4 n-6), adrenic acid (C22:4 n-6), and total n-6 PUFA', 'FADS1 gene', 'unsaturated fatty acids/saturated fatty acids ratio, and unsaturation index', 'membrane fatty acid composition']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range'}, {'cui': 'C4524022', 'cui_str': 'Zinc supplementation'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0057338', 'cui_str': 'delta-5 fatty acid desaturase'}, {'cui': 'C0065017', 'cui_str': 'Linoleoyl-CoA desaturase'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0058624', 'cui_str': 'docosapentaenoic acid'}, {'cui': 'C0003695', 'cui_str': 'Arachidonic acid'}, {'cui': 'C0050877', 'cui_str': 'adrenic acid'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1276035', 'cui_str': 'Pena-Shokeir syndrome type I'}, {'cui': 'C0015690', 'cui_str': 'Unsaturated fatty acid'}, {'cui': 'C0597423', 'cui_str': 'Saturated fat'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",60.0,0.126956,"FADS1 gene was upregulated in the zinc group in relation to placebo at month 12 (p = 0.020). ","[{'ForeName': 'María Catalina', 'Initials': 'MC', 'LastName': 'Hernández', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Rojas', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Carrasco', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Basfi-Fer', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Valenzuela', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Juana', 'Initials': 'J', 'LastName': 'Codoceo', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Inostroza', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Ruz', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile. Electronic address: mruz@med.uchile.cl.'}]",Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS),['10.1016/j.jtemb.2020.126571'] 1259,32540325,Risk Factors for Visual Field Deterioration in the United Kingdom Glaucoma Treatment Study.,"PURPOSE The United Kingdom Glaucoma Treatment Study (UKGTS) investigated the visual field (VF)-preserving effect of medical treatment in open-angle glaucoma (OAG). The objective of this analysis was to identify risk factors associated with VF deterioration. DESIGN Randomized, double-masked, placebo-controlled multicenter trial. PARTICIPANTS Five hundred sixteen participants with previously untreated OAG were recruited prospectively in 10 United Kingdom centers. METHODS Eligibility criteria were modeled on those for the Early Manifest Glaucoma Trial. Study participants were randomized to either latanoprost 0.005% or placebo eye drops. The observation period was 2 years and involved, among other procedures, VF testing and intraocular pressure (IOP) measurement at 11 scheduled visits, with clustering of tests at baseline, 18 months, and 24 months. Guided progression analysis pattern deviation maps were used to determine VF deterioration. Cox regression was used to compute the hazard ratios (HRs) and respective 95% confidence intervals (CIs) while accounting for the correlation within sites. Model selection was guided by backward stepwise selection conducted on the model containing all variables that were significant at the 0.2 level in the univariate analysis. Follow-up variables that showed collinearity with baseline values were not retained in the final model. MAIN OUTCOME MEASURE Time to VF deterioration. RESULTS Treatment with latanoprost reduced the HR, for VF deterioration by 58% (HR, 0.42; 95% CI, 0.27-0.67; P = 0.001). Factors associated with deterioration were bilateral disease (HR, 1.59 for yes vs. no; 95% CI, 1.02-2.50; P = 0.041), higher baseline IOP (HR, 1.07 per mmHg; 95% CI, 1.02-1.12; P = 0.008), and disc hemorrhage at visit 1 (HR, 2.08; 95% CI, 1.07-4.04; P = 0.030). Smoking (current or previous) was associated with a reduced HR, for VF deterioration (HR, 0.59; 95% CI, 0.37-0.93; P = 0.023). No other evaluated factors were found to be statistically significant in the multivariable analysis. CONCLUSIONS In the UKGTS, treatment with latanoprost halved VF deterioration risk. Bilateral disease, higher IOP, and disc hemorrhage were confirmed as risk factors for deterioration; smoking history seemed to be protective against VF deterioration.",2020,"Bilateral disease, higher IOP and disc haemorrhage were confirmed as risk factors for deterioration; smoking history appeared to be protective against VF deterioration.","['Eligibility criteria were modeled on those for the Early Manifest Glaucoma Trial', 'open-angle glaucoma (OAG', 'Five hundred sixteen participants with previously untreated OAG were prospectively recruited in 10 UK centres']","['latanoprost', 'placebo']","['bilateral disease', 'higher baseline IOP', 'disc haemorrhage', 'Time-to-VF deterioration', 'Bilateral disease, higher IOP and disc haemorrhage', 'VF deterioration risk', 'VF testing and intraocular pressure (IOP) measurement', 'reduced HR for VF deterioration', 'HR for VF deterioration']","[{'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205319', 'cui_str': 'Manifest'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0017612', 'cui_str': 'Open-angle glaucoma'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0090306', 'cui_str': 'latanoprost'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0042826', 'cui_str': 'Visual field'}, {'cui': 'C0234708', 'cui_str': 'Raised intraocular pressure'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0042825', 'cui_str': 'Visual field study'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",516.0,0.300799,"Bilateral disease, higher IOP and disc haemorrhage were confirmed as risk factors for deterioration; smoking history appeared to be protective against VF deterioration.","[{'ForeName': 'Panayiota', 'Initials': 'P', 'LastName': 'Founti', 'Affiliation': 'National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom. Electronic address: pfounti@gmail.com.'}, {'ForeName': 'Catey', 'Initials': 'C', 'LastName': 'Bunce', 'Affiliation': ""National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom; King's College London, London School of Hygiene & Tropical Medicine, London, United Kingdom.""}, {'ForeName': 'Anthony P', 'Initials': 'AP', 'LastName': 'Khawaja', 'Affiliation': 'National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom.'}, {'ForeName': 'Caroline J', 'Initials': 'CJ', 'LastName': 'Doré', 'Affiliation': 'Comprehensive Clinical Trials Unit at University College London, London, United Kingdom.'}, {'ForeName': 'Jibran', 'Initials': 'J', 'LastName': 'Mohamed-Noriega', 'Affiliation': 'National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom.'}, {'ForeName': 'David F', 'Initials': 'DF', 'LastName': 'Garway-Heath', 'Affiliation': 'National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Ophthalmology,['10.1016/j.ophtha.2020.06.009'] 1260,32540337,Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study.,"BACKGROUND AND PURPOSE Preclinical data suggest that cetuximab should be continued after end of concurrent radiotherapy+cetuximab due to its efficacy against residual tumor cells in the irradiated tumor bed. Based on this concept the phase II add-on cetuximab (AOC) study was designed. MATERIALS AND METHODS Altogether 63 patients with advanced head and neck cancer were treated with radiochemotherapy (70 Gy, cisplatin 40 mg/m 2 weekly) in combination with concurrent cetuximab (loading dose 400 mg/m 2 , then 250 mg/m 2 weekly). Thereafter patients were randomized to cetuximab consolidation (500 mg/m 2 biweekly × 6) or no further treatment. The primary endpoint was the 2-year locoregional control (LRC) rate. As translational research endpoints serum markers were analyzed before and during treatment and CT-based quantitative image analysis (radiomics) was performed. RESULTS Median follow-up was 24 months. The 2-year LRC rates were 67.9% and 67.7% in the treatment arms with and without consolidation cetuximab, respectively. Higher than median levels of three serum markers were negatively associated with the 2-year LRC rate in the overall patient cohort: Osteopontin, IL8 and FasL2 (p ≤ 0.05). A radiomics model consisting of two radiomics features could be built showing that higher entropy and higher complexity of tumor Hounsfield unit distribution indicates worse LRC (concordance index 0.66). No correlation was found between biological and imaging markers. CONCLUSIONS There was no evidence that consolidation cetuximab would improve the 2-year LRC rate. Prognostic biological and imaging markers could be identified for the overall patient cohort. Studies with larger patient numbers are needed to correlate biological and imaging markers.",2020,"Higher than median levels of three serum markers were negatively associated with the 2-year LRC rate in the overall patient cohort: Osteopontin, IL8 and FasL2 (p≤0.05).","['Altogether 63 patients with advanced head and neck cancer', 'patients with advanced head and neck cancer']","['radiochemotherapy + cetuximab', 'radiochemotherapy (70 Gy, cisplatin 40mg/m2 weekly) in combination with concurrent cetuximab', 'Consolidation cetuximab', 'radiotherapy + cetuximab', 'cetuximab consolidation']","['2-year LRC rates', '2-year LRC rate', '2-year locoregional control (LRC) rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}]","[{'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0995188', 'cui_str': 'cetuximab'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0521530', 'cui_str': 'Lung consolidation'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",63.0,0.0261113,"Higher than median levels of three serum markers were negatively associated with the 2-year LRC rate in the overall patient cohort: Osteopontin, IL8 and FasL2 (p≤0.05).","[{'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Riesterer', 'Affiliation': 'Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland; Center for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Switzerland. Electronic address: oliver.riesterer@ksa.ch.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Pruschy', 'Affiliation': 'Laboratory for Molecular Radiobiology, University of Zurich, Switzerland.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Bender', 'Affiliation': 'Laboratory for Molecular Radiobiology, University of Zurich, Switzerland.'}, {'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Laboratory for Molecular Radiobiology, University of Zurich, Switzerland.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Bogowicz', 'Affiliation': 'Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Tanadini-Lang', 'Affiliation': 'Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Stieb', 'Affiliation': 'Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Kaja', 'Initials': 'K', 'LastName': 'Bertogg', 'Affiliation': 'Clinical Trials Center, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Weber', 'Affiliation': 'Clinical Trials Center, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Ikenberg', 'Affiliation': 'Institute of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Huber', 'Affiliation': 'Department of Otorhinolaryngology, University Hospital Zurich, University of Zurich, Switzerland; Department of Otorhinolaryngology, Cantonal Hospital St. Gallen, Switzerland.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Schmid', 'Affiliation': 'Otorhinolaryngology Clinic Bethanien, Zurich, Switzerland.'}, {'ForeName': 'Marius', 'Initials': 'M', 'LastName': 'Bredell', 'Affiliation': 'Clinic for Oral and Maxillofacial Surgery, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Veit-Haibach', 'Affiliation': 'Department of Nuclear Medicine, University Hospital Zurich, Switzerland; Department of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Rordorf', 'Affiliation': 'Department of Medical Oncology, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Held', 'Affiliation': 'Epidemiology, Biostatistics and Prevention Institute, Department of Biostatistics, University of Zurich, Switzerland.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Glanzmann', 'Affiliation': 'Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland; Department of Radiation Oncology, Cantonal Hospital Lucerne, Switzerland.'}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Studer', 'Affiliation': 'Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland; Department of Radiation Oncology, Cantonal Hospital Lucerne, Switzerland.'}]",Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,['10.1016/j.radonc.2020.06.011'] 1261,32541620,Cost-Effectiveness and Return-on-Investment of the Dynamic Work Intervention Compared With Usual Practice to Reduce Sedentary Behavior.,"OBJECTIVE To assess the cost-effectiveness and return-on-investment (ROI) of the Dynamic Work (DW) Intervention, a worksite intervention aimed at reducing sitting time among office workers. METHODS In total, 244 workers were randomized to the intervention or control group. Overall sitting time, standing time, step counts, quality-adjusted life years (QALYs), and costs were measured over 12 months. The cost-effectiveness analysis was performed from the societal perspective and the ROI analysis from the employers' perspective. RESULTS No significant differences in effects and societal costs were observed between groups. Presenteeism costs were significantly lower in the intervention group. The probability of the intervention being cost-effective was 0.90 at a willingness-to-pay of 20,000&OV0556;/QALY. The probability of financial savings was 0.86. CONCLUSION The intervention may be considered cost-effective from the societal perspective depending on the willingness-to-pay. From the employer perspective, the intervention seems cost-beneficial.",2020,Presenteeism costs were significantly lower in the intervention group.,"['office workers', '244 workers']","['Dynamic Work Intervention', 'Dynamic Work (DW) Intervention']","['Presenteeism costs', 'cost-effectiveness and return-on-investment (ROI', 'Overall sitting time, standing time, step counts, quality-adjusted life years (QALYs), and costs', 'Cost-Effectiveness and Return-on-Investment', 'effects and societal costs', 'probability of financial savings']","[{'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C4517660', 'cui_str': '244'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C4042785', 'cui_str': 'Sickness Presence'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0021953', 'cui_str': 'Investments'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0036245', 'cui_str': 'Savings'}]",244.0,0.0277514,Presenteeism costs were significantly lower in the intervention group.,"[{'ForeName': 'Ângela J', 'Initials': 'ÂJ', 'LastName': 'Ben', 'Affiliation': 'Department of Health Sciences, Faculty Science, Amsterdam Public Health Research Institute (Dr Ben, Dr van Dongen, Dr Bosmans); and Department of Public and Occupational Health, Amsterdam Public Health Research Institute, Amsterdam UMC (Dr Jelsma, Ms Renaud, Dr Huysmans, Dr van Nassau, Dr van der Beek, Dr van der Ploeg), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Judith G M', 'Initials': 'JGM', 'LastName': 'Jelsma', 'Affiliation': ''}, {'ForeName': 'Lidewij R', 'Initials': 'LR', 'LastName': 'Renaud', 'Affiliation': ''}, {'ForeName': 'Maaike A', 'Initials': 'MA', 'LastName': 'Huysmans', 'Affiliation': ''}, {'ForeName': 'Femke', 'Initials': 'F', 'LastName': 'van Nassau', 'Affiliation': ''}, {'ForeName': 'Allard J', 'Initials': 'AJ', 'LastName': 'van der Beek', 'Affiliation': ''}, {'ForeName': 'Hidde P', 'Initials': 'HP', 'LastName': 'van der Ploeg', 'Affiliation': ''}, {'ForeName': 'Johanna M', 'Initials': 'JM', 'LastName': 'van Dongen', 'Affiliation': ''}, {'ForeName': 'Judith E', 'Initials': 'JE', 'LastName': 'Bosmans', 'Affiliation': ''}]",Journal of occupational and environmental medicine,['10.1097/JOM.0000000000001930'] 1262,32541643,"Effects of Valsartan on Restenosis in Patients with Arteriosclerosis Obliterans of the Lower Extremities Undergoing Interventional Therapy: A Prospective, Randomized, Single-Blind Trial.","BACKGROUND The aim of this study was to further clarify the effects of valsartan on restenosis in patients with arteriosclerosis obliterans of the lower extremities. MATERIAL AND METHODS Patients with arteriosclerosis obliterans of the lower extremities undergoing continuous stent implantation in the superficial femoral artery were enrolled and randomly divided into an ARB group and a control group. Patients in the ARB group received valsartan orally in a single-blind manner and were followed up for 6 months. An evaluation was performed based on the criteria for clinical efficacies designed by the Committee of Vascular Disease, Chinese Association of Integrative Medicine. The total clinical effective rate was calculated, and ankle brachial index (ABI) of the patients was assessed. The concentrations of interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) were measured using enzyme-linked immunosorbent assay. The in-stent restenosis of patients was examined by angiography. RESULTS One patient in the control group died due to acute cerebral hemorrhage 4 months after enrollment, and 1 patient was lost to follow-up due to acute myocardial infarction during follow-up 5 months after enrollment. Age, sex, Fontaine stage, and underlying diseases were comparable between the 2 groups. Hs-CRP (3.93±1.43) and IL-6 (11.26±2.29) levels were significant different in the ARB group compared with the control group. The postoperative follow-up showed that ABI was 0.98±0.20 in the ARB group and 0.62±0.48 in the control group. CONCLUSIONS Valsartan inhibited the increase in hs-CRP and IL-6 levels, improved clinical efficacies, increased ABI, and decreased the restenosis rate after the interventional therapy in patients with arteriosclerosis obliterans of the lower extremities.",2020,Hs-CRP (3.93±1.43) and IL-6 (11.26±2.29) levels were significant different in the ARB group compared with the control group.,"['patients with arteriosclerosis obliterans of the lower extremities', 'Patients with Arteriosclerosis Obliterans of the Lower Extremities Undergoing Interventional Therapy', 'Patients with arteriosclerosis obliterans of the lower extremities undergoing continuous stent implantation in the superficial femoral artery']","['valsartan', 'Valsartan', 'ARB']","['total clinical effective rate', 'acute myocardial infarction', 'clinical efficacies, increased ABI', 'hs-CRP and IL-6 levels', 'ABI', 'restenosis rate', 'acute cerebral hemorrhage', 'ankle brachial index (ABI', 'Hs-CRP (3.93±1.43) and IL-6 (11.26±2.29) levels', 'concentrations of interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003850', 'cui_str': 'Arteriosclerosis'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0447106', 'cui_str': 'Superficial femoral artery'}]","[{'cui': 'C0216784', 'cui_str': 'valsartan'}, {'cui': 'C0521942', 'cui_str': 'Angiotensin II receptor antagonist'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1328319', 'cui_str': 'Ankle brachial pressure index'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0333186', 'cui_str': 'Restenosis'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C2937358', 'cui_str': 'Cerebral hemorrhage'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",,0.0416997,Hs-CRP (3.93±1.43) and IL-6 (11.26±2.29) levels were significant different in the ARB group compared with the control group.,"[{'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Yao', 'Affiliation': 'Department of Cardiology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine of Hebei Province, Cangzhou, Hebei, China (mainland).'}, {'ForeName': 'Lixin', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Interventional Vascular Surgery, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine of Hebei Province, Cangzhou, Hebei, China (mainland).'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'Department of Cardiology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine of Hebei Province, Cangzhou, Hebei, China (mainland).'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine of Hebei Province, Cangzhou, Hebei, China (mainland).'}, {'ForeName': 'Nana', 'Initials': 'N', 'LastName': 'Feng', 'Affiliation': 'Department of Cardiology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine of Hebei Province, Cangzhou, Hebei, China (mainland).'}]",Medical science monitor : international medical journal of experimental and clinical research,['10.12659/MSM.919977'] 1263,32535407,An investigation of the impact of social exclusion on attachment to possessions and saving behaviors.,"BACKGROUND AND OBJECTIVES Hoarding disorder (HD) is a debilitating mental illness characterized by extreme difficulty parting with possessions and clutter that can result in dangerous living conditions. One hypothesis about why individuals with HD save possessions is that they possess a pathological attachment to their belongings, which may serve to compensate for unfulfilling interpersonal relationships. However, there is a dearth of empirical work examining this. The current study examined the impact of an experimental manipulation of social exclusion on attachment to possessions and saving behaviors in a sample of individuals with elevated hoarding symptoms. METHODS Participants (n = 117) were selected for scoring above the non-clinical mean on a measure of hoarding symptoms. Participants were randomized to either be included or excluded in a game of Cyberball. They completed a behavioral discarding task and object attachment measure before and after completion of the game. RESULTS Study condition was unrelated to in vivo attachment to possessions and saving behaviors during the discarding task. However, a post hoc mediation model showed that greater feelings of rejection, regardless of condition, were associated with greater in vivo attachment to possessions and subsequent number of items saved during the lab task. LIMITATIONS Limitations include the use of a non-clinical and homogeneous sample. CONCLUSIONS Taken together, individuals prone to feelings of rejection may be at risk for developing HD as they may use possessions to cope with interpersonal stress. Results will be discussed in light of implications for theoretical models and potential treatment targets in HD.",2020,"However, a post hoc mediation model showed that greater feelings of rejection, regardless of condition, were associated with greater in vivo attachment to possessions and subsequent number of items saved during the lab task. ","['individuals with elevated hoarding symptoms', 'Participants (n\xa0=\xa0117']",[],[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",[],[],117.0,0.034374,"However, a post hoc mediation model showed that greater feelings of rejection, regardless of condition, were associated with greater in vivo attachment to possessions and subsequent number of items saved during the lab task. ","[{'ForeName': 'Brittany M', 'Initials': 'BM', 'LastName': 'Mathes', 'Affiliation': 'Florida State University, United States.'}, {'ForeName': 'Norman B', 'Initials': 'NB', 'LastName': 'Schmidt', 'Affiliation': 'Florida State University, United States. Electronic address: schmidt@psy.fsu.edu.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2020.101588'] 1264,32535481,Efficacy and safety of Abelmoschus manihot for IgA nephropathy: A multicenter randomized clinical trial.,"RATIONALE AND OBJECTIVE IgA nephropathy (IgAN) is an important cause for end-stage renal disease worldwide. The treatment for IgAN remains challenging, and few randomized and controlled clinical trials have been conducted to evaluate new therapies. The present study assesses the efficacy and safety of Abelmoschus manihot (AM) in IgAN patients. STUDY DESIGN Randomized, non-inferiority, double-blind, double-dummy multicenter trial. SETTING AND PARTICIPANTS This trial was designed to recruit 1,600 biopsy-proven IgAN patients (proteinuria between 0.5-3.0 g/d and estimated glomerular filtration rate [eGFR] of ≥ 45 ml/min/1.73 m 2 ) across China. INTERVENTIONS The participants were randomized at 1:1 to AM (2.5 g for three times per day) or losartan potassium (100 mg per day) for 48 weeks. OUTCOMES The primary outcome was the change in 24-hour proteinuria from baseline to week 48. The secondary outcomes were the change in eGFR from baseline to week 48, and the incidents of endpoint events (proteinuria ≥ 3.5 g/24 h, doubling of serum creatinine, or receiving renal replacement treatment). RESULTS Among 1,470 randomized patients (mean age, 37.4 [SD, 10.6] years old; 777 [52.9%] were female; mean eGFR, 95.0 [SD, 24.3] mL/min/1.73 m 2 ; mean 24-hour proteinuria, 1.2 [SD, 0.7] g/d), the mean decline in 24-h proteinuria at week 48 was 230 mg and 253 mg in the AM and losartan potassium groups, respectively (P = 0.676). The mean difference in the change in 24-h proteinuria between these two groups was -23.32 mg (95% confident interval: -123.2 to 76.6, p = 0.647). The mean decline in eGFR was 0.41 ml/min/1.73 m 2 and 0.76 ml/min/1.73 m 2 in the AM and losartan potassium groups, respectively (p = 0.661). The mean difference in the change in eGFR between these two groups was -0.43 ml/min/1.73 m 2 (95% confident interval: -1.99 to 1.13, p = 0.589). The incidence of endpoint events was 8.6% in the AM group and 8.2% in the losartan group (p = 0.851). LIMITATIONS The results of the trial may not be generalized to IgAN patients with a proteinuria of > 3.0 g/d and an eGFR of < 45 ml/min/1.73 m 2 . The long-term benefits of AM in reducing the risk of progressive renal dysfunction remains unclear, based on this 48-week observation. CONCLUSION AM can be recommended as a promising treatment for IgAN patients.",2020,The mean difference in the change in eGFR between these two groups was -0.43,"['IgAN patients', '1,470 randomized patients (mean age, 37.4 [SD, 10.6] years old; 777 [52.9%] were female; mean eGFR, 95.0 [SD, 24.3] mL/min/1.73 m 2 ; mean 24-hour proteinuria, 1.2 [SD, 0.7] g/d), the mean decline in 24-h proteinuria at week 48 was 230 mg and 253 mg in the AM and losartan potassium groups, respectively (P\xa0=\xa00.676', 'IgA nephropathy', '1,600 biopsy-proven IgAN patients (proteinuria between 0.5-3.0 g/d and estimated glomerular filtration rate [eGFR] of ≥ 45 ml/min/1.73 m 2 ) across China']","['AM', 'Abelmoschus manihot (AM', 'losartan potassium', 'Abelmoschus manihot', 'losartan']","['change in 24-hour proteinuria', 'eGFR', '24-h proteinuria', 'Efficacy and safety', 'mean decline in eGFR', 'incidence of endpoint events', 'efficacy and safety', 'change in eGFR']","[{'cui': 'C0017661', 'cui_str': 'IgA nephropathy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517741', 'cui_str': '37.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C4068880', 'cui_str': '1.2'}, {'cui': 'C4517474', 'cui_str': '0.7'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0949866', 'cui_str': 'Abelmoschus'}, {'cui': 'C0996896', 'cui_str': 'Manihot'}, {'cui': 'C0700492', 'cui_str': 'Losartan potassium'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0949866', 'cui_str': 'Abelmoschus'}, {'cui': 'C0996896', 'cui_str': 'Manihot'}, {'cui': 'C0700492', 'cui_str': 'Losartan potassium'}, {'cui': 'C0126174', 'cui_str': 'Losartan'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",1470.0,0.162545,The mean difference in the change in eGFR between these two groups was -0.43,"[{'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Li', 'Affiliation': 'Department of Nephrology, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing 100853, China.'}, {'ForeName': 'Hongli', 'Initials': 'H', 'LastName': 'Lin', 'Affiliation': 'Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, China.'}, {'ForeName': 'Zhaohui', 'Initials': 'Z', 'LastName': 'Ni', 'Affiliation': 'Department of Nephrology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.'}, {'ForeName': 'Yongli', 'Initials': 'Y', 'LastName': 'Zhan', 'Affiliation': ""Department of Nephrology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.""}, {'ForeName': 'Yani', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': 'Department of Nephrology, Da Ping Hospital of Third Military Medical University, Chongqing, 400042, China.'}, {'ForeName': 'Hongtao', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Department of Nephrology, First Teaching Hospital of Tianjin University of TCM, Tianjin 300192, China.'}, {'ForeName': 'Jingai', 'Initials': 'J', 'LastName': 'Fang', 'Affiliation': 'Department of Nephrology, The First Hospital of Shanxi Medical University, Taiyuan 030024, China.'}, {'ForeName': 'Niansong', 'Initials': 'N', 'LastName': 'Wang', 'Affiliation': 'Department of Nephrology, The Six Affiliated Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.'}, {'ForeName': 'Wenge', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Department of Nephrology, China-Japan Friendship Hospital, Beijing 100029, China.'}, {'ForeName': 'Guangyan', 'Initials': 'G', 'LastName': 'Cai', 'Affiliation': 'Department of Nephrology, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing 100853, China.'}, {'ForeName': 'Yizhi', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Nephrology, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing 100853, China.'}, {'ForeName': 'Peiqing', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'Department of Nephrology, Heilongjiang Provincial Academy of Traditional Chinese Medicine, Heilongjiang, 150036, China.'}, {'ForeName': 'Xiaoqin', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Nephrology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China.'}, {'ForeName': 'Qinkai', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'Department of Nephrology, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.'}, {'ForeName': 'Zhenjiang', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': ""Department of Nephrology, Shanxi Provincial People's Hospital, Xi'an, 710068, China.""}, {'ForeName': 'Xuefeng', 'Initials': 'X', 'LastName': 'Sun', 'Affiliation': 'Department of Nephrology, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing 100853, China. Electronic address: xfssun@126.com.'}, {'ForeName': 'Xiangmei', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Nephrology, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing 100853, China. Electronic address: xmchen301@126.com.'}]",Phytomedicine : international journal of phytotherapy and phytopharmacology,['10.1016/j.phymed.2020.153231'] 1265,32546477,Paramedic experiences of using an enhanced stroke assessment during a cluster randomised trial: a qualitative thematic analysis.,"BACKGROUND Intravenous thrombolysis is a key element of emergency treatment for acute ischaemic stroke, but hospital service delivery is variable. The Paramedic Acute Stroke Treatment Assessment (PASTA) multicentre cluster randomised controlled trial evaluated whether an enhanced paramedic-initiated stroke assessment pathway could improve thrombolysis volume. This paper reports the findings of a parallel process evaluation which explored intervention paramedics' experience of delivering the enhanced assessment. METHODS Interviewees were recruited from 453 trained intervention paramedics across three UK ambulance services hosting the trial: North East, North West and Welsh Ambulance Services. A semistructured interview guide aimed to (1) explore the stroke-specific assessment and handover procedures which were part of the PASTA pathway and (2) enable paramedics to share relevant views about expanding their role and any barriers/enablers they encountered. Interviews were audiorecorded, transcribed verbatim and analysed following the principles of the constant comparative method. RESULTS Twenty-six interviews were conducted (11 North East, 10 North West and 5 Wales). Iterative data analysis identified four key themes, which reflected paramedics' experiences at different stages of the care pathway: (1) Enhanced assessment at scene: paramedics felt this improved their skillset and confidence. (2) Prealert to hospital: a mixed experience dependent on receiving hospital staff. (3) Handover to hospital team: standardisation of format was viewed as the primary benefit of the PASTA pathway. (4) Assisting in hospital and feedback: due to professional boundaries, paramedics found these aspects harder to achieve, although feedback from the clinical team was valued when available. CONCLUSION Paramedics believed that the PASTA pathway enhanced their skills and the emergency care of stroke patients, but a continuing clinical role postadmission was challenging. Future studies should consider whether interdisciplinary training is needed to enable more radical extension of professional boundaries for paramedics.",2020,The Paramedic Acute Stroke Treatment Assessment (PASTA) multicentre cluster randomised controlled trial evaluated whether an enhanced paramedic-initiated stroke assessment pathway could improve thrombolysis volume.,"['Twenty-six interviews were conducted (11 North East, 10 North West and 5 Wales', 'Interviewees were recruited from 453 trained intervention paramedics across three UK ambulance services hosting the trial: North East, North West and Welsh Ambulance Services']",[],['thrombolysis volume'],"[{'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0037769', 'cui_str': 'West syndrome'}, {'cui': 'C0043015', 'cui_str': 'Wales'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013963', 'cui_str': 'Paramedic'}, {'cui': 'C0002422', 'cui_str': 'Ambulance'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0043114', 'cui_str': 'Welsh'}]",[],"[{'cui': 'C0520997', 'cui_str': 'Thrombolysis'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",26.0,0.046024,The Paramedic Acute Stroke Treatment Assessment (PASTA) multicentre cluster randomised controlled trial evaluated whether an enhanced paramedic-initiated stroke assessment pathway could improve thrombolysis volume.,"[{'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Lally', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK.'}, {'ForeName': 'Anu', 'Initials': 'A', 'LastName': 'Vaittinen', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'McClelland', 'Affiliation': 'Research and Development, North East Ambulance Service NHS Foundation Trust, Newcastle upon Tyne, Tyne and Wear, UK.'}, {'ForeName': 'Christopher I', 'Initials': 'CI', 'LastName': 'Price', 'Affiliation': 'Stroke Research Group, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK c.i.m.price@ncl.ac.uk.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Shaw', 'Affiliation': 'Stroke Research Group, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK.'}, {'ForeName': 'Gary A', 'Initials': 'GA', 'LastName': 'Ford', 'Affiliation': 'Medical Sciences Division, University of Oxford, and Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK.'}, {'ForeName': 'Darren', 'Initials': 'D', 'LastName': 'Flynn', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Exley', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK.'}]",Emergency medicine journal : EMJ,['10.1136/emermed-2019-209392'] 1266,32544560,"Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).","PURPOSE To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 10- and 15-μg bimatoprost implant in subjects with open-angle glaucoma (OAG) and ocular hypertension (OHT) after initial and repeated administrations. DESIGN Randomized, 20-month, multicenter, subject- and efficacy evaluator-masked, parallel-group, phase 3 clinical study. PARTICIPANTS Adults with OAG or OHT in each eye, open iridocorneal angle inferiorly in the study eye, and study eye baseline IOP (hour 0; 8 am) of 22-32 mmHg after washout. METHODS Study eyes received bimatoprost implant 10 μg (n = 198) or 15 μg (n = 198) on day 1 with readministration at weeks 16 and 32, or twice-daily topical timolol maleate 0.5% (n = 198). Intraocular pressure was measured at hours 0 and 2 at each visit. MAIN OUTCOME MEASURES Primary end points were IOP and change from baseline IOP through week 12. Safety measures included treatment-emergent adverse events (TEAEs) and corneal endothelial cell density (CECD). RESULTS Both dose strengths of bimatoprost implant were noninferior to timolol in IOP lowering after each administration. Mean diurnal IOP was 24.0, 24.2, and 23.9 mmHg at baseline and from 16.5-17.2, 16.5-17.0, and 17.1-17.5 mmHg through week 12 in the 10-μg implant, 15-μg implant, and timolol groups, respectively. The incidence of corneal and inflammatory TEAEs of interest (e.g., corneal endothelial cell loss, iritis) was higher with bimatoprost implant than timolol and highest with the 15-μg dose strength. Incidence of corneal TEAEs increased after repeated treatment; with 3 administrations at fixed 16-week intervals, incidence of ≥20% CECD loss was 10.2% (10-μg implant) and 21.8% (15-μg implant). Mean best-corrected visual acuity (BCVA) was stable; 3 implant-treated subjects with corneal TEAEs had >2-line BCVA loss at their last visit. CONCLUSIONS Both dose strengths of bimatoprost implant met the primary end point of noninferiority to timolol through week 12. One year after 3 administrations, IOP was controlled in most subjects without additional treatment. The risk-benefit assessment favored the 10-μg implant over the 15-μg implant. Ongoing studies are evaluating other administration regimens to reduce the potential for CECD loss. The bimatoprost implant has potential to improve adherence and reduce treatment burden in glaucoma.",2020,Both dose strengths of bimatoprost implant were noninferior to timolol in IOP lowering after each administration.,"['Adults with OAG or OHT in each eye, open iridocorneal angle inferiorly in the study eye by clinical gonioscopy, and study eye baseline IOP (H0; 8 am±1 h) of 22-32 mmHg after washout', 'subjects with open-angle glaucoma (OAG) and ocular hypertension (OHT) after initial and repeated administrations']","['10- and 15-μg bimatoprost implant', 'timolol', 'bimatoprost implant 10 μg (n=198) or 15 μg (n=198) on Day 1 with readministration at Weeks 16 and 32, or twice-daily topical timolol maleate', 'Bimatoprost Implant']","['Mean diurnal IOP', 'IOP and change from baseline IOP', 'treatment-emergent adverse events (TEAEs) and corneal endothelial cell density (CECD', 'incidence of corneal and inflammatory TEAEs of interest (eg, corneal endothelial cell loss, iritis', 'Incidence of corneal TEAEs of interest', 'IOP', 'intraocular pressure (IOP)-lowering efficacy and safety', '2-line BCVA loss', 'incidence of ≥20% CECD loss', 'Mean BCVA']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0229238', 'cui_str': 'Structure of iridocorneal angle'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0018071', 'cui_str': 'Gonioscopy'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0017612', 'cui_str': 'Open-angle glaucoma'}, {'cui': 'C0028840', 'cui_str': 'Ocular hypertension'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0937917', 'cui_str': 'bimatoprost'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0040233', 'cui_str': 'Timolol'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376495', 'cui_str': 'Retreatments'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0087093', 'cui_str': 'Timolol maleate'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0429518', 'cui_str': 'Endothelial cell density'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C2717756', 'cui_str': 'Corneal endothelial cell loss'}, {'cui': 'C0022081', 'cui_str': 'Iritis'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205132', 'cui_str': 'Linear'}]",,0.0864011,Both dose strengths of bimatoprost implant were noninferior to timolol in IOP lowering after each administration.,"[{'ForeName': 'Felipe A', 'Initials': 'FA', 'LastName': 'Medeiros', 'Affiliation': 'Department of Ophthalmology, Duke University, Durham, North Carolina.'}, {'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'Walters', 'Affiliation': 'Keystone Research, Ltd., Austin, Texas.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Kolko', 'Affiliation': 'Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet-Glostrup, Glostrup, Denmark; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Coote', 'Affiliation': 'Center for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Bejanian', 'Affiliation': 'Allergan plc, Irvine, California.'}, {'ForeName': 'Margot L', 'Initials': 'ML', 'LastName': 'Goodkin', 'Affiliation': 'Allergan plc, Irvine, California.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Guo', 'Affiliation': 'Allergan plc, Irvine, California.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Allergan plc, Madison, New Jersey.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Robinson', 'Affiliation': 'Allergan plc, Irvine, California. Electronic address: Robinson_Michael@Allergan.com.'}, {'ForeName': 'Robert N', 'Initials': 'RN', 'LastName': 'Weinreb', 'Affiliation': 'Hamilton Glaucoma Center, Shiley Eye Institute and Viterbi Family Department of Ophthalmology, University of California, San Diego, California.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Ophthalmology,['10.1016/j.ophtha.2020.06.018'] 1267,32549196,Efficacy and Safety of Botulinum Toxin Type A on Persistent Myofascial Pain: A Randomized Clinical Trial.,"This study assessed the safety and efficacy of three different doses of BoNT-A for persistent myofascial pain (MFP). One hundred female subjects were randomly assigned into five groups ( n = 20): oral appliance (OA), saline solution (SS) and three BoNT-A groups with different doses. Pain intensity and pressure pain threshold were evaluated up to 24 weeks after treatment. Adverse effects related to muscle contraction, masticatory performance, muscle thickness and mandibular bone volume were also assessed. Changes over time were compared within and between groups. The ""nparLD"" package and Wilcoxon signed-rank test were used to analyze the data. BoNT-A reduced pain intensity ( p < 0.0001) and increased pressure pain threshold ( p < 0.0001) for up to 24 weeks compared to the placebo. No differences were found between BoNT-A and OA at the last follow-up. A transient decline in masticatory performance ( p < 0.05) and muscle contraction ( p < 0.0001), and a decrease in muscle thickness ( p < 0.05) and coronoid and condylar process bone volume ( p < 0.05) were found as dose-related adverse effects of BoNT-A. Regardless of the dose, BoNT-A was as effective as OA on MFP. Notwithstanding, due to BoNT-A dose-related adverse effects, we suggest the use of low doses of BoNT-A in MFP patients that do not benefit from conservative treatments.",2020,A reduced pain intensity ( p < 0.0001) and increased pressure pain threshold ( p < 0.0001) for up to 24 weeks compared to the placebo.,"['Persistent Myofascial Pain', 'persistent myofascial pain (MFP', 'One hundred female subjects']","['placebo', 'Botulinum Toxin Type A', 'oral appliance (OA), saline solution (SS']","['Efficacy and Safety', 'masticatory performance', 'muscle contraction', 'pain intensity', 'pressure pain threshold', 'safety and efficacy', 'muscle thickness', 'coronoid and condylar process bone volume', 'Pain intensity and pressure pain threshold', 'muscle contraction, masticatory performance, muscle thickness and mandibular bone volume']","[{'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0553642', 'cui_str': 'Myofascial pain'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1542418', 'cui_str': 'Appliance'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0026820', 'cui_str': 'Muscle contraction'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}]",100.0,0.166347,A reduced pain intensity ( p < 0.0001) and increased pressure pain threshold ( p < 0.0001) for up to 24 weeks compared to the placebo.,"[{'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'De la Torre Canales', 'Affiliation': 'Department of Prosthodontics and Periodontology, Piracicaba Dental School, University of Campinas, Sao Paulo 13414-903, Brazil.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Alvarez-Pinzon', 'Affiliation': 'Department of Prosthodontics and Periodontology, Piracicaba Dental School, University of Campinas, Sao Paulo 13414-903, Brazil.'}, {'ForeName': 'Victor Ricardo Manuel', 'Initials': 'VRM', 'LastName': 'Muñoz-Lora', 'Affiliation': 'Department of Prosthodontics and Periodontology, Piracicaba Dental School, University of Campinas, Sao Paulo 13414-903, Brazil.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Vieira Peroni', 'Affiliation': 'Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Sao Paulo 13414-903, Brazil.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Farias Gomes', 'Affiliation': 'Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Sao Paulo 13414-903, Brazil.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Sánchez-Ayala', 'Affiliation': 'Department of Dentistry, State University of Ponta Grossa, Paraná 84030-900, Brazil.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Haiter-Neto', 'Affiliation': 'Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Sao Paulo 13414-903, Brazil.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Manfredini', 'Affiliation': 'Department of Dentistry, University of Siena, 53100 Siena, Italy.'}, {'ForeName': 'Célia Marisa', 'Initials': 'CM', 'LastName': 'Rizzatti-Barbosa', 'Affiliation': 'Department of Prosthodontics and Periodontology, Piracicaba Dental School, University of Campinas, Sao Paulo 13414-903, Brazil.'}]",Toxins,['10.3390/toxins12060395'] 1268,32340471,Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine.,"BACKGROUND This analysis characterizes the immunogenicity profile of galcanezumab, a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and inhibits its activity, in phase 3 migraine trials. METHODS Immunogenicity data were analyzed from baseline and double-blind, placebo-controlled phases of the 3-month chronic migraine study REGAIN, the 6-month episodic migraine studies EVOLVE-1 and EVOLVE-2, and from baseline and open-label phases of the 12-month chronic and episodic migraine Study CGAJ. The incidence of baseline antidrug antibodies, treatment-emergent antidrug antibodies, neutralizing antidrug antibodies, and the effect of antidrug antibody titer on pharmacokinetics and pharmacodynamics were assessed. The relationship between antidrug antibody status and efficacy was explored using average change in monthly migraine headache days. Safety analyses assessed the potential relationship between treatment-emergent antidrug antibodies and hypersensitivity events or adverse events related to injection sites. FINDINGS Across studies, 5.9-11.2% of patients had baseline antidrug antibodies. The incidence of treatment-emergent antidrug antibodies was 2.6-12.4% in the galcanezumab group and 0.5-1.7% in the placebo group. The majority of treatment-emergent antidrug antibodies were detected approximately 3-6 months after first study drug dose. Overall, the observed antidrug antibody titer did not impact galcanezumab concentrations, calcitonin gene-related peptide concentrations, or galcanezumab efficacy. There was no evidence that hypersensitivity events or adverse events related to injection sites were mediated by treatment-emergent antidrug antibodies. INTERPRETATION These data showed that immunogenicity did not impact galcanezumab concentrations, calcitonin gene-related peptide concentrations, or the efficacy and hypersensitivity profile of galcanezumab in patients with migraine.",2020,"There was no evidence that hypersensitivity events or adverse events related to injection sites were mediated by treatment-emergent antidrug antibodies. ","['patients with episodic or chronic migraine', 'patients with migraine']","['galcanezumab', 'placebo']","['hypersensitivity events or adverse events', 'efficacy and hypersensitivity profile of galcanezumab', 'galcanezumab concentrations, calcitonin gene-related peptide concentrations, or galcanezumab efficacy', 'incidence of treatment-emergent antidrug antibodies']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C1960870', 'cui_str': 'Transformed migraine'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}]","[{'cui': 'C4694273', 'cui_str': 'galcanezumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0430344', 'cui_str': 'Allergy profile'}, {'cui': 'C4694273', 'cui_str': 'galcanezumab'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0006669', 'cui_str': 'Calcitonin gene-related peptide'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}]",,0.0992328,"There was no evidence that hypersensitivity events or adverse events related to injection sites were mediated by treatment-emergent antidrug antibodies. ","[{'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Martinez', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Nada', 'Initials': 'N', 'LastName': 'Hindiyeh', 'Affiliation': 'Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Anglin', 'Affiliation': 'Eli Lilly Canada Inc, Toronto, ON, Canada.'}, {'ForeName': 'Kavita', 'Initials': 'K', 'LastName': 'Kalidas', 'Affiliation': 'University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Hodsdon', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Kielbasa', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Brian A', 'Initials': 'BA', 'LastName': 'Moser', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Eric M', 'Initials': 'EM', 'LastName': 'Pearlman', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Garces', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}]",Cephalalgia : an international journal of headache,['10.1177/0333102420920642'] 1269,32529206,Effects of oily fish intake on cognitive and socioemotional function in healthy 8-9-year-old children: the FiSK Junior randomized trial.,"BACKGROUND Long-chain n-3 PUFAs (n-3 LCPUFAs) accrete in the brain during childhood and affect brain development. Randomized trials in children show inconsistent effects of n-3 LCPUFAs on cognitive and socioemotional function, and few have investigated effects of fish per se. OBJECTIVES We aimed to investigate the effects of oily fish consumption on overall and domain-specific cognitive and socioemotional scores and explore sex differences. METHODS Healthy 8-9-y-old children (n = 199) were randomly allocated to receive ∼300 g/wk oily fish or poultry (control) for 12 ± 2 wk. At baseline and endpoint, we assessed attention, processing speed, executive functions, memory, emotions, and behavior with a large battery of tests and questionnaires and analyzed erythrocyte fatty acid composition. RESULTS One hundred and ninety-seven (99%) children completed the trial. Children in the fish group consumed 375 (25th-75th percentile: 325-426) g/wk oily fish resulting in 2.3 (95% CI: 1.9, 2.6) fatty acid percentage points higher erythrocyte n-3 LCPUFA than in the poultry group. The overall cognitive performance score tended to improve by 0.17 (95% CI: -0.01, 0.35) points in children who received fish compared with poultry, supported by n-3 LCPUFA dose dependency. This was driven mainly by fewer errors [-1.9 (95% CI: -3.4, -0.3)] in an attention task and improved cognitive flexibility measured as faster reaction time [-51 ms (95% CI: -94, -7 ms)] in a complex relative to a simple task (""mixing cost""). The fish intervention furthermore reduced parent-rated Strength and Difficulties Questionnaire total difficulties by -0.89 (95% CI: -1.60, -0.18) points mainly due to a -0.63 (95% CI: -1.11, -0.16) points reduction in internalizing problems that was reflected in tendency to a decrease in the overall socioemotional problems score of -0.13 (95% CI: -0.26, 0.01) points. The overall effects were similar in boys and girls. CONCLUSIONS Oily fish dose-dependently improved cognitive function, especially attention and cognitive flexibility, and reduced socioemotional problems. The results support the importance of n-3 LCPUFAs for optimal brain function and fish intake recommendations in children.The trial was registered at www.clinicaltrials.gov as NCT02809508.",2020,The fish intervention furthermore reduced parent-rated Strength and Difficulties Questionnaire total difficulties by -0.89,"['One hundred and ninety-seven (99%) children completed the trial', 'Healthy 8-9-y-old children (n\xa0=\xa0199', 'healthy 8-9-year-old children', 'children']","['n-3 LCPUFA', 'n-3 LCPUFAs', 'oily fish intake', 'oily fish consumption', '∼300 g/wk oily fish or poultry (control']","['overall and domain-specific cognitive and socioemotional scores and explore sex differences', 'overall effects', 'attention task and improved cognitive flexibility', 'reaction time ', 'cognitive function, especially attention and cognitive flexibility, and reduced socioemotional problems', 'overall cognitive performance score', 'cognitive and socioemotional function', 'attention, processing speed, executive functions, memory, emotions, and behavior with a large battery of tests and questionnaires and analyzed erythrocyte fatty acid composition', 'parent-rated Strength and Difficulties Questionnaire total difficulties', 'overall socioemotional problems score']","[{'cui': 'C4517622', 'cui_str': '190'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0556218', 'cui_str': 'Fatty fish intake'}, {'cui': 'C0453017', 'cui_str': 'Fatty fish'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0556978', 'cui_str': 'g/week'}, {'cui': 'C0032850', 'cui_str': 'Fowls, Domestic'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0036866', 'cui_str': 'Sex Differences'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0582591', 'cui_str': 'Processing speed'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C3472494', 'cui_str': 'Strengths and difficulties questionnaire'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}]",199.0,0.37571,The fish intervention furthermore reduced parent-rated Strength and Difficulties Questionnaire total difficulties by -0.89,"[{'ForeName': 'Marie N', 'Initials': 'MN', 'LastName': 'Teisen', 'Affiliation': 'Department of Nutrition, Exercise, and Sports, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Stine', 'Initials': 'S', 'LastName': 'Vuholm', 'Affiliation': 'Department of Nutrition, Exercise, and Sports, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Janni', 'Initials': 'J', 'LastName': 'Niclasen', 'Affiliation': 'Department of Psychology, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Juan J', 'Initials': 'JJ', 'LastName': 'Aristizabal-Henao', 'Affiliation': 'Department of Kinesiology, University of Waterloo, Waterloo, Ontario, Canada.'}, {'ForeName': 'Ken D', 'Initials': 'KD', 'LastName': 'Stark', 'Affiliation': 'Department of Kinesiology, University of Waterloo, Waterloo, Ontario, Canada.'}, {'ForeName': 'Svend S', 'Initials': 'SS', 'LastName': 'Geertsen', 'Affiliation': 'Department of Nutrition, Exercise, and Sports, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Camilla T', 'Initials': 'CT', 'LastName': 'Damsgaard', 'Affiliation': 'Department of Nutrition, Exercise, and Sports, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Lotte', 'Initials': 'L', 'LastName': 'Lauritzen', 'Affiliation': 'Department of Nutrition, Exercise, and Sports, University of Copenhagen, Copenhagen, Denmark.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqaa050'] 1270,32526490,Creativity on tap 2: Investigating dose effects of alcohol on cognitive control and creative cognition.,"This preregistered study aimed to replicate and extend research on the role of cognitive control in creative cognition by examining dose effects of alcohol in a randomized controlled trial. A sample of 125 participants was randomly assigned to three experimental groups, either drinking alcoholic beer (BAC = 0.03 or 0.06) or drinking non-alcoholic beer (placebo-control group). Before and after the alcohol intervention, participants completed two tests of cognitive control and two established creative thinking tasks. A BAC of 0.06 led to an impairment of verbal fluency, while working memory performance was unaffected at both alcohol levels. Alcohol had no facilitative or detrimental effects on creative thinking performance, neither in terms of RAT performance, divergent thinking fluency or divergent thinking creativity. These results indicate that moderate alcohol levels have dose-dependent, selective effects on cognitive control, and that minor impairments of cognitive control do not generally increase or attenuate creative thinking performance.",2020,"Alcohol had no facilitative or detrimental effects on creative thinking performance, neither in terms of RAT performance, divergent thinking fluency or divergent thinking creativity.",['A sample of 125 participants'],"['drinking alcoholic beer (BAC\xa0=\xa00.03 or 0.06) or drinking non-alcoholic beer (placebo-control group', 'alcohol', 'cognitive control and two established creative thinking tasks']","['creative thinking performance', 'verbal fluency, while working memory performance', 'RAT performance, divergent thinking fluency or divergent thinking creativity', 'cognitive control and creative cognition']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C4319551', 'cui_str': '125'}]","[{'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0687725', 'cui_str': 'Problem drinker'}, {'cui': 'C0004922', 'cui_str': 'Beer'}, {'cui': 'C0004599', 'cui_str': 'Bacitracin'}, {'cui': 'C4517402', 'cui_str': '0.03'}, {'cui': 'C4517412', 'cui_str': '0.06'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0010297', 'cui_str': 'Creative thought'}]","[{'cui': 'C0010297', 'cui_str': 'Creative thought'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",125.0,0.0319793,"Alcohol had no facilitative or detrimental effects on creative thinking performance, neither in terms of RAT performance, divergent thinking fluency or divergent thinking creativity.","[{'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Benedek', 'Affiliation': 'Institute of Psychology, University of Graz, Austria. Electronic address: mathias.benedek@uni-graz.at.'}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Zöhrer', 'Affiliation': 'Institute of Psychology, University of Graz, Austria.'}]",Consciousness and cognition,['10.1016/j.concog.2020.102972'] 1271,32526502,The effect of rumination and distraction on auditory hallucinatory experiences: An analogue experimental study.,"BACKGROUND AND OBJECTIVES The cognitive model of voices suggests that negative appraisals of hallucinatory experiences result in responses, such as rumination, which maintain voice-hearing. Our principal aim was to investigate the effect of rumination on the frequency of voice-hearing. METHODS A two-group randomised experimental design was employed using a non-clinical sample. A total of 106 participants completed baseline measures of trait rumination, hallucination-proneness, mood and state negative affect, and were presented with a voice-hearing paradigm. False feedback designed to cause a negative interpretation of auditory intrusions was provided and participants were randomly allocated to either a distraction or rumination condition. Participants performed the auditory task for a second time, and the total number of false alarms and distress scores were compared between groups. RESULTS A Mann-Whitney U test revealed that the manipulation of rumination was successful (p = 0.007). We did not detect a statistically significant difference between the distraction and rumination groups for total false alarms (p = 0.282) or distress (p = 0.387) scores. LIMITATIONS Findings largely relate to a female undergraduate psychology sample. CONCLUSION Results of this non-clinical study do not support the hypothesis that rumination leads to an increase in the frequency of voice-hearing on a laboratory task.",2020,"We did not detect a statistically significant difference between the distraction and rumination groups for total false alarms (p = 0.282) or distress (p = 0.387) scores. ","['106 participants completed baseline measures of trait rumination, hallucination-proneness, mood and state negative affect, and were presented with a voice-hearing paradigm', 'auditory hallucinatory experiences', 'female undergraduate psychology sample']","['distraction or rumination condition', 'rumination and distraction']","['distress', 'auditory task', 'total number of false alarms and distress scores', 'frequency of voice-hearing']","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C0018524', 'cui_str': 'Hallucinations'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0033909', 'cui_str': 'Psychology'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C0150189', 'cui_str': 'Distraction training'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205557', 'cui_str': 'False positive'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}]",106.0,0.0413272,"We did not detect a statistically significant difference between the distraction and rumination groups for total false alarms (p = 0.282) or distress (p = 0.387) scores. ","[{'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Anderson', 'Affiliation': 'Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences, The University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Hartley', 'Affiliation': 'Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences, The University of Manchester, Manchester, United Kingdom; Pennine Care NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Morrison', 'Affiliation': 'Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences, The University of Manchester, Manchester, United Kingdom; Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Bucci', 'Affiliation': 'Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences, The University of Manchester, Manchester, United Kingdom; Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK. Electronic address: sandra.bucci@manchester.ac.uk.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2020.101592'] 1272,32526606,Choosing vaginal birth after caesarean section: Motivating factors.,"OBJECTIVES to examine the factors that motivate women who have had a previous caesarean section to consider planning a vaginal birth. DESIGN a qualitative descriptive study with thematic analysis, drawing on interviews with women participating in a two arm, un-blinded randomised controlled trial (RCT) of midwifery continuity of care for increasing the proportion of women planning VBAC. SETTING A Maternity Unit attached to a district hospital in an outer metropolitan area of Sydney, Australia. PARTICIPANTS a purposive sample of 18 women participating in an RCT who had experienced previous caesarean section and had no contraindications for vaginal birth. FINDINGS These women were committed to natural birth and drew on their previous experience of caesarean section to highlight the downside of recovery post caesarean section. Decision making for these women was complex. During the decision-making process, women individualised the information provided to balance risk and chance within the context of their own circumstance. Supportive healthcare providers were important in motivating women towards vaginal birth and midwives were identified as being more supportive than obstetricians. CONCLUSIONS Recovery post caesarean section is an important consideration that is under emphasised in the informed consent process. There is opportunity for midwives to contribute proactively in promoting vaginal birth for women who have experienced a previous caesarean section. IMPLICATIONS FOR PRACTICE women should be assisted to make informed choices with balanced information that includes recovery from surgical birth. Models of care that include a significant role for midwives and strategies that proactively encourage vaginal birth for women after previous caesarean section are needed.",2020,"Supportive healthcare providers were important in motivating women towards vaginal birth and midwives were identified as being more supportive than obstetricians. ","['A Maternity Unit attached to a district hospital in an outer metropolitan area of Sydney, Australia', 'a purposive sample of 18 women participating in an RCT who had experienced previous caesarean section and had no contraindications for vaginal birth', 'motivate women who have had a previous caesarean section to consider planning a vaginal birth', 'women who have experienced a previous caesarean section']",[],[],"[{'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0020006', 'cui_str': 'District hospital'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0269733', 'cui_str': 'Previous caesarean section'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}]",[],[],18.0,0.0830958,"Supportive healthcare providers were important in motivating women towards vaginal birth and midwives were identified as being more supportive than obstetricians. ","[{'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Davis', 'Affiliation': 'University of Canberra and ACT Government Health Directorate, Faculty of Health, Bruce, 2617, ACT, Australia. Electronic address: Deborah.davis@canberra.edu.au.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'S Homer', 'Affiliation': 'Maternal and Child Health Program, Burnet Institute, Melbourne, Australia; Centre for Midwifery, Child and Family Health, Faculty of Health, University of Technology Sydney, Australia.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Clack', 'Affiliation': 'Centre for Midwifery, Child and Family Health, Faculty of Health, University of Technology Sydney, Australia.'}, {'ForeName': 'Sabera', 'Initials': 'S', 'LastName': 'Turkmani', 'Affiliation': 'Centre for Midwifery, Child and Family Health, Faculty of Health, University of Technology Sydney, Australia.'}, {'ForeName': 'Maralyn', 'Initials': 'M', 'LastName': 'Foureur', 'Affiliation': 'Centre for Midwifery, Child and Family Health, Faculty of Health, University of Technology Sydney, Australia; Hunter New England Local Health District & University of Newcastle, NSW, Australia.'}]",Midwifery,['10.1016/j.midw.2020.102766'] 1273,32533800,Building consensus: thresholds for delivery in TRUFFLE-2 randomized intervention study.,,2020,,[],[],[],[],[],[],,0.0379308,,"[{'ForeName': 'B', 'Initials': 'B', 'LastName': 'Mylrea-Foley', 'Affiliation': 'Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Bhide', 'Affiliation': ""Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust and Molecular & Clinical Sciences Research Institute, St George's University of London, London, UK.""}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Mullins', 'Affiliation': 'Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Thornton', 'Affiliation': 'School of Clinical Sciences, University of Nottingham, Division of Obstetrics and Gynaecology, Maternity Department, City Hospital, Nottingham, UK.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Marlow', 'Affiliation': ""UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK.""}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Stampalija', 'Affiliation': 'Unit of Fetal Medicine and Prenatal Diagnosis, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Napolitano', 'Affiliation': ""UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK.""}, {'ForeName': 'C C', 'Initials': 'CC', 'LastName': 'Lees', 'Affiliation': 'Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.'}]",Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology,['10.1002/uog.22124'] 1274,32533985,Do different culture intervals (2 × 24 hours) after thaw of cleavage stage embryos affect pregnancy rates? A randomized controlled trial.,"The aim of the study was to evaluate whether selecting embryos for transfer after prolonged culture after thaw (18-24 h) has better pregnancy rates than selecting embryos for transfer after short culture after thaw (2-5 h). We performed a double-blinded, randomized, controlled trial, evaluating 388 patients submitted to ART treatment who had embryos frozen on day-2 and subsequently transferred. All patients received the same endometrial priming with estradiol valerate followed by vaginal progesterone. Patients were randomized for Frozen embryo transfer 2-5 h after thaw (Group D2) or 18-24 h after thaw (Group D2/D3). The main Outcome Measure was ongoing pregnancy rate (OPR) at 20 weeks' gestation per embryo transfer. A total of 179 patients had embryos transferred 2-5 h after thaw and 209 patients had embryos transferred 18-24 h after thaw. The mean age in group D2 was 36 ± 4.4 and 36 ± 5.4 in group D2/D3. Ongoing pregnancy rate was 28% and 33.5% (p = 0.2) for groups D2 and D2/D3, respectively. These results suggest that increasing the culture time of embryos in one day to improve selection before transfer does not increase ongoing pregnancy rate. CLINICAL TRIAL REGISTRATION NUMBER: NCT03381001.",2020,"Ongoing pregnancy rate was 28% and 33.5% (p = 0.2) for groups D2 and D2/D3, respectively.","['179 patients had embryos transferred 2-5\u202fh after thaw and 209 patients had embryos transferred 18-24\u202fh after thaw', '388 patients submitted to ART treatment who had embryos frozen on day-2 and subsequently transferred']",['estradiol valerate followed by vaginal progesterone'],"['pregnancy rates', 'culture time of embryos', 'ongoing pregnancy rate (OPR', 'Ongoing pregnancy rate']","[{'cui': 'C4517609', 'cui_str': '179'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0013938', 'cui_str': 'Embryo transfer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0013935', 'cui_str': 'Embryos'}, {'cui': 'C0016701', 'cui_str': 'Freezing'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}]","[{'cui': 'C0059623', 'cui_str': 'Estradiol valerate'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0033308', 'cui_str': 'Progesterone'}]","[{'cui': 'C0032975', 'cui_str': 'Pregnancy Rates'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0013935', 'cui_str': 'Embryos'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}]",388.0,0.268769,"Ongoing pregnancy rate was 28% and 33.5% (p = 0.2) for groups D2 and D2/D3, respectively.","[{'ForeName': 'Laudislena', 'Initials': 'L', 'LastName': 'Colodetti', 'Affiliation': 'Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}, {'ForeName': 'Patrícia', 'Initials': 'P', 'LastName': 'Pinho de França', 'Affiliation': 'ORIGEN - Centre for Reproductive Medicine, Belo Horizonte, Brazil.'}, {'ForeName': 'Marcos', 'Initials': 'M', 'LastName': 'Sampaio', 'Affiliation': 'ORIGEN - Centre for Reproductive Medicine, Belo Horizonte, Brazil.'}, {'ForeName': 'Selmo', 'Initials': 'S', 'LastName': 'Geber', 'Affiliation': 'Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; ORIGEN - Centre for Reproductive Medicine, Belo Horizonte, Brazil. Electronic address: selmogeber@origen.com.br.'}]",Cryobiology,['10.1016/j.cryobiol.2020.06.002'] 1275,32538865,ParkinSong: Outcomes of a 12-Month Controlled Trial of Therapeutic Singing Groups in Parkinson's Disease.,"BACKGROUND Parkinson's disease (PD) frequently causes progressive deterioration in speech, voice and cognitive aspects of communication. These affect wellbeing and quality of life and are associated with caregiver strain and burden. Therapeutic singing groups can ameliorate PD-related communication disorders and increase social interaction and wellbeing for caregivers and care recipients. OBJECTIVE To analyse the effects of ParkinSong group singing sessions on Parkinson's communication and wellbeing outcomes for people with PD and caregivers over 12 months. METHODS A 4-armed controlled clinical trial compared ParkinSong with active non-singing control conditions over 12 months. Two dosage levels (weekly versus monthly) were available for each condition. ParkinSong comprised high-effort vocal, respiratory and speech exercises, group singing, and social interaction. PD-specific outcomes included vocal loudness, speech intelligibility, maximum phonation time, respiratory muscle strength, and voice related quality of life (QoL). Wellbeing outcomes were also measured for caregivers and care recipients. RESULTS We recruited 75 people with PD and 44 caregivers who attended weekly ParkinSong, monthly ParkinSong, weekly control or monthly control groups. We found significant improvements in the primary outcome of vocal loudness (p = 0.032), with weekly singers 5.13 dB louder (p = 0.044) and monthly singers 5.69 dB louder (p = 0.015) than monthly controls at 12 months. ParkinSong participants also showed greater improvements in voice-related QoL and anxiety. Caregivers who attended ParkinSong showed greater reductions in depression and stress scores. CONCLUSIONS This 12-month controlled clinical trial of ParkinSong demonstrated improvements in speech loudness and voice-related QoL for participants with PD, and enhanced wellbeing for both caregivers and care recipients. No adverse effects were reported over 12 months and improvements were sustained.",2020,"Therapeutic singing groups can ameliorate PD-related communication disorders and increase social interaction and wellbeing for caregivers and care recipients. ","['people with PD and caregivers over 12 months', '75 people with PD and 44 caregivers who attended weekly ParkinSong, monthly ParkinSong, weekly control or monthly control groups', 'caregivers and care recipients', 'participants with PD, and enhanced wellbeing for both caregivers and care recipients', ""Groups in Parkinson's Disease""]","['ParkinSong group singing sessions', 'Therapeutic Singing', 'ParkinSong with active non-singing control conditions']","[""Parkinson's communication and wellbeing outcomes"", 'vocal loudness, speech intelligibility, maximum phonation time, respiratory muscle strength, and voice related quality of life (QoL', 'voice-related QoL and anxiety', 'wellbeing and quality of life', 'speech loudness and voice-related QoL', 'vocal loudness', 'adverse effects', 'depression and stress scores']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0234857', 'cui_str': 'Singing'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0234795', 'cui_str': 'Vocal intensity'}, {'cui': 'C0037824', 'cui_str': 'Speech Intelligibility'}, {'cui': 'C0234778', 'cui_str': 'Maximum phonation time'}, {'cui': 'C0021724', 'cui_str': 'Structure of intercostal muscle'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0178733', 'cui_str': 'Loudness'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",75.0,0.0520023,"Therapeutic singing groups can ameliorate PD-related communication disorders and increase social interaction and wellbeing for caregivers and care recipients. ","[{'ForeName': 'Jeanette', 'Initials': 'J', 'LastName': 'Tamplin', 'Affiliation': 'Faculty of Fine Arts and Music, The University of Melbourne, Southbank, Victoria, VIC, Australia.'}, {'ForeName': 'Meg E', 'Initials': 'ME', 'LastName': 'Morris', 'Affiliation': 'School of Allied Health, Human Services & Sport, La Trobe University, Bundoora, Victoria, VIC, Australia.'}, {'ForeName': 'Caterina', 'Initials': 'C', 'LastName': 'Marigliani', 'Affiliation': ""Parkinson's Victoria, Surrey Hills, Victoria, VIC, Australia.""}, {'ForeName': 'Felicity A', 'Initials': 'FA', 'LastName': 'Baker', 'Affiliation': 'Faculty of Fine Arts and Music, The University of Melbourne, Southbank, Victoria, VIC, Australia.'}, {'ForeName': 'Gustavo', 'Initials': 'G', 'LastName': 'Noffs', 'Affiliation': 'Centre for Neuroscience of Speech, The University of Melbourne, Carlton, Victoria, VIC, Australia.'}, {'ForeName': 'Adam P', 'Initials': 'AP', 'LastName': 'Vogel', 'Affiliation': 'Centre for Neuroscience of Speech, The University of Melbourne, Carlton, Victoria, VIC, Australia.'}]",Journal of Parkinson's disease,['10.3233/JPD-191838'] 1276,32541530,Comparison of sugammadex and pyridostigmine bromide for reversal of rocuronium-induced neuromuscular blockade in short-term pediatric surgery: A prospective randomized study: Retraction.,,2020,,['short-term pediatric surgery'],['sugammadex and pyridostigmine bromide'],[],"[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0279077', 'cui_str': 'Pediatric surgery'}]","[{'cui': 'C1700695', 'cui_str': 'Sugammadex'}, {'cui': 'C0034262', 'cui_str': 'Pyridostigmine bromide'}]",[],,0.0907641,,[],Medicine,['10.1097/MD.0000000000020879'] 1277,32541572,Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy.,"OBJECTIVES To assess the effects of recombinant human soluble thrombomodulin treatment on 28-day all-cause mortality in subgroups categorized by baseline coagulation biomarker levels (prothrombin fragment 1.2, thrombin-antithrombin complex, D-dimer) in patients with sepsis-associated coagulopathy in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial (SCARLET) (NCT01598831). DESIGN Post hoc, subgroup analysis of a randomized, double-blind, placebo-controlled, multinational, multicenter phase 3 study. SETTING ICUs at 159 sites in 26 countries. PATIENTS Eight-hundred adults with sepsis-associated coagulopathy defined as international normalized ratio greater than 1.40 and platelet count between 30 × 10/L and 150 × 10/L or greater than 30% decrease within 24 hours with concomitant cardiovascular and/or respiratory failure. INTERVENTIONS Patients randomized and treated with recombinant human soluble thrombomodulin (0.06 mg/kg/d; n = 395) or equivalent placebo (n = 405) for 6 days. MEASUREMENTS AND MAIN RESULTS Recombinant human soluble thrombomodulin did not significantly reduce 28-day all-cause mortality in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial: absolute risk reduction was 2.55% (p = 0.32) in patients with sepsis-associated coagulopathy. In this post hoc analysis, mortality steadily increased with increasing baseline prothrombin fragment 1.2 and thrombin-antithrombin complex levels in the placebo group; for those values exceeding the upper limit of normal, the mortality increases in the recombinant human soluble thrombomodulin group were lower or negligible with increasing baseline prothrombin fragment 1.2 and thrombin-antithrombin complex. Consequently, absolute risk reductions were greater in subgroups with higher baseline prothrombin fragment 1.2 or thrombin-antithrombin complex. Absolute risk reductions were also greater in subgroups with baseline coagulation biomarker levels at or above median of the entire study population, ranging from 4.2% (95% CI, -5.0% to 13.4%) to 5.5% (95% CI, -4.0% to 14.9%). CONCLUSIONS Compared with patients receiving placebo, patients treated with recombinant human soluble thrombomodulin having higher baseline thrombin generation biomarker levels had lower mortality. Further research regarding the predictive role of coagulation biomarkers for recombinant human soluble thrombomodulin treatment response in sepsis-associated coagulopathy is warranted to evaluate clinical relevance.",2020,Recombinant human soluble thrombomodulin did not significantly reduce 28-day all-cause mortality in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial: absolute risk reduction was 2.55% (p = 0.32) in patients with sepsis-associated coagulopathy.,"['patients with sepsis-associated coagulopathy in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial (SCARLET) (NCT01598831', 'Patients With Sepsis-Associated Coagulopathy', 'ICUs at 159 sites in 26 countries', 'Eight-hundred adults with sepsis-associated coagulopathy defined as international normalized ratio greater than 1.40 and platelet count between 30 × 10/L and 150 × 10/L or greater than 30% decrease within 24 hours with concomitant cardiovascular and/or respiratory failure']","['equivalent placebo', 'Recombinant Human Soluble Thrombomodulin', 'recombinant human soluble thrombomodulin', 'recombinant human soluble thrombomodulin treatment', 'Recombinant human soluble thrombomodulin', 'placebo']","['Baseline Coagulation Biomarker Levels and Mortality Outcome', 'Absolute risk reductions', 'absolute risk reductions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0005779', 'cui_str': 'Blood coagulation disorder'}, {'cui': 'C0145779', 'cui_str': 'Thrombomodulin'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0525032', 'cui_str': 'International normalized ratio'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}]","[{'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0145779', 'cui_str': 'Thrombomodulin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C3179139', 'cui_str': 'Absolute Risk Reduction'}]",800.0,0.39019,Recombinant human soluble thrombomodulin did not significantly reduce 28-day all-cause mortality in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial: absolute risk reduction was 2.55% (p = 0.32) in patients with sepsis-associated coagulopathy.,"[{'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Levi', 'Affiliation': 'Department of Medicine and Cardiometabolic Programme - NIHR UCLH/UCL BRC, University College London Hospitals NHS Trust, London, United Kingdom.'}, {'ForeName': 'Jean-Louis', 'Initials': 'JL', 'LastName': 'Vincent', 'Affiliation': 'Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.'}, {'ForeName': 'Kosuke', 'Initials': 'K', 'LastName': 'Tanaka', 'Affiliation': 'Asahi Kasei Pharma America Corporation, Waltham, MA.'}, {'ForeName': 'Amanda H', 'Initials': 'AH', 'LastName': 'Radford', 'Affiliation': 'Asahi Kasei Pharma America Corporation, Waltham, MA.'}, {'ForeName': 'Toshihiko', 'Initials': 'T', 'LastName': 'Kayanoki', 'Affiliation': 'Asahi Kasei Pharma America Corporation, Waltham, MA.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Fineberg', 'Affiliation': 'Asahi Kasei Pharma America Corporation, Waltham, MA.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Hoppensteadt', 'Affiliation': 'Loyola University Medical Center, Maywood, IL.'}, {'ForeName': 'Jawed', 'Initials': 'J', 'LastName': 'Fareed', 'Affiliation': 'Loyola University Medical Center, Maywood, IL.'}]",Critical care medicine,['10.1097/CCM.0000000000004426'] 1278,32542334,"A novel botanical formula improves eye fatigue and dry eye: a randomized, double-blind, placebo-controlled study.","BACKGROUND With the frequent use of video display units, eye fatigue is becoming more common globally. An alternative nutritional strategy is needed to prevent the aggravation of eye fatigue symptoms. OBJECTIVES The objective was to evaluate the protective effect of a novel botanical combination of lutein ester, zeaxanthin, and extracts of blackcurrant, chrysanthemum, and goji berry on adults with eye fatigue in a randomized, double-blind, placebo-controlled clinical trial. METHODS We randomly allocated 360 participants into 4 groups to receive placebo and 3 doses of our formula (chewable tablets, containing 6 mg, 10 mg, or 14 mg of lutein) once daily for 90 d. Each participant had 3 visits at baseline (V1), 45 d (V2), and 90 d (V3) during the study. RESULTS Intervention with the formula improved individual scores of eye fatigue symptoms, including eye soreness, blurred vision, dry eye, foreign body sensation, and tearing. Compared with placebo, the formula at all 3 doses significantly decreased the total score of eye fatigue symptoms and increased the visuognosis persistence time at both V2 and V3. According to the Schirmer test, both 10-mg and 14-mg lutein formula groups had improved tear secretion at V3 compared with the placebo. The keratography results indicated that the first tear break-up time, average tear break-up time, and tear meniscus height were significantly increased after formula intervention. The formula at all 3 doses significantly increased the macular pigment optical density at V2 and V3 compared with the placebo, whereas optical coherence tomography showed no significant difference in retinal thickness and retinal volume across all groups at both visits. CONCLUSIONS Our botanical formula improves eye fatigue, dry eye, and macular function without changing the retinal structure, and thus it could serve as an effective nutritional strategy in improving eye fatigue without causing serious side effects.Clinical Trial Registry: chictr.org.cn (ChiCTR1800018987).",2020,"The formula at all 3 doses significantly increased the macular pigment optical density at V2 and V3 compared with the placebo, whereas optical coherence tomography showed no significant difference in retinal thickness and retinal volume across all groups at both visits. ",['adults with eye fatigue'],"['novel botanical combination of lutein ester, zeaxanthin, and extracts of blackcurrant, chrysanthemum, and goji berry', 'placebo and 3 doses of our formula (chewable tablets, containing 6 mg, 10 mg, or 14 mg of lutein', 'placebo']","['visuognosis persistence time', 'individual scores of eye fatigue symptoms, including eye soreness, blurred vision, dry eye, foreign body sensation, and tearing', 'tear break-up time, average tear break-up time, and tear meniscus height', 'eye fatigue, dry eye, and macular function', 'total score of eye fatigue symptoms', 'tear secretion', 'eye fatigue and dry eye', 'retinal thickness and retinal volume', 'macular pigment optical density']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0004095', 'cui_str': 'Accommodative asthenopia'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0873128', 'cui_str': 'LUTEIN ESTERS'}, {'cui': 'C0078752', 'cui_str': 'zeaxanthin'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0453277', 'cui_str': 'Blackcurrants'}, {'cui': 'C0008720', 'cui_str': 'Chrysanthemum'}, {'cui': 'C1088997', 'cui_str': 'Goji Berry Plant'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0304290', 'cui_str': 'Chewable tablet'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0043328', 'cui_str': 'Lutein'}]","[{'cui': 'C0546816', 'cui_str': 'Persistence'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0004095', 'cui_str': 'Accommodative asthenopia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0863081', 'cui_str': 'Soreness in eyes'}, {'cui': 'C0344232', 'cui_str': 'Hazy vision'}, {'cui': 'C0013238', 'cui_str': 'Dry Eye Disease'}, {'cui': 'C0423602', 'cui_str': 'Foreign body sensation'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C1827565', 'cui_str': 'Tear meniscus height'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0035298', 'cui_str': 'Retinal structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C3850163', 'cui_str': 'Macular Pigment'}, {'cui': 'C0439164', 'cui_str': 'OD units'}]",360.0,0.320918,"The formula at all 3 doses significantly increased the macular pigment optical density at V2 and V3 compared with the placebo, whereas optical coherence tomography showed no significant difference in retinal thickness and retinal volume across all groups at both visits. ","[{'ForeName': 'Juntao', 'Initials': 'J', 'LastName': 'Kan', 'Affiliation': 'Nutrilite Health Institute, Shanghai, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': 'Department of Ophthalmology, Aier Eye Hospital, Shanghai, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Vanderbilt Epidemiology Center, Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Hongyue', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Nutrilite Health Institute, Shanghai, China.'}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Nutrilite Health Institute, Shanghai, China.'}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Nutrilite Health Institute, Shanghai, China.'}, {'ForeName': 'Chengrong', 'Initials': 'C', 'LastName': 'Huang', 'Affiliation': 'School of Pharmacy, Fudan University, Shanghai, China.'}, {'ForeName': 'Bryan Y', 'Initials': 'BY', 'LastName': 'Liu', 'Affiliation': 'College of Biotechnology, East China University of Science and Technology, Shanghai, China.'}, {'ForeName': 'Zhensheng', 'Initials': 'Z', 'LastName': 'Gu', 'Affiliation': 'Department of Ophthalmology, Xinhua Hospital, Shanghai, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Du', 'Affiliation': 'Nutrilite Health Institute, Shanghai, China.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqaa139'] 1279,32548702,"Association of diabetes-related autoantibodies with the incidence of asthma, eczema and allergic rhinitis in the TRIGR randomised clinical trial.","AIMS/HYPOTHESIS This paper presents the relationship between islet autoantibodies, precursors of type 1 diabetes, and the development of persistent asthma, allergic rhinitis and atopic eczema. METHODS A total of 2159 newborns who had a first-degree relative with type 1 diabetes and selected HLA genotypes were followed until the youngest participant reached 10 years of age. Islet cell antibodies (ICA) were detected using indirect immunofluorescence. Autoantibodies to insulin (IAA), GAD (GADA), the tyrosine phosphatase-related insulinoma-associated 2 molecule (IA-2A) and zinc transporter 8 (ZnT8A) were quantified with the use of specific radiobinding assays. As an ancillary study, the incidence of asthma, allergic rhinitis and eczema was assessed in 1106 of these children using the International Study of Asthma and Allergies in Childhood (ISAAC) core questionnaire when the children were 9-11 years old. HRs with 95% CIs were calculated to depict the incidence of these diseases following seroconversion to autoantibody positivity. RESULTS The cumulative incidence of atopic eczema, allergic rhinitis and persistent asthma were 22%, 9% and 7.5%, respectively, by 9-11 years of age. The occurrence of diabetes-related autoantibodies showed a protective association with subsequently reported incidence of asthma and eczema. The incidence of rhinitis was not significantly related to the occurrence of IAA or GADA (statistical power was limited), but demonstrated the same inverse relationship as did the other diseases with ICA or when multiple autoantibodies first appeared together. CONCLUSIONS/INTERPRETATION The findings add evidence to the relationships between these atopic diseases and diabetes-related autoimmunity and also suggest that, for eczema, the interaction depends upon which autoantibody appeared first. TRIAL REGISTRATION ClinicalTrials.gov NCT00179777 Graphical abstract.",2020,"The incidence of rhinitis was not significantly related to the occurrence of IAA or GADA (statistical power was limited), but demonstrated the same inverse relationship as did the other diseases with ICA or when multiple autoantibodies first appeared together. ","['2159 newborns who had a first-degree relative with type 1 diabetes and selected HLA genotypes were followed until the youngest participant reached 10\xa0years of age', '1106 of these children using the International Study of Asthma and Allergies in Childhood (ISAAC) core questionnaire when the children were 9-11\xa0years old']",[],"['occurrence of IAA or GADA', 'cumulative incidence of atopic eczema, allergic rhinitis and persistent asthma', 'incidence of asthma, allergic rhinitis and eczema', 'Autoantibodies to insulin (IAA), GAD (GADA', 'incidence of rhinitis', 'Islet cell antibodies (ICA']","[{'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0444502', 'cui_str': 'First degree'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0019630', 'cui_str': 'Class II Histocompatibility Antigens'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0002111', 'cui_str': 'Allergy - specialty'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0580836', 'cui_str': 'Old'}]",[],"[{'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}, {'cui': 'C2607914', 'cui_str': 'Allergic rhinitis'}, {'cui': 'C3266628', 'cui_str': 'Persistent asthma'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0013595', 'cui_str': 'Eczema'}, {'cui': 'C0004358', 'cui_str': 'Autoantibody'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0270549', 'cui_str': 'Generalized anxiety disorder'}, {'cui': 'C0008711', 'cui_str': 'Chronic rhinitis'}, {'cui': 'C0063900', 'cui_str': 'Anti-pancreatic islet cell antibody'}]",2159.0,0.0442462,"The incidence of rhinitis was not significantly related to the occurrence of IAA or GADA (statistical power was limited), but demonstrated the same inverse relationship as did the other diseases with ICA or when multiple autoantibodies first appeared together. ","[{'ForeName': 'Jeffrey P', 'Initials': 'JP', 'LastName': 'Krischer', 'Affiliation': 'Health Informatics Institute, Morsani College of Medicine, University of South Florida, 3650 Spectrum Boulevard, Suite 100, Tampa, FL, 33612, USA. jeffrey.krischer@epi.usf.edu.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cuthbertson', 'Affiliation': 'Health Informatics Institute, Morsani College of Medicine, University of South Florida, 3650 Spectrum Boulevard, Suite 100, Tampa, FL, 33612, USA.'}, {'ForeName': 'Marisa', 'Initials': 'M', 'LastName': 'Couluris', 'Affiliation': 'Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Mikael', 'Initials': 'M', 'LastName': 'Knip', 'Affiliation': ""Children's Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.""}, {'ForeName': 'Suvi M', 'Initials': 'SM', 'LastName': 'Virtanen', 'Affiliation': 'Unit of Public Health Promotion, National Institute for Health and Welfare, Helsinki, Finland.'}]",Diabetologia,['10.1007/s00125-020-05188-3'] 1280,32544846,"A fructose-based meal challenge to assess metabotypes and their metabolic risk profile: A randomized, crossover, controlled trial.","OBJECTIVES The first aim of this study was to determine the metabolic type of individuals based on the postprandial metabolic response after the ingestion of a meal challenge that was high protein and either high glucose (high GI) or fructose (low GI). The second aim was to compare the baseline characteristics between the different metabolic types (metabotypes). The third aim was to assess whether the inclusion of fructose or glucose in a high-protein breakfast modulated the glucose, insulin, and TG response over a 4-h period. METHODS The study included 46 Asian women with a body mass index between 17 and 28 kg/m 2 in a randomized crossover design. Metabolic typing was based on the assessment of the postprandial glycemic, insulin and triacylglycerol (TG) response after the ingestion of two high-protein meal challenges either high in fructose or glucose. Baseline characteristics were compared between the different metabolic types. Baseline and 4-h postprandial blood samples were collected and glucose, insulin, and TG levels were analyzed. Cluster analysis was used to phenotype the participants in distinct groups. Baseline characteristics including anthropometry, glycemic, and lipid profiles and resting metabolic rate were compared among the metabolic types. RESULTS Cluster analysis revealed that women could be grouped into three metabolic types based on postprandial glucose, insulin, and TG response after the fructose meal challenge: cluster 1 with an average glucose + high TG response (highTG; n = 12), cluster 2 with a high glucose + average TG response (highGLU; n = 8), and cluster 3 with an average glucose + average TG response (Avg; n = 26). Post hoc analysis revealed significantly greater waist-to-hip ratio and a worse lipid profile for the highTG cluster and a higher fasting blood glucose, body mass index, fat percentage, and hip circumference in the highGLU cluster. CONCLUSIONS Three metabolic types with a distinct metabolic response could be distinguished after a high fructose meal. The results suggest a different risk profile and may indicate why some people develop diabetes in an obesogenic environment. Improved metabolic-type assessments will enable us to develop and optimize nutritional and medical interventions for individuals with differing diabetes risk.",2020,"Post hoc analysis revealed significantly greater waist-to-hip ratio and a worse lipid profile for the highTG cluster and a higher fasting blood glucose, body mass index, fat percentage, and hip circumference in the highGLU cluster. ","['46 Asian women with a body mass index between 17 and 28 kg/m 2', 'individuals with differing diabetes risk']","['high glucose (high GI) or fructose (low GI', 'fructose-based meal challenge']","['waist-to-hip ratio', 'fasting blood glucose, body mass index, fat percentage, and hip circumference', 'glucose, insulin, and TG levels', 'glucose, insulin, and TG response', 'postprandial glycemic, insulin and triacylglycerol (TG) response', 'Baseline and 4-h postprandial blood samples', 'postprandial glucose, insulin, and TG response', 'anthropometry, glycemic, and lipid profiles and resting metabolic rate', 'postprandial metabolic response']","[{'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]","[{'cui': 'C0860803', 'cui_str': 'Glucose increased'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0016745', 'cui_str': 'Fructose'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1998602', 'cui_str': 'Meals'}]","[{'cui': 'C0205682', 'cui_str': 'Waist/hip ratio'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0562350', 'cui_str': 'Hip circumference'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C4082350', 'cui_str': 'Resting Metabolic Rate'}]",46.0,0.0341195,"Post hoc analysis revealed significantly greater waist-to-hip ratio and a worse lipid profile for the highTG cluster and a higher fasting blood glucose, body mass index, fat percentage, and hip circumference in the highGLU cluster. ","[{'ForeName': 'Stefan Gerardus', 'Initials': 'SG', 'LastName': 'Camps', 'Affiliation': 'Singapore Institute of Food and Biotechnology Innovation, Agency for Science, Technology and Research and National University Health System, Singapore.'}, {'ForeName': 'Huann Rong', 'Initials': 'HR', 'LastName': 'Koh', 'Affiliation': 'Singapore Institute of Food and Biotechnology Innovation, Agency for Science, Technology and Research and National University Health System, Singapore.'}, {'ForeName': 'Nan Xin', 'Initials': 'NX', 'LastName': 'Wang', 'Affiliation': 'Singapore Institute of Food and Biotechnology Innovation, Agency for Science, Technology and Research and National University Health System, Singapore.'}, {'ForeName': 'Christiani Jeyakumar', 'Initials': 'CJ', 'LastName': 'Henry', 'Affiliation': 'Singapore Institute of Food and Biotechnology Innovation, Agency for Science, Technology and Research and National University Health System, Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: jeya_henry@sifbi.a-star.edu.sg.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110799'] 1281,32544854,Effect of ZNF804A gene polymorphism (rs1344706) on the plasticity of the functional coupling between the right dorsolateral prefrontal cortex and the contralateral hippocampal formation.,"ZNF804A has now been recognized as a schizophrenia risk gene by multiple genome-wide association studies with its intronic polymorphism rs1344706 being reported as the first genome-wide significant risk variant for schizophrenia. Although the functional impact of this gene is still unknown, rs1344706's contribution to the functional coupling between the right dorsolateral prefrontal cortex (DLPFC) and the contralateral hippocampal formation (HF) has been reported by several studies. The current study tested whether the right DLPFC-left HF functional coupling showed plasticity during cognitive training (Study I) and whether rs1344706 affected the plasticity (Study II). In Study I, we conducted a randomized controlled trial with 30 subjects receiving 20 sessions of adaptive training on a memory span task (the training group) and 30 subjects practicing on a non-adaptive easy version of the same memory span task for 20 sessions (the control group). All subjects were scanned using fMRI before and after the training. Analyses of resting-state and task-state fMRI data consistently showed that the adaptive memory span training significantly strengthened the right DLPFC-left HF functional coupling. In Study II, we conducted a genetic association study with 101 subjects (combining the data from the training group in Study I with those from an additional subsequent sample of 71 subjects who received the same training and fMRI scans). Results showed that rs1344706 was significantly associated with training-induced changes in functional coupling. Subjects carrying the non-risk allele (C) of rs1344706 showed greater training-induced plasticity than the risk allele (A) homozygotes. These findings expanded our current understanding of the functional impact of the schizophrenia risk variant of ZNF804A gene and suggested that the ZNF804A gene could be used as a prospective target for future antipsychotic drugs and clinical research.",2020,Subjects carrying the non-risk allele (C) of rs1344706 showed greater training-induced plasticity than the risk allele (A) homozygotes.,"['101 subjects (combining the data from the training group in Study', '71 subjects who received the same training and fMRI scans', '30 subjects receiving 20 sessions of adaptive training on a memory span task (the training group) and 30 subjects practicing on a non-adaptive easy version of the same memory span task for 20 sessions (the control group']","['ZNF804A', 'ZNF804A gene polymorphism (rs1344706']",['functional coupling'],"[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0332219', 'cui_str': 'Easy'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0032529', 'cui_str': 'Genetic polymorphism'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}]",101.0,0.0118036,Subjects carrying the non-risk allele (C) of rs1344706 showed greater training-induced plasticity than the risk allele (A) homozygotes.,"[{'ForeName': 'Wan', 'Initials': 'W', 'LastName': 'Zhao', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China.'}, {'ForeName': 'Xiongying', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders & Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing 100088, PR China.'}, {'ForeName': 'Qiumei', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China; School of Mental Health, Jining Medical University, 45# Jianshe South Road, Jining 272013, Shandong Province, PR China.'}, {'ForeName': 'Boqi', 'Initials': 'B', 'LastName': 'Du', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China.'}, {'ForeName': 'Xiaoxiang', 'Initials': 'X', 'LastName': 'Deng', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Ji', 'Affiliation': 'School of Mental Health, Jining Medical University, 45# Jianshe South Road, Jining 272013, Shandong Province, PR China.'}, {'ForeName': 'Yu-Tao', 'Initials': 'YT', 'LastName': 'Xiang', 'Affiliation': 'Faculty of Health Sciences, University of Macau, Avenida da Universidade, Taipa, Macau, PR China.'}, {'ForeName': 'Chuanyue', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders & Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing 100088, PR China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Dong', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China.'}, {'ForeName': 'Chuansheng', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Department of Psychological Science, University of California, Irvine, CA 92697, United States.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China. Electronic address: lijundp@bnu.edu.cn.'}]",NeuroImage. Clinical,['10.1016/j.nicl.2020.102279'] 1282,32554133,A video-game based cognitive training for breast cancer survivors with cognitive impairment: A prospective randomized pilot trial.,"INTRODUCTION We investigated whether a web-based cognitive training video game is an effective approach to improve cognitive decline in combination with our standard of care for rehabilitation of breast cancer (BC) patients. MATERIALS AND METHODS Self-selected BC patients between 18 and 71 years old complaining of disturbing cognitive impairment were studied. The patients received access to a web-based internet video game and online cognitive assessments (Aquasnap, Cambridge, MyCQ™). The early intervention group (n = 23) had a training program of 6 months of at least three times a week for a minimum of 60 min of game playing per week at home in addition to standard of care rehabilitation. The delayed intervention (n = 23) received standard of care for three months, followed by three months of similar MyCQ training. Outcome measures were the MyCQ (sub)scores and Activity of Daily Life (ADL), mood, subjective cognition and functional cognitive status measured by classic neuropsychological tests. RESULTS At baseline the means for CFQ (a measure of self-reported cognitive failure), anxiety, PSQI and self-reflectiveness were beyond normal range in both groups. CFQ improved significantly better in the intervention group (p = 0.029). Combining the evolution over time in the entire population a significant improvement was seen for overall MyCQ score, level of fear, physical and emotional role limitation, and health change (all p < 0.05), but self-reflectivess deteriorated (p < 0.05)). Significant differences in the various MyCQ subtests over time were: improved speed in choice reaction time, visual memory recognition, N back 1 and 2, coding, trail making test B, improved accuracy of N back 1 and 2 (all p < 0.05). CONCLUSION A program of cognitive training improves cognitive functioning over time. ""Aquasnap"" has a beneficial effect on the perception of subjective cognitive functioning (CFQ) but the exact role of video gaming in this process remains uncertain.",2020,"Significant differences in the various MyCQ subtests over time were: improved speed in choice reaction time, visual memory recognition, N back 1 and 2, coding, trail making test B, improved accuracy of N","['Self-selected BC patients between 18 and 71 years old complaining of disturbing cognitive impairment were studied', 'breast cancer (BC) patients', 'breast cancer survivors with cognitive impairment']","['video-game based cognitive training', 'cognitive training', 'web-based cognitive training video game', 'MyCQ training', 'access to a web-based internet video game and online cognitive assessments (Aquasnap, Cambridge, MyCQ™']","['speed in choice reaction time, visual memory recognition, N back 1 and 2, coding, trail making test B, improved accuracy of N', 'cognitive failure), anxiety, PSQI and self-reflectiveness', 'cognitive functioning', 'MyCQ (sub)scores and Activity of Daily Life (ADL), mood, subjective cognition and functional cognitive status measured by classic neuropsychological tests', 'overall MyCQ score, level of fear, physical and emotional role limitation, and health change', 'CFQ']","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]","[{'cui': 'C0042649', 'cui_str': 'Video Games'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0542316', 'cui_str': 'Visual memory'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439658', 'cui_str': 'Classic'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1319227', 'cui_str': 'Level of fear'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",,0.0411642,"Significant differences in the various MyCQ subtests over time were: improved speed in choice reaction time, visual memory recognition, N back 1 and 2, coding, trail making test B, improved accuracy of N","[{'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Bellens', 'Affiliation': 'Multidisciplinary Oncologic Center Antwerp (MOCA), Antwerp University Hospital, Edegem, B2650, Belgium; Centre for Oncological Research (CORE), University of Antwerp, Wilrijk, B2610, Belgium.'}, {'ForeName': 'Ella', 'Initials': 'E', 'LastName': 'Roelant', 'Affiliation': 'Clinical Trial Center (CTC), CRC Antwerp, Antwerp University Hospital, University of Antwerp, Edegem, B2650, Belgium; StatUa, Center for Statistics, University of Antwerp, Antwerp, B2000, Belgium.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Sabbe', 'Affiliation': 'Department of Psychiatry, Antwerp University, Wilrijk, Belgium.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Peeters', 'Affiliation': 'Multidisciplinary Oncologic Center Antwerp (MOCA), Antwerp University Hospital, Edegem, B2650, Belgium; Centre for Oncological Research (CORE), University of Antwerp, Wilrijk, B2610, Belgium.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'van Dam', 'Affiliation': 'Multidisciplinary Oncologic Center Antwerp (MOCA), Antwerp University Hospital, Edegem, B2650, Belgium; Centre for Oncological Research (CORE), University of Antwerp, Wilrijk, B2610, Belgium. Electronic address: peter.vandam@telenet.be.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2020.06.003'] 1283,32554135,The relationship between the tympanostomy tube extrusion time and viscosity.,"OBJECTIVE The purpose of the study was to assess the correlation between the tympanostomy tube extrusion time and the viscosity of the middle ear fluid. METHODS Thirty-three patients who were scheduled for a tympanostomy tube (TT) insertion were included in the study. During the paracentesis procedure, fluid from the middle ear was obtained, and the viscosity was measured with a viscometer. Patients with effusion values below and above the median viscosity value of 439 cP (cP) were assigned to Group 1 and Group 2, respectively. After the surgery, the patients were followed up monthly until the tubes were observed to be extruded. RESULTS The analysis of the correlation between the tube extrusion time and the viscosity was statistically insignificant (p > 0.05). The mean tube extrusion time of Group 1 (12.65 ± 4.152 months) was slightly lower than that of Group 2 (13.81 ± 4.43 months); however, the difference was not statistically significant. CONCLUSION The tube extrusion time can be longer or shorter and is independent of the effusion viscosity. Further studies are needed to clarify the factors that affect the TT extrusion time. TRIAL REGISTRATION NUMBER NCT03848026.",2020,The analysis of the correlation between the tube extrusion time and the viscosity was statistically insignificant (p > 0.05).,"['Patients with effusion values below and above the median viscosity value of 439\xa0cP (cP', 'Thirty-three patients who were scheduled for a tympanostomy tube (TT) insertion were included in the study']",[],"['mean tube extrusion time', 'tube extrusion time and the viscosity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013687', 'cui_str': 'Effusion'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0042784', 'cui_str': 'Viscosity'}, {'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0850121', 'cui_str': 'Tympanic ventilation tube'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0443213', 'cui_str': 'Extrusion'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0042784', 'cui_str': 'Viscosity'}]",33.0,0.0301946,The analysis of the correlation between the tube extrusion time and the viscosity was statistically insignificant (p > 0.05).,"[{'ForeName': 'Nazan', 'Initials': 'N', 'LastName': 'Degirmenci', 'Affiliation': 'Bezmialem Vakif University, Department of Otorhinolaryngology and Head and Neck Surgery, Istanbul, Turkey. Electronic address: ndegirmenci@bezmialem.edu.tr.'}, {'ForeName': 'Selahattin', 'Initials': 'S', 'LastName': 'Tugrul', 'Affiliation': 'Bezmialem Vakif University, Department of Otorhinolaryngology and Head and Neck Surgery, Istanbul, Turkey. Electronic address: selahattintugrul@yahoo.com.'}, {'ForeName': 'Seda Sezen', 'Initials': 'SS', 'LastName': 'Goktas', 'Affiliation': '75. Yil Boyabat State Hospital, Department of Otorhinolaryngology and Head and Neck Surgery, Sinop, Turkey. Electronic address: sedasezengoktas@gmail.com.'}, {'ForeName': 'Erol', 'Initials': 'E', 'LastName': 'Senturk', 'Affiliation': 'Bezmialem Vakif University, Department of Otorhinolaryngology and Head and Neck Surgery, Istanbul, Turkey. Electronic address: erolsent@gmail.com.'}, {'ForeName': 'Omer Faruk', 'Initials': 'OF', 'LastName': 'Calim', 'Affiliation': 'Bezmialem Vakif University, Department of Otorhinolaryngology and Head and Neck Surgery, Istanbul, Turkey. Electronic address: omercalim@yahoo.com.'}, {'ForeName': 'Remzi', 'Initials': 'R', 'LastName': 'Dogan', 'Affiliation': 'Bezmialem Vakif University, Department of Otorhinolaryngology and Head and Neck Surgery, Istanbul, Turkey. Electronic address: dr.remzidogan@hotmail.com.'}, {'ForeName': 'Alper', 'Initials': 'A', 'LastName': 'Yenigun', 'Affiliation': 'Bezmialem Vakif University, Department of Otorhinolaryngology and Head and Neck Surgery, Istanbul, Turkey. Electronic address: alperyenigun@gmail.com.'}, {'ForeName': 'Orhan', 'Initials': 'O', 'LastName': 'Ozturan', 'Affiliation': 'Bezmialem Vakif University, Department of Otorhinolaryngology and Head and Neck Surgery, Istanbul, Turkey. Electronic address: orhanent@yahoo.com.'}]",International journal of pediatric otorhinolaryngology,['10.1016/j.ijporl.2020.110140'] 1284,32559602,Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2.,"OBJECTIVE To assess the efficacy of vilaprisan compared with placebo in the management of the symptoms of uterine fibroids (UF), with a secondary objective to provide a descriptive comparison with ulipristal acetate. STUDY DESIGN The randomized, parallel-group, double-blind, placebo- and active-controlled, multicenter ASTEROID 2 trial assessed the efficacy and safety of vilaprisan versus placebo and ulipristal acetate for two 12-week treatment periods in women with ≥1 UF experiencing heavy menstrual bleeding (HMB). The primary endpoint compared the efficacy of vilaprisan with placebo at 12 weeks, assessed as the absence of bleeding/spotting by bleeding diary. Secondary endpoints compared the efficacy of vilaprisan with ulipristal acetate. Results of the first 12-week treatment period are reported here. RESULTS Women (mean age 42.5 years) were enrolled from 1 June 2015. At baseline, mean menstrual blood loss per 28 days was 214.1 mL and the volume of the three largest UF was 106.2 mL. In total, 155 women completed the initial 12-week treatment period. Complete absence of bleeding/spotting until the end of the 12-week treatment period was achieved by 62.9 % of women receiving vilaprisan versus 0.0 % with placebo (p < .001); 55.4 % of women treated with ulipristal acetate reported absence of bleeding/spotting. The predefined HMB response (<80 mL and >50 % reduction from baseline during the last 28 days of treatment) was observed in 95.7 % of subjects treated with vilaprisan and 86.5 % of subjects treated with ulipristal acetate. Vilaprisan and ulipristal acetate treatment reduced the sum of the volume of the three largest UF by 29.9 % and 23.8 %, respectively, whereas an increase of 6.3 % was observed in the placebo group. No safety concerns, including multiple laboratory parameters, were identified. CONCLUSION Daily administration of vilaprisan 2 mg induced amenorrhea, controlled bleeding, decreased UF size, and was well tolerated in women with HMB associated with UF. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov number: NCT02465814 https://clinicaltrials.gov/ct2/show/NCT02465814.",2020,"Vilaprisan and ulipristal acetate treatment reduced the sum of the volume of the three largest UF by 29.9 % and 23.8 %, respectively, whereas an increase of 6.3 % was observed in the placebo group.","['women with ≥1 UF experiencing heavy menstrual bleeding (HMB', 'women with uterine fibroids', 'Women (mean age 42.5 years) were enrolled from 1 June 2015', '155 women completed the initial 12-week treatment period']","['Vilaprisan and ulipristal acetate', 'ulipristal acetate', 'vilaprisan versus placebo and ulipristal acetate', 'vilaprisan', 'placebo']","['mean menstrual blood loss', 'HMB response', 'Efficacy and safety', 'absence of bleeding/spotting by bleeding diary', 'Complete absence of bleeding/spotting', 'efficacy and safety', 'amenorrhea, controlled bleeding, decreased UF size', 'efficacy of vilaprisan', 'efficacy of vilaprisan with ulipristal acetate', 'absence of bleeding/spotting']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042133', 'cui_str': 'Leiomyoma'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0025323', 'cui_str': 'Menorrhagia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C4508937', 'cui_str': 'vilaprisan'}, {'cui': 'C2723461', 'cui_str': 'Ulipristal acetate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0694689', 'cui_str': 'Menstrual blood'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0002453', 'cui_str': 'Amenorrhea'}, {'cui': 'C0149533', 'cui_str': 'Control of hemorrhage'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0042133', 'cui_str': 'Leiomyoma'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C4508937', 'cui_str': 'vilaprisan'}, {'cui': 'C2723461', 'cui_str': 'Ulipristal acetate'}]",155.0,0.413833,"Vilaprisan and ulipristal acetate treatment reduced the sum of the volume of the three largest UF by 29.9 % and 23.8 %, respectively, whereas an increase of 6.3 % was observed in the placebo group.","[{'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Gemzell-Danielsson', 'Affiliation': ""Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet, and Karolinska University Hospital, S-171 76, Stockholm, Sweden. Electronic address: Kristina.Gemzell@ki.se.""}, {'ForeName': 'Oskari', 'Initials': 'O', 'LastName': 'Heikinheimo', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, PO Box 140, 00029-HUS, Helsinki, Finland. Electronic address: oskari.heikinheimo@helsinki.fi.'}, {'ForeName': 'Janos', 'Initials': 'J', 'LastName': 'Zatik', 'Affiliation': 'Szent Anna Szuleszeti, Nogyogyaszati es Ultrahang Magan Rendelo, 48 Szent Anna utca, Debrecen, Hungary. Electronic address: jzatik@yahoo.com.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Poka', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Debrecen, Nagyerdei krt. 98, 4032, Debrecen, Hungary. Electronic address: pokar@med.unideb.hu.'}, {'ForeName': 'Tomasz', 'Initials': 'T', 'LastName': 'Rechberger', 'Affiliation': 'II Department of Gynecology, Medical University of Lublin, Racławickie 1 Street, 20-059, Lublin, Poland. Electronic address: rechbergt@yahoo.com.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Hudecek', 'Affiliation': 'Department of Obstetrics and Gynecology, Brno University Hospital and Masaryk University Medical School, Jihlavská 20, CZ - 625 00, Brno, Czech Republic. Electronic address: hudecek.robert@fnbrno.cz.'}, {'ForeName': 'Kathrin', 'Initials': 'K', 'LastName': 'Petersdorf', 'Affiliation': 'Bayer AG, Müllerstraße 178, 13342, Berlin, Germany. Electronic address: Kathrin.petersdorf@bayer.com.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Ramirez', 'Affiliation': 'Syneos Health, Frankfurter StraBe 233 Triforum, Haus C1 Neu-Isenburg, 63263, Germany. Electronic address: francisco.ramirez1.ext@bayer.com.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Faustmann', 'Affiliation': 'Bayer AG, Müllerstraße 178, 13342, Berlin, Germany. Electronic address: thomas.faustmann@bayer.com.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Groettrup-Wolfers', 'Affiliation': 'Bayer AG, Müllerstraße 178, 13342, Berlin, Germany. Electronic address: Esther.groettrup-wolfers@bayer.com.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Seitz', 'Affiliation': 'Bayer AG, Müllerstraße 178, 13342, Berlin, Germany. Electronic address: Christian.seitz@bayer.com.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.05.043'] 1285,32559656,Can theory of mind be improved? Positive expectations cause better theory of mind performance in a community sample.,"BACKGROUND AND OBJECTIVES Theory of Mind (ToM) deficits are present in several mental disorders and closely related to problems in social functioning and lower quality of life. While several trainings are aimed at improving ToM performance, it is unknown whether positive expectations on a persons' ToM performance might cause better ToM achievement. METHODS Participants (n = 131) first completed a mock ToM test and were then randomly assigned to either receive standardized positive, negative or no feedback on their ToM performance. Secondly, their expectations on their own ToM performance were assessed. Thirdly, ToM was assessed using the Movie Task for the Assessment of Social Cognition (MASC). RESULTS Participants who received positive feedback resulted in positive expectations on their ToM performance and showed enhanced ToM performance, whereas negative feedback did not lead to negative expectations and negative expectations did not affect a change in ToM performance. LIMITATIONS In the present exploratory study, the effect of positive expectations on ToM performance was assessed in a community sample. Thus, the study should be replicated in a clinical sample for more in-depth results. CONCLUSIONS ToM performance could be enhanced by inducing positive expectations on one's ToM performance, whereas negative feedback had no effect. The present study suggest that interventions that focus on strengthening positive expectations on one's ToM performance could enhance the efficacy of present ToM training methods.",2020,"RESULTS Participants who received positive feedback resulted in positive expectations on their ToM performance and showed enhanced ToM performance, whereas negative feedback did not lead to negative expectations and negative expectations did not affect a change in ToM performance. ",['Participants (n\xa0'],"['standardized positive, negative or no feedback on their ToM performance']","['Movie Task for the Assessment of Social Cognition (MASC', 'enhanced ToM performance', 'ToM performance']",[],"[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0935573', 'cui_str': 'Theory of Mind'}]","[{'cui': 'C0681495', 'cui_str': 'Movies'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0935573', 'cui_str': 'Theory of Mind'}]",131.0,0.0319971,"RESULTS Participants who received positive feedback resulted in positive expectations on their ToM performance and showed enhanced ToM performance, whereas negative feedback did not lead to negative expectations and negative expectations did not affect a change in ToM performance. ","[{'ForeName': 'Laura M-L', 'Initials': 'LM', 'LastName': 'Dorn', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Philipps-University, Marburg, Germany. Electronic address: laura.dorn@staff.uni-marburg.de.'}, {'ForeName': 'Winfried', 'Initials': 'W', 'LastName': 'Rief', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Philipps-University, Marburg, Germany.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Mehl', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Philipps-University, Marburg, Germany; Department of Social Work and Health, Frankfurt University of Applied Sciences, Germany.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2020.101577'] 1286,32526188,"Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials.","BACKGROUND Maternal influenza immunisation can reduce morbidity and mortality associated with influenza infection in pregnant women and young infants. We aimed to determine the vaccine efficacy of maternal influenza immunisation against maternal and infant PCR-confirmed influenza, duration of protection, and the effect of gestational age at vaccination on vaccine efficacy, birth outcomes, and infant growth up to 6 months of age. METHODS We did a pooled analysis of three randomised controlled trials done in Nepal (2011-2014), Mali (2011-2014), and South Africa (2011-2013). Pregnant women, gestational age 17-34 weeks in Nepal, 28 weeks or more in Mali, and 20-36 weeks in South Africa, were enrolled. Women were randomly assigned 1:1 to a study group, in which they received trivalent inactivated influenza vaccine (IIV) in all three trials, or a control group, in which they received saline placebo in Nepal and South Africa or quadrivalent meningococcal conjugate vaccine in Mali. Enrolment at all sites was complete by April 24, 2013. Infants and women were assessed for respiratory illness, and samples from those that met the case definition were tested for influenza by PCR testing. Growth measurements, including length and weight, were obtained at birth at all sites, at 24 weeks in South Africa, and at 6 months in Nepal and Mali. The three trials are registered with ClinicalTrials.gov, numbers NCT01430689, NCT01034254, and NCT02465190. FINDINGS 10 002 women and 9800 liveborn infants were included. Pooled efficacy of maternal vaccination to prevent infant PCR-confirmed influenza up to 6 months of age was 35% (95% CI 19 to 47). The pooled estimate was 56% (28 to 73) within the first 2 months of life, 39% (11 to 58) between 2 and 4 months, and 19% (-9 to 40) between 4 and 6 months. In women, from enrolment during pregnancy to the end of follow-up at 6 months postpartum, the vaccine was 50% (95% CI 32-63) efficacious against PCR-confirmed influenza. Efficacy was 42% (12 to 61) during pregnancy and 60% (36 to 75) postpartum. In women vaccinated before 29 weeks gestational age, the estimated efficacy was 30% (-2 to 52), and in women vaccinated at or after 29 weeks, efficacy was 71% (50 to 83). Efficacy was similar in infants born to mothers vaccinated before or after 29 weeks gestation (34% [95% CI 12 to 51] vs 35% [11 to 52]). There was no overall association between maternal vaccination and low birthweight, stillbirth, preterm birth, and small for gestational age. At 6 months of age, the intervention and control groups were similar in terms of underweight (weight-for-age), stunted (length-for-age), and wasted (weight-for-length). Median centile change from birth to 6 months of age was similar between the intervention and the control groups for both weight and length. INTERPRETATION The assessment of efficacy for women vaccinated before 29 weeks gestational age might have been underpowered, because the point estimate suggests that there might be efficacy despite wide CIs. Estimates of efficacy against PCR-confirmed influenza and safety in terms of adverse birth outcomes should be incorporated into any further consideration of maternal influenza immunisation recommendations. FUNDING Bill & Melinda Gates Foundation.",2020,"Median centile change from birth to 6 months of age was similar between the intervention and the control groups for both weight and length. ","['10', 'women vaccinated before 29 weeks gestational age', 'Nepal (2011-2014), Mali (2011-2014), and South Africa (2011-2013', 'pregnant women and young infants', 'pregnancy', '002 women and 9800 liveborn infants were included', 'Pregnant women, gestational age 17-34 weeks in Nepal, 28 weeks or more in Mali, and 20-36 weeks in South Africa, were enrolled']","['maternal influenza immunisation', 'maternal vaccination', 'saline placebo in Nepal and South Africa or quadrivalent meningococcal conjugate vaccine in Mali', 'trivalent inactivated influenza vaccine (IIV']","['vaccine efficacy, birth outcomes, and infant growth', 'maternal vaccination and low birthweight, stillbirth, preterm birth, and small for gestational age', 'Efficacy, duration of protection, birth outcomes, and infant growth', 'Efficacy', 'Growth measurements, including length and weight']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0027689', 'cui_str': 'Nepal'}, {'cui': 'C0024581', 'cui_str': 'Mali'}, {'cui': 'C0037712', 'cui_str': 'South Africa'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0496655', 'cui_str': 'Singleton, unspecified as to place of birth'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0042200', 'cui_str': 'Influenza vaccination'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0027689', 'cui_str': 'Nepal'}, {'cui': 'C0037712', 'cui_str': 'South Africa'}, {'cui': 'C1660580', 'cui_str': 'Meningococcal conjugate vaccine'}, {'cui': 'C0024581', 'cui_str': 'Mali'}, {'cui': 'C0021403', 'cui_str': 'Influenza virus vaccine'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1286282', 'cui_str': 'Birth outcome'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0235991', 'cui_str': 'Small for gestational age'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]",10002.0,0.36851,"Median centile change from birth to 6 months of age was similar between the intervention and the control groups for both weight and length. ","[{'ForeName': 'Saad B', 'Initials': 'SB', 'LastName': 'Omer', 'Affiliation': 'Yale Institute for Global Health, New Haven, CT, USA; Department of Internal Medicine (Infectious Diseases), Yale School of Medicine, New Haven, CT, USA; Yale School of Nursing, New Haven, CT, USA; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA. Electronic address: saad.omer@yale.edu.'}, {'ForeName': 'Dayna R', 'Initials': 'DR', 'LastName': 'Clark', 'Affiliation': 'Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA.'}, {'ForeName': 'Shabir A', 'Initials': 'SA', 'LastName': 'Madhi', 'Affiliation': 'Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Milagritos D', 'Initials': 'MD', 'LastName': 'Tapia', 'Affiliation': 'Centre pour le Développement des Vaccins, Bamako, Mali; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Marta C', 'Initials': 'MC', 'LastName': 'Nunes', 'Affiliation': 'Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Clare L', 'Initials': 'CL', 'LastName': 'Cutland', 'Affiliation': 'Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Eric A F', 'Initials': 'EAF', 'LastName': 'Simões', 'Affiliation': ""Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Section of Infectious Diseases, Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA; Department of Epidemiology, Center for Global Health Colorado School of Public Health, Aurora, CO, USA.""}, {'ForeName': 'Anushka R', 'Initials': 'AR', 'LastName': 'Aqil', 'Affiliation': 'Department of Health, Behavior, Society, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Katz', 'Affiliation': 'Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Tielsch', 'Affiliation': 'Department of Global Health, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.'}, {'ForeName': 'Mark C', 'Initials': 'MC', 'LastName': 'Steinhoff', 'Affiliation': ""Cincinnati Children's Hospital Global Health Center, Cincinnati, OH, USA.""}, {'ForeName': 'Niteen', 'Initials': 'N', 'LastName': 'Wairagkar', 'Affiliation': 'Bill & Melinda Gates Foundation, Seattle, WA, USA; Vaccines For All, Pune, India.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(19)30479-5'] 1287,32531253,The stability of children's salivary peptidome profiles in response to short-term beverage consumption.,"BACKGROUND Salivary peptidome profiling analysis has advantages of simplicity and non-invasiveness and great potentiality for screening, monitoring or primary diagnosis of diseases, but may be subjected to change against interferences like diet. METHODS We conducted a 5-day study to investigate the influence of 3 kinds of beverages (orange juice, sugar-free tea, and sugar-free liquid yoghurt; water as control) on children's salivary peptidome using mass spectrometry techniques. RESULTS All the groups shared a relatively stable pattern in heatmaps during the experimental days. Principal component analysis plot presented slight shifts in all the intervention groups between the baseline and intervention period while samples were not distinctly separated by date. The numbers of significantly changed peptides after short-term orange juice and tea intervention were four and three, respectively, while no changes occurred in the yoghurt group and control. Four of these peptides were identified as histatin-3, collagen alpha-1(IV) chain, zinc finger protein 805, and quinolinate synthase A. CONCLUSIONS Salivary peptidome has its own stability against beverage intervention, confirming the feasibility and validity of using it as a potential reference for the healthy state of the body, with diet habits recorded and considered as a confounder if necessary.",2020,"Four of these peptides were identified as histatin-3, collagen alpha-1(IV) chain, zinc finger protein 805, and quinolinate synthase A. CONCLUSIONS ","[""children's salivary peptidome using mass spectrometry techniques""]","['beverages (orange juice, sugar-free tea, and sugar-free liquid yoghurt; water as control']",[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0037813', 'cui_str': 'Mass spectrometry measurement'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}, {'cui': 'C0452458', 'cui_str': 'Orange juice'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0039400', 'cui_str': 'Tea'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0043419', 'cui_str': 'Yogurt'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],,0.020256,"Four of these peptides were identified as histatin-3, collagen alpha-1(IV) chain, zinc finger protein 805, and quinolinate synthase A. CONCLUSIONS ","[{'ForeName': 'Fangqiao', 'Initials': 'F', 'LastName': 'Wei', 'Affiliation': 'Department of Preventive Dentistry, Peking University School and Hospital of Stomatology, National Clinical Research Center for Oral Diseases, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, PR China.'}, {'ForeName': 'Xiangyu', 'Initials': 'X', 'LastName': 'Sun', 'Affiliation': 'Department of Preventive Dentistry, Peking University School and Hospital of Stomatology, National Clinical Research Center for Oral Diseases, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, PR China.'}, {'ForeName': 'Peiyuan', 'Initials': 'P', 'LastName': 'Tong', 'Affiliation': 'Department of Preventive Dentistry, Peking University School and Hospital of Stomatology, National Clinical Research Center for Oral Diseases, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, PR China.'}, {'ForeName': 'Yufeng', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': 'Department of Preventive Dentistry, Peking University School and Hospital of Stomatology, National Clinical Research Center for Oral Diseases, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, PR China.'}, {'ForeName': 'Ce', 'Initials': 'C', 'LastName': 'Zhu', 'Affiliation': 'Department of Preventive Dentistry, Peking University School and Hospital of Stomatology, National Clinical Research Center for Oral Diseases, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, PR China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Chen', 'Affiliation': 'Central Laboratory, Peking University School and Hospital of Stomatology, National Clinical Research Center for Oral Diseases, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, PR China.'}, {'ForeName': 'Shuguo', 'Initials': 'S', 'LastName': 'Zheng', 'Affiliation': 'Department of Preventive Dentistry, Peking University School and Hospital of Stomatology, National Clinical Research Center for Oral Diseases, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, PR China. Electronic address: kqzsg86@bjmu.edu.cn.'}]",Clinica chimica acta; international journal of clinical chemistry,['10.1016/j.cca.2020.06.018'] 1288,32535263,Effects of edaravone on postoperative cognitive function in elderly patients undergoing hip joint replacement surgery: A randomized controlled trial.,"BACKGROUND Postoperative cognitive dysfunction (POCD) is a complication of central nervous system in patients after surgery. Edaravone as a brain-protective agent may have protective effect on postoperative cognitive function. The study was designed to explore the effects of edaravone on postoperative cognitive function in elderly patients undergoing hip joint replacement surgery and potential mechanism. PATIENTS AND METHODS Patients undergoing hip joint replacement surgery were randomly allocated into 2 groups: the edaravone group (group E) and the control group (group C). Group E received intravenous edaravone at a dose of 0.5 mg/kg after induction of anesthesia, while group C received normal saline. The cognitive function was evaluated with the Mini-Mental State Examination (MMSE) 1day before surgery,3 days and the 7 days after surgery. Patients' plasma samples were collected to detect the levels of S100β protein (S100β), interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9), superoxide dismutase (SOD) and malondialdehyde (MDA) before the induction of anesthesia, at the end of surgery and on postoperative day 3. RESULTS The MMSE scores in group E were higher than those of group C 3 days after surgery (25.98 ± 1.99 vs 24.86 ± 1.86, p = 0.003). There were remarkable rises (p < 0.05) in plasma IL-6, S100βand MMP-9 levels at the end of surgery and on postoperative day 3 in the two groups, however, edaravone pretreatment could reduce these levels to a certain extent compared with group C (p < 0.05).In group E, the SOD concentration was higher at the end of surgery (16.03 ± 2.46U/ml vs. 13.65 ± 2.53U/ml, p = 0.0001), while the MDA level was lower on postoperative day 3 than those in group C (7.01 ± 2.37 nmol/ml vs. 11.34 ± 3.18 nmol/ml, p = 0.0001). CONCLUSION The results indicated that preoperative intervention with edaravone may improve the postoperative cognitive function in elderly patients undergoing hip joint replacement surgery.",2020,"There were remarkable rises (p< 0.05) in plasma IL-6, S100βand MMP-9 levels at the end of surgery and on postoperative day 3 in the two groups, however, edaravone pretreatment could reduce these levels to a certain extent compared with group C (p< 0.05).In group E, the SOD concentration was higher at the end of surgery (16.03±2.46U/ml vs. 13.65±2.53U/ml, p = 0.0001), while the MDA level was lower on postoperative day 3 than those in group C (7.01±2.37nmol/ml vs. 11.34±3.18nmol/ml, p = 0.0001). ","['eldely patients undergoing hip joint replacement surgery and potential mechanism', 'Patients undergoing hip joint replacement surgery', 'patients after surgery', 'elderly patients undergoing hip joint replacement surgery']","['intravenous edaravone', 'normal saline', 'edaravone', 'Edaravone']","['MDA level', 'MMSE scores', 'cognitive function', 'SOD concentration', 'levels of S100β protein (S100β), interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9), superoxide dismutase (SOD) and malondialdehyde (MDA', 'postoperative cognitive function', 'plasma IL-6, S100βand MMP-9 levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019558', 'cui_str': 'Hip joint structure'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0070694', 'cui_str': 'edaravone'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}]","[{'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2960235', 'cui_str': 'Mini-mental state examination score'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0165519', 'cui_str': 'Gelatinase B'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}]",,0.097904,"There were remarkable rises (p< 0.05) in plasma IL-6, S100βand MMP-9 levels at the end of surgery and on postoperative day 3 in the two groups, however, edaravone pretreatment could reduce these levels to a certain extent compared with group C (p< 0.05).In group E, the SOD concentration was higher at the end of surgery (16.03±2.46U/ml vs. 13.65±2.53U/ml, p = 0.0001), while the MDA level was lower on postoperative day 3 than those in group C (7.01±2.37nmol/ml vs. 11.34±3.18nmol/ml, p = 0.0001). ","[{'ForeName': 'Nan-Nan', 'Initials': 'NN', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Huinan Town, Pudong, Shanghai, 201399, China.'}, {'ForeName': 'Long', 'Initials': 'L', 'LastName': 'Sun', 'Affiliation': 'Department of Anesthesiology, Shuguang Hospital Affiliated to Shanghai University of Chinese Traditional Medicine, 528 Zhangheng Road, Pudong, Shanghai, 201203, China. Electronic address: sun_long2@163.com.'}, {'ForeName': 'Wen-Ting', 'Initials': 'WT', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, Shuguang Hospital Affiliated to Shanghai University of Chinese Traditional Medicine, 528 Zhangheng Road, Pudong, Shanghai, 201203, China.'}, {'ForeName': 'Yang-Liang', 'Initials': 'YL', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Huinan Town, Pudong, Shanghai, 201399, China.'}, {'ForeName': 'Yi-Ming', 'Initials': 'YM', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Huinan Town, Pudong, Shanghai, 201399, China. Electronic address: nange1984@sina.com.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2020.05.092'] 1289,32535338,A serious-game for child sexual abuse prevention: An evaluation of orbit.,"BACKGROUND Greater public and professional awareness of the extent and impact of child sexual abuse (CSA) has prompted the inclusions of prevention initiatives within school curricula. However CSA education is not always soundly grounded in empirical evidence, and evaluations of the impact of programs often inadequate. OBJECTIVE This paper reports on a randomized-control trial of an empirically informed serious-game for CSA prevention, for children aged 8-10 years. The study also evaluates the impact on learning of complementary classroom lessons and part completion of the Orbit game. PARTICIPANTS AND SETTING The evaluation involved 139 students (female = 78; male = 61) aged 8-10 years (Mage = 9.64, SD = 0.33), from an elementary school in Queensland, Australia. METHOD All children were pre-tested and post-tested (at 3 months) for knowledge of abuse prevention using the Children's Knowledge of Abuse Questionnaire-Revised (CKAQ-R-III), and a short form (SF) mapped to the learning objectives of Orbit . Children were assigned to one of three groups; i) play Orbit (n = 50); ii) play Orbit and CSA lessons (n = 55); and iii) control (n = 34). RESULTS Children in the Orbit play, and Orbit play and lesson groups, significantly (p < .001) increased their CKAQ SF scores, whereas those in the control group did not. Furthermore, those children who completed all of Orbit significantly (p < .001) increased their post-test CKAQ scores, whereas those who didn't complete the game did not. CONCLUSIONS This study shows the strength of a serious-games approach for school CSA prevention whilst reporting how child completion can impact learnings.",2020,"RESULTS Children in the Orbit play, and Orbit play and lesson groups, significantly (p < .001) increased their CKAQ SF scores, whereas those in the control group did not.","['child sexual abuse (CSA', 'child sexual abuse prevention', ""All children were pre-tested and post-tested (at 3 months) for knowledge of abuse prevention using the Children's Knowledge of Abuse Questionnaire-Revised (CKAQ-R-III), and a short form (SF) mapped to the learning objectives of Orbit "", 'The evaluation involved 139 students (female\u202f=\u202f78; male\u202f=\u202f61) aged 8-10 years (Mage\u202f=\u202f9.64, SD\u202f=\u202f0.33), from an elementary school in Queensland, Australia', 'children aged 8-10 years']",['play Orbit (n\u202f=\u202f50); ii) play Orbit and CSA lessons (n\u202f=\u202f55); and iii) control'],"['post-test CKAQ scores', 'CKAQ SF scores']","[{'cui': 'C0008062', 'cui_str': 'Sexual Abuse of Child'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C1261558', 'cui_str': 'Abuse prevention'}, {'cui': 'C0562381', 'cui_str': 'Victim of abuse'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0024779', 'cui_str': 'Maps'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0029180', 'cui_str': 'Orbital cavity'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C5191072', 'cui_str': '139'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517449', 'cui_str': '0.33'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0034391', 'cui_str': 'Queensland'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0029180', 'cui_str': 'Orbital cavity'}, {'cui': 'C0008062', 'cui_str': 'Sexual Abuse of Child'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",139.0,0.0282223,"RESULTS Children in the Orbit play, and Orbit play and lesson groups, significantly (p < .001) increased their CKAQ SF scores, whereas those in the control group did not.","[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Jones', 'Affiliation': 'School of Social Sciences, University of the Sunshine Coast, Queensland, Australia. Electronic address: cmjones@usc.edu.au.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Scholes', 'Affiliation': 'Institute for Learning Sciences & Teacher Education, Australian Catholic University, Queensland, Australia. Electronic address: laura.scholes@acu.edu.au.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Rolfe', 'Affiliation': 'Ecoludology Games, Queensland, Australia. Electronic address: ben@ecoludology.com.'}, {'ForeName': 'Colleen', 'Initials': 'C', 'LastName': 'Stieler-Hunt', 'Affiliation': 'School of Creative Industries, University of the Sunshine Coast, Queensland, Australia. Electronic address: cstieler@usc.edu.au.'}]",Child abuse & neglect,['10.1016/j.chiabu.2020.104569'] 1290,32683106,Effect of combined exercise training on pentraxins and pro- inflammatory cytokines in people with multiple sclerosis as a function of disability status.,"OBJECTIVES There is some evidence for beneficial effects of exercise on cytokines in people with multiple sclerosis (MS), but it is unclear if such effects differ by disability status (i.e., stage of the disease). This study investigated the effect of combined exercise training on pentraxins and pro- inflammatory cytokines in people with multiple sclerosis as a function of disability status. METHODS This randomized control trial included 94 women with MS who were randomly assigned into exercise or control conditions with randomization stratified by Expanded Disability Status Scale (EDSS) scores of low (EDSS < 4.5), moderate (4.5 ≤ EDSS ≤ 6), or high (EDSS ≥ 6.5) disability. The exercise program lasted 12 weeks and comprised resistance, endurance, Pilates, balance and stretch exercises performed? days/week; the control condition involved a waitlist control. We measured resting levels of inflammatory factors, functional capacity, and lipid profile before and after the 12-week intervention period. RESULTS Combined exercise training significantly decreased hs-CRP (p = 0.029) and IL-6 (p = 0.001) and increased PTX-3 (p = 0.001) and IFN-ƴ (p = 0.001), but there was no significant change in Fibrin D-dimer (FDD) (p = 0.876) compared with control, and those effects were independent of disability status. 1RM for lat pull-down, knee extension, and seated row and 6MWT (i.e., walking further) significantly increased and TUG performance significantly decreased (i.e., faster performance) (all, p < 0.001) after combined exercise compared with control, and this too was independent of disability status. CONCLUSIONS Exercise may stimulate anti-inflammatory effects in MS, and this is generally not influenced by disability status. Exercise training may be an adjuvant for disease-modifying therapy among people with MS, and such effects might not be moderated by disability status.",2020,"RESULTS Combined exercise training significantly decreased hs-CRP (p = 0.029) and IL-6 (p = 0.001) and increased PTX-3 (p = 0.001) and IFN-ƴ (p = 0.001), but there was no significant change in Fibrin D-dimer (FDD) (p = 0.876) compared with control, and those effects were independent of disability status.","['people with multiple sclerosis', '94 women with MS', 'people with multiple sclerosis (MS']","['Combined exercise training', 'exercise or control conditions with randomization stratified by Expanded Disability Status Scale (EDSS) scores of low (EDSS\xa0<\xa04.5), moderate (4.5\xa0≤', 'exercise program lasted 12\xa0weeks and comprised resistance, endurance, Pilates, balance and stretch exercises performed', 'Exercise training', 'combined exercise training']","['Fibrin D-dimer (FDD', 'resting levels of inflammatory factors, functional capacity, and lipid profile', 'faster performance', 'TUG performance', 'pentraxins and pro- inflammatory cytokines', 'PTX-3', 'IL-6', 'hs-CRP']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C3844009', 'cui_str': '4.5'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0600080', 'cui_str': 'Stretching exercises'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0060323', 'cui_str': 'D-dimer'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0030899', 'cui_str': 'Pentoxifylline'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}]",94.0,0.0328348,"RESULTS Combined exercise training significantly decreased hs-CRP (p = 0.029) and IL-6 (p = 0.001) and increased PTX-3 (p = 0.001) and IFN-ƴ (p = 0.001), but there was no significant change in Fibrin D-dimer (FDD) (p = 0.876) compared with control, and those effects were independent of disability status.","[{'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Faramarzi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran. Electronic address: farmarzi@sku.ac.ir.'}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Banitalebi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Raisi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Masoumeh', 'Initials': 'M', 'LastName': 'Samieyan', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Saberi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Mardaniyan Ghahfarrokhi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Raoof', 'Initials': 'R', 'LastName': 'Negaresh', 'Affiliation': 'Department of Physical Education & Sport Sciences, Faculty of Humanities, Tarbiat Modares University, Tehran, Iran.'}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Motl', 'Affiliation': 'Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, USA.'}]",Cytokine,['10.1016/j.cyto.2020.155196'] 1291,32553888,Effect of practical hyperoxic high-intensity interval training on exercise performance.,"This study investigated the effect of a practical hyperoxic high-intensity interval training (HIIT) on aerobic and anaerobic exercise capacity. Sixteen male athletes were randomized into 2 groups: normoxic HIIT (NHIIT, n = 8) group or hyperoxic HIIT (HHIIT, n = 8) group and trained for 3 weeks (2 days/week) on a cycle ergometer (2-min intervals, with 2-min rest between intervals) at maximal workload, which was obtained during a maximal graded exercise test under normoxia. All training sessions were performed until exhaustion. Participants performed maximal graded exercise, submaximal exercise, and 90-s maximal exercise tests before and after the training period. Maximal oxygen uptake (P < 0.01) increased significantly in both groups. Blood lactate curve during submaximal exercise improved significantly only in the HHIIT group (P < 0.01). Mean power output during maximal exercise increased significantly only in the HHIIT group (P = 0.02). This study demonstrated that a practical hyperoxic HHIIT might be effective for improving aerobic capacity and anaerobic performance.",2020,Blood lactate curve during submaximal exercise improved significantly only in the HHIIT group (P <  0.01).,['Sixteen male athletes'],"['normoxic HIIT (NHIIT, n\u2009=\u20098) group or hyperoxic HIIT (HHIIT, n\u2009=\u20098) group and trained for 3 weeks (2 days/week) on a cycle ergometer (2-min intervals, with 2-min rest between intervals) at maximal workload, which was obtained during a maximal graded exercise test under normoxia', 'maximal graded exercise, submaximal exercise, and 90-s maximal exercise tests', 'practical hyperoxic high-intensity interval training', 'practical hyperoxic high-intensity interval training (HIIT']","['Mean power output during maximal exercise', 'Blood lactate curve during submaximal exercise', 'Maximal oxygen uptake', 'aerobic capacity and anaerobic performance', 'aerobic and anaerobic exercise capacity', 'exercise performance']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]","[{'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0677547', 'cui_str': 'days/week'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}]",16.0,0.0253253,Blood lactate curve during submaximal exercise improved significantly only in the HHIIT group (P <  0.01).,"[{'ForeName': 'Michihiro', 'Initials': 'M', 'LastName': 'Kon', 'Affiliation': 'School of International Liberal Studies, Chukyo University, 101-2 Yagotohonmachi, Showa-ku, Nagoya, 466-8666, Japan; Department of Sports Sciences, Japan Institute of Sports Sciences, 3-15-1 Nishigaoka, Kita-ku, Tokyo, 115-0056, Japan. Electronic address: kon.michihiro@gmail.com.'}, {'ForeName': 'Kohei', 'Initials': 'K', 'LastName': 'Nakagaki', 'Affiliation': 'Department of Sports Sciences, Japan Institute of Sports Sciences, 3-15-1 Nishigaoka, Kita-ku, Tokyo, 115-0056, Japan; Department of Sports Sciences, Yamanashi Gakuin University, 2-4-5 Sakaori, Kofu, Yamanashi, 400-8575, Japan.'}, {'ForeName': 'Yoshiko', 'Initials': 'Y', 'LastName': 'Ebi', 'Affiliation': 'Department of Sports Sciences, Japan Institute of Sports Sciences, 3-15-1 Nishigaoka, Kita-ku, Tokyo, 115-0056, Japan.'}]",Respiratory physiology & neurobiology,['10.1016/j.resp.2020.103481'] 1292,32559278,Diet Quality and Associations with Food Security among Women Eligible for Indiana Supplemental Nutrition Assistance Program-Education.,"BACKGROUND The diet quality among adults receiving nutrition education lessons through Supplemental Nutrition Assistance Program-Education (SNAP-Ed) is currently unknown. OBJECTIVES The objectives of this study were to characterize the diet quality of Indiana SNAP-Ed-eligible women; estimate their mean usual intake of fruits, vegetables, dairy, and whole grains compared to Dietary Guidelines for Americans (DGA) recommendations; and determine if these dietary outcomes differed by food security status. METHODS SNAP-Ed paraprofessionals recruited participants from August 2015 to May 2016 for this secondary analysis of cross-sectional data collected as the baseline assessment for a randomized controlled trial. Participants were SNAP-Ed-eligible women aged ≥18 y interested in nutrition education lessons. Dietary outcomes were assessed by one or two 24-h dietary recalls. The Healthy Eating Index (HEI)-2010 was used to characterize diet quality. Mean usual intake of food groups was estimated using the National Cancer Institute Method. Food security status was classified using the US Household Food Security Survey Module. Data were analyzed in October 2019. RESULTS Mean ± SEM HEI-2010 total score was 42 ± 0.9 for the study sample. Mean ± SE usual intake of servings of fruits (0.61 ± 0.08 cups [144.32 ± 18.93 mL]), vegetables [1.4 ± 0.10 cups (331.2 ± 23.66 mL)], dairy [1.5 ± 0.11 cups (354.88 ± 26.02 mL)], and whole grains [0.48 ± 0.06 ounces (13.61 ± 1.70 g)] did not differ by food security subgroup. Mean HEI-2010 total score was significantly higher by 4.8 ± 2.0 points for the food-secure than for the food-insecure subgroup (P = 0.01). Mean HEI-2010 component scores were 1.1 ± 0.5 points higher for whole grain (P = 0.01) and 1.0 ± 0.5 points higher for dairy (P = 0.05) in the food-secure than in the food-insecure subgroup. The proportions of the study sample not meeting the DGA recommendations for food group intake were ≥85% for both food-secure and -insecure subgroups. CONCLUSIONS Indiana SNAP-Ed-eligible women reported poor diet quality, highlighting their need for nutrition interventions aiming to improve food security and diet as per DGA recommendations in low-income populations.",2020,Mean HEI-2010 total score was significantly higher by 4.8 ± 2.0 points for the food-secure than for the food-insecure subgroup (P = 0.01).,"['Women Eligible for Indiana Supplemental Nutrition Assistance Program-Education', 'Participants were SNAP-Ed-eligible women aged ≥18 y interested in nutrition education lessons', 'SNAP-Ed paraprofessionals recruited participants from August 2015 to May 2016 for this secondary analysis of cross-sectional data collected as the baseline assessment for a randomized controlled trial', 'Indiana SNAP-Ed-eligible women', 'adults receiving nutrition education lessons']",[],"['Mean HEI-2010 total score', 'Mean HEI-2010 component scores', 'Healthy Eating Index', 'Mean\xa0±\xa0SEM HEI-2010 total score', 'Mean\xa0±\xa0SE usual intake of servings of fruits']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0021206', 'cui_str': 'Indiana'}, {'cui': 'C3494397', 'cui_str': 'SNAP Program'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4280021', 'cui_str': 'Healthy Eating Index'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0262878', 'cui_str': 'Scanning electron microscope'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0016767', 'cui_str': 'Fruit'}]",,0.0751539,Mean HEI-2010 total score was significantly higher by 4.8 ± 2.0 points for the food-secure than for the food-insecure subgroup (P = 0.01).,"[{'ForeName': 'Rebecca L', 'Initials': 'RL', 'LastName': 'Rivera', 'Affiliation': 'Department of Nutrition Science, Purdue University, West Lafayette, IN, USA.'}, {'ForeName': 'Yumin', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Statistics, Purdue University, West Lafayette, IN, USA.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': 'Department of Statistics, Purdue University, West Lafayette, IN, USA.'}, {'ForeName': 'Melissa K', 'Initials': 'MK', 'LastName': 'Maulding', 'Affiliation': 'Department of Nutrition and Dietetics, Eastern Illinois University, Charleston, IL, USA.'}, {'ForeName': 'Janet A', 'Initials': 'JA', 'LastName': 'Tooze', 'Affiliation': 'School of Medicine, Wake Forest University, Winston-Salem, NC, USA.'}, {'ForeName': 'Breanne N', 'Initials': 'BN', 'LastName': 'Wright', 'Affiliation': 'Department of Nutrition Science, Purdue University, West Lafayette, IN, USA.'}, {'ForeName': 'Bruce A', 'Initials': 'BA', 'LastName': 'Craig', 'Affiliation': 'Department of Statistics, Purdue University, West Lafayette, IN, USA.'}, {'ForeName': 'Regan L', 'Initials': 'RL', 'LastName': 'Bailey', 'Affiliation': 'Department of Nutrition Science, Purdue University, West Lafayette, IN, USA.'}, {'ForeName': 'Heather A', 'Initials': 'HA', 'LastName': 'Eicher-Miller', 'Affiliation': 'Department of Nutrition Science, Purdue University, West Lafayette, IN, USA.'}]",The Journal of nutrition,['10.1093/jn/nxaa171'] 1293,32562632,Long-term developmental effect of withholding parenteral nutrition in paediatric intensive care units: a 4-year follow-up of the PEPaNIC randomised controlled trial.,"BACKGROUND The PEPaNIC randomised controlled trial, which recruited 1440 critically ill infants and children in 2012-15, showed that withholding parenteral nutrition for 1 week (late-parenteral nutrition), compared with early supplementation within 24 h of admission to the paediatric intensive care unit (early-parenteral nutrition), prevented infections, accelerated recovery, and improved neurocognitive development assessed 2 years later. Because several neurocognitive domains can only be thoroughly assessed from age 4 years onwards, we aimed to determine the effect of late-parenteral nutrition versus early-parenteral nutrition on physical, neurocognitive, and emotional and behavioural development 4 years after randomisation. METHODS This is a preplanned, blinded, 4-year follow-up study of participants included in the PEPaNIC trial (done at University Hospitals Leuven, Belgium; Erasmus Medical Centre Sophia Children's Hospital, Rotterdam, Netherlands; and Stollery Children's Hospital, Edmonton, AB, Canada) and of matched healthy children. Studied outcomes were anthropometrics; health status; parent-reported or caregiver-reported executive functions, and emotional and behavioural problems; and clinical tests for intelligence, visual-motor integration, alertness, motor coordination, and memory. Through multivariable linear and logistic regression analyses, after imputation for missing values (≤30%) and adjustment for risk factors, we investigated the effect of early-parenteral nutrition versus late-parenteral nutrition. This trial is registered with ClinicalTrials.gov, NCT01536275. FINDINGS Between March 8, 2016, and Nov 8, 2019, 684 children from the original PEPaNIC trial (356 from the late-parenteral nutrition group and 328 from the early-parenteral nutrition group) were assessed for neurocognitive development at 4-years follow-up. Compared with the control group (369 healthy children), children who had critical illness had lower height (β-estimate -2·11 [95% CI -3·15 to -1·06]; p<0·0001) and head circumference (-0·42 [-0·67 to -0·18]; p=0.00077); and worse health status (eg, hospital admission odds ratio 4·27 [95% CI 3·12 to 5·84]; p<0·0001), neurocognitive (eg, parent-reported or caregiver-reported total executive functioning β-estimate 3·57 [95% CI 1·95 to 5·18], p<0·0001; total intelligence quotient -7·35 [-9·31 to -5·39], p<0·0001), and parent-reported or caregiver-reported emotional and behavioural developmental outcomes (internalising 2·73 [1·19 to 4·28], p=0·00055; externalising 1·63 [0·19 to 3·08], p=0·027; and total behavioural problems 2·95 [1·44 to 4·46], p=0·00013), adjusted for risk factors. Outcomes were never worse in the late-parenteral nutrition group compared with the early-parenteral nutrition group, but patients in the late-parenteral nutrition group had fewer parent-reported or caregiver-reported internalising (β-estimate -1·88 [95% CI -3·69 to -0·07]; p=0·042), externalising (-1·73 [-3·43 to -0·03]; p=0·046), and total emotional and behavioural problems (-2·44 [-4·22 to -0·67]; p=0·0070) than patients who had received early-parenteral nutrition, after adjusting for risk factors, and were no longer different from healthy controls for these outcomes. INTERPRETATION Omitting early parenteral nutrition use for critically ill children did not adversely affect long-term outcomes 4 years after randomisation and protected against emotional and behavioural problems, further supporting the deimplementation of early parenteral nutrition. FUNDING European Research Council, Methusalem, Flanders Institute for Science and Technology, Research Foundation Flanders, Sophia Foundation, Stichting Agis Zorginnovatie, Erasmus Trustfonds, and the European Society for Clinical Nutrition and Metabolism.",2020,"p=0·00055; externalising 1·63 [0·19 to 3·08], p=0·027; and total behavioural problems 2·95 [1·44 to 4·46], p=0·00013), adjusted for risk factors.","['Between March 8, 2016, and Nov 8, 2019, 684 children from the original PEPaNIC trial (356 from the late-parenteral nutrition group and 328 from the early-parenteral nutrition group', '369 healthy children), children who had critical illness had lower height (β-estimate -2·11', 'paediatric intensive care units', ""participants included in the PEPaNIC trial (done at University Hospitals Leuven, Belgium; Erasmus Medical Centre Sophia Children's Hospital, Rotterdam, Netherlands; and Stollery Children's Hospital, Edmonton, AB, Canada) and of matched healthy children"", '1440 critically ill infants and children in 2012-15, showed that withholding parenteral nutrition for 1 week (late-parenteral nutrition), compared with early supplementation within 24 h of admission to the paediatric intensive care unit (early-parenteral nutrition), prevented infections, accelerated recovery, and improved neurocognitive development assessed 2 years later']","['4·22 to -0·67', '7·35', 'withholding parenteral nutrition']","['neurocognitive development', 'neurocognitive (eg, parent-reported or caregiver-reported total executive functioning β-estimate 3·57', 'anthropometrics; health status; parent-reported or caregiver-reported executive functions, and emotional and behavioural problems; and clinical tests for intelligence, visual-motor integration, alertness, motor coordination, and memory', 'total emotional and behavioural problems (-2·44', 'total intelligence quotient', 'worse health status (eg, hospital admission odds ratio 4·27', 'head circumference (-0·42 [-0·67 to -0·18']","[{'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205313', 'cui_str': 'Original'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0030547', 'cui_str': 'Parenteral nutrition'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0021710', 'cui_str': 'Pediatric intensive care unit'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0004950', 'cui_str': 'Belgium'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C4517576', 'cui_str': '1440'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1442452', 'cui_str': 'One week'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0030547', 'cui_str': 'Parenteral nutrition'}]","[{'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0021704', 'cui_str': 'Intelligence'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0456149', 'cui_str': 'Intelligence quotient'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}, {'cui': 'C0262499', 'cui_str': 'Head circumference'}]",684.0,0.251002,"p=0·00055; externalising 1·63 [0·19 to 3·08], p=0·027; and total behavioural problems 2·95 [1·44 to 4·46], p=0·00013), adjusted for risk factors.","[{'ForeName': 'An', 'Initials': 'A', 'LastName': 'Jacobs', 'Affiliation': 'Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium.'}, {'ForeName': 'Karolijn', 'Initials': 'K', 'LastName': 'Dulfer', 'Affiliation': ""Intensive Care Unit, Department of Paediatrics and Paediatric Surgery, Erasmus Medical Centre, Sophia Children's Hospital, Rotterdam, Netherlands.""}, {'ForeName': 'Renate D', 'Initials': 'RD', 'LastName': 'Eveleens', 'Affiliation': ""Intensive Care Unit, Department of Paediatrics and Paediatric Surgery, Erasmus Medical Centre, Sophia Children's Hospital, Rotterdam, Netherlands.""}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Hordijk', 'Affiliation': ""Intensive Care Unit, Department of Paediatrics and Paediatric Surgery, Erasmus Medical Centre, Sophia Children's Hospital, Rotterdam, Netherlands.""}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Van Cleemput', 'Affiliation': 'Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium.'}, {'ForeName': 'Ines', 'Initials': 'I', 'LastName': 'Verlinden', 'Affiliation': 'Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium.'}, {'ForeName': 'Pieter J', 'Initials': 'PJ', 'LastName': 'Wouters', 'Affiliation': 'Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium.'}, {'ForeName': 'Liese', 'Initials': 'L', 'LastName': 'Mebis', 'Affiliation': 'Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium.'}, {'ForeName': 'Gonzalo Garcia', 'Initials': 'GG', 'LastName': 'Guerra', 'Affiliation': ""Department of Paediatrics, Intensive Care Unit, University of Alberta, Stollery Children's Hospital, Edmonton, Canada.""}, {'ForeName': 'Koen', 'Initials': 'K', 'LastName': 'Joosten', 'Affiliation': ""Intensive Care Unit, Department of Paediatrics and Paediatric Surgery, Erasmus Medical Centre, Sophia Children's Hospital, Rotterdam, Netherlands.""}, {'ForeName': 'Sascha C', 'Initials': 'SC', 'LastName': 'Verbruggen', 'Affiliation': ""Intensive Care Unit, Department of Paediatrics and Paediatric Surgery, Erasmus Medical Centre, Sophia Children's Hospital, Rotterdam, Netherlands.""}, {'ForeName': 'Fabian', 'Initials': 'F', 'LastName': 'Güiza', 'Affiliation': 'Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium.'}, {'ForeName': 'Ilse', 'Initials': 'I', 'LastName': 'Vanhorebeek', 'Affiliation': 'Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium.'}, {'ForeName': 'Greet', 'Initials': 'G', 'LastName': 'Van den Berghe', 'Affiliation': 'Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium. Electronic address: greet.vandenberghe@kuleuven.be.'}]",The Lancet. Child & adolescent health,['10.1016/S2352-4642(20)30104-8'] 1294,32562670,Extended short-term follow-up for a trial of treatment of unruptured arteriovenous malformations.,,2020,,[],[],[],[],[],[],,0.0181838,,"[{'ForeName': 'Peter M', 'Initials': 'PM', 'LastName': 'Rothwell', 'Affiliation': 'Wolfson Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK. Electronic address: peter.rothwell@ndcn.ox.ac.uk.'}]",The Lancet. Neurology,['10.1016/S1474-4422(20)30178-2'] 1295,32565105,Home exercise in the dart-throwing motion plane after distal radius fractures: A pilot randomized controlled trial.,"INTRODUCTION During daily functions, our wrist moves through an oblique plane, named the dart-throwing motion (DTM) plane. This plane is considered a more stable plane because the proximal carpal row remains relatively immobile. However, rehabilitation programs that incorporate exercising in the DTM plane have yet to be explored. PURPOSE OF THE STUDY The purpose of this study was to evaluate the rehabilitation outcomes after treatment in the DTM plane compared with outcomes after treatment in the sagittal plane after distal radius fracture. STUDY DESIGN This is a pilot randomized controlled trial. METHODS Subjects after open reduction internal fixation were assigned into a research group (N = 12; ages 48.7 ± 7.3) and a control group (N = 12; ages 50.8 ± 15). The control group activated the wrist in the sagittal plane, whereas the research group activated the wrist in the DTM plane. Range of motion, pain levels, functional hand motor skills tests, and satisfaction from self-training exercise were measured before and after a 12-session intervention. RESULTS The outcome measures were similar between the treatment groups. The research group reported significantly higher satisfaction rates than the control group on topics such as general satisfaction (research group: 3.4 ± 0.7, control group: 2. 5 ± 1.2, P = .030), motivation to exert oneself (research group: 2.8 ± 1.0, control group: 2.3 ± 1.2, P = .009), progressed function (research group: 3.4 ± 0.7, control group: 2.4 ± 1.1, P = .012), and self-training contribution to the daily function (research group: 3.4 ± 0.7, control group: 2.5 ± 1.2, P = .030). DISCUSSION AND CONCLUSION Pilot results do not favor one treatment method over the other. However, exercising in the DTM plane may contribute to the satisfaction of the client and increase self-training motivation.",2020,The creation of automated software for the patient-specific adjustment of orthoses for 3D printing can be the missing link for integration of 3D printing in the clinics.,"['36 occupational therapy students (age 25.4±1.9 years', 'distal radius fractures']",['Home exercise'],"['preparation time and orthosis weight', 'weight of the 3D-printed orthosis']","[{'cui': 'C1318464', 'cui_str': 'Occupational therapy'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0006086', 'cui_str': 'Brace'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0033161', 'cui_str': 'Printing'}]",36.0,0.0227074,The creation of automated software for the patient-specific adjustment of orthoses for 3D printing can be the missing link for integration of 3D printing in the clinics.,"[{'ForeName': 'Yael', 'Initials': 'Y', 'LastName': 'Kaufman-Cohen', 'Affiliation': 'Department of Occupational Therapy, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Yafi', 'Initials': 'Y', 'LastName': 'Levanon', 'Affiliation': 'Department of Occupational Therapy, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Occupational Therapy Department, Sheba Medical Center, Ramat Gan, Israel.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Friedman', 'Affiliation': 'Department of Physical Therapy, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Yona', 'Initials': 'Y', 'LastName': 'Yaniv', 'Affiliation': 'Orthopedic Department, Sheba Medical Center, Ramat Gan, Israel.'}, {'ForeName': 'Sigal', 'Initials': 'S', 'LastName': 'Portnoy', 'Affiliation': 'Department of Occupational Therapy, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: portnoys@tauex.tau.ac.il.'}]",Journal of hand therapy : official journal of the American Society of Hand Therapists,['10.1016/j.jht.2020.03.027'] 1296,32538252,"Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment.","BACKGROUND 3,4-Methylenedioxymethamphetamine (MDMA) is being actively researched as an adjunct to psychotherapy. It may be beneficial to trust, empathy and cooperative behaviour due to its acute prosocial effects. AIM To test (a) the acute effects of MDMA on measures of empathy, trust and cooperative behaviour, and (b) subacute changes in mood three days after MDMA administration. METHODS Twenty-five participants ( n =7 female), participated in this double-blind, repeated-measures, placebo-controlled experiment. Participants attended two acute sessions, one week apart. Each acute session was followed by a subacute session three days later. Participants received placebo (100 mg ascorbic acid) during one acute session, and MDMA (100 mg MDMA-HCl) at the other, with order counterbalanced. Participants completed the following tasks assessing prosocial behaviour: a trust investment task, a trustworthy face rating task, an empathic stories task, a public project game, a dictator game and an ultimatum game. Participants reported subjective effects. Blood was taken pre-drug, 2 and 4 hours post-drug, and tested for plasma MDMA levels. RESULTS MDMA acutely increased self-reported 'closeness to others' and 'euphoria' and increased plasma concentrations of MDMA. MDMA did not significantly change task-based empathy, trust or cooperative behaviour. Using Bayesian analyses, we found evidence that MDMA and placebo did not differ in their effects on empathy and cooperative behaviour. MDMA did not significantly change subacute mood and this was supported by our Bayesian analyses. CONCLUSION Despite augmentation in plasma MDMA levels and subjective drug effects, we found no increase in prosocial behaviour in a laboratory setting.",2020,"Using Bayesian analyses, we found evidence that MDMA and placebo did not differ in their effects on empathy and cooperative behaviour.",['Twenty-five participants ( n =7 female'],"['MDMA and placebo', 'MDMA (100\u2009mg MDMA-HCl', 'tasks assessing prosocial behaviour: a trust investment task, a trustworthy face rating task, an empathic stories task, a public project game, a dictator game and an ultimatum game', 'placebo (100\u2009mg ascorbic acid', 'MDMA', '3,4-Methylenedioxymethamphetamine', 'placebo']","['empathy, trust and cooperative behaviour, and (b) subacute changes', 'subjective effects', 'plasma MDMA levels and subjective drug effects', 'prosocial behaviour', 'trust, cooperative behaviour and empathy', 'change task-based empathy, trust or cooperative behaviour', 'empathy and cooperative behaviour', 'plasma concentrations of MDMA']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0115471', 'cui_str': 'Methylenedioxymethamphetamine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0023443', 'cui_str': 'Hairy cell leukemia'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0021953', 'cui_str': 'Investments'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}]","[{'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205365', 'cui_str': 'Subacute'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0115471', 'cui_str': 'Methylenedioxymethamphetamine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0728866', 'cui_str': 'drug effects'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",25.0,0.354268,"Using Bayesian analyses, we found evidence that MDMA and placebo did not differ in their effects on empathy and cooperative behaviour.","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Borissova', 'Affiliation': 'Clinical Psychopharmacology Unit, UCL, London, UK.'}, {'ForeName': 'Bart', 'Initials': 'B', 'LastName': 'Ferguson', 'Affiliation': 'UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Matthew B', 'Initials': 'MB', 'LastName': 'Wall', 'Affiliation': 'Clinical Psychopharmacology Unit, UCL, London, UK.'}, {'ForeName': 'Celia Ja', 'Initials': 'CJ', 'LastName': 'Morgan', 'Affiliation': 'Psychopharmacology and Addiction Research Centre, University of Exeter, Exeter, UK.'}, {'ForeName': 'Robin L', 'Initials': 'RL', 'LastName': 'Carhart-Harris', 'Affiliation': 'Neuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Bolstridge', 'Affiliation': 'Neuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.'}, {'ForeName': 'Michael Ap', 'Initials': 'MA', 'LastName': 'Bloomfield', 'Affiliation': 'Clinical Psychopharmacology Unit, UCL, London, UK.'}, {'ForeName': 'Tim M', 'Initials': 'TM', 'LastName': 'Williams', 'Affiliation': 'Neuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Feilding', 'Affiliation': 'Beckley Foundation, Oxford, UK.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Murphy', 'Affiliation': 'Cardiff University Brain Research Imaging Centre, Cardiff, UK.'}, {'ForeName': 'Robin J', 'Initials': 'RJ', 'LastName': 'Tyacke', 'Affiliation': 'Neuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Erritzoe', 'Affiliation': 'Neuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.'}, {'ForeName': 'Lorna', 'Initials': 'L', 'LastName': 'Stewart', 'Affiliation': 'Clinical Psychopharmacology Unit, UCL, London, UK.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Wolff', 'Affiliation': ""School of Biomedical Sciences, King's College London, London, UK.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Nutt', 'Affiliation': 'Neuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.'}, {'ForeName': 'H Valerie', 'Initials': 'HV', 'LastName': 'Curran', 'Affiliation': 'Clinical Psychopharmacology Unit, UCL, London, UK.'}, {'ForeName': 'Will', 'Initials': 'W', 'LastName': 'Lawn', 'Affiliation': 'Clinical Psychopharmacology Unit, UCL, London, UK.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881120926673'] 1297,32541380,5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control.,"On the basis of numerous previous studies, the serotonergic system plays a role in the pathogenesis of obsessive-compulsive disorder (OCD) and effective agents in this pathway, such as 5-hydroxytryptophan, can potentially contribute to treatment of patients with this disorder. Evaluating the efficacy of 5-hydroxytryptophan in treating OCD was the aim of the present randomized, double-blind, placebo-controlled 12-week trial. In a 12-week, randomized double-blind study, 60 patients with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis of moderate to severe OCD and a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of >21 were randomly assigned to receive either fluoxetine plus placebo or fluoxetine plus 5-hydroxytryptophan (100 mg twice daily). All patients, regardless of their treatment group, received fluoxetine at 20 mg/day for the initial 4 weeks of the study followed by 60 mg/day of fluoxetine for the rest of the trial course. Symptoms were assessed using the Y-BOCS at baseline and weeks 4, 8 and 12. General linear model repeated measure showed significant effects for time × treatment interaction on total Y-BOCS (F = 12.07, df = 2.29, P-value <0.001), obsession (F = 8.25, df = 1.91, P-value = 0.001) and compulsion subscale scores (F = 6.64, df = 2.01, P-value = 0.002). 5-Hydroxytryptophan augmentation therapy demonstrated higher partial and complete treatment response rate (P = 0.032 and P = 0.001, respectively) according to the Y-BOCS total scores. The results of this study confirm that 5-hydroxytryptophan may be effective as an augmentative agent in treatment of moderate-to-severe OCD.",2020,"5-Hydroxytryptophan augmentation therapy demonstrated higher partial and complete treatment response rate (P = 0.032 and P = 0.001, respectively) according to the Y-BOCS total scores.","['moderate to severe obsessive-compulsive disorder', '60 patients with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis of moderate to severe OCD and a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of >21', 'patients with this disorder']","['5-Hydroxytryptophan', '5-hydroxytryptophan', 'fluoxetine', 'fluoxetine plus placebo or fluoxetine plus 5-hydroxytryptophan', '5-Hydroxytryptophan augmentation therapy', 'placebo']","['compulsion subscale scores', 'total Y-BOCS', 'higher partial and complete treatment response rate']","[{'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0028768', 'cui_str': 'Obsessive-compulsive disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1136324', 'cui_str': 'Diagnostic and Statistical Manual of Mental Disorders'}, {'cui': 'C0205439', 'cui_str': 'Fifth'}, {'cui': 'C0441792', 'cui_str': 'Editions'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0155339', 'cui_str': ""Brown's tendon sheath syndrome""}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0000578', 'cui_str': '5-Hydroxytryptophan'}, {'cui': 'C0016365', 'cui_str': 'Fluoxetine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0600104', 'cui_str': 'Compulsive behavior'}, {'cui': 'C0459443', 'cui_str': 'Subscale score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0155339', 'cui_str': ""Brown's tendon sheath syndrome""}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",60.0,0.0988532,"5-Hydroxytryptophan augmentation therapy demonstrated higher partial and complete treatment response rate (P = 0.032 and P = 0.001, respectively) according to the Y-BOCS total scores.","[{'ForeName': 'Farzaneh', 'Initials': 'F', 'LastName': 'Yousefzadeh', 'Affiliation': 'Psychiatric Research Center, Roozbeh Psychiatric Hospital.'}, {'ForeName': 'Erfan', 'Initials': 'E', 'LastName': 'Sahebolzamani', 'Affiliation': 'Psychiatric Research Center, Roozbeh Psychiatric Hospital.'}, {'ForeName': 'Arash', 'Initials': 'A', 'LastName': 'Sadri', 'Affiliation': 'Psychiatric Research Center, Roozbeh Psychiatric Hospital.'}, {'ForeName': 'Amirhosein', 'Initials': 'A', 'LastName': 'Mortezaei', 'Affiliation': 'Psychiatric Research Center, Roozbeh Psychiatric Hospital.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Aqamolaei', 'Affiliation': 'Psychiatric Research Center, Roozbeh Psychiatric Hospital.'}, {'ForeName': 'Seyyed Hosein', 'Initials': 'SH', 'LastName': 'Mortazavi', 'Affiliation': 'Psychiatric Research Center, Roozbeh Psychiatric Hospital.'}, {'ForeName': 'Mohammd Reza', 'Initials': 'MR', 'LastName': 'Shalbafan', 'Affiliation': 'Mental Health Research Center, Iran University of Medical Sciences.'}, {'ForeName': 'Salomeh', 'Initials': 'S', 'LastName': 'Ghaffari', 'Affiliation': 'School of Persian Medicine, Iran University of Medical Sciences, Research Institute for Islamic and Complementory Medicine.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Alikhani', 'Affiliation': 'Psychosis Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.'}, {'ForeName': 'Seiedeh Bentolhoda', 'Initials': 'SB', 'LastName': 'Mousavi', 'Affiliation': 'Psychosis Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.'}, {'ForeName': 'Sina', 'Initials': 'S', 'LastName': 'Naderi', 'Affiliation': 'Psychiatric Research Center, Roozbeh Psychiatric Hospital.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Shamabadi', 'Affiliation': 'Psychiatric Research Center, Roozbeh Psychiatric Hospital.'}, {'ForeName': 'Shakiba', 'Initials': 'S', 'LastName': 'Jalilevand', 'Affiliation': 'Psychiatric Research Center, Roozbeh Psychiatric Hospital.'}, {'ForeName': 'Shahin', 'Initials': 'S', 'LastName': 'Akhondzadeh', 'Affiliation': 'Psychiatric Research Center, Roozbeh Psychiatric Hospital.'}]",International clinical psychopharmacology,['10.1097/YIC.0000000000000321'] 1298,32544361,Immunogenicity of an Escherichia coli -produced bivalent human papillomavirus vaccine under different vaccination intervals.,"A new Escherichia coli -produced human papillomavirus (HPV)-16/18 vaccine has been shown to be safe and highly efficacious and was recently licensed in China. As a post hoc analysis of the phase III trial, this study aimed to assess the impact of vaccination time deviations on the specific antibody response and guide the better usage of this vaccine in the real world. A total of 3689 healthy women aged 18-45 years old were randomly assigned to receive the bivalent HPV-16/18 vaccine according to a 0-, 1- and 6-month schedule with a wide vaccination interval. The first vaccination interval between the 1 st and 2 nd doses (the 1 st interval) was divided into three groups: 28-40 d, 41-50 d and 51-60 d. The second vaccination interval between the 2 nd and 3 rd doses (the 2 nd interval) was divided into three groups: 103-139 d, 140-160 d and 161-198 d. The reverse cumulative curves for the IgG of the three groups with different 1 st vaccination intervals or with different 2 nd vaccination intervals at month 7 almost overlapped for both HPV-16 and HPV-18. Compared with the standard vaccination schedule (a 1 st interval of 28-40 d and a 2 nd interval of 140-160 d) subgroup, all the subgroups had GMC ratios greater than 0.83, with the lower limit of 95% CIs higher than 0.64. In conclusion, a slight deviation in the vaccination time of the 2 nd and 3 rd doses has only a minor, insignificant impact on the immune response induced by the Escherichia coli -produced HPV-16/18 vaccine.",2020,The reverse cumulative curves for the IgG of the three groups with different 1 st vaccination intervals or with different 2 nd vaccination intervals at month 7 almost overlapped for both HPV-16 and HPV-18.,"['Escherichia coli -produced bivalent human papillomavirus vaccine under different vaccination intervals', '3689 healthy women aged 18-45\xa0years old']",['bivalent HPV-16/18 vaccine'],"['Immunogenicity', 'GMC ratios']","[{'cui': 'C0014834', 'cui_str': 'Escherichia coli'}, {'cui': 'C1721788', 'cui_str': 'human papillomavirus vaccine, L1 type 16, 18'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio'}]",3689.0,0.0525128,The reverse cumulative curves for the IgG of the three groups with different 1 st vaccination intervals or with different 2 nd vaccination intervals at month 7 almost overlapped for both HPV-16 and HPV-18.,"[{'ForeName': 'Xiao-Juan', 'Initials': 'XJ', 'LastName': 'Yu', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics(SCIBP), School of Public Health, Xiamen University , Xiamen, Fujian, China.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control , Beijing, China.'}, {'ForeName': 'Zhi-Jie', 'Initials': 'ZJ', 'LastName': 'Lin', 'Affiliation': 'Vaccine R&D Department, Xiamen Innovax Biotech Company , Xiamen, Fujian, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zhao', 'Affiliation': 'Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control , Beijing, China.'}, {'ForeName': 'Bi-Zhen', 'Initials': 'BZ', 'LastName': 'Lin', 'Affiliation': 'Vaccine R&D Department, Xiamen Innovax Biotech Company , Xiamen, Fujian, China.'}, {'ForeName': 'You-Lin', 'Initials': 'YL', 'LastName': 'Qiao', 'Affiliation': 'Department of Cancer Epidemiology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, China.'}, {'ForeName': 'Yue-Mei', 'Initials': 'YM', 'LastName': 'Hu', 'Affiliation': 'Department of Vaccine Evaluation, Jiangsu Provincial Center for Disease Control and Prevention , Nanjing, Jiangsu, China.'}, {'ForeName': 'Li-Hui', 'Initials': 'LH', 'LastName': 'Wei', 'Affiliation': ""Department of Obstetrics and Gynecology, Peking University People's Hospital , Beijing, China.""}, {'ForeName': 'Rong-Cheng', 'Initials': 'RC', 'LastName': 'Li', 'Affiliation': 'Center for Vaccine Clinical Research, Guangxi Center for Disease Control and Prevention , Nanning, Guangxi, China.'}, {'ForeName': 'Wei-Dan', 'Initials': 'WD', 'LastName': 'Huang', 'Affiliation': 'Vaccine R&D Department, Xiamen Innovax Biotech Company , Xiamen, Fujian, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Wu', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics(SCIBP), School of Public Health, Xiamen University , Xiamen, Fujian, China.'}, {'ForeName': 'Shou-Jie', 'Initials': 'SJ', 'LastName': 'Huang', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics(SCIBP), School of Public Health, Xiamen University , Xiamen, Fujian, China.'}, {'ForeName': 'Chang-Gui', 'Initials': 'CG', 'LastName': 'Li', 'Affiliation': 'Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control , Beijing, China.'}, {'ForeName': 'Hui-Rong', 'Initials': 'HR', 'LastName': 'Pan', 'Affiliation': 'Vaccine R&D Department, Xiamen Innovax Biotech Company , Xiamen, Fujian, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics(SCIBP), School of Public Health, Xiamen University , Xiamen, Fujian, China.'}]",Human vaccines & immunotherapeutics,['10.1080/21645515.2020.1761202'] 1299,32683215,Intensive upper extremity training improved whole body movement control for children with unilateral spastic cerebral palsy.,"BACKGROUND Children with unilateral spastic cerebral palsy (USCP) exhibit impaired bimanual coordination, gait control, and whole body movement control. Intensive upper extremity training has been found to be effective for improving upper extremity function. However, the effectiveness of the intensive upper extremity training on whole body movement control is not known. RESEARCH QUESTION The present study aimed to evaluate the effects of Constraint Induced Movement Therapy (CIMT) and Hand Arm Bimanual Intensive Therapy (HABIT) on bimanual coordination and gait control during a complex whole body task. METHODS Sixteen children with congenital hemiplegia (age 6-12 years; GMFCS: I-II, MACS: I-II) were randomly assigned to either CIMT or HABIT for 6 h per day training for 15 days. Children were asked to perform two whole body tasks (walking with and without a tray carrying) while 3-D kinematic analysis was performed before and after training. RESULTS After training, the HABIT group increased the symmetry in height of their hands during tray carrying (more leveled tray). Both CIMT and HABIT groups decreased the lateral motion of the tray. The CIMT group increased speed and stride length after training in both the walking and tray carrying tasks. Both groups also increased their minimum toe clearance (all p < 0.05). SIGNIFICANCE Two types of intensive upper extremity training have provided significant improvements to whole body movement control for children with USCP. Adhering to the specificity of practice concept, HABIT improved bimanual coordination after training during the whole body tray carrying tasks. Given extensive interactions between the upper and lower extremities in real-world activities, future studies should focus on the effects of such combined training.",2020,"Both groups also increased their minimum toe clearance (all p < 0.05). ","['children with unilateral spastic cerebral palsy', 'Children with unilateral spastic cerebral palsy (USCP', 'children with USCP', 'Sixteen children with congenital hemiplegia (age 6-12 years; GMFCS']","['CIMT or HABIT', 'Intensive upper extremity training improved whole body movement control', 'CIMT', 'Constraint Induced Movement Therapy (CIMT) and Hand Arm Bimanual Intensive Therapy (HABIT', 'intensive upper extremity training', 'Intensive upper extremity training']","['bimanual coordination and gait control', 'symmetry in height of their hands', 'speed and stride length', 'lateral motion of the tray', 'minimum toe clearance']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0338596', 'cui_str': 'Spastic cerebral palsy'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0270805', 'cui_str': 'Hemiplegic cerebral palsy'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0454279', 'cui_str': 'Movement therapy'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0427083', 'cui_str': 'Control of movement'}]","[{'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332516', 'cui_str': 'Symmetrical'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0184054', 'cui_str': 'Tray'}, {'cui': 'C0040357', 'cui_str': 'Toe structure'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}]",16.0,0.0108967,"Both groups also increased their minimum toe clearance (all p < 0.05). ","[{'ForeName': 'Ya-Ching', 'Initials': 'YC', 'LastName': 'Hung', 'Affiliation': 'Department of Family, Nutrition, and Exercise Sciences, Queens College, City University of New York, 65-30 Kissena Blvd, Flushing, NY 11367, USA. Electronic address: yaching.hung@qc.cuny.edu.'}, {'ForeName': 'Fawzia', 'Initials': 'F', 'LastName': 'Shirzad', 'Affiliation': 'Department of Family, Nutrition, and Exercise Sciences, Queens College, City University of New York, 65-30 Kissena Blvd, Flushing, NY 11367, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Saleem', 'Affiliation': 'Department of Family, Nutrition, and Exercise Sciences, Queens College, City University of New York, 65-30 Kissena Blvd, Flushing, NY 11367, USA.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Gordon', 'Affiliation': 'Department of Biobehavioral Sciences, Teachers College, Columbia University, 525 West 120th Street, Box 199, NY 10027, USA.'}]",Gait & posture,['10.1016/j.gaitpost.2020.07.009'] 1300,32550739,Intravaginal isonicotinic acid hydrazide (INH) versus misoprostol for cervical ripening prior to hysteroscopy.,"OBJECTIVE The aim of the present study was to compare the efficacy of vaginal isoniazid (isonicotinic acid hydrazide [INH]) and vaginal misoprostol in cervical ripening before hysteroscopic surgery. METHODS This randomized controlled trial included patients scheduled for hysteroscopic surgery during April 2016 and June 2017. The inclusion criteria were as follows: postmenopausal women or those at premenopausal age who had not had a vaginal delivery and candidate for diagnostic or operative hysteroscopy with closed cervix before intervention. The INH group (intervention group) received 900 mg of vaginal isoniazid (three 300-mg pills) 6-8 hours before hysteroscopic surgery. The misoprostol group (control group) received 400 micrograms of vaginal misoprostol 6-8 hours before hysteroscopic surgery. Finally, the efficacy of the 2 agents was comparatively analyzed. RESULTS Baseline characteristics were comparable between the groups. In 67 cases in the INH group (95%) and 45 in the misoprostol group (50%), hysteroscopic entry was successful without additional mechanical dilation, and this difference was statistically significant (P=0.001). The odds ratio (OR) obtained in this study was 0.57 for both INH and misoprostol groups (OR, 0.57; 95% confidence interval, 0.43-0.75). Further, 19 cases in the INH group vs. 45 cases in the misoprostol group did not respond to the intervention, indicating statistically significance (P=0.001). CONCLUSION Vaginal INH is more effective than misoprostol in cervical ripening before hysteroscopic surgery and can be a good alternative to misoprostol. TRIAL REGISTRATION Iranian Registry Clinical Trial (IRCT) Identifier: IRCT2015112821506N4.",2020,Baseline characteristics were comparable between the groups.,"['cervical ripening prior to hysteroscopy', 'patients scheduled for hysteroscopic surgery during April 2016 and June 2017', 'postmenopausal women or those at premenopausal age who had not had a vaginal delivery and candidate for diagnostic or operative hysteroscopy with closed cervix before intervention']","['vaginal isoniazid (isonicotinic acid hydrazide [INH]) and vaginal misoprostol', '400 micrograms of vaginal misoprostol 6-8 hours before hysteroscopic surgery', 'misoprostol', 'Intravaginal isonicotinic acid hydrazide (INH', 'vaginal isoniazid']","['hysteroscopic entry', 'odds ratio (OR']","[{'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0020710', 'cui_str': 'Hysteroscopy'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0751614', 'cui_str': 'Surgical Procedures, Hysteroscopic'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0567179', 'cui_str': 'Cervix undilated'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0022209', 'cui_str': 'isoniazid'}, {'cui': 'C0085174', 'cui_str': 'Misoprostol'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0439211', 'cui_str': 'mcg'}, {'cui': 'C1292429', 'cui_str': '8 hours'}, {'cui': 'C0751614', 'cui_str': 'Surgical Procedures, Hysteroscopic'}, {'cui': 'C0442122', 'cui_str': 'Intravaginal'}]","[{'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}]",,0.183447,Baseline characteristics were comparable between the groups.,"[{'ForeName': 'Ladan', 'Initials': 'L', 'LastName': 'Haghighi', 'Affiliation': 'Department of Obstetrics and Gynecology, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Najmi', 'Affiliation': 'Department of Obstetrics and Gynecology, Zanjan University of Medical Sciences, Zanjan, Iran.'}, {'ForeName': 'Samaneh', 'Initials': 'S', 'LastName': 'Rokhgireh', 'Affiliation': 'Endometriosis Research Center,Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Yousef', 'Initials': 'Y', 'LastName': 'Moradi', 'Affiliation': 'Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}]",Obstetrics & gynecology science,['10.5468/ogs.19170'] 1301,32553878,Impact of Platelet-rich Plasma in the Healing of Through-and-through Periapical Lesions Using 2-dimensional and 3-dimensional Evaluation: A Randomized Controlled Trial.,"INTRODUCTION The purpose of this randomized controlled trial was to evaluate the role of platelet-rich plasma (PRP) in the healing of through-and-through periapical lesions using both 2-dimensional periapical radiographs and 3-dimensional (3D) cone-beam computed tomographic imaging. METHODS Thirty-four patients after confirmation of a through-and-through periapical lesion were enrolled and randomly assigned to either the control or PRP group. Periapical surgery was performed, and grafting of the bone defect with PRP was done in the PRP group before suturing. Follow-up was scheduled at 12 months for clinical and radiographic analysis based on Molven's criteria; modified Penn 3D criteria; and resected plane, apical area, and cortical plate indexes. The absolute area and volume of the lesions were measured preoperatively and at follow-up using CorelDRAW X7 (64-bit) (Corel Corporation, Ottawa, Canada) and ITK Snap software (free software under the GNU General Public License developed by the National Institutes of Health, the US National Institute of Biomedical Imaging and BioEngineering, the US National Library of Medicine, the Universities of Pennsylvania and North Carolina, and an independent developer group), respectively. RESULTS Thirty-two patients were available at follow-up. A success rate of 93.7% was observed for both the control and PRP groups on 2-dimensional evaluation, whereas the PRP group exhibited a significantly higher success rate (87.5%) than the control (50%) on 3D assessment. A significantly higher percentage reduction in the lesion volume was documented in the PRP group (92.30 ± 4.72) than the control group (83.04 ± 12.82). Resected plane, apical area, and cortical plate indexes revealed a significantly higher scoring at the resected plane and cortical plate parameter in the PRP group. Overall analysis documented the faster re-establishment of the palatal cortical plate than the buccal cortical plate in through-and-through lesions. CONCLUSIONS These results suggest that PRP improves the healing outcome in through-and-through lesions. CBCT imaging provides better healing assessment after periapical surgery over periapical radiographs in such lesions.",2020,A significantly higher percentage reduction in the lesion volume was documented in the PRP (92.30±4.72) group than the control (83.04±12.82).,"['34 patients after confirmation of through-and-through periapical lesion', '32 patients were available at follow up']","['platelet rich plasma (PRP', 'PRP', '2-dimensional (2D) periapical radiograph and 3-dimensional (3D) cone beam computed tomography (CBCT', 'CBCT', 'Platelet rich plasma', 'control or PRP']","['absolute area and volume of the lesions', 'lesion volume', 'success rate', 'healing outcome']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521091', 'cui_str': 'Confirmation of'}, {'cui': 'C0729269', 'cui_str': 'Periapical'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0729269', 'cui_str': 'Periapical'}, {'cui': 'C1306645', 'cui_str': 'Plain radiography'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C1956110', 'cui_str': 'Cone beam CT'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",32.0,0.0684005,A significantly higher percentage reduction in the lesion volume was documented in the PRP (92.30±4.72) group than the control (83.04±12.82).,"[{'ForeName': 'Ritika', 'Initials': 'R', 'LastName': 'Dhamija', 'Affiliation': 'Department of Conservative Dentistry and Endodontics, Post Graduate Institute of Dental Sciences, Pt. B.D. Sharma University of Health Sciences, Rohtak, Haryana, India.'}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Tewari', 'Affiliation': 'Department of Conservative Dentistry and Endodontics, Post Graduate Institute of Dental Sciences, Pt. B.D. Sharma University of Health Sciences, Rohtak, Haryana, India. Electronic address: tewarisanjayrohtak@yahoo.co.in.'}, {'ForeName': 'Pankaj', 'Initials': 'P', 'LastName': 'Sangwan', 'Affiliation': 'Department of Conservative Dentistry and Endodontics, Post Graduate Institute of Dental Sciences, Pt. B.D. Sharma University of Health Sciences, Rohtak, Haryana, India.'}, {'ForeName': 'Jigyasa', 'Initials': 'J', 'LastName': 'Duhan', 'Affiliation': 'Department of Conservative Dentistry and Endodontics, Post Graduate Institute of Dental Sciences, Pt. B.D. Sharma University of Health Sciences, Rohtak, Haryana, India.'}, {'ForeName': 'Shweta', 'Initials': 'S', 'LastName': 'Mittal', 'Affiliation': 'Department of Conservative Dentistry and Endodontics, Post Graduate Institute of Dental Sciences, Pt. B.D. Sharma University of Health Sciences, Rohtak, Haryana, India.'}]",Journal of endodontics,['10.1016/j.joen.2020.06.004'] 1302,32559734,"Effects of low fructose diet on glycemic control, lipid profile and systemic inflammation in patients with type 2 diabetes: A single-blind randomized controlled trial.","BACKGROUND AND AIM Type 2 diabetes is one of the global epidemic disorders, which causes many side effects on the body. Fructose is a lipogenic monosaccharide. Recent studies have reported the adverse effects of this carbohydrate on diabetes. This study aimed to evaluate the clinical efficacy of a low-fructose diet on the metabolic alterations in patients with type 2 diabetes. METHODS This study was a randomized, single-blind clinical trial on 50 patients with type 2 diabetes. Participants randomly allocated to two groups, to receive either diabetic-diet or diabetic-diet with low-fructose for 8-weeks. Anthropometric measurements, systolic blood pressure (SBP), Diastolic blood pressure (DBP) and metabolic factors were assessed at baseline and the end of the trial. RESULTS At the end of trial, reduction in body weight, waist circumference, and blood pressure were not significant except for DBP (P = 0.013). Statistical analysis showed that low-fructose diet compared to control group significantly declined fasting blood glucose (FBG), Hemoglobin A1c (HbA1c), Triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C) and high-sensitivity C-reactive protein (hs-CRP) (P = 0.015, P = 0.001, P=<0.0001, P= <0.0001 and P= <0.0001 respectively). CONCLUSION Our results showed that eight weeks of low-fructose diet results in a significant improvement in FBG, HbA1c, TG, HDL-C and hs-CRP in patients with type 2 diabetes.",2020,"At the end of trial, reduction in body weight, waist circumference, and blood pressure were not significant except for DBP (P = 0.013).","['50 patients with type 2 diabetes', 'patients with type 2 diabetes']","['diabetic-diet or diabetic-diet with low-fructose for 8-weeks', 'low-fructose diet', 'Fructose', 'low fructose diet']","['fasting blood glucose (FBG), Hemoglobin A1c (HbA1c), Triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C) and high-sensitivity C-reactive protein (hs-CRP', 'Anthropometric measurements, systolic blood pressure (SBP), Diastolic blood pressure (DBP) and metabolic factors', 'glycemic control, lipid profile and systemic inflammation', 'body weight, waist circumference, and blood pressure', 'metabolic alterations', 'FBG, HbA1c, TG, HDL-C and hs-CRP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0011878', 'cui_str': 'Diabetic diet'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0016745', 'cui_str': 'Fructose'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0452314', 'cui_str': 'Low fructose diet'}]","[{'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]",50.0,0.074236,"At the end of trial, reduction in body weight, waist circumference, and blood pressure were not significant except for DBP (P = 0.013).","[{'ForeName': 'Arman', 'Initials': 'A', 'LastName': 'Jalilvand', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, ShahidBeheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Vahideh', 'Initials': 'V', 'LastName': 'Behrouz', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, ShahidBeheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Omid', 'Initials': 'O', 'LastName': 'Nikpayam', 'Affiliation': 'Student Research Committee, Tabriz University of Medical Science, Tabriz, Iran; Department of Clinical Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Golbon', 'Initials': 'G', 'LastName': 'Sohrab', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, ShahidBeheshti University of Medical Sciences, Tehran, Iran. Electronic address: golbonsohrab@yahoo.com.'}, {'ForeName': 'Azita', 'Initials': 'A', 'LastName': 'Hekmatdoost', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, ShahidBeheshti University of Medical Sciences, Tehran, Iran.'}]",Diabetes & metabolic syndrome,['10.1016/j.dsx.2020.04.003'] 1303,32559735,Improving clinical outcomes of diabetic foot ulcers by the 3-month self- and family management support programs in Indonesia: A randomized controlled trial study.,"BACKGROUND AND AIMS Diabetic foot ulcers are the leading cause of lower extremity amputations, which require more effective prevention. Even though previous nursing studies on diabetic foot ulcers have been well performed, programs implementing self- and family management are limited and even underexplored. Therefore, the purpose of the study was to investigate the effect of 3-month self- and family management support programs on clinical outcomes among Indonesians with diabetic foot ulcers. METHOD The randomized controlled trial design was used to answer the research question of the study. A total of 56 eligible participants were enrolled, with 27 in the experimental group and 29 in the control group. The experimental group received self- and family management support programs for three months. Meanwhile, the control group received usual care. Descriptive statistics, multivariate analysis of variance, and Generalized Estimating Equations were used to analyze the data. The significance level was considered at .05 for hypothesis testing. RESULTS The study showed that there were statistically significant improvements in self-management, family supports, hemoglobin A1c, and wound size after implemented the programs for three months (p < .05). CONCLUSIONS With regard to the result of the study, implementing the 3-month self- and family management support programs improves the patients' and families' abilities to perform diabetic foot ulcer care at home.",2020,"The study showed that there were statistically significant improvements in self-management, family supports, hemoglobin A1c, and wound size after implemented the programs for three months (p < .05). ","['A total of 56 eligible participants were enrolled, with 27 in the experimental group and 29 in the control group', 'Indonesia', 'Indonesians with diabetic foot ulcers']","['usual care', 'self- and family management support programs']","['self-management, family supports, hemoglobin A1c, and wound size']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021247', 'cui_str': 'Indonesia'}, {'cui': 'C0021248', 'cui_str': 'Indonesian language'}, {'cui': 'C1456868', 'cui_str': 'Diabetic foot ulcer'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0150232', 'cui_str': 'Family support'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0456389', 'cui_str': 'Size'}]",56.0,0.0239313,"The study showed that there were statistically significant improvements in self-management, family supports, hemoglobin A1c, and wound size after implemented the programs for three months (p < .05). ","[{'ForeName': 'Sumarno Adi', 'Initials': 'SA', 'LastName': 'Subrata', 'Affiliation': 'Ramathibodi School of Nursing, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand; Department of Nursing and Wound Research Center, Faculty of Health Sciences, Universitas Muhammadiyah Magelang, Indonesia.'}, {'ForeName': 'Rutja', 'Initials': 'R', 'LastName': 'Phuphaibul', 'Affiliation': 'Ramathibodi School of Nursing, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand. Electronic address: ruja.phu@mahidol.ac.th.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Grey', 'Affiliation': 'Yale University School of Nursing, United States.'}, {'ForeName': 'Apinya', 'Initials': 'A', 'LastName': 'Siripitayakunkit', 'Affiliation': 'Ramathibodi School of Nursing, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand.'}, {'ForeName': 'Noppawan', 'Initials': 'N', 'LastName': 'Piaseu', 'Affiliation': 'Ramathibodi School of Nursing, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand.'}]",Diabetes & metabolic syndrome,['10.1016/j.dsx.2020.05.028'] 1304,32562310,Impact of Phenol-Enriched Virgin Olive Oils on the Postprandial Levels of Circulating microRNAs Related to Cardiovascular Disease.,"SCOPE We investigate the postprandial modulation of cardiovascular-related microRNAs elicited by extra virgin olive oil (EVOOs) containing different levels of their own polyphenols. METHODS AND RESULTS It is randomized, postprandial, parallel, double-blind study. Twelve healthy participants consumed 30 mL of EVOO containing low (L-EVOO; 250 mg total phenols kg -1 of oil), medium (M-EVOO; 500 mg total phenols kg -1 of oil), and high (H-EVOO; 750 mg total phenols kg -1 of oil) enriched EVOOs. Postprandial plasma microRNAs levels are analyzed by real-time quantitative PCR. The results show that L-EVOO intake is associated with decreased let-7e-5p and miR-328a-3p levels and increased miR-17-5p and miR-20a-5p, concentrations. M-EVOO decreases plasma let-7e-5p and increases miR-17-5p, miR-20a-5p, and miR-192-5p levels. Finally, H-EVOO decreases let-7e-5p, miR-10a-5p, miR-21-5p, and miR-26b-5p levels. CONCLUSION During the postprandial state, the levels of let-7e-5p decrease with EVOO regardless of polyphenol content suggesting a general response to the fatty acid composition of EVOO or/and the presence of at least 250 mg polyphenol kg -1 olive oil. Moreover, the miR-17-92 cluster increases by low and medium polyphenol content suggesting a role in fatty acid metabolism and nutrient sensing. Thus, postprandial modulation of circulating microRNAs levels could be a potential mechanism for the cardiovascular benefits associated with EVOO intake.",2020,"M-EVOO decreased plasma let-7e-5p and increased miR-17-5p, miR-20a-5p and miR-192-5p levels.",['12 healthy participants'],"['consumed 30\xa0mL of EVOO containing Low (L-EVOO; 250\xa0mg total phenols/kg of oil), Medium (M-EVOO; 500\xa0mg total phenols/kg of oil) and high (H-EVOO; 750\xa0mg total phenols/kg of oil) polyphenol', 'Extra Virgin Olive oil (EVOOs', 'Phenol-Enriched Virgin Olive Oils', 'polyphenol/kg olive oil']","['let-7e-5p and miR-328a-3p levels and increased miR-17-5p and miR-20a-5p, concentrations', 'Plasma microRNAs levels', 'L-EVOO intake', 'H-EVOO decreased let-7e-5p, miR-10a-5p, miR-21-5p and miR-26b-5p levels', 'M-EVOO decreased plasma let-7e-5p and increased miR-17-5p, miR-20a-5p and miR-192-5p levels']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0031428', 'cui_str': 'Phenols'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C4517868', 'cui_str': '750'}, {'cui': 'C0071649', 'cui_str': 'Polyphenol'}, {'cui': 'C0555061', 'cui_str': 'Virgin'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}]","[{'cui': 'C0086562', 'cui_str': 'Energy Transfer, Linear'}, {'cui': 'C1101610', 'cui_str': 'MicroRNA'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C4517623', 'cui_str': '192'}]",12.0,0.125285,"M-EVOO decreased plasma let-7e-5p and increased miR-17-5p, miR-20a-5p and miR-192-5p levels.","[{'ForeName': 'Lidia', 'Initials': 'L', 'LastName': 'Daimiel', 'Affiliation': 'Nutritional Control of the Epigenome Group, Instituto Madrileño de Estudios, Avanzados (IMDEA) Food Institute, CEI UAM+CSIC, Madrid, 28049, Spain.'}, {'ForeName': 'Víctor', 'Initials': 'V', 'LastName': 'Micó', 'Affiliation': 'Nutritional Control of the Epigenome Group, Instituto Madrileño de Estudios, Avanzados (IMDEA) Food Institute, CEI UAM+CSIC, Madrid, 28049, Spain.'}, {'ForeName': 'Rosa M', 'Initials': 'RM', 'LastName': 'Valls', 'Affiliation': 'Functional Nutrition, Oxidation and Cardiovascular Disease Research Group, Universitat Rovira i Virgili, Hospital Universitari Sant Joan, EURECAT, Reus, 43204, Spain.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Pedret', 'Affiliation': 'Functional Nutrition, Oxidation and Cardiovascular Disease Research Group, Universitat Rovira i Virgili, Hospital Universitari Sant Joan, EURECAT, Reus, 43204, Spain.'}, {'ForeName': 'María José', 'Initials': 'MJ', 'LastName': 'Motilva', 'Affiliation': ""Food Technology Department, Agrotecnio Center, Escola Tècnica Superior d'Enginyeria Agrària, University of Lleida, Lleida, 25198, Spain.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Rubió', 'Affiliation': 'Instituto de Ciencias de la Vid y del Vino-ICVV, (CSIC-Consejo Superior de Investigaciones Científicas, Universidad de La Rioja, Gobierno de La Rioja), Finca La Grajera, Ctra. de Burgos Km. 6 (LO-20 - salida 13), Logroño, La Rioja, 26007, Spain.'}, {'ForeName': 'Montse', 'Initials': 'M', 'LastName': 'Fitó', 'Affiliation': 'Cardiovascular Risk and Nutrition (Regicor Study Group), Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain. CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, 28029, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Farrás', 'Affiliation': 'Cardiovascular Risk and Nutrition (Regicor Study Group), Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain. CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, 28029, Spain.'}, {'ForeName': 'María Isabel', 'Initials': 'MI', 'LastName': 'Covas', 'Affiliation': 'Cardiovascular Risk and Nutrition (Regicor Study Group), Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain. CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, 28029, Spain.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Solá', 'Affiliation': 'Functional Nutrition, Oxidation and Cardiovascular Disease Research Group, Universitat Rovira i Virgili, Hospital Universitari Sant Joan, EURECAT, Reus, 43204, Spain.'}, {'ForeName': 'José M', 'Initials': 'JM', 'LastName': 'Ordovás', 'Affiliation': 'Nutritional Genomics and Epigenomics Group, Instituto Madrileño de Estudios Avanzados (IMDEA) Food Institute, CEI UAM+CSIC, Madrid, 28049, Spain.'}]",Molecular nutrition & food research,['10.1002/mnfr.202000049'] 1305,32562806,Impact of health warning labels on snack selection: An online experimental study.,"Excessive consumption of energy-dense food increases the risk of obesity, which in turn increases the risk of non-communicable diseases, including heart disease, type 2 diabetes and most non-smoking-related cancers. Health warning labels (HWLs) that communicate the adverse health consequences of excess energy consumption could reduce intake of energy-dense foods. The aim of the current study was to estimate the impact on selection of energy-dense snacks of (a) image-and-text HWLs (b) text-only HWLs and (c) calorie information. In a between-subjects, 3 (HWL: image-and-text, text-only, no label) x 2 (calorie information: present, absent), factorial experimental design, participants (N = 4134) were randomised to view a selection of energy-dense and non-energy-dense snacks with one of five label types or no label. The primary outcome was the proportion of participants selecting an energy-dense snack in a hypothetical vending machine task. The proportion of participants selecting an energy-dense snack was reduced in all label groups, relative to the no label group (no label: 59%; calories only: 54%; text-only HWL: 48%; text-only HWL with calories: 44%; image-and-text HWL: 37%; image-and-text HWL with calories: 38%). Compared to the no label group, participants were least likely to select an energy-dense snack in the image-and-text HWL group (OR = 0.46, 95%CI = 0.40, 0.54, p < 0.001). Health warning labels - particularly those including an image and text - have the potential to reduce selection of energy-dense snacks in an online setting. Their impact on selection and consumption in real-world settings awaits testing.",2020,"The proportion of participants selecting an energy-dense snack was reduced in all label groups, relative to the no label group (no label: 59%; calories only: 54%; text-only HWL: 48%; text-only HWL with calories: 44%; image-and-text HWL: 37%; image-and-text HWL with calories: 38%).","['participants (N\u202f=\u202f4,134', 'snack selection']","['energy-dense snacks of (a) image-and-text HWLs (b) text-only HWLs and (c) calorie information', 'health warning labels', 'energy-dense and non-energy-dense snacks with one of five label types or no label']","['proportion of participants selecting an energy-dense snack', 'proportion of participants selecting an energy-dense snack in a hypothetical vending machine task']","[{'cui': 'C0453863', 'cui_str': 'Snack food'}, {'cui': 'C0031222', 'cui_str': 'Personnel Selection'}]","[{'cui': 'C0439794', 'cui_str': 'Dense'}, {'cui': 'C0453863', 'cui_str': 'Snack food'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0439794', 'cui_str': 'Dense'}, {'cui': 'C0453863', 'cui_str': 'Snack food'}, {'cui': 'C0336779', 'cui_str': 'Machine'}]",4134.0,0.0769476,"The proportion of participants selecting an energy-dense snack was reduced in all label groups, relative to the no label group (no label: 59%; calories only: 54%; text-only HWL: 48%; text-only HWL with calories: 44%; image-and-text HWL: 37%; image-and-text HWL with calories: 38%).","[{'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Clarke', 'Affiliation': 'Behaviour and Health Research Unit, Institute of Public Health, University of Cambridge, Cambridge, UK. Electronic address: ncc42@medschl.cam.ac.uk.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Pechey', 'Affiliation': 'Behaviour and Health Research Unit, Institute of Public Health, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Mantzari', 'Affiliation': 'Behaviour and Health Research Unit, Institute of Public Health, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Anna K M', 'Initials': 'AKM', 'LastName': 'Blackwell', 'Affiliation': 'Tobacco and Alcohol Research Group, School of Psychological Science, University of Bristol, Bristol, UK.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'De-Loyde', 'Affiliation': 'Tobacco and Alcohol Research Group, School of Psychological Science, University of Bristol, Bristol, UK.'}, {'ForeName': 'Richard W', 'Initials': 'RW', 'LastName': 'Morris', 'Affiliation': 'Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'Marcus R', 'Initials': 'MR', 'LastName': 'Munafò', 'Affiliation': 'Tobacco and Alcohol Research Group, School of Psychological Science, University of Bristol, Bristol, UK.'}, {'ForeName': 'Theresa M', 'Initials': 'TM', 'LastName': 'Marteau', 'Affiliation': 'Behaviour and Health Research Unit, Institute of Public Health, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Gareth J', 'Initials': 'GJ', 'LastName': 'Hollands', 'Affiliation': 'Behaviour and Health Research Unit, Institute of Public Health, University of Cambridge, Cambridge, UK.'}]",Appetite,['10.1016/j.appet.2020.104744'] 1306,32567245,Contrast-enhanced CT radiomics for preoperative evaluation of microvascular invasion in hepatocellular carcinoma: A two-center study.,"BACKGROUND The present study constructed and validated the use of contrast-enhanced computed tomography (CT)-based radiomics to preoperatively predict microvascular invasion (MVI) status (positive vs negative) and risk (low vs high) in patients with hepatocellular carcinoma (HCC). METHODS We enrolled 637 patients from two independent institutions. Patients from Institution I were randomly divided into a training cohort of 451 patients and a test cohort of 111 patients. Patients from Institution II served as an independent validation set. The LASSO algorithm was used for the selection of 798 radiomics features. Two classifiers for predicting MVI status and MVI risk were developed using multivariable logistic regression. We also performed a survival analysis to investigate the potentially prognostic value of the proposed MVI classifiers. RESULTS The developed radiomics signature predicted MVI status with an area under the receiver operating characteristic curve (AUC) of .780, .776, and .743 in the training, test, and independent validation cohorts, respectively. The final MVI status classifier that integrated two clinical factors (age and α-fetoprotein level) achieved AUC of .806, .803, and .796 in the training, test, and independent validation cohorts, respectively. For MVI risk stratification, the AUCs of the radiomics signature were .746, .664, and .700 in the training, test, and independent validation cohorts, respectively, and the AUCs of the final MVI risk classifier-integrated clinical stage were .783, .778, and .740, respectively. Survival analysis showed that our MVI status classifier significantly stratified patients for short overall survival or early tumor recurrence. CONCLUSIONS Our CT radiomics-based models were able to predict MVI status and MVI risk of HCC and might serve as a reliable preoperative evaluation tool.",2020,"For MVI risk stratification, the AUCs of the radiomics signature were .746, .664, and .700 in the training, test, and independent validation cohorts, respectively, and the AUCs of the final MVI risk classifier-integrated clinical stage were .783, .778, and .740, respectively.","['451 patients and a test cohort of 111 patients', '637 patients from two independent institutions', 'Patients from Institution', 'patients with hepatocellular carcinoma (HCC', 'hepatocellular carcinoma']","['Contrast-enhanced CT radiomics', 'contrast-enhanced computed tomography (CT)-based radiomics']","['overall survival or early tumor recurrence', 'MVI status and MVI risk']","[{'cui': 'C5191282', 'cui_str': '451'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}]","[{'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0521158', 'cui_str': 'Recurrent tumor'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C1269955', 'cui_str': 'Tumour invasion'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",637.0,0.0281016,"For MVI risk stratification, the AUCs of the radiomics signature were .746, .664, and .700 in the training, test, and independent validation cohorts, respectively, and the AUCs of the final MVI risk classifier-integrated clinical stage were .783, .778, and .740, respectively.","[{'ForeName': 'Xiuming', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Shijian', 'Initials': 'S', 'LastName': 'Ruan', 'Affiliation': 'College of Information Science and Electronic Engineering, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Wenbo', 'Initials': 'W', 'LastName': 'Xiao', 'Affiliation': 'Department of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Jiayuan', 'Initials': 'J', 'LastName': 'Shao', 'Affiliation': 'College of Information Science and Electronic Engineering, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Wuwei', 'Initials': 'W', 'LastName': 'Tian', 'Affiliation': 'College of Information Science and Electronic Engineering, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Weihai', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': ""Department of Radiology, The People's Hospital of Beilun District, Ningbo, China.""}, {'ForeName': 'Zhao', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Department of Radiology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.'}, {'ForeName': 'Dalong', 'Initials': 'D', 'LastName': 'Wan', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Jiacheng', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Huang', 'Affiliation': 'Department of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Yunjun', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Radiology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.'}, {'ForeName': 'Hanjin', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'College of Information Science and Electronic Engineering, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Wenjie', 'Initials': 'W', 'LastName': 'Liang', 'Affiliation': 'Department of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Xueli', 'Initials': 'X', 'LastName': 'Bai', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Tingbo', 'Initials': 'T', 'LastName': 'Liang', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.'}]",Clinical and translational medicine,['10.1002/ctm2.111'] 1307,32563939,Association of Meteorin-Like Hormone with insulin resistance and body composition in healthy Iranian adults.,"BACKGROUND AND AIMS Sedentary behavior and/or physical inactivity are modifiable risk factors for noncommunicable diseases. Myokines are one of the mediators of physical activity health benefits. Relationship between regular physical activity (RPA) and baseline plasma Meteorin-Like Hormone (Metrnl) has not been explored in human. Hence, we compared baseline plasma Metrnl between sedentary individuals and ones with recreational physical activities, and role of Metrnl as a biological messenger between physical activity and insulin resistance and body composition was also explored. METHODS Forty healthy young men (aged: 21 ± 2.1 yrs; BMI: 23 ± 3.44 kg/m 2 ) completed the study. Participants were equally assigned into two groups of control (sedentary) and case (recreational athletes). Baseline plasma Metrnl, glucose, insulin and body composition components and insulin resistance index (HOMA-IR) were assessed under resting conditions. RESULTS Except for baseline blood glucose, baseline plasma Metrnl, insulin, HOMA-IR and body mass index and body fat percentage were similar between two groups (P > 0.05). However, after Metrnl correction for the degree of insulin resistance index (Metrnl/HOMA-IR), recreational athletes showed a significantly greater baseline compared to sedentary subjects (P < 0.05). Baseline blood glucose showed a negative and significant correlation with baseline plasma Metrnl (P < 0.05). CONCLUSIONS Baseline plasma Metrnl is correlated with regular physical activity and insulin sensitivity, but not with body composition parameters. Metrnl may be one possible mediator of the beneficial effects of PA on insulin sensitivity in healthy humans. Hence, increasing awareness of the benefits of physical activity and incorporating physical activity into lifestyle are of great importance for people with non-communicable diseases.",2020,"Baseline plasma Metrnl, glucose, insulin and body composition components and insulin resistance index (HOMA-IR) were assessed under resting conditions. ","['healthy humans', 'Forty healthy young men (aged: 21\xa0±\xa02.1\xa0yrs', 'people with non-communicable diseases', 'healthy Iranian adults']","['Meteorin-Like Hormone with insulin resistance and body composition', 'regular physical activity (RPA) and baseline plasma Meteorin-Like Hormone (Metrnl']","['Baseline blood glucose', 'degree of insulin resistance index (Metrnl/HOMA-IR', 'baseline plasma Metrnl', 'baseline blood glucose, baseline plasma Metrnl, insulin, HOMA-IR and body mass index and body fat percentage', 'Baseline plasma Metrnl, glucose, insulin and body composition components and insulin resistance index (HOMA-IR']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4068876', 'cui_str': '2.1'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4505065', 'cui_str': 'Non-infectious Diseases'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0449432', 'cui_str': 'Component'}]",40.0,0.0269477,"Baseline plasma Metrnl, glucose, insulin and body composition components and insulin resistance index (HOMA-IR) were assessed under resting conditions. ","[{'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Alizadeh', 'Affiliation': 'Faculty of Sport Sciences, University of Mazandaran, Babolsar, Mazandaran, Iran. Electronic address: h.alizadeh.aw@gmail.com.'}, {'ForeName': 'Aliakbar', 'Initials': 'A', 'LastName': 'Alizadeh', 'Affiliation': 'Department of Sport Physiology, Faculty of Sport Sciences, Shahid Chamran University of Ahvaz, Ahvaz, Iran. Electronic address: aliakbar.alizadeh1984@gmail.com.'}]",Diabetes & metabolic syndrome,['10.1016/j.dsx.2020.05.031'] 1308,32568867,Entecavir add-on Peg-interferon therapy plays a positive role in reversing hepatic fibrosis in treatment-naïve chronic hepatitis B patients: a prospective and randomized controlled trial.,"BACKGROUND The efficacy of entecavir (ETV) add-on peg-interferon therapy compared with ETV monotherapy in treatment-naïve hepatitis B virus (HBV) patients remains controversial. We investigated whether adding peg-interferon to ongoing ETV treatment leads to a better curative effect or not. METHODS All patients have been recruited between August 2013 and January 2015 from the Shanghai Public Health Clinical Center and Zhongshan Hospital (China). Eligible HBV patients (n = 144) were randomly divided (1:1) to receive either ETV monotherapy (n = 70) or peg-interferon add-on therapy from week 26 to 52 (n = 74). Patients were followed-up for at least 2 years. Indexes including hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) seroconversion rate, sustained virologic response, transient elastography value, and histological scores were evaluated every 3 months until the end of the study. The rate of patients with HBsAg loss was defined as the primary endpoint criteria. RESULTS At week 26, no patient achieved HBsAg seroconversion in either group. At week 52, one patient in the monotherapy group was HBsAg-negative but there was none in the combination therapy group. The monotherapy group showed significantly better liver function recovery results than the combination therapy group. At week 78, one patient in the combination group had HBsAg seroconverted. At week 104, only three patients in the combination therapy group were HBsAg-negative compared with one patient in monotherapy. The mean alanine aminotransferase and aspartate aminotransferase levels and transient elastography values decreased significantly compared with baseline. Both groups showed a favorable decrease in alpha-fetoprotein (monotherapy: 4.5 [2.8, 7.1] vs. 2.2 [1.8, 3.1] ng/mL, P < 0.001; combination therapy: 5.7 [3.0, 18.8] vs. 3.2 [2.0, 4.3] ng/mL, P < 0.001) and an improved result of liver biopsy examination scores. The combination group showed a better improvement in histology compared with the monotherapy group (mean transient elastography value 6.6 [4.9, 9.8] vs. 7.8 [5.4, 11.1] kPa, P = 0.028). But there was no significant difference in HBsAg conversion rate (1.8% [1/56] vs. 4.1% [3/73], P = 0.809) and HBeAg conversion rate (12.5% [7/56] vs. 11.0% [8/73], P = 0.787), as well as HBV-DNA, sustained virologic response (93.2% vs. 98.5%, P = 0.150) between the two groups. CONCLUSIONS Both therapies supported liver function recovery and histology improvement. Combination therapy did not show better anti-viral efficacy in HBsAg or HBeAg seroconversion compared with monotherapy. However, combination therapy played a more positive role in reversing hepatic fibrosis compared with monotherapy. TRIAL REGISTRATION ClinicalTrials.gov: NCT02849132; https://clinicaltrials.gov/ct2/show/NCT02849132.",2020,"The combination group showed a better improvement in histology compared with the monotherapy group (mean transient elastography value 6.6 [4.9, 9.8] vs. 7.8 [5.4, 11.1] kPa, P = 0.028).","['treatment-naïve chronic hepatitis B patients', 'All patients have been recruited between August 2013 and January 2015 from the Shanghai Public Health Clinical Center and Zhongshan Hospital (China', 'Eligible HBV patients (n = 144']","['Entecavir', 'entecavir (ETV', 'ETV monotherapy (n\u200a=\u200a70) or peg-interferon add-on therapy', 'ETV monotherapy']","['mean alanine aminotransferase and aspartate aminotransferase levels and transient elastography values', 'hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) seroconversion rate, sustained virologic response, transient elastography value, and histological scores', 'HBsAg seroconversion', 'HBsAg-negative', 'hepatic fibrosis', 'histology', 'rate of patients with HBsAg loss', 'HBeAg conversion rate', 'liver function recovery', 'alpha-fetoprotein', 'HBV-DNA, sustained virologic response', 'liver biopsy examination scores', 'HBsAg conversion rate']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0524909', 'cui_str': 'Chronic type B viral hepatitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0019169', 'cui_str': 'Hepatitis B Virus'}, {'cui': 'C4760627', 'cui_str': '144'}]","[{'cui': 'C0971023', 'cui_str': 'entecavir'}, {'cui': 'C0032478', 'cui_str': 'Polyethylene Glycol 400'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0428339', 'cui_str': 'Aspartate transaminase level'}, {'cui': 'C2748260', 'cui_str': 'Transient elastography'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0019168', 'cui_str': 'Hepatitis B surface antigen'}, {'cui': 'C0019167', 'cui_str': 'Hepatitis B e antigen'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0919711', 'cui_str': 'Hepatitis B surface antigen negative'}, {'cui': 'C0239946', 'cui_str': 'Hepatic fibrosis'}, {'cui': 'C0019638', 'cui_str': 'Histology'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0232741', 'cui_str': 'Liver function'}, {'cui': 'C0002210', 'cui_str': 'Alpha fetoprotein'}, {'cui': 'C0369332', 'cui_str': 'Hepatitis B virus DNA'}, {'cui': 'C0193388', 'cui_str': 'Biopsy of liver'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",144.0,0.0480929,"The combination group showed a better improvement in histology compared with the monotherapy group (mean transient elastography value 6.6 [4.9, 9.8] vs. 7.8 [5.4, 11.1] kPa, P = 0.028).","[{'ForeName': 'Jing-Mao', 'Initials': 'JM', 'LastName': 'Yang', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China.'}, {'ForeName': 'Li-Ping', 'Initials': 'LP', 'LastName': 'Chen', 'Affiliation': 'Shanghai Medical College of Fudan University, Shanghai 200032, China.'}, {'ForeName': 'Ya-Jie', 'Initials': 'YJ', 'LastName': 'Wang', 'Affiliation': 'Department of Gastroenterology and Hepatology, Jinshan Hospital, Fudan University, Shanghai 201500, China.'}, {'ForeName': 'Bei', 'Initials': 'B', 'LastName': 'Lyu', 'Affiliation': 'Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Zhao', 'Affiliation': ""Department of Gastroenterology and Hepatology, Dongyang People's Hospital, Dongyang, Zhejiang 322100, China.""}, {'ForeName': 'Zhi-Yin', 'Initials': 'ZY', 'LastName': 'Shang', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China.'}, {'ForeName': 'Zhen-Yu', 'Initials': 'ZY', 'LastName': 'Fan', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China.'}, {'ForeName': 'Sheng-Di', 'Initials': 'SD', 'LastName': 'Wu', 'Affiliation': 'Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Ming', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China.'}, {'ForeName': 'Xian', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China.'}, {'ForeName': 'Shao-Ping', 'Initials': 'SP', 'LastName': 'Huang', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China.'}, {'ForeName': 'Ji-Lin', 'Initials': 'JL', 'LastName': 'Cheng', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China.'}]",Chinese medical journal,['10.1097/CM9.0000000000000857'] 1309,32568876,Effect of temperature maintenance by forced-air warming blankets of different temperatures on changes in inflammatory factors in children undergoing congenital hip dislocation surgery.,"BACKGROUND Hypothermia is associated with many adverse clinical outcomes in pediatric patients, and thus, it is important to find an effective and safe method for preventing peri-operative hypothermia and its associated adverse outcomes in pediatric patients. This study aimed to investigate the effect of forced-air warming blankets with different temperatures on changes in the transforming growth factor-β (TGF-β), tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-10 levels in children undergoing surgical treatment for developmental displacement of the hip (DDH). METHODS The study included 123 children undergoing surgery for DDH under general anesthesia. The patients were randomly assigned to three groups, using a random number table: the 32, 38, and 43°C groups according to the temperature setting of the forced-air warming blankets. For each patient, body temperature was recorded immediately after anesthesia induction and intubation (T0), at initial incision (T1), at 1 h after incision (T2), at 2 h after incision (T3), at the end of surgery (T4), immediately upon return to the ward after surgery (T5), and then at 12 h (T6), 24 h (T7), 36 h (T8), and 48 h (T9) after the surgery. The serum levels of TGF-β, TNF-α, IL-1β, and IL-10 were measured at T0 and T4 for all groups. RESULTS The number of patients with fever in the 38°C group was significantly less than those in the 32 and 43°C groups (χ = 6.630, P = 0.036). At T0, the body temperatures in the 38 and 43°C groups were significantly higher than that in the 32°C group (F = 17.992, P < 0.001). At T2, the body temperature was significantly higher in the 43°C group than those in the 32 and 38°C groups (F = 12.776, P < 0.001). Moreover, at T4, the serum levels of TGF-β (F = 3286.548, P < 0.001) and IL-10 (F = 4628.983, P < 0.001) were significantly increased in the 38°C group, and the serum levels of TNF-α (F = 911.415, P < 0.001) and IL-1β (F = 322.191, P < 0.001) were significantly decreased in the 38°C group, compared with the levels in the 32 and 43°C groups. CONCLUSION Force-air warming blankets set at 38°C maintained stable body temperature with less adverse outcome and effectively inhibited the inflammatory response in pediatric patients undergoing surgery for DDH. CLINICAL TRIAL REGISTRATION ChiCTR1800014820; http://www.chictr.org.cn/showproj.aspx?proj=25240.",2020,"The serum levels of TGF-β, TNF-α, IL-1β, and IL-10 were measured at T0 and T4 for all groups. ","['pediatric patients', 'pediatric patients undergoing surgery for DDH', 'children undergoing congenital hip dislocation surgery', 'children undergoing surgical treatment for developmental displacement of the hip (DDH', '123 children undergoing surgery for DDH under general anesthesia']","['temperature maintenance by forced-air warming blankets', 'forced-air warming blankets']","['IL-1β', 'serum levels of TGF-β, TNF-α, IL-1β, and IL-10', 'serum levels of TGF-β', 'body temperature', 'transforming growth factor-β (TGF-β), tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-10 levels', 'serum levels of TNF-α', 'number of patients with fever', 'IL-10', 'body temperatures', 'inflammatory response']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0019555', 'cui_str': 'Congenital dislocation of hip'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}]","[{'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0184351', 'cui_str': 'Warming blanket'}]","[{'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0040691', 'cui_str': 'Transforming Growth Factor'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015967', 'cui_str': 'Fever'}]",123.0,0.057569,"The serum levels of TGF-β, TNF-α, IL-1β, and IL-10 were measured at T0 and T4 for all groups. ","[{'ForeName': 'Li-Ping', 'Initials': 'LP', 'LastName': 'He', 'Affiliation': ""Department of Operation Room, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong 510623, China.""}, {'ForeName': 'Pei-Zhen', 'Initials': 'PZ', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Yuan-Ming', 'Initials': 'YM', 'LastName': 'Wen', 'Affiliation': ''}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': ''}]",Chinese medical journal,['10.1097/CM9.0000000000000846'] 1310,32576828,Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial.,"Short-term fasting protects tumor-bearing mice against the toxic effects of chemotherapy while enhancing therapeutic efficacy. We randomized 131 patients with HER2-negative stage II/III breast cancer, without diabetes and a BMI over 18 kg m -2 , to receive either a fasting mimicking diet (FMD) or their regular diet for 3 days prior to and during neoadjuvant chemotherapy. Here we show that there was no difference in toxicity between both groups, despite the fact that dexamethasone was omitted in the FMD group. A radiologically complete or partial response occurs more often in patients using the FMD (OR 3.168, P = 0.039). Moreover, per-protocol analysis reveals that the Miller&Payne 4/5 pathological response, indicating 90-100% tumor-cell loss, is more likely to occur in patients using the FMD (OR 4.109, P = 0.016). Also, the FMD significantly curtails chemotherapy-induced DNA damage in T-lymphocytes. These positive findings encourage further exploration of the benefits of fasting/FMD in cancer therapy. Trial number: NCT02126449.",2020,"A radiologically complete or partial response occurs more often in patients using the FMD (OR 3.168, P = 0.039).","['131 patients with HER2-negative stage II/III breast cancer, without diabetes and a BMI over 18\u2009kg\u2009m -2 , to receive either a']","['Fasting mimicking diet', 'chemotherapy', 'fasting mimicking diet (FMD) or their regular diet for 3 days prior to and during neoadjuvant chemotherapy', 'dexamethasone']","['Miller&Payne 4/5 pathological response', 'toxicity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4087376', 'cui_str': 'HER2 negative'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1532718', 'cui_str': 'kg-m'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0184625', 'cui_str': 'Normal diet'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}]","[{'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0040539', 'cui_str': 'TO'}]",131.0,0.0375448,"A radiologically complete or partial response occurs more often in patients using the FMD (OR 3.168, P = 0.039).","[{'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'de Groot', 'Affiliation': 'Department of Medical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Rieneke T', 'Initials': 'RT', 'LastName': 'Lugtenberg', 'Affiliation': 'Department of Medical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Cohen', 'Affiliation': 'Department of Pathology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Marij J P', 'Initials': 'MJP', 'LastName': 'Welters', 'Affiliation': 'Department of Medical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Ilina', 'Initials': 'I', 'LastName': 'Ehsan', 'Affiliation': 'Department of Medical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Maaike P G', 'Initials': 'MPG', 'LastName': 'Vreeswijk', 'Affiliation': 'Department of Human Genetics, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Vincent T H B M', 'Initials': 'VTHBM', 'LastName': 'Smit', 'Affiliation': 'Department of Pathology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Hiltje', 'Initials': 'H', 'LastName': 'de Graaf', 'Affiliation': 'Department of Medical Oncology, Medical center Leeuwarden, P.O. Box 888, 8901 NR, Leeuwarden, The Netherlands.'}, {'ForeName': 'Joan B', 'Initials': 'JB', 'LastName': 'Heijns', 'Affiliation': 'Department of Medical Oncology, Amphia, P.O. Box 90157, 4800 RL, Breda, The Netherlands.'}, {'ForeName': 'Johanneke E A', 'Initials': 'JEA', 'LastName': 'Portielje', 'Affiliation': 'Department of Medical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Agnes J', 'Initials': 'AJ', 'LastName': 'van de Wouw', 'Affiliation': 'Department of Medical Oncology, Viecuri, 5912BL, Venlo, The Netherlands.'}, {'ForeName': 'Alex L T', 'Initials': 'ALT', 'LastName': 'Imholz', 'Affiliation': 'Department of Medical Oncology, Deventer hospital, P.O. Box 5001, 7416 SE, Deventer, The Netherlands.'}, {'ForeName': 'Lonneke W', 'Initials': 'LW', 'LastName': 'Kessels', 'Affiliation': 'Department of Medical Oncology, Deventer hospital, P.O. Box 5001, 7416 SE, Deventer, The Netherlands.'}, {'ForeName': 'Suzan', 'Initials': 'S', 'LastName': 'Vrijaldenhoven', 'Affiliation': 'Department of Medical Oncology, Noordwest hospital group, location Alkmaar, P.O. Box 501, 1815 JD, Alkmaar, The Netherlands.'}, {'ForeName': 'Arnold', 'Initials': 'A', 'LastName': 'Baars', 'Affiliation': 'Department of Medical Oncology, Hospital Gelderse vallei, 6710 HN, Ede, The Netherlands.'}, {'ForeName': 'Elma Meershoek-Klein', 'Initials': 'EM', 'LastName': 'Kranenbarg', 'Affiliation': 'Department of Surgery, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Marjolijn Duijm-de', 'Initials': 'MD', 'LastName': 'Carpentier', 'Affiliation': 'Department of Surgery, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Hein', 'Initials': 'H', 'LastName': 'Putter', 'Affiliation': 'Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, P.O. Box 9600, 2300RC, Leiden, The Netherlands.'}, {'ForeName': 'Jacobus J M', 'Initials': 'JJM', 'LastName': 'van der Hoeven', 'Affiliation': 'Department of Medical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Johan W R', 'Initials': 'JWR', 'LastName': 'Nortier', 'Affiliation': 'Department of Medical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Valter D', 'Initials': 'VD', 'LastName': 'Longo', 'Affiliation': 'Longevity Institute, School of Gerontology, and Department of Biological Sciences, University of Southern California, Los Angeles, CA, 90089, USA.'}, {'ForeName': 'Hanno', 'Initials': 'H', 'LastName': 'Pijl', 'Affiliation': 'Department of Endocrinology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Judith R', 'Initials': 'JR', 'LastName': 'Kroep', 'Affiliation': 'Department of Medical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. j.r.kroep@lumc.nl.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Nature communications,['10.1038/s41467-020-16138-3'] 1311,32579120,Elderly Medication Adherence Intervention Using the My Interventional Drug-Eluting Stent Educational App: Multisite Randomized Feasibility Trial.,"BACKGROUND A lifesaving treatment for myocardial infarction is the placement of a stent in a closed or obstructed coronary artery. The largest modifiable risk factor after receiving a stent is medication adherence to Dual AntiPlatelet Therapy, a combination of P2Y12 inhibitors and aspirin. OBJECTIVE This study aimed to determine the acceptability of a protocol and an intervention using the My Interventional Drug-Eluting Stent Educational App (MyIDEA) and to evaluate medication adherence using the proportion of days covered (PDC) and platelet activation tests in a multisite randomized controlled trial. METHODS Potential participants who received a post percutaneous coronary intervention (PCI) procedure with a drug-eluting stent were approached. All patients older than 50 years and who spoke English were recruited. Participants were recruited, baseline demographics were collected, and the Hospital Anxiety and Depression Scale (HADS), Rapid Estimate of Adult Literacy in Medicine-Short Form, Burden-Benefit questionnaire, 36-Item Short Form Health Survey, and PCI knowledge questionnaire were administered. Block randomization was used to randomize participants to either usual care or MyIDEA supplementation. MyIDEA is a personalized educational intervention based on the Kolb experiential learning theory using patient narratives for education. During the visits, participants' blood was collected to measure platelet suppression from medication. During the second and third encounters, the Morisky medication adherence score and cardiology outcomes were measured. The study was conducted at the University of Illinois Hospital and John H Stroger Jr Cook County Hospital with appropriate ethical approvals. Platelet suppression was measured through aspirin reactive units and P2Y12 reactive units. Medication adherence was measured using the PDC. The analysis team was blinded to the participants' group membership. The primary outcome was a feasibility analysis of recruitment and retention. RESULTS The mean age of participants was 60.4 years (SD 7.1); the majority of patients were black and non-Hispanic. The majority of patients' reading levels were seventh grade or above, and they were not very familiar with other electronic devices for information and communication. The number of control subjects was 21, and the number of participants in the interventional arm was 24. The interventional group was able to use MyIDEA in both the hospital and outpatient setting. However, there was no significant difference in platelet suppression or medication adherence between groups. There were also differences between the groups in terms of depression and anxiety, initially, as measured by HADS. No documented adverse event associated with the intervention was found. CONCLUSIONS Elderly patients are willing to use tablet devices to be educated about health conditions. Additional studies are required to measure the effectiveness and determine the most suitable timing and location for patient education. TRIAL REGISTRATION ClinicalTrials.gov NCT04439864; https://clinicaltrials.gov/ct2/show/NCT04439864.",2020,"However, there was no significant difference in platelet suppression or medication adherence between groups.","['The mean age of participants was 60.4 years (SD 7.1); the majority of patients were black and non-Hispanic', 'University of Illinois Hospital and John H Stroger Jr Cook County Hospital with appropriate ethical approvals', 'Potential participants who received a post percutaneous coronary intervention (PCI) procedure with a drug-eluting stent were approached', 'Elderly patients', 'All patients older than 50 years and who spoke English were recruited']","['usual care or MyIDEA supplementation', 'My Interventional Drug-Eluting Stent Educational App (MyIDEA', 'P2Y12 inhibitors and aspirin']","['Medication adherence', 'Platelet suppression', 'feasibility analysis of recruitment and retention', 'Morisky medication adherence score and cardiology outcomes', 'platelet suppression or medication adherence', 'Burden-Benefit questionnaire, 36-Item Short Form Health Survey, and PCI knowledge questionnaire', 'Hospital Anxiety and Depression Scale (HADS', 'depression and anxiety']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0020898', 'cui_str': 'Illinois'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0335326', 'cui_str': 'Cookery'}, {'cui': 'C0020005', 'cui_str': 'County Hospitals'}, {'cui': 'C0026531', 'cui_str': 'Morality'}, {'cui': 'C0205540', 'cui_str': 'Approved'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1322815', 'cui_str': 'Drug eluting stent'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0234856', 'cui_str': 'Speaking'}, {'cui': 'C0376245', 'cui_str': 'English language'}]","[{'cui': 'C1322815', 'cui_str': 'Drug eluting stent'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}]","[{'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",,0.112566,"However, there was no significant difference in platelet suppression or medication adherence between groups.","[{'ForeName': 'Andrew Dallas', 'Initials': 'AD', 'LastName': 'Boyd', 'Affiliation': 'Department of Biomedical and Health Information Science, University of Illinois at Chicago, Chicago, United States.'}, {'ForeName': 'Chioma Iheanyi', 'Initials': 'CI', 'LastName': 'Ndukwe', 'Affiliation': 'Department of Biomedical and Health Information Science, University of Illinois at Chicago, Chicago, United States.'}, {'ForeName': 'Anandu', 'Initials': 'A', 'LastName': 'Dileep', 'Affiliation': 'Department of Biomedical and Health Information Science, University of Illinois at Chicago, Chicago, United States.'}, {'ForeName': 'Olivia Frances', 'Initials': 'OF', 'LastName': 'Everin', 'Affiliation': 'Department of Biomedical and Health Information Science, University of Illinois at Chicago, Chicago, United States.'}, {'ForeName': 'Yingwei', 'Initials': 'Y', 'LastName': 'Yao', 'Affiliation': 'Biobehavioral Nursing Science, University of Florida, Gainesville, FL, United States.'}, {'ForeName': 'Betty', 'Initials': 'B', 'LastName': 'Welland', 'Affiliation': 'Patient Advisor, Department of Biomedical and Health Information Sciences, University of Illinois at Chicago, Chicago, IL, United States.'}, {'ForeName': 'Jerry', 'Initials': 'J', 'LastName': 'Field', 'Affiliation': 'Patient Advisor, Department of Biomedical and Health Information Sciences, University of Illinois at Chicago, Chicago, IL, United States.'}, {'ForeName': 'Matt', 'Initials': 'M', 'LastName': 'Baumann', 'Affiliation': 'Patient Advisor, Department of Biomedical and Health Information Sciences, University of Illinois at Chicago, Chicago, IL, United States.'}, {'ForeName': 'Jose D', 'Initials': 'JD', 'LastName': 'Flores', 'Affiliation': 'Patient Advisor, Department of Biomedical and Health Information Sciences, University of Illinois at Chicago, Chicago, IL, United States.'}, {'ForeName': 'Adhir', 'Initials': 'A', 'LastName': 'Shroff', 'Affiliation': 'Department of Biomedical and Health Information Science, University of Illinois at Chicago, Chicago, United States.'}, {'ForeName': 'Vicki', 'Initials': 'V', 'LastName': 'Groo', 'Affiliation': 'Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, United States.'}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Dickens', 'Affiliation': 'Department of Biomedical and Health Information Science, University of Illinois at Chicago, Chicago, United States.'}, {'ForeName': 'Rami', 'Initials': 'R', 'LastName': 'Doukky', 'Affiliation': 'Divison of Cardiology, Cook County Health, Chicago, IL, United States.'}, {'ForeName': 'Regeena', 'Initials': 'R', 'LastName': 'Francis', 'Affiliation': 'Divison of Cardiology, Cook County Health, Chicago, IL, United States.'}, {'ForeName': 'Geraldine', 'Initials': 'G', 'LastName': 'Peacock', 'Affiliation': 'Divison of Cardiology, Cook County Health, Chicago, IL, United States.'}, {'ForeName': 'Diana J', 'Initials': 'DJ', 'LastName': 'Wilkie', 'Affiliation': 'Biobehavioral Nursing Science, University of Florida, Gainesville, FL, United States.'}]",JMIR mHealth and uHealth,['10.2196/15900'] 1312,32576004,Application of an education model using the WeChat public platform in the standardized training of anesthesiology residents.,"BACKGROUND Standardized training of clinical residents is an important way to train high-level clinicians and is an important step to ensure quality clinical work. WeChat facilitates efficient information dissemination and feedback, convenient communication. In the new media era, the influence of WeChat has inspired changes in educational methods, to explore the role of an education model using the WeChat public platform in the standardized training of anesthesiology residents. METHODS A total of 40 anesthesiology residents undergoing standardized training in our department from January 2016 to August 2017 were selected as subjects and randomly divided into 2 groups: traditional group (n=20) and WeChat group (n=20). In the WeChat group, in addition to the traditional clinical teaching model (lectures), the residents also received push information from the WeChat public platform for anesthesia education. The residents in the traditional group did not receive the push information and only received traditional clinical teaching. Three months later, assessment scores of and teaching quality in the 2 groups were evaluated. Teaching quality was evaluated using peer assessment and self-assessment questionnaires. RESULTS Residents in the WeChat group performed significantly better on assessments than those in traditional group regarding theoretical knowledge of anesthesiology, understanding mechanisms, operation ability, current knowledge, case analyses and use of professional English (P<0.05). The questionnaire results indicated that the degree of satisfaction of the residents and teachers in the WeChat group was significantly higher than that in the traditional group (P<0.05). The theoretical knowledge scores, operational skill scores and overall scores in the WeChat group were significantly higher than those in the traditional group (P<0.05). CONCLUSIONS Applying an education model based on the WeChat public platform in standardized training of anesthesiology residents can significantly improve teaching efficacy and satisfaction, enhance comprehensive assessment results, and improve teaching quality.",2020,"RESULTS Residents in the WeChat group performed significantly better on assessments than those in traditional group regarding theoretical knowledge of anesthesiology, understanding mechanisms, operation ability, current knowledge, case analyses and use of professional English (P<0.05).","['40 anesthesiology residents undergoing standardized training in our department from January 2016 to August 2017', 'anesthesiology residents']","['push information and only received traditional clinical teaching', 'WeChat']","['teaching quality', 'theoretical knowledge scores, operational skill scores and overall scores', 'Teaching quality', 'teaching efficacy and satisfaction', 'assessment scores of and teaching quality', 'theoretical knowledge of anesthesiology, understanding mechanisms, operation ability, current knowledge, case analyses and use of professional English']","[{'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0580841', 'cui_str': 'Does push'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0039401', 'cui_str': 'Education'}]","[{'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0376245', 'cui_str': 'English language'}]",,0.0113754,"RESULTS Residents in the WeChat group performed significantly better on assessments than those in traditional group regarding theoretical knowledge of anesthesiology, understanding mechanisms, operation ability, current knowledge, case analyses and use of professional English (P<0.05).","[{'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Department of Anesthesiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Guanghui', 'Initials': 'G', 'LastName': 'An', 'Affiliation': 'Department of Anesthesiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Shan', 'Initials': 'S', 'LastName': 'You', 'Affiliation': 'Department of Anesthesiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Shiwei', 'Initials': 'S', 'LastName': 'Huang', 'Affiliation': 'Department of Anesthesiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Jinbao', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. lijinbaoshanghai@163.com.'}]",Annals of palliative medicine,['10.21037/apm-19-390'] 1313,32540553,Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM).,"BACKGROUND The combination of chemotherapy plus anti HER-2 agents is the mainstay of HER-2 positive advanced breast cancer (ABC) therapy. We conducted a phase II trial testing activity and safety of trastuzumab and metronomic capecitabine/cyclophosphamide (HEX) as first-line therapy in HER-2 positive ABC.
Methods. Patients at first relapse or with synchronous metastasis were treated with trastuzumab (4 mg/kg, biweekly) plus oral capecitabine (1500 mg/daily) and cyclophosphamide (50 mg/daily). Primary endpoint was objective response rate (ORR), secondary endpoints progression-free survival (PFS), clinical benefit rate (CBR; PR + CR + SD for ≥ 24 weeks) and tolerability. Optimal two-stage design was applied. RESULTS Sixty patients with measurable ABC, tumors scored as +3 for HER-2 or FISH +, untreated for advanced disease were enrolled. Median age was 62.5 years, visceral metastases were present in most patients (57.9%). Median number of cycles was 16 (range 1-98). ORR was 56.7% (95% CI, 44.1-68.4%), with 5 CR (8.3%) and 29 PR (48.3%). Fifteen patients had SD (25%). The CBR was 78.2%. Nine progressions were observed (15%). Median PFS was 11 months. One year PFS was 47.7%. Median OS was 45.9 months. Worst toxicities were grade 3 hand-foot syndrome in 2 pts (3.3%), grade 3 anaemia in 2 pts (3.3%), grade 2 nausea in 2 pts (3.3%) and grade 3-4 diarrhea in 2 pts (3.3%). Cardiac toxicity grade 1 was reported in 1 pt. CONCLUSIONS Combination of trastuzumab and metronomic oral chemotherapy has clinical activity. The tolerability was excellent and allowed the prolonged delivery of treatment.",2020,"ORR was 56.7% (95% CI, 44.1-68.4%), with 5 CR (8.3%) and 29 PR (48.3%).","['Patients at first relapse or with synchronous metastasis', 'HER-2 positive advanced breast cancer', 'HER-2 positive advanced breast cancer (ABC) therapy', 'Sixty patients with measurable ABC, tumors scored as\xa0+3 for HER-2 or FISH\xa0+, untreated for advanced disease were enrolled', 'Fifteen patients had SD (25']","['trastuzumab', 'cyclophosphamide', 'chemotherapy plus anti HER-2 agents', 'trastuzumab and metronomic capecitabine/cyclophosphamide (HEX', 'trastuzumab and metronomic oral chemotherapy', 'oral capecitabine', 'Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX']","['Median PFS', 'grade 2 nausea', 'Median OS', 'Worst toxicities', 'grade 3 anaemia', 'ORR', 'objective response rate (ORR), secondary endpoints progression-free survival (PFS), clinical benefit rate (CBR; PR\xa0+\xa0CR\xa0+\xa0SD for\xa0≥\xa024 weeks) and tolerability', 'Cardiac toxicity grade 1', 'tolerability', 'Median number of cycles', 'visceral metastases', 'grade 3-4 diarrhea']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0439580', 'cui_str': 'Synchronous'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}]","[{'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0419073', 'cui_str': 'Oral chemotherapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0475270', 'cui_str': 'G2 grade'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0876994', 'cui_str': 'Cardiotoxicity'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",9.0,0.0480206,"ORR was 56.7% (95% CI, 44.1-68.4%), with 5 CR (8.3%) and 29 PR (48.3%).","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Orlando', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy. Electronic address: laura.orlando68@gmail.com.'}, {'ForeName': 'Vito', 'Initials': 'V', 'LastName': 'Lorusso', 'Affiliation': 'Medical Oncology, Istituto Tumori Giovanni Paolo II, IRCCS, Bari, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Giotta', 'Affiliation': 'Medical Oncology, Istituto Tumori Giovanni Paolo II, IRCCS, Bari, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Di Maio', 'Affiliation': 'Department of Oncology, University of Turin at Ordine Mauriziano Hospital, Turin, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Schiavone', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Palma', 'Initials': 'P', 'LastName': 'Fedele', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Annamaria', 'Initials': 'A', 'LastName': 'Quaranta', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Caliolo', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Mariangela', 'Initials': 'M', 'LastName': 'Ciccarese', 'Affiliation': 'Medical Oncology, Ospedale Vito Fazzi, Lecce, Italy.'}, {'ForeName': 'Margherita', 'Initials': 'M', 'LastName': 'Cinefra', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Sante', 'Initials': 'S', 'LastName': 'Romito', 'Affiliation': 'Medical Oncology, Ospedali Riuniti, Foggia, Italy.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Pisconti', 'Affiliation': 'Medical Oncology, Ospedale Moscato, Taranto, Italy.'}, {'ForeName': 'Salvatore Del', 'Initials': 'SD', 'LastName': 'Prete', 'Affiliation': 'Medical Oncology, Ospedale San Giovanni di Dio, Frattamaggiore, Napoli, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Aieta', 'Affiliation': 'Medical Oncology, Ospedale Oncologico Regionale, Rionero in Vulture, Potenza, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Rizzi', 'Affiliation': 'Medical Oncology, Istituto Tumori Giovanni Paolo II, IRCCS, Bari, Italy.'}, {'ForeName': 'Evaristo', 'Initials': 'E', 'LastName': 'Maiello', 'Affiliation': 'Medical Oncology, Ospedale Sollievo Della Sofferenza, IRCCS, San Giovanni Rotondo, Foggia, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Colucci', 'Affiliation': 'Medical Oncology, Istituto Tumori Giovanni Paolo II, IRCCS, Bari, Italy.'}, {'ForeName': 'Saverio', 'Initials': 'S', 'LastName': 'Cinieri', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2020.06.002'] 1314,32540588,Deep transcranial magnetic stimulation for obsessive-compulsive disorder is efficacious even in patients who failed multiple medications and CBT.,"OCD is a chronic and disabling disease with a lifetime prevalence of 2%-3%. About 40-60% of these patients do not adequately respond to pharmacotherapy and CBT. Deep transcranial magnetic stimulation (dTMS) was shown to be safe and effective as a treatment alternative for OCD and recently received regulatory approvals. Yet it is unclear whether patients who failed numerous medications and/or CBT can still benefit from dTMS. Here, we analyzed recent data from a double-blind multicenter dTMS study and found efficacy of this novel treatment even in OCD patient cohorts who previously failed to respond to multiple medications and CBT.",2020,Deep transcranial magnetic stimulation (dTMS) was shown to be safe and effective as a treatment alternative for OCD and recently received regulatory approvals.,"['OCD patient cohorts who previously failed to respond to multiple medications and CBT', 'patients who failed multiple medications and CBT']","['OCD', 'Deep transcranial magnetic stimulation', 'Deep transcranial magnetic stimulation (dTMS']",[],"[{'cui': 'C0009595', 'cui_str': 'Obsessive compulsive personality disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0009595', 'cui_str': 'Obsessive compulsive personality disorder'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}]",[],,0.0274375,Deep transcranial magnetic stimulation (dTMS) was shown to be safe and effective as a treatment alternative for OCD and recently received regulatory approvals.,"[{'ForeName': 'Yiftach', 'Initials': 'Y', 'LastName': 'Roth', 'Affiliation': 'The Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel.'}, {'ForeName': 'Noam', 'Initials': 'N', 'LastName': 'Barnea-Ygael', 'Affiliation': 'The Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel.'}, {'ForeName': 'Lior', 'Initials': 'L', 'LastName': 'Carmi', 'Affiliation': 'Chaim Sheba Medical Center, Ramat Gan, Israel.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Storch', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, TX, USA.'}, {'ForeName': 'Aron', 'Initials': 'A', 'LastName': 'Tendler', 'Affiliation': 'Advanced Mental Health Care, Inc., Palm Beach, FL, USA.'}, {'ForeName': 'Abraham', 'Initials': 'A', 'LastName': 'Zangen', 'Affiliation': 'The Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel. Electronic address: azangen@bgu.ac.il.'}]",Psychiatry research,['10.1016/j.psychres.2020.113179'] 1315,32540624,Effects of night-time bicycling visibility aids on vehicle passing distance.,"Bicycling at night is dangerous, with vehicle passing distances being a key concern, given that the main cause of night-time bicycling fatalities is from motorists hitting bicyclists from behind. However, little is known about vehicle passing distances at night or how they are affected by bicyclist visibility. This study assessed the impact of different bicyclist visibility configurations on vehicle passing distances at night-time. Fourteen licenced drivers with normal vision (age 24.2 ± 3.7 years) drove an experimental vehicle with low-beam headlights around a 1-km section of a closed-road circuit at night. Each lap involved passing two bicyclists displaying one of four visibility configurations: Control (red rear-facing light and reflector), Handlebars (control plus two red rear-facing lights on each handlebar), Helmet (control plus one red rear-facing light on the helmet), and Leg Retro-reflectors (control plus retro-reflective strips positioned on the knees and ankles). Participants were instructed to pass each bicyclist at a distance of 1-metre at a speed no greater than 50 km/hr, consistent with Queensland's Minimum Passing Distance rule. Participants completed eight laps, two for each configuration, in a randomised sequence. Passing distance was measured using a vehicle-mounted ultra-sonic sensor (ToughSonic14; Senix). Following each lap, participants rated the difficulty level in judging the 1-metre passing distance, as well as their estimated passing distance. Visibility configuration significantly affected passing distance (p = 0.001), with wider passing distances for the Handlebar configuration (1.54 ± 0.62 m), followed by the Helmet (1.51 ± 0.63 m), Leg Retro-reflectors (1.50 ± 0.62 m) which were all significantly greater than the Control (1.42 ± 0.57 m), but not significantly different from each other. There was also a significant effect of visibility configuration on difficulty rating (p = 0.035), with the Control rated as the most difficult, followed by Helmet, Handlebars and Leg Retro-reflectors. Overall, additional visibility aids resulted in wider vehicle passing distances, likely due to enhanced visual cues for drivers. The findings suggest that bicyclists should incorporate additional visibility aids to encourage safer passing distances of vehicles at night-time.",2020,"Visibility configuration significantly affected passing distance (p = 0.001), with wider passing distances for the Handlebar configuration (1.54 ± 0.62 m), followed by the Helmet (1.51 ± 0.63 m), Leg Retro-reflectors (1.50 ± 0.62 m) which were all significantly greater than the Control (1.42 ± 0.57 m), but not significantly different from each other.",['Fourteen licenced drivers with normal vision (age 24.2\u202f±\u202f3.7 years) drove an experimental vehicle with low-beam headlights around a 1-km section of a closed-road circuit at night'],"['visibility configurations: Control (red rear-facing light and reflector), Handlebars (control plus two red rear-facing lights on each handlebar), Helmet (control plus one red rear-facing light on the helmet), and Leg Retro-reflectors (control plus retro-reflective strips positioned on the knees and ankles', 'night-time bicycling visibility aids']","['visibility configuration on difficulty rating', 'Leg Retro-reflectors']","[{'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0684312', 'cui_str': 'Vehicle driver'}, {'cui': 'C0234622', 'cui_str': 'Normal vision'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517696', 'cui_str': '3.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0442650', 'cui_str': 'Road'}, {'cui': 'C0240526', 'cui_str': 'Night time'}]","[{'cui': 'C0449830', 'cui_str': 'With configuration'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332575', 'cui_str': 'Red color'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0018884', 'cui_str': 'Helmet'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0185047', 'cui_str': 'Stripping'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0005375', 'cui_str': 'Bicycle'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}]","[{'cui': 'C0449830', 'cui_str': 'With configuration'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}]",,0.0635457,"Visibility configuration significantly affected passing distance (p = 0.001), with wider passing distances for the Handlebar configuration (1.54 ± 0.62 m), followed by the Helmet (1.51 ± 0.63 m), Leg Retro-reflectors (1.50 ± 0.62 m) which were all significantly greater than the Control (1.42 ± 0.57 m), but not significantly different from each other.","[{'ForeName': 'Alex A', 'Initials': 'AA', 'LastName': 'Black', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia. Electronic address: aa.black@qut.edu.au.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Duff', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Madeline', 'Initials': 'M', 'LastName': 'Hutchinson', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Ng', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Kirby', 'Initials': 'K', 'LastName': 'Phillips', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Katelyn', 'Initials': 'K', 'LastName': 'Rose', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Abby', 'Initials': 'A', 'LastName': 'Ussher', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Joanne M', 'Initials': 'JM', 'LastName': 'Wood', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}]",Accident; analysis and prevention,['10.1016/j.aap.2020.105636'] 1316,32537643,Effects of a modestly lower carbohydrate diet in gestational diabetes: a randomized controlled trial.,"BACKGROUND Lower carbohydrate diets have the potential to improve glycemia but may increase ketonemia in women with gestational diabetes (GDM). We hypothesized that modestly lower carbohydrate intake would not increase ketonemia. OBJECTIVE To compare blood ketone concentration, risk of ketonemia, and pregnancy outcomes in women with GDM randomly assigned to a lower carbohydrate diet or routine care. METHODS Forty-six women aged (mean ± SEM) 33.3 ± 0.6 y and prepregnancy BMI 26.8 ± 0.9 kg/m2 were randomly assigned at 28.5 ± 0.4 wk to a modestly lower carbohydrate diet (MLC, ∼135 g/d carbohydrate) or routine care (RC, ∼200 g/d) for 6 wk. Blood ketones were ascertained by finger prick test strips and 3-d food diaries were collected at baseline and end of the intervention. RESULTS There were no detectable differences in blood ketones between completers in the MLC group compared with the RC group (0.1 ± 0.0 compared with 0.1 ± 0.0 mmol/L, n = 33, P = 0.31, respectively), even though carbohydrate and total energy intake were significantly lower in the intervention group (carbohydrate 165 ± 7 compared with 190 ± 9 g, P = 0.04; energy 7040 ± 240 compared with 8230 ± 320 kJ, P <0.01, respectively). Only 20% of participants in the MLC group met the target intake compared with 65% in the RC group (P <0.01). There were no differences in birth weight, rate of large-for-gestational-age infants, percent fat mass, or fat-free mass between groups. CONCLUSIONS An intervention to reduce carbohydrate intake in GDM did not raise ketones to clinical significance, possibly because the target of 135 g/d was difficult to achieve in pregnancy. Feeding studies with food provision may be needed to assess the benefits and risks of low-carbohydrate diets. This trial was registered at www.anzctr.org.au as ACTRN12616000018415.",2020,"There were no differences in birth weight, rate of large-for-gestational-age infants, percent fat mass, or fat-free mass between groups. ","['Forty-six women aged (mean\xa0±\xa0SEM) 33.3\xa0±\xa00.6 y and prepregnancy', 'gestational diabetes', 'women with gestational diabetes (GDM', 'women with GDM randomly assigned to a']","['MLC', 'lower carbohydrate diet or routine care', 'modestly lower carbohydrate diet']","['Blood ketones', 'blood ketones', 'blood ketone concentration, risk of ketonemia, and pregnancy outcomes', 'carbohydrate and total energy intake', 'target intake', 'birth weight, rate of large']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0262878', 'cui_str': 'Scanning electron microscope'}, {'cui': 'C4517716', 'cui_str': '33.3'}, {'cui': 'C4068883', 'cui_str': '0.6'}, {'cui': 'C0439671', 'cui_str': 'Gestational'}, {'cui': 'C0085207', 'cui_str': 'Gestational diabetes mellitus'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]","[{'cui': 'C0259836', 'cui_str': 'Carbohydrate restricted diet'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022634', 'cui_str': 'Ketone'}, {'cui': 'C0427750', 'cui_str': 'Ketone concentration, test strip measurement'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0235430', 'cui_str': 'Ketonemia'}, {'cui': 'C0032972', 'cui_str': 'Outcomes, Pregnancy'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C0549177', 'cui_str': 'Large'}]",46.0,0.19441,"There were no differences in birth weight, rate of large-for-gestational-age infants, percent fat mass, or fat-free mass between groups. ","[{'ForeName': 'Jovana', 'Initials': 'J', 'LastName': 'Mijatovic', 'Affiliation': 'School of Life and Environmental Sciences, The University of Sydney, Sydney, Australia.'}, {'ForeName': 'Jimmy Chun Yu', 'Initials': 'JCY', 'LastName': 'Louie', 'Affiliation': 'School of Biological Sciences, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Marion E C', 'Initials': 'MEC', 'LastName': 'Buso', 'Affiliation': 'Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands.'}, {'ForeName': 'Fiona S', 'Initials': 'FS', 'LastName': 'Atkinson', 'Affiliation': 'School of Life and Environmental Sciences, The University of Sydney, Sydney, Australia.'}, {'ForeName': 'Glynis P', 'Initials': 'GP', 'LastName': 'Ross', 'Affiliation': 'Boden Collaboration Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.'}, {'ForeName': 'Tania P', 'Initials': 'TP', 'LastName': 'Markovic', 'Affiliation': 'Boden Collaboration Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.'}, {'ForeName': 'Jennie C', 'Initials': 'JC', 'LastName': 'Brand-Miller', 'Affiliation': 'School of Life and Environmental Sciences, The University of Sydney, Sydney, Australia.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqaa137'] 1317,32682994,Time limited eating in adolescents with obesity (time LEAd): Study protocol.,"BACKGROUND Time limited eating (TLE) has been shown to be effective for weight loss and improvement of glycemic control in adults with obesity and type 2 diabetes (T2D), but has not been well studied in adolescents. TLE may be a more feasible, flexible and effective dietary intervention for adolescents because it removes the need for intensive counting of calories or macronutrients, and emphasizes eating during a specified time period. OBJECTIVES The aim of this study is to assess the feasibility of a TLE approach in adolescents with obesity using a continuous glucose monitor (CGM) to promote adherence to the intervention. METHODS We propose a prospective, randomized controlled trial, in 60 adolescents (ages 14-18) with obesity (BMI% ≥ 95th percentile). Youth will be randomized to one of three treatment groups for a 12-week intervention: Group 1) Low sugar and carbohydrate education (LSC, 5% of total daily calories from sugar (<35 g)/day; <90 g carbohydrate (CHO)/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback), Group 2) LSC + TLE (16-h fast/8-h feed for 5 days per week) + blinded CGM, and Group 3) LSC + TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy). Outcomes will include change in total body fat (TBF) percentage measured on DEXA scan, BMI status and fasting blood glucose at 12 weeks compared to baseline. CONCLUSIONS TLE is a potentially powerful lifestyle intervention that could be readily integrated into pediatric weight management programs to optimize their impact and accelerate healthy changes. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT03954223.",2020,"TLE may be a more feasible, flexible and effective dietary intervention for adolescents because it removes the need for intensive counting of calories or macronutrients, and emphasizes eating during a specified time period. ","['60 adolescents (ages 14-18) with obesity (BMI%\u202f≥\u202f95th percentile', 'adolescents with obesity (time LEAd', 'adolescents with obesity using a', 'adults with obesity and type 2 diabetes (T2D']","['TLE approach', 'LSC\u202f+\u202fTLE', 'TLE', 'Low sugar and carbohydrate education (LSC, 5% of total daily calories from sugar (<35\u202fg)/day; <90\u202fg carbohydrate (CHO)/day)\u202f+\u202fblinded CGM', 'continuous glucose monitor (CGM']","['total body fat (TBF) percentage measured on DEXA scan, BMI status and fasting blood glucose']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0332186', 'cui_str': 'Definite time'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0439175', 'cui_str': '% of total'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0439087', 'cui_str': '<90'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C4523945', 'cui_str': 'Continuous glucose monitoring'}]","[{'cui': 'C0424677', 'cui_str': 'Total body fat'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}]",,0.0740017,"TLE may be a more feasible, flexible and effective dietary intervention for adolescents because it removes the need for intensive counting of calories or macronutrients, and emphasizes eating during a specified time period. ","[{'ForeName': 'Alaina P', 'Initials': 'AP', 'LastName': 'Vidmar', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America. Electronic address: avidmar@chla.usc.edu.""}, {'ForeName': 'Michael I', 'Initials': 'MI', 'LastName': 'Goran', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Naguib', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Cassandra', 'Initials': 'C', 'LastName': 'Fink', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Choo Phei', 'Initials': 'CP', 'LastName': 'Wee', 'Affiliation': 'CTSI Biostatics Core, Saban Research Institute, Los Angeles, CA, United States of America.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Hegedus', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Kelleen', 'Initials': 'K', 'LastName': 'Lopez', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Janelle', 'Initials': 'J', 'LastName': 'Gonzalez', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Jennifer K', 'Initials': 'JK', 'LastName': 'Raymond', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}]",Contemporary clinical trials,['10.1016/j.cct.2020.106082'] 1318,32557838,The Motor skills At Playtime intervention improves children's locomotor skills: A feasibility study.,"BACKGROUND Interventions are needed to teach fundamental motor skills (FMS) to preschoolers. There is a need to design more practical and effective interventions that can be successfully implemented by non-motor experts and fit within the existing gross motor opportunities such as outdoor free play at the preschool. The purpose of this study was to evaluate the feasibility and efficacy of a non-motor expert FMS intervention that was implemented during outdoor free play, Motor skills At Playtime (MAP). METHODS Participants were preschoolers from two Head Start centres (N = 46; M age = 4.7 ± 0.46 years; 41% boys) and were divided into a MAP (n = 30) or control (outdoor free play; n = 16) group. Children completed either a 1,350-min MAP intervention or control condition (outdoor free play) from January to April of 2018. FMS were assessed before and after each programme using both the Test of Gross Motor Development-3rd Edition and skill outcome measures (running speed, hopping speed, jump distance, throwing speed, kicking speed and catching percentage). Intervention implementation feasibility was measured through daily fidelity checks. Fidelity was evaluated as the percentage of intervention sessions that included all explicit intervention criteria. FMS data were analysed using linear mixed modelling. Models were fit with fixed effects of time and treatment, covariates of sex and height, and a random intercept for each individual. RESULTS The non-motor expert was feasibly able to implement MAP with high fidelity (>93%). There was a significant treatment effect for MAP on process and product locomotor FMS (P < 0.05) and a trend for a treatment effect for MAP on total process FMS (P = 0.07). CONCLUSION Results support that MAP was successfully implemented by a non-motor expert and led to improvements in children's FMS, especially locomotor FMS.",2020,"There was a significant treatment effect for MAP on process and product locomotor FMS (p< 0.05), and a trend for a treatment effect for MAP on total process FMS (p = 0.07). ",['Participants were preschoolers from two Head Start Centers (N = 46; M age = 4.7 ± 0.46 years; 41% boys) and were divided into a MAP (n = 30) or control (outdoor free play; n = 16) group'],"['non-motor expert FMS intervention', '1350-minute MAP intervention or control condition (outdoor free play', 'Playtime intervention']","['outdoor free play, Motor skills', ""children's locomotor skills"", 'MAP on process and product locomotor FMS', 'Gross Motor Development-3 rd Edition (Ulrich, 2019) and skill outcome measures (running speed, hopping speed, jump distance, throwing speed, kicking speed, and catching percentage', 'feasibility and efficacy', 'FMS', 'Motor skills']","[{'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517460', 'cui_str': '0.46'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0026612', 'cui_str': 'Motor Skills'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0026612', 'cui_str': 'Motor Skills'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4517567', 'cui_str': '1350'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0032214', 'cui_str': 'Play'}]","[{'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0026612', 'cui_str': 'Motor Skills'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0439806', 'cui_str': 'Gross'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0441792', 'cui_str': 'Editions'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0078040', 'cui_str': 'VAP protocol'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0231617', 'cui_str': 'Catch'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.0124364,"There was a significant treatment effect for MAP on process and product locomotor FMS (p< 0.05), and a trend for a treatment effect for MAP on total process FMS (p = 0.07). ","[{'ForeName': 'Kara K', 'Initials': 'KK', 'LastName': 'Palmer', 'Affiliation': 'School of Kinesiology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Alison L', 'Initials': 'AL', 'LastName': 'Miller', 'Affiliation': 'School of Public Health, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Sean K', 'Initials': 'SK', 'LastName': 'Meehan', 'Affiliation': 'Department of Kinesiology, University of Waterloo, Waterloo, Ontario, Canada.'}, {'ForeName': 'Leah E', 'Initials': 'LE', 'LastName': 'Robinson', 'Affiliation': 'School of Kinesiology, University of Michigan, Ann Arbor, MI, USA.'}]","Child: care, health and development",['10.1111/cch.12793'] 1319,32552207,"Re: Long-Term Oncological Outcomes from an Early Phase Randomised Controlled Three-Arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).",,2020,,[],"['Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL']",[],[],"[{'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0194401', 'cui_str': 'Complete cystectomy'}, {'cui': 'C0324034', 'cui_str': 'Coral'}]",[],,0.0947995,,"[{'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Cadeddu', 'Affiliation': ''}]",The Journal of urology,['10.1097/JU.0000000000001166'] 1320,32550738,Comparison of pain and proper sample status according to usage of tenaculum and analgesia: a randomized clinical trial.,"OBJECTIVE Colposcopic biopsy is a discomfortable procedure. Additionally, it creates negative influence on sexuality. This study aimed to investigate the relationships among tenaculum, pain perception, and biopsy size during colposcopy. METHODS In total, 228 patients who underwent colposcopy-directed biopsy were included, and randomized into 4 groups based on whether analgesic and tenaculum were used and replaced (tenaculum with n=58/without analgesic n=56, no tenaculum replacement with n=57/without analgesic n=57). Lidocaine hydrochloride (40 mg) plus adrenaline (0.025 mg) was administered in the analgesic groups. The pain was assessed using a linear visual analog scale. The biopsy specimen size was measured in millimeters. RESULTS The mean age of the patients was 42.85±8.88 years. The most frequent colposcopy indications were atypical squamous cells of undetermined significance and human papilloma virus-positive results on cervical cytology (30.2%; n=69). Low- and high-grade intraepithelial lesions were noted in 14.91% (n=34) and 10.96% (n=25) women through colposcopy-directed biopsy results, respectively. Tenaculum replacement increased pain perception in the without analgesic group; however, no statistically significant differences were noted between of the groups with and without tenaculum replacement with analgesic. The size and number of biopsy specimens were not associated with tenaculum replacement and analgesic use. CONCLUSION Administration of analgesics decreased discomfort and pain in patients. Tenaculum replacement aided colposcopists in manipulating the cervix. Additionally, administration of analgesics relieved pain in the tenaculum replacement group. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT03279666.",2020,"Tenaculum replacement increased pain perception in the without analgesic group; however, no statistically significant differences were noted between of the groups with and without tenaculum replacement with analgesic.","['228 patients who underwent colposcopy-directed biopsy', 'patients']","['adrenaline', 'tenaculum and analgesia', 'Lidocaine hydrochloride', 'analgesic and tenaculum were used and replaced (tenaculum with n=58/without analgesic n=56, no tenaculum replacement with n=57/without analgesic n=57']","['Low- and high-grade intraepithelial lesions', 'biopsy specimen size', 'sexuality', 'cervical cytology', 'discomfort and pain', 'pain', 'pain perception']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009417', 'cui_str': 'Colposcopy'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}]","[{'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0180964', 'cui_str': 'Tenaculum'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0546869', 'cui_str': 'Lidocaine hydrochloride'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0559956', 'cui_str': 'Replacement - action'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0856201', 'cui_str': 'Cervical cytology'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}]",228.0,0.0996657,"Tenaculum replacement increased pain perception in the without analgesic group; however, no statistically significant differences were noted between of the groups with and without tenaculum replacement with analgesic.","[{'ForeName': 'Cihan', 'Initials': 'C', 'LastName': 'Comba', 'Affiliation': 'Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of Health Sciences, Sultangazi Haseki Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Gökhan', 'Initials': 'G', 'LastName': 'Demirayak', 'Affiliation': 'Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Sakir Volkan', 'Initials': 'SV', 'LastName': 'Erdogan', 'Affiliation': 'Department of Gynecology and Obstetrics, University of Health Sciences, Bagcilar Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Karaca', 'Affiliation': 'Department of Gynecology and Obstetrics, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey.'}, {'ForeName': 'Omer', 'Initials': 'O', 'LastName': 'Demir', 'Affiliation': 'Department of Gynecology and Obstetrics, Karadeniz Technical University, Trabzon, Turkey.'}, {'ForeName': 'Oguz', 'Initials': 'O', 'LastName': 'Guler', 'Affiliation': 'Department of Gynecology and Obstetrics, Kucukkoy Bilge Hospital, Istanbul, Turkey.'}, {'ForeName': 'Isa Aykut', 'Initials': 'IA', 'LastName': 'Ozdemir', 'Affiliation': 'Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Medipol University Mega Hospital, Istanbul, Turkey.'}]",Obstetrics & gynecology science,['10.5468/ogs.19185'] 1321,32551827,"An Evaluation of Yoga and Meditation to Improve Attention, Hyperactivity, and Stress in High-School Students.","Objective: Problems with attention and stress are common in children and predict academic difficulties and other behavioral and emotional problems. Mind-body interventions such as yoga and meditation improve attention and reduce stress. In this study, we examined the impact of Hatha yoga on attention and stress in ninth graders. Design: A total of 174 ninth graders from a Texas high school were enrolled in the study. Teachers assigned students to a yoga group (YG) or control group (CG) based on their class schedule. The YG participated in 25-min Hatha yoga classes twice weekly over 12 weeks ( n  = 123). The CG included 51 students. Student self-reports on measures of inattention and hyperactivity (the strengths and weaknesses of ADHD [attention-deficit/hyperactivity disorder] symptoms and normal behavior rating scale for ADHD) and stress (perceived stress scale) were obtained at baseline and at 12 weeks. Results: There were no significant differences in baseline levels of inattention ( p  = 0.86), hyperactivity ( p  = 0.25), and perceived stress ( p  = 0.28) between the YG and CG. Regarding inattention scores, there was a significant interaction of group and time ( b  = -1.09, standard error [SE] = 0.30, p  < 0.001). Pairwise t -tests showed a significant reduction in inattention for the YG ( d  = 0.27) but a significant increase in inattention for the CG. Regarding hyperactivity, there was no significant interaction of group and time ( b  = -0.43, SE = 0.26, p  = 0.1). Pairwise t -tests demonstrated a significant reduction in hyperactivity for the YG ( d  = 0.22), but not the CG. The interaction of group and time was not significant in predicting the slope of change in perceived distress ( b  = -0.93, SE = 1.19, p  = 0.43). Pairwise t -tests did not show a significant reduction in perceived distress for either group. Conclusion: These findings suggest that Hatha yoga may improve attention and hyperactivity in high school students.",2020,t -tests showed a significant reduction in inattention for the YG ( d  = 0.27) but a significant increase in inattention for the CG.,"['High-School Students', 'high school students', 'ninth graders', 'A total of 174 ninth graders from a Texas high school were enrolled in the study']","['Hatha yoga', 'Yoga and Meditation', 'yoga group (YG) or control group (CG) based on their class schedule']","['Attention, Hyperactivity, and Stress', 'hyperactivity', 'attention and hyperactivity', 'inattention', 'perceived distress', 'inattention and hyperactivity (the strengths and weaknesses of ADHD [attention-deficit/hyperactivity disorder] symptoms and normal behavior rating scale for ADHD) and stress (perceived stress scale', 'slope of change in perceived distress', 'baseline levels of inattention']","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205443', 'cui_str': 'Ninth'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0039711', 'cui_str': 'Texas'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0424295', 'cui_str': 'Hyperactive behavior'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0424101', 'cui_str': 'Inattention'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C3714552', 'cui_str': 'Debility'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0233512', 'cui_str': 'Normal behavior'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0582653', 'cui_str': 'Perceived stress scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",174.0,0.0385015,t -tests showed a significant reduction in inattention for the YG ( d  = 0.27) but a significant increase in inattention for the CG.,"[{'ForeName': 'Kirti', 'Initials': 'K', 'LastName': 'Saxena', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Christopher D', 'Initials': 'CD', 'LastName': 'Verrico', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Saxena', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Sherin', 'Initials': 'S', 'LastName': 'Kurian', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Alexander', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Ramandeep Singh', 'Initials': 'RS', 'LastName': 'Kahlon', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Ruchir P', 'Initials': 'RP', 'LastName': 'Arvind', 'Affiliation': 'Department of Psychiatry, University of Texas Health-McGovern Medical School, Houston, TX, USA.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Goldberg', 'Affiliation': 'Department of Psychiatry, University of Texas Health-McGovern Medical School, Houston, TX, USA.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'DeVito', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Mirza', 'Initials': 'M', 'LastName': 'Baig', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Anastasia', 'Initials': 'A', 'LastName': 'Grieb', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Jafar', 'Initials': 'J', 'LastName': 'Bakhshaie', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Alessio', 'Initials': 'A', 'LastName': 'Simonetti', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Storch', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Laurel', 'Initials': 'L', 'LastName': 'Williams', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Lex', 'Initials': 'L', 'LastName': 'Gillan', 'Affiliation': 'Institute for Spirituality and Health, Houston, TX, USA.'}]","Journal of alternative and complementary medicine (New York, N.Y.)",['10.1089/acm.2020.0126'] 1322,32555047,"Effect of NSAID Use on Bone Healing in Pediatric Fractures: A Preliminary, Prospective, Randomized, Blinded Study.","BACKGROUND This study aimed to investigate if nonsteroidal anti-inflammatory drugs (NSAIDs) used in the acute phase of bone healing in children with fractures result in delayed union or nonunion as compared with patients who do not take NSAIDs for pain control during this same time period. METHODS In this prospective, randomized, parallel, single-blinded study, skeletally immature patients with long bone fractures were randomized to 1 of 2 groups for their postfracture pain management. The NSAID group was prescribed weight-based ibuprofen, whereas the control group was not allowed any NSAID medication and instead prescribed weight-based acetaminophen. Both groups were allowed to use oxycodone for breakthrough pain. The primary outcome was fracture healing assessed at 2, 6, and 10 weeks. RESULTS One-hundred-two patients were enrolled between February 6, 2014 and September 23, 2016. Ninety-five patients (with 97 fractures) completed a 6-month follow-up (46 patients with 47 fractures in the control group and 49 patients 50 fractures in the NSAID group). None achieved healing at 1 to 2 weeks. By 6 weeks, 37 of 45 patients (82%) of control group and 46 out of 50 patients (92%) of ibuprofen group had healed fractures (P=0.22). At 10 to 12 week follow-up, 46 (98%) of the control group fractures were healed and 50 (100%) of the ibuprofen group fractures were healed. All were healed by 6 months. Healing was documented at a mean of 40 days in the control group and 31 days in the ibuprofen group (P=0.76). The mean number of days breakthrough oxycodone was used was 2.4 days in the control group and 1.9 days in the NSAID group (P=0.48). CONCLUSION Ibuprofen is an effective medication for fracture pain in children and its use does not impair clinical or radiographic long bone fracture healing in skeletally immature patients. LEVEL OF EVIDENCE Level I-therapeutic.",2020,Healing was documented at a mean of 40 days in the control group and 31 days in the ibuprofen group (P=0.76).,"['One-hundred-two patients were enrolled between February 6, 2014 and September 23, 2016', 'skeletally immature patients', 'Pediatric Fractures', 'Ninety-five patients (with 97 fractures) completed a 6-month follow-up (46 patients with 47 fractures in the control group and 49 patients 50 fractures in the NSAID group', 'skeletally immature patients with long bone fractures', 'children with fractures result in delayed union or nonunion as compared with patients who do not take NSAIDs for pain control during this same time period']","['NSAID', 'nonsteroidal anti-inflammatory drugs (NSAIDs', 'Ibuprofen', 'oxycodone', 'ibuprofen', 'acetaminophen']","['healing', 'healed fractures', 'Bone Healing', 'fracture healing', 'mean number of days breakthrough oxycodone', 'Healing']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205252', 'cui_str': 'Immature'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C4517906', 'cui_str': '95'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0222647', 'cui_str': 'Structure of long bone'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332294', 'cui_str': 'Resulting in'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C1948053', 'cui_str': 'Time periods'}]","[{'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0030049', 'cui_str': 'Oxycodone'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}]","[{'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0152231', 'cui_str': 'Fracture, healed'}, {'cui': 'C1321023', 'cui_str': 'Bone healing status'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0444503', 'cui_str': 'Breakthrough'}, {'cui': 'C0030049', 'cui_str': 'Oxycodone'}]",102.0,0.0423132,Healing was documented at a mean of 40 days in the control group and 31 days in the ibuprofen group (P=0.76).,"[{'ForeName': 'Julia A V', 'Initials': 'JAV', 'LastName': 'Nuelle', 'Affiliation': 'Department of Orthopaedic Surgery, University of Missouri Health System, Columbia, MO.'}, {'ForeName': 'Kelsie M', 'Initials': 'KM', 'LastName': 'Coe', 'Affiliation': ''}, {'ForeName': 'Harvey A', 'Initials': 'HA', 'LastName': 'Oliver', 'Affiliation': ''}, {'ForeName': 'James L', 'Initials': 'JL', 'LastName': 'Cook', 'Affiliation': ''}, {'ForeName': 'Daniel G', 'Initials': 'DG', 'LastName': 'Hoernschemeyer', 'Affiliation': ''}, {'ForeName': 'Sumit K', 'Initials': 'SK', 'LastName': 'Gupta', 'Affiliation': ''}]",Journal of pediatric orthopedics,['10.1097/BPO.0000000000001603'] 1323,32559515,Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis.,"Gait dysfunction is common in patients with multiple sclerosis (PwMS). Treatment with prolonged-release fampridine (PR-fampridine) improves walking ability in some PwMS. Associated fampridine-induced changes in the walking pattern are still poorly understood but may provide a better understanding of the mechanisms underlying the beneficial drug effects. 61 PwMS were treated with PR-fampridine in a randomized, monocentric, double-blind and placebo-controlled clinical trial with crossover design (FAMPKIN). Drug-induced improvements in walking speed (Timed-25-Foot Walk; T25FW) and endurance (6-Minute Walk Test; 6MWT) were quantified. In this sub-study of the FAMPKIN trial, fampridine-induced changes in kinetic gait patterns were analyzed by pressure-based foot print analysis during treadmill walking. Vertical ground reaction forces were analyzed during different gait phases. Kinetic data of 44 PwMS was eligible for analysis. During double-blind treatment with PR-fampridine, patients performed significantly better in the T25FW and 6MWT than during placebo treatment (p < 0.0001 for both). At the group level (n = 44), there were no significant changes of gait kinetics under PR-fampridine vs. placebo. However, we found relevant changes of walking kinetics regarding forces during loading, single limb and pre-swing phase in a patient sub-group (n = 8). Interestingly, this sub-group demonstrated superior responsiveness to PR-fampridine in the clinical walking tests compared to those patients without any fampridine-induced changes in kinetics (n = 36). Our results demonstrate fampridine-induced changes in gait kinetics in a sub-group of PwMS. These gait pattern changes were accompanied by improved clinical walking performance under PR-fampridine. These results shed some light on the biomechanical changes in walking patterns underlying enhanced fampridine-induced gait performance.",2020,"At the group level (n = 44), there were no significant changes of gait kinetics under PR-fampridine vs. placebo.","['patients with multiple sclerosis', 'patients with multiple sclerosis (PwMS']","['PR-fampridine', 'prolonged-release fampridine (PR-fampridine', 'placebo']","['clinical walking performance', 'Vertical ground reaction forces', 'walking kinetics', 'gait kinetics', 'Gait dysfunction', 'walking speed (Timed-25-Foot Walk; T25FW) and endurance (6-Minute Walk Test; 6MWT', 'kinetic gait patterns', 'T25FW and 6MWT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}]","[{'cui': 'C0000477', 'cui_str': 'dalfampridine'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0430515', 'cui_str': '6-minute walk test'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}]",61.0,0.124543,"At the group level (n = 44), there were no significant changes of gait kinetics under PR-fampridine vs. placebo.","[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Weller', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Lörincz', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Sutter', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Reuter', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Linnebank', 'Affiliation': 'Department of Neurology, University Witten/Herdecke and Evangelische Kliniken Gelsenkirchen, Munckelstraße 32, 45879 Gelsenkirchen, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Weller', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Zörner', 'Affiliation': 'Spinal Cord Injury Center, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Filli', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland; Spinal Cord Injury Center, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland; Swiss Center for clinical Movement Analysis (SCMA), Balgrist Campus AG, Lengghalde 5, 8008 Zurich, Switzerland. Electronic address: linard.filli@balgrist.ch.'}]",Journal of the neurological sciences,['10.1016/j.jns.2020.116978'] 1324,32559601,Cardiovascular responses to pelvic floor muscle contraction in healthy women: Prospective study.,"OBJECTIVE Analyze the acute heart rate and blood pressure responses to two protocols of pelvic floor muscles contractions in premenopausal and postmenopausal women. METHODS Fifty-four women without pelvic floor muscles disorders were eligible and allocated into two groups: premenopausal and postmenopausal. The groups underwent two protocols and the pelvic floor muscle endurance, heart rate, and blood pressure values were monitored. Both protocols included 10 pelvic floor muscles contractions; one series contained contractions lasting 5 s with 5 s of rest between each contraction and the other series contained contractions lasting 10 s with 10 s of rest. RESULTS In both groups, there was a significant increase in the heart rate during pelvic floor muscles contractions (premenopausal: 71.0 ± 7.3 and 80.3 ± 7.7; postmenopausal: 65.4 ± 6.6 and 73.6 ± 6.6, at rest and contractions peak, respectively) and in systolic blood pressure immediately after the contractions. The observed values during exercise returned to basal values seconds after the contractions. A positive correlation between heart rate and vaginal squeeze pressure (r = 0.45, p = 0.0007 and r = 0.48, p = 0.0003, 5- and 10-s series, respectively) was observed. CONCLUSION The proposed protocol of isometric pelvic floor muscles contractions caused an increase in heart rate and blood pressure within the normal range and might not represent a cardiovascular risk for healthy postmenopausal women without urinary incontinence and without cardiovascular dysfunctions.",2020,The proposed protocol of isometric pelvic floor muscles contractions caused an increase in heart rate and blood pressure within the normal range and might not represent a cardiovascular risk for healthy postmenopausal women without urinary incontinence and without cardiovascular dysfunctions.,"['premenopausal and postmenopausal women', 'healthy women', 'healthy postmenopausal women without urinary incontinence and without cardiovascular dysfunctions', 'Fifty-four women without pelvic floor muscles disorders were eligible and allocated into two groups: premenopausal and postmenopausal']",['pelvic floor muscles contractions'],"['heart rate and blood pressure', 'pelvic floor muscle endurance, heart rate, and blood pressure values', 'heart rate', 'Cardiovascular responses', 'systolic blood pressure', 'heart rate and vaginal squeeze pressure']","[{'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026848', 'cui_str': 'Disorder of muscle'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026820', 'cui_str': 'Muscle contraction'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0413258', 'cui_str': 'Barotrauma of descent'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}]",54.0,0.0281104,The proposed protocol of isometric pelvic floor muscles contractions caused an increase in heart rate and blood pressure within the normal range and might not represent a cardiovascular risk for healthy postmenopausal women without urinary incontinence and without cardiovascular dysfunctions.,"[{'ForeName': 'Alana Maria G', 'Initials': 'AMG', 'LastName': 'Bastos', 'Affiliation': ""Women's Health Research Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.""}, {'ForeName': 'Aparecida M', 'Initials': 'AM', 'LastName': 'Catai', 'Affiliation': 'Cardiovascular Physical Therapy Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.'}, {'ForeName': 'Soraia P', 'Initials': 'SP', 'LastName': 'Jürgensen', 'Affiliation': ""Women's Health Research Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.""}, {'ForeName': 'Grasiela N', 'Initials': 'GN', 'LastName': 'Correia', 'Affiliation': ""Women's Health Research Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.""}, {'ForeName': 'Vanessa S', 'Initials': 'VS', 'LastName': 'Pereira-Baldon', 'Affiliation': ""Women's Health Research Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.""}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Perseguini', 'Affiliation': 'Cardiovascular Physical Therapy Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Borghi-Silva', 'Affiliation': 'Cardiovascular Physical Therapy Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Driusso', 'Affiliation': ""Women's Health Research Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil. Electronic address: pdriusso@ufscar.br.""}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.05.050'] 1325,32569090,"Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial.","Hydromorphone is an alternative to morphine for intrathecal drug delivery system to treat refractory cancer pain; however, there is not enough clinical evidence to prove it. In our study, 233 patients from 12 different pain management centers across China were enrolled, 121 and 112 in the intrathecal hydromorphone (ITHM) and intrathecal morphine (ITMO) groups, respectively. The primary outcome was the clinical success rate, which was defined as ratio of patients achieving ≥50% pain relief. The noninferiority margin was defined as -0.15. Other outcomes included daily visual analogue scale score, breakthrough pain (BTP) incidence, intrathecal dose change, and patient-controlled analgesia bolus count change, GAD-7/PHQ-9. Clinical success was achieved in 85 and 79 of the 121 ITHM patients (70.2%) and 112 ITMO patients (70.5%), respectively. Compared to the corresponding baseline findings, significantly decreased visual analogue scale scores and BTP incidence were noted in both groups. The dose change rate decreased and increased with time in the ITHM and ITMO groups, respectively (ITHM -3.33% vs ITMO 35.4%, P < 0.01, t test) from the third week. The patient-controlled analgesia bolus change rate was lower in the ITHM group than in the ITMO group (ITHM -19.88% vs ITMO 7.79%, P < 0.01, t test) from first week. Our result shows that ITHM is noninferior to ITMO on pain relief to treat refractory cancer pain, however, at different doses and that the doses of morphine tended to increase, whereas those of hydromorphone decreased over time. Hydromorphone offers advantage over morphine in controlling BTP.",2020,"The PCA bolus change rate was lower in the ITHM group than in the ITMO group (ITHM - 19.88% vs ITMO 7.79%, P < .01, t-test) from first week.","['233 patients from 12 different pain management centers across China were enrolled, 121 and 112 in the', 'refractory cancer pain']","['hydromorphone', 'ITMO', 'ITHM', 'Hydromorphone', 'intrathecal morphine', 'intrathecal hydromorphone (ITHM) and intrathecal morphine (ITMO', 'hydromorphone vs morphine', 'intrathecal hydromorphone', 'morphine']","['PCA bolus change rate', 'pain relief', 'Clinical success', 'clinical success rate, which was defined as ratio of patients achieving ≥ 50% pain relief', 'VAS scores and BTP incidence', 'daily visual analog scale (VAS) score, breakthrough pain (BTP) incidence, intrathecal dose change and PCA bolus count change, GAD-7/PHQ-9', 'change rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0677936', 'cui_str': 'Refractory cancer'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0012306', 'cui_str': 'Hydromorphone'}, {'cui': 'C0677897', 'cui_str': 'Intrathecal route'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]","[{'cui': 'C0030131', 'cui_str': 'p-Chloramphetamine'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C1135120', 'cui_str': 'Breakthrough pain'}, {'cui': 'C0677897', 'cui_str': 'Intrathecal route'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0270549', 'cui_str': 'Generalized anxiety disorder'}]",233.0,0.0995406,"The PCA bolus change rate was lower in the ITHM group than in the ITMO group (ITHM - 19.88% vs ITMO 7.79%, P < .01, t-test) from first week.","[{'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Ma', 'Affiliation': 'Department of Pain Medicine, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Jin', 'Affiliation': 'Pain Management Center, Nanjing General Hospital, Nanjing, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Pain Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.'}, {'ForeName': 'Zhi-Ying', 'Initials': 'ZY', 'LastName': 'Feng', 'Affiliation': 'Department of Pain Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Song', 'Affiliation': 'Department of Pain Medicine, the First Affiliated Hospital, China Medical University, Heping, Shenyang, China.'}, {'ForeName': 'Xiao-Qiu', 'Initials': 'XQ', 'LastName': 'Yang', 'Affiliation': 'Department of Pain Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.'}, {'ForeName': 'Fu-Qiang', 'Initials': 'FQ', 'LastName': 'Chen', 'Affiliation': 'Department of Pain Medicine, Qingdao Municipal Hospital, Qingdao, China.'}, {'ForeName': 'Bao-Lin', 'Initials': 'BL', 'LastName': 'Duan', 'Affiliation': ""Department of Pain Medicine, Qinghai Provincial People's Hospital, Xi'ning, China.""}, {'ForeName': 'You-Qing', 'Initials': 'YQ', 'LastName': 'Huang', 'Affiliation': 'Department of Pain Medicine, The 2nd Affiliated Hospital of Kunming Medical University, Kunming, China.'}, {'ForeName': 'Guang-Lun', 'Initials': 'GL', 'LastName': 'Xie', 'Affiliation': 'Department of Pain Medicine, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.'}, {'ForeName': 'Hong-Guang', 'Initials': 'HG', 'LastName': 'Bao', 'Affiliation': 'Department of Pain Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'Department of Pharmacometrics, Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Jiang-Tao', 'Initials': 'JT', 'LastName': 'Xu', 'Affiliation': 'Department of Pain Medicine, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': ""Department of Pain Medicine, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Yan-Qing', 'Initials': 'YQ', 'LastName': 'Liu', 'Affiliation': 'Department of Pain Medicine, Beijing Tiantan Hospital, Capital Medical University, Tiantan, Dongcheng, Beijing, China.'}]",Pain,['10.1097/j.pain.0000000000001957'] 1326,32571454,[Effect of early continuous blood purification on the prognosis of children with septic shock: a prospective randomized controlled clinical trial].,"OBJECTIVE To study the effect of early continuous blood purification (CBP) on the prognosis of children with septic shock. METHODS A prospective analysis was performed for the children with septic shock who did not reach the 6-hour initial recovery target and/or had a fluid overload of >10%. According to the treatment time of CBP, they were divided into an early group with 30 children and a conventional group with 28 children. The two groups were compared in terms of the start time of CBP and 28-day mortality rate, as well as the related indexes in the children who were cured. RESULTS The early group had a significantly earlier start time of CBP than the conventional group (P<0.05). There were 25 children cured in the early group and 22 cured in the conventional group, and there was no significant difference in 28-day mortality rate between the two groups (P>0.05). The children who were cured in the early group had significantly shorter correction time of lactic acid, urine volume, and fluid overload than those in the conventional group (P<0.05). The children who were cured in both groups had significant reductions in the percentages of T-lymphocyte subsets at the beginning (P<0.05); on reexamination on day 7, the percentages of T-lymphocyte subsets were increased and were higher in the early group than in the conventional group (P<0.05). The children who were cured in the early group had significantly shorter duration of CBP treatment, duration of mechanical ventilation, and length of stay in the PICU than those in the conventional group (P<0.05). CONCLUSIONS For children with septic shock who do not reach the 6-hour initial recovery target and/or have a fluid overload of >10%, early CBP treatment can quickly control the disease, shorten the course of disease, and accelerate immune reconstruction.",2020,The early group had a significantly earlier start time of CBP than the conventional group (P<0.05).,"['children with septic shock who did not reach the 6-hour initial recovery target and/or had a fluid overload of >10', 'children with septic shock']","['early continuous blood purification (CBP', 'early continuous blood purification']","['start time of CBP and 28-day mortality rate', 'percentages of T-lymphocyte subsets', 'earlier start time of CBP', '28-day mortality rate', 'shorter duration of CBP treatment, duration of mechanical ventilation, and length of stay in the PICU', 'shorter correction time of lactic acid, urine volume, and fluid overload']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0036983', 'cui_str': 'Septic shock'}, {'cui': 'C0560523', 'cui_str': 'Does not reach'}, {'cui': 'C1292428', 'cui_str': '6 hours'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0546817', 'cui_str': 'Hypervolemia'}]","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0243114', 'cui_str': 'purification'}]","[{'cui': 'C1301880', 'cui_str': 'Start time'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0243114', 'cui_str': 'purification'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0080202', 'cui_str': 'T-Cell Subsets'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0439593', 'cui_str': 'Short duration'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C1046445', 'cui_str': 'Picus'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0064582', 'cui_str': 'lactic acid'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0546817', 'cui_str': 'Hypervolemia'}]",25.0,0.0511144,The early group had a significantly earlier start time of CBP than the conventional group (P<0.05).,"[{'ForeName': 'You-Jun', 'Initials': 'YJ', 'LastName': 'Xie', 'Affiliation': 'Department of Critical Care Medicine, Guangxi Maternity and Child Health Hospital, Nanning 530000, China. xieyoujun55@163.com.'}, {'ForeName': 'Wu-Gui', 'Initials': 'WG', 'LastName': 'Mo', 'Affiliation': ''}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Wei', 'Affiliation': ''}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Wei', 'Affiliation': ''}, {'ForeName': 'Yu-Peng', 'Initials': 'YP', 'LastName': 'Tang', 'Affiliation': ''}, {'ForeName': 'Zhuo', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Gong-Zhi', 'Initials': 'GZ', 'LastName': 'Lu', 'Affiliation': ''}, {'ForeName': 'Zhi-Rong', 'Initials': 'ZR', 'LastName': 'Mo', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1327,32442153,Evaluating Engagement in a Digital and Dietetic Intervention Promoting Healthy Weight Gain in Pregnancy: Mixed Methods Study.,"BACKGROUND Early excess and inadequate gestational weight gain (GWG) have been associated with negative outcomes for mother and child. The use of digital media to deliver pregnancy lifestyle interventions is increasing, but there is little data on participant engagement. The Pregnancy Lifestyle Activity and Nutrition (PLAN) intervention pilot study was an electronic health and dietetic-delivered intervention program promoting healthy GWG in early pregnancy. OBJECTIVE This study aims to explore the interactions of participants with the program and to assess its acceptability. METHODS This study uses both quantitative and qualitative methods using data from parent randomized controlled trial (ACTRN12617000725369). Quantitative data from 22 participants in the intervention arm who completed the study provided measures of the interactions participants had with the digital components of the program and with dietetic consultations. A descriptive qualitative analysis employed semistructured interviews with 9 participants to elicit views on the acceptability of the intervention and its components. RESULTS The electronic delivery of information and recording of weight from 8 to 20 weeks of gestation were universally accepted. Component (face-to-face dietitian, weight tracker, website information delivery, and SMS goal prompting) acceptability and engagement differed between individuals. A total of 4 key themes emerged from the qualitative analysis: supporting lifestyle change, component acceptability and value, delivery platforms, and engagement barriers. CONCLUSIONS The PLAN intervention and its delivery via a blend of personal dietetic consultations and digital program delivery was found to be acceptable and valuable to pregnant women. Individuals responded differently to various components, emphasizing the importance of including women in the development of lifestyle interventions and allowing participants to choose and tailor programs. Larger randomized controlled trials using these insights in a broader section of the community are needed to inform the iterative development of practical, time-efficient, and cost-effective ways of supporting optimal GWG with the potential to optimize outcomes for pregnant women and their child.",2020,The PLAN intervention and its delivery via a blend of personal dietetic consultations and digital program delivery was found to be acceptable and valuable to pregnant women.,"['pregnant women and their child', 'pregnant women', ""Women's Engagement With Pregnancy Lifestyle Activity and Nutrition"", '22 participants in the intervention arm who completed the study provided measures of the interactions participants had with the digital components of the program and with dietetic consultations']","['Electronic Health and Dietetic Intervention', 'electronic health and dietetic-delivered intervention program promoting healthy GWG']",[],"[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0012180', 'cui_str': 'Dietetics'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}]","[{'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0012180', 'cui_str': 'Dietetics'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C1398625', 'cui_str': 'Maternal Weight Gain'}]",[],22.0,0.0728469,The PLAN intervention and its delivery via a blend of personal dietetic consultations and digital program delivery was found to be acceptable and valuable to pregnant women.,"[{'ForeName': 'Jane C', 'Initials': 'JC', 'LastName': 'Willcox', 'Affiliation': 'La Trobe University, Bundoora, Australia.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Chai', 'Affiliation': 'Telethon Kids Institute, Perth, Australia.'}, {'ForeName': 'Lawrence J', 'Initials': 'LJ', 'LastName': 'Beilin', 'Affiliation': 'The University of Western Australia, Perth, Australia.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Prescott', 'Affiliation': 'The University of Western Australia, Perth, Australia.'}, {'ForeName': 'Desiree', 'Initials': 'D', 'LastName': 'Silva', 'Affiliation': 'Joondalup Health Campus, Shenton Avenue, Perth, Australia.'}, {'ForeName': 'Cliff', 'Initials': 'C', 'LastName': 'Neppe', 'Affiliation': 'Joondalup Health Campus, Shenton Avenue, Perth, Australia.'}, {'ForeName': 'Rae-Chi', 'Initials': 'RC', 'LastName': 'Huang', 'Affiliation': 'Telethon Kids Institute, Perth, Australia.'}]",Journal of medical Internet research,['10.2196/17845'] 1328,32442154,Feasibility and Utility of mHealth for the Remote Monitoring of Parkinson Disease: Ancillary Study of the PD_manager Randomized Controlled Trial.,"BACKGROUND Mobile health, predominantly wearable technology and mobile apps, have been considered in Parkinson disease to provide valuable ecological data between face-to-face visits and improve monitoring of motor symptoms remotely. OBJECTIVE We explored the feasibility of using a technology-based mHealth platform comprising a smartphone in combination with a smartwatch and a pair of smart insoles, described in this study as the PD_manager system, to collect clinically meaningful data. We also explored outcomes and disease-related factors that are important determinants to establish feasibility. Finally, we further validated a tremor evaluation method with data collected while patients performed their daily activities. METHODS PD_manager trial was an open-label parallel group randomized study.The mHealth platform consists of a wristband, a pair of sensor insoles, a smartphone (with dedicated mobile Android apps) and a knowledge platform serving as the cloud backend. Compliance was assessed with statistical analysis and the factors affecting it using appropriate regression analysis. The correlation of the scores of our previous algorithm for tremor evaluation and the respective Unified Parkinson's Disease Rating Scale estimations by clinicians were explored. RESULTS Of the 75 study participants, 65 (87%) completed the protocol. They used the PD_manager system for a median 11.57 (SD 3.15) days. Regression analysis suggests that the main factor associated with high use was caregivers' burden. Motor Aspects of Experiences of Daily Living and patients' self-rated health status also influence the system's use. Our algorithm provided clinically meaningful data for the detection and evaluation of tremor. CONCLUSIONS We found that PD patients, regardless of their demographics and disease characteristics, used the system for 11 to 14 days. The study further supports that mHealth can be an effective tool for the ecologically valid, passive, unobtrusive monitoring and evaluation of symptoms. Future studies will be required to demonstrate that an mHealth platform can improve disease management and care. TRIAL REGISTRATION ISRCTN Registry ISRCTN17396879; http://www.isrctn.com/ISRCTN17396879. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR2-10.1186/s13063-018-2767-4.",2020,"The correlation of the scores of our previous algorithm for tremor evaluation and the respective Unified Parkinson's Disease Rating Scale estimations by clinicians were explored. ","['Of the 75 study participants, 65 (87%) completed the protocol', 'Parkinson Disease']",['technology-based mHealth platform'],[],"[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}]",[],75.0,0.0514528,"The correlation of the scores of our previous algorithm for tremor evaluation and the respective Unified Parkinson's Disease Rating Scale estimations by clinicians were explored. ","[{'ForeName': 'Dimitris', 'Initials': 'D', 'LastName': 'Gatsios', 'Affiliation': 'Department of Neurology, Medical School, University of Ioannina, Ioannina, Greece.'}, {'ForeName': 'Angelo', 'Initials': 'A', 'LastName': 'Antonini', 'Affiliation': 'Department of Neuroscience, University of Padua, Padua, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Gentile', 'Affiliation': 'Department of Neuroscience, University of Padua, Padua, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Marcante', 'Affiliation': 'San Camillo Hospital Istituto Di Ricovero e Cura a Carattere Scientifico, Venice, Italy.'}, {'ForeName': 'Clelia', 'Initials': 'C', 'LastName': 'Pellicano', 'Affiliation': 'Laboratory of Neuropsychiatry, Fondazione Santa Lucia Istituto Di Ricovero e Cura a Carattere Scientifico, Rome, Italy.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Macchiusi', 'Affiliation': 'Laboratory of Neuropsychiatry, Fondazione Santa Lucia Istituto Di Ricovero e Cura a Carattere Scientifico, Rome, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Assogna', 'Affiliation': 'Laboratory of Neuropsychiatry, Fondazione Santa Lucia Istituto Di Ricovero e Cura a Carattere Scientifico, Rome, Italy.'}, {'ForeName': 'Gianfranco', 'Initials': 'G', 'LastName': 'Spalletta', 'Affiliation': 'Laboratory of Neuropsychiatry, Fondazione Santa Lucia Istituto Di Ricovero e Cura a Carattere Scientifico, Rome, Italy.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Gage', 'Affiliation': 'Surrey Health Economics Centre, Department of Clinical and Experimental Medicine, University of Surrey, Guildford, United Kingdom.'}, {'ForeName': 'Morro', 'Initials': 'M', 'LastName': 'Touray', 'Affiliation': 'Surrey Health Economics Centre, Department of Clinical and Experimental Medicine, University of Surrey, Guildford, United Kingdom.'}, {'ForeName': 'Lada', 'Initials': 'L', 'LastName': 'Timotijevic', 'Affiliation': 'School of Psychology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom.'}, {'ForeName': 'Charo', 'Initials': 'C', 'LastName': 'Hodgkins', 'Affiliation': 'School of Psychology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Chondrogiorgi', 'Affiliation': 'Department of Neurology, Medical School, University of Ioannina, Ioannina, Greece.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Rigas', 'Affiliation': 'Unit of Medical Technology and Intelligent Information System, Department of Materials Science and Engineering, University of Ioannina, Ioannina, Greece.'}, {'ForeName': 'Dimitrios I', 'Initials': 'DI', 'LastName': 'Fotiadis', 'Affiliation': 'Unit of Medical Technology and Intelligent Information System, Department of Materials Science and Engineering, University of Ioannina, Ioannina, Greece.'}, {'ForeName': 'Spyridon', 'Initials': 'S', 'LastName': 'Konitsiotis', 'Affiliation': 'Department of Neurology, Medical School, University of Ioannina, Ioannina, Greece.'}]",JMIR mHealth and uHealth,['10.2196/16414'] 1329,32444573,"Lessons learned from conducting a pragmatic, randomized, crossover trial on robot-assisted gait training in children with cerebral palsy (PeLoGAIT).","PURPOSE To investigate the effectiveness of outpatient robot-assisted gait training (RAGT) in ambulatory children with spastic cerebral palsy. METHODS Children were randomized to two different intervention sequences within a pragmatic crossover design. They performed five weeks of RAGT (3 sessions per week) and five weeks of usual care (UC). Dimension E of the Gross Motor Function Measure-88 (GMFM E) as the primary outcome as well as Dimension D (GMFM D), and timed walking tests were assessed before and after each treatment sequence and after a 5-week follow-up. RESULTS The trial was stopped early because of recruitment problems. We included 16 children with a mean age of 11.3 years (6.0-15.3 years). GMFM E median (IQR) change scores were -0.7 (-2.8 to 3.5) after RAGT and 0 (-2.4 to 2.4) after UC. Neither GMFM E nor any secondary outcome measure changed significantly after RAGT or UC, nor were any period, follow-up, or carry-over effects observable. CONCLUSIONS RAGT as a single intervention was not effective in improving walking abilities in the included children. It should be embedded in a holistic treatment approach, as it cannot cover all aspects relevant to gait. Furthermore, children's personalized rehabilitation goals should be carefully monitored with individualized measurement instruments.",2020,"Neither GMFM E nor any secondary outcome measure changed significantly after RAGT or UC, nor were any period, follow - up, or carry - over effects observable. ","['children with cerebral palsy (PeLoGAIT', '16 children with a mean age of 11.3 years (6.0-15.3 years', 'ambulatory children with spastic cerebral palsy', 'Children']","['outpatient robot-assisted gait training (RAGT', 'robot-assisted gait training', 'RAGT']","['Dimension D (GMFM D), and timed walking tests', 'walking abilities', 'GMFM E median (IQR) change scores']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517578', 'cui_str': '15.3'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0338596', 'cui_str': 'Spastic cerebral palsy'}]","[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure'}]","[{'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0559964', 'cui_str': 'Ability to walk'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",16.0,0.0332735,"Neither GMFM E nor any secondary outcome measure changed significantly after RAGT or UC, nor were any period, follow - up, or carry - over effects observable. ","[{'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Ammann-Reiffer', 'Affiliation': ""Swiss Children's Rehab, Research Department, University Children's Hospital Zurich, Eleonore Foundation, Affoltern am Albis, Switzerland.""}, {'ForeName': 'Caroline H G', 'Initials': 'CHG', 'LastName': 'Bastiaenen', 'Affiliation': 'Functioning and Rehabilitation, CAPHRI, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Andreas D', 'Initials': 'AD', 'LastName': 'Meyer-Heim', 'Affiliation': ""Swiss Children's Rehab, Research Department, University Children's Hospital Zurich, Eleonore Foundation, Affoltern am Albis, Switzerland.""}, {'ForeName': 'Hubertus J A', 'Initials': 'HJA', 'LastName': 'van Hedel', 'Affiliation': ""Swiss Children's Rehab, Research Department, University Children's Hospital Zurich, Eleonore Foundation, Affoltern am Albis, Switzerland.""}]",Journal of pediatric rehabilitation medicine,['10.3233/PRM-190614'] 1330,32580032,Design of a cluster-randomized trial of the effectiveness and cost-effectiveness of metformin on prevention of type 2 diabetes among prediabetic Mexican adults (the PRuDENTE initiative of Mexico City).,"INTRODUCTION Type 2 diabetes (T2D) is a global epidemic, and nations are struggling to implement effective healthcare strategies to reduce the burden. While efficacy studies demonstrate that metformin can reduce incident T2D by half among younger, obese adults with prediabetes, its real-world effectiveness are understudied, and its use for T2D prevention in primary care is low. We describe the design of a pragmatic trial to evaluate the incremental effectiveness of metformin, as an adjunct to a simple lifestyle counseling. METHODS The ""Prevención de la Diabetes con Ejercicio, Nutrición y Tratamiento"" [Diabetes Prevention with Exercise, Nutrition and Treatment; PRuDENTE, (Spanish acronym)] is a cluster-randomized trial in Mexico City's public primary healthcare system. The study randomly assigns 51 clinics to deliver one of two interventions for 36 months: 1) lifestyle only; 2) lifestyle plus metformin, to 3060 patients ages 30-65 with impaired fasting glucose and obesity. The primary endpoint is incident T2D (fasting glucose ≥126 mg/dL, or HbA1c ≥6.5%). We will also measure a range of implementation-related process outcomes at the clinic-, clinician- and patient-levels to inform interpretations of effectiveness and enable efforts to refine, adapt, adopt and disseminate the model. We will also estimate the cost-effectiveness of metformin as an adjunct to lifestyle counseling in Mexico. DISCUSSION Findings from this pragmatic trial will generate new translational knowledge in Mexico and beyond, both with respect to metformin's real-world effectiveness among an 'at-risk' population, and uncovering facilitators and barriers to the reach, adoption and implementation of metformin preventive therapy in public primary care settings. TRIAL REGISTRATION This trial is registered at Clinicaltrials.gov (NCT03194009).",2020,Nutrición y,"['prediabetic Mexican adults (the PRuDENTE initiative of Mexico City', '3060 patients ages 30-65 with impaired fasting glucose and obesity', 'Nutrición y']","['lifestyle only; 2) lifestyle plus metformin', 'metformin']","['incident T2D (fasting glucose ≥126\u202fmg/dL, or HbA1c ≥6.5']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0025885', 'cui_str': 'Mexico'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1272092', 'cui_str': 'Impaired fasting glycaemia'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]",3060.0,0.0429361,Nutrición y,"[{'ForeName': 'Luis A', 'Initials': 'LA', 'LastName': 'Rodríguez', 'Affiliation': 'Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA. Electronic address: Luis.Rodriguez@ucsf.edu.'}, {'ForeName': 'Simón', 'Initials': 'S', 'LastName': 'Barquera', 'Affiliation': 'Nutrition and Health Research Center, National Institute of Public Health, Cuernavaca, Mexico.'}, {'ForeName': 'Carlos A', 'Initials': 'CA', 'LastName': 'Aguilar-Salinas', 'Affiliation': 'Division of Nutrition, Salvador Zubiran National Institute of Medical Sciences and Nutrition, Mexico City, Mexico.'}, {'ForeName': 'Jaime', 'Initials': 'J', 'LastName': 'Sepúlveda-Amor', 'Affiliation': 'Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA; Institute for Global Health Sciences, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Luz María', 'Initials': 'LM', 'LastName': 'Sánchez-Romero', 'Affiliation': 'Nutrition and Health Research Center, National Institute of Public Health, Cuernavaca, Mexico.'}, {'ForeName': 'Edgar', 'Initials': 'E', 'LastName': 'Denova-Gutiérrez', 'Affiliation': 'Nutrition and Health Research Center, National Institute of Public Health, Cuernavaca, Mexico.'}, {'ForeName': 'Nydia', 'Initials': 'N', 'LastName': 'Balderas', 'Affiliation': 'Nutrition and Health Research Center, National Institute of Public Health, Cuernavaca, Mexico.'}, {'ForeName': 'Lizbeth', 'Initials': 'L', 'LastName': 'Moreno-Loaeza', 'Affiliation': 'Research Unit on Metabolic Diseases, Salvador Zubiran National Institute of Medical Sciences and Nutrition, Mexico City, Mexico; Medical, Dental and Health Sciences, National Autonomous University of Mexico, Mexico City, Mexico.'}, {'ForeName': 'Margaret A', 'Initials': 'MA', 'LastName': 'Handley', 'Affiliation': 'Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA; Division of General Internal Medicine at San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA; UCSF Center for Vulnerable Populations, San Francisco General Hospital, San Francisco, CA, USA.'}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Basu', 'Affiliation': 'Department of Medicine, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Oliva', 'Initials': 'O', 'LastName': 'López-Arellano', 'Affiliation': 'Ministry of Health, Mexico City, Mexico.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Gallardo-Hernández', 'Affiliation': 'Ministry of Health, Mexico City, Mexico.'}, {'ForeName': 'Dean', 'Initials': 'D', 'LastName': 'Schillinger', 'Affiliation': 'Division of General Internal Medicine at San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA; UCSF Center for Vulnerable Populations, San Francisco General Hospital, San Francisco, CA, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106067'] 1331,32449335,Could intraoperative magnesium sulphate protect against postoperative cognitive dysfunction?,"BACKGROUND Although there is much concern about the pathogenesis of postoperative cognitive dysfunction (POCD); no effective prevention strategies are currently described. The aim of this work was to study whether intraoperative magnesium sulphate could have a protective effect against developing POCD and to study its impact on serum level of S100B, a marker of neuronal degeneration. METHODS This is a prospective randomized controlled trial carried out on 80 participants undergoing elective laparoscopic cholecystectomy, 40 participants received conventional general anesthesia (conventional anesthesia group) and 40 participants received conventional general anesthesia with extra administration of intraoperative magnesium sulphate (Mg sulphate group). Cognitive assessment for both groups was done preoperatively and 1 week postoperatively using Paired Associate Learning test (PALT) and Benton Visual Retention Test (BVRT). Quantitative determination of serum S100B was done for both groups preoperatively and one week postoperatively by using an enzyme- linked immunoabsorbent assay technique. RESULTS Postoperative PALT and BVRT were significantly lower than preoperative PALT and BVRT in the conventional anesthesia group (P value =0.043, P value =0.015 respectively), but not in the Mg sulphate group (P value =0.134, P value =0.151 respectively). Postoperative S100B was significantly higher than preoperative S100B in the conventional anesthesia group (P value =0.006), but not in the Mg sulphate group (P value =0.293). CONCLUSIONS Administration of intravenous infusion of magnesium sulphate during conventional general anesthesia can protect against POCD and attenuate the post operative elevation of serum S100B.",2020,"RESULTS Postoperative PALT and BVRT were significantly lower than preoperative PALT and","['80 participants undergoing elective laparoscopic cholecystectomy, 40 participants received']","['intraoperative magnesium sulphate', 'magnesium sulphate', 'conventional general anaesthesia (conventional anaesthesia group) and 40 participants received conventional general anaesthesia with extra administration of intraoperative magnesium sulphate (Mg sulphate group', 'Mg sulphate']","['BVRT', 'Cognitive assessment', 'Paired Associate Learning test (PALT) and Benton Visual Retention test (BVRT', 'Postoperative S100B', 'Postoperative PALT and BVRT']","[{'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0162522', 'cui_str': 'Laparoscopic cholecystectomy'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0024480', 'cui_str': 'Magnesium Sulfate'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0474702', 'cui_str': 'Sulfate measurement'}]","[{'cui': 'C2143012', 'cui_str': 'Benton visual retention test'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0030210', 'cui_str': 'Paired-Associate Learning'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]",80.0,0.0426632,"RESULTS Postoperative PALT and BVRT were significantly lower than preoperative PALT and","[{'ForeName': 'Wael F', 'Initials': 'WF', 'LastName': 'Hassan', 'Affiliation': 'Department of Anesthesia, Surgical ICU and Pain Management University of Beni-Suef, Beni-Suef, Egypt.'}, {'ForeName': 'Mona H', 'Initials': 'MH', 'LastName': 'Tawfik', 'Affiliation': 'Department of Neurology, University of Beni-Suef, Beni-Suef, Egypt - mona.neuro@yahoo.com.'}, {'ForeName': 'Tamer M', 'Initials': 'TM', 'LastName': 'Nabil', 'Affiliation': 'Department of General Surgery, University of Beni-Suef, Beni-Suef, Egypt.'}, {'ForeName': 'Rehab M', 'Initials': 'RM', 'LastName': 'Abd Elkareem', 'Affiliation': 'Department of Clinical and Chemical Pathology, University of Beni-Suef, Beni-Suef, Egypt.'}]",Minerva anestesiologica,['10.23736/S0375-9393.20.14012-4'] 1332,32449336,Comparison between the ultrasound-guided erector spinae block and the subcostal approach to the transversus abdominis plane block in obese patients undergoing sleeve gastrectomy: a randomized controlled trial.,"BACKGROUND Pain control in the morbidly obese has presented as an anesthetic challenge. The aim of this study is to assess the analgesic efficacy of ultrasound guided bilateral erector spinae block compared to bilateral subcostal transversus abdominis plane block. METHODS A prospective randomized, double-blinded controlled study was conducted at Kasr Alainy Hospital on 66 patients scheduled for laparoscopic sleeve gastrectomy. Patients were randomly allocated into three groups and received general anesthesia: bilateral erector spinae block at the level of T9 or bilateral subcostal transversus abdominis block or opioid analgesia (control group). The primary outcome was pain assessment by Visual Analogue Scale. RESULTS Visual Analogue Scale was lower in the erector spinae and transversus abdominis groups compared with the control group throughout the first 12 postoperative hours (P≤0.001). Visual Analogue Scale was lower in the erector spinae group in relation to control group at 18 postoperative hours (P=0.034). Visual Analogue Scale in the erector spinae group was significantly lower compared to transversus abdominis at the 12 postoperative hours. Twenty-four-hour postoperative pethidine consumption was higher in the control group (median 150, IQR 100-200) compared to both erector spinae (median 0, IQR 0-50) and transversus abdominis (median 50, IQR 0-100) groups (P<0.001). Erector spinae group showed less pethidine consumption than transversus abdominis group. CONCLUSIONS Ultrasound-guided single-shot T9 erector spinae plane block lowers postoperative pain scores, and reduces intraoperative and postoperative opioid consumption compared with both the subcostal approach transversus abdominis plane block and the control group in obese patients that had undergone sleeve gastrectomy.",2020,24hours postoperative pethidine consumption was higher in the control group (median 150 and IQR 100-200) compared to both erector spinae (median 0 and IQR 0-50) and transversus abdominis (median 50 and IQR 0-100) groups (p-value <0.001).,"['obese patients that had undergone sleeve gastrectomy', 'obese patients undergoing', '66 patients scheduled for']","['laparoscopic sleeve gastrectomy', 'general anesthesia: bilateral erector spinae block at the level of T9 or bilateral subcostal transversus abdominis block or opioid analgesia (control group', 'ultrasound-guided erector spinae block and the subcostal approach to the transversus abdominis plane block', 'sleeve gastrectomy', 'ultrasound guided bilateral erector spinae block']","['pain assessment by of Visual Analogue Scale', '24hours postoperative pethidine consumption', 'intraoperative and postoperative opioid consumption', 'postoperative pain scores', 'Visual Analogue Scale', 'analgesic efficacy', 'Visual analogue score', 'pethidine consumption', 'Visual analogue scores']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}]","[{'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0224301', 'cui_str': 'Structure of erector spinae muscle'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0442184', 'cui_str': 'Subcostal'}, {'cui': 'C0224378', 'cui_str': 'Structure of transversus abdominis muscle'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}]","[{'cui': 'C0030198', 'cui_str': 'Pain assessment'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0025376', 'cui_str': 'Meperidine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0234621', 'cui_str': 'Visual'}]",66.0,0.160298,24hours postoperative pethidine consumption was higher in the control group (median 150 and IQR 100-200) compared to both erector spinae (median 0 and IQR 0-50) and transversus abdominis (median 50 and IQR 0-100) groups (p-value <0.001).,"[{'ForeName': 'Bassant M', 'Initials': 'BM', 'LastName': 'Abdelhamid', 'Affiliation': 'Department of Anesthesiology, Pain Management and Surgical Intensive Care, Faculty of Medicine, Cairo University, Cairo, Egypt - bassantmohamed197@yahoo.com.'}, {'ForeName': 'Dalia', 'Initials': 'D', 'LastName': 'Khaled', 'Affiliation': 'Department of Anesthesiology, Pain Management and Surgical Intensive Care, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Mohamed A', 'Initials': 'MA', 'LastName': 'Mansour', 'Affiliation': 'Department of Anesthesiology, Pain Management and Surgical Intensive Care, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Mohamed M', 'Initials': 'MM', 'LastName': 'Hassan', 'Affiliation': 'Department of Anesthesiology, National Cancer Institute, Cairo University, Cairo, Egypt.'}]",Minerva anestesiologica,['10.23736/S0375-9393.20.14064-1'] 1333,32446880,Changes in parental feeding practices and preschoolers' food intake following a randomized controlled childhood obesity trial.,"Childhood obesity treatment involving parents is most effective during the preschool age. However, the mechanisms of change are not known. The present study reports on secondary outcomes (changes in parental feeding practices and child food intake) of early obesity treatment. The More and Less study is a randomized controlled trial conducted in Stockholm County, Sweden. Children with obesity (n = 174, mean BMI SDS 3.0, mean age 5 years, 56% girls) and their parents (60% with foreign background, 40% with a university degree) were randomized to: 1) standard treatment focusing on lifestyle recommendations (ST), 2) a parent support program with boosters (PGB), and 3) a parent support program without boosters (PGNB). The Child Feeding Questionnaire (CFQ) was used to measure parental feeding practices. Child food intake was assessed with a Food Frequency Questionnaire (FFQ). We calculated the monthly changes in CFQ practices and FFQ items based on four measurements. We did not find any significant between-group differences in parental feeding practices and child food intake over time. However, general linear models showed that changes in certain feeding practices predicted changes in child food intake. When ST was compared to the parent support groups, some associations moved in opposite directions. For example, increasing maternal restriction predicted increased consumption of cookies/buns in PGNB (b = 2.3, p < 0.05) and decreased consumption of cookies/buns in ST (b = -2.1, p < 0.05). This is among the few studies to examine the effect of parental feeding practices on child food intake and weight status after obesity treatment among preschoolers. We found no evidence that changes in feeding practices or changes in child food intake mediated child weight loss. Future studies should consider other intermediary processes related to general parenting practices and parent-child interactions.",2020,We did not find any significant between-group differences in parental feeding practices and child food habits over time.,"['Children with obesity (n\u202f=\u202f174, mean BMI SDS 3.0, mean age 5 years, 56% girls) and their parents (60% with foreign background, 40% with a university degree', 'child food habits and weight status after obesity treatment among preschoolers', 'Stockholm County, Sweden']","['standard treatment focusing on lifestyle recommendations (ST), 2) a parent support program with boosters (PGB), and 3) a parent support program without boosters (PGNB', 'parental feeding practices']","['Food Frequency Questionnaire (FFQ', 'parental feeding practices and child food habits) of early obesity treatment', 'consumption of cookies/buns in ST', 'Child Feeding Questionnaire (CFQ']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0037506', 'cui_str': 'Sodium lauryl sulfate'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0016468', 'cui_str': 'Eating Habits'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C4706528', 'cui_str': 'Obesity care'}, {'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0020975', 'cui_str': 'Booster vaccination'}]","[{'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0016468', 'cui_str': 'Eating Habits'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C4706528', 'cui_str': 'Obesity care'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C3853210', 'cui_str': 'Cookie'}, {'cui': 'C0005845', 'cui_str': 'Blood urea nitrogen measurement'}]",,0.0264302,We did not find any significant between-group differences in parental feeding practices and child food habits over time.,"[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Somaraki', 'Affiliation': 'Department of Food Studies, Nutrition and Dietetics, Uppsala University, Uppsala, Sweden. Electronic address: maria.somaraki@ikv.uu.se.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Eli', 'Affiliation': 'Unit for Biocultural Variation and Obesity, School of Anthropology and Museum Ethnography, University of Oxford, Oxford, UK; Social Science and Systems in Health, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK. Electronic address: karin.eli@anthro.ox.ac.uk.'}, {'ForeName': 'Kimmo', 'Initials': 'K', 'LastName': 'Sorjonen', 'Affiliation': 'Division of Psychology, Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden. Electronic address: kimmo.sorjonen@ki.se.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Ek', 'Affiliation': 'Division of Pediatrics, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden. Electronic address: anna.ek@ki.se.'}, {'ForeName': 'Pernilla', 'Initials': 'P', 'LastName': 'Sandvik', 'Affiliation': 'Department of Food Studies, Nutrition and Dietetics, Uppsala University, Uppsala, Sweden. Electronic address: pernilla.sandvik@ikv.uu.se.'}, {'ForeName': 'Paulina', 'Initials': 'P', 'LastName': 'Nowicka', 'Affiliation': 'Department of Food Studies, Nutrition and Dietetics, Uppsala University, Uppsala, Sweden; Division of Pediatrics, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden. Electronic address: paulina.nowicka@ikv.uu.se.'}]",Appetite,['10.1016/j.appet.2020.104746'] 1334,32546652,Wisdom of the expert crowd prediction of response for 3 neurology randomized trials.,"OBJECTIVE To explore the accuracy of combined neurology expert forecasts in predicting primary endpoints for trials. METHODS We identified one major randomized trial each in stroke, multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS) that was closing within 6 months. After recruiting a sample of neurology experts for each disease, we elicited forecasts for the primary endpoint outcomes in the trial placebo and treatment arms. Our main outcome was the accuracy of averaged predictions, measured using ordered Brier scores. Scores were compared against an algorithm that offered noncommittal predictions. RESULTS Seventy-one neurology experts participated. Combined forecasts of experts were less accurate than a noncommittal prediction algorithm for the stroke trial (pooled Brier score = 0.340, 95% subjective probability interval [sPI] 0.340 to 0.340 vs 0.185 for the uninformed prediction), and approximately as accurate for the MS study (pooled Brier score = 0.107, 95% confidence interval [CI] 0.081 to 0.133 vs 0.098 for the noncommittal prediction) and the ALS study (pooled Brier score = 0.090, 95% CI 0.081 to 0.185 vs 0.090). The 95% sPIs of individual predictions contained actual trial outcomes among 44% of experts. Only 18% showed prediction skill exceeding the noncommittal prediction. Independent experts and coinvestigators achieved similar levels of accuracy. CONCLUSION In this first-of-kind exploratory study, averaged expert judgments rarely outperformed noncommittal forecasts. However, experts at least anticipated the possibility of effects observed in trials. Our findings, if replicated in different trial samples, caution against the reliance on simple approaches for combining expert opinion in making research and policy decisions.",2020,"Combined forecasts of experts were less accurate than a noncommittal prediction algorithm for the stroke trial (pooled Brier score = 0.340, 95% subjective probability interval [sPI] 0.340 to 0.340 vs 0.185 for the uninformed prediction), and approximately as accurate for the MS study (pooled Brier score = 0.107, 95% confidence interval [CI] 0.081 to 0.133 vs 0.098 for the noncommittal prediction) and the ALS study (pooled Brier score = 0.090, 95% CI 0.081 to 0.185 vs 0.090).",['Seventy-one neurology experts participated'],['placebo'],[],"[{'cui': 'C0450389', 'cui_str': '71'}, {'cui': 'C0027855', 'cui_str': 'Neurology'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.395631,"Combined forecasts of experts were less accurate than a noncommittal prediction algorithm for the stroke trial (pooled Brier score = 0.340, 95% subjective probability interval [sPI] 0.340 to 0.340 vs 0.185 for the uninformed prediction), and approximately as accurate for the MS study (pooled Brier score = 0.107, 95% confidence interval [CI] 0.081 to 0.133 vs 0.098 for the noncommittal prediction) and the ALS study (pooled Brier score = 0.090, 95% CI 0.081 to 0.185 vs 0.090).","[{'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Atanasov', 'Affiliation': 'From Pytho LLC (P.A.), Brooklyn, NY; Department of Neurology (A.D.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Biomedical Ethics Unit, Department of Social Studies of Medicine (A.M., E.V., D.M.B., J.K.), and Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital (I.S.), McGill University, Montreal, Canada; Max Delbrueck Center for Molecular Medicine (F.P.), Berlin; Department of Neurology (F.P.), NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin; Humboldt-Universität zu Berlin (U.D.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin; and Department of Experimental Neurology and Center for Stroke Research Berlin and QUEST Center for Transforming Biomedical Research (U.D.), Berlin Institute of Health, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Diamantaras', 'Affiliation': 'From Pytho LLC (P.A.), Brooklyn, NY; Department of Neurology (A.D.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Biomedical Ethics Unit, Department of Social Studies of Medicine (A.M., E.V., D.M.B., J.K.), and Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital (I.S.), McGill University, Montreal, Canada; Max Delbrueck Center for Molecular Medicine (F.P.), Berlin; Department of Neurology (F.P.), NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin; Humboldt-Universität zu Berlin (U.D.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin; and Department of Experimental Neurology and Center for Stroke Research Berlin and QUEST Center for Transforming Biomedical Research (U.D.), Berlin Institute of Health, Germany.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'MacPherson', 'Affiliation': 'From Pytho LLC (P.A.), Brooklyn, NY; Department of Neurology (A.D.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Biomedical Ethics Unit, Department of Social Studies of Medicine (A.M., E.V., D.M.B., J.K.), and Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital (I.S.), McGill University, Montreal, Canada; Max Delbrueck Center for Molecular Medicine (F.P.), Berlin; Department of Neurology (F.P.), NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin; Humboldt-Universität zu Berlin (U.D.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin; and Department of Experimental Neurology and Center for Stroke Research Berlin and QUEST Center for Transforming Biomedical Research (U.D.), Berlin Institute of Health, Germany.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Vinarov', 'Affiliation': 'From Pytho LLC (P.A.), Brooklyn, NY; Department of Neurology (A.D.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Biomedical Ethics Unit, Department of Social Studies of Medicine (A.M., E.V., D.M.B., J.K.), and Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital (I.S.), McGill University, Montreal, Canada; Max Delbrueck Center for Molecular Medicine (F.P.), Berlin; Department of Neurology (F.P.), NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin; Humboldt-Universität zu Berlin (U.D.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin; and Department of Experimental Neurology and Center for Stroke Research Berlin and QUEST Center for Transforming Biomedical Research (U.D.), Berlin Institute of Health, Germany.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Benjamin', 'Affiliation': 'From Pytho LLC (P.A.), Brooklyn, NY; Department of Neurology (A.D.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Biomedical Ethics Unit, Department of Social Studies of Medicine (A.M., E.V., D.M.B., J.K.), and Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital (I.S.), McGill University, Montreal, Canada; Max Delbrueck Center for Molecular Medicine (F.P.), Berlin; Department of Neurology (F.P.), NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin; Humboldt-Universität zu Berlin (U.D.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin; and Department of Experimental Neurology and Center for Stroke Research Berlin and QUEST Center for Transforming Biomedical Research (U.D.), Berlin Institute of Health, Germany.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Shrier', 'Affiliation': 'From Pytho LLC (P.A.), Brooklyn, NY; Department of Neurology (A.D.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Biomedical Ethics Unit, Department of Social Studies of Medicine (A.M., E.V., D.M.B., J.K.), and Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital (I.S.), McGill University, Montreal, Canada; Max Delbrueck Center for Molecular Medicine (F.P.), Berlin; Department of Neurology (F.P.), NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin; Humboldt-Universität zu Berlin (U.D.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin; and Department of Experimental Neurology and Center for Stroke Research Berlin and QUEST Center for Transforming Biomedical Research (U.D.), Berlin Institute of Health, Germany.'}, {'ForeName': 'Friedemann', 'Initials': 'F', 'LastName': 'Paul', 'Affiliation': 'From Pytho LLC (P.A.), Brooklyn, NY; Department of Neurology (A.D.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Biomedical Ethics Unit, Department of Social Studies of Medicine (A.M., E.V., D.M.B., J.K.), and Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital (I.S.), McGill University, Montreal, Canada; Max Delbrueck Center for Molecular Medicine (F.P.), Berlin; Department of Neurology (F.P.), NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin; Humboldt-Universität zu Berlin (U.D.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin; and Department of Experimental Neurology and Center for Stroke Research Berlin and QUEST Center for Transforming Biomedical Research (U.D.), Berlin Institute of Health, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Dirnagl', 'Affiliation': 'From Pytho LLC (P.A.), Brooklyn, NY; Department of Neurology (A.D.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Biomedical Ethics Unit, Department of Social Studies of Medicine (A.M., E.V., D.M.B., J.K.), and Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital (I.S.), McGill University, Montreal, Canada; Max Delbrueck Center for Molecular Medicine (F.P.), Berlin; Department of Neurology (F.P.), NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin; Humboldt-Universität zu Berlin (U.D.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin; and Department of Experimental Neurology and Center for Stroke Research Berlin and QUEST Center for Transforming Biomedical Research (U.D.), Berlin Institute of Health, Germany.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Kimmelman', 'Affiliation': 'From Pytho LLC (P.A.), Brooklyn, NY; Department of Neurology (A.D.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Biomedical Ethics Unit, Department of Social Studies of Medicine (A.M., E.V., D.M.B., J.K.), and Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital (I.S.), McGill University, Montreal, Canada; Max Delbrueck Center for Molecular Medicine (F.P.), Berlin; Department of Neurology (F.P.), NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin; Humboldt-Universität zu Berlin (U.D.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin; and Department of Experimental Neurology and Center for Stroke Research Berlin and QUEST Center for Transforming Biomedical Research (U.D.), Berlin Institute of Health, Germany. jonathan.kimmelman@mcgill.ca.'}]",Neurology,['10.1212/WNL.0000000000009819'] 1335,32682996,THR1VE! Positive psychology intervention to treat diabetes distress in teens with type 1 diabetes: Rationale and trial design.,"Adolescents with type 1 diabetes (T1D) experience high rates of diabetes distress, which negatively influence self-management and glycemic control. Building on effective positive psychology interventions to improve adherence in adults, as well as our pilot work to adapt these interventions for adolescents, we developed a positive psychology intervention for adolescents with T1D. The goal of THR1VE! is to reduce diabetes distress in adolescents with T1D and improve their diabetes outcomes. This multi-site randomized controlled trial compares a Diabetes Education + text-message-based Positive Affect intervention, to a Diabetes Education control condition. In the ongoing trial, we are evaluating the effects of the intervention on adolescents' diabetes distress, self-management, and glycemic control. This paper describes the rationale, trial design, and methodology of the THR1VE! Study.",2020,"Adolescents with type 1 diabetes (T1D) experience high rates of diabetes distress, which negatively influence self-management and glycemic control.","['Adolescents with type 1 diabetes (T1D) experience high rates of diabetes distress', 'teens with type 1 diabetes', 'adolescents with T1D']","['Diabetes Education + text-message-based Positive Affect intervention', 'Positive psychology intervention']","[""adolescents' diabetes distress, self-management, and glycemic control"", 'diabetes distress']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0231303', 'cui_str': 'Distress'}]","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1510628', 'cui_str': 'Positive Psychology'}]","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",,0.0417244,"Adolescents with type 1 diabetes (T1D) experience high rates of diabetes distress, which negatively influence self-management and glycemic control.","[{'ForeName': 'Sarah S', 'Initials': 'SS', 'LastName': 'Jaser', 'Affiliation': 'Vanderbilt University Medical Center, USA. Electronic address: sarah.jaser@vumc.org.'}, {'ForeName': 'Karishma', 'Initials': 'K', 'LastName': 'Datye', 'Affiliation': 'Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Troy', 'Initials': 'T', 'LastName': 'Morrow', 'Affiliation': 'Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Sinisterra', 'Affiliation': ""Children's National Hospital, USA.""}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'LeStourgeon', 'Affiliation': 'Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Fayo', 'Initials': 'F', 'LastName': 'Abadula', 'Affiliation': 'Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Grace E', 'Initials': 'GE', 'LastName': 'Bell', 'Affiliation': 'Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Randi', 'Initials': 'R', 'LastName': 'Streisand', 'Affiliation': ""Children's National Hospital, USA.""}]",Contemporary clinical trials,['10.1016/j.cct.2020.106086'] 1336,32546421,Small changes in glucose variability induced by low and high glycemic index diets are not associated with changes in β-cell function in adults with pre-diabetes.,"Oscillating glucose levels can increase oxidative stress and may contribute to β-cell dysfunction. We tested the hypothesis that increased glycemic variability contributes to β-cell dysfunction by experimentally altering glucose variability with controlled diets varying in glycemic index (GI). Fifty-two adults with prediabetes received a 2-week moderate GI (GI = 55-58) control diet followed by randomization to a four-week low GI (LGI: GI < 35) or high GI (HGI HI > 70) diet. Those on the HGI diet were randomized to placebo or the antioxidant N-acetylcysteine (NAC). Participants underwent blinded CGMS, fasting oxidative stress markers and an intravenous glucose tolerance test to estimate β-cell function (disposition index: DI). On the control diet, DI was inversely correlated with SD glucose (r = -0.314, p = 0.03), but neither DI nor glucose variability were associated with oxidative stress markers. The LGI diet decreased SD glucose (Control 0.96 ± 0.08 vs. LGI 0.79 ± 0.06, p = 0.02) while the HGI diet increased it (Control 0.88 ± 0.06 vs. HGI 1.06 ± 0.07, p = 0.03). Neither DI nor oxidative stress markers changed after the LGI or HGI diets. NAC had no effect on DI, glucose variability or oxidative stress markers. We conclude small changes in glucose variability induced by dietary GI in adults with pre-diabetes are unlikely to contribute to β-cell dysfunction.",2020,"The LGI diet decreased SD glucose (Control 0.96 ± 0.08 vs. LGI 0.79 ± 0.06, p = 0.02) while the HGI diet increased it (Control 0.88 ± 0.06 vs. HGI 1.06 ± 0.07, p = 0.03).","['Fifty-two adults with prediabetes received a', 'adults with pre-diabetes']","['2-week moderate GI (GI\u202f=\u202f55-58) control diet followed by randomization to a four-week low GI (LGI: GI\u202f<\u202f35) or high GI (HGI HI', 'antioxidant N-acetylcysteine (NAC', 'NAC', 'placebo']","['oxidative stress markers', 'oxidative stress', 'SD glucose', 'glucose variability', 'β-cell function', 'DI, glucose variability or oxidative stress markers']","[{'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0743195', 'cui_str': 'Dietary control'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0007613', 'cui_str': 'Physiology, Cell'}]",52.0,0.0150612,"The LGI diet decreased SD glucose (Control 0.96 ± 0.08 vs. LGI 0.79 ± 0.06, p = 0.02) while the HGI diet increased it (Control 0.88 ± 0.06 vs. HGI 1.06 ± 0.07, p = 0.03).","[{'ForeName': 'Kristina M', 'Initials': 'KM', 'LastName': 'Utzschneider', 'Affiliation': 'Research and Development, Department of Medicine, 1660 S Columbian Way (151), VA Puget Sound Health Care System, Seattle, WA 98108, USA; Division of Metabolism, Endocrinology and Nutrition, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195-6426, USA. Electronic address: kutzschn@uw.edu.'}, {'ForeName': 'Tonya N', 'Initials': 'TN', 'LastName': 'Johnson', 'Affiliation': 'Research and Development, Department of Medicine, 1660 S Columbian Way (151), VA Puget Sound Health Care System, Seattle, WA 98108, USA; Seattle Institute for BIomedical and Clinical Research, Seattle, WA, USA.'}, {'ForeName': 'Kara L', 'Initials': 'KL', 'LastName': 'Breymeyer', 'Affiliation': 'Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Bettcher', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195-6426, USA. Electronic address: bettcher@uw.edu.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Raftery', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195-6426, USA. Electronic address: draftery@uw.edu.'}, {'ForeName': 'Katherine M', 'Initials': 'KM', 'LastName': 'Newton', 'Affiliation': 'Kaiser Permanente Health Research Institute, 1730 Minor Ave, Seattle, WA 98101, USA. Electronic address: Katherine.M.Newton@kp.org.'}, {'ForeName': 'Marian L', 'Initials': 'ML', 'LastName': 'Neuhouser', 'Affiliation': 'Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA. Electronic address: mneuhous@fredhutch.org.'}]",Journal of diabetes and its complications,['10.1016/j.jdiacomp.2020.107586'] 1337,32545416,Risk Factors for Delayed Neurocognitive Recovery According to Brain Biomarkers and Cerebral Blood Flow Velocity.,"Background and Objectives: The aim of this study is to identify risk factors for the development of delayed neurocognitive recovery (dNCR). Methods: 140 patients underwent neurocognitive evaluations (Adenbrooke, MoCa, trial making, and CAM test) and middle cerebral artery (MCA) blood flow velocity (BFV) measurements, one day before cardiac surgery. BFV was re-evaluated after anesthesia induction, before the beginning, middle, end, and after cardiopulmonary bypass (CPB) and postsurgery. To measure glial fibrillary acidic protein (GFAP) and neurofilament heavy chain (Nf-H), blood samples were collected after anesthesia induction, 24 and 48 h after the surgery. Neurocognitive evaluation was repeated 7-10 days after surgery. According to the results, patients were divided into two groups: with dNCR (dNCR group) and without dNCR (non-dNCR group). Results: 101 patients completed participation in this research. GFAP increased in both the non-dNCR group ( p < 0.01) and in the dNCR group ( p < 0.01), but there was no difference between the groups (after 24 h, p 0.342; after 48 h, p 0.273). Nf-H increased in both groups ( p < 0.01), but there was no difference between them (after 24 h, p = 0.240; after 48 h, p = 0.597). MCA BFV was significantly lower in the dNCR group during the bypass (37.13 cm/s SD 7.70 versus 43.40 cm/s SD 9.56; p = 0.001) and after surgery (40.54 cm/s SD 11.21 versus 47.6 cm/s SD 12.01; p = 0.003). Results of neurocognitive tests correlated with CO 2 concentration (Pearson's r 0.40, p < 0.01), hematocrit (r 0.42, p < 0.01), MCA BFV during bypass (r 0.41, p < 0.01), and age (r -0.533, p < 0.01). The probability of developing dNCR increases 1.21 times with every one year of increased age ( p < 0.01). The probability of developing dNCR increases 1.07 times with a decrease of BFV within 1 cm/s during bypass ( p = 0.02 ) . Conclusion : Risk factors contributing to dNCR among the tested patients were older age and middle cerebral artery blood flow velocity decrease during bypass.",2020,"GFAP increased in both the non-dNCR group ( p < 0.01) and in the dNCR group ( p < 0.01), but there was no difference between the groups (after 24 h, p 0.342; after 48 h, p 0.273).","['140 patients underwent neurocognitive evaluations (Adenbrooke, MoCa, trial making, and CAM test) and', '101 patients completed participation in this research']","['dNCR (dNCR group) and without dNCR (non-dNCR group', 'dNCR']","['BFV', 'glial fibrillary acidic protein (GFAP) and neurofilament heavy chain (Nf-H), blood samples', 'Delayed Neurocognitive Recovery', 'Brain Biomarkers and Cerebral Blood Flow Velocity', 'hematocrit', 'GFAP', 'Neurocognitive evaluation', 'MCA BFV', 'middle cerebral artery (MCA) blood flow velocity (BFV) measurements']","[{'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0025750', 'cui_str': ""3,3'-Dichloro-4,4'-Diaminodiphenylmethane""}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0002346', 'cui_str': 'Medicine, Alternative'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0017626', 'cui_str': 'Glial fibrillary acidic protein'}, {'cui': 'C0027834', 'cui_str': 'Neurofilaments'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C1505576', 'cui_str': 'NEFH protein, human'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0000325', 'cui_str': '20-Methylcholanthrene'}, {'cui': 'C0149566', 'cui_str': 'Structure of middle cerebral artery'}, {'cui': 'C0005798', 'cui_str': 'Blood Flow Velocity'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",140.0,0.0362471,"GFAP increased in both the non-dNCR group ( p < 0.01) and in the dNCR group ( p < 0.01), but there was no difference between the groups (after 24 h, p 0.342; after 48 h, p 0.273).","[{'ForeName': 'Rasa', 'Initials': 'R', 'LastName': 'Bukauskienė', 'Affiliation': 'Department of Cardiothoracic and Vascular Surgery, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.'}, {'ForeName': 'Edmundas', 'Initials': 'E', 'LastName': 'Širvinskas', 'Affiliation': 'Department of Cardiothoracic and Vascular Surgery, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.'}, {'ForeName': 'Tadas', 'Initials': 'T', 'LastName': 'Lenkutis', 'Affiliation': 'Department of Cardiothoracic and Vascular Surgery, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.'}, {'ForeName': 'Rimantas', 'Initials': 'R', 'LastName': 'Benetis', 'Affiliation': 'Department of Cardiothoracic and Vascular Surgery, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.'}, {'ForeName': 'Rasa', 'Initials': 'R', 'LastName': 'Steponavičiūtė', 'Affiliation': 'Department of Laboratory Medicine, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.'}]","Medicina (Kaunas, Lithuania)",['10.3390/medicina56060288'] 1338,32558709,Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging.,"PURPOSE Physiological pancreaticoduodenal uptake of radiolabeled exendin-4 in Brunner glands of the proximal duodenum is the most common pitfall for false interpretation of glucagon-like peptide-1 receptor (GLP-1R) imaging. The aim of this study was to analyze the pancreaticoduodenal uptake in GLP-1R PET/CT and SPECT/CT images and to identify additional potential reading pitfalls in patients with suspected insulinoma. METHODS A post hoc analysis of a prospective study, including 52 consecutive patients, was performed. All patients underwent 1 Ga-exendin-4 PET/CT and 2 In-exendin-4 SPECT/CT scans (4 and 72 hours postinjection) in a randomized crossover order. Three board-certified nuclear medicine physicians read all scans independently. They were unaware of other results. Reference standard was surgery with histopathological confirmation of an insulinoma/nesidioblastosis and normalization of blood glucose levels after surgery. RESULTS There were no false-positive readings. However, there were a number of false-negative PET/CT and SPECT/CT readings, respectively: (1) due to false interpretation of uptake in the pancreaticoduodenal region (falsely interpreted as physiological uptake in Brunner glands instead of an insulinoma in 0.6% vs 9.0%), (2) due to ectopic insulinoma (0% vs 2.6%), (3) due to small insulinoma (1.9% vs 5.1%), (4) due to insulinoma overlap with kidneys (1.9% vs 4.5%), and (5) due to nesidioblastosis (0.6% and 1.9%). Pitfalls were identified in all GLP-1R PET/CT and SPECT/CT scans. CONCLUSIONS Peripancreatic uptake, small size of an insulinoma, insulinoma overlap with kidneys, and presence of nesidioblastosis are potential pitfalls in GLP-1R imaging, which can lead to false reading results.",2020,There were no false-positive readings.,"['patients with suspected insulinoma', '52 consecutive patients, was performed']",['GLP-1R PET/CT and SPECT/CT images'],"['blood glucose levels', 'ectopic insulinoma']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0021670', 'cui_str': 'Insulinoma'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0378073', 'cui_str': 'GLP-1R Receptor'}, {'cui': 'C1699633', 'cui_str': 'Positron emission tomography with computed tomography'}, {'cui': 'C3472245', 'cui_str': 'Single photon emission computed tomography with computed tomography'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}]","[{'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}, {'cui': 'C0340464', 'cui_str': 'Ectopic beats'}, {'cui': 'C0021670', 'cui_str': 'Insulinoma'}]",52.0,0.0465109,There were no false-positive readings.,"[{'ForeName': 'Kwadwo', 'Initials': 'K', 'LastName': 'Antwi', 'Affiliation': 'From the Clinic of Radiology and Nuclear Medicine.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Hepprich', 'Affiliation': 'Division of Endocrinology, Diabetology and Metabolism, University Hospital Basel.'}, {'ForeName': 'Natasha A', 'Initials': 'NA', 'LastName': 'Müller', 'Affiliation': 'Faculty of Clinical Medicine, University of Basel, Basel.'}, {'ForeName': 'Jean Claude', 'Initials': 'JC', 'LastName': 'Reubi', 'Affiliation': 'Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Bern, Bern.'}, {'ForeName': 'Melpomeni', 'Initials': 'M', 'LastName': 'Fani', 'Affiliation': 'From the Clinic of Radiology and Nuclear Medicine.'}, {'ForeName': 'Christof', 'Initials': 'C', 'LastName': 'Rottenburger', 'Affiliation': 'From the Clinic of Radiology and Nuclear Medicine.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Nicolas', 'Affiliation': 'From the Clinic of Radiology and Nuclear Medicine.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Kaul', 'Affiliation': 'From the Clinic of Radiology and Nuclear Medicine.'}, {'ForeName': 'Emanuel R', 'Initials': 'ER', 'LastName': 'Christ', 'Affiliation': 'Division of Endocrinology, Diabetology and Metabolism, University Hospital Basel.'}, {'ForeName': 'Damian', 'Initials': 'D', 'LastName': 'Wild', 'Affiliation': 'From the Clinic of Radiology and Nuclear Medicine.'}]",Clinical nuclear medicine,['10.1097/RLU.0000000000003124'] 1339,32554025,swCRTdesign: An R Package for Stepped Wedge Trial Design and Analysis.,"BACKGROUND AND OBJECTIVE Stepped wedge trials (SWTs) are a type of cluster-randomized trial that are commonly used to evaluate health care interventions. Most SWT-related software packages have restrictive assumptions about the study design and correlation structure of the data. The objective of this paper is to present a package and corresponding web-based graphical user interface (GUI) that provide researchers with another, more flexible option for SWT design and analysis. METHODS We developed an R package swCRTdesign ('stepped wedge Cluster Randomized Trial design'), which uses a random effects model to account for correlation in the data induced by a SWT design. Possible sources of correlation include clusters, time within clusters, and treatment within clusters. RESULTS swCRTdesign allows a user to calculate power, simulate SWT data to streamline simulation studies (e.g. to estimate power), and create descriptive summaries and plots. Additionally, a GUI, developed using shiny, is available to calculate power and create power curves and design plots. CONCLUSIONS The swCRTdesign package accommodates a wide variety of SWT designs, and makes it easy to account for some sources of correlation which are not found in other packages. The user-friendly web-based GUI makes some swCRTdesign features accessible to researchers not familiar with R. These two resources will make appropriately complex SWT calculations more accessible to scientists from a wide variety of backgrounds.",2020,"We developed an R package swCRTdesign ('stepped wedge Cluster Randomized Trial design'), which uses a random effects model to account for correlation in the data induced by a SWT design.",[],['swCRTdesign'],[],[],[],[],,0.150645,"We developed an R package swCRTdesign ('stepped wedge Cluster Randomized Trial design'), which uses a random effects model to account for correlation in the data induced by a SWT design.","[{'ForeName': 'Emily C', 'Initials': 'EC', 'LastName': 'Voldal', 'Affiliation': 'Department of Biostatistics, University of Washington, Box 357232, Seattle, WA 98195, United States. Electronic address: voldal@uw.edu.'}, {'ForeName': 'Navneet R', 'Initials': 'NR', 'LastName': 'Hakhu', 'Affiliation': 'Department of Statistics, University of California, Irvine, Irvine, CA 92697, United States.'}, {'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Xia', 'Affiliation': 'Department of Biostatistics, University of Washington, Box 357232, Seattle, WA 98195, United States.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Heagerty', 'Affiliation': 'Department of Biostatistics, University of Washington, Box 357232, Seattle, WA 98195, United States.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Hughes', 'Affiliation': 'Department of Biostatistics, University of Washington, Box 357232, Seattle, WA 98195, United States.'}]",Computer methods and programs in biomedicine,['10.1016/j.cmpb.2020.105514'] 1340,32554770,Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial.,"OBJECTIVE To determine whether comorbidity is associated with clinical (relapses, disability worsening) and MRI outcomes in multiple sclerosis (MS) by conducting a secondary analysis of the CombiRx clinical trial. METHODS CombiRx compared interferon beta-1a, glatiramer acetate, and the combination of these agents. For participants eligible for evaluation of 6-month confirmed disability worsening, we used medical history, concomitant medications, and adverse events to ascertain comorbidity status. Comorbid conditions evaluated included hypertension, dyslipidemia, diabetes mellitus, depression, anxiety disorders, and migraine. Clinical outcomes included disease activity consisting of protocol-defined relapses, disability worsening, and MRI activity. We summarized the prevalence of these comorbid conditions and their association with disease activity and its components using multivariable Cox regression. RESULTS Of the 1,008 participants randomized, 959 (95.1%) were eligible for assessment of 6-month disability worsening; for this subgroup, the median length of follow-up was 3.4 years (range 0.5-6.9 years). Overall, 55.1% of participants had ≥1 comorbidity at enrollment. After adjustment, anxiety (hazard ratio [HR] 1.25, 95% confidence interval [CI] 1.01-1.55) and dyslipidemia (HR 1.32, 95% CI 1.01-1.72) were associated with an increased hazard of any disease activity, while migraine (HR 0.80, 95% CI 0.67-0.97) was associated with a decreased hazard. CONCLUSIONS In this large trial population with rigorously obtained outcomes, comorbid conditions were common among participants and influenced disease outcomes, including relapses. The comorbidity burden of clinical trial participants with MS may be an important factor in the outcome of clinical trials. Additional investigations of the impact of comorbidity on clinical trial outcomes and response to disease-modifying therapies are warranted.",2020,"After adjustment, anxiety (hazard ratio [HR]: 1.25; 95%CI: 1.01-1.55), and dyslipidemia (HR 1.32; 95%CI: 1.01-1.72) were associated with an increased hazard of any disease activity, while migraine (HR 0.80;","['1008 participants randomized, 959 (95.1%) were eligible for assessment of 6-month disability worsening; for this subgroup the median length of follow-up was 3.4 years (range 0.5-6.9 years', 'multiple sclerosis (MS']","['interferon-beta-1a, glatiramer acetate']","['disease activity consisting of protocol-defined relapses, disability worsening and MRI activity', 'hypertension, dyslipidemia, diabetes, depression, anxiety disorders, and migraine', 'dyslipidemia', 'hazard of any disease activity']","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C4517692', 'cui_str': '3.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C4517826', 'cui_str': '6.9'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}]","[{'cui': 'C0254119', 'cui_str': 'Interferon beta-1a'}, {'cui': 'C0000975', 'cui_str': 'Acetate'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemia'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}]",1008.0,0.179747,"After adjustment, anxiety (hazard ratio [HR]: 1.25; 95%CI: 1.01-1.55), and dyslipidemia (HR 1.32; 95%CI: 1.01-1.72) were associated with an increased hazard of any disease activity, while migraine (HR 0.80;","[{'ForeName': 'Amber', 'Initials': 'A', 'LastName': 'Salter', 'Affiliation': 'From the Department of Biostatistics (A.S.), Washington University in St. Louis, MO; College of Pharmacy (K.K.), and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; Department of Medical Epidemiology and Biostatistics (K.K.), Karolinska Institutet, Solna, Sweden; Department of Neurology (K.C.F.), Johns Hopkins School of Medicine, Baltimore, MD; and Department of Biostatistics (G.C.), University of Alabama in Birmingham School of Public Health. amber@wustl.edu.'}, {'ForeName': 'Kaarina', 'Initials': 'K', 'LastName': 'Kowalec', 'Affiliation': 'From the Department of Biostatistics (A.S.), Washington University in St. Louis, MO; College of Pharmacy (K.K.), and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; Department of Medical Epidemiology and Biostatistics (K.K.), Karolinska Institutet, Solna, Sweden; Department of Neurology (K.C.F.), Johns Hopkins School of Medicine, Baltimore, MD; and Department of Biostatistics (G.C.), University of Alabama in Birmingham School of Public Health.'}, {'ForeName': 'Kathryn C', 'Initials': 'KC', 'LastName': 'Fitzgerald', 'Affiliation': 'From the Department of Biostatistics (A.S.), Washington University in St. Louis, MO; College of Pharmacy (K.K.), and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; Department of Medical Epidemiology and Biostatistics (K.K.), Karolinska Institutet, Solna, Sweden; Department of Neurology (K.C.F.), Johns Hopkins School of Medicine, Baltimore, MD; and Department of Biostatistics (G.C.), University of Alabama in Birmingham School of Public Health.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Cutter', 'Affiliation': 'From the Department of Biostatistics (A.S.), Washington University in St. Louis, MO; College of Pharmacy (K.K.), and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; Department of Medical Epidemiology and Biostatistics (K.K.), Karolinska Institutet, Solna, Sweden; Department of Neurology (K.C.F.), Johns Hopkins School of Medicine, Baltimore, MD; and Department of Biostatistics (G.C.), University of Alabama in Birmingham School of Public Health.'}, {'ForeName': 'Ruth Ann', 'Initials': 'RA', 'LastName': 'Marrie', 'Affiliation': 'From the Department of Biostatistics (A.S.), Washington University in St. Louis, MO; College of Pharmacy (K.K.), and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; Department of Medical Epidemiology and Biostatistics (K.K.), Karolinska Institutet, Solna, Sweden; Department of Neurology (K.C.F.), Johns Hopkins School of Medicine, Baltimore, MD; and Department of Biostatistics (G.C.), University of Alabama in Birmingham School of Public Health.'}]",Neurology,['10.1212/WNL.0000000000010024'] 1341,32561468,Enhancing prolonged exposure therapy for PTSD among veterans with oxytocin: Design of a multisite randomized controlled trial.,"Posttraumatic stress disorder (PTSD) is the most highly prevalent mental health disorder among U.S. military Veterans. Prolonged Exposure (PE) therapy is one of the most widely used evidence-based treatments for PTSD, but there is substantial room for improvement in outcomes and retention rates. Accumulating data suggest that oxytocin offers a promising pharmacological approach towards achieving this goal. Therefore, the primary objective of this two-site Phase II study is to examine the ability of oxytocin (vs. placebo) administration combined with PE therapy to (1) reduce PTSD symptom severity, (2) accelerate the rate of PTSD symptom improvement, and (3) improve PE adherence and retention rates. To accomplish these objectives, we will employ a randomized, double-blind, placebo-controlled trial and use standardized, repeated dependent measures of change at five time points (baseline, mid-treatment, end of treatment, and 3 and 6 month follow-up). Intranasal oxytocin (40 IU) will be administered directly prior to each PE therapy session. Findings from this study will provide critical new information regarding the efficacy of oxytocin to augment psychosocial treatment for PTSD, as well as information regarding the physiological mechanisms underlying PTSD and positive treatment response. ClinicalTrials.gov Identifier: NCT04228289.",2020,"Findings from this study will provide critical new information regarding the efficacy of oxytocin to augment psychosocial treatment for PTSD, as well as information regarding the physiological mechanisms underlying PTSD and positive treatment response.","['Posttraumatic stress disorder (PTSD', 'PTSD among veterans with']","['Prolonged Exposure (PE) therapy', 'oxytocin', 'oxytocin (vs. placebo) administration combined with PE therapy', 'Intranasal oxytocin', 'placebo']","['PTSD symptom severity, (2) accelerate the rate of PTSD symptom improvement, and (3) improve PE adherence and retention rates']","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}]","[{'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}]","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0521110', 'cui_str': 'Accelerated'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}]",,0.421747,"Findings from this study will provide critical new information regarding the efficacy of oxytocin to augment psychosocial treatment for PTSD, as well as information regarding the physiological mechanisms underlying PTSD and positive treatment response.","[{'ForeName': 'Julianne C', 'Initials': 'JC', 'LastName': 'Flanagan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA; Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA. Electronic address: hellmuth@musc.edu.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Mitchell', 'Affiliation': 'Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA; Department of Neurology, University of California San Francisco, San Francisco, CA, USA; San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA. Electronic address: jennifer.mitchell@ucsf.edu.'}, {'ForeName': 'Nathaniel L', 'Initials': 'NL', 'LastName': 'Baker', 'Affiliation': 'Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA. Electronic address: bakern@musc.edu.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Woolley', 'Affiliation': 'Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA; San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA. Electronic address: josh.woolley@ucsf.edu.'}, {'ForeName': 'Bethany', 'Initials': 'B', 'LastName': 'Wangelin', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA; Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA. Electronic address: bethany.wangelin@va.gov.'}, {'ForeName': 'Sudie E', 'Initials': 'SE', 'LastName': 'Back', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA; Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA. Electronic address: backs@musc.edu.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'McQuaid', 'Affiliation': 'Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA; San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA. Electronic address: john.mcquaid@va.gov.'}, {'ForeName': 'Thomas C', 'Initials': 'TC', 'LastName': 'Neylan', 'Affiliation': 'Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA; Department of Neurology, University of California San Francisco, San Francisco, CA, USA; San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA. Electronic address: thomas.neylan@ucsf.edu.'}, {'ForeName': 'William R', 'Initials': 'WR', 'LastName': 'Wolfe', 'Affiliation': 'Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA; San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA. Electronic address: william.wolfe@ucsf.edu.'}, {'ForeName': 'Kathleen T', 'Initials': 'KT', 'LastName': 'Brady', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA; Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA. Electronic address: bradykt@musc.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106074'] 1342,32568108,Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia.,"BACKGROUND Carbidopa (CD) and levodopa (LD) extended release (CD-LD ER) capsules are designed to combine both immediate and extended release pharmacokinetics. In the phase 3, randomized, double-blind, ADVANCE-PD trial, patients randomized to CD-LD ER experienced a 1.17-hour greater reduction in OFF time compared to patients randomized to CD-LD IR (p < 0.0001). OBJECTIVE To compare CD-LD IR optimization to CD-LD ER conversion based on patient dyskinesia status at baseline using data from the ADVANCE-PD trial. METHODS This was a retrospective analysis of the ADVANCE-PD study. Patients were categorized by dyskinesia status at baseline into 1) those who had No Dyskinesia (ND), 2) those who had Non-Troublesome Dyskinesia Only (NTDO), and 3) those who had Troublesome Dyskinesia (TD). RESULTS Comparative reductions in OFF time favoring CD-LD ER over CD-LD IR were similar for the ND (-1.08 h, p = 0.0071, n = 183) and NTDO (-1.12 h, p = 0.0104, n = 131) groups, and smaller for the TD group (-0.82 h, p = 0.2382, n = 79). Reductions in OFF time for both CD-LD ER conversion and CD-LD IR adjustment were largest within the ND group and smallest within the TD group (CD-LD ER: ND -2.86 h, NTDO -2.11 h, TD -1.36 h; CD-LD IR: ND -1.78 h, NTDO -0.99 h, TD -0.55 h). CONCLUSION Responses to both CD-LD IR adjustment and CD-LD ER conversion depended on baseline dyskinesia status. Significant reductions in OFF time with CD-LD ER compared to CD-LD IR were observed in the ND and NTDO groups. In the TD group, comparing CD-LD ER conversion to CD-LD IR optimization, benefits were still observed, but there was less reduction in OFF time, less reduction in troublesome dyskinesia, and fewer patients self-rated themselves much or very much improved than in the ND and NTDO groups. These data suggest that in clinical practice, the best chances for success with conversion from CD-LD IR to CD-LD ER are in patients without TD.",2020,Significant reductions in OFF time with CD-LD ER compared to CD-LD IR were observed in the ND and NTDO groups.,"['Patients were categorized by dyskinesia status at baseline into 1) those who had No Dyskinesia (ND), 2) those who had Non-Troublesome Dyskinesia', 'Patients with and without Troublesome and Non-Troublesome Dyskinesia']","['CD-LD IR adjustment and CD-LD ER conversion', 'ND', 'Carbidopa (CD) and levodopa (LD) extended release (CD-LD ER, Rytary®) capsules', 'CD-LD IR optimization to CD-LD ER conversion', 'CD-LD ER', 'Carbidopa and Levodopa Extended Release Capsules (Rytary®']","['troublesome dyskinesia', 'CD-LD IR', 'OFF time', 'OFF time favoring CD-LD ER over CD-LD IR', 'Troublesome Dyskinesia (TD', 'OFF time for both CD-LD ER conversion and CD-LD IR adjustment']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013384', 'cui_str': 'Dyskinesia'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]","[{'cui': 'C0353697', 'cui_str': 'Carbidopa- and levodopa-containing product'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0006982', 'cui_str': 'Carbidopa'}, {'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C3872096', 'cui_str': 'Rytary'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}]","[{'cui': 'C0013384', 'cui_str': 'Dyskinesia'}, {'cui': 'C0353697', 'cui_str': 'Carbidopa- and levodopa-containing product'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}]",,0.017814,Significant reductions in OFF time with CD-LD ER compared to CD-LD IR were observed in the ND and NTDO groups.,"[{'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Hauser', 'Affiliation': 'University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Leonid', 'Initials': 'L', 'LastName': 'Zeitlin', 'Affiliation': 'Quartesian, Princeton, NJ, USA.'}, {'ForeName': 'Stanley', 'Initials': 'S', 'LastName': 'Fisher', 'Affiliation': 'Amneal Pharmaceuticals, Bridgewater, NJ, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': ""D'Souza"", 'Affiliation': 'Amneal Pharmaceuticals, Bridgewater, NJ, USA.'}]",Journal of Parkinson's disease,['10.3233/JPD-202010'] 1343,32568111,Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized Trial.,"BACKGROUND Treatment of patients with late-stage parkinsonism is often sub-optimal. OBJECTIVE To test the effectiveness of recommendations by a movement disorder specialist with expertise in late-stage parkinsonism. METHODS Ninety-one patients with late-stage parkinsonism considered undertreated were included in apragmatic a pragmatic multi-center randomized-controlled trial with six-month follow-up. The intervention group received a letter with treatment recommendations to their primary clinician based on an extensive clinical assessment. Controls received care as usual. The primary outcome was the Unified Parkinson Disease Rating Scale (UPDRS)part-II (Activities of Daily Living). Other outcomes included quality-of-life (PDQ-8), mental health (UPDRS-I), motor function (UPDRS-III), treatment complications (UPDRS-IV), cognition (Mini-mental-state-examination), non-motor symptoms (Non-Motor-Symptoms-scale), health status (EQ-5D-5L) and levodopa-equivalent-daily-dose (LEDD). We also assessed adherence to recommendations. In addition to intention-to-treat analyses, a per-protocol analysis was conducted. RESULTS Sample size calculation required 288 patients, but only 91 patients could be included. Treating physicians followed recommendations fully in 16 (28%) and partially in 21 (36%) patients. The intention-to-treat analysis showed no difference in primary outcome (between-group difference = -1.2, p = 0.45), but there was greater improvement for PDQ-8 in the intervention group (between-group difference = -3.7, p = 0.02). The per-protocol analysis confirmed these findings, and showed less deterioration in UPDRS-part I, greater improvement on UPDRS-total score and greater increase in LEDD in the intervention group. CONCLUSIONS The findings suggest that therapeutic gains may be reached even in this vulnerable group of patients with late-stage parkinsonism, but also emphasize that specialist recommendations need to be accompanied by better strategies to implement these to further improve outcomes.",2020,"The intention-to-treat analysis showed no difference in primary outcome (between-group difference = -1.2, p = 0.45), but there was greater improvement for PDQ-8 in the intervention group (between-group difference = -3.7, p = 0.02).","['patients with late-stage parkinsonism', 'Ninety-one patients with late-stage parkinsonism considered undertreated were included in apragmatic multi-center randomized-controlled trial with six-month follow-up', 'Undertreated Late-Stage Parkinsonism']",['letter with treatment recommendations to their primary clinician based on an extensive clinical assessment'],"['Unified Parkinson Disease Rating Scale (UPDRS)part-II (Activities of Daily Living).Other outcomes included quality-of-life (PDQ-8), mental health (UPDRS-I), motor function (UPDRS-III), treatment complications (UPDRS-IV), cognition (Mini-mental-state-examination), non-motor symptoms (Non-Motor-Symptoms-scale), health status (EQ-5D-5L) and levodopa-equivalent-daily-dose (LEDD', 'PDQ-8', 'UPDRS-total score', 'LEDD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1279941', 'cui_str': 'Late stage'}, {'cui': 'C0242422', 'cui_str': 'Parkinsonism'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0282413', 'cui_str': 'Letters as Topic'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",91.0,0.170072,"The intention-to-treat analysis showed no difference in primary outcome (between-group difference = -1.2, p = 0.45), but there was greater improvement for PDQ-8 in the intervention group (between-group difference = -3.7, p = 0.02).","[{'ForeName': 'Adrianus L A J', 'Initials': 'ALAJ', 'LastName': 'Hommel', 'Affiliation': 'Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Groenhuysen Organisation, Roosendaal, the Netherlands.'}, {'ForeName': 'Marjan J', 'Initials': 'MJ', 'LastName': 'Meinders', 'Affiliation': 'Radboud University Medical Center, Radboud Institute for Health Sciences, Scientici Center for Quality of Healthcare, Nijmegen, the Netherlands.'}, {'ForeName': 'Nico J', 'Initials': 'NJ', 'LastName': 'Weerkamp', 'Affiliation': 'Department of Neurology, Bronovo Medical Center, The Hague, The Netherlands.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Richinger', 'Affiliation': 'Interdisziplinäres Zentrum für Palliativmedizin und Klinik für Neurologie Universität München - Klinikum Großhadern, Munich, Germany. Institute of Nursing Science and -Practice, Paracelsus Medical University Salzburg, Austria.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Schmotz', 'Affiliation': 'Interdisziplinäres Zentrum für Palliativmedizin und Klinik für Neurologie Universität München - Klinikum Großhadern, Munich, Germany. Institute of Nursing Science and -Practice, Paracelsus Medical University Salzburg, Austria.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Lorenzl', 'Affiliation': 'Interdisziplinäres Zentrum für Palliativmedizin und Klinik für Neurologie Universität München - Klinikum Großhadern, Munich, Germany. Institute of Nursing Science and -Practice, Paracelsus Medical University Salzburg, Austria.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Dodel', 'Affiliation': 'Department of Geriatric Medicine, University Hospital Essen, Essen, Germany.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Coelho', 'Affiliation': 'Instituto de Medicina Molecular Universidad di Lisboa, Lisbon, Portugal.'}, {'ForeName': 'Joaquim J', 'Initials': 'JJ', 'LastName': 'Ferreira', 'Affiliation': 'Instituto de Medicina Molecular Universidad di Lisboa, Lisbon, Portugal.'}, {'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Tison', 'Affiliation': 'Service de Neurologie, CHU de Bordeaux, Bordeaux, France and Univ. de Bordeaux, Institut des Maladies Neurodégénératives, CNRS, UMR 5293, Bordeaux, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Boraud', 'Affiliation': 'Service de Neurologie, CHU de Bordeaux, Bordeaux, France and Univ. de Bordeaux, Institut des Maladies Neurodégénératives, CNRS, UMR 5293, Bordeaux, France.'}, {'ForeName': 'Wassilios G', 'Initials': 'WG', 'LastName': 'Meissner', 'Affiliation': 'Service de Neurologie, CHU de Bordeaux, Bordeaux, France and Univ. de Bordeaux, Institut des Maladies Neurodégénératives, CNRS, UMR 5293, Bordeaux, France.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Rosqvist', 'Affiliation': 'Department of Clinical Sciences, Division of Neurology, Lund University, Lund, Sweden.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Timpka', 'Affiliation': 'Department of Clinical Sciences, Division of Neurology, Lund University, Lund, Sweden.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Odin', 'Affiliation': 'Department of Clinical Sciences, Division of Neurology, Lund University, Lund, Sweden.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Wittenberg', 'Affiliation': 'Coordinating Centre for Clinical Trials (KKS), Philipps-University Marburg, Marburg, Germany.'}, {'ForeName': 'Bas R', 'Initials': 'BR', 'LastName': 'Bloem', 'Affiliation': 'Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Department of Neurology, Nijmegen, The Netherlands.'}, {'ForeName': 'Raymond T', 'Initials': 'RT', 'LastName': 'Koopmans', 'Affiliation': 'Radboud University Medical Center, Department of Primary and Community Care, Nijmegen, The Netherlands; Joachim en Anna, Center for Specialized Geriatric Care, Nijmegen, The Netherlands.'}, {'ForeName': 'Anette', 'Initials': 'A', 'LastName': 'Schragand', 'Affiliation': 'UCL Queen Square Institute of Neurology, University College London, Royal Free Campus, Rowland Hill Street, London, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of Parkinson's disease,['10.3233/JPD-202033'] 1344,32570015,Lactobacillus rhamnosus GG and HbA1c in middle age and older adults without type 2 diabetes mellitus: A preliminary randomized study.,"BACKGROUND AND AIMS Probiotic supplementation improves glycemic control in persons with diabetes and the current study examined whether these benefits extend to healthy individuals. METHODS The current study was a 90-day placebo-controlled, double-blind, randomized clinical trial of Lactobacillus rhamnosus GG in healthy middle-aged and older adults. Fasting blood glucose and HbA1c were quantified at baseline and follow up. RESULTS ANCOVA controlling for baseline values showed group differences in follow up HbA1c [F (1,90) = 8.44, p = 0.005]; HbA1c values increased in the placebo group, though remained stable in the probiotic group. CONCLUSIONS If replicated, Lactobacillus rhamnosus GG may protect against changes in glycemic control.",2020,"RESULTS ANCOVA controlling for baseline values showed group differences in follow up HbA1c [F (1,90) = 8.44, p = 0.005]; HbA1c values increased in the placebo group, though remained stable in the probiotic group. ","['middle age and older adults without type 2 diabetes mellitus', 'healthy middle-aged and older adults', 'persons with diabetes']","['placebo', 'Lactobacillus rhamnosus GG', 'Lactobacillus rhamnosus GG and HbA1c', 'Probiotic supplementation']","['glycemic control', 'HbA1c values', 'Fasting blood glucose and HbA1c']","[{'cui': 'C0026062', 'cui_str': 'Middle-age'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1629836', 'cui_str': 'Lactobacillus rhamnosus GG'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}]",,0.163147,"RESULTS ANCOVA controlling for baseline values showed group differences in follow up HbA1c [F (1,90) = 8.44, p = 0.005]; HbA1c values increased in the placebo group, though remained stable in the probiotic group. ","[{'ForeName': 'Victoria E', 'Initials': 'VE', 'LastName': 'Sanborn', 'Affiliation': 'Department of Psychological Sciences, Kent State University, USA. Electronic address: vsanborn@kent.edu.'}, {'ForeName': 'M Andrea', 'Initials': 'MA', 'LastName': 'Azcarate-Peril', 'Affiliation': 'Department of Medicine, Division of Gastroenterology and Hepatology, and UNC Microbiome Core, Center for Gastrointestinal Biology and Disease, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Gunstad', 'Affiliation': 'Department of Psychological Sciences, Kent State University, USA; Brain Health Research Institute, Kent State University, USA.'}]",Diabetes & metabolic syndrome,['10.1016/j.dsx.2020.05.034'] 1345,32574801,Emotion generation and regulation following an intrusion induction: Implications for taboo or autogenous obsessions.,"BACKGROUND AND OBJECTIVES Research demonstrates that autogenous (AO) and reactive obsessions (RO) differ in obsessional content; however, no experimental research has examined differences in emotion generation and regulation. Characterizing this taxonomy with respect to emotion generation and regulation could refine conceptualizations of obsessionality and optimize clinical interventions. METHODS Seventy undergraduates were randomly assigned to imagine a personally-relevant AO or RO. Subsequently, emotional reactivity was assessed. Participants then rated their emotion regulation efforts and the degree to which the intrusion violated their values. RESULTS Broadly aligning with expectations, bootstrapped linear regression models indicated that AOs led to a significant increase in self-conscious emotions (guilt, shame, and embarrassment), and these effects were stronger for those whose values were more severely threatened by the intrusion. A conditional process analysis revealed that the relationship between the AO condition and emotion regulation difficulties was explained by an increase in negative emotional reactivity, and the strength of this effect depended upon the degree of conflict with participants' values. LIMITATIONS The use of an analogue sample, and minimal emotional reactivity in the RO condition, threaten the ecological and external validity of the study. CONCLUSIONS The current study employed a novel experimental design demonstrating a meaningful relationship between AOs and both emotional activation and regulation. Results highlight the relevance of self-conscious emotions to the conceptualization of AOs and the utility of addressing them in the context of exposure therapy.",2020,"Broadly aligning with expectations, bootstrapped linear regression models indicated that AOs led to a significant increase in self-conscious emotions (guilt, shame, and embarrassment), and these effects were stronger for those whose values were more severely threatened by the intrusion.","['taboo or autogenous obsessions', 'Seventy undergraduates']",['imagine a personally-relevant AO or RO'],"['negative emotional reactivity', 'self-conscious emotions (guilt, shame, and embarrassment', 'AO condition and emotion regulation difficulties', 'emotional reactivity']","[{'cui': 'C0039227', 'cui_str': 'Taboo'}, {'cui': 'C0443145', 'cui_str': 'Autogenous'}, {'cui': 'C0233697', 'cui_str': 'Obsessional thoughts'}, {'cui': 'C3816957', 'cui_str': '70'}]","[{'cui': 'C0443145', 'cui_str': 'Autogenous'}, {'cui': 'C0205332', 'cui_str': 'Reactive'}, {'cui': 'C0233697', 'cui_str': 'Obsessional thoughts'}]","[{'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0234421', 'cui_str': 'Consciousness'}, {'cui': 'C0018379', 'cui_str': 'Feeling guilt'}, {'cui': 'C0036938', 'cui_str': 'Shame'}, {'cui': 'C0679112', 'cui_str': 'Embarrassment'}, {'cui': 'C0443145', 'cui_str': 'Autogenous'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}]",70.0,0.0314195,"Broadly aligning with expectations, bootstrapped linear regression models indicated that AOs led to a significant increase in self-conscious emotions (guilt, shame, and embarrassment), and these effects were stronger for those whose values were more severely threatened by the intrusion.","[{'ForeName': 'Noah Chase', 'Initials': 'NC', 'LastName': 'Berman', 'Affiliation': 'College of the Holy Cross, Department of Psychology, 1 College St, Worcester, MA, 01610, USA. Electronic address: nberman@holycross.edu.'}, {'ForeName': 'Jumi', 'Initials': 'J', 'LastName': 'Hayaki', 'Affiliation': 'College of the Holy Cross, Department of Psychology, 1 College St, Worcester, MA, 01610, USA.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Szkutak', 'Affiliation': 'College of the Holy Cross, Department of Psychology, 1 College St, Worcester, MA, 01610, USA.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2020.101593'] 1346,32574844,"Effect of soluble corn fiber supplementation for 1 year on bone metabolism in children, the MetA-bone trial: Rationale and design.","Calcium intake is critical for adequate bone mineralization in adolescence, but it is usually inadequate in US adolescents. A strategy to maximize bone mineralization is to increase calcium absorption, which could be achieved by soluble corn fiber (SCF). There are no studies determining the long-term effects of SCF on bone mass in children. OBJECTIVES To determine the effect of one-year SCF supplementation compared to placebo on bone mass and bone biomarkers in children with low habitual calcium intake. We hypothesize that SCF supplementation will result in a higher bone mineral content and higher levels of bone formation and lower bone resorption biomarkers. METHODS 240 healthy children (10-13 years), with usual low calcium intake, will be randomized to four experimental groups for 1 year: (1) SCF (12 g/d); (2) SCF (12 g/d) + 600 mg/d of calcium; (3) Placebo (maltodextrin); and (4) Placebo +600 mg/d of calcium. The supplements have been pre-mixed with a flavored powder beverage and participants will only need to dilute it in water and drink this twice per day. Bone will be measured using dual energy x-ray absorptiometry (DXA) at baseline, 6 and 12 months. Serum bone biomarkers will be measured at baseline and at 12 months. CONCLUSIONS If supplementing diets with SCF lead to higher bone mass during adolescence, this could help achieve the genetic potential for PBM and to start adult life with stronger bones. If successful, SCF can be incorporated into diets for promoting bone health in adolescents.",2020,"We hypothesize that SCF supplementation will result in a higher bone mineral content and higher levels of bone formation and lower bone resorption biomarkers. ","['240 healthy children (10-13\u202fyears', 'adolescents', 'children with low habitual calcium intake', 'children']","['SCF', 'usual low calcium intake', 'soluble corn fiber supplementation', 'calcium; (3) Placebo (maltodextrin', 'Calcium intake', 'SCF supplementation', 'Placebo +600\u202fmg/d of calcium', 'placebo']","['bone metabolism', 'Serum bone biomarkers', 'bone mineral content and higher levels of bone formation and lower bone resorption biomarkers', 'bone mass and bone biomarkers']","[{'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0489458', 'cui_str': 'Calcium intake'}]","[{'cui': 'C0010028', 'cui_str': 'Zea mays'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0860967', 'cui_str': 'Calcium low'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0489458', 'cui_str': 'Calcium intake'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}]","[{'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0005963', 'cui_str': 'Bone Mineral Content'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0029433', 'cui_str': 'Bone formation'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0005974', 'cui_str': 'Bone resorption'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}]",240.0,0.314368,"We hypothesize that SCF supplementation will result in a higher bone mineral content and higher levels of bone formation and lower bone resorption biomarkers. ","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Palacios', 'Affiliation': 'Dietetics and Nutrition Department, Robert Stempel College of Public Health & Social Work, Florida International University, 11200 SW 8th Street, Miami, FL\xa033199, United States of America. Electronic address: cristina.palacios@fiu.edu.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Trak-Fellermeier', 'Affiliation': 'Dietetics and Nutrition Department, Robert Stempel College of Public Health & Social Work, Florida International University, 11200 SW 8th Street, Miami, FL\xa033199, United States of America.'}, {'ForeName': 'C M', 'Initials': 'CM', 'LastName': 'Pérez', 'Affiliation': 'Department of Biostatistics and Epidemiology, Graduate School of Public Health, Medical Sciences Campus, University of Puerto Rico, 11200 SW 8th Street, Miami, FL\xa033199, United States of America.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Huffman', 'Affiliation': 'Dietetics and Nutrition Department, Robert Stempel College of Public Health & Social Work, Florida International University, 11200 SW 8th Street, Miami, FL\xa033199, United States of America.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Hernandez Suarez', 'Affiliation': 'Vice Provost for Population Health and Well-being, Florida International University, 11200 SW 8th Street, Miami, FL\xa033199, United States of America.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Bursac', 'Affiliation': 'Department of Biostatistics, Robert Stempel College of Public Health, Florida International University, 11200 SW 8th Street, Miami, FL\xa033199, United States of America.'}, {'ForeName': 'T B', 'Initials': 'TB', 'LastName': 'Gambon', 'Affiliation': 'Pediatrician, Citrus Health Network, 551 W 51st Pl, Hialeah, FL 33012, United States of America.'}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Nakatsu', 'Affiliation': 'Department of Agronomy, College of Agriculture, Purdue University, 915 West State Street, West Lafayette, IN 47907-2053, United States of America.'}, {'ForeName': 'C M', 'Initials': 'CM', 'LastName': 'Weaver', 'Affiliation': 'Distinguished Professor emerita, Purdue University, 610 Purdue Mall, West Lafayette, IN 47907, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106061'] 1347,32450939,Effectiveness of a culturally adapted cognitive behavioural therapy-based guided self-help (CACBT-GSH) intervention to reduce social anxiety and enhance self-esteem in adolescents: a randomized controlled trial from Pakistan.,"BACKGROUND Social anxiety is common among adolescents in Pakistan and is associated with low self-esteem. Among the recommended treatments, cognitive behavioural therapy (CBT) is effective, and self-help approaches are encouraged. AIM To determine the effectiveness of culturally adapted CBT-based guided self-help (CACBT-GSH) intervention, using a manual 'Khushi aur Khatoon', for treating social anxiety when added to treatment as usual (TAU) compared with TAU only. METHOD A total of 76 adolescents with social anxiety aged 13-16 years from six schools in Multan, Pakistan were recruited into this randomized controlled trial. Participants were divided into intervention and control groups in a 1:1 ratio. Social anxiety, self-esteem and fear of negative evaluation were assessed through the Liebowtiz Social Anxiety Scale for children and adolescents, the Rosenberg Self-Esteem Scale and the Brief Fear of Negative Evaluation, respectively, at baseline and at the end of the study. Guided self-help using culturally adapted CBT (CACBT)-based self-help manual (eight sessions, one session per week) was provided to the intervention group. The effect of the CACBT-GSH intervention was analysed with ANCOVA. RESULTS There was a statistically significant difference between the intervention and the control groups in favour of intervention. Participants in the intervention group showed reduced symptoms of social anxiety (p < .001), fear of negative evaluation (p < .001) and enhanced self-esteem (p < .001). CONCLUSION The study demonstrated the effectiveness of CACBT-based guided self-help intervention in treating social anxiety and addressing the symptoms associated with it.",2020,"Participants in the intervention group showed reduced symptoms of social anxiety (p < .001), fear of negative evaluation (p < .001) and enhanced self-esteem (p < .001). ","['76 adolescents with social anxiety aged 13-16 years from six schools in Multan, Pakistan', 'adolescents']","['CACBT-GSH intervention', 'culturally adapted CBT-based guided self-help (CACBT-GSH) intervention', 'CACBT-based guided self-help intervention', 'culturally adapted cognitive behavioural therapy-based guided self-help (CACBT-GSH) intervention', 'cognitive behavioural therapy (CBT', 'Guided self-help using culturally adapted CBT (CACBT)-based self-help manual']","['social anxiety and enhance self-esteem', 'Social anxiety, self-esteem and fear of negative evaluation', 'Liebowtiz Social Anxiety Scale', 'reduced symptoms of social anxiety', 'fear of negative evaluation', 'enhanced self-esteem']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0030211', 'cui_str': 'Pakistan'}]","[{'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}]","[{'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",76.0,0.0186652,"Participants in the intervention group showed reduced symptoms of social anxiety (p < .001), fear of negative evaluation (p < .001) and enhanced self-esteem (p < .001). ","[{'ForeName': 'Rizwana', 'Initials': 'R', 'LastName': 'Amin', 'Affiliation': 'Department of Professional Psychology, Bahria University, Islamabad, Pakistan.'}, {'ForeName': 'Amna', 'Initials': 'A', 'LastName': 'Iqbal', 'Affiliation': 'Department of Applied Psychology, Bahauddin Zakariya UniversityMultan, Pakistan.'}, {'ForeName': 'Farooq', 'Initials': 'F', 'LastName': 'Naeem', 'Affiliation': 'University of Toronto and Centre for Addiction & Mental Health, Toronto, Canada.'}, {'ForeName': 'Muhammad', 'Initials': 'M', 'LastName': 'Irfan', 'Affiliation': 'Department of Mental Health, Psychiatry & Behavioural Sciences, Peshawar Medical College, Riphah International University, Islamabad, Pakistan.'}]",Behavioural and cognitive psychotherapy,['10.1017/S1352465820000284'] 1348,32551796,Usefulness of Ninjin'yoeito for Chronic Obstructive Pulmonary Disease Patients with Frailty.,"Objectives: Frail patients with chronic obstructive pulmonary disease (COPD) have a higher risk of mortality, mood disorder, and poor quality of life (QOL). There are few intervention studies in frail patients with COPD, and there is a need for an effective therapy. Ninjin'yoeito (NYT) is a Kampo medicine that has been reported to improve fatigue, psychosomatic vulnerability, and respiratory symptoms. We examined the efficacy of NYT in frailty or prefrailty patients with COPD. Design: Prospective, single-center, open-label, randomized controlled trial. Location: Showa University Hospital, Tokyo, Japan. Subjects: Sixty-two patients (53 males and 9 females) with a mean age of 76 ± 6 years were included in the analysis. Interventions: The patients were divided into two groups: the NYT group ( n  = 31) and the control (standard treatment) group ( n  = 31). Outcome measures: The primary outcome was changes in Kihon checklist (KCL) scores at week 24, which reflect changes in frailty. The secondary outcomes were changes in the following assessment scores at week 24: Simplified Nutritional Appetite Questionnaire (SNAQ) scores, which reflect changes in appetite; COPD Assessment Test (CAT) scores, which reflect changes in QOL in patients with COPD; Hospital Anxiety and Depression Scale (HADS)-Anxiety scores, which reflect changes in anxiety; and HADS-Depression scores, which reflect changes in depression. Results: There was a slight but not significant difference in changes in KCL scores between the NYT and control groups ( p  = 0.09). However, there were statistically significant differences in changes in SNAQ ( p  = 0.03), CAT ( p  = 0.03), HADS-Anxiety ( p  < 0.01), and HADS-Depression ( p  = 0.02) scores between the two groups. Conclusions: Our results suggest that NYT is an effective and promising drug with various effects in patients with COPD who are frail, despite conventional treatment.",2020,"However, there were statistically significant differences in changes in SNAQ ( p  = 0.03), CAT ( p  = 0.03), HADS-Anxiety ( p  < 0.01), and HADS-Depression ( p  = 0.02) scores between the two groups. ","['Chronic Obstructive Pulmonary Disease Patients with Frailty', 'patients with COPD who are frail, despite conventional treatment', 'frailty or prefrailty patients with COPD', 'Frail patients with chronic obstructive pulmonary disease (COPD', 'frail patients with COPD', 'Subjects: Sixty-two patients (53 males and 9 females) with a mean age of 76\u2009±\u20096 years were included in the analysis']","[""Ninjin'yoeito""]","['KCL scores', 'Simplified Nutritional Appetite Questionnaire (SNAQ) scores, which reflect changes in appetite; COPD Assessment Test (CAT) scores, which reflect changes in QOL in patients with COPD; Hospital Anxiety and Depression Scale (HADS)-Anxiety scores, which reflect changes in anxiety; and HADS-Depression scores', 'SNAQ', 'risk of mortality, mood disorder, and poor quality of life (QOL', 'HADS-Anxiety', 'HADS-Depression', 'changes in Kihon checklist (KCL) scores']","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4517835', 'cui_str': '62'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]",[],"[{'cui': 'C0032825', 'cui_str': 'Potassium Chloride'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0558058', 'cui_str': 'Reflecting'}, {'cui': 'C0426587', 'cui_str': 'Altered appetite'}, {'cui': 'C4284282', 'cui_str': 'COPD assessment test'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0525045', 'cui_str': 'Mood disorder'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}]",,0.0350023,"However, there were statistically significant differences in changes in SNAQ ( p  = 0.03), CAT ( p  = 0.03), HADS-Anxiety ( p  < 0.01), and HADS-Depression ( p  = 0.02) scores between the two groups. ","[{'ForeName': 'Kuniaki', 'Initials': 'K', 'LastName': 'Hirai', 'Affiliation': 'Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Tetsuya', 'Initials': 'T', 'LastName': 'Homma', 'Affiliation': 'Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Tomohiro', 'Initials': 'T', 'LastName': 'Matsunaga', 'Affiliation': 'Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Kaho', 'Initials': 'K', 'LastName': 'Akimoto', 'Affiliation': 'Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Shigenori', 'Initials': 'S', 'LastName': 'Yamamoto', 'Affiliation': 'Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hiromitsu', 'Initials': 'H', 'LastName': 'Suganuma', 'Affiliation': 'Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Ayaka', 'Initials': 'A', 'LastName': 'Kashima', 'Affiliation': 'Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Sato', 'Affiliation': 'Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Takaya', 'Initials': 'T', 'LastName': 'Ebato', 'Affiliation': 'Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Yoshito', 'Initials': 'Y', 'LastName': 'Miyata', 'Affiliation': 'Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Ohta', 'Affiliation': 'Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Inoue', 'Affiliation': 'Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Sojiro', 'Initials': 'S', 'LastName': 'Kusumoto', 'Affiliation': 'Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Shintaro', 'Initials': 'S', 'LastName': 'Suzuki', 'Affiliation': 'Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Akihiko', 'Initials': 'A', 'LastName': 'Tanaka', 'Affiliation': 'Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hironori', 'Initials': 'H', 'LastName': 'Sagara', 'Affiliation': 'Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}]","Journal of alternative and complementary medicine (New York, N.Y.)",['10.1089/acm.2020.0083'] 1349,32561426,Recombinant human thrombopoietin in critically ill patients with sepsis-associated thrombocytopenia: A clinical study.,"BACKGROUND Sepsis causes varying degrees of thrombocytopenia that are closely related to the likelihood of patient mortality. This study analysed the effect of recombinant human thrombopoietin (rhTPO) on the platelet count in critically ill patients with sepsis-associated thrombocytopenia and provided a reference for its treatment. MATERIAL/METHODS The study was a retrospective analysis of the clinical data of patients. Patients were divided into an rhTPO group and control group according to rhTPO use during treatment. Demographical and clinical data (age, sex, history of hypertension, diabetes, platelet counts, mortality rate, etc.) of the patients were collected and analysed using statistical software; p < 0.05 was considered statistically significant. RESULTS Of 213 patients, 84 constituted the rhTPO group and 129 constituted the control group. The increase in platelet counts was significantly higher in the rhTPO group than in the control group on the third day (43.01 ± 18.23 × 10 9 /L vs. 36.31 ± 14.17 × 10 9 /L, p = 0.003), fifth day (71.51 ± 39.59 × 10 9 /L vs. 42.95 ± 20.48 × 10 9 /L, p < 0.001) and seventh day (115.36 ± 69.41 × 10 9 /L vs. 62.54 ± 42.70 × 10 9 /L, p < 0.001). Further statistical analysis of the data of patients with platelet counts ≤30 × 10 9 /L and >30 × 10 9 /L and APACHE II scores >15 and ≤15 at the time of diagnosis showed that the increase in platelet counts in the rhTPO group was greater. There was no significant between-group difference in volume of platelet transfusions (rhTPO group 15.42 ± 17.20 vs. control group 10.93 ± 17.48, p = 0.068). The cost of ICU treatment in patients with rhTPO was higher (RMB 126,936.21 ± 86,548.27 vs. 101,685.28 ± 77,291.75, p = 0.027); however, the ICU stay time was shorter (9.20 ± 5.38 vs. 10.88 ± 6.82, p = 0.047). There was no significant difference in 28-day mortality (rhTPO group: 25.0% vs. control group: 34.1%, p = 0.158) between the two groups. CONCLUSION For patients with severe thrombocytopenia or severe sepsis, rhTPO was efficacious in increasing their platelet counts, resulting in a shorter ICU stay time.",2020,The increase in platelet counts was significantly higher in the rhTPO group than in the control group on the third day (43.01±18.23×10 9,"['patients with severe thrombocytopenia or patients with severe sepsis', 'patients with platelet counts', 'critically ill patients with sepsis-associated thrombocytopenia and provided a reference for its treatment', '213 patients', '84 patients constituted the rhTPO group and 129 constituted the control group', 'critically ill patients with sepsis-associated thrombocytopenia', '≤30×10 9']","['recombinant human thrombopoietin (rhTPO', 'Recombinant human thrombopoietin', 'rhTPO']","['ICU stay time', 'platelet counts', 'volume of platelet transfusions', 'cost of ICU treatment', '28-days mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0040034', 'cui_str': 'Thrombocytopenic disorder'}, {'cui': 'C1719672', 'cui_str': 'Severe Sepsis'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0040052', 'cui_str': 'Thrombopoietin'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1520439', 'cui_str': '129 Strain Mouse'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0040052', 'cui_str': 'Thrombopoietin'}]","[{'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0086818', 'cui_str': 'Platelet transfusion'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",213.0,0.0258731,The increase in platelet counts was significantly higher in the rhTPO group than in the control group on the third day (43.01±18.23×10 9,"[{'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': ""Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Jin', 'Affiliation': ""Emergency Department, Xi'an Aerospace General Hospital, Xi'an, China.""}, {'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': ""Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ""Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: wangxuejd2008@126.com.""}, {'ForeName': 'Litao', 'Initials': 'L', 'LastName': 'Guo', 'Affiliation': ""Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: glt2002@xjtu.edu.cn.""}]",International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,['10.1016/j.ijid.2020.06.045'] 1350,32561466,A randomized clinical trial of a collaborative home-based diabetes intervention to reduce emergency department visits and hospitalizations in black individuals with diabetes.,"The prevalence of diabetes mellitus (DM) in black individuals (blacks) is twice that of white individuals (whites), and blacks are more likely to have worse glycemic control, less optimal medication regimens, and higher levels of mistrust in the medical system. These three factors account for higher rates of acute medical care use in blacks with DM. To address this disparity, we developed DM I-TEAM (Diabetes Interprofessional Team to Enhance Adherence to Medical Care), a home-based multidisciplinary behavioral intervention that integrates care from a community health worker (CHW), the participant's primary care physician (PCP), a DM nurse educator, and a clinical pharmacist. Treatment is delivered during 9 sessions over 1 year, and includes diabetes education and goal setting, telehealth visits with participants' PCP and a DM nurse educator, and comprehensive medication reviews by a pharmacist. We describe the rationale and methods for a randomized controlled trial to test the efficacy of DM I-TEAM to reduce emergency department (ED) visits and hospitalizations. We are enrolling 200 blacks with DM during an ED visit. Participants are randomized to DM I-TEAM or Usual Medical Care (UMC). Follow-up assessments are conducted at 6 and 12 months. The primary outcome is the number of ED visits and hospitalizations over 12 months, and is measured by participant self-report and medical record review. Secondary outcomes include hemoglobin A1c (HbA1c), number of potentially inappropriate medications (PIMs), and trust in health care.",2020,"The prevalence of diabetes mellitus (DM) in black individuals (blacks) is twice that of white individuals (whites), and blacks are more likely to have worse glycemic control, less optimal medication regimens, and higher levels of mistrust in the medical system.","['200 blacks with DM during an ED visit', 'blacks with DM', 'black individuals (blacks', 'black individuals with diabetes']","['DM I-TEAM', 'collaborative home-based diabetes intervention', 'DM I-TEAM or Usual Medical Care (UMC']","['hemoglobin A1c (HbA1c), number of potentially inappropriate medications (PIMs), and trust in health care', 'emergency department (ED) visits and hospitalizations', 'prevalence of diabetes mellitus (DM', 'number of ED visits and hospitalizations over 12\u202fmonths, and is measured by participant self-report and medical record review']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}]","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0496675', 'cui_str': 'Medical care'}]","[{'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C4042848', 'cui_str': 'PIM List'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0730229', 'cui_str': 'Medical records review'}]",200.0,0.0803291,"The prevalence of diabetes mellitus (DM) in black individuals (blacks) is twice that of white individuals (whites), and blacks are more likely to have worse glycemic control, less optimal medication regimens, and higher levels of mistrust in the medical system.","[{'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Casten', 'Affiliation': 'Department of Psychiatry and Human Behavior, Sidney Kimmel Medical College at Thomas, Jefferson University, United States of America. Electronic address: Robin.Casten@Jefferson.edu.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Rovner', 'Affiliation': 'Departments of Neurology, Psychiatry, and Ophthalmology, Sidney Kimmel Medical College at Thomas Jefferson University, United States of America.'}, {'ForeName': 'Anna Marie', 'Initials': 'AM', 'LastName': 'Chang', 'Affiliation': 'Department of Emergency Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, United States of America.'}, {'ForeName': 'Judd E', 'Initials': 'JE', 'LastName': 'Hollander', 'Affiliation': 'Department of Emergency Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, United States of America.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Kelley', 'Affiliation': 'Department of Neurology, Sidney Kimmel Medical College at Thomas Jefferson University, United States of America.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Leiby', 'Affiliation': 'Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Medical College at Thomas Jefferson University, United States of America.'}, {'ForeName': 'Ginah', 'Initials': 'G', 'LastName': 'Nightingale', 'Affiliation': 'Jefferson College of Pharmacy at Thomas Jefferson University, United States of America.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Pizzi', 'Affiliation': 'Center for Health Outcomes, Policy, and Economics, Ernest Mario School of Pharmacy, Rutgers University, United States of America.'}, {'ForeName': 'Neva', 'Initials': 'N', 'LastName': 'White', 'Affiliation': 'Center for Urban Health, Thomas Jefferson University Hospital, United States of America.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Rising', 'Affiliation': 'Department of Emergency Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106069'] 1351,32561467,A randomized comparison trial of culturally adapted HIV prevention approaches for Native Americans reducing trauma symptoms versus substance misuse: The Healing Seasons protocol.,"Native Americans (NA) experience interrelated risks of trauma exposure, substance use, and HIV risk behaviors that put them at increased risk for HIV infection. Despite these known risk factors, there are very few published randomized trials testing interventions to reduce trauma-related symptoms and substance misuse among NA. METHODS The Healing Seasons study is a randomized comparsion trial of two counseling strategies, Narrative Exposure Therapy (NET) addressing PTSD or Motivational interviewing with cognitive behavioral therapy skills training (MIST) addressing substance misuse as a means to prevent HIV among NA. Using a community-based participatory research approach, we adapted both evidence-based interventions to be specific to the risk contexts and realities of NA and to include psychoeducational and skill-building components that include cultural-specific stories, virtues, and traditional treatment strategies. Participants, 16 years and older, were recruited from a Pacific Northwest tribal community, screened over the phone, enrolled in person, and randomized in equal numbers to NET or MIST. We stratified by age (16-29 years and 30 or older) and gender (male or female identified) to ensure balance between treatment arms. The primary outcomes were number of sex partners and frequency of sexual acts (with and without condoms), sex under the influence of substances, frequency of substance use, and PTSD severity. DISCUSSION Behavioral interventions for NA are needed to prevent HIV risk behaviors when faced with trauma symptoms and substance misuse. This study will provide evidence to determine feasibility and efficacy of addressing related risk factors as part of counseling-based HIV prevention intervention to reduce sexual risk among this population. TRIAL REGISTRATION ClinicalTrials.gov number, NCT03112369, registered April 12, 2017.",2020,"Using a community-based participatory research approach, we adapted both evidence-based interventions to be specific to the risk contexts and realities of NA and to include psychoeducational and skill-building components that include cultural-specific stories, virtues, and traditional treatment strategies.","['Native Americans reducing trauma symptoms versus substance misuse', 'We stratified by age (16-29\u202fyears and 30 or older) and gender (male or female identified', 'Participants, 16\u202fyears and older, were recruited from a Pacific Northwest tribal community, screened over the phone, enrolled in person']","['NET or MIST', 'culturally adapted HIV prevention approaches', 'Narrative Exposure Therapy (NET) addressing PTSD or Motivational interviewing with cognitive behavioral therapy skills training (MIST', 'counseling-based HIV prevention intervention']","['number of sex partners and frequency of sexual acts (with and without condoms), sex under the influence of substances, frequency of substance use, and PTSD severity', 'HIV risk behaviors']","[{'cui': 'C0282204', 'cui_str': 'Native Americans'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030170', 'cui_str': 'Pacific Northwest'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C1135957', 'cui_str': 'Narration'}, {'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0036911', 'cui_str': 'Sexual partners'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0086931', 'cui_str': 'Risk Behavior'}]",,0.0757073,"Using a community-based participatory research approach, we adapted both evidence-based interventions to be specific to the risk contexts and realities of NA and to include psychoeducational and skill-building components that include cultural-specific stories, virtues, and traditional treatment strategies.","[{'ForeName': 'C R', 'Initials': 'CR', 'LastName': 'Pearson', 'Affiliation': 'Indigenous Wellness Research Institute, School of Social Work, University of Washington, Seattle, WA, USA. Electronic address: pearsonc@uw.edu.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Kaysen', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Huh', 'Affiliation': 'Indigenous Wellness Research Institute, School of Social Work, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Bedard-Gillgan', 'Affiliation': 'Department of Psychiatry, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Walker', 'Affiliation': 'Innovative Programs Research Group, School of Social Work, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Marin', 'Affiliation': 'Indigenous Wellness Research Institute, School of Social Work, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Saluskin', 'Affiliation': 'Yakama Nation Behavioral Health Services, Toppenish, WA, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106070'] 1352,32573782,Laparoscopic versus open colorectal surgery in the acute setting (LaCeS trial): a multicentre randomized feasibility trial.,"BACKGROUND Approximately 30 000 people undergo major emergency abdominal gastrointestinal surgery annually, and 36 per cent of these procedures (around 10 800) are carried out for emergency colorectal pathology. Some 14 per cent of all patients requiring emergency surgery have a laparoscopic procedure. The aims of the LaCeS (laparoscopic versus open colorectal surgery in the acute setting) feasibility trial were to assess the feasibility, safety and acceptability of performing a large-scale definitive phase III RCT, with a comparison of emergency laparoscopic versus open surgery for acute colorectal pathology. METHODS LaCeS was designed as a prospective, multicentre, single-blind, parallel-group, pragmatic feasibility RCT with an integrated qualitative study. Randomization was undertaken centrally, with patients randomized on a 1 : 1 basis between laparoscopic or open surgery. RESULTS A total of 64 patients were recruited across five centres. The overall mean steady-state recruitment rate was 1·2 patients per month per site. Baseline compliance for clinical and health-related quality-of-life data was 99·8 and 93·8 per cent respectively. The conversion rate from laparoscopic to open surgery was 39 (95 per cent c.i. 23 to 58) per cent. The 30-day postoperative complication rate was 27 (13 to 46) per cent in the laparoscopic arm and 42 (25 to 61) per cent in the open arm. CONCLUSION Laparoscopic emergency colorectal surgery may have an acceptable safety profile. Registration number: ISRCTN15681041 ( http://www.controlled-trials.com).",2020,The conversion rate from laparoscopic to open surgery was 39,"['Approximately 30\u2009000 people undergo major emergency abdominal gastrointestinal surgery annually, and 36 per cent of these procedures (around 10\u2009800) are carried out for emergency colorectal pathology', '64 patients were recruited across five centres']","['LaCeS (laparoscopic versus open colorectal surgery', 'Laparoscopic emergency colorectal surgery', 'Laparoscopic versus open colorectal surgery', 'emergency laparoscopic versus open surgery', 'laparoscopic or open surgery']","['Baseline compliance for clinical and health-related quality-of-life data', '30-day postoperative complication rate', 'overall mean steady-state recruitment rate', 'conversion rate', 'feasibility, safety and acceptability']","[{'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0524722', 'cui_str': 'Gastrointestinal surgery'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0562018', 'cui_str': 'cent'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}, {'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0453991', 'cui_str': 'Laces'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0009369', 'cui_str': 'Colorectal surgery'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0348025', 'cui_str': 'Open approach'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205361', 'cui_str': 'Steady'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",64.0,0.291453,The conversion rate from laparoscopic to open surgery was 39,"[{'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Harji', 'Affiliation': 'Department of Colorectal Surgery, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Marshall', 'Affiliation': 'Clinical Trials Research Unit, Leeds, UK.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Gordon', 'Affiliation': 'Clinical Trials Research Unit, Leeds, UK.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Twiddy', 'Affiliation': 'Institute of Clinical and Applied Health Research, University of Hull, Hull, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Pullan', 'Affiliation': 'Clinical Trials Research Unit, Leeds, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Meads', 'Affiliation': 'Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Croft', 'Affiliation': 'Clinical Trials Research Unit, Leeds, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Burke', 'Affiliation': ""Department of Colorectal Surgery, St James's University Hospital, Leeds, UK.""}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Griffiths', 'Affiliation': 'Department of Colorectal Surgery, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Verjee', 'Affiliation': 'Patient and Public Involvement Representative for LaCeS Trial, UK.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Sagar', 'Affiliation': ""Department of Colorectal Surgery, St James's University Hospital, Leeds, UK.""}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Stocken', 'Affiliation': 'Clinical Trials Research Unit, Leeds, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Brown', 'Affiliation': 'Clinical Trials Research Unit, Leeds, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The British journal of surgery,['10.1002/bjs.11703'] 1353,32569757,"A prospective, multi-center randomized, controlled, blinded trial of vagus nerve stimulation for difficult to treat depression: A novel design for a novel treatment.","Few treatment options exist for patients with difficult-to-treat depression (DTD). One potentially efficacious treatment is vagus nerve stimulation (VNS): chronic stimulation of the vagus nerve using an implanted stimulator. Given a series of recent VNS clinical studies, including a large, five-year naturalistic investigation, the Center for Medicare and Medicaid Services (CMS) reconsidered the previous non coverage determination and announced coverage for patients participating in a ""coverage with evidence"" trial. This study, entitled, A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy® System as AdjunctivE Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER), includes DTD patients with at least four unsuccessful antidepressant treatments in the current episode and will randomize both unipolar and bipolar DTD participants, each up to 500 evaluable enrollees. Predetermined interim analyses will define the necessary sample size. All participants will be implanted with VNS devices: half receive active stimulation during year one, and half receive delayed stimulation after year one. Participants will be followed for 5 years. This RCT is unique for DTD studies: 1) large sample size and long study duration (one year of controlled comparison); 2) use of a percent time in response as the primary outcome measure, given the chronic illness and its fluctuating course (vis-à-vis meeting a response criteria at a single time point); 3) inclusion of diverse measures of VNS impact on function, including quality of life, degree of disability, health status, and suicidality.",2020,Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy® System as AdjunctivE Therapy,"['depression', 'patients with difficult-to-treat depression (DTD', 'Subjects With Treatment-Resistant Depression (RECOVER), includes DTD patients with at least four unsuccessful antidepressant treatments in the current episode and will randomize both unipolar and bipolar DTD participants, each up to 500 evaluable enrollees']","['vagus nerve stimulation', 'VNS Therapy® System as AdjunctivE Therapy']","['quality of life, degree of disability, health status, and suicidality']","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332218', 'cui_str': 'Difficult'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0220726', 'cui_str': 'Diastrophic dysplasia'}, {'cui': 'C2063866', 'cui_str': 'Therapy-Resistant Depression'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1272705', 'cui_str': 'Unsuccessful'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0443340', 'cui_str': 'Unipolar'}, {'cui': 'C0443156', 'cui_str': 'Bipolar'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C3816747', 'cui_str': '500'}]","[{'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0018759', 'cui_str': 'Health status'}]",,0.0937023,Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy® System as AdjunctivE Therapy,"[{'ForeName': 'Charles R', 'Initials': 'CR', 'LastName': 'Conway', 'Affiliation': 'Department of Psychiatry, Washington University in St. Louis, 660 S. Euclid Ave, Campus Box 8134, St. Louis, MO 63110, USA. Electronic address: conwaycr@wustl.edu.'}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Olin', 'Affiliation': 'LivaNova PLC, London, United Kingdom. Electronic address: bryan.olin@livanova.com.'}, {'ForeName': 'Scott T', 'Initials': 'ST', 'LastName': 'Aaronson', 'Affiliation': 'Sheppard Pratt Health System, Department of Psychiatry, University of Maryland, Baltimore, MD, USA. Electronic address: SAaronson@sheppardpratt.org.'}, {'ForeName': 'Harold A', 'Initials': 'HA', 'LastName': 'Sackeim', 'Affiliation': 'Departments of Psychiatry and Radiology, Columbia University, New York, NY, USA. Electronic address: has1@columbia.edu.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Bunker', 'Affiliation': 'LivaNova PLC, Houston, TX, USA. Electronic address: Mark.Bunker@livanova.com.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Kriedt', 'Affiliation': 'Department of Psychiatry, Washington University in St. Louis, 660 S. Euclid Ave, Campus Box 8134, St. Louis, MO 63110, USA. Electronic address: ckriedt@wustl.edu.'}, {'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Greco', 'Affiliation': 'LivaNova PLC, SORIN Group Italia S.r.l., Milano, Italy. Electronic address: teresa.greco@livanova.com.'}, {'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Broglio', 'Affiliation': 'Department of Statistics and Data Sciences, University of Texas, Austin, TX, USA.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Vestrucci', 'Affiliation': 'Berry Consultants, Austin, TX, USA; Department of Statistics and Data Sciences, University of Texas, Austin, TX, USA. Electronic address: matteo@berryconsultants.net.'}, {'ForeName': 'A John', 'Initials': 'AJ', 'LastName': 'Rush', 'Affiliation': 'Duke-NUS Medical School, Singapore; Duke University, Durham, NC, USA; Texas Tech University, Permian Basin, TX, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106066'] 1354,32569854,Improving imagery rescripting treatments: Comparing an active versus passive approach.,"BACKGROUND AND OBJECTIVES In imagery rescripting (ImRs), aversive mental images are modified to reduce symptoms in a variety of psychological disorders. However, uniform guidelines on how to optimally implement ImRs do currently not exist. It remains unclear whether therapists should stimulate patients to imagine themselves to actively intervene within the new image, or whether they may imagine helpers to change the situation. We aimed to compare these two variants of ImRs within an analogue experimental setting. METHODS After having watched an aversive film, one-hundred participants were randomly assigned to active ImRs (ImRs-A), passive ImRs (ImRs-P), imagery rehearsal (IRE), or no-intervention control (NIC). Participants were either instructed to rescript the film by imagining themselves intervening in the new script (ImRs-A) or encouraged to imagine helpers to intervene in the imagined situation (ImRs-P). RESULTS Both ImRs increased mastery and elicited less distress than IRE with ImRs-P being experienced as less distressing than ImRs-A. Only ImRs-A led to a stronger increase in positive affect than IRE, whereas groups did not differ with respect to negative affect and self-efficacy. Conditions did not differ regarding the number of film-related intrusive memories. LIMITATIONS As a convenience sample was investigated, results cannot be generalized to clinical samples. CONCLUSION Even though differences regarding symptomatic outcome could not be detected, ImRs-P was experienced as less distressing than ImRs-A. Results suggest that both ImRs lead to different processes during the intervention than mere exposure. Compared to IRE, ImRs increases mastery with ImRs-A and ImRs-P being equally effective.",2020,"Both ImRs increased mastery and elicited less distress than IRE with ImRs-P being experienced as less distressing than ImRs-A. Only ImRs-A led to a stronger increase in positive affect than IRE, whereas groups did not differ with respect to negative affect and self-efficacy.","['After having watched an aversive film, one-hundred participants']","['active ImRs (ImRs-A), passive ImRs (ImRs-P), imagery rehearsal (IRE), or no-intervention control (NIC', 'instructed to rescript the film by imagining themselves intervening in the new script (ImRs-A) or encouraged to imagine helpers to intervene in the imagined situation (ImRs-P']",['number of film-related intrusive memories'],"[{'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C1704407', 'cui_str': '100'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1704608', 'cui_str': 'Film'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0561837', 'cui_str': 'Intrusive memories'}]",100.0,0.0317839,"Both ImRs increased mastery and elicited less distress than IRE with ImRs-P being experienced as less distressing than ImRs-A. Only ImRs-A led to a stronger increase in positive affect than IRE, whereas groups did not differ with respect to negative affect and self-efficacy.","[{'ForeName': 'Marena', 'Initials': 'M', 'LastName': 'Siegesleitner', 'Affiliation': 'LMU Munich, Department of Psychology, Leopoldstraße 13, 80802, Munich, Germany.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Strohm', 'Affiliation': 'LMU Munich, Department of Psychology, Leopoldstraße 13, 80802, Munich, Germany.'}, {'ForeName': 'Charlotte E', 'Initials': 'CE', 'LastName': 'Wittekind', 'Affiliation': 'LMU Munich, Department of Psychology, Leopoldstraße 13, 80802, Munich, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Ehring', 'Affiliation': 'LMU Munich, Department of Psychology, Leopoldstraße 13, 80802, Munich, Germany.'}, {'ForeName': 'Anna E', 'Initials': 'AE', 'LastName': 'Kunze', 'Affiliation': 'LMU Munich, Department of Psychology, Leopoldstraße 13, 80802, Munich, Germany. Electronic address: anna.kunze@psy.lmu.de.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2020.101578'] 1355,32576090,Telemedicine Cognitive Behavioral Therapy for Anxiety After Stroke: Proof-of-Concept Randomized Controlled Trial.,"BACKGROUND AND PURPOSE Disabling anxiety affects a quarter of stroke survivors but access to treatment is poor. We developed a telemedicine model for delivering guided self-help cognitive behavioral therapy (CBT) for anxiety after stroke (TASK-CBT). We aimed to evaluate the feasibility of TASK-CBT in a randomized controlled trial workflow that enabled all trial procedures to be carried out remotely. In addition, we explored the feasibility of wrist-worn actigraphy sensor as a way of measuring objective outcomes in this clinical trial. METHODS We recruited adult community-based stroke patients (n=27) and randomly allocated them to TASK-CBT (n=14) or relaxation therapy (TASK-Relax), an active comparator (n=13). RESULTS In our sample (mean age 65 [±10]; 56% men; 63% stroke, 37% transient ischemic attacks), remote self-enrolment, electronic signature, intervention delivery, and automated follow-up were feasible. All participants completed all TASK-CBT sessions (14/14). Lower levels of anxiety were observed in TASK-CBT when compared with TASK-Relax at both weeks 6 and 20. Mean actigraphy sensor wearing-time was 33 days (±15). CONCLUSIONS Our preliminary feasibility data from the current study support a larger definitive clinical trial and the use of wrist-worn actigraphy sensor in anxious stroke survivors. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03439813.",2020,Lower levels of anxiety were observed in TASK-CBT when compared with TASK-Relax at both weeks 6 and 20.,"['anxious stroke survivors', 'In our sample (mean age 65 [±10]; 56% men; 63% stroke, 37% transient ischemic attacks), remote self-enrolment, electronic signature, intervention delivery, and automated follow-up were feasible', 'adult community-based stroke patients (n=27']","['telemedicine model for delivering guided self-help cognitive behavioral therapy (CBT', 'Telemedicine Cognitive Behavioral Therapy', 'TASK-CBT', 'relaxation therapy (TASK-Relax), an active comparator (n=13', 'wrist-worn actigraphy sensor']","['Mean actigraphy sensor wearing-time', 'Lower levels of anxiety', 'Anxiety']","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C2733435', 'cui_str': 'Guided self-help cognitive behavioral therapy'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0282333', 'cui_str': 'Relaxation training therapy'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C0183210', 'cui_str': 'Sensor device'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C0183210', 'cui_str': 'Sensor device'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",,0.157782,Lower levels of anxiety were observed in TASK-CBT when compared with TASK-Relax at both weeks 6 and 20.,"[{'ForeName': 'Ho-Yan Yvonne', 'Initials': 'HY', 'LastName': 'Chun', 'Affiliation': 'Centre for Clinical Brain Sciences (H.Y.Y.C., A.J.C., M.S.D., G.E.M., W.N.W.), University of Edinburgh, UK.'}, {'ForeName': 'Alan J', 'Initials': 'AJ', 'LastName': 'Carson', 'Affiliation': 'Centre for Clinical Brain Sciences (H.Y.Y.C., A.J.C., M.S.D., G.E.M., W.N.W.), University of Edinburgh, UK.'}, {'ForeName': 'Athanasios', 'Initials': 'A', 'LastName': 'Tsanas', 'Affiliation': 'Centre for Medical Informatics, Usher Institute (A.T.), University of Edinburgh, UK.'}, {'ForeName': 'Martin S', 'Initials': 'MS', 'LastName': 'Dennis', 'Affiliation': 'Centre for Clinical Brain Sciences (H.Y.Y.C., A.J.C., M.S.D., G.E.M., W.N.W.), University of Edinburgh, UK.'}, {'ForeName': 'Gillian E', 'Initials': 'GE', 'LastName': 'Mead', 'Affiliation': 'Centre for Clinical Brain Sciences (H.Y.Y.C., A.J.C., M.S.D., G.E.M., W.N.W.), University of Edinburgh, UK.'}, {'ForeName': 'Clementina', 'Initials': 'C', 'LastName': 'Calabria', 'Affiliation': 'Royal Infirmary of Edinburgh (C.C.), National Health Service Lothian, Edinburgh, UK.'}, {'ForeName': 'William N', 'Initials': 'WN', 'LastName': 'Whiteley', 'Affiliation': 'Centre for Clinical Brain Sciences (H.Y.Y.C., A.J.C., M.S.D., G.E.M., W.N.W.), University of Edinburgh, UK.'}]",Stroke,['10.1161/STROKEAHA.120.029042'] 1356,32584117,Predicting sudden gains before treatment begins: An examination of pretreatment intraindividual variability in symptoms.,"Objective: Sudden gains during psychotherapy have been found to be predictive of positive treatment outcomes. Previous attempts at predicting occurrence of sudden gains have yielded equivocal findings. Recently, intraindividual variability in symptoms during treatment was suggested as a trans-therapeutic and trans-diagnostic predictor of sudden gains. The goal of the present study was to examine this predictor in Internet-delivered treatment for social anxiety disorder (SAD) and to examine whether this predictor predicts sudden gains when measured before treatment begins. Method: We examined data from a preregistered randomized controlled trial (RCT) of Internet-delivered cognitive-behavioral therapy (CBT) for SAD ( n = 101). We measured variability in symptoms both within-treatment and before treatment (i.e. during waitlist). Results: Intraindividual variability in symptoms significantly predicted sudden gains both when measured before treatment or within-treatment and correctly classified 84% and 83% of individuals to sudden gains versus non-sudden gains status, respectively. Conclusions: Intraindividual variability in symptoms can predict sudden gains in Internet-delivered treatment for SAD, thus supporting its trans-diagnostic and trans-therapeutic nature. Predicting sudden gains before treatment begins has implications for treatment planning and clinical decision making as well as for personalized tailoring of interventions. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"Intraindividual variability in symptoms significantly predicted sudden gains both when measured before treatment or within-treatment and correctly classified 84% and 83% of individuals to sudden gains versus non-sudden gains status, respectively. ",['social anxiety disorder (SAD'],['Internet-delivered cognitive-behavioral therapy (CBT'],"['Sudden gains', 'sudden gains']","[{'cui': 'C0031572', 'cui_str': 'Social phobia'}, {'cui': 'C0085159', 'cui_str': 'Seasonal affective disorder'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C1276802', 'cui_str': 'Sudden'}]",,0.0333064,"Intraindividual variability in symptoms significantly predicted sudden gains both when measured before treatment or within-treatment and correctly classified 84% and 83% of individuals to sudden gains versus non-sudden gains status, respectively. ","[{'ForeName': 'Jonathan G', 'Initials': 'JG', 'LastName': 'Shalom', 'Affiliation': 'Department of Psychology, University of Haifa.'}, {'ForeName': 'Asher Y', 'Initials': 'AY', 'LastName': 'Strauss', 'Affiliation': 'Department of Psychology, The Hebrew University of Jerusalem.'}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Huppert', 'Affiliation': 'Department of Psychology, The Hebrew University of Jerusalem.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Andersson', 'Affiliation': 'Department of Behavioural Sciences and Learning, Linkoping University.'}, {'ForeName': 'Or D', 'Initials': 'OD', 'LastName': 'Agassi', 'Affiliation': 'Department of Psychology, University of Haifa.'}, {'ForeName': 'Idan M', 'Initials': 'IM', 'LastName': 'Aderka', 'Affiliation': 'Department of Psychology, University of Haifa.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000587'] 1357,32579432,Does Happiness Improve Health? Evidence From a Randomized Controlled Trial.,"Happier people are healthier, but does becoming happier lead to better health? In the current study, we deployed a comprehensive, 3-month positive psychological intervention as an experimental tool to examine the effects of increasing subjective well-being on physical health in a nonclinical population. In a 6-month randomized controlled trial with 155 community adults, we found effects of treatment on self-reported physical health-the number of days in the previous month that participants felt healthy or sick, as assessed by questions from the Centers for Disease Control and Prevention's Behavioral Risk Factor Surveillance System Questionnaire. In a subsample of 100 participants, we also found evidence that improvements in subjective well-being over the course of the program predicted subsequent decreases in the number of sick days. Combining experimental and longitudinal methodologies, this work provides some evidence for a causal effect of subjective well-being on self-reported physical health.",2020,"Happier people are healthier, but does becoming happier lead to better health?","[""participants felt healthy or sick, as assessed by questions from the Centers for Disease Control and Prevention's Behavioral Risk Factor Surveillance System Questionnaire"", '155 community adults']",[],['number of sick days'],"[{'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0007670', 'cui_str': 'Centers for Disease Control and Prevention (U.S.)'}, {'cui': 'C1136355', 'cui_str': 'Behavior Risk Factor Surveillance System'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]",[],"[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0242806', 'cui_str': 'Illness Days'}]",155.0,0.0428741,"Happier people are healthier, but does becoming happier lead to better health?","[{'ForeName': 'Kostadin', 'Initials': 'K', 'LastName': 'Kushlev', 'Affiliation': 'Department of Psychology, Georgetown University.'}, {'ForeName': 'Samantha J', 'Initials': 'SJ', 'LastName': 'Heintzelman', 'Affiliation': 'Department of Psychology, Rutgers University, Newark.'}, {'ForeName': 'Lesley D', 'Initials': 'LD', 'LastName': 'Lutes', 'Affiliation': 'Department of Psychology, University of British Columbia.'}, {'ForeName': 'Derrick', 'Initials': 'D', 'LastName': 'Wirtz', 'Affiliation': 'Department of Psychology, University of British Columbia.'}, {'ForeName': 'Jacqueline M', 'Initials': 'JM', 'LastName': 'Kanippayoor', 'Affiliation': 'Department of Psychology, University of British Columbia.'}, {'ForeName': 'Damian', 'Initials': 'D', 'LastName': 'Leitner', 'Affiliation': 'Department of Psychology, University of British Columbia.'}, {'ForeName': 'Ed', 'Initials': 'E', 'LastName': 'Diener', 'Affiliation': 'Department of Psychology, University of Virginia.'}]",Psychological science,['10.1177/0956797620919673'] 1358,32579812,Effect on Patient Safety of a Resident Physician Schedule without 24-Hour Shifts.,"BACKGROUND The effects on patient safety of eliminating extended-duration work shifts for resident physicians remain controversial. METHODS We conducted a multicenter, cluster-randomized, crossover trial comparing two schedules for pediatric resident physicians during their intensive care unit (ICU) rotations: extended-duration work schedules that included shifts of 24 hours or more (control schedules) and schedules that eliminated extended shifts and cycled resident physicians through day and night shifts of 16 hours or less (intervention schedules). The primary outcome was serious medical errors made by resident physicians, assessed by intensive surveillance, including direct observation and chart review. RESULTS The characteristics of ICU patients during the two work schedules were similar, but resident physician workload, described as the mean (±SD) number of ICU patients per resident physician, was higher during the intervention schedules than during the control schedules (8.8±2.8 vs. 6.7±2.2). Resident physicians made more serious errors during the intervention schedules than during the control schedules (97.1 vs. 79.0 per 1000 patient-days; relative risk, 1.53; 95% confidence interval [CI], 1.37 to 1.72; P<0.001). The number of serious errors unitwide were likewise higher during the intervention schedules (181.3 vs. 131.5 per 1000 patient-days; relative risk, 1.56; 95% CI, 1.43 to 1.71). There was wide variability among sites, however; errors were lower during intervention schedules than during control schedules at one site, rates were similar during the two schedules at two sites, and rates were higher during intervention schedules than during control schedules at three sites. In a secondary analysis that was adjusted for the number of patients per resident physician as a potential confounder, intervention schedules were no longer associated with an increase in errors. CONCLUSIONS Contrary to our hypothesis, resident physicians who were randomly assigned to schedules that eliminated extended shifts made more serious errors than resident physicians assigned to schedules with extended shifts, although the effect varied by site. The number of ICU patients cared for by each resident physician was higher during schedules that eliminated extended shifts. (Funded by the National Heart, Lung, and Blood Institute; ROSTERS ClinicalTrials.gov number, NCT02134847.).",2020,"The number of serious errors unitwide were likewise higher during the intervention schedules (181.3 vs. 131.5 per 1000 patient-days; relative risk, 1.56; 95% CI, 1.43 to 1.71).",['pediatric resident physicians during their intensive care unit (ICU) rotations'],[],"['number of serious errors unitwide', 'errors', 'serious errors', 'serious medical errors made by resident physicians, assessed by intensive surveillance, including direct observation and chart review']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}]",[],"[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0376531', 'cui_str': 'Errors, Medical'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0541653', 'cui_str': 'Chart evaluation by healthcare professional'}]",,0.0840156,"The number of serious errors unitwide were likewise higher during the intervention schedules (181.3 vs. 131.5 per 1000 patient-days; relative risk, 1.56; 95% CI, 1.43 to 1.71).","[{'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Landrigan', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Shadab A', 'Initials': 'SA', 'LastName': 'Rahman', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Jason P', 'Initials': 'JP', 'LastName': 'Sullivan', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Vittinghoff', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Laura K', 'Initials': 'LK', 'LastName': 'Barger', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Amy L', 'Initials': 'AL', 'LastName': 'Sanderson', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Kenneth P', 'Initials': 'KP', 'LastName': 'Wright', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Conor S', 'Initials': 'CS', 'LastName': ""O'Brien"", 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Salim', 'Initials': 'S', 'LastName': 'Qadri', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Melissa A', 'Initials': 'MA', 'LastName': 'St Hilaire', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Ann C', 'Initials': 'AC', 'LastName': 'Halbower', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Jeffrey L', 'Initials': 'JL', 'LastName': 'Segar', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'John K', 'Initials': 'JK', 'LastName': 'McGuire', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Michael V', 'Initials': 'MV', 'LastName': 'Vitiello', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Horacio O', 'Initials': 'HO', 'LastName': 'de la Iglesia', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Sue E', 'Initials': 'SE', 'LastName': 'Poynter', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Pearl L', 'Initials': 'PL', 'LastName': 'Yu', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Phyllis C', 'Initials': 'PC', 'LastName': 'Zee', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Steven W', 'Initials': 'SW', 'LastName': 'Lockley', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Katie L', 'Initials': 'KL', 'LastName': 'Stone', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': 'Charles A', 'Initials': 'CA', 'LastName': 'Czeisler', 'Affiliation': ""From the Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital (C.P.L., S.A.R., J.P.S., L.K.B., C.S.O., S.Q., M.A.S.H., S.W.L., C.A.C.), the Division of Sleep Medicine, Harvard Medical School (C.P.L., S.A.R., L.K.B., M.A.S.H., S.W.L., C.A.C.), and the Division of General Pediatrics, Department of Pediatrics (C.P.L.), and the Division of Critical Care Medicine, Department of Anesthesiology, Critical Care, and Pain Medicine (A.L.S.), Boston Children's Hospital - all in Boston; the University of California, San Francisco (E.V., K.L.S.), and California Pacific Medical Center Research Institute (K.L.S.), San Francisco; the Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder (K.P.W.), and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (A.C.H.); the University of Iowa Stead Family Children's Hospital, Iowa City (J.L.S.); Seattle Children's Hospital (J.K.M.) and the University of Washington (M.V.V., H.O.I.), Seattle; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati (S.E.P.); University of Virginia Children's Hospital, Charlottesville (P.L.Y.); and the Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University, Feinberg School of Medicine, Chicago (P.C.Z.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1900669'] 1359,32565419,Improving quality of care in less than 1 min: a prospective intervention study on postoperative handovers to the ICU/PACU.,"PURPOSE Standardisation of the postoperative handover process via checklists, trainings or procedural changes has shown to be effective in reducing information loss. The clinical friction of implementing these measures has received little attention. We developed and evaluated a visual aid (VA) and >1 min in situ training intervention to improve the quality of postoperative handovers to the intensive care unit (ICU) and postoperative care unit. MATERIALS AND METHODS The VA was constructed and implemented via a brief (<1 min) training of anaesthesiologic staff during the operation. Ease of implementation was measured by amount of information transferred, handover duration and handover structure. 50 handovers were audio recorded before intervention and 50 after intervention. External validity was evaluated by blinded assessment of the recordings by experienced anaesthesiologists (n=10) on 10-point scales. RESULTS The brief intervention resulted in increased information transfer (9.0-14.8 items, t (98)=7.44, p<0.0001, Cohen's d=1.59) and increased handover duration (81.3-192.8 s, t (98)=6.642, p=0.013, Cohen's d=1.33) with no loss in structure (1.60-1.56, t (98)=0.173, p=0.43). Blinded assessment on 10-point scales by experienced anaesthesiologists showed improved overall handover quality from 7.1 to 7.8 ( t (98)=1.89, p=0.031, Cohen's d=0.21) and improved completeness of information ( t (98)=2.42, p=0.009, Cohen's d=0.28) from 7.3 to 8.3. CONCLUSIONS An intervention consisting of a simple VA and <1 min instructions significantly increased overall quality and amount of information transferred during ICU/postanaesthetic care unit handovers.",2020,An intervention consisting of a simple VA and <1 min instructions significantly increased overall quality and amount of information transferred during ICU/postanaesthetic care unit handovers.,[],['ICU/PACU'],"['information transfer', 'completeness of information', 'Improving quality of care', 'overall quality', 'External validity', 'overall handover quality', 'handover duration']",[],"[{'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0034871', 'cui_str': 'Postoperative anesthesia care unit'}]","[{'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0439812', 'cui_str': 'Completeness'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0034379', 'cui_str': 'Quality of Care'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0042283', 'cui_str': 'Validity (Epidemiology)'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]",50.0,0.0575622,An intervention consisting of a simple VA and <1 min instructions significantly increased overall quality and amount of information transferred during ICU/postanaesthetic care unit handovers.,"[{'ForeName': 'Niklas', 'Initials': 'N', 'LastName': 'Keller', 'Affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine, Campus Virchow Klinikum and Charité Centrum Mitte (CVK/CCM), Charité Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin, Institute of Health, Berlin, Germany niklas.keller@charite.de.'}, {'ForeName': 'Götz', 'Initials': 'G', 'LastName': 'Bosse', 'Affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine, Campus Virchow Klinikum and Charité Centrum Mitte (CVK/CCM), Charité Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin, Institute of Health, Berlin, Germany.'}, {'ForeName': 'Belinda', 'Initials': 'B', 'LastName': 'Memmert', 'Affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine, Campus Virchow Klinikum and Charité Centrum Mitte (CVK/CCM), Charité Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin, Institute of Health, Berlin, Germany.'}, {'ForeName': 'Sascha', 'Initials': 'S', 'LastName': 'Treskatsch', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Campus Benjamin Franklin (CBF), Charité Universitätsmedizin Berlin, Corporate Member of the Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Spies', 'Affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine, Campus Virchow Klinikum and Charité Centrum Mitte (CVK/CCM), Charité Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin, Institute of Health, Berlin, Germany.'}]",BMJ open quality,['10.1136/bmjoq-2019-000668'] 1360,32573382,Stop Signal Task Training Strengthens GABA-mediated Neurotransmission within the Primary Motor Cortex.,"We have recently shown that the efficiency in stopping a response, measured using the stop signal task, is related to GABA A -mediated short-interval intracortical inhibition (SICI) in the primary motor cortex. In this study, we conducted two experiments on humans to determine whether training participants in the stop signal task within one session (Experiment 1) and across multiple sessions (Experiment 2) would increase SICI strength. For each experiment, we obtained premeasures and postmeasures of stopping efficiency and resting-state SICI, that is, during relaxed muscle activity (Experiment 1, n = 45, 15 male participants) and SICI during the stop signal task (Experiment 2, n = 44, 21 male participants). In the middle blocks of Experiment 1 and the middle sessions of Experiment 2, participants in the experimental group completed stop signal task training, whereas control participants completed a similar task without the requirement to stop a response. After training, the experimental group showed increased resting-state SICI strength (Experiment 1) and increased SICI strength during the stop signal task (Experiment 2). Although there were no overall behavioral improvements in stopping efficiency, improvements at an individual level were correlated with increases in SICI strength at rest (Experiment 1) and during successful stopping (Experiment 2). These results provide evidence of neuroplasticity in resting-state and task-related GABA A -mediated SICI in the primary motor cortex after response inhibition training. These results also suggest that SICI and stopping efficiency are temporally linked, such that a change in SICI between time points is correlated with a change in stopping efficiency between time points.",2020,"Although there were no overall behavioral improvements in stopping efficiency, improvements at an individual level were correlated with increases in SICI strength at rest (Experiment 1) and during successful stopping (Experiment 2).",[],['stop signal task training'],"['SICI strength', 'resting-state SICI strength']",[],"[{'cui': 'C0450446', 'cui_str': 'Stops'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0679218', 'cui_str': 'Resting state'}]",,0.0132836,"Although there were no overall behavioral improvements in stopping efficiency, improvements at an individual level were correlated with increases in SICI strength at rest (Experiment 1) and during successful stopping (Experiment 2).","[{'ForeName': 'Nahian S', 'Initials': 'NS', 'LastName': 'Chowdhury', 'Affiliation': 'The University of Sydney.'}, {'ForeName': 'Evan J', 'Initials': 'EJ', 'LastName': 'Livesey', 'Affiliation': 'The University of Sydney.'}, {'ForeName': 'Justin A', 'Initials': 'JA', 'LastName': 'Harris', 'Affiliation': 'The University of Sydney.'}]",Journal of cognitive neuroscience,['10.1162/jocn_a_01597'] 1361,32570178,Effects of a 10-week multimodal dance and art intervention program leading to a public performance in persons with multiple sclerosis - A controlled pilot-trial.,"BACKGROUND Dance therapy is increasingly reported in neurological diseases for improving several motor and cognitive functions, but was mostly studied in partner dance. No individual choreo-based dance program has ever been reported in MS. OBJECTIVES The aim of this pilot study is to investigate effects of a ten-week choreo-based dance intervention on different impairments in MS. PARTICIPANTS Seventeen participants with MS were allocated to a dance group (DG) or an art group (AG) for a ten-week intervention program, with a public live performance at the end of the intervention. METHODS The DG received choreo-based dance courses twice a week for 90 min, while the active control AG weekly contributed to the production by painting, music, spoken word and photo- or videography. Measurements for fatigue and fatigability, physical capacity and coordination, sensory function, cognitive capacity, quality of life and dual task performance took place before and after the intervention. Differences were analysed with Wilcoxon Signed Rank test. RESULTS Both groups improved significantly on executive cognitive performance during dual task and fatigue. Only the DG improved significantly on functional lower limb strength, hand function, coordination, self-reported balance and walking, and showed a trend towards improving on cognition (PASAT). The AG showed significant improvements in on cognitive function (SDMT). CONCLUSION A ten-week multimodal dance intervention has positive effects on impact of fatigue, physical capacity and coordination, and cognitive performance during a dual task. Larger samples, follow-up measurements and research in different disability groups is recommended.",2020,"Only the DG improved significantly on functional lower limb strength, hand function, coordination, self-reported balance and walking, and showed a trend towards improving on cognition (PASAT).","['persons with multiple sclerosis', 'Seventeen participants with MS']","['active control AG weekly contributed to the production by painting, music, spoken word and photo- or videography', 'ten-week choreo-based dance intervention', 'multimodal dance and art intervention program', 'dance group (DG) or an art group (AG']","['functional lower limb strength, hand function, coordination, self-reported balance and walking, and showed a trend towards improving on cognition (PASAT', 'impact of fatigue, physical capacity and coordination, and cognitive performance', 'executive cognitive performance', 'fatigue and fatigability, physical capacity and coordination, sensory function, cognitive capacity, quality of life and dual task performance took place', 'cognitive function (SDMT']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0450331', 'cui_str': '17'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0030208', 'cui_str': 'Paintings'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0010963', 'cui_str': 'Dance'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0562230', 'cui_str': 'Hand functions'}, {'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040833', 'cui_str': 'trends'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0231230', 'cui_str': 'Fatigability'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0442504', 'cui_str': 'Place'}]",17.0,0.0172608,"Only the DG improved significantly on functional lower limb strength, hand function, coordination, self-reported balance and walking, and showed a trend towards improving on cognition (PASAT).","[{'ForeName': 'Fanny', 'Initials': 'F', 'LastName': 'Van Geel', 'Affiliation': 'REVAL Rehabilitation Research Center, Faculty of Rehabilitation Sciences, Hasselt University, Belgium. Electronic address: fanny.vangeel@uhasselt.be.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Van Asch', 'Affiliation': 'Fit Up Neurological and Sport Physiotherapy, Antwerp, Belgium; Move to Sport Foundation, Mechelsesteenweg, Kontich, Belgium.'}, {'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Veldkamp', 'Affiliation': 'REVAL Rehabilitation Research Center, Faculty of Rehabilitation Sciences, Hasselt University, Belgium. Electronic address: renee.veldkamp@uhasselt.be.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Feys', 'Affiliation': 'REVAL Rehabilitation Research Center, Faculty of Rehabilitation Sciences, Hasselt University, Belgium. Electronic address: peter.feys@uhasselt.be.'}]",Multiple sclerosis and related disorders,['10.1016/j.msard.2020.102256'] 1362,32575611,"Effect of a Flaxseed Lignan Intervention on Circulating Bile Acids in a Placebo-Controlled Randomized, Crossover Trial.","Plant lignans and their microbial metabolites, e.g., enterolactone (ENL), may affect bile acid (BA) metabolism through interaction with hepatic receptors. We evaluated the effects of a flaxseed lignan extract (50 mg/day secoisolariciresinol diglucoside) compared to a placebo for 60 days each on plasma BA concentrations in 46 healthy men and women (20-45 years) using samples from a completed randomized, crossover intervention. Twenty BA species were measured in fasting plasma using LC-MS. ENL was measured in 24-h urines by GC-MS. We tested for (a) effects of the intervention on BA concentrations overall and stratified by ENL excretion; and (b) cross-sectional associations between plasma BA and ENL. We also explored the overlap in bacterial metabolism at the genus level and conducted in vitro anaerobic incubations of stool with lignan substrate to identify genes that are enriched in response to lignan metabolism. There were no intervention effects, overall or stratified by ENL at FDR < 0.05. In the cross-sectional analysis, irrespective of treatment, five secondary BAs were associated with ENL excretion (FDR < 0.05). In vitro analyses showed positive associations between ENL production and bacterial gene expression of the bile acid-inducible gene cluster and hydroxysteroid dehydrogenases. These data suggest overlap in community bacterial metabolism of secondary BA and ENL.",2020,In vitro analyses showed positive associations between ENL production and bacterial gene expression of the bile acid-inducible gene cluster and hydroxysteroid dehydrogenases.,['46 healthy men and women (20-45 years) using samples'],"['flaxseed lignan extract (50 mg/day secoisolariciresinol diglucoside', 'Flaxseed Lignan Intervention', 'placebo']","['fasting plasma using LC-MS', 'Circulating Bile Acids', 'BA concentrations overall and stratified by ENL excretion; and (b) cross-sectional associations between plasma BA and ENL', 'plasma BA concentrations']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C0023753', 'cui_str': 'Linum'}, {'cui': 'C0064971', 'cui_str': 'Lignans'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0290196', 'cui_str': 'secoisolariciresinol diglucoside'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0005390', 'cui_str': 'Bile acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0045341', 'cui_str': ""2,3-bis(3'-hydroxybenzyl)butyrolactone""}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0004083', 'cui_str': 'Association'}]",46.0,0.0675738,In vitro analyses showed positive associations between ENL production and bacterial gene expression of the bile acid-inducible gene cluster and hydroxysteroid dehydrogenases.,"[{'ForeName': 'Sandi L', 'Initials': 'SL', 'LastName': 'Navarro', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Levy', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.'}, {'ForeName': 'Keith R', 'Initials': 'KR', 'LastName': 'Curtis', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.'}, {'ForeName': 'Isaac', 'Initials': 'I', 'LastName': 'Elkon', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.'}, {'ForeName': 'Orsalem J', 'Initials': 'OJ', 'LastName': 'Kahsai', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.'}, {'ForeName': 'Hamza S', 'Initials': 'HS', 'LastName': 'Ammar', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.'}, {'ForeName': 'Timothy W', 'Initials': 'TW', 'LastName': 'Randolph', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.'}, {'ForeName': 'Natalie N', 'Initials': 'NN', 'LastName': 'Hong', 'Affiliation': 'Northwest Metabolomics Research Center, Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA 98109, USA.'}, {'ForeName': 'Fausto', 'Initials': 'F', 'LastName': 'Carnevale Neto', 'Affiliation': 'Northwest Metabolomics Research Center, Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA 98109, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Raftery', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Chapkin', 'Affiliation': 'Program in Integrative Nutrition & Complex Diseases, Texas A&M University, College Station, TX 77843, USA.'}, {'ForeName': 'Johanna W', 'Initials': 'JW', 'LastName': 'Lampe', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.'}, {'ForeName': 'Meredith A J', 'Initials': 'MAJ', 'LastName': 'Hullar', 'Affiliation': 'Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.'}]",Nutrients,['10.3390/nu12061837'] 1363,32576202,Pre-implementation adaptation of primary care cancer prevention clinical decision support in a predominantly rural healthcare system.,"BACKGROUND Cancer is a leading cause of death in the United States. Primary care providers (PCPs) juggle patient cancer prevention and screening along with managing acute and chronic health problems. However, clinical decision support (CDS) may assist PCPs in addressing patients' cancer prevention and screening needs during short clinic visits. In this paper, we describe pre-implementation study design and cancer screening and prevention CDS changes made to maximize utilization and better fit a healthcare system's goals and culture. We employed the Consolidated Framework for Implementation Research (CFIR), useful for evaluating the implementation of CDS interventions in primary care settings, in understanding barriers and facilitators that led to those changes. METHODS In a three-arm, pragmatic, 36 clinic cluster-randomized control trial, we integrated cancer screening and prevention CDS and shared decision-making tools (SDMT) into an existing electronic medical record-linked cardiovascular risk management CDS system. The integrated CDS is currently being tested within a predominately rural upper Midwestern healthcare system. Prior to CDS implementation, we catalogued pre-implementation changes made from 2016 to 2018 based on: pre-implementation site engagement; key informant interviews with healthcare system rooming staff, providers, and leadership; and pilot testing. We identified influential barriers, facilitators, and changes made in response through qualitative content analysis of meeting minutes and supportive documents. We then coded pre-implementation changes made and associated barriers and facilitators using the CFIR. RESULTS Based on our findings from system-wide pre-implementation engagement, pilot testing, and key informant interviews, we made changes to accommodate the needs of the healthcare system based on barriers and facilitators that fell within the Intervention Characteristics, Inner Setting, and Outer Setting CFIR domains. Changes included replacing the expansion of medical assistant roles in one intervention arm with targeted SDMT, as well as altering cancer prevention CDS and study design elements. CONCLUSIONS Pre-implementation changes to CDS may help meet healthcare systems' evolving needs and optimize the intervention by being responsive to real-world implementation barriers and facilitators. Frameworks like the CFIR are useful tools for identifying areas where pre-implementation barriers and facilitators may result in design changes, both to research studies and CDS systems. TRIAL REGISTRATION NCT02986230.",2020,"Frameworks like the CFIR are useful tools for identifying areas where pre-implementation barriers and facilitators may result in design changes, both to research studies and CDS systems. ","['Primary care providers (PCPs) juggle patient cancer prevention and screening along with managing acute and chronic health problems', 'predominately rural upper Midwestern healthcare system']",['integrated cancer screening and prevention CDS and shared decision-making tools (SDMT) into an existing electronic medical record-linked cardiovascular risk management CDS system'],[],"[{'cui': 'C2735026', 'cui_str': 'Primary care provider'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0332251', 'cui_str': 'Predominate'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0018696', 'cui_str': 'Healthcare Systems'}]","[{'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C4042765', 'cui_str': 'Decision Support, Clinical'}, {'cui': 'C3179495', 'cui_str': 'Decision Making, Shared'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0525070', 'cui_str': 'Clinical Decision Support Systems'}]",[],,0.0506432,"Frameworks like the CFIR are useful tools for identifying areas where pre-implementation barriers and facilitators may result in design changes, both to research studies and CDS systems. ","[{'ForeName': 'Melissa L', 'Initials': 'ML', 'LastName': 'Harry', 'Affiliation': 'Essentia Health, Essentia Institute of Rural Health, 6AV-2, 502 East Second Street, Duluth, MN, 55805, USA.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Saman', 'Affiliation': 'Essentia Health, Essentia Institute of Rural Health, 6AV-2, 502 East Second Street, Duluth, MN, 55805, USA. Daniel.Saman@EssentiaHealth.org.'}, {'ForeName': 'Anjali R', 'Initials': 'AR', 'LastName': 'Truitt', 'Affiliation': 'HealthPartners Institute, 3311 E. Old Shakopee Road, Bloomington, MN, 55425, USA.'}, {'ForeName': 'Clayton I', 'Initials': 'CI', 'LastName': 'Allen', 'Affiliation': 'Essentia Health, Essentia Institute of Rural Health, 6AV-2, 502 East Second Street, Duluth, MN, 55805, USA.'}, {'ForeName': 'Kayla M', 'Initials': 'KM', 'LastName': 'Walton', 'Affiliation': 'Essentia Health, Essentia Institute of Rural Health, 6AV-2, 502 East Second Street, Duluth, MN, 55805, USA.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': ""O'Connor"", 'Affiliation': 'HealthPartners Institute, 3311 E. Old Shakopee Road, Bloomington, MN, 55425, USA.'}, {'ForeName': 'Heidi L', 'Initials': 'HL', 'LastName': 'Ekstrom', 'Affiliation': 'HealthPartners Institute, 3311 E. Old Shakopee Road, Bloomington, MN, 55425, USA.'}, {'ForeName': 'JoAnn M', 'Initials': 'JM', 'LastName': 'Sperl-Hillen', 'Affiliation': 'HealthPartners Institute, 3311 E. Old Shakopee Road, Bloomington, MN, 55425, USA.'}, {'ForeName': 'Joseph A', 'Initials': 'JA', 'LastName': 'Bianco', 'Affiliation': 'Essentia Health - Ely Clinic, 300 W Conan Street, Ely, MN, 55731, USA.'}, {'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Elliott', 'Affiliation': 'HealthPartners Institute, 3311 E. Old Shakopee Road, Bloomington, MN, 55425, USA.'}]",BMC medical informatics and decision making,['10.1186/s12911-020-01136-8'] 1364,32584263,Determining the Impact of a School-Based Health Education Package for Prevention of Intestinal Worm Infections in the Philippines: Protocol for a Cluster Randomized Intervention Trial.,"BACKGROUND Repeated mass drug administration (MDA) of antihelminthics to at-risk populations is still the main strategy for the control of soil-transmitted helminth (STH) infections. However, MDA, as a stand-alone intervention, does not prevent reinfection. Accordingly, complementary measures to prevent STH reinfection, such as health education and improved sanitation, as part of an integrated control approach, are required to augment the effectiveness of MDA for optimal efficiency and sustainability. OBJECTIVE The aim of this study is to determine the impact and generalizability of a school-based health education package entitled The Magic Glasses for STH prevention in the Philippines. METHODS We conducted a cluster randomized controlled intervention trial, involving 2020 schoolchildren aged 9-10 years, in 40 schools in Laguna Province, Philippines, to evaluate the impact of the school-based health education package for the prevention of STHs. The trial was conducted over the course of 1 year (June 2016 to July 2017). A total of 20 schools were randomly assigned to the intervention arm, in which The Magic Glasses Philippines health education package was delivered with the standard health education activities endorsed by the Philippines Department of Health (DOH) and the Department of Education (DepEd). The other 20 schools comprised the control arm of the study, where the DOH/DepEd's standard health education activities were done. At baseline, parasitological assessments and a knowledge, attitude, and practice survey were carried out in all schools. In addition, height, weight, and hemoglobin levels were obtained from each child (after parental consent), and their school attendance and academic performance in English and mathematics were accessed from the school records. The baseline and 2 follow-up surveys were completed using the same study measurements and quality-control assessments. RESULTS Key results from this cluster randomized intervention trial will shed light on the impact that The Magic Glasses health education package will have against STH infections in schoolchildren in the province of Laguna, located on the Island of Luzon, in the Calabarzon Region of the Philippines. CONCLUSIONS The results of the trial will be used to assess the generalizability of the impact of The Magic Glasses health education package in different epidemiological and cultural settings, providing evidence for translation of this health education package into public health policy and practice in the Asian region and beyond. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry number ACTRN12616000508471; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368849. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/18419.",2020,"The results of the trial will be used to assess the generalizability of the impact of The Magic Glasses health education package in different epidemiological and cultural settings, providing evidence for translation of this health education package into public health policy and practice in the Asian region and beyond. ","['A total of 20 schools', '2020 schoolchildren aged 9-10 years, in 40 schools in Laguna Province, Philippines, to evaluate the impact of the school-based health education package for the prevention of STHs']","['School-Based Health Education Package', 'Magic Glasses Philippines health education package was delivered with the standard health education activities endorsed by the Philippines Department of Health (DOH) and the Department of Education (DepEd']","['height, weight, and hemoglobin levels', 'school attendance and academic performance in English and mathematics']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0037663', 'cui_str': 'Somatotropin'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C3529285', 'cui_str': 'Magic Glass'}, {'cui': 'C4705263', 'cui_str': 'philippin'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]","[{'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0036373', 'cui_str': 'Academic Test Performance'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0024934', 'cui_str': 'Mathematics'}]",20.0,0.0954268,"The results of the trial will be used to assess the generalizability of the impact of The Magic Glasses health education package in different epidemiological and cultural settings, providing evidence for translation of this health education package into public health policy and practice in the Asian region and beyond. ","[{'ForeName': 'Mary Lorraine S', 'Initials': 'MLS', 'LastName': 'Mationg', 'Affiliation': 'Research School of Population Heath, The Australian National University, Canberra, Australia.'}, {'ForeName': 'Gail M', 'Initials': 'GM', 'LastName': 'Williams', 'Affiliation': 'School of Public Health, University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Veronica L', 'Initials': 'VL', 'LastName': 'Tallo', 'Affiliation': 'Department of Epidemiology and Biostatistics, Research Institute for Tropical Medicine, Manila, Philippines.'}, {'ForeName': 'Remigio M', 'Initials': 'RM', 'LastName': 'Olveda', 'Affiliation': 'Department of Epidemiology and Biostatistics, Research Institute for Tropical Medicine, Manila, Philippines.'}, {'ForeName': 'Eindra', 'Initials': 'E', 'LastName': 'Aung', 'Affiliation': 'Research School of Population Heath, The Australian National University, Canberra, Australia.'}, {'ForeName': 'Portia', 'Initials': 'P', 'LastName': 'Alday', 'Affiliation': 'Department of Epidemiology and Biostatistics, Research Institute for Tropical Medicine, Manila, Philippines.'}, {'ForeName': 'Mark Donald', 'Initials': 'MD', 'LastName': 'Reñosa', 'Affiliation': 'Department of Epidemiology and Biostatistics, Research Institute for Tropical Medicine, Manila, Philippines.'}, {'ForeName': 'Chona Mae', 'Initials': 'CM', 'LastName': 'Daga', 'Affiliation': 'Department of Epidemiology and Biostatistics, Research Institute for Tropical Medicine, Manila, Philippines.'}, {'ForeName': 'Jhoys', 'Initials': 'J', 'LastName': 'Landicho', 'Affiliation': 'Department of Epidemiology and Biostatistics, Research Institute for Tropical Medicine, Manila, Philippines.'}, {'ForeName': 'Maria Paz', 'Initials': 'MP', 'LastName': 'Demonteverde', 'Affiliation': 'Department of Epidemiology and Biostatistics, Research Institute for Tropical Medicine, Manila, Philippines.'}, {'ForeName': 'Eunice Dianne', 'Initials': 'ED', 'LastName': 'Santos', 'Affiliation': 'Department of Epidemiology and Biostatistics, Research Institute for Tropical Medicine, Manila, Philippines.'}, {'ForeName': 'Thea Andrea', 'Initials': 'TA', 'LastName': 'Bravo', 'Affiliation': 'Department of Epidemiology and Biostatistics, Research Institute for Tropical Medicine, Manila, Philippines.'}, {'ForeName': 'Franziska A', 'Initials': 'FA', 'LastName': 'Angly Bieri', 'Affiliation': 'Research School of Population Heath, The Australian National University, Canberra, Australia.'}, {'ForeName': 'Yuesheng', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Molecular Parasitology Laboratory, Infectious Diseases Division, QIMR Berghofer Medical Research Institute, Brisbane, Australia.'}, {'ForeName': 'Archie C A', 'Initials': 'ACA', 'LastName': 'Clements', 'Affiliation': 'Faculty of Health Sciences, Curtin University, Perth, Australia.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Steinmann', 'Affiliation': 'Swiss Tropical and Public Health Institute, Basel, Switzerland.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Halton', 'Affiliation': 'School of Public Health and Social Work, Queensland University of Technology, Brisbane, Australia.'}, {'ForeName': 'Donald E', 'Initials': 'DE', 'LastName': 'Stewart', 'Affiliation': 'Research School of Population Heath, The Australian National University, Canberra, Australia.'}, {'ForeName': 'Donald P', 'Initials': 'DP', 'LastName': 'McManus', 'Affiliation': 'Molecular Parasitology Laboratory, Infectious Diseases Division, QIMR Berghofer Medical Research Institute, Brisbane, Australia.'}, {'ForeName': 'Darren J', 'Initials': 'DJ', 'LastName': 'Gray', 'Affiliation': 'Research School of Population Heath, The Australian National University, Canberra, Australia.'}]",JMIR research protocols,['10.2196/18419'] 1365,32442198,No-flip ShangRing circumcision in 10-12 year old boys: Results from randomized clinical trials in Kenya.,"BACKGROUND Attention has recently turned toward the use of device-assisted male circumcision to help scale up male circumcision services in sub-Saharan Africa, with increasing emphasis on younger age groups. We assessed the use of the ShangRing for circumcising the subset of boys aged 10 to 12 years who were enrolled in two randomized clinical trials in Kenya. METHODS We performed a sub-analysis of outcomes in 197 boys aged 10 to 12 years; a subset who were enrolled in two randomized clinical trials to assess the use of the no-flip ShangRing circumcision technique in men and boys. One trial assessed spontaneous detachment vs. planned removal of the ShangRing 7 days post-circumcision. The second trial compared the use of topical vs. injectable anesthesia with ShangRing circumcision. Aside from baseline characteristics, data was collected and analyzed for each trial separately. RESULTS All participants were successfully circumcised. Duration of circumcision, participants requiring a dorsal slit, rate of adverse events, time to complete wound healing, and participant satisfaction were similar between the two groups in each trial. Mean time required for spontaneous ShangRing detachment was 14.82±3.76 days. Topical anesthesia showed a significantly lower mean pain score at the time of application (0.64±1.71 vs. 1.55± 2.21, p = 0.03) as well as postoperatively (0.54±0.88 vs. 1.72±1.56, p<0.0001). Median dwell time of the topical anesthetic was 43 (IQR: 35.5-60) minutes, while the median time it took the injectable anesthetic to take effect was 2.04 (IQR: 1.72-3.09) minutes. CONCLUSION No-flip ShangRing circumcision had a positive safety profile among young adolescent boys, specifically ages 10-12 years. The use of spontaneous device detachment and topical anesthesia with the procedure have shown promising outcomes in this age group. This may have the potential to further increase the acceptability of ShangRing circumcision, and therefore accelerate the scle up of male circumcision services in sub-Saharan Africa. TRIAL REGISTRATION ClinicalTrials.gov registration # NCT02390310.",2020,"Topical anesthesia showed a significantly lower mean pain score at the time of application (0.64±1.71 vs. 1.55± 2.21, p = 0.03) as well as postoperatively (0.54±0.88 vs. 1.72±1.56, p<0.0001).","['boys aged 10 to 12 years who were enrolled in two randomized clinical trials in Kenya', 'young adolescent boys, specifically ages 10-12 years', '10-12 year old boys', '197 boys aged 10 to 12 years', 'in men and boys']","['topical vs. injectable anesthesia with ShangRing circumcision', 'no-flip ShangRing circumcision technique', 'Topical anesthesia']","['Duration of circumcision, participants requiring a dorsal slit, rate of adverse events, time to complete wound healing, and participant satisfaction', 'Median dwell time of the topical anesthetic', 'positive safety profile', 'mean pain score', 'Mean time required for spontaneous ShangRing detachment']","[{'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0001589', 'cui_str': 'Adolescents, Male'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0008819', 'cui_str': 'Circumcision'}, {'cui': 'C0540654', 'cui_str': 'Casper Protein'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0472473', 'cui_str': 'Topical local anesthetic'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0008819', 'cui_str': 'Circumcision'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0184904', 'cui_str': 'Slitting'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0429659', 'cui_str': 'Dwell time'}, {'cui': 'C0040464', 'cui_str': 'Topical anesthetic'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0541879', 'cui_str': 'Detachment psychological'}]",197.0,0.304241,"Topical anesthesia showed a significantly lower mean pain score at the time of application (0.64±1.71 vs. 1.55± 2.21, p = 0.03) as well as postoperatively (0.54±0.88 vs. 1.72±1.56, p<0.0001).","[{'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Al Hussein Alawamlh', 'Affiliation': 'Department of Urology, James Buchanan Brady Foundation, Center for Male Reproductive Medicine and Microsurgery, Weill Cornell College of Cornell University, New York, NY, United States of America.'}, {'ForeName': 'Quentin D', 'Initials': 'QD', 'LastName': 'Awori', 'Affiliation': 'EngenderHealth, Nairobi, Kenya.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Barone', 'Affiliation': 'EngenderHealth, Washington, DC, NY, United States of America.'}, {'ForeName': 'Soo-Jeong', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'Department of Urology, James Buchanan Brady Foundation, Center for Male Reproductive Medicine and Microsurgery, Weill Cornell College of Cornell University, New York, NY, United States of America.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Goldstein', 'Affiliation': 'Department of Urology, James Buchanan Brady Foundation, Center for Male Reproductive Medicine and Microsurgery, Weill Cornell College of Cornell University, New York, NY, United States of America.'}, {'ForeName': 'Philip S', 'Initials': 'PS', 'LastName': 'Li', 'Affiliation': 'Department of Urology, James Buchanan Brady Foundation, Center for Male Reproductive Medicine and Microsurgery, Weill Cornell College of Cornell University, New York, NY, United States of America.'}, {'ForeName': 'Richard K', 'Initials': 'RK', 'LastName': 'Lee', 'Affiliation': 'Department of Urology, James Buchanan Brady Foundation, Center for Male Reproductive Medicine and Microsurgery, Weill Cornell College of Cornell University, New York, NY, United States of America.'}]",PloS one,['10.1371/journal.pone.0233150'] 1366,32444152,Land-walking vs. water-walking interventions in older adults: Effects on aerobic fitness.,"BACKGROUND Low cardiorespiratory fitness is an independent predictor of all-cause and cardiovascular mortality, and interventions that increase fitness reduce risk. Water-walking decreases musculoskeletal impact and risk of falls in older individuals, but it is unclear whether water-walking improves aerobic fitness in the same way as weight-dependent land-walking. This randomized controlled trial involved 3 intervention groups-a no-exercise control group (CG), a land-walking (LW) group, and a water-walking (WW) group-to investigate the comparative impacts of LW and WW to CG on fitness. METHODS Both exercise groups attended individually tailored, center-based, intensity-matched 3 × weekly sessions for 24 weeks, which progressed to 150 min of exercise per week. This was followed by a 24-week no-intervention period. Maximal graded exercise tests were performed on a treadmill at Weeks 0, 24, and 48. RESULTS Maximal oxygen uptake increased from Week 0 to Week 24 in both exercise groups (0.57 ± 0.62 mL/kg/min, 0.03 ± 0.04 L/min for LW; 0.93 ± 0.75 mL/kg/min, 0.06 ± 0.06 L/min for WW, mean ± SE) compared to the CG (-1.75 ± 0.78 mL/kg/min, -0.16 ± 0.05 L/min) (group × time, p < 0.05). Time to exhaustion increased significantly following LW only (123.4 ± 25.5 s), which was significantly greater (p = 0.001) than the CG (24.3 ± 18.5 s). By Week 48, the training-induced adaptations in the exercise groups returned to near baseline levels. CONCLUSION Our study supports current physical-activity recommendations that 150 min/week of moderate-intensity exercise produces improvements in fitness in previously sedentary older individuals. Also, LW and WW elicit similar improvements in fitness if conducted at the same relative intensities. Exercise-naïve older individuals can benefit from the lower impact forces and decreased risk of falls associated with WW without compromising improvements in cardiorespiratory fitness.",2020,"Time to exhaustion increased significantly following LW only (123.4 ± 25.5 s), which was significantly greater (p = 0.001) than the CG (24.3 ± 18.5 s).","['older individuals', 'Exercise-naïve older individuals', 'previously sedentary older individuals', 'older adults']","['moderate-intensity exercise', 'no-exercise control group (CG), a land-walking (LW) group, and a water-walking (WW', 'Land-walking vs. water-walking interventions', 'Water-walking']","['aerobic fitness', 'Maximal oxygen uptake', 'Time to exhaustion']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0557668', 'cui_str': 'Landing'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}]",,0.0350292,"Time to exhaustion increased significantly following LW only (123.4 ± 25.5 s), which was significantly greater (p = 0.001) than the CG (24.3 ± 18.5 s).","[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Haynes', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia.'}, {'ForeName': 'Louise H', 'Initials': 'LH', 'LastName': 'Naylor', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia.'}, {'ForeName': 'Howard H', 'Initials': 'HH', 'LastName': 'Carter', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia.'}, {'ForeName': 'Angela L', 'Initials': 'AL', 'LastName': 'Spence', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, WA 6102, Australia.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Robey', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia.'}, {'ForeName': 'Kay L', 'Initials': 'KL', 'LastName': 'Cox', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia; School of Medicine, The University of Western Australia, Perth, WA 6009, Australia.'}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Maslen', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia.'}, {'ForeName': 'Nicola T', 'Initials': 'NT', 'LastName': 'Lautenschlager', 'Affiliation': 'Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, Melbourne, VIC 3010, Australia; North Western Mental Health, Melbourne Health, Melbourne, VIC 3010, Australia; Division of Psychiatry, WA Centre for Health & Ageing, The University of Western Australia, Perth, WA 6009, Australia.'}, {'ForeName': 'Nicola D', 'Initials': 'ND', 'LastName': 'Ridgers', 'Affiliation': 'Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC 3125, Australia.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Green', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia. Electronic address: danny.green@uwa.edu.au.'}]",Journal of sport and health science,['10.1016/j.jshs.2019.11.005'] 1367,32449228,"Internet-based intervention for postpartum depression in China (""Mommy go""): Protocol for a randomized controlled trial.","AIM The purpose of this study is to design a research protocol for the clinical testing of the ""Mommy go"" for pregnant women with a risk of postpartum depression. DESIGN A non-blinded randomized controlled trial. METHODS A randomized controlled study will be performed from January 2018 to the completion of the study. The intervention group will follow the ""Mommy go"" protocol and the control group will receive traditional support. We will use the Edinburgh Postpartum Depression Scale and the Chinese version of the Postpartum Depression Predictors Inventory-Revised to measure the risk of postpartum depression in pregnant women. The outcomes are clinical data, postpartum depressive mood, self-efficacy, and infant temperament. Outcomes will be assessed using questionnaires and through data generated by digital technologies. DISCUSSION The expected outcomes are increased self-efficacy and infant temperament, reduced postpartum depressive mood, and improvements to postpartum depression. We expect the study to have a clinical impact on future online interventions for postpartum depression in China. IMPACT This study will provide an internet-based intervention for postpartum depression in China. It will be implemented in clinical practice if it can effectively improve postpartum depression. TRIAL REGISTRATION Registered at the Chinese Clinical Trials.gov (ChiCTR1800018804).",2020,"The expected outcomes are increased self-efficacy and infant temperament, reduced postpartum depressive mood and improvements to postpartum depression.","['postpartum depression in China', 'pregnant women with a risk of postpartum depression', 'pregnant women']","['Mommy go"" protocol and the control group will receive traditional support', 'Internet-Based Intervention']","['clinical data, postpartum depressive mood, self-efficacy and infant temperament', 'self-efficacy and infant temperament, reduced postpartum depressive mood and improvements to postpartum depression']","[{'cui': 'C0221074', 'cui_str': 'Postpartum depression'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]","[{'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C3898714', 'cui_str': 'Internet Intervention'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0039474', 'cui_str': 'Temperament'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0221074', 'cui_str': 'Postpartum depression'}]",,0.155209,"The expected outcomes are increased self-efficacy and infant temperament, reduced postpartum depressive mood and improvements to postpartum depression.","[{'ForeName': 'Yu-Hong', 'Initials': 'YH', 'LastName': 'Li', 'Affiliation': 'Nursing College, Anhui Medical University, Hefei, Anhui, P.R. China.'}, {'ForeName': 'Ting-Yu', 'Initials': 'TY', 'LastName': 'Mu', 'Affiliation': 'Nursing College, Anhui Medical University, Hefei, Anhui, P.R. China.'}, {'ForeName': 'Liu', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Nursing College, Anhui Medical University, Hefei, Anhui, P.R. China.'}, {'ForeName': 'Cheng-Lu', 'Initials': 'CL', 'LastName': 'Zhang', 'Affiliation': 'Nursing College, Anhui Medical University, Hefei, Anhui, P.R. China.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Wu', 'Affiliation': 'The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, P.R., China.'}, {'ForeName': 'Jin-Ju', 'Initials': 'JJ', 'LastName': 'Chen', 'Affiliation': 'The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, P.R., China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': 'The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, P.R., China.'}]",Journal of advanced nursing,['10.1111/jan.14436'] 1368,32450456,The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial.,"BACKGROUND AND AIMS The prognostic impact of pre-procedure heart rate (PHR) following percutaneous coronary intervention (PCI) has not yet been fully investigated. This post-hoc analysis sought to assess the impact of PHR on medium-term outcomes among patients having PCI, who were enrolled in the ""all-comers"" GLOBAL LEADERS trial. METHODS AND RESULTS The primary endpoint (composite of all-cause death or new Q-wave myocardial infarction [MI]) and key secondary safety endpoint (bleeding according to Bleeding Academic Research Consortium [BARC] type 3 or 5) were assessed at 2 years. PHR was available in 15,855 patients, and when evaluated as a continuous variable (5 bpm increase) and following adjustment using multivariate Cox regression, it significantly correlated with the primary endpoint (hazard ratio [HR] 1.06, 95% confidence interval [CI] 1.03-1.09, p < 0.001). Using dichotomous cut-off criteria, a PHR>67 bpm was associated with increased all-cause mortality (HR 1.38, 95%CI 1.13-1.69, p = 0.002) and more frequent new Q-wave MI (HR 1.41, 95%CI 1.02-1.93, p = 0.037). No significant association was found between PHR and BARC 3 or 5 bleeding (HR 1.04, 95% CI 0.99-1.09, p = 0.099). There was no interaction with the primary (p-inter = 0.236) or secondary endpoint (p-inter = 0.154) when high and low PHR was analyzed according to different antiplatelet strategies. CONCLUSIONS Elevated PHR was an independent predictor of all-cause mortality at 2 years following PCI in the ""all-comer"" GLOBAL LEADERS trial. The prognostic value of increased PHR on outcomes was not affected by the different antiplatelet strategies in this trial.",2020,"No significant association was found between PHR and BARC 3 or 5 bleeding (HR 1.04, 95% CI 0.99-1.09, p = 0.099).","['patients undergoing percutaneous coronary intervention', 'patients having PCI, who were enrolled in the ""all-comers"" GLOBAL LEADERS trial']",['percutaneous coronary intervention (PCI'],"['PHR and BARC 3 or 5 bleeding', 'primary endpoint (composite of all-cause death or new Q-wave myocardial infarction [MI]) and key secondary safety endpoint (bleeding according to Bleeding Academic Research Consortium [BARC] type 3 or 5', 'PHR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0429089', 'cui_str': 'Electrocardiogram Q waves'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0441731', 'cui_str': 'Type 3'}]",,0.296061,"No significant association was found between PHR and BARC 3 or 5 bleeding (HR 1.04, 95% CI 0.99-1.09, p = 0.099).","[{'ForeName': 'Rutao', 'Initials': 'R', 'LastName': 'Wang', 'Affiliation': ""Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands; Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.""}, {'ForeName': 'Kuniaki', 'Initials': 'K', 'LastName': 'Takahashi', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.'}, {'ForeName': 'Ply', 'Initials': 'P', 'LastName': 'Chichareon', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands; Cardiology Unit, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Gao', 'Affiliation': ""Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands; Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.""}, {'ForeName': 'Norihiro', 'Initials': 'N', 'LastName': 'Kogame', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Modolo', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands; Department of Internal Medicine, Cardiology Division, University of Campinas (UNICAMP), Campinas, Brazil.'}, {'ForeName': 'Mariusz', 'Initials': 'M', 'LastName': 'Tomaniak', 'Affiliation': 'Department of Cardiology, Erasmus Medical University Center, Thorax Centre, Rotterdam, the Netherlands; First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.'}, {'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Kawashima', 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland; Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.'}, {'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Ono', 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland; Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.'}, {'ForeName': 'Hironori', 'Initials': 'H', 'LastName': 'Hara', 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland; Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Schächinger', 'Affiliation': 'Klinikum Fulda, Medizinische Klinik I, Fulda, Germany.'}, {'ForeName': 'Gincho', 'Initials': 'G', 'LastName': 'Tonev', 'Affiliation': ""Multi-profile Hospital for Active Treatment, St George's University, Plovdiv, Bulgaria.""}, {'ForeName': 'Imre', 'Initials': 'I', 'LastName': 'Ungi', 'Affiliation': 'Division of Invasive Cardiology, Second Department of Internal Medicine and Cardiology Center, University of Szeged, Szeged, Hungary.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Botelho', 'Affiliation': 'CT / Instituto Do Coracao Do Triangulo Mineiro, Uberlandia, Brazil.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Eeckhout', 'Affiliation': 'Department of Cardiology, Lausanne University Hospital, Switzerland.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Hamm', 'Affiliation': 'Kerckhoff Heart Center, Campus University of Giessen, Bad Nauheim, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Jüni', 'Affiliation': ""Applied Health Research Centre, Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Toronto, Canada.""}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Vranckx', 'Affiliation': 'Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Hasselt, Belgium.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Windecker', 'Affiliation': 'Department of Cardiology, Bern University Hospital, Bern, Switzerland.'}, {'ForeName': 'Scot', 'Initials': 'S', 'LastName': 'Garg', 'Affiliation': 'East Lancashire Hospitals NHS Trust, Blackburn, Lancashire, United Kingdom.'}, {'ForeName': 'Robert Jan', 'Initials': 'RJ', 'LastName': 'Van Geuns', 'Affiliation': 'Department of Cardiology, Radboudumc, Nijmegen, the Netherlands.'}, {'ForeName': 'Yoshinobu', 'Initials': 'Y', 'LastName': 'Onuma', 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland; Department of Cardiology, Erasmus Medical University Center, Thorax Centre, Rotterdam, the Netherlands.'}, {'ForeName': 'Patrick W', 'Initials': 'PW', 'LastName': 'Serruys', 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland; National Heart and Lung Institute, Imperial College London, London, UK. Electronic address: patrick.w.j.c.serruys@gmail.com.'}]",Atherosclerosis,['10.1016/j.atherosclerosis.2020.04.010'] 1369,32453759,"Postoperative analgesia using dezocine alleviates depressive symptoms after colorectal cancer surgery: A randomized, controlled, double-blind trial.","BACKGROUND Postoperative depression is one of the most common mental disorders in patients undergoing cancer surgery and it often delays postoperative recovery. We investigated whether dezocine, an analgesic with inhibitory effect on the serotonin and norepinephrine reuptake, could relieve postoperative depressive symptoms in patients undergoing colorectal cancer surgery. METHODS This randomized, controlled, single-center, double-blind trial was performed in the Second Affiliated Hospital of the Army Medical University. A total of 120 patients were randomly assigned to receive either sufentanil (1.3 μg/kg) with dezocine (1 mg/kg) (dezocine group; n = 60) or only sufentanil (2.3 μg/kg) (control group; n = 60) for patient-controlled intravenous analgesia after colorectal cancer surgery. The primary outcome was the Beck Depression Inventory score at 2 days after surgery. The secondary outcomes included the Beck Anxiety Inventory, sleep quality, and quality of recovery scores. RESULTS Compared with those in the control group, patients in the dezocine group had lower depression scores (7.3±3.4 vs. 9.9±3.5, mean difference 2.6, 95% CI: 1.4-3.9; P<0.001) at 2 days after surgery and better night sleep quality at the day of surgery (P = 0.010) and at 1 day after the surgery (P<0.001). No significant difference was found in other outcomes between the two groups. CONCLUSIONS Intravenous analgesia using dezocine can relieve postoperative depression symptoms and improve sleep quality in patients undergoing colorectal cancer surgery.",2020,"Compared with those in the control group, patients in the dezocine group had lower depression scores (7.3±3.4 vs. 9.9±3.5, mean difference 2.6, 95% CI: 1.4-3.9; P<0.001) at 2 days after surgery and better night sleep quality at the day of surgery (P = 0.010) and at 1 day after the surgery (P<0.001).","['patients undergoing colorectal cancer surgery', 'A total of 120 patients', 'patients undergoing cancer surgery', 'alleviates depressive symptoms after colorectal cancer surgery', 'Second Affiliated Hospital of the Army Medical University']","['dezocine (1 mg/kg) (dezocine group; n = 60) or only sufentanil (2.3 μg/kg) (control group; n = 60) for patient-controlled intravenous analgesia after colorectal cancer surgery', 'sufentanil', 'dezocine', 'serotonin and norepinephrine reuptake']","['night sleep quality', 'lower depression scores', 'postoperative depressive symptoms', 'Beck Anxiety Inventory, sleep quality, and quality of recovery scores', 'postoperative depression symptoms', 'sleep quality', 'Beck Depression Inventory score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0057626', 'cui_str': 'dezocine'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}]","[{'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0362037', 'cui_str': 'Postoperative depression'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C2960571', 'cui_str': 'Beck depression inventory score'}]",120.0,0.70306,"Compared with those in the control group, patients in the dezocine group had lower depression scores (7.3±3.4 vs. 9.9±3.5, mean difference 2.6, 95% CI: 1.4-3.9; P<0.001) at 2 days after surgery and better night sleep quality at the day of surgery (P = 0.010) and at 1 day after the surgery (P<0.001).","[{'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Zhao', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Zhuoxi', 'Initials': 'Z', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Chunrui', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Guiying', 'Initials': 'G', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Jinping', 'Initials': 'J', 'LastName': 'Ding', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Mingming', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Lijuan', 'Initials': 'L', 'LastName': 'Feng', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Guangyou', 'Initials': 'G', 'LastName': 'Duan', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}]",PloS one,['10.1371/journal.pone.0233412'] 1370,32453774,"Effect of guided counseling on dietary practices of pregnant women in West Gojjam Zone, Ethiopia.","BACKGROUND In Ethiopia, although nutrition education has been given during pregnancy, most women have inadequate nutrient intakes. As a result, the prevalence of malnutrition is high during pregnancy. In this study, we set out to evaluate the effect of guided counseling based on the health belief model and the theory of planned behavior on the dietary practices of pregnant women. METHODS A two-arm parallel cluster randomized controlled community trial was carried out among pregnant women in West, Gojjam Zone, Ethiopia from May 1, 2018, to April 30, 2019. A total of 346 and 348 pregnant women were recruited from the intervention and control clusters, respectively. Of which endline data were collected from 313 and 332 pregnant women in the intervention and control groups, respectively. Each woman in the intervention group attended four counseling sessions. Women in the control group attended the routine nutrition education given by the health care system. Data were collected using a structured questionnaire. McNemar test and Generalized Estimating Equations were used to evaluate the intervention effect. RESULTS The average difference of appropriate dietary practice between the two groups was 30.7%. After controlling for the possible confounders, women in the intervention group had 7.2 times [AOR = 7.187, 95% CI: (4.49, 11.49)] higher odds of having appropriate dietary practices compared with the control group. Dietary diversity and meal frequency of counseled women were 7 [AOR = 6.994, 95% CI: (4.59, 10.66)] and 8 [AOR = 8.146, 95% CI: (5.377, 12.341)] times higher than dietary diversity and meal frequency of women in the control group, respectively. CONCLUSION Counseling based on the health belief model and the theory of planned behavior is an effective approach in increasing the proportion of women who had appropriate dietary practices. Thus, these findings suggest the need for employing trimester based counseling using the HBM and the TPB to improve the dietary practices of pregnant women. TRIAL REGISTRATION The trial was registered in Clinical Trials.gov (NCT03627156).",2020,"Dietary diversity and meal frequency of counseled women were 7 [AOR = 6.994, 95% CI: (4.59, 10.66)] and 8 [AOR = 8.146, 95% CI: (5.377, 12.341)] times higher than dietary diversity and meal frequency of women in the control group, respectively. ","['A total of 346 and 348 pregnant women', '313 and 332 pregnant women in the intervention and control groups, respectively', 'pregnant women in West, Gojjam Zone, Ethiopia from May 1, 2018, to April 30, 2019', 'pregnant women in West Gojjam Zone, Ethiopia', 'women who had appropriate dietary practices', 'pregnant women']","['routine nutrition education', 'guided counseling']",['Dietary diversity and meal frequency'],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517733', 'cui_str': '348'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C4517707', 'cui_str': '313'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037769', 'cui_str': 'West syndrome'}, {'cui': 'C0015024', 'cui_str': 'Ethiopia'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}]",,0.0585045,"Dietary diversity and meal frequency of counseled women were 7 [AOR = 6.994, 95% CI: (4.59, 10.66)] and 8 [AOR = 8.146, 95% CI: (5.377, 12.341)] times higher than dietary diversity and meal frequency of women in the control group, respectively. ","[{'ForeName': 'Yeshalem Mulugeta', 'Initials': 'YM', 'LastName': 'Demilew', 'Affiliation': 'School of Public Health, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.'}, {'ForeName': 'Getu Degu', 'Initials': 'GD', 'LastName': 'Alene', 'Affiliation': 'School of Public Health, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.'}, {'ForeName': 'Tefera', 'Initials': 'T', 'LastName': 'Belachew', 'Affiliation': 'Department of Nutrition and Dietetics, Faculty of Public Health, Jimma University, Jimma, Ethiopia.'}]",PloS one,['10.1371/journal.pone.0233429'] 1371,32456048,Effect of Plyometric versus Ankle Stability Exercises on Lower Limb Biomechanics in Taekwondo Demonstration Athletes with Functional Ankle Instability.,"BACKGROUND This study aimed to compare the effects of plyometric and ankle stability exercises on the dynamic balance and lower limb kinematic and kinetic parameters of Taekwondo demonstration athletes with functional ankle instability. METHODS Fourteen subjects participated in this study and were randomly divided into two groups: a plyometric exercise group ( n = 7) and an ankle stability exercise group ( n = 7). Exercises were performed twice a week for 8 weeks. A Y-balance test was used to measure dynamic balance, and a motion analysis system and force plate were used to collect kinematic and kinetic parameters during single-leg drop landing. A paired t-test was used for intragroup comparisons, and an independent t-test was used for intergroup comparisons. RESULTS In both groups, exercise increased dynamic balance and shock absorption and reduced postural sway on the anteroposterior displacement ( p < 0.05). The plyometric exercise group decreased their ankle dorsiflexion and increased their knee and hip joint flexion at maximum knee flexion ( p < 0.05). In contrast, the stability exercise increased their ankle plantar flexion at initial contact ( p < 0.05). CONCLUSIONS The plyometric exercise group altered their landing strategies using their knee and hip joints to control ankle instability at landing. This study suggests that the application of plyometric exercises in ankle rehabilitation would improve stability and shock absorption and help prevent injuries during Taekwondo demonstrations.",2020,"In both groups, exercise increased dynamic balance and shock absorption and reduced postural sway on the anteroposterior displacement ( p < 0.05).","['Taekwondo Demonstration Athletes with Functional Ankle Instability', 'Fourteen subjects participated in this study', 'Taekwondo demonstration athletes with functional ankle instability']","['plyometric and ankle stability exercises', 'Plyometric versus Ankle Stability Exercises', 'plyometric exercise group altered their landing strategies using their knee and hip joints to control ankle instability at landing', 'plyometric exercise group ( n = 7) and an ankle stability exercise group', 'plyometric exercises', 'plyometric exercise']","['stability exercise increased their ankle plantar flexion', 'ankle dorsiflexion and increased their knee and hip joint flexion at maximum knee flexion', 'dynamic balance and shock absorption and reduced postural sway on the anteroposterior displacement', 'stability and shock absorption']","[{'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0277851', 'cui_str': 'Ankle instability'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0576206', 'cui_str': 'Stability of ankle'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C3178799', 'cui_str': 'Plyometric Drill'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0019558', 'cui_str': 'Hip joint structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0277851', 'cui_str': 'Ankle instability'}, {'cui': 'C0557668', 'cui_str': 'Landing'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}]","[{'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0231784', 'cui_str': 'Plantar flexion'}, {'cui': 'C0231770', 'cui_str': 'Dorsiflexion of foot'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0019558', 'cui_str': 'Hip joint structure'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0036974', 'cui_str': 'Shock'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}]",14.0,0.0237313,"In both groups, exercise increased dynamic balance and shock absorption and reduced postural sway on the anteroposterior displacement ( p < 0.05).","[{'ForeName': 'Ha Min', 'Initials': 'HM', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Therapy, College of Health Sciences, Dankook University, 119, Dandae-ro, Dongnam-gu, Cheonan-si, Chungcheongnam-do 31116, Korea.'}, {'ForeName': 'Seunghue', 'Initials': 'S', 'LastName': 'Oh', 'Affiliation': 'Department of Physical Therapy, Graduate School, Dankook University, 119, Dandae-ro, Dongnam-gu, Cheonan-si, Chungcheongnam-do 31116, Korea.'}, {'ForeName': 'Jung Won', 'Initials': 'JW', 'LastName': 'Kwon', 'Affiliation': 'Department of Physical Therapy, College of Health Sciences, Dankook University, 119, Dandae-ro, Dongnam-gu, Cheonan-si, Chungcheongnam-do 31116, Korea.'}]",International journal of environmental research and public health,['10.3390/ijerph17103665'] 1372,32466190,The Effect of Physical Activity and High Body Mass Index on Health-Related Quality of Life in Individuals with Metabolic Syndrome.,"The main objective of this study was to examine the relationship between the level of physical activity (PA) and the degree of obesity with health-related quality of life (HRQoL) in individuals with metabolic syndrome (MetS) who participated in the Predimed-Plus study. A total of 6875 subjects between 55 and 75 years of age with MetS were selected and randomized in 23 Spanish centers. Subjects were classified according to categories of body mass index (BMI). PA was measured with the validated Registre Gironí del Cor (REGICOR) questionnaire and subjects were classified according to their PA level (light, moderate, vigorous) and the HRQoL was measured with the validated short-form 36 (SF-36) questionnaire. By using the ANOVA model, we found a positive and statistically significant association between the level of PA and the HRQoL (aggregated physical and mental dimensions p < 0.001), but a negative association with higher BMI in aggregated physical dimensions p < 0.001. Furthermore, women obtained lower scores compared with men, more five points in all fields of SF-36. Therefore, it is essential to promote PA and body weight control from primary care consultations to improve HRQoL, paying special attention to the differences that sex incurs.",2020,"Furthermore, women obtained lower scores compared with men, more five points in all fields of SF-36.","['6875 subjects between 55 and 75 years of age with MetS were selected and randomized in 23 Spanish centers', 'Individuals with Metabolic Syndrome', 'individuals with metabolic syndrome (MetS) who participated in the Predimed-Plus study']",['Physical Activity and High Body Mass Index'],"['level of PA and the HRQoL', 'physical activity (PA) and the degree of obesity with health-related quality of life (HRQoL']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",6875.0,0.0214871,"Furthermore, women obtained lower scores compared with men, more five points in all fields of SF-36.","[{'ForeName': 'Alba', 'Initials': 'A', 'LastName': 'Marcos-Delgado', 'Affiliation': 'Institute of Biomedicine (IBIOMED), University of León, 24071 León, Spain.'}, {'ForeName': 'Tania', 'Initials': 'T', 'LastName': 'Fernández-Villa', 'Affiliation': 'Institute of Biomedicine (IBIOMED), University of León, 24071 León, Spain.'}, {'ForeName': 'Miguel Ángel', 'Initials': 'MÁ', 'LastName': 'Martínez-González', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Salas-Salvadó', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Dolores', 'Initials': 'D', 'LastName': 'Corella', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Castañer', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'J Alfredo', 'Initials': 'JA', 'LastName': 'Martínez', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Ángel M', 'Initials': 'ÁM', 'LastName': 'Alonso-Gómez', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Wärnberg', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Vioque', 'Affiliation': 'CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.'}, {'ForeName': 'Dora', 'Initials': 'D', 'LastName': 'Romaguera', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'López-Miranda', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Ramon', 'Initials': 'R', 'LastName': 'Estruch', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Francisco J', 'Initials': 'FJ', 'LastName': 'Tinahones', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Lapetra', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'J LLuís', 'Initials': 'JL', 'LastName': 'Serra-Majem', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'García-Molina', 'Affiliation': 'CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.'}, {'ForeName': 'Josep A', 'Initials': 'JA', 'LastName': 'Tur', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'José Antonio', 'Initials': 'JA', 'LastName': 'de Paz', 'Affiliation': 'Institute of Biomedicine (IBIOMED), University of León, 24071 León, Spain.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Pintó', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Delgado-Rodríguez', 'Affiliation': 'Nutritional Genomics and Epigenomics Group, IMDEA Food, CEI UAM + CSIC, 28049 Madrid, Spain.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Matía-Martín', 'Affiliation': 'Department of Endocrinology and Nutrition, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.'}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Vidal', 'Affiliation': 'CIBER Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.'}, {'ForeName': 'Clotilde', 'Initials': 'C', 'LastName': 'Vázquez', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Lidia', 'Initials': 'L', 'LastName': 'Daimiel', 'Affiliation': 'Nutritional Control of the Epigenome Group, Precision Nutrition and Obesity Program, IMDEA Food, CEI UAM + CSIC, 28049 Madrid, Spain.'}, {'ForeName': 'Emilio', 'Initials': 'E', 'LastName': 'Ros', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Babio', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Ignacio M', 'Initials': 'IM', 'LastName': 'Gimenez-Alba', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Estefanía', 'Initials': 'E', 'LastName': 'Toledo', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'María Dolores', 'Initials': 'MD', 'LastName': 'Zomeño', 'Affiliation': ""Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d'Investigació Médica (IMIM), 08003 Barcelona, Spain.""}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Zulet', 'Affiliation': 'Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31009 Pamplona, Spain.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Vaquero-Luna', 'Affiliation': 'Bioaraba Health Research Institute, Cardiovascular, Respiratory and Metabolic Area, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 48940 Vitoria-Gasteiz, Spain.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Pérez-López', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Pastor-Morel', 'Affiliation': 'Centro de Salud Cabo Huertas, 03540 Alicante, Spain.'}, {'ForeName': 'Aina M', 'Initials': 'AM', 'LastName': 'Galmes-Panades', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'García-Rios', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Casas', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'María Rosa', 'Initials': 'MR', 'LastName': 'Bernal-López', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'José Manuel', 'Initials': 'JM', 'LastName': 'Santos-Lozano', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Nerea', 'Initials': 'N', 'LastName': 'Becerra-Tomás', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Ortega-Azorin', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Zenaida', 'Initials': 'Z', 'LastName': 'Vázquez-Ruiz', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Karla Alejandra', 'Initials': 'KA', 'LastName': 'Pérez-Vega', 'Affiliation': ""Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d'Investigació Médica (IMIM), 08003 Barcelona, Spain.""}, {'ForeName': 'Itziar', 'Initials': 'I', 'LastName': 'Abete', 'Affiliation': 'Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31009 Pamplona, Spain.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Sorto-Sánchez', 'Affiliation': 'Bioaraba Health Research Institute, Cardiovascular, Respiratory and Metabolic Area, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 48940 Vitoria-Gasteiz, Spain.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Palau-Galindo', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Iñigo', 'Initials': 'I', 'LastName': 'Galilea-Zabalza', 'Affiliation': 'Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28040 Madrid, Spain.'}, {'ForeName': 'Júlia', 'Initials': 'J', 'LastName': 'Muñoz-Martínez', 'Affiliation': ""Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d'Investigació Médica (IMIM), 08003 Barcelona, Spain.""}, {'ForeName': 'Vicente', 'Initials': 'V', 'LastName': 'Martín', 'Affiliation': 'Institute of Biomedicine (IBIOMED), University of León, 24071 León, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17103728'] 1373,32469393,"Effects of a multinutrient-fortified milk drink combined with exercise on functional performance, muscle strength, body composition, inflammation, and oxidative stress in middle-aged women: a 4-month, double-blind, placebo-controlled, randomized trial.","BACKGROUND Multinutrient protein-enriched supplements are promoted to augment the effects of exercise on muscle mass and strength, but their effectiveness in middle-aged women, or whether there are any additional benefits to physical function, remains uncertain. OBJECTIVES We aimed to evaluate whether a multinutrient-fortified milk drink (MFMD) could enhance the effects of exercise on functional muscle power (stair climbing) in middle-aged women. Secondary aims were to evaluate the intervention effects on physical function, muscle strength, lean mass (LM), fat mass (FM), bone mineral content (BMC), muscle cross-sectional area (CSA), muscle density, balance, flexibility, aerobic fitness, inflammation, oxidative stress, bone and cartilage turnover, blood pressure, and blood lipids. METHODS In this 4-mo, double-blind, placebo-controlled, randomized trial, 244 women (45-65 y) participated in a multimodal resistance-type exercise program 3 d/wk, with random allocation to a twice-daily MFMD containing added protein, vitamin D, calcium, milk fat globule membrane (phospholipids and other bioactives), and other micronutrients (Ex + MFMD, n = 123) or an energy-matched placebo (Ex + placebo, n = 121). RESULTS A total of 216 women (89%) completed the study. After 4 mo, both groups experienced similar 3.6%-4.3% improvements in the primary outcomes of fast-pace 5- and 10-step stair ascent power. In contrast, Ex + MFMD experienced greater improvements in 5-step regular-pace stair descent time [net difference (95% CI): -0.09 s (-0.18, 0.00 s), P = 0.045], countermovement jump height [0.5 cm (0.04, 1.0 cm), P = 0.038], total body LM [0.3 kg (0.04, 0.60 kg), P = 0.020], FM [-0.6 kg (-1.0, -0.2 kg), P = 0.004], BMC [0.4% (0.1%, 0.6%), P = 0.020], muscle CSA [thigh: 1.8% (0.6%, 2.9%), P = 0.003; lower leg: 0.9% (0.3%, 1.6%), P = 0.005], balance eyes closed [3.3 s (1.1, 5.4 s), P = 0.005], 2-min step performance [8 steps (3, 12 steps), P = 0.003], and sit-and-reach flexibility [1.4 cm (0.6, 2.2 cm), P = 0.026]. MFMD did not enhance the effects of exercise on any measures of muscle strength, gait speed, dynamic balance, reaction time, or blood lipids, and there was no effect of either intervention on blood pressure, markers of inflammation, or cartilage turnover. Ex + placebo had a greater improvement in the oxidative stress marker protein carbonyls (P < 0.01). CONCLUSIONS In middle-aged women, daily consumption of an MFMD did not enhance the effects of a multimodal exercise program on the primary outcome of stair climbing ascent power, but did elicit greater improvements in multiple secondary outcomes including various other measures of functional performance, LM, muscle size, FM, balance, aerobic capacity, flexibility, and bone metabolism.This trial was registered at www.anzctr.org.au as ACTRN12617000383369.",2020,"MFMD did not enhance the effects of exercise on any measures of muscle strength, gait speed, dynamic balance, reaction time, or blood lipids, and there was no effect of either intervention on blood pressure, markers of inflammation, or cartilage turnover.","['middle-aged women', '216 women (89%) completed the study', '244 women (45-65 y) participated in a']","['multinutrient-fortified milk drink combined with exercise', 'MFMD', 'multimodal exercise program', 'multimodal resistance-type exercise program 3 d/wk, with random allocation to a twice-daily MFMD containing added protein, vitamin D, calcium, milk fat globule membrane (phospholipids and other bioactives), and other micronutrients (Ex\xa0+\xa0MFMD, n\xa0=\xa0123) or an energy-matched placebo (Ex\xa0+\xa0placebo, n\xa0=\xa0121', 'multinutrient-fortified milk drink (MFMD', 'Ex\xa0+\xa0placebo', 'placebo']","['physical function, muscle strength, lean mass (LM), fat mass (FM), bone mineral content (BMC), muscle cross-sectional area (CSA), muscle density, balance, flexibility, aerobic fitness, inflammation, oxidative stress, bone and cartilage turnover, blood pressure, and blood lipids', 'functional performance, muscle strength, body composition, inflammation, and oxidative stress', 'countermovement jump height', 'sit-and-reach flexibility', 'BMC', 'oxidative stress marker protein carbonyls', 'blood pressure, markers of inflammation, or cartilage turnover', 'functional performance, LM, muscle size, FM, balance, aerobic capacity, flexibility, and bone metabolism', 'fast-pace 5- and 10-step stair ascent power', 'total body LM', 'muscle strength, gait speed, dynamic balance, reaction time, or blood lipids', 'functional muscle power (stair climbing', '5-step regular-pace stair descent time']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4708905', 'cui_str': '216'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517660', 'cui_str': '244'}]","[{'cui': 'C1532525', 'cui_str': 'Fortified milk'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0670751', 'cui_str': 'milk fat globule'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0031676', 'cui_str': 'Phospholipids'}, {'cui': 'C0040577', 'cui_str': 'Trace element'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0005963', 'cui_str': 'Bone Mineral Content'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0007301', 'cui_str': 'Cartilage tissue'}, {'cui': 'C0031227', 'cui_str': 'Employee Turnover'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0287990', 'cui_str': 'Furin'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0427052', 'cui_str': 'Finding of power of skeletal muscle'}, {'cui': 'C1290942', 'cui_str': 'Climbing stairs'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0205386', 'cui_str': 'Descending'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",244.0,0.577968,"MFMD did not enhance the effects of exercise on any measures of muscle strength, gait speed, dynamic balance, reaction time, or blood lipids, and there was no effect of either intervention on blood pressure, markers of inflammation, or cartilage turnover.","[{'ForeName': 'Robin M', 'Initials': 'RM', 'LastName': 'Daly', 'Affiliation': 'Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Burwood, Melbourne, Victoria, Australia.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Gianoudis', 'Affiliation': 'Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Burwood, Melbourne, Victoria, Australia.'}, {'ForeName': 'Belinda', 'Initials': 'B', 'LastName': 'De Ross', 'Affiliation': 'Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Burwood, Melbourne, Victoria, Australia.'}, {'ForeName': 'Stella L', 'Initials': 'SL', 'LastName': ""O'Connell"", 'Affiliation': 'Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Burwood, Melbourne, Victoria, Australia.'}, {'ForeName': 'Marlena', 'Initials': 'M', 'LastName': 'Kruger', 'Affiliation': 'School of Health Sciences, Massey University, Palmerston North, New Zealand.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Schollum', 'Affiliation': 'Fonterra Co-operative Group Ltd, Palmerston, North New Zealand.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Gunn', 'Affiliation': 'Fonterra Co-operative Group Ltd, Palmerston, North New Zealand.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqaa126'] 1374,32469398,Effect of lean red meat combined with a multicomponent exercise program on muscle and cognitive function in older adults: a 6-month randomized controlled trial.,"BACKGROUND Exercise and increased dietary protein have been linked to improved muscle and cognitive health, but the combination may be more effective. OBJECTIVE In this study performed in community-dwelling older adults undergoing a 3-d/wk resistance-based exercise training program, we investigated whether those who consumed lean red meat compared to carbohydrates on the 3 training days per wk would experience greater exercise-induced improvements in total body and leg lean mass (LM), muscle strength, and executive function (multiple primary outcomes), as well as muscle size and density, functional performance, cognition, inflammatory and neurotrophic markers, blood pressure, and lipid concentrations. DESIGN In a 24-wk, 2-arm parallel randomized controlled trial, 154 adults aged ≥65 y participated in a multicomponent 3-d/wk resistance-based exercise program with random allocation to either a lean red meat group (two 80-g servings of cooked red meat), the exercise plus lean red meat (Ex + Meat) group (n = 77) or a control group receiving carbohydrates in the form of one-half cup (approximately 225 g cooked weight) of rice or pasta or 1 medium potato, the exercise plus carbohydrate control (C + Ex) group (n = 77), on the training days. RESULTS Exercise-induced improvements (mean within group changes) did not significantly differ between groups for the primary outcomes of total body LM (0.6 to 0.8 kg), leg LM (0.1 to 0.2 kg), thigh muscle cross-sectional area (3.7% to 4.9%), leg and back muscle strength (26% to 40%), and executive function (z-score SD: 0.33 to 0.39), nor the secondary outcomes of global cognition function (0.17 to 0.23 SD), fat mass (-0.65 to -0.75 kg), physical function measures (sit-to-stand, both 15%; 4-square step test, 2% to 7%), or systolic blood pressure (-3.2 to -4.1 mm Hg). The Ex + Meat group experienced greater improvements than the C + Ex in arm LM (0.07 kg; 95% CI: 0.01, 0.14; P = 0.029), gait speed (0.05 m/s; 95% CI: 0.00, 0.11; P = 0.042), muscle density (1.0%; 95% CI: 0.2, 1.9; P = 0.015), and appendicular LM in the per-protocol analysis (0.21 kg; 95% CI: 0.02, 0.40; P = 0.03). The C + Ex group had greater net improvements in working memory/learning after 12 wk (SD: 0.24; 95% CI: 0.05, 0.43; P = 0.011) and 24 wk (SD: 0.27; 95% CI: 0.06, 0.49; P = 0.007). Inflammatory and neurotrophic markers did not change in either group. CONCLUSION In healthy community-dwelling older adults undertaking resistance-based exercise training 3-d/wk, participants who consumed lean red meat in line with current Australian dietary recommendations did not experience any significant additional benefits in the primary outcome measures of muscle mass, strength, or cognitive function compared to participants consuming carbohydrates.This trial is registered with the Australian and New Zealand Clinical Trials Registry as ACTRN12613001153707.",2020,"The C + Ex group had greater net improvements in working memory/learning after 12 wk (SD: 0.24; 95% CI: 0.05, 0.43; P = 0.011) and 24 wk (SD: 0.27; 95% CI: 0.06, 0.49; P = 0.007).","['healthy community-dwelling older adults undertaking', 'community-dwelling older adults undergoing a', 'older adults', '154 adults aged ≥65 y participated in a']","['lean red meat combined with a multicomponent exercise program', '3-d/wk resistance-based exercise training program', 'multicomponent 3-d/wk resistance-based exercise program with random allocation to either a lean red meat group (two 80-g servings of cooked red meat), the exercise plus lean red meat (Ex +\xa0Meat) group (n = 77) or a control group receiving carbohydrates in the form of one-half cup (approximately 225 g cooked weight) of rice or pasta or 1 medium potato, the exercise plus carbohydrate control (C\xa0+\xa0Ex', 'resistance-based exercise training 3-d/wk, participants who consumed lean red meat in line with current Australian dietary recommendations']","['muscle and cognitive function', 'muscle density', 'muscle mass, strength, or cognitive function', 'Inflammatory and neurotrophic markers', 'thigh muscle cross-sectional area', 'gait speed', 'leg and back muscle strength', 'executive function', 'total body LM', 'working memory/learning', 'fat mass', 'physical function measures', 'total body and leg lean mass (LM), muscle strength, and executive function (multiple primary outcomes), as well as muscle size and density, functional performance, cognition, inflammatory and neurotrophic markers, blood pressure, and lipid concentrations', 'global cognition function', 'leg LM', 'systolic blood pressure', 'appendicular LM']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C5191279', 'cui_str': '154'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0452848', 'cui_str': 'Red meat'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0335326', 'cui_str': 'Cookery'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0025017', 'cui_str': 'Meat'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0220647', 'cui_str': 'Carcinoma of unknown primary'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C4517652', 'cui_str': '225'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0035567', 'cui_str': 'Rice'}, {'cui': 'C0452694', 'cui_str': 'Pasta'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0032846', 'cui_str': 'Potato'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0224416', 'cui_str': 'Skeletal muscle structure of thigh'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0224334', 'cui_str': 'Skeletal muscle structure of back'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",154.0,0.167933,"The C + Ex group had greater net improvements in working memory/learning after 12 wk (SD: 0.24; 95% CI: 0.05, 0.43; P = 0.011) and 24 wk (SD: 0.27; 95% CI: 0.06, 0.49; P = 0.007).","[{'ForeName': 'Melissa B', 'Initials': 'MB', 'LastName': 'Formica', 'Affiliation': 'Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Melbourne, Australia.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Gianoudis', 'Affiliation': 'Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Melbourne, Australia.'}, {'ForeName': 'Caryl A', 'Initials': 'CA', 'LastName': 'Nowson', 'Affiliation': 'Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Melbourne, Australia.'}, {'ForeName': 'Stella L', 'Initials': 'SL', 'LastName': ""O'Connell"", 'Affiliation': 'Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Melbourne, Australia.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Milte', 'Affiliation': 'Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Melbourne, Australia.'}, {'ForeName': 'Kathryn A', 'Initials': 'KA', 'LastName': 'Ellis', 'Affiliation': 'Neurodegeneration Division, The Florey Institute, Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Robin M', 'Initials': 'RM', 'LastName': 'Daly', 'Affiliation': 'Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Melbourne, Australia.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqaa104'] 1375,32472768,Population-level viral suppression among pregnant and postpartum women in a universal test and treat trial.,"OBJECTIVE(S) We sought to determine whether universal 'test and treat' (UTT) can achieve gains in viral suppression beyond universal antiretroviral treatment (ART) eligibility during pregnancy and postpartum, among women living with HIV. DESIGN A community cluster randomized trial. METHODS The SEARCH UTT trial compared an intervention of annual population testing and universal ART with a control of baseline population testing with ART by country standard, including ART eligibility for all pregnant/postpartum women, in 32 communities in Kenya and Uganda. When testing, women were asked about current pregnancy and live births over the prior year and, if HIV-infected, had their viral load measured. Between arms, we compared population-level viral suppression (HIV RNA <500 copies/ml) among all pregnant/postpartum HIV-infected women at study close (year 3). We also compared year-3 population-level viral suppression and predictors of viral suppression among all 15 to 45-year-old women by arm. RESULTS At baseline, 92 and 93% of 15 to 45-year-old women tested for HIV: HIV prevalence was 12.6 and 12.3%, in intervention and control communities, respectively. Among HIV-infected women self-reporting pregnancy/live birth, prevalence of viral suppression was 42 and 44% at baseline, and 81 and 76% (P = 0.02) at year 3, respectively. Among all 15 to 45-year-old HIV-infected women, year-3 population-level viral suppression was higher in intervention (77%) versus control (68%; P < 0.001). Pregnancy/live birth was a predictor of year-3 viral suppression in control (P = 0.016) but not intervention (P = 0.43). Younger age was a risk factor for nonsuppression in both arms. CONCLUSION The SEARCH intervention resulted in higher population viral suppression among pregnant/postpartum women than a control of baseline universal testing with ART eligibility for pregnant/postpartum women.",2020,Pregnancy/live birth was a predictor of year-3 viral suppression in control (P = 0.016) but not intervention (P = 0.43).,"['all pregnant/postpartum women, in 32 communities in Kenya and Uganda', 'pregnant and postpartum women in a universal test and treat trial', '15 to 45-year-old women by arm', 'women living with HIV']","[""universal 'test and treat' (UTT""]","['year-3 viral suppression', 'HIV: HIV prevalence', 'viral suppression', 'year-3 population-level viral suppression', 'Pregnancy/live birth', 'population viral suppression']","[{'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0032804', 'cui_str': 'Postpartum Women'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0041573', 'cui_str': 'Uganda'}, {'cui': 'C0175671', 'cui_str': 'Universal'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}]","[{'cui': 'C0175671', 'cui_str': 'Universal'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}]",,0.305022,Pregnancy/live birth was a predictor of year-3 viral suppression in control (P = 0.016) but not intervention (P = 0.43).,"[{'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Kabami', 'Affiliation': 'Department of Medicine, Makerere University College of Health Sciences.'}, {'ForeName': 'Laura B', 'Initials': 'LB', 'LastName': 'Balzer', 'Affiliation': 'University of Massachusetts, Amherst, Massachusetts, USA.'}, {'ForeName': 'Hachem', 'Initials': 'H', 'LastName': 'Saddiki', 'Affiliation': 'University of Massachusetts, Amherst, Massachusetts, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Ayieko', 'Affiliation': 'Kenya Medical Research Institute, Nairobi, Kenya.'}, {'ForeName': 'Dalsone', 'Initials': 'D', 'LastName': 'Kwarisiima', 'Affiliation': 'Infectious Diseases Research Collaboration, Kampala, Uganda.'}, {'ForeName': 'Mucunguzi', 'Initials': 'M', 'LastName': 'Atukunda', 'Affiliation': 'Infectious Diseases Research Collaboration, Kampala, Uganda.'}, {'ForeName': 'Edwin D', 'Initials': 'ED', 'LastName': 'Charlebois', 'Affiliation': 'University of California, San Francisco.'}, {'ForeName': 'Tamara D', 'Initials': 'TD', 'LastName': 'Clark', 'Affiliation': 'University of California, San Francisco.'}, {'ForeName': 'Catherine A', 'Initials': 'CA', 'LastName': 'Koss', 'Affiliation': 'University of California, San Francisco.'}, {'ForeName': 'Theodore', 'Initials': 'T', 'LastName': 'Ruel', 'Affiliation': 'University of California, San Francisco.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Bukusi', 'Affiliation': 'Kenya Medical Research Institute, Nairobi, Kenya.'}, {'ForeName': 'Craig R', 'Initials': 'CR', 'LastName': 'Cohen', 'Affiliation': 'University of California, San Francisco.'}, {'ForeName': 'Phillipa', 'Initials': 'P', 'LastName': 'Musoke', 'Affiliation': 'Department of Medicine, Makerere University College of Health Sciences.'}, {'ForeName': 'Maya L', 'Initials': 'ML', 'LastName': 'Petersen', 'Affiliation': 'University of California, Berkeley, California, USA.'}, {'ForeName': 'Diane V', 'Initials': 'DV', 'LastName': 'Havlir', 'Affiliation': 'University of California, San Francisco.'}, {'ForeName': 'Moses R', 'Initials': 'MR', 'LastName': 'Kamya', 'Affiliation': 'Department of Medicine, Makerere University College of Health Sciences.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Chamie', 'Affiliation': 'University of California, San Francisco.'}]","AIDS (London, England)",['10.1097/QAD.0000000000002564'] 1376,32470089,A pilot randomized trial of incentive strategies to promote HIV retesting in rural Uganda.,"BACKGROUND Retesting for HIV is critical to identifying newly-infected persons and reinforcing prevention efforts among at-risk adults. Incentives can increase one-time HIV testing, but their role in promoting retesting is unknown. We sought to test feasibility and acceptability of incentive strategies, including commitment contracts, to promote HIV retesting among at-risk adults in rural Uganda. METHODS At-risk HIV-negative adults were enrolled in a pilot trial assessing feasibility and acceptability of incentive strategies to promote HIV retesting three months after enrollment. Participants were randomized (1:1:3) to: 1) no incentive; 2) standard cash incentive (~US$4); and 3) commitment contract: participants could voluntarily make a low- or high-value deposit that would be returned with added interest (totaling ~US$4 including the deposit) upon retesting or lost if participants failed to retest. Contracts sought to promote retesting by leveraging loss aversion and addressing present bias via pre-commitment. Outcomes included acceptability of trial enrollment, contract feasibility (proportion of participants making deposits), and HIV retesting uptake. RESULTS Of 130 HIV-negative eligible adults, 123 (95%) enrolled and were randomized: 74 (60%) to commitment contracts, 25 (20%) to standard incentives, and 24 (20%) to no incentive. Of contract participants, 69 (93%) made deposits. Overall, 93 (76%) participants retested for HIV: uptake was highest in the standard incentive group (22/25 [88%]) and lowest in high-value contract (26/36 [72%]) and no incentive (17/24 [71%]) groups. CONCLUSION In a randomized trial of strategies to promote HIV retesting among at-risk adults in Uganda, incentive strategies, including commitment contracts, were feasible and had high acceptability. Our findings suggest use of incentives for HIV retesting merits further comparison in a larger trial. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT:02890459.",2020,"Overall, 93 (76%) participants retested for HIV: uptake was highest in the standard incentive group (22/25 [88%]) and lowest in high-value contract (26/36 [72%]) and no incentive (17/24 [71%]) groups. ","['risk adults in rural Uganda', 'At-risk HIV-negative adults', '130 HIV-negative eligible adults, 123 (95%) enrolled', 'HIV retesting in rural Uganda']",['1) no incentive; 2) standard cash incentive (~US$4); and 3) commitment contract: participants could voluntarily make a low- or high-value deposit that would be returned with added interest (totaling ~US$4 including the deposit'],"['acceptability of trial enrollment, contract feasibility (proportion of participants making deposits), and HIV retesting uptake', 'HIV: uptake']","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0041573', 'cui_str': 'Uganda'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0481430', 'cui_str': 'HIV negative'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}]","[{'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0029917', 'cui_str': 'Outpatient Commitment'}, {'cui': 'C0332522', 'cui_str': 'Contracts'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0333562', 'cui_str': 'Deposition'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0332522', 'cui_str': 'Contracts'}, {'cui': 'C0333562', 'cui_str': 'Deposition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}]",130.0,0.175444,"Overall, 93 (76%) participants retested for HIV: uptake was highest in the standard incentive group (22/25 [88%]) and lowest in high-value contract (26/36 [72%]) and no incentive (17/24 [71%]) groups. ","[{'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Chamie', 'Affiliation': 'University of California, San Francisco, California, United States of America.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Ndyabakira', 'Affiliation': 'Infectious Diseases Research Collaboration, Mbarara, Uganda.'}, {'ForeName': 'Kara G', 'Initials': 'KG', 'LastName': 'Marson', 'Affiliation': 'University of California, San Francisco, California, United States of America.'}, {'ForeName': 'Devy M', 'Initials': 'DM', 'LastName': 'Emperador', 'Affiliation': 'University of California, San Francisco, California, United States of America.'}, {'ForeName': 'Moses R', 'Initials': 'MR', 'LastName': 'Kamya', 'Affiliation': 'Makerere University College of Health Sciences, Kampala, Uganda.'}, {'ForeName': 'Diane V', 'Initials': 'DV', 'LastName': 'Havlir', 'Affiliation': 'University of California, San Francisco, California, United States of America.'}, {'ForeName': 'Dalsone', 'Initials': 'D', 'LastName': 'Kwarisiima', 'Affiliation': 'Makerere University Joint AIDS Program, Kampala, Uganda.'}, {'ForeName': 'Harsha', 'Initials': 'H', 'LastName': 'Thirumurthy', 'Affiliation': 'University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.'}]",PloS one,['10.1371/journal.pone.0233600'] 1377,32470147,Effect of non-sedation on post-traumatic stress and psychological health in survivors of critical illness-A substudy of the NONSEDA randomized trial.,"BACKGROUND Critical illness can cause post-traumatic stress and impaired mental health. The NONSEDA trial was a Scandinavian multicenter RCT, assessing non-sedation versus sedation with a daily wake-up call during mechanical ventilation in critically ill adults. The aim of this substudy was to assess the effect of non-sedation on post-traumatic stress and mental health. METHODS This substudy is based on all participating patients from a single NONSEDA trial site (Kolding, Denmark). Patients were randomized to sedation or non-sedation within the first 24 hours of mechanical ventilation. Three months after ICU discharge survivors were examined by a neuropsychologist for post-traumatic stress, anxiety and depression, and filled out the SF-36 questionnaire regarding quality of life. RESULTS The two groups of survivors were similar with regard to baseline characteristics, length of admission and mechanical ventilation. Sedated patients received more propofol and midazolam. Doses of morphine and haloperidole were equal. PRIMARY OUTCOME the number of patients with post-traumatic stress disorder did not differ between groups (non-sedated: 2 patients vs sedated: 0, P = .23). SECONDARY OUTCOMES there were no differences between groups in Beck Anxiety Index (median, non-sedated: 0 vs sedated: 0, P = .62), Beck Depression Index (median, non-sedated: 7 vs sedated: 4, P = .24), SF-36 mental component score (mean, non-sedated: 46.7 vs sedated: 47.5, P = .73) or number of patients with symptoms of post-traumatic stress (8 in both groups, P = .89). CONCLUSION Levels of PTSD, anxiety and depression and quality of life regarding mental health were similar between the non-sedated and sedated group.",2020,"There were no differences between groups in either Beck Anxiety Index (median, non-sedated: 0 vs sedated: 0, p=0.62), Beck Depression Index (median, non-sedated: 7 vs sedated: 4, p=0.24), SF-36 mental component score (mean, non-sedated: 46.7 vs sedated: 47.5, p=0.73) or number of patients with symptoms of posttraumatic stress (8 in both groups, p=0.89). ","['survivors of critical illness', 'critically ill adults', 'participating patients from a single NONSEDA trial-site (Kolding, Denmark']","['propofol and midazolam', 'morphine', 'non-sedation', 'sedation or non-sedation']","['Beck Anxiety Index', 'number of patients with symptoms of posttraumatic stress', 'Beck Depression Index', 'number of patients with posttraumatic stress disorder', 'PTSD, anxiety and depression and quality of life regarding mental health', 'posttraumatic stress and psychological health', 'SF-36 mental component score']","[{'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}]","[{'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0854969,"There were no differences between groups in either Beck Anxiety Index (median, non-sedated: 0 vs sedated: 0, p=0.62), Beck Depression Index (median, non-sedated: 7 vs sedated: 4, p=0.24), SF-36 mental component score (mean, non-sedated: 46.7 vs sedated: 47.5, p=0.73) or number of patients with symptoms of posttraumatic stress (8 in both groups, p=0.89). ","[{'ForeName': 'Helene K', 'Initials': 'HK', 'LastName': 'Nedergaard', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Lillebaelt Hospital Kolding, University Hospital of Southern Denmark, Kolding, Denmark.'}, {'ForeName': 'Hanne I', 'Initials': 'HI', 'LastName': 'Jensen', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Lillebaelt Hospital Kolding, University Hospital of Southern Denmark, Kolding, Denmark.'}, {'ForeName': 'Mette', 'Initials': 'M', 'LastName': 'Stylsvig', 'Affiliation': 'Clinic of Neuropsychology, Odense, Denmark.'}, {'ForeName': 'Hanne T', 'Initials': 'HT', 'LastName': 'Olsen', 'Affiliation': 'Department of Clinical Research, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Strøm', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Palle', 'Initials': 'P', 'LastName': 'Toft', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13648'] 1378,32565123,An acute bout of swimming increases post-exercise energy intake in young healthy men and women.,"Single bouts of land-based exercise (for example, walking, running, cycling) do not typically alter post-exercise energy intake on the day of exercise. However, anecdotal and preliminary empirical evidence suggests that swimming may increase appetite and energy intake. This study compared the acute effects of swimming on appetite, energy intake, and food preference and reward, versus exertion-matched cycling and a resting control. Thirty-two men (n = 17; mean ± SD age 24 ± 2 years, body mass index [BMI] 25.0 ± 2.6 kg/m 2 ) and women (n = 15; age 22 ± 3 years, BMI 22.8 ± 2.3 kg/m 2 ) completed three experimental trials (swimming, cycling, control) in a randomised, crossover design. The exercise trials involved 60-min of 'hard' exercise (self-selected rating of perceived exertion: 15) performed 90-min after a standardised breakfast. Food preference and reward were assessed via the Leeds Food Preference Questionnaire 15-min after exercise, whilst ad libitum energy intake was determined 30-min after exercise. The control trial involved identical procedures except no exercise was performed. Compared with control (3259 ± 1265 kJ), swimming increased ad libitum energy intake (3857 ± 1611 kJ; ES = 0.47, 95% CI of the mean difference between trials 185, 1010 kJ, P = 0.005); the magnitude of increase was smaller after cycling (3652 ± 1619 kJ; ES = 0.31, 95% CI -21, 805 kJ, P = 0.062). Ad libitum energy intake was similar between swimming and cycling (ES = 0.16, 95% CI -207, 618 kJ, P = 0.324). This effect was consistent across sexes and unrelated to food preference and reward which were similar after swimming and cycling compared with control. This study has identified an orexigenic effect of swimming. Further research is needed to identify the responsible mechanism(s), including the relevance of water immersion and water temperature per se.",2020,This effect was consistent across sexes and unrelated to food preference and reward which were similar after swimming and cycling compared with control.,"['young healthy men and women', 'Thirty-two men (n\u202f=\u202f17; mean\u202f±\u202fSD age 24\u202f±\u202f2 years, body mass index [BMI] 25.0\u202f±\u202f2.6\u202fkg/m 2 ) and women (n\u202f=\u202f15', 'age 22\u202f±\u202f3 years, BMI 22.8\u202f±\u202f2.3\u202fkg/m 2 ']","[""60-min of 'hard' exercise (self-selected rating of perceived exertion: 15) performed 90-min after a standardised breakfast"", 'Single bouts of land-based exercise']","['appetite, energy intake, and food preference and reward, versus exertion-matched cycling', 'Ad libitum energy intake', 'appetite and energy intake']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517633', 'cui_str': '2.6'}]","[{'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0018599', 'cui_str': 'Hard'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0557668', 'cui_str': 'Landing'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0016483', 'cui_str': 'Food Preferences'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]",,0.135485,This effect was consistent across sexes and unrelated to food preference and reward which were similar after swimming and cycling compared with control.,"[{'ForeName': 'Alice E', 'Initials': 'AE', 'LastName': 'Thackray', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK. Electronic address: A.E.Thackray@lboro.ac.uk.'}, {'ForeName': 'Scott A', 'Initials': 'SA', 'LastName': 'Willis', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK. Electronic address: S.Willis2@lboro.ac.uk.'}, {'ForeName': 'Aron P', 'Initials': 'AP', 'LastName': 'Sherry', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK. Electronic address: A.P.Sherry@lboro.ac.uk.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Clayton', 'Affiliation': 'School of Science and Technology, Nottingham Trent University, UK. Electronic address: David.Clayton@ntu.ac.uk.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Broom', 'Affiliation': 'Centre for Sport, Exercise and Life Sciences, Coventry University, UK. Electronic address: ad5173@coventry.ac.uk.'}, {'ForeName': 'Mayada', 'Initials': 'M', 'LastName': 'Demashkieh', 'Affiliation': 'Department of Physical Education and Sport Science, Nanyang Technological University, Singapore. Electronic address: Mayada.Demashkieh@nie.edu.sg.'}, {'ForeName': 'Jack A', 'Initials': 'JA', 'LastName': 'Sargeant', 'Affiliation': 'National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK; Diabetes Research Centre, University of Leicester, UK. Electronic address: js928@leicester.ac.uk.'}, {'ForeName': 'Lewis J', 'Initials': 'LJ', 'LastName': 'James', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK. Electronic address: L.James@lboro.ac.uk.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Finlayson', 'Affiliation': 'Faculty of Medicine and Health, University of Leeds, UK. Electronic address: G.S.Finlayson@leeds.ac.uk.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Stensel', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK. Electronic address: D.J.Stensel@lboro.ac.uk.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'King', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK. Electronic address: j.a.king@lboro.ac.uk.'}]",Appetite,['10.1016/j.appet.2020.104785'] 1379,32571453,[Clinical effect of functional chewing training in treatment of oral motor dysfunction in children with cerebral palsy: a prospective randomized controlled clinical trial].,"OBJECTIVE To study the effect of functional chewing training (FuCT) on masticatory function, the severity of tongue thrust, and the severity and frequency of drooling in children with cerebral palsy. METHODS A prospective study was performed for 48 children who were diagnosed with oral motor dysfunction from January 2019 to January 2020, and they were randomly divided into an FuCT group and an oral motor training group, with 24 children in each group. Both groups received FuCT or oral motor training for 12 weeks, and then they were evaluated in terms of the changes in the masticatory function, the severity of tongue thrust, and the severity and frequency of drooling. RESULTS There were no significant differences between the two groups in the masticatory function, the severity of tongue thrust, and the severity and frequency of drooling before treatment (P>0.05). After the 12-week training, the FuCT group showed significant improvements in the masticatory function and the severity of tongue thrust and drooling (P<0.05), but with no improvement in the frequency of drooling (P>0.05), while the oral motor training group had no improvements in the masticatory function, the severity of tongue thrust, and the severity and frequency of drooling (P>0.05). After the 12-week training, the FuCT group had more significantly improvements in the severity of tongue thrust and the severity and frequency of drooling than the oral motor training group (P<0.05). CONCLUSIONS FuCT can effectively improve the masticatory function, the severity of tongue thrust, and the severity and frequency of drooling in children with cerebral palsy.",2020,"There were no significant differences between the two groups in the masticatory function, the severity of tongue thrust, and the severity and frequency of drooling before treatment (P>0.05).","['48 children who were diagnosed with oral motor dysfunction from January 2019 to January 2020', 'children with cerebral palsy']","['FuCT or oral motor training', 'oral motor training', 'FuCT', 'functional chewing training', 'functional chewing training (FuCT']","['masticatory function', 'severity of tongue thrust and the severity and frequency of drooling', 'frequency of drooling', 'oral motor dysfunction', 'masticatory function, the severity of tongue thrust, and the severity and frequency of drooling', 'masticatory function and the severity of tongue thrust and drooling']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0521654', 'cui_str': 'Motor dysfunction'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0024888', 'cui_str': 'Mastication'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C1829460', 'cui_str': 'Tongue thrusting'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0521654', 'cui_str': 'Motor dysfunction'}, {'cui': 'C0013132', 'cui_str': 'Dribbling from mouth'}]",48.0,0.0156327,"There were no significant differences between the two groups in the masticatory function, the severity of tongue thrust, and the severity and frequency of drooling before treatment (P>0.05).","[{'ForeName': 'Qiong-Li', 'Initials': 'QL', 'LastName': 'Fan', 'Affiliation': 'Department of Pediatrics, Second Affiliated Hospital, Army Medical University, Chongqing 400037, China. zhangyuping8888@qq.com.'}, {'ForeName': 'Zhi-Feng', 'Initials': 'ZF', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Xiu-Mei', 'Initials': 'XM', 'LastName': 'Yu', 'Affiliation': ''}, {'ForeName': 'Xiao-Yun', 'Initials': 'XY', 'LastName': 'Zeng', 'Affiliation': ''}, {'ForeName': 'Li-Shuang', 'Initials': 'LS', 'LastName': 'Peng', 'Affiliation': ''}, {'ForeName': 'Li-Sha', 'Initials': 'LS', 'LastName': 'Su', 'Affiliation': ''}, {'ForeName': 'Yu-Ping', 'Initials': 'YP', 'LastName': 'Zhang', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1380,32574117,Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy.,"PURPOSE We report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for dialysis. METHODS After symptomatic measures and high-dose dexamethasone, patients were randomly assigned to receive bortezomib plus dexamethasone (BD), or BD plus cyclophosphamide (C-BD). In patients with < 50% reduction of serum free light chains (sFLCs) after 3 cycles, chemotherapy was reinforced with either cyclophosphamide (BD group) or thalidomide (C-BD group). RESULTS Ninety-two patients were enrolled in each group. At random assignment, characteristics of the 2 groups were similar, including median age (68 years) and serum creatinine level (305.5 and 273.5 µmol/L in BD and C-BD group, respectively). At 3 months, renal response rate (primary end point) was not different (41 v 47 responders in the BD and C-BD groups, respectively; relative risk [RR], 0.87; P = .46). Very good partial response (free light chain reduction ≥ 90%) or more was achieved in 36 and 47 patients, respectively (RR, 0.76; P = .10). After 1 cycle of chemotherapy, 69 in the BD group and 67 patients in the C-BD group had achieved sFLC level ≤ 500 mg/L. Serious adverse events were recorded in 30 and 40 patients, respectively. At 12 months, 19 patients had died (9 in the BD group v 10 in the C-BD group), including 10 (6 in the BD group and 4 in the C-BD group) from myeloma progression and 3 (0 in the BD group and 3 in the C-BD group) from infection. Within median follow-up of 27 months, 43 and 42 patients switched to new therapy, respectively. Overall, 50 patients (24 in the BD group and 26 in the C-BD group) had died. CONCLUSION This randomized study did not show any benefit of C-BD compared with BD on renal recovery of patients with initial CN not requiring dialysis. Adding cyclophosphamide did not sufficiently improve the efficacy-toxicity balance. Patients with myeloma with AKI are fragile, and indication for doublet or triplet regimen should be adapted to frailty.",2020,"Very good partial response (free light chain reduction ≥ 90%) or more was achieved in 36 and 47 patients, respectively (RR, 0.76; P = .10).","['Patients with myeloma with AKI', 'patients with initial CN not requiring dialysis', 'Ninety-two patients were enrolled in each group', 'patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for dialysis', 'Patients With Multiple Myeloma and Acute Kidney Injury']","['BD', 'cyclophosphamide', 'dexamethasone', 'bortezomib plus dexamethasone (BD), or BD plus cyclophosphamide (C-BD', 'C-BD', 'cyclophosphamide (BD group) or thalidomide', 'doublet versus triplet bortezomib-based regimens', 'Triple Bortezomib-Based Regimen']","['sFLC level', 'serum creatinine level', 'died', 'renal recovery', 'adverse events', 'renal response rate', 'efficacy-toxicity balance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0179686', 'cui_str': 'Cast'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0268784', 'cui_str': 'Myeloma kidney'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}]","[{'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0039736', 'cui_str': 'Thalidomide'}, {'cui': 'C0041095', 'cui_str': 'Triplets'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0205174', 'cui_str': 'Triple'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]",92.0,0.0487875,"Very good partial response (free light chain reduction ≥ 90%) or more was achieved in 36 and 47 patients, respectively (RR, 0.76; P = .10).","[{'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Bridoux', 'Affiliation': 'Department of Nephrology, Centre Hospitalier Universitaire de Poitiers, INSERM CIC 1402, Poitiers University, France.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Arnulf', 'Affiliation': 'Department of Hematology and Immunology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, INSERM UMR 1126, Paris, France.'}, {'ForeName': 'Lionel', 'Initials': 'L', 'LastName': 'Karlin', 'Affiliation': 'Department of Clinical Hematology, Centre Hospitalier Universitaire Lyon Sud, Hospices Civils de Lyon, Pierre-Benite, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Blin', 'Affiliation': 'Department of Hematology, Centre Hospitalier Universitaire de Nantes, Nantes, France.'}, {'ForeName': 'Nolwenn', 'Initials': 'N', 'LastName': 'Rabot', 'Affiliation': 'Department of Nephrology and Clinical Immunology, Hôpital Bretonneau, Centre Hospitalier Universitaire de Tours, Tours, France.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Macro', 'Affiliation': 'Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Audard', 'Affiliation': 'Department of Nephrology and Renal Transplantation, Hôpital Henri Mondor, Créteil, Assistance Publique-Hôpitaux de Paris, INSERM U955, Université Paris Est Créteil, Créteil, France.'}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Belhadj', 'Affiliation': 'Department of Hematology, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France.'}, {'ForeName': 'Brigitte', 'Initials': 'B', 'LastName': 'Pegourie', 'Affiliation': 'Department of Hematology, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Gobert', 'Affiliation': 'Department of Nephrology, Centre Hospitalier Avignon, and Clinique Rhône Durance, Avignon, France.'}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Cornec Le Gall', 'Affiliation': 'Department of Nephrology, Centre Hospitalier Universitaire de Brest, INSERM U1078, Université de Brest, Brest, France.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Joly', 'Affiliation': 'Department of Hematology, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Karras', 'Affiliation': 'Department of Nephrology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes Sorbonne Paris Cité, Paris, France.'}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Jaccard', 'Affiliation': 'Centre de référence maladies rares ""amylose AL et autres maladies par dépôt d\'immunoglobulines monoclonales,"" Centre Hospitalier Universitaire de Poitiers, Poitiers, France.'}, {'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Augeul-Meunier', 'Affiliation': 'Department of Hematology, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.'}, {'ForeName': 'Salomon', 'Initials': 'S', 'LastName': 'Manier', 'Affiliation': 'Department of Hematology, Centre Hospitalier Universitaire de Lille, INSERM UMR-S1172, University of Lille, Lille, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Royer', 'Affiliation': ""Department of Hematology, Centre Hospitalier Universitaire d'Amiens, Amiens, France.""}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Caillot', 'Affiliation': 'Department of Clinical Hematology, Centre Hospitalier Universitaire de Dijon, Dijon, France.'}, {'ForeName': 'Mourad', 'Initials': 'M', 'LastName': 'Tiab', 'Affiliation': 'Department of Clinical Hematology, Centre Hospitalier de Vendée, La Roche sur Yon, France.'}, {'ForeName': 'Sébastien', 'Initials': 'S', 'LastName': 'Delbes', 'Affiliation': 'Department of Nephrology, Centre Hospitalier La Rochelle, La Rochelle, France.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Suarez', 'Affiliation': 'Department of Hematology, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Vigneau', 'Affiliation': 'Department of Nephrology, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Caillard', 'Affiliation': 'Department of Nephrology and Transplantation, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Arakelyan-Laboure', 'Affiliation': ""Department of Clinical Hematology and Cellular Therapy, Centre Hospitalier Régional d'Orléans, Orléans, France.""}, {'ForeName': 'Damien', 'Initials': 'D', 'LastName': 'Roos-Weil', 'Affiliation': 'Department of Clinical Hematology, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Sylvie', 'Initials': 'S', 'LastName': 'Chevret', 'Affiliation': 'Department of Biostatistics and Medical Information, UMR 1153, ECSTRRA Team, Inserm, Paris Diderot University, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Jean Paul', 'Initials': 'JP', 'LastName': 'Fermand', 'Affiliation': 'Department of Hematology and Immunology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, INSERM UMR 1126, Paris, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.20.00298'] 1381,32574167,On-line anxiety level detection from biosignals: Machine learning based on a randomized controlled trial with spider-fearful individuals.,"We present performance results concerning the validation for anxiety level detection based on trained mathematical models using supervised machine learning techniques. The model training is based on biosignals acquired in a randomized controlled trial. Wearable sensors were used to collect electrocardiogram, electrodermal activity, and respiration from spider-fearful individuals. We designed and applied ten approaches for data labeling considering individual biosignals as well as subjective ratings. Performance results revealed a selection of trained models adapted for two-level (low and high) and three-level (low, medium and high) classification of anxiety using a minimal set of six features. We obtained a remarkable accuracy of 89.8% for the two-level classification and of 74.4% for the three-level classification using a short time window length of ten seconds when applying the approach that uses subjective ratings for data labeling. Bagged Trees proved to be the most suitable classifier type among the classification models studied. The trained models will have a practical impact on the feasibility study of an augmented reality exposure therapy based on a therapeutic game for the treatment of arachnophobia.",2020,We obtained a remarkable accuracy of 89.8% for the two-level classification and of 74.4% for the three-level classification using a short time window length of ten seconds when applying the approach that uses subjective ratings for data labeling.,['spider-fearful individuals'],[],[],"[{'cui': 'C0037913', 'cui_str': 'Order Araneae'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0027361', 'cui_str': 'Person'}]",[],[],,0.0208422,We obtained a remarkable accuracy of 89.8% for the two-level classification and of 74.4% for the three-level classification using a short time window length of ten seconds when applying the approach that uses subjective ratings for data labeling.,"[{'ForeName': 'Frank R', 'Initials': 'FR', 'LastName': 'Ihmig', 'Affiliation': 'Department of Biomedical Microsystems, Fraunhofer-Institut für Biomedizinische Technik IBMT, Sulzbach/Saar, Germany.'}, {'ForeName': 'Antonio Gogeascoechea', 'Initials': 'AG', 'LastName': 'H', 'Affiliation': 'Faculty of Electrical Engineering, Mathematics and Computer Science, University of Twente, Enschede, The Netherlands.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Neurohr-Parakenings', 'Affiliation': 'Department of Biomedical Microsystems, Fraunhofer-Institut für Biomedizinische Technik IBMT, Sulzbach/Saar, Germany.'}, {'ForeName': 'Sarah K', 'Initials': 'SK', 'LastName': 'Schäfer', 'Affiliation': 'Division of Clinical Psychology and Psychotherapy, Department of Psychology, Saarland University, Saarbrücken, Germany.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Lass-Hennemann', 'Affiliation': 'Division of Clinical Psychology and Psychotherapy, Department of Psychology, Saarland University, Saarbrücken, Germany.'}, {'ForeName': 'Tanja', 'Initials': 'T', 'LastName': 'Michael', 'Affiliation': 'Division of Clinical Psychology and Psychotherapy, Department of Psychology, Saarland University, Saarbrücken, Germany.'}]",PloS one,['10.1371/journal.pone.0231517'] 1382,32683565,"Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).","PURPOSE Palbociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, approved in combination with endocrine therapy for the treatment of women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC). In the phase 2, open-label, PALOMA-1 trial, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) versus letrozole alone (hazard ratio, 0.488; 95% CI 0.319‒0.748; P = 0.0004; median PFS, 20.2 vs 10.2 months, respectively) in postmenopausal women with estrogen receptor-positive (ER+)/HER2- ABC. Here, we present the final overall survival (OS) and updated safety results. METHODS Postmenopausal women with ER+/HER2- ABC were randomized 1:1 to receive either palbociclib (125 mg/day, 3/1 schedule) plus letrozole (2.5 mg/day, continuous) or letrozole alone (2.5 mg/day, continuous). The primary endpoint was investigator-assessed PFS; secondary endpoints included OS and safety. RESULTS A total of 165 patients were randomized. At the data cutoff date of December 30, 2016 (median duration of follow-up, 64.7 months), the stratified hazard ratio for OS was 0.897 (95% CI 0.623-1.294; P = 0.281); median OS in the palbociclib plus letrozole and letrozole alone arms was 37.5 and 34.5 months, respectively. The median time from randomization to first subsequent chemotherapy use was longer with palbociclib plus letrozole than letrozole alone (26.7 and 17.7 months, respectively). The most frequently reported adverse event in the palbociclib plus letrozole arm was neutropenia (any grade, 75%; grade 3 or 4, 59%). CONCLUSIONS Palbociclib plus letrozole treatment led to a numerical but not statistically significant improvement in median OS. Pfizer Inc (NCT00721409).",2020,"CONCLUSIONS Palbociclib plus letrozole treatment led to a numerical but not statistically significant improvement in median OS.","['women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC', '165 patients were randomized', 'postmenopausal women with estrogen receptor-positive (ER+)/HER2- ABC', 'Postmenopausal women with ER+/HER2- ABC']","['letrozole versus letrozole', 'endocrine therapy', 'letrozole', 'palbociclib', 'letrozole alone', 'palbociclib plus letrozole', 'Palbociclib plus letrozole']","['median time', 'neutropenia', 'median OS', 'Overall survival', 'stratified hazard ratio for OS', 'investigator-assessed PFS; secondary endpoints included OS and safety', 'final overall survival (OS) and updated safety results', 'prolonged progression-free survival (PFS']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0152244', 'cui_str': 'Aneurysmal bone cyst'}, {'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0279754', 'cui_str': 'ESR1 positive'}]","[{'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C3853822', 'cui_str': 'palbociclib'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}]",165.0,0.0903289,"CONCLUSIONS Palbociclib plus letrozole treatment led to a numerical but not statistically significant improvement in median OS.","[{'ForeName': 'Richard S', 'Initials': 'RS', 'LastName': 'Finn', 'Affiliation': 'David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, USA. RFinn@mednet.ucla.edu.'}, {'ForeName': 'Katalin', 'Initials': 'K', 'LastName': 'Boer', 'Affiliation': 'Onkologia, Szent Margit Korhaz, Budapest, Hungary.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Bondarenko', 'Affiliation': 'Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine.'}, {'ForeName': 'Ravindranath', 'Initials': 'R', 'LastName': 'Patel', 'Affiliation': 'Comprehensive Blood and Cancer Center, Bakersfield, CA, USA.'}, {'ForeName': 'Tamas', 'Initials': 'T', 'LastName': 'Pinter', 'Affiliation': 'Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Schmidt', 'Affiliation': 'Department of Obstetrics and Gynecology, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Yaroslav V', 'Initials': 'YV', 'LastName': 'Shparyk', 'Affiliation': 'Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.'}, {'ForeName': 'Anu', 'Initials': 'A', 'LastName': 'Thummala', 'Affiliation': 'Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.'}, {'ForeName': 'Nataliia', 'Initials': 'N', 'LastName': 'Voitko', 'Affiliation': 'Kyiv City Clinical Oncology Center, Kyiv, Ukraine.'}, {'ForeName': 'Eustratios', 'Initials': 'E', 'LastName': 'Bananis', 'Affiliation': 'Pfizer Inc, New York, NY, USA.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'McRoy', 'Affiliation': 'Pfizer Inc, New York, NY, USA.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Wilner', 'Affiliation': 'Pfizer Inc, San Diego, CA, USA.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Pfizer Inc, San Diego, CA, USA.'}, {'ForeName': 'Sindy', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Pfizer Inc, San Diego, CA, USA.'}, {'ForeName': 'Dennis J', 'Initials': 'DJ', 'LastName': 'Slamon', 'Affiliation': 'David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, USA.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Ettl', 'Affiliation': 'Department of Obstetrics and Gynecology, Klinikum Rechts Der Isar, Technische Universität München, München, Germany.'}]",Breast cancer research and treatment,['10.1007/s10549-020-05755-7'] 1383,32445461,Cryoprecipitate Utilization Patterns Observed With a Required Prospective Approval Process vs Electronic Dosing Guidance.,"OBJECTIVES We evaluated the impact of electronic medical record (EMR)-guided pooled cryoprecipitate dosing vs our previous practice of requiring transfusion medicine (TM) resident approval for every cryoprecipitate transfusion. METHODS At our hospital, cryoprecipitate pooled from five donors is dosed for adult patients, while single-donor cryoprecipitate is dosed for pediatric patients (defined as patients <50 kg in weight). EMR-based dosing guidance replaced a previously required TM consultation when cryoprecipitate pools were ordered, but a consultation remained required for single-unit orders. Usage was defined as thawed cryoprecipitate; wastage was defined as cryoprecipitate that expired prior to transfusion. RESULTS In the 6 months prior to intervention, 178 ± 13 doses of pooled cryoprecipitate were used per month vs 187 ± 15 doses after the intervention (P = .68). Wastage of pooled cryoprecipitate increased from 7.7% ± 1.5% to 12.7% ± 1.4% (P = .038). There was no change in wastage of pediatric cryoprecipitate doses during the study period. These trends remained unchanged for a full year postimplementation. CONCLUSIONS Electronic dosing guidance resulted in similar cryoprecipitate usage as TM auditing. Increased wastage may result from reduced TM oversight. Product wastage should be balanced against the possibility that real-time audits could delay a lifesaving therapy.",2020,Wastage of pooled cryoprecipitate increased from 7.7% ± 1.5% to 12.7% ± 1.4% (P = .038).,[],[],"['Wastage of pooled cryoprecipitate', 'wastage of pediatric cryoprecipitate doses']",[],[],"[{'cui': 'C0337051', 'cui_str': 'Pool'}, {'cui': 'C0443121', 'cui_str': 'Cryoprecipitate'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}]",,0.035965,Wastage of pooled cryoprecipitate increased from 7.7% ± 1.5% to 12.7% ± 1.4% (P = .038).,"[{'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Kruse', 'Affiliation': 'Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Neally', 'Affiliation': 'Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.'}, {'ForeName': 'Brian C', 'Initials': 'BC', 'LastName': 'Cho', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.'}, {'ForeName': 'Evan M', 'Initials': 'EM', 'LastName': 'Bloch', 'Affiliation': 'Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.'}, {'ForeName': 'Parvez M', 'Initials': 'PM', 'LastName': 'Lokhandwala', 'Affiliation': 'Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.'}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Ness', 'Affiliation': 'Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.'}, {'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'Frank', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.'}, {'ForeName': 'Aaron A R', 'Initials': 'AAR', 'LastName': 'Tobian', 'Affiliation': 'Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Gehrie', 'Affiliation': 'Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.'}]",American journal of clinical pathology,['10.1093/ajcp/aqaa042'] 1384,32443744,Effectiveness of A Pilates Training Program on Cognitive and Functional Abilities in Postmenopausal Women.,"The purpose of this study was to determine the effects of a Pilates exercises program on the cognitive and physical functioning of older Spanish women. This study is a randomized clinical trial; a total of 110 women aged ≥60 years were initially allocated to either a Pilates group (PG, n = 55), who underwent a 12-week Pilates exercise program, or to a control group (CG, n = 55), who did not receive any intervention. Global cognitive function (Mini-Mental State Examination), verbal fluency (Isaacs test), executive function (Trail Making Test), functional flexibility (Back Scratch Test and Chair Sit-and-Reach Test), and lower-body strength (30 s Chair-Stand Test) were assessed before and immediately after the intervention period. The main findings of this study suggest that women in the PG (within-group differences) experienced improvements across all the variables examined except for global cognitive function. When compared with the CG (between-group differences), our analysis revealed significant benefits in the PG for all measures except for global cognitive function and functional flexibility (Back Scratch Test). In conclusion, our results suggest that Pilates has the potential to improve both cognitive and functional abilities among Spanish women aged 60 years and over.",2020,"When compared with the CG (between-group differences), our analysis revealed significant benefits in the PG for all measures except for global cognitive function and functional flexibility (Back Scratch Test).","['Spanish women aged 60 years and over', 'Postmenopausal Women', '110 women aged ≥60 years', 'older Spanish women']","['Pilates Training Program', 'Pilates exercises program', 'Pilates exercise program, or to a control group (CG, n = 55), who did not receive any intervention']","['cognitive and functional abilities', 'global cognitive function and functional flexibility (Back Scratch Test', 'global cognitive function', 'Global cognitive function (Mini-Mental State Examination), verbal fluency (Isaacs test), executive function (Trail Making Test), functional flexibility (Back Scratch Test and Chair Sit-and-Reach Test), and lower-body strength (30 s Chair-Stand Test', 'Cognitive and Functional Abilities', 'cognitive and physical functioning']","[{'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1321049', 'cui_str': 'Pilates exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0430562', 'cui_str': 'Scratch test'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C1268088', 'cui_str': 'Lower body structure'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",110.0,0.0263371,"When compared with the CG (between-group differences), our analysis revealed significant benefits in the PG for all measures except for global cognitive function and functional flexibility (Back Scratch Test).","[{'ForeName': 'Patricia Alexandra', 'Initials': 'PA', 'LastName': 'García-Garro', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, 23071 Jaén, Spain.'}, {'ForeName': 'Fidel', 'Initials': 'F', 'LastName': 'Hita-Contreras', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, 23071 Jaén, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Martínez-Amat', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, 23071 Jaén, Spain.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Achalandabaso-Ochoa', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, 23071 Jaén, Spain.'}, {'ForeName': 'José Daniel', 'Initials': 'JD', 'LastName': 'Jiménez-García', 'Affiliation': 'Department of Teaching Physical Education, Fine Arts and Music, University of Cádiz, 11003 Cádiz, Spain.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cruz-Díaz', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, 23071 Jaén, Spain.'}, {'ForeName': 'Agustín', 'Initials': 'A', 'LastName': 'Aibar-Almazán', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, 23071 Jaén, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17103580'] 1385,32445429,Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial.,"BACKGROUND Cardiac allograft vasculopathy (CAV) is characterized by diffuse thickening of the arterial intima. Statins reduce the incidence of CAV, but despite the use of statins, CAV remains one of the leading causes of long-term death after heart transplant. Inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) substantially reduce cholesterol levels but have not been tested in heart transplant recipients. METHODS The Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients (EVOLVD) trial (ClinicalTrials.gov Identifier: NCT03734211) is a randomized, double-blind trial designed to test the effect of the PCSK9 inhibitor evolocumab on coronary intima thickness in heart transplant recipients. Adults who have received a cardiac transplant within the past 4-8 weeks are eligible. Exclusion criteria include an estimated glomerular filtration rate < 20 mL/min/1.73 m 2 , renal replacement therapy, or contraindications to coronary angiography with intravascular ultrasound. 130 patients will be randomized (1:1) to 12-month treatment with evolocumab or matching placebo. The primary endpoint is the coronary artery intima thickness as measured by intravascular ultrasound. CONCLUSION The EVOLVD trial is a randomized clinical trial designed to show whether treatment with the PCSK9 inhibitor evolocumab can ameliorate CAV over the first year after heart transplant.",2020,"Inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) substantially reduce cholesterol levels but have not been tested in heart transplant recipients. ","['Vasculopathy in De-novo heart transplant recipients', '130 patients', 'Exclusion criteria include an estimated glomerular filtration rate < 20 mL/min/1.73 m 2 , renal replacement therapy, or contraindications to coronary angiography with intravascular ultrasound', 'Adults who have received a cardiac transplant within the past 4 - 8 weeks are eligible', 'heart transplant recipients']","['Cholesterol-lowering with EVOLocumab', 'evolocumab or matching placebo', 'PCSK9 inhibitor evolocumab', 'proprotein convertase subtilisin-kexin type 9 (PCSK9']","['cholesterol levels', 'coronary artery intima thickness as measured by intravascular ultrasound', 'cardiac allograft', 'coronary intima thickness']","[{'cui': 'C0042373', 'cui_str': 'Vascular disorder'}, {'cui': 'C2029943', 'cui_str': 'Transplanted heart present'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0206074', 'cui_str': 'Renal replacement therapy'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to'}, {'cui': 'C0085532', 'cui_str': 'Coronary angiography'}, {'cui': 'C0442123', 'cui_str': 'Intravascular'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0018823', 'cui_str': 'Transplantation of heart'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C3529352', 'cui_str': 'evolocumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1100660', 'cui_str': 'Proprotein Convertase'}, {'cui': 'C0038601', 'cui_str': 'Subtilisins'}, {'cui': 'C0165249', 'cui_str': 'Kexin'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0205042', 'cui_str': 'Coronary artery structure'}, {'cui': 'C0162864', 'cui_str': 'Tunica intima'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0442123', 'cui_str': 'Intravascular'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0564471', 'cui_str': 'Allograft heart'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}]",130.0,0.489633,"Inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) substantially reduce cholesterol levels but have not been tested in heart transplant recipients. ","[{'ForeName': 'Kaspar', 'Initials': 'K', 'LastName': 'Broch', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Einar', 'Initials': 'E', 'LastName': 'Gude', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Kristjan', 'Initials': 'K', 'LastName': 'Karason', 'Affiliation': 'Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.'}, {'ForeName': 'Göran', 'Initials': 'G', 'LastName': 'Dellgren', 'Affiliation': 'Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.'}, {'ForeName': 'Göran', 'Initials': 'G', 'LastName': 'Rådegran', 'Affiliation': 'The Clinic for Heart Failure and Valvular Disease, Skåne University Hospital, Lund, Sweden.'}, {'ForeName': 'Grunde', 'Initials': 'G', 'LastName': 'Gjesdal', 'Affiliation': 'The Clinic for Heart Failure and Valvular Disease, Skåne University Hospital, Lund, Sweden.'}, {'ForeName': 'Finn', 'Initials': 'F', 'LastName': 'Gustafsson', 'Affiliation': 'Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Eiskjaer', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Jyri', 'Initials': 'J', 'LastName': 'Lommi', 'Affiliation': 'Helsinki University Hospital Heart and Lung Center, Helsinki, Finland.'}, {'ForeName': 'Markku', 'Initials': 'M', 'LastName': 'Pentikäinen', 'Affiliation': 'Helsinki University Hospital Heart and Lung Center, Helsinki, Finland.'}, {'ForeName': 'Karl B', 'Initials': 'KB', 'LastName': 'Lemström', 'Affiliation': 'Helsinki University Hospital Heart and Lung Center, Helsinki, Finland.'}, {'ForeName': 'Arne K', 'Initials': 'AK', 'LastName': 'Andreassen', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Gullestad', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}]",Clinical transplantation,['10.1111/ctr.13984'] 1386,32446280,Does performance-based financing curb stock-outs of essential medicines? Results from a randomised controlled trial in Cameroon.,"OBJECTIVE In 2011, the government of Cameroon launched its performance-based financing (PBF) scheme. Our study examined the effects of the PBF intervention on the availability of essential medicines (EM). METHODS Randomised control trial whereby PBF and three distinct comparison groups were randomised in a total of 205 health facilities across three regions. Baseline data were collected between March and May 2012 and endline data 36 months later. We defined availability of multiple EM groups by assessing stock-outs for at least one day over the 30 days prior to the survey date and estimated changes attributable to PBF using a series of difference-in-difference regression models, adjusted for relevant facility-level covariates. Data were analysed stratified by region and area to assess effect heterogeneity. RESULTS Our estimates suggest that PBF intervention had no effect on the stock-outs of antenatal care drugs (P = 0.160), vaccines (P = 0.396), integrated management of childhood illness drugs (P = 0.681) and labour and delivery drugs (P = 0.589). However, the intervention was associated with a significant reduction of 34% in stock-outs of family planning medicines (P = 0.028). We observed effect heterogeneity across regions and areas, with significant decreases in stock-outs of family planning products in North-West region (P = 0.065) and in rural areas (P = 0.043). CONCLUSIONS The PBF intervention in Cameroon had limited effects on the reduction of EMs stock-outs. These poor results were likely the consequence of partial implementation failure, ranging from disruption and discontinuation of services to limited facility autonomy in managing decision-making and considerable delay in performance payment.",2020,"We observed effect heterogeneity across regions and areas, with significant decreases in stock-outs of family planning products in North-West region (p = 0.065) and in rural areas (p = 0.043). ",['205 health facilities across three regions'],"['PBF intervention', 'PBF']","['stock-outs of antenatal care drugs', 'stock-outs of family planning products']","[{'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0243097', 'cui_str': 'financing'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0453908', 'cui_str': 'Stocking'}, {'cui': 'C0439787', 'cui_str': 'Out'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0009861', 'cui_str': 'Family planning service'}]",,0.070051,"We observed effect heterogeneity across regions and areas, with significant decreases in stock-outs of family planning products in North-West region (p = 0.065) and in rural areas (p = 0.043). ","[{'ForeName': 'Isidore', 'Initials': 'I', 'LastName': 'Sieleunou', 'Affiliation': 'University of Montreal Public Health Research Institute, Montreal, QC, Canada.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'De Allegri', 'Affiliation': 'Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Roland Enok Bonong', 'Affiliation': 'School of Public Health, University of Montreal, Montreal, QC, Canada.'}, {'ForeName': 'Samiratou', 'Initials': 'S', 'LastName': 'Ouédraogo', 'Affiliation': 'Institut National de Santé Publique du Québec, Montréal, QC, Canada.'}, {'ForeName': 'Valéry', 'Initials': 'V', 'LastName': 'Ridde', 'Affiliation': 'School of Public Health, University of Montreal, Montreal, QC, Canada.'}]",Tropical medicine & international health : TM & IH,['10.1111/tmi.13447'] 1387,31819947,Evidence That Implementation Intentions Enhance Cognitive Training and Reduce Alcohol Consumption in Heavy Drinkers: A Randomized Trial.,"BACKGROUND Current training tasks to improve the cognitive deficits thought to be involved in sustained heavy drinking need further investigation to optimize their effectiveness. PURPOSE The present study investigated whether combining implementation intention provision with a cognitive training task had a measurable effect on alcohol consumption in heavy drinkers and explored the neural mechanisms underpinning any reductions in subsequent alcohol consumption. METHODS Thirty-two heavy-drinking participants completed approach-avoidance and visual probe training tasks preintervention and postintervention during functional Magnetic Resonance Imaging. Participants in the intervention group were randomized to form implementation intentions and participants in the control condition read a goal intention. Alcohol consumption was recorded preintervention and at 1 month follow-up. RESULTS Compared to the control group, implementation intention provision significantly improved performance on alcohol-avoidance tasks postintervention, t(30) = -2.315, p = .028, d = .85, and reduced alcohol consumption by 6.9 units/week (1 unit = 10 mL or 8 g ethanol), F(1,30) = 4.263, p = .048 (d = .74), at follow-up. However, the analysis of functional Magnetic Resonance Imaging data revealed no significant differences between groups. CONCLUSIONS These findings show for the first time that implementation intentions targeting cognitive processes can significantly reduce alcohol consumption among heavy drinkers. However, there was no evidence that the effects were mediated by changes in neural activity. Further work is required to explore the neural mechanisms underpinning the operation of implementation intentions. TRIAL REGISTRATION This trial was registered (ISRCTN:35503634) and is available at https://www.isrctn.com/ISRCTN35503634.",2020,"Compared to the control group, implementation intention provision significantly improved performance on alcohol-avoidance tasks postintervention, t(30) =","['Heavy Drinkers', 'heavy drinkers', 'Thirty-two heavy-drinking participants completed']","['implementation intentions and participants in the control condition read a goal intention', 'cognitive training task', 'Implementation Intentions Enhance Cognitive Training', 'approach-avoidance and visual probe training tasks preintervention and postintervention during functional Magnetic Resonance Imaging']","['performance on alcohol-avoidance tasks postintervention, t(30) ', 'reduced alcohol consumption', 'neural activity', 'alcohol consumption', 'Alcohol consumption']","[{'cui': 'C0001969', 'cui_str': 'Alcohol intoxication'}, {'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]","[{'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",32.0,0.098739,"Compared to the control group, implementation intention provision significantly improved performance on alcohol-avoidance tasks postintervention, t(30) =","[{'ForeName': 'Elly', 'Initials': 'E', 'LastName': 'Mcgrath', 'Affiliation': 'Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Chris J', 'Initials': 'CJ', 'LastName': 'Armitage', 'Affiliation': 'Manchester Centre for Health Psychology, Division of Psychology and Mental Health, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Shane', 'Initials': 'S', 'LastName': 'Mckie', 'Affiliation': 'Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Millar', 'Affiliation': 'Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Asmuni', 'Initials': 'A', 'LastName': 'Ab-Ghani', 'Affiliation': 'Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Rebecaa', 'Initials': 'R', 'LastName': 'Elliott', 'Affiliation': 'Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.'}]",Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,['10.1093/abm/kaz056'] 1388,32448781,What is the feasibility and observed effect of two implementation packages for stroke rehabilitation therapists implementing upper limb guidelines? A cluster controlled feasibility study.,"BACKGROUND Hand and arm activity after stroke improves with evidence-based rehabilitation. Therapists face known barriers when providing evidence-based rehabilitation and require support to implement guidelines. The aim of this study was to investigate the feasibility of two implementation packages on guideline adherence by occupational therapists and physiotherapists, and explore effect on patient upper limb outcomes. METHOD This was a non-randomised clustered feasibility study of occupational and physiotherapy rehabilitation services (n=3 inpatient and n=3 outpatient services). Services were allocated to one of three groups: (group A) facilitator-mediated implementation package, (group B) self-directed implementation package or (group C) usual care (control); we recruited n=1 inpatient and n=1 outpatient service per group. Outcomes of feasibility, adherence to guidelines (medical file audits) and patient upper limb impairment (Fugl-Meyer Upper Extremity Assessment), activity (Box and Block Test) and practice (minutes/week) were collected at baseline and after 3 months of intervention. RESULTS 29 therapists (8 in group A, 13 in groups B and 8 in group C) and 55 patients participated. Both the facilitator-mediated and the self-directed implementation packages were feasible to deliver in the rehabilitation setting. Therapists in group A improved with respect to guideline adherence (medical file audits; median within-group proportion difference of 0.29 (95% CI 0.22 to 0.36, p<0.0001) preintervention to postintervention). No significant within-group differences from baseline to postintervention were found in group B or group C, and no between-group differences were found for upper limb outcomes. CONCLUSION A facilitator-mediated package was acceptable to therapists working in stroke rehabilitation, and feasibility data suggest increased guideline uptake following implementation. An adequately powered study is planned to understand how to support therapists to provide evidence-based upper limb rehabilitation after stroke. TRIAL REGISTRATION NUMBER Australian New Zealand Clinical Trials Registry (ACTRN12619000596101).",2020,"A facilitator-mediated package was acceptable to therapists working in stroke rehabilitation, and feasibility data suggest increased guideline uptake following implementation.",['n=3 inpatient and n=3 outpatient services'],"['occupational and physiotherapy rehabilitation services', 'facilitator-mediated implementation package, (group B) self-directed implementation package or (group C) usual care (control']","['feasibility, adherence to guidelines (medical file audits) and patient upper limb impairment (Fugl-Meyer Upper Extremity Assessment), activity (Box and Block Test) and practice (minutes/week', 'guideline adherence', 'upper limb outcomes']","[{'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0086751', 'cui_str': 'Outpatient service'}]","[{'cui': 'C0521127', 'cui_str': 'Occupational'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0587660', 'cui_str': 'Rehabilitation service'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0016094', 'cui_str': 'Filing'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0006080', 'cui_str': 'Boxing'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0556975', 'cui_str': 'mins/week'}, {'cui': 'C0525059', 'cui_str': 'Guideline Adherence'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0574997,"A facilitator-mediated package was acceptable to therapists working in stroke rehabilitation, and feasibility data suggest increased guideline uptake following implementation.","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Jolliffe', 'Affiliation': 'Occupational Therapy, Alfred Health, Melbourne, Victoria, Australia l.jolliffe@alfred.org.au.'}, {'ForeName': 'Tammy', 'Initials': 'T', 'LastName': 'Hoffmann', 'Affiliation': 'Faculty of Health Sciences & Medicine, Bond University, Gold Coast, Queensland, Australia.'}, {'ForeName': 'Leonid', 'Initials': 'L', 'LastName': 'Churilov', 'Affiliation': 'Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.'}, {'ForeName': 'Natasha A', 'Initials': 'NA', 'LastName': 'Lannin', 'Affiliation': 'Occupational Therapy, Alfred Health, Melbourne, Victoria, Australia.'}]",BMJ open quality,['10.1136/bmjoq-2020-000954'] 1389,32453393,"Supplementation with vitamin D or ω-3 fatty acids in adolescent girls and young women with endometriosis (SAGE): a double-blind, randomized, placebo-controlled trial.","BACKGROUND Adolescents with endometriosis are a particularly underserved population who struggle with chronic pain. Despite widespread use, there are no published trials examining the individual effects of vitamin D and omega-3 (n-3) fatty acid supplementation on endometriosis-associated pain in adolescents. OBJECTIVES We aimed to determine whether supplementation with vitamin D or ω-3 fatty acids remediates pain, changes frequency of pain medication usage, or affects quality of life in young women with endometriosis. METHODS Women (aged 12-25 y) with surgically confirmed endometriosis and pelvic pain enrolled in a double-blind, randomized, placebo-controlled trial. The primary outcome was pain measured by the visual analog scale (VAS). Secondary outcomes were quality of life, pain catastrophizing, and pain medication usage. Participants were randomly assigned to receive 2000 IU vitamin D3, 1000 mg fish oil, or placebo daily for 6 mo. RESULTS A total of 147 women were screened and 69 were randomly assigned as follows: 27 to vitamin D3; 20 to fish oil; and 22 to placebo. Participants in the vitamin D arm experienced significant improvement in VAS pain [mean (95% CI) worst pain in the past month, from baseline to 6 mo: 7.0 (6.2, 7.8) to 5.5 (4.2, 6.8), P = 0.02]; however, an improvement of nearly identical magnitude was observed in the placebo arm [6.0 (5.1, 6.9) to 4.4 (3.0, 5.8), P = 0.07]. A more modest improvement was observed in the fish oil arm [5.9 (4.8, 7.0) to 5.2 (3.7, 6.8), P = 0.39]. Neither of the intervention arms were statistically different from placebo. CONCLUSIONS In young women with endometriosis, supplementation with vitamin D led to significant changes in pelvic pain; however, these were similar in magnitude to placebo. Supplementation with fish oil resulted in about half of the VAS pain reduction of the other 2 arms. Studies are needed to better define the physiology underlying the observed reduction in pain score in the placebo arm that persisted across 6 mo.This trial was registered at clinicaltrials.gov as NCT02387931.",2020,"In young women with endometriosis, supplementation with vitamin D led to significant changes in pelvic pain; however, these were similar in magnitude to placebo.","['young women with endometriosis', 'adolescent girls and young women with endometriosis (SAGE', 'A total of 147 women were screened and 69 were randomly assigned as follows: 27 to', 'Women (aged 12-25 y) with surgically confirmed endometriosis and pelvic pain enrolled', 'young women with endometriosis, supplementation with', 'Adolescents with endometriosis are a particularly underserved population who struggle with chronic pain', 'endometriosis-associated pain in adolescents']","['vitamin D or ω-3 fatty acids', 'vitamin D3; 20 to fish oil', '2000 IU vitamin D3, 1000 mg fish oil, or placebo', 'placebo', 'vitamin D', 'vitamin D and omega-3 (n-3) fatty acid supplementation']","['quality of life', 'quality of life, pain catastrophizing, and pain medication usage', 'pain measured by the visual analog scale (VAS', 'pelvic pain', 'VAS pain reduction', 'pain', 'VAS pain', 'pain score']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0014175', 'cui_str': 'Endometriosis'}, {'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C1122976', 'cui_str': 'Sage'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0030794', 'cui_str': 'Pain in pelvis'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0872319', 'cui_str': 'Patients, Underserved'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0016157', 'cui_str': 'Fish Oils'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0457083', 'cui_str': 'Usage'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030794', 'cui_str': 'Pain in pelvis'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",147.0,0.819757,"In young women with endometriosis, supplementation with vitamin D led to significant changes in pelvic pain; however, these were similar in magnitude to placebo.","[{'ForeName': 'James L', 'Initials': 'JL', 'LastName': 'Nodler', 'Affiliation': 'Department of Obstetrics and Gynecology, Colorado Center for Reproductive Medicine-Houston, Houston, TX, USA.'}, {'ForeName': 'Amy D', 'Initials': 'AD', 'LastName': 'DiVasta', 'Affiliation': ""Boston Center for Endometriosis, Boston Children's Hospital and Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Allison F', 'Initials': 'AF', 'LastName': 'Vitonis', 'Affiliation': ""Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Karevicius', 'Affiliation': ""Boston Center for Endometriosis, Boston Children's Hospital and Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Maggie', 'Initials': 'M', 'LastName': 'Malsch', 'Affiliation': ""Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, MA, USA.""}, {'ForeName': 'Vishnudas', 'Initials': 'V', 'LastName': 'Sarda', 'Affiliation': ""Division of Adolescent and Young Adult Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Ayotunde', 'Initials': 'A', 'LastName': 'Fadayomi', 'Affiliation': ""Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Holly R', 'Initials': 'HR', 'LastName': 'Harris', 'Affiliation': 'Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Stacey A', 'Initials': 'SA', 'LastName': 'Missmer', 'Affiliation': ""Boston Center for Endometriosis, Boston Children's Hospital and Brigham and Women's Hospital, Boston, MA, USA.""}]",The American journal of clinical nutrition,['10.1093/ajcn/nqaa096'] 1390,32580188,"A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.","INTRODUCTION Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia in Japan for patients with dialysis-dependent (DD) chronic kidney disease (CKD). OBJECTIVE Multicenter, randomized, open-label, noncomparative, phase 3 study to evaluate roxadustat for anemia of non-dialysis-dependent (NDD) CKD in Japan. METHODS Erythropoiesis stimulating agent (ESA)-naïve NDD-CKD patients were randomized to roxadustat (initial dose, 50 or 70 mg 3 times weekly), titrated to maintain hemoglobin (Hb) within 10.0-12.0 g/dL, for ≤24 weeks. Patients with either transferrin saturation of ≥5% or serum ferritin of ≥30 ng/mL during the screening period were eligible. Endpoints included response rate (proportion of patients achieving Hb ≥10.0 or ≥10.5 g/dL and Hb increase ≥1.0 g/dL from baseline) at end of treatment; average Hb (weeks 18-24); change of average Hb from baseline to weeks 18-24; maintenance rate (proportion of patients achieving Hb 10.0-12.0 g/dL at weeks 18-24); rate of rise (RoR) of Hb from weeks 0-4, discontinuation, or dose adjustment. Adverse events were monitored throughout the study. RESULTS Of 135 patients who provided informed consent, 100 were randomized and 99 received roxadustat (50 mg, n = 49; 70 mg, n = 50). The mean (SD) dose of roxadustat per intake at week 22 was 36.3 (22.7) mg in the roxadustat 50 mg group and 36.8 (16.0) mg in the roxadustat 70 mg group. Prior medications included oral iron therapy (20.2%) and intravenous iron therapy (1.0%). Overall response rate (95% CI) was 97.0% (91.4, 99.4; Hb ≥10.0 g/dL) and 94.9% (88.6, 98.3; Hb ≥10.5 g/dL). Mean (SD) Hb (weeks 18-24) was 11.17 (0.62) g/dL. Mean (SD) change of Hb from baseline (weeks 18-24) was 1.34 (0.86) g/dL. Maintenance rate (95% CI) was 88.8% (80.3, 94.5) among patients with ≥1 Hb measurement during weeks 18-24. Mean (SD) RoR of Hb was 0.291 (0.197) g/dL/week (50 mg) and 0.373 (0.235) g/dL/week (70 mg). Nasopharyngitis and hypertension were the most common adverse events. CONCLUSION Roxadustat increased and maintained Hb in ESA-naïve, partially iron-depleted NDD-CKD patients with anemia.",2020,"Overall response rate (95% CI) was 97.0% (91.4, 99.4;","['anemia of non-dialysis-dependent (NDD) CKD in Japan', 'Patients with either transferrin saturation of ≥5% or serum ferritin of ≥30 ng/mL during the screening period were eligible', '135 patients who provided informed consent, 100 were randomized and 99 received', 'anemia in Japan for patients with dialysis-dependent (DD) chronic kidney disease (CKD', 'Erythropoiesis stimulating agent (ESA)-naïve NDD-CKD patients', 'Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis']","['oral iron therapy', 'roxadustat', 'intravenous iron therapy']","['Nasopharyngitis and hypertension', 'Mean (SD) RoR of Hb', 'Adverse events', 'response rate', 'Overall response rate', 'mean (SD) dose of roxadustat per intake']","[{'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1277709', 'cui_str': 'Transferrin saturation'}, {'cui': 'C0696113', 'cui_str': 'Serum ferritin measurement'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0014819', 'cui_str': 'Erythrocyte production'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C1959590', 'cui_str': 'Erythropoiesis Stimulating Agents'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}]",135.0,0.0562269,"Overall response rate (95% CI) was 97.0% (91.4, 99.4;","[{'ForeName': 'Tadao', 'Initials': 'T', 'LastName': 'Akizawa', 'Affiliation': 'Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, akizawa@med.showa-u.ac.jp.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Yamaguchi', 'Affiliation': 'Data Science, Development, Astellas Pharma, Inc., Tokyo, Japan.'}, {'ForeName': 'Tetsuro', 'Initials': 'T', 'LastName': 'Otsuka', 'Affiliation': 'Japan-Asia Clinical Development 2, Development, Astellas Pharma, Inc., Tokyo, Japan.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Reusch', 'Affiliation': 'Therapeutic Area Medical Specialties, Astellas Pharma Europe B.V., Leiden, The Netherlands.'}]",Nephron,['10.1159/000508100'] 1391,32473046,"A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients.","BACKGROUND The risk of invasive pneumococcal disease is significant among solid organ transplant (SOT) recipients. The optimal pneumococcal vaccination strategy for SOT patients is not known. METHODS The potential kidney transplant recipients in dialysis were randomized into two arms: to receive a 23-valent pneumococcal polysaccharide vaccine (PPV23) before transplantation or to receive a 13-valent pneumococcal conjugate vaccine (PCV13) before transplantation and a second dose of PCV13 six months after the transplantation. Serotype-specific antibody concentrations and opsonophagocytic activity (OPA) were measured before and after the first vaccination (visits V1,V2) and six and seven months after the transplantation, for example, before and after the second PCV13 (visits V3,V4). RESULTS Out of 133 participants, 48 (PCV13 arm) and 46 (PPV23 arm) received a kidney transplant, and 37 + 37 in both arms completed the study. After the first vaccination, the geometric mean concentrations (GMCs) in the PCV13 arm were significantly higher for 9/13 serotypes and the OPA geometric mean titers (GMTs) were significantly higher for 4/13 serotypes. At V3, the antibody levels had declined but OPA remained significantly higher for 7/13 (PCV13) vs 4/13 (PPV23) serotypes. At V4, the GMCs for 9/13 serotypes and the GMTs for 12/13 serotypes were significantly higher in the PCV13 arm. The GMCs but not GMTs were lower than at V2. There was no difference in adverse effects. No vaccine-related allograft rejection was detected. CONCLUSIONS The immunogenicity of PCV13 was better in dialysis patients, and revaccination with PCV13 was immunogenic and safe.",2020,"The immunogenicity of PCV13 was better in dialysis patients, and revaccination with PCV13 was immunogenic and safe .","['kidney transplant recipients in dialysis', 'Out of 133 participants, 48 (PCV13 arm) and 46 (PPV23 arm) received a kidney transplant, and 37 + 37 in both arms completed the study', 'kidney transplant recipients', 'solid organ transplant (SOT) recipients', 'SOT patients']","['23-valent pneumococcal polysaccharide vaccine (PPV23) before transplantation or to receive a 13-valent pneumococcal conjugate vaccine (PCV13', '23-valent pneumococcal polysaccharide vaccination']","['geometric mean concentrations (GMCs', 'allograft rejection', 'immunogenicity of PCV13', 'OPA', 'adverse effects', 'antibody levels', 'OPA geometric mean titres (GMTs', 'Serotype-specific antibody concentrations and opsonophagocytic activity (OPA']","[{'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0230348', 'cui_str': 'Both upper arms'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0730400', 'cui_str': 'Solid organ transplant'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0961101', 'cui_str': '23-valent pneumococcal capsular polysaccharide vaccine'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C3152625', 'cui_str': 'Pneumococcal 13-valent conjugate vaccine'}, {'cui': 'C0038410', 'cui_str': 'Streptococcus pneumoniae'}, {'cui': 'C0032594', 'cui_str': 'Polysaccharide'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040739', 'cui_str': 'Allogeneic transplantation'}, {'cui': 'C0035015', 'cui_str': 'Rejection (Psychology)'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0036759', 'cui_str': 'Serotyping'}, {'cui': 'C0443640', 'cui_str': 'Specific antibody'}]",133.0,0.0617085,"The immunogenicity of PCV13 was better in dialysis patients, and revaccination with PCV13 was immunogenic and safe .","[{'ForeName': 'Mari', 'Initials': 'M', 'LastName': 'Eriksson', 'Affiliation': 'HUH Inflammation Center, Division of Infectious Diseases of Helsinki University Hospital, Helsinki University, Helsinki, Finland.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Käyhty', 'Affiliation': 'National Institute for Health and Welfare, Helsinki, Finland.'}, {'ForeName': 'Heikki', 'Initials': 'H', 'LastName': 'Saha', 'Affiliation': 'Division of Nephrology, Tampere University Hospital, Tampere, Finland.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Lahdenkari', 'Affiliation': 'National Institute for Health and Welfare, Helsinki, Finland.'}, {'ForeName': 'Petri', 'Initials': 'P', 'LastName': 'Koskinen', 'Affiliation': 'HUH Abdominal Center, Division of Nephrology, Helsinki University Hospital and Helsinki University, Helsinki, Finland.'}, {'ForeName': 'Heikki', 'Initials': 'H', 'LastName': 'Mäkisalo', 'Affiliation': 'HUH Abdominal Center, Division of Liver Diseases and Transplantation, Helsinki University Hospital and Helsinki University, Helsinki, Finland.'}, {'ForeName': 'Veli-Jukka', 'Initials': 'VJ', 'LastName': 'Anttila', 'Affiliation': 'HUH Inflammation Center, Division of Infectious Diseases of Helsinki University Hospital, Helsinki University, Helsinki, Finland.'}]",Transplant infectious disease : an official journal of the Transplantation Society,['10.1111/tid.13343'] 1392,32474710,Ultrasound-guided pudendal nerve block in patients undergoing open hemorrhoidectomy: a double-blind randomized controlled trial.,"PURPOSE In this double-blind randomized trial, we aimed to compare the postoperative pain, complications, and length of hospital stay in patients undergoing open hemorrhoidectomy under spinal anesthesia with or without the pudendal nerve block. METHODS Patients undergoing Milligan-Morgan hemorrhoidectomy under spinal anesthesia were randomized to undergo a pudendal nerve block or no intervention. Postoperative pain on the visual analogue scale (VAS) at 6, 12, 24, and 48 h; opioid administration; and length of hospital stay were recorded and analyzed. RESULTS Over the study period, 49 patients were included and 23 randomized in the treatment arm. No differences in terms of age, gender, and preoperative risk factors were noted between groups. The pain on the VAS at 6, 12, 24, and 48 h was 2.8 vs. 4.6 (p = 0.046), 3.4 vs. 4.7 (p = 0.697), 1.4 vs. 3.1 (p = 0.016), and 1.0 vs. 2.1 (p = 0.288) in the treatment and control groups respectively. No differences in opioids use or complications were noted. Length of hospital stay was 1.2 vs. 1.8 days respectively (p = 0.046). No complications directly associated to the pudendal nerve block were observed. Multivariate analysis revealed that the pudendal nerve block was an independent factor reducing the postoperative pain. CONCLUSIONS The ultrasound-guided pudendal nerve block in patients undergoing open hemorrhoidectomy under spinal anesthesia showed a statistically significant reduction in postoperative pain and length of hospital stay. The proposed technique appeared to be safe and feasible and may be recommendable in patients undergoing open hemorrhoidectomy. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT04251884.",2020,Length of hospital stay was 1.2 vs. 1.8 days respectively (p = 0.046).,"['patients undergoing open hemorrhoidectomy', 'patients undergoing open', 'Patients undergoing Milligan-Morgan hemorrhoidectomy under spinal anesthesia', '49 patients were included and 23 randomized in the treatment arm', 'patients undergoing open hemorrhoidectomy under spinal anesthesia', 'patients undergoing open hemorrhoidectomy under spinal anesthesia with or without the pudendal nerve block']","['Ultrasound-guided pudendal nerve block', 'pudendal nerve block or no intervention', 'hemorrhoidectomy']","['pain on the VAS', 'postoperative pain', 'Length of hospital stay', 'length of hospital stay', 'opioids use or complications', 'postoperative pain, complications, and length of hospital stay', 'pudendal nerve block', 'postoperative pain and length of hospital stay', 'Postoperative pain on the visual analogue scale (VAS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0473074', 'cui_str': 'Open hemorrhoidectomy'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0582521', 'cui_str': 'Morgan'}, {'cui': 'C0019108', 'cui_str': 'Hemorrhoidectomy'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0394776', 'cui_str': 'Injection of anesthetic agent into pudendal nerve'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0394776', 'cui_str': 'Injection of anesthetic agent into pudendal nerve'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0019108', 'cui_str': 'Hemorrhoidectomy'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0394776', 'cui_str': 'Injection of anesthetic agent into pudendal nerve'}]",49.0,0.227957,Length of hospital stay was 1.2 vs. 1.8 days respectively (p = 0.046).,"[{'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Di Giuseppe', 'Affiliation': 'Surgery, Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Saporito', 'Affiliation': 'Anesthesiology, Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'La Regina', 'Affiliation': 'Surgery, Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland.'}, {'ForeName': 'Edoardo', 'Initials': 'E', 'LastName': 'Tasciotti', 'Affiliation': 'Anesthesiology, Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland.'}, {'ForeName': 'Enea', 'Initials': 'E', 'LastName': 'Ghielmini', 'Affiliation': 'Surgery, University Hospital of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Vannelli', 'Affiliation': 'Surgery, Ospedale Valduce, Como, Italy.'}, {'ForeName': 'Ramon', 'Initials': 'R', 'LastName': 'Pini', 'Affiliation': 'Surgery, Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Mongelli', 'Affiliation': 'Surgery, Ospedale Regionale di Lugano, 6900, Lugano, Switzerland. francesco.mongelli@mail.com.'}]",International journal of colorectal disease,['10.1007/s00384-020-03630-x'] 1393,32584260,"Evaluation of the Clinical and Economic Effects of a Primary Care Anchored, Collaborative, Electronic Health Lifestyle Coaching Program in Denmark: Protocol for a Two-Year Randomized Controlled Trial.","BACKGROUND Obesity is linked to a number of chronic health conditions, such as type 2 diabetes, heart disease, and cancer, and weight loss interventions are often expensive. Recent systematic reviews concluded that app and web-based interventions can improve lifestyle behaviors and weight loss at a reasonable cost, but long-term sustainability needs to be demonstrated. OBJECTIVE This study protocol is for a 2-year randomized controlled trial that aims to evaluate the clinical and economic effects of a primary care, anchored, collaborative, electronic health (eHealth) lifestyle coaching program (long-term Lifestyle change InterVention and eHealth Application [LIVA] 2.0) in obese participants with and without type 2 diabetes. The program's primary outcome is weight loss. Its secondary outcome is the hemoglobin A 1c (HbA 1c ) level, and its tertiary outcomes are retention rate, quality of life (QOL), and cost effectiveness. Analytically, the focus is on associations of participant characteristics with outcomes and sustainability. METHODS We conduct a multicenter trial with a 1-year intervention and 1-year retention. LIVA 2.0 is implemented in municipalities within administrative regions in Denmark, specifically eight municipalities located within the Region of Southern Denmark and two municipalities located within the Capital Region of Denmark. The participants are assessed at baseline and at 6-, 12-, and 24-month follow-ups. Individual data from the LIVA 2.0 platform are combined with clinical measurements, questionnaires, and participants' usage of municipality and health care services. The participants have a BMI ≥30 but ≤45 kg/m2, and 50% of the participants have type 2 diabetes. The participants are randomized in an approximately 60:40 manner, and based on sample size calculations on weight loss and intention-to-treat statistics, 200 participants are randomized to an intervention group and 140 are randomized to a control group. The control group is offered the conventional preventive program of the municipality, and it is compared to the intervention group, which follows the LIVA 2.0 in addition to the conventional preventive program. RESULTS The first baseline assessments have been carried out in March 2018, and the 2-year follow-up will be carried out between March 2020 and April 2021. The hypothesis is that the trial results will demonstrate decreased body weight and that the number of patients who show normalization of their HbA 1c levels in the intervention group will be much higher than that in the control group. The participants in the intervention group are also expected to show a greater decrease in their use of glucose-lowering medication and a greater improvement in their QOL when compared with the control group. Operational costs are expected to be lower than standard care, and the intervention is expected to be cost-effective. CONCLUSIONS This is the first time that an app and web-based eHealth lifestyle coaching program implemented in Danish municipalities will be clinically and economically evaluated. If the LIVA 2.0 eHealth lifestyle coaching program is proven to be effective, there is great potential for decreasing the rates of obesity, diabetes, and related chronic diseases. TRIAL REGISTRATION ClinicalTrials.gov NCT03788915; https://clinicaltrials.gov/ct2/show/NCT03788915. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/19172.",2020,The participants in the intervention group are also expected to show a greater decrease in their use of glucose-lowering medication and a greater improvement in their QOL when compared with the control group.,"['Denmark', 'participants have a BMI ≥30 but ≤45 kg/m2, and 50% of the participants have type 2 diabetes', 'obese participants with and without type 2 diabetes']","['Primary Care Anchored, Collaborative, Electronic Health Lifestyle Coaching Program', 'primary care, anchored, collaborative, electronic health (eHealth) lifestyle coaching program (long-term Lifestyle change InterVention and eHealth Application [LIVA']","['lifestyle behaviors and weight loss', 'body weight', 'QOL', 'hemoglobin', 'weight loss', 'retention rate, quality of life (QOL), and cost effectiveness', 'glucose-lowering medication', 'Operational costs']","[{'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C1293132', 'cui_str': 'Anchoring'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",,0.106368,The participants in the intervention group are also expected to show a greater decrease in their use of glucose-lowering medication and a greater improvement in their QOL when compared with the control group.,"[{'ForeName': 'Carl J', 'Initials': 'CJ', 'LastName': 'Brandt', 'Affiliation': 'Research Unit for General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Jeanette Reffstrup', 'Initials': 'JR', 'LastName': 'Christensen', 'Affiliation': 'Research Unit for General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Jørgen T', 'Initials': 'JT', 'LastName': 'Lauridsen', 'Affiliation': 'Department of Business and Economics, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Jesper Bo', 'Initials': 'JB', 'LastName': 'Nielsen', 'Affiliation': 'Research Unit for General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Søndergaard', 'Affiliation': 'Research Unit for General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Sortsø', 'Affiliation': 'LIVA Healthcare, Copenhagen, Denmark.'}]",JMIR research protocols,['10.2196/19172'] 1394,32442139,Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis: Protocol for a Pilot Randomized Controlled Trial.,"BACKGROUND Juvenile idiopathic arthritis (JIA) is one of the most common types of arthritis among children. According to JIA guidelines for physical activity (PA), structured PA interventions led to improved health outcomes. However, many PA programs, such as yoga and aerobic dance, have not been studied in this population despite being popular among youth. Web-based PA programs could provide patients with accessible and affordable interventions. OBJECTIVE The primary aims of the proposed pilot randomized controlled trial (RCT) are to examine (1) the feasibility of conducting a full-scale RCT to evaluate the effectiveness of two popular types of PA: a yoga training program and an aerobic dance training program, in female adolescents (aged 13-18 years) with JIA compared with an electronic pamphlet control group; and (2) the acceptability of these interventions. METHODS A three-arm prospective randomized open-label study with a parallel group design will be used. A total of 25 female adolescents with JIA who have pain will be randomized in a ratio of 2:2:1 to one of the 3 groups: (1) online yoga training program (group A: n=10); (2) online aerobic dance training program (group B: n=10); and (3) electronic pamphlet control group (group C: n=5). Participants in groups A and B will complete 3 individual 1-hour sessions per week using online exercise videos, as well as a 1-hour virtual group session per week using a videoconferencing platform for 12 weeks. Participants from all groups will have access to an electronic educational pamphlet on PA for arthritis developed by the Arthritis Society. All participants will also take part in weekly online consultations with a research coordinator and discussions on Facebook with participants from their own group. Feasibility (ie, recruitment rate, self-reported adherence to the interventions, dropout rates, and percentage of missing data), acceptability, and usability of Facebook and the videoconferencing platform will be assessed at the end of the program. Pain intensity, participation in general PA, morning stiffness, functional status, fatigue, self-efficacy, patient global assessment, disease activity, and adverse events will be assessed using self-administered electronic surveys at baseline and then weekly until the end of the 12-week program. RESULTS This pilot RCT has been funded by the Arthritis Health Professions Association. This protocol was approved by the Children's Hospital of Eastern Ontario Research Ethics Board (#17/08X). As of May 11, 2020, recruitment and data collection have not started. CONCLUSIONS To our knowledge, this is the first study to evaluate the effectiveness of yoga and aerobic dance as pain management interventions for female adolescents with JIA. The use of online programs to disseminate these 2 PA interventions may facilitate access to alternative methods of pain management. This study can lead to a full-scale RCT. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) PRR1-10.2196/12823.",2020,"Pain intensity, participation in general PA, morning stiffness, functional status, fatigue, self-efficacy, patient global assessment, disease activity, and adverse events will be assessed using self-administered electronic surveys at baseline, weekly, until the end of the 12-week program. ","['Juvenile Idiopathic Arthritis', '25 female adolescents with JIA who have pain', 'female adolescents with JIA', 'female adolescents (aged 13-18 years) with JIA compared with an']","['yoga and aerobic dance', 'electronic pamphlet control group', 'online yoga training program', 'electronic educational pamphlet', 'electronic pamphlet control', 'yoga training program and an aerobic dance training program', 'online aerobic dance training program', 'Yoga and Aerobic Dance']","['Feasibility (ie, recruitment rate', 'dropout rates, and percentage of missing data), acceptability, and usability of Facebook and the video-conferencing platform', 'Pain intensity, participation in general PA, morning stiffness, functional status, fatigue, self-efficacy, patient global assessment, disease activity, and adverse events', 'health outcomes']","[{'cui': 'C3495559', 'cui_str': 'Juvenile chronic arthritis'}, {'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0010963', 'cui_str': 'Dance'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0457086', 'cui_str': 'Morning stiffness - joint'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",25.0,0.0845735,"Pain intensity, participation in general PA, morning stiffness, functional status, fatigue, self-efficacy, patient global assessment, disease activity, and adverse events will be assessed using self-administered electronic surveys at baseline, weekly, until the end of the 12-week program. ","[{'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Toupin April', 'Affiliation': ""Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.""}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Stinson', 'Affiliation': 'Child Health Evaluative Sciences, The Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Cavallo', 'Affiliation': 'École de Réadaptation, Université de Montréal, Montréal, QC, Canada.'}, {'ForeName': 'Laurie', 'Initials': 'L', 'LastName': 'Proulx', 'Affiliation': 'Canadian Arthritis Patient Alliance, Ottawa, ON, Canada.'}, {'ForeName': 'George A', 'Initials': 'GA', 'LastName': 'Wells', 'Affiliation': 'Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada.'}, {'ForeName': 'Ciarán M', 'Initials': 'CM', 'LastName': 'Duffy', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Tania', 'Initials': 'T', 'LastName': 'ElHindi', 'Affiliation': 'Statistics Canada, Ottawa, ON, Canada.'}, {'ForeName': 'Patricia E', 'Initials': 'PE', 'LastName': 'Longmuir', 'Affiliation': ""Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.""}, {'ForeName': 'Lucie', 'Initials': 'L', 'LastName': 'Brosseau', 'Affiliation': 'Faculty of Health Sciences, School of Rehabilitation Sciences, University of Ottawa, Ottawa, ON, Canada.'}]",JMIR research protocols,['10.2196/12823'] 1395,32442141,Computer-Based Stratified Primary Care for Musculoskeletal Consultations Compared With Usual Care: Study Protocol for the STarT MSK Cluster Randomized Controlled Trial.,"BACKGROUND Musculoskeletal (MSK) pain is a major cause of pain and disability. We previously developed a prognostic tool (Start Back Tool) with demonstrated effectiveness in guiding primary care low back pain management by supporting decision making using matched treatments. A logical next step is to determine whether prognostic stratified care has benefits for a broader range of common MSK pain presentations. OBJECTIVE This study seeks to determine, in patients with 1 of the 5 most common MSK presentations (back, neck, knee, shoulder, and multisite pain), whether stratified care involving the use of the Keele Start MSK Tool to allocate individuals into low-, medium-, and high-risk subgroups, and matching these subgroups to recommended matched clinical management options, is clinical and cost-effective compared with usual nonstratified primary care. METHODS This is a pragmatic, two-arm parallel (stratified vs nonstratified care), cluster randomized controlled trial, with a health economic analysis and mixed methods process evaluation. The setting is UK primary care, involving 24 average-sized general practices randomized (stratified by practice size) in a 1:1 ratio (12 per arm) with blinding of trial statistician and outcome data collectors. Randomization units are general practices, and units of observation are adult MSK consulters without indicators of serious pathologies, urgent medical needs, or vulnerabilities. Potential participant records are tagged and individuals invited using a general practitioner (GP) point-of-consultation electronic medical record (EMR) template. The intervention is supported by an EMR template (computer-based) housing the Keele Start MSK Tool (to stratify into prognostic subgroups) and the recommended matched treatment options. The primary outcome using intention-to-treat analysis is pain intensity, measured monthly over 6 months. Secondary outcomes include physical function and quality of life, and an anonymized EMR audit to capture clinician decision making. The economic evaluation is focused on the estimation of incremental quality-adjusted life years and MSK pain-related health care costs. The process evaluation is exploring a range of potential factors influencing the intervention and understanding how it is perceived by patients and clinicians, with quantitative analyses focusing on a priori hypothesized intervention targets and qualitative approaches using focus groups and interviews. The target sample size is 1200 patients from 24 general practices, with >5000 MSK consultations available for anonymized medical record data comparisons. RESULTS Trial recruitment commenced on May 18, 2018, and ended on July 15, 2019, after a 14-month recruitment period in 24 GP practices. Follow-up and interview data collection was completed in February 2020. CONCLUSIONS This trial is the first attempt, as far as we know, at testing a prognostic stratified care approach for primary care patients with MSK pain. The results of this trial should be available by the summer of 2020. TRIAL REGISTRATION ISRCTN Registry ISRCTN15366334; http://www.isrctn.com/ISRCTN15366334. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/17939.",2020,We previously developed a prognostic tool (STarT Back Tool) with demonstrated effectiveness in guiding primary care low back pain management by supporting decision-making using matched treatments.,"['primary care patients with MSK pain', '1200 patients from 24 general practices, with >5000 MSK consultations available for anonymized medical record data comparisons', 'Potential participant records are tagged and individuals invited using a general practitioner (GP) point-of-consultation electronic medical record (EMR) template', 'patients with 1 of the 5 most common MSK presentations (back, neck, knee, shoulder, and multisite pain']","['Computer-Based Stratified Primary Care for Musculoskeletal Consultations Compared With Usual Care', 'EMR template (computer-based) housing']","['intention-to-treat analysis is pain intensity', 'physical function and quality of life, and an anonymized EMR audit to capture clinician decision making']","[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026858', 'cui_str': 'Musculoskeletal pain'}, {'cui': 'C4517548', 'cui_str': '1200'}, {'cui': 'C0015607', 'cui_str': 'Family practice'}, {'cui': 'C4319610', 'cui_str': '5000'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0025102', 'cui_str': 'Medical record'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0037293', 'cui_str': 'Skin tag'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C4317132', 'cui_str': 'Template'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0449450', 'cui_str': 'Presentation'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C4317132', 'cui_str': 'Template'}, {'cui': 'C0020056', 'cui_str': 'Housed'}]","[{'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C0450985', 'cui_str': 'Alcohol use disorders identification test'}, {'cui': 'C0011109', 'cui_str': 'Decision making'}]",,0.143061,We previously developed a prognostic tool (STarT Back Tool) with demonstrated effectiveness in guiding primary care low back pain management by supporting decision-making using matched treatments.,"[{'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Hill', 'Affiliation': 'Institute for Primary, Community and Social Care, Keele University, Stoke-on-Trent, United Kingdom.'}, {'ForeName': 'Stefannie', 'Initials': 'S', 'LastName': 'Garvin', 'Affiliation': 'Keele Clinical Trials Unit, Institute for Primary, Community and Social Care, Keele University, Stoke-on-Trent, United Kingdom.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Institute for Primary, Community and Social Care, Keele University, Stoke-on-Trent, United Kingdom.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Cooper', 'Affiliation': 'Institute for Primary, Community and Social Care, Keele University, Stoke-on-Trent, United Kingdom.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Wathall', 'Affiliation': 'Keele Clinical Trials Unit, Institute for Primary, Community and Social Care, Keele University, Stoke-on-Trent, United Kingdom.'}, {'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'Bartlam', 'Affiliation': 'Nanyang Technological University, Singapore, Singapore.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Saunders', 'Affiliation': 'Institute for Primary, Community and Social Care, Keele University, Stoke-on-Trent, United Kingdom.'}, {'ForeName': 'Martyn', 'Initials': 'M', 'LastName': 'Lewis', 'Affiliation': 'Institute for Primary, Community and Social Care, Keele University, Stoke-on-Trent, United Kingdom.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Protheroe', 'Affiliation': 'Institute for Primary, Community and Social Care, Keele University, Stoke-on-Trent, United Kingdom.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Chudyk', 'Affiliation': 'Institute for Primary, Community and Social Care, Keele University, Stoke-on-Trent, United Kingdom.'}, {'ForeName': 'Hollie', 'Initials': 'H', 'LastName': 'Birkinshaw', 'Affiliation': 'Institute for Primary, Community and Social Care, Keele University, Stoke-on-Trent, United Kingdom.'}, {'ForeName': 'Kate M', 'Initials': 'KM', 'LastName': 'Dunn', 'Affiliation': 'Institute for Primary, Community and Social Care, Keele University, Stoke-on-Trent, United Kingdom.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Jowett', 'Affiliation': 'Health Economics Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Oppong', 'Affiliation': 'Health Economics Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'Hay', 'Affiliation': 'Institute for Primary, Community and Social Care, Keele University, Stoke-on-Trent, United Kingdom.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'van der Windt', 'Affiliation': 'Institute for Primary, Community and Social Care, Keele University, Stoke-on-Trent, United Kingdom.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Mallen', 'Affiliation': 'Institute for Primary, Community and Social Care, Keele University, Stoke-on-Trent, United Kingdom.'}, {'ForeName': 'Nadine E', 'Initials': 'NE', 'LastName': 'Foster', 'Affiliation': 'Institute for Primary, Community and Social Care, Keele University, Stoke-on-Trent, United Kingdom.'}]",JMIR research protocols,['10.2196/17939'] 1396,32442142,Guided Internet-Based Cognitive Behavioral Therapy in Japanese Patients With Obsessive-Compulsive Disorder: Protocol for a Randomized Controlled Trial.,"BACKGROUND Cognitive behavioral therapy for obsessive-compulsive disorder has been established, but access to this therapy in Japan is limited. Internet-based cognitive behavioral therapy may improve treatment accessibility and sufficiently improve obsessive-compulsive symptoms. There are few randomized controlled trials examining the effectiveness of internet-based cognitive behavioral therapy in patients with obsessive-compulsive disorder. We designed a randomized controlled trial protocol to assess the effectiveness of guided internet-based cognitive behavioral therapy in Japanese patients with obsessive-compulsive disorder. OBJECTIVE We aimed to develop a protocol for a randomized controlled trial of internet-based cognitive behavioral therapy in Japanese patients with obsessive-compulsive disorder. METHODS The randomized controlled trial will compare internet-based cognitive behavioral therapy treatment and usual care groups, each consisting of 15 participants (n=30) diagnosed with obsessive-compulsive disorder. We will evaluate the effectiveness of a 12-week intervention. The primary outcome of symptom severity will be measured using the Yale-Brown Obsessive-Compulsive Scale. Secondary outcomes will be assessed with the Obsessive-Compulsive Inventory, Beck Anxiety Inventory, Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, Working Alliance Inventory-Short Form, and the Euro Qol - 5 Dimension. All measures will be assessed at weeks 0 (baseline) and 12 (follow-up). In the statistical analysis comparing treatment effects, the least-squares means and their 95% CIs will be estimated by analysis of covariance with the change in total outcomes scores at week 12. All comparisons are planned, and all P values will be two-sided, with values <.05 considered statistically significant. RESULTS The study will be performed from January 2020 to March 2021, and results are expected to be available in mid-2021. CONCLUSIONS The trial will demonstrate whether internet-based cognitive behavioral therapy improves access and is more effective than more usual care for patients with obsessive-compulsive disorder in Japan. TRIAL REGISTRATION University Hospital Medical Information Network (UMIN) 000039375; https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000044422. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/18216.",2020,"The trial will demonstrate whether internet-based cognitive behavioral therapy improves access and is more effective than more usual care for patients with obsessive-compulsive disorder in Japan. ","['Japanese Patients with Obsessive-Compulsive Disorder', 'Japanese patients with obsessive-compulsive disorder', 'patients with obsessive-compulsive disorder in Japan', 'patients with obsessive-compulsive disorder', '15 participants (n=30) diagnosed with obsessive-compulsive disorder']","['internet-based cognitive behavioral therapy', 'guided internet-based cognitive behavioral therapy', 'Cognitive behavioral therapy', 'Internet-based cognitive behavioral therapy', 'Guided Internet-Based Cognitive Behavioral Therapy']","['symptom severity will be measured using the Yale-Brown Obsessive-Compulsive Scale', 'Obsessive-Compulsive Inventory, Beck Anxiety Inventory, Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, Working Alliance Inventory-Short Form, and the Euro Qol - 5 Dimension', 'obsessive-compulsive symptoms']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028768', 'cui_str': 'Obsessive-compulsive disorder'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0181090', 'cui_str': 'Guide'}]","[{'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0155339', 'cui_str': ""Brown's tendon sheath syndrome""}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C3472214', 'cui_str': 'Obsessive compulsive inventory'}, {'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C1533125', 'cui_str': 'Euro'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C4087290', 'cui_str': 'Obsessive-compulsive symptom'}]",,0.1134,"The trial will demonstrate whether internet-based cognitive behavioral therapy improves access and is more effective than more usual care for patients with obsessive-compulsive disorder in Japan. ","[{'ForeName': 'Kazuki', 'Initials': 'K', 'LastName': 'Matsumoto', 'Affiliation': 'Research Center for Child Mental Development, Chiba University, Chiba, Japan.'}, {'ForeName': 'Sayo', 'Initials': 'S', 'LastName': 'Hamatani', 'Affiliation': 'Research Center for Child Mental Development, Chiba University, Chiba, Japan.'}, {'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Makino', 'Affiliation': 'Research Center for Child Mental Development, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Taku', 'Initials': 'T', 'LastName': 'Uemura', 'Affiliation': 'Research Center for Child Mental Development, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Futoshi', 'Initials': 'F', 'LastName': 'Suzuki', 'Affiliation': 'Research Center for Child Mental Development, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Seina', 'Initials': 'S', 'LastName': 'Shinno', 'Affiliation': 'Department of Integrated Medical Sciences, Graduate School of Medicine, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Tomoki', 'Initials': 'T', 'LastName': 'Ikai', 'Affiliation': 'Department of Primary Health Care, Faculty of Medicine, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Hayashi', 'Affiliation': 'Department of Integrated Advanced Medicine, Graduate School of Medicine, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Chihiro', 'Initials': 'C', 'LastName': 'Sutoh', 'Affiliation': 'Department of Cognitive Behavioral Physiology, Graduate School of Medicine, Chiba University, Chiba, Japan.'}, {'ForeName': 'Eiji', 'Initials': 'E', 'LastName': 'Shimizu', 'Affiliation': 'Research Center for Child Mental Development, Chiba University, Chiba, Japan.'}]",JMIR research protocols,['10.2196/18216'] 1397,32443390,Effects of virtual reality immersive training with computerized cognitive training on cognitive function and activities of daily living performance in patients with acute stage stroke: A preliminary randomized controlled trial: Retraction.,,2020,,['patients with acute stage stroke'],['virtual reality immersive training with computerized cognitive training'],['cognitive function and activities of daily living performance'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}]",,0.160731,,[],Medicine,['10.1097/MD.0000000000020598'] 1398,32444149,Transition to forefoot strike reduces load rates more effectively than altered cadence.,"BACKGROUND Excessive vertical impacts at landing are associated with common running injuries. Two primary gait-retraining interventions aimed at reducing impact forces are transition to forefoot strike and increasing cadence. The objective of this study was to compare the short- and long-term effects of 2 gait-retraining interventions aimed at reducing landing impacts. METHODS A total of 39 healthy recreational runners using a rearfoot strike and a cadence of ≤170 steps/min were randomized into cadence (CAD) or forefoot strike (FFS) groups. All participants performed 4 weeks of strengthening followed by 8 sessions of gait-retraining using auditory feedback. Vertical average load rates (VALR) and vertical instantaneous load rates (VILR) were calculated from the vertical ground reaction force curve. Both cadence and foot strike angle were measured using 3D motion analysis and an instrumented treadmill at baseline and at 1 week, 1 month, and 6 months post retraining. RESULTS ANOVA revealed that the FFS group had significant reductions in VALR (49.7%) and VILR (41.7%), and changes were maintained long term. Foot strike angle in the FFS group changed from 14.2° dorsiflexion at baseline to 3.4° plantarflexion, with changes maintained long term. The CAD group exhibited significant reduction only in VALR (16%) and only at 6 months. Both groups had significant and similar increases in cadence at all follow-ups (CAD, +7.2% to 173 steps/min; and FFS, +6.1% to 172 steps/min). CONCLUSION Forefoot strike gait-retraining resulted in significantly greater reductions in VALR and similar increases in cadence compared to cadence gait-retraining in the short and long term. Cadence gait-retraining resulted in small reductions in VALR at only the 6-month follow-up.",2020,"RESULTS ANOVA revealed that the FFS group had significant reductions in VALR (49.7%) and VILR (41.7%), and changes were maintained long term.",['39 healthy recreational runners using a rearfoot strike and a cadence of ≤170 steps/min were randomized into'],"['2 gait-retraining interventions', 'cadence (CAD) or forefoot strike (FFS', 'gait-retraining using auditory feedback', 'Cadence gait-retraining']","['VALR', 'VILR', 'Vertical average load rates (VALR) and vertical instantaneous load rates (VILR', 'Foot strike angle', 'cadence']","[{'cui': 'C0038452', 'cui_str': 'Employee Strikes'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0439232', 'cui_str': 'min'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1510667', 'cui_str': 'Forefoot region of foot'}, {'cui': 'C0038452', 'cui_str': 'Employee Strikes'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}]","[{'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0038452', 'cui_str': 'Employee Strikes'}, {'cui': 'C0205143', 'cui_str': 'Angular'}]",39.0,0.0737562,"RESULTS ANOVA revealed that the FFS group had significant reductions in VALR (49.7%) and VILR (41.7%), and changes were maintained long term.","[{'ForeName': 'Erin E', 'Initials': 'EE', 'LastName': 'Futrell', 'Affiliation': 'Department of Physical Therapy, Springfield College, Springfield, MA 01109, USA; Spaulding National Running Center, Harvard Medical School, Cambridge, MA 02138, USA. Electronic address: efutrell@springfieldcollege.edu.'}, {'ForeName': 'K Douglas', 'Initials': 'KD', 'LastName': 'Gross', 'Affiliation': 'Department of Physical Therapy, MGH Institute of Health Professions, Boston, MA 02129, USA.'}, {'ForeName': 'Darcy', 'Initials': 'D', 'LastName': 'Reisman', 'Affiliation': 'Department of Physical Therapy, University of Delaware, Newark, DE 19713, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Mullineaux', 'Affiliation': 'School of Sport and Exercise Science, University of Lincoln, Brayford Pool, Lincoln, Lincolnshire, Brayford Pool, LN6 7TS, UK.'}, {'ForeName': 'Irene S', 'Initials': 'IS', 'LastName': 'Davis', 'Affiliation': 'Spaulding National Running Center, Harvard Medical School, Cambridge, MA 02138, USA; Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA 02115, USA.'}]",Journal of sport and health science,['10.1016/j.jshs.2019.07.006'] 1399,32444570,Effects of robot-assisted gait training alongside conventional therapy on the development of walking in children with cerebral palsy.,"PURPOSE To investigate the effects of robot-assisted gait training (RAGT) alongside conventional therapy on the standing and walking abilities of children with cerebral palsy (CP). METHODS The study sample consisted of children (aged 4-18 years) with CP whose gross motor function classification system (GMFCS) was at levels I-V. In total, 75 children with CP were evaluated and 38 patients completed the study. Patients were divided into two groups as GMFCS levels I-III (Group 1) and levels IV-V (Group 2). RAGT (30 min/session) and conventional physiotherapy (30 min/session) were applied together in the treatment. The treatment duration was 60 min per session, 3 or 4 sessions per week, for a total of 30 sessions over 8-10 weeks. 10-meter walk test (10MWT), 6-min walk test (6MinWT), gross motor functional measurement 66 (GMFM66) -D, and -E tests were performed. RESULTS We showed that in both groups of CP patients (mild-moderate and severe), meaningful improvements were seen in the standing (D) and walking (E) sections of GMFM-66 after treatment. When we compared the post-treatment changes in 10-m walk test, 6-min walk test, GMFM66-D, and -E between Groups 1 and 2, we noted that the improvements were statistically significant in favor of Group 1 (p< 0.01). CONCLUSION RAGT in combination with a conventional treatment program was significantly associated with improvements in the standing and walking abilities of children with mild to moderate CP (GMFCS levels I-III).",2020,"CONCLUSION RAGT in combination with a conventional treatment program was significantly associated with improvements in the standing and walking abilities of children with mild to moderate CP (GMFCS levels I-III).","['children with cerebral palsy (CP', 'children (aged 4-18 years) with CP whose gross motor function classification system (GMFCS) was at levels I-V', 'children with cerebral palsy', '75 children with CP were evaluated and 38 patients completed the study']","['robot-assisted gait training (RAGT) alongside conventional therapy', 'conventional physiotherapy', 'RAGT', 'robot-assisted gait training alongside conventional therapy']","['10-m walk test, 6-min walk test, GMFM66-D, and -E', 'standing and walking abilities', '10-meter walk test (10MWT), 6-min walk test (6MinWT), gross motor functional measurement 66 (GMFM66) -D, and -E tests']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0677549', 'cui_str': 'Gross motor functions'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0441925', 'cui_str': 'Level I'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}]","[{'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0439806', 'cui_str': 'Gross'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0441074', 'cui_str': 'Meters'}, {'cui': 'C1275991', 'cui_str': 'E test'}]",75.0,0.0159701,"CONCLUSION RAGT in combination with a conventional treatment program was significantly associated with improvements in the standing and walking abilities of children with mild to moderate CP (GMFCS levels I-III).","[{'ForeName': 'Hamza', 'Initials': 'H', 'LastName': 'Sucuoglu', 'Affiliation': ''}]",Journal of pediatric rehabilitation medicine,['10.3233/PRM-180541'] 1400,32446176,"Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.","INTRODUCTION Safinamide is a reversible and selective monoamine oxidase-B (MAO-B) and sodium channel inhibitor with demonstrated efficacy in mid-to late-stage Parkinson's disease (PD) as an adjunct to l-DOPA. This study aimed to confirm the efficacy and safety of safinamide in PD patients with wearing-off. METHODS This 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study included Japanese PD patients with wearing-off on l-DOPA treatment. Patients were randomized to receive placebo (P), safinamide 50 mg/day (S50), or safinamide 100 mg/day (S100). The primary endpoint was the change from baseline in mean daily ON-time without troublesome dyskinesias (ON-time). Other measures included the changes in mean daily OFF-time, the unified Parkinson's disease rating scale (UPDRS) score, and the PDQ-39 summary index. RESULTS A total of 406 subjects were randomized, of whom 349 completed the study. Baseline characteristics were balanced. Differences in the change of mean daily ON-time at Week 24 compared with the P group were 1.39 h (p = 0.0002) in the S50 group and 1.66 h (p < 0.0001) in the S100 group. Changes from baseline in mean daily OFF-time, UPDRS Part II total score (OFF phase), UPDRS Part III total score (ON phase), and UPDRS Part I also showed significant improvements. Adverse events occurred in 58.9%, 60.2%, and 61.4% of the P, S50, and S100 groups, respectively. The most common adverse drug reactions were dyskinesias (2.1%, 8.3%, and 10.6%) and visual hallucinations (1.4%, 3.0%, and 4.5%). CONCLUSION As an adjunct to l-DOPA, safinamide safely increased ON-time and improved PD symptoms/signs in PD patients with wearing-off.",2020,Differences in the change of mean daily ON-time at Week 24 compared with the P group were 1.39 h (p = 0.0002) in the S50 group and 1.66 h (p < 0.0001) in the S100 group.,"[""patients with Parkinson's disease"", 'PD patients with wearing-off', 'Japanese PD patients with wearing-off on l-DOPA treatment', 'A total of 406 subjects were randomized, of whom 349 completed the study']","['sodium channel inhibitor', 'safinamide', 'placebo (P), safinamide 50\xa0mg/day (S50), or safinamide 100\xa0mg/day (S100', 'placebo']","['Adverse events', 'dyskinesias', 'Efficacy and safety', 'mean daily OFF-time, UPDRS Part II total score (OFF phase), UPDRS Part III total score (ON phase), and UPDRS Part', 'visual hallucinations', 'mean daily ON-time', 'efficacy and safety', ""mean daily OFF-time, the unified Parkinson's disease rating scale (UPDRS) score, and the PDQ-39 summary index"", 'change from baseline in mean daily ON-time without troublesome dyskinesias (ON-time', 'ON-time and improved PD symptoms/signs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0872271', 'cui_str': 'Sodium channel blocker'}, {'cui': 'C1098261', 'cui_str': 'safinamide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4475891', 'cui_str': 'safinamide 50 MG'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4475900', 'cui_str': 'safinamide 100 MG'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0013384', 'cui_str': 'Dyskinesia'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0233763', 'cui_str': 'Visual hallucinations'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0220912', 'cui_str': 'signs'}]",406.0,0.175291,Differences in the change of mean daily ON-time at Week 24 compared with the P group were 1.39 h (p = 0.0002) in the S50 group and 1.66 h (p < 0.0001) in the S100 group.,"[{'ForeName': 'Nobutaka', 'Initials': 'N', 'LastName': 'Hattori', 'Affiliation': 'Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8431, Japan. Electronic address: nhattori@juntendo.ac.jp.'}, {'ForeName': 'Yoshio', 'Initials': 'Y', 'LastName': 'Tsuboi', 'Affiliation': 'Department of Neurology, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan. Electronic address: tsuboi@cis.fukuoka-u.ac.jp.'}, {'ForeName': 'Akihiko', 'Initials': 'A', 'LastName': 'Yamamoto', 'Affiliation': 'Meiji Seika Pharma Co., Ltd., 2-4-16 Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan. Electronic address: akihiko.yamamoto@meiji.com.'}, {'ForeName': 'Yuji', 'Initials': 'Y', 'LastName': 'Sasagawa', 'Affiliation': 'Meiji Seika Pharma Co., Ltd., 2-4-16 Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan. Electronic address: yuuji.sasagawa@meiji.com.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Nomoto', 'Affiliation': 'Department of Neurology and Clinical Pharmacology, Graduate School of Medicine, Ehime University, Shizugawa, Tohon, Ehime, 791-0295, Japan; Saiseikai Imabari Center for Health and Welfare, 7-6-1 Kitamura, Imabari, Ehime, 799-1592, Japan. Electronic address: nomoto@m.ehime-u.ac.jp.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Parkinsonism & related disorders,['10.1016/j.parkreldis.2020.04.012'] 1401,31813632,Effectiveness of two bed bath methods in removing microorganisms from hospitalized patients: A prospective randomized crossover study.,"BACKGROUND Few studies have compared the effectiveness of washing with either soap and water or disposable wet wipes. The objective of this study was to compare the effectiveness of washing with either soap and water or disposable wet wipes in reducing microorganisms in the groin and perineum of hospitalized patients, which could potentially reduce the risk of hospital-acquired urinary tract infections. METHODS In this crossover, block-randomized trial, skin swabs from the groin and perineum areas of patients were obtained before and after these areas were washed with either soap and water or disposable wet wipes. Columbia agar plates and CHROMagar Orientation Medium (Becton Dickinson; Franklin Lakes, NJ) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry procedures were used to identify species of microorganisms. RESULTS Fifty-eight paired skin swabs were obtained. Both washing methods resulted in a statistically significant reduction in the amount of all microorganisms, including microorganisms with the potential to cause urinary tract infections. New species were observed after using both washing methods. No statistically significant difference in the removal of microorganisms was observed between the two washing methods. CONCLUSIONS The two washing methods appear to be equally efficient in removal of microorganisms in the groin and perineum areas, including microorganisms that potentially could cause hospital-acquired urinary tract infections.",2020,"Both washing methods resulted in a statistically significant reduction in the amount of all microorganisms, including microorganisms with the potential to cause urinary tract infections.",['hospitalized patients'],['soap and water or disposable wet wipes'],['removal of microorganisms'],"[{'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0037392', 'cui_str': 'Soap'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0205381', 'cui_str': 'Wet'}]","[{'cui': 'C0015252', 'cui_str': 'Removal'}]",,0.0275957,"Both washing methods resulted in a statistically significant reduction in the amount of all microorganisms, including microorganisms with the potential to cause urinary tract infections.","[{'ForeName': 'Pia L', 'Initials': 'PL', 'LastName': 'Veje', 'Affiliation': 'Department of Regional Health Research, University of Southern Denmark, Odense, Denmark; University College South Denmark, Aabenraa, Denmark; Odense Patient Data Exploratory Network, Odense University Hospital, Odense, Denmark. Electronic address: pveje@health.sdu.dk.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': 'Department of Regional Health Research, University of Southern Denmark, Odense, Denmark; Hospital of Southern Jutland, University Hospital Southern Denmark, Aabenraa, Denmark; Department of Clinical Microbiology, Hospital of Southern Jutland, University Hospital of Southern Denmark, Soenderborg, Denmark.'}, {'ForeName': 'Christian S', 'Initials': 'CS', 'LastName': 'Jensen', 'Affiliation': 'National Center for Infection Control, Infectious Disease Epidemiology & Prevention, Statens Serum Institut, Copenhagen, Denmark.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Sørensen', 'Affiliation': 'Danish Centre for Health Economics, Department of Public Health, University of Southern Denmark, Odense, Denmark; Health Care Outcomes, Research Centre, Royal College of Surgeons in Ireland, Dublin, Ireland.'}, {'ForeName': 'Jette', 'Initials': 'J', 'LastName': 'Primdahl', 'Affiliation': 'Department of Regional Health Research, University of Southern Denmark, Odense, Denmark; Hospital of Southern Jutland, University Hospital Southern Denmark, Aabenraa, Denmark; Danish Hospital for Rheumatic Diseases, Soenderborg, Denmark.'}]",American journal of infection control,['10.1016/j.ajic.2019.10.011'] 1402,32451212,"Efficacy, immunogenicity and safety of a trivalent live human-lamb reassortant rotavirus vaccine (LLR3) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial.","BACKGROUND A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy, immunogenicity and safety of a novel trivalent live human-lamb reassortant rotavirus vaccine (LLR3) against rotavirus gastroenteritis (RVGE). METHODS Healthy children aged 6-13 weeks were enrolled and randomized (1:1) to either 3 oral doses of LLR3 or placebo according to a 0, 1, 2 month schedule. The objectives were to evaluate vaccine efficacy (VE) against RVGE of any-severity, severe RVGE (sRVGE) and inpatient caused by rotavirus serotypes contained in the vaccine and not contained in the vaccine after the third dose. Immunogenicity was also assayed in a subgroup. All adverse events (AEs) were collected from 30 min after each dose for immediate reaction, even to the entire study period, including the serious AEs (SAEs) and intussusception. RESULTS VE against RVGE of any-severity, sRVGE and inpatient caused by any serotype was 56.6% (95% CI: 50.7, 61.8), 70.3% (95% CI: 60.6, 77.6) and 74.0% (95% CI: 57.5, 84.1) respectively. VE against RVGE of any-severity, sRVGE caused by serotypes not contained in vaccine were 54.2% (95% CI: 47.5, 60.1) and 70.4% (95% CI: 60.4, 77.9). The rate of seroconversion and four-fold increase of rotavirus serotype G2-, G3-, and G4-specific IgA is 60.8%, 58.0%, and 60.6% in vaccine group, which was higher than 21.35%, 22.7%, and 23.1% in placebo group (p < 0.0001 for G2, G3, G4), as well as the Geometric Mean Titer (GMT). Through the entire trial, 65.91% and 67.79% of participants reported at least one AE, and 0.02% and 0.02% reported SAEs in the vaccine and placebo groups, respectively. Two intussusception cases were reported both in vaccine and placebo group. CONCLUSIONS In Chinese infants, LLR3 provided a substantial protection against RVGE of any-severity, sRVGE and inpatient caused by any serotype, and showed well immunogenicity and safety.",2020,"In Chinese infants, LLR3 provided a substantial protection against RVGE of any-severity, sRVGE and inpatient caused by any serotype, and showed well immunogenicity and safety.","['healthy Chinese infants', 'Healthy children aged 6-13\xa0weeks']","['trivalent live human-lamb reassortant rotavirus vaccine (LLR3', 'novel trivalent live human-lamb reassortant rotavirus vaccine (LLR3', 'LLR3 or placebo', 'placebo']","['efficacy, immunogenicity and safety', 'vaccine efficacy (VE) against RVGE of any-severity, severe RVGE (sRVGE) and inpatient caused by rotavirus serotypes', 'rotavirus serotype G2-, G3-, and G4-specific IgA', 'rate of seroconversion', 'Geometric Mean Titer (GMT', 'Efficacy, immunogenicity and safety', 'immunogenicity and safety', 'Immunogenicity']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0406810', 'cui_str': 'Carney complex'}, {'cui': 'C0597418', 'cui_str': 'Rotavirus vaccine'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0343363', 'cui_str': 'Viral gastroenteritis due to Rotavirus'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0035870', 'cui_str': 'Rotavirus'}, {'cui': 'C0036759', 'cui_str': 'Serotyping'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0475208', 'cui_str': 'Titer'}]",,0.734975,"In Chinese infants, LLR3 provided a substantial protection against RVGE of any-severity, sRVGE and inpatient caused by any serotype, and showed well immunogenicity and safety.","[{'ForeName': 'Shengli', 'Initials': 'S', 'LastName': 'Xia', 'Affiliation': 'Henan Center for Disease Control and Prevention, Zhengzhou 450000, China.'}, {'ForeName': 'Jialiang', 'Initials': 'J', 'LastName': 'Du', 'Affiliation': 'National Institutes for Food and Drug Control, Beijing 102629, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Su', 'Affiliation': 'Henan Center for Disease Control and Prevention, Zhengzhou 450000, China.'}, {'ForeName': 'Yueyue', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'National Institutes for Food and Drug Control, Beijing 102629, China.'}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Henan Center for Disease Control and Prevention, Zhengzhou 450000, China.'}, {'ForeName': 'Qingchuan', 'Initials': 'Q', 'LastName': 'Yu', 'Affiliation': 'National Institutes for Food and Drug Control, Beijing 102629, China.'}, {'ForeName': 'Zhiqiang', 'Initials': 'Z', 'LastName': 'Xie', 'Affiliation': 'Henan Center for Disease Control and Prevention, Zhengzhou 450000, China.'}, {'ForeName': 'Jiamei', 'Initials': 'J', 'LastName': 'Gao', 'Affiliation': 'National Institutes for Food and Drug Control, Beijing 102629, China.'}, {'ForeName': 'Bianli', 'Initials': 'B', 'LastName': 'Xu', 'Affiliation': 'Henan Center for Disease Control and Prevention, Zhengzhou 450000, China.'}, {'ForeName': 'Xuejun', 'Initials': 'X', 'LastName': 'Gao', 'Affiliation': 'Lanzhou Institute of Biological Products Co Ltd, Lanzhou 730046, China.'}, {'ForeName': 'Tai', 'Initials': 'T', 'LastName': 'Guo', 'Affiliation': 'National Institutes for Food and Drug Control, Beijing 102629, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'National Institutes for Food and Drug Control, Beijing 102629, China. Electronic address: liuyan418@nifdc.org.cn.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'Lanzhou Institute of Biological Products Co Ltd, Lanzhou 730046, China. Electronic address: kathzhou@sina.com.'}, {'ForeName': 'Huan', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China. Electronic address: 13691354049@163.com.'}]",Vaccine,['10.1016/j.vaccine.2020.04.038'] 1403,32451777,Long-term outcomes following intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 5-year treatment arm results from a prospective randomized double-blind sham-controlled multi-center study.,"BACKGROUND Damaged or degenerated vertebral endplates are a significant cause of vertebrogenic chronic low back pain (CLBP). Modic changes are one objective MRI biomarker for these patients. Prior data from the treatment arm of a sham-controlled, RCT showed maintenance of clinical improvements at 2 years following ablation of the basivertebral nerve (BVN). This study reports 5-year clinical outcomes. METHODS In total, 117 US patients were treated successfully with BVN ablation. Patient-reported outcomes of ODI, VAS, postablation treatments, and patient satisfaction were collected at a minimum of 5-years following BVN ablation. Primary outcome was mean change in ODI. Comparisons between the postablation and baseline values were made using an analysis of covariance with alpha 0.05. RESULTS Of the 117 US treated patients 100 (85%) were available for review with a mean follow-up of 6.4 years (5.4-7.8 years). Mean ODI score improved from 42.81 to 16.86 at 5-year follow-up, a reduction of 25.95 points (p < 0.001). Mean reduction in VAS pain score was 4.38 points (baseline of 6.74, p < 0.001). In total, 66% of patients reported a > 50% reduction in pain, 47% reported a > 75% reduction in pain, and 34% of patients reported complete pain resolution. Composite responder rate using thresholds of ≥ 15-point ODI and ≥ 2-point VAS for function and pain at 5 years was 75%. CONCLUSION CLBP patients treated with BVN ablation exhibit sustained clinical improvements in function and pain with high responder rates at a mean of 6.4 years following treatment. BVN ablation is a durable, minimally invasive treatment for vertebrogenic CLBP.",2020,"Mean reduction in VAS pain score was 4.38 points (baseline of 6.74, p < 0.001).","['Of the 117 US treated patients 100\xa0(85%) were available for review with a mean follow-up of 6.4\xa0years (5.4-7.8\xa0years', 'chronic low back pain']","['intraosseous basivertebral nerve ablation', 'BVN ablation']","['mean change in ODI', 'complete pain resolution', 'Mean ODI score', 'function and pain', 'pain', 'Mean reduction in VAS pain score', 'ODI, VAS, postablation treatments, and patient satisfaction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517792', 'cui_str': '5.4'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}]","[{'cui': 'C0595613', 'cui_str': 'Intraosseous route'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}]",117.0,0.243102,"Mean reduction in VAS pain score was 4.38 points (baseline of 6.74, p < 0.001).","[{'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Fischgrund', 'Affiliation': 'William Beaumont Hospital, Oakland University School of Medicine, 3601 W 13 Mile Road, Royal Oak, MI, 48073, USA. jsfischgrund37@gmail.com.'}, {'ForeName': 'Alfred', 'Initials': 'A', 'LastName': 'Rhyne', 'Affiliation': 'OrthoCarolina Spine Center, 2001 Randolph Road, Charlotte, NC, 28207, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Macadaeg', 'Affiliation': 'Indiana Spine Group, 13225 North Meridian Street, Carmel, IN, 46032, USA.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Moore', 'Affiliation': 'Pacific Sports and Spine, 74B Centennial Loop, Suite 300, Eugene, OR, 97401, USA.'}, {'ForeName': 'Evish', 'Initials': 'E', 'LastName': 'Kamrava', 'Affiliation': 'The Spine Institute, 2811 Wilshire Boulevard, Suite 850, Santa Monica, CA, 90403, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Yeung', 'Affiliation': 'Desert Institute for Spine Care, 1635 E Myrtle Avenue, Suite 400, Phoenix, AZ, 85020, USA.'}, {'ForeName': 'Eeric', 'Initials': 'E', 'LastName': 'Truumees', 'Affiliation': 'Seton Spine & Scoliosis Center, 1600 West 38th Street, Suite 200, Austin, TX, 78731, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Schaufele', 'Affiliation': 'Drug Studies America, 400 Tower Road NE, Suite 150, Marietta, GA, 30060, USA.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Yuan', 'Affiliation': 'Memorial Orthopedic Surgical Group, Department of Surgery, Long Beach Memorial Medical Center, 2760 Atlantic Avenue, Long Beach, CA, 90806, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'DePalma', 'Affiliation': 'Virginia iSpine Physicians, 9020 Stony Point Parkway, S-140, Richmond, VA, 23235, USA.'}, {'ForeName': 'David Greg', 'Initials': 'DG', 'LastName': 'Anderson', 'Affiliation': 'Rothman Orthopedic Institute, 3300 Tillman Drive, 2nd Floor, Glenview Corporate Center, Bensalem, PA, 19020, USA.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Buxton', 'Affiliation': 'Maine Medical Partners Neurosurgery and Spine, 195 Fore River Parkway, Suite 490, Portland, ME, 04102, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Reynolds', 'Affiliation': 'Spine Care Medical Group, 455 Hickey Boulevard, Suite 310, Daly City, CA, 94015, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Sikorsky', 'Affiliation': 'Michigan Orthopedic Institute, 26025 Lahser Road, Suite 200B, Southfield, MI, 48033, USA.'}]","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society",['10.1007/s00586-020-06448-x'] 1404,32459129,Consolidation of Reward Memory during Sleep Does Not Require Dopaminergic Activation.,"Sleep enhances memories, especially if they are related to future rewards. Although dopamine has been shown to be a key determinant during reward learning, the role of dopaminergic neurotransmission for amplifying reward-related memories during sleep remains unclear. In this study, we scrutinize the idea that dopamine is needed for the preferential consolidation of rewarded information. We impaired dopaminergic neurotransmission, thereby aiming to wipe out preferential sleep-dependent consolidation of high- over low-rewarded memories during sleep. Following a double-blind, balanced, crossover design, 17 young healthy men received the dopamine d2-like receptor blocker sulpiride (800 mg) or placebo, after learning a motivated learning task. The task required participants to memorize 80 highly and 80 lowly rewarded pictures. Half of them were presented for a short (750 msec) and a long (1500 msec) duration, respectively, which permitted dissociation of the effects of reward on sleep-associated consolidation from those of mere encoding depth. Retrieval was tested after a retention interval of approximately 22 hr that included 8 hr of nocturnal sleep. As expected, at retrieval, highly rewarded memories were remembered better than lowly rewarded memories, under placebo. However, there was no evidence for an effect of reducing dopaminergic neurotransmission with sulpiride during sleep on this differential retention of rewarded information. This result indicates that dopaminergic activation likely is not required for the preferential consolidation of reward-associated memory. Rather, it appears that dopaminergic activation only tags such memories at encoding for intensified reprocessing during sleep.",2020,"As expected, at retrieval, highly rewarded memories were remembered better than lowly rewarded memories, under placebo.",['17 young healthy men'],"['dopamine d2-like receptor blocker sulpiride (800 mg) or placebo', 'dopamine', 'placebo']",[],"[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0038803', 'cui_str': 'Sulpiride'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],17.0,0.110276,"As expected, at retrieval, highly rewarded memories were remembered better than lowly rewarded memories, under placebo.","[{'ForeName': 'Marjan Alizadeh', 'Initials': 'MA', 'LastName': 'Asfestani', 'Affiliation': 'University of Tübingen.'}, {'ForeName': 'Valentin', 'Initials': 'V', 'LastName': 'Brechtmann', 'Affiliation': 'University of Tübingen.'}, {'ForeName': 'João', 'Initials': 'J', 'LastName': 'Santiago', 'Affiliation': 'University of Tübingen.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Peter', 'Affiliation': 'German Center for Diabetes Research (DZD), Tübingen, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Born', 'Affiliation': 'University of Tübingen.'}, {'ForeName': 'Gordon Benedikt', 'Initials': 'GB', 'LastName': 'Feld', 'Affiliation': 'University of Tübingen.'}]",Journal of cognitive neuroscience,['10.1162/jocn_a_01585'] 1405,32454209,"Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention.","Psychedelic drugs, including the serotonin 2a (5-HT 2A ) receptor partial agonist psilocybin, are receiving renewed attention for their possible efficacy in treating a variety of neuropsychiatric disorders. Psilocybin induces widespread dysregulation of cortical activity, but circuit-level mechanisms underlying this effect are unclear. The claustrum is a subcortical nucleus that highly expresses 5-HT 2A receptors and provides glutamatergic inputs to arguably all areas of the cerebral cortex. We therefore tested the hypothesis that psilocybin modulates claustrum function in humans. Fifteen healthy participants (10M, 5F) completed this within-subjects study in which whole-brain resting-state blood-oxygenation level-dependent (BOLD) signal was measured 100 ​min after blinded oral administration of placebo and 10 mg/70 ​kg psilocybin. Left and right claustrum signal was isolated using small region confound correction. Psilocybin significantly decreased both the amplitude of low frequency fluctuations as well as the variance of BOLD signal in the left and right claustrum. Psilocybin also significantly decreased functional connectivity of the right claustrum with auditory and default mode networks (DMN), increased right claustrum connectivity with the fronto-parietal task control network (FPTC), and decreased left claustrum connectivity with the FPTC. DMN integrity was associated with right-claustrum connectivity with the DMN, while FPTC integrity and modularity were associated with right claustrum and left claustrum connectivity with the FPTC, respectively. Subjective effects of psilocybin predicted changes in the amplitude of low frequency fluctuations and the variance of BOLD signal in the left and right claustrum. Observed effects were specific to claustrum, compared to flanking regions of interest (the left and right insula and putamen). This study used a pharmacological intervention to provide the first empirical evidence in any species for a significant role of 5-HT 2A receptor signaling in claustrum functioning, and supports a possible role of the claustrum in the subjective and therapeutic effects of psilocybin.",2020,Psilocybin significantly decreased both the amplitude of low frequency fluctuations as well as the variance of BOLD signal in the left and right claustrum.,"['Fifteen healthy participants (10M, 5F) completed this within-subjects study in which whole-brain resting-state blood-oxygenation level-dependent (BOLD) signal was measured 100\u202fmin after blinded oral administration of', 'humans']","['psilocybin', 'placebo and 10 mg/70\u202fkg psilocybin', 'Psilocybin', 'serotonin 2a (5-HT 2A ) receptor partial agonist psilocybin']","['BOLD signal', 'amplitude of low frequency fluctuations', 'functional connectivity of the right claustrum with auditory and default mode networks (DMN), increased right claustrum connectivity']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0001563', 'cui_str': 'Medication administration: oral'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0033850', 'cui_str': 'Psilocybine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0243192', 'cui_str': 'agonists'}]","[{'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0205213', 'cui_str': 'Low frequency'}, {'cui': 'C0231239', 'cui_str': 'Fluctuation'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0008910', 'cui_str': 'Claustral structure'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",15.0,0.0313229,Psilocybin significantly decreased both the amplitude of low frequency fluctuations as well as the variance of BOLD signal in the left and right claustrum.,"[{'ForeName': 'Frederick S', 'Initials': 'FS', 'LastName': 'Barrett', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA; Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA. Electronic address: fbarrett@jhmi.edu.'}, {'ForeName': 'Samuel R', 'Initials': 'SR', 'LastName': 'Krimmel', 'Affiliation': 'Department of Neural and Pain Sciences, School of Dentistry, and Center to Advance Chronic Pain Research, University of Maryland, Baltimore, MD, 21201, USA.'}, {'ForeName': 'Roland R', 'Initials': 'RR', 'LastName': 'Griffiths', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA; Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA; Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Seminowicz', 'Affiliation': 'Department of Neural and Pain Sciences, School of Dentistry, and Center to Advance Chronic Pain Research, University of Maryland, Baltimore, MD, 21201, USA.'}, {'ForeName': 'Brian N', 'Initials': 'BN', 'LastName': 'Mathur', 'Affiliation': 'Department of Pharmacology, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.'}]",NeuroImage,['10.1016/j.neuroimage.2020.116980'] 1406,32456097,Effects of a Rehabilitation Programme with a Nasal Inspiratory Restriction Device on Exercise Capacity and Quality of Life in COPD.,"OBJECTIVE The objective was to assess the effects of a nasal restriction device for inspiratory muscle training, called Feelbreathe ® , added to a rehabilitation program (RP) on exercise capacity, quality of life, dyspnea and inspiratory muscle strength in patients with stable COPD. METHODS Patients were randomized into three groups, one performed a supervised RP using the Feelbreathe ® device (FB group), the second group developed the same RP with oronasal breathing without FB (ONB group) and the third was the control group (CG). We evaluated inspiratory muscle strength (P Imax ), dyspnea (mMRC), quality of life (CAT) and exercise capacity (6MWT) before and after 8-week of RP. RESULTS A total of 16 patients completed the study, seven in FB group, five in ONB group and four in the CG. After the RP, the FB group showed a significant increase in P Imax (93.3 ± 19.1 vs. 123.0 ± 15.8 mmHg) and in the 6MWT distance (462.9 ± 71.8m vs. 529.1 ± 50.1 m) and a decrease in the CAT score (9.7 ± 6.5 vs. 5.9 ± 6.0) and in the mMRC dyspnea score. FB provides greater improvement in P Imax , dyspnea, quality of life and 6MWT than ONB. CONCLUSIONS The Feelbreathe ® device provides greater improvements in quality of life, dyspnea, exercise capacity and inspiratory muscle strength compared to patients that did not use it.",2020,"The Feelbreathe ® device provides greater improvements in quality of life, dyspnea, exercise capacity and inspiratory muscle strength compared to patients that did not use it.","['16 patients completed the study, seven in FB group, five in ONB group and four in the CG', 'patients with stable COPD', 'Patients']","['nasal restriction device for inspiratory muscle training, called Feelbreathe ® , added to a rehabilitation program (RP', 'Rehabilitation Programme with a Nasal Inspiratory Restriction Device', 'supervised RP using the Feelbreathe ® device (FB group), the second group developed the same RP with oronasal breathing without FB (ONB group) and the third was the control group (CG']","['CAT score', 'P Imax , dyspnea, quality of life and 6MWT', 'quality of life, dyspnea, exercise capacity and inspiratory muscle strength', 'Exercise Capacity and Quality of Life in COPD', 'mMRC dyspnea score', 'exercise capacity, quality of life, dyspnea and inspiratory muscle strength', 'P Imax', 'inspiratory muscle strength (P Imax ), dyspnea (mMRC), quality of life (CAT) and exercise capacity (6MWT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}]","[{'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0454511', 'cui_str': 'Inspiratory muscle training'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0007366', 'cui_str': 'Catalan language'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}]",16.0,0.0239412,"The Feelbreathe ® device provides greater improvements in quality of life, dyspnea, exercise capacity and inspiratory muscle strength compared to patients that did not use it.","[{'ForeName': 'Aurelio', 'Initials': 'A', 'LastName': 'Arnedillo', 'Affiliation': 'Pneumology, Allergy and Thoracic Surgery Department, University Hospital Puerta del Mar, 11009 Cádiz, Spain.'}, {'ForeName': 'Jose L', 'Initials': 'JL', 'LastName': 'Gonzalez-Montesinos', 'Affiliation': 'GALENO Research Group, Department of Physical Education, Faculty of Education Sciences, University of Cádiz, 11003 Puerto Real, Spain.'}, {'ForeName': 'Jorge R', 'Initials': 'JR', 'LastName': 'Fernandez-Santos', 'Affiliation': 'GALENO Research Group, Department of Physical Education, Faculty of Education Sciences, University of Cádiz, 11003 Puerto Real, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Vaz-Pardal', 'Affiliation': 'Bahía Sur Andalusian Center for Sports Medicine, 11100 Cádiz, Spain.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'España-Domínguez', 'Affiliation': 'Pneumology, Allergy and Thoracic Surgery Department, University Hospital Puerta del Mar, 11009 Cádiz, Spain.'}, {'ForeName': 'Jesús G', 'Initials': 'JG', 'LastName': 'Ponce-González', 'Affiliation': 'Biomedical Research and Innovation Institute of Cádiz (INiBICA) Research Unit, Puerta del Mar University Hospital University of Cádiz, 11009 Cádiz, Spain.'}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Cuenca-García', 'Affiliation': 'GALENO Research Group, Department of Physical Education, Faculty of Education Sciences, University of Cádiz, 11003 Puerto Real, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17103669'] 1407,32456170,Acute Effects of a Short Bout of Physical Activity on Cognitive Function in Sport Students.,"Physical activity is a promising intervention to restore cognitive function after prolonged sedentary periods. However, little is known about the effect of short physical activity bouts on cognition especially among individuals that are used to physical activity. Therefore, the goal of the present study was to assess the impact of a single ten-minute physical activity bout on the cognitive domain of visual attention compared to sedentary behavior in a population of physically active sport students. Using a randomized controlled design, 51 healthy and physically active sport students [mean age: 22.3 (SD: 2.0) years, 33.3% female] were allocated to one of the following interventions in the break of a two-hour study course: physical activity group (running for ten minutes) and sedentary control group. Visual attention was measured post-intervention using a modified trail making test. Pre-, post-, and 30 min after intervention, perceived attention, and affective states were measured. Between-group comparisons were used to analyze whether visual attention and/or changes in perceived attention or affective states differed between groups. The physical activity group showed significantly higher visual attention post-intervention compared with the sedentary control group, p = 0.003, d = 0.89. Perceived attention, p = 0.006, d = 0.87, and arousal, p < 0.001, d = 1.68, showed a significantly larger pre- and post-intervention increase in the physical activity group compared with the sedentary control group, which was not evident 30 min after intervention. A single ten-minute running intervention in study breaks might help to restore the basal visual attentional domain of cognition after prolonged sedentary periods more effectively compared with common sedentary behavior in breaks between study lessons.",2020,"The physical activity group showed significantly higher visual attention post-intervention compared with the sedentary control group, ","['population of physically active sport students', 'Sport Students', '51 healthy and physically active sport students [mean age: 22.3 (SD: 2.0) years, 33.3% female']","['physical activity group (running for ten minutes) and sedentary control group', 'Short Bout of Physical Activity']","['visual attention and/or changes in perceived attention or affective states', 'basal visual attentional domain of cognition', 'visual attention', 'perceived attention, and affective states', 'Cognitive Function', 'Visual attention']","[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0556453', 'cui_str': 'Physically active'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517716', 'cui_str': '33.3'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}]","[{'cui': 'C0589102', 'cui_str': 'Visual attention'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",51.0,0.061781,"The physical activity group showed significantly higher visual attention post-intervention compared with the sedentary control group, ","[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Niedermeier', 'Affiliation': 'Department of Sport Science, University of Innsbruck, 6020 Innsbruck, Austria.'}, {'ForeName': 'Elisabeth M', 'Initials': 'EM', 'LastName': 'Weiss', 'Affiliation': 'Department of Psychology, University of Innsbruck, 6020 Innsbruck, Austria.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Steidl-Müller', 'Affiliation': 'Department of Sport Science, University of Innsbruck, 6020 Innsbruck, Austria.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Burtscher', 'Affiliation': 'Department of Sport Science, University of Innsbruck, 6020 Innsbruck, Austria.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Kopp', 'Affiliation': 'Department of Sport Science, University of Innsbruck, 6020 Innsbruck, Austria.'}]",International journal of environmental research and public health,['10.3390/ijerph17103678'] 1408,32459597,Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.,"PURPOSE Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) demonstrated survival benefit versus bevacizumab, carboplatin, and paclitaxel (BCP) in chemotherapy-naïve nonsquamous non-small-cell lung cancer (NSCLC). We present safety and patient-reported outcomes (PROs) to provide additional information on the relative impact of adding atezolizumab to chemotherapy with and without bevacizumab in nonsquamous NSCLC. METHODS Patients were randomly assigned to receive atezolizumab, carboplatin, and paclitaxel (ACP), ABCP, or BCP. Coprimary end points were overall survival and investigator-assessed progression-free survival. The incidence, nature, and severity of adverse events (AEs) were assessed. PROs, a secondary end point, were evaluated using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Core 30 and EORTC QLQ-Lung Cancer 13. RESULTS Overall, 400 (ACP), 393 (ABCP), and 394 (BCP) patients were safety evaluable (ie, intention-to-treat population that received one or more doses of any study treatment). More patients had grade 3/4 treatment-related AEs during the induction versus maintenance phase (ACP, 40.5% v 8.2%; ABCP, 48.6% v 21.2%; BCP, 44.7% v 11.1%). During induction, the incidence of serious AEs (SAEs) was 28.3%, 28.5%, and 26.4% in the ACP, ABCP, and BCP arms, respectively. During maintenance, SAE incidences were 20.0%, 26.3%, and 13.0%, respectively. Completion rates of the PRO questionnaires were > 88% at baseline and remained ≥ 70% throughout most study visits. Across arms, patients on average reported no clinically meaningful worsening of global health status or physical functioning scores through cycle 13. Patients across arms rated common symptoms with chemotherapy and immunotherapy similarly. CONCLUSION ABCP seems tolerable and manageable versus ACP and BCP in first-line nonsquamous NSCLC. Treatment tolerability differed between induction and maintenance phases across treatment arms. PROs reflect a minimal treatment burden (eg, health-related quality of life, symptoms) with each regimen.",2020,"During induction, the incidence of serious AEs (SAEs) was 28.3%, 28.5%, and 26.4% in the ACP, ABCP, and BCP arms, respectively.","['Non-Small-Cell Lung Cancer', 'chemotherapy-naïve nonsquamous non-small-cell lung cancer (NSCLC', 'Patients']","['Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy', 'Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP', 'atezolizumab to chemotherapy with and without bevacizumab', 'ABCP', 'bevacizumab, carboplatin, and paclitaxel (BCP', 'atezolizumab, carboplatin, and paclitaxel (ACP), ABCP, or BCP']","['incidence of serious AEs (SAEs', 'Completion rates of the PRO questionnaires', 'European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Core 30 and EORTC QLQ-Lung Cancer 13', 'global health status or physical functioning scores', 'incidence, nature, and severity of adverse events (AEs', 'overall survival and investigator-assessed progression-free survival', 'Treatment tolerability']","[{'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4055433', 'cui_str': 'atezolizumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451149', 'cui_str': 'EORTC - Quality of life questionnaire'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0349590', 'cui_str': 'Nature'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",,0.253518,"During induction, the incidence of serious AEs (SAEs) was 28.3%, 28.5%, and 26.4% in the ACP, ABCP, and BCP arms, respectively.","[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Reck', 'Affiliation': 'Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Wehler', 'Affiliation': 'Evangelisches Krankenhaus Hamm gGmbH, Hamm, Germany.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Orlandi', 'Affiliation': 'Instituto Nacional del Tórax, Santiago, Chile.'}, {'ForeName': 'Naoyuki', 'Initials': 'N', 'LastName': 'Nogami', 'Affiliation': 'National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Barone', 'Affiliation': 'Università Cattolica del Sacro Cuore, Rome, Italy.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Moro-Sibilot', 'Affiliation': 'Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Mikhail', 'Initials': 'M', 'LastName': 'Shtivelband', 'Affiliation': 'Ironwood Cancer & Research Center, Chandler, AZ.'}, {'ForeName': 'Jose Luis', 'Initials': 'JL', 'LastName': 'González Larriba', 'Affiliation': 'Hospital Clínico San Carlos, Madrid, Spain.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Rothenstein', 'Affiliation': 'Durham Regional Cancer Center, Lakeridge Health, Oshawa, Ontario, Canada.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Früh', 'Affiliation': 'Cantonal Hospital of St Gallen, St Gallen, Switzerland.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Yu', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Deng', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Shelley', 'Initials': 'S', 'LastName': 'Coleman', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Geetha', 'Initials': 'G', 'LastName': 'Shankar', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Hina', 'Initials': 'H', 'LastName': 'Patel', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Kelsch', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Lee', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Piault', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Socinski', 'Affiliation': 'AdventHealth Cancer Institute, Orlando, FL.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.03158'] 1409,32459631,Mobile Delivery of the Diabetes Prevention Program in People With Prediabetes: Randomized Controlled Trial.,"BACKGROUND The Centers for Disease Control and Prevention (CDC) diabetes prevention program (DPP) has formed the foundation for Type 2 Diabetes Mellitus (T2DM) prevention efforts and lifestyle change modifications in multiple care settings. To our knowledge, no randomized controlled trial has verified the efficacy of a fully mobile version of CDC's diabetes prevention program (DPP). OBJECTIVE This study aimed to investigate the long-term weight loss and glycemic efficacy of a mobile-delivered DPP compared with a control group receiving usual medical care. METHODS Adults with prediabetes (N=202) were recruited from a clinic and randomized to either a mobile-delivered, coach-guided DPP (Noom) or a control group that received regular medical care including a paper-based DPP curriculum and no formal intervention. The intervention group learned how to use the Noom program, how to interact with their coach, and the importance of maintaining motivation. They had access to an interactive coach-to-participant interface and group messaging, daily challenges for behavior change, DPP-based education articles, food logging, and automated feedback. Primary outcomes included changes in weight and hemoglobin A 1c (HbA 1c ) levels at 6 and 12 months, respectively. Exploratory secondary outcomes included program engagement as a predictor of changes in weight and HbA 1c levels. RESULTS A total of 202 participants were recruited and randomized into the intervention (n=101) or control group (n=99). In the intention-to-treat (ITT) analyses, changes in the participants' weight and BMI were significantly different at 6 months between the intervention and control groups, but there was no difference in HbA 1c levels (mean difference 0.004%, SE 0.05; P=.94). Weight and BMI were lower in the intervention group by -2.64 kg (SE 0.71; P<.001) and -0.99 kg/m2 (SE 0.29; P=.001), respectively. These differences persisted at 12 months. However, in the analyses that did not involve ITT, program completers achieved a significant weight loss of 5.6% (SE 0.81; P<.001) at 6 months, maintaining 4.7% (SE 0.88; P<.001) of their weight loss at 12 months. The control group lost -0.15% at 6 months (SE 0.64; P=.85) and gained 0.33% (SE 0.70; P=.63) at 12 months. Those randomized to the intervention group who did not start the program had no meaningful weight or HbA 1c level change, similar to the control group. At 1 year, the intervention group showed a 0.23% reduction in HbA 1c levels; those who completed the intervention showed a 0.28% reduction. Those assigned to the control group had a 0.16% reduction in HbA 1c levels. CONCLUSIONS This novel mobile-delivered DPP achieved significant weight loss reductions for up to 1 year compared with usual care. This type of intervention reduces the risk of overt diabetes without the added barriers of in-person interventions. TRIAL REGISTRATION ClinicalTrials.gov NCT03865342; https://clinicaltrials.gov/ct2/show/NCT03865342.",2020,The control group lost -0.15% at 6 months (SE 0.64; P=.85) and gained 0.33% (SE 0.70; P=.63) at 12 months.,"['People with Pre-diabetes', '202 participants were recruited and randomized into the intervention (n=101) or control group (n=99', 'Adults with prediabetes (N=202']","['control group receiving usual medical care', 'mobile-delivered, coach-guided DPP or to a control group that received regular medical care including a paper-based DPP curriculum and no formal intervention', 'Mobile Delivery of the Diabetes Prevention Program', 'mobile-delivered DPP']","['risk of overt diabetes', 'HbA1c', 'program engagement as a predictor of changes in weight and HbA1c', 'weight loss', 'weight and BMI', 'weight loss reductions', 'glycemic efficacy', 'changes in weight and hemoglobin A1c (HbA1c']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0496675', 'cui_str': 'Medical care'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030351', 'cui_str': 'Paper'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",202.0,0.118825,The control group lost -0.15% at 6 months (SE 0.64; P=.85) and gained 0.33% (SE 0.70; P=.63) at 12 months.,"[{'ForeName': 'Tatiana', 'Initials': 'T', 'LastName': 'Toro-Ramos', 'Affiliation': 'Noom, Inc, New York, NY, United States.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Michaelides', 'Affiliation': 'Noom, Inc, New York, NY, United States.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Anton', 'Affiliation': 'Department of Medicine, Division of Endocrinology & Metabolism, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, United States.'}, {'ForeName': 'Zulekha', 'Initials': 'Z', 'LastName': 'Karim', 'Affiliation': 'Department of Medicine, Division of Endocrinology & Metabolism, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, United States.'}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Kang-Oh', 'Affiliation': 'Department of Medicine, Division of Endocrinology & Metabolism, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, United States.'}, {'ForeName': 'Charalambos', 'Initials': 'C', 'LastName': 'Argyrou', 'Affiliation': 'Department of Medicine, Division of Endocrinology & Metabolism, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, United States.'}, {'ForeName': 'Elisavet', 'Initials': 'E', 'LastName': 'Loukaidou', 'Affiliation': 'Department of Medicine, Division of Endocrinology & Metabolism, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, United States.'}, {'ForeName': 'Marina M', 'Initials': 'MM', 'LastName': 'Charitou', 'Affiliation': 'Department of Medicine, Division of Endocrinology & Metabolism, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, United States.'}, {'ForeName': 'Wilson', 'Initials': 'W', 'LastName': 'Sze', 'Affiliation': 'Department of Medicine, Division of Endocrinology & Metabolism, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, United States.'}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Miller', 'Affiliation': 'Department of Medicine, Division of Endocrinology & Metabolism, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, United States.'}]",JMIR mHealth and uHealth,['10.2196/17842'] 1410,32481236,Acute responses of bone specific and related markers to maximal eccentric exercise of the knee extensors and flexors in young men.,"OBJECTIVES The present study determined time-course changes in plasma bone-specific and -related markers following a bout of maximal eccentric contractions (MaxEC) of bilateral knee extensors (KE) and flexors (KF). METHODS Sedentary young men (n=30) performed a bout of 10 sets of 10 MaxEC (30°/s) of KE and KF with each leg, respectively. Maximal voluntary isometric contraction (MVC) torque, muscle soreness (SOR), plasma creatine kinase (CK) activity, insulin, leptin, tumor necrosis factor-α (TNF-α), undercarboxylated-osteocalcin (ucOCN), carboxy-terminal crosslinking telopeptide of type I collagen (CTX-1) and procollagen type I N-terminal propeptide (P1NP) concentrations were measured from before to 7 days after MaxEC. RESULTS Significant changes in MVC (KE: -28%, KF: -38%), SOR and plasma CK activity (peak: 39,163 IU/L) following MaxEC were evident (P<0.05) compared to baseline. Plasma leptin (17%) concentrations decreased at 1 day after MaxEC. In bone related markers, plasma ucOCN concentrations (20%) increased at 7 days after MaxEC, and plasma CTX-1 concentrations decreased at 2, 4 and 7 days after MaxEC (6~7%; P<0.05). CONCLUSION These results demonstrate that a lean effect of bone generation and an enhanced energy anabolism can be induced by a single bout of MaxEC.",2020,"concentrations decreased at 2, 4 and 7 days after MaxEC (6~7%; P<0.05). ","['Sedentary young men (n=30', 'young men']","['bone specific and related markers to maximal eccentric exercise', 'bilateral knee extensors (KE) and flexors (KF', 'I collagen (CTX-1) and procollagen type', 'maximal eccentric contractions (MaxEC']","['concentrations', 'plasma ucOCN concentrations', 'plasma CTX-1', 'Plasma leptin (17%) concentrations', 'Maximal voluntary isometric contraction (MVC) torque, muscle soreness (SOR), plasma creatine kinase (CK) activity, insulin, leptin, tumor necrosis factor-α (TNF-α), undercarboxylated-osteocalcin (ucOCN), carboxy-terminal crosslinking telopeptide of type', 'P1NP) concentrations', 'SOR and plasma CK activity']","[{'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0010377', 'cui_str': 'Crotoxin'}, {'cui': 'C0033235', 'cui_str': 'Procollagen'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0029419', 'cui_str': 'Osteocalcin'}, {'cui': 'C0010377', 'cui_str': 'Crotoxin'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0022205', 'cui_str': 'Muscle isometric contraction'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0858114', 'cui_str': 'Plasma creatine'}, {'cui': 'C0031727', 'cui_str': 'Kinase'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0072053', 'cui_str': 'Procollagen peptide, type 1 N-terminal'}, {'cui': 'C0234233', 'cui_str': 'Soreness'}]",,0.0699251,"concentrations decreased at 2, 4 and 7 days after MaxEC (6~7%; P<0.05). ","[{'ForeName': 'Tsang-Hai', 'Initials': 'TH', 'LastName': 'Huang', 'Affiliation': 'Institute of Physical Education, Health and Leisure Studies, National Cheng Kung University, Tainan City, Taiwan.'}, {'ForeName': 'Jung-Charng', 'Initials': 'JC', 'LastName': 'Lin', 'Affiliation': 'Department of Physical Education, Chinese Culture University, Taipei City, Taiwan.'}, {'ForeName': 'Mi-Chia', 'Initials': 'MC', 'LastName': 'Ma', 'Affiliation': 'Department of Statistics, National Cheng Kung University, Tainan City, Taiwan.'}, {'ForeName': 'Tsung', 'Initials': 'T', 'LastName': 'Yu', 'Affiliation': 'Department of Public Health College of Medicine, National Cheng Kung University, Tainan City, Taiwan.'}, {'ForeName': 'Trevor C', 'Initials': 'TC', 'LastName': 'Chen', 'Affiliation': 'Department of Physical Education, National Taiwan Normal University, Taipei City, Taiwan.'}]",Journal of musculoskeletal & neuronal interactions,[] 1411,32488427,Physiologically Based Dissolution Testing in a Drug Development Process-a Case Study of a Successful Application in a Bioequivalence Study of Trazodone ER Formulations Under Fed Conditions.,"Development of generic extended-release (ER) formulations is challenging. Especially under fed conditions, the risk of failure in bioequivalence trials is high because of long gastric residence times and susceptibility to food effects. We describe the development of a generic trazodone ER formulation that was aided with a biorelevant dissolution evaluation. Trazodone hydrochloride 300-mg monolithic matrix tablets were dissolved both in USP and EMA compliant conditions and in the StressTest device that simulated both physicochemical and mechanical conditions of the gastrointestinal passage. The final formulation was tested against the originator, Trittico XR 300 mg, in a randomized cross-over bioequivalence trial with 44 healthy volunteers, in agreement with EMA guidelines. Initially developed formulations dissolved trazodone similarly to the originator under standard conditions (f 2 factor above 50), but their dissolution kinetics differed significantly in the biorelevant tests. The formulation was optimized by the addition of low-viscosity hypromellose and mannitol. The final formulation was approved for the bioequivalence trial. Calculated C max were 1.92 ± 0.77 and 1.92 ± 0.63 [μg/mL], AUC 0-t were 27.46 ± 8.39 and 29.96 ± 9.09 [μg∙h/mL], and AUC 0-∞ were 28.22 ± 8.91 and 30.82 ± 9.41 [μg∙h/mL] for the originator and test formulations, respectively. The 90% confidence intervals of all primary pharmacokinetic parameters fell within the 80-125% range. In summary, biorelevant dissolution tests supported successful development of a generic trazodone ER formulation pharmaceutically equivalent with the originator under fed conditions. Employment of biorelevant dissolution tests may decrease the risk of failure in bioequivalence trials of ER formulations.",2020,"Initially developed formulations dissolved trazodone similarly to the originator under standard conditions (f 2 factor above 50), but their dissolution kinetics differed significantly in the biorelevant tests.",['44 healthy volunteers'],"['trazodone', 'generic trazodone ER formulation', 'Trazodone ER Formulations', 'Trazodone hydrochloride', 'low-viscosity hypromellose and mannitol']",['dissolution kinetics'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0040805', 'cui_str': 'Trazodone'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0282369', 'cui_str': 'Trazodone hydrochloride'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0042784', 'cui_str': 'Viscosity'}, {'cui': 'C0063242', 'cui_str': 'hypromellose'}, {'cui': 'C0024730', 'cui_str': 'Mannitol'}]","[{'cui': 'C0022702', 'cui_str': 'Kinetics'}]",44.0,0.107498,"Initially developed formulations dissolved trazodone similarly to the originator under standard conditions (f 2 factor above 50), but their dissolution kinetics differed significantly in the biorelevant tests.","[{'ForeName': 'Dorota', 'Initials': 'D', 'LastName': 'Danielak', 'Affiliation': 'Department of Physical Pharmacy and Pharmacokinetics, Faculty of Pharmacy, Poznan University of Medical Sciences, 6 Święcickiego st, 60-781, Poznań, Poland. danielak@ump.edu.pl.'}, {'ForeName': 'Bartłomiej', 'Initials': 'B', 'LastName': 'Milanowski', 'Affiliation': 'Department of Pharmaceutical Technology, Faculty of Pharmacy, Poznan University of Medical Sciences, 6 Grunwaldzka st, 60-780, Poznań, Poland.'}, {'ForeName': 'Krzysztof', 'Initials': 'K', 'LastName': 'Wentowski', 'Affiliation': 'Biofarm Sp. z o.o, 13 Wałbrzyska st, 60-198, Poznań, Poland.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Nogowska', 'Affiliation': 'Biofarm Sp. z o.o, 13 Wałbrzyska st, 60-198, Poznań, Poland.'}, {'ForeName': 'Michał', 'Initials': 'M', 'LastName': 'Kątny', 'Affiliation': 'Biofarm Sp. z o.o, 13 Wałbrzyska st, 60-198, Poznań, Poland.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Rogowski', 'Affiliation': 'Biofarm Sp. z o.o, 13 Wałbrzyska st, 60-198, Poznań, Poland.'}, {'ForeName': 'Łukasz', 'Initials': 'Ł', 'LastName': 'Konwicki', 'Affiliation': 'Biofarm Sp. z o.o, 13 Wałbrzyska st, 60-198, Poznań, Poland.'}, {'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Puk', 'Affiliation': 'Biofarm Sp. z o.o, 13 Wałbrzyska st, 60-198, Poznań, Poland.'}, {'ForeName': 'Jarosław', 'Initials': 'J', 'LastName': 'Pieczuro', 'Affiliation': 'Biofarm Sp. z o.o, 13 Wałbrzyska st, 60-198, Poznań, Poland.'}, {'ForeName': 'Marek', 'Initials': 'M', 'LastName': 'Bawiec', 'Affiliation': 'Institute of Computer Engineering, Control and Robotics, Wroclaw University of Technology, 27 Wybrzeże Wyspańskiego st, 50-370, Wrocław, Poland.'}, {'ForeName': 'Grzegorz', 'Initials': 'G', 'LastName': 'Garbacz', 'Affiliation': 'Physiolution GmbH, Walther-Rathenau Strasse 49a, 17489, Greifswald, Germany.'}, {'ForeName': 'Janina', 'Initials': 'J', 'LastName': 'Lulek', 'Affiliation': 'Department of Pharmaceutical Technology, Faculty of Pharmacy, Poznan University of Medical Sciences, 6 Grunwaldzka st, 60-780, Poznań, Poland.'}]",AAPS PharmSciTech,['10.1208/s12249-020-01662-8'] 1412,32453168,Dislocation rates of perineural catheters placed either perpendicular or parallel to the femoral nerve: A randomised controlled trial.,"BACKGROUND Ultrasound has increased the efficacy of femoral nerve catheters but their postoperative dislocation still remains a common problem. Although catheter placement parallel to the nerve seems to reduce dislocation rates in other nerves and plexuses, the possible advantage for femoral nerve catheter placement remains unclear. OBJECTIVE To compare the dislocation rates of femoral catheters when placed perpendicular or parallel to the femoral nerve. DESIGN Randomised controlled study. SETTING University orthopaedic hospital. Duration of study: October 2018 to June 2019. PATIENTS Eighty patients scheduled for major knee surgery with femoral catheter were enrolled and randomly allocated in two groups. Data from 78 patients could be analysed. INTERVENTIONS The femoral nerve catheters was placed perpendicular to the nerve in Group 1 (n=40), whereas in Group 2 (n=38) parallel to it. For Group 1 the short-axis view of the nerve and an in-plane puncture was used. For Group 2 we used the short-axis view of the nerve and an out-of-plane puncture technique combined with rotation of the transducer to the long-axis view with the needle in-plane. MAIN OUTCOME MEASURES Primary outcome was the catheter dislocation rate in the first 48 h. Secondary outcomes were pain scores and sensory blockade. RESULTS There was no statistically significant difference between the two techniques regarding dislocation of the catheters at 24 or 48 h (at 48 h, Group 1: 15%, Group 2: 2.6%, P = 0.109). Also pain scores, sensory blockade and rescue doses of ropivacaine did not differ between the groups. However, in Group 2 the technique took longer. CONCLUSION Rotating the ultrasound probe to the long-axis in-plane view enabled examination of the catheter position when it was placed parallel to the nerve. The parallel placement of the catheter required more time, but did not significantly improve dislocation rate, pain scores or sensory blockade. TRIAL REGISTRATION Clinicaltrials.gov identifier: NCT03693755.",2020,"The parallel placement of the catheter required more time, but did not significantly improve dislocation rate, pain scores or sensory blockade. ","['University orthopaedic hospital', '78 patients could be analysed', 'Eighty patients scheduled for major knee surgery with femoral catheter', 'Duration of study: October 2018 to June 2019']","['perineural catheters placed either perpendicular or parallel to the femoral nerve', 'ropivacaine', 'plane puncture technique combined with rotation of the transducer to the long-axis view with the needle in-plane']","['Dislocation rates', 'dislocation of the catheters', 'pain scores and sensory blockade', 'catheter dislocation rate', 'dislocation rates', 'pain scores, sensory blockade and rescue doses', 'dislocation rate, pain scores or sensory blockade', 'dislocation rates of femoral catheters']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0187769', 'cui_str': 'Operative procedure on knee'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C1518982', 'cui_str': 'Perineural route'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C1295725', 'cui_str': 'Perpendicular axis'}, {'cui': 'C0015808', 'cui_str': 'Structure of femoral nerve'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0040661', 'cui_str': 'Transducer'}, {'cui': 'C0522487', 'cui_str': 'Long axis'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}]","[{'cui': 'C0012691', 'cui_str': 'Dislocation'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0332206', 'cui_str': 'Blocking'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}]",80.0,0.154648,"The parallel placement of the catheter required more time, but did not significantly improve dislocation rate, pain scores or sensory blockade. ","[{'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Kalimeris', 'Affiliation': ''}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Rupnik', 'Affiliation': ''}, {'ForeName': 'Kathrin', 'Initials': 'K', 'LastName': 'Allenspach', 'Affiliation': ''}, {'ForeName': 'Sandro F', 'Initials': 'SF', 'LastName': 'Fucentese', 'Affiliation': ''}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Götschi', 'Affiliation': ''}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Aguirre', 'Affiliation': ''}, {'ForeName': 'Urs', 'Initials': 'U', 'LastName': 'Eichenberger', 'Affiliation': ''}]",European journal of anaesthesiology,['10.1097/EJA.0000000000001237'] 1413,32450102,Prevalence of microvascular and macrovascular disease in the Glycemia Reduction Approaches in Diabetes - A Comparative Effectiveness (GRADE) Study cohort.,"AIMS The Glycemia Reduction Approaches in Diabetes - A Comparative Effectiveness (GRADE) trial is a randomized clinical trial comparing glycemic effects of four diabetes medications added to metformin in type 2 diabetes (T2D). Microvascular and macrovascular diseases are secondary outcomes. We evaluated the prevalence and risk factor relationships for microvascular and macrovascular complications in the GRADE cohort at study entry. METHODS Complication prevalence and risk factors were analyzed based on data from screening in all consenting participants meeting GRADE eligibility. Logistic regression and Z-statistics were used to assess risk factor relationships with complications. RESULTS We enrolled 5047 T2D participants [mean age 57 years; 36% female; mean known T2D duration 4 years (all < 10 years); mean HbA1c 8.0% (∼64 mmol/mol) at screening]. Urinary albumin/creatinine ratio (ACR) ≥ 30 mg/gram was present in 15.9% participants; peripheral neuropathy (by Michigan Neuropathy Screening Instrument) in 21.5%; cardiovascular autonomic neuropathy by electrocardiography-derived indices in 9.7%; self-reported retinopathy in 1.0%. Myocardial infarction ascertained by self-report or electrocardiogram was present in 7.3%, and self-reported history of stroke in 2.0%. CONCLUSIONS In the GRADE cohort with < 10 years of T2D and a mean HbA1c of 8.0%, diabetes complications were present in a substantial fraction of participants, more so than might otherwise have been expected.",2020,Urinary albumin/creatinine ratio (ACR) ≥30 mg/gram was present in 15.9% participants; peripheral neuropathy (by Michigan Neuropathy Screening Instrument) in 21.5%; cardiovascular autonomic neuropathy by electrocardiography-derived indices in 9.7%; self-reported retinopathy in 1.0%.,"['5047 T2D participants [mean age 57 years; 36% female; mean knownT2D duration 4 years (all<10 years); mean', 'Diabetes ', 'type 2 diabetes (T2D']",['metformin'],"['peripheral neuropathy', 'diabetes complications', 'Myocardial infarction ascertained by self-report or electrocardiogram', 'Urinary albumin/creatinine ratio (ACR) ≥30 mg/gram', 'cardiovascular autonomic neuropathy']","[{'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}, {'cui': 'C0342257', 'cui_str': 'Diabetic complication'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0486293', 'cui_str': 'Albumin/creatinine ratio measurement'}, {'cui': 'C0439208', 'cui_str': 'g'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0259749', 'cui_str': 'Autonomic neuropathy'}]",5047.0,0.0726804,Urinary albumin/creatinine ratio (ACR) ≥30 mg/gram was present in 15.9% participants; peripheral neuropathy (by Michigan Neuropathy Screening Instrument) in 21.5%; cardiovascular autonomic neuropathy by electrocardiography-derived indices in 9.7%; self-reported retinopathy in 1.0%.,"[{'ForeName': 'Kieren J', 'Initials': 'KJ', 'LastName': 'Mather', 'Affiliation': 'Division of Endocrinology & Metabolism, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.'}, {'ForeName': 'Ionut', 'Initials': 'I', 'LastName': 'Bebu', 'Affiliation': 'The Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD, United States. Electronic address: grademail@bsc.gwu.edu.'}, {'ForeName': 'Chelsea', 'Initials': 'C', 'LastName': 'Baker', 'Affiliation': 'Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, United States.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Cohen', 'Affiliation': 'Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, University of Cincinnati College of Medicine & Endocrine Section, Cincinnati VA Medical Center, Cincinnati OH, United States.'}, {'ForeName': 'Jill P', 'Initials': 'JP', 'LastName': 'Crandall', 'Affiliation': 'Division of Endocrinology and Fleischer Institute for Diabetes & Metabolism, Albert Einstein College of Medicine, Bronx, NY, United States.'}, {'ForeName': 'Cyrus', 'Initials': 'C', 'LastName': 'DeSouza', 'Affiliation': 'Division of Diabetes, Endocrinology & Metabolism, University of Nebraska College of Medicine, Omaha, NE, United States.'}, {'ForeName': 'Jennifer B', 'Initials': 'JB', 'LastName': 'Green', 'Affiliation': 'Division of Endocrinology, Department of Medicine, Duke University Medical Center, Durham, NC, United States.'}, {'ForeName': 'M Sue', 'Initials': 'MS', 'LastName': 'Kirkman', 'Affiliation': 'Division of Endocrinology & Metabolism, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, United States.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Krause-Steinrauf', 'Affiliation': 'The Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD, United States.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Larkin', 'Affiliation': 'Massachusetts General Hospital Diabetes Center and Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Pettus', 'Affiliation': 'Division of Endocrinology & Metabolism, Department of Medicine, University of California, San Diego, CA, United States.'}, {'ForeName': 'Elizabeth R', 'Initials': 'ER', 'LastName': 'Seaquist', 'Affiliation': 'Division of Diabetes and Endocrinology, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, United States.'}, {'ForeName': 'Elsayed Z', 'Initials': 'EZ', 'LastName': 'Soliman', 'Affiliation': 'Epidemiological Cardiology Research Center, Department of Epidemiology and Prevention and Department of Internal Medicine-Cardiology Section, Wake Forest School of Medicine, Winston Salem, NC, United States.'}, {'ForeName': 'Emily B', 'Initials': 'EB', 'LastName': 'Schroeder', 'Affiliation': 'Institute for Health Research, Kaiser Permanente Colorado, Aurora, CO, United States.'}, {'ForeName': 'Deborah J', 'Initials': 'DJ', 'LastName': 'Wexler', 'Affiliation': 'Massachusetts General Hospital Diabetes Center and Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Rodica', 'Initials': 'R', 'LastName': 'Pop-Busui', 'Affiliation': 'Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes research and clinical practice,['10.1016/j.diabres.2020.108235'] 1414,32450914,"Update to the AWED (Applying Wolbachia to Eliminate Dengue) trial study protocol: a cluster randomised controlled trial in Yogyakarta, Indonesia.","BACKGROUND The AWED (Applying Wolbachia to Eliminate Dengue) trial is a parallel, two-arm, non-blinded cluster randomised controlled trial that is under way in Yogyakarta, Indonesia, with the aim of measuring the efficacy of Wolbachia-infected Aedes aegypti deployments in reducing dengue incidence in an endemic setting. Enrolment began in January 2018 and is ongoing. The original study protocol was published in April 2018. Here, we describe amendments that have been made to the study protocol since commencement of the trial. METHODS The key protocol amendments are (1) a revised study duration with planned end of participant enrolment in August 2020, (2) the addition of new secondary objectives (i) to estimate serotype-specific efficacy of the Wolbachia intervention and (ii) to compare Ae. aegypti abundance in intervention versus untreated clusters, (3) an additional exposure classification for the per-protocol analysis where the Wolbachia exposure index is calculated using only the cluster-level Wolbachia prevalence in the participant's cluster of residence, (4) power re-estimation using a multinomial sampling method that better accounts for randomness in sampling, and (5) the addition of two trial stopping rules to address the potential for persistently low rates of virologically confirmed dengue case enrolment and Wolbachia contamination into untreated clusters. Additional minor changes to the protocol are also described. DISCUSSION The findings from this study will provide the first experimental evidence for the efficacy of Wolbachia in reducing dengue incidence. Enrolment in the trial will conclude this year (2020) and results will be reported shortly thereafter. TRIAL REGISTRATION ClinicalTrials.gov, identifier: NCT03055585. Registered on 14 February 2017. Last updated 22 March 2020.",2020,"BACKGROUND The AWED (Applying Wolbachia to Eliminate Dengue)",[],"['Wolbachia intervention and (ii) to compare Ae', 'Wolbachia-infected Aedes aegypti deployments']",['aegypti abundance'],[],"[{'cui': 'C0752001', 'cui_str': 'Wolbachia'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0180309', 'cui_str': 'Automated External Defibrillators'}]",[],,0.212877,"BACKGROUND The AWED (Applying Wolbachia to Eliminate Dengue)","[{'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': 'Anders', 'Affiliation': 'Institute of Vector Borne Disease, Monash University, 12 Innovation Walk, Melbourne, 3800, Victoria, Australia. katie.anders@worldmosquito.org.'}, {'ForeName': 'Citra', 'Initials': 'C', 'LastName': 'Indriani', 'Affiliation': 'Department of Biostatistics, Epidemiology and Population Health and Centre for Tropical Medicine, Faculty of Medicine, Universitas Gadjah Mada, Jl. Medika, Yogyakarta, 55281, Indonesia.'}, {'ForeName': 'Riris Andono', 'Initials': 'RA', 'LastName': 'Ahmad', 'Affiliation': 'Department of Biostatistics, Epidemiology and Population Health and Centre for Tropical Medicine, Faculty of Medicine, Universitas Gadjah Mada, Jl. Medika, Yogyakarta, 55281, Indonesia.'}, {'ForeName': 'Warsito', 'Initials': 'W', 'LastName': 'Tantowijoyo', 'Affiliation': 'World Mosquito Program, Centre for Tropical Medicine, Faculty of Medicine, Universitas Gadjah Mada, Jl. Medika, Yogyakarta, 55281, Indonesia.'}, {'ForeName': 'Eggi', 'Initials': 'E', 'LastName': 'Arguni', 'Affiliation': 'Department of Pediatrics and Centre for Tropical Medicine, Faculty of Medicine, Universitas Gadjah Mada, Jl. Medika, Yogyakarta, 55281, Indonesia.'}, {'ForeName': 'Bekti', 'Initials': 'B', 'LastName': 'Andari', 'Affiliation': 'Centre for Tropical Medicine, Faculty of Medicine, Universitas Gadjah Mada, Jl. Medika, Yogyakarta, 55281, Indonesia.'}, {'ForeName': 'Nicholas P', 'Initials': 'NP', 'LastName': 'Jewell', 'Affiliation': 'Centre for Statistical Methodology, London School of Hygiene and Tropical Medicine, Keppel St, London, WC1E 7HT, UK.'}, {'ForeName': 'Suzanne M', 'Initials': 'SM', 'LastName': 'Dufault', 'Affiliation': 'School of Public Health, University of California, 2121 Berkeley Way, Berkeley, 94720-7360, CA, USA.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Ryan', 'Affiliation': 'Institute of Vector Borne Disease, Monash University, 12 Innovation Walk, Melbourne, 3800, Victoria, Australia.'}, {'ForeName': 'Stephanie K', 'Initials': 'SK', 'LastName': 'Tanamas', 'Affiliation': 'Institute of Vector Borne Disease, Monash University, 12 Innovation Walk, Melbourne, 3800, Victoria, Australia.'}, {'ForeName': 'Edwige', 'Initials': 'E', 'LastName': 'Rancès', 'Affiliation': 'Institute of Vector Borne Disease, Monash University, 12 Innovation Walk, Melbourne, 3800, Victoria, Australia.'}, {'ForeName': 'Scott L', 'Initials': 'SL', 'LastName': ""O'Neill"", 'Affiliation': 'Institute of Vector Borne Disease, Monash University, 12 Innovation Walk, Melbourne, 3800, Victoria, Australia.'}, {'ForeName': 'Cameron P', 'Initials': 'CP', 'LastName': 'Simmons', 'Affiliation': 'Institute of Vector Borne Disease, Monash University, 12 Innovation Walk, Melbourne, 3800, Victoria, Australia.'}, {'ForeName': 'Adi', 'Initials': 'A', 'LastName': 'Utarini', 'Affiliation': 'Department of Health Policy and Management, and Centre for Tropical Medicine, Faculty of Medicine, Universitas Gadjah Mada, Jl. Medika, Yogyakarta, 55281, Indonesia.'}]",Trials,['10.1186/s13063-020-04367-2'] 1415,32455853,Low-Intensity Physical Exercise Improves Pain Catastrophizing and Other Psychological and Physical Aspects in Women with Fibromyalgia: A Randomized Controlled Trial.,"Fibromyalgia (FM) is a chronic syndrome characterized by widespread pain and other physical and psychological features. In this study, we aimed to analyze the effect of a low-intensity physical exercise (PE) program, combining endurance training and coordination, on psychological aspects (i.e., pain catastrophizing, anxiety, depression, stress), pain perception (i.e., pain acceptance, pressure pain threshold (PPT), and quality of life and physical conditioning (i.e., self-perceived functional capacity, endurance and functional capacity, power and velocity) in women with FM. For this purpose, a randomized controlled trial was carried out. Thirty-two women with FM were randomly allocated to a PE group (PEG, n = 16), performing an eight-week low-intensity PE program and a control group (CG, n = 16). Pain catastrophizing, anxiety, depression, stress, pain acceptance, PPT, quality of life, self-perceived functional capacity, endurance and functional capacity, power, and velocity were assessed before and after the intervention. We observed a significant improvement in all studied variables in the PEG after the intervention ( p < 0.05). In contrast, the CG showed no improvements in any variable, which further displayed poorer values for PPT ( p < 0.05). In conclusion, a low-intensity combined PE program, including endurance training and coordination, improves psychological variables, pain perception, quality of life, and physical conditioning in women with FM.",2020,"In contrast, the CG showed no improvements in any variable, which further displayed poorer values for PPT ( p < 0.05).","['Women with Fibromyalgia', 'Thirty-two women with FM', 'women with FM']","['low-intensity physical exercise (PE) program, combining endurance training and coordination', 'Low-Intensity Physical Exercise', 'PE group (PEG, n = 16), performing an eight-week low-intensity PE program']","['psychological aspects (i.e., pain catastrophizing, anxiety, depression, stress), pain perception (i.e., pain acceptance, pressure pain threshold (PPT), and quality of life and physical conditioning (i.e., self-perceived functional capacity, endurance and functional capacity, power and velocity', 'Pain catastrophizing, anxiety, depression, stress, pain acceptance, PPT, quality of life, self-perceived functional capacity, endurance and functional capacity, power, and velocity', 'endurance training and coordination, improves psychological variables, pain perception, quality of life, and physical conditioning']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0450357', 'cui_str': '32'}]","[{'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C4704697', 'cui_str': 'Endurance Training'}, {'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032478', 'cui_str': 'Polyethylene Glycol 400'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0032334', 'cui_str': 'podofilox'}, {'cui': 'C4704697', 'cui_str': 'Endurance Training'}, {'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0439828', 'cui_str': 'Variable'}]",32.0,0.0914066,"In contrast, the CG showed no improvements in any variable, which further displayed poorer values for PPT ( p < 0.05).","[{'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Izquierdo-Alventosa', 'Affiliation': 'Unidad de Biomecánica Clínica (UBIC Research Group), Department of Physiotherapy, Faculty of Physiotherapy, Universitat de València, 46010 València, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Inglés', 'Affiliation': 'Freshage Research Group, Department of Physiotherapy, Faculty of Physiotherapy, Universitat de València, Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable (CIBERFES-ISCIII), Fundación Investigación del Hospital Clínico Universitario de Valencia (INCLIVA), 46010 València, Spain.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Cortés-Amador', 'Affiliation': 'Unidad de Biomecánica Clínica (UBIC Research Group), Department of Physiotherapy, Faculty of Physiotherapy, Universitat de València, 46010 València, Spain.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Gimeno-Mallench', 'Affiliation': 'Freshage Research Group, Department of Physiology, Faculty of Medicine, Universitat de València, Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable (CIBERFES-ISCIII), Fundación Investigación del Hospital Clínico Universitario de Valencia (INCLIVA), 46010 València, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Chirivella-Garrido', 'Affiliation': 'Fundación Fivan, Centro de Neurorehabilitación, 46005 Valencia, Spain.'}, {'ForeName': 'Juri', 'Initials': 'J', 'LastName': 'Kropotov', 'Affiliation': 'N.P. Bechtereva Institute of Human Brain, Russian Academy of Science, 197022 St. Petersburg, Russia.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Serra-Añó', 'Affiliation': 'Unidad de Biomecánica Clínica (UBIC Research Group), Department of Physiotherapy, Faculty of Physiotherapy, Universitat de València, 46010 València, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17103634'] 1416,32456572,"Effects of Hemp Extract on Markers of Wellness, Stress Resilience, Recovery and Clinical Biomarkers of Safety in Overweight, But Otherwise Healthy Subjects.","We determined the effects of a commercially available, GRAS (Generally Recognized As Safe) by independent conclusion, CBD-containing hemp oil extract on stress resilience, perceived recovery, mood, affect, body composition, and clinical safety markers in healthy human subjects. Methods: Using a randomized, placebo-controlled, double-blind design, 65 overweight, but otherwise healthy men and women (35.2 ± 11.4 years, 28.5 ± 3.3 kg/m 2 ) ingested either Hemp Oil Extract [Hemp, 60 mg/d PlusCBD TM Extra Strength Hemp Extract Oil (15 mg hemp-derived CBD)] or a placebo (PLA) every day for six weeks while continuing to follow their normal diet and physical activity patterns. Outcome variables included changes in stress resilience, a 14-item panel of various psychometric parameters, heart-rate variability, plasma chromogranin A, body composition, and general markers of health. Data were analyzed using mixed factorial ANOVA, t-tests with 95% confidence intervals, and effect sizes (ES). Results : HDL cholesterol significantly improved in the Hemp group ( p  = 0.004; ES = 0.75). No other statistically significant group x time interaction effects were observed. Statistical tendencies for between-group differences were found for 'I Get Pleasure From Life' ( p  = 0.06, ES = 0.48) and 'Ability to Cope with Stress' ( p  = 0.07, ES = 0.46). Sleep quality (Hemp, p  = 0.005, ES = 0.54) and sleep quantity (Hemp, p  = 0.01, ES = 0.58) exhibited significant within-group changes. All values for hepato-renal function, cardiovascular health, fasting blood lipids, and whole blood cell counts remained within normal clinical limits with no between-group differences over time being identified. Conclusions : Hemp supplementation improved HDL cholesterol, tended to support psychometric measures of perceived sleep, stress response, and perceived life pleasure and was well tolerated with no clinically relevant safety concerns. Registered at clinicaltrials.gov: NCT04294706.",2020,"Statistical tendencies for between-group differences were found for 'I Get Pleasure From Life' ( p  = 0.06, ES = 0.48) and 'Ability to Cope with Stress' ( p  = 0.07, ES = 0.46).","['Overweight, But Otherwise Healthy Subjects', '65 overweight, but otherwise healthy men and women (35.2\u2009±\u200911.4\u2009years, 28.5\u2009±\u20093.3\u2009kg/m 2 ) ingested either', 'healthy human subjects']","['PlusCBD TM', 'Hemp Oil Extract [Hemp, 60\u2009mg', 'Extra Strength Hemp Extract Oil', 'placebo (PLA', 'Hemp Extract', 'placebo']","['I Get Pleasure From Life', 'sleep quantity', 'hepato-renal function, cardiovascular health, fasting blood lipids, and whole blood cell counts', 'support psychometric measures of perceived sleep, stress response, and perceived life pleasure', 'changes in stress resilience, a 14-item panel of various psychometric parameters, heart-rate variability, plasma chromogranin A, body composition, and general markers of health', 'stress resilience, perceived recovery, mood, affect, body composition, and clinical safety markers', 'Sleep quality', 'HDL cholesterol', 'Statistical tendencies', 'time interaction effects', 'Markers of Wellness, Stress Resilience, Recovery and Clinical Biomarkers of Safety']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517533', 'cui_str': '11.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517678', 'cui_str': '28.5'}, {'cui': 'C4517688', 'cui_str': '3.3'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0080105', 'cui_str': 'Human Subjects'}]","[{'cui': 'C0162335', 'cui_str': 'HEMP'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0456170', 'cui_str': 'Left atrial pressure'}]","[{'cui': 'C0679105', 'cui_str': 'Pleasure'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0430045', 'cui_str': 'Fasting blood lipids'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0033920', 'cui_str': 'Psychometric testing'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0055633', 'cui_str': 'Chromogranin A'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol in high density lipoprotein subfraction 2'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",65.0,0.133056,"Statistical tendencies for between-group differences were found for 'I Get Pleasure From Life' ( p  = 0.06, ES = 0.48) and 'Ability to Cope with Stress' ( p  = 0.07, ES = 0.46).","[{'ForeName': 'Hector L', 'Initials': 'HL', 'LastName': 'Lopez', 'Affiliation': 'The Center for Applied Health Sciences, Stow, OH, USA.'}, {'ForeName': 'Kyle R', 'Initials': 'KR', 'LastName': 'Cesareo', 'Affiliation': 'The Center for Applied Health Sciences, Stow, OH, USA.'}, {'ForeName': 'Betsy', 'Initials': 'B', 'LastName': 'Raub', 'Affiliation': 'The Center for Applied Health Sciences, Stow, OH, USA.'}, {'ForeName': 'A William', 'Initials': 'AW', 'LastName': 'Kedia', 'Affiliation': 'The Center for Applied Health Sciences, Stow, OH, USA.'}, {'ForeName': 'Jennifer E', 'Initials': 'JE', 'LastName': 'Sandrock', 'Affiliation': 'The Center for Applied Health Sciences, Stow, OH, USA.'}, {'ForeName': 'Chad M', 'Initials': 'CM', 'LastName': 'Kerksick', 'Affiliation': 'Exercise and Performance Nutrition Laboratory, School of Health Sciences, Lindenwood University, St. Charles, MO, USA.'}, {'ForeName': 'Tim N', 'Initials': 'TN', 'LastName': 'Ziegenfuss', 'Affiliation': 'The Center for Applied Health Sciences, Stow, OH, USA.'}]",Journal of dietary supplements,['10.1080/19390211.2020.1765941'] 1417,30250241,"The effect of brisk walking in the fasted versus fed state on metabolic responses, gastrointestinal function, and appetite in healthy men.","OBJECTIVE To investigate the effect of brisk walking in the fasted versus fed state on gastric emptying rate (GER), metabolic responses and appetite hormone responses. SUBJECTS/METHODS Twelve healthy men completed two 45 min treadmill walks, fasted (FASTED) and followed consumption of a standardised breakfast (FED). GER of a standardised lunch was subsequently measured for 2 h using the 13 C-breath test method. Blood samples were collected at baseline, post-breakfast period, pre-exercise, immediately post exercise, pre-lunch then every 30 min following lunch for 2 h. Circulating concentrations of acylated ghrelin (GHR), glucagon-like peptide-1 (GLP-1), peptide tyrosine tyrosine (PYY), pancreatic polypeptide (PP), glucose, insulin, triglycerides, non-esterified fatty acids (NEFA) and cholesterol were measured. Subjective feelings of appetite were assessed at 15 min intervals throughout. Substrate utilisation was measured every 30 min, and continuously throughout exercise by indirect calorimetry. RESULTS No differences were observed for GER T ½ (FASTED 89 ± 22 vs. FED 89 ± 24 min, P = 0.868) nor T lag (FASTED 55 ± 15 vs. FED 54 ± 14 min, P = 0.704). NEFA concentrations were higher in FASTED at pre-exercise, post exercise and 30 min post exercise (pre-lunch) (all P < 0.05) but no differences were observed for glucose, cholesterol or triglycerides. Carbohydrate oxidation was greater at all time-points during FED exercise (all P < 0.05). Minimal changes in appetite were observed post lunch ingestion with no differences in PYY or GHR observed between trials. GLP-1 concentrations were greater in FED post-breakfast and pre-exercise (P < 0.05), though no differences were observed after lunch. A greater concentration of PP was observed in FED from pre-exercise to 30 min post lunch consumption (all P < 0.05). Insulin concentrations were higher in FED pre-exercise but higher in FASTED 1.5 h post lunch (P < 0.05). CONCLUSION These findings suggest that gastrointestinal function, hunger and appetite regulatory hormones are not sensitive to low-intensity bouts of physical activity and holds positive implications for weight management practices.",2019,"GLP-1 concentrations were greater in FED post-breakfast and pre-exercise (P < 0.05), though no differences were observed after lunch.","['Twelve healthy men completed two', 'healthy men']","['brisk walking', '45\u2009min treadmill walks, fasted (FASTED) and followed consumption of a standardised breakfast (FED', 'glucagon-like peptide-1 ']","['GLP-1), peptide tyrosine tyrosine (PYY), pancreatic polypeptide (PP), glucose, insulin, triglycerides, non-esterified fatty acids (NEFA) and cholesterol', 'glucose, cholesterol or triglycerides', 'Carbohydrate oxidation', 'concentration of PP', 'Substrate utilisation', 'Insulin concentrations', 'Subjective feelings of appetite', 'metabolic responses, gastrointestinal function, and appetite', 'appetite', 'gastric emptying rate (GER), metabolic responses and appetite hormone responses', 'GLP-1 concentrations', 'NEFA concentrations']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0443162', 'cui_str': 'Brisk'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}]","[{'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0077599', 'cui_str': 'tyrosyltyrosine'}, {'cui': 'C0030298', 'cui_str': 'Pancreatic peptide'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0369212', 'cui_str': 'Esterified fatty acid'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0015688', 'cui_str': 'Unesterified fatty acid'}]",12.0,0.0837764,"GLP-1 concentrations were greater in FED post-breakfast and pre-exercise (P < 0.05), though no differences were observed after lunch.","[{'ForeName': 'Victoria J', 'Initials': 'VJ', 'LastName': 'McIver', 'Affiliation': 'School of Healthcare Science, Manchester Metropolitan University, Manchester, M1 5GD, UK.'}, {'ForeName': 'Lewis', 'Initials': 'L', 'LastName': 'Mattin', 'Affiliation': 'School of Healthcare Science, Manchester Metropolitan University, Manchester, M1 5GD, UK.'}, {'ForeName': 'Gethin H', 'Initials': 'GH', 'LastName': 'Evans', 'Affiliation': 'School of Healthcare Science, Manchester Metropolitan University, Manchester, M1 5GD, UK.'}, {'ForeName': 'Adora M W', 'Initials': 'AMW', 'LastName': 'Yau', 'Affiliation': 'School of Healthcare Science, Manchester Metropolitan University, Manchester, M1 5GD, UK. a.yau@mmu.ac.uk.'}]",International journal of obesity (2005),['10.1038/s41366-018-0215-x'] 1418,30538278,"Associations between reliable changes in depression and changes in BMI, total body fatness and visceral adiposity during a 12-month weight loss trial.","We investigated associations between changes in depression and body composition over a 12-month weight loss trial. Of the 298 adults (BMI > 27 m/kg 2 ), 219 with complete depression and body composition data were included. A 10-item Center for Epidemiologic Studies Depression Scale measured depression; dual-energy X-ray absorptiometry measured body composition. Multinomial logistic regression predicted reliable changes in depression by BMI, body fat (BF) and visceral adiposity (VAT). Multiplicative interaction terms tested modification by sex and ethnicity. Participants with increases in body composition were less likely to experience improvements in depression (BMI: RRR = 0.79 (0.68-0.91), p < 0.01; BF: RRR = 0.97 (0.94 - 0.99), p = 0.01; VAT: RRR = 0.99 (0.98-1.00), p = 0.02), but not worsening of depression (BMI: RRR = 1.29 (0.96-1.73), p = 0.10; BF: RRR = 1.04 (0.99-1.09), p = 0.15; VAT: RRR = 1.01 (1.00-1.03), p = 0.18). Sex and ethnicity interaction terms were not significant. However, the relationship was only significant among females, among non-Latinos for BMI and BF, and among Latinos for VAT. Our study supports the association between depression and obesity and highlights the need for longitudinal studies investigating VAT and depression in diverse ethnic groups.",2019,"Participants with increases in body composition were less likely to experience improvements in depression (BMI: RRR = 0.79 (0.68-0.91), p < 0.01; BF: RRR = 0.97 (0.94 - 0.99), p = 0.01; VAT: RRR = 0.99 (0.98-1.00), p = 0.02), but not worsening of depression (BMI: RRR = 1.29 (0.96-1.73), p = 0.10; BF: RRR = 1.04 (0.99-1.09), p = 0.15; VAT: RRR = 1.01 (1.00-1.03), p = 0.18).","['298 adults (BMI\u2009>\u200927\u2009m/kg 2 ), 219 with complete depression and body composition data were included']",[],"['depression and changes in BMI, total body fatness and visceral adiposity', 'body composition', 'depression by BMI, body fat (BF) and visceral adiposity (VAT']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517648', 'cui_str': '219'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0332257', 'cui_str': 'Including'}]",[],"[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}]",298.0,0.0200185,"Participants with increases in body composition were less likely to experience improvements in depression (BMI: RRR = 0.79 (0.68-0.91), p < 0.01; BF: RRR = 0.97 (0.94 - 0.99), p = 0.01; VAT: RRR = 0.99 (0.98-1.00), p = 0.02), but not worsening of depression (BMI: RRR = 1.29 (0.96-1.73), p = 0.10; BF: RRR = 1.04 (0.99-1.09), p = 0.15; VAT: RRR = 1.01 (1.00-1.03), p = 0.18).","[{'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Cameron', 'Affiliation': 'University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA, 92093, USA. ncameron1002@gmail.com.'}, {'ForeName': 'Job G', 'Initials': 'JG', 'LastName': 'Godino', 'Affiliation': 'Center for Wireless and Population Health Systems, 9500 Gilman Drive, La Jolla, CA, 92093, USA.'}, {'ForeName': 'Tricia', 'Initials': 'T', 'LastName': 'Skipper', 'Affiliation': 'Department of Family Medicine and Public Health UC San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Dillon', 'Affiliation': 'Center for Wireless and Population Health Systems, 9500 Gilman Drive, La Jolla, CA, 92093, USA.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Waalen', 'Affiliation': 'Department of Family Medicine and Public Health UC San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Hill', 'Affiliation': 'Center for Wireless and Population Health Systems, 9500 Gilman Drive, La Jolla, CA, 92093, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Patrick', 'Affiliation': 'Department of Family Medicine and Public Health UC San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.'}]",International journal of obesity (2005),['10.1038/s41366-018-0272-1'] 1419,32463163,Peritoneal bridging versus fascial closure in laparoscopic intraperitoneal onlay ventral hernia mesh repair: a randomized clinical trial.,"BACKGROUND Many patients develop seroma after laparoscopic ventral hernia repair. It was hypothesized that leaving the hernial sac in situ may cause this complication. METHODS In this patient- and outcome assessor-blinded, parallel-design single-centre trial, patients undergoing laparoscopic intraperitoneal onlay mesh ventral hernia repair were randomized (1 : 1) to either conventional fascial closure or peritoneal bridging. The primary endpoint was the incidence of seroma 12 months after index surgery detected by CT, evaluated in an intention-to-treat analysis. RESULTS Between September 2017 and May 2018, 62 patients were assessed for eligibility, of whom 25 were randomized to conventional closure and 25 to peritoneal bridging. At 3 months, one patient was lost to follow-up in the conventional and peritoneal bridging groups respectively. No seroma was detected at 6 or 12 months in either group. The prevalence of clinical seroma was four of 25 (16 (95 per cent c.i. 2 to 30) per cent) versus none of 25 patients in the conventional fascial closure and peritoneal bridging groups respectively at 1 month after surgery (P = 0·110), and two of 24 (8 (0 to 19) per cent) versus none of 25 at 3 months (P = 0·235). There were no significant differences between the groups in other postoperative complications (one of 25 versus 0 of 25), rate of recurrent hernia within 1 year (none in either group) or postoperative pain. CONCLUSION Conventional fascial closure and peritoneal bridging did not differ with regard to seroma formation after laparoscopic ventral hernia repair. TRIAL REGISTRATION ClinicalTrials.gov (NCT03344575).",2020,"There were no significant differences between the groups in other postoperative complications (one of 25 versus 0 of 25), rate of recurrent hernia within 1 year (none in either group) or postoperative pain. ","['patients develop seroma after laparoscopic ventral hernia repair', 'patients undergoing laparoscopic intraperitoneal onlay mesh ventral hernia repair', '62 patients were assessed for eligibility, of whom 25 were randomized to', 'Between September 2017 and May 2018']","['conventional closure and 25 to peritoneal bridging', 'laparoscopic intraperitoneal onlay ventral hernia mesh repair', 'Peritoneal bridging versus fascial closure', 'Conventional fascial closure and peritoneal bridging', 'conventional fascial closure or peritoneal bridging']","['rate of recurrent hernia', 'postoperative pain', 'prevalence of clinical seroma', 'seroma formation', 'postoperative complications', 'No seroma', 'incidence of seroma 12\u2009months after index surgery detected by CT, evaluated in an intention-to-treat analysis']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0262627', 'cui_str': 'Seroma'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0019334', 'cui_str': 'Repair of ventral hernia'}, {'cui': 'C0442120', 'cui_str': 'Intraperitoneal'}, {'cui': 'C0021513', 'cui_str': 'Dental Inlays'}, {'cui': 'C0181805', 'cui_str': 'Mesh'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0031153', 'cui_str': 'Peritoneum (serous membrane) structure'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0442120', 'cui_str': 'Intraperitoneal'}, {'cui': 'C0021513', 'cui_str': 'Dental Inlays'}, {'cui': 'C0019326', 'cui_str': 'Hernia of anterior abdominal wall'}, {'cui': 'C0181805', 'cui_str': 'Mesh'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0221821', 'cui_str': 'Dental bridge'}, {'cui': 'C0015641', 'cui_str': 'Fascial'}]","[{'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0262627', 'cui_str': 'Seroma'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}]",62.0,0.371909,"There were no significant differences between the groups in other postoperative complications (one of 25 versus 0 of 25), rate of recurrent hernia within 1 year (none in either group) or postoperative pain. ","[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Ali', 'Affiliation': 'Departments of Surgery, Örebro University Hospital, School of Medical Sciences, Örebro University, Stockholm, Sweden.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Wallin', 'Affiliation': 'Departments of Surgery, Örebro University Hospital, School of Medical Sciences, Örebro University, Stockholm, Sweden.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Fathalla', 'Affiliation': 'Emergency Department, Södersjukhuset, Stockholm, Sweden.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Sandblom', 'Affiliation': 'Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.'}]",BJS open,['10.1002/bjs5.50305'] 1420,32459670,"Effects of combining manual lymphatic drainage and Kinesiotaping on pain, edema, and range of motion in patients with total knee replacement: a randomized clinical trial.","Total knee replacement (TKR) is continuously increasing with significantly faster recovery times. Soft tissue pain and edema of operated limbs play an important role in early functional recovery. The present study aims to evaluate the effectiveness of the combination of Kinesiotaping and Lymphatic drainage for the containment of pain and edema as well as the improvement of the range of motion of the knee as integration with standard postoperative rehabilitation. Ninety-nine TKR patients were included in the randomized clinical trial and divided into three groups: Kinesiotaping and Lymphatic drainage Group, Lymphatic drainage Group, and Kinesiotaping Group. The assessment was carried out on days 2-4-6 postoperation. All the patients had also standard reeducation sessions. It was observed that both Kinesiotaping and Lymphatic drainage was useful in reducing pain and edema. A significantly higher improvement was observed in the group in which Lymphatic drainage was associated with Kinesiotaping with respect to the individual treatments, for pain and leg circumference over and under the knee, and at the ankle. Range of motion of the knee did not show any difference since the flexion degree was similar in all the three groups. No difference was found between Kinesiotaping and Lymphatic drainage. In conclusion, the treatment with a combination Kinesiotaping and Lymphatic drainage provided better results on pain and edema observed as early as the first days after the intervention, thus may be considered a valid support for standard rehabilitation and pharmacological intervention.",2020,Range of motion of the knee did not show any difference since the flexion degree was similar in all the three groups.,"['Ninety-nine TKR patients', 'patients with total knee replacement']","['manual lymphatic drainage and Kinesiotaping', 'Kinesiotaping and Lymphatic drainage', 'Kinesiotaping and Lymphatic drainage Group, Lymphatic drainage Group, and Kinesiotaping Group', 'Total knee replacement (TKR']","['Kinesiotaping and Lymphatic drainage', 'pain, edema, and range of motion', 'flexion degree', 'pain and edema', 'pain and leg circumference']","[{'cui': 'C3828813', 'cui_str': '99'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0556834', 'cui_str': 'Manual lymphatic drainage'}, {'cui': 'C0398480', 'cui_str': 'Drainage of lymphatics'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}]","[{'cui': 'C0398480', 'cui_str': 'Drainage of lymphatics'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}]",99.0,0.031628,Range of motion of the knee did not show any difference since the flexion degree was similar in all the three groups.,"[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Tornatore', 'Affiliation': 'Physical Medicine and Rehabilitation Unit, IRCCS-Istituto Ortopedico Rizzoli, Bagheria.'}, {'ForeName': 'Maria Laura', 'Initials': 'ML', 'LastName': 'De Luca', 'Affiliation': 'Physical Medicine and Rehabilitation Unit, IRCCS-Istituto Ortopedico Rizzoli, Bagheria.'}, {'ForeName': 'Marcello', 'Initials': 'M', 'LastName': 'Ciccarello', 'Affiliation': 'Anesthesia-Resuscitation and Intensive care Unit, Rizzoli Sicilia Department, Bagheria, Palermo, Italy.'}, {'ForeName': 'Maria Grazia', 'Initials': 'MG', 'LastName': 'Benedetti', 'Affiliation': 'Physical Medicine and Rehabilitation Unit, IRCCS-Istituto Ortopedico Rizzoli, Bagheria.'}]",International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation,['10.1097/MRR.0000000000000417'] 1421,32459987,Client memory and learning of treatment contents: An experimental study of intervention strategies and relationship to outcome in a brief treatment for procrastination.,"BACKGROUND AND OBJECTIVES Client memory and learning is limited for psychological treatment contents. This study investigated different approaches to support client memory and learning of treatment contents and the relationship between memory and learning of treatment contents and outcome. METHODS Adult participants (n = 428) were recruited through Amazon's Mechanical Turk and randomized to complete one of three versions of a one-session procrastination intervention. Two versions of the intervention included different amounts of memory support strategy types from the Memory Support Intervention. A control version did not include any types of memory support. Memory and learning of treatment contents were assessed immediately after the intervention and one week later. Procrastination and two mechanisms of procrastination (impulsiveness and self-efficacy) were assessed at baseline and one week after the intervention. RESULTS Contrary to the hypotheses, a version of the intervention with multiple types of memory support strategies was not associated with better memory and learning of treatment contents than a version of the intervention with only one type of memory support strategy or the control intervention. Greater memory and learning of treatment contents predicted improvement in mechanisms of procrastination, but not procrastination itself. LIMITATIONS The mean level of procrastination in this study was lower than in other treatment studies of procrastination. CONCLUSIONS Results partially support the rationale for the Memory Support Intervention that improving client memory and learning of treatment contents can improve outcome. Findings suggest that the Memory Support Intervention may be simplified to include fewer strategies without compromising efficacy.",2020,"Contrary to the hypotheses, a version of the intervention with multiple types of memory support strategies was not associated with better memory and learning of treatment contents than a version of the intervention with only one type of memory support strategy or the control intervention.",['Adult participants (n\xa0=\xa0428'],"[""Amazon's Mechanical Turk""]","['Memory and learning of treatment contents', 'procrastination (impulsiveness and self-efficacy', 'mean level of procrastination', 'Client memory and learning of treatment contents']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4517775', 'cui_str': '428'}]","[{'cui': 'C0325969', 'cui_str': 'Genus Amazona'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0337911', 'cui_str': 'Turks'}]","[{'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0871142', 'cui_str': 'Procrastination'}, {'cui': 'C0564567', 'cui_str': 'Impulsive character'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0008942', 'cui_str': 'Clients'}]",428.0,0.032357,"Contrary to the hypotheses, a version of the intervention with multiple types of memory support strategies was not associated with better memory and learning of treatment contents than a version of the intervention with only one type of memory support strategy or the control intervention.","[{'ForeName': 'Garret G', 'Initials': 'GG', 'LastName': 'Zieve', 'Affiliation': 'University of California, Berkeley, United States.'}, {'ForeName': 'Cara', 'Initials': 'C', 'LastName': 'Woodworth', 'Affiliation': 'University of California, Berkeley, United States.'}, {'ForeName': 'Allison G', 'Initials': 'AG', 'LastName': 'Harvey', 'Affiliation': 'University of California, Berkeley, United States. Electronic address: aharvey@berkeley.edu.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2020.101579'] 1422,32460816,"Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.","INTRODUCTION Neoadjuvant endocrine therapy (NET) has demonstrated efficacy in post-menopausal patients with hormone-responsive breast cancer. This trial was designed to compare the efficacy of neoadjuvant chemotherapy (NCT) with NET in pre-menopausal breast cancer. PATIENTS AND METHODS In this prospective, randomised, phase III study, oestrogen receptor (ER)-positive, HER2-negative, and lymph node-positive pre-menopausal breast cancer patients were recruited from 7 hospitals in South Korea. Enrolled patients were randomly assigned (1:1) to receive 24 weeks of either NCT or NET with goserelin and tamoxifen. The primary purpose was to evaluate the non-inferiority of NET compared to NCT using clinical response, assessed by MRI. Besides, pathological complete response rate (pCR), changes in Ki-67 expression, breast conservation surgery (BCS) rate, and quality of life were included as secondary endpoints. RESULTS A total of 187 patients were assigned to receive NCT (n = 95) or NET (n = 92), and 87 patients in each group completed treatments. More NCT patients had complete response or partial response than NET patients using MRI (NCT 83.7% vs. NET 52.9%, 95% CI 17.6-44.0, p < 0.001) and callipers (NCT 83.9% vs. NET 71.3%, 95% CI 0.4-24.9, p = 0.046). Three NCT patients (3.4%) and one NET patient (1.2%) showed pCR (p < 0.005). No difference existed in the conversion rate of BCS (13.8% for NCT vs. 11.5% for NET, p = 0.531) and Ki-67 change (p = 0.114) between the two groups. Nineteen NCT patients had treatment-related grade 3 or worse events compared with none in the NET group. CONCLUSIONS Better clinical responses were observed in pre-menopausal patients after 24 weeks of NCT compared to those observed after NET. TRIAL REGISTRATION Clinicaltrials.gov, NCT01622361. Registration June 19, 2012.",2020,"More NCT patients had complete response or partial response than NET patients using MRI (NCT 83.7% vs. NET 52.9%, 95% CI 17.6-44.0, p < 0.001) and callipers (NCT 83.9% vs. NET 71.3%, 95% CI 0.4-24.9, p = 0.046).","['pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer', 'post-menopausal patients with hormone-responsive breast cancer', 'lymph node-positive pre-menopausal breast cancer patients were recruited from 7 hospitals in South Korea', 'A total of 187 patients']","['NCT or NET with goserelin and tamoxifen', 'NCT', 'Neoadjuvant endocrine therapy (NET', 'NET', 'neoadjuvant endocrine therapy', 'neoadjuvant chemotherapy (NCT) with NET', 'neoadjuvant chemotherapy']","['Ki-67 change', 'pathological complete response rate (pCR), changes in Ki-67 expression, breast conservation surgery (BCS) rate, and quality of life', 'conversion rate of BCS', 'complete response or partial response']","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034804', 'cui_str': 'Estrogen receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C4087376', 'cui_str': 'HER2 negative'}, {'cui': 'C0024204', 'cui_str': 'Structure of lymph node'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0205342', 'cui_str': 'Responsive'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517618', 'cui_str': '187'}]","[{'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0120107', 'cui_str': 'Goserelin'}, {'cui': 'C0039286', 'cui_str': 'Tamoxifen'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}]",187.0,0.239105,"More NCT patients had complete response or partial response than NET patients using MRI (NCT 83.7% vs. NET 52.9%, 95% CI 17.6-44.0, p < 0.001) and callipers (NCT 83.9% vs. NET 71.3%, 95% CI 0.4-24.9, p = 0.046).","[{'ForeName': 'Hee Jeong', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic ro 43 gil, song pa gu, Seoul, 138-736, South Korea.'}, {'ForeName': 'Woo Chul', 'Initials': 'WC', 'LastName': 'Noh', 'Affiliation': 'Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea.'}, {'ForeName': 'Eun Sook', 'Initials': 'ES', 'LastName': 'Lee', 'Affiliation': 'Department of Surgery, Center for Breast Cancer, Research and Institute and Hospital, National Cancer Center, Goyang, South Korea.'}, {'ForeName': 'Yong Sik', 'Initials': 'YS', 'LastName': 'Jung', 'Affiliation': 'Department of Surgery, School of Medicine, Ajou University, Suwon, South Korea.'}, {'ForeName': 'Lee Su', 'Initials': 'LS', 'LastName': 'Kim', 'Affiliation': 'Division of Breast and Endocrine Surgery, Hallym Sacred Heart Hospital, College of Medicine, Hallyum University, Anyang, South Korea.'}, {'ForeName': 'Wonshik', 'Initials': 'W', 'LastName': 'Han', 'Affiliation': 'Department of Surgery and Cancer Research Institute, College of Medicine, Seoul National University, Seoul, South Korea.'}, {'ForeName': 'Seok Jin', 'Initials': 'SJ', 'LastName': 'Nam', 'Affiliation': 'Department of Surgery, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, South Korea.'}, {'ForeName': 'Gyung -Yub', 'Initials': 'G-', 'LastName': 'Gong', 'Affiliation': 'Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.'}, {'ForeName': 'Hwa Jung', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Department of Preventive Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.'}, {'ForeName': 'Sei Hyun', 'Initials': 'SH', 'LastName': 'Ahn', 'Affiliation': 'Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic ro 43 gil, song pa gu, Seoul, 138-736, South Korea. ahnsh@amc.seoul.kr.'}]",Breast cancer research : BCR,['10.1186/s13058-020-01288-5'] 1423,32466147,The Effects of Multifaceted Ergonomic Interventions on Musculoskeletal Complaints in Intensive Care Units.,"Working at intensive care units (ICUs) is considered a risk factor for developing musculoskeletal complaints (MSC). This study was conducted between January 2017 and June 2019 in two ICUs of a university hospital. It was designed as a pre- and post-assessment of the intervention group (IG) (N = 27) compared with a control group (CG) (N = 23) to determine the effects of a multifaceted ergonomics intervention program in reducing MSC. The IG (N: 35) received a multifaceted ergonomic intervention program, which was implemented by an ERGO team over an 18 month period. Four ergonomic interventions were planned as follows: individual level interventions such as training; stretching exercises and motivation meetings; administrative intervention such as a daily 10 min stretching exercises break; engineering interventions such as lifting and usage of auxiliary devices. The CG (N:29) did not receive any intervention. Cornell Musculoskeletal Discomfort Questionnaire (CMDQ) was used to assess MSC in both groups. At the start of the intervention, both groups were similar concerning the number of visits to doctors due to MSC, the number of sick leave days, and total CMDQ scores ( p > 0.05 for all). Two factor repeated ANOVA measures were performed for between-groups and within-group analyses. The mean of the initial CMSDQ total scores in both groups increased significantly in the 18th month ( p < 0.001). However, the interaction effect of group and time (between and within factors) was not significant ( p = 0.992). Work-related MSC is a common occupational health problem among nurses. This study showed that individual-level interventions are not likely to succeed in eliminating manual patient lifting by nurses. Our results suggested that interventions without administrative measures might have limited success.",2020,The mean of the initial CMSDQ total scores in both groups increased significantly in the 18th month ( p < 0.001).,"['Musculoskeletal Complaints in Intensive Care Units', 'January 2017 and June 2019 in two ICUs of a university hospital']","['multifaceted ergonomics intervention program', 'multifaceted ergonomic intervention program', 'Multifaceted Ergonomic Interventions']","['number of visits to doctors due to MSC, the number of sick leave days, and total CMDQ scores', 'mean of the initial CMSDQ total scores', 'Cornell Musculoskeletal Discomfort Questionnaire (CMDQ']","[{'cui': 'C0277786', 'cui_str': 'Complaint'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}]","[{'cui': 'C0086246', 'cui_str': 'Human Engineering'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0277786', 'cui_str': 'Complaint'}, {'cui': 'C0242807', 'cui_str': 'Sick Leave'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0948594', 'cui_str': 'Musculoskeletal discomfort'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.0244086,The mean of the initial CMSDQ total scores in both groups increased significantly in the 18th month ( p < 0.001).,"[{'ForeName': 'Ayse', 'Initials': 'A', 'LastName': 'Coskun Beyan', 'Affiliation': 'Occupational Medicine Department, Dokuz Eylul University, Izmir 35220, Turkey.'}, {'ForeName': 'Banu', 'Initials': 'B', 'LastName': 'Dilek', 'Affiliation': 'Physical Therapy and Rehabilitation Department, Dokuz Eylul University, Izmir 35220, Turkey.'}, {'ForeName': 'Yucel', 'Initials': 'Y', 'LastName': 'Demiral', 'Affiliation': 'Occupational Medicine Department, Dokuz Eylul University, Izmir 35220, Turkey.'}]",International journal of environmental research and public health,['10.3390/ijerph17103719'] 1424,32466187,Effect of Different Running Exercise Modalities on Post-Exercise Oxidative Stress Markers in Trained Athletes.,"The aim of this study was to examine the effect of running exercise modality on oxidative stress. Thirteen endurance athletes (age: 21.46 ± 0.66 years) performed three different running exercise modalities (Continuous running exercise (CR): continuous running exercise at 75% of VO 2max for 25 min; intermittent running exercise #1 (15/15): intermittent running protocol, 15 s running at 75% of VO 2max , 15 s passive recovery, performed for 50 min; intermittent running exercise #2 (30/30): intermittent running protocol, 30 s running at 75% of VO 2max , 30 s passive recovery, performed for 50 min) in a randomized order. Blood samples were drawn at rest and immediately after each running exercise and assessed for malondialdehyde (MDA), advanced oxidation protein products (AOPP), superoxide dismutase(SOD), and glutathione peroxidase (GPX) activities. MDA increased by 55% following 30/30 exercise ( p < 0.01), while it remained unchanged with CR and15/15 exercise. SOD increased after CR (+13.9%, p < 0.05), and also remained unchanged after 15/15 ( p > 0.05) and decreased after 30/30 (-19.7% p < 0.05). GPX and AOPP did not change after exercise in all experimental sessions ( p > 0.05). In conclusion, 30/30 intermittent running induced higher lipid damages than the 15/15 and CR exercise. 15/15 intermittent exercise promoted a better balance between free radicals production and antioxidant defense compared to continuous exercise and intermittent 30/30 exercise.",2020,"MDA increased by 55% following 30/30 exercise ( p < 0.01), while it remained unchanged with CR and15/15 exercise.","['Thirteen endurance athletes (age: 21.46 ± 0.66 years', 'Trained Athletes']","['running exercise modalities (Continuous running exercise (CR): continuous running exercise at 75% of VO 2max for 25 min; intermittent running exercise #1 (15/15): intermittent running protocol, 15 s running at 75% of VO 2max , 15 s passive recovery, performed for 50 min; intermittent running exercise #2 (30/30): intermittent running protocol, 30 s running at 75% of VO 2max', 'Different Running Exercise Modalities', 'running exercise modality']","['SOD', 'oxidative stress', 'malondialdehyde (MDA), advanced oxidation protein products (AOPP), superoxide dismutase(SOD), and glutathione peroxidase (GPX) activities', 'GPX and AOPP', 'MDA', 'lipid damages', 'Post-Exercise Oxidative Stress Markers']","[{'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0035953', 'cui_str': 'Running'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C1976991', 'cui_str': 'Advanced oxidation protein products'}, {'cui': 'C0017822', 'cui_str': 'Glutathione peroxidase'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0000379', 'cui_str': 'Methylenedioxyamphetamine'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C1979962', 'cui_str': 'After exercise'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",13.0,0.0473095,"MDA increased by 55% following 30/30 exercise ( p < 0.01), while it remained unchanged with CR and15/15 exercise.","[{'ForeName': 'Wajdi', 'Initials': 'W', 'LastName': 'Souissi', 'Affiliation': 'Research Laboratory: Education, Motricité, Sport et Santé, EM2S, LR19JS01, High Institute of Sport and Physical Education, University of Sfax, Sfax 3000, Tunisia.'}, {'ForeName': 'Mohamed Amine', 'Initials': 'MA', 'LastName': 'Bouzid', 'Affiliation': 'Research Laboratory: Education, Motricité, Sport et Santé, EM2S, LR19JS01, High Institute of Sport and Physical Education, University of Sfax, Sfax 3000, Tunisia.'}, {'ForeName': 'Mohamed Amine', 'Initials': 'MA', 'LastName': 'Farjallah', 'Affiliation': 'Research Laboratory: Education, Motricité, Sport et Santé, EM2S, LR19JS01, High Institute of Sport and Physical Education, University of Sfax, Sfax 3000, Tunisia.'}, {'ForeName': 'Lobna', 'Initials': 'L', 'LastName': 'Ben Mahmoud', 'Affiliation': 'Pharmacology Department, Faculty of Medicine, University of Sfax, Sfax 3000, Tunisia.'}, {'ForeName': 'Mariem', 'Initials': 'M', 'LastName': 'Boudaya', 'Affiliation': 'Biochemistry Laboratory, CHU HediChaker, University of Sfax, Sfax 3000, Tunisia.'}, {'ForeName': 'Florian A', 'Initials': 'FA', 'LastName': 'Engel', 'Affiliation': 'Institute of Sport and Sport Science, Heidelberg University, 69120 Heidelberg, Germany.'}, {'ForeName': 'Zouheir', 'Initials': 'Z', 'LastName': 'Sahnoun', 'Affiliation': 'Pharmacology Department, Faculty of Medicine, University of Sfax, Sfax 3000, Tunisia.'}]",International journal of environmental research and public health,['10.3390/ijerph17103729'] 1425,32466961,Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC.,"PURPOSE The present study compared the efficacy of sunitinib and sorafenib as first-line treatment of metastatic clear cell renal cell carcinoma (mCC-RCC) with favorable or intermediate Memorial Sloan Kettering Cancer Center (MSKCC) risk. PATIENTS AND METHODS Treatment-naive patients with mCC-RCC were randomized to receive open-label sunitinib followed by sorafenib (SU/SO) or sorafenib followed by sunitinib (SO/SU). The primary endpoint was first-line progression-free survival (PFS). The secondary endpoints were total PFS and overall survival (OS). RESULTS Of the 124 patients enrolled at 39 institutions from February 2010 to July 2012, 120 were evaluated. The median first-line PFS duration was 8.7 and 7.0 months in the SU/SO and SO/SU groups, respectively (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.42-1.08). The total PFS and OS were not significantly different between the SU/SO and SO/SU groups (27.8 and 22.6 months; HR, 0.73; 95% CI, 0.428-1.246; and 38.4 and 30.9 months; HR, 0.934; 95% CI, 0.588-1.485, respectively). The subgroup analysis revealed that the total PFS with SU/SO was superior to the total PFS with SO/SU in the patients with favorable MSKCC risk and those with < 5 metastatic sites). SO/SU was superior to SU/SO for patients without previous nephrectomy. CONCLUSIONS No statistically significant differences were found in first-line PFS, total PFS, or OS between the 2 treatment arms (ClinicalTrials.gov identifier, NCT01481870).",2020,"No statistically significant differences were found in first-line PFS, total PFS, or OS between the 2 treatment arms (ClinicalTrials.gov identifier, NCT01481870).","['Treatment-naive patients with mCC-RCC', 'mCC-RCC With Favorable/Intermediate Risk', 'metastatic clear cell renal cell carcinoma (mCC-RCC) with favorable or intermediate Memorial Sloan Kettering Cancer Center (MSKCC) risk', 'patients without previous nephrectomy', '124 patients enrolled at 39 institutions from February 2010 to July 2012, 120 were evaluated']","['open-label sunitinib followed by sorafenib (SU/SO) or sorafenib followed by sunitinib (SO/SU', 'sunitinib and sorafenib', 'Sunitinib Versus Sorafenib']","['total PFS and overall survival (OS', 'median first-line PFS duration', 'first-line progression-free survival (PFS', 'first-line PFS, total PFS, or OS', 'total PFS and OS']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0279702', 'cui_str': 'Clear cell carcinoma of kidney'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0027695', 'cui_str': 'Kidney excision'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C4319550', 'cui_str': '120'}]","[{'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C1176020', 'cui_str': 'sunitinib'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]",124.0,0.0953987,"No statistically significant differences were found in first-line PFS, total PFS, or OS between the 2 treatment arms (ClinicalTrials.gov identifier, NCT01481870).","[{'ForeName': 'Yoshihiko', 'Initials': 'Y', 'LastName': 'Tomita', 'Affiliation': 'Department of Urology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. Electronic address: ytomita@med.niigata-u.ac.jp.'}, {'ForeName': 'Sei', 'Initials': 'S', 'LastName': 'Naito', 'Affiliation': 'Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan.'}, {'ForeName': 'Naoto', 'Initials': 'N', 'LastName': 'Sassa', 'Affiliation': 'Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Takahashi', 'Affiliation': 'Department of Urology, Hakodate Goryoukaku Hospital, Hokkaido, Japan.'}, {'ForeName': 'Tsunenori', 'Initials': 'T', 'LastName': 'Kondo', 'Affiliation': ""Department of Urology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.""}, {'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Koie', 'Affiliation': 'Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan; Department of Urology, Gifu University School of Medicine, Seki, Japan.'}, {'ForeName': 'Wataru', 'Initials': 'W', 'LastName': 'Obara', 'Affiliation': 'Department of Urology, Iwate Medical University, Morioka, Japan.'}, {'ForeName': 'Yasuyuki', 'Initials': 'Y', 'LastName': 'Kobayashi', 'Affiliation': 'Department of Urology, Okayama University Graduate School of Medicine, Okayama, Japan.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Teishima', 'Affiliation': 'Department of Urology, Graduate School of Biomedical Health Science, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Takahashi', 'Affiliation': 'Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.'}, {'ForeName': 'Hideyasu', 'Initials': 'H', 'LastName': 'Matsuyama', 'Affiliation': 'Department of Urology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Ueda', 'Affiliation': 'Department of Urology, Chiba Cancer Center, Chiba, Japan.'}, {'ForeName': 'Kenya', 'Initials': 'K', 'LastName': 'Yamaguchi', 'Affiliation': 'Department of Urology, Nihon University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Kishida', 'Affiliation': 'Department of Urology, Kanagawa Cancer Center, Yokohama, Japan.'}, {'ForeName': 'Ryoichi', 'Initials': 'R', 'LastName': 'Shiroki', 'Affiliation': 'Department of Urology, Fujita Health University School of Medicine, Toyoake, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Saika', 'Affiliation': 'Department of Urology, Ehime University, Matsuyama, Japan.'}, {'ForeName': 'Nobuo', 'Initials': 'N', 'LastName': 'Shinohara', 'Affiliation': 'Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.'}, {'ForeName': 'Mototsugu', 'Initials': 'M', 'LastName': 'Oya', 'Affiliation': 'Department of Urology, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hiro-Omi', 'Initials': 'HO', 'LastName': 'Kanayama', 'Affiliation': 'Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.'}]",Clinical genitourinary cancer,['10.1016/j.clgc.2020.01.001'] 1426,32585261,Evaluation of various irrigation activation systems to eliminate bacteria from the root canal system: A randomized controlled single blinded trial.,"OBJECTIVE To evaluate the effect of NaOCl irrigant activation using passive ultrasonic activation, F-files, XP-endo Finisher files and or needle irrigation alone on the reduction of intracanal bacteria from root canals in teeth undergoing root canal treatment. METHODS Eighty patients with asymptomatic apical periodontitis were randomly divided into four groups. Access cavities were prepared and pre-treatment samples were taken (S1). Canals were then prepared and post-instrumentation samples (S2) taken. NaOCl was then activated with the various irrigant activation systems and post-irrigation samples (S3) taken. The samples were processed and colony forming units (CFUs) of bacteria were determined. The reduction in CFUs among the experimental groups were analysed using the Kruskal Wallis test and pairwise comparisons with the Mann-Whitney test. The Friedman test was used to compare the differences in the reduction of CFUs within the groups. RESULTS Overall, for all groups there was a significant reduction in the CFUs from S1 to S2 (P < 0.05) and from S2 to S3 (P < 0.05). Both XP-endo Finisher and passive ultrasonic activation techniques were associated with the greatest reduction in CFUs with no significant difference between them (P = 0.24). However, both were associated with significantly lower CFUs when compared to F-file activation and needle irrigation (P < 0.05). F-file activation reduced the CFUs significantly more compared to needle irrigation (P = 0.04). CONCLUSIONS XP-endo Finisher file activation and passive ultrasonic activation were equivalent in terms of reduction in CFUs. F-file activation did not reduce the CFUs to the same extent as the XP-endo Finisher file and ultrasonic activation but reduced the CFUs more than needle irrigation. CLINICAL SIGNIFICANCE The present study highlights the effect of new XP-endo Finisher file and passive ultrasonic activation in reducing the bacterial load from the root canal system which is important for the success of root canal treatment.",2020,Both XP-endo Finisher and passive ultrasonic activation techniques were associated with the greatest reduction in CFUs with no significant difference between them (P = 0.24).,"['teeth undergoing root canal treatment', 'Eighty patients with asymptomatic apical periodontitis']","['passive ultrasonic activation, F-files, XP-endo Finisher files and or needle irrigation alone', 'new XP-endo Finisher file and passive ultrasonic activation']",['reduction in CFUs'],"[{'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0031030', 'cui_str': 'Apical periodontitis'}]","[{'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0016094', 'cui_str': 'Filing'}, {'cui': 'C0014175', 'cui_str': 'Endometriosis'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0205314', 'cui_str': 'New'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0439158', 'cui_str': 'colonies'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0439148', 'cui_str': 'Unit'}]",80.0,0.0138556,Both XP-endo Finisher and passive ultrasonic activation techniques were associated with the greatest reduction in CFUs with no significant difference between them (P = 0.24).,"[{'ForeName': 'Nidambur Vasudev', 'Initials': 'NV', 'LastName': 'Ballal', 'Affiliation': 'Department of Conservative Dentistry and Endodontics, Manipal College of Dental Sciences, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India. Electronic address: drballal@yahoo.com.'}, {'ForeName': 'Poornika', 'Initials': 'P', 'LastName': 'Gandhi', 'Affiliation': 'Department of Conservative Dentistry and Endodontics, Manipal College of Dental Sciences, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.'}, {'ForeName': 'Padmaja A', 'Initials': 'PA', 'LastName': 'Shenoy', 'Affiliation': 'Department of Microbiology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.'}, {'ForeName': 'Paul M H', 'Initials': 'PMH', 'LastName': 'Dummer', 'Affiliation': 'School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.'}]",Journal of dentistry,['10.1016/j.jdent.2020.103412'] 1427,32585263,Restorations after selective caries removal: 5-Year randomized trial.,"OBJECTIVE To compare the survival of restorations placed in deep caries lesions after selective caries removal to soft dentin (SCRSD) over a 5-year period. A secondary aim was to investigate whether the material (amalgam or resin composite) affected the survival of restorations. METHODS This study used data derived from a multicenter randomized controlled clinical trial (Clinical trials registration NCT00887952). Inclusion criteria were: patients with permanent molars presenting occlusal or proximal deep caries lesions (≥1/2 of the dentin thickness on radiographic examination), positive response to a cold test, absence of spontaneous pain, negative sensitivity to percussion, and absence of periapical lesions. The teeth were randomized into SCRSD and restoration in a single visit or stepwise excavation (SW). Each of these groups was divided according to the filling material: amalgam (AM) or resin composite (RC). Survival analyses were performed to estimate therapy success rates over 5 years (adjusted Weibull regression model). RESULTS 172 restorations were evaluated, 95 from SCRSD group and 77 from SW group, being 61 AMG and 111 RC. The 5-year survival analysis showed similar success rates for SW (76 %) and SCRSD (79 %) as well as for AM and RC (p > 0.05). CONCLUSION This study showed that, after a 5-year follow-up period, the presence of decayed tissue beneath restorations in deep caries lesions did not seem to affect restoration survival. Amalgam and resin composite restorations had similar survival rates, irrespective of the caries removal technique used - SCRSD or SW. CLINICAL SIGNIFICANCE Selective caries removal to soft dentin can be used in the management of deep caries to avoid pulp exposure and preserve tooth structure without affecting restoration longevity.",2020,"Amalgam and resin composite restorations had similar survival rates, irrespective of the caries removal technique used - SCRSD or SW. ","['Inclusion criteria were: patients with permanent molars presenting occlusal or proximal deep caries lesions (≥1/2 of the dentin thickness on radiographic examination), positive response to a cold test, absence of spontaneous pain, negative sensitivity to percussion, and absence of periapical lesions']","['filling material: amalgam (AM) or resin composite (RC', 'material (amalgam or resin composite']","['5-year survival', 'survival rates', 'restoration survival', 'SCRSD', 'survival of restorations']","[{'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0447303', 'cui_str': 'Structure of occlusal surface of tooth'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0333523', 'cui_str': 'Deep caries'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0011429', 'cui_str': 'Dentin structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C1997216', 'cui_str': 'Spontaneous pain'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0030987', 'cui_str': 'Percussion'}, {'cui': 'C0729269', 'cui_str': 'Periapical'}]","[{'cui': 'C0440137', 'cui_str': 'Filling material'}, {'cui': 'C0440138', 'cui_str': 'Amalgam (silver) dental filling material'}, {'cui': 'C0009570', 'cui_str': 'Composite Resins'}, {'cui': 'C0520510', 'cui_str': 'Material'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0205358', 'cui_str': 'Soft'}, {'cui': 'C0011429', 'cui_str': 'Dentin structure'}]",172.0,0.117992,"Amalgam and resin composite restorations had similar survival rates, irrespective of the caries removal technique used - SCRSD or SW. ","[{'ForeName': 'Juliana Jobim', 'Initials': 'JJ', 'LastName': 'Jardim', 'Affiliation': 'Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Heliana Dantas', 'Initials': 'HD', 'LastName': 'Mestrinho', 'Affiliation': 'Brasilia University, Brasilia, DF, Brazil.'}, {'ForeName': 'Bárbara', 'Initials': 'B', 'LastName': 'Koppe', 'Affiliation': 'Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Lilian Marly', 'Initials': 'LM', 'LastName': 'de Paula', 'Affiliation': 'Brasilia University, Brasilia, DF, Brazil.'}, {'ForeName': 'Luana Severo', 'Initials': 'LS', 'LastName': 'Alves', 'Affiliation': 'Federal University of Santa Maria, Santa Maria, RS, Brazil. Electronic address: luanaseal@gmail.com.'}, {'ForeName': 'Paulo Márcio', 'Initials': 'PM', 'LastName': 'Yamaguti', 'Affiliation': 'Brasilia University, Brasilia, DF, Brazil.'}, {'ForeName': 'Júlio César Franco', 'Initials': 'JCF', 'LastName': 'Almeida', 'Affiliation': 'Brasilia University, Brasilia, DF, Brazil.'}, {'ForeName': 'Marisa', 'Initials': 'M', 'LastName': 'Maltz', 'Affiliation': 'Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.'}]",Journal of dentistry,['10.1016/j.jdent.2020.103416'] 1428,32588785,"Association between change in maternal physical activity during pregnancy and infant size, in a sample overweight or obese women.","Physical activity (PA) naturally declines during pregnancy and its effects on infant size are unclear, especially in overweight or obese pregnancies, a low-active subpopulation that tends deliver heavier infants. The objective of this study was to evaluate changes in prenatal PA and infant birthweight in a group of overweight or obese pregnant women. We employed a prospective analysis using data from a randomized controlled exercise trial (2001 to 2006) in sedentary, overweight or obese pregnant women in Michigan. Women with complete data on peak oxygen consumption, daily PA (via pedometers) and birthweight were included in the analyses. Change in PA was estimated via repeated measures analyses, and then its influence on infant birthweight was assessed via linear regression. Eighty-nine pregnant women were included and considered low-active (6,579.91 ± 2379.17 steps/day). PA declined from months 4 to 8 (-399.73 ± 371.38 steps∙day -1 ∙month -1 ). Analyses showed that the decline in PA (β = -0.28 g, 95%CI: -0.70, 0.25 g, p = .35) was not associated with birthweight. The findings of this study demonstrated that the decline in maternal PA during mid- to late-pregnancy, in overweight or obese women, was unrelated to infant birthweight. Future investigations should employ rigorous measurements of PA and infant anthropometry in this subpopulation.",2020,PA declined from months 4 to 8 (-399.73 ± 371.38 steps∙day -1 ∙month -1 ).,"['Eighty-nine pregnant women were included and considered low-active (6,579.91\xa0±\xa02379.17 steps/day', 'group of overweight or obese pregnant women', 'sample overweight or obese women', '2001 to 2006) in sedentary, overweight or obese pregnant women in Michigan']",[],"['peak oxygen consumption, daily PA (via pedometers) and birthweight', 'prenatal PA and infant birthweight', 'maternal PA', 'maternal physical activity']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0025939', 'cui_str': 'Michigan'}]",[],"[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]",89.0,0.122053,PA declined from months 4 to 8 (-399.73 ± 371.38 steps∙day -1 ∙month -1 ).,"[{'ForeName': 'Samantha M', 'Initials': 'SM', 'LastName': 'McDonald', 'Affiliation': 'School of Dental Medicine, East Carolina University , Greenville, North Carolina, USA.'}, {'ForeName': 'SeonAe', 'Initials': 'S', 'LastName': 'Yeo', 'Affiliation': 'College of Nursing, University of North Carolina , Chapel Hill, North Carolina, USA.'}, {'ForeName': 'Jihong', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Department of Epidemiology and Biostatistics, University of South Carolina , Columbia, South Carolina, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Wilcox', 'Affiliation': 'University of South Carolina , Columbia, SC, USA.'}, {'ForeName': 'Xuemei', 'Initials': 'X', 'LastName': 'Sui', 'Affiliation': 'University of South Carolina , Columbia, SC, USA.'}, {'ForeName': 'Russell R', 'Initials': 'RR', 'LastName': 'Pate', 'Affiliation': 'University of South Carolina , Columbia, SC, USA.'}]",Women & health,['10.1080/03630242.2020.1779904'] 1429,32588803,Use of Typhoid Vi-Polysaccharide Vaccine as a Vaccine Probe to Delineate Clinical Criteria for Typhoid Fever.,"Blood cultures (BCs) detect an estimated 50% of typhoid fever cases. There is need for validated clinical criteria to define cases that are BC negative, both to help direct empiric antibiotic treatment and to better evaluate the magnitude of protection conferred by typhoid vaccines. To derive and validate a clinical rule for defining BC-negative typhoid fever, we assessed, in a cluster-randomized effectiveness trial of Vi-polysaccharide (ViPS) typhoid vaccine in Kolkata, India, 14,797 episodes of fever lasting at least 3 days during 4 years of comprehensive, BC-based surveillance of 70,865 persons. A recursive partitioning algorithm was used to develop a decision rule to predict BC-proven typhoid cases with a diagnostic specificity of 97-98%. To validate this rule as a definition for BC-negative typhoid fever, we assessed whether the rule defined culture-negative syndromes prevented by ViPS vaccine. In a training subset of individuals, we identified the following two rules: rule 1: patients aged < 15 years with prolonged fever accompanied by a measured body temperature ≥ 100°F, headache, and nausea; rule 2: patients aged ≥ 15 years with prolonged fever accompanied by nausea and palpable liver but without constipation. The adjusted protective efficacy of ViPS against clinical typhoid defined by these rules in persons aged ≥ 2 years in a separate validation subset was 33% (95% CI: 4-53%). We have defined and validated a clinical rule for predicting BC-negative typhoid fever using a novel vaccine probe approach. If validated in other settings, this rule may be useful to guide clinical care and to enhance typhoid vaccine evaluations.",2020,A recursive partitioning algorithm was used to develop a decision rule to predict BC-proven typhoid cases with a diagnostic specificity of 97-98%.,"['patients aged < 15 years with prolonged fever accompanied by a measured body temperature ≥ 100°F, headache, and nausea; rule 2: patients aged ≥ 15 years with prolonged fever accompanied by nausea and palpable liver but without constipation', 'Kolkata, India, 14,797 episodes of fever lasting at least 3 days during 4 years of comprehensive, BC-based surveillance of 70,865 persons']","['Typhoid Vi-Polysaccharide Vaccine', 'Vi-polysaccharide (ViPS) typhoid vaccine', 'ViPS']",['Blood cultures (BCs) detect'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0886414', 'cui_str': 'Body temperature'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0522637', 'cui_str': 'Measuring ruler'}, {'cui': 'C0577045', 'cui_str': 'Liver palpable'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0078221', 'cui_str': 'Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain'}, {'cui': 'C0032594', 'cui_str': 'Polysaccharide'}, {'cui': 'C0041469', 'cui_str': 'Typhoid vaccine'}]","[{'cui': 'C0200949', 'cui_str': 'Blood culture'}, {'cui': 'C0442726', 'cui_str': 'Detected'}]",,0.333085,A recursive partitioning algorithm was used to develop a decision rule to predict BC-proven typhoid cases with a diagnostic specificity of 97-98%.,"[{'ForeName': 'Md Taufiqul', 'Initials': 'MT', 'LastName': 'Islam', 'Affiliation': 'International Centre for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Im', 'Affiliation': 'International Vaccine Institute, Seoul, Republic of Korea.'}, {'ForeName': 'Faisal', 'Initials': 'F', 'LastName': 'Ahmmed', 'Affiliation': 'International Centre for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Deok Ryun', 'Initials': 'DR', 'LastName': 'Kim', 'Affiliation': 'International Vaccine Institute, Seoul, Republic of Korea.'}, {'ForeName': 'Ashraful Islam', 'Initials': 'AI', 'LastName': 'Khan', 'Affiliation': 'International Centre for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Khalequ', 'Initials': 'K', 'LastName': 'Zaman', 'Affiliation': 'International Centre for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Ali', 'Affiliation': 'Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Marks', 'Affiliation': 'Department of Medicine, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'Firdausi', 'Initials': 'F', 'LastName': 'Qadri', 'Affiliation': 'International Centre for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Jerome H', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'International Vaccine Institute, Seoul, Republic of Korea.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Clemens', 'Affiliation': 'Korea University College of Medicine, Seoul, South Korea.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.19-0968'] 1430,32585039,Ibuprofen in needle procedures in children with cancer-A feasibility and pilot study.,"AIM To investigate the feasibility, and perform a pilot study, of a randomised clinical trial, investigating whether children experience less pain, fear and/or distress when they receive oral ibuprofen vs placebo before a needle is inserted in a subcutaneously implanted intravenous port. METHODS Twenty-three children were included consecutively and randomised to either oral ibuprofen (n = 12) 7.5 mg/kg body weight or placebo (n = 11). The child's pain, fear and distress were reported by parents, nurses and the children (if ≥7 years of age). Feasibility criteria were defined as (a) ≥4 children included/month, (b) ≥80% of eligible patients agreed to participate, (c) >90% treated according to protocol, (d) <5% missing data, (e) s-cortisol samples analysed in ≥90% of the children. RESULTS All feasibility criteria were met except recruitment and consent. Parents, nurses and children reported no trend of benefit of oral ibuprofen with regard to pain, fear and distress compared with placebo. CONCLUSION The study failed to meet important feasibility criteria and was closed due to low recruitment rate and absence of trend of effect. From this data, we cannot state that ibuprofen is not helpful in needle procedures but that it seems unlikely.",2020,"Parents, nurses and children reported no trend of benefit of oral ibuprofen with regard to pain, fear and distress compared with placebo. ","['23 children', 'children with cancer ', 'children experience less pain, fear', 'Feasibility criteria were defined as; 1) ≥4 children included/month, 2) ≥ 80% of eligible patients agreed to participate, 3) ']","['oral ibuprofen vs. placebo', 'Ibuprofen', 'ibuprofen', 'oral ibuprofen', 'placebo']","[""child's pain, fear and distress"", 'pain, fear and distress']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0231303', 'cui_str': 'Distress'}]",23.0,0.0579768,"Parents, nurses and children reported no trend of benefit of oral ibuprofen with regard to pain, fear and distress compared with placebo. ","[{'ForeName': 'Tove', 'Initials': 'T', 'LastName': 'Kamsvåg', 'Affiliation': ""Department of Women's and Children's Health, Pediatric Oncology, Uppsala University, Uppsala, Sweden.""}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Hedén', 'Affiliation': ""Department of Women's and Children's Health, Pediatric Oncology, Uppsala University, Uppsala, Sweden.""}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'von Essen', 'Affiliation': ""Department of Women's and Children's Health, Clinical Psychology in Healthcare, Uppsala University, Uppsala, Sweden.""}, {'ForeName': 'Gustaf', 'Initials': 'G', 'LastName': 'Ljungman', 'Affiliation': ""Department of Women's and Children's Health, Pediatric Oncology, Uppsala University, Uppsala, Sweden.""}]","Acta paediatrica (Oslo, Norway : 1992)",['10.1111/apa.15449'] 1431,32456236,"A Lifestyle (Dietary) Intervention Reduces Tiredness in Children with Subclinical Hypothyroidism, a Randomized Controlled Trial.","PURPOSE Subclinical hypothyroidism (SH) in children and adults is a subject for discussion in terms of whether to treat it or not with respect to the short-term clinical implications and consequences of SH and in the long term. If treatment with thyroxine supplementation is not indicated, no other treatment is available. We investigated whether a lifestyle (dietary) intervention improves or normalizes SH or decreases the presence of Thyroid Stimulating Hormone (TSH) and/or tiredness. Methods : We randomized children aged 1-12 years with SH to the control group (standard care = no treatment) or intervention group (dietary intervention). The dietary intervention consisted of green vegetables, beef, whole milk and butter for 6 months. The rest of the diet remained unchanged. We measured TSH, FreeT4, Lipid profile, Body Mass Index (BMI) and Pediatric Quality of Life (PedQL) multidimensional fatigue scale scores. Results : In total, 62 children were included. After 6 months, TSH decreased in both groups without a significant difference between the groups ( p = 0.98). PedQL fatigue scores for sleep ( p = 0.032) and total fatigue scores ( p = 0.039) improved significantly in the intervention group, compared to the control group. No unfavorable effects occurred in the lipid profile or BMI. Conclusion : The lifestyle (dietary) intervention did not normalize SH and TSH levels, but it significantly reduced tiredness. These results suggest that children's well-being can be improved without medication.",2020,"After 6 months, TSH decreased in both groups without a significant difference between the groups ( p = 0.98).","['children and adults', '62 children were included', 'children aged 1-12 years with SH to the control group (standard care = no treatment) or', 'Children with Subclinical Hypothyroidism']","['dietary intervention consisted of green vegetables, beef, whole milk and butter for 6 months', 'A Lifestyle (Dietary) Intervention', 'thyroxine supplementation', 'intervention group (dietary intervention', 'lifestyle (dietary) intervention']","['Tiredness', 'Thyroid Stimulating Hormone (TSH) and/or tiredness', 'TSH', 'PedQL fatigue scores for sleep', 'normalize SH and TSH levels', 'lipid profile or BMI', 'total fatigue scores', 'tiredness', 'TSH, FreeT4, Lipid profile, Body Mass Index (BMI) and Pediatric Quality of Life (PedQL) multidimensional fatigue scale scores']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0271790', 'cui_str': 'Subclinical hypothyroidism'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0332583', 'cui_str': 'Green color'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0452849', 'cui_str': 'Beef'}, {'cui': 'C0452717', 'cui_str': 'Whole milk'}, {'cui': 'C0006494', 'cui_str': 'Butter'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0040165', 'cui_str': 'levothyroxine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0040160', 'cui_str': 'Thyrotropin'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0271790', 'cui_str': 'Subclinical hypothyroidism'}, {'cui': 'C0202230', 'cui_str': 'Thyroid stimulating hormone measurement'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",62.0,0.037638,"After 6 months, TSH decreased in both groups without a significant difference between the groups ( p = 0.98).","[{'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'van der Gaag', 'Affiliation': 'Department of Pediatrics, Hospital Group Twente, 7609 PP Almelo, The Netherlands.'}, {'ForeName': 'Job', 'Initials': 'J', 'LastName': 'van der Palen', 'Affiliation': 'Faculty of Behavioural, Management and Social Sciences (BMS), University of Twente, 7522 NB Enschede, The Netherlands.'}, {'ForeName': 'Pim', 'Initials': 'P', 'LastName': 'Schaap', 'Affiliation': 'Department of Pediatrics, Hospital Group Twente, 7609 PP Almelo, The Netherlands.'}, {'ForeName': 'Mirthe', 'Initials': 'M', 'LastName': 'van Voorthuizen', 'Affiliation': 'Department of Pediatrics, Hospital Group Twente, 7609 PP Almelo, The Netherlands.'}, {'ForeName': 'Thalia', 'Initials': 'T', 'LastName': 'Hummel', 'Affiliation': 'Department of Pediatrics, Medical Centre Twente, 7512 KZ Enschede, The Netherlands.'}]",International journal of environmental research and public health,['10.3390/ijerph17103689'] 1432,32456250,Effects of the Use of Air Purifier on Indoor Environment and Respiratory System among Healthy Adults.,"Air purifiers have become popular among ordinary families. However, it remains controversial whether indoor air purification improves the respiratory health of healthy adults. A randomized crossover intervention study was conducted with 32 healthy individuals. The subjects were categorized into two groups. One group continuously used true air purifiers, and the other followed with sham air purifiers for 4 weeks. Following this first intervention, all the subjects underwent a 4-week washout period and continued with the second 4-week intervention with the alternate air purifiers. We collected fine particulate matter (PM) ≤ 2.5 µm in aerodynamic diameter (PM2.5), coarse particulate matter between 2.5 and 10 µm in aerodynamic diameter (PM10-2.5) and ozone (O 3 ). The subjects' pulmonary function and fractional exhaled nitric oxide (FeNO) were measured during the study period. The indoor PM2.5 concentrations decreased by 11% with the true air purifiers compared to those with sham air purifiers. However, this decrease was not significant ( p = 0.08). The air purification did not significantly improve the pulmonary function of the study subjects. In contrast, an increase in the indoor PM10-2.5 and O 3 concentration led to a significant decrease in the forced expiratory volume in one second (FEV 1.0 )/forced vital capacity (FVC) and maximal mid-expiratory flow (MMEF), respectively. In conclusion, air purification slightly improved the indoor PM2.5 concentrations in ordinary homes but had no demonstrable impact on improving health.",2020,The indoor PM2.5 concentrations decreased by 11% with the true air purifiers compared to those with sham air purifiers.,"['Healthy Adults', 'healthy adults', '32 healthy individuals']",['Air Purifier'],"['health', 'indoor PM2.5 concentrations', 'pulmonary function', 'Indoor Environment and Respiratory System', ""subjects' pulmonary function and fractional exhaled nitric oxide (FeNO"", 'forced expiratory volume in one second (FEV 1.0 )/forced vital capacity (FVC) and maximal mid-expiratory flow (MMEF']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0262774', 'cui_str': 'Air Purifier'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0035237', 'cui_str': 'Structure of respiratory system'}, {'cui': 'C4523905', 'cui_str': 'Fractional exhaled nitric oxide'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0042834', 'cui_str': 'Vital capacity'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0231985', 'cui_str': 'Mean maximum expiratory flow'}]",32.0,0.016093,The indoor PM2.5 concentrations decreased by 11% with the true air purifiers compared to those with sham air purifiers.,"[{'ForeName': 'Yoshiko', 'Initials': 'Y', 'LastName': 'Yoda', 'Affiliation': 'Department of Public Health, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Tamura', 'Affiliation': 'Center for Health and Environmental Risk Research, National Institute for Environmental Studies, Tsukuba 305-8506, Japan.'}, {'ForeName': 'Sho', 'Initials': 'S', 'LastName': 'Adachi', 'Affiliation': ""Hyogo Regional Center of Japan Environment and Children's Study, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.""}, {'ForeName': 'Naruhito', 'Initials': 'N', 'LastName': 'Otani', 'Affiliation': 'Department of Public Health, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.'}, {'ForeName': 'Shoji F', 'Initials': 'SF', 'LastName': 'Nakayama', 'Affiliation': 'Center for Health and Environmental Risk Research, National Institute for Environmental Studies, Tsukuba 305-8506, Japan.'}, {'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Shima', 'Affiliation': 'Department of Public Health, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.'}]",International journal of environmental research and public health,['10.3390/ijerph17103687'] 1433,32456272,Optimizing the Interaction of Exercise Volume and Metformin to Induce a Clinically Significant Reduction in Metabolic Syndrome Severity: A Randomised Trial.,"Insulin resistance is a central mediating factor of the metabolic syndrome (MetS), with exercise training and metformin proven antidotes to insulin resistance. However, when the two therapies are combined there is conflicting data regarding whether metformin blunts or improves exercise training-induced adaptations. The volume of exercise (duration, intensity, and frequency) on the interaction of exercise training and metformin has yet to be investigated. The aim of this study is therefore to explore the impact of a combination of different exercise volumes and metformin on MetS severity. This is a secondary analysis of data from one of the sites of the 'Exercise in Prevention of Metabolic Syndrome' (EX-MET) study. Ninety-nine adults with MetS were randomized into a 16-week exercise program completing either: (i) moderate-intensity continuous training (MICT) at 60-70% of peak heart rate (HRpeak) for 30 min/session ( n = 34, 150 min/week); (ii) high-volume high-intensity interval training (HIIT) consisting of 4 × 4 min bouts at 85-95% HRpeak, interspersed with 3 min of active recovery at 50-70% HRpeak ( n = 34, 38 min/session, 114 min/week); or (iii) low volume HIIT, 1 × 4 min bout of HIIT at 85-95% HRpeak ( n = 31, 17 min/session, 51 min/week). Metformin intake was monitored and recorded throughout the trial. MetS severity was calculated as z-scores derived from MetS risk factors assessed at pre- and post-intervention. Sixty-five participants had complete pre- and post-intervention data for MetS z-score, of which 18 participants (28%) were taking metformin. Over the 16-week intervention, a similar proportion of participants clinically improved MetS severity (Δ ≥ -0.87) with metformin (8/18, 44%) or without metformin (23/47, 49%) ( p = 0.75). While there were no between-group differences ( p = 0.24), in those who did not take metformin low-volume HIIT had more likely responders (10/15, 67%) compared to MICT (6/16, 38%) and high-volume HIIT (7/16, 44%). In those taking metformin, there was a lower proportion of participants who clinically improved MetS severity following high-volume HIIT (1/6, 17%) compared to MICT (2/4, 50%) and low-volume HIIT (5/8, 63%), but with no between-group difference ( p = 0.23). Moreover, in those who performed high-volume HIIT, there was a statistically significantly higher proportion ( p = 0.03) of likely non-responders with improved MetS severity in participants taking metformin (4/6, 67%) compared to those not taking metformin (3/16, 19%). In individuals with MetS, the effect of high volume HIIT on MetS severity may be blunted in those taking metformin. These findings need to be confirmed in a larger study.",2020,"Over the 16-week intervention, a similar proportion of participants clinically improved MetS severity (Δ ≥ -0.87) with metformin (8/18, 44%) or without metformin (23/47, 49%) ( p = 0.75).","['Ninety-nine adults with MetS', 'Sixty-five participants had complete pre- and post-intervention data for MetS z-score, of which 18 participants (28%) were taking']","['exercise training and metformin', 'Metformin', 'metformin', 'exercise program completing either: (i) moderate-intensity continuous training (MICT', 'MICT', 'high-volume high-intensity interval training (HIIT) consisting of 4 × 4 min bouts at 85-95% HRpeak, interspersed with 3 min of active recovery at 50-70% HRpeak']","['MetS severity', 'volume of exercise (duration, intensity, and frequency']","[{'cui': 'C3828813', 'cui_str': '99'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0450385', 'cui_str': '65'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C1515187', 'cui_str': 'Take'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0205177', 'cui_str': 'Active'}]","[{'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}]",99.0,0.0481252,"Over the 16-week intervention, a similar proportion of participants clinically improved MetS severity (Δ ≥ -0.87) with metformin (8/18, 44%) or without metformin (23/47, 49%) ( p = 0.75).","[{'ForeName': 'Joyce S', 'Initials': 'JS', 'LastName': 'Ramos', 'Affiliation': 'Caring Futures Institute & SHAPE Research Centre, Exercise Science and Clinical Exercise Physiology, College of Nursing and Health Sciences, Flinders University, Room S268, South Wing, Sturt Building, Bedford Park, Adelaide 5042, South Australia, Australia.'}, {'ForeName': 'Lance C', 'Initials': 'LC', 'LastName': 'Dalleck', 'Affiliation': 'Caring Futures Institute & SHAPE Research Centre, Exercise Science and Clinical Exercise Physiology, College of Nursing and Health Sciences, Flinders University, Room S268, South Wing, Sturt Building, Bedford Park, Adelaide 5042, South Australia, Australia.'}, {'ForeName': 'Caitlin E', 'Initials': 'CE', 'LastName': 'Keith', 'Affiliation': 'Caring Futures Institute & SHAPE Research Centre, Exercise Science and Clinical Exercise Physiology, College of Nursing and Health Sciences, Flinders University, Room S268, South Wing, Sturt Building, Bedford Park, Adelaide 5042, South Australia, Australia.'}, {'ForeName': 'Mackenzie', 'Initials': 'M', 'LastName': 'Fennell', 'Affiliation': 'Caring Futures Institute & SHAPE Research Centre, Exercise Science and Clinical Exercise Physiology, College of Nursing and Health Sciences, Flinders University, Room S268, South Wing, Sturt Building, Bedford Park, Adelaide 5042, South Australia, Australia.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Lee', 'Affiliation': 'Caring Futures Institute & SHAPE Research Centre, Exercise Science and Clinical Exercise Physiology, College of Nursing and Health Sciences, Flinders University, Room S268, South Wing, Sturt Building, Bedford Park, Adelaide 5042, South Australia, Australia.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Drummond', 'Affiliation': 'Caring Futures Institute & SHAPE Research Centre, Exercise Science and Clinical Exercise Physiology, College of Nursing and Health Sciences, Flinders University, Room S268, South Wing, Sturt Building, Bedford Park, Adelaide 5042, South Australia, Australia.'}, {'ForeName': 'Shelley E', 'Initials': 'SE', 'LastName': 'Keating', 'Affiliation': 'Centre for Research on Exercise, Physical Activity and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane 4072, Queensland, Australia.'}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Fassett', 'Affiliation': 'Centre for Research on Exercise, Physical Activity and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane 4072, Queensland, Australia.'}, {'ForeName': 'Jeff S', 'Initials': 'JS', 'LastName': 'Coombes', 'Affiliation': 'Centre for Research on Exercise, Physical Activity and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane 4072, Queensland, Australia.'}]",International journal of environmental research and public health,['10.3390/ijerph17103695'] 1434,32458391,Temporal Deployment of Attention by Mental Training: an fMRI Study.,"In this study, we employed a visuo-motor imagery task of alertness as a mental training to examine temporal processing of motor responses within healthy young adults. Participants were divided into two groups (group 1; n = 20 who performed the mental training before the real physical task and a control group who performed the physical task without mental training). We vary the time interval between the imperative stimulus and the preceding one (fore-period) in which temporal preparation and arousal increase briefly. Our behavioural results provide clear evidence that mental training reinforces both temporal preparation and arousal, by shortening reaction time (RT), especially for the shortest fore-periods (FP) within exogenous ""FP 250 ms"" (p = 0.008) and endogenous alertness ""FP 650 ms"" (p = 0.001). We investigated how the brain controls such small temporal changes. We focus our neural hypothesis on three brain regions: anterior insula, dorsolateral prefrontal cortex, and anterior cingulate cortex and three putative circuits: one top-down (from dorsolateral prefrontal cortex to anterior cingulate cortex) and two bottom-up (from anterior insula to dorsolateral prefrontal cortex and anterior cingulate cortex). In fMRI, effective connectivity is strengthened during exogenous alertness between anterior insula and dorsolateral prefrontal cortex (p = 0.001), between anterior insula and cingulate cortex (p = 0.01), and during endogenous alertness between dorsolateral prefrontal cortex and anterior cingulate cortex (p = 0.05). We suggest that attentional reinforcement induced by an intensive and short session of mental training induces a temporal deployment of attention and allow optimizing the time pressure by maintaining a high state of arousal and ameliorating temporal preparation.",2020,"In fMRI, effective connectivity is strengthened during exogenous alertness between anterior insula and dorsolateral prefrontal cortex (p = 0.001), between anterior insula and cingulate cortex (p = 0.01), and during endogenous alertness between dorsolateral prefrontal cortex and anterior cingulate cortex (p = 0.05).",['healthy young adults'],"['Temporal Deployment of Attention by Mental Training', 'mental training before the real physical task and a control group who performed the physical task without mental training', 'visuo-motor imagery task of alertness as a mental training']","['anterior insula and cingulate cortex', 'endogenous alertness between dorsolateral prefrontal cortex and anterior cingulate cortex', 'shortening reaction time (RT']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0442043', 'cui_str': 'Temporal'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}]","[{'cui': 'C0228259', 'cui_str': 'Anterior insula'}, {'cui': 'C0598179', 'cui_str': 'Cingulate Cortex'}, {'cui': 'C0205227', 'cui_str': 'Endogenous'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate Gyrus'}, {'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}]",,0.0136049,"In fMRI, effective connectivity is strengthened during exogenous alertness between anterior insula and dorsolateral prefrontal cortex (p = 0.001), between anterior insula and cingulate cortex (p = 0.01), and during endogenous alertness between dorsolateral prefrontal cortex and anterior cingulate cortex (p = 0.05).","[{'ForeName': 'Souhir', 'Initials': 'S', 'LastName': 'Daly', 'Affiliation': 'LINP2 (Interdisciplinary Laboratory in Neurosciences, Physiology and Psychology), Université Paris Nanterre, 200 Avenue de la république, 92000, Nanterre, France. souhir.daly91@gmail.com.'}, {'ForeName': 'Jade', 'Initials': 'J', 'LastName': 'Thai', 'Affiliation': 'Clinical Research & Imaging Centre (CRICBristol), Bristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol, UK.'}, {'ForeName': 'Chama', 'Initials': 'C', 'LastName': 'Belkhiria', 'Affiliation': 'LINP2 (Interdisciplinary Laboratory in Neurosciences, Physiology and Psychology), Université Paris Nanterre, 200 Avenue de la république, 92000, Nanterre, France.'}, {'ForeName': 'Chistelle', 'Initials': 'C', 'LastName': 'Langley', 'Affiliation': 'Clinical Research & Imaging Centre (CRICBristol), Bristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol, UK.'}, {'ForeName': 'Alain Le', 'Initials': 'AL', 'LastName': 'Blanche', 'Affiliation': 'LINP2 (Interdisciplinary Laboratory in Neurosciences, Physiology and Psychology), Université Paris Nanterre, 200 Avenue de la république, 92000, Nanterre, France.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'de Marco', 'Affiliation': 'LINP2 (Interdisciplinary Laboratory in Neurosciences, Physiology and Psychology), Université Paris Nanterre, 200 Avenue de la république, 92000, Nanterre, France.'}]","Cognitive, affective & behavioral neuroscience",['10.3758/s13415-020-00795-4'] 1435,32462607,Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO ® and OTEMTO ® Studies.,"INTRODUCTION The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report recommends long-acting muscarinic antagonists (LAMA) or long-acting β 2 -agonists (LABA) as first-line treatment for chronic obstructive pulmonary disease (COPD), but many patients remain symptomatic on monotherapy and escalation to dual-bronchodilator therapy may be warranted. METHODS TONADO ® 1&2 and OTEMTO ® 1&2 assessed lung function and patient-reported outcomes in patients with moderate-to-severe (OTEMTO) or moderate-to-very-severe (TONADO) COPD. This pooled post hoc analysis included patients treated with LAMA monotherapy at baseline who were randomised to receive either 5 µg tiotropium (LAMA) or 5/5 µg tiotropium/olodaterol (LAMA/LABA). We assessed changes from baseline and responder rates for trough forced expiratory volume in 1 s (FEV 1 ), St. George's Respiratory Questionnaire (SGRQ) and the Transition Dyspnoea Index (TDI). RESULTS Overall, 151 patients received tiotropium; 148 received tiotropium/olodaterol. Mean differences from baseline with tiotropium/olodaterol versus tiotropium were + 0.074 l (95% confidence interval [CI] 0.033, 0.115; P = 0.0004) for trough FEV 1 , - 2.675 (95% CI - 5.060, - 0.291; P = 0.0280) for SGRQ and 1.148 (95% CI 0.564, 1.732; P = 0.0001) for TDI. Patients were more likely to respond when treated with tiotropium/olodaterol versus tiotropium for trough FEV 1 (odds ratio [OR] 3.14, 95% CI 1.94, 5.06; P < 0.0001), SGRQ (OR 1.49, 95% CI 0.93, 2.40; P = 0.0980) and TDI (OR 2.81, 95% CI 1.71, 4.60; P < 0.0001). Minimum clinically important difference from baseline in any of the analysed outcomes (FEV 1  ≥ 0.1 l, SGRQ ≥ 4.0 points or TDI ≥ 1.0 point) was more likely in patients treated with tiotropium/olodaterol versus tiotropium (OR 2.43, 95% CI 1.32, 4.51; P = 0.0046). CONCLUSION In patients with COPD receiving only LAMA monotherapy, treatment escalation to tiotropium/olodaterol resulted in statistically significant and clinically relevant improvements in lung function, health status and breathlessness. These results support early therapy optimisation to dual bronchodilation with tiotropium/olodaterol in patients receiving tiotropium alone. TRIAL REGISTRATION TONADO ® 1 was registered in the US National Library of Medicine on 9 September 2011 (Clinicaltrials.gov: NCT01431274). TONADO ® 2 was registered in the US National Library of Medicine on 9 September 2011 (Clinicaltrials.gov: NCT01431287). OTEMTO ® 1 was registered in the US National Library of Medicine on 17 October 2013 (Clinicaltrials.gov: NCT01964352). OTEMTO ® 2 was registered in the US National Library of Medicine on 10 December 2013 (Clinicaltrials.gov: NCT02006732).",2020,"Minimum clinically important difference from baseline in any of the analysed outcomes (FEV 1  ≥ 0.1 l, SGRQ ≥ 4.0 points or TDI ≥ 1.0 point) was more likely in patients treated with tiotropium/olodaterol versus tiotropium (OR 2.43, 95% CI 1.32, 4.51; P = 0.0046). ","['® 2 was registered in the US National Library of Medicine on 10 December 2013', 'patients with COPD receiving only', 'Patients with COPD Receiving only LAMA at Baseline', 'patients receiving tiotropium alone', '® 1 was registered in the US National Library of Medicine on 17 October 2013', 'patients with moderate-to-severe (OTEMTO) or moderate-to-very-severe (TONADO) COPD', 'chronic obstructive pulmonary disease (COPD']","['tiotropium (LAMA) or 5/5\xa0µg tiotropium/olodaterol (LAMA/LABA', 'Tiotropium/Olodaterol', 'muscarinic antagonists (LAMA) or long-acting β 2 -agonists (LABA', 'tiotropium/olodaterol', 'LAMA monotherapy', 'tiotropium/olodaterol versus tiotropium', 'Tiotropium', 'tiotropium']","['SGRQ', 'lung function, health status and breathlessness', ""trough forced expiratory volume in 1\xa0s (FEV 1 ), St. George's Respiratory Questionnaire (SGRQ) and the Transition Dyspnoea Index (TDI""]","[{'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0027470', 'cui_str': 'National Library of Medicine'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0003385', 'cui_str': 'Muscarinic receptor antagonist'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0213771', 'cui_str': 'tiotropium'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C3641272', 'cui_str': 'Very severe'}]","[{'cui': 'C0213771', 'cui_str': 'tiotropium'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0003385', 'cui_str': 'Muscarinic receptor antagonist'}, {'cui': 'C2934193', 'cui_str': 'olodaterol'}, {'cui': 'C0243192', 'cui_str': 'agonists'}]","[{'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0444506', 'cui_str': 'Trough'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205976', 'cui_str': 'Toluene di-isocyanate-containing product'}]",,0.511381,"Minimum clinically important difference from baseline in any of the analysed outcomes (FEV 1  ≥ 0.1 l, SGRQ ≥ 4.0 points or TDI ≥ 1.0 point) was more likely in patients treated with tiotropium/olodaterol versus tiotropium (OR 2.43, 95% CI 1.32, 4.51; P = 0.0046). ","[{'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Buhl', 'Affiliation': 'Pulmonary Department, Johannes Gutenberg University Hospital, Mainz, Germany. Roland.Buhl@unimedizin-mainz.de.'}, {'ForeName': 'Dave', 'Initials': 'D', 'LastName': 'Singh', 'Affiliation': 'Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'de la Hoz', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.'}, {'ForeName': 'Wenqiong', 'Initials': 'W', 'LastName': 'Xue', 'Affiliation': 'Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.'}, {'ForeName': 'Gary T', 'Initials': 'GT', 'LastName': 'Ferguson', 'Affiliation': 'Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA.'}]",Advances in therapy,['10.1007/s12325-020-01373-3'] 1436,32459669,"Use of real-time visual feedback during overground walking training on gait symmetry and velocity in patients with post-stroke hemiparesis: randomized controlled, single-blind study.","This study aimed to determine the efficacy of using real-time visual feedback during overground walking training to improve walking function in patients with post-stroke hemiparesis. Twenty-four patients with post-stroke hemiparesis who were able to walk independently under less impact of synergy pattern on the affected lower limbs (Brunnstrom stage IV or V) were randomly assigned to either the experimental group or the control group. All subjects performed overground walking for 30 min, three times a week for 6 weeks, with real-time visual feedback (weight load to the affected lower limb) provided during training for subjects in the experimental group. Outcome measures comprised the timed up-and-go test and gait parameters (step length, stride length, single and double support times, step and stride length ratios, and single support time ratio). In between-group comparison, the changes between pre-test and post-test scores in all parameters were significantly greater in the experimental group than in the control group (P < 0.05), except for double support time and step length ratio. Furthermore, post-test values of all parameters were significantly more improved in the experimental group than in the control group (P < 0.05). Our findings suggest that real-time visual feedback may be an advantageous therapeutic adjunct to reinforce the effects of overground walking training in patients with post-stroke hemiparesis.",2020,"In between-group comparison, the changes between pre-test and post-test scores in all parameters were significantly greater in the experimental group than in the control group (P < 0.05), except for double support time and step length ratio.","['Twenty-four patients with post-stroke hemiparesis who were able to walk independently under less impact of synergy pattern on the affected lower limbs (Brunnstrom stage IV or V', 'patients with post-stroke hemiparesis']","['overground walking training', 'real-time visual feedback during overground walking training']","['gait symmetry and velocity', 'walking function', 'timed up-and-go test and gait parameters (step length, stride length, single and double support times, step and stride length ratios, and single support time ratio', 'double support time and step length ratio']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0018989', 'cui_str': 'Hemiparesis'}, {'cui': 'C2712089', 'cui_str': 'Able to walk'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0392760', 'cui_str': 'Affecting'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0441772', 'cui_str': 'Stage level 4'}]","[{'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C2936181', 'cui_str': 'Visual Feedback'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0332516', 'cui_str': 'Symmetrical'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0427126', 'cui_str': 'Step length'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1264675', 'cui_str': 'Time ratio'}]",24.0,0.0246643,"In between-group comparison, the changes between pre-test and post-test scores in all parameters were significantly greater in the experimental group than in the control group (P < 0.05), except for double support time and step length ratio.","[{'ForeName': 'Jin-Seop', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': 'Department of Physical Therapy, College of Health Science, Sunmoon University, 70 Sumoon-ro 221 Beon-Gil, Tangjeong-Myeon, Asan-Si, Chungcheongnam-do.'}, {'ForeName': 'Duck-Won', 'Initials': 'DW', 'LastName': 'Oh', 'Affiliation': 'Department of Physical Therapy, College of Health and Medical Science, Cheongju University, 298 Daeseong-ro, Cheongwon-gu, Cheongju, Chungcheongbuk-do, Republic of Korea.'}]",International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation,['10.1097/MRR.0000000000000419'] 1437,31388184,Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel.,"BACKGROUND An early detection tool for EOC was constructed from analysis of biomarker expression data from serum collected during the UKCTOCS. METHODS This study included 49 EOC cases (19 Type I and 30 Type II) and 31 controls, representing 482 serial samples spanning seven years pre-diagnosis. A logit model was trained by analysis of dysregulation of expression data of four putative biomarkers, (CA125, phosphatidylcholine-sterol acyltransferase, vitamin K-dependent protein Z and C-reactive protein); by scoring the specificity associated with dysregulation from the baseline expression for each individual. RESULTS The model is discriminatory, passes k-fold and leave-one-out cross-validations and was further validated in a Type I EOC set. Samples were analysed as a simulated annual screening programme, the algorithm diagnosed cases with >30% PPV 1-2 years pre-diagnosis. For Type II cases (~80% were HGS) the algorithm classified 64% at 1 year and 28% at 2 years tDx as severe. CONCLUSIONS The panel has the potential to diagnose EOC one-two years earlier than current diagnosis. This analysis provides a tangible worked example demonstrating the potential for development as a screening tool and scrutiny of its properties. Limits on interpretation imposed by the number of samples available are discussed.",2019,"The model is discriminatory, passes k-fold and leave-one-out cross-validations and was further validated in a Type I EOC set.","['For Type II cases (~80% were HGS', '49 EOC cases (19 Type I and 30 Type II) and 31 controls, representing 482 serial samples spanning seven years pre-diagnosis']",[],[],"[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C1568891', 'cui_str': 'HGS protein, human'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]",[],[],49.0,0.0221786,"The model is discriminatory, passes k-fold and leave-one-out cross-validations and was further validated in a Type I EOC set.","[{'ForeName': 'Matthew R', 'Initials': 'MR', 'LastName': 'Russell', 'Affiliation': 'Stoller Biomarker Discovery Centre and Manchester Molecular Pathology Innovation Centre, Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Ciaren', 'Initials': 'C', 'LastName': 'Graham', 'Affiliation': 'School of Biological Sciences, Queens University Belfast, Chlorine Gardens, Belfast, BT9 5DL, UK.'}, {'ForeName': 'Alfonsina', 'Initials': 'A', 'LastName': ""D'Amato"", 'Affiliation': 'Department of Pharmaceutical Sciences, University of Milan, Milano, Lombardy, Italy.'}, {'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Gentry-Maharaj', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, London, UK.'}, {'ForeName': 'Andy', 'Initials': 'A', 'LastName': 'Ryan', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, London, UK.'}, {'ForeName': 'Jatinderpal K', 'Initials': 'JK', 'LastName': 'Kalsi', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, London, UK.'}, {'ForeName': 'Anthony D', 'Initials': 'AD', 'LastName': 'Whetton', 'Affiliation': 'Stoller Biomarker Discovery Centre and Manchester Molecular Pathology Innovation Centre, Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Usha', 'Initials': 'U', 'LastName': 'Menon', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, London, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Jacobs', 'Affiliation': 'Stoller Biomarker Discovery Centre and Manchester Molecular Pathology Innovation Centre, Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK. i.jacobs@unsw.edu.au.'}, {'ForeName': 'Robert L J', 'Initials': 'RLJ', 'LastName': 'Graham', 'Affiliation': 'School of Biological Sciences, Queens University Belfast, Chlorine Gardens, Belfast, BT9 5DL, UK. r.graham@qub.ac.uk.'}]",British journal of cancer,['10.1038/s41416-019-0544-0'] 1438,31388185,Tumour-infiltrating CD8 + lymphocytes and colorectal cancer recurrence by tumour and nodal stage.,"BACKGROUND Intratumoural T-cell infiltrate intensity cortes wrelaith clinical outcome in stage II/III colorectal cancer (CRC). We aimed to determine whether this association varies across this heterogeneous group. METHODS We performed a pooled analysis of 1804 CRCs from the QUASAR2 and VICTOR trials. Intratumoural CD8 + and CD3 + densities were quantified by immunohistochemistry in tissue microarray (TMA) cores, and their association with clinical outcome analysed by Cox regression. We validated our results using publicly available gene expression data in a pooled analysis of 1375 CRCs from seven independent series. RESULTS In QUASAR2, intratumoural CD8 + was a stronger predictor of CRC recurrence than CD3 + and showed similar discriminative ability to both markers in combination. Pooled multivariable analysis of both trials showed increasing CD8 + density was associated with reduced recurrence risk independent of confounders including DNA mismatch repair deficiency, POLE mutation and chromosomal instability (multivariable hazard ratio [HR] for each two-fold increase = 0.92, 95%CI = 0.87-0.97, P = 3.6 × 10 -3 ). This association was not uniform across risk strata defined by tumour and nodal stage: absent in low-risk (pT3,N0) cases (HR = 1.03, 95%CI = 0.87-1.21, P = 0.75), modest in intermediate-risk (pT4,N0 or pT1-3,N1-2) cases (HR = 0.92, 95%CI = 0.86-1.0, P = 0.046) and strong in high-risk (pT4,N1-2) cases (HR = 0.87, 95%CI = 0.79-0.97, P = 9.4 × 10 -3 ); P INTERACTION  = 0.090. Analysis of tumour CD8A expression in the independent validation cohort revealed similar variation in prognostic value across risk strata (P INTERACTION  = 0.048). CONCLUSIONS The prognostic value of intratumoural CD8 + cell infiltration in stage II/III CRC varies across tumour and nodal risk strata.",2019,"This association was not uniform across risk strata defined by tumour and nodal stage: absent in low-risk (pT3,N0) cases (HR = 1.03, 95%CI = 0.87-1.21, P = 0.75), modest in intermediate-risk (pT4,N0 or pT1-3,N1-2) cases (HR = 0.92, 95%CI = 0.86-1.0, P = 0.046) and strong in high-risk (pT4,N1-2) cases (HR = 0.87, 95%CI = 0.79-0.97, P = 9.4 × 10 -3 ); P INTERACTION  = 0.090.",['stage II/III colorectal cancer (CRC'],[],"['tumour CD8A expression', 'CRC recurrence', 'Tumour-infiltrating CD8 + lymphocytes and colorectal cancer recurrence', 'CD8 + density', 'DNA mismatch repair deficiency, POLE mutation and chromosomal instability', 'Intratumoural CD8 + and CD3 + densities']","[{'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}]",[],"[{'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0242629', 'cui_str': 'Lymphocyte positive for CD8 antigen'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C1155661', 'cui_str': 'DNA mismatch repair'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C0337815', 'cui_str': 'Poles'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C1257806', 'cui_str': 'Chromosome Instability'}, {'cui': 'C0108779', 'cui_str': 'Lymphocyte antigen CD3'}]",1804.0,0.198792,"This association was not uniform across risk strata defined by tumour and nodal stage: absent in low-risk (pT3,N0) cases (HR = 1.03, 95%CI = 0.87-1.21, P = 0.75), modest in intermediate-risk (pT4,N0 or pT1-3,N1-2) cases (HR = 0.92, 95%CI = 0.86-1.0, P = 0.046) and strong in high-risk (pT4,N1-2) cases (HR = 0.87, 95%CI = 0.79-0.97, P = 9.4 × 10 -3 ); P INTERACTION  = 0.090.","[{'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Glaire', 'Affiliation': 'Cancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK.'}, {'ForeName': 'Enric', 'Initials': 'E', 'LastName': 'Domingo', 'Affiliation': 'Cancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Sveen', 'Affiliation': 'Department of Molecular Oncology, Institute for Cancer Research & K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Jarle', 'Initials': 'J', 'LastName': 'Bruun', 'Affiliation': 'Department of Molecular Oncology, Institute for Cancer Research & K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Arild', 'Initials': 'A', 'LastName': 'Nesbakken', 'Affiliation': 'Department of Gastroenterological Surgery & K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Nicholson', 'Affiliation': 'Department of Statistics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Novelli', 'Affiliation': 'Department of Histopathology, UCL, Rockefeller Building, University Street, London, WC1E 6JJ, UK.'}, {'ForeName': 'Kay', 'Initials': 'K', 'LastName': 'Lawson', 'Affiliation': 'Department of Histopathology, UCL, Rockefeller Building, University Street, London, WC1E 6JJ, UK.'}, {'ForeName': 'Dahmane', 'Initials': 'D', 'LastName': 'Oukrif', 'Affiliation': 'Department of Histopathology, UCL, Rockefeller Building, University Street, London, WC1E 6JJ, UK.'}, {'ForeName': 'Wanja', 'Initials': 'W', 'LastName': 'Kildal', 'Affiliation': 'Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Havard E', 'Initials': 'HE', 'LastName': 'Danielsen', 'Affiliation': 'Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Kerr', 'Affiliation': 'Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals Foundation NHS Trust, Oxford, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kerr', 'Affiliation': 'Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, OX3 9 DU, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Tomlinson', 'Affiliation': 'Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.'}, {'ForeName': 'Ragnhild A', 'Initials': 'RA', 'LastName': 'Lothe', 'Affiliation': 'Department of Molecular Oncology, Institute for Cancer Research & K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'David N', 'Initials': 'DN', 'LastName': 'Church', 'Affiliation': 'Cancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK. dchurch@well.ox.ac.uk.'}]",British journal of cancer,['10.1038/s41416-019-0540-4'] 1439,32468955,Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.,"PURPOSE In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We describe exploratory analyses of intracranial efficacy and survival in participants with BMs. PATIENTS AND METHODS Patients were randomly assigned 2:1 to tucatinib or placebo, in combination with trastuzumab and capecitabine. All patients underwent baseline brain magnetic resonance imaging; those with BMs were classified as active or stable. Efficacy analyses were performed by applying RECIST 1.1 criteria to CNS target lesions by investigator assessment. CNS-PFS (intracranial progression or death) and overall survival (OS) were evaluated in all patients with BMs. Confirmed intracranial objective response rate (ORR-IC) was evaluated in patients with measurable intracranial disease. RESULTS There were 291 patients with BMs: 198 (48%) in the tucatinib arm and 93 (46%) in the control arm. The risk of intracranial progression or death was reduced by 68% in the tucatinib arm (hazard ratio [HR], 0.32; 95% CI, 0.22 to 0.48; P < .0001). Median CNS-PFS was 9.9 months in the tucatinib arm versus 4.2 months in the control arm. Risk of death was reduced by 42% in the tucatinib arm (OS HR, 0.58; 95% CI, 0.40 to 0.85; P = .005). Median OS was 18.1 versus 12.0 months. ORR-IC was higher in the tucatinib arm (47.3%; 95% CI, 33.7% to 61.2%) versus the control arm (20.0%; 95% CI, 5.7% to 43.7%; P = .03). CONCLUSION In patients with HER2-positive breast cancer with BMs, the addition of tucatinib to trastuzumab and capecitabine doubled ORR-IC, reduced risk of intracranial progression or death by two thirds, and reduced risk of death by nearly half. To our knowledge, this is the first regimen to demonstrate improved antitumor activity against BMs in patients with HER2-positive breast cancer in a randomized, controlled trial.",2020,"ORR-IC was higher in the tucatinib arm (47.3%; 95% CI, 33.7% to 61.2%) versus the control arm (20.0%; 95% CI, 5.7% to 43.7%; P = .03). ","['patients with HER2-positive breast cancer', 'Patients', 'Previously Treated HER2-Positive Breast Cancer', 'participants with BMs', 'patients with HER2-positive breast cancer with BMs', '291 patients with BMs: 198 (48%) in the tucatinib arm and 93 (46%) in the control arm', 'patients with measurable intracranial disease', 'patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with brain metastases (BMs']","['baseline brain magnetic resonance imaging', 'Tucatinib Plus Trastuzumab and Capecitabine', 'tucatinib or placebo, in combination with trastuzumab and capecitabine']","['risk of intracranial progression or death', 'Risk of death', 'ORR-IC', 'Median OS', 'risk of death', 'intracranial efficacy and survival', 'Median CNS-PFS', 'Intracranial Efficacy and Survival', 'intracranial objective response rate (ORR-IC', 'antitumor activity against BMs', 'CNS-PFS (intracranial progression or death) and overall survival (OS', 'progression-free survival (PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0220650', 'cui_str': 'Secondary malignant neoplasm of brain'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0524466', 'cui_str': 'Intracranial'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0524466', 'cui_str': 'Intracranial'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0028654', 'cui_str': 'Clinical nurse specialist'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0220650', 'cui_str': 'Secondary malignant neoplasm of brain'}]",291.0,0.139198,"ORR-IC was higher in the tucatinib arm (47.3%; 95% CI, 33.7% to 61.2%) versus the control arm (20.0%; 95% CI, 5.7% to 43.7%; P = .03). ","[{'ForeName': 'Nancy U', 'Initials': 'NU', 'LastName': 'Lin', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Borges', 'Affiliation': 'University of Colorado Cancer Center, Aurora, CO.'}, {'ForeName': 'Carey', 'Initials': 'C', 'LastName': 'Anders', 'Affiliation': 'Duke Cancer Institute, Durham, NC.'}, {'ForeName': 'Rashmi K', 'Initials': 'RK', 'LastName': 'Murthy', 'Affiliation': 'MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Elisavet', 'Initials': 'E', 'LastName': 'Paplomata', 'Affiliation': 'Carbone Cancer Center/University of Wisconsin, Madison, WI.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Hamilton', 'Affiliation': 'Sarah Cannon Research Institute/Tennessee Oncology-Nashville, Nashville, TN.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Hurvitz', 'Affiliation': 'University of California Los Angeles Medical Center/Jonsson Comprehensive Cancer Center, Los Angeles, CA.'}, {'ForeName': 'Sherene', 'Initials': 'S', 'LastName': 'Loi', 'Affiliation': 'Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Okines', 'Affiliation': 'Royal Marsden National Health Service (NHS) Foundation Trust, London, United Kingdom.'}, {'ForeName': 'Vandana', 'Initials': 'V', 'LastName': 'Abramson', 'Affiliation': 'Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Philippe L', 'Initials': 'PL', 'LastName': 'Bedard', 'Affiliation': 'University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada.'}, {'ForeName': 'Mafalda', 'Initials': 'M', 'LastName': 'Oliveira', 'Affiliation': ""Hospital Universitario Vall D'Hebron, Barcelona, Spain.""}, {'ForeName': 'Volkmar', 'Initials': 'V', 'LastName': 'Mueller', 'Affiliation': 'Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'Zelnak', 'Affiliation': 'Northside Hospital, Atlanta, GA.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'DiGiovanna', 'Affiliation': 'Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Bachelot', 'Affiliation': 'Centre Léon Bérard, Lyon, France.'}, {'ForeName': 'A Jo', 'Initials': 'AJ', 'LastName': 'Chien', 'Affiliation': 'University of California at San Francisco, San Francisco, CA.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': ""O'Regan"", 'Affiliation': 'Carbone Cancer Center/University of Wisconsin, Madison, WI.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Wardley', 'Affiliation': 'Christie NHS Foundation Trust, Manchester Academic Health Science Centre & Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Conlin', 'Affiliation': 'Providence Cancer Institute, Portland, OR.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cameron', 'Affiliation': 'Edinburgh Cancer Research Centre, Edinburgh, United Kingdom.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Carey', 'Affiliation': 'University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Curigliano', 'Affiliation': 'Istituto Europeo di Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, University of Milano, Milan, Italy.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Gelmon', 'Affiliation': 'British Columbia Cancer-Vancouver Centre, Vancouver, BC, Canada.'}, {'ForeName': 'Sibylle', 'Initials': 'S', 'LastName': 'Loibl', 'Affiliation': 'German Breast Group, Neu-Isenburg, Germany.'}, {'ForeName': 'JoAl', 'Initials': 'J', 'LastName': 'Mayor', 'Affiliation': 'Seattle Genetics, Bothell, WA.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'McGoldrick', 'Affiliation': 'Seattle Genetics, Bothell, WA.'}, {'ForeName': 'Xuebei', 'Initials': 'X', 'LastName': 'An', 'Affiliation': 'Seattle Genetics, Bothell, WA.'}, {'ForeName': 'Eric P', 'Initials': 'EP', 'LastName': 'Winer', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.20.00775'] 1440,31301031,Prospective Longitudinal Trends in Body Composition and Clinical Outcomes 3 Years Following Sleeve Gastrectomy.,"BACKGROUND AND AIMS Longitudinal assessment of body composition following bariatric surgery allows monitoring of health status. Our aim was to elucidate trends of anthropometric and clinical outcomes 3 years following sleeve gastrectomy (SG). METHODS A prospective cohort study of 60 patients who underwent SG. Anthropometrics including body composition analysis measured by multi-frequency bioelectrical impedance analysis, blood tests, liver fat content measured by abdominal ultrasound and habitual physical activity were evaluated at baseline and at 6 (M6), 12 (M12), and 36 (M36) months post-surgery. RESULTS Sixty patients (55% women, age 44.7 ± 8.7 years) who completed the entire follow-up were included. Fat mass (FM) was reduced significantly 1 year post-surgery (55.8 ± 11.3 to 26.7 ± 8.3 kg; P < 0.001) and then increased between 1 and 3 years post-operatively, but remained below baseline level (26.7 ± 8.3 to 33.1 ± 11.1 kg; P < 0.001). Fat free mass (FFM) decreased significantly during the first 6 months (64.7 ± 14.3 to 56.9 ± 11.8 kg; P < 0.001), slightly decreased between M6 and M12 and then reached a plateau through M36. Weight loss ""failure"" (< 50% excess weight loss) was noticed in 5.0% and 28.3% of patients at M12 and M36, respectively. Markers of lipid and glucose metabolism changed thereafter in parallel to the changes observed in FM, with the exception of HDL-C, which increased continuingly from M6 throughout the whole period analyzed (45.0 ± 10.2 to 59.5 ± 15.4 mg/dl; P < 0.001) and HbA1c which continued to decrease between M12 and M36 (5.5 ± 0.4 to 5.3 ± 0.4%; P < 0.001). There were marked within-person variations in trends of anthropometric and clinical parameters during the 3-year follow-up. CONCLUSIONS Weight regain primarily attributed to FM with no further decrease in FFM occurs between 1 and 3 years post-SG. FM increase at mid-term may underlie the recurrence of metabolic risk factors and can govern clinical interventions.",2019,"Fat mass (FM) was reduced significantly 1 year post-surgery (55.8 ± 11.3 to 26.7 ± 8.3 kg; P < 0.001) and then increased between 1 and 3 years post-operatively, but remained below baseline level (26.7 ± 8.3 to 33.1 ± 11.1 kg; P < 0.001).","['Years', '60 patients who underwent SG', 'Sixty patients (55% women, age 44.7\u2009±\u20098.7\xa0years) who completed the entire follow-up were included']","['Sleeve Gastrectomy', 'sleeve gastrectomy (SG']","['Fat free mass', 'FFM', 'Weight loss ""failure', 'Anthropometrics including body composition analysis measured by multi-frequency bioelectrical impedance analysis, blood tests, liver fat content measured by abdominal ultrasound and habitual physical activity', 'Markers of lipid and glucose metabolism', 'Fat mass (FM']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517880', 'cui_str': '8.7'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439751', 'cui_str': 'Entire'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}]","[{'cui': 'C0424679', 'cui_str': 'Fat-free mass'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0162536', 'cui_str': 'Biolectric Impedance'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}]",60.0,0.0308344,"Fat mass (FM) was reduced significantly 1 year post-surgery (55.8 ± 11.3 to 26.7 ± 8.3 kg; P < 0.001) and then increased between 1 and 3 years post-operatively, but remained below baseline level (26.7 ± 8.3 to 33.1 ± 11.1 kg; P < 0.001).","[{'ForeName': 'Shiri', 'Initials': 'S', 'LastName': 'Sherf-Dagan', 'Affiliation': 'Department Gastroenterology, Tel-Aviv Medical Center, Tel Aviv, Israel. shirisherf@gmail.com.'}, {'ForeName': 'Shira', 'Initials': 'S', 'LastName': 'Zelber-Sagi', 'Affiliation': 'Department Gastroenterology, Tel-Aviv Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Assaf', 'Initials': 'A', 'LastName': 'Buch', 'Affiliation': 'Institute of Endocrinology, Metabolism and Hypertension, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Nir', 'Initials': 'N', 'LastName': 'Bar', 'Affiliation': 'Department Gastroenterology, Tel-Aviv Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Muriel', 'Initials': 'M', 'LastName': 'Webb', 'Affiliation': 'Department Gastroenterology, Tel-Aviv Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Nasser', 'Initials': 'N', 'LastName': 'Sakran', 'Affiliation': 'Israeli Center for Bariatric Surgery (ICBS), Assia Medical Group, Assuta Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Asnat', 'Initials': 'A', 'LastName': 'Raziel', 'Affiliation': 'Israeli Center for Bariatric Surgery (ICBS), Assia Medical Group, Assuta Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Goitein', 'Affiliation': 'Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Andrei', 'Initials': 'A', 'LastName': 'Keidar', 'Affiliation': ""Department of General Surgery, Assuta Ashdod Public Hospital, The Ben-Gurion University, Be'er Sheva, Israel.""}, {'ForeName': 'Oren', 'Initials': 'O', 'LastName': 'Shibolet', 'Affiliation': 'Department Gastroenterology, Tel-Aviv Medical Center, Tel Aviv, Israel.'}]",Obesity surgery,['10.1007/s11695-019-04057-2'] 1441,32472292,"The effects of taurine supplementation on glycemic control and serum lipid profile in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.","Previous studies have suggested that taurine has hypoglycemic and hypolipidemic effects on experimental diabetic models. Therefore, this clinical trial was designed to explore the impacts of taurine supplementation on glycemic control and lipid profile in the patients with T2DM. This study was conducted on 45 patients with T2DM in Tabriz Sheikhor-raees Polyclinic and Imam-Reza Hospital Endocrine Center. Subjects were randomly divided into taurine and placebo groups. Accordingly, the taurine group (n = 23) received taurine 3000 mg/daily and the placebo group (n = 22) took crystalline microcellulose/daily for the duration of 8 weeks. At baseline and after the trial completion, fasting blood samples were obtained from the patients to assess the glycemic indicators and lipid profile. Independent t test, paired t test, Pearson's correlation, and analysis of covariance was used for analysis. At the end of the study, levels of FBS (p = 0.01), insulin (p = 0.01), HOMA-IR (p = 0.003), TC (p = 0.013), and LDL-C (p = 0.041) significantly decreased in the taurine group compared to the placebo group. In addition, there was no significant changes in HbA1c, triglyceride, HDL-C, anthropometric indicators or dietary intakes by passing 8 weeks from the intervention. In conclusion, the findings of the current study indicated that taurine supplementation (3000 mg/day) for 8 weeks could improve the glycemic indexes and lipid profiles including TC and LDL-C in the patients with T2DM.",2020,"At the end of the study, levels of FBS (p = 0.01), insulin (p = 0.01), HOMA-IR (p = 0.003), TC (p = 0.013), and LDL-C (p = 0.041) significantly decreased in the taurine group compared to the placebo group.","['patients with T2DM', '45 patients with T2DM in Tabriz Sheikhor-raees Polyclinic and Imam-Reza Hospital Endocrine Center', 'patients with type 2 diabetes']","['taurine', 'taurine 3000\xa0mg/daily and the placebo', 'taurine supplementation', 'taurine and placebo', 'placebo']","['fasting blood samples', 'HOMA-IR', 'HbA1c, triglyceride, HDL-C, anthropometric indicators or dietary intakes', 'glycemic indexes and lipid profiles including TC and LDL-C', 'levels of FBS', 'glycemic control and serum lipid profile', 'glycemic control and lipid profile']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521321', 'cui_str': 'Imam'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0014136', 'cui_str': 'Structure of endocrine system'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0039350', 'cui_str': 'Taurine'}, {'cui': 'C0470279', 'cui_str': '3000'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C3495427', 'cui_str': 'Fanconi-Bickel Syndrome'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0428462', 'cui_str': 'Measurement of serum lipid level'}]",45.0,0.143721,"At the end of the study, levels of FBS (p = 0.01), insulin (p = 0.01), HOMA-IR (p = 0.003), TC (p = 0.013), and LDL-C (p = 0.041) significantly decreased in the taurine group compared to the placebo group.","[{'ForeName': 'Vahid', 'Initials': 'V', 'LastName': 'Maleki', 'Affiliation': 'Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Alizadeh', 'Affiliation': 'Nutrition Research Center, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Esmaeili', 'Affiliation': 'Department of Clinical Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Mahdavi', 'Affiliation': 'Nutrition Research Center, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. mahdavir@tbzmed.ac.ir.'}]",Amino acids,['10.1007/s00726-020-02859-8'] 1442,32469893,Acceptability and tolerability of repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine among healthy African participants in a phase 1 randomized controlled trial.,"INTRODUCTION Intramuscular electroporation (IM/EP) is a vaccine delivery technique that improves the immunogenicity of DNA vaccines. We evaluated the acceptability and tolerability of electroporation among healthy African study participants. METHODS Forty-five participants were administered a DNA vaccine (HIV-MAG) or placebo by electroporation at three visits occurring at four week-intervals. At the end of each visit, participants were asked to rate pain at four times: (1) when the device was placed on the skin and vaccine injected, before the electrical stimulation, (2) at the time of electrical stimulation and muscle contraction, and (3) at 10 minutes and (4) 30 minutes after the procedure was completed. For analyses, pain level was dichotomized as either ""acceptable"" (none/slight/uncomfortable) or ""too much"" (Intense, severe, and very severe) and examined over time using repeated measures models. Optional brief comments made by participants were summarized anecdotally. RESULTS All 45 participants completed all three vaccination visits; none withdrew from the study due to the electroporation procedure. Most (76%) reported pain levels as acceptable at every time point across all vaccination visits. The majority of ""unacceptable"" pain was reported at the time of electrical stimulation. The majority of the participants (97%) commented that they preferred electroporation to standard injection. CONCLUSION Repeated intramuscular electroporation for vaccine delivery was found to be acceptable and feasible among healthy African HIV vaccine trial participants. The majority of participants reported an acceptable pain level at all vaccination time points. Further investigation may be warranted into the value of EP to improve immunization outcomes. ClinicalTrials.gov NCT01496989.",2020,The majority of participants reported an acceptable pain level at all vaccination time points.,"['All 45 participants completed all three vaccination visits; none withdrew from the study due to the electroporation procedure', 'Forty-five participants', 'healthy African participants', 'healthy African study participants', 'healthy African HIV vaccine trial participants']","['DNA vaccine (HIV-MAG) or placebo', 'repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine', 'Intramuscular electroporation (IM/EP']","['Acceptability and tolerability', 'acceptability and tolerability of electroporation', 'pain level', 'rate pain', 'pain levels', 'acceptable pain level']","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0206691', 'cui_str': 'Electropermeabilisation'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0027567', 'cui_str': 'African race'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0376613', 'cui_str': 'DNA Vaccines'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0129439', 'cui_str': 'Myelin associate glycoprotein'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C0206691', 'cui_str': 'Electropermeabilisation'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0486959', 'cui_str': 'Human immunodeficiency virus DNA'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0206691', 'cui_str': 'Electropermeabilisation'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}]",45.0,0.16596,The majority of participants reported an acceptable pain level at all vaccination time points.,"[{'ForeName': 'Juliet', 'Initials': 'J', 'LastName': 'Mpendo', 'Affiliation': 'Uganda Virus Research Institute-International AIDS Vaccine Initiative, HIV Vaccine Program, Entebbe, Uganda.'}, {'ForeName': 'Gaudensia', 'Initials': 'G', 'LastName': 'Mutua', 'Affiliation': 'Kenya AIDS Vaccine Initiative, University of Nairobi, Nairobi, Kenya.'}, {'ForeName': 'Annet', 'Initials': 'A', 'LastName': 'Nanvubya', 'Affiliation': 'Uganda Virus Research Institute-International AIDS Vaccine Initiative, HIV Vaccine Program, Entebbe, Uganda.'}, {'ForeName': 'Omu', 'Initials': 'O', 'LastName': 'Anzala', 'Affiliation': 'Kenya AIDS Vaccine Initiative, University of Nairobi, Nairobi, Kenya.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Nyombayire', 'Affiliation': 'Project San Francisco (PSF), Kigali, Rwanda.'}, {'ForeName': 'Etienne', 'Initials': 'E', 'LastName': 'Karita', 'Affiliation': 'Project San Francisco (PSF), Kigali, Rwanda.'}, {'ForeName': 'Len', 'Initials': 'L', 'LastName': 'Dally', 'Affiliation': 'EMMES Corporation, Rockville, Maryland, United States of America.'}, {'ForeName': 'Drew', 'Initials': 'D', 'LastName': 'Hannaman', 'Affiliation': 'Ichor Medical Systems, Inc., San Diego, California, United States of America.'}, {'ForeName': 'Matt', 'Initials': 'M', 'LastName': 'Price', 'Affiliation': 'International AIDS Vaccine Initiative (IAVI), New York, NY, United States of America.'}, {'ForeName': 'Patricia E', 'Initials': 'PE', 'LastName': 'Fast', 'Affiliation': 'International AIDS Vaccine Initiative (IAVI), New York, NY, United States of America.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Priddy', 'Affiliation': 'International AIDS Vaccine Initiative (IAVI), New York, NY, United States of America.'}, {'ForeName': 'Huub C', 'Initials': 'HC', 'LastName': 'Gelderblom', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.'}, {'ForeName': 'Nancy K', 'Initials': 'NK', 'LastName': 'Hills', 'Affiliation': 'University of California at San Francisco, San Francisco, California, United States of America.'}]",PloS one,['10.1371/journal.pone.0233151'] 1443,32469920,Actor feedback and rigorous monitoring: Essential quality assurance tools for testing behavioral interventions with simulation.,"INTRODUCTION Simulation is a powerful tool for training and evaluating clinicians. However, few studies have examined the consistency of actor performances during simulation based medical education (SBME). The Simulated Communication with ICU Proxies trial (ClinicalTrials.gov NCT02721810) used simulation to evaluate the effect of a behavioral intervention on physician communication. The purpose of this secondary analysis of data generated by the quality assurance team during the trial was to assess how quality assurance monitoring procedures impacted rates of actor errors during simulations. METHODS The trial used rigorous quality assurance to train actors, evaluate performances, and ensure the intervention was delivered within a standardized environment. The quality assurance team evaluated video recordings and documented errors. Actors received both timely, formative feedback and participated in group feedback sessions. RESULTS Error rates varied significantly across three actors (H(2) = 8.22, p = 0.02). In adjusted analyses, there was a decrease in the incidence of actor error over time, and errors decreased sharply after the first group feedback session (Incidence Rate Ratio = 0.25, 95% confidence interval 0.14-0.42). CONCLUSIONS Rigorous quality assurance procedures may help ensure consistent actor performances during SBME.",2020,"In adjusted analyses, there was a decrease in the incidence of actor error over time, and errors decreased sharply after the first group feedback session (Incidence Rate Ratio = 0.25, 95% confidence interval 0.14-0.42). ",[],"['Actor feedback and rigorous monitoring', 'behavioral intervention']","['incidence of actor error over time, and errors', 'Error rates']",[],"[{'cui': 'C0335083', 'cui_str': 'Actor'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0335083', 'cui_str': 'Actor'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",,0.0672195,"In adjusted analyses, there was a decrease in the incidence of actor error over time, and errors decreased sharply after the first group feedback session (Incidence Rate Ratio = 0.25, 95% confidence interval 0.14-0.42). ","[{'ForeName': 'Martha A', 'Initials': 'MA', 'LastName': 'Abshire', 'Affiliation': 'School of Nursing, Johns Hopkins University, Baltimore, Maryland, United States of America.'}, {'ForeName': 'Xintong', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.'}, {'ForeName': 'Pragyashree Sharma', 'Initials': 'PS', 'LastName': 'Basyal', 'Affiliation': 'Outcomes After Critical Illness and Surgery (OACIS) Group, Johns Hopkins University, Baltimore, Maryland, United States of America.'}, {'ForeName': 'Melissa L', 'Initials': 'ML', 'LastName': 'Teply', 'Affiliation': 'Division of Geriatrics, Gerontology, and Palliative Medicine, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.'}, {'ForeName': 'Arun L', 'Initials': 'AL', 'LastName': 'Singh', 'Affiliation': ""Division of Pediatric Palliative Medicine, Prisma Health Children's Hopsital - Upstate, University of South Carolina School of Medicine - Greenville, Greenville, South Carolina, United States of America.""}, {'ForeName': 'Margaret M', 'Initials': 'MM', 'LastName': 'Hayes', 'Affiliation': 'Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America.'}, {'ForeName': 'Alison E', 'Initials': 'AE', 'LastName': 'Turnbull', 'Affiliation': 'Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.'}]",PloS one,['10.1371/journal.pone.0233538'] 1444,32469922,The Community Navigator Study: Results from a feasibility randomised controlled trial of a programme to reduce loneliness for people with complex anxiety or depression.,"BACKGROUND Loneliness is common among people with mental health problems and predicts poorer recovery from depression and anxiety. Needs for support with loneliness and social relationships are often under-addressed in mental health services. The Community Navigator programme was designed to reduce loneliness for adults (aged 18 and above) with complex depression or anxiety who were using secondary mental health services. Acceptability and feasibility of the programme and a trial evaluation were tested in a feasibility randomised controlled trial with qualitative evaluation. METHODS Forty participants with depression or anxiety using secondary mental health services were recruited from mental health services in two London sites and randomised to receive: the Community Navigator programme over six months in addition to routine care (n = 30); or routine care (n = 10). Measures of loneliness, depression, other clinical and social outcomes and service use were collected at baseline and six-months follow-up. Levels of engagement in the programme and rates of trial recruitment and retention were assessed. Programme delivery was assessed through session logs completed by Community Navigators. The acceptability of the programme was explored through qualitative interviews (n = 32) with intervention group participants, their family and friends, programme providers and other involved staff. RESULTS Forty participants were recruited in four months from 65 eligible potential participants asked. No one withdrew from the trial. Follow-up interviews were completed with 35 participants (88%). Process records indicated the programme was delivered as intended: there was a median of seven meetings with their Community Navigator (of a maximum ten) per treatment group participant. Qualitative interviews indicated good acceptability of the programme to stakeholders, and potential utility in reducing loneliness and depression and anxiety. CONCLUSIONS A definitive, multi-site randomised controlled trial is recommended to evaluate the effectiveness and cost-effectiveness of the Community Navigator programme for people with complex anxiety and depression in secondary mental health services.",2020,The Community Navigator programme was designed to reduce loneliness for adults (aged 18 and above) with complex depression or anxiety who were using secondary mental health services.,"['people with complex anxiety and depression in secondary mental health services', 'people with complex anxiety or depression', 'Forty participants were recruited in four months from 65 eligible potential participants asked', 'people with mental health problems', 'adults (aged 18 and above) with complex depression or anxiety who were using secondary mental health services', 'Forty participants with depression or anxiety using secondary mental health services were recruited from mental health services in two London sites and randomised to receive: the']","['Community Navigator programme over six months in addition to routine care (n = 30); or routine care', 'Community Navigator programme']","['Acceptability and feasibility', 'loneliness and depression and anxiety', 'effectiveness and cost-effectiveness', 'loneliness, depression, other clinical and social outcomes and service use']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0025355', 'cui_str': 'Mental health service'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1172410', 'cui_str': 'ASK protein, human'}, {'cui': 'C1446377', 'cui_str': 'Mental health problem'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0023973', 'cui_str': 'London'}, {'cui': 'C0205145', 'cui_str': 'Site'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0023974', 'cui_str': 'Feeling lonely'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",40.0,0.205116,The Community Navigator programme was designed to reduce loneliness for adults (aged 18 and above) with complex depression or anxiety who were using secondary mental health services.,"[{'ForeName': 'Brynmor', 'Initials': 'B', 'LastName': 'Lloyd-Evans', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Frerichs', 'Affiliation': 'The McPin Foundation, London, United Kingdom.'}, {'ForeName': 'Theodora', 'Initials': 'T', 'LastName': 'Stefanidou', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Bone', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Pinfold', 'Affiliation': 'The McPin Foundation, London, United Kingdom.'}, {'ForeName': 'Glyn', 'Initials': 'G', 'LastName': 'Lewis', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Billings', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Barber', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Anjie', 'Initials': 'A', 'LastName': 'Chhapia', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Beverley', 'Initials': 'B', 'LastName': 'Chipp', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Rob', 'Initials': 'R', 'LastName': 'Henderson', 'Affiliation': 'Camden and Islington NHS Foundation Trust, St Pancras Hospital, London, United Kingdom.'}, {'ForeName': 'Prisha', 'Initials': 'P', 'LastName': 'Shah', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Shorten', 'Affiliation': 'Camden and Islington NHS Foundation Trust, St Pancras Hospital, London, United Kingdom.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Giorgalli', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Terhune', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Jones', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Johnson', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}]",PloS one,['10.1371/journal.pone.0233535'] 1445,32469946,Training specificity performing single-joint vs. multi-joint resistance exercises among physically active females: A randomized controlled trial.,"Resistance-training of the lower limbs can be performed using exercises moving one (single-joint exercises) or several joints (multi-joint exercises). This study compared the effects of training one multi-joint exercise (leg press) or two single-joint exercises (leg extension and kickback) on dynamic and isometric strength and the transferability of dynamic strength between exercises. Fifty-three physically active women were randomized to a multi-joint (MJ) training group (age = 21.95±0.82 years, mass = 64.85±5.76 kg, height = 167.35±2.47 cm; n = 20), single-joint (SJ) training group (age = 22.56±1.66 years, mass = 64.85±5.76 kg, height = 165.94±2.84 cm; n = 18), or a control (CON) group (age = 21.27±0.68 years, mass = 68.43±4.86 kg, height = 168.63±2.84 cm; n = 15). The training groups participated in an 8-week supervised single- or multi-joint lower limb training consisting of 18 sessions. Pre- and post-training, six repetitions maximum (RM) and maximal voluntary isometric contraction in the three exercises were assessed, along with electromyography of the superficial quadriceps muscles. Improvements in all dynamic exercises were greatest after training the specific exercises (ES = 1.26-2.14, P<0.001-0.025) and all were greater in the training groups than in the CON group (ES = 1.43-3.31, P<0.001-0.021). The SJ group improved 6RM in leg extension and kickback more than leg press (ES = 1.51 and 2.04, respectively, P<0.001), whereas the MJ group improved leg press 6RM more than kickback (ES = 1.10, P = 0.002). However, leg press and leg extension strength improved similarly in the MJ group (ES = 0.54, P = 0.072). All strength and electromyographic measures remained unchanged in the CON group (ES = 0.00-0.44, P = 0.412-0.966). Improved dynamic strength in leg press, kickback and leg extension is best attained by training the specific exercises, but both training modalities can improve strength across all exercises.",2020,"The SJ group improved 6RM in leg extension and kickback more than leg press (ES = 1.51 and 2.04, respectively, P<0.001), whereas the MJ group improved leg press 6RM more than kickback (ES = 1.10, P = 0.002).","['group (age = 22.56±1.66 years, mass = 64.85±5.76 kg, height = 165.94±2.84 cm; n = 18), or a control (CON) group (age = 21.27±0.68 years, mass = 68.43±4.86 kg, height = 168.63±2.84 cm; n = 15', 'Fifty-three physically active women', 'group (age = 21.95±0.82 years, mass = 64.85±5.76 kg, height = 167.35±2.47 cm; n = 20', 'physically active females']","['multi-joint (MJ) training', 'Training specificity performing single-joint vs. multi-joint resistance exercises', 'Pre- and post-training, six repetitions maximum (RM) and maximal voluntary isometric contraction', 'single-joint (SJ) training', 'SJ', '8-week supervised single- or multi-joint lower limb training consisting of 18 sessions', 'training one multi-joint exercise (leg press) or two single-joint exercises (leg extension and kickback']","['6RM in leg extension and kickback', 'dynamic strength in leg press, kickback and leg extension', 'leg press 6RM', 'All strength and electromyographic measures', 'leg press and leg extension strength']","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0556453', 'cui_str': 'Physically active'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0022205', 'cui_str': 'Muscle isometric contraction'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0556502', 'cui_str': 'Lower limb training'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0086504', 'cui_str': 'Kickbacks'}]","[{'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0086504', 'cui_str': 'Kickbacks'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",53.0,0.0304002,"The SJ group improved 6RM in leg extension and kickback more than leg press (ES = 1.51 and 2.04, respectively, P<0.001), whereas the MJ group improved leg press 6RM more than kickback (ES = 1.10, P = 0.002).","[{'ForeName': 'Nicolay', 'Initials': 'N', 'LastName': 'Stien', 'Affiliation': 'Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Bergen, Norway.'}, {'ForeName': 'Helene', 'Initials': 'H', 'LastName': 'Pedersen', 'Affiliation': 'Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Bergen, Norway.'}, {'ForeName': 'Aril Hagen', 'Initials': 'AH', 'LastName': 'Ravnøy', 'Affiliation': 'Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Bergen, Norway.'}, {'ForeName': 'Vidar', 'Initials': 'V', 'LastName': 'Andersen', 'Affiliation': 'Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Bergen, Norway.'}, {'ForeName': 'Atle Hole', 'Initials': 'AH', 'LastName': 'Saeterbakken', 'Affiliation': 'Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Bergen, Norway.'}]",PloS one,['10.1371/journal.pone.0233540'] 1446,32591274,Distalization rate of maxillary canines in an alveolus filled with leukocyte-platelet-rich fibrin in adults: A randomized controlled clinical split-mouth trial.,"INTRODUCTION The objective of this study was to evaluate the distalization rate and changes in inclination of the maxillary canines in alveoli preserved with leukocyte-platelet-rich fibrin (L-PRF) membranes in adult patients. The null hypothesis was that there are no differences in the canine distalization movement rate between the treated and the control sides. METHODS A total of 21 healthy adult patients with a minimum age of 20 years (mean age, 33 ± 5.9 years) and Angle Class I or Class II Division 1 malocclusion, who had an indication of extraction of the maxillary first premolars and orthodontic distalization of the maxillary canines were included in this study. A randomized controlled clinical split-mouth trial was conducted; the experimental maxillary side was treated with L-PRF membranes, and the other side served as the control. A randomization sequence of the experimental sides among patients was generated using the random number generation function of Microsoft Excel. Neither the patients nor the operators were blinded. Fifteen days after the extractions, distalization was initiated using an elastic chain applying 150 g of force to the canines on a 0.020-in stainless steel archwire. The distalization rate was the main outcome of the study, and it was assessed monthly for 5 months through the intraoral use of a flexible ruler. The degree of inclination of the canines was the secondary outcome, and it was evaluated through cone-beam computed tomography. A Shapiro-Wilk test was performed, and a Wilcoxon signed rank test was subsequently used to compare the experimental and the control group. Spearman rank correlation coefficient was calculated to evaluate the correlation between distalization and inclination for each side. RESULTS Four of the subjects dropped out of the study, leaving a total of 17 patients (n = 17). The distalization rate and inclination of the canines were greater on the control side than on the side treated with L-PRF (P <0.05). A weak correlation was found between the distalization rate and inclination of the canines for both sides (control side, ρ = 0.17; experimental, ρ = 0.11). No harm was observed during the study. CONCLUSIONS The null hypothesis was rejected. The use of L-PRF in young adult patients decreased the rate of distalization and changes in inclination of the maxillary canines compared with the control group. REGISTRATION This trial was not registered. PROTOCOL The protocol was not published before trial commencement.",2020,The distalization rate and inclination of the canines were greater on the control side than on the side treated with L-PRF (P <0.05).,"['adult patients', 'adults', 'young adult patients', '21 healthy adult patients with a minimum age of 20\xa0years (mean age, 33\xa0±\xa05.9\xa0years) and Angle Class I or Class II Division 1 malocclusion, who had an indication of extraction of the maxillary first premolars and orthodontic distalization of the maxillary canines were included in this study']","['leukocyte-platelet-rich fibrin', 'L-PRF membranes', 'L-PRF', 'leukocyte-platelet-rich fibrin (L-PRF) membranes']","['canine distalization movement rate', 'rate of distalization and changes in inclination of the maxillary canines', 'Distalization rate of maxillary canines', 'distalization rate', 'distalization rate and inclination of the canines']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0399523', 'cui_str': 'Malocclusion, Angle class I'}, {'cui': 'C0399524', 'cui_str': 'Malocclusion, Angle class II, division 1'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C1704302', 'cui_str': 'Structure of premolar tooth'}, {'cui': 'C0332276', 'cui_str': 'Orthodontic'}, {'cui': 'C0010482', 'cui_str': 'Structure of canine tooth'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C4505052', 'cui_str': 'Leukocyte- and Platelet-Rich Fibrin'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}]","[{'cui': 'C0010482', 'cui_str': 'Structure of canine tooth'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}]",21.0,0.0473179,The distalization rate and inclination of the canines were greater on the control side than on the side treated with L-PRF (P <0.05).,"[{'ForeName': 'Ariel Adriano', 'Initials': 'AA', 'LastName': 'Reyes Pacheco', 'Affiliation': 'Department of Periodontology and Oral Implantology, Pontifícia Universidad Católica Madre y Maestra, Santo Domingo, Dominican Republic.'}, {'ForeName': 'James Rudolph', 'Initials': 'JR', 'LastName': 'Collins', 'Affiliation': 'Department of Periodontology and Oral Implantology, Pontifícia Universidad Católica Madre y Maestra, Santo Domingo, Dominican Republic.'}, {'ForeName': 'Nelsida', 'Initials': 'N', 'LastName': 'Contreras', 'Affiliation': 'Department of Periodontology and Oral Implantology, Pontifícia Universidad Católica Madre y Maestra, Santo Domingo, Dominican Republic.'}, {'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'Lantigua', 'Affiliation': 'Department of Periodontology and Oral Implantology, Pontifícia Universidad Católica Madre y Maestra, Santo Domingo, Dominican Republic.'}, {'ForeName': 'Matheus Melo', 'Initials': 'MM', 'LastName': 'Pithon', 'Affiliation': 'Department of Orthodontics, Southwest Bahia State University, Jequié, Bahia, Brazil.'}, {'ForeName': 'Orlando Motohiro', 'Initials': 'OM', 'LastName': 'Tanaka', 'Affiliation': 'School of Life Sciences, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil. Electronic address: tanaka.o@pucpr.br.'}]","American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics",['10.1016/j.ajodo.2020.03.020'] 1447,32591295,Noninferiority of heart failure nurse titration versus heart failure cardiologist titration. ETIFIC multicenter randomized trial.,"INTRODUCTION AND OBJECTIVES Beta-blockers, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin-II-receptor-blockers (ARB), and mineralocorticoid-receptor antagonists decrease mortality and heart failure (HF) hospitalizations in HF patients with reduced left ventricular ejection fraction. The effect is dose-dependent. Careful titration is recommended. However, suboptimal doses are common in clinical practice. This study aimed to compare the safety and efficacy of dose titration of the aforementioned drugs by HF nurses vs HF cardiologists. METHODS ETIFIC was a multicenter (n=20) noninferiority randomized controlled open label trial. A total of 320 hospitalized patients with new-onset HF, reduced ejection fraction and New York Heart Association II-III, without beta-blocker contraindications were randomized 1:1 in blocks of 4 patients each stratified by hospital: 164 to HF nurse titration vs 156 to HF cardiologist titration (144 vs 145 analyzed). The primary endpoint was the beta-blocker mean relative dose (% of target dose) achieved at 4 months. Secondary endpoints included ACE inhibitors, ARB, and mineralocorticoid-receptor antagonists mean relative doses, associated variables, adverse events, and clinical outcomes at 6 months. RESULTS The mean±standard deviation relative doses achieved by HF nurses vs HF cardiologists were as follows: beta-blockers 71.09%±31.49% vs 56.29%±31.32%, with a difference of 14.8% (95%CI, 7.5-22.1), P <.001; ACE inhibitors 72.61%±29.80% vs 56.13%±30.37%, P <.001; ARB 44.48%±33.47% vs 43.51%±33.69%, P=.93; and mineralocorticoid-receptor antagonists 71%±32.12% vs 70.47%±29.78%, P=.86; mean±standard deviation visits were 6.41±2.82 vs 2.81±1.58, P <.001, while the number (%) of adverse events were 34 (23.6) vs 30 (20.7), P=.55; and at 6 months HF hospitalizations were 1 (0.69) vs 9 (5.51), P=.01. CONCLUSIONS ETIFIC is the first multicenter randomized trial to demonstrate the noninferiority of HF specialist-nurse titration vs HF cardiologist titration. Moreover, HF nurses achieved higher beta-blocker/ACE inhibitors doses, with more outpatient visits and fewer HF hospitalizations. Trial registry number: NCT02546856.",2020,"Moreover, HF nurses achieved higher beta-blocker/ACE inhibitors doses, with more outpatient visits and fewer HF hospitalizations.","['320 hospitalized patients with new-onset HF, reduced ejection fraction and New York Heart Association II-III, without beta-blocker contraindications were randomized 1:1 in blocks of 4 patients each stratified by hospital: 164 to', 'HF patients with reduced left ventricular ejection fraction']","['angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin-II-receptor-blockers (ARB', 'HF nurse titration vs 156 to HF cardiologist titration']","['mortality and heart failure (HF) hospitalizations', 'safety and efficacy', 'adverse events', 'ACE inhibitors, ARB, and mineralocorticoid-receptor antagonists mean relative doses, associated variables, adverse events, and clinical outcomes at 6 months', 'mean±standard deviation visits', 'beta-blocker mean relative dose']","[{'cui': 'C4517711', 'cui_str': '320'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0001645', 'cui_str': 'Beta adrenergic receptor antagonist'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}]","[{'cui': 'C0003015', 'cui_str': 'Angiotensin-converting enzyme inhibitor'}, {'cui': 'C0521942', 'cui_str': 'Angiotensin II receptor antagonist'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0162621', 'cui_str': 'Titration method'}, {'cui': 'C0175906', 'cui_str': 'Cardiologist'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0003015', 'cui_str': 'Angiotensin-converting enzyme inhibitor'}, {'cui': 'C0521942', 'cui_str': 'Angiotensin II receptor antagonist'}, {'cui': 'C1579268', 'cui_str': 'Mineralocorticoid Antagonists'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0012727', 'cui_str': 'Displacement'}, {'cui': 'C0001645', 'cui_str': 'Beta adrenergic receptor antagonist'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]",320.0,0.116585,"Moreover, HF nurses achieved higher beta-blocker/ACE inhibitors doses, with more outpatient visits and fewer HF hospitalizations.","[{'ForeName': 'Juana', 'Initials': 'J', 'LastName': 'Oyanguren', 'Affiliation': 'Servicio de Cardiología, Hospital Universitario Galdakao-Usansolo, OSI Barrualde-Galdakao-Osakidetza, Servicio Vasco de Salud, Galdakao, Bizkaia, Spain; BIOCRUCES, Instituto de Investigación Sanitaria, Bizkaia, Spain. Electronic address: juanaoy@hotmail.com.'}, {'ForeName': 'Lluisa', 'Initials': 'L', 'LastName': 'Garcia-Garrido', 'Affiliation': ""Unidad de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital Universitario Dr. Josep Trueta, Girona, Spain; Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), Girona, Spain.""}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Nebot-Margalef', 'Affiliation': ""Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Servicio de Cardiología, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.""}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Latorre-García', 'Affiliation': 'BIOCRUCES, Instituto de Investigación Sanitaria, Bizkaia, Spain.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Torcal-Laguna', 'Affiliation': 'BIOCRUCES, Instituto de Investigación Sanitaria, Bizkaia, Spain.'}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Comín-Colet', 'Affiliation': ""Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Servicio de Cardiología, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.""}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Roure', 'Affiliation': ""Unidad de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital Universitario Dr. Josep Trueta, Girona, Spain; Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), Girona, Spain.""}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'González-Costello', 'Affiliation': ""Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Servicio de Cardiología, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.""}, {'ForeName': 'Nicolás', 'Initials': 'N', 'LastName': 'Manito', 'Affiliation': ""Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Servicio de Cardiología, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.""}, {'ForeName': 'José M', 'Initials': 'JM', 'LastName': 'García-Pinilla', 'Affiliation': 'Unidad de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital Virgen de la Victoria, Málaga, Spain; Instituto de Investigación Sanitaria (IDIMA), Málaga, Spain.'}, {'ForeName': 'Yolanda', 'Initials': 'Y', 'LastName': 'Sánchez-Paule', 'Affiliation': 'Unidad de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital Virgen de la Victoria, Málaga, Spain; Instituto de Investigación Sanitaria (IDIMA), Málaga, Spain.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Varela-Román', 'Affiliation': 'Unidad de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital Universitario de Santiago, Santiago de Compostela, La Coruña, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), La Coruña, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Moure', 'Affiliation': 'Unidad de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital Universitario de Santiago, Santiago de Compostela, La Coruña, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), La Coruña, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Segovia-Cubero', 'Affiliation': 'Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Servicio de Cardiología, Hospital Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Soria', 'Affiliation': 'Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Servicio de Cardiología, Hospital Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain.'}, {'ForeName': 'Eunate', 'Initials': 'E', 'LastName': 'Arana-Arri', 'Affiliation': 'BIOCRUCES, Instituto de Investigación Sanitaria, Bizkaia, Spain.'}, {'ForeName': 'Iñaki', 'Initials': 'I', 'LastName': 'Lekuona', 'Affiliation': 'Servicio de Cardiología, Hospital Universitario Galdakao-Usansolo, OSI Barrualde-Galdakao-Osakidetza, Servicio Vasco de Salud, Galdakao, Bizkaia, Spain.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Revista espanola de cardiologia (English ed.),['10.1016/j.rec.2020.04.016'] 1448,32592861,"Antidepressant efficacy and immune effects of bilateral theta burst stimulation monotherapy in major depression: A randomized, double-blind, sham-controlled study.",,2020,,['Major Depression'],['Bilateral Theta Burst Stimulation Monotherapy'],[],"[{'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]",[],,0.446696,,"[{'ForeName': 'Po-Han', 'Initials': 'PH', 'LastName': 'Chou', 'Affiliation': 'Department of Psychiatry, China Medical University Hsinchu Hospital, China Medical University, Hsinchu, Taiwan; Department of Psychiatry, China Medical University Hospital, China Medical University, Taichung, Taiwan; Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan; Taiwan Allied Clinics for Integrative TMS, Taipei, Taiwan.'}, {'ForeName': 'Ming-Kuei', 'Initials': 'MK', 'LastName': 'Lu', 'Affiliation': 'Department of Neurology, China Medical University Hospital, Taichung, Taiwan; College of Medicine, China Medical University, Taichung, Taiwan.'}, {'ForeName': 'Chon-Haw', 'Initials': 'CH', 'LastName': 'Tsai', 'Affiliation': 'Department of Neurology, China Medical University Hospital, Taichung, Taiwan; College of Medicine, China Medical University, Taichung, Taiwan.'}, {'ForeName': 'Wan-Ting', 'Initials': 'WT', 'LastName': 'Hsieh', 'Affiliation': 'Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan.'}, {'ForeName': 'Hui-Chen', 'Initials': 'HC', 'LastName': 'Lai', 'Affiliation': 'Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan.'}, {'ForeName': 'Sergey', 'Initials': 'S', 'LastName': 'Shityakov', 'Affiliation': 'Department of Psychiatry, China Medical University Hospital, China Medical University, Taichung, Taiwan; College of Medicine, China Medical University, Taichung, Taiwan; Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan.'}, {'ForeName': 'Kuan-Pin', 'Initials': 'KP', 'LastName': 'Su', 'Affiliation': 'Department of Psychiatry, China Medical University Hospital, China Medical University, Taichung, Taiwan; College of Medicine, China Medical University, Taichung, Taiwan; Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan; An-Nan Hospital, China Medical University, Tainan, Taiwan. Electronic address: cobolsu@gmail.com.'}]","Brain, behavior, and immunity",['10.1016/j.bbi.2020.06.024'] 1449,32593960,Functional recovery in multiple sclerosis patients undergoing rehabilitation programs is associated with plasma levels of hemostasis inhibitors.,"BACKGROUND Increasing evidence for contribution of hemostasis components in multiple sclerosis (MS) has been reported. Hemostasis protein inhibitors display key regulatory roles, extending to regulation of innate immune response and inflammation, and promotion of blood-brain barrier integrity. Whereas the effects on hemostasis of exercise and rehabilitation strategies have been extensively investigated, relationships between MS rehabilitation strategies and hemostasis have not been previously reported. OBJECTIVES To investigate in MS patients the association between outcomes of rehabilitative exercise and plasma levels of selected hemostasis inhibitors. METHODS Sixty-one severely disabled progressive-MS (P-MS) patients were randomized in the RAGTIME trial to receive 12 walking session of robot-assisted gait training (RAGT) or conventional overground therapy (CT). Outcome parameters were: timed 25-foot walk test (T25FWT) speed, 6-minute walking test (6MWT), Berg Balance Scale (BBS), and MS impact scale-29 (MSIS-29). Plasma levels of coagulation inhibitors protein S (PS), soluble thrombomodulin (sTM), and tissue factor pathway inhibitor (TFPI) were assayed by multiplex assay and ELISA at 4-time points: baseline (T0), intermediate (T1), end of rehabilitation (T2), 3-month follow-up (T3). Descriptive analysis, trend analysis, Spearman's rank and Pearson's correlations, and multiple regression models were used. RESULTS Rehabilitative exercises moderately modified plasma protein concentrations. A significant trend to increase was observed for PS (p=0.015) and TFPI (p=0.047) in the whole population, and for PS (p=0.011) in the CT group. Correlation between TFPI and sTM levels was detectable at all time points in the whole P-MS patients and in RAGT group. The correlation between TFPI and PS, present at T0, was lost during the rehabilitation, and recovered at T3 in the whole population and CT group. During rehabilitation, positive variations of TFPI were inversely related with changes in 6MWT in the whole population (r=-0.309, p=0.021), and in the RAGT group (r=-0.51, p=0.004). In all P-MS, PS T0 levels were associated (r=0.379, p=0.004) with increased gait speed, which in the RAGT group was associated both with PS T0 (r=0.378, p=0.040), and sTM T0 (r=0.453, p=0.012). Accordingly, in the regression model including age, sex and EDSS and the stepwise enter of PS T0, higher PS T0 levels predicted increased gait speed in all P-MS (F=3.4, p=0.016) The regression model in the RAGT group indicated that higher PS and sTM T0 levels were both predictors of increased gait speed (F=5.7, p=0.001). CONCLUSIONS Plasma levels of coagulation inhibitors were related to variations of outcome measurements after high-intensity walking rehabilitation programs. Patients with decreased TFPI levels from T0 to T2 displayed the most significant functional recovery following rehabilitation, and particularly after RAGT. Higher baseline total PS levels were associated with favorable outcomes of rehabilitation therapies in MS. These novel findings, which suggest that plasma levels of hemostasis inhibitors might have implication for rehabilitative therapy options in MS, warrant further investigation.",2020,"Plasma levels of coagulation inhibitors protein S (PS), soluble thrombomodulin (sTM), and tissue factor pathway inhibitor (TFPI) were assayed by multiplex assay and ELISA at 4-time points: baseline (T0), intermediate (T1), end of rehabilitation (T2), 3-month follow-up (T3).","['Sixty-one severely disabled progressive-MS (P-MS) patients', 'multiple sclerosis patients undergoing rehabilitation programs', 'multiple sclerosis (MS']",['12 walking session of robot-assisted gait training (RAGT) or conventional overground therapy (CT'],"['PS T0 levels', 'TFPI levels', 'Higher baseline total PS levels', 'gait speed', 'Plasma levels of coagulation inhibitors protein S (PS), soluble thrombomodulin (sTM), and tissue factor pathway inhibitor (TFPI', 'timed 25-foot walk test (T25FWT) speed, 6-minute walking test (6MWT), Berg Balance Scale (BBS), and MS impact scale-29 (MSIS-29', 'plasma protein concentrations', 'PS', 'TFPI', 'PS and sTM T0 levels', 'TFPI and sTM levels', 'multiplex assay and ELISA at 4-time points: baseline (T0), intermediate (T1), end of rehabilitation (T2), 3-month follow-up (T3']","[{'cui': 'C4517832', 'cui_str': '61'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1095979', 'cui_str': 'Progressive multiple sclerosis'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}]","[{'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0072393', 'cui_str': 'Protein S'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0164707', 'cui_str': 'Tissue factor pathway inhibitor'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1168441', 'cui_str': 'Protein S total'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0145779', 'cui_str': 'Thrombomodulin'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0032120', 'cui_str': 'Plasma protein'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]",61.0,0.0295241,"Plasma levels of coagulation inhibitors protein S (PS), soluble thrombomodulin (sTM), and tissue factor pathway inhibitor (TFPI) were assayed by multiplex assay and ELISA at 4-time points: baseline (T0), intermediate (T1), end of rehabilitation (T2), 3-month follow-up (T3).","[{'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Ziliotto', 'Affiliation': 'Department of Life Sciences and Biotechnology, University of Ferrara; School of Medicine and Surgery, University of Milano - Bicocca, Monza, Italy.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Lamberti', 'Affiliation': 'Department of Biomedical and Surgical Specialties Sciences, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Manfredini', 'Affiliation': 'Department of Biomedical and Surgical Specialties Sciences, University of Ferrara, Ferrara, Italy; Department of Neurosciences/Rehabilitation, Unit of Physical and Rehabilitation Medicine, University Hospital of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Straudi', 'Affiliation': 'Department of Neurosciences/Rehabilitation, Unit of Physical and Rehabilitation Medicine, University Hospital of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Marcello', 'Initials': 'M', 'LastName': 'Baroni', 'Affiliation': 'Department of Life Sciences and Biotechnology, University of Ferrara.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Tisato', 'Affiliation': 'Department of Morphology, Surgery and Experimental Medicine and LTTA Centre, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Carantoni', 'Affiliation': 'Department of Morphology, Surgery and Experimental Medicine and LTTA Centre, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Secchiero', 'Affiliation': 'Department of Morphology, Surgery and Experimental Medicine and LTTA Centre, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Nino', 'Initials': 'N', 'LastName': 'Basaglia', 'Affiliation': 'Department of Neurosciences/Rehabilitation, Unit of Physical and Rehabilitation Medicine, University Hospital of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Marchetti', 'Affiliation': 'Department of Biomedical and Surgical Specialties Sciences, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Bernardi', 'Affiliation': 'Department of Life Sciences and Biotechnology, University of Ferrara. Electronic address: ber@unife.it.'}]",Multiple sclerosis and related disorders,['10.1016/j.msard.2020.102319'] 1450,32460523,"A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up.","Objective: To evaluate the efficacy and long-term safety of vilazodone in children and adolescent outpatients with major depressive disorder (MDD). Methods: Children and adolescents aged 7-17 years of age with MDD were randomized 2:2:1 to 8 weeks of double-blind placebo, vilazodone 15 or 30 mg/day or fluoxetine 20 mg/day, respectively. The primary and secondary efficacy outcomes, respectively, were change from baseline to week 8 in Children's Depression Rating Scale-Revised (CDRS-R) score total score and Clinical Global Impressions-Severity (CGI-S) score analyzed using a mixed model for repeated measurement approach. Patients who completed the 8-week randomized controlled trial (RCT), as well as new ( de novo ) patients, could participate in a 26-week, vilazodone-only, open-label extension (OLE) study. Results: The RCT enrolled 473 patients (60% female) with an average age of 13 years. Change in CDRS-R and CGI-S scores from baseline to week 8 did not differ between patients who received vilazodone and those randomized to placebo. The least-squares mean change from baseline in CDRS-R scores was similar for vilazodone and placebo (-20.7 vs. -20.3, p  = 0.77; least-squares mean difference [LSMD] = -0.40). For fluoxetine, the LSMD versus placebo was -2.3 ( p  = 0.14). The OLE enrolled 330 patients (60% female) with an average age of 13-14 years. Overall, no new safety concerns were identified compared to what is known in adults. Conclusions: Similar improvements in depressive symptoms were observed in all arms. This study does not support the efficacy of vilazodone 15 or 30 mg/day for pediatric patients with MDD. No new or unexpected safety concerns were detected during the RCT or OLE studies.",2020,"The least-squares mean change from baseline in CDRS-R scores was similar for vilazodone and placebo (-20.7 vs. -20.3, p  = 0.77; least-squares mean difference [LSMD] = -0.40).","['pediatric patients with MDD', 'enrolled 330 patients (60% female) with an average age of 13-14 years', 'Children and adolescents aged 7-17 years of age with MDD', 'enrolled 473 patients (60% female) with an average age of 13 years', 'Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up', 'children and adolescent outpatients with major depressive disorder (MDD']","['Vilazodone', 'Placebo', 'OLE', 'RCT', 'placebo', 'fluoxetine', 'placebo, vilazodone 15 or 30\u2009mg/day or fluoxetine', 'vilazodone-only, open-label extension (OLE) study', 'vilazodone']","['Change in CDRS-R and CGI-S scores', ""Children's Depression Rating Scale-Revised (CDRS-R) score total score and Clinical Global Impressions-Severity (CGI-S) score"", 'CDRS-R scores', 'depressive symptoms']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1269683', 'cui_str': 'Major depressive disorder'}, {'cui': 'C4517719', 'cui_str': '330'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}]","[{'cui': 'C1530072', 'cui_str': 'vilazodone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0016365', 'cui_str': 'Fluoxetine'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",473.0,0.134338,"The least-squares mean change from baseline in CDRS-R scores was similar for vilazodone and placebo (-20.7 vs. -20.3, p  = 0.77; least-squares mean difference [LSMD] = -0.40).","[{'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Findling', 'Affiliation': 'Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'McCusker', 'Affiliation': 'CNS, AbbVie, Irvine, California, USA.'}, {'ForeName': 'Jeffrey R', 'Initials': 'JR', 'LastName': 'Strawn', 'Affiliation': 'Anxiety Disorders Research Program, University of Cincinnati, Cincinnati, Ohio, USA.'}]",Journal of child and adolescent psychopharmacology,['10.1089/cap.2019.0176'] 1451,32466678,"Feasibility of Targeting Hispanic Fathers and Children in an Obesity Intervention: "" Papás Saludables Niños Saludables "".","Background: Hispanic children and men carry a high burden for obesity and associated medical conditions. Healthy Dads Healthy Kids was the first obesity prevention intervention targeting fathers and demonstrated weight loss among fathers and behavior change among fathers and children in Australia. The aim of this study was to assess the feasibility of a culturally adapted version of the program for Hispanic families, Papás Saludables Niños Saludables . Methods: A randomized waitlist controlled trial with a process evaluation was conducted to assess the feasibility of Papás Saludables Niños Saludables ( NCT03532048). Fathers, their partner (mother), and one to three children were enrolled. A priori feasibility criteria were: (1) recruit 40 Hispanic fathers and their families in ≤4 months; (2) retain 80% of participants for pre- and postassessments; (3) maintain ≥70% attendance to the 10 sessions; (4) obtain 80% ""excellent"" or ""good"" satisfaction from participants; and (5) collect anthropometric and behavioral data on ≥75% of participants at baseline and follow-up. Results: The study enrolled 90% ( n  = 36) of the goal from one local pediatric clinic between May and August 2018; retained 75% of participants for postassessment; maintained 72% attendance among those who started the program; and achieved 100% ""excellent/good"" satisfaction ratings among the participating fathers and mothers. One hundred percent of participants had most anthropometric and behavioral data at baseline and 72% at follow-up. Conclusions: With oversampling and improvements in the recruitment strategies, Papás Saludables Niños Saludables is feasible for a randomized controlled clinical trial to address whether a father-targeted lifestyle program is efficacious among low-income Hispanic men and their children.",2020,Healthy Kids was the first obesity prevention intervention targeting fathers and demonstrated weight loss among fathers and behavior change among fathers and children in Australia.,"['Healthy Dads', 'low-income Hispanic men and their children', 'Hispanic children and men carry a high burden for obesity and associated medical conditions', 'Hispanic Fathers and Children in an Obesity Intervention', 'fathers and children in Australia', '40 Hispanic fathers and their families in ≤4 months; (2) retain 80% of participants for pre- and postassessments; (3) maintain ≥70% attendance to the 10 sessions; (4', 'Hispanic families, Papás Saludables Niños Saludables ', 'The study enrolled 90% ( n \u2009=\u200936) of the goal from one local pediatric clinic between May and August 2018; retained 75% of participants for postassessment; maintained 72% attendance among those who started the program; and achieved 100% ""excellent/good"" satisfaction ratings among the participating fathers and mothers', 'Fathers, their partner (mother), and one to three children were enrolled']","['obtain 80% ""excellent"" or ""good"" satisfaction from participants; and (5) collect anthropometric and behavioral data on ≥75% of participants at baseline and follow-up']",['weight loss'],"[{'cui': 'C0051767', 'cui_str': 'amsonic acid'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0015670', 'cui_str': 'Father-Child Relationship'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0015671', 'cui_str': 'Father'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C3839701', 'cui_str': 'Pediatric clinic'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]","[{'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}]",90.0,0.0374602,Healthy Kids was the first obesity prevention intervention targeting fathers and demonstrated weight loss among fathers and behavior change among fathers and children in Australia.,"[{'ForeName': 'Teresia M', 'Initials': 'TM', 'LastName': ""O'Connor"", 'Affiliation': ""Department of Pediatrics, Baylor College of Medicine, USDA/ARS Children's Nutrition Research Center, Houston, TX, USA.""}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Beltran', 'Affiliation': ""Department of Pediatrics, Baylor College of Medicine, USDA/ARS Children's Nutrition Research Center, Houston, TX, USA.""}, {'ForeName': 'Salma', 'Initials': 'S', 'LastName': 'Musaad', 'Affiliation': ""Department of Pediatrics, Baylor College of Medicine, USDA/ARS Children's Nutrition Research Center, Houston, TX, USA.""}, {'ForeName': 'Oriana', 'Initials': 'O', 'LastName': 'Perez', 'Affiliation': ""Department of Pediatrics, Baylor College of Medicine, USDA/ARS Children's Nutrition Research Center, Houston, TX, USA.""}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Flores', 'Affiliation': ""Department of Pediatrics, Baylor College of Medicine, USDA/ARS Children's Nutrition Research Center, Houston, TX, USA.""}, {'ForeName': 'Edgar', 'Initials': 'E', 'LastName': 'Galdamez-Calderon', 'Affiliation': ""Department of Pediatrics, Baylor College of Medicine, USDA/ARS Children's Nutrition Research Center, Houston, TX, USA.""}, {'ForeName': 'Tasia', 'Initials': 'T', 'LastName': 'Isbell', 'Affiliation': 'School of Public Health, University of Texas, Houston, TX, USA.'}, {'ForeName': 'Elva M', 'Initials': 'EM', 'LastName': 'Arredondo', 'Affiliation': 'School of Public Health, San Diego State University, San Diego, CA, USA.'}, {'ForeName': 'Ruben', 'Initials': 'R', 'LastName': 'Parra Cardona', 'Affiliation': 'Steve Hicks School of Social Work, University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Cabrera', 'Affiliation': 'Department of Human Development and Quantitative Methodology, University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Stephanie A', 'Initials': 'SA', 'LastName': 'Marton', 'Affiliation': ""Texas Children's Health Plan, Houston, TX, USA.""}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Baranowski', 'Affiliation': ""Department of Pediatrics, Baylor College of Medicine, USDA/ARS Children's Nutrition Research Center, Houston, TX, USA.""}, {'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'Morgan', 'Affiliation': 'Faculty of Education and Arts, Priority Research Center for Physical Activity & Nutrition, University of Newcastle, Newcastle, New South Wales, Australia.'}]",Childhood obesity (Print),['10.1089/chi.2020.0006'] 1452,32469839,Video Narratives Intervention Among Stroke Survivors: Feasibility and Acceptability Study of a Randomized Controlled Trial.,"BACKGROUND A large number of stroke survivors worldwide suffer from moderate to severe disability. In Malaysia, long-term uncontrolled stroke risk factors lead to unforeseen rates of recurrent stroke and a growing incidence of stroke occurrence across ages, predominantly among the elderly population. This situation has motivated research efforts focused on tapping into patient education, especially related to patient self-efficacy of understanding and taking medication appropriately. Video narratives integrated with health belief model constructs have demonstrated potential impacts as an aide to patient education efforts. OBJECTIVE The aim of this study was to investigate the feasibility and acceptability of study procedures based on a randomized controlled trial protocol of a video narratives intervention among poststroke patients. We also aimed to obtain preliminary findings of video narratives related to medication understanding and use self-efficacy (MUSE) and blood pressure control. METHODS A parallel group randomized controlled trial including a control group (without video viewing) and an intervention group (with video viewing) was conducted by researchers at a neurology outpatient clinic on poststroke patients (N=54). Baseline data included patients' sociodemographic characteristics, medical information, and all outcome measures. Measurements of MUSE and blood pressure following the trial were taken during a 3-month follow-up period. Feasibility of the trial was assessed based on recruitment and study completion rates along with patients' feedback on the burden of the study procedures and outcome measures. Acceptability of the trial was analyzed qualitatively. Statistical analysis was applied to ascertain the preliminary results of video narratives. RESULTS The recruitment rate was 60 out of 117 patients (51.3%). Nevertheless, the dropout rate of 10% was within the acceptable range. Patients were aged between 21 and 74 years. Nearly 50 of the patients (>85%) had adequate health literacy and exposure to stroke education. Most of the patients (>80%) were diagnosed with ischemic stroke, whereby the majority had primary hypertension. The technicalities of randomization and patient approach were carried out with minimal challenge and adequate patient satisfaction. The video contents received good responses with respect to comprehension and simplicity. Moreover, an in-depth phone interview with 8 patients indicated that the video narratives were considered to be useful and inspiring. These findings paralleled the preliminary findings of significant improvement within groups in MUSE (P=.001) and systolic blood pressure control (P=.04). CONCLUSIONS The queries and feedback from each phase in this study have been acknowledged and will be taken forward in the full trial. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry ACTRN 12618000174280; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373554.",2020,"These findings also paralleled significant preliminary improvement in MUSE and systolic BP control (P<.05). ","['post-stroke survivors', 'post-stroke patients', 'Patients were aged between 21 and 74 years', 'Most patients (> 80%) were diagnosed with ischemic stroke whereby the majority were primarily hypertensive', 'researchers at the neurology outpatient clinic on post-stroke patients (N=54']","['video narratives intervention', 'control group (without video-viewing) and an intervention group (with video viewing', 'Video narratives integrated with Health Belief Model (HBM']","['dropout rate', 'MUSE and systolic BP control (P<.05', 'recruitment rate', 'adequate health literacy and exposure to stroke education', 'medication understanding and use self-efficacy (MUSE) and blood pressure (BP) control']","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0027855', 'cui_str': 'Neurology'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3714363', 'cui_str': 'Health belief model'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C4303794', 'cui_str': 'Education about stroke'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]",117.0,0.0700293,"These findings also paralleled significant preliminary improvement in MUSE and systolic BP control (P<.05). ","[{'ForeName': 'Jamuna Rani', 'Initials': 'JR', 'LastName': 'Appalasamy', 'Affiliation': 'School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.'}, {'ForeName': 'Joyce Pauline', 'Initials': 'JP', 'LastName': 'Joseph', 'Affiliation': 'Department of Neurology, Hospital Kuala Lumpur, Ministry of Health, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Siva', 'Initials': 'S', 'LastName': 'Seeta Ramaiah', 'Affiliation': 'Medical Department, Subang Jaya Medical Center, Sunway, Malaysia.'}, {'ForeName': 'Anuar Zaini', 'Initials': 'AZ', 'LastName': 'Md Zain', 'Affiliation': 'Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.'}, {'ForeName': 'Kia Fatt', 'Initials': 'KF', 'LastName': 'Quek', 'Affiliation': 'Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.'}, {'ForeName': 'Kyi Kyi', 'Initials': 'KK', 'LastName': 'Tha', 'Affiliation': 'Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.'}]",JMIR aging,['10.2196/17182'] 1453,32470217,Randomized clinical trial to evaluate mometasone lavage vs spray for patients with chronic rhinosinusitis without nasal polyps who have not undergone sinus surgery.,"BACKGROUND There is no consensus regarding the best route of intranasal delivery of corticosteroids in the treatment of chronic rhinosinusitis (CRS). The study objective of this work was to compare the impact of mometasone furoate nasal spray (MFNS) vs mometasone nasal irrigation in the management of CRS patients who have not undergone sinus surgery. METHODS A double-blind, placebo-controlled, randomized clinical trial was conducted in adults with CRS. Individuals with nasal polyps and/or history of sinus surgery were excluded. Patients were randomized to receive 8 weeks of either MFNS or mometasone nasal irrigation. The primary outcome measure was change in the 22-item Sino-Nasal Outcome Test (SNOT-22) score between the 2 groups. Secondary outcome measures included patient global response to treatment and Lund-Kennedy endoscopy scores. RESULTS A total of 43 participants completed the study (n = 22, MFNS; n = 21,mometasone nasal irrigation). Fourteen (64%) participants in the MFNS group and 17 (81%) in the mometasone lavage group had a clinically meaningful improvement in SNOT-22 scores with a proportion difference of 17% (95% confidence interval [CI], -9% to 44%). The least-squares (LS) mean difference between the 2 groups for SNOT-22 was -8.6 (95% CI, -17.7 to 0.58; p = 0.07), whereas the LS mean difference between the 2 groups for Lund-Kennedy endoscopy scores was 0.16 (95% CI, -0.84 to 1.15; p = 0.75). No adverse events were associated with the study. CONCLUSION Both MFNS and mometasone nasal irrigations are beneficial in symptom management of CRS. Our study suggests that patients who perform mometasone lavage do better in a clinically meaningful way, but our results are not definitive and further studies are warranted.",2020,There is no consensus regarding the best route of intranasal delivery of corticosteroids in the treatment of chronic rhinosinusitis (CRS).,"['Individuals with nasal polyps and/or history of sinus surgery', '43 participants completed the study (n = 22, MFNS; n = 21,mometasone nasal irrigation', 'chronic rhinosinusitis (CRS', 'adults with CRS', 'patients with chronic rhinosinusitis without nasal polyps who have not undergone sinus surgery', 'CRS patients who have not undergone sinus surgery']","['MFNS and mometasone nasal irrigations', 'mometasone lavage vs spray', 'MFNS', 'corticosteroids', 'mometasone furoate nasal spray (MFNS) vs mometasone nasal irrigation', 'mometasone lavage', 'MFNS or mometasone nasal irrigation', 'placebo']","['patient global response to treatment and Lund-Kennedy endoscopy scores', 'Lund-Kennedy endoscopy scores', 'adverse events', '22-item Sino-Nasal Outcome Test (SNOT-22) score', 'SNOT-22 scores']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0027430', 'cui_str': 'Polyp of nasal cavity'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0748725', 'cui_str': 'Sinus operation'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0066700', 'cui_str': 'Mometasone furoate'}, {'cui': 'C0461725', 'cui_str': 'Nasal spray'}, {'cui': 'C2350442', 'cui_str': 'Nasal irrigation'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0066700', 'cui_str': 'Mometasone furoate'}, {'cui': 'C0461725', 'cui_str': 'Nasal spray'}, {'cui': 'C0717925', 'cui_str': 'Mometasone-containing product in nasal dose form'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0360564', 'cui_str': 'Mometasone'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0521982', 'cui_str': 'Response to treatment'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C5197689', 'cui_str': 'Sinonasal Outcome Test'}, {'cui': 'C5197690', 'cui_str': 'SNOT-22'}]",43.0,0.259522,There is no consensus regarding the best route of intranasal delivery of corticosteroids in the treatment of chronic rhinosinusitis (CRS).,"[{'ForeName': 'Pawina', 'Initials': 'P', 'LastName': 'Jiramongkolchai', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Peterson', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'Dorina', 'Initials': 'D', 'LastName': 'Kallogjeri', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'Jake J', 'Initials': 'JJ', 'LastName': 'Lee', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Kukuljan', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Liebendorfer', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'John S', 'Initials': 'JS', 'LastName': 'Schneider', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'Cristine N', 'Initials': 'CN', 'LastName': 'Klatt-Cromwell', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Drescher', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'Jay F', 'Initials': 'JF', 'LastName': 'Piccirillo', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}]",International forum of allergy & rhinology,['10.1002/alr.22586'] 1454,32470981,Energy Requirement Is Higher During Weight-Loss Maintenance in Adults Consuming a Low- Compared with High-Carbohydrate Diet.,"BACKGROUND Longer-term feeding studies suggest that a low-carbohydrate diet increases energy expenditure, consistent with the carbohydrate-insulin model of obesity. However, the validity of methodology utilized in these studies, involving doubly labeled water (DLW), has been questioned. OBJECTIVE The aim of this study was to determine whether dietary energy requirement for weight-loss maintenance is higher on a low- compared with high-carbohydrate diet. METHODS The study reports secondary outcomes from a feeding study in which the primary outcome was total energy expenditure (TEE). After attaining a mean Run-in weight loss of 10.5%, 164 adults (BMI ≥25 kg/m2; 70.1% women) were randomly assigned to Low-Carbohydrate (percentage of total energy from carbohydrate, fat, protein: 20/60/20), Moderate-Carbohydrate (40/40/20), or High-Carbohydrate (60/20/20) Test diets for 20 wk. Calorie content was adjusted to maintain individual body weight within ± 2 kg of the postweight-loss value. In analyses by intention-to-treat (ITT, completers, n = 148) and per protocol (PP, completers also achieving weight-loss maintenance, n = 110), we compared the estimated energy requirement (EER) from 10 to 20 wk of the Test diets using ANCOVA. RESULTS Mean EER was higher in the Low- versus High-Carbohydrate group in models of varying covariate structure involving ITT [ranging from 181 (95% CI: 8-353) to 246 (64-427) kcal/d; P ≤0.04] and PP [ranging from 245 (43-446) to 323 (122-525) kcal/d; P ≤0.02]. This difference remained significant in sensitivity analyses accounting for change in adiposity and possible nonadherence. CONCLUSIONS Energy requirement was higher on a low- versus high-carbohydrate diet during weight-loss maintenance in adults, commensurate with TEE. These data are consistent with the carbohydrate-insulin model and lend qualified support for the validity of the DLW method with diets varying in macronutrient composition. This trial was registered at clinicaltrials.gov as NCT02068885.",2020,Mean EER was higher in the Low- versus High-Carbohydrate group in models of varying covariate structure involving ITT [ranging from 181 (95% CI: 8-353) to 246 (64-427) kcal/d; P ≤0.04] and PP [ranging from 245 (43-446) to 323,"['164 adults (BMI\xa0≥25 kg/m2; 70.1% women', 'Adults Consuming a Low- Compared with High-Carbohydrate Diet']","['Moderate-Carbohydrate (40/40/20), or High-Carbohydrate (60/20/20) Test diets']","['weight-loss maintenance', 'total energy expenditure (TEE', 'Mean EER']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0259835', 'cui_str': 'High carbohydrate diet'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0452401', 'cui_str': 'Test diet'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0429629', 'cui_str': 'Total energy expenditure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0489460', 'cui_str': 'Energy requirement'}]",,0.136023,Mean EER was higher in the Low- versus High-Carbohydrate group in models of varying covariate structure involving ITT [ranging from 181 (95% CI: 8-353) to 246 (64-427) kcal/d; P ≤0.04] and PP [ranging from 245 (43-446) to 323,"[{'ForeName': 'Cara B', 'Initials': 'CB', 'LastName': 'Ebbeling', 'Affiliation': 'New Balance Foundation Obesity Prevention Center, Boston, MA, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Bielak', 'Affiliation': 'New Balance Foundation Obesity Prevention Center, Boston, MA, USA.'}, {'ForeName': 'Paul R', 'Initials': 'PR', 'LastName': 'Lakin', 'Affiliation': ""Institutional Centers for Clinical and Translational Research; Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Gloria L', 'Initials': 'GL', 'LastName': 'Klein', 'Affiliation': 'New Balance Foundation Obesity Prevention Center, Boston, MA, USA.'}, {'ForeName': 'Julia M W', 'Initials': 'JMW', 'LastName': 'Wong', 'Affiliation': 'New Balance Foundation Obesity Prevention Center, Boston, MA, USA.'}, {'ForeName': 'Patricia K', 'Initials': 'PK', 'LastName': 'Luoto', 'Affiliation': 'Department of Food and Nutrition, Framingham State University, Framingham, MA, USA.'}, {'ForeName': 'William W', 'Initials': 'WW', 'LastName': 'Wong', 'Affiliation': ""USDA/Agricultural Research Service Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine,Houston, TX, USA.""}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Ludwig', 'Affiliation': 'New Balance Foundation Obesity Prevention Center, Boston, MA, USA.'}]",The Journal of nutrition,['10.1093/jn/nxaa150'] 1455,32474130,Randomized controlled trial protocol for project BRIDGE: A telephone-administered motivational interviewing intervention targeting risky sexual behavior in older people living with HIV.,"PURPOSE By 2020, 70% of people living with HIV in the United States will be greater than 50 years of age. As many as 37% of sexually active older people living with HIV (OPLWH) engage in HIV transmission sexual behaviors. In spite of repeated calls for secondary prevention interventions to reduce condomless sex in OPLWH, no age-appropriate, evidence-based secondary prevention interventions exist for this group. Furthermore, many OPLWH face barriers to engaging in face-to-face secondary prevention services because of HIV- and age-related stigma, comorbid mental and physical health conditions that complicate travel, or geographic isolation. High rates of depression in OPLWH may further complicate engagement in interventions intended to reduce HIV transmissions. Telephone-administered motivational interviewing may be a feasible and efficacious intervention for this population. METHODS This randomized controlled trial will test the efficacy of a 5-session telephone-administered motivational interviewing plus behavioral skills training (teleMI+BST) intervention versus a 5-session telephone-administered coping effectiveness training (teleCET) control intervention to reduce condomless sex in OPLWH. A diverse sample of 336 OPLWH will be recruited across the U.S. The primary analysis will test the efficacy of teleMI+BST to reduce occasions of non-condom protected anal and vaginal intercourse with HIV serodiscordant sex partners. Secondary analyses will examine the efficacy of teleMI+BST to reduce depressive symptoms in mildly depressed OPLWH. CONCLUSION This is the first large-scale RCT intended to reduce HIV sexual transmission risk behavior in OPLWH and will add to the literature on secondary prevention telehealth interventions for people living with HIV. ClinicalTrials.gov Identifier: NCT03004170. This trial has been conducted by the approval of the Institutional Review Board. Participants provided verbal consent to participate in this trial.",2020,The primary analysis will test the efficacy of teleMI+BST to reduce occasions of non-condom protected anal and vaginal intercourse with HIV serodiscordant sex partners.,"['older people living with HIV', 'people living with HIV', 'A diverse sample of 336 OPLWH will be recruited across the U.S']","['teleMI+BST', 'Telephone-administered motivational interviewing', '5-session telephone-administered motivational interviewing plus behavioral skills training (teleMI+BST) intervention versus a 5-session telephone-administered coping effectiveness training (teleCET) control intervention', 'telephone-administered motivational interviewing intervention']",['depressive symptoms'],"[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",336.0,0.216379,The primary analysis will test the efficacy of teleMI+BST to reduce occasions of non-condom protected anal and vaginal intercourse with HIV serodiscordant sex partners.,"[{'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Kahler', 'Affiliation': 'Center to Improve Veteran Involvement in Care, VA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA.'}, {'ForeName': 'Timothy G', 'Initials': 'TG', 'LastName': 'Heckman', 'Affiliation': 'College of Public Health, University of Georgia, 100 Foster Road, Athens, GA 30606, USA.'}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Shen', 'Affiliation': 'College of Public Health, University of Georgia, 100 Foster Road, Athens, GA 30606, USA.'}, {'ForeName': 'Marilyn S', 'Initials': 'MS', 'LastName': 'Huckans', 'Affiliation': 'Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.'}, {'ForeName': 'Sarah W', 'Initials': 'SW', 'LastName': 'Feldstein Ewing', 'Affiliation': 'Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.'}, {'ForeName': 'Jeffrey T', 'Initials': 'JT', 'LastName': 'Parsons', 'Affiliation': 'Mindful Designs, 791 Salem Street, Teaneck, NJ 07666, USA.'}, {'ForeName': 'Alissa', 'Initials': 'A', 'LastName': 'Phelps', 'Affiliation': 'Center to Improve Veteran Involvement in Care, VA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA; Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Sutton', 'Affiliation': 'College of Public Health, University of Georgia, 100 Foster Road, Athens, GA 30606, USA.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Holloway', 'Affiliation': 'Center to Improve Veteran Involvement in Care, VA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA; Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.'}, {'ForeName': 'Travis I', 'Initials': 'TI', 'LastName': 'Lovejoy', 'Affiliation': 'Center to Improve Veteran Involvement in Care, VA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA; Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. Electronic address: lovejoy@ohsu.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106047'] 1456,32475171,Pressurized-Bag Irrigation Versus Hand-Operated Irrigation Pumps During Ureteroscopic Laser Lithotripsy: Comparison of Infectious Complications.,"Introduction and Objectives: A variety of irrigation systems are available during ureteroscopy. We sought to compare gravity-driven pressure bags with hand-operated irrigation pumps in terms of postoperative complications after ureteroscopy with lithotripsy. Methods: A retrospective analysis of 234 patients undergoing flexible ureteropyeloscopy with laser lithotripsy by 24 supervised trainees over 4 years at a single teaching institution. Patients were divided into those who had procedures performed by using gravity-driven pressure bags fixed at 60 to 204 cm H 2 O, vs those who had procedures performed by using a hand-operated irrigation pump capable of delivering 1 to 10 mL per flush. Variables including surgical duration, hypotension, fever, sepsis, and hematuria were extracted from the charts, along with the surgical techniques utilized. Statistical analyses included chi-squared tests and Student's t -tests. Results: There were no differences in gender, age, indication, or stone size in the two groups. Postoperative systemic inflammatory response syndrome was significantly greater in the hand-assisted n  = 11/144 (7.6%) compared with the fixed irrigation group n  = 1/90 (1.1%); p  = 0.032. Emergency room presentations were greater in the hand irrigation group, n  = 46/144 (32%) vs n  = 12/90 (13%) in the pressure-bag irrigation, p  = 0.002. Postoperative fever was also greater in the hand pump irrigation cohort compared with the continuous pressure cohort (13/144 [9%] vs 1/90 [1%], p  = 0.011). No statistical difference was found between the two groups with respect to stone clearance and subsequent procedures required ( p  = 0.123). Conclusions: This analysis suggests that using continuous flow irrigation at a fixed maximum pressure of 150 mmHg (204 cm H 2 O) or less may result in decreased pain, infection, and sepsis compared with handheld pressure irrigation.",2020,"Emergency room presentations were greater in the hand irrigation group n=46/144 (32%) versus n=12/90 (13%) in the pressure-bag irrigation, p= 0.002.","['by 24 supervised trainees over 6 years at a single teaching institution', '234 patients undergoing']","['flexible ureteropyeloscopy with laser lithotripsy', 'gravity driven pressure bags fixed at 60-150 cmH20, versus those who had procedures using a hand operated irrigation pump capable of delivering 1-10mL per flush', 'ureteroscopic laser lithotripsy', 'Pressurized-bag irrigation versus hand-operated irrigation pumps', 'gravity-driven pressure bags to hand-operated irrigation pumps']","['Post-operative SIRS', 'pain, infection, and sepsis', 'unplanned re-admissions and emergency presentations', 'surgical duration, hypotension, fever, sepsis, and haematuria', 'Emergency room presentations', 'Post-operative fever']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0443220', 'cui_str': 'Flexible'}, {'cui': 'C0206099', 'cui_str': 'Laser Lithotripsy'}, {'cui': 'C0282189', 'cui_str': 'Gravity'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0179196', 'cui_str': 'Bag'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0005874', 'cui_str': 'Blushing'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0242966', 'cui_str': 'Systemic inflammatory response syndrome'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0449450', 'cui_str': 'Presentation'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0018965', 'cui_str': 'Blood in urine'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}]",234.0,0.0437799,"Emergency room presentations were greater in the hand irrigation group n=46/144 (32%) versus n=12/90 (13%) in the pressure-bag irrigation, p= 0.002.","[{'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Farag', 'Affiliation': 'Department of Urology, Austin Health, University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Brennan', 'Initials': 'B', 'LastName': 'Timm', 'Affiliation': 'Department of Urology, Austin Health, University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Niall', 'Initials': 'N', 'LastName': 'Davis', 'Affiliation': 'Department of Urology, Tallaght Hospital, Dublin, Ireland.'}, {'ForeName': 'Lih-Ming', 'Initials': 'LM', 'LastName': 'Wong', 'Affiliation': 'Department of Urology, St Vincents Hospital, Melbourne, Australia.'}, {'ForeName': 'Damien M', 'Initials': 'DM', 'LastName': 'Bolton', 'Affiliation': 'Department of Urology, Austin Health, University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Gregory S', 'Initials': 'GS', 'LastName': 'Jack', 'Affiliation': 'Department of Urology, Austin Health, University of Melbourne, Melbourne, Australia.'}]",Journal of endourology,['10.1089/end.2020.0148'] 1457,32484386,"Pamidronate in chronic non-bacterial osteomyelitis: a randomized, double-blinded, placebo-controlled pilot trial.","OBJECTIVE This is the first randomized double-blinded, placebo-controlled pilot trial to investigate the efficacy of pamidronate in reducing radiological and clinical disease activity in chronic non-bacterial osteomyelitis (CNO). METHOD Patients received pamidronate or placebo at baseline and weeks 12 and 24. Whole-body magnetic resonance imaging was performed at baseline and weeks 12 and 36, and computed tomography of the anterior chest wall (ACW) at baseline and week 36. Radiological disease activity was systematically scored in the ACW and spine. Patient-reported outcomes [visual analogue scale (VAS) pain, VAS global health, Health Assessment Questionnaire (HAQ), EuroQol-5 Dimensions (EQ-5D), and 36-item Short-Form Health Survey (SF-36)] and biomarkers of bone turnover and inflammation were assessed at baseline and weeks 1, 4, 12, 24, and 36. Data are expressed as median [interquartile range]. RESULTS Fourteen patients were randomized and 12 were analysed. From baseline to week 36, the radiological disease activity score in the ACW decreased from 5 [4-7] to 2.5 [1-3] in the pamidronate group, but did not change in the placebo group (p = 0.04). From baseline to week 36, VAS pain and VAS global health tended to decrease more in the pamidronate than in the placebo group (p = 0.11, p = 0.08). Physical functioning (HAQ) and health-related quality of life (EQ-5D, SF-36) did not change. Biomarkers of bone turnover decreased only in the pamidronate group (p ≤ 0.02). CONCLUSION Pamidronate may improve radiological and clinical disease activity in CNO. Methods to score radiological disease activity in adult CNO were suggested. Clinical Trials: NCT02594878.",2020,"Physical functioning (HAQ) and health-related quality of life (EQ-5D, SF-36) did not change.","['chronic non-bacterial osteomyelitis (CNO', 'Fourteen patients were randomized and 12 were analysed', 'chronic non-bacterial osteomyelitis']","['placebo', 'pamidronate or placebo', 'pamidronate', 'Pamidronate']","['radiological disease activity score', 'VAS pain and VAS global health', 'Radiological disease activity', 'Biomarkers of bone turnover', 'outcomes [visual analogue scale (VAS) pain, VAS global health, Health Assessment Questionnaire (HAQ), EuroQol-5 Dimensions (EQ-5D), and 36-item Short-Form Health Survey (SF-36)]\xa0and biomarkers of bone turnover and inflammation', 'Physical functioning (HAQ) and health-related quality of life (EQ-5D, SF-36']","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0410422', 'cui_str': 'Chronic multifocal osteomyelitis'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0043603', 'cui_str': 'pamidronate'}]","[{'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0085268', 'cui_str': 'Bone remodeling'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0451208', 'cui_str': 'Health assessment questionnaire'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",14.0,0.488638,"Physical functioning (HAQ) and health-related quality of life (EQ-5D, SF-36) did not change.","[{'ForeName': 'C M', 'Initials': 'CM', 'LastName': 'Andreasen', 'Affiliation': 'Department of Rheumatology, Aarhus University Hospital , Aarhus, Denmark.'}, {'ForeName': 'A G', 'Initials': 'AG', 'LastName': 'Jurik', 'Affiliation': 'Department of Radiology, Aarhus University Hospital , Aarhus, Denmark.'}, {'ForeName': 'B W', 'Initials': 'BW', 'LastName': 'Deleuran', 'Affiliation': 'Department of Rheumatology, Aarhus University Hospital , Aarhus, Denmark.'}, {'ForeName': 'H C', 'Initials': 'HC', 'LastName': 'Horn', 'Affiliation': 'Department of Rheumatology, Odense University Hospital , Odense, Denmark.'}, {'ForeName': 'T B', 'Initials': 'TB', 'LastName': 'Folkmar', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Aarhus University Hospital , Aarhus, Denmark.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Herlin', 'Affiliation': 'Department of Clinical Medicine, Aarhus University , Aarhus, Denmark.'}, {'ForeName': 'E M', 'Initials': 'EM', 'LastName': 'Hauge', 'Affiliation': 'Department of Rheumatology, Aarhus University Hospital , Aarhus, Denmark.'}]",Scandinavian journal of rheumatology,['10.1080/03009742.2020.1724324'] 1458,32484432,Carer administration of as-needed subcutaneous medication for breakthrough symptoms in people dying at home: the CARiAD feasibility RCT.,"BACKGROUND Most people who are dying want to be cared for at home, but only half of them achieve this. The likelihood of a home death often depends on the availability of able and willing lay carers. When people who are dying are unable to take oral medication, injectable medication is used. When top-up medication is required, a health-care professional travels to the dying person's home, which may delay symptom relief. The administration of subcutaneous medication by lay carers, although not widespread UK practice, has proven to be key in achieving better symptom control for those dying at home in other countries. OBJECTIVES To determine if carer administration of as-needed subcutaneous medication for common breakthrough symptoms in people dying at home is feasible and acceptable in the UK, and if it would be feasible to test this intervention in a future definitive randomised controlled trial. DESIGN We conducted a two-arm, parallel-group, individually randomised, open pilot trial of the intervention versus usual care, with a 1 : 1 allocation ratio, using convergent mixed methods. SETTING Home-based care without 24/7 paid care provision, in three UK sites. PARTICIPANTS Participants were dyads of adult patients and carers: patients in the last weeks of their life who wished to die at home and lay carers who were willing to be trained to give subcutaneous medication. Strict risk assessment criteria needed to be met before approach, including known history of substance abuse or carer ability to be trained to competency. INTERVENTION Intervention-group carers received training by local nurses using a manualised training package. MAIN OUTCOME MEASURES Quantitative data were collected at baseline and 6-8 weeks post bereavement and via carer diaries. Interviews with carers and health-care professionals explored attitudes to, experiences of and preferences for giving subcutaneous medication and experience of trial processes. The main outcomes of interest were feasibility, acceptability, recruitment rates, attrition and selection of the most appropriate outcome measures. RESULTS In total, 40 out of 101 eligible dyads were recruited (39.6%), which met the feasibility criterion of recruiting > 30% of eligible dyads. The expected recruitment target (≈50 dyads) was not reached, as fewer than expected participants were identified. Although the overall retention rate was 55% (22/40), this was substantially unbalanced [30% (6/20) usual care and 80% (16/20) intervention]. The feasibility criterion of > 40% retention was, therefore, considered not met. A total of 12 carers (intervention, n  = 10; usual care, n  = 2) and 20 health-care professionals were interviewed. The intervention was considered acceptable, feasible and safe in the small study population. The context of the feasibility study was not ideal, as district nurses were seriously overstretched and unfamiliar with research methods. A disparity in readiness to consider the intervention was demonstrated between carers and health-care professionals. Findings showed that there were methodological and ethics issues pertaining to researching last days of life care. CONCLUSION The success of a future definitive trial is uncertain because of equivocal results in the progression criteria, particularly poor recruitment overall and a low retention rate in the usual-care group. Future work regarding the intervention should include understanding the context of UK areas where this has been adopted, ascertaining wider public views and exploring health-care professional views on burden and risk in the NHS context. There should be consideration of the need for national policy and of the most appropriate quantitative outcome measures to use. This will help to ascertain if there are unanswered questions to be studied in a trial. TRIAL REGISTRATION Current Controlled Trials ISRCTN11211024. FUNDING This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 24, No. 25. See the NIHR Journals Library website for further project information.",2020,"To determine if carer administration of as-needed subcutaneous medication for common breakthrough symptoms in people dying at home is feasible and acceptable in the UK, and if it would be feasible to test this intervention in a future definitive randomised controlled trial. ","['Home-based care without 24/7 paid care provision, in three UK sites', 'In total, 40 out of 101 eligible dyads were recruited (39.6%), which met the feasibility criterion of recruiting >\u200930% of eligible dyads', '12 carers (intervention, n \u2009=\u200910; usual care, n \u2009=\u20092) and 20 health-care professionals were interviewed', 'people dying at home', 'Participants were dyads of adult patients and carers: patients in the last weeks of their life who wished to die at home and lay carers who were willing to be trained to give subcutaneous medication']","['Carer administration of as-needed subcutaneous medication', 'Intervention-group carers received training by local nurses using a manualised training package', 'intervention versus usual care, with a 1\u2009:\u20091 allocation ratio, using convergent mixed methods']","['overall retention rate', 'feasibility, acceptability, recruitment rates, attrition and selection of the most appropriate outcome measures']","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0729338', 'cui_str': 'Care provision regime'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0031222', 'cui_str': 'Personnel Selection'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}]",101.0,0.0884507,"To determine if carer administration of as-needed subcutaneous medication for common breakthrough symptoms in people dying at home is feasible and acceptable in the UK, and if it would be feasible to test this intervention in a future definitive randomised controlled trial. ","[{'ForeName': 'Marlise', 'Initials': 'M', 'LastName': 'Poolman', 'Affiliation': 'School of Health Sciences, Bangor University, Bangor, UK.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Roberts', 'Affiliation': 'School of Health Sciences, Bangor University, Bangor, UK.'}, {'ForeName': 'Stella', 'Initials': 'S', 'LastName': 'Wright', 'Affiliation': 'School of Health Sciences, Bangor University, Bangor, UK.'}, {'ForeName': 'Annie', 'Initials': 'A', 'LastName': 'Hendry', 'Affiliation': 'School of Health Sciences, Bangor University, Bangor, UK.'}, {'ForeName': 'Nia', 'Initials': 'N', 'LastName': 'Goulden', 'Affiliation': 'North Wales Organisation for Randomised Trials in Health, Bangor University, Bangor, UK.'}, {'ForeName': 'Emily Af', 'Initials': 'EA', 'LastName': 'Holmes', 'Affiliation': 'School of Health Sciences, Bangor University, Bangor, UK.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Byrne', 'Affiliation': 'Marie Curie Research Centre, School of Medicine, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Perkins', 'Affiliation': 'Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Hoare', 'Affiliation': 'North Wales Organisation for Randomised Trials in Health, Bangor University, Bangor, UK.'}, {'ForeName': 'Annmarie', 'Initials': 'A', 'LastName': 'Nelson', 'Affiliation': 'Marie Curie Research Centre, School of Medicine, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Hiscock', 'Affiliation': 'School of Health Sciences, Bangor University, Bangor, UK.'}, {'ForeName': 'Dyfrig', 'Initials': 'D', 'LastName': 'Hughes', 'Affiliation': 'School of Health Sciences, Bangor University, Bangor, UK.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': ""O'Connor"", 'Affiliation': 'Sue Ryder Leckhampton Court Hospice, Cheltenham, UK.'}, {'ForeName': 'Betty', 'Initials': 'B', 'LastName': 'Foster', 'Affiliation': 'Public Contributor, North Wales Cancer Patient Forum, North Wales Cancer Treatment Centre, Bodelwyddan, UK.'}, {'ForeName': 'Liz', 'Initials': 'L', 'LastName': 'Reymond', 'Affiliation': 'Brisbane South Palliative Care Collaborative, School of Medicine, Griffith University, Southport, QLD, Australia.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Healy', 'Affiliation': 'Metro South Palliative Care Service, Brisbane, QLD, Australia.'}, {'ForeName': 'Penney', 'Initials': 'P', 'LastName': 'Lewis', 'Affiliation': ""Centre for Medical Law and Ethics, King's College London, London, UK.""}, {'ForeName': 'Bee', 'Initials': 'B', 'LastName': 'Wee', 'Affiliation': 'Harris Manchester College, University of Oxford, Oxford, UK.'}, {'ForeName': 'Rosalynde', 'Initials': 'R', 'LastName': 'Johnstone', 'Affiliation': 'Betsi Cadwaladr University Health Board, Bangor, UK.'}, {'ForeName': 'Rossela', 'Initials': 'R', 'LastName': 'Roberts', 'Affiliation': 'School of Psychology, Bangor University, Bangor, UK.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Parkinson', 'Affiliation': 'Sue Ryder Leckhampton Court Hospice, Cheltenham, UK.'}, {'ForeName': 'Sian', 'Initials': 'S', 'LastName': 'Roberts', 'Affiliation': 'Betsi Cadwaladr University Health Board, Bangor, UK.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Wilkinson', 'Affiliation': 'School of Health Sciences, Bangor University, Bangor, UK.'}]","Health technology assessment (Winchester, England)",['10.3310/hta24250'] 1459,32481355,Effects of virtual reality immersive training with computerized cognitive training on cognitive function and activities of daily living performance in patients with acute stage stroke: A preliminary randomized controlled trial: Retraction.,,2020,,['patients with acute stage stroke'],['virtual reality immersive training with computerized cognitive training'],['cognitive function and activities of daily living performance'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}]",,0.160731,,[],Medicine,['10.1097/MD.0000000000020598'] 1460,32488233,"An Afternoon Hummus Snack Affects Diet Quality, Appetite, and Glycemic Control in Healthy Adults.","BACKGROUND Snacking continues to be a major component in the dietary patterns of most Americans despite conflicting evidence surrounding snacking healthfulness. Low-sugar, highly nutritive snacks, such as hummus, can lead to improvements in diet quality, appetite, and glycemic control. OBJECTIVES The purpose of the study was to examine the effects of afternoon snacking on diet quality, appetite, and glycemic control in healthy adults. METHODS Thirty-nine adults (age: 26 ± 1 y; BMI: 24.4 ± 0.5 kg/m2) randomly completed the following afternoon snack patterns for 6 d/pattern: hummus and pretzels [HUMMUS; 240 kcal; 6 g protein, 31 g carbohydrate (2 g sugar), 11 g fat]; granola bars [BARS; 240 kcal; 4 g protein, 38 g carbohydrate (16 g sugar), 9 g fat]; or no snacking (NO SNACK). On day 7 of each pattern, a standardized breakfast and lunch were provided. The respective snack was provided to participants 3 h after lunch, and appetite, satiety, and mood questionnaires were completed throughout the afternoon. At 3 h postsnack, a standardized dinner was consumed, and an evening snack cooler was provided to be consumed, ad libitum at home, throughout the evening. Lastly, 24 h continuous glucose monitoring was performed. RESULTS HUMMUS reduced subsequent snacking on desserts by ∼20% compared with NO SNACK (P = 0.001) and BARS (P < 0.001). HUMMUS led to greater dietary compensation compared with BARS (122 ± 31% compared with 72 ± 32%, respectively; P < 0.05). HUMMUS reduced indices of appetite (i.e., hunger, desire to eat, and prospective food consumption) by ∼70% compared with NO SNACK (all P < 0.05), whereas BARS did not. Additionally, satiety was ∼30% greater following HUMMUS and BARS compared with NO SNACK (both P < 0.005) with no differences between snacks. Lastly, HUMMUS reduced afternoon blood glucose concentrations by ∼5% compared with BARS (P < 0.05). CONCLUSIONS Acute consumption of a low-sugar, afternoon hummus snack improved diet quality and selected indices of appetite, satiety, and glycemic control in healthy adults. Long-term trials assessing the effects of hummus snacking on health outcomes are warranted.",2020,"HUMMUS led to greater dietary compensation compared with BARS (122 ± 31% compared with 72 ± 32%, respectively; P < 0.05).","['Healthy Adults', 'healthy adults', 'Thirty-nine adults (age: 26\xa0±']","['hummus snacking', 'afternoon snacking', 'afternoon snack patterns for 6 d/pattern: hummus and pretzels [HUMMUS; 240 kcal; 6\xa0g protein, 31\xa0g carbohydrate (2\xa0g sugar), 11\xa0g fat]; granola bars [BARS; 240 kcal; 4\xa0g protein, 38\xa0g carbohydrate (16\xa0g sugar), 9\xa0g fat]; or no snacking (NO SNACK']","['appetite (i.e., hunger, desire to eat, and prospective food consumption', 'BARS', 'satiety', 'dietary compensation', 'afternoon blood glucose concentrations', 'diet quality, appetite, and glycemic control', 'diet quality and selected indices of appetite, satiety, and glycemic control', 'appetite, satiety, and mood questionnaires', 'Diet Quality, Appetite, and Glycemic Control']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C3816447', 'cui_str': '39'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0453218', 'cui_str': 'Hummus'}, {'cui': 'C0439550', 'cui_str': 'Afternoon'}, {'cui': 'C0453863', 'cui_str': 'Snack food'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0458214', 'cui_str': 'Pretzels'}, {'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C1722869', 'cui_str': '(glycyl-prolyl-glycyl-glycyl-alanyl)6-glycine'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0001643', 'cui_str': 'Beta-2 adrenergic receptor'}, {'cui': 'C0086376', 'cui_str': 'G protein'}, {'cui': 'C0456636', 'cui_str': '16G'}]","[{'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0001643', 'cui_str': 'Beta-2 adrenergic receptor'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0152057', 'cui_str': 'Compensation'}, {'cui': 'C0439550', 'cui_str': 'Afternoon'}, {'cui': 'C2585282', 'cui_str': 'Blood glucose concentration'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",3.0,0.0284081,"HUMMUS led to greater dietary compensation compared with BARS (122 ± 31% compared with 72 ± 32%, respectively; P < 0.05).","[{'ForeName': 'Evan J', 'Initials': 'EJ', 'LastName': 'Reister', 'Affiliation': 'Department of Nutrition Science; Purdue University, West Lafayette, IN, USA.'}, {'ForeName': 'Heather J', 'Initials': 'HJ', 'LastName': 'Leidy', 'Affiliation': 'Department of Nutritional Sciences and Department of Pediatrics; University of Texas at Austin; Austin, TX, USA.'}]",The Journal of nutrition,['10.1093/jn/nxaa139'] 1461,32489001,Effects of lingual exercises on oral muscle strength and salivary flow rate in elderly adults: a randomized clinical trial.,"AIM The present study investigated the effects of two types of lingual exercise (tongue-hold swallowing and tongue-pressure resistance training) on oral muscle strength, salivary flow rate and subjective oral health of the elderly. METHODS We randomly assigned 74 elderly adults (≥65 years) to three groups (tongue-hold swallowing, tongue-pressure resistance training and control groups). Each group participated in 8 weeks of their appropriately prescribed intervention. We measured anterior tongue strength, posterior tongue strength, lip strength, salivary flow rate and Oral Health Impact Profile-14 score before and after 8 weeks. Differences before and after intervention were observed with a paired sample t-test. Moreover, analyses of covariance and variance were performed to determine the differences in the measured values between the groups. RESULTS The tongue-hold swallowing group showed improvement in both anterior and posterior tongue strength, while the tongue-pressure resistance training group showed a significant increase in only anterior tongue strength. Both the tongue-hold swallowing and tongue-pressure resistance training groups showed increased salivary secretion, with the tongue-pressure resistance training group showing a higher level of salivary secretion. However, the difference in the subjective oral health scores before and after the intervention was not significant. CONCLUSIONS The two lingual exercises strengthened some aspects of tongue muscles and increased the salivary flow rate, with more salivary secretion in the tongue-pressure resistance training group than in the tongue-hold swallowing group. Any evidence of the lingual exercises being able to enhance subjective oral health could not be found. Geriatr Gerontol Int 2020; ••: ••-••.",2020,"Both the tongue-hold swallowing and tongue-pressure resistance training groups showed increased salivary secretion, with the tongue-pressure resistance training group showing a higher level of salivary secretion.","['74 elderly adults (≥65\u2009years) to three groups ', 'elderly adults']","['tongue-hold swallowing, tongue-pressure resistance training', 'lingual exercises', 'lingual exercise (tongue-hold swallowing and tongue-pressure resistance training']","['anterior tongue strength, posterior tongue strength, lip strength, salivary flow rate and Oral Health Impact Profile-14 score', 'anterior tongue strength', 'subjective oral health scores', 'oral muscle strength and salivary flow rate', 'anterior and posterior tongue strength', 'salivary flow rate', 'oral muscle strength, salivary flow rate and subjective oral health of the elderly', 'salivary secretion']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0040408', 'cui_str': 'Tongue structure'}, {'cui': 'C0675390', 'cui_str': 'ARID1A protein, human'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0226945', 'cui_str': 'Structure of body of tongue'}, {'cui': 'C0226958', 'cui_str': 'Structure of root of tongue'}, {'cui': 'C0023759', 'cui_str': 'Lip structure'}, {'cui': 'C0429177', 'cui_str': 'Salivary flow rate'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0036104', 'cui_str': 'Salivary secretion'}]",74.0,0.0292108,"Both the tongue-hold swallowing and tongue-pressure resistance training groups showed increased salivary secretion, with the tongue-pressure resistance training group showing a higher level of salivary secretion.","[{'ForeName': 'Kyeong-Hee', 'Initials': 'KH', 'LastName': 'Lee', 'Affiliation': 'Department of Dental Hygiene, College of Bioecological Health, Shinhan University, Uijeongbu, Republic of Korea.'}, {'ForeName': 'Eun-Seo', 'Initials': 'ES', 'LastName': 'Jung', 'Affiliation': 'Department of Dental Hygiene, College of Bioecological Health, Shinhan University, Uijeongbu, Republic of Korea.'}, {'ForeName': 'Yoon-Young', 'Initials': 'YY', 'LastName': 'Choi', 'Affiliation': 'Artificial Intelligence Big Data Medical Center, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.'}]",Geriatrics & gerontology international,['10.1111/ggi.13944'] 1462,32585185,"Effectiveness of a brief lay counsellor-delivered, problem-solving intervention for adolescent mental health problems in urban, low-income schools in India: a randomised controlled trial.","BACKGROUND Mental health problems are a leading cause of disability in adolescents worldwide. Problem solving is a well-tested mental health intervention in many populations. We aimed to investigate the effectiveness of a brief, transdiagnostic problem-solving intervention for common adolescent mental health problems when delivered by non-specialist school counsellors in New Delhi, India. METHODS This randomised trial was done in six government-run schools (three all-boys schools, two all-girls schools, and one co-educational school) that serve low-income communities. We recruited participants from grades 9 to 12 (ages 12-20 years) by selecting students with persistently elevated mental health symptoms accompanied by distress or functional impairment. Clinical eligibility criteria were assessed by research assistants using the Hindi-language version of the Strengths and Difficulties Questionnaire (SDQ), with reference to locally validated borderline cutoff scores of 19 or greater for boys and 20 or greater for girls on the SDQ Total Difficulties scale, an abnormal score of 2 or more on the SDQ Impact scale, and persistence of more than 1 month on the SDQ Chronicity index. Participants were randomly allocated (1:1) to problem solving delivered through a brief (2-3 week) counsellor-led intervention with supporting printed materials (intervention group), or problem solving delivered via printed booklets alone (control group). Primary outcomes were adolescent-reported mental health symptoms (SDQ Total Difficulties scale) and idiographic psychosocial problems (Youth Top Problems [YTP]) at 6 weeks. Primary analyses were done on an intention-to-treat basis at the 6-week endpoint. The trial is registered with ClinicalTrials.gov, NCT03630471. FINDINGS Participants were enrolled between Aug 20, and Dec 4, 2018. 283 eligible adolescents were referred to the trial, and 251 (89%) of these were enrolled (mean age 15·61 years; 174 [69%] boys). 125 participants were allocated to each group (after accounting for one participant in the intervention group who withdrew consent after randomisation). Primary outcome data were available for 245 (98%) participants. At 6 weeks, the mean YTP scores were 3·52 (SD 2·66) in the intervention group and 4·60 (2·75) in the control group (adjusted mean difference -1·01, 95% CI -1·63 to -0·38; adjusted effect size 0·36, 95% CI 0·11 to 0·61; p=0·0015). The mean SDQ Total Difficulties scores were 17·48 (5·45) in the intervention group and 18·33 (5·45) in the control group (-0·86, -2·14 to 0·41; 0·16, -0·09 to 0·41; p=0·18). We observed no adverse events. INTERPRETATION A brief lay counsellor-delivered problem-solving intervention combined with printed booklets seemed to have a modest effect on psychosocial outcomes among adolescents with diverse mental health problems compared with problem-solving booklets alone. This counsellor-delivered intervention might be a suitable first-line intervention in a stepped care approach, which is being evaluated in ongoing studies. FUNDING Wellcome Trust.",2020,"At 6 weeks, the mean YTP scores were 3·52 (SD 2·66) in the intervention group and 4·60 (2·75) in the control group (adjusted mean difference -1·01, 95% CI -1·63 to -0·38; adjusted effect size 0·36, 95% CI 0·11 to 0·61;","['125 participants', 'adolescent mental health problems in urban, low-income schools in India', 'common adolescent mental health problems when delivered by non-specialist school counsellors in New Delhi, India', '283 eligible adolescents were referred to the trial, and 251 (89%) of these were enrolled (mean age 15·61 years; 174 [69%] boys', 'adolescents with diverse mental health problems', 'participants from grades 9 to 12 (ages 12-20 years) by selecting students with persistently elevated mental health symptoms accompanied by distress or functional impairment', 'six government-run schools (three all-boys schools, two all-girls schools, and one co-educational school) that serve low-income communities', 'Participants were enrolled between Aug 20, and Dec 4, 2018']","['problem solving delivered through a brief (2-3 week) counsellor-led intervention with supporting printed materials (intervention group), or problem solving delivered via printed booklets alone (control group', 'lay counsellor-delivered problem-solving intervention combined with printed booklets', 'brief lay counsellor-delivered, problem-solving intervention', 'transdiagnostic problem-solving intervention']","['SDQ Total Difficulties scale', 'SDQ Chronicity index', 'psychosocial outcomes', 'mean YTP scores', 'mean SDQ Total Difficulties scores', 'adolescent-reported mental health symptoms (SDQ Total Difficulties scale) and idiographic psychosocial problems (Youth Top Problems [YTP']","[{'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1446377', 'cui_str': 'Mental health problem'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0557802', 'cui_str': 'Specialist school'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0086541', 'cui_str': 'Dry form of cutaneous leishmaniasis'}, {'cui': 'C4708786', 'cui_str': '283'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0761050', 'cui_str': '(GVGVP)251'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0018104', 'cui_str': 'Government'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0033211', 'cui_str': 'Problem solving'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0034036', 'cui_str': 'Printed material'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0033161', 'cui_str': 'Printing'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0023668', 'cui_str': 'Liechtenstein'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C3472494', 'cui_str': 'Strengths and difficulties questionnaire'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0547045', 'cui_str': 'Chronicity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}]",125.0,0.178681,"At 6 weeks, the mean YTP scores were 3·52 (SD 2·66) in the intervention group and 4·60 (2·75) in the control group (adjusted mean difference -1·01, 95% CI -1·63 to -0·38; adjusted effect size 0·36, 95% CI 0·11 to 0·61;","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Michelson', 'Affiliation': 'School of Psychology, University of Sussex, Brighton, UK.'}, {'ForeName': 'Kanika', 'Initials': 'K', 'LastName': 'Malik', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Rachana', 'Initials': 'R', 'LastName': 'Parikh', 'Affiliation': 'Sagath, New Delhi, India; Department of Clinical Psychology, Vrije Universiteit, Amsterdam, Netherlands.'}, {'ForeName': 'Helen A', 'Initials': 'HA', 'LastName': 'Weiss', 'Affiliation': 'Medical Research Council Tropical Epidemiology Group, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Aoife M', 'Initials': 'AM', 'LastName': 'Doyle', 'Affiliation': 'Medical Research Council Tropical Epidemiology Group, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Bhargav', 'Initials': 'B', 'LastName': 'Bhat', 'Affiliation': 'Sangath, Goa, India.'}, {'ForeName': 'Rooplata', 'Initials': 'R', 'LastName': 'Sahu', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Bhagwant', 'Initials': 'B', 'LastName': 'Chilhate', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Sonal', 'Initials': 'S', 'LastName': 'Mathur', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Madhuri', 'Initials': 'M', 'LastName': 'Krishna', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Rhea', 'Initials': 'R', 'LastName': 'Sharma', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Paulomi', 'Initials': 'P', 'LastName': 'Sudhir', 'Affiliation': 'Department of Clinical Psychology, National Institute of Mental Health and Neuro Sciences, Bengaluru, India.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'King', 'Affiliation': 'Division of Psychiatry, Faculty of Brain Sciences, University College London, London, UK.'}, {'ForeName': 'Pim', 'Initials': 'P', 'LastName': 'Cuijpers', 'Affiliation': 'Department of Clinical Psychology, Vrije Universiteit, Amsterdam, Netherlands.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Chorpita', 'Affiliation': 'Department of Psychology, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Christopher G', 'Initials': 'CG', 'LastName': 'Fairburn', 'Affiliation': 'Department of Psychiatry, University of Oxford, Oxford, UK.'}, {'ForeName': 'Vikram', 'Initials': 'V', 'LastName': 'Patel', 'Affiliation': 'Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA; Harvard TH Chan School of Public Health, Boston, MA, USA. Electronic address: vikram_patel@hms.harvard.edu.'}]",The Lancet. Child & adolescent health,['10.1016/S2352-4642(20)30173-5'] 1463,32586176,"Re: Health Care Hotspotting-A Randomized, Controlled Trial.",,2020,,[],[],[],[],[],[],,0.217515,,"[{'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Resnick', 'Affiliation': ''}]",The Journal of urology,['10.1097/JU.0000000000001171.02'] 1464,32586177,Re: Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression among Men with Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial.,,2020,,['Men with Early-Stage Prostate Cancer'],['Behavioral Intervention to Increase Vegetable Consumption'],['Cancer Progression'],"[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}]","[{'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0178874', 'cui_str': 'Tumor progression'}]",,0.0490649,,"[{'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Resnick', 'Affiliation': ''}]",The Journal of urology,['10.1097/JU.0000000000001171'] 1465,32586190,"Re: The Daily Therapy with L-Arginine 2,500 mg and Tadalafil 5 mg in Combination and in Monotherapy for the Treatment of Erectile Dysfunction: A Prospective, Randomized Multicentre Study.",,2020,,['Erectile Dysfunction'],"['L-Arginine 2,500 mg and Tadalafil 5 mg in Combination and in Monotherapy']",[],"[{'cui': 'C0242350', 'cui_str': 'Impotence'}]","[{'cui': 'C0003765', 'cui_str': 'Arginine'}, {'cui': 'C1331168', 'cui_str': 'tadalafil 5 MG'}]",[],,0.018511,,"[{'ForeName': 'Allen D', 'Initials': 'AD', 'LastName': 'Seftel', 'Affiliation': ''}]",The Journal of urology,['10.1097/JU.0000000000001167.03'] 1466,32588047,A Combined Nutrition and Exercise Intervention Influences Serum Vitamin B-12 and 25-Hydroxyvitamin D and Bone Turnover of Healthy Chinese Middle-Aged and Older Adults.,"BACKGROUND Hong Kong faces several public health problems including malnutrition and osteoporosis. Considering the typical Chinese diet and overall low physical activity levels of Chinese adults, timely interventions to improve nutritional status and bone health are needed. OBJECTIVES We examined the effects of a nutrition plus exercise intervention on serum vitamin B-12 and 25-hydroxyvitamin D [25(OH)D], bone turnover markers, and parathyroid hormone (PTH) concentrations in apparently healthy Chinese middle-aged and older adults. METHODS In this 24-wk randomized controlled trial, 180 Chinese adults (85 women, mean ± SD age: 61 ± 6 y) were randomly assigned to receive a fortified milk supplement (2 × 30 g/d) and an exercise program (2 × 1 h/wk including resistance, balance, and aerobic training) or no intervention. The primary outcome was physical performance. In this article we analyzed the secondary outcomes serum vitamin B-12 and 25(OH)D concentrations, assessed at baseline, 12 wk, and 24 wk. Also, bone turnover markers and PTH concentrations were studied. Linear mixed models evaluated group differences over time. RESULTS A significant time × group interaction (P < 0.001) was found for serum vitamin B-12 and 25(OH)D concentrations and the bone turnover markers, but not for serum PTH concentrations (P = 0.09). The intervention increased mean ± SD vitamin B-12 concentrations from baseline (345 ± 119 pmol/L) to 24 wk (484 ± 136 pmol/L), whereas concentrations remained stable within the control. For 25(OH)D concentrations, the intervention group had a greater increase from baseline (54.7 ± 14.2 nmol/L) to 24 wk (80.1 ± 19.2 nmol/L) than the control (60.6 ± 15.2 compared with 65.6 ± 14.6 nmol/L). The ratio of the net effect of bone formation and resorption was greater in the intervention group, suggesting less bone remodeling, irrespective of sex. CONCLUSIONS A fortified milk supplement and exercise intervention successfully improved vitamin B-12 and 25(OH)D concentrations as well as the balance of bone turnover markers of Chinese middle-aged and older adults.This trial was registered at trialregister.nl as NTR6214.",2020,A fortified milk supplement and exercise intervention successfully improved vitamin B-12 and 25(OH)D concentrations as well as the balance of bone turnover markers of Chinese middle-aged and older adults.,"['Healthy Chinese Middle-Aged and Older Adults', 'SD age: 61\xa0±\xa06 y', 'Chinese middle-aged and older adults', '180 Chinese adults (85 women, mean\xa0±', 'Chinese adults', 'apparently healthy Chinese middle-aged and older adults']","['fortified milk supplement', 'exercise program (2\xa0×\xa01\xa0h/wk including resistance, balance, and aerobic training) or no intervention', 'nutrition plus exercise intervention', 'Combined Nutrition and Exercise Intervention', 'fortified milk supplement and exercise intervention']","['serum vitamin B-12 and 25-hydroxyvitamin D [25(OH)D], bone turnover markers, and parathyroid hormone (PTH) concentrations', 'vitamin B-12 and 25(OH)D concentrations', 'serum vitamin B-12 and 25(OH)D concentrations and the bone turnover markers', 'bone formation and resorption', 'physical performance', 'Serum Vitamin B-12 and 25-Hydroxyvitamin D and Bone Turnover', 'serum PTH concentrations', 'serum vitamin B-12 and 25(OH)D concentrations', 'mean\xa0±\xa0SD vitamin B-12 concentrations', 'bone turnover markers and PTH concentrations']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]","[{'cui': 'C1532525', 'cui_str': 'Fortified milk'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0700308', 'cui_str': 'Protium'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0428581', 'cui_str': 'Serum vitamin A measurement'}, {'cui': 'C0042845', 'cui_str': 'Vitamin B 12'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0085268', 'cui_str': 'Bone remodeling'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0020063', 'cui_str': 'PTH protein, human'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0029433', 'cui_str': 'Bone formation'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0428408', 'cui_str': 'Serum parathyroid hormone measurement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",180.0,0.0580461,A fortified milk supplement and exercise intervention successfully improved vitamin B-12 and 25(OH)D concentrations as well as the balance of bone turnover markers of Chinese middle-aged and older adults.,"[{'ForeName': 'Inge', 'Initials': 'I', 'LastName': 'Groenendijk', 'Affiliation': 'Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, Netherlands.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Chan', 'Affiliation': 'Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Woo', 'Affiliation': 'Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Sherlin', 'Initials': 'S', 'LastName': 'Ong', 'Affiliation': 'FrieslandCampina, Amersfoort, Netherlands.'}, {'ForeName': 'Panam', 'Initials': 'P', 'LastName': 'Parikh', 'Affiliation': 'FrieslandCampina, Amersfoort, Netherlands.'}, {'ForeName': 'Marjolijn C E', 'Initials': 'MCE', 'LastName': 'Bragt', 'Affiliation': 'FrieslandCampina, Amersfoort, Netherlands.'}, {'ForeName': 'Lisette C P G M', 'Initials': 'LCPGM', 'LastName': 'de Groot', 'Affiliation': 'Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, Netherlands.'}]",The Journal of nutrition,['10.1093/jn/nxaa149'] 1467,32589153,Evaluation of the Tobbstop Mobile App for Smoking Cessation: Cluster Randomized Controlled Clinical Trial.,"BACKGROUND Mobile apps provide an accessible way to test new health-related methodologies. Tobacco is still the primary preventable cause of death in industrialized countries, constituting an important public health issue. New technologies provide novel opportunities that are effective in the cessation of smoking tobacco. OBJECTIVE This paper aims to evaluate the efficacy and usage of a mobile app for assisting adult smokers to quit smoking. METHODS We conducted a cluster randomized clinical trial. We included smokers older than 18 years who were motivated to stop smoking and used a mobile phone compatible with our mobile app. We carried out follow-up visits at 15, 30, and 45 days, and at 2, 3, 6, and 12 months. Participants of the intervention group had access to the Tobbstop mobile app designed by the research team. The primary outcomes were continuous smoking abstinence at 3 and 12 months. RESULTS A total of 773 participants were included in the trial, of which 602 (77.9%) began the study on their D-Day. Of participants in the intervention group, 34.15% (97/284) did not use the app. The continuous abstention level was significantly larger in the intervention group participants who used the app than in those who did not use the app at both 3 months (72/187, 38.5% vs 13/97, 13.4%; P<.001) and 12 months (39/187, 20.9% vs 8/97, 8.25%; P=.01). Participants in the intervention group who used the app regularly and correctly had a higher probability of not being smokers at 12 months (OR 7.20, 95% CI 2.14-24.20; P=.001) than the participants of the CG. CONCLUSIONS Regular use of an app for smoking cessation is effective in comparison with standard clinical practice. TRIAL REGISTRATION Clinicaltrials.gov NCT01734421; https://clinicaltrials.gov/ct2/show/NCT01734421.",2020,"The continuous abstention level was significantly larger in the intervention group participants who used the app than in those who did not use the app at both 3 months (72/187, 38.5% vs 13/97, 13.4%; P<.001) and 12 months (39/187, 20.9% vs 8/97, 8.25%; P=.01).","['A total of 773 participants were included in the trial, of which 602 (77.9%) began the study on their D-Day', 'smokers older than 18 years who were motivated to stop smoking and used a mobile phone compatible with our mobile app']",[],"['higher probability of not being smokers', 'continuous smoking abstinence', 'continuous abstention level']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439228', 'cui_str': 'day'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0425310', 'cui_str': 'Stopped smoking'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}]",[],"[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",773.0,0.193476,"The continuous abstention level was significantly larger in the intervention group participants who used the app than in those who did not use the app at both 3 months (72/187, 38.5% vs 13/97, 13.4%; P<.001) and 12 months (39/187, 20.9% vs 8/97, 8.25%; P=.01).","[{'ForeName': 'Meritxell', 'Initials': 'M', 'LastName': 'Pallejà-Millán', 'Affiliation': ""Unitat de Suport a la Recerca Camp de Tarragona, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, Reus, Spain.""}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Rey-Reñones', 'Affiliation': 'Departament de Ciències Mèdiques Bàsiques, Universitat Rovira i Virgili, Reus, Spain.'}, {'ForeName': 'Maria Luisa', 'Initials': 'ML', 'LastName': 'Barrera Uriarte', 'Affiliation': 'Institut Català de la Salut, Unitat de Suport a la Recerca Camp de Tarragona, Reus, Spain.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Granado-Font', 'Affiliation': 'Institut Català de la Salut, Unitat de Suport a la Recerca Camp de Tarragona, Reus, Spain.'}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Basora', 'Affiliation': ""Unitat de Suport a la Recerca Camp de Tarragona, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, Reus, Spain.""}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Flores-Mateo', 'Affiliation': ""Unitat de Suport a la Recerca Camp de Tarragona, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, Reus, Spain.""}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Duch', 'Affiliation': ""Departament d'Enginyeria Informàtica i Matemàtiques, Universitat Rovira i Virgili, Tarragona, Spain.""}]",JMIR mHealth and uHealth,['10.2196/15951'] 1468,32589155,Improving the Lifestyle of Adolescents Through Peer Education and Support in Vietnam: Protocol for a Pilot Cluster Randomized Controlled Trial.,"BACKGROUND In Ho Chi Minh City, Vietnam, recent studies found a rapid increase in overweight and obesity in adolescents. There is a need for effective health promotion interventions to support healthy diets and encourage a physically active lifestyle. This study will help fill an evidence gap on effective interventions to prevent excess weight gain in adolescents and generate new insights about peer-led education to promote healthy lifestyles. OBJECTIVE We aim to assess the feasibility and acceptability of a combined peer-led and peer support intervention among junior high school students in Ho Chi Minh City. Additionally, the efficacy of the intervention on adolescents' dietary practices and time spent on physical activity will also be measured in this pilot study. METHODS The Peer Education and Peer Support (PEPS) project is a pilot cluster randomized controlled trial with 2 intervention and 2 control schools. The intervention consists of 4 weekly education sessions of why and how to choose healthy food and drinks and how to be more physically active. Additionally, the intervention includes a school-based and online support system to help maintain student engagement during the intervention. We will use in-depth interviews with students, peer leaders, teachers, and parents; focus group discussions with peer educators; and direct observation of the school environment and peer leaders' interactions with the students. Acceptability and feasibility of the intervention will be assessed. We will also quantitatively assess limited efficacy by measuring changes in student' physical activity levels and dietary behaviors. RESULTS We delivered the peer education intervention at the start of each school year over 3 months for all new grade 6 adolescents in the selected schools, followed by peer support and home engagement activities over 6 months until the end of the school year. There was a baseline assessment and 2 post-intervention assessments: the first immediately after the intervention to assess the short-term impact and the second at the end of the school year to assess the sustained impact on changes in adiposity, diet, and physical activity. CONCLUSIONS The findings of this study will be used to develop a larger-scale cluster randomized controlled trial to examine the impact of a multicomponent, school- and home-based health promotion intervention. The trial will use innovative peer education methods to reduce overweight and obesity and improve dietary choices and physical activity levels in Vietnamese adolescents. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry ACTRN12619000421134; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=376690&isReview=true. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/15930.",2020,"OBJECTIVE We aim to assess the feasibility and acceptability of a combined peer-led and peer support intervention among junior high school students in Ho Chi Minh City.","['overweight and obesity in adolescents', 'Vietnamese adolescents', 'junior high school students in Ho Chi Minh City']","[""discussions with peer educators; and direct observation of the school environment and peer leaders' interactions with the students"", 'combined peer-led and peer support intervention', 'Peer Education and Peer Support', 'multicomponent, school- and home-based health promotion intervention', 'peer education intervention']","['feasibility and acceptability', 'changes in adiposity, diet, and physical activity', 'Acceptability and feasibility']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0042660', 'cui_str': 'Vietnamese language'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0376586', 'cui_str': 'Life-Breath (Philosophy)'}, {'cui': 'C0008848', 'cui_str': 'Cities'}]","[{'cui': 'C0557061', 'cui_str': 'Discussion'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018738', 'cui_str': 'Health promotion'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.0860508,"OBJECTIVE We aim to assess the feasibility and acceptability of a combined peer-led and peer support intervention among junior high school students in Ho Chi Minh City.","[{'ForeName': 'Hong K', 'Initials': 'HK', 'LastName': 'Tang', 'Affiliation': 'Department of Epidemiology, Faculty of Public Health, Ho Chi Minh City, Vietnam.'}, {'ForeName': 'Ngoc-Minh', 'Initials': 'NM', 'LastName': 'Nguyen', 'Affiliation': 'Department of Epidemiology, Faculty of Public Health, Ho Chi Minh City, Vietnam.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Dibley', 'Affiliation': 'The Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.'}, {'ForeName': 'Trang H H D', 'Initials': 'THHD', 'LastName': 'Nguyen', 'Affiliation': 'Department of Epidemiology, Faculty of Public Health, Ho Chi Minh City, Vietnam.'}, {'ForeName': 'Ashraful', 'Initials': 'A', 'LastName': 'Alam', 'Affiliation': 'The Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.'}]",JMIR research protocols,['10.2196/15930'] 1469,32601075,Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.,"PURPOSE Uterine-serous-carcinoma (USC) is an aggressive variant of endometrial cancer. On the basis of preliminary results of a multicenter, randomized phase II trial, trastuzumab (T), a humanized-mAb targeting Her2/Neu, in combination with carboplatin/paclitaxel (C/P), is recognized as an alternative in treating advanced/recurrent HER2/Neu-positive USC. We report the updated survival analysis of NCT01367002. PATIENTS AND METHODS Eligible patients had stage III to IV or recurrent disease. Participants were randomized 1:1 to receive C/P for six cycles ± T followed by maintenance T until progression or toxicity. Progression-free survival (PFS) was the primary endpoint; overall survival (OS) and toxicity were secondary endpoints. RESULTS Sixty-one patients were randomized. After a median-follow-up of 25.9 months, 43 progressions and 38 deaths occurred among 58 evaluable patients. Updated median-PFS continued to favor the T-arm, with medians of 8.0 months versus 12.9 months in the control and T-arms (HR = 0.46; 90% CI, 0.28-0.76; P = 0.005). Median-PFS was 9.3 months versus 17.7 months among 41 patients with stage III to IV disease undergoing primary treatment (HR = 0.44; 90% CI, 0.23-0.83; P = 0.015), and 7.0 months versus 9.2 months among 17 patients with recurrent disease (HR = 0.12; 90% CI, 0.03-0.48; P = 0.004). OS was higher in the T compared with the control arm, with medians of 29.6 months versus 24.4 months (HR = 0.58; 90% CI, 0.34-0.99; P = 0.046). The benefit was most notable in those with stage III to IV disease, with survival median not reached in the T-arm versus 24.4 months in the control arm (HR = 0.49; 90% CI, 0.25-0.97; P = 0.041). Toxicity was not different between arms. CONCLUSIONS Addition of T to C/P increased PFS and OS in women with advanced/recurrent HER2/Neu-positive USC, with the greatest benefit seen for the treatment of stage III to IV disease.",2020,"OS was higher in the T compared with the control arm, with medians of 29.6 months versus 24.4 months (HR = 0.58; 90% CI, 0.34-0.99; P = 0.046).","['Sixty-one patients were randomized', 'Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002', 'Eligible patients had stage III to IV or recurrent disease']","['carboplatin/paclitaxel (C/P', 'Carboplatin-Paclitaxel', 'trastuzumab (T', 'Carboplatin-Paclitaxel-Trastuzumab']","['Median-PFS', 'Progression-free survival (PFS', 'OS', 'Toxicity', 'PFS and OS', 'survival median', 'overall survival (OS) and toxicity']","[{'cui': 'C4517832', 'cui_str': '61'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0854924', 'cui_str': 'Papillary serous endometrial carcinoma'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0277556', 'cui_str': 'Recurrent disease'}]","[{'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0728747', 'cui_str': 'trastuzumab'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0040539', 'cui_str': 'TO'}]",41.0,0.181913,"OS was higher in the T compared with the control arm, with medians of 29.6 months versus 24.4 months (HR = 0.58; 90% CI, 0.34-0.99; P = 0.046).","[{'ForeName': 'Amanda N', 'Initials': 'AN', 'LastName': 'Fader', 'Affiliation': 'John Hopkins School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Dana M', 'Initials': 'DM', 'LastName': 'Roque', 'Affiliation': 'University of Maryland, Baltimore, Maryland.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Siegel', 'Affiliation': 'University of Arkansas for Medical Sciences, Little Rock, Arkansas.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Buza', 'Affiliation': 'Yale University, New Haven, Connecticut.'}, {'ForeName': 'Pei', 'Initials': 'P', 'LastName': 'Hui', 'Affiliation': 'Yale University, New Haven, Connecticut.'}, {'ForeName': 'Osama', 'Initials': 'O', 'LastName': 'Abdelghany', 'Affiliation': 'Yale University, New Haven, Connecticut.'}, {'ForeName': 'Setsuko', 'Initials': 'S', 'LastName': 'Chambers', 'Affiliation': 'University of Arizona, Tucson, Arizona.'}, {'ForeName': 'Angeles Alvarez', 'Initials': 'AA', 'LastName': 'Secord', 'Affiliation': 'Duke University School of Medicine, Durham, North Caroline.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Havrilesky', 'Affiliation': 'Duke University School of Medicine, Durham, North Caroline.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': ""O'Malley"", 'Affiliation': 'The Ohio State University School of Medicine, Columbus, Ohio.'}, {'ForeName': 'Floor J', 'Initials': 'FJ', 'LastName': 'Backes', 'Affiliation': 'The Ohio State University School of Medicine, Columbus, Ohio.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Nevadunsky', 'Affiliation': 'Albert Einstein College/Montefiore Medical Center, Bronx, New York.'}, {'ForeName': 'Babak', 'Initials': 'B', 'LastName': 'Edraki', 'Affiliation': 'John Muir Medical Center, Walnut Creek, California.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Pikaart', 'Affiliation': 'Penrose Cancer Center-St. Francis, Colorado Springs, Colorado.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Lowery', 'Affiliation': 'Walter Reed Medical Center, Bethesda, Maryland.'}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'ElSahwi', 'Affiliation': 'Hackensack Meridian Health, Neptune, New Jersey.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Celano', 'Affiliation': 'Greater Baltimore Medical Center, Baltimore, Maryland.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Bellone', 'Affiliation': 'Yale University, New Haven, Connecticut.'}, {'ForeName': 'Masoud', 'Initials': 'M', 'LastName': 'Azodi', 'Affiliation': 'Yale University, New Haven, Connecticut.'}, {'ForeName': 'Babak', 'Initials': 'B', 'LastName': 'Litkouhi', 'Affiliation': ""Stanford Women's Cancer Center, Palo Alto, California.""}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Ratner', 'Affiliation': 'Yale University, New Haven, Connecticut.'}, {'ForeName': 'Dan-Arin', 'Initials': 'DA', 'LastName': 'Silasi', 'Affiliation': 'Yale University, New Haven, Connecticut.'}, {'ForeName': 'Peter E', 'Initials': 'PE', 'LastName': 'Schwartz', 'Affiliation': 'Yale University, New Haven, Connecticut.'}, {'ForeName': 'Alessandro D', 'Initials': 'AD', 'LastName': 'Santin', 'Affiliation': 'Yale University, New Haven, Connecticut. alessandro.santin@yale.edu.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-0953'] 1470,32598387,Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg.,"BACKGROUND Progestin-only pills are associated with irregular bleeding pattern including amenorrhea. Desogestrel 75mcg even being a pill that inhibits ovulation shows a poor cycle control that limits a more common use. A drospirenone (DRSP)-only pill was developed to improve the bleeding profile. METHODS A phase III study in healthy women aged 18 to 45 years was performed to compare the bleeding profile and safety of women taking a DRSP only pill in a regime of 24 days of 4 mg of DRSP tablets followed by 4 days of placebo versus desogestrel 0.075 mg per day continuously over 9 cycles. A total of 858 women with 6691 drospirenone and 332 women with 2487 desogestrel treatment cycles were analyzed. The primary endpoint was the proportion of women with bleeding/spotting days in each cycle from cycles 2 to 9 and cumulative in cycles 2 to 4 and cycles 7 to 9 including and excluding those with amenorrhea. FINDINGS In each cycle, up to cycle 7, the proportion of women with unscheduled bleeding including those which did not bleed was statistically significantly lower in the DRSP group than in the DSG group (p = 0.0001, chi-square test). The mean [SD] number of unscheduled bleeding and spotting days during cycles 2-9 was statistically significantly lower in the DRSP group than in the DSG group (21.5 [22.86] days vs. 34.7 [33.73] days, p = 0.0003, Wilcoxon-rank-sum-test). Excluding amenorrhoeic women following results were obtained: In the cycles 2-6, the proportion of women with unscheduled bleeding was statistically significantly lower in the DRSP group than in the DSG group (p = 0.0001, chi-square test). The mean [SD] number of bleeding days was 8.6 [8.52] days vs. 12.9 [16.47] days, p = 0.0233. CONCLUSIONS This report describes the improvement in bleeding profile of women using the new DRSP only oral contraceptive in comparison to DSG providing a better quality of live and adherence to the contraceptive method. EudraCT registration number: 2011-002396-42.",2020,"In the cycles 2-6, the proportion of women with unscheduled bleeding was statistically significantly lower in the DRSP group than in the DSG group (p = 0.0001, chi-square test).","['858 women with 6691 drospirenone and 332 women with 2487 desogestrel treatment cycles were analyzed', 'healthy women aged 18 to 45 years', 'Excluding amenorrhoeic women following results were obtained']","['DRSP', 'placebo versus desogestrel', 'drospirenone (DRSP)-only pill', 'drospirenone', 'DRSP tablets', 'Desogestrel']","['mean [SD] number of bleeding days', 'proportion of women with unscheduled bleeding', 'bleeding profile and safety', 'quality of live and adherence', 'bleeding profile', 'proportion of women with bleeding/spotting days', 'proportion of women with unscheduled bleeding including those which did not bleed', 'mean [SD] number of unscheduled bleeding and spotting days']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0043822', 'cui_str': 'drospirenone'}, {'cui': 'C0057558', 'cui_str': 'Desogestrel'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}]","[{'cui': 'C0043822', 'cui_str': 'drospirenone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0057558', 'cui_str': 'Desogestrel'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3854240', 'cui_str': 'Unscheduled'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1299585', 'cui_str': 'Does not'}]",858.0,0.0815399,"In the cycles 2-6, the proportion of women with unscheduled bleeding was statistically significantly lower in the DRSP group than in the DSG group (p = 0.0001, chi-square test).","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Palacios', 'Affiliation': 'Salud y Medicina de la Mujer, Director-Instituto Palacios, Madrid, Spain.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Colli', 'Affiliation': 'Exeltis HealthCare Madrid, Madrid, Spain.'}, {'ForeName': 'P A', 'Initials': 'PA', 'LastName': 'Regidor', 'Affiliation': 'Exeltis Europe, Ismaning, Germany.'}]",PloS one,['10.1371/journal.pone.0231856'] 1471,32599496,Randomized controlled three-arm study of NADA acupuncture for alcohol addiction.,"INTRODUCTION Alcohol addiction compromises cardiovascular health, possibly due to impaired control of the heart and vasculature by the autonomic nervous system. We aimed to assess the effects of National Acupuncture Detoxification Association (NADA) acupuncture on cardiovascular autonomic functions, psychiatric comorbidities and abstinence in patients addicted to alcohol. MATERIAL AND METHODS A randomized sham controlled three-arm study was undertaken in 72 patients (nine females, aged 43.7 ± 9.2 years, mean ± SD) undergoing in-patient rehabilitation for alcohol addiction. Patients were randomly allocated (1:1:1) to receive twenty 30-minute NADA or sham acupuncture sessions within six weeks or no intervention. They were evaluated for craving, depression, anxiety and autonomic control of the heart (heart rate variability, HRV), vasculature (laser Doppler flowmetry) and sweat glands (sympathetic skin response). Testing was performed at baseline, immediately post intervention (sham intervention or control period, respectively) and another four weeks later. Abstinence was assessed one year after study completion. RESULTS Patients in the NADA arm displayed increased HRV immediately post-intervention compared to baseline (SDNN: 72.8 ms ± 34.2 ms vs. 57.9 ms ± 31.2 ms, p = 0.001). This increase was sustained four weeks later (66.2 ms ± 32.4 ms, p = 0.015). HRV remained unaltered following sham or no acupuncture (p = n.s.). Autonomic function of vasculature and sweat glands, psychiatric comorbidities and one-year abstinence did not differ between study arms. CONCLUSIONS NADA acupuncture may improve autonomic cardiac function. However, this improvement appears not to translate into alleviation of psychiatric comorbidities or sustained abstinence.",2020,"This increase was sustained four weeks later (66.2 ms ± 32.4 ms, p = 0.015).","['patients addicted to alcohol', '72 patients (nine females, aged 43.7\xa0±\xa09.2\xa0years, mean\xa0±\xa0SD) undergoing in-patient rehabilitation for alcohol addiction', '34.2']","['NADA or sham acupuncture sessions within six weeks or no intervention', 'National Acupuncture Detoxification Association (NADA) acupuncture', 'sham or no acupuncture', 'NADA acupuncture']","['HRV', 'Autonomic function of vasculature and sweat glands, psychiatric comorbidities and one-year abstinence', 'craving, depression, anxiety and autonomic control of the heart (heart rate variability, HRV), vasculature (laser Doppler flowmetry) and sweat glands (sympathetic skin response', 'autonomic cardiac function', 'cardiovascular autonomic functions, psychiatric comorbidities and abstinence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001973', 'cui_str': 'Alcohol dependence'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C5191219', 'cui_str': '9.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C5191359', 'cui_str': '34.2'}]","[{'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0025516', 'cui_str': 'Detoxication, Drug, Metabolic'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0010343', 'cui_str': 'Croatia'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0005839', 'cui_str': 'blood supply'}, {'cui': 'C0038989', 'cui_str': 'Sweat gland structure'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0162520', 'cui_str': 'Laser doppler flowmetry'}, {'cui': 'C0312646', 'cui_str': 'Finding related to response to skin test'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}]",72.0,0.09429,"This increase was sustained four weeks later (66.2 ms ± 32.4 ms, p = 0.015).","[{'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Krause', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Ana Isabel', 'Initials': 'AI', 'LastName': 'Penzlin', 'Affiliation': 'Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Ritschel', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Barlinn', 'Affiliation': 'Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Heinz', 'Initials': 'H', 'LastName': 'Reichmann', 'Affiliation': 'Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Kerstin', 'Initials': 'K', 'LastName': 'Weidner', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Siepmann', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Timo', 'Initials': 'T', 'LastName': 'Siepmann', 'Affiliation': 'Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. Electronic address: timo.siepmann@ukdd.de.'}]",Addictive behaviors,['10.1016/j.addbeh.2020.106488'] 1472,32607749,"Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.","AIMS/HYPOTHESIS Low-dose IL-2 (ld-IL2) selectively activates and expands regulatory T cells (Tregs) and thus has the potential to skew the regulatory/effector T (Treg/Teff) cell balance towards improved regulation. We investigated which low doses of IL-2 would more effectively and safely activate Tregs during a 1 year treatment in children with recently diagnosed type 1 diabetes. METHODS Dose Finding Study of IL-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes (DF-IL2-Child) was a multicentre, double-blinded, placebo-controlled, dose-finding Phase I/II clinical trial conducted in four centres at university hospitals in France: 24 children (7-14 years old) with type 1 diabetes diagnosed within the previous 3 months were randomly assigned 1:1:1:1 to treatment by a centralised randomisation system, leading to a 7/5/6/6 patient distribution of placebo or IL-2 at doses of 0.125, 0.250 or 0.500 million international units (MIU)/m 2 , given daily for a 5 day course and then fortnightly for 1 year. A study number was attributed to patients by an investigator unaware of the randomisation list and all participants as well as investigators and staff involved in the study conduct and analyses were blinded to treatments. The primary outcome was change in Tregs, expressed as a percentage of CD4 + T cells at day 5. It pre-specified that a ≥60% increase in Tregs from baseline would identify Treg high responders. RESULTS There were no serious adverse events. Non-serious adverse events (NSAEs) were transient and mild to moderate. In treated patients vs placebo, the commonest NSAE was injection site reaction (37.9% vs 3.4%), whereas other NSAEs were at the same level (23.3% vs 19.2%). ld-IL2 induced a dose-dependent increase in the mean proportion of Tregs, from 23.9% (95% CI -11.8, 59.6) at the lowest to 77.2% (44.7, 109.8) at the highest dose, which was significantly different from placebo for all dose groups. However, the individual Treg responses to IL-2 were variable and fluctuated over time. Seven patients, all among those treated with the 0.250 and 0.500 MIU m -2  day -1 doses, were Treg high responders. At baseline, they had lower Treg proportions in CD4 + cells than Treg low responders, and serum soluble IL-2 receptor α (sIL-2RA) and vascular endothelial growth factor receptor 2 (VEGFR2) levels predicted the Treg response after the 5 day course. There was no significant change in glycaemic control in any of the dose groups compared with placebo. However, there was an improved maintenance of induced C-peptide production at 1 year in the seven Treg high responders as compared with low responders. CONCLUSIONS/INTERPRETATION The safety profile at all doses, the dose-dependent effects on Tregs and the observed variability of the Treg response to ld-IL2 in children with newly diagnosed type 1 diabetes call for use of the highest dose in future developments. The better preservation of insulin production in Treg high responders supports the potential of Tregs in regulating autoimmunity in type 1 diabetes, and warrants pursuing the investigation of ld-IL2 for its treatment and prevention. TRIAL REGISTRATION ClinicalTrials.gov NCT01862120. FUNDING Assistance Publique-Hôpitaux de Paris, Investissements d'Avenir programme (ANR-11-IDEX-0004-02, LabEx Transimmunom and ANR-16-RHUS-0001, RHU iMAP) and European Research Council Advanced Grant (FP7-IDEAS-ERC-322856, TRiPoD).",2020,There were no serious adverse events.,"['four centres at university hospitals in France: 24 children (7-14\xa0years old) with type 1 diabetes diagnosed within the previous 3\xa0months', 'children with newly diagnosed type 1 diabetes', 'children with recently diagnosed type 1 diabetes', 'Children']","['IL-2', 'Low-dose IL-2', 'placebo or IL-2', 'placebo']","['serum soluble IL-2 receptor α (sIL-2RA) and', 'mean proportion of Tregs', 'vascular endothelial growth factor receptor 2 (VEGFR2) levels', 'serious adverse events', 'injection site reaction', 'glycaemic control', 'change in Tregs, expressed as a percentage of CD4 + T cells', 'maintenance of induced C-peptide production']","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0332185', 'cui_str': 'Recent'}]","[{'cui': 'C0021756', 'cui_str': 'Interleukin-2'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0034819', 'cui_str': 'Interleukin-2 receptor'}, {'cui': 'C0257766', 'cui_str': 'SILV protein, human'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0378796', 'cui_str': 'KDR Tyrosine Kinase'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0151735', 'cui_str': 'Injection site reaction'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}]",,0.490362,There were no serious adverse events.,"[{'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Rosenzwajg', 'Affiliation': ""Clinical Investigation Center for Biotherapies and Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP.Sorbonne Université, Pitié-Salpêtrière Hospital, 83 Bd de l'Hôpital, F-75013, Paris, France.""}, {'ForeName': 'Randa', 'Initials': 'R', 'LastName': 'Salet', 'Affiliation': 'Department of Paediatrics, Nîmes University Hospital and Inserm U1183, Montpellier University, Montpellier, France.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Lorenzon', 'Affiliation': ""Clinical Investigation Center for Biotherapies and Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP.Sorbonne Université, Pitié-Salpêtrière Hospital, 83 Bd de l'Hôpital, F-75013, Paris, France.""}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Tchitchek', 'Affiliation': ""Clinical Investigation Center for Biotherapies and Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP.Sorbonne Université, Pitié-Salpêtrière Hospital, 83 Bd de l'Hôpital, F-75013, Paris, France.""}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Roux', 'Affiliation': ""Clinical Investigation Center for Biotherapies and Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP.Sorbonne Université, Pitié-Salpêtrière Hospital, 83 Bd de l'Hôpital, F-75013, Paris, France.""}, {'ForeName': 'Claude', 'Initials': 'C', 'LastName': 'Bernard', 'Affiliation': ""Clinical Investigation Center for Biotherapies and Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP.Sorbonne Université, Pitié-Salpêtrière Hospital, 83 Bd de l'Hôpital, F-75013, Paris, France.""}, {'ForeName': 'Jean-Claude', 'Initials': 'JC', 'LastName': 'Carel', 'Affiliation': ""Department of Paediatric Endocrinology and Diabetology, and Centre de Référence des Pathologies Rares de l'Insulino-Sécrétion et de l'Insulino-Sensibilité, Robert-Debré Hospital, AP-HP Nord-Université de Paris Diderot & UFR de Médecine Paris Diderot, Paris, France.""}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Storey', 'Affiliation': ""Department of Paediatric Endocrinology and Diabetology, and Centre de Référence des Pathologies Rares de l'Insulino-Sécrétion et de l'Insulino-Sensibilité, Robert-Debré Hospital, AP-HP Nord-Université de Paris Diderot & UFR de Médecine Paris Diderot, Paris, France.""}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Polak', 'Affiliation': ""Department of Paediatric Endocrinology, Gynecology and Diabetology, and Centre de Référence des Pathologies Rares de l'Insulino-Sécrétion et de l'Insulino-Sensibilité, Necker Enfants Malades Hospital, AP-HP.Centre & Université de Paris, UFR de Médecine Paris Descartes, Paris, France.""}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Beltrand', 'Affiliation': ""Department of Paediatric Endocrinology, Gynecology and Diabetology, and Centre de Référence des Pathologies Rares de l'Insulino-Sécrétion et de l'Insulino-Sensibilité, Necker Enfants Malades Hospital, AP-HP.Centre & Université de Paris, UFR de Médecine Paris Descartes, Paris, France.""}, {'ForeName': 'Chloé', 'Initials': 'C', 'LastName': 'Amouyal', 'Affiliation': 'Department of Diabetology, Pitié-Salpêtrière Hospital, AP-HP. Sorbonne Université, Paris, France.'}, {'ForeName': 'Agnès', 'Initials': 'A', 'LastName': 'Hartemann', 'Affiliation': 'Department of Diabetology, Pitié-Salpêtrière Hospital, AP-HP. Sorbonne Université, Paris, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Corbeau', 'Affiliation': 'Immunology Department, Nîmes University Hospital, Nîmes, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Vicaut', 'Affiliation': 'Lariboisière Hospital, Clinical Trial Unit, AP-HP.Nord, Paris, France.'}, {'ForeName': 'Cecile', 'Initials': 'C', 'LastName': 'Bibal', 'Affiliation': 'Department of Paediatric Endocrinology, Bicêtre Hospital, AP-HP.Université Paris Saclay, Le Kremlin-Bicêtre, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Bougnères', 'Affiliation': 'Department of Paediatric Endocrinology, Bicêtre Hospital, AP-HP.Université Paris Saclay, Le Kremlin-Bicêtre, France.'}, {'ForeName': 'Tu-Anh', 'Initials': 'TA', 'LastName': 'Tran', 'Affiliation': 'Department of Paediatrics, Nîmes University Hospital and Inserm U1183, Montpellier University, Montpellier, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Klatzmann', 'Affiliation': ""Clinical Investigation Center for Biotherapies and Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP.Sorbonne Université, Pitié-Salpêtrière Hospital, 83 Bd de l'Hôpital, F-75013, Paris, France. david.klatzmann@sorbonne-universite.fr.""}]",Diabetologia,['10.1007/s00125-020-05200-w'] 1473,32470492,Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.,"Canagliflozin reduced kidney disease progression in participants with type 2 diabetes in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. This analysis explored potential mediators of the effects of canagliflozin on kidney outcomes. The percent mediating effect of 18 biomarkers indicative of disease was determined by comparing the hazard ratios for the effect of randomized treatment from an unadjusted model and from a model adjusting for the average post-randomization level of each biomarker. Multivariable analyses assessed the joint effects of biomarkers that mediated most strongly in univariable analyses. The kidney outcome was defined as a composite of 40% estimated glomerular filtration rate decline, end-stage kidney disease, or death due to kidney disease. Nine biomarkers (systolic blood pressure [8.9% of effect explained], urinary albumin:creatinine ratio [UACR; 23.9%], gamma glutamyltransferase [4.1%], hematocrit [51.1%], hemoglobin [41.3%], serum albumin [19.5%], erythrocytes [56.7%], serum urate [35.4%], and urine pH [7.5%]) individually mediated the effect of canagliflozin on the kidney outcome. In a parsimonious multivariable model, erythrocyte concentration, serum urate, and systolic blood pressure maximized cumulative mediation (115%). Mediating effects of UACR, but not other mediators, were highly dependent upon the baseline level of UACR: UACR mediated 42% and 7% of the effect in those with baseline UACR 30 mg/g or more and under 30 mg/g, respectively. The identified mediators support existing hypothesized mechanisms for the prevention of kidney outcomes with sodium glucose co-transporter 2 inhibitors. Thus, the disparity in mediating effects across baseline UACR subgroups suggests that the mechanism for kidney protection with canagliflozin may vary across patient subgroups.",2020,"Mediating effects of UACR, but not other mediators, were highly dependent upon the baseline level of UACR: UACR mediated 42% and 7% of the effect in those with baseline UACR 30 mg/g or more and under 30 mg/g, respectively.","['participants with type 2 diabetes in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program', 'patients with type 2 diabetes']","['Canagliflozin', 'UACR', 'canagliflozin']","['erythrocyte concentration, serum urate, and systolic blood pressure maximized cumulative mediation', 'kidney protection', 'serum albumin', 'serum urate', 'urinary albumin:creatinine ratio [UACR; 23.9%], gamma glutamyltransferase', 'hematocrit', 'glomerular filtration rate decline, end-stage kidney disease, or death due to kidney disease', 'hemoglobin', 'kidney disease progression', 'Nine biomarkers (systolic blood pressure']","[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C2974540', 'cui_str': 'canagliflozin'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C2974540', 'cui_str': 'canagliflozin'}]","[{'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0202239', 'cui_str': 'Uric acid measurement'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0680727', 'cui_str': 'Mediation'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0036773', 'cui_str': 'Serum Albumin'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0017040', 'cui_str': 'Gamma-glutamyltransferase'}, {'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",,0.0810127,"Mediating effects of UACR, but not other mediators, were highly dependent upon the baseline level of UACR: UACR mediated 42% and 7% of the effect in those with baseline UACR 30 mg/g or more and under 30 mg/g, respectively.","[{'ForeName': 'JingWei', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ""The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia; Department of Cardiology, Xinqiao Hospital, Army Military Medical University, Chongqing, China; Department of Cardiology, People's Liberation Army General Hospital, Beijing, China.""}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Neal', 'Affiliation': 'The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia; University of New South Wales, Sydney, Australia; Imperial College London, London, UK.'}, {'ForeName': 'Vlado', 'Initials': 'V', 'LastName': 'Perkovic', 'Affiliation': 'The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.'}, {'ForeName': 'Dick', 'Initials': 'D', 'LastName': 'de Zeeuw', 'Affiliation': 'Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center, Groningen, The Netherlands.'}, {'ForeName': 'Brendon L', 'Initials': 'BL', 'LastName': 'Neuen', 'Affiliation': 'The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Arnott', 'Affiliation': 'The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia; University of New South Wales, Sydney, Australia; Royal Prince Alfred Hospital, Sydney, Australia.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Simpson', 'Affiliation': 'Janssen Research & Development, LLC, Raritan, New Jersey, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Oh', 'Affiliation': 'Janssen Research & Development, LLC, Raritan, New Jersey, USA.'}, {'ForeName': 'Kenneth W', 'Initials': 'KW', 'LastName': 'Mahaffey', 'Affiliation': 'Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.'}, {'ForeName': 'Hiddo J L', 'Initials': 'HJL', 'LastName': 'Heerspink', 'Affiliation': 'The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia; University of New South Wales, Sydney, Australia; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center, Groningen, The Netherlands. Electronic address: h.j.lambers.heerspink@umcg.nl.'}]",Kidney international,['10.1016/j.kint.2020.04.051'] 1474,32473365,Central nervous system activities of extract Mangifera indica L.,"ETHNOBOTANICAL RELEVANCE Leaves of Mangifera indica L. have folk-uses in tropical regions of the world as health teas, as a remedy for exhaustion and fatigue, as a vegetable, and as a medicine. Mangifera indica leaf extract (MLE) had previously been demonstrated to alter brain electrical activity in-vivo. The aim of the present series of studies was to investigate whether mangiferin, a major compound in leaves and in MLE, is responsible for the neurocognitive activity of MLE, and if the CNS activities of MLE have translational potential. MATERIALS AND METHODS MLE, tradename Zynamite, is produced by Nektium Pharma, Spain. Isolated mangiferin was tested in-vitro in radioligand binding and enzyme inhibition studies against 106 CNS targets. Changes in the electroencephalograms (EEG's) of MLE and mangiferin were recorded in-vivo from four brain regions. Two double blind randomized placebo-controlled crossover clinical trials were conducted, each with 16 subjects. At 90 min and at 60 min respectively, after oral intake of 500 mg MLE, EEG recordings, psychometric tests, mood state, and tolerability were studied. RESULTS Isolated mangiferin is a selective inhibitor of catechol-O-methyltransferase (COMT) with an IC50 of 1.1 μM, with no activity on the CNS targets of caffeine. Both mangiferin and MLE induce similar changes in long-term potentiation (LTP) in the hippocampus in-vitro, and induce a similar pattern of EEG changes in-vivo. In both translational clinical trials MLE was well tolerated, with no cardiovascular side-effects. In both studies MLE caused significant spectral changes in brain electrical activity in cortical regions during cognitive challenges, different to the attenuated spectral changes induced by caffeine. There were no significant changes in the psychometric tests other than reaction time for all groups. In the second study there was a trend to faster reaction time within group for MLE (p = 0.066) and the percentage improvement in reaction time for MLE compared to placebo was significant (p = 0.049). In the first study MLE improved all scores for Profile of Mood States (POMS), with the score for ""fatigue"" significantly improved (p = 0.015); in the second study the POMS score for ""dejection"" was improved in the caffeine group, p = 0.05. CONCLUSIONS Mangiferin is a COMT inhibitor of moderate potency and is the major CNS-active compound in MLE. Both mangiferin and MLE increase hippocampal LTP in-vitro, and induce a similar pattern of changes in brain electrical activity in-vivo. While the translational clinical trials of MLE are limited by being single dose studies in a small number of subjects, they provide the first clinical evidence that the extract is well tolerated with no cardiovascular side-effects, can induce changes in brain electrical activity, may give a faster reaction time, and decrease fatigue. These CNS activities support the reported folk-uses use of mango leaf tea as a substitute for tea and as a traditional remedy for fatigue and exhaustion. Extract Mangifera indica L., Zynamite, has nootropic potential, and larger clinical studies are needed to realise this potential.",2020,"Both mangiferin and MLE induce similar changes in long term potentiation (LTP) in the hippocampus in-vitro, and induce a similar pattern of EEG changes in-vivo.",['16 subjects'],"['Mangifera indica leaf extract (MLE', 'caffeine', 'mangiferin and MLE', 'MLE', 'extract Mangifera indica L', 'placebo']","['fatigue', 'POMS score for ""dejection', 'Profile of Mood States (POMS', 'brain electrical activity', 'psychometric tests, mood state, and tolerability', 'reaction time for MLE', 'faster reaction time']",[],"[{'cui': 'C4081111', 'cui_str': 'mango leaf extract'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0065654', 'cui_str': 'mangiferin'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0330955', 'cui_str': 'Mangifera indica'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0451394', 'cui_str': 'Profile of mood states'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0234388', 'cui_str': 'Electrical activity of brain'}, {'cui': 'C0033920', 'cui_str': 'Psychometric testing'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C4081111', 'cui_str': 'mango leaf extract'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}]",,0.0364453,"Both mangiferin and MLE induce similar changes in long term potentiation (LTP) in the hippocampus in-vitro, and induce a similar pattern of EEG changes in-vivo.","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'López-Ríos', 'Affiliation': 'Department of Research, Development and Innovation, Nektium Pharma SL, 35118, Las Palmas de Gran Canaria, Spain. Electronic address: llopez@nektium.com.'}, {'ForeName': 'Julia C', 'Initials': 'JC', 'LastName': 'Wiebe', 'Affiliation': 'Department of Research, Development and Innovation, Nektium Pharma SL, 35118, Las Palmas de Gran Canaria, Spain. Electronic address: jwiebe@nektium.com.'}, {'ForeName': 'Tanausú', 'Initials': 'T', 'LastName': 'Vega-Morales', 'Affiliation': 'Department of Research, Development and Innovation, Nektium Pharma SL, 35118, Las Palmas de Gran Canaria, Spain. Electronic address: tvega@nektium.com.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Gericke', 'Affiliation': 'Department of Research, Development and Innovation, Nektium Pharma SL, 35118, Las Palmas de Gran Canaria, Spain; Department of Botany and Plant Biotechnology, University of Johannesburg, Auckland Park, 2006, Johannesburg, South Africa. Electronic address: ngericke@nektium.com.'}]",Journal of ethnopharmacology,['10.1016/j.jep.2020.112996'] 1475,32473403,Testing a self-directed lifestyle intervention among veterans: The D-ELITE pragmatic clinical trial.,"Nearly half of Veterans have obesity, fueling chronic diseases. The Department of Veterans Affairs (VA) offers an evidence-based behavioral weight management intervention called MOVE!, mostly delivered through in-person group sessions. Few eligible Veterans participate due to factors like distance and preferences, mirroring barriers in the general population. Practical alternatives to standard in-person programs are needed to improve access and engagement. A self-directed lifestyle intervention called D-ELITE-delivered through pre-recorded videos by DVD or online streaming-previously efficacious in a general primary care population, may provide such an alternative. This pragmatic clinical trial will evaluate whether D-ELITE improves weight and general health status among Veterans with obesity, relative to VA usual care. The yearlong intervention includes one orientation by phone, supplemental lifestyle coaching primarily via technology-based messages, 12 DVD or online streaming sessions over 3 months, and continued self-directed weight management for months 4-12. Participants use MyFitnessPal.com or paper booklets for self-monitoring weight, diet, and physical activity. Follow-up assessments at 12 and 24 months are administered by mail or phone. The study hypothesis is that compared with usual care, D-ELITE will lead to greater improvements in 12-month weight loss, per VA electronic health records, and general physical health status, assessed using the self-reported SF-12 physical composite score. We will also explore D-ELITE's effects on secondary biometric (e.g., HbA1c) and intermediate (e.g., diet) outcomes, reach, and budget impact. If effective, D-ELITE will offer a potentially scalable, low-cost alternative to VA's existing weight loss interventions by mitigating barriers presented by distance and technology.",2020,"If effective, D-ELITE will offer a potentially scalable, low-cost alternative to VA's existing weight loss interventions by mitigating barriers presented by distance and technology.","['veterans', 'Veterans with obesity, relative to VA usual care']","['supplemental lifestyle coaching primarily via technology-based messages, 12 DVD or online streaming sessions', 'self-directed lifestyle intervention', 'self-directed lifestyle intervention called D-ELITE-delivered through pre-recorded videos by DVD or online streaming-previously efficacious']","['secondary biometric (e.g., HbA1c) and intermediate (e.g., diet) outcomes, reach, and budget impact', 'weight and general health status']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0750927', 'cui_str': 'Developmental verbal dyspraxia'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0042655', 'cui_str': 'Video'}]","[{'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0006347', 'cui_str': 'Budgets'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",,0.02449,"If effective, D-ELITE will offer a potentially scalable, low-cost alternative to VA's existing weight loss interventions by mitigating barriers presented by distance and technology.","[{'ForeName': 'Katherine D', 'Initials': 'KD', 'LastName': 'Hoerster', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States; VA Puget Sound Healthcare System, Seattle Division, Mental Health Service, 1660 South Columbian Way (S-116), Seattle, WA 98108, United States; University of Washington, Department of Psychiatry and Behavioral Sciences, 1100 NE 45(th) Street, Suite 300, Seattle, WA 98105, United States. Electronic address: Katherine.Hoerster@va.gov.'}, {'ForeName': 'Margaret P', 'Initials': 'MP', 'LastName': 'Collins', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Margaret.Collins@va.gov.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Au', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States; University of Washington, Department of Medicine, 1959 NE Pacific St, Seattle, WA 98195, United States. Electronic address: David.Au@va.gov.'}, {'ForeName': 'Amber', 'Initials': 'A', 'LastName': 'Lane', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Amber.Lane2@va.gov.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Epler', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Eric.Epler@va.gov.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'McDowell', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Jennifer.McDowell@va.gov.'}, {'ForeName': 'Anna E', 'Initials': 'AE', 'LastName': 'Barón', 'Affiliation': 'Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, 13001 E. 17(th) Place, Aurora, CO 80045, United States. Electronic address: Anna.Baron@cuanschutz.edu.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Rise', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Peter.Rise@va.gov.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Plumley', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Robert.Plumley@va.gov.'}, {'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Nguyen', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Tanya.Nguyen@va.gov.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Schooler', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Mary.Schooler@va.gov.'}, {'ForeName': 'Linnaea', 'Initials': 'L', 'LastName': 'Schuttner', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States; University of Washington, Department of Medicine, 1959 NE Pacific St, Seattle, WA 98195, United States. Electronic address: Linnaea.Schuttner@va.gov.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': 'University of Illinois at Chicago, Department of Medicine, 1747 W. Roosevelt Rd, Room 586 (MC 275), Chicago, IL 60608, United States. Electronic address: maj2015@uic.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106045'] 1476,32474302,Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome.,"BACKGROUND AND AIMS This study aimed to elucidate whether high-density lipoprotein cholesterol (HDL-C) at 3-month follow-up for patients receiving contemporary lipid-lowering therapy after acute coronary syndrome (ACS) could predict cardiac events. METHODS The HIJ-PROPER study was a multicenter, prospective, randomized trial comparing intensive lipid-lowering therapy (pitavastatin + ezetimibe) and conventional lipid-lowering therapy (pitavastatin monotherapy) after ACS. The entire cohort was divided into three groups according to tertiles of HDL-C levels at 3-month follow-up (Group 1, HDL-C ≤43 mg/dL; Group 2, HDL-C >43, <53.6 mg/dL; Group 3; HDL-C ≥53.6 mg/dL). Baseline characteristics and incidence of the primary endpoint (a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, unstable angina pectoris, or ischemia-driven revascularization) were compared among the three groups. RESULTS The primary endpoint event occurred in 34.8%, 30.1%, and 24.6% of patients in Groups 1, 2, and 3, respectively, and its incidence was significantly higher in Group 1 than in Group 3 (hazard ratio [HR], 1.5; 95% confidence interval [CI], 1.19-1.9; p = 0.001). Irrespective of the treatment regimen, Group 1 had significantly higher rates of the primary endpoint than Group 3 (pitavastatin + ezetimibe therapy: HR, 1.6; 95% CI, 1.12-2.22; p = 0.01 and pitavastatin monotherapy: HR, 1.4; 95% CI, 1.05-1.98; p = 0.02). These trends remained even after adjustment for baseline characteristics and lipid profiles. Multivariate analysis revealed that lower body mass index, prevalence of diabetes mellitus, higher levels of high-sensitivity C reactive protein at baseline, and lower levels of HDL-C at 3-month follow-up were independent predictors of the incidence of primary endpoint. CONCLUSIONS Lower levels of HDL-C at 3-month follow-up are independently associated with higher incidence of cardiovascular events in ACS patients receiving contemporary lipid-lowering therapy.",2020,"Irrespective of the treatment regimen, Group 1 had significantly higher rates of the primary endpoint than Group 3 (pitavastatin + ezetimibe therapy: HR, 1.6; 95% CI, 1.12-2.22; p = 0.01 and pitavastatin monotherapy: HR, 1.4; 95% CI, 1.05-1.98; p = 0.02).","['patients with acute coronary syndrome', 'ACS patients receiving contemporary lipid-lowering therapy', 'patients receiving contemporary lipid-lowering therapy after acute coronary syndrome (ACS']","['intensive lipid-lowering therapy (pitavastatin\xa0+\xa0ezetimibe) and conventional lipid-lowering therapy (pitavastatin monotherapy', 'high-density lipoprotein cholesterol (HDL-C']","['Baseline characteristics and incidence of the primary endpoint (a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, unstable angina pectoris, or ischemia-driven revascularization', 'cardiovascular events', 'lower body mass index, prevalence of diabetes mellitus, higher levels of high-sensitivity C reactive protein at baseline, and lower levels of HDL-C']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0585943', 'cui_str': 'Lipid-lowering therapy'}]","[{'cui': 'C0585943', 'cui_str': 'Lipid-lowering therapy'}, {'cui': 'C1101838', 'cui_str': 'pitavastatin'}, {'cui': 'C1142985', 'cui_str': 'ezetimibe'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0002965', 'cui_str': 'Impending infarction'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0231255', 'cui_str': 'Decreased body mass index'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}]",,0.0661322,"Irrespective of the treatment regimen, Group 1 had significantly higher rates of the primary endpoint than Group 3 (pitavastatin + ezetimibe therapy: HR, 1.6; 95% CI, 1.12-2.22; p = 0.01 and pitavastatin monotherapy: HR, 1.4; 95% CI, 1.05-1.98; p = 0.02).","[{'ForeName': 'Mayui', 'Initials': 'M', 'LastName': 'Nakazawa', 'Affiliation': ""Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.""}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Arashi', 'Affiliation': ""Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. Electronic address: arashi.hiroyuki@twmu.ac.jp.""}, {'ForeName': 'Junichi', 'Initials': 'J', 'LastName': 'Yamaguchi', 'Affiliation': ""Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.""}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Ogawa', 'Affiliation': ""Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.""}, {'ForeName': 'Nobuhisa', 'Initials': 'N', 'LastName': 'Hagiwara', 'Affiliation': ""Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.""}]",Atherosclerosis,['10.1016/j.atherosclerosis.2020.05.005'] 1477,32475294,Sixth-year follow-up of the effects of recreational activities found to eliminate the symptoms of social phobia and shyness.,"BACKGROUND The lack of 6-year follow-up studies that test the effect of recreational activities in the recovery of social phobia and shyness symptoms is the reason to conduct this study. AIM The purpose is to follow the effect of the 12-week recreational activity program found to eliminate social phobia and shyness symptoms after the completion of university studies in its sixth year. METHODS At the end of the 12-week recreational activity program that treats the symptoms of social phobia and shyness in university prep school students, 83 students who participated in the posttest both from intervention and control groups were invited to the study. In the sixth-year follow-up study, a total of 51 voluntary students - 32 from the intervention group and 19 from the control group - were administered the Liebowitz Social Anxiety Scale, the Shyness Scale and the Coopersmith Self-Esteem Inventory. RESULTS When the pretests and the sixth-year scores are compared, it is seen that it still has an improving effect on social phobia and shyness; when the posttests and the sixth-year tests are compared, no difference is seen regarding social phobia whereas it is seen that recovery still continues regarding the symptoms of shyness, and a decrease is seen in self-esteem. DISCUSSION While the improving effect of recreational activities on shyness and social phobia symptoms still continues, their effect on self-esteem decreases. CONCLUSION It is suggested that recreational activities should be included in the programs at universities regarding personal and professional development, and the reasons for the decrease in self-esteem scores should be determined through more detailed studies.",2020,"When the pretests and the sixth-year scores are compared, it is seen that it still has an improving effect on social phobia and shyness; when the posttests and the sixth-year tests are compared, no difference is seen regarding social phobia whereas it is seen that recovery still continues regarding the symptoms of shyness, and a decrease is seen in self-esteem. ","['university prep school students, 83 students who participated in the posttest both from intervention and control groups were invited to the study']","['recreational activities', 'recreational activity program']","['Liebowitz Social Anxiety Scale', 'social phobia and shyness symptoms']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0034872', 'cui_str': 'Recreation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0031572', 'cui_str': 'Social phobia'}, {'cui': 'C0037020', 'cui_str': 'Shyness'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",83.0,0.0164186,"When the pretests and the sixth-year scores are compared, it is seen that it still has an improving effect on social phobia and shyness; when the posttests and the sixth-year tests are compared, no difference is seen regarding social phobia whereas it is seen that recovery still continues regarding the symptoms of shyness, and a decrease is seen in self-esteem. ","[{'ForeName': 'Elif', 'Initials': 'E', 'LastName': 'Karagün', 'Affiliation': 'Faculty of Sports Science, Department of Recreation, Kocaeli University, Kocaeli, Turkey.'}, {'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Yildiz', 'Affiliation': 'Faculty of Medicine, Department of Psychiatry, Kocaeli University, Kocaeli, Turkey.'}, {'ForeName': 'Çiğdem', 'Initials': 'Ç', 'LastName': 'Çağlayan', 'Affiliation': 'Faculty of Medicine, Department of Public Health, Kocaeli University, Kocaeli, Turkey.'}, {'ForeName': 'Zekiye', 'Initials': 'Z', 'LastName': 'Başaran', 'Affiliation': 'Faculty of Sports Sciences, Kocaeli University, Kocaeli, Turkey.'}]",The International journal of social psychiatry,['10.1177/0020764020924702'] 1478,32482565,A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.,"BACKGROUND Tyrosine kinase inhibitor-based adjuvant therapy showed no survival benefits for patients with high-risk nonmetastatic renal cell carcinoma (nmRCC). Five randomized immune-oncology checkpoint inhibitor trials are ongoing. We assessed the effect of stage, grade, and histologic type on cancer-specific mortality (CSM) in candidates for 1 of the 4 North American ongoing immune-oncology checkpoint inhibitor trials of high-risk nmRCC. PATIENTS AND METHODS From the Surveillance, Epidemiology, and End Results database (2001-2015), we identified patients who had undergone surgery for nmRCC and had met the inclusion criteria for the PROSPER RCC (nivolumab in treating patients with localized kidney cancer undergoing nephrectomy), CheckMate 914 (a study comparing the combination of nivolumab and ipilimumab versus placebo in participants with localized renal cell carcinoma), KEYNOTE-564 [safety and efficacy study of pembrolizumab (MK-3475) as monotherapy in the adjuvant treatment of renal cell carcinoma post nephrectomy], or IMmotion010 [a study of atezolizumab as adjuvant therapy in participants with renal cell carcinoma (RCC) at high risk of developing metastasis following nephrectomy] trials. Kaplan-Meier and multivariable Cox regression models were used to assess the 10-year CSM rates in the overall cohort according to stage, grade, and histologic characteristics, and in 4 generated random samples according to the eligible patients for each of the 4 trials. RESULTS Of 116,750 patients who had undergone surgery for nmRCC, 18,559 (15.9%) had fulfilled the inclusion criteria for 1 of the 4 trials. The greatest proportion of higher stage and grade combinations and sarcomatoid histologic features would have qualified for IMmotion010, followed by KEYNOTE-564, CheckMate 914, and PROSPER RCC. Multivariable Cox regression models demonstrated the most unfavorable prognosis for stage N1 grade 3/4 (hazard ratio [HR], 11.5; P < .001), stage T4N0 grade 3/4 (HR, 9.8; P < .001), and sarcomatoid histologic features (HR, 5.5; P < .001). Among the 4 random samples, the difference in the qualifying criteria resulted in the greatest versus progressively lower CSM rates in the IMmotion010, KEYNOTE-564, CheckMate 914, and PROSPER RCC trials, respectively (P < .001). CONCLUSIONS Our findings indicate that participation in adjuvant immunotherapy trials should be predominantly encouraged for patients with high-grade stage T3, T4, and N1 and patients with any stage with sarcomatoid pathologic features.",2020,"Among the 4 random samples, the difference in the qualifying criteria resulted in the greatest versus progressively lower CSM rates in the IMmotion010, KEYNOTE-564, CheckMate 914, and PROSPER RCC trials, respectively (P < .001). ","['patients with localized kidney cancer undergoing', 'High-risk Nonmetastatic Renal Cell Carcinoma', '116,750 patients who had undergone surgery for nmRCC, 18,559 (15.9%) had fulfilled the inclusion criteria for 1 of the 4 trials', 'participants with localized renal cell carcinoma', 'patients with high-grade stage T3, T4, and N1 and patients with any stage with sarcomatoid pathologic features', 'From the Surveillance, Epidemiology, and End Results database (2001-2015', 'patients who had undergone surgery for nmRCC and had met the inclusion criteria for the PROSPER RCC', 'renal cell carcinoma post nephrectomy', 'participants with renal cell carcinoma (RCC) at high risk of developing metastasis following nephrectomy] trials', 'patients with high-risk nonmetastatic renal cell carcinoma (nmRCC']","['Tyrosine kinase inhibitor-based adjuvant therapy', 'pembrolizumab (MK-3475', 'atezolizumab', 'nephrectomy', 'nivolumab and ipilimumab versus placebo']","['10-year CSM rates', 'sarcomatoid histologic features', 'survival benefits', 'cancer-specific mortality (CSM', 'CSM rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0740457', 'cui_str': 'Malignant tumor of kidney'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0007134', 'cui_str': 'Renal cell carcinoma'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0475374', 'cui_str': 'T3 category'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}, {'cui': 'C0014507', 'cui_str': 'Epidemiology'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0027695', 'cui_str': 'Kidney excision'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C1268567', 'cui_str': 'Protein-tyrosine kinase inhibitor'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C3660977', 'cui_str': 'MK-3475'}, {'cui': 'C4055433', 'cui_str': 'atezolizumab'}, {'cui': 'C0027695', 'cui_str': 'Kidney excision'}, {'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C1367202', 'cui_str': 'ipilimumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",116750.0,0.234096,"Among the 4 random samples, the difference in the qualifying criteria resulted in the greatest versus progressively lower CSM rates in the IMmotion010, KEYNOTE-564, CheckMate 914, and PROSPER RCC trials, respectively (P < .001). ","[{'ForeName': 'Carlotta', 'Initials': 'C', 'LastName': 'Palumbo', 'Affiliation': 'Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada; Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. Electronic address: palumbo.carlotta@gmail.com.'}, {'ForeName': 'Elio', 'Initials': 'E', 'LastName': 'Mazzone', 'Affiliation': 'Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada; Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, and Vita-Salute San Raffaele University, Milan, Italy.'}, {'ForeName': 'Francesco A', 'Initials': 'FA', 'LastName': 'Mistretta', 'Affiliation': 'Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada; Department of Urology, European Institute of Oncology, Milan, Italy.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Knipper', 'Affiliation': 'Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada; Martini Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Perrotte', 'Affiliation': 'Division of Urology, University of Montreal Hospital Center, Montreal, QC, Canada.'}, {'ForeName': 'Shahrokh F', 'Initials': 'SF', 'LastName': 'Shariat', 'Affiliation': 'Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern Medical School, Dallas, TX; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.'}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Saad', 'Affiliation': 'Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada; Division of Urology, University of Montreal Hospital Center, Montreal, QC, Canada.'}, {'ForeName': 'Anil', 'Initials': 'A', 'LastName': 'Kapoor', 'Affiliation': 'Division of Urology, Department of Surgery, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Jean-Baptiste', 'Initials': 'JB', 'LastName': 'Lattouf', 'Affiliation': 'Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada; Department of Surgery, Université de Montréal, Montréal, QC, Canada.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Simeone', 'Affiliation': 'Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Briganti', 'Affiliation': 'Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, and Vita-Salute San Raffaele University, Milan, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Antonelli', 'Affiliation': 'Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Pierre I', 'Initials': 'PI', 'LastName': 'Karakiewicz', 'Affiliation': 'Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada; Division of Urology, University of Montreal Hospital Center, Montreal, QC, Canada.'}]",Clinical genitourinary cancer,['10.1016/j.clgc.2019.11.010'] 1479,32483939,Umbilical closure using 2-octyl cyanoacrylate in transumbilical laparoscopic adrenalectomy: A randomized controlled trial.,"OBJECTIVES To evaluate postoperative pain and esthetic outcomes in patients undergoing transumbilical laparoscopic adrenalectomy with wound closure using 2-octyl cyanoacrylate. METHODS A total of 26 patients who underwent laparoscopic adrenalectomy with the transumbilical approach and agreed to participate in this study were included. Patients were randomly divided into two groups: the 2-octyl cyanoacrylate group (Glue group) or the non-use group (non-Glue group). A single surgeon (AM) carried out all procedures between 2014 and 2017. RESULTS There were no significant differences in the clinical background of the Glue and non-Glue groups. The number of patients with moderate or high levels of pain in the resting/moving period on postoperative days 1, 2 and 3 was 6/10 (46%/77%), 6/9 (46%/69%) and 3/5 (23%/38%) in the non-Glue group, and 5/7 (38%/54%), 2/7 (15%/54%) and 1/3 (8%/23%) in the Glue group. These differences were not significant. In the subgroup analysis of patients aged <50 years, the numbers were 4/6 (57%/86%), 5/7 (71%/100%) and 3/5 (43%/71%) in the non-Glue group, and 3/4 (33%/44%), 1/4 (11%/44%) and 0/1 (0%/11%) in the Glue group in the resting/moving period. On postoperative days 2 and 3, these differences were significant (P = 0.035 and 0.037 in the resting period, and P = 0.017 and 0.013 in the moving period). CONCLUSIONS 2-octyl cyanoacrylate can be used safely for laparoscopic adrenalectomy with the transumbilical approach, and might be useful for reducing postoperative pain in patients aged <50 years.",2020,"On postoperative days 2 and 3, these differences were significant (P = 0.035 and 0.037 in the resting period, and P = 0.017 and 0.013 in the moving period). ","['26 patients who underwent', 'patients aged <50\xa0years', 'patients undergoing transumbilical', 'transumbilical laparoscopic adrenalectomy']","['2-octyl cyanoacrylate group (Glue group) or the non-use group (non-Glue group', 'laparoscopic adrenalectomy with the transumbilical approach', 'Umbilical closure using 2-octyl cyanoacrylate', 'laparoscopic adrenalectomy with wound closure using 2-octyl cyanoacrylate']","['postoperative pain and esthetic outcomes', 'number of patients with moderate or high levels of pain', 'postoperative pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0457793', 'cui_str': 'Transumbilical'}, {'cui': 'C0521267', 'cui_str': 'Laparoscopic adrenalectomy'}]","[{'cui': 'C0391770', 'cui_str': '2-octyl cyanoacrylate'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0017780', 'cui_str': 'Glue'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0521267', 'cui_str': 'Laparoscopic adrenalectomy'}, {'cui': 'C0457793', 'cui_str': 'Transumbilical'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0041638', 'cui_str': 'Umbilical structure'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0450015', 'cui_str': 'Method of wound closure'}]","[{'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",26.0,0.050219,"On postoperative days 2 and 3, these differences were significant (P = 0.035 and 0.037 in the resting period, and P = 0.017 and 0.013 in the moving period). ","[{'ForeName': 'Keishiro', 'Initials': 'K', 'LastName': 'Fukumoto', 'Affiliation': 'Department of Urology, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Miyajima', 'Affiliation': 'Department of Urology, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Kazuhiro', 'Initials': 'K', 'LastName': 'Matsumoto', 'Affiliation': 'Department of Urology, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Kobayashi', 'Affiliation': 'Department of Urology, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Naoya', 'Initials': 'N', 'LastName': 'Niwa', 'Affiliation': 'Department of Urology, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Hongo', 'Affiliation': 'Department of Urology, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Isao', 'Initials': 'I', 'LastName': 'Kurihara', 'Affiliation': 'Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Eiji', 'Initials': 'E', 'LastName': 'Kikuchi', 'Affiliation': 'Department of Urology, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Mototsugu', 'Initials': 'M', 'LastName': 'Oya', 'Affiliation': 'Department of Urology, Keio University School of Medicine, Tokyo, Japan.'}]",International journal of urology : official journal of the Japanese Urological Association,['10.1111/iju.14270'] 1480,32479166,Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial.,"BACKGROUND Biannual rituximab infusions over 18 months effectively maintain remission after a ""standard"" remission induction regimen for patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). OBJECTIVE To evaluate the efficacy of prolonged rituximab therapy in preventing AAV relapses in patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who have achieved complete remission after completing an 18-month maintenance regimen. DESIGN Randomized controlled trial. (ClinicalTrials.gov: NCT02433522). SETTING 39 clinical centers in France. PATIENTS 68 patients with GPA and 29 with MPA who achieved complete remission after the first phase of maintenance therapy. INTERVENTION Rituximab or placebo infusion every 6 months for 18 months (4 infusions). MEASUREMENTS The primary end point was relapse-free survival at month 28. Relapse was defined as new or reappearing symptoms or worsening disease, with a Birmingham Vasculitis Activity Score greater than 0. RESULTS From March 2015 to April 2016, 97 patients (mean age, 63.9 years; 35% women) were randomly assigned, 50 to the rituximab and 47 to the placebo group. Relapse-free survival estimates at month 28 were 96% (95% CI, 91% to 100%) and 74% (CI, 63% to 88%) in the rituximab and placebo groups, respectively, an absolute difference of 22% (CI, 9% to 36%) with a hazard ratio of 7.5 (CI, 1.67 to 33.7) ( P  = 0.008). Major relapse-free survival estimates at month 28 were 100% (CI, 93% to 100%) versus 87% (CI, 78% to 97%) ( P  = 0.009), respectively. At least 1 serious adverse event developed in 12 patients (24%) in the rituximab group (with 9 infectious serious adverse events occurring among 6 patients [12%]) versus 14 patients (30%) in the placebo group (with 6 infectious serious adverse events developing among 4 patients [9%]). No deaths occurred in either group. LIMITATION Potential selection bias based on previous rituximab response and tolerance. CONCLUSION Extended therapy with biannual rituximab infusions over 18 months was associated with a lower incidence of AAV relapse compared with standard maintenance therapy. PRIMARY FUNDING SOURCE French Ministry of Health and Hoffmann-La Roche.",2020,"Major relapse-free survival estimates at month 28 were 100% (CI, 93% to 100%) versus 87% (CI, 78% to 97%) ( P  = 0.009), respectively.","['patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who have achieved complete remission after completing an 18-month maintenance regimen', 'Antineutrophil Cytoplasmic Antibody-Associated Vasculitis', 'From March 2015 to April 2016, 97 patients (mean age, 63.9 years; 35% women', '68 patients with GPA and 29 with MPA who achieved complete remission after the first phase of maintenance therapy', '39 clinical centers in France', 'patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV']","['placebo', 'Rituximab or placebo', 'rituximab', 'rituximab therapy']","['Relapse-free survival estimates', 'AAV relapse', 'Major relapse-free survival estimates', 'deaths', 'Relapse', 'relapse-free survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3495801', 'cui_str': 'Granulomatosis with polyangiitis'}, {'cui': 'C2347126', 'cui_str': 'Microscopic polyarteritis nodosa'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0103647', 'cui_str': 'Anti neutrophilic cytoplasm antibody'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0042384', 'cui_str': 'Vasculitis'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205288', 'cui_str': 'Microscopic'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0677908', 'cui_str': 'Maintenance therapy'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0016674', 'cui_str': 'France'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C4047978', 'cui_str': 'Rituximab therapy'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0042384', 'cui_str': 'Vasculitis'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",68.0,0.307403,"Major relapse-free survival estimates at month 28 were 100% (CI, 93% to 100%) versus 87% (CI, 78% to 97%) ( P  = 0.009), respectively.","[{'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Charles', 'Affiliation': 'Cochin Hospital, Paris Descartes University, and Institut Mutualiste Montsouris, Paris, France (P.C.).'}, {'ForeName': 'Élodie', 'Initials': 'É', 'LastName': 'Perrodeau', 'Affiliation': ""Centre d'Epidémiologie Clinique, Hôpital Hôtel-Dieu, Université Paris Descartes, Sorbonne Paris Cité INSERM Unité 1153, Paris, France (É.P., P.R.).""}, {'ForeName': 'Maxime', 'Initials': 'M', 'LastName': 'Samson', 'Affiliation': 'Centre Hospitalier Universitaire de Dijon, INSERM, UMR 1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France (M.S., B.B.).'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Bonnotte', 'Affiliation': 'Centre Hospitalier Universitaire de Dijon, INSERM, UMR 1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France (M.S., B.B.).'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Néel', 'Affiliation': 'CRTI UMR 1064, INSERM, Université de Nantes, and Centre Hospitalier Universitaire Nantes, Nantes, France (A.N.).'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Agard', 'Affiliation': 'Centre Hospitalier Universitaire Nantes, Nantes, France (C.A.).'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Huart', 'Affiliation': 'Centre Hospitalier Universitaire de Toulouse, Toulouse, France (A.H., G.P.).'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Karras', 'Affiliation': 'Hôpital Européen Georges-Pompidou, Université Paris Descartes, Paris, France (A.K.).'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Lifermann', 'Affiliation': 'Centre Hospitalier de Dax, Dax, France (F.L.).'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Godmer', 'Affiliation': 'Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France (P.G.).'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Cohen', 'Affiliation': 'Cochin Hospital, Paris Descartes University, Paris, France (P.C., C.V., X.P., B.T., L.M., L.G.).'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Hanrotel-Saliou', 'Affiliation': 'Hôpital la Cavale Blanche, Centre Hospitalier Universitaire Brest, Brest, France (C.H.).'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Martin-Silva', 'Affiliation': 'Centre Hospitalier Universitaire de Caen, Caen, France (N.M.).'}, {'ForeName': 'Grégory', 'Initials': 'G', 'LastName': 'Pugnet', 'Affiliation': 'Centre Hospitalier Universitaire de Toulouse, Toulouse, France (A.H., G.P.).'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Maurier', 'Affiliation': 'Hôpitaux Privés de Metz, Metz, France (F.M.).'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Sibilia', 'Affiliation': 'Hôpital de Hautepierre, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France (J.S.).'}, {'ForeName': 'Pierre-Louis', 'Initials': 'PL', 'LastName': 'Carron', 'Affiliation': 'Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France (P.C.).'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Gobert', 'Affiliation': 'Clinique Rhône Durance, Avignon, France (P.G.).'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Meaux-Ruault', 'Affiliation': 'Centre Hospitalier Universitaire Jean-Minjoz, Besançon, France (N.M.).'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Le Gallou', 'Affiliation': 'Centre Hospitalier Universitaire de Rennes, Rennes, France (T.L.).'}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Vinzio', 'Affiliation': 'Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France (S.V.).'}, {'ForeName': 'Jean-François', 'Initials': 'JF', 'LastName': 'Viallard', 'Affiliation': 'Centre Hospitalier Universitaire de Bordeaux, Pessac, France (J.V.).'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Hachulla', 'Affiliation': 'Centre Hospitalier Universitaire de Lille, Lille, France (E.H.).'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Vinter', 'Affiliation': 'Cochin Hospital, Paris Descartes University, Paris, France (P.C., C.V., X.P., B.T., L.M., L.G.).'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Puéchal', 'Affiliation': 'Cochin Hospital, Paris Descartes University, Paris, France (P.C., C.V., X.P., B.T., L.M., L.G.).'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Terrier', 'Affiliation': 'Cochin Hospital, Paris Descartes University, Paris, France (P.C., C.V., X.P., B.T., L.M., L.G.).'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Ravaud', 'Affiliation': ""Centre d'Epidémiologie Clinique, Hôpital Hôtel-Dieu, Université Paris Descartes, Sorbonne Paris Cité INSERM Unité 1153, Paris, France (É.P., P.R.).""}, {'ForeName': 'Luc', 'Initials': 'L', 'LastName': 'Mouthon', 'Affiliation': 'Cochin Hospital, Paris Descartes University, Paris, France (P.C., C.V., X.P., B.T., L.M., L.G.).'}, {'ForeName': 'Loïc', 'Initials': 'L', 'LastName': 'Guillevin', 'Affiliation': 'Cochin Hospital, Paris Descartes University, Paris, France (P.C., C.V., X.P., B.T., L.M., L.G.).'}]",Annals of internal medicine,['10.7326/M19-3827'] 1481,32481239,"Sensorimotor and gait training improves proprioception, nerve function, and muscular activation in patients with diabetic peripheral neuropathy: a randomized control trial.","OBJECTIVES To examine the effect of sensorimotor and gait training on proprioception, nerve function, and muscle activation in diabetic peripheral neuropathy (DPN) patients. METHODS Thirty-eight (25 male and 13 female) participants with DPN were selected and randomly allocated to intervention and control group. Participants in the intervention group were provided sensorimotor and gait training for eight weeks (3 days/week) along with diabetes and foot care education; participants in the control group received diabetes and foot care education only. Outcome measures involved proprioception, nerve conduction studies of peroneal and tibial nerve, and activation of lower limb muscles and multifidus while standing with eyes open and eyes closed, and treadmill walking. RESULTS Mixed ANOVA revealed significant time effect and time×group interaction of proprioception in all four directions (p<0.05). The conduction velocity of peroneal nerve revealed significant time effect (p=0.007) and time×group interaction (p=0.022). Interaction effect was found to be significant for medial gastrocnemius and multifidus while standing with eyes open as well as with eyes closed (p≤0.004). Only multifidus showed significant group (p=0.002) and interaction effect (p=0.003) during walking. CONCLUSIONS Sensorimotor and gait training is an effective tool for improvement of proprioception and nerve function. It benefits muscle activation around ankle and multifidus during postural control and walking in DPN patients. Clinical Trials Registry - India, National Institute of Medical Statistics (Indian Council of Medical Research): Registration Number - CTRI/2017/08/009328.",2020,The conduction velocity of peroneal nerve revealed significant time effect (p=0.007) and time×group interaction (p=0.022).,"['Thirty-eight', 'diabetic peripheral neuropathy (DPN) patients', 'patients with diabetic peripheral neuropathy', 'DPN patients', '25 male and 13 female) participants with DPN']","['control group received diabetes and foot care education only', 'Sensorimotor and gait training', 'sensorimotor and gait training']","['proprioception, nerve function, and muscular activation', 'proprioception, nerve function, and muscle activation', 'interaction effect', 'proprioception, nerve conduction studies of peroneal and tibial nerve, and activation of lower limb muscles and multifidus while standing with eyes open and eyes closed, and treadmill walking', 'time effect and time×group interaction of proprioception', 'Interaction effect', 'conduction velocity of peroneal nerve revealed significant time effect']","[{'cui': 'C0450361', 'cui_str': '38'}, {'cui': 'C0740447', 'cui_str': 'Diabetic peripheral neuropathy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C1161230', 'cui_str': 'Foot care education'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure'}]","[{'cui': 'C0033499', 'cui_str': 'Proprioception'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0200125', 'cui_str': 'Nerve conduction study'}, {'cui': 'C0442035', 'cui_str': 'Peroneal'}, {'cui': 'C0040186', 'cui_str': 'Structure of tibial nerve'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0224319', 'cui_str': 'Structure of multifidus muscle'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0266574', 'cui_str': 'Ablepharon'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0234084', 'cui_str': 'Conduction rate of nerve cell and nerve fiber'}, {'cui': 'C0031173', 'cui_str': 'Structure of common peroneal nerve'}, {'cui': 'C0443289', 'cui_str': 'Revealed'}, {'cui': 'C0750502', 'cui_str': 'Significant'}]",,0.0376785,The conduction velocity of peroneal nerve revealed significant time effect (p=0.007) and time×group interaction (p=0.022).,"[{'ForeName': 'Irshad', 'Initials': 'I', 'LastName': 'Ahmad', 'Affiliation': 'Diabetes Research Group, Centre for Physiotherapy and Rehabilitation Sciences, Jamia Millia Islamia (A Central University), New Delhi, India.'}, {'ForeName': 'Shalini', 'Initials': 'S', 'LastName': 'Verma', 'Affiliation': 'Diabetes Research Group, Centre for Physiotherapy and Rehabilitation Sciences, Jamia Millia Islamia (A Central University), New Delhi, India.'}, {'ForeName': 'Majumi M', 'Initials': 'MM', 'LastName': 'Noohu', 'Affiliation': 'Human Performance Lab, Centre for Physiotherapy and Rehabilitation Sciences, Jamia Millia Islamia (A Central University), New Delhi, India.'}, {'ForeName': 'Mohd Yakub', 'Initials': 'MY', 'LastName': 'Shareef', 'Affiliation': 'Ansari Health Centre, Jamia Millia Islamia (A Central University), New Delhi, India.'}, {'ForeName': 'M Ejaz', 'Initials': 'ME', 'LastName': 'Hussain', 'Affiliation': 'Diabetes Research Group, Centre for Physiotherapy and Rehabilitation Sciences, Jamia Millia Islamia (A Central University), New Delhi, India.'}]",Journal of musculoskeletal & neuronal interactions,[] 1482,32481240,Effects of aquatic exercises on postural control and hand function in Multiple Sclerosis: Halliwick versus Aquatic Plyometric Exercises: a randomised trial.,"OBJECTIVES Postural control and hand dexterity are significantly impaired in people with multiple sclerosis (pwMS). Aquatic interventions may have additional benefits in the treatment of pwMS. The purpose of this study is to compare the effects of two different aquatic exercises on postural control and hand function. METHODS Thirty pwMS, relapsing-remitting type were randomly divided into a Halliwick (Hallw) and an Aquatic Plyometric Exercise (APE) group. The Limits of Stability test was used to evaluate postural control using the Biodex Balance System. The Nine-Hole Peg Test was used to evaluate hand dexterity. Both exercise interventions were performed twice a week for 8 weeks, in a pool with a depth of 120 cm and water temperature of 30-31°C. RESULTS Limits of stability improved significantly in both groups (p<0.05) and Hallw group completed the test in a significantly shorter time (p<0.05). Hand dexterity improved significantly in both groups (p<0.01). Following intergroup analysis, Hallw group showed significantly higher improvement in hand dexterity and overall limits of stability test score (p<0.05). CONCLUSIONS This study provides evidence that both Halliwick and APE are effective to treat balance and hand dexterity. This paper is the first evidence on APE for pwMS and showed that it is safe and improved trunk control and hand dexterity.",2020,"RESULTS Limits of stability improved significantly in both groups (p<0.05) and Hallw group completed the test in a significantly shorter time (p<0.05).","['Thirty pwMS, relapsing-remitting type', 'people with multiple sclerosis (pwMS', 'Multiple Sclerosis']","['Halliwick (Hallw) and an Aquatic Plyometric Exercise (APE', 'aquatic exercises', 'Aquatic Plyometric Exercises']","['hand dexterity and overall limits of stability test score', 'Limits of stability', 'Hand dexterity', 'postural control and hand function']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C3178799', 'cui_str': 'Plyometric Drill'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0565699', 'cui_str': 'Ability to perform general manipulative activities'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4760618', 'cui_str': 'Posture Control'}, {'cui': 'C0562230', 'cui_str': 'Hand functions'}]",,0.030325,"RESULTS Limits of stability improved significantly in both groups (p<0.05) and Hallw group completed the test in a significantly shorter time (p<0.05).","[{'ForeName': 'Baris', 'Initials': 'B', 'LastName': 'Gurpinar', 'Affiliation': 'Dokuz Eylul University School of Physical Therapy and Rehabilitation, Izmir, Turkey.'}, {'ForeName': 'Bilge', 'Initials': 'B', 'LastName': 'Kara', 'Affiliation': 'Dokuz Eylul University School of Physical Therapy and Rehabilitation, Izmir, Turkey.'}, {'ForeName': 'Egemen', 'Initials': 'E', 'LastName': 'Idiman', 'Affiliation': 'Private Clinic, Izmir, Turkey.'}]",Journal of musculoskeletal & neuronal interactions,[] 1483,32481241,Therapeutic value of kinesio taping in reducing lower back pain and improving back muscle endurance in adolescents with hemophilia.,"OBJECTIVE This study evaluated whether the use of kinesio taping (KT) would enhance the effect of physical therapy in relieving pain, improving muscle endurance, and boosting functional capacity in adolescents with hemophilia who experience low back pain. METHODS Forty-five adolescents with hemophilia (age; 10-13 years) assigned randomly into three treatment arms; KT applied paraspinal alongside a physical exercise program conducted three times/week for three successive months (KT group; n=15), placebo taping plus physical exercise (Placebo group; n=15), or physical exercise only (Control group; n=15). Lower back pain, back muscle endurance, and functional capacity assessed pre- and post-treatment. RESULTS Lower back pain reduced significantly in the KT group as compared to the control group (P=.001), but not to the placebo group (P=.19). Back muscle endurance increased significantly in the KT group relative to either the placebo (P=.004) or the control group (P=.043). Additionally, functional capacity improved significantly in the KT group as compared to the control (P=.039) group but not to the placebo group (P=.58). CONCLUSION KT is an effective adjunctive therapy to reduce lower back pain, improve back muscle endurance, and enhance functional capacity in adolescents with hemophilia.",2020,"RESULTS Lower back pain reduced significantly in the KT group as compared to the control group (P=.001), but not to the placebo group (P=.19).","['Forty-five adolescents with hemophilia (age; 10-13 years', 'adolescents with hemophilia who experience low back pain', 'adolescents with hemophilia']","['kinesio taping (KT', 'placebo taping plus physical exercise (Placebo', 'KT', 'kinesio taping', 'physical exercise', 'physical therapy', 'placebo']","['back pain', 'Lower back pain, back muscle endurance, and functional capacity assessed pre- and post-treatment', 'Back muscle endurance', 'functional capacity', 'lower back pain and improving back muscle endurance']","[{'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0019069', 'cui_str': 'Hereditary factor VIII deficiency disease'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}]","[{'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0224334', 'cui_str': 'Skeletal muscle structure of back'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",45.0,0.0300428,"RESULTS Lower back pain reduced significantly in the KT group as compared to the control group (P=.001), but not to the placebo group (P=.19).","[{'ForeName': 'Alshimaa R', 'Initials': 'AR', 'LastName': 'Αzab', 'Affiliation': 'Department of Physical Therapy for Pediatrics, Faculty of Physical Therapy, Cairo University, Giza, Egypt.'}, {'ForeName': 'Ragab K', 'Initials': 'RK', 'LastName': 'Elnaggar', 'Affiliation': 'Department of Physical Therapy for Pediatrics, Faculty of Physical Therapy, Cairo University, Giza, Egypt.'}, {'ForeName': 'Reham H', 'Initials': 'RH', 'LastName': 'Diab', 'Affiliation': 'Department of Basic Sciences, Faculty of Physical Therapy, Cairo University, Giza, Egypt.'}, {'ForeName': 'Samah A', 'Initials': 'SA', 'LastName': 'Moawd', 'Affiliation': 'Department of Physical Therapy and Health Rehabilitation, Collage of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.'}]",Journal of musculoskeletal & neuronal interactions,[] 1484,32486840,Impact of a Personalized Audit and Feedback Intervention on Antibiotic Prescribing Practices for Outpatient Pediatric Community-Acquired Pneumonia.,"Antibiotic choice for pediatric community-acquired pneumonia (CAP) varies widely. We aimed to determine the impact of a 6-month personalized audit and feedback program on primary care providers' antibiotic prescribing practices for CAP. Participants in the intervention group received monthly personalized feedback. We then analyzed enrolled providers' CAP antibiotic prescribing practices. Participants diagnosed 316 distinct cases of CAP (214 control, 102 intervention); among these 316 participants, 301 received antibiotics (207 control, 94 intervention). In patients ≥5 years, the intervention group had fewer non-guideline-concordant antibiotics prescribed (22/103 [21.4%] control; 3/51 [5.9%] intervention, P < .05) and received more of the guideline-concordant antibiotics (amoxicillin and azithromycin). Personalized, scheduled audit and feedback in the outpatient setting was feasible and had a positive impact on clinician's selection of guideline-recommended antibiotics. Audit and feedback should be combined with other antimicrobial stewardship interventions to improve guideline adherence in the management of outpatient CAP.",2020,"In patients ≥5 years, the intervention group had fewer non-guideline-concordant antibiotics prescribed (22/103 [21.4%] control; 3/51 [5.9%] intervention, P < .05) and received more of the guideline-concordant antibiotics (amoxicillin and azithromycin).","['Participants diagnosed 316 distinct cases of CAP (214 control, 102 intervention); among these 316 participants, 301 received antibiotics (207 control, 94 intervention', 'pediatric community-acquired pneumonia (CAP', ""primary care providers' antibiotic prescribing practices for CAP"", ""enrolled providers' CAP antibiotic prescribing practices"", 'Outpatient Pediatric Community-Acquired Pneumonia']","['antibiotics (amoxicillin and azithromycin', 'monthly personalized feedback', 'personalized audit and feedback program', 'antimicrobial stewardship interventions', 'Personalized Audit and Feedback Intervention']","['fewer non-guideline-concordant antibiotics', 'guideline adherence']","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0450356', 'cui_str': '316'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0694549', 'cui_str': 'Community acquired pneumonia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C2735026', 'cui_str': 'Primary care provider'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0450985', 'cui_str': 'Alcohol use disorders identification test'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C4505099', 'cui_str': 'Antimicrobial Stewardship'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205388', 'cui_str': 'Few'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0525059', 'cui_str': 'Guideline Adherence'}]",316.0,0.0337686,"In patients ≥5 years, the intervention group had fewer non-guideline-concordant antibiotics prescribed (22/103 [21.4%] control; 3/51 [5.9%] intervention, P < .05) and received more of the guideline-concordant antibiotics (amoxicillin and azithromycin).","[{'ForeName': 'Maria Carmen G', 'Initials': 'MCG', 'LastName': 'Diaz', 'Affiliation': 'Nemours/Alfred I. du Pont Hospital for Children, Wilmington, DE, USA.'}, {'ForeName': 'Lori K', 'Initials': 'LK', 'LastName': 'Handy', 'Affiliation': ""Children's Hospital of Philadelphia, Philadelphia, PA, USA.""}, {'ForeName': 'James H', 'Initials': 'JH', 'LastName': 'Crutchfield', 'Affiliation': 'Lockheed-Martin Corporation, Orlando, FL, USA.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Cadilla', 'Affiliation': ""Nemours Children's Hospital, Orlando, FL, USA.""}, {'ForeName': 'Jobayer', 'Initials': 'J', 'LastName': 'Hossain', 'Affiliation': 'Nemours/Alfred I. du Pont Hospital for Children, Wilmington, DE, USA.'}, {'ForeName': 'Lloyd N', 'Initials': 'LN', 'LastName': 'Werk', 'Affiliation': ""Nemours Children's Hospital, Orlando, FL, USA.""}]",Clinical pediatrics,['10.1177/0009922820928054'] 1485,32585338,Targeting T cells in inflammatory bowel disease.,"T cells play a pivotal role in the immune response underlying inflammatory bowel disease (IBD) pathogenesis. On this basis, over the past 25 years several drugs have assessed to target T cells in IBD patients. Amongst anti-CD3 antibodies, visilizumab and foralumab did not show clinical efficacy in ulcerative colitis (UC) and Crohn's disease (CD) patients, respectively, whereas otelixizumab has been tested in vitro only. The anti-CD4 BF-5 and cM-T412, and the anti-CD25 basiliximab and daclizumab were not effective in CD and UC patients, respectively. The anti-NKG2D antibody NNC0142-0002 showed clinical benefit in CD patients, in particular in biologic naïve ones, in a randomized, double-blind, parallel-group, placebo-controlled trial. The anti-CD40L M90 and the GSK1349571A blocking calcium release-activated calcium (CRAC) channels, which are involved in the T cell activation and proliferation, were tested only in ex vivo/in vitro experiments. Apart from ustekinumab, all the other drugs targeting T cell-derived cytokines failed. The reinduction of lamina propria T cell apoptosis is a mechanism to modulate T cell survival exploited by cyclosporin A, azathioprine and anti-tumor necrosis factor-α agents, such as infliximab, adalimumab and golimumab. In this article, we review the drugs targeting T cells via surface receptors, via T cell-derived cytokines, via CRAC channels or by inducing apoptosis.",2020,"Amongst anti-CD3 antibodies, visilizumab and foralumab did not show clinical efficacy in ulcerative colitis (UC) and Crohn's disease (CD) patients, respectively, whereas otelixizumab has been tested in vitro only.","[""ulcerative colitis (UC) and Crohn's disease (CD) patients""]","['cyclosporin A, azathioprine', 'daclizumab', 'placebo']",[],"[{'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0010592', 'cui_str': 'Cyclosporine'}, {'cui': 'C0004482', 'cui_str': 'Azathioprine'}, {'cui': 'C0663182', 'cui_str': 'Daclizumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.0961703,"Amongst anti-CD3 antibodies, visilizumab and foralumab did not show clinical efficacy in ulcerative colitis (UC) and Crohn's disease (CD) patients, respectively, whereas otelixizumab has been tested in vitro only.","[{'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Giuffrida', 'Affiliation': 'First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Di Sabatino', 'Affiliation': 'First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy. Electronic address: a.disabatino@smatteo.pv.it.'}]",Pharmacological research,['10.1016/j.phrs.2020.105040'] 1486,32585354,The benefits and costs of changing treatment technique in electroconvulsive therapy due to insufficient improvement of a major depressive episode.,"BACKGROUND Electroconvulsive therapy (ECT) technique is often changed after insufficient improvement, yet there has been little research on switching strategies. OBJECTIVE To document clinical outcome in ECT nonresponders who were received a second course using high dose, brief pulse, bifrontotemporal (HD BP BL) ECT, and compare relapse rates and cognitive effects relative to patients who received only one ECT course and as a function of the type of ECT first received. METHODS Patients were classified as receiving Weak, Strong, or HD BP BL ECT during three randomized trials at Columbia University. Nonresponders received HD BP BL ECT. In a separate multi-site trial, Optimization of ECT, patients were randomized to right unilateral or BL ECT and nonresponders also received further treatment with HD BP BL ECT. RESULTS Remission rates with a second course of HD BP BL ECT were high in ECT nonresponders, approximately 60% and 40% in the Columbia University and Optimization of ECT studies, respectively. Clinical outcome was independent of the type of ECT first received. A second course with HD BP BL ECT resulted in greater retrograde amnesia immediately, two months, and six months following ECT. CONCLUSIONS In the largest samples of ECT nonresponders studied to date, a second course of ECT had marked antidepressant effects. Since the therapeutic effects were independent of the technique first administered, it is possible that many patients may benefit simply from longer courses of ECT. Randomized trials are needed to determine whether, when, and how to change treatment technique in ECT.",2020,Clinical outcome was independent of the type of ECT first received.,"['Patients were classified as receiving Weak, Strong, or HD BP BL ECT during three randomized trials at Columbia University', 'patients who received only one ECT course and as a function of the type of ECT first received']","['Electroconvulsive therapy (ECT) technique', 'right unilateral or BL ECT', 'Electroconvulsive Therapy', 'HD BP BL ECT']","['retrograde amnesia', 'HD BP BL ECT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C1762617', 'cui_str': 'Weak'}, {'cui': 'C0442821', 'cui_str': 'Strong'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}]","[{'cui': 'C0002624', 'cui_str': 'Retrograde amnesia'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}]",,0.0665526,Clinical outcome was independent of the type of ECT first received.,"[{'ForeName': 'Harold A', 'Initials': 'HA', 'LastName': 'Sackeim', 'Affiliation': 'Department of Psychiatry, Columbia University, NY, USA; Department of Radiology, Columbia University, NY, USA. Electronic address: has1@columbia.edu.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Prudic', 'Affiliation': 'Department of Psychiatry, Columbia University, NY, USA; New York State Psychiatric Institute, NY, USA.'}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Devanand', 'Affiliation': 'Department of Psychiatry, Columbia University, NY, USA; New York State Psychiatric Institute, NY, USA; Department of Neurology, Columbia University, NY, USA.'}, {'ForeName': 'Mitchell S', 'Initials': 'MS', 'LastName': 'Nobler', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, New York Medical College, NY, USA.'}, {'ForeName': 'Roger F', 'Initials': 'RF', 'LastName': 'Haskett', 'Affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Benoit H', 'Initials': 'BH', 'LastName': 'Mulsant', 'Affiliation': 'Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Centre for Addiction and Mental Health, Toronto, ON, Canada.'}, {'ForeName': 'Peter B', 'Initials': 'PB', 'LastName': 'Rosenquist', 'Affiliation': 'Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University, Augusta, GA, USA.'}, {'ForeName': 'William V', 'Initials': 'WV', 'LastName': 'McCall', 'Affiliation': 'Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University, Augusta, GA, USA.'}]",Brain stimulation,['10.1016/j.brs.2020.06.016'] 1487,32613718,"Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial.","AIM To evaluate the effects of vitamin D on transient elastography (TE, FibroScan) indices of liver steatosis (controlled attenuation parameter [CAP]) and fibrosis (liver stiffness measurement [LSM]) in adults with non-alcoholic fatty liver disease (NAFLD). PATIENTS AND METHODS In this randomized (2:1), double-blind, single-centre, 12-month trial, patients with NAFLD were treated with vitamin D (1000 IU/day) (n = 201) or a matching placebo (n = 110). Two co-primary outcomes were changes in CAP and LSM after 360 days of treatment versus baseline. Two main secondary outcomes were CAP/LSM changes after 180 days of treatment. RESULTS Both CAP and LSM gradually decreased in vitamin D-treated patients and slightly increased in the placebo arm. Vitamin D was superior to placebo for both primary outcomes (mean differences in CAP and LSM changes (-49.5 dB/m [95% CI -59.5 to -39.4] and -0.72 kPa [95% CI -1.43 to 0.00], respectively) and both secondary outcomes (-22.1 dB/m [-32.1 to -12.1] and -0.89 kPa [-1.61 to -0.17], respectively). Of a number of exploratory outcomes (change at 12 months vs. baseline), vitamin D reduced serum uric acid (-17.9 μmol/L [-30.6 to -5.2]), gamma-glutamyltransferase (-8.9 IU/L [-15.5 to -2.3)] and fasting serum insulin levels (-5.1 pmol/L [-9.3 to -0.8]) as well as the homeostatic model assessment of insulin resistance index (-1.6 [-3.1 to -0.2]) (false discovery rate [5%]-adjusted P-values between .0572 and .0952). CONCLUSION Low-medium dose supplementation of vitamin D (1000 IU/day) over 12 months reduces TE indices of liver steatosis (CAP) and fibrosis (LSM) in NAFLD patients.",2020,"Vitamin D was superior to placebo for both primary outcomes (mean differences in CAP and LSM changes -49.5 dB/m [95%CI -59.5 to -39.4] and -0.72 kPa [95%CI -1.43 to 0.00], respectively) and both secondary outcomes (-22.1 dB/m [-32.1 to -12.1] and -0.89 kPa [-1.61 to -0.17], respectively).","['patients with NAFLD', 'adults with non-alcoholic fatty liver disease (NAFLD', 'NAFLD patients']","['Vitamin D', 'vitamin D', 'matching placebo', 'placebo']","['CAP/LSM changes', 'changes in CAP and LSM', 'homeostatic model assessment of insulin resistance index', 'gamma glutamyl transferase', 'TE indices of liver steatosis (CAP) and fibrosis (LSM', 'transient elastography (TE, FibroScan®) indices of liver steatosis [controlled attenuation parameter (CAP)] and fibrosis [liver stiffness measurement (LSM', 'fasting serum insulin levels', 'serum uric acid', 'CAP and LSM']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0017040', 'cui_str': 'Gamma-glutamyltransferase'}, {'cui': 'C0015695', 'cui_str': 'Fatty Liver'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C2748260', 'cui_str': 'Transient elastography'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0455272', 'cui_str': 'Serum urate measurement'}]",,0.800459,"Vitamin D was superior to placebo for both primary outcomes (mean differences in CAP and LSM changes -49.5 dB/m [95%CI -59.5 to -39.4] and -0.72 kPa [95%CI -1.43 to 0.00], respectively) and both secondary outcomes (-22.1 dB/m [-32.1 to -12.1] and -0.89 kPa [-1.61 to -0.17], respectively).","[{'ForeName': 'Vesna', 'Initials': 'V', 'LastName': 'Lukenda Zanko', 'Affiliation': 'Department of Internal Medicine, General Hospital ""Josip Benčević"", Slavonski Brod, Croatia.'}, {'ForeName': 'Viktor', 'Initials': 'V', 'LastName': 'Domislovic', 'Affiliation': 'Department for Gastroenterology and Hepatology, University Hospital Center Zagreb, Zagreb, Croatia.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Trkulja', 'Affiliation': 'Department of Pharmacology, School of Medicine Zagreb, Zagreb, Croatia.'}, {'ForeName': 'Irena', 'Initials': 'I', 'LastName': 'Krznaric-Zrnic', 'Affiliation': 'Department of Gastroenterology, University Hospital Center Rijeka, Rijeka, Croatia.'}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Turk-Wensveen', 'Affiliation': 'Department of Endocrinology, University Hospital Center Rijeka, Rijeka, Croatia.'}, {'ForeName': 'Zeljko', 'Initials': 'Z', 'LastName': 'Krznaric', 'Affiliation': 'Department for Gastroenterology and Hepatology, University Hospital Center Zagreb, Zagreb, Croatia.'}, {'ForeName': 'Tajana', 'Initials': 'T', 'LastName': 'Filipec Kanizaj', 'Affiliation': 'School of Medicine, Zagreb, Croatia.'}, {'ForeName': 'Delfa', 'Initials': 'D', 'LastName': 'Radic-Kristo', 'Affiliation': 'School of Medicine, Zagreb, Croatia.'}, {'ForeName': 'Lidija', 'Initials': 'L', 'LastName': 'Bilic-Zulle', 'Affiliation': 'Clinical Institute for Laboratory Diagnostics, Clinical Hospital Centre, Rijeka and Department of Medical Informatics, Rijeka University School of Medicine, Rijeka, Croatia.'}, {'ForeName': 'Lidija', 'Initials': 'L', 'LastName': 'Orlic', 'Affiliation': 'School of Medicine, Rijeka, Croatia.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Dinjar-Kujundzic', 'Affiliation': 'Department of Gastroenterology, University Hospital Merkur, Zagreb, Croatia.'}, {'ForeName': 'Goran', 'Initials': 'G', 'LastName': 'Poropat', 'Affiliation': 'Department of Gastroenterology, University Hospital Center Rijeka, Rijeka, Croatia.'}, {'ForeName': 'Davor', 'Initials': 'D', 'LastName': 'Stimac', 'Affiliation': 'Department of Gastroenterology, University Hospital Center Rijeka, Rijeka, Croatia.'}, {'ForeName': 'Goran', 'Initials': 'G', 'LastName': 'Hauser', 'Affiliation': 'Department of Gastroenterology, University Hospital Center Rijeka, Rijeka, Croatia.'}, {'ForeName': 'Ivana', 'Initials': 'I', 'LastName': 'Mikolasevic', 'Affiliation': 'Department of Gastroenterology, University Hospital Center Rijeka, Rijeka, Croatia.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14129'] 1488,32609858,"Psychoeducation Program for Substance Use Disorder: Effect on Relapse Rate, Social Functioning, Perceived Wellness, and Coping.","The current study was designed to assess the effect of a psychoeducation program on relapse rate, social functioning, perceived wellness, and ways of coping in individuals with substance use disorder (SUD). The study sample comprised 92 individuals (n = 46 intervention group, n = 46 control group) who received SUD treatment, had undergone detoxification, and agreed to participate in the study. A 10-session psychoeducation program was applied to individuals in the intervention group. Data collection included a urine sample and completion of the Personal Information Form, Social Functioning Scale, Perceived Wellness Scale, and Ways of Coping Scale. The relapse rate in the control group was found to be higher than in the intervention group; thus, it was determined that the relapse prevention psychoeducation program led to positive changes in relapse rate, social functioning, perceived wellness, and stress in individuals with SUD. [Journal of Psychosocial Nursing and Mental Health Services, 58(8), 39-47.].",2020,"The relapse rate in the control group was found to be higher than in the intervention group; thus, it was determined that the relapse prevention psychoeducation program led to positive changes in relapse rate, social functioning, perceived wellness, and stress in individuals with SUD.","['individuals with substance use disorder (SUD', '92 individuals (n = 46 intervention group, n = 46 control group) who received SUD treatment, had undergone detoxification, and agreed to participate in the study']",['psychoeducation program'],"['relapse rate, social functioning, perceived wellness, and stress in individuals with SUD', 'relapse rate', 'urine sample and completion of the Personal Information Form, Social Functioning Scale, Perceived Wellness Scale, and Ways of Coping Scale', 'Relapse Rate, Social Functioning, Perceived Wellness, and Coping', 'relapse rate, social functioning, perceived wellness, and ways of coping']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0038586', 'cui_str': 'Substance use disorder'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0025516', 'cui_str': 'Detoxication, Drug, Metabolic'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0038586', 'cui_str': 'Substance use disorder'}, {'cui': 'C1610733', 'cui_str': 'Urine specimen'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C2983694', 'cui_str': 'Personally Identifiable Information'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C2585826', 'cui_str': 'Social functioning scale'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}]",,0.0150981,"The relapse rate in the control group was found to be higher than in the intervention group; thus, it was determined that the relapse prevention psychoeducation program led to positive changes in relapse rate, social functioning, perceived wellness, and stress in individuals with SUD.","[{'ForeName': 'Maral', 'Initials': 'M', 'LastName': 'Kargin', 'Affiliation': ''}, {'ForeName': 'Duygu', 'Initials': 'D', 'LastName': 'Hicdurmaz', 'Affiliation': ''}]",Journal of psychosocial nursing and mental health services,['10.3928/02793695-20200624-03'] 1489,32610451,"Ultra-Performance Liquid Chromatography-Ion Mobility Separation-Quadruple Time-of-Flight MS (UHPLC-IMS-QTOF MS) Metabolomics for Short-Term Biomarker Discovery of Orange Intake: A Randomized, Controlled Crossover Study.","A major problem with dietary assessments is their subjective nature. Untargeted metabolomics and new technologies can shed light on this issue and provide a more complete picture of dietary intake by measuring the profile of metabolites in biological samples. Oranges are one of the most consumed fruits in the world, and therefore one of the most studied for their properties. The aim of this work was the application of untargeted metabolomics approach with the novel combination of ion mobility separation coupled to high resolution mass spectrometry (IMS-HRMS) and study the advantages that this technique can bring to the area of dietary biomarker discovery, with the specific case of biomarkers associated with orange consumption ( Citrus reticulata ) in plasma samples taken during an acute intervention study (consisting of a randomized, controlled crossover trial in healthy individuals). A total of six markers of acute orange consumption, including betonicines and conjugated flavonoids, were identified with the experimental data and previous literature, demonstrating the advantages of ion mobility in the identification of dietary biomarkers and the benefits that an additional structural descriptor, as the collision cross section value (CCS), can provide in this area.",2020,"A total of six markers of acute orange consumption, including betonicines and conjugated flavonoids, were identified with the experimental data and previous literature, demonstrating the advantages of ion mobility in the identification of dietary biomarkers and the benefits that an additional structural descriptor, as the collision cross section value (CCS), can provide in this area.","['Orange Intake', 'healthy individuals']",['Ultra-Performance Liquid Chromatography-Ion Mobility Separation-Quadruple Time-of-Flight MS (UHPLC-IMS-QTOF MS) Metabolomics'],[],"[{'cui': 'C0440277', 'cui_str': 'Orange - fruit'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0008565', 'cui_str': 'Liquid chromatography measurement'}, {'cui': 'C0022023', 'cui_str': 'Ions'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0036679', 'cui_str': 'Separation'}, {'cui': 'C0205175', 'cui_str': 'Quadruple'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1328813', 'cui_str': 'Metabolomics'}]",[],,0.0369513,"A total of six markers of acute orange consumption, including betonicines and conjugated flavonoids, were identified with the experimental data and previous literature, demonstrating the advantages of ion mobility in the identification of dietary biomarkers and the benefits that an additional structural descriptor, as the collision cross section value (CCS), can provide in this area.","[{'ForeName': 'Leticia', 'Initials': 'L', 'LastName': 'Lacalle-Bergeron', 'Affiliation': 'Research Institute for Pesticides and Water (IUPA), Universitat Jaume I, 12071 Castellón, Spain.'}, {'ForeName': 'Tania', 'Initials': 'T', 'LastName': 'Portolés', 'Affiliation': 'Research Institute for Pesticides and Water (IUPA), Universitat Jaume I, 12071 Castellón, Spain.'}, {'ForeName': 'Francisco J', 'Initials': 'FJ', 'LastName': 'López', 'Affiliation': 'Research Institute for Pesticides and Water (IUPA), Universitat Jaume I, 12071 Castellón, Spain.'}, {'ForeName': 'Juan Vicente', 'Initials': 'JV', 'LastName': 'Sancho', 'Affiliation': 'Research Institute for Pesticides and Water (IUPA), Universitat Jaume I, 12071 Castellón, Spain.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Ortega-Azorín', 'Affiliation': 'Department of Preventive Medicine and Public Health, School of Medicine, University of Valencia, 46010 Valencia, Spain.'}, {'ForeName': 'Eva M', 'Initials': 'EM', 'LastName': 'Asensio', 'Affiliation': 'Department of Preventive Medicine and Public Health, School of Medicine, University of Valencia, 46010 Valencia, Spain.'}, {'ForeName': 'Oscar', 'Initials': 'O', 'LastName': 'Coltell', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.'}, {'ForeName': 'Dolores', 'Initials': 'D', 'LastName': 'Corella', 'Affiliation': 'Department of Preventive Medicine and Public Health, School of Medicine, University of Valencia, 46010 Valencia, Spain.'}]",Nutrients,['10.3390/nu12071916'] 1490,32615331,Fluorescence Imaging of the Ureter in Minimally Invasive Pelvic Surgery.,"STUDY OBJECTIVE Determine near-optimal dose, safety, and efficacy of nerindocianine in pelvic ureter detection with near-infrared fluorescence imaging in women undergoing minimally invasive pelvic surgery with 3 Food and Drug Administration-cleared imaging systems. DESIGN Open label, phase 1/2a study. SETTING University of Alabama at Birmingham. PATIENTS Forty-one female subjects undergoing minimally invasive gynecologic surgery. INTERVENTIONS Subjects received a single dose of nerindocianine sodium, starting at 0.06-mg/kg body weight and increased/decreased until the near-optimal dose was determined (part A). Examine the degree of concordance between endoscopic and robotic devices (part B). MEASUREMENTS AND MAIN RESULTS In part A, composite scores were collected every 10 minutes for 30 minutes and then every 15 minutes through 90 minutes using a scale measuring the anatomy/laterality of ureter visualization. In part B (paired imaging system efficacy), 2 cohorts of 8 subjects each received the near-optimal dose. Composite scores for visualization of the ureter were collected at 10 and 30 minutes postinfusion with the Firefly Imaging System and either the PINPOINT or 1588 AIM endoscope. Composite scores were compared to examine the degree of concordance between devices. Part A comprised 25 total subjects enrolled in dosing groups 1, 2, and 3 (0.06-, 0.12-, and 0.045-mg/kg, respectively). Median time to first ureter visualization was 10 minutes (all groups). The nerindocianine 0.06-mg/kg and 0.12-mg/kg groups had longer length of time of visualization than the 0.045-mg/kg group, resulting in the selection of 0.06 mg/kg as the near-optimal dose. Part B enrolled 16 total subjects in 2 groups dosed at 0.06 mg/kg. Efficacy analysis showed no statistically significant difference in composite scores with Firefly versus PINPOINT or 1588 AIM. CONCLUSION Nerindocianine was well tolerated with visualization of the ureter demonstrated in 88.9% of the subjects through 90 minutes postdosing. No meaningful visualization differences were observed among the Food and Drug Administration-cleared surgical imaging systems used.",2020,Nerindocianine was well-tolerated with visualization of the ureter demonstrated in 88.9% of subjects through 90 minutes post dosing.,"['women undergoing minimally invasive pelvic surgery with three FDA-cleared imaging systems', '25 total subjects enrolled in dosing Groups 1, 2, and 3 (0.06, 0.12, and 0.045 mg/kg, respectively', 'minimally invasive pelvic surgery', ' University of Alabama ', 'Forty-one female subjects undergoing minimally invasive gynecological surgery', 'Part B enrolled 16 total subjects in two groups dosed at 0.06 mg/kg']","['nerindocianine sodium', 'Nerindocianine', 'endoscopic and robotic devices (Part B', 'nerindocianine']","['longer length of time of visualization', 'Median time to first ureter visualization', 'composite scores']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0030797', 'cui_str': 'Pelvic'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0041714', 'cui_str': 'United States Food, Drug Administration'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C4517412', 'cui_str': '0.06'}, {'cui': 'C4517426', 'cui_str': '0.12'}, {'cui': 'C4517410', 'cui_str': '0.045'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0001895', 'cui_str': 'Alabama'}, {'cui': 'C0038902', 'cui_str': 'Operation on female genital organs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0041951', 'cui_str': 'Ureteric'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0360639,Nerindocianine was well-tolerated with visualization of the ureter demonstrated in 88.9% of subjects through 90 minutes post dosing.,"[{'ForeName': 'Warner K', 'Initials': 'WK', 'LastName': 'Huh', 'Affiliation': 'Division of Gynecologic Oncology, University of Alabama, Birmingham, Alabama (Drs. Kim, Johnson, Leath III, Huh, and Ms. Elliott); Department of Obstetrics and Gynecology, University of Tennessee Medical Center Knoxville, Graduate School of Medicine, Knoxville, Tennessee (Dr. Boone); Clinical Research and Development, LI-COR, Inc., Lincoln, Nebraska (Ms. Kovar). Electronic address: whuh@uabmc.edu.'}, {'ForeName': 'John L', 'Initials': 'JL', 'LastName': 'Johnson', 'Affiliation': 'Division of Gynecologic Oncology, University of Alabama, Birmingham, Alabama (Drs. Kim, Johnson, Leath III, Huh, and Ms. Elliott); Department of Obstetrics and Gynecology, University of Tennessee Medical Center Knoxville, Graduate School of Medicine, Knoxville, Tennessee (Dr. Boone); Clinical Research and Development, LI-COR, Inc., Lincoln, Nebraska (Ms. Kovar).'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Elliott', 'Affiliation': 'Division of Gynecologic Oncology, University of Alabama, Birmingham, Alabama (Drs. Kim, Johnson, Leath III, Huh, and Ms. Elliott); Department of Obstetrics and Gynecology, University of Tennessee Medical Center Knoxville, Graduate School of Medicine, Knoxville, Tennessee (Dr. Boone); Clinical Research and Development, LI-COR, Inc., Lincoln, Nebraska (Ms. Kovar).'}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Boone', 'Affiliation': 'Division of Gynecologic Oncology, University of Alabama, Birmingham, Alabama (Drs. Kim, Johnson, Leath III, Huh, and Ms. Elliott); Department of Obstetrics and Gynecology, University of Tennessee Medical Center Knoxville, Graduate School of Medicine, Knoxville, Tennessee (Dr. Boone); Clinical Research and Development, LI-COR, Inc., Lincoln, Nebraska (Ms. Kovar).'}, {'ForeName': 'Charles A', 'Initials': 'CA', 'LastName': 'Leath', 'Affiliation': 'Division of Gynecologic Oncology, University of Alabama, Birmingham, Alabama (Drs. Kim, Johnson, Leath III, Huh, and Ms. Elliott); Department of Obstetrics and Gynecology, University of Tennessee Medical Center Knoxville, Graduate School of Medicine, Knoxville, Tennessee (Dr. Boone); Clinical Research and Development, LI-COR, Inc., Lincoln, Nebraska (Ms. Kovar).'}, {'ForeName': 'Joy L', 'Initials': 'JL', 'LastName': 'Kovar', 'Affiliation': 'Division of Gynecologic Oncology, University of Alabama, Birmingham, Alabama (Drs. Kim, Johnson, Leath III, Huh, and Ms. Elliott); Department of Obstetrics and Gynecology, University of Tennessee Medical Center Knoxville, Graduate School of Medicine, Knoxville, Tennessee (Dr. Boone); Clinical Research and Development, LI-COR, Inc., Lincoln, Nebraska (Ms. Kovar).'}, {'ForeName': 'Kenneth H', 'Initials': 'KH', 'LastName': 'Kim', 'Affiliation': 'Division of Gynecologic Oncology, University of Alabama, Birmingham, Alabama (Drs. Kim, Johnson, Leath III, Huh, and Ms. Elliott); Department of Obstetrics and Gynecology, University of Tennessee Medical Center Knoxville, Graduate School of Medicine, Knoxville, Tennessee (Dr. Boone); Clinical Research and Development, LI-COR, Inc., Lincoln, Nebraska (Ms. Kovar).'}]",Journal of minimally invasive gynecology,['10.1016/j.jmig.2020.06.022'] 1491,32615392,The effects of 6 mo of supplementation with probiotics and synbiotics on gut microbiota in the adults with prediabetes: A double blind randomized clinical trial.,"OBJECTIVES The evidence of 16S rRNA genes in the gut microbiota distinguished a higher Firmicutes-to-Bacteroidetes ratio in individuals who were obese and had diabetes than in a healthy cohort. So, it seems that the modulation of intestinal microbial ecology by pro-/pre-/synbiotics may contribute to the progression and prevention of metabolic diseases. The aim of this study was to assess the effects of probiotics and synbiotic supplementation on the modification of the intestinal microbiome in adults with prediabetes. METHODS In a randomized, double-blinded, placebo-controlled clinical trial, 120 patients with prediabetes were randomly assigned to consume 6 g/d of either a placebo containing maltodextrin (control) or multispecies probiotic or inulin-based synbiotic for 6 mo. Fecal samples were obtained at baseline and after 6 mo of supplementation. Dietary intake was assessed throughout the study (at baseline and after 3 and 6 mo). Total energy, macronutrients, and dietary fiber were calculated using a dietary program Nutritionist 4. DNA was extracted from fecal samples and the numbers of Clostridium perfringens (the represent of phylum Firmicutes), Bacteroides fragilis (the representative of Bacteroidetes) and Escherichia coli (as universal bacteria) were determined by quantitative real-time polymerase chain reactions (qPCR). The changes in the relative abundance of the two fecal bacteria before and after supplementation were analyzed and compared within and between groups. RESULTS There were no significant changes in dietary intake during the study. Six mo of supplementation with probiotics resulted in a statistically significant increase in the abundance of the B. fragilis-to-E.coli ratio (mean difference [MD] ± SE 0.47 ± 0.37, P = 0.04) and decrease of the relative proportion of Firmicutes-to-Bacteroidetes representatives (MD ± SE -118.8 ± 114.6, P = 0.02). Synbiotic had no significant effect on the changes in the bacteria. There were no significant differences between the three groups. CONCLUSION The results of this study suggest that manipulation of the human gut microbiome by using probiotics could provide a potential therapeutic approach in the prevention and management of obesity and metabolic disorders such as diabetes.",2020,"Six mo of supplementation with probiotics resulted in a statistically significant increase in the abundance of the B. fragilis-to-E.coli ratio (mean difference [MD] ± SE 0.47 ± 0.37, P = 0.04) and decrease of the relative proportion of Firmicutes-to-Bacteroidetes representatives (MD ± SE -118.8 ± 114.6, P = 0.02).","['120 patients with prediabetes', 'adults with prediabetes']","['dietary program', 'probiotics and synbiotic supplementation', 'placebo containing maltodextrin (control) or multispecies probiotic or inulin-based synbiotic', 'Synbiotic', 'supplementation with probiotics and synbiotics', 'placebo']","['dietary intake', 'gut microbiota', 'bacteria', 'Total energy, macronutrients, and dietary fiber', 'abundance of the B. fragilis-to-E.coli ratio', 'Dietary intake', 'Fecal samples']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C2936470', 'cui_str': 'Synbiotics'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0021936', 'cui_str': 'Inulin'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0004611', 'cui_str': 'Bacterium'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0014834', 'cui_str': 'Escherichia coli'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]",120.0,0.249584,"Six mo of supplementation with probiotics resulted in a statistically significant increase in the abundance of the B. fragilis-to-E.coli ratio (mean difference [MD] ± SE 0.47 ± 0.37, P = 0.04) and decrease of the relative proportion of Firmicutes-to-Bacteroidetes representatives (MD ± SE -118.8 ± 114.6, P = 0.02).","[{'ForeName': 'Nazila', 'Initials': 'N', 'LastName': 'Kassaian', 'Affiliation': 'Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: nkassaian@gmal.com.'}, {'ForeName': 'Awat', 'Initials': 'A', 'LastName': 'Feizi', 'Affiliation': 'Isfahan Endocrine and Metabolism Research Center and Department of Biostatistics and Epidemiology, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: awat_feiz@hlth.mui.ac.ir.'}, {'ForeName': 'Soodabeh', 'Initials': 'S', 'LastName': 'Rostami', 'Affiliation': 'Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: srostami1876@gmail.com.'}, {'ForeName': 'Ashraf', 'Initials': 'A', 'LastName': 'Aminorroaya', 'Affiliation': 'Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: aminorroaya@med.mui.ac.ir.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Yaran', 'Affiliation': 'Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: yaranmajid@yahoo.com.'}, {'ForeName': 'Masoud', 'Initials': 'M', 'LastName': 'Amini', 'Affiliation': 'Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: M_amini@med.mui.ac.ir.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110854'] 1492,32480307,Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: A randomized trial.,"BACKGROUND The present study was a randomized, double-blind, placebo-controlled, multi-center trial to evaluate the efficacy and safety of prolonged-release melatonin (PRM) in Parkinson's disease (PD) patients with poor sleep quality. METHODS PD patients with a global Pittsburgh Sleep Quality Index (PSQI) score > 5 were included. Patients were assessed using the PSQI, a rapid eye movement sleep behavior disorder screening questionnaire, the Epworth Sleepiness Scale, Non-Motor Symptoms Scale (NMSS), Parkinson's Disease Quality of Life-39 (PDQ-39), and Unified Parkinson's Disease Rating Scale (UPDRS)-III at the beginning of the study and after 4 weeks of treatment with 2 mg of PRM. Partial correlation analysis was performed to investigate the relationship between PSQI score and the other scales. RESULTS Thirty-four PD patients with poor sleep quality were enrolled and divided into 2 groups based on medication; PRM (n = 16) and placebo (n = 18). Regarding efficacy, PSQI was significantly improved in the PRM group compared to the control group. Improvement in the NMSS and PDQ-39 summary index were observed in the PRM but not in the placebo group; UPDRS-III score was not significantly changed in either group. PSQI improvement correlated with improvement in NMSS score and PDQ-39 summary index. Regarding safety, all enrolled subjects did not complain of side effects due to PRM. CONCLUSION PRM is an effective and safe treatment option for subjective sleep quality in PD patients and beneficial effects on sleep quality are associated with improved non-motor symptoms and quality of life in PD patients.",2020,Improvement in the NMSS and PDQ-39 summary index were observed in the PRM but not in the placebo group; UPDRS-III score was not significantly changed in either group.,"['PD patients with a global Pittsburgh Sleep Quality Index (PSQI) score', 'Thirty-four PD patients with poor sleep quality', ""Parkinson's disease (PD) patients with poor sleep quality"", '\xa05 were included', ""Parkinson's disease patients with a poor sleep quality""]","['Prolonged-release melatonin', 'prolonged-release melatonin (PRM', 'PRM', 'placebo']","['subjective sleep quality', ""PSQI, a rapid eye movement sleep behavior disorder screening questionnaire, the Epworth Sleepiness Scale, Non-Motor Symptoms Scale (NMSS), Parkinson's Disease Quality of Life-39 (PDQ-39), and Unified Parkinson's Disease Rating Scale"", 'efficacy, PSQI', 'NMSS and PDQ-39 summary index', 'efficacy and safety', 'NMSS score and PDQ-39 summary index', 'UPDRS-III score']","[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0235162', 'cui_str': 'Difficulty sleeping'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0751772', 'cui_str': 'REM sleep behavior disorder'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3541276', 'cui_str': 'Epworth Sleepiness Scale'}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439070', 'cui_str': 'III'}]",,0.0488383,Improvement in the NMSS and PDQ-39 summary index were observed in the PRM but not in the placebo group; UPDRS-III score was not significantly changed in either group.,"[{'ForeName': 'Jong Hyeon', 'Initials': 'JH', 'LastName': 'Ahn', 'Affiliation': 'Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Neuroscience Center, Samsung Medical Center, Seoul, Republic of Korea.'}, {'ForeName': 'Minkyeong', 'Initials': 'M', 'LastName': 'Kim', 'Affiliation': 'Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Neuroscience Center, Samsung Medical Center, Seoul, Republic of Korea.'}, {'ForeName': 'Suyeon', 'Initials': 'S', 'LastName': 'Park', 'Affiliation': 'Department of Biostatistics, Soonchunhyang University Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Wooyoung', 'Initials': 'W', 'LastName': 'Jang', 'Affiliation': 'Department of Neurology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea.'}, {'ForeName': 'Jinse', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': 'Department of Neurology, Haeundae Paik Hospital, Inje University, Busan, Republic of Korea.'}, {'ForeName': 'Eungseok', 'Initials': 'E', 'LastName': 'Oh', 'Affiliation': 'Department of Neurology, Chungnam National University Hospital, College of Medicine, Daejun, Republic of Korea.'}, {'ForeName': 'Jin Whan', 'Initials': 'JW', 'LastName': 'Cho', 'Affiliation': 'Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Neuroscience Center, Samsung Medical Center, Seoul, Republic of Korea.'}, {'ForeName': 'Ji Sun', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': 'Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Neuroscience Center, Samsung Medical Center, Seoul, Republic of Korea. Electronic address: sunnyfor@hanmail.net.'}, {'ForeName': 'Jinyoung', 'Initials': 'J', 'LastName': 'Youn', 'Affiliation': 'Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Neuroscience Center, Samsung Medical Center, Seoul, Republic of Korea. Electronic address: genian@skku.edu.'}]",Parkinsonism & related disorders,['10.1016/j.parkreldis.2020.03.029'] 1493,32480319,Effectiveness of an app-based cognitive behavioral therapy program for postpartum depression in primary care: A randomized controlled trial.,"OBJECTIVE The objective of this study was to examine the effect of mobile phone applications (App) based cognitive behavioral therapy (CBT) on postpartum depression. METHOD A non-blinded parallel-group randomized controlled trial was conducted. The study population consisted of women attended to three health care centers in Kerman, Iran. Participants were recruited between September and November 2018, and randomized 1:1 to either the intervention group (mobile application access) or control group (no mobile application access). All participants completed the Edinburgh Postnatal Depression Scale (EPDS) at the baseline and 2 months after baseline. Data were analyzed using inferential statistics including chi-square, independent sample t-test, paired t-test and linear regression. RESULTS A total of 75 women with an average age of 27 years participated in this study. Before the intervention, there was no statistically significant difference between the EPDS score between the two groups (p > 0.001). However, in the intervention group, the average EPDS score after intervention was 8.18 and in the control group was 15.05, which was statistically significant (p < 0.001). CONCLUSION These findings provide proof that providing a CBT program using a mobile application can lead to clinically important improvements in outcomes for mothers who suffer from postpartum depression.",2020,"Before the intervention, there was no statistically significant difference between the EPDS score between the two groups (p > 0.001).","['Participants were recruited between September and November 2018', 'postpartum depression in primary care', 'women attended to three health care centers in Kerman, Iran', 'mothers who suffer from postpartum depression', '75 women with an average age of 27 years participated in this study']","['intervention group (mobile application access) or control group (no mobile application access', 'app-based cognitive behavioral therapy program', 'mobile phone applications (App) based cognitive behavioral therapy (CBT']","['Edinburgh Postnatal Depression Scale (EPDS', 'average EPDS score', 'EPDS score']","[{'cui': 'C0221074', 'cui_str': 'Postpartum depression'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C0451144', 'cui_str': 'Edinburgh postnatal depression scale'}, {'cui': 'C3472185', 'cui_str': 'Edinburgh postnatal depression scale score'}]",75.0,0.174326,"Before the intervention, there was no statistically significant difference between the EPDS score between the two groups (p > 0.001).","[{'ForeName': 'Nazanin', 'Initials': 'N', 'LastName': 'Jannati', 'Affiliation': 'Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Shahrzad', 'Initials': 'S', 'LastName': 'Mazhari', 'Affiliation': 'Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Ahmadian', 'Affiliation': 'Medical Informatics Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. Electronic address: ahmadianle@yahoo.com.'}, {'ForeName': 'Moghaddameh', 'Initials': 'M', 'LastName': 'Mirzaee', 'Affiliation': 'Epidemiology and Biostatistics, Kerman University of Medical Sciences, Kerman, Iran.'}]",International journal of medical informatics,['10.1016/j.ijmedinf.2020.104145'] 1494,32485294,Immunological and behavioral responses to in vivo lipopolysaccharide administration in young and healthy obese and normal-weight humans.,"Obesity is associated with an increase prevalence of neuropsychiatric symptoms and diseases, such as depression. Based on the facts that pro-inflammatory cytokines are able to modulate behavior, and that obesity is characterized by a chronic low-grade inflammatory state, inflammation has been hypothesized to contribute to the neuropsychiatric comorbidity in obese individuals. However, a causal link between inflammation and the development of neuropsychiatric symptoms is hard to establish in humans. Here, we used an inflammatory stimulus, i.e. the intravenous injection of lipopolysaccharide (LPS), in a double-blind placebo-controlled design, to determine the vulnerability of obese individuals to inflammation-induced behavioral changes. The hypothesis was that obese individuals would show heightened behavioral response compared to normal-weight subjects for the same inflammatory stimulus, reflecting an increased sensitivity to the behavioral effects of pro-inflammatory cytokines. LPS (dose 0.8 ng/kg body weight, adjusted for estimated blood volume in obese subjects) and placebo (saline) were intravenously injected in 14 obese healthy subjects and 23 normal-weight healthy subjects in a within-subject, randomized, crossover design. LPS administration induced, in both groups, an acute increase in blood concentrations of cytokines (interleukin-6, tumor necrosis factor-α, and IL-10), as well as in body temperature, cortisol, norepinephrine, sickness symptoms, fatigue, negative mood, and state anxiety. There were little differences in the immune and behavioral responses to LPS between obese and normal-weight subjects, but the cortisol response to LPS was strongly attenuated in obese individuals. Higher percentage of body fat was related to a lower cortisol response to LPS. Taken together, the population of young and healthy obese individuals in this study did not exhibit an increased behavioral sensitivity to cytokines, but an attenuated cortisol response to the immune challenge. Future studies will need to determine whether additional physiological and psychological factors interact with the state of obesity to increase the risk for inflammation-induced neuropsychiatric symptoms.",2020,"LPS administration induced, in both groups, an acute increase in blood concentrations of cytokines (interleukin-6, tumor necrosis factor-α and IL-10), as well as in body temperature, cortisol, norepinephrine, sickness symptoms, fatigue, negative mood and state anxiety.","['obese individuals to inflammation-induced behavioral changes', 'obese individuals', 'young and healthy obese and normal-weight humans', '14 obese healthy subjects and 23 normal-weight healthy subjects']","['placebo (saline', 'lipopolysaccharide administration', 'lipopolysaccharide (LPS', 'LPS']","['Immunological and behavioral responses', 'blood concentrations of cytokines (interleukin-6, tumor necrosis factor-α and IL-10), as well as in body temperature, cortisol, norepinephrine, sickness symptoms, fatigue, negative mood and state anxiety', 'behavioral response', 'cortisol response to LPS']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0023810', 'cui_str': 'Lipopolysaccharide'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0205470', 'cui_str': 'Immunologic'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0427728', 'cui_str': 'Blood concentration, dipstick - finding'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0700613', 'cui_str': 'Anxiety state'}, {'cui': 'C0023810', 'cui_str': 'Lipopolysaccharide'}]",14.0,0.0574229,"LPS administration induced, in both groups, an acute increase in blood concentrations of cytokines (interleukin-6, tumor necrosis factor-α and IL-10), as well as in body temperature, cortisol, norepinephrine, sickness symptoms, fatigue, negative mood and state anxiety.","[{'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Lasselin', 'Affiliation': 'Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany; Stress Research Institute, Stockholm University, 10691 Stockholm, Sweden; Department of Clinical Neuroscience, Division for Psychology, Karolinska Institutet, Nobels väg 9, 17177 Stockholm, Sweden. Electronic address: julie.lasselin@su.se.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Benson', 'Affiliation': 'Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Hebebrand', 'Affiliation': 'Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Duisburg-Essen, Germany.'}, {'ForeName': 'Karoline', 'Initials': 'K', 'LastName': 'Boy', 'Affiliation': 'Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany.'}, {'ForeName': 'Vera', 'Initials': 'V', 'LastName': 'Weskamp', 'Affiliation': 'Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany.'}, {'ForeName': 'Analena', 'Initials': 'A', 'LastName': 'Handke', 'Affiliation': 'Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany.'}, {'ForeName': 'Till', 'Initials': 'T', 'LastName': 'Hasenberg', 'Affiliation': 'Helios Adipositas Zentrum West, Helios St. Elisabeth Klinik Oberhausen, Witten/Herdecke University, Josefstr. 3, 46045 Oberhausen, Germany.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Remy', 'Affiliation': 'Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Duisburg-Essen, Germany.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Föcker', 'Affiliation': 'Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Duisburg-Essen, Germany.'}, {'ForeName': 'Meike', 'Initials': 'M', 'LastName': 'Unteroberdörster', 'Affiliation': 'Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany; Department of Neurosurgery, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Brinkhoff', 'Affiliation': 'Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany; Department of Nephrology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany.'}, {'ForeName': 'Harald', 'Initials': 'H', 'LastName': 'Engler', 'Affiliation': 'Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany.'}, {'ForeName': 'Manfred', 'Initials': 'M', 'LastName': 'Schedlowski', 'Affiliation': 'Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany.'}]","Brain, behavior, and immunity",['10.1016/j.bbi.2020.05.071'] 1495,32583707,"Feasibility and Impact of a Yoga Intervention on Cognition, Physical Function, Physical Activity, and Affective Outcomes among People Living with HIV: A Randomized Controlled Pilot Trial.","The purpose of this pilot randomized controlled trial is to assess the feasibility and impact of a triweekly 12-week yoga intervention among people living with HIV (PLWH). Additional objectives included evaluating cognition, physical function, medication adherence, health-related quality of life (HRQoL), and mental health among yoga participants versus controls using blinded assessors. We recruited 22 medically stable PLWH aged ≥35 years. A priori feasibility criteria were ≥70% yoga session attendance and ≥70% of participants satisfied with the intervention using a postparticipation questionnaire. Two participants withdrew from the yoga group. Mean yoga class attendance was 82%, with 100% satisfaction. Intention-to-treat analyses (yoga n = 11, control n = 11) showed no within- or between-group differences in cognitive and physical function. The yoga group improved over time in HRQoL cognition ( P = .047) with trends toward improvements in HRQoL health transition ( P =.063) and depression ( P = .055). This pilot study provides preliminary evidence of feasibility and benefits of yoga for PLWH.",2020,The yoga group improved over time in HRQoL cognition ( P = .047) with trends toward improvements in HRQoL health transition ( P =.063) and depression ( P = .055).,"['22 medically stable PLWH aged ≥35 years', 'People Living with HIV', 'people living with HIV (PLWH']","['Yoga Intervention', 'yoga intervention']","['Mean yoga class attendance', 'cognitive and physical function', 'HRQoL health transition', 'Cognition, Physical Function, Physical Activity, and Affective Outcomes', 'time in HRQoL cognition', 'cognition, physical function, medication adherence, health-related quality of life (HRQoL), and mental health', 'depression']","[{'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0376627', 'cui_str': 'Health Transition'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",22.0,0.106207,The yoga group improved over time in HRQoL cognition ( P = .047) with trends toward improvements in HRQoL health transition ( P =.063) and depression ( P = .055).,"[{'ForeName': 'Adria', 'Initials': 'A', 'LastName': 'Quigley', 'Affiliation': 'Department of Physiotherapy, Dalhousie University, Halifax, Nova Scotia, Canada.'}, {'ForeName': 'Marie-Josée', 'Initials': 'MJ', 'LastName': 'Brouillette', 'Affiliation': 'Department of Psychiatry, McGill University, Montreal, Quebec, Canada.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Gahagan', 'Affiliation': 'School of Health and Human Performance, Dalhousie University, Halifax, Nova Scotia, Canada.'}, {'ForeName': 'Kelly Kathleen', 'Initials': 'KK', 'LastName': ""O'Brien"", 'Affiliation': 'Department of Physiotherapy, University of Toronto, Ontario, Canada.'}, {'ForeName': 'Marilyn', 'Initials': 'M', 'LastName': 'MacKay-Lyons', 'Affiliation': 'Department of Physiotherapy, Dalhousie University, Halifax, Nova Scotia, Canada.'}]",Journal of the International Association of Providers of AIDS Care,['10.1177/2325958220935698'] 1496,32589056,"Practical challenges in the conduct of pragmatic trials embedded in health plans: Lessons of IMPACT-AFib, an FDA-Catalyst trial.","IMPACT-AFib was an 80,000-patient randomized clinical trial implemented by five US insurance companies (health plans) aimed at increasing the use of oral anticoagulants by individuals with atrial fibrillation who were at high risk of stroke and not on treatment. The underlying thesis was that patients could be change agents to initiate prescribing discussions with their providers. We tested the effect of mailing information to both patients and their providers. We used administrative medical claims and pharmacy dispensing data to identify eligible patients, to randomize them to an early or delayed intervention, and to assess clinical outcomes. The core data were analysis-ready datasets each site had created and curated for the FDA's Sentinel System, supplemented by updated ""fresh"" pharmacy and enrollment data to ensure eligibility at the time of intervention. Following mutually agreed upon procedures, sites linked to additional internal source data to implement the intervention-educational information mailed to patients and their providers in the early intervention arm, and to providers of patients in the delayed intervention arm approximately 12 months later. The primary analysis compares the early intervention arm to the delayed intervention arm, prior to the delayed intervention being conducted (i.e. compares intervention to non-intervention). The endpoints of interest were evidence of initiation of anticoagulation (primary) as well as clinical endpoints, including stroke and hospitalization for bleeding. Major challenges, some unanticipated, identified during the planning phase include convening multi-stakeholder investigator teams and advisors, addressing ethical concerns about not intervening in a usual care comparison group, and identifying and avoiding interference with sites' routine programs that were similar to the intervention. Needs and challenges during the implementation phase included the fact that even limited site-specific programming greatly increased time and effort, the need to refresh research data extracts immediately before outreach to patients and providers, potential difficulty identifying low-cost medications such as warfarin that may not be reimbursed by health plans and so not discoverable in dispensing data, the need to develop workarounds when ""providers"" in claims data were facilities, difficulty addressing clustering of patients by provider because providers can have multiple identifiers within and between health plans, and the need to anticipate loss to follow up because of health plan disenrollment or change in benefits. As pragmatic trials begin to shape evidence generation within clinical practice, investigators should anticipate issues inherent to claims data and working with multiple large sites. In IMPACT-AFib, we found that investing in collaboration and communication among all parties throughout all phases of the study helped ensure common understanding, early identification of challenges, and streamlined actual implementation.",2020,"Major challenges, some unanticipated, identified during the planning phase include convening multi-stakeholder investigator teams and advisors, addressing ethical concerns about not intervening in a usual care comparison group, and identifying and avoiding interference with sites' routine programs that were similar to the intervention.",['individuals with atrial fibrillation who were at high risk of stroke and not on treatment'],[],"['initiation of anticoagulation (primary) as well as clinical endpoints, including stroke and hospitalization for bleeding']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",[],"[{'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]",,0.037705,"Major challenges, some unanticipated, identified during the planning phase include convening multi-stakeholder investigator teams and advisors, addressing ethical concerns about not intervening in a usual care comparison group, and identifying and avoiding interference with sites' routine programs that were similar to the intervention.","[{'ForeName': 'Crystal J', 'Initials': 'CJ', 'LastName': 'Garcia', 'Affiliation': 'Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Haynes', 'Affiliation': 'HealthCore, Inc., Wilmington, DE, USA.'}, {'ForeName': 'Sean D', 'Initials': 'SD', 'LastName': 'Pokorney', 'Affiliation': 'Division of Cardiology and Duke Clinical Research Institute, Duke University, Durham, NC, USA.'}, {'ForeName': 'Nancy D', 'Initials': 'ND', 'LastName': 'Lin', 'Affiliation': 'OptumInsight Life Sciences, Inc., Boston, MA, USA.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'McMahill-Walraven', 'Affiliation': 'Aetna Inc., a CVS Health Company, Blue Bell, PA, USA.'}, {'ForeName': 'Vinit', 'Initials': 'V', 'LastName': 'Nair', 'Affiliation': 'Humana Healthcare Research, Humana Inc., Louisville, KY, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Parlett', 'Affiliation': 'HealthCore, Inc., Wilmington, DE, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Martin', 'Affiliation': 'U.S. Food and Drug Administration, Silver Spring, MD, USA.'}, {'ForeName': 'Hussein R', 'Initials': 'HR', 'LastName': 'Al-Khalidi', 'Affiliation': 'Department of Biostatistics and Bioinformatics and Duke Clinical Research Institute, Duke University, Durham, NC, USA.'}, {'ForeName': 'Debbe', 'Initials': 'D', 'LastName': 'McCall', 'Affiliation': 'Rowan Tree Perspectives Consulting, Murrieta, CA, USA.'}, {'ForeName': 'Christopher B', 'Initials': 'CB', 'LastName': 'Granger', 'Affiliation': 'Division of Cardiology and Duke Clinical Research Institute, Duke University, Durham, NC, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Platt', 'Affiliation': 'Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.'}, {'ForeName': 'Noelle M', 'Initials': 'NM', 'LastName': 'Cocoros', 'Affiliation': 'Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.'}]","Clinical trials (London, England)",['10.1177/1740774520928426'] 1497,32584651,The Effect of Temporal Frames in Anti-Smoking Messages on the Extension of Anti-Smoking Arguments to Smokers.,"The present study focused on how exposure to different health message characteristics can affect extension-i.e., the sharing of arguments that were not targeted by the messages but are consistent with the message theme. In the context of anti-smoking campaigns, many messages have either emphasized reasons to quit smoking (why-quit) or ways to quit smoking (how-to-quit). Therefore, guided by construal level theory, the study aimed to examine whether the message characteristic of temporal frames can increase or decrease extension when incorporated into why-quit and how-to-quit anti-smoking messages. Results from a randomized experiment showed that exposure to why-quit messages with distant temporal frames increased extension (vs. no-message control) while why-quit messages with proximal temporal frames did not. Findings further illustrated a potential mechanism, where why-quit messages with proximal frames significantly reduced extension compared to why-quit messages with no temporal frames. Temporal frames did not have a significant effect on extension for how-to-quit messages. Results indicate that emphasizing the present in anti-smoking messages could be detrimental for the extension of why-quit arguments. Implications for applying construal level theory to health message effects research are also discussed.",2020,Temporal frames did not have a significant effect on extension for how-to-quit messages.,['Smokers'],[],[],"[{'cui': 'C0337664', 'cui_str': 'Smoker'}]",[],[],,0.0409015,Temporal frames did not have a significant effect on extension for how-to-quit messages.,"[{'ForeName': 'Stella Juhyun', 'Initials': 'SJ', 'LastName': 'Lee', 'Affiliation': 'Department of Media and Communication, Konkuk University , Seoul, Republic of Korea.'}]",Journal of health communication,['10.1080/10810730.2020.1778820'] 1498,31810517,Stop the bleed: The impact of trauma first aid kits on post-training confidence among community members and medical professionals.,"INTRODUCTION Bystander training to control life-threatening hemorrhage is an important intervention to decrease preventable trauma deaths. We asked if receiving a trauma first aid (TFA) kit in addition to Bleeding Control (BC) 1.0 training improves self-reported confidence among community members (CM) and medical professionals (MP). METHODS Anonymous pre- and post-course surveys assessed exposure to severe bleeding, BC knowledge, and willingness to intervene with and without TFA kits. Surveys were compared using chi-squared tests. RESULTS 80 CM and 60 MP underwent BC training. Both groups demonstrated improved confidence in their ability to stop severe bleeding after the class; however, post-class confidence was significantly modified by receiving a TFA kit. After training, CM confidence was 36.1% without versus 57.0% with a TFA kit(p = 0.008) and MP confidence was 53.8% without versus 87.6% with a TFA kit(p = 0.001). CONCLUSION Receiving a TFA kit was significantly associated with increased post-training confidence among CM and MP. SUMMARY Stop the Bleed training improves confidence in stopping severe bleeding among both medical professionals and community members. By providing participants with a trauma first aid kit, post-class confidence improves significantly regardless of medical training.",2020,"After training, CM confidence was 36.1% without versus 57.0% with a TFA kit(p = 0.008) and MP confidence was 53.8% without versus 87.6% with a TFA kit(p = 0.001). ","['community members and medical professionals', 'community members (CM) and medical professionals (MP']","['Bleed training', 'Bystander training']","['severe bleeding, BC knowledge, and willingness to intervene with and without TFA kits', 'CM confidence', 'confidence in their ability to stop severe bleeding', 'MP confidence']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}]","[{'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0149533', 'cui_str': 'Control of hemorrhage'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0016143', 'cui_str': 'First aid'}, {'cui': 'C0812225', 'cui_str': 'Device kit'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}]",,0.0298185,"After training, CM confidence was 36.1% without versus 57.0% with a TFA kit(p = 0.008) and MP confidence was 53.8% without versus 87.6% with a TFA kit(p = 0.001). ","[{'ForeName': 'Erin G', 'Initials': 'EG', 'LastName': 'Andrade', 'Affiliation': 'Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, USA. Electronic address: andradee@wustl.edu.'}, {'ForeName': 'Jane M', 'Initials': 'JM', 'LastName': 'Hayes', 'Affiliation': 'Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, USA. Electronic address: janehayes@wustl.edu.'}, {'ForeName': 'Laurie J', 'Initials': 'LJ', 'LastName': 'Punch', 'Affiliation': 'Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, USA. Electronic address: ljpunch@wustl.edu.'}]",American journal of surgery,['10.1016/j.amjsurg.2019.11.028'] 1499,31811480,"Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03).","PURPOSE Capecitabine-based adjuvant chemotherapy for colorectal cancer patients often causes adverse events (AEs), such as diarrhea, stomatitis, anorexia, and hand-foot syndrome (HFS). Cystine and theanine were reported to attenuate some chemotherapy-associated AEs, and hence are also expected to attenuate capecitabine-induced AEs. Therefore, we aimed to investigate the safety and efficacy of cystine/theanine treatment in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery. METHODS A total of 100 colorectal cancer patients treated with capecitabine as an adjuvant chemotherapy after surgery were randomly allocated into the cystine/theanine group (n = 52) or the placebo group (n = 48). The primary endpoint was incidence rate of diarrhea of grade 1 or higher in accordance with the Common Terminology Criteria for AEs (CTCAE) v.4.0, Japanese Clinical Oncology Group (JCOG) version. The secondary endpoints included incidence rates of other AEs (CTCAE v.4.0-JCOG), as well as the incidence rate of HFS according to the HFS grading scale. RESULTS There were no significant differences in capecitabine-induced AEs between the two groups. However, the incidence rate of diarrhea of grade 1 or higher tended to be lower in the cystine/theanine group than the placebo group (18.4% vs. 28.9%, p = 0.169) as well as the incidence rate of HFS of grade 1 or higher (CTCAE v.4.0-JCOG or HFS grading scale) (67.4% vs. 77.8%, p = 0.185, 67.3% vs. 80.0%, p = 0.124, respectively). CONCLUSION This trial demonstrated that cystine/theanine treatment of colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery is safe and has the tendency to reduce the incidence rate of diarrhea or HFS. TRIAL REGISTRATION UMIN000024784.",2020,There were no significant differences in capecitabine-induced AEs between the two groups.,"['100 colorectal cancer patients treated with', 'colorectal cancer patients undergoing', 'as an adjuvant chemotherapy after surgery', 'colorectal cancer patients', 'colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery']","['Cystine and theanine', 'capecitabine-based adjuvant chemotherapy', 'cystine/theanine treatment', 'capecitabine', 'Capecitabine-based adjuvant chemotherapy', 'cystine and theanine', 'cystine/theanine', 'placebo']","['incidence rate of diarrhea of grade 1 or higher in accordance with the Common Terminology Criteria for AEs (CTCAE', 'incidence rate of diarrhea', 'safety and efficacy', 'incidence rates of other AEs (CTCAE v.4.0-JCOG), as well as the incidence rate of HFS according to the HFS grading scale', 'incidence rate of HFS of grade 1 or higher (CTCAE v.4.0-JCOG or HFS grading scale']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0010682', 'cui_str': 'Cystine'}, {'cui': 'C0076380', 'cui_str': 'theanine'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1516728', 'cui_str': 'National Cancer Institute common terminology criteria for adverse events'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0028275', 'cui_str': 'Terminology'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C1274034', 'cui_str': 'Clinical oncology'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0549410', 'cui_str': 'Palmar-plantar erythrodysaesthesia syndrome'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",100.0,0.573596,There were no significant differences in capecitabine-induced AEs between the two groups.,"[{'ForeName': 'Reo', 'Initials': 'R', 'LastName': 'Hamaguchi', 'Affiliation': 'Department of Palliative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. reo-h@nifty.com.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Tsuchiya', 'Affiliation': 'Department of Gastroenterological Surgery, Sendai City Medical Center, Sendai Open Hospital, Sendai, Miyagi, Japan.'}, {'ForeName': 'Go', 'Initials': 'G', 'LastName': 'Miyata', 'Affiliation': 'Department of Gastroenterological Surgery, Iwate Prefectural Central Hospital, Morioka, Iwate, Japan.'}, {'ForeName': 'Toshihiko', 'Initials': 'T', 'LastName': 'Sato', 'Affiliation': 'Department of Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan.'}, {'ForeName': 'Kenichi', 'Initials': 'K', 'LastName': 'Takahashi', 'Affiliation': 'Department of Colorectal Surgery, Tohoku Rosai Hospital, Sendai, Miyagi, Japan.'}, {'ForeName': 'Koh', 'Initials': 'K', 'LastName': 'Miura', 'Affiliation': 'Department of Surgery, Miyagi Cancer Center, Sendai, Miyagi, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Oshio', 'Affiliation': 'Department of Surgery, Sendai Medical Center, Sendai, Miyagi, Japan.'}, {'ForeName': 'Hisatsugu', 'Initials': 'H', 'LastName': 'Ohori', 'Affiliation': 'Department of Clinical Oncology, Ishinomaki Red Cross Hospital, Ishinomaki, Miyagi, Japan.'}, {'ForeName': 'Keisuke', 'Initials': 'K', 'LastName': 'Ariyoshi', 'Affiliation': 'JORTC Data Center, Tokyo, Japan.'}, {'ForeName': 'Shunsuke', 'Initials': 'S', 'LastName': 'Oyamada', 'Affiliation': 'JORTC Data Center, Tokyo, Japan.'}, {'ForeName': 'Satoru', 'Initials': 'S', 'LastName': 'Iwase', 'Affiliation': 'Department of Palliative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-019-05205-1'] 1500,31811485,"Quality of life in pediatric oncology patients, caregivers and siblings after psychosocial screening: a randomized controlled trial.","OBJECTIVE We evaluated whether conducting psychosocial screening using a validated measure (the Psychosocial Assessment Tool, PAT) and providing a summary of PAT results to the patient's treating team improves quality of life (QOL) in newly diagnosed patients with cancer, their caregivers and siblings, in general, and in relation to the initial family psychosocial risk. METHODS Families were randomly allocated to an intervention (IG, treating team received PAT summary describing low, medium, or high psychosocial risk) or control group (CG, no summary provided to treating team) in two Canadian pediatric cancer centers. Caregivers (N = 122) of children newly diagnosed with cancer, patients (n = 36), and siblings (n = 25) completed QOL assessments at 2-4 weeks (T1) and 6 months post-diagnosis (T2). Caregivers also completed PAT and proxy QOL for patient and sibling. RESULTS In general, patient-proxy total QOL improved in IG compared to CG over time but only for high psychosocial risk patients (p < .05). Patient proxy cancer-related QOL improved over time regardless of group allocation; caregiver QOL also improved over time (ps < .05). CONCLUSION This study demonstrated the benefits of psychosocial screening results only on proxy patient QOL outcomes with high psychosocial risk near diagnosis. Evaluating QOL benefits in pediatric oncology patients is critical for establishing the clinical value of psychosocial screening. CLINICAL TRIAL REGISTRATION NUMBER NCT02788604 (REGISTERED WITH HTTPS://CLINICALTRIALS.GOV/CT2/SHOW/NCT02788604 ).",2020,"In general, patient-proxy total QOL improved in IG compared to CG over time but only for high psychosocial risk patients (p < .05).","['Families', 'Caregivers (N = 122) of children newly diagnosed with cancer, patients (n = 36), and siblings (n = 25) completed', 'pediatric oncology patients, caregivers and siblings after psychosocial screening', 'pediatric oncology patients', 'proxy patient QOL outcomes with high psychosocial risk near diagnosis', 'newly diagnosed patients with cancer, their caregivers and siblings, in general, and in relation to the initial family psychosocial risk', 'two Canadian pediatric cancer centers']","['intervention (IG, treating team received PAT summary describing low, medium, or high psychosocial risk) or control group (CG, no summary provided to treating team', 'psychosocial screening using a validated measure (the Psychosocial Assessment Tool, PAT']","['Patient proxy cancer-related QOL', 'quality of life (QOL', 'Quality of life', 'QOL assessments', 'patient-proxy total QOL']","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037047', 'cui_str': 'Sibling'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1518931', 'cui_str': 'Pediatric oncology'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0600420', 'cui_str': 'Proxy'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0475806', 'cui_str': '1/3 meter'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0030587', 'cui_str': 'Atrial paroxysmal tachycardia'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1455743', 'cui_str': 'Psychosocial assessment'}, {'cui': 'C0336791', 'cui_str': 'Tool'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0600420', 'cui_str': 'Proxy'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0281588', 'cui_str': 'Assessment of quality of life'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",,0.100382,"In general, patient-proxy total QOL improved in IG compared to CG over time but only for high psychosocial risk patients (p < .05).","[{'ForeName': 'Maru', 'Initials': 'M', 'LastName': 'Barrera', 'Affiliation': 'Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada. maru.barrera@sickkids.ca.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Hancock', 'Affiliation': 'Psychology Department, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8, Canada.'}, {'ForeName': 'Eshetu', 'Initials': 'E', 'LastName': 'Atenafu', 'Affiliation': 'Biostatistics Department, Princess Margaret Cancer Centre, Toronto, Canada.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Alexander', 'Affiliation': 'Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Aden', 'Initials': 'A', 'LastName': 'Solomon', 'Affiliation': 'Psychology Department, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8, Canada.'}, {'ForeName': 'Leandra', 'Initials': 'L', 'LastName': 'Desjardins', 'Affiliation': 'Psychology Department, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8, Canada.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Shama', 'Affiliation': 'Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Chung', 'Affiliation': ""Psychology Department, British Columbia Women and Children's Hospital, Vancouver, Canada.""}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Mills', 'Affiliation': 'Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-019-05160-x'] 1501,31823057,Benefits of using the Brief Pain Inventory in patients with cancer pain: an intervention study conducted in Swedish hospitals.,"PURPOSE The prevalence of cancer pain is too high. There is a need for improvement of pain management in cancer care. The aim of this study was to explore whether the use of the multidimensional pain assessment questionnaire Brief Pain Inventory (BPI) could improve pain relief in hospitalized patients with cancer. METHODS A controlled intervention study was performed at two hospitals in western Sweden, 264 patients were included, 132 formed a control group and 132 an intervention group. All participants completed the BPI and the Edmonton Symptom Assessment Scale (ESAS) at baseline. Only the researcher had access to questionnaires from the control group. The completed forms from the intervention group were presented to the patients' care team. A follow-up took place after 2-5 days when patients in both groups rated the scales a second time. RESULTS In the intervention group, significant differences in all measured items of the BPI were found at follow-up compared with baseline. Symptoms rated with the ESAS also decreased significantly, except shortness of breath. At follow-up, a significant increase in regular use of paracetamol, anti-neuropathic pain drugs and opioids was found, as well as elevated doses of fixed-schedule opioids. In the control group, differences between baseline and follow-up were significant regarding average pain and worst pain over the past 24 h. CONCLUSION Presenting the patient-reported BPI to the care team helped them to focus on patients' pain, identify pain mechanisms and adjust analgesics accordingly. A possible explanation for the results is changes in the medication prescribed.",2020,"In the control group, differences between baseline and follow-up were significant regarding average pain and worst pain over the past 24 h. CONCLUSION Presenting the patient-reported BPI to the care team helped them to focus on patients' pain, identify pain mechanisms and adjust analgesics accordingly.","['patients with cancer pain', 'two hospitals in western Sweden, 264 patients were included, 132 formed a control group and 132 an intervention group', 'hospitalized patients with cancer', 'Swedish hospitals']","['Brief Pain Inventory', 'multidimensional pain assessment questionnaire Brief Pain Inventory (BPI']","['regular use of paracetamol, anti-neuropathic pain drugs and opioids', 'pain relief', 'BPI', 'average pain and worst pain', 'except shortness of breath', 'BPI and the Edmonton Symptom Assessment Scale (ESAS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0596240', 'cui_str': 'Cancer pain'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0038996', 'cui_str': 'Swedish language'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0030198', 'cui_str': 'Pain assessment'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0027796', 'cui_str': 'Neuralgia'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C3494437', 'cui_str': 'Symptom Assessment'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",264.0,0.0362389,"In the control group, differences between baseline and follow-up were significant regarding average pain and worst pain over the past 24 h. CONCLUSION Presenting the patient-reported BPI to the care team helped them to focus on patients' pain, identify pain mechanisms and adjust analgesics accordingly.","[{'ForeName': 'Viveka', 'Initials': 'V', 'LastName': 'Andersson', 'Affiliation': 'The Sahlgrenska Academy, Institute of Health and Care Sciences, University of Gothenburg, Box 457, SE-405 30, Gothenburg, Sweden. viveka.andersson@regionhalland.se.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Bergman', 'Affiliation': 'Primary Health Care Unit, Department of Public Health and Community Medicine, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Box 457, SE-405 30, Gothenburg, Sweden.'}, {'ForeName': 'Ingela', 'Initials': 'I', 'LastName': 'Henoch', 'Affiliation': 'The Sahlgrenska Academy, Institute of Health and Care Sciences, University of Gothenburg, Box 457, SE-405 30, Gothenburg, Sweden.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Simonsson', 'Affiliation': 'Department of Surgery, Hallands Hospital Halmstad, Lasarettsvägen, 302 42, Halmstad, Sweden.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Ahlberg', 'Affiliation': 'The Sahlgrenska Academy, Institute of Health and Care Sciences, University of Gothenburg, Box 457, SE-405 30, Gothenburg, Sweden.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-019-05200-6'] 1502,32590137,Bone turnover markers in children living with HIV remaining on ritonavir-boosted lopinavir or switching to efavirenz.,"INTRODUCTION We previously found lower bone mass but similar bone turnover in pre-pubertal children living with HIV (CLWH) on a ritonavir-boosted lopinavir (LPV/r)-based vs. efavirenz-based antiretroviral therapy regimen 2 years after switch. Here, we evaluate if bone turnover differed between the groups close to the time of switch. METHODS Samples from 108 children remaining on LPV/r and 104 children switched to efavirenz were available for analysis 8 weeks post-randomization. Bone turnover markers, including C-telopeptide of type 1 collagen (CTx), procollagen type-I N-terminal propeptide (P1NP), and osteocalcin were measured. Markers of immune activation were also measured, including IL-6, TNF-alpha, soluble CD14 and high-sensitivity C-reactive protein (CRP). RESULTS Eight weeks post-randomization, we did not detect differences in CTx (1.42 vs. 1.44 ng/mL, p = 0.85) or P1NP concentrations (622 vs. 513 ng/mL, p = 0.68) between treatment groups. At 8 weeks, the treatment groups also had similar levels of IL-6, TNF-alpha, soluble CD14 and high-sensitivity CRP. Osteocalcin (ng/mL) was higher in the LPV/r than efavirenz group both at 8 weeks (88.6 vs. 67.3, p = 0.001) and 2 years (67.6 vs. 49.8, p = 0.001). CONCLUSIONS Overall, we failed to detect difference in bone turnover by P1NP and CTx in virologically-suppressed CLWH on different regimens at a time point close to the switch. We did observe higher levels of total osteocalcin in children remaining on LPV/r compared to children switched to efavirenz. Future studies should focus on uncovering the mechanism and determining whether perturbation in undercarboxylated osteocalcin could explain some of the bone side effects noted with protease inhibitors.",2020,"At 8 weeks, the treatment groups also had similar levels of IL-6, TNF-alpha, soluble CD14 and high-sensitivity CRP.","['children living with HIV remaining on ritonavir-boosted lopinavir or switching to', 'Samples from 108 children remaining on LPV/r and 104 children switched to', 'pre-pubertal children living with HIV (CLWH) on a']","['efavirenz', 'ritonavir-boosted lopinavir (LPV/r)-based vs. efavirenz-based antiretroviral therapy']","['IL-6, TNF-alpha, soluble CD14 and high-sensitivity C-reactive protein (CRP', 'Bone turnover markers, including C-telopeptide of type 1 collagen (CTx), procollagen type-I N-terminal propeptide (P1NP), and osteocalcin', 'levels of IL-6, TNF-alpha, soluble CD14 and high-sensitivity CRP', 'Osteocalcin', 'bone turnover by P1NP and CTx', 'total osteocalcin', 'CTx', 'Bone turnover markers', 'bone turnover', 'P1NP concentrations', 'Markers of immune activation']","[{'cui': 'C0553288', 'cui_str': 'Lives with children'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0674432', 'cui_str': 'lopinavir'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C1628325', 'cui_str': 'Pre-pubertal'}]","[{'cui': 'C0674428', 'cui_str': 'efavirenz'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0674432', 'cui_str': 'lopinavir'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}]","[{'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1448177', 'cui_str': 'TNF protein, human'}, {'cui': 'C0108768', 'cui_str': 'Lymphocyte antigen CD14'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0085268', 'cui_str': 'Bone remodeling'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0631180', 'cui_str': 'C-telopeptide'}, {'cui': 'C0041455', 'cui_str': 'Collagen Type I'}, {'cui': 'C0041457', 'cui_str': 'Type I Procollagen'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0029419', 'cui_str': 'Osteocalcin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0072053', 'cui_str': 'Procollagen peptide, type 1 N-terminal'}, {'cui': 'C0010377', 'cui_str': 'Crotoxin'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439662', 'cui_str': 'Immune'}]",,0.0664262,"At 8 weeks, the treatment groups also had similar levels of IL-6, TNF-alpha, soluble CD14 and high-sensitivity CRP.","[{'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Shiau', 'Affiliation': 'Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA.'}, {'ForeName': 'Michael T', 'Initials': 'MT', 'LastName': 'Yin', 'Affiliation': 'Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.'}, {'ForeName': 'Renate', 'Initials': 'R', 'LastName': 'Strehlau', 'Affiliation': 'Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Department of Pediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Shen', 'Affiliation': 'Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA.'}, {'ForeName': 'Elaine J', 'Initials': 'EJ', 'LastName': 'Abrams', 'Affiliation': 'Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA; Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY, USA; ICAP at Columbia, Mailman School of Public Health, Columbia University, New York, NY, USA.'}, {'ForeName': 'Ashraf', 'Initials': 'A', 'LastName': 'Coovadia', 'Affiliation': 'Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Department of Pediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Kuhn', 'Affiliation': 'Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.'}, {'ForeName': 'Stephen M', 'Initials': 'SM', 'LastName': 'Arpadi', 'Affiliation': 'Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA; Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY, USA; ICAP at Columbia, Mailman School of Public Health, Columbia University, New York, NY, USA. Electronic address: sma2@columbia.edu.'}]",Bone,['10.1016/j.bone.2020.115500'] 1503,32590151,Cryoballoon ablation of pulmonary veins for persistent atrial fibrillation: Results from the multicenter STOP Persistent AF trial.,"BACKGROUND Pulmonary vein isolation (PVI) is the cornerstone of catheter ablation to treat patients with symptomatic drug-refractory atrial fibrillation (AF). OBJECTIVE The purpose of this study was to assess the safety and efficacy of PVI using the cryoballoon catheter to treat patients with persistent AF. METHODS STOP Persistent AF (ClinicalTrials.gov Identifier: NCT03012841) was a prospective, multicenter, single-arm, Food and Drug Administration-regulated trial designed to evaluate the safety and efficacy of PVI-only cryoballoon ablation for drug-refractory persistent AF (continuous episodes <6 months). The primary efficacy endpoint was 12-month freedom from ≥30 seconds of AF, atrial flutter (AFL), or atrial tachycardia (AT) after a 90-day blanking period. The prespecified performance goals were set at >40% and <13% for the primary efficacy and safety endpoints, respectively. Secondary endpoints assessed quality of life using the AFEQT (Atrial Fibrillation Effect on Quality of Life) and SF (Short Form)-12 questionnaires. RESULTS Of 186 total enrollments, 165 subjects (70% male; age 65 ± 9 years; left atrial diameter 4.2 ± 0.6 cm; body mass index 31 ± 6) were treated at 25 sites in the United States, Canada, and Japan. Total procedural, left atrial dwell, and fluoroscopy times were 121 ± 46 minutes, 102 ± 41 minutes, and 19 ± 16 minutes, respectively. At 12 months, the primary efficacy endpoint was 54.8% (95% confidence [CI] 46.7%-62.1%) freedom from AF, AFL, or AT. There was 1 primary safety event, translating to a rate of 0.6% (95% CI 0.1%-4.4%). AFEQT and SF-12 assessments demonstrated significant improvements from baseline to 12 months postablation (P <.001). CONCLUSION The STOP Persistent AF trial demonstrated cryoballoon ablation to be safe and effective in treating patients with drug-refractory persistent AF characterized by continuous AF episodes <6 months.",2020,"AFEQT and SF-12 assessments demonstrated significant improvements from baseline to 12 months post ablation (P<0.001). ","['Persistent Atrial Fibrillation', 'patients with symptomatic drug-refractory atrial fibrillation (AF', 'Of 186 total enrollments, 165 subjects (70% male, 65±9 years, left atrial diameter 4.2±0.6 cm, body mass index 31±6) were treated at 25 sites in the United States, Canada, and Japan']","['Cryoballoon Ablation of Pulmonary Veins', 'Pulmonary vein isolation (PVI', 'PVI-only cryoballoon ablation for drug-refractory persistent AF', 'PVI']","['Total procedure, left atrial dwell, and fluoroscopy times', 'safety and efficacy', 'quality of life using the AFEQT and SF-12 questionnaires', '12-month freedom from ≥30 sec of AF, atrial flutter (AFL), or atrial tachycardia (AT']","[{'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018792', 'cui_str': 'Atrial structure'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0034090', 'cui_str': 'Structure of vein of pulmonary circulation'}, {'cui': 'C3544330', 'cui_str': 'Pulmonary vein isolation'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018792', 'cui_str': 'Atrial structure'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0059387', 'cui_str': 'staphylococcal enterotoxin C'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0004239', 'cui_str': 'Atrial flutter'}, {'cui': 'C0030587', 'cui_str': 'Atrial paroxysmal tachycardia'}]",,0.0320406,"AFEQT and SF-12 assessments demonstrated significant improvements from baseline to 12 months post ablation (P<0.001). ","[{'ForeName': 'Wilber W', 'Initials': 'WW', 'LastName': 'Su', 'Affiliation': 'Banner University Medical Center Phoenix, Phoenix, Arizona.'}, {'ForeName': 'Vivek Y', 'Initials': 'VY', 'LastName': 'Reddy', 'Affiliation': 'Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Kabir', 'Initials': 'K', 'LastName': 'Bhasin', 'Affiliation': 'Northwell Health-Lenox Hill Heart and Lung, New York, New York.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Champagne', 'Affiliation': 'Institut Universitaire de Cardiologie et du Pneumologie de Quebec, Quebec, Canada.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Sangrigoli', 'Affiliation': 'Doylestown Cardiology Associates, Doylestown, Pennsylvania.'}, {'ForeName': 'Kendra M', 'Initials': 'KM', 'LastName': 'Braegelmann', 'Affiliation': 'Medtronic, Inc., Minneapolis, Minnesota.'}, {'ForeName': 'Fred J', 'Initials': 'FJ', 'LastName': 'Kueffer', 'Affiliation': 'Medtronic, Inc., Minneapolis, Minnesota.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Novak', 'Affiliation': 'Royal Jubilee Hospital, Victoria, Canada.'}, {'ForeName': 'Sanjaya K', 'Initials': 'SK', 'LastName': 'Gupta', 'Affiliation': ""Saint Luke's Health System, Kansas City, Missouri.""}, {'ForeName': 'Teiichi', 'Initials': 'T', 'LastName': 'Yamane', 'Affiliation': 'Jikei University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hugh', 'Initials': 'H', 'LastName': 'Calkins', 'Affiliation': 'Johns Hopkins Medical Institutions, Baltimore, Maryland. Electronic address: hcalkins@jhmi.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Heart rhythm,['10.1016/j.hrthm.2020.06.020'] 1504,32590214,Perceived social support and posttraumatic stress symptoms in children and youth in therapy: A parallel process latent growth curve model.,"Many studies show that perceived social support protects against the development of posttraumatic stress symptoms (PTSS) in the aftermath of trauma, but less is known about support in relation to PTSS in trauma therapy. This study examined associations between perceived social support and PTSS in children and adolescents during trauma therapy. Parallel process latent growth curve modeling was used to examine trajectories of perceived social support and PTSS over five measurement waves in a sample of 156 patients, aged between 10 and 18 years (M age = 15.1, SD = 2.2, 79.5% girls), randomized to receive trauma-focused cognitive behavior therapy (TF-CBT) or therapy-as-usual (TAU). Across all participants there was an average decline in PTSS and increase of perceived social support from pre-therapy to 18 months after therapy. Most of the change occurred during therapy and was maintained after therapy. Higher levels of PTSS prior to therapy were associated with lower levels of perceived social support prior to therapy, and a decrease in PTSS was associated with increase in perceived social support. This co-development may have been directed by a third underlying factor or short-term temporal effects. Studies investigating within-person associations over shorter time intervals will benefit our understanding of possible temporal effects.",2020,Across all participants there was an average decline in PTSS and increase of perceived social support from pre-therapy to 18 months after therapy.,"['children and adolescents during trauma therapy', '156 patients, aged between 10 and 18 years (M age\xa0=\xa015.1, SD\xa0=\xa02.2, 79.5% girls', 'children and youth in therapy']",['trauma-focused cognitive behavior therapy (TF-CBT) or therapy-as-usual (TAU'],"['Perceived social support and posttraumatic stress symptoms', 'PTSS', 'perceived social support']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1320387', 'cui_str': 'Trauma therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517629', 'cui_str': '2.2'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}]",156.0,0.02545,Across all participants there was an average decline in PTSS and increase of perceived social support from pre-therapy to 18 months after therapy.,"[{'ForeName': 'Marianne S', 'Initials': 'MS', 'LastName': 'Birkeland', 'Affiliation': 'Norwegian Centre for Violence and Traumatic Stress Studies, Norway. Electronic address: Marianne.s.birkeland@gmail.com.'}, {'ForeName': 'Tonje', 'Initials': 'T', 'LastName': 'Holt', 'Affiliation': 'Division of Mental & Physical Health, Norwegian Institute of Public Health, Norway.'}, {'ForeName': 'Silje M', 'Initials': 'SM', 'LastName': 'Ormhaug', 'Affiliation': 'Norwegian Centre for Violence and Traumatic Stress Studies, Norway.'}, {'ForeName': 'Tine K', 'Initials': 'TK', 'LastName': 'Jensen', 'Affiliation': 'Norwegian Centre for Violence and Traumatic Stress Studies, Norway; Department of Psychology, University of Oslo, Norway.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103655'] 1505,32592694,Delivery of monochorionic twins: lessons learned from the Twin Birth Study.,"BACKGROUND The current literature regarding the recommended mode of delivery of monochorionic-diamniotic twins is limited to small numbers, retrospective studies, and comparisons of outcomes of monochorionic-diamniotic twin pregnancies with those of dichorionic-diamniotic twin pregnancies instead of outcomes of trial of labor vs elective cesarean delivery of monochorionic-diamniotic twins. OBJECTIVE This study aimed to compare perinatal and maternal outcomes of planned cesarean delivery and planned vaginal delivery of monochorionic-diamniotic twins using the Twin Birth Study data. STUDY DESIGN This study is a secondary analysis of the Twin Birth Study. Women were randomized from 32 weeks and 0 days gestation to 38 weeks and 6 days gestation to planned cesarean delivery or planned vaginal delivery. Twin A in the cephalic presentation and estimated weight of each twin between 1500 and 4000 grams were the inclusion criteria. Pregnancies complicated by fetal reduction after 13 weeks of gestation, lethal fetal anomaly, or contraindication to vaginal delivery were excluded. Elective delivery was planned between 37 weeks and 5 to 7 days of gestation and 38 weeks and 6 to 7 days of gestation. Perinatal and maternal outcomes of monochorionic-diamniotic twin pregnancies were compared between those randomized for planned cesarean delivery and those randomized for planned vaginal delivery. In addition, outcomes of monochorionic-diamniotic twin pregnancies were compared with those of dichorionic-diamniotic twin pregnancies. RESULTS Out of the 1393 women in each arm, 346 (24.9%) women in the planned cesarean delivery arm and 324 (23.3%) women in the planned vaginal delivery arm had monochorionic-diamniotic twin pregnancies and were eligible for the first analysis. The rate of cesarean delivery was 39.2% in the planned vaginal delivery arm and was 91.3% in the planned cesarean delivery arm. There was no significant difference in gestational age at delivery between the groups (34.4±1.8 weeks vs 34.5±1.8 weeks; P=.78). No difference was found in maternal outcomes. As for perinatal outcomes, the rate of the primary adverse neonatal composite outcomes in twins A or twins B was similar in both the planned vaginal delivery and the planned cesarean delivery arms (twins A, 1.2% vs 1.2% [P=.92]; twins B, 1.2% vs 3.2% [P=.09]). Within the planned cesarean delivery arm, the rate of primary adverse neonatal composite outcome was higher in twins B than twins A (3.2% vs 1.2%; P=.03). There was no difference in the primary adverse neonatal composite outcome between twins A in the monochorionic-diamniotic group and the dichorionic-diamniotic group (1.2% vs 1.3%; P=.89) or between twins B in similar groups (2.3% vs 2.7%; P=.47). CONCLUSION In monochorionic-diamniotic twin pregnancy between 32 weeks and 0 to 7 days of gestation and 38 weeks and 6 to 7 days of gestation, with twin A in a cephalic presentation, planned cesarean delivery did not decrease or increase the risk of fetal or neonatal death or serious neonatal morbidity, as compared with planned vaginal delivery.",2020,"There was no difference in the primary adverse neonatal composite outcome between twins A in the MCDA group and the DCDA group (1.2% vs. 1.3%, P=0.89), nor between twins B (2.3% vs. 2.7%, P=0.47). ","['Inclusion criteria were twin A in the cephalic presentation, and estimated weight of each twin between 1500-4000 grams', 'MCDA twin pregnancies using the Twin Birth Study data', 'Out of the 1,393 women in each arm, 346 (24.9%) women in the planned CS arm and 324 (23.3', 'women in the planned VD arm had MCDA twins and were eligible for the first analysis']","['planned-cesarean delivery and planned-vaginal delivery', 'DCDA', 'MCDA', 'gestation to planned cesarean section (CS) or planned vaginal delivery (VD']","['gestational age at delivery', 'primary adverse neonatal composite outcome', 'risk of fetal or neonatal death or serious neonatal morbidity', 'rate of CS', 'lethal fetal anomaly or contraindication vaginal delivery', 'maternal outcomes', 'rate of primary adverse neonatal composite outcome', 'rate of the primary adverse neonatal composite outcome in twins A or twin B']","[{'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0041427', 'cui_str': 'Twin sibling'}, {'cui': 'C0205096', 'cui_str': 'Cephalic'}, {'cui': 'C0449450', 'cui_str': 'Presentation'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C4517582', 'cui_str': '1500'}, {'cui': 'C3842327', 'cui_str': '4000'}, {'cui': 'C0439208', 'cui_str': 'g'}, {'cui': 'C2977401', 'cui_str': 'Monochorionic diamniotic twin pregnancy'}, {'cui': 'C0233365', 'cui_str': 'Twin birth'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C4517713', 'cui_str': '324'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0015965', 'cui_str': 'Fetuses'}, {'cui': 'C0410916', 'cui_str': 'Newborn death'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to'}, {'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0041427', 'cui_str': 'Twin sibling'}]",,0.227474,"There was no difference in the primary adverse neonatal composite outcome between twins A in the MCDA group and the DCDA group (1.2% vs. 1.3%, P=0.89), nor between twins B (2.3% vs. 2.7%, P=0.47). ","[{'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Aviram', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. Electronic address: amiraviram25@gmail.com.'}, {'ForeName': 'Hayley', 'Initials': 'H', 'LastName': 'Lipworth', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Elizabeth V', 'Initials': 'EV', 'LastName': 'Asztalos', 'Affiliation': 'Department of Newborn and Developmental Paediatrics, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Elad', 'Initials': 'E', 'LastName': 'Mei-Dan', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Department of Obstetrics and Gynecology, North York General Hospital, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Nir', 'Initials': 'N', 'LastName': 'Melamed', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Xingshan', 'Initials': 'X', 'LastName': 'Cao', 'Affiliation': 'Research Design and Biostatistics, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Arthur', 'Initials': 'A', 'LastName': 'Zaltz', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Lone', 'Initials': 'L', 'LastName': 'Hvidman', 'Affiliation': 'Department of Obstetrics and Gynecology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Jon F R', 'Initials': 'JFR', 'LastName': 'Barrett', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.06.048'] 1506,32618267,"Adherence to Mass Drug Administration with Dihydroartemisinin-Piperaquine and Plasmodium falciparum Clearance in Southern Province, Zambia.","Mass drug administration (MDA) with artemisinin combination therapy is a potentially useful tool for malaria elimination programs, but its success depends partly on drug effectiveness and treatment coverage in the targeted population. As part of a cluster-randomized controlled trial in Southern Province, Zambia evaluating the impact of MDA and household focal MDA (fMDA) with dihydroartemisinin-piperaquine (DHAp), sub-studies were conducted investigating population drug adherence rates and effectiveness of DHAp as administered in clearing Plasmodium falciparum infections following household mass administration. Adherence information was reported for 181,534 of 336,821 DHAp (53.9%) treatments administered during four rounds of MDA/fMDA, of which 153,197 (84.4%) reported completing the full course of DHAp. The proportion of participants fully adhering to the treatment regimen differed by MDA modality (MDA versus fMDA), RDT status, and whether the first dose was observed by those administering treatments. Among a subset of participants receiving DHAp and selected for longitudinal follow-up, 58 were positive for asexual-stage P. falciparum infection by microscopy at baseline. None of the 45 participants followed up at days 3 and/or 7 were slide positive for asexual-stage parasitemia. For those with longer term follow-up, one participant was positive 47 days after treatment, and two additional participants were positive after 69 days, although these two were determined to be new infections by genotyping. High completion of a 3-day course of DHAp and parasite clearance in the context of household MDA are promising as Zambia's National Malaria Programme continues to weigh appropriate interventions for malaria elimination.",2020,None of the 45 participants followed up at days 3 and/or 7 were slide positive for asexual-stage parasitemia.,"['Southern Province, Zambia evaluating the impact of MDA and household focal MDA (fMDA) with', 'Southern Province, Zambia']","['Dihydroartemisinin-Piperaquine', 'DHAp', 'artemisinin combination therapy', 'dihydroartemisinin-piperaquine (DHAp']","['Adherence information', 'MDA modality (MDA versus fMDA), RDT status', 'slide positive for asexual-stage parasitemia']","[{'cui': 'C0043445', 'cui_str': 'Zambia'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C4505223', 'cui_str': 'Mass Administration'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0000379', 'cui_str': 'Methylenedioxyamphetamine'}]","[{'cui': 'C0058108', 'cui_str': 'dihydroartemisinin'}, {'cui': 'C0071105', 'cui_str': 'piperaquine'}, {'cui': 'C0052430', 'cui_str': 'artemisinin'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C4505223', 'cui_str': 'Mass Administration'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0000379', 'cui_str': 'Methylenedioxyamphetamine'}, {'cui': 'C0206743', 'cui_str': 'Malignant rhabdoid tumor'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0332246', 'cui_str': 'Sliding'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0242723', 'cui_str': 'Parasitemia'}]",,0.179382,None of the 45 participants followed up at days 3 and/or 7 were slide positive for asexual-stage parasitemia.,"[{'ForeName': 'Timothy P', 'Initials': 'TP', 'LastName': 'Finn', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Travis R', 'Initials': 'TR', 'LastName': 'Porter', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Hawela', 'Initials': 'H', 'LastName': 'Moonga', 'Affiliation': 'National Malaria Elimination Centre, Zambia Ministry of Health, Chainama Hospital Grounds, Lusaka, Zambia.'}, {'ForeName': 'Kafula', 'Initials': 'K', 'LastName': 'Silumbe', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Rachel F', 'Initials': 'RF', 'LastName': 'Daniels', 'Affiliation': 'The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.'}, {'ForeName': 'Sarah K', 'Initials': 'SK', 'LastName': 'Volkman', 'Affiliation': 'Simmons University, Boston, Massachusetts.'}, {'ForeName': 'Joshua O', 'Initials': 'JO', 'LastName': 'Yukich', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Keating', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Bennett', 'Affiliation': 'Malaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Richard W', 'Initials': 'RW', 'LastName': 'Steketee', 'Affiliation': 'PATH MACEPA, Seattle, Washington.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Miller', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Thomas P', 'Initials': 'TP', 'LastName': 'Eisele', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.19-0667'] 1507,32618386,Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial.,"AIM To assess cardiorenal outcomes by baseline urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) in the contemporary LEADER cohort. MATERIALS AND METHODS LEADER was a multinational, double-blind trial. Patients with type 2 diabetes and high cardiovascular (CV) risk were randomized 1:1 to the glucagon-like peptide-1 analogue liraglutide (≤1.8 mg daily; n = 4668) or placebo (n = 4672) plus standard care and followed for 3.5 to 5 years. Primary composite outcomes were time to first non-fatal myocardial infarction, non-fatal stroke or CV death. Post hoc Cox regression analyses of outcomes by baseline UACR and eGFR subgroups were conducted with adjustment for baseline variables. RESULTS In the LEADER population, 1598 (17.5%), 2917 (31.9%), 1200 (13.1%), 1611 (17.6%), 845 (9.2%) and 966 (10.6%) had UACR = 0, >0 to <15, 15 to <30, 30 to <100, 100 to <300 and ≥300 mg/g, respectively. Increasing UACR and decreasing eGFR were linked with higher risks of the primary outcome, heart failure hospitalization, a composite renal outcome and death (P-values for the Cochran-Armitage test for trends were all <.0001). Across UACR and eGFR subgroups, risks of cardiorenal events and death were generally lower or similar with liraglutide versus placebo. CONCLUSIONS In a contemporary type 2 diabetes population, increasing baseline UACR and declining eGFR were linked with higher risks of cardiorenal events and death.",2020,"Across UACR and eGFR subgroups, risks of cardiorenal events and death were generally lower or similar with liraglutide versus placebo. ",['Patients with T2D and high cardiovascular (CV) risk'],"['glucagon-like peptide-1 analog liraglutide', 'liraglutide', 'placebo']","['UACR', 'Primary composite outcome: time to first non-fatal myocardial infarction, non-fatal stroke or CV death', 'Cardiovascular and renal outcomes', 'heart failure hospitalization, a composite renal outcome and death', 'urinary albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR) and outcomes', 'risks of cardiorenal events and death']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}]","[{'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C1456408', 'cui_str': 'liraglutide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",,0.413189,"Across UACR and eGFR subgroups, risks of cardiorenal events and death were generally lower or similar with liraglutide versus placebo. ","[{'ForeName': 'Ofri', 'Initials': 'O', 'LastName': 'Mosenzon', 'Affiliation': 'Diabetes Unit, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.'}, {'ForeName': 'Stephen C', 'Initials': 'SC', 'LastName': 'Bain', 'Affiliation': 'Diabetes Research Unit Cymru, Swansea University, Swansea, UK.'}, {'ForeName': 'Hiddo J L', 'Initials': 'HJL', 'LastName': 'Heerspink', 'Affiliation': 'Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Idorn', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Johannes F E', 'Initials': 'JFE', 'LastName': 'Mann', 'Affiliation': 'Department of Nephrology, University Hospital, Friedrich Alexander University of Erlangen, Erlangen, Germany.'}, {'ForeName': 'Frederik', 'Initials': 'F', 'LastName': 'Persson', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Pratley', 'Affiliation': 'AdventHealth Translational Research Institute, Orlando, Florida, USA.'}, {'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Rasmussen', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Rossing', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Bernt Johan', 'Initials': 'BJ', 'LastName': 'von Scholten', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Itamar', 'Initials': 'I', 'LastName': 'Raz', 'Affiliation': 'Diabetes Unit, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Diabetes, obesity & metabolism",['10.1111/dom.14126'] 1508,32618395,Video conference vs face-to-face group psychotherapy for distressed cancer survivors: A randomized controlled trial.,"OBJECTIVE This study assesses the effectiveness of face-to-face group positive psychotherapy for cancer survivors (PPC) compared to its online adaptation, online group positive psychotherapy for cancer survivors (OPPC), which is held via videoconference. A two-arm, pragmatic randomized controlled trial was conducted to examine the effects of both interventions on emotional distress, post-traumatic stress symptoms (PTSS), and post-traumatic growth (PTG) among cancer survivors and analyze attrition to treatment. METHODS Adult women with a range of cancer diagnoses were invited to participate if they experienced emotional distress at the end of their primary oncological treatment. Emotional distress, PTSS, and PTG were assessed at baseline, immediately after treatment, and 3 months after treatment. Intention-to-treat analyses were carried out using general linear mixed models to test the effect of the interventions overtime. Logistic regressions were performed to test differential adherence to treatment and retention to follow-up. RESULTS A total of 269 individuals participated. The observed treatment effect was significant in both modalities, PPC and OPPC. Emotional distress (b = -2.24, 95% confidence interval [CI] = -3.15 to -1.33) and PTSS (b = -3.25, 95% CI = -4.97 to -1.53) decreased significantly over time, and PTG (b = 3.08, 95% CI = 0.38-5.78) increased significantly. Treatment gains were sustained across outcomes and over time. Analyses revealed no significant differences between modalities of treatment, after adjusting for baseline differences, finding that OPPC is as effective and engaging as PPC. CONCLUSIONS The OPPC treatment was found to be effective and engaging for female cancer early survivors. These results open the door for psycho-oncology interventions via videoconference, which are likely to lead to greater accessibility and availability of psychotherapy.",2020,"Analyses revealed no significant differences between modalities of treatment, after adjusting for baseline differences, finding that OPPC is as effective and engaging as PPC. ","['female cancer early survivors', 'Adult women with a range of cancer diagnoses were invited to participate if they experienced emotional distress at the end of their primary oncological treatment', '269 individuals participated', 'cancer survivors (PPC', 'Distressed Cancer Survivors', 'cancer survivors (OPPC']","['OPPC', 'Video Conference vs Face-to-Face Group Psychotherapy', 'face-to-face group positive psychotherapy', 'PTSS']","['Emotional distress, PTSS and PTG', 'emotional distress, posttraumatic stress (PTSS) and posttraumatic growth (PTG', 'Emotional distress', 'time, and PTG']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0700361', 'cui_str': 'Emotional distress'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C3887804', 'cui_str': 'Feeling upset'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0086047', 'cui_str': 'Conferences'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0033971', 'cui_str': 'Group psychotherapy'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]","[{'cui': 'C0700361', 'cui_str': 'Emotional distress'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C4704809', 'cui_str': 'Posttraumatic Growth'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",269.0,0.121219,"Analyses revealed no significant differences between modalities of treatment, after adjusting for baseline differences, finding that OPPC is as effective and engaging as PPC. ","[{'ForeName': 'María', 'Initials': 'M', 'LastName': 'Lleras de Frutos', 'Affiliation': ""Psycho-Oncology Department and ICOnnecta't e-Health Program, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Joan Carles', 'Initials': 'JC', 'LastName': 'Medina', 'Affiliation': ""Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Jaume', 'Initials': 'J', 'LastName': 'Vives', 'Affiliation': 'Department of Psychobiology and Methodology of Health Sciences and Sport Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Casellas-Grau', 'Affiliation': ""Psychosocial Observatory in Cancer, Institut Català d'Oncologia. L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Jose Luis', 'Initials': 'JL', 'LastName': 'Marzo', 'Affiliation': 'Universitat de Girona, Girona, Spain.'}, {'ForeName': 'Josep M', 'Initials': 'JM', 'LastName': 'Borràs', 'Affiliation': ""Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Ochoa-Arnedo', 'Affiliation': ""Psycho-Oncology Department and ICOnnecta't e-Health Program, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.""}]",Psycho-oncology,['10.1002/pon.5457'] 1509,32618884,Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.,"BACKGROUND The sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin reduced cardiovascular death or heart failure hospitalizations in type 2 diabetes (T2D) in addition to a reduction of SBP. As heart failure patients often present with low SBP, which can challenge treatment initiation, we explored if empagliflozin's effect on SBP was independent of baseline SBP and heart failure status, and if the effect on cardiovascular and heart failure outcomes was influenced by updated mean SBP or by an early change in SBP after drug initiation. METHODS AND RESULTS A total of 7020 patients were treated with empagliflozin 10 mg, 25 mg or placebo and followed for a median of 3.1 years. All of them had BP measurement at baseline. We evaluated changes in SBP in the context of heart failure status at baseline and according to baseline SBP categories (<120, 120--<130, 130--<140, 140--<160, ≥160 mmHg). The updated mean SBP during the trial was calculated as a time-dependent variable. We then assessed the association of baseline and updated mean SBP with three-point major adverse cardiovascular events (3P-MACE), hospitalization for heart failure, cardiovascular death, hospitalization for heart failure or cardiovascular death, all-cause death, and incident/worsening nephropathy, and whether treatment effect of empagliflozin vs. placebo on these outcomes differed if adjusted for updated mean SBP. Finally, we evaluated the impact of early decline in SBP (≥5 mmHg at week 4) on the treatment effect of empagliflozin vs. placebo on these outcomes. Analyses were performed via Cox regression adjusting for baseline risk factors including a term for treatment subgroup interaction, and by landmark analyses starting at week 4. The difference in SBP reduction at week 12 between empagliflozin and placebo was 3--5 mmHg and similar regardless of baseline SBP category or HF status at baseline. Baseline SBP and updated mean SBP categories showed no association with cardiovascular outcomes, but was associated with new/worsening nephropathy. The treatment effects of empagliflozin on all explored outcomes were independent of updated mean SBP as well of the early drop in SBP on treatment. CONCLUSION In addition to decreasing SBP, empagliflozin reduced cardiovascular, heart failure and renal outcomes independently of updated mean SBP during the trial, and of the early SBP drop. These results suggest a BP-independent effect of empagliflozin on cardiovascular and heart failure outcomes. CLINICALTRIALS. GOV IDENTIFIER NCT01131676.",2020,"In addition to decreasing SBP, empagliflozin reduced cardiovascular, heart failure and renal outcomes independently of updated mean SBP during the trial, and of the early SBP drop.","['7020 patients', 'patients with type 2 diabetes']","['empagliflozin', 'empagliflozin vs. placebo', 'sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin', 'empagliflozin 10\u200amg, 25\u200amg or placebo', 'placebo']","['Heart failure and renal outcomes', 'SBP, empagliflozin reduced cardiovascular, heart failure and renal outcomes', 'blood pressure', 'cardiovascular and heart failure outcomes', 'cardiovascular death or heart failure hospitalizations', 'adverse cardiovascular events (3P-MACE), hospitalization for heart failure, cardiovascular death, hospitalization for heart failure or cardiovascular death, all-cause death, and incident/worsening nephropathy', 'SBP reduction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0598849', 'cui_str': 'Co-Transporters'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C3848773', 'cui_str': 'empagliflozin 10 MG [Jardiance]'}]","[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0286421', 'cui_str': 'ACE protocol 2'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",7020.0,0.0734859,"In addition to decreasing SBP, empagliflozin reduced cardiovascular, heart failure and renal outcomes independently of updated mean SBP during the trial, and of the early SBP drop.","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Böhm', 'Affiliation': 'Klinik für Innere Medizin III, Saarland University Medical Center, Homburg/Saar, Germany.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Fitchett', 'Affiliation': ""St. Michael's Hospital, Division of Cardiology, University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'Anne Pernille', 'Initials': 'AP', 'LastName': 'Ofstad', 'Affiliation': 'Medical Department, Boehringer Ingelheim Ks, Asker, Norway.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Brueckmann', 'Affiliation': 'Boehringer Ingelheim International GmbH & Co KG, Ingelheim.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Kaspers', 'Affiliation': 'Boehringer Ingelheim International GmbH & Co KG, Ingelheim.'}, {'ForeName': 'Jyothis T', 'Initials': 'JT', 'LastName': 'George', 'Affiliation': 'Boehringer Ingelheim International GmbH & Co KG, Ingelheim.'}, {'ForeName': 'Isabella', 'Initials': 'I', 'LastName': 'Zwiener', 'Affiliation': 'Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Zinman', 'Affiliation': 'Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Wanner', 'Affiliation': 'Department of Medicine, Wuerzburg University Clinic, Wuerzburg.'}, {'ForeName': 'Nikolaus', 'Initials': 'N', 'LastName': 'Marx', 'Affiliation': 'Department of Internal Medicine I, Cardiology, University Hospital Aachen, RWTH Aachen University Aachen, Germany.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Mancia', 'Affiliation': 'Clinica Medica, University of Milano-Bicocca, Ospedale San Gerardo, Monza, Italy.'}, {'ForeName': 'Stefan D', 'Initials': 'SD', 'LastName': 'Anker', 'Affiliation': 'Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies (BCRT).'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Mahfoud', 'Affiliation': 'Klinik für Innere Medizin III, Saarland University Medical Center, Homburg/Saar, Germany.'}]",Journal of hypertension,['10.1097/HJH.0000000000002492'] 1510,32619458,"Acute psychological stress, autonomic function, and arterial stiffness among women.","This study aimed to investigate the effect of acute psychological stress on autonomic function and arterial stiffness, and to test a mediating role of changes in autonomic function between acute stress and arterial stiffness. Eighty-five healthy female adults were randomized into either an experimental or control group. The Trier Social Stress Test (TSST) was used to induce acute psychological stress. Autonomic function (measured by pre-ejection period [PEP] from cardiac impedance and high frequency [HF] of heart rate variability [HRV]) and arterial stiffness (measured by carotid and femoral pulse wave velocity [cfPWV] and augmentation index [AIx]) were assessed before and after the TSST. The mean age of the participants was 28.78 (±9.84) years old. Experimental group participants had a significant increase in cfPWV (p = .025) and AIx (p = .017) following the stressor, compared with those in the control group, after controlling for age, body mass index, and systolic blood pressure. However, no significant group differences were observed in changes in PEP (p = .181) and HF (p = .058). Changes in PEP and HF were neither associated with changes in cfPWV (p = .975 and p = .654, respectively), nor in AIx (p = .376 and p = .323, respectively). The results suggest that even a brief period of mild to moderate stress, which does not cause sustainable changes in autonomic function, may still exert significant adverse effects on arterial stiffness. The changes in arterial stiffness were not related to changes in autonomic function. Future experimental studies with several measurement points are recommended to identify distinct effects of stress on autonomic function and arterial stiffness.",2020,"Experimental group participants had a significant increase in cfPWV (p = .025) and AIx (p = .017) following the stressor, compared with those in the control group, after controlling for age, body mass index, and systolic blood pressure.","['The mean age of the participants was 28.78 (±9.84) years old', 'Eighty-five healthy female adults', 'women']",['Trier Social Stress Test (TSST'],"['heart rate variability [HRV]) and arterial stiffness (measured by carotid and femoral pulse wave velocity [cfPWV] and augmentation index [AIx', 'cfPWV', 'Autonomic function', 'Acute psychological stress, autonomic function, and arterial stiffness', 'arterial stiffness', 'autonomic function and arterial stiffness', 'systolic blood pressure', 'autonomic function', 'changes in PEP']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4517892', 'cui_str': '85'}, {'cui': 'C0686752', 'cui_str': 'Well female adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0065404', 'cui_str': 'lysyl-5-fluorotryptophyl-lysine'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0232148', 'cui_str': 'Femoral pulse'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0999177', 'cui_str': 'Aix'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0038443', 'cui_str': 'Psychological Stress'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0031642', 'cui_str': 'Phosphoenolpyruvate'}]",85.0,0.0168326,"Experimental group participants had a significant increase in cfPWV (p = .025) and AIx (p = .017) following the stressor, compared with those in the control group, after controlling for age, body mass index, and systolic blood pressure.","[{'ForeName': 'Jeongok G', 'Initials': 'JG', 'LastName': 'Logan', 'Affiliation': 'University of Virginia, School of Nursing, McLeod Hall 4011, 225 Jeanette Lancaster Way, Charlottesville, VA 22903, United States. Electronic address: jl3zj@virginia.edu.'}, {'ForeName': 'Bethany A', 'Initials': 'BA', 'LastName': 'Teachman', 'Affiliation': 'University of Virginia, Department of Psychology, 207 Gilmer Hall, Charlottesville, VA 22903, United States. Electronic address: bat5x@virginia.edu.'}, {'ForeName': 'Xiaoyue', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'University of Virginia, School of Nursing, McLeod Hall 4034, 225 Jeanette Lancaster Way, Charlottesville, VA 22903, United States. Electronic address: xl5tb@virginia.edu.'}, {'ForeName': 'Charles R', 'Initials': 'CR', 'LastName': 'Farber', 'Affiliation': 'University of Virginia, Public Health Sciences, OMS 3817B, Charlottesville, VA 22908, United States. Electronic address: crf2s@virginia.edu.'}, {'ForeName': 'Zhenqi', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'University of Virginia, School of Medicine, Suite 2100, 450 Ray C. Hunt Drive, Charlottesville, VA 22903, United States. Electronic address: zl3e@virginia.edu.'}, {'ForeName': 'Brian H', 'Initials': 'BH', 'LastName': 'Annex', 'Affiliation': 'Augusta University, Medical College of Georgia, 1120 15th St. Augusta, GA 30912, United States. Electronic address: bannex@augusta.edu.'}]",International journal of psychophysiology : official journal of the International Organization of Psychophysiology,['10.1016/j.ijpsycho.2020.06.015'] 1511,32619524,Design of a randomized placebo controlled trial of high dose intravenous thiamine for the prevention of delirium in allogeneic hematopoietic stem cell transplantation.,"BACKGROUND Delirium is a highly prevalent and preventable neuropsychiatric condition with major health consequences. Thiamine deficiency is a well-established cause of delirium in those with chronic, severe alcoholism, but there remains an underappreciation of its significance in non-alcoholic populations, including patients with cancer. Treatment of suspected thiamine-related mental status changes with high dose intravenous (IV) thiamine has preliminary evidence for improving a variety of cognitive symptoms in oncology inpatient settings but has never been studied for the prevention of delirium in any population. OBJECTIVES The primary objective of this clinical trial is to determine if high dose IV thiamine can prevent delirium in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) for treatment of cancer. Secondary objectives are to determine if thiamine status is predictive of delirium onset and if high dose IV thiamine can attenuate the deleterious impact of delirium on health-related quality of life (HRQOL), functional status, and long-term neuropsychiatric outcomes. METHODS In this phase II study, we are recruiting 60 patients undergoing allogeneic HSCT, randomizing them to treatment with high dose IV thiamine (n = 30) versus placebo (n = 30), and systematically evaluating all participants for delirium and related comorbidities. We use the Delirium Rating Scale to measure the severity and duration of delirium during hospitalization for HSCT. We obtain thiamine levels weekly during the transplantation hospitalization. We assess HRQOL, functional status, depression, post-traumatic stress symptoms, and cognitive function prior to and at one, three, and six months after transplantation.",2020,"Treatment of suspected thiamine-related mental status changes with high dose intravenous (IV) thiamine has preliminary evidence for improving a variety of cognitive symptoms in oncology inpatient settings but has never been studied for the prevention of delirium in any population. ","['60 patients undergoing allogeneic HSCT, randomizing them to treatment with high dose', 'patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) for treatment of cancer', 'Allogeneic Hematopoietic Stem Cell Transplantation', 'patients with cancer']","['Placebo', 'Thiamine', 'thiamine', 'intravenous (IV) thiamine', 'IV thiamine', 'placebo']","['HRQOL, functional status, depression, post-traumatic stress symptoms, and cognitive function', 'Delirium Rating Scale', 'health-related quality of life (HRQOL), functional status, and long-term neuropsychiatric outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039840', 'cui_str': 'Thiamine'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",60.0,0.367689,"Treatment of suspected thiamine-related mental status changes with high dose intravenous (IV) thiamine has preliminary evidence for improving a variety of cognitive symptoms in oncology inpatient settings but has never been studied for the prevention of delirium in any population. ","[{'ForeName': 'Zev M', 'Initials': 'ZM', 'LastName': 'Nakamura', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: zev_nakamura@med.unc.edu.'}, {'ForeName': 'Allison M', 'Initials': 'AM', 'LastName': 'Deal', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Donald L', 'Initials': 'DL', 'LastName': 'Rosenstein', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Quillen', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Stephanie A', 'Initials': 'SA', 'LastName': 'Chien', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'William A', 'Initials': 'WA', 'LastName': 'Wood', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Thomas C', 'Initials': 'TC', 'LastName': 'Shea', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Eliza M', 'Initials': 'EM', 'LastName': 'Park', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106076'] 1512,32619792,Human urine 1 H NMR metabolomics reveals alterations of the protein and carbohydrate metabolism when comparing habitual Average Danish diet vs. healthy New Nordic diet.,"OBJECTIVES The aim of this study was to investigate the alteration of the human urine metabolome by means of diet and to compare the metabolic effects of the nutritionally healthy New Nordic Diet (NND) with an Average Danish Diet (ADD). The NND was designed a decade ago by scientists and chefs, based on local and sustainable foods, including fish, shellfish, vegetables, roots, fruit, and berries. The NND has been proven to lower blood pressure, reduce glycemia, and lead to weight loss. METHODS The human urine metabolome was measured by untargeted proton nuclear magnetic resonance spectroscopy in samples from 142 centrally obese Danes (20-66 years old), randomized to consume the ADD or the NND. The resulting metabolomics data was processed and analyzed using advanced multivariate data analysis methods to reveal effects related to the design factors, including diet, season, sex, and changes in body weight. RESULTS Exploration of the nuclear magnetic resonance profiles revealed unique metabolite markers reflecting changes in protein and carbohydrate metabolism between the two diets. Glycine betaine, glucose, trimethylamine N-oxide and creatinine were increased in urine of the individuals following the NND compared with the ADD population, whereas relative concentrations of tartrate, dimethyl sulfone, and propylene glycol were decreased. Propylene glycol had a strong association with the homeostatic model assessment for insulin resistance in the NND group. The food intake biomarkers found in this study confirm the importance of these as tools for nutritional research. CONCLUSIONS Findings from this study provided new insights into the effects of a healthy diet on glycemia, reduction of inflammation, and weight loss among obese individuals, and alteration of the gut microbiota metabolism.",2020,"Glycine betaine, glucose, trimethylamine N-oxide and creatinine were increased in urine of the individuals following the NND compared with the ADD population, whereas relative concentrations of tartrate, dimethyl sulfone, and propylene glycol were decreased.",['in samples from 142 centrally obese Danes (20-66 years old'],"['nutritionally healthy New Nordic Diet (NND) with an Average Danish Diet (ADD', 'Propylene glycol', 'untargeted proton nuclear magnetic resonance spectroscopy']","['relative concentrations of tartrate, dimethyl sulfone, and propylene glycol', 'glycemia, reduction of inflammation, and weight loss', 'Glycine betaine, glucose, trimethylamine N-oxide and creatinine']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0337800', 'cui_str': 'Danes'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0010969', 'cui_str': 'Danish language'}, {'cui': 'C0033437', 'cui_str': 'Propanediols'}, {'cui': 'C0033727', 'cui_str': 'Proton'}, {'cui': 'C0877853', 'cui_str': 'Spectroscopy, NMR'}]","[{'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0039328', 'cui_str': 'Tartrates'}, {'cui': 'C0058231', 'cui_str': 'methylsulfonylmethane'}, {'cui': 'C0033437', 'cui_str': 'Propanediols'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0005304', 'cui_str': 'Betaine'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0077194', 'cui_str': 'trimethyloxamine'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}]",142.0,0.027383,"Glycine betaine, glucose, trimethylamine N-oxide and creatinine were increased in urine of the individuals following the NND compared with the ADD population, whereas relative concentrations of tartrate, dimethyl sulfone, and propylene glycol were decreased.","[{'ForeName': 'Alessia', 'Initials': 'A', 'LastName': 'Trimigno', 'Affiliation': 'Department of Food Science, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Bekzod', 'Initials': 'B', 'LastName': 'Khakimov', 'Affiliation': 'Department of Food Science, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Savorani', 'Affiliation': 'Department of Applied Science and Technology, Polytechnic of Turin, Turin, Italy.'}, {'ForeName': 'Sanne Kellebjerg', 'Initials': 'SK', 'LastName': 'Poulsen', 'Affiliation': 'Department of Nutrition Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark; Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Arne', 'Initials': 'A', 'LastName': 'Astrup', 'Affiliation': 'Department of Nutrition Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Lars O', 'Initials': 'LO', 'LastName': 'Dragsted', 'Affiliation': 'Department of Nutrition Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Søren Balling', 'Initials': 'SB', 'LastName': 'Engelsen', 'Affiliation': 'Department of Food Science, Faculty of Science, University of Copenhagen, Copenhagen, Denmark. Electronic address: se@food.ku.dk.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110867'] 1513,32619832,Definitive chemoradiotherapy plus cetuximab for cancer in the oesophagus or gastro-oesophageal junction.,"BACKGROUND Chemoradiotherapy is standard treatment for localized oesophageal cancer unsuitable for surgery. We aimed to evaluate the efficacy of cetuximab in combination with chemoradiotherapy. METHODS This non-randomised multicentre phase II trial recruited patients aged 18-75 with WHO performance status 0-2 having squamous cell carcinoma or adenocarcinoma in the oesophagus or gastro-oesophageal junction, T2-4, N0-3, M0 not suitable for surgery. Chemotherapy was three 21-day cycles of fluorouracil 750 mg/m2 D1-5 and oxaliplatin D1 (cycle 1:130mg/m 2, cycle 2-3:85 mg/m 2). Radiotherapy was 50Gy in 2Gy/fraction, 5 days a week, concurrent with cycle 2 and 3 and weekly cetuximab. The primary objective was loco-regional control at one year. RESULTS 52 patients were included. 51 were eligible for toxicity and survival analysis and 46 for recurrence analysis. Full radiotherapy dose was delivered to 80%, 75% received all three cycles of chemotherapy and 75% received four or more doses of cetuximab. The most common related grade III-IV adverse events were gastro-intestinal(16), hypersensitivity(6) and infection(5). There were two drug-related deaths. Within six months from the end of treatment, six patients died from complications from fistulas. The loco-regional control rate at one year was 47.3%(95%CI 30.9%-62.1%). Overall survival at three years was 29.1%(95% CI 17.4-41.9%). CONCLUSIONS Oxaliplatin and fluorouracil given concurrent with radiotherapy and cetuximab had an acceptable safety profile and showed a clinical response in patients with locoregionally advanced oesophageal cancer unsuitable for surgery. However, the primary end-point was not met, and the addition of cetuximab to definitive chemoradiotherapy cannot be recommended.",2020,"Overall survival at three years was 29.1%(95% CI 17.4-41.9%). ","['localized oesophageal cancer unsuitable for surgery', 'cancer in the oesophagus or gastro-oesophageal junction', 'patients with locoregionally advanced oesophageal cancer unsuitable for surgery', 'patients aged 18-75 with WHO performance status 0-2 having squamous cell carcinoma or adenocarcinoma in the oesophagus or gastro-oesophageal junction, T2-4, N0-3, M0 not suitable for surgery', '52 patients were included']","['radiotherapy and cetuximab', 'Chemotherapy', 'Definitive chemoradiotherapy plus cetuximab', 'Oxaliplatin and fluorouracil', 'Full radiotherapy', 'cetuximab', 'Chemoradiotherapy', 'fluorouracil 750 mg/m2 D1-5 and oxaliplatin D1 (cycle 1:130mg', 'Radiotherapy']","['toxicity and survival analysis', 'Overall survival', 'loco-regional control at one year', 'loco-regional control rate']","[{'cui': 'C0392752', 'cui_str': 'Localized'}, {'cui': 'C0546837', 'cui_str': 'Malignant tumor of esophagus'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0014876', 'cui_str': 'Esophageal structure'}, {'cui': 'C0014871', 'cui_str': 'Cardioesophageal junction structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0007137', 'cui_str': 'Squamous cell carcinoma'}, {'cui': 'C0001418', 'cui_str': 'Adenocarcinoma'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0995188', 'cui_str': 'cetuximab'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0443196', 'cui_str': 'Definitive'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C4517868', 'cui_str': '750'}, {'cui': 'C1319266', 'cui_str': 'mg/sq.m'}]","[{'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0038953', 'cui_str': 'Analysis, Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4082117', 'cui_str': 'One year'}]",52.0,0.16028,"Overall survival at three years was 29.1%(95% CI 17.4-41.9%). ","[{'ForeName': 'Gabriella Alexandersson', 'Initials': 'GA', 'LastName': 'von Döbeln', 'Affiliation': 'Theme Cancer, Karolinska University Hospital, Stockholm, Sweden. Electronic address: gabriella.alexandersson-vondobeln@sll.se.'}, {'ForeName': 'Gunnar', 'Initials': 'G', 'LastName': 'Wagenius', 'Affiliation': 'Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Holtved', 'Affiliation': 'Department of Oncology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Anne-Birgitte', 'Initials': 'AB', 'LastName': 'Jacobsen', 'Affiliation': 'Department of Oncology, Oslo University hospital, Oslo, Norway.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Nilsson', 'Affiliation': 'Department of Clinical Sciences Intervention and Technology Karolinska Institutet Division of Upper Abdominal Cancer, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Jingru', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Lene', 'Initials': 'L', 'LastName': 'Baeksgaard', 'Affiliation': 'Department of Oncology, Rigshospitalet, Copenhagen, Denmark.'}]",Cancer treatment and research communications,['10.1016/j.ctarc.2020.100187'] 1514,32620543,"I-FiBH trial: intravenous fluids in benign headaches-a randomised, single-blinded clinical trial.","BACKGROUND Many emergency physicians use an intravenous fluid bolus as part of a 'cocktail' of therapies for patients with headache, but it is unclear if this is beneficial. The objective of this study was to determine if an intravenous fluid bolus helps reduce pain or improve other outcomes in patients who present to the ED with a benign headache. METHODS This was a randomised, single-blinded, clinical trial performed on patients aged 10-65 years old with benign headaches who presented to a single ED in Las Vegas, Nevada, from May 2017 to February 2019. All patients received prochlorperazine and diphenhydramine, and they were randomised to also receive either 20 mL/kg up to 1000 mL of normal saline (the fluid bolus group) or 5 mL of normal saline (the control group). The primary outcome was the difference between groups in mean pain reduction 60 min after the initiation of treatment. Secondarily, we compared groups with regards to pain reduction at 30 min, nausea scores, the use of rescue medications and disposition. RESULTS We screened 67 patients for enrolment, and 58 consented. Of those, 35 were randomised to the fluid bolus group and 23 to the control group. The mean pain score dropped by 48.3 mm over 60 min in the fluid bolus group, compared with 48.7 mm in the control group. The between groups difference of 0.4 mm (95% CI -16.5 to 17.3) was not statistically significant (p=0.96). Additionally, no statistically significant difference was found between groups for any secondary outcome. CONCLUSION Though our study lacked statistical power to detect small but clinically significant differences, ED patients who received an intravenous fluid bolus for their headache had similar improvements in pain and other outcomes compared with those who did not. TRIAL REGISTRATION NUMBER NCT03185130.",2020,"The mean pain score dropped by 48.3 mm over 60 min in the fluid bolus group, compared with 48.7 mm in the control group.","['patients with headache', 'patients aged 10-65 years old with benign headaches who presented to a single ED in Las Vegas, Nevada, from May 2017 to February 2019', '67 patients for enrolment, and 58 consented', 'patients who present to the ED with a benign headache']","['20\u2009mL/kg up to 1000\u2009mL of normal saline (the fluid bolus group) or 5\u2009mL of normal saline', 'prochlorperazine and diphenhydramine']","['pain reduction at 30\u2009min, nausea scores, the use of rescue medications and disposition', 'mean pain reduction', 'mean pain score', 'pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205183', 'cui_str': 'Benign'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0027951', 'cui_str': 'Nevada'}, {'cui': 'C2711213', 'cui_str': 'Consented'}]","[{'cui': 'C1300574', 'cui_str': 'mL/kg'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0033229', 'cui_str': 'Prochlorperazine'}, {'cui': 'C0012522', 'cui_str': 'Diphenhydramine'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0184758', 'cui_str': 'Patient disposition'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",67.0,0.547929,"The mean pain score dropped by 48.3 mm over 60 min in the fluid bolus group, compared with 48.7 mm in the control group.","[{'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Zitek', 'Affiliation': 'Department of Emergency Medicine, Kendall Regional Medical Center, Miami, Florida, USA zitek10@gmail.com.'}, {'ForeName': 'Tiffany', 'Initials': 'T', 'LastName': 'Sigal', 'Affiliation': ""Department of Emergency Medicine, Mike O'Callaghan Federal Medical Center, Nellis Afb, Nevada, USA.""}, {'ForeName': 'Gina', 'Initials': 'G', 'LastName': 'Sun', 'Affiliation': 'Department of Emergency Medicine, University of Nevada, Las Vegas School of Medicine, Las Vegas, Nevada, USA.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Martin Manuel', 'Affiliation': 'Department of Emergency Medicine, University Medical Center of Southern Nevada, Las Vegas, Nevada, USA.'}, {'ForeName': 'Khanhha', 'Initials': 'K', 'LastName': 'Tran', 'Affiliation': 'Department of Emergency Medicine, University Medical Center of Southern Nevada, Las Vegas, Nevada, USA.'}]",Emergency medicine journal : EMJ,['10.1136/emermed-2019-209389'] 1515,32484952,Implicit play or explicit cognitive behaviour therapy: The impact of intervention approaches to facilitate social skills development in adolescents.,"INTRODUCTION Early adolescence is a time of increased social interaction with peers. Social competence is related to pretend play ability in younger children, but a lack of pretend play ability in childhood may also be associated with social challenges in early adolescence. Adolescents who find social situations challenging experience alienation from peers resulting in lowered self-regard. This paper presents an exploratory study comparing an Implicit group intervention (age-appropriate play based group (PB)) to an Explicit group intervention Cognitive Behavioural Therapy (CBT) to increase social ability in adolescents. METHODS Six adolescents, three female and three male, were in the Implicit group (PB; mean age 12.3 years, SD = 1.21). Six male adolescents were in the Explicit group (CBT; mean age 13.3 years, SD = 1.03). All participants were assessed pre- and post the 8-week intervention for social competence, cognitive flexibility and narrative ability. The Implicit group (PB) was assessed through an age appropriate play assessment. Seven participants had a formal diagnosis, including autism spectrum disorder, and all were in mainstream high schools. RESULTS The Explicit group (CBT) showed a medium effect for social engagement, total social skills, emotional engagement and a large effect for a decrease in flexible thinking. The Implicit group (PB) showed a large impact for narrative ability with increases in ability to sequence events, initiation and creation of plot, understanding character roles and total movie score, with medium effects for generation of problems, precise vocabulary and use of symbols. The Implicit group (PB) maintained cognitive flexibility, and decreased in social self-scoring which showed medium effects for externalising and internalising. CONCLUSION This paper contributes to evidence that the choice of social skills intervention impacts different skill sets. For neuro-diverse adolescents, the cognitive intervention impacted social and emotional engagement and the play-based intervention impacted a wider range of abilities related to narrative social interaction.",2020,"The Explicit group (CBT) showed a medium effect for social engagement, total social skills, emotional engagement and a large effect for a decrease in flexible thinking.","['Six adolescents, three female and three male, were in the Implicit group (PB; mean age 12.3\xa0years, SD\xa0=\xa01.21', 'younger children', 'Seven participants had a formal diagnosis, including autism spectrum disorder, and all were in mainstream high schools', 'adolescents', 'Six male adolescents']","['Implicit group intervention (age-appropriate play based group (PB)) to an Explicit group intervention Cognitive Behavioural Therapy (CBT', 'Implicit play or explicit cognitive behaviour therapy']","['ability to sequence events, initiation and creation of plot, understanding character roles and total movie score, with medium effects for generation of problems, precise vocabulary and use of symbols', 'social competence, cognitive flexibility and narrative ability', 'flexible thinking', 'social engagement, total social skills, emotional engagement']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C5191283', 'cui_str': '12.3'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0024500', 'cui_str': 'Mainstreaming (Education)'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0001589', 'cui_str': 'Adolescents, Male'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0004793', 'cui_str': 'Base sequence'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0441513', 'cui_str': 'Construction'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0007952', 'cui_str': 'Character'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0681495', 'cui_str': 'Movies'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0679005', 'cui_str': 'Social Abilities'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C1135957', 'cui_str': 'Narration'}, {'cui': 'C0443220', 'cui_str': 'Flexible'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}]",6.0,0.0174906,"The Explicit group (CBT) showed a medium effect for social engagement, total social skills, emotional engagement and a large effect for a decrease in flexible thinking.","[{'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Goldingay', 'Affiliation': 'School of Health and Social Development, Deakin University, Geelong, Vic., Australia.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Stagnitti', 'Affiliation': 'School of Health and Social Development, Deakin University, Geelong, Vic., Australia.'}, {'ForeName': 'Narelle', 'Initials': 'N', 'LastName': 'Robertson', 'Affiliation': 'School of Health and Social Development, Deakin University, Geelong, Vic., Australia.'}, {'ForeName': 'Genevieve', 'Initials': 'G', 'LastName': 'Pepin', 'Affiliation': 'School of Health and Social Development, Deakin University, Geelong, Vic., Australia.'}, {'ForeName': 'Loretta', 'Initials': 'L', 'LastName': 'Sheppard', 'Affiliation': 'School of Allied Health, Australian Catholic University, Melbourne, Vic., Australia.'}, {'ForeName': 'Belinda', 'Initials': 'B', 'LastName': 'Dean', 'Affiliation': 'School of Nursing and Midwifery, Deakin University, Geelong, Vic., Australia.'}]",Australian occupational therapy journal,['10.1111/1440-1630.12673'] 1516,32580577,"Effectiveness of four types of bandages and kinesio-tape for treating breast-cancer-related lymphoedema: a randomized, single-blind, clinical trial.","OBJECTIVE To compare the effects of four types of bandages and kinesio-tape and determine which one is the most effective in women with unilateral breast cancer-related lymphoedema. DESIGN Randomized, single-blind, clinical trial. SETTING Physiotherapy department in the Women's Health Research Group at the University of Alcalá, Madrid, Spain. SUBJECTS A total of 150 women presenting breast-cancer-related lymphoedema. INTERVENTIONS Participants were randomized into five groups ( n  = 30). All women received an intensive phase of complex decongestive physiotherapy including manual lymphatic drainage, pneumatic compression therapy, therapeutic education, active therapeutic exercise and bandaging. The only difference between the groups was the bandage or tape applied (multilayer; simplified multilayer; cohesive; adhesive; kinesio-tape). MAIN MEASUREMENTS The main outcome was percentage excess volume change. Other outcomes measured were heaviness and tightness symptoms, and bandage or tape perceived comfort. Data were collected at baseline and finishing interventions. RESULTS This study showed significant differences between the bandage groups in absolute value of excess volume ( P  < 0.001). The most effective were the simplified multilayer (59.5%, IQR = 28.7) and the cohesive bandages (46.3%, IQR = 39). The bandages/tape with the least difference were kinesio-tape (4.9%, IQR = 17.7) and adhesive bandage (21.7%, IQR = 17.9). The five groups exhibited a significant decrease in symptoms after interventions, with no differences between groups. In addition, kinesio-tape was perceived as the most comfortable by women and multilayer as the most uncomfortable ( P  < 0.001). CONCLUSION Simplified multilayer seems more effective and more comfortable than multilayer bandage. Cohesive bandage seems as effective as simplified multilayer and multilayer bandage. Kinesio taping seems the least effective.",2020,"The only difference between the groups was the bandage or tape applied (multilayer; simplified multilayer; cohesive; adhesive; kinesio-tape). ","['women with unilateral breast cancer-related lymphoedema', 'A total of 150 women presenting breast-cancer-related lymphoedema', ""Physiotherapy department in the Women's Health Research Group at the University of Alcalá, Madrid, Spain"", 'treating breast-cancer-related lymphoedema']","['complex decongestive physiotherapy including manual lymphatic drainage, pneumatic compression therapy, therapeutic education, active therapeutic exercise and bandaging', 'Kinesio taping', 'bandages and kinesio-tape']","['adhesive bandage', 'symptoms', 'heaviness and tightness symptoms, and bandage or tape perceived comfort', 'kinesio-tape', 'percentage excess volume change']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4018978', 'cui_str': 'Unilateral Breast Cancer'}, {'cui': 'C0024236', 'cui_str': 'Lymphedema'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0587975', 'cui_str': 'Physiotherapy department'}, {'cui': 'C0080339', 'cui_str': ""Woman's Health""}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0556834', 'cui_str': 'Manual lymphatic drainage'}, {'cui': 'C1167944', 'cui_str': 'Pneumatic compression therapy'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0150468', 'cui_str': 'Application of bandage'}, {'cui': 'C0004726', 'cui_str': 'Bandage'}, {'cui': 'C4505491', 'cui_str': 'Kinesiotape'}]","[{'cui': 'C0001512', 'cui_str': 'Adhesive bandage'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439816', 'cui_str': 'Tightness sensation quality'}, {'cui': 'C0004726', 'cui_str': 'Bandage'}, {'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C4505491', 'cui_str': 'Kinesiotape'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",150.0,0.0816891,"The only difference between the groups was the bandage or tape applied (multilayer; simplified multilayer; cohesive; adhesive; kinesio-tape). ","[{'ForeName': 'María', 'Initials': 'M', 'LastName': 'Torres-Lacomba', 'Affiliation': ""Physiotherapy Department, Physiotherapy in Women's Health Research Group, Faculty of Physiotherapy, University of Alcalá, Alcalá de Henares, Madrid, Spain.""}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Navarro-Brazález', 'Affiliation': ""Physiotherapy Department, Physiotherapy in Women's Health Research Group, Faculty of Physiotherapy, University of Alcalá, Alcalá de Henares, Madrid, Spain.""}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Prieto-Gómez', 'Affiliation': ""Physiotherapy Department, Physiotherapy in Women's Health Research Group, Faculty of Physiotherapy, University of Alcalá, Alcalá de Henares, Madrid, Spain.""}, {'ForeName': 'Jean Claude', 'Initials': 'JC', 'LastName': 'Ferrandez', 'Affiliation': ""Physiotherapy Department, Physiotherapy in Women's Health Research Group, Faculty of Physiotherapy, University of Alcalá, Alcalá de Henares, Madrid, Spain.""}, {'ForeName': 'Jean Yves', 'Initials': 'JY', 'LastName': 'Bouchet', 'Affiliation': ""Physiotherapy Department, Physiotherapy in Women's Health Research Group, Faculty of Physiotherapy, University of Alcalá, Alcalá de Henares, Madrid, Spain.""}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Romay-Barrero', 'Affiliation': 'Faculty of Physiotherapy and Nursing, University of Castilla-La Mancha, Toledo, Spain.'}]",Clinical rehabilitation,['10.1177/0269215520935943'] 1517,31807987,Safety and feasibility of inspiratory muscle training for hospitalized patients undergoing hematopoietic stem cell transplantation: a randomized controlled study.,"PURPOSE Patients undergoing hematopoietic stem cell transplantation (HSCT) usually experienced respiratory muscle weakness. Inspiratory muscle training (IMT) at HSCT has not been studied yet. Thus, it is important to evaluate the safety, feasibility, and preliminary effectiveness of IMT for hospitalized patients undergoing HSCT with an unstable and acute clinical condition. METHODS This is a randomized controlled feasibility study. Thirty-one hospitalized patients undergoing HSCT were randomized to the conventional physical rehabilitation (CON) or to the IMT group (conventional physical rehabilitation + IMT). IMT was carried out at 40% of maximal inspiratory pressure (MIP), 5 sessions weekly, 10-20 min/session. Primary outcomes were safety and feasibility (recruitment, adherence, and attrition rates) of IMT. Secondary outcomes were respiratory strength, respiratory rate, oxygen saturation, and frequency of patients with oxygen desaturation, bleeding, dyspnea, and acute pulmonary edema. RESULTS Patients were allocated to the IMT (N = 15; 43.6 years) or to the CON group (N = 16; 46.6 years). The recruitment rate was 100%, the adherence rate was 91%, and attrition was 13% to IMT. Two events were observed in 126 IMT sessions (1.5%). MIP increased in the IMT group (P < 0.01). No differences were observed in respiratory rate and oxygen saturation between groups. Trends to negative outcomes were observed in the CON in comparison to IMT group for a need of oxygen therapy (18% vs. 6%), bleeding (12% vs. 6%), dyspnea (25% vs. 13%), and acute pulmonary edema (6% vs. 0%). CONCLUSIONS IMT is safe, feasible, and improves the inspiratory muscle strength in hospitalized patients undergoing HSCT. TRIAL REGISTRATION Clinical trial registration: NCT03373526.",2020,MIP increased in the IMT group (P < 0.01).,"['Patients undergoing hematopoietic stem cell transplantation (HSCT) usually experienced respiratory muscle weakness', 'hospitalized patients undergoing HSCT', 'Thirty-one hospitalized patients undergoing HSCT', 'hospitalized patients undergoing HSCT with an unstable and acute clinical condition', 'hospitalized patients undergoing hematopoietic stem cell transplantation']","['Inspiratory muscle training (IMT', 'inspiratory muscle training', 'conventional physical rehabilitation (CON) or to the IMT group (conventional physical rehabilitation + IMT', 'CON', 'IMT']","['inspiratory muscle strength', 'safety and feasibility (recruitment, adherence, and attrition rates) of IMT', 'recruitment rate', 'adherence rate', 'MIP', 'acute pulmonary edema', 'bleeding', 'dyspnea', 'respiratory rate and oxygen saturation', 'respiratory strength, respiratory rate, oxygen saturation, and frequency of patients with oxygen desaturation, bleeding, dyspnea, and acute pulmonary edema']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C1836141', 'cui_str': 'Respiratory muscle weakness'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C0443343', 'cui_str': 'Unstable status'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0454511', 'cui_str': 'Inspiratory muscle training'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0454511', 'cui_str': 'Inspiratory muscle training'}, {'cui': 'C4083126', 'cui_str': 'Maximum Inspiratory Pressure'}, {'cui': 'C0155919', 'cui_str': 'Acute pulmonary edema'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range'}]",31.0,0.0564342,MIP increased in the IMT group (P < 0.01).,"[{'ForeName': 'Leonardo Barbosa', 'Initials': 'LB', 'LastName': 'de Almeida', 'Affiliation': 'Federal University of Juiz de Fora, Cardiovascular Research Unit and Exercise Physiology, José Lourenço Kelmer, s/n, Martelos, Juiz de Fora, 36036-900, Brazil. almeidalb@hotmail.com.'}, {'ForeName': 'Patrícia Fernandes', 'Initials': 'PF', 'LastName': 'Trevizan', 'Affiliation': 'Federal University of Juiz de Fora, Cardiovascular Research Unit and Exercise Physiology, José Lourenço Kelmer, s/n, Martelos, Juiz de Fora, 36036-900, Brazil.'}, {'ForeName': 'Mateus Camaroti', 'Initials': 'MC', 'LastName': 'Laterza', 'Affiliation': 'Federal University of Juiz de Fora, Cardiovascular Research Unit and Exercise Physiology, José Lourenço Kelmer, s/n, Martelos, Juiz de Fora, 36036-900, Brazil.'}, {'ForeName': 'Abrahão Elias', 'Initials': 'AE', 'LastName': 'Hallack Neto', 'Affiliation': 'Department of Hematology, Hemotherapy and Bone Marrow Transplantation, Federal University of Juiz de Fora, Juiz de Fora, Brazil.'}, {'ForeName': 'Ana Carolina Amaral de São José', 'Initials': 'ACASJ', 'LastName': 'Perrone', 'Affiliation': 'Department of Hematology, Hemotherapy and Bone Marrow Transplantation, Federal University of Juiz de Fora, Juiz de Fora, Brazil.'}, {'ForeName': 'Daniel Godoy', 'Initials': 'DG', 'LastName': 'Martinez', 'Affiliation': 'Federal University of Juiz de Fora, Cardiovascular Research Unit and Exercise Physiology, José Lourenço Kelmer, s/n, Martelos, Juiz de Fora, 36036-900, Brazil.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-019-05209-x'] 1518,32589686,Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.,"DNA vectors have been widely used as a priming of poxvirus vaccine in prime/boost regimens. Whether the number of DNA impacts qualitatively or quantitatively the immune response is not fully explored. With the aim to reinforce T-cell responses by optimizing the prime-boost regimen, the multicentric EV03/ANRS VAC20 phase I/II trial, randomized 147 HIV-negative volunteers to either 3xDNA plus 1xNYVAC (weeks 0, 4, 8 plus 24; n = 74) or to 2xDNA plus 2xNYVAC (weeks 0, 4 plus 20, 24; n = 73) groups. T-cell responses (IFN-γ ELISPOT) to at least one peptide pool were higher in the 3xDNA than the 2xDNA groups (91% and 80% of vaccinees) (P = 0.049). In the 3xDNA arm, 26 (37%) recipients developed a broader T-cell response (Env plus at least to one of the Gag, Pol, Nef pools) than in the 2xDNA (15; 22%) arms (primary endpoint; P = 0.047) with a higher magnitude against Env (at week 26) (P<0.001). In both groups, vaccine regimens induced HIV-specific polyfunctional CD4 and CD8 T cells and the production of Th1, Th2 and Th17/IL-21 cytokines. Antibody responses were also elicited in up to 81% of vaccines. A higher percentage of IgG responders was noted in the 2xDNA arm compared to the 3xDNA arm, while the 3xDNA group tended to elicit a higher magnitude of IgG3 response against specific Env antigens. We show here that the modulation of the prime strategy, without modifying the route or the dose of administration, or the combination of vectors, may influence the quality of the responses.",2020,T-cell responses (IFN-γ ELISPOT) to at least one peptide pool were higher in the 3xDNA than the 2xDNA groups (91% and 80% of vaccinees) (P = 0.049).,['147 HIV-negative volunteers to either'],"['poxvirus vector (NYVAC)-based HIV vaccine regimens', '3xDNA plus 1xNYVAC', '2xDNA plus 2xNYVAC']","['Antibody responses', 'IgG responders', 'HIV-specific polyfunctional CD4 and CD8 T cells and the production of Th1, Th2 and Th17/IL-21 cytokines', 'broader T-cell response', 'T-cell responses (IFN-γ ELISPOT', 'IgG3 response']","[{'cui': 'C0481430', 'cui_str': 'HIV negative'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0032868', 'cui_str': 'Poxviridae'}, {'cui': 'C0012656', 'cui_str': 'Infectious Disease Vectors'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0003261', 'cui_str': 'Antibody Production'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0920508', 'cui_str': 'Enzyme linked immunospot assay'}, {'cui': 'C0020859', 'cui_str': 'Immunoglobulin IgG3'}]",147.0,0.0624733,T-cell responses (IFN-γ ELISPOT) to at least one peptide pool were higher in the 3xDNA than the 2xDNA groups (91% and 80% of vaccinees) (P = 0.049).,"[{'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Lévy', 'Affiliation': 'Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, équipe 16, Créteil, France.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Lacabaratz', 'Affiliation': 'Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, équipe 16, Créteil, France.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Ellefsen-Lavoie', 'Affiliation': 'Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Stöhr', 'Affiliation': 'MRC Clinical Trials Unit at UCL, London, United Kingdom.'}, {'ForeName': 'Jean-Daniel', 'Initials': 'JD', 'LastName': 'Lelièvre', 'Affiliation': 'Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, équipe 16, Créteil, France.'}, {'ForeName': 'Pierre-Alexandre', 'Initials': 'PA', 'LastName': 'Bart', 'Affiliation': 'Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.'}, {'ForeName': 'Odile', 'Initials': 'O', 'LastName': 'Launay', 'Affiliation': 'Université de Paris, Faculté de médecine Paris Descartes; Inserm, CIC 1417, F-CRIN I-REIVAC; Assistance Publique-Hôpitaux de Paris, CIC Cochin Pasteur, Paris, France.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Weber', 'Affiliation': 'Imperial College London, London, United Kingdom.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Salzberger', 'Affiliation': 'University Hospital, Institute of Clinical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.'}, {'ForeName': 'Aurélie', 'Initials': 'A', 'LastName': 'Wiedemann', 'Affiliation': 'Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, équipe 16, Créteil, France.'}, {'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Surenaud', 'Affiliation': 'Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, équipe 16, Créteil, France.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Koelle', 'Affiliation': 'Department of Medicine & Department of Global Health, University of Washington, Fred Hutchinson Cancer Research Center Seattle, Washington, United States of America.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Wolf', 'Affiliation': 'University Hospital, Institute of Clinical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Wagner', 'Affiliation': 'University Hospital, Institute of Clinical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.'}, {'ForeName': 'Véronique', 'Initials': 'V', 'LastName': 'Rieux', 'Affiliation': 'Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, équipe 16, Créteil, France.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Montefiori', 'Affiliation': 'Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.'}, {'ForeName': 'Nicole L', 'Initials': 'NL', 'LastName': 'Yates', 'Affiliation': 'Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.'}, {'ForeName': 'Georgia D', 'Initials': 'GD', 'LastName': 'Tomaras', 'Affiliation': 'Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Gottardo', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.'}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Mayer', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.'}, {'ForeName': 'Song', 'Initials': 'S', 'LastName': 'Ding', 'Affiliation': 'EuroVacc Foundation, Lausanne, Switzerland.'}, {'ForeName': 'Rodolphe', 'Initials': 'R', 'LastName': 'Thiébaut', 'Affiliation': 'Inserm, Bordeaux Population Health Research Center, UMR 1219, University Bordeaux, ISPED, CIC 1401-EC, Univ Bordeaux, Bordeaux, France.'}, {'ForeName': 'Sheena', 'Initials': 'S', 'LastName': 'McCormack', 'Affiliation': 'MRC Clinical Trials Unit at UCL, London, United Kingdom.'}, {'ForeName': 'Geneviève', 'Initials': 'G', 'LastName': 'Chêne', 'Affiliation': 'Inserm, Bordeaux Population Health Research Center, UMR 1219, University Bordeaux, ISPED, CIC 1401-EC, Univ Bordeaux, Bordeaux, France.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Pantaleo', 'Affiliation': 'Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.'}]",PLoS pathogens,['10.1371/journal.ppat.1008522'] 1519,32592261,Acute performance and physiological responses to repeated-sprint exercise in a combined hot and hypoxic environment.,"We investigated performance, energy metabolism, acid-base balance, and endocrine responses to repeated-sprint exercise in hot and/or hypoxic environment. In a single-blind, cross-over study, 10 male highly trained athletes completed a repeated cycle sprint exercise (3 sets of 3 × 10-s maximal sprints with 40-s passive recovery) under four conditions (control [CON; 20℃, 50% rH, FiO 2 : 20.9%; sea level], hypoxia [HYP; 20℃, 50% rH, FiO 2 : 14.5%; a simulated altitude of 3,000 m], hot [HOT; 35℃, 50% rH, FiO 2 : 20.9%; sea level], and hot + hypoxia [HH; 35℃, 50% rH, FiO 2 : 14.5%; a simulated altitude of 3,000 m]). Changes in power output, muscle and skin temperatures, and respiratory oxygen uptake were measured. Peak (CON: 912 ± 26 W, 95% confidence interval [CI]: 862-962 W, HYP: 915 ± 28 W [CI: 860-970 W], HOT: 937 ± 26 W [CI: 887-987 W], HH: 937 ± 26 W [CI: 886-987 W]) and mean (CON: 808 ± 22 W [CI: 765-851 W], HYP: 810 ± 23 W [CI: 765-855 W], HOT: 825 ± 22 W [CI: 781-868 W], HH: 824 ± 25 W [CI: 776-873 W]) power outputs were significantly greater when exercising in heat conditions (HOT and HH) during the first sprint (p < .05). Heat exposure (HOT and HH) elevated muscle and skin temperatures compared to other conditions (p < .05). Oxygen uptake and arterial oxygen saturation were significantly lower in hypoxic conditions (HYP and HH) versus the other conditions (p < .05). In summary, additional heat stress when sprinting repeatedly in hypoxia improved performance (early during exercise), while maintaining low arterial oxygen saturation.",2020,25 W [CI: 776-873 W]) power outputs were significantly greater when exercising in heat conditions (HOT and HH) during the first sprint (p < .05).,"['22', '10 male highly trained athletes completed a', 'hot and/or hypoxic environment', '26']","['repeated cycle sprint exercise', 'repeated-sprint exercise']","['Heat exposure (HOT and HH) elevated muscle and skin temperatures', 'low arterial oxygen saturation', 'performance, energy metabolism, acid-base balance, and endocrine responses', 'power output, muscle and skin temperatures, and respiratory oxygen uptake', 'Oxygen uptake and arterial oxygen saturation']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0444519', 'cui_str': 'Hot'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0014406', 'cui_str': 'Environment'}]","[{'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0239930', 'cui_str': 'Heat exposure'}, {'cui': 'C0444519', 'cui_str': 'Hot'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0037294', 'cui_str': 'Temperature of skin'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0428175', 'cui_str': 'Oxygen saturation measurement, arterial'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0001117', 'cui_str': 'Acid-base equilibrium'}, {'cui': 'C0014136', 'cui_str': 'Structure of endocrine system'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}]",10.0,0.0615615,25 W [CI: 776-873 W]) power outputs were significantly greater when exercising in heat conditions (HOT and HH) during the first sprint (p < .05).,"[{'ForeName': 'Keiichi', 'Initials': 'K', 'LastName': 'Yamaguchi', 'Affiliation': 'Graduate School of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.'}, {'ForeName': 'Nobukazu', 'Initials': 'N', 'LastName': 'Kasai', 'Affiliation': 'Graduate School of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.'}, {'ForeName': 'Nanako', 'Initials': 'N', 'LastName': 'Hayashi', 'Affiliation': 'Graduate School of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.'}, {'ForeName': 'Haruka', 'Initials': 'H', 'LastName': 'Yatsutani', 'Affiliation': 'Graduate School of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Girard', 'Affiliation': 'School of Human Science (Exercise and Sport Science), The University of Western Australia, Crawley, Australia.'}, {'ForeName': 'Kazushige', 'Initials': 'K', 'LastName': 'Goto', 'Affiliation': 'Graduate School of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.'}]",Physiological reports,['10.14814/phy2.14466'] 1520,32593123,Quality of life changes in response to yoga therapy in patients with schizophrenia: Reanalysis of Three randomized controlled trials.,,2020,,['patients with schizophrenia'],['yoga therapy'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}]",[],,0.0595902,,"[{'ForeName': 'Saeko', 'Initials': 'S', 'LastName': 'Ikai-Tani', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan; Faculty of Kinesiology & Physical Education, University of Toronto, 55 Harbord Street, M5S 2W6, Toronto, ON, Canada. Electronic address: sako0609@gmail.com.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Tani', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan; Kimel Family Translational Imaging-Genetics Laboratory, Centre for Addiction and Mental Health, 1001 Queen St W, M6J 1H4, Toronto, ON, Canada.'}, {'ForeName': 'Saki', 'Initials': 'S', 'LastName': 'Kamiyama', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan.'}, {'ForeName': 'Masaru', 'Initials': 'M', 'LastName': 'Mimura', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Uchida', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan; Geriatric Mental Health Program, Centre for Addiction and Mental Health, 1001 Queen St W, M6J 1H4, Toronto, ON, Canada.'}]",Asian journal of psychiatry,['10.1016/j.ajp.2020.102250'] 1521,32597030,Effect of low energy availability during three consecutive days of endurance training on iron metabolism in male long distance runners.,"We investigated the effect of low energy availability (LEA) during three consecutive days of endurance training on muscle glycogen content and iron metabolism. Six male long distance runners completed three consecutive days of endurance training under LEA or neutral energy availability (NEA) conditions. Energy availability was set at 20 kcal/kg fat-free mass (FFM)/day for LEA and 45 kcal/kg FFM/day for NEA. The subjects ran for 75 min at 70% of maximal oxygen uptake ( V ˙ O 2max ) on days 1-3. Venous blood samples were collected following an overnight fast on days 1-4, immediately and 3 hr after exercise on day 3. The muscle glycogen content on days 1-4 was evaluated by carbon-magnetic resonance spectroscopy. In LEA condition, the body weight and muscle glycogen content on days 2-4, and the FFM on days 2 and 4 were significantly lower than those on day1 (p < .05 vs. day1), whereas no significant change was observed throughout the training period in NEA condition. On day 3, muscle glycogen content before exercise was negatively correlated with serum iron level (immediately after exercise, 3 hr after exercise), serum hepcidin level immediately after exercise, and plasma IL-6 level immediately after exercise (p < .05). Moreover, serum hepcidin level on day 4 was significantly higher in LEA condition than that in NEA condition (p < .05). In conclusion, three consecutive days of endurance training under LEA reduced the muscle glycogen content with concomitant increased serum hepcidin levels in male long distance runners.",2020,"Moreover, serum hepcidin level on day 4 was significantly higher in LEA condition than that in NEA condition (p < .05).","['male long distance runners', 'Six male long distance runners']","['endurance training under LEA or neutral energy availability (NEA) conditions', 'endurance training', 'low energy availability (LEA']","['serum iron level', 'serum hepcidin level immediately after exercise, and plasma IL-6 level', 'muscle glycogen content and iron metabolism', 'Venous blood samples', 'iron metabolism', 'serum hepcidin levels', 'Energy availability', 'body weight and muscle glycogen content', 'serum hepcidin level']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0012751', 'cui_str': 'Distance'}]","[{'cui': 'C4704697', 'cui_str': 'Endurance Training'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C1318312', 'cui_str': 'Serum iron measurement'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0966897', 'cui_str': 'Hepcidin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C1979962', 'cui_str': 'After exercise'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0017911', 'cui_str': 'Glycogen'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0444255', 'cui_str': 'Venous blood specimen'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]",6.0,0.0243692,"Moreover, serum hepcidin level on day 4 was significantly higher in LEA condition than that in NEA condition (p < .05).","[{'ForeName': 'Aya', 'Initials': 'A', 'LastName': 'Ishibashi', 'Affiliation': 'Japan Institute of Sports Sciences, Kitaku, Tokyo, Japan.'}, {'ForeName': 'Chihiro', 'Initials': 'C', 'LastName': 'Kojima', 'Affiliation': 'Japan Institute of Sports Sciences, Kitaku, Tokyo, Japan.'}, {'ForeName': 'Yoko', 'Initials': 'Y', 'LastName': 'Tanabe', 'Affiliation': 'Faculty of Health and Sport Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.'}, {'ForeName': 'Kaito', 'Initials': 'K', 'LastName': 'Iwayama', 'Affiliation': 'Department of Budo and Sport Studies, Tenri University, Tenri, Nara, Japan.'}, {'ForeName': 'Tsutomu', 'Initials': 'T', 'LastName': 'Hiroyama', 'Affiliation': 'Faculty of Health and Sport Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.'}, {'ForeName': 'Toshiki', 'Initials': 'T', 'LastName': 'Tsuji', 'Affiliation': 'Faculty of Health and Sport Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.'}, {'ForeName': 'Akiko', 'Initials': 'A', 'LastName': 'Kamei', 'Affiliation': 'Japan Institute of Sports Sciences, Kitaku, Tokyo, Japan.'}, {'ForeName': 'Kazushige', 'Initials': 'K', 'LastName': 'Goto', 'Affiliation': 'Graduate School of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.'}, {'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Takahashi', 'Affiliation': 'Japan Institute of Sports Sciences, Kitaku, Tokyo, Japan.'}]",Physiological reports,['10.14814/phy2.14494'] 1522,32597035,Effect of milk fat globule membrane supplementation on motor unit adaptation following resistance training in older adults.,"This study aimed to investigate the effect of milk fat globule membrane (MFGM) supplementation on motor unit adaptation following resistance training in older adults. Twenty-five older males and females took MFGM (n = 12) or a placebo (PLA; n = 12) while performing 8 weeks of isometric knee extension training. During the training, the motor unit firing pattern during submaximal contractions, muscle thickness, and maximal muscle strength of knee extensor muscles were measured every 2 weeks. None of the measurements showed significant differences in muscle thickness or maximal muscle strength (MVC) between the two groups (p > .05). Significant decreases in motor unit firing rate following the intervention were observed in PLA, that is, 14.1 ± 2.7 pps at 0 weeks to 13.0 ± 2.4 pps at 4 weeks (p = .003), but not in MFGM (14.4 ± 2.5 pps to 13.8 ± 1.9 pps). Motor unit firing rates in MFGM were significantly higher than those in PLA at 2, 4, 6, and 8 weeks of the intervention, that is, 15.1 ± 2.3 pps in MFGM and 14.5 ± 3.3 pps in PLA at 70% of MVC for motor units recruited at 40% of MVC at 6 weeks (p = .034). Significant differences in firing rates among motor units with different recruitment thresholds were newly observed following the resistance training intervention in MFGM, indicating that motor unit firing pattern is changed in this group. These results suggest that motor unit adaptation following resistance training is modulated by MFGM supplementation in older adults.",2020,"Significant differences in firing rates among motor units with different recruitment thresholds were newly observed following the resistance training intervention in MFGM, indicating that motor unit firing pattern is changed in this group.","['Twenty-five older males and females took MFGM (n\xa0=\xa012) or a', 'older adults']","['milk fat globule membrane supplementation', 'milk fat globule membrane (MFGM) supplementation', 'MFGM supplementation', 'placebo (PLA; n\xa0=\xa012) while performing 8\xa0weeks of isometric knee extension training']","['motor unit firing rate', 'Motor unit firing rates in MFGM', 'firing rates', 'motor unit firing pattern during submaximal contractions, muscle thickness, and maximal muscle strength of knee extensor muscles', 'muscle thickness or maximal muscle strength (MVC', 'motor unit adaptation']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0670751', 'cui_str': 'milk fat globule'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0670751', 'cui_str': 'milk fat globule'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0014007', 'cui_str': 'Dismissed from job'}, {'cui': 'C0670751', 'cui_str': 'milk fat globule'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}]",25.0,0.0321513,"Significant differences in firing rates among motor units with different recruitment thresholds were newly observed following the resistance training intervention in MFGM, indicating that motor unit firing pattern is changed in this group.","[{'ForeName': 'Kohei', 'Initials': 'K', 'LastName': 'Watanabe', 'Affiliation': 'Laboratory of Neuromuscular Biomechanics, School of International Liberal Studies, Chukyo University, Nagoya, Japan.'}, {'ForeName': 'Aleš', 'Initials': 'A', 'LastName': 'Holobar', 'Affiliation': 'Faculty of Electrical Engineering and Computer Science, University of Maribor, Maribor, Slovenia.'}, {'ForeName': 'Aya', 'Initials': 'A', 'LastName': 'Tomita', 'Affiliation': 'Laboratory of Neuromuscular Biomechanics, School of International Liberal Studies, Chukyo University, Nagoya, Japan.'}, {'ForeName': 'Yukiko', 'Initials': 'Y', 'LastName': 'Mita', 'Affiliation': 'Department of Human Nutrition, School of Life Studies, Sugiyama Jogakuen University, Nagoya, Japan.'}]",Physiological reports,['10.14814/phy2.14491'] 1523,32593717,Caring for older veterans with chronic low back pain using a geriatric syndrome approach: Rationale and methods for the aging back clinics (ABC) trial.,"The purpose of the ongoing trial is to improve care of older Veterans with chronic low back pain (CLBP, i.e., low back pain for ≥6 months on ≥ half the days). Current CLBP care is limited by being either overly spine-focused or non-specifically prescribed and both approaches frequently lead to suboptimal reduction in pain and improvement in function. Through prior studies we have laid the foundation for a patient-centered approach to care for older Veterans with CLBP in which the spine is a source of vulnerability but not the sole treatment target. The approach considers CLBP a geriatric syndrome, a final common pathway for the expression of multiple contributors rather than a disease of the spine. We describe here the rationale and design of a randomized controlled trial to test the efficacy of an older Veteran-centered approach to CLBP care in ""Aging Back Clinics (ABCs)"" compared with Usual Care (UC). Three hundred thirty Veterans age 65-89 with CLBP will be randomized to ABCs or UC and followed for 12 months after randomization. We will assess the impact of ABCs on our primary outcome of pain-associated disability with the Oswestry Disability Index at 6 and 12 months, and secondary outcomes of pain intensity, health-related quality of life, balance confidence, mobility and healthcare utilization. If shown efficacious, the approach tested in ABCs has the potential to transform the care of older adults with CLBP by improving the quality of life for millions, reducing morbidity and saving substantial healthcare costs.",2020,"If shown efficacious, the approach tested in ABCs has the potential to transform the care of older adults with CLBP by improving the quality of life for millions, reducing morbidity and saving substantial healthcare costs.","['Three hundred thirty Veterans age 65-89 with CLBP', 'older Veterans with chronic low back pain (CLBP, i.e., low back pain for ≥6\u202fmonths on ≥ half the days', 'older veterans with chronic low back pain using a geriatric syndrome approach', 'older adults with CLBP']","['ABCs or UC', 'older Veteran-centered approach to CLBP care', 'Usual Care (UC']","['pain-associated disability with the Oswestry Disability Index', 'pain intensity, health-related quality of life, balance confidence, mobility and healthcare utilization']","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",330.0,0.0631505,"If shown efficacious, the approach tested in ABCs has the potential to transform the care of older adults with CLBP by improving the quality of life for millions, reducing morbidity and saving substantial healthcare costs.","[{'ForeName': 'Debra K', 'Initials': 'DK', 'LastName': 'Weiner', 'Affiliation': 'Geriatric Research, Education and Clinic Center, VA Pittsburgh Healthcare System, Pittsburgh, PA, United States of America; University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America. Electronic address: debra.weiner@va.gov.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Gentili', 'Affiliation': 'Central Virginia VA Health Care System, Richmond, VA, United States of America; Virginia Commonwealth University Health System, Richmond, VA.'}, {'ForeName': 'Meika A', 'Initials': 'MA', 'LastName': 'Fang', 'Affiliation': 'Geriatric Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States of America; David Geffen School of Medicine at UCLA Los Angeles, Los Angeles, CA, United States of America.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Garay', 'Affiliation': 'VA Pittsburgh Healthcare System, Pittsburgh, PA, United States of America.'}, {'ForeName': 'Thiru', 'Initials': 'T', 'LastName': 'Annaswamy', 'Affiliation': 'VA North Texas Health Care System, Dallas, TX, United States of America; University of Texas Southwestern Medical Center, Dallas, TX, United States of America.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Castle', 'Affiliation': 'Geriatric Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States of America; David Geffen School of Medicine at UCLA Los Angeles, Los Angeles, CA, United States of America.'}, {'ForeName': 'Lenore', 'Initials': 'L', 'LastName': 'Joseph', 'Affiliation': 'Central Virginia VA Health Care System, Richmond, VA, United States of America; Virginia Commonwealth University Health System, Richmond, VA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Lawson', 'Affiliation': 'Central Virginia VA Health Care System, Richmond, VA, United States of America; Virginia Commonwealth University Health System, Richmond, VA.'}, {'ForeName': 'Cathy C', 'Initials': 'CC', 'LastName': 'Lee', 'Affiliation': 'Geriatric Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States of America; David Geffen School of Medicine at UCLA Los Angeles, Los Angeles, CA, United States of America.'}, {'ForeName': 'Una E', 'Initials': 'UE', 'LastName': 'Makris', 'Affiliation': 'VA North Texas Health Care System, Dallas, TX, United States of America; University of Texas Southwestern Medical Center, Dallas, TX, United States of America.'}, {'ForeName': 'Michelle I', 'Initials': 'MI', 'LastName': 'Rossi', 'Affiliation': 'Geriatric Research, Education and Clinic Center, VA Pittsburgh Healthcare System, Pittsburgh, PA, United States of America; University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America.'}, {'ForeName': 'Beverly', 'Initials': 'B', 'LastName': 'Thorn', 'Affiliation': 'University of Alabama, Tuscaloosa, AL, United States of America.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Clemens', 'Affiliation': 'Geriatric Research, Education and Clinic Center, VA Pittsburgh Healthcare System, Pittsburgh, PA, United States of America.'}, {'ForeName': 'Dave', 'Initials': 'D', 'LastName': 'Newman', 'Affiliation': 'Geriatric Research, Education and Clinic Center, VA Pittsburgh Healthcare System, Pittsburgh, PA, United States of America.'}, {'ForeName': 'Subashan', 'Initials': 'S', 'LastName': 'Perera', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America; University of Pittsburgh Graduate School of Public Health, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106077'] 1524,32602065,Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.,"INTRODUCTION Ceftazidime-avibactam combines the established anti-pseudomonal cephalosporin, ceftazidime, with the novel non-β-lactam β-lactamase inhibitor, avibactam. OBJECTIVES The aim of this study was to evaluate the safety of ceftazidime-avibactam in adults using pooled data from two phase II (NCT00690378, NCT00752219) and five phase III (NCT01499290, NCT01726023, NCT01644643, NCT01808093 and NCT01595438/NCT01599806) clinical studies. METHODS Safety data from seven multicentre, randomised, active-comparator studies were pooled by study group at the patient level for descriptive analyses, comprising patients with complicated urinary tract infection (cUTI), including pyelonephritis, complicated intra-abdominal infection (cIAI), or nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP), treated with ceftazidime-avibactam ± metronidazole or comparator. RESULTS In total, 4050 patients (ceftazidime-avibactam ± metronidazole, n = 2024; comparator, n = 2026) were included in the pooled analysis. Adverse events (AEs) up to the last study visit occurred in 996 (49.2%) and 965 (47.6%) patients treated with ceftazidime-avibactam ± metronidazole and comparator, respectively. The most common AEs across treatment groups were diarrhoea, nausea, headache, vomiting and pyrexia. There were few discontinuations due to AEs (2.5% and 1.7% for ceftazidime-avibactam ± metronidazole and comparators, respectively). Overall rates of serious AEs were 8.7% for ceftazidime-avibactam ± metronidazole and 7.2% for comparators; respective rates of AEs with an outcome of death were 2.0% and 1.8%. AEs considered causally related to the study drug or procedures occurred in 10.7% and 9.6% of patients treated with ceftazidime-avibactam ± metronidazole and comparators; the most common drug-related AEs in both groups were diarrhoea, headache, nausea and increased alanine aminotransferase. No impact to the safety profile of ceftazidime-avibactam ± metronidazole was found with regard to intrinsic factors, such as age or renal function at baseline, or extrinsic factors, such as geographical origin. Potentially clinically significant changes in laboratory parameters were infrequent with no trends or safety concerns identified. CONCLUSION The observed safety profile of ceftazidime-avibactam across infection types is consistent with the established safety profile of ceftazidime monotherapy and no new safety findings were identified. This analysis supports the use of ceftazidime-avibactam as a treatment option in adults with cUTI, cIAI and NP, including VAP.",2020,"There were few discontinuations due to AEs (2.5% and 1.7% for ceftazidime-avibactam ± metronidazole and comparators, respectively).","['adults with cUTI, cIAI and NP, including VAP', 'patients with complicated urinary tract infection (cUTI), including pyelonephritis, complicated intra-abdominal infection (cIAI), or nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP), treated with ceftazidime-avibactam\u2009±\u2009metronidazole or comparator', '4050 patients (ceftazidime-avibactam\u2009±\u2009metronidazole, n\u2009=\u20092024; comparator, n\u2009=\u20092026']","['metronidazole', 'Ceftazidime-Avibactam', 'ceftazidime-avibactam\u2009±\u2009metronidazole', 'ceftazidime-avibactam']","['Overall rates of serious AEs', 'diarrhoea, headache, nausea and increased alanine aminotransferase', 'death', 'laboratory parameters', 'Adverse events (AEs', 'diarrhoea, nausea, headache, vomiting and pyrexia']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4552431', 'cui_str': 'Complicated urinary tract infection'}, {'cui': 'C4524048', 'cui_str': 'Complicated intra-abdominal infection'}, {'cui': 'C0949083', 'cui_str': 'Hospital acquired pneumonia'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0087153', 'cui_str': 'Ventilator'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034186', 'cui_str': 'Pyelonephritis'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C3656596', 'cui_str': 'Avibactam and ceftazidime'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}]","[{'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C3656596', 'cui_str': 'Avibactam and ceftazidime'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0151905', 'cui_str': 'Alanine aminotransferase increased'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0015967', 'cui_str': 'Fever'}]",4050.0,0.0542547,"There were few discontinuations due to AEs (2.5% and 1.7% for ceftazidime-avibactam ± metronidazole and comparators, respectively).","[{'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Cheng', 'Affiliation': 'Pfizer, Sandwich, Kent, UK. karen.cheng@pfizer.com.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Newell', 'Affiliation': 'AstraZeneca, Alderley Park, Macclesfield, UK.'}, {'ForeName': 'Joseph W', 'Initials': 'JW', 'LastName': 'Chow', 'Affiliation': 'Pfizer, Collegeville, PA, USA.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Broadhurst', 'Affiliation': 'AstraZeneca, Alderley Park, Macclesfield, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Wilson', 'Affiliation': 'AstraZeneca, Alderley Park, Macclesfield, UK.'}, {'ForeName': 'Katrina', 'Initials': 'K', 'LastName': 'Yates', 'Affiliation': 'AstraZeneca, Alderley Park, Macclesfield, UK.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Wardman', 'Affiliation': 'AstraZeneca, Alderley Park, Macclesfield, UK.'}]",Drug safety,['10.1007/s40264-020-00934-3'] 1525,32599670,Muscle contractile properties of cancer patients receiving chemotherapy: Assessment of feasibility and exercise effects.,"BACKGROUND This pilot trial explores the feasibility of measuring muscle contractile properties in patients with cancer, effects of exercise during chemotherapy on muscle contractile properties and the association between changes in contractile muscle properties and perceived fatigue. METHOD Patients who received (neo)adjuvant chemotherapy for breast or colon cancer were randomized to a 9-12 week exercise intervention or a waitlist-control group. At baseline and follow-up, we measured knee extensor strength using maximal voluntary contraction (MVC), contractile muscle properties of the quadriceps muscle using electrical stimulation, and perceived fatigue using the Multidimensional Fatigue Inventory. Feasibility was assessed by the proportion of patients who successfully completed measurements of contractile muscle properties. Exercise effects on muscle contractile properties were explored using linear regression analyses. Between-group differences >10% were considered potentially relevant. Pearson correlation (r p ) of changes in contractile muscle properties and changes in perceived fatigue was calculated. RESULTS Twenty two of 30 patients completed baseline and follow-up assessments. Measurements of contractile properties were feasible except for muscle fatigability. We found a potentially relevant between-group difference in the rate of force development favoring the intervention group (1192 N/s, 95% CI = -335; 2739). Change in rate of force development was negatively correlated with change in perceived general (r p  = -0.54, P = .04) and physical (r p  = -0.59, P = .02) fatigue. CONCLUSION Chemotherapy induces a decrease in the rate of force development, which may reflect a larger loss in type II muscle fibers. This may be attenuated with (resistance) exercise. The increase in the rate of force development was related to a decrease in perceived fatigue.",2020,"Change in rate of force development was negatively correlated with change in perceived general (r p =-0.54, p=0.04) and physical (r p =-0.59, p=0.02) fatigue). ","['cancer patients receiving', 'Patients who received (neo)adjuvant chemotherapy for breast or colon cancer', 'patients with cancer']","['chemotherapy', 'Chemotherapy', 'exercise intervention or a waitlist-control group']","['perceived fatigue', 'rate of force development', 'knee extensor strength using maximal voluntary contraction (MVC), contractile muscle properties of the quadriceps muscle using electrical stimulation, and perceived fatigue using the Multidimensional Fatigue Inventory', 'muscle contractile properties']","[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0026820', 'cui_str': 'Muscle contraction'}, {'cui': 'C0231493', 'cui_str': 'Muscle property'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0871161', 'cui_str': 'Property'}]",,0.0475002,"Change in rate of force development was negatively correlated with change in perceived general (r p =-0.54, p=0.04) and physical (r p =-0.59, p=0.02) fatigue). ","[{'ForeName': 'Laurien M', 'Initials': 'LM', 'LastName': 'Buffart', 'Affiliation': 'Department of Physiology, Radboudumc, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.'}, {'ForeName': 'Maike G', 'Initials': 'MG', 'LastName': 'Sweegers', 'Affiliation': 'Department of Epidemiology and Biostatistics and Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Cornelis J', 'Initials': 'CJ', 'LastName': 'de Ruijter', 'Affiliation': 'Faculty of Behavioural and Movement Sciences, Amsterdam Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Inge R', 'Initials': 'IR', 'LastName': 'Konings', 'Affiliation': 'Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.'}, {'ForeName': 'Henk M W', 'Initials': 'HMW', 'LastName': 'Verheul', 'Affiliation': 'Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands.'}, {'ForeName': 'Annette A', 'Initials': 'AA', 'LastName': 'van Zweeden', 'Affiliation': 'Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.'}, {'ForeName': 'Cecile', 'Initials': 'C', 'LastName': 'Grootscholten', 'Affiliation': 'Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Mai J', 'Initials': 'MJ', 'LastName': 'Chinapaw', 'Affiliation': 'Department of Public and Occupational Health and Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Teatske M', 'Initials': 'TM', 'LastName': 'Altenburg', 'Affiliation': 'Department of Public and Occupational Health and Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}]",Scandinavian journal of medicine & science in sports,['10.1111/sms.13758'] 1526,32607557,"Effect of daily vitamin B-12 and folic acid supplementation on fracture incidence in elderly individuals with an elevated plasma homocysteine concentration: B-PROOF, a randomized controlled trial.",,2020,,['elderly individuals with an elevated plasma homocysteine concentration'],['daily vitamin B-12 and folic acid supplementation'],['fracture incidence'],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0019878', 'cui_str': 'Homocysteine'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0042845', 'cui_str': 'Vitamin B 12'}, {'cui': 'C0556110', 'cui_str': 'Folic acid supplement agent'}]","[{'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",,0.241614,,[],The American journal of clinical nutrition,['10.1093/ajcn/nqaa129'] 1527,32603956,Leptin mediates improvements in cognitive function following treatment with infliximab in adults with bipolar depression.,"A potential role for leptin in the pathophysiology of bipolar disorder (BD) has been proposed. We recently investigated the effects of the tumor necrosis factor-alpha (TNF-α) antagonist infliximab in individuals with bipolar depression. Leptin is known to interact with the TNF-α system. Herein, we aimed to explore infliximab's effects on leptin and its relationship with brain structure and function. Sixty adults with bipolar depression were enrolled in this randomized, double-blind, 12-week clinical trial of adjunctive infliximab (n = 29) and saline control (n = 31), which were administered intravenously at weeks 0, 2, and 6. Plasma concentrations of leptin, TNF-α and soluble TNF receptors (sTNFR) 1 and 2 were assessed at weeks 0, 2, 6, and 12. We observed a significant decrease in leptin levels in infliximab-treated patients, relative to placebo. Infliximab treatment also significantly reduced TNF-α and sTNFR2, but not sTNFR1 levels. Changes in sTNR2 levels at week 6 significantly determined changes in leptin at week 12 in infliximab-, but not placebo-treated participants. Improvements in verbal memory and increases in global cortical volume were associated with reduction in leptin levels in the treatment group. Mediation analysis indicated that cognitive improvement in infliximab-treated patients was mediated by reductions in leptin levels, which in its turn were determined by decreases in sTNR2 levels. In conclusion, infliximab treatment reduced plasma leptin levels in individuals with BD, through modulation of sTNFR2. Decreases in leptin signaling were associated with an increase in global cortical volume and better performance in a verbal memory task.",2020,"Infliximab treatment also significantly reduced TNF-α and sTNFR2, but not sTNFR1 levels.","['Sixty adults with bipolar depression', 'individuals with BD', 'adults with bipolar depression', 'individuals with bipolar depression']","['Leptin', 'saline control', 'adjunctive infliximab', 'infliximab', 'Infliximab', 'tumor necrosis factor-alpha (TNF-α) antagonist infliximab', 'placebo']","['leptin', 'cognitive improvement', 'global cortical volume and better performance in a verbal memory task', 'cognitive function', 'Plasma concentrations of leptin, TNF-α and soluble TNF receptors (sTNFR', 'verbal memory', 'plasma leptin levels', 'global cortical volume', 'leptin signaling', 'leptin levels', 'TNF-α and sTNFR2', 'sTNR2 levels']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0005587', 'cui_str': 'Bipolar affective disorder, current episode depression'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}]","[{'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0077503', 'cui_str': 'Tumor Necrosis Factor Receptor'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",60.0,0.149116,"Infliximab treatment also significantly reduced TNF-α and sTNFR2, but not sTNFR1 levels.","[{'ForeName': 'Rodrigo B', 'Initials': 'RB', 'LastName': 'Mansur', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Electronic address: rodrigo.mansur@uhn.ca.'}, {'ForeName': 'Mehala', 'Initials': 'M', 'LastName': 'Subramaniapillai', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.'}, {'ForeName': 'Yena', 'Initials': 'Y', 'LastName': 'Lee', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Zihang', 'Initials': 'Z', 'LastName': 'Pan', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.'}, {'ForeName': 'Nicole E', 'Initials': 'NE', 'LastName': 'Carmona', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychology, Ryerson University, Toronto, ON, Canada.'}, {'ForeName': 'Margarita', 'Initials': 'M', 'LastName': 'Shekotikhina', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; University of Ottawa, Department of Psychiatry, Ottawa, ON, Canada.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Iacobucci', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.'}, {'ForeName': 'Nelson', 'Initials': 'N', 'LastName': 'Rodrigues', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.'}, {'ForeName': 'Flora', 'Initials': 'F', 'LastName': 'Nasri', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.'}, {'ForeName': 'Houman', 'Initials': 'H', 'LastName': 'Rashidian', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Rosenblat', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Brietzke', 'Affiliation': ""Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Kingston General Hospital, Providence Care Hospital, Department of Psychiatry, Queen's University School of Medicine, Kingston, ON, Canada.""}, {'ForeName': 'Victoria E', 'Initials': 'VE', 'LastName': 'Cosgrove', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Stanford University, School of Medicine, Palo Alto, CA, USA.'}, {'ForeName': 'Nicole E', 'Initials': 'NE', 'LastName': 'Kramer', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Stanford University, School of Medicine, Palo Alto, CA, USA.'}, {'ForeName': 'Trisha', 'Initials': 'T', 'LastName': 'Suppes', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Stanford University, School of Medicine, Palo Alto, CA, USA.'}, {'ForeName': 'Roger S', 'Initials': 'RS', 'LastName': 'McIntyre', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2020.104779'] 1528,32604427,Association of Successful Ultrasound-Accelerated Catheter-Directed Thrombolysis with Postthrombotic Syndrome: A Post Hoc Analysis of the CAVA Trial.,"BACKGROUND The CAVA trial did not show the anticipated risk reduction for postthrombotic syndrome (PTS) after thrombus removal via additional ultrasound-accelerated catheter-directed thrombolysis (UACDT) in patients with acute iliofemoral deep vein thrombosis (IFDVT). Difficulties in achieving an effective degree of recanalization through thrombolysis may have influenced outcomes. We therefore assessed whether successful UACDT (restored patency ≥ 90%) did reduce the development of PTS. METHODS This CAVA trial post hoc analysis compared the proportion of PTS at 1-year follow-up between patients with successful UACDT and patients that received standard treatment only. In addition, clinical impact as well as determinants of successful thrombolysis were explored. RESULTS UACDT was initiated in 77 (50.7%) patients and considered successful in 41 (53.2%, interrater agreement κ  = 0.7, 95% confidence interval 0.47-0.83). PTS developed in 15/41 (36.6%) patients in the successful UACDT group versus 33/75 (44.0%) controls ( p  = 0.44). In this comparison, successful UACDT was associated with lower Venous Clinical Severity Score (3.50 ± 2.57 vs. 4.82 ± 2.74, p  = 0.02) and higher EuroQOL-5D (EQ-5D) scores (40.2 ± 36.4 vs. 23.4 ± 34.4, p  = 0.01). Compared with unsuccessful UACDT, successful UACDT was associated with a shorter symptom duration at inclusion ( p  = 0.05), and higher rates of performed adjunctive procedures ( p  < 0.001) and stent placement ( p  < 0.001). CONCLUSION Successful UACDT was not associated with a reduced proportion of PTS 1 year after acute IFDVT compared with patients receiving standard treatment alone. There was, however, a significant reduction in symptom severity and improvement of generic quality of life according to the EQ-5D. Better patient selection and optimization of treatment protocols are needed to assess the full potential of UACDT for the prevention of PTS. TRIAL REGISTRATION NUMBER ClinicalTrials.gov number, NCT00970619.",2020,Successful UACDT was not associated with a reduced proportion of PTS 1 year after acute IFDVT compared with patients receiving standard treatment alone.,"['patients with acute iliofemoral deep vein thrombosis (IFDVT', 'with Postthrombotic Syndrome']","['Successful Ultrasound-Accelerated Catheter-Directed Thrombolysis', 'thrombus removal via additional ultrasound-accelerated catheter-directed thrombolysis (UACDT']","['stent placement', 'Venous Clinical Severity Score', 'higher rates of performed adjunctive procedures', 'higher EuroQOL-5D (EQ-5D) scores', 'PTS', 'symptom severity and improvement of generic quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0340714', 'cui_str': 'Iliofemoral deep vein thrombosis'}, {'cui': 'C0032807', 'cui_str': 'Postthrombotic syndrome'}]","[{'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis'}, {'cui': 'C0015252', 'cui_str': 'Removal'}]","[{'cui': 'C0522776', 'cui_str': 'Placement of stent'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0032807', 'cui_str': 'Postthrombotic syndrome'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.355072,Successful UACDT was not associated with a reduced proportion of PTS 1 year after acute IFDVT compared with patients receiving standard treatment alone.,"[{'ForeName': 'Pascale', 'Initials': 'P', 'LastName': 'Notten', 'Affiliation': 'Department of Vascular Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.'}, {'ForeName': 'Carsten W K P', 'Initials': 'CWKP', 'LastName': 'Arnoldussen', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.'}, {'ForeName': 'Rutger', 'Initials': 'R', 'LastName': 'Brans', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.'}, {'ForeName': 'André A E A', 'Initials': 'AAEA', 'LastName': 'de Smet', 'Affiliation': 'Department of Vascular Surgery, Maasstad Hospital, Rotterdam, The Netherlands.'}, {'ForeName': 'Lidwine W', 'Initials': 'LW', 'LastName': 'Tick', 'Affiliation': 'Department of Internal Medicine, Maxima Medical Centre, Eindhoven, The Netherlands.'}, {'ForeName': 'Marlène H W', 'Initials': 'MHW', 'LastName': 'van de Poel', 'Affiliation': 'Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands.'}, {'ForeName': 'Otmar R M', 'Initials': 'ORM', 'LastName': 'Wikkeling', 'Affiliation': 'Department of Vascular Surgery, Nij Smellinghe Hospital, Drachten, The Netherlands.'}, {'ForeName': 'Louis-Jean', 'Initials': 'LJ', 'LastName': 'Vleming', 'Affiliation': 'Department of Internal Medicine, Haga Hospital, The Hague, The Netherlands.'}, {'ForeName': 'Ad', 'Initials': 'A', 'LastName': 'Koster', 'Affiliation': 'Department of Internal Medicine, VieCuri Medical Centre, Venlo, The Netherlands.'}, {'ForeName': 'Kon-Siong G', 'Initials': 'KG', 'LastName': 'Jie', 'Affiliation': 'Department of Internal Medicine, Zuyderland Medical Centre, Sittard, The Netherlands.'}, {'ForeName': 'Esther M G', 'Initials': 'EMG', 'LastName': 'Jacobs', 'Affiliation': 'Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands.'}, {'ForeName': 'Harm P', 'Initials': 'HP', 'LastName': 'Ebben', 'Affiliation': 'Department of Vascular Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands.'}, {'ForeName': 'Nils', 'Initials': 'N', 'LastName': 'Planken', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands.'}, {'ForeName': 'Hugo', 'Initials': 'H', 'LastName': 'Ten Cate', 'Affiliation': 'Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht University Medical Centre, Maastricht, The Netherlands.'}, {'ForeName': 'Cees H A', 'Initials': 'CHA', 'LastName': 'Wittens', 'Affiliation': 'Department of Vascular Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.'}, {'ForeName': 'Arina J', 'Initials': 'AJ', 'LastName': 'Ten Cate-Hoek', 'Affiliation': 'Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht University Medical Centre, Maastricht, The Netherlands.'}]",Thrombosis and haemostasis,['10.1055/s-0040-1713171'] 1529,32627205,"Blood donor recruitment in Guangzhou, China, during the 2019 novel coronavirus (COVID-19) epidemic.","BACKGROUND The coronavirus disease 2019 (COVID-19) epidemic affected blood collection in Guangzhou, China. STUDY DESIGN AND METHODS This paper includes three studies. The observational study reported the trends of blood collection during the epidemic in Guangzhou, China. The cross-sectional survey investigated factors influencing blood donation during the COVID-19 epidemic, and a self-administered questionnaire was given to 1584 street whole blood donors (SWBDs) who donated during the epidemic. The randomized controlled trial involved 19 491 SWBDs who donated in 2019 but did not donate during the epidemic. Trial participants were randomly assigned to two intervention groups: Group 1 completed Questionnaire 1, which contained precautionary measures in response to COVID-19 and other messages about blood donation during the epidemic; Group 2 completed Questionnaire 2, which did not include this information. A control group did not receive any questionnaire. RESULTS As measures were implemented, the number of blood donors increased accordingly. Both first-time and repeat SWBDs perceived the same level of blood need and donated blood because it would save lives. SWBDs who completed Questionnaire 1 expressed a greater intention to donate during the epidemic. Enabling blood donors to perceive a higher level of blood need and a lower level of COVID-19 infection risk related to blood donation mobilized experienced SWBDs to donate within 3 weeks. Intention-to-treat analyses and average-treatment-effect-on-the-treated estimations confirmed that Questionnaire 1 could motivate SWBDs to actually donate blood. CONCLUSION Various measures could ease blood shortage during the COVID-19 epidemic. Administration of Questionnaire 1 could increase blood donations during the epidemic.",2020,Enabling blood donors to perceive a higher level of blood need and a lower level of COVID-19 infection risk related to blood donation mobilized experienced SWBDs to donate within three weeks.,"['19,491 SWBDs who donated in 2019 but did not donate during the epidemic']","['Questionnaire 1, which contained precautionary measures in response to COVID-19 and other messages about blood donation during the epidemic; and group 2 completed Questionnaire 2, which did not include this information']","['blood donations', 'number of blood donors', 'blood shortage']","[{'cui': 'C0442658', 'cui_str': 'Street'}, {'cui': 'C0375876', 'cui_str': 'Whole blood donor'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0014499', 'cui_str': 'Epidemic'}]","[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0005794', 'cui_str': 'Blood Donation'}, {'cui': 'C0014499', 'cui_str': 'Epidemic'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0005794', 'cui_str': 'Blood Donation'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0005795', 'cui_str': 'Blood donor'}, {'cui': 'C0005767', 'cui_str': 'Blood'}]",19491.0,0.0277604,Enabling blood donors to perceive a higher level of blood need and a lower level of COVID-19 infection risk related to blood donation mobilized experienced SWBDs to donate within three weeks.,"[{'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Ou-Yang', 'Affiliation': 'Guangzhou Blood Center, Guangzhou, Guangdong, China.'}, {'ForeName': 'Shi-Jie', 'Initials': 'SJ', 'LastName': 'Li', 'Affiliation': 'Guangzhou Blood Center, Guangzhou, Guangdong, China.'}, {'ForeName': 'Chun-Hua', 'Initials': 'CH', 'LastName': 'Bei', 'Affiliation': 'Guangzhou Blood Center, Guangzhou, Guangdong, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'He', 'Affiliation': 'Guangzhou Blood Center, Guangzhou, Guangdong, China.'}, {'ForeName': 'Jin-Yan', 'Initials': 'JY', 'LastName': 'Chen', 'Affiliation': 'Guangzhou Blood Center, Guangzhou, Guangdong, China.'}, {'ForeName': 'Hua-Qin', 'Initials': 'HQ', 'LastName': 'Liang', 'Affiliation': 'Guangzhou Blood Center, Guangzhou, Guangdong, China.'}, {'ForeName': 'Yong-Shui', 'Initials': 'YS', 'LastName': 'Fu', 'Affiliation': 'Guangzhou Blood Center, Guangzhou, Guangdong, China.'}]",Transfusion,['10.1111/trf.15971'] 1530,32627975,Effect of Chin-down-plus-larynx-tightening maneuver on swallowing function after minimally invasive esophagectomy: A randomized controlled trail.,"BACKGROUND The incidence of swallowing abnormality was high after minimally invasive esophagectomy (MIE) for esophageal cancer (EC). Few reports, however, focused on interventions for dysphagia after esophagectomy. AIM The purpose of this research was to estimate the effect of Chin-down-plus-larynx-tightening maneuver on swallowing function for patients receiving esophagectomy. METHOD This was a 2-arm, parallel-group, single-blind randomized clinical trial, performed in patients suffered from EC from November 2018 to January 2020. Patients were randomly assigned to the intervention group (IG) or the control group (CG). The participants in CG received routine care, and the IG received Chin-down-plus-larynx-tightening maneuver during feeding. The incidence of choking cough, swallowing function, and dietary outcomes were evaluated before and after intervention for 7 days. RESULTS A total of 237 EC cases were enrolled and randomized to the IG (n = 118) or CG (n = 119). There was no significant difference between the two groups in terms of demographic and clinical characteristics. Postoperative choking cough occurred in 5 of 118 cases (4.24%) in IG and 18 of 119 cases (19.4%) in CG, the differences showed statistically significant (P < .001). The analysis showed that the participants in the IG compared with the CG have more total caloric intake of 24 hours and higher K/R (the ratio of calories oral achieved to total calories required of body) significantly from D1 to D7 of intervention (P < .05). CONCLUSION The findings suggest that the Chin-down-plus-larynx-tightening maneuver can improve swallowing function recovery and oral total food intake and calories in EC patients undergoing MIE.",2020,"Postoperative choking cough occurred in 5 of 118 cases (4.24%) in IG and 18 of 119 cases (19.4%) in CG, the differences showed statistically significant (P ","['patients receiving esophagectomy', 'A total of 237 EC cases', 'EC patients undergoing MIE', 'patients suffered from EC from November 2018 to January 2020', 'after minimally invasive esophagectomy']","['Chin-down-plus-larynx-tightening maneuver during feeding', 'Chin-down-plus-larynx-tightening maneuver', 'minimally invasive esophagectomy (MIE', 'CG', 'intervention group (IG) or the control group (CG']","['incidence of choking cough, swallowing function, and dietary outcomes', 'swallowing function', 'total caloric intake', 'Postoperative choking cough', 'swallowing function recovery and oral total food intake and calories']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085198', 'cui_str': 'Esophagectomy'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0014859', 'cui_str': 'Neoplasm of esophagus'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}]","[{'cui': 'C0008114', 'cui_str': 'Chin structure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0023051', 'cui_str': 'Disorder of the larynx'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0085198', 'cui_str': 'Esophagectomy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0008301', 'cui_str': 'Choking'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0599766', 'cui_str': 'Recovery of Function'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0013470', 'cui_str': 'Eating'}, {'cui': 'C0439259', 'cui_str': 'kcal'}]",237.0,0.0724695,"Postoperative choking cough occurred in 5 of 118 cases (4.24%) in IG and 18 of 119 cases (19.4%) in CG, the differences showed statistically significant (P ","[{'ForeName': 'Funa', 'Initials': 'F', 'LastName': 'Yang', 'Affiliation': 'Nursing Department, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.'}, {'ForeName': 'Limin', 'Initials': 'L', 'LastName': 'Zou', 'Affiliation': 'Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.'}, {'ForeName': 'Lijuan', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.'}, {'ForeName': 'Qiyun', 'Initials': 'Q', 'LastName': 'Zou', 'Affiliation': 'Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.'}, {'ForeName': 'Peinan', 'Initials': 'P', 'LastName': 'Chen', 'Affiliation': 'Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.'}, {'ForeName': 'Haibo', 'Initials': 'H', 'LastName': 'Sun', 'Affiliation': 'Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.'}, {'ForeName': 'Xianben', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.'}, {'ForeName': 'Xiaoxia', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': 'Nursing Department, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.'}]",Cancer medicine,['10.1002/cam4.3280'] 1531,32628293,Behavioural activation therapy for depression in adults.,"BACKGROUND Behavioural activation is a brief psychotherapeutic approach that seeks to change the way a person interacts with their environment. Behavioural activation is increasingly receiving attention as a potentially cost-effective intervention for depression, which may require less resources and may be easier to deliver and implement than other types of psychotherapy. OBJECTIVES To examine the effects of behavioural activation compared with other psychological therapies for depression in adults. To examine the effects of behavioural activation compared with medication for depression in adults. To examine the effects of behavioural activation compared with treatment as usual/waiting list/placebo no treatment for depression in adults. SEARCH METHODS We searched CCMD-CTR (all available years), CENTRAL (current issue), Ovid MEDLINE (1946 onwards), Ovid EMBASE (1980 onwards), and Ovid PsycINFO (1806 onwards) on the 17 January 2020 to identify randomised controlled trials (RCTs) of 'behavioural activation', or the main elements of behavioural activation for depression in participants with clinically diagnosed depression or subthreshold depression. We did not apply any restrictions on date, language or publication status to the searches. We searched international trials registries via the World Health Organization's trials portal (ICTRP) and ClinicalTrials.gov to identify unpublished or ongoing trials. SELECTION CRITERIA We included randomised controlled trials (RCTs) of behavioural activation for the treatment of depression or symptoms of depression in adults aged 18 or over. We excluded RCTs conducted in inpatient settings and with trial participants selected because of a physical comorbidity. Studies were included regardless of reported outcomes. DATA COLLECTION AND ANALYSIS Two review authors independently screened all titles/abstracts and full-text manuscripts for inclusion. Data extraction and 'Risk of bias' assessments were also performed by two review authors in duplicate. Where necessary, we contacted study authors for more information. MAIN RESULTS Fifty-three studies with 5495 participants were included; 51 parallel group RCTs and two cluster-RCTs. We found moderate-certainty evidence that behavioural activation had greater short-term efficacy than treatment as usual (risk ratio (RR) 1.40, 95% confidence interval (CI) 1.10 to 1.78; 7 RCTs, 1533 participants), although this difference was no longer evident in sensitivity analyses using a worst-case or intention-to-treat scenario. Compared with waiting list, behavioural activation may be more effective, but there were fewer data in this comparison and evidence was of low certainty (RR 2.14, 95% CI 0.90 to 5.09; 1 RCT, 26 participants). No evidence on treatment efficacy was available for behavioural activation versus placebo and behavioural activation versus no treatment. We found moderate-certainty evidence suggesting no evidence of a difference in short-term treatment efficacy between behavioural activation and CBT (RR 0.99, 95% CI 0.92 to 1.07; 5 RCTs, 601 participants). Fewer data were available for other comparators. No evidence of a difference in short term-efficacy was found between behavioural activation and third-wave CBT (RR 1.10, 95% CI 0.91 to 1.33; 2 RCTs, 98 participants; low certainty), and psychodynamic therapy (RR 1.21, 95% CI 0.74 to 1.99; 1 RCT,60 participants; very low certainty). Behavioural activation was more effective than humanistic therapy (RR 1.84, 95% CI 1.15 to 2.95; 2 RCTs, 46 participants; low certainty) and medication (RR 1.77, 95% CI 1.14 to 2.76; 1 RCT; 141 participants; moderate certainty), but both of these results were based on a small number of trials and participants. No evidence on treatment efficacy was available for comparisons between behavioural activation versus interpersonal, cognitive analytic, and integrative therapies. There was moderate-certainty evidence that behavioural activation might have lower treatment acceptability (based on dropout rate) than treatment as usual in the short term, although the data did not confirm a difference and results lacked precision (RR 1.64, 95% CI 0.81 to 3.31; 14 RCTs, 2518 participants). Moderate-certainty evidence did not suggest any difference in short-term acceptability between behavioural activation and waiting list (RR 1.17, 95% CI 0.70 to 1.93; 8 RCTs. 359 participants), no treatment (RR 0.97, 95% CI 0.45 to 2.09; 3 RCTs, 187 participants), medication (RR 0.52, 95% CI 0.23 to 1.16; 2 RCTs, 243 participants), or placebo (RR 0.72, 95% CI 0.31 to 1.67; 1 RCT; 96 participants; low-certainty evidence). No evidence on treatment acceptability was available comparing behavioural activation versus psychodynamic therapy. Low-certainty evidence did not show a difference in short-term treatment acceptability (dropout rate) between behavioural activation and CBT (RR 1.03, 95% CI 0.85 to 1.25; 12 RCTs, 1195 participants), third-wave CBT (RR 0.84, 95% CI 0.33 to 2.10; 3 RCTs, 147 participants); humanistic therapy (RR 1.06, 95% CI 0.20 to 5.55; 2 RCTs, 96 participants) (very low certainty), and interpersonal, cognitive analytic, and integrative therapy (RR 0.84, 95% CI 0.32 to 2.20; 4 RCTs, 123 participants). Results from medium- and long-term primary outcomes, secondary outcomes, subgroup analyses, and sensitivity analyses are summarised in the text. AUTHORS' CONCLUSIONS This systematic review suggests that behavioural activation may be more effective than humanistic therapy, medication, and treatment as usual, and that it may be no less effective than CBT, psychodynamic therapy, or being placed on a waiting list. However, our confidence in these findings is limited due to concerns about the certainty of the evidence. We found no evidence of a difference in short-term treatment acceptability (based on dropouts) between behavioural activation and most comparison groups (CBT, humanistic therapy, waiting list, placebo, medication, no treatment or treatment as usual). Again, our confidence in all these findings is limited due to concerns about the certainty of the evidence. No data were available about the efficacy of behaioural activation compared with placebo, or about treatment acceptability comparing behavioural activation and psychodynamic therapy, interpersonal, cognitive analytic and integrative therapies. The evidence could be strengthened by better reporting and better quality RCTs of behavioural activation and by assessing working mechanisms of behavioural activation.",2020,"No evidence of a difference in short term-efficacy was found between behavioural activation and third-wave CBT (RR 1.10, 95% CI 0.91 to 1.33; 2 RCTs, 98 participants; low certainty), and psychodynamic therapy (RR 1.21, 95% CI 0.74 to 1.99; 1 RCT,60 participants; very low certainty).","['participants with clinically diagnosed depression or subthreshold depression', '1980 onwards), and Ovid PsycINFO (1806 onwards) on the 17 January 2020', 'Fifty-three studies with 5495 participants were included; 51 parallel group RCTs and two cluster-RCTs', 'adults', 'depression in adults', 'depression or symptoms of depression in adults aged 18 or over']","['Behavioural activation therapy', 'behavioural activation', 'Ovid EMBASE ', 'placebo']","['usual (risk ratio (RR', 'behavioural activation and waiting list', 'short term-efficacy', 'Behavioural activation']","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C2733064', 'cui_str': 'Behavioral activation therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",5495.0,0.306503,"No evidence of a difference in short term-efficacy was found between behavioural activation and third-wave CBT (RR 1.10, 95% CI 0.91 to 1.33; 2 RCTs, 98 participants; low certainty), and psychodynamic therapy (RR 1.21, 95% CI 0.74 to 1.99; 1 RCT,60 participants; very low certainty).","[{'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Uphoff', 'Affiliation': 'Cochrane Common Mental Disorders, University of York, York, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Ekers', 'Affiliation': 'Lanchester Road Hospital, Tees, Esk and Wear Valleys NHS Foundation Trust, Durham, UK.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Robertson', 'Affiliation': 'Cochrane Common Mental Disorders, University of York, York, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Dawson', 'Affiliation': 'Cochrane Common Mental Disorders, University of York, York, UK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Sanger', 'Affiliation': 'Cochrane Common Mental Disorders, University of York, York, UK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'South', 'Affiliation': 'Centre for Reviews and Dissemination, University of York, York, UK.'}, {'ForeName': 'Zainab', 'Initials': 'Z', 'LastName': 'Samaan', 'Affiliation': 'Psychiatry, Faculty of Health Sciences, McMaster University, Hamilton, Canada.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Richards', 'Affiliation': 'School of Psychology, University of Exeter, Exeter, UK.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Meader', 'Affiliation': 'Centre for Reviews and Dissemination, University of York, York, UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Churchill', 'Affiliation': 'Cochrane Common Mental Disorders, University of York, York, UK.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD013305.pub2'] 1532,32622871,Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.,"Efficient therapies are available for the treatment of osteoporosis. Bisphosphonates and denosumab are the most commonly used antiresorptive therapies. Despite differences in the increase in bone mineral density seen with these drugs, the reductions in fracture risk are similar; 50-70%, 20%, and 40% for vertebral, non-vertebral and hip fractures, respectively. The bone-forming treatments; teriparatide and abaloparatide increase bone mineral density more than the antiresorptives and the reductions in fracture risk are 85% and 40-50% for vertebral and non-vertebral fractures, respectively, compared to placebo. The VERO study demonstrated a >50% reduction in vertebral and clinical fractures in women treated with teriparatide compared to risedronate. The dual-action treatment; romosozumab leads to more pronounced increases in BMD than other treatment modalities and reduces the risk of vertebral and clinical fractures by 73% and 36% compared to placebo after 12 months and the sequential treatment regime; romosozumab for 12 months followed by alendronate reduced the risk of vertebral, non-vertebral and hip fractures by 48%, 20% and 38%, respectively compared to alendronate after 2-3 years. The evidence for combination therapy targeting both resorption and formation is limited as only short-term studies with BMD as the endpoint have been performed. All bone-forming and dual-action treatments increase BMD and reduce the fracture risk, however, the effect wears off with time and treatment is therefore only temporary and should be followed by antiresorptive treatment with a bisphosphonate or denosumab. The sequence of treatment matters as the BMD response to teriparatide is reduced in patients previously treated with bisphosphonates; however, based on the findings of the VERO trial, the anti-fracture efficacy of bone-forming treatment in comparison with risedronate seems to be preserved after bisphosphonate therapy. The DATA study suggested that transitioning from denosumab to teriparatide is problematic due to the increase in bone resorption occurring after stopping denosumab. Studies have shown further improvements in BMD when transitioning from oral bisphosphonates to zoledronic acid or denosumab. Management of osteoporosis will in many patients include a long-term treatment plan. This will often include sequential therapy which in severe cases preferably should start with bone-forming followed by antiresorptive treatment. The severity of osteoporosis, reaching a treatment goal, and responding to treatment failure are important factors determining the treatment sequence in the individual patient.",2020,"The dual-action treatment; romosozumab leads to more pronounced increases in BMD than other treatment modalities and reduces the risk of vertebral and clinical fractures by 73% and 36% compared to placebo after 12 months and the sequential treatment regime; romosozumab for 12 months followed by alendronate reduced the risk of vertebral, non-vertebral and hip fractures by 48%, 20% and 38%, respectively compared to alendronate after 2-3 years.","['patients previously treated with', 'postmenopausal osteoporosis with bone-forming and antiresorptive treatments']","['teriparatide', 'zoledronic acid or denosumab', 'Bisphosphonates and denosumab', 'bisphosphonates', 'alendronate', 'bisphosphonate or denosumab', 'risedronate', 'placebo']","['bone mineral density', 'vertebral and clinical fractures', 'risk of vertebral, non-vertebral and hip fractures', 'BMD', 'risk of vertebral and clinical fractures', 'fracture risk', 'BMD response', 'bone resorption']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0029458', 'cui_str': 'Postmenopausal osteoporosis'}, {'cui': 'C1286272', 'cui_str': 'Form of bone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0070093', 'cui_str': 'Teriparatide'}, {'cui': 'C0257685', 'cui_str': 'zoledronic acid'}, {'cui': 'C1690432', 'cui_str': 'denosumab'}, {'cui': 'C0012544', 'cui_str': 'Bisphosphonate'}, {'cui': 'C0102118', 'cui_str': 'Alendronate'}, {'cui': 'C0246719', 'cui_str': 'Risedronate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0549207', 'cui_str': 'Bone structure of spine'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0005974', 'cui_str': 'Bone resorption'}]",,0.0195905,"The dual-action treatment; romosozumab leads to more pronounced increases in BMD than other treatment modalities and reduces the risk of vertebral and clinical fractures by 73% and 36% compared to placebo after 12 months and the sequential treatment regime; romosozumab for 12 months followed by alendronate reduced the risk of vertebral, non-vertebral and hip fractures by 48%, 20% and 38%, respectively compared to alendronate after 2-3 years.","[{'ForeName': 'Bente', 'Initials': 'B', 'LastName': 'Langdahl', 'Affiliation': 'Aarhus University Hospital, Endocrinology and Internal Medicine, Palle Juul Jensen Boulevard 115, DK8200 Aarhus N, Denmark. Electronic address: bente.langdahl@aarhus.rm.dk.'}]",Bone,['10.1016/j.bone.2020.115516'] 1533,32623005,Effect of Behavioral Economic Incentives for Colorectal Cancer Screening in a Randomized Trial.,"BACKGROUND & AIMS Financial incentives might increase participation in prevention such as screening colonoscopy. We studied whether incentives informed by behavioral economics increase participation in risk assessment for colorectal cancer (CRC) and completion of colonoscopy for eligible adults. METHODS Employees of a large academic health system (50-64 y old; n = 1977) were randomly assigned to groups that underwent risk assessment for CRC screening and direct access colonoscopy scheduling (control), or risk assessment, direct access colonoscopy scheduling, a $10 loss-framed incentive to complete risk assessment, and a $25 unconditional incentive for colonoscopy completion (incentive). The primary outcome was the percentage of participants who completed screening colonoscopy within 3 months of initial outreach. Secondary outcomes included the percentage of participants who scheduled colonoscopy and the percentage who completed the risk assessment. RESULTS At 3 months, risk assessment was completed by 19.5% of participants in the control group (95% CI, 17.0-21.9%) and 31.9% of participants in the incentive group (95% CI, 29.0-34.8%) (P < .001). At 3 months, 0.7% of controls had completed a colonoscopy (95% CI, .2%-1.2%) compared with 1.2% of subjects in the incentive group (95% CI, .5%-1.9%) (P = .25). CONCLUSIONS In a randomized trial of participants who underwent risk assessment for CRC with vs without financial incentive, the financial incentive increased CRC risk assessment completion but did not result in a greater completion of screening colonoscopy. Clinicaltrials.gov no: NCT03068052.",2020,"At 3 months, risk assessment was completed by 19.5% of participants in the control group (95% CI: 17.0-21.9%) and 31.9% of participants in the incentive group (95% CI: 29.0-34.8%) (P<.001).","['Employees of a large academic health system (50-64 y old; n=1977', 'colorectal cancer (CRC) and completion of colonoscopy for eligible adults', 'participants who underwent risk assessment for CRC with vs without financial incentive']","['Behavioral Economic Incentives', 'risk assessment for CRC screening and direct access colonoscopy scheduling (control), or risk assessment, direct access colonoscopy scheduling, a $10 loss-framed incentive to complete risk assessment, and a $25 unconditional incentive for colonoscopy completion (incentive']","['percentage of participants who scheduled colonoscopy and the percentage who completed the risk assessment', 'percentage of participants who completed screening colonoscopy within 3 months of initial outreach', 'CRC risk assessment completion', 'risk assessment']","[{'cui': 'C0599987', 'cui_str': 'Employee'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086930', 'cui_str': 'Risk assessment'}, {'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0013556', 'cui_str': 'Economics'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0086930', 'cui_str': 'Risk assessment'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0205539', 'cui_str': 'Scheduled - procedure status'}, {'cui': 'C0080089', 'cui_str': 'Reading Frames'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0086930', 'cui_str': 'Risk assessment'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}]",,0.185879,"At 3 months, risk assessment was completed by 19.5% of participants in the control group (95% CI: 17.0-21.9%) and 31.9% of participants in the incentive group (95% CI: 29.0-34.8%) (P<.001).","[{'ForeName': 'Shivan J', 'Initials': 'SJ', 'LastName': 'Mehta', 'Affiliation': 'Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Health Care Innovation, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: shivan.mehta@pennmedicine.upenn.edu.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Reitz', 'Affiliation': 'Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Health Care Innovation, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Tess', 'Initials': 'T', 'LastName': 'Niewood', 'Affiliation': 'Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Kevin G', 'Initials': 'KG', 'LastName': 'Volpp', 'Affiliation': 'Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Health Care Innovation, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Health Equity Research and Promotion, Philadelphia VA Medical Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Asch', 'Affiliation': 'Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Health Care Innovation, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Health Equity Research and Promotion, Philadelphia VA Medical Center, Philadelphia, Pennsylvania.'}]",Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,['10.1016/j.cgh.2020.06.047'] 1534,32623343,"""Sushi roll"" technique for precise total tongue functional reconstruction using a pre-sutured femoral anterolateral myocutaneous flap.","OBJECTIVES Reconstruction of the total tongue after cancer resection remains one of the challenges in head and neck surgery. Inadequate reconstruction after subtotal or total glossectomy defects leads to poor quality of life. The aim of this study was to explore an economical, practical and effective flap design for functional tongue reconstruction. MATERIAL AND METHODS Sixty patients were randomly divided into two groups, namely, a ""Sushi roll"" technique group (30 patients) and a conventional surgery group (30 patients). Then, the patients underwent total or subtotal tongue reconstruction. Swallowing function, speech intelligibility, cosmetic results, and quality of life were assessed with the appropriate scales. Outcomes were analysed, and a p-value <0.05 was considered significant. RESULTS The perioperative recovery of the ""Sushi roll"" group was superior to that of the conventional group. Relative to patients in the conventional group, patients in the ""Sushi roll"" group showed significantly improved speech intelligibility (p = 0.025), cosmetic results (p < 0.001) and swallowing function (p < 0.001). CONCLUSION The innovative ""Sushi roll"" anterolateral thigh myocutaneous flap approach for total tongue reconstruction creates a free neotongue tip with adequate volume and protuberance and causes minimal damage to the donor site, producing acceptable swallowing function and speech intelligibility.",2020,"Relative to patients in the conventional group, patients in the ""Sushi roll"" group showed significantly improved speech intelligibility (p = 0.025), cosmetic results (p < 0.001) and swallowing function (p < 0.001). ","['head and neck surgery', 'Sixty patients']","['Sushi roll"" technique group', 'conventional surgery', 'Sushi roll"" technique', 'subtotal tongue reconstruction']","['speech intelligibility', 'swallowing function', 'Swallowing function, speech intelligibility, cosmetic results, and quality of life', 'perioperative recovery', 'cosmetic results']","[{'cui': 'C0460004', 'cui_str': 'Structure of head and/or neck'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205257', 'cui_str': 'Incomplete'}, {'cui': 'C0399188', 'cui_str': 'Tongue reconstruction'}]","[{'cui': 'C0037824', 'cui_str': 'Speech Intelligibility'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",60.0,0.0201308,"Relative to patients in the conventional group, patients in the ""Sushi roll"" group showed significantly improved speech intelligibility (p = 0.025), cosmetic results (p < 0.001) and swallowing function (p < 0.001). ","[{'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'Lecturer, Discipline of Oral & Maxillofacial Surgery, The Second Xiangya Hospital, Central South University, Changsha, China. Electronic address: drzhouxi0504@csu.edu.cn.'}, {'ForeName': 'Zhi-Jing', 'Initials': 'ZJ', 'LastName': 'He', 'Affiliation': 'Lecturer, Discipline of Oral & Maxillofacial Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Yu-Xiong', 'Initials': 'YX', 'LastName': 'Su', 'Affiliation': 'Associate Professor, Discipline of Oral & Maxillofacial Surgery, Faculty of Dentistry, the University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Sheng', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': 'Professor and Chief, Discipline of Oral & Maxillofacial Surgery, The Second Xiangya hospital, Central South University, Changsha, China.'}, {'ForeName': 'Zhao Jian', 'Initials': 'ZJ', 'LastName': 'Gong', 'Affiliation': 'Associate Professor, Discipline of Oral & Maxillofacial Surgery, The Second Xiangya hospital, Central South University, Changsha, China.'}, {'ForeName': 'Han Jiang', 'Initials': 'HJ', 'LastName': 'Wu', 'Affiliation': 'Professor and Chief, Discipline of Oral & Maxillofacial Surgery, The Second Xiangya hospital, Central South University, Changsha, China.'}]",Oral oncology,['10.1016/j.oraloncology.2020.104866'] 1535,32623367,"A Novel Narrative E-Writing Intervention for Parents of Children With Chronic Life-Threatening Illnesses: Protocol for a Pilot, Open-Label Randomized Controlled Trial.","BACKGROUND A novel evidence-based Narrative e-Writing Intervention (NeW-I) has been developed and tested in Singapore to advance psychosociospiritual support for parents of children with chronic life-threatening illnesses. NeW-I is informed by an international systematic review and a Singapore-based qualitative inquiry on the lived experience of parental bereavement and supported by literature on anticipatory grief interventions for improving the holistic well-being of parent caregivers of seriously ill children. OBJECTIVE This study's aim was to provide an accessible platform, NeW-I-which is a strengths- and meaning-focused and therapist-facilitated mobile app and web-based counseling platform-that aims to enhance quality of life, spiritual well-being, hope, and perceived social support and reduce depressive symptoms, caregiver burden, and risk of complicated grief among parents of children with chronic life-threatening illnesses. METHODS The NeW-I therapist-facilitated web-based platform comprises a mobile app and a website (both of which have the same content and functionality). NeW-I has been implemented in Singapore as a pilot open-label randomized controlled trial comprising intervention and control groups. Both primary and secondary outcomes will be self-reported by participants through questionnaires. In collaboration with leading pediatric palliative care providers in Singapore, the trial aims to enroll 36 participants in each group (N=72), so that when allowing for 30% attrition at follow-up, the sample size will be adequate to detect a small effect size of 0.2 in the primary outcome measure, with 90% power and two-sided significance level of at least .05. The potential effectiveness of NeW-I and the accessibility and feasibility of implementing and delivering the intervention will be assessed. RESULTS Funding support and institutional review board approval for this study have been secured. Data collection started in January 2019 and is ongoing. CONCLUSIONS NeW-I aspires to enhance holistic pediatric palliative care services through a structured web-based counseling platform that is sensitive to the unique cultural needs of Asian family caregivers who are uncomfortable with expressing emotion even during times of loss and separation. The findings of this pilot study will inform the development of a full-scale NeW-I protocol and further research to evaluate the efficacy of NeW-I in Singapore and in other Asian communities around the world. TRIAL REGISTRATION ClinicalTrials.gov NCT03684382; https://clinicaltrials.gov/ct2/show/NCT03684382. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/17561.",2020,"BACKGROUND A novel evidence-based Narrative e-Writing Intervention (NeW-I) has been developed and tested in Singapore to advance psychosociospiritual support for parents of children with chronic life-threatening illnesses.","['Parents of Children With Chronic Life-Threatening Illnesses', 'parents of children with chronic life-threatening illnesses', 'enroll 36 participants in each group (N=72']",['Narrative E-Writing Intervention'],[],"[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C3537125', 'cui_str': 'Common terminology criteria for adverse events grade 4'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C1135957', 'cui_str': 'Narration'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.175167,"BACKGROUND A novel evidence-based Narrative e-Writing Intervention (NeW-I) has been developed and tested in Singapore to advance psychosociospiritual support for parents of children with chronic life-threatening illnesses.","[{'ForeName': 'Andy Hau Yan', 'Initials': 'AHY', 'LastName': 'Ho', 'Affiliation': 'Psychology Program, School of Social Sciences, Nanyang Technological University, Singapore, Singapore.'}, {'ForeName': 'Oindrila', 'Initials': 'O', 'LastName': 'Dutta', 'Affiliation': 'Psychology Program, School of Social Sciences, Nanyang Technological University, Singapore, Singapore.'}, {'ForeName': 'Geraldine', 'Initials': 'G', 'LastName': 'Tan-Ho', 'Affiliation': 'Psychology Program, School of Social Sciences, Nanyang Technological University, Singapore, Singapore.'}, {'ForeName': 'Toh Hsiang Benny', 'Initials': 'THB', 'LastName': 'Tan', 'Affiliation': 'School of Computer Science and Engineering, Nanyang Technological University, Singapore, Singapore.'}, {'ForeName': 'Casuarine Xinyi', 'Initials': 'CX', 'LastName': 'Low', 'Affiliation': 'Psychology Program, School of Social Sciences, Nanyang Technological University, Singapore, Singapore.'}, {'ForeName': 'Sashikumar', 'Initials': 'S', 'LastName': 'Ganapathy', 'Affiliation': 'Club Rainbow, Singapore, Singapore.'}, {'ForeName': 'Josip', 'Initials': 'J', 'LastName': 'Car', 'Affiliation': 'Centre for Population Health Sciences, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.'}, {'ForeName': 'Ringo Moon-Ho', 'Initials': 'RM', 'LastName': 'Ho', 'Affiliation': 'Psychology Program, School of Social Sciences, Nanyang Technological University, Singapore, Singapore.'}, {'ForeName': 'Chun Yan', 'Initials': 'CY', 'LastName': 'Miao', 'Affiliation': 'School of Computer Science and Engineering, Nanyang Technological University, Singapore, Singapore.'}]",JMIR research protocols,['10.2196/17561'] 1536,32623368,Effectiveness of Using Mental Health Mobile Apps as Digital Antidepressants for Reducing Anxiety and Depression: Protocol for a Multiple Baseline Across-Individuals Design.,"BACKGROUND The use of mental health mobile apps to treat anxiety and depression is widespread and growing. Several reviews have found that most of these apps do not have published evidence for their effectiveness, and existing research has primarily been undertaken by individuals and institutions that have an association with the app being tested. Another reason for the lack of research is that the execution of the traditional randomized controlled trial is time prohibitive in this profit-driven industry. Consequently, there have been calls for different methodologies to be considered. One such methodology is the single-case design, of which, to the best of our knowledge, no peer-reviewed published example with mental health apps for anxiety and/or depression could be located. OBJECTIVE The aim of this study is to examine the effectiveness of 5 apps (Destressify, MoodMission, Smiling Mind, MindShift, and SuperBetter) in reducing symptoms of anxiety and/or depression. These apps were selected because they are publicly available, free to download, and have published evidence of efficacy. METHODS A multiple baseline across-individuals design will be employed. A total of 50 participants will be recruited (10 for each app) who will provide baseline data for 20 days. The sequential introduction of an intervention phase will commence once baseline readings have indicated stability in the measures of participants' mental health and will proceed for 10 weeks. Postintervention measurements will continue for a further 20 days. Participants will be required to provide daily subjective units of distress (SUDS) ratings via SMS text messages and will complete other measures at 5 different time points, including at 6-month follow-up. SUDS data will be examined via a time series analysis across the experimental phases. Individual analyses of outcome measures will be conducted to detect clinically significant changes in symptoms using the statistical approach proposed by Jacobson and Truax. Participants will rate their app on several domains at the end of the intervention. RESULTS Participant recruitment commenced in January 2020. The postintervention phase will be completed by June 2020. Data analysis will commence after this. A write-up for publication is expected to be completed after the follow-up phase is finalized in January 2021. CONCLUSIONS If the apps prove to be effective as hypothesized, this will provide collateral evidence of their efficacy. It could also provide the benefits of (1) improved access to mental health services for people in rural areas, lower socioeconomic groups, and children and adolescents and (2) improved capacity to enhance face-to-face therapy through digital homework tasks that can be shared instantly with a therapist. It is also anticipated that this methodology could be used for other mental health apps to bolster the independent evidence base for this mode of treatment. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) PRR1-10.2196/17159.",2020,Individual analyses of outcome measures will be conducted to detect clinically significant changes in symptoms using the statistical approach proposed by Jacobson and Truax.,['50 participants will be recruited (10 for each app) who will provide baseline data for 20 days'],"['Mental Health Mobile Apps', '5 apps (Destressify, MoodMission, Smiling Mind, MindShift, and SuperBetter']",[],"[{'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0037363', 'cui_str': 'Smiling'}]",[],50.0,0.167334,Individual analyses of outcome measures will be conducted to detect clinically significant changes in symptoms using the statistical approach proposed by Jacobson and Truax.,"[{'ForeName': 'Jamie M', 'Initials': 'JM', 'LastName': 'Marshall', 'Affiliation': 'School of Psychology, Faculty of Medicine and Health, University of New England, Armidale, Australia.'}, {'ForeName': 'Debra A', 'Initials': 'DA', 'LastName': 'Dunstan', 'Affiliation': 'School of Psychology, Faculty of Medicine and Health, University of New England, Armidale, Australia.'}, {'ForeName': 'Warren', 'Initials': 'W', 'LastName': 'Bartik', 'Affiliation': 'School of Psychology, Faculty of Medicine and Health, University of New England, Armidale, Australia.'}]",JMIR research protocols,['10.2196/17159'] 1537,32624365,Could self-locking stand-alone cage reduce adjacent-level ossification development after aneterior cervical discectomy and fusion?,"Numerous studies have shown that cervical arthrodesis is associated with the adjacent-segment pathology (ASP), such as adjacent-level ossification development (ALOD). However, it still remains largely unclear whether the self-locking stand-alone implant system can reduce the incidence of ALOD. In the present study, we prospectively recruited 120 patients with cervical degenerative disc disease (CDDD) who were treated by anterior cervical discectomy and fusion (ACDF). These patients were randomly and evenly divided into the ROI-C group and plate group. Clinical and radiologic follow-up was performed at 3, 6, 12, 24 and 36 months after surgery. Clinical evaluation included preoperative and postoperative assessments of Japanese Orthopaedic Association (JOA) score and Neck Disability Index (NDI) score. The presence and severity of ALOD, as well as the C2-7 Cobb angle, were assessed on the lateral cervical films during follow-up. There were no significant differences in JOA and NDI scores at each time point during the follow-up period between the two groups. ALOD occurred in 8.8% of 58 patients and 6.7% of 104 levels in the cage group. Moreover, ALOD occurred in 20.1% of 57 patients and 17.8% of 101 levels in the plate group. The ALOD was more serious in the plate group compared with the cage group. The C2-7 Cobb angle was significantly improved compared with that before the operation and could be maintained during the follow-up in both groups. The self-locking stand-alone cage was efficacious for ACDF, and it could reduce the incidence of ALOD compared with anterior plate and cage.",2020,There were no significant differences in JOA and NDI scores at each time point during the follow-up period between the two groups.,['120 patients with cervical degenerative disc disease (CDDD) who were treated by anterior cervical discectomy and fusion (ACDF'],[],"['JOA and NDI scores', 'Japanese Orthopaedic Association (JOA) score and Neck Disability Index (NDI) score', 'ALOD']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0158266', 'cui_str': 'Degeneration of intervertebral disc'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0442011', 'cui_str': 'Anterior cervical spine approach'}, {'cui': 'C0206078', 'cui_str': 'Discectomy of spine'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C4552416', 'cui_str': 'ACDF'}]",[],"[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C2959538', 'cui_str': 'Neck disability index score'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205117', 'cui_str': 'Juxta-posed'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0029433', 'cui_str': 'Bone formation'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}]",120.0,0.0182449,There were no significant differences in JOA and NDI scores at each time point during the follow-up period between the two groups.,"[{'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': 'Department of Orthopaedic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Orthopaedic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Lin', 'Affiliation': 'Department of Orthopaedic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.'}, {'ForeName': 'Xilei', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Orthopaedic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Dong', 'Affiliation': 'Department of Orthopaedic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Electronic address: dong.jian@zs-hospital.sh.cn.'}, {'ForeName': 'Xiaogang', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'Department of Orthopaedic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Electronic address: zhou.xiaogang@zs-hospital.sh.cn.'}]",Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,['10.1016/j.jocn.2020.06.014'] 1538,32589977,"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.","BACKGROUND Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer with a median overall survival of less than 6 months. We aimed to assess the response to single-agent selinexor, an oral selective inhibitor of nuclear export, in patients with relapsed or refractory DLBCL who had no therapeutic options of potential clinical benefit. METHODS SADAL was a multicentre, multinational, open-label, phase 2b study done in 59 sites in 19 countries. Patients aged 18 years or older with pathologically confirmed diffuse large B-cell lymphoma, an Eastern Cooperative Oncology Group performance status of 2 or less, who had received two to five lines of previous therapies, and progressed after or were not candidates for autologous stem-cell transplantation were enrolled. Germinal centre B-cell or non-germinal centre B-cell tumour subtype and double or triple expressor status were determined by immunohistochemistry and double or triple hit status was determined by cytogenetics. Patients received 60 mg selinexor orally on days 1 and 3 weekly until disease progression or unacceptable toxicity. The study was initially designed to evaluate both 60 mg and 100 mg twice-weekly doses of selinexor; however, the 100 mg dose was discontinued in the protocol (version 7.0) on March 29, 2017, when an improved therapeutic window was observed at 60 mg. Primary outcome was overall response rate. The primary outcome and safety were assessed in all patients who received 60 mg selinexor under protocol version 6.0, or enrolled under protocol versions 7.0 or higher and received at least one dose of selinexor. This trial is registered at ClinicalTrials.gov, NCT02227251 (active but not enrolling). FINDINGS Between Oct 21, 2015, and Nov 2, 2019, 267 patients were randomly assigned, with 175 allocated to the 60 mg group and 92 to the discontinued 100 mg group. 48 patients assigned to the 60 mg group were excluded due to enrolment before version 6.0 of the protocol; the remaining 127 patients received selinexor 60 mg and were included in analyses of primary outcome and safety. The overall response rate was 28% (36/127; 95% CI 20·7-37·0); 15 (12%) achieved a complete response and 21 (17%) a partial response. The most common grade 3-4 adverse events were thrombocytopenia (n=58), neutropenia (n=31), anaemia (n=28), fatigue (n=14), hyponatraemia (n=10), and nausea (n=8). The most common serious adverse events were pyrexia (n=9), pneumonia (n=6), and sepsis (n=6). There were no deaths judged as related to treatment with selinexor. INTERPRETATION Single-drug oral selinexor induced durable responses and had a manageable adverse events profile in patients with relapsed or refractory DLBCL who received at least two lines of previous chemoimmunotherapy. Selinexor could be considered a new oral, non-cytotoxic treatment option in this setting. FUNDING Karyopharm Therapeutics Inc.",2020,The overall response rate was 28% (36/127; 95% CI 20·7-37·0); 15 (12%) achieved a complete response and 21 (17%) a partial response.,"['patients with relapsed or refractory DLBCL who received at least two lines of previous', '48 patients assigned to the 60 mg group were excluded due to enrolment before version 6.0 of the protocol; the remaining 127 patients received', 'n=31), anaemia (n=28), fatigue (n=14), hyponatraemia (n=10), and nausea (n=8', 'SADAL was a multicentre, multinational, open-label, phase 2b study done in 59 sites in 19 countries', 'patients with relapsed or refractory DLBCL who had no therapeutic options of potential clinical benefit', 'patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL', 'Between Oct 21, 2015, and Nov 2, 2019, 267 patients', 'Patients aged 18 years or older with pathologically confirmed diffuse large B-cell lymphoma, an Eastern Cooperative Oncology Group performance status of 2 or less, who had received two to five lines of previous therapies, and progressed after or were not candidates for autologous stem-cell transplantation were enrolled']","['Selinexor', 'chemoimmunotherapy', 'selinexor']","['overall response rate', 'neutropenia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0855112', 'cui_str': 'Diffuse large B-cell lymphoma refractory'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0020625', 'cui_str': 'Hyponatremia'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0029279', 'cui_str': 'Ornithine carbamoyltransferase'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C4517672', 'cui_str': '267'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0079744', 'cui_str': 'Malignant lymphoma, large B-cell, diffuse'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C1831743', 'cui_str': 'Transplantation of autologous hematopoietic stem cell'}]","[{'cui': 'C3852671', 'cui_str': 'Selinexor'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}]",267.0,0.466967,The overall response rate was 28% (36/127; 95% CI 20·7-37·0); 15 (12%) achieved a complete response and 21 (17%) a partial response.,"[{'ForeName': 'Nagesh', 'Initials': 'N', 'LastName': 'Kalakonda', 'Affiliation': 'University of Liverpool, Liverpool, UK. Electronic address: nagesh.kalakonda@liverpool.ac.uk.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Maerevoet', 'Affiliation': 'Institut Jules Bordet, Brussels, Belgium.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Cavallo', 'Affiliation': 'Department of Molecular Biotechnologies and Health Sciences, Division of Hematology, University of Torino, Turin, Italy.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Follows', 'Affiliation': ""Addenbrooke's Hospital, Cambridge, UK.""}, {'ForeName': 'Andre', 'Initials': 'A', 'LastName': 'Goy', 'Affiliation': 'John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.'}, {'ForeName': 'Joost S P', 'Initials': 'JSP', 'LastName': 'Vermaat', 'Affiliation': 'Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Casasnovas', 'Affiliation': 'Hématologie Clinique, Dijon, France.'}, {'ForeName': 'Nada', 'Initials': 'N', 'LastName': 'Hamad', 'Affiliation': ""St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.""}, {'ForeName': 'Josée M', 'Initials': 'JM', 'LastName': 'Zijlstra', 'Affiliation': 'Amsterdam UMC, Vrije Universiteit, Cancer Center, Amsterdam, Netherlands.'}, {'ForeName': 'Sameer', 'Initials': 'S', 'LastName': 'Bakhshi', 'Affiliation': 'Dr B R Ambedkar Institute Rotary Cancer Hospital AIIMS, New Delhi, India.'}, {'ForeName': 'Reda', 'Initials': 'R', 'LastName': 'Bouabdallah', 'Affiliation': 'Institut Paoli-Calmettes, Marseille, France.'}, {'ForeName': 'Sylvain', 'Initials': 'S', 'LastName': 'Choquet', 'Affiliation': 'Hôpital Pitié Salpêtrière, Paris, France.'}, {'ForeName': 'Ronit', 'Initials': 'R', 'LastName': 'Gurion', 'Affiliation': 'Rabin Medical Centre, Petah Tiqwa, Israel; Tel Aviv University, Petah Tiqwa, Israel.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Hill', 'Affiliation': 'Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Jaeger', 'Affiliation': 'Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Juan Manuel', 'Initials': 'JM', 'LastName': 'Sancho', 'Affiliation': 'ICO-IJC Hospital Universitari Germans Trias I Pujol, Barcelona, Spain.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Schuster', 'Affiliation': 'Stony Brook University, Stony Brook NY, USA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Thieblemont', 'Affiliation': 'Saint-Louis Hospital, Paris, France; Paris Diderot University, Paris, France.'}, {'ForeName': 'Fátima', 'Initials': 'F', 'LastName': 'De la Cruz', 'Affiliation': 'Hospital Universitario Virgen del Rocio, Sevilla, Spain.'}, {'ForeName': 'Miklos', 'Initials': 'M', 'LastName': 'Egyed', 'Affiliation': 'Teaching Hospital Mór Kaposi, Kaposvár, Hungary.'}, {'ForeName': 'Sourav', 'Initials': 'S', 'LastName': 'Mishra', 'Affiliation': 'Institute of Medical Sciences & SUM Hospital, Odisha, India.'}, {'ForeName': 'Fritz', 'Initials': 'F', 'LastName': 'Offner', 'Affiliation': 'Gent University Hospital, Gent Belgium.'}, {'ForeName': 'Theodoros P', 'Initials': 'TP', 'LastName': 'Vassilakopoulos', 'Affiliation': 'Laikon General Hospital National, Athens, Greece; Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Krzysztof', 'Initials': 'K', 'LastName': 'Warzocha', 'Affiliation': 'Instytut Hematologii i Transfuzjologii, Warszawa, Poland.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'McCarthy', 'Affiliation': 'Karyopharm Therapeutics Inc, Newton, MA, USA.'}, {'ForeName': 'Xiwen', 'Initials': 'X', 'LastName': 'Ma', 'Affiliation': 'Karyopharm Therapeutics Inc, Newton, MA, USA.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Corona', 'Affiliation': 'Karyopharm Therapeutics Inc, Newton, MA, USA.'}, {'ForeName': 'Jean-Richard', 'Initials': 'JR', 'LastName': 'Saint-Martin', 'Affiliation': 'Karyopharm Therapeutics Inc, Newton, MA, USA.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Chang', 'Affiliation': 'Karyopharm Therapeutics Inc, Newton, MA, USA.'}, {'ForeName': 'Yosef', 'Initials': 'Y', 'LastName': 'Landesman', 'Affiliation': 'Karyopharm Therapeutics Inc, Newton, MA, USA.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Joshi', 'Affiliation': 'Karyopharm Therapeutics Inc, Newton, MA, USA.'}, {'ForeName': 'Hongwei', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Karyopharm Therapeutics Inc, Newton, MA, USA.'}, {'ForeName': 'Jatin', 'Initials': 'J', 'LastName': 'Shah', 'Affiliation': 'Karyopharm Therapeutics Inc, Newton, MA, USA.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Shacham', 'Affiliation': 'Karyopharm Therapeutics Inc, Newton, MA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kauffman', 'Affiliation': 'Karyopharm Therapeutics Inc, Newton, MA, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Van Den Neste', 'Affiliation': 'Cliniques Universitaires Saint-Luc, Brussels, Belgium.'}, {'ForeName': 'Miguel A', 'Initials': 'MA', 'LastName': 'Canales', 'Affiliation': 'Hospital Universitario La Paz, Madrid, Spain.'}]",The Lancet. Haematology,['10.1016/S2352-3026(20)30120-4'] 1539,32591370,A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).,"BACKGROUND The optimal treatment of recurrent ovarian clear cell carcinoma remains unknown. There is increasing rationale to support the role of immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD - 1)/programmed death-ligand 1 (PD-L1) axis in ovarian clear cell carcinoma. PRIMARY OBJECTIVE To evaluate the efficacy of durvalumab (MEDI-4736) compared with standard chemotherapy in patients with recurrent ovarian clear cell carcinoma. STUDY HYPOTHESIS Patients with recurrent ovarian clear cell carcinoma treated with durvalumab will have improved progression-free survival compared with those treated with chemotherapy of physician's choice. TRIAL DESIGN The MOCCA study is a multicenter, open-label, randomized phase II trial in patients with recurrent ovarian clear cell carcinoma, which recruited from eight sites across Gynecologic Cancer Group Singapore (GCGS), Korean Gynecologic-Oncology Group (KGOG), and Australia New Zealand Gynecological Oncology Group (ANZGOG). Enrolled patients were randomized in a 2:1 ratio to receive durvalumab or physician's choice of chemotherapy until disease progression, intolerable toxicity, or withdrawal of patient consent. MAJOR INCLUSION/EXCLUSION CRITERIA Eligible patients required histologically documented diagnosis of recurrent ovarian clear cell carcinoma, as evidenced by WT1 negativity. All patients must have been of Eastern Cooperative Oncology Group (ECOG) performance status 2 or better, and have had previous treatment with, and progressed or recurred after prior platinum-based chemotherapy. No more than four prior lines of treatment were allowed and prior immune checkpoint inhibitor treatment was not permitted. PRIMARY ENDPOINTS The primary endpoint was the median progression-free survival following treatment with durvalumab, compared with physician's choice of chemotherapy. Progression-free survival was defined as the time from the first day of treatment to the first observation of disease progression, or death due to any cause, or last follow-up. SAMPLE SIZE The target sample size was 46 patients. ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS Accrual has been completed and results are expected to be presented by mid-2021. TRIAL REGISTRATION Clinicaltrials.gov: NCT03405454.",2020,"The primary endpoint was the median progression-free survival following treatment with durvalumab, compared with physician's choice of chemotherapy.","['recurrent ovarian clear cell adenocarcinoma (MOCCA', 'patients with recurrent ovarian clear cell carcinoma', '46 patients', 'All patients must have been of Eastern Cooperative Oncology Group (ECOG) performance status 2 or better, and have had previous treatment with, and progressed or recurred after prior platinum-based chemotherapy', 'Patients with recurrent ovarian clear cell carcinoma treated with', 'patients with recurrent ovarian clear cell carcinoma, which recruited from eight sites across Gynecologic Cancer Group Singapore (GCGS), Korean Gynecologic-Oncology Group (KGOG), and Australia New Zealand Gynecological Oncology Group (ANZGOG']","['standard chemotherapy', ""durvalumab or physician's choice of chemotherapy until disease progression, intolerable toxicity, or withdrawal of patient consent"", 'durvalumab', 'durvalumab (MEDI-4736', ""physician's choice chemotherapy""]","['progression-free survival', 'Progression-free survival', 'median progression-free survival']","[{'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C1518693', 'cui_str': 'Clear cell adenocarcinoma of ovary'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3544205', 'cui_str': 'Ovarian clear cell carcinoma'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C3536920', 'cui_str': 'Platinum compounds'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0699889', 'cui_str': 'Female reproductive neoplasm malignant NOS'}, {'cui': 'C0037173', 'cui_str': 'Singapore'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C1321164', 'cui_str': 'Gynecological oncology'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C4055109', 'cui_str': 'durvalumab'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C3641122', 'cui_str': 'MEDI4736'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",46.0,0.0700606,"The primary endpoint was the median progression-free survival following treatment with durvalumab, compared with physician's choice of chemotherapy.","[{'ForeName': 'Natalie Yl', 'Initials': 'NY', 'LastName': 'Ngoi', 'Affiliation': 'Department of Haematology-Oncology, National University Cancer Institute, Singapore.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Heong', 'Affiliation': 'Department of Medical Oncology, Tan Tock Seng Hospital, Singapore.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Ow', 'Affiliation': 'Department of Haematology-Oncology, National University Cancer Institute, Singapore.'}, {'ForeName': 'Wen Yee', 'Initials': 'WY', 'LastName': 'Chay', 'Affiliation': 'Division of Medical Oncology, National Cancer Centre Singapore, Singapore.'}, {'ForeName': 'Hee Seung', 'Initials': 'HS', 'LastName': 'Kim', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University, Seoul, Republic of Korea.'}, {'ForeName': 'Chel Hun', 'Initials': 'CH', 'LastName': 'Choi', 'Affiliation': 'Department of Obstetrics and Gynecology, Samsung Medical Center, Seoul, Republic of Korea.'}, {'ForeName': 'Geraldine', 'Initials': 'G', 'LastName': 'Goss', 'Affiliation': 'Box Hill Hospital, Box Hill, Victoria, Australia.'}, {'ForeName': 'Jeffrey C', 'Initials': 'JC', 'LastName': 'Goh', 'Affiliation': ""Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.""}, {'ForeName': 'Bee Choo', 'Initials': 'BC', 'LastName': 'Tai', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore, Singapore.'}, {'ForeName': 'Diana Gz', 'Initials': 'DG', 'LastName': 'Lim', 'Affiliation': 'Department of Pathology, National University Hospital, Singapore.'}, {'ForeName': 'Nivashini', 'Initials': 'N', 'LastName': 'Kaliaperumal', 'Affiliation': 'Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore.'}, {'ForeName': 'Veonice B', 'Initials': 'VB', 'LastName': 'Au', 'Affiliation': 'Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore.'}, {'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'Connolly', 'Affiliation': 'Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore.'}, {'ForeName': 'Jae-Weon', 'Initials': 'JW', 'LastName': 'Kim', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University, Seoul, Republic of Korea.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Friedlander', 'Affiliation': 'The Prince of Wales Hospital, Randwick, New South Wales, Australia.'}, {'ForeName': 'Kidong', 'Initials': 'K', 'LastName': 'Kim', 'Affiliation': 'Seoul National University Bundang Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'David Sp', 'Initials': 'DS', 'LastName': 'Tan', 'Affiliation': 'Department of Haematology-Oncology, National University Cancer Institute, Singapore david_sp_tan@nuhs.edu.sg.'}]",International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,['10.1136/ijgc-2020-001604'] 1540,32592995,Proactive Integrated Consultation-Liaison Psychiatry: A new service model for the psychiatric care of general hospital inpatients.,"OBJECTIVE To describe a new service model for the psychiatric care of general hospital inpatients, called Proactive Integrated Consultation-Liaison Psychiatry ('Proactive Integrated Psychological Medicine' in the UK). METHOD The new service model was developed especially for general hospital inpatient populations with multimorbidity, such as older medical inpatients. Its design was informed by the published literature and the clinical experience of C-L psychiatrists. It was operationalized by a process of iterative piloting. RESULTS The rationale for the new model and the principles underpinning it are outlined. Details of how to implement it, including a service manual and associated workbook, are provided. The training of clinicians to deliver it is described. The effectiveness and cost-effectiveness of this new service model is being evaluated. Whilst we have found it feasible to deliver and well-accepted by ward teams, potential challenges to its wider implementation are discussed. CONCLUSION Proactive Integrated Consultation-Liaison Psychiatry (PICLP) is a fusion of proactive consultation and integrated care, operationalized in a field-tested service manual. Initial experience indicates that it is feasible to deliver. Its effectiveness and cost effectiveness for older patients on acute medical wards is currently being evaluated in a large multicentre randomized controlled trial (The HOME Study).",2020,"The new service model was developed especially for general hospital inpatient populations with multimorbidity, such as older medical inpatients.","['general hospital inpatient populations with multimorbidity, such as older medical inpatients', ""general hospital inpatients, called Proactive Integrated Consultation-Liaison Psychiatry ('Proactive Integrated Psychological Medicine' in the UK"", 'general hospital inpatients', 'older patients on acute medical wards']","['Proactive Integrated Consultation-Liaison Psychiatry (PICLP', 'Proactive Integrated Consultation-Liaison Psychiatry']",['effectiveness and cost-effectiveness'],"[{'cui': 'C0020008', 'cui_str': 'Hospitals, General'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1535889', 'cui_str': 'Multimorbidity'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C1305702', 'cui_str': 'Ward'}]","[{'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",,0.0145088,"The new service model was developed especially for general hospital inpatient populations with multimorbidity, such as older medical inpatients.","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Sharpe', 'Affiliation': 'Psychological Medicine Research, University of Oxford Department of Psychiatry, Warneford Hospital, Oxford, UK. Electronic address: michael.sharpe@psych.ox.ac.uk.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Toynbee', 'Affiliation': 'Psychological Medicine Research, University of Oxford Department of Psychiatry, Warneford Hospital, Oxford, UK.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Walker', 'Affiliation': 'Psychological Medicine Research, University of Oxford Department of Psychiatry, Warneford Hospital, Oxford, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': 'Psychological Medicine Research, University of Oxford Department of Psychiatry, Warneford Hospital, Oxford, UK.'}]",General hospital psychiatry,['10.1016/j.genhosppsych.2020.06.005'] 1541,32597789,Assisting Home-Based Resistance Training for Normotensive and Prehypertensive Individuals Using Ambient Lighting and Sonification Feedback: Sensor-Based System Evaluation.,"BACKGROUND Physical exercise is an effective lifestyle intervention to improve blood pressure. Although aerobic sports can be performed anywhere, resistance exercises are traditionally performed at the gym; extending the latter to the home setting may promote an increase in the number of practitioners. OBJECTIVE This study aims to evaluate a sensor-based system that guides resistance exercises through ambient lighting and sonification (A/S) feedback in a home setting in 34 study participants who were normotensive and prehypertensive. METHODS Participants took part in a 1.5-hour exercise session in which they experienced the A/S feedback (ie, experimental condition) as well as a control condition (ie, no feedback) and a reference condition (ie, verbal feedback through a human remote coach). The system was evaluated for improving exercise form (range of motion, timing, and breathing patterns) as well as psychophysiological experience (perceived exertion, attentional focus, competence, and motivation). RESULTS A/S feedback was significantly better than the control for concentric (mean 2.48, SD 0.75 seconds; P<.001) and eccentric (mean 2.92, SD 1.05 seconds; P<.001) contraction times, concentric range of motion consistency (mean 15.64, SD 8.31 cm vs mean 17.94, SD 9.75 cm; P<.001), and perceived exertion (mean 3.37, SD 0.78 vs mean 3.64, SD 0.76; P<.001). However, A/S feedback did not outperform verbal feedback on any of these measures. The breathing technique was best in the control condition (ie, without any feedback). Participants did not show more positive changes in perceived competence with A/S feedback or verbal feedback. CONCLUSIONS The system seemed to improve resistance exercise execution and perception in comparison with the control, but did not outperform a human tele-coach. Further research is warranted to improve the breathing technique.",2020,"RESULTS A/S feedback was significantly better than the control for concentric (mean 2.48, SD 0.75 seconds; P<.001) and eccentric (mean 2.92, SD 1.05 seconds; P<.001) contraction times, concentric range of motion consistency (mean 15.64, SD 8.31 cm","['Participants took part in a 1.5-hour exercise session in which they experienced the A/S feedback (ie, experimental condition) as well as a control condition (ie, no feedback) and a reference condition (ie, verbal feedback through a human remote coach', 'Normotensive and Prehypertensive Individuals Using Ambient Lighting and Sonification Feedback', '34 study participants who were normotensive and prehypertensive']","['Assisting Home-Based Resistance Training', 'guides resistance exercises through ambient lighting and sonification (A/S) feedback', 'Physical exercise']","['blood pressure', 'positive changes in perceived competence with A/S feedback or verbal feedback', 'perceived exertion', 'psychophysiological experience (perceived exertion, attentional focus, competence, and motivation', 'resistance exercise execution and perception', 'contraction times, concentric range of motion consistency']","[{'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0332273', 'cui_str': 'Through'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C2712122', 'cui_str': 'Normal blood pressure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1278561', 'cui_str': 'Judicial execution'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439744', 'cui_str': 'Concentric'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}]",34.0,0.0297682,"RESULTS A/S feedback was significantly better than the control for concentric (mean 2.48, SD 0.75 seconds; P<.001) and eccentric (mean 2.92, SD 1.05 seconds; P<.001) contraction times, concentric range of motion consistency (mean 15.64, SD 8.31 cm","[{'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Radha', 'Affiliation': 'Royal Philips, Eindhoven, Netherlands.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'den Boer', 'Affiliation': 'Eindhoven University of Technology, Eindhoven, Netherlands.'}, {'ForeName': 'Martijn C', 'Initials': 'MC', 'LastName': 'Willemsen', 'Affiliation': 'Eindhoven University of Technology, Eindhoven, Netherlands.'}, {'ForeName': 'Thom', 'Initials': 'T', 'LastName': 'Paardekooper', 'Affiliation': 'The Hague University of Applied Sciences, The Hague, Netherlands.'}, {'ForeName': 'Wijnand A', 'Initials': 'WA', 'LastName': 'IJsselsteijn', 'Affiliation': 'Eindhoven University of Technology, Eindhoven, Netherlands.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Sartor', 'Affiliation': 'Royal Philips, Eindhoven, Netherlands.'}]",JMIR cardio,['10.2196/16354'] 1542,32593791,Differential effects of modafinil on performance of low-performing and high-performing individuals during total sleep deprivation.,"BACKGROUND Individual responses to the effects of inadequate sleep have been well documented; some people are more vulnerable to the effects of sleep loss than others. Fatigue-vulnerable individuals generally require access to effective fatigue countermeasures; however, the question arises as to whether these fatigue-vulnerable individuals receive the same benefits shown in group efficacy data. The present study administered modafinil to individuals to determine its differential effects on performance of best and worst performers during sleep deprivation. METHODS A sample of 22 men, age 21-40 yrs., was tested on 2 separate occasions during which they were kept awake for 36 h. During one period they received 200 mg modafinil; during the other they received placebo. Participants were tested on a variety of tasks while rested and at 5-hr intervals across the continuous wakefulness period. Performance for each cognitive task and subjective measure of fatigue from the placebo period was used to group individuals into high (HP) or low performance (LP) groups to indicate fatigue vulnerability for each task. RESULTS Results indicated that on the MTS task, the HP group performed the same throughout the testing period, regardless of whether they received modafinil or not. However, the LP group significantly improved after receiving modafinil compared to placebo. Performance on the PVT showed the HP group had a small decrease in the number of lapses after receiving modafinil compared to placebo, whereas the LP group had a large decrease in lapses after receiving modafinil compared to placebo. Performance on the RDM showed no difference between groups, regardless of drug condition. Groups did not differ after receiving modafinil on subjective fatigue measured by the POMS. CONCLUSIONS Depending on the task, HP individuals did not benefit substantially when administered modafinil compared to placebo. However, the LP individuals improved after receiving modafinil compared to placebo.",2020,"Performance on the PVT showed the HP group had a small decrease in the number of lapses after receiving modafinil compared to placebo, whereas the LP group had a large decrease in lapses after receiving modafinil compared to placebo.","['low-performing and high-performing individuals during total sleep deprivation', 'group individuals into high (HP) or low performance (LP) groups to indicate fatigue vulnerability for each task', 'A sample of 22 men, age 21-40\u202fyrs., was tested on 2 separate occasions during which they were kept awake for 36\u202fh']","['modafinil', '200\u202fmg modafinil', 'placebo']","['subjective fatigue', 'lapses', 'number of lapses']","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037316', 'cui_str': 'Sleep deprivation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0012655', 'cui_str': 'Diathesis'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0234422', 'cui_str': 'Awake'}, {'cui': 'C0521125', 'cui_str': 'For'}]","[{'cui': 'C0066677', 'cui_str': 'modafinil'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",,0.090569,"Performance on the PVT showed the HP group had a small decrease in the number of lapses after receiving modafinil compared to placebo, whereas the LP group had a large decrease in lapses after receiving modafinil compared to placebo.","[{'ForeName': 'J Lynn', 'Initials': 'JL', 'LastName': 'Caldwell', 'Affiliation': 'Naval Medical Research Unit Dayton, United States of America. Electronic address: jo.caldwell@us.af.mil.'}, {'ForeName': 'Valarie M', 'Initials': 'VM', 'LastName': 'Schroeder', 'Affiliation': 'The Henry M. Jackson Foundation for the Advancement of Military Medicine, United States of America.'}, {'ForeName': 'Christina L', 'Initials': 'CL', 'LastName': 'Kunkle', 'Affiliation': 'The Henry M. Jackson Foundation for the Advancement of Military Medicine, United States of America.'}, {'ForeName': 'Henry G', 'Initials': 'HG', 'LastName': 'Stephenson', 'Affiliation': 'The Henry M. Jackson Foundation for the Advancement of Military Medicine, United States of America.'}]","Pharmacology, biochemistry, and behavior",['10.1016/j.pbb.2020.172968'] 1543,32593895,Effect of administration of β-hydroxy-β-methyl butyrate-enriched formula after liver transplantation: A pilot randomized controlled trial.,"OBJECTIVE Most patients undergoing liver transplantation (LT) have decreased skeletal muscle mass, malnutrition, and decreased physical activity levels. These comorbidities may prevent early recovery after surgery. The aim of this study was to examine the effects of oral nutritional formula-enriched β-hydroxy-β-methyl-butyrate (HMB), a leucine metabolite that promotes muscle synthesis and suppresses proteolysis, on postoperative sarcopenia and other outcomes after adult-to-adult living donor LT (LDLT). METHODS Thirty-three consecutive patients who underwent adult LDLT between March 2017 and October 2018 and who met inclusion criteria were randomly assigned in a 1:1 ratio to the HMB or control group. Patients in the HMB group received two packs of HMB-rich nutrients per day, which contained calcium-HMB (1500 mg), l-arginine (7000 mg), and l -glutamine (7000 mg) per pack orally or enterally from postoperative day 1 to 30 with postoperative rehabilitation. The primary endpoint was grip strength (GS) at 2 mo after LDLT. Secondary endpoints included GS at 1 mo after LDLT, skeletal muscle mass index (SMI) at 1 and 2 mo after LDLT, laboratory findings, incidence of postoperative bacteremia, and postoperative hospital length of stay (LOS). RESULTS Twelve patients in the HMB group and 11 in the control group were included in the final analysis. GS at 1 and 2 mo and SMI values at 2 mo were significantly higher in the HMB group than in the control group (GS: both P < 0.001, SMI: P = 0.04). In the HMB group, white blood cell count 3 wk after LDLT was significantly lower (P = 0.005), and postoperative hospital LOS was significantly shorter (P = 0.028) compared with the control group. The incidence of postoperative bacteremia was lower in the HMB group. CONCLUSIONS Postoperative administration of HMB-enriched formula with rehabilitation significantly increased GS at 1 and 2 mo and SMI at 2 mo and shortened postoperative hospital LOS after LDLT.",2020,"GS at 1 and 2 mo and SMI values at 2 mo were significantly higher in the HMB group than in the control group (GS: both P < 0.001, SMI: P = 0.04).","['patients undergoing liver transplantation (LT', 'after liver transplantation', 'adult-to-adult living donor LT (LDLT', 'Thirty-three consecutive patients who underwent adult LDLT between March 2017 and October 2018 and who met inclusion criteria', 'Twelve patients in the HMB group and 11 in the control group were included in the final analysis']","['HMB', 'oral nutritional formula-enriched β-hydroxy-β-methyl-butyrate (HMB), a leucine metabolite', 'HMB or control group', 'HMB-rich nutrients per day, which contained calcium-HMB (1500 mg), l-arginine (7000 mg), and l -glutamine', 'β-hydroxy-β-methyl butyrate-enriched formula']","['SMI values', 'grip strength (GS', 'white blood cell count', 'incidence of postoperative bacteremia', 'postoperative hospital LOS', 'GS at 1 mo after LDLT, skeletal muscle mass index (SMI) at 1 and 2 mo after LDLT, laboratory findings, incidence of postoperative bacteremia, and postoperative hospital length of stay (LOS', 'GS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023911', 'cui_str': 'Transplantation of liver'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0348050', 'cui_str': 'Live donor'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0066231', 'cui_str': 'Methyl butyrate'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0066231', 'cui_str': 'Methyl butyrate'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0023401', 'cui_str': 'Leucine'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C4517582', 'cui_str': '1500'}, {'cui': 'C0003765', 'cui_str': 'Arginine'}, {'cui': 'C4708914', 'cui_str': '7000'}, {'cui': 'C0017797', 'cui_str': 'Glutamine'}]","[{'cui': 'C0915075', 'cui_str': 'samarium diiodide'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0348050', 'cui_str': 'Live donor'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0587081', 'cui_str': 'Laboratory test finding'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}]",33.0,0.0731392,"GS at 1 and 2 mo and SMI values at 2 mo were significantly higher in the HMB group than in the control group (GS: both P < 0.001, SMI: P = 0.04).","[{'ForeName': 'Naoko', 'Initials': 'N', 'LastName': 'Kamo', 'Affiliation': 'Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Toshimi', 'Initials': 'T', 'LastName': 'Kaido', 'Affiliation': ""Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Gastroenterological and General Surgery, St Luke's International University and Hospital, Tokyo, Japan. Electronic address: kaido@kuhp.kyoto-u.ac.jp.""}, {'ForeName': 'Ryuji', 'Initials': 'R', 'LastName': 'Uozumi', 'Affiliation': 'Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Ito', 'Affiliation': 'Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Shintaro', 'Initials': 'S', 'LastName': 'Yagi', 'Affiliation': 'Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Koichiro', 'Initials': 'K', 'LastName': 'Hata', 'Affiliation': 'Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Kojiro', 'Initials': 'K', 'LastName': 'Taura', 'Affiliation': 'Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Uemoto', 'Affiliation': 'Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110871'] 1544,32593936,Endometrial scratch injury with office hysteroscopy before IVF/ICSI: A randomised controlled trial.,"OBJECTIVE Endometrial scratch injury (ESI) has been proposed to improve endometrial receptivity and thereby increase implantation rates in assisted reproductive technology (ART) treatment. ESI has been widely incorporated into clinical practice despite inconclusive evidence of its effect on reproductive outcomes. We aimed to assess pregnancy and live birth rates in subfertile women receiving ESI before IVF treatment in comparison to controls. STUDY DESIGN This was a randomised controlled trial (RCT) with no blinding of participants, investigators or health care personnel. Women in ART treatment were allocated to either office hysteroscopy with ESI (ESI group) or no intervention (control group). In total 184 women in IVF/ICSI treatment with minimum one previous failed IVF/ICSI cycle, were included in the final analysis. The primary outcome was positive serum hCG (s-hCG). Secondary outcomes were ongoing pregnancy and live birth rate. Only per-protocol analyses were performed as all patients included at one centre had to be excluded. The trial is registered at ClinicalTrials.gov, NCT01743391. RESULTS Our results showed a non-significant increase in positive s-hCG (OR 1.23, 95 % CI (0.65-2.33)), ongoing pregnancy (OR 1.52, 95 % CI (0.73-3.17)), and live birth rates (OR 1.69, 95 % CI (0.78-3.64)) per randomised woman between the ESI and the control group. CONCLUSION We observed no significant differences in positive s-hCG or other reproductive outcomes in the ESI vs. the control group. While the crude estimates of positive reproductive outcomes were higher in the ESI group, statistical significance was not reached, and the study was not powered to show smaller differences. However, data from this study will be re-evaluated in the context of an individual participant data meta-analysis (IPD-MA) of RCTs on ESI.",2020,Women in ART treatment were allocated to either office hysteroscopy with ESI (ESI group) or no intervention (control group).,"['In total 184 women in IVF/ICSI treatment with minimum one previous failed IVF/ICSI cycle, were included in the final analysis', 'Endometrial scratch injury with office hysteroscopy before IVF/ICSI', 'subfertile women receiving ESI before IVF treatment in comparison to controls', 'Women in ART treatment', 'participants, investigators or health care personnel']","['office hysteroscopy with ESI (ESI group) or no intervention (control group', 'ESI']","['positive reproductive outcomes', 'live birth rates', 'ongoing pregnancy and live birth rate', 'ongoing pregnancy', 'positive s-hCG', 'pregnancy and live birth rates', 'positive serum hCG (s-hCG']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517616', 'cui_str': '184'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C0455164', 'cui_str': 'IVF - In vitro fertilization with intracytoplasmic sperm injection (ICSI)'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0311213', 'cui_str': 'Dermatitis verrucosa'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0020710', 'cui_str': 'Hysteroscopy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0035157', 'cui_str': 'Reproductive Technologies'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}]","[{'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0020710', 'cui_str': 'Hysteroscopy'}, {'cui': 'C0311213', 'cui_str': 'Dermatitis verrucosa'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0035150', 'cui_str': 'Reproduction'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1141639', 'cui_str': 'Human chorionic gonadotropin'}]",184.0,0.498981,Women in ART treatment were allocated to either office hysteroscopy with ESI (ESI group) or no intervention (control group).,"[{'ForeName': 'Sine', 'Initials': 'S', 'LastName': 'Berntsen', 'Affiliation': 'Department of Obstetrics and Gynaecology, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark; The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark. Electronic address: sine.berntsen.01@regionh.dk.'}, {'ForeName': 'Kristine Juul', 'Initials': 'KJ', 'LastName': 'Hare', 'Affiliation': 'Department of Obstetrics and Gynaecology, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark.'}, {'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Løssl', 'Affiliation': 'The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark; The Fertility Clinic, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.'}, {'ForeName': 'Jeanette', 'Initials': 'J', 'LastName': 'Bogstad', 'Affiliation': 'The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark; The Fertility Clinic, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Palmø', 'Affiliation': 'Department of Obstetrics and Gynaecology, Holbaek Hospital, Smedelundsgade 60, 4300 Holbaek, Denmark.'}, {'ForeName': 'Lisbeth', 'Initials': 'L', 'LastName': 'Prætorius', 'Affiliation': 'The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Zedeler', 'Affiliation': 'The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Pinborg', 'Affiliation': 'The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark; The Fertility Clinic, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.06.034'] 1545,32594858,"Time-course of changes in performance, biomechanical, physiological and perceptual responses following resistance training sessions.","This study determined the time-course of recovery after resistance training (RT) sessions and the association between changes in performance with changes in biomechanical, physiological and perceptual parameters. After a 4-week familiarization period, 14 resistance-trained males performed 3 experimental conditions, each one including 2 sessions with a recovery interval of 24, 48 h or 72 h, in a randomized order. RT sessions consisted of 5 sets of 8-10RM on squat and leg press exercises. The resistance was equal for the 2 sessions of each condition and repetitions were performed until concentric failure. Volume load (VL) and first set volume load (FSVL) were compared between sessions. Tests before each session included countermovement jump (CMJ), maximal voluntary isometric contraction (MVIC), creatine kinase (CK) and delayed onset muscle soreness (DOMS). (2 × 3) ANOVA with effect sizes (ES) assessed the time-course of recovery and Kendall test the correlation between variables ( α  = 0.05). Significant interaction was observed for all variables, except for CK, where a condition main effect occurred. Comparisons between post and pre-intervals showed VL ( p  = 0.011;ES = -0.90) decreased for 24 h condition, while FSVL remained decreased for 48 h ( p  = 0.031;ES = -0.63) and DOMS increased ( p  = 0.001;ES = 3.52). CMJ ( p  = 0.025;ES = 0.25) and MVIC ( p  = 0.031;ES = 0.14) performance increased at 72 h. FSVL ( r  = 0.424), CMJ ( r  = 0.439), MVIC ( r  = 0.389) and DOMS ( r  = -0.327) were significantly correlated with VL ( p  < 0.05). Time-course of VL showed the necessity of at least 48 h for the reestablishment of performance, though better perceptual responses were evident at 72h. Thus, both recovery intervals may be beneficial after lower-limbs RT until concentric failure, though chronic effects still need to be investigated.",2020,CMJ (p=0.025;ES=0.25) and MVIC,[],"['FSVL', 'resistance training (RT) sessions', 'MVIC', 'CMJ']","['Time-Course of Changes in Performance, Biomechanical, Physiological and Perceptual Responses', 'Volume load (VL) and first set volume load (FSVL', 'MVIC (r=0.389) and DOMS', 'DOMS', 'VL (p=0.011;ES=-0.90) decreased for 24h condition, while FSVL', 'countermovement jump (CMJ), maximal voluntary isometric contraction (MVIC), creatine kinase (CK) and delayed onset muscle soreness (DOMS', 'time-course of recovery and Kendall test']",[],"[{'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0022205', 'cui_str': 'Muscle isometric contraction'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}]","[{'cui': 'C0449247', 'cui_str': 'Time course'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0022205', 'cui_str': 'Muscle isometric contraction'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",14.0,0.0317648,CMJ (p=0.025;ES=0.25) and MVIC,"[{'ForeName': 'Karine Naves De Oliveira', 'Initials': 'KNO', 'LastName': 'Goulart', 'Affiliation': 'Postgraduate Program in Sport Sciences, School of Physical Education, Physiotherapy and Occupational Therapy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}, {'ForeName': 'Nathalia Maria', 'Initials': 'NM', 'LastName': 'Resende', 'Affiliation': 'Physical Education Department, Universidade Federal de Lavras, Lavras, Brazil.'}, {'ForeName': 'Marcos Daniel Motta', 'Initials': 'MDM', 'LastName': 'Drummond', 'Affiliation': 'Postgraduate Program in Sport Sciences, School of Physical Education, Physiotherapy and Occupational Therapy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}, {'ForeName': 'Luciana Maria', 'Initials': 'LM', 'LastName': 'Oliveira', 'Affiliation': 'Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}, {'ForeName': 'Fernando Vitor', 'Initials': 'FV', 'LastName': 'Lima', 'Affiliation': 'Postgraduate Program in Sport Sciences, School of Physical Education, Physiotherapy and Occupational Therapy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}, {'ForeName': 'Leszek Antoni', 'Initials': 'LA', 'LastName': 'Szmuchrowski', 'Affiliation': 'Postgraduate Program in Sport Sciences, School of Physical Education, Physiotherapy and Occupational Therapy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}, {'ForeName': 'Ricardo Toshio', 'Initials': 'RT', 'LastName': 'Fujiwara', 'Affiliation': 'Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}, {'ForeName': 'Bruno Pena', 'Initials': 'BP', 'LastName': 'Couto', 'Affiliation': 'Postgraduate Program in Sport Sciences, School of Physical Education, Physiotherapy and Occupational Therapy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}]",European journal of sport science,['10.1080/17461391.2020.1789227'] 1546,32602170,Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial.,"It is unclear if genetic variants affect smoking cessation treatment response. This study tested whether variants in the cholinergic receptor nicotinic alpha 5 subunit (CHRNA5) predict response to smoking cessation medication by directly comparing the two most effective smoking cessation pharmacotherapies. In this genotype-stratified randomized, double-blind, placebo-controlled clinical trial (May 2015-August 2019 in St Louis, Missouri), smokers were randomized by genotype in blocks of six (1:1:1 ratio) to three conditions: 12 weeks of placebo (n = 273), combination nicotine patch and lozenge (combination nicotine replacement therapy, cNRT, n = 275), or varenicline (n = 274). All participants received counseling and were followed for 12 months. The primary end point was biochemically verified 7-day point prevalence abstinence at the end of treatment (EOT, week 12). Trial registration and eligibility criteria are on clinicaltrials.gov (https://clinicaltrials.gov/) (NCT02351167). We conducted the genetic analyses separately for 516 European ancestry (EA) smokers and 306 non-EA smokers (including 270 African American smokers). In African American smokers, there was a genotype-by-treatment interaction for EOT abstinence (χ 2  = 10.7, degrees of freedom = 2. P = 0.0049): specifically, cNRT was more effective in smokers with rs16969968 GG genotype than was placebo, while varenicline was more effective in smokers of GA/AA genotypes. In EA ancestry smokers, there was no significant genotype-by-treatment interaction. In the whole sample, although both were effective at EOT, only varenicline, and not cNRT, was significantly effective relative to placebo at 6-month follow-up. Importantly, this study suggests that genetic information can further enhance smoking cessation treatment effectiveness.",2020,"In the whole sample, only varenicline, and not cNRT, produced higher abstinence at 6-month follow-up.","['African American smokers', '516 European American (EA) smokers and 306 non-EA smokers (including 270 African American smokers']","['varenicline, and not cNRT', 'placebo', 'cholinergic receptor nicotinic alpha 5 subunit (CHRNA5', 'Varenicline and Combination Nicotine Replacement', 'varenicline', 'combination nicotine patch and lozenge (cNRT, n=275), or varenicline', 'cNRT']",['7-day point prevalence abstinence'],"[{'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4319603', 'cui_str': '270'}]","[{'cui': 'C1569608', 'cui_str': 'varenicline'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0034792', 'cui_str': 'Cholinergic receptor'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0599220', 'cui_str': 'Protein Subunit'}, {'cui': 'C1278444', 'cui_str': 'Nicotine replacement therapy'}, {'cui': 'C0358855', 'cui_str': 'Nicotine Transdermal Patch'}, {'cui': 'C0991564', 'cui_str': 'Lozenge'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}]",,0.197091,"In the whole sample, only varenicline, and not cNRT, produced higher abstinence at 6-month follow-up.","[{'ForeName': 'Li-Shiun', 'Initials': 'LS', 'LastName': 'Chen', 'Affiliation': 'Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA.'}, {'ForeName': 'Timothy B', 'Initials': 'TB', 'LastName': 'Baker', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.'}, {'ForeName': 'J Philip', 'Initials': 'JP', 'LastName': 'Miller', 'Affiliation': 'Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Bray', 'Affiliation': 'Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Smock', 'Affiliation': 'Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA.'}, {'ForeName': 'Jingling', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA.'}, {'ForeName': 'Faith', 'Initials': 'F', 'LastName': 'Stoneking', 'Affiliation': 'Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Culverhouse', 'Affiliation': 'John T. Milliken Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA.'}, {'ForeName': 'Nancy L', 'Initials': 'NL', 'LastName': 'Saccone', 'Affiliation': 'Department of Genetics, Washington University School of Medicine, St Louis, Missouri, USA.'}, {'ForeName': 'Christopher I', 'Initials': 'CI', 'LastName': 'Amos', 'Affiliation': 'Department of Biomedical Data Science, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Carney', 'Affiliation': 'Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA.'}, {'ForeName': 'Douglas E', 'Initials': 'DE', 'LastName': 'Jorenby', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Bierut', 'Affiliation': 'Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA.'}]",Clinical pharmacology and therapeutics,['10.1002/cpt.1971'] 1547,32602177,A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The FERWON-EXT trial.,,2020,,['patients with iron deficiency anemia'],['ferric derisomaltose'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia'}]","[{'cui': 'C3848561', 'cui_str': 'ferric cation'}]",[],,0.0746263,,"[{'ForeName': 'Maureen M', 'Initials': 'MM', 'LastName': 'Achebe', 'Affiliation': ""Divison of Hematology, Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Glaspy', 'Affiliation': 'Department of Medicine, Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, California, USA.'}, {'ForeName': 'Philip A', 'Initials': 'PA', 'LastName': 'Kalra', 'Affiliation': 'Department of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Auerbach', 'Affiliation': 'Department of Medicine, Georgetown University School of Medicine, Washington, District of Columbia, USA.'}, {'ForeName': 'Lars L', 'Initials': 'LL', 'LastName': 'Thomsen', 'Affiliation': 'Department of Clinical and Non-Clinical Research, Pharmacosmos A/S, Holbaek, Denmark.'}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Bhandari', 'Affiliation': 'Department of Renal Medicine, Hull University Teaching Hospitals NHS Trust, Kingston upon Hull, UK.'}]",American journal of hematology,['10.1002/ajh.25920'] 1548,32602347,Machine-Learning Algorithms Based on Screening Tests for Mild Cognitive Impairment.,"BACKGROUND The mobile screening test system for mild cognitive impairment (mSTS-MCI) was developed and validated to address the low sensitivity and specificity of the Montreal Cognitive Assessment (MoCA) widely used clinically. OBJECTIVE This study was to evaluate the efficacy machine learning algorithms based on the mSTS-MCI and Korean version of MoCA. METHOD In total, 103 healthy individuals and 74 patients with MCI were randomly divided into training and test data sets, respectively. The algorithm using TensorFlow was trained based on the training data set, and then its accuracy was calculated based on the test data set. The cost was calculated via logistic regression in this case. RESULT Predictive power of the algorithms was higher than those of the original tests. In particular, the algorithm based on the mSTS-MCI showed the highest positive-predictive value. CONCLUSION The machine learning algorithms predicting MCI showed the comparable findings with the conventional screening tools.",2020,Predictive power of the algorithms was higher than those of the original tests.,"['103 healthy individuals and 74 patients with MCI', 'Mild Cognitive Impairment', 'mild cognitive impairment (mSTS-MCI']",['Machine-Learning Algorithms'],[],"[{'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0560005', 'cui_str': 'mCi'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0871311', 'cui_str': 'Screening test'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0336779', 'cui_str': 'Machine'}, {'cui': 'C0023185', 'cui_str': 'Learning'}]",[],103.0,0.0155207,Predictive power of the algorithms was higher than those of the original tests.,"[{'ForeName': 'Jin-Hyuck', 'Initials': 'JH', 'LastName': 'Park', 'Affiliation': 'Department of Occupational Therapy, College of Medical Science, Soonchunhyang University, Asan, Korea.'}]",American journal of Alzheimer's disease and other dementias,['10.1177/1533317520927163'] 1549,32598909,"Early vaginal progesterone versus placebo in twin pregnancies for the prevention of spontaneous preterm birth: a randomized, double-blind trial.","BACKGROUND In women with a singleton pregnancy and sonographic short cervix in midgestation, vaginal administration of progesterone reduces the risk of early preterm birth and improves neonatal outcomes without any demonstrable deleterious effects on childhood neurodevelopment. In women with twin pregnancies, the rate of spontaneous early preterm birth is 10 times higher than that in singletons, and in this respect, all twins are at an increased risk of preterm birth. However, 6 trials in unselected twin pregnancies reported that vaginal administration of progesterone from midgestation had no significant effect on the incidence of early preterm birth. Such apparent lack of effectiveness of progesterone in twins may be due to inadequate dosage or treatment that is started too late in pregnancy. OBJECTIVE The early vaginal progesterone for the prevention of spontaneous preterm birth in twins, a randomized, placebo-controlled, double-blind trial, was designed to test the hypothesis that among women with twin pregnancies, vaginal progesterone at a dose of 600 mg per day from 11 to 14 until 34 weeks' gestation, as compared with placebo, would result in a significant reduction in the incidence of spontaneous preterm birth between 24 +0 and 33 +6 weeks. STUDY DESIGN The trial was conducted at 22 hospitals in England, Spain, Bulgaria, Italy, Belgium, and France. Women were randomly assigned in a 1:1 ratio to receive either progesterone or placebo, and in the random-sequence generation, there was stratification according to the participating center. The primary outcome was spontaneous birth between 24 +0 and 33 +6 weeks' gestation. Statistical analyses were performed on an intention-to-treat basis. Logistic regression analysis was used to determine the significance of difference in the incidence of spontaneous birth between 24 +0 and 33 +6 weeks' gestation between the progesterone and placebo groups, adjusting for the effect of participating center, chorionicity, parity, and method of conception. Prespecified tests of treatment interaction effects with chorionicity, parity, method of conception, compliance, and cervical length at recruitment were performed. A post hoc analysis using mixed-effects Cox regression was used for further exploration of the effect of progesterone on preterm birth. RESULTS We recruited 1194 women between May 2017 and April 2019; 21 withdrew consent and 4 were lost to follow-up, which left 582 in the progesterone group and 587 in the placebo group. Adherence was good, with reported intake of ≥80% of the required number of capsules in 81.4% of the participants. After excluding births before 24 weeks and indicated deliveries before 34 weeks, spontaneous birth between 24 +0 and 33 +6 weeks occurred in 10.4% (56/541) of participants in the progesterone group and in 8.2% (44/538) in the placebo group (odds ratio in the progesterone group, adjusting for the effect of participating center, chorionicity, parity, and method of conception, 1.35; 95% confidence interval, 0.88-2.05; P=.17). There was no evidence of interaction between the effects of treatment and chorionicity (P=.28), parity (P=.35), method of conception (P=.56), and adherence (P=.34); however, there was weak evidence of an interaction with cervical length (P=.08) suggestive of harm to those with a cervical length of ≥30 mm (odds ratio, 1.61; 95% confidence interval, 1.01-2.59) and potential benefit for those with a cervical length of <30 mm (odds ratio, 0.56; 95% confidence interval, 0.20-1.60). There was no evidence of difference between the 2 treatment groups for stillbirth or neonatal death, neonatal complications, neonatal therapy, and poor fetal growth. In the progesterone group, 1.4% (8/582) of women and 1.9% (22/1164) of fetuses experienced at least 1 serious adverse event; the respective numbers for the placebo group were 1.2% (7/587) and 3.2% (37/1174) (P=.80 and P=.06, respectively). In the post hoc time-to-event analysis, miscarriage or spontaneous preterm birth between randomization and 31 +6 weeks' gestation was reduced in the progesterone group relative to the placebo group (hazard ratio, 0.23; 95% confidence interval, 0.08-0.69). CONCLUSION In women with twin pregnancies, universal treatment with vaginal progesterone did not reduce the incidence of spontaneous birth between 24 +0 and 33 +6 weeks' gestation. Post hoc time-to-event analysis led to the suggestion that progesterone may reduce the risk of spontaneous birth before 32 weeks' gestation in women with a cervical length of <30 mm, and it may increase the risk for those with a cervical length of ≥30 mm.",2020,There was no evidence of difference between the two treatment groups for stillbirth or neonatal death; neonatal complications; neonatal therapy; and poor fetal growth.,"[""women with twin pregnancies, vaginal progesterone at a dose of 600 mg per day from 11-14 until 34 weeks' gestation"", '1,194 women between May 2017 and April 2019; 21 withdrew consent and 4 were lost to follow up, which left 582 in the progesterone group and 587 in the placebo group', 'spontaneous prEterm birth iN TwinS', 'women with a singleton pregnancy and sonographic short cervix in mid-gestation, vaginal administration of', '22 hospitals in England, Spain, Bulgaria, Italy, Belgium and France', 'Twin Pregnancies for prevention of spontaneous preterm birth (EVENTS']","['Placebo', 'progesterone and placebo', 'vaginal progesterone', 'progesterone', 'progesterone or placebo', 'placebo']","['spontaneous birth', 'chrorionicity, parity, method of conception, compliance and cervical length', 'vaginal progesterone', 'preterm birth', 'rate of spontaneous early preterm birth', 'cervical length', 'stillbirth or neonatal death; neonatal complications; neonatal therapy; and poor fetal growth', 'incidence of spontaneous preterm birth', 'incidence of spontaneous birth', 'risk of preterm birth', 'incidence of early preterm birth', 'risk of spontaneous birth', 'miscarriage or spontaneous preterm birth']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0152150', 'cui_str': 'Twin pregnancy'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0033308', 'cui_str': 'Progesterone'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C1302313', 'cui_str': 'Lost to follow-up'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0041427', 'cui_str': 'Twin sibling'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0007874', 'cui_str': 'Cervix uteri structure'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0001561', 'cui_str': 'Medication administration: vaginal'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0006368', 'cui_str': 'Bulgaria'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0004950', 'cui_str': 'Belgium'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0441471', 'cui_str': 'Event'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0033308', 'cui_str': 'Progesterone'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}]","[{'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0030563', 'cui_str': 'Parity'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0009637', 'cui_str': 'Conception'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0033308', 'cui_str': 'Progesterone'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0410916', 'cui_str': 'Newborn death'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0015934', 'cui_str': 'Fetal growth restriction'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}]",1194.0,0.774239,There was no evidence of difference between the two treatment groups for stillbirth or neonatal death; neonatal complications; neonatal therapy; and poor fetal growth.,"[{'ForeName': 'Anoop', 'Initials': 'A', 'LastName': 'Rehal', 'Affiliation': ""Fetal Medicine Research Institute, King's College Hospital, London, United Kingdom.""}, {'ForeName': 'Zsófia', 'Initials': 'Z', 'LastName': 'Benkő', 'Affiliation': ""Fetal Medicine Research Institute, King's College Hospital, London, United Kingdom.""}, {'ForeName': 'Catalina', 'Initials': 'C', 'LastName': 'De Paco Matallana', 'Affiliation': 'Hospital Clínico Universitario Virgen de la Arrixaca and Institute for Biomedical Research of Murcia, IMIB-Arrixaca, Murcia, Spain.'}, {'ForeName': 'Argyro', 'Initials': 'A', 'LastName': 'Syngelaki', 'Affiliation': ""Fetal Medicine Research Institute, King's College Hospital, London, United Kingdom.""}, {'ForeName': 'Deepa', 'Initials': 'D', 'LastName': 'Janga', 'Affiliation': 'North Middlesex University Hospital, London, United Kingdom.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Cicero', 'Affiliation': 'Homerton University Hospital, London, United Kingdom.'}, {'ForeName': 'Ranjit', 'Initials': 'R', 'LastName': 'Akolekar', 'Affiliation': 'Medway Maritime Hospital, Gillingham, United Kingdom.'}, {'ForeName': 'Mandeep', 'Initials': 'M', 'LastName': 'Singh', 'Affiliation': 'Southend University Hospital, Westcliff-on-Sea, United Kingdom.'}, {'ForeName': 'Petya', 'Initials': 'P', 'LastName': 'Chaveeva', 'Affiliation': 'Dr Shterev Hospital, Sofia, Bulgaria.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Burgos', 'Affiliation': 'Hospital Universitario Cruces, Biocruces Bizkaia Health Research Institute, UPV/EHU, Bizkaia, Spain.'}, {'ForeName': 'Francisca S', 'Initials': 'FS', 'LastName': 'Molina', 'Affiliation': 'Hospital Universitario San Cecilio, Instituto de Investigación Biosanitaria, Granada, Spain.'}, {'ForeName': 'Makrina', 'Initials': 'M', 'LastName': 'Savvidou', 'Affiliation': 'Chelsea and Westminster Hospital, Imperial College London, London, United Kingdom.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'De La Calle', 'Affiliation': 'Hospital Universitario La Paz, Madrid, Spain.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Persico', 'Affiliation': 'Ospedale Maggiore Policlinico, Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.'}, {'ForeName': 'Maria Soledad', 'Initials': 'MS', 'LastName': 'Quezada Rojas', 'Affiliation': 'Hospital Universitario ""12 De Octubre,\'\' Madrid, Spain.'}, {'ForeName': 'Ashis', 'Initials': 'A', 'LastName': 'Sau', 'Affiliation': 'Lewisham University Hospital, London, United Kingdom.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Greco', 'Affiliation': 'Royal London Hospital, London, United Kingdom.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': ""O'Gorman"", 'Affiliation': 'Hospital Necker-Enfants Malades, Paris, France.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Plasencia', 'Affiliation': 'Hospiten Group, Tenerife, Spain.'}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Pereira', 'Affiliation': 'Kingston Hospital, Kingston upon Thames, United Kingdom.'}, {'ForeName': 'Jacques C', 'Initials': 'JC', 'LastName': 'Jani', 'Affiliation': 'University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.'}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'Valino', 'Affiliation': 'University Hospital A Coruña, Coruña, Spain.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Del Mar Gil', 'Affiliation': 'Hospital Universitario de Torrejón, Madrid, Spain; School of Health Sciences, Universidad Francisco de Vitoria, Madrid, Spain.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Maclagan', 'Affiliation': 'Fetal Medicine Foundation, London, United Kingdom.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Wright', 'Affiliation': 'University of Exeter, Exeter, United Kingdom.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Wright', 'Affiliation': 'University of Exeter, Exeter, United Kingdom.'}, {'ForeName': 'Kypros H', 'Initials': 'KH', 'LastName': 'Nicolaides', 'Affiliation': ""Fetal Medicine Research Institute, King's College Hospital, London, United Kingdom. Electronic address: kypros@fetalmedicine.com.""}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.06.050'] 1550,32608505,Psychological therapies for women who experience intimate partner violence.,"BACKGROUND Intimate partner violence (IPV) against women is prevalent and strongly associated with mental health problems. Women experiencing IPV attend health services frequently for mental health problems. The World Health Organization recommends that women who have experienced IPV and have a mental health diagnosis should receive evidence-based mental health treatments. However, it is not known if psychological therapies work for women in the context of IPV and whether they cause harm. OBJECTIVES To assess the effectiveness of psychological therapies for women who experience IPV on the primary outcomes of depression, self-efficacy and an indicator of harm (dropouts) at six- to 12-months' follow-up, and on secondary outcomes of other mental health symptoms, anxiety, quality of life, re-exposure to IPV, safety planning and behaviours, use of healthcare and IPV services, and social support. SEARCH METHODS We searched the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR), CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO, and three other databases, to the end of October 2019. We also searched international trials registries to identify unpublished or ongoing trials and handsearched selected journals, reference lists of included trials and grey literature. SELECTION CRITERIA We included randomised controlled trials (RCTs), quasi-RCTs, cluster-RCTs and cross-over trials of psychological therapies with women aged 16 years and older who self-reported recent or lifetime experience of IPV. We included trials if women also experienced co-existing mental health diagnoses or substance abuse issues, or both. Psychological therapies included a wide range of interventions that targeted cognition, motivation and behaviour compared with usual care, no treatment, delayed or minimal interventions. We classified psychological therapies according to Cochrane Common Mental Disorders's psychological therapies list. DATA COLLECTION AND ANALYSIS Two review authors extracted data and undertook 'Risk of Bias' assessment. Treatment effects were compared between experimental and comparator interventions at short-term (up to six months post-baseline), medium-term (six to under 12 months, primary outcome time point), and long-term follow-up (12 months and above). We used standardised mean difference (SMD) for continuous and odds ratio (OR) for dichotomous outcomes, and used random-effects meta-analysis, due to high heterogeneity across trials. MAIN RESULTS We included 33 psychological trials involving 5517 women randomly assigned to experimental (2798 women, 51%) and comparator interventions (2719 women, 49%). Psychological therapies included 11 integrative therapies, nine humanistic therapies, six cognitive behavioural therapy, four third-wave cognitive behavioural therapies and three other psychologically-orientated interventions. There were no trials classified as psychodynamic therapies. Most trials were from high-income countries (19 in USA, three in Iran, two each in Australia and Greece, and one trial each in China, India, Kenya, Nigeria, Pakistan, Spain and UK), among women recruited from healthcare, community, shelter or refuge settings, or a combination of any or all of these. Psychological therapies were mostly delivered face-to-face (28 trials), but varied by length of treatment (two to 50 sessions) and staff delivering therapies (social workers, nurses, psychologists, community health workers, family doctors, researchers). The average sample size was 82 women (14 to 479), aged 37 years on average, and 66% were unemployed. Half of the women were married or living with a partner and just over half of the participants had experienced IPV in the last 12 months (17 trials), 6% in the past two years (two trials) and 42% during their lifetime (14 trials). Whilst 20 trials (61%) described reliable low-risk random-sampling strategies, only 12 trials (36%) described reliable procedures to conceal the allocation of participant status. While 19 trials measured women's depression, only four trials measured depression as a continuous outcome at medium-term follow-up. These showed a probable beneficial effect of psychological therapies in reducing depression (SMD -0.24, 95% CI -0.47 to -0.01; four trials, 600 women; moderate-certainty evidence). However, for self-efficacy, there may be no evidence of a difference between groups (SMD -0.12, 95% CI -0.33 to 0.09; one trial with medium-term follow-up data, 346 women; low-certainty evidence). Further, there may be no difference between the number of women who dropped out from the experimental or comparator intervention groups, an indicator of no harm (OR 1.04, 95% CI 0.75 to 1.44; five trials with medium-term follow-up data, 840 women; low-certainty evidence). Although no trials reported adverse events from psychological therapies or participation in the trial, only one trial measured harm outcomes using a validated scale. For secondary outcomes, trials measured anxiety only at short-term follow-up, showing that psychological therapies may reduce anxiety symptoms (SMD -0.96, 95% CI -1.29 to -0.63; four trials, 158 women; low-certainty evidence). However, within medium-term follow-up, low-certainty evidence revealed that there may be no evidence between groups for the outcomes safety planning (SMD 0.04, 95% CI -0.18 to 0.25; one trial, 337 women), post-traumatic stress disorder (SMD -0.24, 95% CI -0.54 to 0.06; four trials, 484 women) or re-exposure to any form of IPV (SMD 0.03, 95% CI -0.14 to 0.2; two trials, 547 women). AUTHORS' CONCLUSIONS There is evidence that for women who experience IPV, psychological therapies probably reduce depression and may reduce anxiety. However, we are uncertain whether psychological therapies improve other outcomes (self-efficacy, post-traumatic stress disorder, re-exposure to IPV, safety planning) and there are limited data on harm. Thus, while psychological therapies probably improve emotional health, it is unclear if women's ongoing needs for safety, support and holistic healing from complex trauma are addressed by this approach. There is a need for more interventions focused on trauma approaches and more rigorous trials (with consistent outcomes at similar follow-up time points), as we were unable to synthesise much of the research.",2020,"These showed a probable beneficial effect of psychological therapies in reducing depression (SMD -0.24, 95% CI -0.47 to -0.01; four trials, 600 women; moderate-certainty evidence).","['women who experience intimate partner violence', 'women also experienced co-existing mental health diagnoses or substance abuse issues, or both', '82 women (14 to 479), aged 37 years on average, and 66% were unemployed', 'Intimate partner violence (IPV) against women', 'women who have experienced IPV and have a mental health diagnosis', '33 psychological trials involving 5517 women randomly assigned to experimental (2798 women, 51%) and comparator interventions (2719 women, 49', 'Most trials were from high-income countries (19 in USA, three in Iran, two each in Australia and Greece, and one trial each in China, India, Kenya, Nigeria, Pakistan, Spain and UK), among women recruited from healthcare, community, shelter or refuge settings, or a combination of any or all of these', 'Women experiencing IPV attend health services frequently for mental health problems', 'women aged 16 years and older who self-reported recent or lifetime experience of IPV']","['Psychological therapies included 11 integrative therapies, nine humanistic therapies, six cognitive behavioural therapy, four third-wave cognitive behavioural therapies and three other psychologically-orientated interventions', 'psychological therapies', 'Psychological therapies']","['anxiety symptoms', 'post-traumatic stress disorder', 'emotional health', 'mental health symptoms, anxiety, quality of life, re-exposure to IPV, safety planning and behaviours, use of healthcare and IPV services, and social support', 'IPV']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0740858', 'cui_str': 'Substance abuse'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0041674', 'cui_str': 'Unemployed'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0948433', 'cui_str': 'High income'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0018226', 'cui_str': 'Greece'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0028075', 'cui_str': 'Nigeria'}, {'cui': 'C0030211', 'cui_str': 'Pakistan'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0018747', 'cui_str': 'Services, Health'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C1446377', 'cui_str': 'Mental health problem'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0332185', 'cui_str': 'Recent'}]","[{'cui': 'C0841584', 'cui_str': 'Psychological therapies'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0037438', 'cui_str': 'Social support'}]",5517.0,0.386411,"These showed a probable beneficial effect of psychological therapies in reducing depression (SMD -0.24, 95% CI -0.47 to -0.01; four trials, 600 women; moderate-certainty evidence).","[{'ForeName': 'Mohajer', 'Initials': 'M', 'LastName': 'Hameed', 'Affiliation': 'Department of General Practice, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Lorna', 'Initials': 'L', 'LastName': ""O'Doherty"", 'Affiliation': 'Faculty of Health and Life Sciences, Coventry University, Coventry, UK.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Gilchrist', 'Affiliation': ""National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Tirado-Muñoz', 'Affiliation': ""Addiction Research Group, IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.""}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Taft', 'Affiliation': 'The Judith Lumley Centre, La Trobe University, Melbourne, Australia.'}, {'ForeName': 'Patty', 'Initials': 'P', 'LastName': 'Chondros', 'Affiliation': 'Department of General Practice, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Gene', 'Initials': 'G', 'LastName': 'Feder', 'Affiliation': 'Centre for Academic Primary Care, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Tan', 'Affiliation': 'Department of General Practice, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Hegarty', 'Affiliation': 'Department of General Practice, The University of Melbourne, Melbourne, Australia.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD013017.pub2'] 1551,31805778,The EMDR Recent Birth Trauma Protocol: a pilot randomised clinical trial after traumatic childbirth.,"Objective: This pilot study investigated the effectiveness of brief EMDR intervention as compared to treatment-as-usual (TAU) in women with post-partum PTSD symptoms. Design: A pilot randomised controlled trial was conducted to evaluate possible differences between one EMDR session ( n  = 19) and one TAU session ( n  = 18) delivered in a maternity ward in the aftermath of childbirth. Main Outcome Measures: The primary outcome measure was the rate of remission of post-partum post-traumatic stress symptoms (i.e. IES-R score <23) in both groups at 6-weeks (T1) and 12-weeks' post-partum (T2). Secondary outcome measures were mother-to-infant bonding, post-partum depressive symptoms, the presence of flashbacks and level of distress. Results: Most of the women improved their post-partum post-traumatic stress symptoms after only one treatment session. EMDR resulted more effective than TAU in reducing the proportion of women with post-partum post-traumatic stress symptoms at 6-weeks' post-partum (78.9% EMDR vs. 39.9% TAU; p = .020). Moreover, women treated with EMDR experienced less flashbacks and distress as compared to TAU. No significant difference was found between treatments on mother-to-infant bonding and post-partum depressive symptoms. Conclusions: These findings, although preliminary, suggest that a brief EMDR intervention could be a viable and promising tool in the early treatment of post-traumatic stress related to traumatic childbirth.",2020,EMDR resulted more effective than TAU in reducing the proportion of women with post-partum post-traumatic stress symptoms at 6-weeks' post-partum (78.9% EMDR vs. 39.9% TAU; ,['women with post-partum PTSD symptoms'],"['EMDR', 'EMDR session ( n \u2009=\u200919) and one TAU session ( n \u2009=\u200918) delivered in a maternity ward in the aftermath of childbirth', 'EMDR intervention', 'TAU']","['rate of remission of post-partum post-traumatic stress symptoms', 'mother-to-infant bonding and post-partum depressive symptoms', 'proportion of women with post-partum post-traumatic stress symptoms', 'flashbacks and distress', 'mother-to-infant bonding, post-partum depressive symptoms, the presence of flashbacks and level of distress']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0870535', 'cui_str': 'EMDR'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0236720', 'cui_str': 'Flashbacks'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.191435,EMDR resulted more effective than TAU in reducing the proportion of women with post-partum post-traumatic stress symptoms at 6-weeks' post-partum (78.9% EMDR vs. 39.9% TAU; ,"[{'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Chiorino', 'Affiliation': 'Unit of Perinatal Psychology, Consultorio Familiare Accreditato Genitori Oggi - Mangiagalli, Milan, Italy.'}, {'ForeName': 'Maria Caterina', 'Initials': 'MC', 'LastName': 'Cattaneo', 'Affiliation': 'Unit of Perinatal Psychology, Consultorio Familiare Accreditato Genitori Oggi - Mangiagalli, Milan, Italy.'}, {'ForeName': 'Elena A', 'Initials': 'EA', 'LastName': 'Macchi', 'Affiliation': 'Unit of Perinatal Psychology, Consultorio Familiare Accreditato Genitori Oggi - Mangiagalli, Milan, Italy.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Salerno', 'Affiliation': 'Unit of Perinatal Psychology, Consultorio Familiare Accreditato Genitori Oggi - Mangiagalli, Milan, Italy.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Roveraro', 'Affiliation': 'Unit of Perinatal Psychology, Consultorio Familiare Accreditato Genitori Oggi - Mangiagalli, Milan, Italy.'}, {'ForeName': 'Giorgia G', 'Initials': 'GG', 'LastName': 'Bertolucci', 'Affiliation': 'Unit of Perinatal Psychology, Consultorio Familiare Accreditato Genitori Oggi - Mangiagalli, Milan, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Mosca', 'Affiliation': ""Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, NICU, Milan, Italy.""}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Fumagalli', 'Affiliation': ""Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, NICU, Milan, Italy.""}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Cortinovis', 'Affiliation': 'Department of Clinical Sciences and Community Health, Laboratory G.A. Maccacaro, University of Milan, Milan, Italy.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Carletto', 'Affiliation': 'Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Fernandez', 'Affiliation': 'Center of Research and Studies in Psychotraumatology, Milan, Italy.'}]",Psychology & health,['10.1080/08870446.2019.1699088'] 1552,32628582,"Randomized, Parallel Group, Open-Label Bioequivalence Trial of Intramuscular Pegaspargase in Patients With Relapsed Acute Lymphoblastic Leukemia.","PURPOSE Pegylated asparaginase is comparatively safer than native asparaginase in the management of acute lymphoblastic leukemia (ALL). However, the high price and nonavailability in low- and middle-income countries limits its use. In 2014, the first generic of pegaspargase (Hamsyl) was approved in India for use as a second-line treatment option for ALL. The aim of this study was to assess whether the generic pegaspargase (the test product) was bioequivalent with the reference product (Oncaspar). PATIENTS AND METHODS This study was an open-label, parallel-group, comparative pharmacokinetic study in pediatric patients with relapsed ALL receiving their first dose (1,000 IU/m 2 ) of pegaspargase administered intramuscularly. Patients were randomly assigned 1-to-1 to either the test or the reference product. The 2 formulations were considered equivalent if the 90% CIs for area under the plasma asparaginase activity-time curve (AUC 0-t ) geometric mean test-to-reference ratio was within 75% to 133%. RESULTS Twenty-nine patients (6-18 years of age) were enrolled in this study, of whom 24 completed the study criteria and were considered for safety analysis (5 patients were ineligible for the assessment). Three patients were excluded from analysis, because of presence of anti-asparaginase antibodies, leaving 21 patients who were considered for bioequivalence pharmacokinetics data. The point estimate of AUC 0-t for the test-to-reference ratio was 95.05 (90% CI, 75.07% to 120.33%). Maximum plasma concentration, trough concentrations (day 14), half-life, volume of distribution, drug clearance, and changes in the asparagine and glutamine levels were not significantly different between products. Adverse events were comparable in both groups. CONCLUSION Generic and reference pegaspargase had equivalent pharmacokinetics with comparable safety. This could be a safe and cost-effective alternative for patients with ALL, especially in low- and middle-income countries.",2020,"Adverse events were comparable in both groups. ","['pediatric patients with relapsed ALL receiving their first dose (1,000 IU/m 2 ) of pegaspargase administered intramuscularly', 'Patients', 'Three patients were excluded from analysis, because of presence of anti-asparaginase antibodies, leaving 21 patients who were considered for bioequivalence pharmacokinetics data', 'acute lymphoblastic leukemia (ALL', 'Twenty-nine patients (6-18 years of age) were enrolled in this study, of whom 24 completed the study criteria and were considered for safety analysis (5 patients were ineligible for the assessment', 'With Relapsed Acute Lymphoblastic Leukemia', 'patients with ALL, especially in low- and middle-income countries']","['Pegylated asparaginase', 'Intramuscular Pegaspargase']","['Adverse events', 'Maximum plasma concentration, trough concentrations (day 14), half-life, volume of distribution, drug clearance, and changes in the asparagine and glutamine levels', 'plasma asparaginase activity-time curve (AUC 0-t ) geometric mean test-to-reference ratio']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0023449', 'cui_str': 'Acute lymphoid leukemia'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0003993', 'cui_str': 'ASPARAGINASE'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0039789', 'cui_str': 'Equivalencies, Therapeutic'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0450351', 'cui_str': '29'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0454664', 'cui_str': 'Country'}]","[{'cui': 'C0003993', 'cui_str': 'ASPARAGINASE'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C0071568', 'cui_str': 'pegaspargase'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0444506', 'cui_str': 'Trough'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C4085663', 'cui_str': 'Drug clearance'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0003995', 'cui_str': 'Asparagine'}, {'cui': 'C0017797', 'cui_str': 'Glutamine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003993', 'cui_str': 'ASPARAGINASE'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",3.0,0.0573042,"Adverse events were comparable in both groups. ","[{'ForeName': 'Manjunath', 'Initials': 'M', 'LastName': 'Nookala Krishnamurthy', 'Affiliation': 'Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'Gaurav', 'Initials': 'G', 'LastName': 'Narula', 'Affiliation': 'Homi Bhabha National Institute, Anushakthi Nagar, Mumbai, Maharashtra, India.'}, {'ForeName': 'Khushboo', 'Initials': 'K', 'LastName': 'Gandhi', 'Affiliation': 'Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'Ankita', 'Initials': 'A', 'LastName': 'Awase', 'Affiliation': 'Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'Ruta', 'Initials': 'R', 'LastName': 'Pandit', 'Affiliation': 'Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Raut', 'Affiliation': 'Gennova Biopharmaceuticals Ltd, Pune, India.'}, {'ForeName': 'Ritu', 'Initials': 'R', 'LastName': 'Singh', 'Affiliation': 'Gennova Biopharmaceuticals Ltd, Pune, India.'}, {'ForeName': 'Vikram', 'Initials': 'V', 'LastName': 'Gota', 'Affiliation': 'Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'Shripad Dinanath', 'Initials': 'SD', 'LastName': 'Banavali', 'Affiliation': 'Homi Bhabha National Institute, Anushakthi Nagar, Mumbai, Maharashtra, India.'}]",JCO global oncology,['10.1200/GO.20.00113'] 1553,32629403,Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate.,"BACKGROUND Monomethyl fumarate (MMF) is the pharmacologically active metabolite of dimethyl fumarate (DMF). MMF formulated as Bafiertam™ 190 mg and DMF formulated as Tecfidera 240 mg deliver bioequivalent exposure of MMF and therefore possess the same efficacy/safety profiles. DMF is a widely used oral treatment for relapsing-remitting forms of multiple sclerosis (RRMS) but is limited in some patients, primarily female, by issues with gastrointestinal (GI) tolerability. METHODS This was a randomized, double-blind, head-to-head, 5-week study evaluating the GI tolerability of MMF 190 mg vs DMF 240 mg, administered twice daily in healthy subjects, using a derivative of the self-administered Modified Overall Gastrointestinal Symptom Scale (MOGISS). Subjects were stratified (3:1, female:male) and randomized (1:1) to the treatments. The primary endpoint was the Area Under the Curve (AUC) in each of the individual symptoms in the MOGISS over the 5-week treatment period. Other endpoints included the AUC over the 5-week treatment period in the MOGISS composite and total scores; duration and severity of GI events; Number and percentage of subjects reporting GI events during the overall treatment period, and assessment of safety/tolerability. RESULTS Inferential analysis of the hierarchical testing of overall treatment differences in each MOGISS symptom AUC occurred in a predefined sequence starting with Abdominal Pain. For each symptom, LSMean AUC values were lower for MMF than DMF, however, the first primary endpoint, Abdominal Pain, was not statistically different between treatments; thus, all subsequent statistical analyses were considered exploratory. The side effects and safety profiles observed were consistent with the known profiles of DMF, with no new or unique safety concerns noted. CONCLUSIONS Bafiertam showed an improved gastrointestinal tolerability profile compared with Tecfidera, with less severe GI events and fewer days of self-assessed GI symptoms, fewer GI adverse events, and lower discontinuation rates because of GI adverse events.",2020,"The side effects and safety profiles observed were consistent with the known profiles of DMF, with no new or unique safety concerns noted. ",['healthy subjects'],"['DMF', 'Monomethyl fumarate (MMF', 'MMF 190 mg vs DMF']","['LSMean AUC values', 'MOGISS composite and total scores; duration and severity of GI events; Number and percentage of subjects reporting GI events', 'gastrointestinal tolerability profile', 'derivative of the self-administered Modified Overall Gastrointestinal Symptom Scale (MOGISS', 'Area Under the Curve (AUC', 'safety/tolerability', 'Abdominal Pain', 'GI tolerability', 'severe GI events and fewer days of self-assessed GI symptoms, fewer GI adverse events']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0058218', 'cui_str': 'dimethyl fumarate'}, {'cui': 'C3848524', 'cui_str': 'monomethyl fumarate'}, {'cui': 'C0083765', 'cui_str': 'NMF protocol'}, {'cui': 'C4517622', 'cui_str': '190'}]","[{'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0243072', 'cui_str': 'derivatives'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205388', 'cui_str': 'Few'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.0797155,"The side effects and safety profiles observed were consistent with the known profiles of DMF, with no new or unique safety concerns noted. ","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Wynn', 'Affiliation': 'Consultants in Neurology, Ltd, Northbrook, IL 60062, USA.'}, {'ForeName': 'Thomas W', 'Initials': 'TW', 'LastName': 'Lategan', 'Affiliation': 'Banner Life Sciences, 3890 Premier Dr., Suite 110, High Point, NC 27265, USA. Electronic address: Lategan@bannerls.com.'}, {'ForeName': 'Tiffany N', 'Initials': 'TN', 'LastName': 'Sprague', 'Affiliation': 'Banner Life Sciences, 3890 Premier Dr., Suite 110, High Point, NC 27265, USA.'}, {'ForeName': 'Franck S', 'Initials': 'FS', 'LastName': 'Rousseau', 'Affiliation': 'Banner Life Sciences, 3890 Premier Dr., Suite 110, High Point, NC 27265, USA.'}, {'ForeName': 'Edward J', 'Initials': 'EJ', 'LastName': 'Fox', 'Affiliation': 'Central Texas Neurology Consultants, Round Rock, TX 78681, USA.'}]",Multiple sclerosis and related disorders,['10.1016/j.msard.2020.102335'] 1554,32629535,"Radiofrequency Thoracic Sympathectomy for Sympathetically Maintained Chronic Post-Mastectomy Pain, a Preliminary Report: 6-Month Results.","AIM Evaluation of the analgesic efficacy of radiofrequency thoracic sympathectomy for sympathetically maintained post-mastectomy pain syndrome (PMPS). METHODS Patients with PMPS randomized to Group TS (n = 33) received radiofrequency thoracic sympathectomy, and those randomized to Group Sham (n = 33) received no radiofrequency current. Postoperative pain treatment consisted of duloxetine, pregabalin, and tramadol for both groups. The outcome variables were the proportion of patients who showed >50% reduction in their VAS pain score, the pain intensity measured by VAS score, and the global perceived effect (GPE) evaluated during the 6-month follow-up period. RESULTS A significantly higher proportion of patients experienced >50% reduction in pain in Group TS (Group TS 25/30 [83.3%] vs. Group Sham 18/31 [58%], P = 0.032); the proportion of patients who experienced >50% reduction in their pain without analgesics was significantly higher in Group TS (Group TS 10/25 [40%] vs. Group Sham 0/18 [0%], P = 0.001). Furthermore, the proportion of patients treated with tramadol + duloxetine + pregabalin who experienced >50% reduction in their pain was significantly lower in Group TS (Group TS 0/25 [0%] vs. Group Sham 13/18 [75%], P = 0.001). The VAS pain score was significantly lower in Group TS at 2 weeks and at 1, 2, 3, and 6 months following the procedure. The GPE was significantly higher in Group TS (Group TS median GPE [interquartile range]) 7 [5, 7] vs. Group Sham median GPE [interquartile range]) 5 [4, 6]) P < 0.001). CONCLUSIONS Radiofrequency thoracic sympathectomy for sympathetically maintained PMPS decreased VAS pain scores and reduced the need for anti-neuropathic drugs, particularly opioid medications, and provided better patient satisfaction.",2020,"the percentage of patients gained > 50% reduction of their pain without analgesics was significantly higher in group TS, 10/25 (40%) vs. 0/18 (0%),","['sympathetically maintained chronic post-mastectomy pain, a preliminary report', 'Patients with PMPS', 'sympathetically maintained post-mastectomy pain syndrome (PMPS']","['radiofrequency thoracic sympathectomy or group SHAM', 'tramadol +duloxetine+pregabalin', 'Radiofrequency thoracic sympathectomy', 'SHAM', 'duloxetine, pregabalin, and tramadol', 'radiofrequency thoracic sympathectomy']","['VAS pain score', 'pain', 'pain without analgesics', 'VAS pain score, the pain intensity measured by VAS score, and the global perceived effect (GPE']","[{'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0406845', 'cui_str': 'Post-mastectomy pain'}, {'cui': 'C0439611', 'cui_str': 'Preliminary'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}]","[{'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0039038', 'cui_str': 'Sympathectomy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0040610', 'cui_str': 'Tramadol'}, {'cui': 'C0245561', 'cui_str': 'duloxetine'}, {'cui': 'C0657912', 'cui_str': 'pregabalin'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",,0.0607815,"the percentage of patients gained > 50% reduction of their pain without analgesics was significantly higher in group TS, 10/25 (40%) vs. 0/18 (0%),","[{'ForeName': 'Diab Fuad', 'Initials': 'DF', 'LastName': 'Hetta', 'Affiliation': 'Department of Anesthesia and Pain Management, South Egypt Cancer Institute, Assuit University, Assiut, Egypt.'}, {'ForeName': 'Ashraf Amin', 'Initials': 'AA', 'LastName': 'Mohamed', 'Affiliation': 'Department of Anesthesia and Pain Management, South Egypt Cancer Institute, Assuit University, Assiut, Egypt.'}, {'ForeName': 'Helal F', 'Initials': 'HF', 'LastName': 'Hetta', 'Affiliation': 'Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, U.S.A.'}, {'ForeName': 'Essam Ezzat', 'Initials': 'EE', 'LastName': 'Abd El-Hakeem', 'Affiliation': 'Department of Anesthesia and Intensive Care, Assuit University Hospital, Assuit University, Assiut, Egypt.'}, {'ForeName': 'Madona Misheal', 'Initials': 'MM', 'LastName': 'Boshra', 'Affiliation': 'Department of Anesthesia and Pain Management Department, South Egypt, Cancer Institute, Assuit University, Assiut, Egypt.'}, {'ForeName': 'Mohamed Moamen', 'Initials': 'MM', 'LastName': 'El-Barody', 'Affiliation': 'Department of Radiodiagnosis, South Egypt, Cancer Institute, Assuit University, Assiut, Egypt.'}, {'ForeName': 'Montaser A', 'Initials': 'MA', 'LastName': 'Fattah Mohammad', 'Affiliation': 'Department of Anesthesia and Pain Management, South Egypt Cancer Institute, Assuit University, Assiut, Egypt.'}]",Pain practice : the official journal of World Institute of Pain,['10.1111/papr.12933'] 1555,32639649,Trial of restarting and tolerating metformin (TreatMet).,"This randomized, double-blind, placebo-controlled, n-of-1 crossover study assessed whether metformin's side effects are reproducible in patients with a history of metformin intolerance. Participants completed up to four cycles of 2 weeks of metformin exposure and 2 weeks of placebo exposure. Participants completed surveys based on the Gastrointestinal Symptom Rating Scale and the Treatment Satisfaction Questionnaire for Medication. The primary hypotheses were that treatment satisfaction would be equal for placebo and metformin and that more than 30% of the study enrollees would be able to adhere to a higher dose of metformin 6 months after participation. Thirteen patients (all women, mean age 52.4 years) enrolled, three of whom were lost to follow-up or were non-adherent to study protocol. Metformin was associated with significantly lower global treatment satisfaction scores compared with placebo (39.58 vs. 53.75, P < .05 ) but participants could not distinguish metformin from placebo and did not report higher rates of gastrointestinal side effects on metformin. Two out of 10 participants adhered to a higher dose of metformin after trial completion. Metformin appears to have barriers to use beyond its classic gastrointestinal side effects.",2020,,[],['Restarting and Tolerating Metformin (TreatMet'],[],[],"[{'cui': 'C0025598', 'cui_str': 'Metformin'}]",[],,0.0175862,,"[{'ForeName': 'Jeremy N', 'Initials': 'JN', 'LastName': 'Orloff', 'Affiliation': 'Weill Cornell Medicine, Population Health Sciences, New York, New York, USA.'}, {'ForeName': 'Samir H', 'Initials': 'SH', 'LastName': 'Touhamy', 'Affiliation': 'Weill Cornell Medical College, New York, New York, USA.'}, {'ForeName': 'Wanda', 'Initials': 'W', 'LastName': 'Truong', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism Comprehensive Weight Control Center, Weill Cornell Medical College, New York, New York, USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Casper', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism Comprehensive Weight Control Center, Weill Cornell Medical College, New York, New York, USA.'}, {'ForeName': 'Alpana P', 'Initials': 'AP', 'LastName': 'Shukla', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism Comprehensive Weight Control Center, Weill Cornell Medical College, New York, New York, USA.'}, {'ForeName': 'Leon I', 'Initials': 'LI', 'LastName': 'Igel', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism Comprehensive Weight Control Center, Weill Cornell Medical College, New York, New York, USA.'}, {'ForeName': 'James H', 'Initials': 'JH', 'LastName': 'Flory', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York, USA.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14137'] 1556,32594915,"Consumption of whole purple and regular wheat modestly improves metabolic markers in adults with elevated high-sensitivity C-reactive protein: a randomised, single-blind parallel-arm study.","Whole-grain wheat, in particular coloured varieties, may have health benefits in adults with chronic metabolic disease risk factors. Twenty-nine overweight and obese adults with chronic inflammation (high-sensitivity C-reactive protein) > 1·0 mg/l) replaced four daily servings of refined grain food products with bran-enriched purple or regular whole-wheat convenience bars (approximately 41-45 g fibre, daily) for 8 weeks in a randomised, single-blind parallel-arm study where body weight was maintained. Anthropometrics, blood markers of inflammation, oxidative stress, and lipaemia and metabolites of anthocyanins and phenolic acids were compared at days 1, 29 and 57 using repeated-measures ANOVA within groups and ANCOVA between groups at day 57, with day 1 as a covariate. A significant reduction in IL-6 and increase in adiponectin were observed within the purple wheat (PW) group. TNF-α was lowered in both groups and ferulic acid concentration increased in the regular wheat (RW) group. Comparing between wheats, only plasma TNF-α and glucose differed significantly (P < 0·05), that is, TNF-α and glucose decreased with RW and PW, respectively. Consumption of PW or RW products showed potential to improve plasma markers of inflammation and oxidative stress in participants with evidence of chronic inflammation, with modest differences observed based on type of wheat.",2020,Tumor necrosis factor (TNF)-α was lowered in both groups and ferulic acid concentration increased in the regular wheat (RW) group.,"['participants with evidence of chronic inflammation', 'adults with elevated high sensitivity C-reactive protein', '29 overweight and obese adults with chronic inflammation (high sensitivity C-Reactive Protein (hs-CRP) > 1.0 mg/L) replaced four', 'adults with chronic metabolic disease risk factors']",['daily servings of refined grain food products with bran-enriched purple or regular whole wheat convenience bars'],"['interleukin-6 and increase in adiponectin', 'Anthropometrics, blood markers of inflammation, oxidative stress, and lipemia and metabolites of anthocyanins and phenolic acids', 'Tumor necrosis factor (TNF)-α', 'TNF-α and glucose', 'ferulic acid concentration', 'metabolic markers', 'plasma markers of inflammation and oxidative stress', 'plasma TNF-α and glucose']","[{'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0021376', 'cui_str': 'Chronic inflammation'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0439268', 'cui_str': 'mg/L'}, {'cui': 'C0559956', 'cui_str': 'Replacement - action'}, {'cui': 'C1263722', 'cui_str': 'Chronic metabolic disorder'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0007757', 'cui_str': 'Cereal'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0353942', 'cui_str': 'Bran'}, {'cui': 'C0439542', 'cui_str': 'Purple'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0043137', 'cui_str': 'Wheat'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0001643', 'cui_str': 'Beta-2 adrenergic receptor'}]","[{'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0020473', 'cui_str': 'Hyperlipidemia'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0003161', 'cui_str': 'Anthocyanin'}, {'cui': 'C2586298', 'cui_str': 'Hydroxybenzoic acid'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0060291', 'cui_str': 'ferulic acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1513159', 'cui_str': 'Metabolic marker'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}]",29.0,0.0719273,Tumor necrosis factor (TNF)-α was lowered in both groups and ferulic acid concentration increased in the regular wheat (RW) group.,"[{'ForeName': 'Tamer H', 'Initials': 'TH', 'LastName': 'Gamel', 'Affiliation': 'Department of Human Health & Nutritional Sciences, College of Biological Science, University of Guelph, Guelph, OntarioN1G 2W1, Canada.'}, {'ForeName': 'El-Sayed M', 'Initials': 'EM', 'LastName': 'Abdel-Aal', 'Affiliation': 'Guelph Research & Development Centre, Agriculture and Agri-Food Canada, Guelph, OntarioN1G 5C9, Canada.'}, {'ForeName': 'Amy J', 'Initials': 'AJ', 'LastName': 'Tucker', 'Affiliation': 'Department of Human Health & Nutritional Sciences, College of Biological Science, University of Guelph, Guelph, OntarioN1G 2W1, Canada.'}, {'ForeName': 'Shannon M', 'Initials': 'SM', 'LastName': 'Pare', 'Affiliation': 'Department of Human Health & Nutritional Sciences, College of Biological Science, University of Guelph, Guelph, OntarioN1G 2W1, Canada.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Faughnan', 'Affiliation': 'Department of Human Health & Nutritional Sciences, College of Biological Science, University of Guelph, Guelph, OntarioN1G 2W1, Canada.'}, {'ForeName': 'Charlene D', 'Initials': 'CD', 'LastName': ""O'Brien"", 'Affiliation': 'Department of Human Health & Nutritional Sciences, College of Biological Science, University of Guelph, Guelph, OntarioN1G 2W1, Canada.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Dykun', 'Affiliation': 'Department of Human Health & Nutritional Sciences, College of Biological Science, University of Guelph, Guelph, OntarioN1G 2W1, Canada.'}, {'ForeName': 'Iwona', 'Initials': 'I', 'LastName': 'Rabalski', 'Affiliation': 'Guelph Research & Development Centre, Agriculture and Agri-Food Canada, Guelph, OntarioN1G 5C9, Canada.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Pickard', 'Affiliation': 'Infra-Ready Products Ltd, Saskatoon, SaskatchewanS7M 5T2, Canada.'}, {'ForeName': 'Amanda J', 'Initials': 'AJ', 'LastName': 'Wright', 'Affiliation': 'Department of Human Health & Nutritional Sciences, College of Biological Science, University of Guelph, Guelph, OntarioN1G 2W1, Canada.'}]",The British journal of nutrition,['10.1017/S0007114520002275'] 1557,32599215,Who Enrolls in an Online Cancer Survivorship Program? Reach of the INSPIRE Randomized Controlled Trial for Hematopoietic Cell Transplantation Survivors.,"The internet can be a valuable tool in delivering survivorship care to hematopoietic cell transplantation (HCT) cancer survivors. We describe the reach of INSPIRE, an Internet and social media-based randomized controlled trial, to address healthcare and psychosocial needs of HCT survivors. All survivors 2-10 years after HCT for hematologic malignancy or myelodysplasia from 6 transplantation centers in the US were approached by mail and follow-up calls. Eligible participants had access to the Internet, an email address, and did not have active disease in the past 2 years. We used logistic regression to determine characteristics of eligible survivors who were more or less likely to enroll. Of 2578 eligible HCT survivors, 1065 (41%) enrolled in the study. The mean age of enrollees was 56.3 ± 12.6 years (range, 19 to 89 years), 52% were male, and 94% were white. Survivors less likely to enroll included those who were male, age <40 years, and who received an autologous transplant (all P < .001). Compared with white survivors, African Americans were less likely to enroll (P < .001), whereas Native Americans/Alaska Natives were more likely to join the study (P = .03). The reach of the INSPIRE program was broad, including to survivors who traditionally have less access to resources, such as Native Americans/Alaskan Natives and rural residents. Strategies are still needed to improve the enrollment of online studies of survivorship resources for males, young adults, African American, and autologous HCT survivors because their use may improve outcomes.",2020,"Compared with survivors of white race, African Americans were less likely to enroll (P<.001) while Native Americans/Alaska Natives were more likely to join the study (P=.03). ","['eligible survivors who were more or less likely to enroll', 'Survivors less likely to enroll included those who were male, age younger than 40, and who received an autologous transplant (all P<.001', 'hematopoietic cell transplantation survivors', 'Native Americans/Alaskan Natives and rural residents', 'hematopoietic cell transplantation (HCT) cancer survivors', 'Eligible participants had access to the internet, an email address, and did not have active disease in the past two years', '2578 eligible HCT survivors, 1065 (41%) enrolled in the study', 'Mean age of enrollees was 56.3 (SD=12.6; age range 19 to 89 years), 52% were male, and 94% were White']",['HCT'],[],"[{'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0040736', 'cui_str': 'Autogenous transplantation'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0282204', 'cui_str': 'Native Americans'}, {'cui': 'C0682125', 'cui_str': 'Native Alaskians'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}]","[{'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}]",[],2578.0,0.117693,"Compared with survivors of white race, African Americans were less likely to enroll (P<.001) while Native Americans/Alaska Natives were more likely to join the study (P=.03). ","[{'ForeName': 'Jean C', 'Initials': 'JC', 'LastName': 'Yi', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address: jyi@fredhutch.org.'}, {'ForeName': 'Brie', 'Initials': 'B', 'LastName': 'Sullivan', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Wendy M', 'Initials': 'WM', 'LastName': 'Leisenring', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Navneet S', 'Initials': 'NS', 'LastName': 'Majhail', 'Affiliation': 'Cleveland Clinic, Blood and Marrow Transplant Program, Cleveland, Ohio.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Jim', 'Affiliation': 'Moffitt Cancer Center, Tampa, Florida.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Loren', 'Affiliation': 'University of Pennsylvania, Blood & Marrow Transplant, Cell Therapy & Transplant Program, Philadelphia, Pennsylvania.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Uberti', 'Affiliation': 'Barbara Ann Karmanos Cancer Institute, Detroit, Michigan.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Whalen', 'Affiliation': 'University of Nebraska, Blood & Marrow Stem Cell Transplant Program, Omaha, Nebraska.'}, {'ForeName': 'Mary E D', 'Initials': 'MED', 'LastName': 'Flowers', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; University of Washington School of Medicine, Seattle, Washington.'}, {'ForeName': 'Stephanie J', 'Initials': 'SJ', 'LastName': 'Lee', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; University of Washington School of Medicine, Seattle, Washington.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Maynard', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Karen L', 'Initials': 'KL', 'LastName': 'Syrjala', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; University of Washington School of Medicine, Seattle, Washington.'}]",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,['10.1016/j.bbmt.2020.06.017'] 1558,32608151,"A randomized split-face, investigator-blinded study of a picosecond Alexandrite laser for post-inflammatory erythema and acne scars.","The 755 nm picosecond Alexandrite laser has been demonstrated to be effective and well tolerated in patients with acne scars. In this split-face, investigator-blinded study, 16 patients with post-inflammatory erythema (PIE) and acne scars were randomized to receive laser treatment on half the face, with the other half serving as a control. The treatment side demonstrated a significant improvement in both PIE and scars compared to the baseline and also when compared to the control side. Treatment was well-tolerated, with only transient and mild erythema and edema reported as side-effects. In our study, the picosecond Alexandrite laser was safe and effective in the treatment of PIE and acne scars. Comprehensive treatment outcomes should be taken into consideration when deciding on which device to use.",2020,The treatment side demonstrated a significant improvement in both PIE and scars compared to the baseline and also when compared to the control side.,"['16 patients with post-inflammatory erythema (PIE) and acne scars', 'post-inflammatory erythema and acne scars', 'patients with acne scars']","['picosecond Alexandrite laser', 'laser treatment']","['PIE and scars', 'mild erythema and edema', 'tolerated']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0423783', 'cui_str': 'Acne scar'}]","[{'cui': 'C0392245', 'cui_str': 'Alexandrite laser device'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0013604', 'cui_str': 'Edema'}]",16.0,0.0115798,The treatment side demonstrated a significant improvement in both PIE and scars compared to the baseline and also when compared to the control side.,"[{'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Wen', 'Affiliation': 'Department of Dermatology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Dermatology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Hamblin', 'Affiliation': 'Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Xian', 'Initials': 'X', 'LastName': 'Jiang', 'Affiliation': 'Department of Dermatology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.'}]",Dermatologic therapy,['10.1111/dth.13941'] 1559,32603789,Digoxin Initiation and Outcomes in Patients with Heart Failure (HFrEF and HFpEF) and Atrial Fibrillation.,"BACKGROUND Digoxin reduces the risk of heart failure hospitalization but has no effect on mortality in patients with heart failure without atrial fibrillation in the randomized controlled trial setting. Observational studies of digoxin use in patients with atrial fibrillation have suggested a higher risk for poor outcomes. Less is known about this association in patients with heart failure and atrial fibrillation, the examination of which was the objective of the current study. METHODS We conducted an observational propensity score-matched study of predischarge digoxin initiation in 1768 hospitalized patients with heart failure and atrial fibrillation in the Medicare-linked Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) registry, balanced on 56 baseline characteristics (mean age, 79 years; 55% women; 7% African American). Hazard ratios (HRs) and 95% confidence intervals (CIs) for outcomes were estimated for the 884 patients initiated on digoxin compared with 884 not initiated on digoxin. RESULTS HRs (95% CIs) for 30-day, 2-year, and 4-year all-cause mortality were 0.80 (0.55-1.18; P = .261), 0.94 (0.87-1.16; P = .936), and 1.01 (0.90-1.14; P = .729), respectively. Respective HRs (95% CIs) for heart failure readmission were 0.67 (0.49-0.92; P = .014), 0.81 (0.69-0.94; P = .005), and 0.85 (0.74-0.97; P = .022), and those for all-cause readmission were 0.78 (0.64-0.96; P = .016), 0.90 (0.81-1.00; P = .057), and 0.91 (0.83-1.01; P = .603). These associations were homogeneous between patients with left ventricular ejection fraction ≤45% vs >45%. CONCLUSIONS Among hospitalized older patients with heart failure (HFrEF and HFpEF) and atrial fibrillation, initiation of digoxin was associated with a lower risk of heart failure readmission but had no association with mortality.",2020,"Respective HRs (95% CIs) for heart failure readmission were 0.67 (0.49-0.92; p=0.014), 0.81 (0.69-0.94; p=0.005), and 0.85 (0.74-0.97; p=0.022), and those for all-cause readmission were 0.78 (0.64-0.96; p=0.016), 0.90 (0.81-1.00; p=0.057), and 0.91","['1768 hospitalized patients with heart failure and atrial fibrillation in Medicare-linked OPTIMIZE-HF registry, balanced on 56 baseline characteristics (mean age, 79 years; 55% women; 7% African American', 'Patients with Heart Failure ', 'patients with heart failure and atrial fibrillation', '884 patients initiated on', 'patients with atrial fibrillation', 'hospitalized older patients with HFrEF and HFpEF and atrial fibrillation, initiation of', 'patients with heart failure without atrial fibrillation']","['pre-discharge digoxin initiation', 'digoxin', 'HFrEF and HFpEF', 'Digoxin']","['heart failure readmission', '30-day, 2-year, and 4-year all-cause mortality', 'Hazard ratios (HRs) and 95% confidence intervals (CIs) for outcomes']","[{'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0018717', 'cui_str': 'Health Insurance for Aged and Disabled, Title 18'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0012265', 'cui_str': 'Digoxin'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}]","[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0009667', 'cui_str': 'Confidence Intervals'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",1768.0,0.168502,"Respective HRs (95% CIs) for heart failure readmission were 0.67 (0.49-0.92; p=0.014), 0.81 (0.69-0.94; p=0.005), and 0.85 (0.74-0.97; p=0.022), and those for all-cause readmission were 0.78 (0.64-0.96; p=0.016), 0.90 (0.81-1.00; p=0.057), and 0.91","[{'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Singh', 'Affiliation': 'Veterans Affairs Medical Center, Washington, DC; Georgetown University, Washington, DC. Electronic address: nankumar.singh@va.gov.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Moore', 'Affiliation': 'Veterans Affairs Medical Center, Washington, DC; Georgetown University, Washington, DC.'}, {'ForeName': 'Pamela E', 'Initials': 'PE', 'LastName': 'Karasik', 'Affiliation': 'Veterans Affairs Medical Center, Washington, DC; George Washington University, Washington, DC.'}, {'ForeName': 'Phillip H', 'Initials': 'PH', 'LastName': 'Lam', 'Affiliation': 'Veterans Affairs Medical Center, Washington, DC; Georgetown University, Washington, DC; MedStar Washington Hospital Center, Washington, DC.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Wopperer', 'Affiliation': 'Veterans Affairs Medical Center, Washington, DC; Georgetown University, Washington, DC.'}, {'ForeName': 'Cherinne', 'Initials': 'C', 'LastName': 'Arundel', 'Affiliation': 'Veterans Affairs Medical Center, Washington, DC; Georgetown University, Washington, DC; George Washington University, Washington, DC.'}, {'ForeName': 'Lakshmi', 'Initials': 'L', 'LastName': 'Tummala', 'Affiliation': 'Veterans Affairs Medical Center, Washington, DC; Georgetown University, Washington, DC; George Washington University, Washington, DC.'}, {'ForeName': 'Markus S', 'Initials': 'MS', 'LastName': 'Anker', 'Affiliation': 'Charité Campus Virchow Klinikum, Berlin, Germany; Charité Campus Benjamin Franklin, Berlin, Germany; Berlin Institute of Health Center for Regenerative Therapies, Germany; German Centre for Cardiovascular Research, Berlin, Germany.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Faselis', 'Affiliation': 'Veterans Affairs Medical Center, Washington, DC; George Washington University, Washington, DC.'}, {'ForeName': 'Prakash', 'Initials': 'P', 'LastName': 'Deedwania', 'Affiliation': 'Veterans Affairs Medical Center, Washington, DC; University of California, San Francisco.'}, {'ForeName': 'Charity J', 'Initials': 'CJ', 'LastName': 'Morgan', 'Affiliation': 'Veterans Affairs Medical Center, Washington, DC; University of Alabama at Birmingham.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Zeng', 'Affiliation': 'Veterans Affairs Medical Center, Washington, DC; George Washington University, Washington, DC.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Allman', 'Affiliation': 'George Washington University, Washington, DC; University of Alabama at Birmingham.'}, {'ForeName': 'Gregg C', 'Initials': 'GC', 'LastName': 'Fonarow', 'Affiliation': 'University of California, Los Angeles.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ahmed', 'Affiliation': 'Veterans Affairs Medical Center, Washington, DC; Georgetown University, Washington, DC; George Washington University, Washington, DC. Electronic address: ali.ahmed@va.gov.'}]",The American journal of medicine,['10.1016/j.amjmed.2020.05.030'] 1560,32605284,Acute Effects of Beetroot Juice Supplements on Resistance Training: A Randomized Double-Blind Crossover.,"The ingestion of beetroot juice (BJ) has been associated with improvements in physical performance in endurance sports, however the literature on resistance training (RT) is scarce. The aim of this study was to investigate the acute effects of BJ compared to a placebo (PLA) on muscular endurance and movement concentric velocity during RT. Twelve healthy men performed an incremental RT test (back squat and bench press) with three sets, at 60%, 70%, and 80% of their repetition maximum (1-RM). Movement velocity variables, total number of repetitions performed until concentric failure, blood lactate, and ratings of perceived effort post-training were measured. A higher number of repetitions were recorded with BJ compared to those with PLA (13.8 ± 14.4; p < 0.01; effect size (ES) = 0.6). Differences were found at 60% 1-RM (9 ± 10; p < 0.05; ES = 0.61) and 70% 1-RM (3.1 ± 4.8; p < 0.05; ES = 0.49), however, no differences were found at 80% 1-RM (1.7 ± 1; p = 0.12; ES = 0.41). A greater number of repetitions was performed in back squat (13.4 ± 13; p < 0.01; ES = 0.77), but no differences were observed in bench press (0.4 ± 5.1; p = 0.785; ES = 0.03). No differences were found for the rest of the variables ( p > 0.05). Acute supplementation of BJ improved muscular endurance performance in RT.",2020,"A greater number of repetitions was performed in back squat (13.4 ± 13; p < 0.01; ES = 0.77), but no differences were observed in bench press (0.4 ± 5.1; p = 0.785; ES = 0.03).",['Twelve healthy men'],"['placebo (PLA', 'BJ', 'Beetroot Juice Supplements']","['muscular endurance performance', 'number of repetitions', 'Movement velocity variables, total number of repetitions performed until concentric failure, blood lactate, and ratings of perceived effort post-training', 'muscular endurance and movement concentric velocity', 'Resistance Training']","[{'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1095905', 'cui_str': 'Beets preparation'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}]","[{'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439744', 'cui_str': 'Concentric'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]",12.0,0.161723,"A greater number of repetitions was performed in back squat (13.4 ± 13; p < 0.01; ES = 0.77), but no differences were observed in bench press (0.4 ± 5.1; p = 0.785; ES = 0.03).","[{'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Ranchal-Sanchez', 'Affiliation': 'Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, 14004 Córdoba, Spain.'}, {'ForeName': 'Victor Manuel', 'Initials': 'VM', 'LastName': 'Diaz-Bernier', 'Affiliation': 'Department of Nursing, Pharmacology and Physiotherapy, Faculty of Medicine and Nursing, University of Cordoba, 14071 Córdoba, Spain.'}, {'ForeName': 'Candelaria Alonso', 'Initials': 'CA', 'LastName': 'De La Florida-Villagran', 'Affiliation': 'Department of Nursing, Pharmacology and Physiotherapy, Faculty of Medicine and Nursing, University of Cordoba, 14071 Córdoba, Spain.'}, {'ForeName': 'Francisco Jesus', 'Initials': 'FJ', 'LastName': 'Llorente-Cantarero', 'Affiliation': 'Department of Specific Didactics, Faculty of Education, University of Cordoba, 14071 Córdoba, Spain.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Campos-Perez', 'Affiliation': 'Department of Food Science and Technology, Rabanales University Campus, University of Cordoba, 14071 Córdoba, Spain.'}, {'ForeName': 'Jose Manuel', 'Initials': 'JM', 'LastName': 'Jurado-Castro', 'Affiliation': 'Metabolism and Investigation Unit, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, 14004 Córdoba, Spain.'}]",Nutrients,['10.3390/nu12071912'] 1561,32609534,Efficacy of Goreisan in Preventing Transurethral Resection Syndrome in Transurethral Resection of the Prostate: A Randomized-Controlled Study.,"Objectives: Nonconductive irrigation fluids used during transurethral resection (TUR) of the prostate can cause fluid overload and dilutional hyponatremia. TUR syndrome is generally defined as serum sodium at or below 125 mmol/L with cardiovascular and neurologic symptoms. The aim of this study was to evaluate the effects of Goreisan, a traditional Japanese Kampo medicine, on serum sodium levels and the occurrence of TUR syndrome in patients undergoing TUR of the prostate. Design: This was a randomized-controlled trial. Settings/Location: This trial was conducted at the Osaka Medical College Hospital and Keneikai Sanko Hospital. Subjects: Fifty patients scheduled for TUR of the prostate were included. Interventions: Patients in the Goreisan group ( n  = 23) received 2.5 g Goreisan orally on the night before surgery and on the morning of surgery. The control group ( n  = 27) did not receive Goreisan. Surgical procedures, perioperative management, and patient monitoring were otherwise the same in both groups. Outcome Measures: The primary outcome was occurrence of TUR syndrome. The secondary outcome was serum sodium level. Results: Serum sodium remained above 125 mmol/L in all patients, so none of the patients met the criteria for TUR syndrome. However, the Goreisan group had significantly higher intraoperative sodium levels ( p  < 0.001) and significantly higher intraoperative ( p  = 0.008) and postoperative ( p  = 0.02) hemoglobin levels than the control group. Conclusions: These findings indicate that preoperative Goreisan administration can help maintain serum sodium levels in patients undergoing TUR of the prostate.",2020,"However, the Goreisan group had significantly higher intraoperative sodium levels ( p  < 0.001) and significantly higher intraoperative ( p  = 0.008) and postoperative ( p  = 0.02) hemoglobin levels than the control group. ","['Subjects: Fifty patients scheduled for TUR of the prostate were included', 'Patients in the Goreisan group ( n \u2009=\u200923', 'Transurethral Resection of the Prostate', 'Osaka Medical College Hospital and Keneikai Sanko Hospital', 'patients undergoing TUR of the prostate']","['Nonconductive irrigation fluids used during transurethral resection (TUR', 'Goreisan, a traditional Japanese Kampo medicine', 'Goreisan']","['Serum sodium', 'occurrence of TUR syndrome', 'serum sodium level', 'hemoglobin levels', 'intraoperative sodium levels']","[{'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0041400', 'cui_str': 'Turkey - country'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0040771', 'cui_str': 'Transurethral prostatectomy'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0593225', 'cui_str': 'Solution for irrigation'}, {'cui': 'C0205497', 'cui_str': 'Transurethral approach'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0041400', 'cui_str': 'Turkey - country'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0752221', 'cui_str': 'Kampo Medicine'}]","[{'cui': 'C0523891', 'cui_str': 'Sodium measurement, serum'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0349610', 'cui_str': 'TUR syndrome'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0337443', 'cui_str': 'Sodium measurement'}]",50.0,0.0297028,"However, the Goreisan group had significantly higher intraoperative sodium levels ( p  < 0.001) and significantly higher intraoperative ( p  = 0.008) and postoperative ( p  = 0.02) hemoglobin levels than the control group. ","[{'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Fujiwara', 'Affiliation': 'Department of Anesthesiology, Osaka Medical College, Osaka, Japan.'}, {'ForeName': 'Junko', 'Initials': 'J', 'LastName': 'Nakahira', 'Affiliation': 'Department of Anesthesiology, Osaka Medical College, Osaka, Japan.'}, {'ForeName': 'Shoko', 'Initials': 'S', 'LastName': 'Nakano', 'Affiliation': 'Department of Anesthesiology, Osaka Medical College, Osaka, Japan.'}, {'ForeName': 'Toshiyuki', 'Initials': 'T', 'LastName': 'Sawai', 'Affiliation': 'Department of Anesthesiology, Osaka Medical College, Osaka, Japan.'}, {'ForeName': 'Toshiaki', 'Initials': 'T', 'LastName': 'Minami', 'Affiliation': 'Department of Anesthesiology, Osaka Medical College, Osaka, Japan.'}]","Journal of alternative and complementary medicine (New York, N.Y.)",['10.1089/acm.2019.0269'] 1562,32610059,Behavioral economics informed message content in text message reminders to improve cervical screening participation: Two pragmatic randomized controlled trials.,"The objective of the reported research was to assess the impact of text message (SMS) reminders and their content on cervical screening rates. Women invited for cervical screening in Northwest London from February-October 2015 were eligible. 3133 women aged 24-29 (Study 1) were randomized (1, 1) to 'no SMS' (control), or a primary care physician (PCP) endorsed SMS (SMS-PCP). 11,405 women aged 30-64 (Study 2), were randomized (1, 1:1:1:1:1:1) to either: no SMS, an SMS without manipulation (SMS), the SMS-PCP, an SMS with a total or proportionate social norm (SMS-SNT or SMS-SNP), or an SMS with a gain-framed or loss-framed message (SMS-GF and SMS-LF). The primary outcome was participation at 18 weeks. In Study 1 participation was significantly higher in the SMS-PCP arm (31.4%) compared to control (26.4%, aOR, 1.29, 95%CI: 1.09-1·51; p = 0.002). In Study 2 participation was highest in the SMS-PCP (38.4%) and SMS (38.1%) arms compared to control (34.4%), (aOR: 1.19, 95%CI: 1.03-1.38; p = 0.02 and aOR: 1.18, 95%CI: 1.02-1.37; p = 0.03, respectively). The results demonstrate that behavioral SMSs improve cervical screening participation. The message content plays an important role in the impact of SMS. The results from this trial have already been used to designing effective policy for cervical cancer screening. The NHS Cervical Screening Programme started running a London-wide screening SMS campaign which was based on the cervical screening trial described here. According to figures published by Public Health England, after six months attendance increased by 4.8%, which is the equivalent of 13,400 more women being screened at 18 weeks.",2020,"In Study 1 participation was significantly higher in the SMS-PCP arm (31.4%) compared to control (26.4%, aOR, 1.29, 95%CI: 1.09-1·51; p = 0.002).","['3133 women aged 24-29 (Study 1', 'Women invited for cervical screening in Northwest London from February-October 2015 were eligible', '11,405 women aged 30-64 (Study 2']","['behavioral SMSs', ""no SMS' (control), or a primary care physician (PCP) endorsed SMS (SMS-PCP""]","['cervical screening participation', 'SMS-PCP', 'cervical screening rates']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0023973', 'cui_str': 'London'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0033131', 'cui_str': 'Primary care physician'}]","[{'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0795864', 'cui_str': 'Smith-Magenis syndrome'}, {'cui': 'C0033131', 'cui_str': 'Primary care physician'}]",11405.0,0.199584,"In Study 1 participation was significantly higher in the SMS-PCP arm (31.4%) compared to control (26.4%, aOR, 1.29, 95%CI: 1.09-1·51; p = 0.002).","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Huf', 'Affiliation': ""Department of Surgery and Cancer, Imperial College London, St Mary's Hospital Campus, 10th Floor Queen Elizabeth Queen Mother Wing, Praed Street, London W2 1NY, UK.""}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Kerrison', 'Affiliation': 'Research Department of Behavioural Science and Health, University College London, London, UK.'}, {'ForeName': 'Dominic', 'Initials': 'D', 'LastName': 'King', 'Affiliation': ""Department of Surgery and Cancer, Imperial College London, St Mary's Hospital Campus, 10th Floor Queen Elizabeth Queen Mother Wing, Praed Street, London W2 1NY, UK.""}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Chadborn', 'Affiliation': 'Public Health England, Wellington House, 133-155 Waterloo Road, London SE1 8UG, UK.'}, {'ForeName': 'Adele', 'Initials': 'A', 'LastName': 'Richmond', 'Affiliation': 'Breast Cancer Now, 5th Floor Ibex House, 42-47 Minories, London EC3N 1DY, UK.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Cunningham', 'Affiliation': 'West of London Breast Screening Service, Imperial College Healthcare NHS Trust, First Floor, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK.'}, {'ForeName': 'Ellis', 'Initials': 'E', 'LastName': 'Friedman', 'Affiliation': 'Faculty of Public Health, 4 St Andrews Place, London NW1 4LB, UK.'}, {'ForeName': 'Heema', 'Initials': 'H', 'LastName': 'Shukla', 'Affiliation': 'Global Health Capacity, Unit 4, Vista Place, Coy Pond Business Park Ingworth Road, Poole, BH12 1JY, UK.'}, {'ForeName': 'Fu-Min', 'Initials': 'FM', 'LastName': 'Tseng', 'Affiliation': ""Department of Surgery and Cancer, Imperial College London, St Mary's Hospital Campus, 10th Floor Queen Elizabeth Queen Mother Wing, Praed Street, London W2 1NY, UK.""}, {'ForeName': 'Gaby', 'Initials': 'G', 'LastName': 'Judah', 'Affiliation': ""Department of Surgery and Cancer, Imperial College London, St Mary's Hospital Campus, 10th Floor Queen Elizabeth Queen Mother Wing, Praed Street, London W2 1NY, UK.""}, {'ForeName': 'Ara', 'Initials': 'A', 'LastName': 'Darzi', 'Affiliation': ""Department of Surgery and Cancer, Imperial College London, St Mary's Hospital Campus, 10th Floor Queen Elizabeth Queen Mother Wing, Praed Street, London W2 1NY, UK.""}, {'ForeName': 'Ivo', 'Initials': 'I', 'LastName': 'Vlaev', 'Affiliation': 'Warwick Business School, University of Warwick, Scarman Rd, Coventry CV4 7AL, UK. Electronic address: ivo.vlaev@wbs.ac.uk.'}]",Preventive medicine,['10.1016/j.ypmed.2020.106170'] 1563,32610495,Lactobacillus plantarum DR7 Modulated Bowel Movement and Gut Microbiota Associated with Dopamine and Serotonin Pathways in Stressed Adults.,"We have previously reported that the administration of Lactobacillus plantarum DR7 for 12 weeks reduced stress and anxiety in stressed adults as compared to the placebo group, in association with changes along the brain neurotransmitters pathways of serotonin and dopamine-norepinephrine. We now aim to evaluate the effects of DR7 on gut functions, gut microbiota compositional changes, and determine the correlations between microbiota changes and the pathways of brain neurotransmitters. The administration of DR7 prevented an increase of defecation frequency over 12 weeks as compared to the placebo ( p = 0.044), modulating the increase of stress-induced bowel movement. Over 12 weeks, alpha diversity of gut microbiota was higher in DR7 than the placebo group across class ( p = 0.005) and order ( p = 0.018) levels, while beta diversity differed between groups at class and order levels ( p < 0.001). Differences in specific bacterial groups were identified, showing consistency at different taxonomic levels that survived multiplicity correction, along the phyla of Bacteroides and Firmicutes and along the classes of Deltaproteobacteria and Actinobacteria. Bacteroidetes, Bacteroidia, and Bacteroidales which were reduced in abundance in the placebo group showed opposing correlation with gene expression of dopamine beta hydrolase (DBH, dopamine pathway; p < 0.001), while Bacteroidia and Bacteroidales showed correlation with tryptophan hydroxylase-II (TPH2, serotonin pathway; p = 0.001). A correlation was observed between DBH and Firmicutes ( p = 0.002), Clostridia ( p < 0.001), Clostridiales ( p = 0.001), Blautia ( p < 0.001), and Romboutsia ( p < 0.001), which were increased in abundance in the placebo group. Blautia was also associated with TDO ( p = 0.001), whereas Romboutsia had an opposing correlation with TPH2 ( p < 0.001). Deltaproteobacteria and Desulfovibrionales which were decreased in abundance in the placebo group showed opposing correlation with DBH ( p = 0.001), whereas Bilophila was associated with TPH2 ( p = 0.001). Our present data showed that physiological changes induced by L. plantarum DR7 could be associated with changes in specific taxa of the gut microbiota along the serotonin and dopamine pathways.",2020,"Differences in specific bacterial groups were identified, showing consistency at different taxonomic levels that survived multiplicity correction, along the phyla of Bacteroides and Firmicutes and along the classes of Deltaproteobacteria and Actinobacteria.",['Stressed Adults'],"['DR7', 'placebo']","['Lactobacillus plantarum DR7 Modulated Bowel Movement and Gut Microbiota', 'stress-induced bowel movement', 'stress and anxiety', 'TDO', 'Blautia', 'alpha diversity of gut microbiota', 'Romboutsia', 'Bacteroidetes, Bacteroidia, and Bacteroidales', 'Clostridia', 'defecation frequency']","[{'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0317608', 'cui_str': 'Lactobacillus plantarum'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0041260', 'cui_str': 'Tryptophanase'}, {'cui': 'C2658870', 'cui_str': 'Blautia'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C1634514', 'cui_str': 'Class Bacteroidia'}, {'cui': 'C1080663', 'cui_str': 'Bacteroidales'}, {'cui': 'C0009054', 'cui_str': 'Clostridium'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}]",,0.107604,"Differences in specific bacterial groups were identified, showing consistency at different taxonomic levels that survived multiplicity correction, along the phyla of Bacteroides and Firmicutes and along the classes of Deltaproteobacteria and Actinobacteria.","[{'ForeName': 'Guoxia', 'Initials': 'G', 'LastName': 'Liu', 'Affiliation': 'CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.'}, {'ForeName': 'Hui-Xian', 'Initials': 'HX', 'LastName': 'Chong', 'Affiliation': 'School of Industrial Technology, Universiti Sains Malaysia, Penang 11800, Malaysia.'}, {'ForeName': 'Fiona Yi-Li', 'Initials': 'FY', 'LastName': 'Chung', 'Affiliation': 'School of Industrial Technology, Universiti Sains Malaysia, Penang 11800, Malaysia.'}, {'ForeName': 'Yin', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.'}, {'ForeName': 'Min-Tze', 'Initials': 'MT', 'LastName': 'Liong', 'Affiliation': 'School of Industrial Technology, Universiti Sains Malaysia, Penang 11800, Malaysia.'}]",International journal of molecular sciences,['10.3390/ijms21134608'] 1564,32611284,Alteplase for Acute Ischemic Stroke in Patients Aged >80 Years: Pooled Analyses of Individual Patient Data.,"BACKGROUND/PURPOSE Expert guidelines specify no upper age limit for alteplase for thrombolysis of acute ischemic stroke (AIS) but, until recently, European regulatory criteria restricted its use to patients aged 18 to 80 years. We performed pooled analyses of randomized controlled trial (RCT) and registry data to evaluate the benefit-risk profile of alteplase for AIS among patients aged >80 years to support a regulatory application to lift the upper age restriction. METHODS Individual patient data were evaluated from 7 randomized trials of alteplase (0.9 mg/kg) versus placebo or open control for AIS, and the European SITS-UTMOST registry database. Clinical outcomes, including good functional outcome (score 0-1, modified Rankin Scale day 90 or Oxford Handicap Score day 180), were evaluated in the full RCT and registry populations, and specified age-based subgroups (≤80 or >80 years) who met existing European regulatory criteria for alteplase, excluding upper age restriction. RESULTS Regardless of treatment allocation, 90-day mortality was lower among RCT patients aged ≤80 versus >80 years who otherwise met existing European regulatory criteria (246/2405 [10.2%] versus 307/1028 [29.9%], respectively). Among patients aged >80 years, alteplase versus placebo was associated with a higher proportion of good stroke outcome (modified Rankin Scale score 0-1; 99/518 [19.1%] versus 67/510 [13.1%]; P =0.0109) and similar 90-day mortality (153/518 [29.5%] versus 154/510 [30.2%]; P =0.8382). The odds of a good stroke outcome following alteplase allocation in the full RCT population were independent of age ( P =0.7383). Good stroke outcome was reported for almost half (4821/11 169 [43.2%]) of the patients who received alteplase in routine practice. Outcomes in routine practice supported those achieved in RCTs. CONCLUSIONS Alteplase for AIS has a positive benefit-risk profile among patients aged >80 years when administered according to other regulatory criteria. Alteplase for AIS should be evaluated on an individual benefit-risk basis.",2020,"Among patients aged >80 years, alteplase versus placebo was associated with a higher proportion of good stroke outcome (modified Rankin Scale score 0-1; 99/518 [19.1%] versus 67/510 [13.1%]; P =0.0109) and similar 90-day mortality (153/518 [29.5%] versus 154/510 [30.2%]; P =0.8382).","['Individual patient data', 'patients aged >80 years', 'patients aged 18 to 80 years', 'Patients Aged']","['Alteplase', 'alteplase', 'placebo']","['good functional outcome', 'good stroke outcome (modified Rankin Scale score', '90-day mortality', 'Good stroke outcome']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0032143', 'cui_str': 'alteplase'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",,0.126515,"Among patients aged >80 years, alteplase versus placebo was associated with a higher proportion of good stroke outcome (modified Rankin Scale score 0-1; 99/518 [19.1%] versus 67/510 [13.1%]; P =0.0109) and similar 90-day mortality (153/518 [29.5%] versus 154/510 [30.2%]; P =0.8382).","[{'ForeName': 'Erich', 'Initials': 'E', 'LastName': 'Bluhmki', 'Affiliation': 'ADB Building, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany and Hochschule Biberach, University of Applied Sciences, Germany (E.B.).'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Danays', 'Affiliation': 'The Medical Department, Boehringer Ingelheim France SAS, Reims (T.D.).'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Biegert', 'Affiliation': 'The Biostatistics and Data Sciences Corp, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (G.B.).'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Hacke', 'Affiliation': 'The Department of Neurology, University of Heidelberg, Germany (W.H.).'}, {'ForeName': 'Kennedy R', 'Initials': 'KR', 'LastName': 'Lees', 'Affiliation': 'The School of Medicine, Dentistry & Nursing, University of Glasgow, United Kingdom (K.R.L.).'}]",Stroke,['10.1161/STROKEAHA.119.028396'] 1565,32615017,"A Prospective, Multi-Center, Clinical Trial of a 10-kHz Spinal Cord Stimulation System in the Treatment of Chronic Pelvic Pain.","BACKGROUND Chronic pelvic pain (CPP) is a debilitating condition that often leads to disability and does not respond to conventional treatments. This study was conducted to evaluate the effects of paresthesia-independent 10-kHz spinal cord stimulation (SCS) in subjects with CPP. METHODS This prospective, single-arm pilot study enrolled subjects with clinical diagnoses of CPP and mean pain scores of ≥ 5.0 cm on a 10-cm VAS. Subjects underwent trial stimulations with 10-kHz SCS, and those who had successful trial stimulations (≥40% pain relief) received permanently implanted devices and were followed for 12 months. RESULTS Of the 21 subjects who underwent the 10-kHz SCS trial, 17 were successful and 14 subjects received permanent implants. No neurological deficits were observed in any subjects and all adverse events (AEs) were resolved without sequelae during the study period. Over 12 months, mean VAS scores decreased by 72% from baseline, and 10 of 13 subjects (77%) were responders (≥50% pain relief). Pain remission (VAS score ≤ 3.0 cm) was reported by 8 of 13 subjects (62%), and mean pain scores on the short-form McGill Pain Questionnaire 2 decreased as well. Pain Disability Index scores declined by 29 points, and 85% of the subjects reported satisfaction. CONCLUSIONS Paresthesia-independent stimulation with 10-kHz SCS reduced pelvic pain in subjects with CPP and was not associated with any unexpected AEs. While larger, controlled studies are needed, results of this study suggest that this therapeutic modality could potentially treat patients with CPP while improving their quality of life.",2020,"CONCLUSIONS Paresthesia-independent stimulation with 10 kHz SCS reduced pelvic pain in subjects with CPP and was not associated with any unexpected AEs.","['subjects with CPP', '21 subjects who underwent 10 kHz SCS trial, 17 were successful and 14 subjects received permanent implants', 'Chronic Pelvic Pain', 'Chronic pelvic pain (CPP', 'enrolled subjects with clinical diagnoses of CPP and mean pain scores of ≥5.0 cm on a 10-cm visual analog scale (VAS']","['paresthesia independent 10 kHz spinal cord stimulation (10 kHz SCS', '10 kHz SCS', '10 kHz Spinal Cord Stimulation System']","['quality of life', 'mean VAS scores', 'Pain Disability Index (PDI', 'pelvic pain', 'mean pain scores', 'Pain remission', 'neurological deficits', 'McGill Pain Questionnaire (SF-MPQ-2']","[{'cui': 'C0404484', 'cui_str': 'Chronic pelvic pain of female'}, {'cui': 'C0556965', 'cui_str': 'kHz'}, {'cui': 'C0175699', 'cui_str': 'Saethre-Chotzen syndrome'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0332140', 'cui_str': 'Clinical diagnosis'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]","[{'cui': 'C0030554', 'cui_str': 'Paresthesia'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0556965', 'cui_str': 'kHz'}, {'cui': 'C0394477', 'cui_str': 'Neurostimulation of spinal cord tissue'}, {'cui': 'C0175699', 'cui_str': 'Saethre-Chotzen syndrome'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030794', 'cui_str': 'Pain in pelvis'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0521654', 'cui_str': 'Motor dysfunction'}, {'cui': 'C0024985', 'cui_str': 'McGill pain chart questionnaire'}]",17.0,0.0906093,"CONCLUSIONS Paresthesia-independent stimulation with 10 kHz SCS reduced pelvic pain in subjects with CPP and was not associated with any unexpected AEs.","[{'ForeName': 'Jordan L', 'Initials': 'JL', 'LastName': 'Tate', 'Affiliation': 'Alliance Spine and Pain Centers, Canton, Georgia, U.S.A.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Stauss', 'Affiliation': 'Advanced Pain Management, Milwaukee, Wisconsin, U.S.A.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Premier Pain Centers, Shrewsbury, New Jersey, U.S.A.'}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Rotte', 'Affiliation': 'Nevro Corp, Redwood City, California, U.S.A.'}, {'ForeName': 'Jeyakumar', 'Initials': 'J', 'LastName': 'Subbaroyan', 'Affiliation': 'Nevro Corp, Redwood City, California, U.S.A.'}]",Pain practice : the official journal of World Institute of Pain,['10.1111/papr.12932'] 1566,32615020,Comparison of Sevoflurane and Propofol on the Incidence of Postoperative Pain and Quality of Life in Patients Undergoing Total Knee Arthroplasty With Chronic Pain Before Surgery.,"BACKGROUND Propofol and sevoflurane as frequently used general anesthetics can affect postoperative pain. Our study explored whether the incidence of postoperative pain differed among patients with chronic pain undergoing total knee arthroplasty (TKA) anesthetized with sevoflurane or propofol. METHODS Patients were randomly assigned to groups receiving either sevoflurane (Group S, n = 50) or propofol (Group P, n = 47) for anesthesia maintenance during TKA. The incidences of postoperative pain and quality of life (QoL) were measured using the EuroQol 5-Dimension (EQ-5D) scale at 1, 3, and 7 days post-operation (DPO), and 1 and 3 months post-operation (MPO). RESULTS At 3 DPO, fewer patients reported moderate pain (P = 0.001) and more patients reported no pain (P = 0.003) in Group S than that in Group P. At 3 MPO, more patients reported no pain (P = 0.04) and fewer patients reported moderate pain (P = 0.04) in Group S than in Group P. No significant differences were found in the incidence of postoperative pain between the 2 groups of patients at the other time points. The EQ-5D scores were higher in Group S than in Group P (P = 0.022), and the difference was 0.15 at most, which was not optimal. The EQ-5D clinical results might be not very significant. CONCLUSIONS Sevoflurane anesthesia may have potential advantages in reducing postoperative pain in patients undergoing TKA with a preoperative VAS score > 4.",2020,"The EQ-5D scores were higher in Group S than in Group P (p=0.022), and the difference was 0.15 at most, which was not optimal.","['patients undergoing total knee arthroplasty with chronic pain before surgery', 'patients undergoing TKA with a preoperative VAS score > 4', 'patients with chronic pain undergoing total knee arthroplasty (TKA) anesthetized with', 'Patients']","['Propofol and sevoflurane', 'sevoflurane and propofol', 'Sevoflurane anesthesia', 'sevoflurane', 'propofol', 'sevoflurane or propofol', 'anesthesia maintenance during TKA']","['no pain', 'EQ-5D scores', 'postoperative pain', 'pain', 'moderate pain', 'postoperative pain and quality of life', 'postoperative pain and quality of life (QoL']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1720436', 'cui_str': 'Under anesthesia'}]","[{'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}]","[{'cui': 'C0234225', 'cui_str': 'No pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0278139', 'cui_str': 'Moderate pain'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.0570544,"The EQ-5D scores were higher in Group S than in Group P (p=0.022), and the difference was 0.15 at most, which was not optimal.","[{'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Zhao', 'Affiliation': 'Department of Anesthesiology, First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.'}, {'ForeName': 'Xiao-Hui', 'Initials': 'XH', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.'}, {'ForeName': 'Rui-Hong', 'Initials': 'RH', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.'}, {'ForeName': 'Guang-Hong', 'Initials': 'GH', 'LastName': 'Xu', 'Affiliation': 'Department of Anesthesiology, First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.'}, {'ForeName': 'Qi-Ying', 'Initials': 'QY', 'LastName': 'Shen', 'Affiliation': 'Department of Anesthesiology, First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.'}]",Pain practice : the official journal of World Institute of Pain,['10.1111/papr.12931'] 1567,32615109,"Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.","BACKGROUND Indications for liver transplantation for hepatocellular carcinoma are evolving and so-called expanded criteria remain debated. Locoregional therapies are able to downstage hepatocellular carcinoma from beyond to within the Milan criteria. We aimed to investigate the efficacy of liver transplantation after successful hepatocellular carcinoma downstaging. METHODS We did an open-label, multicentre, randomised, controlled trial designed in two phases, 2b and 3, at nine Italian tertiary care and transplantation centres. Patients aged 18-65 years with hepatocellular carcinoma beyond the Milan criteria, absence of macrovascular invasion or extrahepatic spread, 5-year estimated post-transplantation survival of at least 50%, and good liver function (Child-Pugh A-B7) were recruited and underwent tumour downstaging with locoregional, surgical, or systemic therapies according to multidisciplinary decision. After an observation period of 3 months, during which sorafenib was allowed, patients with partial or complete responses according to modified Response Evaluation Criteria in Solid Tumors were randomly assigned (1:1) by an interactive web-response system to liver transplantation or non-transplantation therapies (control group). A block randomisation (block size of 2), stratified by centre and compliance to sorafenib treatment, was applied. Liver transplantation was done with whole or split organs procured from brain-dead donors. The control group received sequences of locoregional and systemic treatment at the time of demonstrated tumour progression. The primary outcomes were 5-year tumour event-free survival for phase 2b and overall survival for phase 3. Analyses were by intention to treat. Organ allocation policy changed during the course of the study and restricted patient accrual to 4 years. This trial is registered with ClinicalTrials.gov, NCT01387503. FINDINGS Between March 1, 2011, and March 31, 2015, 74 patients were enrolled. Median duration of downstaging was 6 months (IQR 4-11). 29 patients dropped out before randomisation and 45 were randomly assigned: 23 to the transplantation group versus 22 to the control group. At data cutoff on July 31, 2019, median follow-up was 71 months (IQR 60-85). 5-year tumour event-free survival was 76·8% (95% CI 60·8-96·9) in the transplantation group versus 18·3% (7·1-47·0) in the control group (hazard ratio [HR] 0·20, 95% CI 0·07-0·57; p=0·003). 5-year overall survival was 77·5% (95% CI 61·9-97·1) in the transplantation group versus 31·2% (16·6-58·5) in the control group (HR 0·32, 95% CI 0·11-0·92; p=0·035). The most common registered grade 3-4 serious adverse events were hepatitis C virus recurrence (three [13%] of 23 patients) and acute transplant rejection (two [9%]) in the transplantation group, and post-embolisation syndrome (two [9%] of 22 patients) in the control group. Treatment-related deaths occurred in four patients: two (8%) of 23 patients in the transplantation group (myocardial infarction and multi-organ failure) versus two (9%) of 22 patients in the control group (liver decompensation). INTERPRETATION Although results must be interpreted with caution owing to the early closing of the trial, after effective and sustained downstaging of eligible hepatocellular carcinomas beyond the Milan criteria, liver transplantation improved tumour event-free survival and overall survival compared with non-transplantation therapies Post-downstaging tumour response could contribute to the expansion of hepatocellular carcinoma transplantation criteria. FUNDING Italian Ministry of Health.",2020,"overall survival was 77·5% (95% CI 61·9-97·1) in the transplantation group versus 31·2% (16·6-58·5) in the control group (HR 0·32, 95% CI 0·11-0·92; p=0·035).","['two phases, 2b and 3, at nine Italian tertiary care and transplantation centres', '29 patients dropped out before randomisation and 45 were randomly assigned: 23 to the transplantation group versus 22 to the control group', 'Between March 1, 2011, and March 31, 2015, 74 patients were enrolled', 'hepatocellular carcinoma after tumour downstaging (XXL', '0·20', 'Patients aged 18-65 years with hepatocellular carcinoma beyond the Milan criteria, absence of macrovascular invasion or extrahepatic spread, 5-year estimated post-transplantation survival of at least 50%, and good liver function (Child-Pugh A-B7) were recruited and underwent tumour downstaging with locoregional, surgical, or systemic therapies according to multidisciplinary decision', 'patients with partial or complete responses according to modified Response Evaluation Criteria in Solid Tumors']","['liver transplantation', 'sorafenib', 'Liver transplantation', 'interactive web-response system to liver transplantation or non-transplantation therapies (control group']","['5-year tumour event-free survival for phase 2b and overall survival', 'overall survival', 'tumour event-free survival', 'hepatitis C virus recurrence', 'acute transplant rejection', 'Median duration of downstaging', '5-year', 'deaths']","[{'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0022275', 'cui_str': 'Italian language'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C1269955', 'cui_str': 'Tumour invasion'}, {'cui': 'C0332261', 'cui_str': 'Spreading'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0232741', 'cui_str': 'Liver function'}, {'cui': 'C4050412', 'cui_str': 'Child-Pugh score'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1709926', 'cui_str': 'RECIST'}]","[{'cui': 'C0023911', 'cui_str': 'Transplantation of liver'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0079500', 'cui_str': 'Hepacivirus'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0018129', 'cui_str': 'Graft rejection'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",74.0,0.208689,"overall survival was 77·5% (95% CI 61·9-97·1) in the transplantation group versus 31·2% (16·6-58·5) in the control group (HR 0·32, 95% CI 0·11-0·92; p=0·035).","[{'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Mazzaferro', 'Affiliation': 'Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy. Electronic address: vincenzo.mazzaferro@istitutotumori.mi.it.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Citterio', 'Affiliation': 'HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Sherrie', 'Initials': 'S', 'LastName': 'Bhoori', 'Affiliation': 'HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Bongini', 'Affiliation': 'HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Rosalba', 'Initials': 'R', 'LastName': 'Miceli', 'Affiliation': 'Clinical Epidemiology and Trial Organization, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Luciano', 'Initials': 'L', 'LastName': 'De Carlis', 'Affiliation': 'General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-CàGranda Hospital, Milan, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Colledan', 'Affiliation': 'Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Salizzoni', 'Affiliation': 'General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Cittàdella Salute e della Scienza di Torino, Turin, Italy.'}, {'ForeName': 'Renato', 'Initials': 'R', 'LastName': 'Romagnoli', 'Affiliation': 'General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Cittàdella Salute e della Scienza di Torino, Turin, Italy.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Antonelli', 'Affiliation': ""General and Liver Transplant Surgery Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Vivarelli', 'Affiliation': 'Hepatobiliary and Abdominal Transplantation Surgery, Hepatology, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Tisone', 'Affiliation': 'Department of Surgical Sciences and Medical Sciences University of Rome-Tor Vergata, Rome, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Rossi', 'Affiliation': 'Department of General Surgery and Organ Transplantation, Sapienza University, Rome, Italy.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Gruttadauria', 'Affiliation': 'Abdominal Surgery and Organ Transplantation Unit, Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, ISMETT, Palermo, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Di Sandro', 'Affiliation': 'General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-CàGranda Hospital, Milan, Italy.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'De Carlis', 'Affiliation': 'General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-CàGranda Hospital, Milan, Italy.'}, {'ForeName': 'Maria Grazia', 'Initials': 'MG', 'LastName': 'Lucà', 'Affiliation': 'Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'De Giorgio', 'Affiliation': 'Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Mirabella', 'Affiliation': 'General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Cittàdella Salute e della Scienza di Torino, Turin, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Belli', 'Affiliation': 'General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-CàGranda Hospital, Milan, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Fagiuoli', 'Affiliation': 'Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Martini', 'Affiliation': 'General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Cittàdella Salute e della Scienza di Torino, Turin, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Iavarone', 'Affiliation': ""Division of Gastroenterology and Hepatology, CRC A M and A Migliavacca Center for Liver Disease, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Svegliati Baroni', 'Affiliation': 'Hepatobiliary and Abdominal Transplantation Surgery, Hepatology, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Angelico', 'Affiliation': 'Department of Surgical Sciences and Medical Sciences University of Rome-Tor Vergata, Rome, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Ginanni Corradini', 'Affiliation': 'Department of General Surgery and Organ Transplantation, Sapienza University, Rome, Italy.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Volpes', 'Affiliation': 'Abdominal Surgery and Organ Transplantation Unit, Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, ISMETT, Palermo, Italy.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Mariani', 'Affiliation': 'Clinical Epidemiology and Trial Organization, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Regalia', 'Affiliation': 'HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Flores', 'Affiliation': 'HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Droz Dit Busset', 'Affiliation': 'HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Sposito', 'Affiliation': 'Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30224-2'] 1568,32616063,Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.,"OBJECTIVES The primary objectives of the study are: 1. To assess the effect of hydroxychloroquine (HCQ) in reducing SARS-CoV-2 viral shedding by PCR in infected pregnant women with mild symptoms. 2. To assess the efficacy of HCQ to prevent SARS-CoV-2 infection in pregnant women in contact with an infected or suspected case. 3. To evaluate the effect of HCQ in preventing the development of the COVID-19 disease in asymptomatic SARS-CoV-2-infected pregnant women. The secondary objectives are: 1. To determine the effect of HCQ on the clinical course and duration of the COVID-19 disease in SARS-CoV-2-infected pregnant women. 2. To determine the impact of HCQ on the risk of hospitalization and mortality of SARS-CoV-2-infected pregnant women. 3. To assess the safety and tolerability of HCQ in pregnant women. 4. To describe the clinical presentation of SARS-CoV-2 infection during pregnancy. 5. To describe the effects of maternal SARS-CoV-2 infection on pregnancy and perinatal outcomes by treatment group. 6. To determine the risk of vertical transmission (intra-utero and intra-partum) of SARS-CoV-2. TRIAL DESIGN Randomized double-blind placebo-controlled two-arm multicentre clinical trial to evaluate the safety and efficacy of HCQ to prevent and/or minimize SARS-CoV-2 infection during pregnancy. Participants will be randomized to receive a 14-day oral treatment course of HCQ or placebo, ratio 1:1. PARTICIPANTS Study population: pregnant women undergoing routine prenatal follow up or attending emergency units at the participating hospitals who report either symptoms/signs suggestive of COVID-19 disease or close contact with a suspected or confirmed COVID-19 case. Inclusion criteria Women will be invited to participate in the trial and sign an informed consent if they meet the following inclusion criteria. • Presenting with fever (≥37.5°C) and/or one mild symptom suggestive of COVID-19 disease (cough, dyspnoea, chills, odynophagia, diarrhoea, muscle pain, anosmia, dysgeusia, headache) OR being contact* of a SARS-CoV-2 confirmed or suspected case in the past 14 days • More than 12 weeks of gestation (dated by ultrasonography) • Agreement to deliver in the study hospitals Exclusion criteria • Known hypersensitivity to HCQ or other 4-amonoquinoline compounds • History of retinopathy of any aetiology • Concomitant use of digoxin, cyclosporine, cimetidine • Known liver disease • Clinical history of cardiac pathology including known long QT syndrome • Unable to cooperate with the requirements of the study • Participating in other intervention studies • Delivery onset (characterized by painful uterine contractions and variable changes of the cervix, including some degree of effacement and slower progression of dilatation up to 5 cm for first and subsequent labours) The study participants will be stratified by clinical presentation and SARS-CoV-2 PCR results. Assignment of participants to study groups will be as follows: • SARS-CoV-2-PCR confirmed, infected pregnant women: a. symptomatic (n=100) b. asymptomatic (n=100) • SARS-CoV-2 PCR negative pregnant women in contact* with a SARS-CoV-2-infected confirmed or suspected case (n=514). *The ECDC definition of close contact will be followed. The trial will be conducted in five hospitals in Spain: Hospital Clínic of Barcelona, Hospital Sant Joan de Déu and Hospital de la Santa Creu i Sant Pau, in Barcelona, and HM Puerta del Sur and Hospital Universitario de Torrejón, in Madrid. INTERVENTION AND COMPARATOR Participants will be randomized to HCQ (400 mg/day for three days, followed by 200 mg/day for 11 days) or placebo (2 tablets for three days, followed by one tablet for 11 days). MAIN OUTCOMES The primary outcome is the number of PCR-confirmed infected pregnant women assessed from collected nasopharyngeal and oropharyngeal swabs at day 21 after treatment start (one week after treatment is completed). RANDOMISATION Allocation of participants to study arms will be done centrally by the trial's Sponsor (the Barcelona Institute for Global Health, ISGlobal) by block randomization. This method will ensure balanced allocation to both arms. The electronic CRF will automatically assign a study number to each participant, depending on her study group and recruitment site. Each number will be related to a treatment number, which assigns them to one of the study arms. BLINDING (MASKING) Participants, caregivers, investigators and those assessing the outcomes will be blinded to group assignment. Study tablets (HCQ and placebo) will be identically packaged in small opaque bottles. NUMBERS TO BE RANDOMISED (SAMPLE SIZE) This study requires 200 SARS-CoV-2 infected and 514 contact pregnant women, randomised 1:1 with 100 and 227 respectively in each study arm. TRIAL STATUS Protocol version 1.0, from May 8 th , 2020. Recruitment is ongoing (first patient recruited the 19 th May 2020 and recruitment end anticipated by December 2020). TRIAL REGISTRATION EudraCT number: 2020-001587-29, registered 2 April 2020. Clinicaltrials.gov identifier: NCT04410562 , retrospectively registered 1 June 2020. FULL PROTOCOL The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.",2020,To assess the efficacy of HCQ to prevent SARS-CoV-2 infection in pregnant women in contact with an infected or suspected case.,"['2020-001587-29, registered 2 April 2020', 'b. asymptomatic (n=100', 'five hospitals in Spain: Hospital Clínic of Barcelona, Hospital Sant Joan de Déu and Hospital de la', 'Study population: pregnant women undergoing routine prenatal follow up or attending emergency units at the participating hospitals who report either symptoms/signs suggestive of COVID-19 disease or close contact with a suspected or confirmed COVID-19 case', 'SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg', '200 SARS-CoV-2 infected and 514 contact pregnant women, randomised 1:1 with 100 and 227 respectively in each study arm', 'SARS-CoV-2-infected pregnant women', 'pregnant women in contact with an infected or suspected case', 'asymptomatic SARS-CoV-2-infected pregnant women', 'infected pregnant women with mild symptoms', 'infected pregnant women: a. symptomatic (n=100', 'pregnant women']","['Santa Creu', 'cimetidine', 'Hydroxychloroquine', 'HCQ', 'hydroxychloroquine (HCQ', 'maternal SARS-CoV-2 infection', 'Study tablets (HCQ and placebo', 'digoxin, cyclosporine', 'HCQ or placebo, ratio 1:1', '4-amonoquinoline', 'gestation (dated by ultrasonography', 'placebo']","['mild symptom suggestive of COVID-19 disease (cough, dyspnoea, chills, odynophagia, diarrhoea, muscle pain, anosmia, dysgeusia, headache', 'safety and efficacy', 'safety and tolerability', 'number of PCR-confirmed infected pregnant women assessed from collected nasopharyngeal and oropharyngeal swabs']","[{'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0332299', 'cui_str': 'Suggestive of'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0436343', 'cui_str': 'Symptom mild'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}]","[{'cui': 'C0008783', 'cui_str': 'Cimetidine'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0012265', 'cui_str': 'Digoxin'}, {'cui': 'C0010592', 'cui_str': 'Cyclosporine'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0011008', 'cui_str': 'Date'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}]","[{'cui': 'C0436343', 'cui_str': 'Symptom mild'}, {'cui': 'C0332299', 'cui_str': 'Suggestive of'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0085593', 'cui_str': 'Chill'}, {'cui': 'C0221150', 'cui_str': 'Swallowing painful'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0003126', 'cui_str': 'Loss of sense of smell'}, {'cui': 'C0013378', 'cui_str': 'Taste sense altered'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C3536619', 'cui_str': 'Nasopharyngeal and oropharyngeal swab'}]",,0.422207,To assess the efficacy of HCQ to prevent SARS-CoV-2 infection in pregnant women in contact with an infected or suspected case.,"[{'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'González', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain. raquel.gonzalez@isglobal.org.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'García-Otero', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Pons-Duran', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Marbán-Castro', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Goncé', 'Affiliation': 'BCNATAL | Barcelona Center for Maternal Fetal and Neonatal Medicine, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Llurba', 'Affiliation': 'Obstetrics and Gynecology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.'}, {'ForeName': 'Maria Del Mar', 'Initials': 'MDM', 'LastName': 'Gil', 'Affiliation': 'Obstetrics and Gynecology Department, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, Spain.'}, {'ForeName': 'Miguel Ángel', 'Initials': 'MÁ', 'LastName': 'Rodríguez-Zambrano', 'Affiliation': 'HM Puerta del Sur, Móstoles, Madrid, Spain.'}, {'ForeName': 'Haily', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Máximo', 'Initials': 'M', 'LastName': 'Ramírez', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Azucena', 'Initials': 'A', 'LastName': 'Bardají', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Menendez', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.'}]",Trials,['10.1186/s13063-020-04557-y'] 1569,32635408,"A Double-Blind, Randomized, Placebo-Controlled Trial of Heat-Killed Pediococcus acidilactici K15 for Prevention of Respiratory Tract Infections among Preschool Children.","Although some probiotic bacteria have been reported to prevent infections in children, there are few well-designed double-blind studies. Here we evaluated the effects of a probiotic strain of lactic acid bacteria (LAB), Pediococcus acidilactici K15, on viral respiratory tract infections in preschool children. A four-month, randomized, double-blind, placebo-controlled study was performed in 172 healthy children aged 3 to 6 years. Subjects were administered dextrin alone or dextrin including heat-killed K15 (5 × 10 10 bacteria). The number of febrile days was the primary outcome. The number of absent days from preschools and the influenza incidence were secondary outcomes. Secretory IgA (sIgA) concentrations in saliva were measured as an exploratory outcome. The primary and secondary outcomes were not significantly different between both groups. Analyses in children with little intake of fermented foods including LAB showed that the duration of a fever significantly decreased by K15 intake. The salivary sIgA level in the K15 group was maintained significantly higher than it was in the placebo group. The effects of K15 on preventing viral respiratory tract infections were not observed without the restriction of fermented foods intake. However, K15 supported anti-infectious immune systems in children who took less fermented foods and the maintenance of salivary sIgA levels in all subjects.",2020,The salivary sIgA level in the K15 group was maintained significantly higher than it was in the placebo group.,"['Preschool Children', '172 healthy children aged 3 to 6 years', 'preschool children']","['probiotic strain of lactic acid bacteria (LAB), Pediococcus acidilactici', 'dextrin alone or dextrin including heat-killed K15', 'Placebo', 'placebo']","['viral respiratory tract infections', 'number of febrile days', 'salivary sIgA levels', 'salivary sIgA level', 'duration of a fever', 'Respiratory Tract Infections', 'Secretory IgA (sIgA) concentrations in saliva']","[{'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C4517601', 'cui_str': '172'}, {'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C1210581', 'cui_str': 'Lactobacillales'}, {'cui': 'C0445653', 'cui_str': 'Pediococcus acidilactici'}, {'cui': 'C0011808', 'cui_str': 'Dextrins'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0162388', 'cui_str': 'Killing'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0877203', 'cui_str': 'Respiratory tract infection viral'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0020838', 'cui_str': 'Immunoglobulin A secretory'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0035243', 'cui_str': 'Respiratory tract infection'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}]",172.0,0.420595,The salivary sIgA level in the K15 group was maintained significantly higher than it was in the placebo group.,"[{'ForeName': 'Haruka', 'Initials': 'H', 'LastName': 'Hishiki', 'Affiliation': 'Department of Pediatrics, Chiba University Hospital, Chiba 260-8670, Japan.'}, {'ForeName': 'Tadaomi', 'Initials': 'T', 'LastName': 'Kawashima', 'Affiliation': 'Research and Development Division, Kikkoman Corporation, Chiba 278-0037, Japan.'}, {'ForeName': 'Noriko M', 'Initials': 'NM', 'LastName': 'Tsuji', 'Affiliation': 'Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology, Ibaraki 305-0046, Japan.'}, {'ForeName': 'Naho', 'Initials': 'N', 'LastName': 'Ikari', 'Affiliation': 'Research and Development Division, Kikkoman Corporation, Chiba 278-0037, Japan.'}, {'ForeName': 'Ryo', 'Initials': 'R', 'LastName': 'Takemura', 'Affiliation': 'Clinical Research Center, Chiba University Hospital, Chiba 260-8677, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Kido', 'Affiliation': 'Institute for Enzyme Research, Tokushima University, Tokushima 770-8503, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Shimojo', 'Affiliation': 'Department of Pediatrics, Chiba University Hospital, Chiba 260-8670, Japan.'}]",Nutrients,['10.3390/nu12071989'] 1570,32636324,One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.,"OBJECTIVE To assess efficacy and tolerability of 1-year erenumab treatment in patients with episodic migraine. METHODS Patients were randomized (n = 955; 1:1:1) during the 24-week double-blind treatment phase (DBTP) to monthly subcutaneous placebo or erenumab 70 or 140 mg. At week 24, 845 patients were rerandomized (1:1) to erenumab 70 or 140 mg during the 28-week dose-blinded active-treatment phase (ATP). Monthly migraine days (MMD), achieving ≥50%, ≥75%, and 100% reduction in MMD, and safety/tolerability were assessed. RESULTS Mean MMD at DBTP baseline was 8.3. At week 52, mean changes (SE) from pre-DBTP baseline/week 24 (pre-ATP baseline) in MMD were -4.2 (0.2)/-1.1 (0.2) (70 mg) and -4.6 (0.2)/-1.8 (0.2) (140 mg) irrespective of treatment during the DBTP. For patients reducing dose from 140 (DBTP) to 70 mg (ATP), change in MMD from week 24 to 52 was -0.1 (0.3), and for those increasing from 70 (DBTP) to 140 mg (ATP), -1.8 (0.3). At week 52, 61.0%, 38.5%, and 19.8% of patients on erenumab 70 mg, and 64.9%, 40.8%, and 21.2% on erenumab 140 mg, achieved ≥50%, ≥75%, and 100% reduction in MMD from DBTP baseline, respectively. Among erenumab-treated patients in DBTP who showed ≥50% reduction in MMD during the last 3 months of DBTP and completed ATP, 86% showed sustained responses at ≥50% during the last 3 months of ATP. Safety of erenumab in ATP was similar to DBTP; exposure-adjusted incidence rates of adverse events were similar for either dose. CONCLUSION Over 52 weeks, erenumab provided sustained efficacy in episodic migraine; the safety profiles were similar between erenumab dose groups in the presence of dose blinding. CLINICALTRIALSGOV IDENTIFIER NCT02456740. CLASSIFICATION OF EVIDENCE Class II evidence that 52 weeks of treatment with erenumab 70 and 140 mg subcutaneously monthly results in sustained reductions in monthly migraine days and similar dose tolerability for patients with episodic migraine.",2020,"Over 52 weeks, erenumab provided sustained efficacy in episodic migraine; the safety profiles were similar between erenumab dose groups in the presence of dose blinding. ","['845 patients', 'patients with episodic migraine', 'Patients were randomized ( n =955; 1:1:1) during the 24-week', 'episodic migraine']","['erenumab 70 or 140mg during the 28-week dose-blinded active-treatment phase (ATP', 'double-blind treatment phase (DBTP) to monthly subcutaneous placebo, erenumab 70 or 140mg']","['safety profiles', 'MMD, and safety/tolerability', 'efficacy and tolerability', 'sustained responses', 'MMD', 'Mean MMD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4760993', 'cui_str': 'Episodic migraine'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C4542165', 'cui_str': 'erenumab'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",845.0,0.0624176,"Over 52 weeks, erenumab provided sustained efficacy in episodic migraine; the safety profiles were similar between erenumab dose groups in the presence of dose blinding. ","[{'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Goadsby', 'Affiliation': ""From the NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College Hospital, London, UK; Department of Neurology (U.R.), Charité Universitätsmedizin Berlin, Germany; Neuro Center (Y.H.), St Görans Hospital, Stockholm, Sweden; Department of Neurology (G.B.), Headache Outpatient Clinic, Medical University of Innsbruck, Austria; Mercy Research (J.H.B.), St. Louis, MO; Amgen Inc. (F.Z., D.E.C., H.P., R.A.L., D.D.M.), Thousand Oaks, CA; Novartis Product Irl Ltd. (I.K.W.), Dublin, Ireland; and Novartis Pharma AG (J.K.), Basel, Switzerland. peter.goadsby@kcl.ac.uk.""}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Reuter', 'Affiliation': ""From the NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College Hospital, London, UK; Department of Neurology (U.R.), Charité Universitätsmedizin Berlin, Germany; Neuro Center (Y.H.), St Görans Hospital, Stockholm, Sweden; Department of Neurology (G.B.), Headache Outpatient Clinic, Medical University of Innsbruck, Austria; Mercy Research (J.H.B.), St. Louis, MO; Amgen Inc. (F.Z., D.E.C., H.P., R.A.L., D.D.M.), Thousand Oaks, CA; Novartis Product Irl Ltd. (I.K.W.), Dublin, Ireland; and Novartis Pharma AG (J.K.), Basel, Switzerland.""}, {'ForeName': 'Yngve', 'Initials': 'Y', 'LastName': 'Hallström', 'Affiliation': ""From the NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College Hospital, London, UK; Department of Neurology (U.R.), Charité Universitätsmedizin Berlin, Germany; Neuro Center (Y.H.), St Görans Hospital, Stockholm, Sweden; Department of Neurology (G.B.), Headache Outpatient Clinic, Medical University of Innsbruck, Austria; Mercy Research (J.H.B.), St. Louis, MO; Amgen Inc. (F.Z., D.E.C., H.P., R.A.L., D.D.M.), Thousand Oaks, CA; Novartis Product Irl Ltd. (I.K.W.), Dublin, Ireland; and Novartis Pharma AG (J.K.), Basel, Switzerland.""}, {'ForeName': 'Gregor', 'Initials': 'G', 'LastName': 'Broessner', 'Affiliation': ""From the NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College Hospital, London, UK; Department of Neurology (U.R.), Charité Universitätsmedizin Berlin, Germany; Neuro Center (Y.H.), St Görans Hospital, Stockholm, Sweden; Department of Neurology (G.B.), Headache Outpatient Clinic, Medical University of Innsbruck, Austria; Mercy Research (J.H.B.), St. Louis, MO; Amgen Inc. (F.Z., D.E.C., H.P., R.A.L., D.D.M.), Thousand Oaks, CA; Novartis Product Irl Ltd. (I.K.W.), Dublin, Ireland; and Novartis Pharma AG (J.K.), Basel, Switzerland.""}, {'ForeName': 'Jo H', 'Initials': 'JH', 'LastName': 'Bonner', 'Affiliation': ""From the NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College Hospital, London, UK; Department of Neurology (U.R.), Charité Universitätsmedizin Berlin, Germany; Neuro Center (Y.H.), St Görans Hospital, Stockholm, Sweden; Department of Neurology (G.B.), Headache Outpatient Clinic, Medical University of Innsbruck, Austria; Mercy Research (J.H.B.), St. Louis, MO; Amgen Inc. (F.Z., D.E.C., H.P., R.A.L., D.D.M.), Thousand Oaks, CA; Novartis Product Irl Ltd. (I.K.W.), Dublin, Ireland; and Novartis Pharma AG (J.K.), Basel, Switzerland.""}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Zhang', 'Affiliation': ""From the NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College Hospital, London, UK; Department of Neurology (U.R.), Charité Universitätsmedizin Berlin, Germany; Neuro Center (Y.H.), St Görans Hospital, Stockholm, Sweden; Department of Neurology (G.B.), Headache Outpatient Clinic, Medical University of Innsbruck, Austria; Mercy Research (J.H.B.), St. Louis, MO; Amgen Inc. (F.Z., D.E.C., H.P., R.A.L., D.D.M.), Thousand Oaks, CA; Novartis Product Irl Ltd. (I.K.W.), Dublin, Ireland; and Novartis Pharma AG (J.K.), Basel, Switzerland.""}, {'ForeName': 'Ian K', 'Initials': 'IK', 'LastName': 'Wright', 'Affiliation': ""From the NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College Hospital, London, UK; Department of Neurology (U.R.), Charité Universitätsmedizin Berlin, Germany; Neuro Center (Y.H.), St Görans Hospital, Stockholm, Sweden; Department of Neurology (G.B.), Headache Outpatient Clinic, Medical University of Innsbruck, Austria; Mercy Research (J.H.B.), St. Louis, MO; Amgen Inc. (F.Z., D.E.C., H.P., R.A.L., D.D.M.), Thousand Oaks, CA; Novartis Product Irl Ltd. (I.K.W.), Dublin, Ireland; and Novartis Pharma AG (J.K.), Basel, Switzerland.""}, {'ForeName': 'Denise E', 'Initials': 'DE', 'LastName': 'Chou', 'Affiliation': ""From the NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College Hospital, London, UK; Department of Neurology (U.R.), Charité Universitätsmedizin Berlin, Germany; Neuro Center (Y.H.), St Görans Hospital, Stockholm, Sweden; Department of Neurology (G.B.), Headache Outpatient Clinic, Medical University of Innsbruck, Austria; Mercy Research (J.H.B.), St. Louis, MO; Amgen Inc. (F.Z., D.E.C., H.P., R.A.L., D.D.M.), Thousand Oaks, CA; Novartis Product Irl Ltd. (I.K.W.), Dublin, Ireland; and Novartis Pharma AG (J.K.), Basel, Switzerland.""}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Klatt', 'Affiliation': ""From the NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College Hospital, London, UK; Department of Neurology (U.R.), Charité Universitätsmedizin Berlin, Germany; Neuro Center (Y.H.), St Görans Hospital, Stockholm, Sweden; Department of Neurology (G.B.), Headache Outpatient Clinic, Medical University of Innsbruck, Austria; Mercy Research (J.H.B.), St. Louis, MO; Amgen Inc. (F.Z., D.E.C., H.P., R.A.L., D.D.M.), Thousand Oaks, CA; Novartis Product Irl Ltd. (I.K.W.), Dublin, Ireland; and Novartis Pharma AG (J.K.), Basel, Switzerland.""}, {'ForeName': 'Hernan', 'Initials': 'H', 'LastName': 'Picard', 'Affiliation': ""From the NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College Hospital, London, UK; Department of Neurology (U.R.), Charité Universitätsmedizin Berlin, Germany; Neuro Center (Y.H.), St Görans Hospital, Stockholm, Sweden; Department of Neurology (G.B.), Headache Outpatient Clinic, Medical University of Innsbruck, Austria; Mercy Research (J.H.B.), St. Louis, MO; Amgen Inc. (F.Z., D.E.C., H.P., R.A.L., D.D.M.), Thousand Oaks, CA; Novartis Product Irl Ltd. (I.K.W.), Dublin, Ireland; and Novartis Pharma AG (J.K.), Basel, Switzerland.""}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Lenz', 'Affiliation': ""From the NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College Hospital, London, UK; Department of Neurology (U.R.), Charité Universitätsmedizin Berlin, Germany; Neuro Center (Y.H.), St Görans Hospital, Stockholm, Sweden; Department of Neurology (G.B.), Headache Outpatient Clinic, Medical University of Innsbruck, Austria; Mercy Research (J.H.B.), St. Louis, MO; Amgen Inc. (F.Z., D.E.C., H.P., R.A.L., D.D.M.), Thousand Oaks, CA; Novartis Product Irl Ltd. (I.K.W.), Dublin, Ireland; and Novartis Pharma AG (J.K.), Basel, Switzerland.""}, {'ForeName': 'Daniel D', 'Initials': 'DD', 'LastName': 'Mikol', 'Affiliation': ""From the NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College Hospital, London, UK; Department of Neurology (U.R.), Charité Universitätsmedizin Berlin, Germany; Neuro Center (Y.H.), St Görans Hospital, Stockholm, Sweden; Department of Neurology (G.B.), Headache Outpatient Clinic, Medical University of Innsbruck, Austria; Mercy Research (J.H.B.), St. Louis, MO; Amgen Inc. (F.Z., D.E.C., H.P., R.A.L., D.D.M.), Thousand Oaks, CA; Novartis Product Irl Ltd. (I.K.W.), Dublin, Ireland; and Novartis Pharma AG (J.K.), Basel, Switzerland.""}]",Neurology,['10.1212/WNL.0000000000010019'] 1571,32639892,Thiazide Use and Decreased Risk of Heart Failure in Nondiabetic Patients Receiving Intensive Blood Pressure Treatment.,"The SPRINT (Systolic Blood Pressure Intervention Trial) study reported that intensive blood pressure (BP) treatment with a systolic BP target of <120 mm Hg decreased the risks of cardiovascular events. However, it remains unknown whether specific medications can further improve cardiovascular outcome in patients receiving intensive BP treatment. This study examined whether thiazide use improves cardiovascular outcome in patients receiving intensive BP treatment. We used data of nondiabetic patients receiving intensive BP treatment in the SPRINT study. The primary outcome was a composite end point of myocardial infarction, acute coronary syndrome, stroke, heart failure, or cardiovascular death. We analyzed hazard ratios for outcomes with 95% CIs in patients taking thiazides compared with those not taking thiazides using Cox proportional hazard models. This study included 2847 patients and the mean follow-up period was 3.3 years. The risk of primary outcome events was significantly lower in patients taking thiazides than in those not taking thiazides in both entire and propensity score-matched cohorts. Particularly, heart failure risk was significantly lower in those taking thiazides. These associations were also observed in various subgroups. In addition, thiazide use was associated with decreased risk of all-cause mortality. Hypokalemia occurred more frequently in patients taking thiazides than in those not taking thiazides. Thiazide use decreased risk of cardiovascular events, particularly heart failure, in nondiabetic high-risk patients receiving intensive BP treatment.",2020,The risk of primary outcome events was significantly lower in patients taking thiazides than in those not taking thiazides in both entire and propensity score-matched cohorts.,"['nondiabetic high-risk patients receiving intensive BP treatment', 'patients receiving intensive BP treatment', 'nondiabetic patients receiving intensive BP treatment in the SPRINT study', 'Nondiabetic Patients Receiving Intensive Blood Pressure Treatment', '2847 patients and the mean follow-up period was 3.3 years']","['thiazide', 'Thiazide', 'intensive blood pressure (BP) treatment with a systolic BP target of <120 mm']","['Risk of Heart Failure', 'Hypokalemia', 'risk of cardiovascular events', 'cardiovascular outcome', 'risk of all-cause mortality', 'heart failure risk', 'risks of cardiovascular events', 'composite end point of myocardial infarction, acute coronary syndrome, stroke, heart failure, or cardiovascular death']","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C4517688', 'cui_str': '3.3'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0012802', 'cui_str': 'Thiazide diuretic'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C4319550', 'cui_str': '120'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0020621', 'cui_str': 'Hypokalemia'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",2847.0,0.0364217,The risk of primary outcome events was significantly lower in patients taking thiazides than in those not taking thiazides in both entire and propensity score-matched cohorts.,"[{'ForeName': 'Tetsuro', 'Initials': 'T', 'LastName': 'Tsujimoto', 'Affiliation': 'From the Department of Diabetes and Endocrinology, Toranomon Hospital Kajigaya, Kanagawa, Japan (T.T.).'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Kajio', 'Affiliation': 'Department of Diabetes, Endocrinology, and Metabolism, Center Hospital, National Center for Global Health and Medicine, Tokyo, Japan (T.T., H.K.).'}]","Hypertension (Dallas, Tex. : 1979)",['10.1161/HYPERTENSIONAHA.120.15154'] 1572,32640669,"Influence of Biopsy Technique on Molecular Genetic Tumor Characterization in Non-Small Cell Lung Cancer-The Prospective, Randomized, Single-Blinded, Multicenter PROFILER Study Protocol.","The detection of molecular alterations is crucial for the individualized treatment of advanced non-small cell lung cancer (NSCLC). Missing targetable alterations may have a major impact on patient's progression free and overall survival. Although laboratory testing for molecular alterations has continued to improve; little is known about how biopsy technique affects the detection rate of different mutations. In the retrospective study detection rate of epidermal growth factor (EGFR) mutations in tissue extracted by bronchoscopic cryobiopsy (CB was significantly higher compared to other standard biopsy techniques. This prospective, randomized, multicenter, single blinded study evaluates the accuracy of molecular genetic characterization of NSCLC for different cell sampling techniques. Key inclusion criteria are suspected lung cancer or the suspected relapse of known NSCLC that is bronchoscopically visible. Patients will be randomized, either to have a CB or a bronchoscopic forceps biopsy (FB). If indicated, a transbronchial needle aspiration (TBNA) of suspect lymph nodes will be performed. Blood liquid biopsy will be taken before tissue biopsy. The primary endpoint is the detection rate of molecular genetic alterations in NSCLC, using CB and FB. Secondary endpoints are differences in the combined detection of molecular genetic alterations between FB and CB, TBNA and liquid biopsy. This trial plans to recruit 540 patients, with 178 evaluable patients per study cohort. A histopathological and molecular genetic evaluation will be performed by the affiliated pathology departments of the national network for genomic medicine in lung cancer (nNGM), Germany. We will compare the diagnostic value of solid tumor tissue, lymph node cells and liquid biopsy for the molecular genetic characterization of NSCLC. This reflects a real world clinical setting, with potential direct impact on both treatment and survival.",2020,Although laboratory testing for molecular alterations has continued to improve; little is known about how biopsy technique affects the detection rate of different mutations.,"['540 patients, with 178 evaluable patients per study cohort', 'advanced non-small cell lung cancer (NSCLC', 'Non-Small Cell Lung Cancer']","['transbronchial needle aspiration (TBNA', 'Biopsy Technique', 'bronchoscopic forceps biopsy (FB']","['detection rate of molecular genetic alterations in NSCLC, using CB and FB', 'epidermal growth factor (EGFR) mutations', 'combined detection of molecular genetic alterations between FB and CB, TBNA and liquid biopsy']","[{'cui': 'C5192767', 'cui_str': '540'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}]","[{'cui': 'C0442342', 'cui_str': 'Transbronchial approach'}, {'cui': 'C0181959', 'cui_str': 'Aspiration needle'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0180936', 'cui_str': 'Biopsy forceps'}]","[{'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0086345', 'cui_str': 'Molecular Genetics'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0242275', 'cui_str': 'Epidermal Growth Factor'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C4505151', 'cui_str': 'Liquid Biopsies'}]",540.0,0.125351,Although laboratory testing for molecular alterations has continued to improve; little is known about how biopsy technique affects the detection rate of different mutations.,"[{'ForeName': 'Maik', 'Initials': 'M', 'LastName': 'Haentschel', 'Affiliation': 'Department of Medical Oncology and Pneumology, Eberhard Karls University, 72076 Tübingen, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Boeckeler', 'Affiliation': 'Department of Medical Oncology and Pneumology, Eberhard Karls University, 72076 Tübingen, Germany.'}, {'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Bonzheim', 'Affiliation': 'Institute of Pathology and Neuropathology, Reference Center for Haematopathology University Hospital, Tuebingen Eberhard-Karls-University, 72076 Tübingen, Germany.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Schimmele', 'Affiliation': 'Department of Internal Medicine, Gastroenterology and Tumor Medicine, Paracelsus Hospital, 73760 Ostfildern-Ruit, Germany.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Spengler', 'Affiliation': 'Department of Medical Oncology and Pneumology, Eberhard Karls University, 72076 Tübingen, Germany.'}, {'ForeName': 'Franz', 'Initials': 'F', 'LastName': 'Stanzel', 'Affiliation': 'Center for Pneumology, 58675 Hemer, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Petermann', 'Affiliation': 'Department for Pulmonary Diseases, Asklepios-Klinik Harburg, 21075 Hamburg, Germany.'}, {'ForeName': 'Kaid', 'Initials': 'K', 'LastName': 'Darwiche', 'Affiliation': 'Department of Interventional Pneumology, Ruhrlandklinik, University Hospital Essen, University of Duisburg-Essen, 45239 Essen, Germany.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Hagmeyer', 'Affiliation': 'Clinic for Pneumology and Allergology, Center of Sleep Medicine and Respiratory Care, Hospital Bethanien Solingen, 42699 Solingen, Germany.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Buettner', 'Affiliation': 'Institute of Pathology, University Hospital of Cologne, 50937 Cologne, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Tiemann', 'Affiliation': 'Institute for Hematopathology Hamburg, 22547 Hamburg, Germany.'}, {'ForeName': 'Hans-Ulrich', 'Initials': 'HU', 'LastName': 'Schildhaus', 'Affiliation': 'Department of Pathology, University Medicine Essen-Ruhrlandklinik, University Duisburg-Essen, 45147 Essen, Germany.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Muche', 'Affiliation': 'Institute of Epidemiology and Medical Biometry, Ulm University, 89075 Ulm, Germany.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Boesmueller', 'Affiliation': 'Institute of Pathology and Neuropathology, Reference Center for Haematopathology University Hospital, Tuebingen Eberhard-Karls-University, 72076 Tübingen, Germany.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Everinghoff', 'Affiliation': 'Department of Medical Oncology and Pneumology, Eberhard Karls University, 72076 Tübingen, Germany.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Mueller', 'Affiliation': 'Department of Medical Oncology and Pneumology, Eberhard Karls University, 72076 Tübingen, Germany.'}, {'ForeName': 'Bijoy', 'Initials': 'B', 'LastName': 'Atique', 'Affiliation': 'Department of Medical Oncology and Pneumology, Eberhard Karls University, 72076 Tübingen, Germany.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Lewis', 'Affiliation': 'NPARU, University of Worcester, Worcester WR2 6AJ, UK.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Zender', 'Affiliation': 'Department of Medical Oncology and Pneumology, Eberhard Karls University, 72076 Tübingen, Germany.'}, {'ForeName': 'Falko', 'Initials': 'F', 'LastName': 'Fend', 'Affiliation': 'Institute of Pathology and Neuropathology, Reference Center for Haematopathology University Hospital, Tuebingen Eberhard-Karls-University, 72076 Tübingen, Germany.'}, {'ForeName': 'Juergen', 'Initials': 'J', 'LastName': 'Hetzel', 'Affiliation': 'Department of Medical Oncology and Pneumology, Eberhard Karls University, 72076 Tübingen, Germany.'}]","Diagnostics (Basel, Switzerland)",['10.3390/diagnostics10070459'] 1573,32640842,Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study.,"Background: Ultra rapid lispro (URLi) is a new insulin lispro formulation that has accelerated absorption and improved postprandial glucose control compared with insulin lispro (Humalog ® ). The compatibility and safety of URLi versus lispro were evaluated in patients with type 1 diabetes using continuous subcutaneous insulin infusion (insulin pump). Methods: In this phase 3, double-blind, crossover study, 49 patients were randomized to two 6-week treatment periods, after a 2-week lead-in period on lispro. The primary endpoint was the rate of infusion set failures due to a pump occlusion alarm, or unexplained hyperglycemia with blood glucose >13.9 mmol/L (250 mg/dL) that did not decrease within 1 h after a correction bolus. Results: There was no significant difference in the rate of infusion set failures between URLi and lispro (0.03 vs. 0.05 events/30 days, P  = 0.375). A higher rate of premature infusion set changes was observed with URLi (1.13 vs. 0.78 events/30 days; P  = 0.028), translating to one additional infusion set change approximately every 3 months. A trend toward improved glycemic control was observed with URLi treatment: Time in range 3.9-10.0 mmol/L (71-180 mg/dL) was 65.7% ± 1.3% versus 63.0% ± 1.3%. Treatment-emergent adverse events (TEAEs) were reported by 46.9% of patients on URLi treatment and 18.8% on lispro. This difference was driven by an increase in infusion site reactions-more than 90% were mild. Incidence of all other TEAEs and severe hypoglycemia was similar between treatments. Conclusions: URLi was compatible with insulin pump use with a safety profile similar to lispro.",2020,"There was no significant difference in the rate of infusion set failures between URLi and lispro (0.03 versus 0.05 events/30 days, p=0.375).","['49 patients', 'patients with type 1 diabetes using continuous subcutaneous insulin infusion (CSII, insulin pump', 'Patients With Type 1 Diabetes']","['URLi versus lispro', ' Ultra rapid lispro (URLi', 'Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion']","['infusion site reactions', 'rate of premature infusion set changes', 'rate of infusion set failures due to a pump occlusion alarm, or unexplained hyperglycemia with blood glucose', 'rate of infusion set failures', 'compatibility and safety', 'Incidence of all other TEAEs and severe hypoglycemia', 'glycemic control']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0199782', 'cui_str': 'Administration of insulin'}, {'cui': 'C1140609', 'cui_str': 'Insulin pump'}]","[{'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0293359', 'cui_str': 'Insulin Lispro'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0199782', 'cui_str': 'Administration of insulin'}]","[{'cui': 'C1096343', 'cui_str': 'Infusion site reaction'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C0336648', 'cui_str': 'Alarm'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4728082', 'cui_str': 'Severe hypoglycaemia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",49.0,0.104417,"There was no significant difference in the rate of infusion set failures between URLi and lispro (0.03 versus 0.05 events/30 days, p=0.375).","[{'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Bode', 'Affiliation': 'Department of Endocrinology, Atlanta Diabetes Associates, Atlanta, Georgia, USA.'}, {'ForeName': 'Satish', 'Initials': 'S', 'LastName': 'Garg', 'Affiliation': 'Department of Endocrinology, Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Norwood', 'Affiliation': 'Department of Endocrinology, Valley Research, Fresno, California, USA.'}, {'ForeName': 'Cristobal', 'Initials': 'C', 'LastName': 'Morales', 'Affiliation': 'Department of Endocrinology, Hospital Universitario Virgen Macarena, Seville, Spain.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Hardy', 'Affiliation': 'TH and DI Medical Development, RL Clinical Design, Delivery, and Analytics, Eli Lilly and Company, Indianapolis, Indiana, USA.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Liu', 'Affiliation': 'TH and DI Medical Development, RL Clinical Design, Delivery, and Analytics, Eli Lilly and Company, Indianapolis, Indiana, USA.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Ignaut', 'Affiliation': 'TH and DI Medical Development, RL Clinical Design, Delivery, and Analytics, Eli Lilly and Company, Indianapolis, Indiana, USA.'}]",Diabetes technology & therapeutics,['10.1089/dia.2020.0224'] 1574,32605142,"Outcomes Assessment of Sustainable and Innovatively Simple Lifestyle Modification at the Workplace - Drinking Electrolyzed-Reduced Water (OASIS-ERW): A Randomized, Double-Blind, Placebo-Controlled Trial.","Oxidative stress has been associated with many diseases as well as aging. Electrolyzed-reduced water (ERW) has been suggested to reduce oxidative stress and improve antioxidant potential. This study investigated the effects of drinking ERW on biomarkers of oxidative stress and health-related indices in healthy adults. We conducted a randomized, double-blind, placebo-controlled clinical trial on 65 participants, who were allocated into two groups. Of these, 61 received intervention (32 with ERW and 29 MW [mineral water]). All participants were instructed to drink 1.5 L/day of ERW or MW for eight weeks. Biomarkers of oxidative stress and health-related indices were assessed at baseline as well as after 4 weeks and 8 weeks of intervention. Of the primary outcome variables assessed, diacron-reactive oxygen metabolites (d-ROMs) and biological antioxidant potential showed a significant interaction between the groups and time, with d-ROMs levels significantly decreased at 8 weeks in ERW compared to those in MW. Among the secondary outcome variables, total, visceral, and subcutaneous fat mass significantly changed over time, with a significant association observed between the groups and time. Thus, daily ERW consumption may be a potential consideration for a sustainable and innovatively simple lifestyle modification at the workplace to reduce oxidative stress, increase antioxidant potential, and decrease fat mass.",2020,"Among the secondary outcome variables, total, visceral, and subcutaneous fat mass significantly changed over time, with a significant association observed between the groups and time.","['healthy adults', '65 participants']","['Placebo', 'Electrolyzed-reduced water (ERW', 'drinking ERW', 'Sustainable and Innovatively Simple Lifestyle Modification at the Workplace - Drinking Electrolyzed-Reduced Water (OASIS-ERW', 'placebo']","['total, visceral, and subcutaneous fat mass', 'diacron-reactive oxygen metabolites (d-ROMs) and biological antioxidant potential showed a significant interaction between the groups and time, with d-ROMs levels']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0162579', 'cui_str': 'Work environment'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0766345', 'cui_str': 'OASIS'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C0222331', 'cui_str': 'Subcutaneous fatty tissue'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0205332', 'cui_str': 'Reactive'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C4049351', 'cui_str': 'Biological antioxidant potential'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",65.0,0.311292,"Among the secondary outcome variables, total, visceral, and subcutaneous fat mass significantly changed over time, with a significant association observed between the groups and time.","[{'ForeName': 'Young Ah', 'Initials': 'YA', 'LastName': 'Choi', 'Affiliation': 'Department of Family Medicine, Bundang Jesaeng General Hospital, Seongnam-si, Gyeonggi-do 13590, Korea.'}, {'ForeName': 'Dong Hyeon', 'Initials': 'DH', 'LastName': 'Lee', 'Affiliation': 'Department of Physiology, School of Medicine, CHA University, Seongnam-si, Gyeonggi-do 13488, Korea.'}, {'ForeName': 'Doo-Yeoun', 'Initials': 'DY', 'LastName': 'Cho', 'Affiliation': 'Department of Clinical Pharmacology, School of Medicine, CHA University, Seongnam-si, Gyeonggi-do 13496, Korea.'}, {'ForeName': 'Yong-Jae', 'Initials': 'YJ', 'LastName': 'Lee', 'Affiliation': 'Department of Family Medicine, Yonsei University College of Medicine, Seoul 06273, Korea.'}]","Antioxidants (Basel, Switzerland)",['10.3390/antiox9070564'] 1575,32613525,Development and Initial Testing of an mHealth Transitions of Care Intervention for Adults with Schizophrenia-Spectrum Disorders Immediately Following a Psychiatric Hospitalization.,"An important period in the care of patients with schizophrenia-spectrum disorders is when they transition from inpatient to outpatient services and are at increased risk for relapse and rehospitalization. Thus, we developed and examined the initial feasibility, acceptability, and clinical effects of an mHealth transitions of care intervention (Mobile After-Care Support; MACS) in an open trial. Ten adults with schizophrenia-spectrum disorders were recruited during their index psychiatric hospitalization and enrolled prior to discharge. Measures of feasibility, acceptability, and MACS targets were administered at baseline and a 1-month follow-up. Drawing on skills from Cognitive Behavioral Therapy for Psychosis (CBTp), MACS delivered brief assessments of clinically relevant variables, followed by just-in-time interventions for patients starting immediately post-discharge. Individuals completed about one session per day on average as expected. Overall, measures of MACS usability and satisfaction were positive. T-test analyses showed that dysfunctional coping strategies significantly decreased from baseline to 1-month follow-up. Results also revealed statistically significant reductions in psychiatric symptoms over 1-month follow-up. This study demonstrates the feasibility and acceptability of MACS, a new app-based intervention targeting transitions of care for patients with psychosis. The field is turning to the use of mobile technology as a means of augmenting service delivery and providing real-time assessment and intervention for patients at risk. MACS is a promising adjunctive intervention that warrants further testing in a randomized controlled trial.",2020,"This study demonstrates the feasibility and acceptability of MACS, a new app-based intervention targeting transitions of care for patients with psychosis.","['patients with schizophrenia-spectrum disorders', 'Ten adults with schizophrenia-spectrum disorders were recruited during their index psychiatric hospitalization and enrolled prior to discharge', 'patients with psychosis', 'Adults with Schizophrenia-Spectrum Disorders']","['MACS', 'Care Intervention', 'care intervention (Mobile After-Care Support; MACS']","['dysfunctional coping strategies', 'psychiatric symptoms', 'feasibility, acceptability, and MACS targets', 'MACS usability and satisfaction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}]","[{'cui': 'C0009545', 'cui_str': 'Active C5b6789'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0001758', 'cui_str': 'Aftercare'}, {'cui': 'C0183683', 'cui_str': 'Support'}]","[{'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0233401', 'cui_str': 'Psychiatric symptom'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0009545', 'cui_str': 'Active C5b6789'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",10.0,0.0587841,"This study demonstrates the feasibility and acceptability of MACS, a new app-based intervention targeting transitions of care for patients with psychosis.","[{'ForeName': 'Ethan', 'Initials': 'E', 'LastName': 'Moitra', 'Affiliation': 'Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, 02912, USA. ethan_moitra@brown.edu.'}, {'ForeName': 'Hyun Seon', 'Initials': 'HS', 'LastName': 'Park', 'Affiliation': 'Psychosocial Research Program, Butler Hospital, Providence, RI, 02906, USA.'}, {'ForeName': 'Brandon A', 'Initials': 'BA', 'LastName': 'Gaudiano', 'Affiliation': 'Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, 02912, USA.'}]",The Psychiatric quarterly,['10.1007/s11126-020-09792-9'] 1576,32610254,"Antioxidant cocktail following a high-sodium meal does not affect vascular function in young, healthy adult humans: a randomized controlled crossover trial.","Chronic high sodium intake is a risk factor for cardiovascular disease as it impairs vascular function through an increase in oxidative stress. The objective of this study was to investigate the acute effects of a high-sodium meal (HSM) and antioxidant (AO) cocktail on vascular function. We hypothesized that a HSM would impair endothelial function, and increase arterial stiffness and wave reflection, while ingestion of the AO cocktail would mitigate this response. Healthy adults ingested either an AO cocktail (vitamin C, E, alpha-lipoic acid) or placebo (PLA) followed by a HSM (1500 mg) in a randomized crossover blinded design. Blood pressure (BP), endothelial function (flow-mediated dilation; FMD) and measures of arterial stiffness (pulse wave velocity; PWV) and wave reflection (augmentation index; AIx) were made at baseline and 30, 60, 90, and 120 min after meal consumption. Forty-one participants (20M/21W; 24 ± 1 years; BMI 23.4 ± 0.4 kg/m 2 ) completed the study. Mean BP increased at 120 min relative to 60 min (60 min: 79 ± 1; 120 min: 81 ± 1 mmHg; time effect P = .01) but was not different between treatments (treatment × time interaction P = .32). AIx decreased from baseline (time effect P < .001) but was not different between treatments (treatment × time interaction P = .31). PWV (treatment × time interaction, P = .91) and FMD (treatment × time interaction P = .65) were also not different between treatments. In conclusion, a HSM does not acutely impair vascular function suggesting young healthy adults can withstand the acute impact of sodium on the vasculature and therefore, the AO cocktail is not necessary to mitigate the response.",2020,AIx decreased from baseline (time effect P < .001) but was not different between treatments (treatment × time interaction P = .31).,"['young healthy adults', 'young, healthy adult humans', 'Healthy adults ingested either an', 'Forty-one participants (20M/21W; 24 ± 1 years; BMI 23.4 ± 0.4 kg/m 2 ) completed the study']","['Antioxidant cocktail following a high-sodium meal', 'HSM', 'AO cocktail (vitamin C, E, alpha-lipoic acid) or placebo (PLA) followed by a HSM', 'high-sodium meal (HSM) and antioxidant (AO) cocktail']","['endothelial function', 'Mean BP', 'FMD', 'Blood pressure (BP), endothelial function (flow-mediated dilation; FMD) and measures of arterial stiffness (pulse wave velocity; PWV) and wave reflection (augmentation index; AIx', 'vascular function', 'PWV']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517655', 'cui_str': '23.4'}, {'cui': 'C4517457', 'cui_str': '0.4'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0678420', 'cui_str': 'Cocktail'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0595879', 'cui_str': 'Sodium high'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0023791', 'cui_str': 'thioctic acid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0016052', 'cui_str': 'Fibromuscular dysplasia'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0999177', 'cui_str': 'Aix'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}]",,0.120549,AIx decreased from baseline (time effect P < .001) but was not different between treatments (treatment × time interaction P = .31).,"[{'ForeName': 'Katarina', 'Initials': 'K', 'LastName': 'Smiljanec', 'Affiliation': 'Department of Kinesiology and Applied Physiology, University of Delaware, Newark, DE. Electronic address: ksmilja@udel.edu.'}, {'ForeName': 'Alexis U', 'Initials': 'AU', 'LastName': 'Mbakwe', 'Affiliation': 'Department of Kinesiology and Applied Physiology, University of Delaware, Newark, DE. Electronic address: ambakwe@udel.edu.'}, {'ForeName': 'Macarena', 'Initials': 'M', 'LastName': 'Ramos-Gonzalez', 'Affiliation': 'Department of Kinesiology and Applied Physiology, University of Delaware, Newark, DE. Electronic address: macramos@udel.edu.'}, {'ForeName': 'Ryan T', 'Initials': 'RT', 'LastName': 'Pohlig', 'Affiliation': 'Biostatistics Core Facility, University of Delaware, STAR, Newark, DE. Electronic address: rpohlig@udel.edu.'}, {'ForeName': 'Shannon L', 'Initials': 'SL', 'LastName': 'Lennon', 'Affiliation': 'Department of Kinesiology and Applied Physiology, University of Delaware, Newark, DE. Electronic address: slennon@udel.edu.'}]","Nutrition research (New York, N.Y.)",['10.1016/j.nutres.2020.05.011'] 1577,32610257,Oral vitamin C treatment increases polymorphonuclear cell functions in type 2 diabetes mellitus patients with poor glycemic control.,"This study investigated the effect of vitamin C on polymorphonuclear (PMN) cell functions in type 2 diabetes mellitus patients with poor glycemic control. We hypothesized that oral vitamin C treatment improves PMN cell functions. Patients (14) received either a vitamin C (1000 mg/d) or placebo (anhydrous calcium hydrogen phosphate) tablet for 6 weeks and were subjected to a 6-week washout period followed by a 6-week treatment crossover period. Blood samples were collected at pretreatment and posttreatment for PMN cell functions (by flow cytometry) and plasma vitamin C concentration. Phagocytosis was examined by incubating whole blood samples with fluorescein isothiocyanate-labeled Staphylococcus aureus, and oxidative burst was simultaneously evaluated by adding hydroethidine. In comparison with placebo, vitamin C increased both PMN cell phagocytosis (pretreatment: placebo, 17.8% ± 1.6% and vitamin C, 19.0% ± 3.4%, P = .70; posttreatment: placebo, 16.6% ± 1.7% and vitamin C, 27.1% ± 2.9%, P = .005) and oxidative burst (pretreatment: placebo, 6.4% ± 0.8% and vitamin C, 7.1% ± 1.2%, P = .60; posttreatment: placebo, 6.9% ± 1.3% and vitamin C, 12.1% ± 1.6%, P = .02). The plasma vitamin C concentration was elevated after vitamin C treatment as compared with that before treatment (P < .001) and was higher than that observed in the placebo treatment group (P < .01). Plasma vitamin C concentration and PMN cell functions were not significantly different before both treatments. We conclude that the 6-week 1000-mg/d vitamin C increased PMN phagocytosis and oxidative burst in type 2 diabetes mellitus patients with poor glycemic control.",2020,The plasma vitamin C concentration was elevated after vitamin C treatment as compared with that before treatment (P < .001) and was higher than that observed in the placebo treatment group (P < .01).,['type 2 diabetes mellitus patients with poor glycemic control'],"['Oral vitamin C treatment', 'placebo, vitamin C', 'oral vitamin C', 'vitamin C', 'placebo (anhydrous calcium hydrogen phosphate) tablet', 'placebo']","['PMN cell functions', 'polymorphonuclear (PMN) cell functions', 'Plasma vitamin C concentration and PMN cell functions', 'Blood samples', 'PMN cell phagocytosis', 'oxidative burst', 'plasma vitamin C concentration', 'polymorphonuclear cell functions', 'PMN phagocytosis and oxidative burst']","[{'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0342299', 'cui_str': 'Poor glycemic control'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0108134', 'cui_str': 'Calcium phosphate dibasic'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}]","[{'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0031308', 'cui_str': 'Phagocytosis'}, {'cui': 'C0085416', 'cui_str': 'Oxidative Burst'}]",,0.155192,The plasma vitamin C concentration was elevated after vitamin C treatment as compared with that before treatment (P < .001) and was higher than that observed in the placebo treatment group (P < .01).,"[{'ForeName': 'Nisa', 'Initials': 'N', 'LastName': 'Chuangchot', 'Affiliation': 'Biomedical Sciences Program, Graduate School, Khon Kaen University, Khon Kaen 40002, Thailand; The Centre for Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand; Exercise and Sport Sciences Development and Research Group, Khon Kaen University, Khon Kaen 40002, Thailand. Electronic address: nisachuang@kku.ac.th.'}, {'ForeName': 'Chongchira', 'Initials': 'C', 'LastName': 'Boonthongkaew', 'Affiliation': 'Biomedical Sciences Program, Graduate School, Khon Kaen University, Khon Kaen 40002, Thailand; Exercise and Sport Sciences Development and Research Group, Khon Kaen University, Khon Kaen 40002, Thailand. Electronic address: chongchira@kkumail.com.'}, {'ForeName': 'Wisitsak', 'Initials': 'W', 'LastName': 'Phoksawat', 'Affiliation': 'The Centre for Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand; Graduate School, Khon Kaen University, Khon Kaen 40002, Thailand. Electronic address: wisitsakphok@kkumail.com.'}, {'ForeName': 'Amonrat', 'Initials': 'A', 'LastName': 'Jumnainsong', 'Affiliation': 'The Centre for Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand; Department of Clinical Immunology and Transfusion Sciences, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand. Electronic address: amonrat@kku.ac.th.'}, {'ForeName': 'Chanvit', 'Initials': 'C', 'LastName': 'Leelayuwat', 'Affiliation': 'The Centre for Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand; Department of Clinical Immunology and Transfusion Sciences, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand. Electronic address: chanvit@kku.ac.th.'}, {'ForeName': 'Naruemon', 'Initials': 'N', 'LastName': 'Leelayuwat', 'Affiliation': 'Exercise and Sport Sciences Development and Research Group, Khon Kaen University, Khon Kaen 40002, Thailand; Department of Physiology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand. Electronic address: naruemon@kku.ac.th.'}]","Nutrition research (New York, N.Y.)",['10.1016/j.nutres.2020.05.010'] 1578,31427720,The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.,,2020,,['patients with relapsed chronic lymphocytic leukemia treated with'],"['idelalisib plus rituximab', 'complex karyotype']",['overall survival'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0023434', 'cui_str': 'Chronic lymphocytic leukemia'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C2698692', 'cui_str': 'idelalisib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0022526', 'cui_str': 'Karyotype determination'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.0533494,,"[{'ForeName': 'Karl-Anton', 'Initials': 'KA', 'LastName': 'Kreuzer', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany. karl-anton.kreuzer@uni-koeln.de.'}, {'ForeName': 'Richard R', 'Initials': 'RR', 'LastName': 'Furman', 'Affiliation': 'Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Stilgenbauer', 'Affiliation': 'Department III of Internal Medicine, Ulm University Medical Center, Ulm, Germany.'}, {'ForeName': 'Ronald L', 'Initials': 'RL', 'LastName': 'Dubowy', 'Affiliation': 'Gilead Sciences, Inc., Foster City, CA, USA.'}, {'ForeName': 'Yeonhee', 'Initials': 'Y', 'LastName': 'Kim', 'Affiliation': 'Gilead Sciences, Inc., Foster City, CA, USA.'}, {'ForeName': 'Veerendra', 'Initials': 'V', 'LastName': 'Munugalavadla', 'Affiliation': 'Gilead Sciences, Inc., Foster City, CA, USA.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Lilienweiss', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Hans Christian', 'Initials': 'HC', 'LastName': 'Reinhardt', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Cramer', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Eichhorst', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hillmen', 'Affiliation': ""St. James's University Hospital, Leeds, UK.""}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': ""O'Brien"", 'Affiliation': 'University of California-Irvine, Irvine Chao Family Comprehensive Cancer Center, Orange, CA, USA.'}, {'ForeName': 'Andrew R', 'Initials': 'AR', 'LastName': 'Pettitt', 'Affiliation': 'University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hallek', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany.'}]",Leukemia,['10.1038/s41375-019-0533-6'] 1579,32615110,"Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.","BACKGROUND The ICON8 study reported no significant improvement in progression-free survival (a primary endpoint) with weekly chemotherapy compared with standard 3-weekly treatment among patients with epithelial ovarian cancer. All ICON8 patients were eligible to take part in the accompanying health-related quality-of-life study, which measured the effect of treatment on self-reported wellbeing, reported here. METHODS In this open-label, randomised, controlled, phase 3, three-arm, Gynecologic Cancer Intergroup (GCIG) trial done at 117 hospital sites in the UK, Australia, New Zealand, Mexico, South Korea, and Republic of Ireland, women (aged at least 18 years) with newly diagnosed, histologically confirmed International Federation of Gynecology and Obstetrics stage IC-IV ovarian cancer and an Eastern Cooperative Oncology Group performance status of 0-2 were randomly assigned (1:1:1) centrally using minimisation to group 1 (intravenous carboplatin area under the curve [AUC]5 or AUC6 and 175 mg/m 2 intravenous paclitaxel every 3 weeks), group 2 (carboplatin AUC5 or AUC6 every 3 weeks and 80 mg/m 2 paclitaxel weekly), or group 3 (carboplatin AUC2 weekly and 80 mg/m 2 paclitaxel weekly). Randomisation was stratified by GCIG group, disease stage, and outcome and timing of surgery. Patients and clinicians were not masked to treatment assignment. Patients underwent immediate or delayed primary surgery according to clinicians' choice. Patients were asked to complete European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-OV28 questionnaires at enrolment, before each chemotherapy cycle, then 6-weekly up to 9 months, 3-monthly up to 2 years, and 6-monthly up to 5 years. Quality of life was a prespecified secondary outcome of the ICON8 study. Within the quality-of-life study, the co-primary endpoints were QLQ-C30 global health score at 9 months (cross-sectional analysis) and mean QLQ-C30 global health score from randomisation to 9 months (longitudinal analysis). Data analyses were done on an intention-to-treat basis. The trial is registered on ClinicalTrials.gov, NCT01654146 and ISRCTN Registry, ISRCTN10356387, and is currently in long-term follow up. FINDINGS Between June 6, 2011, and Nov 28, 2014, 1566 patients were recruited into ICON8 (522 were included in group 1, 523 in group 2, and 521 in group 3). Baseline quality-of-life questionnaires were completed by 1438 (92%) of 1566 patients and 9-month questionnaires by 882 (69%) of 1280 patients. We observed no significant difference in global health score at 9 months (cross-sectional analysis) between study groups (group 2 vs group 1, difference in mean score 2·3, 95% CI -0·4 to 4·9, p=0·095; group 3 vs group 1, -0·8, -3·8 to 2·2, p=0·61). Using longitudinal analysis, we found lower global health scores for those receiving weekly paclitaxel than for those receiving 3-weekly chemotherapy (group 2 vs group 1, mean difference -1·8, 95% CI -3·6 to -0·1, p=0·043; group 3 vs group 1, -2·9, -4·7 to -1·1, p=0·0018). INTERPRETATION We found no evidence of a difference in global quality of life between treatment groups at 9 months; however, patients receiving weekly treatment reported lower mean quality of life across the 9-month period after randomisation. Taken together with the lack of progression-free survival benefit, these findings do not support routine use of weekly paclitaxel-containing regimens in the management of newly diagnosed ovarian cancer. FUNDING Cancer Research UK, Medical Research Council, Health Research Board Ireland, Irish Cancer Society, and Cancer Australia.",2020,"Using longitudinal analysis, we found lower global health scores for those receiving weekly paclitaxel than for those receiving 3-weekly chemotherapy (group 2 vs group 1, mean difference -1·8, 95% CI -3·6 to -0·1, p=0·043; group 3 vs group 1, -2·9, -4·7 to -1·1, p=0·0018). ","['1566 patients and 9-month questionnaires by 882 (69%) of 1280 patients', 'newly diagnosed ovarian cancer (ICON8', 'newly diagnosed ovarian cancer', ""Patients underwent immediate or delayed primary surgery according to clinicians' choice"", 'patients with epithelial ovarian cancer', '117 hospital sites in the UK, Australia, New Zealand, Mexico, South Korea, and Republic of Ireland, women (aged at least 18 years) with newly diagnosed, histologically confirmed International Federation of Gynecology and Obstetrics stage IC-IV ovarian cancer and an Eastern Cooperative Oncology Group performance status of 0-2', 'Between June 6, 2011, and Nov 28, 2014, 1566 patients were recruited into ICON8 (522 were included in group 1, 523 in group 2, and 521 in group 3']","['Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy', 'paclitaxel', 'minimisation to group 1 (intravenous carboplatin area under the curve [AUC]5 or AUC6 and 175 mg/m 2 intravenous paclitaxel every 3 weeks), group 2 (carboplatin AUC5 or AUC6 every 3 weeks and 80 mg/m 2 paclitaxel weekly), or group 3 (carboplatin AUC2 weekly and 80 mg/m 2 paclitaxel', 'paclitaxel-containing regimens', 'chemotherapy']","['global quality of life', 'global health scores', 'mean QLQ-C30 global health score', 'progression-free survival', 'Baseline quality-of-life questionnaires', 'mean quality of life', 'global health score', 'Quality of life', 'Cancer QLQ-C30 and QLQ-OV28 questionnaires', 'QLQ-C30 global health score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0919267', 'cui_str': 'Neoplasm of ovary'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C4721610', 'cui_str': 'Epithelial Ovarian Carcinoma'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0025885', 'cui_str': 'Mexico'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0022067', 'cui_str': 'Republic of Ireland'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0450454', 'cui_str': 'FIGO Stage'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C4517804', 'cui_str': '522'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}]","[{'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C3536920', 'cui_str': 'Platinum compounds'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C0585333', 'cui_str': 'Triweekly'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]",1566.0,0.232117,"Using longitudinal analysis, we found lower global health scores for those receiving weekly paclitaxel than for those receiving 3-weekly chemotherapy (group 2 vs group 1, mean difference -1·8, 95% CI -3·6 to -0·1, p=0·043; group 3 vs group 1, -2·9, -4·7 to -1·1, p=0·0018). ","[{'ForeName': 'Sarah P', 'Initials': 'SP', 'LastName': 'Blagden', 'Affiliation': 'Department of Oncology, University of Oxford, Oxford, UK. Electronic address: sarah.blagden@oncology.ox.ac.uk.'}, {'ForeName': 'Adrian D', 'Initials': 'AD', 'LastName': 'Cook', 'Affiliation': 'Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Poole', 'Affiliation': 'Department of Oncology, University Hospital Coventry, Coventry, UK.'}, {'ForeName': 'Lesley', 'Initials': 'L', 'LastName': 'Howells', 'Affiliation': 'Maggie Keswick Jencks Cancer Caring Centres Trust, London, UK.'}, {'ForeName': 'Ian A', 'Initials': 'IA', 'LastName': 'McNeish', 'Affiliation': 'Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Dean', 'Affiliation': 'Oncology Department, St John of God Subiaco Hospital, Perth, WA, Australia.'}, {'ForeName': 'Jae-Weon', 'Initials': 'JW', 'LastName': 'Kim', 'Affiliation': 'Department of Obstetrics and Gynaecology, Seoul National University Hospital, Seoul, South Korea.'}, {'ForeName': 'Dearbhaile M', 'Initials': 'DM', 'LastName': ""O'Donnell"", 'Affiliation': 'Gynaecology Subgroup, Cancer Trials Ireland, Dublin, Ireland.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Hook', 'Affiliation': ""St James's University Hospital, Leeds, UK.""}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'James', 'Affiliation': 'Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.'}, {'ForeName': 'Ian R', 'Initials': 'IR', 'LastName': 'White', 'Affiliation': 'Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Perren', 'Affiliation': ""St James's University Hospital, Leeds, UK.""}, {'ForeName': 'Rosemary', 'Initials': 'R', 'LastName': 'Lord', 'Affiliation': 'Department of Oncology, Clatterbridge Cancer Centre, Birkenhead, UK.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Dark', 'Affiliation': 'Department of Oncology, Newcastle University, Newcastle, UK.'}, {'ForeName': 'Helena M', 'Initials': 'HM', 'LastName': 'Earl', 'Affiliation': 'NIHR Cambridge Biomedical Research Centre, Cambridge, UK.'}, {'ForeName': 'Marcia', 'Initials': 'M', 'LastName': 'Hall', 'Affiliation': 'Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Kaplan', 'Affiliation': 'Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.'}, {'ForeName': 'Jonathan A', 'Initials': 'JA', 'LastName': 'Ledermann', 'Affiliation': 'UCL Cancer Centre Institute, University College London, London, UK; University College Hospital, London, UK.'}, {'ForeName': 'Andrew R', 'Initials': 'AR', 'LastName': 'Clamp', 'Affiliation': 'Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; University of Manchester, Manchester, UK.'}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30218-7'] 1580,32615473,Acceptance and commitment therapy combined with vestibular rehabilitation for persistent postural-perceptual dizziness: A pilot study.,"PURPOSE This study investigated the feasibility of acceptance and commitment therapy for persistent postural-perceptual dizziness and preliminarily verified the long-term effectiveness of the therapy. MATERIALS AND METHODS This study implemented the within-group pre-post comparison design. We enrolled 27 adult patients who met the criteria of persistent postural-perceptual dizziness. They underwent a treatment program including acceptance and commitment therapy combined with vestibular rehabilitation once a week for a total of six sessions. The primary outcome was changes in the Dizziness Handicap Inventory score 6 months posttreatment. RESULTS All 27 patients completed the acceptance and commitment therapy + vestibular rehabilitation program, and 25 patients (92.6%) could be followed for 6 months posttreatment. For 27 participants, the scores from pretreatment to 6 months posttreatment significantly declined (P < .001), and the Dizziness Handicap Inventory effect size was 1.11 (95% confidence interval = 0.80-1.42). At 6 months posttreatment, 11 patients (40.7%) achieved remission (the score ≤ 14), 16 (59.3%) achieved treatment response (reduction in the score ≥ 18), and 20 (74.1%) achieved remission and/or treatment response. CONCLUSIONS Acceptance and commitment therapy is feasible for persistent postural-perceptual dizziness and might have long-term effectiveness. However, a randomized controlled trial is warranted.",2020,"For 27 participants, the scores from pretreatment to 6 months posttreatment significantly declined (P < .001), and the Dizziness Handicap Inventory effect size was 1.11 (95% confidence interval = 0.80-1.42).","['persistent postural-perceptual dizziness', '27 adult patients who met the criteria of persistent postural-perceptual dizziness']","['Acceptance and commitment therapy combined with vestibular rehabilitation', 'acceptance and commitment therapy', 'acceptance and commitment therapy combined with vestibular rehabilitation']","['Dizziness Handicap Inventory effect size', 'remission', 'Dizziness Handicap Inventory score 6\xa0months posttreatment', 'remission and/or treatment response']","[{'cui': 'C0522360', 'cui_str': 'Persistent postural perceptual dizziness'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0200324', 'cui_str': 'Vestibular rehabilitation'}]","[{'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0231172', 'cui_str': 'Handicap'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C4304791', 'cui_str': 'Dizziness Handicap Inventory score'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",27.0,0.176719,"For 27 participants, the scores from pretreatment to 6 months posttreatment significantly declined (P < .001), and the Dizziness Handicap Inventory effect size was 1.11 (95% confidence interval = 0.80-1.42).","[{'ForeName': 'Junya', 'Initials': 'J', 'LastName': 'Kuwabara', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: jurry7777@hotmail.co.jp.'}, {'ForeName': 'Masaki', 'Initials': 'M', 'LastName': 'Kondo', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: kondo-masaki@umin.ac.jp.'}, {'ForeName': 'Kayoko', 'Initials': 'K', 'LastName': 'Kabaya', 'Affiliation': 'Department of Otolaryngology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: kabaya@med.nagoya-cu.ac.jp.'}, {'ForeName': 'Wakako', 'Initials': 'W', 'LastName': 'Watanabe', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan; Kikuchi Mental Clinic, Ushikubo-cho, Toyokawa 442-0826, Japan. Electronic address: wakakoigarashi@gmail.com.'}, {'ForeName': 'Nao', 'Initials': 'N', 'LastName': 'Shiraishi', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: fecitanno@gmail.com.'}, {'ForeName': 'Mie', 'Initials': 'M', 'LastName': 'Sakai', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: mie.sakai.38@gmail.com.'}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Toshishige', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: yuu0323uchi@yahoo.co.jp.'}, {'ForeName': 'Keiko', 'Initials': 'K', 'LastName': 'Ino', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: miniture_flute@hotmail.com.'}, {'ForeName': 'Meiho', 'Initials': 'M', 'LastName': 'Nakayama', 'Affiliation': 'Department of Otolaryngology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan; Good Sleep Center, Nagoya City University Hospital, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: nakayama@med.nagoya-cu.ac.jp.'}, {'ForeName': 'Shinichi', 'Initials': 'S', 'LastName': 'Iwasaki', 'Affiliation': 'Department of Otolaryngology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: iwashin-tky@umin.ac.jp.'}, {'ForeName': 'Tatsuo', 'Initials': 'T', 'LastName': 'Akechi', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: takechi@med.nagoya-cu.ac.jp.'}]",American journal of otolaryngology,['10.1016/j.amjoto.2020.102609'] 1581,32615488,Effects of the juçara fruit supplementation on metabolic parameters in individuals with obesity: a double-blind randomized controlled trial.,"Adipose tissue inflammation has been proposed as a central mechanism connecting obesity with its metabolic and vascular complications due to the imbalance in the expression of several hormones and adipokines. Berries rich in polyphenols and unsaturated fatty acids have been able to prevent both obesity and adipose tissue inflammation, improving metabolic functions in human subjects and animal models of obesity. Juçara has been considered a super fruit owing to its nutritional composition and relevant biological activities with an interesting response in animals. Thus, we aimed to verify the potential antiobesogenic effect of juçara supplementation in humans. We conducted a double-blind, placebo-controlled, randomized trial with 35 adults with obesity of both sexes. They were assessed for resting metabolic rate, anthropometry and body composition, blood pressure, metabolic parameters and adipokines. Subsequently, they were randomized into two groups to use or not (placebo) 5 g lyophilized juçara for 6 weeks. Supplementation with juçara was significantly effective in reducing body fat, increasing high-density lipoprotein cholesterol and doubling serum adiponectin. Besides, juçara supplementation, high-density lipoprotein cholesterol and neck circumference were predictors to explain the enhancement in adiponectin. Juçara supplementation was determinant to improve adiponectin levels, and it may be considered a novel strategy for the treatment of obesity-related metabolic diseases.",2020,"Supplementation with juçara was significantly effective in reducing body fat, increasing high-density lipoprotein cholesterol and doubling serum adiponectin.","['35 adults with obesity of both sexes', 'individuals with obesity', 'humans']","['juçara fruit supplementation', 'juçara supplementation', 'not (placebo', 'placebo']","['body fat, increasing high-density lipoprotein cholesterol and doubling serum adiponectin', 'resting metabolic rate, anthropometry and body composition, blood pressure, metabolic parameters and adipokines', 'juçara supplementation, high-density lipoprotein cholesterol and neck circumference', 'metabolic parameters', 'adiponectin levels']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C4082350', 'cui_str': 'Resting Metabolic Rate'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1955907', 'cui_str': 'Adipokine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C1630403', 'cui_str': 'Neck circumference'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",35.0,0.113597,"Supplementation with juçara was significantly effective in reducing body fat, increasing high-density lipoprotein cholesterol and doubling serum adiponectin.","[{'ForeName': 'Giovana', 'Initials': 'G', 'LastName': 'Jamar', 'Affiliation': 'Programa de Pós-Graduação Interdisciplinar em Ciências da Saúde, Universidade Federal de São Paulo, Santos, SP, Brazil; Laboratório de Nutrição e Fisiologia Endócrina (LaNFE), Universidade Federal de São Paulo, Santos, SP, Brazil.'}, {'ForeName': 'Aline Boveto', 'Initials': 'AB', 'LastName': 'Santamarina', 'Affiliation': 'Programa de Pós-Graduação Interdisciplinar em Ciências da Saúde, Universidade Federal de São Paulo, Santos, SP, Brazil; Laboratório de Nutrição e Fisiologia Endócrina (LaNFE), Universidade Federal de São Paulo, Santos, SP, Brazil.'}, {'ForeName': 'Ana Carolina', 'Initials': 'AC', 'LastName': 'Flygare', 'Affiliation': 'Programa de Pós-Graduação Interdisciplinar em Ciências da Saúde, Universidade Federal de São Paulo, Santos, SP, Brazil.'}, {'ForeName': 'Antônio', 'Initials': 'A', 'LastName': 'Gagliardi', 'Affiliation': 'Departamento de Medicina Cardiovascular, Angiocorpore Instituto de Medicina Cardiovascular, Santos, SP, Brazil.'}, {'ForeName': 'Veridiana Vera', 'Initials': 'VV', 'LastName': 'de Rosso', 'Affiliation': 'Departamento de Biociências, Instituto de Saúde e Sociedade, Universidade Federal de São Paulo, Santos, SP, Brazil.'}, {'ForeName': 'Victor Zuniga', 'Initials': 'VZ', 'LastName': 'Dourado', 'Affiliation': 'Departamento de Ciências do Movimento Humano, Universidade Federal de São Paulo, Santos, SP, Brazil.'}, {'ForeName': 'Luciana Pellegrini', 'Initials': 'LP', 'LastName': 'Pisani', 'Affiliation': 'Laboratório de Nutrição e Fisiologia Endócrina (LaNFE), Universidade Federal de São Paulo, Santos, SP, Brazil; Departamento de Biociências, Instituto de Saúde e Sociedade, Universidade Federal de São Paulo, Santos, SP, Brazil. Electronic address: lucianapisani@gmail.com.'}]",The Journal of nutritional biochemistry,['10.1016/j.jnutbio.2020.108430'] 1582,32618249,"Cost-Effectiveness of Focal Mass Drug Administration and Mass Drug Administration with Dihydroartemisinin-Piperaquine for Malaria Prevention in Southern Province, Zambia: Results of a Community-Randomized Controlled Trial.","Community-wide administration of antimalarial drugs in therapeutic doses is a potential tool to prevent malaria infection and reduce the malaria parasite reservoir. To measure the effectiveness and cost of using the antimalarial drug combination dihydroartemisinin-piperaquine (DHAp) through different community-wide distribution strategies, Zambia's National Malaria Control Centre conducted a three-armed community-randomized controlled trial. The trial arms were as follows: 1) standard of care (SoC) malaria interventions, 2) SoC plus focal mass drug administration (fMDA), and 3) SoC plus MDA. Mass drug administration consisted of offering all eligible individuals DHAP, irrespective of a rapid diagnostic test (RDT) result. Focal mass drug administration consisted of offering DHAP to all eligible individuals who resided in a household where anyone tested positive by RDT. Results indicate that the costs of fMDA and MDA per person targeted and reached are similar (US$9.01 versus US$8.49 per person, respectively, P = 0.87), but that MDA was superior in all cost-effectiveness measures, including cost per infection averted, cost per case averted, cost per death averted, and cost per disability-adjusted life year averted. Subsequent costing of the MDA intervention in a non-trial, operational setting yielded significantly lower costs per person reached (US$2.90). Mass drug administration with DHAp also met the WHO thresholds for ""cost-effective interventions"" in the Zambian setting in 90% of simulations conducted using a probabilistic sensitivity analysis based on trial costs, whereas fMDA met these criteria in approximately 50% of simulations. A sensitivity analysis using costs from operational deployment and trial effectiveness yielded improved cost-effectiveness estimates. Mass drug administration may be a cost-effective intervention in the Zambian context and can help reduce the parasite reservoir substantially. Mass drug administration was more cost-effective in relatively higher transmission settings. In all scenarios examined, the cost-effectiveness of MDA was superior to that of fMDA.",2020,"Mass drug administration with DHAp also met the WHO thresholds for ""cost-effective interventions"" in the Zambian setting in 90% of simulations conducted using a probabilistic sensitivity analysis based on trial costs, whereas fMDA met these criteria in approximately 50% of simulations.","['Southern Province, Zambia', 'eligible individuals who resided in a household where anyone tested positive by RDT']","['SoC plus focal mass drug administration (fMDA), and 3) SoC plus MDA', 'MDA intervention', 'Focal Mass Drug Administration and Mass Drug Administration with Dihydroartemisinin-Piperaquine', 'antimalarial drug combination dihydroartemisinin-piperaquine (DHAp']","['costs of fMDA and MDA', 'cost-effectiveness of MDA', 'cost-effectiveness estimates', 'cost per infection averted, cost per case averted, cost per death averted, and cost per disability-adjusted life year averted']","[{'cui': 'C0043445', 'cui_str': 'Zambia'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0206743', 'cui_str': 'Malignant rhabdoid tumor'}]","[{'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C4505223', 'cui_str': 'Mass Administration'}, {'cui': 'C0000379', 'cui_str': 'Methylenedioxyamphetamine'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0058108', 'cui_str': 'dihydroartemisinin'}, {'cui': 'C0071105', 'cui_str': 'piperaquine'}, {'cui': 'C0003374', 'cui_str': 'Antimalarial'}, {'cui': 'C0012324', 'cui_str': 'Dihydroxyacetone 3-Phosphate'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0016052', 'cui_str': 'Fibromuscular dysplasia'}, {'cui': 'C0000379', 'cui_str': 'Methylenedioxyamphetamine'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0439234', 'cui_str': 'year'}]",,0.139118,"Mass drug administration with DHAp also met the WHO thresholds for ""cost-effective interventions"" in the Zambian setting in 90% of simulations conducted using a probabilistic sensitivity analysis based on trial costs, whereas fMDA met these criteria in approximately 50% of simulations.","[{'ForeName': 'Joshua O', 'Initials': 'JO', 'LastName': 'Yukich', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Callie', 'Initials': 'C', 'LastName': 'Scott', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Seattle, Washington.'}, {'ForeName': 'Kafula', 'Initials': 'K', 'LastName': 'Silumbe', 'Affiliation': 'PATH MACEPA, Lusaka, Zambia.'}, {'ForeName': 'Bruce A', 'Initials': 'BA', 'LastName': 'Larson', 'Affiliation': 'Department of Global Health, Boston University School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Bennett', 'Affiliation': 'Malaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Timothy P', 'Initials': 'TP', 'LastName': 'Finn', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Busiku', 'Initials': 'B', 'LastName': 'Hamainza', 'Affiliation': 'National Malaria Control Centre, Zambia Ministry of Health, Lusaka, Zambia.'}, {'ForeName': 'Ruben O', 'Initials': 'RO', 'LastName': 'Conner', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Seattle, Washington.'}, {'ForeName': 'Travis R', 'Initials': 'TR', 'LastName': 'Porter', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Keating', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Richard W', 'Initials': 'RW', 'LastName': 'Steketee', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Seattle, Washington.'}, {'ForeName': 'Thomas P', 'Initials': 'TP', 'LastName': 'Eisele', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Miller', 'Affiliation': 'PATH MACEPA, Lusaka, Zambia.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.19-0661'] 1583,32618251,"Treatment Coverage Estimation for Mass Drug Administration for Malaria with Dihydroartemisinin-Piperaquine in Southern Province, Zambia.","Mass drug administration (MDA) is currently being considered as an intervention in low-transmission areas to complement existing malaria control and elimination efforts. The effectiveness of any MDA strategy is dependent on achieving high epidemiologic coverage and participant adherence rates. A community-randomized controlled trial was conducted from November 2014 to March 2016 to evaluate the impact of four rounds of MDA or focal MDA (fMDA)-where treatment was given to all eligible household members if anyone in the household had a positive malaria rapid diagnostic test-on malaria outcomes in Southern Province, Zambia (population approximately 300,000). This study examined epidemiologic coverage and program reach using capture-recapture and satellite enumeration methods to estimate the degree to which the trial reached targeted individuals. Overall, it was found that the percentage of households visited by campaign teams ranged from 62.9% (95% CI: 60.0-65.8) to a high of 77.4% (95% CI: 73.8-81.0) across four rounds of treatment. When the maximum number of visited households across all campaign rounds was used as the numerator, program reach for at least one visit would have been 86.4% (95% CI: 80.8-92.0) in MDA and 83.5% (95% CI: 78.0-89.1) in fMDA trial arms. As per the protocol, the trial provided dihydroartemisinin-piperaquine treatment to an average of 58.8% and 13.3% of the estimated population based on capture-recapture in MDA and fMDA, respectively, across the four rounds.",2020,"Overall, it was found that the percentage of households visited by campaign teams ranged from 62.9% (95% CI: 60.0-65.8) to a high of 77.4% (95% CI: 73.8-81.0) across four rounds of treatment.","['Malaria with Dihydroartemisinin-Piperaquine in Southern Province, Zambia', 'eligible household members if anyone in the household had a positive malaria rapid diagnostic test-on malaria outcomes in Southern Province, Zambia (population approximately 300,000']",['MDA or focal MDA (fMDA)-where treatment'],[],"[{'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0058108', 'cui_str': 'dihydroartemisinin'}, {'cui': 'C0071105', 'cui_str': 'piperaquine'}, {'cui': 'C0043445', 'cui_str': 'Zambia'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0430022', 'cui_str': 'Diagnostic procedure'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}]","[{'cui': 'C4505223', 'cui_str': 'Mass Administration'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0000379', 'cui_str': 'Methylenedioxyamphetamine'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",[],,0.101887,"Overall, it was found that the percentage of households visited by campaign teams ranged from 62.9% (95% CI: 60.0-65.8) to a high of 77.4% (95% CI: 73.8-81.0) across four rounds of treatment.","[{'ForeName': 'Timothy P', 'Initials': 'TP', 'LastName': 'Finn', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Joshua O', 'Initials': 'JO', 'LastName': 'Yukich', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Bennett', 'Affiliation': 'Malaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Travis R', 'Initials': 'TR', 'LastName': 'Porter', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Lungu', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Busiku', 'Initials': 'B', 'LastName': 'Hamainza', 'Affiliation': 'National Malaria Elimination Centre, Zambia Ministry of Health, Chainama Hospital, Lusaka, Zambia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Chizema Kawesha', 'Affiliation': 'National Malaria Elimination Centre, Zambia Ministry of Health, Chainama Hospital, Lusaka, Zambia.'}, {'ForeName': 'Ruben O', 'Initials': 'RO', 'LastName': 'Conner', 'Affiliation': 'PATH MACEPA, Seattle, Washington.'}, {'ForeName': 'Kafula', 'Initials': 'K', 'LastName': 'Silumbe', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Richard W', 'Initials': 'RW', 'LastName': 'Steketee', 'Affiliation': 'PATH MACEPA, Seattle, Washington.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Miller', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Keating', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Thomas P', 'Initials': 'TP', 'LastName': 'Eisele', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.19-0665'] 1584,32618265,"Moving from Malaria Burden Reduction toward Elimination: An Evaluation of Mass Drug Administration in Southern Province, Zambia.","From December 2014 to February 2016, a cluster randomized controlled trial was carried out in 60 health facility catchment areas along Lake Kariba in Zambia's Southern Province. The trial sought to evaluate the impact of four rounds of a mass drug administration (MDA) intervention with dihydroartemisinin-piperaquine (DHAP) or focal MDA with DHAP at the household level compared with a control population that received the standard of care. This study was the first randomized controlled trial with DHAP for MDA in sub-Saharan Africa and was conducted through a collaboration between the National Malaria Elimination Programme in the Zambian Ministry of Health, the PATH Malaria Control and Elimination Partnership in Africa, and the Center for Applied Malaria Research and Evaluation at Tulane University. This article serves as an introduction to a collection of articles designed to explore different aspects of the intervention. By describing the recent history of malaria control in Zambia leading up to the trial-from the scale-up of point-of-care diagnosis and treatment, vector control, and indoor residual spraying early in the twenty-first century, to the efforts made to sustain the gains achieved with that approach-it provides a rationale for the implementation of a trial that has informed a new national strategic plan and solidified malaria elimination as Zambia's national goal.",2020,"By describing the recent history of malaria control in Zambia leading up to the trial-from the scale-up of point-of-care diagnosis and treatment, vector control, and indoor residual spraying early in the twenty-first century, to the efforts made to sustain the gains achieved with that approach-it provides a rationale for the implementation of a trial that has informed a new national strategic plan and solidified malaria elimination as Zambia's national goal.","['sub-Saharan Africa and was conducted through a collaboration between the National Malaria Elimination Programme in the Zambian Ministry of Health, the PATH Malaria Control and Elimination Partnership in Africa, and the Center for Applied Malaria Research and Evaluation at Tulane University', ""60 health facility catchment areas along Lake Kariba in Zambia's Southern Province"", 'Southern Province, Zambia']","['Elimination', 'DHAP', 'mass drug administration (MDA) intervention with dihydroartemisinin-piperaquine (DHAP) or focal MDA with DHAP']",[],"[{'cui': 'C0001738', 'cui_str': 'Sub-Saharan Africa'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001737', 'cui_str': 'Africa'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0007403', 'cui_str': 'Health Catchment Area'}, {'cui': 'C0337049', 'cui_str': 'Lake'}, {'cui': 'C0043445', 'cui_str': 'Zambia'}]","[{'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0058108', 'cui_str': 'dihydroartemisinin'}, {'cui': 'C0071105', 'cui_str': 'piperaquine'}, {'cui': 'C4505223', 'cui_str': 'Mass Administration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205234', 'cui_str': 'Focal'}]",[],,0.0505108,"By describing the recent history of malaria control in Zambia leading up to the trial-from the scale-up of point-of-care diagnosis and treatment, vector control, and indoor residual spraying early in the twenty-first century, to the efforts made to sustain the gains achieved with that approach-it provides a rationale for the implementation of a trial that has informed a new national strategic plan and solidified malaria elimination as Zambia's national goal.","[{'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Miller', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Thomas P', 'Initials': 'TP', 'LastName': 'Eisele', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Maya S', 'Initials': 'MS', 'LastName': 'Fraser', 'Affiliation': 'PATH MACEPA, Seattle, Washington.'}, {'ForeName': 'Manuel T', 'Initials': 'MT', 'LastName': 'Lewis', 'Affiliation': 'PATH MACEPA, Seattle, Washington.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Slutsker', 'Affiliation': 'PATH MACEPA, Seattle, Washington.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Chizema Kawesha', 'Affiliation': 'National Malaria Control Centre, Zambia Ministry of Health, Lusaka, Zambia.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.19-0669'] 1585,32618572,Use of a Mobile App to Augment Psychotherapy in a Community Psychiatric Clinic: Feasibility and Fidelity Trial.,"BACKGROUND Even though 1 in 5 Americans experience some form of mental illness each year, 80% have been shown to discontinue psychotherapy prematurely. The traditional psychotherapy service delivery model, consisting of isolated clinical sessions, lacks the ability to keep patients engaged outside clinical sessions. Newer digital mental health platforms can address the clinical need for a robust tool that tracks mental well-being and improves engagement in patients with depressive symptoms. OBJECTIVE The primary goals of this feasibility study were to (1) assess compliance among providers and their patients with a digital mental health platform protocol, and (2) examine the usability and fidelity of a mobile app through structured participant feedback. METHODS A sample of 30 participants was recruited for a 5-week study from a community-based mental health clinic in Baltimore, Maryland, USA. Inclusion criteria were: aged 18 years or older, having access to a smartphone, and having at least mild-to-moderate depression and/or anxiety as measured by the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) scales, respectively. Eligible participants were randomized into one of two study arms: (1) the intervention arm or (2) the waitlist control arm. Participants in the intervention arm were asked to download the Rose app and were prompted to complete clinical assessments (PHQ-9 and GAD-7) every other week, daily mood and anxiety Likert scales, and daily journal entries. The participants in the waitlist arm served as controls for the study and completed the clinical assessments only. Both arms engaged in weekly psychotherapy sessions, with participant in-app input informing the psychotherapy process of the intervention arm, while those in the waitlist control arm continued their standard care. Outcomes of interest included adherence to completion of in-app assessments and usability of the Rose mobile app assessed through the modified Mobile Application Rating Scale. RESULTS Over the study period, a sample of 30 participants used the Rose app 2834 times to complete clinical assessments. On average, 70% (21; 95% CI 61.14%-77.41%) of participants completed mood and anxiety daily check-ins and journal entries 5 days per week. Nearly all participants (29/30, 97%) completed all PHQ-9 and GAD-7 in-app scales during the study. Subjective impressions showed that 73% (22/30) of participants found the mobile app to be engaging and in line with their needs, and approximately 70% (21/30) of participants reported the app functionality and quality of information to be excellent. Additionally, more than two-thirds of the participants felt that their knowledge and awareness of depression and anxiety management improved through using the app. CONCLUSIONS Steady compliance and high app ratings showcase the utility of the Rose mobile mental health app in augmenting the psychotherapy process for patients with mood disorders and improving mental health knowledge. Future studies are needed to further examine the impact of Rose on treatment outcomes. TRIAL REGISTRATION ClinicalTrials.gov NCT04200170; https://clinicaltrials.gov/ct2/show/NCT04200170.",2020,"On average, 70% (21; 95% CI 61.14%-77.41%) of participants completed mood and anxiety daily check-ins and journal entries 5 days per week.","['patients with depressive symptoms', 'Eligible participants', 'Inclusion criteria were: aged 18 years or older, having access to a smartphone, and having at least mild-to-moderate depression and/or anxiety as measured by the', 'A sample of 30 participants was recruited for a 5-week study from a community-based mental health clinic in Baltimore, Maryland, USA', 'patients with mood disorders and improving mental health knowledge']",['Mobile App to Augment Psychotherapy'],"['knowledge and awareness of depression and anxiety management', 'PHQ-9 and GAD-7', 'Subjective impressions', 'Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) scales', 'modified Mobile Application Rating Scale']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C3839912', 'cui_str': 'Mental health clinic'}, {'cui': 'C0004716', 'cui_str': 'Baltimore'}, {'cui': 'C0024858', 'cui_str': 'Maryland'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0525045', 'cui_str': 'Mood disorder'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]","[{'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0033968', 'cui_str': 'Psychotherapy'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0871652', 'cui_str': 'Management of anxiety'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}]",30.0,0.108425,"On average, 70% (21; 95% CI 61.14%-77.41%) of participants completed mood and anxiety daily check-ins and journal entries 5 days per week.","[{'ForeName': 'Atif', 'Initials': 'A', 'LastName': 'Adam', 'Affiliation': 'Rose: Smarter Mental Health, Washington, DC, United States.'}, {'ForeName': 'Ameena', 'Initials': 'A', 'LastName': 'Jain', 'Affiliation': 'Key Point Health Services, Inc, Baltimore, MD, United States.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Pletnikova', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, United States.'}, {'ForeName': 'Rishi', 'Initials': 'R', 'LastName': 'Bagga', 'Affiliation': 'Rose: Smarter Mental Health, Washington, DC, United States.'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Vita', 'Affiliation': 'Rose: Smarter Mental Health, Washington, DC, United States.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'N Richey', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, United States.'}, {'ForeName': 'Neda', 'Initials': 'N', 'LastName': 'Gould', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, United States.'}, {'ForeName': 'Supriya', 'Initials': 'S', 'LastName': 'Munshaw', 'Affiliation': 'Carey Business School, Johns Hopkins University, Baltimore, MD, United States.'}, {'ForeName': 'Kavi', 'Initials': 'K', 'LastName': 'Misrilall', 'Affiliation': 'Rose: Smarter Mental Health, Washington, DC, United States.'}, {'ForeName': 'Matthew E', 'Initials': 'ME', 'LastName': 'Peters', 'Affiliation': 'Rose: Smarter Mental Health, Washington, DC, United States.'}]",JMIR formative research,['10.2196/17722'] 1586,32618578,Effects of a 12-Week Multifaceted Wearable-Based Program for People With Knee Osteoarthritis: Randomized Controlled Trial.,"BACKGROUND Current guidelines emphasize an active lifestyle in the management of knee osteoarthritis (OA), but up to 90% of patients with OA are inactive. In a previous study, we demonstrated that an 8-week physiotherapist (PT)-led counseling intervention, with the use of a Fitbit, improved step count and quality of life in patients with knee OA, compared with a control. OBJECTIVE This study aimed to examine the effect of a 12-week, multifaceted wearable-based program on physical activity and patient outcomes in patients with knee OA. METHODS This was a randomized controlled trial with a delay-control design. The immediate group (IG) received group education, a Fitbit, access to FitViz (a Fitbit-compatible app), and 4 biweekly phone calls from a PT over 8 weeks. Participants then continued using Fitbit and FitViz independently up to week 12. The delay group (DG) received a monthly electronic newsletter in weeks 1 to 12 and started the same intervention in week 14. Participants were assessed in weeks 13, 26, and 39. The primary outcome was time spent in daily moderate-to-vigorous physical activity (MVPA; in bouts ≥10 min) measured with a SenseWear Mini. Secondary outcomes included daily steps, time spent in purposeful activity and sedentary behavior, Knee Injury and OA Outcome Score, Patient Health Questionnaire-9, Partners in Health Scale, Theory of Planned Behavior Questionnaire, and Self-Reported Habit Index. RESULTS We enrolled 51 participants (IG: n=26 and DG: n=25). Compared with the IG, the DG accumulated significantly more MVPA time at baseline. The adjusted mean difference in MVPA was 13.1 min per day (95% CI 1.6 to 24.5). A significant effect was also found in the adjusted mean difference in perceived sitting habit at work (0.7; 95% CI 0.2 to 1.2) and during leisure activities (0.7; 95% CI 0.2 to 1.2). No significant effect was found in the remaining secondary outcomes. CONCLUSIONS A 12-week multifaceted program with the use of a wearable device, an app, and PT counseling improved physical activity in people with knee OA. TRIAL REGISTRATION ClinicalTrials.gov NCT02585323; https://clinicaltrials.gov/ct2/show/NCT02585323.",2020,The adjusted mean difference in MVPA was 13.1 min per day (95% CI 1.6 to 24.5).,"['enrolled 51 participants (IG: n=26 and DG: n=25', 'people with knee OA', 'patients with knee OA', 'People With Knee Osteoarthritis']","['12-Week Multifaceted Wearable-Based Program', 'PT counseling', 'physiotherapist (PT)-led counseling intervention', 'multifaceted wearable-based program']","['daily steps, time spent in purposeful activity and sedentary behavior, Knee Injury and OA Outcome Score, Patient Health Questionnaire-9, Partners in Health Scale, Theory of Planned Behavior Questionnaire, and Self-Reported Habit Index', 'perceived sitting habit', 'physical activity', 'MVPA', 'MVPA time', 'time spent in daily moderate-to-vigorous physical activity (MVPA; in bouts ≥10 min) measured with a SenseWear Mini']","[{'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C1532253', 'cui_str': 'Sedentary lifestyle'}, {'cui': 'C3476088', 'cui_str': 'Knee Injury and Osteoarthritis Outcome Score'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0018464', 'cui_str': 'Habits'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0445542', 'cui_str': 'Mini'}]",51.0,0.150513,The adjusted mean difference in MVPA was 13.1 min per day (95% CI 1.6 to 24.5).,"[{'ForeName': 'Linda C', 'Initials': 'LC', 'LastName': 'Li', 'Affiliation': 'Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Lynne M', 'Initials': 'LM', 'LastName': 'Feehan', 'Affiliation': 'Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Xie', 'Affiliation': 'Arthritis Research Canada, Richmond, BC, Canada.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Lu', 'Affiliation': 'Arthritis Research Canada, Richmond, BC, Canada.'}, {'ForeName': 'Christopher D', 'Initials': 'CD', 'LastName': 'Shaw', 'Affiliation': 'School of Interactive Art & Technology, Simon Fraser University, Burnaby, BC, Canada.'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Gromala', 'Affiliation': 'School of Interactive Art & Technology, Simon Fraser University, Burnaby, BC, Canada.'}, {'ForeName': 'Siyi', 'Initials': 'S', 'LastName': 'Zhu', 'Affiliation': 'Arthritis Research Canada, Richmond, BC, Canada.'}, {'ForeName': 'J Antonio', 'Initials': 'JA', 'LastName': 'Aviña-Zubieta', 'Affiliation': 'Arthritis Research Canada, Richmond, BC, Canada.'}, {'ForeName': 'Alison M', 'Initials': 'AM', 'LastName': 'Hoens', 'Affiliation': 'Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Koehn', 'Affiliation': 'Arthritis Consumer Experts, Vancouver, BC, Canada.'}, {'ForeName': 'Johnathan', 'Initials': 'J', 'LastName': 'Tam', 'Affiliation': 'Arthritis Research Canada, Richmond, BC, Canada.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Therrien', 'Affiliation': 'Arthritis Research Canada, Richmond, BC, Canada.'}, {'ForeName': 'Anne F', 'Initials': 'AF', 'LastName': 'Townsend', 'Affiliation': 'Division of Health Research, Faculty of Health & Medicine, Lancaster University, Lancashire, United Kingdom.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Noonan', 'Affiliation': 'Mary Pack Arthritis Program, Vancouver General Hospital, Vancouver, BC, Canada.'}, {'ForeName': 'Catherine L', 'Initials': 'CL', 'LastName': 'Backman', 'Affiliation': 'Arthritis Research Canada, Richmond, BC, Canada.'}]",JMIR mHealth and uHealth,['10.2196/19116'] 1587,32645640,The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.,"OBJECTIVE Ocrelizumab inhibits relapsing multiple sclerosis when administered every six months. Based on potential similar memory B cell depletion mechanisms with cladribine and alemtuzumab, we hypothesised that CD20-depletion of B cells by ocrelizumab may exhibit a duration of response exceeding the current licenced treatment interval. METHODS Internet-located information from regulatory submissions and meeting reports relating to the unpublished open-label, phase II ocrelizumab extension trial (NCT00676715) were reviewed. This followed people (54-55/arm) with MS, who switched from placebo or interferon-beta to ocrelizumab for three 600 mg treatment cycles (week 24, 48, 72) or people treated with ocrelizumab for four 600 mg treatment cycles (week 0-72), followed by an 18 month treatment-free period. RESULTS CD19+ B cells were rapidly depleted within 2 weeks and slow CD19+ B cell repopulation began about 6 months after the last infusion with median-repletion of over 15 months. The reduced annualized relapse rate during the published efficacy study appeared to be maintained in the extension study and there were no new T1 gadolinium-enhancing or T2 lesions detected in the treatment-free period. Importantly, within these extension cohorts, there appeared to be fewer adverse events and infections events. CONCLUSIONS Ocrelizumab appears to induce durable relapsing disease inhibition, within 3 treatment cycles Therefore, it may be possible to reduce the frequency of dosing to maintain efficacy, whilst limiting infection and other risks associated with continuous immunosuppression and could allow more effective vaccination against new pathogens. Further studies are now clearly required to determine whether this data is robust.",2020,"CONCLUSIONS Ocrelizumab appears to induce durable relapsing disease inhibition, within 3 treatment cycles",[],"['placebo or interferon-beta to ocrelizumab', 'cladribine and alemtuzumab', 'Ocrelizumab', 'ocrelizumab']","['annualized relapse rate', 'new T1 gadolinium-enhancing or T2 lesions']",[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0015980', 'cui_str': 'Interferon-beta'}, {'cui': 'C1882138', 'cui_str': 'ocrelizumab'}, {'cui': 'C0092801', 'cui_str': 'Cladribine'}, {'cui': 'C0383429', 'cui_str': 'alemtuzumab'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0016911', 'cui_str': 'Gadolinium'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]",,0.0255681,"CONCLUSIONS Ocrelizumab appears to induce durable relapsing disease inhibition, within 3 treatment cycles","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Baker', 'Affiliation': 'Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, United Kingdom. Electronic address: david.baker@qmul.ac.uk.'}, {'ForeName': 'Gareth', 'Initials': 'G', 'LastName': 'Pryce', 'Affiliation': 'Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, United Kingdom.'}, {'ForeName': 'Louisa K', 'Initials': 'LK', 'LastName': 'James', 'Affiliation': 'Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, United Kingdom.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Marta', 'Affiliation': 'Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, United Kingdom; Clinical Board:Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London E1 1BB, United Kingdom.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Schmierer', 'Affiliation': 'Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, United Kingdom; Clinical Board:Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London E1 1BB, United Kingdom.'}]",Multiple sclerosis and related disorders,['10.1016/j.msard.2020.102279'] 1588,32645683,Eye tracking of smoking-related stimuli in tobacco use disorder: A proof-of-concept study combining attention bias modification with alpha-transcranial alternating current stimulation.,"BACKGROUND Tobacco use disorder (TUD) is characterized by the presence of an attentional bias (AB) towards smoking-related stimuli. We investigated whether combining an AB modification paradigm (ABM) with transcranial alternating current stimulation (tACS) applied over the dorsolateral prefrontal cortex (DLPFC) reduces the AB towards smoking-related stimuli, as well as craving level and impulsive choices. METHODS In a sham-controlled, crossover preliminary study, 19 subjects with TUD received two stimulation arms: 1) active tACS (10 Hz, 2 mA, 30 min) combined with ABM and 2) sham tACS combined with ABM, in a randomized order, separated by one week. AB towards smoking cues during passive observation of smoking and neutral cues was assessed with an eye-tracking device and reactions times at a visual-probe task. Craving level was measured with the Questionnaire of Smoking Urges. Impulsive choices were assessed with the delay discounting task. RESULTS Active tACS combined with ABM reduced the amount of time spent looking at smoking-related pictures (p = 0.03), prevented the increase of self-reported desire to smoke (p = 0.026), and reduced the proportion of impulsive choices (p = 0.049), compared to sham tACS combined with ABM. No significant effects were reported on other craving dimensions and on AB based on reaction times. CONCLUSIONS These preliminary findings suggest that combining tACS with ABM may help smokers who wish to quit by reducing the desire to smoke, attention to smoking-cues, and impulsive decision-making.",2020,"RESULTS Active tACS combined with ABM reduced the amount of time spent looking at smoking-related pictures (p = 0.03), prevented the increase of self-reported desire to smoke (p = 0.026), and reduced the proportion of impulsive choices (p = 0.049), compared to sham tACS combined with ABM.","['19 subjects with TUD received two stimulation arms: 1', 'tobacco use disorder']","['tACS with ABM', 'alpha-transcranial alternating current stimulation', 'active tACS (10 Hz, 2 mA, 30 min) combined with ABM and 2) sham tACS combined with ABM', 'AB modification paradigm (ABM) with transcranial alternating current stimulation (tACS']","['Impulsive choices', 'increase of self-reported desire to smoke', 'delay discounting task', 'proportion of impulsive choices', 'craving dimensions and on AB based on reaction times', 'Craving level', 'time spent looking at smoking-related pictures']","[{'cui': 'C0040336', 'cui_str': 'Tobacco abuse'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C3852966', 'cui_str': 'Transcranial Alternating Current Stimulation'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C4277667', 'cui_str': 'Attentional Biases'}]","[{'cui': 'C0021125', 'cui_str': 'Impulsive behaviour'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C3850035', 'cui_str': 'Intertemporal Preferences'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C4277667', 'cui_str': 'Attentional Biases'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}]",19.0,0.0484381,"RESULTS Active tACS combined with ABM reduced the amount of time spent looking at smoking-related pictures (p = 0.03), prevented the increase of self-reported desire to smoke (p = 0.026), and reduced the proportion of impulsive choices (p = 0.049), compared to sham tACS combined with ABM.","[{'ForeName': 'Marine', 'Initials': 'M', 'LastName': 'Mondino', 'Affiliation': ""Department of Psychiatry and Neurosciences, Medical School, Université Laval, CERVO Brain Research Center, Centre intégré universitaire en santé et services sociaux de la Capitale-Nationale, 2325 rue de l'Université, Quebec City, QC, G1V 0A6, Canada.""}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Lenglos', 'Affiliation': ""Department of Psychiatry and Neurosciences, Medical School, Université Laval, CERVO Brain Research Center, Centre intégré universitaire en santé et services sociaux de la Capitale-Nationale, 2325 rue de l'Université, Quebec City, QC, G1V 0A6, Canada.""}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Cinti', 'Affiliation': ""Department of Psychiatry and Neurosciences, Medical School, Université Laval, CERVO Brain Research Center, Centre intégré universitaire en santé et services sociaux de la Capitale-Nationale, 2325 rue de l'Université, Quebec City, QC, G1V 0A6, Canada.""}, {'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Renauld', 'Affiliation': ""Department of Psychiatry and Neurosciences, Medical School, Université Laval, CERVO Brain Research Center, Centre intégré universitaire en santé et services sociaux de la Capitale-Nationale, 2325 rue de l'Université, Quebec City, QC, G1V 0A6, Canada.""}, {'ForeName': 'Shirley', 'Initials': 'S', 'LastName': 'Fecteau', 'Affiliation': ""Department of Psychiatry and Neurosciences, Medical School, Université Laval, CERVO Brain Research Center, Centre intégré universitaire en santé et services sociaux de la Capitale-Nationale, 2325 rue de l'Université, Quebec City, QC, G1V 0A6, Canada. Electronic address: shirley.fecteau@fmed.ulaval.ca.""}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108152'] 1589,32646010,Prediabetes Conversion to Normoglycemia Is Superior Adding a Low-Carbohydrate and Energy Deficit Formula Diet to Lifestyle Intervention-A 12-Month Subanalysis of the ACOORH Trial.,"Lifestyle interventions have been shown to reverse hyperglycemia to normoglycemia. However, these effects are not long-lasting and are accompanied with high dropout rates. As formula diets have been shown to be simple in usage and effective in improving glycemic control, we hypothesised that adding a low-carbohydrate and energy deficit formula diet to a low-intensity lifestyle intervention is superior in reversing prediabetes compared with lifestyle intervention alone. In this predefined subanalysis of an international, multicenter randomised controlled trial ( Almased Concept against Overweight and Obesity and Related Health Risk (ACOORH) study (ID DRKS00006811)), 141 persons with prediabetes were randomised (1:2) into either a control group with lifestyle intervention only (CON, n = 45) or a lifestyle intervention group accompanied with a formula diet (INT, n = 96). Both groups were equipped with telemonitoring devices. INT received a low-carbohydrate formula diet substituting three meals/day (~1200 kcal/day) within the first week, two meals/day during week 2-4, and one meal/day during week 5-26 (1300-1500 kcal/day). Follow-up was performed after 52 weeks and 105 participants (75%, INT: n = 74; CON: n = 31) finished the 26-week intervention phase. Follow-up data after 52 weeks were available from 93 participants (66%, INT: n = 65; CON: n = 28). Compared with CON, significantly more INT participants converted to normoglycemia after 52 weeks (50% vs. 31%; p < 0.05). The risk reduction led to a number-needed-to-treat of 5.3 for INT. Lifestyle intervention with a low-carbohydrate formula diet reduces prediabetes prevalence stronger than lifestyle intervention alone and is effective for type 2 diabetes prevention.",2020,Lifestyle intervention with a low-carbohydrate formula diet reduces prediabetes prevalence stronger than lifestyle intervention alone and is effective for type 2 diabetes prevention.,['141 persons with prediabetes'],"['Normoglycemia', 'Lifestyle interventions', 'Low-Carbohydrate and Energy Deficit Formula Diet to Lifestyle Intervention', 'Lifestyle intervention with a low-carbohydrate formula diet', 'CON', 'control group with lifestyle intervention only (CON, n = 45) or a lifestyle intervention group accompanied with a formula diet']",['normoglycemia'],"[{'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",[],,0.0255759,Lifestyle intervention with a low-carbohydrate formula diet reduces prediabetes prevalence stronger than lifestyle intervention alone and is effective for type 2 diabetes prevention.,"[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Röhling', 'Affiliation': 'West-German Center of Diabetes and Health, Düsseldorf Catholic Hospital Group, 40591 Düsseldorf, Germany.'}, {'ForeName': 'Kerstin', 'Initials': 'K', 'LastName': 'Kempf', 'Affiliation': 'West-German Center of Diabetes and Health, Düsseldorf Catholic Hospital Group, 40591 Düsseldorf, Germany.'}, {'ForeName': 'Winfried', 'Initials': 'W', 'LastName': 'Banzer', 'Affiliation': 'Department of Sports Medicine, Institute for Sports and Sport Science, University of Frankfurt, 60487 Frankfurt, Germany.'}, {'ForeName': 'Aloys', 'Initials': 'A', 'LastName': 'Berg', 'Affiliation': 'Faculty of Medicine, University of Freiburg, 79117 Freiburg, Germany.'}, {'ForeName': 'Klaus-Michael', 'Initials': 'KM', 'LastName': 'Braumann', 'Affiliation': 'Department of Sports and Movement Medicine, Faculty of Psychology and Human Movement Sciences, University of Hamburg, 20148 Hamburg, Germany.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Tan', 'Affiliation': 'Department of Endocrinology, Diabetes and Metabolism and Division of Laboratory Research, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Halle', 'Affiliation': 'Department of Prevention, Rehabilitation and Sports Medicine, Klinikum rechts der Isar, Technical University of Munich (TUM), 80992 Munich, Germany.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'McCarthy', 'Affiliation': 'Public Health Nutrition Research Group, London Metropolitan University, London N7 8DB, UK.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Pinget', 'Affiliation': ""Department Endocrinologie, Diabete et Maladies Métaboliques, Faculte de Medicine de'l University de Strasbourg, 67170 Strasbourg, France.""}, {'ForeName': 'Hans-Georg', 'Initials': 'HG', 'LastName': 'Predel', 'Affiliation': 'Institute of Cardiovascular Research and Sports Medicine, German Sport University Cologne, 50933 Cologne, Germany.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Scholze', 'Affiliation': 'KARDIOS, Cardioligists in Berlin, 10787 Berlin, Germany.'}, {'ForeName': 'Hermann', 'Initials': 'H', 'LastName': 'Toplak', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Medical University of Graz, 8010 Graz, Austria.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Martin', 'Affiliation': 'West-German Center of Diabetes and Health, Düsseldorf Catholic Hospital Group, 40591 Düsseldorf, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': 'Acoorh Study Group', 'Affiliation': ''}]",Nutrients,['10.3390/nu12072022'] 1590,32618242,Assessment of the Acceptability of Testing and Treatment during a Mass Drug Administration Trial for Malaria in Zambia Using Mixed Methods.,"From 2014 to 2016, a community-randomized controlled trial in Southern Province, Zambia, compared mass drug administration (MDA) and focal MDA (fMDA) with the standard of care. Acceptability of the intervention was assessed quantitatively using closed-ended and Likert scale-based questions posed during three household surveys conducted from April to May in 2014, 2015, and 2016 in 40 health catchments that implemented MDA and fMDA and 20 catchments that served as trial controls. In 2014 and 2015, 47 households per catchment were selected, targeting 1,880 households in MDA and fMDA trial arms; in 2016, 55 households per catchment were selected for a target of 2,200 households in MDA and fMDA trial arms. Concurrently, 27 focus group discussions and 23 in-depth interviews with 248 participants were conducted on reasons for testing and treatment refusal, reasons for nonadherence, and community perception of the MDA campaign. Results demonstrated that the MDA campaign was highly accepted with more than 99% of respondents stating that they would take treatment if positive for malaria. High acceptability at baseline could be associated with test-and-treat campaigns recently conducted in the study area. There was a large increase in the acceptability of prophylactic treatment if negative for malaria from the baseline to follow-up survey for adults and children, from 62% to 96% for each. This likely resulted from an intensive community-wide sensitization program that occurred before the first treatment round at each household during community health worker visits.",2020,"There was a large increase in the acceptability of prophylactic treatment if negative for malaria from the baseline to follow-up survey for adults and children, from 62% to 96% for each.","['2014, 2015, and 2016 in 40 health catchments that implemented MDA and fMDA and 20 catchments that served as trial controls', 'In 2014 and 2015, 47 households per catchment were selected, targeting 1,880 households in MDA and fMDA trial arms; in 2016, 55 households per catchment were selected for a target of 2,200 households in MDA and fMDA trial arms', 'Malaria in Zambia Using Mixed Methods', 'From 2014 to 2016, a community-randomized controlled trial in Southern Province, Zambia, compared mass drug administration (MDA) and focal MDA (fMDA) with the standard of care']",[],[],"[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C4505223', 'cui_str': 'Mass Administration'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0000379', 'cui_str': 'Methylenedioxyamphetamine'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0043445', 'cui_str': 'Zambia'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]",[],[],248.0,0.0973838,"There was a large increase in the acceptability of prophylactic treatment if negative for malaria from the baseline to follow-up survey for adults and children, from 62% to 96% for each.","[{'ForeName': 'Kafula', 'Initials': 'K', 'LastName': 'Silumbe', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Timothy P', 'Initials': 'TP', 'LastName': 'Finn', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Todd', 'Initials': 'T', 'LastName': 'Jennings', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Chilumba', 'Initials': 'C', 'LastName': 'Sikombe', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Chiyende', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Busiku', 'Initials': 'B', 'LastName': 'Hamainza', 'Affiliation': 'National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Chizema Kawesha', 'Affiliation': 'National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.'}, {'ForeName': 'Thomas P', 'Initials': 'TP', 'LastName': 'Eisele', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Duncan', 'Initials': 'D', 'LastName': 'Earle', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Richard W', 'Initials': 'RW', 'LastName': 'Steketee', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Miller', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.19-0663'] 1591,32618245,"A Longitudinal Cohort to Monitor Malaria Infection Incidence during Mass Drug Administration in Southern Province, Zambia.","Rigorous evidence of effectiveness is needed to determine where and when to apply mass drug administration (MDA) or focal MDA (fMDA) as part of a malaria elimination strategy. The Zambia National Malaria Elimination Centre recently completed a community-randomized controlled trial in Southern Province to evaluate MDA and fMDA for transmission reduction. To assess the role of MDA and fMDA on infection incidence, we enrolled a longitudinal cohort for an 18-month period of data collection including monthly malaria parasite infection detection based on polymerase chain reaction and compared time to first infection and cumulative infection incidence outcomes across study arms using Cox proportional hazards and negative binomial models. A total of 2,026 individuals from 733 households were enrolled and completed sufficient follow-up for inclusion in analysis. Infection incidence declined dramatically across all study arms during the period of study, and MDA was associated with reduced risk of first infection (hazards ratio: 0.36; 95% CI: 0.16-0.80) and cumulative infection incidence during the first rainy season (first 5 months of follow-up) (incidence rate ratio: 0.34; 95% CI: 0.12-0.95). No significant effect was found for fMDA or for either arm over the full study period. Polymerase chain reaction infection status at baseline was strongly associated with follow-up infection. The short-term effects of MDA suggest it may be an impactful accelerator of transmission reduction in areas with high coverage of case management and vector control and should be considered as part of a malaria elimination strategy.",2020,The short-term effects of MDA suggest it may be an impactful accelerator of transmission reduction in areas with high coverage of case management and vector control and should be considered as part of a malaria elimination strategy.,"['Southern Province, Zambia', '2,026 individuals from 733 households were enrolled and completed sufficient follow-up for inclusion in analysis']","['MDA', 'MDA and fMDA']","['Infection incidence', 'cumulative infection incidence', 'Polymerase chain reaction infection status', 'reduced risk of first infection']","[{'cui': 'C0043445', 'cui_str': 'Zambia'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C4505223', 'cui_str': 'Mass Administration'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0000379', 'cui_str': 'Methylenedioxyamphetamine'}]","[{'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0517627', 'cui_str': 'Infection status'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",2026.0,0.0828922,The short-term effects of MDA suggest it may be an impactful accelerator of transmission reduction in areas with high coverage of case management and vector control and should be considered as part of a malaria elimination strategy.,"[{'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Bennett', 'Affiliation': 'Malaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Travis R', 'Initials': 'TR', 'LastName': 'Porter', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Mulenga C', 'Initials': 'MC', 'LastName': 'Mwenda', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Joshua O', 'Initials': 'JO', 'LastName': 'Yukich', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Timothy P', 'Initials': 'TP', 'LastName': 'Finn', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Lungu', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Kafula', 'Initials': 'K', 'LastName': 'Silumbe', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Mambwe', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Chishimba', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Conceptor', 'Initials': 'C', 'LastName': 'Mulube', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Bridges', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Busiku', 'Initials': 'B', 'LastName': 'Hamainza', 'Affiliation': 'National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Slutsker', 'Affiliation': 'PATH MACEPA, Seattle, Washington.'}, {'ForeName': 'Richard W', 'Initials': 'RW', 'LastName': 'Steketee', 'Affiliation': 'PATH MACEPA, Seattle, Washington.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Miller', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Thomas P', 'Initials': 'TP', 'LastName': 'Eisele', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.19-0657'] 1592,32618247,"Impact of Four Rounds of Mass Drug Administration with Dihydroartemisinin-Piperaquine Implemented in Southern Province, Zambia.","Over the past decade, Zambia has made substantial progress against malaria and has recently set the ambitious goal of eliminating by 2021. In the context of very high vector control and improved access to malaria diagnosis and treatment in Southern Province, we implemented a community-randomized controlled trial to assess the impact of four rounds of community-wide mass drug administration (MDA) and household-level MDA (focal MDA) with dihydroartemisinin-piperaquine (DHAP) implemented between December 2014 and February 2016. The mass treatment campaigns achieved relatively good household coverage (63-79%), were widely accepted by the community (ranging from 87% to 94%), and achieved very high adherence to the DHAP regimen (81-96%). Significant declines in all malaria study end points were observed, irrespective of the exposure group, with the overall parasite prevalence during the peak transmission season declining by 87.2% from 31.3% at baseline to 4.0% in 2016 at the end of the trial. Children in areas of lower transmission (< 10% prevalence at baseline) that received four MDA rounds had a 72% (95% CI = 12-91%) reduction in malaria parasite prevalence as compared with those with the standard of care without any mass treatment. Mass drug administration consistently had the largest short-term effect size across study end points in areas of lower transmission following the first two MDA rounds. In the context of achieving very high vector control coverage and improved access to diagnosis and treatment for malaria, our results suggest that MDA should be considered for implementation in African settings for rapidly reducing malaria outcomes in lower transmission settings.",2020,"Significant declines in all malaria study end points were observed, irrespective of the exposure group, with the overall parasite prevalence during the peak transmission season declining by 87.2% from 31.3% at baseline to 4.0% in 2016 at the end of the trial.","['Southern Province', 'Southern Province, Zambia']","['community-wide mass drug administration (MDA) and household-level MDA (focal MDA) with dihydroartemisinin-piperaquine (DHAP', 'Dihydroartemisinin-Piperaquine', 'MDA']","['malaria parasite prevalence', 'overall parasite prevalence']","[{'cui': 'C0043445', 'cui_str': 'Zambia'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C4505223', 'cui_str': 'Mass Administration'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0058108', 'cui_str': 'dihydroartemisinin'}, {'cui': 'C0071105', 'cui_str': 'piperaquine'}]","[{'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0030498', 'cui_str': 'Parasite'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.0868305,"Significant declines in all malaria study end points were observed, irrespective of the exposure group, with the overall parasite prevalence during the peak transmission season declining by 87.2% from 31.3% at baseline to 4.0% in 2016 at the end of the trial.","[{'ForeName': 'Thomas P', 'Initials': 'TP', 'LastName': 'Eisele', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Bennett', 'Affiliation': 'Malaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Kafula', 'Initials': 'K', 'LastName': 'Silumbe', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Timothy P', 'Initials': 'TP', 'LastName': 'Finn', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Travis R', 'Initials': 'TR', 'LastName': 'Porter', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Chalwe', 'Affiliation': 'Institute for Medical Research and Training, University Teaching Hospital, Lusaka, Zambia.'}, {'ForeName': 'Busiku', 'Initials': 'B', 'LastName': 'Hamainza', 'Affiliation': 'National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.'}, {'ForeName': 'Hawela', 'Initials': 'H', 'LastName': 'Moonga', 'Affiliation': 'National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Kooma', 'Affiliation': 'National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Chizema Kawesha', 'Affiliation': 'National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.'}, {'ForeName': 'Mulakwa', 'Initials': 'M', 'LastName': 'Kamuliwo', 'Affiliation': 'Zambia Ministry of Health, Southern Provincial Health Office, Choma, Zambia.'}, {'ForeName': 'Joshua O', 'Initials': 'JO', 'LastName': 'Yukich', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Keating', 'Affiliation': 'Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Kammerle', 'Initials': 'K', 'LastName': 'Schneider', 'Affiliation': 'PATH MACEPA, Seattle, Washington.'}, {'ForeName': 'Ruben O', 'Initials': 'RO', 'LastName': 'Conner', 'Affiliation': 'PATH MACEPA, Seattle, Washington.'}, {'ForeName': 'Duncan', 'Initials': 'D', 'LastName': 'Earle', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Slutsker', 'Affiliation': 'PATH MACEPA, Seattle, Washington.'}, {'ForeName': 'Richard W', 'Initials': 'RW', 'LastName': 'Steketee', 'Affiliation': 'PATH MACEPA, Seattle, Washington.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Miller', 'Affiliation': 'PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.19-0659'] 1593,32618713,"Antenatal Uterotonics as a Risk Factor for Intrapartum Stillbirth and First-day Death in Haryana, India: A Nested Case-control Study.","BACKGROUND Use of uterotonics like oxytocin to induce or augment labor has been shown to reduce placental perfusion and oxygen supply to the fetus, and studies indicate that it may increase the risk of stillbirth and neonatal asphyxia. Antenatal use of uterotonics, even without the required fetal monitoring and prompt access to cesarean section, is widespread, yet no study has adequately estimated the risk of intrapartum stillbirth and early neonatal deaths ascribed to such use. We conducted a case-control study to estimate this risk. METHODS We conducted a population-based case-control study nested in a cluster-randomized trial. From 2008 to 2010, we followed pregnant women in rural Haryana, India, monthly until delivery. We visited all live-born infants on day 29 to ascertain whether they were alive. We conducted verbal autopsies for stillbirths and neonatal deaths. Cases (n = 2,076) were the intrapartum stillbirths and day-1 deaths (early deaths), and controls (n = 532) were live-born babies who died between day 8 and 28 (late deaths). RESULTS Antenatal administration of uterotonics preceded 74% of early and 62% of late deaths, translating to an adjusted odds ratio (95% confidence interval [CI]) for early deaths of 1.7 (95% CI = 1.4, 2.1), and a population attributable risk of 31% (95% CI = 22%, 38%). CONCLUSIONS Antenatal administration of uterotonics was associated with a substantially increased risk of intrapartum stillbirth and day-1 death. See video abstract: http://links.lww.com/EDE/B707.",2020,"CONCLUSIONS Antenatal administration of uterotonics was associated with a substantially increased risk of intrapartum stillbirth and day-1 death.","['From 2008 to 2010, we followed pregnant women in rural Haryana, India, monthly until delivery']",[],"['risk of intrapartum stillbirth and day-1 death', 'intrapartum stillbirths and day-1 deaths (early deaths']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1720302', 'cui_str': 'Until'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}]",[],"[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0456337', 'cui_str': 'Intrapartum'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1279919', 'cui_str': 'Early'}]",,0.117976,"CONCLUSIONS Antenatal administration of uterotonics was associated with a substantially increased risk of intrapartum stillbirth and day-1 death.","[{'ForeName': 'Sanjana', 'Initials': 'S', 'LastName': 'Brahmawar Mohan', 'Affiliation': 'From the Centre for Health Research and Development, Society for Applied Studies (SAS), New Delhi, India.'}, {'ForeName': 'Halvor', 'Initials': 'H', 'LastName': 'Sommerfelt', 'Affiliation': 'Centre for Intervention Science in Maternal and Child Health (CISMAC) and Centre for International Health (CIH), University of Bergen, Bergen, Norway.'}, {'ForeName': 'J Frederik', 'Initials': 'JF', 'LastName': 'Frøen', 'Affiliation': 'Centre for Intervention Science in Maternal and Child Health (CISMAC) and Centre for International Health (CIH), University of Bergen, Bergen, Norway.'}, {'ForeName': 'Sunita', 'Initials': 'S', 'LastName': 'Taneja', 'Affiliation': 'From the Centre for Health Research and Development, Society for Applied Studies (SAS), New Delhi, India.'}, {'ForeName': 'Tivendra', 'Initials': 'T', 'LastName': 'Kumar', 'Affiliation': 'From the Centre for Health Research and Development, Society for Applied Studies (SAS), New Delhi, India.'}, {'ForeName': 'Kiran', 'Initials': 'K', 'LastName': 'Bhatia', 'Affiliation': 'From the Centre for Health Research and Development, Society for Applied Studies (SAS), New Delhi, India.'}, {'ForeName': 'Lize', 'Initials': 'L', 'LastName': 'van der Merwe', 'Affiliation': 'Centre for Intervention Science in Maternal and Child Health (CISMAC) and Centre for International Health (CIH), University of Bergen, Bergen, Norway.'}, {'ForeName': 'Rajiv', 'Initials': 'R', 'LastName': 'Bahl', 'Affiliation': 'Department of Maternal, Newborn, Child and Adolescent Health, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'Jose C', 'Initials': 'JC', 'LastName': 'Martines', 'Affiliation': 'Centre for Intervention Science in Maternal and Child Health (CISMAC) and Centre for International Health (CIH), University of Bergen, Bergen, Norway.'}, {'ForeName': 'Sarmila', 'Initials': 'S', 'LastName': 'Mazumder', 'Affiliation': 'From the Centre for Health Research and Development, Society for Applied Studies (SAS), New Delhi, India.'}, {'ForeName': 'Nita', 'Initials': 'N', 'LastName': 'Bhandari', 'Affiliation': 'From the Centre for Health Research and Development, Society for Applied Studies (SAS), New Delhi, India.'}]","Epidemiology (Cambridge, Mass.)",['10.1097/EDE.0000000000001224'] 1594,32589978,"Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.","BACKGROUND The addition of rituximab to intensive chemotherapy improves outcomes in patients with B-cell acute lymphoblastic leukaemia. Ofatumumab is an anti-CD20 monoclonal antibody that binds to the small extracellular loop of CD20 and has greater in vitro complement-mediated cytotoxicity than rituximab. In this study, we assessed the activity and safety of ofatumumab in combination with chemotherapy in patients with Philadelphia chromosome (Ph)-negative CD20-positive B-cell acute lymphoblastic leukaemia. METHODS This was a single-arm, phase 2 trial done at the MD Anderson Cancer Center (Houston, TX, USA). Patients with newly diagnosed, Ph-negative B-cell acute lymphoblastic leukaemia or lymphoblastic lymphoma with CD20 expression of at least 1% were eligible. Patients were treated with up to eight courses of the hyper-CVAD regimen (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) on courses 1, 3, 5, and 7 alternating with high-dose methotrexate and cytarabine on courses 2, 4, 6, and 8. Ofatumumab was administered on days 1 and 11 of courses 1 and 3 and on days 1 and 8 of courses 2 and 4 for a total of eight doses. The first dose of ofatumumab was 300 mg intravenously and all subsequent doses were 2000 mg intravenously. Patients received 30 courses of maintenance therapy with 6-mercaptopurine, vincristine, methotrexate, and prednisone (POMP), with four intensification courses (high-dose methotrexate plus L-asparaginase and hyper-CVAD plus ofatumumab on courses 6-7 and 18-19). The primary endpoints were event-free survival, overall response, and overall survival. All enrolled patients were included in the primary and safety analyses. The trial is registered with ClinicalTrials.gov, NCT01363128. FINDINGS Between Aug 26, 2011, and May 18, 2017, 69 patients (67 patients had B-cell acute lymphoblastic leukaemia and two had B-cell lymphoblastic lymphoma; median age 41 years [IQR 32-50]) were enrolled and treated, including 33 (48%) aged between 18 and 39 years. Nine (27%) of 33 patients had Ph-like acute lymphoblastic leukaemia. With a median follow-up of 44 months (26-53), 4-year event-free survival was 59% (95% CI 48-73); 69% (54-87) in adolescents and young adults aged 18-39 years. 4-year overall survival was 68% (58-81); 74% (60-91) in adolescents and young adults. The overall response rate was 98% (64 of 65 patients). The most common non-haematological grade 3 or 4 adverse events were infections (35 [54%] of 65 patients during induction and 53 [78%] of 68 patients during consolidation). Ten (14%) of 69 patients died in complete remission from sepsis (two [3%]), cardiac arrest (one [1%]), therapy-related acute myeloid leukaemia (two [3%]), and haematopoietic stem-cell transplantation complications (five [7%]). None of these deaths were considered related to ofatumumab treatment by the study investigators. INTERPRETATION The combination of hyper-CVAD plus ofatumumab is safe and active in adults with Ph-negative CD20-positive B-cell acute lymphoblastic leukaemia. Modifications of this regimen with the addition of novel monoclonal and bispecific antibody constructs targeting CD19 and CD22 might further improve outcomes and allow reduction in the intensity and duration of chemotherapy. FUNDING Novartis.",2020,4-year overall survival was 68% (58-81); 74% (60-91) in adolescents and young adults.,"['adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia', '33 patients had Ph-like acute lymphoblastic leukaemia', 'patients with Philadelphia chromosome (Ph)-negative CD20-positive B-cell acute lymphoblastic leukaemia', 'adults with Ph-negative CD20-positive B-cell acute lymphoblastic leukaemia', 'Between Aug 26, 2011, and May 18, 2017', '69 patients (67 patients had B-cell acute lymphoblastic leukaemia and two had B-cell lymphoblastic lymphoma; median age 41 years [IQR 32-50]) were enrolled and treated, including 33 (48%) aged between 18 and 39 years', 'patients with B-cell acute lymphoblastic leukaemia', 'Patients with newly diagnosed, Ph-negative B-cell acute lymphoblastic leukaemia or lymphoblastic lymphoma with CD20 expression of at least 1% were eligible']","['6-mercaptopurine, vincristine, methotrexate, and prednisone (POMP), with four intensification courses (high-dose methotrexate plus L-asparaginase and hyper-CVAD plus ofatumumab', 'hyper-CVAD plus ofatumumab', 'ofatumumab in combination with chemotherapy', 'hyper-CVAD regimen (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone', 'methotrexate and cytarabine', 'Hyper-CVAD regimen in combination with ofatumumab', 'rituximab']","['event-free survival, overall response, and overall survival', '4-year event-free survival', 'activity and safety', 'cardiac arrest', 'overall response rate', 'haematopoietic stem-cell transplantation complications', 'complete remission from sepsis', 'therapy-related acute myeloid leukaemia', '4-year overall survival']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3888511', 'cui_str': 'Philadelphia chromosome negative'}, {'cui': 'C4721444', 'cui_str': 'Burkitt cell leukemia'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0031526', 'cui_str': 'Ph1 Chromosome'}, {'cui': 'C0023449', 'cui_str': 'Acute lymphoid leukemia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C3888518', 'cui_str': 'CD20 antigen positive'}, {'cui': 'C0004561', 'cui_str': 'B lymphocyte'}, {'cui': 'C0079748', 'cui_str': 'Precursor cell lymphoblastic lymphoma'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0054946', 'cui_str': 'Lymphocyte antigen CD20'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}]","[{'cui': 'C0000618', 'cui_str': 'mercaptopurine'}, {'cui': 'C0042679', 'cui_str': 'Vincristine'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0003993', 'cui_str': 'ASPARAGINASE'}, {'cui': 'C0082139', 'cui_str': 'CVAD protocol'}, {'cui': 'C1832027', 'cui_str': 'ofatumumab'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0010711', 'cui_str': 'Cytarabine'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}]","[{'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}, {'cui': 'C0018956', 'cui_str': 'Hematopoietic stem cell'}, {'cui': 'C3804957', 'cui_str': 'Transplantation complication'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}]",,0.229832,4-year overall survival was 68% (58-81); 74% (60-91) in adolescents and young adults.,"[{'ForeName': 'Elias', 'Initials': 'E', 'LastName': 'Jabbour', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: ejabbour@mdanderson.org.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Richard-Carpentier', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Yuya', 'Initials': 'Y', 'LastName': 'Sasaki', 'Affiliation': 'Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Konopleva', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Keyur', 'Initials': 'K', 'LastName': 'Patel', 'Affiliation': 'Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Roberts', 'Affiliation': ""Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Zhaohui', 'Initials': 'Z', 'LastName': 'Gu', 'Affiliation': ""Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': 'Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Xuelin', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Sasaki', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'Short', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Nitin', 'Initials': 'N', 'LastName': 'Jain', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Farhad', 'Initials': 'F', 'LastName': 'Ravandi', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Naval G', 'Initials': 'NG', 'LastName': 'Daver', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Tapan M', 'Initials': 'TM', 'LastName': 'Kadia', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Yesid', 'Initials': 'Y', 'LastName': 'Alvarado', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Courtney D', 'Initials': 'CD', 'LastName': 'DiNardo', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Ghayas C', 'Initials': 'GC', 'LastName': 'Issa', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Naveen', 'Initials': 'N', 'LastName': 'Pemmaraju', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Garcia-Manero', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Srdan', 'Initials': 'S', 'LastName': 'Verstovsek', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Sa', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Joseph D', 'Initials': 'JD', 'LastName': 'Khoury', 'Affiliation': 'Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Jorgensen', 'Affiliation': 'Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Champlin', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Issa', 'Initials': 'I', 'LastName': 'Khouri', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Partow', 'Initials': 'P', 'LastName': 'Kebriaei', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Schroeder', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Khouri', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Charles G', 'Initials': 'CG', 'LastName': 'Mullighan', 'Affiliation': ""Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Takahashi', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': ""O'Brien"", 'Affiliation': 'Division of Hematology/Oncology, Department of Medicine, UCI Health, Orange, CA, USA.'}, {'ForeName': 'Hagop', 'Initials': 'H', 'LastName': 'Kantarjian', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}]",The Lancet. Haematology,['10.1016/S2352-3026(20)30144-7'] 1595,32619561,"ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma.","PURPOSE ERGO2 is the first randomized clinical trial on a calorically restricted ketogenic diet (KD) and intermittent fasting (KD-IF) in addition to reirradiation for recurrent malignant gliomas. METHODS AND MATERIALS Fifty patients were randomized 1:1 to reirradiation combined with either a calorically unrestricted diet or KD-IF. The KD-IF schedule included 3 days of KD (21-23 kcal/kg/d), followed by 3 days of fasting and again 3 days of KD. Primary endpoint was progression-free survival (PFS) at 6 months (PFS6). Secondary endpoints were PFS, local PFS, overall survival (OS), frequency of epileptic seizures, rate of ketosis and quality of life. RESULTS Four patients quit the trial before treatment and 3 patients stopped KD-IF prematurely. Of the 20 patients who completed KD-IF, 17 patients developed ketosis at day 6 and glucose levels declined significantly. KD-IF was well-tolerated with a modest weight loss of -2.1 ± 1.8 kg. No severe adverse events attributable to the diet occurred. PFS6 was not significantly different between the 2 groups (KD-IF: 20%; calorically unrestricted diet: 16%). Similarly, no difference in PFS, local PFS6, or OS was observable. Explorative analysis revealed that patients in the KD-IF group who had a glucose level of less than the median (83.5 mg/dL) on day 6 had significantly longer PFS and OS compared with those above the median (P < .05). CONCLUSIONS KD-IF is feasible and effective in inducing ketosis in heavily pretreated patients with recurrent glioma. However, the short schedule reported here failed to increase the efficacy of reirradiation. CLINICALTRIALS. GOV NUMBER NCT01754350.",2020,"PFS6 was not significantly different between the two groups (KD-IF: 20%, SD: 16%).","['50 Patients', 'heavily pretreated patients with recurrent glioma', 'malignant glioma']","['calorie restricted ketogenic diet and fasting in addition to re-irradiation', 're-irradiation combined with either calorically unrestricted diet (SD) or KD-IF', 'ERGO2', 'calorically restricted ketogenic diet (KD) and intermittent fasting (KD-IF']","['ketosis at day 6 and glucose levels', 'progression-free survival (PFS) rate at 6 months (PFS6', 'severe adverse events', 'PFS, local PFS, overall survival (OS), frequency of epileptic seizures, rate of ketosis and quality of life', 'PFS6', 'PFS, local PFS6 and OS', 'PFS and OS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0017638', 'cui_str': 'Glioma'}, {'cui': 'C0555198', 'cui_str': 'Glioma, malignant, no ICD-O subtype'}]","[{'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0259972', 'cui_str': 'Ketogenic diet'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C4042794', 'cui_str': 'Re Irradiation'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C4704881', 'cui_str': 'Intermittent Fasting'}]","[{'cui': 'C0022638', 'cui_str': 'Ketosis'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",50.0,0.0608039,"PFS6 was not significantly different between the two groups (KD-IF: 20%, SD: 16%).","[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Voss', 'Affiliation': 'Dr Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; University Cancer Center Frankfurt, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; German Cancer Consortium, Partner Site Frankfurt, and German Cancer Research Center, Heidelberg, Germany; Frankfurt Cancer Institute, Frankfurt, Germany. Electronic address: martin.voss@kgu.de.'}, {'ForeName': 'Marlies', 'Initials': 'M', 'LastName': 'Wagner', 'Affiliation': 'University Cancer Center Frankfurt, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; German Cancer Consortium, Partner Site Frankfurt, and German Cancer Research Center, Heidelberg, Germany; Frankfurt Cancer Institute, Frankfurt, Germany; Institute of Neuroradiology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'von Mettenheim', 'Affiliation': 'Dr Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; University Cancer Center Frankfurt, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; German Cancer Consortium, Partner Site Frankfurt, and German Cancer Research Center, Heidelberg, Germany; Frankfurt Cancer Institute, Frankfurt, Germany.'}, {'ForeName': 'Patrick N', 'Initials': 'PN', 'LastName': 'Harter', 'Affiliation': 'University Cancer Center Frankfurt, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; German Cancer Consortium, Partner Site Frankfurt, and German Cancer Research Center, Heidelberg, Germany; Frankfurt Cancer Institute, Frankfurt, Germany; Institute of Neurology (Edinger-Institute), University Hospital Frankfurt, Goethe University, Frankfurt, Germany.'}, {'ForeName': 'Katharina J', 'Initials': 'KJ', 'LastName': 'Wenger', 'Affiliation': 'University Cancer Center Frankfurt, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; German Cancer Consortium, Partner Site Frankfurt, and German Cancer Research Center, Heidelberg, Germany; Frankfurt Cancer Institute, Frankfurt, Germany; Institute of Neuroradiology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.'}, {'ForeName': 'Kea', 'Initials': 'K', 'LastName': 'Franz', 'Affiliation': 'University Cancer Center Frankfurt, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; German Cancer Consortium, Partner Site Frankfurt, and German Cancer Research Center, Heidelberg, Germany; Frankfurt Cancer Institute, Frankfurt, Germany; Department of Neurosurgery, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Bojunga', 'Affiliation': 'Department of Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Vetter', 'Affiliation': 'Dr Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; University Cancer Center Frankfurt, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; German Cancer Consortium, Partner Site Frankfurt, and German Cancer Research Center, Heidelberg, Germany; Frankfurt Cancer Institute, Frankfurt, Germany.'}, {'ForeName': 'Ruediger', 'Initials': 'R', 'LastName': 'Gerlach', 'Affiliation': 'Department of Neurosurgery, HELIOS Hospital Erfurt, Erfurt, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Glatzel', 'Affiliation': 'Department of Radiation Oncology, HELIOS Hospital Erfurt, Erfurt, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Paulsen', 'Affiliation': 'Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany.'}, {'ForeName': 'Elke', 'Initials': 'E', 'LastName': 'Hattingen', 'Affiliation': 'University Cancer Center Frankfurt, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; German Cancer Consortium, Partner Site Frankfurt, and German Cancer Research Center, Heidelberg, Germany; Frankfurt Cancer Institute, Frankfurt, Germany; Institute of Neuroradiology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Baehr', 'Affiliation': 'Dr Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; University Cancer Center Frankfurt, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; German Cancer Consortium, Partner Site Frankfurt, and German Cancer Research Center, Heidelberg, Germany; Frankfurt Cancer Institute, Frankfurt, Germany.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Ronellenfitsch', 'Affiliation': 'Dr Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; University Cancer Center Frankfurt, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; German Cancer Consortium, Partner Site Frankfurt, and German Cancer Research Center, Heidelberg, Germany; Frankfurt Cancer Institute, Frankfurt, Germany.'}, {'ForeName': 'Emmanouil', 'Initials': 'E', 'LastName': 'Fokas', 'Affiliation': 'University Cancer Center Frankfurt, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; German Cancer Consortium, Partner Site Frankfurt, and German Cancer Research Center, Heidelberg, Germany; Frankfurt Cancer Institute, Frankfurt, Germany; Department of Radiotherapy and Oncology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.'}, {'ForeName': 'Detlef', 'Initials': 'D', 'LastName': 'Imhoff', 'Affiliation': 'University Cancer Center Frankfurt, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; German Cancer Consortium, Partner Site Frankfurt, and German Cancer Research Center, Heidelberg, Germany; Frankfurt Cancer Institute, Frankfurt, Germany; Department of Radiotherapy and Oncology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.'}, {'ForeName': 'Joachim P', 'Initials': 'JP', 'LastName': 'Steinbach', 'Affiliation': 'Dr Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; University Cancer Center Frankfurt, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; German Cancer Consortium, Partner Site Frankfurt, and German Cancer Research Center, Heidelberg, Germany; Frankfurt Cancer Institute, Frankfurt, Germany.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Rödel', 'Affiliation': 'University Cancer Center Frankfurt, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; German Cancer Consortium, Partner Site Frankfurt, and German Cancer Research Center, Heidelberg, Germany; Frankfurt Cancer Institute, Frankfurt, Germany; Department of Radiotherapy and Oncology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Rieger', 'Affiliation': 'Dr Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; Interdisciplinary Division of Neuro-Oncology, University Hospital Tübingen, Tübingen, Germany.'}]","International journal of radiation oncology, biology, physics",['10.1016/j.ijrobp.2020.06.021'] 1596,32619619,"A commentary on ""Efficacy of single layered intestinal anastomosis over double layered intestinal anastomosis-an open labeled, randomized controlled trial"".",,2020,,[],['single layered intestinal anastomosis'],[],[],"[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0192711', 'cui_str': 'Anastomosis of intestine'}]",[],,0.130852,,"[{'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Liu', 'Affiliation': 'Department of Colorectal Surgery, Changhai Hospital, Second Military Medical University, 200433, Shanghai, China.'}, {'ForeName': 'Zubing', 'Initials': 'Z', 'LastName': 'Mei', 'Affiliation': 'Department of Anorectal Surgery, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China; Anorectal Disease Institute of Shuguang Hospital, 201203, Shanghai, China. Electronic address: herrmayor@126.com.'}, {'ForeName': 'Guixin', 'Initials': 'G', 'LastName': 'Shen', 'Affiliation': 'Department of General Surgery, The Second Affiliated Hospital of Jiaxing University, 314000, Jiaxing, Zhejiang Province, China. Electronic address: jxeysgx1191@163.com.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2020.06.036'] 1597,32619648,Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial.,"BACKGROUND Concurrent chemoradiation is standard-of-care for patients with squamous cell carcinoma of the anus. Poor compliance to chemotherapy, radiotherapy treatment interruptions and unplanned breaks may impact adversely on long-term outcomes. METHODS The ACT II trial recruited 940 patients with localised squamous cell carcinoma of the anus, and assigned patients to mitomycin (week 1) or cisplatin (weeks 1 and 5), with fluorouracil (weeks 1 and 5) and radiotherapy (50.4 Gy in 28 fractions over 38 days). This post hoc analysis examined the association between baseline factors (age, gender, site, T stage and N stage), and compliance to treatment (radiotherapy and chemotherapy), and their effects on locoregional failure-free survival, progression-free survival (PFS) and overall survival (OS). Compliance was categorised into groups. Radiotherapy: six groups according to total dose and overall treatment time (OTT). Chemotherapy: three groups (A = per-protocol; B = dose reduction or delay; C = omitted). RESULTS A total of 931/940 patients were assessable for radiotherapy and 936 for chemotherapy compliance. Baseline glomerular filtration rate <60 ml/min and cisplatin were significantly associated with poor week 5 compliance to chemotherapy (P = 0.003 and 0.02, respectively). Omission of week 5 chemotherapy was associated with significantly worse locoregional failure-free survival [hazard ratio (HR) 2.53 (1.33-4.82) P = 0.005]. Dose reductions/delays or omission of week 5 chemotherapy were associated with significantly worse PFS {HR: 1.56 [95% confidence interval (CI): 1.18-2.06], P = 0.002 and HR: 2.39 (95% CI: 1.44-3.98), P = 0.001, respectively} and OS [HR: 1.92 (95% CI: 1.41-2.63), P < 0.001 and HR: 2.88 (95% CI: 1.63-5.08), P < 0.001, respectively]. Receiving the target radiotherapy dose in >42 days is associated with worse PFS and OS [HR: 1.72 (95% CI: 1.17-2.54), P =0.006]. CONCLUSION Poor compliance to chemotherapy and radiotherapy were associated with worse locoregional failure-free survival, PFS and OS. Treatment interruptions should be minimised, and OTT and total dose maintained. CLINICAL TRIAL NUMBER ISRCTN 26715889.",2020,"<60 mL/min and cisplatin were significantly associated with poor week 5 compliance to chemotherapy (p 0.003 and 0.02, respectively).","['patients with squamous cell carcinoma of the anus (SCCA', '940 patients with localized SCCA, and assigned patients to', 'squamous cell carcinoma of the anus', '931/940 patients were evaluable for radiotherapy and 936 for chemotherapy compliance']","['Chemotherapy', 'chemotherapy and radiotherapy', 'fluorouracil', 'chemotherapy, radiotherapy', 'cisplatin', 'mitomycin', 'radiotherapy (50·4Gy', 'Radiotherapy']","['worse PFS and OS', 'total dose (TD) and overall treatment time (OTT', 'loco-regional failure-free survival (LRFFS), progression-free survival (PFS) and overall survival (OS', 'Baseline Glomerular filtration rate (GR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1412036', 'cui_str': 'Anal squamous cell carcinoma'}, {'cui': 'C4517905', 'cui_str': '940'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0002475', 'cui_str': 'Mitomycin'}]","[{'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}]",940.0,0.148641,"<60 mL/min and cisplatin were significantly associated with poor week 5 compliance to chemotherapy (p 0.003 and 0.02, respectively).","[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Glynne-Jones', 'Affiliation': 'Mount Vernon Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, UK. Electronic address: rob.glynnejones@nhs.net.'}, {'ForeName': 'H M', 'Initials': 'HM', 'LastName': 'Meadows', 'Affiliation': 'Cancer Research UK & University College London Cancer Trials Centre, UCL, London, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Lopes', 'Affiliation': 'Cancer Research UK & University College London Cancer Trials Centre, UCL, London, UK.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Muirhead', 'Affiliation': 'Oxford Cancer & Haematology Centre, Oxford University Hospitals, Oxford, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Sebag-Montefiore', 'Affiliation': 'University of Leeds, Leeds Cancer Centre, Leeds, UK.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Adams', 'Affiliation': 'School of Medicine, Cardiff University, Cardiff, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2020.06.012'] 1598,32619868,Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults.,"Few studies examine the effectiveness of treatments for opioid use disorder (OUD) among Black individuals despite recent evidence suggesting opioid overdose death rates are, in some cases, highest and increasing at a faster rate among Black people compared to other racial/ethnic groups. This secondary analysis study investigated treatment preference, retention, and relapse rates amongst a subgroup of 73 Black participants with OUD (81% male, mean age 39.05, SD = 11.80) participating in a 24-week multisite randomized clinical trial (""X:BOT"") comparing the effectiveness of extended-release naltrexone (XR-NTX) and sublingual buprenorphine-naloxone (BUP-NX) between 2014 and 2017. Chi-square analyses were used to investigate treatment preference assessed at baseline, and logistic regression analyses were used to investigate differences in the odds of retention and relapse assessed over the 24-week course of treatment between treatment groups. Our findings suggest no differences in preference for XR-NTX versus BUP-NX. However, similar to the parent trial, there was an induction hurdle such that only 59.5% of those randomized to XR-NTX successfully initiated medication compared to 91.6% of those randomized to BUP-NX (OR = 0.13, 95% CI = 0.04, 0.52). No significant differences were found in treatment retention (intention-to-treat: OR = 1.19, 95% CI = 0.43, 3.28; per-protocol [i.e., those who initiated medication]: OR = 0.60, 95% CI = 0.20, 1.82) or relapse rates between treatment groups (intention-to-treat: OR = 1.53, 95% CI = 0.57, 4.13; per-protocol: OR = 0.69, 95% CI = 0.23, 2.06). Although there is a significant initiation hurdle with XR-NTX, once inducted, both medications appear similar in effectiveness, but as in the main study, dropout rates were high. Future research is needed on how to improve adherence.",2020,"No significant differences were found in treatment retention (intention-to-treat: OR = 1.19, 95% CI = 0.43, 3.28; per-protocol","['black adults', '73 Black participants with OUD (81% male, mean age 39.05, SD\xa0=\xa011.80) participating']","['extended-release naltrexone (XR-NTX) and sublingual buprenorphine-naloxone (BUP-NX', 'naltrexone', 'buprenorphine-naloxone']",['relapse rates'],"[{'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C0001565', 'cui_str': 'Sublingual route'}, {'cui': 'C1169989', 'cui_str': 'Buprenorphine- and naloxone-containing product'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}]",73.0,0.101327,"No significant differences were found in treatment retention (intention-to-treat: OR = 1.19, 95% CI = 0.43, 3.28; per-protocol","[{'ForeName': 'Angela M', 'Initials': 'AM', 'LastName': 'Haeny', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 34 Park St., New Haven, CT 06511, United States. Electronic address: angela.haeny@yale.edu.'}, {'ForeName': 'LaTrice', 'Initials': 'L', 'LastName': 'Montgomery', 'Affiliation': 'University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience, 3131 Harvey Avenue., Cincinnati, OH 45229, United States.'}, {'ForeName': 'A Kathleen', 'Initials': 'AK', 'LastName': 'Burlew', 'Affiliation': 'University of Cincinnati, Department of Psychology, 2600 Clifton Ave., Cincinnati, OH 45221, United States.'}, {'ForeName': 'Aimee N C', 'Initials': 'ANC', 'LastName': 'Campbell', 'Affiliation': 'Columbia University Irving Medical Center, Department of Psychiatry and New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, United States.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Scodes', 'Affiliation': 'Columbia University Irving Medical Center, Department of Psychiatry and New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, United States.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Pavlicova', 'Affiliation': 'Columbia University Irving Medical Center, Department of Psychiatry and New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, United States.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Rotrosen', 'Affiliation': 'New York University Grossman School of Medicine, One Park Ave., New York, NY 10016, United States.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Nunes', 'Affiliation': 'Columbia University Irving Medical Center, Department of Psychiatry and New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, United States.'}]",Addictive behaviors,['10.1016/j.addbeh.2020.106514'] 1599,32620020,Nasogastric versus Orogastric Bolus Tube Feeding in Preterm Infants: Pilot Randomized Clinical Trial.,"OBJECTIVE According to the most recent metanalysis, the best way to establish safe enteral feeding in preterm babies using nasogastric or orogastric tubes is still not well understood. This study aimed to determine the effects of bolus nasal tubes versus bolus orogastric tubes on the time required to reach full enteral feeding in preterm infants, as well as to compare the incidence rates of adverse events including nonintentional removal or displacement of the feeding tube, aspiration pneumonia/pneumonitis, apnea, necrotizing enterocolitis, gastric residual, and growth parameters between the studied cohort of preterm infants. STUDY DESIGN We conducted an unblinded pilot randomized clinical trial on hemodynamically stable preterm infants (>28 weeks) recruited from level 2 neonatal intensive care unit at Mansoura University Children's Hospital from June 2015 to May 2017. RESULTS Our study included 98 stable preterm infants with mean gestational age (orogastric group: 33.27 ± 1.08, nasogastric group: 33.32 ± 1.57) and mean birthweight (orogastric group: 1,753.3 ± 414.51, nasogastric group: 1,859.6 ± 307.05). Preterm infants who were fed via bolus nasogastric tube achieved full enteral feeding in a significantly shorter duration compared with the infants fed via bolus orogastric tube. The incidence rates of aspiration and feeding tube displacement were significantly higher in the bolus orogastric tube group compared with the bolus nasogastric tube group. There was no difference in the incidence rates of apnea, necrotizing enterocolitis, bradycardia, oxygen desaturation, and gastric residual in both groups. CONCLUSION Preterm infants without any respiratory support receiving bolus nasogastric tube feeding achieved full enteral feeding significantly sooner than those receiving bolus orogastric tube feeding. Additionally, bolus nasogastric tube feeding had a lower incidence of aspiration, tube displacement, and the infants regained birthweight more quickly than those receiving orogastric tube feeding. KEY POINTS · Preterm babies achieve full entral feeds sooner by nasogastric tubes than orogastric tubes.. · Incidence of nasogastric tube displacement and aspiration is less than orogastric tube.. · Infants on nasogastric tubes feeding regain birth weight quicker than those fed by orogastric tubes..",2020,"There was no difference in the incidence rates of apnea, necrotizing enterocolitis, bradycardia, oxygen desaturation, and gastric residual in both groups. ","[""hemodynamically stable preterm infants (>28 weeks) recruited from level 2 neonatal intensive care unit at Mansoura University Children's Hospital from June 2015 to May 2017"", 'preterm infants', '98 stable preterm infants with mean gestational age (orogastric group: 33.27\u2009±\u20091.08, nasogastric group: 33.32\u2009±\u20091.57) and mean birthweight (orogastric group: 1,753.3\u2009±\u2009414.51, nasogastric group: 1,859.6\u2009±\u2009307.05', 'Preterm Infants', 'preterm babies', 'Preterm infants']","['bolus nasal tubes versus bolus orogastric tubes', 'Nasogastric versus Orogastric Bolus Tube Feeding']","['incidence rates of aspiration and feeding tube displacement', 'full enteral feeding', 'incidence rates of apnea, necrotizing enterocolitis, bradycardia, oxygen desaturation, and gastric residual', 'nonintentional removal or displacement of the feeding tube, aspiration pneumonia/pneumonitis, apnea, necrotizing enterocolitis, gastric residual, and growth parameters']","[{'cui': 'C0578150', 'cui_str': 'Hemodynamically stable'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0456948', 'cui_str': 'Level 2'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0450104', 'cui_str': 'Orogastric'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517489', 'cui_str': '1.08'}, {'cui': 'C0694637', 'cui_str': 'Nasogastric route'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infants'}]","[{'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0450104', 'cui_str': 'Orogastric'}, {'cui': 'C0694637', 'cui_str': 'Nasogastric route'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0004056', 'cui_str': 'Aspiration, Psychology'}, {'cui': 'C0041281', 'cui_str': 'Tube feeding of patient'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0086225', 'cui_str': 'Enteral feeding'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0014356', 'cui_str': 'Enterocolitis'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range'}, {'cui': 'C3665864', 'cui_str': 'Gastric residual assessment'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C2945625', 'cui_str': 'Feeding tube'}, {'cui': 'C0032290', 'cui_str': 'Aspiration pneumonia'}, {'cui': 'C3714636', 'cui_str': 'Pneumonitis'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",98.0,0.0690969,"There was no difference in the incidence rates of apnea, necrotizing enterocolitis, bradycardia, oxygen desaturation, and gastric residual in both groups. ","[{'ForeName': 'Ahmed Tawfik', 'Initials': 'AT', 'LastName': 'Badran', 'Affiliation': 'Department of Pediatrics, SUNY Downstate Health Sciences University, Brooklyn, New York.'}, {'ForeName': 'Menna', 'Initials': 'M', 'LastName': 'Hashish', 'Affiliation': ""Neonatal Intensive Care Unit, Mansoura University Children's Hospital, Mansoura, Egypt.""}, {'ForeName': 'Alaa', 'Initials': 'A', 'LastName': 'Ali', 'Affiliation': 'Department of Pediatrics, National Research Center, Cairo, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Shokeir', 'Affiliation': ""Department of Pediatrics, Mansoura University Children's Hospital, Mansoura, Egypt.""}, {'ForeName': 'Abd', 'Initials': 'A', 'LastName': 'Shabaan', 'Affiliation': ""Neonatal Intensive Care Unit, Mansoura University Children's Hospital, Mansoura, Egypt.""}]",American journal of perinatology,['10.1055/s-0040-1713865'] 1600,32621555,"The long-term effectiveness of universal, selective and combined prevention for alcohol use during adolescence: 36-month outcomes from a cluster randomized controlled trial.","AIM To compare the long-term universal outcomes of the Climate Schools programme, the selective preventure programme and their combined implementation to standard substance use education in reducing the uptake of alcohol use, engagement in binge drinking and alcohol-related harms over a 3-year period. DESIGN A cluster-randomized controlled trial. SETTING AND PARTICIPANTS Substance use prevention programmes delivered in Australian secondary schools. Students from 26 Australian secondary schools (n = 2190), mean age at baseline 13.3 years (standard deviation = 0.48), 57.4% male. Schools were recruited between September 2011 and February 2012. INTERVENTIONS Schools were block-randomized to one of four groups: universal prevention (climate; 12 × 40-minute lessons); selective prevention (preventure; 2 × 90-minute sessions); combined prevention (climate and preventure; CAP); or health education as usual (control). The climate intervention delivered 12 × 40-minute lessons aimed at reducing alcohol and cannabis use and related harms. The preventure intervention delivered 2 × 90-minute group sessions to high-risk students. The CAP group implemented the climate programme to the entire year group and the preventure programme to the high-risk students. MEASUREMENTS Participants were all consenting 8th grade students (in 2012) assessed at baseline, post-intervention (6-9 months post-baseline) and at 12, 24 and 36 months post-baseline on measures of alcohol use, knowledge and related harms. Primary outcomes were alcohol use, binge drinking (five or more standard drinks) and alcohol-related harms, obtained from all students regardless of whether or not they received intervention. Intervention effects at 36 months post-baseline were estimated from generalized multi-level mixed models using data from all time-points and accounting for school-level clustering. Exploratory analyses examined intervention effects among low- and high-risk adolescents. FINDINGS Compared with students in the control condition, students in the climate, preventure and CAP groups demonstrated significantly slower increases in their likelihood to drink any alcohol [odds ratio (OR) = 0.64, 95% confidence interval (CI) = 0.50-0.82 for climate; OR = 0.55, 95% CI = 0.43-0.71 for preventure and OR = 0.67, 95% CI = 0.53-0.84 for CAP] to engage in binge drinking (OR = 0.60, 95% CI = 0.44-0.82 for climate; OR = 0.59, 95% CI = 0.44-0.80 for preventure and OR = 0.68, 95% CI = 0.51-0.92 for CAP) and to experience alcohol harms (OR = 0.63, 95% CI = 0.49-0.82 for climate; OR = 0.55, 95% CI = 0.43-0.71 for preventure and OR = 0.64, 95% CI = 0.50-0.81 for CAP). There was no strong evidence that the combined approach showed advantages over universal prevention. The direction and magnitude of effects were consistent in low- and high-risk adolescents. CONCLUSIONS The universal Climate Schools programme and the selective preventure programme were effective in reducing alcohol consumption and alcohol problems compared with standard Australian health education, when trialled individually and together over a 3-year period.",2020,"The universal Climate Schools program and the selective Preventure program were effective in reducing alcohol consumption and alcohol problems compared with standard Australian health education, when trialled individually and together over a 3-year period.","['Substance use prevention programs delivered in Australian secondary schools', 'Schools were recruited between September 2011 and February 2012', 'Students from 26 Australian secondary schools (n = 2,190), mean age at baseline 13.3 years (SD 0.48), 57.4% male']","['universal prevention (Climate;12 x 40min lessons); selective prevention (Preventure; 2 x 90min sessions); combined prevention (Climate and Preventure; CAP); or health education as usual (Control', 'universal, selective and combined prevention']","['likelihood to drink any alcohol', 'alcohol use, binge drinking (5+ standard drinks) and alcohol-related harms', 'engage in binge drinking', 'alcohol consumption and alcohol problems']","[{'cui': 'C0150358', 'cui_str': 'Substance use prevention'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0036530', 'cui_str': 'Secondary school'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517461', 'cui_str': '0.48'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0175671', 'cui_str': 'Universal'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0008946', 'cui_str': 'Climate'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0556346', 'cui_str': 'Drinking binge'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0549393', 'cui_str': 'Alcohol problem'}]",2190.0,0.113799,"The universal Climate Schools program and the selective Preventure program were effective in reducing alcohol consumption and alcohol problems compared with standard Australian health education, when trialled individually and together over a 3-year period.","[{'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Slade', 'Affiliation': 'The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Nicola C', 'Initials': 'NC', 'LastName': 'Newton', 'Affiliation': 'The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Marius', 'Initials': 'M', 'LastName': 'Mather', 'Affiliation': 'The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Emma L', 'Initials': 'EL', 'LastName': 'Barrett', 'Affiliation': 'The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Katrina E', 'Initials': 'KE', 'LastName': 'Champion', 'Affiliation': 'The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Lexine', 'Initials': 'L', 'LastName': 'Stapinski', 'Affiliation': 'The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Patricia J', 'Initials': 'PJ', 'LastName': 'Conrod', 'Affiliation': 'Department of Psychiatry, Université de Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'Maree', 'Initials': 'M', 'LastName': 'Teesson', 'Affiliation': 'The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, New South Wales, Australia.'}]","Addiction (Abingdon, England)",['10.1111/add.15178'] 1601,32621905,The ENGAGE-2 study: Engaging self-regulation targets to understand the mechanisms of behavior change and improve mood and weight outcomes in a randomized controlled trial (Phase 2).,"Despite evidence for effective integrated behavior therapy for treating comorbid obesity and depression, treatment response is highly variable and the underlying neurobiological mechanisms remain unknown. This hampers efforts to identify mechanistic targets in order to optimize treatment precision and potency. Funded within the NIH Science of Behavior Change (SOBC) Research Network, the 2-phased ENGAGE research project applies an experimental precision medicine approach to address this gap. The Phase 1 study focused on demonstrating technical feasibility, target engagement and potential neural mechanisms of responses to an integrated behavior therapy. This therapy combines a video-based behavioral weight loss program and problem-solving therapy for depression, with as-needed intensification of antidepressant medications, and its clinical effectiveness was demonstrated within a parent randomized clinical trial. Here, we describe the ENGAGE Phase 2 (ENGAGE-2) study protocol which builds on Phase 1 in 2 ways: (1) pilot testing of an motivational interviewing-enhanced, integrated behavior therapy in an independent, primarily minority patient sample, and (2) evaluation of a priori defined neural targets, specifically the negative affect (threat and sadness) circuits which demonstrated engagement and malleability in Phase 1, as mediators of therapeutic outcomes. Additionally, the Phase 2 study includes a conceptual and methodological extension to explore the role of microbiome-gut-brain and systemic immunological pathways in integrated behavioral treatment of obesity and depression. This protocol paper documents the conceptualization, design and the transdisciplinary methodologies in ENGAGE-2, which can inform future clinical and translational research in experimental precision medicine for behavior change and chronic disease management. Trial registration: ClinicalTrials.gov #NCT 03,841,682.",2020,"The Phase 1 study focused on demonstrating technical feasibility, target engagement and potential neural mechanisms of responses to an integrated behavior therapy.",[],"['motivational interviewing-enhanced, integrated behavior therapy', 'video-based behavioral weight loss program and problem-solving therapy']",[],[],"[{'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C3179079', 'cui_str': 'Weight Loss Programs'}, {'cui': 'C1303140', 'cui_str': 'Problem solving therapy'}]",[],,0.0347898,"The Phase 1 study focused on demonstrating technical feasibility, target engagement and potential neural mechanisms of responses to an integrated behavior therapy.","[{'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Lv', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, United States.'}, {'ForeName': 'Olusola A', 'Initials': 'OA', 'LastName': 'Ajilore', 'Affiliation': 'Department of Psychiatry, University of Illinois at Chicago, Chicago, IL 60612, United States.'}, {'ForeName': 'Corina R', 'Initials': 'CR', 'LastName': 'Ronneberg', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, United States.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Venditti', 'Affiliation': 'Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States.'}, {'ForeName': 'Mark B', 'Initials': 'MB', 'LastName': 'Snowden', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98104, United States.'}, {'ForeName': 'Philip W', 'Initials': 'PW', 'LastName': 'Lavori', 'Affiliation': 'Department of Biomedical Data Science, Stanford University, Stanford, CA 94305, United States.'}, {'ForeName': 'Lan', 'Initials': 'L', 'LastName': 'Xiao', 'Affiliation': 'Department of Epidemiology and Population Health, Stanford University, Palo Alto, CA 94304, United States.'}, {'ForeName': 'Andrea N', 'Initials': 'AN', 'LastName': 'Goldstein-Piekarski', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, United States; MIRECC VISN21, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, United States.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Wielgosz', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, United States.'}, {'ForeName': 'Nancy E', 'Initials': 'NE', 'LastName': 'Wittels', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, United States.'}, {'ForeName': 'Amruta', 'Initials': 'A', 'LastName': 'Barve', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, United States.'}, {'ForeName': 'Aashutos S', 'Initials': 'AS', 'LastName': 'Patel', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, United States.'}, {'ForeName': 'Tessa L', 'Initials': 'TL', 'LastName': 'Eckley', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, United States.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Stetz', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, United States.'}, {'ForeName': 'Ben S', 'Initials': 'BS', 'LastName': 'Gerber', 'Affiliation': 'Division of Academic Internal Medicine and Geriatrics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, United States.'}, {'ForeName': 'Joshua M', 'Initials': 'JM', 'LastName': 'Smyth', 'Affiliation': 'Departments of Biobehavioral Health and Medicine, Pennsylvania State University, University Park, PA 16802, United States.'}, {'ForeName': 'Janine M', 'Initials': 'JM', 'LastName': 'Simmons', 'Affiliation': 'National Institute of Mental Health (NIMH), National Institutes of Health, Bethesda, MD 20892, United States.'}, {'ForeName': 'Lisa G', 'Initials': 'LG', 'LastName': 'Rosas', 'Affiliation': 'Department of Epidemiology and Population Health, Stanford University, Palo Alto, CA 94304, United States; Department of Medicine, Stanford University, Palo Alto, CA 94304, United States.'}, {'ForeName': 'Leanne M', 'Initials': 'LM', 'LastName': 'Williams', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, United States; MIRECC VISN21, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, United States.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, United States; Department of Medicine, University of Illinois at Chicago, Chicago, IL 60608, United States. Electronic address: maj2015@uic.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106072'] 1602,32621918,Dexmedetomidine pretreatment attenuates myocardial ischemia reperfusion induced acute kidney injury and endoplasmic reticulum stress in human and rat.,"BACKGROUND Patients undergoing cardiopulmonary bypass (CPB) often develop acute kidney injury (AKI) caused by myocardial ischemia reperfusion (MI/R), and this renal injury can be resolved notably by dexmedetomidine. Endoplasmic reticulum (ER) stress was reported to get involved in organ injury including AKI. OBJECTIVES The current study aimed to address the correlation between MI/R induced AKI with ER stress and to assess the effects of dexmedetomidine pretreatment on AKI protection. METHOD Patients selected for heart valve replacement surgery were randomly assigned to NS group (pre-anesthesia with 0.9% NaCl) and DEX group (pre-anesthesia with dexmedetomidine). Rat MI/R model was induced by occluding coronary artery for 30 min followed by 48-hour reperfusion. Rats were randomized into Sham (0.9% NaCl), I/R (MI/R + 0.9% NaCl) and I/R + DEX (MI/R + dexmedetomidine). Organ function and ER stress condition were evaluated by blood chemistry, pathology, and molecular test. RESULTS Clinical data indicated dexmedetomidine pretreatment attenuated AKI and oxidative stress as well as postischemic myocardial injury in patients. Accordingly animal results suggested dexmedetomidine reduced cellular injury and improved postischemic myocardial and renal function. Dexmedetomidine also reduced myocardial and renal cells apoptosis and down-regulated ER stress. CONCLUSIONS These results suggested that dexmedetomidine pretreatment attenuates MI/R injury-induced AKI by relieving the ER stress.",2020,"Dexmedetomidine also reduced myocardial and renal cells apoptosis and down-regulated ER stress. ","['Patients undergoing', 'Patients selected for heart valve replacement surgery', 'human and rat']","['cardiopulmonary bypass (CPB', 'NS group (pre-anesthesia with 0.9% NaCl) and DEX group (pre-anesthesia with dexmedetomidine', 'Dexmedetomidine', '\u202fDEX (MI/R\u202f+\u202fdexmedetomidine', 'dexmedetomidine']","['MI/R injury-induced AKI', 'Endoplasmic reticulum (ER) stress', 'AKI and oxidative stress', 'myocardial and renal cells apoptosis and down-regulated ER stress', 'cellular injury and improved postischemic myocardial and renal function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0190173', 'cui_str': 'Heart valve replacement'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}]","[{'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0011816', 'cui_str': 'Dextromethorphan'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0035124', 'cui_str': 'Reperfusion'}]","[{'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0035126', 'cui_str': 'Ischemia-reperfusion injury'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0014239', 'cui_str': 'Endoplasmic reticulum'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0162638', 'cui_str': 'Apoptosis'}, {'cui': 'C0851285', 'cui_str': 'Regulation'}, {'cui': 'C3178870', 'cui_str': 'Stress, Endoplasmic Reticulum'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}]",,0.0396497,"Dexmedetomidine also reduced myocardial and renal cells apoptosis and down-regulated ER stress. ","[{'ForeName': 'Chaoliang', 'Initials': 'C', 'LastName': 'Tang', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, Anhui, China. Electronic address: chaolt@ustc.edu.cn.'}, {'ForeName': 'Yida', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Gao', 'Affiliation': 'Department of Anesthesia, Critical Care & Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02144, USA.'}, {'ForeName': 'Jiazhen', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': 'Department of Emergency, Huashan Hospital North, Fudan University, Shanghai, 201907, China.'}, {'ForeName': 'Si', 'Initials': 'S', 'LastName': 'Shi', 'Affiliation': 'Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China.'}, {'ForeName': 'Jiawu', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, Anhui, China.'}, {'ForeName': 'Qingtian', 'Initials': 'Q', 'LastName': 'Geng', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, Anhui, China.'}, {'ForeName': 'Xinghan', 'Initials': 'X', 'LastName': 'Liang', 'Affiliation': 'Department of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230000, Anhui, China.'}, {'ForeName': 'Xiaoqing', 'Initials': 'X', 'LastName': 'Chai', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, Anhui, China. Electronic address: xiaoqingchai@163.com.'}]",Life sciences,['10.1016/j.lfs.2020.118004'] 1603,32622071,Delta-like 1 (DLK1) is a possible mediator of vitamin D effects on bone and energy metabolism.,"Vitamin D effects on bone and mineral metabolism are well recognized, and its anti-inflammatory actions are gaining particular interest. Delta-like 1 (DLK1) is a protein, expressed by progenitor cells of different tissues, and increases the size of progenitor cell population during the inflammatory phase of tissue regeneration. DLK1 also plays a role in energy metabolism as it antagonizes insulin signaling in bone. In this one-year randomized clinical trial of overweight elderly individuals that received either 600 or 3750 IU daily cholecalciferol we assessed the effect of vitamin D supplementation on pre-specified secondary outcomes: DLK1, leptin, adiponectin, C-Reactive Protein (CRP) and Vascular Cell Adhesion Molecule (VCAM). We also examined correlations between DLK1 and bone (BMD, bone markers), fat (adipokines, body composition), insulin sensitivity and inflammatory markers. Multivariate analyses were conducted to further explore these associations. Overall, there was a significant increase in serum DLK1 and leptin and a decrease in VCAM, but no change in CRP, after 12 months of vitamin D supplementation. DLK1 was negatively correlated with BMD and positively correlated with bone markers, associations that persisted after adjusting for age, gender and BMI. DLK1 was also positively associated with indices of insulin resistance and negatively with indices of insulin sensitivity. Correlations between DLK1 and fat parameters, such as adipokines, and DXA derived fat mass were less consistent. There were no correlations between DLK1 and inflammatory markers. In conclusion, twelve months supplementation of vitamin D3 increased serum DLK1. DLK1 was negatively associated with indices of bone health and fuel metabolism, and with 1,25(OH) 2 D levels. Similar to the role of DLK1 in animal models, our findings support the hypothesis that DLK1 can be targeted to regulate bone and energy metabolism and develop drugs to improve BMD and insulin sensitivity. However, further studies are needed to explore the role of DLK1 and its relationship to vitamin D metabolites in vivo.",2020,"Correlations between DLK1 and fat parameters, such as adipokines, and DXA derived fat mass were less consistent.",['overweight elderly individuals'],"['Vitamin D', 'Delta-like 1 (DLK1', '600 or 3750\u202fIU daily cholecalciferol', 'vitamin D supplementation', 'vitamin D3']","['bone health and fuel metabolism, and with 1,25(OH) 2 D levels', 'serum DLK1 and leptin', 'serum DLK1', 'DLK1 and inflammatory markers', 'DLK1', 'BMD and insulin sensitivity', 'leptin, adiponectin, C-Reactive Protein (CRP) and Vascular Cell Adhesion Molecule (VCAM', 'VCAM', 'DLK1and bone (BMD, bone markers), fat (adipokines, body composition), insulin sensitivity and inflammatory markers', 'bone and mineral metabolism', 'insulin resistance and negatively with indices of insulin sensitivity']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C4517746', 'cui_str': '3750'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}]","[{'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0556991', 'cui_str': 'Fuel'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0078056', 'cui_str': 'Lymphocyte antigen CD106'}, {'cui': 'C0181734', 'cui_str': 'Bone marker'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C1955907', 'cui_str': 'Adipokine'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.0714769,"Correlations between DLK1 and fat parameters, such as adipokines, and DXA derived fat mass were less consistent.","[{'ForeName': 'Aya', 'Initials': 'A', 'LastName': 'Bassatne', 'Affiliation': 'Calcium Metabolism and Osteoporosis Program, Division of Endocrinology and Metabolism, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.'}, {'ForeName': 'Abbas', 'Initials': 'A', 'LastName': 'Jafari', 'Affiliation': 'Molecular Endocrinology and Stem Cell Research Unit (KMEB), Department of Endocrinology and Metabolism, Odense University Hospital and Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Cellular and Molecular Medicine, Novo Nordisk Foundation Center for Stem Cell Biology (DanStem), University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Moustapha', 'Initials': 'M', 'LastName': 'Kassem', 'Affiliation': 'Molecular Endocrinology and Stem Cell Research Unit (KMEB), Department of Endocrinology and Metabolism, Odense University Hospital and Department of Clinical Research, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Christos', 'Initials': 'C', 'LastName': 'Mantzoros', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Rahme', 'Affiliation': 'Calcium Metabolism and Osteoporosis Program, Division of Endocrinology and Metabolism, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.'}, {'ForeName': 'Ghada', 'Initials': 'G', 'LastName': 'El-Hajj Fuleihan', 'Affiliation': 'Calcium Metabolism and Osteoporosis Program, Division of Endocrinology and Metabolism, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address: gf01@aub.edu.lb.'}]",Bone,['10.1016/j.bone.2020.115510'] 1604,32650033,Effect of clinical inertia and trial participation in younger and older adults with diabetes having comorbidities and progressive complications.,"AIM Clinical inertia is a multifactorial phenomenon, with contributing factors from people with diabetes and their healthcare team. It is widely cited that clinical inertia is minimised by participation in clinical trials. We assessed whether trial participation per se improves metabolic parameters in people with diabetes, or a specific focus on glycaemia is required. METHODS We compared improvement in glycaemic control in a pooled set of people assigned to the ""placebo"" arm from 25 glycaemia-focused trials with a pooled group of people with diabetes allocated to sham or non-pharmacological intervention for the treatment of diabetic retinal disease. Mean change in HbA1c (ANCOVA) was evaluated. RESULTS The overall placebo effect in studies focused on glucose control (N = 3081) was comparable between strata groups with and without complications. Adjusted least square mean change in HbA1c at 24 weeks was between -0.23% (-2.50 mmol/mol) and -0.32% (-3.50 mmol/mol). In studies focused on retinal disease (N = 288), the change from baseline in HbA1c was +0.10% (1.10 mmol/mol) and fasting plasma glucose was +0.50 mmol/L showing no improvement in metabolic parameters at 12 months. CONCLUSIONS Clinical trial participation alone does not seem to improve metabolic parameters in people living with diabetes. The benefits observed in glycaemia-focused studies were independent of age and comorbidities.",2020,The overall placebo effect in studies focused on glucose control (N=3081) was comparable between strata groups with and without complications.,"['people with diabetes and their healthcare team', 'people with diabetes', 'younger and older adults with diabetes having comorbidities and progressive complications', 'people living with diabetes']","['sham or non-pharmacological intervention', 'placebo']","['metabolic parameters', 'fasting plasma glucose', 'Mean change in HbA1c (ANCOVA']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0086390', 'cui_str': 'Health Care Team'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}]","[{'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]",,0.202893,The overall placebo effect in studies focused on glucose control (N=3081) was comparable between strata groups with and without complications.,"[{'ForeName': 'William David', 'Initials': 'WD', 'LastName': 'Strain', 'Affiliation': 'University of Exeter Medical School, Exeter, United Kingdom; Academic Department of Healthcare for the Elderly, Royal Devon & Exeter NHS Foundation Trust, Exeter, United Kingdom. Electronic address: d.strain@exeter.ac.uk.'}, {'ForeName': 'Päivi Maria', 'Initials': 'PM', 'LastName': 'Paldánius', 'Affiliation': ""Children's Hospital, Helsinki University Hospital, Helsinki, Finland; Program for Clinical and Molecular Metabolism, Helsinki University, Helsinki, Finland.""}]",Diabetes research and clinical practice,['10.1016/j.diabres.2020.108310'] 1605,32650771,Validation of the effectiveness of a digital integrated healthcare platform utilizing an AI-based dietary management solution and a real-time continuous glucose monitoring system for diabetes management: a randomized controlled trial.,"BACKGROUND Despite the numerous healthcare smartphone applications for self-management of diabetes, patients often fail to use these applications consistently due to various limitations, including difficulty in inputting dietary information by text search and inconvenient and non-persistent self-glucose measurement by home glucometer. We plan to apply a digital integrated healthcare platform using an artificial intelligence (AI)-based dietary management solution and a continuous glucose monitoring system (CGMS) to overcome those limitations. Furthermore, medical staff will be performing monitoring and intervention to encourage continuous use of the program. The aim of this trial is to examine the efficacy of the program in patients with type 2 diabetes mellitus (T2DM) who have HbA1c 53-69 mmol/mol (7.0-8.5%) and body mass index (BMI) ≥ 23 mg/m 2 . METHODS This is a 48-week, open-label, randomized, multicenter trial consisting of patients with type 2 diabetes. The patients will be randomly assigned to three groups: control group A will receive routine diabetes care; experimental group B will use the digital integrated healthcare platform by themselves without feedback; and experimental group C will use the digital integrated healthcare platform with continuous glucose monitoring and feedback from medical staff. There are five follow-up measures: baseline and post-intervention at weeks 12, 24, 36, and 48. The primary end point is change in HbA1c from baseline to six months after the intervention. DISCUSSION This trial will verify the effectiveness of a digital integrated healthcare platform with an AI-driven dietary solution and a real-time CGMS in patients with T2DM. TRIAL REGISTRATION Clinicaltrials.gov NCT04161170, registered on 08 November 2019. https://clinicaltrials.gov/ct2/show/NCT04161170?term=NCT04161170&draw=2&rank=1.",2020,"There are five follow-up measures: baseline and post-intervention at weeks 12, 24, 36, and 48.","['diabetes management', 'registered on 08 November 2019', 'patients with type 2 diabetes mellitus (T2DM) who have HbA1c 53-69\u2009mmol/mol (7.0-8.5%) and body mass index (BMI)\u2009≥\u200923\u2009mg/m 2 .\nMETHODS', 'patients with type 2 diabetes', 'patients with T2DM']","['digital integrated healthcare platform utilizing an AI-based dietary management solution and a real-time continuous glucose monitoring system', 'control group A will receive routine diabetes care; experimental group B will use the digital integrated healthcare platform by themselves without feedback; and experimental group C will use the digital integrated healthcare platform with continuous glucose monitoring and feedback from medical staff', 'digital integrated healthcare platform with an AI-driven dietary solution', 'digital integrated healthcare platform using an artificial intelligence (AI)-based dietary management solution and a continuous glucose monitoring system (CGMS']",['change in HbA1c'],"[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mol'}, {'cui': 'C4517877', 'cui_str': '8.5'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0003916', 'cui_str': 'Computer Reasoning'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0012160', 'cui_str': 'nutritional management'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C0042950', 'cui_str': 'Volition'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0025106', 'cui_str': 'Medical Staffs'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]",,0.0666465,"There are five follow-up measures: baseline and post-intervention at weeks 12, 24, 36, and 48.","[{'ForeName': 'Sung Woon', 'Initials': 'SW', 'LastName': 'Park', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Gyuri', 'Initials': 'G', 'LastName': 'Kim', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'You-Cheol', 'Initials': 'YC', 'LastName': 'Hwang', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Woo Je', 'Initials': 'WJ', 'LastName': 'Lee', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Hyunjin', 'Initials': 'H', 'LastName': 'Park', 'Affiliation': 'Amazing Food Solution, Inc., Seoul, South Korea.'}, {'ForeName': 'Jae Hyeon', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. jaehyeon@skku.edu.'}]",BMC medical informatics and decision making,['10.1186/s12911-020-01179-x'] 1606,32652092,A double-blind randomized trial comparing lidocaine spray and placebo spray anesthesia prior to cervical laminaria insertion.,"OBJECTIVE To compare pain during laminaria insertion after lidocaine spray versus placebo spray anesthesia in women about to undergo a surgical abortion procedure. STUDY DESIGN A double blind, randomized, placebo-controlled trial of women at 12-24 weeks gestation one day prior to surgical uterine evacuation procedure. Participants received lidocaine 10% or placebo (saline 0.9%) spray to the endocervix and ectocervix two minutes before laminaria insertion. The primary outcome was participants' pain score immediately after initial laminaria insertion, measured using a 10 cm visual analog scale (VAS). Secondary outcomes included scores at speculum removal and 15 min after speculum insertion. RESULTS From 7/2016 through 8/2018, we enrolled 68 and 66 women to the lidocaine and placebo groups, respectively. Baseline characteristics were similar in both groups. The primary outcome did not differ between lidocaine and placebo groups (median VAS 2.0 vs. 2.0 respectively, p = 0.69). Reported VAS after speculum removal and 15 min from speculum insertion were similar in the lidocaine and placebo groups (median 2.0, p = 0.99; median 1.0 vs. 1.5 respectively, p = 0.32). In multivariate analyses, lidocaine use was associated with decreased VAS score at 15 min from speculum insertion [95%CI -0.96 (-1.74 to -0.18), p = 0.016]. Reported VAS ≥7 at 1st laminaria insertion did not differ between lidocaine and placebo groups (5.88% vs. 10.61% respectively, p = 0.362). CONCLUSION In women scheduled for laminaria insertion prior to surgical uterine evacuation at 12-24 weeks gestation, topical application of lidocaine spray to the cervix before insertion did not result in lower reported pain as compared with placebo. IMPLICATIONS Our results imply that physicians should not use topical application of lidocaine spray to the cervix before laminaria insertion to reduce women's pain. Continued efforts must be made to find means to relieve pain by using simple, effective analgesia or adjusting the technique, and not using a tenaculum whenever possible.",2020,"The primary outcome did not differ between lidocaine and placebo groups (median VAS 2.0 vs. 2.0 respectively, p=0.69).","['women at 12-24 weeks gestation one day prior to surgical uterine evacuation procedure', 'women about to undergo a surgical abortion procedure']","['lidocaine spray versus placebo spray anesthesia', 'lidocaine and placebo', 'lidocaine', 'lidocaine 10% or placebo (saline 0.9%) spray to the endocervix and ectocervix two minutes before laminaria insertion', 'lidocaine spray and placebo spray anesthesia', 'lidocaine spray', 'placebo']","['scores at speculum removal and 15 minutes after speculum insertion', 'pain score immediately after initial laminaria insertion, measured using a 10 cm visual analog scale (VAS', 'VAS score']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C1282573', 'cui_str': 'Evacuation procedure'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C4068881', 'cui_str': '0.9'}, {'cui': 'C0227837', 'cui_str': 'Endocervical structure'}, {'cui': 'C0227829', 'cui_str': 'Exocervical structure'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0022980', 'cui_str': 'Laminaria'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0037816', 'cui_str': 'Speculum'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C1442447', 'cui_str': 'Fifteen minutes'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0022980', 'cui_str': 'Laminaria'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",68.0,0.786929,"The primary outcome did not differ between lidocaine and placebo groups (median VAS 2.0 vs. 2.0 respectively, p=0.69).","[{'ForeName': 'Raanan', 'Initials': 'R', 'LastName': 'Meyer', 'Affiliation': 'The Department of Obstetrics and Gynecology, the Chaim Sheba Medical Center, Ramat-Gan, Israel; The Dr. Pinchas Bornstein Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel. Electronic address: raananmeir@gmail.com.'}, {'ForeName': 'Tal', 'Initials': 'T', 'LastName': 'Cahan', 'Affiliation': 'The Department of Obstetrics and Gynecology, the Chaim Sheba Medical Center, Ramat-Gan, Israel.'}, {'ForeName': 'Itai', 'Initials': 'I', 'LastName': 'Yagel', 'Affiliation': 'The Department of Obstetrics and Gynecology, the Chaim Sheba Medical Center, Ramat-Gan, Israel.'}, {'ForeName': 'Arnon', 'Initials': 'A', 'LastName': 'Afek', 'Affiliation': 'The Chaim Sheba Medical Center, Ramat-Gan, Israel; The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.'}, {'ForeName': 'Estela', 'Initials': 'E', 'LastName': 'Derazne', 'Affiliation': 'The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.'}, {'ForeName': 'Yochai', 'Initials': 'Y', 'LastName': 'Bar-Shavit', 'Affiliation': 'The Department of Obstetrics and Gynecology, the Chaim Sheba Medical Center, Ramat-Gan, Israel; The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.'}, {'ForeName': 'Yefet', 'Initials': 'Y', 'LastName': 'Yuval', 'Affiliation': 'The Department of Obstetrics and Gynecology, the Chaim Sheba Medical Center, Ramat-Gan, Israel; The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.'}, {'ForeName': 'Dahlia', 'Initials': 'D', 'LastName': 'Admon', 'Affiliation': 'The Department of Obstetrics and Gynecology, the Chaim Sheba Medical Center, Ramat-Gan, Israel; The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.'}, {'ForeName': 'Avi', 'Initials': 'A', 'LastName': 'Shina', 'Affiliation': 'The Department of Obstetrics and Gynecology, the Chaim Sheba Medical Center, Ramat-Gan, Israel; The Dr. Pinchas Bornstein Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel.'}]",Contraception,['10.1016/j.contraception.2020.07.002'] 1607,32657740,Water-wise hand preparation - the true impact of our practice: A controlled before-and-after study.,"BACKGROUND South Africa (SA) and other countries worldwide are experiencing extreme drought conditions. Since the start of the drought in SA, many ways of saving water have been proposed and innovative water-saving mechanisms have become part of the lives of communities. We investigated water use during surgical scrubbing procedures and possible interventions to reduce water consumption. OBJECTIVES To compare water use during surgical hand preparation before and after the implementation of specific water-saving interventions. METHODS This was a non-randomised controlled study, following a before-and-after design, of orthopaedic theatre personnel scrubbing for surgical cases at Tygerberg Hospital, Cape Town. A control (CON) group (n=32) was established to observe standard practice for baseline measurements including total amount of water used, wash time and water flow rate during surgical hand preparation. After this, three interventions were randomly assigned to a single theatre each, where the same variables were measured. Intervention AS entailed using an alcohol scrub (n=18), intervention SN (n=12) had a dedicated assistant to open and close taps during scrubbing, and intervention SW (n=12) made use of adjusted tap levers to allow the surgeon to open and close taps more easily. Analysis of variance was used to detect global differences between groups, and Tukey's post hoc test was performed to detect differences between groups. RESULTS Significant differences in water use (p<0.001), wash time (p<0.001) and water flow rate (p<0.001) were observed between the four groups. On average, the AS group used the least water per scrub (mean (standard deviation) 0.82 (1.43) L), which was significantly less than the CON (5.56 (1.79) L; p<0.001) and SN (2.29 (0.37) L; p=0.002) groups. The amount of time spent per scrub was significantly less in the AS group than all the other groups (p<0.05 for all comparisons), with no significant differences observed between the CON, SN and SW groups independently. The SW group had the lowest mean water flow rate (0.73 (0.22) L/min), which was significantly lower than the CON group (2.19 (0.84) L/min; p<0.001). The flow rate of the SN group (1.36 (0.66) L/min) was also significantly lower than that of the CON group (p=0.005). CONCLUSIONS Water use during surgical hand preparation can easily be reduced by implementing easy and effective interventions. The practicality of interventions may differ between institutions, and their acceptance by surgical staff is important to ensure compliance. However, ensuring that alternative scrubbing options are available to surgical staff would equate to substantial savings over time.",2020,"RESULTS Significant differences in water use (p<0.001), wash time (p<0.001) and water flow rate (p<0.001) were observed between the four groups.","['surgical cases at Tygerberg Hospital, Cape Town']","['alcohol scrub (n=18), intervention SN (n=12) had a dedicated assistant to open and close taps during scrubbing, and intervention SW (n=12) made use of adjusted tap levers to allow the surgeon to open and close taps more easily', 'control (CON', 'CON', 'orthopaedic theatre personnel scrubbing']","['flow rate', 'water flow rate', 'lowest mean water flow rate', 'amount of time spent per scrub']","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0054434', 'cui_str': 'caffeic acid phenethyl ester'}, {'cui': 'C0557750', 'cui_str': 'Town environment'}]","[{'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C2946035', 'cui_str': 'Scrubs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0011327', 'cui_str': 'Dental assistant'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0034115', 'cui_str': 'Centesis'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0332219', 'cui_str': 'Easy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0475307', 'cui_str': 'Theatre'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}]","[{'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C2946035', 'cui_str': 'Scrubs'}]",,0.0399163,"RESULTS Significant differences in water use (p<0.001), wash time (p<0.001) and water flow rate (p<0.001) were observed between the four groups.","[{'ForeName': 'M S W', 'Initials': 'MSW', 'LastName': 'Potgieter', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. Mswpot@yahoo.com.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Faisal', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ikram', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Burger', 'Affiliation': ''}]",South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,['10.7196/SAMJ.2020.v110i4.14044'] 1608,32653539,The management of diabetes in everyday life study: Design and methods for a pragmatic randomized controlled trial comparing the effectiveness of text messaging versus health coaching.,"Background African American patients with uncontrolled diabetes living in medically underserved areas need effective clinic-based interventions to improve self-care behaviors. Text messaging (TM) and health coaching (HC) are among the most promising low-cost population-based approaches, but little is known about their comparative effectiveness in real-world clinical settings. Objective Use a pragmatic randomized controlled trial design to determine the comparative effectiveness of TM and HC with enhanced usual care (EC) in African American adults with uncontrolled diabetes and multiple chronic health conditions. Methods/design The Management of Diabetes in Everyday Life (MODEL) study is randomizing 646 patients (n = 581with anticipated 90% retention) to 3 intervention arms: TM, HC, and EC. Participants are African American adults living in medically underserved areas of the Mid-South, age ≥ 18, with uncontrolled diabetes (A1c ≥ 8), one or more additional chronic conditions, and who have a phone with texting and voicemail capability. Primary outcome measures: the general diet, exercise, and medication adherence subscales of the revised Summary of Diabetes Self-Care Activities questionnaire assessed at one year. Secondary outcomes: diabetes-specific quality of life, primary care engagement, and average blood sugar (A1c). The study will also assess heterogeneity of treatment effects by six key baseline participant characteristics. Conclusions We describe the design and methods of the MODEL study along with design revisions required during implementation in a pragmatic setting. This trial, upon its conclusion, will allow us to compare the effectiveness of two promising low-cost primary care-based strategies for supporting self-care behaviors among African Americans individuals with uncontrolled diabetes. ClinicalTrials.gov registration number: NCT02957513.",2020,"Secondary outcomes: diabetes-specific quality of life, primary care engagement, and average blood sugar (A1c).","['African American adults with uncontrolled diabetes and multiple chronic health conditions', ' African American patients with uncontrolled diabetes living in medically underserved areas', 'Participants are African American adults living in medically underserved areas of the Mid-South, age ≥ 18, with uncontrolled diabetes (A1c ≥ 8), one or more additional chronic conditions, and who have a phone with texting and voicemail capability', '646 patients (n\u202f=\u202f581with anticipated 90% retention) to 3 intervention arms: TM, HC, and EC', 'African Americans individuals with uncontrolled diabetes']","['Text messaging (TM) and health coaching (HC', 'text messaging versus health coaching', 'TM and HC with enhanced usual care (EC']","['diabetes-specific quality of life, primary care engagement, and average blood sugar (A1c', 'general diet, exercise, and medication adherence subscales of the revised Summary of Diabetes Self-Care Activities questionnaire assessed at one year']","[{'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C3266262', 'cui_str': 'Multiple chronic diseases'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0025112', 'cui_str': 'Area, Medically Underserved'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}]","[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}, {'cui': 'C0301563', 'cui_str': 'General diet'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C4082117', 'cui_str': 'One year'}]",646.0,0.105121,"Secondary outcomes: diabetes-specific quality of life, primary care engagement, and average blood sugar (A1c).","[{'ForeName': 'James E', 'Initials': 'JE', 'LastName': 'Bailey', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; Division of General Internal Medicine, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America. Electronic address: jeb@uthsc.edu.'}, {'ForeName': 'Satya', 'Initials': 'S', 'LastName': 'Surbhi', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; Division of General Internal Medicine, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Gatwood', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Butterworth', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; Q-consult, LLC, St. Petersburg, FL, United States of America.'}, {'ForeName': 'Mace', 'Initials': 'M', 'LastName': 'Coday', 'Affiliation': 'Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Sohul A', 'Initials': 'SA', 'LastName': 'Shuvo', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; Institute for Health Outcomes and Policy, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Ankur A', 'Initials': 'AA', 'LastName': 'Dashputre', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; Institute for Health Outcomes and Policy, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Brooks', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; Department of Surgery, Anne Arundel Medical Center, Annapolis, MD, United States of America.'}, {'ForeName': 'Bonnie L', 'Initials': 'BL', 'LastName': 'Binkley', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Carrie Jo', 'Initials': 'CJ', 'LastName': 'Riordan', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Helmut O', 'Initials': 'HO', 'LastName': 'Steinberg', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; Division of Endocrinology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Mary Lou', 'Initials': 'ML', 'LastName': 'Gutierrez', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'Haley', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Cardella L', 'Initials': 'CL', 'LastName': 'Leak', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Tolley', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106080'] 1609,32621368,A pilot randomized controlled trial of assertive treatment including family involvement and home delivery of medication for young adults with opioid use disorder.,"BACKGROUND AND AIMS Although medications for opioid use disorder (OUD), including extended-release naltrexone (XR-NTX), have demonstrated effectiveness, adherence is often low. We tested the preliminary efficacy of youth opioid recovery support (YORS), a multi-component intervention designed to improve engagement and medication adherence for young adults with OUD. DESIGN Single-site randomized controlled trial with 24-week follow-up. SETTING Community substance use disorder treatment program in Baltimore, MD, USA. PARTICIPANTS Young adults aged 18-26 years enrolled in inpatient/residential OUD treatment intending to pursue outpatient OUD treatment with XR-NTX. Twenty-one participants were randomized to YORS and 20 to treatment as usual (TAU). The analyzed sample was 65.8% male. INTERVENTION AND COMPARATOR Components of YORS include: (1) home delivery of XR-NTX; (2) family engagement; (3) assertive outreach; and (4) contingency management for receipt of XR-NTX doses. The comparator was TAU, which consisted of a standard referral to outpatient care following an inpatient stay. MEASUREMENTS Primary outcomes were number of XR-NTX doses received over 24 weeks and relapse to opioid use (defined as ≥ 10 days of use within 28 days) at 24 weeks. FINDINGS Participants in the YORS condition received more XR-NTX doses [mean = 4.28; standard deviation (SD) = 2.3] compared with those in TAU (mean = 0.70; SD = 1.2), P < 0.01. Participants in the YORS group compared with TAU had lower rates of relapse (61 versus 95%; P < 0.01). Survival analyses revealed group differences on time to relapse with participants in TAU being more likely to relapse sooner compared with participants in the YORS condition [hazard ratio (HR) = 2.72, 95% confidence interval (CI) = 1.26-5.88, P < 0.01]. CONCLUSIONS The youth opioid recovery support intervention for extended-release naltrexone adherence and opioid relapse prevention among young adults with opioid use disorder appeared to improve treatment and relapse outcomes compared with standard treatment.",2020,"Survival analyses revealed group differences on time to relapse with participants in TAU being more likely to relapse sooner compared with participants in the YORS condition (HR 2.72, 95% CI 1.26-5.88, p< .01). ","['young adults with opioid use disorder', 'Young adults aged 18-26 years enrolled in inpatient/residential OUD treatment intending to pursue outpatient OUD treatment with XR-NTX', 'young adults with OUD', 'Community substance use disorder treatment program in Baltimore, Maryland, USA']","['YORS', 'naltrexone (XR-NTX', 'XR-NTX', 'assertive treatment including family involvement and home delivery of medication', 'Youth Opioid Recovery Support (YORS']","['time to relapse', 'rates of relapse', 'number of XR-NTX doses received over 24 weeks and relapse to opioid use', 'engagement and medication adherence']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0038586', 'cui_str': 'Substance use disorder'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0004716', 'cui_str': 'Baltimore'}, {'cui': 'C0024858', 'cui_str': 'Maryland'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0019857', 'cui_str': 'Home birth'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}]",21.0,0.137624,"Survival analyses revealed group differences on time to relapse with participants in TAU being more likely to relapse sooner compared with participants in the YORS condition (HR 2.72, 95% CI 1.26-5.88, p< .01). ","[{'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Fishman', 'Affiliation': 'Mountain Manor Treatment Center,, Baltimore, MD, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Wenzel', 'Affiliation': 'Mountain Manor Treatment Center,, Baltimore, MD, USA.'}, {'ForeName': 'Hoa', 'Initials': 'H', 'LastName': 'Vo', 'Affiliation': 'Mountain Manor Treatment Center,, Baltimore, MD, USA.'}, {'ForeName': 'Jared', 'Initials': 'J', 'LastName': 'Wildberger', 'Affiliation': 'Mountain Manor Treatment Center,, Baltimore, MD, USA.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Burgower', 'Affiliation': 'Mountain Manor Treatment Center,, Baltimore, MD, USA.'}]","Addiction (Abingdon, England)",['10.1111/add.15181'] 1610,32622294,The effects of yoga on functionality appreciation and additional facets of positive body image.,"This study investigated the effects of yoga on functionality appreciation, and the potential mechanisms that could explain the impact of yoga on additional facets of positive body image. Young adult women (N = 114; M age  = 22.19) were randomised to a 10-week Hatha yoga programme or waitlist control group. Participants completed measures of functionality appreciation, body appreciation, body compassion, appearance evaluation, self-objectification, and embodiment at Pretest, Midtest, Posttest, and 1-month Follow-Up. Follow-up data could not be analysed due to high levels of attrition. The remaining data showed that, compared to the control group, women in the yoga programme experienced lower self-objectification at Midtest and greater embodiment over time. Further, all participants experienced improvements in body appreciation, body compassion, and appearance evaluation over time, regardless of their assigned group. Lower self-objectification contributed to improvements in body appreciation and body compassion. In addition, greater embodiment contributed to improvements in body appreciation, body compassion, and appearance evaluation. Contrary to our expectations, yoga did not lead to increased functionality appreciation, nor was functionality appreciation a mediator of the impact of yoga on positive body image. Instead, lower self-objectification, and greater embodiment, drove improvements in positive body image.",2020,"The remaining data showed that, compared to the control group, women in the yoga programme experienced lower self-objectification at Midtest and greater embodiment over time.",['Young adult women (N\u202f=\u202f114; M age \u202f=\u202f22.19'],['Hatha yoga programme or waitlist control group'],"['body appreciation and body compassion', 'functionality appreciation, body appreciation, body compassion, appearance evaluation, self-objectification, and embodiment at Pretest, Midtest, Posttest, and 1-month Follow-Up', 'body appreciation, body compassion, and appearance evaluation']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]",,0.0268438,"The remaining data showed that, compared to the control group, women in the yoga programme experienced lower self-objectification at Midtest and greater embodiment over time.","[{'ForeName': 'Jessica M', 'Initials': 'JM', 'LastName': 'Alleva', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, Maastricht, the Netherlands. Electronic address: Jessica.Alleva@maastrichtuniversity.nl.'}, {'ForeName': 'Tracy L', 'Initials': 'TL', 'LastName': 'Tylka', 'Affiliation': 'Department of Psychology, The Ohio State University, Columbus, OH, United States.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'van Oorsouw', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Montanaro', 'Affiliation': 'Department of Psychology, The University of North Carolina at Charlotte, Charlotte, NC, United States.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Perey', 'Affiliation': 'Chair of Sport and Health Management, Technical University of Munich, Germany.'}, {'ForeName': 'Cheyenne', 'Initials': 'C', 'LastName': 'Bolle', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Jantine', 'Initials': 'J', 'LastName': 'Boselie', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Madelon', 'Initials': 'M', 'LastName': 'Peters', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Jennifer B', 'Initials': 'JB', 'LastName': 'Webb', 'Affiliation': 'Department of Psychology, The University of North Carolina at Charlotte, Charlotte, NC, United States.'}]",Body image,['10.1016/j.bodyim.2020.06.003'] 1611,32627277,Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review.,"The Polyneuropathy And Treatment with Hizentra (PATH) study required subjects with chronic inflammatory demyelinating polyneuropathy (CIDP) to show dependency on immunoglobulin G (IgG) and then be restabilized on IgG before being randomized to placebo or one of two doses of subcutaneous immunoglobulin (SCIG). Nineteen of the 51 subjects (37%) randomized to placebo did not relapse over the next 24 weeks. This article explores the reasons for this effect. A post-hoc analysis of the PATH placebo group was undertaken. A literature search identified other placebo-controlled CIDP trials for review and comparison. In PATH, subjects randomized to placebo who did not relapse were significantly older, had more severe disease, and took longer to deteriorate in the IgG dependency period compared with those who relapsed. Published trials in CIDP, whose primary endpoint was stability or deterioration, had a mean non-deterioration (placebo effect) of 43%, while trials with a primary endpoint of improvement had a placebo response of only 11%. Placebo is an important variable in the design of CIDP trials. Trials designed to show clinical improvement will have a significantly lower effect of this phenomenon than those designed to show stability or deterioration.",2020,Trials designed to show clinical improvement will have a significantly lower effect of this phenomenon than those designed to show stability or deterioration.,"['Nineteen of the 51 subjects (37%) randomized to', 'Chronic Inflammatory Demyelinating Polyneuropathy', 'subjects with chronic inflammatory demyelinating polyneuropathy (CIDP) to show dependency on immunoglobulin G (IgG) and then be restabilized on IgG before being randomized to']","['subcutaneous immunoglobulin (SCIG', 'Placebo', 'PATH placebo', 'placebo']",['stability or deterioration'],"[{'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0393819', 'cui_str': 'Chronic inflammatory demyelinating polyradiculoneuropathy'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0270922', 'cui_str': 'Peripheral demyelinating neuropathy'}, {'cui': 'C0011546', 'cui_str': 'Dependency, Psychology'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0021027', 'cui_str': 'Immunoglobulin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205360', 'cui_str': 'Stable'}]",51.0,0.638825,Trials designed to show clinical improvement will have a significantly lower effect of this phenomenon than those designed to show stability or deterioration.,"[{'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Lewis', 'Affiliation': 'Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, California, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Cornblath', 'Affiliation': 'Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Hans-Peter', 'Initials': 'HP', 'LastName': 'Hartung', 'Affiliation': 'Department of Neurology, UKD and Center for Neurology and Neuropsychiatry, LVR Klinikum, Heinrich Heine University, Düsseldorf, Germany.'}, {'ForeName': 'Gens', 'Initials': 'G', 'LastName': 'Sobue', 'Affiliation': 'Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.'}, {'ForeName': 'John-Philip', 'Initials': 'JP', 'LastName': 'Lawo', 'Affiliation': 'CSL Behring, Marburg, King of Prussia, Pennsylvania, USA.'}, {'ForeName': 'Orell', 'Initials': 'O', 'LastName': 'Mielke', 'Affiliation': 'CSL Behring, Marburg, King of Prussia, Pennsylvania, USA.'}, {'ForeName': 'Billie L', 'Initials': 'BL', 'LastName': 'Durn', 'Affiliation': 'CSL Behring, Marburg, King of Prussia, Pennsylvania, USA.'}, {'ForeName': 'Vera', 'Initials': 'V', 'LastName': 'Bril', 'Affiliation': 'Ellen and Martin Prosserman Centre for Neuromuscular Diseases, Division of Neurology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Ingemar S J', 'Initials': 'ISJ', 'LastName': 'Merkies', 'Affiliation': 'Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Bassett', 'Affiliation': 'Meridian HealthComms Ltd, Manchester, UK.'}, {'ForeName': 'Alexa', 'Initials': 'A', 'LastName': 'Cleasby', 'Affiliation': 'Meridian HealthComms Ltd, Manchester, UK.'}, {'ForeName': 'Ivo N', 'Initials': 'IN', 'LastName': 'van Schaik', 'Affiliation': 'Department of Neurology, Amsterdam University Medical Centres, Amsterdam, The Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of the peripheral nervous system : JPNS,['10.1111/jns.12402'] 1612,32627812,Systemic arterial hypertension and cognition in adults: effects on executive functioning.,"BACKGROUND Central nervous system changes associated to systemic arterial hypertension (SAH) are progressive and may cause negative effects on cognitive performance. The objective of this study was to investigate the relation between SAH and the components of executive functions (EF), inhibitory control (IC), updating and shifting, comparing a control group (without SAH) to patients with SAH, in two levels of severity. METHODS The protocol included the following tests to evaluate EF components: T.O.V.A. Test (IC), Backward Digit Span from Wechsler Adults Intelligence Scale (WAIS-III), Phonemic and Semantic Verbal Fluency (updating), and Trail Making Test Part B (shifting). RESULTS A total of 204 participants was included: 56 from the Control Group (CG), 87 SAH stage 1, and 61 SAH stage 2. The groups were not different for age (52.37±12.29) and education (10.98±4.06). As to controlled blood pressure (BP), duration of hypertension treatment and number of drugs, the SAH 2 group had a worse BP control, longer duration of hypertension treatment and use of more drugs when compared to the SAH 1. The findings revealed that patients with more severe hypertension presented worse performance in updating (Backward Digit Span, phonemic and semantics VF) and shifting (Trail Making Test Part B). CONCLUSION The results suggest that patients with SAH have a significant impairment in EF, more specifically in updating and shifting. Besides that, such damage may be directly proportional to the severity of SAH. It is suggested that future studies include neuroimaging exams to exclude possible cerebrovascular diseases.",2020,"The findings revealed that patients with more severe hypertension presented worse performance in updating (Backward Digit Span, phonemic and semantics VF) and shifting (Trail Making Test Part B). ","['patients with SAH, in two levels of severity', 'patients with SAH', 'adults', '204 participants was included: 56 from the Control Group (CG), 87 SAH stage 1, and 61 SAH stage 2']",[],"['Test (IC), Backward Digit Span from Wechsler Adults Intelligence Scale (WAIS-III), Phonemic and Semantic Verbal Fluency (updating), and Trail Making Test Part B (shifting', 'controlled blood pressure (BP), duration of hypertension treatment and number of drugs', 'executive functions (EF), inhibitory control (IC), updating and shifting', 'performance in updating (Backward Digit Span, phonemic and semantics VF) and shifting (Trail Making Test Part B', 'Systemic arterial hypertension and cognition']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}]",[],"[{'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439781', 'cui_str': 'Backward'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0204456', 'cui_str': 'Wechsler adult intelligence scale'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0036612', 'cui_str': 'Semantics'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0578998', 'cui_str': 'On treatment for hypertension'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0333051', 'cui_str': 'Shift'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",204.0,0.0402133,"The findings revealed that patients with more severe hypertension presented worse performance in updating (Backward Digit Span, phonemic and semantics VF) and shifting (Trail Making Test Part B). ","[{'ForeName': 'Natália Cristina', 'Initials': 'NC', 'LastName': 'Moraes', 'Affiliation': 'Department of Neurology, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Henrique Cotchi Simbo', 'Initials': 'HCS', 'LastName': 'Muela', 'Affiliation': 'Department of Physiology, Faculty of Medicine, Universidade Agostinho Neto, Luanda, Angola.'}, {'ForeName': 'Claudia Maia', 'Initials': 'CM', 'LastName': 'MemÓria', 'Affiliation': 'Department of Neurology, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Valéria Aparecida da', 'Initials': 'VAD', 'LastName': 'Costa-Hong', 'Affiliation': 'Heart Institute, Hypertension Unit, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Michel Ferreira', 'Initials': 'MF', 'LastName': 'Machado', 'Affiliation': 'Heart Institute, Hypertension Unit, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Mario Amore', 'Initials': 'MA', 'LastName': 'Cechinhi', 'Affiliation': 'Department of Neurology, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Nitrini', 'Affiliation': 'Department of Neurology, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Luiz Aparecido', 'Initials': 'LA', 'LastName': 'Bortolotto', 'Affiliation': 'Heart Institute, Hypertension Unit, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Monica Sanches', 'Initials': 'MS', 'LastName': 'Yassuda', 'Affiliation': 'Department of Neurology, Universidade de São Paulo, São Paulo, SP, Brazil.'}]",Arquivos de neuro-psiquiatria,['10.1590/0004-282x20200039'] 1613,32628115,Evaluation of Adaptive Feedback in a Smartphone-Based Game on Health Care Providers' Learning Gain: Randomized Controlled Trial.,"BACKGROUND Although smartphone-based emergency care training is more affordable than traditional avenues of training, it is still in its infancy, remains poorly implemented, and its current implementation modes tend to be invariant to the evolving learning needs of the intended users. In resource-limited settings, the use of such platforms coupled with gamified approaches remains largely unexplored, despite the lack of traditional training opportunities, and high mortality rates in these settings. OBJECTIVE The primary aim of this randomized experiment is to determine the effectiveness of offering adaptive versus standard feedback, on the learning gains of clinicians, through the use of a smartphone-based game that assessed their management of a simulated medical emergency. A secondary aim is to examine the effects of learner characteristics and learning spacing with repeated use of the game on the secondary outcome of individualized normalized learning gain. METHODS The experiment is aimed at clinicians who provide bedside neonatal care in low-income settings. Data were captured through an Android app installed on the study participants' personal phones. The intervention, which was based on successful attempts at a learning task, included adaptive feedback provided within the app to the experimental arm, whereas the control arm received standardized feedback. The primary end point was completion of the second learning session. Of the 572 participants enrolled between February 2019 and July 2019, 247 (43.2%) reached the primary end point. The primary outcome was standardized relative change in learning gains between the study arms as measured by the Morris G effect size. The secondary outcomes were the participants individualized normalized learning gains. RESULTS The effect of adaptive feedback on care providers' learning gain was found to be g=0.09 (95% CI -0.31 to 0.46; P=.47). In exploratory analysis, using normalized learning gains, when subject-treatment interaction and differential time effect was controlled for, this effect increased significantly to 0.644 (95% CI 0.35 to 0.94; P<.001) with immediate repetition, which is a moderate learning effect, but reduced significantly by 0.28 after a week. The overall learning change from the app use in both arms was large and may have obscured a direct effect of feedback. CONCLUSIONS There is a considerable learning gain between the first two rounds of learning with both forms of feedback and a small added benefit of adaptive feedback after controlling for learner differences. We suggest that linking the adaptive feedback provided to care providers to how they space their repeat learning session(s) may yield higher learning gains. Future work might explore in more depth the feedback content, in particular whether or not explanatory feedback (why answers were wrong) enhances learning more than reflective feedback (information about what the right answers are). TRIAL REGISTRATION Pan African Clinical Trial Registry (PACTR) 201901783811130; https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=5836. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR2-10.2196/13034.",2020,"The primary aim of this randomized experiment is to determine the effectiveness of offering adaptive versus standard feedback, on the learning gains of clinicians, through the use of a smartphone-based game that assessed their management of a simulated medical emergency.","[""Health Care Providers' Learning Gain"", '572 participants enrolled between February 2019 and July 2019, 247 (43.2%) reached the primary end point']","['adaptive feedback', 'smartphone-based emergency care training']","['overall learning change', 'learning gain', ""care providers' learning gain"", 'completion of the second learning session', 'individualized normalized learning gains', 'standardized relative change in learning gains']","[{'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0444930', 'cui_str': 'End'}]","[{'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013961', 'cui_str': 'Emergency medical services'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",572.0,0.0972468,"The primary aim of this randomized experiment is to determine the effectiveness of offering adaptive versus standard feedback, on the learning gains of clinicians, through the use of a smartphone-based game that assessed their management of a simulated medical emergency.","[{'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Tuti', 'Affiliation': 'Kellogg College, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Niall', 'Initials': 'N', 'LastName': 'Winters', 'Affiliation': 'Kellogg College, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Hilary', 'Initials': 'H', 'LastName': 'Edgcombe', 'Affiliation': 'Nuffield Division of Anaesthetics, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Muinga', 'Affiliation': 'KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.'}, {'ForeName': 'Conrad', 'Initials': 'C', 'LastName': 'Wanyama', 'Affiliation': 'KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'English', 'Affiliation': 'KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Paton', 'Affiliation': 'Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.'}]",Journal of medical Internet research,['10.2196/17100'] 1614,32628117,"Use of an Unguided, Web-Based Distress Self-Management Program After Breast Cancer Diagnosis: Sub-Analysis of CaringGuidance Pilot Study.","BACKGROUND Unguided, web-based psychoeducational interventions are gaining interest as a way to reach patients while reducing pressure on clinical resources. However, there has been little research on how patients with cancer use these interventions. OBJECTIVE The objective of this analysis was to evaluate how women newly diagnosed with breast cancer used the unguided web-based, psychoeducational distress self-management program CaringGuidance After Breast Cancer Diagnosis while enrolled in a pilot feasibility study. METHODS Women with stage 0 to II breast cancer diagnosed within the prior three months were recruited from clinics primarily in the Northeastern United States for participation in a 12-week pilot study of CaringGuidance plus usual care versus usual care alone. Usage prompts included sets of emails sent weekly for 12 weeks; standardized congratulatory emails after every two hours of program use, and informative emails for each cognitive-behavioral exercise. Individual user activity on the site was automatically tracked by an analytics system and recorded directly in the CaringGuidance database. RESULTS Complete usage data were available for 54 subjects. Ninety-eight percent of the intervention group logged into CaringGuidance independently at least once. Thirty-eight (70%) logged in during all three months, 15 (28%) were intermittent users, and one (2%) was a non-user. Users (n=53) averaged 15.6 (SD 9.85) logins. Mean logins were greatest in month 1 (7.26, SD 4.02) and declined in months 2 (4.32, SD 3.66) and month 3 (4.02, SD 3.82). Eleven (21%) used CaringGuidance with both the frequency and activity level intended at study outset, 9 (17%) exceeded intended frequency and activity (high-high users), and 10 (19%) were below expected usage on both login frequency and activity (low-low users). Low-low users and high-high users differed significantly (P<.001) in the total number of views and unique views of all program components. Change in depressive symptoms and the number of sessions (r=.351) and logins (r=.348) between study months 1 and 2 were significantly correlated (P=.018, .019). Higher baseline distress was associated with more unique views of program resources (r=.281, P=.043). Change in intrusive/avoidant thoughts from baseline to month 3, and the number of users' unique exercise views were negatively correlated (r=-.319, P=.035) so that more unique exercise views, equated with greater decline in intrusive/avoidant thoughts from baseline to month 3. CONCLUSIONS These findings favor the hypothesis that the key ingredient is not the amount of program use, but each user's self-selected activity within the program. More research is needed on the ideal ways to maintain use, and capture and define engagement and enactment of behaviors by people with cancer accessing unguided, self-management web-based programs.",2020,"Higher baseline distress was associated with more unique views of program resources (r=.281, P=.043).","['Women with stage 0 to II breast cancer diagnosed within the prior three months were recruited from clinics primarily in the Northeastern United States for participation in a 12-week pilot study of', 'After Breast Cancer Diagnosis', 'women newly diagnosed with breast cancer', 'patients with cancer']","['unguided web-based, psychoeducational distress self-management program CaringGuidance', 'CaringGuidance plus usual care versus usual care alone', 'Unguided, Web-Based Distress Self-Management Program']","['Mean logins', 'Change in depressive symptoms', 'frequency and activity level', ""number of users' unique exercise views""]","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0441763', 'cui_str': 'Stage 0'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C4082119', 'cui_str': 'Three months'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0031928', 'cui_str': 'Pilot Study'}, {'cui': 'C0678222', 'cui_str': 'Carcinoma of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449911', 'cui_str': 'View'}]",,0.0408537,"Higher baseline distress was associated with more unique views of program resources (r=.281, P=.043).","[{'ForeName': 'Robin M', 'Initials': 'RM', 'LastName': 'Lally', 'Affiliation': 'College of Nursing, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, United States.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Kupzyk', 'Affiliation': 'College of Nursing, University of Nebraska Medical Center, Omaha, NE, United States.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Gallo', 'Affiliation': 'Center for Computational Research, Roswell Park Cancer Center, Buffalo, NY, United States.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Berry', 'Affiliation': 'School of Nursing, University of Washington, Seattle, WA, United States.'}]",Journal of medical Internet research,['10.2196/19734'] 1615,32623140,Emotion self-regulation training in major depressive disorder using simultaneous real-time fMRI and EEG neurofeedback.,"Simultaneous real-time fMRI and EEG neurofeedback (rtfMRI-EEG-nf) is an emerging neuromodulation approach, that enables simultaneous volitional regulation of both hemodynamic (BOLD fMRI) and electrophysiological (EEG) brain activities. Here we report the first application of rtfMRI-EEG-nf for emotion self-regulation training in patients with major depressive disorder (MDD). In this proof-of-concept study, MDD patients in the experimental group (n = 16) used rtfMRI-EEG-nf during a happy emotion induction task to simultaneously upregulate two fMRI and two EEG activity measures relevant to MDD. The target measures included BOLD activities of the left amygdala (LA) and left rostral anterior cingulate cortex (rACC), and frontal EEG asymmetries in the alpha band (FAA, [7.5-12.5] Hz) and high-beta band (FBA, [21-30] Hz). MDD patients in the control group (n = 8) were provided with sham feedback signals. An advanced procedure for improved real-time EEG-fMRI artifact correction was implemented. The experimental group participants demonstrated significant upregulation of the LA BOLD activity, FAA, and FBA during the rtfMRI-EEG-nf task, as well as significant enhancement in fMRI connectivity between the LA and left rACC. Average individual FAA changes during the rtfMRI-EEG-nf task positively correlated with depression and anhedonia severities, and negatively correlated with after-vs-before changes in depressed mood ratings. Temporal correlations between the FAA and FBA time courses and the LA BOLD activity were significantly enhanced during the rtfMRI-EEG-nf task. The experimental group participants reported significant mood improvements after the training. Our results suggest that the rtfMRI-EEG-nf may have potential for treatment of MDD.",2020,"The experimental group participants demonstrated significant upregulation of the LA BOLD activity, FAA, and FBA during the rtfMRI-EEG-nf task, as well as significant enhancement in fMRI connectivity between the LA and left rACC.",['patients with major depressive disorder (MDD'],"['Emotion self-regulation training', 'rtfMRI-EEG-nf for emotion self-regulation training']","['BOLD activities of the left amygdala (LA) and left rostral anterior cingulate cortex (rACC), and frontal EEG asymmetries in the alpha band (FAA, [7.5-12.5] Hz) and high-beta band (FBA, [21-30] Hz', 'Average individual FAA changes', 'depression and anhedonia severities', 'LA BOLD activity', 'fMRI connectivity', 'LA BOLD activity, FAA, and FBA during the rtfMRI-EEG-nf task']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}]","[{'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0002708', 'cui_str': 'Amygdaloid structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C3163631', 'cui_str': 'Rostral'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate Gyrus'}, {'cui': 'C0205123', 'cui_str': 'Coronal'}, {'cui': 'C0332514', 'cui_str': 'Asymmetry'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C0060441', 'cui_str': 'flavone acetic acid'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C4517544', 'cui_str': '12.5'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0178417', 'cui_str': 'Anhedonia'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]",,0.014664,"The experimental group participants demonstrated significant upregulation of the LA BOLD activity, FAA, and FBA during the rtfMRI-EEG-nf task, as well as significant enhancement in fMRI connectivity between the LA and left rACC.","[{'ForeName': 'Vadim', 'Initials': 'V', 'LastName': 'Zotev', 'Affiliation': 'Laureate Institute for Brain Research, Tulsa, OK, USA. Electronic address: vzotev@laureateinstitute.org.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Mayeli', 'Affiliation': 'Laureate Institute for Brain Research, Tulsa, OK, USA; Electrical and Computer Engineering, University of Oklahoma, Tulsa, OK, USA.'}, {'ForeName': 'Masaya', 'Initials': 'M', 'LastName': 'Misaki', 'Affiliation': 'Laureate Institute for Brain Research, Tulsa, OK, USA.'}, {'ForeName': 'Jerzy', 'Initials': 'J', 'LastName': 'Bodurka', 'Affiliation': 'Laureate Institute for Brain Research, Tulsa, OK, USA; Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA. Electronic address: jbodurka@laureateinstitute.org.'}]",NeuroImage. Clinical,['10.1016/j.nicl.2020.102331'] 1616,32623182,"Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).","BACKGROUND Chemotherapy is effective in metastatic pancreatic adenocarcinoma (mPA), but new approaches are still needed to improve patients' survival and quality of life. We have previously published good efficacy and tolerability results on a sequential treatment strategy of gemcitabine followed by an intensified FOLFIRI (5FU+irinotecan) regimen. In the present study, we evaluated the same sequence but replaced gemcitabine by the new gemcitabine + nab-paclitaxel standard first-line combination. PATIENTS AND METHODS We randomised chemotherapy-naive patients with proven mPA, bilirubin levels ≤1.5 upper limit of normal values and performance status 0-2 to alternately receive gemcitabine + nab-paclitaxel for 2 months then FOLFIRI.3 for 2 months in arm A, or gemcitabine + nab-paclitaxel alone until progression in arm B. The primary objective was to increase the 6-month progression-free survival (PFS) rate from 40% (H 0 ) to 60% (H 1 ); using the binomial exact method, 124 patients were required. Analyses were carried out in preplanned modified intention-to-treat (mITT) and per-protocol (PP) populations. RESULTS Between November 2015 and November 2016, 127 patients were enrolled. Main grade III-IV toxicities (% in arm A/B) were: diarrhoea (12.5/1.7), neutropenia (46.9/31, including febrile neutropenia: 1.6/0), skin toxicity (6.3/13.8), and peripheral neuropathy (6.3/8.6). No toxic deaths occurred. The objective response rate was 40.3% (95% confidence interval [CI]: 28.1-53.6) in arm A and 26.7% (95% CI: 16.1-39.7) in arm B. The primary end-point (6-month PFS rate) was 45.2% [one-sided 95% CI: 34.3-56.4] in arm A and 23.3% in arm B [one-sided 95% CI: 14.3-32.3] in the mITT population. In the PP population, median PFS and OS were 7.6 months and 6 months and 14.5 months and 12.2 months in arm A and B, respectively. CONCLUSIONS The FIRGEMAX strategy with gemcitabine + nab-paclitaxel alternating with FOLFIRI.3 every 2 months, appears feasible and effective, with manageable toxicities, in patients able to reach >2mo of treatment. TRIAL REGISTRATION INFORMATION EudraCT: 2014-004449-28: NCT: 0282701.",2020,The objective response rate was 40.3% (95% confidence interval [CI]: 28.1-53.6) in arm A and 26.7% (95% CI: 16.1-39.7) in arm,"['We randomised chemotherapy-naive patients with proven mPA, bilirubin levels ≤1.5 upper limit of normal values and performance status\xa00-2 to alternately receive', 'metastatic pancreatic adenocarcinoma (mPA', 'patients with metastatic pancreatic adenocarcinoma', 'Between November 2015 and November 2016', '127 patients were enrolled']","['gemcitabine\xa0+\xa0nab-paclitaxel', 'Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3', 'gemcitabine\xa0+\xa0nab-paclitaxel standard first-line combination', 'gemcitabine\xa0+\xa0nab-paclitaxel alone until progression in arm B', 'gemcitabine', 'gemcitabine\xa0+\xa0nab-paclitaxel alternating with FOLFIRI.3']","['peripheral neuropathy', 'toxic deaths', 'neutropenia', 'diarrhoea', 'Main grade III-IV toxicities', 'median PFS and OS', 'skin toxicity', 'objective response rate', '6-month progression-free survival (PFS) rate']","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0861727', 'cui_str': 'Pancreatic adenocarcinoma metastatic'}, {'cui': 'C0344395', 'cui_str': 'Bilirubin measurement'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0086715', 'cui_str': 'Normal range'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0449438', 'cui_str': 'Status'}]","[{'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0332270', 'cui_str': 'Alternating'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205617', 'cui_str': 'Poorly differentiated'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1167791', 'cui_str': 'Skin toxicity'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",127.0,0.0595149,The objective response rate was 40.3% (95% confidence interval [CI]: 28.1-53.6) in arm A and 26.7% (95% CI: 16.1-39.7) in arm,"[{'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Rinaldi', 'Affiliation': 'Department of Hepato-gastroenterology, European Hospital, Marseille, France.'}, {'ForeName': 'Anne-Laure', 'Initials': 'AL', 'LastName': 'Pointet', 'Affiliation': 'Department of Hepato-gastroenterology, Georges Pompidou European Hospital, Paris, France.'}, {'ForeName': 'Faiza', 'Initials': 'F', 'LastName': 'Khemissa Akouz', 'Affiliation': 'Department of Hepato-gastroenterology, Saint Jean Hospital, Perpignan, France.'}, {'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Le Malicot', 'Affiliation': 'Biostatistics Department, Francophone Federation of Digestive Cancerology, EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France.'}, {'ForeName': 'Bidaut', 'Initials': 'B', 'LastName': 'Wahiba', 'Affiliation': 'Department of Hepato-gastroenterology, European Hospital, Marseille, France.'}, {'ForeName': 'Samy', 'Initials': 'S', 'LastName': 'Louafi', 'Affiliation': 'Department of Oncology, Sud Francilien Hospital Center, Corbeil-Essonnes, France.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Gratet', 'Affiliation': 'Oncology and Hematology ONCOSUD Unit, Clinic Pasteur, Toulouse, France.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Miglianico', 'Affiliation': 'Department of Radiotherapy, Private Hospital Center, Saint-Grégoire, France.'}, {'ForeName': 'Hortense', 'Initials': 'H', 'LastName': 'Laharie', 'Affiliation': 'Department of Oncology and Radiotherapy, Clinic Tivoli, Bordeaux, France.'}, {'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Bouhier Leporrier', 'Affiliation': 'Department of Hepato-gastroenterology, University Hospital, Caen, France.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Thirot Bidault', 'Affiliation': 'Department of Hepato-gastroenterology, Private Hospital, Antony, France.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Texereau', 'Affiliation': 'Department of Hepato-gastroenterology, Layne Hospital, Mont-De-Marsan, France.'}, {'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Coriat', 'Affiliation': 'Department of Hepato-gastroenterology, Cochin Hospital, APHP, Paris, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Terrebonne', 'Affiliation': 'Department of Hepato-gastroenterology, Haut Lévêque Hospital, Pessac, France.'}, {'ForeName': 'Marie-Claude', 'Initials': 'MC', 'LastName': 'Gouttebel', 'Affiliation': 'Department of Oncology, Drôme Nord Hospital, Romans Sur Isère, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Malka', 'Affiliation': 'Department of Hepato-gastroenterology, Gustave Roussy Cancer Campus, Villejuif, France.'}, {'ForeName': 'Jean-Baptiste', 'Initials': 'JB', 'LastName': 'Bachet', 'Affiliation': 'Department of Hepato-gastroenterology, Pitié-Salpêtrière Hospital, Paris, France.'}, {'ForeName': 'Côme', 'Initials': 'C', 'LastName': 'Lepage', 'Affiliation': 'Department of Hepato-gastroenterology, University Hospital of Dijon, EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Taieb', 'Affiliation': 'Department of Hepato-gastroenterology, Sorbonne Paris City, Paris Descartes University, Georges Pompidou European Hospital, Paris, France. Electronic address: jtaieb75@gmail.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2020.05.018'] 1617,32623958,Effect of Standing on a Standardized Measure of Upper Extremity Function.,"Although many daily activities that require the upper extremity are performed in standing, arm motor function is generally measured in sitting. The purpose of this study was to examine the effect of standing on a measure of upper extremity function, the Jebsen Hand Function Test (JHFT). Twelve nondisabled adults (26.3 ± 3.1 years) completed the JHFT with the right and left arms under two conditions: sitting and standing. Total time to complete the JHFT increased when performed in standing compared with sitting in both arms ( p = .005); mean increase was 4.4% and 5.6% for the right and left arms, respectively. Checker stacking was the only subtest that showed a significant increase in completion time in standing for both arms ( p = .001); card turning showed an increase for the left arm only ( p = .002). Measurement of upper extremity function in standing may provide insight into arm motor capacity within the context of standing postural control demands.",2020,"Total time to complete the JHFT increased when performed in standing compared with sitting in both arms ( p = .005); mean increase was 4.4% and 5.6% for the right and left arms, respectively.",['Twelve nondisabled adults (26.3 ± 3.1 years) completed the JHFT with the right and left arms under two conditions: sitting and standing'],[],"['Total time to complete the JHFT', 'upper extremity function, the Jebsen Hand Function Test (JHFT', 'completion time in standing']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4517668', 'cui_str': '26.3'}, {'cui': 'C4517683', 'cui_str': '3.1'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0451237', 'cui_str': 'Jebsen hand function test'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}]",[],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0451237', 'cui_str': 'Jebsen hand function test'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",12.0,0.0264381,"Total time to complete the JHFT increased when performed in standing compared with sitting in both arms ( p = .005); mean increase was 4.4% and 5.6% for the right and left arms, respectively.","[{'ForeName': 'Jill Campbell', 'Initials': 'JC', 'LastName': 'Stewart', 'Affiliation': 'University of South Carolina, Columbia, USA.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Saba', 'Affiliation': 'University of South Carolina, Columbia, USA.'}, {'ForeName': 'Jessica F', 'Initials': 'JF', 'LastName': 'Baird', 'Affiliation': 'University of South Carolina, Columbia, USA.'}, {'ForeName': 'Melissa B', 'Initials': 'MB', 'LastName': 'Kolar', 'Affiliation': 'University of South Carolina, Columbia, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': ""O'Donnell"", 'Affiliation': 'University of South Carolina, Columbia, USA.'}, {'ForeName': 'Sydney Y', 'Initials': 'SY', 'LastName': 'Schaefer', 'Affiliation': 'Arizona State University, Tempe, USA.'}]","OTJR : occupation, participation and health",['10.1177/1539449220937058'] 1618,32407288,Telemonitoring Versus Usual Care for Elderly Patients With Heart Failure Discharged From the Hospital in the United States: Cost-Effectiveness Analysis.,"BACKGROUND Telemonitoring-guided interventional management reduces the need for hospitalization and mortality of patients with chronic heart failure (CHF). OBJECTIVE This study aimed to analyze the cost-effectiveness of usual care with and without telemonitoring-guided management in patients with CHF discharged from the hospital, from the perspective of US health care providers. METHODS A lifelong Markov model was designed to estimate outcomes of (1) usual care alone for all postdischarge patients with CHF (New York Heart Association [NYHA] class I-IV), (2) usual care and telemonitoring for all postdischarge patients with CHF, (3) usual care for all postdischarge patients with CHF and telemonitoring for patients with NYHA class III to IV, and (4) usual care for all postdischarge patients with CHF plus telemonitoring for patients with NYHA class II to IV. Model inputs were derived from the literature and public data. Sensitivity analyses were conducted to assess the robustness of model. The primary outcomes were total direct medical cost, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER). RESULTS In the base case analysis, universal telemonitoring group gained the highest QALYs (6.2967 QALYs), followed by the telemonitoring for NYHA class II to IV group (6.2960 QALYs), the telemonitoring for NYHA class III to IV group (6.2450 QALYs), and the universal usual care group (6.1530 QALYs). ICERs of the telemonitoring for NYHA class III to IV group (US $35,393 per QALY) and the telemonitoring for NYHA class II to IV group (US $38,261 per QALY) were lower than the ICER of the universal telemonitoring group (US $100,458 per QALY). One-way sensitivity analysis identified five critical parameters: odds ratio of hospitalization for telemonitoring versus usual care, hazard ratio of all-cause mortality for telemonitoring versus usual care, CHF hospitalization cost and monthly outpatient costs for NYHA class I, and CHF hospitalization cost for NYHA class II. In probabilistic sensitivity analysis, probabilities of the universal telemonitoring, telemonitoring for NYHA class II to IV, telemonitoring for NYHA class III to IV, and universal usual care groups to be accepted as cost-effective at US $50,000 per QALY were 2.76%, 76.31%, 18.6%, and 2.33%, respectively. CONCLUSIONS Usual care for all discharged patients with CHF plus telemonitoring-guided management for NYHA class II to IV patients appears to be the preferred cost-effective strategy.",2020,"In the base case analysis, universal telemonitoring group gained the highest QALYs (6.2967 QALYs), followed by the telemonitoring for NYHA class II to IV group (6.2960 QALYs), the telemonitoring for NYHA class III to IV group (6.2450 QALYs), and the universal usual care group (6.1530 QALYs).","['Elderly Patients With Heart Failure', 'postdischarge patients with CHF (New York Heart Association [NYHA] class I-IV), (2', 'patients with chronic heart failure (CHF', 'patients with CHF discharged from the hospital, from the perspective of US health care providers']","['usual care with and without telemonitoring-guided management', 'usual care and telemonitoring for all postdischarge patients with CHF, (3) usual care for all postdischarge patients with CHF and telemonitoring for patients with NYHA class III to IV, and (4) usual care for all postdischarge patients with CHF plus telemonitoring', 'Telemonitoring Versus Usual Care']","['usual care, CHF hospitalization cost and monthly outpatient costs for NYHA class', 'cost-effectiveness', 'total direct medical cost, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0441885', 'cui_str': 'Class 1'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}]","[{'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C1275491', 'cui_str': 'New York Heart Association Classification'}, {'cui': 'C0441887', 'cui_str': 'Class 3'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C1275491', 'cui_str': 'New York Heart Association Classification'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.0172675,"In the base case analysis, universal telemonitoring group gained the highest QALYs (6.2967 QALYs), followed by the telemonitoring for NYHA class II to IV group (6.2960 QALYs), the telemonitoring for NYHA class III to IV group (6.2450 QALYs), and the universal usual care group (6.1530 QALYs).","[{'ForeName': 'Xinchan', 'Initials': 'X', 'LastName': 'Jiang', 'Affiliation': 'School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, China (Hong Kong).'}, {'ForeName': 'Jiaqi', 'Initials': 'J', 'LastName': 'Yao', 'Affiliation': 'School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, China (Hong Kong).'}, {'ForeName': 'Joyce Hs', 'Initials': 'JH', 'LastName': 'You', 'Affiliation': 'School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, China (Hong Kong).'}]",JMIR mHealth and uHealth,['10.2196/17846'] 1619,32632956,Interventions for mycosis fungoides.,"BACKGROUND Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma, a malignant, chronic disease initially affecting the skin. Several therapies are available, which may induce clinical remission for a time. This is an update of a Cochrane Review first published in 2012: we wanted to assess new trials, some of which investigated new interventions. OBJECTIVES To assess the effects of interventions for MF in all stages of the disease. SEARCH METHODS We updated our searches of the following databases to May 2019: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We searched 2 trials registries for additional references. For adverse event outcomes, we undertook separate searches in MEDLINE in April, July and November 2017. SELECTION CRITERIA Randomised controlled trials (RCTs) of local or systemic interventions for MF in adults with any stage of the disease compared with either another local or systemic intervention or with placebo. DATA COLLECTION AND ANALYSIS We used standard methodological procedures expected by Cochrane. The primary outcomes were improvement in health-related quality of life as defined by participants, and common adverse effects of the treatments. Key secondary outcomes were complete response (CR), defined as complete disappearance of all clinical evidence of disease, and objective response rate (ORR), defined as proportion of patients with a partial or complete response. We used GRADE to assess the certainty of evidence and considered comparisons of psoralen plus ultraviolet A (PUVA) light treatment as most important because this is first-line treatment for MF in most guidelines. MAIN RESULTS This review includes 20 RCTs (1369 participants) covering a wide range of interventions. The following were assessed as either treatments or comparators: imiquimod, peldesine, hypericin, mechlorethamine, nitrogen mustard and intralesional injections of interferon-α (IFN-α) (topical applications); PUVA, extracorporeal photopheresis (ECP: photochemotherapy), and visible light (light applications); acitretin, bexarotene, lenalidomide, methotrexate and vorinostat (oral agents); brentuximab vedotin; denileukin diftitox; mogamulizumab; chemotherapy with cyclophosphamide, doxorubicin, etoposide, and vincristine; a combination of chemotherapy with electron beam radiation; subcutaneous injection of IFN-α; and intramuscular injections of active transfer factor (parenteral systemics). Thirteen trials used an active comparator, five were placebo-controlled, and two compared an active operator to observation only. In 14 trials, participants had MF in clinical stages IA to IIB. All participants were treated in secondary and tertiary care settings, mainly in Europe, North America or Australia. Trials recruited both men and women, with more male participants overall. Trial duration varied from four weeks to 12 months, with one longer-term study lasting more than six years. We judged 16 trials as at high risk of bias in at least one domain, most commonly performance bias (blinding of participants and investigators), attrition bias and reporting bias. None of our key comparisons measured quality of life, and the two studies that did presented no usable data. Eighteen studies reported common adverse effects of the treatments. Adverse effects ranged from mild symptoms to lethal complications depending upon the treatment type. More aggressive treatments like systemic chemotherapy generally resulted in more severe adverse effects. In the included studies, CR rates ranged from 0% to 83% (median 31%), and ORR ranged from 0% to 88% (median 47%). Five trials assessed PUVA treatment, alone or combined, summarised below. There may be little to no difference between intralesional IFN-α and PUVA compared with PUVA alone for 24 to 52 weeks in CR (risk ratio (RR) 1.07, 95% confidence interval (CI) 0.87 to 1.31; 2 trials; 122 participants; low-certainty evidence). Common adverse events and ORR were not measured. One small cross-over trial found once-monthly ECP for six months may be less effective than twice-weekly PUVA for three months, reporting CR in two of eight participants and ORR in six of eight participants after PUVA, compared with no CR or ORR after ECP (very low-certainty evidence). Some participants reported mild nausea after PUVA but no numerical data were given. One participant in the ECP group withdrew due to hypotension. However, we are unsure of the results due to very low-certainty evidence. One trial comparing bexarotene plus PUVA versus PUVA alone for up to 16 weeks reported one case of photosensitivity in the bexarotene plus PUVA group compared to none in the PUVA-alone group (87 participants; low-certainty evidence). There may be little to no difference between bexarotene plus PUVA and PUVA alone in CR (RR 1.41, 95% CI 0.71 to 2.80) and ORR (RR 0.94, 95% CI 0.61 to 1.44) (93 participants; low-certainty evidence). One trial comparing subcutaneous IFN-α injections combined with either acitretin or PUVA for up to 48 weeks or until CR indicated there may be little to no difference in the common IFN-α adverse effect of flu-like symptoms (RR 1.32, 95% CI 0.92 to 1.88; 82 participants). There may be lower CR with IFN-α and acitretin compared with IFN-α and PUVA (RR 0.54, 95% CI 0.35 to 0.84; 82 participants) (both outcomes: low-certainty evidence). This trial did not measure ORR. One trial comparing PUVA maintenance treatment to no maintenance treatment, in participants who had already had CR, did report common adverse effects. However, the distribution was not evaluable. CR and OR were not assessable. The range of treatment options meant that rare adverse effects consequently occurred in a variety of organs. AUTHORS' CONCLUSIONS ​​There is a lack of high-certainty evidence to support decision making in the treatment of MF. Because of substantial heterogeneity in design, missing data, small sample sizes, and low methodological quality, the comparative safety and efficacy of these interventions cannot be reliably established on the basis of the included RCTs. PUVA is commonly recommended as first-line treatment for MF, and we did not find evidence to challenge this recommendation. There was an absence of evidence to support the use of intralesional IFN-α or bexarotene in people receiving PUVA and an absence of evidence to support the use of acitretin or ECP for treating MF. Future trials should compare the safety and efficacy of treatments to PUVA, as the current standard of care, and should measure quality of life and common adverse effects.",2020,There was an absence of evidence to support the use of intralesional IFN-α or bexarotene in people receiving PUVA and an absence of evidence to support the use of acitretin or ECP for treating MF.,"['2012', 'mycosis fungoides', 'adults with any stage of the disease compared with either another local or systemic intervention or with', 'Mycosis fungoides (MF', 'Trials recruited both men and women, with more male participants overall', 'All participants were treated in secondary and tertiary care settings, mainly in Europe, North America or Australia', '20 RCTs (1369 participants) covering a wide range of interventions']","['PUVA', 'IFN-α and PUVA', 'imiquimod, peldesine, hypericin, mechlorethamine, nitrogen mustard and intralesional injections of interferon-α (IFN-α) (topical applications); PUVA, extracorporeal photopheresis (ECP: photochemotherapy), and visible light (light applications); acitretin, bexarotene, lenalidomide, methotrexate and vorinostat (oral agents', 'bexarotene', 'IFN-α', 'subcutaneous IFN-α injections combined with either acitretin or PUVA', 'cyclophosphamide, doxorubicin, etoposide, and vincristine', 'bexarotene plus PUVA', 'active transfer factor (parenteral systemics', 'ECP', 'psoralen plus ultraviolet A (PUVA) light treatment', 'placebo']","['quality of life', 'CR rates', 'health-related quality of life', 'ORR', 'mild nausea', 'severe adverse effects', 'common IFN-α adverse effect of flu-like symptoms', 'complete response (CR), defined as complete disappearance of all clinical evidence of disease, and objective response rate (ORR), defined as proportion of patients with a partial or complete response']","[{'cui': 'C0026948', 'cui_str': 'Mycosis fungoides'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439844', 'cui_str': 'Covered'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]","[{'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1532472', 'cui_str': 'Ultra-violet'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0165032', 'cui_str': 'imiquimod'}, {'cui': 'C0338278', 'cui_str': 'peldesine'}, {'cui': 'C0063220', 'cui_str': 'hypericin'}, {'cui': 'C0025033', 'cui_str': 'Mechlorethamine'}, {'cui': 'C0021490', 'cui_str': 'Intralesional injection'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0206373', 'cui_str': 'Extracorporeal photopheresis'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0242377', 'cui_str': 'Visible light'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0050559', 'cui_str': 'Acitretin'}, {'cui': 'C0765273', 'cui_str': 'bexarotene'}, {'cui': 'C1144149', 'cui_str': 'lenalidomide'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0672708', 'cui_str': 'Vorinostat'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0015133', 'cui_str': 'Etoposide'}, {'cui': 'C0042679', 'cui_str': 'Vincristine'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0040673', 'cui_str': 'Transfer Factor'}, {'cui': 'C0030547', 'cui_str': 'Parenteral nutrition'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0016072', 'cui_str': 'Ficusin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0392171', 'cui_str': 'Influenza-like symptoms'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0728938', 'cui_str': 'Partial'}]",,0.46717,There was an absence of evidence to support the use of intralesional IFN-α or bexarotene in people receiving PUVA and an absence of evidence to support the use of acitretin or ECP for treating MF.,"[{'ForeName': 'Arash', 'Initials': 'A', 'LastName': 'Valipour', 'Affiliation': 'Department of Dermatology, Venereology and Allergology, Johann Wolfgang Goethe-University Hospital, Frankfurt am Main, Germany.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Jäger', 'Affiliation': 'Department of Dermatology, Venereology and Allergology, Johann Wolfgang Goethe-University Hospital, Frankfurt am Main, Germany.'}, {'ForeName': 'Peggy', 'Initials': 'P', 'LastName': 'Wu', 'Affiliation': 'Department of Dermatology, University of California Davis, Sacramento, CA, USA.'}, {'ForeName': 'Jochen', 'Initials': 'J', 'LastName': 'Schmitt', 'Affiliation': 'Center for Evidence-Based Healthcare, Faculty of Medicine Carl Gustav Carus, Technischen Universität (TU) Dresden, Dresden, Germany.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Bunch', 'Affiliation': 'c/o Cochrane Skin Group, The University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Weberschock', 'Affiliation': 'Department of Dermatology, Venereology and Allergology, Johann Wolfgang Goethe-University Hospital, Frankfurt am Main, Germany.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD008946.pub3'] 1620,32628612,Process Evaluation of an eHealth Intervention (Food4toddlers) to Improve Toddlers' Diet: Randomized Controlled Trial.,"BACKGROUND Parents seek trustworthy information online to promote healthy eating for their toddlers. Such information must be perceived as relevant and easy to implement and use. OBJECTIVE The objectives of this study were to conduct a process evaluation of the electronic health (eHealth) intervention (Food4toddlers) targeting food environment, parental feeding practices, and toddlers' diet and to examine possible differences in these areas according to education and family composition. METHODS A 2-armed randomized controlled trial, including 298 parent-toddler dyads from Norway, was conducted in 2017. In total, 148 parents in the intervention group received access to an intervention website for 6 months. Data on website usage were retrieved from the learning management platform used (NEO). Participants' satisfaction with the intervention was asked for in a postintervention questionnaire. Chi-square and t tests were used to examine differences in usage and satisfaction between education and family composition groups. RESULTS Most participants were mothers (144/148, 97.2%), lived in two-adult households (148/148, 100%), and were born in Norway (132/148, 89.1%). Mean parental age was 31.5 years (SD 4.2). More than 87.8% (129/147) had a university education degree and 56.5% (83/147) had over 4 years of university education. Most (128/148, 86.5%) intervention participants entered the website at least once (mean days of access 7.4 [SD 7.1]). Most parents reported the website as appropriate to the child's age (71/83, 86%) and self-explanatory (79/83, 95%) and appreciated the interface (52/83, 63%) and layout (46/83, 55%). In total, 61% (51/83) stated that they learned something new from the intervention. Parents with over 4 years of university education and in 1-child households used the intervention website more than those with 4 years or less of university education (8.4 vs 5.9 days in total, P=.04) and households with more than 1 child (8.3 vs 5.8 days in total, P=.04), respectively. CONCLUSIONS The Food4toddlers intervention website was found to be relevant by most participants in the intervention group, although usage of the website differed according to educational level and family composition. For eHealth interventions to be effective, intervention materials such as websites must be used by the target group. Our results highlight the need to include users from different groups when developing interventions. TRIAL REGISTRATION ISRCTN Registry ISRCTN92980420; http://www.isrctn.com/ISRCTN92980420.",2020,"The Food4toddlers intervention website was found to be relevant by most participants in the intervention group, although usage of the website differed according to educational level and family composition.","['Mean parental age was 31.5 years (SD 4.2', 'More than 87.8% (129/147) had a university education degree and 56.5% (83/147) had over 4 years of university education', '298 parent-toddler dyads from Norway, was conducted in 2017']","[""electronic health (eHealth) intervention (Food4toddlers) targeting food environment, parental feeding practices, and toddlers' diet"", 'eHealth Intervention (Food4toddlers']",['university education'],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0030543', 'cui_str': 'Parental Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517758', 'cui_str': '4.2'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0682053', 'cui_str': 'Toddler'}, {'cui': 'C0028423', 'cui_str': 'Norway'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]","[{'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0682053', 'cui_str': 'Toddler'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0013621', 'cui_str': 'Education'}]",,0.0953093,"The Food4toddlers intervention website was found to be relevant by most participants in the intervention group, although usage of the website differed according to educational level and family composition.","[{'ForeName': 'Margrethe', 'Initials': 'M', 'LastName': 'Røed', 'Affiliation': 'Department of Nutrition and Public Health, Faculty of Health and Sports Sciences, University of Agder, Kristiansand, Norway.'}, {'ForeName': 'Frøydis Nordgård', 'Initials': 'FN', 'LastName': 'Vik', 'Affiliation': 'Department of Nutrition and Public Health, Faculty of Health and Sports Sciences, University of Agder, Kristiansand, Norway.'}, {'ForeName': 'Elisabet Rudjord', 'Initials': 'ER', 'LastName': 'Hillesund', 'Affiliation': 'Department of Nutrition and Public Health, Faculty of Health and Sports Sciences, University of Agder, Kristiansand, Norway.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Van Lippevelde', 'Affiliation': 'Department of Nutrition and Public Health, Faculty of Health and Sports Sciences, University of Agder, Kristiansand, Norway.'}, {'ForeName': 'Anine Christine', 'Initials': 'AC', 'LastName': 'Medin', 'Affiliation': 'Department of Nutrition and Public Health, Faculty of Health and Sports Sciences, University of Agder, Kristiansand, Norway.'}, {'ForeName': 'Nina Cecilie', 'Initials': 'NC', 'LastName': 'Øverby', 'Affiliation': 'Department of Nutrition and Public Health, Faculty of Health and Sports Sciences, University of Agder, Kristiansand, Norway.'}]",JMIR human factors,['10.2196/18171'] 1621,32629226,Occurrence of c.976 G>T (p.Val326Leu) and c.452 G>A (p.Trp151Ter) variants in DHCR7 gene in population of polish women with recurrent miscarriage.,"INTRODUCTION Recurrent miscarriage is a serious clinical problem that affects 1-5 % of all couples trying to conceive. Although the incidence of Smith-Lemli-Opitz Syndrome (SLOS, OMIM #270400), an autosomal recessive condition caused by variants in the DHCR7 gene, is very low, (1:83 000), the observed carrier frequency of DHCR7 gene variants in the Polish population is high, ranging from 1:24 to 1:31. It is possible that this carriage may be responsible for early pregnancy loss. OBJECTIVES The aim of the study is to determine the carrier frequency of the p c.976 G>T (p.Val326Leu) and c.452 G>A (p.Trp151Ter) variants in the DHCR7 gene in patients experiencing recurrent miscarriage. METHODS The study group included 480 patients: a study group of 380 with at least 2 miscarriages before the 20th week of pregnancy, and a control group of 100 who had not experienced miscarriage. The variants were identified by genotyping: c.976 G>T (p.Val326Leu) by the TaqMan® SNP Genotyping Assay system, and c.452 G>A (p.Trp151Ter) using the BfaI restriction enzyme. Statistical analysis was performed using R software. RESULTS No examples of c.976 G>T (p.Val326Leu) were found in either group. c.452 G>A (p.Trp151Ter) was found in 22 participants from the study group and 4 from the control group; however, this difference was not significant (Chi2 test p = 0.61). CONCLUSIONS Being a carrier of the c.976 G>T (p.Val326Leu) and c.452 G>A (p.Trp151Ter) variants in theDHCR7 gene is not a risk factor for recurrent miscarriage in the Polish population.",2020,A (p.Trp151Ter) variants in theDHCR7 gene is not a risk factor for recurrent miscarriage in the Polish population.,"['population of polish women with recurrent miscarriage', 'patients experiencing recurrent miscarriage', '480 patients: a study group of 380 with at least 2 miscarriages before the 20th week of pregnancy, and a control group of 100 who had not experienced miscarriage']","['Val326Leu) and c.452 G', 'G']",[],"[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0032376', 'cui_str': 'Polish language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0000809', 'cui_str': 'Recurrent miscarriage'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C4319609', 'cui_str': '480'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319693', 'cui_str': '380'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1704407', 'cui_str': '100'}]",[],[],,0.0226355,A (p.Trp151Ter) variants in theDHCR7 gene is not a risk factor for recurrent miscarriage in the Polish population.,"[{'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Chrzanowska-Steglińska', 'Affiliation': 'Department of Fetal Medicine and Gynaecology, the Medical University of Lodz, Poland. Electronic address: marta.chrzanowska85@interia.pl.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Moczulska', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland; Clinical Genetics Clinic, Central Clinical Hospital of the Medical University of Lodz, Poland.'}, {'ForeName': 'Beata', 'Initials': 'B', 'LastName': 'Skoczylas', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland.'}, {'ForeName': 'Michał', 'Initials': 'M', 'LastName': 'Pietrusiński', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland.'}, {'ForeName': 'Karolina', 'Initials': 'K', 'LastName': 'Antosik', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland.'}, {'ForeName': 'Paulina', 'Initials': 'P', 'LastName': 'Jakiel', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Kacprzak', 'Affiliation': 'Department of Fetal Medicine and Gynaecology, the Medical University of Lodz, Poland.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Borowiec', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Sieroszewski', 'Affiliation': 'Department of Fetal Medicine and Gynaecology, the Medical University of Lodz, Poland.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.05.063'] 1622,32629291,A randomised double-blind trial of cognitive training for the prevention of psychopathology in at-risk youth.,"BACKGROUND The aim of this study was to evaluate the effectiveness of online cognitive training as a means of reducing psychopathology in at-risk youth. METHODS In a double-blind randomised controlled trial, 228 youths (mean age = 18.6, 74.6% female) were randomly allocated to either an intervention group (n = 114; online cognitive training focused on executive functioning) and a control group (n = 114; online cognitive training focused on other cognitive abilities). Participants were assessed online at baseline, post-training, 3-, 6- and 12-month follow-up. The primary outcome of the study was overall psychopathology as measured by the Strengths and Difficulties Questionnaire. Secondary outcomes were executive functioning ability (assessed using the n-back, trail-making and Stroop tasks), day-to-day functioning and risky drinking. RESULTS Mixed model intention-to-treat analyses indicated that psychopathology increased and day-to-day functioning decreased, regardless of intervention group. Those in the intervention group improved more than those in the control group in terms of the n-back task, but this was not statistically significant after adjusting for multiple comparisons. There were no statistically significant effects on risky drinking, or the trail-making and Stroop tasks. CONCLUSION This study failed to provide evidence for the efficacy of cognitive training as a stand-alone intervention for psychopathology.",2020,"Those in the intervention group improved more than those in the control group in terms of the n-back task, but this was not statistically significant after adjusting for multiple comparisons.","['psychopathology in at-risk youth', '228 youths (mean age\xa0=\xa018.6, 74.6% female']","['cognitive training', 'intervention group (n\xa0=\xa0114; online cognitive training focused on executive functioning) and a control group (n\xa0=\xa0114; online cognitive training focused on other cognitive abilities', 'online cognitive training']","['psychopathology increased and day-to-day functioning', 'executive functioning ability (assessed using the n-back, trail-making and Stroop tasks), day-to-day functioning and risky drinking', 'risky drinking, or the trail-making and Stroop tasks', 'overall psychopathology as measured by the Strengths and Difficulties Questionnaire']","[{'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}]","[{'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C2718024', 'cui_str': 'Stroop Task'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C3472494', 'cui_str': 'Strengths and difficulties questionnaire'}]",228.0,0.191026,"Those in the intervention group improved more than those in the control group in terms of the n-back task, but this was not statistically significant after adjusting for multiple comparisons.","[{'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Mewton', 'Affiliation': 'Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia. Electronic address: louisem@unsw.edu.au.'}, {'ForeName': 'Antoinette', 'Initials': 'A', 'LastName': 'Hodge', 'Affiliation': ""Child Development Unit, The Children's Hospital, Westmead, Australia.""}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Gates', 'Affiliation': 'Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Visontay', 'Affiliation': 'The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Briana', 'Initials': 'B', 'LastName': 'Lees', 'Affiliation': 'The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Maree', 'Initials': 'M', 'LastName': 'Teesson', 'Affiliation': 'The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, Australia.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103672'] 1623,32630290,Investigation of the Enhancement Interactions between Double Parallel Cracks on Fatigue Growth Behaviors.,"In this paper, interactions of double parallel cracks were studied by performing experiments and numerical simulations. Fatigue crack propagation tests were carried out to measure crack growth rates in the specimens with double parallel cracks or a single crack. Finite element method was adopted to calculate stress intensity factors at the crack tips. Results show that the double parallel cracks at different positions present a shielding effect or enhancement effect on crack growth rates and stress intensity factors. When the double parallel cracks are offset, crack interactions mostly behave as enhancement effects. Empirical formulas were obtained to calculate the stress intensity factor at the ""dangerous"" crack tip of the double parallel cracks. By modifying the material parameters in Paris equation of the single crack, the double parallel cracks are simplified into a single crack with the same crack growth rates.",2020,Fatigue crack propagation tests were carried out to measure crack growth rates in the specimens with double parallel cracks or a single crack.,[],[],"['crack growth rates', 'Fatigue Growth Behaviors', 'crack growth rates and stress intensity factors']",[],[],"[{'cui': 'C0040441', 'cui_str': 'Fracture of tooth'}, {'cui': 'C0449249', 'cui_str': 'Growth rate'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}]",,0.0674001,Fatigue crack propagation tests were carried out to measure crack growth rates in the specimens with double parallel cracks or a single crack.,"[{'ForeName': 'Zhichao', 'Initials': 'Z', 'LastName': 'Han', 'Affiliation': 'Institute of Mechanical and Electrical Engineering, Beijing University of Chemical Technology, Beijing 100029, China.'}, {'ForeName': 'Caifu', 'Initials': 'C', 'LastName': 'Qian', 'Affiliation': 'Institute of Mechanical and Electrical Engineering, Beijing University of Chemical Technology, Beijing 100029, China.'}, {'ForeName': 'Huifang', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Institute of Mechanical and Electrical Engineering, Beijing University of Chemical Technology, Beijing 100029, China.'}]","Materials (Basel, Switzerland)",['10.3390/ma13132952'] 1624,32631074,"Utility of Neuromuscular Electrical Stimulation to Preserve Quadriceps Muscle Fiber Size and Contractility After Anterior Cruciate Ligament Injuries and Reconstruction: A Randomized, Sham-Controlled, Blinded Trial.","BACKGROUND Anterior cruciate ligament (ACL) injuries and reconstruction (ACLR) promote quadriceps muscle atrophy and weakness that can persist for years, suggesting the need for more effective rehabilitation programs. Whether neuromuscular electrical stimulation (NMES) can be used to prevent maladaptations in skeletal muscle size and function is unclear. PURPOSE To examine whether early NMES use, started soon after an injury and maintained through 3 weeks after surgery, can preserve quadriceps muscle size and contractile function at the cellular (ie, fiber) level in the injured versus noninjured leg of patients undergoing ACLR. STUDY DESIGN Randomized controlled trial; Level of evidence, 1. METHODS Patients (n = 25; 12 men/13 women) with an acute, first-time ACL rupture were randomized to NMES (5 d/wk) or sham (simulated microcurrent electrical nerve stimulation; 5 d/wk) treatment to the quadriceps muscles of their injured leg. Bilateral biopsies of the vastus lateralis were performed 3 weeks after surgery to measure skeletal muscle fiber size and contractility. Quadriceps muscle size and strength were assessed 6 months after surgery. RESULTS A total of 21 patients (9 men/12 women) completed the trial. ACLR reduced single muscle fiber size and contractility across all fiber types ( P < .01 to P < .001) in the injured compared with noninjured leg 3 weeks after surgery. NMES reduced muscle fiber atrophy ( P < .01) through effects on fast-twitch myosin heavy chain (MHC) II fibers ( P < .01 to P < .001). NMES preserved contractility in slow-twitch MHC I fibers ( P < .01 to P < .001), increasing maximal contractile velocity ( P < .01) and preserving power output ( P < .01), but not in MHC II fibers. Differences in whole muscle strength between groups were not discerned 6 months after surgery. CONCLUSION Early NMES use reduced skeletal muscle fiber atrophy in MHC II fibers and preserved contractility in MHC I fibers. These results provide seminal, cellular-level data demonstrating the utility of the early use of NMES to beneficially modify skeletal muscle maladaptations to ACLR. CLINICAL RELEVANCE Our results provide the first comprehensive, cellular-level evidence to show that the early use of NMES mitigates early skeletal muscle maladaptations to ACLR. REGISTRATION NCT02945553 (ClinicalTrials.gov identifier).",2020,NMES reduced muscle fiber atrophy ( P < .01) through effects on fast-twitch myosin heavy chain (MHC) II fibers ( P < .01 to P < .001).,"['Patients (n = 25; 12 men/13 women) with an acute, first-time ACL rupture', '21 patients (9 men/12 women) completed the trial', 'After Anterior Cruciate Ligament Injuries and Reconstruction']","['Anterior cruciate ligament (ACL) injuries and reconstruction (ACLR', 'neuromuscular electrical stimulation (NMES', 'Neuromuscular Electrical Stimulation', 'NMES (5 d/wk) or sham (simulated microcurrent electrical nerve stimulation; 5 d/wk) treatment to the quadriceps muscles of their injured leg']","['maximal contractile velocity', 'preserving power output', 'Quadriceps Muscle Fiber Size and Contractility', 'ACLR reduced single muscle fiber size and contractility', 'Quadriceps muscle size and strength', 'fast-twitch myosin heavy chain (MHC) II fibers', 'contractility in slow-twitch MHC', 'muscle fiber atrophy']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0409312', 'cui_str': 'Rupture of anterior cruciate ligament'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1456574', 'cui_str': 'Injury of anterior cruciate ligament'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}]","[{'cui': 'C0078960', 'cui_str': 'Structure of anterior cruciate ligament of knee joint'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0026820', 'cui_str': 'Muscle contraction'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0231530', 'cui_str': 'Muscle twitch'}, {'cui': 'C0027100', 'cui_str': 'Myosin Heavy Chain'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0024518', 'cui_str': 'Major histocompatibility complex'}, {'cui': 'C0333751', 'cui_str': 'Muscle fiber atrophy'}]",21.0,0.154142,NMES reduced muscle fiber atrophy ( P < .01) through effects on fast-twitch myosin heavy chain (MHC) II fibers ( P < .01 to P < .001).,"[{'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Toth', 'Affiliation': 'Department of Medicine, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Timothy W', 'Initials': 'TW', 'LastName': 'Tourville', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Thomas B', 'Initials': 'TB', 'LastName': 'Voigt', 'Affiliation': 'Department of Medicine, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Rebecca H', 'Initials': 'RH', 'LastName': 'Choquette', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Bradley M', 'Initials': 'BM', 'LastName': 'Anair', 'Affiliation': 'Department of Medicine, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Falcone', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Mathew J', 'Initials': 'MJ', 'LastName': 'Failla', 'Affiliation': 'Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Jennifer E', 'Initials': 'JE', 'LastName': 'Stevens-Lapslaey', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, University of Colorado, Denver, Colorado, USA.'}, {'ForeName': 'Nathan K', 'Initials': 'NK', 'LastName': 'Endres', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Slauterbeck', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Bruce D', 'Initials': 'BD', 'LastName': 'Beynnon', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Vermont, Burlington, Vermont, USA.'}]",The American journal of sports medicine,['10.1177/0363546520933622'] 1625,32658939,Minimal transmission in an influenza A (H3N2) human challenge-transmission model within a controlled exposure environment.,"Uncertainty about the importance of influenza transmission by airborne droplet nuclei generates controversy for infection control. Human challenge-transmission studies have been supported as the most promising approach to fill this knowledge gap. Healthy, seronegative volunteer 'Donors' (n = 52) were randomly selected for intranasal challenge with influenza A/Wisconsin/67/2005 (H3N2). 'Recipients' randomized to Intervention (IR, n = 40) or Control (CR, n = 35) groups were exposed to Donors for four days. IRs wore face shields and hand sanitized frequently to limit large droplet and contact transmission. One transmitted infection was confirmed by serology in a CR, yielding a secondary attack rate of 2.9% among CR, 0% in IR (p = 0.47 for group difference), and 1.3% overall, significantly less than 16% (p<0.001) expected based on a proof-of-concept study secondary attack rate and considering that there were twice as many Donors and days of exposure. The main difference between these studies was mechanical building ventilation in the follow-on study, suggesting a possible role for aerosols.",2020,"One transmitted infection was confirmed by serology in a CR, yielding a secondary attack rate of 2.9% among CR, 0% in IR (p = 0.47 for group difference), and 1.3% overall, significantly less than 16% (p<0.001) expected based on a proof-of-concept study secondary attack rate and considering that there were twice as many Donors and days of exposure.","[""Healthy, seronegative volunteer 'Donors' (n = 52""]",['intranasal challenge with influenza A/Wisconsin/67/2005 (H3N2). '],[],"[{'cui': 'C0521144', 'cui_str': 'Seronegative'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0013018', 'cui_str': 'Donors'}]","[{'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C1615607', 'cui_str': 'Influenza A virus subtype H1N1'}]",[],52.0,0.0134321,"One transmitted infection was confirmed by serology in a CR, yielding a secondary attack rate of 2.9% among CR, 0% in IR (p = 0.47 for group difference), and 1.3% overall, significantly less than 16% (p<0.001) expected based on a proof-of-concept study secondary attack rate and considering that there were twice as many Donors and days of exposure.","[{'ForeName': 'Jonathan S', 'Initials': 'JS', 'LastName': 'Nguyen-Van-Tam', 'Affiliation': 'Health Protection and Influenza Research Group, Division of Epidemiology and Public Heath, University of Nottingham School of Medicine, Nottingham, United Kingdom.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Killingley', 'Affiliation': 'Health Protection and Influenza Research Group, Division of Epidemiology and Public Heath, University of Nottingham School of Medicine, Nottingham, United Kingdom.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Enstone', 'Affiliation': 'Health Protection and Influenza Research Group, Division of Epidemiology and Public Heath, University of Nottingham School of Medicine, Nottingham, United Kingdom.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hewitt', 'Affiliation': 'Health Protection and Influenza Research Group, Division of Epidemiology and Public Heath, University of Nottingham School of Medicine, Nottingham, United Kingdom.'}, {'ForeName': 'Jovan', 'Initials': 'J', 'LastName': 'Pantelic', 'Affiliation': 'University of Maryland School of Public Health, Maryland Institute for Applied Environmental Health, College Park, Maryland, United States of America.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Grantham', 'Affiliation': 'University of Maryland School of Public Health, Maryland Institute for Applied Environmental Health, College Park, Maryland, United States of America.'}, {'ForeName': 'P Jacob', 'Initials': 'PJ', 'LastName': 'Bueno de Mesquita', 'Affiliation': 'University of Maryland School of Public Health, Maryland Institute for Applied Environmental Health, College Park, Maryland, United States of America.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Lambkin-Williams', 'Affiliation': 'hVIVO London, United Kingdom.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Gilbert', 'Affiliation': 'hVIVO London, United Kingdom.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Mann', 'Affiliation': 'hVIVO London, United Kingdom.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Forni', 'Affiliation': 'hVIVO London, United Kingdom.'}, {'ForeName': 'Catherine J', 'Initials': 'CJ', 'LastName': 'Noakes', 'Affiliation': 'University of Leeds School of Civil Engineering, Leeds, United Kingdom.'}, {'ForeName': 'Min Z', 'Initials': 'MZ', 'LastName': 'Levine', 'Affiliation': 'Centers for Disease Control and Prevention, Influenza Division, Atlanta, Georgia, United States of America.'}, {'ForeName': 'LaShondra', 'Initials': 'L', 'LastName': 'Berman', 'Affiliation': 'Centers for Disease Control and Prevention, Influenza Division, Atlanta, Georgia, United States of America.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Lindstrom', 'Affiliation': 'Centers for Disease Control and Prevention, Influenza Division, Atlanta, Georgia, United States of America.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Cauchemez', 'Affiliation': 'Imperial College London, MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, London, United Kingdom.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Bischoff', 'Affiliation': 'Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Tellier', 'Affiliation': 'McGill University, Dept of Medicine, Montreal, Canada.'}, {'ForeName': 'Donald K', 'Initials': 'DK', 'LastName': 'Milton', 'Affiliation': 'University of Maryland School of Public Health, Maryland Institute for Applied Environmental Health, College Park, Maryland, United States of America.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",PLoS pathogens,['10.1371/journal.ppat.1008704'] 1626,32659482,Transcranial random noise stimulation is more effective than transcranial direct current stimulation for enhancing working memory in healthy individuals: Behavioural and electrophysiological evidence.,"BACKGROUND Transcranial direct current stimulation (tDCS) has been shown to improve working memory (WM) performance in healthy individuals, however effects tend to be modest and variable. Transcranial random noise stimulation (tRNS) can be delivered with a direct-current offset (DC-offset) to induce equal or even greater effects on cortical excitability than tDCS. To-date, no research has directly compared the effects of these techniques on WM performance or underlying neurophysiological activity. OBJECTIVE To compare the effects of anodal tDCS, tRNS + DC-offset, or sham stimulation over the left dorsolateral prefrontal cortex (DLPFC) on WM performance and task-related EEG oscillatory activity in healthy adults. METHODS Using a between-subjects design, 49 participants were allocated to receive either anodal tDCS (N = 16), high-frequency tRNS + DC-offset (N = 16), or sham stimulation (N = 17) to the left DLPFC. Changes in WM performance were assessed using the Sternberg WM task completed before and 5- and 25-min post-stimulation. Event-related synchronisation/desynchronisation (ERS/ERD) of oscillatory activity was analysed from EEG recorded during WM encoding and maintenance. RESULTS tRNS induced more pronounced and consistent enhancements in WM accuracy when compared to both tDCS and sham stimulation. Improvements in WM performance following tRNS were accompanied by increased theta ERS and diminished gamma ERD during WM encoding, which were significantly greater than those observed following anodal tDCS or sham stimulation. CONCLUSIONS These findings demonstrate the potential of tRNS + DC-offset to modulate cognitive and electrophysiological measures of WM and raise the possibility that tRNS + DC-offset may be more effective and reliable than tDCS for enhancing WM performance in healthy individuals.",2020,"Improvements in WM performance following tRNS were accompanied by increased theta ERS and diminished gamma ERD during WM encoding, which were significantly greater than those observed following anodal tDCS or sham stimulation. ","['49 participants', 'healthy individuals', 'healthy adults', 'Healthy Individuals']","['Transcranial direct current stimulation (tDCS', 'high-frequency tRNS + DC-offset (N = 16), or sham stimulation (N = 17) to the left DLPFC', 'anodal tDCS', 'tDCS', 'Transcranial random noise stimulation (tRNS', 'Transcranial Direct Current Stimulation', 'Transcranial Random Noise Stimulation', 'anodal tDCS, tRNS + DC-offset, or sham stimulation']","['WM performance and task-related EEG oscillatory activity', 'Event-related synchronisation/desynchronisation (ERS/ERD) of oscillatory activity', 'Changes in WM performance', 'working memory (WM) performance', 'WM accuracy', 'theta ERS and diminished gamma ERD', 'WM performance']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C3852967', 'cui_str': 'Transcranial Random Noise Stimulation'}, {'cui': 'C0442831', 'cui_str': 'Direct current'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0450424', 'cui_str': 'To the left'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}]","[{'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C2931783', 'cui_str': 'Enamel-renal syndrome'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0017011', 'cui_str': 'Gamma radiation'}]",49.0,0.0357647,"Improvements in WM performance following tRNS were accompanied by increased theta ERS and diminished gamma ERD during WM encoding, which were significantly greater than those observed following anodal tDCS or sham stimulation. ","[{'ForeName': 'O W', 'Initials': 'OW', 'LastName': 'Murphy', 'Affiliation': 'Monash Alfred Psychiatry Research Centre, Central Clinical School, The Alfred and Monash University, Melbourne, Australia; Monash Institute of Cognitive and Clinical Neurosciences, School of Psychological Science and Monash Biomedical Imaging, Monash University, Melbourne, Australia; Epworth Centre for Innovation in Mental Health, Epworth Healthcare, Camberwell, VIC, Australia; Department of Psychiatry, Central Clinical School, Monash University, Melbourne, VIC, Australia. Electronic address: oscar.murphy@monash.edu.'}, {'ForeName': 'K E', 'Initials': 'KE', 'LastName': 'Hoy', 'Affiliation': 'Epworth Centre for Innovation in Mental Health, Epworth Healthcare, Camberwell, VIC, Australia; Department of Psychiatry, Central Clinical School, Monash University, Melbourne, VIC, Australia. Electronic address: kate.hoy@monash.edu.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Wong', 'Affiliation': 'Monash Institute of Cognitive and Clinical Neurosciences, School of Psychological Science and Monash Biomedical Imaging, Monash University, Melbourne, Australia; School of Psychology and Public Health, La Trobe University, Bundoora, VIC, Australia. Electronic address: d.wong@latrobe.edu.au.'}, {'ForeName': 'N W', 'Initials': 'NW', 'LastName': 'Bailey', 'Affiliation': 'Epworth Centre for Innovation in Mental Health, Epworth Healthcare, Camberwell, VIC, Australia; Department of Psychiatry, Central Clinical School, Monash University, Melbourne, VIC, Australia. Electronic address: neil.bailey@monash.edu.'}, {'ForeName': 'P B', 'Initials': 'PB', 'LastName': 'Fitzgerald', 'Affiliation': 'Epworth Centre for Innovation in Mental Health, Epworth Healthcare, Camberwell, VIC, Australia; Department of Psychiatry, Central Clinical School, Monash University, Melbourne, VIC, Australia. Electronic address: paul.fitzgerald@monash.edu.'}, {'ForeName': 'R A', 'Initials': 'RA', 'LastName': 'Segrave', 'Affiliation': 'Brain and Mental Health Research Hub, School of Psychological Sciences and Monash Biomedical Imaging, Monash Institute of Cognitive and Clinical Neuroscience, Monash University, Clayton, Australia. Electronic address: rebecca.segrave@monash.edu.'}]",Brain stimulation,['10.1016/j.brs.2020.07.001'] 1627,32659483,Non-invasive vagal nerve stimulation decreases brain activity during trauma scripts.,"BACKGROUND Traumatic stress can have lasting effects on neurobiology and result in psychiatric conditions such as posttraumatic stress disorder (PTSD). We hypothesize that non-invasive cervical vagal nerve stimulation (nVNS) may alleviate trauma symptoms by reducing stress sympathetic reactivity. This study examined how nVNS alters neural responses to personalized traumatic scripts. METHODS Nineteen participants who had experienced trauma but did not have the diagnosis of PTSD completed this double-blind sham-controlled study. In three sequential time blocks, personalized traumatic scripts were presented to participants immediately followed by either sham stimulation (n = 8; 0-14 V, 0.2 Hz, pulse width = 5s) or active nVNS (n = 11; 0-30 V, 25 Hz, pulse width = 40 ms). Brain activity during traumatic scripts was assessed using High Resolution Positron Emission Tomography (HR-PET) with radiolabeled water to measure brain blood flow. RESULTS Traumatic scripts resulted in significant activations within the bilateral medial and orbital prefrontal cortex, premotor cortex, anterior cingulate, thalamus, insula, hippocampus, right amygdala, and right putamen. Greater activation was observed during sham stimulation compared to nVNS within the bilateral prefrontal and orbitofrontal cortex, premotor cortex, temporal lobe, parahippocampal gyrus, insula, and left anterior cingulate. During the first exposure to the trauma scripts, greater activations were found in the motor cortices and ventral visual stream whereas prefrontal cortex and anterior cingulate activations were more predominant with later script presentations for those subjects receiving sham stimulation. CONCLUSION nVNS decreases neural reactivity to an emotional stressor in limbic and other brain areas involved in stress, with changes over repeated exposures suggesting a shift from scene appraisal to cognitively processing the emotional event.",2020,"Greater activation was observed during sham stimulation compared to nVNS within the bilateral prefrontal and orbitofrontal cortex, premotor cortex, temporal lobe, parahippocampal gyrus, insula, and left anterior cingulate.",['Nineteen participants who had experienced trauma but did not have the diagnosis of PTSD completed this double-blind sham-controlled study'],"['invasive cervical vagal nerve stimulation (nVNS', 'active nVNS', 'nVNS']","['bilateral medial and orbital prefrontal cortex, premotor cortex, anterior cingulate, thalamus, insula, hippocampus, right amygdala, and right putamen', 'motor cortices and ventral visual stream whereas prefrontal cortex and anterior cingulate activations', 'Greater activation', 'Brain activity']","[{'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C0205177', 'cui_str': 'Active'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0699036', 'cui_str': 'Orbital'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0228202', 'cui_str': 'Premotor cortex'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate Gyrus'}, {'cui': 'C0039729', 'cui_str': 'Thalamic structure'}, {'cui': 'C0021640', 'cui_str': 'Insular structure'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0002708', 'cui_str': 'Amygdaloid structure'}, {'cui': 'C0026607', 'cui_str': 'Motor cortex'}, {'cui': 'C1704448', 'cui_str': 'Ventral'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0442540', 'cui_str': 'Stream'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0443158', 'cui_str': 'Brain activity'}]",19.0,0.0708328,"Greater activation was observed during sham stimulation compared to nVNS within the bilateral prefrontal and orbitofrontal cortex, premotor cortex, temporal lobe, parahippocampal gyrus, insula, and left anterior cingulate.","[{'ForeName': 'Matthew T', 'Initials': 'MT', 'LastName': 'Wittbrodt', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: mattwittbrodt@emory.edu.'}, {'ForeName': 'Nil Z', 'Initials': 'NZ', 'LastName': 'Gurel', 'Affiliation': 'Department of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, USA.'}, {'ForeName': 'Jonathon A', 'Initials': 'JA', 'LastName': 'Nye', 'Affiliation': 'Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Stacy', 'Initials': 'S', 'LastName': 'Ladd', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Md Mobashir H', 'Initials': 'MMH', 'LastName': 'Shandhi', 'Affiliation': 'Department of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, USA.'}, {'ForeName': 'Minxuan', 'Initials': 'M', 'LastName': 'Huang', 'Affiliation': 'Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Amit J', 'Initials': 'AJ', 'LastName': 'Shah', 'Affiliation': 'Department of Medicine (Cardiology), Emory University School of Medicine, Atlanta, GA, USA; Atlanta VA Medical Center, Decatur, GA, USA.'}, {'ForeName': 'Bradley D', 'Initials': 'BD', 'LastName': 'Pearce', 'Affiliation': 'Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Zuhayr S', 'Initials': 'ZS', 'LastName': 'Alam', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Mark H', 'Initials': 'MH', 'LastName': 'Rapaport', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Murrah', 'Affiliation': 'Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Yi-An', 'Initials': 'YA', 'LastName': 'Ko', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Ammer A', 'Initials': 'AA', 'LastName': 'Haffer', 'Affiliation': 'Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Lucy H', 'Initials': 'LH', 'LastName': 'Shallenberger', 'Affiliation': 'Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Viola', 'Initials': 'V', 'LastName': 'Vaccarino', 'Affiliation': 'Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA; Department of Medicine (Cardiology), Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Omer T', 'Initials': 'OT', 'LastName': 'Inan', 'Affiliation': 'Department of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.'}, {'ForeName': 'J Douglas', 'Initials': 'JD', 'LastName': 'Bremner', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA; Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA; Atlanta VA Medical Center, Decatur, GA, USA.'}]",Brain stimulation,['10.1016/j.brs.2020.07.002'] 1628,32659637,Cost and cost-effectiveness of three strategies for implementing motivational interviewing for substance misuse on medical inpatient units.,"BACKGROUND This study conducted cost and cost-effectiveness analyses of three strategies for implementing motivational interviewing for substance misuse on general medical inpatient units: workshop, apprenticeship, and consult. METHODS The economic analyses were conducted prospectively alongside a type 3 hybrid effectiveness-implementation randomized trial comprising 38 medical providers, 1173 inpatients, and four consultation-liaison motivational interviewing experts. The trial took place in a university affiliated teaching hospital in New Haven, CT, USA. After completing a 1-day workshop on motivational interviewing, providers were randomized to conditions. The primary outcome measure was the number of study-eligible patients who received a motivational interview. The economic analyses included the costs of both start-up and on-going activities in each condition. Incremental cost-effectiveness ratios were used to determine cost effectiveness. Results are presented from the healthcare provider (i.e., hospital) perspective in 2018 US dollars. RESULTS The total cost per patient receiving a motivational interview averaged $804.53, $606.52, and $185.65 for workshop, apprenticeship, and consult, respectively. Workshop and apprenticeship were extended dominated by the combination of consult and doing nothing. Doing nothing is cost effective when the willingness-to-pay for an additional patient receiving a motivational interview is less than $185.65, and consult is cost-effective when the willingness-to-pay for an additional patient receiving a motivational interview is greater than $185.65. CONCLUSIONS Given that typical reimbursements for brief intervention services for substance misuse are $35-$65, none of the three implementation strategies is likely to be economically viable from the healthcare provider perspective.",2020,"The total cost per patient receiving a motivational interview averaged $804.53, $606.52, and $185.65 for workshop, apprenticeship, and consult, respectively.","['substance misuse on medical inpatient units', '38 medical providers, 1173 inpatients, and four consultation-liaison motivational interviewing experts', 'university affiliated teaching hospital in New Haven, CT, USA']",['implementing motivational interviewing'],"['Cost and cost-effectiveness', 'Incremental cost-effectiveness ratios', 'total cost per patient receiving a motivational interview']","[{'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}]",38.0,0.0294972,"The total cost per patient receiving a motivational interview averaged $804.53, $606.52, and $185.65 for workshop, apprenticeship, and consult, respectively.","[{'ForeName': 'Todd A', 'Initials': 'TA', 'LastName': 'Olmstead', 'Affiliation': 'The University of Texas at Austin, Lyndon B. Johnson School of Public Affairs, Sid Richardson Hall, Unit 3, Austin, TX, 78712, USA. Electronic address: tolmstead@austin.utexas.edu.'}, {'ForeName': 'Kimberly A', 'Initials': 'KA', 'LastName': 'Yonkers', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA; Yale School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, 333 Cedar Street, New Haven, CT, 06510, USA; Yale School of Epidemiology and Public Health Division of Chronic Disease, 60 College Street, New Haven, CT, 06520, USA.'}, {'ForeName': 'Ariadna', 'Initials': 'A', 'LastName': 'Forray', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Zimbrean', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Gilstad-Hayden', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Martino', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA; VA Connecticut Healthcare System, Psychology Service, 950 Campbell Avenue (116B), West Haven, CT, 06516, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108156'] 1629,32659641,A comparative study of autologous rectus fascia pubovaginal sling surgery and synthetic transobturator vaginal tape procedure in treatment of women with urodynamic stress urinary incontinence.,"OBJECTIVE To compare short term results of autologous rectus fascia pubovaginal sling surgery with synthetic transobturator vaginal tape procedure in treatment of female stress urinary incontinence (SUI) STUDY DESIGN: It was a comparative study on 30 women between 25-65 years of age with urodynamic proven SUI who were randomly allocated to autologous rectus fascia pubovaginal sling surgery (Group I)(15 women) and synthetic transobturator vaginal tape procedure (Group II) (15 women). Preoperative and postoperative ICIQ (International Consultation on Incontinence Questionnaire) score, urodynamic study and serum CRP and IL-6 were done in all cases. RESULTS The baseline characteristics in terms of age, body mass index (BMI), parity, mean ICIQ score and mean preoperative CRP and IL-6 levels were similar in two groups. Mean operative time was significantly longer (55.60 ± 5.77 vs 25.27 ± 4.32 minutes, p = 0.001) in group I than group II. Mean hospital stay of 7.1 ± 1.2 vs 1.2 ± 0.4 days, mean duration of catheterization 5.8 vs 1.2 day (<0.01) and postoperative urinary retention requiring recathterization were all significantly higher in group I than II. Wound infection was more in group I than in group II (p = 0.01) while groin pain was significantly more in group II (p = 0.01). One patient developed vesicovaginal fistula, while one patient required cutting of tape in group I. Pdet at Q max (Detrusor pressure at peak urine flow) increased significantly in both the groups after surgery. ICIQ score was zero in both the groups indicating 100 % success. Surgical trauma was more in group I as shown by significantly higher CRP levels. CONCLUSION The success rate of the two groups was similar but, autologous rectus fascia sling surgery took longer, had more complications and urinary retention as compared to transobturator vaginal tape procedure.",2020,"Mean operative time was significantly longer (55.60 ± 5.77 vs 25.27 ± 4.32 minutes, p = 0.001) in group I than group II.","['Group II) (15 women', 'women with urodynamic stress urinary incontinence', '30 women between 25-65 years of age with urodynamic proven SUI', 'female stress urinary incontinence']","['autologous rectus fascia pubovaginal sling surgery (Group I)(15 women) and synthetic transobturator vaginal tape procedure', 'autologous rectus fascia pubovaginal sling surgery and synthetic transobturator vaginal tape procedure', 'autologous rectus fascia pubovaginal sling surgery with synthetic transobturator vaginal tape procedure']","['Preoperative and postoperative ICIQ ', 'Mean operative time', 'Mean hospital stay', 'ICIQ score', 'Surgical trauma', 'CRP and IL-6', 'Wound infection', 'postoperative urinary retention requiring recathterization', 'CRP levels', 'complications and urinary retention', 'groin pain', 'vesicovaginal fistula', 'mean duration of catheterization', 'success rate', 'body mass index (BMI), parity, mean ICIQ score and mean preoperative CRP and IL-6 levels', 'Incontinence Questionnaire) score, urodynamic study and serum']","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042059', 'cui_str': 'Urodynamics'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0456369', 'cui_str': 'Proven'}]","[{'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0225234', 'cui_str': 'Structure of fascia of rectus abdominis muscle'}, {'cui': 'C0183346', 'cui_str': 'Sling'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0043241', 'cui_str': 'Local infection of wound'}, {'cui': 'C0080274', 'cui_str': 'Bladder retention of urine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0239783', 'cui_str': 'Inguinal pain'}, {'cui': 'C0042582', 'cui_str': 'Vesicovaginal fistula'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0030563', 'cui_str': 'Parity'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0042059', 'cui_str': 'Urodynamics'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",30.0,0.0224989,"Mean operative time was significantly longer (55.60 ± 5.77 vs 25.27 ± 4.32 minutes, p = 0.001) in group I than group II.","[{'ForeName': 'J B', 'Initials': 'JB', 'LastName': 'Sharma', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: jbsharma@aiims.ac.in.'}, {'ForeName': 'Manasi Kamalakar', 'Initials': 'MK', 'LastName': 'Deoghare', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Neerja', 'Initials': 'N', 'LastName': 'Bhatla', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Garima', 'Initials': 'G', 'LastName': 'Kachhawa', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Reeta', 'Initials': 'R', 'LastName': 'Mahey', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Kumari', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Amlesh', 'Initials': 'A', 'LastName': 'Seth', 'Affiliation': 'Department of Urology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Alpana', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.06.062'] 1630,31705570,Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia.,"BACKGROUND Patients with acute myeloid leukemia (AML) are surviving longer. There are no data on changes in myocardial mechanics from standard of care low-dose anthracycline-based induction chemotherapy in older patients with AML. The aim of this study was to demonstrate the potential utility of strain imaging in detecting early changes in left ventricular function in this patient population after induction chemotherapy. METHODS Thirty two patients enrolled in the ECOG-ACRIN E2906 study (cytarabine and daunorubicin vs clofarabine [Genzyme/Sanofi]) from 2011 to 2014 were evaluated retrospectively. Two-dimensional transthoracic echocardiography (TTE) imaging with Doppler and two-dimensional speckle-tracking echocardiography (2DSTE) using EchoInsight software (Epsilon imaging) were performed before and after induction chemotherapy. RESULTS Eighteen patients received cytarabine and daunorubicin (7 + 3) and 14 received clofarabine. The clofarabine group was older than the 7 + 3 cohort (67.8 ± 4.0 vs 63.7 ± 3.8, P = .007). There were no other significant differences in cardiac risk factors between groups. The 7 + 3 group had a decrease in average peak systolic global longitudinal (-19.1 ± 2.8 to -17.2 ± 3.0, P = .01) and circumferential strain (-29.4 ± 6.3 to -23.9 ± 4.3, P = .011). These changes were not demonstrated in the clofarabine group and were not associated with a decline in left ventricular ejection fraction (LVEF). CONCLUSIONS In older AML patients, standard cytarabine and daunorubicin chemotherapy causes early changes in global longitudinal and circumferential strain not seen with clofarabine therapy. These findings demonstrate subclinical left ventricular dysfunction after exposure to low cumulative doses of anthracycline-based induction chemotherapy and may help us better identify those patients at risk for adverse long-term cardiovascular outcomes.",2019,"These changes were not demonstrated in the clofarabine group and were not associated with a decline in left ventricular ejection fraction (LVEF). ","['Patients with acute myeloid leukemia (AML', 'older patients with AML', 'two patients enrolled in the ECOG-ACRIN E2906 study', 'patient population after induction chemotherapy', 'Thirty', 'older patients treated for acute myeloid leukemia']","['anthracycline-based induction chemotherapy', 'cytarabine and daunorubicin', 'Two-dimensional speckle-tracking strain', 'clofarabine', 'Two-dimensional transthoracic echocardiography (TTE) imaging with Doppler and two-dimensional speckle-tracking echocardiography (2DSTE) using EchoInsight software (Epsilon imaging', 'cytarabine and daunorubicin vs clofarabine [Genzyme/Sanofi', 'standard cytarabine and daunorubicin chemotherapy', 'clofarabine therapy', 'strain imaging']","['myocardial mechanics', 'average peak systolic global longitudinal', 'circumferential strain', 'cardiac risk factors', 'left ventricular ejection fraction (LVEF']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0430797', 'cui_str': 'Electrocorticogram'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C3179010', 'cui_str': 'Induction chemotherapy'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for'}]","[{'cui': 'C0003234', 'cui_str': 'Anthracycline'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C3179010', 'cui_str': 'Induction chemotherapy'}, {'cui': 'C0010711', 'cui_str': 'Cytarabine'}, {'cui': 'C0011015', 'cui_str': 'Daunorubicin'}, {'cui': 'C0439691', 'cui_str': 'Speckled'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0092777', 'cui_str': 'clofarabine'}, {'cui': 'C0013516', 'cui_str': 'Echocardiography'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0554756', 'cui_str': 'Doppler studies'}, {'cui': 'C0037585', 'cui_str': 'Software'}, {'cui': 'C0113456', 'cui_str': ""di(1,N(6)-ethenoadenosine)-5',5'''-P(1),P(4)-tetraphosphate""}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0376706', 'cui_str': 'Mechanics'}, {'cui': 'C0442710', 'cui_str': 'Peak systolic'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0205113', 'cui_str': 'Circumferential'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}]",32.0,0.0385403,"These changes were not demonstrated in the clofarabine group and were not associated with a decline in left ventricular ejection fraction (LVEF). ","[{'ForeName': 'Gregory J', 'Initials': 'GJ', 'LastName': 'Cascino', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Woo Bin', 'Initials': 'WB', 'LastName': 'Voss', 'Affiliation': 'Department of Cardiology, North Shore Hospital, Auckland, New Zealand.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Canaani', 'Affiliation': 'Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Furiasse', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Alfred', 'Initials': 'A', 'LastName': 'Rademaker', 'Affiliation': 'Department of Preventative Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Bonnie', 'Initials': 'B', 'LastName': 'Ky', 'Affiliation': 'Division of Cardiovascular Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Selina', 'Initials': 'S', 'LastName': 'Luger', 'Affiliation': 'Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Jessica K', 'Initials': 'JK', 'LastName': 'Altman', 'Affiliation': 'Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Foran', 'Affiliation': 'Division of Hematology, Mayo Clinic, Jacksonville, Florida.'}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Litzow', 'Affiliation': 'Division of Hematology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Martin S', 'Initials': 'MS', 'LastName': 'Tallman', 'Affiliation': 'Division of Hematologic Oncology, Sloan Kettering Memorial Cancer Center, New York, New York.'}, {'ForeName': 'Vera', 'Initials': 'V', 'LastName': 'Rigolin', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Nausheen', 'Initials': 'N', 'LastName': 'Akhter', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.'}]","Echocardiography (Mount Kisco, N.Y.)",['10.1111/echo.14518'] 1631,32662069,Qigong for the treatment of depressive symptoms: Preliminary evidence of neurobiological mechanisms.,"OBJECTIVES Qigong has been shown to effectively reduce depressive symptoms in older adults with chronic physical illness. Here, we sought to evaluate the effects of qigong on serotonin, cortisol, and Brain-derived Neurotropic Factors (BDNF) levels and test their roles as potential mediators of the effects of qigong on depressive symptoms. METHODS Thirty older adults with chronic physical illness participated in a randomized clinical trial. They were randomly assigned to a qigong group (n = 14) or a control group for cognitive training of executive function and memory (n = 16). The participants provided blood and saliva samples at baseline and post-intervention. Levels of cortisol were measured from the salvia samples, and serotonin and BDNF were measured from the blood samples. RESULTS Consistent with the study findings presented in the primary outcome paper, a significant Group × Time interaction effect emerged on depressive symptoms, explained by greater reductions in the qigong group than the control group. Qigong participants had significantly larger increases in serotonin and BDNF, and decreases in cortisol levels, compared with control group participants. Moreover, treatment-related changes in cortisol levels (but not serotonin or BDNF) fully mediated the beneficial effects of qigong on depressive symptoms. CONCLUSION The findings provide preliminary evidence that treatment-related changes in cortisol may mediate the benefits of qigong on depressive symptoms. Given the limitation of small sample size of the present study, future studies with larger sample sizes and more extended follow-up assessment are warranted to determine the reliability of these findings.",2020,"Qigong participants had significantly larger increases in serotonin and BDNF, and decreases in cortisol levels, compared with control group participants.","['older adults with chronic physical illness', 'Thirty older adults with chronic physical illness', 'depressive symptoms']","['Qigong', 'qigong group (n\xa0=\xa014) or a control group for cognitive training of executive function and memory']","['Levels of cortisol', 'cortisol levels', 'serotonin, cortisol, and BDNF levels', 'serotonin and Brain-derived Neurotropic Factors (BDNF', 'serotonin and BDNF', 'depressive symptoms']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]","[{'cui': 'C0282077', 'cui_str': 'Qigong'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",30.0,0.0837699,"Qigong participants had significantly larger increases in serotonin and BDNF, and decreases in cortisol levels, compared with control group participants.","[{'ForeName': 'Erin Yiqing', 'Initials': 'EY', 'LastName': 'Lu', 'Affiliation': 'Neuropsychiatric Rehabilitation Laboratory, Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR.'}, {'ForeName': 'Posen', 'Initials': 'P', 'LastName': 'Lee', 'Affiliation': 'Department of Occupational Therapy, I-Shou University, Kaohsiung City, Taiwan.'}, {'ForeName': 'Shuhe', 'Initials': 'S', 'LastName': 'Cai', 'Affiliation': 'Department of Orthopedic Rehabilitation, Fujian University of Traditional Chinese Medicine Subsidiary Rehabilitation Hospital, Fuzhou, Fujian, China.'}, {'ForeName': 'Wendy Wing Yan', 'Initials': 'WWY', 'LastName': 'So', 'Affiliation': 'Neuropsychiatric Rehabilitation Laboratory, Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR.'}, {'ForeName': 'Bacon Fung Leung', 'Initials': 'BFL', 'LastName': 'Ng', 'Affiliation': 'Department of Chinese Medicine, Hospital Authority, Hong Kong SAR.'}, {'ForeName': 'Mark P', 'Initials': 'MP', 'LastName': 'Jensen', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington, Seattle, Washington.'}, {'ForeName': 'Wai Ming', 'Initials': 'WM', 'LastName': 'Cheung', 'Affiliation': 'Faculty of Education, The University of Hong Kong, Pokfulam Road, Hong Kong SAR.'}, {'ForeName': 'Hector W H', 'Initials': 'HWH', 'LastName': 'Tsang', 'Affiliation': 'Neuropsychiatric Rehabilitation Laboratory, Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR.'}]",International journal of geriatric psychiatry,['10.1002/gps.5380'] 1632,32633861,Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.,"BACKGROUND Branch retinal vein occlusion (BRVO) is one of the most commonly occurring retinal vascular abnormalities. The most common cause of visual loss in people with BRVO is macular oedema (MO). Grid or focal laser photocoagulation has been shown to reduce the risk of visual loss. Limitations to this treatment exist, however, and newer modalities may have equal or improved efficacy. Antiangiogenic therapy with anti-vascular endothelial growth factor (anti-VEGF) has recently been used successfully to treat MO resulting from a variety of causes. OBJECTIVES To investigate the efficacy and gather evidence from randomised controlled trials (RCTs) on the potential harms of anti-vascular endothelial growth factor (VEGF) agents for the treatment of macular oedema (MO) secondary to branch retinal vein occlusion (BRVO). SEARCH METHODS We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2019, Issue 6); MEDLINE Ovid; Embase Ovid; the ISRCTN registry; ClinicalTrials.gov; and the WHO ICTRP. The date of the last search was 12 June 2019. SELECTION CRITERIA We included randomised controlled trials (RCTs) investigating BRVO. Eligible trials had to have at least six months' follow-up where anti-VEGF treatment was compared with another treatment, no treatment, or placebo. We excluded trials where combination treatments (anti-VEGF plus other treatments) were used; and trials that investigated the dose and duration of treatment without a comparison group (other treatment/no treatment/sham). DATA COLLECTION AND ANALYSIS Two review authors independently extracted the data using standard methodological procedures expected by Cochrane. The primary outcome was the proportion of participants with an improvement from baseline in best-corrected visual acuity of greater than or equal to 15 letters (3 lines) on the Early Treatment in Diabetic Retinopathy Study (ETDRS) Chart at six months and 12 months of follow-up. The secondary outcomes were the proportion of participants who lost greater than or equal to 15 ETDRS letters (3 lines) and the mean visual acuity (VA) change at six and 12 months, as well as the change in central retinal thickness (CRT) on optical coherence tomography from baseline at six and 12 months. We also collected data on adverse events and quality of life (QoL). MAIN RESULTS We found eight RCTs of 1631 participants that met the inclusion criteria after independent and duplicate review of the search results. These studies took place in Europe, North America, Eastern Mediterranean region and East Asia. Included participants were adults aged 18 or over with VA of 20/40 or worse. Studies varied by duration of disease but permitted previously treated eyes as long as there was sufficient treatment-free interval. All anti-VEGF agents (bevacizumab, ranibizumab and aflibercept) and steroids (triamcinolone and dexamethasone) were included. Overall, we judged the studies to be at moderate or unclear risk of bias. Four of the eight studies did not mask participants or outcome assessors, or both. One trial compared anti-VEGF to sham. At six months, eyes receiving anti-VEGF were significantly more likely to have a gain of 15 or more ETDRS letters (risk ratio (RR) 1.72, 95% confidence interval (CI) 1.19 to 2.49; 283 participants; moderate-certainty evidence). Mean VA was better in the anti-VEGF group at six months compared with control (mean difference (MD) 7.50 letters, 95% CI 5.29 to 9.71; 282 participants; moderate-certainty evidence). Anti-VEGF also proved more effective at reducing CRT at six months (MD -57.50 microns, 95% CI -108.63 to -6.37; 281 participants; lower CRT is better; moderate-certainty evidence). There was only very low-certainty evidence on adverse effects. There were no reports of endophthalmitis. Mean change in QoL (measured using the National Eye Institute Visual Functioning Questionnaire VFQ-25) was better in people treated with anti-VEGF compared with people treated with sham (MD 7.6 higher score, 95% CI 4.3 to 10.9; 281 participants; moderate-certainty evidence). Three RCTs compared anti-VEGF with macular laser (total participants = 473). The proportion of eyes gaining 15 or more letters was greater in the anti-VEGF group at six months (RR 2.09, 95% CI 1.44 to 3.05; 2 studies, 201 participants; moderate-certainty evidence). Mean VA in the anti-VEGF groups was better than the laser groups at six months (MD 9.63 letters, 95% CI 7.23 to 12.03; 3 studies, 473 participants; moderate-certainty evidence). There was a greater reduction in CRT in the anti-VEGF group compared with the laser group at six months (MD -147.47 microns, 95% CI -200.19 to -94.75; 2 studies, 201 participants; moderate-certainty evidence). There was only very low-certainty evidence on adverse events. There were no reports of endophthalmitis. QoL outcomes were not reported. Four studies compared anti-VEGF with intravitreal steroid (875 participants). The proportion of eyes gaining 15 or more ETDRS letters was greater in the anti-VEGF group at six months (RR 1.67, 95% CI 1.33 to 2.10; 2 studies, 330 participants; high-certainty evidence) and 12 months (RR 1.76, 95% CI 1.36 to 2.28; 1 study, 307 participants; high-certainty evidence). Mean VA was better in the anti-VEGF group at six months (MD 8.22 letters, 95% CI 5.69 to 10.76; 2 studies, 330 participants; high-certainty evidence) and 12 months (MD 9.15 letters, 95% CI 6.32 to 11.97; 2 studies, 343 participants; high-certainty evidence). Mean CRT also showed a greater reduction in the anti-VEGF arm at 12 months compared with intravitreal steroid (MD -26.92 microns, 95% CI -65.88 to 12.04; 2 studies, 343 participants; moderate-certainty evidence). People receiving anti-VEGF showed a greater improvement in QoL at 12 months compared to those receiving steroid (MD 3.10, 95% CI 0.22 to 5.98; 1 study, 307 participants; moderate-certainty evidence). Moderate-certainty evidence suggested increased risk of cataract and raised IOP with steroids. There was only very low-certainty evidence on APTC events. No cases of endophthalmitis were observed. AUTHORS' CONCLUSIONS The available RCT evidence suggests that treatment of MO secondary to BRVO with anti-VEGF improves visual and anatomical outcomes at six and 12 months.",2020,"Mean VA was better in the anti-VEGF group at six months (MD 8.22 letters, 95% CI 5.69 to 10.76; 2 studies, 330 participants; high-certainty evidence) and 12 months (MD 9.15 letters, 95% CI 6.32 to 11.97; 2 studies, 343 participants; high-certainty evidence).","['macular oedema (MO) secondary to branch retinal vein occlusion (BRVO', '1631 participants that met the inclusion criteria after independent and duplicate review of the search results', 'Included participants were adults aged 18 or over with VA of 20/40 or worse', 'Europe, North America, Eastern Mediterranean region and East Asia', 'macular oedema secondary to branch retinal vein occlusion', 'people with BRVO is macular oedema (MO']","['comparison group (other treatment/no treatment/sham', 'anti-VEGF with intravitreal steroid', 'Antiangiogenic therapy with anti-vascular endothelial growth factor (anti-VEGF', 'placebo', 'anti-VEGF', 'Branch retinal vein occlusion (BRVO', 'VEGF agents (bevacizumab, ranibizumab and aflibercept) and steroids (triamcinolone and dexamethasone', 'Grid or focal laser photocoagulation', 'anti-vascular endothelial growth factor (VEGF) agents', 'Anti-vascular endothelial growth factor']","['CRT', 'visual and anatomical outcomes', 'gain of 15 or more ETDRS letters', 'visual loss', 'endophthalmitis', 'central retinal thickness (CRT', 'Diabetic Retinopathy Study (ETDRS', 'risk of visual loss', 'adverse events', 'adverse events and quality of life (QoL', 'QoL', 'proportion of eyes gaining 15 or more ETDRS letters', 'QoL outcomes', 'proportion of participants with an improvement from baseline in best-corrected visual acuity', 'proportion of eyes gaining 15 or more letters', 'Mean VA', 'Mean CRT', 'proportion of participants who lost greater than or equal to 15 ETDRS letters (3 lines) and the mean visual acuity (VA) change', 'National Eye Institute Visual Functioning Questionnaire VFQ-25', 'adverse effects', 'Mean change in QoL']","[{'cui': 'C0271051', 'cui_str': 'Macular retinal edema'}, {'cui': 'C0175668', 'cui_str': 'Secondary'}, {'cui': 'C0339505', 'cui_str': 'Venous retinal branch occlusion'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0699752', 'cui_str': 'Review of'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0442752', 'cui_str': 'Distance vision 6/12'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C0282645', 'cui_str': 'Mediterranean Region'}, {'cui': 'C0015631', 'cui_str': 'Far east country'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C1517572', 'cui_str': 'Intravitreal route'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C2363719', 'cui_str': 'Antiangiogenic therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0339505', 'cui_str': 'Venous retinal branch occlusion'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C1134659', 'cui_str': 'aflibercept'}, {'cui': 'C0040864', 'cui_str': 'Triamcinolone'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0948675', 'cui_str': 'Focal laser photocoagulation'}]","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0035298', 'cui_str': 'Retinal structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0220784', 'cui_str': 'Anatomic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011884', 'cui_str': 'Retinopathy due to diabetes mellitus'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0282413', 'cui_str': 'Letters as Topic'}, {'cui': 'C3665346', 'cui_str': 'Unspecified visual loss'}, {'cui': 'C0014236', 'cui_str': 'Endophthalmitis'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0439091', 'cui_str': '>='}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1955969', 'cui_str': 'National Eye Institute'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",307.0,0.421011,"Mean VA was better in the anti-VEGF group at six months (MD 8.22 letters, 95% CI 5.69 to 10.76; 2 studies, 330 participants; high-certainty evidence) and 12 months (MD 9.15 letters, 95% CI 6.32 to 11.97; 2 studies, 343 participants; high-certainty evidence).","[{'ForeName': 'Zaid', 'Initials': 'Z', 'LastName': 'Shalchi', 'Affiliation': 'Moorfields Eye Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Mahroo', 'Affiliation': 'Moorfields Eye Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'Catey', 'Initials': 'C', 'LastName': 'Bunce', 'Affiliation': 'London, UK.'}, {'ForeName': 'Danny', 'Initials': 'D', 'LastName': 'Mitry', 'Affiliation': 'Moorfields Eye Hospital NHS Foundation Trust, London, UK.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD009510.pub3'] 1633,32629112,Antibiotic route and duration of therapy for cellulitis: data extracted from a multi-center clinical trial.,"INTRODUCTION Although cellulitis is a relatively common condition, there is uncertainty about the benefit of intravenous (IV) over oral (PO) antibiotic therapy, and the appropriate duration of treatment. METHODS Data extracted from a clinical trial (NCT01876628) of antibiotic therapy for cellulitis were used to assess the association between the route of administration and duration of treatment, and clinical outcome. RESULTS Of 323 patients with antibiotic data, 114 received some IV therapy. IV antibiotic therapy was preferred in those who had received antibiotics prior to trial entry (P < 0.001). Patients characterised as having more severe cellulitis (C-reactive protein > 100 mg/L, affected skin surface area > 5% or systemic inflammatory response syndrome score ≥ 1) were more likely to have had IV therapy. Those given only PO therapy were more likely to have improved at day 5 compared with those given at least a single dose of IV therapy (P = 0.015), and were as likely to be back to their normal activities at day 10 (P = 0.90), and day 30 (P = 0.86). There was no association between initial severity and the duration of antibiotic therapy given within the trial. There was no association between duration of antibiotic therapy and outcome as measured at day 10 and day 30. CONCLUSIONS This study provides evidence that recovery is not associated with the route of antibiotic administration for patients with cellulitis of similar severity, or that a course length of > 5 days results in any additional benefit.",2020,IV antibiotic therapy was preferred in those who had received antibiotics prior to trial entry (p<0.001).,"['323 patients with antibiotic data', '114 patients received some IV therapy']","['antibiotic therapy', 'IV antibiotic therapy', 'intravenous (IV) over oral (PO) antibiotic therapy']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0455142', 'cui_str': 'Intravenous therapy'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0559680', 'cui_str': 'Intravenous antibiotic therapy'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0559681', 'cui_str': 'Oral antibiotic therapy'}]",[],323.0,0.0803809,IV antibiotic therapy was preferred in those who had received antibiotics prior to trial entry (p<0.001).,"[{'ForeName': 'O Martin', 'Initials': 'OM', 'LastName': 'Williams', 'Affiliation': 'Public Health England Microbiology Services Bristol, Bristol Royal Infirmary, Bristol, UK; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Infirmary, Bristol, UK. Electronic address: martinx.williams@uhbw.nhs.uk.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Brindle', 'Affiliation': 'Public Health England Microbiology Services Bristol, Bristol Royal Infirmary, Bristol, UK; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Infirmary, Bristol, UK; School of Clinical Sciences, University of Bristol, Bristol, UK. Electronic address: Richard.brindle@bristol.ac.uk.'}]",International journal of antimicrobial agents,['10.1016/j.ijantimicag.2020.106076'] 1634,32629994,Effects of Artificial Texture Insoles and Foot Arches on Improving Arch Collapse in Flat Feet.,"The arches of the foot play a vital role in cushioning the impact and pressure generated from ground reaction forces due to body weight. Owing to a lack of normal human arch structure, people diagnosed as having flat feet often have discomfort in the soles of their feet. The results may not only cause inappropriate foot pressure distribution on the sole but also further cause foot injuries. This study heavily relies on a homemade foot pressure sensing device equipped with textured insoles of different heights and artificial arches. This was to explore the extent to which the pressure distribution of the foot in people with flat feet could be improved. A further comparison was made of the effects of using the textured insoles with different heights on two different groups of people diagnosed with flat and normal feet respectively. Sixty-five undergraduate and postgraduate volunteers were invited to receive the ink footprint test for measuring their degrees of arch index. Nine of these 65 had 2 flat feet, 3 had a left flat foot, 5 had a right flat foot, and 48 had 2 normal feet. To ensure the same number of subjects in both the control and the experimental groups, 9 of the 48 subjects who had normal feet were randomly selected. In total, 26 subjects (Male: 25, Female: 1; Age: 22 ± 1 years; height: 173.6 ± 2.5 cm; body mass: 68.3 ± 5.4 kg; BMI: 22.6 ± 1.2) were invited to participate in this foot pressure sensing insoles study. The experimental results showed that the use of textured insoles designed with different heights could not effectively improve the plantar pressure distribution and body stability in subjects with flat feet. Conversely, the use of an artificial arch effectively improved the excessive peak in pressure and poor body stability, and alleviated the problem of plantar collapse for patients with flat feet, especially in the inner part of their hallux and forefoot.",2020,The experimental results showed that the use of textured insoles designed with different heights could not effectively improve the plantar pressure distribution and body stability in subjects with flat feet.,"['Flat Feet', 'people diagnosed with flat and normal feet respectively', 'In total, 26 subjects (Male: 25, Female: 1; Age: 22 ± 1 years; height: 173.6 ± 2.5 cm; body mass: 68.3 ± 5.4 kg; BMI: 22.6 ± 1.2) were invited to participate in this foot pressure sensing insoles study', 'Sixty-five undergraduate and postgraduate volunteers', '48 subjects who had normal feet', 'subjects with flat feet', 'Nine of these 65 had 2 flat feet, 3 had a left flat foot, 5 had a right flat foot, and 48 had 2 normal feet']",['Artificial Texture Insoles and Foot Arches'],"['plantar pressure distribution and body stability', 'excessive peak in pressure and poor body stability']","[{'cui': 'C0016202', 'cui_str': 'Flatfeet'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205324', 'cui_str': 'Flat'}, {'cui': 'C0576239', 'cui_str': 'Foot normal'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C4517792', 'cui_str': '5.4'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4068880', 'cui_str': '1.2'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C3873740', 'cui_str': 'Insole'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0450385', 'cui_str': '65'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0205090', 'cui_str': 'Right'}]","[{'cui': 'C2004457', 'cui_str': 'Artificial'}, {'cui': 'C0449582', 'cui_str': 'With texture'}, {'cui': 'C3873740', 'cui_str': 'Insole'}, {'cui': 'C0230467', 'cui_str': 'Structure of arch of foot'}]","[{'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0442802', 'cui_str': 'Excessive'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}]",26.0,0.0206057,The experimental results showed that the use of textured insoles designed with different heights could not effectively improve the plantar pressure distribution and body stability in subjects with flat feet.,"[{'ForeName': 'Yao-Te', 'Initials': 'YT', 'LastName': 'Wang', 'Affiliation': 'Information Management, National Yunlin University of Science and Technology, Yunlin 64002, Taiwan.'}, {'ForeName': 'Jong-Chen', 'Initials': 'JC', 'LastName': 'Chen', 'Affiliation': 'Information Management, National Yunlin University of Science and Technology, Yunlin 64002, Taiwan.'}, {'ForeName': 'Ying-Sheng', 'Initials': 'YS', 'LastName': 'Lin', 'Affiliation': 'Plastic surgery, National Taiwan University Hospital Yunlin Branch, Yunlin 640203, Taiwan.'}]","Sensors (Basel, Switzerland)",['10.3390/s20133667'] 1635,32631157,Tenecteplase versus alteplase after acute ischemic stroke at high age.,"BACKGROUND Stroke prevalence is increasing with age. Alteplase is the only agent approved for thrombolytic treatment for patients with ischemic stroke, including patients ≥80 years. In the present study, the aim was to compare efficacy and safety of tenecteplase and alteplase in patients ≥80 years. METHODS Data from the Norwegian Tenecteplase Stroke Trial, a randomized controlled trial comparing alteplase and tenecteplase, were assessed. RESULTS Of the 273 patients ≥80 years included, mean age was 85.5 years. In the intention-to-treat analyses, 43.1% receiving tenecteplase and 39.9% receiving alteplase reached excellent functional outcome (modified Rankin Scale score 0-1) after 3 months (odds ratio (OR) 1.14, 95% confidence interval (CI) 0.70-1.85, p=0.59). No significant differences among patients in the two treatment groups regarding frequency of symptomatic intracranial hemorrhage during the first 48 h were identified (11 (8.5%) in the tenecteplase group, 10 (7.0%) in the alteplase group, OR 1.23, 95% CI 0.50-3.00, p 0.65). Death within 3 months occurred in 18 patients (14.3%) in the tenecteplase group and in 21 (15.3%) in the alteplase group (p 0.84). After excluding stroke mimics, the proportion of patients with excellent functional outcome was 44.1% in the tenecteplase group and 34.4% in the alteplase group (OR 1.50 CI 0.90-2.52, p 0.12). CONCLUSION No differences in the efficacy and safety of tenecteplase versus alteplase in patients ≥80 years were identified. TRIAL REGISTRATION Clinicaltrials.gov (NCT01949948).",2020,"No significant differences among patients in the two treatment groups regarding frequency of symptomatic intracranial hemorrhage during the first 48 h were identified (11 (8.5%) in the tenecteplase group, 10 (7.0%) in the alteplase group, OR 1.23, 95% CI 0.50-3.00, p 0.65).","['patients with ischemic stroke, including patients ≥80 years', '≥80 years included, mean age was 85.5 years', 'patients ≥80 years were identified', '273 patients', 'Data from the Norwegian Tenecteplase Stroke Trial', 'patients ≥80 years']","['Alteplase', 'tenecteplase and alteplase', 'Tenecteplase versus alteplase']","['efficacy and safety', 'proportion of patients with excellent functional outcome', 'Death', 'frequency of symptomatic intracranial hemorrhage']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0028424', 'cui_str': 'Norwegian language'}, {'cui': 'C0872913', 'cui_str': 'Tenecteplase'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0032143', 'cui_str': 'alteplase'}, {'cui': 'C0872913', 'cui_str': 'Tenecteplase'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0151699', 'cui_str': 'Intracranial hemorrhage'}]",273.0,0.114169,"No significant differences among patients in the two treatment groups regarding frequency of symptomatic intracranial hemorrhage during the first 48 h were identified (11 (8.5%) in the tenecteplase group, 10 (7.0%) in the alteplase group, OR 1.23, 95% CI 0.50-3.00, p 0.65).","[{'ForeName': 'Bente', 'Initials': 'B', 'LastName': 'Thommessen', 'Affiliation': 'Department of Neurology, Division of Medicine, Akershus University Hospital, Lorenskog, Norway.'}, {'ForeName': 'Halvor', 'Initials': 'H', 'LastName': 'Næss', 'Affiliation': 'Department of Neurology, Haukeland University Hospital, Bergen, Norway.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Logallo', 'Affiliation': 'Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway.'}, {'ForeName': 'Christopher E', 'Initials': 'CE', 'LastName': 'Kvistad', 'Affiliation': 'Department of Neurology, Haukeland University Hospital, Bergen, Norway.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Waje-Andreassen', 'Affiliation': 'Department of Neurology, Haukeland University Hospital, Bergen, Norway.'}, {'ForeName': 'Hege', 'Initials': 'H', 'LastName': 'Ihle-Hansen', 'Affiliation': 'Department of Internal Medicine, Bærum Hospital, Drammen, Norway.'}, {'ForeName': 'Håkon', 'Initials': 'H', 'LastName': 'Ihle-Hansen', 'Affiliation': 'Department of Internal Medicine, Bærum Hospital, Drammen, Norway.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Thomassen', 'Affiliation': 'Department of Neurology, Haukeland University Hospital, Bergen, Norway.'}, {'ForeName': 'Ole Morten', 'Initials': 'OM', 'LastName': 'Rønning', 'Affiliation': 'Department of Neurology, Division of Medicine, Akershus University Hospital, Lorenskog, Norway.'}]",International journal of stroke : official journal of the International Stroke Society,['10.1177/1747493020938306'] 1636,31582354,"Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.","BACKGROUND Fludarabine, cyclophosphamide, and rituximab (FCR) has become a gold-standard chemoimmunotherapy regimen for patients with chronic lymphocytic leukaemia. However, the question remains of how to treat treatment-naive patients with IGHV-unmutated chronic lymphocytic leukaemia. We therefore aimed to develop and validate a gene expression signature to identify which of these patients are likely to achieve durable remissions with FCR chemoimmunotherapy. METHODS We did a retrospective cohort study in two cohorts of treatment-naive patients (aged ≥18 years) with chronic lymphocytic leukaemia. The discovery and training cohort consisted of peripheral blood samples collected from patients treated at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), who fulfilled the diagnostic criteria of the International Workshop on Chronic Lymphocytic Leukemia, had received at least three cycles of FCR chemoimmunotherapy, and had been treated between Oct 10, 2000, and Oct 26, 2006 (ie, the MDACC cohort). We did transcriptional profiling on samples obtained from the MDACC cohort to identify genes associated with time to progression. We did univariate Cox proportional hazards analyses and used significant genes to cluster IGHV-unmutated samples into two groups (intermediate prognosis and unfavourable prognosis). After using cross-validation to assess robustness, we applied the Lasso method to standardise the gene expression values to find a minimum gene signature. We validated this signature in an external cohort of treatment-naive patients with IGHV-unmutated chronic lymphocytic leukaemia enrolled on the CLL8 trial of the German Chronic Lymphocytic Leukaemia Study Group who were treated between July 21, 2003, and April 4, 2006 (ie, the CLL8 cohort). FINDINGS The MDACC cohort consisted of 101 patients and the CLL8 cohort consisted of 109 patients. Using the MDACC cohort, we identified and developed a 17-gene expression signature that distinguished IGHV-unmutated patients who were likely to achieve a long-term remission following front-line FCR chemoimmunotherapy from those who might benefit from alternative front-line regimens (hazard ratio 3·83, 95% CI 1·94-7·59; p<0·0001). We validated this gene signature in the CLL8 cohort; patients with an unfavourable prognosis versus those with an intermediate prognosis had a cause-specific hazard ratio of 1·90 (95% CI 1·18-3·06; p=0·008). Median time to progression was 39 months (IQR 22-69) for those with an unfavourable prognosis compared with 59 months (28-84) for those with an intermediate prognosis. INTERPRETATION We have developed a robust, reproducible 17-gene signature that identifies a subset of treatment-naive patients with IGHV-unmutated chronic lymphocytic leukaemia who might substantially benefit from treatment with FCR chemoimmunotherapy. We recommend testing the value of this gene signature in a prospective study that compares FCR treatment with newer alternative therapies as part of a randomised clinical trial. FUNDING Chronic Lymphocytic Leukaemia Global Research Foundation and the National Institutes of Health/National Cancer Institute.",2019,"Median time to progression was 39 months (IQR 22-69) for those with an unfavourable prognosis compared with 59 months (28-84) for those with an intermediate prognosis. ","['patients treated at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), who fulfilled the diagnostic criteria of the International Workshop on Chronic Lymphocytic Leukemia, had received at least three cycles of FCR chemoimmunotherapy, and had been treated between Oct 10, 2000, and Oct 26, 2006 (ie, the MDACC cohort', 'patients with chronic lymphocytic leukaemia', 'chronic lymphocytic leukaemia', 'two cohorts of treatment-naive patients (aged ≥18 years) with chronic lymphocytic leukaemia', 'naive patients with IGHV-unmutated chronic lymphocytic leukaemia', 'external cohort of treatment-naive patients with IGHV-unmutated chronic lymphocytic leukaemia enrolled on the CLL8 trial of the German Chronic Lymphocytic Leukaemia Study Group who were treated between July 21, 2003, and April 4, 2006 (ie, the CLL8 cohort', '101 patients and the CLL8 cohort consisted of 109 patients']","['Fludarabine, cyclophosphamide, and rituximab (FCR', 'fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy', 'FCR chemoimmunotherapy']",['Median time to progression'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0039711', 'cui_str': 'Texas'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0023434', 'cui_str': 'Chronic lymphocytic leukemia'}, {'cui': 'C0059985', 'cui_str': 'fludarabine'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0029279', 'cui_str': 'Ornithine carbamoyltransferase'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}]","[{'cui': 'C0059985', 'cui_str': 'fludarabine'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}]",101.0,0.0518222,"Median time to progression was 39 months (IQR 22-69) for those with an unfavourable prognosis compared with 59 months (28-84) for those with an intermediate prognosis. ","[{'ForeName': 'Carmen D', 'Initials': 'CD', 'LastName': 'Herling', 'Affiliation': 'Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, Cologne, Germany.'}, {'ForeName': 'Kevin R', 'Initials': 'KR', 'LastName': 'Coombes', 'Affiliation': 'Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Benner', 'Affiliation': 'Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Bloehdorn', 'Affiliation': 'Internal Medicine III, University Hospital Ulm, Ulm, Germany.'}, {'ForeName': 'Lynn L', 'Initials': 'LL', 'LastName': 'Barron', 'Affiliation': 'Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Zachary B', 'Initials': 'ZB', 'LastName': 'Abrams', 'Affiliation': 'Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.'}, {'ForeName': 'Tadeusz', 'Initials': 'T', 'LastName': 'Majewski', 'Affiliation': 'Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Jolanta E', 'Initials': 'JE', 'LastName': 'Bondaruk', 'Affiliation': 'Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Jasmin', 'Initials': 'J', 'LastName': 'Bahlo', 'Affiliation': 'Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, Cologne, Germany.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Fischer', 'Affiliation': 'Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, Cologne, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hallek', 'Affiliation': 'Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, Cologne, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Stilgenbauer', 'Affiliation': 'Internal Medicine III, University Hospital Ulm, Ulm, Germany.'}, {'ForeName': 'Bogdan A', 'Initials': 'BA', 'LastName': 'Czerniak', 'Affiliation': 'Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Christopher C', 'Initials': 'CC', 'LastName': 'Oakes', 'Affiliation': 'Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Ferrajoli', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Keating', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Lynne V', 'Initials': 'LV', 'LastName': 'Abruzzo', 'Affiliation': 'Department of Pathology, The Ohio State University, Columbus, OH, USA. Electronic address: lynne.abruzzo@osumc.edu.'}]",The Lancet. Oncology,['10.1016/S1470-2045(19)30503-0'] 1637,32639241,The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2: Part 2.,,2020,,[],[],[],[],[],[],,0.0214642,,"[{'ForeName': 'William H', 'Initials': 'WH', 'LastName': 'Frishman', 'Affiliation': 'Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.'}]",Cardiology in review,['10.1097/CRD.0000000000000328'] 1638,32639460,"A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.","BACKGROUND Pneumococcal disease remains a public health priority worldwide. This phase 2 study (V114-008; NCT02987972; EudraCT 2016-001117-25) compared safety and immunogenicity of 2 clinical lots of V114 (investigational 15-valent pneumococcal vaccine: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 22F*, 23F, 33F*) to 13-valent pneumococcal conjugate vaccine (PCV13) in healthy infants (*serotypes unique to V114). METHODS Healthy infants 6-12 weeks old were randomized to receive a 4-dose regimen of V114 Lot 1, V114 Lot 2 or PCV13 at 2, 4, 6 and 12-15 months old. Adverse events were evaluated after each dose. Primary immunogenicity endpoint was to demonstrate noninferiority of V114 Lot 1 and V114 Lot 2 relative to PCV13 based on proportion of infants achieving serotype-specific IgG concentration ≥0.35 µg/mL for 13 serotypes shared with PCV13 at 1 month postdose 3 (PD3). Serotype-specific IgG geometric mean concentrations (GMCs) for all 15 V114 serotypes were measured at PD3, predose 4 and 1 month postdose 4 (PD4). RESULTS Overall, 1044 of 1051 randomized infants received ≥1 dose of vaccine (V114 Lot 1 [n = 350], V114 Lot 2 [n = 347] or PCV13 [n = 347]). Adverse events were generally comparable across groups. At PD3, both V114 lots met noninferiority criteria for all 13 serotypes shared with PCV13. IgG GMCs were comparable among V114 and PCV13 recipients at PD3 and PD4. Serotype 3 responses were higher following receipt of V114 than PCV13. Both V114 lots induced higher GMCs than PCV13 to the 2 unique V114 serotypes. CONCLUSIONS Immunogenicity of both V114 lots was noninferior to PCV13 for all 13 shared serotypes between the 2 vaccines and displayed comparable safety and tolerability profiles to PCV13.",2020,"At PD3, both V114 lots met noninferiority criteria for all 13 serotypes shared with PCV13.","['healthy infants (*serotypes unique to V114', 'Healthy infants 6-12 weeks old', 'Healthy Infants']","['4-dose regimen of V114 Lot 1, V114 Lot 2 or PCV13', 'vaccine', '13-Valent Pneumococcal Conjugate Vaccine', '13-valent pneumococcal conjugate vaccine (PCV13', 'V114 (investigational 15-valent pneumococcal vaccine']","['IgG GMCs', 'Serotype-specific IgG geometric mean concentrations (GMCs', 'Adverse events', 'safety and immunogenicity']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0036759', 'cui_str': 'Serotyping'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0757769', 'cui_str': 'PLAGL1 protein, human'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C3152625', 'cui_str': 'Pneumococcal 13-valent conjugate vaccine'}, {'cui': 'C0358314', 'cui_str': 'Pneumococcal vaccine'}]","[{'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0036759', 'cui_str': 'Serotyping'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",1051.0,0.0584867,"At PD3, both V114 lots met noninferiority criteria for all 13 serotypes shared with PCV13.","[{'ForeName': 'Heather L', 'Initials': 'HL', 'LastName': 'Platt', 'Affiliation': 'From the Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Greenberg', 'Affiliation': 'Soroka Medical Center, Research, Beersheba, Israel.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Tapiero', 'Affiliation': 'CHU Sainte-Justine, Université de Montréal, Montréal, Québec, Canada.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Clifford', 'Affiliation': 'Coastal Pediatric Research, Charleston, South Carolina.'}, {'ForeName': 'Nicola P', 'Initials': 'NP', 'LastName': 'Klein', 'Affiliation': 'Kaiser Permanente Vaccine Study Center, Oakland, California.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Hurley', 'Affiliation': 'Cottonwood Pediatrics, Research, Murray, Utah.'}, {'ForeName': 'Tulin', 'Initials': 'T', 'LastName': 'Shekar', 'Affiliation': 'From the Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Jianing', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'From the Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Hurtado', 'Affiliation': 'From the Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Shu-Chih', 'Initials': 'SC', 'LastName': 'Su', 'Affiliation': 'From the Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Katrina M', 'Initials': 'KM', 'LastName': 'Nolan', 'Affiliation': 'From the Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Camilo J', 'Initials': 'CJ', 'LastName': 'Acosta', 'Affiliation': 'From the Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Richard D', 'Initials': 'RD', 'LastName': 'McFetridge', 'Affiliation': 'From the Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Kara', 'Initials': 'K', 'LastName': 'Bickham', 'Affiliation': 'From the Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Luwy K', 'Initials': 'LK', 'LastName': 'Musey', 'Affiliation': 'From the Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Pediatric infectious disease journal,['10.1097/INF.0000000000002765'] 1639,32634485,Virtual mind-body treatment for adolescents with neurofibromatosis: Study protocol for a single-blind randomized controlled trial.,"BACKGROUND Neurofibromatoses (NF) are a group of genetically distinct disorders of the nervous system unified by the predisposition to nerve sheath tumors. Although adolescents with NF types 1 and 2 (NF1 and NF2) report poor quality of life and high psychosocial burden, there are no evidence-based interventions to address these needs. This paper presents the study design and protocol for the first randomized controlled trial (RCT) of a mind-body intervention for adolescents with NF, Resilient Youth with NF (RY-NF), versus an educational control group, Health Education for NF (HE-NF), both delivered in groups via secure live video. METHODS This is an ongoing, single-blind efficacy RCT. Recruitment began in November 2019 and will continue until March 2022. We will enroll 200 English-speaking, geographically diverse adolescents (ages 12-17) with NF1 and NF2 who report significant distress or difficulty coping with their NF symptoms. We will use a shared-baseline, linear mixed model to compare the effect of RY-NF versus HE-NF on changes in quality of life (QoL) and psychosocial outcomes from baseline to post-intervention, and 6- and 12-month follow-ups. We will also develop NF-specific minimal clinically important difference (MCID) for QoL variables, and conduct mediation and moderation analyses to understand mechanisms of improvement. DISCUSSION This study has important clinical and public health implications for the psychosocial functioning of adolescents with NF. It provides a model for efficient delivery of virtual psychosocial care for adolescents with rare diseases. Plans for dissemination and implementation of the RY-NF should efficacy be ascertained are also discussed.",2020,"Although adolescents with NF types 1 and 2 (NF1 and NF2) report poor quality of life and high psychosocial burden, there are no evidence-based interventions to address these needs.","['adolescents with NF, Resilient Youth with NF (RY-NF', 'adolescents with neurofibromatosis', 'adolescents with NF', 'adolescents with rare diseases', '200 English-speaking, geographically diverse adolescents (ages 12-17) with NF1 and NF2 who report significant distress or difficulty coping with their NF symptoms']","['educational control group, Health Education for NF (HE-NF', 'Virtual mind-body treatment', 'mind-body intervention', 'RY-NF versus HE-NF']",['quality of life (QoL) and psychosocial outcomes'],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0027831', 'cui_str': 'Neurofibromatosis type 1'}, {'cui': 'C0678236', 'cui_str': 'Rare Diseases'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0027832', 'cui_str': 'Neurofibromatosis type 2'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0582154', 'cui_str': 'Difficulty coping'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1513305', 'cui_str': 'Mind-Body Medicine'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0666435,"Although adolescents with NF types 1 and 2 (NF1 and NF2) report poor quality of life and high psychosocial burden, there are no evidence-based interventions to address these needs.","[{'ForeName': 'Mira', 'Initials': 'M', 'LastName': 'Reichman', 'Affiliation': 'Integrated Brain Health Clinical and Research Program, Psychiatry Department, Massachusetts General Hospital, One Bowdoin, Square, 1st floor Boston, 02114 Boston, MA, United States of America. Electronic address: mreichman@mgh.harvard.edu.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Riklin', 'Affiliation': 'Department of Psychology, Fordham University, Dealy 336, 441 East Fordham Rd, Bronx, NY 10458, United States of America. Electronic address: eriklin@fordham.edu.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Macklin', 'Affiliation': 'Biostatistics Center, Massachusetts General Hospital, 50 Staniford Street, St 560, Boston, MA 02114, United States of America. Electronic address: emacklin@mgh.harvard.edu.'}, {'ForeName': 'Ana-Maria', 'Initials': 'AM', 'LastName': 'Vranceanu', 'Affiliation': 'Integrated Brain Health Clinical and Research Program, Psychiatry Department, Massachusetts General Hospital, One Bowdoin, Square, 1st floor Boston, 02114 Boston, MA, United States of America; Harvard Medical School, One Bowdoin Square, 1st floor Boston, 02114 Boston, MA, United States of America. Electronic address: avranceanu@mgh.harvard.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106078'] 1640,32634486,Team clinic: Expansion of a multidisciplinary care model for adolescents with type 1 diabetes.,"BACKGROUND Adolescent and young adults (AYA) with Type 1 Diabetes (T1D) experience more difficulty with glycemic control than patients in all other age groups. The shared medical appointment (SMA) model has been effective in multiple healthcare populations, but the feasibility and effectiveness of SMA in AYA patients with T1D is unclear. METHODS This research leverages the team's multidisciplinary expertise to develop an engaging intervention toolkit and test the implementation of the Team Clinic care model for the treatment of T1D among middle school adolescents in a large urban children's hospital serving an economically, racially and ethnically diverse population. In Phase 1, the team will manualize the Team Clinic care model into an engaging, age-appropriate educational and intervention toolkit. In Phase 2, the team will conduct a randomized clinical trial to test the feasibility and usability of the toolkit from the provider perspective (team member satisfaction; clinical efficiency; compliance with American Diabetes Association, American Association of Diabetes Educators, and California Children's Services standards; and payor-level cost data) and the preliminary efficacy of the intervention toolkit on patient- and family-level outcomes (attendance, acceptability/satisfaction with care, patient-level cost data, diabetes outcomes, diabetes family conflict, diabetes distress, and depression). DISCUSSION AYA patients with T1D often receive care in clinics and institutions with limited resources and time. This research tests the feasibility and efficacy of an innovative and potentially cost-effective SMA model to address the unique needs of underserved populations, while meeting national and state clinical standards. Trial registration The study is registered with ClinicalTrials.gov (Protocol Record: NCT04190368).",2020,"This research tests the feasibility and efficacy of an innovative and potentially cost-effective SMA model to address the unique needs of underserved populations, while meeting national and state clinical standards.","['Adolescent and young adults (AYA) with Type 1 Diabetes (T1D) experience more difficulty with glycemic control than patients in all other age groups', 'adolescents with type 1 diabetes', 'patients with T1D often receive care in clinics and institutions with limited resources and time', ""middle school adolescents in a large urban children's hospital serving an economically, racially and ethnically diverse population""]",[],"['patient- and family-level outcomes (attendance, acceptability/satisfaction with care, patient-level cost data, diabetes outcomes, diabetes family conflict, diabetes distress, and depression']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0332218', 'cui_str': 'Difficult'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0557797', 'cui_str': 'Middle school'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0013556', 'cui_str': 'Economics'}, {'cui': 'C0032659', 'cui_str': 'Population'}]",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0233542', 'cui_str': 'Family conflict'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",,0.0267749,"This research tests the feasibility and efficacy of an innovative and potentially cost-effective SMA model to address the unique needs of underserved populations, while meeting national and state clinical standards.","[{'ForeName': 'Sarah-Jeanne', 'Initials': 'SJ', 'LastName': 'Salvy', 'Affiliation': 'Research Center for Health Equity, Cedars-Sinai Medical Center, United States of America.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Ruelas', 'Affiliation': 'Keck School of Medicine, University of Southern California, United States of America.'}, {'ForeName': 'Shideh', 'Initials': 'S', 'LastName': 'Majidi', 'Affiliation': 'School of Medicine, University of Colorado Anschutz Medical Campus, United States of America.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Thomas', 'Affiliation': 'Booster Shot Media, United States of America.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Ashwal', 'Affiliation': 'Booster Shot Media, United States of America.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Reid', 'Affiliation': ""The Vision Center, Children's Hospital Los Angeles, United States of America.""}, {'ForeName': 'D Steven', 'Initials': 'DS', 'LastName': 'Fox', 'Affiliation': 'School of Pharmacy, University of Southern California, United States of America.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'McClain', 'Affiliation': 'School of Social Work, University of Southern California, United States of America.'}, {'ForeName': 'Jennifer K', 'Initials': 'JK', 'LastName': 'Raymond', 'Affiliation': ""Center for Endocrinology, Diabetes, & Metabolism, Children's Hospital Los Angeles, United States of America. Electronic address: jraymond@chla.usc.edu.""}]",Contemporary clinical trials,['10.1016/j.cct.2020.106079'] 1641,32634551,Effects of resistance training on hepcidin levels and iron bioavailability in older individuals with end-stage renal disease: A randomized controlled trial.,"Anemia is an inherent complication of older individuals with end-stage renal disease (ESRD) that is associated with inflammation which in turn is an important factor in the activation of hepcidin that contributes to the decrease in serum iron. Athough resistance training (RT) seems to reduce inflammation in ESRD, its influence on hepcidin and iron availability in hemodialysis patients is unclear. Therefore, the aim of this study was to exemine the effects of RT in on inflammatory profile, hepcidin, and iron status in older individuals with ESRD. End-stage renal disease patients (N: 157, age: 66.8 ± 3.6; body mass: 73 ± 15 body mass index:27 ± 3), were assigned to control (CTL n: 76) and exercise groups (RT n: 81). RT consisted of 24 weeks/3 days per week of a moderate intensity. There was an increase in the bioavailability of iron (ΔRT: 22.2; ΔCTL: -1 μg/dL, p < 0.0001), a decrease in hepcidin levels (ΔRT: -7.9; ΔCTL: 0.2 ng/mL, p < 0.0001),and an improvement of the inflammatory profile. These novel findings show that RT is a potential coadjuvant to reduce iron deficiency by decreasing the levels of hepcidin and pro-inflammatory markers in older patients undergoing hemodialysis.",2020,"There was an increase in the bioavailability of iron (ΔRT: 22.2; ΔCTL: -1 μg/dL, p < 0.0001), a decrease in hepcidin levels (ΔRT: -7.9; ΔCTL: 0.2 ng/mL, p < 0.0001),and an improvement of the inflammatory profile.","['N: 157, age: 66.8\u202f±\u202f3.6; body mass: 73\u202f±\u202f15 body mass index:27\u202f±\u202f3', 'older individuals with ESRD', 'older individuals with end-stage renal disease', 'older individuals with end-stage renal disease (ESRD', 'older patients undergoing hemodialysis', 'hemodialysis patients', 'End-stage renal disease patients']","['Athough resistance training (RT', 'RT', 'resistance training']","['inflammatory profile, hepcidin, and iron status', 'hepcidin levels and iron bioavailability', 'hepcidin levels', 'bioavailability of iron']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517844', 'cui_str': '66.8'}, {'cui': 'C4517694', 'cui_str': '3.6'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0966897', 'cui_str': 'Hepcidin'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}]",157.0,0.0490397,"There was an increase in the bioavailability of iron (ΔRT: 22.2; ΔCTL: -1 μg/dL, p < 0.0001), a decrease in hepcidin levels (ΔRT: -7.9; ΔCTL: 0.2 ng/mL, p < 0.0001),and an improvement of the inflammatory profile.","[{'ForeName': 'Sting Ray Gouveia', 'Initials': 'SRG', 'LastName': 'Moura', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Hugo Luca', 'Initials': 'HL', 'LastName': 'Corrêa', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil. Electronic address: hugo.efucb@gmail.com.'}, {'ForeName': 'Rodrigo Vanerson Passos', 'Initials': 'RVP', 'LastName': 'Neves', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Cláudio Avelino Rodrigues', 'Initials': 'CAR', 'LastName': 'Santos', 'Affiliation': 'Federal University of Tocantins, Medicine Department, Tocantins, Brazil.'}, {'ForeName': 'Luiz Sinésio Silva', 'Initials': 'LSS', 'LastName': 'Neto', 'Affiliation': 'Federal University of Tocantins, Medicine Department, Tocantins, Brazil.'}, {'ForeName': 'Victor Lopes', 'Initials': 'VL', 'LastName': 'Silva', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Michel Kendy', 'Initials': 'MK', 'LastName': 'Souza', 'Affiliation': 'Federal University of Tocantins, Medicine Department, Tocantins, Brazil.'}, {'ForeName': 'Lysleine Alves', 'Initials': 'LA', 'LastName': 'Deus', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Andrea Lucena', 'Initials': 'AL', 'LastName': 'Reis', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Herbert Gustavo', 'Initials': 'HG', 'LastName': 'Simões', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Fabiani Lage Rodrigues', 'Initials': 'FLR', 'LastName': 'Beal', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Milton Rocha', 'Initials': 'MR', 'LastName': 'Moraes', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'James W', 'Initials': 'JW', 'LastName': 'Navalta', 'Affiliation': 'University of Nevada, Las Vegas, Department of Kinesiology and Nutrition Sciences, Las Vegas, NV, USA.'}, {'ForeName': 'Jonato', 'Initials': 'J', 'LastName': 'Prestes', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'André Bonadias', 'Initials': 'AB', 'LastName': 'Gadelha', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil; Federal Institute of Education, Science and Technology Goiano, Goiás, Brazil.'}, {'ForeName': 'Thiago Dos Santos', 'Initials': 'TDS', 'LastName': 'Rosa', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}]",Experimental gerontology,['10.1016/j.exger.2020.111017'] 1642,32634745,"Examining sex, adverse childhood experiences, and oxytocin on neuroendocrine reactivity in smokers.","Adverse childhood experiences (ACE) are associated with greater neuroendocrine responses to social stress in substance users. The neuropeptide oxytocin might attenuate this relationship. Given sex differences in ACE exposure and neuroendocrine stress reactivity, it is unknown whether this association is similar for males and females. Therefore, this secondary analysis evaluated the interactive effect of sex, ACE, and acute oxytocin administration on neuroendocrine stress responses in adult cigarette smokers (N = 144). Participants completed the Adverse Childhood Experiences Questionnaire at screening and were randomized to receive intranasal oxytocin or placebo before undergoing the Trier Social Stress Task (TSST). Cortisol levels were assessed at pre- and post-medication administration and at 20 and 40 min following the TSST. Generalized linear mixed models were developed to predict post-TSST cortisol levels. Predictors included treatment assignment (placebo vs. oxytocin), sex (male vs. female), ACE (0-10 total score), pre-medication cortisol levels, and minutes since medication administration. The hypothesized three-way interaction between sex, oxytocin, and ACE scores was significant. Linear associations between ACE scores and cortisol reactivity indicated higher ACE scores were associated with attenuated cortisol response in females, regardless of treatment condition. For males, higher ACE scores were associated with heightened cortisol response, an effect that was attenuated by oxytocin. Results indicate that the association between ACE and neuroendocrine reactivity to social stress, as well as the attenuating effect of oxytocin, is differentially impacted by sex. Males with greater childhood adversity may be more likely to benefit from oxytocin's anxiolytic properties.",2020,"For males, higher ACE scores were associated with heightened cortisol response, an effect that was attenuated by oxytocin.","['adult cigarette smokers (N\u2009=\u2009144', 'smokers', 'Participants completed the Adverse Childhood Experiences Questionnaire at screening']","['oxytocin', 'treatment assignment (placebo vs. oxytocin', 'neuropeptide oxytocin', 'intranasal oxytocin or placebo', 'oxytocin administration']","['sex (male vs. female), ACE (0-10 total score), pre-medication cortisol levels, and minutes since medication administration', 'cortisol response', 'ACE scores', 'Cortisol levels', 'ACE scores and cortisol reactivity indicated higher ACE scores']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337667', 'cui_str': 'Cigarette smoker'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C4284014', 'cui_str': 'Adverse Childhood Experience questionnaire'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0027895', 'cui_str': 'Neuropeptide'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4296616', 'cui_str': 'Adverse Childhood Experiences'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C3469597', 'cui_str': 'Administration of medication'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0205250', 'cui_str': 'High'}]",,0.0291417,"For males, higher ACE scores were associated with heightened cortisol response, an effect that was attenuated by oxytocin.","[{'ForeName': 'Caitlyn O', 'Initials': 'CO', 'LastName': 'Hood', 'Affiliation': 'Department of Psychology, College of Arts & Sciences, University of Kentucky, United States. Electronic address: caitlyn.hood@uky.edu.'}, {'ForeName': 'Rachel L', 'Initials': 'RL', 'LastName': 'Tomko', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Nathaniel L', 'Initials': 'NL', 'LastName': 'Baker', 'Affiliation': 'Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Breanna M', 'Initials': 'BM', 'LastName': 'Tuck', 'Affiliation': 'Steve Hicks School of Social Work, University of Texas at Austin, United States.'}, {'ForeName': 'Julianne C', 'Initials': 'JC', 'LastName': 'Flanagan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States; Ralph H. Johnson VA Medical Center, United States.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Carpenter', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Kevin M', 'Initials': 'KM', 'LastName': 'Gray', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Saladin', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States; Department of Health Sciences and Research, College of Health Professions, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Erin A', 'Initials': 'EA', 'LastName': 'McClure', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2020.104752'] 1643,32634760,Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.,"BACKGROUND Luminal A-like and luminal B-like subtypes have different sensitivity to (neo)adjuvant chemotherapy, but their role in predicting dose-dense (DD) efficacy in the high-risk setting is unknown. In this exploratory analysis of the Gruppo Italiano Mammella 2 (GIM2) trial, we investigated DD efficacy according to luminal-like subtypes. METHODS Patients with node-positive early breast cancer were randomised to receive either DD or standard-interval (SI) anthracycline-based chemotherapy followed by paclitaxel. In our analysis, luminal A-like cohort was identified as having a Ki67 < 20% and a progesterone receptor (PgR) ≥ 20%; luminal B-like cohort as having a Ki67 ≥ 20% and/or a PgR < 20%. RESULTS Out of 2003 patients enrolled in the GIM2 trial, 412 had luminal A-like and 638 luminal B-like breast cancer. After a median follow-up of 7.9 years, disease-free survival (DFS) was 80.8% (95% confidence interval [CI] 76.4-84.5) and 70.5% (66.5-74.2) in luminal A-like and luminal B-like cohorts; overall survival (OS) was 91.6% (88.2-94.1) and 85.1% (81.7-87.9), respectively. We found no significant interaction between treatment and luminal subtype (interaction p = 0.603 and 0.535 for DFS and OS, respectively). When DD efficacy was investigated separately in each cohort, luminal-B like cohort appeared to benefit more from the DD schedule both in terms of DFS (unadjusted hazard ratio [HR] 0.72 [95% CI 0.54-0.96]) and OS (unadjusted HR 0.61 [95% CI 0.40-0.94]), compared with the luminal A-like cohort (unadjusted HR for DFS 0.89 [95% CI 0.59-1.33]; unadjusted HR for OS 0.83 [95% CI 0.45-1.54]). CONCLUSIONS No significant interaction between luminal-like subtype and treatment was observed. Patients in the luminal B-like cohort seemed to benefit more from DD schedule.",2020,"We found no significant interaction between treatment and luminal subtype (interaction p = 0.603 and 0.535 for DFS and OS, respectively).","['2003 patients enrolled in the GIM2 trial, 412 had luminal A-like and 638 luminal B-like breast cancer', 'Patients with node-positive early breast cancer', 'hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype']","['DD or standard-interval (SI) anthracycline-based chemotherapy followed by paclitaxel', 'progesterone receptor (PgR', 'dose-dense adjuvant chemotherapy']","['overall survival (OS', 'disease-free survival (DFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0699493', 'cui_str': 'Luminal'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C4087376', 'cui_str': 'HER2 negative'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0449560', 'cui_str': 'Subtype'}]","[{'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439794', 'cui_str': 'Dense'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0003234', 'cui_str': 'Anthracycline'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0034833', 'cui_str': 'Progesterone receptor'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}]",2003.0,0.206045,"We found no significant interaction between treatment and luminal subtype (interaction p = 0.603 and 0.535 for DFS and OS, respectively).","[{'ForeName': 'Benedetta', 'Initials': 'B', 'LastName': 'Conte', 'Affiliation': 'Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Carrer de Rosselló, 149, 08036, Barcelona, Spain.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Bruzzone', 'Affiliation': 'Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Lambertini', 'Affiliation': 'Medical Oncology Department, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 1632, Genoa, GE, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Viale Benedetto XV, 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Poggio', 'Affiliation': 'Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Bighin', 'Affiliation': 'Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Blondeaux', 'Affiliation': 'Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Michelino', 'Initials': 'M', 'LastName': 'De Laurentiis', 'Affiliation': 'Breast Unit, Istituto Nazionale Tumori-Fondazione ""G. Pascale"", Via Mariano Semmola, 53, 80131, Naples, NA, Italy.'}, {'ForeName': 'Enrichetta', 'Initials': 'E', 'LastName': 'Valle', 'Affiliation': 'Department of Medical Oncology, Ospedale Businco, Via Edward Jenner, 1, 09121, Cagliari, CA, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Cognetti', 'Affiliation': 'Department of Clinical and Molecolar Medicine, La Sapienza University, Viale Regina Elena, 324, 00161, Rome, RM, Italy.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Nisticò', 'Affiliation': 'Department of Medical Oncology 1, Istituto Nazionale Tumori ""Regina Elena"", Via Elio Chianesi, 53, 00128, Rome, RM, Italy.'}, {'ForeName': 'Sabino', 'Initials': 'S', 'LastName': 'De Placido', 'Affiliation': 'Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini, 5, 80131, Naples, NA, Italy.'}, {'ForeName': 'Ornella', 'Initials': 'O', 'LastName': 'Garrone', 'Affiliation': 'Breast Unit, Department of Oncology, Azienda Ospedaliera Santa Croce e Carle, Via Michele Coppino, 26, 12100, Cuneo, CN, Italy.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Gamucci', 'Affiliation': 'Department of Medical Oncology, Ospedale Sandro Pertini, Via dei Monti Tiburtini, 385/389, 00157, Rome, RM, Italy; Department of Medical Oncology, Ospedale SS Trinità, Località San Marciano, 03039, Sora, FR, Italy.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Montemurro', 'Affiliation': 'Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale, 142, 10060, Turin, TO, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Puglisi', 'Affiliation': 'Department of Medicine, University of Udine, Piazzale Massimiliano Kolbe, 4, 33100, Udine, Italy; Department of Medical Oncology, IRCCS Centro di Riferimento Oncologico Aviano - National Cancer Institute, Via Franco Gallini, 2, 33081, Aviano, PN, Italy.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Cardinali', 'Affiliation': 'Breast Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Piero', 'Initials': 'P', 'LastName': 'Fregatti', 'Affiliation': 'Department of Surgical Sciences and Integrated Diagnostic (DISC), University of Genova, Viale Benedetto XV, 6, 1612, Genoa, GE, Italy; Department of Surgery, IRCCS Policlinico San Martino, Largo Rosanna Benzi 10, 1632, Genoa, GE, Italy.'}, {'ForeName': 'Loredana', 'Initials': 'L', 'LastName': 'Miglietta', 'Affiliation': 'Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Boccardo', 'Affiliation': 'Medical Oncology Department, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 1632, Genoa, GE, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Viale Benedetto XV, 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Marcello', 'Initials': 'M', 'LastName': 'Ceppi', 'Affiliation': 'Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Del Mastro', 'Affiliation': 'Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Viale Benedetto XV, 10, 16132, Genoa, GE, Italy; Breast Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy. Electronic address: lucia.delmastro@hsanmartino.it.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2020.05.007'] 1644,32638615,The Feasibility and Efficacy of a Brief Integrative Treatment for Adults With Depression and/or Anxiety: A Randomized Controlled Trial.,"The aim of this study was to investigate the efficacy and suitability of a brief integrative intervention, Personalized Integrative Therapy (PI Therapy), for the treatment of adult depression and/or anxiety. In this 6-week, 3-arm, parallel-group, randomized trial, PI Therapy delivered alone or with nutritional supplements (PI Therapy + Supps) was compared to cognitive behavior therapy (CBT) in 48 adults with depression and/or anxiety. All treatments were delivered as a 1-day workshop plus 6 weeks of reminder phone text messages to reinforce topics and skills covered in the workshop. Affective symptoms decreased significantly and to the same extent in all 3 conditions. At the end of treatment, 33% to 58% of participants reported levels of depressive symptoms in the normal range, and 50% to 58% reported nonclinical levels of anxiety. Compared to CBT and PI Therapy, PI Therapy + Supps was associated with significantly greater improvements in sleep quality. These findings suggest that a brief integrative intervention with or without supplements was comparable to CBT in reducing affective symptoms in adults with depression and/or anxiety. However, sleep quality improved only in the PI Therapy + Supps condition. These findings will require replication with a larger cohort.",2020,Affective symptoms decreased significantly and to the same extent in all 3 conditions.,"['adult depression and/or anxiety', 'adults with depression and/or anxiety', '48 adults with depression and/or anxiety', 'Adults With Depression and/or Anxiety']","['CBT', 'integrative intervention, Personalized Integrative Therapy (PI Therapy', 'PI Therapy delivered alone or with nutritional supplements (PI Therapy + Supps', 'Brief Integrative Treatment', 'cognitive behavior therapy (CBT']","['levels of depressive symptoms', 'affective symptoms', 'nonclinical levels of anxiety', 'Affective symptoms', 'sleep quality']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0038854', 'cui_str': 'Suppository'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0001726', 'cui_str': 'Affective Symptoms'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}]",48.0,0.0323079,Affective symptoms decreased significantly and to the same extent in all 3 conditions.,"[{'ForeName': 'Adrian L', 'Initials': 'AL', 'LastName': 'Lopresti', 'Affiliation': 'Murdoch University, Perth, Western Australia, Australia.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Smith', 'Affiliation': 'Murdoch University, Perth, Western Australia, Australia.'}, {'ForeName': 'Alexandra P', 'Initials': 'AP', 'LastName': 'Metse', 'Affiliation': 'Murdoch University, Perth, Western Australia, Australia.'}, {'ForeName': 'Tiffany', 'Initials': 'T', 'LastName': 'Foster', 'Affiliation': 'Murdoch University, Perth, Western Australia, Australia.'}, {'ForeName': 'Peter D', 'Initials': 'PD', 'LastName': 'Drummond', 'Affiliation': 'Murdoch University, Perth, Western Australia, Australia.'}]",Journal of evidence-based integrative medicine,['10.1177/2515690X20937997'] 1645,32640124,Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts.,"BACKGROUND Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear. METHODS We conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the postexposure prophylactic efficacy of baloxavir in household contacts of index patients with confirmed influenza during the 2018-2019 season in Japan. The participants were assigned in a 1:1 ratio to receive either a single dose of baloxavir or placebo. The primary end point was clinical influenza, as confirmed by reverse-transcriptase-polymerase-chain-reaction testing, over a period of 10 days. The occurrence of baloxavir-selected PA substitutions associated with reduced susceptibility was assessed. RESULTS A total of 752 household contacts of 545 index patients were randomly assigned to receive baloxavir or placebo. Among the index patients, 95.6% had influenza A virus infection, 73.6% were younger than 12 years of age, and 52.7% received baloxavir. Among the participants who could be evaluated (374 in the baloxavir group and 375 in the placebo group), the percentage in whom clinical influenza developed was significantly lower in the baloxavir group than in the placebo group (1.9% vs. 13.6%) (adjusted risk ratio, 0.14; 95% confidence interval [CI], 0.06 to 0.30; P<0.001). Baloxavir was effective in high-risk, pediatric, and unvaccinated subgroups of participants. The risk of influenza infection, regardless of symptoms, was lower with baloxavir than with placebo (adjusted risk ratio, 0.43; 95% CI, 0.32 to 0.58). The incidence of adverse events was similar in the two groups (22.2% in the baloxavir group and 20.5% in the placebo group). In the baloxavir group, the viral PA substitutions I38T/M or E23K were detected in 10 (2.7%) and 5 (1.3%) participants, respectively. No transmission of these variants from baloxavir-treated index patients to participants in the placebo group was detected; however, several instances of transmission to participants in the baloxavir group could not be ruled out. CONCLUSIONS Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza. (Funded by Shionogi; Japan Primary Registries Network number, JapicCTI-184180.).",2020,"CONCLUSIONS Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza.","['A total of 752 household contacts of 545 index patients', 'household contacts of index patients with confirmed influenza during the 2018-2019 season in Japan', 'Household Contacts', 'household contacts of patients with influenza']","['Baloxavir', 'baloxavir', 'Baloxavir Marboxil', 'Baloxavir marboxil (baloxavir', 'baloxavir or placebo', 'placebo']","['postexposure prophylactic efficacy', 'clinical influenza, as confirmed by reverse-transcriptase-polymerase-chain-reaction testing', 'clinical influenza', 'viral PA substitutions I38T/M or E23K', 'incidence of adverse events']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C4517809', 'cui_str': '545'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C4734224', 'cui_str': 'baloxavir'}, {'cui': 'C4688747', 'cui_str': 'Baloxavir marboxil'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0599161', 'cui_str': 'Polymerase Chain Reaction, Reverse Transcriptase'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.380895,"CONCLUSIONS Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza.","[{'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Ikematsu', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Frederick G', 'Initials': 'FG', 'LastName': 'Hayden', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Keiko', 'Initials': 'K', 'LastName': 'Kawaguchi', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Kinoshita', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Menno D', 'Initials': 'MD', 'LastName': 'de Jong', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Nelson', 'Initials': 'N', 'LastName': 'Lee', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Satoru', 'Initials': 'S', 'LastName': 'Takashima', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Noshi', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Tsuchiya', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Takeki', 'Initials': 'T', 'LastName': 'Uehara', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}]",The New England journal of medicine,['10.1056/NEJMoa1915341'] 1646,32665372,Transmitted Home Oximetry and Duration of Home Oxygen in Premature Infants.,"OBJECTIVES To determine if a home oxygen therapy (HOT) management strategy that includes analysis of recorded home oximetry (RHO) data, compared with standard monthly clinic visit assessments, reduces duration of HOT without harm in premature infants. METHODS The RHO trial was an unmasked randomized clinical trial conducted in 9 US medical centers from November 2013 to December 2017, with follow-up to February 2019. Preterm infants with birth gestation ≤37 + 0/7 weeks, discharged on HOT, and attending their first pulmonary visit were enrolled. The intervention was an analysis of transmitted RHO between clinic visits ( n = 97); the standard-care group received monthly clinic visits with in-clinic weaning attempts ( n = 99). The primary outcomes were the duration of HOT and parent-reported quality of life. There were 2 prespecified secondary safety outcomes: change in weight and adverse events within 6 months of HOT discontinuation. RESULTS Among 196 randomly assigned infants (mean birth gestational age: 26.9 weeks; SD: 2.6 weeks; 37.8% female), 166 (84.7%) completed the trial. In the RHO group, the mean time to discontinue HOT was 78.1 days (SE: 6.4), compared with 100.1 days (SE: 8.0) in the standard-care group ( P = .03). The quality-of-life scores improved from baseline to 3 months after discontinuation of HOT in both groups ( P = .002), but the degree of improvement did not differ significantly between groups ( P = .75). CONCLUSIONS RHO was effective in reducing the duration of HOT in premature infants. Parent quality of life improved after discontinuation. RHO allows physicians to determine which infants can be weaned and which need prolonged oxygen therapy between monthly visits.",2020,"The quality-of-life scores improved from baseline to 3 months after discontinuation of HOT in both groups ( P = .002), but the degree of improvement did not differ significantly between groups ( P = .75). ","['Preterm infants with birth gestation ≤37 + 0/7 weeks, discharged on HOT, and attending their first pulmonary visit were enrolled', '9 US medical centers from November 2013 to December 2017, with follow-up to February 2019', 'premature infants', 'Premature Infants', '196 randomly assigned infants (mean birth gestational age: 26.9 weeks; SD: 2.6 weeks; 37.8% female), 166 (84.7%) completed the trial']","['home oxygen therapy (HOT', 'standard-care group received monthly clinic visits with in-clinic weaning attempts']","['weight and adverse events', 'duration of HOT and parent-reported quality of life', 'quality-of-life scores', 'mean time to discontinue HOT', 'duration of HOT', 'Parent quality of life']","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C1960973', 'cui_str': 'Home oxygen therapy'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C4517625', 'cui_str': '196'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C4517633', 'cui_str': '2.6'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C5191361', 'cui_str': '166'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C1960973', 'cui_str': 'Home oxygen therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0008952', 'cui_str': 'Clinic Visits'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0043084', 'cui_str': 'Weaning'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C1960973', 'cui_str': 'Home oxygen therapy'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}]",,0.10675,"The quality-of-life scores improved from baseline to 3 months after discontinuation of HOT in both groups ( P = .002), but the degree of improvement did not differ significantly between groups ( P = .75). ","[{'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Rhein', 'Affiliation': 'Divisions of Neonatology and lawrence.rhein@umassmemorial.org.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'White', 'Affiliation': 'Divisions of Neonatology and.'}, {'ForeName': 'Tregony', 'Initials': 'T', 'LastName': 'Simoneau', 'Affiliation': ""Division of Pediatric Pulmonology, School of Medicine, University of Connecticut and Connecticut Children's Medical Center, Hartford, Connecticut.""}, {'ForeName': 'Nadav', 'Initials': 'N', 'LastName': 'Traeger', 'Affiliation': ""Division of Pediatric Pulmonology, Maria Fareri Children's Hospital, Valhalla, New York.""}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Lahiri', 'Affiliation': 'Division of Pediatric Pulmonology, Larner College of Medicine, The University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Ted', 'Initials': 'T', 'LastName': 'Kremer', 'Affiliation': 'Pediatric Pulmonology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Sheils', 'Affiliation': ""Department of Medicine, Harvard Medical School, Harvard University and Boston Children's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Meyer', 'Affiliation': 'Division of Neonatology, Baystate Health Center, Springfield, Massachusetts.'}, {'ForeName': 'Ted', 'Initials': 'T', 'LastName': 'Rosenkrantz', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, University of Connecticut Health, Farmington, Connecticut.'}, {'ForeName': 'Sankaran', 'Initials': 'S', 'LastName': 'Krishnan', 'Affiliation': ""Division of Pediatric Pulmonology, Maria Fareri Children's Hospital, Valhalla, New York.""}, {'ForeName': 'Tyler', 'Initials': 'T', 'LastName': 'Hartman', 'Affiliation': 'Division of Neonatology, Geisel School of Medicine, Dartmouth College, Manchester, New Hampshire.'}, {'ForeName': 'Henry A', 'Initials': 'HA', 'LastName': 'Feldman', 'Affiliation': ""Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts; and.""}, {'ForeName': 'Elie G', 'Initials': 'EG', 'LastName': 'Abu Jawdeh', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, College of Medicine, University of Kentucky, Lexington, Kentucky.'}]",Pediatrics,['10.1542/peds.2020-0079'] 1647,32663640,"A commentary on ""Effects of edaravone on postoperative cognitive function in elderly patients undergoing hip joint replacement surgery: A randomized controlled trial"" (Int J Surg 2020;80:13-18).",,2020,,['Elderly Patients undergoing Hip Joint Replacement Surgery'],['Edaravone'],['Postoperative Cognitive Function'],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019558', 'cui_str': 'Hip joint structure'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0070694', 'cui_str': 'edaravone'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",,0.104829,,"[{'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Woo', 'Affiliation': 'School of Medicine, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, United Kingdom. Electronic address: wootk@cardiff.ac.uk.'}, {'ForeName': 'Sashiananthan', 'Initials': 'S', 'LastName': 'Ganesananthan', 'Affiliation': 'National Heart and Lung Institute, Imperial College London, United Kingdom.'}, {'ForeName': 'ChunHei', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Surgery and Cancer, Imperial College London, United Kingdom.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2020.07.001'] 1648,32663660,"Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.","BACKGROUND Current guidelines recommend anticoagulation therapy during primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI). However, whether anticoagulation should be continued after pPCI has not been well investigated. METHODS/DESIGN The RIGHT trial is a prospective, multicenter, randomized, double-blind, placebo-controlled trial in STEMI patients treated with pPCI evaluating the prolongation of anticoagulation after the procedure. Patients are randomized in a 1:1 fashion to receive either prolonged anticoagulant or matching placebo (no anticoagulation) for at least 48 hours after the procedure. When randomized to anticoagulation prolongation, the patient is assigned to intravenous unfractionated heparin (UFH) or subcutaneous enoxaparin or intravenous bivalirudin (same drug and same regimen at each center). The primary efficacy endpoint is the composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel) at 30 days. The primary safety endpoint is major bleeding (BARC 3-5) at 30 days. Based on a superiority design and assuming a 35% relative risk reduction (from 7% to 4.5%), 2856 patients will be enrolled, accounting for a 5% drop-out rate (α = 0.05 and power = 80%). CONCLUSION The RIGHT trial tests the hypothesis that post-procedural anticoagulation is superior to no anticoagulation in reducing ischemic events in STEMI patients undergoing pPCI.",2020,"The primary efficacy endpoint is the composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel) at 30 days.","['STEMI patients undergoing pPCI', 'STEMI patients treated with pPCI evaluating the prolongation of anticoagulation after the procedure', 'after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction']","['prolonged anticoagulant or matching placebo (no anticoagulation', 'unfractionated heparin (UFH) or subcutaneous enoxaparin or intravenous bivalirudin', 'anticoagulation prolongation versus no anticoagulation', 'placebo']","['composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel', 'major bleeding (BARC 3-5', 'ischemic events']","[{'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1536220', 'cui_str': 'ST Segment Elevation Myocardial Infarction'}]","[{'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0206460', 'cui_str': 'Enoxaparin'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0168273', 'cui_str': 'bivalirudin'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0442758', 'cui_str': '3/5'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",2856.0,0.600901,"The primary efficacy endpoint is the composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel) at 30 days.","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: eva3321@sina.com.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: spaceeye123@126.com.'}, {'ForeName': 'Jincheng', 'Initials': 'J', 'LastName': 'Guo', 'Affiliation': 'Beijing Luhe Hospital, Capital Medical University, Beijing, China. Electronic address: guojcmd@126.com.'}, {'ForeName': 'Yongjun', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'The Second Hospital of Hebei Medical University, Shijiazhuang, China. Electronic address: lyjbs2009@yeah.net.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Ai', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: aihui0814@126.com.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Gong', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: tjmusky@126.com.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Que', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: quebin@sohu.com.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zhen', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: 13439546840@yeah.net.'}, {'ForeName': 'Jiapeng', 'Initials': 'J', 'LastName': 'Lu', 'Affiliation': 'National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: jiapeng.lu@fwoxford.org.'}, {'ForeName': 'Changsheng', 'Initials': 'C', 'LastName': 'Ma', 'Affiliation': 'Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Electronic address: chshma@vip.sina.com.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Montalescot', 'Affiliation': 'Sorbonne University, ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. Electronic address: gilles.montalescot@aphp.fr.'}, {'ForeName': 'Shaoping', 'Initials': 'S', 'LastName': 'Nie', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: spnie@ccmu.edu.cn.'}]",American heart journal,['10.1016/j.ahj.2020.06.005'] 1649,32664052,Study protocol for the Fex-Can Childhood project: An observational study and a randomized controlled trial focusing on sexual dysfunction and fertility-related distress in young adult survivors of childhood cancer.,"BACKGROUND This study protocol describes the Fex-Can Childhood project, comprising two studies: The Fex-Can Childhood observational study (OS) and the Fex-Can Childhood randomized controlled trial (RCT). The Fex-Can Childhood OS aims to determine the prevalence and predictors of sexual dysfunction and fertility-related distress in young adult childhood cancer survivors (aged 19-40) compared to an age matched comparison group; the Fex-Can Childhood RCT will evaluate the effect of a web-based psycho-educational intervention (Fex-Can intervention) on sexual dysfunction and fertility-related distress. METHODS The Fex-Can Childhood OS will have a population-based cross-sectional design. All individuals treated for childhood cancer in Sweden at the age of 0 to 17 years (current age 19-40) will be identified through the National Quality Registry for Childhood Cancer. Established self-reported instruments will be used to measure sexual function, fertility-related distress, body image, anxiety and depression, and health-related quality of life. Self-efficacy related to sexual function and fertility, and fertility-related knowledge, will be assessed by study-specific measures. Clinical variables will be collected from the registry. Results will be compared to an age-matched comparison group from the general population.Participants in the Fex-Can Childhood OS who report a high level of sexual dysfunction and/or fertility-related distress will be invited to participate in the RCT. The Fex-Can intervention comprises two programs: The Fex-Can Sex and the Fex-Can Fertility targeting sexual dysfunction and fertility-related distress, respectively. The control condition will be a wait-list. Sexual function and fertility-related distress will be the primary outcomes. The secondary outcomes include body image, anxiety and depression, health-related quality of life and self-efficacy related to sexual function and fertility. Post- and follow-up assessments will be conducted directly after end of intervention (primary end point), at 3 months and 6 months after end of intervention. Additionally, a process-evaluation including study-specific items and a qualitative interview will be conducted. DISCUSSION The Fex-Can Childhood project will advance knowledge in the areas of sexual function and fertility-related distress among young adult survivors of childhood cancer. If the Fex-Can intervention proves to be efficacious, steps will be taken to implement it in the follow-up care provided to this population.",2020,The Fex-Can Childhood project will advance knowledge in the areas of sexual function and fertility-related distress among young adult survivors of childhood cancer.,"['Participants in the Fex-Can Childhood OS who report a high level of sexual dysfunction and/or fertility-related distress', 'young adult survivors of childhood cancer', 'All individuals treated for childhood cancer in Sweden at the age of 0 to 17 years (current age 19-40', 'young adult childhood cancer survivors (aged 19-40']","['web-based psycho-educational intervention (Fex-Can intervention', 'Fex-Can Childhood RCT']","['Fex', 'Sexual function and fertility-related distress', 'body image, anxiety and depression, health-related quality of life and self-efficacy related to sexual function and fertility', 'sexual dysfunction and fertility-related distress', 'sexual function, fertility-related distress, body image, anxiety and depression, and health-related quality of life']","[{'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C1518527', 'cui_str': 'Observational Study'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0549622', 'cui_str': 'Sexual disorder'}, {'cui': 'C0015895', 'cui_str': 'Ability to conceive'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C4505050', 'cui_str': 'Survivors of Childhood Cancer'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0521116', 'cui_str': 'Current'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0278092', 'cui_str': 'Sexual function'}, {'cui': 'C0015895', 'cui_str': 'Ability to conceive'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0005891', 'cui_str': 'Body image'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0549622', 'cui_str': 'Sexual disorder'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.0301707,The Fex-Can Childhood project will advance knowledge in the areas of sexual function and fertility-related distress among young adult survivors of childhood cancer.,"[{'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Ljungman', 'Affiliation': ""Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.""}, {'ForeName': 'Poorna', 'Initials': 'P', 'LastName': 'Anandavadivelan', 'Affiliation': ""Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.""}, {'ForeName': 'Kirsi', 'Initials': 'K', 'LastName': 'Jahnukainen', 'Affiliation': ""Division of Haematology-Oncology and Stem Cell Transplantation, Children's Hospital, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland.""}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Lampic', 'Affiliation': ""Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.""}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Wettergren', 'Affiliation': ""Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.""}]",Medicine,['10.1097/MD.0000000000019919'] 1650,32664057,Efficacy of high-dissolution turmeric-sesame formulation for pain relief in adult subjects with acute musculoskeletal pain compared to acetaminophen: A randomized controlled study.,"BACKGROUND Acetaminophen (paracetamol) is one of the most commonly used over-the-counter for pain relief. Management of acute pain with plant-based nutrients has remained suboptimal due to an absence of data supporting acute relief of pain. In the present study, it was hypothesized that high-dissolution liquid treatment of black sesame extract oil, Curcuma longa and Boswellia serrata may provide pain relief in people with acute musculoskeletal pain as quickly as acetaminophen. METHODS In this randomized active controlled open label study, 88 healthy subjects with acute musculoskeletal pain were randomized to receive treatment capsule (Rhuleave-K; 1,000 mg/d) or 1,000 mg/d acetaminophen for 7 days. Change in pain intensity and pain relief at first 6 hours, 3 days, and 7 days were measured. The onset of analgesia was measured by perceptible pain relief and meaningful pain relief. Other measures were McGill Pain Questionnaire and Patient Global Impression Change. RESULTS The treatment formulation resulted in average magnitude of pain relief comparable to the acetaminophen. Sixty-six percent of subjects in the treatment group reported positive response in pain relief (≥50% max TOTPAR; total pain relief) after 6 hours, compared to 73% of control. Seventy-three percent of subjects on treatment were considered positive responders, compared to 80% in the control group. The average time of onset of analgesia was 1 hour for the treatment group, versus 0.83 hour for control. At the end of day 3 and 7, there was significant improvement (P < .001 for day 3 and day 7) in the pain condition of treatment group and was comparable to control (P = .436 for day 3 and P = .529 for day 7). The total McGill Pain score showed significant reduction in pain with the treatment irrespective of the pain intensity statistically equal (P = .468) to control. Both the groups were equal in providing sensory pain relief (P = .942), but the treatment was 8.57 times significantly better (P = .027) than acetaminophen in reducing the unpleasantness and emotional aspects (affective domain) involved with acute pain. CONCLUSION The results showed that the treatment used in the study may act as a natural, fast acting, and safe alternative for acute pain relief comparable to acetaminophen.",2020,"At the end of day 3 and 7, there was significant improvement (P < .001 for day 3 and day 7) in the pain condition of treatment group and was comparable to control (P = .436 for day 3 and P = .529 for day 7).","['adult subjects with acute musculoskeletal pain', '88 healthy subjects with acute musculoskeletal pain', 'people with acute musculoskeletal pain']","['treatment capsule (Rhuleave-K; 1,000\u200amg/d) or 1,000\u200amg/d acetaminophen', 'Acetaminophen (paracetamol', 'acetaminophen', 'high-dissolution turmeric-sesame formulation']","['positive response in pain relief', 'pain relief', 'McGill Pain Questionnaire and Patient Global Impression Change', 'pain intensity and pain relief', 'average time of onset of analgesia', 'unpleasantness and emotional aspects (affective domain', 'perceptible pain relief and meaningful pain relief', 'total McGill Pain score', 'sensory pain relief', 'pain condition', 'pain']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0026858', 'cui_str': 'Musculoskeletal pain'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0041356', 'cui_str': 'Turmeric'}, {'cui': 'C1123051', 'cui_str': 'Sesame'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0024985', 'cui_str': 'McGill pain chart questionnaire'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0449244', 'cui_str': 'Time of onset'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0243152', 'cui_str': 'emotional aspects'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]",88.0,0.0812624,"At the end of day 3 and 7, there was significant improvement (P < .001 for day 3 and day 7) in the pain condition of treatment group and was comparable to control (P = .436 for day 3 and P = .529 for day 7).","[{'ForeName': 'Girish H', 'Initials': 'GH', 'LastName': 'Rudrappa', 'Affiliation': 'Department of Orthopedics, Sapthagiri Institute of Medical Sciences and Research Center, Bangalore, Karnataka.'}, {'ForeName': 'Pruthvi T', 'Initials': 'PT', 'LastName': 'Chakravarthi', 'Affiliation': 'Department of Orthopedics, Sapthagiri Institute of Medical Sciences and Research Center, Bangalore, Karnataka.'}, {'ForeName': 'Irin Rosanna', 'Initials': 'IR', 'LastName': 'Benny', 'Affiliation': 'Amala Institute of Medical Sciences, Amala Nagar, Thrissur, Kerala, India.'}]",Medicine,['10.1097/MD.0000000000020373'] 1651,32664064,"Safety and efficacy of an herbal formula, Gwakhyangjeonggi-san on atopic dermatitis with gastrointestinal symptoms: Protocol for a randomized controlled trial.","INTRODUCTION Gwakhyangjeonggi-san (GJS) is an herbal formula with anti-inflammatory and anti-allergic properties that is broadly used to treat a wide range of diseases including gastrointestinal disorders and allergic diseases. There have been several clinical studies conducted on its effects on atopic dermatitis (AD). So far, no randomized controlled trials have been conducted. Here, we describe the protocol for a randomized controlled study designed to investigate the efficacy and safety of GJS for treating patients with AD that have gastrointestinal symptoms. METHODS AND ANALYSIS A randomized, double-blind, placebo-controlled, parallel-group, clinical trial has been designed to investigate the clinical efficacy and safety of GJS on patients with AD that have gastrointestinal symptoms. A total of 58 participants with AD will be recruited and randomly allocated to the GJS or placebo group in a 1:1 ratio. The participants will be administered GJS or placebo granules 3 times a day for 8 weeks. Data will be collected from the participants at baseline and after 4 and 8 weeks. The primary outcome measure will be the mean change in the SCORing of Atopic Dermatitis (SCORAD) index from baseline to 8 weeks. The secondary outcomes will include the eczema area and severity index (EASI), dermatology life quality index (DLQI), EuroQoL 5 dimensions 5 levels (EQ-5D-5L), and immunological factors. The Korean Gastrointestinal Symptom Rating Scale (KGSRS), Nepean Dyspepsia Index will also be obtained for assessing the gastrointestinal status. DISCUSSION The findings of this study are expected to provide evidence on the safety and effectiveness of GJS and for treating patients with AD that have gastrointestinal symptoms. Additionally, the study will explore the mechanism of GJS action via gut microbiome. This study will provide new perspectives on approaching treatment for AD. ETHICS AND DISSEMINATION The study protocol was approved by the Institutional Review Board of Kyung Hee University Korean Medicine Hospital at Gangdong (KHNMCOH2019-06-002-001). TRIAL REGISTRATION NUMBER This study has been registered at the Korean National Clinical Trial Registry, Clinical Research Information Service (KCT0004299).",2020,The primary outcome measure will be the mean change in the SCORing of Atopic Dermatitis (SCORAD) index from baseline to 8 weeks.,"['Kyung Hee University Korean Medicine Hospital at Gangdong (KHNMCOH2019-06-002-001', '58 participants with AD', 'patients with AD that have gastrointestinal symptoms', 'atopic dermatitis with gastrointestinal symptoms']","['Gwakhyangjeonggi-san', 'herbal formula', 'Gwakhyangjeonggi-san (GJS', 'GJS or placebo', 'GJS', 'placebo']","['Korean Gastrointestinal Symptom Rating Scale (KGSRS', 'eczema area and severity index (EASI), dermatology life quality index (DLQI), EuroQoL 5 dimensions 5 levels (EQ-5D-5L), and immunological factors', 'efficacy and safety', 'Safety and efficacy', 'mean change in the SCORing of Atopic Dermatitis (SCORAD) index']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}]","[{'cui': 'C3850537', 'cui_str': 'gwakhyangjeonggi-san'}, {'cui': 'C0376667', 'cui_str': 'Herbals'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0013595', 'cui_str': 'Eczema'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0451112', 'cui_str': 'Dermatology life quality index'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0456951', 'cui_str': 'Level 5'}, {'cui': 'C0021054', 'cui_str': 'Immunologic substance'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}]",58.0,0.607587,The primary outcome measure will be the mean change in the SCORing of Atopic Dermatitis (SCORAD) index from baseline to 8 weeks.,"[{'ForeName': 'Mi Ju', 'Initials': 'MJ', 'LastName': 'Son', 'Affiliation': 'Clinical Medicine Division, Korea Institute of Oriental Medicine, Daejeon.'}, {'ForeName': 'Min Hee', 'Initials': 'MH', 'LastName': 'Kim', 'Affiliation': 'Department of Ophthalmology, Otolaryngology and Dermatology of Korean Medicine, Kyung Hee University Hospital at Gangdong, Seoul.'}, {'ForeName': 'Minseo', 'Initials': 'M', 'LastName': 'Kang', 'Affiliation': 'Department of Ophthalmology, Otolaryngology and Dermatology of Korean Medicine, Kyung Hee University Hospital at Gangdong, Seoul.'}, {'ForeName': 'Young-Eun', 'Initials': 'YE', 'LastName': 'Kim', 'Affiliation': 'Future Medicine Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.'}, {'ForeName': 'Jeeyoun', 'Initials': 'J', 'LastName': 'Jung', 'Affiliation': 'Clinical Medicine Division, Korea Institute of Oriental Medicine, Daejeon.'}, {'ForeName': 'Inhwa', 'Initials': 'I', 'LastName': 'Choi', 'Affiliation': 'Department of Ophthalmology, Otolaryngology and Dermatology of Korean Medicine, Kyung Hee University Hospital at Gangdong, Seoul.'}]",Medicine,['10.1097/MD.0000000000020675'] 1652,32664066,Prospective study to optimize the health of patients with TIAS (transient ischemic attack) and stroke admitted to the Hamad General Hospital.,"INTRODUCTION Recurrent ischemic strokes (IS) make up to one-third of all strokes. Nine out of 10 strokes are due to modifiable risk factors. Thus, it seems that standard management strategies of modifiable risk factors are yet to improve. Hence, we planned a randomized controlled trial assessing nurses or pharmacists-led aggressive control of comorbidities and their prognostic impact on IS and transient ischemic attacks (TIA). METHODS/DESIGN Prospective study to optimize the health of patients with TIAs and stroke admitted to the Hamad General Hospital (PROMOTE HEALTH) is an assessor-blinded, open-label, randomized, two-arm, controlled trial. Eligible patients have IS or TIA, and an additional modifiable risk factor (Hypertension or dyslipidemia) attending the stroke ward or clinic at the Weill Cornell-affiliated Hamad General Hospital. Stroke specialists will offer the control group the currently practiced best risk factor management strategies. Whereas, in the intervention arm, with the assistance of a nurse and a pharmacist, we will make aggressive attempts to meet targets of defined risk factors. The primary outcomes are the mean difference in blood pressure (BP) and low-density lipoprotein. Whereas myocardial infarction, recurrent stroke events, and mortality serve as the study's secondary outcomes. We require 200 patients per study arm to achieve a power of 80% and an alpha level of <0.05. The Medical Research Center and the Institutional Review Board have approved the study, and it was prospectively registered in a trial registry. DISCUSSION A significant proportion of strokes are due to modifiable preventable risk factors. Despite having the right preventive strategies aimed at mitigating these risk factors, a sizeable proportion of strokes are due to recurring events. This prompted the medical community to evaluate aggressive means of addressing these risk factors. The nurse or pharmacist-led management of comorbidities has been proven to be of value in the management of diabetes and hypertension. It will be of value to demonstrate the effectiveness of utilizing this additional task force in aggressively managing IS or TIA patients with an overarching goal of improving their prognosis. If our intervention proves to be efficacious, this would have a substantial impact on the current stroke practices and guidelines. Additionally, it will invite further research in the area. CLINICAL TRIAL REGISTRATION Clinicaltrials.gov NCT02868723, last updated on September 2018.",2020,The nurse or pharmacist-led management of comorbidities has been proven to be of value in the management of diabetes and hypertension.,"['patients with TIAs and stroke admitted to the Hamad General Hospital (PROMOTE HEALTH', 'Eligible patients have IS or TIA, and an additional modifiable risk factor (Hypertension or dyslipidemia) attending the stroke ward or clinic at the Weill Cornell-affiliated Hamad General Hospital', 'patients with TIAS (transient ischemic attack) and stroke admitted to the Hamad General Hospital']",[],"['mean difference in blood pressure (BP) and low-density lipoprotein', 'myocardial infarction, recurrent stroke events, and mortality serve']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0020008', 'cui_str': 'Hospitals, General'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemia'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C1836785', 'cui_str': 'Recurrent stroke'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",,0.0678786,The nurse or pharmacist-led management of comorbidities has been proven to be of value in the management of diabetes and hypertension.,"[{'ForeName': 'Yahia Z', 'Initials': 'YZ', 'LastName': 'Imam', 'Affiliation': 'Neuroscience Institute, Hamad Medical Corporation.'}, {'ForeName': 'Mouhand F H', 'Initials': 'MFH', 'LastName': 'Mohamed', 'Affiliation': 'Internal Medicine Department, Hamad General Hospital, Hamad Medical Corporation.'}, {'ForeName': 'Mohamed S', 'Initials': 'MS', 'LastName': 'Abdelmoneim', 'Affiliation': 'Neuroscience Institute, Hamad Medical Corporation.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Santos', 'Affiliation': 'Neuroscience Institute, Hamad Medical Corporation.'}, {'ForeName': 'Nima', 'Initials': 'N', 'LastName': 'Alkhawad', 'Affiliation': 'Neuroscience Institute, Hamad Medical Corporation.'}, {'ForeName': 'Abdul', 'Initials': 'A', 'LastName': 'Salam', 'Affiliation': 'Neuroscience Institute, Hamad Medical Corporation.'}, {'ForeName': 'Numan', 'Initials': 'N', 'LastName': 'Amir', 'Affiliation': 'Neuroscience Institute, Hamad Medical Corporation.'}, {'ForeName': 'Maher', 'Initials': 'M', 'LastName': 'Saqqur', 'Affiliation': 'Neuroscience Institute, Hamad Medical Corporation.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Muhammad', 'Affiliation': 'Neuroscience Institute, Hamad Medical Corporation.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Elsoutohy', 'Affiliation': 'Neuroscience Institute, Hamad Medical Corporation.'}, {'ForeName': 'Saadat', 'Initials': 'S', 'LastName': 'Kamran', 'Affiliation': 'Neuroscience Institute, Hamad Medical Corporation.'}, {'ForeName': 'Naveed', 'Initials': 'N', 'LastName': 'Akhtar', 'Affiliation': 'Neuroscience Institute, Hamad Medical Corporation.'}, {'ForeName': 'Abdul Salim', 'Initials': 'AS', 'LastName': 'Kiliyanni', 'Affiliation': 'Radiology Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Own', 'Affiliation': 'Neuroscience Institute, Hamad Medical Corporation.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Deleu', 'Affiliation': 'Neuroscience Institute, Hamad Medical Corporation.'}, {'ForeName': 'Ashfaq', 'Initials': 'A', 'LastName': 'Shuaib', 'Affiliation': 'Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada.'}]",Medicine,['10.1097/MD.0000000000020694'] 1653,32664290,Effects of Pre-Sleep Whey vs. Plant-Based Protein Consumption on Muscle Recovery Following Damaging Morning Exercise.,"Pre-sleep whey protein intake has been shown to improve overnight muscle protein synthesis, muscle size and strength, and muscle recovery. Despite a growing interest in alternative protein sources, such as plant-based protein, there is no evidence regarding the efficacy of plant-based proteins consumed pre-sleep. Therefore, we aimed to compare whey vs. plant-based pre-sleep protein dietary supplementation on muscle recovery in middle-aged men. Twenty-seven recreationally active, middle-aged men performed 5 sets of 15 repetitions of maximal eccentric voluntary contractions (ECC) for the knee extensors (ext) and flexors (flex), respectively, in the morning. Participants consumed 40 g of either whey hydrolysate (WH, n = 9), whey isolate (WI, n = 6), rice and pea combination (RP, n = 6), or placebo (PL, n = 6) 30 min pre-sleep on the day of ECC and the following two nights. Catered meals (15% PRO, 55% CHO, 30% Fat) were provided to participants for 5 days to standardize nutrition. Plasma creatine kinase (CK), interleukin-6 (IL-6), and interleukin-10 (IL-10) were measured at pre, immediately post (+0), +4, +6, +24, +48, and +72 h post-ECC. Isometric (ISOM) and isokinetic (ISOK) maximal voluntary contraction force were measured at pre, immediately post (+0), +24, +48, and +72 h post-ECC. Muscle soreness, thigh circumference, and HOMA-IR were measured at pre, +24, +48, and +72 h post-ECC. CK was increased at +4 h post-ECC, remained elevated at all time points compared to baseline ( p < 0.001), and was significantly greater at +72 h compared to all other time points ( p < 0.001). IL-6 was increased at +6 h ( p = 0.002) with no other time differing from baseline. ISOMext was reduced after ECC ( p = 0.001) and remained reduced until returning to baseline at +72 h. ISOMflex, ISOKext, and ISOKflex were reduced after ECC and remained reduced at +72 h ( p < 0.001). Muscle soreness increased post-ECC ( p < 0.001) and did not return to baseline. Thigh circumference ( p = 0.456) and HOMA-IR ( p = 0.396) did not change post-ECC. There were no significant differences between groups for any outcome measure. These data suggest that middle-aged men consuming 1.08 ± 0.02 g/kg/day PRO did not recover from damaging eccentric exercise at +72 h and that pre-sleep protein ingestion, regardless of protein source, did not aid in muscle recovery when damaging eccentric exercise was performed in the morning.",2020,Thigh circumference ( p = 0.456) and HOMA-IR ( p = 0.396) did not change post-ECC.,"['Twenty-seven recreationally active, middle-aged men', 'middle-aged men']","['whey vs. plant-based pre-sleep protein dietary supplementation', 'maximal eccentric voluntary contractions (ECC', 'Pre-Sleep Whey vs. Plant-Based Protein Consumption', 'whey hydrolysate (WH, n = 9), whey isolate (WI, n = 6), rice and pea combination (RP, n = 6), or placebo (PL, n = 6) 30 min pre-sleep on the day of ECC']","['Muscle soreness', 'ISOMflex, ISOKext, and ISOKflex', 'HOMA-IR', 'Plasma creatine kinase (CK), interleukin-6 (IL-6), and interleukin-10 (IL-10', 'ISOMext', 'Isometric (ISOM) and isokinetic (ISOK) maximal voluntary contraction force', 'IL-6', 'Muscle soreness, thigh circumference, and HOMA-IR', 'CK', 'Thigh circumference']","[{'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C0032098', 'cui_str': 'Kingdom Viridiplantae'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0012177', 'cui_str': 'Proteins, Dietary'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0205409', 'cui_str': 'Isolated'}, {'cui': 'C0035567', 'cui_str': 'Rice'}, {'cui': 'C0030738', 'cui_str': 'Peas'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0858114', 'cui_str': 'Plasma creatine'}, {'cui': 'C0031727', 'cui_str': 'Kinase'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}]",,0.178006,Thigh circumference ( p = 0.456) and HOMA-IR ( p = 0.396) did not change post-ECC.,"[{'ForeName': 'Patrick G', 'Initials': 'PG', 'LastName': 'Saracino', 'Affiliation': 'Department of Nutrition, Food and Exercise Sciences, Institute of Sports Sciences and Medicine, Florida State University, Tallahassee, FL 32306, USA.'}, {'ForeName': 'Hannah E', 'Initials': 'HE', 'LastName': 'Saylor', 'Affiliation': 'Department of Nutrition, Food and Exercise Sciences, Institute of Sports Sciences and Medicine, Florida State University, Tallahassee, FL 32306, USA.'}, {'ForeName': 'Brett R', 'Initials': 'BR', 'LastName': 'Hanna', 'Affiliation': 'Department of Nutrition, Food and Exercise Sciences, Institute of Sports Sciences and Medicine, Florida State University, Tallahassee, FL 32306, USA.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Hickner', 'Affiliation': 'Department of Nutrition, Food and Exercise Sciences, Institute of Sports Sciences and Medicine, Florida State University, Tallahassee, FL 32306, USA.'}, {'ForeName': 'Jeong-Su', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': 'Department of Nutrition, Food and Exercise Sciences, Institute of Sports Sciences and Medicine, Florida State University, Tallahassee, FL 32306, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Ormsbee', 'Affiliation': 'Department of Nutrition, Food and Exercise Sciences, Institute of Sports Sciences and Medicine, Florida State University, Tallahassee, FL 32306, USA.'}]",Nutrients,['10.3390/nu12072049'] 1654,32664361,"Impact of Whole Body Electromyostimulation on Velocity, Power and Body Composition in Postmenopausal Women: A Randomized Controlled Trial.","Menopause is associated with losses in strength and power along with weight and fat mass gains, which may result from menopause-related hormonal changes, aging-associated diseases, and decreased physical activity time. The objective of this study is to analyze if whole-body electromyostimulation (WB-EMS) is suitable for the prevention and treatment of postmenopausal physical deterioration. Thirty-four healthy sedentary women between 55 and 69 years followed an experimental design pre-post test. Both groups conducted 10 weeks of aerobic and strength training program. The experimental group conducted the training with superimposed WB-EMS during exercise. At the end of the intervention, the experimental group obtained better power (Squat: mean difference (MD) = 38.69 W [1.75,75.62], d = 0.81; Bench press: MD = 25.64 W [17.48, 33.82], d = 2.39) and velocity (Squat: MD = 0.04 m·s -1 [0.01, 0.08], d = 0.98; Bench press: MD = 0.10 m·s -1 [0.06, 0.14], d = 1.90) score improvements than the other group ( p Bonferroni < 0.05). Furthermore, trivial to small effects were found in the body composition of the participants of both groups ( p > 0.050). WB-EMS showed a favorable isolated effect on the development of power and velocity, but it induced negligible effects on the body composition of postmenopausal women.",2020,score improvements than the other group ( p Bonferroni < 0.05).,"['Postmenopausal Women', 'postmenopausal women', 'Thirty-four healthy sedentary women between 55 and 69 years followed an experimental design pre-post test']","['whole-body electromyostimulation (WB-EMS', 'Whole Body Electromyostimulation', 'training with superimposed WB-EMS during exercise', 'aerobic and strength training program']","['body composition', 'Velocity, Power and Body Composition', 'score improvements', 'physical activity time']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0032919', 'cui_str': 'Pre-Post Tests'}]","[{'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0587107', 'cui_str': 'During exercise'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",34.0,0.0381312,score improvements than the other group ( p Bonferroni < 0.05).,"[{'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Pano-Rodriguez', 'Affiliation': 'Research Group Human Movement, University of Lleida, E-25001 Lleida, Spain.'}, {'ForeName': 'Jose Vicente', 'Initials': 'JV', 'LastName': 'Beltran-Garrido', 'Affiliation': 'EUSES Health and Sport Sciences School, Rovira i Virgili University, 43870 Tarragona, Spain.'}, {'ForeName': 'Vicenç', 'Initials': 'V', 'LastName': 'Hernandez-Gonzalez', 'Affiliation': 'Nutritional Coaching SL, 08011 Barcelona, Spain.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Nasarre-Nacenta', 'Affiliation': 'Nutritional Coaching SL, 08011 Barcelona, Spain.'}, {'ForeName': 'Joaquin', 'Initials': 'J', 'LastName': 'Reverter-Masia', 'Affiliation': 'EUSES Health and Sport Sciences School, Rovira i Virgili University, 43870 Tarragona, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17144982'] 1655,32634642,Evaluation of the perioperative effects of dexmedetomidine on tympanoplasty operations.,"PURPOSE This randomized double-blind study aimed to evaluate the effects of dexmedetomidine on hemodynamic parameters and the quality of surgery and recovery criteria in tympanoplasty operations. MATERIALS AND METHODS A total of 75 patients 18-55 years undergoing tympanoplasty, who were graded as American Society of Anesthesiologists physical status I-II, were randomly divided into three groups. Group 1 included patients receiving remifentanil alone, Group 2 included patients receiving dexmedetomidine + remifentanil and Group 3 included patients receiving dexmedetomidine + ½ remifentanil. Anesthesia was induced with propofol and cisatracurium. For maintenance of anesthesia, a mixture of 2-2.5% sevoflurane, 40-60% oxygen/air was used. The groups were compared in terms of hemodynamic parameters, surgical area, recovery criteria, modified Aldrete, pain scores, additional analgesic requirements and adverse effects. RESULTS Mean arterial pressure and heart rate values of Group 1 were higher at the time of intubation, incision, spontaneous breathing and extubation compared to Group 2 and Group 3. Surgical field satisfaction was higher in Group 2 and Group 3 than Group 1. Spontaneous breathing, eye opening and verbal cooperation times were shorter in Group 3 compared to Group 2. Eye opening and verbal cooperation times were longer in Group 2 compared to Group 1. The 30-minute modified Aldrete scores was higher in Group 3 compared to Group 1. There was no difference between the groups in terms of postoperative pain and adverse effects. CONCLUSION The use of dexmedetomidine during tympanoplasty operations may provide better hemodynamic control and surgical view, may provide faster recovery and may reduce remifentanil consumption.",2020,"Mean arterial pressure and heart rate values of Group 1 were higher at the time of intubation, incision, spontaneous breathing and extubation compared to Group 2 and Group 3.","['75 patients 18-55\xa0years undergoing tympanoplasty, who were graded as American Society of Anesthesiologists physical status I-II']","['dexmedetomidine + ½ remifentanil', 'remifentanil alone', 'propofol and cisatracurium', 'sevoflurane', 'dexmedetomidine', 'dexmedetomidine + remifentanil']","['Eye opening and verbal cooperation times', 'Mean arterial pressure and heart rate values', 'Surgical field satisfaction', 'Spontaneous breathing, eye opening and verbal cooperation times', 'postoperative pain and adverse effects', 'hemodynamic parameters, surgical area, recovery criteria, modified Aldrete, pain scores, additional analgesic requirements and adverse effects', 'tympanoplasty operations']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0041447', 'cui_str': 'Repair of middle ear'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449438', 'cui_str': 'Status'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C1096766', 'cui_str': 'Cisatracurium'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}]","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0041447', 'cui_str': 'Repair of middle ear'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]",75.0,0.0542959,"Mean arterial pressure and heart rate values of Group 1 were higher at the time of intubation, incision, spontaneous breathing and extubation compared to Group 2 and Group 3.","[{'ForeName': 'Muge', 'Initials': 'M', 'LastName': 'Kosucu', 'Affiliation': 'Medical School of Karadeniz Technical University, Department of Anaesthesiology, 61080 Trabzon, Turkey. Electronic address: mugekk73@hotmail.com.'}, {'ForeName': 'Ersagun', 'Initials': 'E', 'LastName': 'Tugcugil', 'Affiliation': 'Medical School of Karadeniz Technical University, Department of Anaesthesiology, 61080 Trabzon, Turkey.'}, {'ForeName': 'Bengu', 'Initials': 'B', 'LastName': 'Cobanoglu', 'Affiliation': 'Medical School of Karadeniz Technical University, Department of Otorhinolaryngology, 61080 Trabzon, Turkey.'}, {'ForeName': 'Erhan', 'Initials': 'E', 'LastName': 'Arslan', 'Affiliation': 'Medical School of Karadeniz Technical University, Department of Neurosurgery, 61080 Trabzon, Turkey.'}]",American journal of otolaryngology,['10.1016/j.amjoto.2020.102619'] 1656,32634673,Ulipristal acetate versus gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): Long term results of a double-blind randomized controlled trial.,"OBJECTIVE The aim of this study was to compare the effect of ulipristal acetate (UPA) and gonadotropin-releasing hormone agonists (GnRHa) before laparoscopic myomectomy on long term secondary outcomes of the MYOMEX-trial, regarding quality of life, ultrasound characteristics, hemoglobin levels 6 weeks post-operative, sexual function and menstrual bleeding control. A cost-analysis was also performed. Short-term primary and secondary outcomes are reported elsewhere. STUDY DESIGN A double-blind, randomized, controlled, non-inferiority trial in nine hospitals in the Netherlands. Participants were randomized in a 1:1 ratio (block size of four, stratified per hospital) to either UPA or GnRHa pre-treatment. Additional placebo injections containing saline, respectively daily placebo tablets were given to both groups to ensure double-blinding. Surgery was performed within a month after the last tablet. Women were followed up until six months post-surgery. RESULTS A total of 55 participants were randomized: 30 to the UPA- and 25 to the GnRHa-group between May 2015 and July 2017. Uterine volume at six weeks post-operative did not differ significantly between both pre-treatment groups with 170.1 cm 3 (106.8-243.5; N = 29) vs. 152.8 cm 3 (92.3-205.6; N = 23) for the UPA- and GnRHa-group respectively (p = 0.423). Hemoglobin levels six weeks post-operatively recovered back to baseline and were not significantly different between groups with 7.7 mmol/L for the UPA- vs. 8.1 mmol/L for the GnRHa-group (p = 0.157; mean difference -0.4 (CI -0.9, 0.2). Menstrual bleeding pattern, quality of life, effects on general and sexual health showed a significant improvement compared to baseline in both groups without any differences between the treatment groups. Symptom severity scores also decreased significantly at 6 week post-operatively compared to baseline, but did not differ between the treatment groups. Fibroid characteristics at baseline (e.g. mean diameter of largest fibroid) appeared not to be a confounding factor. An exploratory cost analysis showed no significant differences in absenteeism costs, total healthcare and societal costs, after adjustment for confounding factors. CONCLUSION Pre-treatment prior to laparoscopic myomectomy with UPA compared to GnRHa has similar effects on bleeding pattern, menopausal symptoms, sexual functioning, symptom severity and quality of life from baseline up to six months post-operative. Due to the small sample size, these findings should be interpreted with caution. Also, no firm conclusions on costs could be made.",2020,"Menstrual bleeding pattern, quality of life, effects on general and sexual health showed a significant improvement compared to baseline in both groups without any differences between the treatment groups.","['prior to laparoscopic myomectomy (MYOMEX trial', 'A total of 55 participants were randomized: 30 to the UPA- and 25 to the GnRHa-group between May 2015 and July 2017', 'nine hospitals in the Netherlands']","['UPA or GnRHa pre-treatment', 'Ulipristal acetate versus gonadotropin-releasing hormone agonists', 'ulipristal acetate (UPA) and gonadotropin-releasing hormone agonists (GnRHa) before laparoscopic myomectomy', 'placebo injections containing saline, respectively daily placebo tablets']","['Fibroid characteristics', 'Hemoglobin levels', 'Menstrual bleeding pattern, quality of life, effects on general and sexual health', 'absenteeism costs, total healthcare and societal costs', 'bleeding pattern, menopausal symptoms, sexual functioning, symptom severity and quality of life', 'Symptom severity scores', 'Uterine volume', 'quality of life, ultrasound characteristics, hemoglobin levels 6 weeks post-operative, sexual function and menstrual bleeding control']","[{'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C2111517', 'cui_str': 'Laparoscopic myomectomy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C2723461', 'cui_str': 'Ulipristal acetate'}, {'cui': 'C1518041', 'cui_str': 'Gonadotropin releasing hormone analogues'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}]","[{'cui': 'C2723461', 'cui_str': 'Ulipristal acetate'}, {'cui': 'C1518041', 'cui_str': 'Gonadotropin releasing hormone analogues'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C2111517', 'cui_str': 'Laparoscopic myomectomy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}]","[{'cui': 'C0023267', 'cui_str': 'Leiomyofibroma'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0025344', 'cui_str': 'Menstruation'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C2362326', 'cui_str': 'Sexual Health'}, {'cui': 'C0000849', 'cui_str': 'Absenteeism'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0236075', 'cui_str': 'Menopausal symptom'}, {'cui': 'C0278092', 'cui_str': 'Sexual function'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",55.0,0.659859,"Menstrual bleeding pattern, quality of life, effects on general and sexual health showed a significant improvement compared to baseline in both groups without any differences between the treatment groups.","[{'ForeName': 'Inge', 'Initials': 'I', 'LastName': 'De Milliano', 'Affiliation': 'Amsterdam University Medical Center, Department of Obstetrics and Gynecology, Amsterdam Reproduction and Development, De Boelelaan 1117, Amsterdam, The Netherlands.'}, {'ForeName': 'Mei-An', 'Initials': 'MA', 'LastName': 'Middelkoop', 'Affiliation': 'Amsterdam University Medical Center, Department of Obstetrics and Gynecology, Amsterdam Reproduction and Development, De Boelelaan 1117, Amsterdam, The Netherlands. Electronic address: m.middelkoop@amsterdamumc.nl.'}, {'ForeName': 'Judith A F', 'Initials': 'JAF', 'LastName': 'Huirne', 'Affiliation': 'Amsterdam University Medical Center, Department of Obstetrics and Gynecology, Amsterdam Reproduction and Development, De Boelelaan 1117, Amsterdam, The Netherlands.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Kwee', 'Affiliation': 'OLVG, Department of Obstetrics and Gynecology, Jan Tooropstraat 164, Amsterdam, The Netherlands.'}, {'ForeName': 'Peggy M A J', 'Initials': 'PMAJ', 'LastName': 'Geomini', 'Affiliation': 'Máxima Medisch Centrum, Department of Obstetrics and Gynecology, De Run 4600, Veldhoven, The Netherlands.'}, {'ForeName': 'Benedictus C', 'Initials': 'BC', 'LastName': 'Schoot', 'Affiliation': 'Catharina Ziekenhuis, Department of Obstetrics and Gynecology, Michelangelolaan 2, Eindhoven, The Netherlands.'}, {'ForeName': 'Marchien', 'Initials': 'M', 'LastName': 'Van Baal', 'Affiliation': 'Flevoziekenhuis, Department Obstetrics and Gynecology, Hospitaalweg 1, Almere, The Netherlands.'}, {'ForeName': 'Judith E', 'Initials': 'JE', 'LastName': 'Bosmans', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Wouter J K', 'Initials': 'WJK', 'LastName': 'Hehenkamp', 'Affiliation': 'Amsterdam University Medical Center, Department of Obstetrics and Gynecology, Amsterdam Reproduction and Development, De Boelelaan 1117, Amsterdam, The Netherlands. Electronic address: w.hehenkamp@amsterdamumc.nl.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.06.035'] 1657,32635288,The Influence of Proprioceptive Training with the Use of Virtual Reality on Postural Stability of Workers Working at Height.,"The aim of the study was to assess the impact of proprioceptive training with the use of virtual reality (VR) on the level of postural stability of high-altitude workers. Twenty-one men working at height were randomly assigned to the experimental group (EG) with training ( n = 10) and control group (CG) without training ( n = 11). Path length of the displacement of the center of pressure (COP) signal and its components in the anteroposterior and medial-lateral directions were measured with use of an AccuGaitTM force plate before and after intervention (6 weeks, 2 sessions × 30 min a week). Tests were performed at two different platform heights, with or without eyes open and with or without a dual task. Two-way ANOVA revealed statistically significant interaction effects for low-high threat, eyes open-eyes closed, and single task-dual task. Post-training values of average COP length were significantly lower in the EG than before training for all analyzed parameters. Based on these results, it can be concluded that the use of proprioceptive training with use of VR can support, or even replace, traditional methods of balance training.",2020,Post-training values of average COP length were significantly lower in the EG than before training for all analyzed parameters.,"['high-altitude workers', 'Twenty-one men working at height', 'Workers Working at Height']","['Proprioceptive Training', 'proprioceptive training', 'virtual reality (VR', 'control group (CG) without training']","['average COP length', 'Path length of the displacement of the center of pressure (COP) signal']","[{'cui': 'C0238617', 'cui_str': 'High altitude'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0056471', 'cui_str': 'creatinolfosfate'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}]",21.0,0.012365,Post-training values of average COP length were significantly lower in the EG than before training for all analyzed parameters.,"[{'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Cyma-Wejchenig', 'Affiliation': 'Poznan University of Physical Education, 61-871 Poznan, Poland.'}, {'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Tarnas', 'Affiliation': 'Poznan University of Physical Education, 61-871 Poznan, Poland.'}, {'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Marciniak', 'Affiliation': 'Poznan University of Physical Education, 61-871 Poznan, Poland.'}, {'ForeName': 'Rafał', 'Initials': 'R', 'LastName': 'Stemplewski', 'Affiliation': 'Poznan University of Physical Education, 61-871 Poznan, Poland.'}]","Sensors (Basel, Switzerland)",['10.3390/s20133731'] 1658,32635503,"Supplementation with Low Doses of a Cod Protein Hydrolysate on Glucose Regulation and Lipid Metabolism in Adults with Metabolic Syndrome: A Randomized, Double-Blind Study.","The risk of cardiovascular diseases and type 2 diabetes mellitus are increased in subjects with metabolic syndrome (MetS), and hydrolyzed fish protein may have favorable effects on metabolic health. Here, we investigated the effect of 8 weeks supplementation with 4 g of cod protein hydrolysate (CPH) on glucose metabolism, lipid profile and body composition in individuals with MetS in a double-blind, randomized intervention study with a parallel-group design. Subjects received a daily supplement of CPH ( n = 15) or placebo ( n = 15). Primary outcomes were serum fasting and postprandial glucose levels. Secondary outcomes were fasting and postprandial insulin and glucagon-like peptide 1 (GLP-1), fasting lipid concentrations and body composition. No difference was observed between CPH and placebo for insulin, glucose or GLP-1 after 8 weeks intervention. Fasting triacylglycerol decreased in both the CPH group and placebo group, with no change between groups. Fasting total cholesterol and low-density lipoprotein cholesterol decreased significantly within both groups from baseline to study end, but no difference was observed between the two groups. In conclusion, supplementing with a low dose of CPH in subjects with MetS for 8 weeks had no effect on fasting or postprandial levels of insulin, glucose or GLP-1, lipid profile or body composition.",2020,"Fasting total cholesterol and low-density lipoprotein cholesterol decreased significantly within both groups from baseline to study end, but no difference was observed between the two groups.","['Adults with Metabolic Syndrome', 'subjects with metabolic syndrome (MetS', 'individuals with MetS']","['daily supplement of CPH', 'Cod Protein Hydrolysate', 'CPH and placebo', 'CPH', 'cod protein hydrolysate (CPH', 'placebo']","['insulin, glucose or GLP-1', 'Fasting triacylglycerol', 'Fasting total cholesterol and low-density lipoprotein cholesterol', 'fasting or postprandial levels of insulin, glucose or GLP-1, lipid profile or body composition', 'glucose metabolism, lipid profile and body composition', 'Glucose Regulation and Lipid Metabolism', 'fasting and postprandial insulin and glucagon-like peptide 1 (GLP-1), fasting lipid concentrations and body composition', 'serum fasting and postprandial glucose levels']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0007465', 'cui_str': 'Cause of death'}, {'cui': 'C0033631', 'cui_str': 'protein hydrolysates'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}]",,0.426719,"Fasting total cholesterol and low-density lipoprotein cholesterol decreased significantly within both groups from baseline to study end, but no difference was observed between the two groups.","[{'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Jensen', 'Affiliation': 'Centre for Nutrition, Department of Clinical Medicine, University of Bergen, 5021 Bergen, Norway.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Fjeldheim Dale', 'Affiliation': 'Centre for Nutrition, Department of Clinical Medicine, University of Bergen, 5021 Bergen, Norway.'}, {'ForeName': 'Trygve', 'Initials': 'T', 'LastName': 'Hausken', 'Affiliation': 'Centre for Nutrition, Department of Clinical Medicine, University of Bergen, 5021 Bergen, Norway.'}, {'ForeName': 'Jan Gunnar', 'Initials': 'JG', 'LastName': 'Hatlebakk', 'Affiliation': 'Centre for Nutrition, Department of Clinical Medicine, University of Bergen, 5021 Bergen, Norway.'}, {'ForeName': 'Ingeborg', 'Initials': 'I', 'LastName': 'Brønstad', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway.'}, {'ForeName': 'Gülen Arslan', 'Initials': 'GA', 'LastName': 'Lied', 'Affiliation': 'Centre for Nutrition, Department of Clinical Medicine, University of Bergen, 5021 Bergen, Norway.'}, {'ForeName': 'Dag Arne Lihaug', 'Initials': 'DAL', 'LastName': 'Hoff', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, Ålesund Hospital, Møre and Romsdal Hospital Trust, 6026 Ålesund, Norway.'}]",Nutrients,['10.3390/nu12071991'] 1659,32635661,"The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study.","The purpose of the randomized double-blind placebo-controlled trial was to assess the effectiveness of synbiotic preparation containing probiotic Lactobacillus rhamnosus FloraActive™ 19070-2, Lactobacillus acidophilus DSMZ 32418, Bifidobacterium lactis DSMZ 32269, Bifidobacterium longum DSMZ 32946, Bifidobacterium bifidum DSMZ 32403 and fructooligosaccharides in adult patients with diarrhea-dominant IBS (IBS-D). The study included eighty patients with moderate and severe IBS-D who were randomized to receive synbiotics or placebo for eight weeks. Finally, a total of sixty-eight patients finished the study. The primary endpoints included the assessment of the symptoms' severity with IBS symptom severity scale (IBS-SSS), an improvement of IBS global symptoms with Global Improvement Scale (IBS-GIS) and adequate relief of symptoms after four and eight weeks of therapy. Secondary endpoints, which were collected by telephone interviewers three times a week included the assessment of individual IBS symptoms and adverse events. Synbiotic treatment in comparison to placebo significantly improved IBS-GIS ( p = 0.043), and IBS-SSS score inducing a decrease in the total IBS-SSS ( p = 0.042) and in domain-specific scores related to flatulence ( p = 0.028) and bowel habit ( p = 0.028) after four and eight weeks. Patients treated with synbiotics reported in weekly observations a significant amelioration in a feeling of incomplete bowel movements, flatulence, pain, stool pressure and diarrheal stools compared to those receiving placebo. There were no differences in adverse events between both groups. Concluding, the multi-strain synbiotic preparation was associated with a significant improvement in symptoms in IBS-D patients and was well-tolerated. These results suggest that the use of synbiotics offers a benefit for IBS-D patients. [Clinicaltrials.gov NCT04206410 registered 20 December 2019].",2020,"Synbiotic treatment in comparison to placebo significantly improved IBS-GIS ( p = 0.043), and IBS-SSS score inducing a decrease in the total IBS-SSS ( p = 0.042) and in domain-specific scores related to flatulence ( p = 0.028) and bowel habit ( p = 0.028) after four and eight weeks.","['Patients with Diarrhea Predominant Irritable Bowel Syndrome', 'eighty patients with moderate and severe IBS-D', 'adult patients with diarrhea-dominant IBS (IBS-D']","['synbiotics or placebo', 'Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides', 'Placebo', 'placebo']","['feeling of incomplete bowel movements, flatulence, pain, stool pressure and diarrheal stools', 'IBS-SSS score', 'bowel habit', ""assessment of the symptoms' severity with IBS symptom severity scale (IBS-SSS), an improvement of IBS global symptoms with Global Improvement Scale (IBS-GIS) and adequate relief of symptoms"", 'adverse events', 'total IBS-SSS', 'individual IBS symptoms and adverse events', 'IBS-GIS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1262211', 'cui_str': 'Diarrhoea predominant irritable bowel syndrome'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]","[{'cui': 'C2936470', 'cui_str': 'Synbiotics'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0022938', 'cui_str': 'Lactobacillus'}, {'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0873033', 'cui_str': 'fructooligosaccharide'}]","[{'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0205257', 'cui_str': 'Incomplete'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0037052', 'cui_str': 'Sick sinus syndrome'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0815319', 'cui_str': 'Geographical Information Systems'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0027361', 'cui_str': 'Person'}]",80.0,0.390541,"Synbiotic treatment in comparison to placebo significantly improved IBS-GIS ( p = 0.043), and IBS-SSS score inducing a decrease in the total IBS-SSS ( p = 0.042) and in domain-specific scores related to flatulence ( p = 0.028) and bowel habit ( p = 0.028) after four and eight weeks.","[{'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Skrzydło-Radomańska', 'Affiliation': 'Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.'}, {'ForeName': 'Beata', 'Initials': 'B', 'LastName': 'Prozorow-Król', 'Affiliation': 'Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.'}, {'ForeName': 'Halina', 'Initials': 'H', 'LastName': 'Cichoż-Lach', 'Affiliation': 'Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.'}, {'ForeName': 'Emilia', 'Initials': 'E', 'LastName': 'Majsiak', 'Affiliation': 'Faculty of Medicine, Cardinal Stefan Wyszynski University, Wóycickiego 1/3, 01-938 Warszaw, Poland.'}, {'ForeName': 'Joanna B', 'Initials': 'JB', 'LastName': 'Bierła', 'Affiliation': 'Department of Pathology, The Children Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.'}, {'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Kosikowski', 'Affiliation': 'Out-Patient Clinic, Konopnica 96L, 21-030 Motycz, Poland.'}, {'ForeName': 'Mariusz', 'Initials': 'M', 'LastName': 'Szczerbiński', 'Affiliation': 'Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.'}, {'ForeName': 'Jesper', 'Initials': 'J', 'LastName': 'Gantzel', 'Affiliation': 'Biocare Copenhagen, Ole Maaloes Vej 3, DK-2200 Copenhagen, Denmark.'}, {'ForeName': 'Bożena', 'Initials': 'B', 'LastName': 'Cukrowska', 'Affiliation': 'Department of Pathology, The Children Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.'}]",Nutrients,['10.3390/nu12071999'] 1660,32644264,Effects of advanced carbohydrate counting on glucose control and quality of life in children with type 1 diabetes.,"OBJECTIVE The effect of advanced carbohydrate counting (ACC) on metabolic and quality of life (QOL) outcomes is uncertain in children with type 1 diabetes. Our aim was to determine whether ACC would improve HbA1c and QOL scores as compared with standard nutrition in this population. METHODS We randomized 87 patients using pump and rapid-acting analogs in a 1 year randomized multicenter study (age 9.6 ± 3.5 years, diabetes duration 4.6 ± 2.7 years, HbA1c 7.8 ± 0.5% [62 ± 5 mmol/mol]). The ACC group received CC education and the control group received traditional dietary education. HbA1c was measured every 3 months. At 0 and 1 year, general, diabetes-specific, and diet-related QOL were respectively assessed by the KIDSCREEN and WHO-5 questionnaires, the diabetes-specific module of the DISABKIDS, and the diet restriction items of the DSQOLS. RESULTS Mean HbA1c was lower in the ACC than the control group at 3 months (P < .05) and tended to be lower at 6 months (P = .10), 9 months (P = .10), but not at 12 months. The mean of individual average HbA1c during the one-year study period (from M3 to M12) was 7.63 ± 0.43 in the ACC vs 7.85 ± 0.47% in the control group (60 ± 5 vs 62 ± 5 mmol/mol)(P < .05). ACC was associated with significantly higher scores at 1 year on the KIDSCREEN children's psychological scale and the KIDSCREEN parents' physical scale, the DISABKIDS children's treatment scale, and the children's and parents' dietary restriction scales of the DSQOLS (indicating better QOL or lower perceived diet restriction). CONCLUSIONS ACC may be associated with small improvements in metabolic control and QOL scores in children.",2020,"Mean HbA1c was lower in the ACC than the control group at 3 months (p<0.05) and tended to be lower at 6 months (p=0.10), 9 months (p = 0.10), but not at 12 months.","['children with type 1 diabetes', 'Children with Type 1 Diabetes', '87 patients using pump and rapid-acting analogs in a 1-year randomized multi-center study (age 9.6±3.5 yr, diabetes duration 4.6±2.7 yr, HbA1c 7.8±0.5% [62±5\u2009mmol/mol', 'children']","['advanced carbohydrate counting (ACC', 'traditional dietary education', 'ACC', 'Advanced Carbohydrate Counting']","['metabolic and quality of life (QOL) outcomes', 'metabolic control and QOL scores', 'HbA1c and QOL scores', 'Mean HbA1c', 'Glucose Control and Quality of Life', 'mean of individual average HbA1c']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mol'}]","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1562940', 'cui_str': 'Carbohydrate counting'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0027361', 'cui_str': 'Person'}]",87.0,0.0413799,"Mean HbA1c was lower in the ACC than the control group at 3 months (p<0.05) and tended to be lower at 6 months (p=0.10), 9 months (p = 0.10), but not at 12 months.","[{'ForeName': 'Aurelie', 'Initials': 'A', 'LastName': 'Donzeau', 'Affiliation': 'Pediatric Diabetology, University Hospital, Angers, France.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Bonnemaison', 'Affiliation': 'Pediatric Diabetology, University Hospital, Tours, France.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Vautier', 'Affiliation': 'Pediatric Diabetology, University Hospital, Bordeaux, France.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Menut', 'Affiliation': 'Pediatric Diabetology, University Hospital, Nantes, France.'}, {'ForeName': 'Laure', 'Initials': 'L', 'LastName': 'Houdon', 'Affiliation': 'Pediatric Diabetology, University Hospital, St Pierre de la Reunion, France.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Bendelac', 'Affiliation': 'Pediatric Diabetology, University Hospital, Lyon, France.'}, {'ForeName': 'Elise', 'Initials': 'E', 'LastName': 'Bismuth', 'Affiliation': 'Pediatric Diabetology, University Hospital, St Pierre de la Reunion, France.'}, {'ForeName': 'Natacha', 'Initials': 'N', 'LastName': 'Bouhours-Nouet', 'Affiliation': 'Pediatric Diabetology, University Hospital, Angers, France.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Quemener', 'Affiliation': 'Pediatric Diabetology, University Hospital, Angers, France.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Baron', 'Affiliation': 'Pediatric Diabetology, University Hospital, Nantes, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Nicolino', 'Affiliation': 'Pediatric Diabetology, University Hospital, Lyon, France.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Faure', 'Affiliation': 'Pediatric Diabetology, University Hospital, Tours, France.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Pochelu', 'Affiliation': 'Pediatric Diabetology, University Hospital, Bordeaux, France.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Barat', 'Affiliation': 'Pediatric Diabetology, University Hospital, Bordeaux, France.'}, {'ForeName': 'Regis', 'Initials': 'R', 'LastName': 'Coutant', 'Affiliation': 'Pediatric Diabetology, University Hospital, Angers, France.'}]",Pediatric diabetes,['10.1111/pedi.13076'] 1661,32648019,"Correction to: Low-phytate wholegrain bread instead of high-phytate wholegrain bread in a total diet context did not improve iron status of healthy Swedish females: a 12 week, randomized, parallel-design intervention study.",ue to author error the paper was published wit.,2020,ue to author error the paper was published wit.,['healthy Swedish females'],['wholegrain bread'],[],"[{'cui': 'C0038996', 'cui_str': 'Swedish language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0006138', 'cui_str': 'Bread'}]",[],,0.0171175,ue to author error the paper was published wit.,"[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hoppe', 'Affiliation': 'Department of Gastroenterology and Hepatology, Clinical Nutrition Unit, Sahlgrenska University Hospital, Göteborg, Sweden. michael.hoppe@nutrition.gu.se.'}, {'ForeName': 'Alastair B', 'Initials': 'AB', 'LastName': 'Ross', 'Affiliation': 'Department of Biology and Biological Engineering, Food and Nutrition Science, Chalmers University of Technology, Göteborg, Sweden.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Svelander', 'Affiliation': 'Department of Biology and Biological Engineering, Food and Nutrition Science, Chalmers University of Technology, Göteborg, Sweden.'}, {'ForeName': 'Ann-Sofie', 'Initials': 'AS', 'LastName': 'Sandberg', 'Affiliation': 'Department of Biology and Biological Engineering, Food and Nutrition Science, Chalmers University of Technology, Göteborg, Sweden.'}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Hulthén', 'Affiliation': 'Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy at the University of Gothenburg, Göteborg, Sweden.'}]",European journal of nutrition,['10.1007/s00394-020-02286-1'] 1662,32648021,"Reply to the comments by Vorland et al. on our paper: ""low-phytate wholegrain bread instead of high-phytate wholegrain bread in a total diet context did not improve iron status of healthy Swedish females: a 12-week, randomized, parallel-design intervention study"".",,2020,,['healthy Swedish females'],[],[],"[{'cui': 'C0038996', 'cui_str': 'Swedish language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",[],[],,0.0128649,,"[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hoppe', 'Affiliation': 'Department of Gastroenterology and Hepatology, Clinical Nutrition Unit, Sahlgrenska University Hospital, Göteborg, Sweden. michael.hoppe@nutrition.gu.se.'}, {'ForeName': 'Alastair B', 'Initials': 'AB', 'LastName': 'Ross', 'Affiliation': 'Lincoln Research Centre, AgResearch, Springs Road, Lincoln, Christchurch, New Zealand.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Svelander', 'Affiliation': 'Department of Biology and Biological Engineering, Food and Nutrition Science, Chalmers University of Technology, Göteborg, Sweden.'}, {'ForeName': 'Ann-Sofie', 'Initials': 'AS', 'LastName': 'Sandberg', 'Affiliation': 'Department of Biology and Biological Engineering, Food and Nutrition Science, Chalmers University of Technology, Göteborg, Sweden.'}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Hulthén', 'Affiliation': 'Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy at the University of Gothenburg, Göteborg, Sweden.'}]",European journal of nutrition,['10.1007/s00394-020-02288-z'] 1663,32648464,Management and experience of postural placement in postoperative mechanical ventilation of newborns.,"BACKGROUND Congenital diaphragmatic hernia (CDH) is a neonatal condition that mainly occurs when the abdominal organs herniate into the thorax, obstructing the development of the lungs. Postoperative neonatal breathing disorder is one of the main causes of neonatal death. This study summarizes the postoperative nursing status of 30 cases of neonatal CDH in our hospital, and explores the effect of body position in mechanical ventilation care following CDH surgery. METHODS A total of 30 CHD children admitted in our hospital between June, 2018 and October, 2019 were included. The neonates were divided into preterm infant group (n=15) and full-term infant group (n=15). Each child was immediately transferred to the newborn intensive care unit (NICU) ward after surgery and received the hospital's NCIU special care. Besides routine nursing, each child was placed in a randomly selected primary position (the prone position or supine position). After 30 min, their oxygenation indexes were measured, and then their position (prone position or supine position) was changed. After 30 min, the neonates' oxygenation indicators were measured again. A hospital-made satisfaction questionnaire was used to evaluate the parents' satisfaction with nursing care. RESULTS Two children died of respiratory failure (one in the preterm group and one in the full-term group), and the rest were in a stable condition after surgery. There was no significant difference between the rates of parent satisfaction in the two groups (preterm infant group: 96.67% verse full-term group: 93.33%, P>0.05). In both groups, the partial pressure of oxygen in arterial blood (PaO2), partial pressure of oxygen in arterial blood/fraction of inspiration O2 (PaO2/FiO2), and partial pressure of oxygen in arterial blood/partial pressure of oxygen in the alveolar gas (PaO2/PAO2) in prone position were significantly higher than those in supine position (P<0.05); the alveolar-arterial oxygen difference (A-aDO2) was significantly lower than that in the supine position (0.05). CONCLUSIONS The prone position can improve the oxygenation index of children after surgery, and improve their respiratory system function. This method is suitable for newborn postoperative NICU care.",2020,"There was no significant difference between the rates of parent satisfaction in the two groups (preterm infant group: 96.67% verse full-term group: 93.33%, P>0.05).","['30 CHD children admitted in our hospital between June, 2018 and October, 2019 were included', 'postoperative mechanical ventilation of newborns', 'Congenital diaphragmatic hernia (CDH']","['postural placement', ""newborn intensive care unit (NICU) ward after surgery and received the hospital's NCIU special care""]","['respiratory failure', 'alveolar-arterial oxygen difference (A-aDO2', 'rates of parent satisfaction', 'partial pressure of oxygen in arterial blood (PaO2), partial pressure of oxygen in arterial blood/fraction of inspiration O2 (PaO2/FiO2), and partial pressure of oxygen in arterial blood/partial pressure of oxygen in the alveolar gas (PaO2/PAO2) in prone position']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0235833', 'cui_str': 'Congenital diaphragmatic hernia'}]","[{'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205555', 'cui_str': 'Special'}]","[{'cui': 'C1145670', 'cui_str': 'Respiratory failure'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1822073', 'cui_str': 'PaO2'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0202155', 'cui_str': 'Oxygen measurement, partial pressure, arterial'}, {'cui': 'C0017110', 'cui_str': 'Gas'}, {'cui': 'C0033422', 'cui_str': 'Prone body position'}]",30.0,0.0439864,"There was no significant difference between the rates of parent satisfaction in the two groups (preterm infant group: 96.67% verse full-term group: 93.33%, P>0.05).","[{'ForeName': 'Qiong', 'Initials': 'Q', 'LastName': 'Wu', 'Affiliation': ""Department of Outpatient, Huai'an Maternal and Child Health Care Center, Huai'an, China.""}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': ""Department of Neonatology, Huai'an Maternal and Child Health Care Center, Huai'an, China.""}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': ""Department of Outpatient, Huai'an Maternal and Child Health Care Center, Huai'an, China.""}, {'ForeName': 'Yongfeng', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': ""Department of Sterilization Supply Room, Huai'an Maternal and Child Health Care Center, Huai'an, China. zya0626@163.com.""}]",Annals of palliative medicine,['10.21037/apm-20-1003'] 1664,32645162,Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.,"BACKGROUND Patterns of antiretroviral therapy (ART) use and immunologic correlates vary globally, and contemporary trends are not well described. METHODS The REPRIEVE trial (Randomized Trial to Prevent Vascular Events in HIV) enrolled persons with human immunodeficiency virus (HIV) who were aged 40-75 years, receiving ART, and had low-to-moderate cardiovascular disease risk. ART use was summarized within Global Burden of Disease (GBD) super-regions, with adjusted linear and logistic regression analyses examining associations with immune parameters and key demographics. RESULTS A total of 7770 participants were enrolled, with a median age of 50 years (interquartile range, 45-55 years); 31% were female, 43% were black or African American, 15% were Asian, 56% had a body mass index >25 (calculated as weight in kilograms divided by height in meters squared), and 49% were current or former smokers. The median CD4 T-cell count was 620/µL (interquartile range, 447-826/ µ L), and the median duration of prior ART use, 9.5 years (5.3-14.8) years. The most common ART regimens were nucleoside/nucleotide reverse-transcriptase inhibitor (NRTI) plus nonnucleoside reverse-transcriptase inhibitor (43%), NRTI plus integrase strand transfer inhibitor (25%), and NRTI plus protease inhibitor (19%). Entry ART varied by GBD region, with shifts during the trial enrollment period. In adjusted analyses, entry CD4 cell count and CD4/CD8 ratio were associated with GBD region, sex, entry regimen, duration of ART, and nadir CD4 cell count; CD4 and CD8 cell counts were also associated with body mass index and smoking status. CONCLUSIONS There were substantial variations in ART use by geographic region and over time, likely reflecting the local availability of specific medications, changes in treatment guidelines and provider/patient preferences. The analyses of CD4 cell counts and CD4/CD8 ratios may provide valuable insights regarding immune correlates and outcomes in people living with HIV. CLINICAL TRIALS REGISTRATION NCT02344290.",2020,"In adjusted analyses, entry CD4 cell count and CD4/CD8 ratio were associated with GBD region, sex, entry regimen, duration of ART, and nadir CD4 cell count; CD4 and CD8 cell counts were also associated with body mass index and smoking status. ","['HIV) enrolled persons with human immunodeficiency virus (HIV) who were aged 40-75 years, receiving ART, and had low-to-moderate cardiovascular disease risk', 'people living with HIV', '7770 participants were enrolled, with a median age of 50 years (interquartile range, 45-55 years); 31% were female, 43% were black or African American, 15% were Asian, 56% had a body mass index >25 (calculated as weight in kilograms divided by height in meters squared), and 49% were current or former smokers']",['nucleoside/nucleotide reverse-transcriptase inhibitor (NRTI)\u2005plus nonnucleoside reverse-transcriptase inhibitor'],"['GBD region, sex, entry regimen, duration of ART, and nadir CD4 cell count; CD4 and CD8 cell counts', 'entry CD4 cell count and CD4/CD8 ratio', 'median CD4 T-cell count']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0439209', 'cui_str': 'kg'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0441074', 'cui_str': 'Meters'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0337671', 'cui_str': 'Ex-smoker'}]","[{'cui': 'C0028621', 'cui_str': 'Nucleoside'}, {'cui': 'C0028630', 'cui_str': 'Nucleotide'}, {'cui': 'C0282519', 'cui_str': 'Reverse transcriptase inhibitor'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C4277729', 'cui_str': 'Global Burden of Disease'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Cell Counts'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0242629', 'cui_str': 'Lymphocyte positive for CD8 antigen'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}]",7770.0,0.18883,"In adjusted analyses, entry CD4 cell count and CD4/CD8 ratio were associated with GBD region, sex, entry regimen, duration of ART, and nadir CD4 cell count; CD4 and CD8 cell counts were also associated with body mass index and smoking status. ","[{'ForeName': 'Carl J', 'Initials': 'CJ', 'LastName': 'Fichtenbaum', 'Affiliation': 'Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.'}, {'ForeName': 'Heather J', 'Initials': 'HJ', 'LastName': 'Ribaudo', 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Leon-Cruz', 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.'}, {'ForeName': 'Edgar T', 'Initials': 'ET', 'LastName': 'Overton', 'Affiliation': 'Division of Infectious Diseases, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.'}, {'ForeName': 'Markella V', 'Initials': 'MV', 'LastName': 'Zanni', 'Affiliation': 'Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Carlos D', 'Initials': 'CD', 'LastName': 'Malvestutto', 'Affiliation': 'Division of Infectious Diseases, Ohio State University Medical Center, Columbus, Ohio, USA.'}, {'ForeName': 'Judith A', 'Initials': 'JA', 'LastName': 'Aberg', 'Affiliation': 'Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Emma M', 'Initials': 'EM', 'LastName': 'Kileel', 'Affiliation': 'Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Kathleen V', 'Initials': 'KV', 'LastName': 'Fitch', 'Affiliation': 'Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Marije', 'Initials': 'M', 'LastName': 'Van Schalkwyk', 'Affiliation': 'Family Centre for Research with Ubuntu, Division of Adult Infectious Diseases, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa.'}, {'ForeName': 'Nagalingeswaran', 'Initials': 'N', 'LastName': 'Kumarasamy', 'Affiliation': 'Infectious Diseases Medical Centre, Voluntary Health Services, Chennai, India.'}, {'ForeName': 'Esteban', 'Initials': 'E', 'LastName': 'Martinez', 'Affiliation': 'Hospital Clinic and University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Breno Riegel', 'Initials': 'BR', 'LastName': 'Santos', 'Affiliation': 'Infectious Diseases Service, Hospital Nossa, Senhora da Conceição/GHC, Porto Alegre, Brazil.'}, {'ForeName': 'Yvetot', 'Initials': 'Y', 'LastName': 'Joseph', 'Affiliation': 'Les Centres GHESKIO, Port-au-Prince, Haiti.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Lo', 'Affiliation': 'Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Siminski', 'Affiliation': 'Frontier Science and Technology Foundation, Amherst, Massachusetts, USA.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Melbourne', 'Affiliation': 'HIV Medical Sciences, Gilead Sciences, Foster City, California, USA.'}, {'ForeName': 'Craig A', 'Initials': 'CA', 'LastName': 'Sponseller', 'Affiliation': 'Kowa Pharmaceuticals America, Montgomery, Alabama, USA.'}, {'ForeName': 'Patrice', 'Initials': 'P', 'LastName': 'Desvigne-Nickens', 'Affiliation': 'National Heart, Lung and Blood Institute, Baltimore, Maryland, USA.'}, {'ForeName': 'Gerald S', 'Initials': 'GS', 'LastName': 'Bloomfield', 'Affiliation': 'Department of Medicine, Duke Global Health Institute and Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA.'}, {'ForeName': 'Judith S', 'Initials': 'JS', 'LastName': 'Currier', 'Affiliation': 'Division of Infectious Diseases, University of California-Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Udo', 'Initials': 'U', 'LastName': 'Hoffmann', 'Affiliation': 'Cardiac MR PET CT Program and Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Pamela S', 'Initials': 'PS', 'LastName': 'Douglas', 'Affiliation': 'Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Steven K', 'Initials': 'SK', 'LastName': 'Grinspoon', 'Affiliation': 'Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Journal of infectious diseases,['10.1093/infdis/jiaa259'] 1665,32645164,An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus.,"BACKGROUND Chronic kidney disease is a common comorbid condition among persons living with human immunodeficiency virus (PWH). We characterized baseline kidney function in the REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) trial cohort. METHODS REPRIEVE enrolled PWH with low to moderate cardiovascular risk based on traditional risk factors to evaluate the effect of statin therapy on cardiovascular events. We determined baseline estimated glomerular filtration rate (eGFR) with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease, and Cockcroft-Gault equations, and we evaluated baseline factors associated with eGFR <90 mL/min/1.73 m2 by logistic regression. We performed Bland-Altman plots and scatterplots to assess agreement between equations. RESULTS Among 7770 participants enrolled, the median age was 50 years, 31% were female (natal sex), 43% black or African American and 15% Asian, the median body mass index (calculated as calculated as weight in kilograms divided by height in meters squared) was 25.8, and the median CD4 cell count 620/µL. The median CKD-EPI eGFR was 97 mL/min/1.73 m2, and 38% had an eGFR <90 mL/min/1.73 m2. In the adjusted model, factors associated with eGFR <90 mL/min/1.73 m2 included white race, older age, higher body mass index, high-income region of enrollment, hypertension, and tenofovir disoproxil fumarate. The CKD-EPI and Modification of Diet in Renal Disease equations demonstrated strong agreement, particularly at lower eGFR values. Overall, there was 56% concordance between the 3 equations (categories <60, 60 to <90, ≥90 mL/min), improving to 73% after accounting for individual body surface area. CONCLUSIONS REPRIEVE enrolled a diverse cohort including a substantial number of PWH with reduced kidney function. Factors associated with reduced eGFR included traditional risk factors and tenofovir disoproxil fumarate exposure. Three commonly used equations have only fair agreement, with potential implications for both clinical care and epidemiologic studies. CLINICAL TRIALS REGISTRATION NCT02344290.",2020,"In the adjusted model, factors associated with eGFR <90 mL/min/1.73 m2 included white race, older age, higher body mass index, high-income region of enrollment, hypertension, and tenofovir disoproxil fumarate.","['7770 participants enrolled, the median age was 50 years, 31% were female (natal sex), 43% black or African American and 15% Asian, the', 'Human Immunodeficiency Virus', 'persons living with human immunodeficiency virus (PWH']","['tenofovir disoproxil fumarate exposure', 'statin therapy', 'eGFR', 'tenofovir disoproxil fumarate', 'Pitavastatin']","['median CKD-EPI eGFR', 'median CD4 cell count', 'median body mass index', 'glomerular filtration rate (eGFR) with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease, and Cockcroft-Gault equations', 'cardiovascular events']","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0454729', 'cui_str': 'Natal'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}]","[{'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C1278454', 'cui_str': 'Statin prophylaxis'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C1101838', 'cui_str': 'pitavastatin'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Cell Counts'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0014507', 'cui_str': 'Epidemiology'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",7770.0,0.0804019,"In the adjusted model, factors associated with eGFR <90 mL/min/1.73 m2 included white race, older age, higher body mass index, high-income region of enrollment, hypertension, and tenofovir disoproxil fumarate.","[{'ForeName': 'Edgar T', 'Initials': 'ET', 'LastName': 'Overton', 'Affiliation': 'Division of Infectious Diseases, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Kantor', 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.'}, {'ForeName': 'Kathleen V', 'Initials': 'KV', 'LastName': 'Fitch', 'Affiliation': 'Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Muntner', 'Affiliation': 'Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'Khuanchai', 'Initials': 'K', 'LastName': 'Supparatpinyo', 'Affiliation': 'HIV Treatment Clinical Research Site, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Mosepele', 'Initials': 'M', 'LastName': 'Mosepele', 'Affiliation': 'University of Botswana and Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.'}, {'ForeName': 'Lerato', 'Initials': 'L', 'LastName': 'Mohapi', 'Affiliation': 'Soweto Clinical Research Site, Chris Hani Baragwanath Hospital, Johannesburg, Gauteng, South Africa.'}, {'ForeName': 'Sandra Wagner', 'Initials': 'SW', 'LastName': 'Cardoso', 'Affiliation': 'Fiocruz Therapeutic and Prevention HIV/AIDS Clinical Trials Unit, Rio de Janeiro, Brazil.'}, {'ForeName': 'Sandesh', 'Initials': 'S', 'LastName': 'Patil', 'Affiliation': 'Byramjee Jeejeebhoy Government Medical College, Pune, Maharashtra, India.'}, {'ForeName': 'Marcus V G', 'Initials': 'MVG', 'LastName': 'de Lacerda', 'Affiliation': 'Fundação de Medicina Tropical Doutor Heitor Viera Dourado, Manaus, Amazonas, Brazil.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'McComsey', 'Affiliation': 'Division of Pediatric Infectious Diseases and Rheumatology, Case Western Reserve University, Cleveland, Ohio, USA.'}, {'ForeName': 'Judith A', 'Initials': 'JA', 'LastName': 'Aberg', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Pamela S', 'Initials': 'PS', 'LastName': 'Douglas', 'Affiliation': 'Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.'}, {'ForeName': 'Steven K', 'Initials': 'SK', 'LastName': 'Grinspoon', 'Affiliation': 'Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Ribaudo', 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.'}, {'ForeName': 'Christina M', 'Initials': 'CM', 'LastName': 'Wyatt', 'Affiliation': 'Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.'}]",The Journal of infectious diseases,['10.1093/infdis/jiaa222'] 1666,32645934,Effects of Prolonged Whey Protein Supplementation and Resistance Training on Biomarkers of Vitamin B12 Status: A 1-Year Randomized Intervention in Healthy Older Adults (the CALM Study).,"We investigated the effect of long-term whey supplementation on biomarkers of B12 status in healthy older adults subjected to different schemes of supplements and exercise. The total study population examined at baseline consisted of 167 healthy older adults (age ≥ 65 year) who were randomized to 1-y intervention with two daily supplements of (1) whey protein (3.1 µg B12/day) (WHEY-ALL), (2) collagen (1.3 µg B12/day) (COLL), or (3) maltodextrin (0.3 µg B12/day) (CARB). WHEY-ALL was comprised of three groups, who performed heavy resistance training (HRTW), light resistance training (LITW), or no training (WHEY). Dietary intake was assessed through 3-d dietary records. For the longitudinal part of the study, we included only the participants ( n = 110), who met the criteria of ≥ 50% compliance to the nutritional intervention and ≥ 66% and ≥ 75% compliance to the heavy and light training, respectively. Fasting blood samples collected at baseline and 12 months and non-fasting samples collected at 6 and 18 months were examined for methylmalonic acid, B12 and holotranscobalamin. At baseline, the study population ( n = 167) had an overall adequate dietary B12 intake of median (range) 5.3 (0.7-65) µg/day and median B12 biomarker values within reference intervals. The whey intervention (WHEY-ALL) caused an increase in B12 ( P < 0.0001) and holotranscobalamin ( P < 0.0001). In addition, methylmalonic acid decreased in the LITW group ( P = 0.04). No change in B12 biomarkers was observed during the intervention with collagen or carbohydrate, and the training schedules induced no changes. In conclusion, longer-term daily whey intake increased plasma B12 and holotranscobalamin in older individuals. No effect of intervention with collagen or carbohydrate or different training regimes was observed. Interestingly, the biomarkers of B12 status appeared to be affected by fasting vs. non-fasting conditions during sample collection.",2020,The whey intervention (WHEY-ALL) caused an increase in B12 ( P < 0.0001) and holotranscobalamin ( P < 0.0001).,"['older individuals', 'healthy older adults', '167 healthy older adults (age ≥ 65 year', 'participants ( n = 110), who met the criteria of ≥ 50% compliance to the nutritional intervention and ≥ 66% and ≥ 75% compliance to the heavy and light training, respectively', 'Healthy Older Adults (the CALM Study']","['1-y intervention with two daily supplements of (1) whey protein (3.1 µg B12/day) (WHEY-ALL), (2) collagen (1.3 µg B12/day) (COLL), or (3) maltodextrin', 'long-term whey supplementation', 'Prolonged Whey Protein Supplementation and Resistance Training', 'heavy resistance training (HRTW), light resistance training (LITW), or no training (WHEY']","['overall adequate dietary B12 intake of median (range) 5.3', 'plasma B12 and holotranscobalamin', 'Fasting blood samples', 'methylmalonic acid', 'biomarkers of B12 status', 'B12 biomarkers', 'Biomarkers of Vitamin B12 Status', 'Dietary intake', 'holotranscobalamin']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C4517595', 'cui_str': '167'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0150157', 'cui_str': 'Calming'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C4517683', 'cui_str': '3.1'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C4517499', 'cui_str': '1.3'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0042845', 'cui_str': 'Vitamin B 12'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C4708663', 'cui_str': '5.3'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0025787', 'cui_str': 'Methyl malonic acid'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}]",167.0,0.0236391,The whey intervention (WHEY-ALL) caused an increase in B12 ( P < 0.0001) and holotranscobalamin ( P < 0.0001).,"[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Greibe', 'Affiliation': 'Department of Clinical Medicine/Clinical Biochemistry, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark.'}, {'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Reitelseder', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopaedic Surgery M, Bispebjerg Hospital, Nielsine Nielsens Vej 11, DK-2400 Copenhagen NV, Denmark.'}, {'ForeName': 'Rasmus L', 'Initials': 'RL', 'LastName': 'Bechshøft', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopaedic Surgery M, Bispebjerg Hospital, Nielsine Nielsens Vej 11, DK-2400 Copenhagen NV, Denmark.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Bülow', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopaedic Surgery M, Bispebjerg Hospital, Nielsine Nielsens Vej 11, DK-2400 Copenhagen NV, Denmark.'}, {'ForeName': 'Grith W', 'Initials': 'GW', 'LastName': 'Højfeldt', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopaedic Surgery M, Bispebjerg Hospital, Nielsine Nielsens Vej 11, DK-2400 Copenhagen NV, Denmark.'}, {'ForeName': 'Simon R', 'Initials': 'SR', 'LastName': 'Schacht', 'Affiliation': 'Department of Nutrition, Exercise, and Sports, University of Copenhagen, Noerre Alle 51, DK-2200 Copenhagen N, Denmark.'}, {'ForeName': 'Mads L', 'Initials': 'ML', 'LastName': 'Knudsen', 'Affiliation': 'Department of Nutrition, Exercise, and Sports, University of Copenhagen, Noerre Alle 51, DK-2200 Copenhagen N, Denmark.'}, {'ForeName': 'Inge', 'Initials': 'I', 'LastName': 'Tetens', 'Affiliation': 'Department of Nutrition, Exercise, and Sports, University of Copenhagen, Noerre Alle 51, DK-2200 Copenhagen N, Denmark.'}, {'ForeName': 'Marie S', 'Initials': 'MS', 'LastName': 'Ostenfeld', 'Affiliation': 'Arla Foods Ingredients Group P/S, Soenderhoej 10-12, DK-8260 Viby J, Denmark.'}, {'ForeName': 'Ulla R', 'Initials': 'UR', 'LastName': 'Mikkelsen', 'Affiliation': 'Arla Foods Ingredients Group P/S, Soenderhoej 10-12, DK-8260 Viby J, Denmark.'}, {'ForeName': 'Christian W', 'Initials': 'CW', 'LastName': 'Heegaard', 'Affiliation': 'Department of Molecular Biology and Genetics, Aarhus University, Gustav Wieds Vej 10, DK-8000 Aarhus, Denmark.'}, {'ForeName': 'Ebba', 'Initials': 'E', 'LastName': 'Nexo', 'Affiliation': 'Department of Clinical Medicine/Clinical Biochemistry, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Holm', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopaedic Surgery M, Bispebjerg Hospital, Nielsine Nielsens Vej 11, DK-2400 Copenhagen NV, Denmark.'}]",Nutrients,['10.3390/nu12072015'] 1667,32649584,The Effect of Interactive Educational Workshops With or Without Standardized Patients on the Clinical Skills of Midwifery Students in Providing Sexual Health Counseling.,"BACKGROUND AND OBJECTIVES Insufficient skills among health personnel, including midwives, can lead to failure in evaluating and providing sexual health counseling services to clients. Thus, the purpose of this study was to compare the effect of 2 interactive educational workshops with or without standardized patients (SPs) on midwifery students' clinical skills in providing sexual health counseling at Mashhad University of Medical Sciences, Mashhad, Iran, in 2014 to 2015. RESEARCH METHODS In this randomized controlled trial, 62 midwifery students were selected through convenient sampling method and then randomly divided into 2 groups who received 1 of 2 interactive educational workshops, with or without SPs in 10-hour educational programs. The students' skills in providing sexual health counseling were evaluated before and 2 weeks after the education through an Objective Structured Clinical Examination composed of 5 stations using validated checklists. The data were then analyzed using the SPSS Software (Version 16) through descriptive statistics as well as independent t test, paired t test, Mann-Whitney U, χ, and Fisher exact tests. The level of significance was considered by P < 0.05. RESULTS There was no significant difference between the mean scores of students' clinical skills in providing sexual health counseling services in the group educated with or without SPs (22.4 ± 7.0 and 23.0 ± 9.4, P = 0.77). However, 2 weeks after the interventions, the mean scores were 75.8 ± 11.2 and 47.0 ± 8.9, respectively, meaning a significant difference between the study groups (P < 0.0001). CONCLUSIONS Although both teaching methods could promote clinical skills among the midwifery students, the effect of interactive workshop with SPs was much significantly stronger.",2020,"There was no significant difference between the mean scores of students' clinical skills in providing sexual health counseling services in the group educated with or without SPs (22.4 ± 7.0 and 23.0 ± 9.4, P = 0.77).","['Patients on the Clinical Skills of Midwifery Students in Providing Sexual Health Counseling', '62 midwifery students', ""midwifery students' clinical skills in providing sexual health counseling at Mashhad University of Medical Sciences, Mashhad, Iran, in 2014 to 2015""]","['Interactive Educational Workshops With or Without Standardized', '2 interactive educational workshops with or without standardized patients (SPs', '2 interactive educational workshops, with or without SPs in 10-hour educational programs']","[""mean scores of students' clinical skills in providing sexual health counseling services"", 'mean scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008973', 'cui_str': 'Clinical Skills'}, {'cui': 'C0026082', 'cui_str': 'Midwifery'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C2362326', 'cui_str': 'Sexual Health'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0022065', 'cui_str': 'Iran'}]","[{'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0008973', 'cui_str': 'Clinical Skills'}, {'cui': 'C2362326', 'cui_str': 'Sexual Health'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]",62.0,0.0304016,"There was no significant difference between the mean scores of students' clinical skills in providing sexual health counseling services in the group educated with or without SPs (22.4 ± 7.0 and 23.0 ± 9.4, P = 0.77).","[{'ForeName': 'Talat', 'Initials': 'T', 'LastName': 'Khadivzadeh', 'Affiliation': 'From the Nursing and Midwifery Care Research Center (T.K.), School of Nursing and Midwifery, Mashhad University of Medical Sciences; Department of Midwifery (M.A.S.S.), School of Nursing and Midwifery, Mashhad University of Medical Sciences; Department of Midwifery (K.M.), School of Nursing and Midwifery, Mashhad University of Medical Sciences; and Department of Medical-Surgical Nursing (S.R.M.), School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mina', 'Initials': 'M', 'LastName': 'Ardaghi Sefat Seighalani', 'Affiliation': ''}, {'ForeName': 'Khadijeh', 'Initials': 'K', 'LastName': 'Mirzaii', 'Affiliation': ''}, {'ForeName': 'Seyed Reza', 'Initials': 'SR', 'LastName': 'Mazloum', 'Affiliation': ''}]",Simulation in healthcare : journal of the Society for Simulation in Healthcare,['10.1097/SIH.0000000000000439'] 1668,32650604,Nine Months of a Structured Multisport Program Improve Physical Fitness in Preschool Children: A Quasi-Experimental Study.,"Research in preschool children that investigates the impact of different exercise interventions on physical fitness is limited. This pre-post study was aimed at determining if participation in a nine-month structured multisport program (MSG; n = 38) could enhance physical fitness components compared to a formal exercise program (control group (CG); n = 36) among preschool children. Physical fitness was assessed using standardized tests (the standing long jump, sit and reach, 20 m sprint, sit-ups for 30 s, bent-arm hang, medicine ball throw (MBT), grip strength, 4 × 10 m shuttle run, and 20 m shuttle run tests). The structured multisport program involved fundamental/gross and fine motor skills and ball game-based exercises twice a week. The control group was free of any programmed exercise except for the obligatory program in kindergartens. A mixed ANOVA demonstrated significant group-by-time interaction effects for the 4 × 10 m shuttle run, standing long jump, sit-ups, bent-arm hang, grip strength, and sit and reach tests ( p < 0.05). There was no significant group-by-time interaction effect for the 20 m sprint test ( p = 0.794) or for the 20 m shuttle run test ( p = 0.549). Moreover, the MSG and CG performance in the MBT and 20 m shuttle run tests improved to a similar extent from pre- to post-test. Our results indicate that compared to the formal plan, the structured multisport program led to a sustained improvement in physical fitness in healthy 5-to-6-year old children.",2020,"A mixed ANOVA demonstrated significant group-by-time interaction effects for the 4 × 10 m shuttle run, standing long jump, sit-ups, bent-arm hang, grip strength, and sit and reach tests ( p < 0.05).","['Preschool Children', 'n = 36) among preschool children', 'healthy 5-to-6-year old children', 'preschool children']","['structured multisport program involved fundamental/gross and fine motor skills and ball game-based exercises twice a week', 'exercise interventions', 'Structured Multisport Program', 'physical fitness components compared to a formal exercise program (control group (CG']","['Physical Fitness', 'time interaction effect', 'physical fitness', 'Physical fitness', 'MSG and CG performance']","[{'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0439806', 'cui_str': 'Gross'}, {'cui': 'C0205232', 'cui_str': 'Fine'}, {'cui': 'C0026612', 'cui_str': 'Motor Skills'}, {'cui': 'C0039597', 'cui_str': 'Testis structure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0556985', 'cui_str': 'Twice weekly'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]",38.0,0.019258,"A mixed ANOVA demonstrated significant group-by-time interaction effects for the 4 × 10 m shuttle run, standing long jump, sit-ups, bent-arm hang, grip strength, and sit and reach tests ( p < 0.05).","[{'ForeName': 'Boris', 'Initials': 'B', 'LastName': 'Popović', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, 21000 Novi Sad, Serbia.'}, {'ForeName': 'Milan', 'Initials': 'M', 'LastName': 'Cvetković', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, 21000 Novi Sad, Serbia.'}, {'ForeName': 'Draženka', 'Initials': 'D', 'LastName': 'Mačak', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, 21000 Novi Sad, Serbia.'}, {'ForeName': 'Tijana', 'Initials': 'T', 'LastName': 'Šćepanović', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, 21000 Novi Sad, Serbia.'}, {'ForeName': 'Nebojša', 'Initials': 'N', 'LastName': 'Čokorilo', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, 21000 Novi Sad, Serbia.'}, {'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Belić', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, 21000 Novi Sad, Serbia.'}, {'ForeName': 'Nebojša', 'Initials': 'N', 'LastName': 'Trajković', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, 21000 Novi Sad, Serbia.'}, {'ForeName': 'Slobodan', 'Initials': 'S', 'LastName': 'Andrašić', 'Affiliation': 'Faculty of Economics, University of Novi Sad, 24000 Subotica, Serbia.'}, {'ForeName': 'Špela', 'Initials': 'Š', 'LastName': 'Bogataj', 'Affiliation': 'Faculty of Sport, University of Ljubljana, 1000 Ljubljana, Slovenia.'}]",International journal of environmental research and public health,['10.3390/ijerph17144935'] 1669,32668483,Platelet Inhibition with Ticagrelor versus Clopidogrel in Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes.,"BACKGROUND Clopidogrel is currently the only P2Y 12 inhibitor with class I recommendation in patients after percutaneous coronary intervention (PCI) for chronic coronary syndromes (CCS). Diabetic patients have reduced therapeutic response to clopidogrel. PURPOSE This study assessed the antiplatelet effect of ticagrelor versus clopidogrel in diabetic patients after recent PCI for CCS. METHODS Eligible patients were randomly assigned to receive ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily, in addition to aspirin 100 mg once daily for 15 days. P2Y 12 reaction unit (PRU) and percent inhibition were measured by VerifyNow P2Y 12 assay. High on-treatment platelet reactivity (HOPR) was defined as PRU > 208. Bleeding was assessed by the Platelet Inhibition and Patient Outcomes criteria. Cardiac ischemic events were evaluated as adverse events. RESULTS The baseline characteristics of the patients ( n  = 39) were well balanced between the two groups. Both before and 2 to 4 hours after the final study dose on day 15, PRU was lower (41.3 ± 35.8 vs. 192.6 ± 49.5, p  < 0.001; 36.6 ± 25.8 vs. 187.6 ± 70.9, p  < 0.001), percent inhibition was higher (83.0% [70.5%, 96.0%] vs. 16.0% [0%, 25.0%], p  < 0.001; 85.0% [76.0%, 96.5%] vs. 25.0% [0%, 39.0%], p  < 0.001), and HOPR occurred less frequently (0% [0/20] vs. 26.3% [5/19], p  = 0.020; 0% [0/20] vs. 31.6% [6/19], p  = 0.008) in the ticagrelor group ( n  = 20) compared with the clopidogrel group ( n  = 19). No major or minor bleeding, or serious adverse events occurred in both groups. CONCLUSION Ticagrelor achieved greater peak and trough platelet inhibition than did clopidogrel in diabetic patients after recent PCI for CCS, which suggests the potential use of ticagrelor in this clinical setting.",2020,"No major or minor bleeding, or serious adverse events occurred in both groups. ","['chronic coronary syndromes (CCS', 'Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes', 'Diabetic patients', 'diabetic patients after recent PCI for CCS', 'diabetic patients', 'Eligible patients']","['Ticagrelor', 'percutaneous coronary intervention (PCI', 'Clopidogrel', 'ticagrelor 90\u2009mg twice daily or clopidogrel 75\u2009mg once daily, in addition to aspirin', 'clopidogrel', 'ticagrelor']","['percent inhibition', 'Bleeding', 'No major or minor bleeding, or serious adverse events', 'Cardiac ischemic events', 'peak and trough platelet inhibition', 'P2Y 12 reaction unit (PRU) and percent inhibition', 'HOPR', 'Platelet Inhibition']","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0332185', 'cui_str': 'Recent'}]","[{'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C3163568', 'cui_str': 'Ticagrelor 90 MG'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C1124675', 'cui_str': 'clopidogrel 75 MG'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}]","[{'cui': 'C1628982', 'cui_str': '% inhib'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0026193', 'cui_str': 'Minor'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0444506', 'cui_str': 'Trough'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0439148', 'cui_str': 'Unit'}]",,0.0644685,"No major or minor bleeding, or serious adverse events occurred in both groups. ","[{'ForeName': 'Zhenyu', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Ran', 'Initials': 'R', 'LastName': 'Tian', 'Affiliation': 'Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Medical Research and Biometrics Center, Fu-Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Jingyi', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Lihong', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': 'Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Shuyang', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}]",Thrombosis and haemostasis,['10.1055/s-0040-1713375'] 1670,32668588,A High-Protein Meal during a Night Shift Does Not Improve Postprandial Metabolic Response the Following Breakfast: A Randomized Crossover Study with Night Workers.,"The aim of this study was to compare the acute effect of a high-protein/moderate carbohydrate (HP-MCHO) versus low-protein/high-carbohydrate (LP-HCHO) meal served at night on the postprandial metabolic response of male night workers the following breakfast. A randomized crossover study was performed with 14 male night workers (40.9 ± 8.9 years old; 29.1 ± 5.3 kg/m 2 ). Participants underwent two different isocaloric dietary conditions at 1:00 h of the night shift: HP-MCHO (45 en% carbohydrate, 35 en% protein and 20 en% fat) and LP-HCHO (65 en% carbohydrate, 15 en% protein and 20 en% fat). Postprandial capillary glucose levels were determined immediately before the intake of the test meal and 30, 60, 90 and 120 min after the end of the meal. At the end of the work shift (6:30 h), participants received a standard breakfast and postprandial levels of glucose, insulin and triglycerides were determined immediately before and then every 30 min for 2 h (30, 60, 90 and 120 min). Higher values of capillary glucose were found after the LP-HCHO condition compared to the HP-MCHO condition (area under the curve (AUC) = 119.46 ± 1.49 mg/dL × min and 102.95 ± 1.28 mg/dL × min, respectively; p < 0.001). For the metabolic response to standard breakfast as the following meal, no significant differences in glucose, insulin, triglyceride, and HOMA-IR levels were found between interventions. A night meal with a higher percentage of protein and a lower percentage of carbohydrate led to minor postprandial glucose levels during the night shift but exerted no effect on the metabolic response of the following meal. This trial was registered at ClinicalTrials.gov as NCT03456219.",2020,"For the metabolic response to standard breakfast as the following meal, no significant differences in glucose, insulin, triglyceride, and HOMA-IR levels were found between interventions.","['male night workers the following breakfast', '14 male night workers (40.9 ± 8.9 years old; 29.1 ±', 'Night Workers']","['isocaloric dietary conditions at 1:00 h of the night shift: HP-MCHO (45 en% carbohydrate, 35 en% protein and 20 en% fat) and LP-HCHO', 'high-protein/moderate carbohydrate (HP-MCHO) versus low-protein/high-carbohydrate (LP-HCHO) meal']","['postprandial levels of glucose, insulin and triglycerides', 'metabolic response', 'Higher values of capillary glucose', 'glucose, insulin, triglyceride, and HOMA-IR levels', 'Postprandial Metabolic Response', 'Postprandial capillary glucose levels', 'postprandial metabolic response']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0333051', 'cui_str': 'Shift'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0242972', 'cui_str': 'Low protein diet'}, {'cui': 'C1998602', 'cui_str': 'Meals'}]","[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0006901', 'cui_str': 'Structure of capillary blood vessel (organ)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}]",,0.0117049,"For the metabolic response to standard breakfast as the following meal, no significant differences in glucose, insulin, triglyceride, and HOMA-IR levels were found between interventions.","[{'ForeName': 'Nayara B', 'Initials': 'NB', 'LastName': 'Cunha', 'Affiliation': 'Graduate Programme of Health Sciences, Faculty of Medicine, Federal University of Uberlândia, Av. Pará, 1720, Bloco 2U, Campus Umuarama, Uberlândia 38405-320, Minas Gerais, Brazil.'}, {'ForeName': 'Catarina M', 'Initials': 'CM', 'LastName': 'Silva', 'Affiliation': 'Graduate Programme of Health Sciences, Faculty of Medicine, Federal University of Uberlândia, Av. Pará, 1720, Bloco 2U, Campus Umuarama, Uberlândia 38405-320, Minas Gerais, Brazil.'}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'Mota', 'Affiliation': 'Graduate Programme of Health Sciences, Faculty of Medicine, Federal University of Uberlândia, Av. Pará, 1720, Bloco 2U, Campus Umuarama, Uberlândia 38405-320, Minas Gerais, Brazil.'}, {'ForeName': 'Caio A', 'Initials': 'CA', 'LastName': 'Lima', 'Affiliation': 'Graduate Programme of Health Sciences, Faculty of Medicine, Federal University of Uberlândia, Av. Pará, 1720, Bloco 2U, Campus Umuarama, Uberlândia 38405-320, Minas Gerais, Brazil.'}, {'ForeName': 'Kely R C', 'Initials': 'KRC', 'LastName': 'Teixeira', 'Affiliation': 'Graduate Programme of Health Sciences, Faculty of Medicine, Federal University of Uberlândia, Av. Pará, 1720, Bloco 2U, Campus Umuarama, Uberlândia 38405-320, Minas Gerais, Brazil.'}, {'ForeName': 'Thulio M', 'Initials': 'TM', 'LastName': 'Cunha', 'Affiliation': 'Graduate Programme of Health Sciences, Faculty of Medicine, Federal University of Uberlândia, Av. Pará, 1720, Bloco 2U, Campus Umuarama, Uberlândia 38405-320, Minas Gerais, Brazil.'}, {'ForeName': 'Cibele A', 'Initials': 'CA', 'LastName': 'Crispim', 'Affiliation': 'Graduate Programme of Health Sciences, Faculty of Medicine, Federal University of Uberlândia, Av. Pará, 1720, Bloco 2U, Campus Umuarama, Uberlândia 38405-320, Minas Gerais, Brazil.'}]",Nutrients,['10.3390/nu12072071'] 1671,32643265,Multi-focal electro-retinogram response following sub-threshold nano-second laser intervention in age-related macular degeneration.,"IMPORTANCE The effect of sub-threshold nano-second laser (SNL) treatment on retinal function remains unknown. BACKGROUND SNL treatment has been studied as a potential intervention in intermediate age-related macular degeneration (iAMD). This study investigated the longitudinal effect of SNL treatment on retinal function. DESIGN This was a sub-study of the LEAD trial; a 36-month, multi-centre, randomized and sham-controlled trial. PARTICIPANTS Subjects with iAMD. METHODS Eligible participants were assigned randomly to receive SNL or sham treatment to the study eye at 6-monthly visits. Multi-focal electro-retinography (mfERG) was performed at each study visit from a study site. The mfERG responses were grouped into three regions (central, middle and outer rings) and compared between the SNL and sham group. MAIN OUTCOME MEASURES mfERG P1 response amplitude and implicit time. RESULTS Data were collected from 50 subjects (26 in the SNL group, 24 in the sham group). At baseline, the P1 amplitudes of both the study eyes and the fellow eyes were similar between the groups at all rings. In the sham group, the P1 amplitude gradually decreased over time (P < .05). In the SNL group, there was an improvement in P1 amplitude which became statistically significant at the 36-month visit, detected in both the treated and fellow eyes at the central (P = .005) and middle ring (P = .007) but not at the outer ring (P = .070). No difference in P1 implicit time detected between the groups (P > .05). CONCLUSIONS AND RELEVANCE SNL treatment improved electro-physiological function. mfERG could be useful for monitoring AMD progression and evaluating the efficacy of SNL treatment.",2020,"At baseline, the P1 amplitudes of both the study eyes and the fellow eyes were similar between the groups at all rings.","['age-related macular degeneration', 'Eligible participants', 'Subjects with iAMD', '50 subjects (26 in the SNL group, 24 in the sham group']","['subthreshold nanosecond laser intervention', 'SNL', 'subthreshold nanosecond laser (SNL', 'Multifocal electroretinography (mfERG']","['P1 implicit time', 'mfERG P1 response amplitude and implicit time', 'P1 amplitudes', 'Multifocal electroretinogram response', 'P1 amplitude', 'retinal function', 'electrophysiological function']","[{'cui': 'C0242383', 'cui_str': 'Age related macular degeneration'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0017921', 'cui_str': 'Generalized glycogenosis'}, {'cui': 'C0439225', 'cui_str': 'ns'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0439225', 'cui_str': 'ns'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1627756', 'cui_str': 'Multifocal electroretinography'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1627756', 'cui_str': 'Multifocal electroretinography'}, {'cui': 'C0205292', 'cui_str': 'Multifocal'}, {'cui': 'C0456358', 'cui_str': 'ERG response'}, {'cui': 'C0035298', 'cui_str': 'Retinal structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",50.0,0.0750606,"At baseline, the P1 amplitudes of both the study eyes and the fellow eyes were similar between the groups at all rings.","[{'ForeName': 'Chi D', 'Initials': 'CD', 'LastName': 'Luu', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Galina', 'Initials': 'G', 'LastName': 'Makeyeva', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Caruso', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Baglin', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Pyrawy', 'Initials': 'P', 'LastName': 'Sivarajah', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Zhichao', 'Initials': 'Z', 'LastName': 'Wu', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Robyn H', 'Initials': 'RH', 'LastName': 'Guymer', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}]",Clinical & experimental ophthalmology,['10.1111/ceo.13823'] 1672,32647106,A Clinical Application Study of Mixed Reality Technology Assisted Lumbar Pedicle Screws Implantation.,"BACKGROUND This was a prospective comparative study of mixed reality (MR) technology assisted lumbar pedicle screws placement and traditional lumbar pedicle screws placement. MATERIAL AND METHODS Fifty cases of lumbar pedicle screws placement were randomly divided into 2 groups: 25 cases with MR technology in group A, and 25 cases without MR technology in group B. All patients had their scores on the Oswestry disability index (ODI) of low back pain and the visual analog scale (VAS) of the affected lower limb recorded at pre-operation. Blood loss, operative duration, success rate of first penetration by tap, and number of times C-arm fluoroscopy was performed were recorded at intraoperation. The postoperative drainage was recorded. The ODI of low back pain and VAS of the affected lower limb were recorded at 1, 3, and 6 months after operation. RESULTS Group A had less bleeding, shorter operation time, higher success rate of first penetration by tap, and fewer times using C-arm fluoroscopy at intraoperation (P<0.05). There was significant difference in ODI scores and VAS scores at 1 mouth after operation (P<0.05). The postoperative drainage of group A was less than group B (P<0.05). The implantation accuracy of group A was higher than group B (P<0.05). The postoperative recovery rate of low back pain of group A was faster than group B (P<0.05). CONCLUSIONS The safety of spinal surgery and implantation accuracy of pedicle screw fixation system could be increased by MR technology.",2020,The postoperative recovery rate of low back pain of group A was faster than group B (P<0.05).,['Fifty cases of lumbar pedicle screws placement were randomly divided into 2 groups: 25 cases with'],"['pedicle screw fixation system', 'Mixed Reality Technology Assisted Lumbar Pedicle Screws Implantation', 'mixed reality (MR) technology assisted lumbar pedicle screws placement and traditional lumbar pedicle screws placement', 'MR technology in group A, and 25 cases without MR technology in group B']","['ODI of low back pain and VAS of the affected lower limb', 'ODI scores and VAS scores', 'implantation accuracy', 'Oswestry disability index (ODI) of low back pain and the visual analog scale (VAS', 'postoperative recovery rate of low back pain', 'bleeding, shorter operation time', 'Blood loss, operative duration, success rate of first penetration by tap, and number of times C-arm fluoroscopy', 'postoperative drainage']","[{'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C1961768', 'cui_str': 'Pedicle Screws'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C1961768', 'cui_str': 'Pedicle Screws'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C5197824', 'cui_str': 'Mixed Reality'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}]","[{'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0392760', 'cui_str': 'Affecting'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C2960603', 'cui_str': 'Oswestry disability index score'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205321', 'cui_str': 'Penetrating'}, {'cui': 'C0034115', 'cui_str': 'Centesis'}, {'cui': 'C0449809', 'cui_str': 'Number of times'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}]",50.0,0.0239128,The postoperative recovery rate of low back pain of group A was faster than group B (P<0.05).,"[{'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Gu', 'Affiliation': 'The Third Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu, China (mainland).'}, {'ForeName': 'Qingqiang', 'Initials': 'Q', 'LastName': 'Yao', 'Affiliation': 'Department of Orthopedic, Nanjing First Hospital, Nanjing, Jiangsu, China (mainland).'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Department of Orthopedic, Nanjing First Hospital, Nanjing, Jiangsu, China (mainland).'}, {'ForeName': 'Huikang', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Digital Medicine Institute, Nanjing Medical University, Nanjing, Jiangsu, China (mainland).'}, {'ForeName': 'Peiran', 'Initials': 'P', 'LastName': 'Wei', 'Affiliation': 'The Third Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu, China (mainland).'}, {'ForeName': 'Liming', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Orthopedic, Nanjing First Hospital, Nanjing, Jiangsu, China (mainland).'}]",Medical science monitor : international medical journal of experimental and clinical research,['10.12659/MSM.924982'] 1673,32648821,Impacts of prolonged sitting with mild hypercapnia on vascular and autonomic function in healthy recreationally active adults.,"Prolonged sitting, which is known to impair peripheral vascular function, often occurs in spaces (e.g., offices) with mild hypercapnic atmospheres. However, the effects of prolonged sitting in hypercapnic conditions on vascular function are unknown. Therefore, the purpose of this study was to investigate the effects of prolonged sitting in mild hypercapnic conditions on vascular and autonomic function in humans. Twelve healthy young adults participated in two experimental visits that consisted of sitting for 2.5 h in a control condition [normal atmospheric conditions sitting (PSIT)] or a mild hypercapnic condition (HCAP; CO 2  = 1,500 ppm). During each visit, heart rate variability (HRV), blood pressure (BP), pulse wave velocity (PWV), augmentation index (AIx), brachial and popliteal artery flow-mediated dilation (FMD), and near-infrared spectroscopy (NIRS) were assessed before and after prolonged sitting. Sitting significantly decreased AIx in both groups ( P < 0.05). Brachial and popliteal FMD were reduced with sitting ( P < 0.05), and the reduction in popliteal FMD was amplified by HCAP ( P < 0.05). Baseline microvascular oxygenation was decreased following sitting in both groups ( P < 0.05). However, microvascular reoxygenation upon cuff release was slower only in HCAP ( P < 0.05). HRV, HR, BP, and PWV did not significantly change with sitting in either group ( P > 0.05). We conclude that prolonged sitting attenuated both brachial and popliteal endothelial function and was associated with perturbed microcirculation. Additionally, mild hypercapnic conditions further impaired peripheral endothelial and microvascular function. Together, these findings suggest that prolonged sitting is accompanied by a host of deleterious effects on the vasculature, which are exacerbated by mild hypercapnia. NEW & NOTEWORTHY The results of this study reveal that prolonged sitting attenuates endothelial function and microvascular function. Additionally, prolonged sitting with mild hypercapnia, which is similar to everyday environments, further exacerbates peripheral endothelial function and microvascular function.",2020,Baseline microvascular oxygenation was decreased following sitting in both groups (P<0.05).,"['12 healthy young adults', 'healthy recreationally active adults', 'humans']","['experimental visits which consisted of sitting for 2.5 hours in a control condition (PSIT) or a mild hypercapnic condition (HCAP, CO2=1,500 ppm', 'prolonged sitting with mild hypercapnia']","['reduction in popliteal FMD', 'Prolonged sitting attenuated both brachial and popliteal endothelial function', 'peripheral endothelial and microvascular function', 'Brachial and popliteal FMD', 'HRV, HR, BP, and PWV', 'microvascular reoxygenation upon cuff release', 'vascular and autonomic function', 'Baseline microvascular oxygenation', 'heart rate variability (HRV), blood pressure (BP), pulse wave velocity (PWV), augmentation index (AIx), brachial and popliteal artery flow mediated dilation (FMD), and near infrared spectroscopy (NIRS']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0020440', 'cui_str': 'Hypercapnia'}, {'cui': 'C0056451', 'cui_str': 'H-CAP protocol'}, {'cui': 'C0439187', 'cui_str': 'ppm'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0442037', 'cui_str': 'Popliteal'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C0441107', 'cui_str': 'Device cuff'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0032649', 'cui_str': 'Structure of popliteal artery'}, {'cui': 'C0376519', 'cui_str': 'Near-infrared spectroscopy'}]",12.0,0.0577376,Baseline microvascular oxygenation was decreased following sitting in both groups (P<0.05).,"[{'ForeName': 'Ronald J', 'Initials': 'RJ', 'LastName': 'Headid', 'Affiliation': 'School of Health and Kinesiology, University of Nebraska at Omaha, Omaha, Nebraska.'}, {'ForeName': 'Elizabeth J', 'Initials': 'EJ', 'LastName': 'Pekas', 'Affiliation': 'School of Health and Kinesiology, University of Nebraska at Omaha, Omaha, Nebraska.'}, {'ForeName': 'TeSean K', 'Initials': 'TK', 'LastName': 'Wooden', 'Affiliation': 'School of Health and Kinesiology, University of Nebraska at Omaha, Omaha, Nebraska.'}, {'ForeName': 'Won-Mok', 'Initials': 'WM', 'LastName': 'Son', 'Affiliation': 'School of Health and Kinesiology, University of Nebraska at Omaha, Omaha, Nebraska.'}, {'ForeName': 'Gwenael', 'Initials': 'G', 'LastName': 'Layec', 'Affiliation': 'Department of Kinesiology, University of Massachusetts, Amherst, Massachusetts.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Shin', 'Affiliation': 'Wiess School of Natural Sciences, Rice University, Houston, Texas.'}, {'ForeName': 'Song-Young', 'Initials': 'SY', 'LastName': 'Park', 'Affiliation': 'School of Health and Kinesiology, University of Nebraska at Omaha, Omaha, Nebraska.'}]",American journal of physiology. Heart and circulatory physiology,['10.1152/ajpheart.00354.2020'] 1674,32645158,Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial.,"BACKGROUND People with human immunodeficiency virus (PWH) face increased risks for heart failure and adverse heart failure outcomes. Myocardial steatosis predisposes to diastolic dysfunction, a heart failure precursor. We aimed to characterize myocardial steatosis and associated potential risk factors among a subset of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) participants. METHODS Eighty-two PWH without known heart failure successfully underwent cardiovascular magnetic resonance spectroscopy, yielding data on intramyocardial triglyceride (IMTG) content (a continuous marker for myocardial steatosis extent). Logistic regression models were applied to investigate associations between select clinical characteristics and odds of increased or markedly increased IMTG content. RESULTS Median (Q1, Q3) IMTG content was 0.59% (0.28%, 1.15%). IMTG content was increased (> 0.5%) among 52% and markedly increased (> 1.5%) among 22% of participants. Parameters associated with increased IMTG content included age (P = .013), body mass index (BMI) ≥ 25 kg/m2 (P = .055), history of intravenous drug use (IVDU) (P = .033), and nadir CD4 count < 350 cells/mm³ (P = .055). Age and BMI ≥ 25 kg/m2 were additionally associated with increased odds of markedly increased IMTG content (P = .049 and P = .046, respectively). CONCLUSIONS A substantial proportion of antiretroviral therapy-treated PWH exhibited myocardial steatosis. Age, BMI ≥ 25 kg/m2, low nadir CD4 count, and history of IVDU emerged as possible risk factors for myocardial steatosis in this group. CLINICAL TRIALS REGISTRATION NCT02344290; NCT03238755.",2020,IMTG content was increased (> 0.5%) among 52% and markedly increased (> 1.5%) among 22% of participants.,"['Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial', '25 kg/m2 ', 'HIV (REPRIEVE) participants', 'People with human immunodeficiency virus (PWH', 'Eighty-two PWH without known heart failure successfully underwent']","['cardiovascular magnetic resonance spectroscopy, yielding data on intramyocardial triglyceride (IMTG) content', 'Antiretroviral Therapy']","['Median (Q1, Q3', 'Age and BMI ≥', 'myocardial steatosis', 'body mass index (BMI) ≥', 'Myocardial Steatosis', 'IMTG content', 'nadir CD4 count', 'history of intravenous drug use (IVDU']","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}]","[{'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0152254', 'cui_str': 'Fatty degeneration'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Cell Counts'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0242566', 'cui_str': 'Intravenous drug user'}]",,0.0838812,IMTG content was increased (> 0.5%) among 52% and markedly increased (> 1.5%) among 22% of participants.,"[{'ForeName': 'Tomas G', 'Initials': 'TG', 'LastName': 'Neilan', 'Affiliation': 'Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Kim-Lien', 'Initials': 'KL', 'LastName': 'Nguyen', 'Affiliation': 'Division of Cardiology, David Geffen School of Medicine at the University of California, Los Angeles and the Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA.'}, {'ForeName': 'Vlad G', 'Initials': 'VG', 'LastName': 'Zaha', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medicine, Advanced Imaging Research Center, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.'}, {'ForeName': 'Kara W', 'Initials': 'KW', 'LastName': 'Chew', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Leavitt', 'Initials': 'L', 'LastName': 'Morrison', 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.'}, {'ForeName': 'Ntobeko A B', 'Initials': 'NAB', 'LastName': 'Ntusi', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.'}, {'ForeName': 'Mabel', 'Initials': 'M', 'LastName': 'Toribio', 'Affiliation': 'Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Magid', 'Initials': 'M', 'LastName': 'Awadalla', 'Affiliation': 'Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Zsofia D', 'Initials': 'ZD', 'LastName': 'Drobni', 'Affiliation': 'Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Nelson', 'Affiliation': 'Applied Physiology and Advanced Imaging Laboratory, Department of Kinesiology, University of Texas at Arlington, Arlington, Texas, USA.'}, {'ForeName': 'Tricia H', 'Initials': 'TH', 'LastName': 'Burdo', 'Affiliation': 'Department of Neuroscience, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Marije', 'Initials': 'M', 'LastName': 'Van Schalkwyk', 'Affiliation': 'Family Clinical Research Unit, Division of Adult Infectious Diseases, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa.'}, {'ForeName': 'Paul E', 'Initials': 'PE', 'LastName': 'Sax', 'Affiliation': ""Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Skiest', 'Affiliation': 'Department of Medicine, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Tashima', 'Affiliation': 'Division of Infectious Diseases, The Miriam Hospital and Alpert Medical School of Brown University, Providence, Rhode Island, USA.'}, {'ForeName': 'Raphael J', 'Initials': 'RJ', 'LastName': 'Landovitz', 'Affiliation': 'Center for Clinical AIDS Research and Education, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Daar', 'Affiliation': 'Lundquist Institute at Harbor-University of California, Los Angeles Medical Center and David Geffen School of Medicine at the University of Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Alysse G', 'Initials': 'AG', 'LastName': 'Wurcel', 'Affiliation': 'Division of Geographic Medicine and Infectious Diseases, Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Gregory K', 'Initials': 'GK', 'LastName': 'Robbins', 'Affiliation': 'Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Robert K', 'Initials': 'RK', 'LastName': 'Bolan', 'Affiliation': 'Los Angeles Lesbian Gay Bisexual Transgender Center, Los Angeles, California, USA.'}, {'ForeName': 'Kathleen V', 'Initials': 'KV', 'LastName': 'Fitch', 'Affiliation': 'Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Judith S', 'Initials': 'JS', 'LastName': 'Currier', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Gerald S', 'Initials': 'GS', 'LastName': 'Bloomfield', 'Affiliation': 'Duke Clinical Research Institute, Duke Global Health Institute, Department of Medicine, Duke University, Durham, North Carolina, USA.'}, {'ForeName': 'Patrice', 'Initials': 'P', 'LastName': 'Desvigne-Nickens', 'Affiliation': 'National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.'}, {'ForeName': 'Pamela S', 'Initials': 'PS', 'LastName': 'Douglas', 'Affiliation': 'Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.'}, {'ForeName': 'Udo', 'Initials': 'U', 'LastName': 'Hoffmann', 'Affiliation': 'Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Steven K', 'Initials': 'SK', 'LastName': 'Grinspoon', 'Affiliation': 'Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Ribaudo', 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.'}, {'ForeName': 'Rodney', 'Initials': 'R', 'LastName': 'Dawson', 'Affiliation': 'Division of Pulmonology and Department of Medicine, University of Cape Town Lung Institute, Mowbray, Cape Town, South Africa.'}, {'ForeName': 'Matthew Bidwell', 'Initials': 'MB', 'LastName': 'Goetz', 'Affiliation': 'Infectious Diseases Section, Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Mamta K', 'Initials': 'MK', 'LastName': 'Jain', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.'}, {'ForeName': 'Alberta', 'Initials': 'A', 'LastName': 'Warner', 'Affiliation': 'Division of Cardiology, David Geffen School of Medicine at the University of California, Los Angeles and the Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA.'}, {'ForeName': 'Lidia S', 'Initials': 'LS', 'LastName': 'Szczepaniak', 'Affiliation': 'Biomedical Research Consulting in Magnetic Resonance Spectroscopy, Albuquerque, New Mexico, USA.'}, {'ForeName': 'Markella V', 'Initials': 'MV', 'LastName': 'Zanni', 'Affiliation': 'Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.'}]",The Journal of infectious diseases,['10.1093/infdis/jiaa245'] 1675,32645161,Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators.,"The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus. Enrolling 7770 participants from 2015 to 2019 with sites across 5 continents, REPRIEVE will assess the effects of a statin as a cardiovascular disease prevention strategy in people with HIV (PWH) receiving antiretroviral therapy (ART). Although the primary purpose of REPRIEVE, and its substudy assessing coronary plaque, is to assess cardiovascular outcomes, the trial is a rich source of data on population characteristics and critical comorbidities in PWH, particularly across Global Burden of Disease (GBD) regions, reflective of the ethnic, racial, and gender diversity in this global epidemic. The purpose of this Supplement is to leverage the rich phenotyping in REPRIEVE, to provide data on detailed patterns of baseline ART and immune function by GBD region, reproductive aging among cisgender women, and data on the participation and clinical characteristics of transgender participants. We also leveraged REPRIEVE to assess critical comorbidities, including renal dysfunction, muscle function and frailty, and myocardial steatosis. REPRIEVE is a remarkable collaboration between funders, trial networks, clinical research sites, clinical and data coordinating centers, and willing participants who devoted their time to make the trial possible.",2020,The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus.,"['Human Immunodeficiency Virus', 'human immunodeficiency virus', 'Enrolling 7770 participants from 2015 to 2019 with sites across 5 continents', 'people with HIV (PWH) receiving antiretroviral therapy (ART']",[],"['renal dysfunction, muscle function and frailty, and myocardial steatosis']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0429956', 'cui_str': 'Bowels: fully continent'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}]",[],"[{'cui': 'C1565489', 'cui_str': 'Renal impairment'}, {'cui': 'C0231484', 'cui_str': 'Muscle function'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0152254', 'cui_str': 'Fatty degeneration'}]",7770.0,0.113634,The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus.,"[{'ForeName': 'Steven K', 'Initials': 'SK', 'LastName': 'Grinspoon', 'Affiliation': 'Metabolism Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Pamela S', 'Initials': 'PS', 'LastName': 'Douglas', 'Affiliation': 'Division of Cardiology and Duke Clinical Research Center, Duke University School of Medicine, Durham, North Carolina, USA.'}, {'ForeName': 'Udo', 'Initials': 'U', 'LastName': 'Hoffmann', 'Affiliation': 'Cardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Heather J', 'Initials': 'HJ', 'LastName': 'Ribaudo', 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.'}]",The Journal of infectious diseases,['10.1093/infdis/jiaa098'] 1676,32645831,Comparison of Two Dietary Supplements for Treatment of Uric Acid Renal Lithiasis: Citrate vs. Citrate + Theobromine.,"BACKGROUND Uric acid (UA) renal lithiasis has a high rate of recurrence and a prevalence ranging from 10% and 15%, depending on the population. The most important etiological factor is persistence of urinary pH below 5.5 and one of the most common treatments is alkalization with citrate. Recent studies demonstrated that theobromine, which is abundant in chocolate and cocoa, is a potent inhibitor of UA crystallization. AIM The aim was to compare the efficacy of citrate versus citrate + theobromine as treatment for UA lithiasis. METHODS This randomized cross-over trial investigated the efficacy of two treatments in 47 patients with UA renal lithiasis. Urine volume, pH, UA excretion, theobromine excretion, and risk of UA crystallization (RUAC) at baseline and at the end of each intervention period were measured. RESULTS Each treatment significantly reduced the risk of UA crystallization compared to basal values. The RUAC after citrate + theobromine was lower than the RUAC after citrate, although this difference was not statistically significant. CONCLUSION The combined consumption of citrate and theobromine may be a promising strategy for the prevention of UA kidney stones.",2020,Each treatment significantly reduced the risk of UA crystallization compared to basal values.,"['Uric Acid Renal Lithiasis', '47 patients with UA renal lithiasis']","['theobromine', 'Citrate vs. Citrate + Theobromine', 'Two Dietary Supplements', 'citrate versus citrate + theobromine', 'citrate and theobromine']","['risk of UA crystallization', 'Urine volume, pH, UA excretion, theobromine excretion, and risk of UA crystallization (RUAC']","[{'cui': 'C0041980', 'cui_str': 'Uric Acid'}, {'cui': 'C0392525', 'cui_str': 'Nephrolithiasis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0039763', 'cui_str': 'Theobromine'}, {'cui': 'C0008857', 'cui_str': 'Citrates'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0041980', 'cui_str': 'Uric Acid'}, {'cui': 'C0010423', 'cui_str': 'Crystallization'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0039763', 'cui_str': 'Theobromine'}]",47.0,0.0632672,Each treatment significantly reduced the risk of UA crystallization compared to basal values.,"[{'ForeName': 'Yumaira', 'Initials': 'Y', 'LastName': 'Hernandez', 'Affiliation': 'Urology Service of Manacor Hospital, 07500 Balearic Islands, Spain.'}, {'ForeName': 'Antonia', 'Initials': 'A', 'LastName': 'Costa-Bauza', 'Affiliation': 'Laboratory of Renal Lithiasis Research, University Institute of Health Sciences Research (IUNICS-IdISBa), University of Balearic Islands, 07122 Palma de Mallorca, Spain.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Calvó', 'Affiliation': 'Laboratory of Renal Lithiasis Research, University Institute of Health Sciences Research (IUNICS-IdISBa), University of Balearic Islands, 07122 Palma de Mallorca, Spain.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Benejam', 'Affiliation': 'Urology Service of Manacor Hospital, 07500 Balearic Islands, Spain.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Sanchis', 'Affiliation': 'Laboratory of Renal Lithiasis Research, University Institute of Health Sciences Research (IUNICS-IdISBa), University of Balearic Islands, 07122 Palma de Mallorca, Spain.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Grases', 'Affiliation': 'Laboratory of Renal Lithiasis Research, University Institute of Health Sciences Research (IUNICS-IdISBa), University of Balearic Islands, 07122 Palma de Mallorca, Spain.'}]",Nutrients,['10.3390/nu12072012'] 1677,32646062,Oral Administration of Sodium Nitrate to Metabolic Syndrome Patients Attenuates Mild Inflammatory and Oxidative Responses to Acute Exercise.,"The beneficial effects of exercise for the treatment and prevention of metabolic syndrome pathologies have been related to its anti-inflammatory and antioxidant effects. Dietary nitrate supplementation is an emerging treatment strategy to alleviate the symptoms of metabolic syndrome affections and to improve vascular function. In this double-blind crossover trial, metabolic syndrome patients performed two exercise tests for 30 min at 60-70% maximal heart rate after the intake of a placebo or a nitrate-enriched beverage. Acute exercise increased the plasma concentration of TNFα, intercellular adhesion molecule ICAM1, PGE1, PGE2 and the newly detected 16-hydroxypalmitic acid (16-HPAL) in metabolic syndrome patients. The cytokine and oxylipin production by peripheral blood mononuclear cells (PBMCs) and neutrophils could be responsible for the plasma concentrations of TNFα and IL6, but not for the plasma concentration of oxylipins nor its post-exercise increase. The intake of sodium nitrate 30 min before exercise increased the concentration of nitrate and nitrite in the oral cavity and plasma and reduced the oxygen cost of exercise. Additionally, nitrate intake prevented the enhancing effects of acute exercise on the plasma concentration of TNFα, ICAM1, PGE1, PGE2 and 16-HPAL, while reducing the capabilities of PBMCs and neutrophils to produce oxylipins.",2020,"Acute exercise increased the plasma concentration of TNFα, intercellular adhesion molecule ICAM1, PGE1, PGE2 and the newly detected 16-hydroxypalmitic acid (16-HPAL) in metabolic syndrome patients.",['Metabolic Syndrome Patients'],"['Sodium Nitrate', 'placebo or a nitrate-enriched beverage', 'Dietary nitrate supplementation']","['plasma concentration of TNFα, intercellular adhesion molecule ICAM1, PGE1, PGE2 and the newly detected 16-hydroxypalmitic acid (16-HPAL', 'plasma concentration of TNFα, ICAM1, PGE1, PGE2 and 16-HPAL, while reducing the capabilities of PBMCs and neutrophils to produce oxylipins', 'oxygen cost of exercise', 'concentration of nitrate and nitrite']","[{'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0074748', 'cui_str': 'sodium nitrate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0242565', 'cui_str': 'Intercellular Adhesion Molecules'}, {'cui': 'C0063695', 'cui_str': 'Lymphocyte antigen CD54'}, {'cui': 'C0002335', 'cui_str': 'Alprostadil'}, {'cui': 'C0012472', 'cui_str': 'Dinoprostone'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0286501', 'cui_str': '16-hydroxypalmitic acid'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C1956100', 'cui_str': 'Oxylipins'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0028137', 'cui_str': 'Nitrite salt'}]",,0.0495819,"Acute exercise increased the plasma concentration of TNFα, intercellular adhesion molecule ICAM1, PGE1, PGE2 and the newly detected 16-hydroxypalmitic acid (16-HPAL) in metabolic syndrome patients.","[{'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Capó', 'Affiliation': 'Research Group in Community Nutrition and Oxidative Stress, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.'}, {'ForeName': 'Miguel D', 'Initials': 'MD', 'LastName': 'Ferrer', 'Affiliation': 'Research Group in Community Nutrition and Oxidative Stress, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Olek', 'Affiliation': 'Department of Athletics performance, Strength and Conditioning, Poznan University of Physical Education, 61-871 Poznan, Poland.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Salaberry', 'Affiliation': 'Research Group in Community Nutrition and Oxidative Stress, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Suau', 'Affiliation': 'Sports Medicine Service, Consell Insular de Mallorca, 07010 Palma, Spain.'}, {'ForeName': 'Bartolomé', 'Initials': 'B', 'LastName': 'Marí', 'Affiliation': 'Sports Medicine Service, Consell Insular de Mallorca, 07010 Palma, Spain.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Llompart', 'Affiliation': 'Research Group in Community Nutrition and Oxidative Stress, Department of Basic Biology and Health Sciences, University of the Balearic Islands, 07122 Palma, Spain.'}, {'ForeName': 'Josep A', 'Initials': 'JA', 'LastName': 'Tur', 'Affiliation': 'Research Group in Community Nutrition and Oxidative Stress, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Sureda', 'Affiliation': 'Research Group in Community Nutrition and Oxidative Stress, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Pons', 'Affiliation': 'Research Group in Community Nutrition and Oxidative Stress, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.'}]","Antioxidants (Basel, Switzerland)",['10.3390/antiox9070596'] 1678,32650223,Skin carotenoids are inversely associated with adiposity in breast cancer survivors.,"Carotenoids are antioxidants which may mitigate some of the adverse effects of obesity, a condition associated with poor outcomes in breast cancer patients. We hypothesized that baseline skin carotenoids would be inversely associated with adiposity in breast cancer survivors and would increase with weight loss. Skin carotenoid score (SCS) was assessed by resonance Raman spectroscopy in breast cancer survivors (body mass index ≥25 kg/m 2 ) enrolled in a 6-month randomized controlled weight loss trial (n = 47). Measurements included total body fat using dual-energy X-ray absorptiometry, height, weight, waist and hip circumference, dietary intake, and serum biomarkers. Associations between SCS, adiposity measures, and serum biomarkers were assessed at baseline, as was the change in SCS from baseline to 6 months, in the intervention and usual care groups. At baseline, SCS was inversely correlated with all adiposity measures (P ≤ .05). In multivariate analyses, baseline percent body fat had the strongest association with baseline SCS (partial R 2 = 0.20). Baseline SCS was significantly inversely associated with log C-reactive protein levels (regression coefficient β ± SE: -0.051± 0.019; P = .011) and log leptin (β ± SE: -0.019± 0.009; P = .046), but the associations were no longer significant after adjustment for adiposity. Over the 6-month study, the intervention group had a 17.6% increase in SCS compared to a 1.5% decrease in the usual care group (P = .28). In our study of overweight and obese breast cancer survivors, dual-energy X-ray absorptiometry-measured body fat explained a large portion of the variation in skin carotenoids at baseline, suggesting a stronger association than that previously seen in studies using less accurate measures of adiposity.",2020,"In multivariate analyses, baseline percent body fat had the strongest association with baseline SCS (partial R 2 = 0.20).","['breast cancer patients', 'breast cancer survivors', 'overweight and obese breast cancer survivors', 'breast cancer survivors (body mass index ≥25\u202fkg/m 2 ) enrolled in a 6-month randomized controlled weight loss trial (n\u202f=\u202f47']",[],"['Skin carotenoid score (SCS', 'log C-reactive protein levels', 'SCS', 'SCS, adiposity measures, and serum biomarkers', 'weight loss', 'adiposity measures', 'total body fat using dual-energy X-ray absorptiometry, height, weight, waist and hip circumference, dietary intake, and serum biomarkers']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],"[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0007271', 'cui_str': 'Carotinoid'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0424677', 'cui_str': 'Total body fat'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0230097', 'cui_str': 'Structure of waist (surface region)'}, {'cui': 'C0562350', 'cui_str': 'Hip circumference'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}]",,0.0209892,"In multivariate analyses, baseline percent body fat had the strongest association with baseline SCS (partial R 2 = 0.20).","[{'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Cartmel', 'Affiliation': 'Yale School of Public Health, 60 College St, New Haven, CT 06511; Yale Cancer Center, PO Box 208028, New Haven, CT 06519. Electronic address: brenda.cartmel@yale.edu.'}, {'ForeName': 'Chelsea', 'Initials': 'C', 'LastName': 'Anderson', 'Affiliation': 'Yale School of Public Health, 60 College St, New Haven, CT 06511. Electronic address: chelsea.anderson@cancer.org.'}, {'ForeName': 'Melinda L', 'Initials': 'ML', 'LastName': 'Irwin', 'Affiliation': 'Yale School of Public Health, 60 College St, New Haven, CT 06511; Yale Cancer Center, PO Box 208028, New Haven, CT 06519. Electronic address: melinda.irwin@yale.edu.'}, {'ForeName': 'Maura', 'Initials': 'M', 'LastName': 'Harrigan', 'Affiliation': 'Yale School of Public Health, 60 College St, New Haven, CT 06511. Electronic address: maura.harrigan@yale.edu.'}, {'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'Sanft', 'Affiliation': 'Yale Cancer Center, PO Box 208028, New Haven, CT 06519; Yale School of Medicine, 333 Cedar St, New Haven, CT 06511. Electronic address: tara.sanft@yale.edu.'}, {'ForeName': 'Fangyong', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'Yale School of Public Health, 60 College St, New Haven, CT 06511. Electronic address: fangyong.li@yale.edu.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Gellermann', 'Affiliation': 'Longevity Link Corporation, 391 Chipeta Way, Suite E, Salt Lake City, UT 84108. Electronic address: werner@longevitylinkcorporation.com.'}, {'ForeName': 'Igor V', 'Initials': 'IV', 'LastName': 'Ermakov', 'Affiliation': 'Longevity Link Corporation, 391 Chipeta Way, Suite E, Salt Lake City, UT 84108. Electronic address: igor@longevitylinkcorporation.com.'}, {'ForeName': 'Leah M', 'Initials': 'LM', 'LastName': 'Ferrucci', 'Affiliation': 'Yale School of Public Health, 60 College St, New Haven, CT 06511; Yale Cancer Center, PO Box 208028, New Haven, CT 06519. Electronic address: leah.ferrucci@yale.edu.'}]","Nutrition research (New York, N.Y.)",['10.1016/j.nutres.2020.05.012'] 1679,32650231,Race and cultural factors in an RCT of prolonged exposure and sertraline for PTSD.,"The efficacy of treatments for posttraumatic stress disorder (PTSD) among African Americans is less clear given underrepresentation in clinical research. Additionally, intervention research examining race has typically not considered within-group heterogeneity, such as acculturation, ethnic identity, and cultural attitudes. In a randomized controlled trial, African American (n = 43) and Caucasian (n = 130) individuals received prolonged exposure (PE) or sertraline for PTSD, comparing: treatment response, retention, and treatment beliefs and preferences. Indirect effects of cultural variables were also examined. African Americans reported stronger ethnic identity (d = 0.71), less positive attitudes toward other groups (d = 0.36), and less acculturation (d = 0.51) than Caucasians. Noninferiority analyses indicated clinically equivalent PTSD outcomes for African Americans and Caucasians in both treatments. Groups showed comparable improvements in depression and functioning, and similar treatment preferences and beliefs. African Americans attended fewer sessions in PE (d = 0.87) and sertraline (d = 0.53) than Caucasians. Indirect effects analyses indicated positive cultural attitudes toward other ethnoracial groups were consistently associated with better treatment outcome and retention. Despite no differential effectiveness, findings may highlight the need to target retention among African Americans. Within-group cultural aspects of race may be an informative complement to basic, categorical conceptualizations.",2020,Indirect effects analyses indicated positive cultural attitudes toward other ethnoracial groups were consistently associated with better treatment outcome and retention.,"['African Americans', 'posttraumatic stress disorder (PTSD) among African Americans', 'African American (n\xa0=\xa043) and Caucasian (n\xa0=\xa0130) individuals received']","['prolonged exposure (PE) or sertraline', 'sertraline']","['depression and functioning, and similar treatment preferences and beliefs', 'positive attitudes', 'positive cultural attitudes']","[{'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0074393', 'cui_str': 'Sertraline'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0237428', 'cui_str': 'Positive attitude'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}]",130.0,0.0210524,Indirect effects analyses indicated positive cultural attitudes toward other ethnoracial groups were consistently associated with better treatment outcome and retention.,"[{'ForeName': 'Alexander C', 'Initials': 'AC', 'LastName': 'Kline', 'Affiliation': 'PTSD Treatment and Research Program, Case Western Reserve University, Department of Psychological Sciences, 11220 Bellflower Road, Cleveland, OH, 44106-7123, USA. Electronic address: alexander.kline@va.gov.'}, {'ForeName': 'Norah C', 'Initials': 'NC', 'LastName': 'Feeny', 'Affiliation': 'PTSD Treatment and Research Program, Case Western Reserve University, Department of Psychological Sciences, 11220 Bellflower Road, Cleveland, OH, 44106-7123, USA.'}, {'ForeName': 'Lori A', 'Initials': 'LA', 'LastName': 'Zoellner', 'Affiliation': 'Center for Anxiety and Traumatic Stress, University of Washington, Department of Psychology, Guthrie Hall, Box 351525, Seattle, WA, 98195-1525, USA.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103690'] 1680,32650261,Efficacy and safety of systemic tranexamic acid administration in total knee arthroplasty: A case series.,"INTRODUCTION Total knee arthroplasty (TKA) are associated with significant postoperative blood loss. Tranexamic acid (TXA) is a potent agent with antifibrinolytic activity, that can be administered via the intravenous (IV) and/or topical (intra-articular, IA) route, which can possibly interrupt the cascade of events due to hemostatic irregularities close to the source of bleeding. However, the literature contains scarce scientific evidence related to IV only TXA usage in TKA. The current study aims to compare the outcome between patients who were administered IV TXA and a control group in terms of blood loss, transfusion rate, and incidence of deep vein thrombosis (DVT) and thromboembolism (TE). METHODS 110 patients, who underwent TKA were placed into two groups: 1) 34 patients who received IV TXA; and 2) 76 patients in the control group. In the TXA group, patients received an IV TXA dose of 1 g, 30 min before incision. Two drains were placed. RESULTS Usage of IV TXA showed better results when compared to the control group in terms of mean blood transfusion (0.5 less transfusion during hospital stay), hemoglobin drop (10%). No cases of DVT or TE were noted among the two study groups. CONCLUSION Use of IV TXA provided significantly better results compared to no TXA use with respect to all variables related to postoperative blood loss in TKA. Moreover, TXA use is safe in terms of incidence of symptomatic DVT and TE.",2020,Use of IV TXA provided significantly better results compared to no TXA use with respect to all variables related to postoperative blood loss in TKA.,"['total knee arthroplasty', '110 patients, who underwent TKA were placed into two groups: 1) 34 patients who received']","['IV TXA', 'TXA', 'systemic tranexamic acid', 'Tranexamic acid (TXA', 'Total knee arthroplasty (TKA']","['mean blood transfusion', 'DVT or TE', 'Efficacy and safety', 'blood loss, transfusion rate, and incidence of deep vein thrombosis (DVT) and thromboembolism (TE']","[{'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",110.0,0.0314014,Use of IV TXA provided significantly better results compared to no TXA use with respect to all variables related to postoperative blood loss in TKA.,"[{'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Maalouly', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: Josephmaalouly2@gmail.com.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'El Assaad', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: Donna.elassaad@lau.edu.'}, {'ForeName': 'Rami', 'Initials': 'R', 'LastName': 'Ayoubi', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: rami.ayoubi1@gmail.com.'}, {'ForeName': 'Antonios', 'Initials': 'A', 'LastName': 'Tawk', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: Antoniostawk@gmail.com.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Darwish', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: Mohammaddarwish2@gmail.com.'}, {'ForeName': 'Dany', 'Initials': 'D', 'LastName': 'Aouad', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: Dany_aouad@hotmail.com.'}, {'ForeName': 'Georgio', 'Initials': 'G', 'LastName': 'Lati', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: Georgio.lati@gmail.com.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Darwish', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: Mohammaddarwish2@gmail.com.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'El Rassi', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: gselrassi@gmail.com.'}]",International journal of surgery case reports,['10.1016/j.ijscr.2020.06.077'] 1681,32652388,"Buying despite negative consequences: Interaction of craving, implicit cognitive processes, and inhibitory control in the context of buying-shopping disorder.","BACKGROUND Buying-shopping disorder (BSD) is a severe mental disorder in which individuals lose control over their buying/shopping behavior. It is debated whether BSD shares characteristics with other behavioral addictions. The current study aimed at investigating addiction-related concepts, i.e. cue-reactivity/craving, implicit cognitions, and inhibitory control mechanisms, in the context of BSD. METHODS An analog sample of 277 participants completed a cue-reactivity paradigm with shopping-related pictures. To assess implicit cognitions (attentional bias and implicit associations) and inhibitory control, a visual dot probe paradigm, an implicit association test, and an affective shifting task, all with shopping-related and control pictures, were administered. The sequence of the three tasks was randomized across participants. Craving was measured prior and after the cue-reactivity paradigm and after completion of the experimental procedure. BSD severity was assessed using the Pathological Buying Screener (PBS). RESULTS Increases in craving during the cue-reactivity paradigm, but decreases after the experimental procedure were observed. Craving, attentional bias and implicit cognitions were related to BSD severity-but not to inhibitory control. However, we found moderating effects of attentional bias and inhibitory control as well as implicit associations and inhibitory control on the relationship between craving and BSD severity. DISCUSSION/CONCLUSION Results emphasize the role of cue-reactivity/craving, implicit cognitions and inhibitory control in the context of BSD. In line with models for behavioral addictions (I-PACE; Brand et al., 2019), the interaction of affective and cognitive biases towards shopping cues and dysfunctional inhibitory control mechanisms seems to explain the pathological engagement in buying/shopping despite negative consequences.",2020,"Craving, attentional bias and implicit cognitions were related to BSD severity-but not to inhibitory control.",['An analog sample of 277 participants completed a cue-reactivity paradigm with shopping-related pictures'],[],"['Craving', 'BSD severity', 'Craving, attentional bias and implicit cognitions', 'Pathological Buying Screener (PBS', 'implicit cognitions (attentional bias and implicit associations']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0150768', 'cui_str': 'Shopping'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}]",[],"[{'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0150768', 'cui_str': 'Shopping'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C4277667', 'cui_str': 'Attentional Biases'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0004083', 'cui_str': 'Association'}]",277.0,0.020093,"Craving, attentional bias and implicit cognitions were related to BSD severity-but not to inhibitory control.","[{'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Trotzke', 'Affiliation': 'Department of General Psychology: Cognition and Center for Behavioral Addiction Research (CeBAR), University of Duisburg-Essen, Duisburg, Germany; Erwin L. Hahn Institute for Magnetic Resonance Imaging, Essen, Germany. Electronic address: patrick.trotzke@uni-due.de.'}, {'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'Müller', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Brand', 'Affiliation': 'Department of General Psychology: Cognition and Center for Behavioral Addiction Research (CeBAR), University of Duisburg-Essen, Duisburg, Germany; Erwin L. Hahn Institute for Magnetic Resonance Imaging, Essen, Germany.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Starcke', 'Affiliation': 'SRH Berlin School of Popular Arts, Berlin, Germany.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Steins-Loeber', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, University of Bamberg, Bamberg, Germany.'}]",Addictive behaviors,['10.1016/j.addbeh.2020.106523'] 1682,32657195,Improved adenoma detection with linked color imaging technology compared to white-light colonoscopy.,"OBJECTIVES Linked color imaging (LCI) is a new endoscopic technology that may increase colorectal adenoma detection rate (ADR) and polyp detection rate (PDR) by virtual chromoendoscopy. Aim of the present study was to evaluate the effectiveness of LCI in ADR and PDR compared to the HD white-light colonoscopy (WLC) technique. MATERIALS AND METHODS Between October 2016 and June 2018, we enrolled consecutive outpatients prospectively. Eligible patients allocated randomly to undergo HD WLC or LCI colonoscopy technique during instrument withdrawal. Each colonoscopy was performed in a single center by the same three expert endoscopists (with expertise more than 5000 colonoscopies). RESULTS A total of 1278 patients underwent colonoscopy in the study period. ADR and PDR were significantly higher in the LCI group compared to the WLC group (34.4% vs. 26.8%; p  = .007; and 53.3% vs 46.4%; p  = .023, respectively). Similarly, the mean number of adenomas per patient (MAP) was significantly higher with the LCI than WLC (0.64 vs 0.44, respectively; p  = .002). The mean age of patients at the time of colonoscopy was 51.95 years (SD = 13.861) in the LCI group and 51.96 years (SD = 14.028) in the WLC group. No significant differences observed in patient demographic characteristics (there was no difference in gender and age distribution, p  = .986), quality of colonoscopy preparation and withdrawal times (WT) between the two groups (WLC and the LCI groups, 493.9 (SD: 143.5) and 514.0 (SD: 139.5) sec, respectively). CONCLUSIONS According to our results, LCI virtual chromoendoscopic technology was superior compared to conventional HD WLC in detecting colorectal polyps and adenomas.",2020,"No significant differences observed in patient demographic characteristics (there was no difference in gender and age distribution, p  = .986), quality of colonoscopy preparation and withdrawal times (WT) between the two groups (WLC and the LCI groups, 493.9 (SD: 143.5) and 514.0 (SD: 139.5) sec, respectively). ","['Between October 2016 and June 2018, we enrolled consecutive outpatients prospectively', '1278 patients underwent colonoscopy in the study period']","['HD white-light colonoscopy (WLC) technique', 'LCI', 'conventional HD WLC', 'HD WLC or LCI colonoscopy technique', 'Linked color imaging (LCI', 'WLC']","['patient demographic characteristics', 'colorectal adenoma detection rate (ADR) and polyp detection rate (PDR', 'quality of colonoscopy preparation and withdrawal times (WT', 'ADR and PDR', 'mean number of adenomas per patient (MAP']","[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0563228', 'cui_str': 'White light'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C1302401', 'cui_str': 'Adenoma of large intestine'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0001430', 'cui_str': 'Adenoma'}, {'cui': 'C0032584', 'cui_str': 'Polyp'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0024779', 'cui_str': 'Maps'}]",1278.0,0.0214043,"No significant differences observed in patient demographic characteristics (there was no difference in gender and age distribution, p  = .986), quality of colonoscopy preparation and withdrawal times (WT) between the two groups (WLC and the LCI groups, 493.9 (SD: 143.5) and 514.0 (SD: 139.5) sec, respectively). ","[{'ForeName': 'Barbara Dorottya', 'Initials': 'BD', 'LastName': 'Lovász', 'Affiliation': 'Institute of Applied Health Sciences, Semmelweis University, Budapest, Hungary.'}, {'ForeName': 'Milán', 'Initials': 'M', 'LastName': 'Szalai', 'Affiliation': 'Endoscopy Unit, Endo-Kapszula Health Centre, Székesfehérvár, Hungary.'}, {'ForeName': 'László', 'Initials': 'L', 'LastName': 'Oczella', 'Affiliation': 'Institute of Applied Health Sciences, Semmelweis University, Budapest, Hungary.'}, {'ForeName': 'Ádám', 'Initials': 'Á', 'LastName': 'Finta', 'Affiliation': 'Endoscopy Unit, Endo-Kapszula Health Centre, Székesfehérvár, Hungary.'}, {'ForeName': 'Zsolt', 'Initials': 'Z', 'LastName': 'Dubravcsik', 'Affiliation': 'Department of Gastroenterology, OMCH Endoscopy Unit, Bács-Kiskun County Hospital, Kecskemét, Hungary.'}, {'ForeName': 'László', 'Initials': 'L', 'LastName': 'Madácsy', 'Affiliation': 'Endoscopy Unit, Endo-Kapszula Health Centre, Székesfehérvár, Hungary.'}]",Scandinavian journal of gastroenterology,['10.1080/00365521.2020.1786850'] 1683,32654022,Two different therapies for the middle turbinate during endoscopic sinus surgery for chronic rhinosinusitis.,"BACKGROUND The population of patients with chronic rhinosinusitis (CRS) has greatly increased. When medical treatment fails, endoscopic sinus surgery (ESS) is considered. In the present study, the value of two different therapies for the middle turbinate to optimize surgical outcomes was observed. Our objective was to determine a better management approach for the middle turbinate to effectively preserve the middle turbinate mucosa and function and avoid complications following ESS, such as nasal adhesions on the operative side. METHODS Thirty patients [group A; treated prior to 2015 (primary surgery)] undergoing resection of the middle turbinate bone during complete ESS for CRS and 30 patients [group B; treated after 2015 (later surgery)] undergoing middle turbinate preservation and multiapproach therapy during complete ESS for CRS were observed. Nasal cavities were compared using perioperative sinus endoscopy (POSE) and Lund-Kennedy (LKES) scores preoperatively and at 15 days, 2 months and 1 year after ESS. RESULTS Preoperatively, the POSE (8.83 ± 3.81 vs 9.15 ± 3.85, p = 0.45, for groups A and B, respectively) and LKES (4.23 ± 0.74 vs 4.13 ± 0.70, p = 0.34) scores were similar between groups. In group A, anterior adhesions were reported on six sides of the middle turbinate, severe adhesions were observed on two sides, mild adhesions were observed on one side, and adhesions occurred on two sides during follow-up. After retreatment, adhesions were still observed on two sides at 1 year. In group B, only mild anterior adhesions were observed on two sides. There was no difference between group A and group B at 15 days, and the POSE (4.31 ± 1.19 vs 4.07 ± 1.42, p = 0.11, for groups A and B, respectively) and LKES (3.35 ± 0.82 vs 3.33 ± 0.90, p = 0.91) scores were similar between groups. There was no significant difference in LKES (0.22 ± 0.49 vs 0.10 ± 0.35, p = 0.15) scores at 1 year between the two groups. There was a significant difference in the nasal cavities between group A and group B at 2 months and 1 year, where group B showed a better endoscopic appearance than group A at 2 months and 1 year (with POSE scores of 3.48 ± 0.83 vs 2.43 ± 1.38 (p = 0.00) and LKES scores of 1.35 ± 0.86 vs 1.15 ± 0.90 (p = 0.02) at 2 months for groups A and B, respectively, and POSE scores of 1.00 ± 0.96 vs 0.62 ± 0.87 (p = 0.001) at 1 year for groups A and B, respectively). CONCLUSIONS Our results show that middle turbinate preservation and combined therapy was a better ESS method for CRS. Multiapproach middle conchoplasty, which is predominately a submucoperiosteal surgery, can preserve more of the mucosa and functions of the middle turbinate. Unlike the single-approach middle conchoplasty described in previous research, multiapproach middle conchoplasty is achieved by combining a three-step surgical procedure (""surgery, packing and removal"") with ""cocktail-style"" postoperative packing and removal.",2020,"There was a significant difference in the nasal cavities between group A and group B at 2 months and 1 year, where group B showed a better endoscopic appearance than group A at 2 months and 1 year (with POSE scores of 3.48 ± 0.83 vs 2.43 ± 1.38 (p = 0.00) and LKES scores of 1.35 ± 0.86 vs 1.15 ± 0.90 (p = 0.02) at 2 months for groups A and B, respectively, and POSE scores of 1.00 ± 0.96 vs 0.62 ± 0.87 (p = 0.001) at 1 year for groups A and B, respectively). ","['patients with chronic rhinosinusitis (CRS', 'chronic rhinosinusitis', 'Thirty patients [group A']","['endoscopic sinus surgery', 'treated prior to 2015 (primary surgery)] undergoing resection of the middle turbinate bone during complete ESS for CRS and 30 patients [group B; treated after 2015 (later surgery)] undergoing middle turbinate preservation and multiapproach therapy', 'endoscopic sinus surgery (ESS']","['nasal cavities', 'endoscopic appearance', 'LKES', 'LKES scores', 'severe adhesions', 'mild anterior adhesions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0441835', 'cui_str': 'Group A'}]","[{'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0748725', 'cui_str': 'Sinus operation'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0225435', 'cui_str': 'Middle nasal turbinate structure'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0027423', 'cui_str': 'Nasal cavity structure'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0001511', 'cui_str': 'Adhesion'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}]",,0.0319759,"There was a significant difference in the nasal cavities between group A and group B at 2 months and 1 year, where group B showed a better endoscopic appearance than group A at 2 months and 1 year (with POSE scores of 3.48 ± 0.83 vs 2.43 ± 1.38 (p = 0.00) and LKES scores of 1.35 ± 0.86 vs 1.15 ± 0.90 (p = 0.02) at 2 months for groups A and B, respectively, and POSE scores of 1.00 ± 0.96 vs 0.62 ± 0.87 (p = 0.001) at 1 year for groups A and B, respectively). ","[{'ForeName': 'Meichan', 'Initials': 'M', 'LastName': 'Zhu', 'Affiliation': ""Department of Otorhinolaryngology, Guangzhou Twelfth People's Hospital (Guangzhou Otolarynology-Head and Neck Surgery Hospital), Tianhe District, No 1. Tianqiang Road, Guangzhou, 510620, Guangdong, China. zhumeichan@126.com.""}, {'ForeName': 'Yongyi', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': ""Department of Otorhinolaryngology, Guangzhou Twelfth People's Hospital (Guangzhou Otolarynology-Head and Neck Surgery Hospital), Tianhe District, No 1. Tianqiang Road, Guangzhou, 510620, Guangdong, China. yungyi@188.com.""}, {'ForeName': 'Huicheng', 'Initials': 'H', 'LastName': 'Gong', 'Affiliation': ""Department of Otorhinolaryngology, Guangzhou Twelfth People's Hospital (Guangzhou Otolarynology-Head and Neck Surgery Hospital), Tianhe District, No 1. Tianqiang Road, Guangzhou, 510620, Guangdong, China.""}, {'ForeName': 'Yunwen', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': ""Department of Otorhinolaryngology, Guangzhou Twelfth People's Hospital (Guangzhou Otolarynology-Head and Neck Surgery Hospital), Tianhe District, No 1. Tianqiang Road, Guangzhou, 510620, Guangdong, China.""}, {'ForeName': 'Guojie', 'Initials': 'G', 'LastName': 'Tan', 'Affiliation': ""Department of Otorhinolaryngology, Guangzhou Twelfth People's Hospital (Guangzhou Otolarynology-Head and Neck Surgery Hospital), Tianhe District, No 1. Tianqiang Road, Guangzhou, 510620, Guangdong, China.""}]",European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,['10.1007/s00405-020-06184-4'] 1684,32675601,Prosthesis in Anterior Cervical Herniated Disc Approach Does Not Prevent Radiologic Adjacent Segment Degeneration.,"STUDY DESIGN Retrospective analysis using data from RCTs. OBJECTIVE This study aimed to report on the incidence of radiological adjacent segment degeneration (ASD) in patients with cervical radiculopathy due to a herniated disc that were randomized to receive cervical arthroplasty or arthrodesis. SUMMARY OF BACKGROUND DATA Cervical disc prostheses were introduced to prevent ASD in the postsurgical follow-up. However, it is still a controversial issue. METHODS Two hundred fifty-three patients were included in two randomized, double-blinded trials comparing anterior cervical discectomy with arthroplasty (ACDA), with intervertebral cage (ACDF), or without intervertebral cage (ACD) for one-level disc herniation. Neutral lateral radiographs were obtained preoperatively, at 1- and 2-year follow-up after surgery. Radiological ASD was evaluated on X-ray and defined by a decrease in disc height and the presence of anterior osteophyte formation on both the superior and the inferior level in relation to the target level. RESULTS Radiological ASD was present in 34% of patients at baseline and increased to 59% at 2-year follow-up in the arthrodesis groups (ACD and ACDF combined), and to 56% in the arthroplasty group. Progression of radiological ASD was present in 29% of patients in the arthrodesis group and in 31% of patients in the arthroplasty group for 2-year follow-up. CONCLUSIONS Radiological ASD occurs in a similar manner in patients who were subjected to arthrodesis in cervical radiculopathy and in patients who received arthroplasty to maintain motion. Current data tend to indicate that the advantage of cervical prosthesis in preventing radiological ASD is absent. LEVEL OF EVIDENCE 2.",2020,"Progression of radiological ASD was present in 29% of patients in the arthrodesis group and in 31% of patients in the arthroplasty group for 2-year follow-up. ","['Two hundred fifty-three patients', 'patients with cervical radiculopathy due to a herniated disc']","['anterior cervical discectomy with arthroplasty (ACDA), with intervertebral cage (ACDF), or without intervertebral cage (ACD', 'cervical arthroplasty or arthrodesis']","['disc height', 'Progression of radiological ASD', 'Radiological ASD']","[{'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0742186', 'cui_str': 'Cervical radiculopathy'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}]","[{'cui': 'C0442011', 'cui_str': 'Anterior cervical spine approach'}, {'cui': 'C0206078', 'cui_str': 'Discectomy of spine'}, {'cui': 'C0003893', 'cui_str': 'Arthroplasty'}, {'cui': 'C0442106', 'cui_str': 'Intervertebral'}, {'cui': 'C0337189', 'cui_str': 'Cage'}, {'cui': 'C0002873', 'cui_str': 'Anemia of chronic disease'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0003881', 'cui_str': 'Arthrodesis'}]","[{'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C3888829', 'cui_str': 'Adjacent segment degeneration'}]",253.0,0.151115,"Progression of radiological ASD was present in 29% of patients in the arthrodesis group and in 31% of patients in the arthroplasty group for 2-year follow-up. ","[{'ForeName': 'Xiaoyu', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Department of Neurosurgery, Leiden University Medical Centre, Leiden, The Netherlands.'}, {'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Donk', 'Affiliation': 'Department of Orthopaedic Surgery, Via Sana Clinics, Mill, The Netherlands.'}, {'ForeName': 'Mark P', 'Initials': 'MP', 'LastName': 'Arts', 'Affiliation': 'Department of Neurosurgery, Haaglanden Medical Centre, The Hague, The Netherlands.'}, {'ForeName': 'Ronald H M A', 'Initials': 'RHMA', 'LastName': 'Bartels', 'Affiliation': 'Department of Neurosurgery, Radboud University Medical Centre, Nijmegen, The Netherlands.'}, {'ForeName': 'Carmen L A', 'Initials': 'CLA', 'LastName': 'Vleggeert-Lankamp', 'Affiliation': 'Department of Neurosurgery, Leiden University Medical Centre, Leiden, The Netherlands.'}]",Spine,['10.1097/BRS.0000000000003453'] 1685,32675606,Effects of Specific Exercise Therapy on Adolescent Patients With Idiopathic Scoliosis: A Prospective Controlled Cohort Study.,"STUDY DESIGN A prospective controlled cohort study. OBJECTIVE The aim of this study was to explore the interventional effect of exercise therapy on idiopathic scoliosis (IS) and identify an optimal intervention window. SUMMARY OF BACKGROUND DATA Early conservative treatment is helpful for IS. In addition to bracing, current evidence suggests that exercise can play an important role. METHODS We included 99 patients with IS who were treated at the Guangdong Xinmiao Scoliosis Center from August 2013 to September 2017. The inclusion criteria were: new IS diagnosis, Cobb angle 10° to 25°, Risser 0 to 3 grade, only treated with the Xinmiao treatment system (XTS; >3 days/week, >1 h/day), and follow-up >1 year. Patients were divided into three age groups: A, <10 years (n = 29); B, 10 to 12 years (n = 24); and C, 13 to 15 years (n = 46). The percentages of curve improvement (Cobb angle decrease ≥5°), stability (Cobb angle change × ±5°), and progression (Cobb angle increase ≥5°) were compared. RESULTS The groups showed significant differences for major curve correction, Risser sign, first referral, and final follow-up of the main curve (all P < 0.05). The major curve in group A decreased significantly by 6.8° (44% correction), compared to 3.1° (18% correction) and 1.5° (9% correction) in groups B and C, respectively. In group A, 69.0% (20/29) had curve improvement, 27.6% (8/29) stabilized and 3.4% (1/29) progressed. In group B, 45.8% (11/24) improved, 50% (12/24) stabilized, and 4.2% (1/24) progressed. In group C, 26.1% (12/46) improved, 63.0% (29/46) stabilized, and 10.9% (5/46) progressed. There was also a significant difference in final Risser grade among the groups (P < 0.05). CONCLUSION For IS patients with Cobb angles between 10° and 25°, our exercise protocol can effectively control or improve curve progression. Younger patients with a lower Risser grade are most likely to respond. LEVEL OF EVIDENCE 2.",2020,"The groups showed significant differences for major curve correction, Risser sign, first referral, and final follow-up of the main curve (all P < 0.05).","['Younger patients with a lower Risser grade', 'The inclusion criteria were: new IS diagnosis, Cobb angle 10° to 25°, Risser 0 to 3 grade, only treated with the Xinmiao treatment system (XTS; >3\u200adays/week, >1\u200ah/day), and follow-up >1 year', '99 patients with IS who were treated at the Guangdong Xinmiao Scoliosis Center from August 2013 to September 2017', 'Adolescent Patients With Idiopathic Scoliosis']","['exercise therapy', 'Specific Exercise Therapy']","['final Risser grade', 'major curve correction, Risser sign, first referral, and final follow-up of the main curve', 'percentages of curve improvement (Cobb angle decrease ≥5°), stability (Cobb angle change × ±5°), and progression']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0595995', 'cui_str': 'Idiopathic scoliosis'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0563192', 'cui_str': 'Cobb angle'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0677547', 'cui_str': 'days/week'}, {'cui': 'C4280965', 'cui_str': 'Greater than one'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0036439', 'cui_str': 'Scoliosis deformity of spine'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0205369', 'cui_str': 'Specific'}]","[{'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0563192', 'cui_str': 'Cobb angle'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}]",99.0,0.0389948,"The groups showed significant differences for major curve correction, Risser sign, first referral, and final follow-up of the main curve (all P < 0.05).","[{'ForeName': 'Delong', 'Initials': 'D', 'LastName': 'Liu', 'Affiliation': 'Department of Spine Surgery, the 1st Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Yunlin', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Physical Education Institute, Chengdu University of Technology, Chengdu, China.'}, {'ForeName': 'Xuexiang', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': 'Department of sports and Arts, Guangzhou Sport University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Jingfan', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Spine Center, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Xiaoling', 'Initials': 'X', 'LastName': 'Xuan', 'Affiliation': 'Xinmiao Scoliosis Prevention Center of Guangdong Province, Guangzhou, Guangdong, China.'}, {'ForeName': 'Junlin', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Spine Center, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Zifang', 'Initials': 'Z', 'LastName': 'Huang', 'Affiliation': 'Department of Spine Surgery, the 1st Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.'}]",Spine,['10.1097/BRS.0000000000003451'] 1686,32677346,Innovations in Practice: Intensive crisis intervention for adolescent suicidal ideation and behavior - an open trial.,"BACKGROUND Adolescent suicide is a major public health concern worldwide. However, evidence regarding the effectiveness of interventions targeting youth suicide risk is limited. The purpose of this study was to assess the feasibility, acceptability, and clinical outcomes of Intensive Crisis Intervention (ICI), a cognitive-behavioral, family-centered treatment that provides an alternative to longer inpatient care. METHOD Intensive Crisis Intervention was piloted over a two-year period with 50 adolescents (M age  = 15.1 years; 86% Female; 78% Caucasian) admitted to an intensive crisis stabilization unit presenting with suicidal ideation and/or attempts. Data were collected at admission, 30 days, and 3 months post-admission to evaluate changes in suicidal ideation and functioning over time. RESULTS Follow-up data were provided by 88% of study participants. At 3 months, the mean Suicidal Ideation Questionnaire-Junior score improved 34.2 points relative to baseline (effect size of 2.2, p < .0001). Significant improvements in functioning, high rates of consumer satisfaction and readiness for care transition upon discharge were also reported. CONCLUSION Study findings set the stage for a larger, randomized controlled trial to examine the efficacy of ICI in targeting suicidal ideation and behavior in adolescents.",2019,"At 3 months, the mean Suicidal Ideation Questionnaire-Junior score improved 34.2 points relative to baseline (effect size of 2.2, p < .0001).","['adolescents', 'Intensive Crisis Intervention was piloted over a two-year period with 50 adolescents (M age \xa0=\xa015.1\xa0years; 86% Female; 78% Caucasian) admitted to an intensive crisis stabilization unit presenting with suicidal ideation and/or attempts']","['Intensive Crisis Intervention (ICI', 'ICI']","['functioning, high rates of consumer satisfaction and readiness for care transition upon discharge', 'mean Suicidal Ideation Questionnaire-Junior score', 'suicidal ideation and functioning over time']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0010332', 'cui_str': 'Crisis intervention'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0231224', 'cui_str': 'Crisis'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}]","[{'cui': 'C0010332', 'cui_str': 'Crisis intervention'}]","[{'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0009827', 'cui_str': 'Consumer Satisfaction'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C4019079', 'cui_str': 'Care Transition'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",,0.129166,"At 3 months, the mean Suicidal Ideation Questionnaire-Junior score improved 34.2 points relative to baseline (effect size of 2.2, p < .0001).","[{'ForeName': 'Sandra M', 'Initials': 'SM', 'LastName': 'McBee-Strayer', 'Affiliation': ""The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Glenn V', 'Initials': 'GV', 'LastName': 'Thomas', 'Affiliation': ""Nationwide Children's Hospital Big Lots Behavioral Health Services, Columbus, OH, USA.""}, {'ForeName': 'Ericka M', 'Initials': 'EM', 'LastName': 'Bruns', 'Affiliation': ""Nationwide Children's Hospital Big Lots Behavioral Health Services, Columbus, OH, USA.""}, {'ForeName': 'Kendra M', 'Initials': 'KM', 'LastName': 'Heck', 'Affiliation': ""The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Emily R', 'Initials': 'ER', 'LastName': 'Alexy', 'Affiliation': ""The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Bridge', 'Affiliation': ""The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.""}]",Child and adolescent mental health,['10.1111/camh.12340'] 1687,32678062,Effectiveness of Interventions to Increase Colorectal Cancer Screening Among American Indians and Alaska Natives.,"INTRODUCTION Screening rates for colorectal cancer are low in many American Indian and Alaska Native (AI/AN) communities. Direct mailing of a fecal immunochemical test (FIT) kit can address patient and structural barriers to screening. Our objective was to determine if such an evidence-based intervention could increase colorectal cancer screening among AI/AN populations. METHODS We recruited study participants from 3 tribally operated health care facilities and randomly assigned them to 1 of 3 study groups: 1) usual care, 2) mailing of FIT kits, and 3) mailing of FIT kits plus follow-up outreach by telephone and/or home visit from an American Indian Community Health Representative (CHR). RESULTS Among participants who received usual care, 6.4% returned completed FIT kits. Among participants who were mailed FIT kits without outreach, 16.9% returned the kits - a significant increase over usual care (P < .01). Among participants who received mailed FIT kits plus CHR outreach, 18.8% returned kits, which was also a significant increase over usual care (P < .01) but not a significant increase compared with the mailed FIT kit-only group (P = .44). Of 165 participants who returned FIT kits during the study, 39 (23.6%) had a positive result and were referred for colonoscopy of which 23 (59.0%) completed the colonoscopy. Twelve participants who completed a colonoscopy had polyps, and 1 was diagnosed with colorectal cancer. CONCLUSION Direct mailing of FIT kits to eligible community members may be a useful, population-based strategy to increase colorectal cancer screening among AI/AN people.",2020,"Among participants who were mailed FIT kits without outreach, 16.9% returned the kits - a significant increase over usual care (P < .01).","['participants who received usual care, 6.4% returned completed FIT kits', 'Twelve participants who completed a colonoscopy had polyps, and 1 was diagnosed with colorectal cancer', 'American Indians and Alaska Natives', '165 participants who returned FIT kits during the study, 39 (23.6%) had a positive result and were referred for colonoscopy of which 23 (59.0%) completed the colonoscopy', 'study participants from 3 tribally operated health care facilities and randomly assigned them to 1 of 3 study groups: 1']","['usual care, 2) mailing of FIT kits, and 3) mailing of FIT kits plus follow-up outreach by telephone and/or home visit from an American Indian Community Health Representative (CHR']",['usual care'],"[{'cui': 'C4517822', 'cui_str': '6.4'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C1272835', 'cui_str': 'Test kit'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0032584', 'cui_str': 'Polyp'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0682125', 'cui_str': 'Native Alaskians'}, {'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C1272835', 'cui_str': 'Test kit'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0043459', 'cui_str': 'Zellweger syndrome'}]",[],165.0,0.0522286,"Among participants who were mailed FIT kits without outreach, 16.9% returned the kits - a significant increase over usual care (P < .01).","[{'ForeName': 'Donald', 'Initials': 'D', 'LastName': 'Haverkamp', 'Affiliation': 'Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Albuquerque, New Mexico.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'English', 'Affiliation': 'Albuquerque Area Indian Health Board, Albuquerque, New Mexico.'}, {'ForeName': 'Jasmine', 'Initials': 'J', 'LastName': 'Jacobs-Wingo', 'Affiliation': 'Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Albuquerque, New Mexico.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Tjemsland', 'Affiliation': 'Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Albuquerque, New Mexico.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Espey', 'Affiliation': 'Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Albuquerque, New Mexico.'}]",Preventing chronic disease,['10.5888/pcd17.200049'] 1688,32646850,Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial.,"The PRECISION trial was a multicentre randomised study that demonstrated that multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy is superior to standard transrectal ultrasound-guided biopsy for the detection of prostate cancer. The outcomes of studies reporting mpMRI-targeted biopsies are dependent on the quality of the mpMRI but there are currently no scoring systems available for evaluating this. We introduced a novel scoring system, the Prostate Imaging Quality (PI-QUAL) score, to assess the quality of scans in the PRECISION trial. PI-QUAL is a score on a Likert scale from 1 to 5, where 1 means that no mpMRI sequences are of diagnostic quality and 5 implies that each sequence is independently of optimal diagnostic quality. Fifty-eight out of 252 (23%) mpMRI scans chosen at random from each of the 22 centres in this trial were evaluated by two experienced radiologists from the coordinating trial centre, in consensus, blinded to pathology results. Overall, the mpMRI quality in the centres participating in PRECISION was good. MpMRI quality was of sufficient diagnostic quality (PI-QUAL ≥3) for 55 scans (95%) and of good or optimal diagnostic quality (PI-QUAL ≥4) for 35 scans (60%). Fifty-five out of 58 (95%) scans were of diagnostic quality for T2WI, followed by DWI (46/58 scans; 79%), and DCE (38/58 scans; 66%). Further validation of this scoring system is warranted. PATIENT SUMMARY: In this study we developed a scoring system (PI-QUAL) to assess the quality of multiparametric magnetic resonance imaging (mpMRI) in prostate cancer detection. We used scans from 22 centres that participated in the PRECISION trial. Although there was room for improvement in images that used intravenous contrast, we found that mpMRI in the PRECISION trial was of sufficient diagnostic quality (PI-QUAL score ≥3) for 95% of the scans.",2020,In this study we developed a scoring system (PI-QUAL) to assess the quality of multiparametric magnetic resonance imaging (mpMRI) in prostate cancer detection.,"['prostate cancer detection', 'Fifty-eight out of 252 (23']","['multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy', 'standard transrectal ultrasound-guided biopsy', 'Prostate Imaging Quality (PI-QUAL', 'multiparametric magnetic resonance imaging (mpMRI']","['diagnostic quality', 'MpMRI quality', 'mpMRI quality', 'Prostate Imaging Quality (PI-QUAL) score']","[{'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C4517817', 'cui_str': '58'}]","[{'cui': 'C3898221', 'cui_str': 'Multiparametric magnetic resonance elastography'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0373345', 'cui_str': 'Transrectal ultrasound'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0332306', 'cui_str': 'Quality'}]","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C3898221', 'cui_str': 'Multiparametric magnetic resonance elastography'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",252.0,0.0461845,In this study we developed a scoring system (PI-QUAL) to assess the quality of multiparametric magnetic resonance imaging (mpMRI) in prostate cancer detection.,"[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Giganti', 'Affiliation': 'Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK; Division of Surgery & Interventional Science, University College London, London, UK. Electronic address: f.giganti@ucl.ac.uk.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Allen', 'Affiliation': 'Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Emberton', 'Affiliation': 'Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'Caroline M', 'Initials': 'CM', 'LastName': 'Moore', 'Affiliation': 'Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'Veeru', 'Initials': 'V', 'LastName': 'Kasivisvanathan', 'Affiliation': 'Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European urology oncology,['10.1016/j.euo.2020.06.007'] 1689,32649493,Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users: A Randomized Controlled Trial.,"OBJECTIVE To evaluate whether a short course of tamoxifen decreases bothersome bleeding in etonogestrel contraceptive implant users. METHODS In a 90-day, double-blind randomized control trial, we enrolled etonogestrel implant users with frequent or prolonged bleeding or spotting. A sample size of 40 per group (N=80) was planned to compare 10 mg tamoxifen or placebo twice daily for 7 days after 3 consecutive days of bleeding or spotting no more than once per 30 days (maximum three treatments). Participants then entered a 90-day open-label study where all received tamoxifen if needed every 30 days (maximum three treatments). Participants used text messages to record daily bleeding patterns. Our primary outcome was the total number of consecutive amenorrhea days after the first treatment. Secondary outcomes included time to bleeding or spotting cessation and restart after first treatment, overall bleeding patterns, and satisfaction. RESULTS From January 2017 to November 2018, 112 women enrolled in the study; 88 (79%) completed 90 days, and 79 (71%) completed 180 days. Participant characteristics did not differ between groups; mean age 24, majority identified as white not Hispanic with at least some college education. After the first treatment, the tamoxifen group reported an average of 9.8 (95% CI 4.6-15.0) more consecutive days of amenorrhea and more total days of no bleeding (amenorrhea or spotting) in the first 90 days (median 73.5 [range 24-89] vs 68 [range 11-81], P=.001). The placebo group showed a similar treatment benefit after first active use of tamoxifen in the open-label phase. At the end of the randomized study (first 90 days), women who received tamoxifen reported higher satisfaction (median 62 mm [range 16-100]) than those treated with placebo (46 mm [range 0-100]; P=.023). CONCLUSION A short course of tamoxifen reduces problematic bleeding and improves satisfaction in users of etonogestrel implants. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT02903121.",2020,"Secondary outcomes included time to bleeding or spotting cessation and restart after first treatment, overall bleeding patterns, and satisfaction. ","['From January 2017 to November 2018, 112 women enrolled in the study; 88 (79%) completed 90 days, and 79 (71%) completed 180 days', 'enrolled etonogestrel implant users with frequent or prolonged bleeding or spotting', 'users of etonogestrel implants', 'etonogestrel contraceptive implant users', 'Contraceptive Implant Users']","['placebo', 'tamoxifen', 'tamoxifen or placebo']","['total number of consecutive amenorrhea days', 'consecutive days of amenorrhea and more total days of no bleeding (amenorrhea or spotting', 'time to bleeding or spotting cessation and restart after first treatment, overall bleeding patterns, and satisfaction', 'bothersome bleeding', 'higher satisfaction']","[{'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C1306383', 'cui_str': 'Etonogestrel Drug Implant'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0047683', 'cui_str': 'Etonogestrel'}, {'cui': 'C1657106', 'cui_str': 'Contraceptive implant'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039286', 'cui_str': 'Tamoxifen'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0002453', 'cui_str': 'Amenorrhea'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0205250', 'cui_str': 'High'}]",112.0,0.624149,"Secondary outcomes included time to bleeding or spotting cessation and restart after first treatment, overall bleeding patterns, and satisfaction. ","[{'ForeName': 'Alison B', 'Initials': 'AB', 'LastName': 'Edelman', 'Affiliation': 'Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Oregon; the Department of Obstetrics and Gynecology, University of Hawaii, Honolulu, Hawaii; and the Department of Obstetrics & Gynecology, the Permanente Medical Group, San Leandro, California.'}, {'ForeName': 'Bliss', 'Initials': 'B', 'LastName': 'Kaneshiro', 'Affiliation': ''}, {'ForeName': 'Katharine B', 'Initials': 'KB', 'LastName': 'Simmons', 'Affiliation': ''}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Hauschildt', 'Affiliation': ''}, {'ForeName': 'Kise', 'Initials': 'K', 'LastName': 'Bond', 'Affiliation': ''}, {'ForeName': 'Emily R', 'Initials': 'ER', 'LastName': 'Boniface', 'Affiliation': ''}, {'ForeName': 'Jeffrey T', 'Initials': 'JT', 'LastName': 'Jensen', 'Affiliation': ''}]",Obstetrics and gynecology,['10.1097/AOG.0000000000003896'] 1690,32652462,Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: A randomised controlled trial to evaluate the effect of short message service (SMS) reminder.,"BACKGROUND Medication adherence is crucial for improving clinical outcomes in the treatment of patients. We evaluate the effect of short message service (SMS) reminder on medication adherence and serum hormones in patients with breast cancer on aromatase inhibitors. METHODS An open-label, multi-centre, prospective randomised controlled trial of SMS versus Standard Care was conducted. Medication adherence was assessed via self-report using the Simplified Medication Adherence Questionnaire at baseline, 6 month, and 1 year. Androstenedione, estradiol, and estrone were measured at baseline and 1 year. The χ 2 test and mixed effects logistic regression was performed to compare medication adherence between groups. Difference in androstenedione and estrone levels were assessed using analysis of covariance, whereas χ 2 test and logistic regression was used for estradiol. Analysis was based on intention-to-treat. RESULTS A total of 244 patients were randomised to receive weekly SMS reminder (n = 123) or Standard Care (n = 121) between May 2015 and December 2018. The odds of adherence was higher at 6-month in SMS (OR = 1.78, 95% CI 1.04-3.05, p = 0.034), and not significantly different at 1-year (OR = 1.15, 95% CI: 0.67-1.96 p = 0.617). Mixed effects logistic regression analysis showed higher odds of adherence in SMS over the 1-year period (OR = 2.35, 95% CI: 1.01-5.49, p = 0.048). There was no difference in serum hormone levels between groups. CONCLUSION SMS reminder improved medication adherence in the short-term but had no effect on serum hormones levels in the longer term. Future studies could investigate the use of tailored SMS intervention according to patient preference to improve its sustainability.",2020,"CONCLUSION SMS reminder improved medication adherence in the short-term but had no effect on serum hormones levels in the longer term.","['patients with breast cancer on aromatase inhibitors', 'patients', '244 patients', 'women with breast cancer']","['short message service (SMS) reminder', 'SMS', 'adjuvant aromatase inhibitor', 'SMS intervention', 'SMS reminder (n\xa0=\xa0123) or Standard Care']","['Medication adherence', 'Androstenedione, estradiol, and estrone', 'medication adherence and serum hormones', 'odds of adherence', 'serum hormones levels', 'androstenedione and estrone levels', 'serum hormone levels', 'medication adherence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0593802', 'cui_str': 'Aromatase inhibitor'}, {'cui': 'C4517660', 'cui_str': '244'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0593802', 'cui_str': 'Aromatase inhibitor'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0002860', 'cui_str': 'Androstenedione'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0014942', 'cui_str': 'Estrone'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C1287355', 'cui_str': 'Hormone level - finding'}, {'cui': 'C0236379', 'cui_str': 'Estrone measurement'}]",244.0,0.22356,"CONCLUSION SMS reminder improved medication adherence in the short-term but had no effect on serum hormones levels in the longer term.","[{'ForeName': 'Eng Hooi', 'Initials': 'EH', 'LastName': 'Tan', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, 12 Science Drive 2, #10-03F, 117549, Singapore.'}, {'ForeName': 'Andrea Li Ann', 'Initials': 'ALA', 'LastName': 'Wong', 'Affiliation': 'Department of Haematology-Oncology, National University Cancer Institute, NUHS Tower Block Level 7, 1E Kent Ridge Road, 119228, Singapore.'}, {'ForeName': 'Chuan Chien', 'Initials': 'CC', 'LastName': 'Tan', 'Affiliation': 'Department of General Surgery, Ng Teng Fong General Hospital, 1 Jurong East Street 21, 609606, Singapore.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Wong', 'Affiliation': 'Division of Oncology Pharmacy, National University Cancer Institute, NUHS Tower Block Level 7, 1E Kent Ridge Road, 119228, Singapore.'}, {'ForeName': 'Sing Huang', 'Initials': 'SH', 'LastName': 'Tan', 'Affiliation': 'OncoCare Cancer Centre, 6 Napier Road, #02-17/18/19, Gleneagles Medical Centr, 258499, Singapore.'}, {'ForeName': 'Li En Yvonne', 'Initials': 'LEY', 'LastName': 'Ang', 'Affiliation': 'Department of Haematology-Oncology, National University Cancer Institute, NUHS Tower Block Level 7, 1E Kent Ridge Road, 119228, Singapore.'}, {'ForeName': 'Siew Eng', 'Initials': 'SE', 'LastName': 'Lim', 'Affiliation': 'Department of Haematology-Oncology, National University Cancer Institute, NUHS Tower Block Level 7, 1E Kent Ridge Road, 119228, Singapore.'}, {'ForeName': 'Wan Qin', 'Initials': 'WQ', 'LastName': 'Chong', 'Affiliation': 'Department of Haematology-Oncology, National University Cancer Institute, NUHS Tower Block Level 7, 1E Kent Ridge Road, 119228, Singapore.'}, {'ForeName': 'Jingshan', 'Initials': 'J', 'LastName': 'Ho', 'Affiliation': 'Department of Haematology-Oncology, National University Cancer Institute, NUHS Tower Block Level 7, 1E Kent Ridge Road, 119228, Singapore.'}, {'ForeName': 'Soo Chin', 'Initials': 'SC', 'LastName': 'Lee', 'Affiliation': 'Department of Haematology-Oncology, National University Cancer Institute, NUHS Tower Block Level 7, 1E Kent Ridge Road, 119228, Singapore.'}, {'ForeName': 'Bee Choo', 'Initials': 'BC', 'LastName': 'Tai', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, 12 Science Drive 2, #10-03F, 117549, Singapore; Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, 1E Kent Ridge Road, 119228, Singapore. Electronic address: ephtbc@nus.edu.sg.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2020.06.012'] 1691,32653604,"Impact of bupivacaine injection to trocar sites on postoperative pain following laparoscopic hysterectomy: Results from a prospective, multicentre, double-blind randomized controlled trial.","OBJECTIVES Laparoscopic surgery has numerous advantages over open surgery in view of postoperative pain. In this context, to elevate its benefits and patient satisfaction, different pain management interventions have been used so far. This study aimed to evaluate the effect of bupivacaine injection to trocar sites following laparoscopic hysterectomy for the management of postoperative pain. STUDY DESIGN In this study, patients were randomized into two groups (56 cases; 52 controls). A single injection of bupivacaine (0.5 %, 5 mg/mL) was introduced to trocar sites under subcutaneous tissue at a dose of 4 ml for the umbilicus and 2 ml for each 5-mm ancillary trocar site in the study group. No bupivacaine was administered to the control group. The primary aim was to measure differences in 2 -h postoperative numerical rating scale (NRS) pain scores between the two groups. The secondary aims were to evaluate differences between 1-, 4-, 6-, 24- and 48 -h postoperative NRS pain scores, surgical complications, estimated blood loss, duration of operation and analgesic consumption. RESULTS The number of postoperative rescue doses of analgesics was found to be lower in the study group compared to the control group (median of 2 vs. 4; p < 0.01). The 1-, 4-, 6-, 24- and 48-hour postoperative NRS pain scores were also found to be lower in the study group compared to the control group (p < 0.01 at each follow-up). The mean duration of surgery and uterus removal, as well as the estimated blood loss, were not significantly different between the two groups. CONCLUSIONS The present study suggests that bupivacaine injection to trocar sites is an effective and safe method for reducing pain following laparoscopic hysterectomy.",2020,The number of postoperative rescue doses of analgesics was found to be lower in the study group compared to the control group (median of 2 vs. 4; p < 0.01).,['laparoscopic hysterectomy'],"['laparoscopic hysterectomy', 'Laparoscopic surgery', 'bupivacaine injection to trocar sites', 'bupivacaine']","['48-hour postoperative NRS pain scores', '2 -h postoperative numerical rating scale (NRS) pain scores', 'mean duration of surgery and uterus removal', 'postoperative pain', 'postoperative NRS pain scores, surgical complications, estimated blood loss, duration of operation and analgesic consumption', 'estimated blood loss', 'pain', 'number of postoperative rescue doses of analgesics']","[{'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy'}]","[{'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C4060211', 'cui_str': 'Bupivacaine Injection [Sensorcaine]'}, {'cui': 'C0041158', 'cui_str': 'Trocar'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]","[{'cui': 'C0439586', 'cui_str': '48 hours'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C1443559', 'cui_str': 'Estimated blood loss'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.144145,The number of postoperative rescue doses of analgesics was found to be lower in the study group compared to the control group (median of 2 vs. 4; p < 0.01).,"[{'ForeName': 'Ismet', 'Initials': 'I', 'LastName': 'Hortu', 'Affiliation': 'Department of Obstetrics and Gynaecology, Ege University School of Medicine, Izmir, Turkey; Department of Stem Cell, Ege University Institute of Health Sciences, Izmir, Turkey. Electronic address: ismethortu@yahoo.com.'}, {'ForeName': 'Unal', 'Initials': 'U', 'LastName': 'Turkay', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Hasan', 'Initials': 'H', 'LastName': 'Terzi', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Kale', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Mehmet', 'Initials': 'M', 'LastName': 'Yılmaz', 'Affiliation': 'Department of Anaesthesiology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Canan', 'Initials': 'C', 'LastName': 'Balcı', 'Affiliation': 'Department of Anaesthesiology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Umit', 'Initials': 'U', 'LastName': 'Aydın', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Antonio Simone', 'Initials': 'AS', 'LastName': 'Laganà', 'Affiliation': 'Department of Obstetrics and Gynaecology, ""Filippo Del Ponte"" Hospital, University of Insubria, Varese, Italy.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.07.007'] 1692,32653606,Effects of the levonorgestrel intrauterine system on the endometrium after long-term exposure to mifepristone: Secondary outcomes of a randomized controlled trial.,"OBJECTIVE Long-term treatment with progesterone receptor modulators (PRM) is associated with a distinct histological entity termed progesterone receptor modulator associated endometrial changes (PAEC). While accumulating evidence implies that these changes are benign and reversible after cessation of treatment, there are currently no data underpinning their development. Consequently, as a precaution, endometrial shedding is recommended after long-term PRM intake. Avoiding endometrial shedding after treatment with a PRM and prior to the start of a progestin treatment would be beneficial for women in reproductive age to avoid pregnancy and bleeding. However, the endometrial morphology with such a treatment regimen is unknown. The aim of this study was to delineate the endometrial morphology following continuous long-term treatment with the PRM mifepristone and subsequent placement of a levonorgestrel intrauterine system (LNG-IUS) without prior shedding of the endometrium. STUDY DESIGN This study reports the secondary outcome from a double-blinded randomized controlled trial conducted at Karolinska University Hospital, Sweden, November 2009 to January 2015. Healthy women aged 18-43 years with regular menstrual cycles were included. Eligible women were randomized to receive either 50 mg of mifepristone (n = 29) or a comparator (n = 29), every other day for two months followed by insertion of an LNG-IUS 52 mg. Endometrial biopsies were obtained at baseline and three months after placement of the device. The samples were histologically assessed. The main outcome measure of this sub-study was the endometrial morphology including presence of PAEC three months after LNG-IUS insertion. RESULTS Nine and eight paired biopsies from the mifepristone and comparator group, respectively, were included in the histological analysis. There were no differences in baseline characteristics between the groups and all baseline endometrial biopsies were physiological. Three months after LNG-IUS placement the endometrial morphology was still benign without PAEC in all samples treated with either mifepristone or comparator. A progestin effect on the endometrium was seen in all samples. CONCLUSIONS Placement of an LNG-IUS immediately following two months' treatment with the PRM mifepristone, without any prior shedding of the endometrium, may represent a feasible approach in terms of endometrial safety. However, larger studies are needed to confirm our results.",2020,Three months after LNG-IUS placement the endometrial morphology was still benign without PAEC in all samples treated with either mifepristone or comparator.,"['Karolinska University Hospital, Sweden, November 2009 to January 2015', 'Eligible women', 'Healthy women aged 18-43 years with regular menstrual cycles']","['progesterone receptor modulators (PRM', 'mifepristone', 'PRM mifepristone', 'levonorgestrel intrauterine system', 'progestin treatment', 'PRM mifepristone and subsequent placement of a levonorgestrel intrauterine system (LNG-IUS']",['Endometrial biopsies'],"[{'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0025329', 'cui_str': 'Normal menstrual cycle'}]","[{'cui': 'C3653463', 'cui_str': 'Progesterone receptor modulators'}, {'cui': 'C0026088', 'cui_str': 'Mifepristone'}, {'cui': 'C4293465', 'cui_str': 'Levonorgestrel Intrauterine System [Kyleena]'}, {'cui': 'C0033306', 'cui_str': 'Progestational hormone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]","[{'cui': 'C0404066', 'cui_str': 'Endometrial scraping'}]",,0.419988,Three months after LNG-IUS placement the endometrial morphology was still benign without PAEC in all samples treated with either mifepristone or comparator.,"[{'ForeName': 'Kiriaki', 'Initials': 'K', 'LastName': 'Papaikonomou', 'Affiliation': ""Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. Electronic address: kiriaki.papaikonomou@ki.se.""}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Frisendahl', 'Affiliation': ""Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.""}, {'ForeName': 'Alistair R W', 'Initials': 'ARW', 'LastName': 'Williams', 'Affiliation': 'Division of Pathology, The Royal Infirmary of Edinburgh, The University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Gemzell-Danielsson', 'Affiliation': ""Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.""}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.06.056'] 1693,32653721,Leveraging immersive technology to expand access to opioid overdose reversal training in community settings: Results from a randomized controlled equivalence trial.,"BACKGROUND Immersive video (e.g. virtual reality) poses a promising and engaging alternative to standard in-person trainings and can potentially increase access to evidence-based opioid overdose prevention programs (OOPPs). Therefore, the objective of this equivalence study was to test whether the immersive video OOPP was equivalent to a standard in-person OOPP for changes in opioid overdose knowledge and attitudes. METHODS A team of nurses and communication researchers developed a 9-minute immersive video OOPP. To test whether this immersive video OOPP (treatment) demonstrated equivalent gains in opioid overdose response knowledge and attitudes as in-person OOPPs (standard of care control), researchers deployed a two-day field experiment in Philadelphia, Pennsylvania, USA. In this equivalence trial, 9 libraries were randomly assigned to offer treatment or control OOPP to community members attending naloxone giveaway events. In this equivalence design, a difference between treatment and control groups pre- to post-training scores within -1.0 to 1.0 supports equivalence between the trainings. RESULTS Results demonstrate participants (N = 94) exposed to the immersive video OOPP had equivalent improvements on posttest knowledge (β=-0.18, p = .61) and more favorable attitudes about responding to an opioid overdose (β=0.26, p = .02) than those exposed to the standard OOPP. However, these minor differences in knowledge and attitudes were within the equivalence interval indicating that the immersive video OOPP remained equivalently effective for community members. CONCLUSIONS Community partnerships, like those between public health departments and libraries, can provide opportunities for deploying novel immersive video OOPP that, alongside standard offerings, can strengthen community response to the opioid crisis.",2020,"RESULTS Results demonstrate participants (N = 94) exposed to the immersive video OOPP had equivalent improvements on posttest knowledge (β=-0.18, p = .61) and more favorable attitudes about responding to an opioid overdose (β=0.26, p = .02) than those exposed to the standard OOPP.",['community settings'],"['immersive video OOPP (treatment', 'immersive video OOPP', 'control OOPP']","['posttest knowledge', 'favorable attitudes about responding to an opioid overdose']","[{'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0029944', 'cui_str': 'Drug overdose'}]",9.0,0.046718,"RESULTS Results demonstrate participants (N = 94) exposed to the immersive video OOPP had equivalent improvements on posttest knowledge (β=-0.18, p = .61) and more favorable attitudes about responding to an opioid overdose (β=0.26, p = .02) than those exposed to the standard OOPP.","[{'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Herbert', 'Affiliation': 'Woods Institute for the Environment, Stanford University, 473 Via Ortega, Stanford, CA, USA.'}, {'ForeName': 'Sydney', 'Initials': 'S', 'LastName': 'Axson', 'Affiliation': 'School of Nursing, University of Pennsylvania, 418 Curie Boulevard, Philadelphia, PA, USA.'}, {'ForeName': 'Leeann', 'Initials': 'L', 'LastName': 'Siegel', 'Affiliation': 'Annenberg School for Communication, University of Pennsylvania, 620 Walnut Street, Philadelphia, PA, USA.'}, {'ForeName': 'Kyle', 'Initials': 'K', 'LastName': 'Cassidy', 'Affiliation': 'Annenberg School for Communication, University of Pennsylvania, 620 Walnut Street, Philadelphia, PA, USA.'}, {'ForeName': 'Ann Marie', 'Initials': 'AM', 'LastName': 'Hoyt-Brennan', 'Affiliation': 'School of Nursing, University of Pennsylvania, 418 Curie Boulevard, Philadelphia, PA, USA.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Whitney', 'Affiliation': 'School of Nursing, University of Pennsylvania, 418 Curie Boulevard, Philadelphia, PA, USA.'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Herens', 'Affiliation': 'Division of Substance Use Prevention and Harm Reduction, Philadelphia Department of Public Health, 1101 Market Street, 13th Floor, Suite 1320, Philadelphia PA, USA.'}, {'ForeName': 'Nicholas A', 'Initials': 'NA', 'LastName': 'Giordano', 'Affiliation': 'Nell Hodgson Woodruff School of Nursing, Emory University, 1520 Clifton Road, Atlanta, GA, USA. Electronic address: ngiorda@emory.edu.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108160'] 1694,32653726,High rate of antimicrobial resistance and multiple mutations in the dihydrofolate reductase gene among Streptococcus pneumoniae isolated from HIV-infected adults in a community setting in Tanzania.,"OBJECTIVES The aim of this study was to characterize molecular mechanisms of resistance to trimethoprim and other antibiotics in Streptococcus pneumoniae isolates from HIV-infected adults in Dar es Salaam, Tanzania. METHODS A total of 1877 nasopharyngeal swabs were collected and screened for pneumococcal colonization from 537 newly diagnosed individuals with HIV at four clinic visits during a 1-year follow-up from 2017-2018 as part of the randomized clinical trial CoTrimResist (ClinicalTrials.gov ID: NCT03087890). RESULTS A total of 76 pneumococcal isolates were obtained. Of the 70 isolates that could be serotyped, 42 (60.0%) were vaccine serotypes included in pneumococcal conjugate vaccine 23 (PCV23). The majority of isolates (73.7%; 56/76) were non-susceptible to penicillin (MICs of 0.06-2μg/mL). Isolates were frequently resistant to co-trimoxazole (trimethoprim/sulfamethoxazole) (71.1%) but less so to azithromycin (22.4%), erythromycin (21.1%), chloramphenicol (18.4%), tetracycline (14.5%), clindamycin (10.5%) and levofloxacin (0%). Moreover, 26.3% were multidrug-resistant (resistant to ≥3 antibiotic classes). Vaccine-type pneumococci were resistant to more classes of antibiotics, were more frequently resistant to erythromycin, azithromycin, clindamycin and tetracycline, and had higher MICs to penicillin (median, 0.19μg/mL; range, 0.002-1.5μg/mL) compared with non-vaccine serotypes (median, 0.125μg/mL; range, 0.012-0.25μg/mL) (P=0.003). Co-trimoxazole-resistant isolates carried from 1 to 11 different mutations in the dihydrofolate reductase (DHFR) gene, most commonly Ile100Leu (100%), Glu20Asp (91.8%), Glu94Asp (61.2%), Leu135Phe (57.1%), His26Tyr (53.1%), Asp92Ala (53.1%) and His120Gln (53.1%). CONCLUSION Streptococcus pneumoniae isolated from HIV-diagnosed patients were frequently non-susceptible to penicillin and co-trimoxazole. Most isolates carried multiple mutations in DHFR.",2020,"Vaccine-type pneumococci were resistant to more classes of antibiotics; more frequently resistant to erythromycin, azithromycin, clindamycin and tetracycline, and had higher MIC-values towards penicillin (Median 0.19; range 0.002-1.5) versus non-vaccine types (Median 0.125; range 0.012-0.25), p = 0.003.","['1877 nasopharyngeal swabs were collected and screened for pneumococcal colonization from 537 newly diagnosed individuals with HIV at four clinic visits during a one-year follow-up from 2017 -2018', 'Twenty-six percent were multi-drug resistant (resistant to ≥3 antibiotic classes', 'Streptococcus pneumoniae isolates from HIV-infected adults in Dar es Salaam, Tanzania', 'Streptococcus pneumoniae isolated from HIV-infected adults in a community setting in Tanzania']","['clindamycin', 'tetracycline', 'erythromycin, azithromycin, clindamycin and tetracycline', 'levofloxacin', 'chloramphenicol', 'erythromycin', 'azithromycin']",['penicillin non-susceptible minimum inhibitory concentration (MIC'],"[{'cui': 'C0444192', 'cui_str': 'Nasopharyngeal swab'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0038410', 'cui_str': 'Streptococcus pneumoniae'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0008952', 'cui_str': 'Clinic Visits'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0205409', 'cui_str': 'Isolated'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0022595', 'cui_str': 'Darier disease'}, {'cui': 'C0039298', 'cui_str': 'Tanzania'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0008947', 'cui_str': 'Clindamycin'}, {'cui': 'C0039644', 'cui_str': 'Tetracycline'}, {'cui': 'C0014806', 'cui_str': 'Erythromycin'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0282386', 'cui_str': 'Levofloxacin'}, {'cui': 'C0008168', 'cui_str': 'Chloramphenicol'}]","[{'cui': 'C0030842', 'cui_str': 'Penicillin'}, {'cui': 'C0231204', 'cui_str': 'Susceptible'}, {'cui': 'C0427978', 'cui_str': 'MIC'}]",1877.0,0.4074,"Vaccine-type pneumococci were resistant to more classes of antibiotics; more frequently resistant to erythromycin, azithromycin, clindamycin and tetracycline, and had higher MIC-values towards penicillin (Median 0.19; range 0.002-1.5) versus non-vaccine types (Median 0.125; range 0.012-0.25), p = 0.003.","[{'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Manyahi', 'Affiliation': 'Department of Clinical Science, University of Bergen, Bergen, Norway; National Centre for Tropical Infectious Diseases, Department of Medicine, Haukeland University Hospital, Bergen, Norway; Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania. Electronic address: manyahijoel@yahoo.com.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Moyo', 'Affiliation': 'Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania.'}, {'ForeName': 'Said', 'Initials': 'S', 'LastName': 'Aboud', 'Affiliation': 'Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Langeland', 'Affiliation': 'Department of Clinical Science, University of Bergen, Bergen, Norway; National Centre for Tropical Infectious Diseases, Department of Medicine, Haukeland University Hospital, Bergen, Norway.'}, {'ForeName': 'Bjørn', 'Initials': 'B', 'LastName': 'Blomberg', 'Affiliation': 'Department of Clinical Science, University of Bergen, Bergen, Norway; National Centre for Tropical Infectious Diseases, Department of Medicine, Haukeland University Hospital, Bergen, Norway.'}]",Journal of global antimicrobial resistance,['10.1016/j.jgar.2020.06.026'] 1695,32655984,Soothing Your Heart and Feeling Connected: A New Experimental Paradigm to Study the Benefits of Self-Compassion.,"Self-compassion and its cultivation in psychological interventions are associated with improved mental health and well-being. However, the underlying processes for this are not well understood. We randomly assigned 135 participants to study the effect of two short-term self-compassion exercises on self-reported-state mood and psychophysiological responses compared to three control conditions of negative (rumination), neutral, and positive (excitement) valence. Increased self-reported-state self-compassion, affiliative affect, and decreased self-criticism were found after both self-compassion exercises and the positive-excitement condition. However, a psychophysiological response pattern of reduced arousal (reduced heart rate and skin conductance) and increased parasympathetic activation (increased heart rate variability) were unique to the self-compassion conditions. This pattern is associated with effective emotion regulation in times of adversity. As predicted, rumination triggered the opposite pattern across self-report and physiological responses. Furthermore, we found partial evidence that physiological arousal reduction and parasympathetic activation precede the experience of feeling safe and connected.",2019,"Increased self-reported-state self-compassion, affiliative affect, and decreased self-criticism were found after both self-compassion exercises and the positive-excitement condition.",[],"['short-term self-compassion exercises on self-reported-state mood and psychophysiological responses compared to three control conditions of negative (rumination), neutral, and positive (excitement) valence']","['Increased self-reported-state self-compassion, affiliative affect, and decreased self-criticism', 'parasympathetic activation (increased heart rate variability', 'reduced arousal (reduced heart rate and skin conductance']",[],"[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]","[{'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C1510633', 'cui_str': 'Self-Criticism'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}]",135.0,0.0198568,"Increased self-reported-state self-compassion, affiliative affect, and decreased self-criticism were found after both self-compassion exercises and the positive-excitement condition.","[{'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Kirschner', 'Affiliation': 'Mood Disorder Centre, College of Life and Environmental Sciences, University of Exeter.'}, {'ForeName': 'Willem', 'Initials': 'W', 'LastName': 'Kuyken', 'Affiliation': 'Mood Disorder Centre, College of Life and Environmental Sciences, University of Exeter.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Wright', 'Affiliation': 'Mood Disorder Centre, College of Life and Environmental Sciences, University of Exeter.'}, {'ForeName': 'Henrietta', 'Initials': 'H', 'LastName': 'Roberts', 'Affiliation': 'Mood Disorder Centre, College of Life and Environmental Sciences, University of Exeter.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Brejcha', 'Affiliation': 'Mood Disorder Centre, College of Life and Environmental Sciences, University of Exeter.'}, {'ForeName': 'Anke', 'Initials': 'A', 'LastName': 'Karl', 'Affiliation': 'Mood Disorder Centre, College of Life and Environmental Sciences, University of Exeter.'}]",Clinical psychological science : a journal of the Association for Psychological Science,['10.1177/2167702618812438'] 1696,32658496,The effect of feedback-informed cognitive behavioral therapy on treatment outcome: A randomized controlled trial.,"OBJECTIVE Previous studies have shown that feedback-informed treatment can improve outcomes of psychological treatments. This randomized controlled effectiveness trial evaluated the effect of progress feedback on treatment duration, symptom reduction, and dropout in individual cognitive behavioral therapies (CBTs). A control condition where CBT was combined with low-intensive monitoring of progress was compared to an experimental condition where CBT was combined with a high-intensive form of feedback. METHOD Data of 368 outpatients (57.9% female, mean age 41.4 years, SD = 12.2) in secondary care were analyzed using multilevel analyses. Treatment duration was assessed with the number of sessions clients received. Symptom reduction was measured with the Symptom Checklist Revised. Possible moderators of the effect of intensive progress feedback on outcome were explored. RESULTS Clients achieved the same amount of symptom reduction in significantly fewer sessions in the high-intensive feedback condition. Additionally, dropout was significantly lower in the high-intensive feedback condition. Post hoc analyses assessing clients' diagnoses as a possible moderator showed that clients with personality disorders (mainly Cluster C) achieved more symptom reduction in fewer sessions when high-intensity feedback was provided. Also, a high degree of implementation within the experimental condition was associated with fewer treatment sessions. CONCLUSION In sum, the use of high-intensive client feedback reduced treatment duration and reduced dropout of CBT. Thus, feedback-informed CBTs seem to be a promising adaptation of conventional CBT. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,Post hoc analyses assessing clients' diagnoses as a possible moderator showed that clients with personality disorders (mainly Cluster C) achieved more symptom reduction in fewer sessions when high-intensity feedback was provided.,"['Data of 368 outpatients (57.9% female, mean age 41.4 years, SD = 12.2) in secondary care']",['feedback-informed cognitive behavioral therapy'],"['symptom reduction', 'treatment outcome', 'Symptom reduction']","[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3494402', 'cui_str': 'Secondary Care'}]","[{'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0700287', 'cui_str': 'Informing'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",368.0,0.0328832,Post hoc analyses assessing clients' diagnoses as a possible moderator showed that clients with personality disorders (mainly Cluster C) achieved more symptom reduction in fewer sessions when high-intensity feedback was provided.,"[{'ForeName': 'Pauline D', 'Initials': 'PD', 'LastName': 'Janse', 'Affiliation': 'Pro Persona Research.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'de Jong', 'Affiliation': 'Institute of Psychology, Leiden University.'}, {'ForeName': 'Carola', 'Initials': 'C', 'LastName': 'Veerkamp', 'Affiliation': 'HSK Groep.'}, {'ForeName': 'Maarten K', 'Initials': 'MK', 'LastName': 'van Dijk', 'Affiliation': 'Dimence.'}, {'ForeName': 'Giel J M', 'Initials': 'GJM', 'LastName': 'Hutschemaekers', 'Affiliation': 'Pro Persona Research.'}, {'ForeName': 'Marc J P M', 'Initials': 'MJPM', 'LastName': 'Verbraak', 'Affiliation': 'Pro Persona Research.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000549'] 1697,32659247,Children overcoming picky eating (COPE) - A cluster randomised controlled trial.,"OBJECTIVES Food neophobia limits dietary variety in children and adults. Interventions to alleviate the impact of neophobia on children's dietary variety have had varying success. The potential effectiveness of mindfulness, a process of bringing awareness to the present moment, has received little attention. This trial aimed to explore the effectiveness of two mindfulness exercises on novel food acceptance for children. METHODS A cluster-randomised controlled trial with three trial arms compared the impact of two mindfulness exercises (mindful breathing and mindful raisin-eating) and a non-mindful control task on anticipated liking and intake of a novel fruit. Seventy-one children aged 10-12 years engaged in one of the three tasks at school over five days and were offered a novel fruit at the end of the intervention. Children self-reported mindfulness, food neophobia and anxiety at baseline and follow-up. RESULTS Two mixed-effects models showed that, controlling for school effects and covariates (including mindfulness, food neophobia and anxiety), children in the mindful raisin-eating arm reported greater anticipated liking of a novel fruit and children in both mindfulness arms consumed greater amounts of a novel fruit than children in the control arm. Mixed-design ANOVAs indicated that mindfulness, food neophobia and anxiety did not change over time in each trial arm. CONCLUSIONS The results provide promising evidence for the potential effectiveness of mindfulness interventions in encouraging children to try new foods. The mechanisms underlying effectiveness remain unclear and further research, exploring long-term effects and the possibility to generalise these findings to other food groups such as vegetables, is needed.",2020,"Mixed-design ANOVAs indicated that mindfulness, food neophobia and anxiety did not change over time in each trial arm. ","['children and adults', 'Children overcoming picky eating (COPE) ', 'Seventy-one children aged 10-12 years engaged in one of the three tasks at school over five days and were offered a novel fruit at the end of the intervention', 'children']","['mindfulness exercises (mindful breathing and mindful raisin-eating) and a non-mindful control task', 'mindfulness exercises']","['school effects and covariates (including mindfulness, food neophobia and anxiety', 'mindfulness, food neophobia and anxiety', 'Children self-reported mindfulness, food neophobia and anxiety']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0450389', 'cui_str': '71'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0453310', 'cui_str': 'Raisins'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C3840121', 'cui_str': 'Avoidant restrictive food intake disorder'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}]",71.0,0.0797824,"Mixed-design ANOVAs indicated that mindfulness, food neophobia and anxiety did not change over time in each trial arm. ","[{'ForeName': 'Carmel', 'Initials': 'C', 'LastName': 'Bennett', 'Affiliation': 'Birmingham and Solihull Mental Health NHS Foundation Trust, UK. Electronic address: carmelbennett@nhs.net.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Copello', 'Affiliation': 'Birmingham and Solihull Mental Health NHS Foundation Trust, UK; School of Psychology, University of Birmingham, UK.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Jones', 'Affiliation': 'School of Psychology, University of Birmingham, UK.'}, {'ForeName': 'Jackie', 'Initials': 'J', 'LastName': 'Blissett', 'Affiliation': 'Department of Psychology, School of Life and Health Sciences, Aston University, UK.'}]",Appetite,['10.1016/j.appet.2020.104791'] 1698,32659365,Interlaminar stabilization for spinal stenosis in theMedicare population.,"BACKGROUND CONTEXT The number of complex fusions performed on Medicare beneficiaries, defined as ≥age 65, with lumbar spinal stenosis with or without spondylolisthesis has been increasing. Typically, these procedures are longer, more invasive and pose a greater risk for complications. Interlaminar stabilization (ILS) serves as an intermediary between decompression alone and decompression with fusion. PURPOSE The purpose of this study was to prospectively examine the efficacy of ILS in patients ≥age 65 through comparison to fusion in the same age group and ILS in younger patients. STUDY DESIGN/SETTING A prospective, multicentered, randomized controlled trial comparing decompression with ILS to decompression with posterolateral fusion with bilateral pedicle screw instrumentation. PATIENT SAMPLE Patients from 21 sites in the United States underwent surgery for moderate stenosis with up to a grade 1 degenerative spondylolisthesis and failure of conservative treatment with low back pain at 1 or 2 contiguous levels from L1-L5. Preoperatively, patient-reported assessment had to meet the criteria of significant pain and disability (Visual Analog Scale [VAS back pain] ≥50 mm on a 100 mm scale; Oswestry Disability Index [ODI] of ≥20/50). OUTCOME MEASURES The primary outcome was overall Composite Clinical Success (CCS) as determined by ODI scores, incidence of postoperative epidural injections and/or reoperations, incidence of device-related complications, and persistent or progressive neurological deficit. Secondary outcomes included patient satisfaction as measured by VAS for back and worse leg pain and Zurich Claudication Questionnaire scores. Narcotic usage data and radiographic assessment of changes in postoperative posterior disc height and foraminal height were also evaluated. METHODS At 1- or 2-levels, 84 patients ≥age 65 underwent decompression with ILS, 57 patients ≥age 65 underwent decompression with fusion, and 131 patients 0.05). Internal load was significantly lower in the HIGH group ( p = 0.017) regarding LOW and MED by Mann Whitney u test. A significantly lower change during the study in ABK JT ( p = 0.038), ABK H ( p = 0.038) HST 1RM ( p = 0.041) and in terms of fatigue ( p = 0.018) and lactate ( p = 0.012) within the aerobic power-capacity test was presented in HIGH relative to LOW and MED. CONCLUSIONS 120 g/h CHO intake during a mountain marathon might limit neuromuscular fatigue and improve recovery of high intensity run capacity 24 h after a physiologically challenging event when compared to 90 g/h and 60 g/h.",2020,Internal load was significantly lower in the HIGH group ( p = 0.017) regarding LOW and MED by Mann Whitney u test.,['Twenty-six elite trail-runners'],[],"['Abalakov jump time (ABK JT ', 'fatigue', 'Abalakov jump height (ABK H ), half-squat test 1 repetition maximum (HST 1RM ', 'Wilcoxon signed rank test only in LOW and MED', 'ABK H ', 'Internal load', 'Neuromuscular Function and High Intensity Run Capacity Recovery']","[{'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}]",[],"[{'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0667477', 'cui_str': 'TNFRSF11A protein, human'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",,0.0286564,Internal load was significantly lower in the HIGH group ( p = 0.017) regarding LOW and MED by Mann Whitney u test.,"[{'ForeName': 'Aritz', 'Initials': 'A', 'LastName': 'Urdampilleta', 'Affiliation': 'Centro Investigación y Formación ElikaSport, Cerdanyola del Valles, 08290 Barcelona, Spain.'}, {'ForeName': 'Soledad', 'Initials': 'S', 'LastName': 'Arribalzaga', 'Affiliation': 'Institute of Biomedicine (IBIOMED), Physiotherapy Department, University of Leon, Campus de Vegazana, 24071 Leon, Spain.'}, {'ForeName': 'Aitor', 'Initials': 'A', 'LastName': 'Viribay', 'Affiliation': 'Glut4Science, Physiology, Nutrition and Sport, 01004 Vitoria-Gasteiz, Spain.'}, {'ForeName': 'Arkaitz', 'Initials': 'A', 'LastName': 'Castañeda-Babarro', 'Affiliation': 'Health, Physical Activity and Sports Science Laboratory, Department of Physical Activity and Sports, Faculty of Psychology and Education, University of Deusto, 48007 Bizkaia, Spain.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Seco-Calvo', 'Affiliation': 'Institute of Biomedicine (IBIOMED), Physiotherapy Department, University of Leon, Researcher at the Basque Country University, Campus de Vegazana, 24071 Leon, Spain.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Mielgo-Ayuso', 'Affiliation': 'Department of Biochemistry, Molecular Biology and Physiology, Faculty of Health Sciences, University of Valladolid, 42004 Soria, Spain.'}]",Nutrients,['10.3390/nu12072094'] 1706,32679839,Effect of Viewing Video Representation of the Urban Environment and Forest Environment on Mood and Level of Procrastination.,"A common problem among students is the problem of delaying important work activities, which is conceptualized as procrastination. Since procrastination can cause considerable costs for society, we would like to find a method to effectively alleviate the symptoms of this conditioning. It has been proven in an earlier study that staying in the forest environment increases vitality and reduces anxiety, and the negative state of these features can be associated with the intensification of procrastination symptoms. Therefore, it is likely that watching a forest video may decrease the probability or intensity of procrastination. To measure the impact of the forest environment on the level of procrastination of the subjects, a randomized experiment was carried out, in which the subjects watched in random order (on different days) one of two 15-min videos: one showing a walk in the forest area and one showing a walk in an urban environment (control). We measured the level of so-called 'fluid procrastination' including three aspects: 'lack of energy to do the work', 'inability to get to work' and 'pessimistic attitude to do the work' with a set of questions the respondents completed before and after the experiment. The results showed that one aspect of fluid procrastination ('pessimistic attitude to do the work') can be effectively lowered by watching a video showing the forest environment. In contrast, watching a video of an urban environment increased the procrastination levels for two other aspects of procrastination ('lack of energy to do the work', 'inability to get to work'). We also measured three other parameters before and after the experiment: mood state, restoration and vitality. Watching the video from forest area raised mood and restoration and watching the video from urban area, decreased mood, vitality and restoration. The study suggests that watching a video showing forest landscapes could be used as an effective remedy for problems related to procrastination among students.",2020,"Watching the video from forest area raised mood and restoration and watching the video from urban area, decreased mood, vitality and restoration.",[],"['Viewing Video Representation of the Urban Environment and Forest Environment', '15-min videos: one showing a walk in the forest area and one showing a walk in an urban environment (control']","['Mood and Level of Procrastination', 'mood state, restoration and vitality']",[],"[{'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0086312', 'cui_str': 'Forest'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0871142', 'cui_str': 'Procrastination'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}]",,0.0230505,"Watching the video from forest area raised mood and restoration and watching the video from urban area, decreased mood, vitality and restoration.","[{'ForeName': 'Ernest', 'Initials': 'E', 'LastName': 'Bielinis', 'Affiliation': 'Department of Forestry and Forest Ecology, Faculty of Environmental Management and Agriculture, University of Warmia and Mazury, Pl. Łódzki 2, 10-727 Olsztyn, Poland.'}, {'ForeName': 'Jenni', 'Initials': 'J', 'LastName': 'Simkin', 'Affiliation': 'Natural Resources Institute Finland, Latokartanonkaari 9, 00790 Helsinki, Finland.'}, {'ForeName': 'Pasi', 'Initials': 'P', 'LastName': 'Puttonen', 'Affiliation': 'Department of Forest Sciences, University of Helsinki, Latokartanonkaari 7, 00014 Helsinki, Finland.'}, {'ForeName': 'Liisa', 'Initials': 'L', 'LastName': 'Tyrväinen', 'Affiliation': 'Natural Resources Institute Finland, Latokartanonkaari 9, 00790 Helsinki, Finland.'}]",International journal of environmental research and public health,['10.3390/ijerph17145109'] 1707,32682049,"Employee perseverance in a ""no phone use while driving"" organizational road-safety intervention.","INTRODUCTION This interdisciplinary study explores factors that contribute to the perseverance of participants in an organizational ""no phone use while driving"" road-safety intervention. METHOD The study sample comprised 200 employees (mean age 43 years; 104 females [52 %], 96 males [48 %]) from 8 organizations in Israel. Subjects completed a 4-month organizational intervention using a smartphone application that monitored smartphone use, operationalized as taps per minute, where each tap represents a single instance of contact with the screen (e.g., touching, tapping or swiping). The app also silenced notifications during the intervention stage. Changes over time in tapping-while-driving behavior were examined through self-report questionnaires and objectively through the application's monitoring function. Validated measures were used to examine factors associated with perseverance in the program. RESULTS Organizational safety climate and gender (male) were positively related to perseverance in the intervention. Contrary to our hypothesis, safety motivation was not found to influence perseverance. CONCLUSIONS The present intervention is most effective for employees with high safety climate perceptions and for male employees. PRACTICAL APPLICATIONS The organizational intervention presented in the current study was shown to be effective in reducing smartphone use (touching, tapping or swiping) while driving. Our findings show that people will download and use an app that actively reduces their incentive to use their phones at the wheel by silencing incoming notifications. The findings support calls to harness the positive potential of information and communications technologies for organizational interventions.",2020,"The organizational intervention presented in the current study was shown to be effective in reducing smartphone use (touching, tapping or swiping) while driving.","['employees with high safety climate perceptions and for male employees', '200 employees (mean age 43 years; 104 females [52 %], 96 males [48 %]) from 8 organizations in Israel']",[],['safety motivation'],"[{'cui': 'C0599987', 'cui_str': 'Employee'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0008946', 'cui_str': 'Climate'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0022271', 'cui_str': 'Israel'}]",[],"[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}]",200.0,0.0146053,"The organizational intervention presented in the current study was shown to be effective in reducing smartphone use (touching, tapping or swiping) while driving.","[{'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Rispler', 'Affiliation': 'Faculty of Welfare and Health Sciences, Department of Human Services, University of Haifa, Mount Carmel, Haifa, 31905, Israel. Electronic address: clararispler5510@gmail.com.'}, {'ForeName': 'Gil', 'Initials': 'G', 'LastName': 'Luria', 'Affiliation': 'Faculty of Welfare and Health Sciences, Department of Human Services, University of Haifa, Mount Carmel, Haifa, 31905, Israel. Electronic address: gluria@univ.haifa.ac.il.'}]",Accident; analysis and prevention,['10.1016/j.aap.2020.105689'] 1708,32688143,"The effects of multidisciplinary rehabilitation on neuroimaging, biological, cognitive and motor outcomes in individuals with premanifest Huntington's disease.","BACKGROUND Huntington's disease (HD) is a chronic, progressive neurodegenerative condition for which there are currently no proven disease-modifying therapies. Lifestyle factors have been shown to impact on the age of disease onset and progression of disease features. We therefore investigated the effects of a nine-month multidisciplinary rehabilitation intervention on neuroimaging, biological and clinical disease outcomes in individuals with premanifest HD. METHODS 31 individuals with premanifest HD participated in the study. Eighteen participants underwent a nine-month multidisciplinary rehabilitation intervention comprising aerobic and resistance exercise, computerised cognitive training, dual-task training and sleep hygiene and nutritional guidance. The remaining 13 participants were allocated to a standard care control group. Neuroimaging, biological, cognitive, motor and cardiorespiratory fitness data was collected. RESULTS Participants displayed good adherence (87%) and compliance (85%) to the intervention. Maintenance of the shape of the right putamen was observed in the intervention group when compared to the control group. The intervention group displayed significant improvements in verbal learning and memory, attention, cognitive flexibility and processing speed following the intervention when compared to the control group. Performance on the mini-social cognition and emotional assessment (mini-SEA) was maintained in the intervention group, but decreased in the control group. No changes were observed in serum neurofilament light protein levels, postural stability outcomes or cardiorespiratory fitness. CONCLUSION This study adds to the accumulating body of literature to suggest that multidisciplinary rehabilitation is of clinical benefit for individuals with HD. Large randomised controlled trials are necessary to determine the extent to which benefits occur across the spectrum of the disease.",2020,"The intervention group displayed significant improvements in verbal learning and memory, attention, cognitive flexibility and processing speed following the intervention when compared to the control group.","['individuals with HD', 'individuals with premanifest HD', '31 individuals with premanifest HD participated in the study', ""individuals with premanifest Huntington's disease"", 'Eighteen participants underwent a nine-month']","['nine-month multidisciplinary rehabilitation intervention', 'multidisciplinary rehabilitation', 'multidisciplinary rehabilitation intervention comprising aerobic and resistance exercise, computerised cognitive training, dual-task training and sleep hygiene and nutritional guidance', 'standard care control group']","['serum neurofilament light protein levels, postural stability outcomes or cardiorespiratory fitness', 'mini-social cognition and emotional assessment (mini-SEA', 'good adherence', 'neuroimaging, biological, cognitive and motor outcomes', 'verbal learning and memory, attention, cognitive flexibility and processing speed']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0020179', 'cui_str': ""Huntington's chorea""}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4277672', 'cui_str': 'Good Sleep Habits'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0027834', 'cui_str': 'Neurofilaments'}, {'cui': 'C0670902', 'cui_str': 'LIGHT Protein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0042531', 'cui_str': 'Verbal learning'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0582591', 'cui_str': 'Processing speed'}]",18.0,0.0225136,"The intervention group displayed significant improvements in verbal learning and memory, attention, cognitive flexibility and processing speed following the intervention when compared to the control group.","[{'ForeName': 'Danielle M', 'Initials': 'DM', 'LastName': 'Bartlett', 'Affiliation': 'School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Govus', 'Affiliation': 'School of Allied Health, Human Services & Sport, Department of Dietetics, Nutrition and Sport, La Trobe University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Rankin', 'Affiliation': 'School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia; Centre for Sleep Science, School of Human Sciences, Faculty of Science, University of Western Australia, Crawley, Western Australia, Australia.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Lampit', 'Affiliation': 'Department of Psychiatry, University of Melbourne, Victoria, Australia; Department of Neurology, Charité - Universitätsmedizin Berlin, Germany.'}, {'ForeName': 'Kirk', 'Initials': 'K', 'LastName': 'Feindel', 'Affiliation': 'Centre for Microscopy, Characterisation and Analysis, University of Western Australia, Australia.'}, {'ForeName': 'Govinda', 'Initials': 'G', 'LastName': 'Poudel', 'Affiliation': 'Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.'}, {'ForeName': 'Wei-Peng', 'Initials': 'WP', 'LastName': 'Teo', 'Affiliation': 'National Institute of Education, Nanyang Technological University, Singapore.'}, {'ForeName': 'Johnny', 'Initials': 'J', 'LastName': 'Lo', 'Affiliation': 'School of Science, Edith Cowan University, Joondalup, Western Australia, Australia.'}, {'ForeName': 'Nellie', 'Initials': 'N', 'LastName': 'Georgiou-Karistianis', 'Affiliation': 'School of Psychological Sciences, The Turner Institute of Brain and Mental Health, Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'Mel R', 'Initials': 'MR', 'LastName': 'Ziman', 'Affiliation': 'School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia; School of Biomedical Science, University of Western Australia, Crawley, Western Australia, Australia.'}, {'ForeName': 'Travis M', 'Initials': 'TM', 'LastName': 'Cruickshank', 'Affiliation': 'School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia; Exercise Medicine Research Institute, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; Perron Institute for Neurological and Translational Science, Perth, Western Australia, Australia. Electronic address: t.cruickshank@ecu.edu.au.'}]",Journal of the neurological sciences,['10.1016/j.jns.2020.117022'] 1709,32688208,PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery.,"BACKGROUND Enhanced recovery after surgery (ERAS) programs include multiple perioperative elements designed to achieve early recovery after surgery and a shorter length of stay (LOS) in hospital. The PROFAST trial aimed to expand the evidence base for implementing ERAS in advanced gynaecologic oncology surgery. METHODS This prospective, interventional randomised clinical trial enrolled women undergoing surgery for either suspected or diagnosed advanced ovarian cancer, at a reference hospital in gynaecologic oncology in Barcelona (Spain) and who were treated after either an ERAS protocol or conventional management (CM) protocol. All enrolled women who underwent cytoreductive surgery were included in the primary analysis. The primary outcome was reduction in LOS, and secondary outcomes were incidence and type of intraoperative and postoperative complications, rate of readmission and mortality within a 30-d follow-up period. This trial is registered at ClinicalTrials.gov, number NCT02172638. FINDINGS From June 2014 to March 2018, 110 women were recruited, of which eleven were excluded. The ERAS group comprised 50 patients, and the CM group, 49 patients. Both groups were comparable with respect to baseline characteristics and complexity of the cytoreductive surgery, with an overall medium/high Aletti surgical complexity score of 7.4. Overall compliance to the ERAS protocol was 92%. As compared with the patients in the CM group, patients in the ERAS group had a decreased median of LOS of two days (7 versus 9 days; p = 0.0099) and a decreased rate of readmission (6% versus 20%, p = 0.0334). No further significant differences were detected with respect to incidence of intraoperative or postoperative complications, severe (Clavien-Dindo grade IIIB-IV) complications, Comprehensive Complication Index, reoperation during primary stay, or mortality. INTERPRETATION Patients with advanced ovarian cancer in the ERAS program had a decreased LOS and decreased rate of readmission as compared with those in CM, with no increased morbidity or mortality. This study provides important evidence for the benefits of ERAS management even for gynaecologic surgeries of medium/high complexity and suggests that ERAS should be a standard practice for cytoreductive surgeries for peritoneal carcinomatosis.",2020,"No further significant differences were detected with respect to incidence of intraoperative or postoperative complications, severe (Clavien-Dindo grade IIIB-IV) complications, Comprehensive Complication Index, reoperation during primary stay, or mortality. ","['Patients with advanced ovarian cancer', 'enrolled women undergoing surgery for either suspected or diagnosed advanced ovarian cancer, at a reference hospital in gynaecologic oncology in Barcelona (Spain) and who were treated after either an', 'All enrolled women who underwent cytoreductive surgery were included in the primary analysis', 'From June 2014 to March 2018, 110 women were recruited, of which eleven were excluded', 'advanced gynaecologic oncology surgery', 'highcomplexity advanced ovarian cancer surgery']","['PROFAST', 'ERAS', 'ERAS protocol or conventional management (CM) protocol']","['incidence of intraoperative or postoperative complications, severe (Clavien-Dindo grade IIIB-IV) complications, Comprehensive Complication Index, reoperation during primary stay, or mortality', 'incidence and type of intraoperative and postoperative complications, rate of readmission\xa0and mortality within a 30-d\xa0follow-up period', 'rate of readmission', 'morbidity or mortality', 'median of LOS', 'reduction in LOS', 'Overall compliance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0919267', 'cui_str': 'Neoplasm of ovary'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205480', 'cui_str': 'Gynecologic'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C3850079', 'cui_str': 'Cytoreductive surgery'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}]","[{'cui': 'C0381011', 'cui_str': 'ProFast'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}]",110.0,0.308005,"No further significant differences were detected with respect to incidence of intraoperative or postoperative complications, severe (Clavien-Dindo grade IIIB-IV) complications, Comprehensive Complication Index, reoperation during primary stay, or mortality. ","[{'ForeName': 'José Luis', 'Initials': 'JL', 'LastName': 'Sánchez-Iglesias', 'Affiliation': ""Gynecological Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain. Electronic address: jlsanig@yahoo.es.""}, {'ForeName': 'Melchor', 'Initials': 'M', 'LastName': 'Carbonell-Socias', 'Affiliation': ""Gynecological Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.""}, {'ForeName': 'Ma Assumpció', 'Initials': 'MA', 'LastName': 'Pérez-Benavente', 'Affiliation': ""Gynecological Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.""}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Monreal Clua', 'Affiliation': ""Gynecological Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.""}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Manrique-Muñoz', 'Affiliation': ""Unit of Anesthesiology and Resuscitation, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Manel', 'Initials': 'M', 'LastName': 'García Gorriz', 'Affiliation': ""Unit of Anesthesiology and Resuscitation, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Burgos-Peláez', 'Affiliation': ""Nutritional Support Unit, Endocrinology and Nutrition Service, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Hegoi', 'Initials': 'H', 'LastName': 'Segurola Gurrutxaga', 'Affiliation': ""Nutritional Support Unit, Endocrinology and Nutrition Service, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Mónica', 'Initials': 'M', 'LastName': 'Pamies Serrano', 'Affiliation': ""Nutritional Support Unit, Endocrinology and Nutrition Service, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Ma Del', 'Initials': 'MD', 'LastName': 'Pilar Gutiérrez-Barceló', 'Affiliation': ""Nutritional Support Unit, Endocrinology and Nutrition Service, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Serrano-Castro', 'Affiliation': ""Nursing Unit for Gynecologic Oncology and Breast Diseases, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Ma Teresa', 'Initials': 'MT', 'LastName': 'Balcells-Farré', 'Affiliation': ""Data and Innovation Department, Vall d'Hebron Hospital, Barcelona, Spain; Research Group of Healthcare System Management, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.""}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Pérez-Barragán', 'Affiliation': ""Data and Innovation Department, Vall d'Hebron Hospital, Barcelona, Spain; Research Group of Healthcare System Management, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.""}, {'ForeName': 'Axelle', 'Initials': 'A', 'LastName': 'Scaillet-Houberechts', 'Affiliation': ""Data and Innovation Department, Vall d'Hebron Hospital, Barcelona, Spain; Research Group of Healthcare System Management, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.""}, {'ForeName': 'Yolima', 'Initials': 'Y', 'LastName': 'Cossio-Gil', 'Affiliation': ""Data and Innovation Department, Vall d'Hebron Hospital, Barcelona, Spain; Research Group of Healthcare System Management, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.""}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Gil-Moreno', 'Affiliation': ""Gynecological Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Biomedical Research Group in Gynecology, Vall d'Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, CIBERONC, Barcelona, Spain. Electronic address: antonioimma@yahoo.es.""}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2020.06.011'] 1710,32654156,Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis.,"INTRODUCTION Hereditary transthyretin-mediated amyloidosis (hATTR) manifests as multisystem dysfunction, including progressive polyneuropathy. Inotersen, an antisense oligonucleotide, improved the course of neuropathic impairment in patients with hATTR in the pivotal NEURO-TTR study (NCT01737398). To determine inotersen's impact on symptoms and patients' neuropathy experience, we performed a post hoc analysis of the Neuropathy Symptoms and Change (NSC) score. METHODS Stage 1 or 2 hATTR patients were randomized to receive weekly subcutaneous inotersen or placebo for 65 weeks. NSC score was assessed at baseline and 35 and 66 weeks. RESULTS At 66 weeks, inotersen-treated patients had symptom stabilization as compared with worsening in patients receiving placebo, based on total NSC score. There were also improvements in the subdomains of muscle weakness, sensory, pain, and autonomic symptoms, and for various individual items. DISCUSSION Inotersen treatment stabilized neuropathy symptoms, including autonomic symptoms, in patients with hATTR according to NSC score. Thus, the NSC may be an effective measure to assess neuropathy progression and patients' neuropathy experience in clinical practice.",2020,"At 66 weeks, inotersen-treated patients experienced symptom stabilization versus worsening in patients receiving placebo in NSC total score; the subdomains of muscle weakness, sensory, pain, and autonomic symptoms; and for various individual items. ","['patients with hATTR based on the NSC score', 'Stage 1/2 hATTR patients', 'Hereditary Transthyretin Amyloidosis']","['subcutaneous inotersen or placebo', 'placebo']","['NSC score', 'Neuropathy Symptoms and Change (NSC) score', 'muscle weakness, sensory, pain, and autonomic symptoms', 'neuropathic impairment', 'Neuropathy Symptom and Change']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439660', 'cui_str': 'Hereditary'}, {'cui': 'C0032923', 'cui_str': 'Prealbumin'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0002726', 'cui_str': 'Amyloidosis'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0442874', 'cui_str': 'Neuropathy'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0580272', 'cui_str': '1/2'}, {'cui': 'C2751492', 'cui_str': 'Hereditary Amyloidosis, Transthyretin-Related'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C4731850', 'cui_str': 'inotersen'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0442874', 'cui_str': 'Neuropathy'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030552', 'cui_str': 'Paresis'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}]",,0.0554384,"At 66 weeks, inotersen-treated patients experienced symptom stabilization versus worsening in patients receiving placebo in NSC total score; the subdomains of muscle weakness, sensory, pain, and autonomic symptoms; and for various individual items. ","[{'ForeName': 'P James B', 'Initials': 'PJB', 'LastName': 'Dyck', 'Affiliation': 'Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Coelho', 'Affiliation': 'Department of Neurosciences, Centro Hospitalar do Porto, Porto, Portugal.'}, {'ForeName': 'Marcia', 'Initials': 'M', 'LastName': 'Waddington Cruz', 'Affiliation': 'Department of Neurology, Federal University of Rio de Janeiro, University Hospital, Rio de Janeiro, Brazil.'}, {'ForeName': 'Thomas H', 'Initials': 'TH', 'LastName': 'Brannagan', 'Affiliation': 'Department of Peripheral Neuropathy, Columbia University Medical Center, New York, New York, USA.'}, {'ForeName': 'Sami', 'Initials': 'S', 'LastName': 'Khella', 'Affiliation': 'Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Chafic', 'Initials': 'C', 'LastName': 'Karam', 'Affiliation': 'Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.'}, {'ForeName': 'John L', 'Initials': 'JL', 'LastName': 'Berk', 'Affiliation': 'Department of Medicine, Boston University, Boston, Massachusetts, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Polydefkis', 'Affiliation': 'Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA.'}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Kincaid', 'Affiliation': 'Department of Neurology, Indiana University, Indianapolis, Indiana, USA.'}, {'ForeName': 'Janice F', 'Initials': 'JF', 'LastName': 'Wiesman', 'Affiliation': 'Department of Neurology, New York University, New York, New York, USA.'}, {'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Litchy', 'Affiliation': 'Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'Michelle L', 'Initials': 'ML', 'LastName': 'Mauermann', 'Affiliation': 'Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'Elizabeth J', 'Initials': 'EJ', 'LastName': 'Ackermann', 'Affiliation': 'Otonomy, Inc, San Diego, California, USA.'}, {'ForeName': 'Brenda F', 'Initials': 'BF', 'LastName': 'Baker', 'Affiliation': 'Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.'}, {'ForeName': 'Shiangtung W', 'Initials': 'SW', 'LastName': 'Jung', 'Affiliation': 'Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.'}, {'ForeName': 'Spencer', 'Initials': 'S', 'LastName': 'Guthrie', 'Affiliation': 'Aurora Bio, San Francisco, California, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Pollock', 'Affiliation': 'Akcea Therapeutics, Inc., Boston, Massachusetts, USA.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Dyck', 'Affiliation': 'Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.'}]",Muscle & nerve,['10.1002/mus.27023'] 1711,32654257,Improving Follow-up Attendance for Discharged Emergency Care Patients Using Automated Phone System to Self-schedule: A Randomized Controlled Trial.,"BACKGROUND Automated phone appointment reminders have improved adherence with follow-up appointments in a variety of hospital settings, but have mixed results in patients discharged from the emergency department (ED). Increasing adherence to follow-up care has been a priority in the ED to improve patient outcomes and reduce unnecessary future visits. METHODS We conducted a prospective randomized open, blinded end-point (PROBE) trial of 278 adult patients discharged from the ED and referred to a provider for follow-up care. Participants in the intervention arm received a self-scheduling text or phone message that automatically connected them to their referral provider to schedule a follow-up appointment and sent them appointment reminders. Those in the control arm received standard-of-care written instructions to contact listed referral providers. The primary outcome was time to appointment. The secondary outcome was time to return visit to the ED. RESULTS The automated reminders increased the cumulative incidence of keeping the referral appointment after ED discharge (p < 0.001, Gray's test). Of participants randomized to the automated phone intervention, 49.3% (n = 74) kept their follow-up appointment versus 23.4% (n = 30) in the control arm, with a hazard ratio (HR) and 95% confidence interval (CI) over the duration of the study period of 2.4 (1.6 to 3.7; p < 0.001). In a sensitivity analysis using 30 days of follow-up data, 42.0% (n = 63) of participants randomized to the phone intervention kept their follow-up versus 21.1% (n = 27) in the control arm, with a HR (95% CI) of 2.2 (1.4 to 3.5; p < 0.001). There was no difference in ED revisits between the intervention and control group within 120 days postdischarge. CONCLUSIONS An automated self-scheduling phone system significantly improved follow-up adherence after ED discharge, but did not decrease ED revisits.",2020,"An automated self-scheduling phone system significantly improved follow-up adherence after ED discharge, but did not decrease ED revisits.","['278 adult patients discharged from the ED and referred to a provider for follow-up care', 'patients discharged from the emergency department (ED', 'Discharged Emergency Care Patients']",['self-scheduling text or phone message that automatically connected them to their referral provider to schedule a follow-up appointment and sent them appointment reminders'],"['cumulative incidence of keeping the referral appointment after ED discharge', 'time to return visit to the ED', 'ED revisits', 'time to appointment']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C3899107', 'cui_str': 'Follow-Up Care'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0013961', 'cui_str': 'Emergency medical services'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205539', 'cui_str': 'Scheduled - procedure status'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332156', 'cui_str': 'Return to'}]",278.0,0.137672,"An automated self-scheduling phone system significantly improved follow-up adherence after ED discharge, but did not decrease ED revisits.","[{'ForeName': 'Kyla L', 'Initials': 'KL', 'LastName': 'Bauer', 'Affiliation': 'From the, School of Medicine, Washington University, St. Louis, MO, USA.'}, {'ForeName': 'Omolade O', 'Initials': 'OO', 'LastName': 'Sogade', 'Affiliation': 'From the, School of Medicine, Washington University, St. Louis, MO, USA.'}, {'ForeName': 'Brian F', 'Initials': 'BF', 'LastName': 'Gage', 'Affiliation': 'General Medical Sciences, Washington University, St. Louis, MO, USA.'}, {'ForeName': 'Brent', 'Initials': 'B', 'LastName': 'Ruoff', 'Affiliation': 'and the, Department of Emergency Medicine, School of Medicine, Washington University, St. Louis, MO, USA.'}, {'ForeName': 'Lawrence M', 'Initials': 'LM', 'LastName': 'Lewis', 'Affiliation': 'and the, Department of Emergency Medicine, School of Medicine, Washington University, St. Louis, MO, USA.'}]",Academic emergency medicine : official journal of the Society for Academic Emergency Medicine,['10.1111/acem.14080'] 1712,32654362,Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study).,"OBJECTIVE To investigate the efficacy of alternating cycles of sunitinib and everolimus vs standard sequential treatment of sunitinib followed by everolimus in first-line metastatic renal cell carcinoma (mRCC), as alternating blockade of vascular endothelial growth factor receptor (VEGFR) and mammalian target of rapamycin (mTOR) pathways could potentially prevent the occurrence of resistance to anti-VEGFR therapy in mRCC. PATIENTS AND METHODS SUNRISES, a randomised open-label Phase II study, investigated the efficacy of alternating cycles of sunitinib and everolimus vs standard sequential treatment of sunitinib followed by everolimus upon progression. Treatment-naïve patients with clear-cell mRCC were included. Alternating treatment consisted on 12 weeks of sunitinib, followed by 12 weeks of everolimus. The primary endpoint was the progression-free survival (PFS) rate at 1 year. The secondary endpoints included the median PFS, overall survival (OS), response rate, and safety. RESULTS Accrual was low due to the advent of new-generation therapies, and the study was stopped prematurely. Only 41 patients out of the planned 102 patients were accrued, and randomised in a 2:1 ratio (15 patients to the control arm, 26 to the experimental arm). In all, 60.9% of patients had performance status (PS) 0 and 39% PS 1; 63% had a favourable prognostic risk profile, while 36% were intermediate risk. The primary endpoint was not met. The 1-year PFS rate was 49.7% (experimental arm) vs 84.62% (control arm; P = 0.11). There was a trend towards fewer Grade ≥3 adverse events with the alternating approach (50% vs 73.3%; P = 0.14). The median OS was similar in both treatment arms. The other secondary endpoints favoured the control arm. CONCLUSIONS The study failed to show any benefit of alternating cycles of sunitinib and everolimus in patients with mRCC. The alternating approach using an mTOR inhibitor does not seem to prevent the occurrence of resistance to VEGFR blockade.",2020,"PFS rate was 49.7% (experimental arm) versus 84.62% (control arm), p=0.11.","['41 patients out of the planned 102 patients', 'patients with mRCC', 'Treatment-naïve patients with clear-cell mRCC', 'first-line metastatic renal carcinoma (SUNRISES study', 'metastatic renal cell carcinoma (mRCC']","['everolimus', 'rapamycin (mTOR', 'sunitinib and everolimus']","['favourable prognostic risk profile', 'Median OS', 'median PFS, overall survival (OS), response rate and safety', 'progression-free survival (PFS) rate', 'adverse events', 'PFS rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C4721698', 'cui_str': 'Metastatic renal cell carcinoma'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C2931852', 'cui_str': 'Clear-cell metastatic renal cell carcinoma'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0919989', 'cui_str': 'Metastatic renal carcinoma'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0072980', 'cui_str': 'Sirolimus'}, {'cui': 'C0293060', 'cui_str': 'FKBP12-Rapamycin Associated Protein'}, {'cui': 'C1176020', 'cui_str': 'sunitinib'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",102.0,0.0702853,"PFS rate was 49.7% (experimental arm) versus 84.62% (control arm), p=0.11.","[{'ForeName': 'Alejo', 'Initials': 'A', 'LastName': 'Rodriguez-Vida', 'Affiliation': ""Hospital del Mar-Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.""}, {'ForeName': 'Aristotelis', 'Initials': 'A', 'LastName': 'Bamias', 'Affiliation': 'Department of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Emilio', 'Initials': 'E', 'LastName': 'Esteban', 'Affiliation': 'Hospital Central de Asturias, Oviedo, Spain.'}, {'ForeName': 'Maria Isabel', 'Initials': 'MI', 'LastName': 'Saez', 'Affiliation': 'UGCI of Medical Oncology, Hospitales Regional and Universitario Virgen de la Victoria, Málaga, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Lopez-Brea', 'Affiliation': 'Hospital Marqués de Valdecilla, Santander, Spain.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Castellano', 'Affiliation': 'Hospital 12 de Octubre, Madrid, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Caballero', 'Affiliation': 'Hospital General Universitario de Valencia, Valencia, Spain.'}, {'ForeName': 'Jose Luis', 'Initials': 'JL', 'LastName': 'Gonzalez-Larriba', 'Affiliation': 'Hospital Clínico San Carlos, Madrid, Spain.'}, {'ForeName': 'Emiliano', 'Initials': 'E', 'LastName': 'Calvo', 'Affiliation': 'START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Macia', 'Affiliation': 'Pivotal, Madrid, Spain.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Ravaud', 'Affiliation': 'Hôpital Saint André, Bordeaux University Hospital, Bordeaux, France.'}, {'ForeName': 'Joaquim', 'Initials': 'J', 'LastName': 'Bellmunt', 'Affiliation': ""Hospital del Mar-Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.""}]",BJU international,['10.1111/bju.15165'] 1713,32658765,Assessment of stress markers in restrained individuals following physical stress with and without sham CED activation.,"INTRODUCTION Law enforcement and pre-hospital care personnel often confront individuals who must be physically restrained. Many are under the influence of illicit substances, and law enforcement officers may need to use a controlled electrical device (CED) to gain control of the individual and they are often placed into the prone maximum restraint (PMR) position. These techniques have previously been evaluated for their physiologic effects. The purpose of this study was to investigate the psychological effects of anticipating and experiencing a sham CED activation in healthy human subjects who were exercised and restrained compared with no sham activation by assessing the differences in a panel of several known biomarkers of stress. METHODS We performed a randomized, crossover controlled human subject trial to study the stress associated with exercise, physical exhaustion, and restraint with and without an added psychological stress simulating the field use of a CED. Twenty five total subjects; each subject performed two different trials each consisting of a brief period of intense exercise on a treadmill to exhaustion followed by placement in the PMR with and without induced psychological stress. Blood samples were collected for analysis pre and post exercise, as well as 10 min after completion of the exercise. A panel of hormones and stress markers were measured. RESULTS We found no significant differences in any of the stress biomarkers measured between the two study groups. A trend towards higher levels of copeptin was measured in the sham CED activation arm. CONCLUSION During a brief period of intense exercise followed by the psychological stress of anticipated CED application, there did not appear to be statistically significant changes in the stress panel of biomarkers measured, only a trend towards significance for higher copeptin levels in the patients exposed to the psychological stress.",2020,We found no significant differences in any of the stress biomarkers measured between the two study groups.,"['healthy human subjects', 'Twenty five total subjects']",['intense exercise on a treadmill to exhaustion followed by placement in the PMR with and without induced psychological stress'],"['stress biomarkers', 'levels of copeptin']","[{'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0033422', 'cui_str': 'Prone body position'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0035260', 'cui_str': 'Physical restraint'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0038443', 'cui_str': 'Psychological Stress'}]","[{'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0056279', 'cui_str': 'copeptins'}]",25.0,0.0515782,We found no significant differences in any of the stress biomarkers measured between the two study groups.,"[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Sloane', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA. Electronic address: csloane@ucsd.edu.'}, {'ForeName': 'Deborah C', 'Initials': 'DC', 'LastName': 'Mash', 'Affiliation': 'Department of Neurology, Molecular and Cellular Pharmacology, University of Miami, Miami, FL, USA.'}, {'ForeName': 'Theodore C', 'Initials': 'TC', 'LastName': 'Chan', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA.'}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Kolkhorst', 'Affiliation': 'School of Exercise and Nutritional Sciences, San Diego State University San Diego, CA, USA.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Neuman', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA.'}, {'ForeName': 'Edward M', 'Initials': 'EM', 'LastName': 'Castillo', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Lasoff', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Wardi', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA; Division of Pulmonary, Critical Care, and Sleep Medicine, University of California, San Diego, San Diego, CA, USA.'}, {'ForeName': 'Xiaobin', 'Initials': 'X', 'LastName': 'Xie', 'Affiliation': 'Department of Neurology, Molecular and Cellular Pharmacology, University of Miami, Miami, FL, USA.'}, {'ForeName': 'Gary M', 'Initials': 'GM', 'LastName': 'Vilke', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA.'}]",Journal of forensic and legal medicine,['10.1016/j.jflm.2020.101982'] 1714,32658797,Addition of dexmedetomidine to ropivacaine for local infiltration anaesthesia improves analgesic efficacy after tonsillectomy and adenoidectomy: A randomized controlled trial.,"OBJECTIVES The aim of this study was to determine whether the addition of dexmedetomidine to ropivacaine for local infiltration anaesthesia was more effective than ropivacaine alone in attenuating pain after tonsillectomy and adenoidectomy. METHODS This was a double-blind randomized clinical trial. One hundred and twenty children scheduled for tonsillectomy and adenoidectomy using a combination of general anaesthesia and local infiltration anaesthesia were randomized into the dexmedetomidine plus ropivacaine group (DR) and ropivacaine group (R). The children were locally infiltrated with 1 μg kg -1 dexmedetomidine and 0.25% ropivacaine in the DR group or 0.25% ropivacaine alone in the R group. In both groups, local infiltration anaesthesia was performed using 5 ml of solution. The pain scores were recorded at the 1st, 4th, 8th, 12th, 16th, 20th, and 24th hours after surgery using the Face Legs Activity Cry Consolability (FLACC) scale. When the pain score exceeded 4, paracetamol syrup (15 mg kg -1 ) was administered as a rescue analgesic. Time to the first administration of analgesic was recorded. RESULTS 8th, 16th, 20th, and 24th hours after surgery, the children in the DR group had lower pain scores than those in the R group (P<0.05). The time to the first administration of analgesic was significantly longer in the DR group (mean: 10.4 h, range: 9.4-11.4 h) than in the R group (mean: 8.1 h, range: 7.3-8.8 h) (P < 0.001). CONCLUSION The addition of dexmedetomidine to ropivacaine for local infiltration anaesthesia effectively improved the efficacy of analgesia and extended the duration of analgesia after tonsillectomy and adenoidectomy.",2020,The addition of dexmedetomidine to ropivacaine for local infiltration anaesthesia effectively improved the efficacy of analgesia and extended the duration of analgesia after tonsillectomy and adenoidectomy.,['One hundred and twenty children scheduled for tonsillectomy and adenoidectomy using a combination of general anaesthesia and local infiltration anaesthesia'],"['dexmedetomidine plus ropivacaine', 'tonsillectomy and adenoidectomy', 'ropivacaine', 'paracetamol syrup', 'dexmedetomidine']","['pain scores', 'Face Legs Activity Cry Consolability (FLACC) scale', 'efficacy of analgesia and extended the duration of analgesia', 'time to the first administration of analgesic', 'analgesic efficacy', 'pain', 'pain score', 'lower pain scores']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0193959', 'cui_str': 'Tonsillectomy and adenoidectomy'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0198813', 'cui_str': 'Local anesthesia, by infiltration'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0193959', 'cui_str': 'Tonsillectomy and adenoidectomy'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0458173', 'cui_str': 'Syrup'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0010399', 'cui_str': 'Crying'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0262176', 'cui_str': 'Administration of analgesic'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205251', 'cui_str': 'Low'}]",120.0,0.171204,The addition of dexmedetomidine to ropivacaine for local infiltration anaesthesia effectively improved the efficacy of analgesia and extended the duration of analgesia after tonsillectomy and adenoidectomy.,"[{'ForeName': 'Jianhong', 'Initials': 'J', 'LastName': 'Hao', 'Affiliation': ""Department of Anesthesiology, HongHui Hospital, Xi'an JiaoTong University, Xi'an, China.""}, {'ForeName': 'Zanqing', 'Initials': 'Z', 'LastName': 'Wu', 'Affiliation': ""Department of Anesthesiology, HongHui Hospital, Xi'an JiaoTong University, Xi'an, China.""}, {'ForeName': 'Zhenguo', 'Initials': 'Z', 'LastName': 'Luo', 'Affiliation': ""Department of Anesthesiology, HongHui Hospital, Xi'an JiaoTong University, Xi'an, China.""}, {'ForeName': 'Buhuai', 'Initials': 'B', 'LastName': 'Dong', 'Affiliation': ""Department of Anesthesiology, HongHui Hospital, Xi'an JiaoTong University, Xi'an, China. Electronic address: dongbuhai@sina.com.""}]",International journal of pediatric otorhinolaryngology,['10.1016/j.ijporl.2020.110168'] 1715,32658817,Effects of family-focused therapy on suicidal ideation and behavior in youth at high risk for bipolar disorder.,"BACKGROUND Youth who are at clinical and familial risk for bipolar disorder (BD) often have significant suicidal ideation (SI). In a randomized trial, we examined whether family-focused therapy (FFT) is associated with reductions in SI and suicidal behaviors in high-risk youth. METHODS Participants (ages 9-17 years) met diagnostic criteria for unspecified BD or major depressive disorder with active mood symptoms and had at least one relative with BD type I or II. Participants were randomly allocated to 12 sessions in 4 months of FFT or 6 sessions in 4 months of psychoeducation (enhanced care, EC), with pharmacotherapy as needed. Clinician- and child-rated assessments of mood, suicidal thoughts and behaviors, and family conflict were obtained at baseline and 4-6 month intervals over 1-4 years. RESULTS Participants (N=127; mean 13.2±2.6 yrs., 82 female) were followed over an average of 105.9±64.0 weeks. Youth with high baseline levels of SI who received FFT had lower levels of (and fewer weeks with) SI at follow-up compared to youth with high baseline SI who received EC. Participants in FFT had longer intervals without suicidal behaviors than participants in EC. Youths' ratings of family conflict significantly mediated the effects of treatment on SI at follow-up. LIMITATIONS Family conflict was based on questionnaires rather than observer ratings of family interactions. CONCLUSIONS Family psychoeducation with skill training can be an effective deterrent to suicidal thoughts and behaviors in youth at high risk for BD. Reducing parent/offspring conflict should be a central objective of psychosocial interventions for high-risk youth with SI.",2020,"Youths' ratings of family conflict significantly mediated the effects of treatment on SI at follow-up. ","['Youth who are at clinical and familial risk for bipolar disorder (BD', 'youth at high risk for bipolar disorder', 'Participants (N=127; mean 13.2±2.6 yrs., 82 female', 'high-risk youth with SI', 'Participants (ages 9-17 years) met diagnostic criteria for unspecified BD or major depressive disorder with active mood symptoms and had at least one relative with BD type I or II', 'Youth with high baseline levels of SI who received']","['FFT or 6 sessions in 4 months of psychoeducation (enhanced care, EC', 'family-focused therapy', 'FFT', 'skill training', 'family-focused therapy (FFT']","['longer intervals without suicidal behaviors', 'SI and suicidal behaviors', 'mood, suicidal thoughts and behaviors, and family conflict', 'suicidal ideation and behavior']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C1760428', 'cui_str': 'Suicidal behavior'}, {'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0233542', 'cui_str': 'Family conflict'}]",127.0,0.111281,"Youths' ratings of family conflict significantly mediated the effects of treatment on SI at follow-up. ","[{'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Miklowitz', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Los Angeles (UCLA) School of Medicine, University of California, 760 Westwood Plaza Rm A8-256, Los Angeles, 90024-1759 CA, USA. Electronic address: dmiklowitz@mednet.ucla.edu.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Merranko', 'Affiliation': 'Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA.'}, {'ForeName': 'Marc J', 'Initials': 'MJ', 'LastName': 'Weintraub', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Los Angeles (UCLA) School of Medicine, University of California, 760 Westwood Plaza Rm A8-256, Los Angeles, 90024-1759 CA, USA.'}, {'ForeName': 'Patricia D', 'Initials': 'PD', 'LastName': 'Walshaw', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Los Angeles (UCLA) School of Medicine, University of California, 760 Westwood Plaza Rm A8-256, Los Angeles, 90024-1759 CA, USA.'}, {'ForeName': 'Manpreet K', 'Initials': 'MK', 'LastName': 'Singh', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Kiki D', 'Initials': 'KD', 'LastName': 'Chang', 'Affiliation': 'Private Practice, Menlo Park, CA, USA.'}, {'ForeName': 'Christopher D', 'Initials': 'CD', 'LastName': 'Schneck', 'Affiliation': 'Department of Psychiatry, University of Colorado Anschutz Medical Campus, Denver, CO, USA.'}]",Journal of affective disorders,['10.1016/j.jad.2020.06.015'] 1716,32659714,The effect of web-based training on life quality and spousal adjustment for women with breast cancer and their spouses.,"PURPOSE The aim of the study was to examine the effects of web-based training that was structured in line with Roy's Adaptation Model on the ""life quality"" of women with breast cancer, and on the ""spousal adjustment"" of women and their spouses. METHOD The study used a pretest-posttest, quasi-experimental controlled group design and 83 women with breast cancer and their spouses were enrolled. The data were collected at baseline and again three months later using the Functional Assessment of Cancer Therapy-breast cancer scale and the Dyadic Adjustment Scale as data collection tools. RESULTS The average scores of life quality and agreement between spouses in the web-based training group were higher than in the control group. More specifically, the physical well-being (p=0.002), emotional well-being (p<0.001), functional well-being (p=0.001), breast cancer module scores (p<0.001) and dyadic cohesion (p=0.003) and dyadic consensus (p<0.001) sub-dimension scores of the women in the intervention group were higher than those in the control group in the third month. Similarly, the third month mean score of dyadic consensus (p<0.001) and affectional expression (p=0.023) of the spouses in the intervention group were higher than those in the control group. CONCLUSIONS The web-based training programme that was prepared by nurses in line with Roy's Adaptation Model improved the life quality and couples' adjustment in women with breast cancer. Web-based training can be used to improve patient care outcomes because of the continuity of training for women and their spouses.",2020,"Similarly, the third month mean score of dyadic consensus (p<0.001) and affectional expression (p=0.023) of the spouses in the intervention group were higher than those in the control group. ","['women with breast cancer', '83 women with breast cancer and their spouses were enrolled', 'women with breast cancer, and on the ""spousal adjustment"" of women and their spouses', 'women with breast cancer and their spouses']",['web-based training'],"['dyadic consensus (p<0.001) sub-dimension scores', 'life quality and spousal adjustment', 'Functional Assessment of Cancer Therapy-breast cancer scale and the Dyadic Adjustment Scale', 'life quality', 'average scores of life quality', 'emotional well-being (p<0.001), functional well-being (p=0.001), breast cancer module scores (p<0.001) and dyadic cohesion', 'mean score of dyadic consensus (p<0.001) and affectional expression']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0162409', 'cui_str': 'Spouse'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0376298', 'cui_str': 'Consensus'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}]",83.0,0.0223756,"Similarly, the third month mean score of dyadic consensus (p<0.001) and affectional expression (p=0.023) of the spouses in the intervention group were higher than those in the control group. ","[{'ForeName': 'Saadet', 'Initials': 'S', 'LastName': 'Çömez', 'Affiliation': 'Mehmet Akif Ersoy University, Faculty of Health Sciences, Department of Nursing, Burdur, Turkey. Electronic address: saadet.andic@gmail.com.'}, {'ForeName': 'Özgül', 'Initials': 'Ö', 'LastName': 'Karayurt', 'Affiliation': 'Izmir University of Economics, Faculty of Health Sciences, Department of Nursing, Izmir, Turkey.'}]",European journal of oncology nursing : the official journal of European Oncology Nursing Society,['10.1016/j.ejon.2020.101758'] 1717,32659982,"Breakfast Consumption in Low-Income Hispanic Elementary School-Aged Children: Associations with Anthropometric, Metabolic, and Dietary Parameters.","Breakfast consumption is associated with lower obesity prevalence and cardiometabolic risk and higher dietary quality (DQ) in children. Low-income, Hispanic populations are disproportionately affected by obesity and cardiometabolic risks. This study examined the relationship between breakfast consumption groups (BCG) on anthropometric, metabolic, and dietary parameters in predominately low-income, Hispanic children from 16 Texas schools. Cross-sectional data were from TX Sprouts, a school-based gardening, nutrition, and cooking randomized controlled trial. Anthropometric measurements included height, weight, body mass index, body fat percent via bioelectrical impedance, waist circumference, and blood pressure. Metabolic parameters included fasting plasma glucose, insulin, glycated hemoglobin, cholesterol, and triglycerides. DQ and BCG were assessed via two 24-h dietary recalls. Multivariate multiple regression examined relationships between BCG and anthropometric, metabolic, and dietary parameters. This study included 671 students (mean age 9 years, 58% Hispanic, 54% female, 66% free/reduced lunch, 17% breakfast skippers). No relationships were observed between BCG and anthropometric or metabolic parameters. BCG had higher DQ; higher daily protein, total sugar, and added sugar intake; and lower daily fat intake. Skipping breakfast was associated with lower DQ; higher daily fat intake; and lower daily protein intake. Longitudinal research examining breakfast quality on cardiometabolic outcomes in low-income, Hispanic children is warranted.",2020,Breakfast consumption is associated with lower obesity prevalence and cardiometabolic risk and higher dietary quality (DQ) in children.,"['671 students (mean age 9 years, 58% Hispanic, 54% female, 66% free/reduced lunch, 17% breakfast skippers', 'predominately low-income, Hispanic children from 16 Texas schools', 'children', 'Low-Income Hispanic Elementary School-Aged Children', 'low-income, Hispanic children']","['breakfast consumption groups (BCG', 'Breakfast Consumption']","['lower obesity prevalence and cardiometabolic risk and higher dietary quality (DQ', 'anthropometric, metabolic, and dietary parameters', 'height, weight, body mass index, body fat percent via bioelectrical impedance, waist circumference, and blood pressure', 'BCG and anthropometric or metabolic parameters', 'DQ; higher daily protein, total sugar, and added sugar intake; and lower daily fat intake', 'DQ and BCG', 'fasting plasma glucose, insulin, glycated hemoglobin, cholesterol, and triglycerides']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C2697949', 'cui_str': 'Lunch'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0332251', 'cui_str': 'Predominate'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0039711', 'cui_str': 'Texas'}, {'cui': 'C0036375', 'cui_str': 'School'}]","[{'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0162536', 'cui_str': 'Biolectric Impedance'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0556234', 'cui_str': 'Sugar intake'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}]",671.0,0.0198321,Breakfast consumption is associated with lower obesity prevalence and cardiometabolic risk and higher dietary quality (DQ) in children.,"[{'ForeName': 'Matthew R', 'Initials': 'MR', 'LastName': 'Jeans', 'Affiliation': 'Department of Nutritional Sciences, The University of Texas at Austin, 200 W 24th Street, Stop A2700, Austin, TX 78712, USA.'}, {'ForeName': 'Fiona M', 'Initials': 'FM', 'LastName': 'Asigbee', 'Affiliation': 'Department of Nutritional Sciences, The University of Texas at Austin, 200 W 24th Street, Stop A2700, Austin, TX 78712, USA.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Landry', 'Affiliation': 'Department of Nutritional Sciences, The University of Texas at Austin, 200 W 24th Street, Stop A2700, Austin, TX 78712, USA.'}, {'ForeName': 'Sarvenaz', 'Initials': 'S', 'LastName': 'Vandyousefi', 'Affiliation': 'Department of Nutritional Sciences, The University of Texas at Austin, 200 W 24th Street, Stop A2700, Austin, TX 78712, USA.'}, {'ForeName': 'Reem', 'Initials': 'R', 'LastName': 'Ghaddar', 'Affiliation': 'Department of Nutritional Sciences, The University of Texas at Austin, 200 W 24th Street, Stop A2700, Austin, TX 78712, USA.'}, {'ForeName': 'Heather J', 'Initials': 'HJ', 'LastName': 'Leidy', 'Affiliation': 'Department of Nutritional Sciences, The University of Texas at Austin, 200 W 24th Street, Stop A2700, Austin, TX 78712, USA.'}, {'ForeName': 'Jaimie N', 'Initials': 'JN', 'LastName': 'Davis', 'Affiliation': 'Department of Nutritional Sciences, The University of Texas at Austin, 200 W 24th Street, Stop A2700, Austin, TX 78712, USA.'}]",Nutrients,['10.3390/nu12072038'] 1718,32660025,Targeting the Intestinal Microbiota to Prevent Type 2 Diabetes and Enhance the Effect of Metformin on Glycaemia: A Randomised Controlled Pilot Study.,"Early treatment may prevent or delay the onset of type 2 diabetes mellitus (T2DM) in individuals who are at high risk. Lifestyle interventions and the hypoglycemic drug metformin have been shown to reduce T2DM incidence. The effectiveness of such interventions may be enhanced by targeting environmental factors such as the intestinal microbiota, which has been proven to predict the response to lifestyle interventions and play a part in mediating the glucose-lowering effects of metformin. Shifts in the intestinal microbiota ""towards a more balanced state"" may promote glucose homeostasis by regulating short-chain fatty acids' production. This study aimed to investigate the safety and effect of a multi-strain probiotic on glycemic, inflammatory, and permeability markers in adults with prediabetes and early T2DM and to assess whether the probiotic can enhance metformin's effect on glycaemia. A randomised controlled pilot study was conducted in 60 adults with a BMI ≥ 25 kg/m 2 and with prediabetes or T2DM (within the previous 12 months). The participants were randomised to a multi-strain probiotic ( L. plantarum , L. bulgaricus , L. gasseri , B. breve , B. animalis sbsp. lactis , B. bifidum , S. thermophilus , and S. boulardii ) or placebo for 12 weeks. Analyses of the primary outcome (fasting plasma glucose) and secondary outcomes, including, but not limited to, circulating lipopolysaccharide, zonulin, and short chain fatty acids and a metagenomic analysis of the fecal microbiome were performed at baseline and 12 weeks post-intervention. The results showed no significant differences in the primary and secondary outcome measures between the probiotic and placebo group. An analysis of a subgroup of participants taking metformin showed a decrease in fasting plasma glucose, HbA1c, insulin resistance, and zonulin; an increase in plasma butyrate concentrations; and an enrichment of microbial butyrate-producing pathways in the probiotic group but not in the placebo group. Probiotics may act as an adjunctive to metformin by increasing the production of butyrate, which may consequently enhance glucose management.",2020,"Shifts in the intestinal microbiota ""towards a more balanced state"" may promote glucose homeostasis by regulating short-chain fatty acids' production.","['individuals who are at high risk', 'adults with prediabetes and early T2DM', '60 adults with a BMI ≥ 25 kg/m']","['multi-strain probiotic', 'Metformin', 'multi-strain probiotic ( L. plantarum , L. bulgaricus , L. gasseri , B. breve , B. animalis sbsp', 'metformin', 'T2DM', 'placebo']","['T2DM incidence', 'plasma butyrate concentrations', 'glycemic, inflammatory, and permeability markers', 'primary outcome (fasting plasma glucose) and secondary outcomes, including, but not limited to, circulating lipopolysaccharide, zonulin, and short chain fatty acids and a metagenomic analysis of the fecal microbiome', 'fasting plasma glucose, HbA1c, insulin resistance, and zonulin']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C1231534', 'cui_str': 'Curtobacterium plantarum'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0006521', 'cui_str': 'Butyrates'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0031164', 'cui_str': 'Permeability'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0023810', 'cui_str': 'Lipopolysaccharide'}, {'cui': 'C0914216', 'cui_str': 'zonulin'}, {'cui': 'C0015691', 'cui_str': 'Short chain fatty acid'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C1956108', 'cui_str': 'Microbiome'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}]",60.0,0.109416,"Shifts in the intestinal microbiota ""towards a more balanced state"" may promote glucose homeostasis by regulating short-chain fatty acids' production.","[{'ForeName': 'Talia', 'Initials': 'T', 'LastName': 'Palacios', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, Charles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Vitetta', 'Affiliation': 'Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Coulson', 'Affiliation': 'Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.'}, {'ForeName': 'Claire D', 'Initials': 'CD', 'LastName': 'Madigan', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, Charles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia.'}, {'ForeName': 'Yan Y', 'Initials': 'YY', 'LastName': 'Lam', 'Affiliation': 'Department of Biochemistry and Microbiology and New Jersey Institute for Food, Nutrition, and Health, School of Environmental and Biological Sciences, Rutgers University, New Brunswick, NJ 08901, USA.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Manuel', 'Affiliation': 'School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Briskey', 'Affiliation': 'School of Human Movement and Nutrition Sciences, Faculty of Health and Behavioural Sciences, University of Queensland, Brisbane, QLD 4072, Australia.'}, {'ForeName': 'Chelsea', 'Initials': 'C', 'LastName': 'Hendy', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, Charles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia.'}, {'ForeName': 'Ji-Nu', 'Initials': 'JN', 'LastName': 'Kim', 'Affiliation': 'Solarea Bio Inc., Cambridge, MA 02142, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Ishoey', 'Affiliation': 'Solarea Bio Inc., Cambridge, MA 02142, USA.'}, {'ForeName': 'Maria J', 'Initials': 'MJ', 'LastName': 'Soto-Giron', 'Affiliation': 'Solarea Bio Inc., Cambridge, MA 02142, USA.'}, {'ForeName': 'Eric M', 'Initials': 'EM', 'LastName': 'Schott', 'Affiliation': 'Solarea Bio Inc., Cambridge, MA 02142, USA.'}, {'ForeName': 'Gerardo', 'Initials': 'G', 'LastName': 'Toledo', 'Affiliation': 'Solarea Bio Inc., Cambridge, MA 02142, USA.'}, {'ForeName': 'Ian D', 'Initials': 'ID', 'LastName': 'Caterson', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, Charles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia.'}]",Nutrients,['10.3390/nu12072041'] 1719,32661682,"Within-group comparisons led to unsubstantiated conclusions in ""Low-phytate wholegrain bread instead of high-phytate wholegrain bread in a total diet context did not improve iron status of healthy Swedish females: a 12-week, randomized, parallel-design intervention Study"".",,2020,,['healthy Swedish females'],[],[],"[{'cui': 'C0038996', 'cui_str': 'Swedish language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",[],[],,0.027488,,"[{'ForeName': 'Colby J', 'Initials': 'CJ', 'LastName': 'Vorland', 'Affiliation': 'Department of Applied Health Science, Indiana University School of Public Health-Bloomington, Bloomington, IN, USA. cvorland@iu.edu.'}, {'ForeName': 'Luis M', 'Initials': 'LM', 'LastName': 'Mestre', 'Affiliation': 'Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, Bloomington, IN, USA.'}, {'ForeName': 'Sachintha S', 'Initials': 'SS', 'LastName': 'Mendis', 'Affiliation': 'Department of Agricultural and Resource Economics, Colorado State University, Fort Collins, CO, USA.'}, {'ForeName': 'Andrew W', 'Initials': 'AW', 'LastName': 'Brown', 'Affiliation': 'Department of Applied Health Science, Indiana University School of Public Health-Bloomington, Bloomington, IN, USA. awb1@iu.edu.'}]",European journal of nutrition,['10.1007/s00394-020-02287-0'] 1720,32667287,Argatroban Increased the Basal Vein Drainage and Improved Outcomes in Acute Paraventricular Ischemic Stroke Patients.,"BACKGROUND Since venous drainage in acute arterial ischemic stroke has not been thoroughly researched, we evaluate the effect of argatroban, a selective direct thrombin inhibitor, as a therapy to increase the rate of basal vein Rosenthal (BVR) drainage and improve patients' post-stroke outcomes. MATERIAL AND METHODS In this multicenter clinical trial, 60 eligible patients at 4.5 to 48 hours after the stroke onset were recruited. After being randomly allocated into 2 groups, they were treated with standard therapy either alone or with argatroban. RESULTS Compared to the contralateral brain hemisphere, the mean flow velocity (MFV) in BVR drainage was significantly reduced in the stroke-afflicted ipsilateral hemisphere. After treatment with argatroban for 7 days, the MFV from BVR of the ipsilateral hemisphere in the argatroban treated group was significantly increased when compared to the control group. At 90 days after the onset of stroke, the MFV of BVR in the ipsilateral hemisphere was similar in both groups. Compared with controls, the argatroban-treated patients had smaller lesions from baseline to 7 days. Argatroban also improved National Institutes of Health Stroke Scale (NIHSS) scores on day 7 after the onset of stroke. Furthermore, the argatroban group's neurological functions were superior to those of their untreated counterparts after 90 days. No difference was found in the incidence of adverse reactions between the 2 groups. CONCLUSIONS These observations indicate that vein drainage change may contribute to the acute phase of brain edema and the outcomes of ischemic stroke patients.",2020,"Furthermore, the argatroban group's neurological functions were superior to those of their untreated counterparts after 90 days.","['60 eligible patients at 4.5 to 48 hours after the stroke onset were recruited', 'Acute Paraventricular Ischemic Stroke Patients', 'acute arterial ischemic stroke']","['standard therapy either alone or with argatroban', 'argatroban', 'Argatroban']","['neurological functions', 'MFV from BVR of the ipsilateral hemisphere', 'MFV of BVR', 'National Institutes of Health Stroke Scale (NIHSS) scores', 'Basal Vein Drainage', 'incidence of adverse reactions', 'rate of basal vein Rosenthal (BVR) drainage', 'mean flow velocity (MFV) in BVR drainage']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3844009', 'cui_str': '4.5'}, {'cui': 'C0439586', 'cui_str': '48 hours'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}]","[{'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0048470', 'cui_str': 'argatroban'}]","[{'cui': 'C0027767', 'cui_str': 'Nervous system function'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0004789', 'cui_str': 'Structure of basal vein'}, {'cui': 'C0015523', 'cui_str': 'Hereditary factor XI deficiency disease'}, {'cui': 'C0441989', 'cui_str': 'Ipsilateral'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}]",60.0,0.0501248,"Furthermore, the argatroban group's neurological functions were superior to those of their untreated counterparts after 90 days.","[{'ForeName': 'Shoufeng', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'The Graduate School, Tianjin Medical University, Tianjin, China (mainland).'}, {'ForeName': 'Peipei', 'Initials': 'P', 'LastName': 'Liu', 'Affiliation': 'Department of Neurology, Tianjin Huanhu Hospital, Tianjin, China (mainland).'}, {'ForeName': 'Po', 'Initials': 'P', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, Baotou Central Hospital, Baotou, Inner Mongolia, China (mainland).'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Zhang', 'Affiliation': 'Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China (mainland).'}, {'ForeName': 'Lijun', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, Tianjin Fourth Central Hospital, Tianjin, China (mainland).'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Ultrasonography, Tianjin Huanhu Hospital, Tianjin, China (mainland).'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Lu', 'Affiliation': 'Department of Radiology, Tianjin Huanhu Hospital, Tianjin, China (mainland).'}, {'ForeName': 'Xiaofeng', 'Initials': 'X', 'LastName': 'Ma', 'Affiliation': 'Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China (mainland).'}]",Medical science monitor : international medical journal of experimental and clinical research,['10.12659/MSM.924593'] 1721,32667383,"Effectiveness of kinesio taping on postoperative morbidity after impacted mandibular third molar surgery: a prospective, randomized, placebo-controlled clinical study.","Objective Our study seeks to investigate the effectiveness of kinesio taping (KT) on postoperative morbidity compared to placebo and control groups after impacted third molar surgery. Methodology Sixty patients with impacted mandibular third molar were included in this prospective, randomized, placebo-controlled clinical study. After surgical extraction of the impacted tooth, patients were allocated into three groups (20 patients each): group 1 received KT (kinesio), group 2 received placebo taping (placebo), and group 3 received no taping (control). The groups were compared regarding facial swelling, pain and trismus. Swelling was evaluated using a tape measuring method. Pain was assessed by a visual analog scale and the number of analgesic tablets taken. Trismus was determined by measuring maximum mouth opening. Results In the KT group, all parameters reduced significantly on 2nd and 4th postoperative days compared to other groups; however, placebo and control groups revealed comparable outcomes. On 7th day, all groups showed comparable results. Conclusions The KT application is an effective method for reducing morbidity after impacted mandibular third molar surgery. However, placebo taping is not as effective as proper taping. Placebo taping shows similar results compared to no taping regarding facial swelling percentage, pain and trismus.",2020,"In the KT group, all parameters reduced significantly on 2nd and 4th postoperative days compared to other groups; however, placebo and control groups revealed comparable outcomes.","['after impacted mandibular third molar surgery', 'Methodology Sixty patients with impacted mandibular third molar', 'and control groups after impacted third molar surgery']","['kinesio taping (KT', 'Placebo', 'kinesio taping', 'placebo taping (placebo), and group 3 received no taping (control', 'KT (kinesio', 'placebo']","['visual analog scale and the number of analgesic tablets taken', 'Swelling', 'Pain', 'postoperative morbidity', 'facial swelling percentage, pain and trismus', 'morbidity', 'Trismus', 'facial swelling, pain and trismus']","[{'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026369', 'cui_str': 'Structure of wisdom tooth'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0969625', 'cui_str': 'methodology'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0041105', 'cui_str': 'Trismus'}, {'cui': 'C0151602', 'cui_str': 'Facial swelling'}]",60.0,0.249748,"In the KT group, all parameters reduced significantly on 2nd and 4th postoperative days compared to other groups; however, placebo and control groups revealed comparable outcomes.","[{'ForeName': 'Ufuk', 'Initials': 'U', 'LastName': 'Tatli', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, School of Dentistry, Cukurova University, Adana, Turkey.'}, {'ForeName': 'Ilke Coskun', 'Initials': 'IC', 'LastName': 'Benlidayi', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, School of Medicine, Cukurova University, Adana, Turkey.'}, {'ForeName': 'Fariz', 'Initials': 'F', 'LastName': 'Salimov', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, School of Dentistry, Cukurova University, Adana, Turkey.'}, {'ForeName': 'Rengin', 'Initials': 'R', 'LastName': 'Guzel', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, School of Medicine, Cukurova University, Adana, Turkey.'}]",Journal of applied oral science : revista FOB,['10.1590/1678-7757-2020-0159'] 1722,32663379,Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.,"BACKGROUND Pancreatic cancer patients are at risk for venous thromboembolism (VTE); the value of thromboprophylaxis has not been definitively established. METHODS This trial randomized cancer patients initiating a new regimen and at high risk for VTE (Khorana score ≥2) to rivaroxaban 10 mg or placebo up to day 180. This analysis examined the subset of pancreatic cancer patients. The primary efficacy endpoint was the composite of symptomatic deep-vein thrombosis (DVT), asymptomatic proximal DVT, any pulmonary embolism, and VTE-related death. The primary safety endpoint was International Society on Thrombosis and Haemostasis-defined major bleeding. RESULTS In total, 49/1080 (4.5%) patients enrolled had baseline VTE on screening, with higher rates (24/362 [6.6%]) in pancreatic cancer and they were not randomized. Of 841 randomized patients, 273 (32.5%) had pancreatic cancer; 155/273 (57% in each arm) completed the double-blind period. The primary endpoint occurred in 13/135 (9.6%) patients in the rivaroxaban group and in 18/138 (13.0%) in the placebo group (hazard ratio [HR] = 0.70; 95% CI, 0.34-1.43; P = .328) in up-to-day-180 period and 5/135 (3.7%) patients receiving rivaroxaban and 14/138 (10.1%) receiving placebo in the intervention period (HR = 0.35; 95% CI, 0.13-0.97; P = .034). Major bleeding was similar (2 [1.5%] receiving rivaroxaban and 3 [2.3%] receiving placebo). Correlative biomarker studies demonstrated significant decline in D-dimer (weeks 8 and 16) in patients randomized to rivaroxaban compared to placebo (P < .01). CONCLUSIONS In ambulatory pancreatic cancer patients, rivaroxaban did not result in significantly lower incidence of VTE or VTE-related death in the 180-day period. During the intervention period, however, rivaroxaban substantially reduced VTE without increasing major bleeding, suggesting benefit of rivaroxaban prophylaxis in this setting. TRIAL REGISTRATION ClinicalTrials.gov identifier, NCT02555878.",2020,"In ambulatory pancreatic cancer patients, rivaroxaban did not result in significantly lower incidence of VTE or VTE-related death in the 180-day period.","['ambulatory patients with pancreatic cancer', 'cancer patients initiating a new regimen and at high risk for VTE (Khorana score ≥2) to', 'Pancreatic cancer patients', 'pancreatic cancer patients', '841 randomized patients, 273 (32.5%) had pancreatic cancer; 155/273 (57% in each arm) completed the double-blind period', 'ambulatory pancreatic cancer patients']","['rivaroxaban 10 mg or placebo', 'placebo', 'Rivaroxaban thromboprophylaxis', 'rivaroxaban']","['composite of symptomatic deep-vein thrombosis (DVT), asymptomatic proximal DVT, any pulmonary embolism, and VTE-related death', 'Major bleeding', 'International Society on Thrombosis and Haemostasis-defined major bleeding', 'VTE or VTE-related death']","[{'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0235974', 'cui_str': 'Carcinoma of pancreas'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4517710', 'cui_str': '32.5'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}]","[{'cui': 'C3162455', 'cui_str': 'rivaroxaban 10 MG'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C3539106', 'cui_str': 'Defined'}]",841.0,0.591116,"In ambulatory pancreatic cancer patients, rivaroxaban did not result in significantly lower incidence of VTE or VTE-related death in the 180-day period.","[{'ForeName': 'Saroj', 'Initials': 'S', 'LastName': 'Vadhan-Raj', 'Affiliation': 'The UT MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Section of Cytokines and Supportive Oncology, Houston, TX, USA.'}, {'ForeName': 'Mairéad G', 'Initials': 'MG', 'LastName': 'McNamara', 'Affiliation': 'Department of Medical Oncology, The Christie NHS Foundation Trust & Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Marino', 'Initials': 'M', 'LastName': 'Venerito', 'Affiliation': 'Klinik für Gastroenterologie, Hepatologie und Infektiologie Universitätsklinikum, Magdeburg, Germany.'}, {'ForeName': 'Hanno', 'Initials': 'H', 'LastName': 'Riess', 'Affiliation': 'Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Eileen M', 'Initials': 'EM', 'LastName': ""O'Reilly"", 'Affiliation': 'Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Overman', 'Affiliation': 'The UT MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'The UT MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Section of Cytokines and Supportive Oncology, Houston, TX, USA.'}, {'ForeName': 'Ujjwala', 'Initials': 'U', 'LastName': 'Vijapurkar', 'Affiliation': 'Janssen Research & Development, LLC, Raritan, NJ, USA.'}, {'ForeName': 'Simrati', 'Initials': 'S', 'LastName': 'Kaul', 'Affiliation': 'Janssen Scientific Affairs, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Wildgoose', 'Affiliation': 'Janssen Scientific Affairs, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Alok A', 'Initials': 'AA', 'LastName': 'Khorana', 'Affiliation': 'Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.'}]",Cancer medicine,['10.1002/cam4.3269'] 1723,32664000,Depressive symptom severity mediates the association between avoidant problem-solving style and suicidal ideation.,"BACKGROUND The contemporaneous association between avoidant style, a maladaptive social problem-solving strategy, and adolescent suicidal ideation has been well established. However, the mechanisms underlying this association are not well understood. Using cross-lagged panel modeling, the present study examined whether depressive symptom severity mediates the relation between avoidant style and severity of suicidal ideation. The specificity of depressive symptom severity as a mediator was also evaluated by simultaneously testing whether avoidant style mediates the association between depressive symptom and suicidal ideation severity. METHODS The sample included 110 adolescents enrolled in a randomized controlled clinical effectiveness trial. Avoidant style as well as depressive symptom and suicidal ideation severity were assessed via self-report with the Social Problem-Solving Inventory-Revised, Children's Depression Scale-2, and Suicidal Ideation Questionnaire-Junior, respectively, at baseline, 3-and 6-months. RESULTS After accounting for participant age, sex, and treatment condition, path analyses supported the specificity of 3-month depressive symptom severity as a mediator of the association between baseline levels of avoidant style and 6-month suicidal ideation severity. LIMITATIONS Results may not be generalizable to non-clinical samples. Causality cannot be inferred from study results. Data were exclusively collected via self-report. CONCLUSIONS Findings suggest that avoidant style is indirectly related to suicidal ideation through depressive symptom severity. Thus, treatment targeted at improving social problem-solving skills, particularly avoidant style, may help reduce depressive symptoms and lower suicide risk.",2020,"After accounting for participant age, sex, and treatment condition, path analyses supported the specificity of 3-month depressive symptom severity as a mediator of the association between baseline levels of avoidant style and 6-month suicidal ideation severity. ",['110 adolescents enrolled'],[],"[""Social Problem-Solving Inventory-Revised, Children's Depression Scale-2, and Suicidal Ideation Questionnaire-Junior"", 'depressive symptom and suicidal ideation severity', 'avoidant style and 6-month suicidal ideation severity']","[{'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]",[],"[{'cui': 'C0037431', 'cui_str': 'Social problem'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0451069', 'cui_str': 'Child depression scale'}, {'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",110.0,0.0278102,"After accounting for participant age, sex, and treatment condition, path analyses supported the specificity of 3-month depressive symptom severity as a mediator of the association between baseline levels of avoidant style and 6-month suicidal ideation severity. ","[{'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'López', 'Affiliation': 'George Mason University, Department of Psychology. Electronic address: rlopez_jr@post.harvard.edu.'}, {'ForeName': 'Leslie A', 'Initials': 'LA', 'LastName': 'Brick', 'Affiliation': 'Alpert Medical School of Brown University, Department of Psychiatry and Human Behavior.'}, {'ForeName': 'Annamarie B', 'Initials': 'AB', 'LastName': 'Defayette', 'Affiliation': 'George Mason University, Department of Psychology.'}, {'ForeName': 'Emma D', 'Initials': 'ED', 'LastName': 'Whitmyre', 'Affiliation': 'George Mason University, Department of Psychology.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Wolff', 'Affiliation': 'Alpert Medical School of Brown University, Department of Psychiatry and Human Behavior.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Frazier', 'Affiliation': 'Alpert Medical School of Brown University, Department of Psychiatry and Human Behavior.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Spirito', 'Affiliation': 'Alpert Medical School of Brown University, Department of Psychiatry and Human Behavior.'}, {'ForeName': 'Christianne', 'Initials': 'C', 'LastName': 'Esposito-Smythers', 'Affiliation': 'George Mason University, Department of Psychology.'}]",Journal of affective disorders,['10.1016/j.jad.2020.05.120'] 1724,32664094,Effect of phenylephrine infusion on hypotension induced by the beach chair position: A prospective randomized trial.,"BACKGROUND The beach chair position (BCP), used during shoulder surgery, is associated with hypotension, bradycardia, and risk of cerebral hypoperfusion. Phenylephrine is commonly used as a first treatment of choice of intraoperative hypotension during surgery. We evaluated the hemodynamic effects of 2 doses of intravenous phenylephrine infusion administered before being placed in BCP for arthroscopic shoulder surgery. The primary endpoint was the incidence of hypotension after positional change. METHODS Sixty-six patients were randomized to receive either intravenous normal saline (group NS) or intravenous phenylephrine infusion (0.5 μg/kg/min, group LP or 1.0 μg/kg/min, group HP) for 5 minutes before being placed in the BCP. Mean arterial pressure(MAP), heart rate, stroke volume variation, and cardiac index were measured before and after positional change. RESULTS The total incidence of hypotension after the BCP was 93.65%, but was not significantly different among the 3 groups. However, there was a significant difference in trends between the groups for MAP for 5 minutes after BCP (P = .028). Comparison of changes in MAP at 1 minute compared to post-induction MAP was significantly different between group HP and group NS (P = .014). CONCLUSION Infusion of 0.5 and 1.0 μg/kg/min of phenylephrine for 5 minutes before the BCP has no preventive effect for incidence of hypotension. However, this study showed that 1.0 μg/kg/min of phenylephrine infusion for 5 minutes can attenuate the severity of hypotension.",2020,"Comparison of changes in MAP at 1 minute compared to post-induction MAP was significantly different between group HP and group NS (P = .014). ","['Sixty-six patients', 'arthroscopic shoulder surgery']","['phenylephrine', 'phenylephrine infusion', 'intravenous normal saline', 'Phenylephrine', 'intravenous phenylephrine infusion']","['Mean arterial pressure(MAP), heart rate, stroke volume variation, and cardiac index', 'incidence of hypotension after positional change', 'total incidence of hypotension', 'hemodynamic effects', 'hypotension', 'severity of hypotension']","[{'cui': 'C4517841', 'cui_str': '66'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0186321', 'cui_str': 'Operative procedure on shoulder'}]","[{'cui': 'C0031469', 'cui_str': 'Phenylephrine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0232108', 'cui_str': 'Arterial pulse pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C4518814', 'cui_str': 'Stroke volume variation'}, {'cui': 'C0428776', 'cui_str': 'Cardiac index'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",66.0,0.324466,"Comparison of changes in MAP at 1 minute compared to post-induction MAP was significantly different between group HP and group NS (P = .014). ","[{'ForeName': 'Myoung Jin', 'Initials': 'MJ', 'LastName': 'Ko', 'Affiliation': 'Department of Anesthesiology and Pain Medicine.'}, {'ForeName': 'Hyojoong', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine.'}, {'ForeName': 'Hyun-Seong', 'Initials': 'HS', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine.'}, {'ForeName': 'Soo Jee', 'Initials': 'SJ', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine.'}, {'ForeName': 'Yei Heum', 'Initials': 'YH', 'LastName': 'Park', 'Affiliation': 'Department of Anesthesiology and Pain Medicine.'}, {'ForeName': 'Jin-Young', 'Initials': 'JY', 'LastName': 'Bang', 'Affiliation': 'Department of Orthopedic Surgery, Haeundae Paik Hospital of Inje University, Busan, Republic of Korea.'}, {'ForeName': 'Ki Hwa', 'Initials': 'KH', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine.'}]",Medicine,['10.1097/MD.0000000000020946'] 1725,32664101,Randomized trial protocol of interscalene nerve block vs liposomal bupivacaine injection after total shoulder arthroplasty.,"BACKGROUND The possibility of local infiltration analgesia (LIA) replacing interscalene blockade (ISB) as an integral component of a multimodal clinical pathway for total shoulder arthroplasty (TSA) needs to be further investigated. We thus further designed a randomized controlled study to compare LIA with ISB in the treatment of TSA. METHODS This blinded and randomised study was performed after approval of the institutional review board in the first affiliated hospital of Jinan University. The included patients were all aged over 18 years and underwent shoulder arthroplasty because of osteoarthritis of the shoulder. Subjects were randomized into 2 groups as follows: LIA or ISB. The primary outcome of this noninferiority study is opioid consumption within the first 24 hours following surgery. Secondary outcomes included pain scores, length of hospital stay, complication, and satisfaction score. P value < .05 was considered statistically significant. RESULTS For the present trial, we hypothesized that there would be no difference in pain score levels and opioid medication use throughout admission. TRIAL REGISTRATION This study protocol was registered in Research Registry (researchregistry5640).",2020,"For the present trial, we hypothesized that there would be no difference in pain score levels and opioid medication use throughout admission. ","['total shoulder arthroplasty (TSA', 'The included patients were all aged over 18 years and underwent shoulder arthroplasty because of osteoarthritis of the shoulder', 'institutional review board in the first affiliated hospital of Jinan University', 'total shoulder arthroplasty']","['local infiltration analgesia (LIA) replacing interscalene blockade (ISB', 'LIA with ISB', 'LIA or ISB', 'interscalene nerve block vs liposomal bupivacaine injection']","['opioid consumption within the first 24\u200ahours following surgery', 'pain scores, length of hospital stay, complication, and satisfaction score', 'pain score levels']","[{'cui': 'C0186657', 'cui_str': 'Total shoulder replacement'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0186662', 'cui_str': 'Arthroplasty of shoulder'}, {'cui': 'C0409939', 'cui_str': 'Osteoarthritis of glenohumeral joint'}, {'cui': 'C0086911', 'cui_str': 'Ethics Committee, Research'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0559956', 'cui_str': 'Replacement - action'}, {'cui': 'C0589495', 'cui_str': 'Interscalene approach'}, {'cui': 'C0332206', 'cui_str': 'Blocking'}, {'cui': 'C0027741', 'cui_str': 'Nerve block'}, {'cui': 'C0023828', 'cui_str': 'Liposomes'}, {'cui': 'C4060211', 'cui_str': 'Bupivacaine Injection [Sensorcaine]'}]","[{'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.275289,"For the present trial, we hypothesized that there would be no difference in pain score levels and opioid medication use throughout admission. ","[{'ForeName': 'Jianbin', 'Initials': 'J', 'LastName': 'He', 'Affiliation': ""Department of Anesthesiology, The Second Clinical Medical College, Jinan University/Shenzhen People's Hospital.""}, {'ForeName': 'Yalan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, The first affiliated hospital of Jinan University, Guangdong Province, China.'}]",Medicine,['10.1097/MD.0000000000020968'] 1726,32664105,Feasibility of customizing titanium implant with three-dimensional CT imaging of low dose in skull.,"OBJECT To explore the feasibility and practicability of making virtual three-dimensional model of skull defect and customizing titanium implant by skull three-dimensional CT examination of low dose. METHODS Sixty patients with skull defects who underwent skull three-dimensional CT before cranioplasty were randomly divided into 4 groups: group A (conventional dose 120 peak Kilovoltage (kVp), 150 tube current time product (mAs)), low dose group B (120 kVp, 50 mAs), low dose group C (100 kVp, 50 mAs), low dose group D (100 kVp, 30 mAs). After the scanning, we compared radiation doses and image quality among the groups. The CT data were sent to the reconstruction company to produce accurate titanium implants, and neurosurgeons performed cranioplasty. After the operation, patients immediately underwent head CT scans to confirm the accuracy of the implantation position, and a series of clinical functions were evaluated. RESULTS There were significant differences in dose length product (DLP) and effective dose (ED) among the 4 groups (P < .001). The volume CT dose index (CDTIvol), DLP, and ED in group D were, respectively, 87.1%, 86.9%, and 87.3% lower than those in group A (P < .001). All images quality were at or above the general level, and there was no statistical difference (P > .05). Titanium implants were successfully manufactured, every cranioplasty was carried out smoothly, and the clinical function of patients recovered well. CONCLUSION Customizing titanium implant with three-dimensional CT imaging of low dose in skull not only met the clinical requirements, but also significantly reduced the radiation dose and hazard.",2020,"All images quality were at or above the general level, and there was no statistical difference (P > .05).",['Sixty patients with skull defects who underwent skull three-dimensional CT before cranioplasty'],"['customizing titanium implant', 'group A (conventional dose 120 peak Kilovoltage (kVp), 150 tube current time product (mAs', 'head CT scans']","['volume CT dose index (CDTIvol), DLP, and ED', 'dose length product (DLP) and effective dose (ED']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037303', 'cui_str': 'Bone structure of cranium'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C0196112', 'cui_str': 'Cranioplasty'}]","[{'cui': 'C0040302', 'cui_str': 'Titanium'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0025048', 'cui_str': 'Meconium aspiration syndrome'}, {'cui': 'C0202691', 'cui_str': 'CT of head'}]","[{'cui': 'C1956110', 'cui_str': 'Cone beam CT'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",60.0,0.0148684,"All images quality were at or above the general level, and there was no statistical difference (P > .05).","[{'ForeName': 'Min-Xia', 'Initials': 'MX', 'LastName': 'Yang', 'Affiliation': ""Department of Radiology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang Province, China.""}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Ya-Ping', 'Initials': 'YP', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Zhen-Hua', 'Initials': 'ZH', 'LastName': 'Zhao', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021009'] 1727,32664127,Novel airway device Vie Scope in several pediatric airway scenario: A randomized simulation pilot trial.,"CONTEXT Endotracheal intubation of pediatric patients is challenging, especially in the pre-hospital emergency setting and if performed by less experienced providers. Securing an airway should be achieved with a single intubation attempt, as each intubation attempt contributes to morbidity and mortality. A new airway device, the VieScope, was recently introduced into clinical market, but efficacy to reduced intubation attempts remains unclear thus far. OBJECTIVE We aimed to compare endotracheal intubation by paramedics using the Vie Scope in different pediatric airway simulation conditions. METHODS We conducted a randomized, cross-over simulation study. Following a theoretical and practical training session, paramedics performed endotracheal intubation in 3 different pediatric emergency scenarios: normal airway; tongue edema; cardiopulmonary resuscitation using the VieScope. Overall intubation success rate was the primary outcome. Secondary outcomes included number of intubation attempts, time to intubation, Cormack-Lehane grade, POGO score, and ease of use (using 1-100 scale). RESULTS Fifty-five paramedics with at least 2 years of clinical experience and without any previous experience with the VieScope participated in this study. The overall intubation success rate was 100% in all 3 scenarios. The median intubation time was 27 (24-34) versus 27 (25-37) versus 29 (25-40) s for scenarios A, B, and C, respectively. In scenario A, all paramedics performed successful intubation with 1 single intubation attempt, whereas 2% of the paramedics had to perform 2 intubation attempts in scenario B and 9% in scenario C. CONCLUSIONS Results of this simulation study indicate preliminary evidence, that the VieScope enables adequate endotracheal intubation in the pediatric setting. Further clinical studies are needed to confirm these results.",2020,The overall intubation success rate was 100% in all 3 scenarios.,"['Fifty-five paramedics with at least 2 years of clinical experience and without any previous experience with the VieScope participated in this study', 'several pediatric airway scenario', 'pediatric patients']",[],"['overall intubation success rate', 'number of intubation attempts, time to intubation, Cormack-Lehane grade, POGO score, and ease of use (using 1-100 scale', 'median intubation time', 'Overall intubation success rate']","[{'cui': 'C0450382', 'cui_str': '55'}, {'cui': 'C0013963', 'cui_str': 'Paramedic'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",[],"[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",,0.147591,The overall intubation success rate was 100% in all 3 scenarios.,"[{'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Maslanka', 'Affiliation': 'Medical Institute of Maria Sklodowska-Curie.'}, {'ForeName': 'Lukasz', 'Initials': 'L', 'LastName': 'Szarpak', 'Affiliation': 'Comprehensive Cancer Center in Bialystok, Bialystok, Poland.'}, {'ForeName': 'Sanchit', 'Initials': 'S', 'LastName': 'Ahuja', 'Affiliation': 'Department of Anesthesiology, Pain Management and Perioperative Medicine, Henry Ford Health System, Detroit, MI.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Ruetzler', 'Affiliation': 'Departments of Outcomes Research and General Anesthesiology, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH.'}, {'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Smereka', 'Affiliation': 'Department of Emergency Medical Service, Wroclaw Medical University, Wroclaw, Poland.'}]",Medicine,['10.1097/MD.0000000000021084'] 1728,32666396,Modified Encircling Scleral Buckle Technique Without Subretinal Fluid Drainage or Retinopexy.,"INTRODUCTION Scleral buckling (SB) tends to be more challenging and time-consuming for compared to the pars plana vitrectomy for repairing rhegmatogenous retinal detachments (RRDs). This study characterizes a novel and simplified technique for SB. METHODS In this single-masked randomized interventional study, patients with RRDs who were eligible for SB were randomly assigned to either the standard (S) or modified (M) technique of SB. In the modified approach, neither intraoperative break localization nor cryopexy or subretinal fluid drainage was done. A large tire (276/279) was placed where preoperative retinal breaks had been localized with a 240 encircling band placed for support of the remaining retina. Patients were followed for 12 months and the primary outcomes were differences between the surgical groups in operative time, anatomical success, visual acuity, and complication rate. RESULTS Thirty-six eyes were included in the study (18 in each arm). There were no differences in baseline patient demographics or characteristics including gender, age, lens and macular status, preoperative vision, and symptom duration. The mean length of surgery was 72.2 ± 13.2 and 56.2 ± 9.5 min in groups S and M, respectively (P = 0.001). Complete retinal reattachment at the end of month 12 after single surgery was 80.6% overall; 77.8% (14/18) in group S and 83.3% (15/18) in group M (P > 0.999). After 12 months, both groups achieved similar final best-corrected visual acuity (BCVA): 0.26 ± 0.23 and 0.23 ± 0.17 logMAR in groups S and M, respectively (P = 0.231). Controlling for preoperative BCVA on ANCOVA testing, there were no significant differences in visual improvement between the two groups [F (1,26) = 0.02, P = 0.966 (95% CI) - 0.128 to 0.123)]. Scleral perforation (2:1), vitreous hemorrhage (3:2), and transient rise of intraocular pressure (3:4) all occurred at a low and similar rate between the two groups (S:M). CONCLUSION Modified SB technique was non-inferior compared to the standard approach for anatomical and visual outcomes. Shortening surgical time while maintaining low complication rates makes this an appropriate approach to SB, especially for vitreoretinal surgery trainees.",2020,"Shortening surgical time while maintaining low complication rates makes this an appropriate approach to SB, especially for vitreoretinal surgery trainees.","['Thirty-six eyes were included in the study (18 in each arm', 'patients with RRDs who were eligible for SB']","['pars plana vitrectomy', 'standard (S) or modified (M) technique of SB', 'Scleral buckling (SB', 'Modified Encircling Scleral Buckle Technique Without Subretinal Fluid Drainage or Retinopexy', 'Modified SB technique']","['Scleral perforation (2:1), vitreous hemorrhage (3:2), and transient rise of intraocular pressure', 'similar final best-corrected visual acuity (BCVA', 'visual improvement', 'Complete retinal reattachment', 'mean length of surgery', 'baseline patient demographics or characteristics including gender, age, lens and macular status, preoperative vision, and symptom duration', 'operative time, anatomical success, visual acuity, and complication rate']","[{'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0271055', 'cui_str': 'Rhegmatogenous retinal detachment'}, {'cui': 'C0036411', 'cui_str': 'Scleral buckling'}]","[{'cui': 'C0563537', 'cui_str': 'Mechanical vitrectomy by pars plana approach'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0036411', 'cui_str': 'Scleral buckling'}, {'cui': 'C0205113', 'cui_str': 'Circumferential'}, {'cui': 'C1720732', 'cui_str': 'Subretinal fluid'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C1868761', 'cui_str': 'Retinopexy'}]","[{'cui': 'C0549099', 'cui_str': 'Perforation'}, {'cui': 'C0042909', 'cui_str': 'Vitreous hemorrhage'}, {'cui': 'C0040704', 'cui_str': 'Transients'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C1690532', 'cui_str': 'Best corrected visual acuity'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0035298', 'cui_str': 'Retinal structure'}, {'cui': 'C0185042', 'cui_str': 'Reattachment - action'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0023317', 'cui_str': 'Lens clear'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0436359', 'cui_str': 'Time symptom lasts'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0220784', 'cui_str': 'Anatomic'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",36.0,0.258528,"Shortening surgical time while maintaining low complication rates makes this an appropriate approach to SB, especially for vitreoretinal surgery trainees.","[{'ForeName': 'Mostafa', 'Initials': 'M', 'LastName': 'Mafi', 'Affiliation': 'Department of Ophthalmology, Farabi Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Masoud', 'Initials': 'M', 'LastName': 'Mirghorbani', 'Affiliation': 'Department of Ophthalmology, Farabi Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Ghahvehchian', 'Affiliation': 'Department of Ophthalmology, Farabi Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'S Saeed', 'Initials': 'SS', 'LastName': 'Mohammadi', 'Affiliation': 'Department of Ophthalmology, Farabi Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Riazi-Esfahani', 'Affiliation': 'Department of Ophthalmology, Farabi Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Elias', 'Initials': 'E', 'LastName': 'Khalili Pour', 'Affiliation': 'Department of Ophthalmology, Farabi Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Mahmoudi', 'Affiliation': 'Department of Ophthalmology, Farabi Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Khojasteh', 'Affiliation': 'Department of Ophthalmology, Farabi Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. khojaste_hasan@yahoo.com.'}, {'ForeName': 'Bobeck S', 'Initials': 'BS', 'LastName': 'Modjtahedi', 'Affiliation': 'Department of Ophthalmology, Southern California Permanente Medical Group, Baldwin Park, CA, USA.'}]",Ophthalmology and therapy,['10.1007/s40123-020-00279-1'] 1729,32663820,Design and Baseline Characteristics of the Chlorthalidone in Chronic Kidney Disease (CLICK) Trial.,"BACKGROUND Hypertension often accompanies chronic kidney disease (CKD), and diuretics are widely prescribed to reduce blood pressure (BP). Chlorthalidone (CTD) is a thiazide-like diuretic and an effective antihypertensive drug, yet little data exist to support its use in treating hypertension in individuals with advanced CKD. METHODS Chlorthalidone in Chronic Kidney Disease (CLICK) is a phase II, single-institution, multicenter, double-blind randomized control trial to test the hypothesis that CTD improves BP, through reduction of extracellular fluid volume, and results in target organ protection in patients with stage 4 CKD and poorly controlled hypertension. After a single-blind placebo run-in for 2 weeks and confirmation of hypertension by 24-h ambulatory blood pressure (ABP), patients are randomized to either placebo or CTD 12.5 mg once daily (QD) followed by dose escalation. Randomization is stratified by prior loop diuretic use, and the double-blind phase lasts 12 weeks. With a total of 160 patients, the study will have ≥80% power to detect a 6 mm Hg difference in systolic 24-h ABP between the 2 treatment groups. RESULTS Between June 2016 and October 2019, 131 patients have been randomized. The baseline characteristics are as follows: average age 65.8 years, 79% men, 36% Black, 79% with diabetes, mean eGFR 23.2 mL/min/1.73 m2, median urine albumin/creatinine ratio 923 mg/g, average number of BP medications 3.4, 60% on loop diuretics, and 24-h ABP averaged 141.7/73.8 mm Hg. CONCLUSION Among patients with stage 4 CKD and uncontrolled hypertension, CLICK should answer the question whether CTD is safe and effective.",2020,"median urine albumin/creatinine ratio 923 mg/g, average number of BP medications 3.4, 60% on loop diuretics, and 24-h ABP averaged 141.7/73.8 mm Hg. ","['patients with stage 4 CKD and poorly controlled hypertension', '160 patients', 'individuals with advanced CKD', 'patients with stage 4 CKD and uncontrolled hypertension', 'Chronic Kidney Disease (CLICK) Trial', 'Between June 2016 and October 2019, 131 patients have been randomized', 'follows: average age 65.8 years, 79% men, 36% Black, 79% with diabetes, mean eGFR 23.2 mL/min/1.73 m2', 'Chronic Kidney Disease (CLICK']","['Chlorthalidone (CTD', 'CTD', 'placebo or CTD', 'Chlorthalidone', 'placebo']","['blood pressure (BP', 'systolic 24-h ABP', 'median urine albumin/creatinine ratio 923 mg/g, average number of BP medications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2317473', 'cui_str': 'Chronic kidney disease stage 4'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0008294', 'cui_str': 'Chlorthalidone'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}]","[{'cui': 'C0008294', 'cui_str': 'Chlorthalidone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0855316', 'cui_str': 'Blood pressure ambulatory'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0455271', 'cui_str': 'Urine albumin/creatinine ratio measurement'}, {'cui': 'C1300563', 'cui_str': 'g/kg'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]",160.0,0.405279,"median urine albumin/creatinine ratio 923 mg/g, average number of BP medications 3.4, 60% on loop diuretics, and 24-h ABP averaged 141.7/73.8 mm Hg. ","[{'ForeName': 'Rajiv', 'Initials': 'R', 'LastName': 'Agarwal', 'Affiliation': 'Division of Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA, ragarwal@iu.edu.'}, {'ForeName': 'Andrew E', 'Initials': 'AE', 'LastName': 'Cramer', 'Affiliation': 'Division of Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Balmes-Fenwick', 'Affiliation': 'Division of Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA.'}, {'ForeName': 'Arjun D', 'Initials': 'AD', 'LastName': 'Sinha', 'Affiliation': 'Division of Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA.'}, {'ForeName': 'Fangqian', 'Initials': 'F', 'LastName': 'Ouyang', 'Affiliation': 'Department of Biostatistics, Richard M. Fairbanks School of Public Health, Indiana University School of Medicine, Indianapolis, Indiana, USA.'}, {'ForeName': 'Wanzhu', 'Initials': 'W', 'LastName': 'Tu', 'Affiliation': 'Department of Biostatistics, Richard M. Fairbanks School of Public Health, Indiana University School of Medicine, Indianapolis, Indiana, USA.'}]",American journal of nephrology,['10.1159/000508700'] 1730,32664070,Femoral nerve block vs adductor canal block after anterior cruciate ligament reconstruction under general anesthesia: A prospective randomized trial protocol.,"BACKGROUND Femoral nerve block (FNB) is considered the preferred analgesia after anterior cruciate ligament reconstruction (ACLR), but leads to weakness in the quadriceps muscles. Adductor canal block (ACB) is a new sensory block technique that effectively relieves postoperative pain while preserving quadriceps strength. The purpose of our study was to compare the efficacy of FNB vs ACB for pain control after ACLR. METHODS This prospective, randomized, double-blind, controlled, superiority clinical trial was approved by the institutional review board in our university hospital. We enrolled 120 patients set to undergo ACLR in this randomized therapeutic trial. Sixty patients received FNB and the other 60 received ACB for postoperative pain control. All ACB and FNB were performed using ultrasound-guided single-shot procedures. The primary outcomes included maximum voluntary isovolumetric contraction and postoperative pain score. Secondary outcomes included total opioid consumption, length of hospital stay, complication, and satisfaction score. RESULTS This clinical trial might provide some insights to estimate and compare the safety and efficacy of ACB vs FNB following ACLR. TRIAL REGISTRATION This study protocol was registered in Research Registry (researchregistry5569).",2020,"Secondary outcomes included total opioid consumption, length of hospital stay, complication, and satisfaction score. ","['anterior cruciate ligament reconstruction under general anesthesia', '120 patients set to undergo ACLR', 'anterior cruciate ligament reconstruction (ACLR']","['Femoral nerve block vs adductor canal block', 'Femoral nerve block (FNB', 'ACB', 'Adductor canal block (ACB', 'FNB vs ACB', 'FNB']","['postoperative pain control', 'total opioid consumption, length of hospital stay, complication, and satisfaction score', 'maximum voluntary isovolumetric contraction and postoperative pain score']","[{'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}]","[{'cui': 'C0394739', 'cui_str': 'Local anesthetic femoral nerve block'}, {'cui': 'C0225273', 'cui_str': 'Structure of adductor canal'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}]","[{'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}]",120.0,0.34174,"Secondary outcomes included total opioid consumption, length of hospital stay, complication, and satisfaction score. ","[{'ForeName': 'Qingpei', 'Initials': 'Q', 'LastName': 'Xue', 'Affiliation': 'Department of Orthopedics. Qingdao Huangdao Central Hospital.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Jiang', 'Affiliation': ""Department of Orthopedics. Laixi People's Hospital.""}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': ""Department of Orthopedics. Qingdao Huangdao People's Hospital, Shandong, China.""}, {'ForeName': 'Jinkui', 'Initials': 'J', 'LastName': 'Sui', 'Affiliation': 'Department of Orthopedics. Qingdao Huangdao Central Hospital.'}, {'ForeName': 'Yiping', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Orthopedics. Qingdao Huangdao Central Hospital.'}]",Medicine,['10.1097/MD.0000000000020776'] 1731,32664074,Promoting breastfeeding in Chinese women undergoing cesarean section based on the health belief model: A randomized controlled trial.,"BACKGROUND The high rate of cesarean section is an important factor affecting breastfeeding in China. To improve the nation's current situation of breastfeeding, promoting breastfeeding in women undergoing cesarean section is essential. OBJECTIVE To explore the effects of health belief model-based interventions on breastfeeding knowledge, breastfeeding behaviors, and breastfeeding satisfaction of Chinese cesarean women. METHODS A total of 346 cesarean section women were enrolled in the randomized controlled trial conducted at a center in Chengdu, China, between July 1, 2018 and August 31, 2018. While the control group (n = 173) received conventional breastfeeding guidance only, the intervention group (n = 173) received additional interventions based on the health belief model. Questionnaires were distributed to assess breastfeeding knowledge, breastfeeding behavior, and breastfeeding satisfaction at discharge, 42 days postpartum, and 4 months postpartum, respectively. RESULTS At discharge from hospital, the breastfeeding knowledge score of the intervention group was higher than that of the control group (Z = -11.753, P < .001). The exclusive breastfeeding rates in the intervention group at the time of discharge, 42 days postpartum, and 4 months postpartum were 67.3%, 60.7%, and 52.9%, respectively, while those of the control group were 41.2%, 41.6%, and 40.4%, respectively. The differences were statistically significant (χ = 23.353, P < .001; χ = 11.853, P < .001; χ = 4.805, P = .03). The breastfeeding satisfaction of the intervention group was also higher than the control group at the time of discharge, 42 days postpartum and 4 months postpartum (t = 4.955, P < .001; t = 3.051, P = .002; Z = -3.801, P < .001). CONCLUSION The health belief model-based interventions can effectively increase breastfeeding knowledge for Chinese cesarean women and improve their breastfeeding behaviors and breastfeeding satisfaction within 4 months after delivery. CLINICAL TRIAL REGISTRATION ChiCTR1900026006 .",2020,"The breastfeeding satisfaction of the intervention group was also higher than the control group at the time of discharge, 42 days postpartum and 4 months postpartum (","['A total of 346 cesarean section women were enrolled in the randomized controlled trial conducted at a center in Chengdu, China, between July 1, 2018 and August 31, 2018', 'Chinese women undergoing cesarean section based on the health belief model', 'women undergoing cesarean section', 'Chinese cesarean women']","['health belief model-based interventions', 'additional interventions based on the health belief model', 'conventional breastfeeding guidance']","['breastfeeding satisfaction', 'breastfeeding knowledge score', 'breastfeeding behaviors and breastfeeding satisfaction', 'breastfeeding knowledge, breastfeeding behavior, and breastfeeding satisfaction', 'breastfeeding knowledge', 'exclusive breastfeeding rates', 'breastfeeding knowledge, breastfeeding behaviors, and breastfeeding satisfaction']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C3714363', 'cui_str': 'Health belief model'}]","[{'cui': 'C3714363', 'cui_str': 'Health belief model'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}]","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0517671', 'cui_str': 'Knowledge level: breastfeeding'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1319304', 'cui_str': 'Breastfeeding performance'}]",346.0,0.0719075,"The breastfeeding satisfaction of the intervention group was also higher than the control group at the time of discharge, 42 days postpartum and 4 months postpartum (","[{'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Hu', 'Affiliation': 'Department of Nursing, West China Second University Hospital, Sichuan University.'}, {'ForeName': 'Tingting', 'Initials': 'T', 'LastName': 'Ding', 'Affiliation': ""Department of Intensive Care Unit, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.""}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': 'Department of Nursing, West China Second University Hospital, Sichuan University.'}, {'ForeName': 'Biru', 'Initials': 'B', 'LastName': 'Luo', 'Affiliation': 'Department of Nursing, West China Second University Hospital, Sichuan University.'}]",Medicine,['10.1097/MD.0000000000020815'] 1732,32664084,"A 12 week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of HT083 on mild osteoarthritis.","BACKGROUND The increasing prevalence of osteoarthritis among the old population worldwide is a great concern. Two of the biggest complaints of OA patients are joint pain and inflammation. Currently, people are relying on non-steroidal anti-inflammatory drugs (NSAIDs) and steroids to control pain and inflammation. However, long-term use of these pharmaceutical drugs has negative health consequences in the elderly, including gastro-intestinal, respiratory, and renal diseases. Natural products are receiving more attention than ever as alternative treatments against OA for their efficacies and safety. The root of Paeonia lactiflora Pal and the gum resin of Commiphora myrrha have been used as analgesics and anti-inflammatory agents since ancient time. A new herbal formula composed of P. lactiflora root and C. myrrha gum resin extracts, known as HT083, has shown promising antinociceptive and anti-inflammatory effects in a rodent model of OA. We design this study to investigate the safety and the efficacy of HT083 to prevent OA in patients with mild OA. METHODS This is a randomized, double-blind, and placebo-controlled study. A total of 100 eligible participants will be divided into two groups and will be given HT083 and a placebo for 12 weeks in 1:1 ratio. Treatment results will be assessed using a visual analog scale (VAS), Korean-Short Form health survey-36 score (SF-36), personal evaluation, and laboratory analysis. DISCUSSION This trial is expected to provide clinical evidence on the effectiveness and the safety of HT083 as a natural treatment for mild OA. TRIAL REGISTRATION Korean Clinical Research Information Service (CRIS) number KCT0004925 Registered on 2020.04.16.",2020,"A new herbal formula composed of P. lactiflora root and C. myrrha gum resin extracts, known as HT083, has shown promising antinociceptive and anti-inflammatory effects in a rodent model of OA.","['100 eligible participants', 'patients with mild OA', 'mild OA']",['placebo'],"['visual analog scale (VAS), Korean-Short Form health survey-36 score (SF-36), personal evaluation, and laboratory analysis', 'mild osteoarthritis', 'joint pain and inflammation']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0003862', 'cui_str': 'Joint pain'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",100.0,0.275995,"A new herbal formula composed of P. lactiflora root and C. myrrha gum resin extracts, known as HT083, has shown promising antinociceptive and anti-inflammatory effects in a rodent model of OA.","[{'ForeName': 'Donghun', 'Initials': 'D', 'LastName': 'Lee', 'Affiliation': 'Department of Herbal Pharmacology, College of Korean Medicine, Gachon University, Seongnam.'}, {'ForeName': 'Seok Jung', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'Department of Orthopedic Surgery, College of Medicine, The Catholic University of Korea.'}, {'ForeName': 'Hocheol', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Herbal Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.'}]",Medicine,['10.1097/MD.0000000000020907'] 1733,32664090,The myocardial protective effect of monosodium phosphate cardioplegia in cardiopulmonary bypass in infants with an atrial septal defect.,"This study aimed to investigate the myocardial protective effect of liquid sodium phosphocreatine cardiac arrest in extracorporeal circulation surgery treating infants with atrial septal defects.Eighty-four infants with atrial septal defects who required extracorporeal circulation surgery treatment at our hospital from January 2016 to June 2018 were divided into an observation group and a control group through a digitally randomized method, with 42 cases in each group. The control group adopted the conventional modified St Thomas II high potassium cold liquid crystal cardiac arrest, while the observation group adopted the liquid sodium phosphocreatine cardiac arrest.The myocardial enzyme indexes of the 2 groups 3, 6, 12, and 24 hours postoperatively were higher than before establishing the cardiopulmonary bypass and the enzyme indexes of the control group at the same time were higher than that of the observation group; adenosine triphosphate, adenosine diphosphate, and other energy levels and the postoperative recovery rate energy levels of the observation group were higher than those in the control group, the difference was statistically significant (P < .05).Liquid sodium phosphocreatine cardiac arrest used in extracorporeal circulation surgery treating infants with atrial septal defects can reduce myocardial ischemia-reperfusion injury, maintain energy supply during ischemia, strengthen the St Thomas II effect, and aid postoperative cardiac function recovery of high potassium cold liquid crystal cardiac arrest used in infants with atrial septal defects and treated with extracorporeal circulation surgery.",2020,"The myocardial enzyme indexes of the 2 groups 3, 6, 12, and 24 hours postoperatively were higher than before establishing the cardiopulmonary bypass and the enzyme indexes of the control group at the same time were higher than that of the observation group; adenosine triphosphate, adenosine diphosphate, and other energy levels and the postoperative recovery rate energy levels of the observation group were higher than those in the control group, the difference was statistically significant (P < .05).Liquid","['infants with an atrial septal defect', 'extracorporeal circulation surgery treating infants with atrial septal defects', 'Eighty-four infants with atrial septal defects who required extracorporeal circulation surgery treatment at our hospital from January 2016 to June 2018', 'infants with atrial septal defects']","['extracorporeal circulation surgery', 'monosodium phosphate cardioplegia', 'liquid sodium phosphocreatine cardiac arrest']","['myocardial enzyme indexes', 'adenosine triphosphate, adenosine diphosphate, and other energy levels and the postoperative recovery rate energy levels', 'myocardial protective effect']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0018817', 'cui_str': 'Atrial septal defect'}, {'cui': 'C0015354', 'cui_str': 'Extracorporeal circulation procedure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C4319623', 'cui_str': '84'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0015354', 'cui_str': 'Extracorporeal circulation procedure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0031603', 'cui_str': 'Phosphate'}, {'cui': 'C0018791', 'cui_str': 'Induced cardioplegia'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0031634', 'cui_str': 'fosfocreatine'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}]","[{'cui': 'C0014442', 'cui_str': 'Enzyme'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0001480', 'cui_str': 'Adenosine Triphosphate'}, {'cui': 'C0001459', 'cui_str': 'Adenosine diphosphate'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",,0.0127664,"The myocardial enzyme indexes of the 2 groups 3, 6, 12, and 24 hours postoperatively were higher than before establishing the cardiopulmonary bypass and the enzyme indexes of the control group at the same time were higher than that of the observation group; adenosine triphosphate, adenosine diphosphate, and other energy levels and the postoperative recovery rate energy levels of the observation group were higher than those in the control group, the difference was statistically significant (P < .05).Liquid","[{'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Zhai', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000020934'] 1734,32664145,A randomized double-blind placebo-controlled multicenter trial of Bushen Yisui and Ziyin Jiangzhuo formula for constipation in Parkinson disease.,"INTRODUCTION Constipation is a common nonmotor symptom of Parkinson disease (PD). Constipation can also impact patient's quality of life. Chinese herbal medicines have been used for the treatment of constipation in PD. This trial will evaluate the efficacy and safety of a Chinese herbal formula Bushen Yisui and Ziyin Jiangzhuo (BYZJ) for the treatment of constipation in PD. METHODS AND ANALYSIS This randomized, double-blind, placebo-controlled, multicenter clinical trial will involve 4 hospitals in Beijing, China. The study will aim to recruit 90 PD patients with constipation between 30 and 80 years-of age with a score of 1 - 4 on the Hoehn and Yahr scale. Once recruited, Patients will be randomized into a BYZJ group or a placebo group in a 2:1 ratio. The trial will include a 1-week run-in period, a 4-week double-blind treatment period, a 4-week and a 12-week follow-up period. All patients will be educated about PD-related constipation during the run-in period. BYZJ granules and simulated granules will be administered twice daily for 4 weeks to the BYZJ group and the placebo group respectively. Assessments will be performed during run-in period, before the start of treatment (baseline, week 0), and at 4, 8, and 16 weeks. The primary outcome will be measured with the Constipation Severity Instrument, and secondary outcomes will be evaluated with the Patient Assessment of Constipation Quality of Life questionnaire, Bristol Stool Form Scale, Movement Disorders-Unified Parkinson Disease Rating Scale, Nonmotor Symptoms Scale, PD Sleep Scale, Parkinson Fatigue Scale-16. Laxative use (dose and frequency) will also be recorded. Intention-to-treat and per-protocol set analyses will be used to compare symptom improvement between the 2 groups. Any adverse events will be recorded. DISCUSSION If found effective and safe, BYZJ formula will be one of Chinese herb to treat constipation and even other nonmotor or motor symptoms in PD patients. The results will sustain the broader use of BYZJ formula in PD.",2020,BYZJ granules and simulated granules will be administered twice daily for 4 weeks to the BYZJ group and the placebo group respectively.,"['constipation in Parkinson disease', '90 PD patients with constipation between 30 and 80 years-of age with a score of 1 - 4 on the Hoehn and Yahr scale', '4 hospitals in Beijing, China', 'constipation in PD']","['Bushen Yisui and Ziyin Jiangzhuo formula', 'Chinese herbal formula Bushen Yisui and Ziyin Jiangzhuo (BYZJ', 'Chinese herbal medicines', 'placebo']","['efficacy and safety', 'Constipation Severity Instrument, and secondary outcomes will be evaluated with the Patient Assessment of Constipation Quality of Life questionnaire, Bristol Stool Form Scale, Movement Disorders-Unified Parkinson Disease Rating Scale, Nonmotor Symptoms Scale, PD Sleep Scale, Parkinson Fatigue Scale-16']","[{'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4274667', 'cui_str': 'Hoehn and Yahr Scale'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C2352031', 'cui_str': 'bushen yisui'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0376667', 'cui_str': 'Herbals'}, {'cui': 'C1273412', 'cui_str': 'Chinese herbal medicine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1997606', 'cui_str': 'Bristol stool form scale'}, {'cui': 'C0026650', 'cui_str': 'Movement disorder'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}]",,0.305455,BYZJ granules and simulated granules will be administered twice daily for 4 weeks to the BYZJ group and the placebo group respectively.,"[{'ForeName': 'Zhaohui', 'Initials': 'Z', 'LastName': 'Jin', 'Affiliation': 'Parkinson Medical Center, Beijing Rehabilitation Hospital, Capital Medical University.'}, {'ForeName': 'Zhengtang', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Geriatrics Department, China Academy of Chinese Medical Sciences Xiyuan Hospital.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Kang', 'Affiliation': 'Medical Insurance Office, Dongzhimen Hospital of Beijing University of Chinese Medicine.'}, {'ForeName': 'Aoran', 'Initials': 'A', 'LastName': 'Yang', 'Affiliation': 'Traditional Chinese Medicine Rehabilitation Center, Beijing Rehabilitation Hospital, Capital Medical University.'}, {'ForeName': 'Hongbo', 'Initials': 'H', 'LastName': 'Zhao', 'Affiliation': 'Traditional Chinese Medicine Rehabilitation Center, Beijing Rehabilitation Hospital, Capital Medical University.'}, {'ForeName': 'XiaoYan', 'Initials': 'X', 'LastName': 'Yan', 'Affiliation': 'Peking University Clinical Research Institute, Peking University First Hospital.'}, {'ForeName': 'Tianqing', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Neurology Department, Beijing Longfu Hospital, Beijing, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Gao', 'Affiliation': 'Parkinson Medical Center, Beijing Rehabilitation Hospital, Capital Medical University.'}, {'ForeName': 'Aixian', 'Initials': 'A', 'LastName': 'Liu', 'Affiliation': 'Parkinson Medical Center, Beijing Rehabilitation Hospital, Capital Medical University.'}, {'ForeName': 'Boyan', 'Initials': 'B', 'LastName': 'Fang', 'Affiliation': 'Parkinson Medical Center, Beijing Rehabilitation Hospital, Capital Medical University.'}]",Medicine,['10.1097/MD.0000000000021145'] 1735,32664149,"Exploring the efficacy and safety of herbal medicine on Korean obese women with or without metabolic syndrome risk factors: A study protocol for a double-blind, randomized, multi-center, placebo-controlled clinical trial.","BACKGROUND The prevalence of obesity among women is increasing. Obesity is associated with various metabolic syndromes; conventional treatments are limited and may induce serious adverse events due to polytherapy regimens. Currently, demands for complementary and alternative medicine that has a proven safety profile for the treatment of obesity with or without metabolic risk factors are increasing.Our team of preclinical experts reported a significant anti-obesity effect of the Korean herbal medicine, Galgeun-tang (GGT). Thus, we designed this trial to explore the effects of GGT among obese women to accumulate optimal clinical evidence.Obesity is not only a component of metabolic syndrome and a factor associated with an increased risk of cardiovascular disease but is also related to insulin resistance. Previous research has confirmed that an increasing body mass index is highly related with increased risk of metabolic syndrome among overweight and obese individuals. The effectiveness of the Korean medicine herbal formula, GGT on obesity has been previously reported. The objective of this study is to assess the efficacy and safety of GGT for weight loss among obese Korean women with or without high risk for metabolic syndrome. METHODS/DESIGN This study is a randomized, double-blinded, placebo-controlled, multi-center clinical trial. A total of 160 participants will be randomly distributed in 2 groups, the GGT group or the placebo group in a 1:1 ratio using a web-based randomization system. Each group will be administered GGT or placebo 3 times a day for 12 weeks. The primary endpoint is to assess the change in weight from baseline. The secondary endpoints are the following: the changes in body composition measurements, anthropomorphic measurements, obesity screening Laboratory tests, patient self-reported questionnaires, and economic evaluation outcomes. Adverse events will also be reported. DISCUSSION The findings of this study will confirm methodologies regarding the efficacy and safety of GGT for weight loss among obese Korean women with or without metabolic risk factors.",2020,"Our team of preclinical experts reported a significant anti-obesity effect of the Korean herbal medicine, Galgeun-tang (GGT).","['160 participants', 'overweight and obese individuals', 'Korean obese women with or without metabolic syndrome risk factors', 'obese Korean women with or without high risk for metabolic syndrome', 'obese Korean women with or without metabolic risk factors', 'obese women']","['GGT', 'GGT or placebo', 'herbal medicine', 'placebo']","['body composition measurements, anthropomorphic measurements, obesity screening Laboratory tests, patient self-reported questionnaires, and economic evaluation outcomes', 'efficacy and safety', 'change in weight from baseline', 'weight loss']","[{'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]","[{'cui': 'C0017040', 'cui_str': 'Gamma-glutamyltransferase'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0025125', 'cui_str': 'Herbs, Medicinal'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0740216', 'cui_str': 'Obesity screening'}, {'cui': 'C0022885', 'cui_str': 'Laboratory procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0150099', 'cui_str': 'Economic Evaluation'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}]",160.0,0.388628,"Our team of preclinical experts reported a significant anti-obesity effect of the Korean herbal medicine, Galgeun-tang (GGT).","[{'ForeName': 'Youme', 'Initials': 'Y', 'LastName': 'Ko', 'Affiliation': 'Department of Korean Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul.'}, {'ForeName': 'Hyun-Ju', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Oriental Medicine Research Institute, College of Korean Medicine, Gachon University, Seongnam.'}, {'ForeName': 'Hojun', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Korean Rehabilitation Medicine, College of Korean Medicine, Dongguk University, Seoul.'}, {'ForeName': 'Jin-Bong', 'Initials': 'JB', 'LastName': 'Choi', 'Affiliation': 'Department of Oriental Rehabilitation Medicine, Gwangju Oriental Hospital of Dongshin University, Gwangju.'}, {'ForeName': 'Young-Dal', 'Initials': 'YD', 'LastName': 'Kwon', 'Affiliation': 'Department of Korean Medicine Rehabilitation, Gwangju Medical Center, College of Korean Medicine, Wonkwang University, Gwangju.'}, {'ForeName': 'Won-Seok', 'Initials': 'WS', 'LastName': 'Jung', 'Affiliation': 'Department of Korean Rehabilitation Medicine, College of Korean Medicine, Kyung Hee University, Seoul.'}, {'ForeName': 'Bo-Hyoung', 'Initials': 'BH', 'LastName': 'Jang', 'Affiliation': 'Department of Korean Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul.'}, {'ForeName': 'NamKwen', 'Initials': 'N', 'LastName': 'Kim', 'Affiliation': 'Center for Comparative Effectiveness Research & Economic Evaluation in Korean Medicine, Pusan National University, Yangsan.'}, {'ForeName': 'Yun-Kyung', 'Initials': 'YK', 'LastName': 'Song', 'Affiliation': 'Department of Korean Rehabilitation Medicine, College of Korean Medicine, Gachon University, Seongnam, Republic of Korea.'}, {'ForeName': 'Seong-Gyu', 'Initials': 'SG', 'LastName': 'Ko', 'Affiliation': 'Department of Korean Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul.'}]",Medicine,['10.1097/MD.0000000000021153'] 1736,32664177,Effects of Kinect exergames on balance training among community older adults: A randomized controlled trial.,"BACKGROUND Recent years have witnessed wide applications of exergames to balance training among the older adults. However, research concerning balance training with the use of Kinect for Xbox has remained scarce. While previous studies have shown the positive effects of exergames on improving balance and preventing falling among the older adults, there has been a paucity of empirical evidence supporting the superiority of Kinect exercise to conventional exercise over balance training among the older adults. Therefore, this study aimed to compare the feasibility, safety, and effectiveness of Kinect exercise against conventional exercise over balance training among the community older adults. METHOD A total of 20 participants were randomly assigned to the Kinect Exercise Group (N = 10) or the Conventional Exercise Group (N = 10) for a 5-week balance training (45 minutes a time, 2 times a week). Assessor blinding was employed to assess the participants' performance before and after the treatment, including 30-Second Chair Stand Test (30-sec CST), Timed Up and Go (TUG), Functional Reach Test (FRT), and One-Leg Stance Test (OLST) respectively with eyes open and closed. Subjective feeling of the intensity of pain and side effects were recorded throughout the investigation period. Nonparametric statistics was used for data analysis. RESULTS Within-group comparison between the pre-test and post-test indicated that significant differences existed in all of the 5 tests (30-sec CST, TUG, FRT, OLST with eyes open, and OLST with eyes closed) in the Kinect exercise group. To the Conventional exercise group, however, significant differences were only observed in 30-sec CST, FRT and OLST with eyes open. With regard to between-group comparison, significant differences were only found in FRT. CONCLUSION Such results indicated that both treatments were helpful in improving the participants' balance performance, that Kinect exercise was more effective in terms of overall balance ability, and that Kinect exercise was particularly beneficial to functional reach enhancement in comparison with traditional exercise. Kinect exercise could be a feasible, safe, and effective alternative for dynamic balance training among older adults.",2020,"To the Conventional exercise group, however, significant differences were only observed in 30-sec CST, FRT and OLST with eyes open.","['older adults', 'community older adults', 'A total of 20 participants']","['Kinect exergames', 'Kinect exercise to conventional exercise over balance training', 'Kinect Exercise Group (N\u200a=\u200a10) or the Conventional Exercise Group (N\u200a=\u200a10) for a 5-week balance training', 'Kinect exercise', 'Kinect exercise against conventional exercise over balance training']","['Subjective feeling of the intensity of pain and side effects', '30-Second Chair Stand Test (30-sec CST), Timed Up and Go (TUG), Functional Reach Test (FRT), and One-Leg Stance Test (OLST', 'balance training', 'FRT']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C1998271', 'cui_str': 'Functional reach test'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",20.0,0.0207085,"To the Conventional exercise group, however, significant differences were only observed in 30-sec CST, FRT and OLST with eyes open.","[{'ForeName': 'Chi-Min', 'Initials': 'CM', 'LastName': 'Yang', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Chi-Mei Medical Center.'}, {'ForeName': 'Jun Scott', 'Initials': 'JS', 'LastName': 'Chen Hsieh', 'Affiliation': 'Department of Foreign Languages and Literature, Asia University, Taichung.'}, {'ForeName': 'Yi-Chen', 'Initials': 'YC', 'LastName': 'Chen', 'Affiliation': 'Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan, ROC.'}, {'ForeName': 'Shu-Yu', 'Initials': 'SY', 'LastName': 'Yang', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Chi-Mei Medical Center.'}, {'ForeName': 'Hao-Chiang Koong', 'Initials': 'HK', 'LastName': 'Lin', 'Affiliation': 'Department of Information and Learning Technology, National University of Tainan, Tainan.'}]",Medicine,['10.1097/MD.0000000000021228'] 1737,32664809,Outcomes from a pilot patient-centered hospital-to-home transition program for children hospitalized with asthma.,"OBJECTIVE To evaluate a multi-component hospital-to-home (H2H) transition program for children hospitalized with an asthma exacerbation. METHODS A pilot prospective randomized clinical trial of guideline-based asthma care with and without a patient-centered multi-component H2H program among children enrolled in K-8 th grade on Medicaid hospitalized for an asthma exacerbation. H2H program includes 5 components: medications in-hand at discharge, school-based asthma therapy (SBAT) for controller medications, referral for home trigger assessments, communication with the primary care provider (PCP), and patient navigator support. Primary outcomes included feasibility and acceptability. Secondary outcomes included healthcare utilization, asthma morbidity, and caregiver quality of life. RESULTS A total of 32 children were enrolled and randomized. Feasibility outcomes in the intervention group included: medications in-hand at discharge (100%); SBAT for controller medication initiated (100%); home visit referrals made (100%) and home visits completed within 4 weeks of discharge (44%); PCP communication (100%); patient navigator communication at 3 days (81.3%) and 14 days (46.7%). Acceptability outcomes in the intervention group included: 87.5% of families continued SBAT, and 87.5% of families reported it was extremely helpful to have the home visit referral. Adjusting for baseline differences in age, asthma severity and control, there was no significant difference in healthcare utilization outcomes. CONCLUSION These pilot data suggest that comprehensive care coordination initiated during the inpatient stay is feasible and acceptable. A larger trial is justified to determine if the intervention may reduce healthcare utilization for urban, minority children with asthma.",2020,"Adjusting for baseline differences in age, asthma severity and control, there was no significant difference in healthcare utilization outcomes.","['children hospitalized with an asthma exacerbation', 'Children Hospitalized with Asthma', '32 children', 'urban, minority children with asthma', 'children enrolled in K-8 th grade on Medicaid hospitalized for an asthma exacerbation']","['multi-component hospital-to-home (H2H) transition program', 'H2H program includes 5 components: medications in-hand at discharge, school-based asthma therapy (SBAT) for controller medications, referral for home trigger assessments, communication with the primary care provider (PCP), and patient navigator support', 'guideline-based asthma care with and without a patient-centered multi-component H2H program']","['feasibility and acceptability', 'healthcare utilization outcomes', 'healthcare utilization, asthma morbidity, and caregiver quality of life', 'Acceptability outcomes', 'patient navigator communication']","[{'cui': 'C0008098', 'cui_str': 'Children, Hospitalized'}, {'cui': 'C0349790', 'cui_str': 'Exacerbation of asthma'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0026192', 'cui_str': 'Minority Groups'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0025071', 'cui_str': 'Medicaid coverage'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C3871203', 'cui_str': 'At discharge'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C2585524', 'cui_str': 'Referral for'}, {'cui': 'C0032930', 'cui_str': 'Precipitating Factors'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C2735026', 'cui_str': 'Primary care provider'}, {'cui': 'C1709488', 'cui_str': 'Patient navigator'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C1318955', 'cui_str': 'Asthma management'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1709488', 'cui_str': 'Patient navigator'}, {'cui': 'C0009452', 'cui_str': 'Communication'}]",32.0,0.0853024,"Adjusting for baseline differences in age, asthma severity and control, there was no significant difference in healthcare utilization outcomes.","[{'ForeName': 'Kavita', 'Initials': 'K', 'LastName': 'Parikh', 'Affiliation': ""Division of Hospital Medicine, Children's National Hospital, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.""}, {'ForeName': 'Miller', 'Initials': 'M', 'LastName': 'Richmond', 'Affiliation': ""Center for Translational Research, Children's National Research Institute, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.""}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lee', 'Affiliation': ""Center for Translational Research, Children's National Research Institute, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.""}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Fu', 'Affiliation': ""Division of General and Community Pediatrics, Children's National Hospital, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.""}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'McCarter', 'Affiliation': 'Center for Translational Research, Department of Biostatistics and Research Methodology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Hinds', 'Affiliation': ""Department of Nursing Science, Professional Practice & Quality, Children's National Hospital, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.""}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Teach', 'Affiliation': ""Center for Translational Research, Children's National Research Institute, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.""}]",The Journal of asthma : official journal of the Association for the Care of Asthma,['10.1080/02770903.2020.1795877'] 1738,32669140,Meeting nutritional targets of critically ill patients by combined enteral and parenteral nutrition: review and rationale for the EFFORTcombo trial.,"While medical nutrition therapy is an essential part of the care for critically ill patients, uncertainty exists about the right form, dosage, timing and route in relation to the phases of critical illness. As enteral nutrition (EN) is often withheld or interrupted during the intensive care unit (ICU) stay, combined EN and parenteral nutrition (PN) may represent an effective and safe option to achieve energy and protein goals as recommended by international guidelines. We hypothesise that critically ill patients at high nutritional risk may benefit from such a combined approach during their stay on the ICU. Therefore, we aim to test if an early combination of EN and high-protein PN (EN+PN) is effective in reaching energy and protein goals in patients at high nutritional risk, while avoiding overfeeding. This approach will be tested in the here-presented EFFORTcombo trial. Nutritionally high-risk ICU patients will be randomised to either high (≥2·2 g/kg per d) or low protein (≤1·2 g/kg per d). In the high protein group, the patients will receive EN+PN; in the low protein group, patients will be given EN alone. EN will be started in accordance with international guidelines in both groups. Efforts will be made to reach nutrition goals within 48-96 h. The efficacy of the proposed nutritional strategy will be tested as an innovative approach by functional outcomes at ICU and hospital discharge, as well as at a 6-month follow-up.",2020,"Therefore, we aim to test if an early combination of EN and high-protein PN (EN+PN) is effective in reaching calorie and protein goals in patients at high nutritional risk, while avoiding overfeeding.","['critically ill patients at high nutritional risk', 'patients at high nutritional risk, while avoiding overfeeding', 'Critically Ill Patients by Combined Enteral and Parenteral Nutrition', 'Nutritionally high-risk ICU patients']","['EN+PN', 'EN and high-protein PN (EN+PN', 'combined EN and parenteral nutrition (PN', 'medical nutrition therapy', 'enteral nutrition (EN']",[],"[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1268620', 'cui_str': 'At risk for nutritional problem'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1304890', 'cui_str': 'Enteral'}, {'cui': 'C0030547', 'cui_str': 'Parenteral nutrition'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0010337', 'cui_str': 'Care of intensive care unit patient'}]","[{'cui': 'C1304890', 'cui_str': 'Enteral'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0030547', 'cui_str': 'Parenteral nutrition'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1257928', 'cui_str': 'Medical Nutrition Therapy'}]",[],,0.0250541,"Therefore, we aim to test if an early combination of EN and high-protein PN (EN+PN) is effective in reaching calorie and protein goals in patients at high nutritional risk, while avoiding overfeeding.","[{'ForeName': 'Aileen', 'Initials': 'A', 'LastName': 'Hill', 'Affiliation': 'Department of Intensive Care Medicine, Medical Faculty RWTH Aachen, Aachen, Germany.'}, {'ForeName': 'Daren K', 'Initials': 'DK', 'LastName': 'Heyland', 'Affiliation': 'Clinical Evaluation Research Unit, Kingston General Hospital, Kingston, Ontario, Canada.'}, {'ForeName': 'Gunnar', 'Initials': 'G', 'LastName': 'Elke', 'Affiliation': 'Department of Anaesthesiology and Intensive Care Medicine, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.'}, {'ForeName': 'Stefan J', 'Initials': 'SJ', 'LastName': 'Schaller', 'Affiliation': 'Department of Anaesthesiology and Operative Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Reto', 'Initials': 'R', 'LastName': 'Stocker', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Klinik Hirslanden, Zürich, Switzerland.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Haberthür', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Klinik Hirslanden, Zürich, Switzerland.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'von Loeffelholz', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, University Hospital Jena, Jena, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Suchner', 'Affiliation': 'Klinik für Anästhesiologie und Operative Intensivmedizin, Klinikum Darmstadt, Darmstadt, Germany.'}, {'ForeName': 'Zudin A', 'Initials': 'ZA', 'LastName': 'Puthucheary', 'Affiliation': 'William Harvey Research Institute, Queen Mary, University of London, London, UK.'}, {'ForeName': 'Danielle E', 'Initials': 'DE', 'LastName': 'Bear', 'Affiliation': ""Department of Nutrition and Dietetics, Guy's and St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Ney', 'Affiliation': 'Department of Intensive Care Medicine, Medical Faculty RWTH Aachen, Aachen, Germany.'}, {'ForeName': 'Kai C', 'Initials': 'KC', 'LastName': 'Clasen', 'Affiliation': 'Department of Intensive Care Medicine, Medical Faculty RWTH Aachen, Aachen, Germany.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Meybohm', 'Affiliation': 'Department of Anaesthesia and Critical Care, University Hospital Würzburg, Würzburg, Germany.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Lindau', 'Affiliation': 'Department of Anaesthesia and Critical Care, University Hospital Würzburg, Würzburg, Germany.'}, {'ForeName': 'Thea', 'Initials': 'T', 'LastName': 'Laurentius', 'Affiliation': 'Department of Internal Medicine and Geriatrics, Franziskushospital Aachen, Aachen, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Stoppe', 'Affiliation': 'Department of Intensive Care Medicine, Medical Faculty RWTH Aachen, Aachen, Germany.'}]",Nutrition research reviews,['10.1017/S0954422420000165'] 1739,32669161,[Comparison of the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants: a prospective randomized double-blind controlled trial].,"OBJECTIVE To compare the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants. METHODS A total of 98 preterm infants with a gestational age of 28 - <34 weeks between April 2018 and December 2019 were enrolled. They were randomly administered with domestic (n=48) or imported caffeine citrate (n=50) within 6 hours after birth. The therapeutic effects, complications, adverse effects and clinical outcomes were compared between the two groups. RESULTS There were no significant differences in the incidence of apnea within 7 days after birth, daily frequency of apnea, the time of apnea disappearance, the failure rate of intubation-surfactant-extubation strategy, the time of non-invasive assisted ventilation, the duration of oxygen therapy, the duration of caffeine citrate therapy, the length of hospital stay, blood gas analysis results, liver and kidney function testing results between the two groups (P>0.05). There were no significant differences in the incidence of complications and the mortality rate between the two groups (P>0.05). There was no significant difference in the incidence of adverse effects between the two groups (P>0.05). CONCLUSIONS The efficacy and safety of domestic caffeine citrate in the treatment of apnea are similar to those of imported caffeine citrate in preterm infants.",2020,The efficacy and safety of domestic caffeine citrate in the treatment of apnea are similar to those of imported caffeine citrate in preterm infants.,"['98 preterm infants with a gestational age of 28\u2009-\u2009<34 weeks between April 2018 and December 2019 were enrolled', 'apnea in preterm infants', 'preterm infants']","['domestic caffeine citrate', 'domestic (n=48) or imported caffeine citrate', 'domestic and imported caffeine citrate']","['incidence of apnea within 7 days after birth, daily frequency of apnea, the time of apnea disappearance, the failure rate of intubation-surfactant-extubation strategy, the time of non-invasive assisted ventilation, the duration of oxygen therapy, the duration of caffeine citrate therapy, the length of hospital stay, blood gas analysis results, liver and kidney function testing results', 'incidence of adverse effects', 'therapeutic effects, complications, adverse effects and clinical outcomes', 'incidence of complications and the mortality rate']","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}]","[{'cui': 'C0003063', 'cui_str': 'Domestic Animals'}, {'cui': 'C0054436', 'cui_str': 'Caffeine citrate'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0034085', 'cui_str': 'Lung surfactant'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C0554804', 'cui_str': 'Assisted breathing'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}, {'cui': 'C0054436', 'cui_str': 'Caffeine citrate'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0005800', 'cui_str': 'Blood gas analysis'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0232804', 'cui_str': 'Renal function'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",98.0,0.0280981,The efficacy and safety of domestic caffeine citrate in the treatment of apnea are similar to those of imported caffeine citrate in preterm infants.,"[{'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'He', 'Affiliation': 'Department of Neonatology, Xiangya Hospital, Central South University, Changsha 410008, China. shaojieyue@163.com.'}, {'ForeName': 'Zheng-Chang', 'Initials': 'ZC', 'LastName': 'Liao', 'Affiliation': ''}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': ''}, {'ForeName': 'Ming-Jie', 'Initials': 'MJ', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Ji-Min', 'Initials': 'JM', 'LastName': 'Gan', 'Affiliation': ''}, {'ForeName': 'Shao-Jie', 'Initials': 'SJ', 'LastName': 'Yue', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1740,32669306,Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria: Post Hoc Analyses from SPRINT.,"BACKGROUND AND OBJECTIVES It is unclear whether the presence of albuminuria modifies the effects of intensive systolic BP control on risk of eGFR decline, cardiovascular events, or mortality. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS The Systolic Blood Pressure Intervention Trial randomized nondiabetic adults ≥50 years of age at high cardiovascular risk to a systolic BP target of <120 or <140 mm Hg, measured by automated office BP. We compared the absolute risk differences and hazard ratios of ≥40% eGFR decline, the Systolic Blood Pressure Intervention Trial primary cardiovascular composite outcome, and all-cause death in those with or without baseline albuminuria (urine albumin-creatinine ratio ≥30 mg/g). RESULTS Over a median follow-up of 3.1 years, 69 of 1723 (4%) participants with baseline albuminuria developed ≥40% eGFR decline compared with 61 of 7162 (1%) participants without albuminuria. Incidence rates of ≥40% eGFR decline were higher in participants with albuminuria (intensive, 1.74 per 100 person-years; standard, 1.17 per 100 person-years) than in participants without albuminuria (intensive, 0.48 per 100 person-years; standard, 0.11 per 100 person-years). Although effects of intensive BP lowering on ≥40% eGFR decline varied by albuminuria on the relative scale (hazard ratio, 1.48; 95% confidence interval, 0.91 to 2.39 for albumin-creatinine ratio ≥30 mg/g; hazard ratio, 4.55; 95% confidence interval, 2.37 to 8.75 for albumin-creatinine ratio <30 mg/g; P value for interaction <0.001), the absolute increase in ≥40% eGFR decline did not differ by baseline albuminuria (incidence difference, 0.38 events per 100 person-years for albumin-creatinine ratio ≥30 mg/g; incidence difference, 0.58 events per 100 person-years for albumin-creatinine ratio <30 mg/g; P value for interaction =0.60). Albuminuria did not significantly modify the beneficial effects of intensive systolic BP lowering on cardiovascular events or mortality evaluated on relative or absolute scales. CONCLUSIONS Albuminuria did not modify the absolute benefits and risks of intensive systolic BP lowering.",2020,"Albuminuria did not significantly modify the beneficial effects of intensive systolic BP lowering on cardiovascular events or mortality evaluated on relative or absolute scales. ","['nondiabetic adults ≥50 years of age at high cardiovascular risk to a systolic BP target of <120 or <140 mm Hg, measured by automated office BP', 'Patients with and without Albuminuria', 'participants with albuminuria (intensive, 1.74 per 100 person-years; standard, 1.17 per 100 person-years) than in participants without albuminuria (intensive, 0.48 per 100 person-years; standard, 0.11 per 100 person-years']",['Intensive Blood Pressure Control'],"['eGFR decline, cardiovascular events, or mortality', 'Incidence rates of ≥40% eGFR decline']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001925', 'cui_str': 'Albuminuria'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C4517494', 'cui_str': '1.17'}, {'cui': 'C4517461', 'cui_str': '0.48'}, {'cui': 'C4517425', 'cui_str': '0.11'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",,0.459874,"Albuminuria did not significantly modify the beneficial effects of intensive systolic BP lowering on cardiovascular events or mortality evaluated on relative or absolute scales. ","[{'ForeName': 'Alex R', 'Initials': 'AR', 'LastName': 'Chang', 'Affiliation': 'Kidney Health Research Institute, Department of Population Health Sciences, Geisinger Health System, Danville, Pennsylvania achang@geisinger.edu.'}, {'ForeName': 'Holly', 'Initials': 'H', 'LastName': 'Kramer', 'Affiliation': 'Division of Nephrology, Loyola University Medical Center, Maywood, Illinois.'}, {'ForeName': 'Guo', 'Initials': 'G', 'LastName': 'Wei', 'Affiliation': 'Division of Nephrology & Hypertension, University of Utah School of Medicine, Salt Lake City, Utah.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Boucher', 'Affiliation': 'Division of Nephrology & Hypertension, University of Utah School of Medicine, Salt Lake City, Utah.'}, {'ForeName': 'Morgan E', 'Initials': 'ME', 'LastName': 'Grams', 'Affiliation': 'Division of Nephrology, Johns Hopkins School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Berlowitz', 'Affiliation': 'Department of Public Health, University of Massachusetts-Lowell, Lowell, Massachusetts.'}, {'ForeName': 'Udayan', 'Initials': 'U', 'LastName': 'Bhatt', 'Affiliation': 'Division of Nephrology, The Ohio State University College of Medicine, Columbus, Ohio.'}, {'ForeName': 'Debbie L', 'Initials': 'DL', 'LastName': 'Cohen', 'Affiliation': 'Renal Division, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Drawz', 'Affiliation': 'Division of Renal Diseases and Hypertension, University of Minnesota, Minneapolis, Minnesota.'}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Punzi', 'Affiliation': 'Punzi Medical Center, Trinity Hypertension and Metabolic Research Institute, Carollton, Texas.'}, {'ForeName': 'Barry I', 'Initials': 'BI', 'LastName': 'Freedman', 'Affiliation': 'Section on Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Haley', 'Affiliation': 'Division of Nephrology, Mayo Clinic, Jacksonville, Florida.'}, {'ForeName': 'Amret', 'Initials': 'A', 'LastName': 'Hawfield', 'Affiliation': 'Section on Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Horwitz', 'Affiliation': 'Division of Nephrology, MetroHealth Medical Center, Cleveland, Ohio.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'McLouth', 'Affiliation': 'Division of Public Health Sciences, Department of Biostatistics and Data Science, Wake Forest Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Don', 'Initials': 'D', 'LastName': 'Morisky', 'Affiliation': 'Department of Community Health Sciences, University of California, Los Angeles Fielding School of Public Health, Los Angeles, California.'}, {'ForeName': 'Vasilios', 'Initials': 'V', 'LastName': 'Papademetriou', 'Affiliation': 'Department of Cardiology, Veterans Affairs Medical Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Michael V', 'Initials': 'MV', 'LastName': 'Rocco', 'Affiliation': 'Section on Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Wall', 'Affiliation': 'Division of Nephrology, Veterans Affairs Medical Center, Memphis, Tennessee.'}, {'ForeName': 'Daniel E', 'Initials': 'DE', 'LastName': 'Weiner', 'Affiliation': 'Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Athena', 'Initials': 'A', 'LastName': 'Zias', 'Affiliation': 'Stony Brook University School of Medicine, Stony Brook, New York.'}, {'ForeName': 'Srinivasan', 'Initials': 'S', 'LastName': 'Beddhu', 'Affiliation': 'Division of Nephrology & Hypertension, University of Utah School of Medicine, Salt Lake City, Utah.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical journal of the American Society of Nephrology : CJASN,['10.2215/CJN.12371019'] 1741,32672095,"Montmorency tart cherry juice does not reduce markers of muscle soreness, function and inflammation following professional male rugby League match-play.","Rugby League (RL) match-play causes muscle damage, inflammation and symptoms of fatigue. To facilitate recovery, nutritional interventions are often employed, including Montmorency cherry juice (MC). We assessed the effects of MC on recovery following RL match-play in eleven male professional RL players who played in two matches (7-days apart) with MC or placebo (PLB) supplemented for 5-days pre-match, matchday and 2-days post-match. Blood was collected 48h pre-match, half-time, within 30-mins of full-time and 48h post-match to assess Interleukin concentrations (IL-6, -8 -10). Self-reported sleep, fatigue, mood, stress, and muscle-soreness were assessed 24h pre and 24 and 48h post-matches with muscle function assessed 48h pre and 48h post-match. No differences in distance covered (6334 ± 1944 Vs 6596 ± 1776m) and total collisions (28 ± 11 Vs 29 ± 13) were observed between both matches. There was a small albeit significant increase in IL-6, -8 and -10 concentrations pre to post-match in both PLB (IL-6: 0.83 ± 0.92 Vs 2.91 ± 1.40, IL-8: 2.16 ± 1.22 Vs 3.91 ± 1.61 and IL-10: 2.51 ± 2.14 Vs 0.61 ± 0.50 pg . mL -1 ) and MC groups (IL-6: 0.53 ± 0.53 Vs 2.24 ± 1.73, IL-8: 1.85 ± 0.96 Vs 3.46 ± 1.12 and IL-10: 0.48 ± 0.50 Vs 2.54 ± 2.10 pg . mL -1 ), although there were no significant differences between groups ( P <0.05). Likewise, there was a small but significant increase in muscle soreness ( P =0.01) and reduction in CMJ ( P =0.003) with no significant differences between groups. No significant changes in sleep, fatigue or mood ( P >0.05) were observed pre to post-match or between groups. These data suggest MC does not affect the modest changes observed in cytokine responses and markers of recovery from RL match-play.",2020,"There was a small albeit significant increase in IL-6, -8 and -10 concentrations pre to post-match in both PLB (IL-6: 0.83±0.92 Vs 2.91±1.40, IL-8: 2.16±1.22 Vs 3.91±1.61 and IL-10: 2.51±2.14",['eleven male professional RL players who played in two matches (7-days apart) with'],"['MC', 'MC or placebo (PLB', 'IL-8']","['muscle soreness, function and inflammation', 'total collisions', 'sleep, fatigue or mood (P>0.05', 'Self-reported sleep, fatigue, mood, stress, and muscle-soreness', 'muscle soreness', 'Rugby League (RL) match-play causes muscle damage, inflammation and symptoms of fatigue', 'IL-6, -8 and -10 concentrations pre']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0035945', 'cui_str': 'Rugby'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0982074', 'cui_str': 'CHERRY JUICE'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}]","[{'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0035945', 'cui_str': 'Rugby'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage NOS'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]",11.0,0.159867,"There was a small albeit significant increase in IL-6, -8 and -10 concentrations pre to post-match in both PLB (IL-6: 0.83±0.92 Vs 2.91±1.40, IL-8: 2.16±1.22 Vs 3.91±1.61 and IL-10: 2.51±2.14","[{'ForeName': 'James C', 'Initials': 'JC', 'LastName': 'Morehen', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Clarke', 'Affiliation': 'Warrington Wolves Rugby League Club, The Halliwell Jones Stadium, Mike Gregory Way, Warrington, UK.'}, {'ForeName': 'Jake', 'Initials': 'J', 'LastName': 'Batsford', 'Affiliation': 'Warrington Wolves Rugby League Club, The Halliwell Jones Stadium, Mike Gregory Way, Warrington, UK.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Barrow', 'Affiliation': 'Warrington Wolves Rugby League Club, The Halliwell Jones Stadium, Mike Gregory Way, Warrington, UK.'}, {'ForeName': 'Alexander D', 'Initials': 'AD', 'LastName': 'Brown', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK.'}, {'ForeName': 'Claire E', 'Initials': 'CE', 'LastName': 'Stewart', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Morton', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK.'}, {'ForeName': 'Graeme L', 'Initials': 'GL', 'LastName': 'Close', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK.'}]",European journal of sport science,['10.1080/17461391.2020.1797181'] 1742,32671719,Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives.,"Cabozantinib (Cabometyx ® ) is a potent multikinase inhibitor targeting the vascular endothelial growth factor (VEGF) receptor 2, the mesenchymal-epithelial transition factor (MET) receptor, and the ""anexelekto"" (AXL) receptor tyrosine kinase. It is approved for the treatment of advanced hepatocellular carcinoma (HCC) after failure of sorafenib in Europe (since November 2018) and in the USA (since January 2019). The approval of cabozantinib was based on results of the randomized, placebo-controlled, phase 3 CELESTIAL trial in patients with unresectable HCC, who received one or two prior lines of treatment including sorafenib. At the second planned interim analysis, the trial was stopped, because the primary end point overall survival was clearly in favor for cabozantinib. Additionally, median progression-free survival was superior to placebo. The most common ≥ grade 3 relevant adverse events in patients with HCC treated with cabozantinib were palmar-plantar erythrodysesthesia, hypertension, fatigue, and diarrhea. In this review, current data on cabozantinib for the treatment of patients with advanced HCC, with a focus on the management of common adverse events and ongoing clinical trials, are discussed.",2020,"Additionally, median progression-free survival was superior to placebo.","['patients with advanced HCC', 'Advanced Hepatocellular Carcinoma', 'patients with unresectable HCC, who received one or two prior lines of treatment including', 'advanced hepatocellular carcinoma (HCC) after failure of sorafenib in Europe (since\xa0November 2018) and in the USA (since January 2019']","['Cabozantinib (Cabometyx ® ', 'sorafenib', 'Cabozantinib', 'placebo']","['palmar-plantar erythrodysesthesia, hypertension, fatigue, and diarrhea', 'overall survival', 'median progression-free survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}, {'cui': 'C1112459', 'cui_str': 'Liver cell carcinoma non-resectable'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C3181682', 'cui_str': 'cabozantinib'}, {'cui': 'C4237933', 'cui_str': 'Cabometyx'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0549410', 'cui_str': 'Palmar-plantar erythrodysaesthesia syndrome'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",,0.065429,"Additionally, median progression-free survival was superior to placebo.","[{'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Trojan', 'Affiliation': 'Universitätsklinikum Frankfurt, Medizinische Klinik 1, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany. trojan@em.uni-frankfurt.de.'}]",Drugs,['10.1007/s40265-020-01361-5'] 1743,32672864,"Nuevo Amanecer-II: Results of a randomized controlled trial of a community-based participatory, peer-delivered stress management intervention for rural Latina breast cancer survivors.","OBJECTIVE We report results of a community-based multisite, randomized controlled trial of Nuevo Amanecer (NA-II), a 10-week stress management program for rural, low literacy Latina breast cancer survivors. METHODS Trained peers delivered NA-II to Spanish-speaking Latinas with non-metastatic breast cancer in three rural communities. Women were randomized to receive the program immediately or wait 6 months. Assessments were conducted at baseline, 3 months, and 6 months. Primary outcomes were breast cancer-specific quality of life domains; secondary outcomes included general distress symptoms and stress management skills. Intention-to-treat analyses using repeated-measures linear regression models estimated changes in slope between groups. RESULTS Of 153 participants (76 randomized to intervention, 77 to control group), 92% were retained at 6 months. Mean age was 54.8 years (SD = 10.5); 80% had less than high school education. There were no statistically significant treatment × time effects on quality of life. Compared to women in the control group, intervention group women reported greater improvements in anxiety at 6 months (-0.20 vs -0.02, P = .049; range 0-4) as well as three stress management skills: relaxation at 3 months (+0.98 vs -0.07, P < .0001; range 0-4) and 6 months (+0.82 vs +0.04, P < .001), awareness of tension at 3 months (+0.31 vs -0.19, P < .01; range 0-4) and 6 months (+0.29 vs -0.11, P < .05), and coping confidence at 3 months (+0.12 vs -0.23, P < .01; range 0-4). CONCLUSIONS Stress management programs delivered by trained peers in rural community settings can reduce anxiety and improve stress management skills among Latina breast cancer survivors.",2020,"CONCLUSIONS Stress management programs delivered by trained peers in rural community settings can reduce anxiety and improve stress management skills among Latina breast cancer survivors.","['Trained peers delivered NA-II to Spanish-speaking Latinas with non-metastatic breast cancer in three rural communities', 'rural, low literacy Latina breast cancer survivors', 'Latina breast cancer survivors', 'rural Latina breast cancer survivors', 'Mean age was 54.8\u2009years (SD\xa0=\xa010.5); 80% had less than high school education', '153 participants ']","['Nuevo Amanecer (NA-II', 'community-based participatory, peer-delivered stress management intervention']","['quality of life', 'breast cancer-specific quality of life domains; secondary outcomes included general distress symptoms and stress management skills', 'stress management skills: relaxation', 'stress management skills', 'anxiety', 'awareness of tension', 'coping confidence']","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0949335', 'cui_str': 'Latinas'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C0086944', 'cui_str': 'Rural Communities'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517521', 'cui_str': '10.5'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0455002', 'cui_str': 'Education and schooling detail'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0233494', 'cui_str': 'Tension'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}]",153.0,0.0910708,"CONCLUSIONS Stress management programs delivered by trained peers in rural community settings can reduce anxiety and improve stress management skills among Latina breast cancer survivors.","[{'ForeName': 'Anna María', 'Initials': 'AM', 'LastName': 'Nápoles', 'Affiliation': 'Division of Intramural Research, National Institute on Minority Health and Health Disparities, National Institutes of Health, Bethesda, Maryland, USA.'}, {'ForeName': 'Jasmine', 'Initials': 'J', 'LastName': 'Santoyo-Olsson', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, University of California San Francisco (UCSF), San Francisco, California, USA.'}, {'ForeName': 'Anita L', 'Initials': 'AL', 'LastName': 'Stewart', 'Affiliation': 'Center for Aging in Diverse Communities, University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Ortiz', 'Affiliation': 'Círculo de Vida Cancer Support and Resource Center, San Francisco, California, USA.'}, {'ForeName': 'Cathy', 'Initials': 'C', 'LastName': 'Samayoa', 'Affiliation': 'Health Equity Research Lab, Department of Biology, San Francisco State University, San Francisco, California, USA.'}, {'ForeName': 'Alma', 'Initials': 'A', 'LastName': 'Torres-Nguyen', 'Affiliation': 'Kaweah Delta Health Care District, Visalia, California, USA.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Palomino', 'Affiliation': 'Cancer Resource Center of the Desert, El Centro, California, USA.'}, {'ForeName': 'LaVerne', 'Initials': 'L', 'LastName': 'Coleman', 'Affiliation': 'WomenCARE/Entre Nosotras, Family Service Agency of the Central Coast, Park, California, USA.'}, {'ForeName': 'Aday', 'Initials': 'A', 'LastName': 'Urias', 'Affiliation': 'Cancer Resource Center of the Desert, El Centro, California, USA.'}, {'ForeName': 'Nayeli', 'Initials': 'N', 'LastName': 'Gonzalez', 'Affiliation': 'Cancer Resource Center of the Desert, El Centro, California, USA.'}, {'ForeName': 'Silvia Araceli', 'Initials': 'SA', 'LastName': 'Cervantes', 'Affiliation': 'Kaweah Delta Health Care District, Visalia, California, USA.'}, {'ForeName': 'Vicken Y', 'Initials': 'VY', 'LastName': 'Totten', 'Affiliation': 'Kaweah Delta Health Care District, Visalia, California, USA.'}]",Psycho-oncology,['10.1002/pon.5481'] 1744,32668323,A randomized controlled trial of lung ultrasound-guided therapy in heart failure (CLUSTER-HF study).,"BACKGROUND Lung ultrasound (LUS) has emerged as a new tool for the evaluation of congestion in heart failure (HF); incorporation of LUS during follow-up may detect congestion earlier and prompt interventions to prevent hospitalizations. The aim of this study was to test the hypothesis that the incorporation of LUS during follow-up of patients with HF may reduce the rate of adverse events compared with usual care. METHODS In this single-blinded, randomized controlled trial, patients were randomized into an LUS-guided arm or control arm. Patients were followed in 4 prespecified visits during a 6-month period. LUS was performed in every patient visit in both groups; however, LUS results were available for the treating physician only in the LUS group. The primary outcome was the composite of urgent HF visits, rehospitalization for worsening HF, and death from any cause. RESULTS One hundred twenty-six patients were randomized to either LUS (n = 63) or control (n = 63) (age 62.5 ± 10 years, median left ventricular ejection fraction 31%). The primary end point occurred in 30 (47.6%) patients in the control group and 20 (31.7%) patients in the LUS group (P = .041). LUS-guided treatment was associated with a 45% risk reduction in the primary end point (hazard ratio 0.55, 95% CI 0.31-0.98, P = .044), mainly driven by a reduction in urgent HF visits (hazard ratio 0.28, 95% CI 0.13-0.62, P = .001). No significant differences in rehospitalizations for HF or death were found. CONCLUSIONS Incorporation of LUS into clinical follow-up of patients with HF significantly reduced the risk of urgent visits for worsening HF.",2020,"LUS-guided treatment was associated with a 45% risk reduction in the primary end point (hazard ratio 0.55, 95% CI 0.31-0.98, P = .044), mainly driven by a reduction in urgent HF visits (hazard ratio 0.28, 95% CI 0.13-0.62, P = .001).",['One hundred twenty-six patients'],"['LUS-guided arm or control arm', 'lung ultrasound-guided therapy', 'Lung ultrasound (LUS', 'LUS']","['rate of adverse events', 'urgent HF visits', 'rehospitalizations for HF or death', 'composite of urgent HF visits, rehospitalization for worsening HF, and death from any cause', 'risk of urgent visits']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4286019', 'cui_str': 'Lung ultrasound'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",126.0,0.114217,"LUS-guided treatment was associated with a 45% risk reduction in the primary end point (hazard ratio 0.55, 95% CI 0.31-0.98, P = .044), mainly driven by a reduction in urgent HF visits (hazard ratio 0.28, 95% CI 0.13-0.62, P = .001).","[{'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Araiza-Garaygordobil', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico. Electronic address: dargaray@gmail.com.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Gopar-Nieto', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Martinez-Amezcua', 'Affiliation': 'Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Cabello-López', 'Affiliation': 'Centro Médico Nacional ""Siglo XXI,"" Instituto Mexicano del Seguro Social, Mexico City, Mexico.'}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Alanis-Estrada', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Abraham', 'Initials': 'A', 'LastName': 'Luna-Herbert', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Héctor', 'Initials': 'H', 'LastName': 'González-Pacheco', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Cynthia Paola', 'Initials': 'CP', 'LastName': 'Paredes-Paucar', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Martinez Daniel', 'Initials': 'MD', 'LastName': 'Sierra-Lara', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Jose Luis', 'Initials': 'JL', 'LastName': 'Briseño-De la Cruz', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Hugo', 'Initials': 'H', 'LastName': 'Rodriguez-Zanella', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Marco Antonio', 'Initials': 'MA', 'LastName': 'Martinez-Rios', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Arias-Mendoza', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}]",American heart journal,['10.1016/j.ahj.2020.06.003'] 1745,32668823,Effects of α-tocopherol on hemolysis and oxidative stress markers on red blood cells in β-thalassemia major.,"BACKGROUND The accumulation of unpaired α-globin chains in patients with β-thalassemia major may clinically create ineffective erythropoiesis, hemolysis, and chronic anemia. Multiple blood transfusions and iron overload cause cellular oxidative damage. However, α-tocopherol, an antioxidant, is a potent scavenger of lipid radicals in the membranes of red blood cells (RBCs) of patients with β-thalassemia major. PURPOSE To evaluate the effects of α-tocopherol on hemolysis and oxidative stress markers on the RBC membranes of patients with β-thalassemia major. METHODS Forty subjects included in this randomized controlled trial were allocated to the placebo and α-tocopherol groups. Doses of α-tocopherol were based on Institute of Medicine recommendations: 4-8 years old, 200 mg/day; 9-13 years old, 400 mg/day; 14-18 years old, 600 mg/day. Hemolysis, oxidative stress, and antioxidant variables were evaluated before and after 4-week α-tocopherol or placebo treatment, performed before blood transfusions. RESULTS Significant enhancements in plasma haptoglobin were noted in the α-tocopherol group (3.01 mg/dL; range, 0.60-42.42 mg/dL; P=0.021). However, there was no significant intergroup difference in osmotic fragility test results; hemopexin, malondialdehyde, reduced glutathione (GSH), or oxidized glutathione (GSSG) levels; or GSH/GSSG ratio. CONCLUSION Use of α-tocopherol could indirectly improve hemolysis and haptoglobin levels. However, it played no significant role in oxidative stress or as an endogen antioxidant marker in β-thalassemia major.",2020,"Results Significant enhancements in plasma haptoglobin were noted in the α-tocopherol group (3.01 mg/dL; range, 0.60-42.42 mg/dL; P=0.021).","['Methods\n\n\nForty subjects', 'β-thalassemia major', 'patients with β-thalassemia major']","['α-tocopherol or placebo', 'placebo and α-tocopherol', 'α-tocopherol']","['hemolysis and haptoglobin levels', 'oxidative stress', 'Hemolysis, oxidative stress, and antioxidant variables', 'plasma haptoglobin', 'osmotic fragility test results; hemopexin, malondialdehyde, reduced glutathione (GSH), or oxidized glutathione (GSSG) levels; or GSH/GSSG ratio']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0002875', 'cui_str': 'Homozygous beta thalassemia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0019054', 'cui_str': 'Haemolysis'}, {'cui': 'C0018595', 'cui_str': 'Haptoglobin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0029392', 'cui_str': 'Osmotic fragility'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0019067', 'cui_str': 'Hemopexin'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0202053', 'cui_str': 'Glutathione measurement'}, {'cui': 'C0061516', 'cui_str': 'Glutathione Disulfide'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",40.0,0.0385745,"Results Significant enhancements in plasma haptoglobin were noted in the α-tocopherol group (3.01 mg/dL; range, 0.60-42.42 mg/dL; P=0.021).","[{'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Sovira', 'Affiliation': 'Division of Pediatric Emergency & Intensive Care, Department of Pediatrics, Faculty of Medicine, University of Syiah Kualal/Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia.'}, {'ForeName': 'Munar', 'Initials': 'M', 'LastName': 'Lubis', 'Affiliation': 'Division of Pediatric Emergency & Intensive Care, Department of Pediatrics, Faculty of Medicine, University of Sumatera Utara/University of Sumatera Utara Hospital, Medan, Indonesia.'}, {'ForeName': 'Pustika Amalia', 'Initials': 'PA', 'LastName': 'Wahidiyat', 'Affiliation': 'Division of Hematology Oncology, Department of Pediatrics, Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.'}, {'ForeName': 'Franciscus D', 'Initials': 'FD', 'LastName': 'Suyatna', 'Affiliation': 'Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.'}, {'ForeName': 'Djajadiman', 'Initials': 'D', 'LastName': 'Gatot', 'Affiliation': 'Division of Hematology Oncology, Department of Pediatrics, Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.'}, {'ForeName': 'Saptawati', 'Initials': 'S', 'LastName': 'Bardosono', 'Affiliation': 'Department of Nutrition, Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Sadikin', 'Affiliation': 'Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.'}]",Clinical and experimental pediatrics,['10.3345/cep.2019.00542'] 1746,32675334,Parental Perspectives on Continuous Pulse Oximetry Use in Bronchiolitis Hospitalizations.,"BACKGROUND Because of the impact of continuous pulse oximetry (CPOX) on the overdiagnosis of hypoxemia in bronchiolitis, the American Academy of Pediatrics and the Choosing Wisely campaign have issued recommendations for intermittent monitoring. Parental preferences for monitoring may impact adoption of these recommendations, but these perspectives are poorly understood. METHODS Using this cross-sectional survey, we explored parental perspectives on CPOX monitoring before discharge and 1 week after bronchiolitis hospitalizations. During the 1-week call, half of the participants were randomly assigned to receive a verbal statement on the potential harms of CPOX to determine if conveying the concept of overdiagnosis can change parental preferences on monitoring frequency. An aggregate variable measuring favorable perceptions of CPOX was created to determine CPOX affinity predictors. RESULTS In-hospital interviews were completed on 357 patients, of which 306 (86%) completed the 1-week follow-up. Although 25% of parents agreed or strongly agreed that hospital monitors made them feel anxious, 98% agreed that the monitors were helpful. Compared to other vital signs, respiratory rate (87%) and oxygen saturation (84%) were commonly rated as ""extremely important."" Providing an educational statement on CPOX comparatively decreased parental desire for continuous monitoring (40% vs 20%; P < .001). Although there were no significant predictors of CPOX affinity, the effect size of the educational intervention was higher in college-educated parents. CONCLUSIONS Parents find security in CPOX. A brief statement on the potential harms of CPOX use had an impact on stated monitoring preferences. Parental perspectives are important to consider because they may influence the adoption of intermittent monitoring.",2020,Providing an educational statement on CPOX comparatively decreased parental desire for continuous monitoring (40% vs 20%; P < .001).,['Bronchiolitis Hospitalizations'],"['continuous pulse oximetry (CPOX', 'verbal statement']","['respiratory rate', 'oxygen saturation']","[{'cui': 'C0001311', 'cui_str': 'Acute bronchiolitis'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]","[{'cui': 'C1960498', 'cui_str': 'Continuous pulse oximetry'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}]","[{'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}]",,0.0345223,Providing an educational statement on CPOX comparatively decreased parental desire for continuous monitoring (40% vs 20%; P < .001).,"[{'ForeName': 'Kevin W', 'Initials': 'KW', 'LastName': 'Chi', 'Affiliation': ""Division of Pediatric Hospital Medicine, Department of Pediatrics, Lucile Packard Children's Hospital Stanford and School of Medicine, Stanford University, Stanford, California; and kevinchi@stanford.edu.""}, {'ForeName': 'Eric R', 'Initials': 'ER', 'LastName': 'Coon', 'Affiliation': ""Department of Pediatrics, School of Medicine, University of Utah and Primary Children's Hospital, Salt Lake City, Utah.""}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Destino', 'Affiliation': ""Division of Pediatric Hospital Medicine, Department of Pediatrics, Lucile Packard Children's Hospital Stanford and School of Medicine, Stanford University, Stanford, California; and.""}, {'ForeName': 'Alan R', 'Initials': 'AR', 'LastName': 'Schroeder', 'Affiliation': ""Division of Pediatric Hospital Medicine, Department of Pediatrics, Lucile Packard Children's Hospital Stanford and School of Medicine, Stanford University, Stanford, California; and.""}]",Pediatrics,['10.1542/peds.2020-0130'] 1747,32677037,Nutritional interventions for treating foot ulcers in people with diabetes.,"BACKGROUND Foot ulcers in people with diabetes are non-healing, or poorly healing, partial, or full-thickness wounds below the ankle. These ulcers are common, expensive to manage and cause significant morbidity and mortality. The presence of a wound has an impact on nutritional status because of the metabolic cost of repairing tissue damage, in addition to the nutrient losses via wound fluid. Nutritional interventions may improve wound healing of foot ulcers in people with diabetes. OBJECTIVES To evaluate the effects of nutritional interventions on the healing of foot ulcers in people with diabetes. SEARCH METHODS In March 2020 we searched the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase and EBSCO CINAHL Plus. We also searched clinical trials registries for ongoing and unpublished studies, and scanned reference lists of relevant included studies as well as reviews, meta-analyses and health technology reports to identify additional studies. There were no restrictions with respect to language, date of publication or study setting. SELECTION CRITERIA We included randomised controlled trials (RCTs) that evaluated the effect of nutritional interventions on the healing of foot ulcers in people with diabetes. DATA COLLECTION AND ANALYSIS Two review authors, working independently, assessed included RCTs for their risk of bias and rated the certainty of evidence using GRADE methodology, using pre-determined inclusion and quality criteria. MAIN RESULTS We identified nine RCTs (629 participants). Studies explored oral nutritional interventions as follows: a protein (20 g protein per 200 mL bottle), 1 kcal/mL ready-to-drink, nutritional supplement with added vitamins, minerals and trace elements; arginine, glutamine and β-hydroxy-β-methylbutyrate supplement; 220 mg zinc sulphate supplements; 250 mg magnesium oxide supplements; 1000 mg/day omega-3 fatty acid from flaxseed oil; 150,000 IU of vitamin D, versus 300,000 IU of vitamin D; 250 mg magnesium oxide plus 400 IU vitamin E and 50,000 IU vitamin D supplements. The comparator in eight studies was placebo, and in one study a different dose of vitamin D. Eight studies reported the primary outcome measure of ulcer healing; only two studies reported a measure of complete healing. Six further studies reported measures of change in ulcer dimension, these studies reported only individual parameters of ulcer dimensions (i.e. length, width and depth) and not change in ulcer volume. All of the evidence identified was very low certainty. We downgraded it for risks of bias, indirectness and imprecision. It is uncertain whether oral nutritional supplement with 20 g protein per 200 mL bottle, 1 kcal/mL, nutritional supplement with added vitamins, minerals and trace elements, increases the proportion of ulcers healed at six months more than placebo (risk ratio (RR) 0.80, 95% confidence interval (CI) 0.42 to 1.53). It is also uncertain whether arginine, glutamine and β-hydroxy-β-methylbutyrate supplement increases the proportion of ulcers healed at 16 weeks compared with placebo (RR 1.09, 95% CI 0.85 to 1.40). It is uncertain whether the following interventions change parameters of ulcer dimensions over time when compared with placebo; 220 mg zinc sulphate supplement containing 50 mg elemental zinc, 250 mg magnesium oxide supplement, 1000 mg/day omega-3 fatty acid from flaxseed oil supplement, magnesium and vitamin E co-supplementation and vitamin D supplementation. It is also uncertain whether 150,000 IU of vitamin D, impacts ulcer dimensions when compared with 300,000 IU of vitamin D. Two studies explored some of the secondary outcomes of interest for this review. It is uncertain whether oral nutritional supplement with 20 g protein per 200 mL bottle, 1 kcal/mL, nutritional supplement with added vitamins, minerals and trace elements, reduces the number of deaths (RR 0.96, 95% CI 0.06 to 14.60) or amputations (RR 4.82, 95% CI 0.24 to 95.88) more than placebo. It is uncertain whether arginine, glutamine and β-hydroxy-β-methylbutyrate supplement increases health-related quality of life at 16 weeks more than placebo (MD -0.03, 95% CI -0.09 to 0.03). It is also uncertain whether arginine, glutamine and β-hydroxy-β-methylbutyrate supplement reduces the numbers of new ulcers (RR 1.04, 95% CI 0.71 to 1.51), or amputations (RR 0.66, 95% CI 0.16 to 2.69) more than placebo. None of the included studies reported the secondary outcomes cost of intervention, acceptability of the intervention (or satisfaction) with respect to patient comfort, length of patient hospital stay, surgical interventions, or osteomyelitis incidence. One study exploring the impact of arginine, glutamine and β-hydroxy-β-methylbutyrate supplement versus placebo did not report on any relevant outcomes. AUTHORS' CONCLUSIONS Evidence for the impact of nutritional interventions on the healing of foot ulcers in people with diabetes compared with no nutritional supplementation, or compared with a different dose of nutritional supplementation, remains uncertain, with eight studies showing no clear benefit or harm. It is also uncertain whether there is a difference in rates of adverse events, amputation rate, development of new foot ulcers, or quality of life, between nutritional interventions and placebo. More research is needed to clarify the impact of nutritional interventions on the healing of foot ulcers in people with diabetes.",2020,"It is also uncertain whether there is a difference in rates of adverse events, amputation rate, development of new foot ulcers, or quality of life, between nutritional interventions and placebo.",['people with diabetes'],"['arginine, glutamine and β-hydroxy-β-methylbutyrate', 'magnesium oxide plus 400\u2009IU vitamin E and 50,000 IU vitamin D supplements', 'Nutritional interventions', 'nutritional interventions', 'kcal/mL ready-to-drink, nutritional supplement with added vitamins, minerals and trace elements; arginine, glutamine and β-hydroxy-β-methylbutyrate supplement; 220 mg zinc sulphate supplements; 250 mg magnesium oxide supplements; 1000 mg/day omega-3 fatty acid from flaxseed oil; 150,000 IU of vitamin D', 'magnesium oxide supplement, 1000 mg/day omega-3 fatty acid from flaxseed oil supplement, magnesium and vitamin E co-supplementation and vitamin D supplementation', 'vitamin D', 'arginine, glutamine and β-hydroxy-β-methylbutyrate supplement versus placebo', 'placebo']","['ulcer healing', 'health-related quality of life', 'wound healing of foot ulcers', 'numbers of new ulcers', 'complete healing', 'number of deaths', 'proportion of ulcers healed', 'healing of foot ulcers', 'acceptability of the intervention (or satisfaction) with respect to patient comfort, length of patient hospital stay, surgical interventions, or osteomyelitis incidence', 'rates of adverse events, amputation rate, development of new foot ulcers, or quality of life']","[{'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0003765', 'cui_str': 'Arginine'}, {'cui': 'C0017797', 'cui_str': 'Glutamine'}, {'cui': 'C0024477', 'cui_str': 'Magnesium Oxide'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C0420176', 'cui_str': 'Vitamin D supplement therapy'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0560598', 'cui_str': 'kcal/mL'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0042890', 'cui_str': 'Vitamin'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0040577', 'cui_str': 'Trace element'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0078794', 'cui_str': 'Zinc Sulfate'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0030015', 'cui_str': 'Oxides'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0023754', 'cui_str': 'Linseed Oil'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0333293', 'cui_str': 'Healing ulcer'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0085119', 'cui_str': 'Ulcer of foot'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0679133', 'cui_str': 'Respect'}, {'cui': 'C4277744', 'cui_str': 'Patient Comfort'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0239966', 'cui_str': 'Hospital patient'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0029443', 'cui_str': 'Osteomyelitis'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}]",,0.351557,"It is also uncertain whether there is a difference in rates of adverse events, amputation rate, development of new foot ulcers, or quality of life, between nutritional interventions and placebo.","[{'ForeName': 'Zena Eh', 'Initials': 'ZE', 'LastName': 'Moore', 'Affiliation': 'School of Nursing & Midwifery, Royal College of Surgeons in Ireland, Dublin, Ireland.'}, {'ForeName': 'Meave A', 'Initials': 'MA', 'LastName': 'Corcoran', 'Affiliation': 'Department of Endocrinology, Mater Misericordiae University Hospital, Dublin, Ireland.'}, {'ForeName': 'Declan', 'Initials': 'D', 'LastName': 'Patton', 'Affiliation': 'School of Nursing & Midwifery, Royal College of Surgeons in Ireland, Dublin, Ireland.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD011378.pub2'] 1748,32677051,The effects of ketamine on typical and atypical depressive symptoms.,"OBJECTIVE Ketamine's effects on different dimensions of depressive symptomatology, including typical/melancholic and atypical depression, remain largely unknown. This study examined the effects of a single intravenous dose of ketamine on general depressive symptoms (measured using the Montgomery-Asberg Depression Rating Scale (MADRS), typical/melancholic symptoms (measured using the MADRS5), and atypical symptoms (measured using the Scale for Atypical Symptoms (SAS)). METHODS Data from 68 participants with treatment-resistant major depressive disorder (MDD) or bipolar depression were pooled from three separate, double-blind, placebo-controlled, crossover studies investigating ketamine's efficacy in depression. MDD participants were unmedicated; bipolar participants received therapeutic-dose lithium or valproate. Clinical symptoms were collected preinfusion and up to 14 days postinfusion. Effect sizes were calculated for days 1 and 3 postinfusion. The primary measures of interest for this exploratory analysis were total MADRS, MADRS5, and SAS scores. Individual symptoms were also analyzed in an exploratory manner. RESULTS Scores improved significantly at Day 1 postinfusion (MADRS: Cohen's d = 0.64; MADRS5: Cohen's d = 0.61; SAS: Cohen's d = 0.41) and continued to be significantly improved over placebo at Day 3 (MADRS: Cohen's d = 0.49; MADRS5: Cohen's d = 0.43; SAS: Cohen's d = 0.39). Effect sizes were greater for typical/melancholic than atypical symptoms at Day 1 postinfusion. CONCLUSION Ketamine appears to effectively treat both the typical/melancholic and atypical symptoms of depression, but may have early preferential effects for the former.",2020,"RESULTS Scores improved significantly at Day 1 post-infusion (MADRS: Cohen's d=0.64; MADRS5:","['MDD participants were unmedicated; bipolar participants received', '68 participants with treatment-resistant major depressive disorder (MDD) or bipolar depression']","['therapeutic-dose lithium or valproate', 'ketamine', 'Ketamine', 'MADRS5', 'placebo']","['Typical and Atypical Depressive Symptoms', 'total MADRS, MADRS5, and SAS scores', 'general depressive symptoms', 'Montgomery-Asberg Depression Rating Scale (MADRS), typical/melancholic symptoms (measured using the MADRS5), and atypical symptoms (measured using the Scale for Atypical Symptoms (SAS']","[{'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0443156', 'cui_str': 'Bipolar'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0005587', 'cui_str': 'Bipolar affective disorder, current episode depression'}]","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0023870', 'cui_str': 'Lithium'}, {'cui': 'C0080356', 'cui_str': 'Valproate'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205182', 'cui_str': 'Atypical'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0344315', 'cui_str': 'Depressed mood'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",68.0,0.184973,"RESULTS Scores improved significantly at Day 1 post-infusion (MADRS: Cohen's d=0.64; MADRS5:","[{'ForeName': 'L T', 'Initials': 'LT', 'LastName': 'Park', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, Bethesda, MD, USA.'}, {'ForeName': 'D A', 'Initials': 'DA', 'LastName': 'Luckenbaugh', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, Bethesda, MD, USA.'}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Pennybaker', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, Bethesda, MD, USA.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Hopkins', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, Bethesda, MD, USA.'}, {'ForeName': 'I D', 'Initials': 'ID', 'LastName': 'Henter', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, Bethesda, MD, USA.'}, {'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Lener', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, Bethesda, MD, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Kadriu', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, Bethesda, MD, USA.'}, {'ForeName': 'E D', 'Initials': 'ED', 'LastName': 'Ballard', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, Bethesda, MD, USA.'}, {'ForeName': 'C A', 'Initials': 'CA', 'LastName': 'Zarate', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, Bethesda, MD, USA.'}]",Acta psychiatrica Scandinavica,['10.1111/acps.13216'] 1749,32673969,A systematic review and indirect treatment comparison of perampanel versus brivaracetam as adjunctive therapy in patients with focal-onset seizures with or without secondary generalization.,"PURPOSE To date, there has not been a single randomized controlled trial (RCT) conducted to directly compare the efficacy and safety of perampanel to brivaracetam in the adjunctive treatment of focal-onset seizures. This study makes these comparisons through the use of indirect treatment comparison (ITC) methods. METHODS A systematic review was conducted to identify RCTs that evaluated either one of perampanel or brivaracetam in the treatment of patients with focal-onset seizures. The Bucher ITC method was then used to compare efficacy and safety outcomes between perampanel and brivaracetam. Additional subgroup analyses, by levetiracetam usage (prior or concomitant), were conducted. RESULTS Eight RCTs (four comparing perampanel to placebo, four comparing brivaracetam to placebo) were included in the ITC. For patients taking concomitant levetiracetam, perampanel showed a significantly better responder rate compared to brivaracetam [relative risk (RR) and 95 % confidence interval (CI): 2.62 (1.15, 5.99)]. For patients who had previously, or never, taken levetiracetam, there was no difference in the responder rate. In the overall population, both perampanel and brivaracetam were more effective than placebo in terms of responder rate, seizure freedom, and secondarily generalized tonic-clonic seizure responder rate; however, for these outcomes, no evidence of a difference between perampanel and brivaracetam was found. Patients taking brivaracetam showed significantly less dizziness compared to patients taking perampanel. No differences for any other safety outcome were found. CONCLUSION Perampanel and brivaracetam are effective for the adjunctive treatment of focal-onset seizures and display similar adverse event profiles. Perampanel demonstrated an improved focal-onset seizure responder rate compared to brivaracetam in patients taking concomitant levetiracetam. This may be due to the similarity in the mechanism of action between brivaracetam and levetiracetam.",2020,"For patients who had previously, or never, taken levetiracetam, there was no difference in the responder rate.","['focal-onset seizures', 'patients with focal-onset seizures with or without secondary generalization', 'patients with focal-onset seizures']","['perampanel', 'perampanel versus brivaracetam', 'perampanel or brivaracetam', 'levetiracetam, perampanel', 'Perampanel', 'placebo']","['efficacy and safety outcomes', 'dizziness', 'responder rate', 'responder rate, seizure freedom, and secondarily generalized tonic-clonic seizure responder rate', 'efficacy and safety', 'focal-onset seizure responder rate']","[{'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0017324', 'cui_str': 'Generalization (Psychology)'}]","[{'cui': 'C2698764', 'cui_str': 'perampanel'}, {'cui': 'C1699861', 'cui_str': 'Brivaracetam'}, {'cui': 'C0377265', 'cui_str': 'Levetiracetam'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0494475', 'cui_str': 'Tonic-clonic seizure'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}]",,0.188512,"For patients who had previously, or never, taken levetiracetam, there was no difference in the responder rate.","[{'ForeName': 'Eugen', 'Initials': 'E', 'LastName': 'Trinka', 'Affiliation': 'FRCP Department of Neurology, Christian Doppler University Hospital, Paracelsus Medical University, Harrerstrasse 79, A-5020, Salzburg, Austria. Electronic address: eugen@trinka.at.'}, {'ForeName': 'Wan', 'Initials': 'W', 'LastName': 'Tsong', 'Affiliation': 'Formerly Eisai Inc, 100 Tice Blvd, Woodcliff Lake, NJ, 07677, United States. Electronic address: wtsong.esi@gmail.com.'}, {'ForeName': 'Sydney', 'Initials': 'S', 'LastName': 'Toupin', 'Affiliation': 'Quantics Biostatistics, Exchange Tower, 19 Canning Street Fourth Floor, Edinburgh, EH3 8EG, United Kingdom. Electronic address: sydney.toupin@outlook.com.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Patten', 'Affiliation': 'Eisai Ltd. European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, United Kingdom. Electronic address: Anna_Patten@eisai.net.'}, {'ForeName': 'Katy', 'Initials': 'K', 'LastName': 'Wilson', 'Affiliation': 'York Health Economics Consortium, Enterprise House, Innovation Way, University of York, York, YO10 5NQ, United Kingdom. Electronic address: katy.wilson@york.ac.uk.'}, {'ForeName': 'Jaana', 'Initials': 'J', 'LastName': 'Isojarvi', 'Affiliation': 'York Health Economics Consortium, Enterprise House, Innovation Way, University of York, York, YO10 5NQ, United Kingdom. Electronic address: jaana.isojarvi@york.ac.uk.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'James', 'Affiliation': 'Quantics Biostatistics, Exchange Tower, 19 Canning Street Fourth Floor, Edinburgh, EH3 8EG, United Kingdom. Electronic address: Daniel.James@quantics.co.uk.'}]",Epilepsy research,['10.1016/j.eplepsyres.2020.106403'] 1750,30796036,Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry.,"PURPOSE Imaging mass cytometry (IMC) uses metal-conjugated antibodies to provide multidimensional, objective measurement of protein targets. We used this high-throughput platform to perform an 18-plex assessment of HER2 ICD/ECD, cytotoxic T-cell infiltration and other structural and signaling proteins in a cohort of patients treated with trastuzumab to discover associations with trastuzumab benefit. EXPERIMENTAL DESIGN An antibody panel for detection of 18 targets (pan-cytokeratin, HER2 ICD, HER2 ECD, CD8, vimentin, cytokeratin 7, β-catenin, HER3, MET, EGFR, ERK 1-2, MEK 1-2, PTEN, PI3K p110 α, Akt, mTOR, Ki67, and Histone H3) was used with a selection of trastuzumab-treated patients from the Hellenic Cooperative Oncology Group 10/05 trial ( n = 180), and identified a case-control series. RESULTS Patients that recurred after adjuvant treatment with trastuzumab trended toward a decreased fraction of HER2 ECD pixels over threshold compared with cases without recurrence ( P = 0.057). After exclusion of the lowest HER2 expressers, 5-year recurrence events were associated with reduced total extracellular domain (ECD)/intracellular domain (ICD) ratio intensity in tumor ( P = 0.044). These observations are consistent with our previous work using quantitative immunofluorescence, but represent the proof on identical cell content. We also describe the association of the ECD of HER2 with CD8 T-cell infiltration on the same slide. CONCLUSIONS The proximity of CD8 cells as a function of the expression of the ECD of HER2 provides further evidence for the role of the immune system in the mechanism of action of trastuzumab.",2019,"RESULTS Patients that recurred after adjuvant treatment with trastuzumab trended toward a decreased fraction of HER2 ECD pixels over threshold compared with cases without recurrence ( P = 0.057).",['patients treated with trastuzumab to discover associations with trastuzumab benefit'],['trastuzumab'],"['total extracellular domain (ECD)/intracellular domain (ICD) ratio intensity', 'Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells', 'fraction of HER2 ECD pixels', '5-year recurrence events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C0004083', 'cui_str': 'Association'}]","[{'cui': 'C0728747', 'cui_str': 'trastuzumab'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0521119', 'cui_str': 'Extracellular'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0039195', 'cui_str': 'Cytotoxic T lymphocyte'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C1506592', 'cui_str': 'herstatin protein, human'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",,0.0259546,"RESULTS Patients that recurred after adjuvant treatment with trastuzumab trended toward a decreased fraction of HER2 ECD pixels over threshold compared with cases without recurrence ( P = 0.057).","[{'ForeName': 'Daniel E', 'Initials': 'DE', 'LastName': 'Carvajal-Hausdorf', 'Affiliation': 'Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Patsenker', 'Affiliation': 'Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Kelly P', 'Initials': 'KP', 'LastName': 'Stanton', 'Affiliation': 'Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Franz', 'Initials': 'F', 'LastName': 'Villarroel-Espindola', 'Affiliation': 'Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Esch', 'Affiliation': 'Fluidigm Corporation, Markham, Ontario, Canada.'}, {'ForeName': 'Ruth R', 'Initials': 'RR', 'LastName': 'Montgomery', 'Affiliation': 'Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Psyrri', 'Affiliation': 'Attikon University Hospital, Athens, Greece.'}, {'ForeName': 'Konstantine T', 'Initials': 'KT', 'LastName': 'Kalogeras', 'Affiliation': 'Translational Research Section, Hellenic Cooperative Oncology Group, Athens, Greece.'}, {'ForeName': 'Vassiliki', 'Initials': 'V', 'LastName': 'Kotoula', 'Affiliation': 'Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Foutzilas', 'Affiliation': 'Department of Medical Oncology, ""Papageorgiou"" Hospital, Athens, Greece.'}, {'ForeName': 'Kurt A', 'Initials': 'KA', 'LastName': 'Schalper', 'Affiliation': 'Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Yuval', 'Initials': 'Y', 'LastName': 'Kluger', 'Affiliation': 'Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Rimm', 'Affiliation': 'Yale School of Medicine, New Haven, Connecticut. david.rimm@yale.edu.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-18-2599'] 1751,32673278,Effectiveness of the InCharge Prevention Program to Promote Healthier Lifestyles: Protocol for a Randomized Controlled Trial.,"BACKGROUND InCharge is a newly developed school-based health intervention aimed at older adolescents. It aims to promote a healthier lifestyle by increasing self-regulation skills. After the InCharge program's effectiveness was previously investigated in a pilot study, the content of the program was adapted. OBJECTIVE This study describes the protocol of a cluster randomized controlled trial that aims to investigate the effectiveness of the InCharge program. METHODS A cluster randomized controlled trial including 70 classes with older adolescents (aged 16 years or older) in the Netherlands will be conducted to test the effectiveness of the InCharge program. After schools are recruited, randomization occurs at the class level. The trial consists of the following two conditions: an experimental condition and a control condition. Participants in the experimental condition will be given the InCharge intervention, consisting of four lessons of 50 minutes, with each lesson containing three assignments of approximately 15 minutes. While participants in the experimental condition will receive InCharge, participants in the control condition will receive regular academic school courses. Surveys are administered 1 week before the intervention (baseline), 1 week after the intervention (posttest), and 12 weeks after the intervention (follow-up). Variables of interest include, but are not limited to, self-regulation; predictors of snack intake, physical activity, and alcohol use; and interpersonal communication regarding these health behaviors. In addition to surveys, observations will be conducted during the first and fourth lessons, teachers will be interviewed, and focus groups will be held with a selection of students from the intervention condition. RESULTS Enrollment started in September 2017. As of June 2019, a total of 1216 participants were enrolled for this trial. Findings will be published in peer-reviewed journals and presented at conferences. The trial has been approved by the Ethics Review Board of the Faculty of Social and Behavioral Sciences of the University of Amsterdam (reference no.: 2017-PC-8244). CONCLUSIONS In this study protocol, the design of a cluster randomized controlled trial is described, which assesses how effectively the school-based intervention InCharge stimulates healthier lifestyles in late adolescents. We hypothesize that participants in the experimental condition will consume less alcohol, eat fewer unhealthy snacks, and be more physically active compared with participants in the control condition. TRIAL REGISTRATION Netherlands Trial Register (NL6654); https://www.trialregister.nl/trial/6654. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR1-10.2196/17702.",2020,"After the InCharge program's effectiveness was previously investigated in a pilot study, the content of the program was adapted. ","['As of June 2019, a total of 1216 participants were enrolled for this trial', 'late adolescents', 'older adolescents', '70 classes with older adolescents (aged 16 years or older']",['InCharge Prevention Program'],[],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]",[],1216.0,0.164809,"After the InCharge program's effectiveness was previously investigated in a pilot study, the content of the program was adapted. ","[{'ForeName': 'Mathijs', 'Initials': 'M', 'LastName': 'Mesman', 'Affiliation': 'Amsterdam School of Communication Research, University of Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Onrust', 'Affiliation': 'Trimbos Institute, Utrecht, Netherlands.'}, {'ForeName': 'Renée', 'Initials': 'R', 'LastName': 'Verkerk', 'Affiliation': 'Trimbos Institute, Utrecht, Netherlands.'}, {'ForeName': 'Hanneke', 'Initials': 'H', 'LastName': 'Hendriks', 'Affiliation': 'Amsterdam School of Communication Research, University of Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Bas', 'Initials': 'B', 'LastName': 'Van den Putte', 'Affiliation': 'Amsterdam School of Communication Research, University of Amsterdam, Amsterdam, Netherlands.'}]",JMIR research protocols,['10.2196/17702'] 1752,32673356,Comparing feasibility of low-tube-voltage protocol with low-iodine-concentration contrast and high-tube-voltage protocol with high-iodine-concentration contrast in coronary computed tomography angiography.,"BACKGROUND To investigate the feasibility of a low tube voltage (80 kVp) protocol with low concentration contrast media (CM) (iodixanol 320 mgl/ml) as compared with a high tube voltage (100 kVp) protocol with high concentration CM (iomeprol 400 mgl/ml) in coronary CT angiography (CCTA) for patients with body mass index less than 30. MATERIALS AND METHODS A total of 93 patients were randomly assigned into three groups and underwent CCTA as follows: Group A) 100 kVp, 100-350 mAs, 400 mgl/ml CM at 4ml/s, and reconstructed with filtered back projection; Group B and C) 80 kVp, 100-450 mAs, 320 mgl/ml CM at 4 ml/s and 5 ml/s, respectively and reconstructed with iterative reconstruction. Objective and subjective image quality (IQ) was analyzed. RESULTS The image noise, intravascular attenuation, signal-to-noise ratio and contrast-to-noise ratio of major coronary arteries did not differ significantly among three groups. Subjective IQ analyses on vascular attenuation and image noise did not differ significantly, either (all of p > 0.05). Qualitative IQ of Group B and C was non-inferior to that of Group A. Substantial reduction of radiation exposure was achieved in group B (2.60 ± 0.48 mSv) and C (2.72 ± 0.54 mSv), compared with group A (3.58 ± 0.67 mSv) (p < 0.05). CONCLUSION CCTA at 80 kVp with 320 mgl/ml CM and iterative reconstruction is feasible, achieving radiation dose reduction, while preserving IQ.",2020,"Subjective IQ analyses on vascular attenuation and image noise did not differ significantly, either (all of p > 0.05).","['patients with body mass index less than 30', 'A total of 93 patients']","['low tube voltage (80 kVp) protocol with low concentration contrast media (CM) (iodixanol 320 mgl/ml) as compared with a high tube voltage (100 kVp) protocol with high concentration CM (iomeprol 400 mgl/ml) in coronary CT angiography (CCTA', 'CCTA', 'low-tube-voltage protocol with low-iodine-concentration contrast and high-tube-voltage protocol with high-iodine-concentration contrast in coronary computed tomography angiography']","['radiation exposure', 'Objective and subjective image quality (IQ', 'image noise, intravascular attenuation, signal-to-noise ratio and contrast-to-noise ratio of major coronary arteries', 'vascular attenuation and image noise']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C2350056', 'cui_str': 'iodixanol-320'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0635652', 'cui_str': 'iomeprol 400'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C1536105', 'cui_str': 'CT angiography'}, {'cui': 'C0021966', 'cui_str': 'Iodide salt'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}]","[{'cui': 'C0015333', 'cui_str': 'Exposure to radiation'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0442123', 'cui_str': 'Intravascular'}, {'cui': 'C2986823', 'cui_str': 'Signal-To-Noise Ratio'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205042', 'cui_str': 'Coronary artery structure'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}]",93.0,0.0341413,"Subjective IQ analyses on vascular attenuation and image noise did not differ significantly, either (all of p > 0.05).","[{'ForeName': 'Min Jae', 'Initials': 'MJ', 'LastName': 'Cha', 'Affiliation': 'Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Sung Mok', 'Initials': 'SM', 'LastName': 'Kim', 'Affiliation': 'Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Tae Ran', 'Initials': 'TR', 'LastName': 'Ahn', 'Affiliation': 'Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Yeon Hyeon', 'Initials': 'YH', 'LastName': 'Choe', 'Affiliation': 'Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}]",PloS one,['10.1371/journal.pone.0236108'] 1753,32678852,The effect of comprehensive intervention for childhood obesity on dietary diversity among younger children: Evidence from a school-based randomized controlled trial in China.,"BACKGROUND Little evidence from developing countries on dietary transition demonstrates the effects of comprehensive childhood obesity interventions on dietary diversity and food variety among younger children. This study aimed to evaluate the effects of comprehensive childhood obesity interventions on dietary diversity among younger children. METHODS A total of 4846 children aged 7-13 years were included based on a multicenter randomized controlled trial for childhood obesity interventions in 38 primary schools. Nutrition education intervention (NE), physical activity intervention (PA) and comprehensive intervention including both NE and PA (CNP) were carried out separately for 2 semesters. Dietary Diversity Score (DDS9 and DDS28 for 9 and 28 food groupings, respectively), Food Variety Score (FVS, the number of food items) and the proportions of different foods consumed were calculated according to the food intake records collected with the 24-h dietary recall method. RESULTS The intervention effects per day of comprehensive intervention group were 0 (95% Confidence Interval (CI): 0, 0.1; p = 0.382) on DDS9, 0.1 (95% CI: -0.1, 0.2; p = 0.374) on DDS28 and 0.1 (95% CI: -0.1, 0.3; p = 0.186) on FVS of overall diet, which was 0.1 (95% CI: 0, 0.1; p < 0.001) on DDS9, 0 (95% CI: 0, 0.1; p = 0.168) on DDS28 and 0.1 (95% CI: 0, 0.1; p = 0.067) on FVS of dietary scores of breakfast only. Additionally, CNP group had greater increases in cereals, meat and fruits, and more decreases in eggs, fish and dried legumes consumption proportions as compared with the control group. Decreasing side effect on dietary diversity and food variety were found for PA intervention, but not for NE intervention only. CONCLUSIONS Though the comprehensive obesity intervention didn't improve the overall dietary diversity per day, the positive intervention effects were observed on breakfast foods and some foods' consumption.",2020,"Additionally, CNP group had greater increases in cereals, meat and fruits, and more decreases in eggs, fish and dried legumes consumption proportions as compared with the control group.","['younger children', '4846 children aged 7-13 years', '38 primary schools']","['comprehensive childhood obesity interventions', 'childhood obesity interventions', 'comprehensive intervention', 'Nutrition education intervention (NE), physical activity intervention (PA) and comprehensive intervention including both NE and PA (CNP', 'CNP']","['Dietary Diversity Score (DDS9 and DDS28', 'FVS of dietary scores', 'dietary diversity', 'Food Variety Score ', 'cereals, meat and fruits, and more decreases in eggs, fish and dried legumes consumption proportions', 'FVS of overall diet', 'overall dietary diversity']","[{'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0033145', 'cui_str': 'Primary school'}]","[{'cui': 'C2362324', 'cui_str': 'Childhood obesity'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1511518', 'cui_str': 'Copy Number Polymorphisms'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0236026', 'cui_str': 'Fetal valproate syndrome'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0007757', 'cui_str': 'Cereal'}, {'cui': 'C0025017', 'cui_str': 'Meat'}, {'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0013710', 'cui_str': 'Eggs (edible)'}, {'cui': 'C0016163', 'cui_str': 'Fish'}, {'cui': 'C0011682', 'cui_str': 'Desiccation - action'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",4846.0,0.0989589,"Additionally, CNP group had greater increases in cereals, meat and fruits, and more decreases in eggs, fish and dried legumes consumption proportions as compared with the control group.","[{'ForeName': 'Haiquan', 'Initials': 'H', 'LastName': 'Xu', 'Affiliation': 'Institute of Food and Nutrition Development, Ministry of Agriculture and Rural Affairs, Beijing, China.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Ecker', 'Affiliation': 'International Food Policy Research Institute, Washington, DC, United States of America.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing, China.'}, {'ForeName': 'Songming', 'Initials': 'S', 'LastName': 'Du', 'Affiliation': 'Chinese Nutrition Society, Beijing, China.'}, {'ForeName': 'Ailing', 'Initials': 'A', 'LastName': 'Liu', 'Affiliation': 'National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing, China.'}, {'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America.'}, {'ForeName': 'Xiaoqi', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing, China.'}, {'ForeName': 'Tingyu', 'Initials': 'T', 'LastName': 'Li', 'Affiliation': ""Chongqing Children's Hospital, Chongqing, China.""}, {'ForeName': 'Hongwei', 'Initials': 'H', 'LastName': 'Guo', 'Affiliation': 'School of Public Health, Fudan University, Shanghai, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Harbin Medical University, Harbin, China.'}, {'ForeName': 'Guifa', 'Initials': 'G', 'LastName': 'Xu', 'Affiliation': 'Department of Public Health, Shandong University, Jinan, China.'}, {'ForeName': 'Weijia', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': 'Guangzhou Center for Disease Control and Prevention, Guangzhou, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': 'Institute of Child and Adolescent Health, School of Public Health, Peking University, Beijing, China.'}, {'ForeName': 'Junmao', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': 'Institute of Food and Nutrition Development, Ministry of Agriculture and Rural Affairs, Beijing, China.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Chen', 'Affiliation': 'International Food Policy Research Institute, Washington, DC, United States of America.'}, {'ForeName': 'Guansheng', 'Initials': 'G', 'LastName': 'Ma', 'Affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China.'}]",PloS one,['10.1371/journal.pone.0235951'] 1754,32679281,"China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial.","Acute ST-segment elevation myocardial infarction (STEMI) remains a serious life-threatening event. Despite coronary revascularization, patients might still suffer from poor outcomes caused by myocardial no-reflow and ischemic/reperfusion injury. Tongxinluo (TXL), a traditional Chinese medicine, has been preliminarily demonstrated to reduce myocardial no-reflow and ischemic/reperfusion injury. We further hypothesize that TXL treatment is also effective in reducing clinical end points for the patients with STEMI. METHODS AND RESULTS: The CTS-AMI trial is a prospective, randomized, double-blind, placebo-controlled, multicenter clinical study in China. An estimated 3,796 eligible patients with STEMI from about 120 centers are randomized 1:1 ratio to TXL or placebo groups. All enrolled patients are orally administrated a loading dose of 8 capsules of TXL or placebo together with dual antiplatelet agents on admission followed by 4 capsules 3 times a day until 12 months. The primary end point is 30-day major adverse cardiovascular and cerebrovascular events, a composite of cardiac death, myocardial reinfarction, emergency coronary revascularization, and stroke. Secondary end points include each component of the primary end point, 1-year major adverse cardiovascular and cerebrovascular events, and other efficacy and safety parameters. CONCLUSIONS: Results of CTS-AMI trial will determine the clinical efficacy and safety of traditional Chinese medicine TXL capsule in the treatment of STEMI patients in the reperfusion era.",2020,"The primary end point is 30-day major adverse cardiovascular and cerebrovascular events, a composite of cardiac death, myocardial reinfarction, emergency coronary revascularization, and stroke.","['patients with Acute Myocardial Infarction (CTS-AMI', '3,796 eligible patients with STEMI from about 120 centers']","['Tongxinluo (TXL', 'TXL', 'TXL or placebo', 'placebo']","['each component of the primary end point, 1-year major adverse cardiovascular and cerebrovascular events, and other efficacy and safety parameters', '30-day major adverse cardiovascular and cerebrovascular events, a composite of cardiac death, myocardial reinfarction, emergency coronary revascularization, and stroke']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C1742872', 'cui_str': 'tongxinluo'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0376297', 'cui_str': 'Cardiac death'}, {'cui': 'C0948369', 'cui_str': 'Myocardial reinfarction'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]",3796.0,0.355531,"The primary end point is 30-day major adverse cardiovascular and cerebrovascular events, a composite of cardiac death, myocardial reinfarction, emergency coronary revascularization, and stroke.","[{'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Xiangdong', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Haitao', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Kefei', 'Initials': 'K', 'LastName': 'Dou', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Hongbing', 'Initials': 'H', 'LastName': 'Yan', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Shijie', 'Initials': 'S', 'LastName': 'You', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Yanmin', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Liang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Lianjun', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Xiaojin', 'Initials': 'X', 'LastName': 'Gao', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Qiuting', 'Initials': 'Q', 'LastName': 'Dong', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Wenjia', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Guangyuan', 'Initials': 'G', 'LastName': 'Song', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Jiang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Guihao', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Ruijie', 'Initials': 'R', 'LastName': 'Tang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Jin', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Jingang', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Yao', 'Affiliation': 'Peking University Clinical Research Institute, Peking University, Beijing, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Xian', 'Affiliation': 'Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Peterson', 'Affiliation': 'Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Runlin', 'Initials': 'R', 'LastName': 'Gao', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Yuejin', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: yangyjfw@126.com.'}]",American heart journal,['10.1016/j.ahj.2020.06.011'] 1755,32679370,Early application of caffeine improves white matter development in very preterm infants.,"The aim of this study was to evaluate the effect of early prophylactic caffeine treatment on white matter development in very preterm infants using cerebral magnetic resonance imaging. A total of 194 preterm infants (≤32 weeks gestational age) were randomly assigned to the caffeine (n = 96) or placebo (n = 93) treatment group and administered with either caffeine or placebo within 72 h after birth. Cerebral magnetic resonance imaging, including diffuse tensor imaging examination, was performed at 34-36 weeks of corrected gestational age, and the fractional anisotropy (FA) and apparent diffusion coefficient (ADC) values were measured. In total, 160 infants were included in the final analysis, including 80 cases in the placebo group and 80 cases in the caffeine group. There were fewer instances of apnea of prematurity and shorter assisted ventilation times for infants in the caffeine group compared to the placebo group (p < 0.05). Infants in the caffeine group had significantly higher FA values in white matter, including the posterior limb of the internal capsule, the corpus callosum, the frontal, occipital, and parietal white matter, the cerebellum, and the cerebral peduncle, compared to infants in the placebo group. ADC values in the above white matter areas were significantly reduced in the caffeine group. However, there were no significant differences regarding the FA and ADC in the gray matter between the two groups. These results demonstrate that early administration of caffeine improves white matter micro-structural development in preterm infants, but with no significant effect on short-term complications related to prematurity.",2020,"Infants in the caffeine group had significantly higher FA values in white matter, including the posterior limb of the internal capsule, the corpus callosum, the frontal, occipital, and parietal white matter, the cerebellum, and the cerebral peduncle, compared to infants in the placebo group.","['very preterm infants', 'very preterm infants using cerebral magnetic resonance imaging', 'preterm infants', '194 preterm infants (≤32 weeks gestational age', '160 infants were included in the final analysis, including 80 cases in the placebo group and 80 cases in the caffeine group']","['placebo', 'caffeine', 'caffeine or placebo', 'prophylactic caffeine']","['white matter micro-structural development', 'apnea of prematurity and shorter assisted ventilation times', 'FA values', 'fractional anisotropy (FA) and apparent diffusion coefficient (ADC) values', 'FA and ADC', 'ADC values']","[{'cui': 'C3897192', 'cui_str': 'Very preterm infant'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0009653', 'cui_str': 'Condom'}]","[{'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0085672', 'cui_str': 'Microbiology procedure'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0475715', 'cui_str': 'Apnea of prematurity'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0554804', 'cui_str': 'Assisted breathing'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0085406', 'cui_str': 'Anisotropy'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}]",194.0,0.144528,"Infants in the caffeine group had significantly higher FA values in white matter, including the posterior limb of the internal capsule, the corpus callosum, the frontal, occipital, and parietal white matter, the cerebellum, and the cerebral peduncle, compared to infants in the placebo group.","[{'ForeName': 'Shasha', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Xiaoli', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Yanchao', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Brain Imaging, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Yuan', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Ruili', 'Initials': 'R', 'LastName': 'Zhang', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Xiaoan', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Brain Imaging, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Xiaoyang', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China; Center for Perinatal Medicine and Health, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg 40530, Sweden.'}, {'ForeName': 'Falin', 'Initials': 'F', 'LastName': 'Xu', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Changlian', 'Initials': 'C', 'LastName': 'Zhu', 'Affiliation': ""Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China; Center for Brain Repair and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg 40530, Sweden; Department of Women's and Children's Health, Karolinska Institutet, Stockholm 17177, Sweden. Electronic address: changlian.zhu@neuro.gu.se.""}]",Respiratory physiology & neurobiology,['10.1016/j.resp.2020.103495'] 1756,32679400,Determinants of healthcare use by homeless people with schizophrenia or bipolar disorder: results from the French Housing First Study.,"OBJECTIVES There is limited evidence available on the health-seeking behaviours of individuals in relation to determinants of healthcare use. This study aimed to analyse the determinants of healthcare use (including both hospital and outpatient services) among homeless people with severe mental health illnesses. STUDY DESIGN The study used data from a multicentre, randomised, controlled trial conducted in four large French cities (the French Housing First Study). METHODS Data were drawn from 671 homeless people enrolled in the study between August 2011 and April 2014. Mobile mental health outreach teams recruited homeless individuals with severe mental health illnesses who were living on the street or in emergency shelters, hospitals or prisons. Data collection was performed during face-to-face interviews. Healthcare service use included hospitalisations, mental health and regular emergency department (ED) visits and outpatient visits to healthcare facilities or physicians' offices over a 6-month follow-up period. The data were analysed with zero-inflated (ZI) two-part models. RESULTS In total, 61.1% of participants had at least one hospitalisation stay over the previous 6 months, with a mean of 25 (+/- 39.2) hospital days, and the majority (51%) had visited the ED (either for regular or mental health issues) during the same time period. The results confirmed the role of financial barriers (resources and health insurance) in seeking hospital care (P < 0.05). The main predictors for hospital use in the study population were a better social functioning score (odds ratio [OR]: 1.03; P < 0.001) and having schizophrenia (OR: 1.39; P < 0.01). Higher mental health scores (assessed by the Medical Outcomes Study 36-item Short Form Health Survey) (OR: 1.03, P < 0.01) and alcohol dependence (OR: 2.13; P < 0.01) were associated with not using ED healthcare services. Being 'absolutely homeless' predicted an increased use of the ED and a zero use of outpatient services. Inversely, no association with factors related to the homelessness trajectory was found in hospital ZI negative binomial models. CONCLUSION This study is important because a comprehensive understanding of the determinants of healthcare use enables healthcare systems to adapt and develop. The efficiency of medicosocial interventions targeting the homeless population with mental health illnesses must also be assessed. CLINICAL TRIAL NUMBER NCT01570712.",2020,"Healthcare service use included hospitalisations, mental health and regular emergency department (ED) visits and outpatient visits to healthcare facilities or physicians' offices over a 6-month follow-up period.","['homeless people with schizophrenia or bipolar disorder', 'Mobile mental health outreach teams recruited homeless individuals with severe mental health illnesses who were living on the street or in emergency shelters, hospitals or prisons', 'Data were drawn from 671 homeless people enrolled in the study between August 2011 and April 2014', 'four large French cities (the French Housing First Study', 'homeless people with severe mental health illnesses', 'homeless population with mental health illnesses']",['medicosocial interventions'],"['hospitalisations, mental health and regular emergency department (ED) visits and outpatient visits', 'alcohol dependence ', 'social functioning score', 'hospitalisation stay', 'financial barriers (resources and health insurance', 'Higher mental health scores']","[{'cui': 'C0237154', 'cui_str': 'Homeless'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0425242', 'cui_str': 'Homeless single person'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C3178959', 'cui_str': 'Evacuation Shelter'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0033168', 'cui_str': 'Prisons'}, {'cui': 'C0013113', 'cui_str': 'Drawings'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0376246', 'cui_str': 'French language'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0020056', 'cui_str': 'Housed'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0001973', 'cui_str': 'Alcohol dependence'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0021682', 'cui_str': 'Health Insurance'}, {'cui': 'C0205250', 'cui_str': 'High'}]",,0.0642052,"Healthcare service use included hospitalisations, mental health and regular emergency department (ED) visits and outpatient visits to healthcare facilities or physicians' offices over a 6-month follow-up period.","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Loubière', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France; Department of Research and Innovation, Support Unit for Clinical Research and Economic Evaluation, Assistance Publique - Hôpitaux de Marseille, Marseille, 13385, France. Electronic address: sandrine.loubiere@univ-amu.fr.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Tinland', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France; Department of Psychiatry, Sainte-Marguerite University Hospital, Marseille, 13009, France.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Taylor', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Loundou', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France; Department of Research and Innovation, Support Unit for Clinical Research and Economic Evaluation, Assistance Publique - Hôpitaux de Marseille, Marseille, 13385, France.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Girard', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Boyer', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France; Department of Research and Innovation, Support Unit for Clinical Research and Economic Evaluation, Assistance Publique - Hôpitaux de Marseille, Marseille, 13385, France.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Auquier', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France; Department of Research and Innovation, Support Unit for Clinical Research and Economic Evaluation, Assistance Publique - Hôpitaux de Marseille, Marseille, 13385, France.'}]",Public health,['10.1016/j.puhe.2020.05.019'] 1757,32679403,"Commentary on Liu, K. et al. (2018). Handgrip exercise reduces peripherally-inserted central catheter-related venous thrombosis in patients with solid cancers: A randomized controlled trial.",,2020,,['patients with solid cancers'],['Handgrip exercise reduces peripherally-inserted central catheter-related venous thrombosis'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205208', 'cui_str': 'Solid'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0179740', 'cui_str': 'Peripherally inserted central catheter'}, {'cui': 'C0042487', 'cui_str': 'Venous thrombosis'}]",[],,0.162369,,"[{'ForeName': 'Cui', 'Initials': 'C', 'LastName': 'Wen', 'Affiliation': 'Department of Nursing, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, 530021 Nanning, Guangxi, China.'}, {'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Ying', 'Affiliation': 'Department of Nursing, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, 530021 Nanning, Guangxi, China. Electronic address: yanpingying0116@126.com.'}, {'ForeName': 'Jianpeng', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': 'Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, 530021 Nanning, Guangxi, China.'}]",International journal of nursing studies,['10.1016/j.ijnurstu.2020.103691'] 1758,32691207,Does antrum size matter in sleeve gastrectomy? A prospective randomized study.,"BACKGROUND Laparoscopic sleeve gastrectomy (LSG) is a safe and effective bariatric procedure in terms of excess weight loss. Nevertheless, controversies still exist on several technical and operative aspects of LSG. The aim of this study is to evaluate variations in anthropometric features in subjects with a LSG gastric resection starting from 2 cm or 6 cm from the pylorus. Secondary aim was the evaluation of differences in morbidity, food tolerance, and GERD incidence studied with upper endoscopy (UE) and GERD Health-Related Quality-of-Life score. METHODS Patients were prospectively randomized into 2 groups: Group A (at 2 cm proximally to the pylorus) and Group B (at 6 cm proximally to the pylorus). All patients were followed-up at 3, 6, 12, and 24 months. UE was performed in all patients at 12 or 24 months. RESULTS One hundred and fifty met the inclusion criteria and were enrolled in the study. The anthropometric features (BMI, %EWL, %TWL) resulted statistically different in the first 12 months (24.2 ± 3.4 vs 27.5 ± 4.3, 63.7 ± 14.1 vs 59.6 ± 12.5 and 42.9 ± 7.4 vs 38.2 ± 6.2), in favor of group A. At 24 months the differences disappeared (25.2 ± 4.4 vs 26.2 ± 3.3, 62.8 ± 13.1 vs 61.6 ± 10.5 and 41.9 ± 7.4 vs 40.2 ± 6.2). An increased GERD was found in both groups postoperatively with a higher incidence in group A at 6-month follow-up. CONCLUSION Performing the LSG with a radical antrectomy could improve weight loss at 12-month follow-up but expose to lower food tolerance and higher transitory GERD. The differences seem to be reduced to a 24-month.",2020,"An increased GERD was found in both groups postoperatively with a higher incidence in group A at 6-month follow-up. ","['subjects with a LSG gastric resection starting from 2\xa0cm or 6\xa0cm from the pylorus', 'One hundred and fifty met the inclusion criteria and were enrolled in the study', 'Patients']",['Laparoscopic sleeve gastrectomy (LSG'],"['weight loss', 'GERD', 'morbidity, food tolerance, and GERD incidence studied with upper endoscopy (UE) and GERD Health-Related Quality-of-Life score']","[{'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}, {'cui': 'C0017118', 'cui_str': 'Gastrectomy'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0034196', 'cui_str': 'Pyloric structure of stomach'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0017168', 'cui_str': 'Gastroesophageal reflux disease'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0021150', 'cui_str': 'Incidence Studies'}, {'cui': 'C0017195', 'cui_str': 'Endoscopy of stomach'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0229578,"An increased GERD was found in both groups postoperatively with a higher incidence in group A at 6-month follow-up. ","[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Pizza', 'Affiliation': 'Department of Surgery, Hospital ""A. Rizzoli"", Aslnapoli2nord, Naples, Italy. Francesco_pizza@libero.it.'}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': ""D'Antonio"", 'Affiliation': 'Department of Surgery, Hospital ""A. Rizzoli"", Aslnapoli2nord, Naples, Italy.'}, {'ForeName': 'Francesco Saverio', 'Initials': 'FS', 'LastName': 'Lucido', 'Affiliation': 'Division of General, Mininvasive and Bariatric Surgery, University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Gambardella', 'Affiliation': 'Division of General, Mininvasive and Bariatric Surgery, University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Juan Antonio', 'Initials': 'JA', 'LastName': 'Carbonell Asíns', 'Affiliation': 'Bioinformatics and Biostatistics Unit, Biomedical Research Institute (INCLIVA), Valencia, Spain.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': ""Dell'Isola"", 'Affiliation': 'Department of Infectious Diseases, AORN ""Dei Colli"", Naples, Italy.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Tolone', 'Affiliation': 'Division of General, Mininvasive and Bariatric Surgery, University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}]",Surgical endoscopy,['10.1007/s00464-020-07811-1'] 1759,32687804,"Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study.","BACKGROUND Long-term protection and herd immunity induced by existing pertussis vaccines are imperfect, and a need therefore exists to develop new pertussis vaccines. This study aimed to investigate the safety, colonisation, and immunogenicity of the new, live attenuated pertussis vaccine, BPZE1, when given intranasally. METHODS This phase 1b, double-blind, randomised, placebo-controlled, dose-escalation study was done at the phase 1 unit, Karolinska Trial Alliance, Karolinska University Hospital, Stockholm, Sweden. Healthy adults (18-32 years) were screened and included sequentially into three groups of increasing BPZE1 dose strength (10 7 colony-forming units [CFU], 10 8 CFU, and 10 9 CFU), and were randomly assigned (3:1 within each group) to receive vaccine or placebo. Vaccine and placebo were administered in phosphate-buffered saline contained 5% saccharose as 0·4 mL in each nostril. The primary outcome was solicited and unsolicited adverse events between day 0 and day 28. The analysis included all randomised participants who received a vaccine dose. Colonisation with BPZE1 was determined by repeatedly culturing nasopharyngeal aspirates at day 4, day 7, day 11, day 14, day 21, and day 28 after vaccination. Immunogenicity, as serum IgG and IgA responses were assessed at day 0, day 7, day 14, day 21, day 28, 6 months, and 12 months after vaccination. This trial is registered at Clinicaltrials.gov, NCT02453048. FINDINGS Between Sept 1, 2015, and Feb 3, 2016, 120 participants were assessed for eligibility, 48 of whom were enrolled and randomly assigned (3:1) to receive vaccine or placebo, with 12 participants each in a low-dose, medium-dose, and high-dose vaccine group. Adverse events between day 0 and day 28 were reported by one (8%, 95% CI 0-39) of 12 participants in both the placebo and low-dose groups, and two (17%; 2-48) of 12 participants in both the medium-dose and high-dose groups, including cough of grade 2 or more, oropharyngeal pain, and rhinorrhoea and nasal congestion. During this time, none of the participants experienced any spasmodic cough, difficulties in breathing, or adverse events following immunisation concerning vital signs. The tested doses of BPZE1 or placebo were well tolerated, with no apparent difference in solicited or unsolicited adverse events following immunisation between groups. Colonisation at least once after vaccination was observed in 29 (81%; 68-93) of 36 vaccinated participants. The tested vaccine doses were immunogenic, with increases in serum IgG and IgA titres against the four B pertussis antigens from baseline to 12 months. INTERPRETATION The tested vaccine was safe, induced a high colonisation rate in an adult population, and was immunogenic at all doses. These findings justify further clinical development of BPZE1 to ultimately be used as a priming vaccine for neonates or a booster vaccine for adolescents and adults, or both. FUNDING ILiAD Biotechnologies.",2020,"The tested vaccine doses were immunogenic, with increases in serum IgG and IgA titres against the four B pertussis antigens from baseline to 12 months. ","['Between Sept 1, 2015, and Feb 3, 2016, 120 participants were assessed for eligibility, 48 of whom were enrolled and randomly assigned (3:1) to receive', 'Healthy adults (18-32 years']","['vaccine or placebo', 'BPZE1 or placebo', 'Vaccine and placebo', 'live attenuated intranasal pertussis vaccine BPZE1', 'phosphate-buffered saline contained 5% saccharose as 0·4', 'placebo']","['spasmodic cough, difficulties in breathing, or adverse events', 'Safety and immunogenicity', 'Adverse events', 'Immunogenicity, as serum IgG and IgA responses', 'solicited and unsolicited adverse events', 'safety, colonisation, and immunogenicity', 'cough of grade 2 or more, oropharyngeal pain, and rhinorrhoea and nasal congestion', 'serum IgG and IgA titres', 'solicited or unsolicited adverse events', 'Colonisation']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0031237', 'cui_str': 'Pertussis Vaccine'}, {'cui': 'C0031603', 'cui_str': 'Phosphate'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0038636', 'cui_str': 'Sucrose'}]","[{'cui': 'C0277870', 'cui_str': 'Spasmodic cough'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0475270', 'cui_str': 'G2 grade'}, {'cui': 'C2363731', 'cui_str': 'Oropharyngeal pain'}, {'cui': 'C1260880', 'cui_str': 'Nasal discharge'}, {'cui': 'C0027424', 'cui_str': 'Nasal congestion'}, {'cui': 'C0475208', 'cui_str': 'Titer'}]",120.0,0.664209,"The tested vaccine doses were immunogenic, with increases in serum IgG and IgA titres against the four B pertussis antigens from baseline to 12 months. ","[{'ForeName': 'Maja', 'Initials': 'M', 'LastName': 'Jahnmatz', 'Affiliation': 'Public Health Agency of Sweden, Solna, Sweden.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Richert', 'Affiliation': 'University of Bordeaux, National Institute for Health and Medical Research (Inserm), Bordeaux Population Health Research Center, Bordeaux, France; University Hospital Centre CHU, Bordeaux, France; EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France; Inria SISTM team, F-33405, Talence, France.'}, {'ForeName': 'Nabil', 'Initials': 'N', 'LastName': 'Al-Tawil', 'Affiliation': 'Karolinska Trial Alliance, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Jann', 'Initials': 'J', 'LastName': 'Storsaeter', 'Affiliation': 'Public Health Agency of Sweden, Solna, Sweden.'}, {'ForeName': 'Céline', 'Initials': 'C', 'LastName': 'Colin', 'Affiliation': 'University of Bordeaux, National Institute for Health and Medical Research (Inserm), Bordeaux Population Health Research Center, Bordeaux, France; University Hospital Centre CHU, Bordeaux, France; EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Bauduin', 'Affiliation': 'University of Bordeaux, National Institute for Health and Medical Research (Inserm), Bordeaux Population Health Research Center, Bordeaux, France; University Hospital Centre CHU, Bordeaux, France; EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.'}, {'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Thalen', 'Affiliation': 'ILiAD Biotechnologies, New York, NY, USA.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Solovay', 'Affiliation': 'ILiAD Biotechnologies, New York, NY, USA.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Rubin', 'Affiliation': 'ILiAD Biotechnologies, New York, NY, USA.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Mielcarek', 'Affiliation': 'University of Lille, National Centre for Scientific Research (CNRS), National Institute for Health and Medical Research (Inserm), University Hospital Centre CHU Lille, Lille, France; Center for Infection and Immunity of Lille, Institut Pasteur de Lille, Lille, France.'}, {'ForeName': 'Rigmor', 'Initials': 'R', 'LastName': 'Thorstensson', 'Affiliation': 'Public Health Agency of Sweden, Solna, Sweden.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Locht', 'Affiliation': 'University of Lille, National Centre for Scientific Research (CNRS), National Institute for Health and Medical Research (Inserm), University Hospital Centre CHU Lille, Lille, France; Center for Infection and Immunity of Lille, Institut Pasteur de Lille, Lille, France. Electronic address: camille.locht@pasteur-lille.fr.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(20)30274-7'] 1760,32687836,Failure of tDCS to modulate motor excitability and speech motor learning.,"Transcranial direct current stimulation (tDCS) modulates cortical excitability in a polarity-specific way and, when used in combination with a behavioural task, it can alter performance. TDCS has the potential, therefore, for use as an adjunct to therapies designed to treat disorders affecting speech, including, but not limited to acquired aphasias and developmental stuttering. For this reason, it is important to conduct studies evaluating its effectiveness and the parameters optimal for stimulation. Here, we aimed to evaluate the effects of bi-hemispheric tDCS over speech motor cortex on performance of a complex speech motor learning task, namely the repetition of tongue twisters. A previous study in older participants showed that tDCS could modulate performance on a similar task. To further understand the effects of tDCS, we also measured the excitability of the speech motor cortex before and after stimulation. Three groups of 20 healthy young controls received: (i) anodal tDCS to the left IFG/LipM1 and cathodal tDCS to the right hemisphere homologue; or (ii) cathodal tDCS over the left and anodal over the right; or (iii) sham stimulation. Participants heard and repeated novel tongue twisters and matched simple sentences before, during and 10 min after the stimulation. One mA tDCS was delivered concurrent with task performance for 13 min. Motor excitability was measured using transcranial magnetic stimulation to elicit motor-evoked potentials in the lip before and immediately after tDCS. The study was double-blind, randomized, and sham-controlled; the design and analysis were pre-registered. Performance on the task improved from baseline to after stimulation but was not significantly modulated by tDCS. Similarly, a small decrease in motor excitability was seen in all three stimulation groups but did not differ among them and was unrelated to task performance. Bayesian analyses provide substantial evidence in support of the null hypotheses in both cases, namely that tongue twister performance and motor excitability were not affected by tDCS. We discuss our findings in the context of the previous positive results for a similar task. We conclude that tDCS may be most effective when brain function is sub-optimal due to age-related declines or pathology. Further study is required to determine why tDCS failed to modulate excitability in the speech motor cortex in the expected ways.",2020,"Similarly, a small decrease in motor excitability was seen in all three stimulation groups but did not differ among them and were unrelated to task performance.","['older participants', '20 healthy young controls received: (i']","['bi-hemispheric tDCS', 'Transcranial direct current stimulation (tDCS', 'TDCS', 'tDCS', 'anodal tDCS to the left IFG/LipM1 and cathodal tDCS to the right hemisphere homologue; or (ii) cathodal tDCS over the left and anodal over the right; or (iii) sham stimulation']","['tongue twister performance and motor excitability', 'motor excitability', 'Motor excitability']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205139', 'cui_str': 'Hemispheric'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0450424', 'cui_str': 'To the left'}, {'cui': 'C0546911', 'cui_str': 'To the right'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0040408', 'cui_str': 'Tongue structure'}, {'cui': 'C0335670', 'cui_str': 'Twister'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}]",20.0,0.046913,"Similarly, a small decrease in motor excitability was seen in all three stimulation groups but did not differ among them and were unrelated to task performance.","[{'ForeName': 'Charlotte E E', 'Initials': 'CEE', 'LastName': 'Wiltshire', 'Affiliation': 'Wellcome Centre for Integrative Neuroimaging, Department of Experimental Psychology, Radcliffe Observatory Quarter, University of Oxford, OX2 6GG, UK. Electronic address: charlotte.wiltshire@psy.ox.ac.uk.'}, {'ForeName': 'Kate E', 'Initials': 'KE', 'LastName': 'Watkins', 'Affiliation': 'Wellcome Centre for Integrative Neuroimaging, Department of Experimental Psychology, Radcliffe Observatory Quarter, University of Oxford, OX2 6GG, UK. Electronic address: kate.watkins@psy.ox.ac.uk.'}]",Neuropsychologia,['10.1016/j.neuropsychologia.2020.107568'] 1761,32677215,Family functioning moderates the impact of depression treatment on adolescents' suicidal ideations.,"PURPOSE The purpose of this study was to explore whether adolescent-perceived family functioning moderates the depression treatment effects on suicidal ideations. METHODS This is a nonpreregistered exploratory secondary analysis of the TADS RCT, which included four treatment groups: fluoxetine, CBT, their combination, and placebo. A random coefficients regression model with posteriori CONTRAST statements was conducted to examine the effects of depression treatment on adolescents' suicidal ideations over time (N = 439). Baron and Kenny's (1986) and Kraemer et al.'s (2002) approach was followed to explore family functioning as a potential moderator of the treatment effects on suicidal ideations over time. RESULTS Adolescents in the four treatment groups did not differ significantly in their suicidal ideations at initial status; however, those in the combination group had faster reduction in suicidality. Family functioning moderated the relationship between depression treatment and adolescents' suicidal ideations. In particular, the results revealed that for adolescents who reported positive family functioning (n = 249), treatment had a significant impact on their suicidal ideations over time. However, for adolescents who reported negative family functioning (n = 190), type of treatment did not have a differential effect on improvement in severity of suicidal ideation over time. CONCLUSION Findings provided evidence that the process by which depression treatment impacts adolescents' suicidality is contingent upon their family environment. Family-centered approaches to adolescent depression treatment are recommended.",2019,"RESULTS Adolescents in the four treatment groups did not differ significantly in their suicidal ideations at initial status; however, those in the combination group had faster reduction in suicidality.","[""adolescents' suicidal ideations"", ""adolescents' suicidal ideations over time (N\xa0=\xa0439""]","['fluoxetine, CBT, their combination, and placebo']","['suicidality', 'suicidal ideations', 'severity of suicidal ideation']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}, {'cui': 'C0040223', 'cui_str': 'Time'}]","[{'cui': 'C0016365', 'cui_str': 'Fluoxetine'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",,0.0459547,"RESULTS Adolescents in the four treatment groups did not differ significantly in their suicidal ideations at initial status; however, those in the combination group had faster reduction in suicidality.","[{'ForeName': 'Latefa Ali', 'Initials': 'LA', 'LastName': 'Dardas', 'Affiliation': 'School of Nursing, The University of Jordan, Amman, Jordan.'}]",Child and adolescent mental health,['10.1111/camh.12323'] 1762,32677216,A randomized controlled trial of internet-delivered cognitive behaviour therapy for adolescent anxiety disorders in a routine clinical care setting with and without parent sessions.,"BACKGROUND Computerized treatments have been shown to be effective in young people with anxiety disorders within research settings. The aims of this study were to evaluate a self-completed, therapist-supported online treatment for adolescent anxiety disorders in a routine clinical care setting and examine whether additional sessions for parents improved treatment outcome. METHOD Sixty adolescents (13-18 years) referred by primary and secondary care services for treatment of an anxiety disorder and their parent(s) were randomly allocated to begin treatment immediately or after a 16-week waitlist. Half the parents (receiving treatment immediately or after a waitlist) were allocated to receive sessions themselves. Assessments were conducted pre- and posttreatment and at 6-month follow-up. RESULTS There was no significant difference posttreatment between the immediate treatment and waitlist groups in remission of primary anxiety disorder (Odds Ratio (OR) = 2.19, 95% CI: 0.72-6.70). Parent sessions did not significantly improve adolescent outcomes immediately or at 6-month follow-up (OR = 0.75, 95% CI: 0.26-2.15; OR = 1.14, 95% CI: 0.42-3.15). CONCLUSIONS Within a routine clinical care setting, a therapist-supported online treatment failed to deliver significantly better outcomes for adolescents with anxiety disorders than a waitlist. Further research is needed to develop more effective treatments for this population.",2019,"Parent sessions did not significantly improve adolescent outcomes immediately or at 6-month follow-up (OR = 0.75, 95% CI: 0.26-2.15; OR = 1.14, 95% CI: 0.42-3.15). ","['adolescent anxiety disorders', 'Sixty adolescents (13-18\xa0years) referred by primary and secondary care services for treatment of an anxiety disorder and their parent(s', 'adolescent anxiety disorders in a routine clinical care setting with and without parent sessions', 'young people with anxiety disorders within research settings', 'adolescents with anxiety disorders']","['therapist-supported online treatment', 'internet-delivered cognitive behaviour therapy']","['adolescent outcomes', 'remission of primary anxiety disorder']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0553514', 'cui_str': 'Referral source'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C3494402', 'cui_str': 'Secondary Care'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}]","[{'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}]",,0.0586422,"Parent sessions did not significantly improve adolescent outcomes immediately or at 6-month follow-up (OR = 0.75, 95% CI: 0.26-2.15; OR = 1.14, 95% CI: 0.42-3.15). ","[{'ForeName': 'Polly', 'Initials': 'P', 'LastName': 'Waite', 'Affiliation': 'School of Psychology and Clinical Language Sciences, University of Reading, Reading, UK.'}, {'ForeName': 'Tamsin', 'Initials': 'T', 'LastName': 'Marshall', 'Affiliation': 'CAMHS Anxiety & Depression Pathway, Berkshire Healthcare Foundation Trust, School of Psychology and Clinical Language Sciences, University of Reading, Reading, UK.'}, {'ForeName': 'Cathy', 'Initials': 'C', 'LastName': 'Creswell', 'Affiliation': 'School of Psychology and Clinical Language Sciences, University of Reading, Reading, UK.'}]",Child and adolescent mental health,['10.1111/camh.12311'] 1763,32677243,Mindfulness-based stress reduction for mental health in youth: a cluster randomized controlled trial.,"BACKGROUND Mental illness is among the most common causes of morbidity, mortality, and disability in childhood. Mindfulness-based stress reduction (MBSR) has shown significant benefit in mental health; however, evidence of its effectiveness in youth is limited. The objective of this study was to compare the efficacy of MBSR plus usual care versus usual care alone for reducing mental health symptoms in youth. METHODS A two-arm, mixed methods, randomized cluster-controlled trial of 12-18 year olds who were residents of CASA House, a voluntary residential treatment program for adolescents, between January 2011 and March 2013 (clinicaltrials.gov, NCT01307943). INTERVENTIONS Treatment terms were randomized to usual care, or MBSR plus usual care, which included eight MBSR sessions of 2 hr/week. OUTCOMES The primary outcome was impact on emotions and behavior at the end of the program, using the Behavior Assessment System for Children, Second Edition (BASC-2). Secondary outcomes included perceived stress levels, mindfulness, and emotional regulation. RESULTS A total of 85 participants were randomized to either the MBSR arm (n = 45) or control arm (n = 40). Significant differences in favor of MBSR were found on Teacher ratings of the Internalizing Problems (p = .038) and Adaptive Skills subscales (p = .022) on the BASC-2. No significant differences were found on other outcomes. A post hoc analysis found that the MBSR arm had a significantly shorter time to discharge (p = .02). CONCLUSION The results of this study indicate that MBSR is effective for improved coping with internalizing problems and adaptive emotional skills in our sample. Future studies should focus on larger, longer-term studies in youth.",2019,Significant differences in favor of MBSR were found on Teacher ratings of the Internalizing Problems (p = .038) and Adaptive Skills subscales (p = .022) on the BASC-2.,"['mental health in youth', 'youth', '85 participants', '12-18\xa0year olds who were residents of CASA House, a voluntary residential treatment program for adolescents, between January 2011 and March 2013 (clinicaltrials.gov, NCT01307943']","['MBSR plus usual care versus usual care alone', 'MBSR', 'usual care, or MBSR plus usual care, which included eight MBSR sessions of 2\xa0hr/week', 'Mindfulness-based stress reduction (MBSR', 'Mindfulness-based stress reduction']","['shorter time to discharge', 'Adaptive Skills subscales', 'MBSR', 'Teacher ratings of the Internalizing Problems', 'mental health symptoms', 'stress levels, mindfulness, and emotional regulation', 'emotions and behavior at the end of the program, using the Behavior Assessment System for Children, Second Edition (BASC-2']","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0020056', 'cui_str': 'Housed'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0035189', 'cui_str': 'Residential Treatment'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}, {'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1160858', 'cui_str': 'Behavior assessment'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0441795', 'cui_str': 'Second edition'}]",85.0,0.176824,Significant differences in favor of MBSR were found on Teacher ratings of the Internalizing Problems (p = .038) and Adaptive Skills subscales (p = .022) on the BASC-2.,"[{'ForeName': 'Sunita', 'Initials': 'S', 'LastName': 'Vohra', 'Affiliation': 'Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Salima', 'Initials': 'S', 'LastName': 'Punja', 'Affiliation': 'Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Sibinga', 'Affiliation': 'Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Lola', 'Initials': 'L', 'LastName': 'Baydala', 'Affiliation': 'Faculty of Medicine and Dentistry, Department of Pediatrics, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Wikman', 'Affiliation': 'Department of Educational Psychology, Misericordia Hospital Child Health Clinic, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Singhal', 'Affiliation': 'Faculty of Science, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Florin', 'Initials': 'F', 'LastName': 'Dolcos', 'Affiliation': 'Psychology Department, Neuroscience Program, Beckman Institute for Advanced Science & Technology, University of Illinois at Urbana-Champaign, Urbana-Champaign, IL, USA.'}, {'ForeName': 'K Jessica', 'Initials': 'KJ', 'LastName': 'Van Vliet', 'Affiliation': 'Department of Educational Psychology, University of Alberta, Edmonton, AB, Canada.'}]",Child and adolescent mental health,['10.1111/camh.12302'] 1764,32677987,Establishing cross-systems collaborations for implementation: protocol for a longitudinal mixed methods study.,"BACKGROUND Cross-system interventions can help integrate services across different service delivery systems but require organizations to establish strong collaborative relationships for implementation. Contingency theory suggests that the effectiveness of different collaborative strategies (i.e. specific ways organizations align operations and services) varies by context. This paper describes a study of different strategies for fostering collaboration between child welfare and substance abuse treatment agencies and the conditions under which they are effective for implementation. We also describe the development and piloting of the Collaborating Across Systems for Program Implementation (CASPI) tool-a decision-making guide intended to help researchers and organizational leaders identify and use appropriate collaborative strategies for their context. METHODS/DESIGN This multisite longitudinal, mixed methods study, leverages a naturally occurring implementation initiative -- in up to 17 Ohio counties -- to implement Ohio START (Sobriety Treatment and Reducing Trauma). START is a child welfare model that requires strong collaboration with local substance use treatment organizations to promote integrated services. During the first two years, we will identify collaborative strategies associated with improved START implementation (penetration and fidelity) and service delivery outcomes (timeliness), given system, and organizational features. We will conduct a convergent mixed methods study drawing on worker surveys, agency documents, administrative data, formal partner agreements, and group interviews. Data will be integrated and analyzed using Qualitative Comparative Analysis (QCA). To develop the CASPI, an expert panel comprised of implementation experts, and community stakeholders will convene to synthesize our findings and develop contents (including a decision tree). During the final year of the study, we will assess the acceptability, appropriateness, and feasibility of the CASPI in a randomized vignette experiment, and a pilot-test with 3 child welfare agencies that have not yet implemented START. DISCUSSION Our results will lay the groundwork for a larger controlled trial that will test the CASPI's effectiveness for supporting effective and efficient implementation of cross-system interventions like START. The CASPI is expected to help leaders and researchers select and use collaboration strategies tailored to their context and be applicable in a wide range of settings including rural communities. Our work also advances system-level implementation strategies. TRIAL REGISTRATION NCT03931005 , Registered April 29, 2019.",2020,"During the first two years, we will identify collaborative strategies associated with improved START implementation (penetration and fidelity) and service delivery outcomes (timeliness), given system, and organizational features.",['leverages a naturally occurring implementation initiative -- in up to 17 Ohio counties -- to implement Ohio START (Sobriety Treatment and Reducing Trauma'],[],"['START implementation (penetration and fidelity) and service delivery outcomes (timeliness), given system, and organizational features']","[{'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0028905', 'cui_str': 'Ohio'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}]",[],"[{'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0205321', 'cui_str': 'Penetrating'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0029246', 'cui_str': 'Organizations'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]",,0.0363623,"During the first two years, we will identify collaborative strategies associated with improved START implementation (penetration and fidelity) and service delivery outcomes (timeliness), given system, and organizational features.","[{'ForeName': 'Alicia C', 'Initials': 'AC', 'LastName': 'Bunger', 'Affiliation': 'College of Social Work, The Ohio State University, 1947 College Road, Columbus, OH, 43210, USA. Bunger.5@osu.edu.'}, {'ForeName': 'Emmeline', 'Initials': 'E', 'LastName': 'Chuang', 'Affiliation': 'School of Social Welfare, University of California Berkeley, 120 Haviland Hall, Berkeley, CA, 94720, USA.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Girth', 'Affiliation': 'John Glenn College of Public Affairs, The Ohio State University, 1810 College Road, Columbus, OH, 43210, USA.'}, {'ForeName': 'Kathryn E', 'Initials': 'KE', 'LastName': 'Lancaster', 'Affiliation': 'College of Public Health, The Ohio State University, 1841 Neil Avenue, Columbus, OH, 43210, USA.'}, {'ForeName': 'Fawn', 'Initials': 'F', 'LastName': 'Gadel', 'Affiliation': 'Public Children Services Association of Ohio (PCSAO), 37 West Broad Street, Suite 1100, Columbus, OH, 43215, USA.'}, {'ForeName': 'Marla', 'Initials': 'M', 'LastName': 'Himmeger', 'Affiliation': 'Public Children Services Association of Ohio (PCSAO), 37 West Broad Street, Suite 1100, Columbus, OH, 43215, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Saldana', 'Affiliation': 'Oregon Social Learning Center, 10 Shelton McMurphey Blvd., Eugene, OR, 97405, USA.'}, {'ForeName': 'Byron J', 'Initials': 'BJ', 'LastName': 'Powell', 'Affiliation': 'Brown School, Washington University in St. Louis, One Brookings Drive, St. Louis, MO, 63130, USA.'}, {'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Aarons', 'Affiliation': 'UC San Diego, Department of Psychiatry, 9500 Gilman Drive (0812), La Jolla, San Diego, CA, 92093, USA.'}]",Implementation science : IS,['10.1186/s13012-020-01016-9'] 1765,32673766,Making sense of cross-trial comparisons for the frontline treatment of advanced-stage Hodgkin lymphoma.,,2020,,['advanced-stage Hodgkin lymphoma'],[],[],"[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0019829', 'cui_str': 'Hodgkin lymphoma'}]",[],[],,0.0468669,,"[{'ForeName': 'Deepesh P', 'Initials': 'DP', 'LastName': 'Lad', 'Affiliation': 'Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India. Electronic address: deepesh.lad12@gmail.com.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2020.05.012'] 1766,32673830,Accelerated treatment of endocarditis-The POET II trial: Rationale and design of a randomized controlled trial.,"BACKGROUND The optimal antibiotic treatment length for infective endocarditis (IE) is uncertain. International guidelines recommend treatment duration of up to 6 weeks for patients with left-sided IE but are primarily based on historical data and expert opinion. Efficacies of modern therapies, fast recovery seen in many patients with IE, and complications to long hospital stays challenge the rationale for fixed treatment durations in all patients. OBJECTIVE The objective was to conduct a noninferiority randomized controlled trial (acronym POET II) investigating the safety of accelerated (shortened) antibiotic therapy as compared to standard duration in patients with left-sided IE. METHODS The POET II trial is a multicenter, multinational, open-label, noninferiority randomized controlled trial. Patients with definite left-sided IE due to Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis will be eligible for enrolment. Each patient will be randomized to accelerated antibiotic treatment or standard-length treatment (1:1) following clinical stabilization as defined by clinical parameters, laboratory values, and transesophageal echocardiography findings. Accelerated treatment will be between 2 and 4 weeks, whereas standard-length treatment will be between 4 and 6 weeks, depending on microbiologic etiology, complications, need for valve surgery, and prosthetic versus native valve endocarditis. The primary outcome is a composite of all-cause mortality, unplanned cardiac surgery, relapse of bacteremia, or embolization within 6 months of randomization. CONCLUSIONS The POET II trial will investigate the safety of accelerated antibiotic therapy for patients with left-sided IE caused by Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis. The results of the POET II trial will improve the evidence base of treatment recommendations, and clinical practice may be altered.",2020,"The POET II trial will investigate the safety of accelerated antibiotic therapy for patients with left-sided IE caused by Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis.","['patients with left-sided IE caused by Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis', 'patients with left-sided IE']","['accelerated (shortened) antibiotic therapy', 'accelerated antibiotic therapy']","['microbiologic etiology, complications, need for valve surgery, and prosthetic versus native valve endocarditis', 'composite of all-cause mortality, unplanned cardiac surgery, relapse of bacteremia, or embolization within 6\u202fmonths of randomization']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1827151', 'cui_str': 'Left sided infective endocarditis'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C0074992', 'cui_str': 'sphingosine 1-phosphate'}, {'cui': 'C0038172', 'cui_str': 'Staphylococcus aureus'}, {'cui': 'C0085494', 'cui_str': 'Genus Enterococcus'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotic'}]","[{'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C1142550', 'cui_str': 'Native valve endocarditis'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0013931', 'cui_str': 'Embolization - action'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]",,0.224308,"The POET II trial will investigate the safety of accelerated antibiotic therapy for patients with left-sided IE caused by Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis.","[{'ForeName': 'Lauge', 'Initials': 'L', 'LastName': 'Østergaard', 'Affiliation': 'The Heart Center, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Mia Marie', 'Initials': 'MM', 'LastName': 'Pries-Heje', 'Affiliation': 'The Heart Center, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Rasmus Bo', 'Initials': 'RB', 'LastName': 'Hasselbalch', 'Affiliation': 'Department of Cardiology, Herlev-Gentofte Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Rasmussen', 'Affiliation': 'Department of Infectious Diseases, Skåne University Hospital, Lund, Sweden.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Åkesson', 'Affiliation': 'Department of Infectious Diseases, Skåne University Hospital, Lund, Sweden.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Horvath', 'Affiliation': 'Department of Infectious Diseases, The Prince Charles Hospital, Brisbane, Australia.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Povlsen', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Gill', 'Affiliation': 'Department of Cardiology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Niels Eske', 'Initials': 'NE', 'LastName': 'Bruun', 'Affiliation': 'Department of Cardiology, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Katrine', 'Initials': 'K', 'LastName': 'Müllertz', 'Affiliation': 'Department of Cardiology, Nordsjællands Hospital, Hillerød, Denmark.'}, {'ForeName': 'Christian Ditlev', 'Initials': 'CD', 'LastName': 'Tuxen', 'Affiliation': 'Department of Cardiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Nikolaj', 'Initials': 'N', 'LastName': 'Ihlemann', 'Affiliation': 'The Heart Center, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Jannik', 'Initials': 'J', 'LastName': 'Helweg-Larsen', 'Affiliation': 'Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Moser', 'Affiliation': 'Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Emil Loldrup', 'Initials': 'EL', 'LastName': 'Fosbøl', 'Affiliation': 'The Heart Center, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Henning', 'Initials': 'H', 'LastName': 'Bundgaard', 'Affiliation': 'The Heart Center, Rigshospitalet, Copenhagen, Denmark. Electronic address: Henning.Bundgaard@regionh.dk.'}, {'ForeName': 'Kasper', 'Initials': 'K', 'LastName': 'Iversen', 'Affiliation': 'Department of Cardiology, Herlev-Gentofte Hospital, Copenhagen, Denmark.'}]",American heart journal,['10.1016/j.ahj.2020.05.012'] 1767,32673222,The Effects of Telemonitoring on Patient Compliance With Self-Management Recommendations and Outcomes of the Innovative Telemonitoring Enhanced Care Program for Chronic Heart Failure: Randomized Controlled Trial.,"BACKGROUND Telemonitoring enables care providers to remotely support outpatients in self-managing chronic heart failure (CHF), but the objective assessment of patient compliance with self-management recommendations has seldom been studied. OBJECTIVE This study aimed to evaluate patient compliance with self-management recommendations of an innovative telemonitoring enhanced care program for CHF (ITEC-CHF). METHODS We conducted a multicenter randomized controlled trial with a 6-month follow-up. The ITEC-CHF program comprised the provision of Bluetooth-enabled scales linked to a call center and nurse care services to assist participants with weight monitoring compliance. Compliance was defined a priori as weighing at least 4 days per week, analyzed objectively from weight recordings on the scales. The intention-to-treat principle was used to perform the analysis. RESULTS A total of 184 participants (141/184, 76.6% male), with a mean age of 70.1 (SD 12.3) years, were randomized to receive either ITEC-CHF (n=91) or usual care (control; n=93), of which 67 ITEC-CHF and 81 control participants completed the intervention. For the compliance criterion of weighing at least 4 days per week, the proportion of compliant participants in the ITEC-CHF group was not significantly higher than that in the control group (ITEC-CHF: 67/91, 74% vs control: 56/91, 60%; P=.06). However, the proportion of ITEC-CHF participants achieving the stricter compliance standard of at least 6 days a week was significantly higher than that in the control group (ITEC-CHF: 41/91, 45% vs control: 23/93, 25%; P=.005). CONCLUSIONS ITEC-CHF improved participant compliance with weight monitoring, although the withdrawal rate was high. Telemonitoring is a promising method for supporting both patients and clinicians in the management of CHF. However, further refinements are required to optimize this model of care. TRIAL REGISTRATION Australian New Zealand Clinical Trial Registry ACTRN12614000916640; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366691.",2020,"A total of 184 participants (141/184, 76.6% male), with a mean age of 70.1 (SD 12.3) years, were randomized to receive either ITEC-CHF (n=91) or usual care (control; n=93), of which 67 ITEC-CHF and 81 control participants completed the intervention.","['Chronic Heart Failure', 'A total of 184 participants (141/184, 76.6% male), with a mean age of 70.1 (SD 12.3) years']","['Innovative Telemonitoring Enhanced Care Program', 'ITEC-CHF', 'Telemonitoring']",['withdrawal rate'],"[{'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517616', 'cui_str': '184'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C5191283', 'cui_str': '12.3'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}]","[{'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}]",184.0,0.0472483,"A total of 184 participants (141/184, 76.6% male), with a mean age of 70.1 (SD 12.3) years, were randomized to receive either ITEC-CHF (n=91) or usual care (control; n=93), of which 67 ITEC-CHF and 81 control participants completed the intervention.","[{'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Ding', 'Affiliation': 'RECOVER Injury Research Centre, Faculty of Health and Behavioural Sciences, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Rajiv', 'Initials': 'R', 'LastName': 'Jayasena', 'Affiliation': 'The Australian e-Health Research Centre, Commonwealth Scientific & Industrial Research Organisation Health & Biosecurity, Melbourne, Australia.'}, {'ForeName': 'Sheau Huey', 'Initials': 'SH', 'LastName': 'Chen', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Maiorana', 'Affiliation': 'School of Physiotherapy and Exercise Science, Australia Faculty of Health Sciences, Curtin University, Perth, Australia.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Dowling', 'Affiliation': 'Department of Community Health, Peninsula Health, Melbourne, Australia.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Layland', 'Affiliation': 'Department of Cardiology, Peninsula Health, Melbourne, Australia.'}, {'ForeName': 'Norm', 'Initials': 'N', 'LastName': 'Good', 'Affiliation': 'RECOVER Injury Research Centre, Faculty of Health and Behavioural Sciences, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Mohanraj', 'Initials': 'M', 'LastName': 'Karunanithi', 'Affiliation': 'RECOVER Injury Research Centre, Faculty of Health and Behavioural Sciences, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Iain', 'Initials': 'I', 'LastName': 'Edwards', 'Affiliation': 'Department of Community Health, Peninsula Health, Melbourne, Australia.'}]",Journal of medical Internet research,['10.2196/17559'] 1768,32673226,Effectiveness of a Transdiagnostic Guided Internet-Delivered Protocol for Emotional Disorders Versus Treatment as Usual in Specialized Care: Randomized Controlled Trial.,"BACKGROUND Anxiety disorders and depression (emotional disorders) are highly prevalent mental disorders. Extensive empirical evidence supports the efficacy of cognitive behavioral therapy (CBT) for the treatment of these disorders. However, there are still some barriers related to their dissemination and implementation, which make it difficult for patients to receive these treatments, especially in public health care settings where resources are limited. Recent advances in improving CBT dissemination encompass different perspectives. One is the transdiagnostic approach, which offers treatment protocols that can be used for a range of emotional disorders. Another approach is the use of the internet to reach a larger number of people who could benefit from CBT. OBJECTIVE This study aimed to analyze the effectiveness and acceptability of a transdiagnostic internet-delivered protocol (EmotionRegulation) with human and automated guidance in patients from public specialized mental health care settings. METHODS A 2-armed randomized controlled trial (RCT) was conducted to compare the effectiveness of EmotionRegulation with treatment as usual (TAU) in specialized mental health care. In all, 214 participants were randomly assigned to receive either EmotionRegulation (n=106) or TAU (n=108). Measurement assessments were conducted at pre- and postintervention and at a 3-month follow-up. RESULTS The results revealed the superiority of EmotionRegulation over TAU on measures of depression (d=0.41), anxiety (d=0.35), and health-related quality of life (d=-0.45) at posttreatment, and these gains were maintained at the 3-month follow-up. Furthermore, the results for expectations and opinions showed that EmotionRegulation was well accepted by participants. CONCLUSIONS EmotionRegulation was more effective than TAU for the treatment of emotional disorders in the Spanish public mental health system. The implications of this RCT, limitations, and suggestions for future research are discussed. TRIAL REGISTRATION ClinicalTrials.gov NCT02345668; https://clinicaltrials.gov/ct2/show/NCT02345668.",2020,"The results revealed the superiority of EmotionRegulation over TAU on measures of depression (d=0.41), anxiety (d=0.35), and health-related quality of life (d=-0.45) at posttreatment, and these gains were maintained at the 3-month follow-up.","['214 participants', 'specialized mental health care', 'Emotional Disorders Versus Treatment as Usual in Specialized Care', 'patients from public specialized mental health care settings']","['Transdiagnostic Guided Internet-Delivered Protocol', 'transdiagnostic internet-delivered protocol (EmotionRegulation) with human and automated guidance', 'EmotionRegulation', 'TAU', 'EmotionRegulation with treatment as usual (TAU', 'cognitive behavioral therapy (CBT']","['superiority of EmotionRegulation over TAU on measures of depression (d=0.41), anxiety (d=0.35), and health-related quality of life', 'effectiveness and acceptability']","[{'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0184643', 'cui_str': 'Mental health care'}, {'cui': 'C0233459', 'cui_str': 'Emotional disorder'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",214.0,0.109225,"The results revealed the superiority of EmotionRegulation over TAU on measures of depression (d=0.41), anxiety (d=0.35), and health-related quality of life (d=-0.45) at posttreatment, and these gains were maintained at the 3-month follow-up.","[{'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'González-Robles', 'Affiliation': 'Department of Basic and Clinical Psychology, and Psychobiology, Universitat Jaume I, Castellón de la Plana, Spain.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Díaz-García', 'Affiliation': 'Department of Basic and Clinical Psychology, and Psychobiology, Universitat Jaume I, Castellón de la Plana, Spain.'}, {'ForeName': 'Azucena', 'Initials': 'A', 'LastName': 'García-Palacios', 'Affiliation': 'Department of Basic and Clinical Psychology, and Psychobiology, Universitat Jaume I, Castellón de la Plana, Spain.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Roca', 'Affiliation': 'Department of Personality, Assessment, and Clinical Psychology, Universidad Complutense de Madrid, Madrid, Spain.'}, {'ForeName': 'Josep Antoni', 'Initials': 'JA', 'LastName': 'Ramos-Quiroga', 'Affiliation': ""Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Botella', 'Affiliation': 'Department of Basic and Clinical Psychology, and Psychobiology, Universitat Jaume I, Castellón de la Plana, Spain.'}]",Journal of medical Internet research,['10.2196/18220'] 1769,32673228,Evaluating the Impact of the Grading and Assessment of Predictive Tools Framework on Clinicians and Health Care Professionals' Decisions in Selecting Clinical Predictive Tools: Randomized Controlled Trial.,"BACKGROUND While selecting predictive tools for implementation in clinical practice or for recommendation in clinical guidelines, clinicians and health care professionals are challenged with an overwhelming number of tools. Many of these tools have never been implemented or evaluated for comparative effectiveness. To overcome this challenge, the authors developed and validated an evidence-based framework for grading and assessment of predictive tools (the GRASP framework). This framework was based on the critical appraisal of the published evidence on such tools. OBJECTIVE The aim of the study was to examine the impact of using the GRASP framework on clinicians' and health care professionals' decisions in selecting clinical predictive tools. METHODS A controlled experiment was conducted through a web-based survey. Participants were randomized to either review the derivation publications, such as studies describing the development of the predictive tools, on common traumatic brain injury predictive tools (control group) or to review an evidence-based summary, where each tool had been graded and assessed using the GRASP framework (intervention group). Participants in both groups were asked to select the best tool based on the greatest validation or implementation. A wide group of international clinicians and health care professionals were invited to participate in the survey. Task completion time, rate of correct decisions, rate of objective versus subjective decisions, and level of decisional conflict were measured. RESULTS We received a total of 194 valid responses. In comparison with not using GRASP, using the framework significantly increased correct decisions by 64%, from 53.7% to 88.1% (88.1/53.7=1.64; t 193 =8.53; P<.001); increased objective decision making by 32%, from 62% (3.11/5) to 82% (4.10/5; t 189 =9.24; P<.001); decreased subjective decision making based on guessing by 20%, from 49% (2.48/5) to 39% (1.98/5; t 188 =-5.47; P<.001); and decreased prior knowledge or experience by 8%, from 71% (3.55/5) to 65% (3.27/5; t 187 =-2.99; P=.003). Using GRASP significantly decreased decisional conflict and increased the confidence and satisfaction of participants with their decisions by 11%, from 71% (3.55/5) to 79% (3.96/5; t 188 =4.27; P<.001), and by 13%, from 70% (3.54/5) to 79% (3.99/5; t 188 =4.89; P<.001), respectively. Using GRASP decreased the task completion time, on the 90th percentile, by 52%, from 12.4 to 6.4 min (t 193 =-0.87; P=.38). The average System Usability Scale of the GRASP framework was very good: 72.5% and 88% (108/122) of the participants found the GRASP useful. CONCLUSIONS Using GRASP has positively supported and significantly improved evidence-based decision making. It has increased the accuracy and efficiency of selecting predictive tools. GRASP is not meant to be prescriptive; it represents a high-level approach and an effective, evidence-based, and comprehensive yet simple and feasible method to evaluate, compare, and select clinical predictive tools.",2020,"In comparison with not using GRASP, using the framework significantly increased correct decisions by 64%, from 53.7% to 88.1% (88.1/53.7=1.64; t 193 =8.53; P<.001); increased objective decision making by 32%, from 62% (3.11/5) to 82% (4.10/5; t 189 =9.24; P<.001); decreased subjective decision making based on guessing by 20%, from 49% (2.48/5) to 39% (1.98/5; t 188 =-5.47; P<.001); and decreased prior knowledge or experience by 8%, from 71% (3.55/5) to 65% (3.27/5; t 187 =-2.99; P=.003).",[],['GRASP framework'],"['Task completion time, rate of correct decisions, rate of objective versus subjective decisions, and level of decisional conflict', 'correct decisions', 'task completion time', 'prior knowledge or experience', 'objective decision making', 'average System Usability Scale of the GRASP framework', 'decisional conflict', 'confidence and satisfaction']",[],"[{'cui': 'C0220843', 'cui_str': 'Grasp'}]","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0231394', 'cui_str': 'Decisional conflict'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0011109', 'cui_str': 'Decision making'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0220843', 'cui_str': 'Grasp'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",194.0,0.087758,"In comparison with not using GRASP, using the framework significantly increased correct decisions by 64%, from 53.7% to 88.1% (88.1/53.7=1.64; t 193 =8.53; P<.001); increased objective decision making by 32%, from 62% (3.11/5) to 82% (4.10/5; t 189 =9.24; P<.001); decreased subjective decision making based on guessing by 20%, from 49% (2.48/5) to 39% (1.98/5; t 188 =-5.47; P<.001); and decreased prior knowledge or experience by 8%, from 71% (3.55/5) to 65% (3.27/5; t 187 =-2.99; P=.003).","[{'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Khalifa', 'Affiliation': 'Centre for Health Informatics, Australian Institute of Health Innovation, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.'}, {'ForeName': 'Farah', 'Initials': 'F', 'LastName': 'Magrabi', 'Affiliation': 'Centre for Health Informatics, Australian Institute of Health Innovation, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.'}, {'ForeName': 'Blanca', 'Initials': 'B', 'LastName': 'Gallego Luxan', 'Affiliation': 'Centre for Big Data Research in Health, Faculty of Medicine, University of New South Wales, Sydney, Australia.'}]",Journal of medical Internet research,['10.2196/15770'] 1770,32678954,Short-term comparison of two non-surgical treatment modalities of peri-implantitis: Clinical and microbiological outcomes in a two-factorial randomized controlled trial.,"AIM To compare the efficacy of two different therapies (amino acid glycine abrasive powder and a desiccant material) and their combination in the non-surgical treatment of peri-implantitis. MATERIALS AND METHODS This was an examiner-blind randomized clinical trial, with 2-factorial design with a follow-up of 6 months. The combination of the two factors resulted in four interventions: (a) non-surgical debridement alone (C); (b) non-surgical debridement and a desiccant material (H); (c) non-surgical debridement and glycine powder (G); and (d) non-surgical debridement, desiccant material and glycine powder (HG). RESULTS Sixty-four patients with peri-implantitis were randomized, 16 for each intervention. After six months, two implants failed in the G intervention. Mean pocket depth reduction was higher in patients treated with the desiccant material (estimated difference: 0.5 mm; 95% CI from 0.1 to 0.9 mm, p = .0229) while there was no difference in the patients treated with glycine powder (estimated difference: 0.1 mm; 95% CI from -0.3 to 0.5 mm, p = .7333). VAS for pain during intervention and VAS for pain after one week were higher for patients treated with glycine powder (p = .0056 and p = .0339, respectively). The success criteria and other variables did not reveal differences between interventions. CONCLUSIONS In this 6-month follow-up study, pocket reduction was more pronounced in patients using the desiccant material. Pain was higher in patients using glycine. All the interventions resulted in low success rate.",2020,"In this 6-month follow-up study, pocket reduction was more pronounced in patients using the desiccant material.","['Sixty-four patients with peri-implantitis', 'peri-implantitis']","['surgical debridement alone (C); 2.Non-surgical debridement and a desiccant material (H); 3.Non-surgical debridement and glycine powder (G); 4.Non-surgical debridement, desiccant material and glycine powder (HG', 'therapies (amino acid glycine abrasive powder and a desiccant material', 'VAS', 'glycine powder']","['low success rate', 'Pain', 'Mean pocket depth reduction']","[{'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2936258', 'cui_str': 'Dental peri-implantitis'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C2936384', 'cui_str': 'Drying Agents'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0017890', 'cui_str': 'Glycine'}, {'cui': 'C0032861', 'cui_str': 'Powder'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",64.0,0.169204,"In this 6-month follow-up study, pocket reduction was more pronounced in patients using the desiccant material.","[{'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Merli', 'Affiliation': 'University Politecnica delle Marche, Ancona, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Bernardelli', 'Affiliation': 'Clinica Merli, Rimini, Italy.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Giulianelli', 'Affiliation': 'Clinica Merli, Rimini, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Carinci', 'Affiliation': 'Maxillofacial Surgery, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Giorgia', 'Initials': 'G', 'LastName': 'Mariotti', 'Affiliation': 'Clinica Merli, Rimini, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Merli', 'Affiliation': 'Clinica Merli, Rimini, Italy.'}, {'ForeName': 'Giovanpaolo', 'Initials': 'G', 'LastName': 'Pini-Prato', 'Affiliation': 'Tuscany Academy of Dental Research (ATRO), Florence, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Nieri', 'Affiliation': 'Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.'}]",Journal of clinical periodontology,['10.1111/jcpe.13345'] 1771,32679045,Predictors of severe pain during insertion of the levonorgestrel 52 mg intrauterine system among nulligravid women.,"OBJECTIVE To identify sociodemographic and clinical variables associated with severe pain with levonorgestrel 52 mg intrauterine system (IUS) placement among nulligravid women. STUDY DESIGN We performed a secondary analysis of a randomized trial that evaluated intracervical anesthesia before IUS insertion. We assessed factors associated with severe pain (visual analog scale pain score ≥7) immediately after insertion using bivariate and multiple regression analyses. RESULTS Overall, 137/300 (45.7%) subjects reported severe pain. In multiple regression analysis, only intracervical anesthesia [RR 0.55, 95% CI 0.37-0.80] and a history of dysmenorrhea [RR 1.36, 95% CI 1.08-1.72)] were associated with severe pain. CONCLUSIONS Among nulligravid women, a history of dysmenorrhea increases, and intracervical block decreases severe pain during levonorgestrel IUS insertion. IMPLICATIONS Dysmenorrhea increases the risk of severe pain at levonorgestrel intrauterine system insertion, while receiving an intracervical lidocaine block decreases this risk. This information can be useful for counseling women prior to device placement and for selecting candidates who may particularly benefit from interventions to reduce pain.",2020,"In multiple regression analysis, only intracervical anesthesia [RR 0.55, 95% CI 0.37-0.80] and a history of dysmenorrhea [RR 1.36, 95%CI 1.08-1.72)] were associated with severe pain. ",['nulligravid women'],"['lidocaine block', 'levonorgestrel 52mg intrauterine system (IUS) placement', 'levonorgestrel']","['severe pain', 'history of dysmenorrhea', 'severe pain (visual analog scale pain score']","[{'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0937459', 'cui_str': 'Levonorgestrel 833 nanogram/hour prolonged-release intrauterine drug delivery system'}, {'cui': 'C4293370', 'cui_str': 'Intrauterine System'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0023566', 'cui_str': 'Levonorgestrel'}]","[{'cui': 'C0278140', 'cui_str': 'Severe pain'}, {'cui': 'C0475168', 'cui_str': 'H/O: dysmenorrhea'}, {'cui': 'C2732809', 'cui_str': 'Visual analog scale pain score'}]",,0.301743,"In multiple regression analysis, only intracervical anesthesia [RR 0.55, 95% CI 0.37-0.80] and a history of dysmenorrhea [RR 1.36, 95%CI 1.08-1.72)] were associated with severe pain. ","[{'ForeName': 'Letícia Sanchez', 'Initials': 'LS', 'LastName': 'Ferreira', 'Affiliation': 'Department of Obstetrics and Gynecology, Ribeirao Preto Medical School, University of São Paulo, Avenida Bandeirantes, 3900 - Campus Universitário - Monte Alegre, CEP: 14049-900 Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Mariane Nunes', 'Initials': 'MN', 'LastName': 'de Nadai', 'Affiliation': 'Department of Obstetrics and Gynecology, Ribeirao Preto Medical School, University of São Paulo, Avenida Bandeirantes, 3900 - Campus Universitário - Monte Alegre, CEP: 14049-900 Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Omero B', 'Initials': 'OB', 'LastName': 'Poli-Neto', 'Affiliation': 'Department of Obstetrics and Gynecology, Ribeirao Preto Medical School, University of São Paulo, Avenida Bandeirantes, 3900 - Campus Universitário - Monte Alegre, CEP: 14049-900 Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Silvio A', 'Initials': 'SA', 'LastName': 'Franceschini', 'Affiliation': 'Department of Obstetrics and Gynecology, Ribeirao Preto Medical School, University of São Paulo, Avenida Bandeirantes, 3900 - Campus Universitário - Monte Alegre, CEP: 14049-900 Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Cássia R T', 'Initials': 'CRT', 'LastName': 'Juliato', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medical Science, University of Campinas, Caixa Postal 6181, CEP 13084-971 Campinas, SP, Brazil.'}, {'ForeName': 'Ilza Maria U', 'Initials': 'IMU', 'LastName': 'Monteiro', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medical Science, University of Campinas, Caixa Postal 6181, CEP 13084-971 Campinas, SP, Brazil.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Bahamondes', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medical Science, University of Campinas, Caixa Postal 6181, CEP 13084-971 Campinas, SP, Brazil.'}, {'ForeName': 'Carolina Sales', 'Initials': 'CS', 'LastName': 'Vieira', 'Affiliation': 'Department of Obstetrics and Gynecology, Ribeirao Preto Medical School, University of São Paulo, Avenida Bandeirantes, 3900 - Campus Universitário - Monte Alegre, CEP: 14049-900 Ribeirão Preto, SP, Brazil. Electronic address: carol.sales@uol.com.br.'}]",Contraception,['10.1016/j.contraception.2020.07.004'] 1772,32687974,Design and rationale for a randomized trial of a theory- and technology- enhanced physical activity intervention for Latinas: The Seamos Activas II study.,"INTRODUCTION Latina women report disproportionately high rates of physical inactivity and related chronic health conditions. Physical activity (PA) efforts to date have shown modest success in this at-risk population; thus, more effective interventions are necessary to help Latinas reach national PA guidelines and reduce related health disparities. This paper describes the design, rationale, and baseline findings from the Seamos Activas II intervention. METHODS/DESIGN The ongoing RCT will test the efficacy of the Seamos Saludables PA print intervention vs. a theory-and technology-enhanced version (Seamos Activas II). The purpose of the study is to increase the percentage of Latinas meeting the national PA guidelines compared to the prior trial, improve biomarkers related to disease, and extend generalizability to a broader and more representative population of Latinas (i.e. Mexican/Mexican-Americans). Intervention refinements included further targeting key constructs of Social Cognitive Theory, and incorporating interactive text message-based self-monitoring strategies. The primary outcome is change in minutes per week of MVPA measured by ActiGraph GT3X+ accelerometers at 6- and 12-months. Secondary PA outcomes assessed by the 7-Day PA Recall will be used to corroborate findings. RESULTS Participants (N = 199) are Latinas 18-65 years (mean = 43.8) of predominantly Mexican origin (89%). At baseline, objectively measured MVPA was 39.51 min/week (SD = 71.20, median = 10) and self-reported MVPA was 12.47 min/week (SD = 22.54, median = 0).Participants reported generally low self-efficacy and higher cognitive vs. behavioral processes of change. CONCLUSION Addressing interactivity and accountability through text messaging, and more rigorously targeting theoretical constructs may be key to helping Latinas achieve nationally recommended PA levels and thereby reducing health disparities.",2020,"Intervention refinements included further targeting key constructs of Social Cognitive Theory, and incorporating interactive text message-based self-monitoring strategies.","['representative population of Latinas (i.e. Mexican/Mexican-Americans', 'Latina women report disproportionately high rates of physical inactivity and related chronic health conditions', 'Participants (N\u202f=\u202f199) are Latinas 18-65\u202fyears (mean\u202f=\u202f43.8) of predominantly Mexican origin (89', 'Latinas']","['Social Cognitive Theory, and incorporating interactive text message-based self-monitoring strategies', 'theory- and technology- enhanced physical activity intervention']","['low self-efficacy and higher cognitive vs. behavioral processes of change', 'change in minutes per week of MVPA measured by ActiGraph GT3X+ accelerometers']","[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0949335', 'cui_str': 'Latinas'}, {'cui': 'C0025884', 'cui_str': 'Chicanos'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C3890554', 'cui_str': 'Physical Inactivity'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439659', 'cui_str': 'Origins'}]","[{'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C2712043', 'cui_str': 'Lacking belief in own ability'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0702093', 'cui_str': '/minute'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",,0.0266557,"Intervention refinements included further targeting key constructs of Social Cognitive Theory, and incorporating interactive text message-based self-monitoring strategies.","[{'ForeName': 'Tanya J', 'Initials': 'TJ', 'LastName': 'Benitez', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, United States of America.'}, {'ForeName': 'Shira I', 'Initials': 'SI', 'LastName': 'Dunsiger', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, United States of America.'}, {'ForeName': 'Dori J', 'Initials': 'DJ', 'LastName': 'Pekmezi', 'Affiliation': 'Department of Health Behavior, School of Public Health at University of Alabama at Birmingham, Birmingham, AL, United States of America.'}, {'ForeName': 'Britta A', 'Initials': 'BA', 'LastName': 'Larsen', 'Affiliation': 'Department of Family Medicine & Public Health, University of California San Diego, La Jolla, CA, United States of America.'}, {'ForeName': 'Andrea S', 'Initials': 'AS', 'LastName': 'Mendoza-Vasconez', 'Affiliation': 'School of Medicine, Stanford University, Stanford, CA, United States of America.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Linke', 'Affiliation': 'Department of Family Medicine & Public Health, University of California San Diego, La Jolla, CA, United States of America.'}, {'ForeName': 'Beth C', 'Initials': 'BC', 'LastName': 'Bock', 'Affiliation': 'Department of Psychiatry & Human Behavior, Alpert Medical School, Brown University, Providence, RI, United States of America.'}, {'ForeName': 'Kim M', 'Initials': 'KM', 'LastName': 'Gans', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, United States of America; Department of Human Development and Family Studies, University of Connecticut, Storrs, CT, United States of America.'}, {'ForeName': 'Sheri J', 'Initials': 'SJ', 'LastName': 'Hartman', 'Affiliation': 'Department of Family Medicine & Public Health, University of California San Diego, La Jolla, CA, United States of America.'}, {'ForeName': 'Bess H', 'Initials': 'BH', 'LastName': 'Marcus', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, United States of America. Electronic address: bess_marcus@brown.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106081'] 1773,32688045,"Effects of attention training technique on brain function in high- and low-cognitive-attentional syndrome individuals: Regional dynamics before, during, and after a single session of ATT.","OBJECTIVE Attention Training Technique (ATT) is a key therapeutic tool in metacognitive therapy. There are numerous studies on the behavioral effects of ATT, however the neural mechanisms at work in the training are yet to be uncovered. To date there have been no controlled fMRI studies of ATT. METHOD We conducted a randomized double-blind controlled study of two groups with varying levels of cognitive-attentional syndrome (CAS). Groups with high (n = 43) and low (n = 46) levels of CAS underwent a single session of ATT or a control condition (CON) in an MRI scanner. Participants underwent resting state functional MRI (rsfMRI) sessions and rumination induction sessions both pre- and post-intervention Functional connectivity analyses and inter-subject correlations analyses were computed. We also collected data on emotion and attention functioning pre- and post-intervention. RESULTS We did not observe any behavioral effects of ATT. However, direct comparison between ATT and CON sessions revealed greater inter-subject correlations in almost all hubs belonging to the studied functional networks. Moreover, subjects who received ATT showed diminished connectivity in the fronto-parietal network during ruminations and diminished connectivity of the precuneus with lateral occipital cortices and the intraparietal sulcus in abstract thinking and rsfMRI, respectively. Furthermore, some of the observed effects in functional connectivity and inter-subject correlations were specific to different levels of CAS. CONCLUSIONS Our results may support a proposed neural mechanism for ATT: disengagement of attention from CAS-type processing in either low- or high-CAS individuals. It is also possible that some neural effects of ATT are specific to individuals with different levels of CAS.",2020,"Moreover, subjects who received ATT showed diminished connectivity in the fronto-parietal network during ruminations and diminished connectivity of the precuneus with lateral occipital cortices and the intraparietal sulcus in abstract thinking and rsfMRI, respectively.","['two groups with varying levels of cognitive-attentional syndrome (CAS', 'high- and low-cognitive-attentional syndrome individuals']","['Attention Training Technique (ATT', 'attention training technique', 'resting state functional MRI (rsfMRI) sessions and rumination induction sessions']",['brain function'],"[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0556509', 'cui_str': 'Attention training'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C0205263', 'cui_str': 'Induced'}]","[{'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",,0.0498982,"Moreover, subjects who received ATT showed diminished connectivity in the fronto-parietal network during ruminations and diminished connectivity of the precuneus with lateral occipital cortices and the intraparietal sulcus in abstract thinking and rsfMRI, respectively.","[{'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Kowalski', 'Affiliation': 'Faculty of Psychology, University of Warsaw, Stawki 5/7, 00-183, Warsaw, Poland; Institute of Psychology, Polish Academy of Sciences, Stefana Jaracza 1, 00-378, Warsaw, Poland. Electronic address: joachim.kowalski@psych.uw.edu.pl.'}, {'ForeName': 'Małgorzata', 'Initials': 'M', 'LastName': 'Wierzba', 'Affiliation': 'Laboratory of Brain Imaging, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Pasteur Street 3, 02-093, Warsaw, Poland.'}, {'ForeName': 'Marek', 'Initials': 'M', 'LastName': 'Wypych', 'Affiliation': 'Laboratory of Brain Imaging, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Pasteur Street 3, 02-093, Warsaw, Poland.'}, {'ForeName': 'Artur', 'Initials': 'A', 'LastName': 'Marchewka', 'Affiliation': 'Laboratory of Brain Imaging, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Pasteur Street 3, 02-093, Warsaw, Poland.'}, {'ForeName': 'Małgorzata', 'Initials': 'M', 'LastName': 'Dragan', 'Affiliation': 'Faculty of Psychology, University of Warsaw, Stawki 5/7, 00-183, Warsaw, Poland.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103693'] 1774,32688046,Effectiveness of a transdiagnostic group intervention to enhance emotion regulation in young Afghan refugees: A pilot randomized controlled study.,"There are several challenges to providing mental health care for refugees, including high comorbidity and structural barriers. Targeting transdiagnostic processes in a low-threshold group intervention appears particularly promising to meet these challenges. This study examined the feasibility, acceptability and effectiveness of a new transdiagnostic intervention, Skills-Training of Affect Regulation-A Culture-sensitive Approach (STARC), focusing on conveying strategies to improve emotional clarity and to regulate emotions. A parallel-group (STARC vs. waitlist) randomized-controlled study with 44 young male Afghan refugees was conducted in a routine clinical setting (NCT03162679). In intention-to-treat analyses, participants of STARC significantly improved in self-reported difficulties in emotion regulation (Δd STARC-Waitlist  = 1.22), transdiagnostic symptom severity (Δd STARC-Waitlist  = 1.69), posttraumatic stress symptoms (Δd STARC-Waitlist  = 1.19), and caregiver-reported emotional competence (Δd STARC-Waitlist  = -0.90), but not anger reactions (Δd STARC-Waitlist  = 0.50) compared to waitlist. Effects were maintained over 3 months. STARC is a feasible transdiagnostic intervention in a routine clinical setting and effective for young Afghan refugees. If replicated in large-scale studies with active control groups, it might be promising as an initial low-threshold intervention offered in a phased-based and/or stepped care approach.",2020,STARC is a feasible transdiagnostic intervention in a routine clinical setting and effective for young Afghan refugees.,"['young Afghan refugees', '44 young male Afghan refugees']","['STARC', 'transdiagnostic group intervention', 'new transdiagnostic intervention, Skills-Training of Affect Regulation-A Culture-sensitive Approach (STARC']","['self-reported difficulties in emotion regulation', 'emotion regulation', 'transdiagnostic symptom severity', 'caregiver-reported emotional competence', 'posttraumatic stress symptoms']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0034961', 'cui_str': 'Refugee'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0010453', 'cui_str': 'Culture'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}]",44.0,0.0299985,STARC is a feasible transdiagnostic intervention in a routine clinical setting and effective for young Afghan refugees.,"[{'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Koch', 'Affiliation': 'LMU Munich, Department of Psychology, Clinical Psychology and Psychotherapy, Germany; Refugio Munich, Germany. Electronic address: Theresa.koch@refugio-muenchen.de.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Ehring', 'Affiliation': 'LMU Munich, Department of Psychology, Clinical Psychology and Psychotherapy, Germany.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Liedl', 'Affiliation': 'LMU Munich, Department of Psychology, Clinical Psychology and Psychotherapy, Germany; Refugio Munich, Germany.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103689'] 1775,32688047,Power posing for paranoia: A double-blind randomised controlled experimental test using virtual reality.,"Paranoia is theorised to build upon feelings of inferior social rank. Power posing has been shown to increase feelings of power, and hence could reduce paranoia. One hundred participants with current paranoia and 50 individuals without paranoia were recruited. Using a double-blind randomised controlled experimental design, participants twice held powerful or neutral postures before entering neutral virtual reality social environments. In the paranoid sample, those who held a powerful pose did not significantly increase in feelings of power by the end of testing in comparison to controls (group difference = 0.67, C.I. = -1.12; 1.46; p = 0.098), or decrease in paranoia (group difference = -0.23, C.I. = -1.17; 0.72; p = 0.634). In the non-paranoid sample, there was a small significant increase in powerful feelings by the end of testing in the powerful group (group difference = 1.13, C.I. = 0.23; 2.02; p = 0.013), but no significant decrease in paranoia (group difference = -0.71, C.I. = -2.16; 0.74; p = 0.338). Paranoia status was not a modifier on the relationship between condition and feelings of power. We conclude that power posing results in only very small changes in self-reported feelings of power and has no subsequent effect on paranoia.",2020,"In the paranoid sample, those who held a powerful pose did not significantly increase in feelings of power by the end of testing in comparison to controls (group difference = 0.67, C.I. = -1.12; 1.46; p = 0.098), or decrease in paranoia (group difference = ","['One hundred participants with current paranoia and 50 individuals without paranoia were recruited', 'participants twice held powerful or neutral postures before entering neutral virtual reality social environments']",[],"['paranoia', 'powerful feelings', 'feelings of power']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C1456784', 'cui_str': 'Paranoid disorder'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0675390', 'cui_str': 'ARID1A protein, human'}, {'cui': 'C0872410', 'cui_str': 'Posturing'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0037414', 'cui_str': 'Social context'}]",[],"[{'cui': 'C1456784', 'cui_str': 'Paranoid disorder'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}]",100.0,0.16838,"In the paranoid sample, those who held a powerful pose did not significantly increase in feelings of power by the end of testing in comparison to controls (group difference = 0.67, C.I. = -1.12; 1.46; p = 0.098), or decrease in paranoia (group difference = ","[{'ForeName': 'Poppy', 'Initials': 'P', 'LastName': 'Brown', 'Affiliation': 'Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, UK. Electronic address: poppy.brown@psych.ox.ac.uk.'}, {'ForeName': 'Felicity', 'Initials': 'F', 'LastName': 'Waite', 'Affiliation': 'Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, UK; Oxford Health NHS Foundation Trust, UK.'}, {'ForeName': 'Aitor', 'Initials': 'A', 'LastName': 'Rovira', 'Affiliation': 'Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, UK; Oxford Health NHS Foundation Trust, UK.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Freeman', 'Affiliation': 'Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, UK; Oxford Health NHS Foundation Trust, UK.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103691'] 1776,32692952,Posterior Rotational and Translational Stability in Acromioclavicular Ligament Complex Reconstruction: A Comparative Biomechanical Analysis in Cadaveric Specimens.,"BACKGROUND Persistent posterior instability of the acromioclavicular (AC) joint is a reported complication after isolated coracoclavicular (CC) reconstruction. Thus, multiple techniques have been proposed attempting to restore biomechanics of the AC ligament complex (ACLC). PURPOSE/HYPOTHESIS The purpose was to evaluate the posterior translational and rotational stability of an ACLC reconstruction with a dermal allograft (ACLC patch) as compared with 3 suture brace constructs. It was hypothesized that the ACLC patch would better restore AC joint posterior stability. STUDY DESIGN Controlled laboratory study. METHODS A total of 28 cadaveric shoulders (mean ± SD age, 57.6 ± 8.3 years) were randomly assigned to 1 of 4 surgical techniques: ACLC patch, oblique brace, anterior brace, and x-frame brace. The force and torque to achieve 10 mm of posterior translation and 20° of posterior rotation of the AC joint were recorded in the following conditions: intact, transected ACLC, ACLC patch/brace repair, ACLC patch/brace repair with dissected CC ligaments, and ACLC patch/brace repair with CC ligament repair. RESULTS For posterior translation, transection of the ACLC reduced resistance to 16.7% of the native. With the native CC ligaments intact, the ACLC patch (59.1%), oblique brace (54.1%), and anterior brace (60.7%) provided significantly greater stability than the x-frame brace (33.2%; P < .001, P = .008, P < .001, respectively). ACLC patch, oblique brace, and anterior brace continued to have significantly higher posterior translational resistance than the x-frame (35.1%; P < .001, P = .003, P < .001) after transection and subsequent CC ligament repair. For posterior rotation, transection of the ACLC decreased the resistance to 5.4% of the intact state. With the CC ligaments intact, the ACLC patch (77.1%) better restored posterior rotational stability than the oblique (35.3%), anterior (48.5%), and x-frame (23.0%) brace repairs ( P < .001, P = .002, P < .001). CC ligament transection and subsequent repair demonstrated the ACLC patch (41.0%) to have improved stability when compared with the oblique (16.0%), anterior (14.0%), and x-frame (12.7%) repairs ( P = .006, P = .003, P = .002). CONCLUSION ACLC reconstruction with a dermal allograft better restored native posterior rotational stability than other brace constructs, with translational stability similar to the oblique and anterior brace technique at the time of surgery. CLINICAL RELEVANCE Horizontal stability of the AC joint is primarily controlled by the ACLC. Inability to restore AC joint biomechanics can result in persistent posterior instability and lead to functional impairment.",2020,"With the CC ligaments intact, the ACLC patch (77.1%) better restored posterior rotational stability than the oblique (35.3%), anterior (48.5%), and x-frame (23.0%) brace repairs ( P < .001, P = .002, P < .001).","['Cadaveric Specimens', 'Acromioclavicular Ligament Complex Reconstruction', '28 cadaveric shoulders (mean ± SD age, 57.6 ± 8.3 years']","['ACLC reconstruction with a dermal allograft (ACLC patch', '4 surgical techniques: ACLC patch, oblique brace, anterior brace, and x-frame brace', 'ACLC patch', 'intact, transected ACLC, ACLC patch/brace repair, ACLC patch/brace repair with dissected CC ligaments, and ACLC patch/brace repair with CC ligament repair']","['posterior translational and rotational stability', 'restore AC joint posterior stability', 'anterior brace', 'oblique brace', 'posterior rotational stability', 'posterior translational resistance']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0225039', 'cui_str': 'Structure of acromioclavicular ligament'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0023685', 'cui_str': 'Structure of ligament'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0040739', 'cui_str': 'Allogeneic transplantation'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205315', 'cui_str': 'Oblique'}, {'cui': 'C0006086', 'cui_str': 'Brace'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0080089', 'cui_str': 'Reading Frames'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0205239', 'cui_str': 'Dissecting'}, {'cui': 'C0225040', 'cui_str': 'Coracoclavicular ligament structure'}]","[{'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0445237', 'cui_str': 'Rotational'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0001208', 'cui_str': 'Acromioclavicular joint structure'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0006086', 'cui_str': 'Brace'}, {'cui': 'C0205315', 'cui_str': 'Oblique'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}]",28.0,0.0329299,"With the CC ligaments intact, the ACLC patch (77.1%) better restored posterior rotational stability than the oblique (35.3%), anterior (48.5%), and x-frame (23.0%) brace repairs ( P < .001, P = .002, P < .001).","[{'ForeName': 'Daichi', 'Initials': 'D', 'LastName': 'Morikawa', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Joel B', 'Initials': 'JB', 'LastName': 'Huleatt', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Lukas N', 'Initials': 'LN', 'LastName': 'Muench', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Cameron', 'Initials': 'C', 'LastName': 'Kia', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Daniel P', 'Initials': 'DP', 'LastName': 'Berthold', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Mark P', 'Initials': 'MP', 'LastName': 'Cote', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Elifho', 'Initials': 'E', 'LastName': 'Obopilwe', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Kelolli', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Bastian', 'Initials': 'B', 'LastName': 'Scheiderer', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Augustus D', 'Initials': 'AD', 'LastName': 'Mazzocca', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}]",The American journal of sports medicine,['10.1177/0363546520939882'] 1777,32693009,Physical exercise interventions have no effect on serum BDNF concentration in older adults living in long-term nursing homes.,"Physical exercise protects against age-related cognitive decline. Brain-derived neurotrophic factor (BDNF) may mediate some of the cognitive benefits of physical exercise, but the effect of physical exercise on serum BDNF is unclear. Indeed, differential findings have been reported depending on the characteristics of the participants and the intensity, duration, and type of exercise. The aim of this study was to determine whether three different physical exercise interventions alter serum BDNF levels in older adults living in long-term nursing homes (LTNHs) and whether changes in physical, cognitive, and dual-task performance are related to changes in serum BDNF. LTNH study participants (n = 126) were randomly assigned to multicomponent or dual-task training or a walking program and serum BDNF levels were analyzed by ELISA. We also assessed physical, cognitive, and dual-task parameters. Neither the multicomponent, dual-task, nor walking exercise programs caused changes in serum BDNF concentration in older adults living in LTNHs. Changes in BDNF during the interventions were not significantly associated with modifications in physical, cognitive or dual-task performance parameters. Our results provide new evidence clarifying the relationship between physical and cognitive exercise and BDNF.",2020,"Neither the multicomponent, dual-task, nor walking exercise programs caused changes in serum BDNF concentration in older adults living in LTNHs.","['older adults living in long-term nursing homes (LTNHs', 'older adults living in LTNHs', 'LTNH study participants (n\u202f=\u202f126', 'older adults living in long-term nursing homes']","['physical exercise interventions', 'multicomponent or dual-task training or a walking program and serum BDNF levels were analyzed by ELISA', 'Physical exercise', 'multicomponent, dual-task, nor walking exercise programs', 'Physical exercise interventions']","['physical, cognitive, and dual-task parameters', 'physical, cognitive or dual-task performance parameters', 'serum BDNF levels', 'serum BDNF concentration']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0470256', 'cui_str': '126'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",126.0,0.0209679,"Neither the multicomponent, dual-task, nor walking exercise programs caused changes in serum BDNF concentration in older adults living in LTNHs.","[{'ForeName': 'Chloe', 'Initials': 'C', 'LastName': 'Rezola-Pardo', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: chloe.rezola@ehu.eus.'}, {'ForeName': 'Gotzone', 'Initials': 'G', 'LastName': 'Hervás', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: gotzone.hervas@ehu.eus.'}, {'ForeName': 'Haritz', 'Initials': 'H', 'LastName': 'Arrieta', 'Affiliation': 'Department of Nursing II, Faculty of Medicine and Nursery, University of the Basque Country (UPV/EHU), Paseo Dr. J. Beguiristain, 105, Donostia/San Sebastian 20014, Gipuzkoa, Spain; Onkologikoa Foundation, Paseo Doctor Beguiristain, 121, Donostia/San Sebastián 20014, Gipuzkoa, Spain. Electronic address: haritz.arrieta@ehu.eus.'}, {'ForeName': 'Alejandra', 'Initials': 'A', 'LastName': 'Hernández-de Diego', 'Affiliation': 'Zorroaga Foundation, Alto Zorroaga, 1, Donostia/San Sebastian 20014, Gipuzkoa, Spain. Electronic address: s.hernandez@zorroaga.eus.'}, {'ForeName': 'Fatima', 'Initials': 'F', 'LastName': 'Ruiz-Litago', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: fatima.ruiz@ehu.eus.'}, {'ForeName': 'Susana Maria', 'Initials': 'SM', 'LastName': 'Gil', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: susana.gil@ehu.eus.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Rodriguez-Larrad', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: ana.rodriguez@ehu.eus.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Irazusta', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: jon.irazusta@ehu.eus.'}]",Experimental gerontology,['10.1016/j.exger.2020.111024'] 1778,32698540,The Effect of Dynamic Food Labels with Real-Time Feedback on Diet Quality: Results from a Randomized Controlled Trial.,"The rising prevalence of non-communicable diseases has brought attention to the importance of consuming a healthy diet. One strategy to improve diet quality is through front-of-pack (FOP) nutrition labels. Taking advantage of an online grocery store, we allowed consumers to choose the FOP labels they preferred, and combined this information with real-time feedback on the overall nutritional quality of the shopping basket. We hypothesized that these dynamic food labels with real-time feedback (DFLF) would improve nutritional quality of food purchases. This trial followed a two-arm (no-label control and DFLF) crossover design with 125 participants exposed to each condition once in random order via an online grocery store. A first difference regression model allowed for estimating the unbiased effect of the DFLF on diet quality, measured by the weighted average Nutri-Score (ranging 1 to 5) per serving (primary) and changes in select nutrients and calories. The mean weighted Nutri-Score was 0.4 (12.6%) higher in the DFLF arm (CI: [0.2, 0.6]) relative to the control. The DFLF also decreased the amount of sugar per serving by 0.9 g (CI: [-1.7, -0.0]) and total sugar per shop by 169.5 g (CI: [-284.5, -54.5]). The DFLF features significantly improved nutrition quality relative to no labelling, as measured by average Nutri-Score values. These results shed light on the considerable potential of the online shopping environment to improve diet quality through customization and real time feedback.",2020,"The DFLF features significantly improved nutrition quality relative to no labelling, as measured by average Nutri-Score values.",['125 participants exposed to each condition once in random order via an online grocery store'],"['Dynamic Food Labels with Real-Time Feedback', 'dynamic food labels with real-time feedback (DFLF']","['mean weighted Nutri-Score', 'Diet Quality', 'nutritional quality of food purchases', 'nutrition quality', 'diet quality']","[{'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0557778', 'cui_str': 'Supermarket'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0016475', 'cui_str': 'Food Labelling'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C3489446', 'cui_str': 'Nutritive Quality'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}]",125.0,0.0394557,"The DFLF features significantly improved nutrition quality relative to no labelling, as measured by average Nutri-Score values.","[{'ForeName': 'Soye', 'Initials': 'S', 'LastName': 'Shin', 'Affiliation': 'Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore 169857, Singapore.'}, {'ForeName': 'Rob M', 'Initials': 'RM', 'LastName': 'van Dam', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore, Singapore 117549, Singapore.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Finkelstein', 'Affiliation': 'Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore 169857, Singapore.'}]",Nutrients,['10.3390/nu12072158'] 1779,32697957,"Effects of long-term concurrent training to failure or not in muscle power output, muscle quality and cardiometabolic risk factors in older men: A secondary analysis of a randomized clinical trial.","This study investigated the effects of concurrent training performed either with repetitions to failure or not to failure in muscle power, muscle quality (MQ), peak oxygen uptake (VO 2peak ), and visceral fat in older men. This is an ancillary analysis of a randomized controlled trial. 36 older men (mean age ± SD; 67.1 ± 5.1 years) were randomized into three groups: one performing repetitions to failure (RFG, n = 13), another performing repetitions not to failure and 50% of the repetitions of the RFG (NFG, n = 12), and third performing repetitions not to failure with equal training volume of the RFG (ENFG, n = 11). The training was performed twice a week for 20 weeks at intensities ranging from 65 to 80% of maximal strength. In each session, the individuals started with strengthening exercises and then performed aerobic exercise (i.e., walking) on a treadmill. The primary endpoint was change from baseline to post-20 wk of absolute and relative muscle power output during squat and countermovement jump, ultrasound measurements for MQ using quadriceps echo intensity, and visceral fat thickness, as well as their VO 2peak through a maximal incremental test on a treadmill. All training groups improved similarly and significantly jump height (ranging from 9 to 16%) and all their muscle power outcomes (mean change ranging from 2 to 7%) (P < .001). In addition, all groups significantly decreased visceral fat thickness (ranging from -11 to -21%) (P < .001), and significantly increased VO 2peak (ranging from 4 to 8%) (P < .01), with no differences between groups. No changes were observed in the MQ outcomes. Concurrent training performed using repetitions to failure or not to failure promoted similar gains in the muscle power output, aerobic capacity, and visceral fat in healthy older men.",2020,All training groups improved similarly and significantly jump height (ranging from 9 to 16%) and all their muscle power outcomes (mean change ranging from 2 to 7%) (P < .001).,"['36 older men (mean age\u202f±\u202fSD; 67.1\u202f±\u202f5.1\u202fyears', 'healthy older men', 'older men']","['another performing repetitions not to failure and 50% of the repetitions of the RFG (NFG, n\u202f=\u202f12), and third performing repetitions not to failure with equal training volume of the RFG (ENFG, n', 'strengthening exercises and then performed aerobic exercise (i.e., walking) on a treadmill']","['VO 2peak', 'visceral fat thickness', 'MQ outcomes', 'muscle power output, muscle quality and cardiometabolic risk factors', 'change from baseline to post-20\u202fwk of absolute and relative muscle power output during squat and countermovement jump, ultrasound measurements for MQ using quadriceps echo intensity, and visceral fat thickness, as well as their VO 2peak through a maximal incremental test on a treadmill', 'jump height', 'muscle power, muscle quality (MQ), peak oxygen uptake (VO 2peak ), and visceral fat']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0452260', 'cui_str': 'Muscular strength development exercise'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}]","[{'cui': 'C1563740', 'cui_str': 'Abdominal Visceral Fat'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0427052', 'cui_str': 'Finding of power of skeletal muscle'}, {'cui': 'C3251815', 'cui_str': 'Measurement of fluid output'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0013520', 'cui_str': 'Doppler Echocardiography'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0332273', 'cui_str': 'Through'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}]",36.0,0.0273081,All training groups improved similarly and significantly jump height (ranging from 9 to 16%) and all their muscle power outcomes (mean change ranging from 2 to 7%) (P < .001).,"[{'ForeName': 'Juliana L', 'Initials': 'JL', 'LastName': 'Teodoro', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Mikel', 'Initials': 'M', 'LastName': 'Izquierdo', 'Affiliation': 'Navarrabiomed, Complejo Hospitalario de Navarra (CHN)-Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.'}, {'ForeName': 'Larissa X N', 'Initials': 'LXN', 'LastName': 'da Silva', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Bruno M', 'Initials': 'BM', 'LastName': 'Baroni', 'Affiliation': 'Graduate Program in Rehabilitation Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Grazioli', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Lopez', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Carolina G', 'Initials': 'CG', 'LastName': 'Fritsch', 'Affiliation': 'Graduate Program in Rehabilitation Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Régis', 'Initials': 'R', 'LastName': 'Radaelli', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Mikel L', 'Initials': 'ML', 'LastName': 'Saez de Asteasu', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Navarrabiomed, Complejo Hospitalario de Navarra (CHN)-Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.'}, {'ForeName': 'Martim', 'Initials': 'M', 'LastName': 'Bottaro', 'Affiliation': 'College of Physical Education, University of Brasilia, Brasília, DF, Brazil.'}, {'ForeName': 'Juliano', 'Initials': 'J', 'LastName': 'Farinha', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Ronei S', 'Initials': 'RS', 'LastName': 'Pinto', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Eduardo L', 'Initials': 'EL', 'LastName': 'Cadore', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. Electronic address: edu.cadore@ufrgs.br.'}]",Experimental gerontology,['10.1016/j.exger.2020.111023'] 1780,32674036,Effects of a nurse-led medication self-management programme in women with oral treatments for metastatic breast cancer: A mixed-method randomised controlled trial.,"PURPOSE Adherence to medication is the most important challenge facing patients receiving oral anticancer treatment. This study aimed to evaluate the effects of a patient-centred medication self-management support programme in patients with metastatic breast cancer undergoing oral anticancer treatment. METHODS This trial was a two-phased mixed-method randomised controlled study. Eligible participants were 155 patients with metastatic breast cancer newly prescribed an oral chemotherapy or targeted therapy agent. The intervention group received the patient-centred medication self-management support programme conducted by trained nurses. Primary outcome was adherence to medication at three months after the commencement of treatment, calculated by medication possession ratio (MPR). Secondary outcomes included self-efficacy, functional assessment, psychological distress, symptom severity and symptom interference, and patient satisfaction. After the completion of the intervention study, focus group interviews were conducted among intervention nurses. RESULTS Both intervention and control groups maintained more than 90% of MPR and no significant difference was observed in the primary outcome. Regarding secondary outcomes, only general self-efficacy was significantly different in the two groups. In the qualitative study, the intervention nurses perceived improvement in the patients' self-efficacy, ability to anticipate the impact of treatment and adjust to life, and avoidance of loneliness. CONCLUSIONS A significant effect of the programme was not found in the program because the adherence rate was high in both groups. Improvement in the patients' self-efficacy was observed both quantitatively and qualitatively. TRIAL REGISTRATION UMIN Clinical Trials Registry (UMIN-CTR), Japan, UMIN000016597. (27 February 2015).",2020,Both intervention and control groups maintained more than 90% of MPR and no significant difference was observed in the primary outcome.,"['patients receiving oral anticancer treatment', 'Eligible participants were 155 patients with metastatic breast cancer newly prescribed an oral chemotherapy or targeted therapy agent', 'patients with metastatic breast cancer undergoing oral anticancer treatment', 'women with oral treatments for metastatic breast cancer']","['patient-centred medication self-management support programme', 'patient-centred medication self-management support programme conducted by trained nurses', 'nurse-led medication self-management programme']","['self-efficacy, functional assessment, psychological distress, symptom severity and symptom interference, and patient satisfaction', 'adherence to medication', 'adherence rate', 'medication possession ratio (MPR', 'general self-efficacy']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0419073', 'cui_str': 'Oral chemotherapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0036600', 'cui_str': 'Self-medication'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0023175', 'cui_str': 'Lead'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}]",155.0,0.0763852,Both intervention and control groups maintained more than 90% of MPR and no significant difference was observed in the primary outcome.,"[{'ForeName': 'Hiroko', 'Initials': 'H', 'LastName': 'Komatsu', 'Affiliation': 'Japanese Red Cross Kyushu International College of Nursing, 1-1 Asty Munakata-City, Fukuoka-Prefecture, 811-4157, Japan. Electronic address: h-komatsu@jrckicn.ac.jp.'}, {'ForeName': 'Kaori', 'Initials': 'K', 'LastName': 'Yagasaki', 'Affiliation': 'Faculty of Nursing and Medical Care, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. Electronic address: yagasaki@sfc.keio.ac.jp.'}, {'ForeName': 'Takuhiro', 'Initials': 'T', 'LastName': 'Yamaguchi', 'Affiliation': 'Division of Biostatistics, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. Electronic address: yamaguchi@med.tohoku.ac.jp.'}, {'ForeName': 'Ayako', 'Initials': 'A', 'LastName': 'Mori', 'Affiliation': 'Division of Nursing, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. Electronic address: aymori@ncc.go.jp.'}, {'ForeName': 'Hiromi', 'Initials': 'H', 'LastName': 'Kawano', 'Affiliation': 'Nursing Department, Kanagawa Cancer Center, 2-3-1 Nakao, Yokohamashi, Kanagawa, 241-8515, Japan. Electronic address: gairai@kcch.jp.'}, {'ForeName': 'Noriko', 'Initials': 'N', 'LastName': 'Minamoto', 'Affiliation': 'Nursing Division, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba-ken, 277-8577, Japan. Electronic address: nminamot@east.ncc.go.jp.'}, {'ForeName': 'Orie', 'Initials': 'O', 'LastName': 'Honma', 'Affiliation': 'Division of Nursing, Showa University Hospital, 1-5-8, Hatanodai, Shinagawaku, Tokyo, 142-8666, Japan. Electronic address: ori-miya20@cmed.showa-u.ac.jp.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Tamura', 'Affiliation': 'Department of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. Electronic address: ketamura@ncc.go.jp.'}]",European journal of oncology nursing : the official journal of European Oncology Nursing Society,['10.1016/j.ejon.2020.101780'] 1781,32673264,HIV Self-Testing to Promote Serostatus Disclosure Among Men Who Have Sex With Men in China: Protocol for a Stepped Wedge Randomized Controlled Trial.,"BACKGROUND Disclosure of HIV serostatus is important for the prevention of HIV infection among men who have sex with men (MSM). However, knowledge of sexual partners' HIV status among MSM in China is low. As a complement to HIV testing services, HIV self-testing (HIVST) has considerable potential to promote serostatus disclosure. OBJECTIVE The primary objective of our trial is to evaluate the effect of HIVST on improving serostatus disclosure to sexual partners. We hypothesize that MSM in an intervention condition will have a higher awareness of the HIV status of their sexual partners compared with MSM in the control condition. The secondary aims are to evaluate (i) changes in sexual behaviors after disclosure of HIV status by sexual partners, (ii) promotion of the frequency of HIV and syphilis testing on participants and their sexual partners, and (iii) factors that restrict the disclosure of HIV infection to sexual partners. We hypothesize that MSM in the intervention condition will exhibit safer sexual decision making and a higher rate of HIV testing uptake compared with MSM in the control condition. METHODS A stepped wedge randomized controlled trial will be conducted throughout China. Study recruitment of 800 MSM will be promoted through advertisements released on WeChat public accounts. Individuals who are born biologically male, aged ≥18 years, HIV negative, and who have not undergone HIV testing in the past 3 months will be recruited. Eligible men will be randomly divided (1:1:1:1) into four groups and randomized. The group cluster will initiate the intervention so that participants will be provided with 2-4 free finger prick-based HIVST kits until trial completion. The intervention period for participants in each of the four groups will be initiated at 3-month intervals. Men in both groups will be required to complete a baseline and four follow-up surveys every 3 months. The primary intervention outcome will evaluate the effect of the distribution of HIVST kits on improvement in the disclosure of sexual partners' HIV status. The secondary outcomes will be changes in sexual behaviors after disclosure of HIV status from sexual partners, the promotion of the frequency of HIVST on participants and their sexual partners, and the factors that restrict disclosure of HIV status to sexual partners. RESULTS Subject recruitment began in August 2018. The first round of follow-up surveys post intervention is complete, with three rounds remaining to be done. Data analysis was scheduled for April 2020 and the results will be disseminated through conferences and peer-reviewed publications. CONCLUSIONS Few studies have evaluated interventions to increase knowledge of sexual partners' HIV status among MSM. Our trial will provide information on the link between HIVST and HIV serostatus disclosure. The findings of this trial will facilitate the implementation of HIVST services to help control the spread of HIV among MSM in China. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiCTR1800019453; http://www.chictr.org.cn/showproj.aspx?proj=30158. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/17788.",2020,"We hypothesize that MSM in the intervention condition will exhibit safer sexual decision making and a higher rate of HIV testing uptake compared with MSM in the control condition. ","['Eligible men', 'Individuals who are born biologically male, aged ≥18 years, HIV negative, and who have not undergone HIV testing in the past 3 months will be recruited', 'Men', 'Who Have Sex With Men in China', 'men who have sex with men (MSM']","['MSM', 'HIV self-testing (HIVST', 'HIVST']","[""effect of the distribution of HIVST kits on improvement in the disclosure of sexual partners' HIV status"", 'sexual behaviors', 'serostatus disclosure to sexual partners', 'sexual behaviors after disclosure of HIV status from sexual partners, the promotion of the frequency of HIVST on participants and their sexual partners, and the factors that restrict disclosure of HIV status to sexual partners']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0205460', 'cui_str': 'Biologic'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0481430', 'cui_str': 'HIV negative'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}]","[{'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392366', 'cui_str': 'Tests'}]","[{'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0812225', 'cui_str': 'Device kit'}, {'cui': 'C0012625', 'cui_str': 'Information Disclosure'}, {'cui': 'C0036911', 'cui_str': 'Sexual partners'}, {'cui': 'C0458074', 'cui_str': 'HIV status'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]",800.0,0.0993102,"We hypothesize that MSM in the intervention condition will exhibit safer sexual decision making and a higher rate of HIV testing uptake compared with MSM in the control condition. ","[{'ForeName': 'Tianyi', 'Initials': 'T', 'LastName': 'Lu', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology, Department of Laboratory Medicine, First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology, Department of Laboratory Medicine, First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Mao', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology, Department of Laboratory Medicine, First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Erlei', 'Initials': 'E', 'LastName': 'Peng', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology, Department of Laboratory Medicine, First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Yangyang', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology, Department of Laboratory Medicine, First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Zhenxing', 'Initials': 'Z', 'LastName': 'Chu', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology, Department of Laboratory Medicine, First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology, Department of Laboratory Medicine, First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Willa', 'Initials': 'W', 'LastName': 'Dong', 'Affiliation': 'Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}, {'ForeName': 'Yongjun', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology, Department of Laboratory Medicine, First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Junjie', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology, Department of Laboratory Medicine, First Affiliated Hospital of China Medical University, Shenyang, China.'}]",JMIR research protocols,['10.2196/17788'] 1782,32673267,Mobile Health Apps in Pediatric Obesity Treatment: Process Outcomes From a Feasibility Study of a Multicomponent Intervention.,"BACKGROUND Multicomponent family interventions underline current best practice in childhood obesity treatment. Mobile health (mHealth) adjuncts that address eating and physical activity behaviors have shown promise in clinical studies. OBJECTIVE This study aimed to describe process methods for applying an mHealth intervention to reduce the rate of eating and monitor physical activity among children with obesity. METHODS The study protocol was designed to incorporate 2 mHealth apps as an adjunct to usual care treatment for obesity. Children and adolescents (aged 9-16 years) with obesity (BMI ≥98th centile) were recruited in person from a weight management service at a tertiary health care center in the Republic of Ireland. Eligible participants and their parents received information leaflets, and informed consent and assent were signed. Participants completed 2 weeks of baseline testing, including behavioral and quality of life questionnaires, anthropometry, rate of eating by Mandolean, and physical activity level using a smart watch and the myBigO smartphone app. Thereafter, participants were randomized to the (1) intervention (usual clinical care+Mandolean training to reduce the rate of eating) or (2) control (usual clinical care) groups. Gender and age group (9.0-12.9 years and 13.0-16.9 years) stratifications were applied. At the end of a 4-week treatment period, participants repeated the 2-week testing period. Process evaluation measures included recruitment, study retention, fidelity parameters, acceptability, and user satisfaction. RESULTS A total of 20 participants were enrolled in the study. A web-based randomization system assigned 8 participants to the intervention group and 12 participants to the control group. Attrition rates were higher among the participants in the intervention group (5/8, 63%) than those in the control group (3/12, 25%). Intervention participants undertook a median of 1.0 training meal using Mandolean (25th centile 0, 75th centile 9.3), which represented 19.2% of planned intervention exposure. Only 50% (9/18) of participants with smart watches logged physical activity data. Significant differences in psychosocial profile were observed at baseline between the groups. The Child Behavior Checklist (CBCL) mean total score was 71.7 (SD 3.1) in the intervention group vs 57.6 (SD 6.6) in the control group, t-test P<.001, and also different among those who completed the planned protocol compared with those who withdrew early (CBCL mean total score 59.0, SD 9.3, vs 67.9, SD 5.6, respectively; t-test P=.04). CONCLUSIONS A high early attrition rate was a key barrier to full study implementation. Perceived task burden in combination with behavioral issues may have contributed to attrition. Low exposure to the experimental intervention was explained by poor acceptability of Mandolean as a home-based tool for treatment. Self-monitoring using myBigO and the smartwatch was acceptable among this cohort. Further technical and usability studies are needed to improve adherence in our patient group in the tertiary setting.",2020,"Attrition rates were higher among the participants in the intervention group (5/8, 63%) than those in the control group (3/12, 25%).","['children with obesity', 'A total of 20 participants were enrolled in the study', 'Gender and age group (9.0-12.9 years and 13.0-16.9 years) stratifications were applied', 'Pediatric Obesity Treatment', 'Children and adolescents (aged 9-16 years) with obesity (BMI ≥98th centile) were recruited in person from a weight management service at a tertiary health care center in the Republic of Ireland']","['intervention (usual clinical care+Mandolean training to reduce the rate of eating) or (2) control (usual clinical care', 'Multicomponent Intervention']","['recruitment, study retention, fidelity parameters, acceptability, and user satisfaction', 'Attrition rates', 'rate of eating and monitor physical activity', 'behavioral and quality of life questionnaires, anthropometry, rate of eating by Mandolean, and physical activity level', 'psychosocial profile', 'Child Behavior Checklist (CBCL) mean total score']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C2362324', 'cui_str': 'Childhood obesity'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0022067', 'cui_str': 'Republic of Ireland'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0008065', 'cui_str': 'Behavior, Child'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",20.0,0.0668364,"Attrition rates were higher among the participants in the intervention group (5/8, 63%) than those in the control group (3/12, 25%).","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Browne', 'Affiliation': 'School Public Health, Physiotherapy & Sports Science, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'M-Tahar', 'Initials': 'MT', 'LastName': 'Kechadi', 'Affiliation': 'Insight Centre for Data Analytics, School of Computer Science, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Shane', 'Initials': 'S', 'LastName': ""O'Donnell"", 'Affiliation': 'School of Sociology, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Mckenzie', 'Initials': 'M', 'LastName': 'Dow', 'Affiliation': 'School Public Health, Physiotherapy & Sports Science, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Tully', 'Affiliation': 'Division of Population Health Sciences, School of Physiotherapy, Royal College of Surgeons in Ireland, Dublin, Ireland.'}, {'ForeName': 'Gerardine', 'Initials': 'G', 'LastName': 'Doyle', 'Affiliation': 'UCD Michael Smurfit Graduate Business School, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': ""O'Malley"", 'Affiliation': 'Division of Population Health Sciences, School of Physiotherapy, Royal College of Surgeons in Ireland, Dublin, Ireland.'}]",JMIR mHealth and uHealth,['10.2196/16925'] 1783,32687924,"Intake of Lactiplantibacillus plantarum HEAL9 reduces the inflammatory markers soluble fractalkine and CD163 during acute stress: A randomized, double blind, placebo-controlled study.","The intestine and the brain are connected via the brain-gut axis and the intestinal microbiota influences the immune activation and signaling molecules that are involved in the stress response. The aim of the study was to investigate if intake of the probiotic strain Lactiplantibacillus plantarum HEAL9 (LPHEAL9) for four weeks could counteract elevated cortisol and inflammation levels in subjects with chronic stress that are exposed to an acute stress test (Trier Social Stress Test, TSST). Seventy participants were included, and 63 participants completed the study (LPHEAL9, n = 32; placebo, n  =  31). Cardiovascular reactivity and cortisol levels were affected by the TSST, but no differences between the groups were observed. Intake of LPHEAL9 did, however, result in significantly decreased plasma levels of two inflammatory markers (soluble fractalkine and CD163) compared to placebo. In conclusion, intake of LPHEAL9 for four weeks may reduce inflammatory markers coupled to acute stress in chronically stressed individuals.",2020,"Intake of LPHEAL9 did, however, result in significantly decreased plasma levels of two inflammatory markers (soluble fractalkine and CD163) compared to placebo.","['acute stress', 'subjects with chronic stress', 'chronically stressed individuals', 'Seventy participants were included, and 63 participants completed the study (LPHEAL9, n=32; placebo, n=31']","['probiotic strain Lactobacillus plantarum HEAL9 (LPHEAL9', 'Lactobacillus plantarum HEAL9', 'placebo']","['elevated cortisol and inflammation levels', 'plasma levels', 'Cardiovascular reactivity and cortisol levels']","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0317608', 'cui_str': 'Lactobacillus plantarum'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}]",70.0,0.191303,"Intake of LPHEAL9 did, however, result in significantly decreased plasma levels of two inflammatory markers (soluble fractalkine and CD163) compared to placebo.","[{'ForeName': 'Gunilla', 'Initials': 'G', 'LastName': 'Önning', 'Affiliation': 'Biomedical Nutrition, Pure and Applied Biochemistry, Lund University, Lund, Sweden; Probi AB, Lund, Sweden. Electronic address: gunilla.onning@probi.com.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Hillman', 'Affiliation': 'Department of Clinical Sciences Lund, Diabetes Research Laboratory, Lund University, Lund, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Hedin', 'Affiliation': 'Department of Food Technology, Engineering and Nutrition, Lund University, Lund, Sweden.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Montelius', 'Affiliation': 'Probi AB, Lund, Sweden.'}, {'ForeName': 'Joakim', 'Initials': 'J', 'LastName': 'Eriksson', 'Affiliation': 'Ergonomics and Aerosol Technology, Department of Design Studies, Lund University, Lund, Sweden.'}, {'ForeName': 'Siv', 'Initials': 'S', 'LastName': 'Ahrné', 'Affiliation': 'Department of Food Technology, Engineering and Nutrition, Lund University, Lund, Sweden.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Jönsson', 'Affiliation': 'Department of Psychology, Faculty of Education, Kristianstad University, Kristianstad, Sweden.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113083'] 1784,32679434,"Diet-induced differences in estimated plasma glucose concentrations in healthy, non-diabetic adults are detected by continuous glucose monitoring-a randomized crossover trial.","Continuous glucose monitors (CGMs) have been developed for diabetic patients for estimating and controlling plasma glucose changes throughout the day. However, elevated postprandial glucose concentrations may also be detrimental for non-diabetic subjects by increasing the risk of developing vascular complications and type 2 diabetes. Therefore, CGMs may also be valuable in clinical research and we hypothesized that diet-induced differences in estimated plasma glucose concentrations in healthy, non-diabetic adults could be detected by the Abbott FreeStyle Libre Pro CGM. In this single-blind randomized cross-over trial, 23 healthy but overweight or obese men and women therefore consumed two diets differing in glycemic load in randomized order for three consecutive days. Based on the CGM measurements, two-hour total areas under the curve (tAUCs) after breakfast, lunch and dinner were calculated. Additionally, postprandial glucose was measured with the CGM and in plasma during a rice meal challenge. The average tAUC was significantly lower on the low GL diet compared to the high GL diet (P < .0001). The same conclusions were drawn when tAUCs for breakfast (P < .0001), lunch (P < .0001) and dinner (P < .0001) were analyzed separately. During the rice meal challenge, significantly higher glucose responses were observed after the low GL period, as monitored by both the CGM device (P < .0001) and the plasma glucose analysis (P < .0001). The difference between the means of both methods was 0.11 mmol/L (1.78%) with a higher glucose value in plasma. The absolute mean difference was 0.66 mmol/L (10.5%). We conclude that the CGM detected diet-induced differences in estimated plasma glucose concentrations, which supports its use not only in clinical practice, but also for research purposes during dietary interventions in non-diabetic participants.",2020,The average tAUC was significantly lower on the low GL diet compared to the high GL diet (P < .0001).,"['healthy, non-diabetic adults', '23 healthy but overweight or obese men and women', 'non-diabetic participants', 'diabetic patients']",['Continuous glucose monitors (CGMs'],"['elevated postprandial glucose concentrations', 'average tAUC', 'glucose responses', 'plasma glucose analysis', 'plasma glucose concentrations', 'postprandial glucose']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4523945', 'cui_str': 'Continuous glucose monitoring'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0427743', 'cui_str': 'Glucose concentration, test strip measurement'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C2584434', 'cui_str': 'Plasma glucose concentration'}]",23.0,0.0315526,The average tAUC was significantly lower on the low GL diet compared to the high GL diet (P < .0001).,"[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Fechner', 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, PO Box 616, 6200, MD, Maastricht, The Netherlands. Electronic address: eva.fechner@outlook.com.'}, {'ForeName': 'Cara', 'Initials': 'C', 'LastName': ""Op 't Eyndt"", 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, PO Box 616, 6200, MD, Maastricht, The Netherlands. Electronic address: cara.opteyndt@mumc.nl.'}, {'ForeName': 'Theo', 'Initials': 'T', 'LastName': 'Mulder', 'Affiliation': 'Unilever Foods Innovation Center - Hive, Bronland 14, 6708, WH, Wageningen, The Netherlands. Electronic address: theo.mulder@unilever.com.'}, {'ForeName': 'Ronald P', 'Initials': 'RP', 'LastName': 'Mensink', 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, PO Box 616, 6200, MD, Maastricht, The Netherlands. Electronic address: r.mensink@maastrichtuniversity.nl.'}]","Nutrition research (New York, N.Y.)",['10.1016/j.nutres.2020.06.001'] 1785,32679537,Blood pressure postpartum (BP 2 ) RCT protocol: Follow-up and lifestyle behaviour change strategies in the first 12 months after hypertensive pregnancy.,"OBJECTIVES Women who had hypertensive disorders of pregnancy (HDP) are twice as likely to experience maternal cardiovascular disease later in life. The primary aim of this study (BP 2 ) is to compare outcomes of 3 different management strategies, including lifestyle behaviour change (LBC), in the first 12 months postpartum in women who had HDP in their preceding pregnancy. Secondary aims include assessing the effects on other cardiometabolic parameters. STUDY DESIGN Three-arm multicentre randomised trial in metropolitan Australian hospitals, (registration: ACTRN12618002004246) target sample size 480. Participants are randomised to one of three groups: 1) Optimised usual care: information package and family doctor follow-up 6 months postpartum 2) Brief intervention: information package as per group 1, plus assessment and brief LBC counselling at a specialised clinic with an obstetric physician and dietitian 6 months postpartum 3) Extended intervention: as per group 2 plus enrolment into a 6 month telephone-based LBC program from 6 to 12 months postpartum. All women have an outcome assessment at 12 months. MAIN OUTCOME MEASURES Primary outcomes: (a) BP change or (b) weight change and/or waist circumference change. SECONDARY OUTCOMES maternal health-related quality of life, engagement and retention in LBC program, biochemical markers, vascular function testing, infant weight trajectory, incremental cost-effectiveness ratios. The study is powered to detect a 4 mmHg difference in systolic BP between groups, or a 4 kg weight loss difference/2cm waist circumference change. CONCLUSIONS BP 2 will provide evidence regarding the feasibility and effectiveness of postpartum LBC interventions and structured clinical follow-up in improving cardiovascular health markers after HDP.",2020,Participants are randomised to one of three groups: 1) Optimised usual care: information package and family doctor follow-up 6 months postpartum 2),"['women who had HDP in their preceding pregnancy', 'Three-arm multicentre randomised trial in metropolitan Australian hospitals, (registration: ACTRN12618002004246) target sample size 480', 'Women who had hypertensive disorders of pregnancy (HDP']","['LBC counselling at a specialised clinic with an obstetric physician and dietitian 6\xa0months postpartum 3) Extended intervention: as per group 2 plus enrolment into a 6\xa0month telephone-based LBC program', 'Optimised usual care: information package and family doctor follow-up 6\xa0months postpartum 2']","['Blood pressure postpartum (BP 2 ', 'BP change or (b) weight change and/or waist circumference change', 'maternal health-related quality of life, engagement and retention in LBC program, biochemical markers, vascular function testing, infant weight trajectory, incremental cost-effectiveness ratios', 'systolic BP', 'lifestyle behaviour change (LBC']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0852260', 'cui_str': 'Hypertension associated disorders of pregnancy'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}, {'cui': 'C4319609', 'cui_str': '480'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0334932', 'cui_str': 'Dietitian (general)'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C1704221', 'cui_str': 'Family medicine specialist'}, {'cui': 'C0589124', 'cui_str': 'Follow-up 6 months'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C1268766', 'cui_str': 'Blood pressure alteration'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0024921', 'cui_str': 'Maternal Health'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Markers'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C4704805', 'cui_str': 'Weight Trajectory'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",480.0,0.118249,Participants are randomised to one of three groups: 1) Optimised usual care: information package and family doctor follow-up 6 months postpartum 2),"[{'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Henry', 'Affiliation': ""School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia; Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia; The George Institute for Global Health, Sydney, Australia. Electronic address: Amanda.Henry@unsw.edu.au.""}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Arnott', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia; Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Faculty of Medicine, University of New South Wales, Sydney, Australia; Sydney Medical School, University of Sydney, Australia.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Makris', 'Affiliation': 'Faculty of Medicine, University of New South Wales, Sydney, Australia; School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Davis', 'Affiliation': ""School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia; Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia.""}, {'ForeName': 'Annemarie', 'Initials': 'A', 'LastName': 'Hennessy', 'Affiliation': 'School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Beech', 'Affiliation': 'Royal Hospital for Women, Randwick, New South Wales, Australia.'}, {'ForeName': 'Franziska', 'Initials': 'F', 'LastName': 'Pettit', 'Affiliation': 'Department of Renal Medicine, St George Hospital, Kogarah, New South Wales, Australia; St George and Sutherland Clinical School, UNSW Medicine, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Se Homer', 'Affiliation': 'Burnet Institute, Melbourne, Victoria, Australia; Faculty of Health, University of Technology, Sydney, New South Wales, Australia.'}, {'ForeName': 'Maria E', 'Initials': 'ME', 'LastName': 'Craig', 'Affiliation': ""School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia; Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia.""}, {'ForeName': 'Lynne', 'Initials': 'L', 'LastName': 'Roberts', 'Affiliation': ""Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia; St George and Sutherland Clinical School, UNSW Medicine, University of New South Wales, Sydney, Australia.""}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Hyett', 'Affiliation': 'Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Sydney Medical School, University of Sydney, Australia.'}, {'ForeName': 'Georgina', 'Initials': 'G', 'LastName': 'Chambers', 'Affiliation': ""National Perinatal Epidemiology and Statistics Unit, School of Women's and Children's Health and Centre for Big Data Research in Health, University of New South Wales, Sydney, NSW, Australia.""}, {'ForeName': 'Oisin', 'Initials': 'O', 'LastName': 'Fitzgerald', 'Affiliation': ""National Perinatal Epidemiology and Statistics Unit, School of Women's and Children's Health and Centre for Big Data Research in Health, University of New South Wales, Sydney, NSW, Australia.""}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Gow', 'Affiliation': 'Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Mann', 'Affiliation': 'General Practitioner, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Challis', 'Affiliation': ""School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia; Royal Hospital for Women, Randwick, New South Wales, Australia.""}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Gale', 'Affiliation': 'New South Wales Ministry of Health, North Sydney, New South Wales, Australia.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Ruhotas', 'Affiliation': ""Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia.""}, {'ForeName': 'Emilee', 'Initials': 'E', 'LastName': 'Kirwin', 'Affiliation': ""Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia.""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Denney-Wilson', 'Affiliation': 'Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Brown', 'Affiliation': 'Department of Renal Medicine, St George Hospital, Kogarah, New South Wales, Australia; St George and Sutherland Clinical School, UNSW Medicine, University of New South Wales, Sydney, Australia.'}]",Pregnancy hypertension,['10.1016/j.preghy.2020.07.001'] 1786,32682074,Pulmonary deposition of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler formulated using co-suspension delivery technology in healthy male subjects.,"This gamma scintigraphy imaging study assessed pulmonary, extrathoracic and regional lung deposition patterns of a radiolabelled inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β 2 -agonist triple fixed-dose combination budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF 320/14.4/10 μg), delivered by pressurised metered dose inhaler (pMDI) using innovative co-suspension delivery technology (Aerosphere™). In this Phase I, randomised, single-centre, single-dose, two-period, crossover study (NCT03740373), 10 healthy male adults received two actuations of BGF MDI (160/7.2/4.8 μg per actuation) radiolabelled with 99m Tc, not exceeding 5 MBq per actuation. Immediately following each inhalation, subjects performed a 10- or 3-second breath-hold, then exhaled into an exhalation filter. The primary objective was to assess the pulmonary deposition of BGF MDI following the 10-second breath-hold. The secondary objectives were to assess deposition after the 3-second breath-hold and lung regional and extrathoracic deposition after each breath-hold length. Imaging of the lungs, stomach, head and neck was recorded by gamma scintigraphy immediately after exhalation. The mean BGF MDI emitted dose deposited in the lungs was 37.7% for the 10-second breath-hold and 34.5% for the 3-second breath-hold. Emitted dose detected in the exhalation filter was ≤0.4% for both breath-hold lengths. The mean normalised peripheral/central ratio was 0.65 and 0.75 for the 10- and 3-second breath-holds, respectively, while the standardised central/peripheral ratios were 1.79 and 1.40, respectively. There were no new or unexpected safety findings. In conclusion, BGF MDI was efficiently deposited in the central and the peripheral regions of the lungs, with similar regional deposition patterns following a 10- and 3-second breath-hold.",2020,"The mean normalised peripheral/central ratio was 0.65 and 0.75 for the 10- and 3-second breath-holds, respectively, while the standardised central/peripheral ratios were 1.79 and 1.40, respectively.","['10 healthy male adults received', 'healthy male subjects']","['two actuations of BGF MDI', 'budesonide/glycopyrronium/formoterol fumarate dihydrate']","['exhalation filter', 'deposition after the 3-second breath-hold and lung regional and extrathoracic deposition after each breath-hold length', 'mean BGF MDI', 'pulmonary deposition of BGF MDI', 'mean normalised peripheral/central ratio', 'BGF MDI']","[{'cui': 'C0686751', 'cui_str': 'Well male adult'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C4319628', 'cui_str': 'Actuation'}, {'cui': 'C0993596', 'cui_str': 'Metered dose inhaler'}, {'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C3814772', 'cui_str': 'glycopyrronium'}, {'cui': 'C1579393', 'cui_str': 'Formoterol fumarate dihydrate'}]","[{'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0180860', 'cui_str': 'Filter'}, {'cui': 'C0333562', 'cui_str': 'Deposition'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0235744', 'cui_str': 'Interrupted breathing'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0993596', 'cui_str': 'Metered dose inhaler'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",10.0,0.0611695,"The mean normalised peripheral/central ratio was 0.65 and 0.75 for the 10- and 3-second breath-holds, respectively, while the standardised central/peripheral ratios were 1.79 and 1.40, respectively.","[{'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Israel', 'Affiliation': 'Simbec Research Ltd, Merthyr Tydfil, South Wales, CF48 4DR, UK.'}, {'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Kumar', 'Affiliation': 'Kelly Services Global LLC, Suite 401A, 999W. Big Beaver Rd., Troy, MI, 48084, USA.'}, {'ForeName': 'Kiernan', 'Initials': 'K', 'LastName': 'DeAngelis', 'Affiliation': 'Formerly of AstraZeneca, 4222 Emperor Blvd, Suite 560, Durham, NC, 27703, USA.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Aurivillius', 'Affiliation': 'AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 50, Mölndal, Sweden.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Dorinsky', 'Affiliation': 'AstraZeneca, 4222 Emperor Blvd, Suite 560, Durham, NC, 27703, USA. Electronic address: paul.dorinsky1@astrazeneca.com.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Roche', 'Affiliation': 'Respiratory Medicine, Hôpital Cochin (AP-HP), University Paris Descartes, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France.'}, {'ForeName': 'Omar S', 'Initials': 'OS', 'LastName': 'Usmani', 'Affiliation': 'National Heart and Lung Institute (NHLI), Imperial College London & Royal Brompton Hospital, Guy Scadding Building, Dovehouse St, Chelsea, London SW3 6LY, UK.'}]",European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,['10.1016/j.ejps.2020.105472'] 1787,32682174,The renin secretion profile under the influence of sleep deprivation and the neuropeptides CRH and GHRH.,"It is already known that during normal sleep plasma renin activity (PRA) shows oscillations with decreases during rapid-eye-movement (REM) sleep and increases during non-REM (NREM) sleep. We also know that renin correlates positively with slow-wave sleep (SWS). Sleep deprivation is known to enhance significantly SWS and slow wave activity (SWA, known as δ power). Based on these findings we addressed the question whether and to which extent sleep deprivation may affect the synchronization found between PRA and REM sleep during normal sleep and whether this synchronization is affected by other sleep regulating factors. To investigate these questions we compared sleep EEG and sleep-related free renin levels in 48 normal women and men 19-69 years old between nights before and after 40 h of sleep deprivation. During the recovery night, four bolus injections of either GHRH, CRH or placebo were injected via long catheter around sleep onset. When compared to baseline after each of the treatments SWS, SWA and renin levels increased. The characteristical oscillation profiles of renin during normal sleep were also preserved after sleep deprivation. Similar to normal sleep our data support also a distinct link between nocturnal renin secretion and SWS after sleep deprivation and that independent of the applied treatments.",2020,"When compared to baseline after each of the treatments SWS, SWA and renin levels increased.",['48 normal women and men 19-69 years old between nights before and after 40\u2009h of sleep deprivation'],"['GHRH, CRH or placebo']","['renin correlates positively with slow-wave sleep (SWS', 'SWA and renin levels', 'sleep EEG and sleep-related free renin levels']","[{'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0037316', 'cui_str': 'Sleep deprivation'}]","[{'cui': 'C0037668', 'cui_str': 'Somatotropin releasing factor'}, {'cui': 'C0010132', 'cui_str': 'Corticotropin-Releasing Hormone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0035094', 'cui_str': 'Renin'}, {'cui': 'C0234451', 'cui_str': 'Non-rapid eye movement sleep'}, {'cui': 'C0038977', 'cui_str': 'Swahili language'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0200101', 'cui_str': 'Sleep electroencephalogram'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0332296', 'cui_str': 'Free of'}]",48.0,0.0236425,"When compared to baseline after each of the treatments SWS, SWA and renin levels increased.","[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Künzel', 'Affiliation': 'Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Germany; Max-Planck-Institut für Psychiatrie München, Germany. Electronic address: Heike.Kuenzel@med.uni-muenchen.de.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Schüssler', 'Affiliation': 'Max-Planck-Institut für Psychiatrie München, Germany; Universität Regensburg, Klinik und Poliklinik für Psychiatrie, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Yassouridis', 'Affiliation': 'Max-Planck-Institut für Psychiatrie München, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Uhr', 'Affiliation': 'Max-Planck-Institut für Psychiatrie München, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kluge', 'Affiliation': 'Max-Planck-Institut für Psychiatrie München, Germany; Universität Leipzig, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Steiger', 'Affiliation': 'Max-Planck-Institut für Psychiatrie München, Germany.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2020.104799'] 1788,32682457,"S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.","BACKGROUND S-1 plus leucovorin and oxaliplatin showed promising efficacy for treatment of advanced gastric cancer in a randomised phase 2 study. We aimed to evaluate the efficacy and safety of oral TAS-118 (S-1 plus leucovorin) and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer. METHODS We did a randomised, open-label, phase 3 trial in 62 centres across Japan and South Korea. Patients aged 20 years or older, with a histologically confirmed advanced gastric cancer with negative or unknown HER2 status, with Eastern Cooperative Oncology Group performance status of 0 or 1, measurable or evaluable metastatic lesions, and no previous treatment were randomly assigned (1:1) via an interactive web response system using the minimisation method, stratified by performance status, presence of a measurable lesion, and country, to receive TAS-118 (S-1 40-60 mg and leucovorin 25 mg orally twice daily for 7 days) plus oxaliplatin (85 mg/m 2 intravenously on day 1) every 2 weeks, or S-1 (40-60 mg orally twice daily) for 21 days plus cisplatin (60 mg/m 2 intravenously on day 1 or 8) every 5 weeks. The primary endpoint was overall survival in patients who had advanced gastric cancer with measurable or evaluable metastatic lesions and who received the study drug. Safety was assessed in all patients who received the study drug. This study was registered at ClinicalTrials.gov, NCT02322593. FINDINGS Between Jan 28, 2015, and Dec 5, 2016, 711 patients were randomised to TAS-118 plus oxaliplatin (n=356) or S-1 plus cisplatin (n=355). 11 untreated patients and 19 ineligible patients were excluded from the primary analysis (TAS-118 plus oxaliplatin group n=347, S-1 plus cisplatin group n=334) following recommendation from the independent data monitoring committee. After median follow-up of 26·0 months (IQR 22·0-32·8), median overall survival was 16·0 months (95% CI 13·8-18·3) in the TAS-118 plus oxaliplatin group and 15·1 months (95% CI 13·6-16·4) in the S-1 plus cisplatin group (hazard ratio 0·83, 95% CI 0·69-0·99; p=0·039). The most common grade 3 or higher adverse events in the 352 patients in the TAS-118 plus oxaliplatin group and the 348 patients in the S-1 plus cisplatin group were anaemia (56 [16%] vs 64 [18%]), neutropenia (54 [15%] vs 88 [25%]), decreased appetite (53 [15%] vs 46 [13%]), diarrhoea (33 [9%] vs 15 [4%]), and peripheral sensory neuropathy (30 [9%] vs one [<1%]). Serious adverse events were observed in 155 (44%) of 352 patients in the TAS-118 plus oxaliplatin group and 159 (46%) of 348 patients in the S-1 plus cisplatin group. Two treatment-related deaths occurred in the TAS-118 plus oxaliplatin group (pulmonary tuberculosis and viral pneumonia). INTERPRETATION TAS-118 plus oxaliplatin showed a clinically meaningful improvement in efficacy compared with S-1 plus cisplatin, and could be considered a new first-line treatment option for advanced gastric cancer in Asian patients. FUNDING Taiho Pharmaceutical and Yakult Honsha.",2020,"Two treatment-related deaths occurred in the TAS-118 plus oxaliplatin group (pulmonary tuberculosis and viral pneumonia). ","['advanced gastric cancer in Asian patients', 'patients with advanced gastric cancer (SOLAR', 'Patients aged 20 years or older, with a histologically confirmed advanced gastric cancer with negative or unknown HER2 status, with Eastern Cooperative Oncology Group performance status of 0 or 1, measurable or evaluable metastatic lesions, and no previous treatment', 'patients with advanced gastric cancer', 'Between Jan 28, 2015, and Dec 5, 2016, 711 patients', '11 untreated patients and 19 ineligible patients were excluded from the primary analysis ', '62 centres across Japan and South Korea', 'group n=334) following recommendation from the independent data monitoring committee', 'advanced gastric cancer', 'patients who had advanced gastric cancer with measurable or evaluable metastatic lesions and who received the study drug']","['oxaliplatin', 'TAS-118 (S-1 40-60 mg and leucovorin 25 mg orally twice daily for 7 days) plus oxaliplatin', 'TAS-118 plus oxaliplatin', 'S-1', 'leucovorin and oxaliplatin', 'cisplatin', 'S-1 plus cisplatin', 'S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin', 'oral TAS-118 (S-1 plus leucovorin) and oxaliplatin versus S-1 plus cisplatin']","['Safety', 'neutropenia', 'overall survival', 'diarrhoea', 'efficacy and safety', 'anaemia', 'peripheral sensory neuropathy', 'median overall survival', 'adverse events', 'deaths', 'decreased appetite', 'Serious adverse events']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0013175', 'cui_str': 'Clinical drug trial'}]","[{'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0559483', 'cui_str': 'Pentalogy of Cantrell'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0879262', 'cui_str': 'S 1 (combination)'}, {'cui': 'C1125365', 'cui_str': 'Leucovorin 25 MG'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0151313', 'cui_str': 'Sensory neuropathy'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0232462', 'cui_str': 'Decrease in appetite'}]",11.0,0.251793,"Two treatment-related deaths occurred in the TAS-118 plus oxaliplatin group (pulmonary tuberculosis and viral pneumonia). ","[{'ForeName': 'Yoon-Koo', 'Initials': 'YK', 'LastName': 'Kang', 'Affiliation': 'Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Keisho', 'Initials': 'K', 'LastName': 'Chin', 'Affiliation': 'Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.'}, {'ForeName': 'Hyun Cheol', 'Initials': 'HC', 'LastName': 'Chung', 'Affiliation': 'Division of Medical Oncology, Institute for Cancer Research, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea.'}, {'ForeName': 'Shigenori', 'Initials': 'S', 'LastName': 'Kadowaki', 'Affiliation': 'Department of Clinical Oncology, Aichi Cancer Centre Hospital, Aichi, Japan.'}, {'ForeName': 'Sang Cheul', 'Initials': 'SC', 'LastName': 'Oh', 'Affiliation': 'Department of Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Norisuke', 'Initials': 'N', 'LastName': 'Nakayama', 'Affiliation': 'Department of Gastroenterology, Kanagawa Cancer Centre, Kanagawa, Japan.'}, {'ForeName': 'Keun-Wook', 'Initials': 'KW', 'LastName': 'Lee', 'Affiliation': 'Division of Haematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Hara', 'Affiliation': 'Department of Gastroenterology, Saitama Cancer Centre, Saitama, Japan.'}, {'ForeName': 'Ik-Joo', 'Initials': 'IJ', 'LastName': 'Chung', 'Affiliation': 'Department of Haematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University College of Medicine, Hwasun, South Korea.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Tsuda', 'Affiliation': 'Department of Gastroenterological Oncology, Hyogo Cancer Centre, Hyogo, Japan.'}, {'ForeName': 'Se Hoon', 'Initials': 'SH', 'LastName': 'Park', 'Affiliation': 'Department of Medicine, Division of Haematology-Oncology, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Hisashi', 'Initials': 'H', 'LastName': 'Hosaka', 'Affiliation': 'Department of Gastroenterology, Gunma Prefectural Cancer Centre, Gunma, Japan.'}, {'ForeName': 'Shuichi', 'Initials': 'S', 'LastName': 'Hironaka', 'Affiliation': 'Clinical Trial Promotion Department, Chiba Cancer Centre, Chiba, Japan.'}, {'ForeName': 'Yoshinori', 'Initials': 'Y', 'LastName': 'Miyata', 'Affiliation': 'Department of Medical Oncology, Saku Central Hospital Advanced Care Centre, Nagano, Japan.'}, {'ForeName': 'Min-Hee', 'Initials': 'MH', 'LastName': 'Ryu', 'Affiliation': 'Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Hideo', 'Initials': 'H', 'LastName': 'Baba', 'Affiliation': 'Department of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan.'}, {'ForeName': 'Ichinosuke', 'Initials': 'I', 'LastName': 'Hyodo', 'Affiliation': 'Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.'}, {'ForeName': 'Yung-Jue', 'Initials': 'YJ', 'LastName': 'Bang', 'Affiliation': 'Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Narikazu', 'Initials': 'N', 'LastName': 'Boku', 'Affiliation': 'Division of Gastrointestinal Medical Oncology, National Cancer Centre Hospital, Tokyo, Japan. Electronic address: nboku@ncc.go.jp.'}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30315-6'] 1789,32682482,Urgent endoscopic retrograde cholangiopancreatography with sphincterotomy versus conservative treatment in predicted severe acute gallstone pancreatitis (APEC): a multicentre randomised controlled trial.,"BACKGROUND It remains unclear whether urgent endoscopic retrograde cholangiopancreatography (ERCP) with biliary sphincterotomy improves the outcome of patients with gallstone pancreatitis without concomitant cholangitis. We did a randomised trial to compare urgent ERCP with sphincterotomy versus conservative treatment in patients with predicted severe acute gallstone pancreatitis. METHODS In this multicentre, parallel-group, assessor-masked, randomised controlled superiority trial, patients with predicted severe (Acute Physiology and Chronic Health Evaluation II score ≥8, Imrie score ≥3, or C-reactive protein concentration >150 mg/L) gallstone pancreatitis without cholangitis were assessed for eligibility in 26 hospitals in the Netherlands. Patients were randomly assigned (1:1) by a web-based randomisation module with randomly varying block sizes to urgent ERCP with sphincterotomy (within 24 h after hospital presentation) or conservative treatment. The primary endpoint was a composite of mortality or major complications (new-onset persistent organ failure, cholangitis, bacteraemia, pneumonia, pancreatic necrosis, or pancreatic insufficiency) within 6 months of randomisation. Analysis was by intention to treat. This trial is registered with the ISRCTN registry, ISRCTN97372133. FINDINGS Between Feb 28, 2013, and March 1, 2017, 232 patients were randomly assigned to urgent ERCP with sphincterotomy (n=118) or conservative treatment (n=114). One patient from each group was excluded from the final analysis because of cholangitis (urgent ERCP group) and chronic pancreatitis (conservative treatment group) at admission. The primary endpoint occurred in 45 (38%) of 117 patients in the urgent ERCP group and in 50 (44%) of 113 patients in the conservative treatment group (risk ratio [RR] 0·87, 95% CI 0·64-1·18; p=0·37). No relevant differences in the individual components of the primary endpoint were recorded between groups, apart from the occurrence of cholangitis (two [2%] of 117 in the urgent ERCP group vs 11 [10%] of 113 in the conservative treatment group; RR 0·18, 95% CI 0·04-0·78; p=0·010). Adverse events were reported in 87 (74%) of 118 patients in the urgent ERCP group versus 91 (80%) of 114 patients in the conservative treatment group. INTERPRETATION In patients with predicted severe gallstone pancreatitis but without cholangitis, urgent ERCP with sphincterotomy did not reduce the composite endpoint of major complications or mortality, compared with conservative treatment. Our findings support a conservative strategy in patients with predicted severe acute gallstone pancreatitis with an ERCP indicated only in patients with cholangitis or persistent cholestasis. FUNDING The Netherlands Organization for Health Research and Development, Fonds NutsOhra, and the Dutch Patient Organization for Pancreatic Diseases.",2020,"No relevant differences in the individual components of the primary endpoint were recorded between groups, apart from the occurrence of cholangitis (two [2%] of 117 in the urgent ERCP group vs 11 [10%] of 113 in the conservative treatment group; RR 0·18, 95% CI 0·04-0·78; p=0·010).","['predicted severe acute gallstone pancreatitis (APEC', 'patients with predicted severe acute gallstone pancreatitis', 'patients with predicted severe (Acute Physiology and Chronic Health Evaluation II score ≥8, Imrie score ≥3, or C-reactive protein concentration >150 mg/L) gallstone pancreatitis without cholangitis were assessed for eligibility in 26 hospitals in the Netherlands', 'Between Feb 28, 2013, and March 1, 2017', '232 patients', 'patients with cholangitis or persistent cholestasis', 'patients with gallstone pancreatitis without concomitant cholangitis', 'One patient from each group was excluded from the final analysis because of cholangitis (urgent ERCP group) and chronic pancreatitis (conservative treatment group) at admission', 'patients with predicted severe acute gallstone pancreatitis with an']","['ERCP', 'Urgent endoscopic retrograde cholangiopancreatography with sphincterotomy versus conservative treatment', 'ERCP with sphincterotomy versus conservative treatment', 'endoscopic retrograde cholangiopancreatography (ERCP) with biliary sphincterotomy', 'conservative treatment', 'ERCP with sphincterotomy']","['Adverse events', 'composite endpoint of major complications or mortality', 'composite of mortality or major complications (new-onset persistent organ failure, cholangitis, bacteraemia, pneumonia, pancreatic necrosis, or pancreatic insufficiency', 'severe gallstone pancreatitis', 'occurrence of cholangitis']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0521614', 'cui_str': 'Gallstone pancreatitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4758051', 'cui_str': 'APACHE II (Acute Physiology and Chronic Health Evaluation II) score'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0439268', 'cui_str': 'mg/L'}, {'cui': 'C0008311', 'cui_str': 'Cholangitis'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0008370', 'cui_str': 'Cholestasis'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C0149521', 'cui_str': 'Chronic pancreatitis'}, {'cui': 'C0459914', 'cui_str': 'Conservative therapy'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0177047', 'cui_str': 'Sphincterotomy (bladder)'}, {'cui': 'C0459914', 'cui_str': 'Conservative therapy'}, {'cui': 'C0948386', 'cui_str': 'Biliary sphincterotomy'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0349410', 'cui_str': 'Single organ dysfunction'}, {'cui': 'C0008311', 'cui_str': 'Cholangitis'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0267941', 'cui_str': 'Acute necrotizing pancreatitis'}, {'cui': 'C0030293', 'cui_str': 'Pancreatic insufficiency'}, {'cui': 'C0521614', 'cui_str': 'Gallstone pancreatitis'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}]",232.0,0.207888,"No relevant differences in the individual components of the primary endpoint were recorded between groups, apart from the occurrence of cholangitis (two [2%] of 117 in the urgent ERCP group vs 11 [10%] of 113 in the conservative treatment group; RR 0·18, 95% CI 0·04-0·78; p=0·010).","[{'ForeName': 'Nicolien J', 'Initials': 'NJ', 'LastName': 'Schepers', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands; Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, Netherlands. Electronic address: n.schepers@antoniusziekenhuis.nl.'}, {'ForeName': 'Nora D L', 'Initials': 'NDL', 'LastName': 'Hallensleben', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands; Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Marc G', 'Initials': 'MG', 'LastName': 'Besselink', 'Affiliation': 'Department of Surgery, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Marie-Paule G F', 'Initials': 'MGF', 'LastName': 'Anten', 'Affiliation': 'Department of Gastroenterology and Hepatology, Franciscus and Vlietland Hospital, Rotterdam, Netherlands.'}, {'ForeName': 'Thomas L', 'Initials': 'TL', 'LastName': 'Bollen', 'Affiliation': 'Department of Radiology, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'da Costa', 'Affiliation': 'Department of Radiology, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Foke', 'Initials': 'F', 'LastName': 'van Delft', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Sven M', 'Initials': 'SM', 'LastName': 'van Dijk', 'Affiliation': 'Department of Surgery, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Hendrik M', 'Initials': 'HM', 'LastName': 'van Dullemen', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, Netherlands.'}, {'ForeName': 'Marcel G W', 'Initials': 'MGW', 'LastName': 'Dijkgraaf', 'Affiliation': 'Department of Clinical Epidemiology, Biostatistics, and Bioinformatics, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Casper H J', 'Initials': 'CHJ', 'LastName': 'van Eijck', 'Affiliation': 'Department of Surgery, Erasmus MC University Medical Center, Rotterdam, Netherlands.'}, {'ForeName': 'G Willemien', 'Initials': 'GW', 'LastName': 'Erkelens', 'Affiliation': 'Department of Gastroenterology and Hepatology, Gelre Hospital, Apeldoorn, Netherlands.'}, {'ForeName': 'Nicole S', 'Initials': 'NS', 'LastName': 'Erler', 'Affiliation': 'Department of Biostatistics, Erasmus MC University Medical Center, Rotterdam, Netherlands.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Fockens', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Erwin J M', 'Initials': 'EJM', 'LastName': 'van Geenen', 'Affiliation': 'Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.'}, {'ForeName': 'Janneke', 'Initials': 'J', 'LastName': 'van Grinsven', 'Affiliation': 'Department of Surgery, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Robbert A', 'Initials': 'RA', 'LastName': 'Hollemans', 'Affiliation': 'Department of Surgery, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Jeanin E', 'Initials': 'JE', 'LastName': 'van Hooft', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Rene W M', 'Initials': 'RWM', 'LastName': 'van der Hulst', 'Affiliation': 'Department of Gastroenterology and Hepatology, Spaarne Hospital, Haarlem, Netherlands.'}, {'ForeName': 'Jeroen M', 'Initials': 'JM', 'LastName': 'Jansen', 'Affiliation': 'Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands.'}, {'ForeName': 'Frank J G M', 'Initials': 'FJGM', 'LastName': 'Kubben', 'Affiliation': 'Department of Gastroenterology and Hepatology, Maasstad Hospital, Rotterdam, Netherlands.'}, {'ForeName': 'Sjoerd D', 'Initials': 'SD', 'LastName': 'Kuiken', 'Affiliation': 'Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands.'}, {'ForeName': 'Robert J F', 'Initials': 'RJF', 'LastName': 'Laheij', 'Affiliation': 'Department of Gastroenterology and Hepatology, Elisabeth-TweeSteden Hospital, Tilburg, Netherlands.'}, {'ForeName': 'Rutger', 'Initials': 'R', 'LastName': 'Quispel', 'Affiliation': 'Department of Gastroenterology and Hepatology, Reinier de Graaf Group, Delft, Netherlands.'}, {'ForeName': 'Rogier J J', 'Initials': 'RJJ', 'LastName': 'de Ridder', 'Affiliation': 'Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, Netherlands.'}, {'ForeName': 'Marno C M', 'Initials': 'MCM', 'LastName': 'Rijk', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amphia Hospital, Breda, Netherlands.'}, {'ForeName': 'Tessa E H', 'Initials': 'TEH', 'LastName': 'Römkens', 'Affiliation': 'Department of Gastroenterology and Hepatology, Jeroen Bosch Hospital, Den Bosch, Netherlands.'}, {'ForeName': 'Carola H M', 'Initials': 'CHM', 'LastName': 'Ruigrok', 'Affiliation': 'Department of Gastroenterology and Hepatology, Reinier de Graaf Group, Delft, Netherlands.'}, {'ForeName': 'Erik J', 'Initials': 'EJ', 'LastName': 'Schoon', 'Affiliation': 'Department of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, Netherlands.'}, {'ForeName': 'Matthijs P', 'Initials': 'MP', 'LastName': 'Schwartz', 'Affiliation': 'Department of Gastroenterology and Hepatology, Meander Medical Center, Amersfoort, Netherlands.'}, {'ForeName': 'Xavier J N M', 'Initials': 'XJNM', 'LastName': 'Smeets', 'Affiliation': 'Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.'}, {'ForeName': 'B W Marcel', 'Initials': 'BWM', 'LastName': 'Spanier', 'Affiliation': 'Department of Gastroenterology and Hepatology, Rijnstate Hospital, Arnhem, Netherlands.'}, {'ForeName': 'Adriaan C I T L', 'Initials': 'ACITL', 'LastName': 'Tan', 'Affiliation': 'Department of Gastroenterology and Hepatology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands.'}, {'ForeName': 'Willem J', 'Initials': 'WJ', 'LastName': 'Thijs', 'Affiliation': 'Department of Gastroenterology and Hepatology, Martini Hospital, Groningen, Netherlands.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Timmer', 'Affiliation': 'Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Niels G', 'Initials': 'NG', 'LastName': 'Venneman', 'Affiliation': 'Department of Gastroenterology and Hepatology, Medisch Spectrum Twente, Enschede, Netherlands.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Verdonk', 'Affiliation': 'Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Frank P', 'Initials': 'FP', 'LastName': 'Vleggaar', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'van de Vrie', 'Affiliation': 'Department of Gastroenterology and Hepatology, Albert Schweitzer Hospital, Dordrecht, Netherlands.'}, {'ForeName': 'Ben J', 'Initials': 'BJ', 'LastName': 'Witteman', 'Affiliation': 'Department of Gastroenterology and Hepatology, Hospital Gelderse Vallei, Ede, Netherlands.'}, {'ForeName': 'Hjalmar C', 'Initials': 'HC', 'LastName': 'van Santvoort', 'Affiliation': 'Department of Surgery, St Antonius Hospital, Nieuwegein, Netherlands; Department of Surgery, University Medical Center Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Olaf J', 'Initials': 'OJ', 'LastName': 'Bakker', 'Affiliation': 'Department of Surgery, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Marco J', 'Initials': 'MJ', 'LastName': 'Bruno', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(20)30539-0'] 1790,32682483,Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial.,"BACKGROUND Atrial fibrillation and delirium are common consequences of cardiac surgery. Dexmedetomidine has unique properties as sedative agent and might reduce the risk of each complication. This study coprimarily aimed to establish whether dexmedetomidine reduces the incidence of new-onset atrial fibrillation and the incidence of delirium. METHODS A randomised, placebo-controlled trial was done at six academic hospitals in the USA. Patients who had had cardiac surgery with cardiopulmonary bypass were enrolled. Patients were randomly assigned 1:1, stratified by site, to dexmedetomidine or normal saline placebo. Randomisation was computer generated with random permuted block size 2 and 4, and allocation was concealed by a web-based system. Patients, caregivers, and evaluators were all masked to treatment. The study drug was prepared by the pharmacy or an otherwise uninvolved research associate so that investigators and clinicians were fully masked to allocation. Participants were given either dexmedetomidine infusion or saline placebo started before the surgical incision at a rate of 0·1 μg/kg per h then increased to 0·2 μg/kg per h at the end of bypass, and postoperatively increased to 0·4 μg/kg per h, which was maintained until 24 h. The coprimary outcomes were atrial fibrillation and delirium occurring between intensive care unit admission and the earlier of postoperative day 5 or hospital discharge. All analyses were intention-to-treat. The trial is registered with ClinicalTrials.gov, NCT02004613 and is closed. FINDINGS 798 patients of 3357 screened were enrolled from April 17, 2013, to Dec 6, 2018. The trial was stopped per protocol after the last designated interim analysis. Among 798 patients randomly assigned, 794 were analysed, with 400 assigned to dexmedetomidine and 398 assigned to placebo. The incidence of atrial fibrillation was 121 (30%) in 397 patients given dexmedetomidine and 134 (34%) in 395 patients given placebo, a difference that was not significant: relative risk 0·90 (97·8% CI 0·72, 1·15; p=0·34). The incidence of delirium was non-significantly increased from 12% in patients given placebo to 17% in those given dexmedetomidine: 1·48 (97·8% CI 0·99-2·23). Safety outcomes were clinically important bradycardia (requiring treatment) and hypotension, myocardial infarction, stroke, surgical site infection, pulmonary embolism, deep venous thrombosis, and death. 21 (5%) of 394 patients given dexmedetomidine and 8 (2%) of 396 patients given placebo, had a serious adverse event as determined by clinicians. 1 (<1%) of 391 patients given dexmedetomidine and 1 (<1%) of 387 patients given placebo died. INTERPRETATION Dexmedetomidine infusion, initiated at anaesthetic induction and continued for 24 h, did not decrease postoperative atrial arrhythmias or delirium in patients recovering from cardiac surgery. Dexmedetomidine should not be infused to reduce atrial fibrillation or delirium in patients having cardiac surgery. FUNDING Hospira Pharmaceuticals.",2020,The incidence of delirium was non-significantly increased from 12% in patients given placebo to 17% in those given dexmedetomidine: 1·48 (97·8% CI 0·99-2·23).,"['six academic hospitals in the USA', '798 patients of 3357 screened were enrolled from April 17, 2013, to Dec 6, 2018', '391 patients given', 'patients recovering from cardiac surgery', '394 patients given', 'patients having cardiac surgery', '798 patients randomly assigned, 794 were analysed, with 400 assigned to', 'atrial fibrillation and delirium after cardiac surgery (DECADE', 'Patients who had had cardiac surgery with cardiopulmonary bypass were enrolled']","['dexmedetomidine infusion or saline placebo', 'dexmedetomidine or normal saline placebo', 'Dexmedetomidine', 'dexmedetomidine', 'placebo']","['incidence of atrial fibrillation', 'relative risk 0·90', 'postoperative atrial arrhythmias or delirium', 'atrial fibrillation and delirium occurring between intensive care unit admission and the earlier of postoperative day 5 or hospital discharge', 'serious adverse event', 'incidence of delirium', 'atrial fibrillation or delirium', 'important bradycardia (requiring treatment) and hypotension, myocardial infarction, stroke, surgical site infection, pulmonary embolism, deep venous thrombosis, and death', 'incidence of new-onset atrial fibrillation']","[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0521108', 'cui_str': 'Recovering from'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0085611', 'cui_str': 'Atrial arrhythmia'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}]",3357.0,0.797581,The incidence of delirium was non-significantly increased from 12% in patients given placebo to 17% in those given dexmedetomidine: 1·48 (97·8% CI 0·99-2·23).,"[{'ForeName': 'Alparslan', 'Initials': 'A', 'LastName': 'Turan', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA; Department of General Anesthesiology, Cleveland Clinic, Cleveland, OH, USA. Electronic address: turana@ccf.org.'}, {'ForeName': 'Andra', 'Initials': 'A', 'LastName': 'Duncan', 'Affiliation': 'Department of Cardiovascular Anesthesiology, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Leung', 'Affiliation': 'Department of Radiology, Metrohealth Hospital, Cleveland, OH, USA.'}, {'ForeName': 'Nika', 'Initials': 'N', 'LastName': 'Karimi', 'Affiliation': 'Department of Anesthesiology, University of Rochester, Rochester, NY, USA.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Fang', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Guangmei', 'Initials': 'G', 'LastName': 'Mao', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Hargrave', 'Affiliation': 'Department of Cardiovascular Anesthesiology, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Gillinov', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Trombetta', 'Affiliation': 'Department of Cardiovascular Anesthesiology, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Sabry', 'Initials': 'S', 'LastName': 'Ayad', 'Affiliation': 'Department of Regional Practice, Cleveland Clinic, Cleveland, OH, USA; Department of General Anesthesiology, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Manal', 'Initials': 'M', 'LastName': 'Hassan', 'Affiliation': 'Department of Regional Practice, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Feider', 'Affiliation': 'Department of Anesthesia, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Howard-Quijano', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA, USA.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Ruetzler', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA; Department of General Anesthesiology, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Daniel I', 'Initials': 'DI', 'LastName': 'Sessler', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(20)30631-0'] 1791,32682484,"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.","BACKGROUND Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in combination with daratumumab has shown substantial efficacy with tolerable safety in relapsed or refractory multiple myeloma in a phase 1 study. In this study, we aimed to compare the efficacy and safety of carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. METHODS In this randomised, multicentre, open-label, phase 3 study, 466 patients recruited from 102 sites across North America, Europe, Australia, and Asia with relapsed or refractory multiple myeloma were randomly assigned 2:1 to carfilzomib, dexamethasone, and daratumumab (KdD) or carfilzomib and dexamethasone (Kd). All patients received twice per week carfilzomib at 56 mg/m 2 (20 mg/m 2 ; days 1 and 2 during cycle 1). Daratumumab (8 mg/kg) was administered intravenously on days 1 and 2 of cycle 1 and at 16 mg/kg weekly for the remaining doses of the first two cycles, then every 2 weeks for four cycles (cycles 3-6), and every 4 weeks thereafter. Patients received 40 mg dexamethasone weekly (20 mg for patients ≥75 years old starting on the second week). The primary endpoint was progression-free survival assessed by intention to treat. Adverse events were assessed in the safety population. This trial (NCT03158688) is registered with ClinicalTrials.gov, and is active but not recruiting. FINDINGS Between June 13, 2017, and June 25, 2018, 466 patients of 569 assessed for eligibility were enrolled. After median follow-up of approximately 17 months, median progression-free survival was not reached in the KdD group versus 15·8 months in the Kd group (hazard ratio 0·63; 95% CI 0·46-0·85; p=0·0027). Median treatment duration was longer in the KdD versus the Kd group (70·1 vs 40·3 weeks). Grade 3 or higher adverse events were reported in 253 (82%) patients in the KdD group and 113 (74%) patients in the Kd group. The frequency of adverse events leading to treatment discontinuation was similar in both groups (KdD, 69 [22%]; Kd, 38 [25%]). INTERPRETATION KdD significantly prolonged progression-free survival versus Kd in patients with relapsed or refractory multiple myeloma and was associated with a favourable benefit-risk profile. FUNDING Amgen.",2020,Median treatment duration was longer in the KdD versus the Kd group (70·1 vs 40·3 weeks).,"['patients with relapsed or refractory multiple myeloma', '466 patients recruited from 102 sites across North America, Europe, Australia, and Asia with relapsed or refractory multiple myeloma', 'Between June 13, 2017, and June 25, 2018, 466 patients of 569 assessed for eligibility were enrolled', 'patients with relapsed or refractory multiple myeloma (CANDOR']","['dexamethasone', 'carfilzomib, dexamethasone, and daratumumab (KdD) or carfilzomib and dexamethasone (Kd', 'carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone', 'Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone']","['frequency of adverse events leading to treatment discontinuation', 'median progression-free survival', 'Adverse events', 'progression-free survival', 'Median treatment duration', 'efficacy and safety', 'Grade 3 or higher adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C4551538', 'cui_str': 'Plasma cell myeloma refractory'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0003980', 'cui_str': 'Asia'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C2001856', 'cui_str': 'carfilzomib'}, {'cui': 'C2346801', 'cui_str': 'daratumumab'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0444921', 'cui_str': 'Duration of treatment'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0205250', 'cui_str': 'High'}]",466.0,0.106024,Median treatment duration was longer in the KdD versus the Kd group (70·1 vs 40·3 weeks).,"[{'ForeName': 'Meletios', 'Initials': 'M', 'LastName': 'Dimopoulos', 'Affiliation': 'National and Kapodistrian University Athens School of Medicine, Athens, Greece.'}, {'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Quach', 'Affiliation': ""University of Melbourne, St Vincent's Hospital, Fitzroy, VIC, Australia.""}, {'ForeName': 'Maria-Victoria', 'Initials': 'MV', 'LastName': 'Mateos', 'Affiliation': 'Cancer Research Center, University Hospital Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain.'}, {'ForeName': 'Ola', 'Initials': 'O', 'LastName': 'Landgren', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Leleu', 'Affiliation': 'Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Siegel', 'Affiliation': 'John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Weisel', 'Affiliation': 'University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Amgen, Thousand Oaks, CA, USA.'}, {'ForeName': 'Zandra', 'Initials': 'Z', 'LastName': 'Klippel', 'Affiliation': 'Amgen, Thousand Oaks, CA, USA.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Zahlten-Kumeli', 'Affiliation': 'Amgen, Thousand Oaks, CA, USA.'}, {'ForeName': 'Saad Z', 'Initials': 'SZ', 'LastName': 'Usmani', 'Affiliation': 'Atrium Health, Charlotte, NC, USA. Electronic address: usmani@atriumhealth.org.'}]","Lancet (London, England)",['10.1016/S0140-6736(20)30734-0'] 1792,32692247,Clinical study on different doses and fractionated radiotherapies for multiple brain metastases of non-EGFR mutant lung adenocarcinoma.,"BACKGROUND To study the effects and adverse reactions of different doses and fractionated radiotherapies on non-epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma patients with multiple brain metastases. METHODS In total, 80 patients eligible for inclusion were randomly divided into 4 groups. Group A included whole brain radiotherapy (WBRT) alone 300 cGy/fraction ×10 fractions, at a total dose of 3,000 cGy. Group B included WBRT alone 180 cGy/fraction ×22 fractions, at a total dose of 3,960 cGy. Group C included intracranial metastases radiotherapy alone 250 cGy/fraction ×22 fractions at a total dose of 5,500 cGy. Group D included the whole brain + intracranial metastases group (SIB group) whole brain 180 cGy/fraction ×22 fractions intracranial metastases 250 cGy/fraction ×22 fractions, at a total dose 3,960 cGy, 5,500 cGy, respectively. RESULTS The median survival time of intracranial disease-free survival (IPFS) in group A, group B, group C, and group D was 6, 9, 8, and 13 months, respectively (P=0.000). The median overall survival (OS) time was 16, 24.5, 24, and 30 months, respectively (P=0.150). There was a significant difference in IPFS between different doses and fractionated radiotherapies, but there was no difference in OS. Multivariate analysis showed that the radiotherapy dose of intracranial metastases was positively correlated with IPFS and OS. The incidence rate of adverse reaction of memory decline in 0.5, 1, and 2 years in group A, group B, group C, and group D was respectively 10.0%, 15.0%, 5.0%, and 15.0% (P=0.006); 20.0%, 45.0%, 30.0%, and 60.0% (P=0.000); 10.0%, 20.0%, 35.0%, and 65.0% (P=0.000). The incidence rates of memory decline in the groups of WBRT were significantly more increased than in the non-WBRT group. CONCLUSIONS Radiotherapy is effective for multiple brain metastases of lung adenocarcinoma, the increase of radiotherapy dose can improve IPFS and OS, and the adverse reaction of memory decline after WBRT is increased but tolerable. Therefore, WBRT and simultaneous integrated boost (SIB) radiotherapy of intracranial metastases is recommended for multiple brain metastases of non-EGFR-mutant lung adenocarcinoma.",2020,"The incidence rates of memory decline in the groups of WBRT were significantly more increased than in the non-WBRT group. ","['multiple brain metastases of non-EGFR mutant lung adenocarcinoma', '80 patients eligible for inclusion', 'lung adenocarcinoma patients with multiple brain metastases']","['whole brain radiotherapy (WBRT) alone 300 cGy/fraction ×10 fractions', 'WBRT and simultaneous integrated boost (SIB) radiotherapy', 'fractionated radiotherapies', 'whole brain + intracranial metastases group (SIB group) whole brain 180 cGy/fraction ×22 fractions intracranial metastases 250 cGy/fraction ×22 fractions', 'WBRT', 'Radiotherapy']","['median survival time of intracranial disease-free survival (IPFS', 'IPFS', 'OS', 'median overall survival (OS) time', 'incidence rate of adverse reaction of memory decline', 'incidence rates of memory decline']","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0220650', 'cui_str': 'Secondary malignant neoplasm of brain'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0152013', 'cui_str': 'Adenocarcinoma of lung'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}]","[{'cui': 'C1520143', 'cui_str': 'Whole brain radiation therapy'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0556645', 'cui_str': 'cGy'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0524466', 'cui_str': 'Intracranial'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C2348831', 'cui_str': '250'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C2919552', 'cui_str': 'Survival time'}, {'cui': 'C0524466', 'cui_str': 'Intracranial'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}]",80.0,0.0197721,"The incidence rates of memory decline in the groups of WBRT were significantly more increased than in the non-WBRT group. ","[{'ForeName': 'Hongli', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'School of Medicine and Life Science, University of Jinan-Shandong Academy of Medical Sciences, Jining Tumor Hospital, Jinan, China.'}, {'ForeName': 'Xuedong', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': 'Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.'}, {'ForeName': 'Jinzhi', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.'}, {'ForeName': 'Changsheng', 'Initials': 'C', 'LastName': 'Ma', 'Affiliation': 'Department of Radiophysics and Technology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Sun', 'Affiliation': 'Department of Radiophysics and Technology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Shao', 'Affiliation': 'Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. shaoqian2009@sina.com.'}]",Annals of palliative medicine,['10.21037/apm-20-1203'] 1793,32702912,A randomized interventional parallel study to evaluate the effect of pelvic floor muscle training with stabilization exercises of high and low intensity in women with stress urinary incontinence: The PELSTAB study.,"INTRODUCTION The effect of different intensities of pelvic floor muscle training (PFMT) assessed by 2D/3D ultrasound (USG) have not been sufficiently monitored in the literature. The objective of the study will be to evaluate the effect of this intervention by assessing the change in incontinence episode frequency, hiatal area (HA) and hiatal diameter by 2D/3D USG and quality of life over 12 weeks of treatment. METHODS Using a randomized interventional parallel study, patients will be assigned to groups A and B using simple software randomization according to odd and even patient sequence numbers. The following methods will be used for evaluation: change in incontinence episode frequency, power and endurance of pelvic floor muscles assessed by perineometer (in cmH2O), HA (in cm) during contraction, Valsalva manoeuvre assessed by 3D USG, hiatal diameter assessed by 2D USG, the Incontinence Quality of Life scale (I-QoL) and the Patient Global Impression of Improvement score (PGI-I). INTERVENTIONS Group A, high-intensity PFMT 5 times a week for 30 minutes per day. Group B, low-intensity PFMT twice a week for 15 minutes per day. The duration of the intervention will be 12 weeks. DISCUSSION The study protocol presents the starting points, design, and methods of the PELSTAB Study. We expect that, after 12 weeks of high-intensity PFMT, women with stress urinary incontinence will have significantly less incontinence episode frequency, better reduction of HA during contraction and Valsalva manoeuvre, higher power and endurance of pelvic floor muscles and better quality of life compared to the group with low-intensity PFMT. REGISTRATION This study was registered in the ClinicalTrials.govNCT04340323.",2020,"The following methods will be used for evaluation: change in incontinence episode frequency, power and endurance of pelvic floor muscles assessed by perineometer (in cmH2O), HA (in cm) during contraction, Valsalva manoeuvre assessed by 3D USG, hiatal diameter assessed by 2D USG, the Incontinence Quality of Life scale (I-QoL) and",['women with stress urinary incontinence'],"['pelvic floor muscle training with stabilization exercises', 'pelvic floor muscle training (PFMT) assessed by 2D/3D ultrasound (USG']","['incontinence episode frequency, power and endurance of pelvic floor muscles assessed by perineometer (in cmH2O), HA (in\u200acm) during contraction, Valsalva manoeuvre assessed by 3D USG, hiatal diameter assessed by 2D USG, the Incontinence Quality of Life scale (I-QoL', 'incontinence episode frequency, better reduction of HA during contraction and Valsalva manoeuvre, higher power and endurance of pelvic floor muscles and better quality of life', 'incontinence episode frequency, hiatal area (HA) and hiatal diameter by 2D/3D USG and quality of life']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}]","[{'cui': 'C4087139', 'cui_str': 'Pelvic floor muscle training'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}]","[{'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0449622', 'cui_str': 'Muscle assessed'}, {'cui': 'C0491718', 'cui_str': 'Perineometer'}, {'cui': 'C0439476', 'cui_str': 'cmH2O'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0042293', 'cui_str': 'Valsalva maneuver'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.0823383,"The following methods will be used for evaluation: change in incontinence episode frequency, power and endurance of pelvic floor muscles assessed by perineometer (in cmH2O), HA (in cm) during contraction, Valsalva manoeuvre assessed by 3D USG, hiatal diameter assessed by 2D USG, the Incontinence Quality of Life scale (I-QoL) and","[{'ForeName': 'Magdaléna', 'Initials': 'M', 'LastName': 'Hagovská', 'Affiliation': 'aDepartment of Physiatry, Balneology, and Medical Rehabilitation, Institution - Faculty of Medicine, PJ Safarik University bUrogynecology and Physiotherapy in Gynecology and Urology, Institution - Clinic Centrum s.r.o. cDepartment of Gynecology and Obstetrics, Faculty of Medicine , Institution -PJ Safarik University, Kosice dDepartment of Urology, Institution - Jessenius Faculty of Medicine, Martin, Comenius University Bratislava, Slovakia.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Urdzík', 'Affiliation': ''}, {'ForeName': 'Ján', 'Initials': 'J', 'LastName': 'Švihra', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021264'] 1794,32702919,Effect of early activity combined with early nutrition on acquired weakness in ICU patients.,"INTRODUCTION Intensive care unit-acquired weakness (ICU-AW) occurs in 25% to 100% of critically ill patients, and is associated with prolonged mechanical ventilation, extended ICU stay, and total hospital stay, increased hospital costs, higher risk of death, impaired physical function, and decreased quality of life. However, there are not any current guidelines that mention management of ICU-AW. The present study will evaluate the effects of a combination of early nutrition and early exercise compared to those of either early exercise alone or the standard care for patients in ICUs. METHODS This is a 3-arm, parallel, randomized controlled trial including an estimated 147 critically ill patients aged ≥18 years recruited from the ICUs of 2 hospitals in Heilongjiang, China. Patients will be prospectively randomized 1:1:1 to receive early mobilization, early nutrition combined with early mobilization, or standard care (minimal exercises, experience-based initiation and enrollment of nutrition support). Outcomes are assessed at ICU discharge after baseline. The primary outcome is occurrence of ICU-AW according to the Medical Research Council scale at the end of treatment. Muscle strength, organ failure, functional independence, self-care ability, time of ICU stay, duration of mechanical ventilation, and ICU mortality are secondary outcome measures. DISCUSSION This trial has the potential to identify a novel strategy for preventing or managing ICU-AW. The findings may increase the clinical knowledge about nutrition and mobilization interventions for people with ICU-AW, and contribute to the formation of practice guidelines for managing this condition. TRIAL REGISTRATION NUMBER ChiCTR2000033482.",2020,"Muscle strength, organ failure, functional independence, self-care ability, time of ICU stay, duration of mechanical ventilation, and ICU mortality are secondary outcome measures. ","['ICU patients', 'patients in ICUs', '147 critically ill patients aged ≥18 years recruited from the ICUs of 2 hospitals in Heilongjiang, China']","['early nutrition and early exercise', 'early mobilization, early nutrition combined with early mobilization, or standard care (minimal exercises, experience-based initiation and enrollment of nutrition support', 'early activity combined with early nutrition', 'early exercise alone']","['prolonged mechanical ventilation, extended ICU stay, and total hospital stay, increased hospital costs, higher risk of death, impaired physical function, and decreased quality of life', 'Muscle strength, organ failure, functional independence, self-care ability, time of ICU stay, duration of mechanical ventilation, and ICU mortality', 'occurrence of ICU-AW according to the Medical Research Council scale']","[{'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0013459', 'cui_str': 'Early Mobilization'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0242739', 'cui_str': 'Nutritional support'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]","[{'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0206174', 'cui_str': 'Cost, Hospital'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0349410', 'cui_str': 'Single organ dysfunction'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0562734', 'cui_str': 'Ability to perform personal care activity'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C4087120', 'cui_str': 'Intensive care unit acquired weakness'}, {'cui': 'C0079816', 'cui_str': 'Research, Medical'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",147.0,0.141729,"Muscle strength, organ failure, functional independence, self-care ability, time of ICU stay, duration of mechanical ventilation, and ICU mortality are secondary outcome measures. ","[{'ForeName': 'Wendie', 'Initials': 'W', 'LastName': 'Zhou', 'Affiliation': 'aThe Second Affiliated Hospital of Harbin Medical University bSchool of Nursing, Harbin Medical University cDepartment of Rehabilitation, the Second Affiliated Hospital of Harbin Medical University, Harbin city dNursing Department, the First Affiliated Hospital of Jiamusi University, Jiamusi city, China.'}, {'ForeName': 'Baisheng', 'Initials': 'B', 'LastName': 'Shi', 'Affiliation': ''}, {'ForeName': 'Yuying', 'Initials': 'Y', 'LastName': 'Fan', 'Affiliation': ''}, {'ForeName': 'Jinsong', 'Initials': 'J', 'LastName': 'Zhu', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021282'] 1795,32702925,To use indwelling drainage or not in dual-plane breast augmentation mammoplasty patients: A comparative study.,"To explore the necessity of indwelling drainage in dual-plane breast augmentation mammoplasty patients.Female patients (123 in total) were selected from June 2015 to June 2018 in the Department of Plastic Surgery at Peking Union Medical College Hospital and were randomly divided into 2 different groups: the with drainage group (WD group, 57 patients) and the without drainage group (WOD group, 66 patients). In the 2 groups, the operation time, postoperative stay, and hospitalization expenses were recorded. The BREAST-Q Version 2.0 Augmentation Module Pre- and Postoperative Scales (Chinese Version) were used to evaluate psychosocial well-being, sexual well-being, physical well-being, and satisfaction with breasts preoperatively and postoperatively (1 year after operation).Before the operation, no significant differences were found in psychosocial well-being, sexual well-being, physical well-being, or satisfaction with breasts between these 2 groups. In the WOD group, postoperative stay and hospitalization expenses were remarkably decreased, but the operation time was similar, compared with the WD group. Compared with before the operation, both groups had significantly increased scores in psychosocial well-being, sexual well-being, and satisfaction with breasts after the operation. However, no significant differences were found between the 2 groups. No complications were found in any of the patients.Although the operation time was not significantly decreased, patients without drainage could save much more time and money and simultaneously reach similar postoperative effects in psychosocial well-being, sexual well-being, physical well-being, and satisfaction with breasts. Therefore, drainage may not be necessary in patients who undergo dual-plane breast augmentation mammoplasty.",2020,"Compared with before the operation, both groups had significantly increased scores in psychosocial well-being, sexual well-being, and satisfaction with breasts after the operation.","['Female patients (123 in total) were selected from June 2015 to June 2018 in the Department of Plastic Surgery at Peking Union Medical College Hospital', 'patients who undergo dual-plane breast augmentation mammoplasty', 'dual-plane breast augmentation mammoplasty patients']",[],"['operation time, postoperative stay, and hospitalization expenses', 'scores in psychosocial well-being, sexual well-being, and satisfaction with breasts', 'psychosocial well-being, sexual well-being, physical well-being, and satisfaction', 'postoperative stay and hospitalization expenses', 'psychosocial well-being, sexual well-being, physical well-being, or satisfaction with breasts', 'operation time']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0038911', 'cui_str': 'Plastic surgery - specialty'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0191925', 'cui_str': 'Augmentation mammoplasty'}, {'cui': 'C0085076', 'cui_str': 'Mammoplasty'}]",[],"[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",,0.0119244,"Compared with before the operation, both groups had significantly increased scores in psychosocial well-being, sexual well-being, and satisfaction with breasts after the operation.","[{'ForeName': 'Yiding', 'Initials': 'Y', 'LastName': 'Xiao', 'Affiliation': 'aDepartment of Plastic Surgery, Peking Union Medical College Hospital, Beijing bDepartment of Orthopaedics, Qingdao Huangdao District Hospital of Traditional Chinese Medicine, Qingdao, Shandong cDepartment of Information Engineering, Chaoshan Polytechnic College, Puning, Guangdong, China.'}, {'ForeName': 'Jianqiang', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': ''}, {'ForeName': 'Mingzi', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Wenchao', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Qin', 'Affiliation': ''}, {'ForeName': 'Ang', 'Initials': 'A', 'LastName': 'Zeng', 'Affiliation': ''}, {'ForeName': 'Xiaojun', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Zhifei', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Zhu', 'Affiliation': ''}, {'ForeName': 'Nanze', 'Initials': 'N', 'LastName': 'Yu', 'Affiliation': ''}, {'ForeName': 'Loubin', 'Initials': 'L', 'LastName': 'Si', 'Affiliation': ''}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Long', 'Affiliation': ''}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021305'] 1796,32703746,The effects of switching from 10 to 5-dose vials of MR vaccine on vaccination coverage and wastage: A mixed-method study in Zambia.,"INTRODUCTION Vaccines procured for low-income countries are often packaged in multi-dose vials to reduce program costs. To avoid wastage, health workers may refrain from opening a vial if few children attend an immunization session, possibly leading to lower coverage. Lowering the number of doses in a vial may increase coverage and reduce wastage. METHODS We used a mixed methods approach to measure the effects of switching from conventional 10-dose measles containing vaccine (MCV) vials to 5-dose MCV vials on coverage and open vial wastage in 14 districts purposely selected from two provinces in Zambia. The districts were paired based on the number of health facilities and the average size of the health facility catchment population. One district from each pair was randomly allocated to receive 5-dose vials while the other continued with the conventional vials. We applied propensity score matched difference-in-difference analysis to estimate intervention effects on coverage using pre-intervention household survey and post-intervention household survey after 11 months of the intervention. The intervention effects on wastage rates were estimated from multivariate analysis of the administrative data. Key informant interviews were conducted to better understand health workers' behavior and preferences at baseline, midline and endline, and analyzed using thematic analysis techniques. RESULTS MCV coverage rates increased across both arms for both doses. A five percentage-point intervention effect was detected for MCV1 and 3.5 percentage-point effect for MCV2. The MCV wastage rate was 47% lower in facilities using 5-dose vials (16.2%) versus 10-dose vials (30.5%). Healthcare workers reported being more willing to open a 5-dose vial than a 10-dose vial for one child, as they were less concerned about wastage. DISCUSSION Switching 10-dose MCV vials to 5-dose vials improved coverage, decreased wastage, and improved willingness to open a vial. These findings can contribute to strategies for reducing missed opportunities for vaccination.",2020,The MCV wastage rate was 47% lower in facilities using 5-dose vials (16.2%) versus 10-dose vials (30.5%).,"['14 districts purposely selected from two provinces in Zambia', 'Zambia']",['MR vaccine'],"['wastage rates', 'vaccination coverage and wastage', 'MCV wastage rate', 'MCV coverage rates', 'coverage and reduce wastage']","[{'cui': 'C0043445', 'cui_str': 'Zambia'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C4505148', 'cui_str': 'Vaccination Coverage'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",,0.0316677,The MCV wastage rate was 47% lower in facilities using 5-dose vials (16.2%) versus 10-dose vials (30.5%).,"[{'ForeName': 'Kirstin', 'Initials': 'K', 'LastName': 'Krudwig', 'Affiliation': 'John Snow, Inc, United States.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Knittel', 'Affiliation': 'John Snow, Inc, United States.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Karim', 'Affiliation': 'John Snow, Inc, United States.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Kanagat', 'Affiliation': 'John Snow, Inc, United States.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Prosser', 'Affiliation': 'John Snow, Inc, United States. Electronic address: wendy_prosser@jsi.com.'}, {'ForeName': 'Guissimon', 'Initials': 'G', 'LastName': 'Phiri', 'Affiliation': 'Ministry of Health, Zambia, Immunization Program, Zambia.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Mwansa', 'Affiliation': 'Ministry of Health, Zambia, Immunization Program, Zambia.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Steinglass', 'Affiliation': 'John Snow, Inc, United States.'}]",Vaccine,['10.1016/j.vaccine.2020.07.012'] 1797,32705925,Curcumin Improves Delayed Onset Muscle Soreness and Postexercise Lactate Accumulation.,"The efficacy of curcumin supplementation is traditionally limited due to its poor bioavailability. Despite this, curcumin has previously been shown to improve biomarkers of muscle damage. The addition of a novel drug delivery system that improves bioavailability could improve exercise recovery. The purpose of this randomized double-blind placebo-controlled study was to assess the effect of curcumin (combined with LipiSperse) when consumed as a drink on exercise recovery in recreationally trained healthy males aged 18-35 yrs. The study included 28 young healthy males with strength training experience. The participants undertook lower limb resistance exercise to exhaustion. Fourteen participants received curcumin dispersed in water pre and postexercise and 14 received a matched placebo drink. Pain (visual analogue scale), thigh circumference (TC), lactate, creatine kinase, lactate dehydrogenase, high sensitivity C-reactive protein, myoglobin, interleukin-6, interleukin-10, and tumor necrosis factor-alpha were assessed pre, postexercise and 1, 2, 3, 24, 48, and 72 h postexercise. There was less appearance of postexercise capillary lactate in the curcumin group compared to placebo (7.4 vs 8.8 mmol/L). The placebo group rated overall muscle pain as higher compared to the curcumin group at 48- and 72-h postexercise. TC was reduced in the curcumin group compared to the placebo group at 24- and 48-h postexercise. The results suggest curcumin may facilitate a quicker return to exercise training and/or allow a higher training intensity than a placebo by reducing postexercise pain, modulating inflammatory pathways and reducing lactate accumulation in an exercising population.",2020,TC was reduced in the curcumin group compared to the placebo group at 24- and 48-h postexercise.,"['Fourteen participants received', '28 young healthy males with strength training experience', 'recreationally trained healthy males aged 18-35\u2009yrs']","['curcumin dispersed in water pre and postexercise and 14 received a matched placebo drink', 'curcumin (combined with LipiSperse', 'curcumin supplementation', 'placebo']","['overall muscle pain', 'appearance of postexercise capillary lactate', 'postexercise pain, modulating inflammatory pathways and reducing lactate accumulation', 'Delayed Onset Muscle Soreness and Postexercise Lactate Accumulation', 'Pain (visual analogue scale), thigh circumference (TC), lactate, creatine kinase, lactate dehydrogenase, high sensitivity C-reactive protein, myoglobin, interleukin-6, interleukin-10, and tumor necrosis factor', 'TC']","[{'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0010467', 'cui_str': 'Curcumin'}, {'cui': 'C0332624', 'cui_str': 'Dispersion'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0006901', 'cui_str': 'Structure of capillary blood vessel (organ)'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0202113', 'cui_str': 'Lactate dehydrogenase measurement'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0027078', 'cui_str': 'Myoglobin'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}]",28.0,0.356971,TC was reduced in the curcumin group compared to the placebo group at 24- and 48-h postexercise.,"[{'ForeName': 'Alistair R', 'Initials': 'AR', 'LastName': 'Mallard', 'Affiliation': 'RDC Clinical, Brisbane, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Briskey', 'Affiliation': 'RDC Clinical, Brisbane, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Richards BExSSc', 'Affiliation': 'RDC Clinical, Brisbane, Australia.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Rao', 'Affiliation': 'RDC Clinical, Brisbane, Australia.'}]",Journal of dietary supplements,['10.1080/19390211.2020.1796885'] 1798,32705941,Use of chest X-ray in the assessment of community acquired pneumonia in primary care - an intervention study.,"OBJECTIVES The aim of this study was to explore if consequent use of chest X-ray (CXR), when the physician is not sure of the diagnosis of pneumonia after clinical examination and CRP-testing, favors a more restrictive prescribing of antibiotics. DESIGN This was an intervention study conducted between September 2015 and December 2017. SETTING Two intervention primary health care centers (PHCCs) and three control PHCCs in the southeast of Sweden. INTERVENTION All patients were referred for CXR when the physician´s suspicion of pneumonia was 'unsure', or 'quite sure' after CRP-testing. Control units managed patients according to their usual routine after clinical examination and CRP-testing. SUBJECTS A total of 104 patients were included in the intervention group and 81 patients in the control group. The inclusion criteria of the study were clinically suspected pneumonia in patients ≥18 years, with respiratory symptoms for more than 24 h. Main outcome measure: Antibiotic prescribing rate. RESULTS In the intervention group, 85% were referred for CXR and 69% were prescribed antibiotics, as compared to 26% and 77% in the control group. The difference in antibiotic prescribing rate was not statistically significant, unadjusted OR 0.68 [0.35-1.3] and adjusted OR 1.1 [CI 0.43-3.0]. A total of 24% of patients with negative CXR were prescribed antibiotics. CONCLUSION This study could not prove that use of CXR when the physician was not sure of the diagnosis of pneumonia results in lowered antibiotic prescribing rate in primary care. In cases of negative findings on CXR the physicians do not seem to rely on the outcome when it comes to antibiotic prescribing. Key Points Routine use of chest X-ray when the clinical diagnosis of pneumonia is uncertain has not been proven to result in lowered antibiotic prescribing rate. Physicians do not fully rely on chest X-ray outcome and to some extent prescribe antibiotics even if negative, when community-acquired pneumonia is suspected. Chest X-ray is already used in one out of four cases in routine primary care of pneumonia patients in Sweden.",2020,"The difference in antibiotic prescribing rate was not statistically significant, unadjusted OR 0.68 [0.35-1.3] and adjusted OR 1.1 [CI 0.43-3.0].","['pneumonia patients in Sweden', 'Two intervention primary health care centers (PHCCs) and three control PHCCs in the southeast of Sweden', 'patients ≥18 years, with respiratory symptoms for more than 24\u2009h. Main outcome measure: Antibiotic prescribing rate', 'September 2015 and December 2017', 'Control units managed patients according to their usual routine after clinical examination and CRP-testing', '104 patients were included in the intervention group and 81 patients in the control group']","['chest X-ray', 'chest X-ray (CXR']",['antibiotic prescribing rate'],"[{'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0037090', 'cui_str': 'Respiratory symptom'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C3873701', 'cui_str': 'Control unit'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0039985', 'cui_str': 'Plain chest X-ray'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotic'}]",104.0,0.026647,"The difference in antibiotic prescribing rate was not statistically significant, unadjusted OR 0.68 [0.35-1.3] and adjusted OR 1.1 [CI 0.43-3.0].","[{'ForeName': 'Anna B', 'Initials': 'AB', 'LastName': 'Moberg', 'Affiliation': 'Kärna Primary Healthcare Centre, Linköping, Sweden.'}, {'ForeName': 'Moa', 'Initials': 'M', 'LastName': 'Kling', 'Affiliation': 'Kungsgatan Primary Healthcare Centre, Linköping, Sweden.'}, {'ForeName': 'Jakob', 'Initials': 'J', 'LastName': 'Paues', 'Affiliation': 'Department of Health, Medicine and Caring Sciences and Department of Radiological Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Sven Göran', 'Initials': 'SG', 'LastName': 'Fransson', 'Affiliation': 'Department of Health, Medicine and Caring Sciences, General Practice, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Falk', 'Affiliation': 'Kärna Primary Healthcare Centre, Linköping, Sweden.'}]",Scandinavian journal of primary health care,['10.1080/02813432.2020.1794404'] 1799,32708864,Effects of a Multidisciplinary Residential Nutritional Rehabilitation Program in Head and Neck Cancer Survivors-Results from the NUTRI-HAB Randomized Controlled Trial.,"Head and neck cancer survivors frequently experience nutritional challenges, and proper rehabilitation should be offered. The trial objective was to test the effect of a multidisciplinary residential nutritional rehabilitation programme addressing physical, psychological, and social aspects of eating problems after treatment. In a randomized controlled trial, 71 head and neck cancer survivors recruited through a nationwide survey were randomized to the program or a wait-list control group. Inclusion was based on self-reported interest in participation. The primary outcome was change in body weight. Secondary outcomes included physical function, quality of life, and symptoms of anxiety and depression. Differences between groups at the 3-month follow-up were tested. No significant differences were seen in body weight change, but there were overall trends towards greater improvements in physical function (hand grip strength: p = 0.042; maximal mouth opening: p = 0.072) and quality of life (""Role functioning"": p = 0.041; ""Speech problems"": p = 0.040; ""Pain"": p = 0.048) in the intervention group. To conclude, a multidisciplinary residential nutritional rehabilitation program had no effect on body weight in head and neck cancer survivors with self-reported interest in participation, but it may have effect on physical function and quality of life. Further research on relevant outcomes, inclusion criteria, and the program's effect in different subgroups is needed.",2020,"No significant differences were seen in body weight change, but there were overall trends towards greater improvements in physical function (hand grip strength: p = 0.042; maximal mouth opening: p = 0.072) and quality of life (""Role functioning"": p = 0.041; ""Speech problems"": ","['Head and Neck Cancer Survivors', 'head and neck cancer survivors', '71 head and neck cancer survivors recruited through a nationwide survey', 'Head and neck cancer survivors']","['Multidisciplinary Residential Nutritional Rehabilitation Program', 'multidisciplinary residential nutritional rehabilitation programme', 'wait-list control group', 'multidisciplinary residential nutritional rehabilitation program']","['quality of life', 'physical function', 'physical function, quality of life, and symptoms of anxiety and depression', 'body weight', 'change in body weight', 'physical function and quality of life', 'body weight change']","[{'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]","[{'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}]",71.0,0.117048,"No significant differences were seen in body weight change, but there were overall trends towards greater improvements in physical function (hand grip strength: p = 0.042; maximal mouth opening: p = 0.072) and quality of life (""Role functioning"": p = 0.041; ""Speech problems"": ","[{'ForeName': 'Marianne Boll', 'Initials': 'MB', 'LastName': 'Kristensen', 'Affiliation': 'Department of Nursing and Nutrition, University College Copenhagen, Sigurdsgade 26, 2200 Copenhagen N, Denmark.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Wessel', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery & Audiology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark.'}, {'ForeName': 'Anne Marie', 'Initials': 'AM', 'LastName': 'Beck', 'Affiliation': 'Department of Nursing and Nutrition, University College Copenhagen, Sigurdsgade 26, 2200 Copenhagen N, Denmark.'}, {'ForeName': 'Karin B', 'Initials': 'KB', 'LastName': 'Dieperink', 'Affiliation': 'Research Unit of Oncology, Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark.'}, {'ForeName': 'Tina Broby', 'Initials': 'TB', 'LastName': 'Mikkelsen', 'Affiliation': 'REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care, Odense University Hospital, and Department of Clinical Research, University of Southern Denmark, Vestergade 17, 5800 Nyborg, Denmark.'}, {'ForeName': 'Jens-Jakob Kjer', 'Initials': 'JK', 'LastName': 'Møller', 'Affiliation': 'REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care, Odense University Hospital, and Department of Clinical Research, University of Southern Denmark, Vestergade 17, 5800 Nyborg, Denmark.'}, {'ForeName': 'Ann-Dorthe', 'Initials': 'AD', 'LastName': 'Zwisler', 'Affiliation': 'REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care, Odense University Hospital, and Department of Clinical Research, University of Southern Denmark, Vestergade 17, 5800 Nyborg, Denmark.'}]",Nutrients,['10.3390/nu12072117'] 1800,32708893,Timing of Nutrient Ingestion after Mild to Moderate Cycling Exercise Does Not Affect Gastric Emptying Rate in Humans.,"This study examined the effect of carbohydrate drink ingestion timing on gastrointestinal tract blood flow and motility after mild cycling exercise. Eight healthy participants were randomly assigned to ingest a liquid solution with 75 g glucose at either 5 min (PE-5) or 30 min (PE-30) after a single bout of leg cycling exercise according to target heart rate (approximately 120 beats/min). As the control trial (Con), participants ingested the same liquid solution without exercise. Celiac artery blood flow (BF), superior mesenteric artery BF, and gastric emptying rate were assessed by ultrasonography before and for 60 min after ingesting the glucose solution. Blood lactate, glucose, and plasma insulin were also measured at baseline and for 60 min after ingesting the glucose solution. Celiac artery BF significantly decreased from resting baseline immediately after exercise in both the PE-5 and PE-30 trials, and then returned to resting baseline just before the ingestion of glucose solution in the PE-30 trial. After ingesting the glucose solution, changes in celiac artery BF, superior mesenteric artery BF, % gastric emptying rate, blood lactate, blood glucose, and plasma insulin were not significantly different among the three trials. The timing of nutrient ingestion after mild exercise does not seem to impact the subsequent gastrointestinal motility, blood flow, and glycemic responses.",2020,"Celiac artery BF significantly decreased from resting baseline immediately after exercise in both the PE-5 and PE-30 trials, and then returned to resting baseline just before the ingestion of glucose solution in the PE-30 trial.","['Eight healthy participants', 'Humans', 'after mild cycling exercise']","['carbohydrate drink ingestion', 'liquid solution with 75 g glucose at either 5 min (PE-5) or 30 min (PE-30) after a single bout of leg cycling exercise']","['Gastric Emptying Rate', 'Celiac artery blood flow (BF), superior mesenteric artery BF, and gastric emptying rate', 'celiac artery BF, superior mesenteric artery BF, % gastric emptying rate, blood lactate, blood glucose, and plasma insulin', 'gastrointestinal motility, blood flow, and glycemic responses', 'Celiac artery BF', 'gastrointestinal tract blood flow and motility', 'Blood lactate, glucose, and plasma insulin']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0007569', 'cui_str': 'Structure of celiac artery'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0162861', 'cui_str': 'Superior mesenteric artery structure'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0017184', 'cui_str': 'Gastrointestinal Motility'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0007608', 'cui_str': 'Motility, Cell'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}]",8.0,0.0331816,"Celiac artery BF significantly decreased from resting baseline immediately after exercise in both the PE-5 and PE-30 trials, and then returned to resting baseline just before the ingestion of glucose solution in the PE-30 trial.","[{'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Kashima', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}, {'ForeName': 'Saori', 'Initials': 'S', 'LastName': 'Kamimura', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}, {'ForeName': 'Ayumi', 'Initials': 'A', 'LastName': 'Honma', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}, {'ForeName': 'Masako Yamaoka', 'Initials': 'MY', 'LastName': 'Endo', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Miura', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}, {'ForeName': 'Toshio', 'Initials': 'T', 'LastName': 'Kobayashi', 'Affiliation': 'Department of Health Promotion and Development, Graduate School of Health Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, Hiroshima 734-8551, Japan.'}, {'ForeName': 'Yoshiyuki', 'Initials': 'Y', 'LastName': 'Fukuba', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}]",Nutrients,['10.3390/nu12072118'] 1801,32708898,Sex Differences in Maintaining the Requested Handgrip Force Enhanced by Auditory or Visual Feedback.,"Thus far, the differences in effect of auditory or visual feedback in motor learning have presented results derived from mixed groups and sex differences have not been considered. However, perception and processing of auditory stimuli and performance of visual motor tasks appear to be sex-related. The purpose of this study was to investigate the learning of the simple motor task of maintaining a requested handgrip force in separate male and female groups. A total of 31 volunteers (15 males, 16 females) were randomly assigned to one of four experimental groups with defined sex and training conditions (audio or visual feedback). Participants performed training sessions over a period of six days, for which auditory or visual feedback was provided, and the effectiveness of both types of signals was compared. The evident learning effect was found in all groups, and the main effect of sex was significant among visual groups in favor of the males ( p < 0.05). On the other hand, the main effect of feedback conditions was found to be significant among females, beneficially in the case of auditory displays ( p < 0.05). The results lead to the conclusion that an equal number of males and females in mixed experimental groups may be supportive to obtain reliable results. Moreover, in motor-learning studies conducted on females only, a design including auditory feedback would be more suitable.",2020,"The evident learning effect was found in all groups, and the main effect of sex was significant among visual groups in favor of the males ( p < 0.05).","['31 volunteers (15 males, 16 females', 'separate male and female groups']",['defined sex and training conditions (audio or visual feedback'],"['evident learning effect', 'perception and processing of auditory stimuli and performance of visual motor tasks']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C2936181', 'cui_str': 'Visual Feedback'}]","[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0178490', 'cui_str': 'Auditory stimulus'}, {'cui': 'C0234621', 'cui_str': 'Visual'}]",31.0,0.0238798,"The evident learning effect was found in all groups, and the main effect of sex was significant among visual groups in favor of the males ( p < 0.05).","[{'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Tarnas', 'Affiliation': 'Department of Physical Education and Lifelong Sports, Poznan University of Physical Education, Królowej Jadwigi 27/39, 61-871 Poznań, Poland.'}, {'ForeName': 'Rafał', 'Initials': 'R', 'LastName': 'Stemplewski', 'Affiliation': 'Department of Physical Activity Sciences and Health Promotion, Poznan University of Physical Education, Królowej Jadwigi 27/39, 61-871 Poznań, Poland.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Krutki', 'Affiliation': 'Department of Neurobiology, Poznan University of Physical Education, Królowej Jadwigi 27/39, 61-871 Poznań, Poland.'}]",International journal of environmental research and public health,['10.3390/ijerph17145158'] 1802,32709643,Is a definitive trial of prehospital continuous positive airway pressure versus standard oxygen therapy for acute respiratory failure indicated? The ACUTE pilot randomised controlled trial.,"OBJECTIVES To determine the feasibility of a large-scale definitive multicentre trial of prehospital continuous positive airway pressure (CPAP) in acute respiratory failure. DESIGN A single-centre, open-label, individual patient randomised, controlled, external pilot trial. SETTING A single UK Ambulance Service, between August 2017 and July 2018. PARTICIPANTS Adults with respiratory distress and peripheral oxygen saturations below British Thoracic Society target levels despite controlled oxygen treatment. INTERVENTIONS Patients were randomised to prehospital CPAP (O-Two system) versus standard oxygen therapy in a 1:1 ratio using simple randomisation. PRIMARY AND SECONDARY OUTCOME MEASURES Feasibility outcomes comprised recruitment rate, adherence to allocated treatment, retention and data completeness. The primary clinical outcome was 30-day mortality. RESULTS 77 patients were enrolled (target 120), including 7 cases with a diagnosis where CPAP could be ineffective or harmful. CPAP was fully delivered in 74% (target 75%). There were no major protocol violations. Full data were available for all key outcomes (targets ≥90%). Overall 30-day mortality was 27.3%. Of these deceased patients, 14/21 (68%) either did not have a respiratory condition or had ceiling of treatment decisions implemented excluding hospital non-invasive ventilation and critical care. CONCLUSIONS Recruitment rate was below target and feasibility was not demonstrated. Limited compliance with CPAP, and difficulty in identifying patients who could benefit from CPAP, indicate that prehospital CPAP is unlikely to materially reduce mortality. A definitive effectiveness trial of CPAP is therefore not recommended. TRIAL REGISTRATION NUMBER ISRCTN12048261; Post-results.",2020,There were no major protocol violations.,"['77 patients were enrolled (target 120), including 7 cases with a diagnosis where CPAP could be ineffective or harmful', 'Adults with respiratory distress and peripheral oxygen saturations below British Thoracic Society target levels despite controlled oxygen treatment', 'A single UK Ambulance Service, between August 2017 and July 2018', 'Of these deceased patients, 14/21 (68%) either did not have a respiratory condition or had ceiling of treatment decisions implemented excluding hospital non-invasive ventilation and critical care']","['prehospital CPAP (O-Two system) versus standard oxygen therapy', 'CPAP', 'prehospital continuous positive airway pressure versus standard oxygen therapy', 'prehospital continuous positive airway pressure (CPAP']","['30-day mortality', 'recruitment rate, adherence to allocated treatment, retention and data completeness', 'CPAP', 'Overall 30-day mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0476273', 'cui_str': 'Respiratory distress'}, {'cui': 'C2317096', 'cui_str': 'Peripheral oxygen saturation'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0002422', 'cui_str': 'Ambulance'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}, {'cui': 'C0010337', 'cui_str': 'Care of intensive care unit patient'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0439812', 'cui_str': 'Completeness'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",77.0,0.313875,There were no major protocol violations.,"[{'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Fuller', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK g.fuller@sheffield.ac.uk.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Keating', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Goodacre', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Herbert', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Perkins', 'Affiliation': 'Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': 'Andy', 'Initials': 'A', 'LastName': 'Rosser', 'Affiliation': 'West Midlands Ambulance Service NHS Foundation Trust, Brierley Hill, West Midlands, UK.'}, {'ForeName': 'Imogen', 'Initials': 'I', 'LastName': 'Gunson', 'Affiliation': 'West Midlands Ambulance Service NHS Foundation Trust, Brierley Hill, West Midlands, UK.'}, {'ForeName': 'Josh', 'Initials': 'J', 'LastName': 'Miller', 'Affiliation': 'West Midlands Ambulance Service NHS Foundation Trust, Brierley Hill, West Midlands, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Ward', 'Affiliation': 'West Midlands Ambulance Service NHS Foundation Trust, Brierley Hill, West Midlands, UK.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Bradburn', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Praveen', 'Initials': 'P', 'LastName': 'Thokala', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Harris', 'Affiliation': 'School of Medicine and Dentistry, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK.'}, {'ForeName': 'Maggie', 'Initials': 'M', 'LastName': 'Marsh', 'Affiliation': 'Sheffield Emergency Care Forum, Sheffield, UK.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Scott', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Cooper', 'Affiliation': 'Clinical Trials Research Unit, University of Sheffield, Sheffield, UK.'}]",BMJ open,['10.1136/bmjopen-2019-035915'] 1803,32709645,Infant formula composition and educational performance: a protocol to extend follow-up for a set of randomised controlled trials using linked administrative education records.,"INTRODUCTION The effect of infant nutrition on long-term cognition is important for parents and policy makers. However, most clinical trials typically have short follow-up periods, when measures of cognition are poorly predictive of later function. The few trials with longer-term follow-up have high levels of attrition, which can lead to selection bias, and in turn to erroneous interpretation of long-term harms and benefits of infant nutrition. We address the need for unbiased, long-term follow-up, by linking measures of educational performance from administrative education records. Educational performance is a meaningful marker of cognitive function in children and it is strongly correlated with IQ. We aim to evaluate educational performance for children who, as infants, were part of a series of trials that randomised participants to either nutritionally modified infant formula or standard formula. Most trialists anticipated positive effects of these interventions on later cognitive function. METHODS AND ANALYSIS Using data from 1923 participants of seven randomised infant formula trials linked to the English National Pupil Database (NPD), this study will provide new insights into the effect of nutrient intake in infancy on school achievement. Our primary outcome will be the mean differences in z-scores between intervention and control groups for a compulsory Mathematics exam sat at age 16. Secondary outcomes will be z-scores for a compulsory English exam at age 16 and z-scores for compulsory Mathematics and English exams at age 11. We will also evaluate intervention effects on the likelihood of receiving special educational needs (SEN) support. All analyses will be performed separately by trial. ETHICS AND DISSEMINATION Research ethics approval, and approval from the Health Research Authority Confidentiality Advisory Group, has been obtained for this study. The results of this study will be disseminated to scientific, practitioner, and lay audiences, submitted for publication in peer-reviewed journals, and will contribute towards a PhD dissertation.",2020,Our primary outcome will be the mean differences in z-scores between intervention and control groups for a compulsory Mathematics exam sat at age 16.,"['1923 participants of seven randomised infant formula trials linked to the English National Pupil Database (NPD', 'children who, as infants']",['nutritionally modified infant formula or standard formula'],"['z-scores for a compulsory English exam at age 16 and z-scores for compulsory Mathematics and English exams at age 11', 'z-scores', 'educational performance']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0150589', 'cui_str': 'Infant formula'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0034121', 'cui_str': 'Pupil structure'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0150589', 'cui_str': 'Infant formula'}, {'cui': 'C3853255', 'cui_str': 'Standard formula'}]","[{'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0582103', 'cui_str': 'Medical assessment'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0024934', 'cui_str': 'Mathematics'}, {'cui': 'C0036373', 'cui_str': 'Academic Test Performance'}]",1923.0,0.167281,Our primary outcome will be the mean differences in z-scores between intervention and control groups for a compulsory Mathematics exam sat at age 16.,"[{'ForeName': 'Maximiliane', 'Initials': 'M', 'LastName': 'Verfürden', 'Affiliation': 'Great Ormond Street Institute of Child Health, University College London, London, UK m.verfuerden@ucl.ac.uk.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Harron', 'Affiliation': 'Great Ormond Street Institute of Child Health, University College London, London, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Jerrim', 'Affiliation': 'Institute of Education, University College London, London, UK.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Fewtrell', 'Affiliation': 'Great Ormond Street Institute of Child Health, University College London, London, UK.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Gilbert', 'Affiliation': 'Great Ormond Street Institute of Child Health, University College London, London, UK.'}]",BMJ open,['10.1136/bmjopen-2019-035968'] 1804,32709656,"Efficacy, cost-utility and physiological effects of Acceptance and Commitment Therapy (ACT) and Behavioural Activation Treatment for Depression (BATD) in patients with chronic low back pain and depression: study protocol of a randomised, controlled trial including mobile-technology-based ecological momentary assessment (IMPACT study).","INTRODUCTION The IMPACT study focuses on chronic low back pain (CLBP) and depression symptoms, a prevalent and complex problem that represents a challenge for health professionals. Acceptance and Commitment Therapy (ACT) and Brief Behavioural Activation Treatment for Depression (BATD) are effective treatments for patients with persistent pain and depression, respectively. The objectives of this 12 month, multicentre, randomised, controlled trial (RCT) are (i) to examine the efficacy and cost-utility of adding a group-based form of ACT or BATD to treatment-as-usual (TAU) for patients with CLBP and moderate to severe levels of depressive symptoms; (ii) identify pre-post differences in levels of some physiological variables and (iii) analyse the role of polymorphisms in the FKBP5 gene, psychological process measures and physiological variables as mediators or moderators of long-term clinical changes. METHODS AND ANALYSIS Participants will be 225 patients with CLBP and moderate to severe depression symptoms recruited at Parc Sanitari Sant Joan de Déu (St. Boi de Llobregat, Spain) and Hospital del Mar (Barcelona, Spain), randomly allocated to one of the three study arms: TAU vs TAU+ACT versus TAU+BATD. A comprehensive assessment to collect clinical variables and costs will be conducted pretreatment, post-treatment and at 12 months follow-up, being pain interference the primary outcome measure. The following physiological variables will be considered at pretreatment and post-treatment assessments in 50% of the sample: immune-inflammatory markers, hair cortisol and cortisone, serum cortisol, corticosteroid-binding globulin and vitamin D. Polymorphisms in the FKBP5 gene (rs3800373, rs9296158, rs1360780, rs9470080 and rs4713916) will be analysed at baseline assessment. Moreover, we will include mobile-technology-based ecological momentary assessment, through the Pain Monitor app, to track ongoing clinical status during ACT and BATD treatments. Linear mixed-effects models using restricted maximum likelihood, and a full economic evaluation applying bootstrapping techniques, acceptability curves and sensitivity analyses will be computed. ETHICS AND DISSEMINATION This study has been approved by the Ethics Committee of the Fundació Sant Joan de Déu and Hospital del Mar. The results will be actively disseminated through peer-reviewed journals, conference presentations, social media and various community engagement activities. TRIAL REGISTRATION NUMBER NCT04140838.",2020,"Acceptance and Commitment Therapy (ACT) and Brief Behavioural Activation Treatment for Depression (BATD) are effective treatments for patients with persistent pain and depression, respectively.","['patients with chronic low back pain and depression', 'patients with CLBP and moderate to severe levels of depressive symptoms', 'patients with persistent pain and depression, respectively', 'Participants will be 225 patients with CLBP and moderate to severe depression symptoms recruited at Parc Sanitari Sant Joan de Déu (St. Boi de Llobregat, Spain) and Hospital del Mar (Barcelona, Spain']","['Acceptance and Commitment Therapy (ACT) and Brief Behavioural Activation Treatment', 'Acceptance and Commitment Therapy (ACT) and Behavioural Activation Treatment', 'ACT or BATD to treatment-as-usual (TAU', 'TAU vs TAU+ACT\u2009versus TAU+BATD']","['chronic low back pain (CLBP) and depression symptoms', 'immune-inflammatory markers, hair cortisol and cortisone, serum cortisol, corticosteroid-binding globulin and vitamin D. Polymorphisms', 'efficacy and cost-utility', 'Efficacy, cost-utility and physiological effects']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4517652', 'cui_str': '225'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008628', 'cui_str': 'Chromosomal deletion'}, {'cui': 'C0024782', 'cui_str': 'Marathi language'}]","[{'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}, {'cui': 'C0029917', 'cui_str': 'Outpatient Commitment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]","[{'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0010137', 'cui_str': 'Cortisone'}, {'cui': 'C0236396', 'cui_str': 'Serum cortisol measurement'}, {'cui': 'C0040643', 'cui_str': 'Corticotropin binding globulin'}, {'cui': 'C0042890', 'cui_str': 'Vitamin'}, {'cui': 'C0032529', 'cui_str': 'Genetic polymorphism'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",225.0,0.185291,"Acceptance and Commitment Therapy (ACT) and Brief Behavioural Activation Treatment for Depression (BATD) are effective treatments for patients with persistent pain and depression, respectively.","[{'ForeName': 'Juan P', 'Initials': 'JP', 'LastName': 'Sanabria-Mazo', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Carlos G', 'Initials': 'CG', 'LastName': 'Forero', 'Affiliation': 'Department of Medicine, International University of Catalunya, Barcelona, Spain.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Cristobal-Narváez', 'Affiliation': 'Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Suso-Ribera', 'Affiliation': 'Department of Basic and Clinical Psychology and Psychobiology, Universitat Jaume I, Castelló de la Plana, Spain.'}, {'ForeName': 'Azucena', 'Initials': 'A', 'LastName': 'García-Palacios', 'Affiliation': 'Department of Basic and Clinical Psychology and Psychobiology, Universitat Jaume I, Castelló de la Plana, Spain.'}, {'ForeName': 'Ariadna', 'Initials': 'A', 'LastName': 'Colomer-Carbonell', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Adrián', 'Initials': 'A', 'LastName': 'Pérez-Aranda', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Andrés-Rodríguez', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Lance M', 'Initials': 'LM', 'LastName': 'McCracken', 'Affiliation': 'Psychology Department, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': ""D'Amico"", 'Affiliation': 'Personal Social Services Research Unit, London School of Economics and Political Science, London, UK.'}, {'ForeName': 'Pere', 'Initials': 'P', 'LastName': 'Estivill-Rodríguez', 'Affiliation': 'Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain.'}, {'ForeName': 'Bernat', 'Initials': 'B', 'LastName': 'Carreras-Marcos', 'Affiliation': 'Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Montes-Pérez', 'Affiliation': 'Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Comps-Vicente', 'Affiliation': 'Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain.'}, {'ForeName': 'Montserrat', 'Initials': 'M', 'LastName': 'Esteve', 'Affiliation': 'Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERobn), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Mar', 'Initials': 'M', 'LastName': 'Grasa', 'Affiliation': 'Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERobn), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Araceli', 'Initials': 'A', 'LastName': 'Rosa', 'Affiliation': 'Network Centre for Biomedical Research in Mental Health (CIBERSAM), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Antonio I', 'Initials': 'AI', 'LastName': 'Cuesta-Vargas', 'Affiliation': 'Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Maes', 'Affiliation': 'Department of Psychiatry, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Borràs', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Edo', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Sanz', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Feliu-Soler', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Juan R', 'Initials': 'JR', 'LastName': 'Castaño-Asins', 'Affiliation': 'Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain.'}, {'ForeName': 'Juan V', 'Initials': 'JV', 'LastName': 'Luciano', 'Affiliation': 'Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain jvluciano@pssjd.org.'}]",BMJ open,['10.1136/bmjopen-2020-038107'] 1805,32709657,Bridging the gap between physical and mental illness in community pharmacy ( PharMIbridge ): protocol for an Australian cluster randomised controlled trial.,"INTRODUCTION There is a significant life expectancy gap attributable to physical comorbidities for people living with severe and persistent mental illness (SPMI) compared with the general population. Medications are a major treatment for SPMI management and physical illnesses, hence pharmacists are well positioned to support mental healthcare and comorbidities. The randomised controlled trial (RCT) aim is to evaluate effectiveness of an individualised, pharmacist led, support service for people experiencing SPMI focusing on medication adherence and physical comorbidity management, compared with standard care (a medication-management service; MedsCheck). METHODS AND ANALYSIS: PharMIbridge is a cluster RCT, whereby community pharmacies in four Australian regions will be randomised (1:1 ratio), to either Intervention Group (IG) or Comparator Group (CG). All IG and CG pharmacy staff will receive Blended-Mental Health First Aid training. Additionally, IG pharmacists will receive further training on medication adherence, goal setting, motivational interviewing, managing physical health concerns and complex issues relating to psychotropic medication. CG pharmacists will not receive additional training, and will provide standard care (MedsCheck). The primary outcome will be change in participants medication adherence for psychotropic medication over 6-months. Using mixed-effects logistic regression model and a cluster size of 48 pharmacies, a total of 190 participants will need to be recruited to each arm to find a statistically significant difference in medication adherence. Secondary outcomes will be changes in factors associated with cardiometabolic risk and quality of life, emphasising physical and psychological well-being; medication-related problems; adherence to other prescribed medication; pharmacists knowledge, confidence and ability to support people experiencing SPMI; and effects on healthcare utilisation. A within RCT-based economic evaluation comparing the intervention with standard care will be undertaken. ETHICS AND DISSEMINATION The protocol and pharmacist training programme received Griffith University Human Research Ethics Committee approval (HREC/2019/473 and HREC/2019/493 respectively). Results will be published in peer-reviewed journals and available at the Sixth Community Pharmacy Agreement website (http://6cpa.com.au/about-6cpa/). TRIAL REGISTRATION NUMBER ANZCTR12620000577910.",2020,"The randomised controlled trial (RCT) aim is to evaluate effectiveness of an individualised, pharmacist led, support service for people experiencing SPMI focusing on medication adherence and physical comorbidity management, compared with standard care (a medication-management service; MedsCheck).","['people living with severe and persistent mental illness (SPMI', '48 pharmacies, a total of 190 participants']",['Blended-Mental Health First Aid training'],"['cardiometabolic risk and quality of life, emphasising physical and psychological well-being; medication-related problems; adherence to other prescribed medication; pharmacists knowledge, confidence and ability to support people experiencing SPMI; and effects on healthcare utilisation', 'participants medication adherence for psychotropic medication', 'medication adherence']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0870281', 'cui_str': 'Chronic mental disorder'}, {'cui': 'C0031321', 'cui_str': 'Pharmacy service'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517622', 'cui_str': '190'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1276379', 'cui_str': 'First aid education'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0424578', 'cui_str': 'Well in self'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0870281', 'cui_str': 'Chronic mental disorder'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0033978', 'cui_str': 'Psychotherapeutic agent'}]",190.0,0.139524,"The randomised controlled trial (RCT) aim is to evaluate effectiveness of an individualised, pharmacist led, support service for people experiencing SPMI focusing on medication adherence and physical comorbidity management, compared with standard care (a medication-management service; MedsCheck).","[{'ForeName': 'Amanda J', 'Initials': 'AJ', 'LastName': 'Wheeler', 'Affiliation': 'Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia a.wheeler@griffith.edu.au.'}, {'ForeName': 'Claire L', 'Initials': 'CL', 'LastName': ""O'Reilly"", 'Affiliation': 'Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Sarira', 'Initials': 'S', 'LastName': 'El-Den', 'Affiliation': 'Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Byrnes', 'Affiliation': 'Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Ware', 'Affiliation': 'Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia.'}, {'ForeName': 'Sara S', 'Initials': 'SS', 'LastName': 'McMillan', 'Affiliation': 'Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia.'}]",BMJ open,['10.1136/bmjopen-2020-039983'] 1806,32709710,Long-Term Functional Patency and Cost-Effectiveness of Arteriovenous Fistula Creation under Regional Anesthesia: a Randomized Controlled Trial.,"BACKGROUND Regional anesthesia improves short-term blood flow through arteriovenous fistulas (AVFs). We previously demonstrated that, compared with local anesthesia, regional anesthesia improves primary AVF patency at 3 months. METHODS To study the effects of regional versus local anesthesia on longer-term AVF patency, we performed an observer-blinded randomized controlled trial at three university hospitals in Glasgow, United Kingdom. We randomly assigned 126 patients undergoing primary radiocephalic or brachiocephalic AVF creation to receive regional anesthesia (brachial plexus block; 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine) or local anesthesia (0.5% L-bupivacaine and 1% lidocaine). This report includes findings on primary, functional, and secondary patency at 12 months; reinterventions; and additional access procedures (primary outcome measures were previously reported). We analyzed data by intention to treat, and also performed cost-effectiveness analyses. RESULTS At 12 months, we found higher primary patency among patients receiving regional versus local anesthesia (50 of 63 [79%] versus 37 of 63 [59%] patients; odds ratio [OR], 2.7; 95% confidence interval [95% CI], 1.6 to 3.8; P =0.02) as well as higher functional patency (43 of 63 [68%] versus 31 of 63 [49%] patients; OR, 2.1; 95% CI, 1.5 to 2.7; P =0.008). In 12 months, 21 revisional procedures, 53 new AVFs, and 50 temporary dialysis catheters were required. Regional anesthesia resulted in net savings of £195.10 (US$237.36) per patient at 1 year, and an incremental cost-effectiveness ratio of approximately £12,900 (US$15,694.20) per quality-adjusted life years over a 5-year time horizon. Results were robust after extensive sensitivity and scenario analyses. CONCLUSIONS Compared with local anesthesia, regional anesthesia significantly improved both primary and functional AVF patency at 1 year and is cost-effective. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER Local Anaesthesia versus Regional Block for Arteriovenous Fistulae, NCT01706354.",2020,"Regional anesthesia resulted in net savings of £195.10 (US$237.36) per patient at 1 year, and an incremental cost-effectiveness ratio of approximately £12,900 (US$15,694.20) per quality-adjusted life years over a 5-year time horizon.","['126 patients undergoing', 'three university hospitals in Glasgow, United Kingdom']","['primary radiocephalic or brachiocephalic', 'regional versus local anesthesia', 'regional anesthesia (brachial plexus block; 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine', 'Arteriovenous Fistula Creation under Regional Anesthesia', 'local anesthesia, regional anesthesia', 'local anesthesia (0.5% L-bupivacaine and 1% lidocaine']","['functional patency', 'primary patency', 'primary AVF patency', 'incremental cost-effectiveness ratio', 'net savings', 'cost-effective', 'functional AVF patency']","[{'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom of Great Britain and Northern Ireland'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0002911', 'cui_str': 'Regional anesthesia'}, {'cui': 'C0394697', 'cui_str': 'Injection of anesthetic agent into brachial plexus'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0398221', 'cui_str': 'Arteriovenous fistulization'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0449215', 'cui_str': 'aVF'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0036245', 'cui_str': 'Savings'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",126.0,0.356984,"Regional anesthesia resulted in net savings of £195.10 (US$237.36) per patient at 1 year, and an incremental cost-effectiveness ratio of approximately £12,900 (US$15,694.20) per quality-adjusted life years over a 5-year time horizon.","[{'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Aitken', 'Affiliation': 'Department of Renal Surgery, Queen Elizabeth University Hospital, Glasgow, United Kingdom emmaaitken@nhs.net.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Kearns', 'Affiliation': 'Department of Anaesthesia, Critical Care and Pain Medicine, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Lucian', 'Initials': 'L', 'LastName': 'Gaianu', 'Affiliation': 'Scottish Health Technologies Group, Healthcare Improvement Scotland, Edinburgh, United Kingdom.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Jackson', 'Affiliation': 'Department of Renal Surgery, Queen Elizabeth University Hospital, Glasgow, United Kingdom.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Steven', 'Affiliation': 'Department of Anaesthesia, Golden Jubilee National Hospital, Clydebank, United Kingdom.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Kinsella', 'Affiliation': 'Department of Anaesthesia, Critical Care and Pain Medicine, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Clancy', 'Affiliation': 'Department of Renal Surgery, Queen Elizabeth University Hospital, Glasgow, United Kingdom.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Macfarlane', 'Affiliation': 'Department of Anaesthesia, Critical Care and Pain Medicine, University of Glasgow, Glasgow, United Kingdom.'}]",Journal of the American Society of Nephrology : JASN,['10.1681/ASN.2019111209'] 1807,32707403,"Changes to stance limb peak, cumulative, and regional plantar foot forces among normal walking and three mobility aids in healthy older adults.","BACKGROUND Mobility aids are commonly prescribed to offload an injured lower extremity. Device selection may impact stance foot loading patterns and foot health in clinical populations at risk of foot ulceration. RESEARCH QUESTIONS Two questions motivated this study: How does device selection influence peak plantar and regional (rearfoot, mid foot and forefoot) foot forces on the stance foot? Does device selection influence peak, cumulative, and regional plantar forces within a 200 m walking trial? METHODS Twenty-one older adults walked 200 m at self-selected pace in four randomized conditions for this prospective crossover study. Participants used a walker, crutches, wheeled knee walker (WKW), and no assistive device (control condition). Plantar forces were measured using a wireless in-shoe system (Loadsol, Novel Inc., St. Paul, MN). Repeated measures analyses of variance were used to determine differences in peak and cumulative total and regional forces among walking conditions. Paired sample t-tests compared forces during first and last 30 s epochs of each condition to determine device influence over time. RESULTS The WKW reduced peak net forces by 0.29 and 0.35 bodyweight (BW) when compared to the walker or control condition with similar trends in all foot regions. Crutch use had similar peak forces as control. There were no differences in the number of steps taken within devices comparing first and last epochs. Crutches had a 0.04 and 0.07 BW increase in peak net and forefoot forces during the last epoch. Walker use had 66.44 BW lower cumulative forefoot forces in the last epoch. SIGNIFICANCE Crutches had similar stance foot loading as normal walking while a walker lowered forefoot forces at the expense of increased steps. A WKW may be the best choice to 'protect' tissues in the stance foot from exposure to peak and cumulative forces in the forefoot region.",2020,The WKW reduced peak net forces by 0.29 and 0.35 bodyweight (BW) when compared to the walker or control condition with similar trends in all foot regions.,"['healthy older adults', 'Twenty-one older adults walked 200 m at self-selected pace']",['normal walking and three mobility aids'],"['device selection influence peak, cumulative, and regional plantar forces', 'peak net forces', 'Plantar forces', 'peak net and forefoot forces', 'stance limb peak, cumulative, and regional plantar foot forces', 'peak and cumulative total and regional forces among walking conditions', 'cumulative forefoot forces']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0287990', 'cui_str': 'Furin'}]","[{'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C3495449', 'cui_str': 'Mobility aid'}]","[{'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0031222', 'cui_str': 'Personnel Selection'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C1510667', 'cui_str': 'Forefoot region of foot'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]",21.0,0.0456241,The WKW reduced peak net forces by 0.29 and 0.35 bodyweight (BW) when compared to the walker or control condition with similar trends in all foot regions.,"[{'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Kingston', 'Affiliation': 'College of Medicine, University of Saskatchewan, 107 Wiggins Rd, Saskatoon, SK, S7N 5E5, Canada. Electronic address: david.kingston@usask.ca.'}, {'ForeName': 'A Gary', 'Initials': 'AG', 'LastName': 'Linassi', 'Affiliation': 'College of Medicine, University of Saskatchewan, 107 Wiggins Rd, Saskatoon, SK, S7N 5E5, Canada; School of Rehabilitation Science, University of Saskatchewan, Suite 3400, 3rd Floor, 104 Clinic Pl, Saskatoon, SK, S7N 2Z4, Canada. Electronic address: anl931@mail.usask.ca.'}, {'ForeName': 'Audrey R', 'Initials': 'AR', 'LastName': 'Zucker-Levin', 'Affiliation': 'School of Rehabilitation Science, University of Saskatchewan, Suite 3400, 3rd Floor, 104 Clinic Pl, Saskatoon, SK, S7N 2Z4, Canada. Electronic address: audrey.zuckerlevin@usask.ca.'}]",Gait & posture,['10.1016/j.gaitpost.2020.07.015'] 1808,32714774,Workplace-based opportunities to support child care workers' health and safety.,"Child care workers earn among the lowest wages in the United States and they struggle with many health issues. The purpose of this study was to describe workplace supports for nutrition, physical activity, other health behaviors (e.g., smoking cessation, stress management), and occupational health and safety available to child care workers, and thereby inform the development of future workplace-based interventions to improve worker well-being. Between 2015 and 2016, 74 North Carolina child care centers (and directors), participating in a larger randomized controlled trial, completed a Workplace Health and Safety Assessment (interview and observation) measuring four domains: Infrastructure, Organizational Policies and Procedures, Programs and Promotions, and Internal Physical Environment. This study used baseline data to report means and standard deviations. Participating child care centers employed, on average, 12.7 ± 8.4 employees. Total scores from the Workplace Health and Safety Assessment averaged 41.3 ± 12.6 out of a possible 154, demonstrating many missed opportunities for supporting health/safety. More specifically, centers scored on average 9.5 ± 3.9 on Infrastructure (35% of potential points), 11.1 ± 3.9 on Organizational Policies and Procedures (32% of potential), 7.6 ± 5.4 on Programs and Promotions (12% of potential), and 13.1 ± 2.2 on Internal Physical Environment (49% of potential). The most frequent supports available were for occupational health and safety issues, while fewer supports were available for physical activity and other health behaviors. Child care workers could benefit greatly from more comprehensive workplace health and safety interventions; however, strategies must overcome centers' limited capacity and resources.",2020,"Total scores from the Workplace Health and Safety Assessment averaged 41.3 ± 12.6 out of a possible 154, demonstrating many missed opportunities for supporting health/safety.","['Participating child care centers employed, on average, 12.7\xa0±\xa08.4 employees', 'Between 2015 and 2016, 74 North Carolina child care centers (and directors']","['Workplace Health and Safety Assessment (interview and observation) measuring four domains: Infrastructure, Organizational Policies and Procedures, Programs and Promotions, and Internal Physical Environment']",['Total scores'],"[{'cui': 'C0008070', 'cui_str': 'Child day care center'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C4517546', 'cui_str': '12.7'}, {'cui': 'C4517876', 'cui_str': '8.4'}, {'cui': 'C0599987', 'cui_str': 'Employee'}, {'cui': 'C0028407', 'cui_str': 'North Carolina'}]","[{'cui': 'C0162579', 'cui_str': 'Work environment'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0079945', 'cui_str': 'Organizational Policies'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0557720', 'cui_str': 'Physical environment'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0152136,"Total scores from the Workplace Health and Safety Assessment averaged 41.3 ± 12.6 out of a possible 154, demonstrating many missed opportunities for supporting health/safety.","[{'ForeName': 'Amber E', 'Initials': 'AE', 'LastName': 'Vaughn', 'Affiliation': 'Center for Health Promotion and Disease Prevention, The University of North Carolina at Chapel Hill, 1700 Martin L. King Jr. Blvd., CB 7426, Chapel Hill, NC 27599-7426, USA.'}, {'ForeName': 'Erik A', 'Initials': 'EA', 'LastName': 'Willis', 'Affiliation': 'Center for Health Promotion and Disease Prevention, The University of North Carolina at Chapel Hill, 1700 Martin L. King Jr. Blvd., CB 7426, Chapel Hill, NC 27599-7426, USA.'}, {'ForeName': 'Dianne S', 'Initials': 'DS', 'LastName': 'Ward', 'Affiliation': 'Center for Health Promotion and Disease Prevention, The University of North Carolina at Chapel Hill, 1700 Martin L. King Jr. Blvd., CB 7426, Chapel Hill, NC 27599-7426, USA.'}, {'ForeName': 'Falon', 'Initials': 'F', 'LastName': 'Smith', 'Affiliation': 'Center for Health Promotion and Disease Prevention, The University of North Carolina at Chapel Hill, 1700 Martin L. King Jr. Blvd., CB 7426, Chapel Hill, NC 27599-7426, USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Grummon', 'Affiliation': 'Center for Health Promotion and Disease Prevention, The University of North Carolina at Chapel Hill, 1700 Martin L. King Jr. Blvd., CB 7426, Chapel Hill, NC 27599-7426, USA.'}, {'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Linnan', 'Affiliation': 'Department of Health Behavior, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, 307 Rosenau Hall, CB 7440, Chapel Hill, NC 27599-7440, USA.'}]",Preventive medicine reports,['10.1016/j.pmedr.2020.101154'] 1809,32682696,Electronic Decision Support for Management of CKD in Primary Care: A Pragmatic Randomized Trial.,"RATIONALE & OBJECTIVE Most adults with chronic kidney disease (CKD) in the United States are cared for by primary care providers (PCPs). We evaluated the feasibility and preliminary effectiveness of an electronic clinical decision support system (eCDSS) within the electronic health record with or without pharmacist follow-up to improve the management of CKD in primary care. STUDY DESIGN Pragmatic cluster-randomized trial. SETTING & PARTICIPANTS 524 adults with confirmed creatinine-based estimated glomerular filtration rates of 30 to 59mL/min/1.73m 2 cared for by 80 PCPs at the University of California San Francisco. Electronic health record data were used for patient identification, intervention deployment, and outcomes ascertainment. INTERVENTIONS Each PCP's eligible patients were randomly assigned as a group into 1 of 3 treatment arms: (1) usual care; (2) eCDSS: testing of creatinine, cystatin C, and urinary albumin-creatinine ratio with individually tailored guidance for PCPs on blood pressure, potassium, and proteinuria management, cardiovascular risk reduction, and patient education; or (3) eCDSS plus pharmacist counseling (eCDSS-PLUS). OUTCOMES The primary clinical outcome was change in blood pressure over 12 months. Secondary outcomes were PCP awareness of CKD and use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and statin therapy. RESULTS All 80 eligible PCPs participated. Mean patient age was 70 years, 47% were nonwhite, and mean estimated glomerular filtration rate was 56±0.6mL/min/1.73m 2 . Among patients receiving eCDSS with or without pharmacist counseling (n=336), 178 (53%) completed laboratory measurements and 138 (41%) had laboratory measurements followed by a PCP visit with eCDSS deployment. eCDSS was opened by the PCP for 102 (74%) patients, with at least 1 suggested order signed for 83 of these 102 (81%). Changes in systolic blood pressure were-2.1±1.5mm Hg with usual care, -2.8±1.8mm Hg with eCDSS, and -1.1±1.1 with eCDSS-PLUS (P=0.7). PCP awareness of CKD was 16% with usual care, 26% with eCDSS, and 32% for eCDSS-PLUS (P=0.09). In as-treated analyses, PCP awareness of CKD was significantly greater with eCDSS and eCDSS-PLUS (73% and 69%) versus usual care (47%; P=0.002). LIMITATIONS Recruitment of smaller than intended sample size and limited uptake of the testing component of the intervention. CONCLUSIONS Although we were unable to demonstrate the effectiveness of eCDSS to lower blood pressure and uptake of the eCDSS was limited by low testing rates, eCDSS use was high when laboratory measurements were available and was associated with higher PCP awareness of CKD. FUNDING Grants from government (National Institutes of Health) and not-for-profit (American Heart Association) entities. TRIAL REGISTRATION Registered at ClinicalTrials.gov with study number NCT02925962.",2020,"PCP awareness of CKD was 16% with usual care, 26% with eCDSS, and 32% for eCDSS -PLUS (p=0.09).","[' 524 adults with confirmed eGFRCr 30-59 mL/min/1.73m 2 cared for by 80 PCPs at the University of California San Francisco', 'Mean patient age was 70, 47% were non-white, mean eGFRcr was 56 +/-0.6', 'Primary Care', 'All 80 eligible PCPs participated', 'patients receiving eCDSS with or without pharmacist counseling (n=336), 178 (53%) completed labs and 138 (41%) had labs followed by a PCP visit with eCDSS deployment', 'adults with chronic kidney disease (CKD) in the U.S. are cared for by primary care providers (PCP']","['eCDSS', 'electronic clinical decision support system (eCDSS', 'usual care, 2) eCDSS: testing of creatinine, cystatin C and urinary albumin-to-creatinine ratio with individually tailored guidance for PCPs on blood pressure, potassium and proteinuria management, cardiovascular risk-reduction, and patient education, or 3) eCDSS plus pharmacist counseling (eCDSS-PLUS']","['blood pressure', 'blood pressure, and uptake of the eCDSS', 'PCP awareness of CKD', 'systolic blood pressure', 'PCP awareness of CKD as well as use of ACEi/ARB and statin']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0036152', 'cui_str': 'San Francisco'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C4068883', 'cui_str': '0.6'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0525070', 'cui_str': 'Clinical Decision Support Systems'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C2735026', 'cui_str': 'Primary care provider'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0525070', 'cui_str': 'Clinical Decision Support Systems'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0071744', 'cui_str': 'Cystatin C'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0032821', 'cui_str': 'Potassium'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0030688', 'cui_str': 'Patient education'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0525070', 'cui_str': 'Clinical Decision Support Systems'}, {'cui': 'C2735026', 'cui_str': 'Primary care provider'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0521942', 'cui_str': 'Angiotensin II receptor antagonist'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}]",524.0,0.0628094,"PCP awareness of CKD was 16% with usual care, 26% with eCDSS, and 32% for eCDSS -PLUS (p=0.09).","[{'ForeName': 'Carmen A', 'Initials': 'CA', 'LastName': 'Peralta', 'Affiliation': 'Department of Medicine, University of California San Francisco, San Francisco, CA; The Kidney Health Research Collaborative, University of California San Francisco, San Francisco, CA; Cricket Health, Inc, San Francisco, CA. Electronic address: carmenalicia.peralta@ucsf.edu.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Livaudais-Toman', 'Affiliation': 'Department of Medicine, University of California San Francisco, San Francisco, CA; Multiethnic Health Equity Research Center, University of California San Francisco, San Francisco, CA.'}, {'ForeName': 'Marilyn', 'Initials': 'M', 'LastName': 'Stebbins', 'Affiliation': 'Department of Clinical PharmacyUniversity of California San Francisco, San Francisco, CA.'}, {'ForeName': 'Lowell', 'Initials': 'L', 'LastName': 'Lo', 'Affiliation': 'Department of Medicine, University of California San Francisco, San Francisco, CA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Robinson', 'Affiliation': 'Department of Medicine, University of California San Francisco, San Francisco, CA.'}, {'ForeName': 'Sarita', 'Initials': 'S', 'LastName': 'Pathak', 'Affiliation': 'Department of Medicine, University of California San Francisco, San Francisco, CA; Multiethnic Health Equity Research Center, University of California San Francisco, San Francisco, CA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Scherzer', 'Affiliation': 'Department of Medicine, University of California San Francisco, San Francisco, CA; The Kidney Health Research Collaborative, University of California San Francisco, San Francisco, CA.'}, {'ForeName': 'Leah S', 'Initials': 'LS', 'LastName': 'Karliner', 'Affiliation': 'Department of Medicine, University of California San Francisco, San Francisco, CA; Multiethnic Health Equity Research Center, University of California San Francisco, San Francisco, CA.'}]",American journal of kidney diseases : the official journal of the National Kidney Foundation,['10.1053/j.ajkd.2020.05.013'] 1810,32692216,"Treatment of hyperlipidemic acute pancreatitis with modified Dachengqi decoction combining with conventional therapy based on ""six-hollow-organs to be unblocked"" theory.","BACKGROUND The increase of triglyceride (TG) can induce coronary heart disease, atherosclerosis, pancreatitis and other diseases and is the most common inducing factor of acute pancreatitis (AP) second only to biliary tract disease and drinking. The pathogenesis of hyperlipidemic acute pancreatitis (HLAP) is not exactly clear, but it may be related to the toxic effect of the increase of free fatty acids produced by TG decomposition on the pancreas itself, microcirculation disorder of the pancreas, and calcium overload. At present, non-surgical therapy is the main treatment for HLAP. The key to preventing recurrence is to reduce blood lipids, change the diet structure, and reduce weight. This study aimed to treat HLAP with modified Dachengqi decoction combined with conventional therapy, based on the ""six-hollow-organs to be unblocked"" theory. METHODS Forty patients with HLAP who received treatment in the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine and Puding County Hospital of Traditional Chinese Medicine from September 2016 to August 2019 were selected and divided into a control group and an intervention group, each with 20 cases, following a random number table. The control group was treated with conventional therapy while the intervention group was treated with modified Dachengqi decoction combined with conventional therapy. RESULTS After treatment, the cure rate and the total effective rate were 60% and 95% respectively in the intervention group, and 25% and 75% respectively in the control group (P<0.05). The TG, serum amylase, leukocyte count, and neutrophil ratio of the two groups decreased significantly after treatment, and there was a greater decrease in the intervention group than that in the control group, with this being significantly different between the two groups. The gastrointestinal function score, total score of the acute physiology and chronic health evaluation II (APACHE II), and the pain score of the visual analog scale (VAS) decreased markedly in the two groups after the treatment, with scores in the intervention group being significantly lower than those in the control group (P<0.05). CONCLUSIONS Modified Dachengqi decoction combined with conventional therapy has a better therapeutic effect on HLAP than conventional therapy.",2020,"After treatment, the cure rate and the total effective rate were 60% and 95% respectively in the intervention group, and 25% and 75% respectively in the control group (P<0.05).","['hyperlipidemic acute pancreatitis', 'hyperlipidemic acute pancreatitis (HLAP', 'Forty patients with HLAP who received treatment in the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine and Puding County Hospital of Traditional Chinese Medicine from September 2016 to August 2019']","['HLAP with modified Dachengqi decoction combined with conventional therapy', 'modified Dachengqi decoction combining with conventional therapy', 'triglyceride (TG', 'conventional therapy', 'Modified Dachengqi decoction combined with conventional therapy', 'modified Dachengqi decoction combined with conventional therapy']","['gastrointestinal function score, total score of the acute physiology and chronic health evaluation II (APACHE II), and the pain score of the visual analog scale (VAS', 'TG, serum amylase, leukocyte count, and neutrophil ratio', 'cure rate and the total effective rate']","[{'cui': 'C0001339', 'cui_str': 'Acute pancreatitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0030920', 'cui_str': 'Peptic ulcer'}, {'cui': 'C0020005', 'cui_str': 'County Hospitals'}]","[{'cui': 'C0001339', 'cui_str': 'Acute pancreatitis'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1311504', 'cui_str': 'dachengqi decoction'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}]","[{'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0243028', 'cui_str': 'Acute physiology and chronic health evaluation II'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0201885', 'cui_str': 'Amylase measurement, serum'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",40.0,0.0187697,"After treatment, the cure rate and the total effective rate were 60% and 95% respectively in the intervention group, and 25% and 75% respectively in the control group (P<0.05).","[{'ForeName': 'Guoxiong', 'Initials': 'G', 'LastName': 'Liu', 'Affiliation': 'Department of Orthopedics, the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China. zgliuguoxiong@163.com.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Liu', 'Affiliation': 'Department of Orthopedics, the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China.'}, {'ForeName': 'Long', 'Initials': 'L', 'LastName': 'Xiao', 'Affiliation': 'Department of Orthopedics, the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China.'}, {'ForeName': 'Qiaogui', 'Initials': 'Q', 'LastName': 'Kuang', 'Affiliation': 'College of Acupuncture and Orthopedics, Guizhou University of Traditional Chinese Medicine, Guiyang, China.'}, {'ForeName': 'Xingfeng', 'Initials': 'X', 'LastName': 'He', 'Affiliation': 'Department of Orthopedics, the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Puding County Hospital of Traditional Chinese Medicine, Anshun, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': 'Puding County Hospital of Traditional Chinese Medicine, Anshun, China.'}]",Annals of palliative medicine,['10.21037/apm-20-1106'] 1811,32692240,Effectiveness of a multidisciplinary comprehensive intervention model based on the Hospital Elderly Life Program to prevent delirium in patients with severe acute pancreatitis.,"BACKGROUND Pancreatic encephalopathy is the most serious complication of severe acute pancreatitis (SAP) and substantially increases mortality. Delirium is a common clinical manifestation of pancreatic encephalopathy. This study aimed to assess the clinical effects of an improved version of the Hospital Elderly Life Program (HELP) on preventing delirium in elderly patients with SAP. METHODS A total of 106 patients with SAP aged 70 years or older were randomly divided into an experimental group (53 cases) and a control group (53 cases). The experimental group was given 2 weeks of conventional nursing combined with the HELP regimen, while the control group was given 2 weeks of conventional nursing. Conventional nursing included disease care, geriatric syndrome care and observation of critically ill patients. The incidence of delirium, severity of delirium, self-care ability, cognitive function, length of hospital stay, and patient satisfaction were compared between the 2 groups before and after the intervention. RESULTS The incidence of delirium was 4.00% in the experimental group and 16.98% in the control group; the difference was statistically significant (P=0.033). After 2 weeks of intervention, the experimental group showed significantly better self-care ability and cognitive function, shorter hospital stay, and greater patient satisfaction than the control group (all P<0.05). CONCLUSIONS The improved HELP protocol for elderly patients with SAP can reduce the incidence and severity of delirium, improve self-care ability and cognitive function, shorten hospital stay, and increase patient satisfaction.",2020,"After 2 weeks of intervention, the experimental group showed significantly better self-care ability and cognitive function, shorter hospital stay, and greater patient satisfaction than the control group (all P<0.05). ","['patients with severe acute pancreatitis', '106 patients with SAP aged 70 years or older', 'critically ill patients', 'elderly patients with SAP']","['conventional nursing combined with the HELP regimen', 'Hospital Elderly Life Program (HELP', 'multidisciplinary comprehensive intervention model']","['better self-care ability and cognitive function, shorter hospital stay, and greater patient satisfaction', 'incidence of delirium, severity of delirium, self-care ability, cognitive function, length of hospital stay, and patient satisfaction', 'incidence of delirium', 'mortality', 'incidence and severity of delirium, improve self-care ability and cognitive function, shorten hospital stay, and increase patient satisfaction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0001339', 'cui_str': 'Acute pancreatitis'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0562734', 'cui_str': 'Ability to perform personal care activity'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",106.0,0.0291091,"After 2 weeks of intervention, the experimental group showed significantly better self-care ability and cognitive function, shorter hospital stay, and greater patient satisfaction than the control group (all P<0.05). ","[{'ForeName': 'Zhixia', 'Initials': 'Z', 'LastName': 'Dong', 'Affiliation': 'Department of Gastroenterology, the Affiliated Hospital of Jiangnan University, Wuxi, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Song', 'Affiliation': 'Department of Gastroenterology, the Affiliated Hospital of Jiangnan University, Wuxi, China.'}, {'ForeName': 'Minhua', 'Initials': 'M', 'LastName': 'Ge', 'Affiliation': 'Department of Gastroenterology, the Affiliated Hospital of Jiangnan University, Wuxi, China.'}, {'ForeName': 'Chunyan', 'Initials': 'C', 'LastName': 'Lin', 'Affiliation': 'Department of Gastroenterology, the Affiliated Hospital of Jiangnan University, Wuxi, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Hepatobiliary, the Affiliated Hospital of Jiangnan University, Wuxi, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Hepatobiliary, the Affiliated Hospital of Jiangnan University, Wuxi, China.'}, {'ForeName': 'Yanmin', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Department of Gastroenterology, the Affiliated Hospital of Jiangnan University, Wuxi, China. 396285432@qq.com.'}]",Annals of palliative medicine,['10.21037/apm-20-913'] 1812,32692244,The appropriate dose of propofol for anesthesia induction in morbidly obese patients.,"BACKGROUND To investigate the optimal dose of propofol in patients with morbid obesity when the anesthetic induction dosage is calculated based on lean body weight (LBW). METHODS Forty morbid obese patients with body mass index (BMI) ≥35 kg/m2 were randomly divided into two groups: B and M. The sequential method was used in group B to study the EC50 and 95% confidence interval (CI) that met a bispectral index (BIS) value of <50 (the initial dose was set at 2.5 mg/kg). The sequential method was used in group M to obtain the EC50 and 95% CI (the initial dose was set as 3.0 mg/kg) satisfying the mean arterial pressure (MAP) fluctuation margin of >40%. The optimal dose interval of propofol was obtained by synthetically analyzing the results of the two-sequence method. RESULTS There was no significant difference in the general condition between the two groups (P>0.05). There was no significant change in vital signs from when patients entered the operating room to when sufentanil was infused (P>0.05). The probit model of group B was Y=-5.411+2.343X, the EC50 of positive reaction with BIS <50 was 2.310 mg/kg, and 95% CI was 1.850-2.883 mg/kg. The probit model in the M group was Y=3.275 - 0.918X, the EC50 of positive reaction that reached >40% of the whole process of anesthetic induction was 3.567 mg/kg, and 95% CI was 1.233-7.165 mg/kg. CONCLUSIONS The appropriate dosage of propofol was 2.310-3.567 mg/kg when the anesthetic induction dosage for patients with morbid obesity was calculated based on LBW. With this dose, the depth of intubation is satisfactory and the hemodynamics are stable.",2020,There was no significant difference in the general condition between the two groups (P>0.05).,"['morbidly obese patients', 'patients with morbid obesity', 'Forty morbid obese patients with body mass index']","['sufentanil', 'propofol']","['general condition', 'mean arterial pressure (MAP) fluctuation margin', 'bispectral index (BIS) value', 'vital signs']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028756', 'cui_str': 'Morbid obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0231239', 'cui_str': 'Fluctuation'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C1301882', 'cui_str': 'Bispectral index'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}]",40.0,0.023511,There was no significant difference in the general condition between the two groups (P>0.05).,"[{'ForeName': 'Guiping', 'Initials': 'G', 'LastName': 'Xu', 'Affiliation': ""Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China. xgpsyl@126.com.""}, {'ForeName': 'Nannan', 'Initials': 'N', 'LastName': 'Qiao', 'Affiliation': ""Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.""}, {'ForeName': 'Yangyang', 'Initials': 'Y', 'LastName': 'Pan', 'Affiliation': ""Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.""}, {'ForeName': 'Alimujiang', 'Initials': 'A', 'LastName': 'Simayi', 'Affiliation': ""Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.""}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Chen', 'Affiliation': ""Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.""}]",Annals of palliative medicine,['10.21037/apm-20-1223'] 1813,32692245,Clinical research of percutaneous spinal nerve posteromedial ramus destruction in treatment for chronic facet arthrogenic low back pain: a randomized trial.,"BACKGROUND To investigate the clinical effect of percutaneous spinal nerve posteromedial ramus destruction in treatment for chronic facet arthrogenic low back pain. METHODS A total of 118 patients with chronic facet arthrogenic low back pain were enrolled in our hospital from October 2015 to October 2018 and randomly divided into two groups. Of these patients, 59 received conservative treatment as the control group while 59 patients were treated with percutaneous spinal nerve posteromedial ramus destruction as the observation group. Pain score (Visual Analogue Scale, VAS), functional score (Oswestry Disability Index, ODI), treatment score (Japanese Orthopaedic Association, JOA), life quality score (Short Form 36-item Health Survey, SF-36), and lumbar mobility (range of motion, ROM) were evaluated before and after treatment. The treatment effect between two groups was compared. RESULTS The VAS score and ODI score at 2, 4, and 12 weeks after treatment and last follow-up in the observation group were lower than those of the control group (P<0.05). JOA score, SF-36, and ROM were higher than those of the control group (P<0.05). CONCLUSIONS Percutaneous spinal nerve posteromedial ramus destruction has a significant effect in treatment for chronic facet arthrogenic low back pain, which can relieve pain, improve function, and enhance quality of life.",2020,"JOA score, SF-36, and ROM were higher than those of the control group (P<0.05). ","['chronic facet arthrogenic low back pain', '118 patients with chronic facet arthrogenic low back pain were enrolled in our hospital from October 2015 to October 2018 and randomly divided into two groups']","['percutaneous spinal nerve posteromedial ramus destruction as the observation group', 'percutaneous spinal nerve posteromedial ramus destruction']","['Pain score (Visual Analogue Scale, VAS), functional score (Oswestry Disability Index, ODI), treatment score (Japanese Orthopaedic Association, JOA), life quality score (Short Form 36-item Health Survey, SF-36), and lumbar mobility (range of motion, ROM', 'VAS score and ODI score', 'JOA score, SF-36, and ROM']","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0222679', 'cui_str': 'Structure of articular surface of bone'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0037941', 'cui_str': 'Spinal nerve structure'}, {'cui': 'C1261381', 'cui_str': 'Destructive procedure'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0948106', 'cui_str': 'Amniorrhexis'}]",118.0,0.0287034,"JOA score, SF-36, and ROM were higher than those of the control group (P<0.05). ","[{'ForeName': 'Shuang', 'Initials': 'S', 'LastName': 'Feng', 'Affiliation': 'The 908th Hospital of Chinese PLA, Nanchang, China.'}, {'ForeName': 'Qiujin', 'Initials': 'Q', 'LastName': 'Xiao', 'Affiliation': 'The 908th Hospital of Chinese PLA, Nanchang, China.'}, {'ForeName': 'Yinchu', 'Initials': 'Y', 'LastName': 'Shao', 'Affiliation': 'The 908th Hospital of Chinese PLA, Nanchang, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'The 908th Hospital of Chinese PLA, Nanchang, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Yu', 'Affiliation': 'The 908th Hospital of Chinese PLA, Nanchang, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Hu', 'Affiliation': 'The 908th Hospital of Chinese PLA, Nanchang, China.'}, {'ForeName': 'Guoyun', 'Initials': 'G', 'LastName': 'Bu', 'Affiliation': 'The 908th Hospital of Chinese PLA, Nanchang, China. 517730611@qq.com.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'The 908th Hospital of Chinese PLA, Nanchang, China. 47160843@qq.com.'}]",Annals of palliative medicine,['10.21037/apm-20-1374'] 1814,32697444,"Human Amniotic Membrane to treat macular holes that failed to close, Sulfur Hexafluoride endotamponade versus air endotamponade: a prospective comparative study.","PURPOSE To determinate the efficacy of the human amniotic membrane plugs with sulfur hexafluoride versus human amniotic membrane plug with air as endotamponade to treat macular holes that failed to close after vitrectomy plus internal limiting membrane peeling. We focused on multimodal imaging to evaluate pre-operative features and post-operative changes. MATERIALS AND METHODS Prospective interventional comparative study. Twenty eyes of 20 patients affected by macular hole that failed to close were divided into 2 groups: 10 eyes received an amniotic membrane plug with 20% sulfur hexafluoride tamponade and 10 eyes received an amniotic membrane plug with air tamponade. All eyes were studied using multimodal advanced diagnostic tools such as spectral domain optical coherence tomography, optical coherence tomography angiography, microperimetry and adaptive optics to investigate the post-operative results. RESULTS In both groups all macular holes were found successfully closed after 12-months. Mean pre-operative BCVA was 20/400 in the SF6-group and 20/250 in Air-group. Final mean BCVA was 20/63 in both groups. The superficial capillary plexus, studied using optical coherence tomography angiography, showed a statistically significant difference between the treated and the fellow eyes. Adaptive Optics images revealed the presence of a photoreceptor cell mosaic in the area of the amniotic membrane plug. CONCLUSION The human amniotic membrane combined with air endotamponade demonstrated its effectiveness to seal macular holes that failed to close after vitrectomy plus internal limiting membrane peeling. Advanced multimodal diagnostic imaging helped us to better understand the modifications associated with the use of the amniotic membrane in these cases.",2020,"The superficial capillary plexus, studied using optical coherence tomography angiography, showed a statistically significant difference between the treated and the fellow eyes.",['Twenty eyes of 20 patients affected by macular hole that failed to close were divided into 2 groups: 10 eyes received an'],"['amniotic membrane plug with 20% sulfur hexafluoride tamponade and 10 eyes received an amniotic membrane plug with air tamponade', 'sulfur hexafluoride versus human amniotic membrane plug with air as endotamponade', 'Sulfur Hexafluoride endotamponade versus air endotamponade']","['Mean pre-operative BCVA', 'Final mean BCVA']","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0522476', 'cui_str': 'Patient affected'}, {'cui': 'C0024441', 'cui_str': 'Macular hole'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0002630', 'cui_str': 'Structure of amnion'}, {'cui': 'C0182324', 'cui_str': 'Plug'}, {'cui': 'C0038779', 'cui_str': 'Sulfur Hexafluoride'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C2936394', 'cui_str': 'Endotamponade'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}]",20.0,0.0285286,"The superficial capillary plexus, studied using optical coherence tomography angiography, showed a statistically significant difference between the treated and the fellow eyes.","[{'ForeName': 'Tomaso', 'Initials': 'T', 'LastName': 'Caporossi', 'Affiliation': 'Department of NEUROFARBA, Ophthalmology, University of Florence, Careggi, Florence, Italy.'}, {'ForeName': 'Ruggero', 'Initials': 'R', 'LastName': 'Tartaro', 'Affiliation': 'Department of NEUROFARBA, Ophthalmology, University of Florence, Careggi, Florence, Italy.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Finocchio', 'Affiliation': 'Department of NEUROFARBA, Ophthalmology, University of Florence, Careggi, Florence, Italy.'}, {'ForeName': 'Bianca', 'Initials': 'B', 'LastName': 'Pacini', 'Affiliation': 'Department of NEUROFARBA, Ophthalmology, University of Florence, Careggi, Florence, Italy.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'De Angelis', 'Affiliation': 'Department of NEUROFARBA, Ophthalmology, University of Florence, Careggi, Florence, Italy.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Bacherini', 'Affiliation': 'Department of NEUROFARBA, Ophthalmology, University of Florence, Careggi, Florence, Italy.'}, {'ForeName': 'Stanislao', 'Initials': 'S', 'LastName': 'Rizzo', 'Affiliation': ""Department of Ophthalmology, Catholic University of Sacred Hearth-Foundation 'Policlinico Universitario A. Gemelli'-IRCCS, Rome, Italy.""}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000002913'] 1815,32699176,"Effects of food supplementation on cognitive function, cerebral blood flow, and nutritional status in young children at risk of undernutrition: randomized controlled trial.","OBJECTIVE To assess the effects of food supplementation on improving working memory and additional measures including cerebral blood flow in children at risk of undernutrition. DESIGN Randomized controlled trial. SETTING 10 villages in Guinea-Bissau. PARTICIPANTS 1059 children aged 15 months to 7 years; children younger than 4 were the primary population. INTERVENTIONS Supervised isocaloric servings (≈1300 kJ, five mornings each week, 23 weeks) of a new food supplement (NEWSUP, high in plant polyphenols and omega 3 fatty acids, within a wide variety and high fortification of micronutrients, and a high protein content), or a fortified blended food (FBF) used in nutrition programs, or a control meal (traditional rice breakfast). MAIN OUTCOME MEASUREMENTS The primary outcome was working memory, a core executive function predicting long term academic achievement. Additional outcomes were hemoglobin concentration, growth, body composition, and index of cerebral blood flow (CBF i ). In addition to an intention-to-treat analysis, a predefined per protocol analysis was conducted in children who consumed at least 75% of the supplement (820/925, 89%). The primary outcome was assessed by a multivariable Poisson model; other outcomes were assessed by multivariable linear mixed models. RESULTS Among children younger than 4, randomization to NEWSUP increased working memory compared with the control meal (rate ratio 1.20, 95% confidence interval 1.02 to 1.41, P=0.03), with a larger effect in the per protocol population (1.25, 1.06 to 1.47, P=0.009). NEWSUP also increased hemoglobin concentration among children with anemia (adjusted mean difference 0.65 g/dL, 95% confidence interval 0.23 to 1.07, P=0.003) compared with the control meal, decreased body mass index z score gain (-0.23, -0.43 to -0.02, P=0.03), and increased lean tissue accretion (2.98 cm 2 , 0.04 to 5.92, P=0.046) with less fat (-5.82 cm 2 , -11.28 to -0.36, P=0.04) compared with FBF. Additionally, NEWSUP increased CBF i compared with the control meal and FBF in both age groups combined (1.14 mm 2 /s×10 -8 , 0.10 to 2.23, P=0.04 for both comparisons). Among children aged 4 and older, NEWSUP had no significant effect on working memory or anemia, but increased lean tissue compared with FBF (4.31 cm 2 , 0.34 to 8.28, P=0.03). CONCLUSIONS Childhood undernutrition is associated with long term impairment in cognition. Contrary to current understanding, supplementary feeding for 23 weeks could improve executive function, brain health, and nutritional status in vulnerable young children living in low income countries. Further research is needed to optimize nutritional prescriptions for regenerative improvements in cognitive function, and to test effectiveness in other vulnerable groups. TRIAL REGISTRATION ClinicalTrials.gov NCT03017209.",2020,"Among children aged 4 and older, NEWSUP had no significant effect on working memory or anemia, but increased lean tissue compared with FBF (4.31 cm 2 , 0.34 to 8.28, P=0.03). ","['10 villages in Guinea-Bissau', 'young children at risk of undernutrition', 'children at risk of undernutrition', '1059 children aged 15 months to 7 years; children younger than 4 were the primary population']","['NEWSUP', 'food supplementation', 'Supervised isocaloric servings', 'new food supplement (NEWSUP, high in plant polyphenols and omega 3 fatty acids, within a wide variety and high fortification of micronutrients, and a high protein content), or a fortified blended food (FBF) used in nutrition programs, or a control meal (traditional rice breakfast']","['working memory, a core executive function predicting long term academic achievement', 'hemoglobin concentration', 'lean tissue accretion', 'working memory', 'hemoglobin concentration, growth, body composition, and index of cerebral blood flow (CBF i ', 'cerebral blood flow', 'body mass index z score gain', 'CBF', 'executive function, brain health, and nutritional status', 'lean tissue', 'cognitive function, cerebral blood flow, and nutritional status', 'working memory or anemia']","[{'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0018387', 'cui_str': 'Guinea-Bissau'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C0425119', 'cui_str': 'Child at risk'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0032098', 'cui_str': 'Kingdom Viridiplantae'}, {'cui': 'C0071649', 'cui_str': 'Polyphenol'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0040577', 'cui_str': 'Trace element'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0453850', 'cui_str': 'Liquidized food'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0035567', 'cui_str': 'Rice'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}]","[{'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0013658', 'cui_str': 'Educational achievement'}, {'cui': 'C1318517', 'cui_str': 'Hemoglobin concentration, dipstick - finding'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0333038', 'cui_str': 'Accretion'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}]",1059.0,0.234524,"Among children aged 4 and older, NEWSUP had no significant effect on working memory or anemia, but increased lean tissue compared with FBF (4.31 cm 2 , 0.34 to 8.28, P=0.03). ","[{'ForeName': 'Susan B', 'Initials': 'SB', 'LastName': 'Roberts', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA susan.roberts@tufts.edu.'}, {'ForeName': 'Maria A', 'Initials': 'MA', 'LastName': 'Franceschini', 'Affiliation': 'Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA.'}, {'ForeName': 'Rachel E', 'Initials': 'RE', 'LastName': 'Silver', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Salima F', 'Initials': 'SF', 'LastName': 'Taylor', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Augusto Braima', 'Initials': 'AB', 'LastName': 'de Sa', 'Affiliation': 'International Partnership for Human Development, Leesburg, VA, USA and Bissau, Guinea Bissau.'}, {'ForeName': 'Raimundo', 'Initials': 'R', 'LastName': 'Có', 'Affiliation': 'International Partnership for Human Development, Leesburg, VA, USA and Bissau, Guinea Bissau.'}, {'ForeName': 'Aliu', 'Initials': 'A', 'LastName': 'Sonco', 'Affiliation': 'International Partnership for Human Development, Leesburg, VA, USA and Bissau, Guinea Bissau.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Krauss', 'Affiliation': 'Peeled Snacks, Cumberland, RI, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Taetzsch', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Webb', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Sai Krupa', 'Initials': 'SK', 'LastName': 'Das', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'C-Y', 'Initials': 'CY', 'LastName': 'Chen', 'Affiliation': 'Biofortis, Mérieux NutriSciences, Addison, IL, USA.'}, {'ForeName': 'Beatrice L', 'Initials': 'BL', 'LastName': 'Rogers', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Saltzman', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Pei-Yi', 'Initials': 'PY', 'LastName': 'Lin', 'Affiliation': 'Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Schlossman', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Pruzensky', 'Affiliation': 'International Partnership for Human Development, Leesburg, VA, USA and Bissau, Guinea Bissau.'}, {'ForeName': 'Carlito', 'Initials': 'C', 'LastName': 'Balé', 'Affiliation': 'International Partnership for Human Development, Leesburg, VA, USA and Bissau, Guinea Bissau.'}, {'ForeName': 'Kenneth Kwan Ho', 'Initials': 'KKH', 'LastName': 'Chui', 'Affiliation': 'Department of Public Health and Community Medicine, Tufts School of Medicine, Boston, MA, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Muentener', 'Affiliation': 'Department of Psychology, Tufts University, Medford, MA, USA.'}]",BMJ (Clinical research ed.),['10.1136/bmj.m2397'] 1816,32700364,Interventions commonly available during pandemics for heavy menstrual bleeding: an overview of Cochrane Reviews.,"BACKGROUND Within the context of heavy menstrual bleeding, pandemics impact upon women's assessment and treatment by healthcare providers. OBJECTIVES To summarise the evidence from Cochrane Reviews evaluating interventions for heavy menstrual bleeding that are commonly available during pandemics. METHODS We sought published Cochrane Reviews, evaluating interventions that can continue during pandemics for women with heavy menstrual bleeding with no known underlying cause. We identified Cochrane Reviews by searching the Cochrane Database of Systematic Reviews in June 2020. The primary outcome was menstrual bleeding. Secondary outcomes included quality of life, patient satisfaction, side effects, and serious adverse events. We undertook the selection of systematic reviews, data extraction, and quality assessment in duplicate. We resolved any disagreements by discussion. We assessed review quality using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR) 2 tool, and the certainty of the evidence for each outcome using GRADE methods. MAIN RESULTS We included four Cochrane Reviews, with 11 comparisons, data from 44 randomised controlled trials (RCTs), and 3196 women. We assessed all the reviews to be high quality. Non-steroidal anti-inflammatory drugs (NSAIDs) NSAIDs may be more effective in reducing heavy menstrual bleeding than placebo (mean difference (MD) -124 mL per cycle, 95% confidence interval (CI) -186 to -62 mL per cycle; 1 RCT, 11 women; low-certainty evidence). Mefenamic acid may be similar to naproxen (MD 21 mL per cycle, 95% CI -6 to 48 mL per cycle; 2 RCTs, 61 women; low-certainty evidence), and NSAIDs may be similar to combined hormonal contraceptives for heavy menstrual bleeding (MD 25 mL per cycle, 95% CI -22 to 73 mL per cycle; 1 RCT, 26 women; low-certainty evidence). NSAIDs may be be less effective in reducing menstrual bleeding than antifibrinolytics (relative risk (RR) 0.70, 95% CI 0.58 to 0.85; 2 RCTs, 161 women; low-certainty evidence). We are uncertain whether NSAIDs reduce menstrual blood loss more than short-cycle progestogens (RR 0.80, 95% CI 0.49 to 1.32; 1 RCT 32 women; very low-certainty evidence). Antifibrinolytics Antifibrinolytics appear to be more effective in reducing heavy menstrual bleeding than placebo (MD -53 mL per cycle, 95% CI -63 to -44 mL per cycle; 4 RCTs, 565 women; moderate-certainty evidence). Antifibrinolytics may be similar to placebo on the incidence of side effects (RR 1.05, 95% CI 0.93 to 1.18; 1 RCT, 297 women; low-certainty evidence), and they are probably similar on the incidence of serious adverse events (thrombotic events; RR 0.10, 95% CI 0.00 to 2.46; 2 RCT, 468 women; moderate-certainty evidence). Antifibrinolytics may be more effective in reducing heavy menstrual bleeding than short-cycle progestogen (MD -111 mL per cycle, 95% CI -178 mL to -44 mL per cycle; 1 RCT, 46 women; low-certainty evidence). We are uncertain whether antifibrinolytics are similar to short-cycle progestogens on quality of life (RR 1.67, 95% CI 0.76 to 3.64; 1 RCT, 44 women; very low-certainty evidence), patient satisfaction (RR 0.91, 95% CI 0.59 to 1.39; 1 RCT, 42 women; very low-certainty evidence), or side effects (RR 0.85, 95% CI 0.65 to 1.12; 3 RCTs, 211 women; very low-certainty evidence). We are uncertain whether antifibrinolytics are more effective in reducing heavy menstrual bleeding when compared with long-cycle progestogen (MD -9 points per cycle, 95% CI -30 to 12 points per cycle; 2 RCTs, 184 women; low-certainty evidence). Antifibrinolytics may increase self-reported improvement in menstrual bleeding when compared with long-cycle medroxyprogesterone acetate (RR 1.32, 95% CI 1.08 to 1.61; 1 RCT, 94 women; low-certainty evidence). Antifibrinolytics may be similar to long-cycle progestogens on quality of life (MD 5, 95% CI -2.49 to 12.49; 1 RCT, 90 women; low-certainty evidence). We are uncertain whether antifibrinolytics are similar to long-cycle progestogens on side effects (RR 0.58, 95% CI 0.33 to 1.00; 2 RCTs, 184 women; very low-certainty evidence). There were no trials comparing antifibrinolytics to combined hormonal contraceptives. Combined hormonal contraceptives Combined hormonal contraceptives appear to be more effective for heavy menstrual bleeding than placebo or no treatment (RR 13.25, 95% CI 2.94 to 59.64; 2 RCTs, 363 women; moderate-certainty evidence). Combined hormonal contraceptives are probably similar to placebo on the incidence of side effects (RR 1.53, 95% CI 0.90 to 2.60; 2 RCTs, 411 women; moderate-certainty evidence). Progestogens There were no trials comparing progestogens to placebo. Limitations in the evidence included risk of bias in the primary RCTs, inconsistency between the primary RCTs, and imprecision in effect estimates. AUTHORS' CONCLUSIONS There is moderate-certainty evidence that antifibrinolytics and combined hormonal contraceptives reduce heavy menstrual bleeding compared with placebo. There is low-certainty evidence that NSAIDs reduce heavy menstrual bleeding compared with placebo. There is low-certainty evidence that antifibrinolytics are more effective in reducing heavy menstrual bleeding when compared with NSAIDs and short-cycle progestogens, but we are unable to draw conclusions about the effects of antifibrinolytics compared to long-cycle progestogens, on low-certainty evidence.",2020,"Combined hormonal contraceptives are probably similar to placebo on the incidence of side effects (RR 1.53, 95% CI 0.90 to 2.60; 2 RCTs, 411 women; moderate-certainty evidence).","['heavy menstrual bleeding', 'women with heavy menstrual bleeding with no known underlying cause', '3196 women']","['Progestogens', 'Mefenamic acid', 'medroxyprogesterone acetate', 'placebo']","['quality of life', 'quality of life, patient satisfaction, side effects, and serious adverse events', 'heavy menstrual bleeding', 'menstrual blood loss', 'menstrual bleeding', 'patient satisfaction', 'side effects']","[{'cui': 'C0025323', 'cui_str': 'Menorrhagia'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205309', 'cui_str': 'Known'}]","[{'cui': 'C0033306', 'cui_str': 'Progestational hormone'}, {'cui': 'C0025152', 'cui_str': 'mefenamic acid'}, {'cui': 'C0065864', 'cui_str': 'Medroxyprogesterone acetate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0025323', 'cui_str': 'Menorrhagia'}, {'cui': 'C0694689', 'cui_str': 'Menstrual blood'}, {'cui': 'C0025344', 'cui_str': 'Menstruation'}]",4.0,0.562988,"Combined hormonal contraceptives are probably similar to placebo on the incidence of side effects (RR 1.53, 95% CI 0.90 to 2.60; 2 RCTs, 411 women; moderate-certainty evidence).","[{'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Bofill Rodriguez', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Lethaby', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Farquhar', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'James Mn', 'Initials': 'JM', 'LastName': 'Duffy', 'Affiliation': ""King's Fertility, Fetal Medicine Research Institute, London, UK.""}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD013651.pub2'] 1817,32697858,Topical application of autophagy-activating peptide improved skin barrier function and reduced acne symptoms in acne-prone skin.,"BACKGROUND Recent studies about the important roles of autophagy signaling in sebaceous lipogenesis and epidermal differentiation suggest potential benefits of autophagy activation in acne. AIMS To investigate the effects of an autophagy activator on acne-prone skin. METHODS Autophagy signaling in human immortalized SZ95 sebocytes, normal human epidermal keratinocytes, and 3D reconstituted skin was examined. Effects of an autophagy-activating peptide on sebaceous lipogenesis were measured by fluorescence microscopic analysis. The clinical efficacy in acne-prone skin was evaluated through an eight-week, double-blind, randomized, vehicle-controlled study. Changes in skin surface lipid compositions were further analyzed. RESULTS In cultured sebocytes and keratinocytes, the investigated autophagy-activating peptide increased LC3-II expression, indicating a stimulation of autophagy signaling. Testosterone and linoleic acid treatment induced lipogenesis in cultured sebocytes and is further inhibited by the autophagy activator peptide treatment. Increased expression of differentiation marker proteins in cultured keratinocytes was also observed by autophagy-activating peptide. In clinical study, reduction of closed comedones and the amount of skin surface lipids as well as of trans-epidermal water loss (TEWL) were observed in acne-prone skin after autophagy-activating peptide application. In addition, reduction of squalene and increase in cholesterol were observed after an 8-week application. CONCLUSIONS Topical application of an autophagy activator downregulated sebaceous lipogenesis and improved the skin barrier function. Considering the important roles of sebum and skin barrier function in acne pathogenesis, autophagy activation might represent a new therapeutic option in early forms of acne.",2020,"In cultured sebocytes and keratinocytes, the investigated autophagy-activating peptide increased LC3-II expression, indicating a stimulation of autophagy signaling.",['acne-prone skin'],"['autophagy-activating peptide', 'autophagy activator', 'Testosterone and linoleic acid']","['reduction of squalene and increase of cholesterol', 'Increased expression of differentiation marker proteins', 'skin barrier function', 'sebaceous lipogenesis']","[{'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C0033422', 'cui_str': 'Prone body position'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}]","[{'cui': 'C0004391', 'cui_str': 'Autophagocytosis'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0023749', 'cui_str': 'Linoleic acid'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0038071', 'cui_str': 'Squalene'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0007589', 'cui_str': 'Differentiation, Cell'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0596843', 'cui_str': 'Adipogenesis'}]",,0.0186451,"In cultured sebocytes and keratinocytes, the investigated autophagy-activating peptide increased LC3-II expression, indicating a stimulation of autophagy signaling.","[{'ForeName': 'Yoonjin', 'Initials': 'Y', 'LastName': 'Lee', 'Affiliation': 'College of Life Science and Biotechnology, Korea University, Seoul, South Korea.'}, {'ForeName': 'Kayoung', 'Initials': 'K', 'LastName': 'Shin', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, South Korea.'}, {'ForeName': 'Kyong-Oh', 'Initials': 'KO', 'LastName': 'Shin', 'Affiliation': 'Department of Food Science and Nutrition, Hallym University, Chuncheon, South Korea.'}, {'ForeName': 'Seokjeong', 'Initials': 'S', 'LastName': 'Yoon', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, South Korea.'}, {'ForeName': 'Juyeon', 'Initials': 'J', 'LastName': 'Jung', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, South Korea.'}, {'ForeName': 'Eojin', 'Initials': 'E', 'LastName': 'Hwang', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, South Korea.'}, {'ForeName': 'Hwa-Jee', 'Initials': 'HJ', 'LastName': 'Chung', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, South Korea.'}, {'ForeName': 'Amir M', 'Initials': 'AM', 'LastName': 'Hossini', 'Affiliation': 'Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany.'}, {'ForeName': 'Christos C', 'Initials': 'CC', 'LastName': 'Zouboulis', 'Affiliation': 'Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany.'}, {'ForeName': 'Min Jeong', 'Initials': 'MJ', 'LastName': 'Baek', 'Affiliation': 'Dermapro Skin Research Center, DERMAPRO Ltd., Seoul, South Korea.'}, {'ForeName': 'Ji Hwoon', 'Initials': 'JH', 'LastName': 'Baek', 'Affiliation': 'Dermapro Skin Research Center, DERMAPRO Ltd., Seoul, South Korea.'}, {'ForeName': 'Young Min', 'Initials': 'YM', 'LastName': 'Chi', 'Affiliation': 'College of Life Science and Biotechnology, Korea University, Seoul, South Korea.'}, {'ForeName': 'Sangeun', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'Department of Dermatology, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea.'}, {'ForeName': 'Sekyoo', 'Initials': 'S', 'LastName': 'Jeong', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, South Korea.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13636'] 1818,32702783,Aspirin (single dose) for perineal pain in the early postpartum period.,"BACKGROUND Perineal trauma, due to spontaneous tears, surgical incision (episiotomy), or in association with operative vaginal birth, is common after vaginal birth, and is often associated with postpartum perineal pain. Birth over an intact perineum may also lead to perineal pain. There are adverse health consequences associated with perineal pain for the women and their babies in the short- and long-term, and the pain may interfere with newborn care and the establishment of breastfeeding. Aspirin has been used in the management of postpartum perineal pain, and its effectiveness and safety should be assessed. This is an update of the review, last published in 2017. OBJECTIVES To determine the effects of a single dose of aspirin (acetylsalicylic acid), including at different doses, in the relief of acute postpartum perineal pain. SEARCH METHODS For this update, we searched the Cochrane Pregnancy and Childbirth's Trials Register (4 October 2019), ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (4 October 2019) and screened reference lists of retrieved studies. SELECTION CRITERIA Randomised controlled trials (RCTs), assessing single dose aspirin compared with placebo, no treatment, a different dose of aspirin, or single dose paracetamol or acetaminophen, for women with perineal pain in the early postpartum period. We planned to include cluster-RCTs, but none were identified. We excluded quasi-RCTs and cross-over studies. DATA COLLECTION AND ANALYSIS Two review authors independently assessed study eligibility, extracted data and assessed the risk of bias of the included RCTs. Data were checked for accuracy. The certainty of the evidence for the main comparison (aspirin versus placebo) was assessed using the GRADE approach. MAIN RESULTS We included 17 RCTs, 16 of which randomised 1132 women to aspirin or placebo; one RCT did not report numbers of women. Two RCTs (of 16) did not contribute data to meta-analyses. All women had perineal pain post-episiotomy, and were not breastfeeding. Studies were published between 1967 and 1997, and the risk of bias was often unclear, due to poor reporting. We included four comparisons: aspirin versus placebo (15 RCTs); 300 mg versus 600 mg aspirin (1 RCT); 600 mg versus 1200 mg aspirin (2 RCTs); and 300 mg versus 1200 mg aspirin (1 RCT). Aspirin versus placebo Aspirin may result in more women reporting adequate pain relief four to eight hours after administration compared with placebo (risk ratio (RR) 2.03, 95% confidence interval (CI) 1.69 to 2.42; 13 RCTs, 1001 women; low-certainty evidence). It is uncertain whether aspirin compared with placebo has an effect on the need for additional pain relief (RR 0.25, 95% CI 0.17 to 0.37; 10 RCTs, 744 women; very low-certainty evidence), or maternal adverse effects (RR 1.08, 95% CI 0.57 to 2.06; 14 RCTs, 1067 women; very low-certainty evidence), four to eight hours after administration. Analyses based on dose did not reveal any clear subgroup differences. 300 mg versus 600 mg aspirin It is uncertain whether over four hours after administration, 300 mg compared with 600 mg aspirin has an effect on adequate pain relief (RR 0.82, 95% CI 0.36 to 1.86; 1 RCT, 81 women) or the need for additional pain relief (RR 0.68, 95% CI 0.12 to 3.88; 1 RCT, 81 women). There were no maternal adverse effects in either aspirin group. 600 mg versus 1200 mg aspirin It is uncertain whether over four to eight hours after administration, 600 mg compared with 1200 mg aspirin has an effect on adequate pain relief (RR 0.85, 95% CI 0.52 to 1.39; 2 RCTs, 121 women), the need for additional pain relief (RR 1.32, 95% CI 0.30 to 5.68; 2 RCTs, 121 women), or maternal adverse effects (RR 3.00, 95% CI 0.13 to 69.52; 2 RCTs, 121 women). 300 mg versus 1200 mg aspirin It is uncertain whether over four hours after administration, 300 mg compared with 1200 mg aspirin has an effect on adequate pain relief (RR 0.62, 95% CI 0.29 to 1.32; 1 RCT, 80 women) or need for additional pain relief (RR 2.00, 95% CI 0.19 to 21.18; 1 RCT, 80 women). There were no maternal adverse effects in either aspirin group. None of the included RCTs reported on neonatal adverse effects. No RCTs reported on secondary review outcomes of: prolonged hospitalisation due to perineal pain; re-hospitalisation due to perineal pain; fully breastfeeding at discharge; mixed feeding at discharge; fully breastfeeding at six weeks; mixed feeding at six weeks; perineal pain at six weeks; maternal views; or maternal postpartum depression. AUTHORS' CONCLUSIONS Single dose aspirin may increase adequate pain relief in women with perineal pain post-episiotomy compared with placebo. It is uncertain whether aspirin has an effect on the need for additional analgesia, or on maternal adverse effects, compared with placebo. We downgraded the certainty of the evidence because of study limitations (risk of bias), imprecision, and publication bias. Aspirin may be considered for use in non-breastfeeding women with post-episiotomy perineal pain. Included RCTs excluded breastfeeding women, so there was no evidence to assess the effects of aspirin on neonatal adverse effects or breastfeeding. Future RCTs should be designed to ensure low risk of bias, and address gaps in the evidence, such as the secondary outcomes established for this review. Current research has focused on women with post-episiotomy pain; future RCTs could be extended to include women with perineal pain associated with spontaneous tears or operative birth.",2020,"It is uncertain whether aspirin compared with placebo has an effect on the need for additional pain relief (RR 0.25, 95% CI 0.17 to 0.37; 10 RCTs, 744 women; very low-certainty evidence), or maternal adverse effects (RR 1.08, 95% CI 0.57 to 2.06; 14 RCTs, 1067 women; very low-certainty evidence), four to eight hours after administration.","['non-breastfeeding women with post-episiotomy perineal pain', 'women with perineal pain in the early postpartum period', '17 RCTs, 16 of which randomised 1132 women to', 'women with post-episiotomy pain', 'women with perineal pain post-episiotomy']","['aspirin or placebo', 'aspirin versus placebo', 'RCT', 'placebo Aspirin', 'aspirin, or single dose paracetamol or acetaminophen', 'Aspirin', 'aspirin', 'aspirin (acetylsalicylic acid', 'placebo']","['maternal adverse effects', 'prolonged hospitalisation due to perineal pain; re-hospitalisation due to perineal pain; fully breastfeeding at discharge; mixed feeding at discharge; fully breastfeeding at six weeks; mixed feeding at six weeks; perineal pain at six weeks; maternal views; or maternal postpartum depression', 'pain relief', 'neonatal adverse effects', 'additional pain relief', 'adequate pain relief', 'perineal pain']","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0014586', 'cui_str': 'Episiotomy'}, {'cui': 'C0235641', 'cui_str': 'Pain in female perineum'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0406846', 'cui_str': 'Post-episiotomy pain'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0235641', 'cui_str': 'Pain in female perineum'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C3871203', 'cui_str': 'At discharge'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0221074', 'cui_str': 'Postpartum depression'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0549411', 'cui_str': 'Neonatal adverse effect'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}]",,0.696765,"It is uncertain whether aspirin compared with placebo has an effect on the need for additional pain relief (RR 0.25, 95% CI 0.17 to 0.37; 10 RCTs, 744 women; very low-certainty evidence), or maternal adverse effects (RR 1.08, 95% CI 0.57 to 2.06; 14 RCTs, 1067 women; very low-certainty evidence), four to eight hours after administration.","[{'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Shepherd', 'Affiliation': 'Robinson Research Institute, Discipline of Obstetrics and Gynaecology, Adelaide Medical School, The University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Rosalie M', 'Initials': 'RM', 'LastName': 'Grivell', 'Affiliation': 'Department of Obstetrics and Gynaecology, Flinders University and Flinders Medical Centre, Bedford Park, Australia.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD012129.pub3'] 1819,32702837,Effects of Sihogayonggolmoryeo-tang (Saikokaryukotsuboreito or Chai-Hu-Jia-Long-Gu-Mu-Li-Tang) for insomnia disorder with prehypertension or stage 1 hypertension: A study protocol for a randomized controlled trial.,"BACKGROUND Insomnia and hypertension are diseases with a high prevalence and a known association with each other. Sihogayonggolmoryeo-tang (SYM) is an herbal medicine traditionally used for the treatment of insomnia disorder concurrent with hypertension. However, no scientific clinical evidence exists supporting the effects of SYM on these disorders. This study aims to explore the feasibility, effectiveness, and safety of SYM for the treatment of insomnia disorder with concurrent prehypertension or stage 1 hypertension. METHODS A prospective, randomized, wait-list controlled, parallel, pilot clinical trial has been designed for a study to be conducted in Daejeon, Republic of Korea. Thirty insomnia disorder patients with prehypertension or stage 1 hypertension will be randomly assigned to a SYM or wait-list group at a 1:1 ratio. The SYM group will be administered SYM granules twice a day for 4 weeks and followed-up for 2 weeks while the wait-list group will not receive SYM granules. All participants in both groups will be given brochures with instructions for maintaining sleep hygiene and lifestyle modifications to reduce hypertension. Data will be collected at baseline and at 2, 4, and 6 weeks after allocation. The primary outcome is the Insomnia Severity Index score at 4 weeks post-treatment. The secondary outcomes will consist of the Pittsburgh Sleep Quality Index, sleep diary, systolic and diastolic blood pressure, brachial-ankle pulse wave velocity, ankle-brachial index, atherosclerosis biomarkers, the Hospital Anxiety and Depression Scale, the 5-level EuroQol-5 dimensions, and the Patient Global Impression of Change. Adverse events and laboratory test results will be monitored to assess the safety. Data will be recorded in electronic case report forms and analyzed using SPSS Statistics, Version 24.0. DISCUSSION This is the first clinical trial to explore the effectiveness and safety of SYM for the treatment of insomnia disorder concurrent with prehypertension or stage 1 hypertension. The results of this study can form the foundation for a future multicenter, large-scale, confirmatory clinical trial. TRIAL REGISTRATION Clinical Research Information Service, KCT0005001 (registered on May 8, 2020).",2020,Thirty insomnia disorder patients with prehypertension or stage 1 hypertension will be randomly assigned to a SYM or wait-list group at a 1:1 ratio.,"['insomnia disorder with concurrent prehypertension or stage 1 hypertension', 'insomnia disorder concurrent with prehypertension or stage 1 hypertension', 'Thirty insomnia disorder patients with prehypertension or stage 1 hypertension', 'insomnia disorder with prehypertension or stage 1 hypertension', 'Daejeon, Republic of Korea', 'insomnia disorder concurrent with hypertension']","['SYM', 'Sihogayonggolmoryeo-tang (Saikokaryukotsuboreito or Chai-Hu-Jia-Long-Gu-Mu-Li-Tang', 'Sihogayonggolmoryeo-tang (SYM']","['Insomnia Severity Index score', 'Pittsburgh Sleep Quality Index, sleep diary, systolic and diastolic blood pressure, brachial-ankle pulse wave velocity, ankle-brachial index, atherosclerosis biomarkers, the Hospital Anxiety and Depression Scale, the 5-level EuroQol-5 dimensions, and the Patient Global Impression of Change']","[{'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C1696708', 'cui_str': 'Prehypertension'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}]","[{'cui': 'C0381095', 'cui_str': 'saiko-ka-ryukotsu-borei-to'}, {'cui': 'C0164665', 'cui_str': 'Bupleurum root extract'}, {'cui': 'C3495559', 'cui_str': 'Juvenile chronic arthritis'}, {'cui': 'C0205166', 'cui_str': 'Long'}]","[{'cui': 'C4706228', 'cui_str': 'ISI (Insomnia Severity Index) score'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0232154', 'cui_str': 'Ankle pulse'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C1328319', 'cui_str': 'Ankle brachial pressure index'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0456951', 'cui_str': 'Level 5'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",,0.153707,Thirty insomnia disorder patients with prehypertension or stage 1 hypertension will be randomly assigned to a SYM or wait-list group at a 1:1 ratio.,"[{'ForeName': 'Boram', 'Initials': 'B', 'LastName': 'Lee', 'Affiliation': 'aClinical Medicine Division, Korea Institute of Oriental Medicine, Yuseong-gu, Daejeon bDepartment of Oriental Neuropsychiatry, Daejeon Korean Medicine Hospital of Daejeon University, Seo-gu, Daejeon, Republic of Korea.'}, {'ForeName': 'Yeong-Eun', 'Initials': 'YE', 'LastName': 'Jeong', 'Affiliation': ''}, {'ForeName': 'Hyo-Ju', 'Initials': 'HJ', 'LastName': 'Park', 'Affiliation': ''}, {'ForeName': 'Young-Eun', 'Initials': 'YE', 'LastName': 'Choi', 'Affiliation': ''}, {'ForeName': 'Hoseok', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Bo-Young', 'Initials': 'BY', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Changsop', 'Initials': 'C', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'In Chul', 'Initials': 'IC', 'LastName': 'Jung', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000020980'] 1820,32701597,Pharmacologic and psychological interventions for depression treatment in patients with kidney disease.,"PURPOSE OF REVIEW It remains controversial whether existing therapies, including pharmacologic and psychological interventions, are effective for treatment of depression in patients with chronic kidney disease (CKD) and end-stage kidney disease. RECENT FINDINGS Most studies of depression treatment were underpowered or uncontrolled. The CKD Antidepressant Sertraline Trial showed no benefit of a serotonin-selective reuptake inhibitor (SSRI), sertraline, over double-blind matched placebo for the treatment of depressive symptoms in patients with nondialysis CKD. A Trial of Sertraline vs. Cognitive Behavioral Therapy (CBT) for End-stage Renal Disease Patients with Depression showed improvement in depressive symptoms from baseline in both groups and a marginal benefit of sertraline over CBT that was of unclear clinical significance, given the lack of an active control group. SSRIs are associated with poor tolerability in clinical trials and serious adverse outcomes in large retrospective studies. SUMMARY Although the data do not support unlimited use of SSRIs in patients with CKD or end-stage kidney disease, it is reasonable to initiate a cautious trial of sertraline while closely monitoring for depressive symptom improvement and adverse effects. CBT is a low-risk, possibly effective intervention to treat major depressive disorder in patients with kidney disease who have access to such treatments.",2020,"The CKD Antidepressant Sertraline Trial showed no benefit of a serotonin-selective reuptake inhibitor (SSRI), sertraline, over double-blind matched placebo for the treatment of depressive symptoms in patients with nondialysis CKD.","['patients with kidney disease', 'patients with nondialysis CKD', 'patients with CKD or end-stage kidney disease', 'patients with kidney disease who have access to such treatments', 'patients with chronic kidney disease (CKD) and end-stage kidney disease']","['serotonin-selective reuptake inhibitor (SSRI), sertraline', 'CBT', 'Pharmacologic and psychological interventions', 'Sertraline vs. Cognitive Behavioral Therapy (CBT', 'placebo']",['depressive symptoms'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0074393', 'cui_str': 'Sertraline'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",,0.0565791,"The CKD Antidepressant Sertraline Trial showed no benefit of a serotonin-selective reuptake inhibitor (SSRI), sertraline, over double-blind matched placebo for the treatment of depressive symptoms in patients with nondialysis CKD.","[{'ForeName': 'L Parker', 'Initials': 'LP', 'LastName': 'Gregg', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center.'}, {'ForeName': 'S Susan', 'Initials': 'SS', 'LastName': 'Hedayati', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center.'}]",Current opinion in nephrology and hypertension,['10.1097/MNH.0000000000000629'] 1821,32708906,The Contrasting Effects of an Action Video Game on Visuo-Spatial Processing and Proactive Cognitive Control.,"First person shooter or action video games represent one of the most popular genres within the gaming industry. Studies reveal that action gaming experience leads to enhancements of visuo-spatial processing. In contrast, some correlational evidence reveals that experience with action video games may be associated with reduced proactive cognitive control. The two primary goals of the current study were to test the causal nature of the effect of action gaming on proactive cognitive control and to examine whether an increase in visuo-spatial processing and a decrease in proactive cognitive control arise from the same amount of experience playing an action video game. Participants completed tasks measuring visuo-spatial processing and cognitive control before and after 10 practice sessions involving one of three video games or were assigned to a no gaming experience control group. The data revealed the typical increase in visuo-spatial processing and a decrease in proactive, but not reactive, cognitive control following action game training. The sizes of these two training effects were similar in magnitude, but interpretation of the effects was constrained by baseline differences between the four groups of subjects. The possibility of a causal effect of action gaming on proactive cognitive control is interesting within the context of correlational evidence linking greater action gaming experience to reduced cognitive control, poor decision making, and increased impulsivity.",2020,Participants completed tasks measuring visuo-spatial processing and cognitive control before and after 10 practice sessions involving one of three video games or were assigned to a no gaming experience control group.,[],"['tasks measuring visuo-spatial processing and cognitive control before and after 10 practice sessions involving one of three video games or were assigned to a no gaming experience control group', 'action gaming', 'Action Video Game']","['visuo-spatial processing', 'proactive cognitive control', 'Visuo-Spatial Processing and Proactive Cognitive Control']",[],"[{'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C3850026', 'cui_str': 'Auditory Spatial Processing'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0042649', 'cui_str': 'Video Games'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0441472', 'cui_str': 'Action'}]","[{'cui': 'C3850026', 'cui_str': 'Auditory Spatial Processing'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",,0.0152109,Participants completed tasks measuring visuo-spatial processing and cognitive control before and after 10 practice sessions involving one of three video games or were assigned to a no gaming experience control group.,"[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'West', 'Affiliation': 'Department of Psychology and Neuroscience, DePauw University, Greencastle, IN 46135, USA.'}, {'ForeName': 'Edward L', 'Initials': 'EL', 'LastName': 'Swing', 'Affiliation': ""Phoenix Children's Hospital, Phoenix, AZ 85016, USA.""}, {'ForeName': 'Craig A', 'Initials': 'CA', 'LastName': 'Anderson', 'Affiliation': 'Department of Psychology, Iowa State University, Ames, IA 50010, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Prot', 'Affiliation': 'School of Psychological, Social, and Behavioral Sciences, Coventry University, Coventry CV1 5FB, UK.'}]",International journal of environmental research and public health,['10.3390/ijerph17145160'] 1822,32708973,Efficacy of a High-Iron Dietary Intervention in Women with Celiac Disease and Iron Deficiency without Anemia: A Clinical Trial.,"BACKGROUND AND AIM Iron deficiency without anemia (IDWA) is a common finding in celiac disease (CD) and can also persist in case of good compliance and clinical response to a strict gluten-free diet (GFD). This scenario usually presents in CD women of child-bearing age in whom the imbalance between menstrual iron loss and inadequate iron intake from their diet plays the major role. A recommended approach to this condition is yet to be established. This study aimed to compare, in this subset of patients, the efficacy of a dietary approach consisting of an iron-rich diet against the traditional pharmacological oral-replacement therapy. MATERIAL AND METHODS Between February and December 2016, consecutive CD female patients of child-bearing age as referred to our outpatient center with evidence of IDWA (ferritin <15 ng/mL or 15-20 ng/L with transferrin saturation <15%) were enrolled. After the completion of a 7-day weighed food intake recording to assess the usual iron dietary intake, the patients were randomized in two arms to receive a 12-week iron-rich diet (iron intake >20 mg/die) versus oral iron supplementation with ferrous sulfate (FS) (105 mg/day). Blood tests and dietary assessments were repeated at the end of treatment. The degree of compliance and tolerability to the treatments were assessed every month by means of specific questionnaires and symptoms evaluation. RESULTS A total of 22 women were enrolled and divided in the diet group ( n = 10, age 37 ± 8 years) and in the FS group ( n = 12, age 38 ± 10 years). The food intake records demonstrated an inadequate daily intake of iron in all the enrolled subjects. At the end of the treatments, ferritin levels were higher in the FS group (8.5 (5) versus 34 (30.8), p = 0.002). Compliance and tolerability were similar in both treatment groups (89% versus 87%, p = ns). CONCLUSIONS These findings did not support any equivalent efficacy of an iron-rich diet compared to a FS supplementation in non-anemic iron-deficient women affected by CD. However, the diet appeared a well-tolerated approach, and adequate dietary instructions could effectively increase the daily iron consumption, suggesting a role in the long-term management of IDWA, especially in patients who do not tolerate pharmacological supplementation.",2020,"Compliance and tolerability were similar in both treatment groups (89% versus 87%, p = ns). ","['Between February and December 2016, consecutive CD female patients of child-bearing age as referred to our outpatient center with evidence of IDWA (ferritin <15 ng/mL or 15-20 ng/L with transferrin saturation <15%) were enrolled', 'Women with Celiac Disease and Iron Deficiency without Anemia', 'A total of 22 women were enrolled and divided in the diet group ( n = 10, age 37 ± 8 years) and in the FS group ( n = 12, age 38 ± 10 years']","['12-week iron-rich diet (iron intake >20 mg/die) versus oral iron supplementation with ferrous sulfate (FS', 'High-Iron Dietary Intervention', 'dietary approach consisting of an iron-rich diet against the traditional pharmacological oral-replacement therapy', 'FS supplementation']","['Compliance and tolerability', 'daily iron consumption', 'degree of compliance and tolerability', 'Blood tests and dietary assessments', 'ferritin levels']","[{'cui': 'C0007570', 'cui_str': 'Celiac disease'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0340950', 'cui_str': 'Iron deficiency without anemia'}, {'cui': 'C0015879', 'cui_str': 'Ferritin'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0439297', 'cui_str': 'ng/L'}, {'cui': 'C1277709', 'cui_str': 'Transferrin saturation'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0060282', 'cui_str': 'ferrous sulfate'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0518043', 'cui_str': 'Iron intake'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3537005', 'cui_str': 'Iron supplement therapy'}, {'cui': 'C0060282', 'cui_str': 'ferrous sulfate'}, {'cui': 'C0860976', 'cui_str': 'Iron increased'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0279033', 'cui_str': 'Replacement therapy'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0373607', 'cui_str': 'Ferritin measurement'}]",22.0,0.0323893,"Compliance and tolerability were similar in both treatment groups (89% versus 87%, p = ns). ","[{'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Scricciolo', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Elli', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}, {'ForeName': 'Luisa', 'Initials': 'L', 'LastName': 'Doneda', 'Affiliation': 'Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy.'}, {'ForeName': 'Karla A', 'Initials': 'KA', 'LastName': 'Bascunan', 'Affiliation': 'Department of Nutrition, School of Medicine, University of Chile, 8380453 Santiago, Chile.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Branchi', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Ferretti', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Vecchi', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}, {'ForeName': 'Leda', 'Initials': 'L', 'LastName': 'Roncoroni', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}]",Nutrients,['10.3390/nu12072122'] 1823,32708991,"Effect of High versus Low Dairy Consumption on the Gut Microbiome: Results of a Randomized, Cross-Over Study.","The influence of dairy on the gut microbiome has not been studied extensively. We performed a randomized cross-over study to analyze the effect of high dairy intake on the gut microbiome. Subjects were randomly assigned to a high-dairy diet (HDD) (5-6 dairy portions per day) and a low-dairy diet (LDD) (≤1 dairy portion per day) for 6 weeks with a washout period of 4 weeks in between both diets. The gut microbiome was assessed using 16S rRNA gene sequencing. Compositionality and functionality of the gut microbiome was assessed using Quantitative Insights Into Microbial Ecology (QIIME) and Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt). Stool consistency was evaluated using the Bristol stool chart. In total, 46 healthy overweight subjects (BMI range 25-30 kg/m 2 ) completed both intervention periods. During the HDD, there was a significantly higher abundance of the genera Streptococcus , Leuconostoc , and Lactococcus , and the species Streptococcus thermophilus , Erysipelatoclostridium ramosum and Leuconostoc mesenteroides ( p FDR < 0.10). Furthermore, during the HDD, there was a significantly lower abundance of the genera Faecalibacterium and Bilophila , and the species Faecalibacterium prausnitzii , Clostridium aldenense , Acetivibrio ethanolgignens , Bilophila wadsworthia and Lactococcus lactis ( p FDR < 0.10). There were eight subjects who became constipated during the HDD and these subjects all had a lower abundance of F. prausnitzii . This is the first cross-over study in which the effect of an HDD compared to an LDD on the gut microbiome has been studied. An HDD led to a significantly different composition of the gut microbiome, with a particularly lower abundance of F. prausnitzii and a higher abundance of S. thermophilus . Constipation was observed in several subjects during the HDD. Predicted metabolic pathways were not significantly altered due to an HDD.",2020,"An HDD led to a significantly different composition of the gut microbiome, with a particularly lower abundance of F. prausnitzii and a higher abundance of S. thermophilus .","['46 healthy overweight subjects (BMI range 25-30 kg/m 2 ) completed both intervention periods', 'Gut Microbiome']","['High versus Low Dairy Consumption', 'high-dairy diet (HDD) (5-6 dairy portions per day) and a low-dairy diet (LDD']","['abundance of the genera Streptococcus , Leuconostoc , and Lactococcus , and the species Streptococcus thermophilus , Erysipelatoclostridium ramosum and Leuconostoc mesenteroides', 'Stool consistency', 'Predicted metabolic pathways', 'Constipation']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0442749', 'cui_str': '6/5'}, {'cui': 'C0449719', 'cui_str': 'Part'}, {'cui': 'C0439505', 'cui_str': '/day'}]","[{'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C0023411', 'cui_str': 'Leuconostoc'}, {'cui': 'C0085549', 'cui_str': 'Lactococcus'}, {'cui': 'C0318180', 'cui_str': 'Streptococcus salivarius subsp. thermophilus'}, {'cui': 'C0315111', 'cui_str': 'Clostridium ramosum'}, {'cui': 'C0317708', 'cui_str': 'Leuconostoc mesenteroides'}, {'cui': 'C0426740', 'cui_str': 'Consistency of stool'}, {'cui': 'C1291081', 'cui_str': 'Metabolic pathway'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}]",46.0,0.0185083,"An HDD led to a significantly different composition of the gut microbiome, with a particularly lower abundance of F. prausnitzii and a higher abundance of S. thermophilus .","[{'ForeName': 'J Casper', 'Initials': 'JC', 'LastName': 'Swarte', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Coby', 'Initials': 'C', 'LastName': 'Eelderink', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Rianne M', 'Initials': 'RM', 'LastName': 'Douwes', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'M Yusof', 'Initials': 'MY', 'LastName': 'Said', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Shixian', 'Initials': 'S', 'LastName': 'Hu', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Post', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Westerhuis', 'Affiliation': 'Dialyses Center Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Stephan J L', 'Initials': 'SJL', 'LastName': 'Bakker', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Hermie J M', 'Initials': 'HJM', 'LastName': 'Harmsen', 'Affiliation': 'Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}]",Nutrients,['10.3390/nu12072129'] 1824,32707238,Five-year follow-up of early intervention peanut oral immunotherapy.,,2020,,[],[],[],[],[],[],,0.0198285,,"[{'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Herlihy', 'Affiliation': 'The University of North Carolina at Chapel Hill, Chapel Hill, NC. Electronic address: lekoch@email.unc.edu.'}, {'ForeName': 'Edwin H', 'Initials': 'EH', 'LastName': 'Kim', 'Affiliation': 'The University of North Carolina at Chapel Hill, Chapel Hill, NC.'}, {'ForeName': 'A Wesley', 'Initials': 'AW', 'LastName': 'Burks', 'Affiliation': 'The University of North Carolina at Chapel Hill, Chapel Hill, NC.'}, {'ForeName': 'Holly', 'Initials': 'H', 'LastName': 'Barber', 'Affiliation': 'The University of North Carolina at Chapel Hill, Chapel Hill, NC.'}, {'ForeName': 'Quindelyn', 'Initials': 'Q', 'LastName': 'Cook', 'Affiliation': 'Boston University School of Medicine, Boston, Mass.'}, {'ForeName': 'Luanna', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Rochester Regional Health, Rochester, NY.'}, {'ForeName': 'Deanna', 'Initials': 'D', 'LastName': 'Hamilton', 'Affiliation': 'The University of North Carolina at Chapel Hill, Chapel Hill, NC.'}, {'ForeName': 'Brian P', 'Initials': 'BP', 'LastName': 'Vickery', 'Affiliation': 'Emory University, Atlanta, Ga.'}]",The journal of allergy and clinical immunology. In practice,['10.1016/j.jaip.2020.07.009'] 1825,32707289,Effect of an abdominal hypopressive technique programme on pelvic floor muscle tone and urinary incontinence in women: a randomised crossover trial.,"OBJECTIVES To test the effect of a structured abdominal hypopressive technique (AHT) programme on pelvic floor muscle (PFM) tone and urinary incontinence (UI) in women. DESIGN Crossover trial with random assignment of women to one of two groups: Group 1 (AHT followed by rest) and Group 2 (rest followed by AHT). SETTING Two cultural centres in Madrid, Spain. PARTICIPANTS Women aged 20-65 years. INTERVENTIONS Two months of supervised AHT exercises compared with 2 months of rest. MAIN OUTCOME MEASURES Variation in PFM tone and score on the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)]. RESULTS Forty-two women were randomised to two groups (both n=21). No sequence or period effect was noted. The mean difference in PFM tone after the 2-month AHT programme was 59g/cm² [95% confidence interval (CI) 37 to 82]; the between-group difference was 83g/cm² (95% CI 50 to 116; P<0.001). After 2 months, the between-group difference in the ICIQ-SF score was 3.3 points (P<0.001). The majority of participants reported improved body image and sense of well-being. CONCLUSIONS A structured 2-month AHT programme for women showed short-term benefits in PFM tone and UI. In addition, study participants reported improved body image and sense of well-being, and programme satisfaction, as demonstrated by questionnaire at the end of the intervention period. Further research is needed to test the long-term effects and effectiveness of AHT compared with other PFM exercises. ClinicalTrials.gov Identifier NCT0221241.",2020,"After 2 months, the between-group difference in the ICIQ-SF score was 3.3 points (P<0.001).","['women', 'women to one of two groups', 'Forty-two women', 'Two cultural centres in Madrid, Spain', 'Women aged 20-65 years']","['Group 1 (AHT followed by rest) and Group 2 (rest followed by AHT', 'structured abdominal hypopressive technique (AHT) programme', 'supervised AHT exercises', 'AHT', 'abdominal hypopressive technique programme']","['pelvic floor muscle tone and urinary incontinence', 'ICIQ-SF score', 'PFM tone', 'pelvic floor muscle (PFM) tone and urinary incontinence (UI', 'body image and sense of well-being, and programme satisfaction', 'Variation in PFM tone and score on the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF', 'body image and sense of well-being']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026841', 'cui_str': 'Muscle Tension'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0005891', 'cui_str': 'Body image'}, {'cui': 'C0424578', 'cui_str': 'Well in self'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C2711460', 'cui_str': 'International consultation on incontinence questionnaire'}]",42.0,0.187985,"After 2 months, the between-group difference in the ICIQ-SF score was 3.3 points (P<0.001).","[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Soriano', 'Affiliation': 'Universidad Camilo José Cela, Madrid, Spain.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'González-Millán', 'Affiliation': 'Universidad Camilo José Cela, Madrid, Spain.'}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Álvarez Sáez', 'Affiliation': 'Maio Medical Centre, Vigo, Spain.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Curbelo', 'Affiliation': 'Universidad Camilo José Cela, Madrid, Spain; Instituto de Salud Musculoesquelética, Madrid, Spain.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Carmona', 'Affiliation': 'Universidad Camilo José Cela, Madrid, Spain; Instituto de Salud Musculoesquelética, Madrid, Spain. Electronic address: loreto.carmona@inmusc.eu.'}]",Physiotherapy,['10.1016/j.physio.2020.02.004'] 1826,32707294,Effects of stress on 6- and 7-year-old children's emotional memory differs by gender.,"Understanding effects of emotional valence and stress on children's memory is important for educational and legal contexts. This study disentangled the effects of emotional content of to-be-remembered information (i.e., items differing in emotional valence and arousal), stress exposure, and associated cortisol secretion on children's memory. We also examined whether girls' memory is more affected by stress induction. A total of 143 6- and 7-year-old children were randomly allocated to the Trier Social Stress Test for Children (n = 103) or a control condition (n = 40). At 25 min after stressor onset, children incidentally encoded 75 objects varying in emotional valence (crossed with arousal) together with neutral scene backgrounds. We found that response bias corrected memory was worse for low-arousing negative items than for neutral and positive items, with the latter two categories not being different from each other. Whereas boys' memory was largely unaffected by stress, girls in the stress condition showed worse memory for negative items, especially the low-arousing ones, than girls in the control condition. Girls, compared with boys, reported higher subjective stress increases following stress exposure and had higher cortisol stress responses. Whereas a higher cortisol stress response was associated with better emotional memory in girls in the stress condition, boys' memory was not associated with their cortisol secretion. Taken together, our study suggests that 6- and 7-year-old children, more so girls, show memory suppression for negative information. Girls' memory for negative information, compared with that of boys, is also more strongly modulated by stress experience and the associated cortisol response.",2020,A total of 143 6- and 7-year-old children were randomly allocated to the Trier Social Stress Test for Children (n = 103) or a control condition (n = 40).,"[""6- and 7-year-old children's emotional memory differs by gender"", 'A total of 143 6- and 7-year-old children', ""children's memory""]",['Trier Social Stress Test for Children (n\xa0=\xa0103) or a control condition'],"['cortisol response', 'cortisol stress responses', 'cortisol stress response']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517573', 'cui_str': '143'}]","[{'cui': 'C0065404', 'cui_str': 'lysyl-5-fluorotryptophyl-lysine'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]",143.0,0.0372713,A total of 143 6- and 7-year-old children were randomly allocated to the Trier Social Stress Test for Children (n = 103) or a control condition (n = 40).,"[{'ForeName': 'Laurel', 'Initials': 'L', 'LastName': 'Raffington', 'Affiliation': 'Center for Lifespan Psychology, Max Planck Institute for Human Development, 14195 Berlin, Germany; Department of Psychology, University of Texas at Austin, Austin, TX 78712, USA.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Falck', 'Affiliation': 'Center for Lifespan Psychology, Max Planck Institute for Human Development, 14195 Berlin, Germany.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Heim', 'Affiliation': 'Institute of Medical Psychology, Charité - Universitäts medizin Berlin, 10117 Berlin, Germany; Department of Biobehavioral Health, Pennsylvania State University, University Park, PA 16802, USA.'}, {'ForeName': 'Mara', 'Initials': 'M', 'LastName': 'Mather', 'Affiliation': 'Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA 90089, USA.'}, {'ForeName': 'Yee Lee', 'Initials': 'YL', 'LastName': 'Shing', 'Affiliation': 'Center for Lifespan Psychology, Max Planck Institute for Human Development, 14195 Berlin, Germany; Institute of Psychology, Goethe-Universität Frankfurt, 60323 Frankfurt am Main, Germany. Electronic address: shing@psych.uni-frankfurt.de.'}]",Journal of experimental child psychology,['10.1016/j.jecp.2020.104924'] 1827,32707332,An invited commentary: The efficacy of transversus abdominis plane block with or without dexmedetomidine for postoperative analgesia in renal transplantation. A randomized controlled trial.,,2020,,['renal transplantation'],['transversus abdominis plane block with or without dexmedetomidine'],[],"[{'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}]","[{'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}]",[],,0.168804,,"[{'ForeName': 'Yuhang', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University, Guizhou, 563000, China. Electronic address: yulang5301@sina.com.'}, {'ForeName': 'Taowu', 'Initials': 'T', 'LastName': 'Gong', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University, Guizhou, 563000, China. Electronic address: chenmingaini1232@sina.com.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2020.07.008'] 1828,32711802,"Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.","BACKGROUND Patients with inflammatory diseases, such as rheumatoid arthritis, often receive glucocorticoids, but long-term use can produce adverse effects. Evidence from randomised controlled trials to guide tapering of oral glucocorticoids is scarce. We investigated a scheme for tapering oral glucocorticoids compared with continuing low-dose oral glucocorticoids in patients with rheumatoid arthritis. METHODS The Steroid EliMination In Rheumatoid Arthritis (SEMIRA) trial was a double-blind, multicentre, two parallel-arm, randomised controlled trial done at 39 centres from six countries (France, Germany, Italy, Russia, Serbia, and Tunisia). Adult patients with rheumatoid arthritis receiving tocilizumab and glucocorticoids 5-15 mg per day for 24 weeks or more were eligible for inclusion if they had received prednisone 5 mg per day for 4 weeks or more and had stable low disease activaity, confirmed by a Disease Activity Score for 28 joints-erythrocyte sedimentation rate (DAS28-ESR) of 3·2 or less 4-6 weeks before and on the day of randomisation. Patients were randomly assigned 1:1 to either continue masked prednisone 5 mg per day for 24 weeks or to taper masked prednisone reaching 0 mg per day at week 16. All patients received tocilizumab (162 mg subcutaneously every week or 8 mg/kg intravenously every 4 weeks) with or without csDMARDs maintained at stable doses during the entire 24-week study. The primary outcome was the difference in mean DAS28-ESR change from baseline to week 24, with a difference of more than 0·6 defined as clinically relevant between the continued-prednisone group and the tapered-prednisone group. The trial is registered with ClinicalTrials.gov, NCT02573012. FINDINGS Between Oct 21, 2015, and June 9, 2017, 421 patients were screened and 259 (200 [77%] women and 59 [23%] men) were recruited onto the trial. In all 128 patients assigned to the continued-prednisone regimen, disease activity control was superior to that in all 131 patients assigned to the tapered-prednisone regimen; the estimated mean change in DAS28-ESR from baseline to week 24 was 0·54 (95% CI 0·35-0·73) with tapered prednisone and -0·08 (-0·27 to 0·12) with continued prednisone (difference 0·61 [0·35-0·88]; p<0·0001), favouring continuing prednisone 5 mg per day for 24 weeks. Treatment was regarded as successful (defined as low disease activity at week 24, plus absence of rheumatoid arthritis flare for 24 weeks and no confirmed adrenal insufficiency) in 99 (77%) patients in the continued-prednisone group versus 85 (65%) patients in the tapered-prednisone group (relative risk 0·83; 95% CI 0·71-0·97). Serious adverse events occurred in seven (5%) patients in the tapered-prednisone group and four (3%) patients in the continued-prednisone group; no patients had symptomatic adrenal insufficiency. INTERPRETATION In patients who achieved low disease activity with tocilizumab and at least 24 weeks of glucocorticoid treatment, continuing glucocorticoids at 5 mg per day for 24 weeks provided safe and better disease control than tapering glucocorticoids, although two-thirds of patients were able to safely taper their glucocorticoid dose. FUNDING F Hoffmann-La Roche.",2020,"In all 128 patients assigned to the continued-prednisone regimen, disease activity control was superior to that in all 131 patients assigned to the tapered-prednisone regimen; the estimated mean change in DAS28-ESR from baseline to week 24 was 0·54 (95% CI 0·35-0·73) with tapered prednisone and -0·08","['Adult patients with rheumatoid arthritis receiving', 'Between Oct 21, 2015, and June 9, 2017, 421 patients were screened and 259 (200 [77', '0·35-0·88', 'patients with rheumatoid arthritis', '23%] men) were recruited onto the trial', '39 centres from six countries (France, Germany, Italy, Russia, Serbia, and Tunisia', 'women and 59']","['prednisone', 'Continuing versus tapering glucocorticoids', 'tocilizumab', 'continue masked prednisone', 'tapered prednisone and -0·08', 'glucocorticoids', 'tocilizumab and glucocorticoids', 'glucocorticoid', 'continuing low-dose oral glucocorticoids']","['symptomatic adrenal insufficiency', 'mean DAS28-ESR change', 'Steroid EliMination', 'disease activity control', 'Serious adverse events']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0029279', 'cui_str': 'Ornithine carbamoyltransferase'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0035970', 'cui_str': 'Russian federation - Europe'}, {'cui': 'C0036708', 'cui_str': 'Republic of Serbia'}, {'cui': 'C0041388', 'cui_str': 'Tunisia'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0441640', 'cui_str': 'Tapering - action'}, {'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}, {'cui': 'C1609165', 'cui_str': 'tocilizumab'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0001623', 'cui_str': 'Hypoadrenalism'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",421.0,0.383193,"In all 128 patients assigned to the continued-prednisone regimen, disease activity control was superior to that in all 131 patients assigned to the tapered-prednisone regimen; the estimated mean change in DAS28-ESR from baseline to week 24 was 0·54 (95% CI 0·35-0·73) with tapered prednisone and -0·08","[{'ForeName': 'Gerd R', 'Initials': 'GR', 'LastName': 'Burmester', 'Affiliation': 'Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany. Electronic address: gerd.burmester@charite.de.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Buttgereit', 'Affiliation': 'Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany.'}, {'ForeName': 'Corrado', 'Initials': 'C', 'LastName': 'Bernasconi', 'Affiliation': 'Pharmaceuticals Division, F Hoffmann-La Roche, Basel, Switzerland.'}, {'ForeName': 'Jose M', 'Initials': 'JM', 'LastName': 'Álvaro-Gracia', 'Affiliation': 'Hospital General Universitario Gregorio Marañon, Universidad Complutense de Madrid, Spain.'}, {'ForeName': 'Nidia', 'Initials': 'N', 'LastName': 'Castro', 'Affiliation': 'Pharmaceuticals Division, F Hoffmann-La Roche, Basel, Switzerland.'}, {'ForeName': 'Maxime', 'Initials': 'M', 'LastName': 'Dougados', 'Affiliation': 'Rheumatology Service, Université Paris-Descartes, Paris, France.'}, {'ForeName': 'Cem', 'Initials': 'C', 'LastName': 'Gabay', 'Affiliation': 'Department of Rheumatology, Hôpital Cochin, Geneva University Hospitals and Geneva School of Medicine, Geneva, Switzerland.'}, {'ForeName': 'Jacob M', 'Initials': 'JM', 'LastName': 'van Laar', 'Affiliation': 'University Medical Centre Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Jan Michael', 'Initials': 'JM', 'LastName': 'Nebesky', 'Affiliation': 'Pharmaceuticals Division, F Hoffmann-La Roche, Basel, Switzerland.'}, {'ForeName': 'Attila', 'Initials': 'A', 'LastName': 'Pethoe-Schramm', 'Affiliation': 'Pharmaceuticals Division, F Hoffmann-La Roche, Basel, Switzerland.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Salvarani', 'Affiliation': 'Department of Rheumatology and Clinical Immunology, Università di Modena e Reggio Emilia and Azienda unità sanitaria locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.'}, {'ForeName': 'Marc Y', 'Initials': 'MY', 'LastName': 'Donath', 'Affiliation': 'Department of Rheumatology, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Markus R', 'Initials': 'MR', 'LastName': 'John', 'Affiliation': 'Pharmaceuticals Division, F Hoffmann-La Roche, Basel, Switzerland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(20)30636-X'] 1829,32712347,Impact of myoglobin oxygenation state prior to frozen storage on color stability of thawed beef steaks through retail display.,"Consumers consider beef color to be an indicator of freshness and therefore it is a major factor when purchasing beef. The ideal conditions for maintaining color throughout retail display following frozen storage have yet to be well established. Therefore, the objective of this study was to determine the effects of myoglobin oxygenation levels (especially high oxygenation) during freezing on color stability of thawed steaks during retail display (RD) and to determine the impact that frozen storage duration, aging, and packaging films have on meat color after thawing under RD conditions. USDA Choice strip loins (n = 36) were aged for 4 or 20 d. Steaks were randomly assigned to a myoglobin oxygenation level [deoxymyoglobin (DeOxy; packaged within 3 min), oxygenation (Oxy; oxygenated in air for 30 min), or high oxygenation (HiOxy; packaged for 24 h in 80% O 2 )]. Steaks were then vacuum packaged in oxygen permeable or impermeable film and immediately frozen (-10 °C). Following either 0, 2, 4, or 6 months of frozen storage at -5 °C, steaks were removed from the packaging and immediately placed under simulated RD conditions for 7 d. During RD, instrumental color and subjective color were measured every day after the initial 24 h thaw period. Steaks were analyzed for instrumental color (L*, a*, b*), a*:b* ratio, percentage oxymyoglobin, metmyoglobin, and deoxymyoglobin, delta E, redness ratio, subjective discoloration, and lipid oxidation. For all days of RD, steaks that were frozen for 0 months had higher a* values (greater redness) than steaks frozen for 6 months which typically had the lowest a* values (P < .0001). HiOxy steaks frozen for 6 months had the lowest amounts of percentage oxymyoglobin than all other frozen storage periods and myoglobin oxygenation levels on days 4-7 of RD (P < .05). The HiOxy steaks frozen for 4 and 6 months had higher percentage metmyoglobin than DeOxy and Oxy, regardless of packaging (P < .05). Delta E, discoloration, and lipid oxidation were greatest for HiOxy steaks compared to Oxy and DeOxy (P < .05). Extended storage brought about detrimental color effects for all differing levels of myoglobin oxygenation. The HiOxy steaks through the first few days of RD and frozen for under 6 months provided had bright cherry red color, similar to that of DeOxy and Oxy. However, with extended frozen storage and RD, HiOxy steaks had worse color characteristics (more discoloration) than the other myoglobin oxygenation levels.",2020,HiOxy steaks frozen for 6 months had the lowest amounts of percentage oxymyoglobin than all other frozen storage periods and myoglobin oxygenation levels on days 4-7 of RD (P ,['n\xa0=\xa036) were aged for 4 or 20\xa0d. Steaks'],"['myoglobin oxygenation state prior to frozen storage', 'USDA Choice strip loins', 'myoglobin oxygenation level [deoxymyoglobin (DeOxy; packaged within 3\xa0min), oxygenation (Oxy; oxygenated in air for 30\xa0min), or high oxygenation (HiOxy']","['myoglobin oxygenation levels', 'percentage oxymyoglobin, metmyoglobin, and deoxymyoglobin, delta E, redness ratio, subjective discoloration, and lipid oxidation', 'Delta E, discoloration, and lipid oxidation', 'color stability']","[{'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0027078', 'cui_str': 'Myoglobin'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0016701', 'cui_str': 'Freezing'}, {'cui': 'C1698986', 'cui_str': 'Storage'}, {'cui': 'C0085410', 'cui_str': 'Department of Agriculture (U.S.)'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0185047', 'cui_str': 'Stripping'}, {'cui': 'C0446502', 'cui_str': 'Loin (surface region)'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0057444', 'cui_str': 'deoxymyoglobin'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0205250', 'cui_str': 'High'}]","[{'cui': 'C0027078', 'cui_str': 'Myoglobin'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0069830', 'cui_str': 'oxymyoglobin'}, {'cui': 'C0025852', 'cui_str': 'Metmyoglobin'}, {'cui': 'C0057444', 'cui_str': 'deoxymyoglobin'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0332572', 'cui_str': 'Abnormal color'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0205360', 'cui_str': 'Stable'}]",36.0,0.0389964,HiOxy steaks frozen for 6 months had the lowest amounts of percentage oxymyoglobin than all other frozen storage periods and myoglobin oxygenation levels on days 4-7 of RD (P ,"[{'ForeName': 'M L', 'Initials': 'ML', 'LastName': 'Henriott', 'Affiliation': 'Department of Animal Science, University of Nebraska, Lincoln 68583-0908, USA.'}, {'ForeName': 'N J', 'Initials': 'NJ', 'LastName': 'Herrera', 'Affiliation': 'Department of Animal Science, University of Nebraska, Lincoln 68583-0908, USA.'}, {'ForeName': 'F A', 'Initials': 'FA', 'LastName': 'Ribeiro', 'Affiliation': 'Department of Animal Science, University of Nebraska, Lincoln 68583-0908, USA.'}, {'ForeName': 'K B', 'Initials': 'KB', 'LastName': 'Hart', 'Affiliation': 'Department of Animal Science, University of Nebraska, Lincoln 68583-0908, USA.'}, {'ForeName': 'N A', 'Initials': 'NA', 'LastName': 'Bland', 'Affiliation': 'Department of Animal Science, University of Nebraska, Lincoln 68583-0908, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Eskridge', 'Affiliation': 'Department of Statistics, University of Nebraska, Lincoln 68583-0908, USA.'}, {'ForeName': 'C R', 'Initials': 'CR', 'LastName': 'Calkins', 'Affiliation': 'Department of Animal Science, University of Nebraska, Lincoln 68583-0908, USA. Electronic address: ccalkins1@unl.edu.'}]",Meat science,['10.1016/j.meatsci.2020.108232'] 1830,32691848,"The Promise, and Challenges, of Methods to Enhance the External Validity of Randomized Trial Results.",,2020,"Results from randomized trials do not necessarily apply to clinical practice, particularly if the trial sample and target population differ on factors that modify treatment effects.",[],[],[],[],[],[],,0.132061,"Results from randomized trials do not necessarily apply to clinical practice, particularly if the trial sample and target population differ on factors that modify treatment effects.","[{'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Stuart', 'Affiliation': 'Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Catherine R', 'Initials': 'CR', 'LastName': 'Lesko', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.'}]",Clinical pharmacology and therapeutics,['10.1002/cpt.1992'] 1831,32693197,"Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.","Vitamin K antagonists are the only approved oral anticoagulants for long-term prophylaxis against valve thrombosis and thromboembolism in patients with a mechanical heart valve. Despite the proven efficacy and safety of anticoagulation with the oral direct factor Xa inhibitor apixaban compared with warfarin in high-risk populations including subjects with atrial fibrillation or with venous thromboembolism, it remains unknown whether patients with a mechanical heart valve can be safely managed with apixaban. The On-X Aortic Heart Valve and On-X Ascending Aortic Prosthesis with the Vascutek Gelweave Valsalva Graft may have lower rates of valve thrombosis and thromboembolism than conventional bileaflet and tilting disc valves due its unique pyrolytic carbon composition and flared inlet design. DESIGN: PROACT Xa is a randomized, multicenter, open-label, active-controlled trial comparing apixaban with warfarin in patients with an On-X Aortic Heart Valve or On-X Ascending Aortic Prosthesis with the Vascutek Gelweave Valsalva Graft. The study will randomize approximately 1,000 patients from approximately 60 sites in North America who underwent aortic valve replacement at least 3 months prior. Patients will be randomized 1:1 to receiving apixaban 5 mg twice daily or warfarin with a target international normalized ratio of 2.0-3.0. The last randomized participant will be followed for at least 2 years. The primary efficacy outcome is the composite of valve thrombosis and valve-related thromboembolism, and the primary safety outcome is major bleeding. Assuming the primary outcome occurs in warfarin-anticoagulated patients at a rate of 1.75%/patient-year, the study has more than 90% power to assess noninferiority of apixaban treatment with an absolute noninferiority margin of 1.75%/patient-year. A second co-primary analysis is to compare the hazard rate for the apixaban arm to twice the objective performance criterion for thromboembolism and valve thrombosis, that is, 3.4%/patient-year. SUMMARY: PROACT Xa will determine whether patients with an On-X Aortic Heart Valve can be anticoagulated with apixaban as an alternative to warfarin.",2020,"The primary efficacy outcome is the composite of valve thrombosis and valve-related thromboembolism, and the primary safety outcome is major bleeding.","['patients with an On-X Aortic Heart Valve or On-X Ascending Aortic Prosthesis with the Vascutek Gelweave Valsalva Graft', 'subjects with atrial fibrillation or with venous thromboembolism', '1,000 patients from approximately 60 sites in North America who underwent aortic valve replacement at least 3\u202fmonths prior', 'patients with a mechanical heart valve', 'patients with a mechanical On-X Aortic Heart Valve']","['PROACT Xa', 'apixaban 5\u202fmg twice daily or warfarin', 'apixaban versus warfarin', 'apixaban', 'warfarin', 'Vitamin K antagonists', 'apixaban with warfarin']","['efficacy and safety', 'composite of valve thrombosis and valve-related thromboembolism, and the primary safety outcome is major bleeding', 'hazard rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003483', 'cui_str': 'Aortic'}, {'cui': 'C0018825', 'cui_str': 'Cardiac valve prosthesis'}, {'cui': 'C0205385', 'cui_str': 'Ascending'}, {'cui': 'C0175649', 'cui_str': 'Prosthesis'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0018829', 'cui_str': 'Prosthetic heart'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}]","[{'cui': 'C3530472', 'cui_str': 'apixaban 5 MG'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C1096489', 'cui_str': 'Vitamin K antagonist'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",,0.0697264,"The primary efficacy outcome is the composite of valve thrombosis and valve-related thromboembolism, and the primary safety outcome is major bleeding.","[{'ForeName': 'Oliver K', 'Initials': 'OK', 'LastName': 'Jawitz', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC; Department of Surgery, Duke University Medical Center, Durham, NC. Electronic address: oliver.jawitz@duke.edu.'}, {'ForeName': 'Tracy Y', 'Initials': 'TY', 'LastName': 'Wang', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Renato D', 'Initials': 'RD', 'LastName': 'Lopes', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Alma', 'Initials': 'A', 'LastName': 'Chavez', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Brittanny', 'Initials': 'B', 'LastName': 'Boyer', 'Affiliation': 'CryoLife, Inc., Kennesaw, GA.'}, {'ForeName': 'Hwasoon', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Kevin J', 'Initials': 'KJ', 'LastName': 'Anstrom', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Richard C', 'Initials': 'RC', 'LastName': 'Becker', 'Affiliation': 'Division of Cardiovascular Health and Diseases, University of Cincinnati Heart, Lung & Vascular Institute, Cincinnati, OH.'}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Blackstone', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Ruel', 'Affiliation': 'Division of Cardiac Surgery, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Vinod H', 'Initials': 'VH', 'LastName': 'Thourani', 'Affiliation': 'Piedmont Heart Institute, Atlanta, GA.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Puskas', 'Affiliation': ""Department of Cardiovascular Surgery, Mount Sinai St. Luke's, New York, NY.""}, {'ForeName': 'Marc W', 'Initials': 'MW', 'LastName': 'Gerdisch', 'Affiliation': 'Department of Cardiothoracic Surgery, Franciscan Hospital, Indianapolis, IN.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Johnston', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Capps', 'Affiliation': 'CryoLife, Inc., Kennesaw, GA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Alexander', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Lars G', 'Initials': 'LG', 'LastName': 'Svensson', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH.'}]",American heart journal,['10.1016/j.ahj.2020.06.014'] 1832,32698457,"Effects of Pistachio Consumption in a Behavioral Weight Loss Intervention on Weight Change, Cardiometabolic Factors, and Dietary Intake.","Epidemiological studies have linked regular nut consumption with lower body mass index and reduced likelihood of weight gain in adulthood. Nuts can displace other foods in the diet, and thus, promote a healthier dietary pattern. The purpose of this study was to examine the effect of pistachio nut consumption in overweight/obese adults. This randomized controlled study enrolled non-diabetic overweight/obese adults ( n = 100) assigned to a 4-month behavioral weight loss intervention only group (controls) or also prescribed 1.5 oz/day (42 g/day) of pistachios (pistachio group). Outcomes were change in body weight, cardiometabolic factors, and dietary intake. Percent weight change was similar in the two groups (-5.1 [0.5] (mean [SE])% in the control group and -4.9 [0.6]% in the pistachio group, and body mass index (BMI) and waist circumference were reduced in both groups (time effect p ≤ 0.05). The pistachio group (but not the control group) exhibited a significant reduction in both systolic and diastolic blood pressure (time effect p = 0.01). Plasma alpha-carotene, beta-carotene, and lutein concentrations increased significantly in the pistachio group (time effect p < 0.05). Pistachio consumption was associated with increased dietary fiber intake and decreased consumption of sweets. Regular consumption of pistachios was associated with a comparable degree of weight loss, and similar reductions in BMI and waist circumference, in overweight/obese men and women compared to controls, and favorable changes in the diet, in the context of a behavioral weight loss intervention.",2020,"Plasma alpha-carotene, beta-carotene, and lutein concentrations increased significantly in the pistachio group (time effect p < 0.05).","['enrolled non-diabetic overweight/obese adults ( n = 100) assigned to a', 'overweight/obese adults']","['4-month behavioral weight loss intervention only group (controls) or also prescribed 1.5 oz/day (42 g/day) of pistachios (pistachio group', 'pistachio nut consumption', 'Pistachio Consumption']","['BMI and waist circumference', 'body weight, cardiometabolic factors, and dietary intake', 'systolic and diastolic blood pressure', 'dietary fiber intake and decreased consumption of sweets', 'weight loss', 'Plasma alpha-carotene, beta-carotene, and lutein concentrations', 'Weight Change, Cardiometabolic Factors, and Dietary Intake', 'body mass index (BMI) and waist circumference', 'Percent weight change']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0560718', 'cui_str': 'oz/day'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}, {'cui': 'C0459819', 'cui_str': 'Pistachio nut'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0474451', 'cui_str': 'Dietary fiber intake'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0085077', 'cui_str': 'Acute febrile neutrophilic dermatosis'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0051336', 'cui_str': 'Alpha-carotene'}, {'cui': 'C0053396', 'cui_str': 'Beta Carotene'}, {'cui': 'C0043328', 'cui_str': 'Lutein'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0439165', 'cui_str': 'Percent'}]",,0.0181975,"Plasma alpha-carotene, beta-carotene, and lutein concentrations increased significantly in the pistachio group (time effect p < 0.05).","[{'ForeName': 'Cheryl L', 'Initials': 'CL', 'LastName': 'Rock', 'Affiliation': 'Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0901, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Zunshine', 'Affiliation': 'Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0901, USA.'}, {'ForeName': 'Huong Thien', 'Initials': 'HT', 'LastName': 'Nguyen', 'Affiliation': 'Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0901, USA.'}, {'ForeName': 'Annemarie O', 'Initials': 'AO', 'LastName': 'Perez', 'Affiliation': 'Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0901, USA.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Zoumas', 'Affiliation': 'Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0901, USA.'}, {'ForeName': 'Bilge', 'Initials': 'B', 'LastName': 'Pakiz', 'Affiliation': 'Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0901, USA.'}, {'ForeName': 'Martha M', 'Initials': 'MM', 'LastName': 'White', 'Affiliation': 'Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0901, USA.'}]",Nutrients,['10.3390/nu12072155'] 1833,32700212,Right-sided versus left-sided percutaneous transhepatic biliary drainage in the management of malignant biliary obstruction: a randomized controlled study.,"AIM To compare the technical difficulty, safety, radiation exposure and success rates between right-sided and left-sided percutaneous transhepatic biliary drainage (RPTBD and LPTBD) in patients with malignant biliary obstruction (MBO). MATERIALS AND METHODS Fifty patients (28 males, 22 females; mean age 51.78 years) with MBO were randomized to undergo either RPTBD or LPTBD during the study period between June 2016 and May 2018. The procedure time, fluoroscopy time, radiation doses to the operators and patients, technical success, clinical success, complications and effect on quality of life were evaluated and compared between the two groups. RESULTS Twenty-five patients were included in each group. The technical success was 100% in both groups. There was no significant difference between RPTBD and LPTBD groups in terms of major complications [4% and 12%, respectively; p = 0.297] and minor complications [40% and 32%, respectively; p = 0.597]. Further, the average procedure time (37.80 ± 13.07 min vs 41.04 ± 14.94 min), fluoroscopy time (5.88 ± 4.2 min vs 5.97 ± 3.8 min), radiation doses to the operator (136.84 ± 106.67 μSv vs 130.40 ± 106.46 μSv) and to the patient (8.23 ± 5.80 Gycm 2 vs 11.74 ± 11.28 Gycm 2 ) were not significantly different between the groups. Clinical success was achieved in 21 patients (84%) of RPTBD group and 17 patients (68%) of LPTBD group with no significant difference (p = 0.416) between them. CONCLUSION There was no significant difference between RPTBD and LPTBD with reference to the technique, safety, radiation dose, success rates and impact on quality of life suggesting no laterality advantage for biliary drainage in cases of MBO.",2020,"There was no significant difference between RPTBD and LPTBD with reference to the technique, safety, radiation dose, success rates and impact on quality of life suggesting no laterality advantage for biliary drainage in cases of MBO.","['Twenty-five patients were included in each group', 'malignant biliary obstruction', 'Fifty patients (28 males, 22 females; mean age 51.78\xa0years) with MBO', 'patients with malignant biliary obstruction (MBO']","['Right-sided versus left-sided percutaneous transhepatic biliary drainage', 'right-sided and left-sided percutaneous transhepatic biliary drainage (RPTBD and LPTBD', 'RPTBD or LPTBD']","['procedure time, fluoroscopy time, radiation doses to the operators and patients, technical success, clinical success, complications and effect on quality of life', 'Clinical success', 'technique, safety, radiation dose, success rates and impact on quality of life', 'fluoroscopy time', 'technical success', 'technical difficulty, safety, radiation exposure and success rates', 'average procedure time', 'minor complications']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3898473', 'cui_str': 'Malignant biliary obstruction'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C1504490', 'cui_str': 'Percutaneous transhepatic cholangiodrainage'}]","[{'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0449851', 'cui_str': 'Technique'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0015333', 'cui_str': 'Exposure to radiation'}, {'cui': 'C0026193', 'cui_str': 'Minor'}]",25.0,0.0580947,"There was no significant difference between RPTBD and LPTBD with reference to the technique, safety, radiation dose, success rates and impact on quality of life suggesting no laterality advantage for biliary drainage in cases of MBO.","[{'ForeName': 'Rajendra Kumar', 'Initials': 'RK', 'LastName': 'Behera', 'Affiliation': 'Department of Radiodiagnosis, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Deep Narayan', 'Initials': 'DN', 'LastName': 'Srivastava', 'Affiliation': 'Department of Radiodiagnosis, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Pratik', 'Initials': 'P', 'LastName': 'Kumar', 'Affiliation': 'Department of Medical Physics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Sujoy', 'Initials': 'S', 'LastName': 'Pal', 'Affiliation': 'Department of Gastrointestinal Surgery, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Nihar', 'Initials': 'N', 'LastName': 'Ranjan', 'Affiliation': 'Department of Gastrointestinal Surgery, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Pramod', 'Initials': 'P', 'LastName': 'Garg', 'Affiliation': 'Department of Gastroenterology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Peush', 'Initials': 'P', 'LastName': 'Sahni', 'Affiliation': 'Department of Gastrointestinal Surgery, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Kumble Seetharama', 'Initials': 'KS', 'LastName': 'Madhusudhan', 'Affiliation': 'Department of Radiodiagnosis, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India. drmadhuks@gmail.com.'}]",Abdominal radiology (New York),['10.1007/s00261-020-02651-y'] 1834,32697560,"The Effect of a Photochromic Contact Lens on Visual Function Indoors: A Randomized, Controlled Trial.","SIGNIFICANCE Photochromic soft contact lenses contain light-sensitive additives that allow them to darken when exposed to ultraviolet or violet light. One question, however, is whether the lenses influence vision indoors (minimally activated). In this study, we found that the minimally activated lenses improved many aspects of visual function under bright light. PURPOSE Photochromic contact lenses were designed to darken when exposed to outdoor sunlight. The filtering that results improves visual function under bright light conditions. Not all bright light exposures occur outdoors. In this study, we tested whether a photochromic contact lens improved visual function under conditions where the lens was minimally activated (i.e., no more than it normally would be in an indoor environment). METHODS A subject-masked contralateral design was used comparing a photochromic contact lens randomized to one eye against a nonphotochromic contact in the other eye of the same subject. Sixty subjects (mean = 34.90 ± 11.24 years) were tested. The primary endpoints consisted of four visual function outcomes: photostress recovery, glare disability, glare discomfort, and chromatic contrast. Photostress recovery was quantified by measuring the time needed to recover visual acquisition of a grating target after 5 seconds of an intense xenon white flash exposure; glare disability was evaluated as the energy in a surrounding xenon white annulus necessary to veil a central grating target; and glare discomfort was assessed using bioimaging of the squint response. Chromatic contrast was measured as thresholds for a green-yellow (580 nm) grating target superposed on a blue (460 nm) background. RESULTS The minimally activated photochromic contact demonstrated improved visual performance compared with the nonphotochromic control across all visual functions tested (P < .01). CONCLUSIONS Even under conditions of exiguous activation (e.g., as would be expected indoors or while driving at night), a photochromic contact will improve many of the more deleterious aspects of bright light.",2020,"The minimally activated photochromic contact demonstrated improved visual performance compared with the nonphotochromic control across all visual functions tested (P < .01). ",['Sixty subjects (mean = 34.90 ± 11.24 years) were tested'],"['photochromic contact lens', 'Photochromic Contact Lens']","['visual performance', 'four visual function outcomes: photostress recovery, glare disability, glare discomfort, and chromatic contrast', 'Photostress recovery', 'Visual Function Indoors', 'glare discomfort', 'visual function']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C1444754', 'cui_str': 'Length'}]","[{'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1321306', 'cui_str': 'Glare disability'}, {'cui': 'C0278215', 'cui_str': 'Glare'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}]",,0.0395735,"The minimally activated photochromic contact demonstrated improved visual performance compared with the nonphotochromic control across all visual functions tested (P < .01). ","[{'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Renzi-Hammond', 'Affiliation': '1Human Biofactors Laboratory, Institute of Gerontology, Department of Health Promotion and Behavior, College of Public Health, University of Georgia, Athens, Georgia 2Johnson & Johnson Vision Care, Inc., Jacksonville, Florida 3Georgia Center for Sight, Athens, Georgia 4Vision Sciences Laboratory, Behavioral Brain Sciences Program, Department of Psychology, University of Georgia, Athens, Georgia *bhammond@uga.edu.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Buch', 'Affiliation': ''}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Hacker', 'Affiliation': ''}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Cannon', 'Affiliation': ''}, {'ForeName': 'Billy R', 'Initials': 'BR', 'LastName': 'Hammond', 'Affiliation': ''}]",Optometry and vision science : official publication of the American Academy of Optometry,['10.1097/OPX.0000000000001537'] 1835,32700954,A multiple baseline study of a brief alcohol reduction and family engagement intervention for fathers in Kenya.,"OBJECTIVE To evaluate a lay provider-delivered, brief intervention to reduce problem drinking and related family consequences among men in Kenya. The 5-session intervention combines behavioral activation (BA) and motivational interviewing (MI). It integrates family-related material explicitly and addresses central cultural factors through gender transformative strategies. METHOD A nonconcurrent multiple-baseline design was used. We initiated treatment with 9 men ages 30 to 48 who were fathers and screened positive for problem drinking; the median Alcohol Use Identification Test score was 17 (harmful range). Participants were randomized to staggered start dates. We measured the primary outcome of weekly alcohol consumption 4 weeks before treatment, during treatment, and 4 weeks posttreatment using the Timeline Followback measure. Secondary outcomes were assessed using a pre-post assessment (1-month) of men's depression symptoms, drinking- and family-related problem behavior, involvement with child, time with family, family functioning, relationship quality (child and partner), and harsh treatment of child and partner. Men, partners, and children (ages 8-17) reported on family outcomes. RESULTS Eight men completed treatment. Mixed-effects hurdle model analysis showed that alcohol use, both number of days drinking and amount consumed, significantly decreased during and after treatment. Odds of not drinking were 5.1 times higher posttreatment (95% CI [3.3, 7.9]). When men did drink posttreatment, they drank 50% less (95% CI [0.39, 0.65]). Wilcoxon signed-ranks test demonstrated pre-post improvements in depression symptoms and family related outcomes. CONCLUSION Results provide preliminary evidence that a BA-MI intervention developed for lay providers may reduce alcohol use and improve family outcomes among men in Kenya. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"When men did drink posttreatment, they drank 50% less (95% CI [0.39, 0.65]).","['Eight men completed treatment', '9 men ages 30 to 48 who were fathers and screened positive for problem drinking; the median Alcohol Use Identification Test score was 17 (harmful range', 'Men, partners, and children (ages 8-17) reported on family outcomes', 'men in Kenya', 'fathers in Kenya']","['alcohol reduction and family engagement intervention', 'BA-MI intervention', '5-session intervention combines behavioral activation (BA) and motivational interviewing (MI']","[""pre-post assessment (1-month) of men's depression symptoms, drinking- and family-related problem behavior, involvement with child, time with family, family functioning, relationship quality (child and partner), and harsh treatment of child and partner"", 'depression symptoms and family related outcomes']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0015671', 'cui_str': 'Father'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0020792', 'cui_str': 'Identification - mental defense mechanism'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}]","[{'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0500725,"When men did drink posttreatment, they drank 50% less (95% CI [0.39, 0.65]).","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Giusto', 'Affiliation': 'Department of Psychology and Neuroscience.'}, {'ForeName': 'Eric P', 'Initials': 'EP', 'LastName': 'Green', 'Affiliation': 'Duke Global Health Institute.'}, {'ForeName': 'Ryan A', 'Initials': 'RA', 'LastName': 'Simmons', 'Affiliation': 'Department of Biostatistics and Bioinformatics.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Ayuku', 'Affiliation': 'Department of Behavioural Sciences.'}, {'ForeName': 'Puja', 'Initials': 'P', 'LastName': 'Patel', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Eve S', 'Initials': 'ES', 'LastName': 'Puffer', 'Affiliation': 'Department of Psychology and Neuroscience.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000559'] 1836,32702468,Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus - A MASTERMIND precision medicine approach (UKPDS 87).,"AIMS Predicting likely durability of glucose-lowering therapies for people with type 2 diabetes (T2D) could help inform individualised therapeutic choices. METHODS We used data from UKPDS patients with newly-diagnosed T2D randomised to first-line glucose-lowering monotherapy with chlorpropamide-glibenclamide-basal insulin or metformin. In 2339 participants who achieved one-year HbA 1c values <7.5% (<59 mmol/mol)-we assessed relationships between one-year characteristics and time to monotherapy-failure (HbA 1c  ≥ 7.5% or requiring second-line therapy). Model validation was performed using bootstrap sampling. RESULTS Follow-up was median (IQR) 11.0 (8.0-14.0) years. Monotherapy-failure occurred in 72%-82%-75% and 79% for those randomised to chlorpropamide-glibenclamide-basal insulin or metformin respectively-after median 4.5 (3.0-6.6)-3.7 (2.6-5.6)-4.2 (2.7-6.5) and 3.8 (2.6- 5.2) years. Time-to-monotherapy-failure was predicted primarily by HbA 1c and BMI values-with other risk factors varying by type of monotherapy-with predictions to within ±2.5 years for 55%-60%-56% and 57% of the chlorpropamide-glibenclamide-basal insulin and metformin monotherapy cohorts respectively. CONCLUSIONS Post one-year glycaemic durability can be predicted robustly in individuals with newly-diagnosed T2D who achieve HbA 1c values  < 7.5% one year after commencing traditional monotherapies. Such information could be used to help guide glycaemic management for individual patients.",2020,Monotherapy-failure occurred in 72%-82%-75% and 79% for those randomised to chlorpropamide-glibenclamide-basal insulin or metformin respectively-after median 4.5 (3.0-6.6)-3.7 (2.6-5.6)-4.2 (2.7-6.5) and 3.8 (2.6- 5.2) years.,"['2,339 participants who achieved one-year HbA 1c values <7.5% (<59 mmol/mol)-we assessed relationships between one-year characteristics and time to monotherapy-failure (HbA 1c ≥7.5% or requiring second-line therapy', 'people with type 2 diabetes ', 'Patients with Newly-diagnosed Type 2 Diabetes Mellitus', 'UKPDS patients with newly-diagnosed T2D randomised to first']","['chlorpropamide-glibenclamide-basal insulin or metformin', 'line glucose-lowering monotherapy with chlorpropamide-glibenclamide-basal insulin or metformin', 'glucose-lowering therapies', 'Glucose-lowering Monotherapies']","['Monotherapy-failure', 'Time-to-monotherapy-failure']","[{'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mol'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C1710038', 'cui_str': 'Second line treatment'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C0008287', 'cui_str': 'Chlorpropamide'}, {'cui': 'C0017628', 'cui_str': 'Glyburide'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",2339.0,0.0533422,Monotherapy-failure occurred in 72%-82%-75% and 79% for those randomised to chlorpropamide-glibenclamide-basal insulin or metformin respectively-after median 4.5 (3.0-6.6)-3.7 (2.6-5.6)-4.2 (2.7-6.5) and 3.8 (2.6- 5.2) years.,"[{'ForeName': 'Olorunsola F', 'Initials': 'OF', 'LastName': 'Agbaje', 'Affiliation': 'Diabetes Trials Unit, University of Oxford, Oxford, UK. Electronic address: olorunsola.agbaje@dtu.ox.ac.uk.'}, {'ForeName': 'Ruth L', 'Initials': 'RL', 'LastName': 'Coleman', 'Affiliation': 'Diabetes Trials Unit, University of Oxford, Oxford, UK.'}, {'ForeName': 'Andrew T', 'Initials': 'AT', 'LastName': 'Hattersley', 'Affiliation': 'Institute of Biomedical & Clinical Science-University of Exeter Medical School, Exeter, UK.'}, {'ForeName': 'Angus G', 'Initials': 'AG', 'LastName': 'Jones', 'Affiliation': 'Institute of Biomedical & Clinical Science-University of Exeter Medical School, Exeter, UK.'}, {'ForeName': 'Ewan R', 'Initials': 'ER', 'LastName': 'Pearson', 'Affiliation': 'Medical Research Institute, University of Dundee, Dundee, UK.'}, {'ForeName': 'Beverley M', 'Initials': 'BM', 'LastName': 'Shields', 'Affiliation': 'Institute of Biomedical & Clinical Science-University of Exeter Medical School, Exeter, UK.'}, {'ForeName': 'Rury R', 'Initials': 'RR', 'LastName': 'Holman', 'Affiliation': 'Diabetes Trials Unit, University of Oxford, Oxford, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes research and clinical practice,['10.1016/j.diabres.2020.108333'] 1837,32702522,Impact of couple conflict and mediation on how romantic partners are seen: An fMRI study.,"Previous studies on romantic love have reported increased neural activity in the brain's reward circuitry such as the striatum. To date, the extent to which this activity is modulated by couple conflict in general and mediated couple conflict in particular, is unknown. The present study seeks to fill this gap by randomly assigning 36 romantic heterosexual couples to a mediated or non-mediated conflict discussion. Before and after the conflict discussion, self-reports and functional neuroimaging data in response to a picture of the romantic partner versus an unknown person were acquired. Self-reports indicate that mediation increases conflict resolution, satisfaction about the contents and process of the discussion and decreases levels of remaining disagreement. Pre-conflict neuroimaging results replicate previous studies on romantic love, showing activations in the striatum, insula, anterior and posterior cingulate gyrus, orbitofrontal cortex, hippocampus, temporal and occipital poles and amygdala when viewing the romantic partner versus an unknown person. The general effect of conflict on neural activations in response to the romantic partner across both conditions consisted of deactivations in the striatum, insula, thalamus, precuneus and ventral tegmental area. Small volume correction analyses revealed that participants in the mediated condition trended towards having greater activation in the nucleus accumbens than participants in the non-mediated condition when looking at the romantic partner versus the unknown after the conflict discussion. Parametric modulation analyses also revealed greater activity in the nucleus accumbens when viewing the romantic partner versus the unknown for participants who felt more satisfied after the conflict resolution. Our results illustrate that mediation improves conflict resolution and is associated with increased activity in the nucleus accumbens, a key region in the brain's reward circuitry.",2020,Parametric modulation analyses also revealed greater activity in the nucleus accumbens when viewing the romantic partner versus the unknown for participants who felt more satisfied after the conflict resolution.,['36 romantic heterosexual couples to a mediated or non-mediated conflict discussion'],[],"['neural activity', 'conflict resolution']","[{'cui': 'C0019421', 'cui_str': 'Heterosexuality'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0009671', 'cui_str': 'Conflict'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}]",[],"[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0150526', 'cui_str': 'Conflict Resolution'}]",36.0,0.0299096,Parametric modulation analyses also revealed greater activity in the nucleus accumbens when viewing the romantic partner versus the unknown for participants who felt more satisfied after the conflict resolution.,"[{'ForeName': 'Halima', 'Initials': 'H', 'LastName': 'Rafi', 'Affiliation': 'Swiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland; Department of Psychology, University of Geneva, Geneva, Switzerland. Electronic address: Halima.Rafi@unige.ch.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Bogacz', 'Affiliation': 'Swiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland; Computer Vision and Multimedia Laboratory, University of Geneva, Battelle Campus, Carouge, Switzerland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Sander', 'Affiliation': 'Swiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland; Laboratory for the Study of Emotion Elicitation and Expression, Department of Psychology, University of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Klimecki', 'Affiliation': 'Swiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland; Laboratory for the Study of Emotion Elicitation and Expression, Department of Psychology, University of Geneva, Geneva, Switzerland; Laboratory for Behavioral Neurology and Imaging of Cognition, Department of Neuroscience, Medical School, University of Geneva, Geneva, Switzerland. Electronic address: Olga.Klimecki@unige.ch.'}]",Cortex; a journal devoted to the study of the nervous system and behavior,['10.1016/j.cortex.2020.04.036'] 1838,32703191,A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).,"BACKGROUND Although surgery is the definitive curative treatment for biliary tract cancer (BTC), outcomes after surgery alone have not been satisfactory. Adjuvant therapy with S-1 may improve survival in patients with BTC. This study examined the safety and efficacy of 1 year adjuvant S-1 therapy for BTC in a multi-institutional trial. METHODS The inclusion criteria were as follows: histologically proven BTC, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, R0 or R1 surgery performed, cancer classified as Stage IB to III. Within 10 weeks post-surgery, a 42-day cycle of treatment with S-1 (80 mg/m 2 /day orally twice daily on days 1-28 of each cycle) was initiated and continued up to 1 year post surgery. The primary endpoint was adjuvant therapy completion rate. The secondary endpoints were toxicities, disease-free survival (DFS), and overall survival (OS). RESULTS Forty-six patients met the inclusion criteria of whom 19 had extrahepatic cholangiocarcinoma, 10 had gallbladder carcinoma, 9 had ampullary carcinoma, and 8 had intrahepatic cholangiocarcinoma. Overall, 25 patients completed adjuvant chemotherapy, with a 54.3% completion rate while the completion rate without recurrence during the 1 year administration was 62.5%. Seven patients (15%) experienced adverse events (grade 3/4). The median number of courses administered was 7.5. Thirteen patients needed dose reduction or temporary therapy withdrawal. OS and DFS rates at 1/2 years were 91.2/80.0% and 84.3/77.2%, respectively. Among patients who were administered more than 3 courses of S-1, only one patient discontinued because of adverse events. CONCLUSIONS One-year administration of adjuvant S-1 therapy for resected BTC was feasible and may be a promising treatment for those with resected BTC. Now, a randomized trial to determine the optimal duration of S-1 is ongoing. TRIAL REGISTRATION UMIN-CTR, UMIN000009029. Registered 5 October 2012-Retrospectively registered, https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009347.",2020,"Overall, 25 patients completed adjuvant chemotherapy, with a 54.3% completion rate while the completion rate without recurrence during the 1 year administration was 62.5%.","['Forty-six patients met the inclusion criteria of whom 19 had extrahepatic cholangiocarcinoma, 10 had gallbladder carcinoma, 9 had ampullary carcinoma, and 8 had intrahepatic cholangiocarcinoma', 'patients with BTC', 'The inclusion criteria were as follows: histologically proven BTC, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, R0 or R1 surgery performed, cancer classified as Stage IB to III', 'Thirteen patients needed dose reduction or temporary therapy withdrawal']","['adjuvant S-1 therapy', '1\u2009year adjuvant S-1 therapy']","['toxicities, disease-free survival (DFS), and overall survival (OS', 'completion rate without recurrence', 'OS and DFS rates', 'survival', 'adjuvant therapy completion rate', 'safety and efficacy', 'adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C3805278', 'cui_str': 'Extrahepatic Cholangiocarcinoma'}, {'cui': 'C0235782', 'cui_str': 'Carcinoma of gallbladder'}, {'cui': 'C0262401', 'cui_str': 'Carcinoma of ampulla of Vater'}, {'cui': 'C0345905', 'cui_str': 'Intrahepatic bile duct carcinoma'}, {'cui': 'C0750952', 'cui_str': 'Malignant tumor of biliary tract'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0456597', 'cui_str': 'Stage 1B'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0205374', 'cui_str': 'Transitory'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}]","[{'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0879262', 'cui_str': 'S 1 (combination)'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.540534,"Overall, 25 patients completed adjuvant chemotherapy, with a 54.3% completion rate while the completion rate without recurrence during the 1 year administration was 62.5%.","[{'ForeName': 'Osamu', 'Initials': 'O', 'LastName': 'Itano', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan. laplivertiger@gmail.com.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Takemura', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Norihiro', 'Initials': 'N', 'LastName': 'Kishida', 'Affiliation': 'Department of Surgery, Japanese Red Cross Ashikaga Hospital, Tochigi, Japan.'}, {'ForeName': 'Eiji', 'Initials': 'E', 'LastName': 'Tamagawa', 'Affiliation': 'Department of Surgery, Machida Keisen Hospital, Tokyo, Japan.'}, {'ForeName': 'Hiroharu', 'Initials': 'H', 'LastName': 'Shinozaki', 'Affiliation': 'Department of Surgery, Saiseikai Utsunomiya Hospital, Tochigi, Japan.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Ikeda', 'Affiliation': 'Department of Surgery, Sano Kousei General Hospital, Tochigi, Japan.'}, {'ForeName': 'Hidejiro', 'Initials': 'H', 'LastName': 'Urakami', 'Affiliation': 'Department of Surgery, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.'}, {'ForeName': 'Shigenori', 'Initials': 'S', 'LastName': 'Ei', 'Affiliation': 'Department of Surgery, Eiju General Hospital, Tokyo, Japan.'}, {'ForeName': 'Shigeo', 'Initials': 'S', 'LastName': 'Hayatsu', 'Affiliation': 'Department of Surgery, National Hospital Organization Saitama National Hospital, Saitama, Japan.'}, {'ForeName': 'Keiichi', 'Initials': 'K', 'LastName': 'Suzuki', 'Affiliation': 'Department of Surgery, National Hospital Organization Tochigi Medical Center, Tochigi, Japan.'}, {'ForeName': 'Tadayuki', 'Initials': 'T', 'LastName': 'Sakuragawa', 'Affiliation': 'Department of Surgery, Tama Kyuryo Hospital, Tokyo, Japan.'}, {'ForeName': 'Masatsugu', 'Initials': 'M', 'LastName': 'Ishii', 'Affiliation': 'Department of Surgery, Fussa Hospital, Tokyo, Japan.'}, {'ForeName': 'Masaya', 'Initials': 'M', 'LastName': 'Shito', 'Affiliation': 'Department of Surgery, Kawasaki Municipal Kawasaki Hospital, Kanagawa, Japan.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Aiura', 'Affiliation': 'Department of Surgery, Kawasaki Municipal Kawasaki Hospital, Kanagawa, Japan.'}, {'ForeName': 'Hiroto', 'Initials': 'H', 'LastName': 'Fujisaki', 'Affiliation': 'Department of Surgery, Hiratsuka City Hospital, Kanagawa, Japan.'}, {'ForeName': 'Kiminori', 'Initials': 'K', 'LastName': 'Takano', 'Affiliation': 'Department of Surgery, Hiratsuka City Hospital, Kanagawa, Japan.'}, {'ForeName': 'Junichi', 'Initials': 'J', 'LastName': 'Matsui', 'Affiliation': 'Department of Surgery, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan.'}, {'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Minagawa', 'Affiliation': 'Department of Surgery, Saitama City Hospital, Saitama, Japan.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Shinoda', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Minoru', 'Initials': 'M', 'LastName': 'Kitago', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Yuta', 'Initials': 'Y', 'LastName': 'Abe', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Yagi', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Go', 'Initials': 'G', 'LastName': 'Oshima', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Shutaro', 'Initials': 'S', 'LastName': 'Hori', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Kitagawa', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan.'}]",BMC cancer,['10.1186/s12885-020-07185-6'] 1839,32703266,Evaluation of antenatal risk factors for postpartum depression: a secondary cohort analysis of the cluster-randomised GeliS trial.,"BACKGROUND Maternal weight variables are important predictors of postpartum depression (PPD). While preliminary evidence points to an association between pre-pregnancy obesity and PPD, the role of excessive gestational weight gain (GWG) on PPD is less studied. In this secondary cohort analysis of the German 'healthy living in pregnancy' (GeliS) trial, we aimed to investigate associations between weight-related variables and PPD and to assess the influence of GWG on the risk for PPD. METHODS We included women with normal weight, overweight, and obesity (BMI 18.5-40.0 kg/m 2 ). Symptoms of PPD were assessed 6-8 weeks postpartum using the Edinburgh Postnatal Depression Scale. Pre-pregnancy BMI was self-reported. During the course of pregnancy, weight was measured at gynaecological practices within regular check-ups. GWG was defined as the difference between the last measured weight before delivery and the first measured weight at the time of recruitment (≤ 12 th week of gestation). Excessive GWG was classified according to the Institute of Medicine. Multiple logistic regression analyses were used to estimate the odds of PPD in relation to pre-pregnancy BMI, GWG, and excessive GWG adjusting for important confounders. RESULTS Of the total 1583 participants, 45.6% (n = 722) showed excessive GWG and 7.9% (n = 138) experienced PPD. Pre-pregnancy BMI (per 5-unit increase; OR = 1.23, 95% CI 1.08-1.41, p = 0.002) and pre-pregnancy overweight or obesity were significantly positively associated with the odds of developing PPD, particularly among women with an antenatal history of anxiety or depressive symptoms (overweight: OR = 1.93, 95% CI = 1.15-3.22, p = 0.01; obesity: OR = 2.11, 95% CI = 1.13-3.96, p = 0.02). Sociodemographic or lifestyle factors did not additively influence the odds of having PPD. In fully adjusted models, there was no significant evidence that GWG or the occurrence of excessive GWG increased the odds of experiencing PPD (excessive vs. non-excessive: OR = 3.48, 95% CI 0.35-34.94; GWG per 1 kg increase: OR = 1.16, 95% CI 0.94-1.44). CONCLUSION Pre-pregnancy overweight or obesity is associated with PPD independent of concurrent risk factors. History of anxiety or depressive symptoms suggests a stress-induced link between pre-pregnancy weight and PPD. TRIAL REGISTRATION NCT01958307 , ClinicalTrials.gov, retrospectively registered on 9 October 2013.",2020,"RESULTS Of the total 1583 participants, 45.6% (n = 722) showed excessive GWG and 7.9% (n = 138) experienced PPD","['postpartum depression', 'women with normal weight, overweight, and obesity (BMI 18.5-40.0\u2009kg/m 2 ', ""German 'healthy living in pregnancy' (GeliS) trial""]",[],"[' Pre-pregnancy BMI', 'antenatal history of anxiety or depressive symptoms', 'excessive GWG', 'PPD', 'Edinburgh Postnatal Depression Scale. Pre', 'Symptoms of PPD', 'pregnancy BMI', 'pre-pregnancy overweight or obesity']","[{'cui': 'C0221074', 'cui_str': 'Postpartum depression'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517611', 'cui_str': '18.5'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],"[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C2828394', 'cui_str': 'Antenatal'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0442802', 'cui_str': 'Excessive'}, {'cui': 'C1398625', 'cui_str': 'Maternal Weight Gain'}, {'cui': 'C0221074', 'cui_str': 'Postpartum depression'}, {'cui': 'C0451144', 'cui_str': 'Edinburgh postnatal depression scale'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]",1583.0,0.137812,"RESULTS Of the total 1583 participants, 45.6% (n = 722) showed excessive GWG and 7.9% (n = 138) experienced PPD","[{'ForeName': 'Hamimatunnisa', 'Initials': 'H', 'LastName': 'Johar', 'Affiliation': 'Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Hoffmann', 'Affiliation': 'Institute of Nutritional Medicine, Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Georg-Brauchle-Ring 62, 80992, Munich, Germany.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Günther', 'Affiliation': 'Institute of Nutritional Medicine, Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Georg-Brauchle-Ring 62, 80992, Munich, Germany.'}, {'ForeName': 'Seryan', 'Initials': 'S', 'LastName': 'Atasoy', 'Affiliation': 'Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany.'}, {'ForeName': 'Lynne', 'Initials': 'L', 'LastName': 'Stecher', 'Affiliation': 'Institute of Nutritional Medicine, Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Georg-Brauchle-Ring 62, 80992, Munich, Germany.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Spies', 'Affiliation': 'Institute of Nutritional Medicine, Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Georg-Brauchle-Ring 62, 80992, Munich, Germany.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Hauner', 'Affiliation': 'Institute of Nutritional Medicine, Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Georg-Brauchle-Ring 62, 80992, Munich, Germany. hans.hauner@tum.de.'}, {'ForeName': 'Karl-Heinz', 'Initials': 'KH', 'LastName': 'Ladwig', 'Affiliation': 'Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany. Karl-Heinz.Ladwig@tum.de.'}]",BMC medicine,['10.1186/s12916-020-01679-7'] 1840,32703270,The effect of blue dishware versus white dishware on food intake and eating challenges among residents living with dementia: a crossover trial.,"OBJECTIVE Residents living with dementia (RLWD) often experience changes in their visual perception, which could reduce food intake. Inadequate food intake is known to cause malnutrition, which increases the risk of hospitalization, morbidity, and mortality. This study evaluated the effectiveness of using blue dishware compared to white dishware to improve food intake and mitigate eating challenges among 18 RLWD (mean age 84.6 ± 7.9 years, 72.2% female). RESULTS A within-within person crossover design determined differences in food intake and eating challenges between blue and white dishware conditions. Five participants responded to the blue dishware and increased their average food intake by ≥ 10%. Responders were not different from non-responders in terms of demographic or health characteristics. The proportion of eating challenges experienced was not significantly different between the blue and white dishware conditions. Percent food intake was significantly greater at lunch (83.5 ± 19.0%) compared to dinner (75.8 ± 22.1%; p < 0.0001), regardless of dishware condition. However, there were no significant differences for food intake between the dishware conditions, even after matching food choices. Promoting food intake and reducing eating challenges in RLWD likely needs multi-component interventions targeting meal quality, meal access, and mealtime experience. Trial registration ClincialTrials.gov Identifier: NCT04298788. Retrospectively registered: 6 March 2020, https://clinicaltrials.gov/ct2/show/NCT04298788?term=NCT04298788&draw=2&rank=1 .",2020,"Percent food intake was significantly greater at lunch (83.5 ± 19.0%) compared to dinner (75.8 ± 22.1%; p < 0.0001), regardless of dishware condition.","['18 RLWD (mean age 84.6\u2009±\u20097.9\xa0years, 72.2% female', 'Residents living with dementia (RLWD', 'residents living with dementia']",['blue dishware versus white dishware'],"['Percent food intake', 'food intake and eating challenges', 'proportion of eating challenges', 'food intake', 'food intake and mitigate eating challenges', 'risk of hospitalization, morbidity, and mortality', 'average food intake']","[{'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C1260957', 'cui_str': 'Blue color'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0013470', 'cui_str': 'Eating'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",5.0,0.0765427,"Percent food intake was significantly greater at lunch (83.5 ± 19.0%) compared to dinner (75.8 ± 22.1%; p < 0.0001), regardless of dishware condition.","[{'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Donnelly', 'Affiliation': 'University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Wei', 'Affiliation': 'University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Morrison-Koechl', 'Affiliation': 'University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Keller', 'Affiliation': 'University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada. hkeller@uwaterloo.ca.'}]",BMC research notes,['10.1186/s13104-020-05195-y'] 1841,32703288,Randomized control trial testing the effectiveness of implemented depression prevention in high-risk adolescents.,"BACKGROUND Adolescent depression is a global mental health concern. Identification and effective prevention in an early stage are necessary. The present randomized, controlled trial aimed to examine the effectiveness of Cognitive Behavioral Therapy (CBT)-based depression prevention in adolescents with elevated depressive symptoms. This prevention approach is implemented in school communities, which allows to examine effects under real-life circumstances. METHODS A total of 5222 adolescents were screened for elevated depressive symptoms in the second grade of secondary schools; 130 adolescents aged between 12 and 16 years old (M = 13.59; SD = 0.68; 63.8% girls) were randomly assigned to the experimental (OVK 2.0) or control condition (psycho-education). Self- and parent-reported depressive symptoms were assessed at pretest and post intervention, as well as 6- and 12-months follow-up. Clinical assessment of depression was assessed at pretest and 6-months follow-up. RESULTS Intent-to-treat analyses revealed that the decrease in adolescent-rated depressive symptoms was significantly larger in the intervention condition than in the control condition. There was no significant difference in decrease of parent-rated depressive symptoms between both conditions. CONCLUSIONS Based on the findings, we recommend the implementation of screening and prevention in schools, according the basics of this study design. Since this is a new step forward, we discuss the clinical impact and challenges, as well possibilities for future research. TRIAL REGISTRATION The study is registered in the Dutch Trial Register for RCT's ( NTR5725 ). Date registered: 11 March 2016.",2020,"RESULTS Intent-to-treat analyses revealed that the decrease in adolescent-rated depressive symptoms was significantly larger in the intervention condition than in the control condition.","['5222 adolescents were screened for elevated depressive symptoms in the second grade of secondary schools; 130 adolescents aged between 12 and 16\u2009years old (M\u2009=\u200913.59; SD\u2009=\u20090.68; 63.8% girls', 'adolescents with elevated depressive symptoms', 'high-risk adolescents']","['Cognitive Behavioral Therapy (CBT)-based depression prevention', 'experimental (OVK 2.0) or control condition (psycho-education']","['decrease of parent-rated depressive symptoms', 'adolescent-rated depressive symptoms', 'Self- and parent-reported depressive symptoms']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0036530', 'cui_str': 'Secondary school'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4517473', 'cui_str': '0.68'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}]","[{'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0684224', 'cui_str': 'Report'}]",5222.0,0.154615,"RESULTS Intent-to-treat analyses revealed that the decrease in adolescent-rated depressive symptoms was significantly larger in the intervention condition than in the control condition.","[{'ForeName': 'Karlijn W J', 'Initials': 'KWJ', 'LastName': 'de Jonge-Heesen', 'Affiliation': 'GGZ Oost Brabant, P.O. Box 3, 5427 ZG, Boekel, The Netherlands. kwj.heesen@ggzoostbrabant.nl.'}, {'ForeName': 'Sanne P A', 'Initials': 'SPA', 'LastName': 'Rasing', 'Affiliation': 'GGZ Oost Brabant, P.O. Box 3, 5427 ZG, Boekel, The Netherlands.'}, {'ForeName': 'Ad A', 'Initials': 'AA', 'LastName': 'Vermulst', 'Affiliation': 'GGZ Oost Brabant, P.O. Box 3, 5427 ZG, Boekel, The Netherlands.'}, {'ForeName': 'Ron H J', 'Initials': 'RHJ', 'LastName': 'Scholte', 'Affiliation': 'Praktikon, P.O. Box 6909, 6503 GK, Nijmegen, The Netherlands.'}, {'ForeName': 'Kim M', 'Initials': 'KM', 'LastName': 'van Ettekoven', 'Affiliation': 'GGZ Oost Brabant, P.O. Box 3, 5427 ZG, Boekel, The Netherlands.'}, {'ForeName': 'Rutger C M E', 'Initials': 'RCME', 'LastName': 'Engels', 'Affiliation': 'Erasmus School of Social and Behavioural Sciences, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.'}, {'ForeName': 'Daan H M', 'Initials': 'DHM', 'LastName': 'Creemers', 'Affiliation': 'GGZ Oost Brabant, P.O. Box 3, 5427 ZG, Boekel, The Netherlands.'}]",BMC medicine,['10.1186/s12916-020-01656-0'] 1842,32708517,Concurrent Validity of Digital Vascular Auscultation for the Assessment of Blood Flow Obliteration on the Radial Artery in Healthy Subjects.,"This study aimed to determine the validity of digital vascular auscultation for the assessment of changes in the radial pulse in healthy subjects, using Doppler sonography as a validated test referent. Sixty-one non-symptomatic subjects (mean age of 52.5 ± 16.1 years) were assigned and evaluated under one of the following conditions: In condition 1, blood flow of the radial artery was not modified; for condition 2, blood flow of the radial artery was modified using a pressure sleeve around the humerus. The radial pulse was then measured three times with each diagnostic tool by three different blinded evaluators. Both instruments demonstrated a high association between the identification of blood flow modifications or not and the assigned condition ( p < 0.001). A strong concordance between the two devices when detecting the ""changes"" or ""no changes"" in blood flow was demonstrated ( k = 0.936, p < 0.001). Stethoscope sensitivity was 95%, and specificity was 99%. In conclusion, digital vascular auscultation seems to be a valid technique to examine blood flow changes of the radial artery in non-symptomatic subjects, and it could be useful for physical therapists when combined with provocative tests for the screening of possible thoracic outlet syndrome in patients.",2020,"A strong concordance between the two devices when detecting the ""changes"" or ""no changes"" in blood flow was demonstrated ( k = 0.936, p < 0.001).","['Sixty-one non-symptomatic subjects (mean age of 52.5 ± 16.1 years', 'healthy subjects', 'Healthy Subjects']","['digital vascular auscultation', 'Digital Vascular Auscultation']","['changes"" or ""no changes"" in blood flow', 'Stethoscope sensitivity', 'Blood Flow Obliteration', 'radial pulse']","[{'cui': 'C4517832', 'cui_str': '61'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517802', 'cui_str': '52.5'}, {'cui': 'C4319689', 'cui_str': '16.1'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0004339', 'cui_str': 'Auscultation'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0442739', 'cui_str': 'No status change'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0183559', 'cui_str': 'Stethoscope'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0332465', 'cui_str': 'Obliteration'}, {'cui': 'C0232142', 'cui_str': 'Radial pulse'}]",,0.0586544,"A strong concordance between the two devices when detecting the ""changes"" or ""no changes"" in blood flow was demonstrated ( k = 0.936, p < 0.001).","[{'ForeName': 'María-Dolores', 'Initials': 'MD', 'LastName': 'Cortés-Vega', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}, {'ForeName': 'María Jesús', 'Initials': 'MJ', 'LastName': 'Casuso-Holgado', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}, {'ForeName': 'Ángel', 'Initials': 'Á', 'LastName': 'Oliva-Pascual-Vaca', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}, {'ForeName': 'María-Isabel', 'Initials': 'MI', 'LastName': 'García-Bernal', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'González-García', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}, {'ForeName': 'Cleofás', 'Initials': 'C', 'LastName': 'Rodríguez-Blanco', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}]","Diagnostics (Basel, Switzerland)",['10.3390/diagnostics10070494'] 1843,32708555,"Caffeine Supplementation for 4 Days Does Not Induce Tolerance to the Ergogenic Effects Promoted by Acute Intake on Physiological, Metabolic, and Performance Parameters of Cyclists: A Randomized, Double-Blind, Crossover, Placebo-Controlled Study.","The present study investigated whether the caffeine supplementation for four days would induce tolerance to the ergogenic effects promoted by acute intake on physiological, metabolic, and performance parameters of cyclists. A double-blind placebo-controlled cross-over design was employed, involving four experimental trials; placebo (4-day)-placebo (acute)/PP, placebo (4-day)-caffeine (acute)/PC, caffeine (4-day)-caffeine (acute)/CC and caffeine (4-day)-placebo (acute)/CP. Fourteen male recreationally-trained cyclists ingested capsules containing either placebo or caffeine (6 mg∙kg -1 ) for 4 days. On day 5 (acute), capsules containing placebo or caffeine (6 mg∙kg -1 ) were ingested 60 min before completing a 16 km time-trial (TT). CC and PC showed improvements in time (3.54%, ES = 0.72; 2.53%, ES = 0.51) and in output power (2.85%, ES = 0.25; 2.53%, ES = 0.20) ( p < 0.05) compared to CP and PP conditions, respectively. These effects were accompanied by increased heart rate (2.63%, ES = 0.47; 1.99%, ES = 0.34), minute volume (13.11%, ES = 0.61; 16.32%, ES = 0.75), expired O 2 fraction (3.29%, ES = 0.96; 2.87, ES = 0.72), lactate blood concentration (immediately after, 29.51% ES = 0.78; 28.21% ES = 0.73 recovery (10 min), 36.01% ES = 0.84; 31.22% ES = 0.81), and reduction in expired CO 2 fraction (7.64%, ES = 0.64; 7.75%, ES = 0.56). In conclusion, these results indicate that caffeine, when ingested by cyclists in a dose of 6 mg∙kg -1 for 4 days, does not induce tolerance to the ergogenic effects promoted by acute intake on physiological, metabolic, and performance parameters.",2020,"CC and PC showed improvements in time (3.54%, ES = 0.72; 2.53%, ES = 0.51) and in output power (2.85%, ES = 0.25; 2.53%, ES = 0.20) ( p < 0.05) compared to CP and PP conditions, respectively.",['Fourteen male recreationally-trained cyclists ingested capsules containing either'],"['Placebo', 'Caffeine Supplementation', 'placebo or caffeine', 'caffeine supplementation', 'caffeine', 'placebo (4-day)-placebo (acute)/PP, placebo (4-day)-caffeine (acute)/PC, caffeine (4-day)-caffeine (acute)/CC and caffeine (4-day)-placebo', 'placebo']","['acute intake on physiological, metabolic, and performance parameters', 'lactate blood concentration', 'output power', 'heart rate', 'minute volume']","[{'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0332256', 'cui_str': 'Containing'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0427728', 'cui_str': 'Blood concentration, dipstick - finding'}, {'cui': 'C3251815', 'cui_str': 'Measurement of fluid output'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0428679', 'cui_str': 'Minute volume'}]",,0.335508,"CC and PC showed improvements in time (3.54%, ES = 0.72; 2.53%, ES = 0.51) and in output power (2.85%, ES = 0.25; 2.53%, ES = 0.20) ( p < 0.05) compared to CP and PP conditions, respectively.","[{'ForeName': 'Anderson Pontes', 'Initials': 'AP', 'LastName': 'Morales', 'Affiliation': 'Laboratory Research and Innovation in Sports Sciences, Federal University of Rio de Janeiro (UFRJ), Macaé, RJ 27930-560, Brazil.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Sampaio-Jorge', 'Affiliation': 'Laboratory Research and Innovation in Sports Sciences, Federal University of Rio de Janeiro (UFRJ), Macaé, RJ 27930-560, Brazil.'}, {'ForeName': 'Thiago', 'Initials': 'T', 'LastName': 'Barth', 'Affiliation': 'Postgraduate Program in Bioactive Products and Biosciences, Federal University of Rio de Janeiro (UFRJ), Macaé, RJ 27930-560, Brazil.'}, {'ForeName': 'Anna Paola Trindade Rocha', 'Initials': 'APTR', 'LastName': 'Pierucci', 'Affiliation': 'Postgraduate Program in Nutrition, Josué de Castro Nutrition Institute, Federal University of Rio de Janeiro (UFRJ), Macaé, RJ 21941-590, Brazil.'}, {'ForeName': 'Beatriz Gonçalves', 'Initials': 'BG', 'LastName': 'Ribeiro', 'Affiliation': 'Laboratory Research and Innovation in Sports Sciences, Federal University of Rio de Janeiro (UFRJ), Macaé, RJ 27930-560, Brazil.'}]",Nutrients,['10.3390/nu12072101'] 1844,32709005,Importance of Self-Efficacy in Eating Behavior and Physical Activity Change of Overweight and Non-Overweight Adolescent Girls Participating in Healthy Me: A Lifestyle Intervention with Mobile Technology.,"Very little is known about how multicomponent interventions directed to entire populations work in selected groups of adolescents. The aim was to evaluate the effectiveness of the Healthy Me one-year program on changes in healthy eating and physical activity among overweight and non-overweight female students. Randomization involved the allocation of full, partial or null intervention. The randomized field trial was implemented in 48 secondary schools (clusters) all over Poland among 1198 15-year-old girls. In this study, a sample of N = 1111 girls who participated in each evaluation study was analyzed. Using multimedia technologies, efforts were made to improve health behaviors and increase self-efficacy. The main outcome was a health behavior index (HBI), built on the basis of six nutritional indicators and one related to physical activity. HBI was analyzed before and immediately after intervention and at three months' follow-up, and the HBI change was modeled. Statistical analysis included nonparametric tests and generalized linear models with two-way interactions. Comparing the first and third surveys, in the overweight girls, the HBI index improved by 0.348 (SD = 3.17), while in the non-overweight girls it had worsened. After adjusting for other factors, a significant interaction between body weight status and level of self-efficacy as predictors of HBI changes was confirmed. The program turned out to be more beneficial for overweight girls.",2020,"Comparing the first and third surveys, in the overweight girls, the HBI index improved by 0.348 (SD = 3.17), while in the non-overweight girls it had worsened.","['sample of N = 1111 girls who participated in each evaluation study was analyzed', 'Overweight and Non-Overweight Adolescent Girls Participating in Healthy Me', 'healthy eating and physical activity among overweight and non-overweight female students', '48 secondary schools (clusters) all over Poland among 1198 15-year-old girls']",['Healthy Me one-year program'],"['health behavior index (HBI), built on the basis of six nutritional indicators and one related to physical activity', 'HBI index', 'body weight status and level of self-efficacy', 'HBI', 'health behaviors and increase self-efficacy']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0015196', 'cui_str': 'Evaluation Studies'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0036530', 'cui_str': 'Secondary school'}, {'cui': 'C0032356', 'cui_str': 'Poland'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",1111.0,0.0178854,"Comparing the first and third surveys, in the overweight girls, the HBI index improved by 0.348 (SD = 3.17), while in the non-overweight girls it had worsened.","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Dzielska', 'Affiliation': 'Department of Child and Adolescent Health, Institute of Mother and Child, 17a Kasprzaka St., 01-211 Warsaw, Poland.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Mazur', 'Affiliation': 'Department of Child and Adolescent Health, Institute of Mother and Child, 17a Kasprzaka St., 01-211 Warsaw, Poland.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Nałęcz', 'Affiliation': 'Department of Child and Adolescent Health, Institute of Mother and Child, 17a Kasprzaka St., 01-211 Warsaw, Poland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Oblacińska', 'Affiliation': 'Department of Child and Adolescent Health, Institute of Mother and Child, 17a Kasprzaka St., 01-211 Warsaw, Poland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Fijałkowska', 'Affiliation': 'Department of Cardiology, Institute of Mother and Child, 17a Kasprzaka St., 01-211 Warsaw, Poland.'}]",Nutrients,['10.3390/nu12072128'] 1845,32709051,The Effect of Dietary Inorganic Nitrate Supplementation on Cardiac Function during Submaximal Exercise in Men with Heart Failure with Reduced Ejection Fraction (HFrEF): A Pilot Study.,"Heart failure with reduced ejection fraction (HFrEF) is a common end point for patients with coronary artery disease and it is characterized by exercise intolerance due, in part, to a reduction in cardiac output. Nitric oxide (NO) plays a vital role in cardiac function and patients with HFrEF have been identified as having reduced vascular NO. This pilot study aimed to investigate if nitrate supplementation could improve cardiac measures during acute, submaximal exercise. Five male participants (61 ± 3 years) with HFrEF (EF 32 ± 2.2%) completed this pilot study. All participants supplemented with inorganic nitrate (beetroot juice) or a nitrate-depleted placebo for ~13 days prior to testing. Participants completed a three-stage submaximal exercise protocol on a recumbent cycle ergometer with simultaneous echocardiography for calculation of cardiac output (Q), stroke volume (SV), and total peripheral resistance (TPR). Heart rate and blood pressure were measured at rest and during each stage. Both plasma nitrate (mean = ~1028%, p = 0.004) and nitrite (mean = ~109%, p = 0.01) increased following supplementation. There were no differences between interventions at rest, but the percent change in SV and Q from rest to stage two and stage three of exercise was higher following nitrate supplementation (all p > 0.05, ES > 0.8). Both interventions showed decreases in TPR during exercise, but the percent reduction TPR in stages two and three was greater following nitrate supplementation ( p = 0.09, ES = 0.98 and p = 0.14, ES = 0.82, respectively). There were clinically relevant increases in cardiac function during exercise following supplementation with nitrate. The findings from this pilot study warrant further investigation in larger clinical trials.",2020,"Both plasma nitrate (mean = ~1028%, p = 0.004) and nitrite (mean = ~109%, p = 0.01) increased following supplementation.","['Five male participants (61 ± 3 years) with HFrEF (EF 32 ± 2.2%) completed this pilot study', 'Men with Heart Failure with Reduced Ejection Fraction (HFrEF', 'patients with coronary artery disease']","['Nitric oxide (NO', 'Dietary Inorganic Nitrate Supplementation', 'nitrate supplementation', 'inorganic nitrate (beetroot juice) or a nitrate-depleted placebo', 'submaximal exercise protocol on a recumbent cycle ergometer with simultaneous echocardiography', 'reduced ejection fraction (HFrEF']","['percent reduction TPR', 'Heart rate and blood pressure', 'Cardiac Function', 'TPR during exercise', 'cardiac measures', 'cardiac function', 'cardiac output (Q), stroke volume (SV), and total peripheral resistance (TPR', 'plasma nitrate']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}, {'cui': 'C4517629', 'cui_str': '2.2'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0031928', 'cui_str': 'Pilot Study'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}]","[{'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C1095905', 'cui_str': 'Beets preparation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0444334', 'cui_str': 'Recumbent body position'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0013516', 'cui_str': 'Echocardiography'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1258192', 'cui_str': 'Systemic vascular resistance'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0587107', 'cui_str': 'During exercise'}, {'cui': 'C0588131', 'cui_str': 'Cardiac measure'}, {'cui': 'C0007165', 'cui_str': 'Cardiac output'}, {'cui': 'C0038455', 'cui_str': 'Stroke volume'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}]",5.0,0.203872,"Both plasma nitrate (mean = ~1028%, p = 0.004) and nitrite (mean = ~109%, p = 0.01) increased following supplementation.","[{'ForeName': 'Mary N', 'Initials': 'MN', 'LastName': 'Woessner', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 3011, Australia.'}, {'ForeName': 'Itamar', 'Initials': 'I', 'LastName': 'Levinger', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 3011, Australia.'}, {'ForeName': 'Jason D', 'Initials': 'JD', 'LastName': 'Allen', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 3011, Australia.'}, {'ForeName': 'Luke C', 'Initials': 'LC', 'LastName': 'McIlvenna', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 3011, Australia.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Neil', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 3011, Australia.'}]",Nutrients,['10.3390/nu12072132'] 1846,32717294,A Novel Link between the Oxytocin Receptor Gene and Impulsivity.,"Impulsivity includes hasty actions, social intrusiveness or premature decision-making. Neuropeptides like oxytocin alleviate haste and anxiety, and affect fear conditioning. However, no investigations have been done via gene-network based approach with cognitive and interventional genetic association studies to scrutinize the link between impulsive behavior and oxytocin. Here, interactive gene network and pathways associated with impulsivity were reconstructed, and serotonin transporter gene (SLC6A4) and serotoninergic synaptic transmission were identified as the most central gene and pathway related to impulsivity. Young healthy males received intranasal oxytocin or placebo, and impulsivity was evaluated via go/no-go test. Test performance scores then were analyzed based on commission and omission errors, response inhibition and reaction time. Blood DNA was extracted and a 761 bp intronic region in oxytocin receptor (OXTR) gene was amplified and sequenced using PCR-pyrosequencing. Employing Haploview, haplotypes and linkage disequilibrium (LD) pattern among all SNPs in the target sequence were determined based on D' and LOD values, and rs2254298 with the highest LD was indicated as the tag SNP. Oxytocin group and participants with GG genotype showed a significantly decreased commission error and increased inhibition. This means that oxytocin alleviated impulsive behavior, and subjects with GG genotype had lower rate of impulsivity than those with GA and AA genotypes. rs2254298 may modulate the function or expression of the OXTR gene, implying that G allele may increase the expression of OXTR gene compared to A allele. We suggest that intranasal oxytocin may notably moderate impulsive behavior and tendency to make hasty or premature decisions.",2020,Oxytocin group and participants with GG genotype showed a significantly decreased commission error and increased inhibition.,['Young healthy males'],"['Oxytocin', 'oxytocin', 'intranasal oxytocin or placebo', 'intranasal oxytocin']","['commission and omission errors, response inhibition and reaction time', 'Impulsivity includes hasty actions, social intrusiveness or premature decision-making', 'Blood DNA', 'rate of impulsivity', 'commission error and increased inhibition']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0021125', 'cui_str': 'Impulsive behaviour'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0011109', 'cui_str': 'Decision making'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic acid'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",,0.034954,Oxytocin group and participants with GG genotype showed a significantly decreased commission error and increased inhibition.,"[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Bozorgmehr', 'Affiliation': 'Iran Psychiatric Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran. Electronic address: bozorgmehr.a@iums.ac.ir.'}, {'ForeName': 'Razieh', 'Initials': 'R', 'LastName': 'Moayedi', 'Affiliation': 'Department of Mathematics, Payam Noor University of Tehran, Tehran, Iran.'}, {'ForeName': 'Bahman', 'Initials': 'B', 'LastName': 'Sadeghi', 'Affiliation': 'Department of Biochemistry, Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Ghadirivasfi', 'Affiliation': 'Research Center for Addiction and Risky Behavior (ReCARB), Iran University of Medical Sciences (IUMS), Tehran, Iran. Electronic address: gadirivasfi.m@iums.ac.ir.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Taghi Joghataei', 'Affiliation': 'Cellular and Molecular Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Shahbazi', 'Affiliation': 'Department of Neuroscience, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran. Electronic address: shahbazi.a@iums.ac.irshah.'}]",Neuroscience,['10.1016/j.neuroscience.2020.07.033'] 1847,32692370,Association of Gender and Race With Allocation of Advanced Heart Failure Therapies.,"Importance Racial bias is associated with the allocation of advanced heart failure therapies, heart transplants, and ventricular assist devices. It is unknown whether gender and racial biases are associated with the allocation of advanced therapies among women. Objective To determine whether the intersection of patient gender and race is associated with the decision-making of clinicians during the allocation of advanced heart failure therapies. Design, Setting, and Participants In this qualitative study, 46 US clinicians attending a conference for an international heart transplant organization in April 2019 were interviewed on the allocation of advanced heart failure therapies. Participants were randomized to examine clinical vignettes that varied 1:1 by patient race (African American to white) and 20:3 by gender (women to men) to purposefully target vignettes of women patients to compare with a prior study of vignettes of men patients. Participants were interviewed about their decision-making process using the think-aloud technique and provided supplemental surveys. Interviews were analyzed using grounded theory methodology, and surveys were analyzed with Wilcoxon tests. Exposure Randomization to clinical vignettes. Main Outcomes and Measures Thematic differences in allocation of advanced therapies by patient race and gender. Results Among 46 participants (24 [52%] women, 20 [43%] racial minority), participants were randomized to the vignette of a white woman (20 participants [43%]), an African American woman (20 participants [43%]), a white man (3 participants [7%]), and an African American man (3 participants [7%]). Allocation differences centered on 5 themes. First, clinicians critiqued the appearance of the women more harshly than the men as part of their overall impressions. Second, the African American man was perceived as experiencing more severe illness than individuals from other racial and gender groups. Third, there was more concern regarding appropriateness of prior care of the African American woman compared with the white woman. Fourth, there were greater concerns about adequacy of social support for the women than for the men. Children were perceived as liabilities for women, particularly the African American woman. Family dynamics and finances were perceived to be greater concerns for the African American woman than for individuals in the other vignettes; spouses were deemed inadequate support for women. Last, participants recommended ventricular assist devices over transplantation for all racial and gender groups. Surveys revealed no statistically significant differences in allocation recommendations for African American and white women patients. Conclusions and Relevance This national study of health care professionals randomized to clinical vignettes that varied only by gender and race found evidence of gender and race bias in the decision-making process for offering advanced therapies for heart failure, particularly for African American women patients, who were judged more harshly by appearance and adequacy of social support. There was no associated between patient gender and race and final recommendations for allocation of advanced therapies. However, it is possible that bias may contribute to delayed allocation and ultimately inequity in the allocation of advanced therapies in a clinical setting.",2020,Family dynamics and finances were perceived to be greater concerns for the African American woman than for individuals in the other vignettes; spouses were deemed inadequate support for women.,"['Participants were randomized to examine clinical vignettes that varied 1:1 by patient race (African American to white) and 20:3 by gender (women to men) to purposefully target vignettes of women patients to compare with a prior study of vignettes of men patients', '46 US clinicians attending a conference for an international heart transplant organization in April 2019 were interviewed on the allocation of advanced heart failure therapies', 'African American and white women patients', 'African American woman than for individuals in the other vignettes; spouses were deemed inadequate support for women', 'African American women patients', '46 participants (24 [52%] women, 20 [43%] racial minority), participants were randomized to the vignette of a white woman (20 participants [43%]), an African American woman (20 participants [43%]), a white man (3 participants [7%]), and an African American man (3 participants [7']",[],"['severe illness', 'allocation recommendations', 'allocation of advanced therapies by patient race and gender']","[{'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0018823', 'cui_str': 'Transplantation of heart'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0162409', 'cui_str': 'Spouse'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0026192', 'cui_str': 'Minority Groups'}]",[],"[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0079399', 'cui_str': 'Gender'}]",,0.0634317,Family dynamics and finances were perceived to be greater concerns for the African American woman than for individuals in the other vignettes; spouses were deemed inadequate support for women.,"[{'ForeName': 'Khadijah', 'Initials': 'K', 'LastName': 'Breathett', 'Affiliation': 'Sarver Heart Center, Division of Cardiology, Department of Medicine, University of Arizona, Tucson.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Yee', 'Affiliation': 'Sarver Heart Center, Clinical Research Office, University of Arizona, Tucson.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Pool', 'Affiliation': 'College of Nursing, University of Arizona, Tucson.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Hebdon', 'Affiliation': 'College of Nursing, University of Utah, Salt Lake City.'}, {'ForeName': 'Janice D', 'Initials': 'JD', 'LastName': 'Crist', 'Affiliation': 'College of Nursing, University of Arizona, Tucson.'}, {'ForeName': 'Ryan H', 'Initials': 'RH', 'LastName': 'Yee', 'Affiliation': 'Sarver Heart Center, Clinical Research Office, University of Arizona, Tucson.'}, {'ForeName': 'Shannon M', 'Initials': 'SM', 'LastName': 'Knapp', 'Affiliation': 'Statistics Consulting Lab, Bio5 Institute, University of Arizona, Tucson.'}, {'ForeName': 'Sade', 'Initials': 'S', 'LastName': 'Solola', 'Affiliation': 'Department of Medicine, University of Arizona, Tucson.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Luy', 'Affiliation': 'University of Rochester, New York.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Herrera-Theut', 'Affiliation': 'University of Arizona Medical School, Tucson.'}, {'ForeName': 'Leanne', 'Initials': 'L', 'LastName': 'Zabala', 'Affiliation': 'Department of Medicine, University of California, Los Angeles.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Stone', 'Affiliation': 'Department of Psychology, University of Arizona, Tucson.'}, {'ForeName': 'Marylyn M', 'Initials': 'MM', 'LastName': 'McEwen', 'Affiliation': 'College of Nursing, University of Arizona, Tucson.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Calhoun', 'Affiliation': 'Center for Population Health Sciences, University of Arizona, Tucson.'}, {'ForeName': 'Nancy K', 'Initials': 'NK', 'LastName': 'Sweitzer', 'Affiliation': 'Sarver Heart Center, Division of Cardiology, Department of Medicine, University of Arizona, Tucson.'}]",JAMA network open,['10.1001/jamanetworkopen.2020.11044'] 1848,32696600,The detrimental effect of COVID-19 nationwide quarantine on accelerometer-assessed physical activity of heart failure patients.,"AIMS A reduction of habitual physical activity due to prolonged COVID-19 quarantine can have serious consequences for patients with cardiovascular diseases, such as heart failure. This study aimed to explore the effect of COVID-19 nationwide quarantine on accelerometer-assessed physical activity of heart failure patients. METHODS AND RESULTS We analysed the daily number of steps in 26 heart failure patients during a 6-week period that included 3 weeks immediately preceding the onset of the quarantine and the first 3 weeks of the quarantine. The daily number of steps was assessed using a wrist-worn accelerometer worn by the patients as part of an ongoing randomized controlled trial. Multilevel modelling was used to explore the effect of the quarantine on the daily step count adjusted for weather conditions. As compared with the 3 weeks before the onset of the quarantine, the step count was significantly lower during each of the first 3 weeks of the quarantine (P < 0.05). When the daily step count was averaged across the 3 weeks before and during the quarantine, the decrease amounted to 1134 (SE 189) steps per day (P < 0.001), which translated to a 16.2% decrease. CONCLUSIONS The introduction of the nationwide quarantine due to COVID-19 had a detrimental effect on the level of habitual physical activity in heart failure patients, leading to an abrupt decrease of daily step count that lasted for at least the 3-week study period. Staying active and maintaining sufficient levels of physical activity during the COVID-19 pandemic are essential despite the unfavourable circumstances of quarantine.",2020,"The introduction of the nationwide quarantine due to COVID-19 had a detrimental effect on the level of habitual physical activity in heart failure patients, leading to an abrupt decrease of daily step count that lasted for at least the 3-week study period.","['heart failure patients', 'patients with cardiovascular diseases, such as heart failure', '26 heart failure patients']",['COVID-19 nationwide quarantine'],['habitual physical activity'],"[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}]","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0034386', 'cui_str': 'Quarantine'}]","[{'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.0344114,"The introduction of the nationwide quarantine due to COVID-19 had a detrimental effect on the level of habitual physical activity in heart failure patients, leading to an abrupt decrease of daily step count that lasted for at least the 3-week study period.","[{'ForeName': 'Tomas', 'Initials': 'T', 'LastName': 'Vetrovsky', 'Affiliation': 'Faculty of Physical Education and Sport, Charles University, José Martího 269/31, Prague, 162 52, Czech Republic.'}, {'ForeName': 'Tereza', 'Initials': 'T', 'LastName': 'Frybova', 'Affiliation': '2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.'}, {'ForeName': 'Iulian', 'Initials': 'I', 'LastName': 'Gant', 'Affiliation': '2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.'}, {'ForeName': 'Miroslav', 'Initials': 'M', 'LastName': 'Semerad', 'Affiliation': 'Faculty of Physical Education and Sport, Charles University, José Martího 269/31, Prague, 162 52, Czech Republic.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Cimler', 'Affiliation': 'Faculty of Science, University of Hradec Králové, Hradec Králové, Czech Republic.'}, {'ForeName': 'Vaclav', 'Initials': 'V', 'LastName': 'Bunc', 'Affiliation': 'Faculty of Physical Education and Sport, Charles University, José Martího 269/31, Prague, 162 52, Czech Republic.'}, {'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Siranec', 'Affiliation': '2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Miklikova', 'Affiliation': 'Cardiology Department, University Hospital Brno and Medical Faculty of the Masaryk University, Brno, Czech Republic.'}, {'ForeName': 'Jiri', 'Initials': 'J', 'LastName': 'Vesely', 'Affiliation': 'Faculty of Medicine in Hradec Králové, Charles University, Prague, Czech Republic.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Griva', 'Affiliation': 'Department of Cardiology, Tomas Bata Regional Hospital in Zlin, Zlin, Czech Republic.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Precek', 'Affiliation': 'Department of Internal Medicine I-Cardiology, University Hospital Olomouc, Olomouc, Czech Republic.'}, {'ForeName': 'Radek', 'Initials': 'R', 'LastName': 'Pelouch', 'Affiliation': '1st Department of Internal Medicine-Cardioangiology, University Hospital Hradec Králové, Hradec Králové, Czech Republic.'}, {'ForeName': 'Jiri', 'Initials': 'J', 'LastName': 'Parenica', 'Affiliation': 'Cardiology Department, University Hospital Brno and Medical Faculty of the Masaryk University, Brno, Czech Republic.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Belohlavek', 'Affiliation': '2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.'}]",ESC heart failure,['10.1002/ehf2.12916'] 1849,32699128,Early Parenting Intervention - Biobehavioral Outcomes in infants with Neurodevelopmental Disabilities (EPI-BOND): study protocol for an Italian multicentre randomised controlled trial.,"INTRODUCTION Neurodevelopmental disability (ND) represents an adverse condition for infants' socio-emotional and behavioural development as well as for caregiving (eg, parental sensitivity) and mother-infant interaction. Adverse exposures are associated with altered neuroendocrine hormones concentrations (eg, oxytocin and cortisol) and epigenetic regulation (eg, methylation of stress-related genes), which in turn may contribute to less-than-optimal mother-infant interaction. Parental sensitivity is a protective factor for childrens' development and early parental interventions (eg, video-feedback intervention) can promote parental caregiving and better developmental outcomes in children. The present multi-centric and longitudinal randomised controlled trial aims to assess if and to which extent early VFI could benefit both infants and mothers in terms of behavioural outcomes as well as neuroendocrine and epigenetic regulation. METHODS AND ANALYSIS Dyads will be randomly assigned to the video-feedback Intervention Group or Control Group ('dummy' intervention: telephone calls). Infants with ND aged 3 to 18 months will be recruited from three major child neuropsychiatric units in northern Italy. A multi-layer approach to intervention effects will include videotapes of mother-infant interaction, maternal reports as well as saliva samples for hormones concentrations and target-gene methylation analysis (eg, BDNF , NR3C1 , OXTR and SCL6A4 ) that will be obtained at each of the four assessment sessions: T 0 , baseline; T 1 , post-intervention; T 2 , short-term follow-up (3 month); T 3 , long-term follow-up (6 month). Primary effectiveness measures will be infant socio-emotional behaviour and maternal sensitivity. Neuroendocrine hormones concentrations and DNA methylation status of target genes will be secondary outcomes. Feasibility, moderation and confounding variables will be measured and controlled between the two groups. ETHICS AND DISSEMINATION Ethics approval has been obtained in all three participating units. Results of the main trial and each of the secondary endpoints will be submitted for publication in peer-reviewed journals and international conferences. TRIAL REGISTRATION NUMBER NCT03853564; Pre-results.",2020,"Parental sensitivity is a protective factor for childrens' development and early parental interventions (eg, video-feedback intervention) can promote parental caregiving and better developmental outcomes in children.","['children', 'Infants with ND aged 3 to 18 months will be recruited from three major child neuropsychiatric units in northern Italy', 'infants with Neurodevelopmental Disabilities (EPI-BOND']","[""video-feedback Intervention Group or Control Group ('dummy' intervention: telephone calls""]",['infant socio-emotional behaviour and maternal sensitivity'],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0028758', 'cui_str': 'Bonding (Psychology)'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}]","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]",,0.22658,"Parental sensitivity is a protective factor for childrens' development and early parental interventions (eg, video-feedback intervention) can promote parental caregiving and better developmental outcomes in children.","[{'ForeName': 'Rosario', 'Initials': 'R', 'LastName': 'Montirosso', 'Affiliation': '0-3 Center for the at-Risk Infant, Scientific Institute IRCCS E. Medea, Bosisio Parini, Lecco, Italy rosario.montirosso@lanostrafamiglia.it.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Rosa', 'Affiliation': '0-3 Center for the at-Risk Infant, Scientific Institute IRCCS E. Medea, Bosisio Parini, Lecco, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Giorda', 'Affiliation': 'Biology Lab, Scientific Institute IRCCS E. Medea, Bosisio Parini, Lecco, Italy.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Fazzi', 'Affiliation': 'Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Orcesi', 'Affiliation': 'Child Neurology and Psychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Cavallini', 'Affiliation': 'Neuropsychiatry and Neurorehabilitation Unit, Scientific Institute IRCCS E. Medea, Bosisio Parini, Lecco, Italy.'}, {'ForeName': 'Livio', 'Initials': 'L', 'LastName': 'Provenzi', 'Affiliation': 'Child Neurology and Psychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2019-035249'] 1850,32699167,Artificial intelligence mobile health platform for early detection of COVID-19 in quarantine subjects using a wearable biosensor: protocol for a randomised controlled trial.,"INTRODUCTION There is an outbreak of COVID-19 worldwide. As there is no effective therapy or vaccine yet, rigorous implementation of traditional public health measures such as isolation and quarantine remains the most effective tool to control the outbreak. When an asymptomatic individual with COVID-19 exposure is being quarantined, it is necessary to perform temperature and symptom surveillance. As such surveillance is intermittent in nature and highly dependent on self-discipline, it has limited effectiveness. Advances in biosensor technologies made it possible to continuously monitor physiological parameters using wearable biosensors with a variety of form factors. OBJECTIVE To explore the potential of using wearable biosensors to continuously monitor multidimensional physiological parameters for early detection of COVID-19 clinical progression. METHOD This randomised controlled open-labelled trial will involve 200-1000 asymptomatic subjects with close COVID-19 contact under mandatory quarantine at designated facilities in Hong Kong. Subjects will be randomised to receive a remote monitoring strategy (intervention group) or standard strategy (control group) in a 1:1 ratio during the 14 day-quarantine period. In addition to fever and symptom surveillance in the control group, subjects in the intervention group will wear wearable biosensors on their arms to continuously monitor skin temperature, respiratory rate, blood pressure, pulse rate, blood oxygen saturation and daily activities. These physiological parameters will be transferred in real time to a smartphone application called Biovitals Sentinel. These data will then be processed using a cloud-based multivariate physiology analytics engine called Biovitals to detect subtle physiological changes. The results will be displayed on a web-based dashboard for clinicians' review. The primary outcome is the time to diagnosis of COVID-19. ETHICS AND DISSEMINATION Ethical approval has been obtained from institutional review boards at the study sites. Results will be published in peer-reviewed journals.",2020,Subjects will be randomised to receive a remote monitoring strategy (intervention group) or standard strategy (control group) in a 1:1 ratio during the 14 day-quarantine period.,"['200-1000 asymptomatic subjects with close COVID-19 contact under mandatory quarantine at designated facilities in Hong Kong', 'quarantine subjects']","['Artificial intelligence mobile health platform', 'remote monitoring strategy (intervention group) or standard strategy (control group']","['skin temperature, respiratory rate, blood pressure, pulse rate, blood oxygen saturation and daily activities', 'time to diagnosis of COVID-19', 'fever and symptom surveillance']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0034386', 'cui_str': 'Quarantine'}, {'cui': 'C0019907', 'cui_str': 'Hong Kong'}]","[{'cui': 'C0003916', 'cui_str': 'Computer Reasoning'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0037294', 'cui_str': 'Temperature of skin'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0232117', 'cui_str': 'Pulse rate'}, {'cui': 'C0428174', 'cui_str': 'Hemoglobin saturation with oxygen'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}]",1000.0,0.0878264,Subjects will be randomised to receive a remote monitoring strategy (intervention group) or standard strategy (control group) in a 1:1 ratio during the 14 day-quarantine period.,"[{'ForeName': 'Chun Ka', 'Initials': 'CK', 'LastName': 'Wong', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Deborah Tip Yin', 'Initials': 'DTY', 'LastName': 'Ho', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Anthony Raymond', 'Initials': 'AR', 'LastName': 'Tam', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Mi', 'Initials': 'M', 'LastName': 'Zhou', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Yuk Ming', 'Initials': 'YM', 'LastName': 'Lau', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Milky Oi Yan', 'Initials': 'MOY', 'LastName': 'Tang', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Raymond Cheuk Fung', 'Initials': 'RCF', 'LastName': 'Tong', 'Affiliation': 'Harmony Medical Inc, Hong Kong, Hong Kong.'}, {'ForeName': 'Kuldeep Singh', 'Initials': 'KS', 'LastName': 'Rajput', 'Affiliation': 'Biofourmis, Singapore.'}, {'ForeName': 'Gengbo', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': 'Research and Development, Biofourmis, Singapore.'}, {'ForeName': 'Soon Chee', 'Initials': 'SC', 'LastName': 'Chan', 'Affiliation': 'Research and Development, Biofourmis, Singapore.'}, {'ForeName': 'Chung Wah', 'Initials': 'CW', 'LastName': 'Siu', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong cwdsiu@hku.hk.'}, {'ForeName': 'Ivan Fan Ngai', 'Initials': 'IFN', 'LastName': 'Hung', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}]",BMJ open,['10.1136/bmjopen-2020-038555'] 1851,32699168,"Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI).","INTRODUCTION Obstructive sleep apnoea (OSA) and type 2 diabetes mellitus (T2DM) often occur concurrently, and untreated OSA may potentially amplify the high risk of cardiovascular disease in T2DM. Compliance with continuous positive airway pressure (CPAP), the conventional treatment for OSA, can be poor and considering weight loss is the most effective treatment for OSA. This trial examines whether the glucagon-like peptide-1 receptor agonist liraglutide, a glucose-lowering therapy associated with significant weight loss used in T2DM, can improve the severity and symptoms of OSA. METHODS AND ANALYSIS This is an outpatient, single-centred, open-labelled, prospective, phase IV randomised controlled trial in a two-by-two factorial design. One hundred and thirty-two patients with newly diagnosed OSA (apnoea-hypopnoea index (AHI) ≥15 events/hour), and existing obesity and T2DM (glycated haemoglobin (HbA 1c ) ≥47 mmol/mol), will be recruited from diabetes and sleep medicine outpatient clinics in primary and secondary care settings across Liverpool. Patients will be allocated equally, using computer-generated random, permuted blocks of unequal sizes, to each of the four treatment arms for 26 weeks: (i) liraglutide (1.8 mg once per day) alone, (ii) liraglutide 1.8 mg once per day with CPAP, (iii) CPAP alone (conventional care) or (iv) no treatment (control). The primary outcome measure is change in OSA severity, determined by AHI. Secondary outcome measures include effects on glycaemic control (glycated haemoglobin (HbA1c)), body weight and quality of life measures. Exploratory measures include measures of physical activity, MRI-derived measures of regional body composition including fat mass (abdominal subcutaneous, visceral, neck and liver fat) and skeletal muscle mass (cross-sectional analysis of thigh), indices of cardiac function (using transthoracic echocardiography) and endothelial function. ETHICAL APPROVAL The study has been approved by the North West Liverpool Central Research Ethics Committee (14/NW/1019) and it is being conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. TRIAL REGISTRATION NUMBERS ISRCTN16250774. EUDRACT No. 2014-000988-41. UTN U1111-1139-0677.",2020,"Secondary outcome measures include effects on glycaemic control (glycated haemoglobin (HbA1c)), body weight and quality of life measures.","['One hundred and thirty-two patients with newly diagnosed OSA (apnoea-hypopnoea index (AHI) ≥15 events/hour), and existing obesity and T2DM (glycated haemoglobin (HbA 1c ) ≥47\u2009mmol/mol), will be recruited from diabetes and sleep medicine outpatient clinics in primary and secondary care settings across Liverpool', 'patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE']","['UTN', 'liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP', 'liraglutide 1.8\u2009mg once per day with CPAP, (iii) CPAP alone (conventional care) or (iv) no treatment (control', 'liraglutide', 'glucagon-like peptide-1 receptor agonist liraglutide', 'continuous positive airway pressure (CPAP']","['apnea-hypnoea index (AHI', 'glycaemic control (glycated haemoglobin (HbA1c)), body weight and quality of life measures', 'physical activity, MRI-derived measures of regional body composition including fat mass (abdominal subcutaneous, visceral, neck and liver fat) and skeletal muscle mass (cross-sectional analysis of thigh), indices of cardiac function (using transthoracic echocardiography) and endothelial function', 'change in OSA severity, determined by AHI']","[{'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C2111846', 'cui_str': 'Apnea Hypopnea Index'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mol'}, {'cui': 'C4304028', 'cui_str': 'Sleep medicine specialist'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C3494402', 'cui_str': 'Secondary Care'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C1456408', 'cui_str': 'liraglutide'}, {'cui': 'C1562104', 'cui_str': 'Glucagon-like peptide 1 receptor agonist-containing product'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0013516', 'cui_str': 'Echocardiography'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}]",132.0,0.0452433,"Secondary outcome measures include effects on glycaemic control (glycated haemoglobin (HbA1c)), body weight and quality of life measures.","[{'ForeName': 'Victoria S', 'Initials': 'VS', 'LastName': 'Sprung', 'Affiliation': 'Research Institute for Sport & Exercise Sciences, Liverpool John Moores University, Liverpool, UK v.s.sprung@ljmu.ac.uk.'}, {'ForeName': 'Graham J', 'Initials': 'GJ', 'LastName': 'Kemp', 'Affiliation': 'Department of Musculoskeletal & Ageing Science, University of Liverpool, Liverpool, Merseyside, UK.'}, {'ForeName': 'John Ph', 'Initials': 'JP', 'LastName': 'Wilding', 'Affiliation': 'Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Adams', 'Affiliation': 'Liverpool Magnetic Resonance Imaging Centre (LiMRIC), University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Kieran', 'Initials': 'K', 'LastName': 'Murphy', 'Affiliation': 'Liverpool Magnetic Resonance Imaging Centre (LiMRIC), University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Malcolm', 'Initials': 'M', 'LastName': 'Burgess', 'Affiliation': 'Department of Cardiology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Emegbo', 'Affiliation': 'Liverpool Sleep & Ventilation Unit, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Thomas', 'Affiliation': 'Liverpool Sleep & Ventilation Unit, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK.'}, {'ForeName': 'Alexander J', 'Initials': 'AJ', 'LastName': 'Needham', 'Affiliation': 'Liverpool Clinical Trials Unit, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Weimken', 'Affiliation': 'Center for Sleep & Circadian Neurobiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Schwab', 'Affiliation': 'Center for Sleep & Circadian Neurobiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Ari', 'Initials': 'A', 'LastName': 'Manuel', 'Affiliation': 'Liverpool Sleep & Ventilation Unit, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK.'}, {'ForeName': 'Sonya E', 'Initials': 'SE', 'LastName': 'Craig', 'Affiliation': 'Liverpool Sleep & Ventilation Unit, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Cuthbertson', 'Affiliation': 'Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool, UK.'}]",BMJ open,['10.1136/bmjopen-2020-038856'] 1852,32701239,[Inverse ratio ventilation combined with PEEP in infants undergoing thoracoscopic surgery with one lung ventilation for lung cystadenomas: a randomized control trial of 63 cases].,"OBJECTIVE To investigate the effect of inverse ratio ventilation (IRV) combined with positive end-expiratory pressure (PEEP) in infants undergoing thoracoscopic surgery with single lung ventilation (OLV) for lung cystadenomas. METHODS A total of 66 infants undergoing thoracoscopic surgery with OLV for lung cystadenomas in our hospital from February, 2018 to February, 2019 were randomized into conventional ventilation groups (group N, n =33) and inverse ventilation group (group R, n =33). Hemodynamics and respiratory parameters of the infants were recorded and arterial blood gas analysis was performed at 15 min after two lung ventilation (TLV) (T 1 ), OLV30 min (T 2 ), OLV60 min (T 3 ), and 15 min after recovery of TLV (T 4 ). Bronchoalveolar lavage fluid was collected before and after surgery to detect the expression level of advanced glycation end product receptor (RAGE). RESULTS Sixty-three infants were finally included in this study. At T 2 and T 3 , Cdyn, PaO 2 and OI in group R were significantly higher ( P < 0.05) and Ppeak, PaCO 2 and PA-aO 2 were significantly lower than those in group N ( P < 0.05). There was no significant difference in HR or MAP between the two groups at T 2 and T 3 ( P > 0.05). The level of RAGE significantly increased after the surgery in both groups ( P < 0.05), and was significantly lower in R group than in N group ( P < 0.05). CONCLUSIONS In infants undergoing thoracoscopic surgery with OLV for pulmonary cystadenoma, appropriate IRV combined with PEEP does not affect hemodynamic stability and can increases pulmonary compliance, reduce the peak pressure, and improve oxygenation to provide pulmonary protection.",2020,There was no significant difference in HR or MAP between the two groups at T 2 and T 3 ( P > 0.05).,"['infants undergoing', '66 infants undergoing thoracoscopic surgery with OLV for lung cystadenomas in our hospital from February, 2018 to February, 2019 were randomized into', 'infants undergoing thoracoscopic surgery with OLV for pulmonary cystadenoma', 'infants undergoing thoracoscopic surgery with one lung ventilation for lung cystadenomas', 'Sixty-three infants were finally included in this study']","['inverse ratio ventilation (IRV) combined with positive end-expiratory pressure (PEEP', 'thoracoscopic surgery with single lung ventilation (OLV', 'Inverse ratio ventilation combined with PEEP', 'conventional ventilation', 'inverse ventilation group']","['HR or MAP', 'hemodynamic stability', 'level of RAGE', 'Bronchoalveolar lavage fluid', 'Hemodynamics and respiratory parameters', 'Ppeak, PaCO 2 and PA-aO 2']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0751551', 'cui_str': 'Thoracoscopic Surgical Procedures'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0010633', 'cui_str': 'Cystadenoma'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0559312', 'cui_str': 'One lung ventilation'}, {'cui': 'C4319614', 'cui_str': '63'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0439850', 'cui_str': 'Inverse'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0032740', 'cui_str': 'Positive end-expiratory pressure'}, {'cui': 'C0751551', 'cui_str': 'Thoracoscopic Surgical Procedures'}, {'cui': 'C0559312', 'cui_str': 'One lung ventilation'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0024779', 'cui_str': 'Maps'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0034634', 'cui_str': 'Rage'}, {'cui': 'C0006279', 'cui_str': 'Bronchoalveolar lavage fluid sample'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",66.0,0.035269,There was no significant difference in HR or MAP between the two groups at T 2 and T 3 ( P > 0.05).,"[{'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesiology, Guangdong Women and Children's Hospital, Guangzhou 511400, China.""}, {'ForeName': 'Weijian', 'Initials': 'W', 'LastName': 'Huang', 'Affiliation': ""Department of Anesthesiology, Guangdong Women and Children's Hospital, Guangzhou 511400, China.""}, {'ForeName': 'Mudan', 'Initials': 'M', 'LastName': 'He', 'Affiliation': ""Department of Anesthesiology, Guangdong Women and Children's Hospital, Guangzhou 511400, China.""}, {'ForeName': 'Lingli', 'Initials': 'L', 'LastName': 'Peng', 'Affiliation': ""Department of Anesthesiology, Guangdong Women and Children's Hospital, Guangzhou 511400, China.""}, {'ForeName': 'Mingyang', 'Initials': 'M', 'LastName': 'Cai', 'Affiliation': ""Department of Anesthesiology, Guangdong Women and Children's Hospital, Guangzhou 511400, China.""}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Yuan', 'Affiliation': ""Department of Anesthesiology, Guangdong Women and Children's Hospital, Guangzhou 511400, China.""}, {'ForeName': 'Zurong', 'Initials': 'Z', 'LastName': 'Hu', 'Affiliation': ""Department of Anesthesiology, Guangdong Women and Children's Hospital, Guangzhou 511400, China.""}, {'ForeName': 'Kunwei', 'Initials': 'K', 'LastName': 'Li', 'Affiliation': ""Department of Anesthesiology, Guangdong Women and Children's Hospital, Guangzhou 511400, China.""}]",Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,[] 1853,32701242,[Dexmedetomidine combined with protective lung ventilation strategy provides lung protection in patients undergoing radical resection of esophageal cancer with one-lung ventilation].,"OBJECTIVE To investigate the effect of dexmedetomidine combined with pulmonary protective ventilation against lung injury in patients undergoing surgeries for esophageal cancer with one-lung ventilation (OLV). METHODS Forty patients with undergoing surgery for esophageal cancer with OLV were randomly divided into pulmonary protective ventilation strategy group (F group) and dexmedetomidine combined with protective ventilation strategy group (DF group; n =20). In F group, lung protective ventilation strategy during anesthesia was adopte, and in DF group, the patients received intravenous infusion of dexmedetomidine hydrochloride (0.3 μg · kg -1 ·h -1 ) during the surgery starting at 10 min before anesthesia induction in addition to protective ventilation strategy. Brachial artery blood was sampled before ventilation (T 0 ), at 30 and 90 min after the start of OLV (T 1 and T 2 , respectively) and at the end of the surgery (T 3 ) for analysis of superoxide dismutase (SOD), malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), arterial oxygenation pressure (PaO 2 ), oxygenation index (OI) and lung compliance (CL). RESULTS At the time points of T 1 , T 2 and T 3 , SOD level was significantly higher and IL-6 level was significantly lower in the DF group than in F group ( P < 0.05). The patients in DF group showed significantly higher PaO 2 , OI and CL index than those in F group at all the 3 time points. CONCLUSIONS Dexmedetomidine combined with pulmonary protective ventilation strategy can reduce perioperative lung injury in patients undergoing surgery for esophageal cancer with OLV by suppressing inflammation and oxidative stress to improve lung function and reduce adverse effects of the surgery.",2020,"At the time points of T 1 , T 2 and T 3 , SOD level was significantly higher and IL-6 level was significantly lower in the DF group than in F group ( P < 0.05).","['patients undergoing surgeries for esophageal cancer with one-lung ventilation (OLV', 'patients undergoing radical resection of esophageal cancer with one-lung ventilation', 'patients undergoing surgery for esophageal cancer with OLV', 'Forty patients with undergoing surgery for esophageal cancer with OLV']","['Dexmedetomidine combined with protective lung ventilation strategy', 'dexmedetomidine hydrochloride', 'dexmedetomidine combined with pulmonary protective ventilation', 'Dexmedetomidine combined with pulmonary protective ventilation strategy', 'pulmonary protective ventilation strategy group (F group) and dexmedetomidine combined with protective ventilation strategy']","['SOD level', 'superoxide dismutase (SOD), malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), arterial oxygenation pressure (PaO 2 ), oxygenation index (OI) and lung compliance (CL', 'Brachial artery blood', 'lung protective ventilation strategy', 'PaO 2 , OI and CL index', 'IL-6 level']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0014859', 'cui_str': 'Neoplasm of esophagus'}, {'cui': 'C0559312', 'cui_str': 'One lung ventilation'}, {'cui': 'C0302912', 'cui_str': 'Radical'}, {'cui': 'C0015252', 'cui_str': 'Removal'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0554804', 'cui_str': 'Assisted breathing'}, {'cui': 'C0752310', 'cui_str': 'Dexmedetomidine hydrochloride'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441840', 'cui_str': 'Group F'}]","[{'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output'}, {'cui': 'C1278185', 'cui_str': 'Oxygenation index measurement'}, {'cui': 'C0024112', 'cui_str': 'Lung compliance'}, {'cui': 'C0006087', 'cui_str': 'Structure of brachial artery'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",40.0,0.0490837,"At the time points of T 1 , T 2 and T 3 , SOD level was significantly higher and IL-6 level was significantly lower in the DF group than in F group ( P < 0.05).","[{'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Gong', 'Affiliation': 'Department of Anesthesiology, Nanning 530021, China.'}, {'ForeName': 'Xiaomao', 'Initials': 'X', 'LastName': 'Long', 'Affiliation': ""Department Cardiothoracic Surgery, People's Hospital of Guangxi Autonomous Region, Nanning 530021, China.""}, {'ForeName': 'Huijun', 'Initials': 'H', 'LastName': 'Wei', 'Affiliation': 'Department of Anesthesiology, Nanning 530021, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Tang', 'Affiliation': 'Department of Anesthesiology, Nanning 530021, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Nanning 530021, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Ma', 'Affiliation': 'Department of Anesthesiology, Nanning 530021, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': ""People's Hospital of Guangxi Autonomous Region, Nanning 530021, China.""}]",Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,[] 1854,32700772,GLP-1 receptor agonists for Parkinson's disease.,"BACKGROUND Parkinson's disease (PD) is a progressive disorder characterised by both motor and non-motor problems. Glucagon-like peptide-1 (GLP-1) receptor agonists, licensed for treatment of type 2 diabetes, work by stimulating GLP-1 receptors in the pancreas, which triggers the release of insulin. GLP-1 receptors have been found in the brain. Insulin signalling in the brain plays a key role in neuronal metabolism and repair and in synaptic efficacy, but insulin signalling is desensitised in the brain of people with PD. Researchers are exploring the neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders such as PD. OBJECTIVES To evaluate the effectiveness and safety of GLP-1 receptor agonists for Parkinson's disease. SEARCH METHODS We searched the Cochrane Movement Disorders Group trials register; the Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library; and Ovid MEDLINE and Embase. We also searched clinical trials registries, and we handsearched conference abstracts. The most recent search was run on 25 June 2020. SELECTION CRITERIA We included randomised controlled trials (RCTs) of adults with PD that compared GLP-1 receptor agonists with conventional PD treatment, placebo, or no treatment. DATA COLLECTION AND ANALYSIS Two review authors independently assessed studies for inclusion, extracted data, and assessed risk of bias. We rated the quality of evidence using GRADE. We resolved discrepancies between the two data extractors by consultation with a third review author. MAIN RESULTS Through our searches, we retrieved 99 unique records, of which two met our inclusion criteria. One double-blind study of exenatide versus placebo randomised 62 participants, who self-administered exenatide or placebo for 48 weeks and were followed up at 60 weeks after a 12-week washout. One single-blind study of exenatide versus no additional treatment randomised 45 participants; participants in the intervention group self-administered exenatide for 12 months, and all participants were followed up at 14 months and 24 months following absence of exenatide for 2 months and 12 months, respectively. These trials had low risk of bias, except risk of performance bias was high for Aviles-Olmos 2013. Exenatide versus placebo Primary outcomes We found low-certainty evidence suggesting that exenatide improves motor impairment as assessed by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III in the off-medication state (mean difference (MD) -3.10, 95% confidence interval (CI) -6.11 to -0.09). The difference in scores was slightly greater when scores were adjusted for baseline severity of the condition (as reported by study authors) (MD -3.5, 95% CI -6.7 to -0.3), exceeding the minimum clinically important difference (MCID). We found low-certainty evidence suggesting that exenatide has little or no effect on health-related quality of life (HRQoL) as assessed by the Parkinson's Disease Questionnaire (PDQ)-39 Summary Index (SI) (MD -1.80, 95% CI -6.95 to 3.35), the EuroQol scale measuring health status in five dimensions (EQ5D) (MD 0.07, 95% CI -0.03 to 0.16), or the EQ5D visual analogue scale (VAS) (MD 5.00, 95% CI -3.42 to 13.42). Eight serious adverse events (SAEs) were recorded, but all were considered unrelated to the intervention. Low-certainty evidence suggests that exenatide has little or no effect on weight loss (risk ratio (RR) 1.25, 95% CI 0.89 to 1.76). Exenatide versus no treatment Primary outcomes at 14 months We found very low-certainty evidence suggesting that exenatide improves motor impairment as assessed by MDS-UPDRS Part III off medication (MD -4.50, 95% CI -8.64 to -0.36), exceeding the MCID. We are uncertain whether exenatide improves HRQoL as assessed by the PDQ-39 SI (MD 3.50, 95% CI -2.75 to 9.75; very low-quality evidence). We found very low-certainty evidence suggesting that exenatide has little or no effect on the number of SAEs (RR 1.60, 95% 0.40 to 6.32). We found very low-certainty evidence suggesting that exenatide may lead to weight loss (MD -2.40 kg, 95% CI -4.56 to -0.24). Primary outcomes at 24 months We found evidence as reported by study authors to suggest that exenatide improves motor impairment as measured by MDS-UPDRS Part III off medication (MD 5.6 points, 95% CI 2.2 to 9.0). Exenatide may not improve HRQoL as assessed by the PDQ-39 SI (P = 0.682) and may not result in weight loss (MD 0.1 kg, 95% CI 3.0 to 2.8). AUTHORS' CONCLUSIONS Low- or very low-certainty evidence suggests that exenatide may improve motor impairment for people with PD. The difference in motor impairment observed between groups may persist for some time following cessation of exenatide. This raises the possibility that exenatide may have a disease-modifying effect. SAEs were unlikely to be related to treatment. The effectiveness of exenatide for improving HRQoL, non-motor outcomes, ADLs, and psychological outcomes is unclear. Ongoing studies are assessing other GLP-1 receptor agonists.",2020,"Exenatide may not improve HRQoL as assessed by the PDQ-39 SI (P = 0.682) and may not result in weight loss (MD 0.1 kg, 95% CI 3.0 to 2.8). ","[""Parkinson's disease"", 'adults with PD that compared', 'randomised 62 participants, who self-administered', 'people with PD', '45 participants']","['exenatide', 'Glucagon-like peptide-1', 'Exenatide', 'exenatide or placebo', 'GLP-1 receptor agonists', 'GLP-1 receptor agonists with conventional PD treatment, placebo, or no treatment', 'placebo']","['motor impairment', 'health-related quality of life (HRQoL', 'HRQoL', 'weight loss', ""Parkinson's Disease Questionnaire (PDQ)-39 Summary Index (SI"", ""Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS"", 'Eight serious adverse events (SAEs', 'EuroQol scale measuring health status', 'number of SAEs', 'MDS-UPDRS Part III off medication', 'EQ5D visual analogue scale (VAS']","[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0167117', 'cui_str': 'exenatide'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1562104', 'cui_str': 'Glucagon-like peptide 1 receptor agonist-containing product'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0026650', 'cui_str': 'Movement disorder'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",,0.369049,"Exenatide may not improve HRQoL as assessed by the PDQ-39 SI (P = 0.682) and may not result in weight loss (MD 0.1 kg, 95% CI 3.0 to 2.8). ","[{'ForeName': 'Caroline A', 'Initials': 'CA', 'LastName': 'Mulvaney', 'Affiliation': 'Lancaster Medical School, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Gonçalo S', 'Initials': 'GS', 'LastName': 'Duarte', 'Affiliation': 'Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa, Lisboa, Portugal.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Handley', 'Affiliation': 'Lancaster Medical School, Lancaster University, Lancaster, UK.'}, {'ForeName': 'David Jw', 'Initials': 'DJ', 'LastName': 'Evans', 'Affiliation': 'Lancaster Medical School, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Suresh', 'Initials': 'S', 'LastName': 'Menon', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Canada.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Wyse', 'Affiliation': ""The Cure Parkinson's Trust, London, UK.""}, {'ForeName': 'Hedley Ca', 'Initials': 'HC', 'LastName': 'Emsley', 'Affiliation': 'Lancaster Medical School, Lancaster University, Lancaster, UK.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD012990.pub2'] 1855,32702878,"Low-level light therapy using a helmet-type device for the treatment of androgenetic alopecia: A 16-week, multicenter, randomized, double-blind, sham device-controlled trial.","INTRODUCTION Androgenetic alopecia is the most common form of hair loss in both sexes. In recent studies, low-level light therapy (LLLT) has been established as an effective treatment for alopecia. The purpose of this study was to evaluate the safety and efficacy of LLLT using a new helmet-type device for the treatment of androgenetic alopecia. METHOD A randomized, sham device-controlled, double-blind clinical trial was conducted at 2 institutions. Sixty participants diagnosed with androgenetic alopecia aged from 19 to 65 years were recruited. LLLT was performed through a helmet-type device that emitted light with a mean output power of 2.36 mW/cm at a wavelength of 655 nm. Participants were divided into 2 groups, which respectively used the experimental device and a sham device. After tattooing at the central point of the vertex, phototrichograms at that point were obtained at 0, 8, and 16 weeks. The primary endpoint of the study was the difference in the rate of change of hair density between the test group and the control group. RESULTS Comparing the results at baseline and week 16, the experimental group showed an increase in hair density of 41.90 hairs/cm and an increase in hair thickness of 7.50 μm, whereas the control group showed an increase of 0.72 hairs/cm and a decrease of 15.03 μm, respectively (P < .001). No adverse events or side effects occurred. CONCLUSION LLLT showed a significant effect on increasing hair density in patients with androgenetic alopecia. LLLT could be a safe and effective treatment for androgenetic alopecia in both sexes.",2020,"No adverse events or side effects occurred. ","['Sixty participants diagnosed with androgenetic alopecia aged from 19 to 65 years were recruited', 'patients with androgenetic alopecia', 'androgenetic alopecia']","['LLLT', 'Low-level light therapy using a helmet-type device', 'low-level light therapy (LLLT']","['hair thickness', 'safety and efficacy', 'rate of change of hair density', 'hair density']","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0162311', 'cui_str': 'Alopecia hereditaria'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0031765', 'cui_str': 'Light therapy'}, {'cui': 'C4019433', 'cui_str': 'Photobiomodulation Therapy'}, {'cui': 'C0018884', 'cui_str': 'Helmet'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0178587', 'cui_str': 'Density'}]",60.0,0.270093,"No adverse events or side effects occurred. ","[{'ForeName': 'Jung Soo', 'Initials': 'JS', 'LastName': 'Yoon', 'Affiliation': 'aDepartment of Plastic and Reconstructive Surgery, DongGuk University Ilsan Medical Center, Goyang, South Korea bDepartment of Plastic and Reconstructive Surgery, Hanyang University Medical Center, Hanyang University College of Medicine, Seoul cDepartment of Plastic and Reconstructive Surgery, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.'}, {'ForeName': 'Won Young', 'Initials': 'WY', 'LastName': 'Ku', 'Affiliation': ''}, {'ForeName': 'Jang Hyun', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'Hee Chang', 'Initials': 'HC', 'LastName': 'Ahn', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021181'] 1856,32702879,Effects of concurrent aerobic and resistance exercise in frail and pre-frail older adults: A randomized trial of supervised versus home-based programs.,"BACKGROUND This study aimed to investigate the effects of supervised and home-based exercise programs on older people with frailty or pre-frailty. METHODS A total of 146 community-dwelling participants aged 65 and older who were prefrail or frail were randomly allocated into supervised exercise (N = 74) and home exercise (N = 72) groups. The 3-month supervised exercise training consisted of 3 exercise sessions per week, was performed at a hospital and supervised by a physical therapist. Home exercise participants took instructions on exercise and illustrated exercise handouts. The baseline and 3-month follow-up measurements included body composition, strength of selected upper and lower limb muscle groups, grip and leg press strengths, and five physical performance tests. Mixed-model repeated-measures analysis was applied to determine whether two groups differ in terms of changes before and after the intervention and to compare within-group improvements. RESULTS After 3 months of supervised or home-based exercise, the average number of frailty criteria met and fat percentage decreased significantly. Strength of knee extensors, knee flexors and leg press improved significantly in supervised exercise group. In home-based exercise group, the strength of all muscle groups tested improved significantly, except for leg press strength. Walking speed improved in both groups, and timed-up-and-go and timed chair rise tests improved significantly only in supervised exercise group. CONCLUSIONS Three-month supervised or home-based exercise improved walking speed and strength of the limb muscles. Supervised group showed more improvements in the physical performance tests compared with home-based exercise group.",2020,"Walking speed improved in both groups, and timed-up-and-go and timed chair rise tests improved significantly only in supervised exercise group. ","['A total of 146 community-dwelling participants aged 65 and older who were prefrail or frail', 'frail and pre-frail older adults', 'older people with frailty or pre-frailty']","['concurrent aerobic and resistance exercise', 'supervised exercise (N\u200a=\u200a74) and home exercise', 'Home exercise participants took instructions on exercise and illustrated exercise handouts', 'supervised and home-based exercise programs', 'supervised exercise training consisted of 3 exercise sessions per week, was performed at a hospital and supervised by a physical therapist']","['Walking speed', 'walking speed and strength of the limb muscles', 'physical performance tests', 'leg press strength', 'Strength of knee extensors, knee flexors and leg press', 'body composition, strength of selected upper and lower limb muscle groups, grip and leg press strengths, and five physical performance tests']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0079379', 'cui_str': 'Frail Older Adults'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}]","[{'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}]","[{'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0220843', 'cui_str': 'Grasp'}]",146.0,0.0319741,"Walking speed improved in both groups, and timed-up-and-go and timed chair rise tests improved significantly only in supervised exercise group. ","[{'ForeName': 'Nai-Hsin', 'Initials': 'NH', 'LastName': 'Meng', 'Affiliation': 'aDepartment of Physical Medicine and Rehabilitation, China Medical University Hospital bSchool of Medicine, College of Medicine, China Medical University cDepartment of Medical Research dDepartment of Family Medicine, China Medical University Hospital eDepartment of Public Health, College of Public Health, China Medical University fDepartment of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan.'}, {'ForeName': 'Chia-Ing', 'Initials': 'CI', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Chiu-Shong', 'Initials': 'CS', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Chih-Hsueh', 'Initials': 'CH', 'LastName': 'Lin', 'Affiliation': ''}, {'ForeName': 'Chin-Kai', 'Initials': 'CK', 'LastName': 'Chang', 'Affiliation': ''}, {'ForeName': 'Heng-Wei', 'Initials': 'HW', 'LastName': 'Chang', 'Affiliation': ''}, {'ForeName': 'Chuan-Wei', 'Initials': 'CW', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Tsai-Chung', 'Initials': 'TC', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Cheng-Chieh', 'Initials': 'CC', 'LastName': 'Lin', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021187'] 1857,32702891,Efficacy and safety of epidural steroid injection following discectomy for patients with lumbar disc herniation: A protocol.,"BACKGROUND Concerns exist regarding the analgesia effect and safety of epidural steroid injection (ESI) after discectomy. There is an urgent need of studies that efficiently control for confounding, conduct comprehensive and consecutive observation of potential risks of ESI, and investigate its clinical applicability. We thus further designed a randomized controlled study to assess the efficacy of ESI on postoperative pain and complications in patients undergoing unilateral lumbar microdiscectomy. METHODS This prospective, blinded randomized controlled trial was conducted at our single hospital. This study was approved by the Committee at the No.2 People's Hospital of Yibin. All procedures were performed by a single surgeon and informed consent was obtained from each patient. Ninty eligible patients diagnosed at our institution with herniated lumbar disc during a period from June 2020 to July 2021 will be assessed. Group 1 was a mixture of 1 mL of 0.5% bupivacaine and 10 mg of triamcinolone acetonide in 1 mL. Group 2 was a mixture of 1 mL of 0.5% bupivacaine and 1 mL of normal saline. The primary outcome measure was the amount of morphine consumption from a patient-controlled analgesia pump at 12, 24, and 48 hours after surgery. The following secondary outcomes were also assessed: postoperative pain score, back pain score, functional disability, and adverse effect. CONCLUSIONS We hypothesized that the ESI was associated with lower pain score, morphine consumption, and hospital stay, with no significant difference in complications for ESI application after lumbar discectomy in lumbar disc herniation when compared with placebo. TRIAL REGISTRATION This study protocol was registered in Research Registry (researchregistry5683).",2020,"We hypothesized that the ESI was associated with lower pain score, morphine consumption, and hospital stay, with no significant difference in complications for ESI application after lumbar discectomy in lumbar disc herniation when compared with placebo. ","['Ninty eligible patients diagnosed at our institution with herniated lumbar disc during a period from June 2020 to July 2021 will be assessed', 'patients undergoing unilateral lumbar microdiscectomy', 'patients with lumbar disc herniation', ""No.2 People's Hospital of Yibin""]","['bupivacaine and 1 mL of normal saline', 'bupivacaine', 'ESI', 'epidural steroid injection (ESI', 'epidural steroid injection', 'triamcinolone acetonide']","['Efficacy and safety', 'postoperative pain and complications', 'lower pain score, morphine consumption, and hospital stay', 'postoperative pain score, back pain score, functional disability, and adverse effect', 'amount of morphine consumption']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0347984', 'cui_str': 'During'}, {'cui': 'C0042950', 'cui_str': 'Volition'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0457629', 'cui_str': 'Lumbar microdiscectomy'}, {'cui': 'C0281899', 'cui_str': 'Prolapsed lumbar intervertebral disc'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0196394', 'cui_str': 'Epidural steroid injection'}, {'cui': 'C0040866', 'cui_str': 'Triamcinolone acetonide'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",,0.324268,"We hypothesized that the ESI was associated with lower pain score, morphine consumption, and hospital stay, with no significant difference in complications for ESI application after lumbar discectomy in lumbar disc herniation when compared with placebo. ","[{'ForeName': 'Jianping', 'Initials': 'J', 'LastName': 'Cai', 'Affiliation': ""Department of Orthopedics II, The No.2 People's Hospital of Yibin, Sichuan Province, China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Jiang', 'Affiliation': ''}, {'ForeName': 'Beiming', 'Initials': 'B', 'LastName': 'Qiu', 'Affiliation': ''}, {'ForeName': 'Yuguang', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021220'] 1858,32702911,A randomized controlled trial to evaluate the effectiveness and safety of electro acupuncture and transcranial direct current stimulation with computerized cognitive rehabilitation in patients with vascular cognitive impairment.,"BACKGROUND Vascular cognitive impairment (VCI) refers to all cognitive disorders caused by cerebrovascular disorders. For the treatment, many types of pharmacologic and nonpharmacologic treatments are used but their underlying mechanisms and effects are unclear. Regarding nonpharmacologic treatment, electroacupuncture (EA), transcranial direct current stimulation (tDCS), and computerized cognitive rehabilitation treatment (CCRT) are effective. Here, we report the protocol for a randomized controlled trial of the effect and safety of combination therapy of EA or tDCS and CCRT in patients with VCI. METHODS This study will be a prospective, outcome assessor-blinded, parallel-arm, randomized controlled clinical trial. Participants with cognitive impairment caused by stroke after 3 months of onset (n = 45) will be randomly assigned to a CCRT, combination therapy with EA and computerized cognitive rehabilitation treatment, or combination therapy with tDCS and computerized cognitive rehabilitation treatment group. All groups will receive treatment 3 times per week for 8 weeks, giving a total of 24 treatments. The CCRT group will perform a training task like shopping, calculating, and others and involving computerized cognitive assessment and brain training system (RehaCom) for 30 minutes. The combination therapy with EA and computerized cognitive rehabilitation treatment group will receive EA using 8 acupuncture points - baekhoe, sinjeong, both sides of pungji, 4 sites of sishencong - and will be applied using an EA stimulator and receive CCRT for 30 minutes at the same time. The combination therapy with tDCS and computerized cognitive rehabilitation treatment group will receive tDCS treatment and receive CCRT for 30 minutes at the same time. The primary outcome will be evaluated using the Lowenstein occupational therapy cognitive assessment, while other scales assessing walking ability, activities of daily living, and quality of life are considered secondary outcome measures. Outcomes will be evaluated before intervention, at the end of intervention 8 weeks after the first intervention, and 4 weeks after completion of the intervention program. DISCUSSION This study aims to examine the effect and safety of combination therapy with EA or tDCS and CCRT in patients with VCI. This study can be useful in developing new treatment technologies using collaborative research with combined traditional Korean and conventional medicines. TRIAL REGISTRATION This trial has been registered with cris.nih.go.kr (registration number, KCT 0003644 Registered 01 April 2019, http://cris.nih.go.kr).",2020,"The CCRT group will perform a training task like shopping, calculating, and others and involving computerized cognitive assessment and brain training system (RehaCom) for 30 minutes.","['Participants with cognitive impairment caused by stroke after 3 months of onset (n\u200a=\u200a45', 'patients with vascular cognitive impairment', 'patients with VCI']","['electro acupuncture and transcranial direct current stimulation with computerized cognitive rehabilitation', 'CCRT, combination therapy with EA and computerized cognitive rehabilitation treatment, or combination therapy with tDCS and computerized cognitive rehabilitation treatment group', 'tDCS and computerized cognitive rehabilitation treatment', 'training task like shopping, calculating, and others and involving computerized cognitive assessment and brain training system (RehaCom', 'tDCS treatment and receive CCRT', 'EA and computerized cognitive rehabilitation treatment', 'electroacupuncture (EA), transcranial direct current stimulation (tDCS), and computerized cognitive rehabilitation treatment (CCRT', 'EA or tDCS and CCRT', 'CCRT']","['Lowenstein occupational therapy cognitive assessment, while other scales assessing walking ability, activities of daily living, and quality of life']","[{'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3805043', 'cui_str': 'Vascular cognitive impairment'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}, {'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0150768', 'cui_str': 'Shopping'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C1318464', 'cui_str': 'Occupational therapy'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0559964', 'cui_str': 'Ability to walk'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.0792879,"The CCRT group will perform a training task like shopping, calculating, and others and involving computerized cognitive assessment and brain training system (RehaCom) for 30 minutes.","[{'ForeName': 'Hyeng Kyu', 'Initials': 'HK', 'LastName': 'Park', 'Affiliation': 'aDepartment of Physical and Rehabilitation Medicine, Chonnam National University Medical School and Hospital, Gwangju City bDepartment of Acupuncture and Moxibustion Medicine, College of Korean Medicine, Dongshin University, Naju City, Republic of Korea.'}, {'ForeName': 'Min Keun', 'Initials': 'MK', 'LastName': 'Song', 'Affiliation': ''}, {'ForeName': 'Jae Hong', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Jae Young', 'Initials': 'JY', 'LastName': 'Han', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021263'] 1859,32706534,Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease.,"BACKGROUND Vitamin D metabolites support innate immune responses to Mycobacterium tuberculosis . Data from phase 3, randomized, controlled trials of vitamin D supplementation to prevent tuberculosis infection are lacking. METHODS We randomly assigned children who had negative results for M. tuberculosis infection according to the QuantiFERON-TB Gold In-Tube assay (QFT) to receive a weekly oral dose of either 14,000 IU of vitamin D 3 or placebo for 3 years. The primary outcome was a positive QFT result at the 3-year follow-up, expressed as a proportion of children. Secondary outcomes included the serum 25-hydroxyvitamin D (25[OH]D) level at the end of the trial and the incidence of tuberculosis disease, acute respiratory infection, and adverse events. RESULTS A total of 8851 children underwent randomization: 4418 were assigned to the vitamin D group, and 4433 to the placebo group; 95.6% of children had a baseline serum 25(OH)D level of less than 20 ng per milliliter. Among children with a valid QFT result at the end of the trial, the percentage with a positive result was 3.6% (147 of 4074 children) in the vitamin D group and 3.3% (134 of 4043) in the placebo group (adjusted risk ratio, 1.10; 95% confidence interval [CI], 0.87 to 1.38; P = 0.42). The mean 25(OH)D level at the end of the trial was 31.0 ng per milliliter in the vitamin D group and 10.7 ng per milliliter in the placebo group (mean between-group difference, 20.3 ng per milliliter; 95% CI, 19.9 to 20.6). Tuberculosis disease was diagnosed in 21 children in the vitamin D group and in 25 children in the placebo group (adjusted risk ratio, 0.87; 95% CI, 0.49 to 1.55). A total of 29 children in the vitamin D group and 34 in the placebo group were hospitalized for treatment of acute respiratory infection (adjusted risk ratio, 0.86; 95% CI, 0.52 to 1.40). The incidence of adverse events did not differ significantly between the two groups. CONCLUSIONS Vitamin D supplementation did not result in a lower risk of tuberculosis infection, tuberculosis disease, or acute respiratory infection than placebo among vitamin D-deficient schoolchildren in Mongolia. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT02276755.).",2020,"The incidence of adverse events did not differ significantly between the two groups. ","['8851 children underwent randomization: 4418', 'We randomly assigned children who had negative results for M. tuberculosis infection according to the QuantiFERON-TB Gold In-Tube assay (QFT', '29 children in the']","['Vitamin D metabolites', 'vitamin D 3 or placebo', 'Vitamin D supplementation', 'Vitamin D Supplements', 'vitamin D', 'vitamin D supplementation', 'placebo']","['Tuberculosis disease', 'lower risk of tuberculosis infection, tuberculosis disease, or acute respiratory infection', 'positive QFT result at the 3-year follow-up, expressed as a proportion of children', 'acute respiratory infection', 'serum 25-hydroxyvitamin D (25[OH]D) level at the end of the trial and the incidence of tuberculosis disease, acute respiratory infection, and adverse events', 'incidence of adverse events', 'mean 25(OH)D level']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C4704700', 'cui_str': 'Null Results'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0026926', 'cui_str': 'Mycobacterium tuberculosis'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0018026', 'cui_str': 'Gold'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0420176', 'cui_str': 'Vitamin D supplement therapy'}]","[{'cui': 'C0041296', 'cui_str': 'Tuberculosis'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0238990', 'cui_str': 'Acute lower respiratory tract infection'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",8851.0,0.752656,"The incidence of adverse events did not differ significantly between the two groups. ","[{'ForeName': 'Davaasambuu', 'Initials': 'D', 'LastName': 'Ganmaa', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Buyanjargal', 'Initials': 'B', 'LastName': 'Uyanga', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Garmaa', 'Initials': 'G', 'LastName': 'Gantsetseg', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Baigali', 'Initials': 'B', 'LastName': 'Delgerekh', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Davaasambuu', 'Initials': 'D', 'LastName': 'Enkhmaa', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Dorjnamjil', 'Initials': 'D', 'LastName': 'Khulan', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Saranjav', 'Initials': 'S', 'LastName': 'Ariunzaya', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Erdenebaatar', 'Initials': 'E', 'LastName': 'Sumiya', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Batbileg', 'Initials': 'B', 'LastName': 'Bolortuya', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Jutmaan', 'Initials': 'J', 'LastName': 'Yanjmaa', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Tserenkhuu', 'Initials': 'T', 'LastName': 'Enkhtsetseg', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Ankhbat', 'Initials': 'A', 'LastName': 'Munkhzaya', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Murneren', 'Initials': 'M', 'LastName': 'Tunsag', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Polyna', 'Initials': 'P', 'LastName': 'Khudyakov', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Seddon', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Ben J', 'Initials': 'BJ', 'LastName': 'Marais', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Ochirbat', 'Initials': 'O', 'LastName': 'Batbayar', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Ganbaatar', 'Initials': 'G', 'LastName': 'Erdenetuya', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Bazarsaikhan', 'Initials': 'B', 'LastName': 'Amarsaikhan', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Spiegelman', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Jadambaa', 'Initials': 'J', 'LastName': 'Tsolmon', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Adrian R', 'Initials': 'AR', 'LastName': 'Martineau', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}]",The New England journal of medicine,['10.1056/NEJMoa1915176'] 1860,32664175,Cervus and cucumis peptides combined umbilical cord mesenchymal stem cells therapy for rheumatoid arthritis.,"Cervus and cucumis peptides (Lugua polypeptides, LG) are traditional Chinese medicine, which are active components of polypeptide extracted from Sika deer bone and melon seed, and they contain bone induced polypeptide biological factors. Umbilical cord mesenchymal stem cell, (UC-MSC) have tissue repair multiple effects, anti-inflammatory, and immune regulation function, which become a very promising start in rheumatoid arthritis (RA) treatment. Hence, LG combined UC-MSC can significantly enhance the UC-MSC treatment of rheumatoid arthritis (RA).To explore the clinical curative effect and therapeutic mechanism of LG combined UC-MSC for treating RA.119 patients were divided into control and treatment groups, and both groups were treated with methotrexate tablets, leflunomide, and UC-MSC. But, LG were added to the treatment group. In vitro, the effects of LG on UC-MSC cell secretion of anti-inflammatory factors were also performed.The Health Assessment Questionnaire; the 28 joint disease activity score; C reactive protein; the erythrocyte sedimentation rate; rheumatoid factor; and anti-cyclic citrullinated peptide antibody were significantly reduced in treatment group 1 year after treatment (P < .05). In vitro, compared with the control group, the number of hepatocyte growth factor (HGF), the secretion of prostaglandin E2 (PGE2) and tumor necrosis factor-inducible gene 6 protein (TSG6) increased significantly (P < .05).LG combined UC-MSCs can significantly improve the curative effect of RA patients, while LG may reduce inflammatory cytokines, regulate immunity, improve microcirculation, and are conducive to UC-MSCs migration and the repair of damaged tissue.",2020,"In vitro, compared with the control group, the number of hepatocyte growth factor (HGF), the secretion of prostaglandin E2 (PGE2) and tumor necrosis factor-inducible gene 6 protein (TSG6) increased significantly (",['rheumatoid arthritis'],"['umbilical cord mesenchymal stem cells therapy', 'P\u200a<\u200a.05).LG', 'combined UC-MSCs', 'methotrexate tablets, leflunomide, and UC-MSC']","['UC-MSC cell secretion of anti-inflammatory factors', 'erythrocyte sedimentation rate; rheumatoid factor; and anti-cyclic citrullinated peptide antibody', 'number of hepatocyte growth factor (HGF), the secretion of prostaglandin E2 (PGE2) and tumor necrosis factor-inducible gene 6 protein (TSG6', 'curative effect']","[{'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}]","[{'cui': 'C0041633', 'cui_str': 'Umbilical cord structure'}, {'cui': 'C1257975', 'cui_str': 'Mesenchymal stem cell'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0074299', 'cui_str': 'selenomethylselenocysteine'}, {'cui': 'C1246896', 'cui_str': 'Methotrexate Oral Tablet'}, {'cui': 'C0063041', 'cui_str': 'leflunomide'}]","[{'cui': 'C0041633', 'cui_str': 'Umbilical cord structure'}, {'cui': 'C1257975', 'cui_str': 'Mesenchymal stem cell'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0003209', 'cui_str': 'Antiinflammatory agent'}, {'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C0035448', 'cui_str': 'Rheumatoid factor'}, {'cui': 'C0439596', 'cui_str': 'Cyclic'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0062534', 'cui_str': 'Scatter Factor'}, {'cui': 'C0012472', 'cui_str': 'Dinoprostone'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",,0.0240053,"In vitro, compared with the control group, the number of hepatocyte growth factor (HGF), the secretion of prostaglandin E2 (PGE2) and tumor necrosis factor-inducible gene 6 protein (TSG6) increased significantly (","[{'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Qi', 'Affiliation': ""Department of Radiation Oncology, 986 Hospital of People's Liberation Army Air Force.""}, {'ForeName': 'Hongxiang', 'Initials': 'H', 'LastName': 'Gao', 'Affiliation': ""Department of Radiotherapy Oncology, Chang An Hospital, Xi'an, Shaan Xi.""}, {'ForeName': 'Yazheng', 'Initials': 'Y', 'LastName': 'Dang', 'Affiliation': ""Department of Radiation Oncology, 986 Hospital of People's Liberation Army Air Force.""}, {'ForeName': 'Shigao', 'Initials': 'S', 'LastName': 'Huang', 'Affiliation': 'Cancer Centre.'}, {'ForeName': 'Minfei', 'Initials': 'M', 'LastName': 'Peng', 'Affiliation': 'Department of Clinical Laboratory, Taizhou Hospital of Zhejiang Province, Taizhou Enze Medical Center (Group), Linhai, Zhejiang Province, China.'}]",Medicine,['10.1097/MD.0000000000021222'] 1861,32687474,Effect of Adding Telephone-Based Brief Coaching to an mHealth App (Stay Strong) for Promoting Physical Activity Among Veterans: Randomized Controlled Trial.,"BACKGROUND Though maintaining physical conditioning and a healthy weight are requirements of active military duty, many US veterans lose conditioning and rapidly gain weight after discharge from active duty service. Mobile health (mHealth) interventions using wearable devices are appealing to users and can be effective especially with personalized coaching support. We developed Stay Strong, a mobile app tailored to US veterans, to promote physical activity using a wrist-worn physical activity tracker, a Bluetooth-enabled scale, and an app-based dashboard. We tested whether adding personalized coaching components (Stay Strong+Coaching) would improve physical activity compared to Stay Strong alone. OBJECTIVE The goal of this study is to compare 12-month outcomes from Stay Strong alone versus Stay Strong+Coaching. METHODS Participants (n=357) were recruited from a national random sample of US veterans of recent wars and randomly assigned to the Stay Strong app alone (n=179) or Stay Strong+Coaching (n=178); both programs lasted 12 months. Personalized coaching components for Stay Strong+Coaching comprised of automated in-app motivational messages (3 per week), telephone-based human health coaching (up to 3 calls), and personalized weekly goal setting. All aspects of the enrollment process and program delivery were accomplished virtually for both groups, except for the telephone-based coaching. The primary outcome was change in physical activity at 12 months postbaseline, measured by average weekly Active Minutes, captured by the Fitbit Charge 2 device. Secondary outcomes included changes in step counts, weight, and patient activation. RESULTS The average age of participants was 39.8 (SD 8.7) years, and 25.2% (90/357) were female. Active Minutes decreased from baseline to 12 months for both groups (P<.001) with no between-group differences at 6 months (P=.82) or 12 months (P=.98). However, at 12 months, many participants in both groups did not record Active Minutes, leading to missing data in 67.0% (120/179) for Stay Strong and 61.8% (110/178) for Stay Strong+Coaching. Average baseline weight for participants in Stay Strong and Stay Strong+Coaching was 214 lbs and 198 lbs, respectively, with no difference at baseline (P=.54) or at 6 months (P=.28) or 12 months (P=.18) postbaseline based on administrative weights, which had lower rates of missing data. Changes in the number of steps recorded and patient activation also did not differ by arm. CONCLUSIONS Adding personalized health coaching comprised of in-app automated messages, up to 3 coaching calls, plus automated weekly personalized goals, did not improve levels of physical activity compared to using a smartphone app alone. Physical activity in both groups decreased over time. Sustaining long-term adherence and engagement in this mHealth intervention proved difficult; approximately two-thirds of the trial's 357 participants failed to sync their Fitbit device at 12 months and, thus, were lost to follow-up. TRIAL REGISTRATION ClinicalTrials.gov NCT02360293; https://clinicaltrials.gov/ct2/show/NCT02360293. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR2-10.2196/12526.",2020,"All aspects of enrollment process and program delivery were accomplished virtually for both groups, except for the telephone-based coaching.","['Veterans', 'Participants (n=357) were recruited from a national random sample of U.S. Veterans of recent wars and randomly assigned to', 'Average age of participants was 39.8 (8.7) years and 25.2% were female']","['Stay Strong alone versus Stay Strong+Coaching', 'Personalized coaching components for Stay Strong+Coaching comprised of automated in-app motivational messages (3/week), telephone-based human health coaching', 'Personalized health coaching', 'personalized coaching components (Stay Strong+Coaching', 'Telephone-based Brief Coaching to a mHealth App', 'Stay Strong app alone (n=179) or Stay Strong+Coaching', 'Mobile health (mHealth) interventions']","['number of steps recorded and patient activation', 'changes in step counts, weight, and patient activation', 'change in physical activity', 'Physical activity', 'Average baseline weight', 'Physical Activity', 'physical activity', 'levels of physical activity']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0043027', 'cui_str': 'War'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517880', 'cui_str': '8.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0442821', 'cui_str': 'Strong'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C3853034', 'cui_str': 'Patient Activation'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0851408', 'cui_str': 'Changes in physical activity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1303013', 'cui_str': 'Baseline weight'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",357.0,0.0813274,"All aspects of enrollment process and program delivery were accomplished virtually for both groups, except for the telephone-based coaching.","[{'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Damschroder', 'Affiliation': 'Veterans Affairs Center for Clinical Management Research, Ann Arbor Healthcare System, Ann Arbor, MI, United States.'}, {'ForeName': 'Lorraine R', 'Initials': 'LR', 'LastName': 'Buis', 'Affiliation': 'University of Michigan, Department of Family Medicine, Ann Arbor, MI, United States.'}, {'ForeName': 'Felicia A', 'Initials': 'FA', 'LastName': 'McCant', 'Affiliation': 'Veterans Affairs Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, NC, United States.'}, {'ForeName': 'Hyungjin Myra', 'Initials': 'HM', 'LastName': 'Kim', 'Affiliation': 'Veterans Affairs Center for Clinical Management Research, Ann Arbor Healthcare System, Ann Arbor, MI, United States.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Evans', 'Affiliation': 'Veterans Affairs Center for Clinical Management Research, Ann Arbor Healthcare System, Ann Arbor, MI, United States.'}, {'ForeName': 'Eugene Z', 'Initials': 'EZ', 'LastName': 'Oddone', 'Affiliation': 'Veterans Affairs Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, NC, United States.'}, {'ForeName': 'Lori A', 'Initials': 'LA', 'LastName': 'Bastian', 'Affiliation': 'Veterans Affairs Pain Research, Informatics, Multimorbidities, and Education Center, Veterans Affairs Connecticut, West Haven, CT, United States.'}, {'ForeName': 'Gwendolyn', 'Initials': 'G', 'LastName': 'Hooks', 'Affiliation': 'Veterans Affairs Center for Clinical Management Research, Ann Arbor Healthcare System, Ann Arbor, MI, United States.'}, {'ForeName': 'Reema', 'Initials': 'R', 'LastName': 'Kadri', 'Affiliation': 'University of Michigan, Department of Family Medicine, Ann Arbor, MI, United States.'}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'White-Clark', 'Affiliation': 'Veterans Affairs Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, NC, United States.'}, {'ForeName': 'Caroline R', 'Initials': 'CR', 'LastName': 'Richardson', 'Affiliation': 'University of Michigan, Department of Family Medicine, Ann Arbor, MI, United States.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Gierisch', 'Affiliation': 'Veterans Affairs Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, NC, United States.'}]",Journal of medical Internet research,['10.2196/19216'] 1862,32696695,Impact of Self-Monitoring of Blood Pressure on Processes of Hypertension Care and Long-Term Blood Pressure Control.,"Background Self-monitoring of blood pressure (SMBP) improves blood pressure (BP) outcomes at 12-months, but information is lacking on how SMBP affects hypertension care processes and longer-term BP outcomes. Methods and Results We pooled individual participant data from 4 randomized clinical trials of SMBP in the United Kingdom (combined n=2590) with varying intensities of support. Multivariable random effects regression was used to estimate the probability of antihypertensive intensification at 12 months for usual care versus SMBP. Using these data, we simulated 5-year BP control rates using a validated mathematical model. Trial participants were mostly older adults (mean age 66.6 years, SD 9.5), male (53.9%), and predominantly white (95.6%); mean baseline BP was 151.8/85.0 mm Hg. Compared with usual care, the likelihood of antihypertensive intensification increased with both SMBP with feedback to patient or provider alone (odds ratio 1.8, 95% CI 1.2-2.6) and with telemonitoring or self-management (3.3, 2.5-4.2). Over 5 years, we estimated 33.4% BP control (<140/90 mm Hg) with usual care (95% uncertainty interval 27.7%-39.4%). One year of SMBP with feedback to patient or provider alone achieved 33.9% (28.3%-40.3%) BP control and SMBP with telemonitoring or self-management 39.0% (33.1%-45.2%) over 5 years. If SMBP interventions and associated BP control processes were extended to 5 years, BP control increased to 52.4% (45.4%-59.8 %) and 72.1% (66.5%-77.6%), respectively. Conclusions One year of SMBP plus telemonitoring or self-management increases the likelihood of antihypertensive intensification and could improve BP control rates at 5 years; continuing SMBP for 5 years could further improve BP control.",2020,"Compared with usual care, the likelihood of antihypertensive intensification increased with both SMBP with feedback to patient or provider alone (odds ratio 1.8, 95% CI 1.2-2.6) and with telemonitoring or self-management (3.3, 2.5-4.2).","['Trial participants were mostly older adults (mean age 66.6\xa0years, SD 9.5), male (53.9%), and predominantly white (95.6%); mean baseline BP was 151.8/85.0\xa0mm\xa0Hg']","[' Self-monitoring of blood pressure (SMBP', 'SMBP', 'Self-Monitoring of Blood Pressure']","['5-year BP control rates', 'BP control processes', 'BP control rates', 'BP control', 'blood pressure (BP) outcomes']","[{'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517899', 'cui_str': '9.5'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]","[{'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0699419,"Compared with usual care, the likelihood of antihypertensive intensification increased with both SMBP with feedback to patient or provider alone (odds ratio 1.8, 95% CI 1.2-2.6) and with telemonitoring or self-management (3.3, 2.5-4.2).","[{'ForeName': 'Kelsey B', 'Initials': 'KB', 'LastName': 'Bryant', 'Affiliation': 'Columbia University New York NY.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Sheppard', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences University of Oxford United Kingdom.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Ruiz-Negrón', 'Affiliation': 'University of Utah Salt Lake City UT.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Kronish', 'Affiliation': 'Columbia University New York NY.'}, {'ForeName': 'Valy', 'Initials': 'V', 'LastName': 'Fontil', 'Affiliation': 'University of California at San Francisco CA.'}, {'ForeName': 'Jordan B', 'Initials': 'JB', 'LastName': 'King', 'Affiliation': 'University of Utah Salt Lake City UT.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Pletcher', 'Affiliation': 'University of California at San Francisco CA.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Bibbins-Domingo', 'Affiliation': 'University of California at San Francisco CA.'}, {'ForeName': 'Andrew E', 'Initials': 'AE', 'LastName': 'Moran', 'Affiliation': 'Columbia University New York NY.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'McManus', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences University of Oxford United Kingdom.'}, {'ForeName': 'Brandon K', 'Initials': 'BK', 'LastName': 'Bellows', 'Affiliation': 'Columbia University New York NY.'}]",Journal of the American Heart Association,['10.1161/JAHA.120.016174'] 1863,32696704,"Effects of Sugar-Sweetened, Artificially Sweetened, and Unsweetened Beverages on Cardiometabolic Risk Factors, Body Composition, and Sweet Taste Preference: A Randomized Controlled Trial.","Background A 2018 American Heart Association science advisory indicated that, pending further research, artificially sweetened beverages (ASBs) may be an appropriate initial replacement for sugar-sweetened beverages (SSBs) during transition to unsweetened beverages (USBs). Methods and Results We randomly assigned 203 adults (121 males, 82 females; 91.6% retention), who habitually consumed SSBs, to 3 groups and delivered free SSBs, ASBs, or USBs to their homes for 12 months. Outcomes included serum triglyceride to high-density lipoprotein cholesterol ratio (primary), body weight, and sweet taste preference (experimental assessment, 0%-18% sucrose solutions). Change in serum triglyceride to high-density lipoprotein cholesterol ratio was not different between groups. Although overall change in weight also was not different between groups, we found effect modification ( P =0.006) by central adiposity. Among participants in the highest tertile of baseline trunk fat but not other tertiles, weight gain was greater ( P =0.002) for the SSB (4.4±1.0 kg, estimate±SE) compared with ASB (0.5±0.9 kg) or USB (-0.2±0.9 kg) group. Both sweetness threshold (-1.0±0.2% m/v; P =0.005) and favorite concentration (-2.3±0.4% m/v; P <0.0001) decreased in the USB group; neither changed in the SSB group. In the ASB group, sweetness threshold did not change, and favorite concentration decreased (-1.1±0.5% m/v; P =0.02). Pairwise comparison between the ASB and USB groups indicated a difference in sweetness threshold ( P =0.015). Conclusions Replacing SSBs with noncaloric beverages for 12 months did not affect serum triglyceride to high-density lipoprotein cholesterol ratio. Among individuals with central adiposity, replacing SSBs with either ASBs or USBs lowered body weight. However, USBs may have the most favorable effect on sweet taste preference. Registration URL: https://www.clinicaltrials.gov; unique identifier: NCT01295671.",2020,Both sweetness threshold (-1.0±0.2% m/v; P =0.005) and favorite concentration (-2.3±0.4% m/v; P <0.0001) decreased in the USB group; neither changed in the SSB group.,"['203 adults (121 males, 82 females; 91.6% retention), who habitually consumed SSBs, to 3 groups and delivered free SSBs, ASBs, or USBs to their homes for 12\xa0months', 'individuals with central adiposity, replacing SSBs with either ASBs or USBs lowered body weight']","['Sugar-Sweetened, Artificially Sweetened, and Unsweetened Beverages']","['favorite concentration', 'serum triglyceride to high-density lipoprotein cholesterol ratio', 'weight gain', 'serum triglyceride to high-density lipoprotein cholesterol ratio (primary), body weight, and sweet taste preference (experimental assessment, 0%-18% sucrose solutions', 'Cardiometabolic Risk Factors, Body Composition, and Sweet Taste Preference']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C5197754', 'cui_str': 'Sugar-Added Beverages'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C5197916', 'cui_str': 'Artificially Sweetened Beverages'}, {'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4551560', 'cui_str': 'Central obesity'}, {'cui': 'C0559956', 'cui_str': 'Replacement - action'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]","[{'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0542495', 'cui_str': 'Measurement of serum triglyceride level'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0858600', 'cui_str': 'Taste sweet'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0038636', 'cui_str': 'Sucrose'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}]",203.0,0.228294,Both sweetness threshold (-1.0±0.2% m/v; P =0.005) and favorite concentration (-2.3±0.4% m/v; P <0.0001) decreased in the USB group; neither changed in the SSB group.,"[{'ForeName': 'Cara B', 'Initials': 'CB', 'LastName': 'Ebbeling', 'Affiliation': ""New Balance Foundation Obesity Prevention Center Boston Children's Hospital Boston MA.""}, {'ForeName': 'Henry A', 'Initials': 'HA', 'LastName': 'Feldman', 'Affiliation': ""Institutional Centers for Clinical and Translational Research Boston Children's Hospital Boston MA.""}, {'ForeName': 'Sarah K', 'Initials': 'SK', 'LastName': 'Steltz', 'Affiliation': ""New Balance Foundation Obesity Prevention Center Boston Children's Hospital Boston MA.""}, {'ForeName': 'Nicolle L', 'Initials': 'NL', 'LastName': 'Quinn', 'Affiliation': ""Institutional Centers for Clinical and Translational Research Boston Children's Hospital Boston MA.""}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Robinson', 'Affiliation': 'Shape Up Somerville City of Somerville MA.'}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Ludwig', 'Affiliation': ""New Balance Foundation Obesity Prevention Center Boston Children's Hospital Boston MA.""}]",Journal of the American Heart Association,['10.1161/JAHA.119.015668'] 1864,32693198,Short term effects of the REAL media e-learning media literacy substance prevention curriculum: An RCT of adolescents disseminated through a community organization.,"BACKGROUND The primary aim of this study was to evaluate the short-term effects of testing an e-learning program to reduce adolescent substance use and abuse. Early initiation of substance use is linked to a variety of negative outcomes, thus effective intervention programs are needed. One approach is to use media literacy to capitalize on adolescents' immersion with media in a variety of forms. We developed, implemented, and tested an engaging substance use prevention program by collaborating with a youth-oriented community partner (4-H). METHODS 639 middle adolescents from nine U.S. states participated in an RCT of REAL media. Participants completed a series of online surveys and were randomized to use an online substance prevention program (REAL media) or serve as control (delayed program use). Self-report surveys were administered at three points in time. This short-term evaluation uses data from the pretest (Time 1) and short-term posttest three-month surveys, which measured demographics, self-efficacy to counterargue, and injunctive and descriptive substance use norms. RESULTS Participants who completed the REAL media program reported increased self-efficacy to counterargue and decreased positive injunctive norms compared to control participants who did not complete the program. No significant differences were observed for descriptive norms. CONCLUSIONS We found support for the REAL media program in changing key predictors of youth substance use demonstrating (1) the efficacy of media literacy interventions targeting adolescents and (2) that e-learning substance use prevention efforts can be adapted for and implemented through community organizations.",2020,"RESULTS Participants who completed the REAL media program reported increased self-efficacy to counterargue and decreased positive injunctive norms compared to control participants who did not complete the program.",['639 middle adolescents from nine U.S. states participated in an RCT of REAL media'],"['e-learning program', 'engaging substance use prevention program by collaborating with a youth-oriented community partner (4-H', 'REAL media e-learning media literacy substance prevention curriculum', 'online substance prevention program (REAL media) or serve as control (delayed program use']",['self-efficacy to counterargue and decreased positive injunctive norms'],"[{'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}]","[{'cui': 'C0086858', 'cui_str': 'Programmed Learning'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0150358', 'cui_str': 'Substance use prevention'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}]",639.0,0.0245006,"RESULTS Participants who completed the REAL media program reported increased self-efficacy to counterargue and decreased positive injunctive norms compared to control participants who did not complete the program.","[{'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Greene', 'Affiliation': 'Department of Communication, Rutgers, the State University of New Jersey, 4 Huntington St., New Brunswick, NJ, 08901, USA. Electronic address: klgreene@rutgers.edu.'}, {'ForeName': 'Anne E', 'Initials': 'AE', 'LastName': 'Ray', 'Affiliation': 'Department of Health, Behavior & Society, University of Kentucky, 343 Bowman Hall, Lexington, KY, 40536, USA.'}, {'ForeName': 'Hye Jeong', 'Initials': 'HJ', 'LastName': 'Choi', 'Affiliation': 'Department of Health Sciences, University of Missouri, 501 Clark Hall, Columbia, MO, 65211, USA.'}, {'ForeName': 'Shannon D', 'Initials': 'SD', 'LastName': 'Glenn', 'Affiliation': 'Department of Communication, Rutgers, the State University of New Jersey, 4 Huntington St., New Brunswick, NJ, 08901, USA; REAL Prevention, LLC, 130 Pearl Brook Drive, Clifton, NJ, 07013, USA.'}, {'ForeName': 'Rachel E', 'Initials': 'RE', 'LastName': 'Lyons', 'Affiliation': 'Department of 4-H Youth Development, Rutgers, the State University of New Jersey, 88 Lipman Drive, New Brunswick, NJ, 08901, USA.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Hecht', 'Affiliation': 'REAL Prevention, LLC, 130 Pearl Brook Drive, Clifton, NJ, 07013, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108170'] 1865,32698855,Closed drainage versus non-drainage for single-level lumbar discectomy: a prospective randomized controlled study.,"BACKGROUND Postoperative epidural haematoma and wound infection can cause devastating neurological damage in spinal surgery. Closed drainage is a common method to prevent epidural haematoma, infection and related neurological impairment after lumbar decompression; however, it is not clear whether drainage can reduce postoperative complications and improve clinical efficacy. This randomized study aims to explore the role of closed drainage in reducing postoperative complications and improving the clinical efficacy of single-level lumbar discectomy. METHODS A total of 420 patients with single-level lumbar disc herniation were finally included in this study (169 females and 251 males, age 50.0 ± 6.4 years). A total of 214 patients were randomly assigned to the closed drainage group, and 206 patients were assigned to the non-drainage group. The incidence of postoperative fever, symptomatic epidural haematoma, wound infection and the need for revision surgery were compared between the two groups by the chi-square test or Fisher's exact test. The visual analogue scale (VAS) and oswestry disability index (ODI) were used to evaluate the improvement of pain relief and the recovery of lumbar function. The VAS and ODI scores were compared between the two groups using t tests. RESULTS The complications of the two groups were compared and analysed. There was only a statistically significant difference in the postoperative fever rate (p = 0.022), as the non-drainage group had a higher fever rate, but there were no significant differences in the rates of symptomatic epidural haematoma, wound infection or revision operation (p > 0.05). After concrete analysis, for the rate of fever less than 38.5 degrees, there was a statistically significant difference (p = 0.027), but there was no significant difference when the fever was greater than 38.5 degrees (p > 0.05). When comparing the VAS scores of the operation area on the first day after the operation, the pain relief in the closed drainage group was significantly better than that in the non-drainage group, with scores of 5.1 ± 0.8 and 6.0 ± 0.7, respectively (p < 0.001). However, there was no significant difference between the two groups in the other VAS scores of operation areas, the VAS scores of the lower extremity, or the ODI scores (p > 0.05). CONCLUSIONS For single-level lumbar discectomy, closed drainage is beneficial for reducing postoperative low-grade fever and relieving pain in the operation area in the very early postoperative stage. However, drainage does not have a significant impact on reducing the incidence of postoperative complications or improving clinical efficacy. TRIAL REGISTRATION Current Controlled Trials ChiCTR1800016005 , May/06/2018, retrospectively registered.",2020,"However, there was no significant difference between the two groups in the other VAS scores of operation areas, the VAS scores of the lower extremity, or the ODI scores (p > 0.05). ","['214 patients were randomly assigned to the closed drainage group, and 206 patients were assigned to the non-drainage group', 'spinal surgery', '420 patients with single-level lumbar disc herniation were finally included in this study (169 females and 251 males, age 50.0\u2009±\u20096.4\u2009years']","['Closed drainage versus non-drainage', 'closed drainage']","['postoperative low-grade fever and relieving pain', 'pain relief', 'visual analogue scale (VAS) and oswestry disability index (ODI', 'rate of fever less', 'VAS scores of operation areas, the VAS scores of the lower extremity, or the ODI scores', 'rates of symptomatic epidural haematoma, wound infection or revision operation', 'pain relief and the recovery of lumbar function', 'postoperative complications', 'postoperative fever rate', 'VAS and ODI scores', 'fever rate', 'fever', 'postoperative fever, symptomatic epidural haematoma, wound infection and the need for revision surgery', 'VAS scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C4517774', 'cui_str': '420'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0281899', 'cui_str': 'Prolapsed lumbar intervertebral disc'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0761050', 'cui_str': '(GVGVP)251'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517822', 'cui_str': '6.4'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0239574', 'cui_str': 'Low grade pyrexia'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C2960603', 'cui_str': 'Oswestry disability index score'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0238154', 'cui_str': 'Epidural hemorrhage'}, {'cui': 'C0043241', 'cui_str': 'Local infection of wound'}, {'cui': 'C0439616', 'cui_str': 'Revisions'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0424786', 'cui_str': 'Postoperative fever'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}]",420.0,0.0745268,"However, there was no significant difference between the two groups in the other VAS scores of operation areas, the VAS scores of the lower extremity, or the ODI scores (p > 0.05). ","[{'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Guo', 'Affiliation': ""Department of Spine Surgery, Xi'an Jiaotong University College of Medicine, Honghui Hospital, Xi'an, Shaanxi, China.""}, {'ForeName': 'Biao', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': ""Department of Spine Surgery, Xi'an Jiaotong University College of Medicine, Honghui Hospital, Xi'an, Shaanxi, China.""}, {'ForeName': 'Zhaohua', 'Initials': 'Z', 'LastName': 'Ji', 'Affiliation': ""Department of epidemiology, Shaanxi Provincial Key Laboratory of Free Radical Biology and Medicine, The Ministry of Education Key Laboratory of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Air Force Medical University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Gao', 'Affiliation': ""Department of Intensive Care Unit, Xi'an Jiaotong University College of Medicine, Honghui Hospital, Xi'an, Shaanxi, China.""}, {'ForeName': 'Yuting', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ""Department of Computed Tomography, Xi'an Jiaotong University College of Medicine, Honghui Hospital, Xi'an, Shaanxi, China.""}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Yuan', 'Affiliation': ""Department of Spine Surgery, Xi'an Jiaotong University College of Medicine, Honghui Hospital, Xi'an, Shaanxi, China.""}, {'ForeName': 'Dingjun', 'Initials': 'D', 'LastName': 'Hao', 'Affiliation': ""Department of Spine Surgery, Xi'an Jiaotong University College of Medicine, Honghui Hospital, Xi'an, Shaanxi, China. dingjunhaowb@163.com.""}]",BMC musculoskeletal disorders,['10.1186/s12891-020-03504-x'] 1866,32697484,Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy.,"OBJECTIVES To assess the effects of recombinant human soluble thrombomodulin treatment on 28-day all-cause mortality in subgroups categorized by baseline coagulation biomarker levels (prothrombin fragment 1.2, thrombin-antithrombin complex, D-dimer) in patients with sepsis-associated coagulopathy in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial (SCARLET) (NCT01598831). DESIGN Post hoc, subgroup analysis of a randomized, double-blind, placebo-controlled, multinational, multicenter phase 3 study. SETTING ICUs at 159 sites in 26 countries. PATIENTS Eight-hundred adults with sepsis-associated coagulopathy defined as international normalized ratio greater than 1.40 and platelet count between 30 × 10/L and 150 × 10/L or greater than 30% decrease within 24 hours with concomitant cardiovascular and/or respiratory failure. INTERVENTIONS Patients randomized and treated with recombinant human soluble thrombomodulin (0.06 mg/kg/d; n = 395) or equivalent placebo (n = 405) for 6 days. MEASUREMENTS AND MAIN RESULTS Recombinant human soluble thrombomodulin did not significantly reduce 28-day all-cause mortality in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial: absolute risk reduction was 2.55% (p = 0.32) in patients with sepsis-associated coagulopathy. In this post hoc analysis, mortality steadily increased with increasing baseline prothrombin fragment 1.2 and thrombin-antithrombin complex levels in the placebo group; for those values exceeding the upper limit of normal, the mortality increases in the recombinant human soluble thrombomodulin group were lower or negligible with increasing baseline prothrombin fragment 1.2 and thrombin-antithrombin complex. Consequently, absolute risk reductions were greater in subgroups with higher baseline prothrombin fragment 1.2 or thrombin-antithrombin complex. Absolute risk reductions were also greater in subgroups with baseline coagulation biomarker levels at or above median of the entire study population, ranging from 4.2% (95% CI, -5.0% to 13.4%) to 5.5% (95% CI, -4.0% to 14.9%). CONCLUSIONS Compared with patients receiving placebo, patients treated with recombinant human soluble thrombomodulin having higher baseline thrombin generation biomarker levels had lower mortality. Further research regarding the predictive role of coagulation biomarkers for recombinant human soluble thrombomodulin treatment response in sepsis-associated coagulopathy is warranted to evaluate clinical relevance.",2020,Recombinant human soluble thrombomodulin did not significantly reduce 28-day all-cause mortality in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial: absolute risk reduction was 2.55% (p = 0.32) in patients with sepsis-associated coagulopathy.,"['patients with sepsis-associated coagulopathy in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial (SCARLET) (NCT01598831', 'Patients With Sepsis-Associated Coagulopathy', 'ICUs at 159 sites in 26 countries', 'Eight-hundred adults with sepsis-associated coagulopathy defined as international normalized ratio greater than 1.40 and platelet count between 30 × 10/L and 150 × 10/L or greater than 30% decrease within 24 hours with concomitant cardiovascular and/or respiratory failure']","['equivalent placebo', 'Recombinant Human Soluble Thrombomodulin', 'recombinant human soluble thrombomodulin', 'recombinant human soluble thrombomodulin treatment', 'Recombinant human soluble thrombomodulin', 'placebo']","['Baseline Coagulation Biomarker Levels and Mortality Outcome', 'Absolute risk reductions', 'absolute risk reductions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0005779', 'cui_str': 'Blood coagulation disorder'}, {'cui': 'C0145779', 'cui_str': 'Thrombomodulin'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0525032', 'cui_str': 'International normalized ratio'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}]","[{'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0145779', 'cui_str': 'Thrombomodulin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C3179139', 'cui_str': 'Absolute Risk Reduction'}]",800.0,0.39019,Recombinant human soluble thrombomodulin did not significantly reduce 28-day all-cause mortality in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial: absolute risk reduction was 2.55% (p = 0.32) in patients with sepsis-associated coagulopathy.,"[{'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Levi', 'Affiliation': '1Department of Medicine and Cardiometabolic Programme - NIHR UCLH/UCL BRC, University College London Hospitals NHS Trust, London, United Kingdom. 2Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. 3Asahi Kasei Pharma America Corporation, Waltham, MA. 4Loyola University Medical Center, Maywood, IL.'}, {'ForeName': 'Jean-Louis', 'Initials': 'JL', 'LastName': 'Vincent', 'Affiliation': ''}, {'ForeName': 'Kosuke', 'Initials': 'K', 'LastName': 'Tanaka', 'Affiliation': ''}, {'ForeName': 'Amanda H', 'Initials': 'AH', 'LastName': 'Radford', 'Affiliation': ''}, {'ForeName': 'Toshihiko', 'Initials': 'T', 'LastName': 'Kayanoki', 'Affiliation': ''}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Fineberg', 'Affiliation': ''}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Hoppensteadt', 'Affiliation': ''}, {'ForeName': 'Jawed', 'Initials': 'J', 'LastName': 'Fareed', 'Affiliation': ''}]",Critical care medicine,['10.1097/CCM.0000000000004426'] 1867,32700953,Direct and indirect effects of a couple-focused preventive intervention on children's outcomes: A randomized controlled trial with African American families.,"OBJECTIVE This study examined the effects of the Protecting Strong African American Families (ProSAAF) prevention program on children's outcomes more than 2 years after enrollment, including direct effects of the intervention and indirect effects through couple functioning and parent-child relations. METHOD Three hundred forty-six African American couples with an early adolescent child participated; all families lived in rural, low-income communities in the southern United States. Families were randomly assigned to ProSAAF or control conditions and completed four waves of data collection. Couples reported couple functioning at baseline (Wave 1) and at 9-month follow-up (Wave 2), and parent-child relations at 17-month follow-up (Wave 3). Children reported their conduct problems, affiliation with deviant peers, substance use, sexual onset, depressive symptoms, and self-control at 25-month follow-up (Wave 4). RESULTS Path analyses indicated significant indirect effects of ProSAAF on children's outcomes through improvements in couple functioning and better parent-child relations. There were no significant direct effects of the intervention on children's outcomes or significant indirect effects through couple functioning alone. CONCLUSIONS This couple-focused prevention program has positive indirect effects on several child outcomes through the intervening processes of promoting improvements in couple functioning and better parent-child relations. These findings provide cautious optimism regarding the possible benefits of couple-focused programming on participants' children while suggesting ways in which future couple-focused interventions could yield stronger effects on these youth. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"RESULTS Path analyses indicated significant indirect effects of ProSAAF on children's outcomes through improvements in couple functioning and better parent-child relations.","['Three hundred forty-six African American couples with an early adolescent child participated; all families lived in rural, low-income communities in the southern United States', 'African American families', ""participants' children"", ""children's outcomes""]","['ProSAAF', 'couple-focused preventive intervention', 'Protecting Strong African American Families (ProSAAF) prevention program']",['couple functioning and better parent-child relations'],"[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0557130', 'cui_str': 'Lives with family'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C1274040', 'cui_str': 'Result'}]","[{'cui': 'C0442821', 'cui_str': 'Strong'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0030542', 'cui_str': 'Parent-Child Relationship'}]",,0.0600898,"RESULTS Path analyses indicated significant indirect effects of ProSAAF on children's outcomes through improvements in couple functioning and better parent-child relations.","[{'ForeName': 'Justin A', 'Initials': 'JA', 'LastName': 'Lavner', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Allen W', 'Initials': 'AW', 'LastName': 'Barton', 'Affiliation': 'Department of Human Development and Family Studies.'}, {'ForeName': 'Steven R H', 'Initials': 'SRH', 'LastName': 'Beach', 'Affiliation': 'Department of Psychology and Center for Family Research.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000589'] 1868,32702848,The effect of dexmedetomidine and remifentanil on the postoperative sore throat after thyroidectomy.,"BACKGROUND Postoperative sore throat (POST) is an important concern in surgical patients undergoing endotracheal intubation. Its prevalence after thyroidectomy is up to 80%. The current study aimed to assess the effect of dexmedetomidine and remifentanil on postoperative sore throat. METHODS Seventy-four patients who underwent thyroidectomy were randomized to receive either dexmedetomidine (group D) or remifentanil (group R). At anesthesia induction, group D received dexmedetomidine 1 μg/kg over 10 minutes, followed by continuous dexmedetomidine infusion at 0.3 to 0.6 μg/kg/hour during surgery. Group R received remifentanil of 3 to 4 ng/ml during induction, followed by 1.5 to 2.5 ng/ml remifentanil infusion during surgery. POST at rest and swallowing was assessed during the first 24 hours in serial time periods (0-1, 1-6, and 6-24 hours). Hoarseness and postoperative pain score were also assessed. RESULTS POST incidence at rest (0-1, 1-6, and 6-24 hours) and swallowing (1-6 and 6-24 hours) was lower in group D than in group R. POST severity was significantly lower in group D than in group R during each time period. The incidence of postoperative hoarseness was also lower in group D than in group R at 1 to 6 and 6 to 24 hours. The postoperative pain score was lower in group D than in group R during each time period. CONCLUSION Intraoperative dexmedetomidine infusion reduced the incidence and severity of POST for 24 hours after thyroidectomy.",2020,The incidence of postoperative hoarseness was also lower in group D than in group R at 1 to 6 and 6 to 24 hours.,"['surgical patients undergoing endotracheal intubation', 'Seventy-four patients who underwent thyroidectomy', 'postoperative sore throat after thyroidectomy']","['dexmedetomidine and remifentanil', 'remifentanil', 'Postoperative sore throat (POST', 'dexmedetomidine']","['postoperative pain score', 'incidence and severity of POST', 'incidence of postoperative hoarseness', 'swallowing', 'Hoarseness and postoperative pain score', 'postoperative sore throat']","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C4517867', 'cui_str': '74'}, {'cui': 'C0040145', 'cui_str': 'Thyroidectomy'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0031350', 'cui_str': 'Pharyngitis'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0031350', 'cui_str': 'Pharyngitis'}]","[{'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0031350', 'cui_str': 'Pharyngitis'}, {'cui': 'C0019825', 'cui_str': 'Hoarse'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}]",74.0,0.0827207,The incidence of postoperative hoarseness was also lower in group D than in group R at 1 to 6 and 6 to 24 hours.,"[{'ForeName': 'Hyuckgoo', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Yeungnam University College of Medicine, Daegu, Republic of Korea.'}, {'ForeName': 'Hyojin', 'Initials': 'H', 'LastName': 'Kwon', 'Affiliation': ''}, {'ForeName': 'Sungmin', 'Initials': 'S', 'LastName': 'Jeon', 'Affiliation': ''}, {'ForeName': 'Eun Kyung', 'Initials': 'EK', 'LastName': 'Choi', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021060'] 1869,32702849,Effects of Fusu mixture (Wen-Shen-Qian-Yang Method) on sepsis-induced acute respiratory distress syndrome.,"INTRODUCTION Sepsis is the most common etiology of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Capillary leakage caused by lung endothelial injury is the central cause of ARDS. The results of research in modern medicine in reducing endothelial damage and restoring endothelial functions are limited. In the previous clinical observations, we found that the Fusu mixture not only improves the clinical symptoms but also reduces the leakage of pulmonary capillaries. Therefore, the purpose of this study is to determine the clinical efficacy of the Fusu mixture combined with Western medicine in the treatment of ARDS caused by sepsis and to explore the mechanism of traditional Chinese medicine. METHODS This is a prospective, single-center, randomized, single-blind, and controlled clinical study involving 620 eligible patients. The patients will be randomly divided into 2 groups: the Western medicine treatment group and the combination of Chinese and Western medicine treatment group. After 14 days of intervention, the clinical efficacy and safety of the Fusu mixture on sepsis-induced ARDS patients will be observed. The primary outcome will be measured as 28-day mortality. The secondary outcome indices include inflammatory markers (CRP, PCT, IL-6, TNF - α), APACHE II score, SOFA score, days without a ventilator, blood gas analysis (Lac, PaO2 / FiO2), intensive care unit hospital stay time, intensive care unit mortality. Simultaneously, the analysis of the exploratory results will be carried out to analyze the possible mechanism of Fusu mixture in the treatment of sepsis-induced ARDS by the high-throughput sequencing and bioinformatics. DISCUSSION The purpose of this study is to evaluate the clinical efficacy of Fusu mixture in the treatment of sepsis-induced ARDS and explore its possible mechanism of action. If successful, it will provide evidence-based adjuvant therapy for the clinical treatment of ARDS.",2020,"The secondary outcome indices include inflammatory markers (CRP, PCT, IL-6, TNF - α), APACHE II score, SOFA score, days without a ventilator, blood gas analysis (Lac, PaO2 / FiO2), intensive care unit hospital stay time, intensive care unit mortality.","['sepsis-induced acute respiratory distress syndrome', '620 eligible patients']","['Fusu mixture combined with Western medicine', 'Fusu mixture', 'Western medicine treatment group and the combination of Chinese and Western medicine treatment group', 'Fusu mixture (Wen-Shen-Qian-Yang Method']","['clinical efficacy and safety', 'clinical symptoms', 'inflammatory markers (CRP, PCT, IL-6, TNF - α), APACHE II score, SOFA score, days without a ventilator, blood gas analysis (Lac, PaO2\u200a/ FiO2), intensive care unit hospital stay time, intensive care unit mortality', '28-day mortality', 'leakage of pulmonary capillaries', 'endothelial damage and restoring endothelial functions']","[{'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}, {'cui': 'C4708788', 'cui_str': '620'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0014511', 'cui_str': 'Epidermoid cyst'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0032452', 'cui_str': 'Polychlorotriphenyl Compounds'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0489438', 'cui_str': 'APACHE II score'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0087153', 'cui_str': 'Ventilator'}, {'cui': 'C0005800', 'cui_str': 'Blood gas analysis'}, {'cui': 'C0202155', 'cui_str': 'Oxygen measurement, partial pressure, arterial'}, {'cui': 'C0428167', 'cui_str': 'Fraction of inspired oxygen'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0015376', 'cui_str': 'Extravasation'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0006901', 'cui_str': 'Structure of capillary blood vessel (organ)'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",620.0,0.0535987,"The secondary outcome indices include inflammatory markers (CRP, PCT, IL-6, TNF - α), APACHE II score, SOFA score, days without a ventilator, blood gas analysis (Lac, PaO2 / FiO2), intensive care unit hospital stay time, intensive care unit mortality.","[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'aDepartment of Critical Care Medicine bDepartment of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.'}, {'ForeName': 'Kunlan', 'Initials': 'K', 'LastName': 'Long', 'Affiliation': ''}, {'ForeName': 'Chunxia', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Xuemei', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Hongjing', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Peiyang', 'Initials': 'P', 'LastName': 'Gao', 'Affiliation': ''}, {'ForeName': 'Song', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021066'] 1870,32702867,A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections: Study protocol for antiretroviral therapy timing in AIDS patients with toxoplasma encephalitis.,"BACKGROUND Toxoplasma encephalitis (TE) is one of the main opportunistic infections in acquired immunodeficiency syndrome (AIDS) patients, and represents a social burden due to its high prevalence and morbidity. Concomitant antiretroviral therapy (ART), together with effective anti- toxoplasma combination therapy, is an effective strategy to treat AIDS-associated TE (AIDS/TE) patients. However, the timing for the initiation of ART after diagnosis of TE remains controversial. We therefore designed the present study to determine the optimal timing for ART initiation in AIDS/TE patients. METHODS/DESIGN This trial is a 17-center, randomized, prospective clinical study with 2 parallel arms. A total of 200 participants will be randomized at a 1:1 ratio into the 2 arms: the early ART initiation (≤14 days after TE diagnosis) arm and the deferred ART (>14 days after TE diagnosis) arm. The primary outcome will be the difference of mortality between the 2 arms at 48 weeks. The secondary outcomes will be the differences between the 2 arms in the changes of CD4+ counts from baseline to week 48, the rate of virologic suppression (HIV ribonucleic acid <50 copies/mL) from baseline to week 48, the incidence of TE-associated immune reconstitution inflammatory syndrome during the study period, and the incidence of adverse effects during the study period. DISCUSSION This present trial aims to evaluate the optimal timing for ART initiation in AIDS/TE patients, and will provide strong evidence for AIDS/TE treatment should it be successful. TRIAL REGISTRATION This trial was registered as one of the 12 trials under the name of a general project at the chictr.gov (http://www.chictr.org.cn/showproj.aspx?proj=35362) on February 1, 2019, and the registration number of the general project is ChiCTR1900021195.",2020,"The secondary outcomes will be the differences between the 2 arms in the changes of CD4+ counts from baseline to week 48, the rate of virologic suppression (HIV ribonucleic acid <50 copies/mL) from baseline to week 48, the incidence of TE-associated immune reconstitution inflammatory syndrome during the study period, and the incidence of adverse effects during the study period. ","['difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections', 'AIDS patients with toxoplasma encephalitis', '200 participants', 'acquired immunodeficiency syndrome (AIDS) patients', '12 trials under the name of a general project at the chictr.gov (http://www.chictr.org.cn/showproj.aspx?proj=35362) on February 1, 2019, and the registration number of the general project is ChiCTR1900021195']",['Concomitant antiretroviral therapy (ART'],"['incidence of TE-associated immune reconstitution inflammatory syndrome', 'rate of virologic suppression (HIV ribonucleic acid', 'changes of CD4+ counts', 'mortality', 'adverse effects']","[{'cui': 'C0332218', 'cui_str': 'Difficult'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0021051', 'cui_str': 'Immunodeficiency disorder'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0029118', 'cui_str': 'Opportunistic infectious disease'}, {'cui': 'C0001175', 'cui_str': 'AIDS'}, {'cui': 'C0085315', 'cui_str': 'Meningoencephalitis due to acquired toxoplasmosis'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C0237753', 'cui_str': 'Number'}]","[{'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0085315', 'cui_str': 'Meningoencephalitis due to acquired toxoplasmosis'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C1619738', 'cui_str': 'Immune reconstitution inflammatory syndrome'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Cell Counts'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",200.0,0.23435,"The secondary outcomes will be the differences between the 2 arms in the changes of CD4+ counts from baseline to week 48, the rate of virologic suppression (HIV ribonucleic acid <50 copies/mL) from baseline to week 48, the incidence of TE-associated immune reconstitution inflammatory syndrome during the study period, and the incidence of adverse effects during the study period. ","[{'ForeName': 'Yan-Ming', 'Initials': 'YM', 'LastName': 'Zeng', 'Affiliation': 'Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Xiao-Qing', 'Initials': 'XQ', 'LastName': 'He', 'Affiliation': ''}, {'ForeName': 'Yin-Qiu', 'Initials': 'YQ', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Yuan', 'Affiliation': ''}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Bai', 'Affiliation': ''}, {'ForeName': 'Yan-Qiu', 'Initials': 'YQ', 'LastName': 'Lu', 'Affiliation': ''}, {'ForeName': 'Huan', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Yao-Kai', 'Initials': 'YK', 'LastName': 'Chen', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021141'] 1871,32703205,Improving shared decision-making in vascular surgery by implementing decision support tools: study protocol for the stepped-wedge cluster-randomised OVIDIUS trial.,"BACKGROUND Shared decision-making improves the quality of patient care. Unfortunately, shared decision-making is not yet common practice among vascular surgeons. Thus, decision support tools were developed to assist vascular surgeons and their patients in using shared decision-making. This trial aims to evaluate the effectiveness and implementation of decision support tools to improve shared decision-making during vascular surgical consultations in which a treatment decision is to be made. METHODS The study design is a multicentre stepped-wedge cluster-randomised trial. Eligible patients are adult patients, visiting the outpatient clinic of a participating medical centre for whom several treatment options are feasible and who face a primary treatment decision for their abdominal aortic aneurysm, carotid artery disease, intermittent claudication, or varicose veins. Patients and vascular surgeons in the intervention group receive decision support tools that may help them adopt shared decision-making when making the final treatment decision. These decision support tools are decision aids, consultation cards, decision cards, and a practical training. Decision aids are informative websites that help patients become more aware of the pros and cons of the treatment options and their preferences regarding the treatment choice. Consultation cards with text or decision cards with images are used by vascular surgeons during consultation to determine which aspect of a treatment is most important to their patient. In the training vascular surgeons can practice shared decision-making with a patient actor, guided by a medical psychologist. This trial aims to include 502 vascular surgical patients to achieve a clinically relevant improvement in shared decision-making of 10 out of 100 points, using the 5-item OPTION instrument to score the audio-recordings of consultations. DISCUSSION In the OVIDIUS trial the available decision support tools for vascular surgical patients are implemented in clinical practice. We will evaluate whether these tools actually improve shared decision-making in the consultation room. The stepped-wedge cluster-randomised study design will ensure that at the end of the study all participating centres have implemented at least some of the decision support tools and thereby a certain level of shared decision-making. TRIAL REGISTRATION Netherlands Trial Registry, NTR6487 . Registered 7 June 2017. URL: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=6487.",2020,"This trial aims to evaluate the effectiveness and implementation of decision support tools to improve shared decision-making during vascular surgical consultations in which a treatment decision is to be made. ","['Eligible patients are adult patients, visiting the outpatient clinic of a participating medical centre for whom several treatment options are feasible and who face a primary treatment decision for their abdominal aortic aneurysm, carotid artery disease, intermittent claudication, or varicose veins', '502 vascular surgical patients', 'vascular surgical patients']",['URL'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C1708063', 'cui_str': 'First line treatment'}, {'cui': 'C0162871', 'cui_str': 'Abdominal aortic aneurysm'}, {'cui': 'C0007273', 'cui_str': 'Disorder of carotid artery'}, {'cui': 'C0021775', 'cui_str': 'Intermittent claudication'}, {'cui': 'C0042345', 'cui_str': 'Phlebectasia'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]","[{'cui': 'C3541384', 'cui_str': 'URL'}]",[],,0.123521,"This trial aims to evaluate the effectiveness and implementation of decision support tools to improve shared decision-making during vascular surgical consultations in which a treatment decision is to be made. ","[{'ForeName': 'S M L', 'Initials': 'SML', 'LastName': 'de Mik', 'Affiliation': 'Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'F E', 'Initials': 'FE', 'LastName': 'Stubenrouch', 'Affiliation': 'Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'D A', 'Initials': 'DA', 'LastName': 'Legemate', 'Affiliation': 'Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Balm', 'Affiliation': 'Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'D T', 'Initials': 'DT', 'LastName': 'Ubbink', 'Affiliation': 'Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands. d.ubbink@amsterdamumc.nl.'}]",BMC medical informatics and decision making,['10.1186/s12911-020-01186-y'] 1872,32703307,Randomized control trial of advanced cancer patients at a private hospital in Kenya and the impact of dignity therapy on quality of life.,"BACKGROUND Palliative care is a modality of treatment that addresses physical, psychological and spiritual symptoms. Dignity therapy, a form of psychotherapy, was developed by Professor Harvey Chochinov, MD in 2005.The aim of the study was to assess the effect of one session of dignity therapy on quality of life in advanced cancer patients. METHODS This was a randomized control trial of 144 patients (72 in each arm) randomized into group 1 (intervention arm) and group 2 (control arm). Baseline ESAS scores were determined in both arms following which group 1 received Dignity therapy while Group 2 received usual care only. Data collected was presented as printed (Legacy) documents to group 1 participants. These documents were a summary of previous discussions held. Post intervention ESAS scores were obtained in both groups after 6 weeks. Analysis was based on the intention to treat principle and descriptive statistics computed. The main outcome was symptom distress scores on the ESAS (summated out of 100 and symptom specific scores out of 10). The student T-test was used to test for difference in ESAS scores at follow up and graphs were computed for common cancers and comorbidities. RESULTS Of the 144 (72 patients in each arm) patients randomized, 70%were female while 30% were male with a mean age of 50 years. At 6 weeks, 11 patients were lost to follow up, seven died and 126 completed the study. The commonly encountered cancers were gastrointestinal cancers (43%, p = 0.29), breast cancer (27.27% p = 0.71) and gynaecologic cancers (23% p = 0.35). Majority of the patients i.e. 64.3% had no comorbidities. The primary analysis results showed higher scores for the DT group (change in mean = 1.57) compared to the UC group (change in mean = - 0.74) yielding a non-statistically significant difference in change scores of 1.44 (p = 0.670; 95% CI - 5.20 to 8.06). After adjusting for baseline scores, the mean (summated) symptom distress score was not significant (GLM p = 0.78). Dignity therapy group showed a trend towards statistical improvement in anxiety (p = 0.059). The largest effects seen were in improvement of appetite, lower anxiety and improved wellbeing (Cohen effect size 0.3, 0.5 and 0.31 respectively). CONCLUSION Dignity therapy showed no statistical improvement in overall quality of life. Symptom improvement was seen in anxiety and this was a trend towards statistical significance (p = 0.059). TRIAL REGISTRATION Trial registration number PACTR201604001447244 retrospectively registered with Pan African Clinical trials on 28th January 2016.",2020,"The largest effects seen were in improvement of appetite, lower anxiety and improved wellbeing (Cohen effect size 0.3, 0.5 and 0.31 respectively). ","['Of the 144 (72 patients in each arm', '11 patients were lost to follow up, seven died and 126 completed the study', 'advanced cancer patients', '144 patients (72 in each arm', 'advanced cancer patients at a private hospital in Kenya', '70%were female while 30% were male with a mean age of 50\u2009years']","['Dignity therapy', 'dignity therapy']","['quality of life', 'breast cancer', 'Baseline ESAS scores', 'mean (summated) symptom distress score', 'anxiety', 'appetite, lower anxiety and improved wellbeing', 'gynaecologic cancers', 'overall quality of life', 'ESAS scores', 'symptom distress scores', 'gastrointestinal cancers']","[{'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C1302313', 'cui_str': 'Lost to follow-up'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0033173', 'cui_str': 'Private hospital'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C4704841', 'cui_str': 'Dignity'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0205480', 'cui_str': 'Gynecologic'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C3472649', 'cui_str': 'Edmonton symptom assessment system'}, {'cui': 'C0685938', 'cui_str': 'Malignant neoplasm of gastrointestinal tract'}]",144.0,0.182917,"The largest effects seen were in improvement of appetite, lower anxiety and improved wellbeing (Cohen effect size 0.3, 0.5 and 0.31 respectively). ","[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'Weru', 'Affiliation': 'Palliative care, AKUHN, Nairobi, Kenya. john.weru@aku.edu.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Gatehi', 'Affiliation': 'MMED INT. Med, Nairobi, Kenya.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Musibi', 'Affiliation': 'Oncology, Kenyatta National Hospital, Nairobi, Kenya.'}]",BMC palliative care,['10.1186/s12904-020-00614-0'] 1873,32701682,Mechanical Evaluation of 2.7- Versus 3.5-mm Plating Constructs for Midshaft Clavicle Fractures.,"OBJECTIVES This study compares the mechanical performance of 2.7- and 3.5-mm plating constructs for the treatment of midshaft clavicle fractures. METHODS Twenty-four synthetic clavicles were randomly divided into four treatment groups-Synthes 2.7-mm cold-worked calcaneal reconstruction plate with 6 (CRP6) or 8 bicortical screws (CRP8); Synthes 3.5-mm LCP reconstruction plate (RP; and Synthes 3.5-mm LCP precontoured superior-anterior clavicle plate (PCRP). All clavicles were plated, a wedge-shaped inferior cortical defect was created, and testing was performed using a cantilever bending model to determine bending stiffness and yield point for each construct. RESULTS Bending stiffness for the 3.5-mm PCRP construct was markedly higher when compared with the other three constructs, whereas the 3.5-mm RP construct was markedly stiffer than both of the 2.7-mm CR constructs. The yield point for the 3.5-mm PCRP construct was greater than the other three constructs; however, the yield point for the 2.7-mm CRP with six screws and with eight screws was higher than the 3.5-mm RP construct. The amount of displacement required to reach the yield point was highest for the 2.7-mm CRP with six screws. and this was markedly higher than the values for the other three constructs. DISCUSSION The 3.5-mm plates demonstrated increased bending stiffness compared with the 2.7-mm plates. Despite the lower resistance to bending forces, the cold-worked 2.7-mm plate exhibited a markedly higher yield point and required markedly more superior to inferior displacement to initiate plastic deformation when compared with the 3.5-mm LCP RP. LEVEL OF EVIDENCE Level IV.",2020,"RESULTS Bending stiffness for the 3.5-mm PCRP construct was markedly higher when compared with the other three constructs, whereas the 3.5-mm RP construct was markedly stiffer than both of the 2.7-mm CR constructs.","['Twenty-four synthetic clavicles', 'Midshaft Clavicle Fractures']",['Synthes 2.7-mm cold-worked calcaneal reconstruction plate with 6 (CRP6) or 8 bicortical screws (CRP8); Synthes 3.5-mm LCP reconstruction plate (RP; and Synthes 3.5-mm LCP precontoured superior-anterior clavicle plate (PCRP'],['bending stiffness'],"[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0008913', 'cui_str': 'Bone structure of clavicle'}, {'cui': 'C0159658', 'cui_str': 'Fracture of clavicle'}]","[{'cui': 'C4517635', 'cui_str': '2.7'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0006655', 'cui_str': 'Bone structure of calcaneum'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0005975', 'cui_str': 'Bone screw'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C0023234', 'cui_str': 'Coxa plana'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0008913', 'cui_str': 'Bone structure of clavicle'}]","[{'cui': 'C0011119', 'cui_str': 'Bends'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}]",24.0,0.0172024,"RESULTS Bending stiffness for the 3.5-mm PCRP construct was markedly higher when compared with the other three constructs, whereas the 3.5-mm RP construct was markedly stiffer than both of the 2.7-mm CR constructs.","[{'ForeName': 'Mohammad M', 'Initials': 'MM', 'LastName': 'Alzahrani', 'Affiliation': 'From the Department of Orthopaedics (Dr. Alzahrani), College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia, the Rocky Mountain Orthopaedic Associates (Dr. Cota), Grand Junction, CO, the Department of Orthopedic Surgery (Dr. Alkhelaifi), ASPETAR, Orthopaedic and Sports Medicine Hospital, Doha, Qatar, and the Division of Orthopaedic Surgery (Dr. Harvey), McGill University Health Center, Montreal, Quebec, Canada.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Cota', 'Affiliation': ''}, {'ForeName': 'Khalid', 'Initials': 'K', 'LastName': 'Alkhelaifi', 'Affiliation': ''}, {'ForeName': 'Edward J', 'Initials': 'EJ', 'LastName': 'Harvey', 'Affiliation': ''}]",The Journal of the American Academy of Orthopaedic Surgeons,['10.5435/JAAOS-D-19-00495'] 1874,32708396,Effects of Exercise Combined with a Healthy Diet or Calanus finmarchicus Oil Supplementation on Body Composition and Metabolic Markers-A Pilot Study.,"Aging is accompanied by a progressive decline in muscle mass and an increase in fat mass, which are detrimental changes associated with the development of health conditions such as type-2 diabetes mellitus or chronic low-grade inflammation. Although both exercise as well as nutritional interventions are known to be beneficial in counteracting those age-related changes, data to which extent untrained elderly people may benefit is still sparse. Therefore, a randomized, controlled, 12-week interventional trial was conducted in which 134 healthy untrained participants (96 women and 38 men, age 59.4 ± 5.6 years, body mass index (BMI) 28.4 ± 5.8 kg/m 2 ) were allocated to one of four study groups: (1) control group with no intervention (CON); (2) 2×/week aerobic and resistance training only (EX); (3) exercise routine combined with dietary counseling in accordance with the guidelines of the German Nutrition Society (EXDC); (4) exercise routine combined with intake of 2 g/day oil from Calanus finmarchicus (EXCO). Body composition (bioelectrical impedance analysis), as well as markers of glucose metabolism and blood lipids, were analyzed at the beginning and the end of the study. The highest decreases in body fat were observed within the EXCO group (-1.70 ± 2.45 kg, p < 0.001), and the EXDC (-1.41 ± 2.13 kg, p = 0.008) group. Markers of glucose metabolism and blood lipids remained unchanged in all groups. Taken together results of this pilot study suggest that a combination of moderate exercise and intake of oil from Calanus finmarchicus or a healthy diet may promote fat loss in elderly untrained overweight participants.",2020,Markers of glucose metabolism and blood lipids remained unchanged in all groups.,"['elderly untrained overweight participants', '134 healthy untrained participants (96 women and 38 men, age 59.4 ± 5.6 years, body mass index (BMI) 28.4 ± 5.8 kg/m 2 ']","['Exercise Combined with a Healthy Diet or Calanus finmarchicus Oil Supplementation', 'control group with no intervention (CON); (2) 2×/week aerobic and resistance training only (EX); (3) exercise routine combined with dietary counseling in accordance with the guidelines of the German Nutrition Society (EXDC); (4) exercise routine combined with intake of 2 g/day oil from Calanus finmarchicus (EXCO']","['Markers of glucose metabolism and blood lipids', 'Body composition (bioelectrical impedance analysis), as well as markers of glucose metabolism and blood lipids', 'body fat', 'Body Composition and Metabolic Markers']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517794', 'cui_str': '5.6'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517796', 'cui_str': '5.8'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}]","[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0162536', 'cui_str': 'Biolectric Impedance'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C1513159', 'cui_str': 'Metabolic marker'}]",134.0,0.0438269,Markers of glucose metabolism and blood lipids remained unchanged in all groups.,"[{'ForeName': 'Paulina', 'Initials': 'P', 'LastName': 'Wasserfurth', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany.'}, {'ForeName': 'Josefine', 'Initials': 'J', 'LastName': 'Nebl', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany.'}, {'ForeName': 'Jan Philipp', 'Initials': 'JP', 'LastName': 'Schuchardt', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany.'}, {'ForeName': 'Mattea', 'Initials': 'M', 'LastName': 'Müller', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany.'}, {'ForeName': 'Tim Konstantin', 'Initials': 'TK', 'LastName': 'Boßlau', 'Affiliation': 'Department of Exercise Physiology and Sports Therapy, Institute of Sports Science, Justus-Liebig-University Giessen, 35394 Giessen, Germany.'}, {'ForeName': 'Karsten', 'Initials': 'K', 'LastName': 'Krüger', 'Affiliation': 'Department of Exercise Physiology and Sports Therapy, Institute of Sports Science, Justus-Liebig-University Giessen, 35394 Giessen, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Hahn', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany.'}]",Nutrients,['10.3390/nu12072139'] 1875,32708428,Randomised Controlled Trial: Partial Hydrolysation of Casein Protein in Milk Decreases Gastrointestinal Symptoms in Subjects with Functional Gastrointestinal Disorders.,"Unspecific gastrointestinal symptoms associated with milk consumption are common. In addition to lactose, also other components of milk may be involved. We studied whether the partial hydrolysation of milk proteins would affect gastrointestinal symptoms in subjects with functional gastrointestinal disorders. In a randomised, placebo-controlled crossover intervention, subjects ( n = 41) were given ordinary or hydrolysed high-protein, lactose-free milkshakes (500 mL, 50 g protein) to be consumed daily for ten days. After a washout period of ten days, the other product was consumed for another ten days. Gastrointestinal symptoms were recorded daily during the study periods, and a validated irritable bowel syndrome-symptom severity scale (IBS-SSS) questionnaire was completed at the beginning of the study and at the end of both study periods. Blood and urine samples were analysed for markers of inflammation, intestinal permeability and immune activation. Both the IBS-SSS score ( p = 0.001) and total symptom score reported daily ( p = 0.002) were significantly reduced when participants consumed the hydrolysed product. Less bloating was reported during both study periods when compared with the baseline ( p < 0.01 for both groups). Flatulence ( p = 0.01) and heartburn ( p = 0.03) decreased when consuming the hydrolysed product but not when drinking the control product. No significant differences in the levels of inflammatory markers (tumor necrosis factor alpha, TNF-α and interleukin 6, IL-6), intestinal permeability (fatty acid binding protein 2, FABP2) or immune activation (1-methylhistamine) were detected between the treatment periods. The results suggest that the partial hydrolysation of milk proteins (mainly casein) reduces subjective symptoms to some extent in subjects with functional gastrointestinal disorders. The mechanism remains to be resolved.",2020,"No significant differences in the levels of inflammatory markers (tumor necrosis factor alpha, TNF-α and interleukin 6, IL-6), intestinal permeability (fatty acid binding protein 2, FABP2) or immune activation (1-methylhistamine) were detected between the treatment periods.","['subjects ( n = 41', 'Subjects with Functional Gastrointestinal Disorders', 'subjects with functional gastrointestinal disorders']","['ordinary or hydrolysed high-protein, lactose-free milkshakes', 'milk proteins (mainly casein', 'partial hydrolysation of milk proteins', 'Partial Hydrolysation of Casein Protein', 'placebo']","['total symptom score', 'IBS-SSS score', 'subjective symptoms', 'levels of inflammatory markers (tumor necrosis factor alpha, TNF-α and interleukin 6, IL-6), intestinal permeability (fatty acid binding protein 2, FABP2) or immune activation (1-methylhistamine', 'Flatulence', 'irritable bowel syndrome-symptom severity scale (IBS-SSS) questionnaire', 'Less bloating', 'gastrointestinal symptoms', 'heartburn', 'Gastrointestinal symptoms']","[{'cui': 'C0559031', 'cui_str': 'Functional disorder of gastrointestinal tract'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0022949', 'cui_str': 'Lactose'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0026138', 'cui_str': 'Milk protein'}, {'cui': 'C0007332', 'cui_str': 'Caseins'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0037052', 'cui_str': 'Sick sinus syndrome'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0031164', 'cui_str': 'Permeability'}, {'cui': 'C1173118', 'cui_str': 'FABP2 protein, human'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0076065', 'cui_str': 'tele-methylhistamine'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0018834', 'cui_str': 'Heartburn'}]",41.0,0.0657328,"No significant differences in the levels of inflammatory markers (tumor necrosis factor alpha, TNF-α and interleukin 6, IL-6), intestinal permeability (fatty acid binding protein 2, FABP2) or immune activation (1-methylhistamine) were detected between the treatment periods.","[{'ForeName': 'Reijo', 'Initials': 'R', 'LastName': 'Laatikainen', 'Affiliation': 'Booston Oy Ltd., Viikinkaari 6, FI-00790 Helsinki, Finland.'}, {'ForeName': 'Hanne', 'Initials': 'H', 'LastName': 'Salmenkari', 'Affiliation': 'Pharmacology, Medical Faculty, University of Helsinki, P.O. Box 63, FI-00014 Helsinki, Finland.'}, {'ForeName': 'Timo', 'Initials': 'T', 'LastName': 'Sibakov', 'Affiliation': 'Valio Ltd., R&D, P.O. Box 30, FI-00039 Valio, Finland.'}, {'ForeName': 'Heikki', 'Initials': 'H', 'LastName': 'Vapaatalo', 'Affiliation': 'Pharmacology, Medical Faculty, University of Helsinki, P.O. Box 63, FI-00014 Helsinki, Finland.'}, {'ForeName': 'Anu', 'Initials': 'A', 'LastName': 'Turpeinen', 'Affiliation': 'Valio Ltd., R&D, P.O. Box 30, FI-00039 Valio, Finland.'}]",Nutrients,['10.3390/nu12072140'] 1876,32708446,Effects on Gastroesophageal Reflux of Donkey Milk-Derived Human Milk Fortifier Versus Standard Fortifier in Preterm Newborns: Additional Data from the FortiLat Study.,"BACKGROUND Feeding intolerance is a frequent diagnosis in very preterm infants. As seen in the FortiLat trial, human milk fortification with the new donkey milk-derived human milk fortifier (DF) seems to improve feeding tolerance in these infants. The aim of this study was to evaluate the effects of using the DF compared with bovine milk-derived fortifier (BF) on gastroesophageal reflux (GER) in very low birth weight (VLBW) infants. METHODS Over a total of 156 preterm infants were enrolled into the FortiLat trial (GA <32 weeks and birth weight <1500 g) and randomized into the BF arm or DF arm, and we selected all infants with clinical signs of GER and cardiorespiratory (CR) symptoms. All the infants underwent CR and multichannel intraluminal impedance and pH (MII/pH) monitoring associated with gastric ultrasound to evaluate GER and gastric emptying time. RESULTS 10 infants were enrolled, and 5 were in the DF arm. At MII/pH, infants enrolled into the DF arm showed a lower GER frequency than BF arm infants ( p = 0.036). Half gastric emptying time was similar in DF and BF arm infants ( p = 0.744). CONCLUSION The use of donkey-derived human milk fortifier reduced the GER frequency and consequently should be recommended in infants with feeding intolerance.",2020,"Half gastric emptying time was similar in DF and BF arm infants ( p = 0.744). ","['very preterm infants', 'infants with feeding intolerance', 'very low birth weight (VLBW) infants', '156 preterm infants were enrolled into the FortiLat trial (GA', 'Preterm Newborns', '10 infants were enrolled, and 5 were in the DF arm']","['bovine milk-derived fortifier (BF', 'Donkey Milk-Derived Human Milk Fortifier Versus Standard Fortifier']","['feeding tolerance', 'gastroesophageal reflux (GER', 'GER frequency', 'lower GER frequency', 'Half gastric emptying time']","[{'cui': 'C3897192', 'cui_str': 'Very preterm infant'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1820738', 'cui_str': 'Feeding intolerance'}, {'cui': 'C0282666', 'cui_str': 'Very Low Birth Weight'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0026140', 'cui_str': 'Breast milk'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0007452', 'cui_str': 'Cattle'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0324145', 'cui_str': 'Equus asinus'}, {'cui': 'C3853188', 'cui_str': 'Human milk fortifier'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0017168', 'cui_str': 'Gastroesophageal reflux disease'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",156.0,0.0357146,"Half gastric emptying time was similar in DF and BF arm infants ( p = 0.744). ","[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Cresi', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Maggiora', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Pirra', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Tonetto', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Carlotta', 'Initials': 'C', 'LastName': 'Rubino', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Cavallarin', 'Affiliation': 'Institute of Sciences of Food Production, Italian National Research Council, 10126 Turin, Italy.'}, {'ForeName': 'Marzia', 'Initials': 'M', 'LastName': 'Giribaldi', 'Affiliation': 'Research Centre for Engineering and Agro-Food Processing, Council for Agricultural Research and Economics (CREA), 10100 Turin, Italy.'}, {'ForeName': 'Guido E', 'Initials': 'GE', 'LastName': 'Moro', 'Affiliation': 'Italian Association of Human Milk Banks, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Peila', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Coscia', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}]",Nutrients,['10.3390/nu12072142'] 1877,32722659,Cognitive and emotional empathy after stimulation of brain mineralocorticoid and NMDA receptors in patients with major depression and healthy controls.,"Mineralocorticoid receptors (MR) are predominantly expressed in the hippocampus and prefrontal cortex. Both brain areas are associated with social cognition, which includes cognitive empathy (ability to understand others' emotions) and emotional empathy (ability to empathize with another person). MR stimulation improves memory and executive functioning in patients with major depressive disorder (MDD) and healthy controls, and leads to glutamate-mediated N-methyl-D-aspartate receptor (NMDA-R) signaling. We examined whether the beneficial effects of MR stimulation can be extended to social cognition (empathy), and whether DCS would have additional beneficial effects. In this double-blind placebo-controlled single-dose study, we randomized 116 unmedicated MDD patients (mean age 34 years, 78% women) and 116 age-, sex-, and education years-matched healthy controls to four conditions: MR stimulation (fludrocortisone (0.4 mg) + placebo), NMDA-R stimulation (placebo + D-cycloserine (250 mg)), MR and NMDA-R stimulation (both drugs), or placebo. Cognitive and emotional empathy were assessed by the Multifaceted Empathy Test. The study was registered on clinicaltrials.gov (NCT03062150). MR stimulation increased cognitive empathy across groups, whereas NMDA-R stimulation decreased cognitive empathy in MDD patients only. Independent of receptor stimulation, cognitive empathy did not differ between groups. Emotional empathy was not affected by MR or NMDA-R stimulation. However, MDD patients showed decreased emotional empathy compared with controls but, according to exploratory analyses, only for positive emotions. We conclude that MR stimulation has beneficial effects on cognitive empathy in MDD patients and healthy controls, whereas NMDA-R stimulation decreased cognitive empathy in MDD patients. It appears that MR rather than NMDA-R are potential treatment targets to modulate cognitive empathy in MDD.",2020,"Independent of receptor stimulation, cognitive empathy did not differ between groups.","['patients with major depression and healthy controls', 'patients with major depressive disorder (MDD) and healthy controls', '116 unmedicated MDD patients (mean age 34 years, 78% women) and 116 age-, sex-, and education years-matched healthy controls to four conditions']","['MR stimulation', 'brain mineralocorticoid and NMDA receptors', 'MR stimulation (fludrocortisone (0.4\u2009mg)\u2009+\u2009placebo), NMDA-R stimulation (placebo\u2009+\u2009D-cycloserine (250\u2009mg)), MR and NMDA-R stimulation (both drugs), or placebo', 'NMDA-R stimulation', 'placebo']","['Cognitive and emotional empathy', 'cognitive empathy', 'emotional empathy', 'Emotional empathy', 'memory and executive functioning']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517541', 'cui_str': '116'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0066563', 'cui_str': 'Mineralocorticoid Receptor'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0026160', 'cui_str': 'Mineralocorticoid hormone'}, {'cui': 'C0080093', 'cui_str': 'N-Methyl-D-Aspartate Receptors'}, {'cui': 'C0016280', 'cui_str': 'Fludrocortisone'}, {'cui': 'C4517457', 'cui_str': '0.4'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0010590', 'cui_str': 'Cycloserine'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}]",116.0,0.0509834,"Independent of receptor stimulation, cognitive empathy did not differ between groups.","[{'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Nowacki', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Wingenfeld', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kaczmarczyk', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Woo Ri', 'Initials': 'WR', 'LastName': 'Chae', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Ikram', 'Initials': 'I', 'LastName': 'Abu-Tir', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Christian Eric', 'Initials': 'CE', 'LastName': 'Deuter', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Piber', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Hellmann-Regen', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Otte', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany. christian.otte@charite.de.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-020-0777-x'] 1878,32722661,Dose-response effects of d-amphetamine on effort-based decision-making and reinforcement learning.,"Effort-related decision-making and reward learning are both dopamine-dependent, but preclinical research suggests they depend on different dopamine signaling dynamics. Therefore, the same dose of a dopaminergic medication could have differential effects on effort for reward vs. reward learning. However, no study has tested how effort and reward learning respond to the same dopaminergic medication within subjects. The current study aimed to test the effect of therapeutic doses of d-amphetamine on effort for reward and reward learning in the same healthy volunteers. Participants (n = 30) completed the Effort Expenditure for Reward Task (EEfRT) measure of effort-related decision-making, and the Probabilistic Reward Task (PRT) measure of reward learning, under placebo and two doses of d-amphetamine (10 mg, and 20 mg). Secondarily, we examined whether the individual characteristics of baseline working memory and willingness to exert effort for reward moderated the effects of d-amphetamine. d-Amphetamine increased willingness to exert effort, particularly at low to intermediate expected values of reward. Computational modeling analyses suggested this was due to decreased effort discounting rather than probability discounting or decision consistency. Both baseline effort and working memory emerged as moderators of this effect, such that d-amphetamine increased effort more in individuals with lower working memory and lower baseline effort, also primarily at low to intermediate expected values of reward. In contrast, d-amphetamine had no significant effect on reward learning. These results have implications for treatment of neuropsychiatric disorders, which may be characterized by multiple underlying reward dysfunctions.",2020,"Both baseline effort and working memory emerged as moderators of this effect, such that d-amphetamine increased effort more in individuals with lower working memory and lower baseline effort, also primarily at low to intermediate expected values of reward.",['same healthy volunteers'],"['Effort Expenditure for Reward Task (EEfRT) measure of effort-related decision-making, and the Probabilistic Reward Task (PRT) measure of reward learning, under placebo and two doses of d-amphetamine', 'd-amphetamine', 'Amphetamine', 'amphetamine']","['reward and reward learning', 'reward learning']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0015316', 'cui_str': 'Expenditures'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0011109', 'cui_str': 'Decision making'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0011812', 'cui_str': 'Dextroamphetamine'}, {'cui': 'C0002658', 'cui_str': 'Amphetamine'}]","[{'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0013621', 'cui_str': 'Education'}]",,0.0271128,"Both baseline effort and working memory emerged as moderators of this effect, such that d-amphetamine increased effort more in individuals with lower working memory and lower baseline effort, also primarily at low to intermediate expected values of reward.","[{'ForeName': 'Heather E', 'Initials': 'HE', 'LastName': 'Soder', 'Affiliation': 'Faillace Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.'}, {'ForeName': 'Jessica A', 'Initials': 'JA', 'LastName': 'Cooper', 'Affiliation': 'Department of Psychology, Emory University, Atlanta, GA, 30322, USA.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Lopez-Gamundi', 'Affiliation': 'Faillace Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.'}, {'ForeName': 'Jennifer K', 'Initials': 'JK', 'LastName': 'Hoots', 'Affiliation': 'Department of Psychology, University of Illinois at Chicago, Chicago, 60607, IL, USA.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Nunez', 'Affiliation': 'Department of Psychology, University of Illinois at Chicago, Chicago, 60607, IL, USA.'}, {'ForeName': 'Victoria M', 'Initials': 'VM', 'LastName': 'Lawlor', 'Affiliation': 'Department of Psychology, Emory University, Atlanta, GA, 30322, USA.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Lane', 'Affiliation': 'Faillace Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.'}, {'ForeName': 'Michael T', 'Initials': 'MT', 'LastName': 'Treadway', 'Affiliation': 'Department of Psychology, Emory University, Atlanta, GA, 30322, USA. mtreadway@emory.edu.'}, {'ForeName': 'Margaret C', 'Initials': 'MC', 'LastName': 'Wardle', 'Affiliation': 'Department of Psychology, University of Illinois at Chicago, Chicago, 60607, IL, USA. mwardle@uic.edu.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-020-0779-8'] 1879,32702309,"Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.","BACKGROUND Outcomes for children and adults with advanced soft tissue sarcoma are poor with traditional therapy. We investigated whether the addition of pazopanib to preoperative chemoradiotherapy would improve pathological near complete response rate compared with chemoradiotherapy alone. METHODS In this joint Children's Oncology Group and NRG Oncology multicentre, randomised, open-label, phase 2 trial, we enrolled eligible adults (aged ≥18 years) and children (aged between 2 and <18 years) from 57 hospitals in the USA and Canada with unresected, newly diagnosed trunk or extremity chemotherapy-sensitive soft tissue sarcoma, which were larger than 5 cm in diameter and of intermediate or high grade. Eligible patients had Lansky (if aged ≤16 years) or Karnofsky (if aged >16 years) performance status score of at least 70. Patients received ifosfamide (2·5 g/m 2 per dose intravenously on days 1-3 with mesna) and doxorubicin (37·5 mg/m 2 per dose intravenously on days 1-2) with 45 Gy preoperative radiotherapy, followed by surgical resection at week 13. Patients were randomly assigned (1:1) using a web-based system, in an unmasked manner, to receive oral pazopanib (if patients <18 years 350 mg/m 2 once daily; if patients ≥18 years 600 mg once daily) or not (control group), with pazopanib not given immediately before or after surgery at week 13. The study projected 100 randomly assigned patients were needed to show an improvement in the number of participants with a 90% or higher pathological response at week 13 from 40% to 60%. Analysis was done per protocol. This study has completed accrual and is registered with ClinicalTrials.gov, NCT02180867. FINDINGS Between July 7, 2014, and Oct 1, 2018, 81 eligible patients were enrolled and randomly assigned to the pazopanib group (n=42) or the control group (n=39). At the planned second interim analysis with 42 evaluable patients and a median follow-up of 0·8 years (IQR 0·3-1·6) in the pazopanib group and 1 year (0·3-1·6) in the control group, the number of patients with a 90% pathological response or higher was 14 (58%) of 24 patients in the pazopanib group and four (22%) of 18 patients in the control group, with a between-group difference in the number of 90% or higher pathological response of 36·1% (83·8% CI 16·5-55·8). On the basis of an interim analysis significance level of 0·081 (overall one-sided significance level of 0·20, power of 0·80, and O'Brien-Fleming-type cumulative error spending function), the 83·8% CI for response difference was between 16·5% and 55·8% and thus excluded 0. The improvement in pathological response rate with the addition of pazopanib crossed the predetermined boundary and enrolment was stopped. The most common grade 3-4 adverse events were leukopenia (16 [43%] of 37 patients), neutropenia (15 [41%]), and febrile neutropenia (15 [41%]) in the pazopanib group, and neutropenia (three [9%] of 35 patients) and febrile neutropenia (three [9%]) in the control group. 22 (59%) of 37 patients in the pazopanib group had a pazopanib-related serious adverse event. Paediatric and adult patients had a similar number of grade 3 and 4 toxicity. There were seven deaths (three in the pazopanib group and four in the control group), none of which were treatment related. INTERPRETATION In this presumed first prospective trial of soft tissue sarcoma spanning nearly the entire age spectrum, adding pazopanib to neoadjuvant chemoradiotherapy improved the rate of pathological near complete response, suggesting that this is a highly active and feasible combination in children and adults with advanced soft tissue sarcoma. The comparison of survival outcomes requires longer follow-up. FUNDING National Institutes of Health, St Baldrick's Foundation, Seattle Children's Foundation.",2020,"The most common grade 3-4 adverse events were leukopenia (16 [43%] of 37 patients), neutropenia (15 [41%]), and febrile neutropenia (15 [41%]) in the pazopanib group, and neutropenia (three [9%] of 35 patients) and febrile neutropenia (three [9%]) in the control group.","['Between July 7, 2014, and Oct 1, 2018, 81 eligible patients', 'Eligible patients had Lansky (if aged ≤16 years) or Karnofsky (if aged >16 years) performance status score of at least 70', 'children and adults with advanced soft tissue sarcoma', 'enrolled eligible adults (aged ≥18 years) and children (aged between 2 and <18 years) from 57 hospitals in the USA and Canada with unresected, newly diagnosed trunk or extremity chemotherapy-sensitive soft tissue sarcoma, which were larger than 5 cm in diameter and of intermediate or high grade', 'group (n=42) or the control group (n=39', 'children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving']","['pazopanib', 'pazopanib to neoadjuvant chemoradiotherapy', 'doxorubicin (37·5 mg/m 2 per dose intravenously on days 1-2) with 45 Gy preoperative radiotherapy', 'ifosfamide', 'pazopanib to preoperative chemoradiotherapy', 'oral pazopanib', 'preoperative chemoradiotherapy with or without pazopanib (ARST1321']","['pazopanib-related serious adverse event', 'febrile neutropenia', 'neutropenia', 'grade 3 and 4 toxicity', 'Pathological response', 'pathological response rate', 'pathological response', 'leukopenia']","[{'cui': 'C1442824', 'cui_str': 'POU2F1 protein, human'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0206065', 'cui_str': 'Karnofsky performance status'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1261473', 'cui_str': 'Sarcoma'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0441800', 'cui_str': 'Grade'}]","[{'cui': 'C1831796', 'cui_str': 'pazopanib'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0020823', 'cui_str': 'Ifosfamide'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C1831796', 'cui_str': 'pazopanib'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0746883', 'cui_str': 'Febrile neutropenia'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0023530', 'cui_str': 'Leukopenia'}]",100.0,0.19607,"The most common grade 3-4 adverse events were leukopenia (16 [43%] of 37 patients), neutropenia (15 [41%]), and febrile neutropenia (15 [41%]) in the pazopanib group, and neutropenia (three [9%] of 35 patients) and febrile neutropenia (three [9%]) in the control group.","[{'ForeName': 'Aaron R', 'Initials': 'AR', 'LastName': 'Weiss', 'Affiliation': 'Department of Pediatrics, Maine Medical Center, Portland, ME, USA. Electronic address: weissa2@mmc.org.'}, {'ForeName': 'Yen-Lin', 'Initials': 'YL', 'LastName': 'Chen', 'Affiliation': 'Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Scharschmidt', 'Affiliation': ""Department of Orthopaedics, James Cancer Hospital and Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Yueh-Yun', 'Initials': 'YY', 'LastName': 'Chi', 'Affiliation': 'Department of Pediatrics and Preventative Medicine, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Tian', 'Affiliation': 'Department of Biostatistics, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Jennifer O', 'Initials': 'JO', 'LastName': 'Black', 'Affiliation': ""Department of Pathology, Children's Hospital Colorado, Aurora, CO, USA.""}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Davis', 'Affiliation': 'Department of Pathology, Oregon Health & Science University, Portland, OR, USA.'}, {'ForeName': 'Julie C', 'Initials': 'JC', 'LastName': 'Fanburg-Smith', 'Affiliation': ""Department of Pathology, Penn State Children's Hospital, Hershey, PA, USA.""}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Zambrano', 'Affiliation': 'Department of Pathology, Rocky Mountain Hospital for Children, Presbyterian St Luke Medical Centre, Denver, CO, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Anderson', 'Affiliation': 'Department of Biostatistics and Research Decision Sciences, Merck and Co, North Wales, PA, USA.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Arens', 'Affiliation': ""Department of Clinical Trials, Connecticut Children's Medical Center, Hartford, CT, USA.""}, {'ForeName': 'Odion', 'Initials': 'O', 'LastName': 'Binitie', 'Affiliation': 'Department of Sarcoma, Moffitt Cancer Center, Tampa, FL, USA.'}, {'ForeName': 'Edwin', 'Initials': 'E', 'LastName': 'Choy', 'Affiliation': 'Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Justin W', 'Initials': 'JW', 'LastName': 'Davis', 'Affiliation': ""Children's Oncology Group, Monrovia, CA, USA.""}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Hayes-Jordan', 'Affiliation': 'Department of Surgery, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.'}, {'ForeName': 'Simon C', 'Initials': 'SC', 'LastName': 'Kao', 'Affiliation': 'Department of Radiology, University of Iowa Carver College of Medicine, Iowa City, IA, USA.'}, {'ForeName': 'Mark L', 'Initials': 'ML', 'LastName': 'Kayton', 'Affiliation': ""Department of Surgery, Palm Beach Children's Hospital, St Mary's Medical Center, Florida Atlantic University, West Palm Beach, FL, USA.""}, {'ForeName': 'Sandy', 'Initials': 'S', 'LastName': 'Kessel', 'Affiliation': 'Imaging and Radiation Oncology Core Rhode Island, Lincoln, RI, USA.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Lim', 'Affiliation': 'Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'William H', 'Initials': 'WH', 'LastName': 'Meyer', 'Affiliation': 'Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Million', 'Affiliation': 'Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, CA, USA.'}, {'ForeName': 'Scott H', 'Initials': 'SH', 'LastName': 'Okuno', 'Affiliation': 'Department of Oncology, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Ostrenga', 'Affiliation': 'Department of Pharmacy, University of Mississippi Medical Center, Jackson, MS, USA.'}, {'ForeName': 'Marguerite T', 'Initials': 'MT', 'LastName': 'Parisi', 'Affiliation': ""Department of Radiology and Pediatrics, University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, USA.""}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Pryma', 'Affiliation': 'Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'R Lor', 'Initials': 'RL', 'LastName': 'Randall', 'Affiliation': 'Department of Orthopaedic Surgery, University of California Davis, Sacramento, CA, USA.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Rosen', 'Affiliation': 'Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Schlapkohl', 'Affiliation': 'Department of Pediatrics, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.'}, {'ForeName': 'Barry L', 'Initials': 'BL', 'LastName': 'Shulkin', 'Affiliation': ""Department of Diagnostic Imaging, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Ethan A', 'Initials': 'EA', 'LastName': 'Smith', 'Affiliation': ""Department of Radiology and Medical Imaging, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Joel I', 'Initials': 'JI', 'LastName': 'Sorger', 'Affiliation': ""Department of Orthopaedic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Terezakis', 'Affiliation': 'Department of Radiation Oncology, University of Minnesota, Masonic Cancer Center, Minneapolis, MN, USA.'}, {'ForeName': 'Douglas S', 'Initials': 'DS', 'LastName': 'Hawkins', 'Affiliation': ""Department of Pediatrics, University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, USA.""}, {'ForeName': 'Sheri L', 'Initials': 'SL', 'LastName': 'Spunt', 'Affiliation': 'Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA.'}, {'ForeName': 'Dian', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': 'Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA.'}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30325-9'] 1880,32703042,Intralesional immunotherapy for the treatment of anogenital warts in pediatric population.,"BACKGROUND The prevalence of anogenital warts is increasing in adults as well as in pediatric population. The treatment of anogenital warts is challenging, particularly in children as most conventional modalities are painful and associated with high recurrence rates. OBJECTIVES To evaluate the efficacy and safety of intralesional immunotherapy for the treatment of anogenital warts in pediatric patients. METHODS Forty child presenting with multiple anogenital warts were randomly assigned into 3 groups. The first group (15 patients) received intralesional MMR vaccine, the second group (15 patients) received intralesional Candida antigen and the third group (10 patients) received intralesional saline as a control. Each modality was injected into the largest wart at 2-week intervals until complete clearance or for a maximum of 5 sessions. RESULTS Highly significant difference was found between the therapeutic response of anogenital warts to both MMR vaccine and Candida antigen compared to intralesional saline ( p  = .005). No significant difference was observed between MMR vaccine and Candida antigen groups ( p  = .885). Side effects were mild and no recurrence was detected in the 6 month follow-up period. CONCLUSIONS Intralesional immunotherapy is a promising effective and well-tolerated treatment modality for multiple anogenital warts in children.",2020,No significant difference was observed between MMR vaccine and Candida antigen groups (P= 0.885).,"['multiple anogenital warts in children', 'anogenital warts in pediatric patients', 'Forty child presenting with multiple anogenital warts', 'anogenital warts in pediatric population']","['intralesional immunotherapy', 'intralesional MMR vaccine', 'intralesional Candida antigen', 'intralesional saline', 'Intralesional immunotherapy']","['efficacy and safety', 'mild and no recurrence', 'therapeutic response of anogenital warts to both MMR vaccine and Candida antigen']","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0009663', 'cui_str': 'Genital warts'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C1512955', 'cui_str': 'Intralesional route'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}, {'cui': 'C0065828', 'cui_str': 'Measles, mumps and rubella vaccine'}, {'cui': 'C0006836', 'cui_str': 'Candida'}, {'cui': 'C0003320', 'cui_str': 'Antigen'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0521982', 'cui_str': 'Response to treatment'}, {'cui': 'C0009663', 'cui_str': 'Genital warts'}, {'cui': 'C0065828', 'cui_str': 'Measles, mumps and rubella vaccine'}, {'cui': 'C0006836', 'cui_str': 'Candida'}, {'cui': 'C0003320', 'cui_str': 'Antigen'}]",40.0,0.0242088,No significant difference was observed between MMR vaccine and Candida antigen groups (P= 0.885).,"[{'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Nofal', 'Affiliation': 'Dermatology, Venereology and Andrology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.'}, {'ForeName': 'Rania', 'Initials': 'R', 'LastName': 'Alakad', 'Affiliation': 'Dermatology, Venereology and Andrology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.'}]",The Journal of dermatological treatment,['10.1080/09546634.2020.1800573'] 1881,32703244,Treatment fidelity in the Tinnitus Retraining Therapy Trial.,"BACKGROUND Treatment fidelity, defined as ensuring that the recipient receives the intended intervention, is a critical component for accurate estimation of treatment efficacy. Ensuring fidelity and protocol adherence in behavioral trials requires careful planning during the design phase and implementation during the trial. The Tinnitus Retraining Therapy Trial (TRTT) randomized individuals with severe tinnitus to tinnitus retraining therapy (TRT, comprised of tinnitus-specific educational counseling (TC) and sound therapy (ST) using conventional sound generators (SGs)); Partial TRT (TC and placebo SGs); or standard of care (SOC), using a patient-centered care approach. Study audiologists administered both types of counseling in the TRTT, creating a challenge for managing protocol adherence. METHODS We developed methods to enhance treatment fidelity including training, competency assessment, scripts, visual aids, and fidelity monitoring. Protocol monitors identified critical topics and content to be addressed for each type of counseling session, prepared corresponding scripts, and developed training aids and treatment-specific checklists covering those topics. Study audiologists' competency assessment required submission and review by the protocol monitors of an audiotape of one TC and one SOC counseling session. Treatment-specific aids included scripts, a 3-D model of the ear, handouts, and for TC, an illustrated flip-chart with talking points that followed the scripted content. During the trial, audiologists completed treatment-specific checklists during each counseling session, indicating topics covered/discussed and submitted audiotapes of counseling sessions. Protocol monitors reviewed audiotapes using corresponding treatment-specific checklists. Results for individual checklist items were tabulated and proportions calculated. RESULTS Twenty-five audiologists were certified for TC and/or SOC counseling and 24 completed at least one counseling session. Adherence to each of 33 critical items on the TC checklist as assessed by the protocol monitor ranged from 70 to 100% across 37 counseling sessions (median 97%), with no difference between adherence for TRT (median, 97%) and partial TRT (median, 100%). Adherence to each of 44 critical items on the SOC checklist across 30 SOC counseling sessions ranged from 42 to 100% (median, 87.5%). CONCLUSION The TRTT used multiple methods to address treatment fidelity. The close adherence to each treatment type was critical for evaluating the efficacy of the study interventions in this randomized trial. TRIAL REGISTRATION clinicaltrials.gov NCT01177137 . Registered on 5 August 2010.",2020,"Adherence to each of 33 critical items on the TC checklist as assessed by the protocol monitor ranged from 70 to 100% across 37 counseling sessions (median 97%), with no difference between adherence for TRT (median, 97%) and partial TRT (median, 100%).",[],"['audiotape of one TC and one SOC counseling session', 'tinnitus retraining therapy (TRT, comprised of tinnitus-specific educational counseling (TC) and sound therapy (ST) using conventional sound generators (SGs)); Partial TRT (TC and placebo SGs); or standard of care (SOC']",['TC checklist'],[],"[{'cui': 'C0004295', 'cui_str': 'Audiotapes'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0040264', 'cui_str': 'Tinnitus'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0237638', 'cui_str': 'Generator'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0265227', 'cui_str': 'Schinzel-Giedion syndrome'}]","[{'cui': 'C1707357', 'cui_str': 'Checklist'}]",25.0,0.0548366,"Adherence to each of 33 critical items on the TC checklist as assessed by the protocol monitor ranged from 70 to 100% across 37 counseling sessions (median 97%), with no difference between adherence for TRT (median, 97%) and partial TRT (median, 100%).","[{'ForeName': 'Roberta W', 'Initials': 'RW', 'LastName': 'Scherer', 'Affiliation': 'Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. rschere1@jhu.edu.'}, {'ForeName': 'Sue Ann', 'Initials': 'SA', 'LastName': 'Erdman', 'Affiliation': 'Audiologic Rehabilitation Consulting Services, Jensen Beach, FL, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Gold', 'Affiliation': 'Tinnitus and Hyperacusis Center of Maryland, Department of Otolaryngology, University of Maryland Medical Center, Baltimore, MD, USA.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Formby', 'Affiliation': 'Department of Communicative Disorders, University of Alabama, Tuscaloosa, AL, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Trials,['10.1186/s13063-020-04530-9'] 1882,32704564,A quantitative measure of treatment response in recent-onset type 1 diabetes.,"Introduction This paper develops a methodology and defines a measure that can be used to separate subjects that received an experimental therapy into those that benefitted from those that did not in recent-onset type 1 diabetes. Benefit means a slowing (or arresting) the decline in beta-cell function over time. The measure can be applied to comparing treatment arms from a clinical trial or to response at the individual level. Methods An analysis of covariance model was fitted to the 12-month area under the curve C-peptide following a 2-hour mixed meal tolerance test from 492 individuals enrolled on five TrialNet studies of recent-onset type 1 diabetes. Significant predictors in the model were age and C-peptide at study entry. The observed minus the model-based expected C-peptide value (quantitative response, QR) is defined to reflect the effect of the therapy. Results A comparison of the primary hypothesis test for each study included and a t test of the QR value by treatment group were comparable. The results were also confirmed for a new TrialNet study, independent of the set of studies used to derive the model. With our proposed analytical method and using QR as the end-point, we conducted simulation studies, to estimate statistical power in detecting a biomarker that expresses differential treatment effect. The QR in its continuous form provided the greatest statistical power when compared to several ways of defining responder/non-responder using various QR thresholds. Conclusions This paper illustrates the use of the QR, as a measure of the magnitude of treatment effect at the aggregate and subject-level. We show that the QR distribution by treatment group provides a better sense of the treatment effect than simply giving the mean estimates. Using the QR in its continuous form is shown to have higher statistical power in comparison with dichotomized categorization.",2020,Using the QR in its continuous form is shown to have higher statistical power in comparison with dichotomized categorization.,['492 individuals enrolled on five TrialNet studies of recent-onset type 1 diabetes'],[],[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}]",[],[],492.0,0.0175856,Using the QR in its continuous form is shown to have higher statistical power in comparison with dichotomized categorization.,"[{'ForeName': 'Brian N', 'Initials': 'BN', 'LastName': 'Bundy', 'Affiliation': 'Health Informatics Institute University of South Florida Tampa FL USA.'}, {'ForeName': 'Jeffrey P', 'Initials': 'JP', 'LastName': 'Krischer', 'Affiliation': 'Health Informatics Institute University of South Florida Tampa FL USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Endocrinology, diabetes & metabolism",['10.1002/edm2.143'] 1883,32706261,"Acute mitochondrial antioxidant intake improves endothelial function, antioxidant enzyme activity, and exercise tolerance in patients with peripheral artery disease.","Peripheral artery disease (PAD) is a manifestation of atherosclerosis in the leg arteries, which causes claudication. This may be in part due to vascular mitochondrial dysfunction and excessive reactive oxygen species (ROS) production. A mitochondrial-targeted antioxidant (MitoQ) has been shown to improve vascular mitochondrial function that, in turn, led to improved vascular function in older adults and animal models. However, the roles of vascular mitochondria in vascular function including endothelial function and arterial stiffness in patients with PAD are unknown; therefore, with the use of acute MitoQ intake, this study examined the roles of vascular mitochondria in endothelial function, arterial stiffness, exercise tolerance, and skeletal muscle function in patients with PAD. Eleven patients with PAD received either MitoQ or placebo in a randomized crossover design. At each visit, blood samples, brachial and popliteal artery flow-mediated dilation (FMD), peripheral and central pulse-wave velocity (PWV), blood pressure (BP), maximal walking capacity, time to claudication (COT), and oxygen utility capacity were measured pre- and-post-MitoQ and placebo. There were significant group by time interactions ( P < 0.05) for brachial and popliteal FMD that both increased by Δ2.6 and Δ3.3%, respectively, and increases superoxide dismutase (Δ0.03 U/mL), maximal walking time (Δ73.8 s), maximal walking distance (Δ49.3 m), and COT (Δ44.2 s). There were no changes in resting heart rate, BP, malondialdehyde, total antioxidant capacity, PWV, or oxygen utility capacity ( P > 0.05). MitoQ intake may be an effective strategy for targeting the vascular mitochondrial environment, which may be useful for restoring endothelial function, leg pain, and walking time in patients with PAD. NEW & NOTEWORTHY The results of this study reveal for the first time that acute oral intake of mitochondrial-targeted antioxidant (MitoQ, 80 mg) is effective for improving vascular endothelial function and superoxide dismutase in patients with peripheral artery disease (PAD). Acute MitoQ intake is also effective for improving maximal walking capacity and delaying the onset of claudication in patients with PAD. These findings suggest that the acute oral intake of MitoQ-mediated improvements in vascular mitochondria play a pivotal role for improving endothelial function, the redox environment, and skeletal muscle performance in PAD.",2020,"There were no changes in resting heart rate, BP, malondialdehyde, total antioxidant capacity, PWV, or oxygen utility capacity (p>0.05).","['peripheral artery disease patients', '11 patients with PAD received either', 'patients with PAD']","['Acute mitochondrial antioxidant intake', 'mitochondrial-targeted antioxidant (MitoQ', 'MitoQ or placebo']","['maximal walking time (Δ73.8 s), maximal walking distance', 'superoxide dismutase', 'Peripheral artery disease (PAD', 'time interactions (p<0.05) for brachial and popliteal FMD', 'resting heart rate, BP, malondialdehyde, total antioxidant capacity, PWV, or oxygen utility capacity (p>0.05', 'blood samples, brachial and popliteal artery flow-mediated dilation (FMD), peripheral and central pulse-wave velocity (PWV), blood pressure (BP), maximal walking capacity, time to claudication (COT), and oxygen utility capacity', 'endothelial function, antioxidant enzyme activity, and exercise tolerance']","[{'cui': 'C1704436', 'cui_str': 'Peripheral Arterial Diseases'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Arterial Diseases'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0442037', 'cui_str': 'Popliteal'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C1821417', 'cui_str': 'Resting heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0032649', 'cui_str': 'Structure of popliteal artery'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0021775', 'cui_str': 'Intermittent claudication'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0243102', 'cui_str': 'enzyme activity'}, {'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}]",11.0,0.183995,"There were no changes in resting heart rate, BP, malondialdehyde, total antioxidant capacity, PWV, or oxygen utility capacity (p>0.05).","[{'ForeName': 'Song-Young', 'Initials': 'SY', 'LastName': 'Park', 'Affiliation': 'School of Health and Kinesiology, University of Nebraska at Omaha, Omaha, Nebraska.'}, {'ForeName': 'Elizabeth J', 'Initials': 'EJ', 'LastName': 'Pekas', 'Affiliation': 'School of Health and Kinesiology, University of Nebraska at Omaha, Omaha, Nebraska.'}, {'ForeName': 'Ronald J', 'Initials': 'RJ', 'LastName': 'Headid', 'Affiliation': 'School of Health and Kinesiology, University of Nebraska at Omaha, Omaha, Nebraska.'}, {'ForeName': 'Won-Mok', 'Initials': 'WM', 'LastName': 'Son', 'Affiliation': 'School of Health and Kinesiology, University of Nebraska at Omaha, Omaha, Nebraska.'}, {'ForeName': 'TeSean K', 'Initials': 'TK', 'LastName': 'Wooden', 'Affiliation': 'School of Health and Kinesiology, University of Nebraska at Omaha, Omaha, Nebraska.'}, {'ForeName': 'Jiwon', 'Initials': 'J', 'LastName': 'Song', 'Affiliation': 'Department of Health and Exercise Science, University of Oklahoma, Norman, Oklahoma.'}, {'ForeName': 'Gwenael', 'Initials': 'G', 'LastName': 'Layec', 'Affiliation': 'Department of Kinesiology, University of Massachusetts Amherst, Amherst, Massachusetts.'}, {'ForeName': 'Santosh K', 'Initials': 'SK', 'LastName': 'Yadav', 'Affiliation': 'Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska.'}, {'ForeName': 'Paras K', 'Initials': 'PK', 'LastName': 'Mishra', 'Affiliation': 'Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska.'}, {'ForeName': 'Iraklis I', 'Initials': 'II', 'LastName': 'Pipinos', 'Affiliation': 'Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska.'}]",American journal of physiology. Heart and circulatory physiology,['10.1152/ajpheart.00235.2020'] 1884,32708743,Effect of a Nutritional Intervention on the Intestinal Microbiota of Vertically HIV-Infected Children: The Pediabiota Study.,"AIMS The gut microbiota exerts a critical influence in the immune system. The gut microbiota of human virus immunodeficiency (HIV)-infected children remains barely explored. We aimed to characterize the fecal microbiota in vertically HIV-infected children and to explore the effects of its modulation with a symbiotic nutritional intervention. METHODS a pilot, double blind, randomized placebo-controlled study including HIV-infected children who were randomized to receive a nutritional supplementation including prebiotics and probiotics or placebo for four weeks. HIV-uninfected siblings were recruited as controls. The V3-V4 region of the 16S rRNA gene was sequenced in fecal samples. RESULTS 22 HIV-infected children on antiretroviral therapy (ART) and with viral load (VL) <50/mL completed the follow-up period. Mean age was 11.4 ± 3.4 years, eight (32%) were male. Their microbiota showed reduced alpha diversity compared to controls and distinct beta diversity at the genus level (Adonis p = 0.042). Patients showed decreased abundance of commensals Faecalibacterium and an increase in Prevotella, Akkermansia and Escherichia. The nutritional intervention shaped the microbiota towards the control group, without a clear directionality. CONCLUSIONS Vertical HIV infection is characterized by changes in gut microbiota structure, distinct at the compositional level from the findings reported in adults. A short nutritional intervention attenuated bacterial dysbiosis, without clear changes at the community level. SUMMARY In a group of 24 vertically HIV-infected children, in comparison to 11 uninfected controls, intestinal dysbiosis was observed despite effective ART. Although not fully effective to restore the microbiota, a short intervention with pre/probiotics attenuated bacterial dysbiosis.",2020,Their microbiota showed reduced alpha diversity compared to controls and distinct beta diversity at the genus level,"['HIV-infected children', 'Vertically HIV-Infected Children', '22 HIV-infected children on antiretroviral therapy (ART) and with viral load (VL) <50/mL completed the follow-up period', 'vertically HIV-infected children', 'HIV-uninfected siblings', 'Mean age was 11.4 ± 3.4 years, eight (32%) were male']","['nutritional supplementation including prebiotics and probiotics or placebo', 'Nutritional Intervention', 'symbiotic nutritional intervention', 'placebo']","['abundance of commensals Faecalibacterium and an increase in Prevotella, Akkermansia and Escherichia', 'fecal microbiota', 'alpha diversity']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0037047', 'cui_str': 'Sibling'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517533', 'cui_str': '11.4'}, {'cui': 'C4517692', 'cui_str': '3.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C2717875', 'cui_str': 'Prebiotics'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}]","[{'cui': 'C0542329', 'cui_str': 'Commensal parasite'}, {'cui': 'C1229075', 'cui_str': 'Faecalibacterium'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0242946', 'cui_str': 'Prevotella'}, {'cui': 'C1490589', 'cui_str': 'Akkermansia'}, {'cui': 'C0014833', 'cui_str': 'Escherichia'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}]",,0.0511436,Their microbiota showed reduced alpha diversity compared to controls and distinct beta diversity at the genus level,"[{'ForeName': 'Talía', 'Initials': 'T', 'LastName': 'Sainz', 'Affiliation': 'Servicio de Pediatría, Hospital Universitario La Paz and IdiPAZ, 28046 Madrid, Spain.'}, {'ForeName': 'María José', 'Initials': 'MJ', 'LastName': 'Gosalbes', 'Affiliation': 'Área Genómica y Salud, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), 46010 Valencia, Spain.'}, {'ForeName': 'Alba', 'Initials': 'A', 'LastName': 'Talavera', 'Affiliation': 'Bioinformatics Unit, Hospital Universitario Ramón y Cajal and IRYCIS, 28034 Madrid, Spain.'}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'Jimenez-Hernandez', 'Affiliation': 'Área Genómica y Salud, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), 46010 Valencia, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Prieto', 'Affiliation': 'Red de Investigación CoRISpe integrada en la Red en Infectología Pediátrica (RITIP), 28046 Madrid, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Escosa', 'Affiliation': 'Servicio de Pediatría, Hospital Universitario La Paz and IdiPAZ, 28046 Madrid, Spain.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Guillén', 'Affiliation': 'Red de Investigación CoRISpe integrada en la Red en Infectología Pediátrica (RITIP), 28046 Madrid, Spain.'}, {'ForeName': 'José Tomás', 'Initials': 'JT', 'LastName': 'Ramos', 'Affiliation': 'Red de Investigación CoRISpe integrada en la Red en Infectología Pediátrica (RITIP), 28046 Madrid, Spain.'}, {'ForeName': 'María Ángeles', 'Initials': 'MÁ', 'LastName': 'Muñoz-Fernández', 'Affiliation': 'Laboratorio InmunoBiología Molecular, Sección Inmunología, Hospital General Universitario Gregorio Marañón and Spanish HIV HGM BioBank, Madrid Spain, Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28007 Madrid, Spain.'}, {'ForeName': 'Andrés', 'Initials': 'A', 'LastName': 'Moya', 'Affiliation': 'Área Genómica y Salud, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), 46010 Valencia, Spain.'}, {'ForeName': 'Maria Luisa', 'Initials': 'ML', 'LastName': 'Navarro', 'Affiliation': 'Red de Investigación CoRISpe integrada en la Red en Infectología Pediátrica (RITIP), 28046 Madrid, Spain.'}, {'ForeName': 'María José', 'Initials': 'MJ', 'LastName': 'Mellado', 'Affiliation': 'Servicio de Pediatría, Hospital Universitario La Paz and IdiPAZ, 28046 Madrid, Spain.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Serrano-Villar', 'Affiliation': 'Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal and IRYCIS, 28034 Madrid, Spain.'}]",Nutrients,['10.3390/nu12072112'] 1885,32708831,Effect of a Single Nutritional Intervention Previous to a Critical Period of Fat Gain in University Students with Overweight and Obesity: A Randomized Controlled Trial.,"BACKGROUND the present study aimed to investigate the effects of a single nutritional preventive session previous to a critical period linked to fat gain in university students with overweightness and obesity, emulating a nutritional session of a public health system. METHODS In this single-blind randomized controlled trial, 23 students met all the criteria to be included (20.91 ± 2.52-year-old; 52.2% women) who were divided into two groups: intervention group (IG) and control group (CG). Fat mass (FM) by dual-energy X-ray absorptiometry (DXA), physical activity by accelerometry, feeding evaluation through three questionnaires, and a set of healthy lifestyle recommendations were evaluated before and after the national holidays (NH). RESULTS Our findings showed that FM increased significantly in the CG, but not in the IG (CG = 428.1 g; IG = 321.9 g; Δ = 106.2 g; p = 0.654 [95% CI = -379.57, 591.92]). However, no differences were found during the NH between them (Hedges' g effect size = 0.19; p = 0.654). In addition, no statistical differences were observed between groups in feeding evaluations, the set of recommendations performed, and physical activity. CONCLUSION a single preventive session before a critical period, using a similar counselling approach as used in the public health system, might not be enough to promote changes in eating and physical activity patterns and preventing fat gain in overweight/obese university students. Long-term interventions are a must.",2020,"In addition, no statistical differences were observed between groups in feeding evaluations, the set of recommendations performed, and physical activity. ","['university students with overweightness and obesity, emulating a nutritional session of a public health system', 'University Students with Overweight and Obesity', 'overweight/obese university students', '23 students met all the criteria to be included (20.91 ± 2.52-year-old; 52.2% women']","['Single Nutritional Intervention', 'single nutritional preventive session', 'intervention group (IG) and control group (CG']","['FM', 'Fat mass (FM']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517632', 'cui_str': '2.52'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4517801', 'cui_str': '52.2'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0204169', 'cui_str': 'Preventive dental procedure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}]",23.0,0.0394414,"In addition, no statistical differences were observed between groups in feeding evaluations, the set of recommendations performed, and physical activity. ","[{'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Hernández-Jaña', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Huber-Pérez', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Ximena', 'Initials': 'X', 'LastName': 'Palma-Leal', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Guerrero-Ibacache', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Campos-Nuñez', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Juan Pablo', 'Initials': 'JP', 'LastName': 'Zavala-Crichton', 'Affiliation': 'Faculty of Education and Social Sciences, Universidad Andres Bello, 2531015 Viña del Mar, Chile.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Jorquera-Aguilera', 'Affiliation': 'School of Nutrition and Dietetics, Faculty of Science, Universidad Mayor, 8580000 Santiago, Chile.'}, {'ForeName': 'Kabir P', 'Initials': 'KP', 'LastName': 'Sadarangani', 'Affiliation': 'Department of Kinesiology, Universidad Autónoma de Chile, 7500912 Santiago, Chile.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Rodríguez-Rodríguez', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Cristi-Montero', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}]",International journal of environmental research and public health,['10.3390/ijerph17145149'] 1886,32709430,"Yoga in Burn: Role of pranayama breathing exercise on pulmonary function, respiratory muscle activity and exercise tolerance in full-thickness circumferential burns of the chest.","BACKGROUND Circumferential burn of chest (CBC) is a significant type of burn and considers as a major cause of restrictive lung disease (RLD). Patient who has CBC with RLD leads to respiratory symptoms such as breathing difficulty, airway obstruction, reduced exercise capacity and altered pulmonary functions. However, studies examining the role of pranayama breathing exercise on pulmonary function, respiratory muscle activity and exercise tolerance in full thickness circumferential burn of chest are lacking. OBJECTIVE To find the short term effects of pranayama breathing exercise on pulmonary function, respiratory muscle activity and exercise tolerance in full thickness circumferential burns of chest. METHODS Through simple random sampling method thirty subjects (N = 30) with RLD following CBC were allocated to pranayama breathing exercise group (PBE-G; n = 15) and conventional breathing exercise group (CBE-G; n = 15). They received pranayama breathing exercise and conventional breathing exercise for 4 weeks respectively. All the subjects received chest mobility exercise as common treatment. Primary (Numeric Pain Rating Scale - NPRS, forced expiratory volume (FEV1), forced vital capacity (FVC) and maximum voluntary ventilation (MVV) and secondary (Electromyogram of sternocleidomastoid, scalene, external intercostal and diaphragm muscle, 6 min walk test & Global Rating of Change - GRC) outcome measures were measured at baseline, after four weeks and after three months follow up. RESULTS Baseline demographic and clinical variables show homogenous distribution between the groups (p > 0.05). Four weeks following different breathing exercises, PBE-G group shows more significant changes in pain intensity, pulmonary function, respiratory muscle activity, exercise tolerance and global rating of change than CBE-G group (p ≤ 0.05) at four weeks and three months follow up. CONCLUSION Both groups showed improvement over time. However, differences between the groups were noticed small. Still physiotherapy management, which included pranayama breathing exercises with chest mobilization program, had an effective strategy in the treatment of restrictive lung disease following circumferential burn of chest.",2020,"Four weeks following different breathing exercises, PBE-G group shows more significant changes in pain intensity, pulmonary function, respiratory muscle activity, exercise tolerance and global rating of change than CBE-G group (p ≤ 0.05) at four weeks and three months follow up. ","['full-thickness circumferential burns of the chest', 'thirty subjects (N = 30) with RLD following CBC', 'Yoga in Burn', 'full thickness circumferential burns of chest']","['pranayama breathing exercise and conventional breathing exercise', 'conventional breathing exercise', 'pranayama breathing exercises with chest mobilization program', 'pranayama breathing exercise', 'chest mobility exercise']","['Primary (Numeric Pain Rating Scale - NPRS, forced expiratory volume (FEV1), forced vital capacity (FVC) and maximum voluntary ventilation (MVV) and secondary (Electromyogram of sternocleidomastoid, scalene, external intercostal and diaphragm muscle, 6 min walk test & Global Rating of Change - GRC) outcome measures', 'pulmonary function, respiratory muscle activity and exercise tolerance', 'pain intensity, pulmonary function, respiratory muscle activity, exercise tolerance and global rating of change']","[{'cui': 'C0439809', 'cui_str': 'Full thickness'}, {'cui': 'C0205113', 'cui_str': 'Circumferential'}, {'cui': 'C0000912', 'cui_str': 'Accident caused by unspecified fire'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0085581', 'cui_str': 'Restrictive lung disease'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0740396', 'cui_str': 'Chest burning'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}, {'cui': 'C0024967', 'cui_str': 'Maximum voluntary ventilation'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0224153', 'cui_str': 'Structure of sternocleidomastoid muscle'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0011980', 'cui_str': 'Diaphragm structure'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0018226', 'cui_str': 'Greece'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0021724', 'cui_str': 'Structure of intercostal muscle'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",30.0,0.0228202,"Four weeks following different breathing exercises, PBE-G group shows more significant changes in pain intensity, pulmonary function, respiratory muscle activity, exercise tolerance and global rating of change than CBE-G group (p ≤ 0.05) at four weeks and three months follow up. ","[{'ForeName': 'Gopal', 'Initials': 'G', 'LastName': 'Nambi', 'Affiliation': 'Department of Physical Therapy and Health Rehabilitation, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia. Electronic address: physio_gopal@rediffmail.com.'}, {'ForeName': 'Walid Kamal', 'Initials': 'WK', 'LastName': 'Abdelbasset', 'Affiliation': 'Department of Physical Therapy and Health Rehabilitation, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia; Department of Physical Therapy, Kasr Al-Aini Hospital, Cairo University, Giza, Egypt.'}, {'ForeName': 'Ahmed A', 'Initials': 'AA', 'LastName': 'Elshehawy', 'Affiliation': 'Department of Physical Therapy for Cardiovascular/Respiratory Disorder and Geriatrics, Faculty of Physical Therapy, Cairo University, Giza, Egypt; Department of Physical Therapy, Faculty of Applied Medical Sciences, Tabuk University, Tabuk, Saudi Arabia.'}, {'ForeName': 'Heba H', 'Initials': 'HH', 'LastName': 'Eltrawy', 'Affiliation': 'Department of Chest Diseases, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.'}, {'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'Abodonya', 'Affiliation': 'Department of Anesthesia and Intensive Care, Faculty of Medicine, Al-Azhar University, Cairo, Egypt; Department of Surgery, College of Medicine, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.'}, {'ForeName': 'Ayman K', 'Initials': 'AK', 'LastName': 'Saleh', 'Affiliation': 'Department of Surgery, College of Medicine, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia; Department of Orthopedic, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.'}, {'ForeName': 'Ramadan S', 'Initials': 'RS', 'LastName': 'Hussein', 'Affiliation': 'Department of Surgery, College of Medicine, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.'}]",Burns : journal of the International Society for Burn Injuries,['10.1016/j.burns.2020.06.033'] 1887,32706640,"Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.","PURPOSE NRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the first to demonstrate a survival benefit of adjuvant chemoradiotherapy over radiotherapy. This post hoc study sought to determine the prognostic and predictive impact of the WHO-defined molecular subgroups and corresponding molecular alterations within NRG Oncology/RTOG 9802. METHODS IDH1/2 mutations were determined by immunohistochemistry and/or deep sequencing. A custom Ion AmpliSeq panel was used for mutation analysis. 1p/19q codeletion and MGMT promoter methylation were determined by copy-number arrays and/or Illumina 450K array, respectively. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Hazard ratios (HRs) were calculated using the Cox proportional hazard model and tested using the log-rank test. Multivariable analyses (MVAs) were performed incorporating treatment and common prognostic factors as covariates. RESULTS Of the eligible patients successfully profiled for the WHO-defined molecular groups (n = 106/251), 26 (24%) were IDH- wild type, 43 (41%) were IDH- mutant/non-codeleted, and 37(35%) were IDH- mutant/codeleted. MVAs demonstrated that WHO subgroup was a significant predictor of PFS after adjustment for clinical variables and treatment. Notably, treatment with postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine) was associated with longer PFS (HR, 0.32; P = .003; HR, 0.13; P < .001) and OS (HR, 0.38; P = .013; HR, 0.21; P = .029) in the IDH- mutant/non-codeleted and IDH- mutant/codeleted subgroups, respectively. In contrast, no significant difference in either PFS or OS was observed with the addition of PCV in the IDH- wild-type subgroup. CONCLUSION This study is the first to report the predictive value of the WHO-defined diagnostic classification in a set of uniformly treated patients with LGG in a clinical trial. Importantly, this post hoc analysis supports the notion that patients with IDH -mutant high-risk LGG regardless of codeletion status receive benefit from the addition of PCV.",2020,"In contrast, no significant difference in either PFS or OS was observed with the addition of PCV in the IDH- wild-type subgroup. ","['patients with WHO low-grade glioma (LGG, grade II', 'NRG Oncology/RTOG 9802', 'High-Risk Low-Grade Glioma']","['NRG', 'Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine', 'postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine', 'adjuvant chemoradiotherapy over radiotherapy']","['PFS', 'PFS or OS', 'Progression-free survival (PFS) and overall survival (OS', 'Hazard ratios (HRs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1997217', 'cui_str': 'Low grade glioma'}, {'cui': 'C1629836', 'cui_str': 'Lactobacillus rhamnosus GG'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]","[{'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0033223', 'cui_str': 'Procarbazine'}, {'cui': 'C0023972', 'cui_str': 'Lomustine'}, {'cui': 'C0042679', 'cui_str': 'Vincristine'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}, {'cui': 'C3178761', 'cui_str': 'Adjuvant Chemoradiotherapy'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439227', 'cui_str': 'hour'}]",,0.0972708,"In contrast, no significant difference in either PFS or OS was observed with the addition of PCV in the IDH- wild-type subgroup. ","[{'ForeName': 'Erica H', 'Initials': 'EH', 'LastName': 'Bell', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Peixin', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'NRG Oncology Statistics and Data Management Center, Philadelphia, PA.'}, {'ForeName': 'Edward G', 'Initials': 'EG', 'LastName': 'Shaw', 'Affiliation': 'Wake Forest School of Medicine, Winston-Salem, NC.'}, {'ForeName': 'Jan C', 'Initials': 'JC', 'LastName': 'Buckner', 'Affiliation': 'Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Geoffrey R', 'Initials': 'GR', 'LastName': 'Barger', 'Affiliation': 'Wayne State University, Detroit, MI.'}, {'ForeName': 'Dennis E', 'Initials': 'DE', 'LastName': 'Bullard', 'Affiliation': 'Triangle Neurosurgery, Raleigh, NC.'}, {'ForeName': 'Minesh P', 'Initials': 'MP', 'LastName': 'Mehta', 'Affiliation': 'Baptist Hospital of Miami, Miami, FL.'}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Gilbert', 'Affiliation': 'National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Brown', 'Affiliation': 'Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Keith J', 'Initials': 'KJ', 'LastName': 'Stelzer', 'Affiliation': 'Mid-Columbia Medical Center, The Dalles, OR.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'McElroy', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Fleming', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Cynthia D', 'Initials': 'CD', 'LastName': 'Timmers', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Aline P', 'Initials': 'AP', 'LastName': 'Becker', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Andrea L', 'Initials': 'AL', 'LastName': 'Salavaggione', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Ziyan', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Aldape', 'Affiliation': 'Princess Margaret Cancer Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'David G', 'Initials': 'DG', 'LastName': 'Brachman', 'Affiliation': 'Arizona Oncology Services Foundation, Phoenix, AZ.'}, {'ForeName': 'Stanley Z', 'Initials': 'SZ', 'LastName': 'Gertler', 'Affiliation': 'The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada.'}, {'ForeName': 'Albert D', 'Initials': 'AD', 'LastName': 'Murtha', 'Affiliation': 'Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Schultz', 'Affiliation': 'Froedtert and the Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Johnson', 'Affiliation': 'Wichita NCORP, Wichita, KS.'}, {'ForeName': 'Nadia N', 'Initials': 'NN', 'LastName': 'Laack', 'Affiliation': 'Rochester Methodist Hospital, Rochester, MN.'}, {'ForeName': 'Grant K', 'Initials': 'GK', 'LastName': 'Hunter', 'Affiliation': 'Intermountain Medical Center, Murray, UT.'}, {'ForeName': 'Ian R', 'Initials': 'IR', 'LastName': 'Crocker', 'Affiliation': 'Emory University, Atlanta, GA.'}, {'ForeName': 'Minhee', 'Initials': 'M', 'LastName': 'Won', 'Affiliation': 'NRG Oncology Statistics and Data Management Center, Philadelphia, PA.'}, {'ForeName': 'Arnab', 'Initials': 'A', 'LastName': 'Chakravarti', 'Affiliation': 'The Ohio State University, Columbus, OH.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.02983'] 1888,32707101,The Family Check-Up 4 Health: Study protocol of a randomized type II hybrid effectiveness-implementation trial in integrated primary care (the healthy communities 4 healthy students study).,"BACKGROUND Parenting interventions like the Family Check-Up have demonstrated effects on child physical and behavioral health outcomes. However, access to these programs is limited, particularly for populations experiencing health disparities. Primary care settings have become recognized as a potential delivery system in which these programs may be implemented at scale. The purpose of this trial is to test the effectiveness of the Family Check-Up 4 Health (FCU4Health) program, an adaptation of the FCU for primary care, and assess program implementation in an integrated primary care setting. METHODS We will conduct a hybrid type 2 effectiveness-implementation trial in partnership with a primary care clinic in a low-income, majority Latino community. Families with 2- to 5-year-old children will be eligible to participate. Families will be randomized to receive the intervention (n = 130) or services as usual (n = 70) and will be assessed annually over three years. Outcomes are informed by the RE-AIM framework (i.e., reach, effectiveness, adoption, implementation, and maintenance). Effectiveness outcomes include child health behaviors (e.g., Dietary Screener Questionnaire), behavioral health (e.g., Strengths and Difficulties Questionnaire), and parenting (e.g., Proactive Parenting). Early stage implementation outcomes are also included (e.g., cost, acceptability, appropriateness, and feasibility). Effectiveness outcomes will be assessed via intent-to-treat (ITT) analyses. Implementation outcomes will be primarily descriptive with comparisons to prior trials of FCU4Health and the original FCU. PROJECTED OUTCOMES This trial will provide evidence related to the potential of integrated primary care settings to deliver evidence-based preventive interventions with a dual focus on behavioral and physical health.",2020,"The purpose of this trial is to test the effectiveness of the Family Check-Up 4 Health (FCU4Health) program, an adaptation of the FCU for primary care, and assess program implementation in an integrated primary care setting. ","['partnership with a primary care clinic in a low-income, majority Latino community', 'Families with 2- to 5-year-old children', 'integrated primary care (the healthy communities 4 healthy students study']",['Family Check-Up 4 Health (FCU4Health) program'],"['RE-AIM framework (i.e., reach, effectiveness, adoption, implementation, and maintenance', 'cost, acceptability, appropriateness, and feasibility', 'child health behaviors (e.g., Dietary Screener Questionnaire), behavioral health (e.g., Strengths and Difficulties Questionnaire), and parenting (e.g., Proactive Parenting']","[{'cui': 'C1552443', 'cui_str': 'Primary care clinic'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0420160', 'cui_str': 'History and physical examination, school'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C2744535', 'cui_str': 'CD69 protein, human'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0001593', 'cui_str': 'Adoption'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0008078', 'cui_str': 'Child health care'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0870196', 'cui_str': 'Behavioral health'}, {'cui': 'C3472494', 'cui_str': 'Strengths and difficulties questionnaire'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}]",,0.0514529,"The purpose of this trial is to test the effectiveness of the Family Check-Up 4 Health (FCU4Health) program, an adaptation of the FCU for primary care, and assess program implementation in an integrated primary care setting. ","[{'ForeName': 'Cady', 'Initials': 'C', 'LastName': 'Berkel', 'Affiliation': ""REACH Institute, Arizona State University, Tempe, AZ, USA; Phoenix Children's Hospital, Phoenix, AZ, USA. Electronic address: Cady.Berkel@asu.edu.""}, {'ForeName': 'Justin D', 'Initials': 'JD', 'LastName': 'Smith', 'Affiliation': 'Center for Prevention Implementation Methodology (Ce-PIM), Department of Psychiatry and Behavioral Sciences, Department of Preventive Medicine, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Meg M', 'Initials': 'MM', 'LastName': 'Bruening', 'Affiliation': 'Department of Nutrition, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Jordan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Fu', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Mauricio', 'Affiliation': 'REACH Institute, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Kevin J', 'Initials': 'KJ', 'LastName': 'Grimm', 'Affiliation': 'Department of Psychology, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Winslow', 'Affiliation': 'REACH Institute, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Ray', 'Affiliation': 'Bayless Integrated Healthcare, Phoenix, AZ, USA.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Bourne', 'Affiliation': 'Southwest Maricopa Regional Council, First Things First, Peoria, AZ, USA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Dishion', 'Affiliation': 'REACH Institute, Arizona State University, Tempe, AZ, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106088'] 1889,32707159,Obesity blunts cephalic-phase microvascular responses to food.,"Neurally mediated anticipatory responses, also named cephalic-phase responses, and microcirculatory regulation are two important mechanisms to maintain metabolic homeostasis. Altered cephalic-phase responses in obesity and its metabolic consequences have been proposed. There is, however, a lack of studies focusing on in vivo assessment of the microcirculation during this phase in patients with obesity. In this randomized controlled trial, we selected patients with obesity and healthy subjects after clinical and laboratory assessments. Those with obesity were randomized into two groups: experimental (cephalic-phase microvascular response stimulation - CP group, n = 13) and controls (n = 14). Healthy subjects (n = 17) were also included to form a CP control group. Skin microvascular assessment was used as a model of systemic microcirculation. Resting functional capillary density (FCD) and peak FCD during post-occlusive reactive hyperemia (PORH) were measured by dorsal finger videocapillaroscopy and expressed mainly capillary recruitment capacity. Resting red blood cell velocity (RBCV), peak RBCV during PORH (RBCV max ), and time taken to reach RBCV max (TRBCV max ) were assessed by dynamic nailfold videocapillaroscopy and expressed the microhemodynamics. Patients with obesity (with or without stimulus) failed to show an increase on FCD during PORH post-stimulus (p = 0.221 and p = 0.307, respectively) depicting lack of capillary recruitment. In contrast, healthy subjects presented an increase in this microvascular outcome (p = 0.004). Changes in all variables of microhemodynamics occurred in both CP groups (healthy and those with obesity). During CP, we originally demonstrated an absence of capillary recruitment in subjects with obesity. These findings might contribute to the literature of microvascular impairment and metabolic conditions.",2020,"Patients with obesity (with or without stimulus) failed to show an increase on FCD during PORH post-stimulus (p=0.221 and p=0.307, respectively) depicting lack of capillary recruitment.","['healthy subjects', 'Patients with obesity (with or without stimulus', 'group, n=13) and controls (n=14', 'patients with obesity', 'Healthy subjects (n=17) were also included to form a CP control group', 'subjects with obesity', 'patients with obesity and healthy subjects after clinical and laboratory assessments']",['experimental (cephalic-phase microvascular response stimulation - CP'],"['Resting red blood cell velocity (RBCV), peak RBCV during PORH (RBCV max ), and time taken to reach RBCV max (TRBCV max ', 'microvascular outcome', 'Skin microvascular assessment', 'FCD during PORH post-stimulus', 'Resting functional capillary density (FCD) and peak FCD during post-occlusive reactive hyperemia (PORH']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0205096', 'cui_str': 'Cephalic'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1562113', 'cui_str': 'Fleck corneal dystrophy'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0006901', 'cui_str': 'Structure of capillary blood vessel (organ)'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C1947917', 'cui_str': 'Occluded'}, {'cui': 'C0178824', 'cui_str': 'Reactive Hyperemia'}]",17.0,0.0160267,"Patients with obesity (with or without stimulus) failed to show an increase on FCD during PORH post-stimulus (p=0.221 and p=0.307, respectively) depicting lack of capillary recruitment.","[{'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Buss', 'Affiliation': 'Department of Nutrition Federal University of Health Sciences of Porto Alegre (UFCSPA), RS, Brazil; Graduate Program in Health Sciences, UFCSPA, RS, Brazil. Electronic address: carolinebuss@ufcspa.edu.br.'}, {'ForeName': 'Priscila A', 'Initials': 'PA', 'LastName': 'Maranhão', 'Affiliation': 'Clinical and Experimental Research Laboratory on Vascular Biology (BioVasc) Biomedical Center, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil; Faculty of Medicine, Center for Research in Health Technologies and Information Systems (CINTESIS), University of Porto, Porto, Portugal.'}, {'ForeName': 'Maria das Graças C', 'Initials': 'MDGC', 'LastName': 'de Souza', 'Affiliation': 'Clinical and Experimental Research Laboratory on Vascular Biology (BioVasc) Biomedical Center, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Eliete', 'Initials': 'E', 'LastName': 'Bouskela', 'Affiliation': 'Clinical and Experimental Research Laboratory on Vascular Biology (BioVasc) Biomedical Center, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Luiz Guilherme', 'Initials': 'LG', 'LastName': 'Kraemer-Aguiar', 'Affiliation': 'Clinical and Experimental Research Laboratory on Vascular Biology (BioVasc) Biomedical Center, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil; Department of Internal Medicine Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113087'] 1890,32708368,Effect of Sechium edule var. nigrum spinosum (Chayote) on Telomerase Levels and Antioxidant Capacity in Older Adults with Metabolic Syndrome.,"Patients with metabolic syndrome (MetS) have a redox imbalance, due to a decay in antioxidant capacity. Oxidative stress (OxS) is considered an important modulator of telomere shortening and telomerase activity. One of the fruits that has been associated with an antioxidant effect is Sechium edule and although its properties are well established, there is only one exploratory study evaluating its effectiveness in patients with MetS. The present investigation is a much more robust and controlled study, including a placebo group. Hence, we determined the effect of consumption of the dried fruit powder (500 mg, three times per day) for three months. We measured effects on telomerase levels, antioxidant capacity, and markers for OxS. The study was performed in a sample of 75 older adults: placebo group ( n = 30) and experimental group ( n = 45) with the diagnosis of MetS according to the National Adult Treatment Panel of the National Cholesterol Program III (NCEP/ATP III) criteria. All markers were measured before and after three months of treatment. There was a statistically significant decrease in lipoperoxides and protein carbonylation with an increased superoxide dismutase (SOD), as well as sustained levels of telomerase in patients who consumed Sechium edule . Our findings suggest that consumption of this fruit has a hypoglycemic, hypotensive, and antioxidant effect, without altering telomerase levels, which could suggest better protection against telomere shortening.",2020,"There was a statistically significant decrease in lipoperoxides and protein carbonylation with an increased superoxide dismutase (SOD), as well as sustained levels of telomerase in patients who consumed Sechium edule .","['75 older adults', 'Patients with metabolic syndrome (MetS', 'patients with MetS', 'Older Adults with Metabolic Syndrome', 'group ( n = 30) and experimental group ( n = 45) with the diagnosis of MetS according to the National Adult Treatment Panel of the National Cholesterol Program III']","['placebo', 'dried fruit powder', 'Sechium edule var', 'nigrum spinosum (Chayote']","['lipoperoxides and protein carbonylation', 'Oxidative stress (OxS', 'telomerase levels, antioxidant capacity, and markers for OxS', 'superoxide dismutase (SOD', 'Telomerase Levels and Antioxidant Capacity']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0453296', 'cui_str': 'Dried fruit'}, {'cui': 'C0032861', 'cui_str': 'Powder'}]","[{'cui': 'C0023776', 'cui_str': 'Fatty Acid Hydroperoxides'}, {'cui': 'C1563721', 'cui_str': 'Carbonylation, Protein'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0087071', 'cui_str': 'Telomerase Reverse Transcriptase'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}]",75.0,0.0375362,"There was a statistically significant decrease in lipoperoxides and protein carbonylation with an increased superoxide dismutase (SOD), as well as sustained levels of telomerase in patients who consumed Sechium edule .","[{'ForeName': 'Graciela', 'Initials': 'G', 'LastName': 'Gavia-García', 'Affiliation': 'Research Unit on Gerontology, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.'}, {'ForeName': 'Juana', 'Initials': 'J', 'LastName': 'Rosado-Pérez', 'Affiliation': 'Research Unit on Gerontology, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.'}, {'ForeName': 'Itzen', 'Initials': 'I', 'LastName': 'Aguiñiga-Sánchez', 'Affiliation': 'Hematopoiesis and Leukemia Laboratory, Research Unit on Cell Differentiation and Cancer, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.'}, {'ForeName': 'Edelmiro', 'Initials': 'E', 'LastName': 'Santiago-Osorio', 'Affiliation': 'Hematopoiesis and Leukemia Laboratory, Research Unit on Cell Differentiation and Cancer, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.'}, {'ForeName': 'Víctor Manuel', 'Initials': 'VM', 'LastName': 'Mendoza-Núñez', 'Affiliation': 'Research Unit on Gerontology, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.'}]","Antioxidants (Basel, Switzerland)",['10.3390/antiox9070634'] 1891,32710888,Effects of Ramadan intermittent fasting on inflammatory and biochemical biomarkers in males with obesity.,"BACKGROUND To determine the effects of Ramadan intermittent fasting (RIF) on inflammatory (C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α)) and biochemical markers of liver-renal function (aspartate aminotransferase (AST), alanine amino transferase (ALT), bilirubin, lactate dehydrogenase (LDH), urea and creatinine) in males with obesity. MATERIALS AND METHODS Twenty-eight males with obesity were randomly allocated to an experimental group (EG, n = 14) or a control group (CG, n = 14). The EG group completed their fasting rituals for the entire month of Ramadan (30 days) whereas the CG group continued with their normal daily habits. Blood samples were collected 24 h before the start of Ramadan (T0), on the 15th day of Ramadan (T1), the day after the end of Ramadan (T2), and 21 days after the end of Ramadan (T3). Resting plasma volume variation between pre and post-RIF (ΔPV) was calculated. RESULTS Decreases were noted for interleukin-6 (p = 0.02, d = 1.4) and tumor necrosis factor-alpha (p = 0.01, d = 0.7), with no changes for C-reactive protein (p = 0.3; d = 0.1) in the EG compared to CG group. There were no changes (P > 0.05) in ΔPV recorded after RIF for either EG (-0.035 ± 0.02%) and CG (0.055 ± 0.06%). CONCLUSION This study demonstrates that RIF improves systemic inflammation biomarkers in males with obesity. Moreover, RIF did not negatively affect biomarkers of liver and renal function.",2020,"RESULTS Decreases were noted for interleukin-6 (p = 0.02, d = 1.4) and tumor necrosis factor-alpha (p = 0.01, d = 0.7), with no changes for C-reactive protein (p = 0.3; d=0.1) in the EG compared to CG group.","['males with obesity', 'Twenty-eight males with obesity']","['Ramadan intermittent fasting', 'Ramadan intermittent fasting (RIF', 'RIF']","['systemic inflammation biomarkers', 'inflammatory (C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α)) and biochemical markers of liver-renal function (aspartate aminotransferase (AST), alanine amino transferase (ALT), bilirubin, lactate dehydrogenase (LDH), urea and creatinine', 'Blood samples', 'biomarkers of liver and renal function', 'inflammatory and biochemical biomarkers', 'tumor necrosis factor-alpha']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C4283787', 'cui_str': '28'}]","[{'cui': 'C4704881', 'cui_str': 'Intermittent Fasting'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Markers'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0057041', 'cui_str': 'D-amino-acid transaminase'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin'}, {'cui': 'C0202113', 'cui_str': 'Lactate dehydrogenase measurement'}, {'cui': 'C0041942', 'cui_str': 'Urea'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}]",28.0,0.0245917,"RESULTS Decreases were noted for interleukin-6 (p = 0.02, d = 1.4) and tumor necrosis factor-alpha (p = 0.01, d = 0.7), with no changes for C-reactive protein (p = 0.3; d=0.1) in the EG compared to CG group.","[{'ForeName': 'Hassane', 'Initials': 'H', 'LastName': 'Zouhal', 'Affiliation': 'Univ Rennes, M2S (Laboratoire Mouvement, Sport, Santé) - EA 1274, F-35000 Rennes, France. Electronic address: hassane.zouhal@univ-rennes2.fr.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Bagheri', 'Affiliation': 'Department of Exercise Physiology, University of Isfahan, Isfahan, Iran.'}, {'ForeName': 'Damoon', 'Initials': 'D', 'LastName': 'Ashtary-Larky', 'Affiliation': 'Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Alexei', 'Initials': 'A', 'LastName': 'Wong', 'Affiliation': 'Department of Health and Human Performance, Marymount University, Arlington, USA.'}, {'ForeName': 'Raoua', 'Initials': 'R', 'LastName': 'Triki', 'Affiliation': 'ISSEP Ksar Said, University of Manouba, Tunis, Tunisia.'}, {'ForeName': 'Anthony C', 'Initials': 'AC', 'LastName': 'Hackney', 'Affiliation': 'Department of Exercise & Sport Science, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'Ismail', 'Initials': 'I', 'LastName': 'Laher', 'Affiliation': 'Department of Anesthesiology, Pharmacology and Therapeutics, The University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Abderraouf Ben', 'Initials': 'AB', 'LastName': 'Abderrahman', 'Affiliation': 'ISSEP Ksar Said, University of Manouba, Tunis, Tunisia.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113090'] 1892,32711031,Developing and Evaluating ASTHMAXcel Adventures: A Novel Gamified Mobile App for Pediatric Patients with Asthma.,"BACKGROUND The ASTHMAXcel mobile application has been linked to favorable outcomes among adult asthma patients. OBJECTIVE We assessed the impact of ASTHMAXcel Adventures, a gamified, guideline-based, pediatric version on asthma control, knowledge, healthcare utilization, and patient satisfaction. METHODS Pediatric asthma patients received the ASTHMAXcel Adventures mobile intervention on-site only at baseline (Visit 1), 4 months (Visit 2) and 6 months (Visit 3). The Asthma Control Test (ACT), Asthma Illness Representation Scale-Self Administered (AIRS-SR), Pediatric Asthma Impact Survey (PAIS), and Client Satisfaction Questionnaire (CSQ-8) were used to assess asthma control, knowledge, and patient satisfaction. Patients reported the number of asthma-related emergency department (ED) visits, hospitalizations, and oral prednisone use. RESULTS 39 patients completed the study. The proportion of controlled asthma increased from Visit 1 to Visits 2 and 3 (30.8% vs. 53.9%, p=0.04; 30.8% vs. 59.0%, p=0.02), and largely seen in males. Mean AIRS-SR scores increased from baseline pre to post-intervention, with sustained improvements at Visits 2 and 3 (3.55 vs. 3.76, p=0.0006; 3.55 vs. 3.80, p=0.001; 3.55 vs. 3.99, p=0.0001). PAIS scores improved from baseline to Visits 2 and 3 (43.33 vs 34.08, p=0.0006; 43.33 vs. 31.74, p=0.0001). ED visits and prednisone use significantly decreased from baseline to Visits 2 and 3 (ED: 0.46 vs 0.13, p=0.03; 0.46 vs. 0.02, p=0.02; Prednisone: 0.49 vs 0.13, p=0.02; 0.49 vs. 0.03, p=0.003. Satisfaction was high with mean CSQ ∼30 (out of 32) at all visits. CONCLUSION ASTHMAXcel Adventures improved asthma control, knowledge, and quality of life, and reduced ED visits and prednisone use with high satisfaction scores.",2020,"Mean AIRS-SR scores increased from baseline pre to post-intervention, with sustained improvements at Visits 2 and 3 (3.55 vs. 3.76, p=0.0006; 3.55 vs. 3.80, p=0.001; 3.55 vs. 3.99, p=0.0001).","['adult asthma patients', 'Pediatric asthma patients', '39 patients completed the study', 'Pediatric Patients with Asthma']","['Prednisone', 'ASTHMAXcel Adventures mobile intervention']","['number of asthma-related emergency department (ED) visits, hospitalizations, and oral prednisone use', 'asthma control, knowledge, and patient satisfaction', 'asthma control, knowledge, healthcare utilization, and patient satisfaction', 'proportion of controlled asthma', 'Asthma Control Test (ACT), Asthma Illness Representation Scale-Self Administered (AIRS-SR), Pediatric Asthma Impact Survey (PAIS), and Client Satisfaction Questionnaire (CSQ-8', 'Mean AIRS-SR scores', 'PAIS scores', 'asthma control, knowledge, and quality of life, and reduced ED visits', 'Satisfaction']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C4048375', 'cui_str': 'Asthma control test'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",39.0,0.059259,"Mean AIRS-SR scores increased from baseline pre to post-intervention, with sustained improvements at Visits 2 and 3 (3.55 vs. 3.76, p=0.0006; 3.55 vs. 3.80, p=0.001; 3.55 vs. 3.99, p=0.0001).","[{'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Hsia', 'Affiliation': 'Division of Allergy/Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Anjani K', 'Initials': 'AK', 'LastName': 'Singh', 'Affiliation': 'Division of Allergy/Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Obumneme', 'Initials': 'O', 'LastName': 'Njeze', 'Affiliation': 'Division of Allergy/Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Emine', 'Initials': 'E', 'LastName': 'Cosar', 'Affiliation': 'Division of Allergy/Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Wenzhu B', 'Initials': 'WB', 'LastName': 'Mowrey', 'Affiliation': 'Division of Biostatistics, Department of Epidemiology and Population Health, Albert Einstein College of Medicine. Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Feldman', 'Affiliation': ""Department of Pediatrics, Division of Academic General Pediatrics, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY; Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY.""}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Reznik', 'Affiliation': ""Department of Pediatrics, Division of Academic General Pediatrics, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY.""}, {'ForeName': 'Sunit P', 'Initials': 'SP', 'LastName': 'Jariwala', 'Affiliation': 'Division of Allergy/Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY. Electronic address: sjariwal@montefiore.org.'}]","Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology",['10.1016/j.anai.2020.07.018'] 1893,32727601,Effect of self-care counselling on depression and anxiety in women with endometriosis: a randomized controlled trial.,"BACKGROUND Considering the prevalence of endometriosis and consequent depression and anxiety as well as the resultant effects on the body, mind, and quality of life of patients, this study aimed to determine the effects of self-care counselling on depression and anxiety (primary outcome) and on quality of life (secondary outcome) among women with endometriosis. METHOD This randomized controlled clinical trial was conducted on 76 women with endometriosis who were treated at Al-Zahra Teaching and Treatment Center of Tabriz within the 2015-2019 period. The random blocking method was employed to divide the patients into intervention (counselling) and control groups. In the intervention group, seven self-care group counselling sessions were held on a weekly basis. The control group received routine care. A sociodemographic questionnaire, Beck Depression Inventory, Spielberger State-Trait Anxiety Inventory (STAI) and the SF-36 Quality of Life Questionnaire were completed by the researcher through an interview before and 4 weeks after the intervention. RESULTS There was no significant difference between the intervention and control groups in terms of sociodemographic characteristics (p > 0.05). After the intervention, the mean scores of state anxiety (mean difference: - 0.12, 95% confidence interval: - 9.6 to - 14.4, p < 0.001) and trait anxiety (mean difference: - 10.9: 95% confidence interval: - 9.1 to - 12.7, p = 0.001) were significantly lower in the counselling group than those of the control group. The mean score of depression was lower in the counselling group than in the control group; however, it was not significant (p = 0/565). The mean score of quality of life for physical health (mean difference = 17.2, 95% confidence interval: 13.8 to 20.5, p < 0.001) and for mental health (mean difference = 12.0, 95% confidence interval: 9.0 to 14.9, p < 0.001) were significantly higher in the counselling group than in the control group. CONCLUSION Self-care counselling affects the anxiety and quality of life of women with endometriosis. Therefore, in addition to other therapies, this method is proposed to improve quality of life and mental health of patients with endometriosis. TRIAL REGISTRATION IRCT Registration Number: IRCT 20111219008459 N13, registered on February 10, 2019 ( https://irct.ir/user/trial/35915 ).",2020,"The mean score of depression was lower in the counselling group than in the control group; however, it was not significant (p = 0/565).","['women with endometriosis', 'patients with endometriosis', '76 women with endometriosis who were treated at Al-Zahra Teaching and Treatment Center of Tabriz within the 2015-2019 period']","['routine care', 'Self-care counselling', 'self-care counselling']","['quality of life', 'A sociodemographic questionnaire, Beck Depression Inventory, Spielberger State-Trait Anxiety Inventory (STAI) and the SF-36 Quality of Life Questionnaire', 'quality of life and mental health', 'mean score of depression', 'mental health', 'anxiety and quality of life', 'sociodemographic characteristics', 'trait anxiety', 'mean scores of state anxiety', 'depression and anxiety', 'mean score of quality of life for physical health']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0014175', 'cui_str': 'Endometriosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0451497', 'cui_str': 'Spielberger state-trait anxiety inventory'}, {'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0700613', 'cui_str': 'Anxiety state'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}]",76.0,0.140972,"The mean score of depression was lower in the counselling group than in the control group; however, it was not significant (p = 0/565).","[{'ForeName': 'Nooshin', 'Initials': 'N', 'LastName': 'Farshi', 'Affiliation': 'Student Research Committee, Midwifery Department, Nursing and Midwifery Faculty, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Shirin', 'Initials': 'S', 'LastName': 'Hasanpour', 'Affiliation': ""Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. shirinhasanpoor@yahoo.com.""}, {'ForeName': 'Mojgan', 'Initials': 'M', 'LastName': 'Mirghafourvand', 'Affiliation': 'Midwifery Department, Social Determinants of Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Khalil', 'Initials': 'K', 'LastName': 'Esmaeilpour', 'Affiliation': 'Faculty of Education and Psychology, University of Tabriz, Tabriz, Iran.'}]",BMC psychiatry,['10.1186/s12888-020-02795-7'] 1894,32727603,"Research on allergic rhinitis improvement in asthmatic children after dust mite exposure reduction: a randomized, double-blind, cross-placebo study protocol.","BACKGROUND Allergic rhinitis (AR) in children is a major respiratory inflammatory disease with a high incidence that is increasing yearly. In China, 54.93% of children with asthma have AR, which often requires synchronous treatment. House dust mites (HDMs) are common allergens that often cause attacks of AR and asthma. Reducing allergen exposure is one of the most important measures to control and treat AR and asthma attacks. Hestelia Mite Bait, containing 0.1% emamectin, is a new tool for trapping and killing dust mites, reducing the number of dust mites on mattresses and thereby potentially reducing stimulation by allergens and ultimately improving asthma and rhinitis symptoms. This single-centre, randomized, double-blind, cross-placebo trial will explore the improvement in AR in asthmatic children after dust mite exposure reduction. METHODS We will recruit 60 children (aged 3-12 years) who have been diagnosed with AR and asthma and are allergic to dust mites as confirmed by a serum allergen test. Participants will randomly receive the Hestelia Mite Bait intervention for 8 weeks and the placebo intervention for 8 weeks. There will be a 4-week washout period between the two interventions. The primary outcome is the visual analogue scale (VAS) score of AR symptoms; the secondary outcomes include the Rhinitis Control Assessment Test (RCAT) score, Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score, changes in the dust mite level, drug usage for asthma and AR, Asthma Control Questionnaire-5 (ACQ-5) score, and frequencies of acute asthma attacks, emergency visits, and hospitalizations. DISCUSSION This study aims to scientifically and objectively evaluate the effects of mite bait on rhinitis and asthma improvement after dust mite exposure reduction and provides a convenient means for future prevention and treatment of allergic diseases involving the airways in children. TRIAL REGISTRATION www.chictr.org.cn ChiCTR1900024688. Registered on July 21, 2019.",2020,"Hestelia Mite Bait, containing 0.1% emamectin, is a new tool for trapping and killing dust mites, reducing the number of dust mites on mattresses and thereby potentially reducing stimulation by allergens and ultimately improving asthma and rhinitis symptoms.","['children', 'asthmatic children after dust mite exposure reduction', '60 children (aged 3-12\u2009years) who have been diagnosed with AR and asthma and are allergic to dust mites as confirmed by a serum allergen test']","['placebo intervention', 'mite bait', 'Hestelia Mite Bait, containing 0.1% emamectin', 'Hestelia Mite Bait intervention', 'placebo']","['visual analogue scale (VAS) score of AR symptoms; the secondary outcomes include the Rhinitis Control Assessment Test (RCAT) score, Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score, changes in the dust mite level, drug usage for asthma and AR, Asthma Control Questionnaire-5 (ACQ-5) score, and frequencies of acute asthma attacks, emergency visits, and hospitalizations']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0998367', 'cui_str': 'House dust mite'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C2607914', 'cui_str': 'Allergic rhinitis'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0449891', 'cui_str': 'Test allergen used'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0026231', 'cui_str': 'Mite'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C1100440', 'cui_str': 'emamectin'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2607914', 'cui_str': 'Allergic rhinitis'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008711', 'cui_str': 'Chronic rhinitis'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0861155', 'cui_str': 'Rhinoconjunctivitis'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0998367', 'cui_str': 'House dust mite'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0457083', 'cui_str': 'Usage'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C2919686', 'cui_str': 'Asthma control questionnaire'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0582415', 'cui_str': 'Acute asthma'}, {'cui': 'C0004063', 'cui_str': 'Assault'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",60.0,0.158494,"Hestelia Mite Bait, containing 0.1% emamectin, is a new tool for trapping and killing dust mites, reducing the number of dust mites on mattresses and thereby potentially reducing stimulation by allergens and ultimately improving asthma and rhinitis symptoms.","[{'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': ""Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China.""}, {'ForeName': 'YuFen', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': ""Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China.""}, {'ForeName': 'Shuhua', 'Initials': 'S', 'LastName': 'Yuan', 'Affiliation': ""Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China.""}, {'ForeName': 'Jiande', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ""Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China.""}, {'ForeName': 'Luanluan', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': ""Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China.""}, {'ForeName': 'Jinhong', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': ""Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China. zhangjing_yq@163.com.""}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Yin', 'Affiliation': ""Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China. yinyong9999@163.com.""}]",Trials,['10.1186/s13063-020-04614-6'] 1895,32715556,Effect of estradiol vaginal gel on vaginal atrophy in postmenopausal women: A randomized double-blind controlled trial.,"AIM To evaluate the efficacy and safety of 25 μg of estradiol gel on postmenopausal vaginal tissue. METHODS This randomized double-blind controlled trial included postmenopausal women with vaginal atrophy who attended our menopause clinic during July 2017-January 2018. Women were randomly assigned to the estradiol gel group or control group (K-Y® Jelly). Treatment consisted of 2 mL of product applied intravaginally daily for 2 weeks, and two doses per week for the next 6 weeks. The most bothersome symptom (MBS), vaginal health index (VHI), vaginal pH, vaginal maturation index, vaginal maturation value (VMV), female sexual function index (FSFI), serum estradiol level and endometrial thickness were evaluated at baseline, 4 and 8 weeks. RESULTS Seventy-five of 80 women completed the trial. After 8 weeks of treatment, VMV, VHI, vaginal pH and FSFI improved significantly in the estradiol group, with no observed change in the control group. The MBS was decreased in both groups with no significant difference between groups. Serum estradiol level and endometrial thickness were not significantly different between groups at baseline or at week 8. CONCLUSION Estradiol vaginal gel demonstrated an ability to reverse vaginal atrophy with a high safety profile and low systemic absorption of estradiol.",2020,"After 8 weeks of treatment, VMV, VHI, vaginal pH and FSFI improved significantly in the estradiol group, with no observed change in the control group.","['Seventy-five of 80 women completed the trial', 'postmenopausal women with vaginal atrophy who attended our menopause clinic during July 2017-January 2018', 'postmenopausal women', 'postmenopausal vaginal tissue']","['estradiol vaginal gel', 'estradiol gel', 'Estradiol vaginal gel', 'estradiol gel group or control group (K-Y® Jelly']","['vaginal atrophy', 'bothersome symptom (MBS), vaginal health index (VHI), vaginal pH, vaginal maturation index, vaginal maturation value (VMV), female sexual function index (FSFI), serum estradiol level and endometrial thickness', 'efficacy and safety', 'MBS', 'Serum estradiol level and endometrial thickness', 'VMV, VHI, vaginal pH and FSFI']","[{'cui': 'C4319621', 'cui_str': '75'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0241616', 'cui_str': 'Atrophy of vagina'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0347984', 'cui_str': 'During'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}]","[{'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0042257', 'cui_str': 'Vaginal gel'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0241616', 'cui_str': 'Atrophy of vagina'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0429263', 'cui_str': 'Vaginal pH'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0278098', 'cui_str': 'Female sexual function'}, {'cui': 'C0474672', 'cui_str': 'Serum estradiol measurement'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.326198,"After 8 weeks of treatment, VMV, VHI, vaginal pH and FSFI improved significantly in the estradiol group, with no observed change in the control group.","[{'ForeName': 'Prasong', 'Initials': 'P', 'LastName': 'Tanmahasamut', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Titima', 'Initials': 'T', 'LastName': 'Jirasawas', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine Vachira Hospital, Navamindradhiraj University, Bangkok, Thailand.'}, {'ForeName': 'Somsak', 'Initials': 'S', 'LastName': 'Laiwejpithaya', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Chatchai', 'Initials': 'C', 'LastName': 'Areeswate', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Chongdee', 'Initials': 'C', 'LastName': 'Dangrat', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Kittayaporn', 'Initials': 'K', 'LastName': 'Silprasit', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}]",The journal of obstetrics and gynaecology research,['10.1111/jog.14336'] 1896,32715996,Ticagrelor versus Clopidogrel in patients with STEMI treated with thrombolysis: the MIRTOS trial.,"AIMS We aimed to demonstrate whether coronary microvascular function is improved after ticagrelor administration compared to clopidogrel administration in STEMI subjects undergoing thrombolysis. METHODS AND RESULTS MIRTOS is a multicenter study of ticagrelor versus clopidogrel in STEMI subjects treated with fibrinolysis. We enrolled 335 patients <75 years old with STEMI eligible for thrombolysis, of which 167 were randomized to receive clopidogrel and 168 to receive ticagrelor together with thrombolysis. Primary outcome was the difference in post-PCI corrected TIMI frame count (CTFC). All clinical events were recorded in a 3-month follow-up period. From the 335 patients that were randomized, 259 underwent PCI (129 clopidogrel and 130 ticagrelor) and 154 angiographies were analyzable for study primary endpoint. No significant difference was found between the clopidogrel (n=85) and ticagrelor (n=69) groups for CTFC (24.33±17.35 vs 28.33±17.59, p=0.10). No significant differences were observed in MACE and major bleeding events between randomization groups (OR 2.0, 95% CI 0.18-22.2, p=0.99). CONCLUSIONS Thrombolysis with ticagrelor in patients <75 years old was not able to demonstrate superiority compared to clopidogrel in terms of microvascular injury, while there was no difference between the 2 groups in MACE and major bleeding events.",2020,"No significant difference was found between the clopidogrel (n=85) and ticagrelor (n=69) groups for CTFC (24.33±17.35 vs 28.33±17.59, p=0.10).","['patients with STEMI treated with thrombolysis', 'STEMI subjects treated with fibrinolysis', '335 patients <75 years old with STEMI eligible for thrombolysis, of which 167 were randomized to receive', '335 patients that were randomized, 259 underwent', 'STEMI subjects undergoing thrombolysis']","['Ticagrelor', 'ticagrelor together with thrombolysis', 'Clopidogrel', 'PCI (129 clopidogrel and 130 ticagrelor', 'clopidogrel', 'ticagrelor']","['post-PCI corrected TIMI frame count (CTFC', 'MACE and major bleeding events', 'coronary microvascular function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1536220', 'cui_str': 'ST Segment Elevation Myocardial Infarction'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis'}, {'cui': 'C0016017', 'cui_str': 'Fibrinolysis'}, {'cui': 'C4709307', 'cui_str': '335'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4517595', 'cui_str': '167'}]","[{'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C1520439', 'cui_str': '129 Strain Mouse'}, {'cui': 'C4319552', 'cui_str': '130'}]","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0080089', 'cui_str': 'Reading Frames'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0286421', 'cui_str': 'ACE protocol 2'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",335.0,0.0628197,"No significant difference was found between the clopidogrel (n=85) and ticagrelor (n=69) groups for CTFC (24.33±17.35 vs 28.33±17.59, p=0.10).","[{'ForeName': 'Michalis', 'Initials': 'M', 'LastName': 'Hamilos', 'Affiliation': 'Cardiology Department, University Hospital of Heraklion, Greece.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Kanakakis', 'Affiliation': ''}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Anastasiou', 'Affiliation': ''}, {'ForeName': 'Charalambos', 'Initials': 'C', 'LastName': 'Karvounis', 'Affiliation': ''}, {'ForeName': 'Vasilios', 'Initials': 'V', 'LastName': 'Vasilikos', 'Affiliation': ''}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Goudevenos', 'Affiliation': ''}, {'ForeName': 'Lampros', 'Initials': 'L', 'LastName': 'Michalis', 'Affiliation': ''}, {'ForeName': 'Michalis', 'Initials': 'M', 'LastName': 'Koutouzis', 'Affiliation': ''}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Tsiafoutis', 'Affiliation': ''}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Raisakis', 'Affiliation': ''}, {'ForeName': 'Dimitrios', 'Initials': 'D', 'LastName': 'Stakos', 'Affiliation': ''}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Hahalis', 'Affiliation': ''}, {'ForeName': 'Panos', 'Initials': 'P', 'LastName': 'Vardas', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,['10.4244/EIJ-D-20-00268'] 1897,32716001,Effects of pony-assisted therapy on the behavior of older people with neurocognitive disorders living in nursing homes.,"CONTEXT Experienced in psychomotricity in two nursing homes, pony-assisted therapy shows first positive effects on psycho-behavioral symptoms. Recognized in the field of disability and psychiatry, this form of therapy is not developed in gerontology. OBJECTIVES To measure the effects of this therapy on the behavior of elderly people with neurocognitive disorders living in long-term care and especially on the involvement in this activity. Anxiety and apathy were chosen as the measurement criteria. METHODS An intervention study with an experimental cross-study design was conducted over two months for 23 subjects. An intervention group was studied during a period with TAP and a period without TAP. Another group without intervention was also studied. All participants were assessed before and after intervention with the NPI-R scale. The engagement during two TAP sessions and one animation time was also evaluated with the ECPAI scale. RESULTS In the crossover study, positive engagement is more important in participant/pony interaction than in participant/facilitator interaction (p<0.01). The ECPAI score reflecting apathetic behavior was significantly decreased during interaction with the animal than in the interaction with the facilitator in patients undergoing therapy (p<0.01). The ECPAI score reflecting engagement is greater in pony interaction for participants in therapy than in the control group in facilitator interaction (p<0.01). There is no significant change in the scores for the anxiety and apathy items on the NPI-R scale. CONCLUSION TAP participates in the positive engagement of the elderly people in the interaction with the animal. These results are consistent with the conclusions of the studies on animal mediation and confirm the clinical observations collected. TAP could work by improving self-esteem and valuing all of the person's preserved abilities.",2020,The ECPAI score reflecting engagement is greater in pony interaction for participants in therapy than in the control group in facilitator interaction (p<0.01).,"['older people with neurocognitive disorders living in nursing homes', '23 subjects', 'elderly people with neurocognitive disorders living in long-term care']","['pony-assisted therapy', 'TAP', 'TAP and a period without TAP']","['psycho-behavioral symptoms', 'ECPAI score reflecting apathetic behavior', 'self-esteem', 'NPI-R scale']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4041080', 'cui_str': 'Neurocognitive disorder'}, {'cui': 'C0425205', 'cui_str': 'Lives in a nursing home'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]","[{'cui': 'C0324180', 'cui_str': 'Pony'}, {'cui': 'C0557035', 'cui_str': 'Assisting with therapy'}, {'cui': 'C0034115', 'cui_str': 'Centesis'}]","[{'cui': 'C0004941', 'cui_str': 'Behavioral Symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0558058', 'cui_str': 'Reflecting'}, {'cui': 'C0085632', 'cui_str': 'Indifference'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",23.0,0.0238065,The ECPAI score reflecting engagement is greater in pony interaction for participants in therapy than in the control group in facilitator interaction (p<0.01).,"[{'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Carillon', 'Affiliation': 'Sorbonne Université, Paris, France, Pôle médical, Ehpad Arpavie Sainte-Lucie, Issy-les-Moulineaux, France, Pôle médical, Ehpad Korian Hauts de Jardy, Vaucresson, France.'}, {'ForeName': 'Witold', 'Initials': 'W', 'LastName': 'Jarzebowski', 'Affiliation': 'Court Séjour Gériatrique, Centre Hospitalier de Bastia, France.'}, {'ForeName': 'Bénédicte', 'Initials': 'B', 'LastName': 'Fulpin', 'Affiliation': 'Pôle médical, Ehpad Arpavie Sainte-Lucie, Issy-les-Moulineaux, France.'}, {'ForeName': 'Adélaïde', 'Initials': 'A', 'LastName': 'Miliotis', 'Affiliation': 'Pôle médical, Ehpad Korian Hauts de Jardy, Vaucresson, France.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Bernadac', 'Affiliation': 'Pôle médical, Ehpad Korian Hauts de Jardy, Vaucresson, France.'}, {'ForeName': 'Yann', 'Initials': 'Y', 'LastName': 'Saint-Georges Chaumet', 'Affiliation': 'Bioredac, Chambourcy, France.'}, {'ForeName': 'Joël', 'Initials': 'J', 'LastName': 'Belmin', 'Affiliation': 'Sorbonne Université, Paris, France, Service de gériatrie, Hôpital Charles-Foix, AP-HP, Ivry-sur-Seine, France.'}]",Geriatrie et psychologie neuropsychiatrie du vieillissement,['10.1684/pnv.2020.0854'] 1898,32711554,BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.,"BACKGROUND We previously showed that BRCA-like profiles can be used to preselect individuals with the highest risk of carrying BRCA mutations but could also indicate which patients would benefit from double-strand break inducing chemotherapy. A simple, robust, and reliable assay for clinical use that utilizes limited amounts of formalin-fixed, paraffin-embedded tumor tissue to assess BRCAness status in both ER-positive and ER-negative breast cancer (BC) is currently lacking. METHODS A digital multiplex ligation-dependent probe amplification (digitalMLPA) assay was designed to detect copy number alterations required for the classification of BRCA1-like and BRCA2-like BC. The BRCA1-like classifier was trained on 71 tumors, enriched for triple-negative BC; the BRCA2-like classifier was trained on 55 tumors, enriched for luminal-type BC. A shrunken centroid-based classifier was developed and applied on an independent validation cohort. A total of 114 cases of a randomized controlled trial were analyzed, and the association of the classifier result with intensified platinum-based chemotherapy response was assessed. RESULTS The digitalMLPA BRCA1-like classifier correctly classified 91% of the BRCA1-like samples and 82% of the BRCA2-like samples. Patients with a BRCA-like tumor derived significant benefit of high-dose chemotherapy (adjusted hazard ratio (HR) 0.12, 95% CI 0.04-0.44) which was not observed in non-BRCA-like patients (HR 0.9, 95% CI 0.37-2.18) (p = 0.01). Analysis stratified for ER status showed borderline significance. CONCLUSIONS The digitalMLPA is a reliable method to detect a BRCA1- and BRCA2-like pattern on clinical samples and predicts platinum-based chemotherapy benefit in both triple-negative and luminal-type BC.",2020,The digitalMLPA is a reliable method to detect a BRCA1- and BRCA2-like pattern on clinical samples and predicts platinum-based chemotherapy benefit in both triple-negative and luminal-type BC.,[],"['digital multiplex ligation-dependent probe amplification', 'digitalMLPA', 'intensified platinum-based chemotherapy']",[],[],"[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C3494189', 'cui_str': 'Multiplex Ligation-Dependent Probe Amplification'}, {'cui': 'C3536920', 'cui_str': 'Platinum compounds'}]",[],114.0,0.164868,The digitalMLPA is a reliable method to detect a BRCA1- and BRCA2-like pattern on clinical samples and predicts platinum-based chemotherapy benefit in both triple-negative and luminal-type BC.,"[{'ForeName': 'Esther H', 'Initials': 'EH', 'LastName': 'Lips', 'Affiliation': 'Department of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. e.lips@nki.nl.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Benard-Slagter', 'Affiliation': 'Department of Oncogenetics, MRC Holland, Amsterdam, The Netherlands.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Opdam', 'Affiliation': 'Department of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.'}, {'ForeName': 'Caroline E', 'Initials': 'CE', 'LastName': 'Scheerman', 'Affiliation': 'Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Jelle', 'Initials': 'J', 'LastName': 'Wesseling', 'Affiliation': 'Department of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.'}, {'ForeName': 'Frans B L', 'Initials': 'FBL', 'LastName': 'Hogervorst', 'Affiliation': 'Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Sabine C', 'Initials': 'SC', 'LastName': 'Linn', 'Affiliation': 'Department of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.'}, {'ForeName': 'Suvi', 'Initials': 'S', 'LastName': 'Savola', 'Affiliation': 'Department of Oncogenetics, MRC Holland, Amsterdam, The Netherlands.'}, {'ForeName': 'Petra M', 'Initials': 'PM', 'LastName': 'Nederlof', 'Affiliation': 'Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.'}]",Breast cancer research : BCR,['10.1186/s13058-020-01313-7'] 1899,32712083,Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia.,"BACKGROUND Four-component meningococcal B (4CMenB) vaccine is licensed in many countries but has had limited use in adolescents despite this age group being at increased risk of meningococcal disease. OBJECTIVES To assess the safety profile of two doses of 4CMenB in adolescents. METHODS Cluster randomised controlled trial of senior school students in South Australia (SA) with participating schools randomised to intervention (4CMenB) or control. Vaccine safety was monitored using the South Australian Vaccine Safety Surveillance System (SAVSS), a spontaneous reporting system for adverse events following immunisation (AEFI) with enhanced follow-up of AEFI. RESULTS 58,637 doses of 4CMenB vaccine were administered to 30,522 students (median age 16 years) during 2017-2018. Of 18,348 and 12,174 students vaccinated in 2017 and 2018, 97.3% and 84.3%, respectively, received both scheduled doses (N = 28,115). 193 AEFI in 187 students were reported with a reporting rate of 0.32% (95%CI: 0.28-0.39%). Seventy individuals sought medical review, including nine serious adverse events. 98% (166/169) of those who were contactable for AEFI follow-up (87.6% 169/193) reported resolution of the event. Most common AEFI were injection site reaction (126/193), headache (99/193) and nausea (61/193). AEFI were more frequently reported in females (aOR = 1.409 (95%CI: 1.002, 1.980)), schools with high level of educational advantage (adjusted Odds Ratio (aOR) = 1.515 (95%CI: 1.005, 2.284)), following first dose (aOR = 1.619 (95%CI: 1.168, 2.244)), and in 2017 (aOR = 1.437 (95%CI: 1.001, 2.064)). Reported AEFI declined with increasing age (aOR = 0.771 (95%CI: 0.673, 0.883)). CONCLUSION In this largest post-licensure use of 4CMenB in adolescents, the low AEFI reporting rate provides real-world evidence of 4CMenB safety in this age group. (ClinicalTrials.gov number: NCT03089086).",2020,AEFI were more frequently reported in females (aOR = 1.409,"['Of 18,348 and 12,174 students vaccinated in 2017 and 2018, 97.3% and 84.3%, respectively, received both scheduled doses (N\xa0=\xa028,115', 'senior school students in South Australia (SA) with participating schools randomised to', 'Seventy individuals sought medical review, including nine serious adverse events', 'adolescents in Australia', '193 AEFI in 187 students', '30,522 students (median age 16\xa0years) during 2017-2018', 'adolescents']","['meningococcal B vaccine (4CMenB', 'intervention (4CMenB) or control', '4CMenB vaccine', '4CMenB']","['Vaccine safety', 'injection site reaction (126/193), headache (99/193) and nausea', 'AEFI']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0037715', 'cui_str': 'South Australia'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C2721654', 'cui_str': 'Adverse event following immunisation'}, {'cui': 'C4517618', 'cui_str': '187'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C3859491', 'cui_str': 'meningococcal group B vaccine'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3490189', 'cui_str': '4CMenB vaccine'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0151735', 'cui_str': 'Injection site reaction'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C2721654', 'cui_str': 'Adverse event following immunisation'}]",187.0,0.386608,AEFI were more frequently reported in females (aOR = 1.409,"[{'ForeName': 'H S', 'Initials': 'HS', 'LastName': 'Marshall', 'Affiliation': ""Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Australia; Vaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide, Australia. Electronic address: helen.marshall@adelaide.edu.au.""}, {'ForeName': 'A P', 'Initials': 'AP', 'LastName': 'Koehler', 'Affiliation': 'Communicable Disease Control Branch, SA Health, Government of South Australia, Adelaide, Australia.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': ""Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Australia; Vaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide, Australia.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': ""A'Houre"", 'Affiliation': 'Communicable Disease Control Branch, SA Health, Government of South Australia, Adelaide, Australia.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gold', 'Affiliation': 'Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Australia.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Quinn', 'Affiliation': 'National Centre for Immunisation Research and Surveillance (NCIRS), Westmead, Sydney, Australia; Discipline of Child and Adolescent Health, University of Sydney, Sydney, Australia.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Crawford', 'Affiliation': ""Murdoch Children's Research Institute (MCRI), Royal Children's Hospital & Department of Paediatrics, The University of Melbourne, Parkville, Australia.""}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Pratt', 'Affiliation': 'School of Pharmacy and Medical Services, University of South Australia, Adelaide, Australia.'}, {'ForeName': 'T R', 'Initials': 'TR', 'LastName': 'Sullivan', 'Affiliation': 'SAHMRI Women & Kids, South Australian Health & Medical Research Institute, Adelaide, Australia; School of Public Health, The University of Adelaide, Australia.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Macartney', 'Affiliation': 'National Centre for Immunisation Research and Surveillance (NCIRS), Westmead, Sydney, Australia; Discipline of Child and Adolescent Health, University of Sydney, Sydney, Australia.'}]",Vaccine,['10.1016/j.vaccine.2020.07.009'] 1900,32712460,Effect of a newly developed ready-to-use supplementary food on growth indicators in children with mild to moderate malnutrition.,"OBJECTIVES Malnutrition is one of the leading causes of death among children younger than five years. In this study, we aimed to formulate a ready-to-use supplementary food (RUSF), based on local food products, and investigate its efficacy on growth indicators in children with mild to moderate malnutrition. STUDY DESIGN This is a randomized controlled clinical trial. METHODS This study was performed in six health centers in Shahr-e-Rey, Tehran, Iran, between April and October 2017. One hundred children, aged 24-59 months, with mild to moderate malnutrition (weight-for-height Z-score [WHZ] between -3 and -1) were randomly assigned to two groups to receive either 1-3 sachets of RUSF or normal diet for 8 weeks. All mothers and caregivers received nutrition education. Growth indicators including weight and height, WHZ, and body mass index (BMI), along with clinical outcomes, were assessed. RESULTS Children who received RUSF had a significant increase in weight (1.44 ± 0.38 vs 0.7 ± 0.32 kg, respectively, P < 0.001), and BMI (1.2 ± 0.47 vs 0.35 ± 0.33 kg/m 2 , respectively, P < 0.001) compared with the control group. There was a greater daily weight gain during the first 4 weeks (P < 0.001) and throughout the study (P = 0.013) in the RUSF group. Daily height gain was considerably higher in the RUSF group during the first 4 weeks (P = 0.027). Children in the RUSF group had more improvement in WHZ (1.18 ± 0.41 vs 0.41 ± 0.31, P < 0.001) after supplementation. Besides, 92% of the RUSF and 12% of the control group reached to WHZ > -1 at the end of the study (P < 0.001). There was lower prevalence of diarrhea (12% vs 28.6%, respectively, P = 0.01) and marginally lower fever (16% vs 36.7%, respectively, P = 0.05) in the intervention than in the control group. CONCLUSIONS A newly developed RUSF improved growth indicators and clinical outcomes in children with mild to moderate malnutrition. CLINICAL TRIAL REGISTRY NUMBER IRCT2017021315536N6 (registered at www.irct.ir).",2020,Daily height gain was considerably higher in the RUSF group during the first 4 weeks (P = 0.027).,"['children with mild to moderate malnutrition', 'One hundred children, aged 24-59 months, with mild to moderate malnutrition (weight-for-height Z-score [WHZ] between\xa0-3 and\xa0-1', 'six health centers in Shahr-e-Rey, Tehran, Iran, between April and October 2017', 'children younger than five years']","['RUSF or normal diet', 'nutrition education', 'RUSF', 'ready-to-use supplementary food (RUSF']","['diarrhea', 'weight', 'Daily height gain', 'weight and height, WHZ, and body mass index (BMI', 'BMI', 'daily weight gain', 'WHZ', 'fever']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0424670', 'cui_str': 'Weight for height'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0184625', 'cui_str': 'Normal diet'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0015967', 'cui_str': 'Fever'}]",100.0,0.0904359,Daily height gain was considerably higher in the RUSF group during the first 4 weeks (P = 0.027).,"[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Azimi', 'Affiliation': 'Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Esmaillzadeh', 'Affiliation': 'Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Alipoor', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Moslemi', 'Affiliation': 'Food and Drug Laboratories Research Center, Food and Drug Administration, Ministry of Health and Medical Education, Tehran, Iran.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Yaseri', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'Hosseinzadeh-Attar', 'Affiliation': 'Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran; Cardiac Primary Prevention Research Center (CPPRC), Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: hosseinzadeh.md.phd@gmail.com.'}]",Public health,['10.1016/j.puhe.2020.06.025'] 1901,32712569,"A randomized pilot trial of topiramate for alcohol use disorder in veterans with traumatic brain injury: Effects on alcohol use, cognition, and post-concussive symptoms.","BACKGROUND Topiramate is an effective treatment for alcohol use disorder (AUD) and has also been used in the care of mild traumatic brain injury (mTBI). This pilot study aimed to obtain a preliminary assessment of topiramate's efficacy in reducing alcohol use and post-concussive symptoms, and its potential negative impact on cognitive function in 32 Veterans with co-occurring AUD and mTBI. METHODS This was a prospective 12-week, randomized, double-blind, placebo-controlled pilot study of flexible-dose topiramate or placebo. Primary outcome was reduction of drinking days per week within the topiramate arm. Secondary outcomes included between group comparisons of alcohol use and craving, post-concussive symptoms, and cognitive function. RESULTS Drinking days per week significantly decreased within both the topiramate and placebo arm. There were no significant treatment-by-week interactions on alcohol use/craving, or post-concussive symptoms in intent-to-treat analyses. In per-protocol analyses, topiramate significantly reduced number of drinks per week compared with placebo. Topiramate transiently impaired verbal fluency and working memory. Processing speed, cognitive inhibition, and mental flexibility significantly improved between weeks 1 and 12, regardless of treatment arm. CONCLUSIONS Significant improvement occurred in both the topiramate and placebo groups over 12 weeks of treatment in alcohol use and post-concussive symptoms. Among treatment completers there was greater reduction of alcohol use in the topiramate arm. Topiramate was also associated with negative but transient effects on cognitive function. Results suggest both a possible benefit for topiramate treatment in reducing alcohol use and some potential for negative cognitive effects in Veterans with AUD and mTBI.",2020,"Processing speed, cognitive inhibition, and mental flexibility significantly improved between weeks 1 and 12, regardless of treatment arm. ","['32 Veterans with co-occurring AUD and mTBI', 'Veterans with AUD and mTBI', 'veterans with traumatic brain injury']","['Topiramate', 'flexible-dose topiramate or placebo', 'placebo', 'topiramate']","['reduction of alcohol use', 'alcohol use/craving, or post-concussive symptoms', 'alcohol use and craving, post-concussive symptoms, and cognitive function', 'verbal fluency and working memory', 'cognitive function', 'reduction of drinking days', 'Processing speed, cognitive inhibition, and mental flexibility']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}]","[{'cui': 'C0076829', 'cui_str': 'topiramate'}, {'cui': 'C0443220', 'cui_str': 'Flexible'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0546983', 'cui_str': 'Postconcussion syndrome'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0556347', 'cui_str': 'Drinking day'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}]",32.0,0.0870034,"Processing speed, cognitive inhibition, and mental flexibility significantly improved between weeks 1 and 12, regardless of treatment arm. ","[{'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Pennington', 'Affiliation': 'University of California, San Francisco, Department of Psychiatry, 4150 Clement St., San Francisco, CA, USA; San Francisco Veterans Affairs Health Care System (SFVAHCS), 4150 Clement St., San Francisco, CA, USA; Northern California Institute for Research and Education (NCIRE), 4150 Clement St., San Francisco, CA, USA. Electronic address: david.pennington2@va.gov.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Bielenberg', 'Affiliation': 'San Francisco Veterans Affairs Health Care System (SFVAHCS), 4150 Clement St., San Francisco, CA, USA; Northern California Institute for Research and Education (NCIRE), 4150 Clement St., San Francisco, CA, USA.'}, {'ForeName': 'Brooke', 'Initials': 'B', 'LastName': 'Lasher', 'Affiliation': 'San Francisco Veterans Affairs Health Care System (SFVAHCS), 4150 Clement St., San Francisco, CA, USA; Northern California Institute for Research and Education (NCIRE), 4150 Clement St., San Francisco, CA, USA.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Herbst', 'Affiliation': 'University of California, San Francisco, Department of Psychiatry, 4150 Clement St., San Francisco, CA, USA; San Francisco Veterans Affairs Health Care System (SFVAHCS), 4150 Clement St., San Francisco, CA, USA; Northern California Institute for Research and Education (NCIRE), 4150 Clement St., San Francisco, CA, USA.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Abrams', 'Affiliation': 'San Francisco Veterans Affairs Health Care System (SFVAHCS), 4150 Clement St., San Francisco, CA, USA.'}, {'ForeName': 'Tatjana', 'Initials': 'T', 'LastName': 'Novakovic-Agopian', 'Affiliation': 'University of California, San Francisco, Department of Psychiatry, 4150 Clement St., San Francisco, CA, USA; San Francisco Veterans Affairs Health Care System (SFVAHCS), 4150 Clement St., San Francisco, CA, USA; Northern California Institute for Research and Education (NCIRE), 4150 Clement St., San Francisco, CA, USA.'}, {'ForeName': 'Steven L', 'Initials': 'SL', 'LastName': 'Batki', 'Affiliation': 'University of California, San Francisco, Department of Psychiatry, 4150 Clement St., San Francisco, CA, USA; San Francisco Veterans Affairs Health Care System (SFVAHCS), 4150 Clement St., San Francisco, CA, USA; Northern California Institute for Research and Education (NCIRE), 4150 Clement St., San Francisco, CA, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108149'] 1902,32717713,"Effect of lifetime antiepileptic drug treatment history on efficacy and tolerability of adjunctive brivaracetam in adults with focal seizures: Post-hoc analysis of a randomized, placebo-controlled trial.","OBJECTIVE To evaluate the efficacy and tolerability of adjunctive brivaracetam (BRV) in adults with focal seizures by the number of lifetime (previous and concomitant) antiepileptic drugs (AEDs). METHODS Post-hoc analysis of data from N01358 (NCT01261325), a randomized, double-blind, placebo (PBO)-controlled Phase III trial evaluating BRV 100 and 200 mg/day in patients ≥16 years of age with uncontrolled focal seizures. Efficacy and tolerability outcomes were assessed for the 12-week Treatment Period in subgroups of patients with 1-2, 3-4, 5-6, or ≥7 lifetime AEDs. RESULTS 764 patients received at least one dose of trial medication (BRV: 503; PBO: 261; Safety Set), of whom 14.3% had 1-2, 20.8% had 3-4, 21.3% had 5-6, and 43.6% had ≥7 lifetime AEDs. In all lifetime AED subgroups, >85% of patients completed the trial. Patients with a higher number of lifetime AEDs had a younger age at epilepsy onset, longer epilepsy duration, and higher baseline seizure frequency. In patients on BRV, 50% responder rates were 49.3%, 44.4%, 47.2% and 27.4% in patients with 1-2 (n = 75), 3-4 (n = 99), 5-6 (n = 108) and ≥7 (n = 219) lifetime AEDs; 75% responder rates were 36.0%, 21.2%, 22.2% and 12.3%. In patients on PBO, 50% responder rates were 35.3%, 25.9%, 20.4% and 15.9% in patients with 1-2 (n = 34), 3-4 (n = 58), 5-6 (n = 54) and ≥7 (n = 113) lifetime AEDs; 75% responder rates were 26.5%, 6.9%, 3.7% and 4.4%. The Kaplan-Meier estimated probability of patients achieving a sustained 50% or 75% response from the first day of treatment was generally higher in patients with a lower number of lifetime AEDs (both in patients on BRV and PBO). In patients on adjunctive BRV, the incidence of drug related treatment-emergent adverse events (TEAEs) was 34.7%, 26.0%, 44.4% and 47.7% in patients with 1-2 (n = 75), 3-4 (n = 100), 5-6 (n = 108) and ≥7 (n = 220) lifetime AEDs; the incidence of discontinuations due to TEAEs was 1.3%, 3.0%, 8.3% and 10.5%. CONCLUSIONS This post-hoc analysis suggests a numerically higher response to adjunctive BRV in patients with fewer lifetime AEDs. The lowest response was observed in patients with ≥7 lifetime AEDs, although these patients could also benefit from adjunctive BRV treatment. Patients with fewer lifetime AEDs had lower discontinuation of BRV due to TEAEs.",2020,"Efficacy and tolerability outcomes were assessed for the 12-week Treatment Period in subgroups of patients with 1-2, 3-4, 5-6, or ≥7 lifetime AEDs. ","['adults with focal seizures by the number of lifetime (previous and concomitant) antiepileptic drugs (AEDs', 'adults with focal seizures', 'subgroups of patients with 1-2, 3-4, 5-6, or ≥7 lifetime AEDs', 'patients ≥16 years of age with uncontrolled focal seizures']","['adjunctive brivaracetam (BRV', 'adjunctive brivaracetam', 'placebo']","['Efficacy and tolerability outcomes', 'responder rates', 'incidence of drug related treatment-emergent adverse events (TEAEs', 'efficacy and tolerability']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0003299', 'cui_str': 'ANTIEPILEPTICS'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442757', 'cui_str': '3/4'}, {'cui': 'C0442749', 'cui_str': '6/5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}]","[{'cui': 'C1699861', 'cui_str': 'Brivaracetam'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",764.0,0.103758,"Efficacy and tolerability outcomes were assessed for the 12-week Treatment Period in subgroups of patients with 1-2, 3-4, 5-6, or ≥7 lifetime AEDs. ","[{'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Klein', 'Affiliation': 'Mid-Atlantic Epilepsy and Sleep Center, 6410 Rockledge Drive, Suite 610, Bethesda, MD 20817, USA. Electronic address: kleinp@epilepsydc.com.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'McLachlan', 'Affiliation': 'Western University, 339 Windermere Road, London, ON N6A 5A5, Canada. Electronic address: rsmcl@uwo.ca.'}, {'ForeName': 'Kathy', 'Initials': 'K', 'LastName': 'Foris', 'Affiliation': 'UCB Pharma, 2060 Winston Park Drive, Suite 401, Oakville, ON L6H 5R7, Canada. Electronic address: kforis@sympatico.ca.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Nondonfaz', 'Affiliation': ""UCB Pharma, Chemin du Foriest, 1420 Braine-l'Alleud, Belgium. Electronic address: xavier.nondonfaz@ucb.com.""}, {'ForeName': 'Sami', 'Initials': 'S', 'LastName': 'Elmoufti', 'Affiliation': 'UCB Pharma, 8010 Arco Corporate Drive, Raleigh, NC 27617, USA. Electronic address: sami.elmoufti@ucb.com.'}, {'ForeName': 'Svetlana', 'Initials': 'S', 'LastName': 'Dimova', 'Affiliation': 'UCB Pharma, Allée de la Recherche 60, 1070 Brussels, Belgium. Electronic address: svetlana.dimova@ucb.com.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Brandt', 'Affiliation': 'Bethel Epilepsy Center, Mara Hospital, Maraweg 21, 33617 Bielefeld, Germany. Electronic address: christian.brandt@mara.de.'}]",Epilepsy research,['10.1016/j.eplepsyres.2020.106369'] 1903,32718800,Enhanced Antenatal Care: Combining one-to-one and group Antenatal Care models to increase childbirth education and address childbirth fear.,"BACKGROUND We designed and implemented a new model of care, Enhanced Antenatal Care (EAC), which offers a combined approach to midwifery-led care with six one-to-one visits and four group sessions. AIM To assess EAC in terms of women's satisfaction with care, autonomy in decision-making, and its effectiveness in lowering childbirth fear. METHODS This was a quasi-experimental controlled trial comparing 32 nulliparous women who received EAC (n=32) and usual antenatal care (n=60). We compared women's satisfaction with care and autonomy in decision-making post-intervention using chi-square test. We administered a Fear of Birth Scale pre- and post-intervention and assessed change in fear of birth in each group using the Cohen's d for effect size. To isolate the effect of EAC, we then restricted this analysis to women who did not attend classes alongside maternal care (n=13 in EAC and n=13 in usual care). FINDINGS Women's satisfaction with care in terms of monitoring their and their baby's health was similar in both groups. Women receiving EAC were more likely than those in usual care to report having received enough information about the postpartum period (75% vs 30%) and parenting (91% vs 55%). Overall, EAC was more effective than usual care in reducing fear of birth (Cohen's d=-0.21), especially among women not attending classes alongside antenatal care (Cohen's d=-0.83). CONCLUSION This study is the first to report findings on EAC and suggests that this novel model may be beneficial in terms of providing education and support, as well as lowering childbirth fear.",2020,"Overall, EAC was more effective than usual care in reducing fear of birth (Cohen's d=-0.21), especially among women not attending classes alongside antenatal care (Cohen's d=-0.83). ","['Enhanced Antenatal Care', '32 nulliparous women who received EAC (n=32) and usual antenatal care (n=60', 'women who did not attend classes alongside maternal care (n=13 in EAC and n=13 in usual care']","['EAC', 'Fear of Birth Scale pre- and post-intervention']",['fear of birth'],"[{'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0425979', 'cui_str': 'Nulliparous'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0559294', 'cui_str': 'Did not attend'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]","[{'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0005615', 'cui_str': 'Birth'}]",32.0,0.0446806,"Overall, EAC was more effective than usual care in reducing fear of birth (Cohen's d=-0.21), especially among women not attending classes alongside antenatal care (Cohen's d=-0.83). ","[{'ForeName': 'Emma Marie', 'Initials': 'EM', 'LastName': 'Swift', 'Affiliation': 'Faculty of Nursing/Department of Midwifery, University of Iceland, Eirberg við Eiríksgötu, 101 Reykjavík, Iceland. Electronic address: emmas@hi.is.'}, {'ForeName': 'Helga', 'Initials': 'H', 'LastName': 'Zoega', 'Affiliation': 'Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Sturlugata 8, 101 Reykjavík, Iceland; Centre for Big Data Research in Health, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia.'}, {'ForeName': 'Kathrin', 'Initials': 'K', 'LastName': 'Stoll', 'Affiliation': 'Division of Midwifery, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Avery', 'Affiliation': 'University of Minnesota, School of Nursing, Minneapolis, MN, USA.'}, {'ForeName': 'Helga', 'Initials': 'H', 'LastName': 'Gottfreðsdóttir', 'Affiliation': ""Faculty of Nursing/Department of Midwifery, University of Iceland, Eirberg við Eiríksgötu, 101 Reykjavík, Iceland; Women's Clinic, Landspitali University Hospital, 101 Reykjavik, Iceland.""}]",Women and birth : journal of the Australian College of Midwives,['10.1016/j.wombi.2020.06.008'] 1904,32719073,Patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris randomised to an invasive versus conservative strategy: angiographic and procedural results from the After Eighty study.,"OBJECTIVES We aimed to report the angiographic and procedural results of the After Eighty study (ClinicalTrials.gov, NCT01255540), and to identify independent predictors of revascularisation. METHODS Patients of ≥80 years old with non-ST-elevation myocardial infarction and unstable angina pectoris were randomised to an invasive or conservative strategy. Angiographic and procedural results were recorded. Univariate and multivariate analyses were performed to explore variables predicting revascularisation. RESULTS Among 229 patients in the invasive group, 220 underwent immediate coronary angiography (90% performed via the radial artery). Of these patients, 48% had three-vessel disease or left main stenosis, 18% two-vessel disease, 16% one-vessel disease, 17% minor coronary vessel wall changes and two patients had normal coronary arteries. Six patients (3%) underwent coronary artery bypass graft. Percutaneous coronary intervention (PCI) was performed in 107 patients (49%), with 57% treated with bare metal stents, 37% drug-eluting stents and 6% balloon angioplasty. On average, 1.7 lesions were treated and 2 stents delivered per patient. Complications included 1 major PCI-related bleeding (successfully treated), 2 minor access site-related bleedings, 3 side branch occlusions during PCI and 11 periprocedural myocardial infarctions (considered end points). Sex, bundle branch block and smoking were independent predictors of revascularisation. CONCLUSIONS PCI was performed in approximately half of the patients, similar to findings in younger populations. Procedural success was high, with few complications. TRIAL REGISTRATION NUMBER NCT01255540.",2020,"Procedural success was high, with few complications. ","['Patients of ≥80 years old with non-ST-elevation myocardial infarction and unstable angina pectoris', '107 patients (49%), with 57% treated with', 'Patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris randomised to an', '229 patients in the invasive group']","['invasive versus conservative strategy: angiographic', 'bare metal stents, 37% drug-eluting stents and 6% balloon angioplasty', 'invasive or conservative strategy', 'Percutaneous coronary intervention (PCI', 'coronary artery bypass graft', 'immediate coronary angiography']","['major PCI-related bleeding (successfully treated), 2 minor access site-related bleedings, 3 side branch occlusions during PCI and 11 periprocedural myocardial infarctions', 'vessel disease or left main stenosis', 'normal coronary arteries', 'Procedural success']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1276061', 'cui_str': 'Acute non-ST segment elevation myocardial infarction'}, {'cui': 'C0002965', 'cui_str': 'Impending infarction'}, {'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C2825200', 'cui_str': 'Bare metal stent'}, {'cui': 'C1322815', 'cui_str': 'Drug eluting stent'}, {'cui': 'C0002996', 'cui_str': 'Balloon Angioplasty'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0085532', 'cui_str': 'Coronary angiography'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0026193', 'cui_str': 'Minor'}, {'cui': 'C0589360', 'cui_str': 'Site of access'}, {'cui': 'C0205384', 'cui_str': 'Branching'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C4324584', 'cui_str': 'Periprocedural myocardial infarction'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0678234', 'cui_str': 'Form of stenosis'}, {'cui': 'C1299335', 'cui_str': 'Normal coronary arteries'}]",229.0,0.141913,"Procedural success was high, with few complications. ","[{'ForeName': 'Nicolai', 'Initials': 'N', 'LastName': 'Tegn', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Eek', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Abdelnoor', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Aaberge', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Knut', 'Initials': 'K', 'LastName': 'Endresen', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Skårdal', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Erlend Sturle', 'Initials': 'ES', 'LastName': 'Berg', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Gullestad', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Bjørn', 'Initials': 'B', 'LastName': 'Bendz', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway bbendz@ous-hf.no.'}]",Open heart,['10.1136/openhrt-2020-001256'] 1905,32726308,Improved patient satisfaction and diagnostic accuracy in skin diseases with a Visual Clinical Decision Support System-A feasibility study with general practitioners.,"Patient satisfaction is an important indicator of health care quality, and it remains an important goal for optimal treatment outcomes to reduce the level of misdiagnoses and inappropriate or absent therapeutic actions. Digital support tools for differential diagnosis to assist clinicians in reaching the correct diagnosis may be helpful, but how the use of these affect patients is not clear. The primary objective of this feasibility study was to investigate patient experience and satisfaction in a primary care setting where general practitioners (GPs) used a visual clinical decision support system (CDSS) compared with standard consultations. Secondary objectives were diagnostic accuracy and length of consultation. Thirty-one patients with a dermatologist-confirmed skin diagnosis were allocated to consult GPs that had been randomized to conduct either standard consultations (SDR, n = 21) or CDSS (n = 16) on two separate study days one week apart. All patients were diagnosed independently by multiple GPs (n = 3-8) in both the SDR and CDSS study arms. Using the CDSS, more patients felt involved in the decision making (P = 0.05). In addition, more patients were exposed to images during the consultations (P = 6.8e-27), and 83% of those that were shown images replied they felt better supported in the consultation. The use of CDSS significantly improved the diagnostic accuracy (34%, P = 0.007), and did not increase the duration of the consultation (median 10 minutes in both arms). This study shows for the first time that compared with standard GP consultations, CDSS assist the GP on skin related diagnoses and improve patient satisfaction and diagnostic accuracy without impacting the duration of the consultations. This is likely to increase correct treatment choices, patient adherence, and overall result in better healthcare outcomes.",2020,"The use of CDSS significantly improved the diagnostic accuracy (34%, P = 0.007), and did not increase the duration of the consultation (median 10 minutes in both arms).","['Thirty-one patients with a dermatologist-confirmed skin diagnosis', 'general practitioners']","['CDSS', 'visual clinical decision support system (CDSS']","['patient satisfaction and diagnostic accuracy', 'diagnostic accuracy', 'duration of the consultation', 'diagnostic accuracy and length of consultation']","[{'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0259831', 'cui_str': 'Dermatologist'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0017319', 'cui_str': 'General physician'}]","[{'cui': 'C0525070', 'cui_str': 'Clinical Decision Support Systems'}, {'cui': 'C0234621', 'cui_str': 'Visual'}]","[{'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C1444754', 'cui_str': 'Length'}]",31.0,0.0505547,"The use of CDSS significantly improved the diagnostic accuracy (34%, P = 0.007), and did not increase the duration of the consultation (median 10 minutes in both arms).","[{'ForeName': 'Eckhard W', 'Initials': 'EW', 'LastName': 'Breitbart', 'Affiliation': 'Association of Dermatological Prevention (ADP), Hamburg, Germany.'}, {'ForeName': 'Kohelia', 'Initials': 'K', 'LastName': 'Choudhury', 'Affiliation': 'Association of Dermatological Prevention (ADP), Hamburg, Germany.'}, {'ForeName': 'Anders Daniel', 'Initials': 'AD', 'LastName': 'Andersen', 'Affiliation': 'LEO Innovation Lab, Copenhagen, Denmark.'}, {'ForeName': 'Henriette', 'Initials': 'H', 'LastName': 'Bunde', 'Affiliation': 'Association of Dermatological Prevention (ADP), Hamburg, Germany.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Breitbart', 'Affiliation': 'Association of Dermatological Prevention (ADP), Hamburg, Germany.'}, {'ForeName': 'Antonia Maria', 'Initials': 'AM', 'LastName': 'Sideri', 'Affiliation': 'LEO Innovation Lab, Copenhagen, Denmark.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Fengler', 'Affiliation': 'Association of Dermatological Prevention (ADP), Hamburg, Germany.'}, {'ForeName': 'John Robert', 'Initials': 'JR', 'LastName': 'Zibert', 'Affiliation': 'LEO Innovation Lab, Copenhagen, Denmark.'}]",PloS one,['10.1371/journal.pone.0235410'] 1906,32727393,"A stepped-wedge randomised-controlled trial assessing the implementation, impact and costs of a prospective feedback loop to promote appropriate care and treatment for older patients in acute hospitals at the end of life: study protocol.","BACKGROUND Hospitalisation rates for the older population have been increasing with end-of-life care becoming a more medicalised and costly experience. There is evidence that some of these patients received non-beneficial treatment during their final hospitalisation with a third of the non-beneficial treatment duration spent in intensive care units. This study aims to increase appropriate care and treatment decisions and pathways for older patients at the end of life in Australia. This study will implement and evaluate a prospective feedback loop and tailored clinical response intervention at three hospitals in Queensland, Australia. METHODS A stepped-wedge cluster randomised trial will be conducted with up to 21 clinical teams in three acute hospitals over 70 weeks. The study involves clinical teams providing care to patients aged 75 years or older, who are prospectively identified to be at risk of non-beneficial treatment using two validated tools for detecting death and deterioration risks. The intervention's feedback loop will provide the teams with a summary of these patients' risk profiles as a stimulus for a tailored clinical response in the intervention phase. The Consolidated Framework for Implementation Research will be used to inform the intervention's implementation and process evaluation. The study will determine the impact of the intervention on patient outcomes related to appropriate care and treatment at the end of life in hospitals, as well as the associated healthcare resource use and costs. The primary outcome is the proportion of patients who are admitted to intensive care units. A process evaluation will be carried out to assess the implementation, mechanisms of impact, and contextual barriers and enablers of the intervention. DISCUSSION This intervention is expected to have a positive impact on the care of older patients near the end of life, specifically to improve clinical decision-making about treatment pathways and what constitutes appropriate care for these patients. These will reduce the incidence of non-beneficial treatment, and improve the efficiency of hospital resources and quality of care. The process evaluation results will be useful to inform subsequent intervention implementation at other hospitals. TRIAL REGISTRATION Australia New Zealand Clinical Trial Registry (ANZCTR), ACTRN12619000675123p (approved 6 May 2019).",2020,"BACKGROUND Hospitalisation rates for the older population have been increasing with end-of-life care becoming a more medicalised and costly experience.","['21 clinical teams in three acute hospitals over 70\u2009weeks', 'older patients in acute hospitals at the end of life', 'three hospitals in Queensland, Australia', 'older patients at the end of life in Australia', 'patients aged 75\u2009years or older, who are prospectively identified to be at risk of non-beneficial treatment using two validated tools for detecting death and deterioration risks']",[],['proportion of patients who are admitted to intensive care units'],"[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0034391', 'cui_str': 'Queensland'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0583239', 'cui_str': 'Admission to intensive care unit'}]",,0.131548,"BACKGROUND Hospitalisation rates for the older population have been increasing with end-of-life care becoming a more medicalised and costly experience.","[{'ForeName': 'Xing J', 'Initials': 'XJ', 'LastName': 'Lee', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology (QUT), Kelvin Grove, Queensland, Australia. xj.lee@qut.edu.au.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Farrington', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology (QUT), Kelvin Grove, Queensland, Australia.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Carter', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology (QUT), Kelvin Grove, Queensland, Australia.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Shield', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology (QUT), Kelvin Grove, Queensland, Australia.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Graves', 'Affiliation': 'Duke-NUS Postgraduate Medical School, National University of Singapore, Singapore, Singapore.'}, {'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'McPhail', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology (QUT), Kelvin Grove, Queensland, Australia.'}, {'ForeName': 'Gillian', 'Initials': 'G', 'LastName': 'Harvey', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology (QUT), Kelvin Grove, Queensland, Australia.'}, {'ForeName': 'Ben P', 'Initials': 'BP', 'LastName': 'White', 'Affiliation': 'Australia Centre for Heath Law Research, Faculty of Law, Queensland University of Technology, Brisbane, Queensland, Australia.'}, {'ForeName': 'Lindy', 'Initials': 'L', 'LastName': 'Willmott', 'Affiliation': 'Australia Centre for Heath Law Research, Faculty of Law, Queensland University of Technology, Brisbane, Queensland, Australia.'}, {'ForeName': 'Magnolia', 'Initials': 'M', 'LastName': 'Cardona', 'Affiliation': 'Gold Coast University Hospital, Southport, Queensland, Australia.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Hillman', 'Affiliation': 'Simpson Centre for Health Services Research, South West Sydney Clinical School, University of New South Wales, Liverpool, New South Wales, Australia.'}, {'ForeName': 'Leonie', 'Initials': 'L', 'LastName': 'Callaway', 'Affiliation': 'Faculty of Health, Queensland University of Technology, Kelvin Grove, Queensland, Australia.'}, {'ForeName': 'Adrian G', 'Initials': 'AG', 'LastName': 'Barnett', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology (QUT), Kelvin Grove, Queensland, Australia.'}]",BMC geriatrics,['10.1186/s12877-020-01660-2'] 1907,32735335,Effect of a Videoconference-Based Online Group Intervention for Traumatic Stress in Parents of Children With Life-threatening Illness: A Randomized Clinical Trial.,"Importance A substantial proportion of parents whose child is diagnosed with a life-threatening illness experience high levels of distress that can lead to long-term mental health difficulties. This can affect the child's recovery. Objective To evaluate the efficacy of an acceptance and commitment therapy-based group intervention, delivered using videoconferencing, in reducing posttraumatic stress symptoms (PTSS) in these parents. Design, Setting, and Participants This study was a randomized clinical trial of an intervention for parents with elevated acute stress symptoms. It was a single-site study conducted in a tertiary pediatric hospital in Australia. Parents of children aged 0 to 18 years admitted for a life-threatening illness or injury to the oncology, cardiology, or pediatric intensive care departments were eligible. Participants were screened for eligibility within the first month after diagnosis or admission and then were randomized to the intervention group or the waiting list control group 4 to 10 months after diagnosis or admission. Recruitment commenced January 2014, and final postintervention follow-up was completed in February 2018. Data analysis was performed from July to September 2018. Interventions Treatment was a psychological acceptance and commitment therapy-based group therapy program called Take a Breath, which consisted of a 6-session parent-mediated psychological intervention delivered via online videoconferences over the course of 8 weeks. Waiting list control participants received treatment as usual and were offered the intervention 3 months after randomization. Main Outcomes and Measures The primary outcome was PTSS, as measured by the Posttraumatic Stress Disorder Checklist-Version 5 (total score range, 0-80, with higher scores indicating greater symptom severity). The PTSS was measured both before and immediately after the intervention. Changes in psychological skills taught within the intervention were also evaluated, including acceptance, mindfulness, values-based living, and psychological flexibility. Results Of 1232 parents who were assessed for eligibility, 313 were randomized; 161 were allocated to the waiting list control group, and 152 were allocated to the intervention group. Of those allocated, 44 parents in the waiting list group and 37 in the intervention group completed the postintervention questionnaire and were analyzed (81 participants total; mean [SD] age, 37.17 [6.43] years). Sixty-five participants (80.2%) were women, 48 participants (59.3%) were married, and 40 participants (49.4%) lived in rural or regional areas, or in a different state. In addition, 24 parents (29.6%) were in the cardiology illness group, 32 parents (39.5%) were in the oncology group, and 25 parents (30.9%) were in the pediatric intensive care unit group. The intervention group demonstrated significantly greater improvements in PTSS compared with the waiting list group (Cohen d = 1.10; 95% CI, 0.61-1.59; P = .03). The mean Posttraumatic Stress Disorder Checklist-Version 5 scores decreased from 31.7 (95% CI, 27.0-36.4) to 26.2 (95% CI, 21.8-30.7) in the waiting list control group and from 23.3 (95% CI, 18.6-28.1) to 17.8 (95% CI, 13.8-21.8) in the intervention group. Conclusions and Relevance The findings of this study support the use of acceptance and commitment therapy to reduce PTSS in parents of very ill children, regardless of diagnosis. These findings also suggest that a brief, group format using a videoconferencing platform can be used effectively to access hard-to-reach populations, particularly fathers and caregivers living in nonmetropolitan areas. Trial Registration Australian New Zealand Clinical Trials Registry Identifier: ACTRN12611000090910.",2020,"The intervention group demonstrated significantly greater improvements in PTSS compared with the waiting list group (Cohen d = 1.10; 95% CI, 0.61-1.59; P = .03).","['parents with elevated acute stress symptoms', '44 parents in the waiting list group and 37 in the intervention group completed the postintervention questionnaire and were analyzed (81 participants total; mean [SD] age, 37.17 [6.43] years', 'Parents of Children', 'Participants were screened for eligibility within the first month after diagnosis or admission', 'Sixty-five participants (80.2%) were women, 48 participants (59.3%) were married, and 40 participants (49.4%) lived in rural or regional areas, or in a different state', 'tertiary pediatric hospital in Australia', 'With Life-threatening Illness', '24 parents (29.6%) were in the cardiology illness group, 32 parents (39.5%) were in the oncology group, and 25 parents (30.9%) were in the pediatric intensive care unit group', '1232 parents who were assessed for eligibility', 'Parents of children aged 0 to 18 years admitted for a life-threatening illness or injury to the oncology, cardiology, or pediatric intensive care departments were eligible']","['waiting list control', 'Videoconference-Based Online Group Intervention', 'acceptance and commitment therapy-based group intervention, delivered using videoconferencing', 'videoconferencing platform', 'psychological acceptance and commitment therapy-based group therapy program called Take a Breath, which consisted of a 6-session parent-mediated psychological intervention delivered via online videoconferences']","['mean Posttraumatic Stress Disorder Checklist-Version 5 scores', 'acceptance, mindfulness, values-based living, and psychological flexibility', 'PTSS, as measured by the Posttraumatic Stress Disorder Checklist-Version 5 (total score range', 'posttraumatic stress symptoms (PTSS', 'PTSS']","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0450385', 'cui_str': '65'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0555047', 'cui_str': 'Married'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C3537125', 'cui_str': 'Common terminology criteria for adverse events grade 4'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0021710', 'cui_str': 'Pediatric intensive care unit'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C1627360', 'cui_str': 'Pediatric intensive care'}]","[{'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1450049', 'cui_str': 'Videoconference'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}, {'cui': 'C1450048', 'cui_str': 'Videoconferencing'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0033971', 'cui_str': 'Group psychotherapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0225386', 'cui_str': 'Breath'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]",313.0,0.132341,"The intervention group demonstrated significantly greater improvements in PTSS compared with the waiting list group (Cohen d = 1.10; 95% CI, 0.61-1.59; P = .03).","[{'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Muscara', 'Affiliation': ""Clinical Sciences, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.""}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'McCarthy', 'Affiliation': ""Children's Cancer Centre, The Royal Children's Hospital, Parkville, Victoria, Australia.""}, {'ForeName': 'Meredith', 'Initials': 'M', 'LastName': 'Rayner', 'Affiliation': ""Clinical Sciences, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.""}, {'ForeName': 'Jan M', 'Initials': 'JM', 'LastName': 'Nicholson', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Bundoora, Victoria, Australia.'}, {'ForeName': 'Anica', 'Initials': 'A', 'LastName': 'Dimovski', 'Affiliation': ""Clinical Sciences, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'McMillan', 'Affiliation': ""Clinical Sciences, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.""}, {'ForeName': 'Stephen J C', 'Initials': 'SJC', 'LastName': 'Hearps', 'Affiliation': ""Clinical Sciences, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.""}, {'ForeName': 'Jackie', 'Initials': 'J', 'LastName': 'Yamada', 'Affiliation': ""Clinical Sciences, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.""}, {'ForeName': 'Kylie', 'Initials': 'K', 'LastName': 'Burke', 'Affiliation': 'Parenting and Family Support Centre, School of Psychology, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Robyn', 'Initials': 'R', 'LastName': 'Walser', 'Affiliation': 'Department of Psychology, University of California, Berkeley.'}, {'ForeName': 'Vicki A', 'Initials': 'VA', 'LastName': 'Anderson', 'Affiliation': ""Clinical Sciences, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.""}]",JAMA network open,['10.1001/jamanetworkopen.2020.8507'] 1908,32731118,"Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial.","BACKGROUND This long-term follow-up (LTFU) trial was conducted to evaluate the long-term safety and tolerability of brivaracetam (BRV) at individualized doses (maximum of 200 mg/day) in patients with focal seizures. The secondary objective was to evaluate the efficacy of BRV over time. METHODS Two Phase III, randomized, double-blind, historical-controlled conversion-to-monotherapy trials (N01276: NCT00698581; N01306: NCT00699283) were conducted in patients aged ≥16 years with uncontrolled focal seizures. Patients who completed either of these core trials or who met a protocol-defined exit criterion could enter this LTFU trial (N01315; NCT00761774). Patients entered LTFU at a recommended BRV dose of 100 mg/day, with flexible dosing of 50-200 mg/day, as monotherapy or adjunctive therapy; additional AEDs could be prescribed and adapted in dose if clinically indicated. Safety variables included treatment-emergent adverse events (TEAEs). Efficacy variables included duration of continuous monotherapy, reduction in focal seizure frequency and seizure freedom. Safety and efficacy variables were assessed for all patients in the safety set or efficacy set, respectively, regardless of BRV treatment regimen. In addition, a post hoc subgroup analysis was conducted for patients who completed the BRV monotherapy period in either core trial, and entered the LTFU on BRV monotherapy. For this subgroup, TEAEs were summarized by 3-month time intervals over the first 12 months of LTFU. RESULTS 108 patients were enrolled in the LTFU trial between November 2008 and February 2010. 79 (73.1 %) patients discontinued the LTFU trial, most commonly due to lack of efficacy [37 (34.3 %)] and adverse events [16 (14.8 %)]. At core trial baseline, patients had a median of 6.3 focal seizures/28 days and 53 (49.1 %) had failed ≥5 previous lifetime AEDs. During LTFU, 70 (64.8 %) patients had ≥12 months and 56 (51.9 %) patients had ≥24 months of BRV treatment. TEAEs were reported by 98 (90.7 %) patients; most commonly (≥15 % of patients) convulsion (17.6 %), nasopharyngitis (17.6 %), depression (16.7 %) and fatigue (15.7 %). Median percent reduction from baseline in focal seizure frequency/28 days was 56.8 %. Among 86 patients who completed at least 6 months of treatment, 29 (33.7 %) patients were seizure-free for ≥6 months and 22 (25.6 %) were seizure-free for ≥12 months. 50/108 patients were included in the BRV monotherapy subgroup; 33/50 (66.0 %) patients reported a TEAE in the core trials, while 26/50 (52.0 %), 15/37 (40.5 %), 14/33 (42.4 %) and 9/27 (33.3 %) patients reported any TEAE during LTFU months 1-3, 4-6, 7-9 and 10-12, respectively. In the BRV monotherapy subgroup, the most common TEAEs (≥5% of patients) during LTFU months 1-3 were fatigue [3/50 (6.0 %)] and dizziness [3/50 (6.0 %)]. INTERPRETATION Results from the LTFU trial support the long-term safety of BRV at individualized doses of up to 200 mg/day as a well-tolerated, and effective treatment for patients with focal seizures. Efficacy analyses indicate that seizure reductions with brivaracetam were generally maintained over time.",2020,"TEAEs were reported by 98 (90.7 %) patients; most commonly (≥15 % of patients) convulsion (17.6 %), nasopharyngitis (17.6 %), depression (16.7 %) and fatigue (15.7 %).","['patients with focal seizures', '86 patients who completed at least 6 months of treatment, 29 (33.7 %) patients were seizure-free for ≥6 months and 22 (25.6 %) were seizure-free for ≥12 months', 'patients aged ≥16 years with uncontrolled focal seizures', 'adults with focal seizures', '108 patients were enrolled in the LTFU trial between November 2008 and February 2010']","['brivaracetam', 'brivaracetam (BRV', 'LTFU']","['dizziness', 'treatment-emergent adverse events (TEAEs', 'fatigue', 'Safety and efficacy variables', 'focal seizure frequency and seizure freedom', 'adverse events', 'nasopharyngitis', 'depression', 'seizure reductions with brivaracetam']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1299590', 'cui_str': 'Seizure free'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C1699861', 'cui_str': 'Brivaracetam'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1699861', 'cui_str': 'Brivaracetam'}]",108.0,0.524516,"TEAEs were reported by 98 (90.7 %) patients; most commonly (≥15 % of patients) convulsion (17.6 %), nasopharyngitis (17.6 %), depression (16.7 %) and fatigue (15.7 %).","[{'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Arnold', 'Affiliation': 'Department of Neurology, Schön Klinik Vogtareuth, Krankenhausstraße 20, 83569, Vogtareuth, Germany. Electronic address: SArnold@Schoen-Kliniken.de.'}, {'ForeName': 'Cédric', 'Initials': 'C', 'LastName': 'Laloyaux', 'Affiliation': 'UCB Pharma, Allée de la Recherche, 60, B - 1070 Brussels, Belgium. Electronic address: Cedric.Laloyaux@ucb.com.'}, {'ForeName': 'Anne-Liv', 'Initials': 'AL', 'LastName': 'Schulz', 'Affiliation': 'UCB Pharma, Alfred-Nobel-Strasse 10, 40789 Monheim am Rhein, Germany. Electronic address: Anne-Liv.Schulz@ucb.com.'}, {'ForeName': 'Sami', 'Initials': 'S', 'LastName': 'Elmoufti', 'Affiliation': 'UCB Pharma, 8010 Arco Corporate Drive, Raleigh, NC 27617, USA. Electronic address: Sami.Elmoufti@ucb.com.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Yates', 'Affiliation': 'UCB Pharma, 8010 Arco Corporate Drive, Raleigh, NC 27617, USA. Electronic address: Stephen.Yates@ucb.com.'}, {'ForeName': 'Toufic', 'Initials': 'T', 'LastName': 'Fakhoury', 'Affiliation': 'St. Joseph Health System, 1401 Harrodsburg Road, Suite B-280, Lexington, KY 40504, USA. Electronic address: TouficFakhoury@catholichealth.net.'}]",Epilepsy research,['10.1016/j.eplepsyres.2020.106404'] 1909,32732142,"Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years.","Inactivated quadrivalent influenza vaccine (IIV4) containing two influenza A strains (H1N1 and H3N2) and one strain from each B lineage (Victoria and Yamagata) may offer broader protection against seasonal influenza. This study examined the immunogenicity and safety of a candidate IIV4. A randomized, double-blind, controlled phase III clinical trial was conducted in healthy subjects aged ≥3 years. Subjects were randomly assigned into three groups in a 2:1:1 ratio, receiving single dose of IIV4 or inactivated trivalent influenza vaccine (IIV3) which contains either B/Victoria strain (BV) or B/Yamagata strain (BY). Blood samples were collected before and 28 days after vaccination to test hemagglutination inhibition (HI) antibodies of the four influenza strains. Safety information was collected for 28 days after vaccination. A total of 2320 subjects (IIV4: 1160, IIV3-BV: 580, IIV3-BY: 580) were enrolled in this study. After vaccination, the seroconversion rates of IIV4 against H1N1, H3N2, BV and BY strains were 77.15%, 81.93%, 60.14% and 64.57%, respectively. Geometric mean titers (GMTs) against the four influenza strains were 523.91, 274.13, 115.35 and 257.81, respectively. The investigational IIV4 was non-inferiority to IIV3 for the four strains, meanwhile superior to IIV3 for additional B strains (B/BV, B/BY). For safety, there had no significant difference in the incidence of the adverse reactions among the three groups (P = 0.5986). No serious adverse events related to vaccination occurred. The IIV4 had good immunogenicity and safety, which added an influenza B protection with no increased safety concerns. (ClinicalTrials.gov number: NCT03853993).",2020,"After vaccination, the seroconversion rates of IIV4 against H1N1, H3N2, BV and BY strains were 77.15%, 81.93%, 60.14% and 64.57%, respectively.","['A total of 2320 subjects (IIV4: 1160, IIV3-BV: 580, IIV3-BY: 580', 'healthy population aged ≥3\xa0years', 'healthy subjects aged ≥3\xa0years']","['Inactivated quadrivalent influenza vaccine (IIV4) containing two influenza A strains (H1N1 and H3N2) and one strain from each B lineage (Victoria and Yamagata', 'single dose of IIV4 or inactivated trivalent influenza vaccine (IIV3) which contains either B/Victoria strain (BV) or B/Yamagata strain (BY', 'inactivated quadrivalent influenza vaccine']","['immunogenicity and safety', 'Safety information', 'Geometric mean titers (GMTs', 'Blood samples', 'seroconversion rates of IIV4 against H1N1, H3N2, BV and BY strains', 'safety concerns', 'adverse reactions', 'Immunogenicity and safety']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0042645', 'cui_str': 'Victoria'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C4517818', 'cui_str': '580'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C4318638', 'cui_str': 'Quadrivalent Influenza Vaccine'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C1615607', 'cui_str': 'Influenza A virus subtype H1N1'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0580264', 'cui_str': 'H1N1'}, {'cui': 'C0580267', 'cui_str': 'H3N2'}, {'cui': 'C0042645', 'cui_str': 'Victoria'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0021403', 'cui_str': 'Influenza virus vaccine'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0580264', 'cui_str': 'H1N1'}, {'cui': 'C0580267', 'cui_str': 'H3N2'}, {'cui': 'C0042645', 'cui_str': 'Victoria'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}]",2320.0,0.194904,"After vaccination, the seroconversion rates of IIV4 against H1N1, H3N2, BV and BY strains were 77.15%, 81.93%, 60.14% and 64.57%, respectively.","[{'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Chu', 'Affiliation': 'Clinical Trials Assessment Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.'}, {'ForeName': 'Kangwei', 'Initials': 'K', 'LastName': 'Xu', 'Affiliation': 'Division of Respiratory Virus Vaccines, National Institutes for Food and Drug Control, Beijing 102629, China.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Tang', 'Affiliation': 'Clinical Trials Assessment Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.'}, {'ForeName': 'Xiaohui', 'Initials': 'X', 'LastName': 'Tian', 'Affiliation': 'Clinical Research Department, Sinovac Biotech Co., LTD., Beijing 100085, China.'}, {'ForeName': 'Jialei', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': 'Clinical Trials Assessment Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.'}, {'ForeName': 'Tuantuan', 'Initials': 'T', 'LastName': 'Yang', 'Affiliation': 'Clinical Research Department, Sinovac Biotech Co., LTD., Beijing 100085, China.'}, {'ForeName': 'Changgui', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Division of Respiratory Virus Vaccines, National Institutes for Food and Drug Control, Beijing 102629, China. Electronic address: changguili@aliyun.com.'}, {'ForeName': 'Yuemei', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Clinical Trials Assessment Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China. Electronic address: 993832717@qq.com.'}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Zeng', 'Affiliation': 'Clinical Research Department, Sinovac Biotech Co., LTD., Beijing 100085, China. Electronic address: zengg@sinovac.com.'}]",Vaccine,['10.1016/j.vaccine.2020.06.071'] 1910,32714385,Increased Accuracy of Emotion Recognition in Individuals with Autism-Like Traits after Five Days of Magnetic Stimulations.,"Individuals with autism-like traits (ALT) belong to a subclinical group with similar social deficits as autism spectrum disorders (ASD). Their main social deficits include atypical eye contact and difficulty in understanding facial expressions, both of which are associated with an abnormality of the right posterior superior temporal sulcus (rpSTS). It is still undetermined whether it is possible to improve the social function of ALT individuals through noninvasive neural modulation. To this end, we randomly assigned ALT individuals into the real ( n = 16) and sham ( n = 16) stimulation groups. All subjects received five consecutive days of intermittent theta burst stimulation (iTBS) on the rpSTS. Eye tracking data and functional magnetic resonance imaging (fMRI) data were acquired on the first and sixth days. The real group showed significant improvement in emotion recognition accuracy after iTBS, but the change was not significantly larger than that in the sham group. Resting-state functional connectivity (rsFC) between the rpSTS and the left cerebellum significantly decreased in the real group than the sham group after iTBS. At baseline, rsFC in the left cerebellum was negatively correlated with emotion recognition accuracy. Our findings indicated that iTBS of the rpSTS could improve emotion perception of ALT individuals by modulating associated neural networks. This stimulation protocol could be a vital therapeutic strategy for the treatment of ASD.",2020,Resting-state functional connectivity (rsFC) between the rpSTS and the left cerebellum significantly decreased in the real group than the sham group after iTBS.,"['Individuals with Autism', 'Individuals with autism-like traits (ALT) belong to a subclinical group with similar social deficits as autism spectrum disorders (ASD']",['intermittent theta burst stimulation (iTBS'],"['Resting-state functional connectivity (rsFC', 'emotion perception', 'Accuracy of Emotion Recognition', 'emotion recognition accuracy']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}, {'cui': 'C0205211', 'cui_str': 'Subclinical'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}]",,0.0515315,Resting-state functional connectivity (rsFC) between the rpSTS and the left cerebellum significantly decreased in the real group than the sham group after iTBS.,"[{'ForeName': 'Pingping', 'Initials': 'P', 'LastName': 'Liu', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}, {'ForeName': 'Guixian', 'Initials': 'G', 'LastName': 'Xiao', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}, {'ForeName': 'Kongliang', 'Initials': 'K', 'LastName': 'He', 'Affiliation': ""The Fourth People's Hospital of Hefei, Hefei 230000, China.""}, {'ForeName': 'Long', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}, {'ForeName': 'Xinqi', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}, {'ForeName': 'Dandan', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}, {'ForeName': 'Chunyan', 'Initials': 'C', 'LastName': 'Zhu', 'Affiliation': 'Anhui Province Key Laboratory of Cognition and Neuropsychiatric Disorders, Hefei 230032, China.'}, {'ForeName': 'Yanghua', 'Initials': 'Y', 'LastName': 'Tian', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}, {'ForeName': 'Panpan', 'Initials': 'P', 'LastName': 'Hu', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}, {'ForeName': 'Bensheng', 'Initials': 'B', 'LastName': 'Qiu', 'Affiliation': 'Centers for Biomedical Engineering, University of Science and Technology of China, Hefei 230000, China.'}, {'ForeName': 'Gong-Jun', 'Initials': 'GJ', 'LastName': 'Ji', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}]",Neural plasticity,['10.1155/2020/9857987'] 1911,32717350,A sequential multiple assignment randomized trial (SMART) protocol for empirically developing an adaptive preventive intervention for college student drinking reduction.,"College student alcohol use and associated negative consequences are clear public health problems with consequences including damage to self, others, and institutions. This paper describes the protocol of a research study designed to answer a number of important questions in the development of an adaptive preventive intervention (API) to reduce high-risk drinking among first-year college students. The API is designed to educate students and to motivate heavy-drinking college students to engage in existing resources to support reducing high-risk alcohol use, by leveraging technology-based intervention modalities. The primary outcome is a reduction in binge drinking, with secondary outcomes of reducing negative alcohol-related consequences and increasing health services utilization. Adaptive preventive interventions have the potential to reduce the acute and long-term negative health consequences of young adult alcohol use.",2020,"The primary outcome is a reduction in binge drinking, with secondary outcomes of reducing negative alcohol-related consequences and increasing health services utilization.","['college student drinking reduction', 'first-year college students']",['adaptive preventive intervention (API'],"['reduction in binge drinking, with secondary outcomes of reducing negative alcohol-related consequences and increasing health services utilization']","[{'cui': 'C4042862', 'cui_str': 'Alcohol Drinking, College Students'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0556346', 'cui_str': 'Drinking binge'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0686907', 'cui_str': 'Consequence of'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0030672', 'cui_str': 'Health Care Utilization'}]",,0.0187936,"The primary outcome is a reduction in binge drinking, with secondary outcomes of reducing negative alcohol-related consequences and increasing health services utilization.","[{'ForeName': 'Megan E', 'Initials': 'ME', 'LastName': 'Patrick', 'Affiliation': ""Institute for Translational Research in Children's Mental Health, University of Minnesota, 1100 Washington Avenue South, Suite 101, Minneapolis, MN 55415, USA. Electronic address: mpatrick@umn.edu.""}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Boatman', 'Affiliation': 'Division of Biostatistics, University of Minnesota, 420 Delaware Street Southeast, MMC 303 Mayo, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Morrell', 'Affiliation': ""Institute for Translational Research in Children's Mental Health, University of Minnesota, 1100 Washington Avenue South, Suite 101, Minneapolis, MN 55415, USA.""}, {'ForeName': 'Anna C', 'Initials': 'AC', 'LastName': 'Wagner', 'Affiliation': ""Institute for Translational Research in Children's Mental Health, University of Minnesota, 1100 Washington Avenue South, Suite 101, Minneapolis, MN 55415, USA.""}, {'ForeName': 'Grace R', 'Initials': 'GR', 'LastName': 'Lyden', 'Affiliation': 'Division of Biostatistics, University of Minnesota, 420 Delaware Street Southeast, MMC 303 Mayo, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Inbal', 'Initials': 'I', 'LastName': 'Nahum-Shani', 'Affiliation': 'Institute for Social Research, University of Michigan, P.O. Box 1248, 426 Thompson Street, Ann Arbor, MI 48106, USA.'}, {'ForeName': 'Cheryl A', 'Initials': 'CA', 'LastName': 'King', 'Affiliation': 'Department of Psychiatry, University of Michigan, 4250 Plymouth Road, Room 2129, Ann Arbor, MI 48109, USA.'}, {'ForeName': 'Erin E', 'Initials': 'EE', 'LastName': 'Bonar', 'Affiliation': 'Department of Psychiatry, University of Michigan, 4250 Plymouth Road, Room 2129, Ann Arbor, MI 48109, USA; Injury Prevention Center, University of Michigan, 2800 Plymouth Road, NCRC Building 10, Ann Arbor, MI 48109, USA.'}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Lee', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Center for the Study of Health and Risk Behaviors, University of Washington, 1100 Northeast 45(th) Street, Suite 300, Seattle, WA 98105, USA.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Larimer', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Center for the Study of Health and Risk Behaviors, University of Washington, 1100 Northeast 45(th) Street, Suite 300, Seattle, WA 98105, USA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Vock', 'Affiliation': 'Division of Biostatistics, University of Minnesota, 420 Delaware Street Southeast, MMC 303 Mayo, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Almirall', 'Affiliation': 'Institute for Social Research, University of Michigan, P.O. Box 1248, 426 Thompson Street, Ann Arbor, MI 48106, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106089'] 1912,32717448,"Analgesic efficacy of ultrasound guided bilateral transversus thoracis muscle plane block in pediatric cardiac surgery: a randomized, double-blind, controlled study.","STUDY OBJECTIVE Adequate perioperative pain control in children undergoing cardiac surgery is mandatory. Intravenous opioids and neuraxial anesthetic techniques have been used but didn't gained any popularity. The aim of the current study was to evaluate the analgesic efficacy of transversus thoracis plane (TTP) block in pediatric cardiac surgery. DESIGN Superiority, randomized, double-blind, controlled study. SETTING Intraoperative and postoperative in intensive care unit (ICU), Mansoura university children hospital, Egypt. PATIENTS Eighty pediatric patients aged 2-12 years, undergoing cardiac surgery via median sternotomy, were randomly allocated into 2 equal groups, the control group and TTP block group. INTERVENTIONS Controlled group received only fentanyl for perioperative analgesia, while TTP block was performed in the intervention group (TTP group). MEASUREMENTS The primary outcome measure was the total dose of fentanyl in the first postoperative 24 h after extubation, while the secondary outcome measures were postoperative pain score, intraoperative fentanyl consumption, time to extubation and ICU length of stay. MAIN RESULTS During the first postoperative 24 h, total fentanyl consumption was significantly lower (P < 0.05) in the TTP block group (9.892 ± 3.397 μg/kg) than the control group (18.500 ± 3.401 μg/kg) and modified objective pain score was significantly (P < 0.05) lower in TTP block group than the control group all over the time. Total intraoperative fentanyl requirement was significantly (P < 0.05) lower in TTP block group (8.27 ± 1.170 μg/kg) than the control group (13.72 ± 1.186 μg/kg). CONCLUSION The use of TTP block decreased perioperative fentanyl consumption and reduced postoperative pain intensity.",2020,"Total intraoperative fentanyl requirement was significantly (P < 0.05) lower in TTP block group (8.27 ± 1.170 μg/kg) than the control group (13.72 ± 1.186 μg/kg). ","['children undergoing cardiac surgery', 'Intraoperative and postoperative in intensive care unit (ICU), Mansoura university children hospital, Egypt', 'Eighty pediatric patients aged 2-12\xa0years, undergoing cardiac surgery via median sternotomy', 'pediatric cardiac surgery']","['TTP block', 'transversus thoracis plane (TTP) block', 'fentanyl for perioperative analgesia, while TTP block was performed in the intervention group (TTP group', 'control group and TTP block group', 'ultrasound guided bilateral transversus thoracis muscle plane block']","['postoperative pain intensity', 'modified objective pain score', 'perioperative fentanyl consumption', 'Analgesic efficacy', 'analgesic efficacy', 'total fentanyl consumption', 'Total intraoperative fentanyl requirement', 'postoperative pain score, intraoperative fentanyl consumption, time to extubation and ICU length of stay', 'total dose of fentanyl in the first postoperative 24\xa0h after extubation']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0013715', 'cui_str': 'Egypt'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1282959', 'cui_str': 'Median sternotomy'}]","[{'cui': 'C1744608', 'cui_str': 'Structure of transverse thoracis muscle'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C1096288', 'cui_str': 'Perioperative analgesia'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}]","[{'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]",80.0,0.408484,"Total intraoperative fentanyl requirement was significantly (P < 0.05) lower in TTP block group (8.27 ± 1.170 μg/kg) than the control group (13.72 ± 1.186 μg/kg). ","[{'ForeName': 'Ibrahim I', 'Initials': 'II', 'LastName': 'Abdelbaser', 'Affiliation': 'Department of Anesthesiology and Surgical Intensive Care, Faculty of Medicine, Mansoura University, 2 El-Gomhouria St, Mansoura 35516, Egypt. Electronic address: ibraheem2005@mans.edu.eg.'}, {'ForeName': 'Nabil A', 'Initials': 'NA', 'LastName': 'Mageed', 'Affiliation': 'Department of Anesthesiology and Surgical Intensive Care, Faculty of Medicine, Mansoura University, 2 El-Gomhouria St, Mansoura 35516, Egypt.'}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2020.110002'] 1913,32717627,Does a Facebook-enhanced Mindful Self-Compassion intervention improve body image? An evaluation study.,"This study evaluates a brief intervention aimed at improving body image. The intervention comprised a Mindful Self-Compassion workshop complemented by a group discussion on Facebook. Young women (M age = 18.31), screened for body concerns, were allocated by university campus to a 50-minute workshop intervention (n = 42) or a waitlist control (n = 34). Following the workshop, participants in the intervention group utilized self-compassion techniques when experiencing appearance distress and posted about their experiences on a private Facebook group three times per week for two weeks. Findings showed that, relative to control, the intervention group experienced lower upward appearance comparison, social appearance anxiety, body dissatisfaction, and drive for thinness, and higher body appreciation and self-compassion, at posttest and 1-month follow-up. All effects, except those for body dissatisfaction, were held at 3-month follow-up. Additionally, common humanity predicted gains in body appreciation from pretest to posttest. The Mindful Self-Compassion intervention involving a Facebook group may have resonated with young women as it allowed them to share moments of self-compassionate body image experiences in a private and supportive environment.",2020,"Findings showed that, relative to control, the intervention group experienced lower upward appearance comparison, social appearance anxiety, body dissatisfaction, and drive for thinness, and higher body appreciation and self-compassion, at posttest and 1-month follow-up.","['Young women (M age = 18.31), screened for body concerns, were allocated by university campus to a']","['Facebook-enhanced Mindful Self-Compassion intervention', 'Mindful Self-Compassion workshop complemented by a group discussion on Facebook', '50-minute workshop intervention', 'waitlist control']","['lower upward appearance comparison, social appearance anxiety, body dissatisfaction, and drive for thinness, and higher body appreciation and self-compassion']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0009498', 'cui_str': 'Complement'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1282911', 'cui_str': 'Upward'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C2732632', 'cui_str': 'Dissatisfaction with body image'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0039870', 'cui_str': 'Thin build'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}]",,0.0146737,"Findings showed that, relative to control, the intervention group experienced lower upward appearance comparison, social appearance anxiety, body dissatisfaction, and drive for thinness, and higher body appreciation and self-compassion, at posttest and 1-month follow-up.","[{'ForeName': 'Veya', 'Initials': 'V', 'LastName': 'Seekis', 'Affiliation': 'School of Applied Psychology, Griffith University, Gold Coast, Queensland, Australia. Electronic address: v.seekis@griffith.edu.au.'}, {'ForeName': 'Graham L', 'Initials': 'GL', 'LastName': 'Bradley', 'Affiliation': 'School of Applied Psychology, Griffith University, Gold Coast, Queensland, Australia. Electronic address: g.bradley@griffith.edu.au.'}, {'ForeName': 'Amanda L', 'Initials': 'AL', 'LastName': 'Duffy', 'Affiliation': 'School of Applied Psychology, Griffith University, Gold Coast, Queensland, Australia. Electronic address: a.duffy@griffith.edu.au.'}]",Body image,['10.1016/j.bodyim.2020.07.006'] 1914,32717684,"Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes ✰ .","BACKGROUND Injectable disease-modifying therapies (iDMTs) are often used as first-line treatments for relapsing multiple sclerosis. Fingolimod is frequently used following treatment with iDMTs. Whether prior iDMT treatment impacts the effectiveness of subsequent fingolimod therapy is unclear. Here, we assessed switching from iDMTs to fingolimod, and the impact of treatment history on fingolimod escalation using data from the 12-month 'Prospective, Randomized, active-controlled, open-label study to Evaluate patient retention on Fingolimod versus approved first-line disease-modifying thErapies in adults with Relapsing-remitting Multiple Sclerosis' (PREFERMS). The study design and results at the end of randomized treatment (EoRT) in PREFERMS have been published. METHODS Both treatment-naïve patients and those who had previously received an iDMT were eligible for enrolment in PREFERMS, and one treatment switch was permitted on study. Pre-specified exploratory analyses compared outcomes in those randomized to fingolimod or to an iDMT at end of study (EoS), which included time spent on randomized and on switch treatment. Post hoc exploratory analyses (unadjusted for multiplicity owing to the large number of comparisons) among patients randomized to an iDMT who switched to fingolimod, compared outcomes longitudinally before (EoRT) and after (EoS) switching, and compared outcomes at EoRT and EoS among subgroups stratified by iDMT-treatment history. Outcomes included brain volume, various measures of gadolinium-enhancing [Gd+] lesion counts, annualized relapse rate (ARR), Symbol Digit Modalities Test (SDMT) score, patient-reported treatment satisfaction using the Medication Satisfaction Questionnaire (MSQ) and adverse event (AE) rates. RESULTS At EoS, 255 of 439 patients randomized to an iDMT had switched to fingolimod and 27 of 436 patients randomized to fingolimod had switched to an iDMT. By EoS, 44.2% of total treatment exposure in the iDMT group was to fingolimod and the mean time spent on fingolimod in this group was 220 days (approximately 7 months). Outcomes in the fingolimod group at EoS (brain volume, changes in Gd+ lesion counts, ARR, oral SDMT score and MSQ score) were similar to those seen at EoRT, but in the iDMT group these outcomes were more favorable at EoS than at EoRT and were similar to rates seen in the fingolimod group. Among patients who switched from iDMT to fingolimod, there were longitudinal improvements in ARR (EoRT, 0.3 [95% confidence interval (CI), 0.2-0.4]; EoS, 0.2 [0.1-0.3]; odds ratio, 0.5 [0.3-0.9]) and in treatment satisfaction (proportion of patients with MSQ > 5; EoRT, 67.4%; EoS, 90.4%; odds ratio, 5.7 [95% CI, 3.4-9.4]) after fingolimod treatment, and changes in brain volume, Gd+ lesion count, and AEs or AEs causing discontinuation were also more favorable at EoS than at EoRT. In all patient groups stratified by iDMT-treatment history, differences in outcomes narrowed or disappeared after fingolimod treatment. CONCLUSION These analyses indicate that patients in PREFERMS had improved outcomes within months of switching to fingolimod from an iDMT and that improvements occurred irrespective of the number of iDMTs previously administered. These data provide a unique opportunity to explore clinical, radiological and safety outcomes associated with a range of clinically relevant treatment pathways.",2020,"In all patient groups stratified by iDMT-treatment history, differences in outcomes narrowed or disappeared after fingolimod treatment. ","['At EoS, 255 of 439 patients randomized to an iDMT had switched to fingolimod and 27 of 436 patients randomized to', 'Both treatment-naïve patients and those who had previously received an iDMT were eligible for enrolment in PREFERMS, and one treatment switch was permitted on study', ""adults with Relapsing-remitting Multiple Sclerosis' (PREFERMS""]","['fingolimod had switched to an iDMT', 'Fingolimod versus approved first-line disease-modifying thErapies']","['EoS (brain volume, changes in Gd+ lesion counts, ARR, oral SDMT score and MSQ score', 'mean time spent on fingolimod', 'brain volume, various measures of gadolinium-enhancing [Gd+] lesion counts, annualized relapse rate (ARR), Symbol Digit Modalities Test (SDMT) score, patient-reported treatment satisfaction using the Medication Satisfaction Questionnaire (MSQ) and adverse event (AE) rates', 'longitudinal improvements in ARR', 'brain volume, Gd+ lesion count, and AEs or AEs causing discontinuation']","[{'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1699926', 'cui_str': 'fingolimod'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0023636', 'cui_str': 'Licenses'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0751967', 'cui_str': 'Relapsing remitting multiple sclerosis'}]","[{'cui': 'C1699926', 'cui_str': 'fingolimod'}, {'cui': 'C0205540', 'cui_str': 'Approved'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1699926', 'cui_str': 'fingolimod'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0016911', 'cui_str': 'Gadolinium'}, {'cui': 'C0451522', 'cui_str': 'Symbol digit modalities test'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}]",439.0,0.0609136,"In all patient groups stratified by iDMT-treatment history, differences in outcomes narrowed or disappeared after fingolimod treatment. ","[{'ForeName': 'Samuel F', 'Initials': 'SF', 'LastName': 'Hunter', 'Affiliation': 'Advanced Neurosciences Institute, 101 Forrest Crossing Blvd. Suite 103, Franklin, TN 37064, United States. Electronic address: sfhunter@neurosci.us.'}, {'ForeName': 'Florian P', 'Initials': 'FP', 'LastName': 'Thomas', 'Affiliation': 'Hackensack Meridian School of Medicine at Seton Hall University, South Orange, and Hackensack University Medical Center, Hackensack, NJ, United States. Electronic address: florian.thomas@hackensackmeridian.org.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Cascione', 'Affiliation': 'Tampa Neurology Associates, Tampa, FL, United States. Electronic address: me@markcascione.com.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Williams', 'Affiliation': 'Oxford PharmaGenesis, Oxford, United Kingdom. Electronic address: ian.williams@pharmagenesis.com.'}, {'ForeName': 'Xiangyi', 'Initials': 'X', 'LastName': 'Meng', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States. Electronic address: xiangyi.meng@novartis.com.'}, {'ForeName': 'Lesley', 'Initials': 'L', 'LastName': 'Schofield', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States. Electronic address: lesley.schofield@novartis.com.'}, {'ForeName': 'Jamie L', 'Initials': 'JL', 'LastName': 'Weiss', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States. Electronic address: jamie.weiss@novartis.com.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Tenenbaum', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States. Electronic address: nadia.tenebaum@novartis.com.'}, {'ForeName': 'Bruce A C', 'Initials': 'BAC', 'LastName': 'Cree', 'Affiliation': 'UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, United States. Electronic address: bruce.cree@ucsf.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Multiple sclerosis and related disorders,['10.1016/j.msard.2020.102346'] 1915,32721578,The home air in agriculture pediatric intervention (HAPI) trial: Rationale and methods.,"BACKGROUND Data addressing air quality effects on children with asthma in rural U.S. communities are rare. Our community engaged research partnership previously demonstrated associations between neighborhood NH 3 and ambient PM 2.5 and asthma in the agricultural lower Yakima Valley of Washington. As a next step, the partnership desired an intervention approach to address concerns about pediatric asthma in this largely Latino immigrant, farm worker community. OBJECTIVE The Home Air in Agriculture Pediatric Intervention (HAPI) sought to examine the effectiveness of enrichment of an existing asthma education program with portable high-efficiency particulate air (HEPA) cleaners designed to reduce PM 2.5 and NH 3. We investigated the effect of this enriched approach on these exposures and asthma health measures. DESIGN We randomized children with poorly controlled asthma to a control arm (current asthma education program) or an intervention arm (current asthma education program + placement of two indoor air cleaners in the family's home). Outcomes included (1) 14-day integrated samples of indoor air contaminants (PM 2.5 and NH 3 ) at baseline and one-year follow-up and (2) child asthma health metrics at baseline, midpoint (4-6 months) and one-year follow-up. These included the Asthma Control Test, symptoms days, clinical utilization, oral corticosteroid use, pulmonary function, fractional exhaled nitric oxide, and urinary leukotriene E 4 concentration. DISCUSSION To our knowledge, this is the first randomized HEPA cleaner intervention designed to assess NH 3 as well as PM 2.5 and to evaluate health outcomes of children with asthma in an agricultural region.",2020,"OBJECTIVE The Home Air in Agriculture Pediatric Intervention (HAPI) sought to examine the effectiveness of enrichment of an existing asthma education program with portable high-efficiency particulate air (HEPA) cleaners designed to reduce PM 2.5 and NH 3. ","['children with asthma in rural U.S. communities', 'children with asthma in an agricultural region', 'children with poorly controlled asthma to a control arm (current asthma education program) or an']","[""intervention arm (current asthma education program + placement of two indoor air cleaners in the family's home""]","['14-day integrated samples of indoor air contaminants (PM 2.5 and NH 3 ) at baseline and one-year follow-up and (2) child asthma health metrics', 'Asthma Control Test, symptoms days, clinical utilization, oral corticosteroid use, pulmonary function, fractional exhaled nitric oxide, and urinary leukotriene E 4 concentration']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C1679754', 'cui_str': 'Asthma education'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C1679754', 'cui_str': 'Asthma education'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0789995', 'cui_str': 'Air cleaner'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0337099', 'cui_str': 'Air contaminant'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C4704932', 'cui_str': 'Health Metrics'}, {'cui': 'C4048375', 'cui_str': 'Asthma control test'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C4523905', 'cui_str': 'Fractional exhaled nitric oxide'}, {'cui': 'C0125644', 'cui_str': 'LTE4'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",,0.0221442,"OBJECTIVE The Home Air in Agriculture Pediatric Intervention (HAPI) sought to examine the effectiveness of enrichment of an existing asthma education program with portable high-efficiency particulate air (HEPA) cleaners designed to reduce PM 2.5 and NH 3. ","[{'ForeName': 'Erin E', 'Initials': 'EE', 'LastName': 'Masterson', 'Affiliation': 'Department of Environmental & Occupational Health Sciences, University of Washington, Seattle, WA, United States of America. Electronic address: emaster@uw.edu.'}, {'ForeName': 'Lisa B', 'Initials': 'LB', 'LastName': 'Younglove', 'Affiliation': 'Department of Environmental & Occupational Health Sciences, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Perez', 'Affiliation': ""Yakima Valley Farm Worker's Clinic, Toppenish, WA, United States of America.""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Torres', 'Affiliation': 'Northwest Communities Education Center, Radio KDNA, Granger, WA, United States of America.'}, {'ForeName': 'Jennifer E', 'Initials': 'JE', 'LastName': 'Krenz', 'Affiliation': 'Department of Environmental & Occupational Health Sciences, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Maria I', 'Initials': 'MI', 'LastName': 'Tchong French', 'Affiliation': 'Department of Environmental & Occupational Health Sciences, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Riederer', 'Affiliation': 'Department of Environmental & Occupational Health Sciences, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Sampson', 'Affiliation': 'Department of Statistics, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Nervana', 'Initials': 'N', 'LastName': 'Metwali', 'Affiliation': 'Department of Occupational and Environmental Health, University of Iowa, Iowa City, IA, United States of America.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Min', 'Affiliation': 'Department of Environmental & Occupational Health Sciences, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Karen L', 'Initials': 'KL', 'LastName': 'Jansen', 'Affiliation': 'Department of Environmental & Occupational Health Sciences, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Gino', 'Initials': 'G', 'LastName': 'Aisenberg', 'Affiliation': 'School of Social Work, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Ryan S', 'Initials': 'RS', 'LastName': 'Babadi', 'Affiliation': 'Department of Environmental & Occupational Health Sciences, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Stephanie A', 'Initials': 'SA', 'LastName': 'Farquhar', 'Affiliation': 'Department of Environmental & Occupational Health Sciences, University of Washington, Seattle, WA, United States of America; Department of Health Services, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Peter S', 'Initials': 'PS', 'LastName': 'Thorne', 'Affiliation': 'Department of Occupational and Environmental Health, University of Iowa, Iowa City, IA, United States of America.'}, {'ForeName': 'Catherine J', 'Initials': 'CJ', 'LastName': 'Karr', 'Affiliation': 'Department of Environmental & Occupational Health Sciences, University of Washington, Seattle, WA, United States of America; Department of Pediatrics, University of Washington, Seattle, WA, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106085'] 1916,32721655,Do ethics classes influence student behavior? Case study: Teaching the ethics of eating meat.,"Do university ethics classes influence students' real-world moral choices? We aimed to conduct the first controlled study of the effects of ordinary philosophical ethics classes on real-world moral choices, using non-self-report, non-laboratory behavior as the dependent measure. We assigned 1332 students in four large philosophy classes to either an experimental group on the ethics of eating meat or a control group on the ethics of charitable giving. Students in each group read a philosophy article on their assigned topic and optionally viewed a related video, then met with teaching assistants for 50-minute group discussion sections. They expressed their opinions about meat ethics and charitable giving in a follow-up questionnaire (1032 respondents after exclusions). We obtained 13,642 food purchase receipts from campus restaurants for 495 of the students, before and after the intervention. Purchase of meat products declined in the experimental group (52% of purchases of at least $4.99 contained meat before the intervention, compared to 45% after) but remained the same in the control group (52% both before and after). Ethical opinion also differed, with 43% of students in the experimental group agreeing that eating the meat of factory farmed animals is unethical compared to 29% in the control group. We also attempted to measure food choice using vouchers, but voucher redemption rates were low and no effect was statistically detectable. It remains unclear what aspect of instruction influenced behavior.",2020,"Purchase of meat products declined in the experimental group (52% of purchases of at least $4.99 contained meat before the intervention, compared to 45% after) but remained the same in the control group (52% both before and after).",['1332 students in four large philosophy classes to either an experimental group on the ethics of eating meat or a control group on the ethics of charitable giving'],['ordinary philosophical ethics classes'],['Purchase of meat products'],"[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0031534', 'cui_str': 'Philosophy'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0015000', 'cui_str': 'Ethics'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0025017', 'cui_str': 'Meat'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0015000', 'cui_str': 'Ethics'}, {'cui': 'C0456387', 'cui_str': 'Class'}]","[{'cui': 'C0025018', 'cui_str': 'Meat products'}]",1332.0,0.0290026,"Purchase of meat products declined in the experimental group (52% of purchases of at least $4.99 contained meat before the intervention, compared to 45% after) but remained the same in the control group (52% both before and after).","[{'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Schwitzgebel', 'Affiliation': 'University of California at Riverside, USA. Electronic address: eschwitz@ucr.edu.'}, {'ForeName': 'Bradford', 'Initials': 'B', 'LastName': 'Cokelet', 'Affiliation': 'University of Kansas, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Singer', 'Affiliation': 'Princeton University, USA.'}]",Cognition,['10.1016/j.cognition.2020.104397'] 1917,32721815,Effect of intranasal oxytocin administration on self-other distinction: Modulations by psychological distance and gender.,"Preliminary evidence indicates that intranasal oxytocin (OT) administration modulates one's ability to distinguish oneself from others (i.e., self-other distinction). However, previous findings on this topic are contradictory. The current study addressed this issue by (i) using a novel perceptual matching task examining self-other distinction compared to both close and distant others, and (ii) tentatively exploring potential modulations by gender. In a double-blind, placebo-controlled, randomized OT administration study, 100 participants (50 males and 50 females) were randomized to receive intranasal spray of 24 IU OT or placebo (PL). Afterwards, participants completed a geometry perceptual matching task in which different shapes were paired to the self, a friend, or a stranger. Participants were then asked to judge whether each pair of shapes and labels was correctly matched. The results revealed that compared to PL administration, OT facilitated distinction between the self and a friend in males but not in females. These findings provide insights for debates on the role of OT in self-other distinction by revealing modulations by psychological distance and gender, which have implications for the potential clinical applications of OT.",2020,"The results revealed that compared to PL administration, OT facilitated distinction between the self and a friend in males but not in females.",['100 participants (50 males and 50 females'],"['intranasal spray of 24 IU OT or placebo (PL', 'intranasal oxytocin (OT', 'intranasal oxytocin', 'placebo']",[],"[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],100.0,0.104773,"The results revealed that compared to PL administration, OT facilitated distinction between the self and a friend in males but not in females.","[{'ForeName': 'Chunliang', 'Initials': 'C', 'LastName': 'Feng', 'Affiliation': 'Key Laboratory of Brain, Cognition and Education Sciences, Ministry of Education, China; School of Psychology, Center for Studies of Psychological Application, and Guangdong Key Laboratory of Mental Health and Cognitive Science, South China Normal University, China. Electronic address: chunliang.feng@m.scnu.edu.cn.'}, {'ForeName': 'Xinmei', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'Center of Brain Disorder and Cognitive Sciences, College of Psychology and Sociology, Shenzhen Key Laboratory of Affective and Social Cognitive Science, Shenzhen University, Center for Emotion and Brain, Shenzhen Institute of Neuroscience, Shenzhen, China.'}, {'ForeName': 'Xiangru', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Institute of Cognition, Brain and Health, Institute of Psychology and Behavior, Henan University, Kaifeng, China.'}, {'ForeName': 'Ruida', 'Initials': 'R', 'LastName': 'Zhu', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Shangfeng', 'Initials': 'S', 'LastName': 'Han', 'Affiliation': 'Center of Brain Disorder and Cognitive Sciences, College of Psychology and Sociology, Shenzhen Key Laboratory of Affective and Social Cognitive Science, Shenzhen University, Center for Emotion and Brain, Shenzhen Institute of Neuroscience, Shenzhen, China.'}, {'ForeName': 'Yue-Jia', 'Initials': 'YJ', 'LastName': 'Luo', 'Affiliation': 'Center of Brain Disorder and Cognitive Sciences, College of Psychology and Sociology, Shenzhen Key Laboratory of Affective and Social Cognitive Science, Shenzhen University, Center for Emotion and Brain, Shenzhen Institute of Neuroscience, Shenzhen, China. Electronic address: luoyj@szu.edu.cn.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2020.104804'] 1918,32721845,Implementation of magnesium sulphate as an adjunct to multimodal analgesic approach for perioperative pain control in lumbar laminectomy surgery: A randomized placebo-controlled clinical trial.,"OBJECTIVE To investigate the effect of systemic intraoperative administration of magnesium sulphate when used in the context of a multimodal pain management plan on analgesics consumption and pain scores, and perioperative outcomes after lumbar laminectomy surgery. METHODS Seventy-four patients undergoing lumbar laminectomy were enrolled in this randomized, double-blind, placebo-controlled trial. Participants were randomly allocated to receive magnesium (20 mg/kg iv given as bolus before anesthesia induction followed by 20 mg/kg/h civ until surgery completion) or saline. Hemodynamic variables and desflurane consumption were noted at predefined time-intervals intraoperatively. Primary outcome was postoperative cumulative analgesic consumption over 24 h, while pain intensity (assessed by Visual Analogue Scale [VAS] at 1, 2, 4, 6 and 24 h), intraoperative hemodynamics and opioid requirements, recovery profile, time to first analgesic request, and adverse effects constituted secondary end-points. RESULTS Demographics, surgery duration, desflurane requirements, and recovery profile were comparable between groups. Magnesium attenuated hemodynamic response during incision and emergence from anesthesia. Postoperative analgesics consumption in morphine iv equivalents (mean difference -9.24 [95 %CI -13.31, -5.17] mg; p = 0.001) and VAS scores at all-time points of assessment were lower in magnesium group; this effect peaked at 4 h (mean difference -2.15 [95 %CI -3.21,-1.09; p = 0.001]. Magnesium reduced intraoperative remifentanil consumption and prolonged the time-interval to first rescue analgesia (p < 0.01). No notable adverse effects were recorded. CONCLUSION It occurs that magnesium infusion during lumbar laminectomy surgery potentiates perioperative analgesia and reduces analgesic requirements up to 24 h postoperatively. No profound adverse effect on either intraoperative hemodynamics or any other clinically relevant endpoints becomes evident.",2020,Magnesium reduced intraoperative remifentanil consumption and prolonged the time-interval to first rescue analgesia (p < 0.01).,"['lumbar laminectomy surgery', 'Seventy-four patients undergoing lumbar laminectomy']","['Magnesium', 'placebo', 'magnesium (20\u202fmg/kg iv given as bolus before anesthesia induction followed by 20\u202fmg/kg/h civ until surgery completion) or saline', 'magnesium sulphate', 'magnesium', 'morphine']","['adverse effects', 'time-interval to first rescue analgesia', 'intraoperative remifentanil consumption', 'analgesics consumption and pain scores, and perioperative outcomes', 'postoperative cumulative analgesic consumption over 24\u202fh, while pain intensity (assessed by Visual Analogue Scale [VAS] at 1, 2, 4, 6 and 24\u202fh), intraoperative hemodynamics and opioid requirements, recovery profile, time to first analgesic request, and adverse effects constituted secondary end-points', 'analgesic requirements', 'hemodynamic response', 'Postoperative analgesics consumption', 'Hemodynamic variables and desflurane consumption', 'Demographics, surgery duration, desflurane requirements, and recovery profile', 'VAS scores']","[{'cui': 'C1112614', 'cui_str': 'Lumbar laminectomy'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C4517867', 'cui_str': '74'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0473960', 'cui_str': 'Induction of general anesthesia'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C1320755', 'cui_str': 'mg/kg/hr'}, {'cui': 'C0022326', 'cui_str': 'Ivory Coast'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0024480', 'cui_str': 'Magnesium Sulfate'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0420259', 'cui_str': 'Analgesics requested'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0063252', 'cui_str': 'desflurane'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",74.0,0.791883,Magnesium reduced intraoperative remifentanil consumption and prolonged the time-interval to first rescue analgesia (p < 0.01).,"[{'ForeName': 'Georgia', 'Initials': 'G', 'LastName': 'Tsaousi', 'Affiliation': 'Department of Anesthesiology and ICU, Aristotle University Thessaloniki, University Campus, 54124, Thessaloniki, Greece. Electronic address: tsaousig@otenet.gr.'}, {'ForeName': 'Anastasia', 'Initials': 'A', 'LastName': 'Nikopoulou', 'Affiliation': 'Department of Anesthesiology and ICU, Aristotle University Thessaloniki, University Campus, 54124, Thessaloniki, Greece. Electronic address: anastasian1991@windowslive.com.'}, {'ForeName': 'Ioakeim', 'Initials': 'I', 'LastName': 'Pezikoglou', 'Affiliation': 'Department of Anesthesiology and ICU, Aristotle University Thessaloniki, University Campus, 54124, Thessaloniki, Greece. Electronic address: makispez@gmail.com.'}, {'ForeName': 'Vasiliki', 'Initials': 'V', 'LastName': 'Birba', 'Affiliation': 'Department of Anesthesiology and ICU, Aristotle University Thessaloniki, University Campus, 54124, Thessaloniki, Greece. Electronic address: bsbvasso@yahoo.gr.'}, {'ForeName': 'Vasilios', 'Initials': 'V', 'LastName': 'Grosomanidis', 'Affiliation': 'Department of Anesthesiology and ICU, Aristotle University Thessaloniki, University Campus, 54124, Thessaloniki, Greece. Electronic address: grosoman@otenet.gr.'}]",Clinical neurology and neurosurgery,['10.1016/j.clineuro.2020.106091'] 1919,32726364,Four weeks of augmented eccentric loading using a novel leg press device improved leg strength in well-trained athletes and professional sprint track cyclists.,"This study assessed the efficacy of strength training using augmented eccentric loading to provoke increases in leg strength in well-trained athletes, and sprint track cyclists, using a novel leg press device. Twelve well-trained athletes were randomly allocated traditional resistance training (TRAD, n = 6), or resistance training using augmented eccentric loading (AEL, n = 6). A further 5 full-time, professional sprint track cyclists from a senior national squad programme also trained with augmented eccentric loading (AEL-ATH) alongside their usual sport-specific training. Participants completed four weeks of twice-weekly resistance training using the leg press exercise. In TRAD the lowering phase of the lift was set relative to concentric strength. In AEL and AEL-ATH the lowering phase was individualised to eccentric strength. Concentric, eccentric, isometric and coupled eccentric-concentric leg press strength, and back squat 1 repetition maximum (1RM), were assessed pre- and post-training. The AEL and AEL-ATH groups performed the eccentric phase with an average 26 ± 4% greater load across the programme. All groups experienced increases in concentric (5%, 7% and 3% for TRAD, AEL & AEL-ATH respectively), eccentric (7%, 11% and 6% for TRAD, AEL & AEL-ATH respectively), and squat 1RM (all p < 0.05), where the AEL-ATH group experienced relatively greater increases (13% vs. 5% in TRAD and AEL, p < 0.01). The TRAD and AEL groups also increased isometric strength (p < 0.05). A four-week period of augmented eccentric loading increased leg strength in well-trained athletes and track cyclists. The eccentric leg press stimulus was well-tolerated, supporting the inclusion of such training in the preparation programmes of athletes.",2020,"All groups experienced increases in concentric (5%, 7% and 3% for TRAD, AEL & AEL-ATH respectively), eccentric (7%, 11% and 6% for TRAD, AEL & AEL-ATH respectively), and squat 1RM (all p < 0.05), where the AEL-ATH group experienced relatively greater increases (13% vs. 5% in TRAD and AEL, p < 0.01).","['Twelve well-trained athletes', 'well-trained athletes and track cyclists', 'well-trained athletes and professional sprint track cyclists']","['strength training', 'augmented eccentric loading', 'resistance training using the leg press exercise', 'traditional resistance training (TRAD, n = 6), or resistance training using augmented eccentric loading (AEL, n = 6']","['concentric', 'Concentric, eccentric, isometric and coupled eccentric-concentric leg press strength, and back squat 1 repetition maximum (1RM', 'leg strength', 'squat 1RM', 'isometric strength']","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0040594', 'cui_str': 'Track'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0023440', 'cui_str': 'Acute myeloid leukemia, M6 type'}]","[{'cui': 'C0439744', 'cui_str': 'Concentric'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0806909', 'cui_str': 'Max'}]",,0.0141622,"All groups experienced increases in concentric (5%, 7% and 3% for TRAD, AEL & AEL-ATH respectively), eccentric (7%, 11% and 6% for TRAD, AEL & AEL-ATH respectively), and squat 1RM (all p < 0.05), where the AEL-ATH group experienced relatively greater increases (13% vs. 5% in TRAD and AEL, p < 0.01).","[{'ForeName': 'Mellissa', 'Initials': 'M', 'LastName': 'Harden', 'Affiliation': 'Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle, United Kingdom.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Wolf', 'Affiliation': 'English Institute of Sport, Manchester, United Kingdom.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Evans', 'Affiliation': 'The Football Association, Burton on Trent, United Kingdom.'}, {'ForeName': 'Kirsty Marie', 'Initials': 'KM', 'LastName': 'Hicks', 'Affiliation': 'Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle, United Kingdom.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Thomas', 'Affiliation': 'Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle, United Kingdom.'}, {'ForeName': 'Glyn', 'Initials': 'G', 'LastName': 'Howatson', 'Affiliation': 'Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle, United Kingdom.'}]",PloS one,['10.1371/journal.pone.0236663'] 1920,32730289,Acute effects of kinesiology tape tension on soleus muscle h-reflex modulations during lying and standing postures.,"Kinesiology tape (KT) has been widely used in the areas of sports and rehabilitation. However, there is no gold standard for the tape tension used during a KT application. The purpose of this study was to examine the effects of KT application with different tension intensities on soleus muscle Hoffmann-reflex (H-reflex) modulation during lying and standing postures. Fifteen healthy university students were tested with 3 tape tension intensities during separate visits with a randomized sequence: tape-on no tension (0KT), moderate (about 50% of the maximal tape tension: (ModKT), and maximal tape tension (MaxKT). During each experimental visit, the H-reflex measurements on the soleus muscle were taken before, during, and after the KT application for both lying and standing postures. The H-wave and M-wave recruitment curves were generated using surface electromyography (EMG). There was a main effect for posture (p = 0.001) for the maximal peak-to-peak amplitude of the H-wave and M-wave (Hmax/Mmax) ratio, showing the depressed Hmax/Mmax ratio during standing, when compared to the lying posture. Even though the tension factor had a large effect (ηp2 = 0.165), different tape tensions showed no significant differential effects for the Hmax/Mmax ratio. The spinal motoneuron excitability was not altered, even during the maximal tension KT application on the soleus muscle. Thus, the tension used during a KT application should not be a concern in terms of modulating the sensorimotor activity ascribed to elastic taping during lying and standing postures.",2020,"There was a main effect for posture (p = 0.001) for the maximal peak-to-peak amplitude of the H-wave and M-wave (Hmax/Mmax) ratio, showing the depressed Hmax/Mmax ratio during standing, when compared to the lying posture.",['Fifteen healthy university students'],"['kinesiology tape tension', '3 tape tension intensities during separate visits with a randomized sequence: tape-on no tension (0KT), moderate (about 50% of the maximal tape tension: (ModKT), and maximal tape tension (MaxKT', 'KT', 'Kinesiology tape (KT']","['spinal motoneuron excitability', 'soleus muscle Hoffmann-reflex (H-reflex) modulation', 'soleus muscle h-reflex modulations', 'maximal peak-to-peak amplitude of the H-wave and M-wave (Hmax/Mmax) ratio']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C0233494', 'cui_str': 'Tension'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0004793', 'cui_str': 'Base sequence'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}]","[{'cui': 'C0026609', 'cui_str': 'Motor neuron'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}, {'cui': 'C0242694', 'cui_str': 'Soleus muscle structure'}, {'cui': 'C0034929', 'cui_str': 'Reflex'}, {'cui': 'C0018447', 'cui_str': 'H-reflex'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.0133263,"There was a main effect for posture (p = 0.001) for the maximal peak-to-peak amplitude of the H-wave and M-wave (Hmax/Mmax) ratio, showing the depressed Hmax/Mmax ratio during standing, when compared to the lying posture.","[{'ForeName': 'Yung-Sheng', 'Initials': 'YS', 'LastName': 'Chen', 'Affiliation': 'Department of Exercise and Health Sciences, University of Taipei, Taipei, Taiwan.'}, {'ForeName': 'Wei-Chin', 'Initials': 'WC', 'LastName': 'Tseng', 'Affiliation': 'Department of Exercise and Health Sciences, University of Taipei, Taipei, Taiwan.'}, {'ForeName': 'Che-Hsiu', 'Initials': 'CH', 'LastName': 'Chen', 'Affiliation': 'Department of Sport Performance, National Taiwan University of Sports, Taichung, Taiwan.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Bezerra', 'Affiliation': 'Escola Superior de Desporto e Lazer, Instituto Politécnico de Viana do Castelo, Melgaço, Portugal.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Ye', 'Affiliation': 'Department of Health, Exercise Science, and Recreation Management, The University of Mississippi, Oxford, Mississippi, United States of America.'}]",PloS one,['10.1371/journal.pone.0236587'] 1921,32731011,The effect of Hatha yoga intervention on students' creative ability.,"There is increasing demand for individual creativity as organizations seek innovative ways to remain relevant. Higher education institutions, particularly business schools, are sensitive to this demand and are constantly in search for innovative ways to enhance the creative ability of their students. Prior studies have shown encouraging results for physical activity-oriented interventions. Building on this research, this study uses Randomized Controlled Trial (RCT) to understand if an acute combinatory intervention, involving both physical and mental exercises embodied in Hatha yoga can improve individual creativity. This study uses 92 MBA student participants to investigate the impact of a 20-minute Hatha yoga session intervention against a short 20-minute case study session for the control group. Creative ability of the participants is operationalized through divergent and convergent thinking, which are then assessed through counter-balanced forms of Guilford Alternate Uses tasks and Remote Associate Test, respectively. The results show that while Hatha yoga significantly improves divergent thinking, the control group shows deterioration in divergent thinking. There is no effect on convergent thinking. These findings lend some support to the executive function hypothesis. The study also finds that prodding a person to be more creative on a routine academic task may not enhance their creative ability.",2020,There is no effect on convergent thinking.,"['92 MBA student participants', ""students' creative ability""]",['Hatha yoga intervention'],"['divergent thinking', 'individual creativity']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0010297', 'cui_str': 'Creative thought'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0010297', 'cui_str': 'Creative thought'}]",92.0,0.0286741,There is no effect on convergent thinking.,"[{'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Bollimbala', 'Affiliation': 'Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India; T A Pai Management Institute, Manipal, Karnataka, 576104, India. Electronic address: ashish@tapmi.edu.in.'}, {'ForeName': 'P S', 'Initials': 'PS', 'LastName': 'James', 'Affiliation': 'IFIM Business School, Bangalore, Karnataka, India.'}, {'ForeName': 'Shirshendu', 'Initials': 'S', 'LastName': 'Ganguli', 'Affiliation': 'T A Pai Management Institute, Manipal, Karnataka, 576104, India. Electronic address: shirshenduganguli@tapmi.edu.in.'}]",Acta psychologica,['10.1016/j.actpsy.2020.103121'] 1922,32731714,Optimization of pathogenetic therapy in patients with chronic obstructive lung disease.,"OBJECTIVE The aim of the study is to increase the effectiveness of the treatment of exacerbation of COPD group B GOLD II with the use of combined therapy of the combined drug PulmoBRIZ containing two components - ambroxol and acetylcysteine and the course of halotherapy. PATIENTS AND METHODS Materials and methods: We observed 60 patients with COPD B, GOLD II. They were divided into two groups: the first - the main (n=30) - patients receiving basic therapy, mucolytic therapy - a combination of Ambroxol and acetylcysteine - 200/30 to 1 tabl. 2 times a day, number 7 days and, from the 3rd day - sessions of halotherapy 1 time per day № 10. The second group, the control group (n=30), followed only basic therapy, did not take mucolytics and halotherapy sessions. RESULTS Results: Patients receiving therapy with the combination of ambroxol and acetylcysteine and halotherapy sessions experienced a significant increase in FEV1 by 8.3% (p <0.05); the Tiffon index was 7.2% (p<0.05), reactive anxiety levels (RA) and manifestations of autonomic dysfunction decreased, whereas in patients in the control group these indicators did not improve significantly. CONCLUSION Conclusions: The proposed complex therapy of COPD patients with the inclusion of the combined drug ambroxol and acetylcysteine and halotherapy sessions contributes to the improvement of the quality of life of patients.",2020,"The second group, the control group (n=30), followed only basic therapy, did not take mucolytics and halotherapy sessions. ","['60 patients with COPD B, GOLD II', 'COPD patients', 'patients with chronic obstructive lung disease']","['followed only basic therapy, did not take mucolytics and halotherapy sessions', 'ambroxol and acetylcysteine and halotherapy sessions', 'acetylcysteine and halotherapy sessions', 'basic therapy, mucolytic therapy - a combination of Ambroxol and acetylcysteine - 200/30 to 1 tabl', 'pathogenetic therapy']","['reactive anxiety levels (RA) and manifestations of autonomic dysfunction', 'Tiffon index', 'FEV1']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0018026', 'cui_str': 'Gold'}]","[{'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0026698', 'cui_str': 'Mucolytic agent'}, {'cui': 'C0002421', 'cui_str': 'Ambroxol'}, {'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}]","[{'cui': 'C0205332', 'cui_str': 'Reactive'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0205319', 'cui_str': 'Manifest'}, {'cui': 'C0013363', 'cui_str': 'Dysautonomia'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}]",60.0,0.0175743,"The second group, the control group (n=30), followed only basic therapy, did not take mucolytics and halotherapy sessions. ","[{'ForeName': 'Mаksym M', 'Initials': 'MM', 'LastName': 'Potyazhenko', 'Affiliation': 'Ukrainian Medical Stomatological Academy, Poltava, Ukraine.'}, {'ForeName': 'Kostiantyn Ye', 'Initials': 'KY', 'LastName': 'Ishcheikin', 'Affiliation': 'Ukrainian Medical Stomatological Academy, Poltava, Ukraine.'}, {'ForeName': 'Tetiana V', 'Initials': 'TV', 'LastName': 'Nastroga', 'Affiliation': 'Ukrainian Medical Stomatological Academy, Poltava, Ukraine.'}, {'ForeName': 'Nina L', 'Initials': 'NL', 'LastName': 'Sokolyuk', 'Affiliation': 'Ukrainian Medical Stomatological Academy, Poltava, Ukraine.'}, {'ForeName': 'Oksana Ye', 'Initials': 'OY', 'LastName': 'Kitura', 'Affiliation': 'Ukrainian Medical Stomatological Academy, Poltava, Ukraine.'}, {'ForeName': 'Inesa M', 'Initials': 'IM', 'LastName': 'Gorodnytska', 'Affiliation': 'Ukrainian Medical Stomatological Academy, Poltava, Ukraine.'}]","Wiadomosci lekarskie (Warsaw, Poland : 1960)",[] 1923,32736460,"[Aortic valve replacement via J-shaped partial upper sternotomy: randomized trial, mid-term results].","OBJECTIVE To evaluate the effectiveness and safety of aortic valve replacement through upper partial J-shaped sternotomy compared to conventional sternotomy. MATERIAL AND METHODS There were 240 procedures of isolated aortic valve replacement for the period 2012-2017. According to inclusion criteria, 112 patients were randomized into 2 groups: group I - median sternotomy, group II - upper partial J-shaped sternotomy. Mean age of patients was 56.1±14.3 and 53.1±14.9 years, respectively ( p =0.284). Females prevailed in both groups (55.4% vs. 57.1%, p =0.848). Peak pressure gradient on the aortic valve was 106.2±23.9 and 102.8±25.3 mm Hg, respectively ( p =0.484). RESULTS In-hospital mortality was 1.8% ( n =1) in group I ( p =0.315). Incidence of postoperative complications (complete atrioventricular blockade, ventricular septal defect) was similar ( p =1.0). Mean time cross clamping in I and II groups was 65.5±12.5 and 64.7±13.1 min ( p =0.729). Mean follow-up period was 31.6 and 33.5 months, respectively. Kaplan-Meier survival rate was 92.6 and 93.0%, respectively (log-rank test=0,767). Freedom from thromboembolic events was 91.7 and 90% (log-rank test=0.213). CONCLUSION. U Pper partial J-shaped sternotomy is safe and effective for aortic valve surgery and characterized by similar outcomes compared to conventional sternotomy.",2020,"U Pper partial J-shaped sternotomy is safe and effective for aortic valve surgery and characterized by similar outcomes compared to conventional sternotomy.",['There were 240 procedures of isolated aortic valve replacement for the period 2012-2017'],"['conventional sternotomy', 'aortic valve replacement through upper partial J-shaped sternotomy', 'group I - median sternotomy, group II - upper partial J-shaped sternotomy', 'Aortic valve replacement via J-shaped partial upper sternotomy', 'U\n\n\nPper partial J-shaped sternotomy']","['Incidence of postoperative complications (complete atrioventricular blockade, ventricular septal defect', 'Kaplan-Meier survival rate', 'Peak pressure gradient on the aortic valve', 'hospital mortality', 'Mean time cross clamping', 'thromboembolic events']","[{'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0185792', 'cui_str': 'Sternotomy'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0441843', 'cui_str': 'Group I'}, {'cui': 'C1282959', 'cui_str': 'Median sternotomy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332206', 'cui_str': 'Blocking'}, {'cui': 'C0018818', 'cui_str': 'Ventricular septal defect'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0445174', 'cui_str': 'Peak pressure'}, {'cui': 'C0003501', 'cui_str': 'Aortic valve structure'}, {'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}]",112.0,0.0217576,"U Pper partial J-shaped sternotomy is safe and effective for aortic valve surgery and characterized by similar outcomes compared to conventional sternotomy.","[{'ForeName': 'Yu A', 'Initials': 'YA', 'LastName': 'Shneider', 'Affiliation': 'Federal Center for High Medical Technologies of the Ministry of Health, Kaliningrad, Russia.'}, {'ForeName': 'M D', 'Initials': 'MD', 'LastName': 'Tsoi', 'Affiliation': 'Federal Center for High Medical Technologies of the Ministry of Health, Kaliningrad, Russia.'}, {'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Fomenko', 'Affiliation': 'Federal Center for High Medical Technologies of the Ministry of Health, Kaliningrad, Russia.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Pavlov', 'Affiliation': 'Federal Center for High Medical Technologies of the Ministry of Health, Kaliningrad, Russia.'}, {'ForeName': 'P A', 'Initials': 'PA', 'LastName': 'Shilenko', 'Affiliation': 'Federal Center for High Medical Technologies of the Ministry of Health, Kaliningrad, Russia.'}]",Khirurgiia,['10.17116/hirurgia202007125'] 1924,32736462,[Effectiveness of light strengthened endoprosthesis in the treatment of middle and large ventral hernia].,"OBJECTIVE To evaluate an effectiveness of light strengthened polypropylene endoprosthesis in the treatment of patients with middle and large ventral hernias. MATERIAL AND METHODS Early and long-term outcomes of surgical treatment were analyzed in 60 patients with middle and large ventral hernias. Onlay hernia repair was performed. Patients were divided into two groups by 30 patients. Abdominal wall repair with conventional polypropylene endoprosthesis was performed in the first group, light strengthened endoprosthesis was used in the second group. RESULTS Application of light strengthened polypropylene endoprosthesis was accompanied by reduced inflammatory response and higher intensity of reparative processes in the area of implantation in early postoperative period. Moreover, we observed better functional state of abdominal rectus muscles in long-term postoperative period in the same group. Improved physical component of health by 4.5% was found in the 2 nd group. As a result, incidence of excellent outcomes increased by 13.3%, good results by 6.7%, incidence of satisfactory results decreased by 20%. Recurrent hernia was absent. CONCLUSION Light strengthened endoprosthesis is effective and advisable in patients with middle and large ventral hernia.",2020,"RESULTS Application of light strengthened polypropylene endoprosthesis was accompanied by reduced inflammatory response and higher intensity of reparative processes in the area of implantation in early postoperative period.","['patients with middle and large ventral hernias', 'patients with middle and large ventral hernia', '60 patients with middle and large ventral hernias', 'middle and large ventral hernia']","['light strengthened endoprosthesis', 'Light strengthened endoprosthesis', 'light strengthened polypropylene endoprosthesis', 'Abdominal wall repair with conventional polypropylene endoprosthesis']","['inflammatory response and higher intensity of reparative processes', 'Recurrent hernia', 'physical component of health', 'incidence of satisfactory results', 'functional state of abdominal rectus muscles']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0019326', 'cui_str': 'Hernia of anterior abdominal wall'}]","[{'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C4704931', 'cui_str': 'Endoprostheses'}, {'cui': 'C0032582', 'cui_str': 'Polypropylene'}, {'cui': 'C0198542', 'cui_str': 'Repair of abdominal wall'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0448311', 'cui_str': 'Rectus eye muscle structure'}]",60.0,0.016704,"RESULTS Application of light strengthened polypropylene endoprosthesis was accompanied by reduced inflammatory response and higher intensity of reparative processes in the area of implantation in early postoperative period.","[{'ForeName': 'B S', 'Initials': 'BS', 'LastName': 'Sukovatikh', 'Affiliation': 'Kursk state medical university, Kursk, Russia.'}, {'ForeName': 'Yu Yu', 'Initials': 'YY', 'LastName': 'Blinkov', 'Affiliation': 'Kursk state medical university, Kursk, Russia.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Netyaga', 'Affiliation': 'Kursk state medical university, Kursk, Russia.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Zatolokina', 'Affiliation': 'Kursk state medical university, Kursk, Russia.'}, {'ForeName': 'Yu Yu', 'Initials': 'YY', 'LastName': 'Polevoy', 'Affiliation': 'Kursk state medical university, Kursk, Russia.'}, {'ForeName': 'V A', 'Initials': 'VA', 'LastName': 'Zhukovskiy', 'Affiliation': 'Saint-Petersburg State University of Industrial Technologies and Design, Saint-Petersburg, Russia.'}]",Khirurgiia,['10.17116/hirurgia202007139'] 1925,32736464,[Early and long-term outcomes of minimally invasive interventions in urgent colon surgery].,"OBJECTIVE To analyze the results of minimally invasive surgical treatment of patients with urgent colon diseases. MATERIAL AND METHODS There were 89 patients with urgent colon diseases. All patients were divided into 2 groups: the main group - 31 patients who underwent laparoscopic surgeries, the control group - 58 patients operated via open access. Both groups were comparable by age and underlying disease. However, significant differences in gender, severity of comorbidities and complications of the underlying disease were observed. RESULTS Surgery time, postoperative morbidity (9.7% vs. 6.9%) and postoperative hospital-stay were similar in both groups. Quality of life was significantly better in the main group compared with the control group if colostomy was absent. In case of stoma, there were no between-group differences. CONCLUSION Laparoscopic surgery is associated with reduced need for analgesics, similar duration of intervention and postoperative morbidity. Complete restoration of quality of life in these patients is observed in 6 months after surgery. Colostomy results similar quality of life after laparoscopic and open surgery.",2020,"Surgery time, postoperative morbidity (9.7% vs. 6.9%) and postoperative hospital-stay were similar in both groups.","['patients with urgent colon diseases', 'urgent colon surgery', 'There were 89 patients with urgent colon diseases']","['minimally invasive interventions', 'Laparoscopic surgery', 'laparoscopic and open surgery', 'laparoscopic surgeries, the control group - 58 patients operated via open access']","['quality of life', 'Complete restoration of quality of life', 'Quality of life', 'postoperative hospital-stay', 'Surgery time, postoperative morbidity', 'gender, severity of comorbidities and complications of the underlying disease']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0009373', 'cui_str': 'Disorder of colon'}, {'cui': 'C0192817', 'cui_str': 'Operation on colon'}]","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0348025', 'cui_str': 'Open approach'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0444454', 'cui_str': 'Access'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",89.0,0.0477338,"Surgery time, postoperative morbidity (9.7% vs. 6.9%) and postoperative hospital-stay were similar in both groups.","[{'ForeName': 'B M', 'Initials': 'BM', 'LastName': 'Niyozbekov', 'Affiliation': ""Russian People's Friendship University, Moscow, Russia.""}, {'ForeName': 'T Z', 'Initials': 'TZ', 'LastName': 'Rzaev', 'Affiliation': ""Russian People's Friendship University, Moscow, Russia.""}, {'ForeName': 'Z B', 'Initials': 'ZB', 'LastName': 'Khalilov', 'Affiliation': 'Central Hospital of Baku, Baku, Republic of Azerbaijan.'}, {'ForeName': 'F S', 'Initials': 'FS', 'LastName': 'Kurbanov', 'Affiliation': ""Russian People's Friendship University, Moscow, Russia.""}, {'ForeName': 'R Kh', 'Initials': 'RK', 'LastName': 'Azimov', 'Affiliation': 'Central Clinical Hospital of the Russian Academy of Sciences, Moscow, Russia.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Chinikov', 'Affiliation': ""Russian People's Friendship University, Moscow, Russia.""}, {'ForeName': 'I S', 'Initials': 'IS', 'LastName': 'Panteleeva', 'Affiliation': ""Russian People's Friendship University, Moscow, Russia.""}]",Khirurgiia,['10.17116/hirurgia202007154'] 1926,32736535,Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness.,"BACKGROUND Treatment with tumor-Infiltrating Lymphocytes (TIL) is an innovative therapy for advanced melanoma with promising clinical phase I/II study results and likely beneficial cost-effectiveness. As a randomized controlled trial on the effectiveness of TIL therapy in advanced melanoma compared to ipilimumab is still ongoing, adoption of TIL therapy by the field is confronted with uncertainty. To deal with this, scenario drafting can be used to identify potential barriers and enables the subsequent anticipation on these barriers. This study aims to inform adoption decisions of TIL by evaluating various scenarios and evaluate their effect on the cost-effectiveness. METHODS First, 14 adoption scenarios for TIL-therapy were drafted using a Delphi approach with a group of involved experts. Second, the likelihood of the scenarios taking place within 5 years was surveyed among international experts using a web-based questionnaire. Third, based on the questionnaire results and recent literature, scenarios were labeled as being either ""likely"" or ""-unlikely"". Finally, the cost-effectiveness of TIL treatment involving the ""likely"" scored scenarios was calculated. RESULTS Twenty-nine experts from 12 countries completed the questionnaire. The scenarios showed an average likelihood ranging from 29 to 58%, indicating that future developments of TIL-therapy were surrounded with quite some uncertainty. Eight of the 14 scenarios were labeled as ""likely"". The net monetary benefit per patient is presented as a measure of cost-effectiveness, where a positive value means that a scenario is cost-effective. For six of these scenarios the cost-effectiveness was calculated: ""Commercialization of TIL production"" (the price was assumed to be 3 times the manufacturing costs in the academic setting) (-€51,550), ""Pharmaceutical companies lowering the prices of ipilimumab"" (€11,420), ""Using TIL-therapy combined with ipilimumab"" (-€10,840), ""Automatic TIL production"" (€22,670), ""TIL more effective"" (€23,270), ""Less Interleukin-2"" (€20,370). CONCLUSIONS Incorporating possible future developments, TIL-therapy was calculated to be cost-effective compared to ipilimumab in the majority of ""likely"" scenarios. These scenarios could function as facilitators for adoption. Contrary, TIL therapy was expected to not be cost-effective when sold at commercial prices, or when combined with ipilimumab. These scenarios should be considered in the adoption decision as these may act as crucial barriers.",2020,"Incorporating possible future developments, TIL-therapy was calculated to be cost-effective compared to ipilimumab in the majority of ""likely"" scenarios.",['advanced melanoma'],"['ipilimumab', 'TIL therapy']",[],"[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}]","[{'cui': 'C1367202', 'cui_str': 'ipilimumab'}, {'cui': 'C0280661', 'cui_str': 'TIL therapy'}]",[],14.0,0.0242862,"Incorporating possible future developments, TIL-therapy was calculated to be cost-effective compared to ipilimumab in the majority of ""likely"" scenarios.","[{'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Lindenberg', 'Affiliation': 'Division of Psychosocial Research and Epidemiology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.'}, {'ForeName': 'Valesca', 'Initials': 'V', 'LastName': 'Retèl', 'Affiliation': 'Division of Psychosocial Research and Epidemiology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.'}, {'ForeName': 'Maartje', 'Initials': 'M', 'LastName': 'Rohaan', 'Affiliation': 'Department of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.'}, {'ForeName': 'Joost', 'Initials': 'J', 'LastName': 'van den Berg', 'Affiliation': 'Biotherapeutics Unit (BTU), The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Haanen', 'Affiliation': 'Department of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.'}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'van Harten', 'Affiliation': 'Division of Psychosocial Research and Epidemiology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands. w.v.harten@nki.nl.'}]",BMC cancer,['10.1186/s12885-020-07166-9'] 1927,32735422,The Effects of a Preconditioning Rolling Session on Subsequent Eccentric Exercise-Induced Muscle Damage.,"West, JT, Miller, WM, Jeon, S, and Ye, X. The effects of a preconditioning rolling session on subsequent eccentric exercise-induced muscle damage. J Strength Cond Res 34(8): 2112-2119, 2020-The aim of this study was to examine the effects of a preexercise unilateral quadriceps muscle rolling intervention on subsequent ipsilateral (IPSI) or contralateral (CTRA) knee extension eccentric exercise-induced muscle damage. Twenty-seven healthy volunteers (14 men) underwent an eccentric exercise protocol (6 sets of 10 repetitions with 75% of the maximal isometric strength) with a single-leg knee extension machine. Before the eccentric exercise, the subjects were randomly assigned to either (a) IPSI group: rolling the ipsilateral knee extensor muscles, (b) CTRA: rolling the contralateral muscles, or (c) Control: sitting for 6 minutes (same duration as the rolling intervention protocol) relaxed. The muscle soreness, passive knee extension range of motion, and knee extension isometric strength were measured before, immediately, 24 hours, and 48 hours after exercise. The magnitudes of the range of motion decrement were attenuated in both the IPSI (p = 0.031) and CTRA (p = 0.014) groups 24 hours after the eccentric exercise, when compared with the control. Isometric strength (p = 0.783) and muscle soreness (p = 0.586) responses were not significantly different among the 3 groups (time points and sexes merged). Additionally, women displayed an overall faster recovery than men in isometric strength (p = 0.001) and muscle soreness (p = 0.024), evidenced by the measurements at 48 hours after exercise. Our study suggests that unilateral quadriceps rolling intervention before high-intensity muscle-damaging exercise has a beneficial effect on maintaining range of motion in both the ipsilateral and contralateral muscles.",2020,"The magnitudes of the range of motion decrement were attenuated in both the IPSI (p = 0.031) and CTRA (p = 0.014) groups 24 hours after the eccentric exercise, when compared with the control.","['J Strength Cond Res 34(8', 'Twenty-seven healthy volunteers (14 men']","['eccentric exercise protocol (6 sets of 10 repetitions with 75% of the maximal isometric strength) with a single-leg knee extension machine', 'Preconditioning Rolling Session', 'preconditioning rolling session', 'preexercise unilateral quadriceps muscle rolling intervention', 'IPSI group: rolling the ipsilateral knee extensor muscles, (b) CTRA: rolling the contralateral muscles, or (c) Control: sitting for 6 minutes (same duration as the rolling intervention protocol) relaxed']","['Subsequent Eccentric Exercise-Induced Muscle Damage', 'muscle soreness, passive knee extension range of motion, and knee extension isometric strength', 'magnitudes of the range of motion decrement', 'subsequent eccentric exercise-induced muscle damage', 'muscle soreness ', 'muscle soreness', 'Isometric strength', 'subsequent ipsilateral (IPSI) or contralateral (CTRA) knee extension eccentric exercise-induced muscle damage']","[{'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0336779', 'cui_str': 'Machine'}, {'cui': 'C1709632', 'cui_str': 'Precondition'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0441989', 'cui_str': 'Ipsilateral'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441988', 'cui_str': 'Contralateral'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}]","[{'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage NOS'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0449286', 'cui_str': 'Degree'}, {'cui': 'C0441989', 'cui_str': 'Ipsilateral'}, {'cui': 'C0441988', 'cui_str': 'Contralateral'}]",27.0,0.0249743,"The magnitudes of the range of motion decrement were attenuated in both the IPSI (p = 0.031) and CTRA (p = 0.014) groups 24 hours after the eccentric exercise, when compared with the control.","[{'ForeName': 'Jonathan T', 'Initials': 'JT', 'LastName': 'West', 'Affiliation': 'Department of Health, Exercise Science, and Recreation Management, The University of Mississippi, University, Mississippi.'}, {'ForeName': 'William M', 'Initials': 'WM', 'LastName': 'Miller', 'Affiliation': ''}, {'ForeName': 'Sunggun', 'Initials': 'S', 'LastName': 'Jeon', 'Affiliation': ''}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Ye', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003678'] 1928,32735423,Effectiveness of a Generic vs. Specific Program Training to Prevent the Short-Term Detraining on Repeated-Sprint Ability of Youth Soccer Players.,"Rodríguez-Fernández, A, Villa, JG, Sánchez-Sánchez, J, and Rodríguez-Marroyo, JA. Effectiveness of a generic vs. specific program training to prevent the short-term detraining on repeated-sprint ability of youth soccer players. J Strength Cond Res 34(8): 2128-2135, 2020-The aim of this study was to analyze the effects of 2 short-term training programs to prevent the negative effect of detraining on repeated-sprint ability (RSA) performance. The study was performed during a 2-week midseason break without official matches. Forty-five youth soccer players (17.7 ± 0.8 years, 175.4 ± 5.5 cm, and 67.2 ± 5.1 kg) were split into 3 groups during the intervention period: inactivity group (IN; N = 16), generic high-intensity training group (GG; N = 15), and specific training group (SG; N = 14). IN was instructed to avoid performing physical activity during the 2-week training intervention. However, GG and SG performed 8 training sessions. GG performed a generic aerobic interval training consisting of 4 repetitions of 4 minutes of exercise at 90-95% of maximal heart rate. SG performed a specific conditioning through small-sided games (4 vs. 4, 4 × 4-minute) and repeated sprints (6 × 30-m). Testing sessions included an RSA test and a Yo-Yo intermittent recovery test level 1 (YYIR1). Repeated-sprint ability performance only improved after the training intervention in SG (∼2%, p < 0.01, (Equation is included in full-text article.)= 0.23-0.25). Both GG and IN declined their performance in post-test (∼2%, p < 0.01, (Equation is included in full-text article.)= 0.19-0.22). No significant effect, group × time, was analyzed for YYIR1 performance. This study suggests that only specific training, based on small-sided games and repeated sprints, leads to short-term improvements on RSA performance in youth soccer players.",2020,"Repeated-sprint ability performance only improved after the training intervention in SG (∼2%, p < 0.01, (Equation is included in full-text article.)= 0.23-0.25).","['Youth Soccer Players', 'J Strength Cond Res 34(8', 'youth soccer players', 'Forty-five youth soccer players (17.7 ± 0.8 years, 175.4 ± 5.5 cm, and 67.2 ± 5.1 kg']","['generic vs. specific program training', 'Generic vs. Specific Program Training', 'generic high-intensity training group (GG; N = 15), and specific training']","['YYIR1 performance', 'repeated-sprint ability (RSA) performance', 'RSA performance', 'Repeated-sprint ability performance']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C4517598', 'cui_str': '17.7'}, {'cui': 'C4517481', 'cui_str': '0.8'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3844008', 'cui_str': '5.5'}]","[{'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0456947', 'cui_str': 'Level 1'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0085732', 'cui_str': 'Ability'}]",,0.0153561,"Repeated-sprint ability performance only improved after the training intervention in SG (∼2%, p < 0.01, (Equation is included in full-text article.)= 0.23-0.25).","[{'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Rodríguez-Fernández', 'Affiliation': '1VALFIS Research Group, Institute of Biomedicine (IBIOMED), University of León, León, Spain; 2Faculty of Health Sciences, University Isabel I, Burgos, Spain; and 3Pontifical University of Salamanca, Salamanca, Spain.'}, {'ForeName': 'José G', 'Initials': 'JG', 'LastName': 'Villa', 'Affiliation': ''}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Sánchez-Sánchez', 'Affiliation': ''}, {'ForeName': 'Jose A', 'Initials': 'JA', 'LastName': 'Rodríguez-Marroyo', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003670'] 1929,32735426,Acute Effects of Different Rest Intervals Between Sets of Resistance Exercise on Neuromuscular Fatigue in Trained Older Women.,"Jambassi Filho, JC, Gurjão, ALD, Prado, AKG, Gallo, LH, and Gobbi, S. Acute effects of different rest intervals between sets of resistance exercise on neuromuscular fatigue in trained older women. J Strength Cond Res 34(8): 2235-2240, 2020-The aim of this study was to investigate the acute effect of different rest intervals (RIs) between sets on total volume, time under tension, maximal voluntary contraction (MVC), and integrated electromyography (iEMG) activity of the vastus lateralis (VL) and vastus medialis (VM) muscles. Twenty-one resistance-trained older women (66.4 ± 4.4 years; 69.1 ± 11.4 kg; 157.5 ± 5.0 cm) completed 3 different test sessions, performed 48-72 hours apart, in a randomized and counterbalanced within-subjects design. In 2 test sessions, the participants performed 3 sets to voluntary exhaustion with loads that corresponded to 15 maximum repetitions, with either 1-minute RI (RI-1) or 3-minute RI (RI-3). In another test session, the participants remained at rest for 15 minutes. The total volume of exercise and time under tension for the RI-3 session was statistically higher (p ≤ 0.05) than the RI-1 session. Postexercise MVC for the RI-3 session showed significantly greater reductions (-7.8%; p ≤ 0.05) compared with the RI-1 and control sessions. No significant changes in postexercise iEMG activity of the VL and VM were shown for any of the sessions (all p > 0.05). The findings of this study suggest that different RIs between sets lead to different acute neuromuscular responses. The longer RI seemed to induce higher neuromuscular fatigue, likely due to higher total volume and time under tension. Thus, longer RI may be a strategy that possibly would lead to greater long-term gains in muscle strength and hypertrophy of the lower limbs in trained older women.",2020,No significant changes in postexercise iEMG activity of the VL and VM were shown for any of the sessions (all p > 0.05).,"['J Strength Cond Res 34(8', 'trained older women', 'Twenty-one resistance-trained older women (66.4 ± 4.4 years; 69.1 ± 11.4 kg; 157.5 ± 5.0 cm', 'Trained Older Women']","['Resistance Exercise', 'resistance exercise']","['postexercise iEMG activity of the VL and VM', 'total volume, time under tension, maximal voluntary contraction (MVC), and integrated electromyography (iEMG) activity of the vastus lateralis (VL) and vastus medialis (VM) muscles', 'total volume and time under tension', 'Postexercise MVC', 'neuromuscular fatigue', 'Neuromuscular Fatigue', 'total volume of exercise and time under tension for the RI-3 session']","[{'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C4517761', 'cui_str': '4.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517533', 'cui_str': '11.4'}]","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0224445', 'cui_str': 'Structure of vastus medialis muscle'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0233494', 'cui_str': 'Tension'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0234116', 'cui_str': 'Neuromuscular fatigue'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.0376553,No significant changes in postexercise iEMG activity of the VL and VM were shown for any of the sessions (all p > 0.05).,"[{'ForeName': 'José C', 'Initials': 'JC', 'LastName': 'Jambassi Filho', 'Affiliation': '1Department of Physical Education, Institute of Biosciences, São Paulo State University, Sao Paulo, Brazil; 2School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil; 3Department of Physical Education, Federal University of São Francisco Valley, Petrolina, Brazil; 4Department of Physical Education, Faculty of Physical Education, Federal University of Mato Grosso, Cuiabá, Brazil; and 5Federal University of Paraná, Curitiba, Paraná, Brazil.'}, {'ForeName': 'André L D', 'Initials': 'ALD', 'LastName': 'Gurjão', 'Affiliation': ''}, {'ForeName': 'Alexandre K G', 'Initials': 'AKG', 'LastName': 'Prado', 'Affiliation': ''}, {'ForeName': 'Luiza H', 'Initials': 'LH', 'LastName': 'Gallo', 'Affiliation': ''}, {'ForeName': 'Sebastião', 'Initials': 'S', 'LastName': 'Gobbi', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000002409'] 1930,32735427,Use of Visual Feedback During Jump-Squat Training Aids Improvement in Sport-Specific Tests in Athletes.,"Vanderka, M, Bezák, A, Longová, K, Krčmár, M, and Walker, S. Use of visual feedback during jump-squat training aids improvement in sport-specific tests in athletes. J Strength Cond Res 34(8): 2250-2257, 2020-This study investigated the effects of instantaneous performance feedback during the jump-squat exercise over a 6-week training period. Twenty-five strength-trained athletes were randomly divided into an instant feedback (n = 13, half-squat 3-repetition maximum (3RM)/body mass = 2.38 ± 0.19) or a nonfeedback (n = 12, half-squat 3RM/body mass = 2.03 ± 0.44) group. Both groups performed the same training program (3 × week), consisting of 4 sets of 8 repetitions (weeks 1-3) and 8 sets of 4 repetitions (weeks 4-6) using a barbell with a load that maximized the average concentric power output (Pmax) of each athlete. Subjects in the instant feedback group were given real-time data after each repetition. Pre-, mid-, and post-training testing consisted of maximum 20-, 30-, and 50-m running speed, 3RM back half-squat load, Pmax and the load that maximized average concentric power output (Pmax load), countermovement jump (CMJ), and squat jump (SJ) height. Results revealed that the feedback group significantly improved all selected tests vs. nonfeedback (time × group interaction, p < 0.01). Significant improvements after training for 20, 30, 50 m, 3RM load, Pmax load, CMJ, and SJ were observed in the feedback group only (p < 0.01). Training without instant feedback did not lead to significant performance improvements; this group actually demonstrated significant decreases in SJ and Pmax (W) and Pmax load (p < 0.05). The results of this study indicate that the use of instant feedback during jump-squat training in athletes was beneficial for improving multiple performance tasks over 6 weeks of training. Instant feedback is an important element of power training to maximize adaptations when training strength-trained athletes.",2020,Training without instant feedback did not lead to significant performance improvements; this group actually demonstrated significant decreases in SJ and Pmax (W) and Pmax load (p < 0.05).,"['J Strength Cond Res 34(8', 'Athletes', 'Twenty-five strength-trained athletes']","['jump-squat exercise', 'Visual Feedback During Jump-Squat Training Aids']","['concentric power output (Pmax load), countermovement jump (CMJ), and squat jump (SJ) height', 'SJ and Pmax (W) and Pmax load', 'Vanderka, M, Bezák, A, Longová, K, Krčmár, M, and Walker, S. Use of visual feedback', 'multiple performance tasks', '3RM load, Pmax load, CMJ, and SJ']","[{'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C2936181', 'cui_str': 'Visual Feedback'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}]","[{'cui': 'C0439744', 'cui_str': 'Concentric'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0043016', 'cui_str': 'Walker'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C2936181', 'cui_str': 'Visual Feedback'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}]",,0.0150862,Training without instant feedback did not lead to significant performance improvements; this group actually demonstrated significant decreases in SJ and Pmax (W) and Pmax load (p < 0.05).,"[{'ForeName': 'Marián', 'Initials': 'M', 'LastName': 'Vanderka', 'Affiliation': '1Department of Track and Field, Faculty of Physical Education and Sport, Comenius University, Bratislava, Slovakia; 2Hamar Institute for Human Performance, Faculty of Physical Education and Sport, Comenius University, Bratislava, Slovakia; and 3Neuromuscular Research Center, Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.'}, {'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Bezák', 'Affiliation': ''}, {'ForeName': 'Katarína', 'Initials': 'K', 'LastName': 'Longová', 'Affiliation': ''}, {'ForeName': 'Matúš', 'Initials': 'M', 'LastName': 'Krčmár', 'Affiliation': ''}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Walker', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000002634'] 1931,32738416,"Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.","BACKGROUND Despite 1-4 % of NSCLC tumors harboring mutations in the HER2 gene, there are no approved HER2-pathway-targeted treatments available. We report an open-label, single-arm, multicenter phase II study investigating the efficacy and safety of afatinib in Asian patients with HER2-mutation positive (HER2m+) NSCLC. METHODS Eligible patients for Part A had confirmed stage IIIb/IV HER2m + NSCLC, had failed one or two prior lines of chemotherapy, and were EGFR/HER2-inhibitor naïve. Patients received oral afatinib 40 mg/day in continuous 28-day cycles, until disease progression or intolerable adverse events (AEs). Patients qualified for Part B if they had > 12 weeks' clinical benefit and Eastern Cooperative Oncology Group performance status ≤ 2. In Part B, patients were to receive afatinib at the last received dose, plus paclitaxel 80 mg/m 2 weekly, until disease progression or intolerable AEs. The primary endpoint in Part A was objective response (OR); secondary endpoints included disease control (DC), progression-free survival (PFS), and overall survival (OS). Further exploratory endpoints were OR, DC, and PFS in Part B. RESULTS Eighteen patients received afatinib in Part A. No patient achieved an OR; 11 patients (61.1 %) achieved stable disease, and six patients (33.3 %) had progressive disease. DC rate was therefore 61.1 % (95 % confidence interval [CI]: 35.7, 82.7). A decrease in tumor size from baseline of > 0 to < 30 % was observed in eight patients. At the time of analysis, 16 patients (88.9 %) had progressed or died. Median PFS was 2.76 months (95 % CI: 1.87, 4.60) and median OS was 10.02 months (95 % CI: 8.47, 10.08). All patients experienced ≥ 1 AE, most commonly diarrhea (66.7 %) and rash (33.3 %). No patients met the inclusion criteria for Part B, and recruitment was slow; therefore, the study was terminated. CONCLUSIONS This study found no clinical benefit of afatinib for EGFR TKI-naïve patients with HER2m + NSCLC.",2020,"Median PFS was 2.76 months (95 % CI: 1.87, 4.60) and median OS was 10.02 months (95 % CI: 8.47, 10.08).","['Eighteen patients received afatinib in Part A', ""Patients qualified for Part B if they had > 12 weeks' clinical benefit and Eastern Cooperative Oncology Group performance status ≤ 2"", 'EGFR TKI-naïve patients with HER2m\u202f+\u202fNSCLC', 'Asian patients with HER2-mutation positive (HER2m+) NSCLC', 'Eligible patients for Part A had confirmed stage IIIb/IV HER2m', 'patients with advanced non-small cell lung cancer harboring HER2 mutations']","['Afatinib', 'oral afatinib', 'plus paclitaxel 80\u202fmg/m 2 weekly, until disease progression or intolerable AEs', 'chemotherapy', 'afatinib']","['OR, DC, and PFS in Part B', 'diarrhea', 'DC rate', 'progressive disease', 'Median PFS', 'median OS', 'objective response (OR); secondary endpoints included disease control (DC), progression-free survival (PFS), and overall survival (OS', 'progressed or died', 'efficacy and safety', 'tumor size', 'stable disease', 'rash']","[{'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2987648', 'cui_str': 'Afatinib'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0456599', 'cui_str': 'Stage 3B'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0475311', 'cui_str': 'Harbor'}]","[{'cui': 'C2987648', 'cui_str': 'Afatinib'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0475440', 'cui_str': 'Tumor size'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}]",,0.160329,"Median PFS was 2.76 months (95 % CI: 1.87, 4.60) and median OS was 10.02 months (95 % CI: 8.47, 10.08).","[{'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Fan', 'Affiliation': 'Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Hunan Cancer Hospital, Changsha, China.'}, {'ForeName': 'Chengzhi', 'Initials': 'C', 'LastName': 'Zhou', 'Affiliation': 'The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.'}, {'ForeName': 'Huijuan', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.'}, {'ForeName': 'Yongqian', 'Initials': 'Y', 'LastName': 'Shu', 'Affiliation': 'The First Affiliated Hospital with Nanjing Medical University, Jiangsu, China.'}, {'ForeName': 'Jacky', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai, China.'}, {'ForeName': 'Hairui', 'Initials': 'H', 'LastName': 'Hua', 'Affiliation': 'Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai, China.'}, {'ForeName': 'Dennis Chin-Lun', 'Initials': 'DC', 'LastName': 'Huang', 'Affiliation': 'Boehringer Ingelheim Taiwan Limited, Taipei, Taiwan.'}, {'ForeName': 'Caicun', 'Initials': 'C', 'LastName': 'Zhou', 'Affiliation': 'Medical Oncology, Shanghai Pulmonary Hospital, Shanghai, China. Electronic address: caicunzhoudr@163.com.'}]","Lung cancer (Amsterdam, Netherlands)",['10.1016/j.lungcan.2020.07.017'] 1932,32741829,Music Playlists for People with Dementia: Trialing A Guide for Caregivers.,"BACKGROUND Music programs have the potential to provide an effective non-pharmacological tool for caregivers to reduce depression and agitation and increase quality of life in people with dementia. However, where such programs are not facilitated by a trained music therapist, caregivers need greater access to information about how to use music most effectively in response to key challenges to care, and how to pre-empt and manage adverse responses. OBJECTIVE This study reports on the trial of a Guide for use of music with 45 people with dementia and their caregivers in residential care facilities and home-based care. METHODS The study used a pre-post experimental design in which participants were randomly allocated to a treatment group or a waitlist control group. RESULTS Improvements to quality of life were found in the experimental group over the 6-week period. Significant increases in Interest, Responsiveness, Initiation, Involvement, and Enjoyment were reported for individual listening sessions. CONCLUSION The Guide can provide an effective protocol for caregivers to follow in selecting music to manage particular challenges to care, confirming the need for caregivers to be prepared to monitor and manage potential negative responses.",2020,"Significant increases in Interest, Responsiveness, Initiation, Involvement, and Enjoyment were reported for individual listening sessions. ","['45 people with dementia and their caregivers in residential care facilities and home-based care', 'People with Dementia', 'people with dementia']","['Music Playlists', 'waitlist control group']","['quality of life', 'Interest, Responsiveness, Initiation, Involvement, and Enjoyment']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0035186', 'cui_str': 'Residential Facilities'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0679105', 'cui_str': 'Pleasure'}]",45.0,0.0631866,"Significant increases in Interest, Responsiveness, Initiation, Involvement, and Enjoyment were reported for individual listening sessions. ","[{'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Garrido', 'Affiliation': 'MARCS Institute for Brain, Behaviour & Development, Western Sydney University, Penrith, Australia.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Dunne', 'Affiliation': 'MARCS Institute for Brain, Behaviour & Development, Western Sydney University, Penrith, Australia.'}, {'ForeName': 'Catherine J', 'Initials': 'CJ', 'LastName': 'Stevens', 'Affiliation': 'MARCS Institute for Brain, Behaviour & Development, Western Sydney University, Penrith, Australia.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Chang', 'Affiliation': 'School of Nursing & Midwifery, Western Sydney University, Penrith, Australia.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-200457'] 1933,32741832,"""Camminando e Leggendo ...   Ricordo"" (Walking and Reading ...   I Remember): Prevention of Frailty Through the Promotion of Physical Activity and Reading in People with Mild Cognitive Impairment. Results from the TREDEM Registry.","BACKGROUND Frailty is a condition of increased vulnerability to exogenous and endogenous stressors, which is correlated with aging, functional decline, institutionalization, hospitalization, and mortality. Given the multifaceted nature of frailty, programs aimed at its prevention are recommended to act on multiple domains. OBJECTIVE The present intervention program aimed at assessing the effects of combined physical and cognitive training in older people with mild cognitive impairment (MCI) and at investigating how their frailty status changed over one year of follow-up. METHODS Two-hundred and seven participants were recruited among outpatients of the Cognitive Impairment Center who agreed to receive a comprehensive assessment. Forty-six participants, who joined a structured program of physical activity and group readings for a period of one year, were defined as active. The remaining 161, who decided not to engage in those activities, were considered controls. In both groups, frailty status was assessed at baseline and over one year of follow-up. RESULTS Control participants showed twice the risk of becoming frail at 12 months compared with those in the active group. Participants in the active group had more than three times the probability of improving their frailty status compared with the control group from T0 to T12. Age and NPI scores were significantly associated with worsening frailty status. When analyses were restricted to participants who were robust at baseline, the frailty status varied significantly between groups over time. CONCLUSION Findings of the present study confirm the beneficial effects of physical activity and reading to prevent frailty in older people with MCI.",2020,Participants in the active group had more than three times the probability of improving their frailty status compared with the control group from T0 to T12.,"['older people with mild cognitive impairment (MCI', 'older people with MCI', 'Forty-six participants, who joined a structured program of physical activity and group readings for a period of one year, were defined as active', 'People with Mild Cognitive Impairment', 'Two-hundred and seven participants were recruited among outpatients of the Cognitive Impairment Center who agreed to receive a comprehensive assessment']",['combined physical and cognitive training'],"['Age and NPI scores', 'risk of becoming frail', 'frailty status', 'probability of improving their frailty status']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",207.0,0.0444372,Participants in the active group had more than three times the probability of improving their frailty status compared with the control group from T0 to T12.,"[{'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Gallucci', 'Affiliation': 'Cognitive Impairment Center, Local Health Authority n. 2 Marca Trevigiana, Treviso, Italy.'}, {'ForeName': 'Anna Paola', 'Initials': 'AP', 'LastName': 'Mazzarolo', 'Affiliation': 'Cognitive Impairment Center, Local Health Authority n. 2 Marca Trevigiana, Treviso, Italy.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Focella', 'Affiliation': 'Cognitive Impairment Center, Local Health Authority n. 2 Marca Trevigiana, Treviso, Italy.'}, {'ForeName': 'Cinzia', 'Initials': 'C', 'LastName': 'Piovesan', 'Affiliation': 'Epidemiology Unit, Local Health Authority n. 2 Marca Trevigiana, Treviso, Italy.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Mazzetto', 'Affiliation': 'Health Promotion Unit, Local Health Authority n. 2 Marca Trevigiana, Treviso, Italy.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Ramigni', 'Affiliation': 'Epidemiology Unit, Local Health Authority n. 2 Marca Trevigiana, Treviso, Italy.'}, {'ForeName': 'Emanuele', 'Initials': 'E', 'LastName': 'Marzetti', 'Affiliation': 'Institute of Internal Medicine and Geriatrics, Università Cattolica del Sacro Cuore, Rome, Italy.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-200542'] 1934,32741946,Factors Associated with Dose Modification of Lenalidomide Plus Dexamethasone Therapy in Multiple Myeloma.,"Long-term combination treatment with lenalidomide and low-dose dexamethasone is important to achieve a curative effect in patients with multiple myeloma (MM). In this study, the plasma concentration of lenalidomide was measured at 3 h after oral administration, when the drug is in the elimination phase and can be easily measured in outpatients, to identify factors that may lead to the discontinuation of this combination therapy. Patients were assigned to continuation or discontinuation of therapy groups, and the baseline characteristics of patients, lenalidomide concentration, and concentration/dose (C/D) ratios reflecting oral clearance were compared between the two groups. The efficacy and severity of adverse events were also compared. The results showed that patients who discontinued or modified treatment had low plasma concentrations of lenalidomide and C/D ratios, indicating high oral clearance of lenalidomide. The estimated creatinine clearance rate was negatively correlated with the C/D ratio. The plasma concentrations of lenalidomide were independent from kidney function and differed significantly among patients. Taken together, the results indicate that low plasma concentrations of lenalidomide and low C/D ratios may lead to discontinuation of combination therapy in patients with MM. This suggests that early measurement of lenalidomide plasma continuation would help to prevent discontinuation of therapy or a delay in modifying the dose of lenalidomide.",2020,"The results showed that patients who discontinued or modified treatment had low plasma concentrations of lenalidomide and C/D ratios, indicating high oral clearance of lenalidomide.","['patients with MM', 'Multiple Myeloma', 'patients with multiple myeloma (MM']","['lenalidomide and low-dose dexamethasone', 'Lenalidomide Plus Dexamethasone Therapy']","['efficacy and severity of adverse events', 'plasma concentration of lenalidomide', 'creatinine clearance rate', 'low plasma concentrations of lenalidomide and C/D ratios', 'plasma concentrations of lenalidomide']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}]","[{'cui': 'C1144149', 'cui_str': 'lenalidomide'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1144149', 'cui_str': 'lenalidomide'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.0463423,"The results showed that patients who discontinued or modified treatment had low plasma concentrations of lenalidomide and C/D ratios, indicating high oral clearance of lenalidomide.","[{'ForeName': 'Yoko', 'Initials': 'Y', 'LastName': 'Kado', 'Affiliation': 'Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University.'}, {'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Tsujimoto', 'Affiliation': 'Department of Clinical Pharmacy, Kyoto Pharmaceutical University.'}, {'ForeName': 'Shin-Ichi', 'Initials': 'SI', 'LastName': 'Fuchida', 'Affiliation': 'Department of Hematology, Japan Community Health Care Organization, Kyoto Kuramaguchi Medical Center.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Okano', 'Affiliation': 'Department of Hematology, Japan Community Health Care Organization, Kyoto Kuramaguchi Medical Center.'}, {'ForeName': 'Mayumi', 'Initials': 'M', 'LastName': 'Hatsuse', 'Affiliation': 'Department of Hematology, Japan Community Health Care Organization, Kyoto Kuramaguchi Medical Center.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Murakami', 'Affiliation': 'Department of Hematology, Japan Community Health Care Organization, Kyoto Kuramaguchi Medical Center.'}, {'ForeName': 'Hikofumi', 'Initials': 'H', 'LastName': 'Sugii', 'Affiliation': 'Department of Pharmacy, Japan Community Health Care Organization, Kyoto Kuramaguchi Medical Center.'}, {'ForeName': 'Kumi', 'Initials': 'K', 'LastName': 'Ueda', 'Affiliation': 'Department of Pharmacy, Japan Community Health Care Organization, Kyoto Kuramaguchi Medical Center.'}, {'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Toda', 'Affiliation': 'Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University.'}, {'ForeName': 'Tetsuya', 'Initials': 'T', 'LastName': 'Minegaki', 'Affiliation': 'Department of Clinical Pharmacy, Kyoto Pharmaceutical University.'}, {'ForeName': 'Kohshi', 'Initials': 'K', 'LastName': 'Nishiguchi', 'Affiliation': 'Department of Clinical Pharmacy, Kyoto Pharmaceutical University.'}, {'ForeName': 'Yuichi', 'Initials': 'Y', 'LastName': 'Muraki', 'Affiliation': 'Department of Clinical Pharmacoepidemiological, Kyoto Pharmaceutical University.'}, {'ForeName': 'Chihiro', 'Initials': 'C', 'LastName': 'Shimazaki', 'Affiliation': 'Department of Hematology, Japan Community Health Care Organization, Kyoto Kuramaguchi Medical Center.'}, {'ForeName': 'Eishi', 'Initials': 'E', 'LastName': 'Ashihara', 'Affiliation': 'Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University.'}]",Biological & pharmaceutical bulletin,['10.1248/bpb.b20-00337'] 1935,32742091,Second Class Functional Treatment: Andreasen Activator vs Twin Block.,"Aim The purpose of this research is to analyze and compare the dental and skeletal changes induced by two functional devices, Andreasen Activator and Clark's twin block, on the sagittal and vertical plane, by means of cephalometric analysis, of the lateral cephalograms prescribed at the beginning and at the end of the treatment for a second skeletal class, first division with normal or deep bite. Materials and methods Twenty patients, 8 females and 12 males, fulfilling criteria for inclusion, were divided randomly into two groups: group I was treated with Andreasen activator, the second group with Clark's twin block. The duration of the therapy was about 18 months plus less 2 months. Pretreatment and posttreatment cephalometric radiographs were analyzed using angular (SNA, SNB, ANB, SnaSnp-GoGn angles), linear (Sna-Snp, Co-Gn, Co-Go, Go-Gn) skeletal parameters and dental one (U1-SnaSnp angle, L1-GoGn angle, Overjet and Overbite). To evaluate the posttreatment changes in the single groups and between them, paired and unpaired t -test was used. Results In both of the two groups analyzed, all the sagittal and vertical, angular and linear, skeletal measurements appear to be increased in a statistically significant way, except SNA angle and the distance Sna-Snp. Regarding the dental parameters, in the group treated with Andreasen activator, only Overjet and Overbite showed statistically significant differences. On the other hand, twin block induced statistical changes about Overjet, Overbite and also U1/SnaSnp, but not about L1/GoGn. The advancement of the mandible determines a greater prominence of the chin and lower lip, an increment of the labial mental angle and a reduction of the convexity of the profile. Also, the decrease of the overjet and, consequently, of the dental exposure improve the esthetic appearance of the patient's face. Conclusion Both functional treatments showed a lower jaw advanced on the sagittal plane and increased in size. In the upper jaw no significant changes were observed. It was also evident a dental compensation both on sagittal and vertical planes. Clinical significance The functional devices studied, Andreasen activator and twin block, seem to obtain more skeletal than dental results when the patients were treated at the peak of pubertal growth. How to cite this article Baccaglione G, Rota E, Ferrari M, et al. Second Class Functional Treatment: Andreasen Activator vs Twin Block. Int J Clin Pediatr Dent 2020;13(2):144-149.",2020,"Regarding the dental parameters, in the group treated with Andreasen activator, only Overjet and Overbite showed statistically significant differences.","['Twenty patients, 8 females and 12 males, fulfilling criteria for inclusion']","['Second Class Functional Treatment: Andreasen Activator vs Twin Block', 'Second Class Functional Treatment', ""Andreasen activator, the second group with Clark's twin block""]","['size', 'angular (SNA, SNB, ANB, SnaSnp-GoGn angles), linear (Sna-Snp, Co-Gn, Co-Go, Go-Gn) skeletal parameters and dental one (U1-SnaSnp angle, L1-GoGn angle, Overjet and Overbite', ""esthetic appearance of the patient's face""]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}]","[{'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C1562632', 'cui_str': 'Hoover technique'}, {'cui': 'C0041427', 'cui_str': 'Twin sibling'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0376252', 'cui_str': 'Shona language'}, {'cui': 'C0796693', 'cui_str': 'Sentinel lymph node biopsy'}, {'cui': 'C0068053', 'cui_str': 'N-hydroxysuccinimidyl-5-azido-2-nitrobenzoate'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0752046', 'cui_str': 'Single Nucleotide Polymorphism'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}, {'cui': 'C0596028', 'cui_str': 'Horizontal overbite'}, {'cui': 'C1305740', 'cui_str': 'Overbite'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}]",,0.0241414,"Regarding the dental parameters, in the group treated with Andreasen activator, only Overjet and Overbite showed statistically significant differences.","[{'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Baccaglione', 'Affiliation': 'Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Rota', 'Affiliation': 'Department of Orthodontics, University of Milano Bicocca, Monza, Italy.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Ferrari', 'Affiliation': 'Department of Orthodontics, University of Milano Bicocca, Monza, Italy.'}, {'ForeName': 'Marcello', 'Initials': 'M', 'LastName': 'Maddalone', 'Affiliation': 'Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.'}]",International journal of clinical pediatric dentistry,['10.5005/jp-journals-10005-1725'] 1936,32718986,"Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study.","PURPOSE This randomized, double-blind, placebo-controlled, parallel-group, phase II trial assessed the efficacy and safety of adagloxad simolenin (OBI-822; a Globo H epitope covalently linked to keyhole limpet hemocyanin (KLH)) with adjuvant OBI-821 in metastatic breast cancer (MBC). METHODS At 40 sites in Taiwan, USA, Korea, India, and Hong Kong, patients with MBC of any molecular subtype and ≤2 prior progressive disease events with stable/responding disease after the last anticancer regimen were randomized (2:1) to adagloxad simolenin (AS/OBI-821) or placebo, subcutaneously for nine doses with low-dose cyclophosphamide. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival, correlation of clinical outcome with humoral immune response and Globo H expression, and safety. RESULTS Of 349 patients randomized, 348 received study drug. Patients with the following breast cancer subtypes were included: hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) (70.4%), triple negative (12.9%), and HER2+ (16.7%), similarly distributed between treatment arms. Median PFS was 7.6 months (95% CI: 6.5-10.9) with AS/OBI-821 (n=224) and 9.2 months (95% CI: 7.3-11.3) with placebo (n=124) (HR=0.96; 95% CI: 0.74-1.25; p=0.77), with no difference by breast cancer subtype. AS/OBI-821 recipients with anti-Globo H IgG titer ≥1:160 had significantly longer median PFS (11.1 months (95% CI: 9.3-17.6)) versus those with titers <1:160 (5.5 months (95% CI: 3.7-5.6); HR=0.52; p<0.0001) and placebo recipients (HR=0.71; p=0.03). Anti-KLH immune responses were similar at week 40 between AS/OBI-821 recipients with anti-Globo IgG titer ≥1:160 and those with anti-Globo IgG titer <1:160. The most common adverse events with AS/OBI-821 were grade 1 or 2 injection site reactions (56.7%; placebo, 8.9%) and fever (20.1%; placebo, 6.5%). CONCLUSION AS/OBI-821 did not improve PFS in patients with previously treated MBC. However, humoral immune response to Globo H correlated with improved PFS in AS/OBI-821 recipients, leading the way to further marker-driven studies. Treatment was well tolerated.NCT01516307.",2020,AS/OBI-821 recipients with anti-Globo H IgG titer ≥1:160 had significantly longer median PFS (11.1 months (95% CI: 9.3-17.6)) versus those with titers <1:160 (5.5 months (95% CI: 3.7-5.6); HR=0.52; p<0.0001) and placebo recipients (HR=0.71; p=0.03).,"['patients with metastatic breast cancer', 'metastatic breast cancer (MBC', 'patients with previously treated MBC', '349 patients randomized, 348 received study drug', 'Patients with the following breast cancer subtypes were included']","['OBI-822)/OBI-821', 'Globo H-KLH vaccine adagloxad simolenin ', 'adagloxad simolenin ', 'adagloxad simolenin (AS/OBI-821) or placebo, subcutaneously for nine doses with low-dose cyclophosphamide', 'placebo']","['Anti-KLH immune responses', 'Median PFS', 'PFS', 'tolerated', 'overall survival, correlation of clinical outcome with humoral immune response and Globo H expression, and safety', 'efficacy and safety', 'median PFS', 'progression-free survival (PFS', 'fever', 'hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C4517733', 'cui_str': '348'}, {'cui': 'C0013175', 'cui_str': 'Clinical drug trial'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0449560', 'cui_str': 'Subtype'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C1175421', 'cui_str': 'Globo-H'}, {'cui': 'C0064332', 'cui_str': 'Keyhole-limpet hemocyanin'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}]","[{'cui': 'C0064332', 'cui_str': 'Keyhole-limpet hemocyanin'}, {'cui': 'C0301872', 'cui_str': 'Immune response'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0010101', 'cui_str': 'Correlation Studies'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0020967', 'cui_str': 'Humoral Immunity'}, {'cui': 'C1175421', 'cui_str': 'Globo-H'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}]",349.0,0.523881,AS/OBI-821 recipients with anti-Globo H IgG titer ≥1:160 had significantly longer median PFS (11.1 months (95% CI: 9.3-17.6)) versus those with titers <1:160 (5.5 months (95% CI: 3.7-5.6); HR=0.52; p<0.0001) and placebo recipients (HR=0.71; p=0.03).,"[{'ForeName': 'Chiun-Sheng', 'Initials': 'CS', 'LastName': 'Huang', 'Affiliation': 'Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Alice L', 'Initials': 'AL', 'LastName': 'Yu', 'Affiliation': 'Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital & Chang Gung University, Linkou, Taiwan.'}, {'ForeName': 'Ling-Ming', 'Initials': 'LM', 'LastName': 'Tseng', 'Affiliation': 'Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Louis W C', 'Initials': 'LWC', 'LastName': 'Chow', 'Affiliation': 'UNIMED Medical Institute, Hong Kong, China.'}, {'ForeName': 'Ming-Feng', 'Initials': 'MF', 'LastName': 'Hou', 'Affiliation': 'Division of Breast Surgery, Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Sara A', 'Initials': 'SA', 'LastName': 'Hurvitz', 'Affiliation': 'Jonsson Comprehensive Cancer Center, Department of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Schwab', 'Affiliation': 'Moores Cancer Center, University of California San Diego, San Diego, California, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'L Murray', 'Affiliation': 'Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Hsien-Kun', 'Initials': 'HK', 'LastName': 'Chang', 'Affiliation': 'Department of Internal Medicine, Division of Hematology-Oncology, Chang Gung Memorial Hospital, Linkou, Taiwan.'}, {'ForeName': 'Hong-Tai', 'Initials': 'HT', 'LastName': 'Chang', 'Affiliation': 'Department of Surgery, Kaohsiung Municipal United Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Shin-Cheh', 'Initials': 'SC', 'LastName': 'Chen', 'Affiliation': 'Department of General Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan.'}, {'ForeName': 'Sung-Bae', 'Initials': 'SB', 'LastName': 'Kim', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, The Republic of Korea.'}, {'ForeName': 'Jung-Tung', 'Initials': 'JT', 'LastName': 'Hung', 'Affiliation': 'Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Linkou, Taiwan.'}, {'ForeName': 'Shir-Hwa', 'Initials': 'SH', 'LastName': 'Ueng', 'Affiliation': 'Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Linkou, Taiwan.'}, {'ForeName': 'Su-Hua', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Department of Statistics and Biometrics, OBI Pharma Inc, Taipei, Taiwan.'}, {'ForeName': 'Chwen-Cheng', 'Initials': 'CC', 'LastName': 'Chen', 'Affiliation': 'Institute of Biotechnology and Pharmaceutical Research, National Health Research Institute, Taipei, Taiwan.'}, {'ForeName': 'Hope S', 'Initials': 'HS', 'LastName': 'Rugo', 'Affiliation': 'Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA hope.rugo@ucsf.edu.'}]",Journal for immunotherapy of cancer,['10.1136/jitc-2019-000342'] 1937,32725954,Ibuprofen does not prevent postbronchoscopy fever in children undergoing broncho-alveolar lavage.,"BACKGROUND Fiber-optic bronchoscopy (FOB) of the lower airways is a routine examination performed for investigating varying respiratory complaints in children. A common side effect is a transient high fever on the day of the FOB. Such episodes are usually unrelated to an infectious process but may cause clinical uncertainty and parental anxiety. We have previously shown that a single dose of systemic dexamethasone significantly reduces the rate of fever postbronchoscopy (FPB). RESEARCH QUESTION To prospectively analyze the effect of a prophylactic dose of ibuprofen upon the FPB. STUDY DESIGN AND METHODS Children presenting for elective FOB and broncho-alveolar lavage (BAL) were randomized, in a double-blind fashion, to receive a single dose of ibuprofen syrup 10 mg/kg or placebo prior to the procedure. Parents were contacted the next day to record the presence or absence of fever. RESULTS Sixty-one children were included in the final analysis. Thirty-one children were in the treatment group and 30 in the placebo group. FPB occurred in 40 children (65%). There was no difference in the rate of FPB between placebo (63%) and treatment (67%) groups (P = .717). Fifty (82%) children had a positive BAL culture. Among them, 38 had FPB (76%) compared with only 2 of 11 (18%) of those with negative culture (P = .00026, relative risk 4.18). About 80% of positive cultures grew Haemophilus influenza. There was no significant difference between the number of BALs with a positive culture between the treatment and placebo groups (87% vs 77%, P = .35). CONCLUSION FPB occurs in around twothirds of children when BAL is performed. Fever occurred significantly more frequently when BAL culture is positive. A single standard dose of the nonsteroidal anti-inflammatory drug ibuprofen administered before a FOB does not prevent FPB.",2020,There was no difference in in the rate of FPB between placebo (63%) and treatment (67%) groups (p=0.717).,"['children undergoing broncho-alveolar lavage', 'children', 'Sixty one children were included in the final analysis', 'Children presenting for elective FOB and broncho-alveolar lavage (BAL', 'Fifty (82%) children had a positive BAL culture']","['systemic dexamethasone', 'Ibuprofen', 'ibuprofen syrup 10mg/kg or placebo', 'ibuprofen', 'Fiber-optic bronchoscopy (FOB', 'placebo']","['FPB', 'rate of fever post bronchoscopy (FPB', 'number of BALs with a positive culture', 'postbronchoscopy fever', 'rate of FPB', 'Fever']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0396473', 'cui_str': 'Bronchoscopy and bronchoalveolar lavage'}, {'cui': 'C4517832', 'cui_str': '61'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0189391', 'cui_str': 'Fiberoptic bronchoscopy'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0010453', 'cui_str': 'Culture'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0458173', 'cui_str': 'Syrup'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0189391', 'cui_str': 'Fiberoptic bronchoscopy'}]","[{'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0006290', 'cui_str': 'Bronchoscopy'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0012383', 'cui_str': 'Dimercaprol'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0010453', 'cui_str': 'Culture'}]",61.0,0.633658,There was no difference in in the rate of FPB between placebo (63%) and treatment (67%) groups (p=0.717).,"[{'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Joseph', 'Affiliation': 'Pediatric Pulmonary Unit, Pediatric division, Shaare Zedek Medical Center, Jerusalem, Israel.'}, {'ForeName': 'Shmuel', 'Initials': 'S', 'LastName': 'Goldberg', 'Affiliation': 'Pediatric Pulmonary Unit, Pediatric division, Shaare Zedek Medical Center, Jerusalem, Israel.'}, {'ForeName': 'Shlomo', 'Initials': 'S', 'LastName': 'Cohen', 'Affiliation': 'Pediatric Pulmonary Unit, Pediatric division, Shaare Zedek Medical Center, Jerusalem, Israel.'}, {'ForeName': 'Elie', 'Initials': 'E', 'LastName': 'Picard', 'Affiliation': 'Pediatric Pulmonary Unit, Pediatric division, Shaare Zedek Medical Center, Jerusalem, Israel.'}]",Pediatric pulmonology,['10.1002/ppul.24992'] 1938,32726003,[Large- scale prospective clinical study on prophylactic intervention of COVID-19 in community population using Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules].,"To scientifically evaluate the intervention effect of Chinese medicine preventive administration(combined use of Huo-xiang Zhengqi Oral Liquid and Jinhao Jiere Granules) on community population in the case of coronavirus disease 2019(COVID-19), a large cohort, prospective, randomized, and parallel-controlled clinical study was conducted. Total 22 065 subjects were included and randomly divided into 2 groups. The non-intervention group was given health guidance only, while the traditional Chinese medicine(TCM) intervention group was given two coordinated TCM in addition to health guidance. The medical instructions were as follows. Huoxiang Zhengqi Oral Liquid: oral before meals, 10 mL/time, 2 times/day, a course of 5 days. Jinhao Jiere Granules: dissolve in boiling water and take after meals, 8 g/time, 2 times/day, a course of 5 days, followed up for 14 days, respectively. The study found that with the intake of medication, the incidence rate of TCM intervention group was basically maintained at a low and continuous stable level(0.01%-0.02%), while the non-intervention group showed an overall trend of continuous growth(0.02%-0.18%) from 3 to 14 days. No suspected or confirmed COVID-19 case occurred in either group. There were 2 cases of colds in the TCM intervention group and 26 cases in the non-intervention group. The incidence of colds in the TCM intervention group was significantly lower(P<0.05) than that in the non-intervention group. In the population of 16-60 years old, the incidence rate of non-intervention and intervention groups were 0.01% and 0.25%, respectively. The difference of colds incidence between the two groups was statistically significant(P<0.05). In the population older than 60 years old, they were 0.04% and 0.21%, respectively. The incidence of colds in the non-intervention group was higher than that in the intervention group, but not reaching statistical difference. The protection rate of TCM for the whole population was 91.8%, especially for the population of age 16-60(95.0%). It was suggested that TCM intervention(combined use of Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules) could effectively protect community residents against respiratory diseases, such as colds, which was worthy of promotion in the community. In addition, in terms of safety, the incidence of adverse events and adverse reactions in the TCM intervention group was relatively low, which was basically consistent with the drug instructions.",2020,"The incidence of colds in the non-intervention group was higher than that in the intervention group, but not reaching statistical difference.","['community population using Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules', 'community population in the case of coronavirus disease 2019(COVID-19', 'Total 22 065 subjects']","['TCM intervention', 'health guidance only, while the traditional Chinese medicine(TCM) intervention group was given two coordinated TCM in addition to health guidance', 'Chinese medicine preventive administration(combined use of Huo-xiang Zhengqi Oral Liquid and Jinhao Jiere Granules']","['protection rate of TCM', 'incidence rate', 'colds incidence', 'adverse events and adverse reactions', 'incidence of colds']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1871293', 'cui_str': 'Huoxiang-zhengqi'}, {'cui': 'C1273619', 'cui_str': 'Oral Liquid Product'}, {'cui': 'C0010837', 'cui_str': 'Cytoplasmic Granules'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0427184', 'cui_str': 'No incoordination'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0204169', 'cui_str': 'Preventive dental procedure'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C1273619', 'cui_str': 'Oral Liquid Product'}, {'cui': 'C0010837', 'cui_str': 'Cytoplasmic Granules'}]","[{'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0009443', 'cui_str': 'Common cold'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}]",22065.0,0.020795,"The incidence of colds in the non-intervention group was higher than that in the intervention group, but not reaching statistical difference.","[{'ForeName': 'Bo-Hua', 'Initials': 'BH', 'LastName': 'Yan', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Zhi-Wei', 'Initials': 'ZW', 'LastName': 'Jiang', 'Affiliation': 'Beijing Key Tech Statistical Consulting Co., Ltd. Beijing 100015, China.'}, {'ForeName': 'Jie-Ping', 'Initials': 'JP', 'LastName': 'Zeng', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Jian-Yuan', 'Initials': 'JY', 'LastName': 'Tang', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Ding', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Jie-Lai', 'Initials': 'JL', 'LastName': 'Xia', 'Affiliation': ""Air Force Military Medical University of People's Liberation Army Xi'an 710032, China.""}, {'ForeName': 'Shao-Rong', 'Initials': 'SR', 'LastName': 'Qin', 'Affiliation': 'Taiji Group Co., Ltd. Chongqing 408000, China.'}, {'ForeName': 'Si-Cen', 'Initials': 'SC', 'LastName': 'Jin', 'Affiliation': 'Taiji Group Co., Ltd. Chongqing 408000, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Zhang', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Zhi-Hong', 'Initials': 'ZH', 'LastName': 'Wang', 'Affiliation': 'Chengdu Zhongxiang Pharmaceutical Technology Co., Ltd. Chengdu 610000, China.'}, {'ForeName': 'Hai-Yan', 'Initials': 'HY', 'LastName': 'Li', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Xiao-Ya', 'Initials': 'XY', 'LastName': 'Sang', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Li-Na', 'Initials': 'LN', 'LastName': 'Wu', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Shi-Yun', 'Initials': 'SY', 'LastName': 'Tang', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Meng-Yao', 'Initials': 'MY', 'LastName': 'Tao', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Qiao-Ling', 'Initials': 'QL', 'LastName': 'Wang', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Jun-Dong', 'Initials': 'JD', 'LastName': 'Wang', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Hong-Yan', 'Initials': 'HY', 'LastName': 'Xie', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Qi-Yuan', 'Initials': 'QY', 'LastName': 'Chen', 'Affiliation': 'Yingmenkou Community Service Center Chengdu 610036, China.'}, {'ForeName': 'Sheng-Wen', 'Initials': 'SW', 'LastName': 'Yang', 'Affiliation': ""Xi'anlu Community Service Center Chengdu 610072, China.""}, {'ForeName': 'Nian-Shuang', 'Initials': 'NS', 'LastName': 'Hu', 'Affiliation': 'Jiangxijie Community Service Center Chengdu 610041, China.'}, {'ForeName': 'Jian-Qiong', 'Initials': 'JQ', 'LastName': 'Yang', 'Affiliation': 'Supo Community Service Center Chengdu 610091, China.'}, {'ForeName': 'Xiao-Xia', 'Initials': 'XX', 'LastName': 'Bao', 'Affiliation': 'Caoshi Yuhe Community Service Center Chengdu 610014, China.'}, {'ForeName': 'Qiong', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Shuangnan Community Service Center Chengdu 610047, China.'}, {'ForeName': 'Xiao-Li', 'Initials': 'XL', 'LastName': 'Yang', 'Affiliation': 'Yulin Community Service Center Chengdu 610044, China.'}, {'ForeName': 'Chang-Yong', 'Initials': 'CY', 'LastName': 'Jiang', 'Affiliation': 'Jinyang Community Service Center Chengdu 610045, China.'}, {'ForeName': 'Hong-Yan', 'Initials': 'HY', 'LastName': 'Luo', 'Affiliation': 'Caotang Community Service Center Chengdu 610072, China.'}, {'ForeName': 'Zheng-Hua', 'Initials': 'ZH', 'LastName': 'Cai', 'Affiliation': 'Xinhua Shaocheng Community Service Center Chengdu 610014, China.'}, {'ForeName': 'Shu-Guang', 'Initials': 'SG', 'LastName': 'Yu', 'Affiliation': 'Chengdu University of Traditional Chinese Medicine Chengdu 611137, China.'}]",Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,['10.19540/j.cnki.cjcmm.20200430.501'] 1939,32723033,Increases in speed do not change gait symmetry or variability in world-class race walkers.,"The aim of this study was to analyse changes in gait variability and symmetry with increasing speed in race walkers. Eighteen international athletes race walked on an instrumented treadmill at speeds of 11, 12, 13 and 14 km·h -1 in a randomised order for 3 min each. Spatiotemporal and ground reaction force data were recorded for 30 s at each speed. Gait variability was measured using median absolute deviation and inter-leg symmetry was measured using the symmetry angle. There was an overall effect of speed on all absolute values except push-off force, but symmetry and variability (except flight time) did not change with increased speed, step length and step frequency. Most athletes were asymmetrical for at least one variable, but none was asymmetrical for more than half of the variables measured. Therefore, being asymmetrical or having higher variability (<5%) in a few variables is normal. Taking all findings together, practitioners should exercise caution when deciding on the need for corrective interventions and should not be concerned that increasing gait speed could increase injury risk through changes to athletes' asymmetry. Race walking coaches should test at competition speeds to ensure that flight times, and any variability or asymmetry, are measured appropriately.",2020,"There was an overall effect of speed on all absolute values except push-off force, but symmetry and variability (except flight time) did not change with increased speed, step length and step frequency.","['Eighteen international athletes race walked on an instrumented treadmill at speeds of 11, 12, 13 and 14 km·h -1']",[],"['speed, step length and step frequency', 'gait variability and symmetry', 'Gait variability']","[{'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}]",[],"[{'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0427126', 'cui_str': 'Step length'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0332516', 'cui_str': 'Symmetrical'}]",18.0,0.0396385,"There was an overall effect of speed on all absolute values except push-off force, but symmetry and variability (except flight time) did not change with increased speed, step length and step frequency.","[{'ForeName': 'Catherine B', 'Initials': 'CB', 'LastName': 'Tucker', 'Affiliation': 'Carnegie School of Sport, Headingley Campus, Leeds Beckett University , Leeds, UK.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Hanley', 'Affiliation': 'Carnegie School of Sport, Headingley Campus, Leeds Beckett University , Leeds, UK.'}]",Journal of sports sciences,['10.1080/02640414.2020.1798730'] 1940,32723804,"Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.","BACKGROUND AND OBJECTIVES Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates genes related to iron metabolism. The efficacy (noninferiority) and safety of daprodustat compared with standard therapy (darbepoetin alfa) was evaluated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS This was a randomized, phase 3, double-blind, active-control study in Japanese patients receiving hemodialysis with anemia of CKD. Participants' treatment was switched from current erythropoiesis-stimulating agents (ESAs) to daprodustat 4 mg once daily or darbepoetin alfa 10-60 μ g once weekly (on the basis of the prestudy ESA dose). Dose was adjusted every 4 weeks for daprodustat or every 2 weeks for darbepoetin alfa, according to a protocol-specified algorithm. The primary end point was mean hemoglobin during weeks 40-52 in the intent-to-treat population. RESULTS Of 332 participants screened, 271 participants were randomized (safety evaluation: 271 participants; efficacy evaluation: 267 intent-to-treat population). The mean hemoglobin during weeks 40-52 were maintained within the target range in both groups (10.9 g/dl [95% confidence interval (95% CI), 10.8 to 11.0] for daprodustat, and 10.8 g/dl [95% CI, 10.7 to 11.0] for darbepoetin alfa). Daprodustat was noninferior to darbepoetin alfa, as the lower bound of the confidence interval for the treatment difference (0.1 g/dl; 95% CI, -0.1 to 0.2 g/dl) was greater than the noninferiority criterion of -1.0 g/dl. For most participants, hemoglobin was maintained within the target range (10.0-12.0 g/dl) during weeks 40-52 (88% daprodustat; 90% darbepoetin alfa). Geometric mean hepcidin levels decreased more at week 52 with daprodustat (-37%; 95% CI, -49 to -23) than with darbepoetin alfa (-20%; 95% CI, -36 to -1), and an increase in total iron-binding capacity was observed in the daprodustat group. Frequency of adverse events were generally similar between daprodustat and darbepoetin alfa. CONCLUSIONS Oral daprodustat was noninferior to darbepoetin alfa as measured by mean hemoglobin over weeks 40-52 in Japanese patients receiving hemodialysis switched from ESAs. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER 201754, Clinicaltrials.gov, NCT02969655.",2020,"Geometric mean hepcidin levels decreased more at week 52 with daprodustat (-37%; 95% CI, -49 to -23) than with darbepoetin alfa (-20%; 95% CI, -36 to -1), and an increase in total iron-binding capacity was observed in the daprodustat group.","['Japanese Hemodialysis Patients with Anemia', 'Japanese patients receiving hemodialysis switched from ESAs', 'Japanese patients receiving hemodialysis with anemia of CKD', '332 participants screened, 271 participants were randomized', '271 participants; efficacy evaluation: 267 intent-to-treat population']","['current erythropoiesis-stimulating agents (ESAs) to daprodustat 4 mg once daily or darbepoetin alfa', 'standard therapy (darbepoetin alfa', 'Daprodustat Compared with Darbepoetin Alfa']","['Efficacy and Safety', 'Geometric mean hepcidin levels', 'mean hemoglobin', 'hemoglobin', 'total iron-binding capacity', 'Frequency of adverse events']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0014819', 'cui_str': 'Erythrocyte production'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C4517672', 'cui_str': '267'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0014819', 'cui_str': 'Erythrocyte production'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0937950', 'cui_str': 'darbepoetin alfa'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0966897', 'cui_str': 'Hepcidin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0700379', 'cui_str': 'Total iron binding capacity'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",271.0,0.415077,"Geometric mean hepcidin levels decreased more at week 52 with daprodustat (-37%; 95% CI, -49 to -23) than with darbepoetin alfa (-20%; 95% CI, -36 to -1), and an increase in total iron-binding capacity was observed in the daprodustat group.","[{'ForeName': 'Tadao', 'Initials': 'T', 'LastName': 'Akizawa', 'Affiliation': 'Division of Nephrology, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Masaomi', 'Initials': 'M', 'LastName': 'Nangaku', 'Affiliation': 'Division of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Taeko', 'Initials': 'T', 'LastName': 'Yonekawa', 'Affiliation': 'Medicines Development, Japan Development, GlaxoSmithKline, Tokyo, Japan taeko.yonekawa@gsk.com.'}, {'ForeName': 'Nobuhiko', 'Initials': 'N', 'LastName': 'Okuda', 'Affiliation': 'Medicines Development, Japan Development, GlaxoSmithKline, Tokyo, Japan.'}, {'ForeName': 'Shinya', 'Initials': 'S', 'LastName': 'Kawamatsu', 'Affiliation': 'Clinical Operations, Japan Development, GlaxoSmithKline, Tokyo, Japan.'}, {'ForeName': 'Tomohiro', 'Initials': 'T', 'LastName': 'Onoue', 'Affiliation': 'Biomedical Data Sciences, Japan Development, GlaxoSmithKline, Tokyo, Japan.'}, {'ForeName': 'Yukihiro', 'Initials': 'Y', 'LastName': 'Endo', 'Affiliation': 'Medicines Development, Japan Development, GlaxoSmithKline, Tokyo, Japan.'}, {'ForeName': 'Katsutoshi', 'Initials': 'K', 'LastName': 'Hara', 'Affiliation': 'Clinical Pharmacology, Japan Development, GlaxoSmithKline, Tokyo, Japan.'}, {'ForeName': 'Alexander R', 'Initials': 'AR', 'LastName': 'Cobitz', 'Affiliation': 'Medicine Delivery, GlaxoSmithKline, Collegeville, Pennsylvania.'}]",Clinical journal of the American Society of Nephrology : CJASN,['10.2215/CJN.16011219'] 1941,32729819,Bioequivalence study of two formulations of memantine hydrochloride tablets in healthy male Chinese subjects under fasting and fed conditions
.,"PURPOSE Memantine is currently the only drug that acts on the glutamate energy system to treat Alzheimer's disease. A generic memantine tablet was developed to offer an alternative to the marketed tablet formulation. The purpose of this study was to assess the bioequivalence of two different memantine formulations among healthy male Chinese subjects under fasting and fed conditions. MATERIALS AND METHODS We carried out single-center, randomized, single-dose, open-label, two-period, cross-over studies which including 20 healthy male Chinese subjects under fasting and fed conditions, respectively. Plasma samples were collected prior to and up to 240 hours after dosing. Key pharmacokinetic parameters including area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t ), area from time zero to infinite (AUC 0-∞ ), and C max were used for bioequivalence assessment. RESULTS Under fasting condition, the 90% CIs of the geometric mean ratios of the test/reference drug for memantine were 106.5 - 114.0% for C max , 99.4 - 107.9% for AUC 0-t , and 100.0 - 109.6% for AUC 0-∞ . Under fed condition, the 90% CIs of the geometric mean ratios of the test/reference drug for memantine were 94.8 - 104.3% for C max , 98.2 - 110.5% for AUC 0-t , and 99.2 - 113.0% for AUC 0-∞ . CONCLUSION The observed pharmacokinetic parameters of memantine of the test drug were similar to those of the reference formulation both in the fasting and fed state. That is to say, the test formulation of memantine 10-mg tablet is bioequivalent to the reference formulation (Ebixa 10-mg tablet).",2020,The observed pharmacokinetic parameters of memantine of the test drug were similar to those of the reference formulation both in the fasting and fed state.,"['20 healthy male Chinese subjects under fasting and fed conditions, respectively', 'healthy male Chinese subjects under fasting and fed conditions', 'healthy male Chinese subjects under fasting and fed conditions\u2029']","['memantine hydrochloride tablets', 'memantine', 'memantine formulations', 'Memantine']","['plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t ), area from time zero to infinite (AUC 0-∞ ), and C max', 'geometric mean ratios of the test/reference drug for memantine']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0342895', 'cui_str': 'Fish-eye disease'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0771988', 'cui_str': 'Memantine hydrochloride'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0025242', 'cui_str': 'Memantine'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0919414', 'cui_str': '0'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0025242', 'cui_str': 'Memantine'}]",20.0,0.0343325,The observed pharmacokinetic parameters of memantine of the test drug were similar to those of the reference formulation both in the fasting and fed state.,"[{'ForeName': 'Juntao', 'Initials': 'J', 'LastName': 'Zheng', 'Affiliation': ''}, {'ForeName': 'Jiangying', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Liping', 'Initials': 'L', 'LastName': 'Mai', 'Affiliation': ''}, {'ForeName': 'Xiyong', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': ''}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Guoping', 'Initials': 'G', 'LastName': 'Zhong', 'Affiliation': ''}]",International journal of clinical pharmacology and therapeutics,['10.5414/CP203683'] 1942,32729820,"Pharmacokinetics, pharmacodynamics, and tolerability of JY09 in healthy Chinese subjects: A titrating, dose-escalating study
.","OBJECTIVES To evaluate the pharmacokinetics, pharmacodynamics, and tolerability of JY09, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, in healthy subjects. MATERIALS AND METHODS Healthy subjects were enrolled into 5 cohorts (0.3, 0.7, 1.5, 3.0, and 6.0 mg JY09) and received subcutaneous JY09 or placebo according to a randomized, double-blind, placebo-controlled, single-center, dose-escalating phase I trial design. Blood samples were collected over a 42-day period, and JY09 in plasma was determined by an electrochemical luminescence method. For the pharmacodynamic evaluation, oral glucose tolerance tests (OGTTs) were conducted predose and on day 5 after the target dose, during which plasma glucose, insulin, C-peptide, and glucagon concentrations were analyzed. Tolerability was assessed using physical examination and queries, vital sign measurements, laboratory analysis, and detection of immunogenicity. RESULTS In healthy Chinese subjects, JY09 exhibited a dose-dependent increase in AUC 0-inf and C max from 0.7 to 6.0 mg JY09. The half-life of JY09 was ~ 9.3 days, and the peak concentration was reached at ~ 60 - 72 hours. Following the OGTT, an increase in C-peptide concentration was observed after exposure to JY09 at the dose of 6.0 mg compared to the placebo group. JY09 was well tolerated in healthy Chinese subjects following a single dose of up to 6.0 mg. No symptomatic hypoglycemia was reported, and the most commonly observed adverse event was suppressed appetite, and its incidence was dose-dependent. Four subjects (13%) developed anti-JY09 antibodies. CONCLUSION JY09 has a long half-life of ~ 9.3 days, with an acceptable safety profile.",2020,"In healthy Chinese subjects, JY09 exhibited a dose-dependent increase in AUC 0-inf and C max from 0.7 to 6.0 mg JY09.","['Healthy subjects were enrolled into 5 cohorts (0.3, 0.7, 1.5, 3.0, and 6.0 mg JY09) and received', 'healthy Chinese subjects', 'healthy subjects']","['subcutaneous JY09 or placebo', 'placebo']","['symptomatic hypoglycemia', 'tolerated', 'plasma glucose, insulin, C-peptide, and glucagon concentrations', 'Blood samples', 'AUC 0-inf and C max', 'peak concentration', 'C-peptide concentration', 'pharmacokinetics, pharmacodynamics, and tolerability', 'physical examination and queries, vital sign measurements, laboratory analysis, and detection of immunogenicity', 'Tolerability', 'Pharmacokinetics, pharmacodynamics, and\xa0tolerability']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C4068885', 'cui_str': '0.3'}, {'cui': 'C4517474', 'cui_str': '0.7'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}, {'cui': 'C0017687', 'cui_str': 'Glucagon'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C3543841', 'cui_str': 'Query'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}]",,0.236705,"In healthy Chinese subjects, JY09 exhibited a dose-dependent increase in AUC 0-inf and C max from 0.7 to 6.0 mg JY09.","[{'ForeName': 'Guangyu', 'Initials': 'G', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Bei', 'Initials': 'B', 'LastName': 'Cao', 'Affiliation': ''}, {'ForeName': 'Yuanxun', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Geng', 'Affiliation': ''}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Lin', 'Affiliation': ''}, {'ForeName': 'Junyi', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': ''}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': ''}, {'ForeName': 'Zuyi', 'Initials': 'Z', 'LastName': 'Weng', 'Affiliation': ''}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Bai', 'Affiliation': ''}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ''}]",International journal of clinical pharmacology and therapeutics,['10.5414/CP203730'] 1943,32729824,Multiple-dose pharmacokinetics and safety of amoxicillin/clavulanate in healthy elderly subjects
.,"BACKGROUND Amoxicillin/clavulanate is a widely used oral formulation of penicillin combined with a β-lactamase inhibitor. When using amoxicillin/clavulanate in the elderly, the risk of adverse drug reaction may be greater. This study aimed to evaluate the pharmacokinetics (PKs) and safety of multiple-dose amoxicillin/clavulanate administration in healthy elderly subjects and to compare the observed PK profiles with those in healthy younger adults. An open-label, one-sequence, multiple administration study was conducted in 16 healthy elderly subjects. MATERIALS AND METHODS Subjects orally received amoxicillin and clavulanate 750/187.5 twice daily for 9 days. For PK analysis, serial blood samples were collected up to 12 hours after the last administration of amoxicillin/clavulanate. The demographic and PK data of this study were compared to those of healthy young adults from a separate study with a similar design. Safety assessments including clinical laboratory tests, physical examination, vital signs, and adverse event (AE) monitoring were performed throughout the study. RESULTS All AEs were mild, and no serious AEs were reported in this study. The systemic exposure of amoxicillin and clavulanate was ~ 90% and 60% higher, respectively, in the elderly subjects than in the younger subjects. However, the time required to reach maximum concentration at steady state and the elimination half-life were similar in the two age groups. CONCLUSION Although multiple administration of amoxicillin/clavulanate 750/187.5 mg was safe and well-tolerated, the systemic exposure of amoxicillin and clavulanate was higher in elderly subjects than in younger subjects.",2020,"The systemic exposure of amoxicillin and clavulanate was ~ 90% and 60% higher, respectively, in the elderly subjects than in the younger subjects.","['healthy young adults', 'healthy younger adults', 'healthy elderly subjects', '16 healthy elderly subjects', 'healthy elderly subjects\u2029', 'elderly subjects than in younger subjects', 'Subjects orally received']","['Amoxicillin/clavulanate', 'amoxicillin/clavulanate', 'amoxicillin and clavulanate']","['systemic exposure of amoxicillin and clavulanate', 'clinical laboratory tests, physical examination, vital signs, and adverse event (AE) monitoring', 'safe and well-tolerated, the systemic exposure of amoxicillin and clavulanate']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0054066', 'cui_str': 'Amoxicillin and clavulanate'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0054066', 'cui_str': 'Amoxicillin and clavulanate'}, {'cui': 'C4505474', 'cui_str': 'Clinical Laboratory Tests'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}]",16.0,0.0121701,"The systemic exposure of amoxicillin and clavulanate was ~ 90% and 60% higher, respectively, in the elderly subjects than in the younger subjects.","[{'ForeName': 'Sang Won', 'Initials': 'SW', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'Yewon', 'Initials': 'Y', 'LastName': 'Choi', 'Affiliation': ''}, {'ForeName': 'Kyungho', 'Initials': 'K', 'LastName': 'Jang', 'Affiliation': ''}, {'ForeName': 'Seo Hyun', 'Initials': 'SH', 'LastName': 'Yoon', 'Affiliation': ''}, {'ForeName': 'Jae-Yong', 'Initials': 'JY', 'LastName': 'Chung', 'Affiliation': ''}]",International journal of clinical pharmacology and therapeutics,['10.5414/CP203773'] 1944,32727707,Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.,"BACKGROUND The role of maintenance therapy for malignant pleural mesothelioma (MPM) is unknown. We performed a randomized phase II trial to determine if continuation of pemetrexed after first-line pemetrexed and platinum would improve progression-free survival (PFS). PATIENTS AND METHODS Eligible patients with unresectable MPM, without disease progression following 4 to 6 cycles of pemetrexed and platinum were randomized 1:1 to observation or continuation of pemetrexed until progression, stratified by number of cycles (< 6 or 6), cis- or carboplatin containing regimen, and histology. Study size was calculated based on the assumption that observation would produce a median PFS of 3 months and pemetrexed would yield median PFS of 6 months. RESULTS A total of 72 patients were registered from December 2010 to June 2016. The study closed early after 53 patients were randomized; 49 eligible (22 on the observation arm and 27 on the pemetrexed arm) were included in the analysis. The median PFS was 3 months (95% confidence interval [CI], 2.6-11.9 months) on observation and 3.4 months (95% CI, 2.8-9.8 months) on pemetrexed (hazard ratio [HR], 0.99; 95% CI, 0.51-1.90; P = .9733). The median overall survival (OS) was 11.8 months (95% CI, 9.3-28.7 months) for observation, and 16.3 months (95% CI, 10.5-26.0 months) for pemetrexed (HR, 0.86; 95% CI, 0.44-1.71; P = .6737). Grade 3 or 4 toxicities on the pemetrexed arm included anemia (8%), lymphopenia (8%), neutropenia (4%), and fatigue (4%). A higher baseline level of soluble mesothelin-related peptide was associated with worse PFS (HR, 1.86; 95% CI, 1.00-3.46; P = .049). CONCLUSION Maintenance pemetrexed following initial pemetrexed and platinum chemotherapy does not improve PFS in patients with MPM.",2020,"A higher baseline level of soluble mesothelin-related peptide was associated with worse PFS (HR, 1.86; 95% CI, 1.00-3.46; P = .049). ","['patients with MPM', 'malignant pleural mesothelioma (MPM', '53 patients were randomized; 49 eligible (22 on the observation arm and 27 on the pemetrexed arm) were included in the analysis', '72 patients were registered from December 2010 to June 2016', 'Eligible patients with unresectable MPM, without disease progression following 4 to 6 cycles of']","['cis- or carboplatin containing regimen, and histology', 'pemetrexed and platinum chemotherapy', 'pemetrexed and platinum', 'pemetrexed after first-line pemetrexed and platinum', 'Maintenance Pemetrexed']","['PFS', 'neutropenia', 'median overall survival (OS', 'anemia', 'Grade 3 or 4 toxicities', 'lymphopenia', 'progression-free survival (PFS', 'median PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0812413', 'cui_str': 'Malignant mesothelioma of pleura'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0007099', 'cui_str': 'Carcinoma in situ'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0019638', 'cui_str': 'Histology'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0024312', 'cui_str': 'Lymphocytopenia'}]",72.0,0.170713,"A higher baseline level of soluble mesothelin-related peptide was associated with worse PFS (HR, 1.86; 95% CI, 1.00-3.46; P = .049). ","[{'ForeName': 'Arkadiusz Z', 'Initials': 'AZ', 'LastName': 'Dudek', 'Affiliation': 'Regions Cancer Care Center, HealthPartners Inc, Minneapolis, MN. Electronic address: arkadiusz.z.dudek@healthpartners.com.'}, {'ForeName': 'Xiaofei', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Alliance Statistics and Data Center, Duke University, Durham, NC.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Gu', 'Affiliation': 'Alliance Statistics and Data Center, Duke University, Durham, NC.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Duong', 'Affiliation': 'Alliance Statistics and Data Center, Duke University, Durham, NC.'}, {'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Stinchcombe', 'Affiliation': 'Duke Cancer Institute, Duke University, Durham, NC.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Kratzke', 'Affiliation': 'Division of Hematology, Oncology and Transplantation, University of Minnesota/Masonic Cancer Center, Minneapolis, MN.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Borghaei', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, PA.'}, {'ForeName': 'Everett E', 'Initials': 'EE', 'LastName': 'Vokes', 'Affiliation': 'Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL.'}, {'ForeName': 'Hedy L', 'Initials': 'HL', 'LastName': 'Kindler', 'Affiliation': 'Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL.'}]",Clinical lung cancer,['10.1016/j.cllc.2020.06.025'] 1945,32730310,Monetary incentives for improving smartphone-measured oral hygiene behaviors in young children: A randomized pilot trial.,"AIMS To assess feasibility, acceptability, and early efficacy of monetary incentive-based interventions on fostering oral hygiene in young children measured with a Bluetooth-enabled toothbrush and smartphone application. DESIGN A stratified, parallel-group, three-arm individually randomized controlled pilot trial. SETTING Two Los Angeles area Early Head Start (EHS) sites. PARTICIPANTS 36 parent-child dyads enrolled in an EHS home visit program for 0-3 year olds. INTERVENTIONS Eligible dyads, within strata and permuted blocks, were randomized in equal allocation to one of three groups: waitlist (delayed monetary incentive) control group, fixed monetary incentive package, or lottery monetary incentive package. The intervention lasted 8 weeks. OUTCOMES Primary outcomes were a) toothbrushing performance: mean number of Bluetooth-recorded half-day episodes per week when the child's teeth were brushed, and b) dental visit by the 2-month follow-up among children with no prior dental visit. The a priori milestone of 20% more frequent toothbrushing identified the intervention for a subsequent trial. Feasibility and acceptability measures were also assessed, including frequency of parents syncing the Bluetooth-enabled toothbrush to the smartphone application and plaque measurement from digital photographs. FINDINGS Digital monitoring of toothbrushing was feasible. Mean number of weekly toothbrushing episodes over 8 weeks was 3.9 in the control group, 4.1 in the fixed incentive group, and 6.0 in the lottery incentive group. The lottery group had 53% more frequent toothbrushing than the control group and 47% more frequent toothbrushing than the fixed group. Exploratory analyses showed effects concentrated among children ≤24 months. Follow-up dental visit attendance was similar across groups. iPhone 7 more reliably captured evaluable images than Photomed Cannon G16. CONCLUSIONS Trial protocol and outcome measures were deemed feasible and acceptable. Results informed the study protocol for a fully powered trial of lottery incentives versus a delayed control using the smart toothbrush and remote digital incentive program administration. TRIAL REGISTRATION ClinicalTrials.gov identifier NCT03862443.",2020,The lottery group had 53% more frequent toothbrushing than the control group and 47% more frequent toothbrushing than the fixed group.,"['young children', 'young children measured with a Bluetooth-enabled toothbrush and smartphone application', 'Two Los Angeles area', '36 parent-child dyads enrolled in an EHS home visit program for 0-3 year olds']","['monetary incentive-based interventions', 'waitlist (delayed monetary incentive) control group, fixed monetary incentive package, or lottery monetary incentive package']","['Mean number of weekly toothbrushing episodes', ""toothbrushing performance: mean number of Bluetooth-recorded half-day episodes per week when the child's teeth were brushed, and b) dental visit"", 'Feasibility and acceptability measures', 'frequent toothbrushing', 'feasibility, acceptability, and early efficacy', 'smartphone-measured oral hygiene behaviors']","[{'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0562342', 'cui_str': 'Empowered'}, {'cui': 'C0183975', 'cui_str': 'Toothbrush'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0183975', 'cui_str': 'Toothbrush'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0040461', 'cui_str': 'Brushing of teeth'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0029164', 'cui_str': 'Dental Hygiene'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",,0.0928108,The lottery group had 53% more frequent toothbrushing than the control group and 47% more frequent toothbrushing than the fixed group.,"[{'ForeName': 'Justin S', 'Initials': 'JS', 'LastName': 'White', 'Affiliation': 'Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, California, United States of America.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Ramos-Gomez', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, University of California San Francisco, San Francisco, California, United States of America.""}, {'ForeName': 'Jenny X', 'Initials': 'JX', 'LastName': 'Liu', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, University of California San Francisco, San Francisco, California, United States of America.""}, {'ForeName': 'Bonnie', 'Initials': 'B', 'LastName': 'Jue', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, University of California San Francisco, San Francisco, California, United States of America.""}, {'ForeName': 'Tracy L', 'Initials': 'TL', 'LastName': 'Finlayson', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, University of California San Francisco, San Francisco, California, United States of America.""}, {'ForeName': 'Jeremiah R', 'Initials': 'JR', 'LastName': 'Garza', 'Affiliation': 'Section of Pediatric Dentistry, School of Dentistry, University of California Los Angeles, Los Angeles, California, United States of America.'}, {'ForeName': 'Alexandra H', 'Initials': 'AH', 'LastName': 'Crawford', 'Affiliation': 'California Protons Cancer Therapy Center, University of California San Diego Health, San Diego, California, United States of America.'}, {'ForeName': 'Sarit', 'Initials': 'S', 'LastName': 'Helman', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, University of California San Francisco, San Francisco, California, United States of America.""}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Santo', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, University of California San Francisco, San Francisco, California, United States of America.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Cheng', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, University of California San Francisco, San Francisco, California, United States of America.""}, {'ForeName': 'James G', 'Initials': 'JG', 'LastName': 'Kahn', 'Affiliation': 'Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, California, United States of America.'}, {'ForeName': 'Stuart A', 'Initials': 'SA', 'LastName': 'Gansky', 'Affiliation': 'Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, California, United States of America.'}]",PloS one,['10.1371/journal.pone.0236692'] 1946,32730325,The safety and feasibility of a Halliwick style of aquatic physiotherapy for falls and balance dysfunction in people with Parkinson's Disease: A single blind pilot trial.,"BACKGROUND There is growing evidence that aquatic physiotherapy may be effective for people with Parkinson's Disease (PD) but most studies have investigated land based type exercises in the aquatic environment. Few studies have examined customised aquatic therapies such as the Halliwick concept which focuses on trunk rotation and core stabilisation. OBJECTIVE The primary aim was to determine the feasibility of a Halliwick style aquatic physiotherapy intervention for people with PD. The secondary aim was to compare the Halliwick intervention with traditional aquatic and land based physiotherapy in terms of disease severity, balance and fear of falling. METHODS Halliwick style aquatic, traditional aquatic and land based physiotherapy were trialled in a single blind pilot study. All interventions ran for 60 minutes per week over 12 weeks. Feasibility outcomes were safety, adherence and attrition. Secondary outcomes included the Unified Parkinson's Disease Rating Scale motor subsection (UPDRS-III), Berg Balance Scale (BBS), Mini BESTest and modified Falls Efficacy Scale (mFES). RESULTS 30 participants with moderate PD were recruited. Participant mean age was 72 years (SD 8.4; range 51-86) with moderate disease severity (median Hoehn & Yahr score 3; IQR 1).No falls occurred during intervention sessions, however ten participants reported falls during the study period. No other adverse consequences were reported. All groups had adherence over 85%. No within group significant differences were found in UPDRS-III, BBS or mFES scores post-intervention for all groups, but the Halliwick aquatic group improved significantly in the Mini BESTest post-intervention (p = 0.011, 95% CI -7.36,-1.31, t (10) = -2.98). CONCLUSIONS Despite people with PD being a vulnerable population, aquatic physiotherapy, including the Halliwick style is a safe treatment option. Promising results for balance in the Halliwick aquatic group were observed, but further studies with larger sample sizes is required to increase confidence in the results.",2020,"No within group significant differences were found in UPDRS-III, BBS or mFES scores post-intervention for all groups, but the Halliwick aquatic group improved significantly in the Mini BESTest post-intervention (p = 0.011, 95% CI -7.36,-1.31, t (10) = -2.98). ","['Participant mean age was 72 years (SD 8.4; range 51-86) with moderate disease severity (median Hoehn & Yahr score 3; IQR 1).No falls occurred during intervention sessions, however ten participants reported falls during the study period', ""people with Parkinson's Disease"", '30 participants with moderate PD', ""people with Parkinson's Disease (PD"", 'people with PD']","['Halliwick style aquatic, traditional aquatic and land based physiotherapy', 'aquatic physiotherapy', 'Halliwick style aquatic physiotherapy intervention', 'Halliwick intervention with traditional aquatic and land based physiotherapy', 'Halliwick style of aquatic physiotherapy']","['safety, adherence and attrition', 'UPDRS-III, BBS or mFES scores', 'adverse consequences', 'disease severity, balance and fear of falling', ""Unified Parkinson's Disease Rating Scale motor subsection (UPDRS-III), Berg Balance Scale (BBS"", 'Mini BESTest and modified Falls Efficacy Scale (mFES']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517876', 'cui_str': '8.4'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0557668', 'cui_str': 'Landing'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0686907', 'cui_str': 'Consequence of'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0877040', 'cui_str': 'Fear of falling'}, {'cui': 'C0445542', 'cui_str': 'Mini'}]",30.0,0.0617848,"No within group significant differences were found in UPDRS-III, BBS or mFES scores post-intervention for all groups, but the Halliwick aquatic group improved significantly in the Mini BESTest post-intervention (p = 0.011, 95% CI -7.36,-1.31, t (10) = -2.98). ","[{'ForeName': 'Aan Fleur', 'Initials': 'AF', 'LastName': 'Terrens', 'Affiliation': 'Movement Disorder Program, Peninsula Health, VIC, Australia.'}, {'ForeName': 'Sze-Ee', 'Initials': 'SE', 'LastName': 'Soh', 'Affiliation': 'Department of Physiotherapy, Monash University, VIC, Australia.'}, {'ForeName': 'Prue', 'Initials': 'P', 'LastName': 'Morgan', 'Affiliation': 'Department of Physiotherapy, Monash University, VIC, Australia.'}]",PloS one,['10.1371/journal.pone.0236391'] 1947,32736540,Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial.,"BACKGROUND The value of chemotherapy in soft tissue sarcoma (STS) remains controversial. Several expert teams consider that chemotherapy provides a survival advantage and should be proposed in high-risk (HR) patients. However, the lack of accuracy in identifying HR patients with conventional risk factors (large, deep, FNCLCC grade 3, extremity STS) is an issue that cannot be neglected. For example, while the FNCLCC grading system is a powerful tool, it has several limitations. CINSARC, a 67-gene signature, has proved to be an additional independent factor for predicting metastatic spread and outperforms histological grade. Regardless of FNCLCC grade, CINSARC stratifies patients into two separate prognostic groups: one with an excellent prognosis (low-risk (LR) CINSARC) and the other with a worse outcome (HR-CINSARC) in terms of metastatic relapse. Here we evaluate the role of chemotherapy in grade 1-2 STS patients with HR-CINSARC and assess the prognostic value of CINSARC in patients treated with standard of care. METHODS CHIC is a parallel, randomized, open-label, multicenter study evaluating the effect on metastasis-free survival of adding perioperative chemotherapy to standard of care in patients with grade ½ STS sarcoma defined as HR by CINSARC. In this target selection design, 600 patients will be screened with CINSARC to randomize 250 HR-CINSARC patients between standard of care and standard of care plus chemotherapy (4 cycles of 3 weeks of intravenous chemotherapy with doxorubicin in combination with dacarbazine or ifosfamide according to histologic subtype). LR-CINSARC patients will be treated by standard of care according to the investigator. The primary endpoint is metastasis-free survival. Secondary endpoints include overall survival, disease-free survival and safety. Furthermore, the prognostic value of CINSARC will be evaluated by comparing LR-CINSARC patients to HR-CINSARC patients randomized in standard of care. DISCUSSION CHIC is a prospective randomized phase III trial designed to comprehensively evaluate the benefit of chemotherapy in HR-CINSARC patients and to prospectively validate the prognostic value of CINSARC in grade ½ STS sarcoma patients. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT04307277 Date of registration: 13 March 2020.",2020,"CINSARC, a 67-gene signature, has proved to be an additional independent factor for predicting metastatic spread and outperforms histological grade.","['soft tissue sarcoma (STS', '600 patients will be screened with CINSARC to randomize 250 HR-CINSARC patients between standard of care and standard of', 'patients with grade ½ STS sarcoma defined as HR by CINSARC', 'grade ½ STS sarcoma patients', 'grade 1-2 STS patients with HR-CINSARC and assess the prognostic value of CINSARC in patients treated with standard of care', 'patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma']","['care plus chemotherapy', 'perioperative chemotherapy', 'intravenous chemotherapy with doxorubicin in combination with dacarbazine or ifosfamide', 'peri-operative chemotherapy']","['overall survival, disease-free survival and safety', 'metastasis-free survival']","[{'cui': 'C1261473', 'cui_str': 'Sarcoma'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0392752', 'cui_str': 'Localized'}]","[{'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0413365', 'cui_str': 'Intravenous chemotherapy'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0010927', 'cui_str': 'Dacarbazine'}, {'cui': 'C0020823', 'cui_str': 'Ifosfamide'}, {'cui': 'C0347985', 'cui_str': 'During values'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332296', 'cui_str': 'Free of'}]",600.0,0.117648,"CINSARC, a 67-gene signature, has proved to be an additional independent factor for predicting metastatic spread and outperforms histological grade.","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Filleron', 'Affiliation': 'Biostatistics Unit, Institut Claudius Regaud, IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse Cedex, France. Filleron.thomas@iuct-oncopole.fr.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Le Guellec', 'Affiliation': 'Department of Pathology, Institut Claudius Regaud, IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse, France.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Chevreau', 'Affiliation': 'Department of Medical Oncology, Institut Claudius Regaud IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse, France.'}, {'ForeName': 'Bastien', 'Initials': 'B', 'LastName': 'Cabarrou', 'Affiliation': 'Biostatistics Unit, Institut Claudius Regaud, IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse Cedex, France.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Lesluyes', 'Affiliation': 'INSERM U1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Lodin', 'Affiliation': 'Clinical Trials Office, Institut Claudius Regaud, IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse, France.'}, {'ForeName': 'Angélique', 'Initials': 'A', 'LastName': 'Massoubre', 'Affiliation': 'Clinical Trials Office, Institut Claudius Regaud, IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse, France.'}, {'ForeName': 'Muriel', 'Initials': 'M', 'LastName': 'Mounier', 'Affiliation': 'Clinical Trials Office, Institut Claudius Regaud, IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse, France.'}, {'ForeName': 'Muriel', 'Initials': 'M', 'LastName': 'Poublanc', 'Affiliation': 'Clinical Trials Office, Institut Claudius Regaud, IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Chibon', 'Affiliation': 'Department of Pathology, Institut Claudius Regaud, IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse, France.'}, {'ForeName': 'Thibaud', 'Initials': 'T', 'LastName': 'Valentin', 'Affiliation': 'INSERM U1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.'}]",BMC cancer,['10.1186/s12885-020-07207-3'] 1948,32736542,"Study protocol of the Aerobic exercise and CogniTIVe functioning in women with breAsT cancEr (ACTIVATE) trial: a two-arm, two-centre randomized controlled trial.","BACKGROUND Up to 75% of women diagnosed with breast cancer report chemotherapy-related cognitive changes (CRCC) during treatment, including decreased memory, attention, and processing speed. Though CRCC negatively impacts everyday functioning and reduces overall quality of life in women diagnosed with breast cancer, effective interventions to prevent and/or manage CRCC are elusive. Consequently, women seldom receive advice on how to prevent or manage CRCC. Aerobic exercise is associated with improved cognitive functioning in healthy older adults and adults with cognitive impairments. Accordingly, it holds promise as an intervention to prevent and/or manage CRCC. However, evidence from randomized controlled trials (RCTs) supporting a beneficial effect of aerobic exercise on CRCC is limited. The primary aim of the ACTIVATE trial is to evaluate the impact of supervised aerobic exercise on CRCC in women receiving chemotherapy for breast cancer. METHODS The ACTIVATE trial is a two-arm, two-centre RCT. Women diagnosed with stage I-III breast cancer and awaiting neo-adjuvant or adjuvant chemotherapy are recruited from hospitals in Ottawa (Ontario) and Vancouver (British Columbia), Canada. Recruits are randomized to the intervention group (aerobic exercise during chemotherapy) or the wait-list control group (usual care during chemotherapy and aerobic exercise post-chemotherapy). The primary outcome is cognitive functioning as measured by a composite cognitive summary score (COGSUM) of several neuropsychological tests. Secondary outcomes are self-reported cognitive functioning, quality of life, and brain structure and functioning (measured by magnetic resonance imaging (MRI)/functional MRI and electroencephalography). Assessments take place pre-chemotherapy (pre-intervention), mid-way through chemotherapy (mid-intervention/mid-wait period), end of chemotherapy (post-intervention/post-wait period; primary endpoint), 16-weeks post-chemotherapy, and at 1-year post-baseline. DISCUSSION Aerobic exercise is a promising intervention for preventing and/or managing CRCC and enhancing quality of life among women diagnosed with breast cancer. The ACTIVATE trial tests several novel hypotheses, including that aerobic exercise can prevent and/or mitigate CRCC and that this effect is mediated by the timing of intervention delivery (i.e., during versus post-chemotherapy). Findings may support prescribing exercise during (or post-) chemotherapy for breast cancer and elucidate the potential role of aerobic exercise as a management strategy for CRCC in women with early-stage breast cancer. TRIAL REGISTRATION The trial was registered with the ClinicalTrials.gov database ( NCT03277898 ) on September 11, 2017.",2020,Recruits are randomized to the intervention group (aerobic exercise during chemotherapy) or the wait-list control group (usual care during chemotherapy and aerobic exercise post-chemotherapy).,"['women diagnosed with breast cancer report chemotherapy-related cognitive changes (CRCC', 'women receiving chemotherapy for breast cancer', 'women with breAsT cancEr', 'Women diagnosed with stage I-III breast cancer and awaiting neo-adjuvant or adjuvant chemotherapy are recruited from hospitals in Ottawa (Ontario) and Vancouver (British Columbia), Canada', 'women diagnosed with breast cancer', 'women with early-stage breast cancer', 'healthy older adults and adults with cognitive impairments']","['CRCC', 'supervised aerobic exercise', 'Aerobic exercise', 'Aerobic exercise and CogniTIVe functioning', 'intervention group (aerobic exercise during chemotherapy) or the wait-list control group (usual care during chemotherapy and aerobic exercise post-chemotherapy', 'prescribing exercise during (or post-) chemotherapy', 'aerobic exercise']","['self-reported cognitive functioning, quality of life, and brain structure and functioning (measured by magnetic resonance imaging (MRI)/functional MRI and electroencephalography', 'cognitive functioning as measured by a composite cognitive summary score (COGSUM) of several neuropsychological tests', 'overall quality of life', 'cognitive functioning']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0006193', 'cui_str': 'British Columbia'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439577', 'cui_str': 'Post-chemotherapy'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0687676', 'cui_str': 'After values'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.341436,Recruits are randomized to the intervention group (aerobic exercise during chemotherapy) or the wait-list control group (usual care during chemotherapy and aerobic exercise post-chemotherapy).,"[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Brunet', 'Affiliation': 'School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, 125 University Private, Montpetit Hall, Ottawa, ON, K1N 6N5, Canada. jennifer.brunet@uottawa.ca.'}, {'ForeName': 'Meagan', 'Initials': 'M', 'LastName': 'Barrett-Bernstein', 'Affiliation': 'School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, 125 University Private, Montpetit Hall, Ottawa, ON, K1N 6N5, Canada.'}, {'ForeName': 'Kendra', 'Initials': 'K', 'LastName': 'Zadravec', 'Affiliation': 'Rehabiliation Sciences Graduate Program, Faculty of Medicine, University of British Columbia, T114-2211 Wesbrook Mall, Vancouver, BC, V6T 1Z7, Canada.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Taljaard', 'Affiliation': 'The Ottawa Hospital Research Institute, Clinical Epidemiology Program, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'LeVasseur', 'Affiliation': 'British Columbia Cancer Agency, Vancouver, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.'}, {'ForeName': 'Amirrtha', 'Initials': 'A', 'LastName': 'Srikanthan', 'Affiliation': 'Department of Medicine, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.'}, {'ForeName': 'Kelcey A', 'Initials': 'KA', 'LastName': 'Bland', 'Affiliation': 'Mary MacKillop Institute for Health Research, Australian Catholic University, Level 5, 215 Spring Street, Melbourne, VIC, 3000, Australia.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Collins', 'Affiliation': 'School of Psychology, Faculty of Social Sciences, University of Ottawa, 136 Jean-Jacques Lussier, Vanier Hall, Ottawa, ON, K1N 6N5, Canada.'}, {'ForeName': 'Julia W Y', 'Initials': 'JWY', 'LastName': 'Kam', 'Affiliation': 'Department of Psychology & Hotchkiss Brain Institute, University of Calgary, 2500 Campus Drive, Calgary, AB, T2N 1N4, Canada.'}, {'ForeName': 'Todd C', 'Initials': 'TC', 'LastName': 'Handy', 'Affiliation': 'Department of Psychology, University of British Columbia, 3406-2136 West Mall, Vancouver, BC, V6T 1Z4, Canada.'}, {'ForeName': 'Sherri', 'Initials': 'S', 'LastName': 'Hayden', 'Affiliation': 'Division of Neurology/Faculty of Medicine, University of British Columbia, P213-2211 Westbrook Mall, Vancouver, BC, V6T 2B5, Canada.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Simmons', 'Affiliation': 'British Columbia Cancer Agency, Vancouver, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.'}, {'ForeName': 'Andra M', 'Initials': 'AM', 'LastName': 'Smith', 'Affiliation': 'School of Psychology, Faculty of Social Sciences, University of Ottawa, 136 Jean-Jacques Lussier, Vanier Hall, Ottawa, ON, K1N 6N5, Canada.'}, {'ForeName': 'Naznin', 'Initials': 'N', 'LastName': 'Virji-Babul', 'Affiliation': 'Department of Physical Therapy, Faculty of Medicine, University of British Columbia, 2215 Westbrook Mall, Vancouver, BC, V6T 1Z3, Canada.'}, {'ForeName': 'Kristin L', 'Initials': 'KL', 'LastName': 'Campbell', 'Affiliation': 'Department of Physical Therapy, Faculty of Medicine, University of British Columbia, 2215 Westbrook Mall, Vancouver, BC, V6T 1Z3, Canada.'}]",BMC cancer,['10.1186/s12885-020-07196-3'] 1949,32736555,Experiential learning for children's dental anxiety: a cluster randomized trial.,"BACKGROUND Dental anxiety (DA) has an impact on the quality of dental treatment and may have long-lasting implications for children. A recent study introducing experiential learning (EL) into children's oral health promotion resulted in better oral hygiene. The purpose of the study is to evaluate whether EL can reduce children's DA. METHODS In September 2018, we recruited 988 children aged 7-8 years from 24 classes to participate in a cluster-randomized trial. Classes were randomly assigned to EL (in which children received a lively presentation on oral health and participated in a role play in a simulated dental clinic in the classroom) or the Tell-Show-Do (TSD) group (in which children received a conventional TSD behavior management). The primary outcome was the prevalence of high DA after the procedure of pit and fissure sealant (PFS), assessed by a modified Children's Fear Survey Schedule-Dental Subscale. Secondary outcomes were changes in blood pressures (BP) and pulse rates (PR) before and after the PFS procedure. The intervention effects were estimated by means of mixed effect models, which included covariates of gender and school (and baseline value for BP and PR only), and a random cluster effect. RESULTS In 396 children of the EL group who received the PFS treatment, the prevalence of high DA (score ≥ 38) was 18.5%, compared with 24.3% in 391 children of the TSD group (OR = 0.65; 95% confidence interval, 0.46-0.93; P = 0.019). The increases in BP and PR after the PFS were also significantly less in the EL group. CONCLUSION School-based experiential learning intervention before a dental visit is feasible and effective in reducing children's dental anxiety during PFS. TRIAL REGISTRATION The trial was registered in Chinese Clinical Trial Registry on 5 January 2020 (No.: ChiCTR2000028878 , retrospectively registered).",2020,"CONCLUSION School-based experiential learning intervention before a dental visit is feasible and effective in reducing children's dental anxiety during PFS. ","['In September 2018, we recruited 988 children aged 7-8\u2009years from 24 classes to participate in a cluster-randomized trial', ""children's dental anxiety"", '396 children of the EL group who received the', 'children']","['Experiential learning', 'PFS', 'lively presentation on oral health and participated in a role play in a simulated dental clinic in the classroom) or the Tell-Show-Do (TSD', 'experiential learning (EL', 'EL', 'School-based experiential learning intervention', 'conventional TSD behavior management']","['changes in blood pressures (BP) and pulse rates (PR', 'BP and PR', 'prevalence of high DA', ""prevalence of high DA after the procedure of pit and fissure sealant (PFS), assessed by a modified Children's Fear Survey Schedule-Dental Subscale""]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0085380', 'cui_str': 'Dental phobia'}, {'cui': 'C5191354', 'cui_str': '396'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0243012', 'cui_str': 'Active Learning'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0243012', 'cui_str': 'Active Learning'}, {'cui': 'C0031992', 'cui_str': 'Pit Fissure Sealants'}, {'cui': 'C0449450', 'cui_str': 'Presentation'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0011344', 'cui_str': 'Dental clinic'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0150143', 'cui_str': 'Behavior management'}]","[{'cui': 'C1268766', 'cui_str': 'Blood pressure alteration'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0232117', 'cui_str': 'Pulse rate'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0085380', 'cui_str': 'Dental phobia'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0031992', 'cui_str': 'Pit Fissure Sealants'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0451158', 'cui_str': 'Fear survey schedule'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}]",988.0,0.160375,"CONCLUSION School-based experiential learning intervention before a dental visit is feasible and effective in reducing children's dental anxiety during PFS. ","[{'ForeName': 'Minmin', 'Initials': 'M', 'LastName': 'Zhu', 'Affiliation': 'Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, 518054, China. zhuminmin1982@163.com.'}, {'ForeName': 'Hongbing', 'Initials': 'H', 'LastName': 'Yu', 'Affiliation': 'Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, 518054, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Xie', 'Affiliation': 'Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, 518054, China.'}, {'ForeName': 'Hongwen', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Shenzhen Nanshan Maternal and Child Health Care Hospital, Shenzhen, 518054, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'He', 'Affiliation': 'Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, 518054, China.'}, {'ForeName': 'Huimin', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, 518054, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Su', 'Affiliation': 'Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, 518054, China.'}, {'ForeName': 'Xueqi', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Shenzhen Nanshan Maternal and Child Health Care Hospital, Shenzhen, 518054, China. 756296691@qq.com.'}]",BMC oral health,['10.1186/s12903-020-01204-5'] 1950,32736576,The role of vaginal palpation in motor learning of the pelvic floor muscles for women with stress urinary incontinence: study protocol for a randomized controlled trial.,"BACKGROUND Approximately 30 to 50% of women are unable to correctly perform pelvic floor muscle (PFM) contractions. For women to benefit from a pelvic floor muscle training (PFMT) programme for stress urinary incontinence (SUI), the awareness phase of PFMT cannot be omitted. The purpose of this study is to evaluate whether vaginal palpation together with verbal instructions about PFMs and body awareness techniques helps women with SUI learn how to correctly contract the PFMs and improve their functions. METHODS This single-centre, double-blind randomized controlled trial with two intervention groups was designed following the standard protocol items for randomized interventional trials (SPIRIT). The results will be reported in a manner consistent with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. Patients with SUI (n = 172) will be recruited. The experimental group will receive verbal instructions about PFM function and body awareness techniques together with vaginal palpation; the control group will receive similar protocol without vaginal palpation. The primary outcome includes the number of fast-twitch muscle fibres assessed by vaginal palpation and visual observation. Secondary outcomes include power and muscular endurance that will be assessed by visual observation and vaginal palpation (Oxford scale), the use of accessory muscles during the voluntary contraction of PFMs, and the self-efficacy and the expectations for the results using the self-efficacy scale of pelvic floor exercises. DISCUSSION This study will determine whether vaginal palpation can help women with SUI to correctly perform PFM contractions and improve their functions. TRIAL REGISTRATION ClinicalTrials.gov NCT03325543 . Registered on 30 November 2017. Study protocol version 1; 30 November 2020. Prospectively registered.",2020,"For women to benefit from a pelvic floor muscle training (PFMT) programme for stress urinary incontinence (SUI), the awareness phase of PFMT cannot be omitted.","['women with SUI', 'Patients with SUI (n\u2009=\u2009172', 'women with stress urinary incontinence', 'women with SUI learn', 'Study protocol version 1; 30 November 2020']","['pelvic floor muscle training (PFMT) programme', 'vaginal palpation in motor learning of the pelvic floor muscles', 'verbal instructions about PFM function and body awareness techniques together with vaginal palpation; the control group will receive similar protocol without vaginal palpation']","['power and muscular endurance that will be assessed by visual observation and vaginal palpation (Oxford scale), the use of accessory muscles during the voluntary contraction of PFMs, and the self-efficacy and the expectations for the results using the self-efficacy scale of pelvic floor exercises', 'number of fast-twitch muscle fibres assessed by vaginal palpation and visual observation']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517601', 'cui_str': '172'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C2599718', 'cui_str': 'Clinical Trial Protocols'}, {'cui': 'C2607870', 'cui_str': 'Version'}]","[{'cui': 'C4087139', 'cui_str': 'Pelvic floor muscle training'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0030247', 'cui_str': 'Palpation'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0231484', 'cui_str': 'Muscle function'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0199219', 'cui_str': 'Inspection'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0030247', 'cui_str': 'Palpation'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0158784', 'cui_str': 'Accessory skeletal muscle'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0262718', 'cui_str': 'Pelvic floor exercises'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0231530', 'cui_str': 'Muscle twitch'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0225326', 'cui_str': 'Fiber'}]",,0.120631,"For women to benefit from a pelvic floor muscle training (PFMT) programme for stress urinary incontinence (SUI), the awareness phase of PFMT cannot be omitted.","[{'ForeName': 'Letícia', 'Initials': 'L', 'LastName': 'de Azevedo Ferreira', 'Affiliation': 'Department of Gynaecology, Federal University of Sao Paulo (UNIFESP), Rua Napoleão de Barros, 608 - Vila Clementino, São Paulo, SP, CEP 04024-002, Brazil. leticia_azfe@hotmail.com.'}, {'ForeName': 'Fátima Faní', 'Initials': 'FF', 'LastName': 'Fitz', 'Affiliation': 'Department of Gynaecology, Federal University of Sao Paulo (UNIFESP), Rua Napoleão de Barros, 608 - Vila Clementino, São Paulo, SP, CEP 04024-002, Brazil.'}, {'ForeName': 'Márcia Maria', 'Initials': 'MM', 'LastName': 'Gimenez', 'Affiliation': 'Department of Gynaecology, Federal University of Sao Paulo (UNIFESP), Rua Napoleão de Barros, 608 - Vila Clementino, São Paulo, SP, CEP 04024-002, Brazil.'}, {'ForeName': 'Mayanni Magda Pereira', 'Initials': 'MMP', 'LastName': 'Matias', 'Affiliation': 'Department of Gynaecology, Federal University of Sao Paulo (UNIFESP), Rua Napoleão de Barros, 608 - Vila Clementino, São Paulo, SP, CEP 04024-002, Brazil.'}, {'ForeName': 'Maria Augusta Tezelli', 'Initials': 'MAT', 'LastName': 'Bortolini', 'Affiliation': 'Department of Gynaecology, Federal University of Sao Paulo (UNIFESP), Rua Napoleão de Barros, 608 - Vila Clementino, São Paulo, SP, CEP 04024-002, Brazil.'}, {'ForeName': 'Rodrigo Aquino', 'Initials': 'RA', 'LastName': 'Castro', 'Affiliation': 'Department of Gynaecology, Federal University of Sao Paulo (UNIFESP), Rua Napoleão de Barros, 608 - Vila Clementino, São Paulo, SP, CEP 04024-002, Brazil.'}]",Trials,['10.1186/s13063-020-04624-4'] 1951,32742443,Concurrent or Sequential Chemoradiotherapy after 3-4 Cycles Induction Chemotherapy for LS-SCLC with Bulky Tumor.,"The current study was to compare the efficacy and safety between concurrent and sequential chemoradiotherapy after 3-4 cycles of induction chemotherapy for limited-stage small-cell lung cancer (LS-SCLC) with bulky tumor. From July 2012 to September 2015, a total of 68 patients with stage IIIA and IIIB SCLC who had completed 3-4 cycles of etoposide plus cisplatin/carboplatin and achieved clinical complete response (cCR) or clinical partial response (cPR) were randomized into the two groups equally. The concurrent group received radiotherapy combined with oral etoposide and cisplatin and the sequential group received sequential chemoradiotherapy. Thoracic radiotherapy was performed using intensity-modulated radiation therapy (IMRT) with 95% PTV 60Gy/30 times. After completing chemoradiotherapy, patients received prophylactic cranial irradiation. The primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival (OS) and toxicity. The median follow-up time was 63.3 months (95% confidence interval [CI], 50.8-75.8). Better PFS and OS were observed in concurrent group (median PFS, 26.0 months [95% CI, 9.0-43.0] versus 13.1 months [95%CI, 9.7-16.6], p=0.023; median OS, 35.0 months [95% CI, 25.4-44.6] versus 22.0 months [95% CI, 17.0-27.1], p=0.015). There was no significant difference in the incidence of radiation esophagitis and radiation pneumonitis between the two groups (p=0.795, p=0.525). This study demonstrated that after the completion of 3-4 cycles of chemotherapy with a remission, concurrent chemoradiotherapy with oral etoposide and cisplatin improved survival compared with sequential chemoradiotherapy in LS-SCLC with bulky tumor. ClinicalTrials.gov Identifier: NCT01745445.",2020,"There was no significant difference in the incidence of radiation esophagitis and radiation pneumonitis between the two groups (p=0.795, p=0.525).","['limited-stage small-cell lung cancer (LS-SCLC) with bulky tumor', 'and achieved clinical complete response (cCR) or clinical partial response (cPR', 'From July 2012 to September 2015, a total of 68 patients with stage IIIA and IIIB SCLC who had completed 3-4 cycles of']","['chemoradiotherapy with oral etoposide and cisplatin', 'radiotherapy combined with oral etoposide and cisplatin and the sequential group received sequential chemoradiotherapy', 'prophylactic cranial irradiation', 'intensity-modulated radiation therapy (IMRT) with 95% PTV', 'induction chemotherapy', 'etoposide plus cisplatin/carboplatin', 'sequential chemoradiotherapy', 'Sequential Chemoradiotherapy', 'Thoracic radiotherapy']","['Better PFS and OS', 'incidence of radiation esophagitis and radiation pneumonitis', 'survival', 'efficacy and safety', 'median follow-up time', 'progression-free survival (PFS', 'overall survival (OS) and toxicity']","[{'cui': 'C0278725', 'cui_str': 'Small cell lung cancer limited stage'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0149925', 'cui_str': 'Small cell carcinoma of lung'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0456598', 'cui_str': 'Stage 3A'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0442757', 'cui_str': '3/4'}]","[{'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0015133', 'cui_str': 'Etoposide'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0079172', 'cui_str': 'Cranial Irradiation'}, {'cui': 'C1512814', 'cui_str': 'Intensity modulated radiation therapy'}, {'cui': 'C0454199', 'cui_str': 'Planning target volume'}, {'cui': 'C3179010', 'cui_str': 'Induction chemotherapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}]","[{'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0238113', 'cui_str': 'Radiation esophagitis'}, {'cui': 'C0206063', 'cui_str': 'Radiation pneumonitis'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0040539', 'cui_str': 'TO'}]",68.0,0.204591,"There was no significant difference in the incidence of radiation esophagitis and radiation pneumonitis between the two groups (p=0.795, p=0.525).","[{'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': ""Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.""}, {'ForeName': 'Wencheng', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': ""Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.""}, {'ForeName': 'Puchun', 'Initials': 'P', 'LastName': 'Er', 'Affiliation': ""Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.""}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': ""Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.""}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Guan', 'Affiliation': ""Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.""}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Qian', 'Affiliation': ""Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.""}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ""Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.""}, {'ForeName': 'Zhiyong', 'Initials': 'Z', 'LastName': 'Yuan', 'Affiliation': ""Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.""}, {'ForeName': 'Lujun', 'Initials': 'L', 'LastName': 'Zhao', 'Affiliation': ""Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.""}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Wang', 'Affiliation': ""Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.""}, {'ForeName': 'Qingsong', 'Initials': 'Q', 'LastName': 'Pang', 'Affiliation': ""Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.""}]",Journal of Cancer,['10.7150/jca.41136'] 1952,32742507,Remote Ischemic Conditioning in Acute Ischemic Stroke - A Clinical Trial Design.,"Remote ischemic conditioning represents an intervention based on blood flow reduction applied at a distance from the lesion. The mechanism is supposed to elicit neurovascular protection, anti-inflammatory action, reduced excitotoxicity and metabolic protection. This study aims to explore the efficiency and safety of remote ischemic conditioning during the first five days following in patients who are ineligible for reperfusion treatment (intravenous thrombolysis or/and mechanical thrombectomy). We hypothesized that this intervention would reduce the infarct size (neuroprotection in the reperfusion window) and improve functional recovery. We aim to conduct a double-blind controlled trial, multicenter in two hospitals in Romania. Two hundred patients with acute ischemic stroke randomly divided into an experimental group and a control group will be included. The subjects in the experimental group will be subjected to remote ischemic conditioning twice daily with a maximum of 180 mmHg for 5 days, and a guideline- based treatment as well. The subjects in the control group will receive cuff inflation to 30 mmHg, which will induce sham preconditioning. The primary outcome measure will be radiological - the difference between baseline brain infarct volume and the volume at 180 days in the experimental group versus the control group. The second outcome considers clinical scores such as NIHSS, mRS, IADL, ADL, MOCA, PHQ-9 at baseline, 90 and 180 days; tolerance and side effects of remote ischemic conditioning; the reccurence of stroke or other vascular events at 180 days; incidence of stroke-associated comorbidities and the proportion of death of any cause within 180 days.",2020,This study aims to explore the efficiency and safety of remote ischemic conditioning during the first five days following in patients who are ineligible for reperfusion treatment (intravenous thrombolysis or/and mechanical thrombectomy).,"['patients who are ineligible for reperfusion treatment (intravenous thrombolysis or/and mechanical thrombectomy', 'multicenter in two hospitals in Romania', 'Two hundred patients with acute ischemic stroke']",['Remote Ischemic Conditioning'],"['efficiency and safety', 'radiological - the difference between baseline brain infarct volume and the volume', 'clinical scores such as NIHSS, mRS, IADL, ADL, MOCA, PHQ-9 at baseline, 90 and 180 days; tolerance and side effects of remote ischemic conditioning; the reccurence of stroke or other vascular events at 180 days; incidence of stroke-associated comorbidities and the proportion of death of any cause']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035124', 'cui_str': 'Reperfusion'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0162578', 'cui_str': 'Removal of thrombus'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0035826', 'cui_str': 'Romania'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}]","[{'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0751955', 'cui_str': 'Brain Infarct'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1697238', 'cui_str': 'NIH stroke scale'}, {'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}, {'cui': 'C0150641', 'cui_str': 'Instrumental activities of daily living'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0025750', 'cui_str': ""3,3'-Dichloro-4,4'-Diaminodiphenylmethane""}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",200.0,0.147632,This study aims to explore the efficiency and safety of remote ischemic conditioning during the first five days following in patients who are ineligible for reperfusion treatment (intravenous thrombolysis or/and mechanical thrombectomy).,"[{'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Poalelungi', 'Affiliation': 'Neurology Department, Emergency Clinical Hospital Bucharest, Bucharest, Romania.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Turiac', 'Affiliation': 'Radiology Department, Emergency Clinical Hospital Bucharest, Bucharest, Romania.'}, {'ForeName': 'Delia', 'Initials': 'D', 'LastName': 'Tulba', 'Affiliation': 'Neurology Department, Colentina Clinical Hospital, Bucharest, Romania.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Stoian', 'Affiliation': 'Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.'}, {'ForeName': 'Bogdan Ovidiu', 'Initials': 'BO', 'LastName': 'Popescu', 'Affiliation': 'Neurology Department, Colentina Clinical Hospital, Bucharest, Romania.'}]",Journal of medicine and life,['10.25122/jml-2020-0049'] 1953,32742512,The Effect of Cognitive-Behavioral Counseling on Lifestyle in Pregnant Women: A Randomized Controlled Clinical Trial.,"The lifestyle of pregnant women has a close relationship with maternal and fetal health. In pregnant women, health-promoting behaviors lead to the promotion of quality of life and improvement of pregnancy outcomes. Therefore, the present study aimed to determine the effect of cognitive-behavioral counseling on pregnant women's lifestyle. This randomized controlled clinical trial study was performed in the health centers of Sanandaj, Iran. Seventy pregnant women were randomly assigned to intervention (n = 35) and control (n = 35) groups. The study was completed with 33 pregnant women in each group. In addition to routine pregnancy care, the control group received, the intervention group received 8 consecutive 60-90-minute counseling sessions with a cognitive-behavioral approach weekly. The Walker Health Promotion Lifestyle Questionnaire was completed before, immediately, and one month after the intervention by the participants of control and intervention groups. Data were collected from February until June 2017. Data were analyzed using SPSS version 16. The mean score of lifestyle in the intervention and control group was 139.78 ± 21.71 and 142.63 ± 19.12 before the intervention, which reached 151 ± 17.72 and 159.14 ± 14.77, respectively, after the intervention. The difference was significant in the intervention group (P = 0.001) but not in the control group (P = 0.619). Also, the mean scores of the two groups were not significantly different before intervention (P = 0.574), but this difference was statistically significant after the intervention (P = 0.029) and one month after the intervention (P = 0.001). Based on the results of this study, cognitive-behavioral counseling improves the lifestyle of pregnant women. Therefore, it is suggested that this type of counseling be used along with other services to improve the lifestyle of pregnant women in health care centers.",2020,"Also, the mean scores of the two groups were not significantly different before intervention (P = 0.574), but this difference was statistically significant after the intervention (P = 0.029) and one month after the intervention (P = 0.001).","['Seventy pregnant women', 'Pregnant Women', 'health centers of Sanandaj, Iran', '33 pregnant women in each group', 'pregnant women in health care centers', ""pregnant women's lifestyle"", 'pregnant women']","['intervention group received 8 consecutive 60-90-minute counseling sessions with a cognitive-behavioral approach weekly', 'Cognitive-Behavioral Counseling', 'cognitive-behavioral counseling']","['mean scores', 'mean score of lifestyle', 'Walker Health Promotion Lifestyle Questionnaire']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0023676', 'cui_str': 'Life style'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C4546207', 'cui_str': 'Behavioral counseling'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0043016', 'cui_str': 'Walker'}, {'cui': 'C0018738', 'cui_str': 'Health promotion'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",70.0,0.0403728,"Also, the mean scores of the two groups were not significantly different before intervention (P = 0.574), but this difference was statistically significant after the intervention (P = 0.029) and one month after the intervention (P = 0.001).","[{'ForeName': 'Mahnaz', 'Initials': 'M', 'LastName': 'Farhodimoghadam', 'Affiliation': 'Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Sousan', 'Initials': 'S', 'LastName': 'Heydarpour', 'Affiliation': 'Department of Midwifery, Faculty of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Nader', 'Initials': 'N', 'LastName': 'Salari', 'Affiliation': 'Department of Biostatistics, School of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Nasrin', 'Initials': 'N', 'LastName': 'Jaberghaderi', 'Affiliation': 'Department of Psychiatry, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}]",Journal of medicine and life,['10.25122/jml-2019-0163'] 1954,32742515,"Comparison of the Effects of Haloperidol, Metoclopramide, Dexmedetomidine and Ginger on Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy.","Nausea is a mental sensation of unease and discomfort before vomiting. Vomiting refers to the return of the contents of the upper gastrointestinal tract to the mouth caused by contractions of chest and abdomen muscles. Postoperative nausea and vomiting is an unpleasant experience with high treatment costs. Therefore, this study aimed to compare the effects of haloperidol, metoclopramide, dexmedetomidine, and ginger on postoperative nausea and vomiting after laparoscopy. This double-blind clinical trial was performed on all laparoscopy candidates at Valiasr hospital, Arak, Iran. The patients were randomly divided into four groups (haloperidol, metoclopramide, dexmedetomidine and ginger), and all patients underwent general anesthesia using fentanyl, midazolam, atracurium, and propofol. After intubation, tube fixation, and stable hemodynamic conditions, the patients received four ginger capsules with a hint of lemon. A group of patients received 25 μg of dexmedetomidine. In the Plasil group, 10 mg of metoclopramide was given 30 minutes before the completion of surgery. In addition, 0.5 cc of haloperidol (5 mg) was administered to a group of patients. Heart rate, blood pressure, and oxygen saturation were recorded from the beginning of surgery, every 15 minutes until the end of the surgery. Furthermore, the occurrence of nausea and vomiting was recorded during recovery, 2 and 4 hours after surgery. Data were then analyzed using the SPSS software v.23. Eighty-eight patients were enrolled in the study. The youngest and the oldest were 30 years and 70 years old, respectively, and the mean age was 48.02 ± 9.31 years. Moreover, the number of women in the four groups was higher than that of men. Blood pressure in the dexmedetomidine group was lower than the other four groups (P <0.05). The lowest heart rate was observed in the haloperidol group, while the highest heart rate was seen in the plasil group (P <0.05). The occurrence of vomiting and nausea was not significantly different between the four groups (P <0.05). Our results showed no significant difference in postoperative nausea and vomiting between the four drugs. Due to the hemodynamic changes induced by each drug, it is best to use these drugs based on the patient's condition. Ginger is also a herbal remedy that has fewer side effects, and this drug can be a good option for patients when there is no contraindication.",2020,Blood pressure in the dexmedetomidine group was lower than the other four groups (P <0.05).,"['After Laparoscopic Cholecystectomy', 'The youngest and the oldest were 30 years and 70 years old, respectively, and the mean age was 48.02 ± 9.31 years', 'Eighty-eight patients were enrolled in the study', 'all laparoscopy candidates at Valiasr hospital, Arak, Iran']","['general anesthesia using fentanyl, midazolam, atracurium, and propofol', 'Haloperidol, Metoclopramide, Dexmedetomidine and Ginger', 'metoclopramide', 'haloperidol', 'haloperidol, metoclopramide, dexmedetomidine, and ginger', 'dexmedetomidine', 'haloperidol, metoclopramide, dexmedetomidine and ginger']","['postoperative nausea and vomiting', 'Postoperative nausea and vomiting', 'Nausea', 'nausea and vomiting', 'Postoperative Nausea and Vomiting', 'highest heart rate', 'Blood pressure', 'occurrence of vomiting and nausea', 'lowest heart rate', 'Heart rate, blood pressure, and oxygen saturation']","[{'cui': 'C0162522', 'cui_str': 'Laparoscopic cholecystectomy'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517898', 'cui_str': '88'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022065', 'cui_str': 'Iran'}]","[{'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0004234', 'cui_str': 'Atracurium'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0018546', 'cui_str': 'Haloperidol'}, {'cui': 'C0025853', 'cui_str': 'Metoclopramide'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0162751', 'cui_str': 'Ginger'}]","[{'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}]",88.0,0.0295143,Blood pressure in the dexmedetomidine group was lower than the other four groups (P <0.05).,"[{'ForeName': 'Amir Reza', 'Initials': 'AR', 'LastName': 'Naemi', 'Affiliation': 'Department of Surgery, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Vahid', 'Initials': 'V', 'LastName': 'Kashanitabar', 'Affiliation': 'Department of Surgery, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Kamali', 'Affiliation': 'Department of Anesthesiology and Critical Care, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Ashkan', 'Initials': 'A', 'LastName': 'Shiva', 'Affiliation': 'Department of Surgery, Arak University of Medical Sciences, Arak, Iran.'}]",Journal of medicine and life,['10.25122/jml-2019-0070'] 1955,32742520,Salivary and Serum Glucose Levels in Diabetes Mellitus Patients versus Control - A Randomised Control Trial.,"Oral fluids provide a readily available and non-invasive medium for the diagnosis of a wide range of diseases and clinical situations. Diabetes mellitus is a common chronic metabolic disorder that affects millions of people. Our objective was to compare the salivary and serum glucose levels in patients with diabetes mellitus and healthy individuals. Two ml of unstimulated whole saliva was collected by the spitting method. Also, 2 ml of the patient's intravenous blood was obtained from the forearm's median cephalic vein. Both the samples were centrifuged at 2000 rpm for 2-3 minutes. Ten μl of both saliva and serum were taken out and added to glucose reagent. These were kept in a temperature-controlled water bath at 37°C for 10 minutes. The color change was noted, and the optical density was measured in a semi-auto analyzer. The presence of glucose was detected in both groups; however, the levels were raised in people with diabetes compared to healthy individuals. The present study indicated a substantial increase in salivary and serum glucose levels in diabetic patients compared to healthy controls. The concentration of glucose in saliva increases with the increase in serum glucose concentration.",2020,"The presence of glucose was detected in both groups; however, the levels were raised in people with diabetes compared to healthy individuals.","['Diabetes Mellitus Patients', 'diabetic patients compared to healthy controls', 'patients with diabetes mellitus and healthy individuals']",[],"['serum glucose concentration', 'concentration of glucose in saliva', 'Salivary and Serum Glucose Levels', 'salivary and serum glucose levels', 'presence of glucose', 'optical density']","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0027361', 'cui_str': 'Person'}]",[],"[{'cui': 'C0202041', 'cui_str': 'Glucose measurement, serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0439164', 'cui_str': 'OD units'}]",,0.0246428,"The presence of glucose was detected in both groups; however, the levels were raised in people with diabetes compared to healthy individuals.","[{'ForeName': 'Avanindra', 'Initials': 'A', 'LastName': 'Kumar', 'Affiliation': 'Department Of Oral Pathology and Microbiology, Patna Dental College And Hospital, Patna, India.'}, {'ForeName': 'Tanoj', 'Initials': 'T', 'LastName': 'Kumar', 'Affiliation': 'Department Of Oral Pathology, Patna Dental College And Hospital, Patna, India.'}, {'ForeName': 'Manish', 'Initials': 'M', 'LastName': 'Bhargava', 'Affiliation': 'Department Of Oral Pathology, Manav Rachna Dental College, Faridabad, Hayana, India.'}, {'ForeName': 'Rachna', 'Initials': 'R', 'LastName': 'Raj', 'Affiliation': 'Department Of Public Health Dentistry, Patna Dental College And Hospital, Patna, India.'}, {'ForeName': 'Vikas', 'Initials': 'V', 'LastName': 'Vaibhav', 'Affiliation': 'Department Of Dentistry, Vardhman Institute Of Medical Science, Pavapuri, Nalanda, Bihar, India.'}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Kishore', 'Affiliation': 'Bihar Government, Primary Health Centre, Sahdei Buzurg, Vaishali, Bihar, India.'}]",Journal of medicine and life,['10.25122/jml-2020-0062'] 1956,32742581,Effect of different types of exercise on sleep deprivation and functional capacity in middle aged patients after coronary artery bypass grafting.,"Introduction There are still many gaps in research concerning the effect of different physical training modalities on sleep quality in the population underwent coronary artery bypass graft (CABG) surgeries. Objective The purpose of this study was to compare the effect of different exercise types on sleep quality and functional capacity after CABG. Material and Methods 80 Participants aged 45-65 years were randomized to two groups: aerobic group (AG), and combined aerobic and resistance group (ARG). Training lasted ten consecutive weeks with 30 uninterrupted sessions. The actigraph together with Pittsburg Sleep Quality Index (PSQI) were used in sleep quality assessment. Six-minute walk test (6MWT) was used in assessment of functional capacity. The actigraph (Actiwatch Minimitter Company, Incorporated (INC) - Sunriver, OR, USA) was placed on the non-dominant wrist and activities were monitored continuously while being recorded at one-minute intervals. The participants kept the device for a period of 96 hours, filled PSQI, and did 6MWT before the first and last training sessions. Results There was significant decrease in the mean value of sleep latency, fragmentation index, light sleep duration and sleep quality scores (p<0.01); and significant increase in total sleep duration, deep sleep duration, number of points on the actigraphy, sleep efficiency and functional capacity in both (AG) and (ARG) (p<0.01), that difference was more significant in the aerobic group (AG) (p<0.01). Conclusions Both modes of exercise (aerobic alone and combined aerobic and resistance exercises) can improve sleep quality and functional capacity, but isolated aerobic exercise can do that more significantly.",2020,"There was significant decrease in the mean value of sleep latency, fragmentation index, light sleep duration and sleep quality scores (p<0.01); and significant increase in total sleep duration, deep sleep duration, number of points on the actigraphy, sleep efficiency and functional capacity in both (AG) and (ARG) (p<0.01), that difference was more significant in the aerobic group (AG) (p<0.01). ","['population underwent coronary artery bypass graft (CABG) surgeries', '45-65 years', '80 Participants aged', 'middle aged patients after coronary artery bypass grafting']","['exercise', 'Six-minute walk test (6MWT', 'physical training modalities', 'exercise (aerobic alone and combined aerobic and resistance exercises', 'aerobic group (AG), and combined aerobic and resistance group (ARG']","['sleep quality and functional capacity', 'sleep deprivation and functional capacity', 'actigraph together with Pittsburg Sleep Quality Index (PSQI', 'mean value of sleep latency, fragmentation index, light sleep duration and sleep quality scores', 'total sleep duration, deep sleep duration, number of points on the actigraphy, sleep efficiency and functional capacity in both (AG) and (ARG', 'sleep quality']","[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0037316', 'cui_str': 'Sleep deprivation'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C4505222', 'cui_str': 'Sleep Onset Latency'}, {'cui': 'C0332472', 'cui_str': 'Fragmentation'}, {'cui': 'C0278182', 'cui_str': 'Light sleep'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0424574', 'cui_str': 'Duration of sleep'}, {'cui': 'C0234451', 'cui_str': 'Non-rapid eye movement sleep'}, {'cui': 'C0449956', 'cui_str': 'Number of points'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}]",80.0,0.0339722,"There was significant decrease in the mean value of sleep latency, fragmentation index, light sleep duration and sleep quality scores (p<0.01); and significant increase in total sleep duration, deep sleep duration, number of points on the actigraphy, sleep efficiency and functional capacity in both (AG) and (ARG) (p<0.01), that difference was more significant in the aerobic group (AG) (p<0.01). ","[{'ForeName': 'Hady', 'Initials': 'H', 'LastName': 'Atef', 'Affiliation': 'Cairo University, Physical Therapy for Internal Medicine - Cairo - Egypt.'}, {'ForeName': 'Zeinab', 'Initials': 'Z', 'LastName': 'Helmy', 'Affiliation': 'Cairo University, Physical Therapy for Internal Medicine - Cairo - Egypt.'}, {'ForeName': 'Abeer', 'Initials': 'A', 'LastName': 'Farghaly', 'Affiliation': 'Cairo University, Physical Therapy for Internal Medicine - Cairo - Egypt.'}]","Sleep science (Sao Paulo, Brazil)",['10.5935/1984-0063.20190136'] 1957,32742589,Sleep quality in children with atopic dermatitis during flares and after treatment.,"Background Little is known on sleep quality of children with atopic dermtitis (AD) during flares and how treatment impacts their sleep. The purpose of this study is to evaluate variations in sleep quality of children with AD during flares and its response to intensified treatment. Material and Methods Prospective case-crossover study in 10 children with moderate-severe AD. At baseline, AD severity was assessed using SCORAD and patients were prescribed intensified AD therapy. All subjects were monitored by actigraphy during 14 days and returned for SCORAD assessment. Results Subjects' age was 5.6 ± 5.3 years; 50% were female. Sleep duration was decreased in all subjects and awakenings were increased in 90%. Parental perception of sleep significantly differed from actigraphy results: parents estimated less sleep duration and less awakenings. Nocturnal sleep efficiency at baseline was reduced in 50%. After intensified treatment, median SCORAD decreased from 58.5 to 31.3 (p=0.005), with significant improvement in sleep loss and pruritus visual analogue scales. Despite improvement of SCORAD and parental perception of sleep loss and pruritus, objective sleep duration and efficiency measured by actigraphy did not vary significantly after intensified treatment. Change in SCORAD, sleep loss and pruritus scales did not correlate significantly with change in sleep duration, efficiency or other actigraphic sleep quality measurements. Conclusions Children with moderate-severe AD have sleep quality abnormalities, with decreased sleep duration, low sleep efficiency and increased awakenings. Improvement in AD severity upon intensified AD treatment was associated with improved parental perception of sleep loss, but not of objective sleep quality assessed by actigraphy.",2020,"Change in SCORAD, sleep loss and pruritus scales did not correlate significantly with change in sleep duration, efficiency or other actigraphic sleep quality measurements. ","['children with AD during flares', '10 children with moderate-severe AD', 'children with atopic dermtitis (AD', ""Results\n\n\nSubjects' age was 5.6 ± 5.3 years; 50% were female"", 'children with atopic dermatitis during flares and after treatment']",[],"['sleep duration, low sleep efficiency and increased awakenings', 'SCORAD and parental perception of sleep loss and pruritus, objective sleep duration and efficiency', 'objective sleep quality', 'Sleep quality', 'Sleep duration', 'Change in SCORAD, sleep loss and pruritus scales', 'parental perception of sleep loss', 'sleep loss and pruritus visual analogue scales', 'sleep quality abnormalities', 'sleep duration, efficiency or other actigraphic sleep quality measurements', 'sleep duration and less awakenings', 'sleep quality', 'median SCORAD', 'Nocturnal sleep efficiency', 'Parental perception of sleep']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0392707', 'cui_str': 'Atopy'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517794', 'cui_str': '5.6'}, {'cui': 'C4708663', 'cui_str': '5.3'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}, {'cui': 'C0001758', 'cui_str': 'Aftercare'}]",[],"[{'cui': 'C0424574', 'cui_str': 'Duration of sleep'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1720052', 'cui_str': 'Awakening'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0235161', 'cui_str': 'Sleep loss'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0240526', 'cui_str': 'Night time'}]",10.0,0.0353943,"Change in SCORAD, sleep loss and pruritus scales did not correlate significantly with change in sleep duration, efficiency or other actigraphic sleep quality measurements. ","[{'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Kahn', 'Affiliation': 'Pontificia Universidad Catolica de Chile, Division of Pediatrics, School of Medicine - Santiago - Metropolitana - Chile.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Iturriaga', 'Affiliation': 'Pontificia Universidad Católica de Chile, Santiago, Chile., Department of Pediatric Infectious Diseases and Immunology - Santiagio - Metropolitana - Chile.'}, {'ForeName': 'Katalina', 'Initials': 'K', 'LastName': 'Bertran', 'Affiliation': 'Clinica Alemana Santiago UDD, Pediatrics - Santiago - Metropolitana - Chile.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Fernandez', 'Affiliation': 'Centro de Estudios para el Desarrollo, Desarrollo - Santiago - Metropolitana - Chile.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Perez-Mateluna', 'Affiliation': 'Pontificia Universidad Católica de Chile, Santiago, Chile., Department of Pediatric Infectious Diseases and Immunology - Santiagio - Metropolitana - Chile.'}, {'ForeName': 'Arturo', 'Initials': 'A', 'LastName': 'Borzutzky', 'Affiliation': 'Pontificia Universidad Católica de Chile, Santiago, Chile., Department of Pediatric Infectious Diseases and Immunology - Santiagio - Metropolitana - Chile.'}, {'ForeName': 'Pablo E', 'Initials': 'PE', 'LastName': 'Brockmann', 'Affiliation': 'Pontificia Universidad Catolica de Chile, Pediatric Sleep Center-Department Pediatric Cardiology and Pulmonology - Santiago - Metropolitana - Chile.'}]","Sleep science (Sao Paulo, Brazil)",['10.5935/1984-0063.20190139'] 1958,32721986,Effect of a Multicomponent Intervention Program on Community-Dwelling People With Intellectual Disabilities.,"Objective To investigate the effectiveness of a novel and complex intervention in community-dwelling people with intellectual disabilities. Methods Forty-three participants completed the experiment. The subjects were randomly assigned the experimental (n=33) or control (n=10) groups. The multicomponent intervention program comprised exercise and nutrition management and behavior modification. The intervention was performed for 60 minutes once weekly for 10 weeks. The assessment included anthropometric data, body composition and blood pressure analysis, and blood tests. In addition, pulmonary function, physical function, and health-related quality of life were measured before and after the intervention. Results No adverse events occurred during the intervention. After the intervention, the experimental group showed a significantly higher increase in high-density lipoprotein cholesterol level than did the control group (effect size=0.152, p=0.019). Conclusion This innovative intervention was effective in improving cardiovascular health. Even greater effects could be achieved through improvements in implementation strategies to increase compliance.",2020,"After the intervention, the experimental group showed a significantly higher increase in high-density lipoprotein cholesterol level than did the control group (effect size=0.152, p=0.019). ","['Methods\n\n\nForty-three participants completed the experiment', 'community-dwelling people with intellectual disabilities', 'Community-Dwelling People With Intellectual Disabilities']","['novel and complex intervention', 'multicomponent intervention program comprised exercise and nutrition management and behavior modification', 'Multicomponent Intervention Program']","['cardiovascular health', 'anthropometric data, body composition and blood pressure analysis, and blood tests', 'adverse events', 'pulmonary function, physical function, and health-related quality of life', 'high-density lipoprotein cholesterol level']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0450368', 'cui_str': '43'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3714756', 'cui_str': 'Intellectual disability'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1258068', 'cui_str': 'Nutrition management'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}]","[{'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement'}]",43.0,0.0433813,"After the intervention, the experimental group showed a significantly higher increase in high-density lipoprotein cholesterol level than did the control group (effect size=0.152, p=0.019). ","[{'ForeName': 'Ye-Soon', 'Initials': 'YS', 'LastName': 'Kim', 'Affiliation': 'Department of Healthcare and Public Health Research, National Rehabilitation Research Institute, National Rehabilitation Center, Seoul, Korea.'}, {'ForeName': 'Jong-Hoon', 'Initials': 'JH', 'LastName': 'Moon', 'Affiliation': 'Department of Healthcare and Public Health Research, National Rehabilitation Research Institute, National Rehabilitation Center, Seoul, Korea.'}, {'ForeName': 'Bo Kyoon', 'Initials': 'BK', 'LastName': 'Hong', 'Affiliation': 'Department of Occupational Therapy, Graduate School, Yonsei University, Wonju, Korea.'}, {'ForeName': 'Seung Hee', 'Initials': 'SH', 'LastName': 'Ho', 'Affiliation': 'Department of Healthcare and Public Health Research, National Rehabilitation Research Institute, National Rehabilitation Center, Seoul, Korea.'}]",Annals of rehabilitation medicine,['10.5535/arm.19124'] 1959,32723141,External Loop Recorders: Primary Care Placement Is Noninferior to Hospital-Based Cardiac Unit.,"Introduction: External loop recorders (ELRs) are recommended for the investigation of syncope and palpitations. This study aimed to compare rates of arrhythmia detection between primary care (PC) and hospital-based cardiac unit (HBCU) fitted ELRs. Methods: Data were captured from January to December 2015. Twenty-eight general practitioner practices and 1 hospital took part. Patients were divided into those with ELR fitted in PC or HBCU. All ELR data were analyzed by a cardiac physiologist. Results: A total of 560 ELR recordings were analyzed; 219 (PC) versus 341 (HBCU). There was no difference between the baseline characteristics (all P s > .05). The predominant indication for ELR in each group were palpitations; between-group variation was observed for syncope ( P = .0004). There were no significant between-group differences in the number of recordings per patient; however, PC group wore the ELR for less time (median 7 days vs median 14 days; P < .0001). There were no differences in arrhythmia detection between PC- and HBCU-fitted ELRs (16.2% [n = 39] vs 21.7% [n = 74], respectively; P = .28). PC placement of ELRs was highest in very remote rural communities ( P = .005) and correlated with distance from HBCU ( r = 0.39; P = .04). Conclusions: This study showed no difference in detection of arrhythmias between PC and HBCU fitted ELRs. This suggests adequate ELR recording can be completed by suitably trained staff in PC. Furthermore, ELRs were fitted for less time in PC without an adverse effect on diagnostic yield. ELR usage increased with increasing distance from the specialist center and rurality suggesting improved local access to arrhythmia detection services.",2020,PC placement of ELRs was highest in very remote rural communities ( P = .005) and correlated with distance from HBCU ( r = 0.39; P = .04). ,['Twenty-eight general practitioner practices and 1 hospital took part'],"['External Loop Recorders', 'Introduction: External loop recorders (ELRs']","['arrhythmia detection', 'PC placement of ELRs', 'detection of arrhythmias']","[{'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1515187', 'cui_str': 'Take'}]","[{'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0445022', 'cui_str': 'Loop'}, {'cui': 'C0182913', 'cui_str': 'Recorder'}]","[{'cui': 'C0003811', 'cui_str': 'Cardiac arrhythmia'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]",28.0,0.0566794,PC placement of ELRs was highest in very remote rural communities ( P = .005) and correlated with distance from HBCU ( r = 0.39; P = .04). ,"[{'ForeName': 'Kara J', 'Initials': 'KJ', 'LastName': 'Callum', 'Affiliation': 'NHS Highland, Raigmore Hospital, Inverness, UK.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Hall', 'Affiliation': 'NHS Highland, Raigmore Hospital, Inverness, UK.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Jack', 'Affiliation': 'NHS Highland, Raigmore Hospital, Inverness, UK.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Farman', 'Affiliation': 'NHS Highland, Raigmore Hospital, Inverness, UK.'}, {'ForeName': 'Gordon F', 'Initials': 'GF', 'LastName': 'Rushworth', 'Affiliation': 'University of the Highlands and Islands, Centre for Health Science, Inverness, UK.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Leslie', 'Affiliation': 'NHS Highland, Raigmore Hospital, Inverness, UK.'}]",Journal of primary care & community health,['10.1177/2150132720946147'] 1960,32723679,Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.,"OBJECTIVE To explore the relationship between tumor size and response to combined anti-vascular targeted therapy using the anti-angiogenesis inhibitor, bevacizumab, and the tubulin-binding vascular disrupting agent, fosbretabulin. METHODS An exploratory, post-hoc analysis of the randomized phase II trial, Gynecologic Oncology Group-0186I, was performed. One hundred and seven patients with recurrent ovarian carcinoma, treated with up to 3 prior regimens, were randomized to bevacizumab 15 mg/kg body weight with or without intravenous fosbretabulin 60 mg/m 2 body surface area every 21 days until progression or unacceptable toxicity. The primary analysis favored the combination (HR 0.69; 95% CI, 0.47-1.00; p = .049) [Monk BJ, et al. J Clin Oncol 2016;34:2279-86]. The Cox proportional hazards model was used to estimate the treatment effect in various subpopulations. RESULTS With extended follow-up, the median PFS for bevacizumab plus fosbretabulin was 7.6  months as compared to 4.8  months with bevacizumab alone (HR 0.74; 90% CI, 0.54-1.02). Overall survival was similar in the experimental and control arms (25.2 vs 24.4 mos, respectively, HR 0.85; 90% CI, 0.59-1.22; p = .461). Eighty-one patients had measurable disease and median tumor size was 5.7  cm. In the ≤5.7  cm subgroup, the HR for progression or death was 0.77 (90% CI 0.45-1.31). Patients with tumors >5.7  cm (n = 40) had a HR for progression or death of 0.55; 90% CI, 0.32-0.96; p = .075). CONCLUSIONS Although no significant survival benefit was observed, the trend showing a reduced HR for progression or death with increasing tumor size when fosbretabulin is added to bevacizumab compared to bevacizumab alone warrants further study.",2020,"RESULTS With extended follow-up","['recurrent ovarian cancer', 'One hundred and seven patients with recurrent ovarian carcinoma']","['bevacizumab 15\u202fmg/kg body weight with or without intravenous fosbretabulin 60\u202fmg/m 2 body surface area', 'combined anti-vascular targeted therapy using the anti-angiogenesis inhibitor, bevacizumab', 'bevacizumab', 'Bevacizumab plus fosbretabulin']","['survival benefit', 'Overall survival', 'measurable disease and median tumor size', 'HR for progression or death', 'median PFS for bevacizumab plus fosbretabulin']","[{'cui': 'C0278689', 'cui_str': 'Recurrent ovarian cancer'}, {'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0560741', 'cui_str': 'mg/kg body weight'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0056154', 'cui_str': 'fosbretabulin'}, {'cui': 'C0005902', 'cui_str': 'Body surface area'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0596087', 'cui_str': 'Angiogenesis inhibitor'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0475440', 'cui_str': 'Tumor size'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0056154', 'cui_str': 'fosbretabulin'}]",107.0,0.0982756,"RESULTS With extended follow-up","[{'ForeName': 'Krishnansu S', 'Initials': 'KS', 'LastName': 'Tewari', 'Affiliation': 'University of California, Irvine, Division of Gynecologic Oncology, Orange, CA, United States. Electronic address: ktewari@uci.edu.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Sill', 'Affiliation': 'NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park, Buffalo, NY 14263, United States. Electronic address: sillm@nrgoncology.org.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Coleman', 'Affiliation': 'MD Anderson Cancer Center, Houston, TX, United States.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Aghajanian', 'Affiliation': 'Memorial Sloan-Kettering Cancer Center, New York, NY, United States. Electronic address: aghajanc@MSKCC.org.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Mannel', 'Affiliation': 'The Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, 800 NE 10(th) St., SOCC 6043, Oklahoma City, OK 73104, United States. Electronic address: robert-mannel@ouhsc.edu.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'DiSilvestro', 'Affiliation': 'Women and Infants Hospital of Rhode Island, 101 Dudley St., Providence, RI 02905, United States. Electronic address: PDiSilvestro@WIHRI.org.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Powell', 'Affiliation': 'Washington University School of Medicine, 4911 Barnes Jewish Hospital Plaza, St. Louis, MO 63110, United States. Electronic address: mpowell@wustl.edu.'}, {'ForeName': 'Leslie M', 'Initials': 'LM', 'LastName': 'Randall', 'Affiliation': 'University of California, Irvine, Division of Gynecologic Oncology, Orange, CA, United States. Electronic address: Leslie.Randall@vcuhealth.org.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Farley', 'Affiliation': ""Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, Pheonix, AZ 85013, United States. Electronic address: John.farley@chw.edu.""}, {'ForeName': 'Stephen C', 'Initials': 'SC', 'LastName': 'Rubin', 'Affiliation': 'Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111, United States. Electronic address: stephen.rubin@fccc.edu.'}, {'ForeName': 'Bradley J', 'Initials': 'BJ', 'LastName': 'Monk', 'Affiliation': ""Arizona Oncology (US Oncology Network), University of Arizona College of Medicine-Phoenix, Creighton University School of Medicine, St. Joseph's Hospital, Phoenix, AZ, United States. Electronic address: Bradley.Monk@usoncology.com.""}]",Gynecologic oncology,['10.1016/j.ygyno.2020.07.015'] 1961,32727422,Binary Tönnis classification: simplified modification demonstrates better inter- and intra-observer reliability as well as agreement in surgical management of hip pathology.,"BACKGROUND The traditional Tönnis Classification System has inherent drawbacks as it is vulnerable to the subjectivity of a four-grade system. A two-grade classification could potentially be more reliable. The purpose of this study is to (1) compare the inter-observer and intra-observer reliability of the traditional Tönnis Classification System and a simplified Binary Tönnis Classification System for hip osteoarthritis and to (2) evaluate the clinical applicability of both systems. Our hypothesis is that the proposed Binary Tönnis Classification System will have better reliability and agreement for surgical decision-making. METHODS Forty consecutive patients were selected to participate in this study. Patients were included in this study if they were between 35 and 60 years old. Patients were excluded if they had prior hip surgeries or conditions. All radiographs were randomized and blinded by a non-observer. Five fellowship-trained hip surgeons from a single center, in a fully crossed design, analyzed and graded all the radiographs utilizing the traditional Tönnis Classification System and the proposed Binary Tönnis Classification System. Intra- and inter-observer reliability values for both the systems were calculated using the Cohen's κ coefficient. A multi-rater κ was calculated using the weighted Fleiss method. RESULTS The study sample contained 40 anterosuperior hip radiographs. For the traditional Tönnis Classification System, the weighted κ showed a fair inter-observer reliability (κ = 0.474) and excellent intra-observer reliability (κ mean = 0.866). For the proposed Binary Tönnis Classification System, both inter-observer and intra-observer reliability demonstrated excellent values, (κ = 0.858 and 0.928, respectively). On average, the Binary Tönnis Classification System correctly captured 87% of cases. When the traditional Tönnis Classification System was dichotomized, the capture rate was 84%. CONCLUSION A simplified binary Tönnis Classification System demonstrates better reliability and clinical implementation than the traditional Tönnis Classification System.",2020,"For the traditional Tönnis Classification System, the weighted κ showed a fair inter-observer reliability (κ = 0.474) and excellent intra-observer reliability (κ mean = 0.866).","['Forty consecutive patients were selected to participate in this study', 'Patients were included in this study if they were between 35 and 60\u2009years old', 'Patients were excluded if they had prior hip surgeries or conditions']",['traditional Tönnis Classification System and a simplified Binary Tönnis Classification System'],"['excellent intra-observer reliability', 'Intra- and inter-observer reliability values']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0596706', 'cui_str': 'Hip surgery'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0008902', 'cui_str': 'Classification'}]","[{'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",40.0,0.0162168,"For the traditional Tönnis Classification System, the weighted κ showed a fair inter-observer reliability (κ = 0.474) and excellent intra-observer reliability (κ mean = 0.866).","[{'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Shapira', 'Affiliation': 'American Hip Institute Research Foundation, Des Plaines, IL, 60018, USA.'}, {'ForeName': 'Jeffrey W', 'Initials': 'JW', 'LastName': 'Chen', 'Affiliation': 'Vanderbilt University School of Medicine, Nashville, TN, 37232, USA.'}, {'ForeName': 'Rishika', 'Initials': 'R', 'LastName': 'Bheem', 'Affiliation': 'American Hip Institute Research Foundation, Des Plaines, IL, 60018, USA.'}, {'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'Rosinsky', 'Affiliation': 'American Hip Institute Research Foundation, Des Plaines, IL, 60018, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Maldonado', 'Affiliation': 'American Hip Institute Research Foundation, Des Plaines, IL, 60018, USA.'}, {'ForeName': 'Ajay C', 'Initials': 'AC', 'LastName': 'Lall', 'Affiliation': 'American Hip Institute Research Foundation, Des Plaines, IL, 60018, USA.'}, {'ForeName': 'Benjamin G', 'Initials': 'BG', 'LastName': 'Domb', 'Affiliation': 'American Hip Institute Research Foundation, Des Plaines, IL, 60018, USA. drdomb@americanhipinstitute.org.'}]",BMC musculoskeletal disorders,['10.1186/s12891-020-03520-x'] 1962,32727451,Assessing and reporting patient participation by means of patient preferences and experiences.,"BACKGROUND Although patient participation is strongly associated with high quality of healthcare, valid means to measure and report a comprehensive notion of patient participation are scarce. The Patient Preferences for Patient Participation (4Ps) is a new healthcare practice and research tool, comprising patients' preferences as well as experiences. The 4Ps employs 12 items for the patient to conceptualise patient participation. The aim of this paper is to describe how the two perspectives of patient participation, namely preferences and experiences, can be combined to visualise and report preference-based patient participation. METHODS With four response alternatives in each section, the 4Ps offers sixteen possible combinations of degree of match per item. Theoretical and clinical principles fostered a tentative order of six ranks and three levels of preference-based patient participation. To test the standard, statistical analyses for ordinal data were performed, using data from a randomised controlled trial evaluating an intervention aiming to improve patient participation. Further, structures for visualising the preference-based patient participation of individuals and groups were suggested. RESULTS Data from the 4Ps demonstrated the individuals' preference-based patient participation, indicating either a match or a mismatch for each item. Mismatches represented either the experience of participation surpassing the patient's preferences, or the patient's preferences for patient participation not being established. At group level, the suggested approach for visualising and reporting the 4Ps demonstrated that the intervention group had a significantly higher proportion of sufficient preference-based patient participation for certain items than the control group. These results had not been identified earlier, when using the preferences and experiences of patient participation as separate measures. CONCLUSIONS Ways to easily acquaint stakeholders with patients' preferences for patient participation are needed, in order for healthcare staff to better use resources to match the basic requirements of individuals and groups. While the 4Ps can guide professionals to patient participation as framed in legislations, concept analyses and by patients, a visualisation of the results is needed to capture preference-based patient participation. The proposed route to representing degree of match in preferences and experiences may also be relevant to other dimensions of quality of healthcare.",2020,"At group level, the suggested approach for visualising and reporting the 4Ps demonstrated that the intervention group had a significantly higher proportion of sufficient preference-based patient participation for certain items than the control group.",['With four response alternatives in each section'],[],['proportion of sufficient preference-based patient participation for certain items'],[],[],"[{'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0030699', 'cui_str': 'Client participation'}, {'cui': 'C0205423', 'cui_str': 'Certain'}]",,0.0188797,"At group level, the suggested approach for visualising and reporting the 4Ps demonstrated that the intervention group had a significantly higher proportion of sufficient preference-based patient participation for certain items than the control group.","[{'ForeName': 'Ann Catrine', 'Initials': 'AC', 'LastName': 'Eldh', 'Affiliation': 'Department of Health, Medicine and Caring Sciences, Linköping University, SE-581 83, Linköping, Sweden. ann.catrine.eldh@liu.se.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Holmefur', 'Affiliation': 'School of Health Sciences, Faculty of Medicine and Health, Örebro University, S701 82, Örebro, Sweden.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Luhr', 'Affiliation': 'School of Health Sciences, Faculty of Medicine and Health, Örebro University, S701 82, Örebro, Sweden.'}, {'ForeName': 'Marika', 'Initials': 'M', 'LastName': 'Wenemark', 'Affiliation': 'Department of Health, Medicine and Caring Sciences, Linköping University, SE-581 83, Linköping, Sweden.'}]",BMC health services research,['10.1186/s12913-020-05574-y'] 1963,32727493,Implementation of family psychosocial risk assessment in pediatric cancer with the Psychosocial Assessment Tool (PAT): study protocol for a cluster-randomized comparative effectiveness trial.,"BACKGROUND Childhood cancer affects and is affected by multiple levels of the social ecology, including social and relational determinants of health (e.g., economic stability, housing, childcare, healthcare access, child and family problems). The 2015 Standards of Psychosocial Care in Pediatric Cancer outline optimal psychosocial care sensitive to these ecological factors, starting with assessment of psychosocial healthcare needs to promote medical and psychosocial outcomes across all children with cancer. To address the first standard of family psychosocial assessment, the Psychosocial Assessment Tool (PAT) is a validated screener ready for broad implementation. METHOD The PAT will be implemented across a national sample of 18 pediatric cancer programs ranging in size (annual new patients) in a mixed methods, comparative effectiveness study, guided by the Interactive Systems Framework for Dissemination and Implementation, comparing two implementation strategies. It is hypothesized that implementation will be more successful at the patient/family, provider, and institutional level when training (strategy I) is combined with implementation expanded resources (strategy II). There are three aims: (1) Refine the two implementation strategies using semi-structured qualitative interviews with 19 stakeholders including parent advocates, providers, pediatric oncology organization representatives, healthcare industry leaders; (2) Compare the two theoretically based and empirically informed strategies to implement the PAT in English and Spanish using a cluster-randomized controlled trial across 18 sites. Stratified by size, sites will be randomized to cohort (3) and strategy (2). Outcomes include adoption and penetration of screening (patient/family), staff job satisfaction/burnout (provider), and cost-effective use of resources consistent with family risk (institution); (3) Based on the results of the trial and feedback from the first and second aim, we will develop and disseminate a web-based PAT Implementation Toolkit. DISCUSSION Use of the PAT across children's cancer programs nationally can achieve the assessment standard and inform equitable delivery of psychosocial care matched to family need for all patients. TRIAL REGISTRATION ClinicalTrials.gov , NCT04446728 , registered 23 June 2020.",2020,It is hypothesized that implementation will be more successful at,"['18 pediatric cancer programs ranging in size (annual new patients', 'children with cancer', 'pediatric cancer with the Psychosocial Assessment Tool (PAT']","['PAT', 'Psychosocial Assessment Tool (PAT']","['adoption and penetration of screening (patient/family), staff job satisfaction/burnout (provider), and cost-effective use of resources consistent with family risk (institution']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1455743', 'cui_str': 'Psychosocial assessment'}, {'cui': 'C0336791', 'cui_str': 'Tool'}]","[{'cui': 'C1455743', 'cui_str': 'Psychosocial assessment'}, {'cui': 'C0336791', 'cui_str': 'Tool'}]","[{'cui': 'C0001593', 'cui_str': 'Adoption'}, {'cui': 'C0205321', 'cui_str': 'Penetrating'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0022397', 'cui_str': 'Work Satisfaction'}, {'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}]",18.0,0.0715876,It is hypothesized that implementation will be more successful at,"[{'ForeName': 'Anne E', 'Initials': 'AE', 'LastName': 'Kazak', 'Affiliation': ""Nemours Children's Health System, Wilmington, DE, USA. anne.kazak@nemours.org.""}, {'ForeName': 'Janet A', 'Initials': 'JA', 'LastName': 'Deatrick', 'Affiliation': 'University of Pennsylvania School of Nursing, Philadelphia, PA, USA.'}, {'ForeName': 'Michele A', 'Initials': 'MA', 'LastName': 'Scialla', 'Affiliation': 'A.I. du Pont Hospital for Children, Wilmington, DE, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Sandler', 'Affiliation': ""Nemours Children's Clinic, Jacksonville, FL, USA.""}, {'ForeName': 'Rebecca E', 'Initials': 'RE', 'LastName': 'Madden', 'Affiliation': ""The Children's Hospital of Philadelphia, Philadelphia, PA, USA.""}, {'ForeName': 'Lamia P', 'Initials': 'LP', 'LastName': 'Barakat', 'Affiliation': ""The Children's Hospital of Philadelphia, Philadelphia, PA, USA.""}]",Implementation science : IS,['10.1186/s13012-020-01023-w'] 1964,32727496,"Efficacy of combining intravitreal injections of ranibizumab with micropulse diode laser versus intravitreal injections of ranibizumab alone in diabetic macular edema (ReCaLL): a single center, randomised, controlled, non-inferiority clinical trial.","BACKGROUND To evaluate if a combination therapy with micropulse diode laser (MPL) shows non-inferiority on visual acuity (BCVA) within 12 months in comparison to standard therapy, i.e. intravitreal injection of ranibizumab alone. SETTING Institutional. Prospective randomized single-center trial. METHODS Patients with diabetic macular edema (DME) received three intravitreal injections of 0.5 mg ranibizumab during the upload phase and were then randomised 1:1 to receive either the same dosage of ranibizumab (0.5 mg) injections pro re nata alone (IVOM-Group; n = 9), or with two additional treatments with micropulse diode laser (IVOM+Laser-Group; n = 10). The primary endpoint was change in BCVA after 12 months. Secondary endpoints were change in central macular thickness and overall number of ranibizumab injections. RESULTS BCVA increased significantly in both groups (IVOM: + 5.86, p < 0.001; IVOM+Laser: + 9.30; p < 0.001) with corresponding decrease in central macular thickness (IVOM: - 105 μm, p < 0.01; IVOM+Laser: - 125 μm; p < 0.01). Patients with additional laser treatment had better visual improvement (group comparison p = 0.075) and needed fewer ranibizumab injections (cumulative proportion of injections 9.68 versus 7.46 in IVOM-Group and IVOM+Laser-Group, respectively). CONCLUSION Non-inferiority of combination therapy in comparison to standard therapy alone could be demonstrated. Patients with additional laser therapy needed fewer ranibizumab injections. TRIAL REGISTRATION Registered 10 February 2014 on ClinicalTrials.gov; NCT02059772 .",2020,"RESULTS BCVA increased significantly in both groups (IVOM: + 5.86, p < 0.001; IVOM+Laser: + 9.30; p < 0.001) with corresponding decrease in central macular thickness (IVOM: - 105 μm, p < 0.01; IVOM+Laser: - 125 μm; p < 0.01).","['Patients with additional laser therapy needed fewer ranibizumab injections', 'diabetic macular edema (ReCaLL', 'Patients with diabetic macular edema (DME']","['ranibizumab alone', 'intravitreal injections of 0.5\u2009mg ranibizumab', 'micropulse diode laser (MPL', 'ranibizumab with micropulse diode laser', 'ranibizumab (0.5\u2009mg) injections pro re nata alone (IVOM-Group; n\u2009=\u20099), or with two additional treatments with micropulse diode laser (IVOM+Laser-Group; n\u2009=\u200910']","['change in central macular thickness and overall number of ranibizumab injections', 'visual acuity (BCVA', 'change in BCVA', 'visual improvement', 'central macular thickness', 'BCVA']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0205388', 'cui_str': 'Few'}, {'cui': 'C4050112', 'cui_str': 'ranibizumab Injection'}, {'cui': 'C0730285', 'cui_str': 'Macular edema due to diabetes mellitus'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C1554888', 'cui_str': 'Intravitreal Injections'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0392254', 'cui_str': 'Semiconductor laser device'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0067792', 'cui_str': 'N-acetyltryptophanamide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C4050112', 'cui_str': 'ranibizumab Injection'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0234621', 'cui_str': 'Visual'}]",,0.230585,"RESULTS BCVA increased significantly in both groups (IVOM: + 5.86, p < 0.001; IVOM+Laser: + 9.30; p < 0.001) with corresponding decrease in central macular thickness (IVOM: - 105 μm, p < 0.01; IVOM+Laser: - 125 μm; p < 0.01).","[{'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Furashova', 'Affiliation': 'Department of Ophthalmology, Klinikum Chemnitz gGmbH, Flemmingstrasse 2, 09116, Chemnitz, Germany. o.furashova@skc.de.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Strassburger', 'Affiliation': 'Department of Ophthalmology, Klinikum Chemnitz gGmbH, Flemmingstrasse 2, 09116, Chemnitz, Germany.'}, {'ForeName': 'Klio Ai', 'Initials': 'KA', 'LastName': 'Becker', 'Affiliation': 'Hessemer MVZ, Augenmedizin Darmstadt, Martinspfad 72, 64285, Darmstadt, Germany.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Engelmann', 'Affiliation': 'Department of Ophthalmology, Klinikum Chemnitz gGmbH, Flemmingstrasse 2, 09116, Chemnitz, Germany.'}]",BMC ophthalmology,['10.1186/s12886-020-01576-w'] 1965,32730798,"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a doubleblind, randomised withdrawal phase.","BACKGROUND Cushing's disease is a rare endocrine disorder characterised by cortisol overproduction with severe complications. Therapies for cortisol reduction are often necessary. Here we report the outcomes from the pivotal phase III study of osilodrostat (a potent oral inhibitor of cytochrome P450 11B1, mitochondrial [11β-hydroxylase]; Novartis Pharma AG, Basel, Switzerland) in patients with Cushing's disease. METHODS LINC 3 was a prospective, multicentre, open-label, phase III study with a double-blind randomised withdrawal period, that comprised four periods. Patients aged 18-75 years, with confirmed persistent or recurrent Cushing's disease (defined as mean 24-h urinary free cortisol [UFC] concentration >1·5 times the upper limit of normal [ULN] and morning plasma adrenocorticotropic hormone above the lower limit of normal) who had previously had pituitary surgery or irradiation, or were newly diagnosed and who refused surgery or were not surgical candidates, were recruited from 66 hospital sites and private clinical practices in 19 countries. In period 1, open-label osilodrostat was initiated in all participants and adjusted every 2 weeks (1-30 mg twice daily; film-coated tablets for oral administration) on the basis of mean 24-h UFC concentration and safety until week 12. In period 2, weeks 13-24, osilodrostat was continued at the therapeutic dose determined during period 1. In period 3, beginning at week 26, participants who had a mean 24-h UFC concentration of less than or equal to the ULN at week 24, without up-titration after week 12, were randomly assigned (1:1), via an interactive-response technology, stratified by osilodrostat dose at week 24 and history of pituitary irradiation, to continue osilodrostat or switch to placebo for 8 weeks. Participants and investigators were masked to treatment assignment. Ineligible participants continued open-label osilodrostat. In period 4, weeks 35-48, all participants were given open-label osilodrostat until core-study end. The primary objective was to compare the efficacy of osilodrostat versus placebo at the end of period 3. The primary endpoint was the proportion of participants who had been randomly assigned to treatment or placebo with a complete response (ie, mean 24-h UFC concentration of ≤ULN) at the end of the randomised withdrawal period (week 34), without up-titration during this period. The key secondary endpoint was the proportion of participants with a complete response at the end of the single-arm, open-label period (ie, period 2, week 24) without up-titration during weeks 13-24. Analysis was by intention-to-treat for all patients who received at least one dose of osilodrostat (full analysis set; key secondary endpoint) or randomised treatment (randomised analysis set; primary endpoint) and safety was assessed in all enrolled patients who received at least one dose of osilodrostat and had at least one post-baseline safety assessment. LINC 3 is registered with ClinicalTrials.gov, NCT02180217, and is now complete. FINDINGS Between Nov 12, 2014, and March 22, 2017, 202 patients were screened and 137 were enrolled. The median age was 40·0 years (31·0-49·0) and 106 (77%) participants were female. 72 (53%) participants were eligible for randomisation during the withdrawal phase, of whom 36 were assigned to continue osilodrostat and 35 were assigned to placebo; one patient was not randomly assigned due to investigator decision and continued open-label osilodrostat. More patients maintained a complete response with osilodrostat versus with placebo at week 34 (31 [86%] vs ten [29%]; odds ratio 13·7 [95% CI 3·7-53·4]; p<0·0001). At week 24, 72 (53%; 95% CI 43·9-61·1) of 137 patients maintained a complete response without up-titration after week 12. Most common adverse events (ie, occurred in >25% of participants) were nausea (57 [42%]), headache (46 [34%]), fatigue (39 [28%]), and adrenal insufficiency (38 [28%]). Hypocortisolism occurred in 70 (51%) patients and adverse events related to adrenal hormone precursors occurred in 58 (42%) patients. One patient died, unrelated to study drug, after the core study phase. INTERPRETATION Twice-daily osilodrostat rapidly reduced mean 24-h UFC and sustained this reduction alongside improvements in clinical signs of hypercortisolism; it was also generally well tolerated. Osilodrostat is an effective new treatment option that is approved in Europe for the treatment of endogenous Cushing's syndrome and in the USA for Cushing's disease. FUNDING Novartis Pharma AG.",2020,More patients maintained a complete response with osilodrostat versus with placebo at week 34 (31 [86%] vs ten [29%]; odds ratio 13·7 [95% CI 3·7-53·4]; p<0·0001).,"[""patients with Cushing's disease"", '72 (53%) participants were eligible for randomisation during the withdrawal phase, of whom 36 were assigned to continue osilodrostat and 35 were assigned to', 'participants who had a mean 24-h UFC concentration of less than or equal to the ULN at week 24, without up-titration after week 12', 'Between Nov 12, 2014, and March 22, 2017, 202 patients were screened and 137 were enrolled', '137 patients', 'The median age was 40·0 years (31·0-49·0) and 106 (77%) participants were female', ""Patients aged 18-75 years, with confirmed persistent or recurrent Cushing's disease (defined as mean 24-h urinary free cortisol [UFC] concentration >1·5 times the upper limit of normal [ULN] and morning plasma adrenocorticotropic hormone above the lower limit of normal) who had previously had pituitary surgery or irradiation, or were newly diagnosed and who refused surgery or were not surgical candidates, were recruited from 66 hospital sites and private clinical practices in 19 countries"", ""patients with Cushing's disease (LINC 3""]","['osilodrostat versus placebo', 'investigator decision and continued open-label osilodrostat', 'osilodrostat', 'placebo']","['headache', 'adrenal hormone precursors', 'proportion of participants with a complete response', 'fatigue', 'complete response (ie, mean 24-h UFC concentration of ≤ULN', 'Efficacy and safety', 'adrenal insufficiency', 'nausea', 'Hypocortisolism']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0221406', 'cui_str': 'Pituitary dependent hypercortisolism'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439090', 'cui_str': '<='}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0162621', 'cui_str': 'Titration method'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4517569', 'cui_str': '137'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0474662', 'cui_str': 'Cortisol measurement, free, urine'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C1271647', 'cui_str': 'Plasma ACTH level'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0032002', 'cui_str': 'Disorder of pituitary gland'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0017095', 'cui_str': 'Trash'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0033175', 'cui_str': 'Private Room'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0454664', 'cui_str': 'Country'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0175566', 'cui_str': 'Open'}]","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C1445654', 'cui_str': 'Adrenal hormone'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0001623', 'cui_str': 'Hypoadrenalism'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0001403', 'cui_str': ""Addison's disease""}]",202.0,0.359008,More patients maintained a complete response with osilodrostat versus with placebo at week 34 (31 [86%] vs ten [29%]; odds ratio 13·7 [95% CI 3·7-53·4]; p<0·0001).,"[{'ForeName': 'Rosario', 'Initials': 'R', 'LastName': 'Pivonello', 'Affiliation': 'Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy. Electronic address: rosario.pivonello@unina.it.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Fleseriu', 'Affiliation': 'Northwest Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health and Science University, Portland, OR, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Newell-Price', 'Affiliation': 'Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Bertagna', 'Affiliation': 'Department of Endocrinology, Centre de Référence des Maladies Rares de la Surrénale, Hôpital Cochin, Faculté de Médecine Paris Descartes, Université Paris 5, Paris, France.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Findling', 'Affiliation': 'Division of Endocrinology and Molecular Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Shimatsu', 'Affiliation': 'Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan; Advanced Medical Care Center, Kusatsu General Hospital, Kusatsu, Japan.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Gu', 'Affiliation': 'Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Auchus', 'Affiliation': 'Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Rattana', 'Initials': 'R', 'LastName': 'Leelawattana', 'Affiliation': 'Prince of Songkla University, Songkhla, Thailand.'}, {'ForeName': 'Eun Jig', 'Initials': 'EJ', 'LastName': 'Lee', 'Affiliation': 'Pituitary Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Jung Hee', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Lacroix', 'Affiliation': ""Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Laplanche', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': ""O'Connell"", 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Libuse', 'Initials': 'L', 'LastName': 'Tauchmanova', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Alberto M', 'Initials': 'AM', 'LastName': 'Pedroncelli', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Beverly M K', 'Initials': 'BMK', 'LastName': 'Biller', 'Affiliation': 'Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The lancet. Diabetes & endocrinology,['10.1016/S2213-8587(20)30240-0'] 1966,32730842,The association between REM sleep and decision-making: Supporting evidences.,"Studies suggest that REM sleep is important for the maintenance of prefrontal cortex functioning. Therefore, reducing REM sleep may have an impact on cognitive functions such as impulse control and decision-making processes. This study examined the association between impulsiveness and sensation seeking personality traits, REM sleep and performance on a decision-making computer task following a habitual night of sleep and a partial sleep deprivation (PSD) condition with advanced wake-up time. Eighteen young adults participated in two experimental conditions: a control (habitual bedtime and wake time) and a 50% PSD with an advanced wake time. Impulsiveness and sensation seeking personality traits were measured with a personality inventory (NEO-PI-3), sleep was assessed using standard polysomnography and the Iowa Gambling Task (IGT) was completed at noon following each sleep condition. Results showed that when sleep deprived, participants choose more often to play riskier decks of cards during the last half of the IGT. Results also showed that REM sleep duration and REM sleep deprivation were associated with riskier decisions on the IGT. Moreover, impulsiveness was associated with riskier decisions after a normal night of sleep. These findings suggest that REM sleep duration and impulsiveness are important factors to consider while investigating decision-making processes under conditions of uncertainty and risk.",2020,"Results showed that when sleep deprived, participants choose more often to play riskier decks of cards during the last half of the IGT.",['Eighteen young adults'],['control (habitual bedtime and wake time) and a 50% PSD with an advanced wake time'],"['personality inventory (NEO-PI-3), sleep was assessed using standard polysomnography and the Iowa Gambling Task (IGT', 'REM sleep duration and REM sleep deprivation', 'Impulsiveness and sensation seeking personality traits']","[{'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0521112', 'cui_str': 'Bedtime'}, {'cui': 'C0442696', 'cui_str': 'Waking'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0037316', 'cui_str': 'Sleep deprivation'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}]","[{'cui': 'C0003944', 'cui_str': 'As If Personality'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0142580', 'cui_str': 'PI3 protein, human'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0162701', 'cui_str': 'Polysomnography'}, {'cui': 'C0022037', 'cui_str': 'Iowa'}, {'cui': 'C0016995', 'cui_str': 'Gambling'}, {'cui': 'C0037322', 'cui_str': 'Rapid eye movement sleep'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0751506', 'cui_str': 'REM Sleep Deprivation'}, {'cui': 'C0564567', 'cui_str': 'Impulsive character'}, {'cui': 'C0871336', 'cui_str': 'Sensation seeking'}, {'cui': 'C0233849', 'cui_str': 'Character trait finding'}]",18.0,0.0117207,"Results showed that when sleep deprived, participants choose more often to play riskier decks of cards during the last half of the IGT.","[{'ForeName': 'Jean-François', 'Initials': 'JF', 'LastName': 'Brunet', 'Affiliation': 'Laboratoire du Sommeil, Département de Psychoéducation et de Psychologie, Université du Québec en Outaouais, Gatineau, Canada, J8X 3X7.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'McNeil', 'Affiliation': 'Behavioral and Metabolic Research Unit, School of Human Kinetics, University of Ottawa, Ottawa, Canada, K1N 6N5.'}, {'ForeName': 'Éric', 'Initials': 'É', 'LastName': 'Doucet', 'Affiliation': 'Behavioral and Metabolic Research Unit, School of Human Kinetics, University of Ottawa, Ottawa, Canada, K1N 6N5.'}, {'ForeName': 'Geneviève', 'Initials': 'G', 'LastName': 'Forest', 'Affiliation': 'Laboratoire du Sommeil, Département de Psychoéducation et de Psychologie, Université du Québec en Outaouais, Gatineau, Canada, J8X 3X7. Electronic address: genevieve.forest@uqo.ca.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113109'] 1967,32730905,Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patients undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial.,"BACKGROUND New antithrombotic strategies that reduce primary thrombosis and restenosis might improve vascular outcomes in patients with peripheral artery disease (PAD) undergoing arterial angioplasty. The study objective is to evaluate the potential benefit of apixaban plus aspirin compared with standard of care dual antiplatelet therapy (DAPT) in reducing thrombotic restenosis and artery re-occlusion in patients undergoing endovascular infrapopliteal revascularization. STUDY DESIGN This multicenter, parallel-group, prospective, randomized, open-label, blinded-endpoint adjudication, proof-of-concept, exploratory trial aims to randomize 200 patients 72 hours after successful infrapopliteal angioplasty for critical limb ischemia (CLI). Patients will be randomly assigned in a 1:1 ratio to receive oral apixaban (2.5 mg twice daily) plus aspirin (100 mg once daily) for 12 months or clopidogrel (75 mg daily) for at least 3 months on a background of aspirin (100 mg once daily) for 12 months. The primary endpoint is the composite of target lesion revascularization (TLR), major amputation, or restenosis/occlusion (RAS) in addition to major adverse cardiovascular events - MACE (myocardial infarction, stroke or cardiovascular death) at 12 months. The primary safety endpoint is the composite of major bleeding or clinically relevant non-major bleeding at 12 months. SUMMARY This study will evaluate the efficacy and safety of apixaban 2.5 mg twice daily plus aspirin compared with DAPT (clopidogrel plus aspirin) in patients with CLI undergoing endovascular infrapopliteal revascularization and might prove the concept of an alternative antithrombotic regimen for these patients to be tested in a future large randomized clinical trial.",2020,"The primary endpoint is the composite of target lesion revascularization (TLR), major amputation, or restenosis/occlusion (RAS) in addition to major adverse cardiovascular events - MACE (myocardial infarction, stroke or cardiovascular death) at 12 months.","['200 patients 72 hours after successful infrapopliteal angioplasty for critical limb ischemia (CLI', 'patients with peripheral artery disease (PAD) undergoing arterial angioplasty', 'patients undergoing InfraPoPliteal angioplasty for critical limb ischemia', 'patients with CLI undergoing endovascular infrapopliteal revascularization', 'patients undergoing endovascular infrapopliteal revascularization']","['apixaban plus aspirin', 'apixaban 2.5 mg twice daily plus aspirin', 'Apixaban versus ClopidoGRel', 'standard of care dual antiplatelet therapy (DAPT', 'DAPT (clopidogrel plus aspirin', 'aspirin', 'clopidogrel', 'oral apixaban']","['composite of target lesion revascularization (TLR), major amputation, or restenosis/occlusion (RAS) in addition to major adverse cardiovascular events - MACE (myocardial infarction, stroke or cardiovascular death', 'thrombotic restenosis and artery re-occlusion', 'composite of major bleeding or clinically relevant non-major bleeding at 12 months', 'efficacy and safety']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0162577', 'cui_str': 'Angioplasty of blood vessel'}, {'cui': 'C1142264', 'cui_str': 'Critical limb ischemia'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Arterial Diseases'}, {'cui': 'C0397654', 'cui_str': 'Angioplasty of artery'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}]","[{'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C3530461', 'cui_str': 'apixaban 2.5 MG'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0014742', 'cui_str': 'Erythema multiforme'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0333186', 'cui_str': 'Restenosis'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0286421', 'cui_str': 'ACE protocol 2'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.221901,"The primary endpoint is the composite of target lesion revascularization (TLR), major amputation, or restenosis/occlusion (RAS) in addition to major adverse cardiovascular events - MACE (myocardial infarction, stroke or cardiovascular death) at 12 months.","[{'ForeName': 'Rodrigo Bruno', 'Initials': 'RB', 'LastName': 'Biagioni', 'Affiliation': 'São Paulo State Public Servant Hospital, São Paulo, Brazil. Electronic address: rbbiagioni@gmail.com.'}, {'ForeName': 'Renato Delascio', 'Initials': 'RD', 'LastName': 'Lopes', 'Affiliation': 'Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Leandro Barile', 'Initials': 'LB', 'LastName': 'Agati', 'Affiliation': 'Science Valley Research Institute, Santo André, São Paulo, Brazil.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Sacilotto', 'Affiliation': 'São Paulo State Public Servant Hospital, São Paulo, Brazil.'}, {'ForeName': 'Nelson', 'Initials': 'N', 'LastName': 'Wolosker', 'Affiliation': 'Albert Einstein Hospital, São Paulo, Brazil; Hospital das Clínicas de São Paulo, São Paulo University, São Paulo, Brazil.'}, {'ForeName': 'Marcone Lima', 'Initials': 'ML', 'LastName': 'Sobreira', 'Affiliation': 'Universidade Estadual Paulista (UNESP), Botucatu, Brazil.'}, {'ForeName': 'Bruno Leonardo', 'Initials': 'BL', 'LastName': 'de Freitas Soares', 'Affiliation': 'Santa Casa de Maceio, Maceio, Alagoas, Brazil.'}, {'ForeName': 'Edwaldo Edner', 'Initials': 'EE', 'LastName': 'Joviliano', 'Affiliation': 'Hospital das Clínicas de Ribeirão Preto, São Paulo University Medical School (USP), Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Walkiria Hueb', 'Initials': 'WH', 'LastName': 'Bernardi', 'Affiliation': 'Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil.'}, {'ForeName': 'Valter Castelli', 'Initials': 'VC', 'LastName': 'Junior', 'Affiliation': 'Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil.'}, {'ForeName': 'Roberto Augusto', 'Initials': 'RA', 'LastName': 'Caffaro', 'Affiliation': 'Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Fioranelli', 'Affiliation': 'Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil.'}, {'ForeName': 'Bonno', 'Initials': 'B', 'LastName': 'Van Bellen', 'Affiliation': 'Beneficência Portuguesa de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Ivan Benaduce', 'Initials': 'IB', 'LastName': 'Casella', 'Affiliation': 'Hospital das Clínicas de São Paulo, São Paulo University, São Paulo, Brazil.'}, {'ForeName': 'Ronald José Ribeiro', 'Initials': 'RJR', 'LastName': 'Fidelis', 'Affiliation': 'Vascular and Endovascular Surgery-Federal University of Bahia.'}, {'ForeName': 'Ronald Luiz Gomes', 'Initials': 'RLG', 'LastName': 'Flumignan', 'Affiliation': 'Federal University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Anthony James', 'Initials': 'AJ', 'LastName': 'Comerota', 'Affiliation': 'Inova Heart and Vascular Institute, Falls Church, VA, USA.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Ramacciotti', 'Affiliation': 'Hemostasis & Thrombosis Research Laboratories at Loyola University Medical Center, Maywood, IL, USA; Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil.'}]",American heart journal,['10.1016/j.ahj.2020.06.010'] 1968,32737091,Choice of ANaesthesia for EndoVAScular treatment of acute ischaemic stroke at posterior circulation (CANVAS II): protocol for an exploratory randomised controlled study.,"INTRODUCTION Observational and interventional studies indicate that the type of anaesthesia may be associated with the postprocedural neurological function in patients with anterior circulation acute ischaemic stroke undergoing endovascular treatment. Patients with acute posterior circulation ischaemic stroke may experience different physiological changes and result in severe neurological outcome. However, the effect of the type of anaesthesia on postprocedure neurological function remained unclear in this population. METHODS AND ANALYSIS This is an exploratory randomised controlled trial that will be carried out at Beijing Tiantan Hospital, Capital Medical University. Patients with acute posterior circulation ischaemic stroke and deemed suitable for emergency endovascular recanalisation will be recruited in this trial. Eighty-four patients will be randomised to receive either general anaesthesia or conscious sedation with 1:1 allocation ratio. The primary endpoint is the 90-day modified Rankin Scale. ETHICS AND DISSEMINATION The study has been reviewed by and approved by Ethics Committee of Beijing Tiantan Hospital of Capital Medical University (KY2017-074-02). If the results are positive, the study will indicate whether the type of anaesthesia affects neurological outcome after endovascular treatment of posterior stroke. The findings of the study will be published in peer-reviewed journals and presented at national or international conferences. TRIAL REGISTRATION NUMBER NCT03317535.",2020,"If the results are positive, the study will indicate whether the type of anaesthesia affects neurological outcome after endovascular treatment of posterior stroke.","['Patients with acute posterior circulation ischaemic stroke', 'Beijing Tiantan Hospital of Capital Medical University (KY2017-074-02', 'patients with anterior circulation acute ischaemic stroke undergoing endovascular treatment', 'acute ischaemic stroke at posterior circulation (CANVAS II', 'Beijing Tiantan Hospital, Capital Medical University']","['ANaesthesia', 'general anaesthesia or conscious sedation with 1:1 allocation ratio', 'emergency endovascular recanalisation']","['90-day modified Rankin Scale', 'postprocedure neurological function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0005775', 'cui_str': 'Circulation, Blood'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0006909', 'cui_str': 'Capital'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0079159', 'cui_str': 'Conscious sedation'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0034771', 'cui_str': 'Recanalization'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0027767', 'cui_str': 'Nervous system function'}]",84.0,0.174259,"If the results are positive, the study will indicate whether the type of anaesthesia affects neurological outcome after endovascular treatment of posterior stroke.","[{'ForeName': 'Fa', 'Initials': 'F', 'LastName': 'Liang', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Yan', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Youxuan', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Xiuheng', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Minyu', 'Initials': 'M', 'LastName': 'Jian', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Shu', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Zhongrong', 'Initials': 'Z', 'LastName': 'Miao', 'Affiliation': 'Department of Interventional Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Ruquan', 'Initials': 'R', 'LastName': 'Han', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Yuming', 'Initials': 'Y', 'LastName': 'Peng', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China florapym766@163.com.'}]",BMJ open,['10.1136/bmjopen-2019-036358'] 1969,32737097,Ensemble programme for early intervention in informal caregivers of psychiatric adult patients: a protocol for a randomised controlled trial.,"INTRODUCTION Informal caregivers play a major role in the support and maintenance of community patients with severe psychiatric disorders. A pilot study showed that an individualised brief intervention such as the Ensemble programme leads to significant improvements in psychological health state and optimism. METHODS AND ANALYSIS This randomised controlled trial aims to compare the efficacy of using Ensemble in improving informal caregivers' psychological health states and the ability to play an active role in their situations with that of support as usual. Improvements on the psychological health global index will be measured three times (T0-pre, T1-post and T3 2 months follow) with standardised questionnaires (the Global Severity Index of Brief Inventory Symptoms, the Life Orientation Test-Revised, the 36-item Medical Outcome Study Short-Form Health Survey and the French Zarit Burden Interview). Differences between groups in post-test and pretest values will be examined using an analysis of covariance for each outcome variable. The severity of illness measured by the Social and Occupational Functioning Assessment Scale will also be collected at T0 and T2 to compare eventual patient improvements. At the end of the programme, the experiences of the 20 patients participating in the Ensemble programme will be evaluated qualitatively. ETHICS AND DISSEMINATION The research protocol received full authorisation from the Human Research Ethics Committee of the Vaud state, Switzerland. The principal paper will concern the results of the experimental design used to test the Ensemble programme. The research team will prioritise open access publications. TRIAL REGISTRATION NUMBER NCT04020497.",2020,"A pilot study showed that an individualised brief intervention such as the Ensemble programme leads to significant improvements in psychological health state and optimism. ","['informal caregivers of psychiatric adult patients', 'community patients with severe psychiatric disorders', '20 patients participating in the Ensemble programme will be evaluated qualitatively']",[],"['severity of illness measured by the Social and Occupational Functioning Assessment Scale', 'Global Severity Index of Brief Inventory Symptoms, the Life Orientation Test-Revised, the 36-item Medical Outcome Study Short-Form Health Survey and the French Zarit Burden Interview', 'psychological health state and optimism', 'psychological health global index']","[{'cui': 'C1319882', 'cui_str': 'Informal caregiver'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}]",[],"[{'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0521127', 'cui_str': 'Occupational'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0582640', 'cui_str': 'Life orientation test'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0543472', 'cui_str': 'Outcome Studies'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0376246', 'cui_str': 'French language'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0237428', 'cui_str': 'Positive attitude'}]",20.0,0.0922263,"A pilot study showed that an individualised brief intervention such as the Ensemble programme leads to significant improvements in psychological health state and optimism. ","[{'ForeName': 'Shyhrete', 'Initials': 'S', 'LastName': 'Rexhaj', 'Affiliation': 'La Source, School of Nursing, University of Applied Sciences and Arts Western Switzerland, HES-SO, Lausanne, Vaud, Switzerland s.rexhaj@ecolelasource.ch.'}, {'ForeName': 'Shadya', 'Initials': 'S', 'LastName': 'Monteiro', 'Affiliation': 'La Source, School of Nursing, University of Applied Sciences and Arts Western Switzerland, HES-SO, Lausanne, Vaud, Switzerland.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Golay', 'Affiliation': 'Community Psychiatry Service, Department of Psychiatry, Lausanne, CHUV, Lausanne, VD, Switzerland.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Coloni-Terrapon', 'Affiliation': 'La Source, School of Nursing, University of Applied Sciences and Arts Western Switzerland, HES-SO, Lausanne, Vaud, Switzerland.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Wenger', 'Affiliation': 'La Source, School of Nursing, University of Applied Sciences and Arts Western Switzerland, HES-SO, Lausanne, Vaud, Switzerland.'}, {'ForeName': 'Jérôme', 'Initials': 'J', 'LastName': 'Favrod', 'Affiliation': 'La Source, School of Nursing, University of Applied Sciences and Arts Western Switzerland, HES-SO, Lausanne, Vaud, Switzerland.'}]",BMJ open,['10.1136/bmjopen-2020-038781'] 1970,32737249,Correction: Cost-utility analysis of learning and coping versus standard education in cardiac rehabilitation: a randomised controlled trial with 3 years of follow-up.,,2020,,['cardiac rehabilitation'],['learning and coping versus standard education'],[],"[{'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}]","[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013621', 'cui_str': 'Education'}]",[],,0.11373,,[],Open heart,['10.1136/openhrt-2019-001184corr1'] 1971,32738130,"Influence of concurrent capecitabine based chemoradiotherapy with bevacizumab on the survival rate, late toxicity and health-related quality of life in locally advanced rectal cancer: a prospective phase II CRAB trial.","Background Few studies reported early results on efficacy, toxicity of combined modality treatment for locally advanced rectal cancer (LARC) by adding bevacizumab to preoperative chemoradiotherapy, but long-term data on survival, and late complications are lacking. Further, none of the studies reported on the assessment of quality of life (QOL). Patients and methods After more than 5 years of follow-up, we updated the results of our previous phase II trial in 61 patients with LARC treated with neoadjuvant capecitabine, radiotherapy and bevacizumab (CRAB study) before surgery and adjuvant chemotherapy. Secondary endpoints of updated analysis were local control (LC), disease free (DFS) and overall survival (OS), late toxicity and longitudinal health related QOL (before starting the treatment and one year after the treatment) with questionnaire EORTC QLQ-C30 and EORTC QLQ-CR38. Results Median follow-up was 67 months. During the follow-up period, 16 patients (26.7%) died. The 5-year OS, DFS and LC rate were 72.2%, 70% and 92.4%. Patients with pathological positive nodes or pathological T3-4 tumors had significantly worse survival than patients with pathological negative nodes or T0-2 tumors. Nine patients (14.8%) developed grade 33 late complications of combined modality treatment, first event 12 months and last 87 months after operation (median time 48 months). Based on EORTC QLQ-C30 scores one year after treatment there were no significant changes in global QOL and three symptoms (pain, insomnia and diarrhea), but physical and social functioning significantly decreased. Based on QLQ-CR38 scores body image scores significantly increase, problems with weight loss significantly decrease, but sexual dysfunction in men and chemotherapy side effects significantly increase. Conclusions Patients with LARC and high risk factors, such as positive pathological lymph nodes and high pathological T stage, deserve more aggressive treatment in the light of improving long-term survival results. Patients after multimodality treatment should be given greater attention to the regulation of individual aspects of quality of life and the occurrence of late side effects.",2020,"Based on EORTC QLQ-C30 scores one year after treatment there were no significant changes in global QOL and three symptoms (pain, insomnia and diarrhea), but physical and social functioning significantly decreased.","['61 patients with LARC treated with', 'locally advanced rectal cancer (LARC', 'locally advanced rectal cancer', 'Patients with pathological positive nodes or pathological T3-4 tumors']","['neoadjuvant capecitabine, radiotherapy and bevacizumab (CRAB study) before surgery and adjuvant chemotherapy', 'capecitabine based chemoradiotherapy with bevacizumab', 'bevacizumab']","['5-year OS, DFS and LC rate', 'grade 33 late complications', 'local control (LC), disease free (DFS) and overall survival (OS), late toxicity and longitudinal health related QOL', 'questionnaire EORTC QLQ-C30 and EORTC QLQ-CR38', 'survival', 'physical and social functioning', 'quality of life (QOL', 'efficacy, toxicity', 'QLQ-CR38 scores body image scores', 'sexual dysfunction', 'global QOL and three symptoms (pain, insomnia and diarrhea', 'survival rate, late toxicity and health-related quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007113', 'cui_str': 'Rectal cancer'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}]","[{'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0010260', 'cui_str': 'Infraorder Brachyura'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0005891', 'cui_str': 'Body image'}, {'cui': 'C0549622', 'cui_str': 'Sexual disorder'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",61.0,0.0636662,"Based on EORTC QLQ-C30 scores one year after treatment there were no significant changes in global QOL and three symptoms (pain, insomnia and diarrhea), but physical and social functioning significantly decreased.","[{'ForeName': 'Vaneja', 'Initials': 'V', 'LastName': 'Velenik', 'Affiliation': 'Division of Radiotherapy, Institute of Oncology, Ljubljana, Slovenia.'}, {'ForeName': 'Vesna', 'Initials': 'V', 'LastName': 'Zadnik', 'Affiliation': 'Division of Epidemiology, Institute of Oncology, Ljubljana, Slovenia.'}, {'ForeName': 'Mirko', 'Initials': 'M', 'LastName': 'Omejc', 'Affiliation': 'Division of Surgery, University Medical Center Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Grosek', 'Affiliation': 'Division of Surgery, University Medical Center Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Mojca', 'Initials': 'M', 'LastName': 'Tuta', 'Affiliation': 'Division of Radiology, Institute of Oncology, Ljubljana, Slovenia.'}]",Radiology and oncology,['10.2478/raon-2020-0043'] 1972,32738599,Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial.,"OBJECTIVES IRX-2 is a primary-cell-derived immune-restorative consisting of multiple human cytokines that act to overcome tumor-mediated immunosuppression and provide an in vivo tumor vaccination to increase tumor infiltrating lymphocytes (TILs). A randomized phase II trial was conducted of the IRX regimen 3 weeks prior to surgery consisting of an initial dose of cyclophosphamide followed by 10 days of regional perilymphatic IRX-2 cytokine injections and daily oral indomethacin, zinc and omeprazole (Regimen 1) compared to the identical regimen without IRX-2 cytokines (Regimen 2). METHODS A total of 96 patients with previously untreated, stage II-IV oral cavity SCC were randomized 2:1 to experimental (1) or control (2) regimens (64:32). Paired biopsy and resection specimens from 62 patients were available for creation of tissue microarray (n = 39), and multiplex immunohistology (n = 54). Increases in CD8+ TIL infiltrate scores of at least 10 cells/mm 2 were used to characterize immune responders (IR). RESULTS Regimen 1 was associated with significant increases in CD8+ infiltrates (p = 0.01) compared to Regimen 2. In p16 negative cancers (n = 26), significant increases in CD8+ and overall TILs were evident in Regimen 1 (p = 0.004, and 0.04 respectively). IRs were more frequent in Regimen 1 (74% vs 31%, p = 0.01). Multiplex immunohistology for PD-L1 expression confirmed an increase in PD-L1 H score for Regimen 1 compared to Regimen 2 (p = 0.11). CONCLUSIONS The findings demonstrate significant increases in TILs after perilymphatic IRX-2 injections. Three quarters of patients showed significant immune responses to IRX-2. (NCT02609386).",2020,"RESULTS Regimen 1 was associated with significant increases in CD8+ infiltrates (p = 0.01) compared to Regimen 2.","['96 patients with previously untreated, stage II-IV oral cavity SCC', 'oral squamous cell carcinoma']","['indomethacin, zinc and omeprazole', 'cyclophosphamide', 'neoadjuvant IRX-2 immunotherapy']","['PD-L1 H score', 'CD8+ TIL infiltrate scores', 'CD8+ infiltrates', 'CD8+ and overall TILs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0585362', 'cui_str': 'Squamous cell carcinoma of mouth'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0007137', 'cui_str': 'Squamous cell carcinoma'}]","[{'cui': 'C0021246', 'cui_str': 'Indomethacin'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0028978', 'cui_str': 'Omeprazole'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0758290', 'cui_str': 'IRX 2'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}]","[{'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0079722', 'cui_str': 'Tumor-Infiltrating Lymphocytes'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",96.0,0.0184539,"RESULTS Regimen 1 was associated with significant increases in CD8+ infiltrates (p = 0.01) compared to Regimen 2.","[{'ForeName': 'Gregory T', 'Initials': 'GT', 'LastName': 'Wolf', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States. Electronic address: gregwolf@umich.edu.'}, {'ForeName': 'Siyu', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Bellile', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States.'}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Sartor', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Rozek', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States.'}, {'ForeName': 'Dafydd', 'Initials': 'D', 'LastName': 'Thomas', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States.'}, {'ForeName': 'Ariane', 'Initials': 'A', 'LastName': 'Nguyen', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Zarins', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States.'}, {'ForeName': 'Jonathan B', 'Initials': 'JB', 'LastName': 'McHugh', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Oral oncology,['10.1016/j.oraloncology.2020.104928'] 1973,32738662,"Reaching reliable change using short, daily, cognitive training exercises delivered on a mobile application: The case of Relationship Obsessive Compulsive Disorder (ROCD) symptoms and cognitions in a subclinical cohort.","BACKGROUND Relationship Obsessive Compulsive Disorder (ROCD) is a presentation of OCD centering on interpersonal relationships. The aim of this Randomized Control Trial (RCT) was to assess the efficacy of short, game like, daily cognitive interventions delivered via mobile application in reducing subclinical ROCD symptoms and associated phenomena. METHODS Fifty university students identified as having subclinical levels of ROCD symptoms (using the Structured Clinical Interview for DSM-5 Clinical Version) were randomized into: immediate-use group (iApp group; n = 25) and delayed-use group (dApp group; n = 25). The iApp group started using the evaluated cognitive-behavioral training application at baseline for 15 days (T0 to T1). The dApp group commenced using the application at T1 for 15 days (T1 to T2). All participants completed questionnaires at baseline (T0), 15 days from baseline (T1), and 30 days from baseline (T2). RESULTS Repeated measure MANOVAs showed significant Group (iApp vs. dApp) × Time (T0 vs. T1) interactions. These interactions indicated greater decrease in ROCD symptoms, OCD beliefs and social anxiety symptoms, as well as a greater increase in self-esteem in the iApp group compared to dApp group at T1. Moreover, the Reliable Change Index (RCI) indicated reliable change on ROCD symptoms for a significant portion of participants (42-52%). LIMITATIONS Sample size and the use of self-report measures limits the generalizability of the results. CONCLUSIONS Short, daily cognitive training interventions delivered via mobile applications may be useful in reducing subclinical ROCD symptoms and associated features. Further testing is needed for clinical populations.",2020,"Moreover, the Reliable Change Index (RCI) indicated reliable change on ROCD symptoms for a significant portion of participants (42-52%). ",['Fifty university students identified as having subclinical levels of ROCD symptoms (using the Structured Clinical Interview for DSM-5 Clinical Version'],"['immediate-use group (iApp group; n\xa0=\xa025) and delayed-use group (dApp group; n\xa0=\xa025', 'cognitive training exercises delivered on a mobile application']","['subclinical ROCD symptoms', 'Relationship Obsessive Compulsive Disorder (ROCD) symptoms and cognitions', 'ROCD symptoms, OCD beliefs and social anxiety symptoms', 'subclinical ROCD symptoms and associated phenomena', 'self-esteem', 'ROCD symptoms']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0205211', 'cui_str': 'Subclinical'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0028768', 'cui_str': 'Obsessive-compulsive disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0199182', 'cui_str': 'History taking'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C2607870', 'cui_str': 'Version'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0063684', 'cui_str': 'Amylin'}, {'cui': 'C0088932', 'cui_str': '1-(diethylaminopropyl)-4-phenylpiperazine'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}]","[{'cui': 'C0205211', 'cui_str': 'Subclinical'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0028768', 'cui_str': 'Obsessive-compulsive disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0009595', 'cui_str': 'Obsessive compulsive personality disorder'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}]",,0.0611703,"Moreover, the Reliable Change Index (RCI) indicated reliable change on ROCD symptoms for a significant portion of participants (42-52%). ","[{'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Cerea', 'Affiliation': 'Department of General Psychology, University of Padova, Via Venezia, 8, 35131 Padua, Italy. Electronic address: silvia.cerea@unipd.it.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Ghisi', 'Affiliation': 'Department of General Psychology, University of Padova, Via Venezia, 8, 35131 Padua, Italy.'}, {'ForeName': 'Gioia', 'Initials': 'G', 'LastName': 'Bottesi', 'Affiliation': 'Department of General Psychology, University of Padova, Via Venezia, 8, 35131 Padua, Italy.'}, {'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Carraro', 'Affiliation': 'Department of General Psychology, University of Padova, Via Venezia, 8, 35131 Padua, Italy.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Broggio', 'Affiliation': 'Department of General Psychology, University of Padova, Via Venezia, 8, 35131 Padua, Italy.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Doron', 'Affiliation': 'Baruch Ivcher School of Psychology, Interdisciplinary Center Herzliya, PO Box 167, Herzliya 46150, Israel. Electronic address: gdoron@idc.ac.il.'}]",Journal of affective disorders,['10.1016/j.jad.2020.07.043'] 1974,32743115,"Effects of Dietary Guidance without Dietary Fiber Supplements on the Symptoms, Quality of Life, and Dietary Intake in Patients with Fecal Incontinence.","Objectives Dietary fiber (DF) supplements improve fecal incontinence (FI). Here, we investigated the effects of dietary guidance without DF supplements in patients with FI. Methods This was an interventional study on the nutritional guidance alone by a dietitian where outcomes were compared before and one month after the guidance. In this study, participants attended a one 20-min dietary guidance session and received individual guidance on dietary management according to the 2017 Japanese FI guidelines, between January 2016 and March 2019. The main assessment items used were as follows: (i) the Fecal Incontinence Severity Index (FISI) to assess symptoms, (ii) the Fecal Incontinence Quality of Life Scale (FIQL) to assess the quality of life, and (iii) the dietary intake per day. Results Out of 61 patients who participated in this study, 50 (82%) completed the entire study and 29 (48%) continued a self-controlled diet therapy without drug treatment. Of the 50 patients, the FISI and FIQL scores were significantly improved after the guidance (FISI: 19 before vs. 10.5 after, P < 0.001; FIQL: 2.9 before vs. 3.2 after, P < 0.001). There was no statistically significant difference in the overall DF intake before and after the dietary guidance. However, foods containing DF changed significantly after the guidance. The intake of rice was significantly increased, whilst that of fruits, dairy products, and confectioneries was significantly reduced after the guidance. Conclusions Individual dietary guidance without DF supplements was effective. These results suggested that increasing rice consumption and restricting some foods had positive effects on improving FI.",2020,"The intake of rice was significantly increased, whilst that of fruits, dairy products, and confectioneries was significantly reduced after the guidance. ","['61 patients who participated in this study, 50 (82%) completed the entire study and 29 (48%) continued a self-controlled diet therapy without drug treatment', 'Patients with Fecal Incontinence', 'patients with FI', 'participants attended a one 20-min dietary guidance session and received individual guidance on dietary management according to the 2017 Japanese FI guidelines, between January 2016 and March 2019']","['Objectives\n\n\nDietary fiber (DF) supplements', 'dietary guidance without DF supplements', 'Dietary Guidance without Dietary Fiber Supplements']","['intake of rice', 'Symptoms, Quality of Life, and Dietary Intake', 'Fecal Incontinence Severity Index (FISI) to assess symptoms, (ii) the Fecal Incontinence Quality of Life Scale (FIQL) to assess the quality of life, and (iii) the dietary intake per day', 'fecal incontinence (FI', 'overall DF intake', 'FISI and FIQL scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439751', 'cui_str': 'Entire'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0684274', 'cui_str': 'Self-control'}, {'cui': 'C0012160', 'cui_str': 'nutritional management'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}]","[{'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0035567', 'cui_str': 'Rice'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0474451', 'cui_str': 'Dietary fiber intake'}]",61.0,0.0294812,"The intake of rice was significantly increased, whilst that of fruits, dairy products, and confectioneries was significantly reduced after the guidance. ","[{'ForeName': 'Kaoru', 'Initials': 'K', 'LastName': 'Nakano', 'Affiliation': 'Kameda Kyobashi Clinic, Tokyo, Japan.'}, {'ForeName': 'Tomoko', 'Initials': 'T', 'LastName': 'Takahashi', 'Affiliation': 'Department of Gastroenterological Surgery, Kameda Medical Center, Chiba, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Tsunoda', 'Affiliation': 'Department of Gastroenterological Surgery, Kameda Medical Center, Chiba, Japan.'}, {'ForeName': 'Yukiko', 'Initials': 'Y', 'LastName': 'Shimizu', 'Affiliation': 'Kameda Kyobashi Clinic, Tokyo, Japan.'}]","Journal of the anus, rectum and colon",['10.23922/jarc.2020-008'] 1975,32743119,Efficacy of enhanced emergency department discharge for chronic hypertension management - Results of a randomized controlled trial.,"Introduction Achieve BP is a randomized controlled trial (RCT) of an education intervention for patients with chronic hypertension who have uncontrolled blood pressure (BP) at discharge from an urban emergency department (ED). The study examined efficacy and moderators of an educational intervention in an RCT on BP control at 180-day post-intervention. Methods Participants were recruited from a single, urban ED and randomized to receive or not to receive hypertension education. To minimize potential bias, participants were all started on an evidence-based anti-hypertensive regimen and medications were dispensed directly to participants by the study team. Bivariate analysis was performed to examine differences in sociodemographic characteristics between patients achieving BP control and those who did not. Paired t -test was used to compare the difference of systolic and diastolic BP between baseline and 180 days post-discharge. Multiple logistic regression analysis examined interaction of covariates and intervention on achieving BP control. Results One hundred and thirty-nine participants were randomized into the study. All were African-American with a mean age of 47.6 (SD = 10.8) years; 51% were male, 63% had smoked cigarettes and 15% had diabetes. A total of 66 patients completed the study (47.4%), 44 of whom (67%) achieved BP control. However, there was no difference in BP reduction or control between the two groups. Age and smoking status showed moderation effects on intervention efficacy. Conclusion Despite a neutral effect of our intervention, a high level of BP control was achieved overall, suggesting that the ED may be a viable location for efforts aimed at reducing the impact of chronic hypertension in predominantly African American communities.",2020,"However, there was no difference in BP reduction or control between the two groups.","['patients with chronic hypertension who have uncontrolled blood pressure (BP) at discharge from an urban emergency department (ED', 'Methods\n\n\nParticipants were recruited from a single, urban ED and randomized to receive or not to receive hypertension education', 'All were African-American with a mean age of 47.6 (SD\xa0=\xa010.8) years; 51% were male, 63% had smoked cigarettes and 15% had diabetes', 'One hundred and thirty-nine participants', 'chronic hypertension management ']","['education intervention', 'educational intervention', 'enhanced emergency department discharge']","['BP reduction', 'systolic and diastolic BP', 'BP control']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C3871203', 'cui_str': 'At discharge'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0204946', 'cui_str': 'Hypertension education'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517523', 'cui_str': '10.8'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}, {'cui': 'C5191072', 'cui_str': '139'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",139.0,0.10667,"However, there was no difference in BP reduction or control between the two groups.","[{'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Gleason Comstock', 'Affiliation': 'Department of Family Medicine & Public Health Sciences, School of Medicine, Wayne State University, 3939 Woodward, Detroit, MI, 48201, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Janisse', 'Affiliation': 'Department of Family Medicine & Public Health Sciences, School of Medicine, Wayne State University, 3939 Woodward, Detroit, MI, 48201, USA.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Streater', 'Affiliation': 'Center for Urban Studies, Wayne State University, 700 Cass Ave, Detroit, MI, 48202, USA.'}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'Brody', 'Affiliation': 'Department of Emergency Medicine, School of Medicine, Wayne State University, 4201 St. Antoine, UHC-6G, Detroit, MI, 48202, USA.'}, {'ForeName': 'Allen', 'Initials': 'A', 'LastName': 'Goodman', 'Affiliation': 'Department of Economics, Wayne State University 656 Kirby St, 2074 FAB, Detroit, MI, 48202, USA.'}, {'ForeName': 'Liying', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Family Medicine & Public Health Sciences, School of Medicine, Wayne State University, 3939 Woodward, Detroit, MI, 48201, USA.'}, {'ForeName': 'LynnMarie', 'Initials': 'L', 'LastName': 'Mango', 'Affiliation': 'Wayne State University Integrative Biosciences Center (iBIO), 6135 Woodward Ave, Detroit, MI, 48202, USA.'}, {'ForeName': 'Rachelle', 'Initials': 'R', 'LastName': 'Dawood', 'Affiliation': 'Wayne State University Integrative Biosciences Center (iBIO), 6135 Woodward Ave, Detroit, MI, 48202, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Costello', 'Affiliation': 'Department of Family Medicine & Public Health Sciences, School of Medicine, Wayne State University, 3939 Woodward, Detroit, MI, 48201, USA.'}, {'ForeName': 'Shayla', 'Initials': 'S', 'LastName': 'Patton', 'Affiliation': 'Department of Family Medicine & Public Health Sciences, School of Medicine, Wayne State University, 3939 Woodward, Detroit, MI, 48201, USA.'}, {'ForeName': 'Aniruddha', 'Initials': 'A', 'LastName': 'Paranjpe', 'Affiliation': 'Department of Family Medicine & Public Health Sciences, School of Medicine, Wayne State University, 3939 Woodward, Detroit, MI, 48201, USA.'}, {'ForeName': 'Connor', 'Initials': 'C', 'LastName': 'Welsh', 'Affiliation': 'Michigan State University College of Human Medicine, Secchia Center, 15 Michigan St NE, Grand Rapids, MI, 49503, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Welch', 'Affiliation': 'Cardiovascular Research Institute, School of Medicine, Wayne State University, 421 E Canfield St. Detroit, MI 48201, USA.'}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'Levy', 'Affiliation': 'Cardiovascular Research Institute, School of Medicine, Wayne State University, 421 E Canfield St. Detroit, MI 48201, USA.'}]",Contemporary clinical trials communications,['10.1016/j.conctc.2020.100613'] 1976,32743120,Evaluating a personalized treatment for substance use disorder in people with mild intellectual disability or borderline intellectual functioning: A study protocol of a multiple baseline across individuals design.,"Background The prevalence of substance use disorder (SUD) in people with Mild Intellectual Disabilities or Borderline Intellectual Functioning (MID-BIF) is high. However, an effective personalized treatment for people with MID-BIF and SUD is lacking. This paper describes the study protocol of the effectiveness study of Take it Personal!+, a personalized treatment for people with MID-BIF and SUD. Methods The effectiveness of Take it Personal!+ in decreasing substance use will be assessed in a non-concurrent multiple baseline across individuals design comprising ten participants with MID-BIF and SUD. The participants with MID-BIF and SUD will be randomly allocated to one of the five baseline lengths (7-11 days). Substance use, will be assessed during baseline, intervention, and post-treatment phase using a daily diary method. Discussion If this study shows that Take it Personal!+ is effective in decreasing substance use, the gap in treatment for people with MID-BIF and SUD will be filled. Trial registration The study is registered in the Netherlands Trial Register (Trial NL4935, registered July 2, 2019).",2020,"If this study shows that Take it Personal!+ is effective in decreasing substance use, the gap in treatment for people with MID-BIF and SUD will be filled. ","['participants with MID-BIF and SUD', 'people with mild intellectual disability or borderline intellectual functioning', 'people with MID-BIF and SUD', 'people with Mild Intellectual Disabilities or Borderline Intellectual Functioning (MID-BIF']",['Personal'],[],"[{'cui': 'C0026106', 'cui_str': 'Mild intellectual disability'}, {'cui': 'C0006009', 'cui_str': 'Borderline intellectual disability'}, {'cui': 'C0038586', 'cui_str': 'Substance use disorder'}, {'cui': 'C0027361', 'cui_str': 'Person'}]",[],[],10.0,0.150572,"If this study shows that Take it Personal!+ is effective in decreasing substance use, the gap in treatment for people with MID-BIF and SUD will be filled. ","[{'ForeName': 'Lotte C F', 'Initials': 'LCF', 'LastName': 'Gosens', 'Affiliation': 'Research and Development, Pluryn, P.O. Box 53, 6500, AB, Nijmegen, the Netherlands.'}, {'ForeName': 'Roy', 'Initials': 'R', 'LastName': 'Otten', 'Affiliation': 'Research and Development, Pluryn, P.O. Box 53, 6500, AB, Nijmegen, the Netherlands.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Didden', 'Affiliation': 'Behavioral Science Institute, Radboud University, Nijmegen, P.O. Box 9104, 6500, HE, Nijmegen, the Netherlands.'}, {'ForeName': 'Evelien A P', 'Initials': 'EAP', 'LastName': 'Poelen', 'Affiliation': 'Research and Development, Pluryn, P.O. Box 53, 6500, AB, Nijmegen, the Netherlands.'}]",Contemporary clinical trials communications,['10.1016/j.conctc.2020.100616'] 1977,32743253,Effect of a Brief Family-Based Treatment on Complicated Grief in Bereaved Older Adults.,"Background The current study compared the effectiveness of family-based complicated grief therapy with individual-based complicated grief therapy on improvement in complicated grief symptoms of bereaved older adults. Methods Two community senior centers referred 29 older adults who lost their spouses. The study used a single-blinded randomized trial design, comparing family-based complicated grief therapy with individual-based complicated grief therapy on complicated grief symptoms and social impairment. Results Relative to individual-based complicated grief therapy, participants in the family-based complicated grief therapy group demonstrated improvement in social impairments and complicated grief symptoms. Conclusion The findings suggest that a family-based delivery model for complicated grief may be superior to an individually provided approach in reducing complicated grief symptoms, and in improving work and social functions in bereavement.",2018,"Results Relative to individual-based complicated grief therapy, participants in the family-based complicated grief therapy group demonstrated improvement in social impairments and complicated grief symptoms. ","['29 older adults who lost their spouses', 'Bereaved Older Adults', 'bereaved older adults']","['Brief Family-Based Treatment', 'family-based complicated grief therapy with individual-based complicated grief therapy']","['social impairments and complicated grief symptoms', 'Complicated Grief']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0162409', 'cui_str': 'Spouse'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C0018235', 'cui_str': 'Normal grief reaction'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C0018235', 'cui_str': 'Normal grief reaction'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",29.0,0.0179109,"Results Relative to individual-based complicated grief therapy, participants in the family-based complicated grief therapy group demonstrated improvement in social impairments and complicated grief symptoms. ","[{'ForeName': 'Ilsung', 'Initials': 'I', 'LastName': 'Nam', 'Affiliation': 'Department of Social Welfare, Sungkonghoe University, Seoul, Korea.'}]",Annals of geriatric medicine and research,['10.4235/agmr.2018.22.2.94'] 1978,32743303,Efficacy and Safety of X-incision with Inversed Morcellation in Holmium Laser Enucleation of the Prostate: Comparison to Conventional Morcellation.,"Background Three-quarters of aged men experience lower urinary tract symptoms with benign prostate hypertrophy (BPH). Transurethral resection of the prostate (TURP) and holmium laser enucleation of the prostate (HoLEP) are standard endosurgical procedures in patients with BPH. Previous studies reported better results in patients undergoing HoLEP than in those undergoing TURP. Methods This study compared the efficiency and safety of conventional morcellation and morcellation performed after X-incision during enucleation, a newly added technique in HoLEP. Overall, 174 patients were selected as the final study population. The populations were stratified with respect to resected volumes. A t-test were used to compare the conventional morcellation and X-incision procedure groups. Results In morcellation times and rates, there were significant differences in stratified resected mass (g) between the groups. The results also showed a decreased incidence of bladder injury as a surgical complication. Conclusion We believe morcellation performed after X-incision procedure during enucleation is efficient and safe for older adults with BPH.",2019,"In morcellation times and rates, there were significant differences in stratified resected mass (g) between the groups.","['174 patients were selected as the final study population', 'patients with BPH', 'older adults with BPH', 'aged men experience lower urinary tract symptoms with benign prostate hypertrophy (BPH']","['Conventional Morcellation', 'Holmium Laser Enucleation', 'conventional morcellation and X-incision procedure groups', 'conventional morcellation and morcellation performed after X-incision', 'Transurethral resection of the prostate (TURP) and holmium laser enucleation of the prostate (HoLEP', 'HoLEP', 'X-incision with Inversed Morcellation']","['efficiency and safety', 'Efficacy and Safety', 'incidence of bladder injury']","[{'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0005001', 'cui_str': 'Hypertrophy, Benign Prostatic'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0574785', 'cui_str': 'Lower urinary tract symptoms'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C4042900', 'cui_str': 'Morcellation'}, {'cui': 'C0441085', 'cui_str': 'Holmium:YAG laser device'}, {'cui': 'C0014392', 'cui_str': 'Enucleation'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0040771', 'cui_str': 'Transurethral prostatectomy'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}]","[{'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0403677', 'cui_str': 'Injury of bladder'}]",174.0,0.031599,"In morcellation times and rates, there were significant differences in stratified resected mass (g) between the groups.","[{'ForeName': 'Dae Hyoung', 'Initials': 'DH', 'LastName': 'Park', 'Affiliation': 'Department of Urology, National Medical Center, Seoul, Korea.'}, {'ForeName': 'Jong Bouk', 'Initials': 'JB', 'LastName': 'Lee', 'Affiliation': 'Department of Urology, National Medical Center, Seoul, Korea.'}, {'ForeName': 'Chun Ha', 'Initials': 'CH', 'LastName': 'Hwang', 'Affiliation': 'Department of Urology, National Medical Center, Seoul, Korea.'}, {'ForeName': 'Jong Hyun', 'Initials': 'JH', 'LastName': 'Yoon', 'Affiliation': 'Department of Urology, National Medical Center, Seoul, Korea.'}, {'ForeName': 'Jung Hyun', 'Initials': 'JH', 'LastName': 'Jo', 'Affiliation': 'Department of Urology, National Medical Center, Seoul, Korea.'}, {'ForeName': 'Tae Wook', 'Initials': 'TW', 'LastName': 'Jeong', 'Affiliation': 'Department of Urology, National Medical Center, Seoul, Korea.'}, {'ForeName': 'Woong', 'Initials': 'W', 'LastName': 'Na', 'Affiliation': 'Department of Urology, National Medical Center, Seoul, Korea.'}]",Annals of geriatric medicine and research,['10.4235/agmr.19.0031'] 1979,32743735,FAB: First UK feasibility trial of a future randomised controlled trial of Family focused treatment for Adolescents with Bipolar disorder.,"BACKGROUND This first mixed-methods UK trial examined the feasibility and acceptability of a future definitive randomised controlled trial (RCT) to evaluate whether Family Focussed Treatment for Adolescents with Bipolar Disorder (FFT-A) UK version can improve family functioning and well-being as part of the management of Paediatric Bipolar Disorder (PBD). METHOD The trial used a randomised, parallel group, non-blinded design where participants received FFT-A UK (16 sessions over 6 months) immediately or after 12 months (delayed arm). Measures of family functioning, well-being and quality of life of the young person and the main carer (most commonly a parent) were completed at baseline, 6 and 12-months in both arms. Primary outcome measures included rates of eligibility, consent and retention along with estimates of variability in the measures and assessment of the intervention delivery. Qualitative interviews allowed assessment of participants' views about FFT-A and the trial processes. RESULTS Twenty-seven of 36 young persons with PBD and their families consented; of these, 14 families were randomised to the immediate and 13 to the delayed arm. Two families from the immediate arm withdrew consent and discontinued participation. Quantitative measures were completed by 22 families (88%) at 6-months and 21 families (84%) at 12-months. Qualitative interviews were conducted with 30 participants (9 young people, 15 parents and 6 other family members). Nine families attended 3 post-trial focus groups. CONCLUSION It was feasible to recruit and retain to this trial. The results highlighted that trial design and measures were acceptable to participants. A benefit in family relationships was reported by participants which they attributed to the intervention in qualitative interviews. Families recommended that future modifications include definitive trial(s) recruiting participants in the age range 15-25 years as it felt this was the age range with maximum need. Trial registration ISRCTN, ISRCTN59769322. Registered 20 January 2014, http://www.isrctn.com/ISRCTN59769322.",2020,"UK version can improve family functioning and well-being as part of the management of Paediatric Bipolar Disorder (PBD). ","['30 participants (9 young people, 15 parents and 6 other family members', 'Adolescents with Bipolar Disorder (FFT-A', 'Twenty-seven of 36 young persons with PBD and their families consented; of these, 14 families', 'Adolescents with Bipolar disorder']","['FAB', 'FFT-A UK']","['rates of eligibility, consent and retention along with estimates of variability in the measures and assessment of the intervention delivery', 'Quantitative measures', 'family functioning, well-being and quality of life of the young person and the main carer']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0086282', 'cui_str': 'Person in the family'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0015576', 'cui_str': 'Family'}]","[{'cui': 'C0021031', 'cui_str': 'Immunoglobulin, F(ab) fragment'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}]","[{'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0680051', 'cui_str': 'Family functioning capacity'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}]",9.0,0.206574,"UK version can improve family functioning and well-being as part of the management of Paediatric Bipolar Disorder (PBD). ","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Newcastle University, Newcastle upon Tyne, UK. aditya.sharma@ncl.ac.uk.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Glod', 'Affiliation': 'Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Forster', 'Affiliation': 'Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'McGovern', 'Affiliation': 'Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'McGurk', 'Affiliation': 'Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Barron Millar', 'Affiliation': 'Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'T D', 'Initials': 'TD', 'LastName': 'Meyer', 'Affiliation': 'Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Miklowitz', 'Affiliation': 'Department of Psychiatry, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Ryan', 'Affiliation': 'Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Vale', 'Affiliation': 'Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Le Couteur', 'Affiliation': 'Newcastle University, Newcastle upon Tyne, UK.'}]",International journal of bipolar disorders,['10.1186/s40345-020-00189-y'] 1980,32743758,Effects of bifrontal transcranial direct current stimulation on brain glutamate levels and resting state connectivity: multimodal MRI data for the cathodal stimulation site.,"Transcranial direct current stimulation (tDCS) over prefrontal cortex (PFC) regions is currently proposed as therapeutic intervention for major depression and other psychiatric disorders. The in-depth mechanistic understanding of this bipolar and non-focal stimulation technique is still incomplete. In a pilot study, we investigated the effects of bifrontal stimulation on brain metabolite levels and resting state connectivity under the cathode using multiparametric MRI techniques and computational tDCS modeling. Within a double-blind cross-over design, 20 subjects (12 women, 23.7 ± 2 years) were randomized to active tDCS with standard bifrontal montage with the anode over the left dorsolateral prefrontal cortex (DLPFC) and the cathode over the right DLPFC. Magnetic resonance spectroscopy (MRS) was acquired before, during, and after prefrontal tDCS to quantify glutamate (Glu), Glu + glutamine (Glx) and gamma aminobutyric acid (GABA) concentration in these areas. Resting-state functional connectivity MRI (rsfcMRI) was acquired before and after the stimulation. The individual distribution of tDCS induced electric fields (efields) within the MRS voxel was computationally modelled using SimNIBS 2.0. There were no significant changes of Glu, Glx and GABA levels across conditions but marked differences in the course of Glu levels between female and male participants were observed. Further investigation yielded a significantly stronger Glu reduction after active compared to sham stimulation in female participants, but not in male participants. For rsfcMRI neither significant changes nor correlations with MRS data were observed. Exploratory analyses of the effect of efield intensity distribution on Glu changes showed distinct effects in different efield groups. Our findings are limited by the small sample size, but correspond to previously published results of cathodal tDCS. Future studies should address gender and efield intensity as moderators of tDCS induced effects.",2020,"Further investigation yielded a significantly stronger Glu reduction after active compared to sham stimulation in female participants, but not in male participants.","['20 subjects (12 women, 23.7\u2009±\u20092\xa0years']","['Transcranial direct current stimulation (tDCS', 'bifrontal transcranial direct current stimulation', 'active tDCS with standard bifrontal montage with the anode over the left dorsolateral prefrontal cortex (DLPFC) and the cathode over the right DLPFC', 'bifrontal stimulation', 'Magnetic resonance spectroscopy (MRS']","['Glu levels', 'quantify glutamate (Glu), Glu\u2009+\u2009glutamine (Glx) and gamma aminobutyric acid (GABA) concentration', 'brain metabolite levels', 'MRS data', 'Glu reduction', 'Resting-state functional connectivity MRI (rsfcMRI', 'Glu, Glx and GABA levels', 'brain glutamate levels']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0445448', 'cui_str': 'Bifrontal'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0003103', 'cui_str': 'Anode'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0007441', 'cui_str': 'Cathode'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}]","[{'cui': 'C0017789', 'cui_str': 'Glutamates'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0017797', 'cui_str': 'Glutamine'}, {'cui': 'C0016904', 'cui_str': 'Gamma-aminobutyric acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]",20.0,0.0699055,"Further investigation yielded a significantly stronger Glu reduction after active compared to sham stimulation in female participants, but not in male participants.","[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Mezger', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'Boris-Stephan', 'Initials': 'BS', 'LastName': 'Rauchmann', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'Andre R', 'Initials': 'AR', 'LastName': 'Brunoni', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Bulubas', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Thielscher', 'Affiliation': 'Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Werle', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'Matin', 'Initials': 'M', 'LastName': 'Mortazavi', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'Temmuz', 'Initials': 'T', 'LastName': 'Karali', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Stöcklein', 'Affiliation': 'Department of Radiology, University Hospital LMU Munich, Munich, Germany.'}, {'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Ertl-Wagner', 'Affiliation': 'Department of Medical Imaging, The Hospital for Sick Children, University of Toronto, Toronto, Canada.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Goerigk', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Padberg', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Keeser', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany. daniel.keeser@med.uni-muenchen.de.'}]",European archives of psychiatry and clinical neuroscience,['10.1007/s00406-020-01177-0'] 1981,32743789,"Evaluation of BepanGel Hydrogel Efficacy and Tolerability Using an Abrasive Wound Model in a Within-Person, Single-Center, Randomized, Investigator-Blind Clinical Investigation.","INTRODUCTION Over the last few years, it has been demonstrated that a moist environment enhances the healing process and reduces scar formation of wounds. Such moist conditions can be created and maintained using hydrogels. The aim of this study was to evaluate wound healing, cooling efficacy, local tolerability, and cosmetic appearance of abrasive wounds treated with BepanGel wound care hydrogel. METHODS This study was designed as a within-person, single-center, randomized, investigator-blind clinical investigation comparing a hydrogel-treated test field with an untreated test field in an abrasive wound model. In 33 subjects, two small superficial wounds were induced on the non-dominant forearms. Wounds were treated with BepanGel and covered with a standard semi-occlusive wound plaster or covered with a plaster alone for 11 consecutive days. Wound healing efficacy, cooling effect, and tolerability of the treatment were assessed over 12 investigational days. During follow-up at day 31, the cosmetic appearance of the wounds was evaluated. RESULTS On day 12, the test field treated with BepanGel was completely healed in nearly all subjects (97.0%) in contrast with the test field treated with a plaster alone (18.2%, AUC days 2-12 p < 0.0001) as assessed by a blinded investigator. Two-thirds of the unblinded subjects indicated an immediate cooling effect of the hydrogel (p = 0.0555). At the end of the investigation, the cosmetic appearance of the BepanGel-treated test fields scored superior to the fields treated with a plaster alone as evaluated by a blinded investigator (p = 0.0005) and the unblinded subjects (p = 0.0078). The hydrogel was generally well tolerated and no signs of infection or adverse events (AEs) related to the treatment were observed. CONCLUSION This evaluation shows that treatment of superficial cutaneous wounds with BepanGel results in improved wound healing as demonstrated by faster wound closure and a considerably better cosmetic appearance, while providing immediate cooling. TRIAL REGISTRATION NUMBER EUDAMED-No.: CIV-19-09-029744.",2020,"The hydrogel was generally well tolerated and no signs of infection or adverse events (AEs) related to the treatment were observed. ","['33 subjects, two small superficial wounds were induced on the non-dominant forearms']","['BepanGel and covered with a standard semi-occlusive wound plaster or covered with a plaster alone', 'BepanGel wound care hydrogel']","['cosmetic appearance', 'Wound healing efficacy, cooling effect, and tolerability', 'wound healing, cooling efficacy, local tolerability, and cosmetic appearance', 'tolerated and no signs of infection or adverse events (AEs', 'wound healing', 'immediate cooling effect']","[{'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0332804', 'cui_str': 'Superficial wound'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0016536', 'cui_str': 'Forearm structure'}]","[{'cui': 'C0439844', 'cui_str': 'Covered'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1947917', 'cui_str': 'Occluded'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0460977', 'cui_str': 'Plasters'}, {'cui': 'C0886052', 'cui_str': 'Wound care'}, {'cui': 'C0063083', 'cui_str': 'Hydrogel'}]","[{'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}]",,0.0224654,"The hydrogel was generally well tolerated and no signs of infection or adverse events (AEs) related to the treatment were observed. ","[{'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Bayer Consumer Care AG, Peter Merian-Strasse 84, 4002, Basel, Switzerland.'}, {'ForeName': 'Raffaella', 'Initials': 'R', 'LastName': 'de Salvo', 'Affiliation': 'Bayer Consumer Care AG, Peter Merian-Strasse 84, 4002, Basel, Switzerland.'}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Trapp', 'Affiliation': 'Bayer Consumer Care AG, Peter Merian-Strasse 84, 4002, Basel, Switzerland.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Wigger-Alberti', 'Affiliation': 'Bioskin GmbH, Messberg 4, 20095, Hamburg, Germany.'}, {'ForeName': 'Ragna', 'Initials': 'R', 'LastName': 'Williams', 'Affiliation': 'Bioskin GmbH, Messberg 4, 20095, Hamburg, Germany.'}, {'ForeName': 'Lucie', 'Initials': 'L', 'LastName': 'Delcour', 'Affiliation': 'Oystershell Laboratories, Nijverheidsweg 10, 9820, Merelbeke, Belgium.'}, {'ForeName': 'Bart', 'Initials': 'B', 'LastName': 'Rossel', 'Affiliation': 'Oystershell Laboratories, Nijverheidsweg 10, 9820, Merelbeke, Belgium.'}, {'ForeName': 'Maarten T', 'Initials': 'MT', 'LastName': 'Huisman', 'Affiliation': 'Oystershell Laboratories, Nijverheidsweg 10, 9820, Merelbeke, Belgium. mh@oystershell.be.'}]",Dermatology and therapy,['10.1007/s13555-020-00432-5'] 1982,32743813,Local prolonged release of antibiotic for prevention of sternal wound infections postcardiac surgery-A novel technology.,"INTRODUCTION Sternal wound infection (SWI) is a devastating postcardiac surgical complication. D-PLEX 100 (D-PLEX) is a localized prolonged release compound applied as a prophylactic at the completion of surgery to prevent SWI. The D-PLEX technology platform is built as a matrix of alternating layers of polymers and lipids, entrapping an antibiotic (doxycycline). The objective of this study was to assess the safety profile and pharmacokinetics of D-PLEX in reducing SWI rates postcardiac surgery. METHOD Eighty-one patients were enrolled in a prospective single-blind randomized controlled multicenter study. Sixty patients were treated with both D-PLEX and standard of care (SOC) and 21 with SOC alone. Both groups were followed 6 months for safety endpoints. SWI was assessed at 90 days. RESULTS No SWI-related serious adverse events (SAEs) occurred in either group. The mean plasma C max in patients treated with D-PLEX was about 10 times lower than the value detected following the oral administration of doxycycline hyclate with an equivalent overall dose, and followed by a very low plasma concentration over the next 30 days. There were no sternal infections in the D-PLEX group (0/60) while there was one patient with a sternal infection in the control group (1/21, 4.8%). CONCLUSION D-PLEX was found to be safe for use in cardiac surgery patients. By providing localized prophylactic prolonged release of broad-spectrum antibiotics, D-PLEX has the potential to prevent SWI postcardiac surgery and long-term postoperative hospitalization, reducing high-treatment costs, morbidity, and mortality.",2020,"RESULTS No SWI-related serious adverse events (SAEs) occurred in either group.","['cardiac surgery patients', 'Eighty-one patients', 'Sixty patients were treated with both D-PLEX and standard of care (SOC) and 21 with SOC alone']","['doxycycline', 'D-PLEX', 'antibiotic (doxycycline']","['sternal infection', 'sternal infections', 'mean plasma C max', 'SWI', 'serious adverse events (SAEs']","[{'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517884', 'cui_str': '81'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0013090', 'cui_str': 'Doxycycline'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}]","[{'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0043241', 'cui_str': 'Local infection of wound'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",60.0,0.0487843,"RESULTS No SWI-related serious adverse events (SAEs) occurred in either group.","[{'ForeName': 'Erez', 'Initials': 'E', 'LastName': 'Kachel', 'Affiliation': 'Department of Cardiac Surgery, Poriya Medical Center, Tiberias, Israel.'}, {'ForeName': 'Yaron', 'Initials': 'Y', 'LastName': 'Moshkovitz', 'Affiliation': 'Department of Cardiothoracic Surgery, Assuta Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Leonid', 'Initials': 'L', 'LastName': 'Sternik', 'Affiliation': 'Department of Cardiac Surgery, Sheba Medical Centre, Tel Hashomer, Israel.'}, {'ForeName': 'Gideon', 'Initials': 'G', 'LastName': 'Sahar', 'Affiliation': 'Department of Cardiothoracic Surgery, Soroka Medical Center, Beer Sheva, Israel.'}, {'ForeName': 'Liza', 'Initials': 'L', 'LastName': 'Grosman-Rimon', 'Affiliation': 'Department of Cardiac Surgery, Poriya Medical Center, Tiberias, Israel.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Belotserkovsky', 'Affiliation': 'PolyPid Ltd, Petach-Tikva, Israel.'}, {'ForeName': 'Malka', 'Initials': 'M', 'LastName': 'Reichart', 'Affiliation': 'PolyPid Ltd, Petach-Tikva, Israel.'}, {'ForeName': 'Yafit', 'Initials': 'Y', 'LastName': 'Stark', 'Affiliation': 'PolyPid Ltd, Petach-Tikva, Israel.'}, {'ForeName': 'Noam', 'Initials': 'N', 'LastName': 'Emanuel', 'Affiliation': 'PolyPid Ltd, Petach-Tikva, Israel.'}]",Journal of cardiac surgery,['10.1111/jocs.14890'] 1983,32743968,Crestal Bone Changes and Patient Satisfaction with Single Implant-Retained Mandibular Overdentures with Dalla Bona and Locator Attachments with Immediate Loading Protocols. A Randomized Controlled Clinical Study.,"PURPOSE There is no enough evidence present on the success of single implant-retained mandibular overdentures (SIMO) with Dalla Bona and Locator attachments. This study aims to compare crestal bone loss and patient satisfaction with SIMO with Dalla Bona and Locator attachment following immediate loading protocols. MATERIAL AND METHODS Twelve patients included in Group 1 received immediate SIMO with Dalla Bona attachments, and another twelve patients in Group 2 received immediate SIMO with Locator attachments in the mid symphyseal region. The follow-up was scheduled at six months and 12 months after implant placement. The patient satisfaction with the denture was evaluated with the visual analog scale (VAS) score. The data obtained were statistically analyzed with the independent student t-test for intergroup comparison and repeated measures of ANOVA followed by Bonferroni's Post hoc analysis for intragroup comparison of mean crestal bone loss at a different time interval. RESULTS Ten patients each in both the groups were available for follow-up. Crestal bone loss at 6 months follow-up for Dalla Bona group was 0.42 ±0.10 mm on the mesial side and 0.43 ±0.14 mm on the distal side and at 1 year 1.54 ±0.16 mm on the mesial side and 1.66 ±0.13 mm on the distal side. The mean crestal bone loss at 6 months follow-up for Locator group was 0.48 ±0.16 mm on the mesial side and 0.45 ±0.11 mm on the distal side and at 1 year was 1.71 ±0.22 mm on mesial side and 1.74 ±0.28 mm on the distal side. There was difference in bone loss at 6 months (mesial: 0.06 mm, p = 0.327; distal:0.02 mm; p = 0.726) and at 1 year (mesial: 0.17 mm, p = 0.063; distal: 0.08 mm; p = 0.423) in between two groups but the difference was statistically insignificant.There was a significant difference found in the VAS score for patient satisfaction with SIMO with Dalla Bona attachments and Locator attachments at 6 months (54.2 vs. 51.8, p = 0.005) and 1 year (60.6 vs. 55.2, p = 0.005). CONCLUSIONS Patient satisfaction with SIMO with Dalla Bona attachments was higher during the follow-up.SIMO with Dalla Bona attachments had less crestal bone loss and less prosthetic complications when compared to Locator attachments, although the difference in the bone loss was statistically insignificant. This article is protected by copyright. All rights reserved.",2020,"There was difference in bone loss at 6 months (mesial: 0.06 mm, p = 0.327; distal:0.02 mm; p = 0.726) and at 1 year (mesial: 0.17 mm, p = 0.063; distal: 0.08 mm; p = 0.423) in between two groups but the difference was statistically insignificant.",[],"['immediate SIMO with Dalla Bona attachments, and another twelve patients in Group 2 received immediate SIMO with Locator attachments']","['VAS score', 'visual analog scale (VAS) score', 'Crestal Bone Changes and Patient Satisfaction', 'bone loss', 'crestal bone loss', 'prosthetic complications', 'Crestal bone loss', 'crestal bone loss and patient satisfaction with SIMO with Dalla Bona and Locator attachment', 'mean crestal bone loss']",[],"[{'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0011459', 'cui_str': 'Overlay denture'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}]","[{'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0011459', 'cui_str': 'Overlay denture'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",12.0,0.0435881,"There was difference in bone loss at 6 months (mesial: 0.06 mm, p = 0.327; distal:0.02 mm; p = 0.726) and at 1 year (mesial: 0.17 mm, p = 0.063; distal: 0.08 mm; p = 0.423) in between two groups but the difference was statistically insignificant.","[{'ForeName': 'Kunal', 'Initials': 'K', 'LastName': 'Nischal', 'Affiliation': 'Department of Prosthodontics, Rajarajeswari Dental College and Hospital, Bengaluru, Karnataka, India.'}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Kumar Mishra', 'Affiliation': 'Department of Prosthodontics, Peoples College of Dental Sciences and Research Centre, Bhopal, Madhya Pradesh, India.'}, {'ForeName': 'Ramesh', 'Initials': 'R', 'LastName': 'Chowdhary', 'Affiliation': 'Department of Prosthodontics, Rajarajeswari Dental College and Hospital, Bengaluru, Karnataka, India.'}]",Journal of prosthodontics : official journal of the American College of Prosthodontists,['10.1111/jopr.13230'] 1984,32743999,[The effect of transcranial direct current stimulation on dysfunction of bilateral posterior cingulate cortex after sleep deprivation: a preliminary study].,"Objective: To investigate the effects of transcranial direct current stimulation (tDCS) on the disturbance of brain network dysfunction after sleep deprivation (SD). Methods: The experimental design of self-control was used in the study. All 16 subjects received 2 times of 24 h SD with an interval of 3 weeks. After the first normal sleep, 24 h SD and transcranial electrical stimulation (true or false stimulation) intervention (the current magnitude of true and false stimulation was 1 mA, and the action time was 20 min and 2 s, respectively. The intervention experiment lasted for 20 min. ) and the resting magnetic resonance imaging data were collected after the second transcranial electrical stimulation (sham or true stimulation). The resting fMRI data were collected as baseline before SD, the bilateral posterior cingulate cortex in the default mode network was selected as the seed point, and the functional connectivity between the seed points and the whole brain was calculated. Results: Compared with the rest wakefulness, the functional connectivity among bilateral posterior cingulate cortex, bilateral thalamus and hippocampus was increased ( P ＜0. 01), but connected with the right precuneus, bilateral insula was decreased after 24 h SD ( P ＜0. 01). Compared with the sham tDCS group, the functional connectivity between left posterior cingulate cortex seed point and right precuneus of tDCS group was increased ( P ＜0. 01); but decreased with the bilateral thalamus, insula and right cerebral cortex ( P ＜0. 01). There was a decrease in the functional connectivity among the right posterior cingulate cortex and the bilateral thalamus, right insula, and cerebral cortex( P ＜0. 01). Conclusion: 24-hours sleep deprivation can cause functional connection disorder of bilateral posterior cingulate gyrus, and transcranial electrical stimulation can improve the functional connection disorder after sleep deprivation to some extent.",2020,"Compared with the sham tDCS group, the functional connectivity between left posterior cingulate cortex seed point and right precuneus of tDCS group was increased ( P ＜0.",[],"['transcranial direct current stimulation (tDCS', 'sham tDCS', 'transcranial direct current stimulation', 'transcranial electrical stimulation (sham or true stimulation', 'transcranial electrical stimulation (true or false stimulation) intervention', 'transcranial electrical stimulation']","['bilateral thalamus, insula and right cerebral cortex', 'resting fMRI data', 'bilateral thalamus, right insula, and cerebral cortex', 'functional connectivity among bilateral posterior cingulate cortex, bilateral thalamus and hippocampus', 'functional connectivity between left posterior cingulate cortex seed point and right precuneus', 'functional connectivity']",[],"[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0455803', 'cui_str': 'Transcranial electrical stimulation'}, {'cui': 'C0205238', 'cui_str': 'True'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205237', 'cui_str': 'False'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0039729', 'cui_str': 'Thalamic structure'}, {'cui': 'C0021640', 'cui_str': 'Insular structure'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0007776', 'cui_str': 'Structure of cerebral cortex'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0175191', 'cui_str': 'Posterior Cingulate Gyri'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0036563', 'cui_str': 'Plant seeds'}]",,0.0365165,"Compared with the sham tDCS group, the functional connectivity between left posterior cingulate cortex seed point and right precuneus of tDCS group was increased ( P ＜0.","[{'ForeName': 'Qing-Qing', 'Initials': 'QQ', 'LastName': 'Meng', 'Affiliation': ""Department of Geriatric Neurology, Sleep Medicine Research Center, the General Hospital of the People's Liberation Army, Beijing 100853.""}, {'ForeName': 'Ji-Yuan', 'Initials': 'JY', 'LastName': 'Li', 'Affiliation': 'Department of MRI, Beijing Shijitan Hospital Capital Medical University, Beijing 100038.'}, {'ForeName': 'Da-Long', 'Initials': 'DL', 'LastName': 'Guo', 'Affiliation': 'Air Force Institute of Aviation Medicine, Aviation Medical Engineering Research Center, Beijing 100037.'}, {'ForeName': 'Yong-Cong', 'Initials': 'YC', 'LastName': 'Shao', 'Affiliation': 'Beijing Institute of Basic Medical Sciences, Cognitive and Mental Health Research Center, Beijing 100850, China.'}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ""Department of Geriatric Neurology, Sleep Medicine Research Center, the General Hospital of the People's Liberation Army, Beijing 100853.""}]",Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology,['10.12047/j.cjap.5886.2020.023'] 1985,32744034,"Efficacy of Rebixiao Chinese herbal tablets and Chinese formula granules in acute gout arthritis patients: a randomized, multicenter, double-blind, controlled trial.","OBJECTIVE To evaluate the clinical efficacy and safety of Rebixiao (RBX) Chinese herbal tablets (CHT) and Chinese formula granules (CFG) in the treatment of acute gout arthritis (AGA). METHODS This randomized, multicenter, double-blind, controlled trial included 165 AGA patients with the damp-heat symptom pattern who were randomly divided into an RBX CHT group and an RBX CFG group and treated for 7 d at three centers. The total effective rates of the joint symptom score, Traditional Chinese Medicine (TCM) symptoms score, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were used to evaluate the clinical efficacy. Safety assessments were also performed. RESULTS Of the 165 enrolled patients, 147 completed the clinical observation. There was no difference in baseline between the two groups. The total effective rates of the joint symptom score were 94.36% and 97.36%, and the total effective rates of the TCM symptoms score were 95.77% and 97.36% in the CFG group and CHT group, respectively. No statistical difference was found between the two groups (P > 0.05). Additionally, ESR and CRP were similar in both groups (P > 0.05). Furthermore, treatment efficacy regarding TCM and joint symptoms, the ESR, and CRP were consistent within each center and among the different centers (P > 0.05). In addition, the incidence of adverse events was 4.22% and 2.63% in the CFG group and CHT group, respectively, and no difference was observed between the two groups (P > 0.05). CONCLUSION RBX CFG and CHT have significant and similar efficacy in the treatment of AGA, and CFG did not increase adverse side effects.",2020,"In addition, the incidence of adverse events was 4.22% and 2.63% in the CFG group and CHT group, respectively, and no difference was observed between the two groups (P > 0.05). ","['acute gout arthritis (AGA', '165 AGA patients with the damp-heat symptom pattern', '165 enrolled patients', 'acute gout arthritis patients']","['Rebixiao (RBX) Chinese herbal tablets (CHT) and Chinese formula granules (CFG', 'RBX CHT', 'RBX CFG', 'CFG', 'Rebixiao Chinese herbal tablets', 'CHT']","['ESR and CRP', 'clinical efficacy', 'total effective rates of the joint symptom score', 'efficacy regarding TCM and joint symptoms, the ESR, and CRP', 'total effective rates of the TCM symptoms score', 'incidence of adverse events', 'adverse side effects', 'total effective rates of the joint symptom score, Traditional Chinese Medicine (TCM) symptoms score, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP']","[{'cui': 'C0149896', 'cui_str': 'Primary gout'}, {'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205381', 'cui_str': 'Wet'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0436318', 'cui_str': 'Symptom pattern'}]","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0376667', 'cui_str': 'Herbals'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0010837', 'cui_str': 'Cytoplasmic Granules'}]","[{'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",165.0,0.167079,"In addition, the incidence of adverse events was 4.22% and 2.63% in the CFG group and CHT group, respectively, and no difference was observed between the two groups (P > 0.05). ","[{'ForeName': 'Shasha', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Dai', 'Affiliation': 'Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Yang', 'Affiliation': 'Department of Pharmacy, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China.'}, {'ForeName': 'Wenfei', 'Initials': 'W', 'LastName': 'Leng', 'Affiliation': 'Department of Rheumatology, Traditional Chinese Medicine Hospital Dianjiang Chongqing, Chongqing 408300, China.'}, {'ForeName': 'Xiufeng', 'Initials': 'X', 'LastName': 'Peng', 'Affiliation': 'Department of Rheumatology, Traditional Chinese Medicine Hospital Dianjiang Chongqing, Chongqing 408300, China.'}, {'ForeName': 'Guojun', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'Department of Rheumatology, Traditional Chinese Medicine Hospital Yongchuan Chongqing, Chongqing 402160, China.'}, {'ForeName': 'Jinbing', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Department of Marketing, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Shenzhen 518000, China.'}, {'ForeName': 'Jianping', 'Initials': 'J', 'LastName': 'Gan', 'Affiliation': 'Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China.'}, {'ForeName': 'Fenglin', 'Initials': 'F', 'LastName': 'Zhu', 'Affiliation': 'Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China.'}, {'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Wu', 'Affiliation': 'Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China.'}]",Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan,['10.19852/j.cnki.jtcm.2020.04.016'] 1986,32744035,"Effects of Qizhukangxian granules on idiopathic pulmonary fibrosis: a randomized, double blind, placebo-controlled and multicenter clinical pilot trial.","OBJECTIVE To evaluate the effects of Qizhukangxian granules (QG) on idiopathic pulmonary fibrosis (IPF). METHODS This is a randomized, double blind, placebo-controlled and multicenter clinical pilot trial. Six medical centers in Tianjin, China, participated in the study. A total of 120 IPF patients were enrolled and randomized into two groups, with 60 patients in each group. The treatment group was treated with QG, while the control group received a Qizhukangxian placebo. The pharmacological treatment lasted for 48 weeks from the enrollment date. The indexes of patients were recorded on the admission day and at the end of the 24th and 48th weeks. Data were analyzed to study the effects of QG; forced vital capacity, change in forced vital capacity and maximal 6-min walk test (6MWT) distance were the primary endpoints. Secondary endpoints were percentage of patients with episodes of acute exacerbation of IPF, pulmonary function, changes in pulse oxygen saturation during the 6MWT, dyspnea score, St. George's respiratory questionnaire score, arterial blood gas analyses and the total Traditional Chinese Medicine symptom pattern score. RESULTS After 24 weeks of treatment, QG showed greater efficacy than the placebo in certain parameters, including the dyspnea score, Traditional Chinese Medicine symptom pattern score and some indicators in the St. George's respiratory questionnaire score. Analysis of the indexes obtained from all patients at the end of the 48th week showed that the therapeutic effects in the treatment group were significantly better than those in the control group because remarkable differences were observed in most of the primary and secondary endpoints between the two groups, except for the maximal distance of the 6MWT and arterial blood gas analyses. No adverse reaction was observed in either group during the 48-week trial treatment period. CONCLUSION QG could effectively treat IPF patients by ameliorating pulmonary function, improving the quality of life and lowering the percentage of acute exacerbations.",2020,"After 24 weeks of treatment, QG showed greater efficacy than the placebo in certain parameters, including the dyspnea score, Traditional Chinese Medicine symptom pattern score and some indicators in the St. George's respiratory questionnaire score.","['idiopathic pulmonary fibrosis (IPF', '120 IPF patients', 'Six medical centers in Tianjin, China, participated in the study', 'idiopathic pulmonary fibrosis']","['Qizhukangxian placebo', 'Qizhukangxian granules', 'QG', 'Qizhukangxian granules (QG', 'placebo']","['quality of life', ""percentage of patients with episodes of acute exacerbation of IPF, pulmonary function, changes in pulse oxygen saturation during the 6MWT, dyspnea score, St. George's respiratory questionnaire score, arterial blood gas analyses and the total Traditional Chinese Medicine symptom pattern score"", 'maximal distance of the 6MWT and arterial blood gas analyses', 'adverse reaction', 'vital capacity, change in forced vital capacity and maximal 6-min walk test (6MWT) distance', ""dyspnea score, Traditional Chinese Medicine symptom pattern score and some indicators in the St. George's respiratory questionnaire score"", 'therapeutic effects']","[{'cui': 'C1800706', 'cui_str': 'Idiopathic pulmonary fibrosis'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0010837', 'cui_str': 'Cytoplasmic Granules'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C2242482', 'cui_str': 'Exacerbation of idiopathic pulmonary fibrosis'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3472502', 'cui_str': ""Saint George's respiratory questionnaire score""}, {'cui': 'C0150411', 'cui_str': 'Analysis of arterial blood gases and pH'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0436318', 'cui_str': 'Symptom pattern'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0042834', 'cui_str': 'Vital capacity'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",120.0,0.113792,"After 24 weeks of treatment, QG showed greater efficacy than the placebo in certain parameters, including the dyspnea score, Traditional Chinese Medicine symptom pattern score and some indicators in the St. George's respiratory questionnaire score.","[{'ForeName': 'Sijia', 'Initials': 'S', 'LastName': 'Guo', 'Affiliation': 'Department of Respiratory Medicine, the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China.'}, {'ForeName': 'Yalin', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': 'Department of Respiratory Medicine, the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China.'}, {'ForeName': 'Jihong', 'Initials': 'J', 'LastName': 'Feng', 'Affiliation': 'Department of Respiratory Medicine, the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China.'}, {'ForeName': 'Shuang', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'Department of Neurology, the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China.'}, {'ForeName': 'Yuechuan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Respiratory Medicine, Tianjin Chest Hospital, Tianjin 300300, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Liu', 'Affiliation': 'Department of Respiratory Medicine, the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.'}, {'ForeName': 'Luqing', 'Initials': 'L', 'LastName': 'Wei', 'Affiliation': 'Department of Respiratory Medicine, the Affiliated Hospital of Tianjin Armed Police Medical College, Tianjin 300162, China.'}, {'ForeName': 'Xian', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Respiratory Medicine, Tianjin Beichen Traditional Chinese Medicine Hospital, Tianjin 300400, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Xie', 'Affiliation': 'Department of Respiratory Medicine, Tianjin Dongli Traditional Chinese Medicine Hospital, Tianjin 300300, China.'}, {'ForeName': 'Zengtao', 'Initials': 'Z', 'LastName': 'Sun', 'Affiliation': 'Department of Hospital Management, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.'}]",Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan,['10.19852/j.cnki.jtcm.2020.04.017'] 1987,32744043,The effects of an integrative training program on elite young soccer players' physical performance.,"BACKGROUND The aim of this study was to investigate the effects of a short duration and low weekly frequency integrative program on sprint, agility and jump performance in elite youth soccer players. METHODS Twenty-eight elite youth soccer players, members of two professional clubs, playing in the U19 developmental championship participated in this study. They were divided into 2 groups: the intervention group (EG,n=15) and the control group (CG, n=13). The duration of the intervention program was 8 weeks with a frequency of twice per week. The performance of the participants in the 10 meters and 30 meters speed, countermovement jump (CMJ), squat jump (SJ) and agility (Illinois agility test, Arrowhead agility test) was measured at the beginning and the end of the 8-week study. RESULTS There was no statistically significant difference in any performance measured between the two groups. CONCLUSIONS The results of the present study indicate that the addition of allowing frequency and short duration training intervention program did not enhance the physical fitness indicators, in high-level young soccer players.",2020,"The performance of the participants in the 10 meters and 30 meters speed, countermovement jump (CMJ), squat jump (SJ) and agility (Illinois agility test, Arrowhead agility test) was measured at the beginning and the end of the 8-week study. ","['high-level young soccer players', 'elite youth soccer players', 'Twenty-eight elite youth soccer players, members of two professional clubs, playing in the U19 developmental championship participated in this study', ""elite young soccer players' physical performance""]","['short duration and low weekly frequency integrative program', 'integrative training program']","['30 meters speed, countermovement jump (CMJ), squat jump (SJ) and agility (Illinois agility test, Arrowhead agility test', 'sprint, agility and jump performance']","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0149651', 'cui_str': 'Clubbing'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0458003', 'cui_str': 'Developmental'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0439593', 'cui_str': 'Short duration'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0441074', 'cui_str': 'Meters'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0020898', 'cui_str': 'Illinois'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0453107', 'cui_str': 'Arrowhead'}]",,0.0158345,"The performance of the participants in the 10 meters and 30 meters speed, countermovement jump (CMJ), squat jump (SJ) and agility (Illinois agility test, Arrowhead agility test) was measured at the beginning and the end of the 8-week study. ","[{'ForeName': 'Christos', 'Initials': 'C', 'LastName': 'Karydopoulos', 'Affiliation': 'Laboratory of Evaluation of Human Biological Performance, Department of Physical Education and Sports Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Dimitrios', 'Initials': 'D', 'LastName': 'Kapralos', 'Affiliation': 'Laboratory of Evaluation of Human Biological Performance, Department of Physical Education and Sports Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Evangelia', 'Initials': 'E', 'LastName': 'Kouidi', 'Affiliation': 'Laboratory of Sports Medicine, Department of Physical Education and Sports Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Yiannis', 'Initials': 'Y', 'LastName': 'Michailidis', 'Affiliation': 'Laboratory of Evaluation of Human Biological Performance, Department of Physical Education and Sports Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece - ioannimd@phed.auth.gr.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Metaxas', 'Affiliation': 'Laboratory of Evaluation of Human Biological Performance, Department of Physical Education and Sports Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}]",The Journal of sports medicine and physical fitness,['10.23736/S0022-4707.20.11195-2'] 1988,32744045,Effects of coordination training on the technical development in 10-13 years old football players.,"BACKGROUND The purpose of this study was to determine the effects of coordination training carried out by 10-13 years old male football players on the performance of dribbling, passing, shooting, ball bouncing and wall-volley skills. METHODS A total of 45 male football players were divided into three 15 participants groups. The experimental group performed 30 min coordination training three days a week for ten weeks while the control group one continued their routine training and control group two performed unstructured football training. Measurements included Mor and Christian, Yeagley and Johnson football skill tests. Pre- and post-test measurements were compared by an ANOVA 2 × 3. A significant level of P < 0.05 was established. RESULTS All the skills, dribbling (P < 0.001), passing (P < 0.001), shooting (P < 0.001), ball bouncing (P = 0.047) and wall-volley (P < 0.001), improved after ten weeks in the experimental group, while only passing (P = 0.006), shooting (P = 0.007) and wall-volley (P< 0.001) improved in the control group one and none of the skills improved in the control group two (P > 0.05). The improvement was significant in the experimental group in comparison with the control groups (P < 0.001). CONCLUSIONS The implementation of coordination exercises in combination with structured football training has been shown to be effective in improving general football ability among 10-13 male players.",2020,"RESULTS All the skills, dribbling (P < 0.001), passing (P < 0.001), shooting (P < 0.001)","['10-13 years old male football players on the performance of dribbling, passing, shooting, ball bouncing and wall-volley skills', '10-13 male players', '45 male football players', '10-13 years old football players']","['coordination training', 'coordination exercises in combination with structured football training', 'control group one continued their routine training and control group two performed unstructured football training']","['wall-volley', 'Mor and Christian, Yeagley and Johnson football skill tests']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0016517', 'cui_str': 'American or Canadian football - sport'}, {'cui': 'C0013132', 'cui_str': 'Dribbling from mouth'}, {'cui': 'C1444774', 'cui_str': 'Shooting sensation quality'}, {'cui': 'C0039597', 'cui_str': 'Testis structure'}, {'cui': 'C0205380', 'cui_str': 'Walled'}]","[{'cui': 'C0419112', 'cui_str': 'Coordination training'}, {'cui': 'C0203990', 'cui_str': 'Coordination exercise'}, {'cui': 'C0016517', 'cui_str': 'American or Canadian football - sport'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0205448', 'cui_str': '2'}]","[{'cui': 'C0205380', 'cui_str': 'Walled'}, {'cui': 'C1138348', 'cui_str': 'moira protein, Drosophila'}, {'cui': 'C0008532', 'cui_str': 'Christian religion'}, {'cui': 'C0016517', 'cui_str': 'American or Canadian football - sport'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",45.0,0.0133178,"RESULTS All the skills, dribbling (P < 0.001), passing (P < 0.001), shooting (P < 0.001)","[{'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Kösal', 'Affiliation': 'Department of Sport Performance and Condition, Kocaeli University, Kocaeli, Turkey.'}, {'ForeName': 'Gazanfer K', 'Initials': 'GK', 'LastName': 'GÜl', 'Affiliation': 'Department of Sport Performance and Condition, Kocaeli University, Kocaeli, Turkey.'}, {'ForeName': 'Murat', 'Initials': 'M', 'LastName': 'Doğanay', 'Affiliation': 'Department of Sport Performance and Condition, Kocaeli University, Kocaeli, Turkey - muratdoganay41@gmail.com.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Álvarez-García', 'Affiliation': 'Department of Nursing, University of Jaén, Jaén, Spain.'}]",The Journal of sports medicine and physical fitness,['10.23736/S0022-4707.20.11270-2'] 1989,32744056,Continuation of aspirin therapy before pars plana vitrectomy: Safe or not?,"PURPOSE To assess the safety of pars plana vitrectomy (PPV) in patients undergoing systemic treatment with aspirin. METHODS This prospective study enrolled consecutive patients undergoing PPV under percutaneous retrobulbar anesthesia between February 2016 and July 2018. Sixty-seven eyes from 67 patients on regular aspirin therapy were randomized into two groups: the continuation group (33 eyes), with aspirin continued during the perioperative period; and the discontinuation group (34 eyes), with aspirin discontinued for 3 to 7 days before surgery. Forty-three eyes from 43 patients who had no antiplatelet/anticoagulant therapy were used as a control group. RESULTS There was no significant difference in the incidence of hemorrhagic complications or the need for additional operations due to hemorrhagic complications among the three groups ( p  = 0.740 and p  = 0.324, respectively). None of the patients in these three groups suffered from thromboembolic events during the follow-up period. Except for one case (3.0%) of lid ecchymosis in the continuation group, no eye experienced bleeding complications associated with the retrobulbar local anesthesia. In the continuation group, three eyes (9.1%) demonstrated postoperative hyphema that resolved spontaneously. In the discontinuation group, two eyes (5.9%) suffered from postoperative vitreous hemorrhage, of which one eye required secondary surgery and the other cleared spontaneously. One eye (2.9%) in the discontinuation group demonstrated postoperative hyphema that absorbed spontaneously. Three eyes (7.0%) in the control group experienced hyphema that absorbed spontaneously. CONCLUSION The outcomes of our study indicate that PPV under retrobulbar anesthesia can be safely performed without discontinuing systemic aspirin therapy.",2020,"There was no significant difference in the incidence of hemorrhagic complications or the need for additional operations due to hemorrhagic complications among the three groups ( p  = 0.740 and p  = 0.324, respectively).","['patients undergoing systemic treatment with aspirin', 'enrolled consecutive patients undergoing PPV under percutaneous retrobulbar anesthesia between February 2016 and July 2018', 'Sixty-seven eyes from 67 patients on regular', 'Forty-three eyes from 43 patients who had no antiplatelet/anticoagulant therapy were used as a control group']","['aspirin therapy before pars plana vitrectomy', 'pars plana vitrectomy (PPV', 'PPV under retrobulbar anesthesia', 'aspirin therapy', 'aspirin', 'aspirin discontinued']","['hyphema that absorbed spontaneously', 'bleeding complications', 'postoperative hyphema', 'postoperative vitreous hemorrhage', 'hemorrhagic complications', 'lid ecchymosis', 'thromboembolic events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0563537', 'cui_str': 'Mechanical vitrectomy by pars plana approach'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0459804', 'cui_str': 'Retrobulbar space'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C4517852', 'cui_str': '67'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0450368', 'cui_str': '43'}, {'cui': 'C0150457', 'cui_str': 'Anticoagulant therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C4303556', 'cui_str': 'Aspirin therapy'}, {'cui': 'C0563537', 'cui_str': 'Mechanical vitrectomy by pars plana approach'}, {'cui': 'C0459804', 'cui_str': 'Retrobulbar space'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}]","[{'cui': 'C0020581', 'cui_str': 'Hyphema'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0042909', 'cui_str': 'Vitreous hemorrhage'}, {'cui': 'C0333275', 'cui_str': 'Hemorrhagic'}, {'cui': 'C0013491', 'cui_str': 'Ecchymosis'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}]",,0.0144918,"There was no significant difference in the incidence of hemorrhagic complications or the need for additional operations due to hemorrhagic complications among the three groups ( p  = 0.740 and p  = 0.324, respectively).","[{'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ""Department of Cardiology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Qingjian', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Che', 'Affiliation': 'Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': 'Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Yiwen', 'Initials': 'Y', 'LastName': 'Qian', 'Affiliation': 'Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Zhiliang', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai, China.'}]",European journal of ophthalmology,['10.1177/1120672120946930'] 1990,32744215,Effect of culinary education curriculum on Mediterranean diet adherence and food cost savings in families: a randomised controlled trial.,"OBJECTIVE Diet-related diseases are the leading cause of morbidity and mortality in the USA. While the critical aspects of a healthy diet are well known, the relationship between community-based, teaching kitchen education and dietary behaviours is unclear. We examined the effect of a novel culinary medicine education programme on Mediterranean diet adherence and food cost savings. DESIGN Families were randomised to a hands-on, teaching kitchen culinary education class (n = 18) or non-kitchen-based dietary counselling (n = 23) for 6 weeks. The primary outcome was adherence to the validated nine-point Mediterranean diet score, and the secondary outcome was food cost savings per family. SETTING The Goldring Center for Culinary Medicine, a community teaching kitchen in New Orleans. PARTICIPANTS Families (n = 41) of at least one child and one parent. RESULTS Compared with families receiving traditional dietary counselling, those participating in hands-on, kitchen-based nutrition education were nearly three times as likely to follow a Mediterranean dietary pattern (OR 2·93, 95% CI 1·73, 4·95; P  <  0·001), experiencing a 0·43-point increase in Mediterranean diet adherence after 6 weeks (B  =  0·43; P  <  0·001). Kitchen-based nutrition education projects to save families $US 21·70 per week compared with standard dietary counselling by increasing the likelihood of consuming home-prepared v. commercially-prepared meals (OR 1·56, 95% CI 1·08, 2·25; P  =  0·018). CONCLUSIONS Community-based culinary medicine education improves Mediterranean diet adherence and associates with food cost savings among a diverse sample of families. Hands-on culinary medicine education may be a novel evidence-based tool to teach healthful dietary habits and prevent chronic disease.",2020,"CONCLUSIONS Community-based culinary medicine education improves Mediterranean diet adherence and associates with food cost savings among a diverse sample of families.","['Families (n = 41) of at least one child and one parent', 'families', 'The Goldring Center for Culinary Medicine, a community teaching kitchen in New Orleans']","['novel culinary medicine education programme', 'teaching kitchen culinary education class (n = 18) or non-kitchen-based dietary counselling', 'culinary education curriculum']","['Mediterranean diet adherence', 'adherence to the validated nine-point Mediterranean diet score', 'Mediterranean diet adherence and food cost savings', 'food cost savings per family']","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0557653', 'cui_str': 'Kitchen'}, {'cui': 'C0205314', 'cui_str': 'New'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0557653', 'cui_str': 'Kitchen'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}]","[{'cui': 'C1138412', 'cui_str': 'Mediterranean Diet'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0085550', 'cui_str': 'Cost Savings'}, {'cui': 'C0015576', 'cui_str': 'Family'}]",,0.0706344,"CONCLUSIONS Community-based culinary medicine education improves Mediterranean diet adherence and associates with food cost savings among a diverse sample of families.","[{'ForeName': 'Alexander C', 'Initials': 'AC', 'LastName': 'Razavi', 'Affiliation': 'Goldring Center for Culinary Medicine, Tulane University School of Medicine,New Orleans, 70119LA, USA.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Sapin', 'Affiliation': 'Goldring Center for Culinary Medicine, Tulane University School of Medicine,New Orleans, 70119LA, USA.'}, {'ForeName': 'Dominique J', 'Initials': 'DJ', 'LastName': 'Monlezun', 'Affiliation': 'Goldring Center for Culinary Medicine, Tulane University School of Medicine,New Orleans, 70119LA, USA.'}, {'ForeName': 'Isabella G', 'Initials': 'IG', 'LastName': 'McCormack', 'Affiliation': 'Goldring Center for Culinary Medicine, Tulane University School of Medicine,New Orleans, 70119LA, USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Latoff', 'Affiliation': 'Goldring Center for Culinary Medicine, Tulane University School of Medicine,New Orleans, 70119LA, USA.'}, {'ForeName': 'Kathrine', 'Initials': 'K', 'LastName': 'Pedroza', 'Affiliation': 'Goldring Center for Culinary Medicine, Tulane University School of Medicine,New Orleans, 70119LA, USA.'}, {'ForeName': 'Colleen', 'Initials': 'C', 'LastName': 'McCullough', 'Affiliation': 'Goldring Center for Culinary Medicine, Tulane University School of Medicine,New Orleans, 70119LA, USA.'}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Sarris', 'Affiliation': 'Goldring Center for Culinary Medicine, Tulane University School of Medicine,New Orleans, 70119LA, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Schlag', 'Affiliation': 'Goldring Center for Culinary Medicine, Tulane University School of Medicine,New Orleans, 70119LA, USA.'}, {'ForeName': 'Amber', 'Initials': 'A', 'LastName': 'Dyer', 'Affiliation': 'Goldring Center for Culinary Medicine, Tulane University School of Medicine,New Orleans, 70119LA, USA.'}, {'ForeName': 'Timothy S', 'Initials': 'TS', 'LastName': 'Harlan', 'Affiliation': 'Goldring Center for Culinary Medicine, Tulane University School of Medicine,New Orleans, 70119LA, USA.'}]",Public health nutrition,['10.1017/S1368980020002256'] 1991,32744221,Targeting fear of positive evaluation in patients with social anxiety disorder via a brief cognitive behavioural therapy protocol: a proof-of-principle study.,"BACKGROUND Our aim was to develop a brief cognitive behavioural therapy (CBT) protocol to augment treatment for social anxiety disorder (SAD). This protocol focused specifically upon fear of positive evaluation (FPE). To our knowledge, this is the first protocol that has been designed to systematically target FPE. AIMS To test the feasibility of a brief (two-session) CBT protocol for FPE and report proof-of-principle data in the form of effect sizes. METHOD Seven patients with a principal diagnosis of SAD were recruited to participate. Following a pre-treatment assessment, patients were randomized to either (a) an immediate CBT condition (n = 3), or (b) a comparable wait-list (WL) period (2 weeks; n = 4). Two WL patients also completed the CBT protocol following the WL period (delayed CBT condition). Patients completed follow-up assessments 1 week after completing the protocol. RESULTS A total of five patients completed the brief, FPE-specific CBT protocol (two of the seven patients were wait-listed only and did not complete delayed CBT). All five patients completed the protocol and provided 1-week follow-up data. CBT patients demonstrated large reductions in FPE-related concerns as well as overall social anxiety symptoms, whereas WL patients demonstrated an increase in FPE-related concerns. CONCLUSIONS Our brief FPE-specific CBT protocol is feasible to use and was associated with large FPE-specific and social anxiety symptom reductions. To our knowledge, this is the first treatment report that has focused on systematic treatment of FPE in patients with SAD. Our protocol warrants further controlled evaluation.",2020,"CBT patients demonstrated large reductions in FPE-related concerns as well as overall social anxiety symptoms, whereas WL patients demonstrated an increase in FPE-related concerns. ","['Seven patients with a principal diagnosis of SAD were recruited to participate', 'patients with social anxiety disorder via a brief', 'patients with SAD', 'social anxiety disorder (SAD']","['CBT', 'FPE', 'cognitive behavioural therapy protocol', 'immediate CBT condition', 'FPE-specific CBT protocol', 'cognitive behavioural therapy (CBT) protocol']","['FPE-related concerns', 'overall social anxiety symptoms']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332137', 'cui_str': 'Principal diagnosis'}, {'cui': 'C0031572', 'cui_str': 'Social phobia'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205369', 'cui_str': 'Specific'}]","[{'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",7.0,0.0246387,"CBT patients demonstrated large reductions in FPE-related concerns as well as overall social anxiety symptoms, whereas WL patients demonstrated an increase in FPE-related concerns. ","[{'ForeName': 'Justin W', 'Initials': 'JW', 'LastName': 'Weeks', 'Affiliation': 'Nebraska Medicine, Department of Psychology, University of Nebraska Medical Center, Department of Psychiatry, Omaha, NE68198-4185, USA.'}, {'ForeName': 'M Taylor', 'Initials': 'MT', 'LastName': 'Wilmer', 'Affiliation': 'Adult Anxiety Clinic of Temple, Temple University, Philadelphia, PA, USA.'}, {'ForeName': 'Carrie M', 'Initials': 'CM', 'LastName': 'Potter', 'Affiliation': 'Adult Anxiety Clinic of Temple, Temple University, Philadelphia, PA, USA.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Waldron', 'Affiliation': 'Adult Anxiety Clinic of Temple, Temple University, Philadelphia, PA, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Versella', 'Affiliation': 'Adult Anxiety Clinic of Temple, Temple University, Philadelphia, PA, USA.'}, {'ForeName': 'Simona C', 'Initials': 'SC', 'LastName': 'Kaplan', 'Affiliation': 'Adult Anxiety Clinic of Temple, Temple University, Philadelphia, PA, USA.'}, {'ForeName': 'Dane', 'Initials': 'D', 'LastName': 'Jensen', 'Affiliation': 'Adult Anxiety Clinic of Temple, Temple University, Philadelphia, PA, USA.'}, {'ForeName': 'Richard G', 'Initials': 'RG', 'LastName': 'Heimberg', 'Affiliation': 'Adult Anxiety Clinic of Temple, Temple University, Philadelphia, PA, USA.'}]",Behavioural and cognitive psychotherapy,['10.1017/S1352465820000491'] 1992,32744354,Consistent Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of Diabetic Kidney Disease Categories - Insights from the EMPA-REG OUTCOME trial.,"AIMS Diabetes is the leading cause of kidney failure. Additionally, elevated albuminuria predicts increased cardio/kidney risk. Recent evidence shows a shift toward non-albuminuric phenotypes of diabetic kidney disease (DKD; i.e., reduced glomerular filtration rate [GFR] without overt albuminuria). Interventions that could lower cardio/kidney risk in patients with DKD across the albuminuria spectrum are needed. MATERIALS AND METHODS EMPA-REG OUTCOME randomized participants (1:1:1) to empagliflozin 10mg, 25mg or placebo, added to standard of care. Post hoc, patients with different clinical phenotypes of DKD at baseline were categorized in three subgroups: 1) overt DKD (overt albuminuria [UACR >300 mg/g] with any eGFR; n = 769); 2) non-overt DKD (kidney impairment [eGFR <60 ml/min/1.73m 2 ] without overt albuminuria [UACR ≤300mg/g]; n = 1290); 3) 'all others' (eGFR ≥60 ml/min/1.73m 2 without overt albuminuria; n = 4893). Analyses included cardiovascular (CV; death, hospitalization for heart failure, all-cause hospitalization) and selected kidney outcomes, change in eGFR and kidney safety. Cox proportional hazards models assessed consistency of treatment effect across subgroups. RESULTS Empagliflozin significantly reduced risk of CV and kidney outcomes across all subgroups (P-values for interaction >0.05), consistent with the overall trial population findings. Empagliflozin also significantly reduced the yearly loss of eGFR, assessed by chronic slopes, in all subgroups. The adverse event profile of empagliflozin was similar across all subgroups. CONCLUSIONS Empagliflozin may improve CV and kidney outcomes and slow progression of kidney disease in type 2 diabetes patients with DKD, irrespective of its clinical form, both with or without the presence of overt albuminuria. This article is protected by copyright. All rights reserved.",2020,"RESULTS Empagliflozin significantly reduced risk of CV and kidney outcomes across all subgroups (P-values for interaction >0.05), consistent with the overall trial population findings.","['patients with DKD', ""patients with different clinical phenotypes of DKD at baseline were categorized in three subgroups: 1) overt DKD (overt albuminuria [UACR >300 mg/g] with any eGFR; n\xa0=\xa0769); 2) non-overt DKD (kidney impairment [eGFR <60 ml/min/1.73m 2 ] without overt albuminuria [UACR ≤300mg/g]; n\xa0=\xa01290); 3) 'all others' (eGFR ≥60 ml/min/1.73m 2 without overt albuminuria; n\xa0=\xa04893"", 'type 2 diabetes patients with DKD']","['Empagliflozin', 'empagliflozin', 'empagliflozin 10mg, 25mg or placebo']","['CV and kidney outcomes and slow progression of kidney disease', 'yearly loss of eGFR', 'cardiovascular (CV; death, hospitalization for heart failure, all-cause hospitalization) and selected kidney outcomes, change in eGFR and kidney safety', 'risk of CV and kidney outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011881', 'cui_str': 'Kidney disorder due to diabetes mellitus'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0031437', 'cui_str': 'Phenotype'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0001925', 'cui_str': 'Albuminuria'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C1300563', 'cui_str': 'g/kg'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C1565489', 'cui_str': 'Renal impairment'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}]","[{'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C3848773', 'cui_str': 'empagliflozin 10 MG [Jardiance]'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",,0.149974,"RESULTS Empagliflozin significantly reduced risk of CV and kidney outcomes across all subgroups (P-values for interaction >0.05), consistent with the overall trial population findings.","[{'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Wanner', 'Affiliation': 'Department of Medicine, Division of Nephrology, Wuerzburg University Clinic, Wuerzburg, Germany.'}, {'ForeName': 'Silvio E', 'Initials': 'SE', 'LastName': 'Inzucchi', 'Affiliation': 'Section of Endocrinology, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Zinman', 'Affiliation': 'Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Koitka-Weber', 'Affiliation': 'Department of Medicine, Division of Nephrology, Wuerzburg University Clinic, Wuerzburg, Germany.'}, {'ForeName': 'Michaela Mattheus Dipl', 'Initials': 'MMD', 'LastName': 'Biomath', 'Affiliation': 'Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.'}, {'ForeName': 'Jyothis T', 'Initials': 'JT', 'LastName': 'George', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': 'Maximilian', 'Initials': 'M', 'LastName': 'von Eynatten', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': 'Sibylle J', 'Initials': 'SJ', 'LastName': 'Hauske', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Diabetes, obesity & metabolism",['10.1111/dom.14158'] 1993,32744358,"Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with T2DM: A multi-center, randomized, double-blind, placebo-controlled, phase 3b trial.","AIMS To assess the efficacy and safety of polyethylene glycol loxenatide (PEX168), a new glucagon-like peptide receptor agonist, as an add-on to metformin therapy in Chinese patients with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS This was a multicenter, randomized, double-blind, placebo-controlled phase 3b trial. After metformin monotherapy (≥1500 mg/day) for ≥8 weeks, patients with uncontrolled T2DM [glycated hemoglobin (HbA1c) 7.0%-10.5%] from 44 sites were randomized (1:1:1) to metformin + placebo, metformin + PEX168 100 μg, and metformin + PEX168 200 μg. The core treatment period lasted for 24 weeks, followed by a 28-week extension period. The primary endpoint was the change in HbA1c levels at week 24. The main secondary endpoint was the proportion of patients with HbA1c <7.0% at week 24. RESULTS The least-square mean (standard error) change in HbA1c levels was significantly greater (P < 0.001 for superiority) in PEX168 groups [-1.16% (0.08%) and - 1.14% (0.08%) with 100 μg and 200 μg, respectively] than in the placebo group [0.35% (0.08%)]. The proportion of patients with HbA1c <7.0% at week 24 was significantly higher in the PEX168 100 μg (37.4%) and PEX168 200 μg (40.6%) groups than in the placebo group (16.8%, both P < 0.001). The gastrointestinal reactions were mild; the risks of hypoglycemia and weight gain did not increase. Anti-PEX168 antibodies were noted in less than 2% of patients. No treatment-emergent SAEs occurred. CONCLUSION The subcutaneous injection of PEX168 once a week can effectively, continuously, and safely improve HbA1c levels in patients with T2DM when combined with metformin. This article is protected by copyright. All rights reserved.",2020,The least-square mean (standard error) change in HbA1c levels was significantly greater (P < 0.001 for superiority) in PEX168 groups,"['patients with T2DM', 'patients with uncontrolled T2DM [glycated hemoglobin (HbA1c) 7.0%-10.5%] from 44 sites', 'Chinese patients with type 2 diabetes mellitus (T2DM', 'patients with T2DM when combined with']","['metformin monotherapy', 'metformin + placebo, metformin + PEX168 100\u2009μg, and metformin + PEX168 200\u2009μg', 'polyethylene glycol loxenatide (PEX168', 'polyethylene glycol loxenatide', 'PEX168', 'metformin therapy', 'metformin', 'placebo']","['Anti-PEX168 antibodies', 'risks of hypoglycemia and weight gain', 'Efficacy and safety', 'change in HbA1c levels', 'HbA1c levels', 'proportion of patients with HbA1c', 'least-square mean (standard error) change in HbA1c levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4517521', 'cui_str': '10.5'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4079755', 'cui_str': 'PEX168'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4077947', 'cui_str': 'polyethylene glycol loxenatide'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C4079755', 'cui_str': 'PEX168'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023189', 'cui_str': 'Analysis, Least-Squares'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0038137', 'cui_str': 'standards'}]",,0.513072,The least-square mean (standard error) change in HbA1c levels was significantly greater (P < 0.001 for superiority) in PEX168 groups,"[{'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Gao', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China.""}, {'ForeName': 'Xiaofeng', 'Initials': 'X', 'LastName': 'Lv', 'Affiliation': 'Department of Endocrinology and Metabolism, General Hospital of Beijing Military Region, Beijing, China.'}, {'ForeName': 'Zhaohui', 'Initials': 'Z', 'LastName': 'Mo', 'Affiliation': 'Department of Endocrinology, the Third Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': 'Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Qiu', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Department of Endocrinology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.'}, {'ForeName': 'Gangyi', 'Initials': 'G', 'LastName': 'Yang', 'Affiliation': 'Department of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.'}, {'ForeName': 'Weijuan', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': 'Departments of Endocrinology, Chongqing Three Gorges Central Hospital, Chongqing, China.'}, {'ForeName': 'Quanmin', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Endocrinology, The PLA Rocket Force Characteristic Medical Center, Beijing, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China.""}, {'ForeName': 'Yuqian', 'Initials': 'Y', 'LastName': 'Bao', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China.""}, {'ForeName': 'Weiping', 'Initials': 'W', 'LastName': 'Jia', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China.""}]","Diabetes, obesity & metabolism",['10.1111/dom.14163'] 1994,32729586,Effects of intragastric tryptophan on acute changes in the plasma tryptophan/large neutral amino acids ratio and relationship with subsequent energy intake in lean and obese men.,"Circulating tryptophan/large neutral amino acids (tryptophan/LNAA) ratio, an indicator of brain serotonin levels, may be important in appetite regulation, together with gastrointestinal (gastric emptying, plasma cholecystokinin) mechanisms. We have compared effects of intragastric tryptophan ('Trp') on the plasma tryptophan/LNAA ratio in lean and obese men, and the associations of the tryptophan/LNAA ratio, gastric emptying and CCK concentrations with energy intake. Lean and obese male participants (n = 16 each) received 3 g Trp or volume-matched control intragastrically, 15 min before a mixed-nutrient drink (300 mL, 400 kcal) (t = 0 min) in randomised, double-blind fashion. Plasma amino acid (for calculation of the plasma tryptophan/LNAA ratio) and CCK concentrations were measured from t = -20-60 min. Gastric emptying was assessed from t = 0-60 min, and ad-libitum energy intake from a standardised buffet-style meal from t = 60-90 min. The increase in the plasma tryptophan/LNAA ratio was less in obese, than lean, participants (P < 0.05), and greater in lean participants who reduced their energy intake (by >0 kcal) after Trp compared with those who did not (by ≤0 kcal) (P < 0.05). Moreover, in participants who reduced their energy intake, the ratio was lower in obese, than in lean (P < 0.05). There was a trend for an inverse correlation between energy intake with the plasma tryptophan/LNAA ratio in lean (r = -0.4, P = 0.08), but not in obese, participants. There was no significant difference in gastric emptying or CCK between participants who reduced their energy intake and those who did not. In conclusion, the plasma tryptophan/LNAA ratio appears to be a determinant of the suppression of energy intake in response to tryptophan in normal-weight people, but not in those with obesity. The role of the plasma tryptophan/LNAA ratio to regulate energy intake, and potential changes in obesity, warrant evaluation in prospective studies.",2020,There was no significant difference in gastric emptying or CCK between participants who reduced their energy intake and those who did not.,"['Lean and obese male participants (n = 16 each) received', 'lean and obese men']","['intragastric tryptophan', ""intragastric tryptophan ('Trp"", '3 g Trp or volume-matched control intragastrically, 15 min before a mixed-nutrient drink']","['plasma tryptophan/LNAA ratio in lean', 'plasma tryptophan/LNAA ratio', 'Gastric emptying', 'tryptophan/LNAA ratio, gastric emptying and CCK concentrations with energy intake', 'gastric emptying or CCK', 'Plasma amino acid (for calculation of the plasma tryptophan/LNAA ratio) and CCK concentrations', 'energy intake']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0442113', 'cui_str': 'Intragastric'}, {'cui': 'C0041249', 'cui_str': 'Tryptophan'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0452428', 'cui_str': 'Drink'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0041249', 'cui_str': 'Tryptophan'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0017127', 'cui_str': 'Gastric emptying'}, {'cui': 'C0008328', 'cui_str': 'Cholecystokinin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}, {'cui': 'C1441506', 'cui_str': 'Calculation technique'}]",,0.103926,There was no significant difference in gastric emptying or CCK between participants who reduced their energy intake and those who did not.,"[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Hajishafiee', 'Affiliation': 'Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia. christine.feinle@adelaide.edu.au.'}, {'ForeName': 'Sina S', 'Initials': 'SS', 'LastName': 'Ullrich', 'Affiliation': 'Institute for Prevention and Cancer Epidemiology, Faculty of Medicine and Medical Centre, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Steinert', 'Affiliation': 'Department of Surgery, Division of Visceral and Transplantation Surgery, University Hospital Zürich, Zürich, Switzerland.'}, {'ForeName': 'Sally D', 'Initials': 'SD', 'LastName': 'Poppitt', 'Affiliation': 'Human Nutrition Unit, School of Biological Sciences, Department of Medicine, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Natalie D', 'Initials': 'ND', 'LastName': 'Luscombe-Marsh', 'Affiliation': 'Commonwealth Scientific and Industrial Research Organisation - Health and Biosecurity, Adelaide, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Horowitz', 'Affiliation': 'Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia. christine.feinle@adelaide.edu.au.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Feinle-Bisset', 'Affiliation': 'Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia. christine.feinle@adelaide.edu.au.'}]",Food & function,['10.1039/d0fo00773k'] 1995,32726666,Intermittent theta burst stimulation over the dorsomedial prefrontal cortex modulates resting-state connectivity in depressive patients: A sham-controlled study.,"The mechanisms underlying repetitive transcranial magnetic stimulation (rTMS) treatment are largely unknown. Although there is a general lack of sham controlled studies, findings show altered functional connectivity to the stimulated region following treatment. When targeting the dorsolateral prefrontal cortex (dlPFC), connectivity with the subgenual anterior cingulate cortex (sgACC) is predictive of response, but less is known about the effects on functional connectivity of targeting the dorsomedial PFC (dmPFC). Here, 30 patients with an ongoing depressive episode were recruited and randomized to 20 sessions at target intensity of either active or sham intermittent theta burst stimulation (iTBS) over dmPFC. Those receiving sham were offered active treatment in a subsequent open phase. A seven minute resting-state scan and depressive symptom assessment was performed before and after treatment. After exclusions due to attrition and excessive head movements 23 patients remained for analysis. Seed-based resting-state connectivity was calculated using two seeds for the dmPFC target as well as the sgACC. A symptom related increase in dmPFC connectivity after active treatment, compared to sham treatment, was found. The effect was observed in a region overlapping the precuneus and the posterior cingulate cortex (PCC), suggesting an increase in the connectivity between the targeted salience network and the default mode network mediating improvement in depressive symptoms. Connectivity between the precuneus and both the sgACC and the treatment target was predictive of symptom improvement following active treatment. The findings have implications for understanding the mechanisms behind iTBS and may inform future efforts to individualize the treatment.",2020,Connectivity between the precuneus and both the sgACC and the treatment target was predictive of symptom improvement following active treatment.,"['30 patients with an ongoing depressive episode', 'depressive patients']","['repetitive transcranial magnetic stimulation (rTMS', 'Intermittent theta burst stimulation', 'active or sham intermittent theta burst stimulation (iTBS) over dmPFC']",['dmPFC connectivity'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0349217', 'cui_str': 'Depressive episode, unspecified'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}]","[{'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}]",30.0,0.0349908,Connectivity between the precuneus and both the sgACC and the treatment target was predictive of symptom improvement following active treatment.,"[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Persson', 'Affiliation': 'Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden. Electronic address: jonas.persson@neuro.uu.se.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Struckmann', 'Affiliation': 'Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gingnell', 'Affiliation': 'Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden; Department of Psychology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Fällmar', 'Affiliation': 'Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Bodén', 'Affiliation': 'Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden.'}]",Behavioural brain research,['10.1016/j.bbr.2020.112834'] 1996,32726727,Effects of a health education program targeted to Chinese women adhering to their cultural practice of doing the month: A randomized controlled trial.,"BACKGROUND ""Doing the month"" is a prevalent Chinese postpartum custom which is believed to restore health after delivery. However, some traditional practices are potentially harmful for women's health. OBJECTIVES To examine the effect of an evidence-based health education program on Chinese postpartum women's adherence to traditional practices of doing the month and the effect of adherence to doing the month on maternal physiological and psychological health. METHODS A randomized controlled trial was conducted. During December 2016-July 2017, we recruited postpartum women at a tertiary hospital. Women randomized to the intervention group received evidence-based health education within 1 week after returning home and received a second visit 1 month later. The control group received routine postpartum home visits. Adherence to doing the month was measured by the Adherence to Doing-the-Month Practices questionnaire (ADP). Maternal physical health was measured by the Chair Stand Test and Postpartum Symptom Checklist. Maternal psychological health was measured by the Edinburgh Postnatal Depression Scale (EPDS). Descriptive statistics, t-test, and chi-squared test were used to analyze the differences in scores and symptoms of the two groups. RESULTS We recruited 124 eligible postpartum women and 108 of them (54 intervention group, 54 control group) completed this study. The ADP score of the intervention group was significantly lower than that of the control group (p < 0.001). The number of participants in the experimental group with poor appetite and indigestion was significantly lower than that of control group. No significant differences were found in numbers of symptoms and average EPDS scores between the 2 study groups (p > 0.05). CONCLUSIONS Evidence-based health education can reduce postpartum women's adherence to some traditional practices of doing the month and improve women's physical health.",2020,"No significant differences were found in numbers of symptoms and average EPDS scores between the 2 study groups (p > 0.05). ","['During December 2016-July 2017, we recruited postpartum women at a tertiary hospital', '124 eligible postpartum women and 108 of them (54 intervention group, 54 control group) completed this study', ""Chinese postpartum women's"", 'Chinese women adhering to their cultural practice of doing the month']","['health education program', 'routine postpartum home visits', 'evidence-based health education program', 'evidence-based health education']","['Edinburgh Postnatal Depression Scale (EPDS', 'poor appetite and indigestion', 'Maternal physical health', 'ADP score', 'Maternal psychological health', 'numbers of symptoms and average EPDS scores', 'Chair Stand Test and Postpartum Symptom Checklist']","[{'cui': 'C0032804', 'cui_str': 'Postpartum Women'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0451144', 'cui_str': 'Edinburgh postnatal depression scale'}, {'cui': 'C0232462', 'cui_str': 'Decrease in appetite'}, {'cui': 'C0013395', 'cui_str': 'Indigestion'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C3472185', 'cui_str': 'Edinburgh postnatal depression scale score'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0451524', 'cui_str': 'Symptom checklist'}]",124.0,0.0672713,"No significant differences were found in numbers of symptoms and average EPDS scores between the 2 study groups (p > 0.05). ","[{'ForeName': 'YanQun', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Wuhan University School of Health Sciences, China.'}, {'ForeName': 'JuYing', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': 'Obstetrics Department of Hubei Maternal and Child Health Hospital, China.'}, {'ForeName': 'XiaoLi', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Wuhan University School of Health Sciences, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': 'Emory University Nell Hodgson Woodruff School of Nursing, China. Electronic address: yuyun7169@163.com.'}, {'ForeName': 'JinBing', 'Initials': 'J', 'LastName': 'Bai', 'Affiliation': 'Wuhan University School of Health Sciences, China.'}]",Midwifery,['10.1016/j.midw.2020.102796'] 1997,32735216,Perceived Effectiveness and Motivations for the Use of Web-Based Mental Health Programs: Qualitative Study.,"BACKGROUND The prevalence of depression is high and has been stable despite increased treatment, research, and dissemination. People encounter barriers to seeking traditional mental health services, which could be mitigated by using web-based prevention methods. OBJECTIVE This study aims to understand what people at high risk for depression perceive as effective aspects of web-based mental health programs and what motivates people at high risk for depression to use web-based mental health programs. METHODS We conducted an inductive content analysis using telephone interview data from 77 participants at high risk for depression who were recruited from 2 randomized controlled trials (RCTs). Participants from the first RCT were working men who had been randomly assigned to 1 of the following 3 groups: control group, who had access to general depression information from a website called BroMatters; intervention group 1, who had access to the BroMatters website along with the associated BroHealth web-based mental health program; and intervention group 2, who had access to the BroMatters website, the BroHealth web-based mental health program, and telephone sessions with a life coach. Participants from the second RCT were men and women who had been assigned to the intervention group, who received access to the HardHat web-based mental health program, or the control group, who only received access to the HardHat web-based mental health program following completion of the RCT. Participants for this inductive content analysis study were recruited from the intervention groups in both RCTs. Two groups of participants (n=41 and n=20) were recruited from the BroHealth RCT, and a third group comprised 16 participants that were recruited from the HardHat RCT. RESULTS We generated four categories regarding the perceived effectiveness of web-based programs and five categories related to what motivates the use of web-based programs. Participants identified awareness, program medium and functionality, program content, and coaches as categories related to the effectiveness of the programs. Categories of motivators to use web-based programs included providing reminders or incentives, promotion of the programs, providing appropriate medium and functionality, appropriate content, and perceived need. The final category related to motivators reflects perceptions of participants who were either unsure about what motivates them or believed that there is no way to motivate use. CONCLUSIONS Conflicting evidence was obtained regarding the perceived effectiveness of aspects of the content and functionality of web-based programs. In general, web-based mental health programs were perceived to help increase mental health awareness, especially when it includes live access to a coach. However, the results also revealed that it is difficult to motivate people to begin using web-based mental health programs. Strategies that may motivate the use of such programs include perceived personal need, effective promotion, providing incentives and reminders, and improving functionality.",2020,"In general, web-based mental health programs were perceived to help increase mental health awareness, especially when it includes live access to a coach.","['Participants from the first RCT were working men who had been randomly assigned to 1 of the following 3 groups', 'Two groups of participants (n=41 and n=20) were recruited from the BroHealth RCT, and a third group comprised 16 participants that were recruited from the HardHat RCT', '77 participants at high risk for depression who were recruited from 2 randomized controlled trials (RCTs', 'Participants from the second RCT were men and women who had been assigned to the intervention group, who received']","['control group, who had access to general depression information from a website called BroMatters; intervention group 1, who had access to the BroMatters website along with the associated BroHealth web-based mental health program; and intervention group 2, who had access to the BroMatters website, the BroHealth web-based mental health program, and telephone sessions with a life coach', 'access to the HardHat web-based mental health program, or the control group, who only received access to the HardHat web-based mental health program following completion of the RCT']",[],"[{'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]",[],77.0,0.075457,"In general, web-based mental health programs were perceived to help increase mental health awareness, especially when it includes live access to a coach.","[{'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Eccles', 'Affiliation': 'Work & Mental Health Research Unit, The Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Molly', 'Initials': 'M', 'LastName': 'Nannarone', 'Affiliation': 'Work & Mental Health Research Unit, The Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Bonnie', 'Initials': 'B', 'LastName': 'Lashewicz', 'Affiliation': 'Department of Community Health Sciences,, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Attridge', 'Affiliation': 'Attridge Consulting, Inc, Minneapolis, MN, United States.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Marchand', 'Affiliation': 'School of Industrial Relations, University of Montreal, Montreal, QC, Canada.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Aiken', 'Affiliation': 'Office of Research and Innovation, Dalhousie University, Halifax, NS, Canada.'}, {'ForeName': 'Kendall', 'Initials': 'K', 'LastName': 'Ho', 'Affiliation': 'Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Jianli', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Work & Mental Health Research Unit, The Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada.'}]",Journal of medical Internet research,['10.2196/16961'] 1998,32735218,Effects of an mHealth Brisk Walking Intervention on Increasing Physical Activity in Older People With Cognitive Frailty: Pilot Randomized Controlled Trial.,"BACKGROUND Cognitive frailty is the coexistence of physical frailty and cognitive impairment and is an at-risk state for many adverse health outcomes. Moderate-to-vigorous physical activity (MVPA) is protective against the progression of cognitive frailty. Physical inactivity is common in older people, and brisk walking is a feasible form of physical activity that can enhance their MVPA. Mobile health (mHealth) employing persuasive technology has been successful in increasing the levels of physical activity in older people. However, its feasibility and effects on older people with cognitive frailty are unclear. OBJECTIVE We aimed to identify the issues related to the feasibility of an mHealth intervention and the trial (ie, recruitment, retention, participation, and compliance) and to examine the effects of the intervention on cognitive function, physical frailty, walking time, and MVPA. METHODS An open-label, parallel design, randomized controlled trial (RCT) was employed. The eligibility criteria for the participants were age ≥60 years, having cognitive frailty, and having physical inactivity. In the intervention group, participants received both conventional behavior change intervention and mHealth (ie, smartphone-assisted program using Samsung Health and WhatsApp) interventions. In the control group, participants received conventional behavior change intervention only. The outcomes included cognitive function, frailty, walking time, and MVPA. Permuted block randomization in 1:1 ratio was used. The feasibility issue was described in terms of participant recruitment, retention, participation, and compliance. Wilcoxon signed-rank test was used to test the within-group effects in both groups separately. RESULTS We recruited 99 participants; 33 eligible participants were randomized into either the intervention group (n=16) or the control (n=17) group. The median age was 71.0 years (IQR 9.0) and the majority of them were females (28/33, 85%). The recruitment rate was 33% (33/99), the participant retention rate was 91% (30/33), and the attendance rate of all the face-to-face sessions was 100% (33/33). The majority of the smartphone messages were read by the participants within 30 minutes (91/216, 42.1%). ActiGraph (58/66 days, 88%) and smartphone (54/56 days, 97%) wearing compliances were good. After the interventions, cognitive function improvement was significant in both the intervention (P=.003) and the control (P=.009) groups. The increase in frailty reduction (P=.005), walking time (P=.03), step count (P=.02), brisk walking time (P=.009), peak cadence (P=.003), and MVPA time (P=.02) were significant only in the intervention group. CONCLUSIONS Our mHealth intervention is feasible for implementation in older people with cognitive impairment and is effective at enhancing compliance with the brisk walking training program delivered by the conventional behavior change interventions. We provide preliminary evidence that this mHealth intervention can increase MVPA time to an extent sufficient to yield clinical benefits (ie, reduction in cognitive frailty). A full-powered and assessor-blinded RCT should be employed in the future to warrant these effects. TRIAL REGISTRATION HKU Clinical Trials Registry HKUCTR-2283; http://www.hkuctr.com/Study/Show/31df4708944944bd99e730d839db4756.",2020,"After the interventions, cognitive function improvement was significant in both the intervention (P=.003) and the control (P=.009) groups.","['older people with cognitive impairment', 'participants were age ≥60 years, having cognitive frailty, and having physical inactivity', 'older people with cognitive frailty', 'older people', '99 participants; 33 eligible participants', 'Older People']","['conventional behavior change intervention and mHealth (ie, smartphone-assisted program using Samsung Health and WhatsApp) interventions', 'conventional behavior change intervention', 'ActiGraph', 'mHealth intervention', 'Mobile health (mHealth) employing persuasive technology', 'mHealth Brisk Walking Intervention', 'Moderate-to-vigorous physical activity (MVPA']","['cognitive function, physical frailty, walking time, and MVPA', 'attendance rate', 'cognitive function improvement', 'frailty reduction', 'recruitment rate', 'participant retention rate', 'Physical Activity', 'walking time', 'brisk walking time', 'MVPA time', 'cognitive function, frailty, walking time, and MVPA', 'peak cadence']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C3890554', 'cui_str': 'Physical Inactivity'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0443162', 'cui_str': 'Brisk'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0443162', 'cui_str': 'Brisk'}, {'cui': 'C0444505', 'cui_str': 'Peak'}]",33.0,0.0726845,"After the interventions, cognitive function improvement was significant in both the intervention (P=.003) and the control (P=.009) groups.","[{'ForeName': 'Rick Yc', 'Initials': 'RY', 'LastName': 'Kwan', 'Affiliation': 'Centre for Gerontological Nursing, School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong (China).'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Lee', 'Affiliation': 'Centre for Gerontological Nursing, School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong (China).'}, {'ForeName': 'Paul H', 'Initials': 'PH', 'LastName': 'Lee', 'Affiliation': 'School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Hong Kong (China).'}, {'ForeName': 'Mimi', 'Initials': 'M', 'LastName': 'Tse', 'Affiliation': 'Centre for Gerontological Nursing, School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong (China).'}, {'ForeName': 'Daphne Sk', 'Initials': 'DS', 'LastName': 'Cheung', 'Affiliation': 'Centre for Gerontological Nursing, School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong (China).'}, {'ForeName': 'Ladda', 'Initials': 'L', 'LastName': 'Thiamwong', 'Affiliation': 'College of Nursing, University of Central Florida, Orlando, FL, United States.'}, {'ForeName': 'Kup-Sze', 'Initials': 'KS', 'LastName': 'Choi', 'Affiliation': 'School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Hong Kong (China).'}]",JMIR mHealth and uHealth,['10.2196/16596'] 1999,32735221,Effectiveness of a Mobile App Intervention for Anxiety and Depression Symptoms in University Students: Randomized Controlled Trial.,"BACKGROUND Depression and anxiety symptoms are common among university students, but many do not receive treatment. This is often because of lack of availability, reluctance to seek help, and not meeting the diagnostic criteria required to access services. Internet-based interventions, including smartphone apps, can overcome these issues. However, a large number of apps are available, each with little evidence of their effectiveness. OBJECTIVE This study aims to evaluate for the first time the effectiveness of a self-guided mobile app, Feel Stress Free, for the treatment of depression and anxiety symptoms in students. METHODS A web-based randomized controlled trial compared a cognitive behavioral therapy (CBT)-based mobile app Feel Stress Free with a wait-list control. University students self-identified as experiencing symptoms of anxiety or depression and were randomized to 6 weeks of intervention (n=84) or control (n=84), unblinded. The app is self-guided and incorporates behavioral relaxation activities, mood tracking and thought challenging, and minigames. Participants completed the Hospital Anxiety and Depression Scale online at baseline and every fortnight. RESULTS At week 6, the primary end point, there was evidence that the Feel Stress Free app reduced depression symptoms (mean difference -1.56; 95% CI -2.67 to -0.44; P=.006) but only very weak evidence that it reduced anxiety symptoms (mean difference -1.36; 95% CI -2.93 to 0.21; P=.09). At week 4, there was evidence to support the effectiveness of the intervention for anxiety symptoms (mean difference -1.94; 95% CI -3.11 to -0.77; P=.001) and, though weaker, depression symptoms (mean difference -1.08; 95% CI -2.12 to -0.04; P=.04). At week 6, 83% (34/41) of participants indicated that they were using the app weekly or more frequently. CONCLUSIONS The Feel Stress Free app is a promising mobile intervention for treating symptoms of anxiety and depression in students and overcomes many of the barriers to traditional CBT. Further research is needed to establish its effectiveness at and beyond 6 weeks. TRIAL REGISTRATION ClinicalTrials.gov NCT03032952; https://clinicaltrials.gov/ct2/show/NCT03032952.",2020,The Feel Stress Free app is a promising mobile intervention for treating symptoms of anxiety and depression in students and overcomes many of the barriers to traditional CBT.,"['depression and anxiety symptoms in students', 'University students self-identified as experiencing symptoms of anxiety or depression', 'University Students', 'university students']","['Mobile App Intervention', 'cognitive behavioral therapy (CBT)-based mobile app Feel Stress Free with a wait-list control']","['anxiety symptoms', 'Hospital Anxiety and Depression Scale online', 'Feel Stress Free app reduced depression symptoms', 'Anxiety and Depression Symptoms', 'depression symptoms']","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]","[{'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",,0.247771,The Feel Stress Free app is a promising mobile intervention for treating symptoms of anxiety and depression in students and overcomes many of the barriers to traditional CBT.,"[{'ForeName': 'Tayla', 'Initials': 'T', 'LastName': 'McCloud', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Jones', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Lewis', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Vaughan', 'Initials': 'V', 'LastName': 'Bell', 'Affiliation': 'Division of Psychology & Language Sciences, University College London, London, United Kingdom.'}, {'ForeName': 'Elias', 'Initials': 'E', 'LastName': 'Tsakanikos', 'Affiliation': ""Health Service and Population Research Department, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.""}]",JMIR mHealth and uHealth,['10.2196/15418'] 2000,32735225,Use of a Smartphone App for Weight Loss Versus a Paper-Based Dietary Diary in Overweight Adults: Randomized Controlled Trial.,"BACKGROUND Mobile health (mHealth) tools may be useful platforms for dietary monitoring and assessment. OBJECTIVE This study aims to evaluate the effectiveness of a mobile dietary self-monitoring app for weight loss versus a paper-based diary among adults with a BMI of 23 kg/m 2 or above. METHODS A total of 33 men and 17 women aged 18-39 years participated in a 6-week randomized controlled trial. We randomly assigned participants to one of two groups: (1) a smartphone app group (n=25) or (2) a paper-based diary group (n=25). The smartphone app group recorded foods and dietary supplements that they consumed and received immediate dietary feedback using Well-D, a dietary self-monitoring app developed by our team. The paper-based diary group was instructed to record foods or supplements that they consumed using a self-recorded diary. The primary outcomes were weight, BMI, waist circumference, body fat mass, and skeletal muscle mass. We also examined changes in nutrient intake, including energy, carbohydrate, protein, fat, dietary fiber, vitamins, and minerals, using 3-day 24-hour recalls. Differences in changes between the two groups were analyzed using independent t tests or Wilcoxon Mann-Whitney tests. All of the data were analyzed using intent-to-treat analysis. RESULTS The mean number of days recorded was 18.5 (SD 14.1) for the app group and 15.5 (SD 10.1) for the paper-based diary group. The differences in changes in weight, BMI, and waist circumference were not significantly different between the app group and paper-based diary group (P=.33, .34, and .70, respectively). Similarly, changes in body fat mass or skeletal muscle mass did not differ between the two groups (P=.71 and .054, respectively). Although energy intake was reduced in both groups, there was no significant difference in changes in energy intake between the two groups (P=.98). CONCLUSIONS There were no differences in changes in anthropometric measures and nutrient intake between the app group and the paper-based diary group. Both mobile dietary self-monitoring app and paper-based diary may be useful for improving anthropometric measures. TRIAL REGISTRATION Clinical Research Information Service KCT0003170; https://cris.nih.go.kr/cris/search/search_result_st01_en.jsp?seq=11642<ype=&rtype=.",2020,There were no differences in changes in anthropometric measures and nutrient intake between the app group and the paper-based diary group.,"['Overweight Adults', '33 men and 17 women aged 18-39 years', 'adults with a BMI of 23 kg/m 2 or above']","['smartphone app group (n=25) or (2) a paper-based diary group', 'Smartphone App', 'smartphone app group recorded foods and dietary supplements that they consumed and received immediate dietary feedback using Well-D, a dietary self-monitoring app developed by our team', 'mobile dietary self-monitoring app']","['weight, BMI, waist circumference, body fat mass, and skeletal muscle mass', 'weight, BMI, and waist circumference', 'Weight Loss', 'nutrient intake, including energy, carbohydrate, protein, fat, dietary fiber, vitamins, and minerals, using 3-day 24-hour recalls', 'anthropometric measures and nutrient intake', 'body fat mass or skeletal muscle mass', 'weight loss', 'mean number of days recorded', 'energy intake']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030351', 'cui_str': 'Paper'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0042890', 'cui_str': 'Vitamin'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}]",33.0,0.148849,There were no differences in changes in anthropometric measures and nutrient intake between the app group and the paper-based diary group.,"[{'ForeName': 'Jeong Sun', 'Initials': 'JS', 'LastName': 'Ahn', 'Affiliation': 'Department of Food and Nutrition, College of Human Ecology, Seoul National University, Seoul, Republic of Korea.'}, {'ForeName': 'Heejin', 'Initials': 'H', 'LastName': 'Lee', 'Affiliation': 'Department of Food and Nutrition, College of Human Ecology, Seoul National University, Seoul, Republic of Korea.'}, {'ForeName': 'Jiae', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Platform Development Team, Bluecore, Seoul, Republic of Korea.'}, {'ForeName': 'Haemin', 'Initials': 'H', 'LastName': 'Park', 'Affiliation': 'Platform Development Team, Bluecore, Seoul, Republic of Korea.'}, {'ForeName': 'Dong Woo', 'Initials': 'DW', 'LastName': 'Kim', 'Affiliation': 'Department of Home Economics, Korea National Open University, Seoul, Republic of Korea.'}, {'ForeName': 'Jung Eun', 'Initials': 'JE', 'LastName': 'Lee', 'Affiliation': 'Department of Food and Nutrition, College of Human Ecology, Seoul National University, Seoul, Republic of Korea.'}]",JMIR mHealth and uHealth,['10.2196/14013'] 2001,32732573,Platelet-rich Plasma or Autologous Blood Do Not Reduce Pain or Improve Function in Patients with Lateral Epicondylitis: A Randomized Controlled Trial.,"BACKGROUND Platelet-rich plasma (PRP) and autologous blood are commonly used therapies for lateral epicondylitis, but the evidence from randomized, placebo-controlled trials is conflicting. Thus, it is still unclear if patients benefit from these treatments. QUESTIONS/PURPOSES In the setting of a randomized, placebo-controlled trial, we compared PRP, autologous blood, and saline injections in the treatment of lateral epicondylitis with respect to: (1) VAS pain scores, and (2) functional outcomes (DASH score and grip strength) 1 year after treatment. METHODS We performed a parallel-group, randomized, controlled participant- and assessor-blinded study including adults with clinically diagnosed lateral epicondylitis. We defined lateral epicondylitis as pain in the lateral humeral epicondyle area exacerbated during resisted wrist extension and epicondyle compression. The participants were recruited from a secondary referral center, after not responding to initial nonoperative treatment. Patients with other concomitant upper-limb symptoms and surgical treatment of the elbow were excluded. Randomization sequence was generated with computer software and concealed from the investigators. We randomized 119 participants to receive an injection of PRP, autologous blood, or saline (1:1:1) in the proximal insertion of the extensor carpi radialis brevis muscle; 40 participants received PRP, 40 received autologous blood, and 39 received a saline injection. To prepare the PRP, we collected venous blood with a syringe kit followed by centrifugation, whereas autologous blood group received unprepared blood injection. Two unblinded investigators gave injections while the participant was unable to see the injection. There was no formal postinjection rehabilitation protocol and the use of NSAIDs was similar between different treatment arms. Follow-up visits were at 4, 8, 12, 26, and 52 weeks after the injection. The primary outcome measure was improvement in pain, measured with VAS scale (without specification as to whether the pain was activity related or at rest; range 0-10; a higher score indicates worse pain; the minimum clinically important difference [MCID] on the 10-cm scale was 1.5 cm), from baseline to 52 weeks. The secondary outcomes were the DASH score (range 0-100; a higher indicates a poorer outcome, and the MCID was 10.2 points) and grip strength. All patients were included in the analyses, and analyses were performed using the intention-to-treat principle. There was no crossover between treatment groups. At 52 weeks, nearly all (95% [38 of 40]) participants in autologous blood group were available for analysis whereas 78% (31 of 40) and 82% (32 of 39) were available in PRP and saline groups. This study was registered at ClinicalTrials.gov and funded by the local hospital district. With 40 patients in each group, we had 80% power to detect a clinically important improvement in pain (1.5 cm on the 10-cm VAS pain scale). RESULTS There were no clinically important differences in the mean VAS pain or DASH scores among the groups at any timepoint. At 52 weeks, the mean difference in the VAS score for pain was -0.2 (95% CI -1.5 to 1.1; p = 0.75) for PRP versus saline and 0.5 (95% CI -0.7 to 1.7; p = 0.40) for autologous blood versus saline. The corresponding mean differences in the DASH score were 0.0 (95% CI -9.2 to 9.2; p > 0.99) and 7.7 (95% CI -1.3 to 16.7; p = 0.09) and those for grip strength were 1.4 kg (95% CI -3.3 to 6.1; p = 0.56) and -0.2 kg (95% CI -5.0 to 4.5; p = 0.92). No complications occurred because of the injections. CONCLUSIONS PRP or autologous blood injections did not improve pain or function at 1 year of follow-up in people with lateral epicondylitis compared with those who were given a saline injection. However, because the 95% CIs did not exclude the MCID in VAS scores for autologous blood versus saline at 52 weeks, it is possible that a larger study could identify a between-group difference that we missed, but the effect size of that difference (based on our findings), even if present, is likely still to be small. Until or unless future randomized trials convincingly show a benefit either to PRP or autologous blood injections, we recommend against their use in patients with lateral epicondylitis. LEVEL OF EVIDENCE Level II, therapeutic study.",2020,"CONCLUSIONS PRP or autologous blood injections did not improve pain or function at 1 year of follow-up in people with lateral epicondylitis compared with those who were given a saline injection.","['Patients with other concomitant upper-limb symptoms and surgical treatment of the elbow were excluded', 'participants were recruited from a secondary referral center, after not responding to initial nonoperative treatment', '119 participants to receive an', 'Patients with Lateral Epicondylitis', 'patients with lateral epicondylitis', 'adults with clinically diagnosed lateral epicondylitis']","['PRP or autologous blood injections', 'injection of PRP, autologous blood, or saline (1:1:1) in the proximal insertion of the extensor carpi radialis brevis muscle; 40 participants received PRP, 40 received autologous blood, and 39 received a saline injection', 'PRP versus saline', 'PRP, autologous blood, and saline injections', 'Platelet-rich Plasma or Autologous Blood', 'placebo']","['improvement in pain, measured with VAS scale', 'VAS score for pain', 'pain or function', '10-cm VAS pain scale', 'lateral epicondylitis with respect to: (1) VAS pain scores, and (2) functional outcomes (DASH score and grip strength', 'grip strength', 'pain', 'DASH score', 'mean VAS pain or DASH scores', 'VAS scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C3658282', 'cui_str': 'Secondary Referral Center'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0039516', 'cui_str': 'Lateral epicondylitis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C2957363', 'cui_str': 'Injection of platelet-rich plasma'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0039516', 'cui_str': 'Lateral epicondylitis'}, {'cui': 'C0679133', 'cui_str': 'Respect'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",119.0,0.492009,"CONCLUSIONS PRP or autologous blood injections did not improve pain or function at 1 year of follow-up in people with lateral epicondylitis compared with those who were given a saline injection.","[{'ForeName': 'Lasse', 'Initials': 'L', 'LastName': 'Linnanmäki', 'Affiliation': 'L. Linnanmäki, K. Kanto, J. Lehtinen, Tays Hatanpää Hospital, Tampere University Hospital, Tampere, Finland T. Karjalainen, Central Finland Central Hospital, Jyväskylä, Finland O. V. Leppänen, Department of Hand and Microsurgery, Tampere University Hospital, Tampere, Finland.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Kanto', 'Affiliation': ''}, {'ForeName': 'Teemu', 'Initials': 'T', 'LastName': 'Karjalainen', 'Affiliation': ''}, {'ForeName': 'Olli V', 'Initials': 'OV', 'LastName': 'Leppänen', 'Affiliation': ''}, {'ForeName': 'Janne', 'Initials': 'J', 'LastName': 'Lehtinen', 'Affiliation': ''}]",Clinical orthopaedics and related research,['10.1097/CORR.0000000000001185'] 2002,32732574,CORR Insights®: Platelet-rich Plasma or Autologous Blood Do Not Reduce Pain or Improve Function in Patients with Lateral Epicondylitis: A Randomized Controlled Trial.,,2020,,['Patients with Lateral Epicondylitis'],[],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039516', 'cui_str': 'Lateral epicondylitis'}]",[],[],,0.233205,,"[{'ForeName': 'Nash H', 'Initials': 'NH', 'LastName': 'Naam', 'Affiliation': 'N. H. Naam, Professor of Clinical Hand Surgery, Southern Illinois University, Southern Illinois Hand Center, Effingham, IL, USA.'}]",Clinical orthopaedics and related research,['10.1097/CORR.0000000000001249'] 2003,32732583,Letter to the Editor: Does an Antimicrobial Incision Drape Prevent Intraoperative Contamination? A Randomized Controlled Trial of 1187 Patients.,,2020,,['1187 Patients'],[],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}]",[],[],,0.137678,,"[{'ForeName': 'Zhen Chang', 'Initials': 'ZC', 'LastName': 'Liang', 'Affiliation': 'Z. C. Liang, M. S. Y. Chong, S. S. Tan, B. Z. Chin, D. Murphy, J. H. P. Hui, National University of Singapore, Department of Orthopaedic Surgery, National University Health System, Singapore.'}, {'ForeName': 'Mark Seng Ye', 'Initials': 'MSY', 'LastName': 'Chong', 'Affiliation': ''}, {'ForeName': 'Sara Shuhui', 'Initials': 'SS', 'LastName': 'Tan', 'Affiliation': ''}, {'ForeName': 'Brian Zhaojie', 'Initials': 'BZ', 'LastName': 'Chin', 'Affiliation': ''}, {'ForeName': 'Diarmuid', 'Initials': 'D', 'LastName': 'Murphy', 'Affiliation': ''}, {'ForeName': 'James Hoi Po', 'Initials': 'JHP', 'LastName': 'Hui', 'Affiliation': ''}]",Clinical orthopaedics and related research,['10.1097/CORR.0000000000001331'] 2004,32736622,"Uncovering spatial variation in maternal healthcare service use at subnational level in Jimma Zone, Ethiopia.","BACKGROUND Analysis of disaggregated national data suggest uneven access to essential maternal healthcare services within countries. This is of concern as it hinders equitable progress in health outcomes. Mounting an effective response requires identification of subnational areas that may be lagging behind. This paper aims to explore spatial variation in maternal healthcare service use at health centre catchment, village and household levels. Spatial correlations of service use with household wealth and women's education levels were also assessed. METHODS Using survey data from 3758 households enrolled in a cluster randomized trial geographical variation in the use of maternity waiting homes (MWH), antenatal care (ANC), delivery care and postnatal care (PNC) was investigated in three districts in Jimma Zone. Correlations of service use with education and wealth levels were also explored among 24 health centre catchment areas using choropleth maps. Global spatial autocorrelation was assessed using Moran's I. Cluster analyses were performed at village and household levels using Getis Ord Gi* and Kulldorf spatial scan statistics to identify cluster locations. RESULTS Significant global spatial autocorrelation was present in ANC use (Moran's I = 0.15, p value = 0.025), delivery care (Moran's I = 0.17, p value = 0.01) and PNC use (Moran's I = 0.31, p value < 0.01), but not MWH use (Moran's I = -0.005, p value = 0.94) suggesting clustering of villages with similarly high (hot spots) and/or low (cold spots) service use. Hot spots were detected in health centre catchments in Gomma district while Kersa district had cold spots. High poverty or low education catchments generally had low levels of service use, but there were exceptions. At village level, hot and cold spots were detected for ANC, delivery care and PNC use. Household-level analyses revealed a primary cluster of elevated MWH-use not detected previously. Further investigation of spatial heterogeneity is warranted. CONCLUSIONS Sub-national variation in maternal healthcare services exists in Jimma Zone. There was relatively higher poverty and lower education in areas where service use cold spots were identified. Re-directing resources to vulnerable sub-groups and locations lagging behind will be necessary to ensure equitable progress in maternal health.",2020,"RESULTS Significant global spatial autocorrelation was present in ANC use (Moran's I = 0.15, p value = 0.025), delivery care (Moran's I = 0.17, p value = 0.01) and PNC use (Moran's I = 0.31, p value < 0.01), but not MWH use (Moran's I = -0.005, p value = 0.94) suggesting clustering of villages with similarly high (hot spots) and/or low (cold spots) service use.","['maternal healthcare service use at health centre catchment, village and household levels', '3758 households enrolled in a cluster randomized trial geographical variation in the use of maternity waiting homes (MWH), antenatal care (ANC), delivery care and postnatal care (PNC) was investigated in three districts in Jimma Zone', 'maternal healthcare service use at subnational level in Jimma Zone, Ethiopia']",[],"['delivery care', 'Global spatial autocorrelation']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0557829', 'cui_str': 'Healthcare services'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C1171257', 'cui_str': 'Delivery care'}, {'cui': 'C0032782', 'cui_str': 'Postpartum care'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}, {'cui': 'C0015024', 'cui_str': 'Ethiopia'}]",[],"[{'cui': 'C1171257', 'cui_str': 'Delivery care'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0814927', 'cui_str': 'Spatial Autocorrelation'}]",3758.0,0.0712674,"RESULTS Significant global spatial autocorrelation was present in ANC use (Moran's I = 0.15, p value = 0.025), delivery care (Moran's I = 0.17, p value = 0.01) and PNC use (Moran's I = 0.31, p value < 0.01), but not MWH use (Moran's I = -0.005, p value = 0.94) suggesting clustering of villages with similarly high (hot spots) and/or low (cold spots) service use.","[{'ForeName': 'Jaameeta', 'Initials': 'J', 'LastName': 'Kurji', 'Affiliation': 'School of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand Crescent, Ottawa, Ontario, K1G 5Z3, Canada. jkurj022@uottawa.ca.'}, {'ForeName': 'Benoit', 'Initials': 'B', 'LastName': 'Talbot', 'Affiliation': 'School of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand Crescent, Ottawa, Ontario, K1G 5Z3, Canada.'}, {'ForeName': 'Gebeyehu', 'Initials': 'G', 'LastName': 'Bulcha', 'Affiliation': 'Jimma Zone Health Office, Jimma Zone, Oromia Region, Jimma, Ethiopia.'}, {'ForeName': 'Kunuz Haji', 'Initials': 'KH', 'LastName': 'Bedru', 'Affiliation': 'Jimma Zone Health Office, Jimma Zone, Oromia Region, Jimma, Ethiopia.'}, {'ForeName': 'Sudhakar', 'Initials': 'S', 'LastName': 'Morankar', 'Affiliation': 'Department of Health, Behaviour & Society, Jimma University, Jimma, Ethiopia.'}, {'ForeName': 'Lakew Abebe', 'Initials': 'LA', 'LastName': 'Gebretsadik', 'Affiliation': 'Department of Health, Behaviour & Society, Jimma University, Jimma, Ethiopia.'}, {'ForeName': 'Muluemebet Abera', 'Initials': 'MA', 'LastName': 'Wordofa', 'Affiliation': 'Department of Population & Family Health, Jimma University, Jimma, Ethiopia.'}, {'ForeName': 'Vivian', 'Initials': 'V', 'LastName': 'Welch', 'Affiliation': 'Centre for Global Health, Bruyere Research Institute, Ottawa, Canada.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Labonte', 'Affiliation': 'School of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand Crescent, Ottawa, Ontario, K1G 5Z3, Canada.'}, {'ForeName': 'Manisha A', 'Initials': 'MA', 'LastName': 'Kulkarni', 'Affiliation': 'School of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand Crescent, Ottawa, Ontario, K1G 5Z3, Canada.'}]",BMC health services research,['10.1186/s12913-020-05572-0'] 2005,32736639,Enhancing healthcare efficiency to achieve the Quadruple Aim: an exploratory study.,"OBJECTIVE Healthcare is battling a conflict between the Quadruple Aims-reducing costs; improving population health, patient experience, and team well-being-and productivity. This quasi-experimental pilot study tested a 2 week intervention aimed to address the Quadruple Aims while improving productivity. Participants were 25 employees and their patients in a primary care clinic. One provider and their team implemented an efficiency-focused intervention that modified work roles and processes focused on utilizing all team members' skills as allowable by applicable licensure restrictions. The five remaining providers and their teams comprised the reference group, who continued patient care as usual. Study outcomes were measured via provider/staff and patient surveys and administrative data. RESULTS In total, 46 team surveys and 156 patient surveys were collected. Clinic output data were retrieved for 467 visits. Compared to the reference team, the intervention team performed better in all Quadruple Aims and productivity measures. The intervention group offered 48% more patient slots than the average reference team. These preliminary results support the feasibility of introducing substantial process changes that show promising improvement in both the Quadruple Aims and productivity. A larger-scale study over a longer time period is needed to confirm findings and examine feasibility and cost-effectiveness.",2020,"Compared to the reference team, the intervention team performed better in all Quadruple Aims and productivity measures.","['In total, 46 team surveys and 156 patient surveys were collected', 'Participants were 25 employees and their patients in a primary care clinic']",[],['provider/staff and patient surveys and administrative data'],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0599987', 'cui_str': 'Employee'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic'}]",[],"[{'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C1292785', 'cui_str': 'Administrative action'}]",25.0,0.0256599,"Compared to the reference team, the intervention team performed better in all Quadruple Aims and productivity measures.","[{'ForeName': 'Bengt B', 'Initials': 'BB', 'LastName': 'Arnetz', 'Affiliation': 'Department of Family Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA. arnetzbe@msu.edu.'}, {'ForeName': 'Courtney M', 'Initials': 'CM', 'LastName': 'Goetz', 'Affiliation': 'Department of Family Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA.'}, {'ForeName': 'Judith E', 'Initials': 'JE', 'LastName': 'Arnetz', 'Affiliation': 'Department of Family Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA.'}, {'ForeName': 'Sukhesh', 'Initials': 'S', 'LastName': 'Sudan', 'Affiliation': 'Department of Family Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'vanSchagen', 'Affiliation': 'Department of Family Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA.'}, {'ForeName': 'Kyle', 'Initials': 'K', 'LastName': 'Piersma', 'Affiliation': 'Trinity Health, Livonia, MI, USA.'}, {'ForeName': 'Fredric', 'Initials': 'F', 'LastName': 'Reyelts', 'Affiliation': 'Mercy Health, Grand Rapids, MI, USA.'}]",BMC research notes,['10.1186/s13104-020-05199-8'] 2006,32736660,Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.,"BACKGROUND Office-based buprenorphine treatment of opioid use disorder (OUD) does not typically include in-person directly observed therapy (DOT), potentially leading to non-adherence. Video DOT technologies may safeguard against this issue and thus enhance likelihood of treatment success. We describe the rationale and protocol for the Trial of Adherence Application for Buprenorphine treatment (TAAB) study, a pilot randomized controlled trial (RCT) to evaluate the effects of video DOT delivered via a smartphone app on office-based buprenorphine treatment outcomes, namely illicit opioid use and retention. METHODS Participants will be recruited from office-based opioid addiction treatment programs in outpatient clinics at two urban medical centers and randomized to either video DOT (intervention) delivered via a HIPAA-compliant, asynchronous, mobile health (mHealth) technology platform, or treatment-as-usual (control). Eligibility criteria are: 18 years or older, prescribed sublingual buprenorphine for a cumulative total of 28 days or less from the office-based opioid treatment program, and able to read and understand English. Patients will be considered ineligible if they are unable or unwilling to use the intervention, provide consent, or complete weekly study visits. All participants will complete 13 in-person weekly visits and be followed via electronic health record data capture at 12- and 24-weeks post-randomization. Data gathered include the following: demographics; current and previous treatment for OUD; self-reported diversion of prescribed buprenorphine; status of their mental and physical health; and self-reported lifetime and past 30-day illicit substance use. Participants provide urine samples at each weekly visit to test for illicit drugs and buprenorphine. The primary outcome is percentage of weekly urines that are negative for opioids over the 12-weeks. The secondary outcome is engagement in treatment at week 12. DISCUSSION Video DOT delivered through mHealth technology platform offers possibility of improving patients' buprenorphine adherence by providing additional structure and accountability. The TAAB study will provide important preliminary estimates of the impact of this mHealth technology for patients initiating buprenorphine, as well as the feasibility of study procedures, thus paving the way for further research to assess feasibility and generate preliminary data for design of a future Phase III trial. Trial Registration ClinicalTrails.gov, NCT03779997, Registered on December 19, 2018.",2020,"We describe the rationale and protocol for the Trial of Adherence Application for Buprenorphine treatment (TAAB) study, a pilot randomized controlled trial (RCT) to evaluate the effects of video DOT delivered via a smartphone app on office-based buprenorphine treatment outcomes, namely illicit opioid use and retention. ","['patients initiating', 'Participants will be recruited from office-based opioid addiction treatment programs in outpatient clinics at two urban medical centers and randomized to either', 'for a cumulative total of 28\xa0days or less from the office-based opioid treatment program, and able to read and understand English', 'Eligibility criteria are: 18\xa0years or older, prescribed', 'opioid use disorder patients receiving office-based']","['Video directly observed therapy intervention', 'sublingual buprenorphine', 'video DOT (intervention) delivered via a HIPAA-compliant, asynchronous, mobile health (mHealth) technology platform, or treatment-as-usual (control', 'buprenorphine', 'Buprenorphine', 'video DOT delivered via a smartphone app']",['percentage of weekly urines that are negative for opioids'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0524662', 'cui_str': 'Opioid dependence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0586740', 'cui_str': 'Able to read'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0872145', 'cui_str': 'Directly Observed Therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0001565', 'cui_str': 'Sublingual route'}, {'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C0600593', 'cui_str': 'Public Law 104-191'}, {'cui': 'C0566588', 'cui_str': 'Compliant'}, {'cui': 'C0439581', 'cui_str': 'Asynchronous'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}]",,0.149029,"We describe the rationale and protocol for the Trial of Adherence Application for Buprenorphine treatment (TAAB) study, a pilot randomized controlled trial (RCT) to evaluate the effects of video DOT delivered via a smartphone app on office-based buprenorphine treatment outcomes, namely illicit opioid use and retention. ","[{'ForeName': 'Zachery A', 'Initials': 'ZA', 'LastName': 'Schramm', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, University of Washington, Mailbox 359780, 325 Ninth Avenue, Seattle, WA, 98104, USA.'}, {'ForeName': 'Brian G', 'Initials': 'BG', 'LastName': 'Leroux', 'Affiliation': 'Department of Biostatistics, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Andrea C', 'Initials': 'AC', 'LastName': 'Radick', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, University of Washington, Mailbox 359780, 325 Ninth Avenue, Seattle, WA, 98104, USA.'}, {'ForeName': 'Alicia S', 'Initials': 'AS', 'LastName': 'Ventura', 'Affiliation': 'Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.'}, {'ForeName': 'Jared W', 'Initials': 'JW', 'LastName': 'Klein', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, University of Washington, Mailbox 359780, 325 Ninth Avenue, Seattle, WA, 98104, USA.'}, {'ForeName': 'Jeffrey H', 'Initials': 'JH', 'LastName': 'Samet', 'Affiliation': 'Department of Community Health Sciences, Boston University School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Saxon', 'Affiliation': 'Center of Excellence in Substance Abuse Treatment and Education, VA Puget Sound Health Care System, Seattle, WA, USA.'}, {'ForeName': 'Theresa W', 'Initials': 'TW', 'LastName': 'Kim', 'Affiliation': 'Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.'}, {'ForeName': 'Judith I', 'Initials': 'JI', 'LastName': 'Tsui', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, University of Washington, Mailbox 359780, 325 Ninth Avenue, Seattle, WA, 98104, USA. tsuij@uw.edu.'}]",Addiction science & clinical practice,['10.1186/s13722-020-00203-9'] 2007,32736776,Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study.,"BACKGROUND The mechanisms surrounding cancer-associated venous thromboembolism (VTE) are not well characterized. AVERT, a randomized placebo controlled thromboprophylaxis study in ambulatory cancer patients, provides a unique opportunity to gain insights into thrombotic mechanism(s). METHODS All available citrated platelet-free plasma samples collected at the point of randomization from individuals enrolled in the AVERT study were evaluated for the expression of D-dimer, soluble P-selectin (sP- selectin), active plasminogen activator inhibitor 1 (aPAI-1), clot lysis time (CLT) and activated factor XIa-C1 inhibitor complex (FXIa-C1). We compared the differential expression of sP-selectin, aPAI-1, CLT and FXIa-C1 among individual tumor types with normal controls. We evaluated the impact of disease type (hematologic versus solid organ malignancy) and stage (metastatic versus non-metastatic) on individual biomarker expression. RESULTS We included 449 AVERT participants in this analysis. Baseline expression of the selected thrombosis biomarkers differed significantly by individual tumor type compared with normal controls. Levels of aPAI-1, CLT, FXIa-C1 and sP-selectin were significantly elevated in individuals with lymphoma compared to individuals with non-metastatic solid organ malignancies (p<0.05). Individuals with metastatic solid organ disease had elevated levels of D-dimer and sP-selectin compared to those with non-metastatic disease (p<0.05). CONCLUSION Among a cohort of ambulatory patients at intermediate to high risk of VTE, these exploratory findings suggest that baseline activation of coagulation and fibrinolysis pathways vary significantly by tumor type and disease stage.",2020,"Levels of aPAI-1, CLT, FXIa-C1 and sP-selectin were significantly elevated in individuals with lymphoma compared to individuals with non-metastatic solid organ malignancies (p<0.05).","['449 AVERT participants in this analysis', 'All available citrated platelet-free plasma samples collected at the point of randomization from individuals enrolled in the AVERT study', 'ambulatory cancer patients', 'cancer patients at risk for venous thromboembolism', 'Individuals with metastatic solid organ disease']","['VTE', 'placebo']","['Levels of aPAI-1, CLT, FXIa-C1 and sP-selectin', 'expression of D-dimer, soluble P-selectin (sP- selectin), active plasminogen activator inhibitor 1 (aPAI-1), clot lysis time (CLT) and activated factor XIa-C1 inhibitor complex (FXIa-C1', 'Baseline expression of the selected thrombosis biomarkers']","[{'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0008857', 'cui_str': 'Citrates'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0444263', 'cui_str': 'Plasma specimen'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0440790', 'cui_str': 'Solid organ'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0066198', 'cui_str': 'methyl 4-azidophenylacetimidate'}, {'cui': 'C0282651', 'cui_str': 'Selectins'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0060323', 'cui_str': 'D-dimer'}, {'cui': 'C0134835', 'cui_str': 'Lymphocyte antigen CD62'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0030190', 'cui_str': 'Plasminogen activator inhibitor-1'}, {'cui': 'C0200464', 'cui_str': 'Fibrinolysin assay, screening'}, {'cui': 'C0015524', 'cui_str': 'Coagulation factor XIa'}, {'cui': 'C1446194', 'cui_str': 'Serum C1 esterase inhibitor antigen level'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",449.0,0.0336838,"Levels of aPAI-1, CLT, FXIa-C1 and sP-selectin were significantly elevated in individuals with lymphoma compared to individuals with non-metastatic solid organ malignancies (p<0.05).","[{'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Ilich', 'Affiliation': 'Department of Medicine, University of North Carolina, Chapel Hill, NC, USA; These authors contributed equally.'}, {'ForeName': 'Vaibhav', 'Initials': 'V', 'LastName': 'Kumar', 'Affiliation': 'Department of Medicine, University of North Carolina, Chapel Hill, NC, USA; These authors contributed equally.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Henderson', 'Affiliation': 'Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'Ranjeeta', 'Initials': 'R', 'LastName': 'Mallick', 'Affiliation': 'Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Canada.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Wells', 'Affiliation': 'Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Canada.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Carrier', 'Affiliation': 'Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Canada.'}, {'ForeName': 'Nigel S', 'Initials': 'NS', 'LastName': 'Key', 'Affiliation': 'Department of Medicine, University of North Carolina, Chapel Hill, NC, USA; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA. Electronic address: nigel_key@med.unc.edu.'}]",Thrombosis research,['10.1016/S0049-3848(20)30394-7'] 2008,32737862,"Effectiveness of virtual reality games for falls, postural oscillations, pain and quality of life of individual HAM/TSP: a randomized, controlled, clinical trial.","People with HTLV-1 associated myelopathy or tropical spastic paraparesis (HAM/TSP) have sensorimotor losses and postural instability, resulting in frequent falls. These findings stimulate the use of exercise protocols associated with postural control. This study investigated the effectiveness of a balance training exercise protocol through a virtual game. This is a randomized crossover clinical trial performed in subjects with imbalance disorders (HAM/TSP). To evaluate postural oscillations by baropodometry (total area, anterior, posterior and lateral projection), the Footwork® system was used and by cinemetry (angle of the body, hip and ankle alignment in the lateral view), the CVMob system. In addition, the Brief Pain Inventory and the WHOQoL Bref were used to measure pain intensity and quality of life. Comparison tests of the averages (intra and inter groups) and correlations were applied considering an alpha of 5% and power of 80%. The study was approved by the Ethics Committee of the Catholic University of Salvador and registered in the Clinical Trials database (NCT02877030). The final sample consisted of 26, predominantly female subjects. An increase in the postural oscillations of the control subjects (p < 0.05), a reduction in the occurrence of falls (p = 0.039) and an improvement in the quality of life of the control-test group (p < 0.05) were observed. Virtual game training did not improve the static balance, promoting an increase in postural oscillations. Immediately after the application of the protocol, there was a reduction in fall occurrence and improvement in the quality of life.",2020,"An increase in the postural oscillations of the control subjects (p < 0.05), a reduction in the occurrence of falls (p = 0.039) and an improvement in the quality of life of the control-test group (p < 0.05) were observed.","['People with HTLV-1 associated myelopathy or tropical spastic paraparesis (HAM/TSP', 'subjects with imbalance disorders (HAM/TSP']","['balance training exercise protocol', 'Virtual game training', 'virtual reality games']","['quality of life', 'static balance', 'falls, postural oscillations, pain and quality of life of individual HAM/TSP', 'postural oscillations', 'fall occurrence', 'pain intensity and quality of life', 'occurrence of falls']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0020094', 'cui_str': 'Human T-lymphotropic virus 1'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0005956', 'cui_str': 'Bone marrow disorder'}, {'cui': 'C0030481', 'cui_str': 'Human T-cell lymphotropic virus 1-associated myelopathy'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0020094', 'cui_str': 'Human T-lymphotropic virus 1'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0005956', 'cui_str': 'Bone marrow disorder'}, {'cui': 'C0030481', 'cui_str': 'Human T-cell lymphotropic virus 1-associated myelopathy'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",,0.0290692,"An increase in the postural oscillations of the control subjects (p < 0.05), a reduction in the occurrence of falls (p = 0.039) and an improvement in the quality of life of the control-test group (p < 0.05) were observed.","[{'ForeName': 'Naiane Araújo', 'Initials': 'NA', 'LastName': 'Patrício', 'Affiliation': 'Doutoranda em Medicina e Saúde pela Universidade Federal da Bahia, Salvador, BA, Brazil. naianearaujopatricio@gmail.com.'}, {'ForeName': 'Diogo Guedes', 'Initials': 'DG', 'LastName': 'Vidal', 'Affiliation': 'Unidade de Investigação em Energia, Ambiente e Saúde (FP-ENAS), Universidade Fernando Pessoa, Porto (Portugal), Colaborador de pesquisa da Escola Bahiana de Medicina e Saúde Pública, Bahia, Brasil.'}, {'ForeName': 'Elen Beatriz', 'Initials': 'EB', 'LastName': 'Pinto', 'Affiliation': 'Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil.'}, {'ForeName': 'Katia Nunes', 'Initials': 'KN', 'LastName': 'Sá', 'Affiliation': 'Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil.'}, {'ForeName': 'Abrahão Fontes', 'Initials': 'AF', 'LastName': 'Baptista', 'Affiliation': 'Universidade Federal do ABC, Sao Bernardo, Sao Paulo, Brazil.'}]",Journal of neurovirology,['10.1007/s13365-020-00880-x'] 2009,32735428,Different Foot Positioning During Calf Training to Induce Portion-Specific Gastrocnemius Muscle Hypertrophy.,"Nunes, JP, Costa, BDV, Kassiano, W, Kunevaliki, G, Castro-e-Souza, P, Rodacki, ALF, Fortes, LS, and Cyrino, ES. Different foot positioning during calf training to induce portion-specific gastrocnemius muscle hypertrophy. J Strength Cond Res 34(8): 2347-2351, 2020-The aim of this study was to compare the changes in gastrocnemius muscle thickness (MT) between conditions such as which foot was pointed outward (FPO), foot was pointed inward (FPI), or foot was pointed forward (FPF). Twenty-two young men (23 ± 4 years) were selected and performed a whole-body resistance training program 3 times per week for 9 weeks, with differences in the exercise specific for calves. The calf-raise exercise was performed unilaterally, in a pin-loaded seated horizontal leg-press machine, in 3 sets of 20-25 repetitions for training weeks 1-3 and 4 sets for weeks 4-9. Each subject's leg was randomly assigned for 1 of the 3 groups according to the foot position: FPO, FPI, and FPF. Measurements with a B-mode ultrasound were performed to assess changes in MT of medial and lateral gastrocnemius heads. After the training period, there were observed increases in MT of both medial (FPO = 8.4%, FPI = 3.8%, and FPF = 5.8%) and lateral (FPO = 5.5%, FPI = 9.1%, and FPF = 6.4%) gastrocnemius heads, and significant differences for magnitude of the gains were observed between FPO and FPI conditions (p < 0.05). Positioning FPO potentiated the increases in MT of the medial gastrocnemius head, whereas FPI provided greater gains for the lateral gastrocnemius head. Our results suggest that head-specific muscle hypertrophy may be obtained selectively for gastrocnemius after 9 weeks of calf training in young male adults.",2020,"Positioning FPO potentiated the increases in MT of the medial gastrocnemius head, whereas FPI provided greater gains for the lateral gastrocnemius head.","['J Strength Cond Res 34(8', 'young male adults', 'Twenty-two young men (23 ± 4 years']","['calf training', 'Different Foot Positioning', 'Calf Training']","['Nunes, JP, Costa, BDV, Kassiano, W, Kunevaliki, G, Castro-e-Souza, P, Rodacki, ALF, Fortes, LS, and Cyrino, ES', 'MT of both medial', 'gastrocnemius muscle thickness (MT']","[{'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0230445', 'cui_str': 'Structure of calf of leg'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0150305', 'cui_str': 'Positioning - therapy'}]","[{'cui': 'C0035561', 'cui_str': 'Bone structure of rib'}, {'cui': 'C1431931', 'cui_str': 'ALF protein, human'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0242691', 'cui_str': 'Gastrocnemius muscle structure'}]",22.0,0.0207449,"Positioning FPO potentiated the increases in MT of the medial gastrocnemius head, whereas FPI provided greater gains for the lateral gastrocnemius head.","[{'ForeName': 'João Pedro', 'Initials': 'JP', 'LastName': 'Nunes', 'Affiliation': '1Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, Brazil; 2Department of Physical Education, Federal University of Paraná, Curitiba, Brazil; and 3Department of Physical Education, Federal University of Paraíba, João Pessoa, Brazil.'}, {'ForeName': 'Bruna D V', 'Initials': 'BDV', 'LastName': 'Costa', 'Affiliation': ''}, {'ForeName': 'Witalo', 'Initials': 'W', 'LastName': 'Kassiano', 'Affiliation': ''}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Kunevaliki', 'Affiliation': ''}, {'ForeName': 'Pâmela', 'Initials': 'P', 'LastName': 'Castro-E-Souza', 'Affiliation': ''}, {'ForeName': 'André L F', 'Initials': 'ALF', 'LastName': 'Rodacki', 'Affiliation': ''}, {'ForeName': 'Leonardo S', 'Initials': 'LS', 'LastName': 'Fortes', 'Affiliation': ''}, {'ForeName': 'Edilson S', 'Initials': 'ES', 'LastName': 'Cyrino', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003674'] 2010,32735501,Efficacy of pramipexole combined with levodopa for Parkinson's disease treatment and their effects on QOL and serum TNF- α levels.,"PURPOSE To investigate the efficacy of combining the dopamine receptor agonist pramipexole with levodopa for Parkinson's disease (PD) treatment and to measure their effects on quality of life and tumor necrosis factor (TNF)-α levels in PD patients. BASIC PROCEDURE In total, 160 PD patients who were admitted to our hospital were equally randomized into a control treatment group (levodopa alone) and the study group (pramipexole combined with levodopa). Both groups were treated for 12 weeks. FINDINGS After treatment, scores from the Unified Parkinson's Disease Rating Scales (1-3), the Hamilton Depression Scale, and the Parkinson's Disease Questionnaire (PDQ-39) were significantly decreased in both groups, whereas Mini-Mental State Examination scores were significantly increased. After treatment, the study group had significantly lower scores for all scales except the Mini-Mental State Examination, for which those who received combined treatment had significantly higher scores than the control group. The incidence of adverse reactions was significantly lower in the study group than in the control group. Furthermore, after treatment, serum TNF-α levels were significantly decreased in both groups compared with pre-treatment levels. CONCLUSION Pramipexole combined with levodopa relieved PD symptoms and improved the quality of life of PD patients, potentially by suppressing serum TNF-α levels.",2020,"After treatment, the study group had significantly lower scores for all scales except the Mini-Mental State Examination, for which those who received combined treatment had significantly higher scores than the control group.","['PD patients', '160 PD patients who were admitted to our hospital', ""Parkinson's disease (PD""]","['dopamine receptor agonist pramipexole with levodopa', 'pramipexole combined with levodopa', 'Pramipexole', 'control treatment group (levodopa alone) and the study group (pramipexole combined with levodopa', 'levodopa']","['quality of life', 'quality of life and tumor necrosis factor (TNF)-α levels', 'Mini-Mental State Examination scores', ""Unified Parkinson's Disease Rating Scales"", ""Hamilton Depression Scale, and the Parkinson's Disease Questionnaire (PDQ-39"", 'QOL and serum TNF- α levels', 'serum TNF-α levels', 'PD symptoms', 'incidence of adverse reactions']","[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0178601', 'cui_str': 'Dopamine receptor agonist'}, {'cui': 'C0074710', 'cui_str': 'Pramipexole'}, {'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2960235', 'cui_str': 'Mini-mental state examination score'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}]",160.0,0.0158009,"After treatment, the study group had significantly lower scores for all scales except the Mini-Mental State Examination, for which those who received combined treatment had significantly higher scores than the control group.","[{'ForeName': 'Jinzhong', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Department of Neurology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Hong', 'Affiliation': 'Department of Neurology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.'}, {'ForeName': 'Zhilong', 'Initials': 'Z', 'LastName': 'Yang', 'Affiliation': 'Department of Neurology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Ding', 'Affiliation': 'Department of Neurology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Ren', 'Affiliation': 'Department of Neurology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.'}]",The Journal of international medical research,['10.1177/0300060520922449'] 2011,32744426,Effectiveness of a couple-based psychosocial intervention on patients with prostate cancer and their partners: A quasi-experimental study.,"AIMS To understand the effectiveness of a couple-based psychosocial information package (PIP) and multimedia psychosocial intervention (MPI) on patients with prostate cancer and their partners. DESIGN A random assignment and quasi-experimental design were used. METHODS From August 2015-March 2018, 103 newly diagnosed patients with prostate cancer and their partners were divided into a control group (CG) (N = 50), PIP group (N = 25) and MPI group (N = 28). The CG received usual care, the PIP group received information manuals and telephone counselling for 6-week and the MPI group received multimedia films and manuals and professional support for 6 weeks. The three groups were posttested 6, 10, 18 and 24 weeks after the pre-test. The outcome measurements included disease appraisals, emotion status, relationship satisfaction, health-related quality of life (HRQOL) and satisfaction with MPI. RESULTS/FINDINGS Partners in the MPI and PIP groups experienced significant improvements in positive and negative affect or mental HRQOL as compared with the CG. The effectiveness of MPI and PIP on negative affect, mental HRQOL, however, were not statistically significant in patients with prostate cancer. Nevertheless, patients were satisfied with the MPI. CONCLUSION Nurses can provide different types of interventions for partners, depending on personal preferences and available resources. IMPACT There is a lack of studies that focus on the effectiveness of couple-based psychosocial intervention on both the patients with prostate cancer and their partners in Asia. Partners in the multimedia psychosocial intervention group and psychosocial information package group experienced improvements in positive affect, negative affect or health-related quality of life as compared with the control group. Patients in both intervention groups experienced similar negative affect and health-related quality of life as compared with the control group. The couple-based psychosocial interventions can be provided by nurses based on partners' preferences and available resources.",2020,"Partners in the multimedia psychosocial intervention group and psychosocial information package group experienced improvements in positive affect, negative affect or health-related quality of life as compared with the control group.","['patients with prostate cancer', 'patients with prostate cancer and their partners', 'From August 2015-March 2018', 'patients with prostate cancer and their partners in Asia', '103 newly diagnosed patients with prostate cancer and their partners']","['control group (CG', 'couple-based psychosocial intervention', 'couple-based psychosocial information package (PIP) and multimedia psychosocial intervention (MPI', 'multimedia psychosocial intervention group and psychosocial information package', 'PIP group received information manuals and telephone counselling for 6-week and the MPI group received multimedia films and manuals and professional support for 6\xa0weeks', 'PIP group']","['positive and negative affect or mental HRQOL', 'disease appraisals, emotion status, relationship satisfaction, health-related quality of life (HRQOL) and satisfaction with MPI', 'positive affect, negative affect or health-related quality of life', 'negative affect and health-related quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0003980', 'cui_str': 'Asia'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C0376478', 'cui_str': 'Multimedium'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0183683', 'cui_str': 'Support'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0376478', 'cui_str': 'Multimedium'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",,0.0174023,"Partners in the multimedia psychosocial intervention group and psychosocial information package group experienced improvements in positive affect, negative affect or health-related quality of life as compared with the control group.","[{'ForeName': 'Ching-Hui', 'Initials': 'CH', 'LastName': 'Chien', 'Affiliation': 'College of Nursing, National Taipei University of Nursing and Health Sciences, Taipei CIty, Taiwan.'}, {'ForeName': 'Hsiao-Jen', 'Initials': 'HJ', 'LastName': 'Chung', 'Affiliation': 'Department of Urology, Taipei Veterans General Hospital, Taipei City, Taiwan.'}, {'ForeName': 'Kuan-Lin', 'Initials': 'KL', 'LastName': 'Liu', 'Affiliation': 'Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Keelung, Kee-Lung City, Taiwan.'}, {'ForeName': 'See-Tong', 'Initials': 'ST', 'LastName': 'Pang', 'Affiliation': 'Division of Urology, Department of Surgery, Chang Memorial Hospital at Linkou, Tao-Yuan City, Taiwan.'}, {'ForeName': 'Chun-Te', 'Initials': 'CT', 'LastName': 'Wu', 'Affiliation': 'Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Keelung, Kee-Lung City, Taiwan.'}, {'ForeName': 'Ying-Hsu', 'Initials': 'YH', 'LastName': 'Chang', 'Affiliation': 'College of Medicine, Chang Gung University, Tao-Yuan City, Taiwan.'}, {'ForeName': 'Xuan-Yi', 'Initials': 'XY', 'LastName': 'Huang', 'Affiliation': 'College of Nursing, National Taipei University of Nursing and Health Sciences, Taipei CIty, Taiwan.'}, {'ForeName': 'Yen-Hwa', 'Initials': 'YH', 'LastName': 'Chang', 'Affiliation': 'Department of Urology, Taipei Veterans General Hospital, Taipei City, Taiwan.'}, {'ForeName': 'Tzu-Ping', 'Initials': 'TP', 'LastName': 'Lin', 'Affiliation': 'Department of Urology, Taipei Veterans General Hospital, Taipei City, Taiwan.'}, {'ForeName': 'Wei-Yu', 'Initials': 'WY', 'LastName': 'Lin', 'Affiliation': 'College of Medicine, Chang Gung University, Tao-Yuan City, Taiwan.'}, {'ForeName': 'Cheng-Keng', 'Initials': 'CK', 'LastName': 'Chuang', 'Affiliation': 'Division of Urology, Department of Surgery, Chang Memorial Hospital at Linkou, Tao-Yuan City, Taiwan.'}]",Journal of advanced nursing,['10.1111/jan.14471'] 2012,32744448,"Reduction of endometriosis-related pain: efficacy of trace elements in a double-blind, randomised, placebo controlled trial.",,2020,,[],['placebo'],[],[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.6278,,"[{'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Mares', 'Affiliation': 'Department of Gynecology and Obstetrics, CHU Nîmes, Nimes, France - pierre.mares@chu-nimes.fr.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Pivano', 'Affiliation': 'Clin-experts, Paris, France.'}, {'ForeName': 'Auréa', 'Initials': 'A', 'LastName': 'Cophignon', 'Affiliation': 'Department of Research and Development, Laboratoires Pronutri, Carros, France.'}, {'ForeName': 'Renaud', 'Initials': 'R', 'LastName': 'Urbinelli', 'Affiliation': 'Clin-experts, Paris, France.'}, {'ForeName': 'Aubert', 'Initials': 'A', 'LastName': 'Agostini-Ferrandes', 'Affiliation': 'Department of Gynecology and Obstetrics, CHU AP-HM Marseille, Marseille, France.'}]",Minerva ginecologica,['10.23736/S0026-4784.20.04538-4'] 2013,32744473,The transformative effects of a participatory social empowerment intervention in the MAISHA intimate partner violence trial in Tanzania.,"Intimate partner violence is an important public health problem, with far-reaching consequences for women's physical and emotional health and social well-being. There is evidence that intimate partner violence is preventable. The MAISHA study, a randomised controlled trial of the impact of a gender training intervention on intimate partner violence for women in Tanzania, found that those who participated in gender training were less likely to report past-year physical violence. As part of the study, a sample of women participated in longitudinal qualitative enquiry. To better understand the processes of change associated with intimate partner violence prevention, we explored narratives from in-depth interviews and focus group discussions with women who had participated in the training. The study drew on feminist political theory on agency and change, which we sought to understand in a setting with high rates of intimate partner violence that a standalone intervention was unlikely to change. The study found that gender training, which seeks to develop political consciousness and transformation, can promote a sense of efficacy amongst participants who feel validated through the collective learning process. Important yet under examined cognitive elements of change processes deserve more attention in the design, delivery and evaluation of violence prevention gender training.",2020,"The MAISHA study, a randomised controlled trial of the impact of a gender training intervention on intimate partner violence for women in Tanzania, found that those who participated in gender training were less likely to report past-year physical violence.","['intimate partner violence for women in Tanzania, found that those who participated in gender training were less likely to report past-year physical violence', 'women participated in longitudinal qualitative enquiry', 'MAISHA intimate partner violence trial in Tanzania', 'participants who feel validated through the collective learning process', 'women who had participated in the training']","['participatory social empowerment intervention', 'standalone intervention', 'gender training intervention']",[],"[{'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0039298', 'cui_str': 'Tanzania'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0476480', 'cui_str': 'Physical violence'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0205556', 'cui_str': 'Qualitative'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C1522240', 'cui_str': 'Process'}]","[{'cui': 'C0679959', 'cui_str': 'Empowerment'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",[],,0.0255634,"The MAISHA study, a randomised controlled trial of the impact of a gender training intervention on intimate partner violence for women in Tanzania, found that those who participated in gender training were less likely to report past-year physical violence.","[{'ForeName': 'Shelley', 'Initials': 'S', 'LastName': 'Lees', 'Affiliation': 'Department of Global and Health Development, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Marchant', 'Affiliation': 'Department of Global and Health Development, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Selestine', 'Affiliation': 'Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania.'}, {'ForeName': 'Gerry', 'Initials': 'G', 'LastName': 'Mshana', 'Affiliation': 'Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania.'}, {'ForeName': 'Saidi', 'Initials': 'S', 'LastName': 'Kapiga', 'Affiliation': 'Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania.'}, {'ForeName': 'Sheila', 'Initials': 'S', 'LastName': 'Harvey', 'Affiliation': 'Department of Global and Health Development, London School of Hygiene and Tropical Medicine, London, UK.'}]","Culture, health & sexuality",['10.1080/13691058.2020.1779347'] 2014,32744483,Hypnotic intervention in people with fibromyalgia: A randomized controlled trial.,"Fibromyalgia affects the quality of life of the patients, as well as their family. It also affects their social, labor, physical, and psychological dynamics. We aimed to evaluate the effectiveness of audio-recorded hypnosis in ameliorating fibromyalgia symptoms. We enrolled 97 individuals with fibromyalgia (mean age: 45 years) and randomly distributed them to two groups (48 in the experimental group and 47 in the control group). Individuals in both groups maintained their standard pharmacological treatment and continued their usual physical or psychological activities. The experimental group received an audio-recorded hypnosis intervention in the first session; subsequently, they received another audio hypnosis session to use for daily practice for a month. We evaluated the pre- and post-intervention pain intensity, pain interference, fatigue intensity, fatigue interference, depressive symptomatology, and satisfaction with life. We found that the self-administered audio-recorded hypnotic intervention significantly decreased the intensity and interference of pain and fatigue, as well as the depressive symptomatology. Audio-recorded clinical hypnosis techniques could provide an effective, practical, and economical alternative for reducing fibromyalgia-related symptoms.",2020,"We found that the self-administered audio-recorded hypnotic intervention significantly decreased the intensity and interference of pain and fatigue, as well as the depressive symptomatology.","['people with fibromyalgia', '97 individuals with fibromyalgia (mean age: 45\xa0years']","['audio-recorded hypnosis', 'Hypnotic intervention', 'self-administered audio-recorded hypnotic intervention', 'audio-recorded hypnosis intervention']","['fibromyalgia symptoms', 'pre- and post-intervention pain intensity, pain interference, fatigue intensity, fatigue interference, depressive symptomatology, and satisfaction with life', 'intensity and interference of pain and fatigue']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0020587', 'cui_str': 'Hypnotherapy'}, {'cui': 'C0020591', 'cui_str': 'Hypnotic agent'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}]","[{'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0376558', 'cui_str': 'Life'}]",97.0,0.0437787,"We found that the self-administered audio-recorded hypnotic intervention significantly decreased the intensity and interference of pain and fatigue, as well as the depressive symptomatology.","[{'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Aravena', 'Affiliation': 'Universidad de Concepción [University of Concepción] , Chile.'}, {'ForeName': 'Felipe E', 'Initials': 'FE', 'LastName': 'García', 'Affiliation': 'Universidad Santo Tomás [Saint Thomas University] , Chile.'}, {'ForeName': 'Arnoldo', 'Initials': 'A', 'LastName': 'Téllez', 'Affiliation': 'Universidad Autónoma de Nuevo León [Autonomous University of Nuevo León] , Monterrey, Mexico.'}, {'ForeName': 'Patricio R', 'Initials': 'PR', 'LastName': 'Arias', 'Affiliation': 'Magister in Instituto de Investigación Conductual [Behavioral Research Institute] , Ecuador.'}]",The American journal of clinical hypnosis,['10.1080/00029157.2020.1742088'] 2015,32744512,Hepatitis B core-related antigen levels predict pegylated interferon-α therapy response in HBeAg-positive chronic hepatitis B.,"BACKGROUND Serum hepatitis B core-related antigen (HBcrAg) levels reflect intrahepatic hepatitis B virus (HBV) replication activity. We aimed to study whether HBcrAg levels predict response to peginterferon (PEG-IFN) treatment in HBeAg positive chronic hepatitis B (CHB) patients. METHODS We studied HBcrAg levels in 222 HBeAg-positive patients treated with PEG-IFN with or without lamivudine for 52 weeks in a global randomized trial and compared kinetics across treatment arms and types of response. Optimal HBcrAg cut-offs for stopping therapy were compared to and combined with the currently recommended HBsAg-based stopping-rules. RESULTS Baseline HBcrAg levels could not discriminate between responders and non-responders (p=0.91). HBcrAg levels of patients responding to PEG-IFN therapy showed a more pronounced on-treatment decline (mean declines 3.4 vs 1.0 log U/mL; p<0.0001), which was sustained until the end of follow-up (mean declines week 3.8 vs. 1.0 log U/mL; p<0.0001). In the PEG-IFN monotherapy group, HBcrAg levels of >8.35 log U/mL at week 24 identified 19 patients (19%) of whom 1 (NPV=95%) achieved a response. The performance of this HBcrAg-based stopping rule alone was not superior to the one based on HBsAg >20,000 IU/mL. Among patients with an HBsAg <20,000 (n=56), 9 (16%) had an HBcrAg >8.35, of whom 8 achieved no response (NPV 89%). CONCLUSIONS HBeAg-positive CHB patients with a response to PEG-IFN therapy achieve a more pronounced HBcrAg decline. HBcrAg levels at week 24 of therapy could be used to identify non-responders in combination with the established HBsAg based stopping-rules.",2020,"The performance of this HBcrAg-based stopping rule alone was not superior to the one based on HBsAg >20,000 IU/mL. Among patients with an HBsAg <20,000 (n=56), 9 (16%) had an HBcrAg >8.35, of whom 8 achieved no response (NPV 89%). ","['222 HBeAg-positive patients treated with', 'HBeAg positive chronic hepatitis B (CHB) patients', 'HBeAg-positive chronic hepatitis B']","['PEG-IFN with or without lamivudine', 'peginterferon (PEG-IFN']",['treatment decline'],"[{'cui': 'C0019167', 'cui_str': 'Hepatitis B e antigen'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0524909', 'cui_str': 'Chronic type B viral hepatitis'}]","[{'cui': 'C0032478', 'cui_str': 'Polyethylene Glycol 400'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0209738', 'cui_str': 'Lamivudine'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}]",,0.0695603,"The performance of this HBcrAg-based stopping rule alone was not superior to the one based on HBsAg >20,000 IU/mL. Among patients with an HBsAg <20,000 (n=56), 9 (16%) had an HBcrAg >8.35, of whom 8 achieved no response (NPV 89%). ","[{'ForeName': 'Boris Jb', 'Initials': 'BJ', 'LastName': 'Beudeker', 'Affiliation': 'Department of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Zwier Ma', 'Initials': 'ZM', 'LastName': 'Groothuismink', 'Affiliation': 'Department of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'de Man', 'Affiliation': 'Department of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Harry LA', 'Initials': 'H', 'LastName': 'Janssen', 'Affiliation': 'Department of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Annemiek A', 'Initials': 'AA', 'LastName': 'van der Eijk', 'Affiliation': 'Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Andre', 'Initials': 'A', 'LastName': 'Boonstra', 'Affiliation': 'Department of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Milan J', 'Initials': 'MJ', 'LastName': 'Sonneveld', 'Affiliation': 'Department of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.'}]",Antiviral therapy,['10.3851/IMP3367'] 2016,32739331,Which brand should be more nervous about nutritional information disclosure: McDonald's or Subway?,"This study examines the health halo and horn effects in the context of two fast food brands commonly associated with healthy and unhealthy food (i.e., Subway and McDonald's). Health halo is consumers' tendency to overestimate the healthiness of certain food categories or items based on a single claim, whereas health horn is the tendency to underestimate it. Specifically, we investigated the moderating effects of nutritional information disclosure and dietary restraint on consumers' behavioral intentions. Two items from the McDonald's and Subway menus each served as stimuli. They represented health halo confirmation (Roast Chicken sandwich) or disconfirmation (Italian Spicy sandwich) and health horn confirmation (Big Mac burger) or disconfirmation (McSpicy Cajun Burger). This study employed a 2 (nutritional information: present vs. absent) × 4 (menu item type: a health halo or horn associated with Subway or McDonald's menu items with favorable and unfavorable nutritional profiles) and 2 (dietary restraint: restrained eaters vs. unrestrained eaters) × 4 (menu item type: a health halo or horn associated with Subway or McDonald's menu items with favorable and unfavorable nutritional profiles) mixed factorial design. Participants were randomly assigned to one of two experimental conditions (nutritional information: present vs. absent) and presented with all four menu items. There was a decrease in behavioral intentions toward all menu items except the one representing health horn disconfirmation. In particular, behavioral intentions were most substantially weakened for the item that entailed a health halo disconfirmation (Italian Spicy sandwich). The findings not only delineate the different practices companies adopt but also underscore the importance of nutritional information disclosure in helping consumers make healthier food choices.",2020,"In particular, behavioral intentions were most substantially weakened for the item that entailed a health halo disconfirmation (Italian Spicy sandwich).","[""consumers' behavioral intentions""]","[""absent)\u202f×\u202f4 (menu item type: a health halo or horn associated with Subway or McDonald's menu items with favorable and unfavorable nutritional profiles) and 2 (dietary restraint: restrained eaters vs. unrestrained eaters"", 'nutritional information disclosure and dietary restraint', ""health halo or horn associated with Subway or McDonald's menu items""]",['behavioral intentions'],"[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0162425', 'cui_str': 'Intention'}]","[{'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0181278', 'cui_str': 'Halo brace'}, {'cui': 'C0019939', 'cui_str': 'Horns'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0524709', 'cui_str': 'Subways'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0035260', 'cui_str': 'Physical restraint'}, {'cui': 'C0012625', 'cui_str': 'Information Disclosure'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0162425', 'cui_str': 'Intention'}]",,0.0167676,"In particular, behavioral intentions were most substantially weakened for the item that entailed a health halo disconfirmation (Italian Spicy sandwich).","[{'ForeName': 'Meeyoung', 'Initials': 'M', 'LastName': 'Joe', 'Affiliation': 'Foodservice Management Lab, Symbiotic Life Tech Research Institute, Yonsei University, Samsung Hall 505, Yonseiro 50, Seoul, Seodaemun-gu, 03722, Republic of Korea. Electronic address: cookie22@yonsei.ac.kr.'}, {'ForeName': 'Seoki', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'School of Hospitality Management, The Pennsylvania State University, 217 Mateer Building University Park, PA, 16802, USA. Electronic address: leeseoki@psu.edu.'}, {'ForeName': 'Sunny', 'Initials': 'S', 'LastName': 'Ham', 'Affiliation': 'Dept. of Food & Nutrition, Foodservice Management Lab, Symbiotic Life Tech Research Institute, Yonsei University, Samsung Hall 510, Yonseiro 50, Seoul, Seodaemun-gu, 03722, Republic of Korea. Electronic address: sham2@yonsei.ac.kr.'}]",Appetite,['10.1016/j.appet.2020.104805'] 2017,32739355,Exclusive endocrine therapy or partial breast irradiation for women aged ≥70  years with luminal A-like early stage breast cancer (NCT04134598 - EUROPA): Proof of concept of a randomized controlled trial comparing health related quality of life by patient reported outcome measures.,"BACKGROUND Postoperative radiation therapy after breast conserving surgery in the older adult population is a matter of debate; although radiation therapy was shown to benefit these patients concerning local disease control, the absolute benefit was small and potentially negligible. Partial breast irradiation has been introduced as an alternative treatment approach for low-risk patients. Older adult patients with early breast cancer constitute a unique population with regards to prognosis and potential comorbidities, thus minimizing treatment to maintain health-related quality of life (HRQoL) without compromising survival is extremely important. Estimates of the patient's risk of benefit and/or harm with treatment should be performed together with an assessment of baseline comorbidities, life expectancy, and care preferences. Published data suggest that radiation therapy or endocrine therapy alone resulted in excellent disease control in older women with early breast cancer, and that the combination of both treatments has less incremental benefit than expected. Conversely, the toxicity profile of endocrine therapy is well known, often significantly impacting long term HRQoL of these potentially frail patients. METHODS Patients older than 70  years receiving breast conserving surgery with T1N0, Luminal A-like tumors will be randomized to receive partial breast irradiation-alone or endocrine therapy-alone. The main objectives are to determine patient reported outcome measures in terms of HRQoL, as assessed by the EORTC QLQ-C30 using the global health status of patients, and to demonstrate a non-inferior local control rate between arms. Secondary endpoints are represented by individual scales from QLQ-C30 and module QLQ-BR45 scores; ELD14 questionnaire; geriatric COre DatasEt assessment; distant control rate, adverse events rates, breast cancer specific, and overall survival. DISCUSSION The EUROPA trial is a new randomized trial focused on older adults (≥70  years) affected by good prognosis primary breast cancer. Our assumption is that postoperative radiation therapy-alone avoids the long-term toxicity of endocrine therapy and favorably impacts on HRQoL in this population. In the current report we present the trial's background and methods, focusing on perspectives in the field of precision medicine. TRIAL REGISTRATION The trial is registered with ClinicalTrial.gov Identifier NCT04134598 / EUROPA trial.",2020,"Published data suggest that radiation therapy or endocrine therapy alone resulted in excellent disease control in older women with early breast cancer, and that the combination of both treatments has less incremental benefit than expected.","['Patients older than 70\u202f years receiving breast conserving surgery with T1N0, Luminal A-like tumors', 'older women with early breast cancer', 'Older adult patients with early breast cancer', 'low-risk patients', 'older adults (≥70 \u202fyears) affected by good prognosis primary breast cancer', 'women aged ≥70 \u202fyears with luminal A-like early stage breast cancer (NCT04134598 - EUROPA']","['Postoperative radiation therapy', 'Partial breast irradiation', 'partial breast irradiation-alone or endocrine therapy-alone', 'Exclusive endocrine therapy or partial breast irradiation', 'radiation therapy or endocrine therapy alone']","['toxicity profile', 'individual scales from QLQ-C30 and module QLQ-BR45 scores; ELD14 questionnaire; geriatric COre DatasEt assessment; distant control rate, adverse events rates, breast cancer specific, and overall survival', 'excellent disease control']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0917927', 'cui_str': 'Breast conserving surgery'}, {'cui': 'C0699493', 'cui_str': 'Luminal'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0278250', 'cui_str': 'Prognosis good'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0242751', 'cui_str': 'Europa'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}]","[{'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0150098', 'cui_str': 'Data Set'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0443203', 'cui_str': 'Distant'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",,0.197402,"Published data suggest that radiation therapy or endocrine therapy alone resulted in excellent disease control in older women with early breast cancer, and that the combination of both treatments has less incremental benefit than expected.","[{'ForeName': 'Icro', 'Initials': 'I', 'LastName': 'Meattini', 'Affiliation': 'Department of Experimental and Clinical Biomedical Sciences ""M. Serio"", University of Florence, Florence, Italy; Azienda Ospedaliero Universitaria Careggi, Florence, Italy. Electronic address: icro.meattini@unifi.it.'}, {'ForeName': 'Philip M P', 'Initials': 'PMP', 'LastName': 'Poortmans', 'Affiliation': 'Iridium Kankernetwerk, Wilrijk-Antwerp, Belgium; University of Antwerp, Faculty of Medicine and Health Sciences, Wilrijk-Antwerp, Belgium.'}, {'ForeName': 'Livia', 'Initials': 'L', 'LastName': 'Marrazzo', 'Affiliation': 'Azienda Ospedaliero Universitaria Careggi, Florence, Italy.'}, {'ForeName': 'Isacco', 'Initials': 'I', 'LastName': 'Desideri', 'Affiliation': 'Department of Experimental and Clinical Biomedical Sciences ""M. Serio"", University of Florence, Florence, Italy; Azienda Ospedaliero Universitaria Careggi, Florence, Italy.'}, {'ForeName': 'Etienne', 'Initials': 'E', 'LastName': 'Brain', 'Affiliation': 'Institut Curie, Hopital René Huguenin, Saint-Cloud, France.'}, {'ForeName': 'Marije', 'Initials': 'M', 'LastName': 'Hamaker', 'Affiliation': 'Diakonessenhuis, Utrecht, the Netherlands.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Lambertini', 'Affiliation': 'Breast Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa, Genoa, Italy.'}, {'ForeName': 'Guido', 'Initials': 'G', 'LastName': 'Miccinesi', 'Affiliation': 'Istituto per lo Studio, la Prevenzione e la Rete Oncologica (ISPRO), Florence, Italy.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Russell', 'Affiliation': 'The Netherland Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Calogero', 'Initials': 'C', 'LastName': 'Saieva', 'Affiliation': 'Istituto per lo Studio, la Prevenzione e la Rete Oncologica (ISPRO), Florence, Italy.'}, {'ForeName': 'Vratislav', 'Initials': 'V', 'LastName': 'Strnad', 'Affiliation': 'Universitatklinikum Erlangen, Erlangen, Germany.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Visani', 'Affiliation': 'Department of Experimental and Clinical Biomedical Sciences ""M. Serio"", University of Florence, Florence, Italy; Azienda Ospedaliero Universitaria Careggi, Florence, Italy.'}, {'ForeName': 'Orit', 'Initials': 'O', 'LastName': 'Kaidar-Person', 'Affiliation': 'Sheba Tel Hashomer, Ramat Gan, Israel.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Livi', 'Affiliation': 'Department of Experimental and Clinical Biomedical Sciences ""M. Serio"", University of Florence, Florence, Italy; Azienda Ospedaliero Universitaria Careggi, Florence, Italy.'}]",Journal of geriatric oncology,['10.1016/j.jgo.2020.07.013'] 2018,32739411,Apple polyphenol-rich drinks dose-dependently decrease early-phase postprandial glucose concentrations following a high-carbohydrate meal: A randomised controlled trial in healthy adults and in vitro studies.,"BACKGROUND Previous research demonstrated that a high dose of phlorizin-rich apple extract (AE) can markedly inhibit early-phase postprandial glycemia, but efficacy of lower doses of the AE is unclear. OBJECTIVE To determine whether lower AE doses reduce early-phase postprandial glycemia in healthy adults and investigate mechanisms. DESIGN In a randomised, controlled, double-blinded, cross-over acute trial, drinks containing 1.8 g (HIGH), 1.35 g (MED), 0.9 g (LOW), or 0 g (CON) of a phlorizin-rich AE were consumed before 75 g starch/sucrose meal. Postprandial blood glucose, insulin, C-peptide, glucose-dependent insulinotropic polypeptide (GIP) and polyphenol metabolites concentrations were measured 0-240 min, acetaminophen concentrations to assess gastric emptying rate, and 24 h urinary glucose excretion. Effects of AE on intestinal glucose transport were investigated in Caco-2/TC7 cells. RESULTS AE significantly reduced plasma glucose iAUC 0-30 min at all doses: mean differences (95% CI) relative to CON were-15.6 (-23.3, -7.9), -11.3 (-19.6, -3.0) and-8.99 (-17.3, -0.7) mmol/L/min for HIGH, MEDIUM and LOW respectively, delayed T max (HIGH, MEDIUM and LOW 45 min vs. CON 30 min), but did not lower C max . Similar dose-dependent treatment effects were observed for insulin, C-peptide, and GIP. Gastric emptying rates and urinary glucose excretion did not differ. Serum phloretin, quercetin and epicatechin metabolites were detected postprandially. A HIGH physiological AE dose equivalent decreased total glucose uptake by 48% in Caco-2/TC7 cells. CONCLUSIONS Phlorizin-rich AE, even at a low dose, can slightly delay early-phase glycaemia without affecting peak and total glycaemic response.",2020,"RESULTS AE significantly reduced plasma glucose iAUC 0-30 min at all doses: mean differences (95% CI) relative to CON were-15.6 (-23.3, -7.9), -11.3 (-19.6, -3.0)",['healthy adults'],"['Apple polyphenol-rich drinks', 'phlorizin-rich apple extract (AE', 'AE', 'phlorizin-rich AE were consumed before 75 g starch/sucrose meal']","['Postprandial blood glucose, insulin, C-peptide, glucose-dependent insulinotropic polypeptide (GIP) and polyphenol metabolites concentrations', 'gastric emptying rate, and 24 h urinary glucose excretion', 'total glucose uptake', 'Serum phloretin, quercetin and epicatechin metabolites', 'Gastric emptying rates and urinary glucose excretion', 'total glycaemic response', 'insulin, C-peptide, and GIP', 'early-phase postprandial glucose concentrations', 'plasma glucose iAUC', 'delayed T max ', 'intestinal glucose transport']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0003625', 'cui_str': 'Malus'}, {'cui': 'C0071649', 'cui_str': 'Polyphenol'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0031562', 'cui_str': 'Phlorhizin'}, {'cui': 'C3257517', 'cui_str': 'Apple extract'}, {'cui': 'C0038179', 'cui_str': 'Starch'}, {'cui': 'C0038636', 'cui_str': 'Sucrose'}, {'cui': 'C1998602', 'cui_str': 'Meals'}]","[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}, {'cui': 'C0017132', 'cui_str': 'Gastric inhibitory polypeptide'}, {'cui': 'C0071649', 'cui_str': 'Polyphenol'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0031560', 'cui_str': 'Phloretin'}, {'cui': 'C0034392', 'cui_str': 'Quercetin'}, {'cui': 'C0014485', 'cui_str': '(-)-Epicatechin'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0427743', 'cui_str': 'Glucose concentration, test strip measurement'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0005528', 'cui_str': 'Biological transport'}]",,0.233603,"RESULTS AE significantly reduced plasma glucose iAUC 0-30 min at all doses: mean differences (95% CI) relative to CON were-15.6 (-23.3, -7.9), -11.3 (-19.6, -3.0)","[{'ForeName': 'E J', 'Initials': 'EJ', 'LastName': 'Prpa', 'Affiliation': ""Department of Nutritional Sciences, Faculty of Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, UK.""}, {'ForeName': 'C P', 'Initials': 'CP', 'LastName': 'Corpe', 'Affiliation': ""Department of Nutritional Sciences, Faculty of Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, UK.""}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Atkinson', 'Affiliation': ""Department of Nutritional Sciences, Faculty of Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, UK.""}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Blackstone', 'Affiliation': ""Department of Nutritional Sciences, Faculty of Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, UK.""}, {'ForeName': 'E S', 'Initials': 'ES', 'LastName': 'Leftley', 'Affiliation': ""Department of Nutritional Sciences, Faculty of Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, UK.""}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Parekh', 'Affiliation': ""Department of Nutritional Sciences, Faculty of Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, UK.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Philo', 'Affiliation': 'Quadram Institute Bioscience, Norwich Research Park, Norwich, UK.'}, {'ForeName': 'P A', 'Initials': 'PA', 'LastName': 'Kroon', 'Affiliation': 'Quadram Institute Bioscience, Norwich Research Park, Norwich, UK.'}, {'ForeName': 'W L', 'Initials': 'WL', 'LastName': 'Hall', 'Affiliation': ""Department of Nutritional Sciences, Faculty of Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, UK. Electronic address: wendy.hall@kcl.ac.uk.""}]",The Journal of nutritional biochemistry,['10.1016/j.jnutbio.2020.108466'] 2019,32739495,Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis.,"BACKGROUND/AIMS Despite high mortality of alcohol-associaed hepatitis, there has been limited advancement in treatment strategies. Defeat Alcoholic Steatohepatitis (DASH) is a multicenter, randomized, double-blind controlled trial whose primary objective was to evaluate the safety and efficacy of a novel combination of 3 drugs targeting different perturbations in AH. METHODS Severe AH was diagnosed by liver biopsy or clinical and biochemical criteria and model for end stage liver disease (MELD) score ≥ 20stratified by MELD scores (20-25 and ≥ 26) and randomized to a combination of an interleukin receptor 1 antagonist, Anakinra(100 mg daily for 14 days) to suppress acute inflammation, pentoxifylline (400 mg three times a day for 28 days) to prevent hepatorenal syndrome, and zinc sulfate (220 mg orally once daily for 6 months) or the standard of care therapy including methylprednisolone 32 mg orally once daily for 28 days. The primary efficacy outcome was the unadjusted log-rank test of the Kaplan-Meier survival estimates for the two treatment groups at 180 days. RESULTS Between July 2012 to March 2018, 500 subjects with severe AH were screened of which 104 subjects were enrolled with MELD score of 25.6 ± 3.2 (20.0-35.0) in the investigational arm and 25.8 ± 4.5 (20.0-40.0) in the standard of care arm. Causes of screen failures included not meeting eligibility criteria (n = 347), declining to participate (n = 39), and other reasons (n = 10). CONCLUSIONS Data from the DASH consortium studies will determine if a combination of drugs targeting multiple mechanisms of injury in the severe AH will improve clinical outcomes.",2020,"The primary efficacy outcome was the unadjusted log-rank test of the Kaplan-Meier survival estimates for the two treatment groups at 180 days. ","['Between July 2012 to March 2018, 500 subjects with severe AH were screened of which 104 subjects were enrolled with MELD score of 25.6\u202f±\u202f3.2 (20.0-35.0) in the investigational arm and 25.8\u202f±\u202f4.5 (20.0-40.0) in the standard of care arm', 'Severe AH was diagnosed by liver biopsy or clinical and biochemical criteria and model for end stage liver disease (MELD) score\u202f≥']","['interleukin receptor 1 antagonist, Anakinra(100\u202fmg daily for 14\u202fdays) to suppress acute inflammation, pentoxifylline', 'zinc sulfate (220\u202fmg orally once daily for 6\u202fmonths) or the standard of care therapy including methylprednisolone']","['safety and efficacy', 'unadjusted log-rank test of the Kaplan-Meier survival estimates']","[{'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C4048785', 'cui_str': 'Model for end stage liver disease score'}, {'cui': 'C4517687', 'cui_str': '3.2'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C3844009', 'cui_str': '4.5'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0193388', 'cui_str': 'Biopsy of liver'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C3826979', 'cui_str': 'Model for end-stage liver disease'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0206553', 'cui_str': 'Interleukin Receptor'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1260953', 'cui_str': 'Suppressed'}, {'cui': 'C0333361', 'cui_str': 'Acute inflammation'}, {'cui': 'C0030899', 'cui_str': 'Pentoxifylline'}, {'cui': 'C0078794', 'cui_str': 'Zinc Sulfate'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0667477', 'cui_str': 'TNFRSF11A protein, human'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}]",104.0,0.725088,"The primary efficacy outcome was the unadjusted log-rank test of the Kaplan-Meier survival estimates for the two treatment groups at 180 days. ","[{'ForeName': 'Srinivasan', 'Initials': 'S', 'LastName': 'Dasarathy', 'Affiliation': 'Cleveland Clinic, USA. Electronic address: dasaras@ccf.org.'}, {'ForeName': 'Mack C', 'Initials': 'MC', 'LastName': 'Mitchell', 'Affiliation': 'University of Texas at Southwestern University, USA.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Barton', 'Affiliation': 'University of Massachusetts, USA.'}, {'ForeName': 'Craig J', 'Initials': 'CJ', 'LastName': 'McClain', 'Affiliation': 'University of Louisville, USA.'}, {'ForeName': 'Gyongyi', 'Initials': 'G', 'LastName': 'Szabo', 'Affiliation': 'Harvard Medical School & Beth Israel Deaconess Medical Center, USA.'}, {'ForeName': 'Laura E', 'Initials': 'LE', 'LastName': 'Nagy', 'Affiliation': 'Cleveland Clinic, USA.'}, {'ForeName': 'Svetlana', 'Initials': 'S', 'LastName': 'Radaeva', 'Affiliation': 'National Institute of Alcohol Abuse and Alcoholism, USA.'}, {'ForeName': 'Arthur J', 'Initials': 'AJ', 'LastName': 'McCullough', 'Affiliation': 'Cleveland Clinic, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106094'] 2020,32739509,The RHyAS study Reducing Hyperpigmentation After Sclerotherapy a randomized clinical trial.,"INTRODUCTION The use of sclerotherapy for the treatment of varicose veins is one of the most common medical procedures performed in the western world, and hyperpigmentation is one of the most frequent, dreaded, minor adverse event. There has recently been some interest in investigating the inflammatory response of the local endothelium after sclerotherapy and the possible benefits of venoactive drugs due to their pleiotropic properties. The aim of this study is to evaluate whether adding a venoactive drug (sulodexide) to the standard sclerotherapy treatment protocol for patients with varicose veins can reduce the occurrence of post-sclerotherapy hyperpigmentation. METHODS We carried out a prospective, multicentre, randomized, controlled trial, with a parallel-group design. It included 720 patients with telangiectasia, reticular or varicose veins who were candidates for sclerotherapy. Patients with reflux in deep system or saphenous veins were excluded. Group A consisted of 354 patients, who received an oral dose of sulodexide twice a day for seven days prior to scheduled sclerotherapy. The treatment then continued for three months. Group B consisted of 366 patients, who received the standard sclerotherapy protocol. Polidocanol was used as the sclerosing agent and 20-30mmhg compression stockings were used in both groups for seven days. Control photographs were taken, and a follow-up examination took place after 1 and 3 months. Computer software was used to analyse the treated area for incidence of hyperpigmentation, total area of hyperpigmentation, skin tone increase in the hyperpigmented area, vein disappearance, and incidence of major bleeding. The sample size was calculated to give a statistical power of 80%. Student's t-test and the Chi-square test were used for comparative analyses, as appropriate. The level of significance was set at < 0.05 RESULTS: A total of 609 patients completed the 3-month follow-up: 312 in group A and 297 in group B. After 1 month, the incidence of hyperpigmentation was 8.7% in group A and 14.8% in group B (p=0.01). Group A developed an average area of hyperpigmentation of 10.7% compared with 18.2% in group B (p=0.01), and the skin tone of the hyperpigmented area was lower in group A than in group B (p=0.02). However, the latter difference was not significant after three months. The overall vein disappearance rate was similar in both groups. CONCLUSIONS Our analysis shows that, by adding a venoactive drug (sulodexide) to the standard sclerotherapy protocol, the occurrence of hyperpigmentation is reduced without affecting the desired therapeutic vein elimination response.",2020,"Group A developed an average area of hyperpigmentation of 10.7% compared with 18.2% in group B (p=0.01), and the skin tone of the hyperpigmented area was lower in group A than in group B (p=0.02).","['609 patients completed the 3-month follow-up: 312 in group A and 297 in group', 'Patients with reflux in deep system or saphenous veins were excluded', '354 patients', 'patients with varicose veins', '720 patients with telangiectasia, reticular or varicose veins who were candidates for sclerotherapy']","['venoactive drug (sulodexide', 'standard sclerotherapy protocol', 'standard sclerotherapy treatment protocol', 'sulodexide', 'Polidocanol', 'sclerotherapy']","['incidence of hyperpigmentation, total area of hyperpigmentation, skin tone increase in the hyperpigmented area, vein disappearance, and incidence of major bleeding', 'incidence of hyperpigmentation', 'average area of hyperpigmentation', 'skin tone of the hyperpigmented area', 'overall vein disappearance rate', 'Hyperpigmentation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C4517706', 'cui_str': '312'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4317146', 'cui_str': 'Acid reflux'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0036186', 'cui_str': 'Saphenous vein structure'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0042345', 'cui_str': 'Phlebectasia'}, {'cui': 'C4517865', 'cui_str': '720'}, {'cui': 'C0039446', 'cui_str': 'Telangiectasis'}, {'cui': 'C0439739', 'cui_str': 'Reticular'}, {'cui': 'C0036435', 'cui_str': 'Injection of sclerosing agent'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0061450', 'cui_str': 'sulodexide'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0036435', 'cui_str': 'Injection of sclerosing agent'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0071330', 'cui_str': 'polidocanol'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0162834', 'cui_str': 'Hyperpigmentation'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0037290', 'cui_str': 'Skin pigmentation'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",720.0,0.0554183,"Group A developed an average area of hyperpigmentation of 10.7% compared with 18.2% in group B (p=0.01), and the skin tone of the hyperpigmented area was lower in group A than in group B (p=0.02).","[{'ForeName': 'Alejandro Jose Gonzalez', 'Initials': 'AJG', 'LastName': 'Ochoa', 'Affiliation': 'HGZ #12 Instituto Mexicano Seguro Social, San Luis R.C., Sonora, Mexico; CLINEDEM, San Luis R.C., Sonora, Mexico.'}, {'ForeName': 'Joaquín', 'Initials': 'J', 'LastName': 'Carrillo', 'Affiliation': 'Instituto Nacional Seguridad Social y de Servicio Trabajadores del Estado, Mexicali, Baja California, Mexico.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Manríquez', 'Affiliation': 'Instituto Nacional Seguridad Social y de Servicio Trabajadores del Estado, Mexicali, Baja California, Mexico.'}, {'ForeName': 'Flavio', 'Initials': 'F', 'LastName': 'Manrique', 'Affiliation': 'Hospital General Tijuana, Tijuana, Baja California, Mexico.'}, {'ForeName': 'Alejandro Nuricumbo', 'Initials': 'AN', 'LastName': 'Vazquez', 'Affiliation': 'Instituto Seguridad Social y de Servicio Trabajadores del Estado Baja California, Mexicali, Baja California, Mexico.'}]",Journal of vascular surgery. Venous and lymphatic disorders,['10.1016/j.jvsv.2020.06.019'] 2021,32739537,Percutaneous complete revascularization strategies using sirolimus-eluting biodegradable polymer-coated stents in patients presenting with acute coronary syndrome and multivessel disease: Rationale and design of the BIOVASC trial.,"BACKGROUND Complete revascularization in patients with an acute coronary syndrome and multivessel disease is superior compared to culprit-only treatment. However, it is unknown whether direct complete or staged complete revascularization should be pursued. METHODS The BIOVASC study is an investigator-initiated, prospective, multicenter, randomized, 2-arm, international, open-label, noninferiority trial. We will randomize 1,525 patients 1:1 to immediate complete revascularization (experimental arm) or culprit-only plus staged complete revascularization (control arm). Patients will be enrolled in approximately 30 sites in Belgium, Italy, the Netherlands, and Spain. The primary end point is a composite of all-cause mortality, nonfatal myocardial infarction, any unplanned ischemia-driven revascularization (excluding staged procedures in the control arm at the predetermined time), and cerebrovascular events (MACCE) at 1 year post index procedure. CONCLUSIONS The BIOVASC study aims to further refine the treatment algorithm for acute coronary syndrome patients with multivessel disease in terms of optimal timing for complete revascularization (Clinicaltrials.gov NCT03621501).",2020,The BIOVASC study aims to further refine the treatment algorithm for acute coronary syndrome patients with multivessel disease in terms of optimal timing for complete revascularization (Clinicaltrials.gov NCT03621501).,"['acute coronary syndrome patients with multivessel disease', 'patients presenting with acute coronary syndrome and multivessel disease', 'patients with an acute coronary syndrome and multivessel disease', '1,525 patients 1:1 to', 'Patients will be enrolled in approximately 30 sites in Belgium, Italy, the Netherlands, and Spain']","['immediate complete revascularization (experimental arm) or culprit-only plus staged complete revascularization (control arm', 'sirolimus-eluting biodegradable polymer-coated stents']","['composite of all-cause mortality, nonfatal myocardial infarction, any unplanned ischemia-driven revascularization (excluding staged procedures in the control arm at the predetermined time), and cerebrovascular events (MACCE']","[{'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0004950', 'cui_str': 'Belgium'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C0037747', 'cui_str': 'Spain'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0072980', 'cui_str': 'Sirolimus'}, {'cui': 'C0032521', 'cui_str': 'Polymer'}, {'cui': 'C0453946', 'cui_str': 'Coat'}, {'cui': 'C0038257', 'cui_str': 'Stent'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",1525.0,0.0551991,The BIOVASC study aims to further refine the treatment algorithm for acute coronary syndrome patients with multivessel disease in terms of optimal timing for complete revascularization (Clinicaltrials.gov NCT03621501).,"[{'ForeName': 'Wijnand K', 'Initials': 'WK', 'LastName': 'den Dekker', 'Affiliation': 'Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Thoraxcenter, Rotterdam, the Netherlands. Electronic address: w.dendekker@erasmusmc.nl.'}, {'ForeName': 'Nicolas M', 'Initials': 'NM', 'LastName': 'Van Mieghem', 'Affiliation': 'Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Thoraxcenter, Rotterdam, the Netherlands.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Bennett', 'Affiliation': 'Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Manel', 'Initials': 'M', 'LastName': 'Sabate', 'Affiliation': 'Cardiovascular institute, Hospital Clinic University of Barcelona, IDIBAPS, Barcelona, Spain.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Esposito', 'Affiliation': 'Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Rutger J', 'Initials': 'RJ', 'LastName': 'van Bommel', 'Affiliation': 'Department of Cardiology, Tergooi Blaricum, Blaricum, the Netherlands.'}, {'ForeName': 'Joost', 'Initials': 'J', 'LastName': 'Daemen', 'Affiliation': 'Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Thoraxcenter, Rotterdam, the Netherlands.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Vrolix', 'Affiliation': 'Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Cummins', 'Affiliation': 'Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Thoraxcenter, Rotterdam, the Netherlands.'}, {'ForeName': 'Mattie J', 'Initials': 'MJ', 'LastName': 'Lenzen', 'Affiliation': 'Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Thoraxcenter, Rotterdam, the Netherlands.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Boersma', 'Affiliation': 'Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Thoraxcenter, Rotterdam, the Netherlands.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Zijlstra', 'Affiliation': 'Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Thoraxcenter, Rotterdam, the Netherlands.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Diletti', 'Affiliation': 'Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Thoraxcenter, Rotterdam, the Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American heart journal,['10.1016/j.ahj.2020.06.006'] 2022,32739548,ERAS protocol with respiratory prehabilitation versus conventional perioperative protocol in elective gastrectomy- a randomized controlled trial.,"BACKGROUND Several studies have investigated the efficacy of enhanced recovery programs in patients undergoing gastrectomy. The role of prehabilitation in these programs has not been evaluated in this subset of patients. This study incorporated incentive spirometry as a type of respiratory prehabilitation in the Enhanced Recovery After Surgery (ERAS) protocol for gastrectomy. METHODS In this single-center, prospective, open-labeled randomized controlled trial, 58 patients were randomized into two groups - a conventional perioperative care group and an ERAS group. The patients in the ERAS group received a supervised regimen of preoperative volume-oriented incentive spirometry as respiratory prehabilitation in addition to other ERAS care elements. The length of hospitalization (LOH) was assessed as the primary outcome, while the postoperative peak expiratory flow rate (PEFR) and the incidence of surgical and pulmonary complications were the secondary outcomes. RESULTS The patients in the ERAS group had a shorter median LOH compared to the conventional group (11 days vs 13 days, p = 0.003). The patients in the ERAS group also had smaller fall in postoperative PEFR from baseline, which was significant on the second postoperative day (p = 0.011). None of the patients were found to have anastomotic leaks. The incidence of surgical complications was comparable between the groups (p = 0.137). CONCLUSION ERAS protocol reduced the duration of hospitalization without increasing the complications compared to conventional perioperative protocol. Respiratory prehabilitation in the form of a supervised schedule of incentive spirometry helped in the preservation of lung functions in the postoperative period.",2020,"The patients in the ERAS group had a shorter median LOH compared to the conventional group (11 days vs 13 days, p = 0.003).","['patients undergoing gastrectomy', '58 patients']","['supervised regimen of preoperative volume-oriented incentive spirometry as respiratory prehabilitation in addition to other ERAS care elements', 'conventional perioperative care group and an ERAS']","['postoperative PEFR', 'length of hospitalization (LOH', 'incidence of surgical complications', 'postoperative peak expiratory flow rate (PEFR) and the incidence of surgical and pulmonary complications', 'anastomotic leaks', 'shorter median LOH', 'duration of hospitalization']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017118', 'cui_str': 'Gastrectomy'}]","[{'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0454512', 'cui_str': 'Incentive spirometry'}, {'cui': 'C5192101', 'cui_str': 'Prehabilitation'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C5197734', 'cui_str': 'Enhanced Postsurgical Recovery'}, {'cui': 'C0013879', 'cui_str': 'Chemical element'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0150706', 'cui_str': 'Perioperative care'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030735', 'cui_str': 'Peak expiratory flow rate'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0524869', 'cui_str': 'Heterozygosity, Loss of'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0919691', 'cui_str': 'Anastomotic leak'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]",58.0,0.0386538,"The patients in the ERAS group had a shorter median LOH compared to the conventional group (11 days vs 13 days, p = 0.003).","[{'ForeName': 'Nagalakshmi', 'Initials': 'N', 'LastName': 'Swaminathan', 'Affiliation': 'Department of Anaesthesiology & Critical Care, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, 605006, India.'}, {'ForeName': 'Pankaj', 'Initials': 'P', 'LastName': 'Kundra', 'Affiliation': 'Department of Anaesthesiology & Critical Care, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, 605006, India. Electronic address: p_kundra@hotmail.com.'}, {'ForeName': 'Ramya', 'Initials': 'R', 'LastName': 'Ravi', 'Affiliation': 'Department of Anaesthesiology & Critical Care, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, 605006, India.'}, {'ForeName': 'Vikram', 'Initials': 'V', 'LastName': 'Kate', 'Affiliation': 'Department of Surgery, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, 605006, India.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2020.07.027'] 2023,32739562,Health Information Preferences and Curability Beliefs Among Patients with Advanced Cancer.,"CONTEXT Accurate prognostic understanding is associated with increased advance care planning, symptom control, and patient autonomy in oncology. The impact of prognostic understanding on patients' health and prognostic information preferences (HIPs) is unknown and has important implications for healthcare communication. OBJECTIVES The present study: 1) characterized the HIPs of patients with advanced cancer; 2) examined differences in HIPs between patients with varying curability beliefs and; 3) identified differences in the characteristics and psychological well-being of patients with varying curability beliefs. METHODS This cross-sectional study utilized a secondary data analysis of baseline data (pre-randomization) for patients enrolled in a large randomized, controlled psychotherapy trial. 206 participants were recruited from outpatient clinics at a single facility. INCLUSION CRITERIA ≥18 years old, English-speaking, stage-IV solid tumor cancer, Distress Thermometer score ≥4. RESULTS Most participants preferred as many details as possible about their cancer, treatment (69.4%, n=143), and likely outcome of their disease (72.3%, n=149). Most participants accurately described their cancer as unlikely curable or incurable (62.6%, n=129). There were no significant differences in HIPs based on level of prognostic understanding. Poorer prognostic understanding was associated with religiosity and better quality of life and existential well-being. CONCLUSION In the present study, prognostic understanding (i.e., curability beliefs) was not associated with HIPs. Therefore, oncology clinicians must evaluate patients' interest and preferences for receiving information. Future research should further clarify preferences for the framing and content of prognostic information from providers and improve the measurement of prognostic understanding to facilitate patient-centered end of life care.",2020,"Most participants accurately described their cancer as unlikely curable or incurable (62.6%, n=129).","['patients with advanced cancer', 'Patients with Advanced Cancer', ""patients' health and prognostic information preferences (HIPs"", 'patients enrolled in a large randomized, controlled psychotherapy trial', '≥18 years old, English-speaking, stage-IV solid tumor cancer, Distress Thermometer score ≥4', '206 participants were recruited from outpatient clinics at a single facility']",[],"['Curability Beliefs', 'religiosity and better quality of life and existential well-being']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0441772', 'cui_str': 'Stage level 4'}, {'cui': 'C0280100', 'cui_str': 'Solid tumour'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0039818', 'cui_str': 'Thermometer'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0037179', 'cui_str': 'Single person'}]",[],"[{'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0681189', 'cui_str': 'Religiosity'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0018684', 'cui_str': 'Health'}]",206.0,0.0604436,"Most participants accurately described their cancer as unlikely curable or incurable (62.6%, n=129).","[{'ForeName': 'Rebecca M', 'Initials': 'RM', 'LastName': 'Saracino', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center. Electronic address: jamesr@mskcc.org.'}, {'ForeName': 'Laura C', 'Initials': 'LC', 'LastName': 'Polacek', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center; Psychology Department, Fordham University.'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Applebaum', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Rosenfeld', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center; Psychology Department, Fordham University.'}, {'ForeName': 'Hayley', 'Initials': 'H', 'LastName': 'Pessin', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Breitbart', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2020.07.023'] 2024,32739563,A Question Prompt List for advanced cancer patients promoting advance care planning: a French randomised trial.,"CONTEXT Advance care planning is essential to enable informed medical decisions to be made and to reduce aggressiveness in EOL care. OBJECTIVES This study aimed to explore whether a Question Prompt List (QPL) adapted to French language and culture could promote discussions, particularly on prognosis and EOL issues, among advanced cancer patients attending outpatient palliative care (PC) consultations. METHODS In this multicentre randomised study, patients assigned to the intervention arm received a QPL to help them prepare for the next consultation one month later. The main inclusion criteria were advanced cancer patients referred to the PC team with an estimated life expectancy of less than one year. The primary endpoint was the number of questions raised, globally and by topic. The secondary objectives were the impact of the QPL on psychological symptoms, quality-of-life (QoL), satisfaction with care and coping styles at two months. RESULTS Patients (n=71) in the QPL arm asked more questions (mean 21.8 versus 18.2, p-value=0.03) than patients in the control arm (n=71), particularly on PC (5.6 versus 3.7, p-value=0.012) and EOL issues (2.2 versus 1, p=0.018), but not on prognosis (4.3 versus 3.6, NS). At two months, there was no change in anxiety, depression or QoL in either arm; patient satisfaction with doctors' technical skills was scored higher (p-value=0.024) and avoidance coping responses were less frequent (self-distraction, p-value=0.015; behavioural disengagement, p-value=0.025) in the QPL arm. CONCLUSIONS Questions on PC and EOL issues in outpatient palliative care consultations were more frequent and patient satisfaction was better when a QPL was made available prior to the consultation.",2020,"At two months, there was no change in anxiety, depression or QoL in either arm; patient satisfaction with doctors' technical skills was scored higher (p-value=0.024) and avoidance coping responses were less frequent (self-distraction, p-value=0.015; behavioural disengagement, p-value=0.025) in the QPL arm. ","['advanced cancer patients', 'advanced cancer patients attending outpatient palliative care (PC) consultations', 'advanced cancer patients referred to the PC team with an estimated life expectancy of less than one year']","['QPL', 'Question Prompt List (QPL']","['number of questions raised, globally and by topic', 'psychological symptoms, quality-of-life (QoL), satisfaction with care and coping styles', ""anxiety, depression or QoL in either arm; patient satisfaction with doctors' technical skills"", 'avoidance coping responses']","[{'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0023671', 'cui_str': 'Life Expectancy'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C4082117', 'cui_str': 'One year'}]",[],"[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0442818', 'cui_str': 'Raised'}, {'cui': 'C1522168', 'cui_str': 'Topical route'}, {'cui': 'C0233397', 'cui_str': 'Psychological symptom'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0449851', 'cui_str': 'Technique'}]",,0.0675166,"At two months, there was no change in anxiety, depression or QoL in either arm; patient satisfaction with doctors' technical skills was scored higher (p-value=0.024) and avoidance coping responses were less frequent (self-distraction, p-value=0.015; behavioural disengagement, p-value=0.025) in the QPL arm. ","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Bouleuc', 'Affiliation': ""Institut Curie, Palliative Care Unit, Supportive Care Department, 26 rue d'Ulm, 75005 Paris, France; PSL, Paris Sciences Lettre, University Paris, France. Electronic address: carole.bouleuc@curie.net.""}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Savignoni', 'Affiliation': ""Institut Curie, Biometric Unit, Clinical Research Department, 26 rue d'Ulm, 75005 Paris, France; PSL, Paris Sciences Lettre, University Paris, France.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Chevrier', 'Affiliation': ""Institut Curie, Biometric Unit, Clinical Research Department, 26 rue d'Ulm, 75005 Paris, France; PSL, Paris Sciences Lettre, University Paris, France.""}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Renault-Tessier', 'Affiliation': ""Institut Curie, Palliative Care Unit, Supportive Care Department, 26 rue d'Ulm, 75005 Paris, France; PSL, Paris Sciences Lettre, University Paris, France.""}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Burnod', 'Affiliation': ""Institut Curie, Palliative Care Unit, Supportive Care Department, 26 rue d'Ulm, 75005 Paris, France; PSL, Paris Sciences Lettre, University Paris, France.""}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Chvetzoff', 'Affiliation': 'Centre Léon Bérard, Palliative Care Department, 28 Promenade Léa et Napoléon Bullukian, 69008 Lyon, France.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Poulain', 'Affiliation': ""Polyclinique de l'Ormeau, Palliative Care Department, 12 Bis Chemin de l'Ormeau, 65000 Tarbes, France.""}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Copel', 'Affiliation': 'Diaconesses Croix Saint Simon Hospital, Palliative Care Department, 12-18 rue Sergent Bauchat, 75012 Paris, France.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Cottu', 'Affiliation': ""Institut Curie, Medical Oncology Department 26 rue d'Ulm, 75005 Paris, France; PSL, Paris Sciences Lettre, University Paris, France.""}, {'ForeName': 'J Y', 'Initials': 'JY', 'LastName': 'Pierga', 'Affiliation': ""Institut Curie, Medical Oncology Department 26 rue d'Ulm, 75005 Paris, France; PSL, Paris Sciences Lettre, University Paris, France.""}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Brédart', 'Affiliation': ""Institut Curie, Psycho-Oncology Unit, 26 rue d'Ulm, 75005 Paris, France; Paris Descartes University Institute of Psychology, 71 Avenue Edouard Vaillant, 92100 Boulogne-Billancourt,France.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Dolbeault', 'Affiliation': ""Institut Curie, Psycho-Oncology Unit, 26 rue d'Ulm, 75005 Paris, France; CESP, University Paris-Sud, \u2028UVSQ, INSERM, University Paris-Saclay, Villejuif, \u2028France \u2028.""}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2020.07.026'] 2025,32739569,Randomized Controlled Trial of Advance Notification Phone Calls vs Text Messages Prior to Mailed Fecal Test Outreach.,"BACKGROUND & AIMS Mailing fecal immunochemical test (FITs) to individuals who are due for screening (mailed FIT outreach) increases colorectal cancer (CRC) screening. Little is known about how phone-based advance notifications (primers) affect the effectiveness of these programs. METHODS We performed a prospective study of patients at a large urban health center, 50-75 years old and due for screening, with no record of a prior FIT. Participants were randomly assigned to groups that received a live phone call primer (n = 1203) or a text message primer (n = 1622), from June through December 2018. The participants were then mailed a FIT kit, followed by 2 automated calls, and live reminder calls delivered by the care team. The main outcome was completion of FIT within 3 months of assignment to the live phone call or text message group. RESULTS Participants had FIT completion rate of 16.8%, a mean age of 58 years, and 80% were Latino. In adjusted intention to treat analyses (n = 2825), FIT completion rates were higher in the patients assigned to receive a live phone call vs text message primer (percentage point difference, 3.3%; 95% CI, 0.4%-6.2%). Between-group differences increased to 7.3% points (95% CI, 3.6%-11.0%) in the per-protocol analysis of 2144 participants reached by the text message (1320/1622, 81%), live call (438/1203, 36%), or voice message (386/1203, 32%). This rate increased to 14.9% points (95% CI; 9.6%-20.1%) in the per-protocol analysis of 1758 participants reached by the text message or reached by the live call. CONCLUSIONS In a randomized trial, advance notification live phone calls outperformed text messages in reminding health center patients who had not previously completed a FIT to complete a mailed FIT. Clinicaltrials.gov no: NCT03167125.",2020,"In adjusted intention to treat analyses (n = 2825), FIT completion rates were higher in the patients assigned to receive a live phone call vs text message primer (percentage point difference, 3.3%; 95% CI, 0.4%-6.2%).","['individuals who are due for screening (mailed FIT outreach) increases colorectal cancer (CRC) screening', 'patients at a large urban health center, 50-75 years old and due for screening, with no record of a prior FIT', 'reminding health center patients who had not previously completed a FIT to complete a mailed FIT']",['live phone call primer (n = 1203) or a text message primer'],"['FIT completion rate', 'FIT completion rates', 'voice message']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C0036572', 'cui_str': 'Seizure'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0041933', 'cui_str': 'Urban Health'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332127', 'cui_str': 'No record of'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0557033', 'cui_str': 'Reminding'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0206415', 'cui_str': 'Oligonucleotide Primers'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}]","[{'cui': 'C0036572', 'cui_str': 'Seizure'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0042939', 'cui_str': 'Voice'}]",2825.0,0.236928,"In adjusted intention to treat analyses (n = 2825), FIT completion rates were higher in the patients assigned to receive a live phone call vs text message primer (percentage point difference, 3.3%; 95% CI, 0.4%-6.2%).","[{'ForeName': 'Gloria D', 'Initials': 'GD', 'LastName': 'Coronado', 'Affiliation': ''}, {'ForeName': 'Denis B', 'Initials': 'DB', 'LastName': 'Nyongesa', 'Affiliation': ''}, {'ForeName': 'Amanda F', 'Initials': 'AF', 'LastName': 'Petrik', 'Affiliation': ''}, {'ForeName': 'Jamie H', 'Initials': 'JH', 'LastName': 'Thompson', 'Affiliation': ''}, {'ForeName': 'Anne L', 'Initials': 'AL', 'LastName': 'Escaron', 'Affiliation': ''}, {'ForeName': 'Brittany', 'Initials': 'B', 'LastName': 'Younger', 'Affiliation': ''}, {'ForeName': 'Shelby', 'Initials': 'S', 'LastName': 'Harbison', 'Affiliation': ''}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Leo', 'Affiliation': ''}]",Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,['10.1016/j.cgh.2020.07.053'] 2026,32739611,Changes in technology acceptance among older people with dementia: the role of social robot engagement.,"OBJECTIVE Emerging technologies such as social robots have shown to be effective in reducing loneliness and agitation for older people with dementia. However, the acceptance of technology (specifically social robots) was found to be low for older people with dementia. The current understanding of changes in technology acceptance following direct exposure is limited and lacks rigorous study design. This study examined the change in technology acceptance after a direct interaction with a humanoid social robot (Kabochan) that was deployed for long-term care facilities' residents with dementia. METHODS The technology acceptance was assessed using randomised control trials for a time frame of 32 weeks. A total of 103 residents clinically diagnosed with dementia, with a mean age of 87.2 years (SD = 7.4), were recruited from seven long-term care facilities in Hong Kong and were randomly allocated to either Kabochan-engagement group or control group. Participants in the engagement group interacted with Kabochan in an individual, non-facilitated approach. The behavioural engagement with Kabochan was observed by care workers and recorded into constructive engagement and non-engagement. Questionnaire surveys were taken placed at pre- and post-exposure with Kabochan to measure attitudes and beliefs towards technology. The questionnaire was based on previous studies on technology acceptance and included attitudes towards technology, perceived usefulness, perceived ease of use, technology self-efficacy, technology anxiety, and facilitating conditions. RESULTS Perceived ease of use was improved at week 32 for participants who interacted with Kabochan (F = 4.239, p = 0.042) with a small effect (η p 2 = 0.043) in comparison to usual care group. Results further demonstrated that the magnitude of belief changes was related to the intensity of constructive behavioural engagement. Specifically, resident-robot behavioural engagement moderately improved attitudes towards technology (F = 11.62, p < 0.001, η p 2 = 0.11) and perceived usefulness (F = 5.75, p = 0.02, η p 2 = 0.06). CONCLUSIONS The study tentatively supports that exposure to Kabochan has potential for changing perceived ease of use but not for other beliefs and attitudes towards technology among long-term care residents with dementia. Direct engagement with a humanoid social robot might be promising in improving the perceived ease of use towards technology.",2020,"Perceived ease of use was improved at week 32 for participants who interacted with Kabochan (F = 4.239, p = 0.042) with a small effect (η p 2 = 0.043) in comparison to usual care group.","['103 residents clinically diagnosed with dementia, with a mean age of 87.2 years (SD = 7.4), were recruited from seven long-term care facilities in Hong Kong', ""long-term care facilities' residents with dementia"", 'older people with dementia']","['humanoid social robot (Kabochan', 'humanoid social robot', 'Kabochan-engagement group or control group', 'Kabochan']","['Perceived ease of use', 'attitudes towards technology']","[{'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517858', 'cui_str': '7.4'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0019907', 'cui_str': 'Hong Kong'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0039421', 'cui_str': 'Technology'}]",103.0,0.0256322,"Perceived ease of use was improved at week 32 for participants who interacted with Kabochan (F = 4.239, p = 0.042) with a small effect (η p 2 = 0.043) in comparison to usual care group.","[{'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Ke', 'Affiliation': 'Sau Po Centre on Ageing, the University of Hong Kong, Hong Kong. Electronic address: kechen@hku.hk.'}, {'ForeName': 'Vivian Wei-Qun', 'Initials': 'VW', 'LastName': 'Lou', 'Affiliation': 'Sau Po Centre on Ageing, the University of Hong Kong, Hong Kong; Social Work and Social Administration, the University of Hong Kong, Pok Fu Lam, Hong Kong. Electronic address: wlou@hku.hk.'}, {'ForeName': 'Kelvin Cheng-Kian', 'Initials': 'KC', 'LastName': 'Tan', 'Affiliation': 'Social Work and Social Administration, the University of Hong Kong, Pok Fu Lam, Hong Kong. Electronic address: u3004055@connect.hku.hk.'}, {'ForeName': 'Man Yi', 'Initials': 'MY', 'LastName': 'Wai', 'Affiliation': 'Hong Kong Sheng Kung Hui Welfare Council Ltd, Hong Kong. Electronic address: gwai@skhwc.org.hk.'}, {'ForeName': 'Lai Lok', 'Initials': 'LL', 'LastName': 'Chan', 'Affiliation': 'Hong Kong Sheng Kung Hui Welfare Council Ltd, Hong Kong. Electronic address: llchan@skhwc.org.hk.'}]",International journal of medical informatics,['10.1016/j.ijmedinf.2020.104241'] 2027,32739652,"Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.","BACKGROUND Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the cornerstone for prevention ischemic events in patients with acute coronary syndromes (ACS) and undergoing percutaneous coronary intervention. However, the optimal antiplatelet strategy for ACS patients with both high bleeding and high ischemic risks is unclear. STUDY DESIGN The OPT-BIRISK trial is a multicenter, double-blinded, placebo-controlled randomized study designed to test the superiority of extended antiplatelet therapy with clopidogrel monotherapy compared with aspirin and clopidogrel for reduction of bleeding events in ACS patients with both high bleeding and high ischemic risks (""bi-risk""). A total of 7,700 patients who completed 9- to 12-month dual antiplatelet therapy after new-generation drug-eluting stent implantation for the treatment of ACS will be randomized to receive clopidogrel monotherapy or aspirin plus clopidogrel for 9 months followed by aspirin monotherapy for 3 months. The primary end point is Bleeding Academic Research Consortium type 2, 3, or 5 bleedings at 9 months after randomization. The key secondary end point is major adverse cardiac and cerebral events at 9 months after randomization, defined as a composite of all-cause death, myocardial infarction, stroke, or coronary artery revascularization. CONCLUSIONS OPT-BIRISK is the first large-scale randomized trial aimed to explore the optimal antiplatelet strategy for bi-risk ACS patients after percutaneous coronary intervention in current clinical practice. The results will add evidence regarding de-escalation antiplatelet therapy for patients at special risk.",2020,"The primary end point is Bleeding Academic Research Consortium type 2, 3, or 5 bleedings at 9 months after randomization.","['7,700 patients who completed 9- to 12-month dual antiplatelet therapy after new-generation drug-eluting stent implantation for the treatment of ACS', 'patients with acute coronary syndromes (ACS) and undergoing percutaneous coronary intervention', 'acute coronary syndrome patients with both high bleeding and ischemic risk', 'patients at special risk', 'ACS patients with both high bleeding and high ischemic risks (""bi-risk']","['clopidogrel alone versus clopidogrel plus aspirin', 'aspirin and a P2Y12 inhibitor', 'aspirin monotherapy', 'aspirin and clopidogrel', 'clopidogrel monotherapy or aspirin plus clopidogrel', 'placebo']","['major adverse cardiac and cerebral events', 'composite of all-cause death, myocardial infarction, stroke, or coronary artery revascularization', 'bleeding events', 'Bleeding Academic Research Consortium type 2, 3, or 5 bleedings']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C1322815', 'cui_str': 'Drug eluting stent'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205555', 'cui_str': 'Special'}]","[{'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0205042', 'cui_str': 'Coronary artery structure'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]",7700.0,0.0625651,"The primary end point is Bleeding Academic Research Consortium type 2, 3, or 5 bleedings at 9 months after randomization.","[{'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.'}, {'ForeName': 'Quanmin', 'Initials': 'Q', 'LastName': 'Jing', 'Affiliation': 'Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.'}, {'ForeName': 'Xiaozeng', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.'}, {'ForeName': 'Shubing', 'Initials': 'S', 'LastName': 'Qiao', 'Affiliation': 'Fu Wai Hospital of Chinese Academy of Medical Science, Beijing, China.'}, {'ForeName': 'Shaoliang', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'Nanjing First Hospital of Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Dominick J', 'Initials': 'DJ', 'LastName': 'Angiolillo', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA.'}, {'ForeName': 'Yaling', 'Initials': 'Y', 'LastName': 'Han', 'Affiliation': 'Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China. Electronic address: hanyaling@263.net.'}]",American heart journal,['10.1016/j.ahj.2020.07.005'] 2028,32739670,"The effects of a transitional care program on discharge readiness, transitional care quality, health services utilization and satisfaction among Chinese kidney transplant recipients: A randomized controlled trial.","BACKGROUND Kidney transplantation is the major treatment for end-stage renal disease (ESRD). However, kidney transplant recipients (KTRs) face severe challenges during the transition period from hospital discharge to home, increasing the risk of early hospital readmission (EHR) and affecting patient safety. Nevertheless, knowledge of effective transitional care for KTRs is limited in China. OBJECTIVE To evaluate the effectiveness of an innovative transitional care program in improving discharge readiness, transitional care quality, health services utilization and patient satisfaction among KTRs in China. DESIGN A prospective randomized controlled trial. SETTINGS AND PARTICIPANTS Patients admitted to undergo kidney transplantation were recruited in a general tertiary hospital in Chengdu, China. METHODS A total of 220 eligible patients were recruited and randomly assigned to the intervention and control groups. Participants in the intervention group received a transitional care intervention developed by the research team, including a risk assessment for early readmission, health education from admission to predischarge, individualized discharge planning, and a telephone follow-up once per week for one month and WeChat follow-up postdischarge. The control group received routine care of comparable length and follow-up contact. A trained research assistant collected all patients' baseline data on admission (T0), evaluated the discharge readiness (by the Readiness for Hospital Discharge Scale) on the day of discharge (T1), collected data on transitional care quality (by the Care Transition Measure-15) and patients' satisfaction with transitional care services (by a self-developed patient satisfaction scale) on the 30th day postdischarge (T2), and collected data on hospital readmission, unscheduled outpatient department visits, and emergency room visits on the 30th and 90th days (by a self-developed health services utilization record table) (T3) postdischarge. Intervention effects were analyzed using independent samples t-tests, Wilcoxon-Mann-Whitney U tests, Chi-square tests or Fisher's exact test. RESULTS Compared with the control group, the intervention group showed significantly better discharge readiness (personal status, P<0.001; knowledge, P = 0.010; coping ability, P<0.001; expected support, P = 0.007; total score, P<0.001), better transitional care quality (importance of preferences, P<0.001; management preparation, P<0.001; critical understanding, P = 0.003; written and understandable care plan, P = 0.012; total score, P<0.001), lower readmission rate at T2 (P = 0.033) and at T3 (P = 0.013), lower emergency room visit rate at T3 (P = 0.014), and better satisfaction with transitional care services (P<0.001). CONCLUSIONS This study provides evidence that an innovative transitional care program is effective in promoting KTRs' discharge readiness, transitional care quality, reducing hospital readmission and emergency room visits, and improving their satisfaction with transitional care services. TRIAL REGISTRATION Clinical Trials ChiCTR1800014971.",2020,"Compared with the control group, the intervention group showed significantly better discharge readiness (personal status, P<0.001; knowledge, P = 0.010; coping ability, P<0.001; expected support, P = 0.007; total score, P<0.001), better transitional care quality (importance of preferences, P<0.001; management preparation, P<0.001; critical understanding, P = 0.003; written and understandable care plan, P = 0.012; total score, P<0.001), lower readmission rate at T2 (P = 0.033) and at T3 (P = 0.013), lower emergency room visit rate at T3 (P = 0.014), and better satisfaction with transitional care services (P<0.001). ","['A total of 220 eligible patients', 'KTRs in China', 'Chinese kidney transplant recipients', 'Patients admitted to undergo kidney transplantation were recruited in a general tertiary hospital in Chengdu, China']","['transitional care program', 'transitional care intervention developed by the research team, including a risk assessment for early readmission, health education from admission to predischarge, individualized discharge planning, and a telephone follow-up once per week for one month and WeChat follow-up postdischarge', 'routine care of comparable length and follow-up contact', 'innovative transitional care program']","['discharge readiness', ""discharge readiness (by the Readiness for Hospital Discharge Scale) on the day of discharge (T1), collected data on transitional care quality (by the Care Transition Measure-15) and patients' satisfaction with transitional care services (by a self-developed patient satisfaction scale) on the 30th day postdischarge (T2), and collected data on hospital readmission, unscheduled outpatient department visits, and emergency room visits on the 30th and 90th days (by a self-developed health services utilization record table) (T3) postdischarge"", 'lower emergency room visit rate', 'lower readmission rate', 'discharge readiness, transitional care quality, health services utilization and satisfaction', 'discharge readiness, transitional care quality, health services utilization and patient satisfaction', 'risk of early hospital readmission (EHR) and affecting patient safety', 'transitional care quality', ""samples t-tests, Wilcoxon-Mann-Whitney U tests, Chi-square tests or Fisher's exact test""]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}]","[{'cui': 'C4019071', 'cui_str': 'Transition Care'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0086930', 'cui_str': 'Risk assessment'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0012622', 'cui_str': 'Discharge planning'}, {'cui': 'C0178941', 'cui_str': 'Telephone follow-up'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C4082115', 'cui_str': 'One month'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}]","[{'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4019071', 'cui_str': 'Transition Care'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C4019079', 'cui_str': 'Care Transition'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C3854240', 'cui_str': 'Unscheduled'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0030672', 'cui_str': 'Health Care Utilization'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0039224', 'cui_str': 'Table'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0522476', 'cui_str': 'Patient affected'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0242927', 'cui_str': 'Mann-Whitney U Test'}, {'cui': 'C0008041', 'cui_str': 'Chi-Square Test'}, {'cui': 'C0325045', 'cui_str': 'Martes pennanti'}]",220.0,0.0555818,"Compared with the control group, the intervention group showed significantly better discharge readiness (personal status, P<0.001; knowledge, P = 0.010; coping ability, P<0.001; expected support, P = 0.007; total score, P<0.001), better transitional care quality (importance of preferences, P<0.001; management preparation, P<0.001; critical understanding, P = 0.003; written and understandable care plan, P = 0.012; total score, P<0.001), lower readmission rate at T2 (P = 0.033) and at T3 (P = 0.013), lower emergency room visit rate at T3 (P = 0.014), and better satisfaction with transitional care services (P<0.001). ","[{'ForeName': 'Rujun', 'Initials': 'R', 'LastName': 'Hu', 'Affiliation': 'West China School of Nursing/West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China; Emergency Department, Affiliated Hospital of Zunyi Medical University, Zunyi Medical University, Zunyi 563000, Guizhou, China; School of Nursing, Zunyi Medical University, Zunyi 563000, Guizhou, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Gu', 'Affiliation': 'Department of Urology/Institute of Urology/Organ Transplantation Center,West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.'}, {'ForeName': 'Qiling', 'Initials': 'Q', 'LastName': 'Tan', 'Affiliation': 'Department of Urology/Institute of Urology/Organ Transplantation Center,West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.'}, {'ForeName': 'KaiZhi', 'Initials': 'K', 'LastName': 'Xiao', 'Affiliation': 'Department of Urology/Institute of Urology/Organ Transplantation Center,West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.'}, {'ForeName': 'Xiaoqin', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Urology/Institute of Urology/Organ Transplantation Center,West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.'}, {'ForeName': 'Xiaoyi', 'Initials': 'X', 'LastName': 'Cao', 'Affiliation': 'Department of Nephrology, Hemodialysis Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.'}, {'ForeName': 'Turun', 'Initials': 'T', 'LastName': 'Song', 'Affiliation': 'Department of Urology/Institute of Urology/Organ Transplantation Center,West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.'}, {'ForeName': 'Xiaolian', 'Initials': 'X', 'LastName': 'Jiang', 'Affiliation': 'West China School of Nursing/West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. Electronic address: jiangxiaolianhl@163.com.'}]",International journal of nursing studies,['10.1016/j.ijnurstu.2020.103700'] 2029,32739671,Effects and mediating mechanisms of a structured limbs-exercise program on general cognitive function in older adults with mild cognitive impairment: A randomized controlled trial.,"BACKGROUND Exercise is known to prevent cognitive decline. Sleep quality and depression symptoms, which are associated with processing speed, are considered as common mediators in the exercise-cognition putative model. However, these mediating mechanisms have not been empirically tested in an intervention study. OBJECTIVE The aim of this study was to evaluate the effects of a structured limbs-exercise program on general cognitive function, and to test the mediating effects and mediating pathways of depressive symptoms, sleep quality and processing speed in the relationship of exercise-induced cognitive benefits. DESIGN A two-arm and assessor-blinded randomized controlled trial. SETTINGS AND PARTICIPANTS Community-dwelling older adults with mild cognitive impairment living in an urban area in Chifeng, China. METHODS Participants (N=116) were randomly allocated to one of the two arms: (1) a 24-week structured limbs-exercise program (3 supervised limb exercise sessions /week, 60 min /session for the first 12 weeks and 3 unsupervised practice sessions /week, 60 min /session for the following 12 weeks) or (2) health promotion classes alone. Measures of depressive symptoms, sleep quality, processing speed, and general cognitive function were collected at baseline, 12-week, and 24-week. Multivariate analysis of variance and structural equation modeling was used to test the effectiveness and mechanisms of structured limbs-exercise-induced cognitive improvement respectively. RESULTS The structured limbs-exercise program was beneficial for maintaining general cognitive function at 12 weeks (mean difference = 1.20, 95% CI [0.354, 2.054], p = 0.006) and at 24 weeks (mean difference = 1.59, 95% CI [0.722, 2.458], p = 0.001) in the intervention group. The results from the goodness-of-fit indices of structural equation modeling show as following: (1) The effect of structured limbs-exercise program on cognitive function was partially mediated by depressive symptoms, sleep quality, and processing speed, with 69.22% of joint mediation proportion; (2) Relative to the combined Z values of depressive symptoms and processing speed, sleep quality was more strongly related to cognitive function in the structured limbs-exercise program (Z= 9.294, p<0.01); (3) Processing speed was affected by depressive symptoms, sleep quality, and in turn, yielding a significant effect on cognitive function; and (4) Five potential mediating pathways for improvement in general cognitive function in the structured limbs-exercise intervention were identified. CONCLUSION This study shows that this exercise program can maintain general cognitive function for older adults with mild cognitive impairment. Mediating variables include depressive symptoms, sleep quality and processing speed. Future research should continue to incorporate path-oriented intervention strategies in the exercise intervention to maximize improvements in cognitive function. Registration number: ChiCTR1800016299.",2020,"The structured limbs-exercise program was beneficial for maintaining general cognitive function at 12 weeks (mean difference = 1.20, 95% CI [0.354, 2.054], p = 0.006) and at 24 weeks (mean difference = 1.59, 95% CI [0.722, 2.458], p = 0.001) in the intervention group.","['Community-dwelling older adults with mild cognitive impairment living in an urban area in Chifeng, China', 'Participants (N=116', 'older adults with mild cognitive impairment']","['exercise program', '24-week structured limbs-exercise program (3 supervised limb exercise sessions /week, 60\xa0min /session for the first 12 weeks and 3 unsupervised practice sessions /week, 60\xa0min /session for the following 12 weeks) or (2) health promotion classes alone', 'structured limbs-exercise program']","['general cognitive function', 'depressive symptoms, sleep quality, and processing speed', 'depressive symptoms, sleep quality', 'depressive symptoms and processing speed, sleep quality', 'cognitive function', 'depressive symptoms, sleep quality, processing speed, and general cognitive function', 'depressive symptoms, sleep quality and processing speed', 'Sleep quality and depression symptoms']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0018738', 'cui_str': 'Health promotion'}, {'cui': 'C0456387', 'cui_str': 'Class'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0582591', 'cui_str': 'Processing speed'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}]",116.0,0.141098,"The structured limbs-exercise program was beneficial for maintaining general cognitive function at 12 weeks (mean difference = 1.20, 95% CI [0.354, 2.054], p = 0.006) and at 24 weeks (mean difference = 1.59, 95% CI [0.722, 2.458], p = 0.001) in the intervention group.","[{'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'School of Medicine, Huzhou University, Huzhou Central Hospital, Huzhou, Zhejiang 313000, China. Electronic address: aring2000@163.com.'}, {'ForeName': 'Bei', 'Initials': 'B', 'LastName': 'Wu', 'Affiliation': 'Rory Meyers College of Nursing, New York University, New York, NY 10010, USA. Electronic address: bei.wu@nyu.edu.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Tao', 'Affiliation': 'AdventHealth Whole-Person Research, Orlando, FL 32804, USA. Electronic address: Hong.Tao@AdventHealth.com.'}, {'ForeName': 'Nannan', 'Initials': 'N', 'LastName': 'Chai', 'Affiliation': 'School of Nursing, Chifeng University, Chifeng, Inner Mongolia 024000, China. Electronic address: 151606873@qq.com.'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': 'School of Medicine, Huzhou University, Huzhou Central Hospital, Huzhou, Zhejiang 313000, China. Electronic address: 17858368692@163.com.'}, {'ForeName': 'Xueting', 'Initials': 'X', 'LastName': 'Zhen', 'Affiliation': 'School of Medicine, Huzhou University, Huzhou Central Hospital, Huzhou, Zhejiang 313000, China. Electronic address: zhenxueting1029@163.com.'}, {'ForeName': 'Xianglian', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'School of Medicine, Huzhou University, Huzhou Central Hospital, Huzhou, Zhejiang 313000, China. Electronic address: 18777119676@163.com.'}]",International journal of nursing studies,['10.1016/j.ijnurstu.2020.103706'] 2030,32739704,Aerobic exercise or stretching as add-on to inpatient treatment of depression: Similar antidepressant effects on depressive symptoms and larger effects on working memory for aerobic exercise alone.,"BACKGROUND Aerobic exercise (AE) has positive effects on symptom severity and cognitive symptoms of depression. Since data on AE as add-on to inpatient treatment in depression is still scarce, we conducted this double-blind randomized controlled study. METHODS Patients aged between 18 and 60 years were recruited into the study if Hamilton Depression Rating Scale 17 (HDRS-17) score was >16. Participants were randomly assigned to either AE or basic stretching activities (control), which took place 3x/week for 6 weeks. Primary outcome was depression severity as assessed with the HDRS-17 and the Beck Depression Inventory (BDI). Further physiological and psychological variables and cognitive performance were assessed as secondary outcomes. RESULTS Forty-two patients were included in the analysis (exercise: n = 22; control: n = 20). Regardless of group allocation, we found a significant short-term time effect for symptom-severity (HDRS17: p<0.001, η²=0.70; BDI: p<0.001, η²=0.51), mental toughness (p<0.001, η²=0.32), physical self-description endurance score (p = 0.013, η²=0.16), cognitive flexibility (p = 0.013, η²=0.14), and body mass index (BMI) (p = 0.006, η²=0.19). Working memory showed a significant time by group interaction in favor of AE (p = 0.043, η²=0.10). Short-term effects on symptom severity, mental toughness and BMI remained stable across the 6-month follow-up period. Finally, self-reported physical activity increased significantly from baseline to follow-up (p = 0.014, η²=0.15). LIMITATIONS The sample-size is rather small. The control intervention might have been too active as to find a time by group interaction for symptom severity. CONCLUSIONS AE was associated with comparably large depression alleviation vs. stretching and with add-on benefits on working memory.",2020,"Short-term effects on symptom severity, mental toughness and BMI remained stable across the 6-month follow-up period.","['Forty-two patients were included in the analysis (exercise: n\xa0=\xa022; control: n\xa0=\xa020', 'Patients aged between 18 and 60 years']","['Aerobic exercise or stretching', 'Aerobic exercise (AE', 'AE or basic stretching activities (control', 'aerobic exercise alone']","['mental toughness', 'depression severity as assessed with the HDRS-17 and the Beck Depression Inventory (BDI', 'physical activity', 'symptom severity, mental toughness and BMI', 'physical self-description endurance score', 'Hamilton Depression Rating Scale 17 (HDRS-17) score', 'cognitive flexibility', 'body mass index (BMI']","[{'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0270814', 'cui_str': 'Spastic syndrome'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}]",42.0,0.225194,"Short-term effects on symptom severity, mental toughness and BMI remained stable across the 6-month follow-up period.","[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Imboden', 'Affiliation': 'Psychiatric Services Solothurn, Solothurn, Switzerland, and University of Basel, Basel, Switzerland; Private Clinic Wyss, Muenchenbuchsee, Switzerland. Electronic address: christian.imboden@pkwyss.ch.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Gerber', 'Affiliation': 'Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Beck', 'Affiliation': 'Psychiatric University Hospital, University of Basel, Basel, Switzerland; Private Clinic Sonnenhalde, Riehen, Switzerland.'}, {'ForeName': 'Edith', 'Initials': 'E', 'LastName': 'Holsboer-Trachsler', 'Affiliation': 'Psychiatric University Hospital, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Pühse', 'Affiliation': 'Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Hatzinger', 'Affiliation': 'Psychiatric Services Solothurn, Solothurn, Switzerland, and University of Basel, Basel, Switzerland.'}]",Journal of affective disorders,['10.1016/j.jad.2020.07.052'] 2031,32739716,The comparison of access to an eHealth resource to current practice on mother and co-parent teamwork and breastfeeding rates: A randomized controlled trial.,"BACKGROUND Breastfeeding rates are suboptimal, putting mothers and their infants' health at risk. One modifiable risk factor amenable to intervention is partner support. Having women work as a team with their co-parents to meet their breastfeeding goals has been found to improve breastfeeding outcomes. eHealth resources have been found to be accessible and feasible ways to provide breastfeeding education yet, the best way to design breastfeeding interventions for mothers and their co-parents is not known. OBJECTIVES To compare two study conditions to determine: (1) which way is more effective to provide breastfeeding education to women and their co-parents on increasing breastfeeding rates and associated secondary outcomes, such as breastfeeding knowledge, attitude, self-efficacy and overcoming challenges; (2) the difference in co-parenting and partner support between the study groups; (3) how parents in both groups preferred to access breastfeeding information; and (4) the groups' satisfaction with the eHealth resource that was provided. DESIGN This study used a randomized controlled trial design (Clinicaltrials.org #NCT03492411). Participants were randomly allocated to study groups with concealed opaque envelopes by a blinded research assistant. Participants in Study Condition #1 (SC1) accessed a previously created, online e-Health resource, in addition to other generally available resources they could access in the community; participants in Study Condition #2 (SC2) accessed only the generally available resources. SETTING Participants were recruited in health care providers' offices and services for expectant parents in Ontario and via social media throughout Canada. PARTICIPANTS Expectant women (n = 113) and their co-parents (n = 104) were enrolled. METHODS After eligibility was determined, consents obtained and baseline surveys completed, group allocation was conducted. SC1 had a virtual meeting with a research assistant to review the eHealth resource. Weekly emails were sent to all participants for 6 weeks as reminders. Follow-up data were electronically collected from mothers and co-parents at 2 weeks post enrollment and 4, 12, 26 and 52-weeks postpartum. RESULTS Breastfeeding rates were high in both groups (SC1 63% and SC2 57% 'exclusive' 6 months) and (SC1 71% and SC2 78% 'any' 12 months) and not statistically significantly different. High scores were found in both groups in secondary outcome measures. Generally available breastfeeding resources were used in both groups with websites being used often and rated as most helpful. SC1 rated the eHealth resource provided to them highly. CONCLUSION The findings suggest both mothers and their co-parents should be targeted in breastfeeding education and web-based resources designed to meet their needs.",2020,"RESULTS Breastfeeding rates were high in both groups (SC1 63% and SC2 57% 'exclusive' 6 months) and (SC1 71% and SC2 78% 'any' 12 months) and not statistically significantly different.","['Expectant women (n\xa0=\xa0113) and their co-parents (n\xa0=\xa0104) were enrolled', 'Participants in Study Condition', ""Participants were recruited in health care providers' offices and services for expectant parents in Ontario and via social media throughout Canada""]",[],['Breastfeeding rates'],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C3179065', 'cui_str': 'Social Medium'}, {'cui': 'C0006823', 'cui_str': 'Canada'}]",[],"[{'cui': 'C0006147', 'cui_str': 'Breast fed'}]",104.0,0.0703829,"RESULTS Breastfeeding rates were high in both groups (SC1 63% and SC2 57% 'exclusive' 6 months) and (SC1 71% and SC2 78% 'any' 12 months) and not statistically significantly different.","[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Abbass-Dick', 'Affiliation': 'Faculty of Health Sciences, Ontario Tech University, 2000 Simcoe Street North, Oshawa ON, L1G 0C5, Canada. Electronic address: jennifer.abbassdick@ontariotechu.ca.'}, {'ForeName': 'Winnie', 'Initials': 'W', 'LastName': 'Sun', 'Affiliation': 'Faculty of Health Sciences, Ontario Tech University, 2000 Simcoe Street North, Oshawa ON, L1G 0C5, Canada.'}, {'ForeName': 'Amber', 'Initials': 'A', 'LastName': 'Newport', 'Affiliation': 'Durham Region Health Department, Canada.'}, {'ForeName': 'Fangli', 'Initials': 'F', 'LastName': 'Xie', 'Affiliation': 'Durham Region Health Department, Canada.'}, {'ForeName': 'Debbie', 'Initials': 'D', 'LastName': 'Godfrey', 'Affiliation': 'Durham Region Health Department, Canada.'}, {'ForeName': 'William M', 'Initials': 'WM', 'LastName': 'Goodman', 'Affiliation': 'Faculty of Business and Information Technology, Ontario Tech University.'}]",Midwifery,['10.1016/j.midw.2020.102812'] 2032,32739846,Comparison of topical capsaicin and topical piroxicam in the treatment of acute trauma-induced pain: A randomized double-blind trial.,"BACKGROUND This study aimed to compare the analgesic efficacy of topical capsaicin and topical piroxicam in acute musculoskeletal injuries. METHODS This is a prospective, randomized, controlled, double-blinded study. The data for the 67 patients in the piroxicam group and the 69 in the capsaicin group were examined. The initial visual analog scale (VAS) scores were compared with the 60th and 120th minute as well as the 24th and 72nd hour values. Differences between the VAS scores, clinical effectiveness of the treatment and side effects were evaluated. RESULTS In the capsaicin group, the mean difference in the delta VAS scores was significantly higher at each measurement time. The mean of the percentage of reduction in the VAS scores of the topical capsaicin group was significantly higher than that in the topical piroxicam group. The highest difference in terms of both outcomes was determined at the 72nd hour VAS change. Mean differences were 1.53 (95% CI: 0.85-2.221) and 19.7 (95% CI: 12.4-27.2) respectively (p < 0.001). In the capsaicin group, the clinical effect of the treatment was found significantly higher (p < 0.01). The difference between the clinical effectiveness of the groups regarding the treatment outcomes was also statistically significant (p < 0.001). There was no significant difference between the patient groups regarding the presence of side effects. CONCLUSION Topical capsaicin can be used as an alternative to topical piroxicam initially and at follow-up in patients presenting to the emergency department with acute pain as there were no observable differences in side-effects between the two groups.",2020,"In the capsaicin group, the clinical effect of the treatment was found significantly higher (p < 0.01).","['patients presenting to the emergency department with acute pain', 'acute musculoskeletal injuries', 'acute trauma-induced pain', '67 patients in the']","['topical capsaicin', 'topical capsaicin and topical piroxicam', 'piroxicam', 'capsaicin', 'Topical capsaicin', 'topical piroxicam']","['VAS scores, clinical effectiveness of the treatment and side effects', 'side effects', 'delta VAS scores', 'analgesic efficacy', 'initial visual analog scale (VAS) scores', 'VAS scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0184567', 'cui_str': 'Acute pain'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0272448', 'cui_str': 'Injury of musculoskeletal system'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C3210186', 'cui_str': 'Capsaicin-containing product in transdermal dose form'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0031990', 'cui_str': 'Piroxicam'}, {'cui': 'C0006931', 'cui_str': 'Capsaicin'}]","[{'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C3850123', 'cui_str': 'Treatment Effectiveness'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0861012,"In the capsaicin group, the clinical effect of the treatment was found significantly higher (p < 0.01).","[{'ForeName': 'Abdullah Osman', 'Initials': 'AO', 'LastName': 'Kocak', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Ataturk University, Erzurum, Turkey. Electronic address: abdullahmrym86@gmail.com.'}, {'ForeName': 'Sinem', 'Initials': 'S', 'LastName': 'Dogruyol', 'Affiliation': 'Department of Emergency Medicine, Manisa Merkez Efendi State Hospital, Manisa, Turkey.'}, {'ForeName': 'Ilker', 'Initials': 'I', 'LastName': 'Akbas', 'Affiliation': 'Department of Emergency Medicine, Bingol State Hospital, Bingol, Turkey.'}, {'ForeName': 'Tugba Sanalp', 'Initials': 'TS', 'LastName': 'Menekse', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Ataturk University, Erzurum, Turkey.'}, {'ForeName': 'Sultan Tuna Akgol', 'Initials': 'STA', 'LastName': 'Gur', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Ataturk University, Erzurum, Turkey.'}, {'ForeName': 'Meryem Betos', 'Initials': 'MB', 'LastName': 'Kocak', 'Affiliation': 'Department of Familiy Medicine, Faculty of Medicine, Ataturk University, Erzurum, Turkey.'}, {'ForeName': 'Bora', 'Initials': 'B', 'LastName': 'Cekmen', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Karabuk University, Karabuk, Turkey.'}, {'ForeName': 'Serhat', 'Initials': 'S', 'LastName': 'Orun', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Namik Kemal University, Tekirdağ, Turkey.'}, {'ForeName': 'Zeynep', 'Initials': 'Z', 'LastName': 'Cakir', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Ataturk University, Erzurum, Turkey.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2020.05.104'] 2033,32739862,Benefits of social cognitive skills training within routine community mental health services: Evidence from a non-randomized parallel controlled study.,"Although social cognitive impairments are evident in patients with schizophrenia across many cultures, psychosocial interventions are less used in Eastern countries. Despite a growing emphasis on community care in mental health services in Eastern countries, the synergistic effects of social cognitive intervention strategies on routine community mental health services are not well documented. This study aimed to adapt a group-based social cognitive skills training (SCST) program for use in a Korean context and evaluate its feasibility and preliminary effects among community-dwelling individuals with schizophrenia. Forty-seven patients were assigned to either the SCST + treatment as usual (TAU) group (n = 21) or the TAU only group (n = 24). Participants completed tasks to assess social cognition, social functioning, neurocognition, and psychiatric symptoms before and after treatment. Over a period of approximately 12 weeks, drop-out rates were comparably low in both groups, and the attendance rates for the SCST program were high (85.7 %, mean sessions attended = 20.56/24 sessions). The SCST + TAU group demonstrated significant improvements in facial affect recognition, social functioning, and psychiatric symptoms compared to the TAU only group. A non-significant trend in theory of mind was observed, along with no improvements in social perception and neurocognition. The adapted version of the SCST program is feasible for implementation and demonstrates promise for enhancing social cognition and functioning in Korean outpatients with schizophrenia.",2020,The adapted version of the SCST program is feasible for implementation and demonstrates promise for enhancing social cognition and functioning in Korean outpatients with schizophrenia.,"['mental health services in Eastern countries', 'community-dwelling individuals with schizophrenia', 'Korean outpatients with schizophrenia', 'Forty-seven patients', 'routine community mental health services', 'patients with schizophrenia']","['TAU', 'social cognitive skills training', 'social cognitive skills training (SCST) program', 'SCST + TAU', 'SCST program', 'SCST + treatment as usual (TAU']","['social cognition, social functioning, neurocognition, and psychiatric symptoms', 'facial affect recognition, social functioning, and psychiatric symptoms', 'attendance rates', 'social perception and neurocognition']","[{'cui': 'C0025355', 'cui_str': 'Mental health service'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0009475', 'cui_str': 'Mental Health Services, Community'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0579088', 'cui_str': 'Cognitive skills training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0233401', 'cui_str': 'Psychiatric symptom'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0037427', 'cui_str': 'Perception, Social'}]",47.0,0.0204504,The adapted version of the SCST program is feasible for implementation and demonstrates promise for enhancing social cognition and functioning in Korean outpatients with schizophrenia.,"[{'ForeName': 'Jae Eun', 'Initials': 'JE', 'LastName': 'Lim', 'Affiliation': 'Department of Psychology, Korea University, Seoul, Republic of Korea.'}, {'ForeName': 'Ye-Jin', 'Initials': 'YJ', 'LastName': 'Kwon', 'Affiliation': 'Department of Psychology, Korea University, Seoul, Republic of Korea.'}, {'ForeName': 'Soo-Yun', 'Initials': 'SY', 'LastName': 'Jung', 'Affiliation': 'Department of Psychology, Korea University, Seoul, Republic of Korea.'}, {'ForeName': 'Kiho', 'Initials': 'K', 'LastName': 'Park', 'Affiliation': 'Department of Psychology, Korea University, Seoul, Republic of Korea; Korea University Mind Health Institute, Seoul, Republic of Korea.'}, {'ForeName': 'Wonhye', 'Initials': 'W', 'LastName': 'Lee', 'Affiliation': 'Department of Clinical Psychology, National Center for Mental Health, Seoul, Republic of Korea.'}, {'ForeName': 'Seung-Hwan', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Department of Psychiatry, Inje University Ilsan-Paik Hospital, Goyang, Republic of Korea.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'P Horan', 'Affiliation': 'Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Kee-Hong', 'Initials': 'KH', 'LastName': 'Choi', 'Affiliation': 'Department of Psychology, Korea University, Seoul, Republic of Korea; Korea University Mind Health Institute, Seoul, Republic of Korea; Department of Psychology, Wesleyan University, Middletown, USA. Electronic address: kchoi1@korea.ac.kr.'}]",Asian journal of psychiatry,['10.1016/j.ajp.2020.102314'] 2034,32734480,"Correction to: Health economic evaluation of an internet intervention for depression (deprexis), a randomized controlled trial.",An amendment to this paper has been published and can be accessed via the original article.,2020,An amendment to this paper has been published and can be accessed via the original article.,[],['internet intervention'],[],[],"[{'cui': 'C3898714', 'cui_str': 'Internet Intervention'}]",[],,0.08344,An amendment to this paper has been published and can be accessed via the original article.,"[{'ForeName': 'Viola', 'Initials': 'V', 'LastName': 'Gräfe', 'Affiliation': 'Department of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Universitätsstraße 25, 33615, Bielefeld, Germany. viola.graefe@uni-bielefeld.de.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Moritz', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Greiner', 'Affiliation': 'Department of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Universitätsstraße 25, 33615, Bielefeld, Germany.'}]",Health economics review,['10.1186/s13561-020-00280-1'] 2035,32735112,Bicarbonate Unlocks the Ergogenic Action of Ketone Monoester Intake in Endurance Exercise.,"PURPOSE We recently reported that oral ketone ester (KE) intake before and during the initial 30 min of a ~3h 15 min simulated cycling race (RACE) transiently decreased blood pH and bicarbonate without affecting maximal performance in the final quarter of the event. We hypothesized that acid-base disturbances due to KE overrules the ergogenic potential of exogenous ketosis in endurance exercise. METHODS Nine well-trained male cyclists participated in a similar RACE consisting of 3h submaximal intermittent cycling (IMT180') followed by a 15-min time-trial (TT15') preceding an all-out sprint at 175% of lactate threshold (SPRINT). In a randomized cross-over design participants received either i) 65g ketone ester (KE), ii) 300 mg/kg body weight NaHCO3 (BIC), iii) KE+BIC or iv) a control drink (CON), together with consistent 60g per h carbohydrate intake. RESULTS KE ingestion transiently elevated blood D-ß-hydroxybutyrate to ~2-3 mM during the initial 2 hours of RACE (p< 0.001 vs. CON). In KE, blood pH concomitantly dropped from 7.43 to 7.36 whilst bicarbonate decreased from 25.5 to 20.5 mM (both p<0.001 vs. CON). Additional BIC resulted in 0.5 to 0.8 mM higher blood D-ß-hydroxybutyrate during the first half of IMT180' (p < 0.05 vs. KE) and increased blood bicarbonate to 31.1±1.8 mM and blood pH to 7.51±0.03 by the end of IMT180' (p<0.001 vs. KE). Mean power output during TT15' was similar between KE, BIC and CON at ~255 W, but was 5% higher in KE+BIC (p=0.02 vs. CON). Time-to-exhaustion in the sprint was similar between all conditions at ~60s (p=0.88). Gastrointestinal symptoms were similar between groups. DISCUSSION Co-ingestion of oral bicarbonate and KE enhances high-intensity performance at the end of an endurance exercise event without causing gastrointestinal distress.",2020,Time-to-exhaustion in the sprint was similar between all conditions at ~60s (p=0.88).,['Nine well-trained male cyclists participated in a similar RACE consisting of 3h'],"['bicarbonate and KE', 'i', ""submaximal intermittent cycling (IMT180') followed by a 15-min time-trial (TT15') preceding an all-out sprint at 175% of lactate threshold (SPRINT"", 'Bicarbonate', 'oral ketone ester (KE', '65g ketone ester (KE), ii) 300 mg/kg body weight NaHCO3 (BIC), iii', 'control drink (CON']","['blood pH', 'blood pH and bicarbonate', 'Time-to-exhaustion', 'blood D-ß-hydroxybutyrate', 'blood bicarbonate', 'KE ingestion transiently elevated blood D-ß-hydroxybutyrate', 'Mean power output during TT15', 'Gastrointestinal symptoms']","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}]","[{'cui': 'C0005367', 'cui_str': 'Bicarbonate'}, {'cui': 'C0022634', 'cui_str': 'Ketone'}, {'cui': 'C0014898', 'cui_str': 'Ester'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0560741', 'cui_str': 'mg/kg body weight'}, {'cui': 'C0074722', 'cui_str': 'Sodium Bicarbonate'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0452428', 'cui_str': 'Drink'}]","[{'cui': 'C0853363', 'cui_str': 'Blood pH'}, {'cui': 'C0005367', 'cui_str': 'Bicarbonate'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0020332', 'cui_str': 'Hydroxybutyrates'}, {'cui': 'C0853263', 'cui_str': 'Blood bicarbonate'}, {'cui': 'C0022634', 'cui_str': 'Ketone'}, {'cui': 'C0014898', 'cui_str': 'Ester'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}]",,0.0531584,Time-to-exhaustion in the sprint was similar between all conditions at ~60s (p=0.88).,"[{'ForeName': 'Chiel', 'Initials': 'C', 'LastName': 'Poffé', 'Affiliation': '1Exercise Physiology Research Group, Department of Movement Sciences, KU Leuven, Leuven, Belgium 2Department of Physical and Rehabilitation Medicine; University Hospitals Leuven, Leuven, Belgium 3Locomotor and neurological disorders, Department of Development and Regeneration, Faculty of Medicine, KU Leuven, Leuven, Belgium 4Bakala Academy-Athletic Performance Center, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'Ramaekers', 'Affiliation': ''}, {'ForeName': 'Stijn', 'Initials': 'S', 'LastName': 'Bogaerts', 'Affiliation': ''}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hespel', 'Affiliation': ''}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002467'] 2036,32735113,The Effect of Preexercise Expiratory Muscle Loading on Exercise Tolerance in Healthy Men.,"PURPOSE Acute non-fatiguing inspiratory muscle loading transiently increases diaphragm excitability and global inspiratory muscle strength, and may improve subsequent exercise performance. We investigated the effect of acute expiratory muscle loading on expiratory muscle function and exercise tolerance in healthy men. METHODS Ten males cycled at 90% of peak power output to the limit of tolerance (TLIM) after: 1) 2 × 30 expiratory efforts against a pressure-threshold load of 40% maximal expiratory gastric pressure (PgaMAX) (EML-EX); and 2) 2 × 30 expiratory efforts against a pressure-threshold load of 10% PgaMAX (SHAM-EX). Changes in expiratory muscle function were assessed by measuring the mouth pressure (PEMAX) and PgaMAX responses to maximal expulsive efforts, and magnetically evoked (1-Hz) gastric twitch pressure (Pgatw). RESULTS Expiratory loading at 40% of PgaMAX increased PEMAX (10 ± 5%, P = 0.001) and PgaMAX (9 ± 5%, P = 0.004). Conversely, there was no change in PEMAX (166 ± 40 vs. 165 ± 35 cmH2O, P = 1.000) or PgaMAX (196 ± 38 vs. 192 ± 39 cmH2O, P = 0.215) from before to after expiratory loading at 10% of PgaMAX. Exercise time was not different in EML-EX vs. SHAM-EX (7.91 ± 1.96 vs. 8.09 ± 1.77 min, 95% CI = -1.02 to 0.67, P = 0.651). Similarly, exercise-induced expiratory muscle fatigue was not different in EML-EX vs. SHAM-EX (-28 ± 12 vs. -26 ± 7% reduction in Pgatw amplitude, P = 0.280). Perceptual ratings of dyspnea and leg discomfort were not different during EML-EX vs. SHAM-EX. CONCLUSION Acute expiratory muscle loading enhances expiratory muscle function but does not improve subsequent severe-intensity exercise tolerance in healthy men.",2020,"Exercise time was not different in EML-EX vs. SHAM-EX (7.91 ± 1.96 vs. 8.09 ± 1.77 min, 95% CI = -1.02 to 0.67, P = 0.651).","['Healthy Men', 'healthy men', 'Ten males cycled at 90% of peak power output to the limit of tolerance (TLIM) after: 1) 2 × 30']","['Preexercise Expiratory Muscle Loading', 'acute expiratory muscle loading', 'expiratory efforts against a pressure-threshold load of 40% maximal expiratory gastric pressure (PgaMAX) (EML-EX); and 2) 2 × 30 expiratory efforts against a pressure-threshold load of 10% PgaMAX (SHAM-EX']","['mouth pressure (PEMAX) and PgaMAX responses to maximal expulsive efforts, and magnetically evoked (1-Hz) gastric twitch pressure (Pgatw', 'Exercise time', 'expiratory muscle fatigue', 'diaphragm excitability and global inspiratory muscle strength', 'expiratory muscle function and exercise tolerance', 'Perceptual ratings of dyspnea and leg discomfort', 'expiratory muscle function', 'Expiratory loading']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}]","[{'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0429216', 'cui_str': 'Gastric pressure'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C1444748', 'cui_str': 'Evoked'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0231530', 'cui_str': 'Muscle twitch'}, {'cui': 'C0439587', 'cui_str': 'Exercise time'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0242979', 'cui_str': 'Muscle fatigue'}, {'cui': 'C0011980', 'cui_str': 'Diaphragm structure'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0231484', 'cui_str': 'Muscle function'}, {'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0859235', 'cui_str': 'Leg discomfort'}]",,0.116673,"Exercise time was not different in EML-EX vs. SHAM-EX (7.91 ± 1.96 vs. 8.09 ± 1.77 min, 95% CI = -1.02 to 0.67, P = 0.651).","[{'ForeName': 'Tim A', 'Initials': 'TA', 'LastName': 'Hardy', 'Affiliation': '1School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom 2School of Sport & Exercise, University of Gloucestershire, Gloucester, United Kingdom 3School of Sport & Health Sciences, College of Life & Environmental Sciences, University of Exeter, Exeter, United Kingdom 4Department of Cardiovascular Diseases, Mayo Clinic in Florida, Jacksonville, FL.'}, {'ForeName': 'Stephen C', 'Initials': 'SC', 'LastName': 'How', 'Affiliation': ''}, {'ForeName': 'Bryan J', 'Initials': 'BJ', 'LastName': 'Taylor', 'Affiliation': ''}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002468'] 2037,32735114,Multidirectional Walking in Hematopoietic Stem Cell Transplant Patients.,"BACKGROUND The effect of a peri-transplant multidirectional walking intervention to target losses in physical function and quality of life has not been investigated. PURPOSE This study examined the effects of a novel multidirectional walking program on physical function and quality of life in adults receiving a hematopoietic stem cell transplant (HSCT). METHODS Thirty-five adults receiving an autologous or allogeneic HSCT were randomized to a multidirectional walking (WALK) or usual care (CONT) group. The WALK group received supervised training during hospitalization; the CONT group received usual care. Patients were assessed at admission (t0), three to five days post-HSCT (t1), and 30-days post-HSCT (t2). Physical function measures included the six-minute walk test (6MWT), the Physical Performance Test, and the Timed-Up-and-Go. Health-related quality of life (QOL) was collected using the FACT-BMT questionnaire. RESULTS There were no significant between-group changes for physical function or QOL. However, after the intervention (t1 to t2), the WALK group showed significant improvement in aerobic capacity (6MWT, p=.01), physical (p<.01) and functional well-being (p=.04), and overall QOL scores (p<.01). The CONT group saw no significant changes in physical function or QOL. Effect sizes showed the WALK group had a larger positive effect on physical function and QOL. Minimal clinically important differences in the 6MWT and FACT-BMT were exceeded in the WALK group. CONCLUSION A multi-directional walking program during the transplant period may be effective at increasing aerobic capacity and QOL for patients receiving HSCT compared to no structured exercise.",2020,"Minimal clinically important differences in the 6MWT and FACT-BMT were exceeded in the WALK group. ","['Thirty-five adults receiving an autologous or allogeneic HSCT', 'adults receiving a hematopoietic stem cell transplant (HSCT', 'Hematopoietic Stem Cell Transplant Patients']","['HSCT', 'peri-transplant multidirectional walking intervention', 'Multidirectional Walking', 'novel multidirectional walking program', 'supervised training during hospitalization; the CONT group received usual care', 'multidirectional walking (WALK) or usual care (CONT']","['6MWT and FACT-BMT', 'physical function and QOL', 'Health-related quality of life (QOL', 'six-minute walk test (6MWT), the Physical Performance Test, and the Timed-Up-and-Go', 'aerobic capacity (6MWT, p=.01), physical (p<.01) and functional well-being (p=.04), and overall QOL scores', 'physical function and quality of life', 'physical function or QOL', 'aerobic capacity and QOL']","[{'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0005961', 'cui_str': 'Transplantation of bone marrow'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",35.0,0.0340436,"Minimal clinically important differences in the 6MWT and FACT-BMT were exceeded in the WALK group. ","[{'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Potiaumpai', 'Affiliation': '1Penn State Cancer Institute, Hershey, PA 2Sylvester Comprehensive Cancer Center, Miami, FL 3Dana-Farber Cancer Institute, Boston, MA 4University of Miami, Coral Gables, FL 5Ultimate Software, Weston, FL.'}, {'ForeName': 'Stacy', 'Initials': 'S', 'LastName': 'Cutrono', 'Affiliation': ''}, {'ForeName': 'Tamia', 'Initials': 'T', 'LastName': 'Medina', 'Affiliation': ''}, {'ForeName': 'Maximillian', 'Initials': 'M', 'LastName': 'Koeppel', 'Affiliation': ''}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Pereira', 'Affiliation': ''}, {'ForeName': 'William F', 'Initials': 'WF', 'LastName': 'Pirl', 'Affiliation': ''}, {'ForeName': 'Kevin A', 'Initials': 'KA', 'LastName': 'Jacobs', 'Affiliation': ''}, {'ForeName': 'Moataz', 'Initials': 'M', 'LastName': 'Eltoukhy', 'Affiliation': ''}, {'ForeName': 'Joseph F', 'Initials': 'JF', 'LastName': 'Signorile', 'Affiliation': ''}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002474'] 2038,32730946,"Domain-specific Involvement of the Posterior Parietal Cortex in Attention Network and Attentional Control of ADHD: A Randomized, Cross-over, Sham-controlled tDCS Study.","Transcranial direct current stimulation (tDCS) has been increasingly used in attention-deficit hyperactivity disorder (ADHD) with mixed results. Previous studies merely targeted the dorsolateral prefrontal cortex and right inferior frontal gyrus with partial or no improving effects on cognitive deficits respectively. Posterior parietal cortex is another region involved in attentional functioning of ADHD, however, its contribution to attention functions has not been explored via tDCS studies in this disease. Moreover, attention networks are not investigated in the previous tDCS studies in ADHD. Here, we explored the effects of anodal tDCS over the right posterior parietal cortex (r-PPC) on attentional functioning (attention networks, selective attention, shifting attention) and response inhibition in ADHD children. 19 children with ADHD were recruited and underwent anodal/sham tDCS (1 mA, 20 min) during task performance in a randomized cross-over design. Our results show an improving effect of anodal r-PPC tDCS specifically on the orienting but alerting or executive networks, in line with findings of healthy populations. Furthermore, activation of the r-PPC had a deteriorating effect on the top-down attentional control required for selective attention measured by the Stroop test. Modeling of the current flow showed a stronger electrical field induced in the inferior PPC (BA 39,40) which mediates bottom-up attentional control. No significant effect on shifting attention and response inhibition was found. Our results show a domain-specific involvement of the r-PPC in attention orienting network of ADHD children. Activation of the r-PPC improves bottom-up but hinders top-down attentional control suggesting a critical role of the r-PPC in bottom-up attentional control in ADHD.",2020,"Our results show an improving effect of anodal r-PPC tDCS specifically on the orienting but alerting or executive networks, in line with findings of healthy populations.","['ADHD', 'ADHD children', '19 children with ADHD']","['Transcranial direct current stimulation (tDCS', 'anodal tDCS', 'anodal r-PPC tDCS', 'anodal/sham tDCS']","['attentional functioning (attention networks, selective attention, shifting attention', 'shifting attention and response inhibition']","[{'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0456855', 'cui_str': 'Right posterior'}, {'cui': 'C0030560', 'cui_str': 'Parietal lobe structure'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0233421', 'cui_str': 'Selective inattention'}, {'cui': 'C0333051', 'cui_str': 'Shift'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}]",19.0,0.0442588,"Our results show an improving effect of anodal r-PPC tDCS specifically on the orienting but alerting or executive networks, in line with findings of healthy populations.","[{'ForeName': 'Mohammad Ali', 'Initials': 'MA', 'LastName': 'Salehinejad', 'Affiliation': 'Leibniz Research Centre for Working Environment and Human Factors, Department of Psychology and Neurosciences, Dortmund, Germany; Ruhr-University Bochum, International Graduate School of Neuroscience, Bochum, Germany.'}, {'ForeName': 'Elnaz', 'Initials': 'E', 'LastName': 'Ghayerin', 'Affiliation': 'Department of Psychology, Shahid Beheshti University, Tehran, Iran.'}, {'ForeName': 'Vahid', 'Initials': 'V', 'LastName': 'Nejati', 'Affiliation': 'Department of Psychology, Shahid Beheshti University, Tehran, Iran. Electronic address: nejati@sbu.ac.ir.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Yavari', 'Affiliation': 'Leibniz Research Centre for Working Environment and Human Factors, Department of Psychology and Neurosciences, Dortmund, Germany.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Nitsche', 'Affiliation': 'Leibniz Research Centre for Working Environment and Human Factors, Department of Psychology and Neurosciences, Dortmund, Germany; University Medical Hospital Bergmannsheil, Department of Neurology, Bochum, Germany.'}]",Neuroscience,['10.1016/j.neuroscience.2020.07.037'] 2039,32730948,An Integrative Clustering Approach to tDCS Individual Response Variability in Cognitive Performance: Beyond a Null Effect on Working Memory.,"Despite the growing interest in the use of transcranial direct current stimulation (tDCS) for the modulation of human cognitive function, there are contradictory findings regarding the cognitive benefits of this technique. Inter-individual response variability to tDCS may play a significant role. We explored the effects of anodal versus sham tDCS over the left prefrontal cortex (LPFC) on working memory performance, taking into account the inter-individual variability. Twenty-nine healthy volunteers received an 'offline' anodal tDCS (1.5 mA, 15 min) to the left prefrontal cortex (F3 electrode site) in an intra-individual, cross-over, sham-controlled experimental design. n-back and Sternberg task performance was assessed before (baseline), immediately after tDCS administration (T1) and 5 min post-T1 (T2). We applied an integrative clustering approach to characterize both the group and individual responses to tDCS, as well as identifying naturally occurring subgroups that may be present within the total sample. Anodal tDCS failed to improve working memory performance in the total sample. Cluster analysis identified a subgroup of 'responders' who significantly improved their performance after anodal (vs. sham) stimulation, although not to a greater extent than the best baseline or sham condition. The proportion of 'responders' ranged from 15% to 59% across task conditions and behavioral outputs. Our findings show a high inter-individual variability of the tDCS response, suggesting that the use of tCDS may not be an effective tool to improve working memory performance in healthy subjects. We propose that the use of clustering methods is more suitable in identifying 'responders' and for evaluating the efficacy of this technique.",2020,"Cluster analysis identified a subgroup of 'responders' who significantly improved their performance after anodal (vs. sham) stimulation, although not to a greater extent than the best baseline or sham condition.","['Twenty-nine healthy volunteers', 'healthy subjects']","['Anodal tDCS', 'transcranial direct current stimulation (tDCS', 'anodal versus sham tDCS', ""offline' anodal tDCS (1.5mA, 15min) to the left prefrontal cortex (F3 electrode site) in an intra-individual, cross-over, sham-controlled experimental design""]","['n-back and Sternberg task performance', 'working memory performance']","[{'cui': 'C0450351', 'cui_str': '29'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0450424', 'cui_str': 'To the left'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0013812', 'cui_str': 'Electrode'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0010366', 'cui_str': 'Genetic crossing over'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}]","[{'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}]",29.0,0.0384338,"Cluster analysis identified a subgroup of 'responders' who significantly improved their performance after anodal (vs. sham) stimulation, although not to a greater extent than the best baseline or sham condition.","[{'ForeName': 'Luque-Casado', 'Initials': 'LC', 'LastName': 'Antonio', 'Affiliation': 'Area of Sport Sciences, Faculty of Sports Sciences and Physical Education, Center for Sport Studies, King Juan Carlos University, Madrid, Spain.'}, {'ForeName': 'Rodríguez-Freiría', 'Initials': 'RF', 'LastName': 'Rocío', 'Affiliation': 'Department of Physical Education and Sport, Faculty of Sports Sciences and Physical Education, University of A Coruna, Performance and Health Group, A Coruña, Spain.'}, {'ForeName': 'Fogelson', 'Initials': 'F', 'LastName': 'Noa', 'Affiliation': 'Area of Sport Sciences, Faculty of Sports Sciences and Physical Education, Center for Sport Studies, King Juan Carlos University, Madrid, Spain.'}, {'ForeName': 'Iglesias-Soler', 'Initials': 'IS', 'LastName': 'Eliseo', 'Affiliation': 'Department of Physical Education and Sport, Faculty of Sports Sciences and Physical Education, University of A Coruna, Performance and Health Group, A Coruña, Spain.'}, {'ForeName': 'Fernández-Del-Olmo', 'Initials': 'FD', 'LastName': 'Miguel', 'Affiliation': 'Area of Sport Sciences, Faculty of Sports Sciences and Physical Education, Center for Sport Studies, King Juan Carlos University, Madrid, Spain. Electronic address: miguel.delolmo@urjc.es.'}]",Neuroscience,['10.1016/j.neuroscience.2020.07.036'] 2040,32732022,"Effects of a leaflet on breast cancer screening knowledge, explicit attitudes, and implicit associations.","OBJECTIVE To assess the effect of an information leaflet on knowledge, explicit attitudes, implicit associations, and attendance for breast cancer screening. METHODS Dutch women (aged 49-75 years) were approached three months before their breast cancer screening invitation. After providing informed consent, participants were randomised to receiving the information leaflet (intervention condition) or not (control condition). Screening knowledge, explicit attitudes, and implicit associations were assessed through web-based questionnaires, at baseline and two weeks later. Actual screening attendance data were collected. RESULTS In total, 988 women completed both questionnaires. Participants in the leaflet condition scored higher on knowledge (9.9 versus 9.6, p < 0.001, scale 0-11), and more often had positive explicit attitudes (97 % versus 95 %, p = 0.03), than those in the control condition. This contrast was bigger among first-time invitees. Implicit associations were not correlated with explicit attitudes or attendance. Explicit attitudes were moderately correlated with attendance (r=.30, p < 0.001). CONCLUSION The information leaflet led to more knowledge and more positive explicit attitudes. Implicit associations towards breast cancer screening were not correlated with attendance. PRACTICE IMPLICATIONS Encouragement to learn about the screening programme can increase levels of knowledge of invitees and therefore support their decision-making about participation. This might be especially relevant for first-time invitees.",2020,"Participants in the leaflet condition scored higher on knowledge (9.9 versus 9.6, p < 0.001, scale 0-11), and more often had positive explicit attitudes (97 % versus 95 %, p = 0.03), than those in the control condition.","['988 women completed both questionnaires', 'Dutch women (aged 49-75 years']",['information leaflet (intervention condition) or not (control condition'],"['Explicit attitudes', 'positive explicit attitudes', 'Implicit associations towards breast cancer screening', 'breast cancer screening knowledge, explicit attitudes, and implicit associations', 'knowledge']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0281182', 'cui_str': 'Screening for malignant neoplasm of breast'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",988.0,0.0280732,"Participants in the leaflet condition scored higher on knowledge (9.9 versus 9.6, p < 0.001, scale 0-11), and more often had positive explicit attitudes (97 % versus 95 %, p = 0.03), than those in the control condition.","[{'ForeName': 'Lindy M', 'Initials': 'LM', 'LastName': 'Kregting', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, the Netherlands. Electronic address: l.kregting@erasmusmc.nl.'}, {'ForeName': 'Nicolien T', 'Initials': 'NT', 'LastName': 'van Ravesteyn', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, the Netherlands.'}, {'ForeName': 'Wolfert', 'Initials': 'W', 'LastName': 'Spijker', 'Affiliation': 'Bevolkingsonderzoek Zuid-West, Rotterdam, the Netherlands.'}, {'ForeName': 'Tessa', 'Initials': 'T', 'LastName': 'Dierks', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, the Netherlands.'}, {'ForeName': 'Clare A', 'Initials': 'CA', 'LastName': 'Aitken', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, the Netherlands.'}, {'ForeName': 'H Amarens', 'Initials': 'HA', 'LastName': 'Geuzinge', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, the Netherlands.'}, {'ForeName': 'Ida J', 'Initials': 'IJ', 'LastName': 'Korfage', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, the Netherlands.'}]",Patient education and counseling,['10.1016/j.pec.2020.06.032'] 2041,32736216,Combined exercise training improves cognitive functions in multiple sclerosis patients with cognitive impairment: A single-blinded randomized controlled trial.,"BACKGROUND Cognitive impairment is common in patients with multiple sclerosis (MS). The effects of different exercise trainings on cognitive functions in patients with MS are promising. However, the effects are not yet clear in MS patients with cognitive impairment. This study aimed to investigate the effect of combined exercise training on different cognitive functions in MS patients with cognitive impairment. METHODS Relapsing-remitting and mild disabled MS patients with cognitive impairment were randomly assigned to two groups: Exercise Group (EG, n:17) and the Control Group (CG, n:17). The EG received a combined exercise training consisting of aerobic and Pilates training in three sessions per week for 8 weeks while the CG performed the relaxation exercises at home. Cognitive functions, walking capacity, fatigue, mood, and quality of life were assessed at baseline and after eight weeks using the Brief Repeatable Battery of Neuropsychological Tests (BRB-N), Six-Minute Walk Test (6-MWT), Fatigue Impact Scale (FIS), Beck's Depression Inventory (BDI) and MS Quality of Life-54 (MSQoL-54), respectively. RESULTS This study showed significant group-by-time interactions on long-term verbal memory, walking capacity, cognitive fatigue, and physical quality of life in favor of the EG (p<0.003). Moreover, verbal memory, visuospatial memory, verbal fluency, information processing speed, walking capacity, fatigue, and quality of life improved in the EG (p<0.05) while only verbal memory increased in the CG (p<0.05). Furthermore, the change in visuospatial memory was associated with the change in mental quality of life (r:0.352, p: 0.041) while the change in verbal fluency (r: -0.362, p:0.035) and processing speed (r: -0.356, p:0.039) were associated with the change in mood. CONCLUSION Combined exercise training has beneficial effects on different cognitive functions in mild disabled RRMS patients with cognitive impairment. In addition, there is a mutual relationship in improvements in cognitive functions, mood, and quality of life after exercise.",2020,"This study showed significant group-by-time interactions on long-term verbal memory, walking capacity, cognitive fatigue, and physical quality of life in favor of the EG (p<0.003).","['mild disabled RRMS patients with cognitive impairment', 'multiple sclerosis patients with cognitive impairment', 'patients with MS', 'Relapsing-remitting and mild disabled MS patients with cognitive impairment', 'patients with multiple sclerosis (MS', 'MS patients with cognitive impairment']","['Combined exercise training', 'combined exercise training consisting of aerobic and Pilates training', 'exercise trainings', 'Exercise Group (EG, n:17) and the Control Group (CG, n:17', 'combined exercise training']","['change in visuospatial memory', 'verbal fluency', 'long-term verbal memory, walking capacity, cognitive fatigue, and physical quality of life', 'processing speed', 'Cognitive functions, walking capacity, fatigue, mood, and quality of life', 'cognitive functions', ""Brief Repeatable Battery of Neuropsychological Tests (BRB-N), Six-Minute Walk Test (6-MWT), Fatigue Impact Scale (FIS), Beck's Depression Inventory (BDI) and MS Quality of Life-54 (MSQoL-54), respectively"", 'verbal memory, visuospatial memory, verbal fluency, information processing speed, walking capacity, fatigue, and quality of life improved in the EG (p<0.05) while only verbal memory', 'mental quality of life', 'cognitive functions, mood, and quality of life']","[{'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0018576', 'cui_str': 'Handicapped'}, {'cui': 'C1522002', 'cui_str': 'RRM Motif'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C2733557', 'cui_str': 'Fatigue impact scale'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0021420', 'cui_str': 'Information Processing'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",,0.0502248,"This study showed significant group-by-time interactions on long-term verbal memory, walking capacity, cognitive fatigue, and physical quality of life in favor of the EG (p<0.003).","[{'ForeName': 'Cagla', 'Initials': 'C', 'LastName': 'Ozkul', 'Affiliation': 'Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey. Electronic address: caglaozkul@hotmail.com.'}, {'ForeName': 'Arzu', 'Initials': 'A', 'LastName': 'Guclu-Gunduz', 'Affiliation': 'Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey.'}, {'ForeName': 'Kader', 'Initials': 'K', 'LastName': 'Eldemir', 'Affiliation': 'Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey.'}, {'ForeName': 'Yasemin', 'Initials': 'Y', 'LastName': 'Apaydin', 'Affiliation': 'Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey.'}, {'ForeName': 'Gokhan', 'Initials': 'G', 'LastName': 'Yazici', 'Affiliation': 'Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey.'}, {'ForeName': 'Ceyla', 'Initials': 'C', 'LastName': 'Irkec', 'Affiliation': 'Gazi University, Faculty of Medicine, Department of Neurology, Ankara, Turkey.'}]",Multiple sclerosis and related disorders,['10.1016/j.msard.2020.102419'] 2042,32736299,"A beverage containing ora-pro-nobis flour improves intestinal health, weight, and body composition: A double-blind randomized prospective study.","OBJECTIVE The aim of this study was to verify the effect of a beverage containing ora-pro-nobis (OPN) flour on intestinal microbiota, gastrointestinal symptoms, and anthropometric parameters in women. METHODS This prospective, double-blinded, randomized clinical trial included 24 women volunteers. For 6 wk, the test group received a beverage supplemented with OPN, and the control group received the same beverage without OPN. Fecal microbiota were evaluated by the fluorescence in situ hybridization method. Each participant responded to a questionnaire based on the Gastrointestinal Symptom Rating Scale. The data were analyzed by Student's t test to compare the effects between treatments (P < 0.05). RESULTS Supplementation with the OPN beverage reduced weight (P = 0.008), waist circumference (P = 0.010), and body fat (P = 0.000). Additionally, the treatment increased satiety (P = 0.039), reduced eructation (P = 0.038) and constipation (P = 0.017), and improved feces consistency (P = 0.017). CONCLUSION The OPN flour beverage has an effect on weight reduction, body fat composition, and improvement in gastrointestinal symptoms. These results highlight the beneficial effects of ora-pro-nobis flour beverage against the development of obesity.",2020,"RESULTS Supplementation with the OPN beverage reduced weight (P = 0.008), waist circumference (P = 0.010), and body fat (P = 0.000).","['24 women volunteers', 'women']","['beverage containing ora-pro-nobis (OPN) flour', 'beverage supplemented with OPN, and the control group received the same beverage without OPN']","['weight', 'waist circumference', 'feces consistency', 'satiety', 'Gastrointestinal Symptom Rating Scale', 'intestinal health, weight, and body composition', 'weight reduction, body fat composition, and improvement in gastrointestinal symptoms', 'reduced eructation', 'Fecal microbiota', 'intestinal microbiota, gastrointestinal symptoms, and anthropometric parameters', 'body fat', 'constipation']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0016260', 'cui_str': 'Flour'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0014724', 'cui_str': 'Eructation'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}]",24.0,0.165472,"RESULTS Supplementation with the OPN beverage reduced weight (P = 0.008), waist circumference (P = 0.010), and body fat (P = 0.000).","[{'ForeName': 'Camilla Ribeiro', 'Initials': 'CR', 'LastName': 'Vieira', 'Affiliation': 'Department of Nutrition, Universidade Federal de Alfenas, Alfenas, Brazil.'}, {'ForeName': 'Mariana', 'Initials': 'M', 'LastName': 'Grancieri', 'Affiliation': 'Department of Nutrition and Health, Universidade Federal de Viçosa, Viçosa, Brazil.'}, {'ForeName': 'Hércia Stampini Duarte', 'Initials': 'HSD', 'LastName': 'Martino', 'Affiliation': 'Department of Nutrition and Health, Universidade Federal de Viçosa, Viçosa, Brazil.'}, {'ForeName': 'Dionéia Evangelista', 'Initials': 'DE', 'LastName': 'César', 'Affiliation': 'Department of Biology, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil.'}, {'ForeName': 'Roberta Ribeiro Silva', 'Initials': 'RRS', 'LastName': 'Barra', 'Affiliation': 'Department of Nutrition, Universidade Federal de Alfenas, Alfenas, Brazil. Electronic address: betaribeiro@hotmail.com.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110869'] 2043,32737072,Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS.,"OBJECTIVE To better understand ozanimod's mechanism of action (MOA), we conducted exploratory analyses from a phase 1 study to characterize ozanimod's effect on circulating leukocyte subsets in patients with relapsing multiple sclerosis. METHODS An open-label pharmacodynamic study randomized patients to oral ozanimod hydrochloride (HCl) 0.5 (n = 13) or 1 mg/d (n = 11) for ∼12 weeks (including 7-day dose escalation). Circulating leukocyte subsets were quantified using flow cytometry (days 28, 56, and 85) and epigenetic cell counting (days 2, 5, 28, 56, and 85) and compared with baseline (day 1) using descriptive statistics. RESULTS Ozanimod caused dose-dependent reductions in absolute lymphocyte counts. Observed by both methodologies, circulating CD19 + B- and CD3 + T-cell counts were reduced by >50% with ozanimod HCl 0.5 mg and >75% with 1 mg at day 85. Based on flow cytometry, ozanimod HCl 1 mg showed greater decreases in CD4 + than CD8 + T cells, greater decreases in both CD4 + and CD8 + central memory vs effector memory T cells, and reductions in mean CD4 + and CD8 + naive T cells by ≥90% at day 85. In the flow cytometry analysis, changes in monocytes, natural killer, and natural killer T cells were minimal. Using epigenetic cell counting, greater reductions for Th17 than T regulatory cells were determined. CONCLUSION Ozanimod induced dose-dependent reductions in circulating B- and T-cell counts and differential effects on naive and memory CD4 + and CD8 + T cells and CD19 + B cells. Data characterized with both a novel epigenetic cell-counting method and flow cytometry support ozanimod's MOA. CLINICAL TRIAL REGISTRATION clinicaltrials.gov NCT02797015.",2020,"Based on flow cytometry, ozanimod HCl 1 mg showed greater decreases in CD4 + than CD8 + T cells, greater decreases in both CD4 + and CD8 + central memory vs effector memory T cells, and reductions in mean CD4 + and CD8 + naive T cells by ≥90% at day 85.","['patients with relapsing multiple sclerosis', 'relapsing MS']","['sphingosine-1-phosphate receptor modulator ozanimod', 'ozanimod HCl', 'oral ozanimod hydrochloride (HCl']","['circulating CD19 + B- and CD3 + T-cell counts', 'Circulating leukocyte subsets', 'absolute lymphocyte counts', 'circulating B- and T-cell counts and differential effects on naive and memory CD4 + and CD8 + T cells and CD19 + B cells', 'CD4 + and CD8 + central memory vs effector memory T cells, and reductions in mean CD4 + and CD8 + naive T cells', 'changes in monocytes, natural killer, and natural killer T cells']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0856120', 'cui_str': 'Multiple sclerosis relapse'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}]","[{'cui': 'C4760638', 'cui_str': 'Sphingosine Receptor Modulators'}, {'cui': 'C4278675', 'cui_str': 'ozanimod'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0108748', 'cui_str': 'Lymphocyte antigen CD19'}, {'cui': 'C1277786', 'cui_str': 'CD3 T-cell count procedure'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C3544087', 'cui_str': 'Absolute lymphocyte count'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0443199', 'cui_str': 'Differential'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0242629', 'cui_str': 'Lymphocyte positive for CD8 antigen'}, {'cui': 'C0004561', 'cui_str': 'B lymphocyte'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C4543203', 'cui_str': 'Effector'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0026473', 'cui_str': 'Monocyte'}, {'cui': 'C0205296', 'cui_str': 'Natural'}, {'cui': 'C2350466', 'cui_str': 'Natural Killer T-Cell'}]",,0.0568721,"Based on flow cytometry, ozanimod HCl 1 mg showed greater decreases in CD4 + than CD8 + T cells, greater decreases in both CD4 + and CD8 + central memory vs effector memory T cells, and reductions in mean CD4 + and CD8 + naive T cells by ≥90% at day 85.","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Harris', 'Affiliation': 'From Bristol-Myers Squibb Company (S.H., J.Q.T.), Princeton, NJ; Data Clarity Consulting Ltd. (H.S.), Stockport, England, United Kingdom; and Department of Neurology, Weill Institute for Neurosciences (C.M.S., B.A.C.C., S.S.Z.), and Program in Immunology (C.M.S., S.S.Z.), University of California San Francisco (UCSF). sarah.harris@bms.com.'}, {'ForeName': 'Jonathan Q', 'Initials': 'JQ', 'LastName': 'Tran', 'Affiliation': 'From Bristol-Myers Squibb Company (S.H., J.Q.T.), Princeton, NJ; Data Clarity Consulting Ltd. (H.S.), Stockport, England, United Kingdom; and Department of Neurology, Weill Institute for Neurosciences (C.M.S., B.A.C.C., S.S.Z.), and Program in Immunology (C.M.S., S.S.Z.), University of California San Francisco (UCSF).'}, {'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'Southworth', 'Affiliation': 'From Bristol-Myers Squibb Company (S.H., J.Q.T.), Princeton, NJ; Data Clarity Consulting Ltd. (H.S.), Stockport, England, United Kingdom; and Department of Neurology, Weill Institute for Neurosciences (C.M.S., B.A.C.C., S.S.Z.), and Program in Immunology (C.M.S., S.S.Z.), University of California San Francisco (UCSF).'}, {'ForeName': 'Collin M', 'Initials': 'CM', 'LastName': 'Spencer', 'Affiliation': 'From Bristol-Myers Squibb Company (S.H., J.Q.T.), Princeton, NJ; Data Clarity Consulting Ltd. (H.S.), Stockport, England, United Kingdom; and Department of Neurology, Weill Institute for Neurosciences (C.M.S., B.A.C.C., S.S.Z.), and Program in Immunology (C.M.S., S.S.Z.), University of California San Francisco (UCSF).'}, {'ForeName': 'Bruce A C', 'Initials': 'BAC', 'LastName': 'Cree', 'Affiliation': 'From Bristol-Myers Squibb Company (S.H., J.Q.T.), Princeton, NJ; Data Clarity Consulting Ltd. (H.S.), Stockport, England, United Kingdom; and Department of Neurology, Weill Institute for Neurosciences (C.M.S., B.A.C.C., S.S.Z.), and Program in Immunology (C.M.S., S.S.Z.), University of California San Francisco (UCSF).'}, {'ForeName': 'Scott S', 'Initials': 'SS', 'LastName': 'Zamvil', 'Affiliation': 'From Bristol-Myers Squibb Company (S.H., J.Q.T.), Princeton, NJ; Data Clarity Consulting Ltd. (H.S.), Stockport, England, United Kingdom; and Department of Neurology, Weill Institute for Neurosciences (C.M.S., B.A.C.C., S.S.Z.), and Program in Immunology (C.M.S., S.S.Z.), University of California San Francisco (UCSF).'}]",Neurology(R) neuroimmunology & neuroinflammation,['10.1212/NXI.0000000000000839'] 2044,32737087,"Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study.","INTRODUCTION Opioid agonist treatment is effective for opioid dependence and newer extended-release buprenorphine (BUP-XR) injections represent a significant development. The Community Long-Acting Buprenorphine (CoLAB) study aims to evaluate client outcomes among people with opioid dependence receiving 48 weeks of BUP-XR treatment, and examines the implementation of BUP-XR in diverse community healthcare settings in Australia. METHODS AND ANALYSIS The CoLAB study is a prospective single-arm, multicentre, open-label trial of monthly BUP-XR injections in people with opioid dependence. Participants are being recruited from a network of general practitioner and specialist drug treatment services located in the states of New South Wales, Victoria and South Australia in Australia. Following a minimum 7 days on 8-32 mg of sublingual buprenorphine (±naloxone), participants will receive monthly subcutaneous BUP-XR injections administered by a healthcare practitioner at intervals of 28 days (-2/+14 days). The primary endpoint is participant retention in treatment at 48 weeks after treatment initiation. Secondary endpoints will evaluate dosing schedule variations, craving, withdrawal, substance use, health and well-being, and client-reported treatment experience. Qualitative and costing substudies will examine implementation barriers and facilitators at the client and provider level. ETHICS AND DISSEMINATION The study has received ethics approval from the St Vincent's Hospital Sydney Human Research Ethics Committee (Ref. HREC/18/SVH/221). The findings will be disseminated via publication in peer-reviewed journals, presentations at national and international scientific conferences, and in relevant community organisation publications and forums. TRIAL REGISTRATION NUMBER NCT03809143 PROTOCOL IDENTIFIER: CoLAB1801, V.4.0 dated 01 August 2019.",2020,"The Community Long-Acting Buprenorphine (CoLAB) study aims to evaluate client outcomes among people with opioid dependence receiving 48 weeks of BUP-XR treatment, and examines the implementation of BUP-XR in diverse community healthcare settings in Australia. ","['people with opioid dependence receiving 48 weeks of BUP-XR treatment, and examines the implementation of BUP-XR in diverse community healthcare settings in Australia', 'Participants are being recruited from a network of general practitioner and specialist drug treatment services located in the states of New South Wales, Victoria and South Australia in Australia', 'people with opioid dependence']","['depot buprenorphine', 'Buprenorphine (CoLAB', 'subcutaneous BUP-XR injections', 'BUP-XR injections', 'sublingual buprenorphine (±naloxone']","['participant retention', 'dosing schedule variations, craving, withdrawal, substance use, health and well-being, and client-reported treatment experience']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0524662', 'cui_str': 'Opioid dependence'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0086034', 'cui_str': 'Community Healthcare'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0043015', 'cui_str': 'Wales'}, {'cui': 'C0042645', 'cui_str': 'Victoria'}, {'cui': 'C0037715', 'cui_str': 'South Australia'}]","[{'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0001565', 'cui_str': 'Sublingual route'}]","[{'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]",,0.105725,"The Community Long-Acting Buprenorphine (CoLAB) study aims to evaluate client outcomes among people with opioid dependence receiving 48 weeks of BUP-XR treatment, and examines the implementation of BUP-XR in diverse community healthcare settings in Australia. ","[{'ForeName': 'Briony', 'Initials': 'B', 'LastName': 'Larance', 'Affiliation': 'National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Byrne', 'Affiliation': 'National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Lintzeris', 'Affiliation': 'Discipline of Addiction Medicine, University of Sydney, Surry Hills, New South Wales, Australia.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Nielsen', 'Affiliation': 'National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Grebely', 'Affiliation': 'The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Louisa', 'Initials': 'L', 'LastName': 'Degenhardt', 'Affiliation': 'National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Jeyran', 'Initials': 'J', 'LastName': 'Shahbazi', 'Affiliation': 'National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Marian', 'Initials': 'M', 'LastName': 'Shanahan', 'Affiliation': 'National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Lancaster', 'Affiliation': 'Centre for Social Research in Health, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Dore', 'Affiliation': 'The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Ali', 'Affiliation': 'National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Farrell', 'Affiliation': 'National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia michael.farrell@unsw.edu.au.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2019-034389'] 2045,32737263,Transradial Crossover Balloon Occlusion Technique for Primary Access Hemostasis During Transcatheter Aortic Valve Replacement: Initial Experience With the Oceanus 140 cm and 200 cm Balloon Catheters.,"OBJECTIVES The crossover balloon occlusion technique (CBOT) facilitates primary access hemostasis in patients undergoing transfemoral transcatheter aortic valve replacement (TAVR). The CBOT is usually performed through the contralateral femoral artery. The aim of this study was to evaluate, in patients undergoing TAVR, the safety and feasibility of transradial CBOT using the new Oceanus balloon dilatation catheter (iVascular). METHODS This multicenter study included 104 patients (mean age, 81 ± 7 years; 43% women) undergoing transfemoral TAVR. A modified CBOT through the radial artery was performed in all patients with the Oceanus balloon catheter. Data regarding transradial CBOT, balloon performance, vascular complications, and 30-day clinical events were recorded. RESULTS Up to 21% of patients had a height >170 cm and 17% presented with severe aortic/iliofemoral tortuosity. The transradial CBOT (left radial 74%, right radial 26%) was performed using either the 140 cm Oceanus (37.5%) or the 200 cm Oceanus (62.5%) balloon catheter. The balloon reached the femoral artery in all patients, and balloon inflation achieved an appropriate vessel closure in 98%. There were no complications related to the balloon catheter, and only 1 patient (1.0%) suffered a minor vascular complication related to the secondary radial access. The 30-day rates of primary access major vascular complications and death were 3.8% and 1.9%, respectively. CONCLUSION In patients undergoing transfemoral TAVR, transradial CBOT with the Oceanus balloon dilatation catheter was feasible and safe. A balloon length up to 200 cm allowed the use of this technique (from right or left radial access) in all patients regardless of patient height or the presence of a challenging vascular anatomy.",2020,"There were no complications related to the balloon catheter, and only 1 patient (1.0%) suffered a minor vascular complication related to the secondary radial access.","['104 patients (mean age, 81 ± 7 years; 43% women) undergoing transfemoral TAVR', 'patients undergoing', 'patients undergoing transfemoral transcatheter aortic valve replacement (TAVR', 'patients with the Oceanus balloon catheter']","['transradial CBOT using the new Oceanus balloon dilatation catheter (iVascular', 'Transcatheter Aortic Valve Replacement', 'Transradial Crossover Balloon Occlusion Technique', 'TAVR', 'crossover balloon occlusion technique (CBOT']","['30-day rates of primary access major vascular complications and death', 'transradial CBOT, balloon performance, vascular complications, and 30-day clinical events', 'transradial CBOT', 'severe aortic/iliofemoral tortuosity']","[{'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}, {'cui': 'C0441127', 'cui_str': 'Balloon dilatation catheter'}]","[{'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C0887842', 'cui_str': 'Balloon Occlusion'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0441127', 'cui_str': 'Balloon dilatation catheter'}, {'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C0887842', 'cui_str': 'Balloon Occlusion'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0003483', 'cui_str': 'Aortic'}, {'cui': 'C0333076', 'cui_str': 'Tortuosity'}]",104.0,0.101355,"There were no complications related to the balloon catheter, and only 1 patient (1.0%) suffered a minor vascular complication related to the secondary radial access.","[{'ForeName': 'Lucía', 'Initials': 'L', 'LastName': 'Junquera', 'Affiliation': ''}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Vilalta', 'Affiliation': ''}, {'ForeName': 'Ramiro', 'Initials': 'R', 'LastName': 'Trillo', 'Affiliation': ''}, {'ForeName': 'Manel', 'Initials': 'M', 'LastName': 'Sabaté', 'Affiliation': ''}, {'ForeName': 'Azeem', 'Initials': 'A', 'LastName': 'Latib', 'Affiliation': ''}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Nombela-Franco', 'Affiliation': ''}, {'ForeName': 'César', 'Initials': 'C', 'LastName': 'Moris', 'Affiliation': ''}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Garcia Del Blanco', 'Affiliation': ''}, {'ForeName': 'Mariano', 'Initials': 'M', 'LastName': 'Larman', 'Affiliation': ''}, {'ForeName': 'José Maria', 'Initials': 'JM', 'LastName': 'Hernandez', 'Affiliation': ''}, {'ForeName': 'Andres', 'Initials': 'A', 'LastName': 'Iñiguez', 'Affiliation': ''}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Amat-Santos', 'Affiliation': ''}, {'ForeName': 'Eduard', 'Initials': 'E', 'LastName': 'Fernandez-Nofrerias', 'Affiliation': ''}, {'ForeName': 'Ander', 'Initials': 'A', 'LastName': 'Regueiro', 'Affiliation': ''}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Colombo', 'Affiliation': ''}, {'ForeName': 'Georgios', 'Initials': 'G', 'LastName': 'Tzanis', 'Affiliation': ''}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Jiménez-Quevedo', 'Affiliation': ''}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Pérez-Serranos', 'Affiliation': ''}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Duran-Priu', 'Affiliation': ''}, {'ForeName': 'Lluis', 'Initials': 'L', 'LastName': 'Duocastella', 'Affiliation': ''}, {'ForeName': 'Jean-Michel', 'Initials': 'JM', 'LastName': 'Paradis', 'Affiliation': ''}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Rodés Cabau', 'Affiliation': 'Quebec Heart & Lung Institute, Laval University 2725 Chemin Ste-Foy, G1V 4GS Quebec City, Quebec, Canada. josep.rodes@criucpq.ulaval.ca.'}]",The Journal of invasive cardiology,[] 2046,32737350,Effects of combining exercise with long-chain polyunsaturated fatty acid supplementation on cognitive function in the elderly: a randomised controlled trial.,"Multifactorial lifestyle intervention is known to be more effective for ameliorating cognitive decline than single factor intervention; however, the effects of combining exercise with long-chain polyunsaturated fatty acids (LCPUFA) on the elderlies' cognitive function remain unclear. We conducted a randomised, single-masked placebo-controlled trial in non-demented elderly Japanese individuals. Participants were randomly allocated to the exercise with LCPUFA, placebo, or no exercise with placebo (control) groups. Participants in the exercise groups performed 150 min of exercise per week, comprised resistance and aerobic training, for 24 weeks with supplements of either LCPUFA (docosahexaenoic acid, 300 mg/day; eicosapentaenoic acid, 100 mg/day; arachidonic acid, 120 mg/day) or placebo. Cognitive functions were evaluated by neuropsychological tests prior to and following the intervention. The per-protocol set analysis (n = 76) revealed no significant differences between the exercise and the control groups in changes of neuropsychological tests. Subgroup analysis for participants with low skeletal muscle mass index (SMI) corresponding to sarcopenia cut-off value showed changes in selective attention, while working memory in the exercise with LCPUFA group was better than in the control group. These findings suggest that exercise with LCPUFA supplementation potentially improves attention and working memory in the elderly with low SMI.",2020,The per-protocol set analysis (n = 76) revealed no significant differences between the exercise and the control groups in changes of neuropsychological tests.,"['elderly', 'non-demented elderly Japanese individuals', 'elderly with low SMI']","['exercise with LCPUFA, placebo, or no exercise with placebo (control', 'Multifactorial lifestyle intervention', '150\xa0min of exercise per week, comprised resistance and aerobic training', 'LCPUFA (docosahexaenoic acid, 300\xa0mg/day; eicosapentaenoic acid, 100\xa0mg/day; arachidonic acid, 120\xa0mg/day) or placebo', 'combining exercise with long-chain polyunsaturated fatty acids (LCPUFA', 'combining exercise with long-chain polyunsaturated fatty acid supplementation', 'LCPUFA supplementation', 'placebo']","['neuropsychological tests', 'Cognitive functions', 'cognitive function', 'attention and working memory']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0860630', 'cui_str': 'Demented'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic acid'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0003695', 'cui_str': 'Arachidonic acid'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}]",,0.127031,The per-protocol set analysis (n = 76) revealed no significant differences between the exercise and the control groups in changes of neuropsychological tests.,"[{'ForeName': 'Hisanori', 'Initials': 'H', 'LastName': 'Tokuda', 'Affiliation': 'Institute for Health Care Science, Suntory Wellness Ltd., Kyoto, Japan. Hisanori_Tokuda@suntory.co.jp.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Ito', 'Affiliation': 'Safety Science Institute, Suntory MONOZUKURI Expert Ltd., Kyoto, Japan.'}, {'ForeName': 'Toshiaki', 'Initials': 'T', 'LastName': 'Sueyasu', 'Affiliation': 'Institute for Health Care Science, Suntory Wellness Ltd., Kyoto, Japan.'}, {'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Sasaki', 'Affiliation': 'Institute for Health Care Science, Suntory Wellness Ltd., Kyoto, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Morita', 'Affiliation': 'Institute for Health Care Science, Suntory Wellness Ltd., Kyoto, Japan.'}, {'ForeName': 'Yoshihisa', 'Initials': 'Y', 'LastName': 'Kaneda', 'Affiliation': 'Institute for Health Care Science, Suntory Wellness Ltd., Kyoto, Japan.'}, {'ForeName': 'Tomohiro', 'Initials': 'T', 'LastName': 'Rogi', 'Affiliation': 'Institute for Health Care Science, Suntory Wellness Ltd., Kyoto, Japan.'}, {'ForeName': 'Sumio', 'Initials': 'S', 'LastName': 'Kondo', 'Affiliation': 'Medical Corporation Kenshokai, Fukushima Healthcare Center, Osaka, Japan.'}, {'ForeName': 'Motoki', 'Initials': 'M', 'LastName': 'Kouzaki', 'Affiliation': 'Laboratory of Neurophysiology, Graduate School of Human and Environmental Studies, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Tsukiura', 'Affiliation': 'Department of Cognitive and Behavioral Sciences, Graduate School of Human and Environmental Studies, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Shibata', 'Affiliation': 'Institute for Health Care Science, Suntory Wellness Ltd., Kyoto, Japan.'}]",Scientific reports,['10.1038/s41598-020-69560-4'] 2047,32736046,"Evaluation of sedative effects of an intranasal dosage form containing saffron, lettuce seeds and sweet violet in primary chronic insomnia: A randomized, double-dummy, double-blind placebo controlled clinical trial.","ETHNOPHARMACOLOGICAL RELEVANCE Traditional Persian Medicine (TPM) has been established as a valuable source of medicinal plants for the treatment of insomnia for thousands of years. Accordingly, oil extracts from plants' parts have been widely used to alleviate central nervous system (CNS) ailments including sleep disorders. A number of preparations have been recommended by TPM for the treatment of insomnia. Among them, an intranasal formulation containing oily macerates of Viola odorata L., Crocus sativus L. and Lactuca sativa L. stands out. AIM OF THE STUDY In the present double-dummy, double-blind placebo controlled clinical trial, we aim to evaluate the effectiveness of a combination of violet oil, saffron oil, and lettuce seeds oil nasal drop compared with the placebo (sesame oil). MATERIALS AND METHODS Fifty patients with primary chronic insomnia were randomly assigned in TPM-treatment or placebo groups, received either two drops of the herbal oil or placebo into each nostril every noon and evening for 8 weeks. Before the study commencement and after 1, 4 and 8 weeks of treatment, Insomnia Severity Index (ISI) and Pittsburgh Sleep Quality Index (PSQI) questionnaires were completed by all patients. The primary outcome measure was considered as any changes in ISI scores between the first visit and after 8 weeks. Changes in PSQI scores during the study and possible side effects were also assessed. The multicompound herbal oil was standardized using HPLC analysis and contained 0.02 mg/mL crocin and 4 μg/mL isoquercitrin. RESULTS Our study revealed a significant reduction in the ISI and PSQI scores from baseline by the study endpoint (P ≤ 0.01). The mean ISI scores in week 8 decreased significantly for the intervention group (P = 0.001) and also the placebo group (P < 0.01) when compared with baseline. Moreover, the use of hypnotic drugs in the intervention group was significantly reduced (P < 0.001), while in the control group was maintained at baseline level. CONCLUSIONS It seems that intranasal use of the multi-herbal preparation can be used to improve chronic insomnia and to reduce the dose of conventional hypnotic medications in insomniac patients.",2020,The mean ISI scores in week 8 decreased significantly for the intervention group (P=0.001) and also the placebo group (P<0.01) when compared with baseline.,"['primary chronic insomnia', 'Fifty patients with primary chronic insomnia']","['violet oil, saffron oil, and lettuce seeds oil nasal drop', 'placebo (sesame oil', 'TPM-treatment or placebo', 'TPM', 'intranasal dosage form containing saffron, lettuce seeds and sweet violet', 'herbal oil or placebo', 'placebo']","['ISI scores', 'mean ISI scores', 'chronic insomnia', 'PSQI scores', 'ISI and PSQI scores', 'Insomnia Severity Index (ISI) and Pittsburgh Sleep Quality Index (PSQI) questionnaires']","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0751249', 'cui_str': 'Chronic insomnia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0330463', 'cui_str': 'Viola'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0162753', 'cui_str': 'Saffron Stain'}, {'cui': 'C0242765', 'cui_str': 'Lettuce'}, {'cui': 'C0036563', 'cui_str': 'Plant seeds'}, {'cui': 'C0991524', 'cui_str': 'Nasal drops'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0036845', 'cui_str': 'Sesame Oil'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0031188', 'cui_str': 'Persian language'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0013058', 'cui_str': 'Pharmaceutical dose form'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0330464', 'cui_str': 'Viola odorata'}, {'cui': 'C0376667', 'cui_str': 'Herbals'}]","[{'cui': 'C4706228', 'cui_str': 'ISI (Insomnia Severity Index) score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0751249', 'cui_str': 'Chronic insomnia'}, {'cui': 'C4545801', 'cui_str': 'Pittsburgh Sleep Quality Index score'}, {'cui': 'C4520529', 'cui_str': 'Insomnia severity index'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}]",50.0,0.415055,The mean ISI scores in week 8 decreased significantly for the intervention group (P=0.001) and also the placebo group (P<0.01) when compared with baseline.,"[{'ForeName': 'Zhila', 'Initials': 'Z', 'LastName': 'Taherzadeh', 'Affiliation': 'Targeted Drug Delivery Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Hosein', 'Initials': 'H', 'LastName': 'Khaluyan', 'Affiliation': 'Department of Traditional Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Milad', 'Initials': 'M', 'LastName': 'Iranshahy', 'Affiliation': 'Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Fariborz', 'Initials': 'F', 'LastName': 'Rezaeitalab', 'Affiliation': 'Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mohammad Hosein', 'Initials': 'MH', 'LastName': 'Eshaghi Ghalibaf', 'Affiliation': 'Anesthesiology, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Behjat', 'Initials': 'B', 'LastName': 'Javadi', 'Affiliation': 'Department of Traditional Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: javadib@mums.ac.ir.'}]",Journal of ethnopharmacology,['10.1016/j.jep.2020.113116'] 2048,32736164,The presence of a caregiver is associated with patient outcomes in patients with Parkinson's disease and atypical parkinsonisms.,"INTRODUCTION Approximately 88% of men and 79% of women with Parkinson's disease (PD) identify an informal caregiver. Although caregivers can play a key role in supporting patients, little is known about how and whether PD patients with and without caregivers differ in terms of physical, cognitive, and mood outcomes. This study explored whether caregiver presence was associated with variations in patient presentation and outcomes in a palliative PD and atypical PD population. METHODS Secondary data on individuals with PD and their caregivers came from baseline data of a 3-site randomized controlled trial of outpatient palliative care for PD in the US and Canada. Measures included: MDS UPDRS III, Montreal Cognitive Assessment, quality of life (QOL) measures, depression, prolonged grief, spirituality (FACIT SP-12) and Palliative Performance Scale. RESULTS Of 210 participants, 175 (83%) had a caregiver. Patients with caregivers had greater motor difficulty, lower cognitive scores, and greater palliative needs as measured by the Palliative Performance Scale. Despite poorer cognitive and motor function, those with caregivers had higher QOL as measured by the Quality of Life in Alzheimer Disease and less spiritual distress. There were no group differences on anxiety, depression, or grief. Caregiver presence moderated the association between lower MoCA score and worse motor symptoms. CONCLUSION Findings of the present study highlight the influence of caregiver engagement on PD patient outcomes. These findings have implications for clinical practice and suggest that presence of a caregiver may be an important modifying variable on patient outcomes to examine in future research.",2020,"Patients with caregivers had greater motor difficulty, lower cognitive scores, and greater palliative needs as measured by the Palliative Performance Scale.","['Of 210 participants, 175 (83%) had a caregiver', ""patients with Parkinson's disease and atypical parkinsonisms"", 'Secondary data on individuals with PD and their caregivers came from baseline data of a 3-site randomized controlled trial of outpatient palliative care for PD in the US and Canada', ""Approximately 88% of men and 79% of women with Parkinson's disease (PD) identify an informal caregiver""]",[],"['Palliative Performance Scale', 'MDS UPDRS III, Montreal Cognitive Assessment, quality of life (QOL) measures, depression, prolonged grief, spirituality (FACIT SP-12) and Palliative Performance Scale', 'anxiety, depression, or grief', 'lower MoCA score and worse motor symptoms', 'motor difficulty, lower cognitive scores']","[{'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C0585086', 'cui_str': 'Has a caregiver'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C4302185', 'cui_str': 'Atypical Parkinsonism'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0960273', 'cui_str': 'CAME'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C1319882', 'cui_str': 'Informal caregiver'}]",[],"[{'cui': 'C4720846', 'cui_str': 'Palliative performance scale'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0018235', 'cui_str': 'Normal grief reaction'}, {'cui': 'C0237104', 'cui_str': 'Spirituality'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C4721272', 'cui_str': 'Montreal cognitive assessment score'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",210.0,0.115968,"Patients with caregivers had greater motor difficulty, lower cognitive scores, and greater palliative needs as measured by the Palliative Performance Scale.","[{'ForeName': 'Lindsay Penny', 'Initials': 'LP', 'LastName': 'Prizer', 'Affiliation': 'Division of General Medicine and Geriatrics, Emory University School of Medicine, 6 Executive Park, 1st Floor, Atlanta, GA, 30329, USA. Electronic address: lprizer@emory.edu.'}, {'ForeName': 'Benzi M', 'Initials': 'BM', 'LastName': 'Kluger', 'Affiliation': 'Departments of Neurology and Medicine, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Sillau', 'Affiliation': 'Department of Neurology, University of Colorado School of Medicine, USA.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Katz', 'Affiliation': 'Weill Institute for Neurosciences, School of Medicine, University of California San Francisco, USA.'}, {'ForeName': 'Nicholas B', 'Initials': 'NB', 'LastName': 'Galifianakis', 'Affiliation': 'Weill Institute for Neurosciences, School of Medicine, University of California San Francisco, USA.'}, {'ForeName': 'Janis M', 'Initials': 'JM', 'LastName': 'Miyasaki', 'Affiliation': 'Parkinson and Movement Disorders Program, Neuropalliative Care, Department of Medicine, University of Alberta, Canada.'}]",Parkinsonism & related disorders,['10.1016/j.parkreldis.2020.07.003'] 2049,31813658,The efficacy of pentosan polysulfate monotherapy for preventing recurrent urinary tract infections in women: A multicenter open-label randomized controlled trial.,"BACKGROUND/PURPOSE Pentosan polysulfate sodium (PPS), a semi-synthetic polysaccharide that adheres to bladder mucosa, is effective in treating interstitial cystitis. We evaluated the clinical benefit of PPS for the prevention of recurrent urinary tract infection (UTI) in women. METHODS We conducted a multicenter, open-label, prospective, phase II, randomized controlled trial enrolling women with recurrent UTI ≥ 2 times in the past 6 months or ≥ 3 times in the past 12 months. Patients received oral PPS monotherapy for 16 weeks in treatment group. All patients were followed every 28 days until UTI recurrence or up to 112 days. The primary endpoint was the UTI recurrence-free survival. Adverse events were recorded as secondary endpoint. RESULTS A total of 26 women were eligible for analysis. In the PPS group, none (0%) of the 12 patients had UTI recurrence during the study period. However, 9 (64%) of 14 patients had UTI recurrence in the control group. The UTI recurrence-free survival was significantly higher in the PPS group than in the control group (log-rank test p = 0.0004). One adverse event which led to discontinuation of the trial regimen was regarded as irrelevance of PPS treatment. The limitation was the small number of cases. CONCLUSION Among women with recurrent UTI, 16-week PPS monotherapy significantly reduced UTI recurrence when compared with the control group.",2020,The UTI recurrence-free survival was significantly higher in the PPS group than in the control group (log-rank test p = 0.0004).,"['26 women were eligible for analysis', 'enrolling women with recurrent UTI\xa0≥\xa02 times in the past 6 months or\xa0≥\xa03 times in the past 12 months', 'women with recurrent UTI', 'women']","['oral PPS monotherapy', 'pentosan polysulfate monotherapy', 'PPS', 'Pentosan polysulfate sodium (PPS']","['UTI recurrence-free survival', 'recurrent urinary tract infections', 'Adverse events', 'UTI recurrence']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0262655', 'cui_str': 'Recurrent urinary tract infection'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0524684', 'cui_str': 'pentosan polysulfate sodium'}, {'cui': 'C0600296', 'cui_str': 'Pentosan Polysulfate'}]","[{'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease'}, {'cui': 'C0262655', 'cui_str': 'Recurrent urinary tract infection'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",26.0,0.0950051,The UTI recurrence-free survival was significantly higher in the PPS group than in the control group (log-rank test p = 0.0004).,"[{'ForeName': 'Chi-Shin', 'Initials': 'CS', 'LastName': 'Tseng', 'Affiliation': 'Department of Urology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan.'}, {'ForeName': 'Shang-Jen', 'Initials': 'SJ', 'LastName': 'Chang', 'Affiliation': 'Department of Urology, Taipei Tzu Chi Hospital, New Taipei, Taiwan.'}, {'ForeName': 'En', 'Initials': 'E', 'LastName': 'Meng', 'Affiliation': 'Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.'}, {'ForeName': 'Hong-Chiang', 'Initials': 'HC', 'LastName': 'Chang', 'Affiliation': 'Department of Urology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan.'}, {'ForeName': 'Yuan-Ju', 'Initials': 'YJ', 'LastName': 'Lee', 'Affiliation': 'Department of Urology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan. Electronic address: leeyuanju@hotmail.com.'}]",Journal of the Formosan Medical Association = Taiwan yi zhi,['10.1016/j.jfma.2019.11.007'] 2050,32740079,The Bowel CLEANsing National Initiative: A Low-Volume Same-Day Polyethylene Glycol (PEG) Preparation vs Low-Volume Split-Dose PEG With Bisacodyl or High-Volume Split-Dose PEG Preparations-A Randomized Controlled Trial.,"INTRODUCTION Bowel cleanliness has been shown to be superior with split-dose vs nonsplit preparations; we aimed to directly assess the poorly characterized comparative efficacies of split-dose vs same-day polyethylene glycol (PEG) regimens. METHODS In this study, one of a series of randomized trials performed across 10 Canadian endoscopy units, patients undergoing colonoscopies between 10:30 and 16:30 were allocated to PEG low-volume same-day (15 mg bisacodyl the day before, 2 L the morning of the procedure), low-volume split-dose (15 mg bisacodyl the day before, 1 L + 1 L), or high-volume split-dose (2 L + 2 L). Coprimary endpoints were adequate bowel cleansing based on the Boston Bowel Preparation Scale using in turn different threshold cutoffs. RESULTS Overall, 1,750 subjects were randomized equally across the 3 groups, with no differences in adequate bowel cleanliness rates (low-volume same-day, 90.5%; high-volume split-dose, 92.2%; P = 0.34; and low-volume split-dose, 87.9%; P = 0.17) for the Boston Bowel Preparation Scale ≥6 and 2 for each segment. Willingness to repeat the preparation was not significantly different between low-volume same-day (91.0%) and low-volume split-dose (92.5%; P = 0.40) but was greater than the high-volume split-dose (68.9%; P < 0.01). No significant differences were noted for withdrawal time, cecal intubation, or polyp detection rates. DISCUSSION In this large randomized trial of PEG regimens, low-volume same-day resulted in similar bowel cleanliness compared with high-volume or low-volume split-dosing. Willingness to repeat and tolerability were superior with low-volume same-day compared with high-volume split-dose and similar to low-volume split-dose.",2020,"Overall, 1,750 subjects were randomized equally across the 3 groups, with no differences in adequate bowel cleanliness rates (low-volume same-day, 90.5%; high-volume split-dose, 92.2%; P = 0.34; and low-volume split-dose, 87.9%; P = 0.17) for the Boston Bowel Preparation Scale ≥6 and 2 for each segment.","['10 Canadian endoscopy units, patients undergoing colonoscopies between 10:30 and 16:30 were allocated to', '1,750 subjects']","['Low-Volume Same-Day Polyethylene Glycol (PEG) Preparation vs Low-Volume Split-Dose PEG With Bisacodyl or High-Volume Split-Dose PEG Preparations', 'PEG low-volume same-day']","['adequate bowel cleansing based on the Boston Bowel Preparation Scale using in turn different threshold cutoffs', 'withdrawal time, cecal intubation, or polyp detection rates', 'adequate bowel cleanliness rates']","[{'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032483', 'cui_str': 'Polyethylene Glycols'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0005632', 'cui_str': 'Bisacodyl'}, {'cui': 'C0205250', 'cui_str': 'High'}]","[{'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4302285', 'cui_str': 'BBPS - Boston bowel preparation scale'}, {'cui': 'C0541749', 'cui_str': 'Does turn'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0007531', 'cui_str': 'Cecum structure'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0032584', 'cui_str': 'Polyp'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0522513', 'cui_str': 'With cleanliness'}]",1750.0,0.0386822,"Overall, 1,750 subjects were randomized equally across the 3 groups, with no differences in adequate bowel cleanliness rates (low-volume same-day, 90.5%; high-volume split-dose, 92.2%; P = 0.34; and low-volume split-dose, 87.9%; P = 0.17) for the Boston Bowel Preparation Scale ≥6 and 2 for each segment.","[{'ForeName': 'Alan N', 'Initials': 'AN', 'LastName': 'Barkun', 'Affiliation': 'McGill University Health Center, McGill University, Montreal, Québec, Canada.'}, {'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Martel', 'Affiliation': 'McGill University Health Center, McGill University, Montreal, Québec, Canada.'}, {'ForeName': 'Ian L', 'Initials': 'IL', 'LastName': 'Epstein', 'Affiliation': 'Dalhousie University, Halifax, Nova Scotia, Canada.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Hallé', 'Affiliation': 'Hôpital du Saint-Sacrement, Québec, Québec, Canada.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Hilsden', 'Affiliation': 'University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'James', 'Affiliation': 'University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Alaa', 'Initials': 'A', 'LastName': 'Rostom', 'Affiliation': 'University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Sey', 'Affiliation': 'Western University, London, Ontario, Canada.'}, {'ForeName': 'Harminder', 'Initials': 'H', 'LastName': 'Singh', 'Affiliation': 'University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Sultanian', 'Affiliation': 'Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Jennifer J', 'Initials': 'JJ', 'LastName': 'Telford', 'Affiliation': 'University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'von Renteln', 'Affiliation': 'Université de Montréal, Montreal, Quebec, Canada.'}]",The American journal of gastroenterology,['10.14309/ajg.0000000000000760'] 2051,32740081,Translumbosacral Neuromodulation Therapy for Fecal Incontinence: A Randomized Frequency Response Trial.,"INTRODUCTION Treatments for fecal incontinence (FI) remain unsatisfactory because they do not remedy the underlying multifactorial dysfunction(s) including anorectal neuropathy. The aim of this study was to investigate the optimal dose frequency, clinical effects, and safety of a novel treatment, translumbosacral neuromodulation therapy (TNT), aimed at improving neuropathy. METHODS Patients with FI were randomized to receive 6 sessions of weekly TNT treatments consisting of 600 repetitive magnetic stimulations over each of 2 lumbar and 2 sacral sites with either 1, 5, or 15 Hz frequency. Stool diaries, FI severity indices, anorectal neurophysiology and sensorimotor function, and quality of life were compared. Primary outcome measure was the change in FI episodes/week. Responders were patients with ≥50% decrease in weekly FI episodes. RESULTS Thirty-three patients with FI participated. FI episodes decreased significantly ([INCREMENT] ±95% confidence interval, 4.2 ± 2.8 (1 Hz); 2 ± 1.7 (5 Hz); 3.4 ± 2.5 (15 Hz); P < 0.02) in all 3 groups when compared with baseline. The 1 Hz group showed a significantly higher (P = 0.04) responder rate (91 ± 9.1%) when compared with the 5 Hz group (36 ± 18.2%) or 15 Hz (55 ± 18.2%); no difference was found between the 5 and 15 Hz groups (P = 0.667). Anal neuropathy, squeeze pressure, and rectal capacity improved significantly only in the 1 Hz (P < 0.05) group compared with baseline, but not in other groups. Quality of life domains improved significantly (P < 0.05) with 1 and 5 Hz groups. No device-related serious adverse events were noted. DISCUSSION TNT significantly improves FI symptoms in the short term, and the 1 Hz frequency was overall better than 5 and 15 Hz. Both anorectal neuropathy and physiology significantly improved, demonstrating mechanistic improvement. TNT is a promising, novel, safe, efficacious, and noninvasive treatment for FI (see Visual Abstract, Supplementary Digital Content 3, http://links.lww.com/AJG/B598).",2020,"Anal neuropathy, squeeze pressure, and rectal capacity improved significantly only in the 1 Hz (P < 0.05) group compared with baseline, but not in other groups.","['Fecal Incontinence', 'Thirty-three patients with FI participated', 'Patients with FI']","['Translumbosacral Neuromodulation Therapy', 'translumbosacral neuromodulation therapy (TNT', 'TNT']","['change in FI episodes/week', 'Quality of life domains', 'responder rate', 'FI episodes', 'Stool diaries, FI severity indices, anorectal neurophysiology and sensorimotor function, and quality of life', 'Anal neuropathy, squeeze pressure, and rectal capacity', 'FI symptoms']","[{'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0394674', 'cui_str': 'Neurostimulation/modulation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0027901', 'cui_str': 'Neurophysiology'}, {'cui': 'C0589515', 'cui_str': 'Sensorimotor functions'}, {'cui': 'C0003461', 'cui_str': 'Anal structure'}, {'cui': 'C0442874', 'cui_str': 'Neuropathy'}, {'cui': 'C0413258', 'cui_str': 'Barotrauma of descent'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0205052', 'cui_str': 'Rectal'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",33.0,0.187516,"Anal neuropathy, squeeze pressure, and rectal capacity improved significantly only in the 1 Hz (P < 0.05) group compared with baseline, but not in other groups.","[{'ForeName': 'Satish S C', 'Initials': 'SSC', 'LastName': 'Rao', 'Affiliation': 'Division of Neurogastroenterology/Motility.'}, {'ForeName': 'Xuelian', 'Initials': 'X', 'LastName': 'Xiang', 'Affiliation': 'Division of Neurogastroenterology/Motility.'}, {'ForeName': 'Amol', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Division of Neurogastroenterology/Motility.'}, {'ForeName': 'Tanisa', 'Initials': 'T', 'LastName': 'Patcharatrakul', 'Affiliation': 'Division of Neurogastroenterology/Motility.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': 'Division of Neurogastroenterology/Motility.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Parr', 'Affiliation': 'Division of Neurogastroenterology/Motility.'}, {'ForeName': 'Deepak', 'Initials': 'D', 'LastName': 'Ayyala', 'Affiliation': 'Department of Population Health Sciences, Medical College of Georgia, Augusta University, Augusta, Georgia, USA.'}, {'ForeName': 'Shaheen', 'Initials': 'S', 'LastName': 'Hamdy', 'Affiliation': 'Department of Medicine, Manchester Academic Health Sciences Centre, University of Manchester, Manchester UK.'}]",The American journal of gastroenterology,['10.14309/ajg.0000000000000766'] 2052,32740086,Peripheral Corticotropin-Releasing Factor Triggers Jejunal Mast Cell Activation and Abdominal Pain in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.,"INTRODUCTION To determine the effect of peripheral CRF on intestinal barrier function in diarrhea-predominant IBS (IBS-D). Irritable bowel syndrome (IBS) pathophysiology has been linked to life stress, epithelial barrier dysfunction, and mast cell activation. Corticotropin-releasing factor (CRF) is a major mediator of stress responses in the gastrointestinal tract, yet its role on IBS mucosal function remains largely unknown. METHODS Intestinal response to sequential i.v. 5-mL saline solution (placebo) and CRF (100 μg) was evaluated in 21 IBS-D and 17 healthy subjects (HSs). A 20-cm jejunal segment was perfused with an isosmotic solution and effluents collected at baseline, 30 minutes after placebo, and 60 minutes after CRF. We measured water flux, albumin output, tryptase release, stress hormones, cardiovascular and psychological responses, and abdominal pain. A jejunal biopsy was obtained for CRF receptor expression assessment. RESULTS Water flux did not change after placebo in IBS-D and HS but significantly increased after CRF in IBS-D (P = 0.007). Basal luminal output of albumin was higher in IBS-D and increased further after CRF in IBS-D (P = 0.042). Basal jejunal tryptase release was higher in IBS-D, and CRF significantly increased it in both groups (P = 0.004), the response being higher in IBS-D than in HS (P = 0.0023). Abdominal pain worsened only in IBS-D after CRF and correlated with jejunal tryptase release, water flux, and albumin output. IBS-D displayed jejunal up-regulation of CRF2 and down-regulation of CRF1 compared with HS. DISCUSSION Stress via CRF-driven mast cell activation seems to be relevant in the pathophysiology of IBS-D.",2020,"RESULTS Water flux did not change after placebo in IBS-D and HS but significantly increased after CRF in IBS-D (P = 0.007).","['Patients', '21 IBS-D and 17 healthy subjects (HSs', 'diarrhea-predominant IBS (IBS-D']","['placebo', 'Corticotropin-releasing factor (CRF', 'peripheral CRF', '5-mL saline solution (placebo) and CRF']","['Irritable bowel syndrome', 'IBS-D and HS', 'IBS-D, and CRF', 'Basal jejunal tryptase release', 'Abdominal pain', 'water flux, albumin output, tryptase release, stress hormones, cardiovascular and psychological responses, and abdominal pain', 'jejunal tryptase release, water flux, and albumin output', 'Basal luminal output of albumin']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C1262211', 'cui_str': 'Diarrhoea predominant irritable bowel syndrome'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0010132', 'cui_str': 'Corticotropin-Releasing Hormone'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0010132', 'cui_str': 'Corticotropin-Releasing Hormone'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0022378', 'cui_str': 'Jejunal'}, {'cui': 'C0147080', 'cui_str': 'Tryptase'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C3251815', 'cui_str': 'Measurement of fluid output'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0699493', 'cui_str': 'Luminal'}]",21.0,0.0765273,"RESULTS Water flux did not change after placebo in IBS-D and HS but significantly increased after CRF in IBS-D (P = 0.007).","[{'ForeName': 'Mar', 'Initials': 'M', 'LastName': 'Guilarte', 'Affiliation': ""Allergy Section, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Vicario', 'Affiliation': ""Translational Mucosal Immunology Group, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Martínez', 'Affiliation': ""Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Inés', 'Initials': 'I', 'LastName': 'de Torres', 'Affiliation': ""Department of Pathology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Lobo', 'Affiliation': ""Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Pigrau', 'Affiliation': ""Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'González-Castro', 'Affiliation': ""Translational Mucosal Immunology Group, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Bruno K', 'Initials': 'BK', 'LastName': 'Rodiño-Janeiro', 'Affiliation': ""Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Eloísa', 'Initials': 'E', 'LastName': 'Salvo-Romero', 'Affiliation': ""Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Fortea', 'Affiliation': ""Translational Mucosal Immunology Group, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Pardo-Camacho', 'Affiliation': ""Translational Mucosal Immunology Group, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Antolín', 'Affiliation': ""Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Esteban', 'Initials': 'E', 'LastName': 'Saperas', 'Affiliation': ""Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Azpiroz', 'Affiliation': ""Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Santos', 'Affiliation': ""Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Alonso-Cotoner', 'Affiliation': ""Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}]",The American journal of gastroenterology,['10.14309/ajg.0000000000000789'] 2053,32740283,Preliminary Impact of an Adapted Emotion Regulation Intervention for Adolescents with Overweight and Obesity Attempting to Lose Weight.,"OBJECTIVE This study examines the acceptability, feasibility, and preliminary impact of a program (HealthTRAC) combining 2 efficacious interventions (one targeting emotion regulation [TRAC] and the other a standardized behavioral weight management intervention [SBWC]) to improve weight management outcomes among a sample of adolescents with overweight and obesity. METHOD Adolescents with overweight or obesity (N = 38), ages 13 to 17 years, were enrolled and randomized into either the SBWC or HealthTRAC. Data were collected at baseline (before intervention), at the end of the 16-week intervention (postintervention), and 4 months after completing the intervention (4 months). Assessments included adolescent self-reports of intervention acceptability and reported emotion regulation (ER) abilities and caregiver report of adolescent ER skills. Body mass index (BMI) was used to examine the impact on adolescent weight outcomes. Analyses of covariance controlling for baseline values were used to evaluate study outcomes. RESULTS Eighty-four percent (n = 32) of participants completed the immediate postintervention and 4-month follow-up assessments. Adolescents in both conditions reported high treatment satisfaction. Adolescents randomized to HealthTRAC demonstrated greater reductions in BMI relative to SBWC and reported greater use of emotion regulation skills. Finally, caregivers of adolescents randomized to HealthTRAC also reported greater improvements in emotion regulation abilities among their adolescents at the 4-month follow-up. CONCLUSION Findings suggest that the HealthTRAC intervention was acceptable, feasible to deliver, and demonstrated a positive impact on BMI and emotion regulation abilities. These data suggest that ER is related to health decision-making and is relevant to most overweight/obese adolescents seeking to lose weight.",2020,Adolescents randomized to HealthTRAC demonstrated greater reductions in BMI relative to SBWC and reported greater use of emotion regulation skills.,"['adolescents with overweight and obesity', 'Adolescents with overweight or obesity (N = 38), ages 13 to 17 years', 'Adolescents with Overweight and Obesity Attempting to Lose Weight']","['HealthTRAC', 'HealthTRAC intervention', 'program (HealthTRAC) combining 2 efficacious interventions', 'standardized behavioral weight management intervention [SBWC', 'SBWC or HealthTRAC', 'Adapted Emotion Regulation Intervention']","['emotion regulation skills', 'BMI and emotion regulation abilities', 'adolescent self-reports of intervention acceptability and reported emotion regulation (ER) abilities and caregiver report of adolescent ER skills', 'Body mass index (BMI', 'BMI relative to SBWC', 'emotion regulation abilities']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen'}, {'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}]","[{'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}]",,0.0336946,Adolescents randomized to HealthTRAC demonstrated greater reductions in BMI relative to SBWC and reported greater use of emotion regulation skills.,"[{'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Hadley', 'Affiliation': 'Department of Counseling Psychology and Human Services, College of Education, University of Oregon, Eugene, OR.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Houck', 'Affiliation': 'Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Barker', 'Affiliation': 'Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI.'}, {'ForeName': 'Brittany', 'Initials': 'B', 'LastName': 'Wickham', 'Affiliation': ""Bradley/Hasbro Children's Research Center/Rhode Island Hospital, Providence, RI.""}, {'ForeName': 'Jaclyn', 'Initials': 'J', 'LastName': 'Bogner', 'Affiliation': 'Department of Counseling Psychology and Human Services, College of Education, University of Oregon, Eugene, OR.'}, {'ForeName': 'Elissa', 'Initials': 'E', 'LastName': 'Jelalian', 'Affiliation': 'Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI.'}]",Journal of developmental and behavioral pediatrics : JDBP,['10.1097/DBP.0000000000000837'] 2054,32740286,"Ergogenic Effects of 8 Days of Sceletium Tortuosum Supplementation on Mood, Visual Tracking, and Reaction in Recreationally Trained Men and Women.","Hoffman, JR, Marcus, I, Dubnov-Raz, G, and Gepner, Y. Ergogenic effects of 8 days of Sceletium tortuosum supplementation on mood, visual tracking, and reaction in recreationally trained men and women. J Strength Cond Res XX(X): 000-000, 2020-Sceletium tortuosum (ST) is a South African plant that has been reported to promote a sense of well-being in healthy individuals and used in treating people with anxiety, stress, or depression. These studies have been conducted in middle-aged and older adults, but no investigations have been performed in a healthy, young adult population. Thus, the purpose of this study was to examine the effect of 8 days of ST extract (25-mg) supplementation on changes in reactive agility, visual tracking, and mood. Sixty recreationally trained men (n = 48) and women (n = 12), between 20 and 35 years, were randomly assigned to 1 of 2 groups: ST or placebo (PL). Subjects were tested on 2 occasions: before supplementation and 2-hours after supplementation on day 8. Subjects completed a subjective questionnaire to assess alertness and energy using a visual analog scale (VAS). In addition, subjects completed the Profile of Mood States questionnaire and performed reactive agility and visual tracking assessments. Significant improvements were noted for ST in complex reactive performance that required subjects to respond to repeated visual stimuli with a cognitive load compared with PL. However, no significant changes were noted between the groups in either VAS or total mood score. In addition, no differences were observed in simple reaction assessments. The results of this study demonstrate an ergogenic benefit in complex reactive tasks that include a cognitive load. However, in this subject population studied, no benefits in mood were observed.",2020,Significant improvements were noted for ST in complex reactive performance that required subjects to respond to repeated visual stimuli with a cognitive load compared with PL.,"['middle-aged and older adults', 'Sixty recreationally trained men (n = 48) and women (n = 12), between 20 and 35 years', 'Recreationally Trained Men and Women']","['J Strength Cond Res XX(X', '2020-Sceletium tortuosum (ST', 'ST extract (25-mg) supplementation', 'Sceletium Tortuosum Supplementation', 'ST or placebo (PL']","['VAS or total mood score', 'mood, visual tracking, and reaction', 'subjective questionnaire to assess alertness and energy using a visual analog scale (VAS', 'reactive agility, visual tracking, and mood', 'simple reaction assessments', 'Profile of Mood States questionnaire and performed reactive agility and visual tracking assessments', 'Mood, Visual Tracking, and Reaction']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205332', 'cui_str': 'Reactive'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0451394', 'cui_str': 'Profile of mood states'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]",60.0,0.0716422,Significant improvements were noted for ST in complex reactive performance that required subjects to respond to repeated visual stimuli with a cognitive load compared with PL.,"[{'ForeName': 'Jay R', 'Initials': 'JR', 'LastName': 'Hoffman', 'Affiliation': 'Department of Molecular Biology, Ariel University, Ariel, Israel.'}, {'ForeName': 'Irit', 'Initials': 'I', 'LastName': 'Markus', 'Affiliation': 'Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine and Sylvan Adams Sports Institute, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Gal', 'Initials': 'G', 'LastName': 'Dubnov-Raz', 'Affiliation': ""The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.""}, {'ForeName': 'Yftach', 'Initials': 'Y', 'LastName': 'Gepner', 'Affiliation': 'Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine and Sylvan Adams Sports Institute, Tel Aviv University, Tel Aviv, Israel.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003693'] 2055,32740288,Decline in Unintentional Lifting Velocity Is Both Load and Exercise Specific.,"Beck, M, Varner, W, LeVault, L, Boring, J, and Fahs, CA. Decline in unintentional lifting velocity is both load and exercise specific. J Strength Cond Res XX(X): 000-000, 2020-When monitoring the mean concentric velocity (MCV) for velocity-based resistance training, often a threshold in the decline in the MCV is used to regulate the number of repetitions performed. However, it is not clear if the decline in the MCV is affected by the type of exercise or the relative load used. Therefore, the purpose of this study was to compare the decline in the MCV between the overhead press (OHP) and deadlift (DL) during sets to fatigue at different loads. Thirty individuals (23 ± 3 years) with current training experience with both the OHP and DL completed a 1 repetition maximum (1RM) protocol for the OHP and DL. Subjects then returned to the laboratory on 2 separate occasions and completed 1 set of the OHP and DL to volitional fatigue at either 70 or 90% of their 1RM in a randomized order. The open barbell system measured the MCV of all repetitions. The absolute and relative (%) decline in the MCV was calculated for each condition and compared between loads (70 vs. 90% 1RM) and between lifts (OHP vs. DL). An alpha level of 0.05 was used at the criterion for statistical significance. The absolute decline in the MCV was greatest for the 70% OHP condition (0.36 ± 0.12 m·s) followed by 90% OHP (0.19 ± 0.10 m·s), 70% DL (0.16 ± 0.08 m·s), and 90% DL (0.09 ± 0.06 m·s); all were significantly different from one another (p < 0.05) except for 70% DL vs. 90% OHP (p = 0.441). There was a greater relative decline in the MCV for the OHP compared with the DL (50.1 ± 11.8% vs. 28.5 ± 11.8%; p < 0.001) and for 70% 1RM compared with 90% 1RM (44.5 ± 12.0% vs. 34.1 ± 12.0%; p < 0.001). These data suggest the decline in the MCV is both exercise and load specific. Applying a uniform velocity decline threshold for velocity-based training may reduce training volume to different extents depending on the exercise and relative load used.",2020,There was a greater relative decline in the MCV for the OHP compared with the DL (50.1 ± 11.8% vs. 28.5 ± 11.8%; p < 0.001) and for 70% 1RM compared with 90% 1RM (44.5 ± 12.0% vs. 34.1 ± 12.0%; p < 0.001).,['Thirty individuals (23 ± 3 years) with current training experience with both the OHP and DL completed a 1 repetition maximum (1RM) protocol for the OHP and DL'],['J Strength Cond Res XX(X'],"['overhead press (OHP) and deadlift (DL', 'Beck, M, Varner, W, LeVault, L, Boring, J, and Fahs, CA', 'mean concentric velocity (MCV']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}]","[{'cui': 'C2945608', 'cui_str': 'Bore'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439744', 'cui_str': 'Concentric'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}]",,0.0284101,There was a greater relative decline in the MCV for the OHP compared with the DL (50.1 ± 11.8% vs. 28.5 ± 11.8%; p < 0.001) and for 70% 1RM compared with 90% 1RM (44.5 ± 12.0% vs. 34.1 ± 12.0%; p < 0.001).,"[{'ForeName': 'Maddison', 'Initials': 'M', 'LastName': 'Beck', 'Affiliation': 'Department of Exercise Science, Lindenwood University Belleville, Belleville, Illinois.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Varner', 'Affiliation': 'Department of Exercise Science, Lindenwood University Belleville, Belleville, Illinois.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'LeVault', 'Affiliation': 'Department of Exercise Science, Lindenwood University Belleville, Belleville, Illinois.'}, {'ForeName': 'Johnathan', 'Initials': 'J', 'LastName': 'Boring', 'Affiliation': 'School of Health Sciences, Lindenwood University, St. Charles, Missouri.'}, {'ForeName': 'Christopher A', 'Initials': 'CA', 'LastName': 'Fahs', 'Affiliation': 'College of Health Sciences, Logan University, Chesterfield, Missouri.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003786'] 2056,32740289,A 28-Day Carbohydrate-Restricted Diet Improves Markers of Cardiovascular Disease in Professional Firefighters.,"Waldman, HS, Smith, JW, Lamberth, J, Fountain, BJ, Bloomer, RJ, Butawan, MB, and McAllister, MJ. A 28-day carbohydrate-restricted diet improves markers of cardiovascular disease in professional firefighters. J Strength Cond Res XX(X): 000-000, 2020-This study compared the effects of a 4-week, nonketogenic, carbohydrate-restricted (<25% of calories) diet (CRD) on markers of inflammation and oxidative stress in professional firefighters (FF). Subjects (n = 15) reported to the laboratory for 2 sessions (i.e., baseline and post-CRD) where blood was drawn from an antecubital vein after a 10-hour overnight fast. Dependent variables measured at baseline and post-CRD included adiponectin, insulin, human growth hormone, cortisol, C-reactive protein, albumin, lipids, glucose, amylase, creatine kinase, malondialdehyde (MDA), advance oxidation protein products (AOPP), total nitrate + nitrite, and soluble intracellular adhesion molecule-1. Compared with baseline, the CRD resulted in dramatic improvements to subjects' cardiometabolic profiles, including decreases in AOPP (51.3 ± 27.3 vs. 32.9 ± 7.9 ng·ml), MDA (1.6 ± 0.6 vs. 1.1 ± 0.5 µmol·L), and triglycerides (84.4 ± 34.4 vs. 64.2 ± 14.4 mg·dl), respectively. In addition, the CRD increased total cholesterol (151.5 ± 23.0 vs. 167.7 ± 38.2 mg·dl) and high-density lipoprotein cholesterol (46.3 ± 12.7 vs. 50.6 ± 15.5 mg·dl), but no differences were found with low-density lipoprotein cholesterol. Overall, our results show a 4-week CRD can favorably improve some markers of cardiovascular health in male FF.",2020,"Compared with baseline, the CRD resulted in dramatic improvements to subjects' cardiometabolic profiles, including decreases in AOPP (51.3 ± 27.3 vs. 32.9 ± 7.9 ng·ml), MDA (1.6 ± 0.6 vs. 1.1 ± 0.5 µmol·L), and triglycerides (84.4 ± 34.4 vs. 64.2 ± 14.4 mg·dl), respectively.","['male FF', 'professional firefighters', 'professional firefighters (FF', 'Professional Firefighters']","['nonketogenic, carbohydrate-restricted (<25% of calories) diet (CRD', 'J Strength Cond Res XX(X', '28-Day Carbohydrate-Restricted Diet', 'carbohydrate-restricted diet']","['CRD increased total cholesterol', 'Waldman, HS, Smith, JW, Lamberth, J, Fountain, BJ, Bloomer, RJ, Butawan, MB, and McAllister, MJ', 'cardiovascular health', 'low-density lipoprotein cholesterol', 'high-density lipoprotein cholesterol', 'adiponectin, insulin, human growth hormone, cortisol, C-reactive protein, albumin, lipids, glucose, amylase, creatine kinase, malondialdehyde (MDA), advance oxidation protein products (AOPP), total nitrate + nitrite, and soluble intracellular adhesion molecule-1']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0221459', 'cui_str': 'Fire fighter'}]","[{'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C3489532', 'cui_str': 'Cone-Rod Dystrophy 2'}, {'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C3489532', 'cui_str': 'Cone-Rod Dystrophy 2'}, {'cui': 'C0020443', 'cui_str': 'Hypercholesterolemia'}, {'cui': 'C0347795', 'cui_str': ""Reversed Colles' fracture""}, {'cui': 'C0453894', 'cui_str': 'Bloomers'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0169964', 'cui_str': 'Somatropin'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0002712', 'cui_str': 'Amylases'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0028137', 'cui_str': 'Nitrite salt'}, {'cui': 'C0175996', 'cui_str': 'Protoplasm'}, {'cui': 'C0007578', 'cui_str': 'Cell Adhesion Molecules'}]",,0.0871791,"Compared with baseline, the CRD resulted in dramatic improvements to subjects' cardiometabolic profiles, including decreases in AOPP (51.3 ± 27.3 vs. 32.9 ± 7.9 ng·ml), MDA (1.6 ± 0.6 vs. 1.1 ± 0.5 µmol·L), and triglycerides (84.4 ± 34.4 vs. 64.2 ± 14.4 mg·dl), respectively.","[{'ForeName': 'Hunter S', 'Initials': 'HS', 'LastName': 'Waldman', 'Affiliation': 'Department of Kinesiology, Human Performance Lab, University of North Alabama, Florence, Alabama.'}, {'ForeName': 'JohnEric W', 'Initials': 'JW', 'LastName': 'Smith', 'Affiliation': 'Department of Kinesiology, Applied Physiology Lab, Mississippi State University, Starkville, Mississippi.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Lamberth', 'Affiliation': 'Department of Kinesiology, Applied Physiology Lab, Mississippi State University, Starkville, Mississippi.'}, {'ForeName': 'Brent J', 'Initials': 'BJ', 'LastName': 'Fountain', 'Affiliation': 'Department of Food Science, Nutrition, and Health Promotion, Mississippi State University, Starkville, Mississippi.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Bloomer', 'Affiliation': 'School of Health Studies, The University of Memphis, Memphis, Tennessee.'}, {'ForeName': 'Matthew B', 'Initials': 'MB', 'LastName': 'Butawan', 'Affiliation': 'School of Health Studies, The University of Memphis, Memphis, Tennessee.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'McAllister', 'Affiliation': 'Department of Health and Human Performance, Metabolic & Applied Physiology Lab, Texas State University, San Marcos, Texas.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003749'] 2057,32740291,Effect of Carbohydrate Mouth Rinse on Resistance Exercise Performance.,"Green, MS, Kimmel, CS, Martin, TD, Mouser, JG, and Brune, MP. Effect of carbohydrate mouth rinse on resistance exercise performance. J Strength Cond Res XX(X): 000-000, 2020-A carbohydrate mouth rinse (CMR) has been shown to enhance short duration endurance performance and raises the possibility that a similar strategy could improve performance during resistance exercise. Eighteen male and female (N = 36) resistance trained subjects (mean values ± SD; age: 21.5 ± 1.6 years, height: 1.72 ± 0.09 m, body mass: 72.8 ± 13.4 kg, and body fat: 16.7 ± 5.8%) performed 3 experimental visits during which bench press resistance exercise (4 × 10 repetitions at 65% of 1 repetition maximum [1RM] with 120 seconds recovery) and repetitions to failure at 60% 1RM were performed. Subjects rinsed 25 ml of water (WAT), noncaloric placebo (PLA), or 6.4% maltodextrin (CHO) solution for 10 seconds during exercise in a crossover, counter-balanced manner. Rating of perceived exertion (RPE), pleasure-displeasure (FS), number of repetitions to fatigue (REPS), and postexercise blood glucose (GLU) and lactate (LA) were measured. Compared with WAT (17.7 ± 0.8), PLA (19.0 ± 0.7; p = 0.025), and CHO (18.7 ± 0.8; p = 0.039) resulted in higher REPS, with no difference between PLA and CHO treatments (p = 0.310). Rating of perceived exertion progressively increased each set (p < 0.0001), but was not affected by treatment (p = 0.897). Pleasure-displeasure declined during recovery from sets 3 and 4 (p < 0.05) but was also not affected by treatment (p = 0.692). Postexercise GLU (p = 0.103) and LA (p = 0.620) were not different between treatments. Although a placebo effect was present for REPS, this study failed to detect an effect of CMR on REPS, RPE, FS, GLU, or LA on upper-body resistance exercise.",2020,"Rating of perceived exertion progressively increased each set (p < 0.0001), but was not affected by treatment (p = 0.897).","['Eighteen male and female (N = 36) resistance trained subjects (mean values ± SD; age: 21.5 ± 1.6 years, height: 1.72 ± 0.09 m, body mass: 72.8 ± 13.4 kg, and body fat: 16.7 ± 5.8%) performed 3']","['J Strength Cond Res XX(X', 'carbohydrate mouth rinse', 'carbohydrate mouth rinse (CMR', 'experimental visits during which bench press resistance exercise', 'Carbohydrate Mouth Rinse', 'Subjects rinsed 25 ml of water (WAT), noncaloric placebo (PLA), or 6.4% maltodextrin (CHO) solution']","['resistance exercise performance', 'Pleasure-displeasure', 'REPS, RPE, FS, GLU, or LA on upper-body resistance exercise', 'Resistance Exercise Performance', 'Rating of perceived exertion (RPE), pleasure-displeasure (FS), number of repetitions to fatigue (REPS), and postexercise blood glucose (GLU) and lactate (LA', 'Rating of perceived exertion', 'Postexercise GLU', 'Green, MS, Kimmel, CS, Martin, TD, Mouser, JG, and Brune, MP']","[{'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517508', 'cui_str': '1.6'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C4517513', 'cui_str': '1.72'}, {'cui': 'C4517419', 'cui_str': '0.09'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C4517558', 'cui_str': '13.4'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C4517590', 'cui_str': '16.7'}, {'cui': 'C4517796', 'cui_str': '5.8'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0026647', 'cui_str': 'Oromucosal solution for gargle'}, {'cui': 'C0454326', 'cui_str': 'Bench press'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1701810', 'cui_str': 'Rinse'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4517822', 'cui_str': '6.4'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0037633', 'cui_str': 'Solution'}]","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0679105', 'cui_str': 'Pleasure'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C1268087', 'cui_str': 'Upper body structure'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0332583', 'cui_str': 'Green color'}]",36.0,0.176787,"Rating of perceived exertion progressively increased each set (p < 0.0001), but was not affected by treatment (p = 0.897).","[{'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Green', 'Affiliation': 'Department of Kinesiology and Health Promotion, Troy University, Troy, Alabama.'}, {'ForeName': 'Cody S', 'Initials': 'CS', 'LastName': 'Kimmel', 'Affiliation': ''}, {'ForeName': 'Tyler D', 'Initials': 'TD', 'LastName': 'Martin', 'Affiliation': ''}, {'ForeName': 'James G', 'Initials': 'JG', 'LastName': 'Mouser', 'Affiliation': ''}, {'ForeName': 'Madison P', 'Initials': 'MP', 'LastName': 'Brune', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003755'] 2058,32740293,Hemodynamic responses of resistance exercise performed with repetitions to failure and not to failure in adults with hypertension.,"OBJECTIVE To evaluate and compare the hemodynamic responses of resistance exercise (RE) performed with repetitions to failure vs. not to failure in individuals with hypertension. METHODS Twenty participants were randomly allocated to perform three experimental sessions: a RE session performed with repetitions to failure (RF); a RE session performed with repetitions not to failure (NRF); and a non-exercise control session (Con). RE sessions were composed of four sets of 10 repetitions in four exercises involving large muscle groups. To ensure that the sets could be performed with RF or NRF, intensities corresponding to 75% and 50% of one-repetition maximum test were adopted in RF and NRF sessions, respectively. The Con was performed in seated rest. Blood pressure and rate-pressure product were measured before, during and after the experimental sessions for 1 h. RESULTS SBP and DBP decreased after NRF compared with Con (systolic post 1 h: -7.7 ± 1.1 mmHg, P < 0.001; diastolic post 1 h: -4.2 ± 0.7 mmHg, P = 0.001), and after RF compared with Con (systolic post 1 h: -8.2 ± 1.3 mmHg, P < 0.001; diastolic post 1 h: -7.4 ± 1.4 mmHg, P < 0.001). No significant difference was found in blood pressure between RF and NRF sessions after 1 h. Rate-pressure product was lower during NRF compared with RF (P = 0.001), suggesting a higher cardiovascular demand during the RF session. CONCLUSION The RF and NRF sessions are equally effective to promote post-exercise hypotension. In addition, NRF session can reduce cardiac demand during the exercise and should be recommended in adults with hypertension.",2020,"No significant difference was found in blood pressure between RF and NRF sessions after 1 h. Rate-pressure product was lower during NRF compared with RF (P = 0.001), suggesting a higher cardiovascular demand during the RF session. ","['Twenty participants', 'individuals with hypertension', 'adults with hypertension']","['resistance exercise (RE', 'NRF session', 'RE session performed with repetitions to failure (RF); a RE session performed with repetitions not to failure (NRF); and a non-exercise control session (Con', 'resistance exercise']","['Rate-pressure product', 'blood pressure', 'SBP and DBP', 'Blood pressure and rate-pressure product']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}]",20.0,0.0252005,"No significant difference was found in blood pressure between RF and NRF sessions after 1 h. Rate-pressure product was lower during NRF compared with RF (P = 0.001), suggesting a higher cardiovascular demand during the RF session. ","[{'ForeName': 'Lucas B', 'Initials': 'LB', 'LastName': 'Domingues', 'Affiliation': 'Postgraduate Program in Cardiology, Universidade Federal do Alegre.'}, {'ForeName': 'Eduardo L', 'Initials': 'EL', 'LastName': 'Cadore', 'Affiliation': 'Sports and Exercise Training Study Group, Hospital de Clínicas Alegre.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Ferrari', 'Affiliation': 'Postgraduate Program in Cardiology, Universidade Federal do Alegre.'}]",Blood pressure monitoring,['10.1097/MBP.0000000000000478'] 2059,32740306,Integration of Person-Centered Narratives into the Electronic Health Record: Study Protocol.,"BACKGROUND Incorporating a patient's personal narrative into the electronic health record (EHR) is an opportunity to more fully integrate the patient's values and beliefs into care, thus creating opportunities to deliver high-quality/high-value, person-centered care. OBJECTIVES To present a study protocol of a narrative intervention that aims to: (a) compare the effects of the narrative intervention to usual care on primary outcome of person's (patient) perceptions of quality of communication; (b) compare the effects of the narrative intervention on secondary outcomes of biopsychosocial well-being; and (c) examine the feasibility and acceptability of the narrative intervention from the perspective of both persons: the patient and the acute care bedside nurse. METHODS A randomized control trial is being conducted with a targeted enrollment of 80 patient participants and 80 nurse participants. The patient participants include individuals who are admitted to the acute care hospital for either heart failure or end-stage renal disease. An acute care beside nurse who has cared for the patient participant is also enrolled. Through a 1:1 random allocation scheme, stratified by illness, we will enroll 40 in the narrative intervention group and 40 in the usual care group. Patient participants will be assessed for patient-reported outcomes of patient's perception of quality of communication and biopsychosocial well-being. RESULTS The study began in October 2019; 53 potential patient participants have been approached, 21 have enrolled, and 20 have completed the data collection process. DISCUSSION The testing and integration of a person-centered narrative into the EHR is a novel approach to provide opportunities for improvement in communication between patients and nurses. The results from this study will provide important preliminary knowledge to inform future randomized clinical trials of narrative interventions leading to advances in how to best provide high-value, high-quality, person-centered care for persons living with serious illness.",2020,The testing and integration of a person-centered narrative into the EHR is a novel approach to provide opportunities for improvement in communication between patients and nurses.,"['80 patient participants and 80 nurse participants', 'October 2019; 53 potential patient participants have been approached, 21 have enrolled, and 20 have completed the data collection process', 'patient participants include individuals who are admitted to the acute care hospital for either heart failure or end-stage renal disease', 'persons living with serious illness']","['narrative intervention', 'narrative intervention to usual care']","['feasibility and acceptability', ""patient's perception of quality of communication and biopsychosocial well-being""]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0010995', 'cui_str': 'Data Collection'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C3661916', 'cui_str': 'Acute care hospital'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0221423', 'cui_str': 'Illness'}]","[{'cui': 'C1135957', 'cui_str': 'Narration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0018684', 'cui_str': 'Health'}]",,0.0644748,The testing and integration of a person-centered narrative into the EHR is a novel approach to provide opportunities for improvement in communication between patients and nurses.,"[{'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Coats', 'Affiliation': 'University of Colorado College of Nursing, Anschutz Medical Campus, Aurora, Colorado.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Shive', 'Affiliation': 'University of Colorado College of Nursing, Anschutz Medical Campus, Aurora, Colorado.'}, {'ForeName': 'Ardith', 'Initials': 'A', 'LastName': 'Doorenbos', 'Affiliation': 'University of Illinois-Chicago College of Nursing.'}, {'ForeName': 'Sarah J', 'Initials': 'SJ', 'LastName': 'Schmiege', 'Affiliation': 'Colorado School of Public Health, Aurora, Colorado.'}]",Nursing research,['10.1097/NNR.0000000000000463'] 2060,32740320,Incidence of gastric insufflation at high compared with low laryngeal mask cuff pressure in a first-generation laryngeal mask detected by ultrasound: A randomised controlled cross-over trial.,": The success of ventilation with a laryngeal mask depends crucially on the seal between the mask and the periglottic tissue. Increasing the laryngeal mask's cuff volume is known to reduce oral air leakage but may lead to gastric insufflation. We hypothesised that a lower cuff pressure would result in less gastric insufflation. We sought to compare gastric insufflation with laryngeal mask cuff pressures of 20 cmH2O (CP20) and 60 cmH2O (CP60) during increasing peak airway pressures in a randomised controlled double-blind cross-over study. We also evaluated the incidence of gastric insufflation at the recommended peak airway pressure of 20 cmH2O or less and during both intermittent positive airway pressure and continuous positive airway pressure. METHODS After obtaining ethics approval and written informed consent, 184 patients ventilated via laryngeal mask received a stepwise increase in peak airway pressure from 15 to 30 cmH2O with CP20 and CP60 in turn. Gastric insufflation was determined via real-time ultrasound and measurement of the cross-sectional area of the gastric antrum. The primary endpoint was the incidence of gastric insufflation at the different laryngeal mask cuff pressures. RESULTS Data from 164 patients were analysed. Gastric insufflation occurred less frequently at CP20 compared with CP60 (P < 0.0001). Gastric insufflation was detected in 35% of cases with CP20 and in 48% with CP60 at a peak airway pressure of 20 cmH2O or less. Gastric insufflation occurred more often during continuous than during intermittent positive airway pressures (P < 0.01). CONCLUSION A laryngeal mask cuff pressure of 20 cmH2O may reduce the risk of gastric insufflation during mechanical ventilation. Surprisingly, peak airway pressure of 20 cmH2O or less may already induce significant gastric insufflation. Continuous positive airway pressure should be avoided due to an increased risk of gastric insufflation. TRIAL REGISTRATION NUMBER DRKS00010583 (www.drks.de). CLINICAL TRIAL REGISTRATION The study was registered in the German Clinical Trials Register (DRKS00010583) https://www.drks.de.",2020,"Gastric insufflation occurred more often during continuous than during intermittent positive airway pressures (P < 0.01). ","['184 patients ventilated via laryngeal mask', '164 patients were analysed']","['low laryngeal mask cuff pressure', 'gastric insufflation with laryngeal mask cuff pressures of 20\u200acmH2O (CP20) and 60\u200acmH2O (CP60']","['risk of gastric insufflation', 'peak airway pressure', 'Gastric insufflation', 'incidence of gastric insufflation at the different laryngeal mask cuff pressures', 'gastric insufflation']","[{'cui': 'C4517616', 'cui_str': '184'}, {'cui': 'C1299448', 'cui_str': 'Patient ventilated'}, {'cui': 'C0162645', 'cui_str': 'Laryngeal mask'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C3165198', 'cui_str': 'Laryngeal mask cuff'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0021634', 'cui_str': 'Insufflation'}, {'cui': 'C0439476', 'cui_str': 'cmH2O'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0021634', 'cui_str': 'Insufflation'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C3165198', 'cui_str': 'Laryngeal mask cuff'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}]",184.0,0.0730888,"Gastric insufflation occurred more often during continuous than during intermittent positive airway pressures (P < 0.01). ","[{'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Hell', 'Affiliation': 'From the Department of Anaesthesiology and Critical Care, Medical Centre (JH, HP, JS, WB, HB, SS, AS) and Faculty of Medicine, University of Freiburg, Freiburg, Germany (JH, HP, JS, WB, HB, SS, AS).'}, {'ForeName': 'Holger', 'Initials': 'H', 'LastName': 'Pohl', 'Affiliation': ''}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Spaeth', 'Affiliation': ''}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Baar', 'Affiliation': ''}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Buerkle', 'Affiliation': ''}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Schumann', 'Affiliation': ''}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Schmutz', 'Affiliation': ''}]",European journal of anaesthesiology,['10.1097/EJA.0000000000001269'] 2061,32736578,Brief motivational therapy versus enhanced usual care for alcohol use disorders in primary care in Chile: study protocol for an exploratory randomized trial.,"BACKGROUND Harmful alcohol use is a leading cause of global disability and death. However, increased detection and brief intervention capacity of more severe alcohol use disorders has not been accompanied by increased availability of treatment services. Incorporating treatment for such disorders into primary care is of paramount importance for improving access and health outcomes. This study aims to estimate the effectiveness of a Brief Motivational Treatment (BMT) applied in primary care for treatment of these disorders. METHODS A parallel-group, single-blinded, severity-stratified, randomized clinical trial will test the superiority of BMT over enhanced usual care. Eligible participants will be those seeking treatment and who fulfill DSM-V criteria for alcohol use disorder and criteria for harmful alcohol use. With an estimated a loss to follow-up of 20%, a total of 182 participants will be recruited and equally randomized to each treatment group. The intervention group will receive an adaptation of the motivational enhancement therapy, as manualized in Project MATCH. This treatment consists of four 45-min sessions provided by a general psychologist with at least 3 years of primary care experience. The primary outcome is the change from baseline in the drinks per drinking day during the last 90 days, which will be captured using the Timeline Follow Back method. Secondary outcomes will describe the changes in alcohol use pattern, motivational status, and severity of the disorder. All participants will be analyzed according to the group they were allocated, regardless of the treatment actually received. Mean differences (MD) will be computed for continuous outcomes and relative risks (RR) and RR reductions (RRR) for dichotomous results. Linear models will deliver the subgroup analyses. Missingness is assumed to be associated with the baseline alcohol use pattern and severity, so a multiple imputation method will be used to handle missing data. DISCUSSION This trial aims to test the superiority of BMT over enhanced usual care with a reasonable superiority margin, over which the BMT could be further considered for incorporation into PC in Chile. Its pragmatic approach ultimately aims to inform policymakers about the benefit of including a brief psychosocial treatment into PC. TRIAL REGISTRATION ClinicalTrials.gov NCT04345302 . Registered on 28 April 2020.",2020,"However, increased detection and brief intervention capacity of more severe alcohol use disorders has not been accompanied by increased availability of treatment services.","['Eligible participants will be those seeking treatment and who fulfill DSM-V criteria for alcohol use disorder and criteria for harmful alcohol use', 'alcohol use disorders in primary care in Chile', '182 participants']","['motivational enhancement therapy', 'Brief Motivational Treatment (BMT', 'BMT', 'Brief motivational therapy']","['relative risks (RR) and RR reductions (RRR', 'changes in alcohol use pattern, motivational status, and severity of the disorder']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0008107', 'cui_str': 'Chile'}]","[{'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",182.0,0.0501927,"However, increased detection and brief intervention capacity of more severe alcohol use disorders has not been accompanied by increased availability of treatment services.","[{'ForeName': 'Nicolas A', 'Initials': 'NA', 'LastName': 'Barticevic', 'Affiliation': 'Department of Family Medicine, School of Medicine, Pontificia Universidad Católica de Chile, Alameda 340, PO 8331150, Santiago, Chile.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Poblete', 'Affiliation': 'Department of Public Health, School of Medicine, Pontificia Universidad Católica de Chile, Alameda 340, PO 8331150, Santiago, Chile. fcpoblete@uc.cl.'}, {'ForeName': 'Soledad M', 'Initials': 'SM', 'LastName': 'Zuzulich', 'Affiliation': 'Nursing School, Pontificia Universidad Católica de Chile, Alameda 340, PO 8331150, Santiago, Chile.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Rodriguez', 'Affiliation': 'Department of Public Health, School of Medicine, Pontificia Universidad Católica de Chile, Alameda 340, PO 8331150, Santiago, Chile.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Bradshaw', 'Affiliation': 'Department of Public Health, School of Medicine, Pontificia Universidad Católica de Chile, Alameda 340, PO 8331150, Santiago, Chile.'}]",Trials,['10.1186/s13063-020-04589-4'] 2062,32736583,Online patient simulation training to improve clinical reasoning: a feasibility randomised controlled trial.,"BACKGROUND Online patient simulations (OPS) are a novel method for teaching clinical reasoning skills to students and could contribute to reducing diagnostic errors. However, little is known about how best to implement and evaluate OPS in medical curricula. The aim of this study was to assess the feasibility, acceptability and potential effects of eCREST - the electronic Clinical Reasoning Educational Simulation Tool. METHODS A feasibility randomised controlled trial was conducted with final year undergraduate students from three UK medical schools in academic year 2016/2017 (cohort one) and 2017/2018 (cohort two). Student volunteers were recruited in cohort one via email and on teaching days, and in cohort two eCREST was also integrated into a relevant module in the curriculum. The intervention group received three patient cases and the control group received teaching as usual; allocation ratio was 1:1. Researchers were blind to allocation. Clinical reasoning skills were measured using a survey after 1 week and a patient case after 1 month. RESULTS Across schools, 264 students participated (18.2% of all eligible). Cohort two had greater uptake (183/833, 22%) than cohort one (81/621, 13%). After 1 week, 99/137 (72%) of the intervention and 86/127 (68%) of the control group remained in the study. eCREST improved students' ability to gather essential information from patients over controls (OR = 1.4; 95% CI 1.1-1.7, n = 148). Of the intervention group, most (80/98, 82%) agreed eCREST helped them to learn clinical reasoning skills. CONCLUSIONS eCREST was highly acceptable and improved data gathering skills that could reduce diagnostic errors. Uptake was low but improved when integrated into course delivery. A summative trial is needed to estimate effectiveness.",2020,"eCREST improved students' ability to gather essential information from patients over controls (OR = 1.4; 95% CI 1.1-1.7, n = 148).","['final year undergraduate students from three UK medical schools in academic year 2016/2017 (cohort one) and 2017/2018 (cohort two', '264 students participated (18.2% of all eligible', 'Student volunteers were recruited in cohort one via email and on teaching days, and in cohort two eCREST was also integrated into a relevant module in the curriculum']","['control group received teaching as usual; allocation ratio', 'Online patient simulation training']","['Clinical reasoning skills', 'clinical reasoning', 'Uptake']","[{'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0036378', 'cui_str': 'Medical School'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C4517610', 'cui_str': '18.2'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0085137', 'cui_str': 'Patient Simulation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}]",264.0,0.147911,"eCREST improved students' ability to gather essential information from patients over controls (OR = 1.4; 95% CI 1.1-1.7, n = 148).","[{'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Plackett', 'Affiliation': 'Department of Applied Health Research, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK. ruth.plackett.15@ucl.ac.uk.'}, {'ForeName': 'Angelos P', 'Initials': 'AP', 'LastName': 'Kassianos', 'Affiliation': 'Department of Applied Health Research, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Kambouri', 'Affiliation': 'Institute of Education, UCL, London, UK.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Kay', 'Affiliation': 'Department of Applied Health Research, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Mylan', 'Affiliation': 'Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Hopwood', 'Affiliation': 'UCL Medical School, UCL, London, UK.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Schartau', 'Affiliation': 'Primary Care and Population Health Department, UCL, London, UK.'}, {'ForeName': 'Shani', 'Initials': 'S', 'LastName': 'Gray', 'Affiliation': 'Department of Applied Health Research, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Timmis', 'Affiliation': 'Department of Applied Health Research, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Bennett', 'Affiliation': 'Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Valerio', 'Affiliation': 'Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Veena', 'Initials': 'V', 'LastName': 'Rodrigues', 'Affiliation': 'Norwich Medical School, UEA, Norwich, UK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Player', 'Affiliation': 'Norwich Medical School, UEA, Norwich, UK.'}, {'ForeName': 'Willie', 'Initials': 'W', 'LastName': 'Hamilton', 'Affiliation': 'Institute of Health Service Research, University of Exeter, Exeter, UK.'}, {'ForeName': 'Rosalind', 'Initials': 'R', 'LastName': 'Raine', 'Affiliation': 'Department of Applied Health Research, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Duffy', 'Affiliation': 'Wolfson Institute of Preventive Medicine, QMUL, London, UK.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Sheringham', 'Affiliation': 'Department of Applied Health Research, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK.'}]",BMC medical education,['10.1186/s12909-020-02168-4'] 2063,32736592,muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial.,"OBJECTIVES To determine if a specific intervention reduces the composite of progression of patients with COVID-19-related disease to organ failure or death as measured by time to incidence of any one of the following: death, invasive mechanical ventilation, ECMO, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance <15ml/min). TRIAL DESIGN Randomised, parallel arm, open-label, adaptive platform Phase 2/3 trial of potential disease modifying therapies in patients with late stage 1/stage 2 COVID-19-related disease, with a diagnosis based either on a positive assay or high suspicion of COVID-19 infection by clinical, laboratory and radiological assessment. PARTICIPANTS Patients aged 18 and over, with a clinical picture strongly suggestive of COVID-19-related disease (with/without a positive COVID-19 test) AND a risk count (as defined below) >3 OR ≥3 if risk count includes ""Radiographic severity score >3"". A risk count is calculated by the following features on admission (1 point for each): radiographic severity score >3, male gender, non-white ethnicity, diabetes, hypertension, neutrophils >8.0 x10 9 /L, age >40 years and CRP >40 mg/L. Patients should be considered an appropriate subject for intervention with immunomodulatory or other disease modifying agents in the opinion of the investigator and are able to swallow capsules or tablets. The complete inclusion and exclusion criteria as detailed in the Additional file 1 should be fulfilled. Drug specific inclusion and exclusion criteria will also be applied to the active arms. Patients will be enrolled prior to the need for invasive mechanical ventilation, cardiac or renal support. Participants will be recruited across multiple centres in the UK including initially at Cambridge University Hospitals NHS Foundation Trust and St George's University NHS Foundation Trust. Other centres will be approached internationally in view of the evolving pandemic. INTERVENTION AND COMPARATOR There is increasing evidence of the role of immunomodulation in altering the course of COVID-19. Additionally, various groups have demonstrated the presence of pulmonary shunting in patients with COVID-19 as well as other cardiovascular complications. TACTIC-E will assess the efficacy of the novel immunomodulatory agent EDP1815 versus the approved cardio-pulmonary drugs, Dapagliflozin in combination with Ambrisentan versus the prevailing standard of care. EDP1815 will be given as 2 capsules twice daily (1.6 x 10 11 cells) for up to 7 days with the option to extend up to 14 days at the discretion of the principal investigator or their delegate, if the patient is felt to be clinically responding to treatment, is tolerating treatment, and is judged to be likely to benefit from a longer treatment course. Ambrisentan 5mg and Dapagliflozin 10mg will be given in combination once daily orally for up to maximum of 14 days. Patients will be randomised in a 1:1:1 ratio across treatments. Each active arm will be compared with standard of care alone. Additional arms may be added as the trial progresses. No comparisons will be made between active arms in this platform trial. MAIN OUTCOMES The primary outcome is the incidence (from baseline up to Day 14) to the occurrence of the any one of the following events: death, invasive mechanical ventilation, extra corporeal membrane oxygenation, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance <15ml/min). RANDOMISATION Eligible patients will be randomised using a central web-based randomisation service (Sealed Envelope) in a 1:1:1 ratio, stratified by site to one of the treatment arms or standard of care. BLINDING (MASKING) This is an open-label trial. Data analysis will not be blinded. NUMBERS TO BE RANDOMISED (SAMPLE SIZE) There is no fixed sample size for this study. There will be an early biomarker-based futility analysis performed at a point during the study. If this biomarker futility analysis is not conclusive, then a second futility analysis based on clinical endpoints will be performed after approximately 125 patients have been recruited per arm. Provisionally, further analyses of clinical endpoints will be performed after 229 patients per active arm and later 469 patients per arm have been recruited. Further additional analyses may be triggered by the independent data monitoring committee. TRIAL STATUS TACTIC-E Protocol version number 1.0 date May 27 th , 2020. Recruitment starts on the 3 rd of July 2020. The end trial date will be 18 months after the last patient's last visit and cannot be accurately predicted at this time. TRIAL REGISTRATION Registered on EU Clinical Trials Register EudraCT Number: 2020-002229-27 registered: 9 June 2020. The trial was also registered on ClinicalTrials.gov (NCT04393246) on 19 May 2020. FULL PROTOCOL The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.",2020,"To determine if a specific intervention reduces the composite of progression of patients with COVID-19-related disease to organ failure or death as measured by time to incidence of any one of the following: death, invasive mechanical ventilation, ECMO, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance <15ml/min). ","['125 patients have been recruited per arm', 'patients with late stage', ""Participants will be recruited across multiple centres in the UK including initially at Cambridge University Hospitals NHS Foundation Trust and St George's University NHS Foundation Trust"", 'pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E', 'Patients aged 18 and over, with a clinical picture strongly suggestive of COVID-19-related disease (with/without a positive COVID-19 test) AND a risk count (as defined below) ', '229 patients per active arm and later 469 patients per arm have been recruited', 'Patients will be enrolled prior to the need for invasive mechanical ventilation, cardiac or renal support', 'patients with COVID-19-related disease to organ failure or death']","['specific intervention', 'EDP1815', 'Ambrisentan 5mg and Dapagliflozin']","['Radiographic severity score', 'presence of pulmonary shunting', 'death, invasive mechanical ventilation, ECMO, cardiovascular organ support (inotropes or balloon pump), or renal failure', 'incidence (from baseline up to Day 14) to the occurrence of the any one of the following events: death, invasive mechanical ventilation, extra corporeal membrane oxygenation, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance <15ml/min']","[{'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1279941', 'cui_str': 'Late stage'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0796085', 'cui_str': 'Nance-Horan syndrome'}, {'cui': 'C0016617', 'cui_str': 'Foundations'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0013230', 'cui_str': 'Investigational New Drugs'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}, {'cui': 'C0332299', 'cui_str': 'Suggestive of'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C1868981', 'cui_str': 'Invasive mechanical ventilation'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0349410', 'cui_str': 'Single organ dysfunction'}, {'cui': 'C0011065', 'cui_str': 'Death'}]","[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1949327', 'cui_str': 'ambrisentan 5 MG'}, {'cui': 'C2353951', 'cui_str': 'dapagliflozin'}]","[{'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1868981', 'cui_str': 'Invasive mechanical ventilation'}, {'cui': 'C0015357', 'cui_str': 'Extracorporeal membrane oxygenation'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0009346', 'cui_str': 'Balloon pump'}, {'cui': 'C0035078', 'cui_str': 'Renal insufficiency'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine'}, {'cui': 'C0439232', 'cui_str': 'min'}]",,0.40292,"To determine if a specific intervention reduces the composite of progression of patients with COVID-19-related disease to organ failure or death as measured by time to incidence of any one of the following: death, invasive mechanical ventilation, ECMO, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance <15ml/min). ","[{'ForeName': 'Ing Ni', 'Initials': 'IN', 'LastName': 'Lu', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. ing.lu@addenbrookes.nhs.uk.'}, {'ForeName': 'Spoorthy', 'Initials': 'S', 'LastName': 'Kulkarni', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Fisk', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Michalis', 'Initials': 'M', 'LastName': 'Kostapanos', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Banham-Hall', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Sonakshi', 'Initials': 'S', 'LastName': 'Kadyan', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Bond', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Norton', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Cope', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Galloway', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Hall', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Jayne', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Ian B', 'Initials': 'IB', 'LastName': 'Wilkinson', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Cheriyan', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}]",Trials,['10.1186/s13063-020-04618-2'] 2064,32736596,"ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial.","OBJECTIVES Stage 1: To evaluate the safety and efficacy of candidate agents as add-on therapies to standard of care (SoC) in patients hospitalised with COVID-19 in a screening stage. Stage 2: To confirm the efficacy of candidate agents selected on the basis of evidence from Stage 1 in patients hospitalised with COVID-19 in an expansion stage. TRIAL DESIGN ACCORD is a seamless, Phase 2, adaptive, randomised controlled platform study, designed to rapidly test candidate agents in the treatment of COVID-19. Designed as a master protocol with each candidate agent being included via its own sub-protocol, initially randomising equally between each candidate and a single contemporaneous SoC arm (which can adapt into 2:1). Candidate agents currently include bemcentinib, MEDI3506, acalabrutinib, zilucoplan and nebulised heparin. For each candidate a total of 60 patients will be recruited in Stage 1. If Stage 1 provides evidence of efficacy and acceptable safety the candidate will enter Stage 2 where a total of approximately 126 patients will be recruited into each study arm sub-protocol. Enrollees and outcomes will not be shared across the Stages; the endpoint, analysis and sample size for Stage 2 may be adjusted based on evidence from Stage 1. Additional arms may be added as new potential candidate agents are identified via candidate agent specific sub-protocols. PARTICIPANTS The study will include hospitalised adult patients (≥18 years) with confirmed SARS-CoV-2 infection, the virus that causes COVID-19, that clinically meet Grades 3 (hospitalised - mild disease, no oxygen therapy), Grades 4 (hospitalised, oxygen by mask or nasal prongs) and 5 (hospitalised, non-invasive ventilation or high flow oxygen) of the WHO Working Group on the Clinical Characteristics of COVID-19 9-point category ordinal scale. Participants will be recruited from England, Northern Ireland, Wales and Scotland. INTERVENTION AND COMPARATOR Comparator is current standard of care (SoC) for the treatment of COVID-19. Current candidate experimental arms include bemcentinib, MEDI3506, acalabrutinib, zilucoplan and nebulised heparin with others to be added over time. Bemcentinib could potentially reduce viral infection and blocks SARS-CoV-2 spike protein; MEDI3506 is a clinic-ready anti-IL-33 monoclonal antibody with the potential to treat respiratory failure caused by COVID; acalabrutinib is a BTK inhibitor which is anti-viral and anti-inflammatory; zilucoplan is a complement C5 inhibitor which may block the severe inflammatory response in COVID-19 and; nebulised heparin has been shown to bind with the spike protein. ACCORD is linked with the UK national COVID therapeutics task force to help prioritise candidate agents. MAIN OUTCOMES Time to sustained clinical improvement of at least 2 points (from randomisation) on the WHO 9-point category ordinal scale, live discharge from the hospital, or considered fit for discharge (a score of 0, 1, or 2 on the ordinal scale), whichever comes first, by Day 29 (this will also define the ""responder"" for the response rate analyses). RANDOMISATION An electronic randomization will be performed by Cenduit using Interactive Response Technology (IRT). Randomisation will be stratified by baseline severity grade. Randomisation will proceed with an equal allocation to each arm and a contemporaneous SoC arm (e.g. 1:1 if control and 1 experimental arm; 1:1:1 if two experimental candidate arms etc) but will be reviewed as the trial progresses and may be changed to 2:1 in favour of the candidate agents. BLINDING (MASKING) The trial is open label and no blinding is currently planned in the study. NUMBERS TO BE RANDOMISED (SAMPLE SIZE) This will be in the order of 60 patients per candidate agent for Stage 1, and 126 patients for Stage 2. However, sample size re-estimation may be considered after Stage 1. It is estimated that up to 1800 patients will participate in the overall study. TRIAL STATUS Master protocol version ACCORD-2-001 - Master Protocol (Amendment 1) 22 nd April 2020, the trial has full regulatory approval and recruitment is ongoing in the bemcentinib (first patient recruited 6/5/2020), MEDI3506 (first patient recruited 19/5/2020), acalabrutinib (first patient recruited 20/5/2020) and zilucoplan (first patient recruited 19/5/2020) candidates (and SoC). The recruitment dates of each arm will vary between candidate agents as they are added or dropped from the trial, but will have recruited and reported within a year. TRIAL REGISTRATION EudraCT 2020-001736-95 , registered 28 th April 2020. FULL PROTOCOL The full protocol (Master Protocol with each of the candidate sub-protocols) is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.",2020,Bemcentinib could potentially reduce viral infection and blocks SARS-CoV-2 spike protein; MEDI3506 is a clinic-ready anti-IL-33 monoclonal antibody with the potential to treat respiratory failure caused by COVID; acalabrutinib is a BTK inhibitor which is anti-viral and anti-inflammatory; zilucoplan is a complement C5 inhibitor which may block the severe inflammatory response in COVID-19 and; nebulised heparin has been shown to bind with the spike protein.,"['patients hospitalised with COVID-19 in a screening stage', 'patients hospitalised with COVID-19 in an expansion stage', 'Participants will be recruited from England, Northern Ireland, Wales and Scotland', 'hospitalised adult patients (≥18 years) with confirmed SARS-CoV-2 infection, the virus that causes COVID-19, that clinically meet Grades 3 (hospitalised - mild disease, no oxygen therapy), Grades 4 (hospitalised, oxygen by mask or nasal prongs) and 5 (hospitalised, non-invasive ventilation or high flow oxygen) of the WHO Working Group on the Clinical Characteristics of COVID-19 9-point category ordinal scale', 'bemcentinib (first patient recruited 6/5/2020), MEDI3506 (first patient recruited 19/5/2020), acalabrutinib (first patient recruited 20/5/2020) and zilucoplan (first patient recruited 19/5/2020) candidates (and SoC', '22 nd April 2020', '2020-001736-95', 'Hospitalised Patients', '1800 patients will participate in the overall study', '60 patients will be recruited in Stage 1', '60 patients per candidate agent for Stage 1, and 126 patients for Stage 2', 'Master protocol version ACCORD-2-001 - Master Protocol (Amendment 1', '126 patients will be recruited into each study arm sub-protocol']","['ACCORD', 'heparin', 'EudraCT']","['Time to sustained clinical improvement of at least 2 points (from randomisation) on the WHO 9-point category ordinal scale, live discharge from the hospital, or considered fit for discharge (a score of 0, 1, or 2 on the ordinal scale', 'Efficacy and Safety', 'safety and efficacy']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0028415', 'cui_str': 'Northern Ireland'}, {'cui': 'C0043015', 'cui_str': 'Wales'}, {'cui': 'C0036453', 'cui_str': 'Scotland'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0042769', 'cui_str': 'Viral disease'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}, {'cui': 'C3537125', 'cui_str': 'Common terminology criteria for adverse events grade 4'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0445087', 'cui_str': 'Nasal prongs'}, {'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439080', 'cui_str': 'Ordinal number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C4078312', 'cui_str': 'acalabrutinib'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0444649', 'cui_str': 'Master'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}]","[{'cui': 'C0019134', 'cui_str': 'heparin'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439080', 'cui_str': 'Ordinal number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0036572', 'cui_str': 'Seizure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",60.0,0.215769,Bemcentinib could potentially reduce viral infection and blocks SARS-CoV-2 spike protein; MEDI3506 is a clinic-ready anti-IL-33 monoclonal antibody with the potential to treat respiratory failure caused by COVID; acalabrutinib is a BTK inhibitor which is anti-viral and anti-inflammatory; zilucoplan is a complement C5 inhibitor which may block the severe inflammatory response in COVID-19 and; nebulised heparin has been shown to bind with the spike protein.,"[{'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Wilkinson', 'Affiliation': 'University of Southampton, Southampton, Hampshire, UK.'}, {'ForeName': 'Rupert', 'Initials': 'R', 'LastName': 'Dixon', 'Affiliation': 'IQVIA, Reading, UK.'}, {'ForeName': 'Clive', 'Initials': 'C', 'LastName': 'Page', 'Affiliation': ""King's College London, London, UK.""}, {'ForeName': 'Miles', 'Initials': 'M', 'LastName': 'Carroll', 'Affiliation': 'Public Health England, London, UK.'}, {'ForeName': 'Gareth', 'Initials': 'G', 'LastName': 'Griffiths', 'Affiliation': 'University of Southampton, Southampton, Hampshire, UK. G.O.Griffiths@soton.ac.uk.'}, {'ForeName': 'Ling-Pei', 'Initials': 'LP', 'LastName': 'Ho', 'Affiliation': 'NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'De Soyza', 'Affiliation': 'Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Felton', 'Affiliation': 'Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Keir E', 'Initials': 'KE', 'LastName': 'Lewis', 'Affiliation': 'Swansea University, Swansea, UK.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Phekoo', 'Affiliation': 'University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Chalmers', 'Affiliation': 'University of Dundee, Dundee, UK.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Gordon', 'Affiliation': 'Imperial College London, London, UK.'}, {'ForeName': 'Lorcan', 'Initials': 'L', 'LastName': 'McGarvey', 'Affiliation': ""Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Jillian', 'Initials': 'J', 'LastName': 'Doherty', 'Affiliation': 'University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Read', 'Affiliation': 'University of Southampton, Southampton, Hampshire, UK.'}, {'ForeName': 'Manu', 'Initials': 'M', 'LastName': 'Shankar-Hari', 'Affiliation': ""King's College London, London, UK.""}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'Martinez-Alier', 'Affiliation': 'IQVIA, Reading, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': ""O'Kelly"", 'Affiliation': 'IQVIA, Dublin, Ireland.'}, {'ForeName': 'Graeme', 'Initials': 'G', 'LastName': 'Duncan', 'Affiliation': 'IQVIA, Edinburgh, UK.'}, {'ForeName': 'Roelize', 'Initials': 'R', 'LastName': 'Walles', 'Affiliation': 'IQVIA, Reading, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Sykes', 'Affiliation': 'IQVIA, Reading, UK.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Summers', 'Affiliation': 'University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Dave', 'Initials': 'D', 'LastName': 'Singh', 'Affiliation': 'University of Manchester, Manchester, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Trials,['10.1186/s13063-020-04584-9'] 2065,32736597,PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.,"OBJECTIVES Hydroxychloroquine has shown to have antiviral activity in vitro against coronaviruses, specifically SARS-CoV-2. It is believed to block virus infection by increasing endosomal pH required for virus cell fusion and glycosylation of viral surface proteins. In addition to its antiviral activity, hydroxychloroquine has an immune-modulating activity that may synergistically enhance its antiviral effect in vivo, making it a potentially promising drug for the prevention and the cure of SARS-CoV-19. However, randomized controlled trials are needed to assess whether it can be used safely to treat COVID-19 patients or to prevent infection. The main objective of the present study is to evaluate the efficacy of hydroxychloroquine for (I) the prevention of COVID-19 or related symptoms in SARS-CoV-2-exposed subjects, such as as household members/contacts of COVID-19 patients and (II) the treatment of early-phase asymptomatic or paucisymptomatic COVID-19 patients. TRIAL DESIGN This is a controlled, open label, cluster-randomized, superiority trial with parallel group design. Subjects will be randomized either to receive hydroxychloroquine or to observation (2:1). PARTICIPANTS SARS-CoV-2-exposed subjects, including household members and/or contacts of COVID-19 patients and healthcare professionals (Group 1) or patients with COVID-19 (positive PCR test on a rhinopharyngeal or oropharyngeal swab for SARS-CoV-2), asymptomatic or paucisymptomatic in home situations who are not undergoing treatment with any anti COVID-19 medication (Group 2), will be enrolled. Paucisymptomatic patients are defined as patients with a low number of mild symptoms. All subjects must be aged ≥18 years, male or female, must be willing and able to give informed consent and must not have any contraindications to take hydroxychloroquine (intolerance or previous toxicity for hydroxychloroquine/chloroquine, bradycardia or reduction in heart rhythm with arrhythmia, ischemic heart disease, retinopathy, congestive heart failure with use of diuretics, favism or glucose-6-phosphate dehydrogenase (G6PD) deficiency, diabetes type 1, major comorbidities such as advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmia, any oncologic/hematologic malignancy, severe neurological and mental illness, current use of medications with known significant drug-drug interactions, and known prolonged QT syndrome or current use of drugs with known QT prolongation). The study is monocentric and will be conducted at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS. Subjects will be enrolled from a large epidemic region (North-Central Italy). The Public Health Departments of several Italian regions will collaborate by identifying potentially eligible subjects. INTERVENTION AND COMPARATOR The participants will be randomized (2:1 randomization) to receive either hydroxychloroquine (Arm A) or to Observation (Arm B). Hydroxychloroquine will be administered with the following schedule: Group1: A loading dose hydroxychloroquine 400 mg twice daily on day 1, followed by a weekly dose of hydroxychloroquine 200 mg twice daily on days 8, 15 and 22, for a total of one month of treatment. Group 2: A loading dose hydroxychloroquine 400 mg twice daily on day 1 followed by 200 mg twice daily for a total of 5-7 days. The comparator in this trial is observation given that currently neither treatment is administered to asymptomatic or paucisymptomatic subjects, nor prophylaxis is available for contacts. Hydroxychloroquine will be shipped to subjects within 24 hours of randomization. Given the extraordinary nature of the COVID-19 pandemic, only telephonic interviews will be carried out and electronic Patient Reported Outcomes (ePRO) completed. During treatment, each subject will be contacted every other day for the first week and weekly thereafter (Group 2) or weekly (Group 1) by a study physician to assess early onset of any COVID-19 symptom or any adverse reaction to hydroxychloroquine and to check subject compliance. Furthermore, all subjects will receive periodic ePROs which may be completed through smartphone or tablets to record drug self-administration and onset of any symptom or adverse event. All subjects will be followed up for a total of 6 months by periodic telephonic interviews and ePROs. MAIN OUTCOMES The primary endpoint/outcome measure for this trial is: for Group 1, the proportion of subjects who become symptomatic and/or swab-positive in each arm within one month of randomization; for Group 2, the proportion of subjects who become swab-negative in each arm within 14 days of randomization. RANDOMIZATION All household members and/or contacts of each COVID-19 index case, and the COVID-19 patient himself/herself, fulfilling all inclusion criteria will be grouped into a single cluster and this cluster will be randomized (2:1) to either arm A or arm B. Information on each subject will be recorded in specific data records. Randomization lists will be stratified according to the following factors regarding COVID-19 index cases: 1. COVID-19 risk level on the basis of province of residence (high vs. low/intermediate); 2. Index case is a healthcare professional (yes vs.no) 3. Index case with COVID-19 treatment (yes vs. no) An independent statistician not otherwise involved in the trial will generate the allocation sequence, and COVID-19 response teams will be unaware of the allocation of clusters. Randomization will be performed through an interactive web-based electronic data-capturing database. An Independent Data Monitoring Committee has been established. BLINDING (MASKING) This study is open label. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE) For Group 1, a sample size of about 2000 SARS-CoV-2-exposed subjects such as household members and/or contacts of COVID-19 patients will take part in the study. Assuming around 1.5-2.0 asymptomatic household members and/or contacts for each COVID-19 patient, we expect to identify approximately 1000-1300 COVID-19 index cases to be randomized. An interim analysis on efficacy is planned using standard alpha-spending function. For Group 2, sufficient power for primary objective (negative swab within 14 days of randomization) will be reached given a sample size of 300 asymptomatic or paucisymptomatic COVID-19 subjects in home situations not treated for COVID-19 (25%-30% of about 1000-1300 expected index cases). Since up to date reduced evidence about COVID-19 infection epidemiology, the continuous update of diagnostic and therapeutic approaches, the sample size estimation could be updated after a one third of population will be recruited and eventually modified according to a substantial protocol amendment. An interim analysis at 100 enrolled COVID-19 patients is planned. We have planned a Generalized Estimating Equation analysis, which is more efficient than a cluster level analysis, to take advantage of subject-specific covariates. The above reported sample size analysis is therefore to be considered conservative. TRIAL STATUS The current version of the PROTECT trial protocol is 'Final version, 15 April 2020'. The study started on 9 th May 2020. The first patient was enrolled on 14 th May 2020. Recruitment is expected to last through September 2020. TRIAL REGISTRATION The PROTECT trial is registered in the EudraCT database (no. 2020-001501-24) and in ClinicalTrials.gov ( NCT04363827 ), date of registration 24 April 2020. FULL PROTOCOL The full PROTECT protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interests of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol (Protocol final version, 15 th April 2020). The study protocol has been reported in accordance with Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).",2020,"We have planned a Generalized Estimating Equation analysis, which is more efficient than a cluster level analysis, to take advantage of subject-specific covariates.","['SARS-CoV-2-exposed subjects, such as as household members/contacts of COVID-19 patients and (II) the treatment of early-phase asymptomatic or paucisymptomatic COVID-19 patients', 'Subjects will be enrolled from a large epidemic region (North-Central Italy', 'in heart rhythm with arrhythmia, ischemic heart disease, retinopathy, congestive heart failure with use of diuretics, favism or glucose-6-phosphate dehydrogenase (G6PD) deficiency, diabetes type 1, major comorbidities such as advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmia, any oncologic/hematologic malignancy, severe neurological and mental illness', 'SARS-CoV-2-exposed subjects, including household members and/or contacts of COVID-19 patients and healthcare professionals (Group 1) or patients with COVID-19 (positive PCR test on a rhinopharyngeal or oropharyngeal swab for SARS-CoV-2), asymptomatic or paucisymptomatic in home situations who are not undergoing treatment with any anti COVID-19 medication (Group 2), will be enrolled', '2000 SARS-CoV-2-exposed subjects such as household members', 'All subjects must be aged ≥18 years, male or female', 'Coronavirus disease (COVID-19']","['hydroxychloroquine (intolerance', 'hydroxychloroquine', 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS', 'Hydroxychloroquine', 'hydroxychloroquine/chloroquine, bradycardia or reduction']",['proportion of subjects who become symptomatic and/or swab-positive'],"[{'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0014499', 'cui_str': 'Epidemic'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0232187', 'cui_str': 'Cardiac rhythm type'}, {'cui': 'C0003811', 'cui_str': 'Cardiac arrhythmia'}, {'cui': 'C0151744', 'cui_str': 'Myocardial ischemia'}, {'cui': 'C0035309', 'cui_str': 'Retinal disorder'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0012798', 'cui_str': 'Diuretic'}, {'cui': 'C0015702', 'cui_str': 'Favism'}, {'cui': 'C2939465', 'cui_str': 'Deficiency of glucose-6-phosphate dehydrogenase'}, {'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0011946', 'cui_str': 'Dialysis procedure'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0085612', 'cui_str': 'Ventricular arrhythmia'}, {'cui': 'C0205478', 'cui_str': 'Oncologic'}, {'cui': 'C0376545', 'cui_str': 'Hematologic neoplasm'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0027442', 'cui_str': 'Nasopharyngeal'}, {'cui': 'C0521367', 'cui_str': 'Oropharyngeal structure'}, {'cui': 'C0183753', 'cui_str': 'Swab'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0231199', 'cui_str': 'Intolerance'}, {'cui': 'C0008269', 'cui_str': 'Chloroquine'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0183753', 'cui_str': 'Swab'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]",,0.210316,"We have planned a Generalized Estimating Equation analysis, which is more efficient than a cluster level analysis, to take advantage of subject-specific covariates.","[{'ForeName': 'Oriana', 'Initials': 'O', 'LastName': 'Nanni', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. oriana.nanni@irst.emr.it.'}, {'ForeName': 'Pierluigi', 'Initials': 'P', 'LastName': 'Viale', 'Affiliation': 'Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.'}, {'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'Vertogen', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Lilli', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Zingaretti', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Caterina', 'Initials': 'C', 'LastName': 'Donati', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Masini', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Monti', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Patrizia', 'Initials': 'P', 'LastName': 'Serra', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Vespignani', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Veruska', 'Initials': 'V', 'LastName': 'Grossi', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Annibale', 'Initials': 'A', 'LastName': 'Biggeri', 'Affiliation': 'Dipartimento di Statistica, Informatica, Applicazioni ""G. Parenti"" (DISIA), Università degli studi Firenze, Florence, Italy.'}, {'ForeName': 'Emanuela', 'Initials': 'E', 'LastName': 'Scarpi', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Galardi', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Bertoni', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Americo', 'Initials': 'A', 'LastName': 'Colamartini', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Falcini', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Mattia', 'Initials': 'M', 'LastName': 'Altini', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Ilaria', 'Initials': 'I', 'LastName': 'Massa', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Raffaella', 'Initials': 'R', 'LastName': 'Gaggeri', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Martinelli', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}]",Trials,['10.1186/s13063-020-04527-4'] 2066,32742090,Clinical and Radiographic Evaluation of Aloe vera vs Formocresol as a Pulpotomy Medicament in Primary Molars: A Double Blinded Randomized Controlled Trial.,"Aim The aim of this clinical trial is to compare the clinical and radiographic success of Aloe vera and formocresol (FC) as a pulpotomy medicament in primary molars. Materials and methods A total of 72 asymptomatic or symptomatic vital primary molars were selected and were assigned to two groups: group II: Buckley's FC, group II: Aloe vera gel. The clinical and radiographic success were evaluated using Zurn and Seale criteria. The data were statistically analyzed using the Chi-square test. Results At three and 6 months follow-up, the clinical success rate of Aloe vera and FC was equally effective. Aloe vera showed a higher radiographic success rate compared to FC ( p > 0.05). At 6 months follow-up, FC showed a higher radiographic success rate compared to Aloe vera ( p > 0.05). Conclusion The clinical and radiographic success of both groups were equally effective at the end of 6 months follow-up. Aloe vera can be considered as an alternative pulpotomy medicament to FC. But, further long-term follow-up studies and histological studies are required. How to cite this article Subramanyam D, Somasundaram S. Clinical and Radiographic Evaluation of Aloe vera vs Formocresol as a Pulpotomy Medicament in Primary Molars: A Double Blinded Randomized Controlled Trial. Int J Clin Pediatr Dent 2020;13(2):138-143.",2020,"At three and 6 months follow-up, the clinical success rate of Aloe vera and FC was equally effective. ","['72 asymptomatic or symptomatic vital primary molars', 'Primary Molars', 'primary molars']","[""Buckley's FC, group II: Aloe vera gel"", 'Aloe vera vs Formocresol', 'Aloe vera and formocresol (FC']","['clinical and radiographic success', 'clinical success rate of Aloe vera and FC was equally effective', 'radiographic success rate']","[{'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0442732', 'cui_str': 'Vital'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0974143', 'cui_str': 'Aloe vera gel'}, {'cui': 'C0718405', 'cui_str': 'Aloe vera'}, {'cui': 'C0016583', 'cui_str': 'Formocresols'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0718405', 'cui_str': 'Aloe vera'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.0752573,"At three and 6 months follow-up, the clinical success rate of Aloe vera and FC was equally effective. ","[{'ForeName': 'Divya', 'Initials': 'D', 'LastName': 'Subramanyam', 'Affiliation': 'Department of Pediatric and Preventive Dentistry, Asan Memorial Dental College and Hospital, Chengalpattu, Tamil Nadu, India.'}, {'ForeName': 'Sujatha', 'Initials': 'S', 'LastName': 'Somasundaram', 'Affiliation': 'Department of Pediatric and Preventive Dentistry, Saveetha Dental College, Chennai, Tamil Nadu, India.'}]",International journal of clinical pediatric dentistry,['10.5005/jp-journals-10005-1724'] 2067,32742096,Comparative Evaluation of Success of Biodentine and Mineral Trioxide Aggregate with Formocresol as Pulpotomy Medicaments in Primary Molars: An In Vivo Study.,"Aim The study was designed to evaluate and compare the success of Biodentine and mineral trioxide aggregate (MTA) in comparison to formocresol as pulpotomy medicaments over 9 months of the follow-up period. Materials and methods The sample of 60 deciduous molars of patients aged 4-7 years were incorporated in the study. The molars were randomly allocated to the experimental and control groups. Following coronal pulp removal and achieving hemostasis, the radicular pulp was covered with either Biodentine or MTA (experimental groups). In the control group, a cotton pellet soaked with diluted formocresol (one-fifth dilution of Buckley's formocresol) was placed over the radicular pulp for 1 minute. All pulpotomized molars were later restored with stainless steel crowns (SSCs). Results The achieved clinical success over 9 months of the follow-up period was 100, 95, and 70% with Biodentine, MTA, and formocresol, respectively. The achieved radiographic success over 9 months of the follow-up period was 95, 60, and 25% with Biodentine, MTA, and formocresol, respectively. Conclusion Favorable biological, physical, mechanical, and good manipulation properties of Biodentine show that this material can be used efficiently as a pulpotomy medicament in the clinical practice. How to cite this article Ahuja S, Surabhi K, Gandhi K, et al. Comparative Evaluation of Success of Biodentine and Mineral Trioxide Aggregate with Formocresol as Pulpotomy Medicaments in Primary Molars: An In Vivo Study. Int J Clin Pediatr Dent 2020;13(2):167-173.",2020,"The achieved radiographic success over 9 months of the follow-up period was 95, 60, and 25% with Biodentine, MTA, and formocresol, respectively. ","['Primary Molars', '60 deciduous molars of patients aged 4-7 years']","['Biodentine and mineral trioxide aggregate (MTA', 'Biodentine or MTA', 'Biodentine and Mineral Trioxide Aggregate with Formocresol as Pulpotomy Medicaments', 'cotton pellet soaked with diluted formocresol', 'stainless steel crowns (SSCs']","['radiographic success', 'clinical success']","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C3502756', 'cui_str': 'biodentine'}, {'cui': 'C0253527', 'cui_str': 'mineral trioxide aggregate'}, {'cui': 'C0016583', 'cui_str': 'Formocresols'}, {'cui': 'C0034104', 'cui_str': 'Pulpotomy'}, {'cui': 'C0456386', 'cui_str': 'Medicament'}, {'cui': 'C0010196', 'cui_str': 'Gossypium'}, {'cui': 'C0441436', 'cui_str': 'Pellet gun missile'}, {'cui': 'C0204774', 'cui_str': 'Soak'}, {'cui': 'C1720119', 'cui_str': 'Dilute'}, {'cui': 'C0038126', 'cui_str': 'Stainless steel material'}, {'cui': 'C0010384', 'cui_str': 'Crown'}]","[{'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",60.0,0.0257589,"The achieved radiographic success over 9 months of the follow-up period was 95, 60, and 25% with Biodentine, MTA, and formocresol, respectively. ","[{'ForeName': 'Shilpa', 'Initials': 'S', 'LastName': 'Ahuja', 'Affiliation': 'Department of Pedodontics and Preventive Dentistry, Inderprastha Dental College and Hospital, Ghaziabad, Uttar Pradesh, India.'}, {'ForeName': 'Kumari', 'Initials': 'K', 'LastName': 'Surabhi', 'Affiliation': 'Department of Pedodontics and Preventive Dentistry, Inderprastha Dental College and Hospital, Ghaziabad, Uttar Pradesh, India.'}, {'ForeName': 'Kapil', 'Initials': 'K', 'LastName': 'Gandhi', 'Affiliation': 'Department of Pedodontics and Preventive Dentistry, Inderprastha Dental College and Hospital, Ghaziabad, Uttar Pradesh, India.'}, {'ForeName': 'Rishabh', 'Initials': 'R', 'LastName': 'Kapoor', 'Affiliation': 'Department of Pedodontics and Preventive Dentistry, Inderprastha Dental College and Hospital, Ghaziabad, Uttar Pradesh, India.'}, {'ForeName': 'Ritika', 'Initials': 'R', 'LastName': 'Malhotra', 'Affiliation': 'Department of Pedodontics and Preventive Dentistry, Inderprastha Dental College and Hospital, Ghaziabad, Uttar Pradesh, India.'}, {'ForeName': 'Dipanshu', 'Initials': 'D', 'LastName': 'Kumar', 'Affiliation': 'Department of Pedodontics and Preventive Dentistry, Inderprastha Dental College and Hospital, Ghaziabad, Uttar Pradesh, India.'}]",International journal of clinical pediatric dentistry,['10.5005/jp-journals-10005-1740'] 2068,32742120,Effectiveness of color and picture labeling in improving the knowledge on topical medications among patients with psoriasis: A randomized controlled trial.,"Aim and Objective The success of topical treatment in patients with psoriasis is still below par in Malaysia. The contributing factors include patients' understanding and knowledge about prescribed topical medications. The aim of this study was to assess the effectiveness of color and picture labeling (C and P labeling) in improving the knowledge about topical medications among patients with psoriasis. Materials and Methods An unblinded randomized controlled trial was undertaken at the dermatology clinic of a tertiary care hospital. Consent from the patients fulfilling inclusion criteria were obtained, and they were included in this study. They were randomized into two groups, namely Gp-1 (C and P labeling) and Gp-2 (conventional labeling). Both groups were assessed at week 0, 6, and 12 (visit 1, 2, and 3) using knowledge assessment list and psoriasis severity assessment score. For visit 2 (week 6), reinforcement of their understanding of topical treatment was performed. Results A total of 101 patients were recruited. Only 91 of them completed the study. The mean ages were 44.52 (±16.61) and 45.49 (±15.84) years, with 70.3% males and approximately half Malay ethnics. The changes of knowledge and comparison of Topical Application Assessment Score between the groups showed an incremental raise of significance with every visit ( P = 0.006 [week 1], 0.004 [week 6], and 0.002 [week 12]). Psoriasis Area and Severity Index 75 could not draw any conclusion as patients who achieved >75% improvement were inadequate. Conclusion C and P labeling was effective in improving the understanding and knowledge of patients with psoriasis. Both groups showed improvement in body surface area and Dermatology Life Quality Index for every visit; however, it was statistically insignificant.",2020,The changes of knowledge and comparison of Topical Application Assessment Score between the groups showed an incremental raise of significance with every visit ( P = 0.006,"['dermatology clinic of a tertiary care hospital', 'patients with psoriasis', 'The mean ages were 44.52 (±16.61) and 45.49 (±15.84) years, with 70.3% males and approximately half Malay ethnics', 'patients with psoriasis is still below par in Malaysia', 'A total of 101 patients were recruited']","['color and picture labeling', 'namely Gp-1 (C and P labeling) and Gp-2 (conventional labeling', 'color and picture labeling (C and P labeling']","['Psoriasis Area and Severity Index', 'body surface area and Dermatology Life Quality Index', 'knowledge assessment list and psoriasis severity assessment score']","[{'cui': 'C3812390', 'cui_str': 'Dermatology clinic'}, {'cui': 'C0337954', 'cui_str': 'Tertiary care hospital'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0024549', 'cui_str': 'Malay language'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}, {'cui': 'C0032405', 'cui_str': 'Poly ADP Ribose Polymerase'}, {'cui': 'C0024552', 'cui_str': 'Malaysia'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0005902', 'cui_str': 'Body surface area'}, {'cui': 'C0451112', 'cui_str': 'Dermatology life quality index'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}]",101.0,0.0317941,The changes of knowledge and comparison of Topical Application Assessment Score between the groups showed an incremental raise of significance with every visit ( P = 0.006,"[{'ForeName': 'Norazlima', 'Initials': 'N', 'LastName': 'Mohd Ali', 'Affiliation': 'Department of Dermatology, Hospital Pulau Pinang, Penang, Ministry of Health, Malaysia.'}, {'ForeName': 'Chan Chin', 'Initials': 'CC', 'LastName': 'Lee', 'Affiliation': 'Department of Dermatology, Hospital Pulau Pinang, Penang, Ministry of Health, Malaysia.'}, {'ForeName': 'Nurul Shafaril Niza', 'Initials': 'NSN', 'LastName': 'Mohd Akhir', 'Affiliation': 'Department of Pharmacy, Hospital Pulau Pinang, Penang, Ministry of Health, Malaysia.'}, {'ForeName': 'Ahmad Syafiq', 'Initials': 'AS', 'LastName': 'Ahmad Izani', 'Affiliation': 'Department of Pharmacy, Hospital Pulau Pinang, Penang, Ministry of Health, Malaysia.'}, {'ForeName': 'Chin Tho', 'Initials': 'CT', 'LastName': 'Leong', 'Affiliation': 'Clinical Research Centre, Hospital Pulau Pinang, Penang, Ministry of Health, Malaysia.'}, {'ForeName': 'Jaya', 'Initials': 'J', 'LastName': 'Muneswarao', 'Affiliation': 'Department of Pharmacy, Hospital Kulim, Kedah, Ministry of Health, Malaysia.'}, {'ForeName': 'Ashutosh Kumar', 'Initials': 'AK', 'LastName': 'Verma', 'Affiliation': 'Faculty of Pharmacy, MAHSA University, Selangor, Malaysia.'}]",Journal of pharmacy & bioallied sciences,['10.4103/jpbs.JPBS_140_19'] 2069,32742143,Associations between Perceived Racial Discrimination and Tobacco Cessation among Diverse Treatment Seekers.,"Objectives This study investigated a) racial/ethnic differences in past-year discrimination experiences and b) associations between discrimination and smoking abstinence. Design Prospective, longitudinal analysis of smoking status. Perceived past-year discrimination was assessed at baseline. ANCOVAs and intent-to-treat hierarchical logistic regressions were conducted. Setting Dual-site (Tampa, FL and Miami, FL) randomized controlled trial testing the effects of a group cessation intervention plus pharmacotherapy. Participants Treatment-seeking adult smokers (N=347; non-Hispanic White, non-Hispanic African American/Black, or Hispanic). Main Outcome Measures Biochemically verified 7-day point prevalence abstinence (7-day ppa) was assessed immediately post-intervention and at 6-month follow-up. Results After controlling for covariates, African Americans/Blacks reported greater perceived discrimination compared with non-Hispanic Whites (P=.02), and Hispanics (P=.06). Non-Hispanic Whites and Hispanics did not differ in perceived racial/ethnic discrimination experiences over the past year. Irrespective of race/ethnicity, past-year perceived discrimination was inversely associated with 7-day ppa, both post-intervention (AOR=.97, CI: .95-.99) and at 6-months (AOR=.98, CI: .96-.99). Among African Americans/Blacks, past-year perceived discrimination was inversely associated with 7-day ppa, both post-intervention (AOR=.95, CI: .92-.97) and at 6-months (AOR=.97, CI: .94-.99). Perceived discrimination was unrelated to 7-day ppa among Hispanics. Among non-Hispanic Whites, past-year perceived discrimination was inversely associated with post-intervention 7-day ppa (AOR=.95, CI: .91-.99), but not 6-months. Conclusions Perceived racial/ethnic discrimination was greater among African American/Black smokers compared with non-Hispanic Whites. Perceived discrimination was negatively associated with tobacco cessation in the full sample, and for African Americans at 6-months post-intervention. These data have implications for intervention delivery and health disparities.",2020,"After controlling for covariates, African Americans/Blacks reported greater perceived discrimination compared with non-Hispanic Whites (P=.02), and Hispanics (P=.06).","['Hispanic Whites and Hispanics', 'Participants\n\n\nTreatment-seeking adult smokers (N=347; non-Hispanic White, non-Hispanic African American/Black, or Hispanic']",[],['7-day point prevalence abstinence (7-day ppa'],"[{'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}]",[],"[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}]",347.0,0.0647083,"After controlling for covariates, African Americans/Blacks reported greater perceived discrimination compared with non-Hispanic Whites (P=.02), and Hispanics (P=.06).","[{'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Webb Hooper', 'Affiliation': 'National Institute on Minority Health and Health Disparities, National Institutes of Health, Bethesda, MD (former affiliation when study was conducted: Case Western Reserve University School of Medicine, Case Comprehensive Cancer Center, Cleveland, OH).'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Calixte-Civil', 'Affiliation': 'Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Verzijl', 'Affiliation': 'Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL.'}, {'ForeName': 'Karen O', 'Initials': 'KO', 'LastName': 'Brandon', 'Affiliation': 'Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL.'}, {'ForeName': 'Taghrid', 'Initials': 'T', 'LastName': 'Asfar', 'Affiliation': 'Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL.'}, {'ForeName': 'Tulay', 'Initials': 'T', 'LastName': 'Koru-Sengul', 'Affiliation': 'Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL.'}, {'ForeName': 'Michael H', 'Initials': 'MH', 'LastName': 'Antoni', 'Affiliation': 'Department of Psychology, University of Miami, Coral Gables, FL.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Lee', 'Affiliation': 'Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL.'}, {'ForeName': 'Vani N', 'Initials': 'VN', 'LastName': 'Simmons', 'Affiliation': 'Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL.'}, {'ForeName': 'Thomas H', 'Initials': 'TH', 'LastName': 'Brandon', 'Affiliation': 'Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL.'}]",Ethnicity & disease,['10.18865/ed.30.3.411'] 2070,32742146,Impact of COVID-19 on Clinical Research and Inclusion of Diverse Populations.,"The randomized clinical trial (RCT) has long been recognized as the 'gold standard' for developing evidence for clinical treatments and vaccines; however, the successful implementation and translation of these findings is predicated upon external validity. The generalization of RCT findings are jeopardized by the lack of participation of at-risk groups such as African Americans, with long-recognized disproportional representation. Distinct factors that deter participation in RCTs include distrust, access, recruitment strategies, perceptions of research, and socioeconomic factors. While strategies have been implemented to improve external validity with greater participation among all segments of the population in RCTs, the coronavirus disease 2019 (COVID-19) pandemic may exacerbate disparities in RCT participation with the potential impact of delaying treatment development and vaccine interventions that are applicable and generalizable. Thus, it is essential to include diverse populations in such strategies and RCTs. This Perspective aims to direct attention to the additional harm from the pandemic as well as a refocus on the unresolved lack of inclusion of diverse populations in conducting RCTs.",2020,"The randomized clinical trial (RCT) has long been recognized as the 'gold standard' for developing evidence for clinical treatments and vaccines; however, the successful implementation and translation of these findings is predicated upon external validity.",[],[],[],[],[],[],,0.0335871,"The randomized clinical trial (RCT) has long been recognized as the 'gold standard' for developing evidence for clinical treatments and vaccines; however, the successful implementation and translation of these findings is predicated upon external validity.","[{'ForeName': 'Daniel T', 'Initials': 'DT', 'LastName': 'Lackland', 'Affiliation': 'Division of Translational Neurosciences and Population Studies, Department of Neurology, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Catrina', 'Initials': 'C', 'LastName': 'Sims-Robinson', 'Affiliation': 'Division of Translational Neurosciences and Population Studies, Department of Neurology, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Joy N', 'Initials': 'JN', 'LastName': 'Jones Buie', 'Affiliation': 'Division of Translational Neurosciences and Population Studies, Department of Neurology, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Jenifer H', 'Initials': 'JH', 'LastName': 'Voeks', 'Affiliation': 'Division of Translational Neurosciences and Population Studies, Department of Neurology, Medical University of South Carolina, Charleston, SC.'}]",Ethnicity & disease,['10.18865/ed.30.3.429'] 2071,32742180,"The effect of hydroalcoholic Berberis integerrima fruits extract on the lipid profile, antioxidant parameters and liver and kidney function tests in patients with nonalcoholic fatty liver disease.","Background Non-alcoholic fatty liver disease (NAFLD) is one of the hepatic disorders which is characterized by increasing fat deposits in the liver. This disorder may lead to elevation the activity of liver enzymes and is associated with obesity, dyslipidemia, hypertension, and type II diabetes. The aim of present study was to investigate the effect of Berberis integerrima extract on NAFLD patients compare to placebo. Methods The present clinical trial was performed on 42 NAFLD patients who were randomly divided into two groups. The case group received a capsule (750 mg) containing hydro-alcoholic extract of Berberis integerrima extract every 12 h for 2 months, while the control (placebo) group received a capsule containing cellulose. Baseline characteristics, biochemical factors, antioxidant parameter, functional liver and renal test were evaluated before and after the treatment. Results Comparison rate of different parameters in case group before and after treatment demonstrated that BMI, cholesterol, triglyceride, LDL-C, fasting blood glucose, liver enzymes and renal parameters such as aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase were significantly decreased while HDL-C, glutathione peroxidase enzyme, and total antioxidant capacity were significantly elevated. The comparison of the mean parameters difference in two groups indicated that cholesterol, triglyceride, LDL-C, fasting blood glucose, liver enzymes and renal factors were significantly decreased, however HDL-C, glutathione peroxidase enzyme, and total antioxidant capacity were significantly increased in case group compared to control group. Conclusion The study findings revealed that the Berberis integerrima extract could reduce biochemical factors of blood, except HDL-C and increases total antioxidant capacity and glutathione peroxidase enzyme. Therefore, hydro-alcoholic extract of Berberis integerrima may be used as a great supplementary medicine in treating NAFLD.",2020,"The comparison of the mean parameters difference in two groups indicated that cholesterol, triglyceride, LDL-C, fasting blood glucose, liver enzymes and renal factors were significantly decreased, however HDL-C, glutathione peroxidase enzyme, and total antioxidant capacity were significantly increased in case group compared to control group. ","['patients with nonalcoholic fatty liver disease', '42 NAFLD patients who were randomly divided into two groups']","['capsule containing cellulose', 'hydroalcoholic Berberis integerrima fruits extract', 'capsule (750\xa0mg) containing hydro-alcoholic extract of Berberis integerrima extract every 12\xa0h for 2\xa0months, while the control (placebo']","['lipid profile, antioxidant parameters and liver and kidney function tests', 'Baseline characteristics, biochemical factors, antioxidant parameter, functional liver and renal test', 'BMI, cholesterol, triglyceride, LDL-C, fasting blood glucose, liver enzymes and renal parameters such as aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase', 'total antioxidant capacity and glutathione peroxidase enzyme', 'HDL-C, glutathione peroxidase enzyme, and total antioxidant capacity', 'cholesterol, triglyceride, LDL-C, fasting blood glucose, liver enzymes and renal factors']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0007648', 'cui_str': 'Cellulose'}, {'cui': 'C0949843', 'cui_str': 'Barberry'}, {'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C4517868', 'cui_str': '750'}, {'cui': 'C0687725', 'cui_str': 'Problem drinker'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0443764', 'cui_str': 'Liver enzyme'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0017822', 'cui_str': 'Glutathione peroxidase'}, {'cui': 'C0014442', 'cui_str': 'Enzyme'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}]",42.0,0.0394124,"The comparison of the mean parameters difference in two groups indicated that cholesterol, triglyceride, LDL-C, fasting blood glucose, liver enzymes and renal factors were significantly decreased, however HDL-C, glutathione peroxidase enzyme, and total antioxidant capacity were significantly increased in case group compared to control group. ","[{'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Afsharinasab', 'Affiliation': 'Department of Clinical Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Mohammad-Sadeghipour', 'Affiliation': 'Department of Clinical Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Reza Hajizadeh', 'Affiliation': 'Department of Clinical Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Khoshdel', 'Affiliation': 'Department of Clinical Biochemistry, Faculty of Medicine, and Pistachio Safety Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.'}, {'ForeName': 'Vahid', 'Initials': 'V', 'LastName': 'Mirzaiey', 'Affiliation': 'Department of Internal Medicine, School of Medicine, and Physiology-Pharmacology Research Center, Ali Ibn Abitaleb Educational and Tretment Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.'}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Mahmoodi', 'Affiliation': 'Department of Clinical Biochemistry, Afzalipoor Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.'}]",Saudi journal of biological sciences,['10.1016/j.sjbs.2020.04.037'] 2072,32742324,Three-year clinical observation of the outcomes of transepithelial and epithelial-off accelerated corneal collagen crosslinking treatment for different types of progressive keratoconus.,"In the present study, the clinical and long-term effects of accelerated transepithelial corneal collagen crosslinking (ATE-CXL) and accelerated epithelial-off corneal collagen crosslinking (A-CXL) for the treatment of different types of progressive keratoconus were compared. A total of 70 patients, including 96 eyes with advanced keratoconus, were enrolled in the study. ATE-CXL or A-CXL was performed on one or two eyes of each subject according to corneal thickness, keratoconus type and surgical approach. Patients were divided into the following four groups: Group A, ATE-CXL for central keratoconus; group B, A-CXL for central keratoconus; group C, ATE-CXL for peripheral keratoconus; and group D, A-CXL for peripheral keratoconus. Uncorrected distant visual acuity (UDVA), best-corrected distant (BD)VA and corneal astigmatism (CA) were evaluated in all patients by routine ophthalmology pre-operatively and 3 years post-operatively. Topographical features, including maximum corneal curvature (K max ), thinnest corneal thickness (TCT), anterior corneal elevation (ACE) and corneal endothelial cell density (ECD) were also compared across groups. The results suggested that pre- and post-operative UDVA, BDVA, K max , CA and ACE values differed in all four groups (P<0.05), whereas no differences were observed between pre- and post-operative TCT and ECD (P>0.05). Concordant results were obtained between groups A and C and groups B and D. ATE-CXL achieved better control of central keratoconus UDVA, K max and CA as compared with A-CXL. The difference between pre- and post-operative UDVA, K max and CA as compared with A-CXL was highly correlated with the change in intraocular pressure and treatment effectiveness. There was a statistically significant improvement in BDVA with ATE-CXL for treatment of central keratoconus compared with that after A-CXL treatment (P=0.032). There were statistically significant improvements in BDVA (P=0.047), CA (P=0.045) and ACE (P=0.012) with A-CXL treatment of peripheral keratoconus when compared with ATE-CXL treatment. Central, and to a lesser extent, peripheral, keratoconus may be effectively controlled by either approach, with disease stabilization 3 years later. ATE-CXL is suggested to be the most suitable treatment for keratoconus of <400 µm with a corneal thickness of >400 µm; however, A-CXL yields superior long-term outcomes.",2020,"Concordant results were obtained between groups A and C and groups B and D. ATE-CXL achieved better control of central keratoconus UDVA, K max and CA as compared with A-CXL.","['70 patients, including 96 eyes with advanced keratoconus, were enrolled in the study']","['accelerated transepithelial corneal collagen crosslinking (ATE-CXL) and accelerated epithelial-off corneal collagen crosslinking (A-CXL', 'ATE-CXL or A-CXL', 'ATE', 'CXL', 'ATE-CXL for central keratoconus; group B, A-CXL for central keratoconus; group C, ATE-CXL for peripheral keratoconus; and group D, A-CXL']","['CA', 'intraocular pressure and treatment effectiveness', 'Uncorrected distant visual acuity (UDVA), best-corrected distant (BD)VA and corneal astigmatism (CA', 'BDVA', 'pre- and post-operative UDVA, K max and CA', 'maximum corneal curvature (K max ), thinnest corneal thickness (TCT), anterior corneal elevation (ACE) and corneal endothelial cell density (ECD', 'pre- and post-operative UDVA, BDVA, K max , CA and ACE values', 'control of central keratoconus UDVA, K max and CA']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0022578', 'cui_str': 'Keratoconus'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0521110', 'cui_str': 'Accelerated'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0022578', 'cui_str': 'Keratoconus'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0441838', 'cui_str': 'Group D'}]","[{'cui': 'C0339682', 'cui_str': 'Regular astigmatism - corneal'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0443203', 'cui_str': 'Distant'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0205168', 'cui_str': 'Thin'}, {'cui': 'C0429493', 'cui_str': 'Corneal thickness'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0429518', 'cui_str': 'Endothelial cell density'}, {'cui': 'C0702240', 'cui_str': 'Elevation - value'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0022578', 'cui_str': 'Keratoconus'}]",70.0,0.0227661,"Concordant results were obtained between groups A and C and groups B and D. ATE-CXL achieved better control of central keratoconus UDVA, K max and CA as compared with A-CXL.","[{'ForeName': 'Jin-Rong', 'Initials': 'JR', 'LastName': 'Huang', 'Affiliation': 'Department of Ophthalmology, The Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.'}, {'ForeName': 'Hong-Fei', 'Initials': 'HF', 'LastName': 'Liao', 'Affiliation': 'Department of Ophthalmology, The Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.'}, {'ForeName': 'Chun-Hong', 'Initials': 'CH', 'LastName': 'Wan', 'Affiliation': 'Department of Ophthalmology, The First Affiliated Hospital of Jiangxi Medical College, Shangrao, Jiangxi 334000, P.R. China.'}, {'ForeName': 'Li-Miao', 'Initials': 'LM', 'LastName': 'Gong', 'Affiliation': 'Department of Ophthalmology, The First Affiliated Hospital of Jiangxi Medical College, Shangrao, Jiangxi 334000, P.R. China.'}, {'ForeName': 'Liang-Fei', 'Initials': 'LF', 'LastName': 'He', 'Affiliation': 'Department of Ophthalmology, The First Affiliated Hospital of Jiangxi Medical College, Shangrao, Jiangxi 334000, P.R. China.'}, {'ForeName': 'Hong-Ji', 'Initials': 'HJ', 'LastName': 'Jiang', 'Affiliation': 'Department of Ophthalmology, The First Affiliated Hospital of Jiangxi Medical College, Shangrao, Jiangxi 334000, P.R. China.'}, {'ForeName': 'Biao', 'Initials': 'B', 'LastName': 'Li', 'Affiliation': 'Department of Ophthalmology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Shao', 'Affiliation': 'Department of Ophthalmology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.'}]",Experimental and therapeutic medicine,['10.3892/etm.2020.8741'] 2073,32742338,Ameliorative effects of ceftriaxone sodium combined with dexamethasone on infantile purulent meningitis and associated effects on brain-derived neurotrophic factor levels.,"The aim of the present study was to evaluate the role of ceftriaxone sodium combined with dexamethasone on the treatment of infant purulent meningitis (PM) and to measure brain-derived neurotrophic factor (BDNF) levels in children with PM. Of the 177 patients enrolled into the present study, 92 patients received ceftriaxone sodium+dexamethasone (combination group) and 85 patients received ceftriaxone sodium alone (monotherapy group). The time taken for the body temperature, peripheral blood (PB) and cerebrospinal fluid (CSF) white blood cell (WBC) counts to recover back to normal levels were compared between the two groups. In addition, changes in the CSF WBC counts, CSF protein and sugar concentrations, BDNF levels, effective treatment rates and incidence of adverse reactions three days before treatment (T1), after one week of treatment (T2) and after two weeks of treatment (T3) were compared between the two groups. In the combination group, the recovery time of body temperature, WBC counts in both PB and CSF were significantly lower compared with those in the monotherapy group. The combination group also exhibited lower CSF protein concentrations and higher CSF sugar concentrations at T2 and T3 compared with those in the monotherapy group (P<0.05). The effective treatment rate of the combination group was significantly higher compared with that of the monotherapy group (P=0.006). CSF protein at T1, T2 T3, and CSF sugar concentrations and BDNF levels at T1 were significantly lower in the combination group than in the monotherapy group (P<0.05) while the CSF sugar concentrations at T2, T3 were higher in the combination group than in the monotherapy group (P<0.05). Taken together, these observations suggest that ceftriaxone combined with dexamethasone was superior compared with that of ceftriaxone alone for the treatment of infantile PM, and that this combination therapy may improve the effective treatment rate and accelerate patient rehabilitation.",2020,"In the combination group, the recovery time of body temperature, WBC counts in both PB and CSF were significantly lower compared with those in the monotherapy group.","['children with PM', 'infant purulent meningitis (PM', '177 patients enrolled into the present study, 92 patients received']","['ceftriaxone sodium+dexamethasone (combination group', 'dexamethasone', 'ceftriaxone sodium combined with dexamethasone', 'ceftriaxone sodium alone (monotherapy', 'ceftriaxone']","['CSF protein concentrations and higher CSF sugar concentrations', 'recovery time of body temperature, WBC counts in both PB and CSF', 'effective treatment rate and accelerate patient rehabilitation', 'CSF WBC counts, CSF protein and sugar concentrations, BDNF levels, effective treatment rates and incidence of adverse reactions', 'CSF protein at T1, T2 T3, and CSF sugar concentrations and BDNF levels', 'brain-derived neurotrophic factor (BDNF) levels', 'brain-derived neurotrophic factor levels', 'CSF sugar concentrations', 'infantile purulent meningitis', 'time taken for the body temperature, peripheral blood (PB) and cerebrospinal fluid (CSF) white blood cell (WBC) counts', 'effective treatment rate']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439665', 'cui_str': 'Purulent'}, {'cui': 'C0025289', 'cui_str': 'Meningitis'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0007561', 'cui_str': 'Ceftriaxone'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0700527', 'cui_str': 'Ceftriaxone sodium'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0007810', 'cui_str': 'Proteins, Cerebrospinal Fluid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0521110', 'cui_str': 'Accelerated'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0855357', 'cui_str': 'CSF white blood cell count'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0231330', 'cui_str': 'Infancy'}, {'cui': 'C0439665', 'cui_str': 'Purulent'}, {'cui': 'C0025289', 'cui_str': 'Meningitis'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0439157', 'cui_str': 'counts'}]",177.0,0.0192445,"In the combination group, the recovery time of body temperature, WBC counts in both PB and CSF were significantly lower compared with those in the monotherapy group.","[{'ForeName': 'Yiwen', 'Initials': 'Y', 'LastName': 'Zeng', 'Affiliation': 'Department of Pediatrics, Yongchuan Hospital of Chongqing Medical University, Yongchuan, Chongqing 402160, P.R. China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Department of Pediatrics, Yongchuan Hospital of Chongqing Medical University, Yongchuan, Chongqing 402160, P.R. China.'}]",Experimental and therapeutic medicine,['10.3892/etm.2020.8769'] 2074,32742354,Ultrasound-guided transversus abdominis plane block using ropivacaine and dexmedetomidine in patients undergoing caesarian sections to relieve post-operative analgesia: A randomized controlled clinical trial.,"Dexmedetomidine, which is a highly selective α2 adrenoreceptor agonist, enhances the analgesic efficacy and prolongs the analgesic duration when administered in combination with local anesthetics. The current study aimed to evaluate the effects of dexmedetomidine combined with ropivacaine in ultrasound-guided transversus abdominis plane (TAP) block on post-operative analgesia following cesarean section (CS). A total of 70 patients scheduled for CS were divided randomly into 2 groups: The ropivacaine (R) group, in which patients were administered bilateral 20 ml 0.3% ropivacaine and 2 ml 0.9% normal saline, and the dexmedetomidine (RD) group, in which patients were administered bilateral 20 ml 0.3% ropivacaine and 2 ml dexmedetomidine (0.5 µg/kg). The primary outcome was pain-free duration, and secondary outcomes included heart rate (HR) and mean blood pressure (MBP) measurements, visual analogue scale (VAS) pain scores, number of patients who required rescue analgesic, time to first request for analgesia and patient satisfaction. There was no significant difference in HR and MBP between the two groups at 1 h post-surgery (P>0.05). However, VAS pain scores decreased at 6 and 8 h post-surgery [2 (1-2) vs. 0 (0-0.25) and 2 (2-3) vs. 0 (0-1), respectively; P<0.05], pain-free duration was prolonged (5.91±1.08 vs. 9.62±1.46 h; P<0.05), the number of patients who required rescue analgesic was reduced (19 vs. 9; P<0.05), the time to first request for analgesia was prolonged (7.10±1.21 vs. 11.60±2.11 h; P<0.05) and patient satisfaction was improved [3.5 (3-4) vs. 4 (4-5); P<0.05] in the RD group compared with the R group. Furthermore, no bradycardia or hypotension was observed. In conclusion, the results of the present study demonstrated that adding 0.5 µg/kg dexmedetomidine to 0.3% ropivacaine used in TAP block in patients undergoing CS prolonged pain-free duration, decreased VAS pain scores, reduced the number of patients who required rescue analgesic, prolonged the time to first request for analgesia and improved the patient satisfaction without serious side effects.",2020,There was no significant difference in HR and MBP between the two groups at 1 h post-surgery (P>0.05).,"['cesarean section (CS', '70 patients scheduled for CS', 'patients undergoing caesarian sections to relieve post-operative analgesia']","['Ultrasound-guided transversus abdominis plane block using ropivacaine and dexmedetomidine', 'bilateral 20 ml 0.3% ropivacaine and 2 ml 0.9% normal saline, and the dexmedetomidine (RD', 'Dexmedetomidine', 'ropivacaine', 'ultrasound-guided transversus abdominis plane (TAP) block', 'bilateral 20 ml 0.3% ropivacaine and 2 ml dexmedetomidine', 'dexmedetomidine', 'ropivacaine (R']","['pain-free duration, and secondary outcomes included heart rate (HR) and mean blood pressure (MBP) measurements, visual analogue scale (VAS) pain scores, number of patients who required rescue analgesic, time to first request for analgesia and patient satisfaction', 'number of patients who required rescue analgesic', 'patient satisfaction', 'analgesic efficacy', 'pain-free duration', 'bradycardia or hypotension', 'pain-free duration, decreased VAS pain scores', 'time to first request for analgesia', 'VAS pain scores', 'HR and MBP']","[{'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332303', 'cui_str': 'Relieved by'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C4068885', 'cui_str': '0.3'}, {'cui': 'C4068881', 'cui_str': '0.9'}, {'cui': 'C0439166', 'cui_str': '% normal'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C0908489', 'cui_str': 'Pain-Free'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0686900', 'cui_str': 'Request for'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C2732809', 'cui_str': 'Visual analog scale pain score'}]",70.0,0.284536,There was no significant difference in HR and MBP between the two groups at 1 h post-surgery (P>0.05).,"[{'ForeName': 'Haitao', 'Initials': 'H', 'LastName': 'Qian', 'Affiliation': ""Department of Anesthesiology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222000, P.R. China.""}, {'ForeName': 'Qingwei', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.'}, {'ForeName': 'Pin', 'Initials': 'P', 'LastName': 'Zhu', 'Affiliation': ""Department of Anesthesiology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222000, P.R. China.""}, {'ForeName': 'Xiaobao', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222000, P.R. China.""}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Tian', 'Affiliation': ""Department of Anesthesiology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222000, P.R. China.""}, {'ForeName': 'Jiying', 'Initials': 'J', 'LastName': 'Feng', 'Affiliation': ""Department of Anesthesiology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222000, P.R. China.""}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': ""Department of Anesthesiology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222000, P.R. China.""}, {'ForeName': 'Zhibin', 'Initials': 'Z', 'LastName': 'Zhao', 'Affiliation': ""Department of Anesthesiology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222000, P.R. China.""}, {'ForeName': 'Hengfei', 'Initials': 'H', 'LastName': 'Luan', 'Affiliation': ""Department of Anesthesiology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222000, P.R. China.""}]",Experimental and therapeutic medicine,['10.3892/etm.2020.8781'] 2075,32742377,Use of the modified Glasgow Coma Scale score to guide sequential invasive-noninvasive mechanical ventilation weaning in patients with AECOPD and respiratory failure.,"Sequential invasive-noninvasive ventilation (NIV) improves the outcomes of patients with respiratory failure caused by acute exacerbation of chronic obstructive pulmonary disease (AECOPD); however, there is no clear consensus on the optimal timing of the switch to sequential invasive-NIV in these patients. In the present study, a potential role for the modified Glasgow Coma Scale (GCS) score to guide sequential weaning was investigated. Patients with AECOPD and respiratory failure were prospectively recruited from three study centers (Wenling Hospital Affiliated to Wenzhou Medical University, the First Affiliated Hospital of Wenzhou Medical University and Changsha Central Hospital) between January 1st 2016 and December 31st 2018. Patients were randomly assigned to group A and B, with the switching point for sequential weaning strategy in the two groups being a modified GCS score ≥13 and 10 points, respectively. Each group included 240 patients. Baseline demographic characteristics were comparable in the two groups. The duration of invasive mechanical ventilation (IMV) in group A was significantly shorter than that in group B. However, there were no significant between-group differences with respect to the incidence of re-intubation, ventilator-associated pneumonia, in-hospital mortality or the length of hospital stay. Use of a modified GCS score ≥13 as the switching point for sequential invasive-NIV may help decrease the duration of IMV in patients with AECOPD and respiratory failure.",2020,The duration of invasive mechanical ventilation (IMV) in group A was significantly shorter than that in group B.,"['patients with AECOPD and respiratory failure', '240 patients', 'Patients with AECOPD and respiratory failure were prospectively recruited from three study centers (Wenling Hospital Affiliated to Wenzhou Medical University, the First Affiliated Hospital of Wenzhou Medical University and Changsha Central Hospital) between January 1st 2016 and December 31st 2018', 'patients with respiratory failure caused by acute exacerbation of chronic obstructive pulmonary disease (AECOPD']","['Sequential invasive-noninvasive ventilation (NIV', 'sequential invasive-noninvasive mechanical ventilation weaning']","['incidence of re-intubation, ventilator-associated pneumonia, in-hospital mortality or the length of hospital stay', 'Baseline demographic characteristics', 'duration of invasive mechanical ventilation (IMV', 'duration of IMV', 'modified Glasgow Coma Scale score', 'modified Glasgow Coma Scale (GCS) score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0340044', 'cui_str': 'Acute exacerbation of chronic obstructive airways disease'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}, {'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0205435', 'cui_str': 'First'}, {'cui': 'C0015127', 'cui_str': 'etiology'}]","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}, {'cui': 'C1868982', 'cui_str': 'Noninvasive mechanical ventilation'}, {'cui': 'C0043084', 'cui_str': 'Weaning'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0087153', 'cui_str': 'Ventilator'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C1868981', 'cui_str': 'Invasive mechanical ventilation'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0017594', 'cui_str': 'Glasgow coma scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0256637,The duration of invasive mechanical ventilation (IMV) in group A was significantly shorter than that in group B.,"[{'ForeName': 'Jin-Bo', 'Initials': 'JB', 'LastName': 'Zhang', 'Affiliation': ""Emergency Intensive Care Unit, Wenling Hospital Affiliated to Wenzhou Medical University, The First People's Hospital of Wenling, Wenling, Zhejiang 317500, P.R. China.""}, {'ForeName': 'Jin-Qiang', 'Initials': 'JQ', 'LastName': 'Zhu', 'Affiliation': ""Emergency Intensive Care Unit, Wenling Hospital Affiliated to Wenzhou Medical University, The First People's Hospital of Wenling, Wenling, Zhejiang 317500, P.R. China.""}, {'ForeName': 'Lie-Xiang', 'Initials': 'LX', 'LastName': 'Cao', 'Affiliation': ""Emergency Intensive Care Unit, Wenling Hospital Affiliated to Wenzhou Medical University, The First People's Hospital of Wenling, Wenling, Zhejiang 317500, P.R. China.""}, {'ForeName': 'Xiao-Hong', 'Initials': 'XH', 'LastName': 'Jin', 'Affiliation': ""Emergency Intensive Care Unit, Wenling Hospital Affiliated to Wenzhou Medical University, The First People's Hospital of Wenling, Wenling, Zhejiang 317500, P.R. China.""}, {'ForeName': 'Li-Li', 'Initials': 'LL', 'LastName': 'Chen', 'Affiliation': ""Emergency Intensive Care Unit, Wenling Hospital Affiliated to Wenzhou Medical University, The First People's Hospital of Wenling, Wenling, Zhejiang 317500, P.R. China.""}, {'ForeName': 'Yu-Kang', 'Initials': 'YK', 'LastName': 'Song', 'Affiliation': ""Emergency Intensive Care Unit, Wenling Hospital Affiliated to Wenzhou Medical University, The First People's Hospital of Wenling, Wenling, Zhejiang 317500, P.R. China.""}, {'ForeName': 'Shi-Fang', 'Initials': 'SF', 'LastName': 'Zhou', 'Affiliation': 'Department of Emergency Care, Changsha Central Hospital, Changsha, Hunan 410004, P.R. China.'}, {'ForeName': 'Ji-Hong', 'Initials': 'JH', 'LastName': 'Ma', 'Affiliation': 'Intensive Care Unit, First Affiliated Hospital of Wenzhou Medical University, Wenling, Zhejiang 325000, P.R. China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Fu', 'Affiliation': ""Emergency Intensive Care Unit, Wenling Hospital Affiliated to Wenzhou Medical University, The First People's Hospital of Wenling, Wenling, Zhejiang 317500, P.R. China.""}, {'ForeName': 'Jin-Zhong', 'Initials': 'JZ', 'LastName': 'Xu', 'Affiliation': ""Emergency Intensive Care Unit, Wenling Hospital Affiliated to Wenzhou Medical University, The First People's Hospital of Wenling, Wenling, Zhejiang 317500, P.R. China.""}, {'ForeName': 'Mei-Ping', 'Initials': 'MP', 'LastName': 'Dong', 'Affiliation': ""Emergency Intensive Care Unit, Wenling Hospital Affiliated to Wenzhou Medical University, The First People's Hospital of Wenling, Wenling, Zhejiang 317500, P.R. China.""}, {'ForeName': 'Lai-Chao', 'Initials': 'LC', 'LastName': 'Yan', 'Affiliation': ""Emergency Intensive Care Unit, Wenling Hospital Affiliated to Wenzhou Medical University, The First People's Hospital of Wenling, Wenling, Zhejiang 317500, P.R. China.""}, {'ForeName': 'Xian-Dan', 'Initials': 'XD', 'LastName': 'Wu', 'Affiliation': ""Emergency Intensive Care Unit, Wenling Hospital Affiliated to Wenzhou Medical University, The First People's Hospital of Wenling, Wenling, Zhejiang 317500, P.R. China.""}, {'ForeName': 'Hui-Ping', 'Initials': 'HP', 'LastName': 'Wang', 'Affiliation': ""Emergency Intensive Care Unit, Wenling Hospital Affiliated to Wenzhou Medical University, The First People's Hospital of Wenling, Wenling, Zhejiang 317500, P.R. China.""}, {'ForeName': 'Jun-Yang', 'Initials': 'JY', 'LastName': 'Zhou', 'Affiliation': ""Emergency Intensive Care Unit, Wenling Hospital Affiliated to Wenzhou Medical University, The First People's Hospital of Wenling, Wenling, Zhejiang 317500, P.R. China.""}, {'ForeName': 'Yan-Qiu', 'Initials': 'YQ', 'LastName': 'Wang', 'Affiliation': ""Emergency Intensive Care Unit, Wenling Hospital Affiliated to Wenzhou Medical University, The First People's Hospital of Wenling, Wenling, Zhejiang 317500, P.R. China.""}]",Experimental and therapeutic medicine,['10.3892/etm.2020.8884'] 2076,32740449,"Factors Associated with the Recurrence, Persistence and Clearance of Asymptomatic Bacterial Vaginosis among Young African American Women: A Repeated Measures Latent Class Analysis.","BACKGROUND While risk factors of recurrent and persistent bacterial vaginosis (BV) have been explored in the literature, the longitudinal incidence patterns of BV remain elusive. METHODS We conducted a secondary analysis of longitudinal data from a randomized clinical trial of metronidazole treatment for asymptomatic BV. Repeated Measures Latent Class Analysis (RMLCA) was used to identify distinct longitudinal patterns of incident BV cases. Multinomial regression analysis was used to determine the predictors of class membership. The multivariable model included age, last BV treatment, douching frequency, birth control, sexual risk behavior and assignment to treatment arm. RESULTS A total of 858 African American women, asymptomatic for BV were included in the analysis. Three emergent patterns of BV over 12-months were identified by RMLCA: persistent (55.9%), recurrent (30.5%) and clearance (13.5%). Participants who had douched at least once had significantly lower odds to be in the recurrent class versus the clearance class (adjusted Odds Ratio [adjOR]: 0.55; 95% Confidence Interval [CI]: 0.18-0.63). Women who had sex with women (WSW) had significantly lower odds of belonging to the persistent class versus the clearance class (adjOR: 0.38; 95% CI: 0.22-0.68) and the recurrent class (adjOR: 0.43; 95% CI: 0.23-0.81). Those who were assigned to the treatment arm had significantly increased odds of being in the recurrent class versus the clearance class (adjOR: 1.92; 95% CI: 1.22-3.03). Women >21 years were significantly more likely to be in the recurrent class (adjOR: 1.88; 95% CI: 1.17-3.00) than in the clearance class. CONCLUSION Assessment of BV cases revealed distinct patterns of recurrence and persistence of BV which were significantly associated with douching, being in the treatment arm, and being a woman who had sex with women.",2020,Participants who had douched at least once had significantly lower odds to be in the recurrent class versus the clearance class (adjusted Odds Ratio [adjOR]: 0.55; 95% Confidence Interval [CI]: 0.18-0.63).,"['asymptomatic BV', 'Young African American Women', '858 African American women, asymptomatic for BV', 'Women who had sex with women (WSW', 'woman who had sex with women']",['metronidazole'],"['recurrence and persistence of BV', 'Recurrence, Persistence and Clearance of Asymptomatic Bacterial Vaginosis']","[{'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0085166', 'cui_str': 'Bacterial vaginosis'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1533642', 'cui_str': 'Women Who Have Sex With Women'}]","[{'cui': 'C0025872', 'cui_str': 'Metronidazole'}]","[{'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0546816', 'cui_str': 'Persistence'}, {'cui': 'C0085166', 'cui_str': 'Bacterial vaginosis'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}]",858.0,0.0658257,Participants who had douched at least once had significantly lower odds to be in the recurrent class versus the clearance class (adjusted Odds Ratio [adjOR]: 0.55; 95% Confidence Interval [CI]: 0.18-0.63).,"[{'ForeName': 'Makella S', 'Initials': 'MS', 'LastName': 'Coudray', 'Affiliation': 'Department of Epidemiology, Robert Stempel College of Public Health and Social Work, Florida International University (FIU), Miami, FL.'}, {'ForeName': 'Diana M', 'Initials': 'DM', 'LastName': 'Sheehan', 'Affiliation': 'Department of Epidemiology, Robert Stempel College of Public Health and Social Work, Florida International University (FIU), Miami, FL.'}, {'ForeName': 'Tan', 'Initials': 'T', 'LastName': 'Li', 'Affiliation': 'Department of Biostatistics, Robert Stempel College of Public Health and Social Work, FIU, Miami, FL.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Cook', 'Affiliation': 'Department of Epidemiology, College of Public Health and Health Professions, University of Florida (UF), Gainesville, FL.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Schwebke', 'Affiliation': 'Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Purnima', 'Initials': 'P', 'LastName': 'Madhivanan', 'Affiliation': 'Department of Health Promotion Sciences, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ.'}]",Sexually transmitted diseases,['10.1097/OLQ.0000000000001256'] 2077,32740469,Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation.,"BACKGROUND Results from trials and nonexperimental studies are often directly compared, with little attention paid to differences between study populations. When target and trial population data are available, accounting for these differences through transporting trial results to target populations of interest provides useful perspective. We aimed to compare two-year risk differences (RDs) for ischemic stroke, mortality, and gastrointestinal bleeding in older adults with atrial fibrillation initiating dabigatran and warfarin when using trial transport methods versus nonexperimental methods. METHODS We identified Medicare beneficiaries who initiated warfarin or dabigatran from a 20% nationwide sample. To transport treatment effects observed in the randomized evaluation of long-term anticoagulation trial, we applied inverse odds weights to standardize estimates to two Medicare target populations of interest, initiators of: (1) dabigatran and (2) warfarin. Separately, we conducted a nonexperimental study in the Medicare populations using standardized morbidity ratio weighting to control measured confounding. RESULTS Comparing dabigatran to warfarin, estimated two-year RDs for ischemic stroke were similar with trial transport and nonexperimental methods. However, two-year mortality RDs were closer to the null when using trial transport versus nonexperimental methods for the dabigatran target population (transported RD: -0.57%; nonexperimental RD: -1.9%). Estimated gastrointestinal bleeding RDs from trial transport (dabigatran initiator RD: 1.8%; warfarin initiator RD: 1.9%) appeared more harmful than nonexperimental results (dabigatran initiator RD: 0.14%; warfarin initiator RD: 0.57%). CONCLUSIONS Differences in study populations can and should be considered quantitatively to ensure results are relevant to populations of interest, particularly when comparing trial with nonexperimental findings. See video abstract: http://links.lww.com/EDE/B703.",2020,"Estimated gastrointestinal bleeding RDs from trial transport (dabigatran initiator RD: 1.8%; warfarin initiator RD: 1.9%) appeared more harmful than nonexperimental results (dabigatran initiator RD: 0.14%; warfarin initiator RD: 0.57%). ","['Reweighting Oranges to Apples', 'Medicare beneficiaries who initiated warfarin or dabigatran from a 20% nationwide sample', 'older adults with atrial fibrillation initiating']","['dabigatran and warfarin', 'dabigatran and (2) warfarin']","['ischemic stroke, mortality, and gastrointestinal bleeding', 'Estimated gastrointestinal bleeding RDs', 'mortality RDs']","[{'cui': 'C0440277', 'cui_str': 'Orange - fruit'}, {'cui': 'C0003625', 'cui_str': 'Malus'}, {'cui': 'C0018717', 'cui_str': 'Health Insurance for Aged and Disabled, Title 18'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C2348066', 'cui_str': 'dabigatran'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}]","[{'cui': 'C2348066', 'cui_str': 'dabigatran'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}]","[{'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0017181', 'cui_str': 'Gastrointestinal hemorrhage'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",,0.123728,"Estimated gastrointestinal bleeding RDs from trial transport (dabigatran initiator RD: 1.8%; warfarin initiator RD: 1.9%) appeared more harmful than nonexperimental results (dabigatran initiator RD: 0.14%; warfarin initiator RD: 0.57%). ","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Webster-Clark', 'Affiliation': 'From the Department of Epidemiology, University of North Carolina, Chapel Hill, NC.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Lund', 'Affiliation': 'From the Department of Epidemiology, University of North Carolina, Chapel Hill, NC.'}, {'ForeName': 'Til', 'Initials': 'T', 'LastName': 'Stürmer', 'Affiliation': 'From the Department of Epidemiology, University of North Carolina, Chapel Hill, NC.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Poole', 'Affiliation': 'From the Department of Epidemiology, University of North Carolina, Chapel Hill, NC.'}, {'ForeName': 'Ross J', 'Initials': 'RJ', 'LastName': 'Simpson', 'Affiliation': 'Department of Medicine, University of North Carolina, Chapel Hill, NC.'}, {'ForeName': 'Jessie K', 'Initials': 'JK', 'LastName': 'Edwards', 'Affiliation': 'From the Department of Epidemiology, University of North Carolina, Chapel Hill, NC.'}]","Epidemiology (Cambridge, Mass.)",['10.1097/EDE.0000000000001230'] 2078,32740476,Efficacy of Intragastric Balloon Placement and Botulinum Toxin Injection in Bariatric Endoscopy.,"BACKGROUND To evaluate the results obtained from the combination of intragastric botulinum toxin A (IGBTA), intragastric balloon (IGB), and IGBTA(+)IGB in the treatment of obesity. MATERIALS AND METHODS Three separate treatment groups were set up. IGBTA, IGB, and IGBTA(+)IGB were administered to Group 1, 2, and 3, respectively. The body mass indexes (BMI) of patients were measured before and 6 months after the treatment. The intragroup and intergroup treatment results have been evaluated. P<0.05 was considered significant. RESULTS The mean BMI decreased by 1.6 kg/m in 40 patients who received IGBTA in group 1 (P<0.001), 3.95 kg/m in 42 patients who received IGB in group 2 (P<0.001), and 4.9 kg/m in 39 patients who received IGBTA and IGB in group 3 (P<0.001) after 6 months of treatment. The intolerance because of the application was the highest in group 3, followed by group 2. CONCLUSION The treatment was most successful in group 3 followed by group 2 and group 1, respectively. The authors recommend the group 3 treatment, provided that nausea, vomiting, and flatulence have a high index of probability in such a treatment. However, when deciding between group 1 and group 2 treatments, the authors recommend opting for group 2 treatment that shows to be more efficient.",2020,"The treatment was most successful in group 3 followed by group 2 and group 1, respectively.",['Bariatric Endoscopy'],"['intragastric botulinum toxin A (IGBTA), intragastric balloon (IGB), and IGBTA(+)IGB', 'IGBTA and IGB', 'IGB', 'Intragastric Balloon Placement and Botulinum Toxin Injection']","['mean BMI', 'nausea, vomiting, and flatulence']","[{'cui': 'C1450026', 'cui_str': 'Bariatrics'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}]","[{'cui': 'C0442113', 'cui_str': 'Intragastric'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}, {'cui': 'C0006055', 'cui_str': 'botulinum toxin'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C1321035', 'cui_str': 'Injection of botulinum toxin'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}]",42.0,0.0453207,"The treatment was most successful in group 3 followed by group 2 and group 1, respectively.","[{'ForeName': 'Murat', 'Initials': 'M', 'LastName': 'Kanlioz', 'Affiliation': 'Private Beylikduzu Kolan Hospital, Clinic of General Surgery.'}, {'ForeName': 'Uğur', 'Initials': 'U', 'LastName': 'Ekici', 'Affiliation': 'Istanbul Gelişim University, Health Science Colleges, Istanbul.'}, {'ForeName': 'Faik', 'Initials': 'F', 'LastName': 'Tatli', 'Affiliation': 'Department of General Surgery, Faculty of Medicine, Harran University, Şanliurfa.'}, {'ForeName': 'Turgay', 'Initials': 'T', 'LastName': 'Karatas', 'Affiliation': 'Department of Anatomy, Faculty of Medicine, İnonu University, Malatya, Turkey.'}]","Surgical laparoscopy, endoscopy & percutaneous techniques",['10.1097/SLE.0000000000000829'] 2079,32740481,"17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.","OBJECTIVE To examine responder rates and vasomotor symptom-free days with oral 17β-estradiol/progesterone (E2/P4; TX-001HR) versus placebo in the REPLENISH trial. METHODS REPLENISH (NCT01942668) was a phase 3, randomized, double-blind, placebo-controlled, multicenter trial, evaluating single, oral, softgel E2/P4 capsules in postmenopausal women (40-65 y) with a uterus and vasomotor symptoms (VMS). Women with moderate to severe hot flushes (≥7/d or ≥50/wk) were randomized (VMS substudy) to daily E2/P4 (mg/mg) of 1/100, 0.5/100, 0.5/50, 0.25/50, or placebo. Proportions of women with ≥50% or ≥75% reductions in moderate to severe VMS (responders), and those with no severe VMS as well as the weekly number of days without moderate to severe VMS with TX-001HR versus placebo were determined. Mixed model repeated measures was used to analyze data and Fisher exact test was employed to compare E2/P4 versus placebo. RESULTS Seven hundred twenty-six women were eligible for the VMS efficacy analysis (E2/P4 1/100 [n = 141], 0.5/100 [n = 149], 0.5/50 [n = 147], 0.25/50 [n = 154], or placebo [n = 135]). Significantly more women treated with all E2/P4 doses versus placebo were ≥50% responders and ≥75% responders at weeks 4 and 12 (P < 0.05) and also had significantly more days per week without moderate to severe VMS at week 12 (1.9-3.0 d for E2/P4 versus 1.3 d for placebo; P < 0.05). The proportion of women without severe hot flushes at week 12 was 43% to 56% for all E2/P4 doses versus 26% for placebo (P ≤ 0.01). CONCLUSIONS Women treated with E2/P4 had a greater response to treatment with more VMS-free days than with placebo. The E2/P4 1/100 dose (Bijuva [E2 and P4] capsules) represents an oral treatment option for postmenopausal women with moderate to severe VMS and a uterus.",2020,(P < 0.05) and also had significantly more days per week without moderate to severe VMS at week 12 (1.9-3.0 d for E2/P4 versus 1.3 d for placebo; P < 0.05).,"['n\u200a=\u200a135', 'postmenopausal women (40-65 y) with a uterus and vasomotor symptoms (VMS', 'postmenopausal women with moderate to severe VMS and a uterus', 'Women with moderate to severe hot flushes (≥7/d or ≥50/wk', 'Seven hundred twenty-six women were eligible for the VMS efficacy analysis (E2/P4\u200a1/100 [n\u200a=\u200a141], 0.5/100']","['oral 17β-estradiol/progesterone (E2/P4; TX-001HR', 'TX-001HR versus placebo', '17β-estradiol/progesterone', 'placebo']","['severe VMS', 'moderate to severe VMS', 'proportion of women without severe hot flushes']","[{'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0600142', 'cui_str': 'Menopausal flushing'}, {'cui': 'C4517862', 'cui_str': '700'}, {'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C4517572', 'cui_str': '141'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0033308', 'cui_str': 'Progesterone'}, {'cui': 'C4279222', 'cui_str': 'TX-001HR'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0600142', 'cui_str': 'Menopausal flushing'}]",726.0,0.691782,(P < 0.05) and also had significantly more days per week without moderate to severe VMS at week 12 (1.9-3.0 d for E2/P4 versus 1.3 d for placebo; P < 0.05).,"[{'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Kaunitz', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, FL.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Bitner', 'Affiliation': 'Spectrum Health, Grand Rapids, MI.'}, {'ForeName': 'Ginger D', 'Initials': 'GD', 'LastName': 'Constantine', 'Affiliation': 'EndoRheum Consultants, LLC, Malvern, PA.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Bernick', 'Affiliation': 'TherapeuticsMD, Boca Raton, FL.'}, {'ForeName': 'Shelli', 'Initials': 'S', 'LastName': 'Graham', 'Affiliation': 'TherapeuticsMD, Boca Raton, FL.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Mirkin', 'Affiliation': 'TherapeuticsMD, Boca Raton, FL.'}]","Menopause (New York, N.Y.)",['10.1097/GME.0000000000001615'] 2080,32740891,A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease.,"BACKGROUND Because of their well-described immunosuppressive properties, allogeneic adult human mesenchymal stromal cells (MSC) derived from bone marrow have demonstrated safety and efficacy in steroid refractory acute graft versus host disease (SR aGVHD). Clinical trials have resulted in variable success and an optimal source of MSC has yet to be defined. Based on the importance of maternal-fetal interface immune tolerance, extraembryonic fetal tissues, such as the umbilical cord, may provide an superior tissue source of MSC to mediate immunomodulation in aGVHD. METHODS A two-dose cohort trial allogeneic Wharton's Jelly-derived mesenchymal stromal cells (WJMSC, referred to as MSCTC-0010, here) were tested in 10 patients with de novo high risk (HR) or SR aGVHD post allogeneic hematopoietic stem cell transplantation (allo-HCT). Following Good Manufacturing Practices isolation, expansion and cryostorage, WJMSC were thawed and administered via intravenous infusions on days 0 and 7 at one of two doses (low dose cohort, 2 × 10 6 /kg, n = 5; high dose cohort, 10 × 10 6 /kg, n = 5). To evaluate safety, patients were monitored for infusion related toxicity, Treatment Related Adverse Events (TRAE) til day 42, or ectopic tissue formation at day 90. Clinical responses were monitored at time points up to 180 days post infusion. Serum biomarkers ST2 and REG3α were acquired 1 day prior to first MSCTC-0010 infusion and on day 14. RESULTS Safety was indicated, e.g., no infusion-related toxicity, no development of TRAE, nor ectopic tissue formation in either low or high dose cohort was observed. Clinical response was suggested at day 28: the overall response rate (ORR) was 70%, 4 of 10 patients had a complete response (CR) and 3 had a partial response (PR). By study day 90, the addition of escalated immunosuppressive therapy was necessary in 2 of 9 surviving patients. Day 100 and 180 post infusion survival was 90% and 60%, respectively. Serum biomarker REG3α decreased, particularly in the high dose cohort, and with REG3α decrease correlated with clinical response. CONCLUSIONS Treatment of patients with de novo HR or SR aGVHD with low or high dose MSCTC-0010 was safe: the infusion was well-tolerated, and no TRAEs or ectopic tissue formation was observed. A clinical improvement was seen in about 70% patients, with 4 of 10 showing a complete response that may have been attributable to MSCTC-0010 infusions. These observations indicate safety of two different doses of MSCTC-0010, and suggest that the 10 × 10 6 cells/ kg dose be tested in an expanded randomized, controlled Phase 2 trial. Graphical abstract.",2020,"RESULTS Safety was indicated, e.g., no infusion-related toxicity, no development of TRAE, nor ectopic tissue formation in either low or high dose cohort was observed.",['10 patients with de novo high risk (HR) or SR aGVHD post allogeneic hematopoietic stem cell transplantation (allo-HCT'],"[""Wharton's Jelly-Derived Mesenchymal Stromal Cells"", ""allogeneic Wharton's Jelly-derived mesenchymal stromal cells (WJMSC"", 'MSCTC-0010']","['Serum biomarkers', 'Adverse Events (TRAE) til day 42, or ectopic tissue formation', 'overall response rate (ORR', 'Serum biomarker REG3α', 'partial response (PR', 'tolerated, and no TRAEs or ectopic tissue formation', 'no infusion-related toxicity, no development of TRAE, nor ectopic tissue formation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0856825', 'cui_str': 'Acute graft-versus-host disease'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}]","[{'cui': 'C0230987', 'cui_str': ""Structure of Wharton's jelly""}, {'cui': 'C3178844', 'cui_str': 'Mesenchymal Stromal Cells'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0079722', 'cui_str': 'Tumor-Infiltrating Lymphocytes'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0008519', 'cui_str': 'Ectopic tissue'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}]",10.0,0.118327,"RESULTS Safety was indicated, e.g., no infusion-related toxicity, no development of TRAE, nor ectopic tissue formation in either low or high dose cohort was observed.","[{'ForeName': 'Rupal P', 'Initials': 'RP', 'LastName': 'Soder', 'Affiliation': 'Midwest Stem Cell Therapy Center, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Buddhadeb', 'Initials': 'B', 'LastName': 'Dawn', 'Affiliation': 'University of Nevada, Las Vegas School of Medicine, Las Vegas, NV, USA.'}, {'ForeName': 'Mark L', 'Initials': 'ML', 'LastName': 'Weiss', 'Affiliation': 'Midwest Institute of Comparative Stem Cell Biotechnology and Department of Anatomy and Physiology, Kansas State University, Manhattan, KS, USA.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Dunavin', 'Affiliation': 'University of California, San Francisco, CA, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Weir', 'Affiliation': 'Institute for Advancing Medical Innovation Medical Center, University of Kansas, Kansas City, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Mitchell', 'Affiliation': 'Midwest Stem Cell Therapy Center, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Meizhang', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Pathology & Laboratory Medicine, Univeristy of Kansas Medical Center, Kansas City, USA.'}, {'ForeName': 'Leyla', 'Initials': 'L', 'LastName': 'Shune', 'Affiliation': 'Blood and Marrow Transplant Program, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 210, Westwood, KS, 66205, USA.'}, {'ForeName': 'Anurag K', 'Initials': 'AK', 'LastName': 'Singh', 'Affiliation': 'Blood and Marrow Transplant Program, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 210, Westwood, KS, 66205, USA.'}, {'ForeName': 'Siddhartha', 'Initials': 'S', 'LastName': 'Ganguly', 'Affiliation': 'Blood and Marrow Transplant Program, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 210, Westwood, KS, 66205, USA.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Morrison', 'Affiliation': 'Blood and Marrow Transplant Program, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 210, Westwood, KS, 66205, USA.'}, {'ForeName': 'Haitham', 'Initials': 'H', 'LastName': 'Abdelhakim', 'Affiliation': 'Blood and Marrow Transplant Program, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 210, Westwood, KS, 66205, USA.'}, {'ForeName': 'Andrew K', 'Initials': 'AK', 'LastName': 'Godwin', 'Affiliation': 'Pathology & Laboratory Medicine, Univeristy of Kansas Medical Center, Kansas City, USA.'}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Abhyankar', 'Affiliation': 'Midwest Stem Cell Therapy Center, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'McGuirk', 'Affiliation': 'Blood and Marrow Transplant Program, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 210, Westwood, KS, 66205, USA. jmcguirk@kumc.edu.'}]",Stem cell reviews and reports,['10.1007/s12015-020-10015-8'] 2081,32740892,Impact of respiratory physical therapy on heart rate autonomic control in children with leukemia.,"INTRODUCTION Considering that heart rate (HR) autonomic control is impaired in cancer and subsequent respiratory effort may overload the heart, we aimed to evaluate the effect of a respiratory physical therapy session on HR autonomic regulation in children with leukemia so as to confirm its safety. METHODS We selected children with leukemia (n = 10) and healthy children (n = 11), which were submitted to a session of respiratory physical therapy. We used Spiron Kids (NCS, Brazil), Children's Voldyne (HUDSON RCI, USA), and Shaker (NCS, Brazil) as respiratory devices. The respiratory exercise protocols were founded on three standardized protocols. HR variability (HRV) was analyzed before, in the first minute and 5 to 10 min after intervention. RESULTS We recognized no change between rest and recovery from intervention in HRV (rMSSD-square root mean square of the differences between adjacent normal R-R intervals)-Control: p = 0.8111, Leukemia: p = 0.1197, among groups: p = 0.6574; SD1-standard deviation from instantaneous beat-to-beat variability-Control: p = 0.8111, Leukemia: p = 0.131, among groups: p = 0.6556; 0V-with no variation (3 equal symbols, for example (2,2,2)-Control: p = 0.3679, Leukemia: p = 0.3553, among groups: p = 0.7421); 2UV-with two variations to the contrary (the three symbols form a peak or a valley, for instance (3,5,3)-Control: p = 0.3679, Leukemia: p = 0.2359, among groups: p = 0.4007). HF-high frequency component, range 0.15 to 0.4 Hz-decreased 0 to 1 min after intervention in the leukemia group (p = 0.0303) and no change was observed in the control group between rest versus recovery from intervention (p = 0.9761). No significant change was reported in HF between groups (p = 0.8700). Two leukemia subjects treated with vincristine presented different HRV responses to the intervention group. CONCLUSION A respiratory physical therapy session did not significantly change autonomic control of HR in children with leukemia. Yet, clinicians should be mindful of subjects undergoing treatment with vincristine.",2020,Hz-decreased 0 to 1 min after intervention in the leukemia group (p = 0.0303) and no change was observed in the control group between rest versus recovery from intervention (p = 0.9761).,"['children with leukemia (n\u2009=\u200910) and healthy children (n\u2009=\u200911', 'children with leukemia']","['vincristine', 'respiratory physical therapy session', 'respiratory physical therapy']","['heart rate autonomic control', 'autonomic control of HR', 'HR autonomic regulation', 'HR variability (HRV', 'HRV responses']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0023418', 'cui_str': 'Leukemia'}, {'cui': 'C0686744', 'cui_str': 'Well child'}]","[{'cui': 'C0042679', 'cui_str': 'Vincristine'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0220905', 'cui_str': 'regulations'}]",2.0,0.0195659,Hz-decreased 0 to 1 min after intervention in the leukemia group (p = 0.0303) and no change was observed in the control group between rest versus recovery from intervention (p = 0.9761).,"[{'ForeName': 'Jociele M', 'Initials': 'JM', 'LastName': 'Kirizawa', 'Affiliation': 'Autonomic Nervous System Center, Sao Paulo State University, UNESP, Av. Hygino Muzzi Filho, 737. Mirante, 17.525-900-Marília, Presidente Prudente, SP, Brazil.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Garner', 'Affiliation': 'Autonomic Nervous System Center, Sao Paulo State University, UNESP, Av. Hygino Muzzi Filho, 737. Mirante, 17.525-900-Marília, Presidente Prudente, SP, Brazil.'}, {'ForeName': 'Vitor E', 'Initials': 'VE', 'LastName': 'Valenti', 'Affiliation': 'Autonomic Nervous System Center, Sao Paulo State University, UNESP, Av. Hygino Muzzi Filho, 737. Mirante, 17.525-900-Marília, Presidente Prudente, SP, Brazil. vitor.valenti@unesp.br.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-020-05629-0'] 2082,32740914,"Attainment, attendance, and school difficulties in UK primary schoolchildren with probable ADHD.","BACKGROUND Among children aged 6-16, there is a clear association between attention-deficit/hyperactivity disorder (ADHD) symptoms and academic attainment. We wanted to know whether this association was replicated in younger children. AIMS To explore the relationship between children aged 4-8 with probable ADHD and their academic attainment and school attendance. Secondly, the study aimed to explore their behaviour within school and their reported attitudes towards school. SAMPLE A total of 1,152 children who were taking part in the Supporting Teachers and Children in Schools (STARS) cluster randomized controlled trial. METHODS ADHD status was established by using the Strengths and Difficulties Questionnaire predictive algorithm to identify children with probable ADHD. Using baseline data, random-effects regression models on ADHD status were fitted to attainment, attendance, special educational needs (SEN) provision, and attitudes towards school and classroom behaviour; models that were also fitted to attainment were evaluated again at 9, 18, and 30 months after baseline. RESULTS Children with probable ADHD (n = 47) were more likely than controls (n = 1,105) to have below-expected attainment in literacy (odds ratio (OR) 16.7, 95% CI 6.93-to-40.1), numeracy (OR 11.3, 95% CI 5.34-to-24.1) and to be identified as having SEN (OR-55.2, 95%-CI 22.1-to-137). Their attendance was poorer with more unauthorized absences (rate ratio (RR)-1.91, 95%-CI-1.57-to-2.31). They had more teacher-reported behavioural problems (mean difference (MD) 5.0, 95%-CI 4.6-to-5.4) and less positive attitudes towards school (MD -1.1, 95% CI -0.56 to -1.85). Poorer attainment in literacy and numeracy persisted at all follow-ups. CONCLUSIONS Children aged as young as 4 whose behaviour indicates probable ADHD struggle to cope at school in terms of academic attainment, attendance, classroom behaviour, and attitude towards school when compared to other children. Early identification and intervention to help these children manage in school are needed.",2020,"They had more teacher-reported behavioural problems (mean difference (MD) 5.0, 95%-CI 4.6-to-5.4) and less positive attitudes towards school (MD -1.1, 95% CI -0.56 to -1.85).","['1,152 children who were taking part in the Supporting Teachers and Children in Schools (STARS) cluster randomized controlled trial', 'younger children', 'children aged 6-16', 'UK primary schoolchildren with probable ADHD', 'children aged 4-8 with probable ADHD and their academic attainment and school attendance', 'Children with probable ADHD ', 'children with probable ADHD']",[],"['attainment, attendance, special educational needs (SEN) provision, and attitudes towards school and classroom behaviour; models', 'unauthorized absences (rate ratio (RR)-1.91, 95%-CI-1.57-to-2.31', 'positive attitudes towards school', 'Attainment, attendance, and school difficulties', 'behavioural problems']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}]",[],"[{'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0237428', 'cui_str': 'Positive attitude'}, {'cui': 'C0580094', 'cui_str': 'School problem'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}]",1152.0,0.0856296,"They had more teacher-reported behavioural problems (mean difference (MD) 5.0, 95%-CI 4.6-to-5.4) and less positive attitudes towards school (MD -1.1, 95% CI -0.56 to -1.85).","[{'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'May', 'Affiliation': 'Exeter Medical School, University of Exeter, UK.'}, {'ForeName': 'Tamsin', 'Initials': 'T', 'LastName': 'Ford', 'Affiliation': 'Department of Psychiatry, Child and Adolescent Psychiatry, Cambridge, UK.'}, {'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'Janssens', 'Affiliation': 'Department of Public Health, University of Southern Denmark, Odense C, Denmark.'}, {'ForeName': 'Tamsin', 'Initials': 'T', 'LastName': 'Newlove-Delgado', 'Affiliation': 'Child Mental Health Research Group, Institute of Health Research, College of Medicine and Health, Exeter, UK.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Emma Russell', 'Affiliation': 'Centre for Academic Mental Health, Population Health Sciences, University of Bristol Medical School, UK.'}, {'ForeName': 'Javid', 'Initials': 'J', 'LastName': 'Salim', 'Affiliation': 'Exeter Medical School, University of Exeter, UK.'}, {'ForeName': 'Obioha C', 'Initials': 'OC', 'LastName': 'Ukoumunne', 'Affiliation': 'NIHR ARC South West Peninsula (PenARC), University of Exeter, UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Hayes', 'Affiliation': 'Child Mental Health Research Group, Institute of Health Research, College of Medicine and Health, Exeter, UK.'}]",The British journal of educational psychology,['10.1111/bjep.12375'] 2083,32740947,The mindful shield: The effects of mindfulness training on resilience and leadership in military leaders.,"OBJECTIVES The purpose of this study was to address military leader perceptions of their resilience, transformational leadership behaviors, and leadership effectiveness before and after experiencing Mindfulness-Based Attention Training (MBAT). METHODS Participants were formal and informal leaders in the Kansas Air National Guard. The study used a mixed-methods sequential exploratory design. Phase I involved analyzing pretest and posttest results obtained from a Jha Lab study for three self-report assessments in an intervention group (n = 36) vs a control group (n = 37). The qualitative data in phase II was obtained from individual interviews of participants (n = 12) following the Jha Lab study. RESULTS The phase I quantitative results confirmed the null hypotheses-no significant differences found-for all research questions. Phase II resulted in eight thematic codes, six of which were central to the experiences described by participants (Halting, Sensing, Being, Shielding, Considering, and Engaging) and two that were not (Obstructing, and Escaping). CONCLUSIONS The key finding was that the descriptions of mindful thoughts and behaviors were consistent across participants indicating that MBAT accurately presents mindfulness during the course and the training had positive effects on participant mindfulness, primarily in the areas of being present to self, shielding the self through reperceiving, and then consciously altering behavior based on the new perspective. Results should direct future resiliency course development, leadership course curricula, and aid understanding of how leaders mentally conceptualize stress, incorporate resilient behaviors and then apply that knowledge to their own leadership behaviors.",2020,The phase I quantitative results confirmed the null hypotheses-no significant differences found-for all research questions.,"['Participants were formal and informal leaders in the Kansas Air National Guard', 'military leaders']","['Mindfulness-Based Attention Training (MBAT', 'mindfulness training']",[],"[{'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0278253', 'cui_str': 'Guarded prognosis'}, {'cui': 'C0026126', 'cui_str': 'Military personnel'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0556509', 'cui_str': 'Attention training'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",[],,0.0136607,The phase I quantitative results confirmed the null hypotheses-no significant differences found-for all research questions.,"[{'ForeName': 'Kelly R M', 'Initials': 'KRM', 'LastName': 'Ihme', 'Affiliation': 'College of Doctoral Studies, University of the Rockies, Colorado Springs, Colorado.'}, {'ForeName': 'Peggy', 'Initials': 'P', 'LastName': 'Sundstrom', 'Affiliation': 'Program Chair, Organizational Development and Leadership, Ashford University College of Doctoral Studies, San Diego, California.'}]",Perspectives in psychiatric care,['10.1111/ppc.12594'] 2084,32741075,Efficacy and safety of intralesional steroid injection in the treatment of melasma.,"BACKGROUND The etiopathogenesis of melasma is not yet completely elucidated; however, certain inflammatory cytokines are involved in its pathogenesis as interleukin (IL) 1a, IL 1b, IL6, prostaglandin (PG) D2and PGE2. Corticosteroid suppressive effect on these cytokines may explain its therapeutic effect in the treatment of melasma. AIMS To assess the efficacy and safety of intralesional triamcinolone versus Kligman's formula in treatment of melasma. METHODS This study included 2 groups of female patients with melasma; group1 (treatment group) included 22 patients who were treated by intralesional injection of triamcinolone acetonide at a concentration of 4 mg/mL once monthly for four sessions as a maximum and group 2 (control group), included 22 patients who were treated by Kligman's formula once daily for 3 months. All patients were evaluated by dermoscope before treatment and at each follow-up visit to record any adverse effects of treatment. RESULTS The severity of melasma, assessed by MASI score, significantly decreased in both groups at the end of third month. There was no statistically significant difference in the therapeutic response between both groups. No side effects were reported with triamcinolone injection except for mild pain during injection, while Kligman's formula was associated with dermatitis, irritation, and burning sensation. CONCLUSIONS Triamcinolone injection at low concentration could be an effective treatment modality of melasma.",2020,"The severity of melasma, assessed by MASI score, significantly decreased in both groups at the end of third month.","['melasma', '2 groups of female patients with melasma; group1 (treatment group) included 22 patients who were treated by']","[""Kligman's formula"", 'triamcinolone', 'intralesional triamcinolone', ""Kligman's formula once daily for 3\xa0months"", 'intralesional steroid injection', 'Triamcinolone', 'intralesional injection of triamcinolone acetonide']","['dermatitis, irritation, and burning sensation', 'Efficacy and safety', 'efficacy and safety', 'therapeutic response', 'mild pain', 'severity of melasma, assessed by MASI score']","[{'cui': 'C0025218', 'cui_str': 'Chloasma'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0040864', 'cui_str': 'Triamcinolone'}, {'cui': 'C1512955', 'cui_str': 'Intralesional route'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1261311', 'cui_str': 'Injection of steroid'}, {'cui': 'C0021490', 'cui_str': 'Intralesional injection'}, {'cui': 'C0040866', 'cui_str': 'Triamcinolone acetonide'}]","[{'cui': 'C0011603', 'cui_str': 'Dermatitis'}, {'cui': 'C0441723', 'cui_str': 'Irritation'}, {'cui': 'C0085624', 'cui_str': 'Burning sensation'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0521982', 'cui_str': 'Response to treatment'}, {'cui': 'C0278138', 'cui_str': 'Mild pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0025218', 'cui_str': 'Chloasma'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",22.0,0.0686983,"The severity of melasma, assessed by MASI score, significantly decreased in both groups at the end of third month.","[{'ForeName': 'Amany Abd Elrahman', 'Initials': 'AAE', 'LastName': 'Nassar', 'Affiliation': 'Faculty of Medicine, Zagazig University, Zagazig, Egypt.'}, {'ForeName': 'Al-Shimaa M', 'Initials': 'AM', 'LastName': 'Ibrahim', 'Affiliation': 'Dermatology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.'}, {'ForeName': 'Asmaa Atef', 'Initials': 'AA', 'LastName': 'Mahmoud', 'Affiliation': 'Dermatology, Venereology and Andrology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13628'] 2085,32741099,"Retzius-sparing robot-assisted radical prostatectomy improves early recovery of urinary continence: a randomized, controlled, single-blind trial with a 1-year follow-up.","OBJECTIVE To evaluate the impact of Retzius-sparing robot-assisted radical prostatectomy (posterior approach) on early recovery of urinary continence (UC) compared to the conventional approach (anterior approach) for the treatment of clinically localized prostate cancer (PCa). METHODS 110 consecutive patients with clinically localized PCa were prospectively randomized in a 1:1 ratio to anterior group (n = 55) or posterior group (n = 55). The primary outcome was immediate UC defined as freedom from any pad use within 1 week after removal of urinary catheter. UC rate following surgery was also calculated with Kaplan-Meier curves and log-rank test was used for the statistical comparison. Intraoperative outcomes, pathologic data and oncologic outcome including positive surgical margin (PSM) and biochemical recurrence-free survival (BCRFS) were also compared between the two groups. The comparison of the two approaches was also analyzed in subgroups by risk stratification. RESULTS 69.1% of men who underwent posterior approach achieved immediate UC compared with 30.9% in the anterior group (RR = 2.24, 95% CI: 1.48 - 3.51, p = 0.000). The relative Kaplan-Meier curves regarding UC during 12-month follow-up revealed statistically better recovery of posterior approach when compared with anterior approach (HR = 1.51, 95% CI: 1.01 - 2.24, log-rank p = 0.007). No statistically significant differences were observed between the groups regarding complications (p = 0.399), PSM (p = 0.225), and BCRFS (HR = 4.80, 95% CI: 0.97 - 23.78, log-rank p = 0.111). In subanalyses, no significant difference regarding continence recovery in high-risk patients was observed between the two approaches (HR = 1.26; 95% CI: 0.63 - 2.51, log rank p = 0.415). CONCLUSIONS The Retzius-sparing approach significantly improved early recovery of UC compared to the conventional approach. Further prospective studies are needed to confirm the benefits of Retzius-sparing approach for clinically localized prostate cancer, especially for high-risk cases.",2020,"The relative Kaplan-Meier curves regarding UC during 12-month follow-up revealed statistically better recovery of posterior approach when compared with anterior approach (HR = 1.51, 95% CI: 1.01 - 2.24, log-rank p = 0.007).","['clinically localized prostate cancer (PCa', '110 consecutive patients with clinically localized PCa']","['Retzius-sparing robot-assisted radical prostatectomy', 'Retzius-sparing robot-assisted radical prostatectomy (posterior approach', 'conventional approach (anterior approach']","['Intraoperative outcomes, pathologic data and oncologic outcome including positive surgical margin (PSM) and biochemical recurrence-free survival (BCRFS', 'PSM', 'urinary continence', 'immediate UC defined as freedom from any pad use within 1 week after removal of urinary catheter', 'immediate UC', 'UC rate', 'early recovery of UC', 'BCRFS', 'continence recovery', 'early recovery of urinary continence (UC']","[{'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0392752', 'cui_str': 'Localized'}]","[{'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}, {'cui': 'C0205512', 'cui_str': 'Posterior approach'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0205511', 'cui_str': 'Anterior approach'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0205478', 'cui_str': 'Oncologic'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1709603', 'cui_str': 'Positive Surgical Margins'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease'}, {'cui': 'C0542565', 'cui_str': 'Bladder control'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0332568', 'cui_str': 'Pad'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C1442452', 'cui_str': 'One week'}, {'cui': 'C0194049', 'cui_str': 'Removal of urinary drainage device'}, {'cui': 'C1279919', 'cui_str': 'Early'}]",110.0,0.109697,"The relative Kaplan-Meier curves regarding UC during 12-month follow-up revealed statistically better recovery of posterior approach when compared with anterior approach (HR = 1.51, 95% CI: 1.01 - 2.24, log-rank p = 0.007).","[{'ForeName': 'Xuefeng', 'Initials': 'X', 'LastName': 'Qiu', 'Affiliation': 'Department of Urology, Affiliated Drum Tower hospital, Medical School of Nanjing University, Nanjing, 210008, China.'}, {'ForeName': 'Youjian', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Urology, Affiliated Drum Tower hospital, Medical School of Nanjing University, Nanjing, 210008, China.'}, {'ForeName': 'Mengxia', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': 'Department of Urology, Affiliated Drum Tower hospital, Medical School of Nanjing University, Nanjing, 210008, China.'}, {'ForeName': 'Linfeng', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': 'Department of Urology, Affiliated Drum Tower hospital, Medical School of Nanjing University, Nanjing, 210008, China.'}, {'ForeName': 'Suhan', 'Initials': 'S', 'LastName': 'Guo', 'Affiliation': 'School of Artificial Intelligence, Nanjing University, Nanjing, 210008, China.'}, {'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'Marra', 'Affiliation': 'Department of Urology, San Giovanni Battista Hospital, Città della Salute e della Scienza and University of Turin, Turin, Italy.'}, {'ForeName': 'Joel Elliot', 'Initials': 'JE', 'LastName': 'Rosenberg', 'Affiliation': 'University of Minnesota Medical School, Minneapolis, Minnesota, United States.'}, {'ForeName': 'Haoxin', 'Initials': 'H', 'LastName': 'Ma', 'Affiliation': 'Department of Urology, Affiliated Drum Tower hospital, Medical School of Nanjing University, Nanjing, 210008, China.'}, {'ForeName': 'Xiaogong', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Urology, Affiliated Drum Tower hospital, Medical School of Nanjing University, Nanjing, 210008, China.'}, {'ForeName': 'Hongqian', 'Initials': 'H', 'LastName': 'Guo', 'Affiliation': 'Department of Urology, Affiliated Drum Tower hospital, Medical School of Nanjing University, Nanjing, 210008, China.'}]",BJU international,['10.1111/bju.15195'] 2086,32741133,Repeated abobotulinumtoxinA (Dysport®) injection effect on walking velocity in persons with spastic hemiparesis caused by stroke or traumatic brain injury.,"INTRODUCTION Botulinum toxin (BoNT) injections were shown to improve muscle tone of limbs in patients with spasticity. However, limited data are available regarding the effects of repeated BoNT injections on walking ability. OBJECTIVE To assess changes in walking velocity (WV), step length, and cadence under different test conditions after repeated treatment with abobotulinumtoxinA (aboBoNT-A; Dysport®) in spastic lower limb muscles. DESIGN Secondary analysis of an open-label, multiple-cycle extension (NCT01251367) to a phase III, double-blind, randomized, placebo-controlled, single-treatment cycle study, in adults with chronic hemiparesis (NCT01249404). SETTING Fifty-two centers across Australia, Belgium, the Czech Republic, France, Hungary, Italy, Poland, Portugal, Russia, Slovakia, and the United States. PATIENTS 352 ambulatory adults (18-80 years) with spastic hemiparesis and gait dysfunction caused by stroke or traumatic brain injury, with a comfortable barefoot WV of 0.1 to 0.8 m/s. INTERVENTIONS Up to four aboBoNT-A treatment cycles, administered to spastic lower limb muscles. MAIN OUTCOME MEASUREMENTS Changes from baseline in comfortable and maximal barefoot and with shoes WV (m/s), step length (m/step), and cadence (steps/min). RESULTS At Week 12 after four injections, WV improved by 0.08 to 0.10 m/s, step length by 0.03 to 0.04 m/step, and cadence by 3.9 to 6.2 steps/min depending on test condition (all p<0.0001 to 0.0003 versus baseline). More patients (7 to 17%) became unlimited community ambulators (WV ≥0.8 m/s) across test conditions compared with baseline, with 39% of 151 patients classified as unlimited community ambulators in at least one test condition and 17% in all four test conditions. CONCLUSIONS Clinically meaningful and statistically significant improvements in WV, step length and cadence under all four test conditions were observed in patients with spastic hemiparesis after each aboBoNT-A treatment cycle. This article is protected by copyright. All rights reserved.",2020,"CONCLUSIONS Clinically meaningful and statistically significant improvements in WV, step length and cadence under all four test conditions were observed in patients with spastic hemiparesis after each aboBoNT-A treatment cycle.","['patients with spasticity', 'adults with chronic hemiparesis (NCT01249404', 'patients with spastic hemiparesis', 'persons with spastic hemiparesis caused by stroke or traumatic brain injury', 'spastic lower limb muscles', 'Fifty-two centers across Australia, Belgium, the Czech Republic, France, Hungary, Italy, Poland, Portugal, Russia, Slovakia, and the United States', '352 ambulatory adults (18-80\u2009years) with spastic hemiparesis and gait dysfunction caused by stroke or traumatic brain injury, with a comfortable barefoot WV of 0.1']","['Botulinum toxin (BoNT) injections', 'Repeated abobotulinumtoxinA (Dysport®) injection', 'abobotulinumtoxinA (aboBoNT-A; Dysport®', 'placebo']","['WV, step length and cadence', 'walking velocity', 'muscle tone of limbs', 'Changes from baseline in comfortable and maximal barefoot and with shoes WV (m/s), step length (m/step), and cadence (steps/min', 'walking velocity (WV), step length, and cadence under different test conditions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0018989', 'cui_str': 'Hemiparesis'}, {'cui': 'C0154694', 'cui_str': 'Spastic hemiplegia'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0004950', 'cui_str': 'Belgium'}, {'cui': 'C0206578', 'cui_str': 'Czech republic'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0020174', 'cui_str': 'Hungary'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0032356', 'cui_str': 'Poland'}, {'cui': 'C0032729', 'cui_str': 'Portugal'}, {'cui': 'C0035970', 'cui_str': 'Russian federation - Europe'}, {'cui': 'C0206579', 'cui_str': 'Slovakia'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0277844', 'cui_str': 'Barefoot walking'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C4517420', 'cui_str': '0.1'}]","[{'cui': 'C0006055', 'cui_str': 'botulinum toxin'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C2719424', 'cui_str': 'AbobotulinumtoxinA'}, {'cui': 'C0591427', 'cui_str': 'Dysport'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0427126', 'cui_str': 'Step length'}, {'cui': 'C0026841', 'cui_str': 'Muscle Tension'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0277844', 'cui_str': 'Barefoot walking'}, {'cui': 'C0036988', 'cui_str': 'Shoes'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0449910', 'cui_str': 'Test conditions'}]",352.0,0.0929913,"CONCLUSIONS Clinically meaningful and statistically significant improvements in WV, step length and cadence under all four test conditions were observed in patients with spastic hemiparesis after each aboBoNT-A treatment cycle.","[{'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Esquenazi', 'Affiliation': 'MossRehab, Elkins Park, PA, USA.'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Brashear', 'Affiliation': 'University of California, Davis, Sacramento, CA, USA.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Deltombe', 'Affiliation': 'Service de Médecine Physique et Réadaptation, Centre Hospitalier Universitaire UCL, Namur site Godinne, Yvoir, Belgium.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Rudzinska-Bar', 'Affiliation': 'Department of Neurology, Faculty of Medicine and Health Service, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland.'}, {'ForeName': 'Malgorzata', 'Initials': 'M', 'LastName': 'Krawczyk', 'Affiliation': 'Centrum Medyczne Plejady ul, Miłkowskiego 11a/128, Kraków-Podgórze, Kraków, Poland.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Skoromets', 'Affiliation': 'Pavlov First St Petersburg State Medical University, St Petersburg, Russia.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': ""O'Dell"", 'Affiliation': 'Department of Rehabilitation Medicine, Weill Cornell Medicine, Baker Pavilion, New York, NY, USA.'}, {'ForeName': 'Anne-Sophie', 'Initials': 'AS', 'LastName': 'Grandoulier', 'Affiliation': 'Ipsen Innovation, Les Ulis, France.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Vilain', 'Affiliation': 'Ipsen Innovation, Les Ulis, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Picaut', 'Affiliation': 'Ipsen Innovation, Les Ulis, France.'}, {'ForeName': 'Jean-Michel', 'Initials': 'JM', 'LastName': 'Gracies', 'Affiliation': 'EA 7377 BIOTN, Université Paris-Est Créteil, Service de Rééducation Neurolocomotrice, Hôpitaux Universitaires Henri Mondor, 51, avenue du Maréchal De Lattre De Tassigny, 94010, Créteil, France.'}]","PM & R : the journal of injury, function, and rehabilitation",['10.1002/pmrj.12459'] 2087,32741143,Pulmonary adverse events of low-dose methotrexate in the randomized double-blind placebo-controlled Cardiovascular Inflammation Reduction Trial.,"OBJECTIVE We previously reported that low-dose methotrexate (LD-MTX) was associated with increased risk of pulmonary adverse events (AEs) in a large placebo-controlled randomized trial. Herein, we report details on predictors and severity of pulmonary AEs. METHODS This was a pre-specified analysis of pulmonary AEs in the Cardiovascular Inflammation Reduction Trial. Adults with known cardiovascular disease and diabetes/metabolic syndrome were randomly allocated to LD-MTX (target dose 15-20 mg/week) or placebo after 6-8 weeks of open-label run-in with LD-MTX. Individuals with systemic inflammatory diseases were excluded. Pulmonary AEs were blindly adjudicated. We described severe pulmonary AEs and examined associations of baseline characteristics with pulmonary AEs of LD-MTX. RESULTS A total of 2,391 subjects were randomized to LD-MTX and 2,395 to placebo. There were 13 severe pulmonary AEs (0.5%) and seven (0.3%) cases of possible pneumonitis in the LD-MTX group, compared to eight (0.3%) and one (<0.1%), respectively, in the placebo group. Among those randomized to LD-MTX, risk factors for any pulmonary AE included: female sex (HR 1.69, 95%CI 1.16. 2.45 vs. male), White race (HR 2.35, 95%CI 1.03-5.36 vs. others) and insulin use (HR 1.60, 95%CI 1.11-2.30 vs. non-use). Risk factors for severe pulmonary AEs included only older baseline age (HR 1.09 per increasing year, 95%CI 1.02-1.16). CONCLUSION In this large placebo-controlled trial, pulmonary AEs, including possible pneumonitis, were uncommon but were more likely to occur in those randomized to LD-MTX. White race, older age, male sex, and insulin use were associated with increased risk of pulmonary AE of LD-MTX.",2020,"Risk factors for severe pulmonary AEs included only older baseline age (HR 1.09 per increasing year, 95%CI 1.02-1.16). ","['Adults with known cardiovascular disease and diabetes/metabolic syndrome', 'Individuals with systemic inflammatory diseases', '2,391 subjects']","['open-label run-in with LD-MTX', 'methotrexate (LD-MTX', 'methotrexate', 'LD-MTX', 'placebo']","['severe pulmonary AEs', 'possible pneumonitis', 'Pulmonary adverse events', 'risk of pulmonary AE of LD-MTX']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C1290884', 'cui_str': 'Inflammatory disorder'}]","[{'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0332149', 'cui_str': 'Possible'}, {'cui': 'C3714636', 'cui_str': 'Pneumonitis'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}]",2391.0,0.666728,"Risk factors for severe pulmonary AEs included only older baseline age (HR 1.09 per increasing year, 95%CI 1.02-1.16). ","[{'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Sparks', 'Affiliation': ""Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Paul F', 'Initials': 'PF', 'LastName': 'Dellaripa', 'Affiliation': ""Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Glynn', 'Affiliation': 'Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Nina P', 'Initials': 'NP', 'LastName': 'Paynter', 'Affiliation': 'Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Chang', 'Initials': 'C', 'LastName': 'Xu', 'Affiliation': ""Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Ridker', 'Affiliation': 'Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Daniel H', 'Initials': 'DH', 'LastName': 'Solomon', 'Affiliation': ""Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.""}]","Arthritis & rheumatology (Hoboken, N.J.)",['10.1002/art.41452'] 2088,32741226,Effect of listening to synchronous versus motivational music during warm-up on the diurnal variation of short-term maximal performance and subjective experiences.,"Which type of music is better for improving short-term maximal performance (STMP) and subjective experiences, and under what conditions? The present study was designed to address this issue by investigating the effects of listening to synchronous versus motivational music during warm-up, as a function of time of day, on exercise performance. In a random order, 16 highly trained physical education students (male) performed the 30-s Continuous Jump (CJ 30 ) during six sessions separated at minimum by 48 h of recovery: after two warm-ups with synchronous music (WUSM), after two warm-ups with motivational music (WUMM), and after two warm-ups without music (WUWM), at 07:00 and 17:00 h. The maximal jump height (H max ), mean jump height of all jumps (H mean ), and fatigue index (F %) were measured during the test. Body temperature was collected before and after the warm-up, and at the end of the CJ 30 test. The rated perceived exertion (RPE) and the feelings states (FS) were obtained immediately after the warm-up and the test. The results revealed that H mean , H max , and temperature were higher at 17:00 than 07:00 h in all experimental conditions. Moreover, H mean and H max were higher with WUSM and WUMM than WUWM at both times of day, with greater improvement in the morning. After performing the CJ 30 test, RPE scores were higher with WUMM than WUWM at both times of day. Moreover, FS scores were more positive with WUMM than WUWM in the morning. Furthermore, WUMM resulted in better H max and H mean at both times of day than WUSM. However, FS and RPE were independent of types of music. Findings suggested the use of music during warm-up to increase STMP, RPE, and FS at both times of day, and reduce the morning-afternoon difference in the CJ 30 test. More importantly, a warm-up with motivational music is more beneficial than a warm-up with synchronous music for improving STMP, either in the morning or in the afternoon.",2020,"Moreover, H mean and H max were higher with WUSM and WUMM than WUWM at both times of day, with greater improvement in the morning.",['16 highly trained physical education students (male'],"['30-s Continuous Jump (CJ 30 ) during six sessions separated at minimum by 48\xa0h of recovery: after two warm-ups with synchronous music (WUSM), after two warm-ups with motivational music (WUMM), and after two warm-ups without music (WUWM', 'listening to synchronous versus motivational music']","['maximal jump height (H max ), mean jump height of all jumps (H mean ), and fatigue index', 'FS scores', 'H mean and H max', 'STMP, RPE, and FS', 'RPE scores', 'Body temperature', 'H mean , H max , and temperature', 'better H max and H mean', 'rated perceived exertion (RPE) and the feelings states (FS']","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0031806', 'cui_str': 'Physical Education, Training'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C2350169', 'cui_str': 'Warming-Up Exercise'}, {'cui': 'C0439580', 'cui_str': 'Synchronous'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0004309', 'cui_str': 'Auditory Perception'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0035322', 'cui_str': 'Structure of retinal pigment epithelium'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C1301808', 'cui_str': 'State'}]",16.0,0.0230271,"Moreover, H mean and H max were higher with WUSM and WUMM than WUWM at both times of day, with greater improvement in the morning.","[{'ForeName': 'Yosra', 'Initials': 'Y', 'LastName': 'Belkhir', 'Affiliation': 'Research Laboratory: Education, Motricité, Sport Et Santé, EM2S, LR19JS01, Sfax University , Sfax, Tunisia.'}, {'ForeName': 'Ghazi', 'Initials': 'G', 'LastName': 'Rekik', 'Affiliation': 'Research Laboratory: Education, Motricité, Sport Et Santé, EM2S, LR19JS01, Sfax University , Sfax, Tunisia.'}, {'ForeName': 'Hamdi', 'Initials': 'H', 'LastName': 'Chtourou', 'Affiliation': 'High Institute of Sport and Physical Education of Sfax, Sfax University , Sfax, Tunisia.'}, {'ForeName': 'Nizar', 'Initials': 'N', 'LastName': 'Souissi', 'Affiliation': 'High Institute of Sport and Physical Education of Ksar-said, Manouba University , Tunis, Tunisia.'}]",Chronobiology international,['10.1080/07420528.2020.1797764'] 2089,32741231,Predictors of the effect of an arm sling on gait efficiency in stroke patients with shoulder subluxation: a pre-post design clinical trial.,"BACKGROUND The predictors affecting the gait efficiency were not known for the arm sling, including general and stroke-related characteristics. PURPOSE This study investigated the predictors of gait efficiency when walking with and without an arm sling in individuals with hemiplegia with shoulder subluxation. METHODS A total of 57 individuals with shoulder subluxation were recruited. Individuals assigned odd numbers walked with the arm sling first and those with even numbers walked without the arm sling first in a pre-post design. Outcome measures were the energy cost, energy consumption, and heart rate during a 6-min walk test and a 10-m walk test. Gait efficiency is defined as energy consumption divided by the distance walked, with lower energy costs reflecting higher gait efficiency. Age, MMSE scores adjusted for education, and significant variables ( p < .01) in the univariate analyses were entered into multiple regression analyses, to identify the predictors of changes of gait efficiency. RESULTS Energy cost and energy consumption were lower and walking endurance was higher when walking with an arm sling than when without an arm sling. Spasticity ( p = .02), shoulder pain ( p = .03), consistency of handedness and sling position worn ( p = .02), function of upper extremity ( p = .03) and walking aids ( p = .01) were predictors of gait efficiency. CONCLUSION An arm sling may improve gait efficiency in individuals with hemiplegia and shoulder subluxation able to walk with a single cane, who have consistency in handedness and sling position, and with good upper extremity function, including no shoulder pain and reduced spasticity.",2020,"Spasticity ( p = .02), shoulder pain ( p = .03), consistency of handedness and sling position worn ( p = .02), function of upper extremity ( p = .03) and walking aids ( p = .01) were predictors of gait efficiency. ","['57 individuals with shoulder subluxation were recruited', 'individuals with hemiplegia with shoulder subluxation', 'individuals with hemiplegia and shoulder subluxation', 'stroke patients with shoulder subluxation']",[],"['Gait efficiency', 'function of upper extremity', 'consistency of handedness and sling position worn', 'gait efficiency', 'Energy cost and energy consumption', 'energy cost, energy consumption, and heart rate during a 6-min walk test and a 10-m walk test', 'Spasticity', 'shoulder pain', 'walking aids', 'walking endurance']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0434744', 'cui_str': 'Subluxation of shoulder joint'}, {'cui': 'C0018991', 'cui_str': 'Hemiplegia'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",[],"[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0023114', 'cui_str': 'Handedness'}, {'cui': 'C0183346', 'cui_str': 'Sling'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0557834', 'cui_str': 'Walking aid'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}]",57.0,0.0764909,"Spasticity ( p = .02), shoulder pain ( p = .03), consistency of handedness and sling position worn ( p = .02), function of upper extremity ( p = .03) and walking aids ( p = .01) were predictors of gait efficiency. ","[{'ForeName': 'Yeon-Gyu', 'Initials': 'YG', 'LastName': 'Jeong', 'Affiliation': 'Department of Physical Therapy, Yeoju Institute of Technology , Yeoju-si, Republic of Korea.'}, {'ForeName': 'Yeon-Jae', 'Initials': 'YJ', 'LastName': 'Jeong', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, School of Medicine, Hanyang University , Seoul, Republic of Korea.'}, {'ForeName': 'Hyun-Sook', 'Initials': 'HS', 'LastName': 'Kim', 'Affiliation': 'Department of Physical Therapy, Yeoju Institute of Technology , Yeoju-si, Republic of Korea.'}, {'ForeName': 'Kyu Hoon', 'Initials': 'KH', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, School of Medicine, Hanyang University , Seoul, Republic of Korea.'}]",Physiotherapy theory and practice,['10.1080/09593985.2020.1799458'] 2090,32741240,A social dancing pilot intervention for older adults at high risk for Alzheimer's disease and related dementias.,"Close to 6 million older US adults have Alzheimer's disease or related dementias, yet there is currently no cure or effective treatment. This single-blind randomized controlled trial (clinicaltrials.gov: NCT03475316) aims to establish feasibility, and explore the relative efficacy, of a 6-month social ballroom dancing intervention versus a 6-month active control intervention (treadmill walking) for improving executive function in 32 older adults at increased risk for Alzheimer's disease or related dementias. Dementia-at-risk status is determined with cut-scores on the memory impairment screen (≥3 to ≤6) and/or the AD-8 Dementia Screening Interview (≥1). The primary outcome is a composite executive function score from digit-symbol substitution, flanker interference and walking-while-talking tasks. The secondary outcome is functional neuroplasticity during fMRI-adapted versions of digit-symbol substitution, flanker interference and walking-while-talking.",2020,"Close to 6 million older US adults have Alzheimer's disease or related dementias, yet there is currently no cure or effective treatment.","[""older adults at high risk for Alzheimer's disease and related dementias"", ""32 older adults at increased risk for Alzheimer's disease or related dementias""]","['active control intervention (treadmill\xa0walking', 'social ballroom dancing intervention']","['composite executive function score from digit-symbol substitution, flanker interference and walking-while-talking tasks', 'functional neuroplasticity during fMRI-adapted versions of digit-symbol substitution, flanker interference and walking-while-talking']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0027880', 'cui_str': 'Plasticity, Neuronal'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C2607870', 'cui_str': 'Version'}]",32.0,0.104066,"Close to 6 million older US adults have Alzheimer's disease or related dementias, yet there is currently no cure or effective treatment.","[{'ForeName': 'Helena M', 'Initials': 'HM', 'LastName': 'Blumen', 'Affiliation': 'Department of Medicine, Albert Einstein College of Medicine, Bronx, NY\xa010461, USA.'}, {'ForeName': 'Emmeline', 'Initials': 'E', 'LastName': 'Ayers', 'Affiliation': 'Department of Neurology, Albert Einstein College of Medicine, Bronx, NY\xa010461, USA.'}, {'ForeName': 'Cuiling', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, Albert Einstein College of Medicine, Bronx, NY\xa010461, USA.'}, {'ForeName': 'Anne F', 'Initials': 'AF', 'LastName': 'Ambrose', 'Affiliation': 'Department of Rehabilitation Medicine, Albert Einstein College of Medicine, Bronx, NY\xa010461, USA.'}, {'ForeName': 'Joe', 'Initials': 'J', 'LastName': 'Verghese', 'Affiliation': 'Department of Medicine, Albert Einstein College of Medicine, Bronx, NY\xa010461, USA.'}]",Neurodegenerative disease management,['10.2217/nmt-2020-0002'] 2091,32741251,Physical and Cognitive Performance During Upper-Extremity Versus Full-Body Exercise Under Dual Tasking Conditions.,"The purpose of this study was to investigate physical and cognitive performance during dual task conditions of upper-extremity (UE) or full-body (FB) rowing exercise. In a crossover counterbalanced design, college-aged male and female participants completed five conditions: (a) Sitting, (b) Single task UE rowing, (c) Single task FB rowing, (d) Dual task UE rowing, and (e) Dual task FB rowing. For single task UE and FB rowing conditions, participants were asked to row as hard as possible. After sitting and dual-task conditions, we administered the Paced Auditory Serial Addition Test (PASAT) and a word-list memory test. We analyzed participants' absolute differences (single task - dual task) in power output and their cognitive test scores to compare UE and FB rowing. There were no significant absolute differences from sitting to dual task conditions of UE and FB rowing for either PASAT ( p  = 0.958) or word list memory ( p  = 0.899) cognitive scores. Absolute power output loss from single to dual task conditions was significantly higher in FB versus UE for PASAT ( p  = 0.039; d  = 0.54) and word list memory ( p  = 0.021; d  = 0.66) in the dual task condition. These results suggest that, while cognitive performance was preserved regardless of the amount of muscle mass activated during dual task rowing, physical performance suffered more during FB than UE rowing under the dual task condition. These findings have important implications for optimizing cognitive and physical performance in dual task situations.",2020,Absolute power output loss from single to dual task conditions was significantly higher in FB versus UE for PASAT (,['college-aged male and female participants completed five conditions: (a'],"['dual task conditions of upper-extremity (UE) or full-body (FB) rowing exercise', 'Physical and Cognitive Performance During Upper-Extremity Versus Full-Body Exercise Under Dual Tasking Conditions', 'Sitting, (b) Single task UE rowing, (c) Single task FB rowing, (d) Dual task UE rowing, and (e) Dual task FB rowing', 'Paced Auditory Serial Addition Test (PASAT) and a word-list memory test']","['physical and cognitive performance', 'word list memory', 'sitting to dual task conditions of UE and FB rowing']","[{'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C4505111', 'cui_str': 'Rowing'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0589060', 'cui_str': 'Paced auditory serial addition test'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C4505111', 'cui_str': 'Rowing'}]",,0.0154677,Absolute power output loss from single to dual task conditions was significantly higher in FB versus UE for PASAT (,"[{'ForeName': 'Sarah C', 'Initials': 'SC', 'LastName': 'Duckworth', 'Affiliation': 'Department of Kinesiology, Samford University, Birmingham, Alabama, United States.'}, {'ForeName': 'Carrie S', 'Initials': 'CS', 'LastName': 'Higginbotham', 'Affiliation': 'Department of Kinesiology, Samford University, Birmingham, Alabama, United States.'}, {'ForeName': 'Joseph A', 'Initials': 'JA', 'LastName': 'Pederson', 'Affiliation': 'Department of Kinesiology, Samford University, Birmingham, Alabama, United States.'}, {'ForeName': 'Rebecca R', 'Initials': 'RR', 'LastName': 'Rogers', 'Affiliation': 'Department of Kinesiology, Samford University, Birmingham, Alabama, United States.'}, {'ForeName': 'Mallory R', 'Initials': 'MR', 'LastName': 'Marshall', 'Affiliation': 'Department of Kinesiology, Samford University, Birmingham, Alabama, United States.'}, {'ForeName': 'Tyler D', 'Initials': 'TD', 'LastName': 'Williams', 'Affiliation': 'Department of Kinesiology, Samford University, Birmingham, Alabama, United States.'}, {'ForeName': 'Christopher G', 'Initials': 'CG', 'LastName': 'Ballmann', 'Affiliation': 'Department of Kinesiology, Samford University, Birmingham, Alabama, United States.'}]",Perceptual and motor skills,['10.1177/0031512520945088'] 2092,32741294,"Assessment of acute aerobic exercise in the morning versus evening on asprosin, spexin, lipocalin-2, and insulin level in overweight/obese versus normal weight adult men.","The aim of this study was to examine the acute effect of aerobic exercise when performed in the morning and evening on obesity-related hormones of asprosin, spexin, lipocalin-2, and insulin in normal weight (NW) and overweight/obese (OW/OO) adults. A total of 20 adult male individuals (10 NW and 10 OW/OO) volunteered their participation. Both groups were subjected to an aerobic exercise protocol in moderate intensity (heart rate reserve of 55-59%) for 30 min at two different time periods of the day (morning: 08:00-10:00 h, evening: 20.00-22.00 h) at least 3 d apart. BeBis analysis revealed the OW/OO group consumed significantly less energy (1781.59 ± 410.71 kcal) as compared with NW group (2380.28 ± 445.50 kcal) before the evening exercise (about 3 d) ( p <.05). As compared with the NW group, basal serum asprosin, insulin, and lipocalin-2 hormone levels were higher in the OW/OO group, and serum spexin level was lower in OW/OO group ( p <.05). Body temperature significantly increased after morning and evening aerobic exercise in both groups. The increase in body temperature was significantly higher after the evening exercise in the OW/OO group compared to the NW group ( p <.05). Significant decrease in serum asprosin lipocalin-2, and insulin levels was observed in both groups after exercise ( p <.05). Evening aerobic exercise more greatly decreased serum asprosin, lipocalin-2, and insulin level in the OW/OO group as compared with the NW group ( p <.05). In conclusion, it is thought that negative energy balance caused by psychological energy restriction and evening aerobic exercise, which leads to a further increase in body temperature, triggers greater decrease of orexigenic signals (suppression of appetite), and is more effective in the development of adipose tissue inflammation and insulin sensitivity, especially in OW/OO group.",2020,The increase in body temperature was significantly higher after the evening exercise in the OW/OO group compared to the NW group ( p <.05).,"['overweight/obese versus normal weight adult men', 'normal weight (NW) and overweight/obese (OW/OO) adults', '20 adult male individuals (10 NW and 10 OW/OO) volunteered their participation']","['Evening aerobic exercise', 'aerobic exercise protocol', 'acute aerobic exercise', 'aerobic exercise']","['asprosin, spexin, lipocalin-2, and insulin level', 'serum spexin level', 'body temperature', 'serum asprosin lipocalin-2, and insulin levels', 'basal serum asprosin, insulin, and lipocalin-2 hormone levels', 'Body temperature', 'serum asprosin, lipocalin-2, and insulin level']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0587117', 'cui_str': 'Evening'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}]","[{'cui': 'C0215955', 'cui_str': 'LCN2 protein, human'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C1287355', 'cui_str': 'Hormone level - finding'}]",20.0,0.0498627,The increase in body temperature was significantly higher after the evening exercise in the OW/OO group compared to the NW group ( p <.05).,"[{'ForeName': 'Halil İbrahim', 'Initials': 'Hİ', 'LastName': 'Ceylan', 'Affiliation': 'Faculty of Kazim Karabekir Education, Physical Education and Sports Teaching Department, Ataturk University , Erzurum, Turkey.'}, {'ForeName': 'Özcan', 'Initials': 'Ö', 'LastName': 'Saygın', 'Affiliation': 'Faculty of Sports Sciences, Coaching Science Department, Mugla Sitki Kocman University , Muğla, Turkey.'}, {'ForeName': 'Ümmühani', 'Initials': 'Ü', 'LastName': 'Özel Türkcü', 'Affiliation': 'Faculty of Medicine, Medical Biochemistry Department, Mugla Sitki Kocman University , Muğla, Turkey.'}]",Chronobiology international,['10.1080/07420528.2020.1792482'] 2093,32741328,Secondary Injury Prevention Program May Decrease Contralateral Anterior Cruciate Ligament Injuries in Female Athletes: 2-year Injury Rates in the ACL-SPORTS Randomized Control Trial.,"OBJECTIVE To determine if the addition of perturbation training to a secondary injury prevention program reduced the rate of second anterior cruciate ligament (ACL) injuries compared to the prevention program alone. DESIGN Single-blinded randomized control trial. METHODS Thirty-nine female athletes who intended to return to cutting/pivoting sports were enrolled 3-9 months after primary ACLR. Athletes were randomized into either progressive strengthening, agility, plyometric, and prevention (SAPP) or SAPP plus perturbation training (SAPP+PERT) groups; each had ten sessions over 5 weeks. Occurrence and side of second ACL injury were recorded for two years after primary ACLR. RESULTS There were nine second ACL injuries in the two years after ACLR. There was no statistically significant difference in rate or side of second ACL injury between the SAPP+PERT and SAPP groups. CONCLUSION Adding perturbation training to a secondary ACL injury prevention program did not affect the rate of second ACL injuries in female athletes. J Orthop Sports Phys Ther, Epub 1 Aug 2020. doi:10.2519/jospt.2020.9407 .",2020,"There was no statistically significant difference in rate or side of second ACL injury between the SAPP+PERT and SAPP groups. ","['Thirty-nine female athletes who intended to return to cutting/pivoting sports were enrolled 3-9 months after primary ACLR', 'female athletes', 'Female Athletes']","['perturbation training to a secondary injury prevention program', 'progressive strengthening, agility, plyometric, and prevention (SAPP) or SAPP plus perturbation training (SAPP+PERT']","['Occurrence and side of second ACL injury', 'Contralateral Anterior Cruciate Ligament Injuries', 'rate or side of second ACL injury', 'rate of second ACL injuries', 'rate of second anterior cruciate ligament (ACL) injuries']","[{'cui': 'C3816447', 'cui_str': '39'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0000925', 'cui_str': 'Incised wound'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205225', 'cui_str': 'Principal'}]","[{'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0150638', 'cui_str': 'Preventing injury'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C1456574', 'cui_str': 'Injury of anterior cruciate ligament'}, {'cui': 'C0441988', 'cui_str': 'Contralateral'}, {'cui': 'C0078960', 'cui_str': 'Structure of anterior cruciate ligament of knee joint'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}]",39.0,0.0258922,"There was no statistically significant difference in rate or side of second ACL injury between the SAPP+PERT and SAPP groups. ","[{'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Johnson', 'Affiliation': 'Biomechanics and Movement Science, University of Delaware, Newark DE.'}, {'ForeName': 'Jacob J', 'Initials': 'JJ', 'LastName': 'Capin', 'Affiliation': 'Department of Physical Therapy, University of Delaware, Newark DE.'}, {'ForeName': 'Amelia J H', 'Initials': 'AJH', 'LastName': 'Arundale', 'Affiliation': 'Department of Physical Therapy, University of Delaware, Newark DE.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Zarzycki', 'Affiliation': 'Department of Physical Therapy, University of Delaware, Newark DE.'}, {'ForeName': 'Angela H', 'Initials': 'AH', 'LastName': 'Smith', 'Affiliation': 'Department of Physical Therapy, University of Delaware, Newark DE.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Snyder-Mackler', 'Affiliation': 'Biomechanics and Movement Science, University of Delaware, Newark DE.'}]",The Journal of orthopaedic and sports physical therapy,['10.2519/jospt.2020.9407'] 2094,32741375,"HAPPi Kneecaps! Protocol for a participant- and assessor-blinded, randomised, parallel group feasibility trial of foot orthoses for adolescents with patellofemoral pain.","BACKGROUND Patellofemoral pain (PFP) is a common cause of knee pain in adolescents, but there are limited evidence-based treatment options for this population. Foot orthoses can improve pain and function in adults with PFP, and may be effective for adolescents. The primary aim of this study is to determine the feasibility of conducting a full-scale randomised controlled trial (RCT) evaluating the effects of contoured foot orthoses on knee pain severity and patient-perceived global change, compared to flat shoe insoles, in adolescents with PFP. The secondary aim is to provide an estimate of treatment effects for foot orthoses, compared to flat insoles, in adolescents with PFP. METHODS This randomised, controlled, participant- and assessor-blinded, feasibility trial has two parallel groups. Forty adolescents (aged 12-18 years) with clinical symptoms of PFP will be recruited from Queensland, Australia. Participants will be randomised to receive either prefabricated contoured foot orthoses or flat shoe insoles. Both interventions will be fit by a physiotherapist, and worn for 3 months. Feasibility will be evaluated through assessing willingness of volunteers to enrol, number of eligible participants, recruitment rate, adherence with the study protocol, adverse effects, success of blinding, and drop-out rate. Secondary outcomes will evaluate knee-related pain, symptoms, function, quality of life, global rating of change, patient acceptable symptom state, and use of co-interventions, at 6 weeks and 3 months. Primary outcomes will be reported descriptively, while estimates of standard deviation and between-group differences (with 95% confidence intervals) will be reported for secondary outcomes. DISCUSSION Findings of this study will inform the feasibility of a full-scale RCT investigating the efficacy of contoured foot orthoses in adolescents with PFP. This full-scale study is necessary to improve the evidence base for management of adolescent PFP, and enhance outcomes for this population. TRIAL REGISTRATION ACTRN12619000957190 .",2020,"Secondary outcomes will evaluate knee-related pain, symptoms, function, quality of life, global rating of change, patient acceptable symptom state, and use of co-interventions, at 6 weeks and 3 months.","['adults with PFP', 'adolescents with PFP', 'Forty adolescents (aged 12-18\u2009years) with clinical symptoms of PFP will be recruited from Queensland, Australia', 'adolescents with patellofemoral pain']","['foot orthoses', 'prefabricated contoured foot orthoses or flat shoe insoles', 'contoured foot orthoses', 'Foot orthoses']","['knee-related pain, symptoms, function, quality of life, global rating of change, patient acceptable symptom state, and use of co-interventions', 'knee pain severity', 'pain and function']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034391', 'cui_str': 'Queensland'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0205324', 'cui_str': 'Flat'}, {'cui': 'C0036988', 'cui_str': 'Shoes'}, {'cui': 'C3873740', 'cui_str': 'Insole'}]","[{'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0231749', 'cui_str': 'Knee pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",,0.235322,"Secondary outcomes will evaluate knee-related pain, symptoms, function, quality of life, global rating of change, patient acceptable symptom state, and use of co-interventions, at 6 weeks and 3 months.","[{'ForeName': 'Isobel C', 'Initials': 'IC', 'LastName': ""O'Sullivan"", 'Affiliation': 'Division of Physiotherapy, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Queensland, 4072, Australia.'}, {'ForeName': 'Kay M', 'Initials': 'KM', 'LastName': 'Crossley', 'Affiliation': 'La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, College of Science, Health and Engineering, La Trobe University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Kamper', 'Affiliation': 'School of Public Health, University of Sydney, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Marienke', 'Initials': 'M', 'LastName': 'van Middelkoop', 'Affiliation': 'Department of General Practice, Erasmus MC University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Bill', 'Initials': 'B', 'LastName': 'Vicenzino', 'Affiliation': 'Division of Physiotherapy, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Queensland, 4072, Australia.'}, {'ForeName': 'Melinda M', 'Initials': 'MM', 'LastName': 'Franettovich Smith', 'Affiliation': 'Division of Physiotherapy, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Queensland, 4072, Australia.'}, {'ForeName': 'Hylton B', 'Initials': 'HB', 'LastName': 'Menz', 'Affiliation': 'La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, College of Science, Health and Engineering, La Trobe University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Anne J', 'Initials': 'AJ', 'LastName': 'Smith', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, Western Australia, Australia.'}, {'ForeName': 'Kylie', 'Initials': 'K', 'LastName': 'Tucker', 'Affiliation': 'School of Biomedical Sciences, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Karina T', 'Initials': 'KT', 'LastName': ""O'Leary"", 'Affiliation': 'Division of Physiotherapy, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Queensland, 4072, Australia.'}, {'ForeName': 'Natalie J', 'Initials': 'NJ', 'LastName': 'Collins', 'Affiliation': 'Division of Physiotherapy, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Queensland, 4072, Australia. n.collins1@uq.edu.au.'}]",Journal of foot and ankle research,['10.1186/s13047-020-00417-9'] 2095,32741496,Dosage of booster phone calls following an SBIRT intervention in the emergency department for reducing substance use.,"Brief Interventions (BIs) for problematic drug use in general medical settings, including in Emergency Departments (EDs), have shown disappointing results compared to those that target problematic alcohol use. Telephone booster calls may augment the impact of a BI delivered in the ED. The current study uses data from the National Drug Abuse Treatment Clinical Trials Network (CTN) Protocol 0047, ""Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments (SMART-ED)"", a multisite randomized clinical trial conducted in six EDs in the U.S. We examine dose effects of telephone boosters (0, 1, or 2 calls completed) with non-treatment seeking patients who we randomized to the BI-Booster condition and who endorsed problematic drug use during their ED visit (N = 427). We assessed primary outcomes at 3-, 6-, and 12-month follow-ups, which included past month use of the primary drug of choice, use of any drug, and heavy drinking. There were no significant differences among those completing 0, 1, or 2 booster calls on any of the three main outcomes at 3-, 6-, and 12-months post-BI in the ED. Patients who were older were significantly more likely to complete booster calls. Taken together, these findings raise questions about the clinical utility of booster phone calls following screening and BIs targeting heterogeneous drug use in the ED.",2020,"There were no significant differences among those completing 0, 1, or 2 booster calls on any of the three main outcomes at 3-, 6-, and 12-months post-BI in the ED.",['patients who we randomized to the BI-Booster condition and who endorsed problematic drug use during their ED visit (N\xa0=\xa0427'],"['telephone boosters (0, 1, or 2 calls completed) with non-treatment seeking', 'SBIRT intervention', 'Brief Interventions (BIs']","['past month use of the primary drug of choice, use of any drug, and heavy drinking']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020975', 'cui_str': 'Booster vaccination'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0449889', 'cui_str': 'Drug used'}, {'cui': 'C0347984', 'cui_str': 'During'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0020975', 'cui_str': 'Booster vaccination'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}]","[{'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}]",,0.0390799,"There were no significant differences among those completing 0, 1, or 2 booster calls on any of the three main outcomes at 3-, 6-, and 12-months post-BI in the ED.","[{'ForeName': 'Mary A', 'Initials': 'MA', 'LastName': 'Hatch-Maillette', 'Affiliation': 'Alcohol and Drug Abuse Institute, University of Washington, Seattle, WA 98105, United States of America; Department of Psychiatry & Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98195, United States of America. Electronic address: hatchm@uw.edu.'}, {'ForeName': 'Dennis M', 'Initials': 'DM', 'LastName': 'Donovan', 'Affiliation': 'Alcohol and Drug Abuse Institute, University of Washington, Seattle, WA 98105, United States of America; Department of Psychiatry & Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98195, United States of America.'}, {'ForeName': 'Tanja C', 'Initials': 'TC', 'LastName': 'Laschober', 'Affiliation': 'Alcohol and Drug Abuse Institute, University of Washington, Seattle, WA 98105, United States of America.'}]",Journal of substance abuse treatment,['10.1016/j.jsat.2020.108043'] 2096,32741497,Pretreatment social network characteristics relate to increased risk of dropout and unfavorable outcomes among women in a residential treatment setting for substance use.,"Increased retention in residential treatment for substance use disorder (SUD) has been associated with more favorable clinical outcomes for residents. Yet SUD treatment dropout remains high. It is essential to uncover factors contributing to these high rates. Little is known about whether features of an individual's social network prior to treatment entry are related to number of days in treatment or to clinical status at treatment termination. To examine these relationships, we analyzed data from 241 women (58.5% Hispanic) entering an SUD residential treatment facility, who agreed to participate in a parent randomized control trial. We assessed characteristics of these women's social networks prior to treatment entry at baseline. We extracted clinician-determined progress at treatment termination and days in treatment two months after treatment entry from clinical records. Data-driven analyses using purposeful selection of predictors showed that the overall size of the social network was associated with increased likelihood of being classified as having achieved good clinical progress in treatment at termination and that number of drug users in the pretreatment social network was related to staying fewer days in treatment. Contrary to our hypothesis, we found no significant associations between other pretreatment social support network characteristics (i.e., social support) and treatment retention or clinical discharge status. Future research should examine how features of social networks change through treatment and how these changes relate to treatment outcomes.",2020,Data-driven analyses using purposeful selection of predictors showed that the overall size of the social network was associated with increased likelihood of being classified as having achieved good clinical progress in treatment at termination and that number of drug users in the pretreatment social network was related to staying fewer days in treatment.,"['women in a residential treatment setting for substance use', '241 women (58.5% Hispanic) entering an SUD residential treatment facility, who agreed to participate in a parent randomized control trial']",[],[],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0035189', 'cui_str': 'Residential Treatment'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0038586', 'cui_str': 'Substance use disorder'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],[],241.0,0.0245503,Data-driven analyses using purposeful selection of predictors showed that the overall size of the social network was associated with increased likelihood of being classified as having achieved good clinical progress in treatment at termination and that number of drug users in the pretreatment social network was related to staying fewer days in treatment.,"[{'ForeName': 'Inna', 'Initials': 'I', 'LastName': 'Arnaudova', 'Affiliation': 'Department of Psychiatry, University of California -, Los Angeles, United States of America.'}, {'ForeName': 'Haomiao', 'Initials': 'H', 'LastName': 'Jin', 'Affiliation': 'Suzanne Dworak-Peck School of Social Work, University of Southern California, United States of America.'}, {'ForeName': 'Hortensia', 'Initials': 'H', 'LastName': 'Amaro', 'Affiliation': 'Herbert Wertheim College of Medicine and Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL, United States of America. Electronic address: hamaro@fiu.edu.'}]",Journal of substance abuse treatment,['10.1016/j.jsat.2020.108044'] 2097,32741499,Acute and extended exposure to episodic future thinking in a treatment seeking addiction sample: A pilot study.,"Individuals with addictive disorders commonly exhibit a shortened temporal window (shortened period of time an individual can imagine into their own future), which interferes with treatment focusing on long-term sobriety or reductions in use. Episodic future thinking (EFT) involves generating personalized cues related to anticipated, positive future events. EFT has been shown to reduce impulsive decision-making and the reinforcing value of addictive substances; however, this has only been shown in nontreatment samples. The current study examined the feasibility and impact of a 1-week EFT protocol on decision-making and alcohol motivation in a sample of individuals receiving treatment for alcohol use disorder. We randomly assigned twenty-eight individuals currently enrolled in community-based alcohol use disorder treatment to either an EFT protocol or a control episodic recent thinking (ERT) protocol. Participants completed assessments of delay discounting, alcohol demand, craving, self-efficacy, consideration of consequences, and mindfulness at baseline, after 1 week of EFT practice, and at 1-week follow-up. We observed patterns of reductions in alcohol demand indices, delay discounting rates, and an increase in mindfulness after both acute (1 session) and extended (4 sessions) exposure to EFT. These proof-of-concept findings lay the foundation for a randomized controlled trial of EFT as a supplement to addictions treatment.",2020,"We observed patterns of reductions in alcohol demand indices, delay discounting rates, and an increase in mindfulness after both acute (1 session) and extended (4 sessions) exposure to EFT.","['individuals receiving treatment for alcohol use disorder', 'Individuals with addictive disorders']","['EFT protocol', 'Episodic future thinking (EFT', 'community-based alcohol use disorder treatment to either an EFT protocol or a control episodic recent thinking (ERT) protocol', 'EFT']","['delay discounting, alcohol demand, craving, self-efficacy, consideration of consequences, and mindfulness', 'alcohol demand indices, delay discounting rates', 'decision-making and alcohol motivation']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0016884', 'cui_str': 'Future'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332185', 'cui_str': 'Recent'}]","[{'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0686907', 'cui_str': 'Consequence of'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C3850035', 'cui_str': 'Intertemporal Preferences'}, {'cui': 'C0011109', 'cui_str': 'Decision making'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}]",28.0,0.0202314,"We observed patterns of reductions in alcohol demand indices, delay discounting rates, and an increase in mindfulness after both acute (1 session) and extended (4 sessions) exposure to EFT.","[{'ForeName': 'Herry', 'Initials': 'H', 'LastName': 'Patel', 'Affiliation': ""Peter Boris Centre for Addictions Research, McMaster University/St. Joseph's Healthcare Hamilton. Electronic address: patelhn@mcmaster.ca.""}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Amlung', 'Affiliation': ""Peter Boris Centre for Addictions Research, McMaster University/St. Joseph's Healthcare Hamilton; Michael G. DeGroote Centre for Medicinal Cannabis Research, McMaster University; Department of Psychiatry & Behavioural Neurosciences, McMaster University.""}]",Journal of substance abuse treatment,['10.1016/j.jsat.2020.108046'] 2098,32741502,Oxytocin-enhanced group therapy for methamphetamine use disorder: Randomized controlled trial.,"BACKGROUND Methamphetamine (METH) use is a public health crisis that disproportionately affects men who have sex with men (MSM). There are currently no FDA-approved pharmacological interventions to treat methamphetamine use disorder (MUD). MUD is associated with social impairments and extremely high treatment attrition rates. Administration of oxytocin, a neuropeptide involved in social attachment, may be a novel approach to addressing these issues. Moreover, oxytocin administration has shown promise for reducing METH-related addictive behavior in animal models, but has not yet been investigated in clinical trials for MUD. Last, oxytocin is known to modulate stress responsivity via regulation of the autonomic nervous system, which is dysregulated in METH users. We hypothesize that oxytocin, in combination with group psychotherapy, will increase treatment engagement, reduce addiction behavior, and mitigate stress hyperreactivity. METHODS This is a randomized, double blind trial of oxytocin 40-IU (n = 24) or placebo (n = 24) administered intranasally prior to each of six weekly motivational interviewing group therapy (MIGT) sessions for MUD in MSM. PRIMARY OUTCOME (a) session attendance. SECONDARY OUTCOMES (b) group cohesion, (c) anxiety, (d) METH craving, (e) METH use, and (f) in-session cardiac physiology. RESULTS Participants receiving oxytocin had significantly higher group therapy attendance than those receiving placebo, OR 3.26, 95% CI [1.27-8.41], p = .014. There was a small effect of oxytocin on group cohension, but not anxiety or craving. METH use did not change over the six-week MIGT course in either treatment arm. Participants receiving oxytocin had lower average heart rates during MIGT sessions and higher heart rate variability. There were positive main effects of MIGT over Time regardless of study drug. CONCLUSIONS This evidence, and the lack of any serious adverse events, suggests that oxytocin may safely increase treatment attendance. One possible mechanism by which it may do so is its modulation of the autonomic nervous system. Further investigation is warranted.",2020,"RESULTS Participants receiving oxytocin had significantly higher group therapy attendance than those receiving placebo, OR 3.26, 95% CI [1.27-8.41], p = .014.","['methamphetamine use disorder', 'men who have sex with men (MSM']","['motivational interviewing group therapy (MIGT) sessions for MUD in MSM', 'oxytocin', 'oxytocin 40-IU (n\xa0=\xa024) or placebo', 'MIGT', 'Methamphetamine (METH', 'Oxytocin-enhanced group therapy', 'placebo']","['addiction behavior', 'b) group cohesion, (c) anxiety, (d) METH craving', 'therapy attendance', 'average heart rates', 'heart rate variability', 'anxiety or craving', 'a) session attendance']","[{'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}]","[{'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0033971', 'cui_str': 'Group psychotherapy'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0085281', 'cui_str': 'Addiction'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}]",,0.674374,"RESULTS Participants receiving oxytocin had significantly higher group therapy attendance than those receiving placebo, OR 3.26, 95% CI [1.27-8.41], p = .014.","[{'ForeName': 'Christopher S', 'Initials': 'CS', 'LastName': 'Stauffer', 'Affiliation': 'San Francisco Veterans Affairs Medical Center, United States of America; University of California, San Francisco, United States of America; Portland Veterans Affairs Medical Center & Oregon Health and Science University, United States of America. Electronic address: christopher.stauffer@va.gov.'}, {'ForeName': 'Jenna M', 'Initials': 'JM', 'LastName': 'Moschetto', 'Affiliation': 'San Francisco Veterans Affairs Medical Center, United States of America; University of California, San Francisco, United States of America.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'McKernan', 'Affiliation': 'San Francisco Veterans Affairs Medical Center, United States of America; University of California, San Francisco, United States of America.'}, {'ForeName': 'Nathan', 'Initials': 'N', 'LastName': 'Meinzer', 'Affiliation': 'Slalom Consulting, LLC, United States of America.'}, {'ForeName': 'Chavy', 'Initials': 'C', 'LastName': 'Chiang', 'Affiliation': 'San Francisco Veterans Affairs Medical Center, United States of America.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Rapier', 'Affiliation': 'San Francisco Veterans Affairs Medical Center, United States of America.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'Hsiang', 'Affiliation': 'University of California, San Francisco, United States of America.'}, {'ForeName': 'Jerika', 'Initials': 'J', 'LastName': 'Norona', 'Affiliation': 'San Francisco Veterans Affairs Medical Center, United States of America.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Borsari', 'Affiliation': 'San Francisco Veterans Affairs Medical Center, United States of America; University of California, San Francisco, United States of America.'}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Woolley', 'Affiliation': 'San Francisco Veterans Affairs Medical Center, United States of America; University of California, San Francisco, United States of America.'}]",Journal of substance abuse treatment,['10.1016/j.jsat.2020.108059'] 2099,32741505,A randomized trial of an integrated cognitive behavioral treatment protocol for adolescents receiving home-based services for co-occurring disorders.,"The current study conducted a preliminary test of whether community mental health clinic staff could implement a multicomponent cognitive behavioral treatment, developed for adolescents with substance misuse (alcohol and/or marijuana) and comorbid psychiatric symptoms. We randomized a total of 111 families, with an adolescent 12-18 years old, referred to a home-based services program for youth with co-occurring substance use and mental health problems, to receive treatment from either masters-level therapists who received intensive cognitive behavioral therapy (I-CBT) training or from masters-level therapists who took part in a typical brief continuing education-style CBT workshop (treatment as usual, or TAU). Each family's therapist and insurance company determined the frequency and intensity of treatment. We administered follow-up assessments at 3, 6, and 12 months. There was a small, but not statistically significant, reduction in the percent days of heavy drinking and marijuana use over time for both conditions, with the overall effect across the three follow-up points favoring the I-CBT condition. There were no differences on alcohol use days or other drug use. There was also a small, but nonsignificant, positive effect over time on externalizing symptoms, depressed mood, and anxiety, favoring the I-CBT condition. Youth in the I-CBT condition relative to TAU had significantly fewer juvenile justice contacts, while the pattern of costly service use varied, with higher rates at 6-month and lower rates at 12-month follow-ups. If therapists pay greater attention to parent training and provide more parent-adolescent communication sessions, outcomes may improve above standard community care. Training enhancements, to better meet the needs of community therapists and their clinic settings, may also produce better overall results for parents and adolescents.",2020,"There was a small, but not statistically significant, reduction in the percent days of heavy drinking and marijuana use over time for both conditions, with the overall effect across the three follow-up points favoring the I-CBT condition.","['adolescents with substance misuse (alcohol and/or marijuana) and comorbid psychiatric symptoms', 'adolescents receiving home-based services for co-occurring disorders', 'community mental health clinic staff', '111 families, with an adolescent 12-18\xa0years old, referred to a home-based services program for youth with co-occurring substance use and mental health problems, to receive treatment from either masters-level therapists who received']","['integrated cognitive behavioral treatment protocol', 'multicomponent cognitive behavioral treatment', 'intensive cognitive behavioral therapy (I-CBT) training or from masters-level therapists who took part in a typical brief continuing education-style CBT workshop (treatment as usual, or TAU']","['externalizing symptoms, depressed mood, and anxiety', 'juvenile justice contacts']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0233401', 'cui_str': 'Psychiatric symptom'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C3839912', 'cui_str': 'Mental health clinic'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C1446377', 'cui_str': 'Mental health problem'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0444649', 'cui_str': 'Master'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]","[{'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0444649', 'cui_str': 'Master'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0013626', 'cui_str': 'Continuing Education'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0344315', 'cui_str': 'Depressed mood'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C3146221', 'cui_str': 'Juvenile'}, {'cui': 'C0022437', 'cui_str': 'Justice'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}]",111.0,0.0500393,"There was a small, but not statistically significant, reduction in the percent days of heavy drinking and marijuana use over time for both conditions, with the overall effect across the three follow-up points favoring the I-CBT condition.","[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Wolff', 'Affiliation': 'Brown University, Department of Psychiatry and Human Behavior, United States of America; Rhode Island Hospital, Providence, RI, United States of America. Electronic address: Jennifer_Wolff@Brown.edu.'}, {'ForeName': 'Christianne', 'Initials': 'C', 'LastName': 'Esposito-Smythers', 'Affiliation': 'George Mason University, United States of America.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Frazier', 'Affiliation': 'Brown University, Department of Psychiatry and Human Behavior, United States of America; Emma Pendleton Bradley Hospital, Riverside, RI, United States of America.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Stout', 'Affiliation': 'Brown University, Department of Psychiatry and Human Behavior, United States of America; Decision Sciences Institute, United States of America.'}, {'ForeName': 'Judy', 'Initials': 'J', 'LastName': 'Gomez', 'Affiliation': 'Brown University, Department of Psychiatry and Human Behavior, United States of America.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Massing-Schaffer', 'Affiliation': 'Brown University, Department of Psychiatry and Human Behavior, United States of America.'}, {'ForeName': 'Bridget', 'Initials': 'B', 'LastName': 'Nestor', 'Affiliation': 'Brown University, Department of Psychiatry and Human Behavior, United States of America.'}, {'ForeName': 'Shayna', 'Initials': 'S', 'LastName': 'Cheek', 'Affiliation': 'Brown University, Department of Psychiatry and Human Behavior, United States of America.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Graves', 'Affiliation': 'Brown University, Department of Psychiatry and Human Behavior, United States of America.'}, {'ForeName': 'Shirley', 'Initials': 'S', 'LastName': 'Yen', 'Affiliation': 'Brown University, Department of Psychiatry and Human Behavior, United States of America.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Hunt', 'Affiliation': 'Brown University, Department of Psychiatry and Human Behavior, United States of America; Emma Pendleton Bradley Hospital, Riverside, RI, United States of America.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Spirito', 'Affiliation': 'Brown University, Department of Psychiatry and Human Behavior, United States of America.'}]",Journal of substance abuse treatment,['10.1016/j.jsat.2020.108055'] 2100,32741619,First effective mHealth nutrition and lifestyle coaching program for subfertile couples undergoing in vitro fertilization treatment: a single-blinded multicenter randomized controlled trial.,"OBJECTIVE To study compliance and effectiveness of the mHealth nutrition and lifestyle coaching program Smarter Pregnancy in couples undergoing in vitro fertilization (IVF) treatment with or without intracytoplasmic sperm injection (ICSI). DESIGN Multicenter, single-blinded, randomized controlled trial, conducted from July 2014 to March 2017. SETTING IVF clinics. PATIENT(S) A total of 626 women undergoing IVF treatment with or without ICSI and 222 male partners. INTERVENTIONS(S) Couples were randomly assigned to the light (control group) or regular (intervention group) Smarter Pregnancy program. Both groups filled out a baseline screening questionnaire on nutrition and lifestyle behaviors, and the intervention group received coaching tailored to inadequate behaviors during the 24-week period. MAIN OUTCOME MEASURE(S) Difference in improvement of a composite dietary and lifestyle risk score for the intake of vegetables, fruits, folic acid supplements, smoking, and alcohol use after 24 weeks of the program. RESULT(S) Compared with control subjects, women and men in the intervention group showed a significantly larger improvement of inadequate nutrition behaviors after 24 weeks of coaching. At the same time, the women also showed a significantly larger improvement of inadequate lifestyle behaviors. CONCLUSION(S) The mHealth coaching program Smarter Pregnancy is effective and improves the most important nutritional and lifestyle behaviors among couples undergoing IVF/ICSI treatment. International multicenter randomized trials are recommended to study the effect of using Smarter Pregnancy on pregnancy, live birth, and neonatal outcome. NETHERLANDS TRIAL REGISTER NUMBER NTR4150.",2020,"Compared with control subjects, women and men in the intervention group showed a significantly larger improvement of inadequate nutrition behaviors after 24 weeks of coaching.","['couples undergoing in\xa0vitro fertilization (IVF) treatment with or without', 'couples undergoing IVF/ICSI treatment', 'conducted from July 2014 to March\xa02017', 'IVF clinics', 'subfertile couples undergoing in\xa0vitro fertilization treatment', '626 women undergoing IVF treatment with or without ICSI and 222 male partners']","['mHealth nutrition and lifestyle coaching program', 'intracytoplasmic sperm injection (ICSI', 'light (control group) or regular (intervention group', 'coaching tailored']","['composite dietary and lifestyle risk score', 'inadequate lifestyle behaviors', 'inadequate nutrition behaviors', 'pregnancy, live birth, and neonatal outcome']","[{'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0455164', 'cui_str': 'IVF - In vitro fertilization with intracytoplasmic sperm injection (ICSI)'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}]","[{'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0455164', 'cui_str': 'IVF - In vitro fertilization with intracytoplasmic sperm injection (ICSI)'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0557773', 'cui_str': 'Coach'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",626.0,0.0948992,"Compared with control subjects, women and men in the intervention group showed a significantly larger improvement of inadequate nutrition behaviors after 24 weeks of coaching.","[{'ForeName': 'Elsje C', 'Initials': 'EC', 'LastName': 'Oostingh', 'Affiliation': 'Department of Obstetrics and Gynecology, Erasmus Medical Center, University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Maria P H', 'Initials': 'MPH', 'LastName': 'Koster', 'Affiliation': 'Department of Obstetrics and Gynecology, Erasmus Medical Center, University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Matthijs R', 'Initials': 'MR', 'LastName': 'van Dijk', 'Affiliation': 'Department of Obstetrics and Gynecology, Erasmus Medical Center, University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Sten P', 'Initials': 'SP', 'LastName': 'Willemsen', 'Affiliation': 'Department of Obstetrics and Gynecology, Erasmus Medical Center, University Medical Center, Rotterdam, the Netherlands; Department of Biostatistics, Erasmus Medical Center, University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Frank J M', 'Initials': 'FJM', 'LastName': 'Broekmans', 'Affiliation': 'Division of Reproductive Medicine, Department of Obstetrics and Gynecology, University Medical Center, Utrecht, the Netherlands.'}, {'ForeName': 'Annemieke', 'Initials': 'A', 'LastName': 'Hoek', 'Affiliation': 'University of Groningen, Department of Obstetrics and Gynecology, University Medical Center, Groningen, the Netherlands.'}, {'ForeName': 'Marriëte', 'Initials': 'M', 'LastName': 'Goddijn', 'Affiliation': 'Center for Reproductive Medicine, Department of Obstetrics and Gynecology, University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Nicole F', 'Initials': 'NF', 'LastName': 'Klijn', 'Affiliation': 'Division of Reproductive Medicine, Department of Obstetrics and Gynecology, University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Evert J P', 'Initials': 'EJP', 'LastName': 'van Santbrink', 'Affiliation': 'Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Reinier de Graaf Gasthuis, Delft, the Netherlands.'}, {'ForeName': 'Eric A P', 'Initials': 'EAP', 'LastName': 'Steegers', 'Affiliation': 'Department of Obstetrics and Gynecology, Erasmus Medical Center, University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Joop S E', 'Initials': 'JSE', 'LastName': 'Laven', 'Affiliation': 'Department of Obstetrics and Gynecology, Erasmus Medical Center, University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Régine P M', 'Initials': 'RPM', 'LastName': 'Steegers-Theunissen', 'Affiliation': 'Department of Obstetrics and Gynecology, Erasmus Medical Center, University Medical Center, Rotterdam, the Netherlands. Electronic address: r.steegers@erasmusmc.nl.'}]",Fertility and sterility,['10.1016/j.fertnstert.2020.04.051'] 2101,32741642,"The effect of a single 75 mg preoperative dose of pregabalin on postoperative pain in rhinoplasty: A double-blinded, placebo-controlled randomized clinical trial.","The goal of this study was to evaluate the effect of a single preoperative dose of 75 mg of pregabalin on postoperative pain in rhinoplasty. Volunteers with a physical status of ASA I were included in our study after informed written consent. This was a randomized, double-blinded, placebo-controlled clinical trial. All pregabalin and placebo capsules were given to patients orally 1 h prior to surgery. A standard open rhinoplasty procedure was performed on all patients. All patients underwent the same general anesthesia and postoperative analgesic protocol, with the only difference between the two studied groups being the use of a single dose of pregabalin prior to surgery. Finally, pain intensity was measured at 2, 4, 6, 12, and 24 h after surgery, using a horizontal visual analogue scale (VAS), and was analyzed statistically. 128 volunteers - 33 men (25.8%) and 95 women (74.2%) - with a mean age of 26.23 ± 7.16 were included in this study. Pain intensity scores were consistently lower in patients who received pregabalin preoperatively (p = 0.002); however, the incidence of nausea, drowsiness, difficulty in concentrating, dry mouth, and constipation showed no differences between the two study groups (p > 0.05). In conclusion, the administration of pregabalin should be added to the perioperative protocol whenever appropriate.",2020,"p = 0.002); however, the incidence of nausea, drowsiness, difficulty in concentrating, dry mouth, and constipation showed no differences between the two study groups (p > 0.05).","['rhinoplasty', '128 volunteers - 33 men (25.8%) and 95 women (74.2%) - with a mean age of 26.23\xa0±\xa07.16 were included in this study', 'Volunteers with a physical status of ASA I']","['pregabalin', 'pregabalin and placebo', 'placebo']","['pain intensity', 'postoperative pain', 'horizontal visual analogue scale (VAS', 'incidence of nausea, drowsiness, difficulty in concentrating, dry mouth, and constipation', 'Pain intensity scores']","[{'cui': 'C0035467', 'cui_str': 'Rhinoplasty'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}]","[{'cui': 'C0657912', 'cui_str': 'pregabalin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0205126', 'cui_str': 'Horizontal'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0043352', 'cui_str': 'Xerostomia'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",128.0,0.422842,"p = 0.002); however, the incidence of nausea, drowsiness, difficulty in concentrating, dry mouth, and constipation showed no differences between the two study groups (p > 0.05).","[{'ForeName': 'Arash', 'Initials': 'A', 'LastName': 'Mohammadi', 'Affiliation': 'School of Dentistry, Kermanshah University of Medical Sciences (KUMS), Iran.'}, {'ForeName': 'Yasaman', 'Initials': 'Y', 'LastName': 'Yazdani', 'Affiliation': 'Clinical Trials Center, KUMS, Iran.'}, {'ForeName': 'Hesamedin', 'Initials': 'H', 'LastName': 'Nazari', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, School of Dentistry, KUMS, Iran. Electronic address: H.nazari@kums.ac.ir.'}, {'ForeName': 'Mansour', 'Initials': 'M', 'LastName': 'Choubsaz', 'Affiliation': 'Anesthesiology and Intensive Care, School of Medicine, KUMS, Iran.'}, {'ForeName': 'Bahram', 'Initials': 'B', 'LastName': 'Azizi', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, School of Dentistry, KUMS, Iran.'}, {'ForeName': 'Hamed', 'Initials': 'H', 'LastName': 'Nazari', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, School of Dentistry, KUMS, Iran.'}, {'ForeName': 'Roya', 'Initials': 'R', 'LastName': 'Safari-Faramani', 'Affiliation': 'Epidemiology, Research Center for Environmental Determinants of Health, KUMS, Iran.'}, {'ForeName': 'Seyed Mojtaba', 'Initials': 'SM', 'LastName': 'Amiri', 'Affiliation': 'Department of Biostatistics and Epidemiology, School of Health, KUMS, Iran.'}]",Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,['10.1016/j.jcms.2020.03.006'] 2102,32741710,Combining Platelet-Rich Plasma Instillation With Core Decompression Improves Functional Outcome and Delays Progression in Early-Stage Avascular Necrosis of Femoral Head: a 4.5- to 6-Year Prospective Randomized Comparative Study.,"BACKGROUND Avascular necrosis of femoral head is a debilitating disease frequently progressing to femoral head collapse and joint destruction. The efficacy of core decompression (CD) remains controversial. METHODS About 40 consecutive age-matched and gender-matched patients (53 hips) were randomized into 2 groups by computer-generated algorithm table in a prospective randomized double-blinded comparative study. Group A (platelet-rich plasma [PRP] with CD) included 19 patients (25 hips), and group B (CD only) included 21 patients (28 hips). Postoperative Harris Hip Score and magnetic resonance imaging to quantify the necrotic area by using modified Kerboul angle were done and evaluated. Mean follow-up was 64.3 months (range, 54-72) and 63.7 months (range, 56-72) in groups A and B, respectively. RESULTS There was statistically significant difference between PRP and control groups in pain score (P = .00), functional score (P = .02), and Harris Hip Score (P = .00) at final follow-up. There was no progression in stage 1 disease. Stage 2 disease showed 24% progression in group A and 43% progression in group B. The difference was statistically significant (P = .025). Survivorship from femoral head collapse, any procedure, and total hip arthroplasty was 84%/68% (P = .00), 76%/57% (P = .02), and 92%/78% (P = .01) in 2 groups, which was statistically significant. CONCLUSION PRP use after CD provides significant pain relief, better midterm functional outcome, retards the progression, and enhances the survivorship free from reoperation for hip arthroplasty and femoral head collapse in early stages of avascular necrosis of hip than CD alone.",2020,"There was statistically significant difference between PRP and control groups in pain score (P = .00), functional score (P = .02), and Harris Hip Score (P = .00) at final follow-up.","['Early-Stage Avascular Necrosis of Femoral Head', '40 consecutive age-matched and gender-matched patients (53 hips', '19 patients (25 hips), and group B (CD only) included 21 patients (28 hips']","['computer-generated algorithm table', 'core decompression (CD', 'platelet-rich plasma [PRP] with CD', 'Platelet-Rich Plasma Instillation With Core Decompression']","['pain relief', 'Functional Outcome and Delays Progression', 'Harris Hip Score', 'pain score', 'functional score', 'total hip arthroplasty']","[{'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0410480', 'cui_str': 'Avascular necrosis of the head of femur'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0011117', 'cui_str': 'Decompression'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0039224', 'cui_str': 'Table'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0011117', 'cui_str': 'Decompression'}, {'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0184959', 'cui_str': 'Instillation'}]","[{'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C2919875', 'cui_str': 'Harris hip score'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}]",,0.0526426,"There was statistically significant difference between PRP and control groups in pain score (P = .00), functional score (P = .02), and Harris Hip Score (P = .00) at final follow-up.","[{'ForeName': 'Aditya K', 'Initials': 'AK', 'LastName': 'Aggarwal', 'Affiliation': 'Department of Orthopaedic Surgery, Post Graduate Institute of Medical Education & Research, Chandigarh, India.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Poornalingam', 'Affiliation': 'Department of Orthopaedic Surgery, Post Graduate Institute of Medical Education & Research, Chandigarh, India.'}, {'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Jain', 'Affiliation': 'Department of Transfusion Medicine, Post Graduate Institute of Medical Education & Research, Chandigarh, India.'}, {'ForeName': 'Mahesh', 'Initials': 'M', 'LastName': 'Prakash', 'Affiliation': 'Department of Radiodiagnosis, Post Graduate Institute of Medical Education & Research, Chandigarh, India.'}]",The Journal of arthroplasty,['10.1016/j.arth.2020.07.010'] 2103,32741773,Ubiquinol supplementation in elderly patients undergoing aortic valve replacement: biochemical and clinical aspects.,"Epidemiological data show a rise in the mean age of patients affected by heart disease undergoing cardiac surgery. Senescent myocardium reduces the tolerance to ischemic stress and there are indications about age-associated deficit in post-operative cardiac performance. Coenzyme Q10 (CoQ10), and more specifically its reduced form ubiquinol (QH), improve several conditions related to bioenergetic deficit or increased exposure to oxidative stress. This trial (Eudra-CT 2009-015826-13) evaluated the clinical and biochemical effects of ubiquinol in 50 elderly patients affected by severe aortic stenosis undergoing aortic valve replacement and randomized to either placebo or 400 mg/day ubiquinol from 7 days before to 5 days after surgery. Plasma and cardiac tissue CoQ10 levels and oxidative status, circulating troponin I, CK-MB (primary endpoints), IL-6 and S100B were assessed. Moreover, main cardiac adverse effects, NYHA class, contractility and myocardial hypertrophy (secondary endpoints) were evaluated during a 6-month follow-up visit. Ubiquinol treatment counteracted the post-operative plasma CoQ10 decline (p<0.0001) and oxidation (p=0.038) and curbed the post-operative increase in troponin I (QH, 1.90 [1.47-2.48] ng/dL; placebo, 4.03 [2.45-6.63] ng/dL; p=0.007) related to cardiac surgery. Moreover, ubiquinol prevented the adverse outcomes that might have been associated with defective left ventricular ejection fraction recovery in elderly patients.",2020,Ubiquinol treatment counteracted the post-operative plasma CoQ10 decline (p<0.0001) and oxidation (p=0.038) and curbed the post-operative increase in troponin,"['50 elderly patients affected by severe aortic stenosis undergoing aortic valve replacement and randomized to either', 'elderly patients undergoing aortic valve replacement', 'mean age of patients affected by heart disease undergoing cardiac surgery', 'elderly patients']","['Coenzyme Q10 (CoQ10', 'Ubiquinol supplementation', 'placebo or 400 mg/day ubiquinol', 'dL; placebo']","['Plasma and cardiac tissue CoQ10 levels and oxidative status, circulating troponin', 'troponin', 'main cardiac adverse effects, NYHA class, contractility and myocardial hypertrophy (secondary endpoints', 'post-operative plasma CoQ10 decline (p<0.0001) and oxidation']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0522476', 'cui_str': 'Patient affected'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0003507', 'cui_str': 'Aortic valve stenosis'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0018799', 'cui_str': 'Heart disease'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}]","[{'cui': 'C0056077', 'cui_str': 'Ubiquinone'}, {'cui': 'C0077656', 'cui_str': 'ubiquinol'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C1272575', 'cui_str': 'Heart tissue'}, {'cui': 'C0056077', 'cui_str': 'Ubiquinone'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0041199', 'cui_str': 'Troponin'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C1275491', 'cui_str': 'New York Heart Association Classification'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C3495916', 'cui_str': 'Myocardial hypertrophy'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}]",50.0,0.241265,Ubiquinol treatment counteracted the post-operative plasma CoQ10 decline (p<0.0001) and oxidation (p=0.038) and curbed the post-operative increase in troponin,"[{'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Orlando', 'Affiliation': 'Department of Life and Environmental Sciences, Università Politecnica delle Marche, Via Brecce Bianche, Ancona 60100, Italy.'}, {'ForeName': 'Jacopo', 'Initials': 'J', 'LastName': 'Sabbatinelli', 'Affiliation': 'Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona 60100, Italy.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Silvestri', 'Affiliation': 'Department of Life and Environmental Sciences, Università Politecnica delle Marche, Via Brecce Bianche, Ancona 60100, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Marcheggiani', 'Affiliation': 'Department of Life and Environmental Sciences, Università Politecnica delle Marche, Via Brecce Bianche, Ancona 60100, Italy.'}, {'ForeName': 'Ilenia', 'Initials': 'I', 'LastName': 'Cirilli', 'Affiliation': 'Department of Life and Environmental Sciences, Università Politecnica delle Marche, Via Brecce Bianche, Ancona 60100, Italy.'}, {'ForeName': 'Phiwainkosi Vusi', 'Initials': 'PV', 'LastName': 'Dludla', 'Affiliation': 'Department of Life and Environmental Sciences, Università Politecnica delle Marche, Via Brecce Bianche, Ancona 60100, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Molardi', 'Affiliation': 'Cardiac Surgery Department, Parma University Hospital, Parma 43126, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Nicolini', 'Affiliation': 'Cardiac Surgery Department, Parma University Hospital, Parma 43126, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Tiano', 'Affiliation': 'Department of Life and Environmental Sciences, Università Politecnica delle Marche, Via Brecce Bianche, Ancona 60100, Italy.'}]",Aging,['10.18632/aging.103742'] 2104,32742199,Cost utility of a pharmacist-led minor ailment service compared with usual pharmacist care.,"Background A cluster randomised controlled trial (cRCT) performed from July 2018 to March 2019 demonstrated the clinical impact of a community pharmacist delivered minor ailment service (MAS) compared with usual pharmacist care (UC). MAS consisted of a technology-based face-to-face consultation delivered by trained community pharmacists. The consultation was guided by clinical pathways for assessment and management, and communication systems, collaboratively agreed with general practitioners. MAS pharmacists were trained and provided monthly practice support by a practice change facilitator. The objective of this study was to assess the cost utility of MAS, compared to UC. Methods Participants recruited were adult patients with symptoms suggestive of a minor ailment condition, from community pharmacies located in Western Sydney. Patients received MAS (intervention) or UC (control) and were followed-up by telephone 14-days following consultation with the pharmacist. A cost utility analysis was conducted alongside the cRCT. Transition probabilities and costs were directly derived from cRCT study data. Utility values were not available from the cRCT, hence we relied on utility values reported in the published literature which were used to calculate quality adjusted life years (QALYs), using the area under the curve method. A decision tree model was used to capture the decision problem, considering a societal perspective and a 14-day time horizon. Deterministic and probabilistic sensitivity analyses assessed robustness and uncertainty of results, respectively. Results Patients (n = 894) were recruited from 30 pharmacies and 82% (n = 732) responded to follow-up. On average, MAS was more costly but also more effective (in terms of symptom resolution and QALY gains) compared to UC. MAS patients (n = 524) gained an additional 0.003 QALYs at an incremental cost of $7.14 (Australian dollars), compared to UC (n = 370) which resulted in an ICER of $2277 (95% CI $681.49-3811.22) per QALY. Conclusion Economic findings suggest that implementation of MAS within the Australian context is cost effective. Trial registration Registered with Australian New Zealand Clinical Trials Registry (ANZCTR) and allocated the ACTRN: ACTRN12618000286246. Registered on 23 February 2018.",2020,"On average, MAS was more costly but also more effective (in terms of symptom resolution and QALY gains) compared to UC.","['Participants recruited were adult patients with symptoms suggestive of a minor ailment condition, from community pharmacies located in Western Sydney', 'Results\n\n\nPatients (n\u2009=\u2009894) were recruited from 30 pharmacies and 82% (n\u2009=\u2009732) responded to follow-up']","['community pharmacist delivered minor ailment service (MAS) compared with usual pharmacist care (UC', 'ACTRN', 'MAS', 'pharmacist-led minor ailment service compared with usual pharmacist care', 'MAS (intervention) or UC (control) and were followed-up by telephone 14-days following consultation with the pharmacist']",['cost utility of MAS'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332299', 'cui_str': 'Suggestive of'}, {'cui': 'C0026193', 'cui_str': 'Minor'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0009478', 'cui_str': 'Community Pharmacies'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0031321', 'cui_str': 'Pharmacy service'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0402003', 'cui_str': 'Community pharmacist'}, {'cui': 'C0026193', 'cui_str': 'Minor'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0026193', 'cui_str': 'Minor'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0557854', 'cui_str': 'Services'}]",,0.0986612,"On average, MAS was more costly but also more effective (in terms of symptom resolution and QALY gains) compared to UC.","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Dineen-Griffin', 'Affiliation': 'Graduate School of Health, University of Technology Sydney, Sydney, NSW Australia.'}, {'ForeName': 'Constanza', 'Initials': 'C', 'LastName': 'Vargas', 'Affiliation': 'Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, NSW Australia.'}, {'ForeName': 'Kylie A', 'Initials': 'KA', 'LastName': 'Williams', 'Affiliation': 'Graduate School of Health, University of Technology Sydney, Sydney, NSW Australia.'}, {'ForeName': 'Shalom I', 'Initials': 'SI', 'LastName': 'Benrimoj', 'Affiliation': 'University of Granada, Granada, Spain.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Garcia-Cardenas', 'Affiliation': 'Graduate School of Health, University of Technology Sydney, Sydney, NSW Australia.'}]",Cost effectiveness and resource allocation : C/E,['10.1186/s12962-020-00220-0'] 2105,32742206,"Diabetic Foot Surveillance Using Mobile Phones and Automated Software Messaging, a Randomized Observational Trial.","Background Early detection of diabetic foot ulcers can improve outcomes. However, patients do not always monitor their feet or seek medical attention when ulcers worsen. New approaches for diabetic-foot surveillance are needed. The goal of this study was to determine if patients would be willing and able to regularly photograph their feet; evaluate different foot-imaging approaches; and determine clinical adequacy of the resulting pictures. Methods We recruited adults with diabetes and assigned them to Self Photo (SP), Assistive Device (AD), or Other Party (OP) groups. The SP group photographed their own feet, while the AD group used a selfie stick; the OP group required another adult to photograph the patient's foot. For 8 weeks, we texted all patients requesting that they text us a photo of each foot. The collected images were evaluated for clinical adequacy. Numbers of (i) submitted and (ii) clinically useful images were compared among groups using generalized linear models and generalized linear mixed models. Results A total of 96 patients consented and 88 participated. There were 30 patients in SP, 29 in AD, and 29 in OP. The completion rate was 77%, with no significant differences among groups. However, 74.1% of photographs in SC, 83.7% in AD, 92.6% in OP were determined to be clinically adequate, and these differed statistically significantly. Conclusions Patients with diabetes are willing and able to take photographs of their feet, but using selfie sticks or having another adult take the photographs increases the clinical adequacy of the photographs. Level of Evidence: II .",2020,"The completion rate was 77%, with no significant differences among groups.","['adults with diabetes and assigned them to', '30 patients in SP, 29 in AD, and 29 in OP', '96 patients consented and 88 participated']","['Self Photo (SP), Assistive Device (AD), or Other Party (OP']","['completion rate', 'Numbers of (i) submitted and (ii) clinically useful images']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0036605', 'cui_str': 'Assistive equipment'}, {'cui': 'C2711213', 'cui_str': 'Consented'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0036605', 'cui_str': 'Assistive equipment'}]","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}]",96.0,0.112727,"The completion rate was 77%, with no significant differences among groups.","[{'ForeName': 'Chris A', 'Initials': 'CA', 'LastName': 'Anthony', 'Affiliation': 'Department of Orthopaedic Surgery University of Iowa, Iowa City, IA.'}, {'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'Femino', 'Affiliation': 'Department of Orthopedics and Rehabilitation.'}, {'ForeName': 'Aaron C', 'Initials': 'AC', 'LastName': 'Miller', 'Affiliation': 'Department of Epidemiology.'}, {'ForeName': 'Linnea A', 'Initials': 'LA', 'LastName': 'Polgreen', 'Affiliation': 'Department of Pharmacy Practice and Science.'}, {'ForeName': 'Edward O', 'Initials': 'EO', 'LastName': 'Rojas', 'Affiliation': 'Carver College of Medicine.'}, {'ForeName': 'Shelby L', 'Initials': 'SL', 'LastName': 'Francis', 'Affiliation': 'Department of Internal Medicine.'}, {'ForeName': 'Alberto M', 'Initials': 'AM', 'LastName': 'Segre', 'Affiliation': 'Department of Computer Science.'}, {'ForeName': 'Philip M', 'Initials': 'PM', 'LastName': 'Polgreen', 'Affiliation': 'Department of Epidemiology.'}]",The Iowa orthopaedic journal,[] 2106,32742286,Impact of Self-Efficacy Strategies Education on Self-Care Behaviors among Heart Failure Patients.,"Background: Self-efficacy in self-care behaviors is an effective framework for measuring patients' degree of ability to perform self-care behaviors that significantly affect their recovery process and quality of life. This study was designed to investigate the effects of education based on self-efficacy strategies on self-care behaviors in heart failure patients. Methods : A semi-experimental study was conducted on 80 heart failure patients divided into 2 equal groups of test and control. The intervention group received three 60-minute practical and theoretical training sessions based on self-care and self-efficacy strategies, while the control group received the usual care services. Self-care behaviors and self-efficacy were evaluated before training, shortly after training, and 3 months after the training program using the Sullivan self-efficacy questionnaire for heart failure patients and the European self-care behaviors questionnaires. Results : The mean age of the patients was 55.00±8.48 and 51.61±8.51 years in the intervention and control groups, respectively. Women comprised 73.7% (n=59) of the study population. The mean score for the self-care and self-efficacy questionnaires in the experimental group was 23.50±6.58 and 18.57±6.64, correspondingly, before the intervention, which increased to 42.64±6.74 (P<0.014) and 32.29±7.06 (P<0.001), respectively, shortly after the intervention. A significant improvement also occurred at 3 months' follow-up (P<0.001). Self-care behaviors also revealed a positive correlation with self-efficacy shortly after the intervention (r=0.82, P<0.001) and 3 months after the intervention (r=0.85, P<0.001). Conclusion : The implementation of educational interventions based on self-efficacy strategies could have positive effects on health-promoting behaviors among heart failure patients.",2020,"Self-care behaviors and self-efficacy were evaluated before training, shortly after training, and 3 months after the training program using the Sullivan self-efficacy questionnaire for heart failure patients and the European self-care behaviors questionnaires. ","['heart failure patients', '80 heart failure patients divided into 2 equal groups of test and control', 'Heart Failure Patients', 'heart failure patients and the European self-care behaviors questionnaires']","['Self-Efficacy Strategies Education', '60-minute practical and theoretical training sessions based on self-care and self-efficacy strategies, while the control group received the usual care services']","['Self-care behaviors', 'Self-care behaviors and self-efficacy', 'mean score for the self-care and self-efficacy questionnaires', 'Self-Care Behaviors']","[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0474417', 'cui_str': 'Self-care behavior'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C3853333', 'cui_str': 'Sixty minutes'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0557854', 'cui_str': 'Services'}]","[{'cui': 'C0474417', 'cui_str': 'Self-care behavior'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",80.0,0.0201471,"Self-care behaviors and self-efficacy were evaluated before training, shortly after training, and 3 months after the training program using the Sullivan self-efficacy questionnaire for heart failure patients and the European self-care behaviors questionnaires. ","[{'ForeName': 'Nooshin', 'Initials': 'N', 'LastName': 'Peyman', 'Affiliation': 'Department of Health Education and Health Promotion, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Fateme', 'Initials': 'F', 'LastName': 'Shahedi', 'Affiliation': 'Department of Radiology, School of Paramedical Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.'}, {'ForeName': 'Mahbubeh', 'Initials': 'M', 'LastName': 'Abdollahi', 'Affiliation': 'Department of Public Health, School of Health, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Doosti', 'Affiliation': 'Health Science Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Zohre', 'Initials': 'Z', 'LastName': 'Zadehahmad', 'Affiliation': 'Health Sciences Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.'}]",The journal of Tehran Heart Center,[] 2107,32742316,Radix Puerariae rebalances vasomotor factors and improves left ventricular diastolic dysfunction in patients with essential hypertension.,"The aim of the present study was to validate the beneficial role of Radix Puerariae in rebalancing the plasma levels of endothelin, angiotensin II (AngII) and calcitonin gene-related peptide (CGRP) in patients with essential hypertension (EHT). A total of 150 patients with EHT were enrolled consecutively and randomized to receive antihypertensive drugs according to guideline-directed medical therapy (GDMT group) and GDMT plus Radix Puerariae (GDMT + RP group). The blood pressure was recorded biweekly. At baseline and at the end of the follow-up (12 weeks), the plasma levels of endothelin, AngII and CGRP were detected, whilst the left ventricular (LV) diastolic function was evaluated by echocardiography. At baseline, the two groups did not differ in terms of demographic characteristics and LV diastolic dysfunction. At the end of the follow-up, lower blood pressure was observed in the GDMT + RP compared with that in the GDMT group. The plasma levels of AngII and endothelin were also significantly lower in the GDMT + RP group. The plasma levels of CGRP increased significantly in the GDMT + RP compared with those in the GDMT group. The addition of Radix Puerariae improved LV diastolic function, with the percentage of dysfunction decreasing to only 9%, while this percentage remained significantly elevated (21%) in the GDMT group. The results of the present study demonstrated that Radix Puerariae is able to regulate blood pressure and the plasma levels of endothelin, AngII and CGRP in patients with EHT. LV diastolic dysfunction was also improved, as detected by echocardiography.",2020,"At the end of the follow-up, lower blood pressure was observed in the GDMT + RP compared with that in the GDMT group.","['patients with essential hypertension (EHT', 'patients with essential hypertension', '150 patients with EHT', 'patients with EHT']","['GDMT + RP', 'antihypertensive drugs according to guideline-directed medical therapy (GDMT group) and GDMT plus Radix Puerariae (GDMT + RP group', 'GDMT']","['plasma levels of endothelin, AngII and CGRP', 'left ventricular (LV) diastolic function', 'blood pressure', 'demographic characteristics and LV diastolic dysfunction', 'plasma levels of CGRP', 'LV diastolic function', 'plasma levels of AngII and endothelin', 'LV diastolic dysfunction', 'left ventricular diastolic dysfunction', 'blood pressure and the plasma levels of endothelin, AngII and CGRP', 'plasma levels of endothelin, angiotensin II (AngII) and calcitonin gene-related peptide (CGRP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085580', 'cui_str': 'Essential hypertension'}, {'cui': 'C4321486', 'cui_str': '150'}]","[{'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0242726', 'cui_str': 'Plant roots'}, {'cui': 'C0950068', 'cui_str': 'Puerariae'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0079284', 'cui_str': 'Endothelin'}, {'cui': 'C0006669', 'cui_str': 'Calcitonin gene-related peptide'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0520863', 'cui_str': 'Diastolic dysfunction'}, {'cui': 'C1273070', 'cui_str': 'Left ventricular diastolic dysfunction'}, {'cui': 'C0003009', 'cui_str': 'angiotensin II'}]",150.0,0.0202948,"At the end of the follow-up, lower blood pressure was observed in the GDMT + RP compared with that in the GDMT group.","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Cardiology, Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, and The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Jinan, Shandong 250012, P.R. China.'}, {'ForeName': 'Su', 'Initials': 'S', 'LastName': 'Liang', 'Affiliation': 'Department of Traditional Chinese Medicine, Jinan Maternity and Child Care Hospital, Jinan, Shandong 250001, P.R. China.'}, {'ForeName': 'Peili', 'Initials': 'P', 'LastName': 'Bu', 'Affiliation': 'Department of Cardiology, Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, and The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Jinan, Shandong 250012, P.R. China.'}, {'ForeName': 'Ershun', 'Initials': 'E', 'LastName': 'Liang', 'Affiliation': 'Department of Cardiology, Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, and The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Jinan, Shandong 250012, P.R. China.'}, {'ForeName': 'Fangfang', 'Initials': 'F', 'LastName': 'Yan', 'Affiliation': 'Department of Traditional Chinese Medicine, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.'}, {'ForeName': 'Yifan', 'Initials': 'Y', 'LastName': 'Xing', 'Affiliation': 'Department of Traditional Chinese Medicine, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.'}, {'ForeName': 'Pengfei', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiology, Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, and The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Jinan, Shandong 250012, P.R. China.'}]",Experimental and therapeutic medicine,['10.3892/etm.2020.8746'] 2108,32742381,Effects of fast-track anesthesia on miR-1 and neuropeptides in serum of patients undergoing cardiac surgery.,"Effects of fast-track anesthesia (FTA) on miR-1 and neuropeptides in serum of patients undergoing cardiac surgery were investigated. A total of 147 patients who underwent cardiac surgery at Jining No. 1 people's Hospital from August 2015 to July 2018 were selected. There were 72 patients who received the FTA technology during cardiac surgery in the intervention group, and 75 patients who received routine anesthesia during cardiac surgery in the control group. Venous blood was, respectively, collected before anesthesia (T0), 30 min after artery opening (T1), 60 min after artery opening (T2), and 180 min after artery opening (T3). Expression of serum miR-1 in patients at T0 to T3 were detected by real-time fluorescence quantitative PCR. Expression of neuropeptide indexes such as neuron-specific enolase (NSE), S100β protein (S100β), and amyloid β-protein (Aβ) in serum of patients in the two groups at T0 to T3 were detected by ELISA, and the correlation of expression of serum miR-1, serum NSE, S100β and Aβ was analyzed. There was no significant difference in the expression of serum miR-1 between the two groups at T0 (P>0.05). There was no significant difference in the expression of NSE, S100β and Aβ between the two groups at T0 (P>0.05). Expression of serum NSE, S100β and Aβ in both groups increased gradually, and expression of serum NSE, S100β and Aβ in the intervention group were significantly lower than those in the control group at T1-T3 (P<0.05). There was a positive correlation between expression of serum miR-1, serum NSE, S100β and Aβ (r=0.773, P<0.05; r=0.683, P<0.05; r=0.769, P<0.05). Application of the FTA technology in cardiac surgery can effectively reduce the level of serum miR-1 in patients undergoing surgical treatment and improve their neurological function.",2020,"There was no significant difference in the expression of NSE, S100β and Aβ between the two groups at T0 (P>0.05).","['patients undergoing surgical treatment', '72 patients who received the FTA technology during cardiac surgery in the intervention group, and 75 patients who received', 'patients undergoing cardiac surgery', ""147 patients who underwent cardiac surgery at Jining No. 1 people's Hospital from August 2015 to July 2018 were selected""]","['fast-track anesthesia', 'fast-track anesthesia (FTA', 'FTA technology', 'routine anesthesia']","['Expression of neuropeptide indexes such as neuron-specific enolase (NSE), S100β protein (S100β), and amyloid β-protein (Aβ', 'expression of NSE, S100β and Aβ', 'expression of serum miR-1', 'expression of serum NSE, S100β and Aβ', 'expression of serum miR-1, serum NSE, S100β and Aβ', 'Expression of serum miR-1', 'Expression of serum NSE, S100β and Aβ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0040594', 'cui_str': 'Track'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0040594', 'cui_str': 'Track'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0027895', 'cui_str': 'Neuropeptide'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0202144', 'cui_str': 'Neuron-specific enolase measurement'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0002716', 'cui_str': 'Amyloid Substance'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1101610', 'cui_str': 'MicroRNA'}]",147.0,0.0224751,"There was no significant difference in the expression of NSE, S100β and Aβ between the two groups at T0 (P>0.05).","[{'ForeName': 'Hongxia', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, Jining No. 1 People's Hospital, Jining, Shandong 272011, P.R. China.""}, {'ForeName': 'Yongjian', 'Initials': 'Y', 'LastName': 'Chai', 'Affiliation': ""Department of Anesthesiology, First People's Hospital of Jinan, Jinan, Shandong 250000, P.R. China.""}, {'ForeName': 'Qinggang', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': ""Medical Department, The People's Hospital of Zhangqiu Area, Jinan, Shandong 250200, P.R. China.""}, {'ForeName': 'Qingtao', 'Initials': 'Q', 'LastName': 'Han', 'Affiliation': ""Interventional Vascular Diseases, The People's Hospital of Zhangqiu Area, Jinan, Shandong 250200, P.R. China.""}, {'ForeName': 'Zhenqian', 'Initials': 'Z', 'LastName': 'Lv', 'Affiliation': 'Cardiac Surgery, Qingdao Fuwai Cardiovascular Disease Hospital, Qingdao, Shandong 266034, P.R. China.'}]",Experimental and therapeutic medicine,['10.3892/etm.2020.8823'] 2109,32742410,Effects of rivastigmine hydrogen tartrate and donepezil hydrochloride on the cognitive function and mental behavior of patients with Alzheimer's disease.,"The present study aimed to examine the effects of rivastigmine hydrogen tartrate and donepezil hydrochloride on the cognitive function and mental behavior of patients with Alzheimer's disease (AD). For this purpose, a total of 126 patients with AD admitted to Luoyang Central Hospital from January, 2018 to December, 2018 were enrolled. Patients were divided into different groups according to the treatment they selected. Patients treated with single-agent donepezil were separated into a monotherapy group (n=56), and patients receiving donepezil plus rivastigmine were placed in the combination group (n=70). Before and after treatment, the cognitive functions, mental behavior and quality of life of the patients in the two groups were respectively evaluated by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), the Mini-Mental State Examination (MMSE), the Blessed-Roth Dementia Scale (BRDS) and the QOL-AD. In addition, the serum bradykinin level was detected by enzyme-linked immunosorbent assay. Following treatment, the MMSE score, BRDS, ADAS-Cog and QOL-AD scores were improved compared with those before treatment (P<0.05). However, following treatment, the 4 scores in the combination group were significantly higher than those in the monotherapy group (P<0.05). No significant differences were observed in the incidence of adverse reactions between the 2 groups (P>0.05). Following treatment, the bradykinin level in both groups was significantly decreased (P<0.05), although the decrease in the combination group was more significant than that in the monotherapy group (P<0.05). On the whole, the findings of the present study indicate that rivastigmine hydrogen tartrate used in combination with donepezil hydrochloride relieves the symptoms and improves the quality of life of patients with AD more effectively, which may be related to the reduction of the bradykinin level in these patients.",2020,"Following treatment, the MMSE score, BRDS, ADAS-Cog and QOL-AD scores were improved compared with those before treatment (P<0.05).","[""patients with Alzheimer's disease"", '126 patients with AD admitted to Luoyang Central Hospital from January, 2018 to December, 2018 were enrolled', ""patients with Alzheimer's disease (AD""]","['donepezil plus rivastigmine', 'single-agent donepezil', 'rivastigmine hydrogen tartrate and donepezil hydrochloride', 'donepezil hydrochloride']","['quality of life', 'cognitive function and mental behavior', ""Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), the Mini-Mental State Examination (MMSE), the Blessed-Roth Dementia Scale (BRDS) and the QOL-AD"", 'serum bradykinin level', 'incidence of adverse reactions', 'bradykinin level', 'cognitive functions, mental behavior and quality of life', 'MMSE score, BRDS, ADAS-Cog and QOL-AD scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0527316', 'cui_str': 'donepezil'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0649350', 'cui_str': 'rivastigmine'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0772415', 'cui_str': 'Rivastigmine tartrate'}, {'cui': 'C0771848', 'cui_str': 'Donepezil hydrochloride'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0450989', 'cui_str': ""Alzheimer's Disease Assessment Scale""}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0152110', 'cui_str': 'Meralgia paresthetica'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0006101', 'cui_str': 'Bradykinin measurement'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C2960235', 'cui_str': 'Mini-mental state examination score'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",126.0,0.022547,"Following treatment, the MMSE score, BRDS, ADAS-Cog and QOL-AD scores were improved compared with those before treatment (P<0.05).","[{'ForeName': 'Xiaohong', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Rehabilitation, Luoyang Central Hospital, Luoyang, Henan 471000, P.R. China.'}, {'ForeName': 'Ronghua', 'Initials': 'R', 'LastName': 'Yu', 'Affiliation': 'Department of Rehabilitation, Luoyang Central Hospital, Luoyang, Henan 471000, P.R. China.'}, {'ForeName': 'Huilin', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, Luoyang Central Hospital, Luoyang, Henan 471000, P.R. China.'}, {'ForeName': 'Ruifeng', 'Initials': 'R', 'LastName': 'Zheng', 'Affiliation': 'Department of Rehabilitation, Luoyang Central Hospital, Luoyang, Henan 471000, P.R. China.'}]",Experimental and therapeutic medicine,['10.3892/etm.2020.8872'] 2110,32742412,Quantification evaluation of structural autograft versus morcellized fragments autograft in patients who underwent single-level lumbar laminectomy.,"Posterolateral fusion (PLIF) with autogenous bone graft is considered the gold standard for lumbar spinal fusion. However, the fusion rate and effectiveness of locally derived corticocancellous structural autograft vs. morcellized fragments autograft for lumbar PLIF, following single level lumbar laminectomy in patients with symptomatic lumbar spinal stenosis, remain unknown. Thus, the present study aimed to compare the fusion rates of corticocancellous structural autograft and morcellized fragments autograft for the treatment of lumbar PLIF. A randomized self-controlled trial was conducted comprising of 135 patients with symptomatic lumbar spinal stenosis, single level lumbar laminectomy and PLIF, with corticocancellous structural autograft (group 1) and morcellized fragments autograft (group 2). The primary outcome measurements included the PLIF rate, radio density and dimensions of PLIF mass on both sides, which were assessed via X-rays at 3, 6 and 12 months, postoperatively. Furthermore, changes in bilateral bone fusion bridges were assessed via CT scanning, according to the Lenke CT fusion measurement criteria. The follow-up period lasted for 1 year (period between January 2013 and January 2018). Of the 135 patients were initially included in the present study, 7 patients were lost during the following up process. Therefore, data from 128 patents were eventually assessed, 94.8% of surgical levels were observed at Honghui Hospital. According to the Lenke CT fusion measurement criteria, the overall unilateral fusion rates were 71.9% (92/128) in group 1 and 31.3% (40/128) in group 2. Furthermore, both the radio density and dimensions of PLIF mass significantly decreased at a faster rate in group 1 compared with group 2 (radio density; 0.65-0.49 vs. 0.63-0.61; P<0.05 and PLIF mass; 398-124 vs. 376-223 mm 2 ; P<0.05). The CT scan results demonstrated that the mean volume of bone graft was significantly greater in group 1 compared with group 2, at 12 months postoperatively (1.47 vs. 1 cm 3 ; P<0.05). Taken together, the results of the present study suggested that corticocancellous structural autograft is more effective for earlier resorption and stabilization of patients undergoing PLIF, compared with morcellized fragments autograft.",2020,"The CT scan results demonstrated that the mean volume of bone graft was significantly greater in group 1 compared with group 2, at 12 months postoperatively (1.47 vs. 1 cm 3 ; P<0.05).","['135 patients were initially included in the present study, 7 patients were lost during the following up process', 'lumbar PLIF', '135 patients with symptomatic lumbar spinal stenosis, single level lumbar laminectomy and PLIF, with corticocancellous structural autograft (group 1) and morcellized fragments autograft (group 2', 'patients with symptomatic lumbar spinal stenosis', 'patients who underwent single-level lumbar laminectomy']","['structural autograft versus morcellized fragments autograft', 'Posterolateral fusion (PLIF) with autogenous bone graft', 'corticocancellous structural autograft and morcellized fragments autograft']","['bilateral bone fusion bridges', 'overall unilateral fusion rates', 'PLIF rate, radio density and dimensions of PLIF mass on both sides, which were assessed via X-rays', 'radio density and dimensions of PLIF mass', 'mean volume of bone graft']","[{'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0158288', 'cui_str': 'Spinal stenosis of lumbar region'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1112614', 'cui_str': 'Lumbar laminectomy'}, {'cui': 'C0040736', 'cui_str': 'Autogenous transplantation'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0332255', 'cui_str': 'Fragment of'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}]","[{'cui': 'C0040736', 'cui_str': 'Autogenous transplantation'}, {'cui': 'C0332255', 'cui_str': 'Fragment of'}, {'cui': 'C0332195', 'cui_str': 'Posterolateral'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0440800', 'cui_str': 'Autogenous bone graft'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0185364', 'cui_str': 'Osteoplasty'}, {'cui': 'C0221821', 'cui_str': 'Dental bridge'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0034546', 'cui_str': 'Radio'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0005976', 'cui_str': 'Bone graft'}]",7.0,0.0467972,"The CT scan results demonstrated that the mean volume of bone graft was significantly greater in group 1 compared with group 2, at 12 months postoperatively (1.47 vs. 1 cm 3 ; P<0.05).","[{'ForeName': 'Xiaobin', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': ""Department of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, School of Medicine, Xi'an, Shaanxi 710054, P.R. China.""}, {'ForeName': 'Dezhi', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesiology, Honghui Hospital, Xi'an Jiaotong University, School of Medicine, Xi'an, Shaanxi 710054, P.R. China.""}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': ""Department of Orthopedics, The Fifth Hospital of Province, Xi'an, Shaanxi 710000, P.R. China.""}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Yan', 'Affiliation': ""Department of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, School of Medicine, Xi'an, Shaanxi 710054, P.R. China.""}, {'ForeName': 'Dingjun', 'Initials': 'D', 'LastName': 'Hao', 'Affiliation': ""Department of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, School of Medicine, Xi'an, Shaanxi 710054, P.R. China.""}, {'ForeName': 'Baorong', 'Initials': 'B', 'LastName': 'He', 'Affiliation': ""Department of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, School of Medicine, Xi'an, Shaanxi 710054, P.R. China.""}]",Experimental and therapeutic medicine,['10.3892/etm.2020.8831'] 2111,32742427,"Effects of Zoledronic Acid Treatment on Fracture Healing, Morbidity and Mortality in Elderly Patients with Osteoporotic Hip Fractures.","Background In this study, the effects of zoledronic acid (ZolA) administered at different times to patients undergoing surgical treatment for hip fracture were investigated. Materials and methods Ninety patients who underwent surgical treatment for osteoporotic (OP) hip fractures between February 2013 and September 2016 in our hospital were included in the study. After surgical treatment, patients were allocated into three groups: group I-patients who had osteosynthesis using proximal femoral nail (PFN) for an intertrochanteric fracture of the femur were given ZolA within 1 week after fracture and before discharge; group II-patients who had osteosynthesis using the PFN for an intertrochanteric fracture of the femur were given ZolA within 1 month after fracture post-discharge; group III-patients in the same age group who had a hemiarthroplasty (HA) for an intertrochanteric fracture of the femur were administered ZolA before discharge. In addition, all patients were given daily oral calcium and vitamin D3. The Radiographic Union Score for Hip (RUSH), Harris Hip Score (HHS), and bone mineral density (BMD) were used at the follow-up as evaluation criteria, and complications were noted. Results There were no significant differences between groups in terms of demographic data and laboratory outcomes ( p > 0.05). Radiographic Union Score for Hip scores were similar between groups I and II ( p > 0.05). Fracture union occurred by the sixth month in all patients whose results were evaluated. No statistically significant difference was found between three groups ( p > 0.05). There was no difference between the three groups in the hip and vertebrae BMD and t scores ( p > 0.05). When t and BMD scores before treatment were compared with those at 1 year after treatment, a benefit from ZolA treatment was observed in all three groups ( p < 0.05). Conclusion This study shows that the timing of ZolA administration has no effect on fracture healing and complication incidence in elderly patients with hip fractures. In addition, ZolA was found to be beneficial in increasing BMD of both femur and vertebra in all groups, but there was no significant difference between the groups. Clinical significance The study demonstrated that ZolA may be used early in the treatment of osteoporotic hip fractures with PFN. How to cite this article Sargin S, Konya MN, Gulcu A, et al. Effects of Zoledronic Acid Treatment on Fracture Healing, Morbidity and Mortality in Elderly Patients with Osteoporotic Hip Fractures. Strategies Trauma Limb Reconstr 2019;14(3):126-131.",2019,There was no difference between the three groups in the hip and vertebrae BMD and t scores ( p > 0.05).,"['patients undergoing surgical treatment for hip fracture', 'Elderly Patients with Osteoporotic Hip Fractures', 'elderly patients with hip fractures', 'Ninety patients who underwent surgical treatment for osteoporotic (OP) hip fractures between February 2013 and September 2016 in our hospital were included in the study', 'osteoporotic hip fractures with PFN']","['oral calcium and vitamin D3', 'zoledronic acid (ZolA', 'osteosynthesis using proximal femoral nail (PFN', 'Zoledronic Acid Treatment', 'ZolA administration', 'ZolA within 1 week after fracture and before discharge; group II-patients who had osteosynthesis using the PFN for an intertrochanteric fracture of the femur were given ZolA within 1 month after fracture post-discharge; group III-patients in the same age group who had a hemiarthroplasty (HA', 'ZolA']","['Radiographic Union Score for Hip (RUSH), Harris Hip Score (HHS), and bone mineral density (BMD', 'hip and vertebrae BMD and t scores', 'Fracture union', 'demographic data and laboratory outcomes', 'BMD of both femur and vertebra', 'BMD scores', 'Radiographic Union Score for Hip scores', 'Fracture Healing, Morbidity and Mortality', 'fracture healing and complication incidence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0027342', 'cui_str': 'Nail plate structure'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0257685', 'cui_str': 'zoledronic acid'}, {'cui': 'C0016642', 'cui_str': 'Internal fixation of fracture'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0027342', 'cui_str': 'Nail plate structure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C1442452', 'cui_str': 'One week'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162385', 'cui_str': 'Intertrochanteric fracture'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}, {'cui': 'C0744743', 'cui_str': 'Hemi-Arthroplasty'}]","[{'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C2919875', 'cui_str': 'Harris hip score'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0549207', 'cui_str': 'Bone structure of spine'}, {'cui': 'C3854607', 'cui_str': 'T score'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0152231', 'cui_str': 'Fracture, healed'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",90.0,0.0158072,There was no difference between the three groups in the hip and vertebrae BMD and t scores ( p > 0.05).,"[{'ForeName': 'Serdar', 'Initials': 'S', 'LastName': 'Sargin', 'Affiliation': 'Department of Orthopaedics and Traumatology, Balıkesir University, Balıkesir, Turkey.'}, {'ForeName': 'Mehmet N', 'Initials': 'MN', 'LastName': 'Konya', 'Affiliation': 'Department of Orthopaedics and Traumatology, Afyon Kocatepe University, Afyonkarahisar, Turkey.'}, {'ForeName': 'Anıl', 'Initials': 'A', 'LastName': 'Gulcu', 'Affiliation': 'Department of Orthopaedics and Traumatology, Alaaddin Keykubat University, Alanya, Antalya, Turkey.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Aslan', 'Affiliation': 'Department of Orthopaedics and Traumatology, Alaaddin Keykubat University, Alanya, Antalya, Turkey.'}]",Strategies in trauma and limb reconstruction,['10.5005/jp-journals-10080-1439'] 2112,32742619,Combining group psychotherapy and yoga exercises improves quality of life in mental health professionals: a controlled randomized clinical trial.,"Purpose This study aims to investigate the effects of combining 12-week group psychotherapy with yoga exercises on stress perception and quality of life in mental health professionals. Design/methodology/approach This study was a parallel-arm randomized controlled trial, in which the participants was unaware of which group was the experimental one. Participants involved in our research were assigned to two groups of separate treatment that followed for three months group psychotherapy combined with yoga program for stress management or usual stress coping strategies. Findings The findings did not reveal a significant difference in stress perception assessed in the two groups either before or after intervention but reveal a significant difference in the quality of life in the two groups before and after the psycho behavioral interventions. Originality/value The findings did not reveal a significant difference in stress perception assessed in the two groups either before or after intervention but reveal a significant difference in the quality of life in the two groups before and after the psycho behavioral interventions.",2019,The findings did not reveal a significant difference in stress perception assessed in the two groups either before or after intervention but reveal a significant difference in the quality of life in the two groups before and after the psycho behavioral interventions.,['mental health professionals'],"['psychotherapy combined with yoga program for stress management or usual stress coping strategies', 'psychotherapy with yoga exercises', 'psychotherapy and yoga exercises']","['quality of life', 'stress perception and quality of life', 'Originality/value', 'stress perception']","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]","[{'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.0498848,The findings did not reveal a significant difference in stress perception assessed in the two groups either before or after intervention but reveal a significant difference in the quality of life in the two groups before and after the psycho behavioral interventions.,"[{'ForeName': 'Marilena', 'Initials': 'M', 'LastName': 'Maglia', 'Affiliation': 'CTA-Villa Chiara Psychiatric Rehabilitation Clinic and Research, Mascalucia, Italy and University of Catania, Catania, Italy.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Auditore', 'Affiliation': 'CTA-Villa Chiara Psychiatric Rehabilitation Clinic and Research, Mascalucia, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Pipitone', 'Affiliation': 'Vidya Vahini Trust, Uttarkashi, India and Yoga Vidya, Siracusa, Italy.'}, {'ForeName': 'Rachele', 'Initials': 'R', 'LastName': 'DiPasqua', 'Affiliation': 'CTA-Villa Chiara Psychiatric Rehabilitation Clinic and Research, Mascalucia, Italy.'}, {'ForeName': 'Lucio', 'Initials': 'L', 'LastName': 'Inguscio', 'Affiliation': 'Department of Psychology, University of Rome La Sapienza, Rome, Italy.'}, {'ForeName': 'Pasquale', 'Initials': 'P', 'LastName': 'Caponnetto', 'Affiliation': 'University of Catania, Catania, Italy.'}]",Mental illness,['10.1108/MIJ-10-2019-0007'] 2113,32742622,Effects of nature-based mindfulness training on resilience/symptom load in professionals with high work-related stress-levels: findings from the WIN-Study.,"Purpose The levels of work-related stress and the incidence rates of subsequent related illnesses are increasing in our society, leading to high individual and socioeconomic burdens. Mindfulness training has been shown to be an effective method of improving stress resilience. This paper aims to investigate the efficacy of nature-based mindfulness training in professionals with high levels of work-related stress. Design/methodology/approach In this controlled pilot study, a total of 56 volunteers completed a nature-based mindfulness training progam and were compared to 8 participants (waitlist controls). Psychometric assessments were performed at baseline and after two and four months of training. Findings After two months of training, the scores for self-efficacy, sense of coherence, level of mindfulness and overall psychiatric symptom load had significantly improved in the intervention group, while the control group did not show any significant improvements. A comparison between the intervention and control groups showed a significant difference regarding the sense of coherence only. Research limitations/implications Since this was an exploratory study with a small control group, further studies are needed to verify our findings. Practical implications In conclusion, nature-based mindfulness training seems to be a promising tool for the improvement of resilience and overall psychological health in professionals. Originality/value This was the first study to systematically investigate effects of nature-based mindfulness training in people with high work-related stress.",2019,"After two months of training, the scores for self-efficacy, sense of coherence, level of mindfulness and overall psychiatric symptom load had significantly improved in the intervention group, while the control group did not show any significant improvements.","['56 volunteers completed a nature-based mindfulness training progam and were compared to 8 participants (waitlist controls', 'professionals with high levels of work-related stress', 'professionals with high work-related stress-levels', 'people with high work-related stress']","['nature-based mindfulness training', 'Mindfulness training']","['scores for self-efficacy, sense of coherence, level of mindfulness and overall psychiatric symptom load', 'Originality/value', 'sense of coherence only']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0349590', 'cui_str': 'Nature'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0349590', 'cui_str': 'Nature'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C3178983', 'cui_str': 'Salutogenesis'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0233401', 'cui_str': 'Psychiatric symptom'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",56.0,0.0159639,"After two months of training, the scores for self-efficacy, sense of coherence, level of mindfulness and overall psychiatric symptom load had significantly improved in the intervention group, while the control group did not show any significant improvements.","[{'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Lücke', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital Bonn, Bonn, Germany.'}, {'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'Braumandl', 'Affiliation': 'GrenZENlos - Naturseminare, Neukirchen vorm Wald, Germany.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Becker', 'Affiliation': 'Comes Unternehmensberatung, Oldenburg, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Moeller', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital Bonn, Bonn, Germany.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Custal', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-Nuremberg, Nuremberg, Germany.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Philipsen', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital Bonn, Bonn, Germany.'}, {'ForeName': 'Helge H O', 'Initials': 'HHO', 'LastName': 'Müller', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital Bonn, Bonn, Germany.'}]",Mental illness,['10.1108/MIJ-10-2019-0001'] 2114,32742637,The effectiveness of a contingent financial incentive to improve trial follow up; a randomised study within a trial (SWAT).,"Objectives To evaluate the effectiveness of a contingent financial incentive (£10 note in addition to a routinely provided £10 voucher) versus no contingent financial incentive, on improving the retention rate in a randomised controlled trial (RCT). Methods A two arm 'Study within a Trial' (SWAT) embedded within a host RCT (SCIMITAR+). Participants were randomised to the SWAT using a 2:1 (intervention:control) allocation ratio. The primary outcome measure was the proportion of participants completing a CO breath measurement at the first SCIMITAR+ follow up time point (6 months). Secondary outcomes were withdrawing from follow-up after contact and time from assessment due date to completion.  Analyses were conducted using logistic or Cox Proportional Hazards regression as appropriate. Results A total of 434 participants were randomised into this SWAT. Completion of the CO breath measurement at 6 months was 88.5% (n=247) in the intervention arm of the SWAT and 85.4% (n=123) in the control arm (Difference 3.1%, OR 1.29, 95% CI 0.71-2.33, p=0.41). There was also no evidence of a difference in the proportion of participants withdrawing from follow-up after contact (intervention n=7 (2.5%), control n=5 (3.5%); OR 0.76, 95% CI 0.23-2.44, p=0.64), nor in terms of proximity of 6-month visit completion to due date (HR 1.07, 95% CI 0.86-1.33, p=0.55). Conclusion It is unclear if contingent financial incentives increased rates of face-to-face follow-up completion within the SCIMITAR+ trial population. However, the sample size of this SWAT was constrained by the size of the host trial and power was limited. This SWAT adds to the body of evidence for initiatives to increase response rates in trials.",2019,Contingent financial incentives did not statistically significantly increase rates of face-to-face follow-up completion within the SCIMITAR+ trial population.,['434 participants'],"['contingent financial incentive', ""Trial' (SWAT) embedded within a host RCT (SCIMITAR""]","['CO breath measurement', 'proportion of participants completing a CO breath measurement', 'withdrawing from follow-up after contact and time from assessment due date to completion']",[],"[{'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0225386', 'cui_str': 'Breath'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C2825543', 'cui_str': 'Estimated date of delivery'}]",434.0,0.270546,Contingent financial incentives did not statistically significantly increase rates of face-to-face follow-up completion within the SCIMITAR+ trial population.,"[{'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Arundel', 'Affiliation': 'Department of Health Sciences, University of York, York, YO10 5DD, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Coleman', 'Affiliation': 'Department of Health Sciences, University of York, York, YO10 5DD, UK.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Fairhurst', 'Affiliation': 'Department of Health Sciences, University of York, York, YO10 5DD, UK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Peckham', 'Affiliation': 'Department of Health Sciences, University of York, York, YO10 5DD, UK.'}, {'ForeName': 'Della', 'Initials': 'D', 'LastName': 'Bailey', 'Affiliation': 'Department of Health Sciences, University of York, York, YO10 5DD, UK.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Gilbody', 'Affiliation': 'Department of Health Sciences, University of York, York, YO10 5DD, UK.'}]",F1000Research,['10.12688/f1000research.21059.2'] 2115,32742642,A period of 10 weeks of increased protein consumption does not alter faecal microbiota or volatile metabolites in healthy older men: a randomised controlled trial.,"Diet has a major influence on the composition and metabolic output of the gut microbiome. Higher-protein diets are often recommended for older consumers; however, the effect of high-protein diets on the gut microbiota and faecal volatile organic compounds (VOC) of elderly participants is unknown. The purpose of the study was to establish if the faecal microbiota composition and VOC in older men are different after a diet containing the recommended dietary intake (RDA) of protein compared with a diet containing twice the RDA (2RDA). Healthy males (74⋅2 (sd 3⋅6) years; n 28) were randomised to consume the RDA of protein (0⋅8 g protein/kg body weight per d) or 2RDA, for 10 weeks. Dietary protein was provided via whole foods rather than supplementation or fortification. The diets were matched for dietary fibre from fruit and vegetables. Faecal samples were collected pre- and post-intervention for microbiota profiling by 16S ribosomal RNA amplicon sequencing and VOC analysis by head space/solid-phase microextraction/GC-MS. After correcting for multiple comparisons, no significant differences in the abundance of faecal microbiota or VOC associated with protein fermentation were evident between the RDA and 2RDA diets. Therefore, in the present study, a twofold difference in dietary protein intake did not alter gut microbiota or VOC indicative of altered protein fermentation.",2020,"After correcting for multiple comparisons, no significant differences in the abundance of faecal microbiota or VOC associated with protein fermentation were evident between the RDA and 2RDA diets.","['Healthy males (74⋅2 (sd 3⋅6) years; n 28', 'older men', 'healthy older men']",[],"['faecal microbiota composition and VOC', 'faecal microbiota or volatile metabolites', 'gut microbiota or VOC indicative of altered protein fermentation', 'abundance of faecal microbiota or VOC associated with protein fermentation']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0025266', 'cui_str': 'Man'}]",[],"[{'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C2350439', 'cui_str': 'Volatile Organic Compounds'}, {'cui': 'C0443769', 'cui_str': 'Volatile agent'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015852', 'cui_str': 'Fermentation'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}]",28.0,0.0232378,"After correcting for multiple comparisons, no significant differences in the abundance of faecal microbiota or VOC associated with protein fermentation were evident between the RDA and 2RDA diets.","[{'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Mitchell', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'E J', 'Initials': 'EJ', 'LastName': 'McKenzie', 'Affiliation': 'Department of Physiology, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'C J', 'Initials': 'CJ', 'LastName': 'Mitchell', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Milan', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Zeng', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'R F', 'Initials': 'RF', 'LastName': ""D'Souza"", 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Ramzan', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Sharma', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Rettedal', 'Affiliation': 'Food Nutrition & Health Team, AgResearch, Palmerston North, New Zealand.'}, {'ForeName': 'S O', 'Initials': 'SO', 'LastName': 'Knowles', 'Affiliation': 'Food Nutrition & Health Team, AgResearch, Palmerston North, New Zealand.'}, {'ForeName': 'N C', 'Initials': 'NC', 'LastName': 'Roy', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Sjödin', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Copenhagen University, Copenhagen, Denmark.'}, {'ForeName': 'K-H', 'Initials': 'KH', 'LastName': 'Wagner', 'Affiliation': 'Department of Nutritional Sciences and Research Platform Active Ageing, University of Vienna, Vienna, Austria.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': ""O'Sullivan"", 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Cameron-Smith', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}]",Journal of nutritional science,['10.1017/jns.2020.15'] 2116,32742646,Attenuation of glycaemic and insulin responses following tapioca resistant maltodextrin consumption in healthy subjects: a randomised cross-over controlled trial.,"Resistant maltodextrin (RMD) from various sources of starch has been extensively studied. However, studies which reported the effects of tapioca RMD (TRM) on glucose and insulin response are lacking. This study investigated the effect of TRM on postprandial plasma glucose and serum insulin in healthy subjects. Additionally, satiety and gastrointestinal tolerability were also evaluated. Sixteen healthy participants received five different treatments on five separate days. Participants received 50 g of either: glucose (GL), tapioca maltodextrin (TM), TRM, MIX15% (7⋅5 g TRM + 42⋅5 g TM) or MIX50% (25 g TRM + 25 g TM). Plasma glucose, serum insulin and subjective appetite responses were measured postprandially over 180 min. Gastrointestinal symptoms were evaluated by questionnaire before and after each test day. Results showed that at 30 min after treatment drinks, plasma glucose after TRM was significantly lowest (104⋅60 (sem 2⋅63 mg/dl) than after GL (135⋅87 (sem 4⋅88) mg/dl; P <0⋅001), TM (127⋅93 (sem 4⋅05) mg/dl; P = 0⋅001), MIX15% (124⋅67 (sem 5⋅73) mg/dl; P = 0⋅039) and MIX50% (129⋅33 (sem 5⋅23) mg/dl; P = 0⋅003) (1 mg/dl = 0⋅0555 mmol/l). In addition, TRM also significantly reduced serum insulin (13⋅01 (sem 2⋅12) μIU/ml) compared with GL (47⋅90 (sem 11⋅93) μIU/ml; P = 0⋅013), TM (52⋅96 (sem 17⋅68) μIU/ml; P = 0⋅002) and MIX50% (33⋅16 (sem 4⋅99) μIU/ml; P = 0⋅008). However, there were no significant differences in subjective appetite between treatments ( P > 0⋅05). A single high dose of TRM (50 g) caused flatulence ( P < 0⋅05). Tapioca resistant maltodextrin has low digestibility in the small intestine and, therefore, reduced incremental plasma glucose and serum insulin, without affecting satiety in healthy subjects over 180 min. Gastrointestinal tolerability of TRM should be considered when consumed in high doses.",2020,A single high dose of TRM (50 g) caused flatulence ( P < 0⋅05).,"['healthy subjects over 180 min', 'Sixteen healthy participants', 'healthy subjects']","['μIU', 'Tapioca resistant maltodextrin', 'tapioca RMD (TRM', 'tapioca resistant maltodextrin consumption', 'TRM', 'glucose (GL), tapioca maltodextrin (TM), TRM, MIX15% (7⋅5 g TRM + 42⋅5 g TM) or MIX50', 'Resistant maltodextrin (RMD']","['Plasma glucose, serum insulin and subjective appetite responses', 'serum insulin', 'postprandial plasma glucose and serum insulin', 'satiety and gastrointestinal tolerability', 'plasma glucose after TRM', 'Gastrointestinal tolerability', 'subjective appetite', 'flatulence', 'Gastrointestinal symptoms']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C3715157', 'cui_str': '16'}]","[{'cui': 'C0007335', 'cui_str': 'Manihot esculenta'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C1853698', 'cui_str': 'Rippling muscle disease'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}]","[{'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}]",16.0,0.0769949,A single high dose of TRM (50 g) caused flatulence ( P < 0⋅05).,"[{'ForeName': 'Junaida', 'Initials': 'J', 'LastName': 'Astina', 'Affiliation': 'Food and Nutrition Program, Department of Nutrition and Dietetics, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Suwimol', 'Initials': 'S', 'LastName': 'Sapwarobol', 'Affiliation': 'Department of Nutrition and Dietetics, Chulalongkorn University, Bangkok, Thailand.'}]",Journal of nutritional science,['10.1017/jns.2020.22'] 2117,32743079,"Testing the Mechanism of Action of Computerized Cognitive Training in Young Adults with Depression: Protocol for a Blinded, Randomized, Controlled Treatment Trial.","Background Depression is associated with a broad range of cognitive deficits, including processing speed (PS) and executive functioning (EF). Cognitive symptoms commonly persist with the resolution of affective symptoms and increase risk of relapse and recurrence. The cognitive control network is comprised of brain areas implicated in EF and mood regulatory functions. Prior research has demonstrated the effectiveness of computerized cognitive training (CCT) focused on PS and EF in mitigating both cognitive and affective symptoms of depression. Methods Ninety participants aged 18-29 with a current diagnosis of major depressive disorder or persistent depressive disorder, or a Hamilton Depression Rating Scale score ≥12, will be randomized to either PS/EF CCT, verbal CCT, or waitlist control. Participants in the active groups will complete 15 min of training 5 days/week for 8 weeks. Clinical and neuropsychological assessments will be completed at baseline, week 4, week 8, and 3-month follow-up. Structural and functional magnetic resonance imaging (fMRI) will be completed at baseline and week 8. We will compare changes in mood, cognition, daily functioning, and fMRI data. We will explore cognitive control network functioning using resting-state and task-based fMRI. Results Recruitment began in October 2019; we expect to finish recruitment by April 2022 and subsequently begin data analysis. Conclusions This study is innovative in that it will include both active and waitlist control conditions and will explore changes in neural activation. Identifying the neural networks associated with improvements following CCT will allow for the development of more precise and effective interventions. Trial Registration ClinicalTrials.gov NCT03869463; https://clinicaltrials.gov/ct2/show/NCT03869463.",2020,This study is innovative in that it will include both active and waitlist control conditions and will explore changes in neural activation.,"['Ninety participants aged 18-29 with a current diagnosis of major depressive disorder or persistent depressive disorder, or a Hamilton Depression Rating Scale score ≥12', 'Young Adults with Depression']","['computerized cognitive training (CCT', 'CCT', 'PS/EF CCT, verbal CCT, or waitlist control', 'Computerized Cognitive Training', 'functional magnetic resonance imaging (fMRI']","['processing speed (PS) and executive functioning (EF', 'mood, cognition, daily functioning, and fMRI data', 'risk of relapse and recurrence']","[{'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0013415', 'cui_str': 'Dysthymia'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]","[{'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",90.0,0.300516,This study is innovative in that it will include both active and waitlist control conditions and will explore changes in neural activation.,"[{'ForeName': 'Sara N', 'Initials': 'SN', 'LastName': 'Rushia', 'Affiliation': 'Department of Psychology, The Graduate Center, City University of New York, New York, NY 10016, USA.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Schiff', 'Affiliation': 'Department of Psychology, The Graduate Center, City University of New York, New York, NY 10016, USA.'}, {'ForeName': 'Dakota A', 'Initials': 'DA', 'LastName': 'Egglefield', 'Affiliation': 'Department of Psychology, The Graduate Center, City University of New York, New York, NY 10016, USA.'}, {'ForeName': 'Jeffrey N', 'Initials': 'JN', 'LastName': 'Motter', 'Affiliation': 'Department of Psychiatry, Columbia University Medical Center, New York, NY 10032, USA.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Grinberg', 'Affiliation': 'Department of Psychology, The Graduate Center, City University of New York, New York, NY 10016, USA.'}, {'ForeName': 'Daniel G', 'Initials': 'DG', 'LastName': 'Saldana', 'Affiliation': 'Department of Psychology, The Graduate Center, City University of New York, New York, NY 10016, USA.'}, {'ForeName': 'Al Amira Safa', 'Initials': 'AAS', 'LastName': 'Shehab', 'Affiliation': 'Department of Psychology, The Graduate Center, City University of New York, New York, NY 10016, USA.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Fan', 'Affiliation': 'Department of Psychology, Queens College, City University of New York, Flushing, NY 11367, USA.'}, {'ForeName': 'Joel R', 'Initials': 'JR', 'LastName': 'Sneed', 'Affiliation': 'Department of Psychology, The Graduate Center, City University of New York, New York, NY 10016, USA.'}]",Journal of psychiatry and brain science,['10.20900/jpbs.20200014'] 2118,32743082,"Assessing the potentials of two local topical ointments as affordable treatment against tungiasis infestation: A self-experimentation in Igbokoda, Nigeria.","Infestations caused by penetration of Tunga penetrans (Siphonaptera: Hectopsyllidae) in cutaneous sub-layers present morbidities and resulting mortalities if surgical treatment remains the obtainable. Considering the neglected nature of this infestation and the absence of marketable product, we report an observation on the use of grounded naphthalene in kerosene ointment, and powder of Piper guineense in coconut oil ointment as affordable treatment of embedded tungiasis flea in Igbokoda. A total of 80 individuals partitioned into two groups of 40 individuals each were assigned the locally made topical ointment irrespective of stages of tungiasis lesions. The mean of stage I, II and III tungiasis lesions treated with grounded naphthalene in kerosene ointment respectively decreased from 1.83, 3.42 and 3.89 to 0 after 5-6 days ( p  < .05). Also, the mean of stage I, II and III tungiasis lesions treated with grounded P. guineense ointment respectively decreased from 1.52, 3.10 and 5.00 to 0 after 6 to 7 days of treatment exposure ( p  < .05). Very high significant difference between stages and exposure days of participants assigned the two topical ointment was recorded p  < .0001 and p  = .0005 respectively. Naphthalene ointment and to a lesser extent P. guineense ointment is best to control and hinder development cycle of embedded fleas irrespective of infested part and stage of infection.",2020,Infestations caused by penetration of Tunga penetrans ,['80 individuals partitioned into two groups of 40 individuals each were assigned the locally made topical ointment irrespective of stages of tungiasis lesions'],['Naphthalene ointment'],"['mean of stage I, II and III tungiasis lesions']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0991554', 'cui_str': 'Cutaneous ointment'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0277356', 'cui_str': 'Tunga penetrans infestation'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]","[{'cui': 'C0027375', 'cui_str': 'Naphthalene'}, {'cui': 'C0028912', 'cui_str': 'Ointment'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0277356', 'cui_str': 'Tunga penetrans infestation'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]",80.0,0.0179476,Infestations caused by penetration of Tunga penetrans ,"[{'ForeName': 'Victor N', 'Initials': 'VN', 'LastName': 'Enwemiwe', 'Affiliation': 'Department of Animal and Environmental Biology, Delta State University, Abraka, Nigeria.'}, {'ForeName': 'Cynthia C', 'Initials': 'CC', 'LastName': 'Ojianwuna', 'Affiliation': 'Department of Animal and Environmental Biology, Delta State University, Abraka, Nigeria.'}, {'ForeName': 'Okorie O', 'Initials': 'OO', 'LastName': 'Anyaele', 'Affiliation': 'Department of Zoology, University of Ibadan, Ibadan, Nigeria.'}]",Parasite epidemiology and control,['10.1016/j.parepi.2020.e00168'] 2119,32743094,A novel approach for knee osteoarthritis using high molecular weight hyaluronic acid conjugated to plasma fibrinogen - interim findings of a double-blind clinical study.,"Objective Osteoarthritis (OA) is a widespread degenerative joint disease leading to progressive loss of function and pain. Available treatments do not provide long-term relief or improvement. This study aimed to assess the safety and efficacy of a novel intra articular supplement, made of high molecular-weight hyaluronic acid (HA) uniquely conjugated to either purified (RegenoGel) or autologous plasma-derived fibrinogen (RegenoGel-OSP), as a long-term treatment for knee OA. Methods Sixty-seven consecutive participants (mean age 67.26 ± 7 years) with symptomatic OA were randomly assigned to receive intraarticular injections of either RegenoGel, RegenoGel-OSP or saline solution (placebo). The active treatment groups received a second, repeat injection of the corresponding treatment at the 3-month evaluation, at which time, the placebo group was divided into two subgroups, one receiving RegenoGel and the other receiving RegenoGel-OSP. The OA symptoms were assessed by VAS, WOMAC, and IKDC questionnaires at baseline and at 1, 3, 4, and 6 months following the first injection. OA-related quality of life was evaluated by the SF-12 survey. Results Our preliminary data suggests that both fibrin-HA formulations have positive effects on OA symptoms for all assessed parameters with the most prominent trend for reduction in OA-associated pain. Pooled data analysis of RegenoGel and RegenoGel-OSP shows significantly improved VAS scores compared to placebo at three months after the first injection, and sustained for another three months after the second injection. Both RegenoGel, RegenoGel-OSP had an excellent safety profile. Conclusions Interim analysis results indicate that RegenoGel and RegenoGel-OSP are safe and are potentially effective for at least six months in alleviating pain and symptoms of knee OA.",2020,"Pooled data analysis of RegenoGel and RegenoGel-OSP shows significantly improved VAS scores compared to placebo at three months after the first injection, and sustained for another three months after the second injection.",['Methods\n\n\nSixty-seven consecutive participants (mean age 67.26 ± 7 years) with symptomatic OA'],"['RegenoGel and the other receiving RegenoGel-OSP', 'fibrin-HA formulations', 'novel intra articular supplement, made of high molecular-weight hyaluronic acid (HA) uniquely conjugated to either purified (RegenoGel) or autologous plasma-derived fibrinogen (RegenoGel-OSP', 'RegenoGel, RegenoGel-OSP or saline solution (placebo', 'RegenoGel and RegenoGel-OSP', 'placebo']","['VAS, WOMAC, and IKDC questionnaires', 'OA symptoms', 'OA-related quality of life', 'safety and efficacy', 'pain and symptoms of knee OA', 'VAS scores']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4517852', 'cui_str': '67'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}]","[{'cui': 'C0015982', 'cui_str': 'Fibrin'}, {'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0442108', 'cui_str': 'Intra-articular'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0026385', 'cui_str': 'Molecular Weight'}, {'cui': 'C0301869', 'cui_str': 'Conjugate'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0016006', 'cui_str': 'Fibrinogen'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",67.0,0.124489,"Pooled data analysis of RegenoGel and RegenoGel-OSP shows significantly improved VAS scores compared to placebo at three months after the first injection, and sustained for another three months after the second injection.","[{'ForeName': 'Leonid', 'Initials': 'L', 'LastName': 'Kandel', 'Affiliation': 'Joint Replacement and Reconstruction Unit, Department of Orthopedic Surgery, Hadassah Mount Scopus Hospital, Jerusalem, Israel.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Agar', 'Affiliation': 'Department of Orthopedic Surgery, Shamir Medical Center, Beer Yaakov, Israel.'}, {'ForeName': 'Ori', 'Initials': 'O', 'LastName': 'Elkayam', 'Affiliation': 'Rheumatology Institute, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel.'}, {'ForeName': 'Aybek', 'Initials': 'A', 'LastName': 'Sharipov', 'Affiliation': 'Department of Orthopedic Surgery, Shaarei Zedek Medical Center, Jerusalem, Israel.'}, {'ForeName': 'Omer', 'Initials': 'O', 'LastName': 'Slevin', 'Affiliation': 'Department of Orthopedic Surgery, Meir Medical Center, Kfar Saba, Israel.'}, {'ForeName': 'Gurion', 'Initials': 'G', 'LastName': 'Rivkin', 'Affiliation': 'Joint Replacement and Reconstruction Unit, Department of Orthopedic Surgery, Hadassah Mount Scopus Hospital, Jerusalem, Israel.'}, {'ForeName': 'Moshe', 'Initials': 'M', 'LastName': 'Dahan', 'Affiliation': 'Department of Orthopedic Surgery, Shamir Medical Center, Beer Yaakov, Israel.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Aloush', 'Affiliation': 'Rheumatology Institute, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel.'}, {'ForeName': 'Amos B', 'Initials': 'AB', 'LastName': 'Pyeser', 'Affiliation': 'Department of Orthopedic Surgery, Shaarei Zedek Medical Center, Jerusalem, Israel.'}, {'ForeName': 'Yaron', 'Initials': 'Y', 'LastName': 'Brin', 'Affiliation': 'Department of Orthopedic Surgery, Meir Medical Center, Kfar Saba, Israel.'}, {'ForeName': 'Yiftah', 'Initials': 'Y', 'LastName': 'Beer', 'Affiliation': 'Department of Orthopedic Surgery, Shamir Medical Center, Beer Yaakov, Israel.'}, {'ForeName': 'Avner', 'Initials': 'A', 'LastName': 'Yayon', 'Affiliation': 'Procore Ltd., Ness Ziona, Israel.'}]",Heliyon,['10.1016/j.heliyon.2020.e04475'] 2120,32743105,Virtual immersive sensorimotor training (VIST) in collegiate soccer athletes: A quasi-experimental study.,"A burgeoning area of innovation in sports is the use of extended realities to provide athletes with novel training environments. Evidence has demonstrated that virtual environments can be useful therapeutic tools with demonstrated positive outcomes. The purpose of this pilot investigation was to determine the effects of virtual immersive sensorimotor training intervention by quantifying 1) the training effect measured via change in performance pre-to post-intervention on the virtual reality exercises, 2) the difference in the in clinical measures of functional sensorimotor control, 3) the injury incidence rate, and 4) on-field performance during soccer competitions. Statistical analyses were used to describe differences between an experimental and a control group. Participants were recruited from the men and women's soccer teams at two universities in the United States. Participants at one university were in the experimental group (n = 78) and received virtual immersive sensorimotor training, consisting of nine novel exercises in headset virtual reality, twice each week for six weeks. Participants at the second university were in the control group (n = 52). The virtual exercises were developed with reference to the rehabilitative principles of neuroplasticity to train various neurologic processes, contributing to overall sensorimotor control. This includes vestibular, visual and oculomotor activities, cervical neuromotor control training, movement coordination, and postural/balance exercises. The results indicate significant positive training effects pre-to post-intervention in seven of the nine training exercises (p ≤ 0.005) and improvement in clinical tests of cervical neuromotor control, balance, and inspection time (p ≤ 0.009) in the experimental group compared to the control. One of the virtual training exercises was positively associated with on-field performance (p = 0.022). No differences in injury rate or overall on-field performance metrics between the experimental and control were detected. This research study provides evidence of training and positive transfer from virtual to real-world environments, supporting the use of these novel virtual exercises to improve measures of sensorimotor control in healthy soccer athletes.",2020,No differences in injury rate or overall on-field performance metrics between the experimental and control were detected.,"['collegiate soccer athletes', 'Participants at one university were in the experimental group (n = 78) and received', 'Participants at the second university were in the control group (n = 52', ""Participants were recruited from the men and women's soccer teams at two universities in the United States"", 'healthy soccer athletes']","['virtual immersive sensorimotor training, consisting of nine novel exercises in headset virtual reality', 'virtual immersive sensorimotor training intervention', 'cervical neuromotor control training, movement coordination, and postural/balance exercises', 'Virtual immersive sensorimotor training (VIST']","['clinical tests of cervical neuromotor control, balance, and inspection time', 'injury rate or overall on-field performance metrics']","[{'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1301808', 'cui_str': 'State'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0150219', 'cui_str': 'Balance exercises'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0199219', 'cui_str': 'Inspection'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0699680', 'cui_str': 'Metric'}]",78.0,0.0236732,No differences in injury rate or overall on-field performance metrics between the experimental and control were detected.,"[{'ForeName': 'Jennifer C', 'Initials': 'JC', 'LastName': 'Reneker', 'Affiliation': 'Department of Population Health Sciences, School of Population Health, University of Mississippi Medical Center, USA.'}, {'ForeName': 'W Cody', 'Initials': 'WC', 'LastName': 'Pannell', 'Affiliation': 'Department of Physical Therapy, School of Health Related Professions, University of Mississippi Medical Center, USA.'}, {'ForeName': 'Ryan M', 'Initials': 'RM', 'LastName': 'Babl', 'Affiliation': 'Department of Physical Therapy, School of Health Related Professions, University of Mississippi Medical Center, USA.'}, {'ForeName': 'Yunxi', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Data Science, School of Population Health, University of Mississippi Medical Center, USA.'}, {'ForeName': 'Seth T', 'Initials': 'ST', 'LastName': 'Lirette', 'Affiliation': 'Department of Data Science, School of Population Health, University of Mississippi Medical Center, USA.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Adah', 'Affiliation': 'Department of Physical Therapy, School of Health Related Professions, University of Mississippi Medical Center, USA.'}, {'ForeName': 'Matthew R', 'Initials': 'MR', 'LastName': 'Reneker', 'Affiliation': 'Athletic Department, Mississippi College, USA.'}]",Heliyon,['10.1016/j.heliyon.2020.e04527'] 2121,32738891,Effects of anesthetic method on inflammatory response in patients with Parkinson's disease: a randomized controlled study.,"BACKGROUND The pathogenesis of Parkinson's disease (PD) involves degeneration of dopaminergic neurons, which is influenced by innate and adaptive immunity. IL-17 is a characteristic cytokine secreted by Th17 cells, which acts as a powerful stimulator of neutrophil migration and infiltration and promotes the secretion of inflammatory cytokines. General anesthesia and surgical stress induce immune and inflammatory responses that activate the immunosuppressive mechanism in the perioperative period. The present study investigated changes in levels of inflammatory cytokines, such as IL-17, IL-1β, and TNF-α, in patients with PD undergoing general anesthesia with inhalational anesthetics or TIVA. METHODS Adult patients, aged 40-75 years, scheduled for cerebral stimulator implantation were enrolled. Upon arrival at the operating theater, patients were allocated to the inhalational (I) or TIVA (T) group using block randomization. In group I, anesthesia was induced by tracheal intubation 1-2 min after intravenous administration of propofol (1-2 mg/kg) and rocuronium (0.6-1 mg/kg). Thereafter, anesthesia was maintained with 1-2 vol% sevoflurane, 0.01-0.2 μg/kg/min remifentanil, and O 2 /air (FiO 2 0.4). In group T, propofol (3-6 μg/mL), remifentanil (2-6 ng/mL), and rocuronium (0.6-1 mg/kg) were administered using target controlled infusion (TCI) for induction of anesthesia. Blood samples were obtained preoperatively (T0), 2 h after induction of anesthesia (T1), and 24 h after surgery (T2). IL-17, IL-1β, and TNF-α levels were evaluated by ELISA. RESULTS Serum levels of IL-17 were elevated at T2 in group I compared to group T but the difference was not statistically significant. IL-1β tended to be greater in group I compared to group T, but the differences were not significant. TNF-α was slightly higher at all time points in group T and showed a tendency to increase at T2 in both groups, but this was not statistically significant. CONCLUSIONS TIVA may be useful for inhibiting neuroinflammation by inhibiting the increase in serum levels of IL-17 24 h after implantation surgery. Serum IL-17 level may be used as a biomarker for PD progression. TRIAL REGISTRATION Clinical Research Information Service of Korea National Institute of Health (CRIS) Identification number: KCT0002061 . Registered 25 October 2019 - Retrospectively registered, https://cris.nih.go.kr/cris/search/search_result_st01.jsp?seq=15125.",2020,"RESULTS Serum levels of IL-17 were elevated at T2 in group I compared to group T but the difference was not statistically significant.","['Korea National Institute of Health (CRIS', ""patients with Parkinson's disease"", 'patients with PD undergoing general anesthesia with', 'Adult patients, aged 40-75\u2009years, scheduled for cerebral stimulator implantation were enrolled', 'Registered 25 October 2019 - Retrospectively registered, https://cris.nih.go.kr/cris/search/search_result_st01.jsp?seq=15125']","['rocuronium', 'inhalational (I) or TIVA (T', 'anesthetic method', 'inhalational anesthetics or TIVA', 'remifentanil', 'propofol', 'IL-17']","['IL-1β', 'levels of inflammatory cytokines, such as IL-17, IL-1β, and TNF-α', 'TNF-α', 'Serum levels of IL-17', 'IL-17, IL-1β, and TNF-α levels', 'inflammatory response', 'Serum IL-17 level']","[{'cui': 'C0022771', 'cui_str': 'Korea'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0175727', 'cui_str': 'Stimulator'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0600375', 'cui_str': 'Registers'}]","[{'cui': 'C0209337', 'cui_str': 'Rocuronium'}, {'cui': 'C3854651', 'cui_str': 'TIVA'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0384648', 'cui_str': 'Interleukin 17'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0384648', 'cui_str': 'Interleukin 17'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",,0.16134,"RESULTS Serum levels of IL-17 were elevated at T2 in group I compared to group T but the difference was not statistically significant.","[{'ForeName': 'Won Jung', 'Initials': 'WJ', 'LastName': 'Hwang', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, South Korea.""}, {'ForeName': 'Min A', 'Initials': 'MA', 'LastName': 'Joo', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, South Korea.""}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Joo', 'Affiliation': ""Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, South Korea. jiyo1004@catholic.ac.kr.""}]",BMC anesthesiology,['10.1186/s12871-020-01112-9'] 2122,32738911,Transcutaneous Neuromodulation improved inflammation and sympathovagal ratio in patients with primary biliary ssscholangitis and inadequate response to Ursodeoxycholic acid: a pilot study.,"BACKGROUND At present, ursodeoxycholic acid (UDCA) is internationally recognized as a therapeutic drug in clinic. However, about 40% Primary Biliary Cholangitis (PBC) patients are poor responders to UDCA. It has been demonstrated that Transcutaneous Neuromodulation (TN) can be involved in gut motility, metabolism of bile acids, immune inflammation, and autonomic nerve. Therefore, this study aimed to explore the effect of TN combined with UDCA on PBC and related mechanisms. METHODS According to inclusion and exclusion criteria, 10 healthy volunteers and 15 PBC patients were recruited to control group and TN group, respectively. PBC patients were alternately but blindly assigned to group A (TN combined with UDCA) and group B (sham-TN combined with UDCA), and a crossover design was used. The TN treatment was performed via the posterior tibial nerve and acupoint ST36 (Zusanli) 1 h twice/day for 2 weeks. T test and nonparametric test were used to analyze the data. RESULTS 1. TN combined with UDCA improved the liver function of PBC patients shown by a significant decrease of alkaline phosphatase and gamma-glutamyltransferase (γ-GT) (P < 0.05). 2. The treatment also decreased serum IL-6 levels (P < 0.05), but not the level of Tumor Necrosis Factor-α, IL-1β or IL-10. 3. TN combined with UDCA regulated autonomic function, enhanced vagal activity, and decreased the sympathovagal ratio assessed by the spectral analysis of heart rate variability (P < 0.05). 4. There was no change in 13 bile acids in serum or stool after TN or sham-TN. CONCLUSIONS TN cssombined with UDCA can significantly improve the liver function of PBC patients. It is possibly via the cholinergic anti-inflammatory pathway. TN might be a new non-drug therapy for PBC. Further studies are required. TRIAL REGISTRATION The study protocol was registered in Chinese Clinical Trial Registry (number ChiCTR1800014633 ) on 25 January 2018.",2020,"The treatment also decreased serum IL-6 levels (P < 0.05), but not the level of Tumor Necrosis Factor-α, IL-1β or IL-10. 3.","['10 healthy volunteers and 15 PBC patients', 'patients with primary biliary ssscholangitis', 'PBC patients']","['Ursodeoxycholic acid', 'ursodeoxycholic acid (UDCA', 'TN combined with UDCA) and group B (sham-TN combined with UDCA', 'Transcutaneous Neuromodulation (TN', 'TN combined with UDCA', 'UDCA', 'Transcutaneous Neuromodulation']","['inflammation and sympathovagal ratio', 'UDCA regulated autonomic function, enhanced vagal activity', '13 bile acids in serum or stool', 'alkaline phosphatase and gamma-glutamyltransferase (γ-GT', 'serum IL-6 levels', 'liver function', 'sympathovagal ratio']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0008312', 'cui_str': 'Primary biliary cholangitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}]","[{'cui': 'C0042105', 'cui_str': 'ursodeoxycholic acid'}, {'cui': 'C0394674', 'cui_str': 'Neurostimulation/modulation'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0042105', 'cui_str': 'ursodeoxycholic acid'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0005390', 'cui_str': 'Bile acid'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0017040', 'cui_str': 'Gamma-glutamyltransferase'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0232741', 'cui_str': 'Liver function'}]",10.0,0.0241157,"The treatment also decreased serum IL-6 levels (P < 0.05), but not the level of Tumor Necrosis Factor-α, IL-1β or IL-10. 3.","[{'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'The Second Department of Gastroenterology, The First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Dalian, 116011, Liaoning, China.'}, {'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Department of Gastroenterology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Wu Hou District, Chengdu, 610041, China.'}, {'ForeName': 'Lixia', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'The Second Department of Gastroenterology, The First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Dalian, 116011, Liaoning, China.'}, {'ForeName': 'Honggang', 'Initials': 'H', 'LastName': 'Shi', 'Affiliation': 'The Second Department of Gastroenterology, The First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Dalian, 116011, Liaoning, China.'}, {'ForeName': 'Bojia', 'Initials': 'B', 'LastName': 'Liu', 'Affiliation': 'The Second Department of Gastroenterology, The First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Dalian, 116011, Liaoning, China.'}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Lin', 'Affiliation': 'The Second Department of Gastroenterology, The First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Dalian, 116011, Liaoning, China.'}, {'ForeName': 'Qingyong', 'Initials': 'Q', 'LastName': 'Chang', 'Affiliation': 'The Second Department of Neurosurgery, Affiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Dalian, 116001, Liaoning, China. qychang0409@163.com.'}, {'ForeName': 'Jiande D Z', 'Initials': 'JDZ', 'LastName': 'Chen', 'Affiliation': 'Division of Gastroenterology and Hepatology, Johns Hopkins Center for Neurogastroenterology, Baltimore, MD, 21224, USA. jiandedzchen@gmail.com.'}, {'ForeName': 'Zhijun', 'Initials': 'Z', 'LastName': 'Duan', 'Affiliation': 'The Second Department of Gastroenterology, The First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Dalian, 116011, Liaoning, China. cathydoctor@sina.com.'}]",BMC complementary medicine and therapies,['10.1186/s12906-020-03036-w'] 2123,32738955,"Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.","BACKGROUND Treatment of dysplastic Barrett's oesophagus prevents progression to adenocarcinoma; however, the optimal diagnostic strategy for Barrett's oesophagus is unclear. The Cytosponge-trefoil factor 3 (TFF3) is a non-endoscopic test for Barrett's oesophagus. The aim of this study was to investigate whether offering this test to patients on medication for gastro-oesophageal reflux would increase the detection of Barrett's oesophagus compared with standard management. METHODS This multicentre, pragmatic, randomised controlled trial was done in 109 socio-demographically diverse general practice clinics in England. Randomisation was done both at the general practice clinic level (cluster randomisation) and at the individual patient level, and the results for each type of randomisation were analysed separately before being combined. Patients were eligible if they were aged 50 years or older, had been taking acid-suppressants for symptoms of gastro-oesophageal reflux for more than 6 months, and had not undergone an endoscopy procedure within the past 5 years. General practice clinics were selected by the local clinical research network and invited to participate in the trial. For cluster randomisation, clinics were randomly assigned (1:1) by the trial statistician using a computer-generated randomisation sequence; for individual patient-level randomisation, patients were randomly assigned (1:1) by the general practice clinics using a centrally prepared computer-generated randomisation sequence. After randomisation, participants received either standard management of gastro-oesophageal reflux (usual care group), in which participants only received an endoscopy if required by their general practitioner, or usual care plus an offer of the Cytosponge-TFF3 procedure, with a subsequent endoscopy if the procedure identified TFF3-positive cells (intervention group). The primary outcome was the diagnosis of Barrett's oesophagus at 12 months after enrolment, expressed as a rate per 1000 person-years, in all participants in the intervention group (regardless of whether they had accepted the offer of the Cytosponge-TFF3 procedure) compared with all participants in the usual care group. Analyses were intention-to-treat. The trial is registered with the ISRCTN registry, ISRCTN68382401, and is completed. FINDINGS Between March 20, 2017, and March 21, 2019, 113 general practice clinics were enrolled, but four clinics dropped out shortly after randomisation. Using an automated search of the electronic prescribing records of the remaining 109 clinics, we identified 13 657 eligible patients who were sent an introductory letter with 14 days to opt out. 13 514 of these patients were randomly assigned (per practice or at the individual patient level) to the usual care group (n=6531) or the intervention group (n=6983). Following randomisation, 149 (2%) of 6983 participants in the intervention group and 143 (2%) of 6531 participants in the usual care group, on further scrutiny, did not meet all eligibility criteria or withdrew from the study. Of the remaining 6834 participants in the intervention group, 2679 (39%) expressed an interest in undergoing the Cytosponge-TFF3 procedure. Of these, 1750 (65%) met all of the eligibility criteria on telephone screening and underwent the procedure. Most of these participants (1654 [95%]; median age 69 years) swallowed the Cytosponge successfully and produced a sample. 231 (3%) of 6834 participants had a positive Cytosponge-TFF3 result and were referred for an endoscopy. Patients who declined the offer of the Cytosponge-TFF3 procedure and all participants in the usual care group only had an endoscopy if deemed necessary by their general practitioner. During an average of 12 months of follow-up, 140 (2%) of 6834 participants in the intervention group and 13 (<1%) of 6388 participants in the usual care group were diagnosed with Barrett's oesophagus (absolute difference 18·3 per 1000 person-years [95% CI 14·8-21·8]; rate ratio adjusted for cluster randomisation 10·6 [95% CI 6·0-18·8], p<0·0001). Nine (<1%) of 6834 participants were diagnosed with dysplastic Barrett's oesophagus (n=4) or stage I oesophago-gastric cancer (n=5) in the intervention group, whereas no participants were diagnosed with dysplastic Barrett's oesophagus or stage I gastro-oesophageal junction cancer in the usual care group. Among 1654 participants in the intervention group who swallowed the Cytosponge device successfully, 221 (13%) underwent endoscopy after testing positive for TFF3 and 131 (8%, corresponding to 59% of those having an endoscopy) were diagnosed with Barrett's oesophagus or cancer. One patient had a detachment of the Cytosponge from the thread requiring endoscopic removal, and the most common side-effect was a sore throat in 63 (4%) of 1654 participants. INTERPRETATION In patients with gastro-oesophageal reflux, the offer of Cytosponge-TFF3 testing results in improved detection of Barrett's oesophagus. Cytosponge-TFF3 testing could also lead to the diagnosis of treatable dysplasia and early cancer. This strategy will lead to additional endoscopies with some false positive results. FUNDING Cancer Research UK, National Institute for Health Research, the UK National Health Service, Medtronic, and the Medical Research Council.",2020,The Cytosponge-trefoil factor 3 (TFF3) is a non-endoscopic test for Barrett's oesophagus.,"['Patients were eligible if they were aged 50 years or older, had been taking acid-suppressants for symptoms of gastro-oesophageal reflux for more than 6 months, and had not undergone an endoscopy procedure within the past 5 years', 'Patients who declined the offer of the Cytosponge-TFF3 procedure and all participants in the usual care group only had an endoscopy if deemed necessary by their general practitioner', 'remaining 109 clinics, we identified 13\u2008657 eligible patients who were sent an introductory letter with 14 days to opt out', '6983 participants in the intervention group and 143 (2%) of 6531 participants in the usual care group, on further scrutiny, did not meet all eligibility criteria or withdrew from the study', 'Between March 20, 2017, and March 21, 2019, 113 general practice clinics were enrolled, but four clinics dropped out shortly after randomisation', ""1654 participants in the intervention group who swallowed the Cytosponge device successfully, 221 (13%) underwent endoscopy after testing positive for TFF3 and 131 (8%, corresponding to 59% of those having an endoscopy) were diagnosed with Barrett's oesophagus or cancer"", ""6834 participants were diagnosed with dysplastic Barrett's oesophagus (n=4) or stage"", '231 (3%) of 6834 participants had a positive Cytosponge-TFF3 result and were referred for an endoscopy', '109 socio-demographically diverse general practice clinics in England', 'patients with gastro-oesophageal reflux']","[""Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus"", 'standard management of gastro-oesophageal reflux (usual care group), in which participants only received an endoscopy if required by their general practitioner, or usual care plus an offer of the Cytosponge-TFF3 procedure, with a subsequent endoscopy if the procedure identified TFF3-positive cells (intervention group']","[""diagnosis of Barrett's oesophagus"", ""diagnosed with dysplastic Barrett's oesophagus or stage I gastro-oesophageal junction cancer"", ""diagnosed with Barrett's oesophagus""]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0017168', 'cui_str': 'Gastroesophageal reflux disease'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0660409', 'cui_str': 'TFF3 protein, human'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0282413', 'cui_str': 'Letters as Topic'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439787', 'cui_str': 'Out'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4517573', 'cui_str': '143'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0015607', 'cui_str': 'Family practice'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0004763', 'cui_str': ""Barrett's esophagus""}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0334044', 'cui_str': 'Dysplasia'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0014282', 'cui_str': 'England'}]","[{'cui': 'C0660409', 'cui_str': 'TFF3 protein, human'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0004763', 'cui_str': ""Barrett's esophagus""}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0017168', 'cui_str': 'Gastroesophageal reflux disease'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439178', 'cui_str': '% positive cells'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0004763', 'cui_str': ""Barrett's esophagus""}, {'cui': 'C0334044', 'cui_str': 'Dysplasia'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0014871', 'cui_str': 'Cardioesophageal junction structure'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]",6834.0,0.132661,The Cytosponge-trefoil factor 3 (TFF3) is a non-endoscopic test for Barrett's oesophagus.,"[{'ForeName': 'Rebecca C', 'Initials': 'RC', 'LastName': 'Fitzgerald', 'Affiliation': 'MRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, UK; Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK. Electronic address: rcf29@mrc-cu.cam.ac.uk.'}, {'ForeName': 'Massimiliano', 'Initials': 'M', 'LastName': 'di Pietro', 'Affiliation': 'MRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, UK; Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': ""O'Donovan"", 'Affiliation': 'MRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, UK; Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Maroni', 'Affiliation': ""Cancer Research UK and King's College London Cancer Prevention Trials Unit, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.""}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Muldrew', 'Affiliation': ""Cancer Research UK and King's College London Cancer Prevention Trials Unit, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.""}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Debiram-Beecham', 'Affiliation': 'MRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Gehrung', 'Affiliation': 'Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Offman', 'Affiliation': ""Cancer Prevention Group, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.""}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Tripathi', 'Affiliation': 'MRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, UK; Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Samuel G', 'Initials': 'SG', 'LastName': 'Smith', 'Affiliation': 'Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.'}, {'ForeName': 'Benoit', 'Initials': 'B', 'LastName': 'Aigret', 'Affiliation': ""Cancer Research UK and King's College London Cancer Prevention Trials Unit, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.""}, {'ForeName': 'Fiona M', 'Initials': 'FM', 'LastName': 'Walter', 'Affiliation': 'The Primary Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Rubin', 'Affiliation': 'Institute of Population Health Sciences, Newcastle University, Sir James Spence Institute, Royal Victoria Infirmary, Newcastle upon Tyne, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Sasieni', 'Affiliation': ""Cancer Research UK and King's College London Cancer Prevention Trials Unit, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.""}]","Lancet (London, England)",['10.1016/S0140-6736(20)31099-0'] 2124,32739044,Fully automated postoperative ventilation in cardiac surgery patients: a randomised clinical trial.,"BACKGROUND Ensuring that lung-protective ventilation is achieved at scale is challenging in perioperative practice. Fully automated ventilation may be more effective in delivering lung-protective ventilation. Here, we compared automated lung-protective ventilation with conventional ventilation after elective cardiac surgery in haemodynamically stable patients. METHODS In this single-centre investigator-led study, patients were randomly assigned at the end of cardiac surgery to receive either automated (adaptive support ventilation) or conventional ventilation. The primary endpoint was the proportion of postoperative ventilation time characterised by exposure to predefined optimal, acceptable, and critical (injurious) ventilatory parameters in the first three postoperative hours. Secondary outcomes included severe hypoxaemia (Spo 2 <85%) and resumption of spontaneous breathing. Data are presented as mean (95% confidence intervals [CIs]). RESULTS We randomised 220 patients (30.4% females; age: 62-76 yr). Subjects randomised to automated ventilation (n=109) spent a 29.7% (95% CI: 22.1-37.4) higher mean proportion of postoperative ventilation time receiving optimal postoperative ventilation after surgery (P<0.001) compared with subjects receiving conventional postoperative ventilation (n=111). Automated ventilation also reduced the proportion of postoperative ventilation time that subjects were exposed to injurious ventilatory settings by 2.5% (95% CI: 1-4; P=0.003). Severe hypoxaemia was less likely in subjects randomised to automated ventilation (risk ratio: 0.26 [0.22-0.31]; P<0.01). Subjects resumed spontaneous breathing more rapidly when randomised to automated ventilation (hazard ratio: 1.38 [1.05-1.83]; P=0.03). CONCLUSIONS Fully automated ventilation in haemodynamically stable patients after cardiac surgery optimised lung-protective ventilation during postoperative ventilation, with fewer episodes of severe hypoxaemia and an accelerated resumption of spontaneous breathing. CLINICAL TRIAL REGISTRATION NCT03180203.",2020,"Subjects resumed spontaneous breathing more rapidly when randomised to automated ventilation (hazard ratio: 1.38 [1.05-1.83]; P=0.03). ","['cardiac surgery patients', '220 patients (30.4% females; age: 62-76 yr', 'haemodynamically stable patients']","['automated lung-protective ventilation with conventional ventilation', 'cardiac surgery to receive either automated (adaptive support ventilation) or conventional ventilation', 'postoperative ventilation time receiving optimal postoperative ventilation', 'automated ventilation', 'conventional postoperative ventilation']","['severe hypoxaemia (Spo 2 <85%) and resumption of spontaneous breathing', 'proportion of postoperative ventilation time characterised by exposure to predefined optimal, acceptable, and critical (injurious) ventilatory parameters', 'proportion of postoperative ventilation time', 'spontaneous breathing', 'Severe hypoxaemia', 'severe hypoxaemia']","[{'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0578150', 'cui_str': 'Hemodynamically stable'}]","[{'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C4285752', 'cui_str': 'Adaptive servo-ventilation'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0040223', 'cui_str': 'Time'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0700292', 'cui_str': 'Hypoxemia'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",220.0,0.205065,"Subjects resumed spontaneous breathing more rapidly when randomised to automated ventilation (hazard ratio: 1.38 [1.05-1.83]; P=0.03). ","[{'ForeName': 'Ashley J R', 'Initials': 'AJR', 'LastName': 'De Bie', 'Affiliation': 'Department of Intensive Care Unit, Catharina Hospital Eindhoven, Eindhoven, Netherlands; Department of Electrical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands. Electronic address: ashleydebiedekker@gmail.com.'}, {'ForeName': 'Ary Serpa', 'Initials': 'AS', 'LastName': 'Neto', 'Affiliation': 'Department of Intensive Care and Laboratory of Experimental Intensive Care and Anesthesiology, Amsterdam University Medical Centers, Amsterdam, Netherlands; Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'van Meenen', 'Affiliation': 'Department of Intensive Care and Laboratory of Experimental Intensive Care and Anesthesiology, Amsterdam University Medical Centers, Amsterdam, Netherlands.'}, {'ForeName': 'Arthur R', 'Initials': 'AR', 'LastName': 'Bouwman', 'Affiliation': 'Department of Intensive Care Unit, Catharina Hospital Eindhoven, Eindhoven, Netherlands.'}, {'ForeName': 'Arnout N', 'Initials': 'AN', 'LastName': 'Roos', 'Affiliation': 'Department of Intensive Care Unit, Catharina Hospital Eindhoven, Eindhoven, Netherlands.'}, {'ForeName': 'Joost R', 'Initials': 'JR', 'LastName': 'Lameijer', 'Affiliation': 'Department of Radiology, Catharina Hospital Eindhoven, Eindhoven, Netherlands.'}, {'ForeName': 'Erik H M', 'Initials': 'EHM', 'LastName': 'Korsten', 'Affiliation': 'Department of Intensive Care Unit, Catharina Hospital Eindhoven, Eindhoven, Netherlands; Department of Electrical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands.'}, {'ForeName': 'Marcus J', 'Initials': 'MJ', 'LastName': 'Schultz', 'Affiliation': 'Department of Intensive Care and Laboratory of Experimental Intensive Care and Anesthesiology, Amsterdam University Medical Centers, Amsterdam, Netherlands; Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Nuffield Department of Medicine, University of Oxford, Oxford, UK.'}, {'ForeName': 'Alexander J G H', 'Initials': 'AJGH', 'LastName': 'Bindels', 'Affiliation': 'Department of Intensive Care Unit, Catharina Hospital Eindhoven, Eindhoven, Netherlands.'}]",British journal of anaesthesia,['10.1016/j.bja.2020.06.037'] 2125,32739080,No Major Functional Benefit After Bicompartmental Knee Arthroplasty Compared to Total Knee Arthroplasty at 5-Year Follow-Up.,"BACKGROUND In case of isolated medial and patellofemoral joint arthritis, bicompartmental knee arthroplasty (BCA) is an alternative to total knee arthroplasty (TKA). The purpose of our prospective, randomized study is to compare the clinical outcome of BCA vs TKA. METHODS Eighty patients with isolated medial and patellofemoral osteoarthritis were randomly assigned to either BCA or TKA. Patients were evaluated preoperatively, 3, 6, and 12 months, and 2 and 5 years after the procedure. Knee Society Score, Oxford Knee Score, and the University of California,Los Angeles activity scores were calculated at each follow-up; Forgotten Joint Score was assessed at final follow-up. RESULTS There was an improvement in Knee Society Score, Oxford Knee Score, and the University of California,Los Angeles scores in both groups but no significant differences between both groups at any follow-up. The Forgotten Joint Score at 5-year follow-up was not significantly different either. Range of motion was significantly greater in the BCA group from 1-year follow-up onward. CONCLUSION Our study did not show significant differences in clinical scores between BCA and TKA; only range of motion was significantly greater in BCA. Therefore, it is questionable whether this difference justifies the complexity of BCA associated with higher risk of failure. Maybe staged patellofemoral joint arthroplasty in the presence of a well-functioning UKA is an option for BCA and an alternative to revision to TKA. Long-term studies are needed to explore the potential benefits of BCA.",2020,Our study did not show significant differences in clinical scores between BCA and TKA; only range of motion was significantly greater in BCA.,['Eighty patients with isolated medial and patellofemoral osteoarthritis'],"['BCA', 'BCA or TKA', 'bicompartmental knee arthroplasty (BCA']","['Knee Society Score, Oxford Knee Score, and the University of California,Los Angeles activity scores', 'Knee Society Score, Oxford Knee Score, and the University of California,Los Angeles scores', 'Range of motion', 'Forgotten Joint Score']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205409', 'cui_str': 'Isolated'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C1542808', 'cui_str': 'Patellofemoral osteoarthritis'}]","[{'cui': 'C0086511', 'cui_str': 'Total knee replacement'}]","[{'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1997265', 'cui_str': 'Oxford knee score'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C4759288', 'cui_str': 'Forgotten Joint Score'}]",80.0,0.0372399,Our study did not show significant differences in clinical scores between BCA and TKA; only range of motion was significantly greater in BCA.,"[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Schrednitzki', 'Affiliation': 'Department of Orthopaedic Surgery, Kremmen, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Beier', 'Affiliation': 'Department of Orthopaedic Surgery, Kremmen, Germany.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Marx', 'Affiliation': 'Department of Orthopaedic Surgery, Kremmen, Germany.'}, {'ForeName': 'Andreas M', 'Initials': 'AM', 'LastName': 'Halder', 'Affiliation': 'Department of Orthopaedic Surgery, Kremmen, Germany.'}]",The Journal of arthroplasty,['10.1016/j.arth.2020.07.003'] 2126,32739102,Can botulinum toxin help in managing children with functional constipation and obstructed defecation?,"BACKGROUND Functional constipation (FC) is a common pediatric healthcare problem worldwide. Obstructed defection syndrome (ODS) is frequently presented with an inability to coordinate the bowel movement with pelvic floor muscles. Botulinum toxin (BT) intraanal sphincteric injection can improve the obstructed defecation by relaxing the anal sphincter and reducing the required force to propel the stools. PURPOSE This study aimed to compare the changes in Rintala scores (as a mean of assessing defecatory function), in children with FC and ODS, managed by BT injection, bowel management program (BMP), and senna based laxatives (SBL), versus a control group managed by BMP and SBL only. METHODS Prospective randomized controlled study, started at December 2017 on 40 pediatric patients, divided into 2 equal groups (group A: managed by BMP and SBL, group B: like group A with once intraanal sphincteric BT injection) suffering from FC, ODS, with contrast enema showing persistence of ≤90 rectoanal angle (RAA) even with trials of defecation. Patients were excluded if they have neuromuscular abnormalities, hypothyroidism, previous colorectal or anal surgery. Rintala score was assessed before treatment, at 2 months, and 6 months after management. RESULTS The study included 18 females (45%) and 22 males (55%). Group A had equal gender distribution and mean age of 6.9 years, while group B had 12 males with mean age of 7.35 years. The mean follow up period was 11.35 months in group A and 11.6 months in group B. Mean Rintala scores of both groups at initial presentation, 2 months and 6 months follow up were: group A: 9.10, 9.40, 10.90; group B: 9.30, 10.70, 11.05 respectively, and showed no statistically significant difference (p value: 0.884, 0.294, 0.923 respectively). No complications were detected from BT injection like allergic reactions, neuromuscular urinary or lower limbs disturbances. CONCLUSION Intraanal sphincteric injection of botulinum toxin by the mentioned technique and dose, did not result in additional defecatory functional improvement (when assessed by Rintala score) over the routine protocol (using bowel management program and laxatives) of managing functional constipation with obstructed defecation. ANNOUNCEMENT: a preliminary report of this work was presented in the 34th Egyptian pediatric surgery association (EPSA) meeting in Cairo in November 2019. TYPE OF STUDY Treatment/prospective study. LEVEL OF EVIDENCE Level I.",2020,"No complications were detected from BT injection like allergic reactions, neuromuscular urinary or lower limbs disturbances. ","['Patients were excluded if they have neuromuscular abnormalities, hypothyroidism, previous colorectal or anal surgery', 'children with FC and ODS, managed by BT injection, bowel management program (BMP), and senna based laxatives (SBL), versus a control group managed by BMP and SBL only', '34th Egyptian pediatric surgery association (EPSA) meeting in Cairo in November 2019', '18 females (45%) and 22 males (55', 'Group A had equal gender distribution and mean age of 6.9\u202fyears, while group B had 12 males with mean age of 7.35\u202fyears', 'started at December 2017 on 40 pediatric patients, divided into 2 equal groups (group A']","['botulinum toxin', 'Botulinum toxin (BT) intraanal sphincteric injection', 'managed by BMP and SBL, group B: like group A with once intraanal sphincteric BT injection) suffering from FC, ODS, with contrast enema showing persistence of ≤90 rectoanal angle (RAA']","['BT injection like allergic reactions, neuromuscular urinary or lower limbs disturbances']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0020676', 'cui_str': 'Hypothyroidism'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0401146', 'cui_str': 'Constipation - functional'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C1321035', 'cui_str': 'Injection of botulinum toxin'}, {'cui': 'C0150155', 'cui_str': 'Bowel care'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0330722', 'cui_str': 'Cassia acutifolia'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0282090', 'cui_str': 'Laxative'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013717', 'cui_str': 'Egyptian language'}, {'cui': 'C0279077', 'cui_str': 'Pediatric surgery'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517826', 'cui_str': '6.9'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0006055', 'cui_str': 'botulinum toxin'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0150155', 'cui_str': 'Bowel care'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0330722', 'cui_str': 'Cassia acutifolia'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0282090', 'cui_str': 'Laxative'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C1321035', 'cui_str': 'Injection of botulinum toxin'}, {'cui': 'C0401146', 'cui_str': 'Constipation - functional'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C1282538', 'cui_str': 'Contrast enema'}, {'cui': 'C0546816', 'cui_str': 'Persistence'}, {'cui': 'C0205143', 'cui_str': 'Angular'}]","[{'cui': 'C1321035', 'cui_str': 'Injection of botulinum toxin'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}]",40.0,0.0425796,"No complications were detected from BT injection like allergic reactions, neuromuscular urinary or lower limbs disturbances. ","[{'ForeName': 'Ahmed B', 'Initials': 'AB', 'LastName': 'Radwan', 'Affiliation': 'Pediatric Surgery Department, Faculty of Medicine, Ain-Shams University, Cairo, Egypt. Electronic address: Ahmedbassiouny@med.asu.edu.eg.'}, {'ForeName': 'Mohamed A', 'Initials': 'MA', 'LastName': 'Gadallah', 'Affiliation': 'Pediatric Surgery Department, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.'}, {'ForeName': 'Mohammed R', 'Initials': 'MR', 'LastName': 'Shahawy', 'Affiliation': 'General Surgery Department, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.'}, {'ForeName': 'Ayman A', 'Initials': 'AA', 'LastName': 'Albagdady', 'Affiliation': 'Pediatric Surgery Department, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.'}, {'ForeName': 'Ayman A', 'Initials': 'AA', 'LastName': 'Talaat', 'Affiliation': 'General Surgery Department, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.'}]",Journal of pediatric surgery,['10.1016/j.jpedsurg.2020.06.044'] 2127,32739115,The Impact of Treatment Crossover and Prostate-specific Antigen Flare with Enzalutamide and Abiraterone in Metastatic Castrate Resistant Prostate Cancer.,,2020,,['Metastatic Castrate Resistant Prostate Cancer'],['Enzalutamide and Abiraterone'],[],"[{'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C1328504', 'cui_str': 'Hormone refractory prostate cancer'}]","[{'cui': 'C3496793', 'cui_str': 'enzalutamide'}, {'cui': 'C0754011', 'cui_str': 'abiraterone'}]",[],,0.0247388,,"[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'McGrane', 'Affiliation': 'Sunrise Oncology Centre, Royal Cornwall Hospital, Truro, UK.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Rowe', 'Affiliation': 'Sunrise Oncology Centre, Royal Cornwall Hospital, Truro, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Hidayat', 'Affiliation': 'Sunrise Oncology Centre, Royal Cornwall Hospital, Truro, UK.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Walter', 'Affiliation': 'Edinburgh Oncology Centre, Western General Hospital, Edinburgh, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Victor', 'Affiliation': 'Sunrise Oncology Centre, Royal Cornwall Hospital, Truro, UK.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Norris', 'Affiliation': 'Exeter Oncology Centre, Royal Devon & Exeter Hospital, Exeter, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Pollard', 'Affiliation': 'Sunrise Oncology Centre, Royal Cornwall Hospital, Truro, UK.'}]",Clinical oncology (Royal College of Radiologists (Great Britain)),['10.1016/j.clon.2020.07.009'] 2128,32739184,RE: Ang et al.: Randomized clinical trial comparing femtosecond LASIK and small-incision lenticule extraction (Ophthalmology. 2020;127:724-730).,,2020,,[],['femtosecond LASIK and small-incision lenticule extraction'],[],[],"[{'cui': 'C0752094', 'cui_str': 'Laser assisted in situ keratomileusis'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}]",[],,0.0877184,,"[{'ForeName': 'Avi', 'Initials': 'A', 'LastName': 'Wallerstein', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, McGill University, Montreal, Quebec, Canada; LASIK MD, Montreal, Quebec, Canada. Electronic address: awallerstein@lasikmd.com.'}, {'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Gauvin', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, McGill University, Montreal, Quebec, Canada; LASIK MD, Montreal, Quebec, Canada.'}]",Ophthalmology,['10.1016/j.ophtha.2020.06.032'] 2129,32739224,Randomized controlled trial of the foot reflexology on pain and anxiety severity during dressing change in burn patients.,"BACKGROUND One of the most important problems in burn patients was pain, especially in dressing changes. This pain can lead to anxiety in the patient. The aim of this study was to determine the effect of foot reflexology on pain and anxiety severity in burn patients. METHODS This study was a randomized controlled trial, in which 66 patients with burn injuries referred to Vali-e-asr Hospital, Arak, Iran participated. After obtaining written consent, patients were enrolled to study according to inclusion criteria and then, divided into intervention (n = 33) and control (n = 33) groups using simple random allocation. In the intervention group, in addition to standard care, reflexology was performed for one week on Saturday, Monday and Wednesday (three times in a week). The intervention was done one hour before dressing change in a separate room for 30 min. The control group received only standard care during this time (both intervention and control groups were the same in the type of treatment, and reflexology was considered as an extra care in the intervention group). Severity of pain and anxiety in both groups was measured using visual analog scale twice a day (5-10 min before dressing change and 5-10 min after dressing change) for six days. SPSS software ver. 15 was used for statistical analysis. Mean and standard deviation were used for quantitative variables and qualitative variables were reported as frequency and percentage. Data were analyzed using Chi‑square, Mann-Whitney, Fisher's exact tests, and paired t-test. The Kolmogorov-Smirnov test was used to check the normality of data. RESULTS The results showed no significant difference in severity of pain (p = 0.25) and anxiety (p = 0.37) between the two groups on the first day, before the intervention. In the following days, the results showed no significant difference between the two groups in the second and third treatments after intervention . However, the mean pain scores showed a significant difference between the two groups in the forth (p = 0.005), fifth (p = 0.001), and sixth (p = 0.001) days after intervention. Anxiety scores also showed a significant difference between the two groups on the fourth (p = 0.01), fifth (p = 0.001), and sixth (p = 0.001) days. CONCLUSIONS Our results showed foot reflexology is an appropriate and safe intervention for management of pain and anxiety of burn patients. Therefore, it can be used as a complementary method alongside other methods.",2020,"In the following days, the results showed no significant difference between the two groups in the second and third treatments after intervention .","['66 patients with burn injuries referred to Vali-e-asr Hospital, Arak, Iran participated', 'burn patients']",['foot reflexology'],"['anxiety', 'severity of pain', 'Anxiety scores', 'mean pain scores', 'Severity of pain and anxiety', 'Mean and standard deviation', 'pain and anxiety severity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006434', 'cui_str': 'Burn injury'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0000912', 'cui_str': 'Accident caused by unspecified fire'}]","[{'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0034945', 'cui_str': 'Reflexology'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}]",66.0,0.044738,"In the following days, the results showed no significant difference between the two groups in the second and third treatments after intervention .","[{'ForeName': 'Fahimeh', 'Initials': 'F', 'LastName': 'Davodabady', 'Affiliation': 'Clinical Research Development Center of Amiralmomenin Hospital, Arak University of Medical Sciences, Arak, Iran. Electronic address: davodabadi.f@arakmu.ac.ir.'}, {'ForeName': 'Vahid', 'Initials': 'V', 'LastName': 'Naseri-Salahshour', 'Affiliation': 'School of Nursing and Midwifery, Saveh University of Medical Sciences, Saveh, Iran. Electronic address: vahidnaseri1994@yahoo.com.'}, {'ForeName': 'Mahbobeh', 'Initials': 'M', 'LastName': 'Sajadi', 'Affiliation': 'Clinical Research Development Center of Amiralmomenin Hospital, Arak University of Medical Sciences, Arak, Iran. Electronic address: m.sajadi@arakmu.ac.ir.'}, {'ForeName': 'Abolfazl', 'Initials': 'A', 'LastName': 'Mohtarami', 'Affiliation': 'School of Medicine, Arak University of Medical Sciences, Arak, Iran. Electronic address: doctor_a_mohtarami@yahoo.com.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Rafiei', 'Affiliation': 'School of Health, Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: f.rafiei87@yahoo.com.'}]",Burns : journal of the International Society for Burn Injuries,['10.1016/j.burns.2020.06.035'] 2130,32739240,Attitudes Toward Computers Moderate the Effect of Computerized Cognitive Trainings in Oldest-Old Senior Living Center Residents.,"BACKGROUND AND OBJECTIVES Computerized cognitive interventions (CCIs) have been increasingly implemented among older adults with mild cognitive impairment (MCI). However, older individuals' attitudes toward technology may limit CCI engagement. This exploratory-developmental study examined whether a ""multi-functional interactive computer system"" (MICS), which provides pleasurable activities via computer, would improve attitudes toward computers and in turn increase the efficacy of a subsequent CCI. RESEARCH DESIGN AND METHODS A phase one double-blind trial randomized 49 seniors with MCI to a MICS + CCI condition or a CCI-only condition. Attitudes toward technology use was assessed using The Attitudes Toward Computers Questionnaire (ATCQ), and cognition was assessed using episodic memory and executive function composite scores at baseline, the ends of MICS and CCI phases, and 3-month follow-up. RESULTS The MICS + CCI group did not show significantly greater improvement in cognition than the CCI only group. Secondary analyses indicated that improvement in executive function from baseline occurred in both groups. Participants who did show improved attitudes toward computers, whether through MICS or simply computer exposure itself, showed improvement in executive function. DISCUSSION AND IMPLICATION Participants in the MICS + CCI group used MICS less than expected. A more structured and supervised approach may be needed to facilitate MICS exposure. Improved attitudes toward computers regardless of MICS exposure may benefit candidates for CCI.",2020,"Participants who did show improved attitudes toward computers, whether through MICS or simply computer exposure itself, showed improvement in executive function. ","['Oldest-Old Senior Living Center Residents', 'older adults with mild cognitive impairment (MCI', '49 seniors with MCI to a MICS\u202f+\u202fCCI condition or a CCI-only condition']","['multi-functional interactive computer system"" (MICS', 'Computerized cognitive interventions (CCIs', 'Computerized Cognitive Trainings']","['executive function', 'cognition', 'Attitudes Toward Computers Questionnaire (ATCQ), and cognition was assessed using episodic memory and executive function composite scores']","[{'cui': 'C0001795', 'cui_str': 'Oldest Old'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0009612', 'cui_str': 'Computer Systems'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0009612', 'cui_str': 'Computer Systems'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]","[{'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",49.0,0.016054,"Participants who did show improved attitudes toward computers, whether through MICS or simply computer exposure itself, showed improvement in executive function. ","[{'ForeName': 'Feng Vankee', 'Initials': 'FV', 'LastName': 'Lin', 'Affiliation': 'Elaine C. Hubbard Center for Nursing Research on Aging, School of Nursing (FVL, KC, KM, AJ), University of Rochester Medical Center, Rochester, NY; Department of Psychiatry, School of Medicine and Dentistry (FVL, AP, BPC), University of Rochester Medical Center, Rochester, NY; Department of Brain and Cognitive Sciences (FVL), University of Rochester; Department of Neuroscience, School of Medicine and Dentistry (FVL), University of Rochester Medical Center, Rochester, NY; Department of Neurology, School of Medicine and Dentistry (FVL, AP), University of Rochester Medical Center, Rochester, NY.'}, {'ForeName': 'Kaylin', 'Initials': 'K', 'LastName': 'Cottone', 'Affiliation': 'Elaine C. Hubbard Center for Nursing Research on Aging, School of Nursing (FVL, KC, KM, AJ), University of Rochester Medical Center, Rochester, NY.'}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Mcdermott', 'Affiliation': 'Elaine C. Hubbard Center for Nursing Research on Aging, School of Nursing (FVL, KC, KM, AJ), University of Rochester Medical Center, Rochester, NY.'}, {'ForeName': 'Alanna', 'Initials': 'A', 'LastName': 'Jacobs', 'Affiliation': 'Elaine C. Hubbard Center for Nursing Research on Aging, School of Nursing (FVL, KC, KM, AJ), University of Rochester Medical Center, Rochester, NY.'}, {'ForeName': 'Dallas', 'Initials': 'D', 'LastName': 'Nelson', 'Affiliation': 'Division of Geriatrics & Aging, Department of Medicine, School of Medicine and Dentistry (DN), University of Rochester Medical Center, Rochester, NY.'}, {'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Porsteinsson', 'Affiliation': 'Department of Psychiatry, School of Medicine and Dentistry (FVL, AP, BPC), University of Rochester Medical Center, Rochester, NY; Department of Neurology, School of Medicine and Dentistry (FVL, AP), University of Rochester Medical Center, Rochester, NY.'}, {'ForeName': 'Benjamin P', 'Initials': 'BP', 'LastName': 'Chapman', 'Affiliation': 'Department of Psychiatry, School of Medicine and Dentistry (FVL, AP, BPC), University of Rochester Medical Center, Rochester, NY; Department of Public Health, School of Medicine and Dentistry (BPC), University of Rochester Medical Center, Rochester, NY. Electronic address: ben_chapman@urmc.rochester.edu.'}]",The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,['10.1016/j.jagp.2020.07.001'] 2131,32746835,Individualized prediction of survival benefit from primary tumor resection for patients with unresectable metastatic colorectal cancer.,"BACKGROUND The impact of primary tumor resection (PTR) on the prognosis of unresectable metastatic colorectal cancer (mCRC) patients remains debatable. We aimed to develop several prognostic nomograms which could be useful in predicting whether patients might benefit from PTR or not. METHODS Patients diagnosed as mCRC without resected metastasis were identified from the Surveillance Epidemiology and End Results database and randomly assigned into two groups: a training cohort (6369 patients) and a validation cohort (2774 patients). Univariate and multivariable Cox analyses were performed to identify the independent predictors and construct nomograms that could independently predict the overall survival (OS) of unresectable mCRC patients in PTR and non-PTR groups, respectively. The performance of these nomograms was assessed by the concordance index (C-index), calibration curves, and decision curve analysis (DCA). RESULTS Based on the result of univariate and multivariable Cox analyses, two nomograms were respectively constructed to predict the 1-year OS rates of unresectable mCRC patients when receiving PTR and not. The first one included age, gender, tumor grade, proximal colon, N stage, CEA, chemotherapy, radiotherapy, histology type, brain metastasis, liver metastasis, lung metastasis, and bone metastasis. The second nomogram included age, race, tumor grade, primary site, CEA, chemotherapy, brain metastasis, and bone metastasis. These nomograms showed favorable sensitivity with the C-index range of 0.700-0.725. The calibration curves and DCAs also exhibited adequate fit and ideal net benefits in prognosis prediction and clinical application. CONCLUSIONS These practical prognosis nomograms could assist clinicians in making appropriate treatment decisions to effectively manage the disease.",2020,"The performance of these nomograms was assessed by the concordance index (C-index), calibration curves, and decision curve analysis (DCA). ","['Patients diagnosed as mCRC without resected metastasis were identified from the Surveillance Epidemiology and End Results database and randomly assigned into two groups: a training cohort (6369 patients) and a validation cohort (2774 patients', 'patients might benefit from PTR or not', 'patients with unresectable metastatic colorectal cancer', 'unresectable metastatic colorectal cancer (mCRC) patients']",['primary tumor resection (PTR'],"['overall survival (OS', '1-year OS rates', 'concordance index (C-index), calibration curves, and decision curve analysis (DCA']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}, {'cui': 'C0014507', 'cui_str': 'Epidemiology'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C4761063', 'cui_str': 'Tumor resection'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C4761063', 'cui_str': 'Tumor resection'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0006751', 'cui_str': 'Calibration'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]",6369.0,0.0342859,"The performance of these nomograms was assessed by the concordance index (C-index), calibration curves, and decision curve analysis (DCA). ","[{'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Gastroenterology, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215006, Jiangsu, China.'}, {'ForeName': 'Yujie', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'Department of Oncology, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215006, Jiangsu, China.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Jiang', 'Affiliation': 'Department of Gastroenterology, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215006, Jiangsu, China.'}, {'ForeName': 'Jinzhou', 'Initials': 'J', 'LastName': 'Zhu', 'Affiliation': 'Department of Gastroenterology, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215006, Jiangsu, China.'}, {'ForeName': 'Su', 'Initials': 'S', 'LastName': 'Yan', 'Affiliation': 'Department of Gastroenterology, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215006, Jiangsu, China. yansu@suda.edu.cn.'}]",World journal of surgical oncology,['10.1186/s12957-020-01972-y'] 2132,32746841,"Person-centred, occupation-based intervention program supported with problem-solving therapy for type 2 diabetes: a randomized controlled trial.","BACKGROUND Individuals with diabetes mellitus have difficulty solving problems in meaningful occupations and have similar difficulties with self-care regimens. We examined the effects of an occupation-based intervention supported with problem-solving therapy in individuals with type 2 diabetes mellitus on participation in and satisfaction with meaningful occupations, diabetes-related psychosocial self-efficacy, preferred coping strategies and individual well-being. METHODS This study was planned as a single-blind, randomised controlled study with a 3-month follow-up involving 67 adults with type 2 diabetes. The Canadian Occupational Performance Measure, Diabetes Empowerment Scale, Brief COPE and five-item World Health Organisation Well-Being Index were used. This programme included evaluations, diabetes education, and problem-solving therapy. The intervention was conducted for 6 weeks, and each weekly session lasted approximately 60 min. Differences between groups were analysed using the Mann-Whitney U test, and the Friedman test was used to calculate group-time interaction differences (i.e., baseline, after 6 weeks and after 3 months). RESULTS All participants identified the most significant occupational performance problems in self-care as personal care. Significant improvement was reported in the intervention group compared to the control group regarding participation in meaningful occupation, satisfaction with performance, psychosocial self-efficacy, and well-being results (p < 0.001) after the programme and 3 months of follow-up. Participant use of effective coping strategies, active coping and acceptance strategies, and self-efficacy, as revealed by the results, suggested improvement in favour of the intervention group (p < 0.05). CONCLUSIONS Occupation-based problem-solving therapy encourages participation in meaningful occupations and improves psychosocial self-efficacy, effective coping styles, and well-being in patients with type 2 diabetes mellitus. Problem-solving therapies that incorporate individuals' priorities via meaningful occupation can be used to lead to a meaningful and quality life for individuals with type 2 diabetes mellitus. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT03783598 . Retrospectively Registered. First Posted-December 21, 2018, Last Update Posted-February 18, 2020.",2020,"Significant improvement was reported in the intervention group compared to the control group regarding participation in meaningful occupation, satisfaction with performance, psychosocial self-efficacy, and well-being results (p < 0.001) after the programme and 3 months of follow-up.","['individuals with type 2 diabetes mellitus', 'patients with type 2 diabetes mellitus', '67 adults with type 2 diabetes', 'Individuals with diabetes mellitus']","['Occupation-based problem-solving therapy', 'occupation-based intervention supported with problem-solving therapy', 'Person-centred, occupation-based intervention program supported with problem-solving therapy']","['effective coping strategies, active coping and acceptance strategies, and self-efficacy', 'meaningful occupation, satisfaction with performance, psychosocial self-efficacy, and well-being results', 'Canadian Occupational Performance Measure, Diabetes Empowerment Scale, Brief COPE and five-item World Health Organisation', 'psychosocial self-efficacy, effective coping styles']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1303140', 'cui_str': 'Problem solving therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C2364069', 'cui_str': 'Able to cope'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C2585956', 'cui_str': 'Canadian occupational performance measure'}, {'cui': 'C0679959', 'cui_str': 'Empowerment'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0043236', 'cui_str': 'Worldwide Health'}, {'cui': 'C0029237', 'cui_str': 'Organization'}]",67.0,0.0295576,"Significant improvement was reported in the intervention group compared to the control group regarding participation in meaningful occupation, satisfaction with performance, psychosocial self-efficacy, and well-being results (p < 0.001) after the programme and 3 months of follow-up.","[{'ForeName': 'Zeynep', 'Initials': 'Z', 'LastName': 'Bahadır Ağce', 'Affiliation': 'Department of Occupational Therapy, Uskudar University, İstanbul, Turkey. fztzeynepbahadir@gmail.com.'}, {'ForeName': 'Gamze', 'Initials': 'G', 'LastName': 'Ekici', 'Affiliation': 'Department of Occupational Therapy, Hacettepe University, Ankara, Turkey.'}]",Health and quality of life outcomes,['10.1186/s12955-020-01521-x'] 2133,32746864,The efficacy and safety of intrathecal dexmedetomidine for parturients undergoing cesarean section: a double-blind randomized controlled trial.,"BACKGROUND The efficacy and safety of spinal anesthesia by intrathecal dexmedetomidine (DEX) for parturients undergoing cesarean section are still lack of evidence. This aim of our study was to evaluate the efficacy and safety of intrathecal DEX for parturients undergoing cesarean section to provide more data evidence for intrathecal applications. METHODS Three hundred parturients undergoing cesarean section under spinal anesthesia were randomly assigned into three groups: group B: 9.0 mg (1.2 ml) of 0.75% bupivacaine with saline (1 ml); group FB: 9.0 mg (1.2 ml) of 0.75% bupivacaine with 20 μg of fentanyl (1 ml); group DB: 9.0 mg (1.2 ml) of 0.75% bupivacaine with 5 μg of DEX (1 ml). Intraoperative block characteristics, parturients' postoperative quality of recovery, maternal and neonatal outcomes and the plasma concentration of DEX were measured. All parturients were followed up for 30 days to determine whether nerve injury occurred. RESULTS Compared with group B, the duration of sensory block in group FB and group DB were significantly prolonged (108.4 min [95% Confidence Interval (CI) = 104.6-112.3] in group B, and 122.0 min [95% CI = 116.8-127.3] in group FB, 148.2 min [95% CI = 145.3-151.1] in group DB). The overall score of quality recovery in group DB (71.6 [95% CI = 71.0-72.2]) was significantly higher than that in group FB (61.5 [95% CI = 60.8-62.2]) and group B (61.7 [95% CI = 61.0-62.4]). There was no statistically significant difference among the three groups for PH, PaO 2 , and PaCO 2 of newborn. The plasma concentration of DEX in umbilical artery and umbilical vein was low and cannot be detected. The 30-days follow-up of parturients did not show any new onset of back, buttock or leg pain or paresthesia. CONCLUSIONS DEX is a potential local anesthetic adjuvant that the intrathecal combination of 5 μg DEX can safely exhibit a facilitatory block effect and improve parturients' recovery quality. TRIAL REGISTRATION Chinese Clinical Trial Registry (Registration number # ChiCTR1900022019 ; Date of Registration on March 20th, 2019).",2020,The overall score of quality recovery in group DB (71.6 [95% CI = 71.0-72.2]) was significantly higher than that in group FB (61.5,"['parturients undergoing cesarean section', 'Three hundred parturients undergoing cesarean section under spinal anesthesia']","['bupivacaine with saline', 'DEX', 'intrathecal DEX', 'bupivacaine with 20\u2009μg of fentanyl', 'spinal anesthesia by intrathecal dexmedetomidine (DEX', 'bupivacaine with 5\u2009μg of DEX', 'intrathecal dexmedetomidine']","['duration of sensory block', ""Intraoperative block characteristics, parturients' postoperative quality of recovery, maternal and neonatal outcomes and the plasma concentration of DEX"", 'overall score of quality recovery', 'efficacy and safety', 'new onset of back, buttock or leg pain or paresthesia', 'plasma concentration of DEX in umbilical artery and umbilical vein']","[{'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}]","[{'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0677897', 'cui_str': 'Intrathecal route'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0332162', 'cui_str': 'Onset of'}, {'cui': 'C0006497', 'cui_str': 'Buttock structure'}, {'cui': 'C0023222', 'cui_str': 'Pain in lower limb'}, {'cui': 'C0030554', 'cui_str': 'Paresthesia'}, {'cui': 'C0041632', 'cui_str': 'Structure of umbilical artery'}, {'cui': 'C0041637', 'cui_str': 'Structure of umbilical vein'}]",300.0,0.551791,The overall score of quality recovery in group DB (71.6 [95% CI = 71.0-72.2]) was significantly higher than that in group FB (61.5,"[{'ForeName': 'Xiao-Xiao', 'Initials': 'XX', 'LastName': 'Li', 'Affiliation': 'Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou, Jiangsu, China.'}, {'ForeName': 'Yu-Mei', 'Initials': 'YM', 'LastName': 'Li', 'Affiliation': ""Feng Xian People's Hospital of Jiangsu Province, Xuzhou, Jiangsu, China.""}, {'ForeName': 'Xue-Li', 'Initials': 'XL', 'LastName': 'Lv', 'Affiliation': 'Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou, Jiangsu, China.'}, {'ForeName': 'Xing-He', 'Initials': 'XH', 'LastName': 'Wang', 'Affiliation': 'Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou, Jiangsu, China.'}, {'ForeName': 'Su', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou, Jiangsu, China. liusu112277@gmail.com.'}]",BMC anesthesiology,['10.1186/s12871-020-01109-4'] 2134,32742613,"Effect of Donepezil on Cognitive Impairment, Quality of Life, and Depression in Multiple Sclerosis Patients: A Randomized Clinical Trial.","Background Cognitive impairment is one of the debilitating consequences of multiple sclerosis (MS) with negative effects on daily life, individual and social activities, quality of life (QOL), and depression. No approved medication is introduced so far for affected individuals. We aimed to evaluate the efficacy of donepezil on cognitive performance, QOL, and depression in MS. Methods This is a double-blinded randomized clinical trial conducted on 100 patients with MS during 2018. Patients were assessed prior to intervention abbreviated mental test (AMT), prospective and retrospective mental questionnaire (PRMQ), everyday memory questionnaire (EMQ), digit span test, Beck depression inventory (BDI), and MSQOL questionnaire. Then patients were randomly divided into two groups of treatment (daily regimen of 10 mg donepezil) and placebo for 3 months. Subjects were reassessed using the same instruments at the end of intervention. Results Fifty patients remained in each group at the end of study. The mean age in donepezil and placebo groups was 31.9 ± 5.89 and 30.65 ± 5.43 years, respectively. EMQ, PRMQ, digit span test, MSQOL, and depression scores improved following donepezil therapy ( P < 0.001) while no statistically significant difference was found in the placebo group ( P > 0.05). Comparison of two groups also showed more favorable scores in donepezil group with respect to all assessment tools ( P < 0.001). Conclusions Donepezil could effectively improve cognitive impairment in MS patients. Also, its positive effect on QOL and depression could result in a smaller number of interventions in this group of patients.",2020,"EMQ, PRMQ, digit span test, MSQOL, and depression scores improved following donepezil therapy ( P < 0.001) while no statistically significant difference was found in the placebo group ( P > 0.05).","['MS patients', '100 patients with MS during 2018', 'Fifty patients remained in each group at the end of study', 'Multiple Sclerosis Patients']","['Donepezil', 'donepezil and placebo', 'donepezil', 'placebo']","['Cognitive Impairment, Quality of Life, and Depression', 'intervention abbreviated mental test (AMT), prospective and retrospective mental questionnaire (PRMQ), everyday memory questionnaire (EMQ), digit span test, Beck depression inventory (BDI), and MSQOL questionnaire', 'QOL and depression', 'EMQ, PRMQ, digit span test, MSQOL, and depression scores', 'cognitive performance, QOL, and depression in MS', 'favorable scores', 'cognitive impairment', 'daily life, individual and social activities, quality of life (QOL), and depression']","[{'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0527316', 'cui_str': 'donepezil'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0450977', 'cui_str': 'Abbreviated mental test'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0035363', 'cui_str': 'Retrospective Study'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0588977', 'cui_str': 'Everyday memory questionnaire'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",100.0,0.109202,"EMQ, PRMQ, digit span test, MSQOL, and depression scores improved following donepezil therapy ( P < 0.001) while no statistically significant difference was found in the placebo group ( P > 0.05).","[{'ForeName': 'Mohammad Mahdi', 'Initials': 'MM', 'LastName': 'Shahpouri', 'Affiliation': 'Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Barekatain', 'Affiliation': 'Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Mahgol', 'Initials': 'M', 'LastName': 'Tavakoli', 'Affiliation': 'Department of Psychology, School of Educational Sciences and Psychology, University of Isfahan, Isfahan, Iran.'}, {'ForeName': 'Shervin', 'Initials': 'S', 'LastName': 'Badihian', 'Affiliation': 'Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Vahid', 'Initials': 'V', 'LastName': 'Shaygannejad', 'Affiliation': 'Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.'}]",International journal of preventive medicine,['10.4103/ijpvm.IJPVM_154_19'] 2135,32742827,A Pilot Study on the Effects of Nut Consumption on Cardiovascular Biomarkers.,"BACKGROUND Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in the United States and changes in lifestyle can minimize the likelihood of succumbing to heart disease. Anti-inflammatory agents are commonly used to reduce the chronic inflammatory state behind the pathogenesis of CVD. Multiple studies have been published correlating nut consumption with a reduction in both heart attacks and strokes. The goal of this study is to determine to what extent the consumption of almonds, hazelnuts, and walnuts have on the blood markers associated with cardiac disease and inflammation. METHODS This was a six-week study in which subject's baseline values act as controls. Fasting blood draws occurred at week 0, week 2, and after four weeks of intervention (week 6). All participants had undesirable lipid profiles and no medications related to heart disease. RESULTS Total cholesterol (TC): high-density lipoprotein (HDL-C) ratio was lowered a statistically significant amount at the six-week time point (3.89 ± 0.74) compared to both the zero-week (4.93 ± 1.16, p < 0.01) and two-week (4.63 ± 1.20, p < 0.5) timepoints. Low-density lipoprotein (LDL) measurements were lowered a statistically significant amount at the six-week time point (135.6 ± 15.0 mg/dL) compared to the zero-week (159.7 ± 12.3 mg/dL, p < 0.01). Erythrocyte sedimentation rate (ESR) was lowered a statistically significant amount at six-week time point (10.44 ± 5.05 mm/h) compared to the zero-week (14.44 ± 5.12 mm/h, p < 0.01). CONCLUSIONS Blood markers associated with CVD specifically and the general marker for inflammation associated with many chronic diseases can be favorably modified with the consumption of specific nuts as demonstrated by this study.",2020,"Erythrocyte sedimentation rate (ESR) was lowered a statistically significant amount at six-week time point (10.44 ± 5.05 mm/h) compared to the zero-week (14.44 ± 5.12 mm/h, p < 0.01). ",[],['Nut Consumption'],"['Fasting blood draws', 'Low-density lipoprotein (LDL) measurements', 'undesirable lipid profiles', 'Erythrocyte sedimentation rate (ESR', 'Cardiovascular Biomarkers', 'Total cholesterol (TC): high-density lipoprotein (HDL-C) ratio']",[],"[{'cui': 'C0028723', 'cui_str': 'Nut'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0005834', 'cui_str': 'Collection of blood specimen for laboratory'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.0247625,"Erythrocyte sedimentation rate (ESR) was lowered a statistically significant amount at six-week time point (10.44 ± 5.05 mm/h) compared to the zero-week (14.44 ± 5.12 mm/h, p < 0.01). ","[{'ForeName': 'Jacob J', 'Initials': 'JJ', 'LastName': 'Adashek', 'Affiliation': 'Internal Medicine, University of South Florida, Tampa, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Redding', 'Affiliation': 'Neuromusculoskeletal Medicine/Osteopathic Manipulative Medicine/Family Medicine, Western University of Health Sciences, Pomona, USA.'}]",Cureus,['10.7759/cureus.8798'] 2136,32742930,Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China.,"Objective To establish non-inferiority of gonadotropin-releasing hormone degarelix compared with goserelin in suppressing and maintaining castrate testosterone levels from Day 28 to Day 364 in Chinese patients with prostate cancer. Methods This is an open-label, multi-centre study in which men aged ≥18 years were randomised in a 1:1 ratio to once-a-month subcutaneous injection of either degarelix (240/80 mg) or goserelin (3.6 mg) for 12 months. The primary endpoint was difference in 1-year cumulative probability of suppressing testosterone to ≤0.5 ng/mL. Non-inferiority was to be established if the lower 95% confidence interval (CI) limit for difference in cumulative probability between the treatment arms was greater than -10%. Secondary endpoints included cumulative probability of prostate-specific-antigen-progression-free-survival (PSA-PFS). Safety was also assessed. Results Baseline demographics and disease characteristics were similar between degarelix ( n =142) and goserelin ( n =141) treatment arms. The difference in cumulative probability of maintaining castrate levels from Day 28-364 was 3.6% (95% CI:-1.5%, 8.7%), demonstrating non-inferiority of degarelix. The cumulative probability of PSA-PFS at Day 364 was higher for degarelix (82.3%, 95% CI: 74.7%, 87.7%) versus goserelin (71.7%, 95% CI: 63.2%, 78.5%, p =0.038). Adverse events (AEs) were similar between treatment arms, except for more injection site reactions with degarelix versus goserelin. Four (2.8%) and nine (6.4%) patients discontinued due to AEs in degarelix and goserelin groups, respectively. Conclusion Degarelix was non-inferior to goserelin in achieving and maintaining testosterone suppression at castrate levels during 1-year treatment. PSA-PFS was significantly higher with degarelix, suggesting improved disease control. Both treatments were well tolerated.",2020,"Adverse events (AEs) were similar between treatment arms, except for more injection site reactions with degarelix versus goserelin.","['patients with prostate cancer', 'Day 28 to Day 364 in Chinese patients with prostate cancer', 'men aged ≥18 years']","['gonadotropin-releasing hormone degarelix', 'degarelix', 'Degarelix', 'degarelix versus goserelin', 'goserelin']","['Safety', 'cumulative probability of maintaining castrate levels', 'suppressing and maintaining castrate testosterone levels', 'tolerated', 'PSA-PFS', 'cumulative probability', 'cumulative probability of prostate-specific-antigen-progression-free-survival (PSA-PFS', 'Efficacy and safety', '1-year cumulative probability of suppressing testosterone to ≤0.5\xa0ng/mL. Non-inferiority', 'Adverse events (AEs', 'cumulative probability of PSA-PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0023610', 'cui_str': 'Gonadorelin'}, {'cui': 'C1455035', 'cui_str': 'degarelix'}, {'cui': 'C0120107', 'cui_str': 'Goserelin'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1260953', 'cui_str': 'Suppressed'}, {'cui': 'C0523912', 'cui_str': 'Testosterone measurement'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0178415', 'cui_str': 'Raised prostate specific antigen'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0237666', 'cui_str': 'Inferiority feeling'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.525198,"Adverse events (AEs) were similar between treatment arms, except for more injection site reactions with degarelix versus goserelin.","[{'ForeName': 'Yinghao', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': 'Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Liping', 'Initials': 'L', 'LastName': 'Xie', 'Affiliation': 'Department of Urology, First Affiliated Hospital, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Xu', 'Affiliation': ""Department of Urology, Peking University People's Hospital, Beijing, China.""}, {'ForeName': 'Jørn S', 'Initials': 'JS', 'LastName': 'Jakobsen', 'Affiliation': 'Global Clinical Research and Development, Ferring Pharmaceuticals A/S, Copenhagen, Denmark.'}, {'ForeName': 'Weiqing', 'Initials': 'W', 'LastName': 'Han', 'Affiliation': 'Department of Urology, Hunan Cancer Hospital, Hunan Province, China.'}, {'ForeName': 'Per S', 'Initials': 'PS', 'LastName': 'Sørensen', 'Affiliation': 'Global Clinical Research and Development, Ferring Pharmaceuticals A/S, Copenhagen, Denmark.'}, {'ForeName': 'Xiaofeng', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ""Department of Urology, Peking University People's Hospital, Beijing, China.""}]",Asian journal of urology,['10.1016/j.ajur.2019.09.003'] 2137,32742984,Effects of prostaglandin E combined with continuous renal replacement therapy on septic acute kidney injury.,"BACKGROUND The effects of prostaglandin E (PGE) combined with continuous renal replacement therapy (CRRT) on renal function and inflammatory responses in patients with septic acute kidney injury (SAKI) remain unclear. AIM To investigate the effects of PGE combined with CRRT on urinary augmenter of liver regeneration (ALR), urinary Na+/H+ exchanger 3 (NHE3), and serum inflammatory cytokines in patients with SAKI. METHODS The clinical data of 114 patients with SAKI admitted to Yichang Second People's Hospital from May 2017 to January 2019 were collected. Fifty-three cases treated by CRRT alone were included in a control group, while the other 61 cases treated with PGE combined with CRRT were included in an experimental group. Their urinary ALR, urinary NHE3, serum inflammatory cytokines, renal function indices, and immune function indices were detected. Changes in disease recovery and the incidence of adverse reactions were observed. The 28-d survival curve was plotted. RESULTS Before treatment, urinary ALR, urinary NHE3, blood urea nitrogen (BUN), serum creatinine (SCr), CD3+ T lymphocytes, CD4+ T lymphocytes, and CD4+/CD8+ T lymphocyte ratio in the control and experimental groups were approximately the same. After treatment, urinary ALR and NHE3 decreased, while BUN, SCr, CD3+ T lymphocytes, CD4+ T lymphocytes, and CD4+/CD8+ T lymphocyte ratio increased in all subjects. Urinary ALR, urinary NHE3, BUN, and SCr in the experimental group were significantly lower than those in the control group, while CD3+ T lymphocytes, CD4+ T lymphocytes, and CD4+/CD8+ T lymphocyte ratio were significantly higher than those in the control group ( P < 0.05). After treatment, the levels of tumor necrosis factor-α, interleukin-18, and high sensitivity C-reactive protein in the experimental group were significantly lower than those in the control group ( P < 0.05). The time for urine volume recovery and intensive care unit treatment in the experimental group was significantly shorter than that in the control group ( P < 0.05), although there was no statistically significant difference in hospital stays between the two groups. The total incidence of adverse reactions did not differ statistically between the two groups. The 28-d survival rate in the experimental group (80.33%) was significantly higher than that in the control group (66.04%). CONCLUSION PGE combined with CRRT is clinically effective for treating SAKI, and the combination therapy can significantly improve renal function and reduce inflammatory responses.",2020,"The time for urine volume recovery and intensive care unit treatment in the experimental group was significantly shorter than that in the control group ( P < 0.05), although there was no statistically significant difference in hospital stays between the two groups.","['patients with septic acute kidney injury (SAKI', 'patients with SAKI', 'septic acute kidney injury', ""114 patients with SAKI admitted to Yichang Second People's Hospital from May 2017 to January 2019 were collected""]","['prostaglandin E combined with continuous renal replacement therapy', 'prostaglandin E (PGE) combined with continuous renal replacement therapy (CRRT', 'CRRT', 'PGE combined with CRRT']","['levels of tumor necrosis factor-α, interleukin-18, and high sensitivity C-reactive protein', '28-d survival curve', '28-d survival rate', 'urinary ALR and NHE3 decreased, while BUN, SCr, CD3+ T lymphocytes, CD4+ T lymphocytes, and CD4+/CD8+ T lymphocyte ratio', 'CD3+ T lymphocytes, CD4+ T lymphocytes, and CD4+/CD8+ T lymphocyte ratio', 'urinary augmenter of liver regeneration (ALR), urinary Na+/H+ exchanger 3 (NHE3), and serum inflammatory cytokines', 'Urinary ALR, urinary NHE3, BUN, and SCr', 'total incidence of adverse reactions', 'urinary ALR, urinary NHE3, serum inflammatory cytokines, renal function indices, and immune function indices', 'disease recovery and the incidence of adverse reactions', 'urinary ALR, urinary NHE3, blood urea nitrogen (BUN), serum creatinine (SCr), CD3+ T lymphocytes, CD4+ T lymphocytes, and CD4+/CD8+ T lymphocyte ratio', 'time for urine volume recovery and intensive care unit treatment', 'renal function and reduce inflammatory responses', 'hospital stays', 'renal function and inflammatory responses']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0033559', 'cui_str': 'E series prostaglandin'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C3649547', 'cui_str': 'Continuous renal replacement therapy'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0383327', 'cui_str': 'Interleukin 18'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0023907', 'cui_str': 'Liver Regeneration'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0005845', 'cui_str': 'Blood urea nitrogen measurement'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C0108779', 'cui_str': 'Lymphocyte antigen CD3'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0018894', 'cui_str': 'Helper cell'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1817756', 'cui_str': 'Immunologic function'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",114.0,0.0199947,"The time for urine volume recovery and intensive care unit treatment in the experimental group was significantly shorter than that in the control group ( P < 0.05), although there was no statistically significant difference in hospital stays between the two groups.","[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Lei', 'Affiliation': ""Department of Nephrology, the Second People's Hospital of Three Gorges University (Yichang Second People's Hospital), Yichang 443000, Hubei Province, China.""}, {'ForeName': 'Ming-Jun', 'Initials': 'MJ', 'LastName': 'Wang', 'Affiliation': ""Department of Nephrology, the Second People's Hospital of Three Gorges University (Yichang Second People's Hospital), Yichang 443000, Hubei Province, China.""}, {'ForeName': 'Sheng', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': ""Department of Nephrology, the Second People's Hospital of Three Gorges University (Yichang Second People's Hospital), Yichang 443000, Hubei Province, China.""}, {'ForeName': 'Da-Jun', 'Initials': 'DJ', 'LastName': 'Hu', 'Affiliation': ""Department of Nephrology, the Second People's Hospital of Three Gorges University (Yichang Second People's Hospital), Yichang 443000, Hubei Province, China.""}]",World journal of clinical cases,['10.12998/wjcc.v8.i13.2738'] 2138,32743011,Intra-articular Administration of Tranexamic Acid Has No Effect in Reducing Intra-articular Hemarthrosis and Postoperative Pain After Primary ACL Reconstruction Using a Quadruple Hamstring Graft: A Randomized Controlled Trial.,"Background Insufficient data are available to support the routine use of tranexamic acid (TXA) in anterior cruciate ligament (ACL) surgeries with respect to administration method and frequency, exposure duration, dose, and adverse effects. Purpose To investigate whether intra-articular (IA) administration of TXA could reduce hemarthrosis and postoperative pain in patients after ACL reconstruction. Study Design Randomized controlled trial; Level of evidence, 1. Methods A total of 47 patients were included in this study, which was performed between July 2017 and May 2019. Single-bundle reconstructions using autologous hamstring tendon grafts were performed in all patients. The patients were randomized into 2 groups: the TXA group (received the index procedure with 100-mL IA injection of TXA [30 mg/mL]) and a control group (did not receive IA injection of TXA). No patients received a drain. Blood loss was calculated on the basis of hemoglobin balance at postoperative day (PD) 2. The visual analog scale (VAS) for pain score was assessed at PD 3. The midpatellar circumference was measured at PD 2 and PD 5. Knee range of motion (ROM) was evaluated 6 weeks after surgery. Results The mean ± SD blood loss was 467 ± 242 mL in the TXA group and 558 ± 236 mL in the control group. No significant differences were found for blood loss ( P = .20), VAS pain scores ( P = .28), ROM at postoperative week 6 ( P = .61), or patellar circumference at PD 2 ( P = .75) and PD 5 ( P = .84). Conclusion This study showed that IA administration of 3.0 g of TXA had no effect in reducing blood loss and postoperative pain after primary anatomic single-bundle ACL reconstruction using quadruple hamstring autografts. Registration NCT04042688 (ClinicalTrials.gov identifier).",2020,"No significant differences were found for blood loss ( P = .20), VAS pain scores ( P = .28), ROM at postoperative week 6 ( P = .61), or patellar circumference at PD 2 ( P = .75) and PD 5 ( P = .84). ","['anterior cruciate ligament (ACL) surgeries', '47 patients were included in this study, which was performed between July 2017 and May 2019', 'patients after ACL reconstruction']","['tranexamic acid (TXA', 'TXA', 'autologous hamstring tendon grafts', 'drain', 'index procedure with 100-mL IA injection of TXA [30 mg/mL]) and a control group (did not receive IA injection of TXA', 'Tranexamic Acid', 'Quadruple Hamstring Graft']","['Intra-articular Hemarthrosis and Postoperative Pain', 'ROM', 'visual analog scale (VAS) for pain score', 'patellar circumference', 'hemarthrosis and postoperative pain', 'midpatellar circumference', 'Knee range of motion (ROM', 'blood loss and postoperative pain', 'VAS pain scores', 'mean ± SD blood loss', 'Blood loss', 'blood loss']","[{'cui': 'C0078960', 'cui_str': 'Structure of anterior cruciate ligament of knee joint'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C1279739', 'cui_str': 'Tendon transplantation'}, {'cui': 'C0013103', 'cui_str': 'Drainage procedure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0021488', 'cui_str': 'Intra-articular injection'}, {'cui': 'C0439294', 'cui_str': 'g/L'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0205175', 'cui_str': 'Quadruple'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}]","[{'cui': 'C0442108', 'cui_str': 'Intra-articular'}, {'cui': 'C0018924', 'cui_str': 'Hemarthrosis'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0030647', 'cui_str': 'Bone structure of patella'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0576094', 'cui_str': 'Knee joint - range of movement'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C2732809', 'cui_str': 'Visual analog scale pain score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",47.0,0.190976,"No significant differences were found for blood loss ( P = .20), VAS pain scores ( P = .28), ROM at postoperative week 6 ( P = .61), or patellar circumference at PD 2 ( P = .75) and PD 5 ( P = .84). ","[{'ForeName': 'Ja-Woon', 'Initials': 'JW', 'LastName': 'Lee', 'Affiliation': 'Department of Orthopaedic Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Sang-Gyun', 'Initials': 'SG', 'LastName': 'Kim', 'Affiliation': 'Department of Orthopedic Surgery, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea.'}, {'ForeName': 'Su-Hyun', 'Initials': 'SH', 'LastName': 'Kim', 'Affiliation': 'Department of Orthopedic Surgery, Naval Maritime Medical Center, Jinju, Republic of Korea.'}, {'ForeName': 'Hyun-Woo', 'Initials': 'HW', 'LastName': 'Cho', 'Affiliation': 'Department of Orthopaedic Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Ji-Hoon', 'Initials': 'JH', 'LastName': 'Bae', 'Affiliation': 'Department of Orthopaedic Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.'}]",Orthopaedic journal of sports medicine,['10.1177/2325967120933135'] 2139,32743341,Cost-effectiveness of brief structured interventions to discontinue long-term benzodiazepine use: an economic analysis alongside a randomised controlled trial.,"Background: In Spain, long-term use of benzodiazepine is prevalent in 7% of the population; however, this longer-term use lacks clinical benefits, costs €90million per year and side-effects further add extra cost through adverse health outcomes. This study aims to estimate the cost-effectiveness of primary care services stepped dose reduction of long-term benzodiazepines using either Structured Interview with Follow-up (SIF) or Without Follow-up (SIW), compared to Treatment as Usual (TAU). Design: Cost-effectiveness analysis was conducted alongside randomised control utilizing data from three arm cluster randomized trial. Setting: Primary care. Participants: 75 general practitioners were randomised to one of the three arms (TAU, SIW, SIF). Measurements: Cost and Cost per Quality-Adjusted Life Year (QALY) Results: Compared to usual care, providing SIW per participant costs an additional €117.94 and adding patient follow-up, €218.4. As a result of intervention, participants showed a gain of, on average, for SIW 0.0144 QALY (95% CI -0.0137 to 0.0425) and for SIF 0.0340 QALYs (0.0069 to 0.0612). The Incremental Cost Effectiveness Ratio was €8190.28/QALY (SIW) and €6423.53/QALY (SIF). At the Spanish reimbursement threshold (€45,000 per QALY) the chance interventions are cost effective is 79.8% for SIW and 97.7% for SIF. Conclusions: Brief structured interventions to discontinue long-term benzodiazepine use represent value for money, particularly with scheduled follow-up appointments, and would represent a cost-effective investment by the Spanish healthcare to reduce prevalence of long-term use.",2020,"Compared to usual care, providing SIW per participant costs an additional €117.94 and adding patient follow-up, €218.4.",['Participants: 75 general practitioners'],"['benzodiazepine', 'long-term benzodiazepines using either Structured Interview with Follow-up (SIF) or Without Follow-up (SIW', 'discontinue long-term benzodiazepine']","['Cost and Cost per Quality-Adjusted Life Year (QALY) Results', 'Cost-effectiveness', 'cost effective', 'cost-effectiveness', 'Incremental Cost Effectiveness Ratio was €8190.28/QALY (SIW) and €6423.53/QALY (SIF']","[{'cui': 'C0017319', 'cui_str': 'General physician'}]","[{'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.12435,"Compared to usual care, providing SIW per participant costs an additional €117.94 and adding patient follow-up, €218.4.","[{'ForeName': 'Dominic', 'Initials': 'D', 'LastName': 'Trépel', 'Affiliation': 'School of Medicine, Trinity College Dublin, Dublin, D02 PN40, Ireland.'}, {'ForeName': 'Shehzad', 'Initials': 'S', 'LastName': 'Ali', 'Affiliation': 'Mental Health and Additions Research Group, Department of Health Sciences, University of York, UK, Heslington, York,, YO10 5DD, UK.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Gilbody', 'Affiliation': 'Mental Health and Additions Research Group, Department of Health Sciences, University of York, UK, Heslington, York,, YO10 5DD, UK.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Leiva', 'Affiliation': 'Instituto de Investigación Sanitaria de Palma, Palma, 07120, Spain.'}, {'ForeName': 'Dean', 'Initials': 'D', 'LastName': 'Mcmillan', 'Affiliation': 'Mental Health and Additions Research Group, Department of Health Sciences, University of York, UK, Heslington, York,, YO10 5DD, UK.'}, {'ForeName': 'Ferran', 'Initials': 'F', 'LastName': 'Bejarano', 'Affiliation': 'Institut Català de la Salut, DAP Camp de Tarragona, Catalunya, Catalunya, Spain.'}, {'ForeName': 'Ermengol', 'Initials': 'E', 'LastName': 'Sempere', 'Affiliation': 'Conselleria de Sanitat Universal i Salut Pública, Paterna Health Care Centre, Valencia, 46010, Spain.'}, {'ForeName': 'Caterina', 'Initials': 'C', 'LastName': 'Vicens', 'Affiliation': 'Instituto de Investigación Sanitaria de Palma, Palma, 07120, Spain.'}]",HRB open research,['10.12688/hrbopenres.13049.1'] 2140,32743350,Assessing the Impact of a Game-Centered Mobile App on Community-Dwelling Older Adults' Health Activation.,"Background Older adults experience normative age-graded declines in physical and cognitive performance and many must manage one or more chronic conditions. Exercise programs can help to improve both their physical health and their knowledge, skill, and confidence in managing aspects of their own healthcare, yet a significant barrier is motivating them to adhere to such programs. The purpose of this investigation was to evaluate the impact of a game-centered mobile app (Bingocize®) on older adults' knowledge, skill, and confidence for managing aspects of their healthcare. Methods Community-dwelling older adults (N=84) with mobility and not engaged in any structured exercise program were recruited from rural community senior centers in Kentucky and Tennessee. Participants were randomly assigned to (a) a version that included health education, or (b) health education and an exercise component. Participants used the app in a group setting for 10 weeks, twice per week, for one hour. The Patient Activation Measure (PAM-10) was used to assess group changes in knowledge, skill, and confidence for managing aspects of their healthcare. The design was a two (Group: Exercise + Health Education vs. Health Education-only) x two (Time: Pre- vs. Post-intervention) and an analyses of variance, with significance p<.05, was used to detect within and between group differences. Results PAM-10 values significantly increased from pre- to post-intervention for both groups, as did knowledge of the health topics (all p < 0.05). Attendance was >93% in both groups. Conclusions Bingocize® engendered high attendance and improved health activation of older adults; however, additional research is needed to examine whether changes in activation result in long-term changes in health behaviour. The Bingocize® mobile app is an enjoyable and effective way to increase health activation in community-dwelling older adults.",2019,The Bingocize® mobile app is an enjoyable and effective way to increase health activation in community-dwelling older adults.,"['community-dwelling older adults', 'Methods\n\n\nCommunity-dwelling older adults (N=84) with mobility and not engaged in any structured exercise program were recruited from rural community senior centers in Kentucky and Tennessee', 'older adults', ""Community-Dwelling Older Adults' Health Activation""]","['Game-Centered Mobile App', 'Exercise + Health Education vs. Health Education-only) x two (Time: Pre- vs. Post-intervention', 'game-centered mobile app (Bingocize®', 'version that included health education, or (b) health education and an exercise component']","['health activation', 'knowledge, skill, and confidence for managing aspects of their healthcare', 'Attendance', 'PAM-10 values']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0086944', 'cui_str': 'Rural Communities'}, {'cui': 'C3658240', 'cui_str': 'Centers for the Aged'}, {'cui': 'C0022557', 'cui_str': 'Kentucky'}, {'cui': 'C0039514', 'cui_str': 'Tennessee'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0449432', 'cui_str': 'Component'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C2931826', 'cui_str': 'Potassium aggravated myotonia'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.0352254,The Bingocize® mobile app is an enjoyable and effective way to increase health activation in community-dwelling older adults.,"[{'ForeName': 'K Jason', 'Initials': 'KJ', 'LastName': 'Crandall', 'Affiliation': 'Western Kentucky University Center for Applied Science in Health and Aging, 2413 Nashville Road Suite, 123, Bowling Green, USA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Shake', 'Affiliation': 'Western Kentucky University Department of Psychological Sciences, 1906 College Heights Blvd, KTH 1002, Bowling Green, USA.'}, {'ForeName': 'Uta', 'Initials': 'U', 'LastName': 'Ziegler', 'Affiliation': 'Western Kentucky University School of Engineering and Applied Science, 1906 College Heights Blvd., COHH 4036, Bowling Green, USA.'}]",OBM integrative and complimentary medicine,['10.21926/obm.icm.1903041'] 2141,32743591,Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19.,"INTRODUCTION Use of hydroxychloroquine in hospitalized patients with COVID-19, especially in combination with azithromycin, has raised safety concerns. Here, we report safety data from three outpatient randomized clinical trials. METHODS We conducted three randomized, double-blind, placebo-controlled trials investigating hydroxychloroquine as pre-exposure prophylaxis, post-exposure prophylaxis and early treatment for COVID-19. We excluded individuals with contraindications to hydroxychloroquine. We collected side effects and serious adverse events. We report descriptive analyses of our findings. RESULTS We enrolled 2,795 participants. The median age of research participants was 40 (IQR 34-49) years, and 59% (1633/2767) reported no chronic medical conditions. Overall 2,324 (84%) participants reported side effect data, and 638 (27%) reported at least one medication side effect. Side effects were reported in 29% with daily, 36% with twice weekly, 31% with once weekly hydroxychloroquine compared to 19% with placebo. The most common side effects were upset stomach or nausea (25% with daily, 18% with twice weekly, 16% with weekly, vs. 10% for placebo), followed by diarrhea, vomiting, or abdominal pain (23% for daily, 16% twice weekly, 12% weekly, vs. 6% for placebo). Two individuals were hospitalized for atrial arrhythmias, one on placebo and one on twice weekly hydroxychloroquine. No sudden deaths occurred. CONCLUSION Data from three outpatient COVID-19 trials demonstrated that gastrointestinal side effects were common but mild with the use of hydroxychloroquine, while serious side effects were rare. No deaths occurred related to hydroxychloroquine. Randomized clinical trials can safely investigate whether hydroxychloroquine is efficacious for COVID-19.",2020,No deaths occurred related to hydroxychloroquine.,"['hospitalized patients with COVID-19', 'Two individuals were hospitalized for atrial arrhythmias, one on', 'We enrolled 2,795 participants']","['placebo', 'azithromycin', 'Hydroxychloroquine', 'hydroxychloroquine']","['Side effects', 'sudden deaths', 'gastrointestinal side effects', 'diarrhea, vomiting, or abdominal pain', 'deaths', 'upset stomach or nausea']","[{'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0085611', 'cui_str': 'Atrial arrhythmia'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0011071', 'cui_str': 'Sudden death'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0235309', 'cui_str': 'Upset stomach'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",2795.0,0.557474,No deaths occurred related to hydroxychloroquine.,"[{'ForeName': 'Sarah M M', 'Initials': 'SMM', 'LastName': 'Lofgren', 'Affiliation': ''}, {'ForeName': 'Melanie R', 'Initials': 'MR', 'LastName': 'Nicol', 'Affiliation': ''}, {'ForeName': 'Ananta S', 'Initials': 'AS', 'LastName': 'Bangdiwala', 'Affiliation': ''}, {'ForeName': 'Katelyn A', 'Initials': 'KA', 'LastName': 'Pastick', 'Affiliation': ''}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Okafor', 'Affiliation': ''}, {'ForeName': 'Caleb P', 'Initials': 'CP', 'LastName': 'Skipper', 'Affiliation': ''}, {'ForeName': 'Matthew F', 'Initials': 'MF', 'LastName': 'Pullen', 'Affiliation': ''}, {'ForeName': 'Nicole W', 'Initials': 'NW', 'LastName': 'Engen', 'Affiliation': ''}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Abassi', 'Affiliation': ''}, {'ForeName': 'Darlisha A', 'Initials': 'DA', 'LastName': 'Williams', 'Affiliation': ''}, {'ForeName': 'Alanna A', 'Initials': 'AA', 'LastName': 'Nascene', 'Affiliation': ''}, {'ForeName': 'Margaret L', 'Initials': 'ML', 'LastName': 'Axelrod', 'Affiliation': ''}, {'ForeName': 'Sylvian A', 'Initials': 'SA', 'LastName': 'Lother', 'Affiliation': ''}, {'ForeName': 'Lauren J', 'Initials': 'LJ', 'LastName': 'MacKenzie', 'Affiliation': ''}, {'ForeName': 'Glen', 'Initials': 'G', 'LastName': 'Drobot', 'Affiliation': ''}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Marten', 'Affiliation': ''}, {'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Cheng', 'Affiliation': ''}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Zarychanshi', 'Affiliation': ''}, {'ForeName': 'Ilan S', 'Initials': 'IS', 'LastName': 'Schwartz', 'Affiliation': ''}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Silverman', 'Affiliation': ''}, {'ForeName': 'Zain', 'Initials': 'Z', 'LastName': 'Chagla', 'Affiliation': ''}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'Kelley', 'Affiliation': ''}, {'ForeName': 'Emily G', 'Initials': 'EG', 'LastName': 'McDonald', 'Affiliation': ''}, {'ForeName': 'Todd C', 'Initials': 'TC', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'Katherine Huppler', 'Initials': 'KH', 'LastName': 'Hullsiek', 'Affiliation': ''}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Boulware', 'Affiliation': ''}, {'ForeName': 'Radha', 'Initials': 'R', 'LastName': 'Rajasingham', 'Affiliation': ''}]",medRxiv : the preprint server for health sciences,['10.1101/2020.07.16.20155531'] 2142,32743594,COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19.,"Background Interleukin-6 (IL-6)-mediated hyperinflammation may contribute to the high mortality of coronavirus disease 2019 (Covid-19). Tocilizumab, an IL-6 receptor blocking monoclonal antibody, has been repurposed for Covid-19, but prospective trials and dose-finding studies in Covid-19 are lacking. Methods We conducted a phase 2 trial of low-dose tocilizumab in hospitalized adult patients with Covid-19, radiographic pulmonary infiltrate, fever, and C-reactive protein (CRP) >= 40 mg/L who did not require mechanical ventilation. Dose cohorts were determined by a trial Operations Committee, stratified by CRP and epidemiologic risk factors. A range of doses from 40 to 200 mg (low-dose tocilizumab) was evaluated, with allowance for one repeat dose at 24-48 hours. The primary objective was to assess the relationship of dose to fever resolution and CRP response. Outcomes were compared with retrospective controls with Covid-19. Correlative studies evaluating host antibody response were performed in parallel. Findings A total of 32 patients received low-dose tocilizumab. This cohort had improved fever resolution (75.0% vs. 34.2%, p = 0.001) and CRP decline (86.2% vs. 14.3%, p < 0.001) in the 24-48 hours following drug administration, as compared to the retrospective controls (N=41). The probabilities of fever resolution or CRP decline did not appear to be dose-related in this small study (p=0.80 and p=0.10, respectively). Within the 28-day follow-up, 5 (15.6%) patients died. For patients who recovered, median time to clinical recovery was 3 days (IQR, 2-5). Clinically presumed and/or cultured bacterial superinfections were reported in 5 (15.6%) patients. Correlative biological studies demonstrated that tocilizumab-treated patients produced anti-SARS-CoV-2 antibodies comparable to controls. Interpretation Low-dose tocilizumab was associated with rapid improvement in clinical and laboratory measures of hyperinflammation in hospitalized patients with Covid-19. Results of this trial and its correlative biological studies provide rationale for a randomized, controlled trial of low-dose tocilizumab in Covid-19.",2020,"This cohort had improved fever resolution (75.0% vs. 34.2%, p = 0.001) and CRP decline (86.2% vs. 14.3%, p < 0.001) in the 24-48 hours following drug administration, as compared to the retrospective controls (N=41).","['32 patients received', 'hospitalized adult patients with Covid-19, radiographic pulmonary infiltrate, fever, and C-reactive protein (CRP) >= 40 mg/L who did not require mechanical ventilation', 'hospitalized patients with Covid-19']","['low-dose tocilizumab', 'Tocilizumab', 'tocilizumab']","['fever resolution', 'median time to clinical recovery', 'relationship of dose to fever resolution and CRP response', 'CRP decline', 'probabilities of fever resolution or CRP decline']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0235896', 'cui_str': 'Lung infiltration'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0439091', 'cui_str': '>='}, {'cui': 'C0439268', 'cui_str': 'mg/L'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}]","[{'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C1609165', 'cui_str': 'tocilizumab'}]","[{'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0033204', 'cui_str': 'Probability'}]",32.0,0.285825,"This cohort had improved fever resolution (75.0% vs. 34.2%, p = 0.001) and CRP decline (86.2% vs. 14.3%, p < 0.001) in the 24-48 hours following drug administration, as compared to the retrospective controls (N=41).","[{'ForeName': 'Garth W', 'Initials': 'GW', 'LastName': 'Strohbehn', 'Affiliation': ''}, {'ForeName': 'Brian L', 'Initials': 'BL', 'LastName': 'Heiss', 'Affiliation': ''}, {'ForeName': 'Sherin J', 'Initials': 'SJ', 'LastName': 'Rouhani', 'Affiliation': ''}, {'ForeName': 'Jonathan A', 'Initials': 'JA', 'LastName': 'Trujillo', 'Affiliation': ''}, {'ForeName': 'Jovian', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': ''}, {'ForeName': 'Alec J', 'Initials': 'AJ', 'LastName': 'Kacew', 'Affiliation': ''}, {'ForeName': 'Emily F', 'Initials': 'EF', 'LastName': 'Higgs', 'Affiliation': ''}, {'ForeName': 'Jeffrey C', 'Initials': 'JC', 'LastName': 'Bloodworth', 'Affiliation': ''}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Cabanov', 'Affiliation': ''}, {'ForeName': 'Rachel C', 'Initials': 'RC', 'LastName': 'Wright', 'Affiliation': ''}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Koziol', 'Affiliation': ''}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Weiss', 'Affiliation': ''}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Danahey', 'Affiliation': ''}, {'ForeName': 'Theodore G', 'Initials': 'TG', 'LastName': 'Karrison', 'Affiliation': ''}, {'ForeName': 'Cuoghi C', 'Initials': 'CC', 'LastName': 'Edens', 'Affiliation': ''}, {'ForeName': 'Iazsmin Bauer', 'Initials': 'IB', 'LastName': 'Ventura', 'Affiliation': ''}, {'ForeName': 'Natasha N', 'Initials': 'NN', 'LastName': 'Pettit', 'Affiliation': ''}, {'ForeName': 'Bhakti', 'Initials': 'B', 'LastName': 'Patel', 'Affiliation': ''}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Pisano', 'Affiliation': ''}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Strek', 'Affiliation': ''}, {'ForeName': 'Thomas F', 'Initials': 'TF', 'LastName': 'Gajewski', 'Affiliation': ''}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Ratain', 'Affiliation': ''}, {'ForeName': 'Pankti D', 'Initials': 'PD', 'LastName': 'Reid', 'Affiliation': ''}]",medRxiv : the preprint server for health sciences,['10.1101/2020.07.20.20157503'] 2143,32743900,Does intensity of stimulus and culture matter in death anxiety?,"Two experiments were designed to study the effect of mortality salience (MS) and terror attack news on socioreligious attribution of Muslims in Pakistan. The first sample of students (n = 238) was taken from public and private universities of Pakistan. The age range of the sample was 18-37 years. Participants were randomly assigned to one of eight conditions: 2 (MS vs. pain salience) × 4 (non-Muslims attacking Muslims vs. Muslims attacking non-Muslims vs. Muslims attacking Muslims vs. weather news). Results indicated a non-significant main effect of MS (p = .83) on socioreligious attribution. Similarly, a non-significant interaction effect (p = .76.) on socioreligious attribution was found. However, the main effect of terror news was significant (p = .01). Post hoc analyses revealed that individuals exposed to the news video showing Muslims attacking non-Muslims scored significantly higher than the rest. Study II was conducted to compare the results of Study I by observing the effect of MS and four news videos after introducing MS through death simulation. The sample of students (n = 120) was taken from public and private universities of Rawalpindi and Islamabad. The age range of the sample was 18-37 years. Participants were randomly assigned to one of eight conditions: 2 (MS vs. pain salience) × 4 (non-Muslims attacking Muslims vs. Muslims attacking non-Muslims vs. Muslims attacking Muslims vs. weather news). Results indicated a significant main effect of MS (p = .001) on socioreligious attribution. Similarly, findings indicated a significant interaction effect (ρ = .001) on socioreligious attribution. These studies were conducted within the culture and religion in question. Further studies on terror management theory are needed in Pakistan to benefit from the work being done on post-traumatic stress disorder with reference to Pakistan.",2020,Post hoc analyses revealed that individuals exposed to the news video showing Muslims attacking non-Muslims scored significantly higher than the rest.,"['students (n = 238) was taken from public and private universities of Pakistan', 'sample of students (n = 120) was taken from public and private universities of Rawalpindi and Islamabad', 'Muslims in Pakistan', 'The age range of the sample was 18-37\u2009years']",['eight conditions: 2 (MS vs. pain salience'],"['mortality salience (MS', 'socioreligious attribution']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0033175', 'cui_str': 'Private Room'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0030211', 'cui_str': 'Pakistan'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0022126', 'cui_str': 'Islam'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",238.0,0.0231727,Post hoc analyses revealed that individuals exposed to the news video showing Muslims attacking non-Muslims scored significantly higher than the rest.,"[{'ForeName': 'Saiyida', 'Initials': 'S', 'LastName': 'Tasmeera', 'Affiliation': 'Department of Psychology, Foundation University Islamabad, Rawalpindi, Pakistan.'}, {'ForeName': 'Tanvir', 'Initials': 'T', 'LastName': 'Akhtar', 'Affiliation': 'Department of Psychology, Foundation University Islamabad, Rawalpindi, Pakistan.'}, {'ForeName': 'M Yasir Masood', 'Initials': 'MYM', 'LastName': 'Afaq', 'Affiliation': 'Department of Psychology, National University of Modern Languages, Islamabad, Pakistan.'}]",PsyCh journal,['10.1002/pchj.380'] 2144,32743919,Effects of strength-based intervention on health outcomes of family caregivers of persons with dementia: A study protocol.,"AIMS This study aims at identifying the health effects of a strength-based intervention on family caregivers of persons with dementia and to explore the underlying mechanism. The perception of family caregivers on the strength-based intervention will also be explored. DESIGN This sequential mixed-method study comprises a double-blind randomized controlled trial and a descriptive qualitative study. METHODS A group of 372 family caregivers of persons with dementia will be recruited from community settings. They will be randomized to receive the strength-based intervention or a dementia education program. Based on Antonovksy's theory of salutogenesis, the strength-based intervention integrates skills of narrative therapy and empowerment strategies. It comprises 14 weekly group-based sessions and two bi-weekly follow-up telephone calls. The education program serves as the control intervention. Validated instruments are used to measure sense of coherence, coping, caregiver burden, and health-related quality of life at baseline, 14 weeks, and 22 weeks. Mixed-effects models and path analysis will be used to identify the treatment effect and the mediating mechanism. A subsample of 30 caregivers who report differential changes in the health outcome will be engaged in qualitative interviews. The study was funded in 2017. DISCUSSION This study marks the first attempt to adopt a theory-driven strength-based approach to improve the health outcomes of family caregivers of persons with dementia. The stringent and comprehensive evaluation will inform its effects and the underlying mechanism. IMPACT This study will have important theoretical and public health implications. Theoretically, the study will enhance understanding of Antonovsky's theory of salutogenesis by examining the modifiability of sense of coherence and the way it enhances health-related outcomes. In terms of public health implications, the strength-based intervention focusing on optimizing the inner strength can provide a new paradigm to promote the adjustment of family caregivers of persons with dementia. TRIAL REGISTRATION This project was registered in the Clinical Trials Registry of the Centre for Clinical Research and Biostatistics (registration number: CUHK_CCRB00551; date registered: 6 April 2017).",2020,"Validated instruments are used to measure sense of coherence, coping, caregiver burden, and health-related quality of life at baseline, 14 weeks, and 22 weeks.","['A group of 372 family caregivers of persons with dementia will be recruited from community settings', 'family caregivers of persons with dementia']","['strength-based intervention', 'strength-based intervention or a dementia education program']","['health outcomes', 'sense of coherence, coping, caregiver burden, and health-related quality of life']","[{'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C3178983', 'cui_str': 'Salutogenesis'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.0385617,"Validated instruments are used to measure sense of coherence, coping, caregiver burden, and health-related quality of life at baseline, 14 weeks, and 22 weeks.","[{'ForeName': 'Sfy', 'Initials': 'S', 'LastName': 'Doris', 'Affiliation': 'School of Nursing, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Sheung-Tak', 'Initials': 'ST', 'LastName': 'Cheng', 'Affiliation': 'Department of Health and Physical Education, The Education University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Esther Oi-Wah', 'Initials': 'EO', 'LastName': 'Chow', 'Affiliation': 'Department of Social and Behavioural Sciences, The City University of Hong Kong, Hong Kong, UK.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Kwok', 'Affiliation': 'Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Brendan', 'Initials': 'B', 'LastName': 'Mccormack', 'Affiliation': 'Division of Nursing, Occupational Therapy & Arts Therapies, Queen Margaret University, Edinburgh, UK.'}]",Journal of advanced nursing,['10.1111/jan.14470'] 2145,32743950,A pilot study of the preliminary efficacy of Pain Buddy: A novel intervention for the management of children's cancer-related pain.,"OBJECTIVES Cancer-related pain in children is prevalent and undermanaged. Mobile health (mHealth) applications provide a promising avenue to address the gap in pain management in children with cancer. Pain Buddy is a multicomponent mHealth application developed to manage cancer-related pain in children. The goal of this paper is to present preliminary efficacy data of the impact of Pain Buddy on children's pain severity and frequency. METHODS In a randomized controlled trial over 60 days, children (N = 48) reported daily pain on a tablet while receiving usual care. Those in the intervention group (N = 20) received remote symptom monitoring and skills training for pain management. Children in the attention control group (N = 28) only reported on their pain. RESULTS Both groups experienced significant reductions in average daily pain over the study period (B = -0.10, z = -3.40, P = 0.001), with no group differences evident (z = -0.83, P = 0.40). However, the intervention group reported significantly fewer instances of moderate to severe pain compared with the control group, t(4125) = 2.67, P = 0.007. In addition, the intervention group reported no instances of moderate to severe pain toward the end of the study period. CONCLUSION Pain Buddy is an innovative and interactive mHealth application that aims to improve pain and symptom management among children with cancer. The findings from this pilot study suggest that Pain Buddy may aid in the reduction of pain severity in children during cancer treatment.",2020,Pain Buddy is an innovative and interactive mHealth application that aims to improve pain and symptom management among children with cancer.,"[""children's pain severity and frequency"", 'children', '60 days, children (N\xa0=\xa048', 'children with cancer', ""children's cancer-related pain"", 'children during cancer treatment']","['remote symptom monitoring and skills training for pain management', 'Pain Buddy']","['moderate to severe pain', 'daily pain', 'average daily pain', 'pain severity', 'pain and symptom management', 'pain']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0596240', 'cui_str': 'Cancer pain'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C1273397', 'cui_str': 'Pain and symptom management'}]",,0.0571252,Pain Buddy is an innovative and interactive mHealth application that aims to improve pain and symptom management among children with cancer.,"[{'ForeName': 'John F', 'Initials': 'JF', 'LastName': 'Hunter', 'Affiliation': 'Department of Psychological Science, University of California-Irvine, Irvine, California.'}, {'ForeName': 'Amanda M', 'Initials': 'AM', 'LastName': 'Acevedo', 'Affiliation': 'Department of Psychological Science, University of California-Irvine, Irvine, California.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Gago-Masague', 'Affiliation': 'Department of Computer Science, University of California-Irvine, Irvine, California.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Kain', 'Affiliation': 'Center on Stress and Health, School of Medicine, University of California-Irvine, Orange, California.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Yun', 'Affiliation': ""CHOC Children's Hospital, Hyundai Cancer Institute, Orange, California.""}, {'ForeName': 'Lilibeth', 'Initials': 'L', 'LastName': 'Torno', 'Affiliation': ""CHOC Children's Hospital, Hyundai Cancer Institute, Orange, California.""}, {'ForeName': 'Brooke N', 'Initials': 'BN', 'LastName': 'Jenkins', 'Affiliation': 'Center on Stress and Health, School of Medicine, University of California-Irvine, Orange, California.'}, {'ForeName': 'Michelle A', 'Initials': 'MA', 'LastName': 'Fortier', 'Affiliation': 'Center on Stress and Health, School of Medicine, University of California-Irvine, Orange, California.'}]",Pediatric blood & cancer,['10.1002/pbc.28278'] 2146,32743954,Prucalopride in diabetic and connective tissue disease-related gastroparesis: Randomized placebo-controlled crossover pilot trial.,"BACKGROUND Gastroparesis, defined by delayed gastric emptying in the absence of mechanical outlet obstruction, is a frequent neuropathic complication of diabetes mellitus, and effective treatments are lacking. Prucalopride is a pan-gut prokinetic with selective agonist effects on serotonin 5-HT4 receptors in the gut. This study aimed to assess the effect of prucalopride 4 mg daily on Gastroparesis Cardinal Symptom Index (GCSI), meal-related symptom score (MRSS), and gastric emptying rate in diabetic or connective tissue disease (CTD)-related gastroparesis patients. METHODS This was a double-blind crossover trial of four-week treatment periods with prucalopride or placebo divided by two weeks of washout. GSCI, MRSS, gastric emptying scintigraphy, PAGI-SYM, and PAGI-QoL were assessed at baseline and the end of each treatment period. Daily bowel movement (BM) frequency and gastrointestinal symptoms were recorded in each period. KEY RESULTS Fifteen gastroparesis patients (13 diabetic, 2 CTD) were enrolled. GCSI scores were lower than baseline but not different between treatment arms. MRSS scores over time or cumulative score were not significantly different between groups. Gastric emptying was more rapid in the prucalopride treatment period, with mean four-hour meal retention of 22 ± 6% in PRU period vs 40 ± 9% in the placebo period (P = 0.05). Weekly BM frequency was significantly higher in prucalopride than placebo periods (10.5 ± 1.8 vs 7.5 ± 0.8, P < 0.0001). Perception of weight loss was higher in patients on prucalopride. Analysis of diabetic gastroparesis (n = 13) population did not change the conclusions. CONCLUSION AND INFERENCE Prucalopride at 4 mg accelerates gastric emptying and bowel movement frequency but does not appear to ameliorate gastroparesis or meal-related symptoms in this study.",2020,"Gastric emptying was more rapid in the prucalopride treatment period, with mean four-hour meal retention of 22 ± 6% in PRU period vs 40 ± 9% in the placebo period (P = 0.05).","['diabetic or connective tissue disease (CTD)-related gastroparesis patients', 'diabetic and connective tissue disease-related gastroparesis', 'Fifteen gastroparesis patients (13 diabetic, 2 CTD) were enrolled']","['Prucalopride', 'prucalopride', 'prucalopride or placebo', 'placebo']","['Weekly BM frequency', 'gastric emptying and bowel movement frequency', 'MRSS scores over time or cumulative score', 'GCSI scores', 'GSCI, MRSS, gastric emptying scintigraphy, PAGI-SYM, and PAGI-QoL', 'Gastric emptying', 'Gastroparesis Cardinal Symptom Index (GCSI), meal-related symptom score (MRSS), and gastric emptying rate', 'Daily bowel movement (BM) frequency and gastrointestinal symptoms', 'Perception of weight loss']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0009782', 'cui_str': 'Disorder of connective tissue'}, {'cui': 'C0152020', 'cui_str': 'Gastroparesis syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}]","[{'cui': 'C0913506', 'cui_str': 'prucalopride'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0426642', 'cui_str': 'Frequency of bowel action'}, {'cui': 'C0017127', 'cui_str': 'Gastric emptying'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0152020', 'cui_str': 'Gastroparesis syndrome'}, {'cui': 'C0326926', 'cui_str': 'Cardinalis cardinalis'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}]",15.0,0.270697,"Gastric emptying was more rapid in the prucalopride treatment period, with mean four-hour meal retention of 22 ± 6% in PRU period vs 40 ± 9% in the placebo period (P = 0.05).","[{'ForeName': 'Christopher N', 'Initials': 'CN', 'LastName': 'Andrews', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Woo', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Buresi', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Curley', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Milli', 'Initials': 'M', 'LastName': 'Gupta', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Tack', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders (TARGID), University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Wilsack', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Yasmin', 'Initials': 'Y', 'LastName': 'Nasser', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}]",Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,['10.1111/nmo.13958'] 2147,32744134,A Simple Goal Elicitation Tool Improves Shared Decision Making in Outpatient Orthopedic Surgery: A Randomized Controlled Trial.,"Introduction . Shared decision making involves educating the patient, eliciting their goals, and collaborating on a decision for treatment. Goal elicitation is challenging for physicians as previous research has shown that patients do not bring up their goals on their own. Failure to properly elicit patient goals leads to increased patient misconceptions and decisional conflict. We performed a randomized controlled trial to test the efficacy of a simple goal elicitation tool in improving patient involvement in decision making. Methods . We conducted a randomized, single-blind study of new patients presenting to a single, outpatient surgical center. Prior to their consultation, the intervention group received a demographics questionnaire and a goal elicitation worksheet. The control group received a demographics questionnaire only. After the consultation, both groups were asked to complete the Perceived Involvement in Care Scale (PICS) survey. We compared the mean PICS scores for the intervention and control groups using a nonparametric Mann-Whitney Wilcoxon test. Secondary analysis included a qualitative content analysis of the patient goals. Results . Our final cohort consisted of 96 patients (46 intervention, 50 control). Both groups were similar in terms of demographic composition. The intervention group had a significantly higher mean (SD) PICS score compared to the control group (9.04 [2.15] v. 7.54 [2.27], P < 0.01). Thirty-nine percent of patient goals were focused on receiving a diagnosis or treatment, while 21% of patients wanted to receive education regarding their illness or their treatment options. Discussion . A single-step goal elicitation tool was effective in improving patient-perceived involvement in their care. This tool can be efficiently implemented in both academic and nonacademic settings.",2020,"The intervention group had a significantly higher mean (SD) PICS score compared to the control group (9.04 [2.15] v. 7.54 [2.27], P < 0.01).","['96 patients (46 intervention, 50 control', 'Outpatient Orthopedic Surgery', 'new patients presenting to a single, outpatient surgical center']","['demographics questionnaire and a goal elicitation worksheet', 'demographics questionnaire only']","['mean PICS scores', 'qualitative content analysis of the patient goals', 'mean (SD) PICS score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0018017', 'cui_str': 'Goal'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0730321', 'cui_str': 'Punctate inner choroidopathy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205556', 'cui_str': 'Qualitative'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018017', 'cui_str': 'Goal'}]",96.0,0.0671466,"The intervention group had a significantly higher mean (SD) PICS score compared to the control group (9.04 [2.15] v. 7.54 [2.27], P < 0.01).","[{'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Mertz', 'Affiliation': 'VOICES Health Policy Research Center, Department of Orthopaedic Surgery, Stanford University, CA, USA.'}, {'ForeName': 'Romil F', 'Initials': 'RF', 'LastName': 'Shah', 'Affiliation': 'VOICES Health Policy Research Center, Department of Orthopaedic Surgery, Stanford University, CA, USA.'}, {'ForeName': 'Sara L', 'Initials': 'SL', 'LastName': 'Eppler', 'Affiliation': 'VOICES Health Policy Research Center, Department of Orthopaedic Surgery, Stanford University, CA, USA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Yao', 'Affiliation': 'VOICES Health Policy Research Center, Department of Orthopaedic Surgery, Stanford University, CA, USA.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Safran', 'Affiliation': 'VOICES Health Policy Research Center, Department of Orthopaedic Surgery, Stanford University, CA, USA.'}, {'ForeName': 'Ariel', 'Initials': 'A', 'LastName': 'Palanca', 'Affiliation': 'VOICES Health Policy Research Center, Department of Orthopaedic Surgery, Stanford University, CA, USA.'}, {'ForeName': 'Serena S', 'Initials': 'SS', 'LastName': 'Hu', 'Affiliation': 'VOICES Health Policy Research Center, Department of Orthopaedic Surgery, Stanford University, CA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Gardner', 'Affiliation': 'VOICES Health Policy Research Center, Department of Orthopaedic Surgery, Stanford University, CA, USA.'}, {'ForeName': 'Derek F', 'Initials': 'DF', 'LastName': 'Amanatullah', 'Affiliation': 'VOICES Health Policy Research Center, Department of Orthopaedic Surgery, Stanford University, CA, USA.'}, {'ForeName': 'Robin N', 'Initials': 'RN', 'LastName': 'Kamal', 'Affiliation': 'VOICES Health Policy Research Center, Department of Orthopaedic Surgery, Stanford University, CA, USA.'}]",Medical decision making : an international journal of the Society for Medical Decision Making,['10.1177/0272989X20943520'] 2148,32744184,Pregnancy outcomes among women born in Somalia and Sweden giving birth in the Stockholm area - a population-based study.,"BACKGROUND Studies report that women born in some African countries, after migrating to the Nordic countries, have worse pregnancy outcomes than women born in the receiving countries. With the aim of identifying unmet needs among Somali-born women, we here study this subgroup. OBJECTIVE We compared pregnancy outcomes among women born in Somalia to women born in Sweden. Further, we investigated whether the proactive maternal observation of fetal movements has effects on birth outcomes among women born in Somalia. METHODS In Stockholm, half of the maternity clinics were randomized to intervention, in which midwives were instructed to be proactive towards women by promoting daily self-monitoring of fetal movements. Data for 623 women born in Somalia and 26 485 born in Sweden were collected from a population-based register. RESULTS An Apgar score below 7 (with stillbirth counting as 0) at 5 minutes was more frequent in babies of women born in Somalia as compared to babies of women born in Sweden (RR 2.17, 95% CI 1.25-3.77). Babies born small for gestational age were more common among women born in Somalia (RR 2.22, CI 1.88-2.61), as were babies born after 41 + 6 gestational weeks (RR 1.65, CI 1.29-2.12). Somali-born women less often contacted obstetric care for decreased fetal movements than did Swedish-born women (RR 0.19, CI 0.08-0.36). The differences between women born in Somalia and women born in Sweden were somewhat lower (not statistically significant) among women allocated to proactivity as compared to the Routine-care group. CONCLUSIONS A higher risk of a negative outcome for mother and baby is seen among women born in Somalia compared to women born in Sweden. We suggest it may be worthwhile to investigate whether a Somali-adapted intervention with proactivity concerning self-monitoring of fetal movements may improve pregnancy outcomes in this migrant population.",2020,"The differences between women born in Somalia and women born in Sweden were somewhat lower (not statistically significant) among women allocated to proactivity as compared to the Routine-care group. ","['women born in Somalia and Sweden giving birth in the Stockholm area - a population-based study', '623 women born in Somalia and 26 485 born in Sweden were collected from a population-based register', 'women born in Somalia', 'women born in Somalia to women born in Sweden', 'women born in Somalia compared to women born in Sweden', 'Somali-born women', 'women born in some African countries']",['proactive towards women by promoting daily self-monitoring of fetal movements'],"['Pregnancy outcomes', 'Apgar score', 'fetal movements']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1277513', 'cui_str': 'Born in Somalia'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1277386', 'cui_str': 'Born in Sweden'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0337847', 'cui_str': 'Somalis'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0454695', 'cui_str': 'African country'}]","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0015946', 'cui_str': 'Fetal movement activity'}]","[{'cui': 'C0032972', 'cui_str': 'Outcomes, Pregnancy'}, {'cui': 'C0003533', 'cui_str': 'Finding of Apgar score'}, {'cui': 'C0015946', 'cui_str': 'Fetal movement activity'}]",,0.0919175,"The differences between women born in Somalia and women born in Sweden were somewhat lower (not statistically significant) among women allocated to proactivity as compared to the Routine-care group. ","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Akselsson', 'Affiliation': 'Department of Health Promoting Science, Sophiahemmet University , Stockholm, Sweden.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Lindgren', 'Affiliation': ""Department of Women and Children's Health, Karolinska Institutet , Stockholm, Sweden.""}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Georgsson', 'Affiliation': 'The Swedish Red Cross University College , Stockholm, Sweden.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Pettersson', 'Affiliation': 'Department of Clinical Science, Intervention and Technology, Karolinska Institutet , Stockholm, Sweden.'}, {'ForeName': 'Viktor', 'Initials': 'V', 'LastName': 'Skokic', 'Affiliation': 'Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , Gothenburg, Sweden.'}, {'ForeName': 'Ingela', 'Initials': 'I', 'LastName': 'Rådestad', 'Affiliation': 'Department of Health Promoting Science, Sophiahemmet University , Stockholm, Sweden.'}]",Global health action,['10.1080/16549716.2020.1794107'] 2149,32744186,Improving Sleep among Adults with Multiple Sclerosis using Mindfulness plus Sleep Education.,"We explored the feasibility of a mindfulness plus sleep education intervention, SleepWell!, delivered via videoconference compared to onsite among adults with MS. A non-randomized wait-list control design was used. Participants wore actigraphy watches and kept sleep diaries for seven days pre- and post intervention. Questionnaires were completed pre-intervention, post-intervention, and three months post-intervention. One group was conducted onsite. Three groups participated via videoconference. Attrition among videoconference groups was 23% compared to 57% in the onsite group. Within group analysis showed moderate-to-large effect sizes on sleep efficiency (d=0.78) and total sleep time (d=0.54) in the videoconference groups. One-way repeated measures ANOVA post-hoc analysis suggested small-to-medium effect over three months on sleep quality (ηp2 =0.28), physical health quality of life (ηp2 =0.42), mental health quality of life (ηp2 =0.13), and mindfulness (ηp2 =0.29). Results indicate feasibility of providing our intervention via videoconferencing. Preliminary analysis suggests that SleepWell! improves sleep and mindfulness among adults with MS.",2020,"One-way repeated measures ANOVA post-hoc analysis suggested small-to-medium effect over three months on sleep quality (ηp2 =0.28), physical health quality of life (ηp2 =0.42), mental health quality of life (ηp2 =0.13), and mindfulness (ηp2 =0.29).","['adults with MS', 'Adults with Multiple Sclerosis using Mindfulness plus Sleep Education']","['videoconference', 'mindfulness plus sleep education intervention, SleepWell!, delivered via videoconference']","['total sleep time', 'physical health quality of life', 'actigraphy watches and kept sleep diaries', 'mental health quality of life', 'sleep quality', 'sleep efficiency', 'sleep and mindfulness', 'Improving Sleep']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C1450049', 'cui_str': 'Videoconference'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",,0.0268273,"One-way repeated measures ANOVA post-hoc analysis suggested small-to-medium effect over three months on sleep quality (ηp2 =0.28), physical health quality of life (ηp2 =0.42), mental health quality of life (ηp2 =0.13), and mindfulness (ηp2 =0.29).","[{'ForeName': 'Rebecca A', 'Initials': 'RA', 'LastName': 'Lorenz', 'Affiliation': 'School of Nursing, University at Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Auerbach', 'Affiliation': 'School of Nursing, University at Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Nisbet', 'Affiliation': 'School of Nursing, University at Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'Loralee', 'Initials': 'L', 'LastName': 'Sessanna', 'Affiliation': 'School of Nursing, University at Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'Nouf', 'Initials': 'N', 'LastName': 'Alanazi', 'Affiliation': 'School of Nursing, University at Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Lach', 'Affiliation': 'School of Nursing, Saint Louis University, Saint Louis, MO, USA.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Newland', 'Affiliation': 'Goldfarb School of Nursing at Barnes-Jewish College, St Louis, MO, USA.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Fisher', 'Affiliation': 'School of Nursing, University at Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'Krupa', 'Initials': 'K', 'LastName': 'Pandey', 'Affiliation': 'Multiple Sclerosis Center, Department of Neurology, Hackensack University Medical Center, Hackensack Meridian School of Medicine, Hackensack, NJ, USA.'}, {'ForeName': 'Florian P', 'Initials': 'FP', 'LastName': 'Thomas', 'Affiliation': 'Multiple Sclerosis Center, Department of Neurology, Hackensack University Medical Center, Hackensack Meridian School of Medicine, Hackensack, NJ, USA.'}, {'ForeName': 'Yu-Ping', 'Initials': 'YP', 'LastName': 'Chang', 'Affiliation': 'School of Nursing, University at Buffalo, Buffalo, NY, USA.'}]",Western journal of nursing research,['10.1177/0193945920947409'] 2150,32744208,Projecting effectiveness after ending a randomized controlled trial: a two-state Markov microsimulation model.,"OBJECTIVE To investigate the behavior of restricted mean survival time (RMST) and designs of a two-state Markov microsimulation model through a 2 × 4 × 2 full factorial experiment. METHOD By projecting patient-wise 15-year-post-trial survival, we estimated life-year-gained between an intervention and a control group using data from the Cardiovascular Outcomes for People Using Anticoagulation Strategies Study (COMPASS). Projections considered either in-trial events or post-trial medications. They were compared based on three factors: (i) choice of probability of death, (ii) lengths of cycle, and (iii) usage of half-a-cycle age correction. Three-way analysis of variance and post-hoc Tukey's Honest Significant Difference test compared means among factors. RESULTS When both in-trial events and post-trial study medications were considered, monthly, quarterly, or semiannually were not different from one other in projected life-year-gained. However, the annual one was different from the others: mean and 95 percent confidence interval 252.2 (190.5-313.9) days monthly, 251.8 (192.0-311.6) quarterly, 249.1 (189.7-308.5) semiannually, and 240.8 (178.5-303.1) annually. The other two factors also impacted life-year-gained: background probability (269.1 [260.3-277.9] days projected with REACH-based-probabilities, 227.7 [212.6-242.8] with a USA life table); half-a-cycle age correction (245.5 [199.0-292] with correction and 251.4 [209.1-293.7] without correction). When not considering post-trial medications, only the choice of probability of death appeared to impact life-year-gained. CONCLUSION For a large trial or cohort, to optimally project life-year-gained, one should consider using (i) annual projections, (ii) life table probabilities, (iii) in-trial events, and (iv) post-trial medication use.",2020,"When not considering post-trial medications, only the choice of probability of death appeared to impact life-year-gained. ","['By projecting patient-wise 15-year-post-trial survival, we estimated life-year-gained between an intervention and a control group using data from the Cardiovascular Outcomes for People Using Anticoagulation Strategies Study (COMPASS']",[],"['probability of death, (ii) lengths of cycle, and (iii) usage of half-a-cycle age correction', 'mean survival time (RMST']","[{'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}]",[],"[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0457083', 'cui_str': 'Usage'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086595', 'cui_str': 'Mean Survival Time'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}]",292.0,0.223307,"When not considering post-trial medications, only the choice of probability of death appeared to impact life-year-gained. ","[{'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Yuan', 'Affiliation': 'Population Health Research Institute, DBCVSRI, 20 Copeland Avenue, Hamilton, ONL8L 2X2, Canada.'}, {'ForeName': 'Shrikant I', 'Initials': 'SI', 'LastName': 'Bangdiwala', 'Affiliation': 'Population Health Research Institute, DBCVSRI, 20 Copeland Avenue, Hamilton, ONL8L 2X2, Canada.'}, {'ForeName': 'Wesley', 'Initials': 'W', 'LastName': 'Tong', 'Affiliation': 'Population Health Research Institute, DBCVSRI, 20 Copeland Avenue, Hamilton, ONL8L 2X2, Canada.'}, {'ForeName': 'Andre', 'Initials': 'A', 'LastName': 'Lamy', 'Affiliation': 'Population Health Research Institute, DBCVSRI, 20 Copeland Avenue, Hamilton, ONL8L 2X2, Canada.'}]",International journal of technology assessment in health care,['10.1017/S0266462320000446'] 2151,32746948,Television advertisements for high sugar foods and beverages: Effect on children's snack food intake.,"Energy-dense food advertising affects children's eating behaviour. However, the impact of high sugar food advertising specifically on the intake of sweet foods is underexplored. This study sought to determine whether children would increase their intake of sugar, and total energy, following high sugar food advertising (relative to toy advertising) and whether dental health, weight status, and socioeconomic status (SES) would moderate any effect. In a cross-over, randomised controlled trial, 101 UK children (40 male) aged 8-10 years were exposed to high sugar food/beverage and toy advertisements embedded within a cartoon. Their subsequent intake of snack foods and beverages varying in sugar content was measured. A dental examination was performed and height and weight measurements were taken. Home postcode provided by parents was used to assign participants to SES quintiles. Children consumed a significantly greater amount of energy (48.6kcal, 95% CI 13.5-83.7, p=0.007) and sugar (6.0g, 95% CI 1.3 to 10.7, p=0.012) following food advertisements compared with after toy advertisements. This was driven by increased intake of the items with most sugar (chocolate, jelly sweets). Children of healthy weight and with dental caries had the greatest intake response to food advertising exposure, but there were no differences by SES. Acute experimental food advertising exposure increases food intake in children. Specifically, high sugar food and beverage advertising promotes the consumption of high sugar food items. The debate around the negative health effects of food advertising on children should be widened to include dental health as well as overall dietary health and obesity.",2020,"Children consumed a significantly greater amount of energy (48.6kcal, 95% CI 13.5-83.7, p=0.007) and sugar (6.0g, 95% CI 1.3 to 10.7, p=0.012) following food advertisements compared with after toy advertisements.","['children', ""children's snack food intake"", 'Children of healthy weight and with dental caries', '101 UK children (40 male) aged 8-10 years', ""children's eating behaviour""]",['high sugar food/beverage and toy advertisements embedded within a cartoon'],"['intake of sugar, and total energy', 'sugar content', 'amount of energy']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0453863', 'cui_str': 'Snack food'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0015745', 'cui_str': 'Eating Behavior'}]","[{'cui': 'C0453865', 'cui_str': 'Sweet food'}, {'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}, {'cui': 'C0040565', 'cui_str': 'Toy'}, {'cui': 'C0949214', 'cui_str': 'Advertisements'}, {'cui': 'C0007306', 'cui_str': 'Cartoons'}]","[{'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}]",101.0,0.124295,"Children consumed a significantly greater amount of energy (48.6kcal, 95% CI 13.5-83.7, p=0.007) and sugar (6.0g, 95% CI 1.3 to 10.7, p=0.012) following food advertisements compared with after toy advertisements.","[{'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Kearney', 'Affiliation': 'Department of Orthodontics, Liverpool University Dental Hospital, Liverpool, United Kingdom.'}, {'ForeName': 'Rhian', 'Initials': 'R', 'LastName': 'Fitzgerald', 'Affiliation': 'Department of Orthodontics, Liverpool University Dental Hospital, Liverpool, United Kingdom.'}, {'ForeName': 'Girvan', 'Initials': 'G', 'LastName': 'Burnside', 'Affiliation': 'Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Higham', 'Affiliation': 'School of Dentistry, University of Liverpool, Liverpool, United Kingdom.'}, {'ForeName': 'Norah', 'Initials': 'N', 'LastName': 'Flannigan', 'Affiliation': 'Department of Orthodontics, Liverpool University Dental Hospital, Liverpool, United Kingdom.'}, {'ForeName': 'Jason C G', 'Initials': 'JCG', 'LastName': 'Halford', 'Affiliation': 'Department of Psychology, University of Liverpool, Liverpool, United Kingdom.'}, {'ForeName': 'Emma J', 'Initials': 'EJ', 'LastName': 'Boyland', 'Affiliation': 'Department of Psychology, University of Liverpool, Liverpool, United Kingdom.'}]",The British journal of nutrition,['10.1017/S0007114520003116'] 2152,32746950,Investigating cultural differences in the effects of expressive suppression when processing traumatic distressing material.,"BACKGROUND While suppression is associated with detrimental post-traumatic psychological adjustment, research has not considered the effect of culture on this relationship. AIMS This study investigated cultural differences in the effects of expressive suppression, whilst watching a traumatic film, on subjective distress, psychophysiological responses and intrusive memory. METHOD Australians of European heritage or East Asian Australian participants (n = 82) were randomly assigned to either a suppression group (instructed to suppress their emotions during the film) or a control group (no instructions regarding emotion management). Electrodermal activity, heart rate and heart rate variability (root mean square of the successive differences; RMSSD) were measured pre-, during and post-film. Participants reported the number of film-related intrusions in the 5 min and 7 days post-viewing. RESULTS While the European Australian group did not differ significantly on RMSSD, the East Asian suppression group scored significantly higher on RMSSD during the film than the East Asian control group. Second, those in the suppression groups, regardless of cultural background, reported significantly fewer intrusions immediately post-film than controls. Third, we found that for the European Australian group, change in heart rate interacted with group (control versus suppression) when predicting weekly intrusions. However, for the East Asian group change in heart rate did not interact with group when predicting weekly intrusions. CONCLUSIONS The findings are discussed in the context of current research on culture and emotion regulation and implications for post-traumatic stress disorder.",2020,"While the European Australian group did not differ significantly on RMSSD, the East Asian suppression group scored significantly higher on RMSSD during the film than the East Asian control group.",['Australians of European heritage or East Asian Australian participants (n = 82'],['suppression group (instructed to suppress their emotions during the film) or a control group (no instructions regarding emotion management'],"['Electrodermal activity, heart rate and heart rate variability (root mean square of the successive differences; RMSSD', 'number of film-related intrusions', 'heart rate', 'RMSSD', 'subjective distress, psychophysiological responses and intrusive memory']","[{'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}]","[{'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0424129', 'cui_str': 'Suppressed emotion'}, {'cui': 'C0347984', 'cui_str': 'During'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0561837', 'cui_str': 'Intrusive memories'}]",82.0,0.0302343,"While the European Australian group did not differ significantly on RMSSD, the East Asian suppression group scored significantly higher on RMSSD during the film than the East Asian control group.","[{'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Nagulendran', 'Affiliation': 'School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Norton', 'Affiliation': 'School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Jobson', 'Affiliation': 'School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia.'}]",Behavioural and cognitive psychotherapy,['10.1017/S1352465820000508'] 2153,32746952,Cocoa-rich chocolate and body composition in postmenopausal women. A randomized clinical trial.,"During menopause, women undergo a series of physiological changes that include a redistribution of fat tissue. This study was designed to investigate the effect of adding 10g of cocoa-rich chocolate to the habitual diet of postmenopausal women daily on body composition. We conducted a 6-month, 2-arm randomized, controlled trial. Postmenopausal women (57.2±3.6 years, n = 132) were recruited in primary care clinics. Participants in the control group (CG) did not receive any intervention. Those of the intervention group (IG) received 10g daily of 99%-cocoa chocolate in addition to their habitual diet for 6-months. This quantity comprises 59 Kcal and 65.4 mg of polyphenols. The primary outcomes were the between-group differences in body composition variables, measured by impendancemetry at the end of the study. The main effect of the intervention showed a favourable reduction in the IG with respect to the CG in body fat mass (-0.63 kg [95%CI: -1.15 to -0.11], p=0.019), (Cohen's d = -0.450) and body fat percentage (-0.79% [95%CI: -1.31 to -0.26], p=0.004), (Cohen's d = -0.539). A non-significant decrease was also observed in body mass index (-0.20 kg/m2 [95%CI: -0.44 to 0.03], p=0.092), (Cohen's d = -0.345). Both the body fat mass and the body fat percentage showed a decrease in the IG for the 3 body segments analysed (trunk, arms and legs). Daily addition of 10 g of cocoa-rich chocolate to the habitual diet of postmenopausal women reduces their body fat mass and body fat percentage without modifying their weight.",2020,"Both the body fat mass and the body fat percentage showed a decrease in the IG for the 3 body segments analysed (trunk, arms and legs).","['postmenopausal women', 'Postmenopausal women (57.2±3.6 years, n = 132) were recruited in primary care clinics', 'postmenopausal women daily on body composition']","['polyphenols', 'cocoa-rich chocolate', 'Cocoa-rich chocolate', '99%-cocoa chocolate']","['body fat percentage', 'body mass index', 'body composition variables', 'body fat mass and body fat percentage without modifying their weight', 'body fat mass']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}]","[{'cui': 'C0071649', 'cui_str': 'Polyphenol'}, {'cui': 'C0006622', 'cui_str': 'Theobroma cacao'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}]","[{'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]",132.0,0.0920202,"Both the body fat mass and the body fat percentage showed a decrease in the IG for the 3 body segments analysed (trunk, arms and legs).","[{'ForeName': 'Irene A', 'Initials': 'IA', 'LastName': 'Garcia-Yu', 'Affiliation': 'Instituto de Investigación Biomédica de Salamanca (IBSAL), Unidad de Investigación de Atención Primaria de Salamanca (APISAL). Servicio de Salud de Castilla y León (SACYL), Salamanca, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Garcia-Ortiz', 'Affiliation': 'Instituto de Investigación Biomédica de Salamanca (IBSAL), Unidad de Investigación de Atención Primaria de Salamanca (APISAL). Servicio de Salud de Castilla y León (SACYL), Salamanca, Spain.'}, {'ForeName': 'Manuel A', 'Initials': 'MA', 'LastName': 'Gomez-Marcos', 'Affiliation': 'Instituto de Investigación Biomédica de Salamanca (IBSAL), Unidad de Investigación de Atención Primaria de Salamanca (APISAL). Servicio de Salud de Castilla y León (SACYL), Salamanca, Spain.'}, {'ForeName': 'Emiliano', 'Initials': 'E', 'LastName': 'Rodriguez-Sanchez', 'Affiliation': 'Instituto de Investigación Biomédica de Salamanca (IBSAL), Unidad de Investigación de Atención Primaria de Salamanca (APISAL). Servicio de Salud de Castilla y León (SACYL), Salamanca, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Lugones-Sanchez', 'Affiliation': 'Instituto de Investigación Biomédica de Salamanca (IBSAL), Unidad de Investigación de Atención Primaria de Salamanca (APISAL). Servicio de Salud de Castilla y León (SACYL), Salamanca, Spain.'}, {'ForeName': 'Jose A', 'Initials': 'JA', 'LastName': 'Maderuelo-Fernandez', 'Affiliation': 'Instituto de Investigación Biomédica de Salamanca (IBSAL), Unidad de Investigación de Atención Primaria de Salamanca (APISAL). Servicio de Salud de Castilla y León (SACYL), Salamanca, Spain.'}, {'ForeName': 'Jose I', 'Initials': 'JI', 'LastName': 'Recio-Rodriguez', 'Affiliation': 'Instituto de Investigación Biomédica de Salamanca (IBSAL), Unidad de Investigación de Atención Primaria de Salamanca (APISAL). Servicio de Salud de Castilla y León (SACYL), Salamanca, Spain.'}]",The British journal of nutrition,['10.1017/S0007114520003086'] 2154,32744369,Clinical outcomes of topical bimatoprost for non-segmental facial vitiligo: a preliminary study.,"BACKGROUND Vitiligo is a common acquired pigmentary disorder. Bimatoprost ophthalmic solution was indicated in the treatment of open-angle glaucoma and eyebrow hypotrichosis. However, lid hyperpigmentation was reported as a complication. OBJECTIVE To study the efficacy and safety of 0.01% bimatoprost solution compared with 0.1% tacrolimus ointment in patients with non-segmental facial vitiligo. METHODS Patients with more than 2 vitiliginous patches on the face were enrolled. Vitiliginous patches were randomized to receive topical 0.1% tacrolimus ointment or 0.01% bimatoprost ophthalmic solution, applied twice daily for 12 weeks. The vitiligo surface area (VSA, cm 2 ) was calculated, and the percentage of repigmentation was assessed. RESULTS Ten patients completed the study. At the baseline, the mean VSA was comparable between the two groups. By week 12, the VSA decreased at a statistically significant level among both groups compared to the baseline (p < 0.05). However, there was not a statistically significant difference between both groups. In terms of repigmentation at week 12, 20% of the patients in the bimatoprost group and 10% in the tacrolimus group achieved >50% repigmentation, the overall grading score between two groups were not different at a statistically significant level. The side effects of bimatoprost were reported as itching and burning. There were no changes in intraocular pressure in 2 patients who had lid involvement. CONCLUSION Topical bimatoprost solutions were safe and effective for the treatment of non-segmental facial vitiligo with comparable results to tacrolimus ointment. It can be considered as an alternative treatment for facial vitiligo.",2020,Topical bimatoprost solutions were safe and effective for the treatment of non-segmental facial vitiligo with comparable results to tacrolimus ointment.,"['Vitiliginous patches', 'Patients with more than 2 vitiliginous patches on the face were enrolled', 'non-segmental facial vitiligo', 'patients with non-segmental facial vitiligo']","['tacrolimus ointment', 'topical bimatoprost', 'Topical bimatoprost solutions', 'bimatoprost solution', 'topical 0.1% tacrolimus ointment or 0.01% bimatoprost ophthalmic solution', 'tacrolimus', 'Bimatoprost ophthalmic solution']","['safe and effective', 'lid hyperpigmentation', 'mean VSA', 'overall grading score', 'itching and burning', 'VSA', 'efficacy and safety', 'intraocular pressure']","[{'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0205122', 'cui_str': 'Segmental'}, {'cui': 'C0042900', 'cui_str': 'Vitiligo'}]","[{'cui': 'C1253468', 'cui_str': 'Tacrolimus Topical Ointment'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0937917', 'cui_str': 'bimatoprost'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C4517393', 'cui_str': '0.01'}, {'cui': 'C1237705', 'cui_str': 'bimatoprost Ophthalmic Solution [Lumigan]'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0162834', 'cui_str': 'Hyperpigmentation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0000912', 'cui_str': 'Accident caused by unspecified fire'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}]",,0.0483403,Topical bimatoprost solutions were safe and effective for the treatment of non-segmental facial vitiligo with comparable results to tacrolimus ointment.,"[{'ForeName': 'Silada', 'Initials': 'S', 'LastName': 'Kanokrungsee', 'Affiliation': 'Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, 270 Rama IV Rd, Bangkok, Thailand, 10400.'}, {'ForeName': 'Duangrat', 'Initials': 'D', 'LastName': 'Pruettivorawongse', 'Affiliation': 'Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, 270 Rama IV Rd, Bangkok, Thailand, 10400.'}, {'ForeName': 'Natta', 'Initials': 'N', 'LastName': 'Rajatanavin', 'Affiliation': 'Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, 270 Rama IV Rd, Bangkok, Thailand, 10400.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13648'] 2155,32744373,A transitional care intervention for hypertension control for older people with diabetes: A cluster randomized controlled trial.,"AIMS To evaluate the effect of a nurse-coordinated hospital-initiated transitional care programme on hypertension control for older people with diabetes in China. DESIGN A cluster randomized controlled trial. METHODS A total of 10 wards (clusters) of four acute care hospitals participated in the trial. They were randomly assigned to the intervention group or the control group. A total of 270 participants (135 in each group) were recruited from these wards. Data were collected between June 2016 - June 2017. Participants in the intervention group received a 6-month hospital to home transitional care programme coordinated by discharge nurses and community nurses. The programme comprised self-management education, lifestyle changes, individualized medication treatment, structured telephone support, and primary care visits. Outcomes were measured at baseline, and 3 months and 6 months from the baseline. RESULTS The mean age was 70.9 (SD 5.8) years and 55% of participants were men. The intervention group demonstrated a statistically significant decrease in mean systolic blood pressure of 10.7 mmHg and mean diastolic blood pressure of 4.1 mmHg compared with the control group. The findings also demonstrated significant improvements in HbA1c, hypertension knowledge, diabetes knowledge, treatment adherence, quality of life, hospital readmission, and emergency department visits in the intervention group compared with the control group. However, no significant differences in adverse events were observed between the two groups. CONCLUSIONS A hospital-initiated and nurse-coordinated transitional care intervention improves hypertension control and reduces hospital readmissions for older people with diabetes. IMPACT Lack hospital to home transitional care for hospitalized older people with hypertension and diabetes can result in high readmission rates and emergency department visits. A hospital-initiated and nurse-coordinated transitional care intervention built on collaboration between acute care hospitals and community health centres results in improved hypertension control and reduced readmissions for older people with diabetes and other chronic conditions. An integrated and well-coordinated care services between acute care hospitals and community health centres can strengthen the primary care approach to supporting self-management of hypertension, diabetes, and other ageing-associated health conditions for community-dwelling older people. TRIAL REGISTRATION The trial was registered with the Australia New Zealand Clinical Trials Registry (ID: ACTRN12617001352392).",2020,"The findings also demonstrated significant improvements in HbA1c, hypertension knowledge, diabetes knowledge, treatment adherence, quality of life, hospital readmission, and emergency department visits in the intervention group compared with the control group.","['hospitalized older people with hypertension and diabetes', '270 participants (135 in each group) were recruited from these wards', 'older people with diabetes and other chronic conditions', 'older people with diabetes in China', 'older people with diabetes', 'acute care hospitals and community health centres', 'The mean age was 70.9 (SD 5.8) years and 55% of participants were men', '10 wards (clusters) of four acute care hospitals participated in the trial', 'community-dwelling older people']","['self-management education, lifestyle changes, individualized medication treatment, structured telephone support, and primary care visits', 'transitional care intervention', 'hospital-initiated and nurse-coordinated transitional care intervention', 'nurse-coordinated hospital-initiated transitional care programme', '6-month hospital to home transitional care programme coordinated by discharge nurses and community nurses']","['mean systolic blood pressure', 'HbA1c, hypertension knowledge, diabetes knowledge, treatment adherence, quality of life, hospital readmission, and emergency department visits', 'mean diastolic blood pressure', 'adverse events', 'hospital readmissions']","[{'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C4319603', 'cui_str': '270'}, {'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C3661916', 'cui_str': 'Acute care hospital'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517796', 'cui_str': '5.8'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C3469597', 'cui_str': 'Administration of medication'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C4019071', 'cui_str': 'Transition Care'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0427184', 'cui_str': 'No incoordination'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0557521', 'cui_str': 'Community nurse'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C4505265', 'cui_str': 'Therapeutic Adherence'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",270.0,0.0772155,"The findings also demonstrated significant improvements in HbA1c, hypertension knowledge, diabetes knowledge, treatment adherence, quality of life, hospital readmission, and emergency department visits in the intervention group compared with the control group.","[{'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Tu', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.'}, {'ForeName': 'Lily Dongxia', 'Initials': 'LD', 'LastName': 'Xiao', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.'}, {'ForeName': 'Shahid', 'Initials': 'S', 'LastName': 'Ullah', 'Affiliation': 'College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Fuller', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.'}, {'ForeName': 'Huiyun', 'Initials': 'H', 'LastName': 'Du', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.'}]",Journal of advanced nursing,['10.1111/jan.14466'] 2156,32744380,"Pharmacokinetics, Pharmacodynamics, and Tolerability of Single- and Multiple-Doses of Janagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Chinese Subjects with Type 2 Diabetes Mellitus.","AIMS To evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and tolerability of janagliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor, in Chinese subjects with T2DM. MATERIALS AND METHODS In this study, 36 subjects with T2DM were randomly assigned in a 1:1:1:1 ratio to receive janagliflozin 25 mg, janagliflozin 50 mg, dapagliflozin 10 mg, or placebo. Subjects received a single dose on Day 1, and were treated once daily from Day 4 to Day 17. RESULTS Following oral administration, janagliflozin was rapidly absorbed, reaching C max at 2 h. Mean half-life (t 1/2 ) at steady state was approximately 21-23 h. There was no significant accumulation with multiple doses (accumulation factor < 2). In subjects treated with janagliflozin 25 mg, janagliflozin 50 mg, dapagliflozin 10 mg, or placebo, change in mean 24-hour urinary glucose excretion (UGE) from baseline was 92.35, 94.17, 87.61, and 6.26 g after multiple doses, and change in mean FPG level from baseline to Day 17 was -2.18, -2.66, -2.79, and 1.70 mmol/L respectively. Most adverse events were mild or moderate with no deaths, serious adverse events, or discontinuations due to adverse events. CONCLUSIONS Single and multiple oral administration (14 days) of janagliflozin 25 mg and 50 mg exhibited favorable PK, PD, and tolerability profiles in Chinese subjects with T2DM, and were comparable to dapagliflozin 10 mg. Janagliflozin 25 mg and 50 mg are recommended for further clinical investigation. (Registration No.: CTR20181665, http://www.chinadrugtrials. org.cn/) This article is protected by copyright. All rights reserved.",2020,"Most adverse events were mild or moderate with no deaths, serious adverse events, or discontinuations due to adverse events. ","['Chinese Subjects with Type 2 Diabetes Mellitus', 'Chinese subjects with T2DM', '36 subjects with T2DM']","['dapagliflozin', 'janagliflozin', 'Janagliflozin', 'janagliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor', 'janagliflozin 25 mg, janagliflozin 50 mg, dapagliflozin 10 mg, or placebo', 'Single- and Multiple-Doses of Janagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor']","['mean 24-hour urinary glucose excretion (UGE', 'favorable PK, PD, and tolerability profiles', 'mean FPG level', 'Mean half-life', 'Pharmacokinetics, Pharmacodynamics, and Tolerability', 'pharmacokinetics (PK), pharmacodynamics (PD), and tolerability']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0017739', 'cui_str': 'Glucose-Sodium Transport System'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C3709918', 'cui_str': 'dapagliflozin 10 MG'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}]",36.0,0.0478004,"Most adverse events were mild or moderate with no deaths, serious adverse events, or discontinuations due to adverse events. ","[{'ForeName': 'Xiaojiao', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Xiaoxue', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Jingrui', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Qianqian', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Cuiyun', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Gao', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'He', 'Initials': 'H', 'LastName': 'Wen', 'Affiliation': 'Sihuan Pharmaceutical Holdings Group Ltd., Beijing, China.'}, {'ForeName': 'Xixi', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Sihuan Pharmaceutical Holdings Group Ltd., Beijing, China.'}, {'ForeName': 'Xinran', 'Initials': 'X', 'LastName': 'Tang', 'Affiliation': 'Sihuan Pharmaceutical Holdings Group Ltd., Beijing, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Department of Pediatrics, First Hospital, Jilin University, Jilin, China.'}, {'ForeName': 'Yanhua', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14156'] 2157,32744395,"Effects of Insulin Degludec and Insulin Glargine U300 on Glycemic Stability in Individuals with Type 1 Diabetes: a Multicenter, Randomized Controlled Crossover Study.","AIMS Information on the relative effects of insulin degludec (IDeg) and insulin glargine U300 (IGlarU300) on glycemic stability is limited and inconsistent. We directly compared the effects of these insulins on glycemic stability. MATERIALS AND METHODS In this multicenter, crossover trial, 46 individuals with type 1 diabetes and essentially undetectable circulating C-peptide were randomly assigned to the IDeg-first/IGlarU300-second or the IGlarU300-first/IDeg-second groups, and were treated with the respective basal insulins for 4-week periods. Data were collected in the last week of each treatment period. The primary aim was to examine the potential noninferiority of IDeg relative to IGlarU300 with regard to day-to-day variability, as evaluated by the standard deviation (SD), of fasting blood glucose (FBG) levels. Intraday glycemic variability and other parameters were also determined by continuous glucose monitoring (CGM). RESULTS The SD of FBG for IDeg was noninferior to that for IGlarU300. The mean of FBG, coefficient of variation (CV) of FBG, and various glycemic variability indexes determined by CGM did not differ between the two insulins. Whereas the administered doses of the insulins also did not differ, the mean glycemic value was lower for IDeg than IGlarU300; the time above the target range (>180 mg/dL [10.0 mmol/L]) and the time below the target range (<70 mg/dL [3.9 mmol/L]) were shorter and longer, respectively, for IDeg than IGlarU300. CONCLUSIONS Our data suggest that IDeg and IGlarU300 have comparable glucose-stabilizing effects in individuals with type 1 diabetes. However, the glucose-lowering effect of IDeg may be greater than that of IGlarU300 when titrated with a unit-based protocol. CLINICAL TRIAL REGISTRY NUMBER: jRCTs051180138 (Japan Registry of Clinical Trials). This article is protected by copyright. All rights reserved.",2020,"Whereas the administered doses of the insulins also did not differ, the mean glycemic value was lower for IDeg than IGlarU300; the time above the target range (>180 mg/dL [10.0 mmol/L]) and the time below the target range (<70 mg/dL [3.9 mmol/L]) were shorter and longer, respectively, for IDeg than IGlarU300. ","['Individuals with Type 1 Diabetes', '46 individuals with type 1 diabetes and essentially undetectable circulating C-peptide', 'individuals with type 1 diabetes']","['insulin degludec (IDeg) and insulin glargine U300 (IGlarU300', 'IGlarU300', 'Insulin Degludec and Insulin Glargine U300', 'IDeg-first/IGlarU300-second or the IGlarU300-first/IDeg-second groups']","['Glycemic Stability', 'mean of FBG, coefficient of variation (CV) of FBG, and various glycemic variability indexes', 'glucose-stabilizing effects', 'SD of FBG for IDeg', 'mean glycemic value', 'glycemic stability', 'standard deviation (SD), of fasting blood glucose (FBG) levels', 'Intraday glycemic variability']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}]","[{'cui': 'C3491971', 'cui_str': 'insulin degludec'}, {'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0184512', 'cui_str': 'Stabilized'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C3491971', 'cui_str': 'insulin degludec'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",46.0,0.0370373,"Whereas the administered doses of the insulins also did not differ, the mean glycemic value was lower for IDeg than IGlarU300; the time above the target range (>180 mg/dL [10.0 mmol/L]) and the time below the target range (<70 mg/dL [3.9 mmol/L]) were shorter and longer, respectively, for IDeg than IGlarU300. ","[{'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Miura', 'Affiliation': 'Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, Kobe, Japan.'}, {'ForeName': 'Kazuhiko', 'Initials': 'K', 'LastName': 'Sakaguchi', 'Affiliation': 'Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, Kobe, Japan.'}, {'ForeName': 'Natsu', 'Initials': 'N', 'LastName': 'Otowa-Suematsu', 'Affiliation': 'Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, Kobe, Japan.'}, {'ForeName': 'Tomoko', 'Initials': 'T', 'LastName': 'Yamada', 'Affiliation': 'Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, Kobe, Japan.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'So', 'Affiliation': 'Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, Kobe, Japan.'}, {'ForeName': 'Hisako', 'Initials': 'H', 'LastName': 'Komada', 'Affiliation': 'Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, Kobe, Japan.'}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Okada', 'Affiliation': 'Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, Kobe, Japan.'}, {'ForeName': 'Yushi', 'Initials': 'Y', 'LastName': 'Hirota', 'Affiliation': 'Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, Kobe, Japan.'}, {'ForeName': 'Yoshikazu', 'Initials': 'Y', 'LastName': 'Tamori', 'Affiliation': 'Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, Kobe, Japan.'}, {'ForeName': 'Wataru', 'Initials': 'W', 'LastName': 'Ogawa', 'Affiliation': 'Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, Kobe, Japan.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14161'] 2158,32744418,Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials.,"Associations between body mass index (BMI) and the cardiovascular (CV) and kidney efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) are uncertain; therefore, data analyzed separately from the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial and the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN 6) were examined. These international, randomized, placebo-controlled trials investigated liraglutide and semaglutide (both subcutaneous) in patients with T2D and at high risk of CV events. In post hoc analyses, patients were categorized by baseline BMI (<25 kg/m 2 , ≥25-<30 kg/m 2 , ≥30-<35 kg/m 2 , ≥35 kg/m 2 ), and CV and kidney outcomes with GLP-1RA versus placebo analyzed. All baseline BMI data from LEADER (n = 9331) and SUSTAIN 6 (n = 3290) were included (91% and 92% of patients with overweight or obesity, respectively). In SUSTAIN 6, nominally significant heterogeneity of semaglutide efficacy by baseline BMI was observed for CV death/myocardial infarction/stroke (major adverse CV events [MACE], primary outcome of both; p interaction  = 0.02); otherwise, there was no statistical heterogeneity for either GLP-1RA versus placebo across BMI categories for key CV and kidney outcomes. The lack of statistical heterogeneity from these cardiorenal outcomes implies that liraglutide and semaglutide may be beneficial for many patients and is likely not to depend on their baseline BMI, but further study is needed. This article is protected by copyright. All rights reserved.",2020,"All baseline BMI data from LEADER (n = 9331) and SUSTAIN 6 (n = 3290) were included (91% and 92% of patients with overweight or obesity, respectively).","['patients with type 2 diabetes (T2D', 'Diabetes', 'Subjects with Type 2 Diabetes ', 'type 2 diabetes', 'patients with T2D and at high risk of CV events']","['liraglutide', 'liraglutide and semaglutide (both subcutaneous', 'glucagon-like peptide-1 receptor agonists liraglutide and semaglutide', 'GLP-1RA versus placebo', 'Semaglutide', 'glucagon-like peptide-1 receptor agonists (GLP-1RAs', 'placebo']","['semaglutide efficacy', 'body mass index (BMI) and the cardiovascular (CV) and kidney efficacy', 'CV death/myocardial infarction/stroke (major adverse CV events [MACE']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]","[{'cui': 'C1456408', 'cui_str': 'liraglutide'}, {'cui': 'C3885068', 'cui_str': 'semaglutide'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C1562104', 'cui_str': 'Glucagon-like peptide 1 receptor agonist-containing product'}, {'cui': 'C0018301', 'cui_str': 'Guadeloupe island'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C3885068', 'cui_str': 'semaglutide'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0286421', 'cui_str': 'ACE protocol 2'}]",6.0,0.113111,"All baseline BMI data from LEADER (n = 9331) and SUSTAIN 6 (n = 3290) were included (91% and 92% of patients with overweight or obesity, respectively).","[{'ForeName': 'Subodh', 'Initials': 'S', 'LastName': 'Verma', 'Affiliation': ""Li Ka Shing Knowledge Institute, St. Michael's Hospital and University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'Darren K', 'Initials': 'DK', 'LastName': 'McGuire', 'Affiliation': 'Division of Cardiology, University of Texas Southwestern Medical Center Dallas, Texas, USA.'}, {'ForeName': 'Stephen C', 'Initials': 'SC', 'LastName': 'Bain', 'Affiliation': 'Institute of Life Science, Swansea University, Swansea, UK.'}, {'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': ""Brigham and Women's Hospital Heart and Vascular Center & Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Lawrence A', 'Initials': 'LA', 'LastName': 'Leiter', 'Affiliation': ""Li Ka Shing Knowledge Institute, St. Michael's Hospital and University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'C David', 'Initials': 'CD', 'LastName': 'Mazer', 'Affiliation': ""Li Ka Shing Knowledge Institute, St. Michael's Hospital and University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'Tea', 'Initials': 'T', 'LastName': 'Monk Fries', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Pratley', 'Affiliation': 'AdventHealth Translational Research Institute, Orlando, Florida, USA.'}, {'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Rasmussen', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Hrvoje', 'Initials': 'H', 'LastName': 'Vrazic', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Zinman', 'Affiliation': 'Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Ontario, Toronto, Canada.'}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Buse', 'Affiliation': 'University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14160'] 2159,32744424,Comparison of High-Flow and Conventional Nasal Cannula Oxygen in Patients Undergoing Endobronchial Ultrasonography.,"BACKGROUND Oxygen therapy is required to prevent hypoxemia during the endobronchial ultrasonography(EBUS) procedure. AIMS We aimed to compare the effectiveness of oxygen therapy delivered via high-flow nasal cannula(HFNC) and conventional nasal cannula(CNC) in patients undergoing EBUS. Primary outcome was proportion of the patients who desaturated. Patient compliance and satisfaction were also evaluated. METHODS This single-center prospective interventional study was conducted in a tertiary hospital among patients who presented to the EBUS unit in 2018 and 2019. Patients were randomly assigned to the HFNC group or the CNC group. RESULTS The study included 170 patients (111 men and 59 women) with a mean age of 58 ± 14 years. The number of patients experiencing desaturation while receiving oxygen was statistically significantly lower (P < 0.001) in HFNC group (n = 5) compared with CNC group (n = 26). Oxygen therapy was adjusted in 2 patients in the CNC group due to desaturation. Saturation was significantly higher in the HFNC group (P < 0.0001) at the end of the EBUS procedure. HR at the end of EBUS was lower in the HFNC group, but this difference was not statistically significant (96 ± 16 vs. 101 ± 19, P = 0.13). Five patients in the HFNC group and 18 patients in the CNC group reported discomfort during the procedure (P = 0.006). CONCLUSION Oxygen therapy delivered by HFNC seems to be safer and more effective than by CNC in patients undergoing EBUS. Oxygen therapy with HFNC may be considered as an alternative to CNC because it may increase patient comfort and thereby improve compliance. This article is protected by copyright. All rights reserved.",2020,Saturation was significantly higher in the HFNC group (P < 0.0001) at the end of the EBUS procedure.,"['patients undergoing EBUS', 'tertiary hospital among patients who presented to the EBUS unit in 2018 and 2019', 'Patients Undergoing Endobronchial Ultrasonography', '170 patients (111 men and 59 women) with a mean age of 58 ± 14 years']","['High-Flow and Conventional Nasal Cannula Oxygen', 'oxygen therapy delivered via high-flow nasal cannula(HFNC) and conventional nasal cannula(CNC', 'CNC', 'Oxygen therapy', 'HFNC']","['number of patients experiencing desaturation while receiving oxygen', 'Saturation', 'Patient compliance and satisfaction', 'proportion of the patients who desaturated', 'discomfort']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3160856', 'cui_str': 'Endobronchial ultrasound'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannulae'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0522534', 'cui_str': 'Saturated'}, {'cui': 'C1321605', 'cui_str': 'Compliance behavior'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}]",170.0,0.0893192,Saturation was significantly higher in the HFNC group (P < 0.0001) at the end of the EBUS procedure.,"[{'ForeName': 'Elif', 'Initials': 'E', 'LastName': 'Yilmazel Ucar', 'Affiliation': 'Department of Pulmonary Diseases, Ataturk University School of Medicine, 25240, Yakutiye, Erzurum, Turkey.'}, {'ForeName': 'Ömer', 'Initials': 'Ö', 'LastName': 'Araz', 'Affiliation': 'Department of Pulmonary Diseases, Ataturk University School of Medicine, 25240, Yakutiye, Erzurum, Turkey.'}, {'ForeName': 'Bugra', 'Initials': 'B', 'LastName': 'Kerget', 'Affiliation': 'Department of Pulmonary Diseases, Ataturk University School of Medicine, 25240, Yakutiye, Erzurum, Turkey.'}, {'ForeName': 'Metin', 'Initials': 'M', 'LastName': 'Akgun', 'Affiliation': 'Department of Pulmonary Diseases, Ataturk University School of Medicine, 25240, Yakutiye, Erzurum, Turkey.'}, {'ForeName': 'Leyla', 'Initials': 'L', 'LastName': 'Saglam', 'Affiliation': 'Department of Pulmonary Diseases, Ataturk University School of Medicine, 25240, Yakutiye, Erzurum, Turkey.'}]",Internal medicine journal,['10.1111/imj.15001'] 2160,32744578,"The Effects of Concurrent Training Order on Satellite Cell-Related Markers, Body Composition, Muscular and Cardiorespiratory Fitness in Older Men with Sarcopenia.","OBJECTIVES Concurrent Training (CT) is described as a combination of resistance training (RT) and endurance training (ET) in a periodized program to maximize all aspects of physical performance. To date, effects of CT order on muscular and cardiorespiratory fitness adaptations are controversial. Owing to the age-related decrement in satellite cells (SC) which are critical for fiber repair, conservation, muscle hypertrophy as well as cardiorespiratory fitness, the present study examined the response of SC related markers to CT order in older sarcopenic men. PARTICIPANTS Thirty older men (age= 64.3 ± 3.5 years) were randomly assigned into one of 3 groups, ET followed by RT (E+R; n=10), RT followed by ET (R+E; n= 10) or a control (C; n=10). INTERVENTION The training protocol consisted of 3 exercise sessions per week for 8 weeks. Blood samples were obtained at baseline and 48 hours after the final training session. RESULTS Weight, skeletal muscle mass, lower and upper body power, maximal oxygen consumption (VO2max), Paired Box 7 (Pax7), and Myogenic factor 5 (Myf5) significantly increased, while were percent body fat significantly decreased following E+R and R+E compared to C. Importantly, the improvement in skeletal muscle mass, lower and upper body power, Myf5 and Pax7 in the E+R was significantly greater than the R+E group. Myogenin (Myog) and Paired Box 3 (Pax3) significantly increased (P < 0.01) in both training groups compared to no changes in C. CONCLUSION An 8-week CT intervention improves SC related markers, body composition and enhances power and VO2max in older sarcopenic participants, regardless of the order of RT and ET. However, performing ET before RT may be more effective at enhancing skeletal muscle mass, Myf5 and Pax7, in addition to both lower and upper body power. While both CT programs produced notable physiological and performance benefits, performing ET before RT during CT may provide the greatest therapeutic benefits for aging individuals.",2020,"Myogenin (Myog) and Paired Box 3 (Pax3) significantly increased (P < 0.01) in both training groups compared to no changes in C. CONCLUSION ","['older sarcopenic men', 'older sarcopenic participants', 'Older Men with Sarcopenia', 'Thirty older men (age= 64.3 ± 3.5 years']","['R+E', 'Concurrent Training', 'Concurrent Training (CT', 'CT intervention', 'CT', 'resistance training (RT) and endurance training (ET']","['Satellite Cell-Related Markers, Body Composition, Muscular and Cardiorespiratory Fitness', 'Myogenin (Myog) and Paired Box 3 (Pax3', 'Blood samples', 'SC related markers, body composition and enhances power and VO2max', 'Weight, skeletal muscle mass, lower and upper body power, maximal oxygen consumption (VO2max), Paired Box 7 (Pax7), and Myogenic factor 5 (Myf5', 'skeletal muscle mass, lower and upper body power, Myf5 and Pax7 in the E+R']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0872084', 'cui_str': 'Sarcopenia'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C4704697', 'cui_str': 'Endurance Training'}]","[{'cui': 'C0205868', 'cui_str': 'Perineuronal satellite cell'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0067053', 'cui_str': 'Myogenin'}, {'cui': 'C0006080', 'cui_str': 'Boxing'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1268087', 'cui_str': 'Upper body structure'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C0067052', 'cui_str': 'Myogenic Factor 5'}, {'cui': 'C0332282', 'cui_str': 'Following'}]",30.0,0.0126955,"Myogenin (Myog) and Paired Box 3 (Pax3) significantly increased (P < 0.01) in both training groups compared to no changes in C. CONCLUSION ","[{'ForeName': 'B H', 'Initials': 'BH', 'LastName': 'Moghadam', 'Affiliation': 'Julien S Baker, Faculty of Social Sciences, Centre for Health and Exercise Science Research, Department of Sport, Physical Education and Health, Hong Kong Baptist University, Kowloon Tong, Hong Kong, Office Tel: +852 3411 8032, Fax: +852 3411 5757, e-mail: jsbaker@hkbu.edu.hk.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Bagheri', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Ashtary-Larky', 'Affiliation': ''}, {'ForeName': 'G M', 'Initials': 'GM', 'LastName': 'Tinsley', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Eskandari', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Wong', 'Affiliation': ''}, {'ForeName': 'B H', 'Initials': 'BH', 'LastName': 'Moghadam', 'Affiliation': ''}, {'ForeName': 'R B', 'Initials': 'RB', 'LastName': 'Kreider', 'Affiliation': ''}, {'ForeName': 'J S', 'Initials': 'JS', 'LastName': 'Baker', 'Affiliation': ''}]","The journal of nutrition, health & aging",['10.1007/s12603-020-1431-3'] 2161,32744599,Group-Based vs Individual Pelvic Floor Muscle Training to Treat Urinary Incontinence in Older Women: A Randomized Clinical Trial.,"Importance Urinary incontinence is one of the most prevalent health concerns experienced by older women (aged ≥60 years). Individual pelvic floor muscle training (PFMT) is the recommended first-line treatment for stress or mixed urinary incontinence in women, but human and financial resources limit its delivery. Whether group-based PFMT performs as well as individual PFMT in this population remains unclear. Objective To assess the efficacy of group-based PFMT relative to individual PFMT for urinary incontinence in older women. Design, Setting, and Participants The Group Rehabilitation or Individual Physiotherapy (GROUP) study is a single-blind, randomized, noninferiority trial conducted in 2 Canadian research centers, from July 1, 2012, to June 2, 2018. A total of 362 community-dwelling women aged 60 years or older with symptoms of stress or mixed urinary incontinence were enrolled. Interventions After an individual session conducted to learn how to contract pelvic floor muscles, participants completed 12-week PFMT as part of a group of 8 women (n = 178) or in individual sessions (n = 184). Main Outcomes and Measures The primary outcome measure was the percentage reduction in urinary incontinence episodes at 1 year, as reported in a 7-day bladder diary and relative to pretreatment baseline. Secondary outcomes included lower urinary tract-related signs, symptoms, and quality of life immediately following treatment and at 1 year. Per-protocol analysis was used. Results Among 362 women who were randomized (mean [SD] age, 67.9 [5.8] years), 319 women (88%) completed the 1-year follow-up and were included in the per-protocol analysis. Median percentage reduction in urinary incontinence episodes was 70% (95% CI, 44%-89%) in individual PFMT compared with 74% (95% CI, 46%-86%) in group-based PFMT. The upper boundary of the 95% CI for the difference in the percentage reduction in urinary incontinence episodes at 1 year was lower than the prespecified margin for noninferiority of 10% (difference, 4%; 95% CI, -10% to 7%; P = .58), confirming noninferiority. Individual PFMT and group-based PFMT had similar effectiveness for all secondary outcomes at 1 year. Adverse events were minor and uncommon. Conclusions and Relevance Results of the GROUP study suggest that group-based PFMT is not inferior to the recommended individual PFMT for the treatment of stress and mixed urinary incontinence in older women. Widespread use in clinical practice may help increase continence-care affordability and treatment availability. Trial Registration ClinicalTrials.gov Identifier: NCT02039830.",2020,"Median percentage reduction in urinary incontinence episodes was 70% (95% CI, 44%-89%) in individual PFMT compared with 74% (95% CI, 46%-86%) in group-based PFMT.","['older women', 'Older Women', '362 women who were randomized (mean [SD] age, 67.9 [5.8] years), 319 women (88%) completed the 1-year follow-up and were included in the per-protocol analysis', 'older women (aged ≥60 years', '2 Canadian research centers, from July 1, 2012, to June 2, 2018', '362 community-dwelling women aged 60 years or older with symptoms of stress or mixed urinary incontinence were enrolled']","['Individual pelvic floor muscle training (PFMT', 'Individual Pelvic Floor Muscle Training', 'Group Rehabilitation or Individual Physiotherapy (GROUP', 'Individual PFMT and group-based PFMT', 'group-based PFMT relative to individual PFMT']","['percentage reduction in urinary incontinence episodes at 1 year, as reported in a 7-day bladder diary and relative to pretreatment baseline', 'Adverse events', 'urinary incontinence episodes', 'lower urinary tract-related signs, symptoms, and quality of life']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517796', 'cui_str': '5.8'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0869256', 'cui_str': 'Mixed urinary incontinence'}]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4087139', 'cui_str': 'Pelvic floor muscle training'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0163299', 'cui_str': 'A 7'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0430970', 'cui_str': 'Urinary frequency volume chart'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0729866', 'cui_str': 'Lower urinary tract structure'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",362.0,0.140746,"Median percentage reduction in urinary incontinence episodes was 70% (95% CI, 44%-89%) in individual PFMT compared with 74% (95% CI, 46%-86%) in group-based PFMT.","[{'ForeName': 'Chantale', 'Initials': 'C', 'LastName': 'Dumoulin', 'Affiliation': 'School of Rehabilitation, Faculty of Medicine, Université de Montréal and Research Center of the Institut Universitaire de Gériatrie de Montréal, Montréal, Québec, Canada.'}, {'ForeName': 'Mélanie', 'Initials': 'M', 'LastName': 'Morin', 'Affiliation': ""School of Rehabilitation, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Research Center of the Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Québec, Canada.""}, {'ForeName': 'Coraline', 'Initials': 'C', 'LastName': 'Danieli', 'Affiliation': 'Research Institute of the McGill University Health Center, Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Québec, Canada.'}, {'ForeName': 'Licia', 'Initials': 'L', 'LastName': 'Cacciari', 'Affiliation': 'School of Rehabilitation, Faculty of Medicine, Université de Montréal and Research Center of the Institut Universitaire de Gériatrie de Montréal, Montréal, Québec, Canada.'}, {'ForeName': 'Marie-Hélène', 'Initials': 'MH', 'LastName': 'Mayrand', 'Affiliation': ""Department of Obstetrics and Gynecology and Social and Preventive Medicine, Université de Montréal, Research Center of the Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.""}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Tousignant', 'Affiliation': ""School of Rehabilitation, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Research Center of the Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Québec, Canada.""}, {'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Abrahamowicz', 'Affiliation': 'Department of Epidemiology, Biostatistics, and Occupational Health, McGill University and Research Institute of the McGill University Health Center, Montreal, Québec, Canada.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA internal medicine,['10.1001/jamainternmed.2020.2993'] 2162,32739310,The feasibility and impact of a pre-surgical exercise intervention program (prehabilitation) for patients undergoing cystectomy for bladder cancer.,"OBJECTIVE To assess the feasibility of a prehabilitation program for cystectomy patients and to determine the effectiveness of the program in improving strength and functional capacity in the peri-operative period. MATERIALS AND METHODS This phase I/II study accrued patients ≥60 years old from 01/2013-10/2017 with biopsy-proven bladder cancer, Karnofsky performance score ≥70 and a sedentary baseline lifestyle to participate in a 4-week supervised pre-operative exercise training program. Primary outcomes were feasibility and safety; secondary outcomes included changes in fitness, patient-reported QOL, peri-operative complications and readmissions. Student's t-tests and Wilcoxon signed-rank test were performed. RESULTS Fifty-four patients enrolled in the program. Successful completion, defined as patients who began the program and adhered to >70% of the sessions, was attained by 41 of 51 patients (80.4%, 90% CI [71% - 90%]. There were no adverse events. Fitness and patient-reported QOL improved post-intervention, with sustained improvements in general and mental health 90-days post-surgery. The primary limitation is no control group. CONCLUSION Prehabilitation prior to cystectomy is feasible, safe, and results in improvements in patient strength, endurance and sustained improvements in patient-reported QOL from baseline. Efforts to further evaluate the impact of prehabilitation in this population in an expanded and randomized fashion are warranted.",2020,"Fitness and patient-reported QOL improved post-intervention, with sustained improvements in general and mental health 90-days post-surgery.","['Fifty-four patients enrolled in the program', 'patients undergoing cystectomy for bladder cancer', 'cystectomy patients', 'patients ≥60 years old from 01/2013-10/2017 with biopsy-proven bladder cancer, Karnofsky performance score ≥70 and a sedentary baseline lifestyle to participate in a']","['prehabilitation program', '4-week supervised pre-operative exercise training program', 'pre-surgical exercise intervention program (prehabilitation']","['feasibility and safety; secondary outcomes included changes in fitness, patient-reported QOL, peri-operative complications and readmissions', 'strength and functional capacity']","[{'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0010651', 'cui_str': 'Bladder excision'}, {'cui': 'C0005684', 'cui_str': 'Malignant tumor of urinary bladder'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0206065', 'cui_str': 'Karnofsky performance status'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0023676', 'cui_str': 'Life style'}]","[{'cui': 'C5192101', 'cui_str': 'Prehabilitation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}]",54.0,0.0336175,"Fitness and patient-reported QOL improved post-intervention, with sustained improvements in general and mental health 90-days post-surgery.","[{'ForeName': 'Deborah R', 'Initials': 'DR', 'LastName': 'Kaye', 'Affiliation': 'Division of Urology, Department of Surgery, Duke University, Durham, North Carolina, USA.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Schafer', 'Affiliation': 'Department of Urology, Michigan Medicine, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Thelen-Perry', 'Affiliation': 'Department of Urology, Michigan Medicine, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Parker', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Michigan Medicine, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Iglay-Reger', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Michigan Medicine, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Daignault-Newton', 'Affiliation': 'Department of Urology, Michigan Medicine, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Yongmei', 'Initials': 'Y', 'LastName': 'Qin', 'Affiliation': 'Department of Urology, Michigan Medicine, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Todd M', 'Initials': 'TM', 'LastName': 'Morgan', 'Affiliation': 'Department of Urology, Michigan Medicine, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Alon Z', 'Initials': 'AZ', 'LastName': 'Weizer', 'Affiliation': 'Department of Urology, Michigan Medicine, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Samuel D', 'Initials': 'SD', 'LastName': 'Kaffenberger', 'Affiliation': 'Department of Urology, Michigan Medicine, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Lindsey A', 'Initials': 'LA', 'LastName': 'Herrel', 'Affiliation': 'Department of Urology, Michigan Medicine, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Khaled S', 'Initials': 'KS', 'LastName': 'Hafez', 'Affiliation': 'Department of Urology, Michigan Medicine, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Cheryl T', 'Initials': 'CT', 'LastName': 'Lee', 'Affiliation': 'Department of Urology, The Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Ted A', 'Initials': 'TA', 'LastName': 'Skolarus', 'Affiliation': 'Department of Urology, Michigan Medicine, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Englesbe', 'Affiliation': 'Department of Surgery, Michigan Medicine, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Montgomery', 'Affiliation': 'Department of Urology, Michigan Medicine, Ann Arbor, Michigan, USA. Electronic address: montrose@med.umich.edu.'}]",Urology,['10.1016/j.urology.2020.05.104'] 2163,32739319,Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial.,"BACKGROUND AND PURPOSE This study evaluated the clinical significance of preoperative sarcopenia according to adjuvant concurrent chemo-radiotherapy (XP-RT) or chemotherapy alone (XP) in the D2 dissected gastric cancer patient cohort of the ARTIST trial. MATERIALS AND METHODS Skeletal muscles at the L3 vertebra level from preoperative computed tomography images among the ARTIST trial participants were measured using validated in-house software. Skeletal muscle index (SMI) was defined as the measured skeletal muscle area divided by the square of the height, and sarcopenia was defined according to the Korean-specific cutoff, i.e. L3 SMI ≤49 cm 2 /m 2 for men and ≤31 cm 2 /m 2 for women. RESULTS Among the 440 patients in whom we were able to evaluate L3 SMI, 75 (17.0%) met the definition for preoperative sarcopenia. No differences in treatment-related toxicities or treatment compliance were observed according to the presence of preoperative sarcopenia in either treatment arm. In the subgroup of patients without preoperative sarcopenia, recurrence was significantly lower in the XP-RT arm than that in the XP arm (p = 0.02). Recurrence-free survival (RFS) was also significantly higher in the XP-RT arm (p = 0.02, hazard ratio 0.633, 95% confidence interval 0.433-0.926) in this subgroup. In the multivariate analysis, and after adjusting for significant prognostic factors, the superior outcome of XP-RT arm regarding RFS was maintained in the subgroup of the patients without preoperative sarcopenia. CONCLUSIONS Superior clinical outcomes of adjuvant XP-RT over XP were only observed in patients without preoperative sarcopenia.",2020,No differences in treatment-related toxicities or treatment compliance were observed according to the presence of preoperative sarcopenia in either treatment arm.,"['Skeletal muscles at the L3 vertebra level from preoperative computed tomography images among the ARTIST trial participants were measured using validated in-house software', '440 patients in whom we were able to evaluate L3 SMI, 75 (17.0%) met the definition for preoperative sarcopenia', 'D2 dissected gastric cancer', 'D2 dissected gastric cancer patient cohort of the ARTIST trial']","['adjuvant concurrent chemo-radiotherapy (XP-RT) or chemotherapy alone (XP', 'baseline sarcopenia']","['Skeletal muscle index (SMI', 'preoperative sarcopenia, recurrence', 'Recurrence-free survival (RFS']","[{'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0223522', 'cui_str': 'Bone structure of L3'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0402043', 'cui_str': 'Artist'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0020056', 'cui_str': 'Housed'}, {'cui': 'C0037585', 'cui_str': 'Software'}, {'cui': 'C4517777', 'cui_str': '440'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0872084', 'cui_str': 'Sarcopenia'}, {'cui': 'C0205239', 'cui_str': 'Dissecting'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}]","[{'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0392920', 'cui_str': 'Antineoplastic chemotherapy regimen'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0872084', 'cui_str': 'Sarcopenia'}]","[{'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0872084', 'cui_str': 'Sarcopenia'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease'}]",440.0,0.0407846,No differences in treatment-related toxicities or treatment compliance were observed according to the presence of preoperative sarcopenia in either treatment arm.,"[{'ForeName': 'Jeong', 'Initials': 'J', 'LastName': 'Il Yu', 'Affiliation': 'Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: ro.yuji651@gmail.com.'}, {'ForeName': 'Changhoon', 'Initials': 'C', 'LastName': 'Choi', 'Affiliation': 'Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jeeyun', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Departments of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Won Ki', 'Initials': 'WK', 'LastName': 'Kang', 'Affiliation': 'Departments of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Se Hoon', 'Initials': 'SH', 'LastName': 'Park', 'Affiliation': 'Departments of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Seung Tae', 'Initials': 'ST', 'LastName': 'Kim', 'Affiliation': 'Departments of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jung Yong', 'Initials': 'JY', 'LastName': 'Hong', 'Affiliation': 'Departments of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Sung', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Departments of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Tae Sung', 'Initials': 'TS', 'LastName': 'Sohn', 'Affiliation': 'Departments of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jun Ho', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Departments of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Ji Yeong', 'Initials': 'JY', 'LastName': 'An', 'Affiliation': 'Departments of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Min Gew', 'Initials': 'MG', 'LastName': 'Choi', 'Affiliation': 'Departments of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jae Moon', 'Initials': 'JM', 'LastName': 'Bae', 'Affiliation': 'Departments of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Kyoung-Mee', 'Initials': 'KM', 'LastName': 'Kim', 'Affiliation': 'Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Heewon', 'Initials': 'H', 'LastName': 'Han', 'Affiliation': 'Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea.'}, {'ForeName': 'Kyunga', 'Initials': 'K', 'LastName': 'Kim', 'Affiliation': 'Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea.'}, {'ForeName': 'Heerim', 'Initials': 'H', 'LastName': 'Nam', 'Affiliation': 'Department of Radiation Oncology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Do Hoon', 'Initials': 'DH', 'LastName': 'Lim', 'Affiliation': 'Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: dh8.lim@samsung.com.'}]",Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,['10.1016/j.radonc.2020.07.043'] 2164,32739320,Reduced dose posterior to prostate correlates with increased PSA progression in voxel-based analysis of 3 randomised phase 3 trials.,"PURPOSE Reducing margins during treatment planning to decrease dose to healthy organs surrounding the prostate can risk inadequate treatment of subclinical disease. This study aimed to investigate whether lack of dose to subclinical disease is associated with increased disease progression by utilizing high-quality prostate radiotherapy clinical trial data to identify anatomically-localised regions where dose variation is associated with PSA progression (PSAP). METHODS AND MATERIALS Planned dose distributions for 683 patients of the 'Trial-A's name' were deformably registered onto a single exemplar computed tomography (CT) dataset. These were divided into high-risk and intermediate-risk sub-groups for analysis. Three independent voxel-based statistical tests, utilizing permutation testing, Cox regression modelling and LASSO feature selection, were applied to identify regions where dose variation was associated with PSAP. Results from the intermediate-risk 'Trial-A' sub-group were externally validated by registering dose distributions from 'Trial-B' (n=388) and 'Trial-C' (n=253) trials onto the same exemplar and repeating the tests on each of these data sets. RESULTS Voxel-based Cox regression revealed regions where reduced dose was correlated with increased PSA progression. Reduced dose in regions associated with coverage at the posterior prostate, in the immediate periphery of the posterior prostate and in regions corresponding to the posterior oblique beams or posterior lateral beam boundary, was associated with increased PSAP for 'Trial-A' and 'Trial-B' patients, but not for 'Trial-C' patients. Reduced dose to the seminal vesicles (SV) region was also associated with increased PSAP for 'Trial-A' intermediate-risk patients. CONCLUSIONS Ensuring adequate dose coverage at the posterior prostate and immediately surrounding posterior region (including the SV), where aggressive cancer spread may be occurring, may improve tumour control. It is recommended that particular care is taken when defining margins at the prostate posterior, acknowledging the trade-off between quality of life due to rectal dose and the preferences of clinicians and patients.",2020,"Reduced dose to the seminal vesicles (SV) region was also associated with increased PSAP for 'Trial-A' intermediate-risk patients. ","[""683 patients of the 'Trial-A's name' were deformably registered onto a single exemplar computed tomography (CT) dataset""]",[],['PSA progression'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0150098', 'cui_str': 'Data Set'}]",[],"[{'cui': 'C0178415', 'cui_str': 'Raised prostate specific antigen'}]",,0.0428037,"Reduced dose to the seminal vesicles (SV) region was also associated with increased PSAP for 'Trial-A' intermediate-risk patients. ","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Marcello', 'Affiliation': 'Department of Physics, University of Western Australia, Western Australia, Australia; Department of Radiation Oncology, Sir Charles Gairdner Hospital, Western Australia, Australia. Electronic address: 20739859@student.uwa.edu.au.'}, {'ForeName': 'J W', 'Initials': 'JW', 'LastName': 'Denham', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, New South Wales, Australia.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Kennedy', 'Affiliation': 'Department of Radiation Oncology, Sir Charles Gairdner Hospital, Western Australia, Australia.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Haworth', 'Affiliation': 'School of Physics, University of Sydney, New South Wales, Australia.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Steigler', 'Affiliation': 'Prostate Cancer Trials Group, School of Medicine and Public Health, University of Newcastle, New South Wales, Australia.'}, {'ForeName': 'P B', 'Initials': 'PB', 'LastName': 'Greer', 'Affiliation': 'School of Mathematical and Physical Sciences, University of Newcastle, New South Wales, Australia; Department of Radiation Oncology, Calvary Mater Newcastle, New South Wales, Australia.'}, {'ForeName': 'L C', 'Initials': 'LC', 'LastName': 'Holloway', 'Affiliation': 'Department of Medical Physics, Liverpool Cancer Centre, New South Wales, Australia; South Western Sydney Clinical School, University of New South Wales, New South Wales, Australia; Centre for Medical Radiation Physics, University of Wollongong, New South Wales, Australia.'}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Dowling', 'Affiliation': 'School of Mathematical and Physical Sciences, University of Newcastle, New South Wales, Australia; CSIRO, Queensland, Australia.'}, {'ForeName': 'M G', 'Initials': 'MG', 'LastName': 'Jameson', 'Affiliation': 'Department of Medical Physics, Liverpool Cancer Centre, New South Wales, Australia; South Western Sydney Clinical School, University of New South Wales, New South Wales, Australia; Centre for Medical Radiation Physics, University of Wollongong, New South Wales, Australia; Cancer Research Team, Ingham Institute for Applied Medical Research, New South Wales, Australia.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Roach', 'Affiliation': 'Department of Medical Physics, Liverpool Cancer Centre, New South Wales, Australia; South Western Sydney Clinical School, University of New South Wales, New South Wales, Australia; Cancer Research Team, Ingham Institute for Applied Medical Research, New South Wales, Australia.'}, {'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Joseph', 'Affiliation': 'School of Surgery, University of Western Australia, Western Australia, Australia; 5D Clinics, Claremont, Western Australia, Australia; GenesisCare WA, Western Australia, Australia.'}, {'ForeName': 'S L', 'Initials': 'SL', 'LastName': 'Gulliford', 'Affiliation': 'Radiotherapy Department, University College London Hospitals NHS Foundation Trust, London, United Kingdom; Department of Medical Physics and Biomedical Engineering, University College London, London, UK.'}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Dearnaley', 'Affiliation': 'Academic UroOncology Unit, The Institute of Cancer Research and the Royal Marsden NHS Trust, London, United Kingdom.'}, {'ForeName': 'M R', 'Initials': 'MR', 'LastName': 'Sydes', 'Affiliation': 'MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, United Kingdom.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Hall', 'Affiliation': 'Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Ebert', 'Affiliation': 'Department of Physics, University of Western Australia, Western Australia, Australia; Department of Radiation Oncology, Sir Charles Gairdner Hospital, Western Australia, Australia; 5D Clinics, Claremont, Western Australia, Australia.'}]","International journal of radiation oncology, biology, physics",['10.1016/j.ijrobp.2020.07.030'] 2165,32739460,The effect of moderate-intensity aerobic training on pulmonary function and estrogen receptor-alpha gene in postmenopausal women with vitamin D deficiency: A randomized control trial.,"BACKGROUND The impact of aerobic training on pulmonary function by modulating gene expression of estrogen receptor-alpha (ERα), sex hormones and 25-hydroxy vitamin D (Vit D) in postmenopausal women (PMW) with Vit D deficiency is uncertain. OBJECTIVE The purpose of this study was to examine the effect of 12 weeks of moderate-intensity aerobic training on pulmonary function, ERα gene expression, serum levels of sex hormones and Vit D in PMW with Vit D deficiency. METHODS Twenty-nine sedentary PMW with Vit D deficiency (aged 45-65 yrs) were randomized to exercise (EX, n = 15) and control (C, n = 14) groups. The EX group performed moderate-intensity aerobic training for 12 weeks (50-60 min/day, 3 days/week at 65-70% of maximal heart rate reserve), but the C group participated in no intervention and maintain their normal lifestyle during 12 weeks. The pulmonary function parameters, ERα gene expression, serum levels of sex hormones and Vit D were measured at baseline and week-12. RESULTS After 12 weeks of aerobic exercise intervention, the increase in lymphocyte ERα gene expression (p = 0.005, estimate of effect size/Eta = 32.8%) and serum Vit D (p = 0.001, Eta = 54.7%) were significantly higher in the EX group compared to the C group, whereas pulmonary function parameters and sex hormones (17β-estradiol and progesterone) were not significantly different (P > 0.05). CONCLUSIONS The results suggested that 12 weeks of moderate-intensity aerobic training increased lymphocyte ERα gene expression as well as serum Vit D in sedentary PMW with Vit D deficiency although pulmonary function was not improved.",2020,"After 12 weeks of aerobic exercise intervention, the increase in lymphocyte ERα gene expression (p = 0.005, estimate of effect size/Eta = 32.8%) and serum Vit D (p = 0.001, Eta = 54.7%) were significantly higher in the EX group compared to the C group, whereas pulmonary function parameters and sex hormones (17β-estradiol and progesterone) were not significantly different (P > 0.05). ","['postmenopausal women with vitamin D deficiency', 'postmenopausal women (PMW) with Vit D deficiency', 'Twenty-nine sedentary PMW with Vit D deficiency (aged 45-65 yrs']","['aerobic exercise intervention', 'aerobic training', 'C group participated in no intervention and maintain their normal lifestyle', 'exercise (EX', 'moderate-intensity aerobic training']","['pulmonary function, ERα gene expression, serum levels of sex hormones and Vit D', 'estrogen receptor-alpha (ERα), sex hormones and 25-hydroxy vitamin D (Vit D', 'pulmonary function parameters and sex hormones (17β-estradiol and progesterone', 'lymphocyte ERα gene expression', 'serum Vit D', 'pulmonary function and estrogen receptor-alpha gene', 'pulmonary function parameters, ERα gene expression, serum levels of sex hormones and Vit D']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042870', 'cui_str': 'Vitamin D deficiency'}, {'cui': 'C0450351', 'cui_str': '29'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}]","[{'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0036884', 'cui_str': 'Sex hormone'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0665341', 'cui_str': 'Estrogen Receptors alpha'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0033308', 'cui_str': 'Progesterone'}, {'cui': 'C0024264', 'cui_str': 'Lymphocyte'}, {'cui': 'C0428586', 'cui_str': 'Serum vitamin D measurement'}, {'cui': 'C0017337', 'cui_str': 'Gene'}]",29.0,0.0296952,"After 12 weeks of aerobic exercise intervention, the increase in lymphocyte ERα gene expression (p = 0.005, estimate of effect size/Eta = 32.8%) and serum Vit D (p = 0.001, Eta = 54.7%) were significantly higher in the EX group compared to the C group, whereas pulmonary function parameters and sex hormones (17β-estradiol and progesterone) were not significantly different (P > 0.05). ","[{'ForeName': 'Abbas', 'Initials': 'A', 'LastName': 'Malandish', 'Affiliation': 'Department of Exercise Physiology, Faculty of Sport Sciences, Urmia University, Urmia, Iran. Electronic address: malandish@gmail.com.'}, {'ForeName': 'Bakhtyar', 'Initials': 'B', 'LastName': 'Tartibian', 'Affiliation': ""Department of Sport Injuries & Corrective Exercises, Faculty of Physical Education & Sport Sciences, Allameh Tabataba'i University, Tehran, Iran. Electronic address: ba.tartibian@gmail.com.""}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Rahmati', 'Affiliation': 'Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: rahmati_bio@yahoo.com.'}, {'ForeName': 'Roghaiyeh', 'Initials': 'R', 'LastName': 'Afsargharehbagh', 'Affiliation': 'Department of Interventional Cardiology, Shohada Hospital, Urmia University of Medical Sciences, Urmia, Iran. Electronic address: r.afsargarebag@gmail.com.'}, {'ForeName': 'Zeinab', 'Initials': 'Z', 'LastName': 'Sheikhlou', 'Affiliation': 'Department of Exercise Physiology, Faculty of Sport Sciences, Urmia University, Urmia, Iran. Electronic address: Z.sheikhlou@gmail.com.'}]",Respiratory physiology & neurobiology,['10.1016/j.resp.2020.103510'] 2166,32739466,Lavender and dodder combined herbal syrup versus citalopram in major depressive disorder with anxious distress: A double-blind randomized trial.,"BACKGROUND Major depressive disorder (MDD) accompanied by anxious distress is a chronic and disabling disorder. Its conventional drug therapies often have low patient compliance due to drug-related side effects. In Persian medicine, lavender-dodder syrup is one formula often recommended for such disorders. OBJECTIVE This study compares the effects of lavender-dodder syrup to the standard drug, citalopram, for treating MDD with anxious distress. DESIGN, SETTING, PARTICIPANTS AND INTERVENTION This six-week, double-blind, randomized, clinical trial was carried out in a psychiatric outpatient clinic. During the six-week intervention period, patients in citalopram group received citalopram tablets 20 mg/d plus 5 mL placebo syrup every 12 h; patients in group B received placebo tablets once daily plus 5 mL of lavender-dodder herbal syrup every 12 h. MAIN OUTCOME MEASURES Primary outcome measures, depression and anxiety, were evaluated using the Hamilton Depression/Anxiety Rating Scales, and were scored at the beginning of the study and at weeks three and six. Secondary outcome measures including response to treatment and remission rates were also compared between the two groups. RESULTS Fifty-six participants with MDD and anxious distress were randomly assigned to two groups. Mean depression scores significantly decreased in citalopram and herbal groups at weeks three and six (time effect: P < 0.001), although the observed changes were not significantly different between the groups (intervention effect: P = 0.61). Mean anxiety scores were not significantly different between the two groups at week three (P = 0.75). However, at the end of week six, the observed decrease was significantly higher in the herbal syrup group than the citalopram group (intervention effect: P = 0.007). CONCLUSION The herbal syrup is an effective and tolerable supplement for treating MDD with anxious distress. TRIAL REGISTRATION NUMBER IRCT2016102430459N1 on Iranian Registry of Clinical Trials.",2020,"Mean depression scores significantly decreased in citalopram and herbal groups at weeks three and six (time effect: P < 0.001), although the observed changes were not significantly different between the groups (intervention effect: P = 0.61).","['major depressive disorder with anxious distress', 'Fifty-six participants with MDD and anxious distress', 'psychiatric outpatient clinic']","['Lavender and dodder combined herbal syrup versus citalopram', 'citalopram', 'placebo syrup', 'citalopram tablets 20\xa0mg', 'lavender-dodder syrup', 'placebo tablets once daily plus 5\xa0mL of lavender-dodder herbal syrup every 12\xa0h']","['Mean anxiety scores', 'Mean depression scores', 'response to treatment and remission rates', 'depression and anxiety', 'Hamilton Depression/Anxiety Rating Scales']","[{'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}]","[{'cui': 'C0524903', 'cui_str': 'Lavender'}, {'cui': 'C0996947', 'cui_str': 'Dodder'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0376667', 'cui_str': 'Herbals'}, {'cui': 'C0458173', 'cui_str': 'Syrup'}, {'cui': 'C0008845', 'cui_str': 'Citalopram'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1245573', 'cui_str': 'Citalopram Oral Tablet'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0521982', 'cui_str': 'Response to treatment'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",56.0,0.364875,"Mean depression scores significantly decreased in citalopram and herbal groups at weeks three and six (time effect: P < 0.001), although the observed changes were not significantly different between the groups (intervention effect: P = 0.61).","[{'ForeName': 'Toktam Sadat', 'Initials': 'TS', 'LastName': 'Firoozeei', 'Affiliation': 'Department of Persian Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran 1668753961, Iran.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Barekatain', 'Affiliation': 'Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan 8145831451, Iran.'}, {'ForeName': 'Mehrdad', 'Initials': 'M', 'LastName': 'Karimi', 'Affiliation': 'Department of Persian Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran 1668753961, Iran.'}, {'ForeName': 'Arman', 'Initials': 'A', 'LastName': 'Zargaran', 'Affiliation': 'Department of Traditional Pharmacy, School of Persian Medicine, Tehran University of Medical Sciences, Tehran 1668753961, Iran.'}, {'ForeName': 'Shahin', 'Initials': 'S', 'LastName': 'Akhondzadeh', 'Affiliation': 'Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran 1449614353, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Rezaeizadeh', 'Affiliation': 'Department of Persian Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran 1668753961, Iran. Electronic address: rezaeizadeh@sina.tums.ac.ir.'}]",Journal of integrative medicine,['10.1016/j.joim.2020.06.002'] 2167,32739493,Patient-centered and efficacious advance care planning in cancer: Protocol and key design considerations for the PEACe-compare trial.,"BACKGROUND Failure to deliver care near the end of life that reflects the needs, values and preferences of patients with advanced cancer remains a major shortcoming of our cancer care delivery system. METHODS A mixed-methods comparative effectiveness trial of in-person advance care planning (ACP) discussions versus web-based ACP is currently underway at oncology practices in Western Pennsylvania. Patients with advanced cancer and their caregivers are invited to enroll. Participants are randomized to either (1) in-person ACP discussions via face-to-face visits with a nurse facilitator following the Respecting Choices® Conversation Guide or (2) web-based ACP using the PREPARE for your care™ web-based ACP tool. The trial compares the effect of these two interventions on patient and family caregiver outcomes (engagement in ACP, primary outcome; ACP discussions; advance directive (AD) completion; quality of end-of-life (EOL) care; EOL goal attainment; caregiver psychological symptoms; healthcare utilization at EOL) and assesses implementation costs. Factors influencing ACP effectiveness are assessed via in-depth interviews with patients, caregivers and clinicians. DISCUSSION This trial will provide new and much-needed empirical evidence about two patient-facing ACP approaches that successfully overcome limitations of traditional written advance directives but entail very different investments of time and resources. It is innovative in using mixed methods to evaluate not only the comparative effectiveness of these approaches, but also the contexts and mechanisms influencing effectiveness. Data from this study will inform clinicians, payers and health systems seeking to adopt and scale the most effective and efficient ACP strategy in real-world oncology settings.",2020,"The trial compares the effect of these two interventions on patient and family caregiver outcomes (engagement in ACP, primary outcome; ACP discussions; advance directive (AD) completion; quality of end-of-life (EOL) care; EOL goal attainment; caregiver psychological symptoms; healthcare utilization at EOL) and assesses implementation costs.","['Patients with advanced cancer and their caregivers are invited to enroll', 'patients with advanced cancer']","['person advance care planning (ACP) discussions versus web-based ACP', 'person ACP discussions via face-to-face visits with a nurse facilitator following the Respecting Choices® Conversation Guide or (2) web-based ACP using the PREPARE for your care™ web-based ACP tool']","['patient and family caregiver outcomes (engagement in ACP, primary outcome; ACP discussions; advance directive (AD) completion; quality of end-of-life (EOL) care; EOL goal attainment; caregiver psychological symptoms; healthcare utilization at EOL) and assesses implementation costs', 'ACP effectiveness']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0600371', 'cui_str': 'Advance care planning'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0679133', 'cui_str': 'Respect'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0336791', 'cui_str': 'Tool'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0600371', 'cui_str': 'Advance care planning'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}, {'cui': 'C0001683', 'cui_str': 'Advance Directives'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0233397', 'cui_str': 'Psychological symptom'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.133077,"The trial compares the effect of these two interventions on patient and family caregiver outcomes (engagement in ACP, primary outcome; ACP discussions; advance directive (AD) completion; quality of end-of-life (EOL) care; EOL goal attainment; caregiver psychological symptoms; healthcare utilization at EOL) and assesses implementation costs.","[{'ForeName': 'Judith M', 'Initials': 'JM', 'LastName': 'Resick', 'Affiliation': 'Palliative Research Center (PaRC), Section of Palliative Care and Medical Ethics, Division of General Internal Medicine, University of Pittsburgh, 230 McKee Place, Pittsburgh, PA, 15213, USA. Electronic address: jmr58@pitt.edu.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Arnold', 'Affiliation': 'Palliative Research Center (PaRC), Section of Palliative Care and Medical Ethics, Division of General Internal Medicine, University of Pittsburgh, 230 McKee Place, Pittsburgh, PA, 15213, USA. Electronic address: rabob@pitt.edu.'}, {'ForeName': 'Rebecca L', 'Initials': 'RL', 'LastName': 'Sudore', 'Affiliation': 'Division of Geriatrics, Department of Medicine, University of California, San Francisco, USA; San Francisco Veterans Affairs Health Care System, SFVAMC 4150 Clement Street, #151R, San Francisco, CA 94121, USA. Electronic address: Rebecca.Sudore@ucsf.edu.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Farrell', 'Affiliation': 'People Designs, Inc., 1304 Broad Street, Durham, NC 27705, USA. Electronic address: dfarrell@peopledesigns.com.'}, {'ForeName': 'Shane', 'Initials': 'S', 'LastName': 'Belin', 'Affiliation': 'Palliative Research Center (PaRC), Section of Palliative Care and Medical Ethics, Division of General Internal Medicine, University of Pittsburgh, 230 McKee Place, Pittsburgh, PA, 15213, USA. Electronic address: belin@pitt.edu.'}, {'ForeName': 'Andrew D', 'Initials': 'AD', 'LastName': 'Althouse', 'Affiliation': 'Center for Research on Health Care Data Center, University of Pittsburgh School of Medicine, 200 Meyran Avenue, Suite 300, Pittsburgh, PA 15213, USA. Electronic address: ada62@pitt.edu.'}, {'ForeName': 'Betty', 'Initials': 'B', 'LastName': 'Ferrell', 'Affiliation': 'Division of Nursing Research and Education, Department of Population Sciences, City of Hope Medical Center, 1500 Duarte Road, Duarte, CA 91010, USA. Electronic address: BFerrell@coh.org.'}, {'ForeName': 'Bernard J', 'Initials': 'BJ', 'LastName': 'Hammes', 'Affiliation': 'Respecting Choices, A Division of C-TAC Innovations, PO Box 258, Oregon, WI 53575-0258, USA. Electronic address: bhammes@respectingchoices.org.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Chu', 'Affiliation': 'Department of Medicine, Division of Hematology-Oncology and Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: chue2@upmc.edu.'}, {'ForeName': 'Douglas B', 'Initials': 'DB', 'LastName': 'White', 'Affiliation': 'University of Pittsburgh, School of Medicine, Department of Critical Care Medicine, Clinical Research, Investigation, and Systems Modeling of Acute Illness Center, Program on Ethics and Decision Making, 600 Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15213, USA. Electronic address: douglas.white@pitt.edu.'}, {'ForeName': 'Kimberly J', 'Initials': 'KJ', 'LastName': 'Rak', 'Affiliation': 'University of Pittsburgh, School of Medicine, Department of Critical Care Medicine, Clinical Research, Investigation, and Systems Modeling of Acute Illness Center, Program on Ethics and Decision Making, 3520 Fifth Ave, Suite100, Pittsburgh, PA 15213, USA. Electronic address: kjr8@pitt.edu.'}, {'ForeName': 'Yael', 'Initials': 'Y', 'LastName': 'Schenker', 'Affiliation': 'Palliative Research Center (PaRC), Section of Palliative Care and Medical Ethics, Division of General Internal Medicine, University of Pittsburgh, 230 McKee Place, Pittsburgh, PA, 15213, USA. Electronic address: yas28@pitt.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106071'] 2168,32739494,Cancer history and risk factors in healthy older people enrolling in the ASPREE clinical trial.,"BACKGROUND Cancer is a leading cause of death globally. Given the elevated risk of cancer with age and an ageing population, it is important to understand the changing burden of cancer in older populations. The ASPirin in Reducing Events in the Elderly (ASPREE) study randomised healthy older individuals to 100 mg aspirin or placebo, with clinical outcomes and disability-free survival endpoints. Detailed baseline data provides a rare opportunity to explore cancer burden in a uniquely healthy older population. METHODS At study enrolment (2010-2014), self-reported personal cancer history, cancer type and cancer risk factor data were sought from 19,114 participants (Australia, n = 16,703; U.S., n = 2411). Eligible participants were healthy, free of major diseases and expected to survive 5 years. RESULTS Nearly 20% of enrolling ASPREE participants reported a prior cancer diagnosis; 18% of women and 22% of men, with women diagnosed younger (16% vs 6% of diagnoses <50 years). Cancer prevalence increased with age. Prevalence of prostate and breast cancer history were higher in U.S. participants; melanoma and colorectal cancer were higher in Australian participants. Cancer history prevalence was not associated with contemporary common risk factors nor previous aspirin use, but was associated with poor health ratings in men. Blood and breast cancer history were more common with past aspirin use. CONCLUSIONS Personal cancer history in healthy older ASPREE participants was as expected for the most common cancer types in the respective populations, but was not necessarily aligned with known risk factors. We attribute this to survivor bias, likely driven by entry criteria. TRIAL REGISTRATION International Standard Randomised Controlled Trial Number Register (ISRCTN83772183) and clinicaltrials.gov (NCT01038583).",2020,Prevalence of prostate and breast cancer history were higher in U.S. participants; melanoma and colorectal cancer were higher in Australian participants.,"['healthy older individuals to 100\u202fmg', 'Eligible participants were healthy, free of major diseases and expected to survive 5\u202fyears', 'healthy older ASPREE participants', 'healthy older people enrolling', 'At study enrolment (2010-2014), self-reported personal cancer history, cancer type and cancer risk factor data were sought from 19,114 participants (Australia, n\u202f=\u202f16,703; U.S., n\u202f=\u202f2411', 'uniquely healthy older population']","['ASPirin', 'aspirin or placebo']","['Cancer history and risk factors', 'Prevalence of prostate and breast cancer history', 'Cancer prevalence']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}]",19114.0,0.463069,Prevalence of prostate and breast cancer history were higher in U.S. participants; melanoma and colorectal cancer were higher in Australian participants.,"[{'ForeName': 'Suzanne G', 'Initials': 'SG', 'LastName': 'Orchard', 'Affiliation': 'Department of Epidemiology & Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: Suzanne.orchard@monash.edu.'}, {'ForeName': 'Jessica E', 'Initials': 'JE', 'LastName': 'Lockery', 'Affiliation': 'Department of Epidemiology & Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: Jessica.lockery@monash.edu.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Gibbs', 'Affiliation': 'The Walter & Eliza Hall Institute of Medical Research, University of Melbourne,1G Royal Parade, Parkville, Victoria 3052, Australia. Electronic address: Peter.gibbs@petermac.org.'}, {'ForeName': 'Galina', 'Initials': 'G', 'LastName': 'Polekhina', 'Affiliation': 'Department of Epidemiology & Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: Galhina.polekhina@monash.edu.'}, {'ForeName': 'Rory', 'Initials': 'R', 'LastName': 'Wolfe', 'Affiliation': 'Department of Epidemiology & Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: Rory.wolfe@monash.edu.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Zalcberg', 'Affiliation': 'Department of Epidemiology & Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: John.zalcberg@monash.edu.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Haydon', 'Affiliation': 'Department of Epidemiology & Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: Andrew.haydon@monash.edu.'}, {'ForeName': 'John J', 'Initials': 'JJ', 'LastName': 'McNeil', 'Affiliation': 'Department of Epidemiology & Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: John.mcneil@monash.edu.'}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Nelson', 'Affiliation': 'Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool St (Private Bag 23), Hobart 7000, Tasmania, Australia. Electronic address: Mark.nelson@utas.edu.au.'}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Reid', 'Affiliation': 'School of Public Health, Curtin University, Kent Street, Bentley, Perth 6102, Western Australia, Australia. Electronic address: Christpher.reid@curtin.edu.au.'}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Kirpach', 'Affiliation': 'Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute (HHRI), 701 Park Avenue, Suite PP7.700, Minneapolis 55415, Minnesota, USA. Electronic address: bkirpach@bermancenter.org.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Murray', 'Affiliation': 'Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute (HHRI), 701 Park Avenue, Suite PP7.700, Minneapolis 55415, Minnesota, USA; Division of Geriatrics, Department of Medicine, Hennepin Healthcare and University of Minnesota, East River Parkway, Minneapolis 55455, Minnesota, USA. Electronic address: AMurray@bermancenter.org.'}, {'ForeName': 'Robyn L', 'Initials': 'RL', 'LastName': 'Woods', 'Affiliation': 'Department of Epidemiology & Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: Robyn.woods@monash.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Contemporary clinical trials,['10.1016/j.cct.2020.106095'] 2169,32747306,Results of a randomised controlled trial between an ORC collagen hemostatic agent and a carrier-bound fibrin sealant.,"INTRODUCTION Despite ongoing optimisation of surgical techniques, hemostasis continues to be a fundamental challenge in many operations today. This randomised controlled trial compared the efficacy of a new hemostatic agent made of oxidised regenerated cellulose and collagen (ORC-Coll) with that of a conventional carrier-bound fibrin sealant (CBFS). METHODS Hemostasis was investigated representatively in the case of post-thyroidectomy bleeding from the resection surface. To demonstrate that ORC-Coll (mediCipio® A) has at least the same hemostatic efficacy as CBFS (Tachosil®), the volume of drainage fluid at the time of drain removal was used as the primary endpoint in a non-inferiority test with a significance level of 5%. The secondary endpoints included number and size of hemostatic agents required, adhesion of the hemostatic agent to the bleeding surface, intraoperative hemostatic effect, duration of drainage and adverse events during a six-month follow-up period. RESULTS A total of 150 patients (ORC-Coll: 75; CBFS: 75) were included. After operation, total volume of drainage fluid was 68.20±44.56mL in the ORC group and 68.21±40.20mL in the CBFS group. The non-inferiority of ORC-Coll compared to CBFS with regard to hemostatic efficacy was shown at a significance level of 5%. The results demonstrated effectiveness in achieving hemostasis without adverse events. CONCLUSIONS ORC-Coll is an effective hemostatic agent and barrier sealant without blood components, which ensures reliable prevention of intra- and postoperative bleeding. With use of the new technique, any risks associated with the use of human blood components are a priori eliminated.",2020,The non-inferiority of ORC-Coll compared to CBFS with regard to hemostatic efficacy was shown at a significance level of 5%.,['150 patients (ORC-Coll: 75; CBFS: 75) were included'],"['new hemostatic agent made of oxidised regenerated cellulose and collagen (ORC-Coll', 'ORC collagen hemostatic agent and a carrier-bound fibrin sealant', 'conventional carrier-bound fibrin sealant (CBFS']","['number and size of hemostatic agents required, adhesion of the hemostatic agent to the bleeding surface, intraoperative hemostatic effect, duration of drainage and adverse events', 'hemostatic efficacy', 'total volume of drainage fluid']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0139977', 'cui_str': 'regenerated cellulose'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0007294', 'cui_str': 'Genetic disorder carrier'}, {'cui': 'C0332297', 'cui_str': 'Bounded by'}, {'cui': 'C0016004', 'cui_str': 'Autologous Fibrin Tissue Adhesive'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0019120', 'cui_str': 'Hemostatic agent'}, {'cui': 'C0139977', 'cui_str': 'regenerated cellulose'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C3876617', 'cui_str': 'Collagen hemostatic agent'}, {'cui': 'C0007294', 'cui_str': 'Genetic disorder carrier'}, {'cui': 'C0332297', 'cui_str': 'Bounded by'}, {'cui': 'C0016004', 'cui_str': 'Autologous Fibrin Tissue Adhesive'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0019120', 'cui_str': 'Hemostatic agent'}, {'cui': 'C0001511', 'cui_str': 'Adhesion'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}]",150.0,0.0919327,The non-inferiority of ORC-Coll compared to CBFS with regard to hemostatic efficacy was shown at a significance level of 5%.,"[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Pallaske', 'Affiliation': 'Medichema GmbH, Weststraße 57, 09112 Chemnitz, Germany. Electronic address: fpallaske@medichema.com.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Seebauer', 'Affiliation': 'Department of Oral and Maxillofacial Surgery/Plastic Surgery, University Medicine Greifswald, Walther-Rathenau Str. 42a, 17475 Greifswald, Germany. Electronic address: seebauerc@uni-greifswald.de.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Kaltofen', 'Affiliation': 'General and Visceral Surgery, Klinikum Chemnitz gGmbH, Flemmingstraße 2, 09116 Chemnitz, Germany. Electronic address: d.kaltofen@skc.de.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Dziomber', 'Affiliation': 'General and Visceral Surgery, Klinikum Chemnitz gGmbH, Flemmingstraße 2, 09116 Chemnitz, Germany. Electronic address: s.dziomber@skc.de.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Rudolph', 'Affiliation': 'General and Visceral Surgery, Klinikum Chemnitz gGmbH, Flemmingstraße 2, 09116 Chemnitz, Germany. Electronic address: h.rudolph@skc.de.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Schwanebeck', 'Affiliation': 'Carl-Gustav-Carus Faculty of Medicine, Technische Universität Dresden, Coordinating Centre for Clinical Trials Dresden, Fetscherstraße 74, 01307 Dresden, Germany. Electronic address: uta.schwanebeck@uniklinikum-dresden.de.'}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Grählert', 'Affiliation': 'Carl-Gustav-Carus Faculty of Medicine, Technische Universität Dresden, Coordinating Centre for Clinical Trials Dresden, Fetscherstraße 74, 01307 Dresden, Germany. Electronic address: xina.graehlert@uniklinikum-dresden.de.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Schulze', 'Affiliation': 'Carl-Gustav-Carus Faculty of Medicine, Technische Universität Dresden, Coordinating Centre for Clinical Trials Dresden, Fetscherstraße 74, 01307 Dresden, Germany. Electronic address: gabriele.schulze@uniklinikum-dresden.de.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Pallaske', 'Affiliation': 'Kreiskrankenhaus Stollberg gGmbH, Hospital of Internal Medicine II, Jahnsdorfer Straße 7, 09366 Stollberg, Germany. Electronic address: anett.reinstein@web.de.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Boese-Landgraf', 'Affiliation': 'General and Visceral Surgery, Klinikum Chemnitz gGmbH, Flemmingstraße 2, 09116 Chemnitz, Germany. Electronic address: j.boese.landgraf@gmail.com.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Schlömann', 'Affiliation': 'Technische Universität Bergakademie Freiberg, Institute of Biosciences, 09599 Freiberg, Germany. Electronic address: michael.schloemann@ioez.tu-freiberg.de.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Daeschlein', 'Affiliation': 'Department of Oral and Maxillofacial Surgery/Plastic Surgery, University Medicine Greifswald, Walther-Rathenau Str. 42a, 17475 Greifswald, Germany. Electronic address: georg.daeschlein@med.uni-greifswald.de.'}]",Journal of visceral surgery,['10.1016/j.jviscsurg.2020.06.015'] 2170,32747309,Fluoroscopic imaging optimization in children during percutaneous nephrolithotrispy.,"INTRODUCTION AND OBJECTIVES Radiation protection management recommends radiation exposures that are as low as reasonably achievable (ALARA), while still maintaining image quality. The aim of the study is to compare radiation exposure during pediatric percutaneous nephrolithotomy (PCNL) before and after implementation of strategy for optimization of fluoroscopic imaging by measuring the Dose Area Product (DAP) and the Fluoroscopy time (FT) and study its effect on surgical outcomes. PATIENTS & METHODS We prospectively observed 56 children (group 1) undergoing PCNL for kidney stones in whom a radiation dose reduction strategy was adopted. The strategy included several intraoperative measures, including: optimizing position by keeping the fluoroscopy table as far from the X-ray tube as possible and the image intensifier close to the patient, preventing use of fluoroscopy for positioning, use of pulsed mode with last image hold technique, beam collimation and use of a designated fluoroscopy technician. Outcomes were compared to those in 42 children (group 2) before implementing dose reduction strategy. RESULTS DAP was decreased by 44% from 2.46 in group 2 to 1.38 mGy m2 in group 1 (p < 0.04). Total fluoroscopy time was significantly reduced by 55% from 100.8 s in group 2-45 s in group 1 (p < 0.002) after protocol implementation with very little loss of image quality. CONCLUSIONS Radiation exposure in children undergoing PCNL can be reduced significantly after optimization of fluoroscopy imaging. A reduced radiation protocol did not increase surgical complexity, operative time, or complication rates while reducing radiation exposure in a population vulnerable to its hazardous effects.",2020,"A reduced radiation protocol did not increase surgical complexity, operative time, or complication rates while reducing radiation exposure in a population vulnerable to its hazardous effects.","['We prospectively observed 56 children (group 1) undergoing PCNL for kidney stones in whom a radiation dose reduction strategy was adopted', 'children during percutaneous nephrolithotrispy']","['pediatric percutaneous nephrolithotomy (PCNL', 'Fluoroscopic imaging optimization']","['surgical complexity, operative time, or complication rates', 'DAP', 'Total fluoroscopy time']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0162428', 'cui_str': 'Removal of calculus of renal pelvis through percutaneous nephrostomy'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0022650', 'cui_str': 'Kidney stone'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0425382', 'cui_str': 'Adopted'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}]","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0162428', 'cui_str': 'Removal of calculus of renal pelvis through percutaneous nephrostomy'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",56.0,0.0394728,"A reduced radiation protocol did not increase surgical complexity, operative time, or complication rates while reducing radiation exposure in a population vulnerable to its hazardous effects.","[{'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Fahmy', 'Affiliation': 'Faculty of Medicine, Urology Department, Alexandria University, Egypt. Electronic address: drahmedfahmy@yahoo.com.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Elgebaly', 'Affiliation': 'Faculty of Medicine, Urology Department, Alexandria University, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Youssif', 'Affiliation': 'Faculty of Medicine, Urology Department, Alexandria University, Egypt.'}]",Journal of pediatric urology,['10.1016/j.jpurol.2020.07.009'] 2171,32747329,"Effect of an E-Learning Module on Personal Protective Equipment Proficiency by Prehospital Personnel: Web-Based, Randomized Controlled Trial.","BACKGROUND To avoid misuse of personal protective equipment (PPE), ensure healthcare workers' safety and avoid shortages, effective communication of up-to-date infection control guidelines is essential. As prehospital teams are particularly at risk of contamination given their challenging work environment, a specific gamified electronic learning (e-learning) module targeting this audience might provide significant advantages as it requires neither the presence of learners nor the repetitive use of equipment for demonstration. OBJECTIVE The aim of this study was to evaluate whether a gamified e-learning module could improve the rate of adequate PPE choice by prehospital personnel in the context of the coronavirus disease 2019 pandemic. METHODS This was an individual-level randomized, controlled, quadruple-blind (investigators, participants, outcome assessors and data analysts) closed web-based trial. All emergency prehospital personnel working in Geneva, Switzerland, were eligible for inclusion, and were invited to participate by e-mail, in April 2020. Participants were informed that the study aim was to assess their knowledge regarding PPE, and that they would be presented with both the guidelines and the e-learning module, though they were unaware that there were two different study paths. All participants first answered a pre-intervention quiz designed to establish their profile and baseline knowledge. The control group then accessed the guidelines before answering a second set of questions, and were then granted access to the e-learning module. The e-learning group was shown the e-learning module right after the guidelines before answering the second set of questions. RESULTS Out of the 291 randomized participants, 176 (60.5%) completed the trial. There was no significant difference in baseline knowledge between groups. Though the baseline proportion of adequate PPE choice was high (75% [50;75]), description of the donning sequence was in most cases incorrect. After either intervention, adequate choice of PPE increased significantly in both groups (P<.001). Though the median of the difference in the proportion of correct answers was slightly higher in the e-learning group (17% [8;33] versus 8% [8;33]), it did not reach statistical significance (P=.27). Confidence in the ability to use PPE was maintained in the e-learning group (P=.27) but significantly decreased in the control group (P=.04). CONCLUSIONS Among prehospital personnel with an already relatively high knowledge and experience regarding PPE use, both web-based study paths increased the rate of adequate choice of PPE. There was no major added value of the gamified e-learning module apart from preserving participants' confidence in their ability of correctly using PPE. CLINICALTRIAL ",2020,"There was no major added value of the gamified e-learning module apart from preserving participants' confidence in their ability of correctly using PPE. ","['Out of the 291 randomized participants, 176 (60.5%) completed the trial', 'Personal Protective Equipment Proficiency by Prehospital Personnel', 'All emergency prehospital personnel working in Geneva, Switzerland, were eligible for inclusion, and were invited to participate by e-mail, in April 2020']","['gamified e-learning module', 'E-Learning Module', 'personal protective equipment (PPE']","['baseline knowledge', 'adequate PPE choice', 'proportion of correct answers', 'adequate choice of PPE']","[{'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1443871', 'cui_str': 'Personal protective equipment'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0557351', 'cui_str': 'Employed'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C1443871', 'cui_str': 'Personal protective equipment'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}]",291.0,0.0691654,"There was no major added value of the gamified e-learning module apart from preserving participants' confidence in their ability of correctly using PPE. ","[{'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Suppan', 'Affiliation': 'Division of Emergency Medicine, Department of Anesthesiology, Clinical Pharmacology, Intensive Care and Emergency Medicine, University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, Geneva, CH.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Abbas', 'Affiliation': 'Infection Control Program and WHO Collaborating Centre on Patient Safety, The University of Geneva Hospitals and Faculty of Medicine, Geneva, CH.'}, {'ForeName': 'Loric', 'Initials': 'L', 'LastName': 'Stuby', 'Affiliation': 'Genève TEAM Ambulances, Geneva, CH.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Cottet', 'Affiliation': 'Division of Emergency Medicine, Department of Anesthesiology, Clinical Pharmacology, Intensive Care and Emergency Medicine, University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, Geneva, CH.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Larribau', 'Affiliation': 'Division of Emergency Medicine, Department of Anesthesiology, Clinical Pharmacology, Intensive Care and Emergency Medicine, University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, Geneva, CH.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Golay', 'Affiliation': 'Division of Emergency Medicine, Department of Anesthesiology, Clinical Pharmacology, Intensive Care and Emergency Medicine, University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, Geneva, CH.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Iten', 'Affiliation': 'Infection Control Program and WHO Collaborating Centre on Patient Safety, The University of Geneva Hospitals and Faculty of Medicine, Geneva, CH.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Harbarth', 'Affiliation': 'Infection Control Program and WHO Collaborating Centre on Patient Safety, The University of Geneva Hospitals and Faculty of Medicine, Geneva, CH.'}, {'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Gartner', 'Affiliation': 'Division of Emergency Medicine, Department of Anesthesiology, Clinical Pharmacology, Intensive Care and Emergency Medicine, University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, Geneva, CH.'}, {'ForeName': 'Mélanie', 'Initials': 'M', 'LastName': 'Suppan', 'Affiliation': 'Division of Anesthesiology, Department of Anesthesiology, Clinical Pharmacology, Intensive Care and Emergency Medicine, University of Geneva Hospitals and Faculty of Medicine, Geneva, CH.'}]",Journal of medical Internet research,['10.2196/21265'] 2172,32747351,"Protocol for economic evaluation alongside the SHINE (Supporting Healthy Image, Nutrition and Exercise) cluster randomised controlled trial.","INTRODUCTION Limited evidence exists on the cost-effectiveness of interventions to prevent obesity and promote healthy body image in adolescents. The SHINE (Supporting Healthy Image, Nutrition and Exercise) study is a cluster randomised control trial (cRCT) aiming to deliver universal education about healthy nutrition and physical activity to adolescents, as well as targeted advice to young people with body image concerns who are at risk of developing disordered eating behaviours. This paper describes the methods for the economic evaluation of the SHINE cRCT, to determine whether the intervention is cost-effective as an obesity prevention measure. METHODS AND ANALYSIS A public payer perspective will be adopted, with intervention costs collected prospectively. Within-trial cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) will quantify the incremental costs and health gains of the intervention as compared with usual practice (ie, teacher-delivered curriculum). CEA will present results as cost per body mass index unit saved. CUA will present results as cost per quality-adjusted life year gained. A modelled CUA will extend the target population, time horizon and decision context to provide valuable information to policymakers on the potential for incremental cost offsets attributable to disease prevention arising from intervention. Intervention costs and effects will be extrapolated to the population of Australian adolescents in Grade 7 of secondary school (approximate age 13 years) and modelled over the cohort's lifetime. Modelled CUA results will be presented as health-adjusted life years saved and healthcare cost-savings of diseases averted. Incremental cost-effectiveness ratios will be calculated as the difference in costs between the intervention and comparator divided by the difference in benefit. Semi-structured interviews with key intervention stakeholders will explore the potential impact of scalability on cost-effectiveness. These data will be thematically analysed to inform sensitivity analysis of the base case economic evaluation, such that cost-effectiveness evidence is reflective of the potential for scalability. ETHICS AND DISSEMINATION Ethics approval was obtained from the Deakin University Human Research Ethics Committee (#2017-269) and the Victorian Department of Education and Training (#2018_003630). Study findings will be disseminated through peer-reviewed academic papers and participating schools will receive annual reports over the 3 years of data collection. TRIAL REGISTRATION NUMBER ACTRN 12618000330246; Pre-results.",2020,"This paper describes the methods for the economic evaluation of the SHINE cRCT, to determine whether the intervention is cost-effective as an obesity prevention measure. ","['young people with body image concerns who are at risk of developing disordered eating behaviours', ""population of Australian adolescents in Grade 7 of secondary school (approximate age 13 years) and modelled over the cohort's lifetime"", 'adolescents']","['CUA', 'CEA', 'cost-utility analysis (CUA']",['Incremental cost-effectiveness ratios'],"[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0005891', 'cui_str': 'Body image'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0855228', 'cui_str': 'Eating disorder symptom'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0036530', 'cui_str': 'Secondary school'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}]","[{'cui': 'C3853052', 'cui_str': 'Cost-Utility Analysis'}, {'cui': 'C1511536', 'cui_str': 'Cost-Effectiveness Analysis'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.0974056,"This paper describes the methods for the economic evaluation of the SHINE cRCT, to determine whether the intervention is cost-effective as an obesity prevention measure. ","[{'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Brown', 'Affiliation': 'Deakin University, Geelong, Deakin Health Economics, Institute for Health Transformation, Geelong, Victoria, Australia victoria.brown@deakin.edu.au.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Williams', 'Affiliation': 'Deakin University, Geelong, Institute for Health Transformation, School of Health and Social Development, Geelong, Victoria, Australia.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'McGivern', 'Affiliation': 'Deakin University, Geelong, Institute for Health Transformation, School of Health and Social Development, Geelong, Victoria, Australia.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Sawyer', 'Affiliation': ""Department of Paediatrics, The University of Melbourne; Centre for Adolescent Health Royal Children's Hospital, Melbourne, Victoria, Australia.""}, {'ForeName': 'Liliana', 'Initials': 'L', 'LastName': 'Orellana', 'Affiliation': 'Deakin University, Geelong, Faculty of Health, Geelong, Victoria, Australia.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Luo', 'Affiliation': 'Deakin University, Geelong, School of Information Technology, Geelong, Victoria, Australia.'}, {'ForeName': 'Kylie D', 'Initials': 'KD', 'LastName': 'Hesketh', 'Affiliation': 'Deakin University, Geelong, Institute for Physical Activity and Nutrition, Faculty of Health, Geelong, Victoria, Australia.'}, {'ForeName': 'Denise E', 'Initials': 'DE', 'LastName': 'Wilfley', 'Affiliation': 'School of Medicine, Washington University in St. Louis, Missouri, Missouri, USA.'}, {'ForeName': 'Marj', 'Initials': 'M', 'LastName': 'Moodie', 'Affiliation': 'Deakin University, Geelong, Deakin Health Economics, Institute for Health Transformation, Geelong, Victoria, Australia.'}]",BMJ open,['10.1136/bmjopen-2020-038050'] 2173,32747975,TAS-303 effects on urethral sphincter function in women with stress urinary incontinence: phase I study.,"INTRODUCTION AND HYPOTHESIS TAS-303, which selectively inhibits noradrenaline reuptake, was developed for treating stress urinary incontinence (SUI). The proximal urethra mainly comprises smooth muscle fibers in which α1 adrenergic receptors are abundant. This study was conducted to evaluate the effect of TAS-303 on urethral function and its safety profile in female patients with SUI. METHODS In total, 16 women (age, 20-64 years) with SUI and > 5.0 g of leakage in the 1-h pad test at screening were randomized and administered the assigned treatment in a double-blind manner. The primary end point was change in the maximal urethral closure pressure (MUCP) at 6 h post-dose. The secondary end point was change in the urethral closure pressure of the entire urethra and each urethral region (proximal, middle, and distal) at 6 h post-dose. The results were analyzed using a t-test. RESULTS The mean change ± standard deviation in MUCP at 6 h post-dose was 3.473 ± 12.154 cmH 2 O for TAS-303 and 2.615 ± 9.794 cmH 2 O for placebo (between-group difference: 0.858 cmH 2 O, P = 0.8047). The mean changes ± standard deviation in urethral closure pressure of the proximal urethra at 6 h after the administration of TAS-303 18 mg and placebo were 3.863 ± 10.941 and 1.634 ± 12.093, respectively (between-group difference: 2.229 cmH 2 O, P = 0.5976). CONCLUSIONS No significant difference in MUCP and urethral closure pressure was found between TAS-303 and placebo. However, the change in the proximal urethral closure pressure with TAS-303 was larger than that with placebo. This suggests that TAS-303 has pharmacological effects on urethral sphincteric function.",2020,No significant difference in MUCP and urethral closure pressure was found between TAS-303 and placebo.,"['women with stress urinary incontinence', 'female patients with SUI', '16 women (age, 20-64 years) with SUI and\u2009>\u20095.0\xa0g of leakage in the 1-h pad test at screening']","['placebo', 'TAS-303 and placebo', 'TAS-303']","['mean changes ± standard deviation in urethral closure pressure of the proximal urethra', 'maximal urethral closure pressure (MUCP', 'MUCP and urethral closure pressure', 'urethral sphincteric function', 'proximal urethral closure pressure with TAS-303', 'urethral sphincter function', 'urethral closure pressure of the entire urethra and each urethral region (proximal, middle, and distal', 'urethral function', 'mean change ± standard deviation in MUCP']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0015376', 'cui_str': 'Extravasation'}, {'cui': 'C0700308', 'cui_str': 'Protium'}, {'cui': 'C0332568', 'cui_str': 'Pad'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0559483', 'cui_str': 'Pentalogy of Cantrell'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0041967', 'cui_str': 'Urethral'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0559483', 'cui_str': 'Pentalogy of Cantrell'}, {'cui': 'C0429819', 'cui_str': 'Urethral sphincter function'}, {'cui': 'C1281574', 'cui_str': 'Entire urethra'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0422815', 'cui_str': 'Urethral function'}]",16.0,0.148755,No significant difference in MUCP and urethral closure pressure was found between TAS-303 and placebo.,"[{'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Yono', 'Affiliation': 'Department of Urology, Nishi Kumamoto Hospital, Souseikai, Kumamoto, Japan. m-yonou@nishikuma.com.'}, {'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Irie', 'Affiliation': 'Department of Clinical Pharmacology, Nishi Kumamoto Hospital, Souseikai, Kumamoto, Japan.'}, {'ForeName': 'Momokazu', 'Initials': 'M', 'LastName': 'Gotoh', 'Affiliation': 'Department of Urology, Nagoya University Graduate School of Medicine, Aichi, Japan.'}]",International urogynecology journal,['10.1007/s00192-020-04470-7'] 2174,32747990,Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate-a post hoc analysis of a randomized clinical trial.,"BACKGROUND Skeletal-related events (SREs) are critical events for patients with bone metastasis from non-small cell lung cancer (NSCLC). Thus, bone-modifying agents are recommended in this population. However, the baseline risk factors of SREs in patients with bone metastasis from NSCLC are not well established. METHODS We analyzed the patient-level data from the zoledronate arm of a clinical trial comparing denosumab with zoledronate in patients with bone metastasis ( ClinicalTrial.gov ID: NCT00330759) available at Project Data Sphere, a broad-access research platform. The primary endpoint was the first SRE from the inclusion to the trial, and the time to the first SRE was analyzed using Cox proportional hazards model. RESULTS We analyzed 302 patients with NSCLC without a documented history of osteopenia or osteoporosis included in the zoledronate arm of the trial. Ninety-eight patients (32%) had at least one SRE. The univariate analysis showed that low serum albumin and elevated serum alkaline phosphatase (ALP) are significant baseline risk factors for SREs (hazard ratio (HR) [95% confidence interval (CI)]; 2.27 [1.43-3.61], and 1.91 [1.26-2.90], respectively). Additionally, osteoblastic and mixed type of bone metastasis showed a significantly lower risk of SREs compared with the osteolytic lesion (HR [95% CI]; 0.39 [0.21-0.72], and 0.31 [0.15-0.63], respectively). These factors also showed a significant association with the risk of SREs in multivariate analysis. CONCLUSIONS We revealed that osteolytic bone metastasis, low serum albumin, and elevated serum ALP are risk factors for SREs in patients with bone metastasis from NSCLC.",2020,The univariate analysis showed that low serum albumin and elevated serum alkaline phosphatase (ALP) are significant baseline risk factors for SREs (hazard ratio (HR),"['patients with bone metastasis from NSCLC', 'Ninety-eight patients (32%) had at least one SRE', 'patients with bone metastasis ( ClinicalTrial.gov ID', 'patients with bone metastasis', '302 patients with NSCLC without a documented history of osteopenia or osteoporosis included in the zoledronate arm of the trial', 'patients with bone metastasis from non-small cell lung cancer undergoing treatment with', 'patients with bone metastasis from non-small cell lung cancer (NSCLC']","['denosumab with zoledronate', 'zoledronate']","['low serum albumin and elevated serum alkaline phosphatase (ALP', 'osteolytic bone metastasis, low serum albumin', 'SREs (hazard ratio (HR', 'time to the first SRE', 'risk of SREs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0153690', 'cui_str': 'Secondary malignant neoplasm of bone'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C4319627', 'cui_str': '98'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C3532898', 'cui_str': 'History of osteopenia'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0392938', 'cui_str': 'Zoledronate'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C1690432', 'cui_str': 'denosumab'}, {'cui': 'C0392938', 'cui_str': 'Zoledronate'}]","[{'cui': 'C0580493', 'cui_str': 'Serum albumin low'}, {'cui': 'C0750857', 'cui_str': 'Alkaline phosphatase serum increased'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0153690', 'cui_str': 'Secondary malignant neoplasm of bone'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",302.0,0.277759,The univariate analysis showed that low serum albumin and elevated serum alkaline phosphatase (ALP) are significant baseline risk factors for SREs (hazard ratio (HR),"[{'ForeName': 'Hirotaka', 'Initials': 'H', 'LastName': 'Miyashita', 'Affiliation': 'Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, NY, USA. miyashita.hirotaka@gmail.com.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Cruz', 'Affiliation': 'Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, NY, USA.'}, {'ForeName': 'Cardinale', 'Initials': 'C', 'LastName': 'Smith', 'Affiliation': 'Division of Hematology and Medical Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-020-05665-w'] 2175,32747995,Improved metabolic function and cognitive performance in middle-aged adults following a single dose of wild blueberry.,"PURPOSE Research has demonstrated cognitive benefits following acute polyphenol-rich berry consumption in children and young adults. Berry intake also has been associated with metabolic benefits. No study has yet examined cognitive performance in middle-aged adults. We investigated the relationships among cognitive and metabolic outcomes in middle-aged adults following wild blueberry (WBB) consumption. METHODS Thirty-five individuals aged 40-65 years participated in a randomized, double blind, cross-over study. Participants consumed a breakfast meal and 1-cup equivalent WBB drink or matched placebo beverage on two occasions. Participants completed cognitive tasks and had blood drawn before and at regular intervals for 8 h after each meal/treatment. Changes in episodic memory and executive function (EF) were assessed alongside plasma levels of glucose, insulin, and triglyceride. RESULTS Analysis of the memory-related Auditory Verbal Learning Task (AVLT) word recognition measure revealed a decrease in performance over the test day after placebo intake, whereas performance after WBB was maintained. For the AVLT word rejection measure, participants identified more foils following WBB in comparison to placebo. Benefits were also observed for EF on the Go/No-Go task with fewer errors following WBB intake on cognitively demanding invalid No-Go trials in comparison to placebo. Furthermore, in comparison to placebo, response times were faster for the Go/No-Go task, specifically at 4 h and 8 h following WBB treatment. We also observed reduced post-meal glucose and insulin, but not triglyceride, concentrations in comparison to placebo over the first 2 h following ingestion. Though the addition of Age, BMI, glucose and insulin as covariates to the analysis reduced the significant effect of beverage for AVLT word rejection, metabolic outcomes did not interact with treatment to predict cognitive performance with the exception of one isolated trend. CONCLUSIONS This study indicated acute cognitive benefits of WBB intake in cognitively healthy middle-aged individuals, particularly in the context of demanding tasks and cognitive fatigue. WBB improved glucose and insulin responses to a meal. Further research is required to elucidate the underlying mechanism by which WBB improves cognitive function.",2020,Benefits were also observed for EF on the Go/No-Go task with fewer errors following WBB intake on cognitively demanding invalid No-Go trials in comparison to placebo.,"['middle-aged adults following wild blueberry (WBB) consumption', 'middle-aged adults', 'Thirty-five individuals aged 40-65\xa0years', 'cognitively healthy middle-aged individuals', 'children and young adults']","['breakfast meal and 1-cup equivalent WBB drink or matched placebo', 'acute polyphenol-rich berry consumption', 'placebo']","['cognitive performance', 'metabolic function and cognitive performance', 'cognitive tasks and had blood drawn', 'memory-related Auditory Verbal Learning Task (AVLT) word recognition measure', 'episodic memory and executive function (EF', 'plasma levels of glucose, insulin, and triglyceride', 'cognitive function', 'WBB improved glucose and insulin responses']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0445392', 'cui_str': 'Wild'}, {'cui': 'C0950037', 'cui_str': 'Blueberries'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0220647', 'cui_str': 'Carcinoma of unknown primary'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0445392', 'cui_str': 'Wild'}, {'cui': 'C0950037', 'cui_str': 'Blueberries'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0071649', 'cui_str': 'Polyphenol'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0005135', 'cui_str': 'Berry'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0005834', 'cui_str': 'Collection of blood specimen for laboratory'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0445392', 'cui_str': 'Wild'}, {'cui': 'C0950037', 'cui_str': 'Blueberries'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",35.0,0.240134,Benefits were also observed for EF on the Go/No-Go task with fewer errors following WBB intake on cognitively demanding invalid No-Go trials in comparison to placebo.,"[{'ForeName': 'Adrian R', 'Initials': 'AR', 'LastName': 'Whyte', 'Affiliation': 'School of Psychology and Clinical Language Sciences, University of Reading, Earley Gate, Whiteknights, Reading, RG6 6AL, UK.'}, {'ForeName': 'Sajida', 'Initials': 'S', 'LastName': 'Rahman', 'Affiliation': 'Centre for Nutrition Research, Department of Food Science and Nutrition, Illinois Institute of Technology, Chicago, IL, USA.'}, {'ForeName': 'Lynne', 'Initials': 'L', 'LastName': 'Bell', 'Affiliation': 'School of Psychology and Clinical Language Sciences, University of Reading, Earley Gate, Whiteknights, Reading, RG6 6AL, UK.'}, {'ForeName': 'Indika', 'Initials': 'I', 'LastName': 'Edirisinghe', 'Affiliation': 'Centre for Nutrition Research, Department of Food Science and Nutrition, Illinois Institute of Technology, Chicago, IL, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Krikorian', 'Affiliation': 'Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati Academic Health Centre, Cincinnati, OH, USA.'}, {'ForeName': 'Claire M', 'Initials': 'CM', 'LastName': 'Williams', 'Affiliation': 'School of Psychology and Clinical Language Sciences, University of Reading, Earley Gate, Whiteknights, Reading, RG6 6AL, UK. claire.williams@reading.ac.uk.'}, {'ForeName': 'Britt', 'Initials': 'B', 'LastName': 'Burton-Freeman', 'Affiliation': 'Centre for Nutrition Research, Department of Food Science and Nutrition, Illinois Institute of Technology, Chicago, IL, USA.'}]",European journal of nutrition,['10.1007/s00394-020-02336-8'] 2176,32748071,"A new self-designed ""tongue root holder"" device to aid fiberoptic intubation.","OBJECTIVE In this study, we aimed to assess the feasibility of fiberoptic intubation (FOI), using a new, self-designed, ""tongue root holder"" device, in combination with the jaw thrust maneuver. METHODS Three hundred patients undergoing elective surgery requiring orotracheal intubation were enrolled. Patients presented at least one or more risk factors for difficult airway. The patients were randomly allocated at a 1:1 ratio to one of two groups: group L, FOI with tongue root holder, or group C, standard FOI. Orotracheal FOI was performed after commencement of anesthesia. The jaw thrust maneuver was applied in both groups to facilitate advancement of the fiberoptic bronchoscope. The primary endpoint was the feasibility of FOI. The secondary endpoints were number of attempts, time to intubation, and airway clearance at the soft palate and epiglottis levels. RESULTS The FOI was achieved in all 150 patients in group L, significantly higher than that in group C (100% vs 95.3%; P = 0.015). Less attempts of intubation were made in group L (P = 0.039). Mean time to successful intubation on the first attempt was shorter in group L (P < 0.001). The mean times to view the vocal cord and carina were also shorter in group L (P = 0.011 and P < 0.001, respectively). Airway clearance was better in group L at both the soft palate and the glottis levels (P = 0.010 and P = 0.038, respectively). CONCLUSIONS This study shows that FOI is feasible with the newly introduced, self-designed, ""tongue root holder"" device, when combined with the jaw thrust maneuver in patients with risk factors for difficult airway. The device also provides better airway clearance, less intubation attempts, and shorter time to intubation at first attempt. CLINICAL RELEVANCE Fiberoptic bronchoscope has been the gold standard for routine management of difficult airway. A technique to open the airway is introduced to reduce the incidence rate of upper airway obstruction.",2020,"The mean times to view the vocal cord and carina were also shorter in group L (P = 0.011 and P < 0.001, respectively).","['Three hundred patients undergoing elective surgery requiring orotracheal intubation were enrolled', 'patients with risk factors for difficult airway']","['FOI with tongue root holder, or group C, standard FOI', 'fiberoptic intubation (FOI']","['feasibility of FOI', 'mean times to view the vocal cord and carina', 'incidence rate of upper airway obstruction', 'FOI', 'Airway clearance', 'Orotracheal FOI', 'glottis levels', 'Mean time to successful intubation', 'number of attempts, time to intubation, and airway clearance at the soft palate and epiglottis levels']","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0396621', 'cui_str': 'Orotracheal intubation'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0332218', 'cui_str': 'Difficult'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}]","[{'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0226956', 'cui_str': 'Structure of pharyngeal portion of dorsum of tongue'}, {'cui': 'C1551377', 'cui_str': 'Holder'}, {'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0042930', 'cui_str': 'Vocal cord structure'}, {'cui': 'C0225594', 'cui_str': 'Structure of carina of trachea'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0740852', 'cui_str': 'Upper airway obstruction'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0472580', 'cui_str': 'Orotracheal fiberoptic intubation'}, {'cui': 'C0017681', 'cui_str': 'Glottis structure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030219', 'cui_str': 'Soft palate structure'}, {'cui': 'C0014540', 'cui_str': 'Epiglottis structure'}]",300.0,0.0458913,"The mean times to view the vocal cord and carina were also shorter in group L (P = 0.011 and P < 0.001, respectively).","[{'ForeName': 'Xiaofei', 'Initials': 'X', 'LastName': 'Cao', 'Affiliation': ""Department of Anesthesiology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, People's Republic of China.""}, {'ForeName': 'Junbei', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': ""Department of Anesthesiology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, People's Republic of China.""}, {'ForeName': 'Yin', 'Initials': 'Y', 'LastName': 'Fang', 'Affiliation': ""Department of Anesthesiology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, People's Republic of China.""}, {'ForeName': 'Zhengnian', 'Initials': 'Z', 'LastName': 'Ding', 'Affiliation': ""Department of Anesthesiology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, People's Republic of China. dingzhengnian@yeah.net.""}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Qi', 'Affiliation': ""Department of Anesthesiology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, People's Republic of China. taoqinjmu@hotmail.com.""}]",Clinical oral investigations,['10.1007/s00784-020-03297-2'] 2177,32748114,No impact of a prescription booklet on medication consumption in nursing home residents from 2011 to 2014: a controlled before-after study.,"BACKGROUND Older persons are particularly exposed to adverse events from medication. Among the various strategies to reduce polypharmacy, educational approaches have shown promising results. We aimed to evaluate the impact on medication consumption, of a booklet designed to aid physicians with prescriptions for elderly nursing home residents. METHODS Among 519 nursing homes using an electronic pill dispenser, we recorded the daily number of times that a drug was administered for each resident, over a period of 4 years. The intervention group comprised 113 nursing homes belonging to a for-profit geriatric care provider that implemented a booklet delivered to prescribers and pharmacists and specifically designed to aid with prescriptions for elderly nursing home residents. The remaining 406 nursing homes where no such booklet was introduced comprised the control group. Data were derived from electronic pill dispensers. The effect of the intervention on medication consumption was assessed with multilevel regression models, adjusted for nursing home status. The main outcomes were the average daily number of times that a medication was administered and the number of drugs with different presentation identifier codes per resident per month. RESULTS 96,216 residents from 519 nursing homes were included between 1 January 2011 and 31 December 2014. The intervention group and the control group both decreased their average daily use of medication (- 0.05 and - 0.06). The booklet did not have a statistically significant effect (exponentiated difference-in-differences coefficient 1.00, 95% confidence interval 0.99-1.02, P = .45). CONCLUSION We observed an overall decrease in medication consumption in both the control and intervention groups. Our analysis did not provide any evidence that this reduction was related to the use of the booklet. Other factors, such as national policy or increased physician awareness, may have contributed to our findings.",2020,The intervention group and the control group both decreased their average daily use of medication (- 0.05 and - 0.06).,"['519 nursing homes using an', 'nursing home residents from 2011 to 2014', 'Older persons', '96,216 residents from 519 nursing homes were included between 1 January 2011 and 31 December 2014', 'elderly nursing home residents', '406 nursing homes']","['113 nursing homes belonging to a for-profit geriatric care provider that implemented a booklet delivered to prescribers and pharmacists and specifically designed to aid with prescriptions for elderly nursing home residents', 'prescription booklet', 'electronic pill dispenser']","['average daily number of times that a medication', 'medication consumption', 'number of drugs with different presentation identifier codes per resident per month']","[{'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0180463', 'cui_str': 'Dispenser'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0449809', 'cui_str': 'Number of times'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0449450', 'cui_str': 'Presentation'}, {'cui': 'C0600091', 'cui_str': 'Identifier'}, {'cui': 'C0009219', 'cui_str': 'Coding'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",96216.0,0.0222552,The intervention group and the control group both decreased their average daily use of medication (- 0.05 and - 0.06).,"[{'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Sanchez', 'Affiliation': 'Fondation Korian Pour le Bien Vieillir, 25 Rue Balzac, 75008, Paris, France.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Payet', 'Affiliation': 'Hospices Civils de Lyon, Pôle Information Médicale Evaluation Recherche, 162 Av Lacassagne, 69003, Lyon, France.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Herr', 'Affiliation': 'Université de Versailles Saint Quentin, UMR 1168 Vieillissement et Maladies chroniques, Approches épidémiologique et de santé publique, 16 Av Paul Vaillant Couturier, 94807, Villejuif, France.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Ecarnot', 'Affiliation': 'Department of Cardiology, University Hospital Jean Minjoz, Boulevard Fleming, 25000, Besançon, France. fiona.ecarnot@univ-fcomte.fr.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Blochet', 'Affiliation': 'Medissimo, 8 Rue Charles Edouard Jeanneret, 78300, Poissy, France.'}, {'ForeName': 'Didier', 'Initials': 'D', 'LastName': 'Armaingaud', 'Affiliation': 'Fondation Korian Pour le Bien Vieillir, 25 Rue Balzac, 75008, Paris, France.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Chrusciel', 'Affiliation': 'Centre Hospitalier de Troyes, Pôle Information Médicale Évaluation Performance, 101 Av Anatole France, 10000, Troyes, France.'}, {'ForeName': 'Jean-Luc', 'Initials': 'JL', 'LastName': 'Novella', 'Affiliation': 'Department of Geriatrics and Internal Medicine, Maison Blanche Hospital, Reims University Hospitals, 45 Rue Cognacq-Jay, 51000, Reims, France.'}, {'ForeName': 'Rachid', 'Initials': 'R', 'LastName': 'Mahmoudi', 'Affiliation': 'Department of Geriatrics and Internal Medicine, Maison Blanche Hospital, Reims University Hospitals, 45 Rue Cognacq-Jay, 51000, Reims, France.'}]",Aging clinical and experimental research,['10.1007/s40520-020-01670-5'] 2178,32748165,Clinical outcomes of double continuous suture in femtosecond laser-assisted lamellar keratoplasty for keratoconus.,"To assess the surgical outcomes in patients who underwent femtosecond laser-assisted lamellar keratoplasty with double continuous suture for keratoconus, 100 patients (102 eyes) with keratoconus in advanced stages undergoing femtosecond laser-assisted lamellar keratoplasty in Shandong Eye Hospital were studied. In the management of keratoconus, 50 patients (52 eyes) received double continuous suture, and 50 patients (50 eyes) underwent interrupted suture. The follow-up duration was 1 year. Best-corrected visual acuity (BCVA), corneal astigmatism, cosmetic outcomes, and surgical complications were measured as outcome indicators. The epithelium healed at 3 ± 2 days and 4 ± 2 days in the double continuous suture group and the interrupted suture groups, respectively (P > 0.05). At 6 months after surgery, the average visual acuity was 20/125 and 20/100 (P > 0.05), and the average BCVA was 20/32 and 20/40 (P > 0.05), respectively. At 1 year after surgery, the average visual acuity was 20/63 and 20/80 (P > 0.05), and the average BCVA was 20/32 and 20/25 (P > 0.05), respectively; the mean curvature was 43.24 ± 5.15 D and 43.31 ± 5.58 D (P > 0.05), the mean astigmatism was 3.21 ± 1.74 D and 5.35 ± 1.37 D (P < 0.05).The looseness of sutures were found in 2 patients and 15 patients in both groups, respectively (P < 0.05). No postoperative infection or immune rejection occurred in either group during the follow-up. Comparing with the interrupted suture, using the continuous suture in femtosecond laser-assisted lamellar keratoplasty for keratoconus markedly limited the looseness of sutures with lesser corneal astigmatism and better visual quality postoperative.",2020,"< 0.05).The looseness of sutures were found in 2 patients and 15 patients in both groups, respectively (P < 0.05).","['50 patients (52 eyes) received', ' 100 patients (102 eyes) with keratoconus in advanced stages undergoing femtosecond laser-assisted lamellar keratoplasty in Shandong Eye Hospital were studied', 'patients who underwent']","['interrupted suture', 'femtosecond laser-assisted lamellar keratoplasty with double continuous suture for keratoconus', 'double continuous suture in femtosecond laser-assisted lamellar keratoplasty', 'double continuous suture']","['Best-corrected visual acuity (BCVA), corneal astigmatism, cosmetic outcomes, and surgical complications', 'average visual acuity', 'postoperative infection or immune rejection', 'surgical outcomes', 'average BCVA', 'mean curvature']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0022578', 'cui_str': 'Keratoconus'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C1531960', 'cui_str': 'Femtosecond pulsed laser device'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0022591', 'cui_str': 'Lamellar keratoplasty'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0443239', 'cui_str': 'Interrupted'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C1531960', 'cui_str': 'Femtosecond pulsed laser device'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0022591', 'cui_str': 'Lamellar keratoplasty'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0022578', 'cui_str': 'Keratoconus'}]","[{'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0339682', 'cui_str': 'Regular astigmatism - corneal'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0392618', 'cui_str': 'Postoperative infection'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0035015', 'cui_str': 'Rejection (Psychology)'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",,0.0802877,"< 0.05).The looseness of sutures were found in 2 patients and 15 patients in both groups, respectively (P < 0.05).","[{'ForeName': 'Yanni', 'Initials': 'Y', 'LastName': 'Jia', 'Affiliation': 'Shandong Eye Hospital, Shandong Eye Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, 372 Jingsi Road, Jinan, 250021, China.'}, {'ForeName': 'Xiaolin', 'Initials': 'X', 'LastName': 'Qi', 'Affiliation': 'Shandong Eye Hospital, Shandong Eye Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, 372 Jingsi Road, Jinan, 250021, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Shandong Eye Hospital, Shandong Eye Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, 372 Jingsi Road, Jinan, 250021, China.'}, {'ForeName': 'Mingna', 'Initials': 'M', 'LastName': 'Liu', 'Affiliation': 'Shandong Eye Hospital, Shandong Eye Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, 372 Jingsi Road, Jinan, 250021, China.'}, {'ForeName': 'Weiyun', 'Initials': 'W', 'LastName': 'Shi', 'Affiliation': 'Shandong Eye Hospital, Shandong Eye Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, 372 Jingsi Road, Jinan, 250021, China.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Gao', 'Affiliation': 'Shandong Eye Hospital, Shandong Eye Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, 372 Jingsi Road, Jinan, 250021, China. gaohua100@126.com.'}]",Lasers in medical science,['10.1007/s10103-020-03114-y'] 2179,32748181,Comparable effects on tear film parameters after femtosecond laser-assisted and conventional cataract surgery.,"PURPOSE Dry eye symptoms after conventional cataract surgery are a very common problem. Until now, only few data are available on objective tear film parameters in regard to femtosecond laser-assisted cataract surgery (LCS). Aim of this study was therefore to analyze and compare tear film parameter changes between LCS and conventional cataract surgery. METHODS A consecutive group of 34 patients, scheduled for cataract surgery, were randomly selected for either LCS or conventional cataract surgery (17 patients/group). Tear film assessments including tear film osmolarity, Schirmer test, MMP-9 analysis via quantitative ELISA, corneal sensitivity, corneal fluorescein staining, and conjunctival fluorescein staining were sequentially evaluated pre- as well as 1 and 3 months postoperatively. RESULTS Both groups showed no significant difference in baseline characteristics. All surgeries were performed without any complications. After 1 and 3 months, there was no statistically significant difference in regard to tear film osmolarity (1 month: p = 0.81, 3 months: p = 1.0), Schirmer test (1 month: p = 0.35, 3 month: p = 0.08), and MMP-9 concentration (1 month: p = 0.36, 3 month: p = 0.28) between the two groups. CONCLUSIONS Neither LCS nor conventional cataract surgery affected objective tear film parameters significantly during our 3-month postoperative observation period. Hence, both surgical techniques can be equally used to treat patients without prior dry eye symptoms.",2020,"After 1 and 3 months, there was no statistically significant difference in regard to tear film osmolarity (1 month:","['34 patients, scheduled for cataract surgery']","['conventional cataract surgery', 'LCS', 'femtosecond laser-assisted and conventional cataract surgery', 'femtosecond laser-assisted cataract surgery (LCS', 'LCS or conventional cataract surgery', 'LCS and conventional cataract surgery']","['Tear film assessments including tear film osmolarity, Schirmer test, MMP-9 analysis via quantitative ELISA, corneal sensitivity, corneal fluorescein staining, and conjunctival fluorescein staining', 'MMP-9 concentration', 'tear film osmolarity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C1531960', 'cui_str': 'Femtosecond pulsed laser device'}]","[{'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0029387', 'cui_str': 'Osmolarity'}, {'cui': 'C0200152', 'cui_str': ""Schirmer's test""}, {'cui': 'C0165519', 'cui_str': 'Gelatinase B'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0060520', 'cui_str': 'Fluorescein'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",34.0,0.01766,"After 1 and 3 months, there was no statistically significant difference in regard to tear film osmolarity (1 month:","[{'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Schargus', 'Affiliation': 'Department of Ophthalmology, Heinrich-Heine-University Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany. marc.schargus@gmx.de.'}, {'ForeName': 'Svetlana', 'Initials': 'S', 'LastName': 'Ivanova', 'Affiliation': 'Institute for Vision Science, University Eye Clinic, Ruhr-University Bochum, Bochum, Germany.'}, {'ForeName': 'Gesa', 'Initials': 'G', 'LastName': 'Stute', 'Affiliation': 'Experimental Eye Research Institute, University Eye Clinic, Ruhr-University Bochum, Bochum, Germany.'}, {'ForeName': 'H Burkhard', 'Initials': 'HB', 'LastName': 'Dick', 'Affiliation': 'Institute for Vision Science, University Eye Clinic, Ruhr-University Bochum, Bochum, Germany.'}, {'ForeName': 'Stephanie C', 'Initials': 'SC', 'LastName': 'Joachim', 'Affiliation': 'Experimental Eye Research Institute, University Eye Clinic, Ruhr-University Bochum, Bochum, Germany.'}]",International ophthalmology,['10.1007/s10792-020-01532-z'] 2180,32748184,Comparison Between Intravenous Nalbuphine and Lidocaine in Reducing Propofol-Induced Injection Pain During Gastroscopy: A Randomized Controlled Trial.,"INTRODUCTION Intravenous propofol anesthesia is widely used in painless endoscopy. However, propofol injection pain is a common adverse effect. This study investigated the effects of nalbuphine and lidocaine in reducing propofol-induced injection pain. METHODS In this double-blind, randomized study, 330 patients were randomly divided into three groups by using a random number table: the nalbuphine group (N), lidocaine group (L), and control group (C). The N, L, and C groups received either 0.1 mg/kg nalbuphine, 0.5 mg/kg lidocaine, or an equivalent volume of normal saline, respectively, as pretreatment drug. Then propofol was manually injected. The primary outcome of this study was the incidence of propofol-induced injection pain, and secondary outcomes included the severity of propofol-induced injection pain, vital signs, and adverse events, including hypotension, bradycardia (< 50 beats/min), hypoxemia (SpO 2  < 90%), drowsiness, physical movement, and cough. RESULTS The percentages of patients with propofol injection pain were higher in group C than in group N and group L (64, 34, and 27%, respectively, p < 0.05). The percentage of patients with severe pain after propofol injection was significantly higher in group C than in group N and group L (12, 1, and 0%, respectively, p < 0.05). The doses of propofol in group C and group L were significantly higher than that in group N. More patients suffered hypoxemia in group N than in group C and group L. Then, less patients got physical movement and cough in group N. CONCLUSIONS Pretreatment with nalbuphine 0.1 mg/kg was effective in reducing propofol-induced injection pain and propofol consumption. Propofol combined with nalbuphine can be safely and effectively used during gastroscopy. TRIAL REGISTRATION Chinese Clinical Trial Registry; ChiCTR1900025438.",2020,"The percentage of patients with severe pain after propofol injection was significantly higher in group C than in group N and group L (12, 1, and 0%, respectively, p < 0.05).","['painless endoscopy', '330 patients']","['Propofol combined with nalbuphine', 'nalbuphine', 'Propofol-Induced Injection Pain', 'lidocaine', 'nalbuphine and lidocaine', 'Intravenous propofol anesthesia', '0.1\xa0mg/kg nalbuphine, 0.5\xa0mg/kg lidocaine', 'propofol', 'Nalbuphine and Lidocaine']","['incidence of propofol-induced injection pain', 'suffered hypoxemia', 'severity of propofol-induced injection pain, vital signs, and adverse events, including hypotension, bradycardia (<\u200950 beats/min), hypoxemia (SpO 2 \u2009<\u200990%), drowsiness, physical movement, and cough', 'propofol injection pain', 'percentage of patients with severe pain']","[{'cui': 'C0234226', 'cui_str': 'Painless'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C4517719', 'cui_str': '330'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0027348', 'cui_str': 'Nalbuphine'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C1096717', 'cui_str': 'Pain during injection'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0444500', 'cui_str': '0.5'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C1096717', 'cui_str': 'Pain during injection'}, {'cui': 'C0700292', 'cui_str': 'Hypoxemia'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0439087', 'cui_str': '<90'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C4282968', 'cui_str': 'Propofol Injection'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0278140', 'cui_str': 'Severe pain'}]",330.0,0.0736753,"The percentage of patients with severe pain after propofol injection was significantly higher in group C than in group N and group L (12, 1, and 0%, respectively, p < 0.05).","[{'ForeName': 'Jiang', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, People's Republic of China.""}, {'ForeName': 'Jinjuan', 'Initials': 'J', 'LastName': 'Duan', 'Affiliation': ""Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, People's Republic of China.""}, {'ForeName': 'Cuiyu', 'Initials': 'C', 'LastName': 'Xie', 'Affiliation': ""Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, People's Republic of China.""}, {'ForeName': 'Yongqi', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': ""Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, People's Republic of China.""}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': ""Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, People's Republic of China. luyao-mz@163.com.""}]",Pain and therapy,['10.1007/s40122-020-00188-y'] 2181,32748345,Advanced Notification Calls Prior to Mailed Fecal Immunochemical Test in Previously Screened Patients: a Randomized Controlled Trial.,"BACKGROUND Phone calls as part of multimodal fecal immunochemical test (FIT) outreach are effective but resource-intensive. Previous studies of advanced notification calls before FIT mailing have not differentiated patients' prior screening status. OBJECTIVE To determine the effectiveness of a phone call preceding mailing of a FIT kit on test completion rate for patients who have completed a prior FIT. DESIGN Randomized controlled trial nested within a larger study. All patients were assigned to receive organized mailed FIT outreach in the larger study. PARTICIPANTS Patients in a safety-net health setting ages 50-75 years old with a previously negative FIT. INTERVENTIONS Patients were assigned to either receive an advanced notification phone call or no phone call preceding a mailed FIT kit. Both groups received an informational postcard prior to the mailed FIT. MAIN MEASURES The primary outcome was FIT completion rate at 1 year. The secondary outcomes were FIT completion rates at 60, 90, and 180 days, rates stratified by demographic subgroups, and rates according to outcome of the phone call. KEY RESULTS A total of 1645 patients were assigned to advanced notification calls and 1595 were assigned to no call preceding the FIT mailing. Although FIT completion rate was higher at day 60 (55.5% vs. 50.8%, p < 0.01), an advanced notification call did not significantly improve FIT completion at 1 year (70.9% vs. 69.9%, p = 0.52). Of the patients assigned to receive an advanced notification call, 90.5% were spoken with or left a voicemail; patients who were spoken with were more likely to complete a FIT at 1 year compared with patients who were only left a voicemail or could not be left a voicemail (79.9% vs. 69.2% vs. 49.6%, p < 0.01). CONCLUSIONS Advanced notification phone calls prior to FIT mailing did not improve rates at 1 year for patients with a previously negative FIT.",2020,"Although FIT completion rate was higher at day 60 (55.5% vs. 50.8%, p < 0.01), an advanced notification call did not significantly improve FIT completion at 1 year (70.9% vs. 69.9%, p = 0.52).","['patients who have completed a prior FIT', 'Previously Screened Patients', '1645 patients were assigned to advanced notification calls and 1595 were assigned to no call preceding the FIT mailing', 'Patients in a safety-net health setting ages 50-75 years old with a previously negative FIT']","['advanced notification phone call or no phone call preceding a mailed FIT kit', 'informational postcard prior to the mailed FIT', 'phone call preceding mailing of a FIT kit', 'organized mailed FIT outreach']","['FIT completion rate at 1 year', 'FIT completion rates', 'FIT completion', 'FIT completion rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0422202', 'cui_str': 'Notifications'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205160', 'cui_str': 'Negative'}]","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0422202', 'cui_str': 'Notifications'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C1272835', 'cui_str': 'Test kit'}, {'cui': 'C2717852', 'cui_str': 'Postcards'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1300196', 'cui_str': 'Organized'}]","[{'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439234', 'cui_str': 'year'}]",1645.0,0.113703,"Although FIT completion rate was higher at day 60 (55.5% vs. 50.8%, p < 0.01), an advanced notification call did not significantly improve FIT completion at 1 year (70.9% vs. 69.9%, p = 0.52).","[{'ForeName': 'Briton', 'Initials': 'B', 'LastName': 'Lee', 'Affiliation': 'School of Medicine, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Shreya', 'Initials': 'S', 'LastName': 'Patel', 'Affiliation': 'Division of Gastroenterology, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Carly', 'Initials': 'C', 'LastName': 'Rachocki', 'Affiliation': 'Division of Gastroenterology, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Issaka', 'Affiliation': 'Clinical Research & Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Vittinghoff', 'Affiliation': 'Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Jean A', 'Initials': 'JA', 'LastName': 'Shapiro', 'Affiliation': 'Centers for Disease Control and Prevention, Atlanta, GA, USA.'}, {'ForeName': 'Uri', 'Initials': 'U', 'LastName': 'Ladabaum', 'Affiliation': 'Division of Gastroenterology, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Ma', 'Initials': 'M', 'LastName': 'Somsouk', 'Affiliation': 'Division of Gastroenterology, University of California San Francisco, San Francisco, CA, USA. Ma.somsouk@ucsf.edu.'}]",Journal of general internal medicine,['10.1007/s11606-020-06009-4'] 2182,32748372,Effect of transcranial direct current stimulation (tDCS) on food craving and eating when using a control method that minimizes guessing of the real vs. control condition.,"PURPOSE Validation of transcranial direct current stimulation (tDCS) to treat obesity is hampered by evidence that participants can distinguish real from the traditional-control condition. Correctly guessing the real condition precludes knowing if it is neuromodulation or expectation that suppresses food craving and eating. Therefore, this study tested the putative efficacy of tDCS to the dorsolateral prefrontal cortex (DLPFC) to reduce food craving and eating when an alternative control condition was used that would be difficult to distinguish from the real condition. METHODS N = 28 adults with a 26-50 BMI range received a typical 20-min 2 mA current session of tDCS targeting the DLPFC as the real condition and a same duration/current tDCS session targeting the sensorimotor cortex (SMC), a region not expected to affect appetite, as the control. Food image craving ratings, in-lab food consumption, and momentary ratings of physical sensations were measured. RESULTS DLPFC failed to reduce food craving and consumption compared to SMC stimulation. When interviewed, 71% of participants were unable to guess real from control conditions. Those who guessed DLPFC tDCS as real attributed their guess to increased number and frequency of sensations. However, their sensation ratings during tDCS did not differ between conditions. CONCLUSIONS The results question if tDCS suppresses craving and eating at all, or if the DLPFC is the best target to do so. The results also indicate that alternate-site constant stimulation as the control method may strengthen the scientific evaluation of tDCS to treat obesity. LEVEL OF EVIDENCE Level I, experimental study.",2020,"RESULTS DLPFC failed to reduce food craving and consumption compared to SMC stimulation.","['N\u2009', '28 adults with a 26-50 BMI range']","['transcranial direct current stimulation (tDCS', 'tDCS', 'typical 20-min 2\xa0mA current session of tDCS targeting the DLPFC as the real condition and a same duration/current tDCS session targeting the sensorimotor cortex (SMC']","['Food image craving ratings, in-lab food consumption, and momentary ratings of physical sensations', 'food craving and consumption', 'food craving and eating', 'sensation ratings', 'number and frequency of sensations']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C3499125', 'cui_str': 'Sensory Motor Cortex'}]","[{'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0872380', 'cui_str': 'Food craving'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}]",28.0,0.0334459,"RESULTS DLPFC failed to reduce food craving and consumption compared to SMC stimulation.","[{'ForeName': 'Carl E', 'Initials': 'CE', 'LastName': 'Stevens', 'Affiliation': 'Department of Psychology, The University of Alabama at Birmingham, 415 Campbell Hall, 1300 University Blvd., Birmingham, AL, 35294-1170, USA.'}, {'ForeName': 'Marissa A', 'Initials': 'MA', 'LastName': 'Lausen', 'Affiliation': 'Department of Psychology, The University of Alabama at Birmingham, 415 Campbell Hall, 1300 University Blvd., Birmingham, AL, 35294-1170, USA.'}, {'ForeName': 'Laura E', 'Initials': 'LE', 'LastName': 'Wagstaff', 'Affiliation': 'Department of Psychology, The University of Alabama at Birmingham, 415 Campbell Hall, 1300 University Blvd., Birmingham, AL, 35294-1170, USA.'}, {'ForeName': 'Tommy R', 'Initials': 'TR', 'LastName': 'McRae', 'Affiliation': 'Department of Psychology, The University of Alabama at Birmingham, 415 Campbell Hall, 1300 University Blvd., Birmingham, AL, 35294-1170, USA.'}, {'ForeName': 'Bethany R', 'Initials': 'BR', 'LastName': 'Pittman', 'Affiliation': 'Department of Psychology, The University of Alabama at Birmingham, 415 Campbell Hall, 1300 University Blvd., Birmingham, AL, 35294-1170, USA.'}, {'ForeName': 'Franklin R', 'Initials': 'FR', 'LastName': 'Amthor', 'Affiliation': 'Department of Psychology, The University of Alabama at Birmingham, 415 Campbell Hall, 1300 University Blvd., Birmingham, AL, 35294-1170, USA.'}, {'ForeName': 'Mary M', 'Initials': 'MM', 'LastName': 'Boggiano', 'Affiliation': 'Department of Psychology, The University of Alabama at Birmingham, 415 Campbell Hall, 1300 University Blvd., Birmingham, AL, 35294-1170, USA. boggiano@uab.edu.'}]",Eating and weight disorders : EWD,['10.1007/s40519-020-00970-z'] 2183,32739897,"The effect of creatine supplementation on muscle function in childhood myositis: A randomized, double-blind, placebo-controlled feasibility study.","OBJECTIVE To evaluate the feasibility of studying creatine in juvenile dermatomyositis (JDM). Secondary objectives were to determine the effect of creatine on muscle function and metabolism, aerobic capacity, fatigue, physical activity and quality of life, as well as its safety. METHODS We conducted a 6-month double-blind, randomized, multiple-baseline design; patients were assigned to creatine or placebo. Feasibility was assessed using attended study visits, completed study procedures, and adherence. Muscle function, aerobic capacity and muscle strength were assessed with standardized exercise tests. Muscle metabolism was assessed using a 31-Phosphorus Magnetic Resonance Spectroscopy protocol. Fatigue, physical activity and quality of life were assessed by questionnaires. Statistical significance was estimated using a randomization (permutation) test. Changes in outcome measures taken at baseline and end-of-study were calculated using paired t tests. RESULTS Median (range) adherence to the study drug was 88.5% (20.5-95.5%) and the proportion of subjects with 80% adherence or higher was 76.9%. There were no missed study visits. There were no statistically significant changes in muscle function, strength, aerobic capacity, disease activity, fatigue, physical activity or quality of life while subjects were on creatine compared to placebo. There were statistically significant adaptations in muscle metabolism (e.g., decrease in change in muscle pH following exercise, and decrease in Phosphate/Phosphocreatine ratio) at the end-of-study, compared to baseline. There were no significant adverse effects. CONCLUSION Creatine supplementation in children with JDM is feasible to study, and is safe and well-tolerated; it may lead to improvements in muscle metabolism.",2020,"There were no statistically significant changes in muscle function, strength, aerobic capacity, disease activity, fatigue, physical activity or quality of life while subjects were on creatine compared to placebo.","['children with JDM', 'childhood myositis', 'juvenile dermatomyositis (JDM']","['creatine supplementation', 'Creatine supplementation', 'creatine or placebo', 'placebo']","['Muscle function, aerobic capacity and muscle strength', 'muscle function, strength, aerobic capacity, disease activity, fatigue, physical activity or quality of life', 'adverse effects', 'muscle function', 'change in muscle pH following exercise, and decrease in Phosphate/Phosphocreatine ratio', 'Fatigue, physical activity and quality of life', 'Median (range) adherence', 'Muscle metabolism', 'muscle function and metabolism, aerobic capacity, fatigue, physical activity and quality of life, as well as its safety', 'muscle metabolism']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0263666', 'cui_str': 'Childhood type dermatomyositis'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0027121', 'cui_str': 'Myositis'}]","[{'cui': 'C0010286', 'cui_str': 'Creatine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0231484', 'cui_str': 'Muscle function'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1979962', 'cui_str': 'After exercise'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0031603', 'cui_str': 'Phosphate'}, {'cui': 'C0031634', 'cui_str': 'fosfocreatine'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.503986,"There were no statistically significant changes in muscle function, strength, aerobic capacity, disease activity, fatigue, physical activity or quality of life while subjects were on creatine compared to placebo.","[{'ForeName': 'Saunya', 'Initials': 'S', 'LastName': 'Dover', 'Affiliation': 'From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Stephens', 'Affiliation': 'From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.'}, {'ForeName': 'Jane E', 'Initials': 'JE', 'LastName': 'Schneiderman', 'Affiliation': 'From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.'}, {'ForeName': 'Eleanor', 'Initials': 'E', 'LastName': 'Pullenayegum', 'Affiliation': 'From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.'}, {'ForeName': 'Greg D', 'Initials': 'GD', 'LastName': 'Wells', 'Affiliation': 'From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.'}, {'ForeName': 'Deborah M', 'Initials': 'DM', 'LastName': 'Levy', 'Affiliation': 'From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.'}, {'ForeName': 'Jo-Anne', 'Initials': 'JA', 'LastName': 'Marcuz', 'Affiliation': 'From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.'}, {'ForeName': 'Kristi', 'Initials': 'K', 'LastName': 'Whitney', 'Affiliation': 'From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Schulze', 'Affiliation': 'From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Tein', 'Affiliation': 'From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.'}, {'ForeName': 'Brian M', 'Initials': 'BM', 'LastName': 'Feldman', 'Affiliation': 'From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.'}]",The Journal of rheumatology,['10.3899/jrheum.191375'] 2184,32739927,Improving Medical Students' OSCE Performance in Telehealth: The Effects of a Telephone Medicine Curriculum.,"PURPOSE To report on the implementation of a telephone medicine curriculum as part of the core clerkship in pediatrics for students at Johns Hopkins University School of Medicine and evaluate the curriculum's effect on student performance on a telephone medicine case as part of a required objective structured clinical exam (OSCE). METHOD Using a prospective cohort design with a convenience sample of third-year medical students during the 2016-2017 and 2017-2018 academic years, the authors compared the OSCE scores of students assigned to the curriculum to both historical and concurrent control groups of students who had not received the curriculum. Additionally, the authors compared the costs of the recommended testing by students in each group using the 2018 Centers for Medicare and Medicaid Services Clinical Laboratory Fee Schedule. RESULTS Students assigned to the telephone medicine curriculum (students in the intervention group) had a significantly higher mean overall score on the simulated OSCE telephone medicine case compared to the students in the control groups who did not receive the curriculum (the mean score for students in the intervention group was 7.38 vs 6.92 for students in the control groups, P = .02). Additionally, the intervention group had statistically significantly lower costs for their recommended testing compared to the control groups (the median value for tests ordered by students in the intervention group was $27.91 vs $51.23 for students in the control groups, P = .03). CONCLUSIONS;: Implementing a dedicated telephone medicine curriculum for medical students improves their overall performance and delivery of high-value care via telephone medicine as part of an OSCE. Medical educators should pursue ongoing research into effective methods for teaching medical students and residents how to navigate digital encounters.",2020,"RESULTS Students assigned to the telephone medicine curriculum (students in the intervention group) had a significantly higher mean overall score on the simulated OSCE telephone medicine case compared to the students in the control groups who did not receive the curriculum (the mean score for students in the intervention group was 7.38 vs 6.92 for students in the control groups, P = .02).","[""pediatrics for students at Johns Hopkins University School of Medicine and evaluate the curriculum's effect on student performance on a telephone medicine case as part of a required objective structured clinical exam (OSCE"", 'convenience sample of third-year medical students during the 2016-2017 and 2017-2018 academic years, the authors compared the OSCE scores of students assigned to the curriculum to both historical and concurrent control groups of students who had not received the curriculum', ""Medical Students' OSCE Performance in Telehealth""]","['telephone medicine curriculum', 'Telephone Medicine Curriculum']","['mean overall score', 'lower costs']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0582103', 'cui_str': 'Medical assessment'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C3812881', 'cui_str': 'Author'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0162648', 'cui_str': 'Telemedicine'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",,0.0205669,"RESULTS Students assigned to the telephone medicine curriculum (students in the intervention group) had a significantly higher mean overall score on the simulated OSCE telephone medicine case compared to the students in the control groups who did not receive the curriculum (the mean score for students in the intervention group was 7.38 vs 6.92 for students in the control groups, P = .02).","[{'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Hindman', 'Affiliation': ""D.J. Hindman is assistant professor, Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. S.R. Kochis is an allergy and immunology fellow, Division of Allergy and Immunology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. A. Apfel is a biostatistician, Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. J. Prudent is a second-year resident, Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio. T. Kumra is assistant professor, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. W.C. Golden is associate professor, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. J. Jung is associate professor, Department of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. A.K. Pahwa is assistant professor, Departments of Medicine and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.""}, {'ForeName': 'Suzanne R', 'Initials': 'SR', 'LastName': 'Kochis', 'Affiliation': ''}, {'ForeName': 'Ariella', 'Initials': 'A', 'LastName': 'Apfel', 'Affiliation': ''}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Prudent', 'Affiliation': ''}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Kumra', 'Affiliation': ''}, {'ForeName': 'W Christopher', 'Initials': 'WC', 'LastName': 'Golden', 'Affiliation': ''}, {'ForeName': 'Julianna', 'Initials': 'J', 'LastName': 'Jung', 'Affiliation': ''}, {'ForeName': 'Amit K', 'Initials': 'AK', 'LastName': 'Pahwa', 'Affiliation': ''}]",Academic medicine : journal of the Association of American Medical Colleges,['10.1097/ACM.0000000000003622'] 2185,32739962,"Transversus Abdominis Plane Block With Liposomal Bupivacaine for Pain After Cesarean Delivery in a Multicenter, Randomized, Double-Blind, Controlled Trial.","BACKGROUND In women undergoing cesarean delivery under spinal anesthesia with intrathecal morphine, transversus abdominis plane (TAP) block with bupivacaine hydrochloride (HCl) may not improve postsurgical analgesia. This lack of benefit could be related to the short duration of action of bupivacaine HCl. A retrospective study reported that TAP block with long-acting liposomal bupivacaine (LB) reduced opioid consumption and improved analgesia following cesarean delivery. Therefore, we performed a prospective multicenter, randomized, double-blind trial examining efficacy and safety of TAP block with LB plus bupivacaine HCl versus bupivacaine HCl alone. METHODS Women (n = 186) with term pregnancies undergoing elective cesarean delivery under spinal anesthesia were randomized (1:1) to TAP block with LB 266 mg plus bupivacaine HCl 50 mg or bupivacaine HCl 50 mg alone. Efficacy was evaluated in a protocol-compliant analysis (PCA) set that was defined a priori. The primary end point was total postsurgical opioid consumption (oral morphine equivalent dosing [MED]) through 72 hours. Pain intensity was measured using a visual analog scale. Adverse events (AEs) after treatment were recorded through day 14. RESULTS Total opioid consumption through 72 hours was reduced with LB plus bupivacaine HCl versus bupivacaine HCl alone (least squares mean [LSM] [standard error (SE)] MED, 15.5 mg [6.67 mg] vs 32.0 mg [6.25 mg]). This corresponded to an LSM treatment difference of -16.5 mg (95% confidence interval [CI], -30.8 to -2.2 mg; P = .012). The area under the curve of imputed pain intensity scores through 72 hours supported noninferiority of LB plus bupivacaine HCl versus bupivacaine HCl alone (LSM [SE], 147.9 [21.13] vs 178.5 [19.78]; LSM treatment difference, -30.6; 95% CI, -75.9 to 14.7), with a prespecified noninferiority margin of 36 (P = .002). In an analysis of all treated patients, including those not meeting criteria for inclusion in the PCA, there was no difference in postsurgical opioid consumption between groups. In the LB plus bupivacaine HCl group, 63.6% of patients experienced an AE after treatment versus 56.2% in the bupivacaine HCl-alone group. Serious AEs after treatment were rare (≈3% in both groups). CONCLUSIONS TAP block using LB plus bupivacaine HCl as part of a multimodal analgesia protocol incorporating intrathecal morphine resulted in reduced opioid consumption after cesarean delivery in the PCA set. Results suggest that with correct TAP block placement and adherence to a multimodal postsurgical analgesic regimen, there is an opioid-reducing benefit of adding LB to bupivacaine TAP blocks after cesarean delivery (ClinicalTrials.gov identifier: NCT03176459).",2020,"RESULTS Total opioid consumption through 72 hours was reduced with LB plus bupivacaine HCl versus bupivacaine HCl alone (least squares mean [LSM] [standard error (SE)]","['women undergoing cesarean delivery under spinal anesthesia with', 'Women (n = 186) with term pregnancies undergoing elective cesarean delivery under spinal anesthesia']","['intrathecal morphine, transversus abdominis plane (TAP) block with bupivacaine hydrochloride (HCl', 'TAP block with LB plus bupivacaine HCl', 'bupivacaine HCl versus bupivacaine HCl alone (least squares mean [LSM] [standard error (SE', 'bupivacaine HCl', 'bupivacaine HCl versus bupivacaine HCl alone (LSM [SE', 'bupivacaine HCl alone', 'bupivacaine HCl-alone', 'bupivacaine TAP blocks', 'TAP block with long-acting liposomal bupivacaine (LB', 'TAP block with LB 266 mg plus bupivacaine HCl 50 mg or bupivacaine HCl 50 mg alone', 'Liposomal Bupivacaine']","['pain intensity scores', 'Total opioid consumption', 'opioid consumption and improved analgesia', 'Pain', 'Pain intensity', 'postsurgical opioid consumption', 'Efficacy', 'Adverse events (AEs', 'opioid consumption', 'postsurgical analgesia', 'total postsurgical opioid consumption (oral morphine equivalent dosing [MED']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0232991', 'cui_str': 'Term pregnancy'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}]","[{'cui': 'C0677897', 'cui_str': 'Intrathecal route'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0224378', 'cui_str': 'Structure of transversus abdominis muscle'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0887621', 'cui_str': 'Bupivacaine hydrochloride'}, {'cui': 'C0023828', 'cui_str': 'Liposomes'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0023189', 'cui_str': 'Analysis, Least-Squares'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0360457', 'cui_str': 'Morphine-containing product in oral dose form'}, {'cui': 'C0205163', 'cui_str': 'Equal'}]",186.0,0.647685,"RESULTS Total opioid consumption through 72 hours was reduced with LB plus bupivacaine HCl versus bupivacaine HCl alone (least squares mean [LSM] [standard error (SE)]","[{'ForeName': 'Srdjan S', 'Initials': 'SS', 'LastName': 'Nedeljkovic', 'Affiliation': ""From the Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Attila', 'Initials': 'A', 'LastName': 'Kett', 'Affiliation': ""Department of Anesthesiology, Saint Peter's University Hospital, New Brunswick, New Jersey.""}, {'ForeName': 'Manuel C', 'Initials': 'MC', 'LastName': 'Vallejo', 'Affiliation': 'Department of Anesthesiology, West Virginia University, Morgantown, West Virginia.'}, {'ForeName': 'Jean-Louis', 'Initials': 'JL', 'LastName': 'Horn', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Brendan', 'Initials': 'B', 'LastName': 'Carvalho', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Xiaodong', 'Initials': 'X', 'LastName': 'Bao', 'Affiliation': 'Department of Anesthesia, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Naida M', 'Initials': 'NM', 'LastName': 'Cole', 'Affiliation': ""From the Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Leslie', 'Initials': 'L', 'LastName': 'Renfro', 'Affiliation': 'Department of Anesthesiology, University of Minnesota, Minneapolis, Minnesota.'}, {'ForeName': 'Jeffrey C', 'Initials': 'JC', 'LastName': 'Gadsden', 'Affiliation': ''}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Song', 'Affiliation': 'Pacira BioSciences, Inc, Parsippany, New Jersey.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Pacira BioSciences, Inc, Parsippany, New Jersey.'}, {'ForeName': 'Ashraf S', 'Initials': 'AS', 'LastName': 'Habib', 'Affiliation': ''}]",Anesthesia and analgesia,['10.1213/ANE.0000000000005075'] 2186,32739974,"New evidence on prognostic features, prevention and treatment of congenital Cytomegalovirus infection.","PURPOSE OF REVIEW Congenital Cytomegalovirus (CMV) infection remains a major cause of lifelong disability, with no systematic screening implemented in pregnancy or the postnatal period. In this review article, we outline the preventive strategies, antenatal prognostic features and experimental therapies as well as evidence of efficacy from recent trials. RECENT FINDINGS A recent randomized, double blinded, placebo-controlled study investigated the efficacy of Valaciclovir in women contracting primary CMV in the periconception period or first trimester. They concluded that Valaciclovir at a dose of 8 g/day is effective in reducing the rate of foetal CMV infection following early maternal primary infection. Administration of CMV hyperimmune globulin (HIG) was investigated in a recent randomized double-masked controlled trial. This study concluded that CMV HIG was ineffective at reducing the risk of congenital CMV among women with primary CMV in early pregnancy. SUMMARY Congenital CMV infection remains a significant cause of disability. There is currently no vaccine available, with the best preventive strategy being patient education on transmission as well as hygiene measures to reduce risk of exposure. Experimental therapies have been investigated in recent years and there is evidence supporting the use of Valaciclovir. Data for the efficacy of CMV HIG remains inconsistent and administration is currently limited to clinical trial settings.",2020,"This study concluded that CMV HIG was ineffective at reducing the risk of congenital CMV among women with primary CMV in early pregnancy. ","['women with primary CMV in early pregnancy', 'women contracting primary CMV in the periconception period or first trimester']","['Valaciclovir', 'CMV hyperimmune globulin (HIG', 'CMV HIG', 'placebo']","['risk of congenital CMV', 'rate of foetal CMV infection']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0010823', 'cui_str': 'Cytomegalovirus infection'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0332522', 'cui_str': 'Contracts'}, {'cui': 'C0032979', 'cui_str': 'First trimester pregnancy'}]","[{'cui': 'C0249458', 'cui_str': 'valacyclovir'}, {'cui': 'C0010823', 'cui_str': 'Cytomegalovirus infection'}, {'cui': 'C0017649', 'cui_str': 'Globulin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0009678', 'cui_str': 'congenital'}, {'cui': 'C0010823', 'cui_str': 'Cytomegalovirus infection'}]",,0.471966,"This study concluded that CMV HIG was ineffective at reducing the risk of congenital CMV among women with primary CMV in early pregnancy. ","[{'ForeName': 'Mercede', 'Initials': 'M', 'LastName': 'Sebghati', 'Affiliation': ""Fetal Medicine Unit, St George's University Hospitals.""}, {'ForeName': 'Asma', 'Initials': 'A', 'LastName': 'Khalil', 'Affiliation': ""Fetal Medicine Unit, St George's University Hospitals.""}]",Current opinion in obstetrics & gynecology,['10.1097/GCO.0000000000000651'] 2187,32740133,Influence of a Preadmission Procedure-Specific Consent Document on Patient Recall of Informed Consent at 4 Weeks After Total Hip Replacement: A Randomized Controlled Trial.,"OBJECTIVES Consent is a legal and ethical requirement for undertaking surgical procedures; however, the literature suggests that there continues to be poor recall among patients of the surgical risks discussed during the consent process. The aim of this study was to evaluate whether the addition of a preadmission procedure-specific consent document would improve patient recall of surgical risks at 4 weeks after total hip replacement in patients consented with a procedure-specific consent form. METHODS A prospective randomized controlled trial allocated seventy adult patients who were undergoing a primary total hip replacement to either receive (intervention group) or not receive (control group) a preadmission procedure-specific consent document. All patients were also consented with a procedure-specific consent form on the morning of surgery and were contacted 4 weeks later to assess recall of surgical risks. RESULTS There was a very poor recall rate seen in both the intervention group (16%) and the control group (13%), with no statistically significant difference between them (P = 0.49). A large number (30%) of patients could not recall a single risk. A subgroup analysis excluding these ""consent nonresponders"" did show a significantly increased recall rate in the intervention group (24.5% versus 18.25%, P = 0.02). CONCLUSIONS Patient recall of potential complications of total hip replacement was poor despite the intervention. Although not effective overall, the use of a preadmission procedure-specific consent document did improve recall of potential complications of surgery in a subset of patients. The phenomenon of consent nonresponders is worth exploring in future research.",2020,"Although not effective overall, the use of a preadmission procedure-specific consent document did improve recall of potential complications of surgery in a subset of patients.","['Patient Recall of Informed Consent at 4 Weeks', 'seventy adult patients who were undergoing a primary total hip replacement to either', 'patients consented with a procedure-specific consent form', 'After Total Hip Replacement']",['receive (intervention group) or not receive (control group) a preadmission procedure-specific consent document'],"['recall rate seen', 'patient recall of surgical risks', 'recall rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0009797', 'cui_str': 'Informed Consent Forms'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0009797', 'cui_str': 'Informed Consent Forms'}]","[{'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",70.0,0.0452716,"Although not effective overall, the use of a preadmission procedure-specific consent document did improve recall of potential complications of surgery in a subset of patients.","[{'ForeName': 'Fiachra Richard', 'Initials': 'FR', 'LastName': 'Power', 'Affiliation': 'From the Cappagh National Orthopaedic Hospital, Dublin, Ireland.'}, {'ForeName': 'Aine', 'Initials': 'A', 'LastName': 'McClean', 'Affiliation': ''}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Cashman', 'Affiliation': ''}]",Journal of patient safety,['10.1097/PTS.0000000000000756'] 2188,32740159,Direct oral anticoagulants in chronic kidney disease: an update.,"PURPOSE OF REVIEW Direct oral anticoagulants (DOACs) are variably eliminated by the kidneys rendering their use potentially problematic in patients with chronic kidney disease (CKD) or necessitating appropriate dose adjustment. RECENT FINDINGS Both observational and limited randomized trial data for DOACs compared with no treatment or with warfarin for patients with atrial fibrillation on maintenance dialysis were recently published. In a randomized trial in patients on hemodialysis, there was no significant difference in vascular calcification between patients who received rivaroxaban with or without vitamin K2 or vitamin K antagonists. A randomized trial of apixaban versus warfarin was terminated owing to poor enrollment and preliminary results identified no difference in clinical outcomes between groups. However, valuable pharmacodynamic data will be forthcoming from that trial. In observational research, among patients newly diagnosed with atrial fibrillation, there were opposing trends in the associations of apixaban initiation versus no oral anticoagulation with ischemic versus hemorrhagic stroke and no association was present with the overall risk of stroke or embolism. In another study comparing apixaban with warfarin initiation, apixaban was associated with less bleeding. Regular-dose apixaban (5 mg twice daily) associated with reduced rates of ischemic stroke or systemic embolism, whereas no such association was present for those prescribed the reduced dose (2.5 mg twice daily). SUMMARY DOACs may be used after appropriate dose adjustment for an established clinical indication in patients with advanced CKD. Quality evidence for oral anticoagulation, with any specific agent or dose, for stroke prevention in hemodialysis continues to be lacking.",2020,"Regular-dose apixaban (5 mg twice daily) associated with reduced rates of ischemic stroke or systemic embolism, whereas no such association was present for those prescribed the reduced dose (2.5 mg twice daily). ","['patients newly diagnosed with atrial fibrillation', 'patients with atrial fibrillation on maintenance dialysis', 'chronic kidney disease', 'patients with chronic kidney disease (CKD) or necessitating appropriate dose adjustment', 'patients with advanced CKD']","['apixaban with warfarin initiation, apixaban', 'apixaban versus warfarin', 'Regular-dose apixaban', 'warfarin', 'rivaroxaban', 'vitamin K2 or vitamin K antagonists', 'Direct oral anticoagulants']","['vascular calcification', 'bleeding', 'overall risk of stroke or embolism', 'rates of ischemic stroke or systemic embolism']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}]","[{'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C0065936', 'cui_str': 'menatetrenone'}, {'cui': 'C1096489', 'cui_str': 'Vitamin K antagonist'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}]","[{'cui': 'C0342649', 'cui_str': 'Vascular calcification'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0013922', 'cui_str': 'Embolism'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}]",,0.0523301,"Regular-dose apixaban (5 mg twice daily) associated with reduced rates of ischemic stroke or systemic embolism, whereas no such association was present for those prescribed the reduced dose (2.5 mg twice daily). ","[{'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Mavrakanas', 'Affiliation': 'Department of Medicine, McGill University, Montreal, QC & Department of Medicine, Geneva University Hospitals & Faculty of Medicine, Geneva, Switzerland.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Charytan', 'Affiliation': 'Division of Nephrology, NYU Grossman School of Medicine, New York, New York.'}, {'ForeName': 'Wolfgang C', 'Initials': 'WC', 'LastName': 'Winkelmayer', 'Affiliation': 'Selzman Institute for Kidney Health, Section of Nephrology, Baylor College of Medicine, Houston, Texas, USA.'}]",Current opinion in nephrology and hypertension,['10.1097/MNH.0000000000000634'] 2189,32740179,Skin-to-Skin Care Is a Safe and Effective Comfort Measure for Infants Before and After Neonatal Cardiac Surgery.,"OBJECTIVES To determine the effect of skin-to-skin care on stress, pain, behavioral organization, and physiologic stability of infants with critical congenital heart disease before and after neonatal cardiac surgery. DESIGN A baseline response-paired design was used, with infants acting as their own controls before, during, and after skin-to-skin care at two distinct time points: once in the preoperative period (T1) and once in the postoperative period (T2). SETTING Cardiac ICU and step-down unit in a large metropolitan freestanding children's hospital. SUBJECTS Convenience sample of 30 infants admitted preoperatively for critical congenital heart disease. INTERVENTIONS Eligible infants were placed into skin-to-skin care for 1 hour with their biological mothers once each at T1 and T2. MEASUREMENTS AND MAIN RESULTS Measurements of stress (salivary cortisol), pain and behavior state (COMFORT scale), and physiologic stability (vital signs) were assessed immediately before skin-to-skin care, 30 minutes into skin-to-skin care, and 30 minutes after skin-to-skin care ended. At both T1 and T2, infant pain scores were significantly decreased (p < 0.0001) and infants moved into a calmer behavior state (p < 0.0001) during skin-to-skin care as compared to baseline. At T1, infants also had significantly reduced heart rate (p = 0.002) and respiratory rate (p < 0.0001) and increased systolic blood pressure (p = 0.033) during skin-to-skin care. At both T1 and T2, infant cortisol remained stable and unchanged from pre-skin-to-skin care to during skin-to-skin care (p = 0.096 and p = 0.356, respectively), and significantly increased from during skin-to-skin care to post-skin-to-skin care (p = 0.001 and p = 0.023, respectively). Exploratory analysis revealed differences in cortisol reactivity for infants with higher baseline cortisol (> 0.3 μg/dL) versus lower (≤ 0.3 μg/dL) prior to skin-to-skin care. Infants with higher baseline cortisol at T2 experienced significantly reduced cortisol during skin-to-skin care (p = 0.025). No significant differences in demographics or baseline variables were found between infants in either group. CONCLUSIONS Skin-to-skin care is a low-cost, low-risk intervention that promotes comfort and supports physiologic stability in infants before and after neonatal cardiac surgery.",2020,"At both T1 and T2, infant pain scores were significantly decreased (p < 0.0001) and infants moved into a calmer behavior state (p < 0.0001) during skin-to-skin care as compared to baseline.","['infants before and after neonatal cardiac surgery', 'infants with critical congenital heart disease before and after neonatal cardiac surgery', 'Infants Before and After Neonatal Cardiac Surgery', 'Convenience sample of 30 infants admitted preoperatively for critical congenital heart disease', ""large metropolitan freestanding children's hospital""]","['skin-to-skin care', 'Skin-to-Skin Care']","['stress, pain, behavioral organization, and physiologic stability', 'Measurements of stress (salivary cortisol), pain and behavior state (COMFORT scale), and physiologic stability (vital signs', 'heart rate', 'systolic blood pressure', 'respiratory rate', 'cortisol reactivity', 'infant pain scores']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0152021', 'cui_str': 'Congenital heart disease'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}]","[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0150773', 'cui_str': 'Skin care'}]","[{'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",30.0,0.0256545,"At both T1 and T2, infant pain scores were significantly decreased (p < 0.0001) and infants moved into a calmer behavior state (p < 0.0001) during skin-to-skin care as compared to baseline.","[{'ForeName': 'Amy J', 'Initials': 'AJ', 'LastName': 'Lisanti', 'Affiliation': ""Nursing and Clinical Care Services, Children's Hospital of Philadelphia, Philadelphia, PA.""}, {'ForeName': 'Abigail C', 'Initials': 'AC', 'LastName': 'Demianczyk', 'Affiliation': ""Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, PA.""}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Costarino', 'Affiliation': ""Cardiac Critical Care Medicine, Children's Hospital of Philadelphia, Philadelphia, PA.""}, {'ForeName': 'Maria G', 'Initials': 'MG', 'LastName': 'Vogiatzi', 'Affiliation': ""Adrenal and Puberty Center, Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA.""}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Hoffman', 'Affiliation': 'Laboratory of Innovative & Translational Nursing Research, University of Pennsylvania School of Nursing, Philadelphia, PA.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Quinn', 'Affiliation': 'Office of Nursing Research, University of Pennsylvania School of Nursing, Philadelphia, PA.'}, {'ForeName': 'Jesse L', 'Initials': 'JL', 'LastName': 'Chittams', 'Affiliation': 'Biostatistics Analysis Core, Office of Nursing Research, University of Pennsylvania School of Nursing, Philadelphia, PA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Medoff-Cooper', 'Affiliation': ""Nursing and Clinical Care Services, Children's Hospital of Philadelphia, Philadelphia, PA.""}]",Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies,['10.1097/PCC.0000000000002493'] 2190,32740180,Investigating the Efficacy of Hydrocolloid Dressing for Preventing Nasotracheal Tube-Related Pressure Injury in the PICU.,"OBJECTIVES To investigate the efficacy of hydrocolloid dressing in reducing the occurrence rate and severity of nasotracheal tube-related pressure injury. DESIGN Randomized controlled trial. SETTING A PICU in a tertiary medical center in southern China. PATIENTS Pediatric patients received invasive mechanical ventilation via nasotracheal tubes. INTERVENTIONS The hydrocolloid dressing was cut into an optimal square size, which should cover the area from the nasal columella to the ala. MEASUREMENTS AND MAIN RESULTS Eligible participants were randomly allocated to the control group and the experimental group. The participants in the experimental group received hydrocolloid dressing to protect nasal skin from the beginning of nasotracheal intubation, while the participants in the control group received the current care procedure (without hydrocolloid dressing) unless pressure injuries occurred. The hydrocolloid dressing was changed daily to assess the nasal skin. The pressure injury staging system that was redefined and updated by the National Pressure Ulcer Advisory Panel in 2016 was used. The mean duration of nasotracheal intubation was 150.10 ± 117.09 hours in the experimental group and 161.75 ± 120.72 hours in the control group. Forty-five participants had nasotracheal tube-related pressure injuries in control group, whereas 26 patients had in experimental group (72.6% vs 43.3%; absolute difference, 29.3%, 95% CI, 12.5-46%; p = 0.001). The median survival times of the nasal skin integrity were 95.5 hours in the control group and 219.5 hours in the experimental group (p < 0.001). CONCLUSIONS Hydrocolloid dressing can not only reduce the occurrence rate of nasotracheal tube-related pressure injury in the child with long-term nasotracheal intubation but also improve the endurance of the nasal skin significantly.",2020,"The median survival times of the nasal skin integrity were 95.5 hours in the control group and 219.5 hours in the experimental group (p < 0.001). ","['A PICU in a tertiary medical center in southern China', 'Pediatric patients received']","['invasive mechanical ventilation via nasotracheal tubes', 'hydrocolloid dressing', 'current care procedure (without hydrocolloid dressing', 'Hydrocolloid dressing', 'Hydrocolloid Dressing']","['occurrence rate', 'mean duration of nasotracheal intubation', 'nasal skin', 'nasotracheal tube-related pressure injuries', 'median survival times of the nasal skin integrity']","[{'cui': 'C1046445', 'cui_str': 'Picus'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1868981', 'cui_str': 'Invasive mechanical ventilation'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0122734', 'cui_str': 'Hydrocolloid dressing'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0396625', 'cui_str': 'Nasotracheal intubation'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0332679', 'cui_str': 'Crushing injury'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C2919552', 'cui_str': 'Survival time'}, {'cui': 'C1286235', 'cui_str': 'Integrity of skin'}]",,0.0311669,"The median survival times of the nasal skin integrity were 95.5 hours in the control group and 219.5 hours in the experimental group (p < 0.001). ","[{'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ""Pediatric Intensive Care Unit, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.""}, {'ForeName': 'Jinlu', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ""Pediatric Intensive Care Unit, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.""}, {'ForeName': 'Jine', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': ""Pediatric Intensive Care Unit, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.""}, {'ForeName': 'Yanxuan', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': ""Pediatric Intensive Care Unit, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.""}, {'ForeName': 'Yufeng', 'Initials': 'Y', 'LastName': 'Liang', 'Affiliation': ""Pediatric Intensive Care Unit, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Lin', 'Affiliation': ""Department of Nursing, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.""}]",Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies,['10.1097/PCC.0000000000002494'] 2191,32740188,Nurse-Implemented Goal-Directed Strategy to Improve Pain and Sedation Management in a Pediatric Cardiac ICU.,"OBJECTIVES To assess the impact of a nurse-implemented goal-directed sedation strategy on patient care and nursing practice in a pediatric cardiac ICU. DESIGN Quality improvement project with a pre-post interval measurement plan. SETTING Thirty-one bed pediatric cardiac ICU in a freestanding tertiary care children's hospital. PATIENTS Postoperative pediatric cardiac surgery patients. INTERVENTIONS The implementation of cardiac-Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE), a nurse-implemented goal directed strategy to improve pain and sedation management in a pediatric cardiac ICU which included daily team discussion of the patient's trajectory of illness (acute, titration, or weaning phase), prescription of a sedation target score based on the patient's trajectory of illness, arousal assessments, and opioid and/or sedative titration. Withdrawal Assessment Scores were used to assess and manage iatrogenic withdrawal symptoms. MEASUREMENTS AND MAIN RESULTS Data related to opioid and sedation use, pain and sedation scores, and the occurrence and management of iatrogenic withdrawal symptoms were reviewed on 1,243 patients during four separate time periods: one pre-implementation and three discontinuous post-implementation time intervals. Patient age and complexity were consistent across the data collection periods. Post-implementation opioids and benzodiazepines use was reduced about 50% without a concomitant increase in the use of other sedative classes. Few post-intervention patients were discharged from the pediatric cardiac ICU or to home on methadone (pediatric cardiac ICU: pre 19% to post 3%; hospital: pre 12% to post 1.3%). Documentation of pain, sedation, and withdrawal scores became more consistent and nurses reported satisfaction with their patient's comfort management. CONCLUSIONS The implementation of a nurse-driven goal-directed plan such as cardiac-RESTORE to manage pediatric cardiac ICU patient pain and sedation is possible, sustainable, and associated with reduced sedative and methadone use.",2020,Post-implementation opioids and benzodiazepines use was reduced about 50% without a concomitant increase in the use of other sedative classes.,"['Postoperative pediatric cardiac surgery patients', ""Thirty-one bed pediatric cardiac ICU in a freestanding tertiary care children's hospital""]","['benzodiazepines', 'Sedation Titration', 'nurse-implemented goal-directed sedation strategy']","['Withdrawal Assessment Scores', 'opioid and sedation use, pain and sedation scores, and the occurrence and management of iatrogenic withdrawal symptoms', 'Documentation of pain, sedation, and withdrawal scores']","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C0179281', 'cui_str': 'Pediatric bed'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}]","[{'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0162621', 'cui_str': 'Titration method'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0439851', 'cui_str': 'Direct'}]","[{'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0087169', 'cui_str': 'Withdrawal symptom'}, {'cui': 'C0175636', 'cui_str': 'Documentation procedure'}]",1243.0,0.0880508,Post-implementation opioids and benzodiazepines use was reduced about 50% without a concomitant increase in the use of other sedative classes.,"[{'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Lincoln', 'Affiliation': ""Department of Cardiovascular and Critical Care Nursing Services, Boston Children's Hospital, Boston, MA.""}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Whelan', 'Affiliation': ""Department of Cardiovascular and Critical Care Nursing Services, Boston Children's Hospital, Boston, MA.""}, {'ForeName': 'Lauren P', 'Initials': 'LP', 'LastName': 'Hartwell', 'Affiliation': ""Department of Cardiology, Boston Children's Hospital, Boston, MA.""}, {'ForeName': 'Kimberlee', 'Initials': 'K', 'LastName': 'Gauvreau', 'Affiliation': ""Department of Cardiology, Boston Children's Hospital, Boston, MA.""}, {'ForeName': 'Brenda L', 'Initials': 'BL', 'LastName': 'Dodsen', 'Affiliation': ""Information Services Department, Clinical Integration Architect, Boston Children's Hospital, Boston, MA.""}, {'ForeName': 'Joan M', 'Initials': 'JM', 'LastName': 'LaRovere', 'Affiliation': ""Department of Cardiology, Boston Children's Hospital, Boston, MA.""}, {'ForeName': 'Ravi R', 'Initials': 'RR', 'LastName': 'Thiagarajan', 'Affiliation': ""Department of Cardiology, Boston Children's Hospital, Boston, MA.""}, {'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Hickey', 'Affiliation': ""Department of Cardiovascular and Critical Care Nursing Services, Boston Children's Hospital, Boston, MA.""}, {'ForeName': 'Martha A Q', 'Initials': 'MAQ', 'LastName': 'Curley', 'Affiliation': ''}]",Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies,['10.1097/PCC.0000000000002505'] 2192,32740192,Dexmedetomidine Sedation in Mechanically Ventilated Critically Ill Children: A Pilot Randomized Controlled Trial.,"OBJECTIVES To assess the feasibility, safety, and efficacy of a sedation protocol using dexmedetomidine as the primary sedative in mechanically ventilated critically ill children. DESIGN Open-label, pilot, prospective, multicenter, randomized, controlled trial. The primary outcome was the proportion of sedation scores in the target sedation range in the first 48 hours. Safety outcomes included device removal, adverse events, and vasopressor use. Feasibility outcomes included time to randomization and protocol fidelity. SETTING Six tertiary PICUs in Australia and New Zealand. PATIENTS Critically ill children, younger than 16 years old, requiring intubation and mechanical ventilation and expected to be mechanically ventilated for at least 24 hours. INTERVENTIONS Children randomized to dexmedetomidine received a dexmedetomidine-based algorithm targeted to light sedation (State Behavioral Scale -1 to +1). Children randomized to usual care received sedation as determined by the treating clinician (but not dexmedetomidine), also targeted to light sedation. MEASUREMENTS AND MAIN RESULTS Sedation with dexmedetomidine as the primary sedative resulted in a greater proportion of sedation measurements in the light sedation range (State Behavioral Scale -1 to +1) over the first 48 hours (229/325 [71%] vs 181/331 [58%]; p = 0.04) and the first 24 hours (66/103 [64%] vs 48/116 [41%]; p < 0.001) compared with usual care. Cumulative midazolam dosage was significantly reduced in the dexmedetomidine arm compared with usual care (p = 0.002).There were more episodes of hypotension and bradycardia with dexmedetomidine (including one serious adverse event) but no difference in vasopressor requirements. Median time to randomization after intubation was 6.0 hours (interquartile range, 2.0-9.0 hr) in the dexmedetomidine arm compared with 3.0 hours (interquartile range, 1.0-7.0 hr) in the usual care arm (p = 0.24). CONCLUSIONS A sedation protocol using dexmedetomidine as the primary sedative was feasible, appeared safe, achieved early, light sedation, and reduced midazolam requirements. The findings of this pilot study justify further studies of sedative agents in critically ill children.",2020,Cumulative midazolam dosage was significantly reduced in the dexmedetomidine arm compared with usual care (p = 0.002).There were more episodes of hypotension and bradycardia with dexmedetomidine (including one serious adverse event) but no difference in vasopressor requirements.,"['Critically ill children, younger than 16 years old, requiring intubation and mechanical ventilation and expected to be mechanically ventilated for at least 24 hours', 'Mechanically Ventilated Critically Ill Children', 'critically ill children', 'Six tertiary PICUs in Australia and New Zealand', 'mechanically ventilated critically ill children']","['dexmedetomidine-based algorithm targeted to light sedation (State Behavioral Scale -1 to +1', 'Dexmedetomidine Sedation', 'dexmedetomidine', 'usual care received sedation as determined by the treating clinician (but not dexmedetomidine']","['hypotension and bradycardia', 'proportion of sedation scores', 'feasibility, safety, and efficacy', 'proportion of sedation measurements', 'light sedation range (State Behavioral Scale -1 to +1', 'time to randomization and protocol fidelity', 'device removal, adverse events, and vasopressor use', 'Cumulative midazolam dosage', 'Median time to randomization after intubation']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0042491', 'cui_str': 'Ventilation'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C1046445', 'cui_str': 'Picus'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0752250', 'cui_str': 'Removal of device'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0042397', 'cui_str': 'Vasoconstrictor agent'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}]",,0.154635,Cumulative midazolam dosage was significantly reduced in the dexmedetomidine arm compared with usual care (p = 0.002).There were more episodes of hypotension and bradycardia with dexmedetomidine (including one serious adverse event) but no difference in vasopressor requirements.,"[{'ForeName': 'Simon J', 'Initials': 'SJ', 'LastName': 'Erickson', 'Affiliation': ""Paediatric Critical Care, Perth Children's Hospital, Perth, WA, Australia.""}, {'ForeName': 'Johnny', 'Initials': 'J', 'LastName': 'Millar', 'Affiliation': ""Paediatric Intensive Care Unit, Royal Children's Hospital, Melbourne, VIC, Australia.""}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Anderson', 'Affiliation': ""Paediatric Intensive Care Unit, Starship Children's Hospital, Auckland, New Zealand.""}, {'ForeName': 'Marino S', 'Initials': 'MS', 'LastName': 'Festa', 'Affiliation': ""Kids Critical Care Research, The Children's Hospital at Westmead, Westmead, NSW, Australia.""}, {'ForeName': 'Lahn', 'Initials': 'L', 'LastName': 'Straney', 'Affiliation': 'Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Yahya', 'Initials': 'Y', 'LastName': 'Shehabi', 'Affiliation': 'School of Clinical Sciences, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Debbie A', 'Initials': 'DA', 'LastName': 'Long', 'Affiliation': ""Paediatric Intensive Care Unit, Queensland Children's Hospital, Brisbane, QLD, Australia.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies,['10.1097/PCC.0000000000002483'] 2193,32740218,Direct oral anticoagulants in chronic kidney disease: an update.,"PURPOSE OF REVIEW Direct oral anticoagulants (DOACs) are variably eliminated by the kidneys rendering their use potentially problematic in patients with chronic kidney disease (CKD) or necessitating appropriate dose adjustment. RECENT FINDINGS Both observational and limited randomized trial data for DOACs compared with no treatment or with warfarin for patients with atrial fibrillation on maintenance dialysis were recently published. In a randomized trial in patients on hemodialysis, there was no significant difference in vascular calcification between patients who received rivaroxaban with or without vitamin K2 or vitamin K antagonists. A randomized trial of apixaban versus warfarin was terminated owing to poor enrollment and preliminary results identified no difference in clinical outcomes between groups. However, valuable pharmacodynamic data will be forthcoming from that trial. In observational research, among patients newly diagnosed with atrial fibrillation, there were opposing trends in the associations of apixaban initiation versus no oral anticoagulation with ischemic versus hemorrhagic stroke and no association was present with the overall risk of stroke or embolism. In another study comparing apixaban with warfarin initiation, apixaban was associated with less bleeding. Regular-dose apixaban (5 mg twice daily) associated with reduced rates of ischemic stroke or systemic embolism, whereas no such association was present for those prescribed the reduced dose (2.5 mg twice daily). SUMMARY DOACs may be used after appropriate dose adjustment for an established clinical indication in patients with advanced CKD. Quality evidence for oral anticoagulation, with any specific agent or dose, for stroke prevention in hemodialysis continues to be lacking.",2020,"Regular-dose apixaban (5 mg twice daily) associated with reduced rates of ischemic stroke or systemic embolism, whereas no such association was present for those prescribed the reduced dose (2.5 mg twice daily). ","['patients newly diagnosed with atrial fibrillation', 'patients with atrial fibrillation on maintenance dialysis', 'chronic kidney disease', 'patients with chronic kidney disease (CKD) or necessitating appropriate dose adjustment', 'patients with advanced CKD']","['apixaban with warfarin initiation, apixaban', 'apixaban versus warfarin', 'Regular-dose apixaban', 'warfarin', 'rivaroxaban', 'vitamin K2 or vitamin K antagonists', 'Direct oral anticoagulants']","['vascular calcification', 'bleeding', 'overall risk of stroke or embolism', 'rates of ischemic stroke or systemic embolism']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}]","[{'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C0065936', 'cui_str': 'menatetrenone'}, {'cui': 'C1096489', 'cui_str': 'Vitamin K antagonist'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}]","[{'cui': 'C0342649', 'cui_str': 'Vascular calcification'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0013922', 'cui_str': 'Embolism'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}]",,0.0523301,"Regular-dose apixaban (5 mg twice daily) associated with reduced rates of ischemic stroke or systemic embolism, whereas no such association was present for those prescribed the reduced dose (2.5 mg twice daily). ","[{'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Mavrakanas', 'Affiliation': 'Department of Medicine, McGill University, Montreal, QC & Department of Medicine, Geneva University Hospitals & Faculty of Medicine, Geneva, Switzerland.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Charytan', 'Affiliation': 'Division of Nephrology, NYU Grossman School of Medicine, New York, New York.'}, {'ForeName': 'Wolfgang C', 'Initials': 'WC', 'LastName': 'Winkelmayer', 'Affiliation': 'Selzman Institute for Kidney Health, Section of Nephrology, Baylor College of Medicine, Houston, Texas, USA.'}]",Current opinion in nephrology and hypertension,['10.1097/MNH.0000000000000634'] 2194,32740235,Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.,"OBJECTIVE The optimal neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. METHODS S1505 (NCT02562716) was a randomized phase II study of perioperative chemotherapy with mFOLFIRINOX (Arm 1) or gemcitabine/nab-paclitaxel (Arm 2). Measured parameters included resection rate, margin positivity, pathologic response, and toxicity. RESULTS Between 2015 and 2018, 147 patients were randomized. Of these, 44 (30%) were deemed ineligible (43 by central review). Of the 103 eligible patients, 77 (76%) completed preoperative therapy and underwent surgery; reasons patients did not undergo surgery included toxicity related to preoperative therapy (n = 9), progression (n = 9), or other (n = 7). Of the 77, 73 (95%) underwent successful resection; 21 (29%) required vascular reconstruction, 62 (85%) had negative (R0) margins, and 24 (33%) had a complete or major pathologic response to therapy. The grade 3-5 postoperative complication rate was 16%. Of the 73 patients completing surgery, 57 (78%) started and 46 (63%) completed postoperative therapy. This study represents the first prospective trial evaluating modern systemic therapy delivered in a neoadjuvant/perioperative format for resectable PDA. CONCLUSIONS We have demonstrated: (1) Based on the high percentage of enrolled, but ineligible patients, it is clear that adherence to strict definitions of resectable PDA is challenging; (2) Patients can tolerate modern systemic therapy and undergo successful surgical resection without prohibitive perioperative complications; (3) Completion of adjuvant therapy in the perioperative format is difficult; (4) Major pathologic response rate of 33% is encouraging.",2020,"Of the 77, 73 (95%) underwent successful resection; 21 (29%) required vascular reconstruction, 62 (85%) had negative (R0) margins, and 24 (33%) had a complete or major pathologic response to therapy.","['103 eligible patients, 77 (76%) completed preoperative therapy and underwent surgery; reasons patients did not undergo surgery included toxicity related to preoperative therapy (n = 9), progression (n = 9), or other (n = 7', 'resectable pancreatic ductal adenocarcinoma (PDA', 'Resectable Pancreatic Ductal Adenocarcinoma', 'resectable PDA', '73 patients completing surgery, 57 (78%) started and 46 (63%) completed postoperative therapy', 'Between 2015 and 2018, 147 patients were randomized', '44 (30%) were deemed ineligible (43 by central review']","['SWOG S1505', 'perioperative chemotherapy with mFOLFIRINOX (Arm 1) or gemcitabine/nab-paclitaxel', 'Gemcitabine/Nab-paclitaxel']","['vascular reconstruction', 'complete or major pathologic response', 'grade 3-5 postoperative complication rate', 'resection rate, margin positivity, pathologic response, and toxicity']","[{'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C1335302', 'cui_str': 'Ductal adenocarcinoma of pancreas'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0282443', 'cui_str': 'Review'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}]","[{'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0040539', 'cui_str': 'TO'}]",147.0,0.0486099,"Of the 77, 73 (95%) underwent successful resection; 21 (29%) required vascular reconstruction, 62 (85%) had negative (R0) margins, and 24 (33%) had a complete or major pathologic response to therapy.","[{'ForeName': 'Syed A', 'Initials': 'SA', 'LastName': 'Ahmad', 'Affiliation': 'University of Cincinnati, Cincinnati, Ohio.'}, {'ForeName': 'Mai', 'Initials': 'M', 'LastName': 'Duong', 'Affiliation': 'SWOG Statistical and Data Management Center, Seattle, Washington.'}, {'ForeName': 'Davendra P S', 'Initials': 'DPS', 'LastName': 'Sohal', 'Affiliation': 'University of Cincinnati, Cincinnati, Ohio.'}, {'ForeName': 'Namita S', 'Initials': 'NS', 'LastName': 'Gandhi', 'Affiliation': 'Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Muhammad Shaalan', 'Initials': 'MS', 'LastName': 'Beg', 'Affiliation': 'UT Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Wang-Gillam', 'Affiliation': 'Washington University Siteman Cancer Center, St. Louis, Missouri.'}, {'ForeName': 'James L', 'Initials': 'JL', 'LastName': 'Wade', 'Affiliation': 'Heartland NCORP/Cancer Care Specialists of Illinois, Decatur, Illinois.'}, {'ForeName': 'Elena Gabriela', 'Initials': 'EG', 'LastName': 'Chiorean', 'Affiliation': 'University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Guthrie', 'Affiliation': 'SWOG Statistical and Data Management Center, Seattle, Washington.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Lowy', 'Affiliation': 'University of California, San Diego, La Jolla, California.'}, {'ForeName': 'Philip A', 'Initials': 'PA', 'LastName': 'Philip', 'Affiliation': 'Wayne State University/Karmanos Cancer Institute, Detroit, Michigan.'}, {'ForeName': 'Howard S', 'Initials': 'HS', 'LastName': 'Hochster', 'Affiliation': 'Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.'}]",Annals of surgery,['10.1097/SLA.0000000000004155'] 2195,32748501,Technology-enabled collaborative care for youth with early psychosis: A protocol for a feasibility study to improve physical health behaviours.,"AIM Individuals with psychotic disorders have poorer health outcomes and die earlier due to cardiovascular diseases when compared to healthy populations. Contributing factors include low levels of physical activity, poor nutrition and tobacco smoking. Currently, patients navigate a fragmented health-care system to seek physical and mental health services, often without access to evidence-based health promotion interventions, especially in non-academic settings or rural areas, increasing client barriers at the individual and provider level. To address these gaps, we wish to test the feasibility and impact of a Technology-Enabled Collaborative Care for Youth (TECC-Y) model to improve healthy behaviours among youth with early psychosis. The model addresses geographical barriers and maldistribution of physical and mental health care. METHODS A randomized controlled trial, including youth (ages of 16-29) with early psychosis (diagnosed in the past 5 years) residing in Ontario, Canada. Our primary outcome is client engagement. Secondary outcomes include smoking status, physical health and nutrition. Participants are randomly assigned to either a health coach supervised by a virtual care team, or a self-directed learning group (e-platform with psychoeducational materials). Assessments are conducted at baseline, 6, 12 and 24 weeks. RESULTS This paper presents the protocol of the study. Recruitment commenced in August 2018. This study was registered on 16 July 2018 on clinicaltrials.gov (Registry ID: NCT03610087). CONCLUSIONS TECC-Y will determine if a technology-based collaborative care model engages youth with early psychosis, and whether this will be associated with changes in smoking, physical health and nutrition.",2020,"Participants are randomly assigned to either a health coach supervised by a virtual care team, or a self-directed learning group (e-platform with psychoeducational materials).","['16 July 2018 on clinicaltrials.gov (Registry ID: NCT03610087', 'Individuals with psychotic disorders', 'youth (ages of 16-29) with early psychosis (diagnosed in the past 5\u2009years) residing in Ontario, Canada', 'youth with early psychosis']","['Technology-Enabled Collaborative Care for Youth (TECC-Y) model', 'health coach supervised by a virtual care team, or a self-directed learning group (e-platform with psychoeducational materials', 'Technology-enabled collaborative care']","['physical activity, poor nutrition and tobacco smoking', 'smoking status, physical health and nutrition', 'healthy behaviours']","[{'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C0006823', 'cui_str': 'Canada'}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0562342', 'cui_str': 'Empowered'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C2317129', 'cui_str': 'Health coach'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0520510', 'cui_str': 'Material'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C0453996', 'cui_str': 'Tobacco smoking behavior - finding'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",,0.0553073,"Participants are randomly assigned to either a health coach supervised by a virtual care team, or a self-directed learning group (e-platform with psychoeducational materials).","[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Selby', 'Affiliation': 'Addictions Research Program, Centre for Addiction and Mental Health, Toronto, Canada.'}, {'ForeName': 'Lenka', 'Initials': 'L', 'LastName': 'Vojtila', 'Affiliation': 'Nicotine Dependence Clinic, Centre for Addiction and Mental Health, Toronto, Canada.'}, {'ForeName': 'Iqra', 'Initials': 'I', 'LastName': 'Ashfaq', 'Affiliation': 'Nicotine Dependence Clinic, Centre for Addiction and Mental Health, Toronto, Canada.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Dragonetti', 'Affiliation': 'Nicotine Dependence Clinic, Centre for Addiction and Mental Health, Toronto, Canada.'}, {'ForeName': 'Osnat C', 'Initials': 'OC', 'LastName': 'Melamed', 'Affiliation': 'Department of Family and Community Medicine, Toronto, Canada.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Carriere', 'Affiliation': 'Department of Psychiatry, University of Toronto, Toronto, Canada.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'LaChance', 'Affiliation': ""St. Mary's Hospital Centre, McGill University, Montreal, Canada.""}, {'ForeName': 'Sara Ahola', 'Initials': 'SA', 'LastName': 'Kohut', 'Affiliation': 'Department of Psychiatry, University of Toronto, Toronto, Canada.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Hahn', 'Affiliation': 'Department of Psychiatry, Institute of Medical Science, Toronto, Canada.'}, {'ForeName': 'Benoit H', 'Initials': 'BH', 'LastName': 'Mulsant', 'Affiliation': 'Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada.'}]",Early intervention in psychiatry,['10.1111/eip.13018'] 2196,32748504,Acute and chronic effects of resistance training on skeletal muscle markers of mitochondrial remodeling in older adults.,"We investigated the acute and chronic effects of resistance training (RT) on skeletal muscle markers of mitochondrial content and remodeling in older, untrained adults. Sixteen participants (n = 6 males, n = 10 females; age = 59 ± 4 years) completed 10 weeks of full-body RT (2 day/week). Muscle biopsies from the vastus lateralis were obtained prior to RT (Pre), 24 hr following the first training session (Acute), and 72 hr following the last training session (Chronic). Protein levels of mitochondrial electron transport chain complexes I-V (+39 to +180%, p ≤ .020) and markers of mitochondrial fusion Mfn1 (+90%, p = .003), Mfn2 (+110%, p < .001), and Opa1 (+261%, p = .004) increased following chronic RT. Drp1 protein levels also increased (+134%, p = .038), while Fis1 protein levels did not significantly change (-5%, p = .584) following chronic RT. Interestingly, protein markers of mitochondrial biogenesis (i.e., PGC-1α, TFAM, and NRF1) or mitophagy (i.e., Pink1 and Parkin) were not significantly altered (p > .050) after 10 weeks of RT. In summary, chronic RT promoted increases in content of electron transport chain proteins (i.e., increased protein levels of all five OXPHOS complexes) and increase in the levels of proteins related to mitochondrial dynamics (i.e., increase in fusion protein markers) in skeletal muscle of older adults. These results suggest that chronic RT could be a useful strategy to increase mitochondrial protein content in older individuals.",2020,"Drp1 protein levels also increased (+134%, p = .038), while Fis1 protein levels did not significantly change (-5%, p = .584) following chronic RT.","['older individuals', 'older, untrained adults', 'Sixteen participants (n\xa0=\xa06 males, n\xa0=\xa010 females; age\xa0=\xa059\xa0±\xa04\xa0years', 'older adults']","['resistance training (RT', 'resistance training']","['protein markers of mitochondrial biogenesis (i.e., PGC-1α, TFAM, and NRF1) or mitophagy (i.e., Pink1 and Parkin', 'Drp1 protein levels', 'markers of mitochondrial fusion Mfn1', 'Protein levels of mitochondrial electron transport chain complexes I-V ', 'Fis1 protein levels', 'mitochondrial protein content']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C3494456', 'cui_str': 'Mitochondrial Biogenesis'}, {'cui': 'C1820119', 'cui_str': 'Mitochondrial Degradation'}, {'cui': 'C1311470', 'cui_str': 'PARK2 protein, human'}, {'cui': 'C0428479', 'cui_str': 'Protein level - finding'}, {'cui': 'C1156067', 'cui_str': 'Mitochondrial Fusion'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0013846', 'cui_str': 'Electron transfer'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0171406', 'cui_str': 'NADH dehydrogenase (ubiquinon)'}, {'cui': 'C0949610', 'cui_str': 'Mitochondrial Protein'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}]",16.0,0.0315857,"Drp1 protein levels also increased (+134%, p = .038), while Fis1 protein levels did not significantly change (-5%, p = .584) following chronic RT.","[{'ForeName': 'Paulo H C', 'Initials': 'PHC', 'LastName': 'Mesquita', 'Affiliation': 'School of Kinesiology, Auburn University, Auburn, AL, USA.'}, {'ForeName': 'Donald A', 'Initials': 'DA', 'LastName': 'Lamb', 'Affiliation': 'Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, AL, USA.'}, {'ForeName': 'Hailey A', 'Initials': 'HA', 'LastName': 'Parry', 'Affiliation': 'School of Kinesiology, Auburn University, Auburn, AL, USA.'}, {'ForeName': 'Johnathon H', 'Initials': 'JH', 'LastName': 'Moore', 'Affiliation': 'School of Kinesiology, Auburn University, Auburn, AL, USA.'}, {'ForeName': 'Morgan A', 'Initials': 'MA', 'LastName': 'Smith', 'Affiliation': 'School of Kinesiology, Auburn University, Auburn, AL, USA.'}, {'ForeName': 'Christopher G', 'Initials': 'CG', 'LastName': 'Vann', 'Affiliation': 'School of Kinesiology, Auburn University, Auburn, AL, USA.'}, {'ForeName': 'Shelby C', 'Initials': 'SC', 'LastName': 'Osburn', 'Affiliation': 'School of Kinesiology, Auburn University, Auburn, AL, USA.'}, {'ForeName': 'Carlton D', 'Initials': 'CD', 'LastName': 'Fox', 'Affiliation': 'School of Kinesiology, Auburn University, Auburn, AL, USA.'}, {'ForeName': 'Bradley A', 'Initials': 'BA', 'LastName': 'Ruple', 'Affiliation': 'School of Kinesiology, Auburn University, Auburn, AL, USA.'}, {'ForeName': 'Kevin W', 'Initials': 'KW', 'LastName': 'Huggins', 'Affiliation': 'Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, AL, USA.'}, {'ForeName': 'Andrew D', 'Initials': 'AD', 'LastName': 'Fruge', 'Affiliation': 'Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, AL, USA.'}, {'ForeName': 'Kaelin C', 'Initials': 'KC', 'LastName': 'Young', 'Affiliation': 'School of Kinesiology, Auburn University, Auburn, AL, USA.'}, {'ForeName': 'Andreas N', 'Initials': 'AN', 'LastName': 'Kavazis', 'Affiliation': 'School of Kinesiology, Auburn University, Auburn, AL, USA.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Roberts', 'Affiliation': 'School of Kinesiology, Auburn University, Auburn, AL, USA.'}]",Physiological reports,['10.14814/phy2.14526'] 2197,32748551,Acute effects of high-intensity interval training session and endurance exercise on pulmonary function and cardiorespiratory coupling.,"The aim of this study was to determine the acute effects of high-intensity interval training (HIIT) exercise and endurance exercise (EE) on pulmonary function, sympathetic/parasympathetic balance, and cardiorespiratory coupling (CRC) in healthy participants. Using a crossover repeated-measurements design, four females and four males were exposed to EE (20 min at 80% maximal heart rate [HR]), HIIT (1 min of exercise at 90% maximal HR per 1 min of rest, 10 times), or control condition (resting). Pulmonary function, HR, CRC, and heart rate variability (HRV) were assessed before and after the interventions. Results revealed no significant effects of EE or HIIT on pulmonary function. The EE, but not HIIT, significantly increased CRC. In contrast, HRV was markedly changed by HIIT, not by EE. Indeed, both the low-frequency (LF HRV ) and high-frequency (HF HRV ) components of HRV were increased and decreased, respectively, after HIIT. The increase in LF HRV was greater after HIIT than after EE. Therefore, a single bout of HIIT or EE has no effects on pulmonary function. Moreover, CRC and cardiac autonomic regulation are targeted differently by the two exercise modalities.",2020,Results revealed no significant effects of EE or HIIT on pulmonary function.,"['healthy participants', 'four females and four males']","['high-intensity interval training session and endurance exercise', 'HIIT (1\xa0min of exercise at 90% maximal HR per 1\xa0min of rest, 10 times), or control condition (resting', 'high-intensity interval training (HIIT) exercise and endurance exercise (EE']","['EE or HIIT on pulmonary function', 'HRV', 'LF HRV', 'CRC', 'low-frequency (LF HRV ) and high-frequency (HF HRV ) components of HRV', 'pulmonary function', 'Pulmonary function, HR, CRC, and heart rate variability (HRV', 'pulmonary function, sympathetic/parasympathetic balance, and cardiorespiratory coupling (CRC', 'pulmonary function and cardiorespiratory coupling']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0419120', 'cui_str': 'Muscular endurance development exercise'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0205213', 'cui_str': 'Low frequency'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]",,0.0230243,Results revealed no significant effects of EE or HIIT on pulmonary function.,"[{'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Andrade', 'Affiliation': 'Centro de Investigación en Fisiología del Ejercicio, Facultad de Ciencias, Universidad Mayor, Santiago, Chile.'}, {'ForeName': 'Alexis', 'Initials': 'A', 'LastName': 'Arce-Alvarez', 'Affiliation': 'Escuela de Kinesiología, Facultad de Salud, Universidad Católica Silva Henríquez, Santiago, Chile.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Parada', 'Affiliation': 'Centro de Investigación en Fisiología del Ejercicio, Facultad de Ciencias, Universidad Mayor, Santiago, Chile.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Uribe', 'Affiliation': 'Centro de Investigación en Fisiología del Ejercicio, Facultad de Ciencias, Universidad Mayor, Santiago, Chile.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Gordillo', 'Affiliation': 'Centro de Investigación en Fisiología del Ejercicio, Facultad de Ciencias, Universidad Mayor, Santiago, Chile.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Dupre', 'Affiliation': 'Centro de Investigación en Fisiología del Ejercicio, Facultad de Ciencias, Universidad Mayor, Santiago, Chile.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Ojeda', 'Affiliation': 'Centro de Investigación en Fisiología del Ejercicio, Facultad de Ciencias, Universidad Mayor, Santiago, Chile.'}, {'ForeName': 'Fiorella', 'Initials': 'F', 'LastName': 'Palumbo', 'Affiliation': 'Centro de Investigación en Fisiología del Ejercicio, Facultad de Ciencias, Universidad Mayor, Santiago, Chile.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Castro', 'Affiliation': 'Centro de Investigación en Fisiología del Ejercicio, Facultad de Ciencias, Universidad Mayor, Santiago, Chile.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Vasquez-Muñoz', 'Affiliation': 'Centro de Investigación en Fisiología del Ejercicio, Facultad de Ciencias, Universidad Mayor, Santiago, Chile.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Del Rio', 'Affiliation': 'Laboratory of Cardiorespiratory Control, Department of Physiology, Pontificia Universidad Católica de Chile, Santiago, Chile.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Ramirez-Campillo', 'Affiliation': 'Centro de Investigación en Fisiología del Ejercicio, Facultad de Ciencias, Universidad Mayor, Santiago, Chile.'}, {'ForeName': 'Mikel', 'Initials': 'M', 'LastName': 'Izquierdo', 'Affiliation': 'Navarrabiomed, Complejo Hospitalario de Navarra (CHN)-Universidad Pública de Navarra (UPNA), IDISNA, Pamplona, Spain.'}]",Physiological reports,['10.14814/phy2.14455'] 2198,32748570,"Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Single-Center Open-Label, Randomized Crossover Studies in Healthy Japanese Volunteers.","Two open-label, single-dose, randomized crossover studies were conducted in healthy Japanesemen to (1) assess dose proportionality of 5 doses (1.38, 2.75, 5.5, 8.25, and 11.0 mg) of Lafenta, a novel matrix-type transdermal fentanyl patch with a rate-controlling membrane; and (2) compare patch bioequivalence (11.0 mg) with a commercially available reference patch (Durotep MT Patch [16.8 mg]). Pharmacokinetics, adhesion performance, residual fentanyl, and safety parameters were assessed. Increases in mean AUC 0-t and C max after application of the test patch were dose proportional. The test patch (11.0 mg) was bioequivalent to the 16.8-mg reference patch in terms of mean AUC 0-inf , AUC 0-t , and C max . Residual fentanyl levels 72 hours postapplication were lower in the test than in the reference patch. Differences in adhesion performance between the test and the reference patch did not affect delivery efficacy and reliability of the novel matrix patch. Safety findings were in line with previous experiences with fentanyl. Both studies showed low variation in fentanyl exposure and delivery via the test patch. The test patch provided equivalent fentanyl exposure at a lower dose than the reference patch formulation with lower variability and the potential to lower medicinal waste.",2020,Differences in adhesion performance between the test and the reference patch did not affect delivery efficacy and reliability of the novel matrix patch.,['Healthy Japanese Volunteers'],"['Lafenta, a novel matrix-type transdermal fentanyl patch with a rate-controlling membrane; and (2) compare patch bioequivalence', 'Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch']","['mean AUC 0-t and C max', 'Pharmacokinetics, adhesion performance, residual fentanyl, and safety parameters', 'adhesion performance', 'Safety, Tolerability, and Dose Proportionality', 'Residual fentanyl levels 72\xa0hours postapplication']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0040652', 'cui_str': 'Transdermal route'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0039789', 'cui_str': 'Equivalencies, Therapeutic'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0001511', 'cui_str': 'Adhesion'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0524136', 'cui_str': 'Fentanyl measurement'}, {'cui': 'C1292423', 'cui_str': '72 hours'}]",,0.019171,Differences in adhesion performance between the test and the reference patch did not affect delivery efficacy and reliability of the novel matrix patch.,"[{'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Lorch', 'Affiliation': ""Richmond Pharmacology Ltd., St George's University London, London, UK.""}, {'ForeName': 'Tomasz', 'Initials': 'T', 'LastName': 'Pierscionek', 'Affiliation': ""Richmond Pharmacology Ltd., St George's University London, London, UK.""}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Freier', 'Affiliation': 'Richmond Research Institute, London, UK.'}, {'ForeName': 'Christopher S', 'Initials': 'CS', 'LastName': 'Spencer', 'Affiliation': 'Richmond Research Institute, London, UK.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Täubel', 'Affiliation': ""Richmond Pharmacology Ltd., St George's University London, London, UK.""}]",Clinical pharmacology in drug development,['10.1002/cpdd.846'] 2199,32748666,The cognitive augmented mobility program (CAMP): feasibility and preliminary efficacy.,"BACKGROUND Best evidence suggests incorporating task-specific training, aerobics, and strengthening to improve mobility and gait in persons with stroke (PWS). Related research suggests incorporating cognitive problem-solving strategy training may lead to better skill maintenance and transfer. The present study examined the feasibility and preliminary outcomes of an evidence-based cognitive augmented mobility program (CAMP) for PWS. METHODS A single-arm pre-post and follow-up design was conducted, in two blocks (NCT03683160). Participants completed an exercise intervention with an integrated cognitive strategy component and had weekly 1:1 sessions with a physiotherapist trained in Cognitive Orientation to daily Occupational Performance (CO-OP), focusing on goal practice and cognitive strategy use. CAMP consisted of a pre-intervention education and goal-setting session and 16 90-minute sessions held in a group format, 2x/wk for 8 weeks. Assessments were conducted 1 week prior to beginning the intervention, 1 week post-intervention, and at a 4-5 week follow-up. RESULTS CAMP was found to be feasible with 96% session attendance and strong participant satisfaction. Pre to post-CAMP intervention, a large effect was found for endurance (r = 0.53), balance (r = 0.59), mobility (r = 0.63) and goal attainment (r = 0.63) indicators, and large effects were maintained at follow-up for balance, mobility, and goal attainment. A medium effect was found for functional independence (r = 0.38), gait speed (r = 0.39), and balance confidence (r = 0.38). A small effect was found for participation (r = 0.27) and overall stroke recovery (r = 0.25). CONCLUSIONS Preliminary results suggest CAMP is feasible; there may be a beneficial effect of combining best evidence for mobility and fitness with cognitive strategy training. The positive results for skill maintenance and transfer suggest further investigation is warranted.",2020,"Pre to post-CAMP intervention, a large effect was found for endurance (r = 0.53), balance (r = 0.59), mobility (r = 0.63) and goal attainment (r = 0.63) indicators, and large effects were maintained at follow-up for balance, mobility, and goal attainment.",['persons with stroke (PWS'],"['exercise intervention with an integrated cognitive strategy component and had weekly 1:1 sessions with a physiotherapist trained in Cognitive Orientation to daily Occupational Performance (CO-OP), focusing on goal practice and cognitive strategy use', 'evidence-based cognitive augmented mobility program (CAMP']","['gait speed ', 'overall stroke recovery', 'balance confidence', 'functional independence', 'mobility']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0029266', 'cui_str': 'Orientation'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0521127', 'cui_str': 'Occupational'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}]",,0.0264507,"Pre to post-CAMP intervention, a large effect was found for endurance (r = 0.53), balance (r = 0.59), mobility (r = 0.63) and goal attainment (r = 0.63) indicators, and large effects were maintained at follow-up for balance, mobility, and goal attainment.","[{'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Dittmann', 'Affiliation': ""St. John's Rehab Research Program, Sunnybrook Research Institute , Toronto, ON, Canada.""}, {'ForeName': 'Kay-Ann', 'Initials': 'KA', 'LastName': 'Allen', 'Affiliation': ""St. John's Rehab Research Program, Sunnybrook Research Institute , Toronto, ON, Canada.""}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Bergner', 'Affiliation': ""St. John's Rehab Research Program, Sunnybrook Research Institute , Toronto, ON, Canada.""}, {'ForeName': 'Joyce', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute , Toronto, ON, Canada.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Inness', 'Affiliation': 'Toronto Rehabilitation Institute, University Health Network , Toronto, ON, Canada.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Linkewich', 'Affiliation': 'North & East GTA Stroke Network, Sunnybrook Health Sciences Centre , Toronto, ON, Canada.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Pacione', 'Affiliation': ""St. John's Rehab Research Program, Sunnybrook Research Institute , Toronto, ON, Canada.""}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Shaffer', 'Affiliation': ""St. John's Rehab Research Program, Sunnybrook Research Institute , Toronto, ON, Canada.""}, {'ForeName': 'Ada', 'Initials': 'A', 'LastName': 'Tang', 'Affiliation': 'School of Rehabilitation Science, McMaster University , Hamilton, ON, Canada.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'McEwen', 'Affiliation': ""St. John's Rehab Research Program, Sunnybrook Research Institute , Toronto, ON, Canada.""}]",Physiotherapy theory and practice,['10.1080/09593985.2020.1790068'] 2200,32748765,Increased hand hygiene compliance in nursing homes after a multimodal intervention: A cluster randomized controlled trial (HANDSOME).,"OBJECTIVE To assess the effect of a multimodal intervention on hand hygiene compliance (HHC) in nursing homes. DESIGN, SETTING, AND PARTICIPANTS HHC was evaluated using direct, unobtrusive observation in a cluster randomized controlled trial at publicly funded nursing homes in the Netherlands. In total, 103 nursing home organizations were invited to participate; 18 organizations comprising 33 nursing homes (n = 66 nursing home units) participated in the study. Nursing homes were randomized into a control group (no intervention, n = 30) or an intervention group (multimodal intervention, n = 36). The primary outcome measure was HHC of nurses. HHC was appraised at baseline and at 4, 7, and 12 months after baseline. Observers and nurses were blinded. INTERVENTION Audits regarding hand hygiene (HH) materials and personal hygiene rules, 3 live lessons, an e-learning program, posters, and a photo contest. We used a new method to teach the nurses the WHO-defined 5 moments of HH: Room In, Room Out, Before Clean, and After Dirty. RESULTS HHC increased in both arms. The increase after 12 months was larger for units in the intervention arm (from 12% to 36%) than for control units (from 13% to 21%) (odds ratio [OR], 2.10; confidence interval [CI], 1.35-3.28). The intervention arm exhibited a statistically significant increase in HHC at 4 of the 5 WHO-defined HH moments. At follow-up, HHC in the intervention arm remained statistically significantly higher (OR, 1.93; 95% CI, 1.59-2.34) for indications after an activity (from 37% to 39%) than for indications before an activity (from 14% to 27%). CONCLUSIONS The HANDSOME intervention is successful in improving HHC in nursing homes.",2020,"The increase after 12 months was larger for units in the intervention arm (from 12% to 36%) than for control units (from 13% to 21%) (odds ratio [OR], 2.10; confidence interval [CI], 1.35-3.28).","['Nursing homes', 'nursing homes', 'nurses the WHO-defined 5 moments of HH', 'nursing homes after a multimodal intervention', 'publicly funded nursing homes in the Netherlands', '103 nursing home organizations were invited to participate; 18 organizations comprising 33 nursing homes (n = 66 nursing home units) participated in the study']","['control group (no intervention, n = 30) or an intervention group (multimodal intervention', 'multimodal intervention']","['hygiene compliance', 'hand hygiene compliance (HHC', 'HHC of nurses', 'HHC']","[{'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C3494474', 'cui_str': 'Hand Hygiene'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0016820', 'cui_str': 'Funds'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0020405', 'cui_str': 'Hygiene'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C3494474', 'cui_str': 'Hand Hygiene'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}]",103.0,0.110308,"The increase after 12 months was larger for units in the intervention arm (from 12% to 36%) than for control units (from 13% to 21%) (odds ratio [OR], 2.10; confidence interval [CI], 1.35-3.28).","[{'ForeName': 'Gwen R', 'Initials': 'GR', 'LastName': 'Teesing', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'Vicki', 'Initials': 'V', 'LastName': 'Erasmus', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'Daan', 'Initials': 'D', 'LastName': 'Nieboer', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'Mariska', 'Initials': 'M', 'LastName': 'Petrignani', 'Affiliation': 'Municipal Public Health Service Haaglanden. Den Haag, The Netherlands.'}, {'ForeName': 'Marion P G', 'Initials': 'MPG', 'LastName': 'Koopmans', 'Affiliation': 'Viroscience Department, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'Margreet C', 'Initials': 'MC', 'LastName': 'Vos', 'Affiliation': 'Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Verduijn-Leenman', 'Affiliation': 'Pieter van Foreest, Delft, The Netherlands (retired).'}, {'ForeName': 'Jos M G A', 'Initials': 'JMGA', 'LastName': 'Schols', 'Affiliation': 'Department of Health Services Research and Department of Family Medicine, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Jan H', 'Initials': 'JH', 'LastName': 'Richardus', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'Helen A C M', 'Initials': 'HACM', 'LastName': 'Voeten', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.'}]",Infection control and hospital epidemiology,['10.1017/ice.2020.319'] 2201,32748972,Theory of mind and loneliness: Effects of a conversation-based training at school.,"Conversation-based training programmes are known to be effective in enhancing theory of mind (ToM). The possible consequences of such training programmes on the understanding of other constructs have rarely been investigated. The present research aimed to evaluate the effects of two different types of conversation-based training on ToM and loneliness. Two hundred and ten fourth and fifth graders (52% boys; Mage = 9.66 years, SD = 0.85), randomly divided into two groups (ToM and no-ToM training condition), were administered at a 5-week intervention. ToM and loneliness were measured before and twice after the intervention (1 week and 2 months later). Linear mixed-effects models showed that, soon after the intervention, children in the ToM training condition obtained significantly higher ToM scores and significantly lower loneliness scores compared to children in the no-ToM training condition. Nonetheless, at the follow-up, ToM and loneliness scores were not significantly different for the two training conditions. These findings suggest that a relatively short intervention based on group discussion of mental states is sufficient to improve mentalizing abilities and to tackle feelings of loneliness among fourth and fifth graders in the short but not in the long term.",2020,"Linear mixed-effects models showed that, soon after the intervention, children in the ToM training condition obtained significantly higher ToM scores and significantly lower loneliness scores compared to children in the no-ToM training condition.","['Two hundred and ten fourth and fifth graders (52% boys; Mage\xa0=\xa09.66\u2009years, SD\xa0=\xa00.85']","['conversation-based training', 'conversation-based training at school', 'Conversation-based training programmes']","['ToM and loneliness', 'ToM and loneliness scores', 'mentalizing abilities', 'loneliness scores', 'ToM scores']","[{'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0205438', 'cui_str': 'Fourth'}, {'cui': 'C0205439', 'cui_str': 'Fifth'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517483', 'cui_str': '0.85'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0036375', 'cui_str': 'School'}]","[{'cui': 'C0935573', 'cui_str': 'Theory of Mind'}, {'cui': 'C0023974', 'cui_str': 'Feeling lonely'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0085732', 'cui_str': 'Ability'}]",210.0,0.014564,"Linear mixed-effects models showed that, soon after the intervention, children in the ToM training condition obtained significantly higher ToM scores and significantly lower loneliness scores compared to children in the no-ToM training condition.","[{'ForeName': 'Marcella', 'Initials': 'M', 'LastName': 'Caputi', 'Affiliation': 'Department of Psychology, University of Turin, Turin, Italy.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Cugnata', 'Affiliation': 'University Centre for Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University, Milan, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Brombin', 'Affiliation': 'University Centre for Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University, Milan, Italy.'}]",International journal of psychology : Journal international de psychologie,['10.1002/ijop.12707'] 2202,32748975,Printed educational materials: effects on professional practice and healthcare outcomes.,"BACKGROUND Printed educational materials are widely used dissemination strategies to improve the quality of healthcare professionals' practice and patient health outcomes. Traditionally they are presented in paper formats such as monographs, publication in peer-reviewed journals and clinical guidelines. This is the fourth update of the review. OBJECTIVES To assess the effect of printed educational materials (PEMs) on the practice of healthcare professionals and patient health outcomes. To explore the influence of some of the characteristics of the printed educational materials (e.g. source, content, format) on their effect on healthcare professionals' practice and patient health outcomes. SEARCH METHODS We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), HealthStar, CINAHL, ERIC, CAB Abstracts, Global Health, and EPOC Register from their inception to 6 February 2019. We checked the reference lists of all included studies and relevant systematic reviews. SELECTION CRITERIA We included randomised trials (RTs), controlled before-after studies (CBAs) and interrupted time series studies (ITSs) that evaluated the impact of PEMs on healthcare professionals' practice or patient health outcomes. We included three types of comparisons: (1) PEM versus no intervention, (2) PEM versus single intervention, (3) multifaceted intervention where PEM is included versus multifaceted intervention without PEM. Any objective measure of professional practice (e.g. prescriptions for a particular drug), or patient health outcomes (e.g. blood pressure) were included. DATA COLLECTION AND ANALYSIS Two reviewers undertook data extraction independently. Disagreements were resolved by discussion. For analyses, we grouped the included studies according to study design, type of outcome and type of comparison. For controlled trials, we reported the median effect size for each outcome within each study, the median effect size across outcomes for each study and the median of these effect sizes across studies. Where data were available, we re-analysed the ITS studies by converting all data to a monthly basis and estimating the effect size from the change in the slope of the regression line between before and after implementation of the PEM. We reported median changes in slope for each outcome, for each study, and then across studies. We standardised all changes in slopes by their standard error, allowing comparisons and combination of different outcomes. We categorised each PEM according to potential effects modifiers related to the source of the PEMs, the channel used for their delivery, their content, and their format. We assessed the risks of bias of all the included studies. MAIN RESULTS We included 84 studies: 32 RTs, two CBAs and 50 ITS studies. Of the 32 RTs, 19 were cluster RTs that used various units of randomisation, such as practices, health centres, towns, or areas. The majority of the included studies (82/84) compared the effectiveness of PEMs to no intervention. Based on the RTs that provided moderate-certainty evidence, we found that PEMs distributed to healthcare professionals probably improve their practice, as measured with dichotomous variables, compared to no intervention (median absolute risk difference (ARD): 0.04; interquartile range (IQR): 0.01 to 0.09; 3,963 healthcare professionals randomised within 3073 units). We could not confirm this finding using the evidence gathered from continuous variables (standardised mean difference (SMD): 0.11; IQR: -0.16 to 0.52; 1631 healthcare professionals randomised within 1373 units ), from the ITS studies (standardised median change in slope = 0.69; 35 studies), or from the CBA study because the certainty of this evidence was very low. We also found, based on RTs that provided moderate-certainty evidence, that PEMs distributed to healthcare professionals probably make little or no difference to patient health as measured using dichotomous variables, compared to no intervention (ARD: 0.02; IQR: -0.005 to 0.09; 935,015 patients randomised within 959 units). The evidence gathered from continuous variables (SMD: 0.05; IQR: -0.12 to 0.09; 6,737 patients randomised within 594 units) or from ITS study results (standardised median change in slope = 1.12; 8 studies) do not strengthen these findings because the certainty of this evidence was very low. Two studies (a randomised trial and a CBA) compared a paper-based version to a computerised version of the same PEM. From the RT that provided evidence of low certainty, we found that PEM in computerised versions may make little or no difference to professionals' practice compared to PEM in printed versions (ARD: -0.02; IQR: -0.03 to 0.00; 139 healthcare professionals randomised individually). This finding was not strengthened by the CBA study that provided very low certainty evidence (SMD: 0.44; 32 healthcare professionals). The data gathered did not allow us to conclude which PEM characteristics influenced their effectiveness. The methodological quality of the included studies was variable. Half of the included RTs were at risk of selection bias. Most of the ITS studies were conducted retrospectively, without prespecifying the expected effect of the intervention, or acknowledging the presence of a secular trend. AUTHORS' CONCLUSIONS The results of this review suggest that, when used alone and compared to no intervention, PEMs may slightly improve healthcare professionals' practice outcomes and patient health outcomes. The effectiveness of PEMs compared to other interventions, or of PEMs as part of a multifaceted intervention, is uncertain.",2020,"Of the 32 RTs, 19 were cluster RTs that used various units of randomisation, such as practices, health centres, towns, or areas.","['84 studies: 32 RTs, two CBAs and 50 ITS studies']","['printed educational materials (PEMs', 'PEM versus no intervention, (2) PEM versus single intervention, (3) multifaceted intervention where PEM is included versus multifaceted intervention without PEM', 'PEMs', 'CBA']",[],"[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C3850091', 'cui_str': 'Controlled Before and After Studies'}]","[{'cui': 'C0033161', 'cui_str': 'Printing'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0047130', 'cui_str': '3-(2-phenylethyl)-4-methylsydnone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0025922', 'cui_str': 'Mouse, Inbred CBA'}]",[],,0.159797,"Of the 32 RTs, 19 were cluster RTs that used various units of randomisation, such as practices, health centres, towns, or areas.","[{'ForeName': 'Anik', 'Initials': 'A', 'LastName': 'Giguère', 'Affiliation': 'Department of Family Medicine and Emergency Medicine, Laval University, Québec, Canada.'}, {'ForeName': 'Hervé Tchala Vignon', 'Initials': 'HTV', 'LastName': 'Zomahoun', 'Affiliation': 'Health and Social Services Systems, Knowledge Translation and Implementation Component of the SPOR-SUPPORT Unit of Québec, Centre de recherche sur les soins et les services de première ligne - Université Laval, Quebec, Canada.'}, {'ForeName': 'Pierre-Hugues', 'Initials': 'PH', 'LastName': 'Carmichael', 'Affiliation': 'Quebec Excellence Centre on Aging (CEVQ), Québec City, Canada.'}, {'ForeName': 'Claude Bernard', 'Initials': 'CB', 'LastName': 'Uwizeye', 'Affiliation': 'Laval University Research Center on Primary Health Care and Services (CERSSPL-UL), Québec, Canada.'}, {'ForeName': 'France', 'Initials': 'F', 'LastName': 'Légaré', 'Affiliation': ""Centre de recherche sur les soins et les services de première ligne de l'Université Laval (CERSSPL-UL), Université Laval, Quebec, Canada.""}, {'ForeName': 'Jeremy M', 'Initials': 'JM', 'LastName': 'Grimshaw', 'Affiliation': 'Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada.'}, {'ForeName': 'Marie-Pierre', 'Initials': 'MP', 'LastName': 'Gagnon', 'Affiliation': 'Population Health and Optimal Health Practices Research Unit, CHU de Québec - Université Laval Research Centre, Québec City, Canada.'}, {'ForeName': 'David U', 'Initials': 'DU', 'LastName': 'Auguste', 'Affiliation': ""Département de médecine familiale et de médecine d'urgence, Université Laval, Québec, Canada.""}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Massougbodji', 'Affiliation': 'Health and Social Services Systems, Knowledge Translation and Implementation Component of the SPOR-SUPPORT Unit of Québec, Quebec SPOR-SUPPORT Unit, Québec, Canada.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD004398.pub4'] 2203,32749027,"Effect of humour intervention programme on depression, anxiety, subjective well-being, cognitive function and sleep quality in Chinese nursing home residents.","AIM To evaluate the effect of an 8-week humour intervention programme on reducing depression and anxiety and improving subjective well-being, cognitive function and sleep quality in nursing home residents. DESIGN A single-blinded and quasi-experimental design with repeated measures. METHODS Seventy-four older adults were recruited from May 2018-September 2018, with 37 older adults in the humour group received humour intervention and 37 in the control group received no intervention. The intervention was an 8-week humour intervention programme for older adults to learn to use humour and release their emotions. Primary outcomes include depression, anxiety and subjective well-being and secondary outcomes were cognitive function and sleep quality. Two-way repeated measures ANOVA was used to compare the differences of outcome measures between the two groups. Outcomes were measured at baseline, 8 and 16 weeks. RESULTS There was no significant difference between the two groups at baseline. The adherence to the sessions of humour intervention over the 8-weeks was 97.6%. Two-way repeated measures ANOVA revealed significant improvement in depression, anxiety, subjective well-being and sleep quality during the postintervention (8 weeks) and follow-up (16 weeks) periods in the humour group versus the control group. However, a significant time × group interaction for cognitive function was only found during postintervention. CONCLUSION The humour intervention programme was effective in reducing depression and anxiety symptoms and increasing subjective well-being, cognitive function and sleep quality in older adults. IMPACT Physical and mental health problems are common among older adults in nursing homes. The study demonstrated that humour intervention has feasibility and potential to be used as an effective non-pharmacological intervention in improving well-beings of Chinese nursing home residents. TRIAL REGISTRATION ChiCTR1800016148.",2020,"The humour intervention programme was effective in reducing depression and anxiety symptoms and increasing subjective well-being, cognitive function and sleep quality in older adults. ","['older adults', 'Chinese nursing home residents', 'older adults in nursing homes', 'Seventy-four older adults were recruited from May 2018-September 2018, with 37 older adults in the humour group received', 'nursing home residents']","['humour intervention', 'humour intervention and 37 in the control group received no intervention', 'humour intervention programme']","['depression, anxiety, subjective well-being, cognitive function and sleep quality', 'depression, anxiety, subjective well-being and sleep quality', 'depression and anxiety and improving subjective well-being, cognitive function and sleep quality', 'cognitive function', 'depression and anxiety symptoms and increasing subjective well-being, cognitive function and sleep quality', 'depression, anxiety and subjective well-being and secondary outcomes were cognitive function and sleep quality']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C4517867', 'cui_str': '74'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",74.0,0.0292749,"The humour intervention programme was effective in reducing depression and anxiety symptoms and increasing subjective well-being, cognitive function and sleep quality in older adults. ","[{'ForeName': 'Jinping', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'Department of Nursing, Zhongshan Hospital of Fudan University, Shanghai, China.'}, {'ForeName': 'Huiru', 'Initials': 'H', 'LastName': 'Yin', 'Affiliation': 'School of Nursing, Jilin University, Jilin, China.'}, {'ForeName': 'Xinxin', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'First Hospital of Jilin University, Jilin, China.'}, {'ForeName': 'Guangwei', 'Initials': 'G', 'LastName': 'Zhang', 'Affiliation': 'First Hospital of Jilin University, Jilin, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Jia', 'Affiliation': 'School of Nursing, Jilin University, Jilin, China.'}, {'ForeName': 'Binghan', 'Initials': 'B', 'LastName': 'Shang', 'Affiliation': 'School of Nursing, Jilin University, Jilin, China.'}, {'ForeName': 'Jinyang', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'Peking University Shenzhen graduate school, Peking, China.'}, {'ForeName': 'Chunyan', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'First Hospital of Jilin University, Jilin, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'School of Nursing, Jilin University, Jilin, China.'}]",Journal of advanced nursing,['10.1111/jan.14472'] 2204,32749561,Brushing associated with oral irrigation in maintaining implants and overdentures hygiene - a randomized clinical trial.,"Evaluate, through a randomized clinical trial, the efficacy of brushing associated with oral irrigation in maintaining implant and overdenture hygiene. Thirty-eight participants, who had a clinically acceptable conventional maxillary complete denture and mandibular overdenture retained by either implants or mini-implants using an O-ring-retained system, were enrolled to participate in the study. They were instructed to use two different hygiene methods, in a random sequence for a period of 14 days, with a 7-day wash-out interposed period: (I) mechanical brushing (MB); (II) association of mechanical brushing with oral irrigation (WP). Biofilms from both subgingival sulci and overdentures were collected and processed by Checkerboard DNA-DNA hybridization method at baseline and after using the proposed hygiene protocols. Comparisons were performed using Wilcoxon test and Friedman test with Benjamini-Hochberg false discovery rate, followed by Conover post-hoc test (α = 0.05). In the subgingival sulci-related biofilm, a lower number of microbial cells were detected, after WP compared to the MB method (P < 0.001). The findings of overdenture-related biofilm suggest that both methods were similar (P = 0.607) being the identified microbiota qualitatively coincident after each method. Despite the number of microbial counts, it was concluded that the association of mechanical brushing with oral irrigation was more effective in reducing microorganisms in the subgingival sulci biofilm; however, the same outcome was not observed in the overdentures.",2020,The findings of overdenture-related biofilm suggest that both methods were similar (P = 0.607) being the identified microbiota qualitatively coincident after each method.,"['Thirty-eight participants, who had a clinically acceptable conventional maxillary complete denture and mandibular overdenture retained by either implants or mini-implants using an O-ring-retained system, were enrolled to participate in the study']","['oral irrigation', '7-day wash-out interposed period: (I) mechanical brushing (MB); (II) association of mechanical brushing with oral irrigation (WP']",['number of microbial cells'],"[{'cui': 'C0450361', 'cui_str': '38'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0011455', 'cui_str': 'Complete denture'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0011459', 'cui_str': 'Overlay denture'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0521164', 'cui_str': 'Annular shape'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0399271', 'cui_str': 'Oral irrigation'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0040461', 'cui_str': 'Brushing of teeth'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}]",38.0,0.0465847,The findings of overdenture-related biofilm suggest that both methods were similar (P = 0.607) being the identified microbiota qualitatively coincident after each method.,"[{'ForeName': 'Marcela Moreira', 'Initials': 'MM', 'LastName': 'Salles', 'Affiliation': 'Department of Dental Materials and Prosthodontics, Dental School of Ribeirão Preto, University of São Paulo, Avenida do Café, SN, Ribeirão Preto, SP, 14040-904, Brazil.'}, {'ForeName': 'Viviane de Cássia', 'Initials': 'VC', 'LastName': 'Oliveira', 'Affiliation': 'Department of Dental Materials and Prosthodontics, Dental School of Ribeirão Preto, University of São Paulo, Avenida do Café, SN, Ribeirão Preto, SP, 14040-904, Brazil.'}, {'ForeName': 'Ana Paula', 'Initials': 'AP', 'LastName': 'Macedo', 'Affiliation': 'Department of Dental Materials and Prosthodontics, Dental School of Ribeirão Preto, University of São Paulo, Avenida do Café, SN, Ribeirão Preto, SP, 14040-904, Brazil.'}, {'ForeName': 'Cássio', 'Initials': 'C', 'LastName': 'do Nascimento', 'Affiliation': 'Department of Dental Materials and Prosthodontics, Dental School of Ribeirão Preto, University of São Paulo, Avenida do Café, SN, Ribeirão Preto, SP, 14040-904, Brazil.'}, {'ForeName': 'Cláudia Helena', 'Initials': 'CH', 'LastName': 'Silva-Lovato', 'Affiliation': 'Department of Dental Materials and Prosthodontics, Dental School of Ribeirão Preto, University of São Paulo, Avenida do Café, SN, Ribeirão Preto, SP, 14040-904, Brazil.'}, {'ForeName': 'Helena de Freitas Oliveira', 'Initials': 'HFO', 'LastName': 'Paranhos', 'Affiliation': 'Department of Dental Materials and Prosthodontics, Dental School of Ribeirão Preto, University of São Paulo, Avenida do Café, SN, Ribeirão Preto, SP, 14040-904, Brazil. helenpar@forp.usp.br.'}]",Odontology,['10.1007/s10266-020-00543-7'] 2205,32749579,Role of carbonated water technique to enhance Tc-99m tetrofosmin myocardial perfusion imaging by reducing subdiaphragmatic artefacts.,"OBJECTIVE Myocardial perfusion imaging (MPI) with single-photon emission computed tomography (SPECT) is confounded by the extracardiac artefacts cause by hepatobiliary clearance of the radiotracers. Various techniques have been evaluated to lessen those artefacts. In this study, we endeavoured to determine the effect of carbonated water in reducing such infracardiac artefact so to improve MPI image quality, sensitivity and specificity. METHODS A total of 1000 patients were prospectively enrolled and randomised into two equal groups as A and B. Group A were given 250 ml of carbonated beverages and Group B were given 250 ml plain water immediately after radiotracer injection. Images were evaluated qualitatively and quantitatively for the interfering extracardiac artefacts. RESULTS The qualitative analysis favoured carbonated water in reducing the interfering intestinal activity during rest as well as stress (p = 0.005 and p < 0.001, respectively). Quantitative calculation showed significant improvement of myocardium to extracardiac ratio with carbonated water ingestion in rest (p = 0.031) and vasodilator stress studies (p = 0.004). However, for exercise stress studies quantitative evaluation were not statistically different between the two protocols (p = 0.855). CONCLUSION Carbonated water ingestion is an easy and effective way to enhance SPECT image quality by mitigating extracardiac artefacts.",2020,"However, for exercise stress studies quantitative evaluation were not statistically different between the two protocols (p = 0.855). ",['A total of 1000 patients'],"['carbonated water technique', '250\xa0ml of carbonated beverages and Group B', 'carbonated', 'Myocardial perfusion imaging (MPI) with single-photon emission computed tomography (SPECT']","['MPI image quality, sensitivity and specificity', 'interfering intestinal activity', 'vasodilator stress studies']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C3494193', 'cui_str': 'Soda Water'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0007025', 'cui_str': 'Carbonated drink'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0007026', 'cui_str': 'Carbonate'}, {'cui': 'C2350390', 'cui_str': 'Myocardial Perfusion Imaging'}, {'cui': 'C0040399', 'cui_str': 'Single photon emission computerized tomography'}]","[{'cui': 'C0428857', 'cui_str': 'Myocardial perfusion'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0036668', 'cui_str': 'Sensitivity and Specificity'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0042402', 'cui_str': 'Vasodilator agent'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",1000.0,0.0302971,"However, for exercise stress studies quantitative evaluation were not statistically different between the two protocols (p = 0.855). ","[{'ForeName': 'Saba', 'Initials': 'S', 'LastName': 'Hussain', 'Affiliation': 'Department of Cardiology, National Institute of Cardiovascular Disease, Rafiqui (H.J) Shaheed Road, Karachi, Pakistan. sabahussain23@gmail.com.'}, {'ForeName': 'Fateh Ali Tipoo', 'Initials': 'FAT', 'LastName': 'Sultan', 'Affiliation': 'Cardiology Section, Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan.'}]",Annals of nuclear medicine,['10.1007/s12149-020-01504-4'] 2206,32749614,Correction to: Does antrum size matter in sleeve gastrectomy? A prospective randomized study.,This article was updated to correct Juan Antonio Carbonell Asíns' name in the author listing: Juan Antonio (given name) Carbonell Asíns (family name).,2020,This article was updated to correct Juan Antonio Carbonell Asíns' name in the author listing: Juan Antonio (given name),"[""correct Juan Antonio Carbonell Asíns' name in the author listing: Juan Antonio (given name""]",[],[],"[{'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C3812881', 'cui_str': 'Author'}, {'cui': 'C1443235', 'cui_str': 'Forename'}]",[],[],,0.0118661,This article was updated to correct Juan Antonio Carbonell Asíns' name in the author listing: Juan Antonio (given name),"[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Pizza', 'Affiliation': 'Department of Surgery, Hospital ""A. Rizzoli"", Aslnapoli2nord, Naples, Italy. Francesco_pizza@libero.it.'}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': ""D'Antonio"", 'Affiliation': 'Department of Surgery, Hospital ""A. Rizzoli"", Aslnapoli2nord, Naples, Italy.'}, {'ForeName': 'Francesco Saverio', 'Initials': 'FS', 'LastName': 'Lucido', 'Affiliation': 'Division of General, Mininvasive and Bariatric Surgery, University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Gambardella', 'Affiliation': 'Division of General, Mininvasive and Bariatric Surgery, University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Juan Antonio', 'Initials': 'JA', 'LastName': 'Carbonell Asíns', 'Affiliation': 'Bioinformatics and Biostatistics Unit, Biomedical Research Institute (INCLIVA), Valencia, Spain.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': ""Dell'Isola"", 'Affiliation': 'Department of Infectious Diseases, AORN ""Dei Colli"", Naples, Italy.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Tolone', 'Affiliation': 'Division of General, Mininvasive and Bariatric Surgery, University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}]",Surgical endoscopy,['10.1007/s00464-020-07863-3'] 2207,32749625,Web-Based Cognitive Training to Improve Working Memory in Persons with Co-Occurring HIV Infection and Cocaine Use Disorder: Outcomes from a Randomized Controlled Trial.,"Neurocognitive impairment (NCI) remains a persistent complication of HIV disease that nearly half of persons with HIV experience, and rates are even higher in persons who use substances such as cocaine. Cognitive training is a promising intervention for HIV-associated NCI. In this randomized controlled trial, we examined the feasibility and effectiveness of a web-based cognitive training program to improve working memory in a sample of 58 persons with HIV and cocaine use disorder. Participants were randomly assigned to either the experimental working memory training arm or the attention control training arm and completed up to 48 daily sessions over 10 weeks. Overall, treatment completion (74%) and retention rates (97%) were high, and participant feedback indicated the intervention was acceptable. Our results show that the intervention successfully reduced working memory deficits in the experimental arm relative to the control arm. Our findings support both the feasibility and effectiveness of cognitive training in this population.",2020,Participants were randomly assigned to either the experimental working memory training arm or the attention control training arm and completed up to 48 daily sessions over 10 weeks.,"['Persons with Co-Occurring HIV Infection and Cocaine Use Disorder', '58 persons with HIV and cocaine use disorder']","['Cognitive training', 'cognitive training', 'Web-Based Cognitive Training', 'web-based cognitive training program', 'experimental working memory training arm or the attention control training']","['working memory deficits', 'retention rates', 'working memory']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0019693', 'cui_str': 'Human immunodeficiency virus infection'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}]",58.0,0.0536141,Participants were randomly assigned to either the experimental working memory training arm or the attention control training arm and completed up to 48 daily sessions over 10 weeks.,"[{'ForeName': 'Sheri L', 'Initials': 'SL', 'LastName': 'Towe', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Duke University School of Medicine, Box 102848, Durham, NC, 27710, USA. sheri.towe@duke.edu.'}, {'ForeName': 'Jeremiah T', 'Initials': 'JT', 'LastName': 'Hartsock', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Duke University School of Medicine, Box 102848, Durham, NC, 27710, USA.'}, {'ForeName': 'Yunan', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Duke University School of Medicine, Box 102848, Durham, NC, 27710, USA.'}, {'ForeName': 'Christina S', 'Initials': 'CS', 'LastName': 'Meade', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Duke University School of Medicine, Box 102848, Durham, NC, 27710, USA.'}]",AIDS and behavior,['10.1007/s10461-020-02993-0'] 2208,32740321,Minimum effective volume of 0.5% ropivacaine for ultrasound-guided costoclavicular brachial plexus block: A dose finding study.,"BACKGROUND Costoclavicular brachial plexus block (CC-BPB) is a relatively new regional anaesthetic technique and there are no data on the minimum effective volume 90 (MEV90) of 0.5% ropivacaine required for an ultrasound-guided CC-BPB. OBJECTIVE To determine the MEV90 of 0.5% ropivacaine required to produce surgical anaesthesia with an ultrasound-guided CC-BPB. DESIGN Prospective up-down sequential allocation study design. SETTING University teaching hospital in Hong Kong from March 2016 to December 2017. PATIENTS Forty-eight, ASA physical status I to III patients, aged 70 years or less and scheduled for elective forearm or hand surgery under an ultrasound-guided CC-BPB, were recruited. INTERVENTION Ultrasound-guided CC-BPB was performed with the assigned volume of 0.5% ropivacaine. The Dixon 'up-and-down' sequential allocation method using the biased coin design was used to determine the MEV90 of 0.5% ropivacaine. The assigned volume of ropivacaine was based on the outcome of the previous patient. After a block failure the next patient received a volume increase of 2 ml. If the block was a success, the next patient was allocated, with a probability of b = 0.11, to receive 2 ml less, or, with a probability of 1 - b = 0.89, the same volume. MAIN OUTCOME MEASURES A successful block was defined as a minimum score of 14 of 16 points, using a composite sensory and motor block score at 45 min after the injection. The study was stopped when 45 successful blocks were achieved. MEV90 with 95% confidence interval was calculated using the centred isotonic regression for point and interval dose response studies. RESULTS The MEV90 of 0.5% ropivacaine for ultrasound-guided CC-BPB was 20.9 (95% confidence interval, 20.7 to 21.8) ml. The mean ± SD time to readiness for surgery was 31.4 ± 12.60 min. CONCLUSION The MEV90 of 0.5% ropivacaine required to produce surgical anaesthesia with an ultrasound-guided CC-BPB is 20.9 ml. CLINICAL TRIAL REGISTRATION The trial was registered with the Chinese Clinical Trials Registry (www.chictr.org.cn, ChiCTR-IOR-15007515, principal investigator: Manoj Kumar Karmakar, date of registration: 4 December 2015). CLINICAL TRIAL NUMBER AND REGISTRY URL ChiCTR-IOR-15007515, Chinese Clinical Trials Registry (www.chictr.org.cn).",2020,"The MEV90 of 0.5% w/v ropivacaine required to produce surgical anaesthesia with an ultrasound-guided CC-BPB is 20.9 ml. ","['III patients, aged 70 years or less and scheduled for elective forearm or hand surgery under an ultrasound-guided CC-BPB, were recruited', 'University teaching hospital in Hong Kong from March 2016 to December 2017', 'Forty-eight, ASA physical status']","['ropivacaine', 'Costoclavicular brachial plexus block (CC-BPB']",['mean\u200a±\u200aSD time to readiness'],"[{'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0016536', 'cui_str': 'Forearm structure'}, {'cui': 'C0187067', 'cui_str': 'Operative procedure on hand'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C1608675', 'cui_str': '4-iodo-N-(4-(4-(2-methoxyphenyl)-piperazin-1-yl)butyl)-benzamide'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0019907', 'cui_str': 'Hong Kong'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449438', 'cui_str': 'Status'}]","[{'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0394697', 'cui_str': 'Injection of anesthetic agent into brachial plexus'}, {'cui': 'C1608675', 'cui_str': '4-iodo-N-(4-(4-(2-methoxyphenyl)-piperazin-1-yl)butyl)-benzamide'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}]",45.0,0.0788485,"The MEV90 of 0.5% w/v ropivacaine required to produce surgical anaesthesia with an ultrasound-guided CC-BPB is 20.9 ml. ","[{'ForeName': 'Ming H', 'Initials': 'MH', 'LastName': 'Wong', 'Affiliation': 'From the Department of Anaesthesia & Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China (MHW, MKK, LYHM, BS, WS).'}, {'ForeName': 'Manoj K', 'Initials': 'MK', 'LastName': 'Karmakar', 'Affiliation': ''}, {'ForeName': 'Louis Y H', 'Initials': 'LYH', 'LastName': 'Mok', 'Affiliation': ''}, {'ForeName': 'Banchobporn', 'Initials': 'B', 'LastName': 'Songthamwat', 'Affiliation': ''}, {'ForeName': 'Winnie', 'Initials': 'W', 'LastName': 'Samy', 'Affiliation': ''}]",European journal of anaesthesiology,['10.1097/EJA.0000000000001287'] 2209,32740327,Effects of a Mind Map-Based Life Review Program on Anxiety and Depressive Symptoms on Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial.,"BACKGROUND Cancer patients undergoing chemotherapy often experience psychological distress. The mind map-based life review program (MBLRP) offers the potential to reduce patients' negative emotions. However, its effects remain unknown. OBJECTIVE The objective of this study is to determine the effects of the MBLRP on anxiety and depressive symptoms in cancer patients undergoing chemotherapy. METHODS A randomized controlled trial with repeated measures was adopted. Eighty-four cancer patients undergoing chemotherapy were recruited from a general hospital in Fujian, China. Participants were randomly assigned to an experimental group (n = 40) or a control group (n = 44). The participants in the experimental group received the MBLRP plus routine care. The participants in the control group received routine care. Outcomes were measured at baseline, on the second day, and at 4 weeks after the MBLRP. RESULTS In terms of anxiety, multivariate test statistics showed significant differences in within-group (F = 11.343, P < .001), between-group (F = 8.873, P = .004), and interaction effects (group × time) (F = 19.595, P < .001). For the depressive symptoms, the results showed that the within-group effect (F = 12.385, P < .001), group effect (F = 18.000, P < .001), and group × time effect (F = 26.544, P < .001) were statistically significant, favoring the MBLRP experimental group. CONCLUSIONS The MBLRP has the potential to reduce anxiety and depressive symptoms in cancer patients undergoing chemotherapy. Further research is needed within larger more representative samples. IMPLICATIONS FOR PRACTICE The MBLRP is a nurse-led, nonpharmacological program that could be recommended for cancer patients undergoing chemotherapy and integrated into clinical practice.",2020,"In terms of anxiety, multivariate test statistics showed significant differences in within-group (F = 11.343, P < .001), between-group (F = 8.873, P = .004), and interaction effects (group × time) (F = 19.595, P < .001).","['Cancer patients undergoing chemotherapy often experience psychological distress', 'Cancer Patients', 'cancer patients undergoing chemotherapy', 'cancer patients undergoing', 'Eighty-four cancer patients undergoing chemotherapy were recruited from a general hospital in Fujian, China']","['routine care', 'Mind Map-Based Life Review Program', 'Undergoing Chemotherapy', 'MBLRP', 'MBLRP plus routine care', 'chemotherapy']","['anxiety and depressive symptoms', 'Anxiety and Depressive Symptoms', 'interaction effects']","[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C4319623', 'cui_str': '84'}, {'cui': 'C0020008', 'cui_str': 'Hospitals, General'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0024779', 'cui_str': 'Maps'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",84.0,0.186932,"In terms of anxiety, multivariate test statistics showed significant differences in within-group (F = 11.343, P < .001), between-group (F = 8.873, P = .004), and interaction effects (group × time) (F = 19.595, P < .001).","[{'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Author Affiliations: School of Nursing, Fujian Medical University (Drs Chen, Xiao, and Zheng); and Department of Oncology, Fujian Medical University Union Hospital (Drs Zheng and Lin), Fuzhou, China.'}, {'ForeName': 'Jianwei', 'Initials': 'J', 'LastName': 'Zheng', 'Affiliation': ''}, {'ForeName': 'Huimin', 'Initials': 'H', 'LastName': 'Xiao', 'Affiliation': ''}, {'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Lin', 'Affiliation': ''}, {'ForeName': 'Xiaoling', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ''}]",Cancer nursing,['10.1097/NCC.0000000000000874'] 2210,32740328,Effectiveness of Self-administered Acupressure for Family Caregivers of Advanced Cancer Patients With Insomnia: A Randomized Controlled Trail.,"BACKGROUND Sleep disturbances are common among family caregivers (FCs) of patients with advanced cancer. Self-administered acupressure can combat insomnia, but no study has been conducted to evaluate its efficacy in caregivers of patients with advanced cancer. OBJECTIVE The aim of this study is to investigate whether self-administered acupressure improves sleep quality for FCs of patients with advanced cancer. METHODS Family caregivers of patients with advanced cancer who reported sleep disturbance (Pittsburgh Sleep Quality Index scores >5 in recent months) were recruited. The experimental group self-administered acupressure at the Baihui (GV20), Fengchi (GB20), Neiguan (PC6), and Shenmen (HT7) points over a 12-week period, whereas the comparison group received sleep hygiene education. Sleep quality was assessed subjectively at 4, 8, and 12 weeks after the intervention using the Pittsburgh Sleep Quality Index and objectively using actigraphy measurements. Improvements in sleep quality were analyzed using a generalized estimating equation. RESULTS Compared with the control group, the experimental group demonstrated significantly lower sleep latency (Wald χ = 11.49, P = .001) and significantly better sleep efficiency (Wald χ = 5.24, P = .02) according to actigraphy measurements, but Pittsburgh Sleep Quality Index scores did not differ significantly between the groups. CONCLUSIONS Self-administered acupressure did not demonstrate favorable effects on subjective sleep quality, but did reduce sleep latency and improve sleep efficiency, according to actigraphy measurements. Self-administered acupressure may help relaxation and sedation and promote sleep in FCs. IMPLICATIONS FOR PRACTICE Healthcare providers may consider advising FCs to apply this self-administered acupressure to improve their sleep latency and sleep efficiency.",2020,"Compared with the control group, the experimental group demonstrated significantly lower sleep latency (Wald χ = 11.49, P = .001) and significantly better sleep efficiency (Wald χ = 5.24, P = .02) according to actigraphy measurements, but Pittsburgh Sleep Quality Index scores did not differ significantly between the groups. ","['Family Caregivers of Advanced Cancer Patients With Insomnia', 'patients with advanced cancer', 'family caregivers (FCs) of patients with advanced cancer', 'Family caregivers of patients with advanced cancer who reported', 'caregivers of patients with advanced cancer']","['Self-administered Acupressure', 'acupressure', 'acupressure at the Baihui (GV20), Fengchi (GB20), Neiguan (PC6), and Shenmen (HT7) points over a 12-week period, whereas the comparison group received sleep hygiene education', 'Self-administered acupressure']","['subjective sleep quality', 'Pittsburgh Sleep Quality Index scores', 'sleep disturbance (Pittsburgh Sleep Quality Index scores', 'sleep latency and improve sleep efficiency', 'Sleep quality', 'sleep latency', 'Pittsburgh Sleep Quality Index and objectively using actigraphy measurements', 'sleep quality', 'sleep efficiency', 'sleep latency and sleep efficiency']","[{'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0282614', 'cui_str': 'Acupressure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4277672', 'cui_str': 'Good Sleep Habits'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C4545801', 'cui_str': 'Pittsburgh Sleep Quality Index score'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C4505222', 'cui_str': 'Sleep Onset Latency'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",,0.0182259,"Compared with the control group, the experimental group demonstrated significantly lower sleep latency (Wald χ = 11.49, P = .001) and significantly better sleep efficiency (Wald χ = 5.24, P = .02) according to actigraphy measurements, but Pittsburgh Sleep Quality Index scores did not differ significantly between the groups. ","[{'ForeName': 'Kwo-Chen', 'Initials': 'KC', 'LastName': 'Lee', 'Affiliation': 'Author Affiliations: School of Nursing, China Medical University, and Department of Nursing, China Medical University Hospital (Drs Lee, Lin, and Wang); and College of Nursing, Hungkuang University (Dr Chao), Taichung, Taiwan.'}, {'ForeName': 'Yann-Fen C', 'Initials': 'YC', 'LastName': 'Chao', 'Affiliation': ''}, {'ForeName': 'Yun-Ping', 'Initials': 'YP', 'LastName': 'Lin', 'Affiliation': ''}, {'ForeName': 'Hsiao-Chiao', 'Initials': 'HC', 'LastName': 'Wang', 'Affiliation': ''}]",Cancer nursing,['10.1097/NCC.0000000000000870'] 2211,32740409,Effect of direct renin inhibition on vascular function after long-term treatment with aliskiren in hypertensive and diabetic patients.,"OBJECTIVE We tested the hypothesis that chronic treatment with the direct renin inhibitor aliskiren improves vascular function in resistance and conduit arteries of type two diabetic and hypertensive patients. METHOD Sixteen patients with mild essential hypertension and with a previous diagnosis of noninsulin-dependent diabetes mellitus were included in the study. Patients were then randomized to aliskiren (150 mg once daily, n = 9), or ramipril (5 mg once daily, n = 7). Each patient underwent a biopsy of the subcutaneous tissue and small arteries were dissected and mounted on a pressurized micromyograph to evaluate endothelium dependent vasorelaxation in response to acetylcholine ± N omega-nitro-L-arginine methyl ester hydrochloride in vessels precontracted with norepinephrine. Endothelial function has been quantified also in large conduit arteries by flow-mediated dilation. RESULTS A similar office blood pressure-lowering effect was observed with the two drugs, although changes in DBP were not statistically significant in the ramipril group. Aliskiren significantly improved endothelium-dependent relaxation in subcutaneous resistance arteries, as well as increased flow-mediated dilation in conduit arteries, whereas the effects induced by ramipril did not reach statistical significance. Only aliskiren significantly increased the expression of p1177-endothelial nitric oxide synthase in the endothelium. Both aliskiren and ramipril had a negligible effect on markers of oxidative stress. CONCLUSION Aliskiren restored endothelial function and induced a more prompt peripheral vasodilation in hypertensive and diabetic patients possibly through the increased production of nitric oxide via the enhanced expression and function of the active phosphorylated form of endothelial nitric oxide synthase.",2020,"A similar office blood pressure-lowering effect was observed with the two drugs, although changes in DBP were not statistically significant in the ramipril group.","['Sixteen patients with mild essential hypertension and with a previous diagnosis of noninsulin-dependent diabetes mellitus were included in the study', 'hypertensive and diabetic patients', 'type two diabetic and hypertensive patients']","['aliskiren', 'direct renin inhibition', 'Aliskiren', 'direct renin inhibitor aliskiren', 'ramipril', 'aliskiren and ramipril', 'N omega-nitro-L-arginine methyl ester hydrochloride', 'norepinephrine']","['markers of oxidative stress', 'endothelial function', 'expression of p1177-endothelial nitric oxide synthase', 'office blood pressure-lowering effect', 'changes in DBP', 'vascular function', 'endothelium-dependent relaxation']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0085580', 'cui_str': 'Essential hypertension'}, {'cui': 'C0332132', 'cui_str': 'Prior diagnosis'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C1120110', 'cui_str': 'aliskiren'}, {'cui': 'C0373719', 'cui_str': 'Renin measurement'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0072973', 'cui_str': 'Ramipril'}, {'cui': 'C0083536', 'cui_str': 'N(G)-Nitroarginine Methyl Ester'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}]","[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0669365', 'cui_str': 'NOS3 protein, human'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}]",16.0,0.048178,"A similar office blood pressure-lowering effect was observed with the two drugs, although changes in DBP were not statistically significant in the ramipril group.","[{'ForeName': 'Carmine', 'Initials': 'C', 'LastName': 'Savoia', 'Affiliation': ""Division of Cardiology, Clinical and Molecular Medicine Department, Sant'Andrea Hospital, Sapienza University of Rome, Rome.""}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'De Ciuceis', 'Affiliation': 'Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, Brescia.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Paini', 'Affiliation': 'Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, Brescia.'}, {'ForeName': 'Raffaella', 'Initials': 'R', 'LastName': 'Carletti', 'Affiliation': 'Department of Radiological, Oncological and Pathological Sciences.'}, {'ForeName': 'Emanuele', 'Initials': 'E', 'LastName': 'Arrabito', 'Affiliation': ""Division of Cardiology, Clinical and Molecular Medicine Department, Sant'Andrea Hospital, Sapienza University of Rome, Rome.""}, {'ForeName': 'Carmine', 'Initials': 'C', 'LastName': 'Nicoletti', 'Affiliation': 'Section of Histology and Medical Embryology, Department of Anatomy, Histology, Forensic Medicine and Orthopaedics.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Mercantini', 'Affiliation': ""Surgical Department of Clinical Sciences Biomedical Technologies and Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.""}, {'ForeName': 'Cira', 'Initials': 'C', 'LastName': 'Di Gioia', 'Affiliation': 'Department of Radiological, Oncological and Pathological Sciences.'}, {'ForeName': 'Allegra', 'Initials': 'A', 'LastName': 'Battistoni', 'Affiliation': ""Division of Cardiology, Clinical and Molecular Medicine Department, Sant'Andrea Hospital, Sapienza University of Rome, Rome.""}, {'ForeName': 'Sarassunta', 'Initials': 'S', 'LastName': 'Ucci', 'Affiliation': ""Division of Cardiology, Clinical and Molecular Medicine Department, Sant'Andrea Hospital, Sapienza University of Rome, Rome.""}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Filippini', 'Affiliation': 'Section of Histology and Medical Embryology, Department of Anatomy, Histology, Forensic Medicine and Orthopaedics.'}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Agabiti Rosei', 'Affiliation': 'Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, Brescia.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Volpe', 'Affiliation': ""Division of Cardiology, Clinical and Molecular Medicine Department, Sant'Andrea Hospital, Sapienza University of Rome, Rome.""}, {'ForeName': 'Maria L', 'Initials': 'ML', 'LastName': 'Muiesan', 'Affiliation': 'Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, Brescia.'}, {'ForeName': 'Damiano', 'Initials': 'D', 'LastName': 'Rizzoni', 'Affiliation': 'Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, Brescia.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Salvetti', 'Affiliation': 'Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, Brescia.'}]",Journal of hypertension,['10.1097/HJH.0000000000002595'] 2212,32740502,Evaluation of Intranasal Dexmedetomidine as a Procedural Sedative for Ophthalmic Examination of Children With Glaucoma.,"PRECIS This study evaluated 2 doses of intranasal dexmedetomidine (IND) (3.0 and 3.5 µg/kg) as a procedural sedative for postoperative examination of children with glaucoma. A dose of 3.5 µg/kg was more efficacious and obviated the need for repeated general anesthesia. PURPOSE This study was carried out to determine the safety and effective dose of IND as a procedural sedative for postoperative follow-up examinations after glaucoma surgery in children in place of repeated examination under anesthesia. MATERIALS AND METHODS In this prospective randomized double-blinded interventional study, consecutive children aged 6 months to 6 years were randomized to receive 3.0 and 3.5 µg/kg IND using a mucosal atomizer device in the preoperative area of the operating room, under continuous monitoring of vital signs. Intranasal midazolam 0.25 mg/kg was used as a rescue agent in case of inadequate sedation, and general anesthesia was administered in case of persistent failure. All infants underwent a complete anterior and posterior segment evaluation including intraocular pressure and corneal diameter measurements. RESULTS A total of 30 and 31 children aged 23.9±15.0 and 19.2±10.1 months, respectively, received 3.0 and 3.5 µg/kg IND. Adequate sedation was possible in 18 of 30 (60%) children receiving 3.0 µg/kg and 24 of 31 (77.4%) receiving 3.5 µg/kg IND alone (P=0.17). In combination with midazolam, successful sedations were 86.6% versus 100%, respectively (P=0.052). One patient in the 3.5 µg/kg group had ventricular arrhythmia, reversed with dextrose-saline infusion and injection glycopyrrolate. CONCLUSIONS IND appears to be a safe and effective procedural sedative for postoperative follow-up examinations of pediatric glaucoma patients at doses of 3 and 3.5 µg/kg. The dose of 3.5 µg/kg was successful in more children.",2020,"In combination with midazolam, successful sedations were 86.6% versus 100%, respectively (P=0.052).","['children with glaucoma', 'Children With Glaucoma', 'children in place of repeated examination under anesthesia', 'A total of 30 and 31 children aged 23.9±15.0 and 19.2±10.1 months, respectively, received 3.0 and 3.5\u2009µg/kg IND', 'consecutive children aged 6 months to 6 years']","['IND', 'dextrose-saline infusion and injection glycopyrrolate', 'Intranasal Dexmedetomidine', 'midazolam', 'intranasal dexmedetomidine (IND', 'Intranasal midazolam']","['Adequate sedation', 'successful sedations', 'intraocular pressure and corneal diameter measurements', 'ventricular arrhythmia']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0558588', 'cui_str': 'Examination under anesthesia'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0017970', 'cui_str': 'Glycopyrrolate'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}]","[{'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0429514', 'cui_str': 'Corneal diameter'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0085612', 'cui_str': 'Ventricular arrhythmia'}]",,0.297403,"In combination with midazolam, successful sedations were 86.6% versus 100%, respectively (P=0.052).","[{'ForeName': 'Deepika', 'Initials': 'D', 'LastName': 'Dhingra', 'Affiliation': 'Advanced Eye Centre.'}, {'ForeName': 'Babita', 'Initials': 'B', 'LastName': 'Ghai', 'Affiliation': 'Department of Anaesthesiology and Critical Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Pranshuta', 'Initials': 'P', 'LastName': 'Sabharwal', 'Affiliation': 'Department of Anaesthesiology and Critical Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Vikas', 'Initials': 'V', 'LastName': 'Saini', 'Affiliation': 'Department of Anaesthesiology and Critical Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Sagarika', 'Initials': 'S', 'LastName': 'Snehi', 'Affiliation': 'Advanced Eye Centre.'}, {'ForeName': 'Manpreet', 'Initials': 'M', 'LastName': 'Kaur', 'Affiliation': 'Advanced Eye Centre.'}, {'ForeName': 'Surinder S', 'Initials': 'SS', 'LastName': 'Pandav', 'Affiliation': 'Advanced Eye Centre.'}, {'ForeName': 'Sushmita', 'Initials': 'S', 'LastName': 'Kaushik', 'Affiliation': 'Advanced Eye Centre.'}]",Journal of glaucoma,['10.1097/IJG.0000000000001607'] 2213,32740578,Abdominoplasty with Scarpa Fascia Preservation: Randomized Controlled Trial with Assessment of Scar Quality and Cutaneous Sensibility.,"BACKGROUND Scarpa fascia preservation during abdominoplasty has been shown to reduce complications associated with the traditional technique. As an extension of a previously published randomized controlled trial, this study aims to clarify whether preservation of Scarpa fascia during abdominoplasty has an influence on scar quality or sensibility recovery. METHODS This was a single-center clinical trial, involving 160 patients randomly assigned to one of two surgical procedures: classic full abdominoplasty (group A) and abdominoplasty with preservation of Scarpa fascia (group B). Patients were later convoked to assess scar quality and abdominal cutaneous sensibility. Scar quality was evaluated through the Patient and Observer Scar Assessment Scale. Cutaneous sensibility was measured on the upper and lower abdomen, using light touch, Semmes-Weinstein testing (5.07/10-g monofilament), and a 25-gauge needle. RESULTS A total of 99 patients (group A, 54 patients; group B, 45 patients) responded to contact, with a mean follow-up time of 44 months. Concerning scar quality, Patient and Observer Scar Assessment Scale scores were similar between groups. On the upper abdomen, there was a statistically significant difference between groups on cutaneous sensibility, on the examination with the Semmes-Weinstein 5.07/10-g monofilament (group A, 79.6 percent; group B, 93.3 percent; p = 0.046) and pain (group A, 90.7 percent; group B, 100 percent; p = 0.044). No statistically significant differences were found between groups on the lower abdomen. A considerable proportion of patients (two-thirds) still presented sensibility alterations in the subumbilical area 3½ years after abdominoplasty. CONCLUSION Scarpa fascia preservation during abdominoplasty does not influence scar quality, but it improves sensibility recovery in the supraumbilical area. CLINICAL QUESTION/LEVEL OF EVIDENCE Therapeutic, II.",2020,"On the upper abdomen, there was a statistically significant difference between groups on cutaneous sensibility, on the examination with the Semmes-Weinstein 5.07/10-g monofilament (group A, 79.6 percent; group B, 93.3 percent; p = 0.046) and pain (group A, 90.7 percent; group B, 100 percent; p = 0.044).","['99 patients (group A, 54 patients; group B, 45 patients', '160 patients randomly assigned to one of two surgical procedures']","['classic full abdominoplasty (group A) and abdominoplasty with preservation of Scarpa fascia', 'Abdominoplasty with Scarpa Fascia Preservation']","['Patient and Observer Scar Assessment Scale', 'Cutaneous sensibility', 'Concerning scar quality, Patient and Observer Scar Assessment Scale scores', 'Scar quality', 'sensibility recovery', 'scar quality or sensibility recovery', 'scar quality', 'pain', 'scar quality and abdominal cutaneous sensibility', 'Scar Quality and Cutaneous Sensibility', 'cutaneous sensibility']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]","[{'cui': 'C0439658', 'cui_str': 'Classic'}, {'cui': 'C0198542', 'cui_str': 'Repair of abdominal wall'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0015641', 'cui_str': 'Fascial'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0439823', 'cui_str': 'Sensibilities'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}]",160.0,0.0753179,"On the upper abdomen, there was a statistically significant difference between groups on cutaneous sensibility, on the examination with the Semmes-Weinstein 5.07/10-g monofilament (group A, 79.6 percent; group B, 93.3 percent; p = 0.046) and pain (group A, 90.7 percent; group B, 100 percent; p = 0.044).","[{'ForeName': 'Catarina S', 'Initials': 'CS', 'LastName': 'Novais', 'Affiliation': 'Porto, Portugal From Porto University Medical School; the Department of Plastic, Aesthetic, and Reconstructive Surgery, São João University Hospital; the Department of Surgery and Physiology, Faculty of Medicine, Porto University; the Plastic Surgery Department, Portuguese Institute of Oncology of Porto; the Interdisciplinary Centre of Marine and Environmental Research; and the Department of Biology, Faculty of Sciences, University of Porto.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Carvalho', 'Affiliation': ''}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Valença-Filipe', 'Affiliation': ''}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Rebelo', 'Affiliation': ''}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Peres', 'Affiliation': ''}, {'ForeName': 'António', 'Initials': 'A', 'LastName': 'Costa-Ferreira', 'Affiliation': ''}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000007024'] 2214,32740676,Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.,"OBJECTIVE Patients with schizophrenia are at higher risk of cardiovascular morbidity and mortality than healthy individuals. This study was conducted to compare the effect of lurasidone and olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia. METHODS The present study was a randomized open-label, parallel design, active-controlled clinical trial. After recruitment and randomization of 101 patients, a baseline assessment was done by PANSS, SOFAS, lipid profile, fasting blood glucose, HbA 1c , serum insulin and serum hs-CRP. HOMA-IR, atherogenic index, coronary risk index and cardiovascular risk indices were calculated as derived parameters. Patients received either lurasidone 80 mg or olanzapine 10 mg as monotherapy and followed up after 6 weeks. RESULTS There was a significant increase in fasting blood glucose (p < 0.001), HbA 1c (p < 0.001) and serum insulin (p < 0.001) after 6 weeks of therapy in both the treatment groups but the difference between the groups was not significant (FBS, p = 0.209; HbA1c, p = 0.209; serum insulin, p = 0.720). Olanzapine showed worsening of lipid profile (p < 0.001) while the same improved with lurasidone (p < 0.001) and the difference between the groups was found to be significant (p < 0.001). Serum HDL level decreased in both the treatment groups (olanzapine, p < 0.001; lurasidone, p < 0.001) but the difference between the groups was not significant (p = 0.333). There was an increase in hs-CRP levels in both the treatment groups (olanzapine, p < 0.001; lurasidone, p < 0.001) with no significant difference between them (p = 0.467). Atherogenic index, coronary risk index and cardiovascular risk index increased significantly in the olanzapine group as compared with the lurasidone group (p < 0.001). CONCLUSION Lurasidone showed a favourable effect on lipid profile and cardiovascular risk indices over olanzapine. However, long-term studies are needed to establish and generalize the findings. TRIAL REGISTRATION ClinicalTrials.gov NCT03304457.",2020,"There was a significant increase in fasting blood glucose (p < 0.001), HbA 1c (p < 0.001) and serum insulin (p < 0.001) after 6 weeks of therapy in both the treatment groups but the difference between the groups was not significant (FBS, p = 0.209; HbA1c, p = 0.209; serum insulin, p = 0.720).","['unmedicated patients with schizophrenia', 'Patients with schizophrenia']","['olanzapine', 'lurasidone', 'Olanzapine', 'lurasidone and olanzapine', 'lurasidone 80 mg or olanzapine 10 mg as monotherapy']","['fasting blood glucose', 'cardiometabolic parameters', 'serum insulin', 'Serum HDL level', 'Atherogenic index, coronary risk index and cardiovascular risk index', 'lipid profile and cardiovascular risk indices', 'PANSS, SOFAS, lipid profile, fasting blood glucose, HbA 1c , serum insulin and serum hs-CRP', 'cardiovascular morbidity and mortality', 'hs-CRP levels', 'HOMA-IR, atherogenic index, coronary risk index and cardiovascular risk indices', 'worsening of lipid profile']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}]","[{'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C2003424', 'cui_str': 'lurasidone'}, {'cui': 'C0988260', 'cui_str': 'olanzapine 10 MG'}]","[{'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C1301700', 'cui_str': 'Cardiovascular morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}]",101.0,0.0355811,"There was a significant increase in fasting blood glucose (p < 0.001), HbA 1c (p < 0.001) and serum insulin (p < 0.001) after 6 weeks of therapy in both the treatment groups but the difference between the groups was not significant (FBS, p = 0.209; HbA1c, p = 0.209; serum insulin, p = 0.720).","[{'ForeName': 'Monalisa', 'Initials': 'M', 'LastName': 'Jena', 'Affiliation': 'Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.'}, {'ForeName': 'Archana', 'Initials': 'A', 'LastName': 'Mishra', 'Affiliation': 'Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Biswa Ranjan', 'Initials': 'BR', 'LastName': 'Mishra', 'Affiliation': 'Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.'}, {'ForeName': 'Santanu', 'Initials': 'S', 'LastName': 'Nath', 'Affiliation': 'Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.'}, {'ForeName': 'Rituparna', 'Initials': 'R', 'LastName': 'Maiti', 'Affiliation': 'Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India. pharm_rituparna@aiimsbhubaneswar.edu.in.'}]",Psychopharmacology,['10.1007/s00213-020-05628-3'] 2215,32740716,Efficacy of exercise rehabilitation program accompanied by experiential music for recovery of aphasia in single cerebrovascular accidents: a randomized controlled trial.,"BACKGROUND The current study aims to evaluate the effects of daily traditional experiential music listening for clinical recovery of post-stroke aphasia. METHODS This was a prospective randomized trial with seventy-nine stroke survivors who suffered from post-stroke aphasia. All patients underwent a neuropsychological evaluation, at time = 0 during the admission at the rehabilitation structure (baseline), and 6 months post-stroke. All cases received standard treatment for stroke and post-stroke aphasia in terms of medical care and rehabilitation. Furthermore, patients were randomized to receive either standard care only or standard care with daily traditional experiential music listening. Computer tomography perfusion and neurological examination were assessed to all patients. Recovery was measured by the score at Aachener Aphasie Test. RESULTS The statistically significant differences between the control group (CG) and the rest of the patients were the clinical characteristics (hemiparesis) (p = 0.002), the cerebral blood flow in affected areas (p = 0.000), and the Mini-Mental Test (mMT) (p = 0.000). Only group and mMT were independent predictor factors for recovery, according to multivariate analysis odd ratio (ΟR) (95% confidence interval) 0.022 (0.009-0.435) and 0.658 (0.142-0.224) respectively. CONCLUSIONS The results of this study are promising and suggest that an enriched sound environment is beneficial for patients with post-stroke aphasia since the recovery rate is higher when standard care was combined with daily music listening.",2020,"Only group and mMT were independent predictor factors for recovery, according to multivariate analysis odd ratio (ΟR) (95% confidence interval) 0.022 (0.009-0.435) and 0.658 (0.142-0.224) respectively. ","['single cerebrovascular accidents', 'seventy-nine stroke survivors who suffered from post-stroke aphasia']","['exercise rehabilitation program accompanied by experiential music', 'daily traditional experiential music listening', 'standard care only or standard care with daily traditional experiential music listening']","['cerebral blood flow', 'Mini-Mental Test (mMT', 'Computer tomography perfusion and neurological examination', 'clinical characteristics (hemiparesis']","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0003537', 'cui_str': 'Aphasia'}]","[{'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0025365', 'cui_str': 'Mental Tests'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0040395', 'cui_str': 'Diagnostic tomography'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0027853', 'cui_str': 'Neurological examination'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0018989', 'cui_str': 'Hemiparesis'}]",,0.230267,"Only group and mMT were independent predictor factors for recovery, according to multivariate analysis odd ratio (ΟR) (95% confidence interval) 0.022 (0.009-0.435) and 0.658 (0.142-0.224) respectively. ","[{'ForeName': 'Katerina', 'Initials': 'K', 'LastName': 'Aravantinou-Fatorou', 'Affiliation': 'First Department of Medicine, Laiko General Hospital, Athens, Greece.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Fotakopoulos', 'Affiliation': ""Department of Neurosurgery, General Hospital of Pyrgos 'Andreas Papandreou', Sintriada, 27100, Pyrgos Ilias, Greece. gfotakop@yahoo.gr.""}]",Irish journal of medical science,['10.1007/s11845-020-02328-x'] 2216,32740723,"A single-blind, randomised, crossover study to reduce hypoglycaemia risk during postprandial exercise with closed-loop insulin delivery in adults with type 1 diabetes: announced (with or without bolus reduction) vs unannounced exercise strategies.","AIMS/HYPOTHESIS For individuals living with type 1 diabetes, closed-loop insulin delivery improves glycaemic control. Nonetheless, maintenance of glycaemic control during exercise while a prandial insulin bolus remains active is a challenge even to closed-loop systems. We investigated the effect of exercise announcement on the efficacy of a closed-loop system, to reduce hypoglycaemia during postprandial exercise. METHODS A single-blind randomised, crossover open-label trial was carried out to compare three strategies applied to a closed-loop system at mealtime in preparation for exercise taken 90 min after eating at a research testing centre: (1) announced exercise to the closed-loop system (increases target glucose levels) in addition to a 33% reduction in meal bolus (A-RB); (2) announced exercise to the closed-loop system and a full meal bolus (A-FB); (3) unannounced exercise and a full meal bolus (U-FB). Participants performed 60 min of exercise at 60% [Formula: see text] 90 min after eating breakfast. The investigators were not blinded to the interventions. However, the participants were blinded to the sensor glucose readings and to the insulin infusion rates throughout the intervention visits. RESULTS The trial was completed by 37 adults with type 1 diabetes, all using insulin pumps: mean±SD, 40.0 ± 15.0 years of age, HbA 1c 57.1 ± 10.8 mmol/mol (7.3 ± 1.0%). Reported results were based on plasma glucose values. During exercise and the following 1 h recovery period, time spent in hypoglycaemia (<3.9 mmol/l; primary outcome) was reduced with A-RB (mean ± SD; 2.0 ± 6.2%) and A-FB (7.0 ± 12.6%) vs U-FB (13.0 ± 19.0%; p < 0.0001 and p = 0.005, respectively). During exercise, A-RB had the least drop in plasma glucose levels: A-RB -0.3 ± 2.8 mmol/l, A-FB -2.6 ± 2.9 mmol/l vs U-FB -2.4 ± 2.7 mmol/l (p < 0.0001 and p = 0.5, respectively). Comparison of A-RB vs U-FB revealed a decrease in the time spent in target (3.9-10 mmol/l) by 12.7% (p = 0.05) and an increase in the time spent in hyperglycaemia (>10 mmol/l) by 21% (p = 0.001). No side effects were reported during the applied strategies. CONCLUSIONS/INTERPRETATION Combining postprandial exercise announcement, which increases closed-loop system glucose target levels, with a 33% meal bolus reduction significantly reduced time spent in hypoglycaemia compared with the other two strategies, yet at the expense of more time spent in hyperglycaemia. TRIAL REGISTRATION ClinicalTrials.gov NCT0285530 FUNDING: JDRF (2-SRA-2016-210-A-N), the Canadian Institutes of Health Research (354024) and the Fondation J.-A. DeSève chair held by RR-L.",2020,"During exercise, A-RB had the least drop in plasma glucose levels: A-RB -0.3 ± 2.8 mmol/l, A-FB -2.6 ± 2.9 mmol/l vs U-FB -2.4 ± 2.7 mmol/l (p < 0.0001 and p = 0.5, respectively).","['adults with type 1 diabetes', '37 adults with type 1 diabetes, all using insulin pumps: mean±SD, 40.0\u2009±\u200915.0\xa0years of age, HbA 1c 57.1\u2009±\u200910.8\xa0mmol/mol (7.3\u2009±\u20091.0', 'individuals living with type 1 diabetes']","['postprandial exercise with closed-loop insulin delivery', 'exercise announcement', 'unannounced exercise strategies', 'closed-loop system at mealtime in preparation for exercise taken 90\xa0min after eating at a research testing centre: (1) announced exercise to the closed-loop system (increases target glucose levels) in addition to a 33% reduction in meal bolus (A-RB); (2) announced exercise to the closed-loop system and a full meal bolus (A-FB); (3) unannounced exercise and a full meal bolus (U-FB']","['plasma glucose levels', 'insulin infusion rates', 'time spent', 'hypoglycaemia risk', 'time spent in hypoglycaemia', 'plasma glucose values', 'time spent in hyperglycaemia', 'glycaemic control', 'side effects']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0240016', 'cui_str': 'Insulin used'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C4517523', 'cui_str': '10.8'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mol'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}]","[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0443183', 'cui_str': 'Closed loop'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0587119', 'cui_str': 'Mealtimes'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1998602', 'cui_str': 'Meals'}]","[{'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4544151', 'cui_str': 'Insulin infusion rate'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",,0.134208,"During exercise, A-RB had the least drop in plasma glucose levels: A-RB -0.3 ± 2.8 mmol/l, A-FB -2.6 ± 2.9 mmol/l vs U-FB -2.4 ± 2.7 mmol/l (p < 0.0001 and p = 0.5, respectively).","[{'ForeName': 'Sémah', 'Initials': 'S', 'LastName': 'Tagougui', 'Affiliation': 'Montreal Clinical Research Institute (IRCM), 110 Pine Ave W, Montreal, QC, H2W 1R7, Canada.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Taleb', 'Affiliation': 'Montreal Clinical Research Institute (IRCM), 110 Pine Ave W, Montreal, QC, H2W 1R7, Canada.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Legault', 'Affiliation': 'Montreal Clinical Research Institute (IRCM), 110 Pine Ave W, Montreal, QC, H2W 1R7, Canada.'}, {'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Suppère', 'Affiliation': 'Montreal Clinical Research Institute (IRCM), 110 Pine Ave W, Montreal, QC, H2W 1R7, Canada.'}, {'ForeName': 'Virginie', 'Initials': 'V', 'LastName': 'Messier', 'Affiliation': 'Montreal Clinical Research Institute (IRCM), 110 Pine Ave W, Montreal, QC, H2W 1R7, Canada.'}, {'ForeName': 'Inès', 'Initials': 'I', 'LastName': 'Boukabous', 'Affiliation': 'Montreal Clinical Research Institute (IRCM), 110 Pine Ave W, Montreal, QC, H2W 1R7, Canada.'}, {'ForeName': 'Azadeh', 'Initials': 'A', 'LastName': 'Shohoudi', 'Affiliation': 'Montreal Heart Institute, Montreal, QC, Canada.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Ladouceur', 'Affiliation': ""École de Santé Publique de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Rémi', 'Initials': 'R', 'LastName': 'Rabasa-Lhoret', 'Affiliation': 'Montreal Clinical Research Institute (IRCM), 110 Pine Ave W, Montreal, QC, H2W 1R7, Canada. remi.rabasa-lhoret@ircm.qc.ca.'}]",Diabetologia,['10.1007/s00125-020-05244-y'] 2217,32740754,Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial.,"BACKGROUND Catheter-based renal denervation (RDN) reduces blood pressure (BP) throughout the 24-h period, as reported in several randomized sham-controlled trials. Reduction of BP in the early morning hours is especially important due to increased cardiovascular risks during that time. OBJECTIVE In this report, we examine the impact of RDN on systolic BP (SBP) and diastolic BP (DBP) during the critical morning surge period in a post-hoc analysis of patients in the SPYRAL HTN-ON MED trial. METHODS AND RESULTS Ambulatory BP measurements were collected at baseline and 6 months for treatment and control patient groups over 24-h periods. Average morning BP surge is the difference between average morning BP and average nighttime BP, and the morning surge slope reflects the rate of change of BP from nighttime to morning. Mean morning DBP surge slopes were significantly lower for RDN vs. control groups at 6 months (1.1 vs. 3.6 mmHg/h; p = 0.029). In the RDN group, morning DBP surge slopes were significantly lower at 6 months compared to baseline (1.1 vs. 4.1 mmHg/h; p = 0.006). Similar patterns were observed for mean morning SBP surge slope but did not reach statistical significance. CONCLUSIONS This decrease in the morning DBP surge slope, an index of the sympathetically-mediated morning BP surge, thus indicates a drop in late morning BP relative to early morning/nocturnal BP in the RDN group. Thus, RDN appears effective in attenuating the slope of morning surge in DBP that might indicate possible benefits in a high-risk hypertensive population. CLINICAL TRIAL REGISTRATION https://www.clinicaltrials.gov (NCT02439775), registered May 12, 2015.",2020,Mean morning DBP surge slopes were significantly lower for RDN vs. control groups at 6 months (1.1 vs. 3.6 mmHg/h; p = 0.029).,['patients in the SPYRAL HTN-ON MED trial'],['Catheter-based renal denervation (RDN'],"['Reduction of BP', 'systolic BP (SBP) and diastolic BP (DBP', 'cardiovascular risks', 'blood pressure (BP', 'Average morning BP surge', 'Mean morning DBP surge slopes', 'morning DBP surge slope, an index of the sympathetically-mediated morning BP surge', 'morning DBP surge slopes', 'mean morning SBP surge slope']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0011307', 'cui_str': 'Denervation - action'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}]",,0.0926878,Mean morning DBP surge slopes were significantly lower for RDN vs. control groups at 6 months (1.1 vs. 3.6 mmHg/h; p = 0.029).,"[{'ForeName': 'Kazuomi', 'Initials': 'K', 'LastName': 'Kario', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, 3311-1, Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. kkario@jichi.ac.jp.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Weber', 'Affiliation': 'Department of Medicine, SUNY Downstate College of Medicine, Brooklyn, NY, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Böhm', 'Affiliation': 'Department of Internal Medicine, Klinik für Innere Medizin III, Universitätsklinikum Des Saarlandes, Saarland University, Homburg/Saar, Germany.'}, {'ForeName': 'Raymond R', 'Initials': 'RR', 'LastName': 'Townsend', 'Affiliation': 'Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Mahfoud', 'Affiliation': 'Department of Internal Medicine, Klinik für Innere Medizin III, Universitätsklinikum Des Saarlandes, Saarland University, Homburg/Saar, Germany.'}, {'ForeName': 'Roland E', 'Initials': 'RE', 'LastName': 'Schmieder', 'Affiliation': 'Department of Nephrology and Hypertension, Universitätsklinikum Erlangen, Erlangen, Germany.'}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Tsioufis', 'Affiliation': 'Department of Cardiology, National and Kapodistrian University of Athens, Hippocratio Hospital, Athens, Greece.'}, {'ForeName': 'Sidney A', 'Initials': 'SA', 'LastName': 'Cohen', 'Affiliation': 'Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Fahy', 'Affiliation': 'Coronary and Structural Heart, Medtronic PLC, Santa Rosa, CA, USA.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Kandzari', 'Affiliation': 'Department of Interventional Cardiology, Piedmont Heart Institute, Atlanta, GA, USA.'}]",Clinical research in cardiology : official journal of the German Cardiac Society,['10.1007/s00392-020-01718-6'] 2218,32740807,Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study.,"INTRODUCTION Neoadjuvant chemotherapy (NAC) is a well-established therapeutic option for patients with locally advanced disease often allowing downstaging and facilitation of breast conserving therapy. With evolution of better targeted treatment regimens and awareness of improved outcomes for significant responders, use of NAC has expanded particularly for triple negative and HER2-positive (HER2+) breast cancer. In this study, we explore utility of neoadjuvant chemotherapy for hormone receptor-positive HER2-negative (HR+ HER2-) patients. METHODS Patients with HR+ HER2- breast cancer treated with chemotherapy before or after surgery were identified from 2010 to 2015 in the NCDB. Multivariable regression models adjusted for covariates were used to determine associations within these groups. RESULTS Among 134,574 patients (clinical stage 2A, 64%; 2B, 21%; 3, 15%), 105,324 (78%) had adjuvant chemotherapy (AC) and 29,250 (22%) received NAC. Use of NAC increased over time (2010-2015; 13.2-19.4% and PR = 1.34 for 2015; p < 0.0001). Patients were more likely to receive NAC with cT3, cT4, and cN+ disease. Patients less likely to receive NAC were age ≥ 50, lobular carcinoma, increased Charlson-Deyo score, and government insurance. Complete response (pCR) was noted in 8.3% of NAC patients. Axillary downstaging occurred in 21% of patients, and predictors included age < 50 years, black race, poorly differentiated grade, invasive ductal histology, and either ER or PR negativity. CONCLUSIONS NAC use among HR+ HER2- breast cancer patients has expanded over time and offers downstaging of disease for some patients, with pCR seen in only a small subset, but downstaging of the axilla in 21%. Further analysis is warranted to determine the subgroup of patients with HR+ HER2- disease who benefit from this approach.",2020,Use of NAC increased over time (2010-2015; 13.2-19.4% and PR = 1.34 for 2015; p < 0.0001).,"['Patients with HR+\u2009HER2- breast cancer treated with chemotherapy before or after surgery were identified from 2010 to 2015 in the NCDB', '134,574 patients (clinical stage 2A, 64%; 2B, 21%; 3, 15%), 105,324 (78%) had adjuvant chemotherapy (AC) and 29,250 (22%) received', 'HR+\u2009HER2- breast cancer patients', 'patients with locally advanced disease', 'hormone receptor-positive breast cancer']","['NAC', 'neoadjuvant versus adjuvant chemotherapy', 'Neoadjuvant chemotherapy (NAC', 'neoadjuvant chemotherapy']","['Complete response (pCR', 'Axillary downstaging']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0205563', 'cui_str': 'Clinical stage finding'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]","[{'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}]","[{'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0004454', 'cui_str': 'Axillary'}]",134574.0,0.0330664,Use of NAC increased over time (2010-2015; 13.2-19.4% and PR = 1.34 for 2015; p < 0.0001).,"[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Zeidman', 'Affiliation': 'Mount Sinai Health System, New York, USA. mikezeidman@gmail.com.'}, {'ForeName': 'J Jaime', 'Initials': 'JJ', 'LastName': 'Alberty-Oller', 'Affiliation': 'Mount Sinai Health System, New York, USA.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Ru', 'Affiliation': 'Mount Sinai Health System, New York, USA.'}, {'ForeName': 'Kereeti V', 'Initials': 'KV', 'LastName': 'Pisapati', 'Affiliation': 'Mount Sinai Health System, New York, USA.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Moshier', 'Affiliation': 'Mount Sinai Health System, New York, USA.'}, {'ForeName': 'Soojin', 'Initials': 'S', 'LastName': 'Ahn', 'Affiliation': 'Mount Sinai Health System, New York, USA.'}, {'ForeName': 'Madhu', 'Initials': 'M', 'LastName': 'Mazumdar', 'Affiliation': 'Mount Sinai Health System, New York, USA.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Port', 'Affiliation': 'Mount Sinai Health System, New York, USA.'}, {'ForeName': 'Hank', 'Initials': 'H', 'LastName': 'Schmidt', 'Affiliation': 'Mount Sinai Health System, New York, USA.'}]",Breast cancer research and treatment,['10.1007/s10549-020-05809-w'] 2219,32740882,Comparison of the therapeutic effect of Meibomian Thermal Pulsation LipiFlow® on obstructive and hyposecretory meibomian gland dysfunction patients.,"PURPOSE To explore the effect of Meibomian Thermal Pulsation LipiFlow® on obstructive and hyposecretory meibomian gland dysfunction. METHODS Twenty-five subjects diagnosed with obstructive meibomian gland dysfunction (OMGD) and another 25 hyposecretory meibomian gland dysfunction (HMGD) patients were collected receiving the unilateral treatment with LipiFlow®. We evaluated the parameters variables including Standard Patient Evaluation of Eye Dryness (SPEED), Ocular Surface Disease Index (OSDI), Schirmer I test (SIT), noninvasive keratographic breakup time (NIKBUT), tear meniscus height (TMH), and lipid layer thickness (LLT), partial blink rate (PBR), meibomian gland loss, meibomian gland morphology with LipiView®. Meibomian gland expressibility and secretion quality were evaluated for OMGD subjects. All the results were recorded pre-therapy and 4 weeks, 8 weeks, 12 weeks post-therapy. RESULTS SPEED, OSDI, and PB decreased, meanwhile, NIKBUT, TMH, SIT, and LLT increased compared with baseline in both groups after treatment (P < 0.001), whereas the magnitude of the improvement in the OMGD group was greater than that in the HMGD group (P < 0.001). There was no significant posttreatment structural meibomian gland change in both groups. The meibomian gland expressibility and secretion quality score increased after treatment in the OMGD group (P < 0.001). CONCLUSIONS The Meibomian Thermal Pulsation LipiFlow® is effective for both obstructive and hyposecretory meibomian gland dysfunction and the therapeutic effect on obstructive meibomian gland dysfunction is greater than that on hyposecretory meibomian gland dysfunction.",2020,"The meibomian gland expressibility and secretion quality score increased after treatment in the OMGD group (P < 0.001). ","['obstructive and hyposecretory meibomian gland dysfunction patients', 'Twenty-five subjects diagnosed with obstructive meibomian gland dysfunction (OMGD) and another 25 hyposecretory meibomian gland dysfunction (HMGD) patients were collected receiving the']","['HMGD', 'Meibomian Thermal Pulsation LipiFlow®', 'unilateral treatment with LipiFlow®']","['meibomian gland expressibility and secretion quality score', 'Standard Patient Evaluation of Eye Dryness (SPEED), Ocular Surface Disease Index (OSDI', 'SPEED, OSDI, and PB decreased, meanwhile, NIKBUT, TMH, SIT, and LLT', 'structural meibomian gland change', 'I test (SIT), noninvasive keratographic breakup time (NIKBUT), tear meniscus height (TMH), and lipid layer thickness (LLT), partial blink rate (PBR), meibomian gland loss, meibomian gland morphology with LipiView®', 'Meibomian gland expressibility and secretion quality']","[{'cui': 'C1275684', 'cui_str': 'Meibomian gland dysfunction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C1275684', 'cui_str': 'Meibomian gland dysfunction'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0025181', 'cui_str': 'Structure of meibomian gland'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0314719', 'cui_str': 'Dry eyes'}, {'cui': 'C1557335', 'cui_str': 'Ocular surface disease'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1827565', 'cui_str': 'Tear meniscus height'}, {'cui': 'C1301514', 'cui_str': 'Schirmer I test'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0005757', 'cui_str': 'Blinking'}, {'cui': 'C0332437', 'cui_str': 'Associated morphology'}]",25.0,0.0238317,"The meibomian gland expressibility and secretion quality score increased after treatment in the OMGD group (P < 0.001). ","[{'ForeName': 'Bowen', 'Initials': 'B', 'LastName': 'Li', 'Affiliation': 'The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology and Chongqing Eye Institute, Chongqing, China.'}, {'ForeName': 'Hongxue', 'Initials': 'H', 'LastName': 'Fu', 'Affiliation': 'The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology and Chongqing Eye Institute, Chongqing, China.'}, {'ForeName': 'Tingting', 'Initials': 'T', 'LastName': 'Liu', 'Affiliation': 'The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology and Chongqing Eye Institute, Chongqing, China.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Xu', 'Affiliation': 'The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology and Chongqing Eye Institute, Chongqing, China. xumeihome@163.com.'}]",International ophthalmology,['10.1007/s10792-020-01533-y'] 2220,32740950,A Randomised Controlled Trial on the Effect of Partially Hydrolyzed Guar Gum (PHGG) Supplementation on DAiarrhea Frequency and Gut Microbiome Count Among Pelvic Radiation Patients.,"BACKGROUND Radiation therapy is the treatment of pelvic cancers, with diarrhea often being the most frequent acute side effect. This study aimed to determine the efficacy of partially hydrolyzed guar gum (PHGG) usage in reducing radiotherapy-induced diarrhea and improving bacterial count, nutritional status and quality of life (QoL) among cancer patients. METHODS Adult patients undergoing pelvic radiation were recruited and randomized to receive supplementation of either 10g of PHGG or placebo (maltodextrin) twice daily 14 days prior and 14 days during pelvic radiation. Diarrhea frequency, faecal samples, nutritional status and QoL were assessed at baseline, day 14, 28 (two weeks after pelvic radiation) and day 45 (at the completion of pelvic radiation, two weeks post supplementation). RESULTS A total of 30 patients (mean age 56.5 ± 10.8 years, 75% malnourished) participated.. The mean of diarrhea frequency in Intervention Group (IG) was higher compared to the control (CG) from day 14 and 28 but reduced at day 45. There was a significant intervention effect after controlling for confounders (i.e. Baseline diarrhea, age, nutritional status) (p <0.05). Bifidobacterium count increased by double among IG at 14 days of PHGG supplementation, where such trend was not observed in CG. CONCLUSION Supplementation of PHGG potentially increased the bifidobacterial count and seemed to have post supplementation effects by reducing the frequency of diarrhea upon the completion of pelvic radiation treatment. TRIAL REGISTRATION ISRCTN registry (Study ID: ISRCTN17271186). This article is protected by copyright. All rights reserved.",2020,The mean of diarrhea frequency in Intervention Group (IG) was higher compared to the control (CG) from day 14 and 28 but reduced at day 45.,"['cancer patients', 'Pelvic Radiation Patients', 'Adult patients undergoing pelvic radiation', '30 patients (mean age 56.5 ± 10.8 years, 75% malnourished) participated']","['PHGG or placebo (maltodextrin', 'partially hydrolyzed guar gum (PHGG', 'Partially Hydrolyzed Guar Gum (PHGG) Supplementation']","['Bifidobacterium count', 'mean of diarrhea frequency', 'DAiarrhea Frequency and Gut Microbiome Count', 'bifidobacterial count', 'frequency of diarrhea', 'Diarrhea frequency, faecal samples, nutritional status and QoL', 'diarrhea and improving bacterial count, nutritional status and quality of life (QoL']","[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030797', 'cui_str': 'Pelvic'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517523', 'cui_str': '10.8'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}]","[{'cui': 'C0061996', 'cui_str': 'guar gum'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0004618', 'cui_str': 'Bacterial count'}]",30.0,0.0979944,The mean of diarrhea frequency in Intervention Group (IG) was higher compared to the control (CG) from day 14 and 28 but reduced at day 45.,"[{'ForeName': 'Dzairudzee', 'Initials': 'D', 'LastName': 'Rosli', 'Affiliation': 'Hospital Tawau, Ministry, of Health Malaysia, Tawau, Sabah, Malaysia.'}, {'ForeName': 'Suzana', 'Initials': 'S', 'LastName': 'Shahar', 'Affiliation': 'Dietetic Programme, Centre for Healthy Aging and Wellness, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Zahara A', 'Initials': 'ZA', 'LastName': 'Manaf', 'Affiliation': 'Dietetic Programme, Centre for Healthy Aging and Wellness, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Lau Hui', 'Initials': 'LH', 'LastName': 'Jin', 'Affiliation': 'Nutrition Programme, Centre for Healthy Aging and Wellness, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Nurul Yuziana Mohd', 'Initials': 'NYM', 'LastName': 'Yusof', 'Affiliation': 'Faculty Sains and Technology, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Mohd Roslan', 'Initials': 'MR', 'LastName': 'Haron', 'Affiliation': 'Hospital Sultan Ismail, Ministry of Health Malaysia, Johor, Malaysia.'}, {'ForeName': 'Hazreen Abdul', 'Initials': 'HA', 'LastName': 'Majid', 'Affiliation': 'Centre for Population Health and Preventive Medicine, University Malaya, Malaysia.'}]",JPEN. Journal of parenteral and enteral nutrition,['10.1002/jpen.1987'] 2221,32740957,Surgical method for establishing posthepatectomy liver failure.,"We read with great interest the article by Chen et al. entitled ""Randomized Trial of Spheroid Reservoir Bioartificial Liver in Porcine Model of Posthepatectomy Liver Failure"".",2020,"entitled ""Randomized Trial of Spheroid Reservoir Bioartificial Liver in Porcine Model of Posthepatectomy Liver Failure"".",[],[],[],[],[],[],,0.020696,"entitled ""Randomized Trial of Spheroid Reservoir Bioartificial Liver in Porcine Model of Posthepatectomy Liver Failure"".","[{'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Golriz', 'Affiliation': 'Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ramouz', 'Affiliation': 'Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Arianeb', 'Initials': 'A', 'LastName': 'Mehrabi', 'Affiliation': 'Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.'}]","Hepatology (Baltimore, Md.)",['10.1002/hep.31482'] 2222,32740972,Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes.,"The RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial found that dexamethasone 6 mg once per day for 10 days reduced deaths by one-third in ventilated patients and by one-fifth in other patients, receiving oxygen therapy. This equates to the prevention of one death in around eight ventilated patients, or one in around 25 patients requiring oxygen.",2020,"The RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial found that dexamethasone 6 mg once per day for 10 days reduced deaths by one-third in ventilated patients and by one-fifth in other patients, receiving oxygen therapy.","['eight ventilated patients, or one in around 25 patients requiring oxygen', 'COVID-19 patients', 'people with and without diabetes']","['dexamethasone', 'Dexamethasone therapy']",['deaths'],"[{'cui': 'C1299448', 'cui_str': 'Patient ventilated'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}]",25.0,0.0717853,"The RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial found that dexamethasone 6 mg once per day for 10 days reduced deaths by one-third in ventilated patients and by one-fifth in other patients, receiving oxygen therapy.","[{'ForeName': 'G', 'Initials': 'G', 'LastName': 'Rayman', 'Affiliation': 'The Ipswich Diabetes Centre, East Suffolk and North Essex NHS Foundation Trust, Colchester, United Kingdom.'}, {'ForeName': 'A N', 'Initials': 'AN', 'LastName': 'Lumb', 'Affiliation': 'Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Kennon', 'Affiliation': 'Department of Diabetes, Queen Elizabeth University Hospital, Glasgow, United Kingdom.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Cottrell', 'Affiliation': 'Swansea Bay University Health Board, Port Talbot, United Kingdom.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Nagi', 'Affiliation': 'Mid Yorkshire Hospital NHS Trust, Wakefield, United Kingdom.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Page', 'Affiliation': 'Diabetes Centre, Ipswich Hospital NHS Trust, Ipswich, United Kingdom.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Voigt', 'Affiliation': 'Ninewells Hospital, NHS Tayside, Dundee, United Kingdom.'}, {'ForeName': 'H C', 'Initials': 'HC', 'LastName': 'Courtney', 'Affiliation': 'Belfast Health and Social Care Trust, Belfast, United Kingdom.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Atkins', 'Affiliation': 'University Hospitals of Leicester NHS Trust, Leicester, United Kingdom.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Platts', 'Affiliation': 'Cardiff and Vale University Health Board, Cardiff, United Kingdom.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Higgins', 'Affiliation': 'University Hospitals of Leicester NHS Trust, Leicester, United Kingdom.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Dhatariya', 'Affiliation': 'Diabetes Centre, Norfolk & Norwich University Hospital NHS Trust, Norwich, United Kingdom.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Patel', 'Affiliation': 'University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Narendran', 'Affiliation': 'Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Kar', 'Affiliation': 'NHS Diabetes Programme, NHS England, London, United Kingdom.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Newland-Jones', 'Affiliation': 'University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Stewart', 'Affiliation': 'Gladstone Centre, Wrexham Maelor Hospital, Wrexham, United Kingdom.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Burr', 'Affiliation': 'Diabetes UK, London, United Kingdom.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Thomas', 'Affiliation': ""Diabetes Centre King's College Hospital, London, United Kingdom.""}]",Diabetic medicine : a journal of the British Diabetic Association,['10.1111/dme.14378'] 2223,32740976,Alertness Training Improves Spatial Bias and Functional Ability in Spatial Neglect.,"OBJECTIVE We conducted a multi-site, randomized, double-blinded controlled trial to examine the effectiveness of a digital health intervention targeting the intrinsic regulation of goal-directed alertness in patients with chronic hemispatial neglect. METHODS Forty-nine participants with hemispatial neglect that demonstrated significant spatially biased attention following acquired brain injury were randomly assigned to the experimental attention remediation treatment or active control group. The participants engaged with the remotely administered interventions for twelve weeks. The primary outcome was spatial bias on the Posner cueing task (response time difference: left - right target trials). Secondary outcomes included functional abilities (measured via the Catherine Bergego scale and Barthel index), spatial cognition, executive function, quality of life and sleep. Assessments were conducted prior to and immediately following participation in the experimental intervention or control condition, and again after a three-month no contact period. RESULTS Compared with the active control group, the intervention group exhibited a significant improvement in the primary outcome-a reduction in spatially biased attention on the Posner cueing task (p=0.010, Cohen's d=0.96)-as well as significant improvements in functional abilities as measured on the Catherine Bergego and Barthel indices (p=0.027, Cohen's d=0.24). INTERPRETATION Our results demonstrate that our attention training program was effective in improving the debilitating attention deficits common to hemispatial neglect. This benefit generalized to improvements in real-world functional abilities. This safe, highly scalable and self-administered treatment for hemispatial neglect may serve as a useful addition to the existing standard of care. This article is protected by copyright. All rights reserved.",2020,"Compared with the active control group, the intervention group exhibited a significant improvement in the primary outcome-a reduction in spatially biased attention on the Posner cueing task (p=0.010, Cohen's d=0.96)-as well as significant improvements in functional abilities as measured on the Catherine Bergego and Barthel indices (p=0.027, Cohen's d=0.24). ","['patients with chronic hemispatial neglect', 'Forty-nine participants with hemispatial neglect that demonstrated significant spatially biased attention following acquired brain injury']","['experimental attention remediation treatment or active control group', 'digital health intervention', 'Alertness Training']","['spatial bias on the Posner cueing task (response time difference: left - right target trials', 'spatially biased attention on the Posner cueing task', 'Spatial Bias and Functional Ability in Spatial Neglect', 'functional abilities', 'Catherine Bergego and Barthel indices', 'debilitating attention deficits', 'functional abilities (measured via the Catherine Bergego scale and Barthel index), spatial cognition, executive function, quality of life and sleep']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0751421', 'cui_str': 'Hemispatial Neglect'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C4277667', 'cui_str': 'Attentional Biases'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0005346', 'cui_str': 'Biases'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C4277667', 'cui_str': 'Attentional Biases'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0521874', 'cui_str': 'Victim of neglect'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C0041671', 'cui_str': 'Attention Deficit Disorder'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}]",49.0,0.274797,"Compared with the active control group, the intervention group exhibited a significant improvement in the primary outcome-a reduction in spatially biased attention on the Posner cueing task (p=0.010, Cohen's d=0.96)-as well as significant improvements in functional abilities as measured on the Catherine Bergego and Barthel indices (p=0.027, Cohen's d=0.24). ","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Van Vleet', 'Affiliation': 'Research and Development, Posit Science, San Francisco, CA.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Bonato', 'Affiliation': 'Department of Physical Medicine & Rehabilitation, Harvard Medical School, Boston, MA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Fabara', 'Affiliation': 'Spaulding Rehabilitation Hospital, Charlestown, MA.'}, {'ForeName': 'Sawsan', 'Initials': 'S', 'LastName': 'Dabit', 'Affiliation': 'Research and Development, Posit Science, San Francisco, CA.'}, {'ForeName': 'Sarah-Jane', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'Research and Development, Posit Science, San Francisco, CA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Chiu', 'Affiliation': 'Department of psychology, University of Massachusetts, Boston, MA.'}, {'ForeName': 'Antonio Luigi', 'Initials': 'AL', 'LastName': 'Bisogno', 'Affiliation': 'Department of Neuroscience and Padua Neuroscience Center, University of Padua, Italy.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Merzenich', 'Affiliation': 'Research and Development, Posit Science, San Francisco, CA.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Corbetta', 'Affiliation': 'Department of Neuroscience and Padua Neuroscience Center, University of Padua, Italy.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'DeGutis', 'Affiliation': 'VA Boston Healthcare System, Boston, MA.'}]",Annals of neurology,['10.1002/ana.25862'] 2224,32741071,Comparing the different oxycodone doses of prevent oxycodone for prevention of preventing fentanyl-induced cough during induction of general anesthesia.,"BACKGROUND Fentanyl-induced cough (FIC) usually occurs after the intravenous administration of fentanyl during general anesthesia induction. It is a transient condition depending on the fentanyl administration dose and injection speed. Oxycodone can also prevent FIC because it has been proven to treat coughing. This study aimed to evaluate the efficacy of different oxycodone doses to prevent FIC during general anesthesia induction. METHODS In a double-blind randomized controlled trial, 210 adult patients who were undergoing elective surgery, classified as American Society of Anesthesiologists physical status I ～ II, and aged 20-65 years were randomly assigned into five equally sized groups: Sham group, Group Ⅰ, Group Ⅱ, Group III, and Group Ⅳ. Groups Ⅰ ～ Ⅳ were each intravenously injected with oxycodone 0.025, 0.05, 0.075, and 0.100 mg/kg, while an equal volume of normal saline was given instead of oxycodone in the Sham group. Five minutes later, fentanyl 3μg/kg was intravenously injected within 5 s, then 2 min later the other drugs were administered for general anesthesia induction. The occurrence and severity of coughing were observed within 2 min of the fentanyl injection. Vital signs and intensities of coughing were recorded and analyzed. RESULTS Coughing incidences were each 57.1, 50, 42.8, 33.3, and 21.4% in the Sham group and Groups Ⅰ ～ Ⅳ. Significant differences were found in the incidences of coughing between the Sham group and Groups III ~ IV. No significant differences in FIC incidences have been detected between the Sham group and Groups Ⅰ ～ Ⅱ. However, no significant difference in FIC incidence existed between Group Ⅲ and Group Ⅳ. Cough severities in Groups Ⅲ and Ⅳ were significantly lower than in Groups Ⅰ and Ⅱ (P < 0.05). No significant differences existed in the hypotension or severe bradycardia incidences during anesthesia induction among the five groups (P>0.05). CONCLUSION Oxycodone 0.075 mg/kg provided more effective FIC prevention during general anesthesia induction.",2020,No significant differences in FIC incidences have been detected between the Sham group and Groups Ⅰ,"['210 adult patients who were undergoing elective surgery, classified as American Society of Anesthesiologists physical status', 'I ～ II, and aged 20-65 years']","['fentanyl', 'oxycodone', 'Oxycodone']","['incidences of coughing', 'FIC incidences', 'Vital signs and intensities of coughing', 'hypotension or severe bradycardia incidences', 'Cough severities', 'FIC incidence', 'Coughing incidences', 'occurrence and severity of coughing', 'effective FIC prevention']","[{'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0030049', 'cui_str': 'Oxycodone'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]",210.0,0.0682328,No significant differences in FIC incidences have been detected between the Sham group and Groups Ⅰ,"[{'ForeName': 'Bizhao', 'Initials': 'B', 'LastName': 'Dai', 'Affiliation': ""Department of Anesthesiology, The Affiliated Xuzhou No, People's Hospital of Xuzhou Medical University, Xuzhou, 221002, Jiangsu, China.""}, {'ForeName': 'Xiaofei', 'Initials': 'X', 'LastName': 'Cao', 'Affiliation': 'Department of Anesthesiology, First Affiliated Hospital of Nanjing Medical University, Nanjing Jiangsu Province, 210029, Jiangsu, China.'}]",International journal of clinical practice,['10.1111/ijcp.13642'] 2225,32745031,A School-Based Intervention to Increase HPV Vaccination Rates.,"BACKGROUND The human papillomavirus (HPV) is responsible for over 33,000 cancer diagnoses each year in the United States. HPV vaccination rates remain 25%-30% lower than other preteen immunizations. OBJECTIVE The aim of this project was to increase the HPV vaccination rate among adolescents presenting to a school-based health center (SBHC) using provider recommendation and parent education. METHODS This project examined whether HPV vaccine acceptance improved over 8 weeks following implementation of a clinic policy requiring immunization records to be reviewed at every visit, along with providing parents with written recommendations and education. RESULTS Thirty-six students were found to be lacking HPV vaccination. Parents of these children received written recommendations and education on the HPV vaccine. Fifteen parents consented to the HPV vaccine for their child, a 1400% increase in HPV vaccine acceptance when compared to the same time period in 2017. CONCLUSIONS This study found that a SBHC practice initiative led to an increase in HPV vaccine acceptance. There was also an increase in the acceptance of other vaccines such as Tdap, MenACWY, and Influenza. IMPLICATIONS FOR NURSING Provider recommendation was influential in improving HPV vaccination rates. SBHC are an ideal alternative setting to improve vaccine acceptance among parents.",2019,"Fifteen parents consented to the HPV vaccine for their child, a 1400% increase in HPV vaccine acceptance when compared to the same time period in 2017. ","['Thirty-six students', 'adolescents presenting to a school-based health center (SBHC) using provider recommendation and parent education', 'Fifteen parents consented to the']","['SBHC', 'HPV vaccine']","['HPV vaccination rates', 'HPV Vaccination Rates', 'HPV vaccine acceptance', 'HPV vaccination rate', 'acceptance of other vaccines such as Tdap, MenACWY, and Influenza']","[{'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C2711213', 'cui_str': 'Consented'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C1512511', 'cui_str': 'Human papillomavirus vaccine'}]","[{'cui': 'C1997921', 'cui_str': 'Vaccination for human papillomavirus'}, {'cui': 'C1512511', 'cui_str': 'Human papillomavirus vaccine'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C3653931', 'cui_str': 'OTHER VACCINES'}, {'cui': 'C2003457', 'cui_str': 'MenACWY'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}]",36.0,0.0324161,"Fifteen parents consented to the HPV vaccine for their child, a 1400% increase in HPV vaccine acceptance when compared to the same time period in 2017. ","[{'ForeName': 'Tiffany', 'Initials': 'T', 'LastName': 'Edwards', 'Affiliation': 'Nanticoke Health Services, Seaford, Delaware.'}, {'ForeName': 'Gwendolyn L', 'Initials': 'GL', 'LastName': 'Hooper', 'Affiliation': 'Capstone College of Nursing, University of Alabama, Tuscaloosa.'}]",Journal of doctoral nursing practice,['10.1891/2380-9418.12.2.196'] 2226,32745038,Family Journaling to Reduce Stress Manifestations in Patients and Families After Critical Illness.,"BACKGROUND Few studies have clearly provided evidence evaluating the effectiveness of family-written journals in reducing stress after critical illness. OBJECTIVE Study whether critical care unit (CCU) patients and their families who participated in journaling compared to those who did not, experience lower stress manifestations after discharge. METHODS Non-randomized controlled trial conducted with CCU patients who required mechanical ventilation for more than 24 hours and a CCU stay more than 72 hours, along with one of their family members. RESULTS At 1 and 4 months following CCU discharge, patients with family members who journaled reported fewer stress symptoms when compared to patients who did not have journals (mean Posttraumatic Stress Syndrome 14 [PTSS-14] scores 31.8 vs. 38.1 and 32.2 vs. 34.7, respectively). Family members who journaled, compared to those who did not, reported fewer stress manifestations at 1 month however not at 4 months (mean PTSS-14 scores 26.9 vs. 43.7 and 28.0 vs. 24.4, respectively). There was no significant difference in CCU memories between patient groups at 1 and 4 months. CONCLUSION AND IMPLICATIONS FOR NURSING Research is needed with larger samples however this study supports journaling as a low-cost, nurse-driven, stress reduction intervention for both patients recovering from critical illness and their family members who visit them.",2019,"Family members who journaled, compared to those who did not, reported fewer stress manifestations at 1 month however not at 4 months (mean PTSS-14 scores 26.9 vs. 43.7 and 28.0 vs. 24.4, respectively).","['Patients and Families After Critical Illness', 'patients who required mechanical ventilation for more than 24 hours and a CCU stay more than 72 hours, along with one of their family members', 'critical care unit (CCU) patients and their families who participated in journaling compared to those who did not, experience lower stress manifestations after discharge']",['CCU'],"['stress symptoms', 'stress manifestations', 'CCU memories']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C0086282', 'cui_str': 'Person in the family'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0205319', 'cui_str': 'Manifest'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}]","[{'cui': 'C0021708', 'cui_str': 'Intensive care unit'}]","[{'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0205319', 'cui_str': 'Manifest'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}]",,0.0549166,"Family members who journaled, compared to those who did not, reported fewer stress manifestations at 1 month however not at 4 months (mean PTSS-14 scores 26.9 vs. 43.7 and 28.0 vs. 24.4, respectively).","[{'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Hamilton', 'Affiliation': ""Saint Martin's University, Lacey, Washington, and Providence St. Peter Hospital, Olympia, Washington.""}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Wilhite', 'Affiliation': 'Providence St. Peter Hospital, Olympia, Washington.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Grefe', 'Affiliation': 'Providence St. Peter Hospital, Olympia, Washington.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Hart', 'Affiliation': 'Providence St. Peter Hospital, Olympia, Washington.'}, {'ForeName': 'Ruyun', 'Initials': 'R', 'LastName': 'Jin', 'Affiliation': 'Medical Data Research Center, Providence Health & Services, Portland, Oregon.'}]",Journal of doctoral nursing practice,['10.1891/2380-9418.12.2.254'] 2227,32745085,"Anopheles bionomics, insecticide resistance and malaria transmission in southwest Burkina Faso: A pre-intervention study.","BACKGROUND Twenty-seven villages were selected in southwest Burkina Faso to implement new vector control strategies in addition to long lasting insecticidal nets (LLINs) through a Randomized Controlled Trial (RCT). We conducted entomological surveys in the villages during the dry cold season (January 2017), dry hot season (March 2017) and rainy season (June 2017) to describe malaria vectors bionomics, insecticide resistance and transmission prior to this trial. METHODS We carried out hourly catches (from 17:00 to 09:00) inside and outside 4 houses in each village using the Human Landing Catch technique. Mosquitoes were identified using morphological taxonomic keys. Specimens belonging to the Anopheles gambiae complex and Anopheles funestus group were identified using molecular techniques as well as detection of Plasmodium falciparum infection and insecticide resistance target-site mutations. RESULTS Eight Anopheles species were detected in the area. Anopheles funestus s.s was the main vector during the dry cold season. It was replaced by Anopheles coluzzii during the dry hot season whereas An. coluzzii and An. gambiae s.s. were the dominant species during the rainy season. Species composition of the Anopheles population varied significantly among seasons. All insecticide resistance mechanisms (kdr-w, kdr-e and ace-1 target site mutations) investigated were found in each members of the An. gambiae complex but at different frequencies. We observed early and late biting phenotypes in the main malaria vector species. Entomological inoculation rates were 2.61, 2.67 and 11.25 infected bites per human per month during dry cold season, dry hot season and rainy season, respectively. CONCLUSION The entomological indicators of malaria transmission were high despite the universal coverage with LLINs. We detected early and late biting phenotypes in the main malaria vector species as well as physiological insecticide resistance mechanisms. These data will be used to evaluate the impact of complementary tools to LLINs in an upcoming RCT.",2020,"Entomological inoculation rates were 2.61, 2.67 and 11.25 infected bites per human per month during dry cold season, dry hot season and rainy season, respectively. ","['Twenty-seven villages', 'villages during the dry cold season (January 2017), dry hot season (March 2017) and rainy season (June 2017) to describe malaria vectors bionomics, insecticide resistance and transmission prior to this trial', 'southwest Burkina Faso']",[],['Entomological inoculation rates'],"[{'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0011682', 'cui_str': 'Desiccation - action'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}, {'cui': 'C0444519', 'cui_str': 'Hot'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0012656', 'cui_str': 'Infectious Disease Vectors'}, {'cui': 'C0005550', 'cui_str': 'Bionomics'}, {'cui': 'C0021575', 'cui_str': 'Insecticide Resistance'}, {'cui': 'C0040722', 'cui_str': 'transmission'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0006409', 'cui_str': 'Burkina Faso'}]",[],"[{'cui': 'C0042196', 'cui_str': 'Vaccination'}]",27.0,0.022626,"Entomological inoculation rates were 2.61, 2.67 and 11.25 infected bites per human per month during dry cold season, dry hot season and rainy season, respectively. ","[{'ForeName': 'Dieudonné Diloma', 'Initials': 'DD', 'LastName': 'Soma', 'Affiliation': 'Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso.'}, {'ForeName': 'Barnabas Mahugnon', 'Initials': 'BM', 'LastName': 'Zogo', 'Affiliation': 'MIVEGEC, Université de Montpellier, CNRS, IRD, Montpellier, France.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Somé', 'Affiliation': 'Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso.'}, {'ForeName': ""Bertin N'Cho"", 'Initials': 'BN', 'LastName': 'Tchiekoi', 'Affiliation': 'MIVEGEC, Université de Montpellier, CNRS, IRD, Montpellier, France.'}, {'ForeName': 'Domonbabele François de Sales', 'Initials': 'DFS', 'LastName': 'Hien', 'Affiliation': 'Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso.'}, {'ForeName': 'Hermann Sié', 'Initials': 'HS', 'LastName': 'Pooda', 'Affiliation': 'Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso.'}, {'ForeName': 'Sanata', 'Initials': 'S', 'LastName': 'Coulibaly', 'Affiliation': 'Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso.'}, {'ForeName': 'Jacques Edounou', 'Initials': 'JE', 'LastName': 'Gnambani', 'Affiliation': 'Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ouari', 'Affiliation': 'Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso.'}, {'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Mouline', 'Affiliation': 'Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso.'}, {'ForeName': 'Amal', 'Initials': 'A', 'LastName': 'Dahounto', 'Affiliation': 'Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso.'}, {'ForeName': 'Georges Anicet', 'Initials': 'GA', 'LastName': 'Ouédraogo', 'Affiliation': 'Université Nazi Boni, Bobo-Dioulasso, Burkina Faso.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Fournet', 'Affiliation': 'MIVEGEC, Université de Montpellier, CNRS, IRD, Montpellier, France.'}, {'ForeName': 'Alphonsine Amanan', 'Initials': 'AA', 'LastName': 'Koffi', 'Affiliation': ""Institut Pierre Richet (IPR), Bouaké, Côte d'Ivoire.""}, {'ForeName': 'Cédric', 'Initials': 'C', 'LastName': 'Pennetier', 'Affiliation': 'MIVEGEC, Université de Montpellier, CNRS, IRD, Montpellier, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Moiroux', 'Affiliation': 'Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso.'}, {'ForeName': 'Roch Kounbobr', 'Initials': 'RK', 'LastName': 'Dabiré', 'Affiliation': 'Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso.'}]",PloS one,['10.1371/journal.pone.0236920'] 2228,32745092,Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial.,"BACKGROUND Emerging evidence suggests aspirin may be an effective venous thromboembolism (VTE) prophylaxis for orthopaedic trauma patients, with fewer bleeding complications. We used a patient-centered weighted composite outcome to globally evaluate aspirin versus low-molecular-weight heparin (LMWH) for VTE prevention in fracture patients. METHODS We conducted an open-label randomized clinical trial of adult patients admitted to an academic trauma center with an operative extremity fracture, or a pelvis or acetabular fracture. Patients were randomized to receive LMWH (enoxaparin 30-mg) twice daily (n = 164) or aspirin 81-mg twice daily (n = 165). The primary outcome was a composite endpoint of bleeding complications, deep surgical site infection, deep vein thrombosis, pulmonary embolism, and death within 90 days of injury. A Global Rank test and weighted time to event analysis were used to determine the probability of treatment superiority for LMWH, given a 9% patient preference margin for oral administration over skin injections. RESULTS Overall, 18 different combinations of outcomes were experienced by patients in the study. Ninety-nine patients in the aspirin group (59.9%) and 98 patients in the LMWH group (59.4%) were event-free within 90 days of injury. Using a Global Rank test, the LMWH had a 50.4% (95% CI, 47.7-53.2%, p = 0.73) probability of treatment superiority over aspirin. In the time to event analysis, LMWH had a 60.5% probability of treatment superiority over aspirin with considerable uncertainty (95% CI, 24.3-88.0%, p = 0.59). CONCLUSION The findings of the Global Rank test suggest no evidence of superiority between LMWH or aspirin for VTE prevention in fracture patients. LMWH demonstrated a 60.5% VTE prevention benefit in the weighted time to event analysis. However, this difference did not reach statistical significance and was similar to the elicited patient preferences for aspirin.",2020,The findings of the Global Rank test suggest no evidence of superiority between LMWH or aspirin for VTE prevention in fracture patients.,"['orthopaedic trauma patients', 'adult patients admitted to an academic trauma center with an operative extremity fracture, or a pelvis or acetabular fracture', 'fracture patients']","['LMWH', 'aspirin versus low-molecular-weight heparin (LMWH', 'LMWH or aspirin', 'Aspirin versus low-molecular-weight heparin', 'aspirin', 'LMWH (enoxaparin']","['composite endpoint of bleeding complications, deep surgical site infection, deep vein thrombosis, pulmonary embolism, and death within 90 days of injury']","[{'cui': 'C1274117', 'cui_str': 'Trauma & orthopedics'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0040786', 'cui_str': 'Trauma center'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0030797', 'cui_str': 'Pelvic'}, {'cui': 'C0347804', 'cui_str': 'Fracture of acetabulum'}]","[{'cui': 'C0019139', 'cui_str': 'Low molecular weight heparin'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0206460', 'cui_str': 'Enoxaparin'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}]",99.0,0.246285,The findings of the Global Rank test suggest no evidence of superiority between LMWH or aspirin for VTE prevention in fracture patients.,"[{'ForeName': 'Bryce E', 'Initials': 'BE', 'LastName': 'Haac', 'Affiliation': 'Department of Surgery, R A Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.'}, {'ForeName': 'Nathan N', 'Initials': 'NN', 'LastName': ""O'Hara"", 'Affiliation': 'Department of Orthopaedics, R A Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.'}, {'ForeName': 'Theodore T', 'Initials': 'TT', 'LastName': 'Manson', 'Affiliation': 'Department of Orthopaedics, R A Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.'}, {'ForeName': 'Gerard P', 'Initials': 'GP', 'LastName': 'Slobogean', 'Affiliation': 'Department of Orthopaedics, R A Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.'}, {'ForeName': 'Renan C', 'Initials': 'RC', 'LastName': 'Castillo', 'Affiliation': 'Department of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.'}, {'ForeName': 'Robert V', 'Initials': 'RV', 'LastName': ""O'Toole"", 'Affiliation': 'Department of Orthopaedics, R A Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.'}, {'ForeName': 'Deborah M', 'Initials': 'DM', 'LastName': 'Stein', 'Affiliation': 'Department of Surgery, R A Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",PloS one,['10.1371/journal.pone.0235628'] 2229,32745306,A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares.,"BACKGROUND Hyperbaric oxygen has been reported to improve disease activity in hospitalised ulcerative colitis (UC) patients. AIM To evaluate dosing strategies with hyperbaric oxygen for hospitalised UC patients. METHODS We enrolled UC patients hospitalised for acute flares (Mayo score 6-12). Initially, all patients received 3 days of hyperbaric oxygen at 2.4 atmospheres (90 minutes with two air breaks) in addition to intravenous steroids. Day 3 responders (reduction of partial Mayo score ≥ 2 points and rectal bleeding score ≥ 1 point) were randomised to receive a total of 5 days vs 3 days of hyperbaric oxygen. RESULTS We treated 20 patients with hyperbaric oxygen (75% prior biologic failure). Day 3 response was achieved in 55% (n = 11/20), with significant reductions in stool frequency, rectal bleeding and CRP (P < 0.01). A more significant reduction in disease activity was observed with 5 days vs 3 days of hyperbaric oxygen (P = 0.03). Infliximab or colectomy was required in only three patients (15%) despite a predicted probability of 80% for second-line therapy. Day 3 hyperbaric oxygen responders were less likely to require re-hospitalisation or colectomy by 3 months vs non-responders (0% vs 66%, P = 0.002). No treatment-related adverse events were observed. CONCLUSION Hyperbaric oxygen appears to be effective for optimising response to intravenous steroids in UC patients hospitalised for acute flares, with low rates of re-hospitalisation or colectomy at 3 months. An optimal clinical response is achieved with 5 days of hyperbaric oxygen. Larger phase 3 trials are needed to confirm efficacy and obtain labelled approval.",2020,"Day 3 hyperbaric oxygen responders were less likely to require re-hospitalisation or colectomy by 3 months vs non-responders (0% vs 66%, P = 0.002).","['hospitalised ulcerative colitis (UC) patients', 'hospitalised UC patients', 'enrolled UC patients hospitalised for acute flares (Mayo score 6-12', '20 patients with hyperbaric oxygen (75% prior biologic failure', 'ulcerative colitis patients hospitalised for moderate to severe flares', 'UC patients hospitalised for acute flares']","['hyperbaric oxygen at 2.4 atmospheres (90\xa0minutes with two air breaks) in addition to intravenous steroids', 'Hyperbaric oxygen', 'Infliximab or colectomy', 'hyperbaric oxygen therapy', 'hyperbaric oxygen']","['require re-hospitalisation or colectomy', 'disease activity', 'stool frequency, rectal bleeding and CRP', 'adverse events']","[{'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0454788', 'cui_str': 'Mayo'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}]","[{'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C4517631', 'cui_str': '2.4'}, {'cui': 'C0004178', 'cui_str': 'Atmosphere'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0563322', 'cui_str': 'Intravenous steroid injection'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C0009274', 'cui_str': 'Excision of colon'}, {'cui': 'C0020431', 'cui_str': 'Hyperbaric oxygen therapy'}]","[{'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0009274', 'cui_str': 'Excision of colon'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0018932', 'cui_str': 'Hematochezia'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",20.0,0.0836522,"Day 3 hyperbaric oxygen responders were less likely to require re-hospitalisation or colectomy by 3 months vs non-responders (0% vs 66%, P = 0.002).","[{'ForeName': 'Parambir S', 'Initials': 'PS', 'LastName': 'Dulai', 'Affiliation': 'University of California San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Laura E', 'Initials': 'LE', 'LastName': 'Raffals', 'Affiliation': 'Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Hudesman', 'Affiliation': 'NYU Langone Health, New York, NY, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Chiorean', 'Affiliation': 'Virginia Mason, Seattle, WA, USA.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Cross', 'Affiliation': 'University of Maryland, Baltimore, MD, USA.'}, {'ForeName': 'Tasneem', 'Initials': 'T', 'LastName': 'Ahmed', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Winter', 'Affiliation': 'Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Chang', 'Affiliation': 'NYU Langone Health, New York, NY, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Fudman', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Sadler', 'Affiliation': 'University of California San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Ernest L', 'Initials': 'EL', 'LastName': 'Chiu', 'Affiliation': 'NYU Langone Health, New York, NY, USA.'}, {'ForeName': 'Frank L', 'Initials': 'FL', 'LastName': 'Ross', 'Affiliation': 'NYU Langone Health, New York, NY, USA.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Toups', 'Affiliation': 'Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'M Hassan', 'Initials': 'MH', 'LastName': 'Murad', 'Affiliation': 'Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Kinjal', 'Initials': 'K', 'LastName': 'Sethuraman', 'Affiliation': 'University of Maryland, Baltimore, MD, USA.'}, {'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Holm', 'Affiliation': 'Virginia Mason, Seattle, WA, USA.'}, {'ForeName': 'Renie', 'Initials': 'R', 'LastName': 'Guilliod', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Levine', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Jay C', 'Initials': 'JC', 'LastName': 'Buckey', 'Affiliation': 'Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.'}, {'ForeName': 'Corey A', 'Initials': 'CA', 'LastName': 'Siegel', 'Affiliation': 'Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.'}]",Alimentary pharmacology & therapeutics,['10.1111/apt.15984'] 2230,31910030,Trafficking of nonesterified fatty acids in insulin resistance and relationship to dysglycemia.,"In adipose, insulin functions to suppress intracellular lipolysis and secretion of nonesterified fatty acid (NEFA) into plasma. We applied glucose and NEFA minimal models (MM) following a frequently sampled intravenous glucose tolerance test (FSIVGTT) to assess glucose-specific and NEFA-specific insulin resistance. We used total NEFA and individual fatty acids in the NEFA MM, comparing the model parameters in metabolic syndrome (MetSyn) subjects ( n = 52) with optimally healthy controls (OptHC; n = 14). Results are reported as mean difference (95% confidence interval). Using the glucose MM, MetSyn subjects had lower [-73% (-82, -57)] sensitivity to insulin (S i ) and higher [138% (44, 293)] acute insulin response to glucose (AIR g ). Using the NEFA MM, MetSyn subjects had lower [-24% (-35, -13)] percent suppression, higher [32% (15, 52)] threshold glucose (g s ), and a higher [81% (12, 192)] affinity constant altering NEFA secretion (ϕ). Comparing fatty acids, percent suppression was lower in myristic acid (MA) than in all other fatty acids, and the stearic acid (SA) response was so unique that it did not fit the NEFA MM. MA and SA percent of total were increased at 50 min after glucose injection, whereas oleic acid (OA) and palmitic acid (PA) were decreased ( P < 0.05). We conclude that the NEFA MM, as well as the response of individual NEFA fatty acids after a FSIVGTT, differ between OptHC and MetSyn subjects and that the NEFA MM parameters differ between individual fatty acids.",2020,"Comparing fatty acids, percent suppression was lower in myristic acid (MA) than in all other fatty acids, and the stearic acid (SA) response was so unique that it did not fit the NEFA MM.",['metabolic syndrome (MetSyn) subjects ( n = 52) with optimally healthy controls (OptHC; n = 14'],"['total NEFA and individual fatty acids', 'glucose and NEFA minimal models (MM) following a frequently sampled intravenous glucose tolerance test (FSIVGTT']","['acute insulin response to glucose (AIR g ', 'oleic acid (OA) and palmitic acid (PA', 'response of individual NEFA fatty acids', 'MA and SA percent of total', 'stearic acid (SA) response']","[{'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0021911', 'cui_str': 'Intravenous Glucose Tolerance'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0028928', 'cui_str': '9 cis-octadecenoic acid'}, {'cui': 'C0030234', 'cui_str': 'Palmitic acid'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0439175', 'cui_str': '% of total'}, {'cui': 'C0038229', 'cui_str': 'Octadecanoic acid'}]",,0.0180102,"Comparing fatty acids, percent suppression was lower in myristic acid (MA) than in all other fatty acids, and the stearic acid (SA) response was so unique that it did not fit the NEFA MM.","[{'ForeName': 'Rachel E', 'Initials': 'RE', 'LastName': 'Walker', 'Affiliation': 'Department of Nutritional Sciences; The Pennsylvania State University, University Park, Pennsylvania.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Ford', 'Affiliation': 'Department of Nutritional Sciences; The Pennsylvania State University, University Park, Pennsylvania.'}, {'ForeName': 'Raymond C', 'Initials': 'RC', 'LastName': 'Boston', 'Affiliation': 'Department of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Olga V', 'Initials': 'OV', 'LastName': 'Savinova', 'Affiliation': 'Sanford Research/University of South Dakota, Sioux Falls, South Dakota.'}, {'ForeName': 'William S', 'Initials': 'WS', 'LastName': 'Harris', 'Affiliation': 'Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota.'}, {'ForeName': 'Michael H', 'Initials': 'MH', 'LastName': 'Green', 'Affiliation': 'Department of Nutritional Sciences; The Pennsylvania State University, University Park, Pennsylvania.'}, {'ForeName': 'Gregory C', 'Initials': 'GC', 'LastName': 'Shearer', 'Affiliation': 'Department of Nutritional Sciences; The Pennsylvania State University, University Park, Pennsylvania.'}]",American journal of physiology. Endocrinology and metabolism,['10.1152/ajpendo.00331.2019'] 2231,32396568,Psychological symptoms and quality of life after repeated exposure to earthquake: A cohort study in Italy.,"In 2005, a random sample of 200 people were assessed in Camerino, Italy, eight years after an earthquake. Psychological symptom levels were low and only one person had current Post-Traumatic Stress Disorder (PTSD). In 2016 a new earthquake occurred in Camerino. The study aims to assess the impact of the second exposure in the same cohort. A longitudinal study was conducted, 130 participants were re-interviewed between July and December 2017. Psychological symptoms were self-rated on the Brief Symptom Inventory (BSI) and the Global Severity Index (GSI) was analysed. Post-traumatic stress symptoms were self-rated on the Impact of Event Scale-Revised (IES-R). Subjective quality of life (SQOL) was assessed on the Manchester Short Assessment of Quality of Life (MANSA). Mean scores of GSI and IES-R were significantly higher than in 2005 (p<0.01 and p<0.001), whilst SQOL remained almost unchanged (p = 0.163). In 2017, 16.9% of the sample had reached the PTSD threshold whilst in 2005 only the 0.5% had reached it. Despite low symptom levels several years after an earthquake, people can show psychological distress after a new exposure, whilst average quality of life levels are not affected.",2020,"Mean scores of GSI and IES-R were significantly higher than in 2005 (p<0.01 and p<0.001), whilst SQOL remained almost unchanged (p = 0.163).","['In 2005, a random sample of 200 people were assessed in Camerino, Italy, eight years after an earthquake', 'after repeated exposure to earthquake: A cohort study in Italy', '130 participants were re-interviewed between July and December 2017']",[],"['SQOL', 'Manchester Short Assessment of Quality of Life (MANSA', 'Subjective quality of life (SQOL', 'Psychological symptom levels', 'Psychological symptoms and quality of life', 'Mean scores of GSI and IES-R', 'Psychological symptoms were self-rated on the Brief Symptom Inventory (BSI) and the Global Severity Index (GSI', 'PTSD threshold']","[{'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0013463', 'cui_str': 'Earthquake'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}]",[],"[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0281588', 'cui_str': 'Assessment of quality of life'}, {'cui': 'C0233397', 'cui_str': 'Psychological symptom'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C3472482', 'cui_str': 'Impact of event scale revised'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}]",130.0,0.0279868,"Mean scores of GSI and IES-R were significantly higher than in 2005 (p<0.01 and p<0.001), whilst SQOL remained almost unchanged (p = 0.163).","[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Altamore', 'Affiliation': 'Unit for Social and Community Psychiatry (WHO Collaborating Centre for Mental Health Services Development), Queen Mary University of London, London, United Kingdom.'}, {'ForeName': 'Iolanda', 'Initials': 'I', 'LastName': 'Grappasonni', 'Affiliation': 'Department of Medicinal and Health Products Sciences, University of Camerino, Camerino, Italy.'}, {'ForeName': 'Neelam', 'Initials': 'N', 'LastName': 'Laxhman', 'Affiliation': 'Unit for Social and Community Psychiatry (WHO Collaborating Centre for Mental Health Services Development), Queen Mary University of London, London, United Kingdom.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Scuri', 'Affiliation': 'Department of Medicinal and Health Products Sciences, University of Camerino, Camerino, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Petrelli', 'Affiliation': 'Department of Medicinal and Health Products Sciences, University of Camerino, Camerino, Italy.'}, {'ForeName': 'Giuliana', 'Initials': 'G', 'LastName': 'Grifantini', 'Affiliation': 'Mental Health Department Camerino, Camerino, Italy.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Accaramboni', 'Affiliation': 'Mental Health Department Camerino, Camerino, Italy.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Priebe', 'Affiliation': 'Unit for Social and Community Psychiatry (WHO Collaborating Centre for Mental Health Services Development), Queen Mary University of London, London, United Kingdom.'}]",PloS one,['10.1371/journal.pone.0233172'] 2232,32741784,Comparison of the effects of treadmill and vibration training in children with attention deficit hyperactivity disorder: A randomized controlled trial.,"OBJECTIVE The aim of this study was to compare the effects of treadmill training (TT) and whole body vibration training (WBVT) on attention, severity of attention deficit hyperactivity disorder (ADHD) symptoms and impairment of executive function behaviors, and quality of life in children with ADHD. METHODS Thirty children (7-11 years of age) with ADHD were randomly assigned to either the 'TT' group or the 'WBVT in addition to TT' group (TT + WBVT). Both groups received TT for 8 weeks (3 days/week). The TT + WBWT group also received WBVT for 15 minutes. Stroop Test TBAG Form, Behavior Rating Inventory of Executive Function (BRIEF), Conners' Rating Scale (CRS) and Pediatric Quality of Life Inventory (PedsQL) were applied at baseline and after 8 weeks of training. RESULTS All assessment results significantly improved in both groups at the end of the program compared to baseline values (p < 0,05). There were significant differences between groups regarding improvements in CTRS-R/L and BRIEF-Teacher form in favor of the TT + WBVT group. CONCLUSIONS The findings suggest that exercise training including TT and WBVT might be used in the treatment of ADHD but further research is required to provide evidence of the effectiveness of the whole body vibration training in the management of ADHD.",2020,"All assessment results significantly improved in both groups at the end of the program compared to baseline values (p < 0,05).","['children with ADHD', 'Thirty children (7-11 years of age) with ADHD', 'children with attention deficit hyperactivity disorder']","['treadmill training (TT) and whole body vibration training (WBVT', 'WBVT', ""TT' group or the 'WBVT in addition to TT' group (TT\u200a+\u200aWBVT"", 'treadmill and vibration training']","['CTRS-R/L and BRIEF-Teacher', 'attention, severity of attention deficit hyperactivity disorder (ADHD) symptoms and impairment of executive function behaviors, and quality of life', ""Stroop Test TBAG Form, Behavior Rating Inventory of Executive Function (BRIEF), Conners' Rating Scale (CRS) and Pediatric Quality of Life Inventory (PedsQL""]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C2718024', 'cui_str': 'Stroop Task'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}]",30.0,0.0442106,"All assessment results significantly improved in both groups at the end of the program compared to baseline values (p < 0,05).","[{'ForeName': 'Elif', 'Initials': 'E', 'LastName': 'Durgut', 'Affiliation': 'Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Bezmialem Vakif University, Istanbul, Turkey.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Cahid Orengul', 'Affiliation': 'Department of Child and Adolescent Psychiatry, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.'}, {'ForeName': 'Z Candan', 'Initials': 'ZC', 'LastName': 'Algun', 'Affiliation': 'Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Istanbul Medipol University, Istanbul, Turkey.'}]",NeuroRehabilitation,['10.3233/NRE-203040'] 2233,32741788,"The effect of additional neuromuscular electrical stimulation applied to erector spinae muscles on functional capacity, balance and mobility in post stroke patients.","OBJECTIVE The aim of this study was to investigate the effects of neuromuscular electric stimulation applied to the erector spinae on balance, motor function and functional capacity in patients with stroke in a randomized controlled trial. METHODS Sixty patients with stroke were recruited and randomly distributed into two groups: control group and neuromuscular electric stimulation group. All participants underwent conventional physical therapy five times a week for six weeks. The neuromuscular electric stimulation group received additional electrical stimulation. Outcome measures were evaluated with Brunnel Balance Assessment, Stroke Rehabilitation Movement Assessment, Functional Ambulation Classification, Adapted Patient Evaluation and Conference System, Postural Assesment Scale for Stroke patients, Short Form-36, and Minimental State Examination scales. RESULTS Significant differences were observed in all scores at the end of the study in both groups. Postural Assesment Scale for Stroke patients and Stroke Rehabilitation Movement Assessment scores were higher in the neuromuscular electric stimulation group compared to the control group (p < 0.05). All the other scores were not statistically significant. CONCLUSION It is recommended to evaluate and treat trunk muscle, which is usually neglected in treatment, and to consider the combination of conventional treatment and neuromuscular electric stimulation when designing an ideal rehabilitation program.",2020,Postural Assesment Scale for Stroke patients and Stroke Rehabilitation Movement Assessment scores were higher in the neuromuscular electric stimulation group compared to the control group (p < 0.05).,"['Sixty patients with stroke', 'post stroke patients', 'patients with stroke']","['additional neuromuscular electrical stimulation', 'neuromuscular electric stimulation group received additional electrical stimulation', 'neuromuscular electric stimulation', 'conventional physical therapy', 'control group and neuromuscular electric stimulation group']","['functional capacity, balance and mobility', 'Brunnel Balance Assessment, Stroke Rehabilitation Movement Assessment, Functional Ambulation Classification, Adapted Patient Evaluation and Conference System, Postural Assesment Scale for Stroke patients, Short Form-36, and Minimental State Examination scales', 'balance, motor function and functional capacity', 'Postural Assesment Scale for Stroke patients and Stroke Rehabilitation Movement Assessment scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0687676', 'cui_str': 'After values'}]","[{'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C1960377', 'cui_str': 'Assessment of sense of balance'}, {'cui': 'C0204097', 'cui_str': 'Stroke rehabilitation'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0086047', 'cui_str': 'Conferences'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}]",60.0,0.028647,Postural Assesment Scale for Stroke patients and Stroke Rehabilitation Movement Assessment scores were higher in the neuromuscular electric stimulation group compared to the control group (p < 0.05).,"[{'ForeName': 'Furkan', 'Initials': 'F', 'LastName': 'Bilek', 'Affiliation': 'Department of Physiotherapy and Rehabilitation, Faculty of Health Science, University of Firat, Elazig, Turkey.'}, {'ForeName': 'Gulnihal', 'Initials': 'G', 'LastName': 'Deniz', 'Affiliation': 'Department of Anatomy, Faculty of Medicine, University of Firat, Elazig, Turkey.'}, {'ForeName': 'Zubeyde', 'Initials': 'Z', 'LastName': 'Ercan', 'Affiliation': 'Department of Physiotherapy and Rehabilitation, Faculty of Health Science, University of Firat, Elazig, Turkey.'}, {'ForeName': 'Nilufer', 'Initials': 'N', 'LastName': 'Cetisli Korkmaz', 'Affiliation': 'School of Physiotherapy and Rehabilitation, University of Pamukkale, Denizli, Turkey.'}, {'ForeName': 'Gokhan', 'Initials': 'G', 'LastName': 'Alkan', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Faculty of Medicine, University of Firat, Elazig, Turkey.'}]",NeuroRehabilitation,['10.3233/NRE-203114'] 2234,32741789,"Te.M.P.O., an app for using temporal musical mismatch in post stroke neurorehabilitation: A preliminary randomized controlled study.","BACKGROUND Recently, the potential rehabilitation value of music has been examined and music-based interventions and techniques such as the Negative Mismatch (MMN) have been increasingly investigated in the neurological rehabilitation context. OBJECTIVE The aim of this study was to investigate the effectiveness of a negative mismatch-based therapy on the disability and quality of life in patients with stroke in sub-acute phase. METHODS Thirty patients with a stroke diagnosis in sub-acute phase were randomly assigned to one of two groups: Mismatch (Mg) or Control (CTRLg) group. Both groups used an innovative Android application: Temporal Musical Patterns Organisation (Te.M.P.O). The Disability Rating Scale (DRS), the Modified Barthel Index (MBI) and the Stroke Specific Quality of Life scale (SSQoL) were used at the baseline (T0) and after four weeks of training (T1), in order to assess changes over time. RESULTS Statistical analysis was performed using the data of 24 (Mg = 12, CTRLg = 12) subjects. The results show a major improvement of the Mg with respect to the CTRLg in all clinical scales score. CONCLUSION The temporal negative mismatch-based therapy performed with the Te.M.P.O. application could be useful in improving the disability and the quality of life in stroke survivors in a sub-acute phase.",2020,"The Disability Rating Scale (DRS), the Modified Barthel Index (MBI) and the Stroke Specific Quality of Life scale (SSQoL) were used at the baseline (T0) and after four weeks of training (T1), in order to assess changes over time. ","['patients with stroke in sub-acute phase', 'Thirty patients with a stroke diagnosis in sub-acute phase']","['Mismatch (Mg) or Control (CTRLg', 'negative mismatch-based therapy']","['disability and quality of life', 'Disability Rating Scale (DRS), the Modified Barthel Index (MBI) and the Stroke Specific Quality of Life scale (SSQoL']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0439557', 'cui_str': 'Acute phase'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0451125', 'cui_str': 'Disability rating scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale'}]",30.0,0.0341592,"The Disability Rating Scale (DRS), the Modified Barthel Index (MBI) and the Stroke Specific Quality of Life scale (SSQoL) were used at the baseline (T0) and after four weeks of training (T1), in order to assess changes over time. ","[{'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Verna', 'Affiliation': 'Fondazione Santa Lucia IRCCS, Rome, Italy.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'De Bartolo', 'Affiliation': 'Fondazione Santa Lucia IRCCS, Rome, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Iosa', 'Affiliation': 'Fondazione Santa Lucia IRCCS, Rome, Italy.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Fadda', 'Affiliation': 'Fondazione Santa Lucia IRCCS, Rome, Italy.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Pinto', 'Affiliation': 'Fondazione Santa Lucia IRCCS, Rome, Italy.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Caltagirone', 'Affiliation': 'Fondazione Santa Lucia IRCCS, Rome, Italy.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'De Angelis', 'Affiliation': 'Fondazione Santa Lucia IRCCS, Rome, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Tramontano', 'Affiliation': 'Fondazione Santa Lucia IRCCS, Rome, Italy.'}]",NeuroRehabilitation,['10.3233/NRE-203126'] 2235,32741790,Impact of smart force feedback rehabilitation robot training on upper limb motor function in subacute stage of stroke.,"OBJECTIVE To explore the impact of rehabilitation robot training (RRT) on upper limb motor function and daily activity ability in patients with stroke. METHODS Forty patients meeting the inclusion criteria were randomly divided into the treatment group (TRE) and the control group (CON). Group TRE was trained with an upper limb rehabilitation robot and group CON was trained with traditional occupational therapy. The training time was six weeks, and the upper limb function and daily activities were then assessed. RESULTS (1) There was no statistical significance in the Fugl-Meyer (FM) score, Wolf Motor Function Test (WMFT) score, and Modified Barthel Index (MBI) score between the two groups before treatment (P > 0.05). (2) After treatment, the FM score, WMFT score, and MBI score were significantly higher than before treatment (P < 0.01). (3) There was no significant significance between the two groups after treatment. (P > 0.05). CONCLUSIONS Both RRT and traditional occupational therapy training are useful for the recovery of upper limb motor function and daily life ability in the sub-acute stage of stroke.",2020,Both RRT and traditional occupational therapy training are useful for the recovery of upper limb motor function and daily life ability in the sub-acute stage of stroke.,"['Forty patients meeting the inclusion criteria', 'subacute stage of stroke', 'patients with stroke']","['smart force feedback rehabilitation robot training', 'upper limb rehabilitation robot and group CON was trained with traditional occupational therapy', 'control group (CON', 'RRT and traditional occupational therapy training', 'rehabilitation robot training (RRT']","['Fugl-Meyer (FM) score', ' Wolf Motor Function Test (WMFT) score, and Modified Barthel Index (MBI) score', 'upper limb motor function and daily activity ability', 'upper limb function and daily activities', 'FM score, WMFT score, and MBI score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205365', 'cui_str': 'Subacute'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0235048', 'cui_str': 'Smarting pain'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C1318464', 'cui_str': 'Occupational therapy'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0325001', 'cui_str': 'Wolf'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",40.0,0.0191896,Both RRT and traditional occupational therapy training are useful for the recovery of upper limb motor function and daily life ability in the sub-acute stage of stroke.,"[{'ForeName': 'Quan', 'Initials': 'Q', 'LastName': 'Xu', 'Affiliation': 'Department of Mechanical Engineering, Division of Intelligent and Biomimetic Machinery, State Key Laboratory of Tribology, Tsinghua University, Beijing, China.'}, {'ForeName': 'Chong', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Mechanical Engineering, Division of Intelligent and Biomimetic Machinery, State Key Laboratory of Tribology, Tsinghua University, Beijing, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Pan', 'Affiliation': 'Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Department of Mechanical Engineering, Division of Intelligent and Biomimetic Machinery, State Key Laboratory of Tribology, Tsinghua University, Beijing, China.'}, {'ForeName': 'Tianyu', 'Initials': 'T', 'LastName': 'Jia', 'Affiliation': 'Department of Mechanical Engineering, Division of Intelligent and Biomimetic Machinery, State Key Laboratory of Tribology, Tsinghua University, Beijing, China.'}, {'ForeName': 'Zhibin', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Department of Mechanical Engineering, Division of Intelligent and Biomimetic Machinery, State Key Laboratory of Tribology, Tsinghua University, Beijing, China.'}, {'ForeName': 'Di', 'Initials': 'D', 'LastName': 'Ma', 'Affiliation': 'Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.'}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Pang', 'Affiliation': 'Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.'}, {'ForeName': 'Linghong', 'Initials': 'L', 'LastName': 'Ji', 'Affiliation': 'Department of Mechanical Engineering, Division of Intelligent and Biomimetic Machinery, State Key Laboratory of Tribology, Tsinghua University, Beijing, China.'}]",NeuroRehabilitation,['10.3233/NRE-203130'] 2236,32738837,"Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study.","Background Levonadifloxacin is a novel broad-spectrum anti-MRSA agents belonging to the benzoquinolizine subclass of quinolone. It is developed for oral or intravenous administration for the treatment of infections caused by Gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA). Objectives To establish the non-inferiority of levonadifloxacin compared with linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and to compare the safety of the two antimicrobials. Subjects and methods This was a Phase 3, multicentre, randomized, open-label, active- comparator study with 500 subjects. Oral levonadifloxacin 1000 mg was compared with oral linezolid 600 mg whereas IV levonadifloxacin 800mg was compared with IV linezolid 600 mg, each treatment was administered twice daily for 7-10 days. Non-inferiority was evaluated by comparing oral levonadifloxacin to oral linezolid and IV levonadifloxacin to IV linezolid for overall clinical response at TOC (Test of Cure) Visit. Results The clinical cure rates observed at the TOC in the mITT (modified Intent to treat) populations for levonadifloxacin was numerically higher compared to linezolid in the IV sub-group [(91.0% verses 87.8%); treatment difference of 3.2% (95%CI, -4.5 to 10.9)] and in the oral sub-group (95.2% versus 93.6%); treatment difference of 1.6 % [95%CI, -4.2 to 7.3]). As the lowerbound of the 95% CI around the treatment difference was greater than -15% for both subgroups, the primary objective of the study was met. Therefore, both IV levonadifloxacin and oral levonadifloxacin were non-inferior to IV linezolid and oral linezolid, respectively. The majority of subjects in the micro-ITT population had a baseline infection caused by S. aureus with approximately 30% of subjects having MRSA. Levonadifloxacin (IV and oral) had a higher clinical cure rate at TOC for MRSA patients compared with linezolid (IV and oral), (95.0% vs. 89.3% respectively). Levonadifloxacin showed evidence of favourable clinical and microbiological efficacy in subjects with concurrent bacteraemia as well as in subjects with diabetes including diabetic foot infections caused by Gram-positive pathogens including MRSA. Pharmacokinetic analysis showed that bioavailability of oral levonadifloxacin was 90% and similar pharmacokinetic profile of levonadifloxacin by both routes provide an option for IV to oral switch for the treatment of subjects. Incidences of treatment-emergent adverse events (TEAEs) were similar between treatment groups and between IV (20.8% vs. 22.4%, for levonadifloxacin and linezolid, respectively) and oral therapy (16.0% vs. 13.5%, respectively), There were no SAEs or deaths related to study drug and the majority of the AEs observed were mild in nature. Overall, the administration of both IV and oral levonadifloxacin was well-tolerated in subjects with ABSSSI. Conclusions The results demonstrate that IV and oral levonadifloxacin therapy has excellent clinical activity against MRSA and offers advantage compared to other quinolones which generally lack MRSA coverage. Levonadifloxacin is safe and well tolerated in the treatment of ABSSSI caused by Gram -positive pathogens including MRSA as well as non-inferior to IV and oral linezolid, respectively. Similar pharmacokinetic profile of IV and oral levonadifloxacin provides an option for IV to oral switch for the treatment of subjects. Both oral and IV levonadifloxacin have recently been granted approval in India for the treatment of ABSSSI including diabetic foot infections and concurrent bacteraemia in adults (18 years of age or older). ClinicalTrials.gov Registration: NCT03405064. CTRI No.: CTRI/2017/06/008843.",2020,"Levonadifloxacin (IV and oral) had a higher clinical cure rate at TOC for MRSA patients compared with linezolid (IV and oral), (95.0% vs. 89.3% respectively).","['subjects with ABSSSI', 'adults (18 years of age or older', '500 subjects', 'acute bacterial skin and skin structure infections (ABSSSI', 'subjects', 'Subjects and methods']","['linezolid and oral linezolid', 'oral linezolid 600 mg whereas IV levonadifloxacin', 'levonadifloxacin and oral levonadifloxacin', 'linezolid and IV levonadifloxacin to IV linezolid', 'Linezolid', 'levonadifloxacin', 'Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin', 'Levonadifloxacin', 'IV and oral levonadifloxacin', 'linezolid', 'Oral levonadifloxacin']","['Efficacy and Safety', 'favourable clinical and microbiological efficacy', 'Incidences of treatment-emergent adverse events (TEAEs', 'clinical cure rate', 'bioavailability of oral levonadifloxacin', 'clinical cure rates']","[{'cui': 'C4552483', 'cui_str': 'ABSSSI'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C4552481', 'cui_str': 'Acute bacterial skin and skin structure infection'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0663241', 'cui_str': 'linezolid'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1127473', 'cui_str': 'linezolid 600 MG'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0343401', 'cui_str': 'Methicillin resistant Staphylococcus aureus infection'}, {'cui': 'C0450442', 'cui_str': 'Agent'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0025953', 'cui_str': 'microbiology'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]",,0.0470759,"Levonadifloxacin (IV and oral) had a higher clinical cure rate at TOC for MRSA patients compared with linezolid (IV and oral), (95.0% vs. 89.3% respectively).","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Bhatia', 'Affiliation': 'Wockhardt Ltd., Mumbai, Maharashtra.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Mastim', 'Affiliation': 'Wockhardt Ltd., Mumbai, Maharashtra.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Shah', 'Affiliation': 'Wockhardt Ltd., Mumbai, Maharashtra.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Gutte', 'Affiliation': 'Wockhardt Ltd., Mumbai, Maharashtra.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Joshi', 'Affiliation': 'Wockhardt Ltd., Mumbai, Maharashtra.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Kumbhar', 'Affiliation': 'Wockhardt Ltd., Mumbai, Maharashtra.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Periasamy', 'Affiliation': 'Wockhardt R and D Centre, Aurangabad, Maharashtra.'}, {'ForeName': 'S R', 'Initials': 'SR', 'LastName': 'Palwe', 'Affiliation': 'Wockhardt R and D Centre, Aurangabad, Maharashtra.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Chavan', 'Affiliation': 'Wockhardt R and D Centre, Aurangabad, Maharashtra.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Bhagwat', 'Affiliation': 'Wockhardt R and D Centre, Aurangabad, Maharashtra.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Patel', 'Affiliation': 'Wockhardt R and D Centre, Aurangabad, Maharashtra.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Llorens', 'Affiliation': ""Wockhardt's Morton Grove Pharmaceuticals Inc., Morton Grove, Illinois, USA.""}, {'ForeName': 'H D', 'Initials': 'HD', 'LastName': 'Friedland', 'Affiliation': ""Wockhardt's Morton Grove Pharmaceuticals Inc., Morton Grove, Illinois, USA.""}]",The Journal of the Association of Physicians of India,[] 2237,32738875,Topical citicoline and vitamin B12 versus placebo in the treatment of diabetes-related corneal nerve damage: a randomized double-blind controlled trial.,"BACKGROUND To evaluate the effects of topical citicoline and vitamin B12 (Cit-B12: OMK2, Omikron Italia srl, Italy) on corneal innervation of patients with diabetic neuropathy. METHODS This prospective, randomized, double blind, placebo-controlled study included 30 patients randomised with a 2:1 ratio to Cit-B12 or placebo 3 times daily for 18 months. At baseline and at months 4, 8, 12, 18 patients underwent the Ocular Surface Disease Index questionnaire (OSDI), tear break-up time, evaluation of corneal and conjunctival staining, Schirmer I test, Cochet-Bonnet esthesiometry, and confocal biomicroscopy of corneal sub-basal plexus (SBP). Fiber lenght density (FLD) was calculated using NeuronJ and expressed in mm/mm2. Raw data and differences from baseline were analysed in the two groups. RESULTS 29/30 patients concluded the study. The two groups had similar FLD at baseline; it progressively improved up to month 18 in both groups (Cit-B12, p < 0.0001; controls, < 0.0001-0.03); improvement at month 18 vs baseline was higher in Cit-B12 than placebo (33% vs 15%, p = 0.04). A progressive amelioration of corneal sensitivity (baseline, 28 ± 18 mm; month 18, 52 ± 10 mm, p < 0.0001), conjunctival staining (P = 0.04) and OSDI questionnaire (P = 0.05) were shown on Cit-B12 group alone. Both treatments were well tolerated and adherence during the study was high. CONCLUSIONS Cit-B12 ameliorated both morphology and function of corneal nerves in patients with diabetes, thus suggesting a neuroregenerative effect. TRIAL REGISTRATION Trial registration NCT03906513 , retrospectively registered on 08 April 2019.",2020,"The two groups had similar FLD at baseline; it progressively improved up to month 18 in both groups (Cit-B12, p < 0.0001; controls, < 0.0001-0.03); improvement at month 18 vs baseline was higher in Cit-B12 than placebo (33% vs 15%, p = 0.04).","['patients with diabetes', '30 patients randomised with a 2:1 ratio to Cit-B12 or', 'diabetes-related corneal nerve damage', 'patients with diabetic neuropathy']","['topical citicoline and vitamin B12 (Cit-B12: OMK2, Omikron Italia srl, Italy', 'Topical citicoline and vitamin B12 versus placebo', 'placebo']","['tolerated and adherence', 'corneal sensitivity', 'conjunctival staining', 'Ocular Surface Disease Index questionnaire (OSDI), tear break-up time, evaluation of corneal and conjunctival staining, Schirmer I test, Cochet-Bonnet esthesiometry, and confocal biomicroscopy of corneal sub-basal plexus (SBP', 'OSDI questionnaire', 'Fiber lenght density (FLD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0010725', 'cui_str': 'Citicoline'}, {'cui': 'C0042845', 'cui_str': 'Vitamin B 12'}, {'cui': 'C0161479', 'cui_str': 'Nerve injury'}, {'cui': 'C0011882', 'cui_str': 'Diabetic neuropathy'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0010725', 'cui_str': 'Citicoline'}, {'cui': 'C0042845', 'cui_str': 'Vitamin B 12'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C3203718', 'cui_str': 'Conjunctival staining'}, {'cui': 'C1557335', 'cui_str': 'Ocular surface disease'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C1301514', 'cui_str': 'Schirmer I test'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0178587', 'cui_str': 'Density'}]",30.0,0.584673,"The two groups had similar FLD at baseline; it progressively improved up to month 18 in both groups (Cit-B12, p < 0.0001; controls, < 0.0001-0.03); improvement at month 18 vs baseline was higher in Cit-B12 than placebo (33% vs 15%, p = 0.04).","[{'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Fogagnolo', 'Affiliation': ""Eye Clinic, Università degli Studi di Milano; ASST Santi Paolo e Carlo, San Paolo Hospital, Via di Rudini', 8, 20142, Milan, Italy. fogagnolopaolo@googlemail.com.""}, {'ForeName': 'Ettore', 'Initials': 'E', 'LastName': 'Melardi', 'Affiliation': ""Eye Clinic, Università degli Studi di Milano; ASST Santi Paolo e Carlo, San Paolo Hospital, Via di Rudini', 8, 20142, Milan, Italy.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Tranchina', 'Affiliation': ""Eye Clinic, Università degli Studi di Milano; ASST Santi Paolo e Carlo, San Paolo Hospital, Via di Rudini', 8, 20142, Milan, Italy.""}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Rossetti', 'Affiliation': ""Eye Clinic, Università degli Studi di Milano; ASST Santi Paolo e Carlo, San Paolo Hospital, Via di Rudini', 8, 20142, Milan, Italy.""}]",BMC ophthalmology,['10.1186/s12886-020-01584-w'] 2238,32738878,Supine versus semi-Fowler's positions for tracheal extubation in abdominal surgery-a randomized clinical trial.,"BACKGROUND Tracheal extubation is commonly performed in the supine position. However, in patients undergoing abdominal surgery, the supine position increases abdominal wall tension, especially during coughing and deep breathing, which may aggravate pain and lead to abdominal wound dehiscence. The semi-Fowler's position may reduce abdominal wall tension, but its safety and comfort in tracheal extubation have not been reported. We aimed to evaluate the safety and comfort of different extubation positions in patients undergoing abdominal surgery. METHODS We enrolled 141 patients with an American Society of Anesthesiologists grade of I-III who underwent abdominal surgery. All patients were anesthetized with propofol, fentanyl, cisatracurium, and sevoflurane. After surgery, all patients were transferred to the post-anesthesia care unit (PACU). Patients were then randomly put into the semi-Fowler's (n = 70) or supine (n = 71) position while 100% oxygen was administered. The endotracheal tube was removed after the patients opened their eyes and regained consciousness. Vital signs, coughing, and pain and comfort scores before and/or after extubation were recorded until the patients left the PACU. RESULTS In comparison with the supine position, the semi-Fowler's position significantly decreased the wound pain scores at all intervals after extubation (3.51 ± 2.50 vs. 4.58 ± 2.26, 2.23 ± 1.68 vs. 3.11 ± 2.00, 1.81 ± 1.32 vs. 2.59 ± 1.88, P = 0.009, 0.005 and 0.005, respectively), reduced severe coughing (8[11.43%] vs. 21[29.58%], P = 0.008) and bucking after extubation (3[4.29%] vs. 18[25.35%], P < 0.001), and improved the comfort scores 5 min after extubation (6.11 ± 2.30 vs. 5.17 ± 1.78, P = 0.007) and when leaving from post-anesthesia care unit (7.17 ± 2.27 vs. 6.44 ± 1.79, P = 0.034). The incidences of vomiting, emergence agitation, and respiratory complications were of no significant difference. CONCLUSION Tracheal extubation in the semi-Fowler's position is associated with less coughing, sputum suction, and pain, and more comfort, without specific adverse effects when compared to the conventional supine position. TRIAL REGISTRATION Chinese Clinical Trial Registry, ChiCTR1900025566 . Registered on 1st September 2019.",2020,"In comparison with the supine position, the semi-Fowler's position significantly decreased the wound pain scores at all intervals after extubation (3.51 ± 2.50 vs. 4.58 ± 2.26, 2.23 ± 1.68 vs. 3.11 ± 2.00, 1.81 ± 1.32 vs. 2.59 ± 1.88, P = 0.009, 0.005 and 0.005, respectively), reduced severe coughing (8[11.43%] vs. 21[29.58%], P = 0.008) and bucking after extubation (3[4.29%] vs. 18[25.35%], P < 0.001), and improved the comfort scores 5 min after extubation (6.11 ± 2.30 vs. 5.17 ± 1.78, P = 0.007) and when leaving from post-anesthesia care unit (7.17 ± 2.27 vs. 6.44 ± 1.79, P = 0.034).","['141 patients with an American Society of Anesthesiologists grade of I-III who underwent abdominal surgery', 'patients undergoing abdominal surgery']","[""Supine versus semi-Fowler's positions"", 'propofol, fentanyl, cisatracurium, and sevoflurane']","['Tracheal extubation', 'coughing, sputum suction, and pain', 'reduced severe coughing', 'safety and comfort', 'wound pain scores', 'comfort scores', 'Vital signs, coughing, and pain and comfort scores', 'incidences of vomiting, emergence agitation, and respiratory complications']","[{'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}]","[{'cui': 'C0038846', 'cui_str': 'Supine body position'}, {'cui': 'C1882998', 'cui_str': ""Semi-Fowler's position""}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C1096766', 'cui_str': 'Cisatracurium'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}]","[{'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C0038638', 'cui_str': 'Suction drainage'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0241745', 'cui_str': 'Wound pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0920253', 'cui_str': 'Agitated Emergence'}, {'cui': 'C0161818', 'cui_str': 'Respiratory complication'}]",141.0,0.147185,"In comparison with the supine position, the semi-Fowler's position significantly decreased the wound pain scores at all intervals after extubation (3.51 ± 2.50 vs. 4.58 ± 2.26, 2.23 ± 1.68 vs. 3.11 ± 2.00, 1.81 ± 1.32 vs. 2.59 ± 1.88, P = 0.009, 0.005 and 0.005, respectively), reduced severe coughing (8[11.43%] vs. 21[29.58%], P = 0.008) and bucking after extubation (3[4.29%] vs. 18[25.35%], P < 0.001), and improved the comfort scores 5 min after extubation (6.11 ± 2.30 vs. 5.17 ± 1.78, P = 0.007) and when leaving from post-anesthesia care unit (7.17 ± 2.27 vs. 6.44 ± 1.79, P = 0.034).","[{'ForeName': 'Qiongfang', 'Initials': 'Q', 'LastName': 'Zhu', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Zheyan', 'Initials': 'Z', 'LastName': 'Huang', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Qiaomei', 'Initials': 'Q', 'LastName': 'Ma', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Zehui', 'Initials': 'Z', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yubo', 'Initials': 'Y', 'LastName': 'Kang', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Miaoyin', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Tiantian', 'Initials': 'T', 'LastName': 'Gan', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Minxue', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, The Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Rd, Guangzhou, China.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Huang', 'Affiliation': 'Department of Anesthesiology, The Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Rd, Guangzhou, China. huangf25@mail2.sysu.edu.cn.'}]",BMC anesthesiology,['10.1186/s12871-020-01108-5'] 2239,32738880,"Effects of a staff education programme about person-centred care and promotion of thriving on relatives' satisfaction with quality of care in nursing homes: a multi-centre, non-equivalent controlled before-after trial.","BACKGROUND As part of a nursing home intervention study, the aim of this paper was 1) to evaluate the effects of a staff education programme about person-centred care and promotion of thriving on relatives' satisfaction with quality of care and their perceptions of the person-centredness of the environment, and 2) to outline factors of importance to explain the variance in relatives' satisfaction with quality of care. Relatives are often referred to as vital for the operationalisation of person-centredness in nursing homes, representing an important source of information for care planning and quality of care assessments. However, the evidence for effects of person-centredness in nursing homes on relatives' experiences is sparse and little is known on what could explain their satisfaction with the quality of care. METHODS A multi-centre, non-equivalent controlled group before-after design with study sites in Australia, Norway and Sweden. Staff in the intervention group participated in a 14-month education on person-centredness, person-centred care, thriving and caring environment. Staff in the control group received a one-hour lecture before the intervention period. Data were collected at baseline, after the intervention and six months after the end of the intervention, and analysed using descriptive statistics, a generalised linear model and hierarchical multiple regression. RESULTS In general, relatives from both the intervention and control nursing homes were satisfied with the quality of care, and no statistically significant overall between-group-effects of the intervention were revealed on satisfaction with quality of care or perceptions of the person-centredness of environment. A person-centred environment in terms of safety and hospitality were identified as factors of prominent importance for the relatives' satisfaction with the quality of care. CONCLUSION The findings of this paper provide a foundation for future research in terms of intervention design in nursing home contexts. Staff availability, approachability, competence and communication with relatives may be important factors to consider to improve quality of care from the perspective of relatives, but more research both with and for relatives to people living in nursing homes is necessary to identify the keys to success. TRIAL REGISTRATION ClinicalTrials.gov- NCT02714452 . Registered on March 19, 2016.",2020,"In general, relatives from both the intervention and control nursing homes were satisfied with the quality of care, and no statistically significant overall between-group-effects of the intervention were revealed on satisfaction with quality of care or perceptions of the person-centredness of environment.","['A multi-centre, non-equivalent controlled group before-after design with study sites in Australia, Norway and Sweden', 'nursing homes']","['staff education programme', '14-month education on person-centredness, person-centred care, thriving and caring environment']",['satisfaction with quality of care or perceptions of the person-centredness of environment'],"[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0028423', 'cui_str': 'Norway'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}]","[{'cui': 'C0588974', 'cui_str': 'Staff education'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0014406', 'cui_str': 'Environment'}]","[{'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C4759659', 'cui_str': 'With quality'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0014406', 'cui_str': 'Environment'}]",,0.0540053,"In general, relatives from both the intervention and control nursing homes were satisfied with the quality of care, and no statistically significant overall between-group-effects of the intervention were revealed on satisfaction with quality of care or perceptions of the person-centredness of environment.","[{'ForeName': 'Qarin', 'Initials': 'Q', 'LastName': 'Lood', 'Affiliation': 'The Medical Faculty, Department of nursing, Umeå University, Vårdvetarhuset, Hus A, plan 5, 90187, Umeå, Sweden. qarin.lood@neuro.gu.se.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Sjögren', 'Affiliation': 'The Medical Faculty, Department of nursing, Umeå University, Vårdvetarhuset, Hus A, plan 5, 90187, Umeå, Sweden.'}, {'ForeName': 'Ådel', 'Initials': 'Å', 'LastName': 'Bergland', 'Affiliation': 'Lovisenberg Diaconal University College, Lovisenberggaten 15b, 0456, Oslo, Norway.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Lindkvist', 'Affiliation': 'Department of Epidemiology and Global Health, Umeå University, Försörjningsvägen 7D, 907 37, Umeå, Sweden.'}, {'ForeName': 'Marit', 'Initials': 'M', 'LastName': 'Kirkevold', 'Affiliation': 'Faculty of Medicine, Institute of Health and Society, Oslo University, Nedre Ullevål 9, 0850, Oslo, Norway.'}, {'ForeName': 'Per-Olof', 'Initials': 'PO', 'LastName': 'Sandman', 'Affiliation': 'The Medical Faculty, Department of nursing, Umeå University, Vårdvetarhuset, Hus A, plan 5, 90187, Umeå, Sweden.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Edvardsson', 'Affiliation': 'The Medical Faculty, Department of nursing, Umeå University, Vårdvetarhuset, Hus A, plan 5, 90187, Umeå, Sweden.'}]",BMC geriatrics,['10.1186/s12877-020-01677-7'] 2240,32738887,Problems of subgroup analysis in randomized controlled trial.,"Multiple subgroup analyses of the same data increase the risk of generating false positive findings. All outcomes and planned subgroup analyses should thus be prespecified and described in the original trial registry. When outcome changes during an ongoing trial seem justifiable, publications must disclose and explain such changes.",2020,Multiple subgroup analyses of the same data increase the risk of generating false positive findings.,[],[],[],[],[],[],,0.195421,Multiple subgroup analyses of the same data increase the risk of generating false positive findings.,"[{'ForeName': 'Hans-Joachim', 'Initials': 'HJ', 'LastName': 'Priebe', 'Affiliation': 'Department of Anesthesiology and Critical Care, Medical Center University of Freiburg, Hugstetter Straße 55, 79095, Freiburg, Germany. hans-joachim.priebe@uniklinik-freiburg.de.'}]",BMC anesthesiology,['10.1186/s12871-020-01105-8'] 2241,32739045,Minimising haemodynamic lability during changeover of syringes infusing norepinephrine in adult critical care patients: a multicentre randomised controlled trial.,"BACKGROUND Arterial pressure lability is common during the process of replacing syringes used for norepinephrine infusions in critically ill patients. It is unclear if there is an optimal approach to minimise arterial pressure instability during this procedures. We investigated whether 'double pumping' changeover (DPC) or automated changeover (AC) reduced blood pressure lability in critically ill adults compared with quick syringe changeover (QC). METHODS Patients requiring a norepinephrine infusion syringe change were randomised in a non-blinded trial undertaken in six ICUs. Randomisation was minimised by norepinephrine flow rate at inclusion and centre. The primary outcome was the frequency of increased/decreased mean arterial pressure (defined by 15 mm Hg from baseline measurements) within 15 min of switching the syringe compared with QC. RESULTS Patients (mean age: 64 (range:18-88)) yr were randomly assigned to QC (n=95), DPC (n=95), or AC (n=96). Increased MAP was the commonest consequence of syringe changeovers. MAP variability was most frequent after DPC (89/224 changeovers; 39.7%) compared with 57/223 (25.6%) changeovers after quick syringe switch and 46/181 (25.4%) in patients randomised to receive automated changeover (P=0.001). Fewer events occurred with QC compared with DPC (P=0.002). Sensitivity analysis based on mixed models showed that performing several changeovers on a single patient had no impact. Both type of changeover and norepinephrine dose before syringe changeover were independently associated with MAP variations >15 mm Hg. CONCLUSIONS Quick changeover of norepinephrine syringes was associated with less blood pressure lability compared with DPC. The prevalence of MAP variations was the same between AC and QC. CLINICAL TRIAL REGISTRATION NCT02304939.",2020,MAP variability was most frequent after DPC (89/224 changeovers; 39.7%) compared with 57/223 (25.6%) changeovers after quick syringe switch and 46/181 (25.4%) in patients randomised to receive automated changeover (P=0.001).,"['critically ill adults', 'adult critical care patients', 'Patients requiring a', 'critically ill patients', 'Patients (mean age: 64 (range:18-88', 'n=95), DPC (n=95), or AC (n=96']","['norepinephrine infusion syringe', 'norepinephrine infusions', ""double pumping' changeover (DPC) or automated changeover (AC"", 'norepinephrine syringes', 'QC', 'norepinephrine', 'quick syringe changeover (QC']","['haemodynamic lability', 'frequency of increased/decreased mean arterial pressure', 'blood pressure lability', 'prevalence of MAP variations', 'MAP variability']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0010337', 'cui_str': 'Care of intensive care unit patient'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0205554', 'cui_str': 'Automated'}]","[{'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0039142', 'cui_str': 'Syringe'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0520854', 'cui_str': 'Decreased mean arterial pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0024779', 'cui_str': 'Maps'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}]",,0.626804,MAP variability was most frequent after DPC (89/224 changeovers; 39.7%) compared with 57/223 (25.6%) changeovers after quick syringe switch and 46/181 (25.4%) in patients randomised to receive automated changeover (P=0.001).,"[{'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Poiroux', 'Affiliation': 'Medical Intensive Care Department, Angers University Hospital, Angers, France; UMR CNRS 6015-INSERM UI083 MitoVasc Institute, University of Angers, Angers, France. Electronic address: lapoiroux@chu-angers.fr.'}, {'ForeName': 'Cyril', 'Initials': 'C', 'LastName': 'Le Roy', 'Affiliation': 'Medical Intensive Care Department, Angers University Hospital, Angers, France.'}, {'ForeName': 'Anne-Sylvie', 'Initials': 'AS', 'LastName': 'Ramelet', 'Affiliation': 'Institute of Higher Education and Research in Healthcare (IUFRS), University of Lausanne, Lausanne, Switzerland; Department Woman-Mother-Child, Lausanne University Hospital, Lausanne, Switzerland.'}, {'ForeName': 'Mélaine', 'Initials': 'M', 'LastName': 'Le Brazic', 'Affiliation': 'Medical Intensive Care Department, Nantes University Hospital, Nantes, France.'}, {'ForeName': 'Leslie', 'Initials': 'L', 'LastName': 'Messager', 'Affiliation': 'Department of Anesthesiology and Critical Care, Critical Care Unit, Angers University Hospital, Angers, France.'}, {'ForeName': 'Amélie', 'Initials': 'A', 'LastName': 'Gressent', 'Affiliation': 'Medical Intensive Care Unit, Rouen University Hospital, Rouen, France.'}, {'ForeName': 'Yolaine', 'Initials': 'Y', 'LastName': 'Alcourt', 'Affiliation': 'Intensive Care Department, Vendée Regional Hospital, La Roche-sur-Yon, France.'}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Haubertin', 'Affiliation': 'Department of Anaesthesiology and Critical Care, Critical Care Unit, University Teaching Hospital of Purpan, Toulouse, France.'}, {'ForeName': 'Jean-François', 'Initials': 'JF', 'LastName': 'Hamel', 'Affiliation': 'Department of Methodology and Biostatistics, Angers University Hospital, Angers, France.'}, {'ForeName': 'Lise', 'Initials': 'L', 'LastName': 'Piquilloud', 'Affiliation': 'Medical Intensive Care Department, Angers University Hospital, Angers, France; Adult Intensive Care and Burn Unit, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; UMR CNRS 6015-INSERM UI083 MitoVasc Institute, University of Angers, Angers, France.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Mercat', 'Affiliation': 'Medical Intensive Care Department, Angers University Hospital, Angers, France.'}]",British journal of anaesthesia,['10.1016/j.bja.2020.06.041'] 2242,32739049,"Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study.","PURPOSE Interest in Toll-like receptor (TLR) agonists for cancer treatment has been renewed after promising preliminary clinical data in combination with checkpoint inhibitors. This first-in-human study assessed the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of intravenous GSK1795091, a synthetic TLR4 agonist, in healthy volunteers as a precursor to evaluation in patients with cancer. METHODS Healthy participants were randomized (1:3; double-blinded manner) to receive placebo or a single intravenous injection of GSK1795091 at doses of 7-100 ng. The primary objective was to evaluate the safety and tolerability of GSK1795091; secondary and exploratory objectives were to characterize GSK1795091 PK and PD properties. FINDINGS Forty participants received study treatment (10 received placebo and 30 received GSK1795091). Overall, 3 of the 10 participants (30%) who received placebo and 16 of the 30 (53%) who received GSK1795091 experienced ≥1 adverse event (AE). The most common AEs were influenza-like illness, headache, back pain, and increased body temperature. One participant experienced late-occurring AEs (alanine aminotransferase and aspartate aminotransferase increases), considered possibly related to GSK1795091. No serious AEs were reported. GSK1795091 PK properties were characterized by dose proportional increase in exposure. Transient and dose-dependent changes in induced cytokine and chemokine concentrations and immune cell counts were observed 1-4 h after GSK1795091 administration and returned to baseline within 24 h. IMPLICATIONS Intravenously administered GSK1795091 was acceptably tolerated in healthy volunteers, had favorable PK properties, and stimulated immune cell changes in a dose-dependent manner, providing evidence of target engagement and downstream pharmacology. These results supported the design and initiation of a repeat-dose study of intravenous GSK1795091 in combination with other immunotherapies in patients with advanced cancer. ClinicalTrials.gov identifier: NCT02798978.",2020,"Transient and dose-dependent changes in induced cytokine and chemokine concentrations and immune cell counts were observed 1-4 h after GSK1795091 administration and returned to baseline within 24 h. ","['patients with cancer', 'patients with advanced cancer', 'healthy volunteers', 'Forty participants received study treatment (10 received', 'Healthy Individuals', 'Healthy participants']","['GSK1795091', 'Placebo', 'placebo and 30 received GSK1795091', 'TLR4 Agonist GSK1795091', 'placebo']","['induced cytokine and chemokine concentrations and immune cell counts', 'safety and tolerability', 'late-occurring AEs (alanine aminotransferase and aspartate aminotransferase increases', 'influenza-like illness, headache, back pain, and increased body temperature', 'safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) properties', 'Safety, Pharmacokinetics, and Pharmacodynamics', 'adverse event (AE']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1321919', 'cui_str': 'TLR4 protein, human'}, {'cui': 'C0243192', 'cui_str': 'agonists'}]","[{'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0282554', 'cui_str': 'Cytokines, Chemotactic'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0151904', 'cui_str': 'Aspartate aminotransferase increased'}, {'cui': 'C0392171', 'cui_str': 'Influenza-like symptoms'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.553993,"Transient and dose-dependent changes in induced cytokine and chemokine concentrations and immune cell counts were observed 1-4 h after GSK1795091 administration and returned to baseline within 24 h. ","[{'ForeName': 'Bruce A', 'Initials': 'BA', 'LastName': 'Hug', 'Affiliation': 'R&D Pharmaceuticals, GSK, Upper Providence, PA, USA. Electronic address: bruce.a.hug@gsk.com.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Matheny', 'Affiliation': 'R&D Pharmaceuticals, GSK, Upper Providence, PA, USA.'}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Burns', 'Affiliation': 'Global Clinical Sciences & Delivery, GSK, Abbotsford, Victoria, Australia.'}, {'ForeName': 'Herbert', 'Initials': 'H', 'LastName': 'Struemper', 'Affiliation': 'Clinical Pharmacology Modeling & Simulation, GSK, Research Triangle Park, NC, USA.'}, {'ForeName': 'Xiaowei', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'R&D Pharmaceuticals, GSK, Upper Providence, PA, USA.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Washburn', 'Affiliation': 'R&D Pharmaceuticals, GSK, Upper Providence, PA, USA.'}]",Clinical therapeutics,['10.1016/j.clinthera.2020.05.022'] 2243,32739058,Reflective metacognition and objective structured clinical examination performance in introductory pharmacy practice experiences.,"BACKGROUND AND PURPOSE Objective structured clinical examinations (OSCEs) allow for holistic evaluation of clinical competence, but integration of reflective practices on OSCE performance has not been well-studied. EDUCATIONAL ACTIVITY AND SETTING To develop metacognitive skills, second-year pharmacy students completed a self-reflection assignment on a mock medication therapy management OSCE in an introductory pharmacy practice experience course. Students who completed the course during the prior year (no self-reflection assignment) served as the control. The study assessed the correlation of students' reflections of their OCSE abilities to OSCE performance and evaluated if student demographics influenced the correlation. FINDINGS There were 107 students in the control group and 95 students in the intervention group. A higher proportion of students passed the overall OSCE in the control group (67.4%) compared to the intervention group (58.9%), but this was not statistically significant. Neither gender, age, nor Pharmacy College Admissions Test score had an effect on OSCE pass rates. Grade point average did have a significant effect on OSCE pass rates (P = .019). Overall, no statistically significant association was seen in summative OSCE performance between students who used structured, guided questions to reflect on their formative OSCE performance and those who did not (P > .05). SUMMARY Despite this study's results, faculty continue to embrace the concept of reflective practice. Further research is needed to assess the value and role of reflective practice in pharmacy education.",2020,"A higher proportion of students passed the overall OSCE in the control group (67.4%) compared to the intervention group (58.9%), but this was not statistically significant.","['Students who completed the course during the prior year (no self-reflection assignment) served as the control', '107 students in the control group and 95 students in the intervention group', 'introductory pharmacy practice experiences']",[],"['OSCE pass rates', 'overall OSCE', 'summative OSCE performance', 'formative OSCE performance']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0031321', 'cui_str': 'Pharmacy service'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]",[],"[{'cui': 'C0282416', 'cui_str': 'Overall'}]",107.0,0.0292768,"A higher proportion of students passed the overall OSCE in the control group (67.4%) compared to the intervention group (58.9%), but this was not statistically significant.","[{'ForeName': 'Amulya', 'Initials': 'A', 'LastName': 'Tatachar', 'Affiliation': 'Department of Pharmacotherapy, University of North Texas System College of Pharmacy, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, United States. Electronic address: amulya.tatachar@unthsc.edu.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Wettergreen', 'Affiliation': 'Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 E. Montview Blvd., Aurora, CO 80045, United States. Electronic address: sara.wettergreen@cuanschutz.edu.'}, {'ForeName': 'Shara', 'Initials': 'S', 'LastName': 'Summers', 'Affiliation': 'Department of Pharmacotherapy, University of North Texas System College of Pharmacy, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, United States.'}]",Currents in pharmacy teaching & learning,['10.1016/j.cptl.2020.04.030'] 2244,32739072,The effectiveness of an oral hygiene program combined with health-promoting counseling for rural adults with cardiometabolic risks: A quasi-experimental design.,"AIM The aim of this study was to explore the effectiveness of an oral hygiene program combined with home-phone health promoting counseling for rural adults with metabolic syndrome. BACKGROUND Metabolic syndrome is an important risk factor for cardiometabolic diseases. Evidence indicates that the poor oral hygiene and unhealthy lifestyles are closely related to metabolic syndrome. METHODS A prospective quasi-experimental design involved a total of 136 community adults, with metabolic syndrome living in two rural townships, were clustered and conveniently assigned to intervention and control group between June 2017 and December 2018. The primary outcome was the change in cardiometabolic biomarkers. The secondary outcome comprised changes in the health-promoting behaviors. The intervention effect was assessed using a generalized estimating equation model. RESULTS There were 80 and 56 participants in the intervention and control group, respectively. The mean age was 56 years and ranged from 33 to 70 years. The intervention group exhibited a greater improvement in body mass index (P < 0.01), waist circumference (P < 0.05), body fat percentage (P < 0.05), triglyceride level (P < 0.05), use of dental floss (P < 0.05), regular tooth scaling (P < 0.05), physical activity (P < 0.001), and total score of health-promoting behaviors (P < 0.001) than the control group. CONCLUSION This study supports the use of an oral hygiene program combined with home-phone counseling, which offers more advantages than its counterpart. Considering the global epidemic of cardiometabolic diseases, this is a community health nursing model worth to replicate and evaluate. Further study should consider innovative strategies to improve the awareness and adoption of a healthy lifestyle in residents with cardiometabolic risks.",2020,"The intervention group exhibited a greater improvement in body mass index (P < 0.01), waist circumference (P < 0.05), body fat percentage (P < 0.05), triglyceride level (P < 0.05), use of dental floss (P < 0.05), regular tooth scaling (P < 0.05), physical activity (P < 0.001), and total score of health-promoting behaviors (P < 0.001) than the control group. ","['rural adults with metabolic syndrome', '136 community adults, with metabolic syndrome living in two rural townships, were clustered and conveniently assigned to intervention and control group between June 2017 and December 2018', 'The mean age was 56\u202fyears and ranged from 33 to 70\u202fyears', 'residents with cardiometabolic risks', 'rural adults with cardiometabolic risks']","['oral hygiene program combined with health-promoting counseling', 'oral hygiene program combined with home-phone counseling', 'oral hygiene program combined with home-phone health promoting counseling']","['waist circumference', 'use of dental floss', 'body fat percentage', 'body mass index', 'triglyceride level', 'regular tooth scaling', 'physical activity', 'total score of health-promoting behaviors', 'change in cardiometabolic biomarkers', 'health-promoting behaviors']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]","[{'cui': 'C0029164', 'cui_str': 'Dental Hygiene'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}]","[{'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0162350', 'cui_str': 'Dental floss'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0202236', 'cui_str': 'Triglycerides measurement'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0204173', 'cui_str': 'Scaling of tooth'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0517496', 'cui_str': 'Health promotion behavior'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",136.0,0.0293092,"The intervention group exhibited a greater improvement in body mass index (P < 0.01), waist circumference (P < 0.05), body fat percentage (P < 0.05), triglyceride level (P < 0.05), use of dental floss (P < 0.05), regular tooth scaling (P < 0.05), physical activity (P < 0.001), and total score of health-promoting behaviors (P < 0.001) than the control group. ","[{'ForeName': 'Jui-Chu', 'Initials': 'JC', 'LastName': 'Huang', 'Affiliation': 'Department of Internal Medicine, Chang Gung Memorial Hospital, Yunlin, Taiwan.'}, {'ForeName': 'Ming-Shyan', 'Initials': 'MS', 'LastName': 'Lin', 'Affiliation': 'Department of Cardiology, Chang Gung Memorial Hospital, Yunlin, Taiwan.'}, {'ForeName': 'Wen-Nan', 'Initials': 'WN', 'LastName': 'Chiu', 'Affiliation': 'Department of Nursing, Chang Gung University of Science and Technology, Yunlin, Taiwan.'}, {'ForeName': 'Tung-Jung', 'Initials': 'TJ', 'LastName': 'Huang', 'Affiliation': 'Department of Internal Medicine, Chang Gung Memorial Hospital, Yunlin, Taiwan.'}, {'ForeName': 'Mei-Yen', 'Initials': 'MY', 'LastName': 'Chen', 'Affiliation': 'Department of Nursing, Chang Gung University of Science and Technology, Chiayi, Taiwan; School of Nursing, Chang Gung University, Taoyuan, Taiwan; Department of Cardiology, Chang Gung Memorial Hospital, Chiayi, Taiwan. Electronic address: meiyen@mail.cgust.edu.tw.'}]",Applied nursing research : ANR,['10.1016/j.apnr.2020.151333'] 2245,32739073,A quasi-experimental study of the effect of an intervention on older stroke survivors' functionality.,,2020,,"[""older stroke survivors' functionality""]",[],[],"[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]",[],[],,0.0196864,,"[{'ForeName': 'Odete', 'Initials': 'O', 'LastName': 'Araújo', 'Affiliation': 'School of Nursing, University of Minho, Braga, Portugal; Health Sciences Research Unit, Nursing (UICISA E: UMinho), Portugal; Research Group ""Ageing C: Ageing Cluster"" - CINTESIS - Center for Health Technology and Services Research, Porto, Edifício da Biblioteca Geral (BGUM), Campus de Gualtar, 4710-057 Braga, Portugal. Electronic address: odete.araujo@ese.uminho.pt.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Lage', 'Affiliation': 'School of Nursing, University of Minho, Edifício da Biblioteca Geral (BGUM), Campus de Gualtar, 4710-057 Braga, Portugal. Electronic address: ilage@ese.uminho.pt.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Cabrita', 'Affiliation': 'Faculty of Pharmacy, University of Lisbon, Avenida Professor Gama Pinto, 1649-003 Lisboa, Portugal. Electronic address: jcabrita@ff.ul.pt.'}, {'ForeName': 'Laetitia', 'Initials': 'L', 'LastName': 'Teixeira', 'Affiliation': 'Institute of Biomedical Sciences Abel Salazar, University of Porto, Rua Jorge de Viterbo Ferreira 228, 4050-343 Porto, Portugal.'}]",Applied nursing research : ANR,['10.1016/j.apnr.2020.151280'] 2246,32510737,Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.,"BACKGROUND The inflammatory biomarker interleukin-6 (IL-6) is associated with mortality in atrial fibrillation (AF). OBJECTIVE To investigate if repeated IL-6 measurements improve the prognostication for stroke or systemic embolism, major bleeding, and mortality in anticoagulated patients with AF. METHODS IL-6 levels by ELISA were measured at study entry and at 2 months in 4830 patients in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial with 1.8 years median follow-up. In the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, IL-6 was measured at study entry, 3, 6, and 12 months in 2559 patients with 2.0 years median follow-up. Associations between a second IL-6 measurement and outcomes, adjusted for baseline IL-6, clinical variables, and other cardiovascular biomarkers, were analyzed by Cox regression. RESULTS Median IL-6 levels were 2.0 ng/L (interquartile range [IQR] 1.30-3.20) and 2.10 ng/L (IQR 1.40-3.40) at the two time-points in ARISTOTLE, and, in RE-LY, 2.5 ng/L (IQR 1.6-4.3), 2.5 ng/L (IQR 1.6-4.2), 2.4 ng/L (IQR 1.6, 3.9), and 2.4 ng/L (IQR 1.5, 3.9), respectively. IL-6 was associated with mortality; hazard ratios per 50% higher IL-6 at 2 or 3 months, respectively, were 1.32 (95% confidence interval, 1.23-1.41; P < .0001) in ARISTOTLE, and 1.11 (1.01-1.22, P = .0290) in RE-LY; with improved C index from 0.74 to 0.76 in ARISTOTLE, but not in the smaller RE-LY cohort. There were no consistent associations with second IL-6 and stroke or systemic embolism, or major bleeding. CONCLUSIONS Persistent systemic inflammatory activity, assessed by repeated IL-6 measurements, is associated with mortality independent of established clinical risk factors and other strong cardiovascular biomarkers in anticoagulated patients with AF.",2020,"IL-6 was associated with mortality; hazard ratios per 50% higher IL-6 at 2 or 3 months, respectively, were 1.32 (95% confidence interval, 1.23-1.41; P < .0001) in ARISTOTLE, and 1.11 (1.01-1.22, P = .0290) in RE-LY; with improved C index from 0.74 to 0.76 in ARISTOTLE, but not in the smaller RE-LY cohort.","['4830 patients in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial with 1.8\xa0years median follow-up', 'anticoagulated patients with AF', 'anticoagulated patients with atrial fibrillation', '2559 patients with 2.0\xa0years median follow-up']",['repeated IL-6 measurements'],"['interleukin-6 and risk of mortality', 'second IL-6 and stroke or systemic embolism, or major bleeding', 'Median IL-6 levels', 'baseline IL-6, clinical variables, and other cardiovascular biomarkers', 'IL-6', 'stroke or systemic embolism, major bleeding, and mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0919829', 'cui_str': 'IL-6 assay'}]","[{'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013922', 'cui_str': 'Embolism'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",2559.0,0.35274,"IL-6 was associated with mortality; hazard ratios per 50% higher IL-6 at 2 or 3 months, respectively, were 1.32 (95% confidence interval, 1.23-1.41; P < .0001) in ARISTOTLE, and 1.11 (1.01-1.22, P = .0290) in RE-LY; with improved C index from 0.74 to 0.76 in ARISTOTLE, but not in the smaller RE-LY cohort.","[{'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Aulin', 'Affiliation': 'Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Ziad', 'Initials': 'Z', 'LastName': 'Hijazi', 'Affiliation': 'Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Agneta', 'Initials': 'A', 'LastName': 'Siegbahn', 'Affiliation': 'Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Ulrika', 'Initials': 'U', 'LastName': 'Andersson', 'Affiliation': 'Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Alexander', 'Affiliation': 'Duke Clinical Research Institute, Duke University Medical Center, Duke Health, Durham, NC, USA.'}, {'ForeName': 'Stuart J', 'Initials': 'SJ', 'LastName': 'Connolly', 'Affiliation': 'Population Health Research Institute, McMaster U and Hamilton Health Sciences, Hamilton, ON, Canada.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Ezekowitz', 'Affiliation': 'Thomas Jefferson Medical College and the Heart Center, Wynnewood, PA, USA.'}, {'ForeName': 'Bernard J', 'Initials': 'BJ', 'LastName': 'Gersh', 'Affiliation': 'Mayo Clinic College of Medicine, Rochester, MN, USA.'}, {'ForeName': 'Christopher B', 'Initials': 'CB', 'LastName': 'Granger', 'Affiliation': 'Duke Clinical Research Institute, Duke University Medical Center, Duke Health, Durham, NC, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Horowitz', 'Affiliation': 'University of Adelaide, Adelaide, SA, Australia.'}, {'ForeName': 'Elaine M', 'Initials': 'EM', 'LastName': 'Hylek', 'Affiliation': 'Boston University Medical Center, Boston, MA, USA.'}, {'ForeName': 'Renato D', 'Initials': 'RD', 'LastName': 'Lopes', 'Affiliation': 'Duke Clinical Research Institute, Duke University Medical Center, Duke Health, Durham, NC, USA.'}, {'ForeName': 'Salim', 'Initials': 'S', 'LastName': 'Yusuf', 'Affiliation': 'Population Health Research Institute, McMaster U and Hamilton Health Sciences, Hamilton, ON, Canada.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Wallentin', 'Affiliation': 'Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Oldgren', 'Affiliation': 'Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.'}]",Journal of thrombosis and haemostasis : JTH,['10.1111/jth.14947'] 2247,32745555,Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency.,"BACKGROUND Granulomatous and lymphocytic interstitial lung disease (GLILD) is a life-threatening complication in patients with CVID, but the optimal treatment is unknown. OBJECTIVE Determine if rituximab with azathioprine or mycophenolate mofetil improves the HRCT of the chest and/or PFTs in patients with CVID and GLILD. METHODS A retrospective chart review was performed of clinical and laboratory data in 39 patients with CVID and GLILD who completed immunosuppressive therapy. Chest HRCT scans, performed prior to therapy and after the conclusion of therapy, were blinded, randomized, and scored independently by two radiologists. Differences between pre- and post-treatment HRCT scores, PFTs and lymphocyte subsets were analyzed. Whole exome sequencing was performed on all patients. RESULTS Immunosuppressive therapy improved CT scores (p<0.0001), FVC (p=0.0017), FEV1 (p=0.037), TLC (p=0.013) but not DLCO (p=0.12). Nine patients relapsed and six completed re-treatment, and 5/6 (83%) of these patients had improved HRCT scores (p=0.063). Relapse was associated with an increased number of B cells (p=0.016) and activated CD4 T cells (p=0.016). Four (10%) patients had pneumonia on active treatment, and 2 (5%) patients died after completion of therapy. Eight (21%) patients had a damaging mutation in a gene known to predispose (TNFRSF13B, n=3) or cause a CVID-like PID (CTLA4, n=2; KMT2D, n=2; BIRC4, n=1). Immunosuppression improved the HRCT scores in patients with (p=0.0078) and without (p<0.0001) a damaging mutation. CONCLUSIONS Immunosuppressive therapy improved the radiographic abnormalities and pulmonary function of patients with GLILD. A majority of patients had sustained remissions.",2020,Relapse was associated with an increased number of B cells (p=0.016) and activated CD4 T cells (p=0.016).,"['39 patients with CVID and GLILD who completed immunosuppressive therapy', 'patients with CVID', 'patients with CVID and GLILD', 'granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency', 'patients with GLILD']","['Immunosuppressive therapy', 'Immunosuppression', 'rituximab with azathioprine or mycophenolate mofetil', 'Rituximab and antimetabolite']","['HRCT scores', 'number of B cells', 'radiographic abnormalities and pulmonary function', 'FEV1', 'CT scores', 'FVC', 'activated CD4 T cells', 'sustained remissions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009447', 'cui_str': 'Common variable agammaglobulinemia'}, {'cui': 'C0439667', 'cui_str': 'Granulomatous'}, {'cui': 'C2939172', 'cui_str': 'Lymphocytic'}, {'cui': 'C0206062', 'cui_str': 'Interstitial lung disease'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0021079', 'cui_str': 'Immunosuppressive therapy'}]","[{'cui': 'C0021079', 'cui_str': 'Immunosuppressive therapy'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0004482', 'cui_str': 'Azathioprine'}, {'cui': 'C0209368', 'cui_str': 'mycophenolate mofetil'}, {'cui': 'C0003376', 'cui_str': 'Antimetabolite'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0004561', 'cui_str': 'B lymphocyte'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C3714541', 'cui_str': 'Forced vital capacity'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}]",39.0,0.0622029,Relapse was associated with an increased number of B cells (p=0.016) and activated CD4 T cells (p=0.016).,"[{'ForeName': 'James W', 'Initials': 'JW', 'LastName': 'Verbsky', 'Affiliation': 'Division of Pediatric Rheumatology; Department of Pediatrics; Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Mary K', 'Initials': 'MK', 'LastName': 'Hintermeyer', 'Affiliation': ""Children's Wisconsin.""}, {'ForeName': 'Pippa M', 'Initials': 'PM', 'LastName': 'Simpson', 'Affiliation': 'Department of Quantitative Health Sciences; Department of Pediatrics; Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Mingen', 'Initials': 'M', 'LastName': 'Feng', 'Affiliation': 'Department of Quantitative Health Sciences; Department of Pediatrics; Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Jody', 'Initials': 'J', 'LastName': 'Barbeau', 'Affiliation': 'Department of Quantitative Health Sciences; Department of Pediatrics; Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Nagarjun', 'Initials': 'N', 'LastName': 'Rao', 'Affiliation': 'Department of Pathology, Aurora Clinical Laboratories/Great Lakes Pathologists, Aurora West Allis Medical Center, West Allis, WI.'}, {'ForeName': 'Carlyne D', 'Initials': 'CD', 'LastName': 'Cool', 'Affiliation': 'Department of Pathology and Division of Pulmonary and Critical Care Medicine, University of Colorado Anschutz Medical Campus, National Jewish Health.'}, {'ForeName': 'Luis A', 'Initials': 'LA', 'LastName': 'Sosa-Lozano', 'Affiliation': 'Division of Diagnostic Radiology; Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Dhiraj', 'Initials': 'D', 'LastName': 'Baruah', 'Affiliation': 'Division of Thoracic Radiology, Medical University of South Carolina.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Hammelev', 'Affiliation': 'Division of Allergy/Clinical Immunology; Department of Pediatrics; Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Alyssa', 'Initials': 'A', 'LastName': 'Busalacchi', 'Affiliation': 'Division of Allergy/Clinical Immunology; Department of Pediatrics; Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Rymaszewski', 'Affiliation': 'Division of Allergy/Clinical Immunology; Department of Pediatrics; Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Woodliff', 'Affiliation': 'Division of Allergy/Clinical Immunology; Department of Pediatrics; Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Shaoying', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'Division of Pediatric Rheumatology; Department of Pediatrics; Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Bausch-Jurken', 'Affiliation': 'Division of Allergy/Clinical Immunology; Department of Pediatrics; Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Routes', 'Affiliation': 'Division of Allergy/Clinical Immunology; Department of Pediatrics; Medical College of Wisconsin, Milwaukee, WI. Electronic address: jroutes@mcw.edu.'}]",The Journal of allergy and clinical immunology,['10.1016/j.jaci.2020.07.021'] 2248,32745598,Changes in Intrinsic Brain Connectivity in Family-Focused Therapy Versus Standard Psychoeducation Among Youth at High Risk for Bipolar Disorder.,"OBJECTIVE We compared intrinsic network connectivity in symptomatic youth at high risk (HR) for bipolar disorder (BD) and healthy comparison (HC) youth, and, in HR youth, investigated treatment-related changes in intrinsic connectivity following family focused therapy for high-risk youth (FFT-HR) versus standardized family psychoeducation. METHOD HR youth (N=34; age 9-17 years; mean 14 years, 56% girls) with depressive and/or hypomanic symptoms and at least one first- or second-degree relative with BD I or II were randomly assigned to 4 months of FFT-HR (12 sessions of psychoeducation, communication, and problem-solving skills training) or Enhanced Care (EC; 3 family and 3 individual psychoeducation sessions). Before and after 4-months of treatment, participants underwent resting state functional magnetic resonance imaging (rs-fMRI). A whole brain independent component analysis compared rs-fMRI networks in HR youth and 30 age-matched HC youth at a pretreatment baseline. Then, we identified pretreatment to post-treatment (4-month) changes in network connectivity in HR youth receiving FFT-HR (n=16) or EC (n=18) and correlated these changes with depression improvement. RESULTS At baseline, HR youth had greater connectivity between the ventrolateral prefrontal cortex (VLPFC) and the anterior default mode network (aDMN) than did HCs (p=.004). Over 4 months of treatment, FFT-HR-assigned HR youth had increased VLPFC-aDMN connectivity from pre- to post-treatment (p=.003), whereas HR youth in EC showed no significant change over time (p=.11) (treatment by time interaction, [t(31)=3.33, CI 95% [0.27, 1.14], p=.002]. Reduction in depression severity over 4 months inversely correlated with enhanced anterior DMN (r= -.71) connectivity in the FFT-HR but not in the EC (r=-.07) group (z=-2.17, p=.015). CONCLUSION Compared to standard psychoeducation, FFT-HR is associated with stronger connectivity between the VLPFC and aDMN, suggesting possible enhancements of self- and illness awareness and emotion regulation.",2020,"Compared to standard psychoeducation, FFT-HR is associated with stronger connectivity between the VLPFC and aDMN, suggesting possible enhancements of self- and illness awareness and emotion regulation.","['Youth at High Risk for Bipolar Disorder', 'Family', 'HR youth (N=34; age 9-17 years; mean 14 years, 56% girls) with depressive and/or hypomanic symptoms and at least one first- or second-degree relative with BD I or II', 'symptomatic youth at high risk (HR) for bipolar disorder (BD) and healthy comparison (HC) youth, and, in HR youth']","['FFT-HR (n=16) or EC', 'Focused Therapy Versus Standard Psychoeducation', 'FFT-HR (12 sessions of psychoeducation, communication, and problem-solving skills training) or Enhanced Care (EC; 3 family and 3 individual psychoeducation sessions', 'resting state functional magnetic resonance imaging (rs-fMRI']","['VLPFC-aDMN connectivity', 'depression severity', 'depression improvement']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0443298', 'cui_str': 'Second degree'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}]","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0033211', 'cui_str': 'Problem solving'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",,0.0256181,"Compared to standard psychoeducation, FFT-HR is associated with stronger connectivity between the VLPFC and aDMN, suggesting possible enhancements of self- and illness awareness and emotion regulation.","[{'ForeName': 'Manpreet K', 'Initials': 'MK', 'LastName': 'Singh', 'Affiliation': 'Stanford University School of Medicine, California. Electronic address: mksingh@stanford.edu.'}, {'ForeName': 'Akua F', 'Initials': 'AF', 'LastName': 'Nimarko', 'Affiliation': 'Stanford University School of Medicine, California.'}, {'ForeName': 'Amy S', 'Initials': 'AS', 'LastName': 'Garrett', 'Affiliation': 'University of Texas, Health Science Center at San Antonio.'}, {'ForeName': 'Aaron J', 'Initials': 'AJ', 'LastName': 'Gorelik', 'Affiliation': 'University of California-Davis.'}, {'ForeName': 'Donna J', 'Initials': 'DJ', 'LastName': 'Roybal', 'Affiliation': 'University of California, Los Angeles School of Medicine.'}, {'ForeName': 'Patricia D', 'Initials': 'PD', 'LastName': 'Walshaw', 'Affiliation': 'University of California, Los Angeles School of Medicine.'}, {'ForeName': 'Kiki D', 'Initials': 'KD', 'LastName': 'Chang', 'Affiliation': 'private practice, Menlo Park, California.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Miklowitz', 'Affiliation': 'University of California, Los Angeles School of Medicine.'}]",Journal of the American Academy of Child and Adolescent Psychiatry,['10.1016/j.jaac.2020.07.892'] 2249,32745667,Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trials.,"BACKGROUND AND PURPOSE This study aimed to identify anatomically-localised regions where planned radiotherapy dose is associated with gastrointestinal toxicities in healthy tissues throughout the pelvic anatomy. MATERIALS AND METHODS Planned dose distributions for up to 657 patients of the Trans Tasman Radiation Oncology Group 03.04 RADAR trial were deformably registered onto a single exemplar computed tomography dataset. Voxel-based multiple comparison permutation dose difference testing, Cox regression modelling and LASSO feature selection were used to identify regions where dose-increase was associated with grade≥2 rectal bleeding (RB) or tenesmus, according to the LENT/SOMA scale. This was externally validated by registering dose distributions from the RT01 (n=388) and CHHiP (n=241) trials onto the same exemplar and repeating the tests on each of these data sets, and on all three datasets combined. RESULTS Voxel-based Cox regression and permutation dose difference testing revealed regions where increased dose was correlated with gastrointestinal toxicity. Grade≥2 RB was associated with posteriorly extended lateral beams that manifested high doses (> 55 Gy) in a small rectal volume adjacent to the clinical target volume. A correlation was found between grade≥2 tenesmus and increased low-intermediate dose (∼25 Gy) at the posterior beam region, including the posterior rectum and perirectal fat space (PRFS). CONCLUSIONS The serial response of the rectum with respect to RB has been demonstrated in patients with posteriorly extended lateral beams. Similarly, the parallel response of the PRFS with respect to tenesmus has been demonstrated in patients treated with the posterior beam.",2020,"A correlation was found between grade≥2 tenesmus and increased low-intermediate dose (∼25 Gy) at the posterior beam region, including the posterior rectum and perirectal fat space (PRFS). ","['patients with posteriorly extended lateral beams', '657 patients of the Trans Tasman Radiation Oncology Group 03.04 RADAR trial were deformably registered onto a single exemplar computed tomography dataset']",[],"['grade≥2 rectal bleeding (RB) or tenesmus', 'gastrointestinal toxicity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0243005', 'cui_str': 'Radiation oncology'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0034513', 'cui_str': 'Radar'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0150098', 'cui_str': 'Data Set'}]",[],"[{'cui': 'C0018932', 'cui_str': 'Hematochezia'}, {'cui': 'C0232726', 'cui_str': 'Rectal tenesmus'}, {'cui': 'C1142499', 'cui_str': 'Gastrointestinal toxicity'}]",,0.0350618,"A correlation was found between grade≥2 tenesmus and increased low-intermediate dose (∼25 Gy) at the posterior beam region, including the posterior rectum and perirectal fat space (PRFS). ","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Marcello', 'Affiliation': 'Department of Physics, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009, Australia; Department of Radiation Oncology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA, 6009, Australia. Electronic address: 20739859@student.uwa.edu.au.'}, {'ForeName': 'J W', 'Initials': 'JW', 'LastName': 'Denham', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, University Drive, Callaghan, NSW, 2308, Australia.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Kennedy', 'Affiliation': 'Department of Radiation Oncology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA, 6009, Australia.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Haworth', 'Affiliation': 'School of Physics, University of Sydney, Physics Road, Camperdown, NSW, 2006, Australia.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Steigler', 'Affiliation': 'Prostate Cancer Trials Group, School of Medicine and Public Health, University of Newcastle, University Drive, Callaghan, NSW, 2308, Australia.'}, {'ForeName': 'P B', 'Initials': 'PB', 'LastName': 'Greer', 'Affiliation': 'School of Mathematical and Physical Sciences, University of Newcastle, University Drive, Callaghan, NSW, 2308, Australia; Department of Radiation Oncology, Calvary Mater Newcastle, Corner of Edith & Platt Street, Waratah, NSW, 2298, Australia.'}, {'ForeName': 'L C', 'Initials': 'LC', 'LastName': 'Holloway', 'Affiliation': 'Department of Medical Physics, Liverpool Cancer Centre, 1 Campbell Street, Liverpool, NSW, 2170, Australia; South Western Sydney Clinical School, University of New South Wales, Goulburn Street, Liverpool, NSW, 2170, Australia; Centre for Medical Radiation Physics, University of Wollongong, Northfields Avenue, Wollongong, NSW, 2522, Australia.'}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Dowling', 'Affiliation': 'School of Mathematical and Physical Sciences, University of Newcastle, University Drive, Callaghan, NSW, 2308, Australia; CSIRO, Butterfield Street, Herston, QLD, 4029, Australia.'}, {'ForeName': 'M G', 'Initials': 'MG', 'LastName': 'Jameson', 'Affiliation': 'Department of Medical Physics, Liverpool Cancer Centre, 1 Campbell Street, Liverpool, NSW, 2170, Australia; South Western Sydney Clinical School, University of New South Wales, Goulburn Street, Liverpool, NSW, 2170, Australia; Centre for Medical Radiation Physics, University of Wollongong, Northfields Avenue, Wollongong, NSW, 2522, Australia; Cancer Research Team, Ingham Institute for Applied Medical Research, 1 Campbell Street, Liverpool, NSW, 2170, Australia.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Roach', 'Affiliation': 'Department of Medical Physics, Liverpool Cancer Centre, 1 Campbell Street, Liverpool, NSW, 2170, Australia; South Western Sydney Clinical School, University of New South Wales, Goulburn Street, Liverpool, NSW, 2170, Australia; Cancer Research Team, Ingham Institute for Applied Medical Research, 1 Campbell Street, Liverpool, NSW, 2170, Australia.'}, {'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Joseph', 'Affiliation': 'School of Surgery, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009, Australia; 5D Clinics, Claremont, 261 Stirling Highway, Claremont, WA, 6010, Australia; GenesisCare WA, 24 Salvado Road, Wembley, WA, 6014, Australia.'}, {'ForeName': 'S L', 'Initials': 'SL', 'LastName': 'Gulliford', 'Affiliation': 'Radiotherapy Department, University College London Hospitals NHS Foundation Trust, Gower Street, Bloomsbury, London, WC1E 6BT, United Kingdom; Department of Medical Physics and Biomedical Engineering, University College London, Gower Street, Bloomsbury, London, WC1E 6BT, United Kingdom.'}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Dearnaley', 'Affiliation': 'Academic UroOncology Unit, The Institute of Cancer Research and the Royal Marsden NHS Trust, 15 Cotswold Road, Sutton, London, SM2 5NG, Australia.'}, {'ForeName': 'M R', 'Initials': 'MR', 'LastName': 'Sydes', 'Affiliation': 'MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College 90 High Holborn, London, WC1B 9LJ, United Kingdom.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Hall', 'Affiliation': 'Clinical Trials and Statistics Unit, The Institute of Cancer Research, 15 Cotswold Rd, Sutton, SM2 5NG, United Kingdom.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Ebert', 'Affiliation': 'Department of Physics, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009, Australia; Department of Radiation Oncology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA, 6009, Australia; 5D Clinics, Claremont, 261 Stirling Highway, Claremont, WA, 6010, Australia.'}]",Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,['10.1016/j.radonc.2020.07.048'] 2250,32745703,"Randomized controlled trial of the COPE-P intervention to improve mental health, healthy lifestyle behaviors, birth and post-natal outcomes of minority pregnant women: Study protocol with implications.","BACKGROUND Emotionally distressed pregnant minority women experience multiple adverse outcomes, including pre-eclampsia, preterm birth, operative deliveries and low birth weight. Although the United States Preventive Services Task Force recommends screening in pregnant women, many practices do not screen because efficacious interventions and systems are not in place to treat them. AIM Purpose of this randomized controlled trial (RCT) is to test a group delivered manualized cognitivebehavioral skills building intervention entitled COPE-P versus an attention control program on the mental health, birth and postpartum outcomes of minority pregnant women experiencing depressive, anxiety and stress symptoms. METHODS Design is a longitudinal randomized block RCT with repeated measures (beginning with screening prior to 18 weeks, group prenatal care in both groups from 16 + 1 to 31 + 1 weeks and ending at 6 months postpartum) at two study sites (New York city and Columbus, Ohio). Race/ethnicity is being blocked to ensure equal numbers of Hispanic and Black women. 384 women are being recruited from antenatal clinics if they are: between 18 and 40 years; in an uncomplicated singleton pregnancy <18 weeks; and self-identify as Black or Hispanic. Valid and reliable measures are being used to assess healthy lifestyle behaviors and mental health outcomes immediately following the interventions, six - eight weeks postpartum and at the children's six-month well baby visit. Birth and delivery outcomes also are being assessed. CONCLUSION If found to be efficacious, the COPE-P intervention could be a key solution to managing those with emotional distress and improving their outcomes.",2020,"If found to be efficacious, the COPE-P intervention could be a key solution to managing those with emotional distress and improving their outcomes.","['minority pregnant women experiencing depressive, anxiety and stress symptoms', 'minority pregnant women', '384 women are being recruited from antenatal clinics if they are: between 18 and 40\u202fyears; in an uncomplicated singleton pregnancy <18\u202fweeks; and self-identify as Black or Hispanic', 'pregnant women']","['COPE-P intervention', 'COPE-P versus an attention control program']","['healthy lifestyle behaviors and mental health outcomes', 'mental health, healthy lifestyle behaviors, birth and post-natal outcomes']","[{'cui': 'C0026192', 'cui_str': 'Minority Groups'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1274027', 'cui_str': 'Antenatal clinic'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}]","[{'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C4277664', 'cui_str': 'Healthy Lifestyles'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0454729', 'cui_str': 'Natal'}]",384.0,0.137281,"If found to be efficacious, the COPE-P intervention could be a key solution to managing those with emotional distress and improving their outcomes.","[{'ForeName': 'Bernadette Mazurek', 'Initials': 'BM', 'LastName': 'Melnyk', 'Affiliation': 'Health Promotion, College of Nursing, Pediatrics & Psychiatry, College of Medicine, the Helene Fuld Health Trust National Institute for Evidence-based Practice in Nursing and Healthcare, The Ohio State University, 1585 Neil Ave, Columbus, OH 43210, United States of America. Electronic address: melnyk.15@osu.edu.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Gennaro', 'Affiliation': 'William F. Connell School of Nursing, Boston College, Chestnut Hill, MA, United States of America.'}, {'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Szalacha', 'Affiliation': 'Research Methodology and Biostatistics Core, USF Health Morsani College of Medicine, College of Nursing, University of South Florida, United States of America.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Hoying', 'Affiliation': 'Consumer Core, the Helene Fuld Health Trust National Institute for Evidence-based Practice in Nursing and Healthcare, The Ohio State University College of Nursing, Columbus, OH, United States of America.'}, {'ForeName': 'Caitlin', 'Initials': 'C', 'LastName': ""O'Connor"", 'Affiliation': 'William F. Connell School of Nursing, Boston College, Chestnut Hill, MA, United States of America.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Cooper', 'Affiliation': 'The Ohio State University College of Nursing, Columbus, OH, United States of America.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Gibeau', 'Affiliation': 'Midwifery, Jacobi Medical Center, Bronx, NY, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106090'] 2251,32745732,Smartphone-based application to improve medication adherence in patients after surgical coronary revascularization.,"BACKGROUND Secondary preventive therapies play a key role in the prevention of adverse events after coronary artery bypass grafting (CABG). However, adherence to secondary preventive drugs after CABG is often poor. With the increasing penetration of smartphones, health-related smartphone applications might provide an opportunity to improve medication adherence. We aimed to evaluate the effectiveness and feasibility of using a smartphone-based application to improve medication adherence in patients after CABG. METHODS The Measurement and Improvement Studies of Surgical coronary revascularizatION: medication adherence (MISSION-2) study is a multicenter randomized controlled trial that planned to enroll over 1000 patients who underwent isolated CABG at one of four large teaching hospitals in China; all enrolled participants had access to a smartphone and were able to operate at least three smartphone applications. The investigators randomly assigned the participants to one of two groups: (1) the intervention group with an advanced smartphone application for 6 months which was designed specifically for this trial and did not exist before. Participants could receive medication reminders and cardiac health education by the smartphone application or (2) the control group with usual care. The primary outcome was CABG secondary preventive medication adherence as measured by the translated Chinese version of the 8-item Morisky Medication Adherence Scale (MMAS-8) at 6 months after randomization. The secondary outcomes were mortality, major adverse cardiovascular and cerebrovascular events (MACCE), cardiovascular rehospitalization, self-reported secondary preventive medication use after 6 months of follow-up, blood pressure (BP), body mass index (BMI), and self-reported smoking status. All analyses were conducted using the intention-to-treat principle. RESULTS A total of 1000 patients (mean age, 57.28 [SD, 9.09] years; 85.5% male) with coronary heart disease after CABG were enrolled between September 2015 and September 2016 and were randomly assigned to the intervention (n = 501) or control group (n = 499). At 6 months, the proportion of low-adherence participants, categorized by MMAS-8 scores, was 11.8% in the intervention group and 11.7% in the control group (RR = 1.005, 95% CI 0.682 to 1.480, P = 1.000). Similar results were found in sensitivity analyses that considered participants who withdrew from the study, or were lost to follow-up as nonadherent. There were no significant differences in the secondary clinical outcome measures, and there were no significant differences in the primary outcome across the subgroups tested. In the intervention group, the proportion of participants who used and operated the application during the first month after CABG was 88.1%; however, the use rate decreased sharply from 42.5% in the second month to 9.2% by the end of the study (6 months). CONCLUSIONS A smartphone-based application supporting secondary prevention among patients after CABG did not lead to a greater adherence to secondary preventive medications. The limited room for improvement in medication adherence and the low participants' engagement with the smartphone applications might account for these non-significant outcomes.",2020,A smartphone-based application supporting secondary prevention among patients after CABG did not lead to a greater adherence to secondary preventive medications.,"['patients after CABG', 'coronary artery bypass grafting (CABG', 'patients after surgical coronary revascularization', '1000 patients who underwent isolated CABG at one of four large teaching hospitals in China; all enrolled participants had access to a smartphone and were able to operate at least three smartphone applications', '1000 patients (mean age, 57.28 [SD, 9.09] years; 85.5% male) with coronary heart disease after CABG were enrolled between September 2015 and September 2016']","['Surgical coronary revascularizatION', 'smartphone-based application', 'Smartphone-based application', 'medication reminders and cardiac health education by the smartphone application or (2) the control group with usual care', 'intervention group with an advanced smartphone application']","['proportion of low-adherence participants, categorized by MMAS-8 scores', 'mortality, major adverse cardiovascular and cerebrovascular events (MACCE), cardiovascular rehospitalization, self-reported secondary preventive medication use after 6 months of follow-up, blood pressure (BP), body mass index (BMI), and self-reported smoking status', 'CABG secondary preventive medication adherence as measured by the translated Chinese version of the 8-item Morisky Medication Adherence Scale (MMAS-8', 'medication adherence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0205409', 'cui_str': 'Isolated'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0066409', 'cui_str': 'Methylmethacrylate'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0204169', 'cui_str': 'Preventive dental procedure'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0040710', 'cui_str': 'Translating'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",1000.0,0.0677726,A smartphone-based application supporting secondary prevention among patients after CABG did not lead to a greater adherence to secondary preventive medications.,"[{'ForeName': 'Chunyu', 'Initials': 'C', 'LastName': 'Yu', 'Affiliation': 'National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Chongyang', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Junzhe', 'Initials': 'J', 'LastName': 'Du', 'Affiliation': 'National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Hanning', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Heng', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Limeng', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Jue', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.'}, {'ForeName': 'Huishan', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiovascular Surgery, General Hospital of Shenyang Military Region, Shenyang, Liaoning, China.'}, {'ForeName': 'Zhigang', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Department of Cardiovascular Surgery, TEDA International Cardiovascular Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Tianjin, China.'}, {'ForeName': 'Chenfei', 'Initials': 'C', 'LastName': 'Rao', 'Affiliation': 'National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: raochenfeifuwai@126.com.'}, {'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Zheng', 'Affiliation': 'National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: zhengzhe@fuwai.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American heart journal,['10.1016/j.ahj.2020.06.019'] 2252,32745733,"Rationale and design of a prospective, randomized, controlled, multicenter study to evaluate the safety and efficacy of transcatheter heart valve replacement in female patients with severe symptomatic aortic stenosis requiring aortic valve intervention (Randomized researcH in womEn all comers wIth Aortic stenosis [RHEIA] trial).","BACKGROUND Limited data suggest that transcatheter (TAVR) as compared with surgical aortic valve replacement (SAVR) may be more effective in female than male patients. To date, most evidence is derived from subgroup analyses of large trials, and a dedicated randomized trial evaluating whether there is a difference in outcomes between these interventions in women is warranted. The RHEIA trial will compare the safety and efficacy of TAVR with SAVR in women with severe symptomatic aortic stenosis requiring aortic valve intervention, irrespective of surgical risk. METHODS/DESIGN The RHEIA trial is a prospective, randomized, controlled study that will enroll up to 440 patients across 35 sites in Europe. Women with severe symptomatic aortic stenosis, with any but prohibitive surgical risk status, will be randomized 1:1 to undergo aortic valve intervention with either transfemoral TAVR with the SAPIEN 3 or SAPIEN 3 Ultra device or SAVR and followed up for 1 year. The objective is to determine whether TAVR is non-inferior to SAVR in this patient population and, if this is fulfilled whether TAVR is actually superior to SAVR. The primary safety/efficacy endpoint is a composite of all-cause mortality, all stroke, and re-hospitalization (for valve or procedure-related symptoms or worsening congestive heart failure) at 1 year post-procedure. Other outcomes (assessed at 30 days and/or 1 year) include all-cause mortality; bleeding, vascular, cardiac, cerebrovascular and renal complications; aortic valve prosthesis and left ventricular function; cognitive function, health status, and quality of life. DISCUSSION The RHEIA study has been designed to evaluate the safety and efficacy of TAVR compared with SAVR specifically in women with severe symptomatic aortic stenosis, irrespective of the level of surgical risk. The results will be the first to provide specific randomized evidence to guide treatment selection in female patients with severe symptomatic aortic stenosis. TRIAL REGISTRATION clinicaltrials.gov: NCT04160130.",2020,"The RHEIA study has been designed to evaluate the safety and efficacy of TAVR compared with SAVR specifically in women with severe symptomatic aortic stenosis, irrespective of the level of surgical risk.","['440 patients across 35 sites in Europe', 'female than male patients', 'Women with severe symptomatic aortic stenosis, with any but prohibitive surgical risk status', 'female patients with severe symptomatic aortic stenosis', 'women with severe symptomatic aortic stenosis requiring aortic valve intervention, irrespective of surgical risk', 'female patients with severe symptomatic aortic stenosis requiring aortic valve intervention (Randomized researcH in womEn all comers wIth Aortic stenosis [RHEIA', 'women with severe symptomatic aortic stenosis']","['surgical aortic valve replacement (SAVR', 'transcatheter (TAVR', 'transcatheter heart valve replacement', 'TAVR with SAVR', 'TAVR']","['composite of all-cause mortality, all stroke, and re-hospitalization (for valve or procedure-related symptoms or worsening congestive heart failure', 'safety and efficacy', 'cause mortality; bleeding, vascular, cardiac, cerebrovascular and renal complications; aortic valve prosthesis and left ventricular function; cognitive function, health status, and quality of life']","[{'cui': 'C4517777', 'cui_str': '440'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0003507', 'cui_str': 'Aortic valve stenosis'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0003501', 'cui_str': 'Aortic valve structure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}, {'cui': 'C0442343', 'cui_str': 'Transcatheter approach'}, {'cui': 'C0190173', 'cui_str': 'Heart valve replacement'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0182431', 'cui_str': 'Aortic valve prosthesis'}, {'cui': 'C0080310', 'cui_str': 'Left ventricular function'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.159675,"The RHEIA study has been designed to evaluate the safety and efficacy of TAVR compared with SAVR specifically in women with severe symptomatic aortic stenosis, irrespective of the level of surgical risk.","[{'ForeName': 'Helene', 'Initials': 'H', 'LastName': 'Eltchaninoff', 'Affiliation': 'Department of Cardiology, Rouen University Hospital, FHU REMOD-VHF, Rouen, France. Electronic address: helene.eltchaninoff@chu-rouen.fr.'}, {'ForeName': 'Nikolaos', 'Initials': 'N', 'LastName': 'Bonaros', 'Affiliation': 'Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: nikolaos.bonaros@tirol-kliniken.at.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Prendergast', 'Affiliation': ""St. Thomas' Hospital, London, United Kingdom. Electronic address: bernard.prendergast@gstt.nhs.uk.""}, {'ForeName': 'Fabian', 'Initials': 'F', 'LastName': 'Nietlispach', 'Affiliation': 'CardioVascularCenter, Hirslanden Klinik Im Park, Zurich, Switzerland. Electronic address: fabian.nietlispach@hirslanden.ch.'}, {'ForeName': 'Mariuca', 'Initials': 'M', 'LastName': 'Vasa-Nicotera', 'Affiliation': 'University Heart Center Frankfurt, Frankfurt, Germany. Electronic address: mariuca.vasa-nicotera@kgu.de.'}, {'ForeName': 'Alaide', 'Initials': 'A', 'LastName': 'Chieffo', 'Affiliation': 'Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: chieffo.alaide@hsr.it.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Pibarot', 'Affiliation': 'Department of Cardiology, Quebec Heart & Lung Institute, Laval University, Quebec City, QC, Canada. Electronic address: philippe.pibarot@med.ulaval.ca.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Bramlage', 'Affiliation': 'Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany. Electronic address: peter.bramlage@ippmed.de.'}, {'ForeName': 'Lenka', 'Initials': 'L', 'LastName': 'Sykorova', 'Affiliation': 'Edwards Lifesciences, Prague, Czech Republic. Electronic address: lenka_sykorova@edwards.com.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Kurucova', 'Affiliation': 'Edwards Lifesciences, Prague, Czech Republic. Electronic address: jana_kurucova@edwards.com.'}, {'ForeName': 'Jeroen J', 'Initials': 'JJ', 'LastName': 'Bax', 'Affiliation': 'Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: j.j.bax@lumc.nl.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Windecker', 'Affiliation': 'Department of Cardiology, Bern University Hospital, Bern, Switzerland. Electronic address: Stephan.Windecker@insel.ch.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Dumonteil', 'Affiliation': 'Groupe Cardiovasculaire Interventionnel, Clinique Pasteur Toulouse, France. Electronic address: ndumonteil@clinique-pasteur.com.'}, {'ForeName': 'Didier', 'Initials': 'D', 'LastName': 'Tchetche', 'Affiliation': 'Groupe Cardiovasculaire Interventionnel, Clinique Pasteur Toulouse, France. Electronic address: dtchetche@clinique-pasteur.com.'}]",American heart journal,['10.1016/j.ahj.2020.06.016'] 2253,32745734,Optimal antiplatelet therapy for prevention of gastrointestinal injury evaluated by ANKON magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial.,"BACKGROUND Gastrointestinal injury is a common complication in patients treated with antiplatelet agents after percutaneous coronary intervention (PCI). However, the effects of different antiplatelet regimens on the incidence and severity of gastrointestinal injury have not been well studied, principally due to the lack of a low-risk sensitive and accurate detection system. TRIAL DESIGN OPT-PEACE is a multicenter, randomized, double-blind, placebo-controlled trial. Gastrointestinal injury will be evaluated with the ANKON magnetically controlled capsule endoscopy system (AMCE), a minimally invasive approach for detecting mucosal lesions in the stomach, duodenum and small intestine. Patients without AMCE-detected gastrointestinal erosions, ulceration or bleeding after drug-eluting stent implantation are enrolled and treated with open-label aspirin (100 mg/d) plus clopidogrel (75 mg/d) for 6 months. Thereafter, 480 event-free patients will undergo repeat AMCE and are randomly assigned in a 1:1:1 ratio to receive aspirin plus clopidogrel, aspirin plus placebo or clopidogrel plus placebo for an additional 6 months. A final AMCE is performed at 12 months. The primary endpoint is the incidence of gastric or intestinal mucosal lesions (erosions, ulceration, or bleeding) within 12 months after enrollment. CONCLUSIONS OPT-PEACE is the first study to investigate the incidence and severity of gastrointestinal injury in patients receiving different antiplatelet therapy regimens after stent implantation. This trial will inform clinical decision-making for personalized antiplatelet therapy post-PCI.",2020,"The primary endpoint is the incidence of gastric or intestinal mucosal lesions (erosions, ulceration, or bleeding) within 12 months after enrollment. ","['480 event-free patients will undergo repeat AMCE', 'patients receiving different antiplatelet therapy regimens after stent implantation', 'patients treated with antiplatelet agents after percutaneous coronary intervention (PCI']","['aspirin plus clopidogrel, aspirin plus placebo or clopidogrel plus placebo', 'open-label aspirin', 'clopidogrel', 'placebo']","['incidence of gastric or intestinal mucosal lesions (erosions, ulceration, or bleeding', 'gastrointestinal erosions, ulceration or bleeding']","[{'cui': 'C4319609', 'cui_str': '480'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1721048', 'cui_str': 'Capsule endoscopy'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0085826', 'cui_str': 'Antiplatelet agent'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0175566', 'cui_str': 'Open'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0026724', 'cui_str': 'Mucosal'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0333307', 'cui_str': 'Superficial ulcer'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C1261962', 'cui_str': 'Gastrointestinal erosion'}]",,0.524049,"The primary endpoint is the incidence of gastric or intestinal mucosal lesions (erosions, ulceration, or bleeding) within 12 months after enrollment. ","[{'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Cardiology, General hospital of Northern Theater Command, Shenyang, China.'}, {'ForeName': 'Xiaozeng', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiology, General hospital of Northern Theater Command, Shenyang, China.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Bao', 'Affiliation': 'Department of Cardiology, General hospital of Northern Theater Command, Shenyang, China.'}, {'ForeName': 'Zhuan', 'Initials': 'Z', 'LastName': 'Liao', 'Affiliation': 'Digestive Endoscopy Center, Department of Gastroenterology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Cardiology, General hospital of Northern Theater Command, Shenyang, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Han', 'Affiliation': 'Department of Endoscopy, General hospital of Northern Theater Command, Shenyang, China.'}, {'ForeName': 'Heyang', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiology, General hospital of Northern Theater Command, Shenyang, China.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Xu', 'Affiliation': 'Department of Cardiology, General hospital of Northern Theater Command, Shenyang, China.'}, {'ForeName': 'Zhaoshen', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Digestive Endoscopy Center, Department of Gastroenterology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Gregg W', 'Initials': 'GW', 'LastName': 'Stone', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, Mount Sinai Heart and the Cardiovascular Research Foundation, New York.'}, {'ForeName': 'Yaling', 'Initials': 'Y', 'LastName': 'Han', 'Affiliation': 'Department of Cardiology, General hospital of Northern Theater Command, Shenyang, China. Electronic address: hanyaling@263.net.'}]",American heart journal,['10.1016/j.ahj.2020.06.004'] 2254,32745768,Oxylipin regulation by phenolic compounds from coffee beverage: Positive outcomes from a randomized controlled trial in healthy adults and macrophage derived foam cells.,"Oxylipins are considered biomarkers related to cardiovascular diseases (CVDs). They are generated in vivo via the oxygenation of polyunsaturated fatty acids as a result of oxidative stress and inflammation. Oxylipins are involved in vascular functions and are produced during foam cell formation in atherogenesis. Additionally, the consumption coffee is associated with the regulation on a particular oxylipin group, the F 2t -isoprostanes (F 2t -IsoPs). This function has been attributed to the chlorogenic acids (CGAs) from the coffee beverage. Considering the anti-inflammatory and antioxidant properties of CGAs, we evaluated the effects of two types of coffee that provided 787 mg CGAs/day (Coffee A) and 407 mg CGAs/day (Coffee B) by reducing 35 selected oxylipins in healthy subjects. Furthermore, we assessed the effect of CGAs on the cellular proatherogenic response in foam cells by using an oxidized LDL (oxLDL)-macrophage interaction model. After eight weeks of coffee consumption, the contents of 12 urine oxylipins were reduced. However, the effect of Coffee A showed a stronger decrease in IsoPs, dihomo-IsoPs, prostaglandins (PGs) and PG metabolites, probably due to its higher content of CGAs. Neither of the two coffees reduced the levels of oxLDL. Moreover, the in vitro oxylipin induction by oxLDL on foam cells was ameliorated by phenolic acids and CGAs, including the inhibition of IsoPs and PGs by caffeoylquinic and dicaffeoylquinic acids, respectively, while the phenolic acids maintained both antioxidant and anti-inflammatory activities. These findings suggest that coffee antioxidants are strong regulators of oxylipins related to CVDs. The clinical trial was registered on the International Clinical Trials Registry Platform, WHO primary registry (RPCEC00000168).",2020,"However, the effect of Coffee A showed a stronger decrease in IsoPs, dihomo-IsoPs, prostaglandins (PGs) and PG metabolites, probably due to its higher content of CGAs.","['healthy adults and macrophage derived foam cells', 'healthy subjects']",['CGAs'],"['levels of oxLDL', 'IsoPs, dihomo-IsoPs, prostaglandins (PGs) and PG metabolites']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0024432', 'cui_str': 'Macrophage'}, {'cui': 'C0016390', 'cui_str': 'Foam cell'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0055633', 'cui_str': 'Chromogranin A'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0348035', 'cui_str': 'Oxidized low density lipoprotein'}, {'cui': 'C0997851', 'cui_str': 'Geodia'}, {'cui': 'C0033554', 'cui_str': 'Prostaglandin'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}]",,0.0588372,"However, the effect of Coffee A showed a stronger decrease in IsoPs, dihomo-IsoPs, prostaglandins (PGs) and PG metabolites, probably due to its higher content of CGAs.","[{'ForeName': 'Oscar J', 'Initials': 'OJ', 'LastName': 'Lara-Guzmán', 'Affiliation': 'Vidarium - Nutrition, Health and Wellness Research Center, Nutresa Business Group, Calle 8 Sur No. 50-67, Medellín, Colombia.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Medina', 'Affiliation': 'Research Group on Quality, Safety and Bioactivity of Plant Foods, Department of Food Science and Technology, CEBAS (CSIC), P.O. Box 164, 30100, Campus University Espinardo, Murcia, Spain.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Álvarez', 'Affiliation': 'Grupo de Investigación en Sustancias Bioactivas, Facultad de Ciencias Farmacéuticas y Alimentarias, Universidad de Antioquia, Calle 70 No. 52-21, Medellín, Colombia.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Oger', 'Affiliation': 'Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, University of Montpellier, ENSCM, Faculty of Pharmacy, Montpellier, France.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Durand', 'Affiliation': 'Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, University of Montpellier, ENSCM, Faculty of Pharmacy, Montpellier, France.'}, {'ForeName': 'Jean-Marie', 'Initials': 'JM', 'LastName': 'Galano', 'Affiliation': 'Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, University of Montpellier, ENSCM, Faculty of Pharmacy, Montpellier, France.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Zuluaga', 'Affiliation': 'Vidarium - Nutrition, Health and Wellness Research Center, Nutresa Business Group, Calle 8 Sur No. 50-67, Medellín, Colombia.'}, {'ForeName': 'Ángel', 'Initials': 'Á', 'LastName': 'Gil-Izquierdo', 'Affiliation': 'Research Group on Quality, Safety and Bioactivity of Plant Foods, Department of Food Science and Technology, CEBAS (CSIC), P.O. Box 164, 30100, Campus University Espinardo, Murcia, Spain. Electronic address: angelgil@cebas.csic.es.'}, {'ForeName': 'Katalina', 'Initials': 'K', 'LastName': 'Muñoz-Durango', 'Affiliation': 'Vidarium - Nutrition, Health and Wellness Research Center, Nutresa Business Group, Calle 8 Sur No. 50-67, Medellín, Colombia. Electronic address: kmunoz@serviciosnutresa.com.'}]",Free radical biology & medicine,['10.1016/j.freeradbiomed.2020.07.020'] 2255,32746317,Should Hands Be Restricted When Measuring Able-Bodied Participants To Evaluate Machine Learning Controlled Prosthetic Hands?,"OBJECTIVE When evaluating methods for machine-learning controlled prosthetic hands, able-bodied participants are often recruited, for practical reasons, instead of participants with upper limb absence (ULA). However, able-bodied participants have been shown to often perform myoelectric control tasks better than participants with ULA. It has been suggested that this performance difference can be reduced by restricting the wrist and hand movements of able-bodied participants. However, the effect of such restrictions on the consistency and separability of the electromyogram's (EMG) features remains unknown. The present work investigates whether the EMG separability and consistency between unaffected and affected arms differ and whether they change after restricting the unaffected limb in persons with ULA. METHODS Both arms of participants with unilateral ULA were compared in two conditions: with the unaffected hand and wrist restricted or not. Furthermore, it was tested if the effect of arm and restriction is influenced by arm posture (arm down, arm in front, or arm up). RESULTS Fourteen participants (two women, age=53.4±4.05) with acquired transradial limb loss were recruited. We found that the unaffected limb generated more separated EMG than the affected limb. Furthermore, restricting the unaffected hand and wrist lowered the separability of the EMG when the arm was held down. CONCLUSION Limb restriction is a viable method to make the EMG of able-bodied participants more similar to that of participants with ULA. SIGNIFICANCE Future research that evaluates methods for machine learning controlled hands in able-bodied participants should restrict the participants' hand and wrist.",2020,Both arms of participants with unilateral ULA were compared in two conditions: with the unaffected hand and wrist restricted or not.,"['persons with ULA', 'participants with upper limb absence (ULA', 'Fourteen participants (two women, age=53.4±4.05) with acquired transradial limb loss were recruited']",[],['EMG separability and consistency'],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439661', 'cui_str': 'Acquired'}, {'cui': 'C0002695', 'cui_str': 'Amputee'}]",[],"[{'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}]",14.0,0.0755387,Both arms of participants with unilateral ULA were compared in two conditions: with the unaffected hand and wrist restricted or not.,"[{'ForeName': 'Morten B', 'Initials': 'MB', 'LastName': 'Kristoffersen', 'Affiliation': ''}, {'ForeName': 'Andreas W', 'Initials': 'AW', 'LastName': 'Franzke', 'Affiliation': ''}, {'ForeName': 'Corry K Van Der', 'Initials': 'CKV', 'LastName': 'Sluis', 'Affiliation': ''}, {'ForeName': 'Raoul M', 'Initials': 'RM', 'LastName': 'Bongers', 'Affiliation': ''}, {'ForeName': 'Alessio', 'Initials': 'A', 'LastName': 'Murgia', 'Affiliation': ''}]",IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society,['10.1109/TNSRE.2020.3007803'] 2256,32746395,Do Social Threat Cognitions Decrease With School-Based CBT and Predict Treatment Outcome in Adolescents With Social Anxiety Disorder?,"Evidence suggests that Social Anxiety Disorder (SAD) is less responsive to cognitive behavioral treatment (CBT) compared to other anxiety disorders. Therefore, exploring what might facilitate clinical benefit is essential. Social threat cognitions, characterized by exaggerated perceptions of negative evaluation by others, may be one important avenue to examine. The current study investigated whether youths' social threat cognitions decreased with Skills for Academic and Social Success (SASS), a group, school-based CBT designed for SAD, and whether decreases predicted SAD severity and treatment response. Participants included 138 high school students with SAD randomly assigned to SASS, or a nonspecific school counseling intervention. SASS participants showed significantly decreased social threat cognitions at 5-month follow-up. Treatment responders had significantly greater reductions in social threat cognitions compared to nonresponders at post-intervention and follow-up. These findings suggest that social threat cognitions may be important to assess and monitor when treating youth with SAD.",2019,Treatment responders had significantly greater reductions in social threat cognitions compared to nonresponders at post-intervention and follow-up.,"['Participants included 138 high school students with SAD randomly assigned to', 'Adolescents With Social Anxiety Disorder']","['SASS', 'cognitive behavioral treatment (CBT', 'SASS, or a nonspecific school counseling intervention']","['SAD severity and treatment response', 'Social Anxiety Disorder (SAD', 'social threat cognitions']","[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0031572', 'cui_str': 'Social phobia'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0031572', 'cui_str': 'Social phobia'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",138.0,0.0160378,Treatment responders had significantly greater reductions in social threat cognitions compared to nonresponders at post-intervention and follow-up.,"[{'ForeName': 'Julie L', 'Initials': 'JL', 'LastName': 'Ryan', 'Affiliation': 'William James College, Clinical Psychology Department.'}, {'ForeName': 'Jeremy K', 'Initials': 'JK', 'LastName': 'Fox', 'Affiliation': 'Montclair State University, Psychology Department.'}, {'ForeName': 'Sarah R', 'Initials': 'SR', 'LastName': 'Lowe', 'Affiliation': 'Montclair State University, Psychology Department.'}, {'ForeName': 'Carrie Masia', 'Initials': 'CM', 'LastName': 'Warner', 'Affiliation': 'Montclair State University, Psychology Department.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.33.4.331'] 2257,32746402,Rumination and Mindlessness Processes: Trajectories of Change in a 42-Day Mindfulness-Based Intervention.,"This preliminary study aimed to understand the effects of an autonomous mindfulness-based intervention (MBI) on mindlessness propensities: rumination, automatic pilot functioning, and attentional distractibility. The ecological momentary assessment was completed by community participants assigned to two nonrandomized groups: an experimental group ( n = 45) that practiced 20-minute daily mindfulness meditation for 42 days and a control group ( n = 44) that was on the waiting list for the MBI. All participants completed a self-assessment on rumination and mindlessness propensities twice a day. The MBI led to a favorable gradual decrease in automatic pilot functioning and attentional distractibility. Rumination evolved in three stages: a rapid decrease during the first week, a stabilization phase between the 10th and 30th days, and an additional decrease after 30 days of practice. This innovative study provides a promising perspective regarding rumination, automatic pilot functioning, and attentional distractibility dynamic trajectories over the course of an MBI.",2018,The MBI led to a favorable gradual decrease in automatic pilot functioning and attentional distractibility.,[],"['autonomous mindfulness-based intervention (MBI', 'practiced 20-minute daily mindfulness meditation']","['Rumination and Mindlessness Processes', 'automatic pilot functioning and attentional distractibility', 'mindlessness propensities: rumination, automatic pilot functioning, and attentional distractibility', 'Rumination']",[],"[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0233415', 'cui_str': 'Cognitive function: distractibility'}]",,0.0350849,The MBI led to a favorable gradual decrease in automatic pilot functioning and attentional distractibility.,"[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Andreotti', 'Affiliation': 'University of Lille Nord de France, Lille, France eva.andreotti@gmail.com.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Congard', 'Affiliation': 'Psy CLE Research Center, Aix Marseille University, Aix-en-Provence, France.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Le Vigouroux', 'Affiliation': 'Psy CLE Research Center, Aix Marseille University, Aix-en-Provence, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Dauvier', 'Affiliation': 'Psy CLE Research Center, Aix Marseille University, Aix-en-Provence, France.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Illy', 'Affiliation': 'Immanence SAS, Manosque, France.'}, {'ForeName': 'Rollon', 'Initials': 'R', 'LastName': 'Poinsot', 'Affiliation': 'Immanence SAS, Manosque, France.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Antoine', 'Affiliation': 'University of Lille Nord de France, Lille, France.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.32.2.127'] 2258,32746404,Feasibility Study of Group Cognitive Behavioral Therapy for Severe Health Anxiety.,"Severe health anxiety (SHA) is prevalent, often undiagnosed, persistent untreated, and costly. Meta-analyses have shown effectiveness of mostly individual cognitive behavioral therapy (CBT), whereas Group-CBT has only been studied and shown feasibility in one uncontrolled study of psychiatric outpatients also including self-referrals. We aimed to examine feasibility of Group-CBT for physician-referred psychiatric outpatients with SHA and a future randomized controlled trial (RCT). Group-CBT was conducted in two groups of seven participants. Feasibility was examined about recruitment rate, attrition, organization, and effectiveness. Effectiveness was measured by standardized self-report questionnaires: Whiteley Index-7 (WI-7) and Short Health Anxiety Inventory, and clinician rated remission and functioning from baseline to 3-month follow-up (3FU). Recruitment rate was 1.4 participant per month. Attrition showed dropout of 7%. Organization harbored only one senior therapist. Group-CBT showed effectiveness on all measures except WI-7 at 3FU; this latter explained by participants with concurrent borderline personality disorder. Group-CBT seems feasible for physician-referred psychiatric outpatients with SHA. With modifications, an RCT seems feasible.",2018,Group-CBT showed effectiveness on all measures except WI-7 at 3FU; this latter explained by participants with concurrent borderline personality disorder.,"['Severe Health Anxiety', 'physician-referred psychiatric outpatients with SHA']","['CBT', 'individual cognitive behavioral therapy (CBT', 'Group Cognitive Behavioral Therapy', 'Group-CBT']","['standardized self-report questionnaires: Whiteley Index-7 (WI-7) and Short Health Anxiety Inventory, and clinician rated remission and functioning from baseline to 3-month follow-up (3FU', 'Severe health anxiety (SHA', 'rate, attrition, organization, and effectiveness', 'Recruitment rate']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C2959402', 'cui_str': 'Short health anxiety inventory'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}]",7.0,0.0202844,Group-CBT showed effectiveness on all measures except WI-7 at 3FU; this latter explained by participants with concurrent borderline personality disorder.,"[{'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Skjernov', 'Affiliation': 'Clinic for Liaison Psychiatry in Koege, Region Zealand, Denmark matsk@regionsjaelland.dk.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Fink', 'Affiliation': 'Research Clinic for Functional Disorders and Psychosomatics, Aarhus, Denmark.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Fallon', 'Affiliation': 'Columbia University Medical Center, New York City, New York.'}, {'ForeName': 'Flemming', 'Initials': 'F', 'LastName': 'Rasmussen', 'Affiliation': 'Clinic for Liaison Psychiatry in Koege, Region Zealand, Denmark.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Simonsen', 'Affiliation': 'Psychiatric Research Unit, Region Zealand, Denmark.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.32.4.223'] 2259,32746412,Is It Possible to Enhance Intensity in Guided Imagery Exercises? An Experimental Study.,"OBJECTIVE Guided imagery exercises can have a powerful impact on distressing mental images. Clinically, it is usually recommended to experience these exercises as intensely as possible. However, patients sometimes object to the related instructions. In this study, we tested whether typical clinical instructions aiming at increasing intensity led to a stronger effect of the exercise. METHODS Sixty-four healthy participants watched a trauma movie clip. Then they were pseudo-randomized into one of two strategies (intense, less intense) or a waiting control condition. Dependent variables were self-reported emotional intensity and psychophysiology measures. RESULTS Participants in the intense ImRS strategy did not experience the exercise as more intense than those in the less intense ImRS strategy on any outcome measure. Both ImRS strategies showed increased sympathetic activation compared to a decrease of activation in the waiting control group. CONCLUSIONS Our results suggest that emotional intensity in guided imagery exercises may not depend very much on the therapist's instructions.",2018,"RESULTS Participants in the intense ImRS strategy did not experience the exercise as more intense than those in the less intense ImRS strategy on any outcome measure.",['Sixty-four healthy participants watched a trauma movie clip'],"['Guided imagery exercises', 'waiting control condition']","['sympathetic activation', 'emotional intensity and psychophysiology measures']","[{'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0681495', 'cui_str': 'Movies'}, {'cui': 'C0175722', 'cui_str': 'Clip'}]","[{'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0033933', 'cui_str': 'Psychology, Physiological'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",64.0,0.0274889,"RESULTS Participants in the intense ImRS strategy did not experience the exercise as more intense than those in the less intense ImRS strategy on any outcome measure.","[{'ForeName': 'Laura Elise', 'Initials': 'LE', 'LastName': 'Seebauer', 'Affiliation': 'Biological and Personality Psychology, University of Freiburg, Germany laura.seebauer@psychologie.uni-freiburg.de.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Naumann', 'Affiliation': 'Biological and Personality Psychology, University of Freiburg, Germany.'}, {'ForeName': 'Anneke', 'Initials': 'A', 'LastName': 'Jacobs', 'Affiliation': 'Biological and Personality Psychology, University of Freiburg, Germany.'}, {'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Thier', 'Affiliation': 'Biological and Personality Psychology, University of Freiburg, Germany.'}, {'ForeName': 'Gitta A', 'Initials': 'GA', 'LastName': 'Jacob', 'Affiliation': 'Biological and Personality Psychology, University of Freiburg, Germany.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.32.1.38'] 2260,32746413,Can Distressing Sexual Thoughts Be Regulated? Experiential Willingness Versus Distraction.,"This study examines the effects of different techniques on the management of unwanted sexual thoughts. Participants ( N = 150; 67 who found sexual thoughts distressing, 83 participants who did not) were randomly placed into one of three experimental conditions: experiential willingness, distraction, or no strategies for dealing with unwanted sexual thoughts. Participants answered questions assessing attitudes about their sexual thoughts and recorded sexual thought frequency for a 3-minute period pre- and post-intervention. Thought frequencies decreased for all groups post intervention for both the distressed and nondistressed samples. Acceptability of thoughts increased for the experiential willingness group, remained similar for the distraction group, and decreased for the control group. The findings indicate that distraction was more easily implemented, more commonly used, and equally effective to experiential willingness at reducing sexual thoughts in the short term. However, the short experiential willingness intervention increased acceptability of sexual thoughts, which could have an impact on longer-term results.",2018,"Acceptability of thoughts increased for the experiential willingness group, remained similar for the distraction group, and decreased for the control group.","['Participants ( N = 150; 67 who found sexual thoughts distressing, 83 participants who did not']","['experiential willingness, distraction, or no strategies for dealing with unwanted sexual thoughts', 'Experiential Willingness Versus Distraction']","['acceptability of sexual thoughts', 'Acceptability of thoughts', 'sexual thoughts']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0039869', 'cui_str': 'Thinking'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C1299585', 'cui_str': 'Does not'}]","[{'cui': 'C0150189', 'cui_str': 'Distraction training'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0039869', 'cui_str': 'Thinking'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0039869', 'cui_str': 'Thinking'}]",83.0,0.0150235,"Acceptability of thoughts increased for the experiential willingness group, remained similar for the distraction group, and decreased for the control group.","[{'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Lee', 'Affiliation': 'Utah State University, Logan City, Queensland, Australia eric.lee@usu.edu.'}, {'ForeName': 'Joseph A', 'Initials': 'JA', 'LastName': 'Sherwood', 'Affiliation': 'Utah State University, Logan City, Queensland, Australia.'}, {'ForeName': 'Jesse M', 'Initials': 'JM', 'LastName': 'Crosby', 'Affiliation': 'Utah State University, Logan City, Queensland, Australia.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Twohig', 'Affiliation': 'Utah State University, Logan City, Queensland, Australia.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.32.1.49'] 2261,32746639,Feasibility and Acceptability of Light Therapy to Reduce Fatigue in Adolescents and Young Adults Receiving Cancer-Directed Therapy.,"OBJECTIVE/BACKGROUND Fatigue is one of the most consistent and distressing symptoms reported by adolescent/young adult (AYA) oncology patients. Bright white light (BWL) is used to treat fatigue in adult oncology but has not been explored in AYA oncology patients. The purpose of the current study was to determine the feasibility and acceptability of BWL for AYA who were receiving cancer-directed therapy. PARTICIPANTS 51 AYA patients with newly diagnosed solid tumors, including lymphoma. METHODS Participants were randomized to dim red light (DRL, n = 25) or BWL (n = 26) from devices retrofitted with adherence monitors for 30 minutes upon awakening daily for 8 weeks. Side effects were assessed via modified Systematic Assessment for Treatment-Emergent Effects (SAFTEE). Participants completed the PedsQL Multidimensional Fatigue Scale. RESULTS Of patients approached, 73% consented and participated. Mean adherence was 57% of days on study with 30.68 average daily minutes of usage. BWL did not cause more extreme treatment-emergent effects over DRL. Patients in the BWL group demonstrated significant improvement on all fatigue outcomes by both self-report and parent proxy report, which was not observed in the DRL group. CONCLUSIONS This is the first study to evaluate the feasibility and acceptability of light therapy to reduce fatigue in AYA patients receiving cancer-directed therapy. These findings demonstrate the feasibility and acceptability of the intervention and provide preliminary evidence of the potential benefits of BWL, which warrants further study in a confirmatory efficacy trial. ClinicalTrials.gov Identifier Number: NCT02429063.",2020,"Patients in the BWL group demonstrated significant improvement on all fatigue outcomes by both self-report and parent proxy report, which was not observed in the DRL group. ","['Adolescents and Young Adults Receiving Cancer-Directed Therapy', 'patients receiving cancer-directed therapy', '51 AYA patients with newly diagnosed solid tumors, including lymphoma', 'Participants', 'adolescent/young adult (AYA) oncology patients']","['Bright white light (BWL', 'Light Therapy', 'light therapy', 'dim red light (DRL, n =\xa025) or BWL']","['fatigue outcomes', 'PedsQL Multidimensional Fatigue Scale', 'feasibility and acceptability of BWL', 'Mean adherence']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0280100', 'cui_str': 'Solid tumour'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0024299', 'cui_str': 'Malignant lymphoma'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}]","[{'cui': 'C0423899', 'cui_str': 'Above average intellect'}, {'cui': 'C0563228', 'cui_str': 'White light'}, {'cui': 'C0031765', 'cui_str': 'Light therapy'}, {'cui': 'C0114346', 'cui_str': 'dimesna'}, {'cui': 'C0563227', 'cui_str': 'Red light'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0423899', 'cui_str': 'Above average intellect'}, {'cui': 'C0563228', 'cui_str': 'White light'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",51.0,0.115296,"Patients in the BWL group demonstrated significant improvement on all fatigue outcomes by both self-report and parent proxy report, which was not observed in the DRL group. ","[{'ForeName': 'Valerie McLaughlin', 'Initials': 'VM', 'LastName': 'Crabtree', 'Affiliation': ""Department of Psychology, St. Jude Children's Research Hospital , Memphis, Tennessee.""}, {'ForeName': 'Kayla N', 'Initials': 'KN', 'LastName': 'LaRosa', 'Affiliation': ""Department of Psychology, St. Jude Children's Research Hospital , Memphis, Tennessee.""}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'MacArthur', 'Affiliation': ""Department of Psychology, St. Jude Children's Research Hospital , Memphis, Tennessee.""}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Russell', 'Affiliation': ""Department of Psychology, St. Jude Children's Research Hospital , Memphis, Tennessee.""}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': ""Department of Biostatistics, St. Jude Children's Research Hospital , Memphis, Tennessee.""}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': ""Department of Biostatistics, St. Jude Children's Research Hospital , Memphis, Tennessee.""}, {'ForeName': 'Haitao', 'Initials': 'H', 'LastName': 'Pan', 'Affiliation': ""Department of Biostatistics, St. Jude Children's Research Hospital , Memphis, Tennessee.""}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Brigden', 'Affiliation': ""Department of Psychology, St. Jude Children's Research Hospital , Memphis, Tennessee.""}, {'ForeName': 'Laura E', 'Initials': 'LE', 'LastName': 'Schwartz', 'Affiliation': ""Department of Psychology, St. Jude Children's Research Hospital , Memphis, Tennessee.""}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Wilson', 'Affiliation': 'Department of Ophthalmology, University of Tennessee Health Science Center , Memphis, Tennessee.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Pappo', 'Affiliation': ""Department of Oncology, St. Jude Children's Research Hospital , Memphis, Tennessee.""}]",Behavioral sleep medicine,['10.1080/15402002.2020.1797744'] 2262,32746647,Is Lanreotide Really Useful in High Output Stoma? Comparison between Lanreotide to Conventional Antidiarrheal Treatment Alone.,"BACKGROUND The incidence of high-output stoma (HOS) was reported to be approximately 3 to 16% in the literature, and HOS can cause dehydration. This complication is often severe enough to warrant hospital readmission and may result in renal failure. The aim of this study was to show a decrease of 50% in ileostomy output in the experimental arm using lanreotide treatment. METHODS Patients with an ileostomy output ≥ 1.5 l/24 hours were included in this prospective, open, multicentre randomized trial. Patients were randomly allocated between treatment arms with either lanreotide (LAN) and antidiarrhoeal treatments (TAD) (LAN-TAD group) or antidiarrhoeal treatments only (TADS group). The primary outcome was ileostomy output after 72 days. The secondary endpoints were ileostomy output during the first 6 days, blood urea and creatinine values, hospital length of stay and serious adverse events. RESULTS In the per-protocol analysis, there were nine patients in the control group (TADS) and six patients in the experimental group (TAD-LAN group). The stoma outputs at Day 3 (D3) in the experimental and control groups were 1,900 ± 855.7 mL and 1,728.6 ± 845.5 mL, respectively ( p  = 0.2). No differences were found concerning stoma output at D6, renal function, or hospital length of stay between the two groups. CONCLUSION The trial was prematurely stopped due to the low number of patients included. The question of the usefulness of somatostatin analogues in HOS persists, especially as the cost of this treatment is high, and there is a lack of evidence of its effectiveness.",2020,"No differences were found concerning stoma output at D6, renal function, or hospital length of stay between the two groups. ","['Patients with an ileostomy output ≥', '1.5\u2009l/24\u2009hours']","['Lanreotide', 'lanreotide treatment', 'lanreotide (LAN) and antidiarrhoeal treatments (TAD) (LAN-TAD group) or antidiarrhoeal treatments only (TADS group']","['stoma output at D6, renal function, or hospital length of stay', 'ileostomy output', 'ileostomy output during the first 6\u2009days, blood urea and creatinine values, hospital length of stay and serious adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020883', 'cui_str': 'Creation of ileostomy'}, {'cui': 'C3251815', 'cui_str': 'Measurement of fluid output'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0439227', 'cui_str': 'hour'}]","[{'cui': 'C0209211', 'cui_str': 'lanreotide'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0057150', 'cui_str': 'DAT protocol 1'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C1955856', 'cui_str': 'Stoma site'}, {'cui': 'C3251815', 'cui_str': 'Measurement of fluid output'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0020883', 'cui_str': 'Creation of ileostomy'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0005845', 'cui_str': 'Blood urea nitrogen measurement'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.099775,"No differences were found concerning stoma output at D6, renal function, or hospital length of stay between the two groups. ","[{'ForeName': 'Yannis', 'Initials': 'Y', 'LastName': 'Mesli', 'Affiliation': 'Department of Digestive Surgery, Strasbourg University Hospital, Strasbourg, France.'}, {'ForeName': 'Lise', 'Initials': 'L', 'LastName': 'Holterbach', 'Affiliation': 'Pôle de Santé Publique - Santé au Travail - Groupe Methode en Recherche Clinique CHRU Strasbourg, Strasbourg, France.'}, {'ForeName': 'Jean-Baptiste', 'Initials': 'JB', 'LastName': 'Delhorme', 'Affiliation': 'Department of Digestive Surgery, Strasbourg University Hospital, Strasbourg, France.'}, {'ForeName': 'Zaher', 'Initials': 'Z', 'LastName': 'Lakkis', 'Affiliation': 'Department of Digestive Surgery, Besançon University Hospital (Jean Minjoz), Besançon, France.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Ortega-Deballon', 'Affiliation': 'Department of Digestive Surgery, Dijon University Hospital, Dijon, France.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Deguelte', 'Affiliation': 'Department of Digestive Surgery, Reims University Hospital, Reims, France.'}, {'ForeName': 'Serge', 'Initials': 'S', 'LastName': 'Rohr', 'Affiliation': 'Department of Digestive Surgery, Strasbourg University Hospital, Strasbourg, France.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Brigand', 'Affiliation': 'Department of Digestive Surgery, Strasbourg University Hospital, Strasbourg, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Meyer', 'Affiliation': 'Pôle de Santé Publique - Santé au Travail - Groupe Methode en Recherche Clinique CHRU Strasbourg, Strasbourg, France.'}, {'ForeName': 'Benoit', 'Initials': 'B', 'LastName': 'Romain', 'Affiliation': 'Department of Digestive Surgery, Strasbourg University Hospital, Strasbourg, France.'}]",Journal of investigative surgery : the official journal of the Academy of Surgical Research,['10.1080/08941939.2020.1800871'] 2263,32746654,Effects on consumers' subjective understanding of a new front-of-pack nutritional label: a study on Italian consumers.,"Front-of-pack nutritional label (FOPL) systems have been developed worldwide to amplify and simplify nutritional information and induce healthier choices. This study explores consumers' internal reactions - in terms of subjective understanding and liking - to a new FOPL: the NutrInform Battery. The investigation aims to assess the clear comprehension by consumers of the information provided by the NutrInform Battery FOPL scheme, based on a sample of 200 Italian respondents, in a real-life setting, with products representative of the most widely consumed food categories, using a between-subject design. Participants were randomly assigned to one of the two conditions: products marked with NutrInform Battery or Nutri-Score labels. The results provided evidence of the effectiveness of NutrInform Battery in being perceived by consumers as an informative FOPL scheme. Specifically, consumers found NutrInform Battery more informative and helpful than Nutri-Score in terms of their understanding of the product composition.",2020,The results provided evidence of the effectiveness of NutrInform Battery in being perceived by consumers as an informative FOPL scheme.,"['Italian consumers', '200 Italian respondents, in a real-life setting, with products representative of the most widely consumed food categories, using a between-subject design']","['NutrInform Battery or Nutri-Score labels', 'new front-of-pack nutritional label']",[],"[{'cui': 'C0022275', 'cui_str': 'Italian language'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}]","[{'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0184967', 'cui_str': 'Insertion of pack'}]",[],200.0,0.0292144,The results provided evidence of the effectiveness of NutrInform Battery in being perceived by consumers as an informative FOPL scheme.,"[{'ForeName': 'Marco Francesco', 'Initials': 'MF', 'LastName': 'Mazzù', 'Affiliation': 'Department of Business and Management, LUISS University, Rome, Italy.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Romani', 'Affiliation': 'Department of Business and Management, LUISS University, Rome, Italy.'}, {'ForeName': 'Antea', 'Initials': 'A', 'LastName': 'Gambicorti', 'Affiliation': 'Department of Business and Management, LUISS University, Rome, Italy.'}]",International journal of food sciences and nutrition,['10.1080/09637486.2020.1796932'] 2264,32746664,Real-life efficiency and safety comparison study of emollient ointment based on glycerophosphoinositol (GPI) salt of choline and other emollient products in patients with atopic dermatitis.,"INTRODUCTION The aim of this study was to investigate the effectiveness and safety of emollient preparations in comparison with the emollient ointment containing glycerophosphoinositol salt of choline in patients with atopic dermatitis (AD). METHODS In a 'real-life' study, 300 patients with moderate AD were age-stratified and divided into two groups: patients applying GPI emollient and the comparator. We evaluated the effectiveness of AD treatment using: Eczema Area and Severity Index (EASI), Three Item Severity (TIS), Visual Analogue Scale (VAS) and Four-Item Itch Questionnaire. RESULTS The GPI emollient was superior in reduction AD symptoms in children: VAS (-2.58 ± 0.25), TIS (-2.22 ± 0.22), EASI (-15.27 ± 1.77), and adults: VAS (-2.42 ± 0.19), TIS (-2.22 ± 0.17), EASI (-13.22 ± 1.53), as compared to the other emollient in children: VAS (-0.67 ± 0.19), TIS (0.47 ± 0.19), EASI (-3.71 ± 1.01) and adults: VAS (-0.86 ± 0.09), TIS (0.77 ± 0.09), EASI (-2.95 ± 0.46), p  < .001. Similar results were observed in Four Item Itch Questionnaire. CONCLUSION Both emollients showed good safety and tolerance profile and reduced AD symptoms. The GPI emollient seems to be more slightly effective in reducing AD symptoms as compared to the other commercially available emollient.",2020,The GPI emollient seems to be more slightly effective in reducing AD symptoms as compared to the other commercially available emollient.,"['patients with atopic dermatitis (AD', '300 patients with moderate AD were age-stratified and divided into two groups: patients applying GPI emollient and the comparator', 'patients with atopic dermatitis']","['glycerophosphoinositol salt of choline', 'glycerophosphoinositol (GPI) salt of choline']","['reduction AD symptoms', 'good safety and tolerance profile and reduced AD symptoms', 'effectiveness and safety', 'Eczema Area and Severity Index (EASI), Three Item Severity (TIS), Visual Analogue Scale (VAS) and Four-Item Itch Questionnaire']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0017759', 'cui_str': 'Glucose-6-phosphate isomerase'}, {'cui': 'C0013983', 'cui_str': 'Emollient'}]","[{'cui': 'C0061585', 'cui_str': 'glycerylphosphoinositol'}, {'cui': 'C0036140', 'cui_str': 'Salts'}, {'cui': 'C0008405', 'cui_str': 'Choline'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0013595', 'cui_str': 'Eczema'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",300.0,0.0210753,The GPI emollient seems to be more slightly effective in reducing AD symptoms as compared to the other commercially available emollient.,"[{'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Marko', 'Affiliation': 'Division of Biomedical Science, Department of Immunopathology, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.'}, {'ForeName': 'Rafał', 'Initials': 'R', 'LastName': 'Pawliczak', 'Affiliation': 'Division of Biomedical Science, Department of Immunopathology, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.'}]",The Journal of dermatological treatment,['10.1080/09546634.2020.1800567'] 2265,32746774,"Effects of two weekly servings of cod for 16 weeks in pregnancy on maternal iodine status and infant neurodevelopment: Mommy's Food, a randomized controlled trial.","Background Mild-to-moderate iodine deficiency is still present in many countries, particularly in pregnant women. Observational studies suggest that mild-to-moderate iodine deficiency during pregnancy may be associated with impaired thyroid function and child neurodevelopment. Randomized controlled food trials to increase iodine status are scarce. We assessed the impact of an increased intake of cod during pregnancy on maternal iodine status, and infant neurodevelopment. Methods In this randomized controlled trial, pregnant women in Bergen, Norway, recruited through Haukeland University Hospital, were randomly assigned (1:1) to an intervention of 200 g of cod twice a week for 16 weeks (gestational week 20-36) or to continue with their standard diet (control group). Randomization was done by lottery. Primary outcome was urinary iodine concentration (UIC) (spot samples from six consecutive days) measured post intervention. Secondary outcome was infant neurodevelopment assessed by the cognitive, language and motor scales of the Bayley Scales of Infant and Toddler Developmental 3rd edition (Bayley-III) at 11 months of age. In addition, maternal thyroid function was measured (TSH, fT3, fT4) at baseline and post intervention. The trial was registered in ClinicalTrials.gov, NCT02610959. Results Between Jan 2016 until Feb 2017, 137 women were recruited. Post intervention UIC was higher in the intervention group (n=61) (median (IQR) 98 (64-145) µg/L), compared to control (n= 61) (median (IQR) 73 (52-120) µg/L) (p= 0.028), also after adjusting for baseline UIC (p=0.048). Infants of mothers in the intervention group had a lower cognitive composite score on the Bayley-III compared to the control group, (p= 0.045). There were no group differences in the Bayley III language- or motor composite scores. Maternal thyroid hormones (TSH, fT3, fT4) did not differ between the groups post intervention. Conclusions Increased cod intake during pregnancy improved the iodine status in women with mild-to-moderate iodine deficiency, however, did not affect thyroid function. The negative effect on cognition should be followed up to assess whether this is a stable effect over time. More studies are warranted to enable good health advice on iodine nutrition in pregnancy.",2020,"Infants of mothers in the intervention group had a lower cognitive composite score on the Bayley-III compared to the control group, (p= 0.045).","['Results Between Jan 2016 until Feb 2017', 'pregnant women in Bergen, Norway, recruited through Haukeland University Hospital', '137 women were recruited', 'pregnant women']",[],"['lower cognitive composite score', 'urinary iodine concentration (UIC) (spot samples', 'Maternal thyroid hormones (TSH, fT3, fT4', 'infant neurodevelopment assessed by the cognitive, language and motor scales of the Bayley Scales of Infant and Toddler Developmental 3rd edition (Bayley-III', 'Bayley III language- or motor composite scores', 'maternal iodine status and infant neurodevelopment', 'maternal thyroid function', 'maternal iodine status, and infant neurodevelopment']","[{'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0028423', 'cui_str': 'Norway'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C4517569', 'cui_str': '137'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",[],"[{'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021966', 'cui_str': 'Iodide salt'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0040135', 'cui_str': 'Thyroid hormone'}, {'cui': 'C0040160', 'cui_str': 'Thyrotropin'}, {'cui': 'C0560014', 'cui_str': 'ft3'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0682053', 'cui_str': 'Toddler'}, {'cui': 'C0458003', 'cui_str': 'Developmental'}, {'cui': 'C0205437', 'cui_str': 'Third'}, {'cui': 'C0441792', 'cui_str': 'Editions'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0040132', 'cui_str': 'Thyroid structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",137.0,0.201058,"Infants of mothers in the intervention group had a lower cognitive composite score on the Bayley-III compared to the control group, (p= 0.045).","[{'ForeName': 'Maria Wik', 'Initials': 'MW', 'LastName': 'Markhus', 'Affiliation': 'Institute of Marine Research, 115347, Seafood, Nutrition and Environmental state, Bergen, Hordaland, Norway; maria.wik.markhus@hi.no.'}, {'ForeName': 'Mari', 'Initials': 'M', 'LastName': 'Hysing', 'Affiliation': 'University of Bergen Faculty of Psychology, 87364, Department of Psychosocial Science, Bergen, Norway.'}, {'ForeName': 'Lisa Kolden', 'Initials': 'LK', 'LastName': 'Midtbø', 'Affiliation': 'Institute of Marine Research, 115347, Seafood, Nutrition and Environmental state, Bergen, Hordaland, Norway; lisa.kolden.midtbo@moreforsk.no.'}, {'ForeName': 'Ive', 'Initials': 'I', 'LastName': 'Nerhus', 'Affiliation': 'Institute of Marine Research, 115347, Seafood, Nutrition and Environmental state, Bergen, Hordaland, Norway; i.nerhus@gmail.com.'}, {'ForeName': 'Synnøve', 'Initials': 'S', 'LastName': 'Næss', 'Affiliation': 'Institute of Marine Research, 115347, Seafood, Nutrition and Environmental state, Bergen, Hordaland, Norway; synnoeve.naess@hi.no.'}, {'ForeName': 'Inger', 'Initials': 'I', 'LastName': 'Aakre', 'Affiliation': 'Institute of Marine Research, 115347, Seafood, Nutrition and Environmental state, Bergen, Hordaland, Norway; Inger.Aakre@hi.no.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Kvestad', 'Affiliation': 'NORCE Norwegian Research Centre AS, 521537, Regional Centre for Child and Youth Mental Health and Child Welfare, Bergen, Hordaland, Norway; inkv@norceresearch.no.'}, {'ForeName': 'Lisbeth', 'Initials': 'L', 'LastName': 'Dahl', 'Affiliation': 'Institute of Marine Research, 115347, Seafood, Nutrition and Environmental state, Bergen, Hordaland, Norway; Lisbeth.Dahl@hi.no.'}, {'ForeName': 'Marian', 'Initials': 'M', 'LastName': 'Kjellevold', 'Affiliation': 'Institute of Marine Research, 115347, Seafood, Nutrition and Environmental state, Bergen, Hordaland, Norway; marian.kjellevold@hi.no.'}]",Thyroid : official journal of the American Thyroid Association,['10.1089/thy.2020.0115'] 2266,32746877,Chest physiotherapy improves lung aeration in hypersecretive critically ill patients: a pilot randomized physiological study.,"BACKGROUND Besides airway suctioning, patients undergoing invasive mechanical ventilation (iMV) benefit of different combinations of chest physiotherapy techniques, to improve mucus removal. To date, little is known about the clearance effects of oscillating devices on patients with acute respiratory failure undergoing iMV. This study aimed to assess (1) the effects of high-frequency chest wall oscillation (HFCWO) on lung aeration and ventilation distribution, as assessed by electrical impedance tomography (EIT), and (2) the effect of the association of HFCWO with recruitment manoeuvres (RM). METHODS Sixty critically ill patients, 30 classified as normosecretive and 30 as hypersecretive, who received ≥ 48 h of iMV, underwent HFCWO; patients from both subgroups were randomized to receive RM or not, according to two separated randomization sequences. We therefore obtained four arms of 15 patients each. After baseline record (T0), HFCWO was applied for 10 min. At the end of the treatment (T1) or after 1 (T2) and 3 h (T3), EIT data were recorded. At the beginning of each step, closed tracheobronchial suctioning was performed. In the RM subgroup, tracheobronchial suctioning was followed by application of 30 cmH 2 O to the patient's airway for 30 s. At each step, we assessed the change in end-expiratory lung impedance (ΔEELI) and in tidal impedance variation (ΔTIV), and the center of gravity (COG) through EIT. We also analysed arterial blood gases (ABGs). RESULTS ΔTIV and COG did not differ between normosecretive and hypersecretive patients. Compared to T0, ΔEELI significantly increased in hypersecretive patients at T2 and T3, irrespective of the RM; on the contrary, no differences were observed in normosecretive patients. No differences of ABGs were recorded. CONCLUSIONS In hypersecretive patients, HFCWO significantly improved aeration of the dorsal lung region, without affecting ABGs. The application of RM did not provide any further improvements. TRIAL REGISTRATION Prospectively registered at the Australian New Zealand Clinical Trial Registry ( www.anzctr.org.au ; number of registration: ACTRN12615001257550; date of registration: 17th November 2015).",2020,"Compared to T0, ΔEELI significantly increased in hypersecretive patients at T2 and T3, irrespective of the RM; on the contrary, no differences were observed in normosecretive patients.","['hypersecretive critically ill patients', 'Sixty critically ill patients, 30 classified as normosecretive and 30 as hypersecretive, who received ≥\u200948\u2009h of iMV, underwent HFCWO; patients from both subgroups', '15 patients each', 'patients undergoing invasive mechanical ventilation (iMV', 'patients with acute respiratory failure undergoing iMV']","['Chest physiotherapy', 'tracheobronchial suctioning', 'RM', 'high-frequency chest wall oscillation (HFCWO']","['lung aeration', 'arterial blood gases (ABGs', 'aeration of the dorsal lung region', 'change in end-expiratory lung impedance (ΔEELI) and in tidal impedance variation (ΔTIV), and the center of gravity (COG) through EIT', 'ABGs', 'lung aeration and ventilation distribution']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C1868981', 'cui_str': 'Invasive mechanical ventilation'}, {'cui': 'C1136075', 'cui_str': 'High-Frequency Chest Compression'}, {'cui': 'C0264490', 'cui_str': 'Acute respiratory failure'}]","[{'cui': 'C0199467', 'cui_str': 'Physiotherapy of chest'}, {'cui': 'C0278385', 'cui_str': 'Tracheobronchial suctioning'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C1136075', 'cui_str': 'High-Frequency Chest Compression'}]","[{'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0150411', 'cui_str': 'Analysis of arterial blood gases and pH'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0442700', 'cui_str': 'End-expiration'}, {'cui': 'C0162537', 'cui_str': 'Impedance'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0282189', 'cui_str': 'Gravity'}, {'cui': 'C0040395', 'cui_str': 'Diagnostic tomography'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}]",60.0,0.196393,"Compared to T0, ΔEELI significantly increased in hypersecretive patients at T2 and T3, irrespective of the RM; on the contrary, no differences were observed in normosecretive patients.","[{'ForeName': 'Federico', 'Initials': 'F', 'LastName': 'Longhini', 'Affiliation': 'Anesthesia and Intensive Care Unit, Department of Medical and Surgical Sciences, University Hospital Mater Domini, Magna Graecia University, Catanzaro, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Bruni', 'Affiliation': 'Anesthesia and Intensive Care Unit, Department of Medical and Surgical Sciences, University Hospital Mater Domini, Magna Graecia University, Catanzaro, Italy.'}, {'ForeName': 'Eugenio', 'Initials': 'E', 'LastName': 'Garofalo', 'Affiliation': 'Anesthesia and Intensive Care Unit, Department of Medical and Surgical Sciences, University Hospital Mater Domini, Magna Graecia University, Catanzaro, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Ronco', 'Affiliation': ""Anesthesia and Intensive Care, Sant'Andrea Hospital, ASL VC, Vercelli, Italy.""}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Gusmano', 'Affiliation': ""Anesthesia and Intensive Care, Sant'Andrea Hospital, ASL VC, Vercelli, Italy.""}, {'ForeName': 'Gianmaria', 'Initials': 'G', 'LastName': 'Cammarota', 'Affiliation': 'Department of Anesthesia and Intensive Care, ""Maggiore della carità"" University Hospital, Novara, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Pasin', 'Affiliation': 'Department of Anesthesia and Intensive Care, Azienda Ospedaliera-Università di Padova, Padua, Italy.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Frigerio', 'Affiliation': 'ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Chiumello', 'Affiliation': 'SC Anestesia e Rianimazione, Ospedale San Paolo - Polo Universitario, ASST Santi Paolo e Carlo, Milan, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Navalesi', 'Affiliation': 'Department of Anesthesia and Intensive Care, Azienda Ospedaliera-Università di Padova, Padua, Italy. paolo.navalesi@unipd.it.'}]","Critical care (London, England)",['10.1186/s13054-020-03198-6'] 2267,32746899,"Comparison of conventional, burst and high-frequency spinal cord stimulation on pain relief in refractory failed back surgery syndrome patients: study protocol for a prospective randomized double-blinded cross-over trial (MULTIWAVE study).","BACKGROUND While the evolution of technology provides new opportunities to manage chronic refractory pain using different waveform modalities of spinal cord stimulation in failed back surgery syndrome (FBSS), there is no randomized controlled trial available to compare the efficacy of these different stimulations waveforms to date. MULTIWAVE is a prospective, randomized, double-blinded, crossover trial study designed to compare the clinical efficacy of tonic conventional stimulation (TCS), burst stimulation (BURST) and high-frequency stimulation (HF) in FBSS patients over a 15-month period in SCS implanted patients. METHODS/DESIGN Twenty-eight patients will be recruited in the Poitiers University Hospital, in Niort and La Rochelle Hospitals in France. Eligible patients with post-operative low back and leg pain with an average visual analog scale (VAS) score ≥ 5 for low back pain are implanted and randomly assigned to one of the six arms (in a 1:1:1:1:1:1 ratio), where they receive a 3-month combination of TCS, BURST and HF including one treatment modality per month and varying the order of the modality received within the six possible combinations. Patients receiving intrathecal drug delivery, peripheral nerve stimulation and back resurgery related to the original back pain complaint and experimental therapies are excluded from this study. Patients included in the spinal cord stimulation group undergo trial stimulation, and they all receive a TCS treatment for 2 months, as the gold standard modality. Thereafter, patients are randomly assigned to one of the six arms for the total duration of 3-month crossover period. Then, patients choose their preferred stimulation modality (TCS, BURST, or HF) for the follow-up period of 12 months. Outcome assessments are performed at baseline (first implant), before randomization (2 months after baseline) and at 1, 2, 3, 6, 9 and 15 months post-randomization. Our primary outcome is the average global VAS of pain over 5-day pain diary period between baseline and after each period of stimulation. Additional outcomes include changes in leg and back pain intensity, functional disability, quality of life, psychological state, paraesthesia intensity perception, patient satisfaction and the number of adverse events. DISCUSSION Recruitment began in February 2017 and will continue through 2019. TRIAL REGISTRATION Clinicaltrials.gov NCT03014583 . Registered on 9 January 2017.",2020,"Additional outcomes include changes in leg and back pain intensity, functional disability, quality of life, psychological state, paraesthesia intensity perception, patient satisfaction and the number of adverse events. ","['FBSS patients over a 15-month period in SCS implanted patients', 'Patients receiving intrathecal drug delivery, peripheral nerve stimulation and back resurgery related to the original back pain complaint and experimental therapies are excluded from this study', 'Eligible patients with post-operative low back and leg pain with an average visual analog scale (VAS) score\u2009≥\u20095 for low back pain', 'failed back surgery syndrome (FBSS', 'Twenty-eight patients will be recruited in the Poitiers University Hospital, in Niort and La Rochelle Hospitals in France', 'refractory failed back surgery syndrome patients']","['tonic conventional stimulation (TCS), burst stimulation (BURST) and high-frequency stimulation (HF', 'TCS, BURST and HF', 'conventional, burst and high-frequency spinal cord stimulation', 'TCS']","['average global VAS of pain over 5-day pain diary period', 'pain relief', 'changes in leg and back pain intensity, functional disability, quality of life, psychological state, paraesthesia intensity perception, patient satisfaction and the number of adverse events']","[{'cui': 'C1963763', 'cui_str': 'Failed Back Surgery Syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0175699', 'cui_str': 'Saethre-Chotzen syndrome'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0677897', 'cui_str': 'Intrathecal route'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0031119', 'cui_str': 'Peripheral nerve structure'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205313', 'cui_str': 'Original'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0277786', 'cui_str': 'Complaint'}, {'cui': 'C0949266', 'cui_str': 'Investigational Therapies'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0023222', 'cui_str': 'Pain in lower limb'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}]","[{'cui': 'C3543842', 'cui_str': 'TONICS'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0394477', 'cui_str': 'Neurostimulation of spinal cord tissue'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0451366', 'cui_str': 'Pain diary'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0030554', 'cui_str': 'Paresthesia'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",28.0,0.372222,"Additional outcomes include changes in leg and back pain intensity, functional disability, quality of life, psychological state, paraesthesia intensity perception, patient satisfaction and the number of adverse events. ","[{'ForeName': 'Maxime', 'Initials': 'M', 'LastName': 'Billot', 'Affiliation': 'PRISMATICS Lab (Predictive Research in Spine/Neuromodulation Management and Thoracic Innovation/Cardiac Surgery), Poitiers University Hospital, Poitiers, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Naiditch', 'Affiliation': 'PRISMATICS Lab (Predictive Research in Spine/Neuromodulation Management and Thoracic Innovation/Cardiac Surgery), Poitiers University Hospital, Poitiers, France.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Brandet', 'Affiliation': 'PRISMATICS Lab (Predictive Research in Spine/Neuromodulation Management and Thoracic Innovation/Cardiac Surgery), Poitiers University Hospital, Poitiers, France.'}, {'ForeName': 'Bertille', 'Initials': 'B', 'LastName': 'Lorgeoux', 'Affiliation': 'PRISMATICS Lab (Predictive Research in Spine/Neuromodulation Management and Thoracic Innovation/Cardiac Surgery), Poitiers University Hospital, Poitiers, France.'}, {'ForeName': 'Sandrine', 'Initials': 'S', 'LastName': 'Baron', 'Affiliation': 'PRISMATICS Lab (Predictive Research in Spine/Neuromodulation Management and Thoracic Innovation/Cardiac Surgery), Poitiers University Hospital, Poitiers, France.'}, {'ForeName': 'Amine', 'Initials': 'A', 'LastName': 'Ounajim', 'Affiliation': 'PRISMATICS Lab (Predictive Research in Spine/Neuromodulation Management and Thoracic Innovation/Cardiac Surgery), Poitiers University Hospital, Poitiers, France.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Roulaud', 'Affiliation': 'PRISMATICS Lab (Predictive Research in Spine/Neuromodulation Management and Thoracic Innovation/Cardiac Surgery), Poitiers University Hospital, Poitiers, France.'}, {'ForeName': 'Aline', 'Initials': 'A', 'LastName': 'Roy-Moreau', 'Affiliation': 'Pain Clinic, Nord-Deux-Sèvres Hospital Center, Thouars, France.'}, {'ForeName': 'Géraldine', 'Initials': 'G', 'LastName': 'de Montgazon', 'Affiliation': 'Pain Clinic/Palliative Care, Hospital Center La Rochelle, La Rochelle, France.'}, {'ForeName': 'Elodie', 'Initials': 'E', 'LastName': 'Charrier', 'Affiliation': 'Pain Management and Research Centre, Poitiers University School of Medicine, Poitiers, France.'}, {'ForeName': 'Lorraine', 'Initials': 'L', 'LastName': 'Misbert', 'Affiliation': 'Pain Management and Research Centre, Poitiers University School of Medicine, Poitiers, France.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Maillard', 'Affiliation': 'PRISMATICS Lab (Predictive Research in Spine/Neuromodulation Management and Thoracic Innovation/Cardiac Surgery), Poitiers University Hospital, Poitiers, France.'}, {'ForeName': 'Tanguy', 'Initials': 'T', 'LastName': 'Vendeuvre', 'Affiliation': 'PRISMATICS Lab (Predictive Research in Spine/Neuromodulation Management and Thoracic Innovation/Cardiac Surgery), Poitiers University Hospital, Poitiers, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Rigoard', 'Affiliation': 'PRISMATICS Lab (Predictive Research in Spine/Neuromodulation Management and Thoracic Innovation/Cardiac Surgery), Poitiers University Hospital, Poitiers, France. philippe.rigoard@chu-poitiers.fr.'}]",Trials,['10.1186/s13063-020-04587-6'] 2268,32746904,"Fermented soy supplementation improves indicators of quality of life: a randomized, placebo-controlled, double-blind trial in adults experiencing heartburn.","OBJECTIVE To determine if fermented soy supplementation relieves heartburn and improves gastrointestinal symptoms and quality of life, a randomized, double-blind parallel study was conducted with adults experiencing mild or moderate heartburn. Participants consumed up to 3, 1 g sachets of flavored, Lactobacillus delbrueckii fermented with soy flour (n = 23) or placebo (maltodextrin) (n = 27) sachets per heartburn incident as needed for 3 weeks. Symptom intensity at 5, 15, and 30 min post-administration was assessed using a Likert-like scale. The Gastrointestinal Symptoms Rating Scale (GSRS) and Gastro-esophageal Reflux Disease Quality of Life Questionnaire (GERD-QOL) were administered at baseline, post-intervention and following a 1-week washout. RESULTS No significant differences between groups were seen for heartburn severity or frequency, GSRS syndromes, or GERD-QOL domains. However, individual QOL items related to inconvenience of taking medications, fear of eating, inability to concentrate at work, and disturbance of after-meal activities and rest improved with fermented soy compared to placebo. Frequency of heartburn, diarrhea, and bloating improved during washout vs. baseline for the fermented soy group compared to placebo. Lactobacillus delbrueckii fermented soy supplementation improved QOL indicators and may decrease heartburn occurrence over time vs. an acute effect; efficacy of daily intake and longer duration requires investigation.",2020,"No significant differences between groups were seen for heartburn severity or frequency, GSRS syndromes, or GERD-QOL domains.","['adults experiencing heartburn', 'adults experiencing mild or moderate heartburn']","['Lactobacillus delbrueckii fermented soy supplementation', 'fermented soy supplementation', 'Lactobacillus delbrueckii fermented with soy flour', 'Fermented soy supplementation', 'placebo (maltodextrin', 'placebo']","['heartburn occurrence', 'heartburn severity or frequency, GSRS syndromes, or GERD-QOL domains', 'QOL indicators', 'Gastrointestinal Symptoms Rating Scale (GSRS) and Gastro-esophageal Reflux Disease Quality of Life Questionnaire (GERD-QOL', 'gastrointestinal symptoms and quality of life', 'Frequency of heartburn, diarrhea, and bloating', 'inconvenience of taking medications, fear of eating, inability to concentrate at work, and disturbance of after-meal activities and rest', 'indicators of quality of life', 'Symptom intensity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0018834', 'cui_str': 'Heartburn'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}]","[{'cui': 'C0317588', 'cui_str': 'Lactobacillus delbrueckii'}, {'cui': 'C0037733', 'cui_str': 'Soya bean'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0771806', 'cui_str': 'Soya flour'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}]","[{'cui': 'C0018834', 'cui_str': 'Heartburn'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0017168', 'cui_str': 'Gastroesophageal reflux disease'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C1290952', 'cui_str': 'Taking medication'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0235198', 'cui_str': 'Unable to concentrate'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}]",,0.446808,"No significant differences between groups were seen for heartburn severity or frequency, GSRS syndromes, or GERD-QOL domains.","[{'ForeName': 'Asmaa', 'Initials': 'A', 'LastName': 'Fatani', 'Affiliation': 'Department of Food Science and Human Nutrition, University of Florida, 359 FSHN Building, 572 Newell Drive, Gainesville, FL, USA.'}, {'ForeName': 'Kadi', 'Initials': 'K', 'LastName': 'Vaher', 'Affiliation': 'Lallemand Bio-Ingredients, Akadeemia tee 21/3, Tallinn, 12618, Estonia.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Rivero-Mendoza', 'Affiliation': 'Department of Food Science and Human Nutrition, University of Florida, 359 FSHN Building, 572 Newell Drive, Gainesville, FL, USA.'}, {'ForeName': 'Karima', 'Initials': 'K', 'LastName': 'Alabasi', 'Affiliation': 'Department of Food Science and Human Nutrition, University of Florida, 359 FSHN Building, 572 Newell Drive, Gainesville, FL, USA.'}, {'ForeName': 'Wendy J', 'Initials': 'WJ', 'LastName': 'Dahl', 'Affiliation': 'Department of Food Science and Human Nutrition, University of Florida, 359 FSHN Building, 572 Newell Drive, Gainesville, FL, USA. wdahl@ufl.edu.'}]",BMC research notes,['10.1186/s13104-020-05205-z'] 2269,32746928,The effects of nudging and pricing on healthy food purchasing behavior in a virtual supermarket setting: a randomized experiment.,"BACKGROUND Evidence on what strategies - or combination of strategies - are most effective and equitable in promoting healthier diets is needed. This study examined the efficacy of nudging and pricing strategies on increasing healthy food purchases and the potential differential effect by socio-economic position (SEP) among Dutch adults in a virtual supermarket. METHODS A randomized study design was conducted within a virtual supermarket (SN VirtuMart). Participants were exposed to five within-subject study conditions (control, nudging, pricing, price salience and price salience with nudging) and randomized to one of three between-subject study arms (a 25% price increase on unhealthy products, a 25% discount on healthy products, or a 25% price increase and discount). In total, 455 participants of low and high SEP (using either education or income as proxy) were randomized to conduct their weekly shopping in a virtual supermarket for five consecutive weeks. The primary outcome included the percentage of healthy purchases. Data were analyzed using linear mixed models. RESULTS In total, 346 (76%) adults completed all five shops within the SN VirtuMart. Median age was 32.5, 49.2% had high education and 32.8% had high income. Out of the 12 conditions, four conditions were statistically significantly different from the control condition. Nudging and non-salient pricing strategies alone did not statistically significantly increase healthy food purchases, whereas a combination of salient price increases and discounts led to an increase in the percentage of healthy food purchases (B 4.5, 95%CI 2.6; 6.4). Combining salient pricing and nudging strategies led to increases in the percentage of healthy products in all three pricing arms, with largest effects found in the combined price increase and discount arm (B = 4.0, 95%CI = 2.0; 6.0). Effects were not modified by SEP. CONCLUSIONS Combining health-related price increases and discounts and combining these salient pricing strategies with nudges in a supermarket setting seems to stimulate healthy food purchases for both low and high SEP populations. However, further research in real-world settings is needed. TRIAL REGISTRATION This randomized trial ( NTR7293 ) was registered in the Dutch trial registry ( www.trialregister.nl ).",2020,"Combining salient pricing and nudging strategies led to increases in the percentage of healthy products in all three pricing arms, with largest effects found in the combined price increase and discount arm (B = 4.0, 95%CI = 2.0; 6.0).","['Dutch adults in a virtual supermarket', 'In total, 346 (76%) adults completed all five shops within the SN VirtuMart', 'healthy food purchasing behavior in a virtual supermarket setting', 'Median age was 32.5, 49.2% had high education and 32.8% had high income', '455 participants of low and high SEP (using either education or income as proxy']","['price increase on unhealthy products, a 25% discount on healthy products, or a 25% price increase and discount', 'nudging and pricing', 'nudging and pricing strategies']","['percentage of healthy products', 'percentage of healthy purchases', 'percentage of healthy food purchases']","[{'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0557778', 'cui_str': 'Supermarket'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0041472', 'cui_str': 'Murine typhus'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517710', 'cui_str': '32.5'}, {'cui': 'C0424933', 'cui_str': 'Higher education'}, {'cui': 'C0948433', 'cui_str': 'High income'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0600420', 'cui_str': 'Proxy'}]","[{'cui': 'C0080045', 'cui_str': 'Prices'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0033118', 'cui_str': 'Pricing'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0016452', 'cui_str': 'Foods'}]",455.0,0.088994,"Combining salient pricing and nudging strategies led to increases in the percentage of healthy products in all three pricing arms, with largest effects found in the combined price increase and discount arm (B = 4.0, 95%CI = 2.0; 6.0).","[{'ForeName': 'Jody C', 'Initials': 'JC', 'LastName': 'Hoenink', 'Affiliation': 'Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Data Science, Amsterdam Public Health research institute, De Boelelaan, 1117, Amsterdam, the Netherlands. j.c.hoenink@amsterdamumc.nl.'}, {'ForeName': 'Joreintje D', 'Initials': 'JD', 'LastName': 'Mackenbach', 'Affiliation': 'Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Data Science, Amsterdam Public Health research institute, De Boelelaan, 1117, Amsterdam, the Netherlands.'}, {'ForeName': 'Wilma', 'Initials': 'W', 'LastName': 'Waterlander', 'Affiliation': 'Department of Public Health, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health Research Institute, Meibergdreef 9, Amsterdam, the Netherlands.'}, {'ForeName': 'Jeroen', 'Initials': 'J', 'LastName': 'Lakerveld', 'Affiliation': 'Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Data Science, Amsterdam Public Health research institute, De Boelelaan, 1117, Amsterdam, the Netherlands.'}, {'ForeName': 'Nynke', 'Initials': 'N', 'LastName': 'van der Laan', 'Affiliation': 'Department of Communication and Cognition, Tilburg University, Tilburg, the Netherlands.'}, {'ForeName': 'Joline W J', 'Initials': 'JWJ', 'LastName': 'Beulens', 'Affiliation': 'Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Data Science, Amsterdam Public Health research institute, De Boelelaan, 1117, Amsterdam, the Netherlands.'}]",The international journal of behavioral nutrition and physical activity,['10.1186/s12966-020-01005-7'] 2270,32746941,"Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial.","INTRODUCTION Depression is a highly prevalent condition in the elderly, with a vast impact on quality of life, life expectancy, and medical outcomes. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed agents in this condition and, although generally safe, tolerability issues cannot be overlooked. Vortioxetine is an antidepressant with a novel mechanism of action. Based on studies to date, it may have a promising tolerability profile in the elderly, as it does not adversely affect psychomotor or cognitive performance and does not alter cardiovascular and endocrine parameters. The present study aims to assess the tolerability profile of vortioxetine in comparison with the SSRIs considered as a single group in elderly participants with depression. The rate of participants withdrawing from treatment due to adverse events after 6 months of follow up will be the primary outcome. METHODS AND ANALYSIS This is a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial funded by the Italian Medicines Agency (AIFA - Agenzia Italiana del Farmaco). Thirteen Italian Community Psychiatric Services will consecutively enrol elderly participants suffering from an episode of major depression over a period of 12 months. Participants will be assessed at baseline and after 1, 3 and 6 months of follow up. At each time point, the following validated rating scales will be administered: Montgomery-Åsberg Depression Rating Scale (MADRS), Antidepressant Side-Effect Checklist (ASEC), EuroQual 5 Dimensions (EQ-5D), Short Blessed Test (SBT), and Charlson Age-Comorbidity Index (CACI). Outcome assessors and the statistician will be masked to treatment allocation. A total of 358 participants (179 in each group) will be enrolled. ETHICS AND DISSEMINATION This study will fully adhere to the ICH E6 Guideline for Good Clinical Practice. Participants' data will be managed and safeguarded according to the European Data Protection Regulation 2016/679. An external Ethical Advisory Board will help guarantee high ethical standards. TRIAL REGISTRATION Clinicaltrials.gov: NCT03779789 , Registered on 19 December 2018. Submitted on 19 December. EudraCT number: 2018-001444-66. TRIAL STATUS Protocol version 1.5; 09/06/2018. Recruitment started In February 2019 and it is ongoing. It is expected to end approximately on 30 September 2021.",2020,"The rate of participants withdrawing from treatment due to adverse events after 6 months of follow up will be the primary outcome. ","['358 participants (179 in each group) will be enrolled', 'EudraCT number: 2018-001444-66', 'elderly participants with depression', 'Thirteen Italian Community Psychiatric Services will consecutively enrol elderly participants suffering from an episode of major depression over a period of 12\u2009months', 'elderly with major depression']","['vortioxetine', 'Vortioxetine', 'Selective serotonin reuptake inhibitors (SSRIs']","['Montgomery-Åsberg Depression Rating Scale (MADRS), Antidepressant Side-Effect Checklist (ASEC), EuroQual 5 Dimensions (EQ-5D), Short Blessed Test (SBT), and Charlson Age-Comorbidity Index (CACI', 'adverse events', 'Tolerability and efficacy', 'tolerability profile']","[{'cui': 'C4517609', 'cui_str': '179'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0022275', 'cui_str': 'Italian language'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C3661282', 'cui_str': 'vortioxetine'}, {'cui': 'C0360105', 'cui_str': 'Selective serotonin re-uptake inhibitor'}]","[{'cui': 'C2960593', 'cui_str': 'Montgomery-Åsberg depression rating scale'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",358.0,0.142161,"The rate of participants withdrawing from treatment due to adverse events after 6 months of follow up will be the primary outcome. ","[{'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Ostuzzi', 'Affiliation': 'Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Gastaldon', 'Affiliation': 'Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy. chiara.gastaldon@univr.it.'}, {'ForeName': 'Angelo', 'Initials': 'A', 'LastName': 'Barbato', 'Affiliation': 'Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': ""D'Avanzo"", 'Affiliation': 'Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Tettamanti', 'Affiliation': 'Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Monti', 'Affiliation': 'Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Aguglia', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics Maternal and Child Health, University of Genoa, Genoa, Italy.'}, {'ForeName': 'Eugenio', 'Initials': 'E', 'LastName': 'Aguglia', 'Affiliation': 'Department of Clinical and Experimental Medicine, Psychiatry Unit, University of Catania, U.O.C. Clinica Psichiatrica, A.O.U. Policlinico-Vittorio Emanuele, Presidio ""G. Rodolico"", Catania, Italy.'}, {'ForeName': 'Maria Chiara', 'Initials': 'MC', 'LastName': 'Alessi', 'Affiliation': 'Dipartimento di Neuroscienze, Imaging e Scienze Cliniche Università ""G. D\'Annunzio Chieti-Pescara"", Chieti, Italy.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Amore', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics Maternal and Child Health, University of Genoa, Genoa, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Bartoli', 'Affiliation': 'Dipartimento di Medicina e Chirurgia, Università di Milano Bicocca, Milan, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Biondi', 'Affiliation': 'Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Bortolaso', 'Affiliation': 'Department of Medicine and Surgery, Division of Psychiatry, University of Insubria, Varese, Italy.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Callegari', 'Affiliation': 'Department of Medicine and Surgery, Division of Psychiatry, University of Insubria, Varese, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Carrà', 'Affiliation': 'Dipartimento di Medicina e Chirurgia, Università di Milano Bicocca, Milan, Italy.'}, {'ForeName': 'Rosangela', 'Initials': 'R', 'LastName': 'Caruso', 'Affiliation': 'Institute of Psychiatry, Department of Biomedical and Specialty Surgical Sciences, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Cavallotti', 'Affiliation': 'Department of Mental Health, ASST Santi Paolo e Carlo, Milan, Italy.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Crocamo', 'Affiliation': 'Dipartimento di Medicina e Chirurgia, Università di Milano Bicocca, Milan, Italy.'}, {'ForeName': 'Armando', 'Initials': 'A', 'LastName': ""D'Agostino"", 'Affiliation': 'Department of Mental Health, ASST Santi Paolo e Carlo, Milan, Italy.'}, {'ForeName': 'Pasquale', 'Initials': 'P', 'LastName': 'De Fazio', 'Affiliation': 'Azienda Ospedaliera Universitaria Mater Domini, Università Magna Grecia, Catanzaro, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Di Natale', 'Affiliation': 'Dipartimento di Neuroscienze, Imaging e Scienze Cliniche Università ""G. D\'Annunzio Chieti-Pescara"", Chieti, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Giusti', 'Affiliation': ""Dipartimento di Medicina Clinica, Sanità Pubblica, Scienze della Vita e dell'Ambiente, Università degli Studi dell'Aquila, L'Aquila, Italy.""}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Grassi', 'Affiliation': 'Institute of Psychiatry, Department of Biomedical and Specialty Surgical Sciences, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Martinotti', 'Affiliation': 'Dipartimento di Neuroscienze, Imaging e Scienze Cliniche Università ""G. D\'Annunzio Chieti-Pescara"", Chieti, Italy.'}, {'ForeName': 'Michela', 'Initials': 'M', 'LastName': 'Nosé', 'Affiliation': 'Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Papola', 'Affiliation': 'Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.'}, {'ForeName': 'Marianna', 'Initials': 'M', 'LastName': 'Purgato', 'Affiliation': 'Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Rodolico', 'Affiliation': 'Department of Clinical and Experimental Medicine, Psychiatry Unit, University of Catania, U.O.C. Clinica Psichiatrica, A.O.U. Policlinico-Vittorio Emanuele, Presidio ""G. Rodolico"", Catania, Italy.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Roncone', 'Affiliation': ""Dipartimento di Medicina Clinica, Sanità Pubblica, Scienze della Vita e dell'Ambiente, Università degli Studi dell'Aquila, L'Aquila, Italy.""}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Tarsitani', 'Affiliation': 'Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Turrini', 'Affiliation': 'Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Zanini', 'Affiliation': 'Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Amaddeo', 'Affiliation': 'Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.'}, {'ForeName': 'Mirella', 'Initials': 'M', 'LastName': 'Ruggeri', 'Affiliation': 'Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.'}, {'ForeName': 'Corrado', 'Initials': 'C', 'LastName': 'Barbui', 'Affiliation': 'Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.'}]",Trials,['10.1186/s13063-020-04460-6'] 2271,32747036,Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms.,"OBJECTIVES Various combinations of estrogens and progestogens are available for menopausal hormone therapy that differ in their efficacy and safety profile. We evaluated the efficacy and long-term safety of low-dose estradiol (0.5 mg) / dydrogesterone (2.5 mg) in subgroups of postmenopausal women with vasomotor symptoms. ANALYSIS Efficacy analysis was performed on data from 2 previously published studies for subgroups defined by age, duration of menopause, and body mass index at baseline. The primary efficacy variable was the number of moderate to severe hot flushes from baseline to week 13. Long-term safety was evaluated in relation to age and duration of menopause. Safety variables included adverse events to week 52 and change from baseline to endpoint in laboratory and vital sign values. RESULTS The treatment difference seen in the overall population in favour of low-dose estradiol/dydrogesterone was also observed in the subgroups of patients aged 45 to < 55 years (p < 0.01) and ≥55 years (p < 0.05), with menopause duration of >12 months to <60 months (p < 0.05) and ≥ 60 months (p < 0.005), and with a BMI at baseline of <25 kg/m 2 (p < 0.05) and 25 to <30 kg/m 2 (p < 0.01). Low-dose estradilol/dydrogesterone was well tolerated across the different subgroups. The incidence of breast-related adverse events was very low. No breast malignancy was reported. Only one adverse endometrial outcome of simple hyperplasia was observed. CONCLUSION The results of our analyses confirmed the consistent treatment effect on vasomotor symptoms and the favourable safety profile of 0.5 mg 17β estradiol and 2.5 mg dydrogesterone in different patient subgroups.",2020,"The treatment difference seen in the overall population in favour of low-dose estradiol/dydrogesterone was also observed in the subgroups of patients aged 45 to < 55 years (p < 0.01) and ≥55 years (p < 0.05), with menopause duration of >12 months to <60 months (p < 0.05) and ≥ 60 months (p < 0.005), and with a BMI at baseline of <25 kg/m 2 (p < 0.05) and 25 to <30 kg/m 2 (p < 0.01).",['subgroups of postmenopausal women with vasomotor symptoms'],"['low-dose estradiol', 'estrogens and progestogens', 'low-dose continuous combined hormone replacement therapy with 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone', 'dydrogesterone', 'Low-dose estradilol/dydrogesterone']","['laboratory and vital sign values', 'number of moderate to severe hot flushes', 'incidence of breast-related adverse events', 'Efficacy and safety', 'adverse endometrial outcome of simple hyperplasia', 'adverse events', 'vasomotor symptoms']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C0033306', 'cui_str': 'Progestational hormone'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0282402', 'cui_str': 'Hormone replacement therapy'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0013340', 'cui_str': 'Dydrogesterone'}]","[{'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0600142', 'cui_str': 'Menopausal flushing'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0020507', 'cui_str': 'Hyperplasia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.0304071,"The treatment difference seen in the overall population in favour of low-dose estradiol/dydrogesterone was also observed in the subgroups of patients aged 45 to < 55 years (p < 0.01) and ≥55 years (p < 0.05), with menopause duration of >12 months to <60 months (p < 0.05) and ≥ 60 months (p < 0.005), and with a BMI at baseline of <25 kg/m 2 (p < 0.05) and 25 to <30 kg/m 2 (p < 0.01).","[{'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Tsiligiannis', 'Affiliation': 'National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London SW3 6NP, UK.'}, {'ForeName': 'Bettina C', 'Initials': 'BC', 'LastName': 'Wick-Urban', 'Affiliation': 'Meda Pharma GmbH & Co. KG (A Mylan Company), Benz Street 1, 61350 Bad Homburg, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'van der Stam', 'Affiliation': 'Mylan Healthcare BV, Krijgsman, 1186 DM Amstelveen NH, the Netherlands.'}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Stevenson', 'Affiliation': 'National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London SW3 6NP, UK. Electronic address: j.stevenson@imperial.ac.uk.'}]",Maturitas,['10.1016/j.maturitas.2020.05.002'] 2272,32747146,Effects of orthognathic surgery on quality of life compared with nonsurgical controls in an American population.,"INTRODUCTION To determine the psychosocial effects of a facial skeletal mal-relationship with its subsequent surgical correction in a group of patients treated using surgical orthodontics compared with a matched group of nontreated controls. METHODS This study was approved by The Ohio State University Institutional Review Board. Subjects were patients presenting with facial skeletal mal-relationships whose proposed treatment plans included orthognathic surgery. This study used valid and reliable questionnaires: Orthognathic Quality of Life Questionnaire (OQLQ), Beck Depression Inventory II (Children's Depression Inventory - 2), Satisfaction with Life Scale, and State Trait Anxiety Inventory (State Trait Anxiety Inventory for Children), administered at 3 different stages of treatment (time 1 = initial pretreatment, time 2 = before oral surgery, and time 3 = at completion of treatment). Matched controls recruited at each time point completed the same questionnaires. RESULTS A total of 267 subjects were recruited to participate in this study. There were no significant differences between treatment and control groups in age, sex, education level, or employment status at any of the 3 time points. The randomization test was used to compare values for all outcome variables between groups at the 3 stages of treatment. For the pretreatment period, T 1 , there were significant differences between patients and controls in domains 1 (P = 0.0126), 2 (P = 0.0000), and 3 (P = 0.0000) of the OQLQ (social aspects, facial esthetics, and oral function, respectively) as well as total OQLQ (P = 0.0000). For the presurgery period, T 2 , there were significant differences between patients and controls in domains 2 (P = 0.0136) and 3 (P = 0.0001) of the OQLQ (facial esthetics and oral function) as well as total OQLQ (P = 0.0291). Finally, for the posttreatment period, T 3, there was a significant difference between patients and controls only in domain 3 (P = 0.0196) of the OQLQ (oral function). CONCLUSIONS The psychosocial profile of patients with a facial skeletal mal-relationship does not differ from the general population in depression, anxiety, and overall satisfaction with life. However, these patients do report a reduced quality of life based on condition-specific measures in social aspects, facial esthetics, and oral function. Concerns about oral function remain even up to 2 years after treatment is completed.",2020,"The psychosocial profile of patients with a facial skeletal mal-relationship does not differ from the general population in depression, anxiety, and overall satisfaction with life.","['A total of 267 subjects were recruited to participate in this study', 'Subjects were patients presenting with facial skeletal mal-relationships whose proposed treatment plans included orthognathic surgery', 'nonsurgical controls in an American population', 'patients treated using surgical orthodontics compared with a matched group of nontreated controls']","['facial skeletal mal-relationship with its subsequent surgical correction', 'orthognathic surgery']","['quality of life', ""reliable questionnaires: Orthognathic Quality of Life Questionnaire (OQLQ), Beck Depression Inventory II (Children's Depression Inventory - 2), Satisfaction with Life Scale, and State Trait Anxiety Inventory"", 'OQLQ (social aspects, facial esthetics, and oral function, respectively) as well as total OQLQ', 'OQLQ (facial esthetics and oral function', 'quality of life based on condition-specific measures in social aspects, facial esthetics, and oral function', 'total OQLQ']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517672', 'cui_str': '267'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C0024551', 'cui_str': 'Malayalam language'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0185624', 'cui_str': 'Orthognathic Surgery'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0332276', 'cui_str': 'Orthodontic'}, {'cui': 'C0024908', 'cui_str': 'Matched Groups'}]","[{'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C0024551', 'cui_str': 'Malayalam language'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0185624', 'cui_str': 'Orthognathic Surgery'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0582668', 'cui_str': 'Satisfaction with life scale'}, {'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",267.0,0.0270258,"The psychosocial profile of patients with a facial skeletal mal-relationship does not differ from the general population in depression, anxiety, and overall satisfaction with life.","[{'ForeName': 'Lydia', 'Initials': 'L', 'LastName': 'Lancaster', 'Affiliation': 'Formerly, Division of Orthodontics, College of Dentistry, The Ohio State University, Columbus, Ohio; currently, Private Practice, Dayton, Ohio.'}, {'ForeName': 'Rashelle D', 'Initials': 'RD', 'LastName': 'Salaita', 'Affiliation': 'Formerly, Division of Orthodontics, College of Dentistry, The Ohio State University, Columbus, Ohio; currently, Private Practice, Columbus, Ohio.'}, {'ForeName': 'Charu', 'Initials': 'C', 'LastName': 'Swamy', 'Affiliation': 'Formerly, Division of Orthodontics, College of Dentistry, The Ohio State University, Columbus, Ohio; currently, Private Practice, Boston, Mass.'}, {'ForeName': 'Shiva', 'Initials': 'S', 'LastName': 'Shanker', 'Affiliation': 'Division of Orthodontics, College of Dentistry, The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'Kelly S', 'Initials': 'KS', 'LastName': 'Kennedy', 'Affiliation': 'Division of Oral & Maxillofacial Surgery and Dental Anesthesiology, College of Dentistry, The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'F Michael', 'Initials': 'FM', 'LastName': 'Beck', 'Affiliation': 'Division of Biosciences, College of Dentistry, The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'William M', 'Initials': 'WM', 'LastName': 'Johnston', 'Affiliation': 'Emeritus, Division of Restorative and Prosthetic Dentistry, College of Dentistry, The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'Allen R', 'Initials': 'AR', 'LastName': 'Firestone', 'Affiliation': 'Division of Orthodontics, College of Dentistry, The Ohio State University, Columbus, Ohio. Electronic address: firestone@dentistry.dent.ohio-state.edu.'}]","American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics",['10.1016/j.ajodo.2019.09.020'] 2273,32747173,Effect of a QI Intervention on Nursing Assistants' Pain Knowledge and Reporting Behavior.,"BACKGROUND Pain among long-term care residents is often underdiagnosed and inadequately treated. We examined the effect of a multimodal intervention on certified nursing assistants' pain recognition knowledge and verbal reporting behavior. Secondarily, we examined pain documentation in a newly established pain log compared with pain verbally reported to nurses and documented in the electronic health record (EHR). DESIGN Quality improvement project using a pretest-posttest design. SETTING A skilled nursing and rehabilitation facility in Southwestern Pennsylvania including two long-term care units and one transitional rehabilitation unit. PARTICIPANTS/SUBJECTS Fifty-six nursing assistants. METHODS The intervention was a face-to-face educational session with a training video and introduction of a new pain log used to document residents' pain. Pain knowledge was measured before and after the educational intervention. Multiple measures were used to examine nursing assistants' pain reporting. RESULTS Nursing assistants' pain knowledge improved (p < .001). There was no change in verbal pain reporting behaviors. The percent of pain episodes documented in the electronic health record that were reported to nurses varied by unit type (45% on the long-term care units vs. 100% on the rehabilitation unit) but remained unchanged postintervention. Pain logs were used more often on the rehabilitation than the long-term care units; use was low overall. Nursing assistant reports that nurses provided feedback on their reports of resident pain increased from 45% in week 1 to 75% in week 4. CONCLUSIONS Although the multimodal intervention improved nursing assistants' pain knowledge and their perceptions of the feedback they received from nurses when they reported pain, it had no effect on certified nursing assistants reporting of pain to nurses (per nurse report).",2020,"RESULTS Nursing assistants' pain knowledge improved (p < .001).","['A skilled nursing and rehabilitation facility in Southwestern Pennsylvania including two long-term care units and one transitional rehabilitation unit', ""certified nursing assistants' pain recognition knowledge and verbal reporting behavior"", 'Fifty-six nursing assistants']","['QI Intervention', 'multimodal intervention']","['verbal pain reporting behaviors', 'Pain logs', 'pain knowledge', 'resident pain', ""Nursing Assistants' Pain Knowledge and Reporting Behavior"", 'pain episodes', 'Pain knowledge']","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C3845566', 'cui_str': 'Rehabilitation facility'}, {'cui': 'C0030853', 'cui_str': 'Pennsylvania'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0007836', 'cui_str': 'Certification'}, {'cui': 'C0028663', 'cui_str': 'Nursing aid'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0028663', 'cui_str': 'Nursing aid'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}]",,0.0285966,"RESULTS Nursing assistants' pain knowledge improved (p < .001).","[{'ForeName': 'Jessica A', 'Initials': 'JA', 'LastName': 'Joy', 'Affiliation': 'University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Lorraine M', 'Initials': 'LM', 'LastName': 'Novosel', 'Affiliation': 'University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Dianxu', 'Initials': 'D', 'LastName': 'Ren', 'Affiliation': 'University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Engberg', 'Affiliation': 'Health Promotion and Development, University of Pittsburgh, Pittsburgh, Pennsylvania. Electronic address: sje1@pitt.edu.'}]",Pain management nursing : official journal of the American Society of Pain Management Nurses,['10.1016/j.pmn.2020.06.010'] 2274,32747190,EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study.,"INTRODUCTION Continuing tyrosine kinase inhibitor (TKI) therapy may be beneficial when patients with non-small-cell lung cancer and EGFR mutations experience gradual disease progression after initial EGFR-TKI treatment. We aimed to compare the efficacy of simultaneous EGFR-TKI and chemotherapy with that of sequential treatment after patients' disease gradually progressed after first-line EGFR-TKI treatment. PATIENTS AND METHODS Patients with gradual progression who were EGFR-T790M mutation negative were randomly divided into two groups. In the concurrent group, patients were treated with pemetrexed plus cisplatin along with the same EGFR-TKI. In the sequential group, patients continued with EGFR-TKI until the disease progressed again, according to RECIST, then switched to chemotherapy. We evaluated the patients' progression-free survival (PFS) and overall survival times. RESULTS Ninety-nine patients were enrolled: 49 in the concurrent group and 50 in the sequential group. The median PFS (mPFS) was 7.7 months (95% confidence interval [CI], 3.6-11.7) in the concurrent group and 5.7 months (95% CI, 3.5-7.9) in the sequential group (hazard ratio = 0.66; 95% CI, 0.44-1.00; P = .026), respectively. For the sequential group, the mPFS1 and mPFS2 were 1.8 months (95% CI, 1.4-2.3) and 3.8 months (95% CI, 3.1-4.5), respectively. The median overall survival of the concurrent group was longer than that of the sequential group (20.0 vs. 14.7 months; hazard ratio = 0.52; 95% CI, 0.32-0.85; P = .038). CONCLUSION For patients with advanced non-small-cell lung cancer and gradual progression who are EGFR-T790M mutation negative after initial EGFR-TKI therapy, EGFR-TKI combined with chemotherapy confers longer PFS and overall survival than sequential EGFR-TKI and chemotherapy does.",2020,"The median overall survival of the concurrent group was longer than that of the sequential group (20.0 vs. 14.7 months; hazard ratio = 0.52; 95% CI, 0.32-0.85; P = .038). ","['patients with non-small-cell lung cancer and EGFR mutations experience gradual disease progression after initial EGFR-TKI treatment', ""patients' disease gradually progressed after first-line EGFR-TKI treatment"", 'Patients with gradual progression who were EGFR-T790M mutation negative', 'patients with advanced non-small-cell lung cancer and gradual progression who are EGFR-T790M mutation negative after initial EGFR-TKI therapy', 'Patients With Advanced Lung Cancer and Gradual Progression', 'Ninety-nine patients were enrolled: 49 in the concurrent group and 50 in the sequential group']","['EGFR-TKI combined with chemotherapy', 'TKI Therapy', 'pemetrexed plus cisplatin', 'Combined With Concurrent or Sequential Chemotherapy', 'simultaneous EGFR-TKI and chemotherapy', 'tyrosine kinase inhibitor (TKI) therapy']","['median PFS (mPFS', 'mPFS1 and mPFS2', 'PFS and overall survival', 'EGFR Tyrosine Kinase Inhibitor (TKI', 'median overall survival', ""patients' progression-free survival (PFS) and overall survival times""]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0439833', 'cui_str': 'Gradual'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C1443775', 'cui_str': 'Epidermal growth factor receptor antagonist-containing product'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C4524268', 'cui_str': 'Advanced lung cancer'}, {'cui': 'C3828813', 'cui_str': '99'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C1443775', 'cui_str': 'Epidermal growth factor receptor antagonist-containing product'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1268567', 'cui_str': 'Protein-tyrosine kinase inhibitor'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1443775', 'cui_str': 'Epidermal growth factor receptor antagonist-containing product'}, {'cui': 'C1268567', 'cui_str': 'Protein-tyrosine kinase inhibitor'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2919552', 'cui_str': 'Survival time'}]",99.0,0.0627778,"The median overall survival of the concurrent group was longer than that of the sequential group (20.0 vs. 14.7 months; hazard ratio = 0.52; 95% CI, 0.32-0.85; P = .038). ","[{'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Chang', 'Affiliation': 'Pulmonary Department, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Jianlin', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Pulmonary Department, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Huiping', 'Initials': 'H', 'LastName': 'Qiang', 'Affiliation': 'Pulmonary Department, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Jiajun', 'Initials': 'J', 'LastName': 'Teng', 'Affiliation': 'Pulmonary Department, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Jialin', 'Initials': 'J', 'LastName': 'Qian', 'Affiliation': 'Pulmonary Department, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Minfang', 'Initials': 'M', 'LastName': 'Lv', 'Affiliation': 'Department of Immunology, Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, and Shanghai Key Laboratory of Clinical Geriatric Medicine, Fudan University, Shanghai, China.'}, {'ForeName': 'Yanwei', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Pulmonary Department, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Yuqing', 'Initials': 'Y', 'LastName': 'Lou', 'Affiliation': 'Pulmonary Department, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Yizhuo', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Pulmonary Department, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Runbo', 'Initials': 'R', 'LastName': 'Zhong', 'Affiliation': 'Pulmonary Department, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Baohui', 'Initials': 'B', 'LastName': 'Han', 'Affiliation': 'Pulmonary Department, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Tianqing', 'Initials': 'T', 'LastName': 'Chu', 'Affiliation': 'Pulmonary Department, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China. Electronic address: ctqxkyy@163.com.'}]",Clinical lung cancer,['10.1016/j.cllc.2020.06.005'] 2275,32747206,Parenteral nutrition impairs plasma bile acid and gut hormone responses to mixed meal testing in lean healthy men.,"BACKGROUND & AIMS To investigate the acute effects of intravenous vs enteral meal administration on circulating bile acid and gut hormone responses. METHODS In a randomized crossover design, we compared the effects of duodenal (via a nasoduodenal tube) vs parenteral (intravenous) administration over 180 min of identical mixed meals on circulating bile acid and gut hormone concentrations in eight healthy lean men. We analysed the bile acid and gut hormone responses in two periods: the intraprandial period from time point (T) 0 until T180 during meal administration and the postprandial period from T180 until T360, after discontinuation of meal administration. RESULTS Intravenous meal administration decreased the intraprandial (AUC (μmol/L∗min) duodenal 1469 ± 284 vs intravenous 240 ± 39, p < 0.01) and postprandial bile acid response (985 ± 240 vs 223 ± 5, p < 0.05) and was accompanied by decreased gut hormone responses including glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, glucagon-like peptide 2 and fibroblast growth factor 19. Furthermore, intravenous meal administration elicited greater glucose concentrations, but similar insulin concentrations compared to enteral administration. CONCLUSIONS Compared to enteral administration, parenteral nutrition results in lower postprandial bile acid and gut hormone responses in healthy lean men. This was accompanied by higher glucose concentrations in the face of similar insulin concentrations exposing a clear incretin effect of enteral mixed meal administration. The alterations in bile acid homeostasis were apparent after only one intravenous meal.",2020,"284 vs intravenous 240 ± 39, p < 0.01) and postprandial bile acid response (985 ± 240 vs 223 ± 5, p < 0.05) and was accompanied by decreased gut hormone responses including glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, glucagon-like peptide 2 and fibroblast growth factor 19.","['eight healthy lean men', 'healthy lean men', 'lean healthy men']","['duodenal (via a nasoduodenal tube) vs parenteral (intravenous) administration over 180\xa0min of identical mixed meals', 'Parenteral nutrition', 'intravenous vs enteral meal']","['gut hormone responses including glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, glucagon-like peptide 2 and fibroblast growth factor 19', 'glucose concentrations', 'bile acid and gut hormone responses', 'bile acid homeostasis', 'intraprandial (AUC (μmol/L∗min) duodenal 1469\xa0±', 'circulating bile acid and gut hormone responses', 'plasma bile acid and gut hormone responses', 'postprandial bile acid response', 'postprandial bile acid and gut hormone responses', 'insulin concentrations']","[{'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0013303', 'cui_str': 'Duodenal'}, {'cui': 'C3204189', 'cui_str': 'Nasoduodenal feeding tube'}, {'cui': 'C0030547', 'cui_str': 'Parenteral nutrition'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C1304890', 'cui_str': 'Enteral'}]","[{'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0017132', 'cui_str': 'Gastric inhibitory polypeptide'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0912332', 'cui_str': 'Glucagon-like peptide 2'}, {'cui': 'C1431711', 'cui_str': 'FGF19 protein, human'}, {'cui': 'C0427743', 'cui_str': 'Glucose concentration, test strip measurement'}, {'cui': 'C0005390', 'cui_str': 'Bile acid'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0013303', 'cui_str': 'Duodenal'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",8.0,0.043536,"284 vs intravenous 240 ± 39, p < 0.01) and postprandial bile acid response (985 ± 240 vs 223 ± 5, p < 0.05) and was accompanied by decreased gut hormone responses including glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, glucagon-like peptide 2 and fibroblast growth factor 19.","[{'ForeName': 'Emma C E', 'Initials': 'ECE', 'LastName': 'Meessen', 'Affiliation': 'Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Guido J', 'Initials': 'GJ', 'LastName': 'Bakker', 'Affiliation': 'Department of Vascular Medicine, Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Max', 'Initials': 'M', 'LastName': 'Nieuwdorp', 'Affiliation': 'Department of Vascular Medicine, Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Geesje M', 'Initials': 'GM', 'LastName': 'Dallinga-Thie', 'Affiliation': 'Department of Vascular Medicine, Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'E Marleen', 'Initials': 'EM', 'LastName': 'Kemper', 'Affiliation': 'Department of Hospital Pharmacy, Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Steven W', 'Initials': 'SW', 'LastName': 'Olde Damink', 'Affiliation': 'Department of Surgery, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, the Netherlands; Department of General, Visceral and Transplantation Surgery, RWTH University Hospital Aachen, Germany.'}, {'ForeName': 'Johannes A', 'Initials': 'JA', 'LastName': 'Romijn', 'Affiliation': 'Department of Internal Medicine, Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Bolette', 'Initials': 'B', 'LastName': 'Hartmann', 'Affiliation': 'Department of Biomedical Sciences and NNF Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Jens J', 'Initials': 'JJ', 'LastName': 'Holst', 'Affiliation': 'Department of Biomedical Sciences and NNF Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Filip K', 'Initials': 'FK', 'LastName': 'Knop', 'Affiliation': 'Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Albert K', 'Initials': 'AK', 'LastName': 'Groen', 'Affiliation': 'Department of Vascular Medicine, Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Frank G', 'Initials': 'FG', 'LastName': 'Schaap', 'Affiliation': 'Department of Surgery, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, the Netherlands; Department of General, Visceral and Transplantation Surgery, RWTH University Hospital Aachen, Germany.'}, {'ForeName': 'Maarten R', 'Initials': 'MR', 'LastName': 'Soeters', 'Affiliation': 'Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: m.r.soeters@amsterdamumc.nl.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.06.032'] 2276,32747361,"Afabicin, a first-in-class anti-staphylococcal antibiotic, in the treatment of acute bacterial skin and skin structure infections: clinical non-inferiority to vancomycin/linezolid.","Afabicin (formerly Debio 1450, AFN-1720) is a prodrug of afabicin desphosphono, an enoyl-acyl carrier protein reductase (FabI) inhibitor, and is a first-in-class antibiotic with novel mode of action to specifically target fatty acid synthesis in Staphylococcus spp. The efficacy, safety and tolerability of afabicin were compared with vancomycin/linezolid in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) due to staphylococci in this multicenter, parallel group, double-blind and double-dummy phase 2 study. Randomized patients (1:1:1) received either: low dose (LD) afabicin (IV 80 mg, then oral 120 mg, BID); high dose (HD) afabicin (IV 160 mg, then oral 240 mg, BID); or vancomycin/linezolid (IV vancomycin 1 g or 15 mg/kg, then oral linezolid 600 mg, BID). The most frequent baseline pathogen was Staphylococcus aureus (97.5% of microbiological intent-to-treat [mITT] population), and 50.4% of patients had methicillin-resistant S. aureus Clinical response rates at 48-72 h post-randomization in the mITT population were comparable among treatment groups (94.6%, 90.1% and 91.1%, respectively). Both LD and HD afabicin were non-inferior to vancomycin/linezolid (differences: -3.5%, 95% CI [-10.8%, 3.9%] and 1.0%, 95% CI [-7.3%, 9.2%], respectively). Most common treatment-emergent adverse events were mild, and were headache (9.1% and 16.8%) and nausea (6.4% and 8.4%) with LD and HD afabicin, respectively.Afabicin was efficacious and well-tolerated in the treatment of ABSSSI due to staphylococci, and these data support further development of afabicin for the treatment of ABSSSI and potentially other types of staphylococcal infections.",2020,"Both LD and HD afabicin were non-inferior to vancomycin/linezolid (differences: -3.5%, 95% CI [-10.8%, 3.9%] and 1.0%, 95% CI [",[],"[' low dose (LD) afabicin ', 'Afabicin (formerly Debio 1450, AFN-1720', 'vancomycin/linezolid', 'vancomycin/linezolid (IV vancomycin', 'linezolid']","['headache', 'efficacy, safety and tolerability', 'nausea', 'methicillin-resistant S. aureus Clinical response rates']",[],"[{'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C4517603', 'cui_str': '1720'}, {'cui': 'C0042313', 'cui_str': 'Vancomycin'}, {'cui': 'C0663241', 'cui_str': 'linezolid'}]","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C1955827', 'cui_str': 'Methicillin-Resistant'}, {'cui': 'C0038172', 'cui_str': 'Staphylococcus aureus'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",,0.0523739,"Both LD and HD afabicin were non-inferior to vancomycin/linezolid (differences: -3.5%, 95% CI [-10.8%, 3.9%] and 1.0%, 95% CI [","[{'ForeName': 'Frederick', 'Initials': 'F', 'LastName': 'Wittke', 'Affiliation': 'Debiopharm International SA, Lausanne, Switzerland.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Vincent', 'Affiliation': 'Debiopharm International SA, Lausanne, Switzerland.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Southbay Pharma Research, Buena Park, California, USA.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Heller', 'Affiliation': 'Long Beach Clinical Trials, Long Beach, California, USA.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Kabler', 'Affiliation': 'Sunrise Hospital and Medical Center, Las Vegas, Nevada, USA.'}, {'ForeName': 'J Scott', 'Initials': 'JS', 'LastName': 'Overcash', 'Affiliation': 'eStudySite, San Diego, California, USA.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Leylavergne', 'Affiliation': 'Debiopharm International SA, Lausanne, Switzerland.'}, {'ForeName': 'Guennaelle', 'Initials': 'G', 'LastName': 'Dieppois', 'Affiliation': 'Debiopharm International SA, Lausanne, Switzerland guennaelle.dieppois@debiopharm.com.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.00250-20'] 2277,32747412,Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial.,"OBJECTIVE There is a lack of robust data on significant gastrointestinal bleeding in older people using aspirin. We calculated the incidence, risk factors and absolute risk using data from a large randomised, controlled trial. DESIGN Data were extracted from an aspirin versus placebo primary prevention trial conducted throughout 2010-2017 ('ASPirin in Reducing Events in the Elderly (ASPREE)', n=19 114) in community-dwelling persons aged ≥70 years. Clinical characteristics were collected at baseline and annually. The endpoint was major GI bleeding that resulted in transfusion, hospitalisation, surgery or death, adjudicated independently by two physicians blinded to trial arm. RESULTS Over a median follow-up of 4.7 years (88 389 person years), there were 137 upper GI bleeds (89 in aspirin arm and 48 in placebo arm, HR 1.87, 95% CI 1.32 to 2.66, p<0.01) and 127 lower GI bleeds (73 in aspirin and 54 in placebo arm, HR 1.36, 95% CI 0.96 to 1.94, p=0.08) reflecting a 60% increase in bleeding overall. There were two fatal bleeds in the placebo arm. Multivariable analyses indicated age, smoking, hypertension, chronic kidney disease and obesity increased bleeding risk. The absolute 5-year risk of bleeding was 0.25% (95% CI 0.16% to 0.37%) for a 70 year old not on aspirin and up to 5.03% (2.56% to 8.73%) for an 80 year old taking aspirin with additional risk factors. CONCLUSION Aspirin increases overall GI bleeding risk by 60%; however, the 5-year absolute risk of serious bleeding is modest in younger, well individuals. These data may assist patients and their clinicians to make informed decisions about prophylactic use of aspirin. TRIAL REGISTRATION NUMBER ASPREE. NCT01038583.",2020,"The absolute 5-year risk of bleeding was 0.25% (95% CI 0.16% to 0.37%) for a 70 year old not on aspirin and up to 5.03% (2.56% to 8.73%) for an 80 year old taking aspirin with additional risk factors. ","[""primary prevention trial conducted throughout 2010-2017 ('ASPirin in Reducing Events in the Elderly (ASPREE)', n=19\u2009114) in community-dwelling persons aged ≥70 years"", 'older persons', 'older people using']","['Aspirin', 'aspirin', 'aspirin versus placebo']","['major GI bleeding that resulted in transfusion, hospitalisation, surgery or death', 'overall GI bleeding risk', 'GI bleeds', 'absolute 5-year risk of bleeding', 'smoking, hypertension, chronic kidney disease and obesity increased bleeding risk', 'bleeding overall', 'fatal bleeds', '5-year absolute risk of serious bleeding', 'Major GI bleeding', 'gastrointestinal bleeding']","[{'cui': 'C0033144', 'cui_str': 'Primary prevention'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0017181', 'cui_str': 'Gastrointestinal hemorrhage'}, {'cui': 'C0332294', 'cui_str': 'Resulting in'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}]",,0.488227,"The absolute 5-year risk of bleeding was 0.25% (95% CI 0.16% to 0.37%) for a 70 year old not on aspirin and up to 5.03% (2.56% to 8.73%) for an 80 year old taking aspirin with additional risk factors. ","[{'ForeName': 'Suzanne E', 'Initials': 'SE', 'LastName': 'Mahady', 'Affiliation': 'School of Public Health & Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Victoria, Australia suzanne.mahady@monash.edu.'}, {'ForeName': 'Karen L', 'Initials': 'KL', 'LastName': 'Margolis', 'Affiliation': 'HealthPartners Institute, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Chan', 'Affiliation': 'Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Galina', 'Initials': 'G', 'LastName': 'Polekhina', 'Affiliation': 'School of Public Health & Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Victoria, Australia.'}, {'ForeName': 'Robyn L', 'Initials': 'RL', 'LastName': 'Woods', 'Affiliation': 'School of Public Health & Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Victoria, Australia.'}, {'ForeName': 'Rory', 'Initials': 'R', 'LastName': 'Wolfe', 'Affiliation': 'School of Public Health & Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Victoria, Australia.'}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Nelson', 'Affiliation': 'Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Jessica E', 'Initials': 'JE', 'LastName': 'Lockery', 'Affiliation': 'School of Public Health & Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Victoria, Australia.'}, {'ForeName': 'Erica M', 'Initials': 'EM', 'LastName': 'Wood', 'Affiliation': 'School of Public Health & Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Victoria, Australia.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Reid', 'Affiliation': 'School of Public Health & Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Victoria, Australia.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Ernst', 'Affiliation': 'Department of Pharmacy Practice and Science, College of Pharmacy, The University of Iowa, Iowa City, Iowa, USA.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Murray', 'Affiliation': 'Division of Geriatrics, Department of Medicine, Hennepin Healthcare, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Ltp', 'Initials': 'L', 'LastName': 'Thao', 'Affiliation': 'School of Public Health & Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Victoria, Australia.'}, {'ForeName': 'John J', 'Initials': 'JJ', 'LastName': 'McNeil', 'Affiliation': 'School of Public Health & Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Victoria, Australia.'}]",Gut,['10.1136/gutjnl-2020-321585'] 2278,32747417,Prognostic and Predictive Biomarkers in Metastatic Colorectal Cancer Patients Receiving Regorafenib.,"Regorafenib is a tyrosine kinase inhibitor approved by the Food and Drug Administration (FDA) for the treatment of chemotherapy-refractory metastatic colorectal cancer (mCRC) patients. Regorafenib inhibits signaling through multiple receptors associated with angiogenesis, metastasis, and tumor immunity. Here we report biomarker results from LCCC1029, a randomized, placebo controlled, phase II trial of chemotherapy ± regorafenib in second-line mCRC patients. A panel of 20 soluble protein biomarkers (termed the Angiome) was assessed in the plasma of 149 patients from the LCCC1029 trial both at baseline and along the treatment continuum. Baseline protein levels were analyzed for prognostic and predictive value for progression-free survival (PFS) and overall survival (OS). Changes in protein levels during treatment were analyzed for potential pharmacodynamic effects. Six markers (HGF, IL-6, PlGF, VEGF-R1, OPN, and IL-6R) were found to be prognostic for PFS. Nine markers (IL-6, TIMP-1, PlGF, VCAM-1, ICAM-1, OPN, TSP-2, HGF, and VEGF-R1) were prognostic for OS. Higher baseline levels of OPN (Pintx=0.0167), VCAM-1 (Pintx=0.0216), and PDGF-AA (Pintx=0.0435) appeared to predict for PFS benefit from regorafenib compared to placebo. VCAM-1 was also potentially predictive of OS benefit from regorafenib compared to placebo (Pintx=0.0124). On-treatment changes of six markers reflected potential on-target effect of regorafenib. Consistent results were observed in an Italian cohort where 105 late-stage mCRC patients received regorafenib monotherapy. The key findings of this study suggest that VCAM-1 may be a predictive biomarker for regorafenib benefit while multiple protein markers may be prognostic of outcome in mCRC patients.",2020,"Nine markers (IL-6, TIMP-1, PlGF, VCAM-1, ICAM-1, OPN, TSP-2, HGF, and VEGF-R1) were prognostic for OS.","['Metastatic Colorectal Cancer Patients Receiving Regorafenib', 'second-line mCRC patients', '149 patients from the LCCC1029 trial both at baseline and along the treatment continuum', 'chemotherapy-refractory metastatic colorectal cancer (mCRC) patients']","['regorafenib', 'chemotherapy ± regorafenib', 'Regorafenib', 'regorafenib monotherapy', 'placebo']","['progression-free survival (PFS) and overall survival (OS', 'Six markers (HGF, IL-6, PlGF, VEGF-R1, OPN, and IL-6R', 'OPN', 'Baseline protein levels', 'Nine markers (IL-6, TIMP-1, PlGF, VCAM-1, ICAM-1, OPN, TSP-2, HGF, and VEGF-R1', 'VCAM-1 ', 'protein levels']","[{'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2980094', 'cui_str': 'regorafenib'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C5191071', 'cui_str': '149'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}]","[{'cui': 'C2980094', 'cui_str': 'regorafenib'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1504871', 'cui_str': 'PGF protein, human'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C1699800', 'cui_str': 'IL6R protein, human'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0428479', 'cui_str': 'Protein level - finding'}, {'cui': 'C0145947', 'cui_str': 'Tissue inhibitor of metalloproteinases 1'}, {'cui': 'C0078056', 'cui_str': 'Lymphocyte antigen CD106'}, {'cui': 'C0063695', 'cui_str': 'Lymphocyte antigen CD54'}, {'cui': 'C0530678', 'cui_str': 'thrombospondin 2'}]",149.0,0.156656,"Nine markers (IL-6, TIMP-1, PlGF, VCAM-1, ICAM-1, OPN, TSP-2, HGF, and VEGF-R1) were prognostic for OS.","[{'ForeName': 'Yingmiao', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Medicine, Duke Medical Center.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Lyu', 'Affiliation': 'Duke Cancer Institute.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Bell Burdett', 'Affiliation': 'Preventive Medicine, Northwestern University.'}, {'ForeName': 'Alexander B', 'Initials': 'AB', 'LastName': 'Sibley', 'Affiliation': 'Duke Cancer Institute, Duke University.'}, {'ForeName': 'Ace J', 'Initials': 'AJ', 'LastName': 'Hatch', 'Affiliation': 'Diagnostics, Almac Diagnostics.'}, {'ForeName': 'Mark D', 'Initials': 'MD', 'LastName': 'Starr', 'Affiliation': 'Medicine, Duke Medical Center.'}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Brady', 'Affiliation': 'Medicine, Duke Medical Center.'}, {'ForeName': 'Kelli', 'Initials': 'K', 'LastName': 'Hammond', 'Affiliation': 'Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Marmorino', 'Affiliation': 'Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Rossini', 'Affiliation': 'Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Goldberg', 'Affiliation': 'Medicine, The West Virginia University Cancer Institute.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Falcone', 'Affiliation': 'Department of Oncology, Transplantes and New Technologies in Medicine, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori and University of Pisa.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Cremolini', 'Affiliation': 'Department of Oncology, Transplantes and New Technologies in Medicine, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori and University of Pisa.'}, {'ForeName': 'Kouros', 'Initials': 'K', 'LastName': 'Owzar', 'Affiliation': 'Biostatistics and Bioinformatics, Duke University.'}, {'ForeName': 'Anastasia', 'Initials': 'A', 'LastName': 'Ivanova', 'Affiliation': 'UNC/Biostat.'}, {'ForeName': 'Dominic T', 'Initials': 'DT', 'LastName': 'Moore', 'Affiliation': 'Biostatistics, Lineberger Comprehensive Cancer Center.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Lee', 'Affiliation': 'Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill.'}, {'ForeName': 'Hanna K', 'Initials': 'HK', 'LastName': 'Sanoff', 'Affiliation': 'Hematology/Oncology, University of North Carolina at Chapel Hill.'}, {'ForeName': 'Federico', 'Initials': 'F', 'LastName': 'Innocenti', 'Affiliation': 'Eshelman School of Pharmacy, University of North Carolina at Chapel Hill.'}, {'ForeName': 'Andrew B', 'Initials': 'AB', 'LastName': 'Nixon', 'Affiliation': 'Medicine, Duke Medical Center anixon@duke.edu.'}]",Molecular cancer therapeutics,['10.1158/1535-7163.MCT-20-0249'] 2279,32747473,Reducing Antibiotic Prescribing in Primary Care for Respiratory Illness.,"BACKGROUND One-third of outpatient antibiotic prescriptions for pediatric acute respiratory tract infections (ARTIs) are inappropriate. We evaluated a distance learning program's effectiveness for reducing outpatient antibiotic prescribing for ARTI visits. METHODS In this stepped-wedge clinical trial run from November 2015 to June 2018, we randomly assigned 19 pediatric practices belonging to the Pediatric Research in Office Settings Network or the NorthShore University HealthSystem to 4 wedges. Visits for acute otitis media, bronchitis, pharyngitis, sinusitis, and upper respiratory infection for children 6 months to <11 years old without recent antibiotic use were included. Clinicians received the intervention as 3 program modules containing online tutorials and webinars on evidence-based communication strategies and antibiotic prescribing, booster video vignettes, and individualized antibiotic prescribing feedback reports over 11 months. The primary outcome was overall antibiotic prescribing rates for all ARTI visits. Mixed-effects logistic regression compared prescribing rates during each program module and a postintervention period to a baseline control period. Odds ratios were converted to adjusted rate ratios (aRRs) for interpretability. RESULTS Among 72 723 ARTI visits by 29 762 patients, intention-to-treat analyses revealed a 7% decrease in the probability of antibiotic prescribing for ARTI overall between the baseline and postintervention periods (aRR 0.93; 95% confidence interval [CI], 0.90-0.96). Second-line antibiotic prescribing decreased for streptococcal pharyngitis (aRR 0.66; 95% CI, 0.50-0.87) and sinusitis (aRR 0.59; 95% CI, 0.44-0.77) but not for acute otitis media (aRR 0.93; 95% CI, 0.83-1.03). Any antibiotic prescribing decreased for viral ARTIs (aRR 0.60; 95% CI, 0.51-0.70). CONCLUSIONS This program reduced antibiotic prescribing during outpatient ARTI visits; broader dissemination may be beneficial.",2020,"Any antibiotic prescribing decreased for viral ARTIs (aRR 0.60; 95% CI, 0.51-0.70). ","['children 6 months to <11 years old without recent antibiotic use were included', 'Primary Care for Respiratory Illness', 'November 2015 to June 2018, we randomly assigned 19 pediatric practices belonging to the Pediatric Research in Office Settings Network or the NorthShore University HealthSystem to 4 wedges']",[],"['acute otitis media, bronchitis, pharyngitis, sinusitis, and upper respiratory infection', 'acute otitis media', 'sinusitis', 'streptococcal pharyngitis', 'viral ARTIs', 'probability of antibiotic prescribing for ARTI overall', 'overall antibiotic prescribing rates']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0439639', 'cui_str': 'Wedge'}]",[],"[{'cui': 'C0271429', 'cui_str': 'Acute otitis media'}, {'cui': 'C0006277', 'cui_str': 'Bronchitis'}, {'cui': 'C0001344', 'cui_str': 'Acute pharyngitis'}, {'cui': 'C0037199', 'cui_str': 'Sinusitis'}, {'cui': 'C0041912', 'cui_str': 'Upper respiratory infection'}, {'cui': 'C0036689', 'cui_str': 'Streptococcal sore throat'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C4759838', 'cui_str': 'Acute respiratory tract infection'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",19.0,0.190718,"Any antibiotic prescribing decreased for viral ARTIs (aRR 0.60; 95% CI, 0.51-0.70). ","[{'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Kronman', 'Affiliation': 'Department of Pediatrics, University of Washington, Seattle, Washington; matthew.kronman@seattlechildrens.org.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Gerber', 'Affiliation': ""Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.""}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Grundmeier', 'Affiliation': ""Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.""}, {'ForeName': 'Chuan', 'Initials': 'C', 'LastName': 'Zhou', 'Affiliation': 'Department of Pediatrics, University of Washington, Seattle, Washington.'}, {'ForeName': 'Jeffrey D', 'Initials': 'JD', 'LastName': 'Robinson', 'Affiliation': 'Department of Communication, College of Liberal Arts and Sciences, Portland State University, Portland, Oregon.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Heritage', 'Affiliation': 'Department of Sociology, University of California, Los Angeles, Los Angeles, California.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Stout', 'Affiliation': 'Department of Pediatrics, University of Washington, Seattle, Washington.'}, {'ForeName': 'Dennis', 'Initials': 'D', 'LastName': 'Burges', 'Affiliation': 'Department of Pediatrics, University of Washington, Seattle, Washington.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Hedrick', 'Affiliation': 'Department of Pediatrics, University of Washington, Seattle, Washington.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Warren', 'Affiliation': 'Department of Pediatrics, University of Washington, Seattle, Washington.'}, {'ForeName': 'Madeleine', 'Initials': 'M', 'LastName': 'Shalowitz', 'Affiliation': 'NorthShore University HealthSystem, Evanston, Illinois.'}, {'ForeName': 'Laura P', 'Initials': 'LP', 'LastName': 'Shone', 'Affiliation': 'Primary Care Research, American Academy of Pediatrics, Itasca, Illinois; and.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Steffes', 'Affiliation': 'Primary Care Research, American Academy of Pediatrics, Itasca, Illinois; and.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Wright', 'Affiliation': 'Primary Care Research, American Academy of Pediatrics, Itasca, Illinois; and.'}, {'ForeName': 'Alexander G', 'Initials': 'AG', 'LastName': 'Fiks', 'Affiliation': ""Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.""}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Mangione-Smith', 'Affiliation': 'Kaiser Permanente Washington Health Research Institute, Seattle, Washington.'}]",Pediatrics,['10.1542/peds.2020-0038'] 2280,32754689,Different management options for primary varicose veins in females: A prospective study.,"Background The aim of this study was to evaluate the long-term follow-up results of different management modalities in treating primary uncomplicated lower limb female varicosities. Methods A prospective study took place within a 3-year period from June 2010 until May 2012. Patients were divided into 3 groups: group I ( n  = 35) included those who underwent open surgical treatment. Group II ( n  = 25) included those who subjected to ultrasound-guided foam sclerotherapy (USGFS). While group III ( n  = 20) included those who treated with endovenous laser therapy (EVLT). The patients were followed up for 6 years. Results All selected patients were female aged from 35-62 years with a mean of 47 ± 7.6 years. Thirty-five patients (43.75%) were treated surgically by saphenofemoral junction disconnection (SFJD), and great saphenous vein (GSV) stripping; 25 patients (31.25%) with ultrasound-guided foam sclerotherapy and the remaining 20 patients (25%) were treated with endovenous laser therapy. A significant success rate of GSV ablation was obtained for the endovenous laser therapy treated group over the ultrasound-guided foam sclerotherapy treated patients (P = .023). There was no significant difference between the surgically treated group and those group treated with endovenous laser therapy (P = .85). Recurrence was observed following long-term follow-up after 6 years in 8.5% in group I, 36% in group II, and 10% in group III, respectively. Venous clinical severity score (VCSS) and health-related quality of life score (HRQOLS) improved significantly in all treated groups. Conclusions Long-term follow-up of patients with primary superficial varicosities among females is mandatory to elucidate the postoperative recurrence, especially those who underwent ultrasound-guided foam sclerotherapy. In addition to the observation of the development of newly formed varicosities in susceptible individuals which might develop later following long-term follow-up.",2019,A significant success rate of GSV ablation was obtained for the endovenous laser therapy treated group over the ultrasound-guided foam sclerotherapy treated patients (P = .023).,"['primary varicose veins in females', 'Thirty-five patients (43.75%) were treated surgically by saphenofemoral junction disconnection (SFJD), and great saphenous vein (GSV) stripping; 25 patients (31.25%) with', 'selected patients were female aged from 35-62 years with a mean of 47 ± 7.6 years']","['ultrasound-guided foam sclerotherapy', 'ultrasound-guided foam sclerotherapy (USGFS', 'endovenous laser therapy (EVLT', 'endovenous laser therapy', 'open surgical treatment']","['Recurrence', 'Venous clinical severity score (VCSS) and health-related quality of life score (HRQOLS', 'success rate of GSV ablation']","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0042345', 'cui_str': 'Phlebectasia'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0447132', 'cui_str': 'Structure of saphenofemoral junction'}, {'cui': 'C0392907', 'cui_str': 'Great saphenous vein structure'}, {'cui': 'C0185047', 'cui_str': 'Stripping'}, {'cui': 'C4517704', 'cui_str': '31.25'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0991510', 'cui_str': 'Foam'}, {'cui': 'C0036435', 'cui_str': 'Injection of sclerosing agent'}, {'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]","[{'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0392907', 'cui_str': 'Great saphenous vein structure'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}]",,0.0204489,A significant success rate of GSV ablation was obtained for the endovenous laser therapy treated group over the ultrasound-guided foam sclerotherapy treated patients (P = .023).,"[{'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Mousa', 'Affiliation': 'Department of Vascular & Endovascular Surgery, Al-Hussain University Hospital, Faculty of Medicine for Males, Al-Azhar University, Cairo, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'El Azzazi', 'Affiliation': 'Department of Diagnostic and Interventional Radiology, Al-Hussain University Hospital, Faculty of Medicine for Males, Al-Azhar University, Cairo, Egypt.'}, {'ForeName': 'Mai A', 'Initials': 'MA', 'LastName': 'Elkalla', 'Affiliation': 'Medical Student, Faculty of Medicine, Helwan University, Cairo, Egypt.'}]",Surgery open science,['10.1016/j.sopen.2019.05.002'] 2281,32754694,Laparoscopic Heller myotomy and Dor fundoplication in the same day surgery setting with a trained team and an enhanced recovery protocol.,"Background The length of stay after Heller myotomy is 1-5 days. The aim was to report feasibility of the procedure as same day surgery (SDS). Methods Three steps of Enhanced Recovery After Surgery protocol: preoperatively, clear liquid diet for 24 hours, in preoperative area: antiemetics as dermal patch/IV form, 2: Intraoperatively, intubation in semi upright position, IV analgesics and antiemetics. 3: Postoperatively, clear liquid diet and discharge instructions. Patients were followed using a phone questionnaire. Values are median (interquartile range). Results Fifty-seven patients, 32 M (56%)/25F (44%), age 48 (35-59). First 45 were inpatient with LOS of 1 day. Last 12 were planned as same day surgery, 1/12 was discharged on POD#2, 11/12 (92%) were performed as same day surgery. The duration of operation: 139.5 min (114-163) inpatient: vs 123 (107-139) same day surgery, P < .01. Questionnaires were obtained in 78% inpatient at 40 months (25.6-67) vs 82% same day surgery at 8 (4-12). All were satisfied with the operation with no difference between the 2 groups. Conclusion Heller myotomy can be planned as same day surgery and performed successfully in majority of patients with a trained team and an Enhanced Recovery After Surgery protocol focused on prevention of nausea, and pain control in perioperative period.",2019,"All were satisfied with the operation with no difference between the 2 groups. ","['age 48 (35-59', 'Fifty-seven patients, 32\u202fM']","['Laparoscopic Heller myotomy and Dor fundoplication', 'clear liquid diet']","['length of stay', 'nausea, and pain control', 'Questionnaires']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517815', 'cui_str': '57'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4505238', 'cui_str': 'Laparoscopic Heller Cardiomyotomy'}, {'cui': 'C0140057', 'cui_str': 'delta Opioid Receptor'}, {'cui': 'C0192499', 'cui_str': 'Esophagogastric fundoplasty'}, {'cui': 'C2184084', 'cui_str': 'Clear liquid diet'}]","[{'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.0668922,"All were satisfied with the operation with no difference between the 2 groups. ","[{'ForeName': 'Chandni', 'Initials': 'C', 'LastName': 'Kaushik', 'Affiliation': 'McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth).'}, {'ForeName': 'Madison', 'Initials': 'M', 'LastName': 'Milhoan', 'Affiliation': 'McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth).'}, {'ForeName': 'Anshu', 'Initials': 'A', 'LastName': 'Khanna', 'Affiliation': 'McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth).'}, {'ForeName': 'Andre', 'Initials': 'A', 'LastName': 'Miller', 'Affiliation': 'Memorial Hermann Southeast Esophageal Disease Center.'}, {'ForeName': 'Munish', 'Initials': 'M', 'LastName': 'Chawla', 'Affiliation': 'Memorial Hermann Southeast Esophageal Disease Center.'}, {'ForeName': 'Charles C', 'Initials': 'CC', 'LastName': 'Miller', 'Affiliation': 'McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth).'}, {'ForeName': 'Farzaneh', 'Initials': 'F', 'LastName': 'Banki', 'Affiliation': 'McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth).'}]",Surgery open science,['10.1016/j.sopen.2019.06.003'] 2282,32754701,Smartphone application supplements laparoscopic training through simulation by reducing the need for feedback from expert tutors.,"Background Simulation training is a validated, highly effective tool for learning laparoscopy. Feedback plays a crucial role in motor skills training. We present an app to guide students during advanced laparoscopy simulation training and evaluate its effect on training. Methods A smartphone(iOS)-app was developed. A group of trainees were randomized to use the app (YAPP) or not use the app (NAPP). We used blinded analysis with validated rating scales to assess their performance before and after the training. The number of requests for tutor feedback per session was recorded. Finally, the participants in the YAPP group completed a survey about their experience with the app. Results Fifteen YAPP and 10 NAPP completed the training program. There were no statistically significant differences between their skills performance scores (P = .338). The number of tutor feedback requests in the YAPP and NAPP was of 4 (3-6) and 13 (10-14) (P < .001), respectively. All participants in the YAPP group found the app was useful. Conclusion The use of a smartphone app reduces the need for expert tutor feedback without decreasing the degree of skills acquisition.",2019,There were no statistically significant differences between their skills performance scores (P = .338).,[],"['YAPP', 'advanced laparoscopy simulation training', 'app (YAPP) or not use the app (NAPP', '\n\n\nSimulation training']","['number of tutor feedback requests', 'skills performance scores', 'number of requests for tutor feedback per session']",[],"[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C4042947', 'cui_str': 'Simulation Training'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0445107', 'cui_str': 'Not used'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C1272683', 'cui_str': 'Requested'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0686900', 'cui_str': 'Request for'}]",,0.0384906,There were no statistically significant differences between their skills performance scores (P = .338).,"[{'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Quezada', 'Affiliation': 'Digestive Surgery Department, Division of Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Achurra', 'Affiliation': 'Digestive Surgery Department, Division of Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile.'}, {'ForeName': 'Domenech', 'Initials': 'D', 'LastName': 'Asbun', 'Affiliation': 'Department of Surgery, UCSF Fresno, Fresno, CA, USA.'}, {'ForeName': 'Karol', 'Initials': 'K', 'LastName': 'Polom', 'Affiliation': 'General Surgery and Surgical Oncology Department, University of Siena, Siena, Italy.'}, {'ForeName': 'Franco', 'Initials': 'F', 'LastName': 'Roviello', 'Affiliation': 'General Surgery and Surgical Oncology Department, University of Siena, Siena, Italy.'}, {'ForeName': 'Erwin', 'Initials': 'E', 'LastName': 'Buckel', 'Affiliation': 'Digestive Surgery Department, Division of Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Inzunza', 'Affiliation': 'Digestive Surgery Department, Division of Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Escalona', 'Affiliation': 'Digestive Surgery Department, Division of Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Jarufe', 'Affiliation': 'Digestive Surgery Department, Division of Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Varas', 'Affiliation': 'Digestive Surgery Department, Division of Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile.'}]",Surgery open science,['10.1016/j.sopen.2019.05.006'] 2283,32754748,"Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial.","CONTEXT Combination therapy with somatostatin receptor ligand (SRL) plus pegvisomant for acromegaly patients is recommended after maximizing dose on monotherapy. Lower-dose combination regimens are not well-studied. OBJECTIVE To compare cost-effectiveness and efficacy of three lower-dose combination regimens in controlled and uncontrolled acromegaly. DESIGN AND SETTING Prospective, randomized, open-label, parallel arm study at a tertiary referral pituitary center. PATIENTS Adults with acromegaly regardless of response to prior SRL and biochemical control status at baseline, stratified by SRL dose required for IGF-I normalization during any 3-month period within 12 months preceding enrollment. INTERVENTION Combination therapy for 24-32 weeks on Arm A, high-dose SRL (lanreotide 120 mg/octreotide LAR 30 mg) plus weekly pegvisomant (40-160 mg/week); Arm B, low-dose SRL (lanreotide 60 mg/octreotide LAR 10 mg) plus weekly pegvisomant; or Arm C, low-dose SRL plus daily pegvisomant (15-60 mg/day). MAIN OUTCOME MEASURE Monthly treatment cost in each Arm in subjects completing ≥24 weeks of therapy. RESULTS Sixty patients were enrolled and 52 evaluable. Fifty of 52 (96%) demonstrated IGF-I control regardless of prior SRL responsiveness (Arm A, 14/15 [93.3%]; Arm B, 22/23 [95.7%]; Arm C, 14/14 [100%]). Arm B was least costly (mean, $9,837±1,375 per month); Arm C was most expensive (mean, $22,543±11,158 per month) and Arm A had an intermediate cost (mean, $14,261±1,645 per month). Approximately 30% required pegvisomant dose uptitration. Rates of adverse events were all <10%. CONCLUSIONS Low-dose SRL plus weekly pegvisomant represents a novel dosing option for achieving cost-effective, optimal biochemical control in patients with uncontrolled acromegaly requiring combination therapy.",2020,"Arm B was least costly (mean, $9,837±1,375 per month); Arm C was most expensive (mean, $22,543±11,158 per month) and Arm A had an intermediate cost (mean, $14,261±1,645 per month).","['tertiary referral pituitary center', 'patients with uncontrolled acromegaly requiring combination therapy', 'Sixty patients were enrolled and 52 evaluable', 'Adults with acromegaly regardless of response to prior SRL and biochemical control status at baseline, stratified by SRL dose required for IGF-I normalization during any 3-month period within 12 months preceding enrollment']","['SRL (lanreotide 120 mg/octreotide LAR 30 mg) plus weekly pegvisomant', 'SRL (lanreotide 60 mg/octreotide LAR 10 mg) plus weekly pegvisomant; or Arm C, low-dose SRL plus daily pegvisomant', 'somatostatin receptor ligand (SRL) plus pegvisomant', 'novel combination regimen']","['cost-effectiveness and efficacy', 'Rates of adverse events', 'Cost-effectiveness and efficacy', 'IGF-I control regardless of prior SRL responsiveness']","[{'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0032002', 'cui_str': 'Disorder of pituitary gland'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0001206', 'cui_str': 'Acromegaly'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0074830', 'cui_str': 'Somatostatin Receptor'}, {'cui': 'C0023688', 'cui_str': 'Ligands'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0021665', 'cui_str': 'Somatomedin C'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}]","[{'cui': 'C0074830', 'cui_str': 'Somatostatin Receptor'}, {'cui': 'C0023688', 'cui_str': 'Ligands'}, {'cui': 'C0209211', 'cui_str': 'lanreotide'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0028833', 'cui_str': 'Octreotide'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0913469', 'cui_str': 'pegvisomant'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205314', 'cui_str': 'New'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021665', 'cui_str': 'Somatomedin C'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0074830', 'cui_str': 'Somatostatin Receptor'}, {'cui': 'C0023688', 'cui_str': 'Ligands'}]",60.0,0.043846,"Arm B was least costly (mean, $9,837±1,375 per month); Arm C was most expensive (mean, $22,543±11,158 per month) and Arm A had an intermediate cost (mean, $14,261±1,645 per month).","[{'ForeName': 'Vivien', 'Initials': 'V', 'LastName': 'Bonert', 'Affiliation': 'Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Mirocha', 'Affiliation': 'Biostatistics and Bioinformatics Research Center, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Carmichael', 'Affiliation': 'Division of Endocrinology and Metabolism, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.'}, {'ForeName': 'Kevin C J', 'Initials': 'KCJ', 'LastName': 'Yuen', 'Affiliation': 'Department of Neuroendocrinology and Neurosurgery, Barrow Neurological Institute, University of Arizona College of Medicine and Creighton School of Medicine, Phoenix, Arizona, USA.'}, {'ForeName': 'Takako', 'Initials': 'T', 'LastName': 'Araki', 'Affiliation': 'Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Shlomo', 'Initials': 'S', 'LastName': 'Melmed', 'Affiliation': 'Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgaa444'] 2284,32754804,Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes.,"AIMS/HYPOTHESIS The aim of this study was to determine if retention of C-peptide following immunotherapy using recombinant GAD65 conjugated to aluminium hydroxide (GAD-alum) is influenced by HLA risk haplotypes DR3-DQ2 and DR4-DQ8. METHODS HLA-dependent treatment effect of GAD-alum therapy on C-peptide retention in individuals with recent-onset type 1 diabetes was evaluated using individual-level patient data from three placebo-controlled, randomised clinical trials using a mixed repeated measures model. RESULTS A significant and dose-dependent effect was observed in individuals positive for the genotypes that include HLA-DR3-DQ2 but not HLA-DR4-DQ8 and in the broader subgroup of individuals positive for all genotypes that include HLA-DR3-DQ2 (i.e. including those also positive for HLA-DR4-DQ8). Higher doses (three or four injections) showed a treatment effect ratio of 1.596 (95% CI 1.132, 2.249; adjusted p = 0.0035) and 1.441 (95% CI 1.188, 1.749; adjusted p = 0.0007) vs placebo for the two respective HLA subgroups. CONCLUSIONS/INTERPRETATION GAD65-specific immunotherapy has a significant effect on C-peptide retention in individuals with recent-onset type 1 diabetes who have the DR3-DQ2 haplotype. Graphical abstract.",2020,"Higher doses (three or four injections) showed a treatment effect ratio of 1.596 (95% CI 1.132, 2.249; adjusted p = 0.0035) and 1.441 (95% CI 1.188, 1.749; adjusted p = 0.0007) vs placebo for the two respective HLA subgroups. ","['individuals with recent-onset type 1 diabetes who have the DR3-DQ2 haplotype', 'individuals with recent-onset type 1 diabetes']","['placebo', 'recombinant GAD65 conjugated to aluminium hydroxide (GAD-alum', 'GAD-alum therapy', 'GAD-alum immunotherapy']",['HLA-DR3-DQ2'],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0018591', 'cui_str': 'Haplotypes'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0301869', 'cui_str': 'Conjugate'}, {'cui': 'C0002371', 'cui_str': 'Aluminum Hydroxide'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}]","[{'cui': 'C0019772', 'cui_str': 'HLA-DR3 antigen'}]",,0.276531,"Higher doses (three or four injections) showed a treatment effect ratio of 1.596 (95% CI 1.132, 2.249; adjusted p = 0.0035) and 1.441 (95% CI 1.188, 1.749; adjusted p = 0.0007) vs placebo for the two respective HLA subgroups. ","[{'ForeName': 'Ulf', 'Initials': 'U', 'LastName': 'Hannelius', 'Affiliation': 'Diamyd Medical AB, Kungsgatan 29, 111 56, Stockholm, Sweden. ulf.hannelius@diamyd.com.'}, {'ForeName': 'Craig A', 'Initials': 'CA', 'LastName': 'Beam', 'Affiliation': 'Department of Biomedical Sciences, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.'}, {'ForeName': 'Johnny', 'Initials': 'J', 'LastName': 'Ludvigsson', 'Affiliation': ""Crown Princess Victoria Children's Hospital, Linköping, Sweden. Johnny.Ludvigsson@liu.se.""}]",Diabetologia,['10.1007/s00125-020-05227-z'] 2285,32749890,Effect of aerobic training with silymarin consumption on glycemic indices and liver enzymes in men with type 2 diabetes.,"This study investigated the effect of eight weeks of aerobic training (AT) combined with silymarin (S)consumption on glycemic indices and liver enzymes in men with type 2 diabetes (T2D). In this clinical trial, 60 middle-aged male volunteers were randomly divided into 4 groups, including: (1) C + placebo(C) (2) AT + placebo (3), S and (4) AT + S. AT was performed for eight weeks, three sessions per week, each session for 20-45 minutes at an intensity of 60-85% of maximal heart rate reserve, and S receiving groups consumed 140 mg/kg S daily (in two servings). AT reduced glycemic indices and liver enzymes in men with T2D ( p  ≤ .05). S decreased blood glucose, insulin, HOMA-IR, AST, ALT and ALP in men with T2D ( p  ≤ .05). Exercise along with silymarin decreased blood glucose, insulin, HOMA-IR, AST, ALT and ALP. Also, reduction of AST and blood glucose in the AT + S group was more favourable than the effect of S alone ( p  ≤ .05). It seems that simultaneous AT and S has interactive effects on reducing glycemic indices and liver enzymes in men with T2D.",2020,"S decreased blood glucose, insulin, HOMA-IR, AST, ALT and ALP in men with T2D ( p  ≤ .05).","['men with type 2 diabetes', 'men with type 2 diabetes (T2D', '60 middle-aged male volunteers', 'men with T2D']","['aerobic training with silymarin consumption', 'C\u2009+\u2009placebo(C) (2) AT\u2009+\u2009placebo (3), S and (4) AT\u2009+\u2009S. AT', 'aerobic training (AT) combined with silymarin (S)consumption']","['glycemic indices and liver enzymes', 'blood glucose, insulin, HOMA-IR, AST, ALT and ALP', 'reduction of AST and blood glucose']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0037135', 'cui_str': 'Silymarin'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0443764', 'cui_str': 'Liver enzyme'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",60.0,0.0344757,"S decreased blood glucose, insulin, HOMA-IR, AST, ALT and ALP in men with T2D ( p  ≤ .05).","[{'ForeName': 'Keyvan', 'Initials': 'K', 'LastName': 'Ghalandari', 'Affiliation': 'Department of Physical Education and Sport Sciences, Gachsaran Branch, Islamic Azad University, Gachsaran, Iran.'}, {'ForeName': 'Mojtaba', 'Initials': 'M', 'LastName': 'Shabani', 'Affiliation': 'Department of Physical Education and Sport Sciences, Gachsaran Branch, Islamic Azad University, Gachsaran, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Khajehlandi', 'Affiliation': 'Department of Physical Education and Sport Sciences, Gachsaran Branch, Islamic Azad University, Gachsaran, Iran.'}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Mohammadi', 'Affiliation': 'Department of Physical Education and Sport Sciences, Gachsaran Branch, Islamic Azad University, Gachsaran, Iran.'}]",Archives of physiology and biochemistry,['10.1080/13813455.2020.1797104'] 2286,32749916,Switching Ratio from Parenteral to Oral Methadone 1:1.2 Is Safer Compared with Ratio 1:2 in Patients with Controlled Cancer Pain: A Multicenter Randomized-Controlled Trial (RATIOMTD-010810).,"Background: The most commonly used switching ratio from parenteral to oral methadone is 1:2. Methadone is highly bioavailable and a lower ratio might result in similar analgesia with less toxicity. Objective: To compare success and side effects with two ratios from parenteral to oral methadone: 1:2 versus 1:1.2 in hospitalized patients with cancer pain. Design: A multicenter double-blind randomized clinical trial. Settings/Particiants: Inpatients with well-controlled cancer pain with parenteral methadone requiring rotation to the oral route. Measurements: Outcomes included pain intensity (Brief Inventory Pain), opioid toxicity (Common Toxicology Criteria for Adverse Events), and methadone dose. Success was defined as no toxicity with good pain control at 72 hours. Results: Thirty-nine of forty-four randomized patients were evaluable: 21 in ratio 1:2 and 18 in ratio 1:1.2. Seventy-one percent male. Median age 65 years. No significant differences in basal clinical characteristics between both groups. Median methadone dose pre/post switching was 24.5 mg ±13.5 and 49 mg ±27.3 for ratio 1:2, versus 23.3 mg ±9.4 ( p : not significant) and 28 mg ±11.3 ( p  < 0.01) for ratio 1:1.2. Pain was well controlled without differences between both ratios. Drowsiness at day +1 ( p  < 0.017) and myoclonus at day +3 ( p  < 0.019) were more prevalent in group 1:2. Success was observed in 12 patients in ratio 1:2 versus 18 in ratio 1:1.2 ( p  < 0.001). Methadone side effects were observed in 12 patients in ratio 1:2 (mainly neurotoxicity symptoms) versus 2 in ratio 1:1.2 ( p  < 0.005). Conclusion: Ratio 1:1.2 when changing from parenteral to oral methadone resulted in lower toxicity and no difference in analgesia. More conservative dose adjustment during methadone route change should be considered. European Clinical Trials Register (EudraCT No. 2010-024092-39).",2020,Drowsiness at day +1 ( p  < 0.017) and myoclonus at day +3 ( p  < 0.019) were more prevalent in group 1:2.,"['of forty-four randomized patients were evaluable: 21 in ratio 1:2 and 18 in ratio 1:1.2', 'hospitalized patients with cancer pain', 'Settings/Particiants: Inpatients with well-controlled cancer pain with parenteral methadone requiring rotation to the oral route', 'Median age 65 years', 'Results: Thirty-nine', 'Seventy-one percent male', 'Patients with Controlled Cancer Pain']","['EudraCT', 'methadone', 'Methadone']","['Drowsiness', 'Success', 'pain intensity (Brief Inventory Pain), opioid toxicity (Common Toxicology Criteria for Adverse Events), and methadone dose', 'Methadone side effects', 'Pain', 'basal clinical characteristics', 'analgesia', 'toxicity with good pain control', 'lower toxicity']","[{'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0596240', 'cui_str': 'Cancer pain'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C3853142', 'cui_str': 'Well controlled'}, {'cui': 'C0030547', 'cui_str': 'Parenteral nutrition'}, {'cui': 'C0025605', 'cui_str': 'Methadone'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C1527415', 'cui_str': 'Oral route'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C3816447', 'cui_str': '39'}, {'cui': 'C0450389', 'cui_str': '71'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0025605', 'cui_str': 'Methadone'}]","[{'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0412850', 'cui_str': 'Poisoning by opiate analgesic drug'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0040541', 'cui_str': 'Toxicology'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0025605', 'cui_str': 'Methadone'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0205251', 'cui_str': 'Low'}]",,0.318745,Drowsiness at day +1 ( p  < 0.017) and myoclonus at day +3 ( p  < 0.019) were more prevalent in group 1:2.,"[{'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'González-Barboteo', 'Affiliation': ""Palliative Care Department, Hospital Duran i Reynals, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Porta-Sales', 'Affiliation': ""Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Nabal-Vicuña', 'Affiliation': 'Supportive Palliative Care Team, Hospital Universitari Arnau de Vilanova, Lleida, Spain.'}, {'ForeName': 'Leyre', 'Initials': 'L', 'LastName': 'Díez-Porres', 'Affiliation': 'Palliative Care Department, Hospital Universitario La Paz, Madrid, Spain.'}, {'ForeName': 'Jaume', 'Initials': 'J', 'LastName': 'Canal-Sotelo', 'Affiliation': 'Supportive Palliative Care Team, Hospital Universitari Santa Maria, Lleida, Spain.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Alonso-Babarro', 'Affiliation': 'Palliative Care Department, Hospital Universitario La Paz, Madrid, Spain.'}, {'ForeName': 'Yolanda', 'Initials': 'Y', 'LastName': 'Vílches-Aguirre', 'Affiliation': 'Palliative Care Department, Hospital Universitario La Paz, Madrid, Spain.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Pérez-Pujol', 'Affiliation': ""Clinical Research and Clinical Trials Unit (UICEC), Bellvitge Biomedical Research Institute (IDIBELL), Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Mireia', 'Initials': 'M', 'LastName': 'Sanllorente', 'Affiliation': ""Clinical Research and Clinical Trials Unit (UICEC), Bellvitge Biomedical Research Institute (IDIBELL), Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Llorens-Torromé', 'Affiliation': ""Palliative Care Department, Hospital Duran i Reynals, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Gómez-Batiste Alentorn', 'Affiliation': ""Palliative Care Department, Hospital Duran i Reynals, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Bruera', 'Affiliation': 'Department of Palliative Care and Rehabilitation Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}]",Journal of palliative medicine,['10.1089/jpm.2020.0244'] 2287,32749918,"Acute Effects of Turmeric Extracts on Knee Joint Pain: A Pilot, Randomized Controlled Trial.","Turmeric extracts (TEs) have been shown to be suitable as a pain treatment for human joint arthritis. In a pilot, randomized clinical trial, 68 individuals with mild/moderate knee joint pain (KJP) consumed a new formulation of water-soluble TEs and insoluble curcuminoids (B-Turmactive ® ) or brewer's yeast as a placebo for 1 week. Our hypothesis was that B-Turmactive would have a short-term analgesic effect on KJP measured by the self-reported Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). After 3 days and 1 week, both treatments reduced pain when walking on a flat surface ( P  < .01), going up or down stairs ( P  < .001), and sitting or lying ( P  < .05), but only B-Turmactive reduced pain at night while in bed and in an upright standing position ( P  < .01). Concerning global KJP, it was reduced by both treatments after 3 days and 1 week of the intervention ( P  < .001), being less with B-Turmactive after 1 week ( P  = .012 vs. 3 weeks). Although no intertreatment differences were observed, only B-Turmactive decreased high-sensitivity C-reactive protein levels ( P  = .045) at 1 week, which indicates a prompt analgesic effect mediated by a decrease in inflammatory status.",2020,"After 3 days and 1 week, both treatments reduced pain when walking on a flat surface ( P  < .01), going up or down stairs ( P  < .001), and sitting or lying ( P  < .05), but only B-Turmactive reduced pain at night while in bed and in an upright standing position ( P  < .01).",['68 individuals with mild/moderate knee joint pain (KJP'],"['Turmeric extracts (TEs', ""new formulation of water-soluble TEs and insoluble curcuminoids (B-Turmactive ® ) or brewer's yeast as a placebo"", 'Turmeric Extracts']","['Knee Joint Pain', 'sensitivity C-reactive protein levels', 'inflammatory status', 'pain']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0231749', 'cui_str': 'Knee pain'}]","[{'cui': 'C0077524', 'cui_str': 'Turmeric extract'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0036025', 'cui_str': 'Saccharomyces cerevisiae'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0231749', 'cui_str': 'Knee pain'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",68.0,0.0378062,"After 3 days and 1 week, both treatments reduced pain when walking on a flat surface ( P  < .01), going up or down stairs ( P  < .001), and sitting or lying ( P  < .05), but only B-Turmactive reduced pain at night while in bed and in an upright standing position ( P  < .01).","[{'ForeName': 'Lorena', 'Initials': 'L', 'LastName': 'Calderón-Pérez', 'Affiliation': 'Eurecat, Technological Center of Catalonia, Nutrition and Health Unit, Reus, Spain.'}, {'ForeName': 'Elisabet', 'Initials': 'E', 'LastName': 'Llauradó', 'Affiliation': 'Eurecat, Technological Center of Catalonia, Nutrition and Health Unit, Reus, Spain.'}, {'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Companys', 'Affiliation': 'Eurecat, Technological Center of Catalonia, Nutrition and Health Unit, Reus, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Pla-Pagà', 'Affiliation': 'Eurecat, Technological Center of Catalonia, Nutrition and Health Unit, Reus, Spain.'}, {'ForeName': 'Noemí', 'Initials': 'N', 'LastName': 'Boqué', 'Affiliation': 'Eurecat, Technological Center of Catalonia, Nutrition and Health Unit, Reus, Spain.'}, {'ForeName': 'Francesc', 'Initials': 'F', 'LastName': 'Puiggrós', 'Affiliation': 'Eurecat, Technological Center of Catalonia, Nutrition and Health Unit, Reus, Spain.'}, {'ForeName': 'Rosa-M', 'Initials': 'RM', 'LastName': 'Valls', 'Affiliation': 'Eurecat, Technological Center of Catalonia, Nutrition and Health Unit, Reus, Spain.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Pedret', 'Affiliation': 'Eurecat, Technological Center of Catalonia, Nutrition and Health Unit, Reus, Spain.'}, {'ForeName': 'Josep Manuel', 'Initials': 'JM', 'LastName': 'Llabrés', 'Affiliation': 'PLAMECA S.A. (Medicinal Plants and Food Supplements, S.A.), Barcelona, Spain.'}, {'ForeName': 'Lluís', 'Initials': 'L', 'LastName': 'Arola', 'Affiliation': 'Eurecat, Technological Center of Catalonia, Nutrition and Health Unit, Reus, Spain.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Solà', 'Affiliation': 'Functional Nutrition, Oxidation and Cardiovascular Diseases Research Group (NFOC-Salut), Faculty of Medicine and Health Sciences, Rovira i Virgili University, Reus, Spain.'}]",Journal of medicinal food,['10.1089/jmf.2020.0074'] 2288,32749930,Conducting Goals-of-Care Discussions Takes Less Time Than Imagined.,"PURPOSE To describe the length of encounter during visits where goals-of-care (GoC) discussions were expected to take place. METHODS Oncologists from community, academic, municipal, and rural hospitals were randomly assigned to receive a coaching model of communication skills to facilitate GoC discussions with patients with newly diagnosed advanced solid-tumor cancer with a prognosis of < 2 years. Patients were surveyed after the first restaging visit regarding the quality of the GoC discussion on a scale of 0-10 (0 = worst; 10 = best), with ≥ 8 indicating a high-quality GoC discussion. Visits were audiotaped, and total encounter time was measured. RESULTS The median face-to-face time oncologists spent during a GoC discussion was 15 minutes (range, 10-20 minutes). Among the different hospital types, there was no significant difference in encounter time. There was no difference in the length of the encounter whether a high-quality GoC discussion took place or not (15 v 14 minutes; P = .9). If there was imaging evidence of cancer progression, the median encounter time was 18 minutes compared with 13 minutes for no progression ( P = .03). In a multivariate model, oncologist productivity, patient age, and Medicare coverage affected duration of the encounter. CONCLUSION Oncologists can complete high-quality GoC discussions in 15 minutes. These data refute the common misperception that discussing such matters with patients with advanced cancer requires significant time.",2020,"Among the different hospital types, there was no significant difference in encounter time.","['Oncologists from community, academic, municipal, and rural hospitals', 'with patients with newly diagnosed advanced solid-tumor cancer with a prognosis of < 2 years', 'patients with advanced cancer']",['coaching model of communication skills to facilitate GoC discussions'],"['median encounter time', 'total encounter time', 'encounter time']","[{'cui': 'C0259990', 'cui_str': 'Oncologists'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0020023', 'cui_str': 'Rural Hospitals'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0280100', 'cui_str': 'Solid tumour'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0033325', 'cui_str': 'Determination of prognosis'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}]","[{'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0870313', 'cui_str': 'Communication skills'}, {'cui': 'C2930505', 'cui_str': 'Goals of Care'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",,0.0336893,"Among the different hospital types, there was no significant difference in encounter time.","[{'ForeName': 'Sofya', 'Initials': 'S', 'LastName': 'Pintova', 'Affiliation': 'Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Leibrandt', 'Affiliation': 'Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.'}, {'ForeName': 'Cardinale B', 'Initials': 'CB', 'LastName': 'Smith', 'Affiliation': 'Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.'}, {'ForeName': 'Kerin B', 'Initials': 'KB', 'LastName': 'Adelson', 'Affiliation': 'Smilow Cancer Hospital at Yale, New Haven, CT.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Gonsky', 'Affiliation': 'Division of Hematology and Medical Oncology, Department of Medicine, NYC Health and Hospitals/Kings County; and State University of New York Downstate Medical Center, Brooklyn, NY.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Egorova', 'Affiliation': 'Department of Population Health Science and Policy at Mount Sinai, New York, NY.'}, {'ForeName': 'Rebeca', 'Initials': 'R', 'LastName': 'Franco', 'Affiliation': 'Departments of Medicine and Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY.'}, {'ForeName': 'Nina A', 'Initials': 'NA', 'LastName': 'Bickell', 'Affiliation': 'Departments of Medicine and Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY.'}]",JCO oncology practice,['10.1200/JOP.19.00743'] 2289,32749938,Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial.,"PURPOSE To assess the effects of bevacizumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) as first-line treatment of RAS mutant unresectable colorectal liver metastases. METHODS From October 2013 to December 2017, patients with RAS mutant unresectable liver-limited metastases from colorectal cancer were randomly assigned to receive mFOLFOX6 plus bevacizumab (arm A) or mFOLFOX6 alone (arm B). The resectability of liver metastases was determined by a local multidisciplinary team. The primary end point was the actual rate of patients converted to R0 resection for liver metastases. Secondary end points included tumor response, survival, and toxicity. The block randomization method was used. RESULTS The intention-to-treat population comprised 241 patients. A total of 121 patients were randomly assigned to arm A and 120 to arm B. The median follow-up time was 37.0 months for all patients. The R0 resection rates for liver metastases were 22.3% (27 of 121 patients) in arm A and 5.8% (7 of 120 patients) in arm B, with a significant difference ( P < .01). Patients in arm A had significantly better objective response rates (54.5% v 36.7%; P < .01), median progression-free survival (9.5 v 5.6 months; P < .01) and median overall survival (25.7 v 20.5 months; P = .03) compared with those in arm B. The addition of bevacizumab was associated with more frequent proteinuria (9.9% v 3.3%; P = .04) and hypertension (8.3% v 2.5%; P < .05). CONCLUSION For patients with initially unresectable RAS mutant colorectal liver metastases, bevacizumab combined with mFOLFOX6 increased the resectability of liver metastases and improved response rates and survival compared with mFOLFOX6 alone.",2020,"The R0 resection rates for liver metastases were 22.3% (27 of 121 patients) in arm A and 5.8% (7 of 120 patients) in arm B, with a significant difference ( P < .01).","['From October 2013 to December 2017', 'RAS Mutant Unresectable Colorectal Liver-Limited Metastases', 'patients with RAS mutant unresectable liver-limited metastases from colorectal cancer', 'RAS mutant unresectable colorectal liver metastases', 'A total of 121 patients were randomly assigned to arm A and 120 to arm B']","['mFOLFOX6 plus bevacizumab (arm A) or mFOLFOX6 alone', 'bevacizumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6', 'Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone', 'bevacizumab']","['frequent proteinuria', 'median progression-free survival', 'resectability of liver metastases', 'R0 resection rates for liver metastases', 'objective response rates', 'median overall survival', 'actual rate of patients converted to R0 resection for liver metastases', 'response rates and survival', 'hypertension', 'tumor response, survival, and toxicity']","[{'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0494165', 'cui_str': 'Secondary malignant neoplasm of liver'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C4319550', 'cui_str': '120'}]","[{'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}]","[{'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0494165', 'cui_str': 'Secondary malignant neoplasm of liver'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0040539', 'cui_str': 'TO'}]",121.0,0.164236,"The R0 resection rates for liver metastases were 22.3% (27 of 121 patients) in arm A and 5.8% (7 of 120 patients) in arm B, with a significant difference ( P < .01).","[{'ForeName': 'Wentao', 'Initials': 'W', 'LastName': 'Tang', 'Affiliation': ""Department of General Surgery, Zhongshan Hospital, Fudan University, and Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive, Shanghai, People's Republic of China.""}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Ren', 'Affiliation': ""Department of General Surgery, Zhongshan Hospital, Fudan University, and Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive, Shanghai, People's Republic of China.""}, {'ForeName': 'Qinghai', 'Initials': 'Q', 'LastName': 'Ye', 'Affiliation': ""Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.""}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Wei', 'Affiliation': ""Department of General Surgery, Zhongshan Hospital, Fudan University, and Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive, Shanghai, People's Republic of China.""}, {'ForeName': 'Guodong', 'Initials': 'G', 'LastName': 'He', 'Affiliation': ""Department of General Surgery, Zhongshan Hospital, Fudan University, and Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive, Shanghai, People's Republic of China.""}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Lin', 'Affiliation': ""Department of General Surgery, Zhongshan Hospital, Fudan University, and Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive, Shanghai, People's Republic of China.""}, {'ForeName': 'Xiaoying', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ""Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.""}, {'ForeName': 'Mingliang', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': ""Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.""}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Liang', 'Affiliation': ""Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.""}, {'ForeName': 'Yuehong', 'Initials': 'Y', 'LastName': 'Cui', 'Affiliation': ""Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.""}, {'ForeName': 'Tianshu', 'Initials': 'T', 'LastName': 'Liu', 'Affiliation': ""Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.""}, {'ForeName': 'Jianmin', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': ""Department of General Surgery, Zhongshan Hospital, Fudan University, and Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive, Shanghai, People's Republic of China.""}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.20.00174'] 2290,32749941,Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.,"PURPOSE The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) for women with high-risk endometrial cancer (EC). Because The Cancer Genome Atlas defined an EC molecular classification with strong prognostic value, we investigated prognosis and impact of chemotherapy for each molecular subgroup using tissue samples from PORTEC-3 trial participants. METHODS Paraffin-embedded tissues of 423 consenting patients were collected. Immunohistochemistry for p53 and mismatch repair (MMR) proteins, and DNA sequencing for POLE exonuclease domain were done to classify tumors as p53 abnormal (p53abn), POLE- ultramutated ( POLE mut), MMR-deficient (MMRd), or no specific molecular profile (NSMP). The primary end point was recurrence-free survival (RFS). Kaplan-Meier method, log-rank test, and Cox model were used for analysis. RESULTS Molecular analysis was successful in 410 high-risk EC (97%), identifying the 4 subgroups: p53abn EC (n = 93; 23%), POLE mut (n = 51; 12%), MMRd (n = 137; 33%), and NSMP (n = 129; 32%). Five-year RFS was 48% for patients with p53abn EC, 98% for POLE mut EC, 72% for MMRd EC, and 74% for NSMP EC ( P < .001). The 5-year RFS with CTRT versus RT for p53abn EC was 59% versus 36% ( P = .019); 100% versus 97% for patients with POLE mut EC ( P = .637); 68% versus 76% ( P = .428) for MMRd EC; and 80% versus 68% ( P = .243) for NSMP EC. CONCLUSION Molecular classification has strong prognostic value in high-risk EC, with significantly improved RFS with adjuvant CTRT for p53abn tumors, regardless of histologic type. Patients with POLE mut EC had an excellent RFS in both trial arms. EC molecular classification should be incorporated in the risk stratification of these patients as well as in future trials to target specific subgroups of patients.",2020,The 5-year RFS with CTRT versus RT for p53abn EC was 59% versus 36% (,"['High-Risk Endometrial Cancer', 'Paraffin-embedded tissues of 423 consenting patients were collected', 'Women With High-Risk Endometrial Cancer', 'women with high-risk endometrial cancer (EC']","['Chemoradiotherapy Versus Radiotherapy', 'combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT', 'POLE', 'MMRd']","['excellent RFS', 'recurrence-free survival (RFS', '5-year RFS']","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0007103', 'cui_str': 'Endometrial neoplasms malignant'}, {'cui': 'C0030415', 'cui_str': 'Paraffin'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0337815', 'cui_str': 'Poles'}]","[{'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0341703', 'cui_str': 'Adult Fanconi syndrome'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease'}, {'cui': 'C0439234', 'cui_str': 'year'}]",423.0,0.203555,The 5-year RFS with CTRT versus RT for p53abn EC was 59% versus 36% (,"[{'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'León-Castillo', 'Affiliation': 'Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Stephanie M', 'Initials': 'SM', 'LastName': 'de Boer', 'Affiliation': 'Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Melanie E', 'Initials': 'ME', 'LastName': 'Powell', 'Affiliation': 'Department of Clinical Oncology, Barts Health National Health Service Trust, London, United Kingdom.'}, {'ForeName': 'Linda R', 'Initials': 'LR', 'LastName': 'Mileshkin', 'Affiliation': 'Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.'}, {'ForeName': 'Helen J', 'Initials': 'HJ', 'LastName': 'Mackay', 'Affiliation': 'Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Leary', 'Affiliation': 'Department of Medical Oncology, Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Hans W', 'Initials': 'HW', 'LastName': 'Nijman', 'Affiliation': 'Department of Medical Oncology, Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Naveena', 'Initials': 'N', 'LastName': 'Singh', 'Affiliation': 'Department of Pathology, Barts Health National Health Service Trust, London, United Kingdom.'}, {'ForeName': 'Pamela M', 'Initials': 'PM', 'LastName': 'Pollock', 'Affiliation': 'Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Bessette', 'Affiliation': 'Canadian Cancer Trials Group, Department of Obstetrics and Gynecology, University of Sherbrooke, Sherbrooke, Quebec, Canada.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Fyles', 'Affiliation': 'Canadian Cancer Trials Group, Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Haie-Meder', 'Affiliation': 'Department of Radiotherapy, Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Vincent T H B M', 'Initials': 'VTHBM', 'LastName': 'Smit', 'Affiliation': 'Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Edmondson', 'Affiliation': ""Division of Cancer Sciences, University of Manchester, St Mary's Hospital, Manchester, United Kingdom.""}, {'ForeName': 'Hein', 'Initials': 'H', 'LastName': 'Putter', 'Affiliation': 'Department of Biostatistics, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Henry C', 'Initials': 'HC', 'LastName': 'Kitchener', 'Affiliation': ""Division of Cancer Sciences, University of Manchester, St Mary's Hospital, Manchester, United Kingdom.""}, {'ForeName': 'Emma J', 'Initials': 'EJ', 'LastName': 'Crosbie', 'Affiliation': ""Division of Cancer Sciences, University of Manchester, St Mary's Hospital, Manchester, United Kingdom.""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'de Bruyn', 'Affiliation': 'Department of Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Remi A', 'Initials': 'RA', 'LastName': 'Nout', 'Affiliation': 'Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Nanda', 'Initials': 'N', 'LastName': 'Horeweg', 'Affiliation': 'Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Carien L', 'Initials': 'CL', 'LastName': 'Creutzberg', 'Affiliation': 'Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Tjalling', 'Initials': 'T', 'LastName': 'Bosse', 'Affiliation': 'Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.20.00549'] 2291,32749942,Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.,"PURPOSE In SOLO1, maintenance olaparib (300 mg twice daily) significantly improved progression-free survival (PFS) for patients with newly diagnosed BRCA1 - and/or BRCA2 -mutated advanced ovarian cancer compared with placebo (hazard ratio [HR], 0.30; 95% CI, 0.23 to 0.41; median not reached v 13.8 months). We investigated PFS in SOLO1 for subgroups of patients based on preselected baseline factors. PATIENTS AND METHODS Investigator-assessed PFS subgroup analyses of SOLO1 included clinical response after platinum-based chemotherapy (complete [CR] or partial response [PR]), surgery type (upfront or interval surgery), disease status after surgery (residual or no gross residual disease), and BRCA mutation status ( BRCA1 or BRCA2 ). Additionally, we evaluated PFS in patients with stage III disease who underwent upfront surgery and had no gross residual disease. We also report objective response rate. RESULTS The risk of disease progression or death was reduced with olaparib compared with placebo by 69% (HR, 0.31; 95% CI, 0.21 to 0.46) and 63% (HR, 0.37; 95% CI, 0.24 to 0.58) in patients undergoing upfront or interval surgery; 56% (HR, 0.44; 95% CI, 0.25 to 0.77) and 67% (HR, 0.33; 95% CI, 0.23 to 0.46) in patients with residual or no residual disease after surgery; 66% (HR, 0.34; 95% CI, 0.24 to 0.47) and 69% in women with clinical CR or PR at baseline (HR, 0.31; 95% CI, 0.18 to 0.52); and 59% (HR, 0.41; 95% CI, 0.30 to 0.56) and 80% (HR 0.20; 95% CI, 0.10 to 0.37) in patients with a BRCA1 or BRCA2 mutation, respectively. CONCLUSION Patients with newly diagnosed advanced ovarian cancer achieve substantial benefit from maintenance olaparib treatment regardless of baseline surgery outcome, response to chemotherapy, or BRCA mutation type.",2020,"The risk of disease progression or death was reduced with olaparib compared with placebo by 69% (HR, 0.31; 95% CI, 0.21 to 0.46) and 63% (HR, 0.37; 95% CI, 0.24 to 0.58) in patients undergoing upfront or interval surgery; 56% (HR, 0.44; 95% CI, 0.25 to 0.77) and 67% (HR, 0.33; 95% CI, 0.23 to 0.46) in patients with residual or no residual disease after surgery; 66% (HR, 0.34; 95% CI, 0.24 to 0.47) and 69% in women with clinical CR or PR at baseline (HR, 0.31; 95% CI, 0.18 to 0.52); and 59% (HR, 0.41; 95% CI, 0.30 to 0.56) and 80% (HR 0.20; 95% CI, 0.10 to 0.37) in patients with a BRCA1 or BRCA2 mutation, respectively. ","['Patients With Newly Diagnosed Advanced Ovarian Cancer', 'Patients with newly diagnosed advanced ovarian cancer', 'patients with stage III disease who underwent upfront surgery and had no gross residual disease']","['Maintenance Olaparib', 'platinum-based chemotherapy (complete [CR] or partial response [PR]), surgery type (upfront or interval surgery', 'placebo']","['progression-free survival (PFS', 'risk of disease progression or death', 'disease status after surgery (residual or no gross residual disease), and BRCA mutation status ( BRCA1 or BRCA2 ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0919267', 'cui_str': 'Neoplasm of ovary'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439806', 'cui_str': 'Gross'}, {'cui': 'C0543478', 'cui_str': 'Residual Tumour'}]","[{'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C2316164', 'cui_str': 'olaparib'}, {'cui': 'C3536920', 'cui_str': 'Platinum compounds'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0439806', 'cui_str': 'Gross'}, {'cui': 'C0543478', 'cui_str': 'Residual Tumour'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C1528558', 'cui_str': 'BRCA1 protein, human'}, {'cui': 'C2973986', 'cui_str': 'BRCA2 protein, human'}]",,0.426993,"The risk of disease progression or death was reduced with olaparib compared with placebo by 69% (HR, 0.31; 95% CI, 0.21 to 0.46) and 63% (HR, 0.37; 95% CI, 0.24 to 0.58) in patients undergoing upfront or interval surgery; 56% (HR, 0.44; 95% CI, 0.25 to 0.77) and 67% (HR, 0.33; 95% CI, 0.23 to 0.46) in patients with residual or no residual disease after surgery; 66% (HR, 0.34; 95% CI, 0.24 to 0.47) and 69% in women with clinical CR or PR at baseline (HR, 0.31; 95% CI, 0.18 to 0.52); and 59% (HR, 0.41; 95% CI, 0.30 to 0.56) and 80% (HR 0.20; 95% CI, 0.10 to 0.37) in patients with a BRCA1 or BRCA2 mutation, respectively. ","[{'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'DiSilvestro', 'Affiliation': 'Women & Infants Hospital, Providence, RI.'}, {'ForeName': 'Nicoletta', 'Initials': 'N', 'LastName': 'Colombo', 'Affiliation': 'European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), University of Milan-Bicocca, Milan, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Scambia', 'Affiliation': 'Fondazione Policlinico Universitario A Gemelli, IRCCS, Università Cattolica, Rome, Italy.'}, {'ForeName': 'Byoung-Gie', 'Initials': 'BG', 'LastName': 'Kim', 'Affiliation': 'Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Oaknin', 'Affiliation': ""Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.""}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Friedlander', 'Affiliation': 'University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, New South Wales, Australia.'}, {'ForeName': 'Alla', 'Initials': 'A', 'LastName': 'Lisyanskaya', 'Affiliation': 'St Petersburg City Oncology Dispensary, St Petersburg, Russia.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Floquet', 'Affiliation': 'Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Leary', 'Affiliation': 'Gustave-Roussy Cancer Campus, Villejuif, France.'}, {'ForeName': 'Gabe S', 'Initials': 'GS', 'LastName': 'Sonke', 'Affiliation': 'The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Charlie', 'Initials': 'C', 'LastName': 'Gourley', 'Affiliation': 'Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Banerjee', 'Affiliation': 'The Royal Marsden National Health Service Foundation Trust and Institute of Cancer Research, London, United Kingdom.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Oza', 'Affiliation': 'Princess Margaret Cancer Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'González-Martín', 'Affiliation': 'Clínica Universidad de Navarra, Madrid, Spain.'}, {'ForeName': 'Carol A', 'Initials': 'CA', 'LastName': 'Aghajanian', 'Affiliation': 'Memorial Sloan-Kettering Cancer Center, New York, NY.'}, {'ForeName': 'William H', 'Initials': 'WH', 'LastName': 'Bradley', 'Affiliation': 'Froedtert and the Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Cara A', 'Initials': 'CA', 'LastName': 'Mathews', 'Affiliation': 'Women & Infants Hospital, Providence, RI.'}, {'ForeName': 'Joyce', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Elizabeth S', 'Initials': 'ES', 'LastName': 'Lowe', 'Affiliation': 'AstraZeneca, Gaithersburg, MD.'}, {'ForeName': 'Ralph', 'Initials': 'R', 'LastName': 'Bloomfield', 'Affiliation': 'AstraZeneca, Cambridge, United Kingdom.'}, {'ForeName': 'Kathleen N', 'Initials': 'KN', 'LastName': 'Moore', 'Affiliation': 'Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.20.00799'] 2292,32749998,Immediate and Long-Term Effects of an 8-Week Digital Mental Health Intervention on Adults With Poorly Managed Type 2 Diabetes: Protocol for a Randomized Controlled Trial.,"BACKGROUND Diabetes is a leading cause of years of life lost and accounts for approximately one-fourth of health care dollars spent in the United States. Many of these costs are related to poor medication adherence and lack of self-care behaviors and are thus preventable. Depression, which is more prevalent among people with diabetes than in the general population, predicts poorer management of one's diabetes, whereas positive affect predicts engaging in more positive health behaviors. Consequently, interventions that improve depression and positive affect may also improve diabetes-related outcomes among people with diabetes. Although preliminary research on the impact of such interventions among people with diabetes is promising, these studies focused primarily on in-person interventions, have had small samples, and lack long-term follow-up. OBJECTIVE This study aims to examine the short- and long-term effects of a digital therapeutic platform focused on mental health among adults with poorly managed type 2 diabetes and elevated levels of depression. METHODS This is a randomized controlled trial in which adults with a type 2 diabetes diagnosis, elevated hemoglobin A 1c (HbA 1c ) levels (≧7), and moderate to severe depressive symptoms will be randomly assigned to a positive emotion regulation skills intervention group or a sham digital intervention with only psychoeducational content. The study will take place over 14 months, including the 8-week intervention (or control) delivered via a digital therapeutic platform (Happify Health) and follow-up assessments at 3, 6, and 12 months postintervention. Throughout the intervention and for 1 week at each postintervention follow-up, participants will complete daily assessments of diabetes-related distress, diabetes regimen adherence, and mood. Our primary outcome, HbA 1c , will be self-reported every 3 months throughout the study. Secondary and exploratory outcomes will be assessed at baseline; at 8 weeks; and at 3, 6, and 12 months postintervention. RESULTS Recruitment is expected to begin in June 2020. Participants will begin the study as they are recruited and will finish in waves. The final wave of data collection from the 8-week intervention is expected for winter 2020, with the completion of the 12-month follow-up in winter 2021. CONCLUSIONS Although previous research suggests that in-person psychological interventions have promising effects on both psychological and physical outcomes among adults with diabetes, digital interventions can be advantageous because they are easily scalable and reduce many barriers that prevent people from seeking treatment. This trial will provide important information about the effects of a digital mental health intervention among adults with type 2 diabetes, assessing both short- and long-term effects of this intervention on HbA1c, depressive symptoms, and other diabetes-specific outcomes. If successful, this may introduce a scalable intervention that would help reduce some of the preventable costs associated with diabetes. TRIAL REGISTRATION ClinicalTrials.gov NCT04068805; https://clinicaltrials.gov/ct2/show/NCT04068805. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) PRR1-10.2196/18578.",2020,"Although previous research suggests that in-person psychological interventions have promising effects on both psychological and physical outcomes among adults with diabetes, digital interventions can be advantageous because they are easily scalable and reduce many barriers that prevent people from seeking treatment.","['adults with a type 2 diabetes diagnosis, elevated hemoglobin', 'people with diabetes', 'adults with diabetes', 'adults with type 2 diabetes', 'adults with poorly managed type 2 diabetes and elevated levels of depression', 'Adults With Poorly Managed Type 2 Diabetes']","['digital therapeutic platform', '8-week intervention (or control) delivered via a digital therapeutic platform (Happify Health', '8-Week Digital Mental Health Intervention', 'positive emotion regulation skills intervention group or a sham digital intervention with only psychoeducational content', 'digital mental health intervention']",['mental health'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0549448', 'cui_str': 'Increased hemoglobin'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205169', 'cui_str': 'Bad'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1319226', 'cui_str': 'Level of depression'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]",,0.176142,"Although previous research suggests that in-person psychological interventions have promising effects on both psychological and physical outcomes among adults with diabetes, digital interventions can be advantageous because they are easily scalable and reduce many barriers that prevent people from seeking treatment.","[{'ForeName': 'Eliane', 'Initials': 'E', 'LastName': 'Boucher', 'Affiliation': 'Happify Health, New York, NY, United States.'}, {'ForeName': 'Judith T', 'Initials': 'JT', 'LastName': 'Moskowitz', 'Affiliation': 'Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.'}, {'ForeName': 'Gina M', 'Initials': 'GM', 'LastName': 'Kackloudis', 'Affiliation': 'Happify Health, New York, NY, United States.'}, {'ForeName': 'Julia L', 'Initials': 'JL', 'LastName': 'Stafford', 'Affiliation': 'Happify Health, New York, NY, United States.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Kwok', 'Affiliation': 'Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.'}, {'ForeName': 'Acacia C', 'Initials': 'AC', 'LastName': 'Parks', 'Affiliation': 'Happify Health, New York, NY, United States.'}]",JMIR research protocols,['10.2196/18578'] 2293,32749999,Comparing Web-Based and Lab-Based Cognitive Assessment Using the Cambridge Neuropsychological Test Automated Battery: A Within-Subjects Counterbalanced Study.,"BACKGROUND Computerized assessments are already used to derive accurate and reliable measures of cognitive function. Web-based cognitive assessment could improve the accessibility and flexibility of research and clinical assessment, widen participation, and promote research recruitment while simultaneously reducing costs. However, differences in context may influence task performance. OBJECTIVE This study aims to determine the comparability of an unsupervised, web-based administration of the Cambridge Neuropsychological Test Automated Battery (CANTAB) against a typical in-person lab-based assessment, using a within-subjects counterbalanced design. The study aims to test (1) reliability, quantifying the relationship between measurements across settings using correlational approaches; (2) equivalence, the extent to which test results in different settings produce similar overall results; and (3) agreement, by quantifying acceptable limits to bias and differences between measurement environments. METHODS A total of 51 healthy adults (32 women and 19 men; mean age 36.8, SD 15.6 years) completed 2 testing sessions, which were completed on average 1 week apart (SD 4.5 days). Assessments included equivalent tests of emotion recognition (emotion recognition task [ERT]), visual recognition (pattern recognition memory [PRM]), episodic memory (paired associate learning [PAL]), working memory and spatial planning (spatial working memory [SWM] and one touch stockings of Cambridge), and sustained attention (rapid visual information processing [RVP]). Participants were randomly allocated to one of the two groups, either assessed in-person in the laboratory first (n=33) or with unsupervised web-based assessments on their personal computing systems first (n=18). Performance indices (errors, correct trials, and response sensitivity) and median reaction times were extracted. Intraclass and bivariate correlations examined intersetting reliability, linear mixed models and Bayesian paired sample t tests tested for equivalence, and Bland-Altman plots examined agreement. RESULTS Intraclass correlation (ICC) coefficients ranged from ρ=0.23-0.67, with high correlations in 3 performance indices (from PAL, SWM, and RVP tasks; ρ≥0.60). High ICC values were also seen for reaction time measures from 2 tasks (PRM and ERT tasks; ρ≥0.60). However, reaction times were slower during web-based assessments, which undermined both equivalence and agreement for reaction time measures. Performance indices did not differ between assessment settings and generally showed satisfactory agreement. CONCLUSIONS Our findings support the comparability of CANTAB performance indices (errors, correct trials, and response sensitivity) in unsupervised, web-based assessments with in-person and laboratory tests. Reaction times are not as easily translatable from in-person to web-based testing, likely due to variations in computer hardware. The results underline the importance of examining more than one index to ascertain comparability, as high correlations can present in the context of systematic differences, which are a product of differences between measurement environments. Further work is now needed to examine web-based assessments in clinical populations and in larger samples to improve sensitivity for detecting subtler differences between test settings.",2020,"However, reaction times were slower during web-based assessments, which undermined both equivalence and agreement for reaction time measures.","['51 healthy adults (32 women and 19 men; mean age 36.8, SD 15.6 years']","['Web-Based and Lab-Based Cognitive Assessment Using the Cambridge Neuropsychological Test Automated Battery', 'Cambridge Neuropsychological Test Automated Battery (CANTAB', 'assessed in-person in the laboratory first (n=33) or with unsupervised web-based assessments on their personal computing systems first']","['equivalent tests of emotion recognition (emotion recognition task [ERT]), visual recognition (pattern recognition memory [PRM]), episodic memory (paired associate learning [PAL]), working memory and spatial planning (spatial working memory [SWM] and one touch stockings of Cambridge), and sustained attention (rapid visual information processing [RVP', 'reaction times', 'Performance indices (errors, correct trials, and response sensitivity) and median reaction times', 'Performance indices']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C4505411', 'cui_str': 'CANTAB'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0205435', 'cui_str': 'First'}]","[{'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning'}, {'cui': 'C0152054', 'cui_str': 'Touch'}, {'cui': 'C0445269', 'cui_str': 'Socks'}, {'cui': 'C0589099', 'cui_str': 'Sustained attention'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0021420', 'cui_str': 'Information Processing'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",51.0,0.109663,"However, reaction times were slower during web-based assessments, which undermined both equivalence and agreement for reaction time measures.","[{'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Backx', 'Affiliation': 'Cambridge Cognition Ltd, Cambridge, United Kingdom.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Skirrow', 'Affiliation': 'Cambridge Cognition Ltd, Cambridge, United Kingdom.'}, {'ForeName': 'Pasquale', 'Initials': 'P', 'LastName': 'Dente', 'Affiliation': 'Cambridge Cognition Ltd, Cambridge, United Kingdom.'}, {'ForeName': 'Jennifer H', 'Initials': 'JH', 'LastName': 'Barnett', 'Affiliation': 'Cambridge Cognition Ltd, Cambridge, United Kingdom.'}, {'ForeName': 'Francesca K', 'Initials': 'FK', 'LastName': 'Cormack', 'Affiliation': 'Cambridge Cognition Ltd, Cambridge, United Kingdom.'}]",Journal of medical Internet research,['10.2196/16792'] 2294,32750063,Family nurture intervention in the NICU increases autonomic regulation in mothers and children at 4-5 years of age: Follow-up results from a randomized controlled trial.,"BACKGROUND Maturation of multiple neurobehavioral systems, including autonomic regulation, is altered by preterm birth. The purpose of this study was to determine the long-term effects of Family Nurture Intervention (FNI) in the NICU on autonomic regulation of preterm infants and their mothers. METHOD A subset of infants and mothers (48% of infants, 51% of mothers) randomly assigned to either standard are (SC), or SC plus the FNI in the NICU in a prior RCT (ClincalTrials.gov; NCT01439269) returned for follow-up assessments when the children were 4 to 5 years corrected age (CA). ECGs were collected for 10 minutes in mothers and their children while children were in their mothers' laps. Heart rate, standard deviation for heart rate, respiratory sinus arrhythmia (RSA)-an index of parasympathetic regulation, and a measure of vagal efficiency were quantified. RESULTS Both children and mothers in the FNI group had significantly greater levels of RSA compared to the SC group (child: mean difference = 0.60, 95% CI 0.17 to 1.03, p = 0.008; mother: mean difference = 0.64, 95% CI 0.07 to 1.21, p = 0.031). In addition, RSA increased more rapidly in FNI children between infancy and the 4 to 5-year follow-up time point (SC = +3.11±0.16 loge msec2, +3.67±0.19 loge msec2 for FNI, p<0.05). These results show that the rate of increase in RSA from infancy to childhood is more rapid in FNI subjects. CONCLUSION Although these preliminary follow-up results are based on approximately half of subjects originally enrolled in the RCT, they suggest that FNI-NICU led to healthier autonomic regulation in both mother and child, when measured during a brief face-to-face socioemotional interaction. A Pavlovian autonomic co-conditioning mechanism may underly these findings that can be exploited therapeutically.",2020,"Both children and mothers in the FNI group had significantly greater levels of RSA compared to the SC group (child: mean difference = 0.60, 95% CI 0.17 to 1.03, p = 0.008; mother: mean difference = 0.64, 95% CI 0.07 to 1.21, p = 0.031).","['mothers and children at 4-5 years of age', 'preterm infants and their mothers']","['RSA', 'Family nurture intervention', 'Family Nurture Intervention (FNI', 'NICU']","['Heart rate, standard deviation for heart rate, respiratory sinus arrhythmia (RSA)-an index of parasympathetic regulation, and a measure of vagal efficiency', 'autonomic regulation', 'levels of RSA', 'RSA']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}]","[{'cui': 'C0003813', 'cui_str': 'Sinus arrhythmia'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0003813', 'cui_str': 'Sinus arrhythmia'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.0640867,"Both children and mothers in the FNI group had significantly greater levels of RSA compared to the SC group (child: mean difference = 0.60, 95% CI 0.17 to 1.03, p = 0.008; mother: mean difference = 0.64, 95% CI 0.07 to 1.21, p = 0.031).","[{'ForeName': 'Martha G', 'Initials': 'MG', 'LastName': 'Welch', 'Affiliation': 'Department of Pediatrics, Columbia University Medical Center, New York, NY, United States of America.'}, {'ForeName': 'Joseph L', 'Initials': 'JL', 'LastName': 'Barone', 'Affiliation': 'Department of Pediatrics, Columbia University Medical Center, New York, NY, United States of America.'}, {'ForeName': 'Stephen W', 'Initials': 'SW', 'LastName': 'Porges', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.'}, {'ForeName': 'Amie A', 'Initials': 'AA', 'LastName': 'Hane', 'Affiliation': 'Department of Pediatrics, Columbia University Medical Center, New York, NY, United States of America.'}, {'ForeName': 'Katie Y', 'Initials': 'KY', 'LastName': 'Kwon', 'Affiliation': 'Department of Pediatrics, Columbia University Medical Center, New York, NY, United States of America.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Ludwig', 'Affiliation': 'Department of Pediatrics, Columbia University Medical Center, New York, NY, United States of America.'}, {'ForeName': 'Raymond I', 'Initials': 'RI', 'LastName': 'Stark', 'Affiliation': 'Department of Pediatrics, Columbia University Medical Center, New York, NY, United States of America.'}, {'ForeName': 'Amanda L', 'Initials': 'AL', 'LastName': 'Surman', 'Affiliation': 'Department of Pediatrics, Columbia University Medical Center, New York, NY, United States of America.'}, {'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Kolacz', 'Affiliation': 'Traumatic Stress Research Consortium, Kinsey Institute, Indiana University, Bloomington, IN, United States of America.'}, {'ForeName': 'Michael M', 'Initials': 'MM', 'LastName': 'Myers', 'Affiliation': 'Department of Pediatrics, Columbia University Medical Center, New York, NY, United States of America.'}]",PloS one,['10.1371/journal.pone.0236930'] 2295,32750143,Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy.,"BACKGROUND There is limited data regarding the impact of body mass index (BMI) on outcomes in advanced breast cancer (BC), especially in patients treated with endocrine therapy (ET) + CDK 4/6 inhibitors. METHODS Pooled analysis of individual patient-level data from MONARCH 2 and 3 trials. Patients were classified according to baseline BMI into underweight (<18.5 kg/m2), normal (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2) and obese (≥30 kg/m2) and divided into two treatment groups: abemaciclib + ET vs. placebo + ET. Primary endpoint was progression-free survival (PFS) according to BMI in each treatment group. Secondary endpoints were response rate (RR), adverse events (AEs) according to BMI, and loss of weight (≥5% from baseline) during treatment. RESULTS This analysis included 1,138 patients (757 received abemaciclib + ET and 381 placebo+ET). There was no difference in PFS between BMI categories in either groups, although normal weight patients presented a numerically higher benefit with abemaciclib + ET (interaction test p=.07). Normal/underweight patients presented higher overall RR in the abemaciclib + ET group compared to overweight/obese (49.4% vs 41.6%, OR = 0.73 95% CI = 0.54 to 0.99), as well as higher neutropenia frequency (51.0% vs 40.4%, p=.004). Weight loss was more frequent in the abemaciclib + ET group (OR = 3.23; 95% CI = 2.09 to5.01). CONCLUSIONS Adding abemaciclib to ET prolongs PFS regardless of BMI, showing that overweight/obese patients also benefit from this regimen. Our results elicit the possibility of a better effect of abemaciclib in normal/underweight patients compared to overweight/obese. More studies analyzing body composition parameters in patients under CDK 4/6 inhibitors may further clarify this hypothesis.",2020,"There was no difference in PFS between BMI categories in either groups, although normal weight patients presented a numerically higher benefit with abemaciclib + ET (interaction test p=.07).","['patients treated with endocrine therapy (ET) + CDK 4/6 inhibitors', 'Pooled analysis of individual patient-level data from MONARCH 2 and 3 trials', '1,138 patients (757 received abemaciclib + ET and 381 placebo+ET', 'advanced breast cancer (BC', 'metastatic breast cancer patients treated with', 'Patients were classified according to baseline BMI into underweight (<18.5\u2009kg/m2), normal (18.5-24.9\u2009kg/m2), overweight (25-29.9\u2009kg/m2) and obese (≥30\u2009kg/m2']","['abemaciclib + ET vs. placebo + ET', 'abemaciclib and endocrine therapy']","['Weight loss', 'PFS between BMI categories', 'neutropenia frequency', 'response rate (RR), adverse events (AEs) according to BMI, and loss of weight', 'progression-free survival (PFS', 'overall RR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0243045', 'cui_str': 'cdk Proteins'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0337051', 'cui_str': 'Pool'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C3852841', 'cui_str': 'abemaciclib'}, {'cui': 'C4708787', 'cui_str': '381'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C4517611', 'cui_str': '18.5'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C3852841', 'cui_str': 'abemaciclib'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",1138.0,0.0959562,"There was no difference in PFS between BMI categories in either groups, although normal weight patients presented a numerically higher benefit with abemaciclib + ET (interaction test p=.07).","[{'ForeName': 'Maria Alice', 'Initials': 'MA', 'LastName': 'Franzoi', 'Affiliation': ""Clinical Trials Support Unit, Institut Jules Bordet, and l'Université Libre de Bruxelles (U.L.B), Brussels, Belgium.""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Eiger', 'Affiliation': ""Clinical Trials Support Unit, Institut Jules Bordet, and l'Université Libre de Bruxelles (U.L.B), Brussels, Belgium.""}, {'ForeName': 'Lieveke', 'Initials': 'L', 'LastName': 'Ameye', 'Affiliation': ""Clinical Trials Support Unit, Institut Jules Bordet, and l'Université Libre de Bruxelles (U.L.B), Brussels, Belgium.""}, {'ForeName': 'Noam', 'Initials': 'N', 'LastName': 'Ponde', 'Affiliation': 'Oncology Department, AC Camargo Cancer Center, São Paulo, Brazil.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Caparica', 'Affiliation': ""Clinical Trials Support Unit, Institut Jules Bordet, and l'Université Libre de Bruxelles (U.L.B), Brussels, Belgium.""}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'De Angelis', 'Affiliation': ""Clinical Trials Support Unit, Institut Jules Bordet, and l'Université Libre de Bruxelles (U.L.B), Brussels, Belgium.""}, {'ForeName': 'Mariana', 'Initials': 'M', 'LastName': 'Brandão', 'Affiliation': ""Clinical Trials Support Unit, Institut Jules Bordet, and l'Université Libre de Bruxelles (U.L.B), Brussels, Belgium.""}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Desmedt', 'Affiliation': 'Oncology Department, AC Camargo Cancer Center, São Paulo, Brazil.'}, {'ForeName': 'Serena', 'Initials': 'S', 'LastName': 'Di Cosimo', 'Affiliation': 'Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'Kotecki', 'Affiliation': 'Oncology Department, Institut Jules Bordet, Brussels, Belgium.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Lambertini', 'Affiliation': 'University of Genova and IRCCS Ospedale Policlinico San Martino, Genova, Italy.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Awada', 'Affiliation': 'Oncology Department, Institut Jules Bordet, Brussels, Belgium.'}, {'ForeName': 'Martine', 'Initials': 'M', 'LastName': 'Piccart', 'Affiliation': 'Oncology Department, Institut Jules Bordet, Brussels, Belgium.'}, {'ForeName': 'Evandro', 'Initials': 'E', 'LastName': 'de Azambuja', 'Affiliation': ""Clinical Trials Support Unit, Institut Jules Bordet, and l'Université Libre de Bruxelles (U.L.B), Brussels, Belgium.""}]",Journal of the National Cancer Institute,['10.1093/jnci/djaa116'] 2296,32750174,A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder.,"BACKGROUND & AIMS Alcohol use disorder (AUD) is associated with microbial alterations that worsen with cirrhosis. Fecal microbiota transplant (FMT) could be a promising approach. APPROACH & RESULTS In this phase 1, double-blind, randomized clinical trial, AUD-related cirrhosis patients with problem drinking (AUDIT-10>8) were randomized 1:1 into receiving one placebo or FMT enema from a donor enriched in Lachnospiraceae and Ruminococcaceae. 6-month safety was the primary outcome. Alcohol craving questionnaire, alcohol consumption (urinary ethylglucuronide/creatinine, Etg), quality of life (QOL), cognition, serum IL-6 and lipopolysaccharide-binding protein (LBP), plasma/stool short-chain fatty acids (SCFA) and stool microbiota were tested at baseline and day 15. A 6-month follow-up with serious adverse events (SAE) analysis was performed. 20 patients with AUD-related cirrhosis [65±6.4 years, all men, MELD 8.9±2.7] with similar demographics, cirrhosis and AUD severity were included. Craving reduced significantly in 90% of FMT versus 30% in placebo at day15(p=0.02) with lower urinary Etg (p=0.03), improved cognition and psychosocial QOL. There was reduction in serum IL-6 and LBP and increased butyrate/isobutyrate compared to baseline in FMT but not placebo. Microbial diversity increased with higher Ruminococcaceae and other SCFA producing taxa post-FMT but not placebo, which were linked with SCFA levels. At 6 months, patients with any SAEs (8 vs 2, p=0.02), AUD-related SAEs (7 vs 1, p=0.02) and SAEs/patient [median(IQR),1.5(1.25) vs 0(0.25) in FMT,p=0.02] were higher in placebo versus FMT. CONCLUSIONS This phase 1 trial shows that FMT is safe and associated with short-term reduction in alcohol craving and consumption with favorable microbial changes versus placebo in patients with alcohol-related cirrhosis with alcohol misuse. There was also a reduction in AUD-related events over 6 months in patients assigned to FMT.",2020,There was reduction in serum IL-6,"['cirrhosis patients with problem drinking (AUDIT-10>8', 'patients with alcohol-related cirrhosis with alcohol misuse', '20 patients with AUD-related cirrhosis [65±6.4 years, all men, MELD 8.9±2.7] with similar demographics, cirrhosis and AUD severity were included']","['Fecal Microbiota Transplant', 'FMT', 'placebo or FMT enema from a donor enriched in Lachnospiraceae and Ruminococcaceae', 'Fecal microbiota transplant (FMT', 'placebo']","['AUD-related SAEs', 'Craving', 'cognition and psychosocial QOL', 'Microbial diversity', 'serum IL-6', 'Alcohol craving questionnaire, alcohol consumption (urinary ethylglucuronide/creatinine, Etg), quality of life (QOL), cognition, serum IL-6 and lipopolysaccharide-binding protein (LBP), plasma/stool short-chain fatty acids (SCFA) and stool microbiota', 'and LBP and increased butyrate/isobutyrate']","[{'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0450985', 'cui_str': 'Alcohol use disorders identification test'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C3826979', 'cui_str': 'Model for end-stage liver disease'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0014268', 'cui_str': 'Giving patient an enema'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C1210564', 'cui_str': 'Lachnospiraceae'}, {'cui': 'C2584567', 'cui_str': 'Ruminococcaceae'}]","[{'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0556385', 'cui_str': 'Craving for alcohol'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0298229', 'cui_str': 'Ethyl glucuronide'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0065054', 'cui_str': 'lipopolysaccharide-binding protein'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0015691', 'cui_str': 'Short chain fatty acid'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0006521', 'cui_str': 'Butyrates'}]",20.0,0.423902,There was reduction in serum IL-6,"[{'ForeName': 'Jasmohan S', 'Initials': 'JS', 'LastName': 'Bajaj', 'Affiliation': 'Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, United States.'}, {'ForeName': 'Edith A', 'Initials': 'EA', 'LastName': 'Gavis', 'Affiliation': 'Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, United States.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Fagan', 'Affiliation': 'Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, United States.'}, {'ForeName': 'James B', 'Initials': 'JB', 'LastName': 'Wade', 'Affiliation': 'Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, United States.'}, {'ForeName': 'Leroy R', 'Initials': 'LR', 'LastName': 'Thacker', 'Affiliation': 'Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, United States.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Fuchs', 'Affiliation': 'Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, United States.'}, {'ForeName': 'Samarth', 'Initials': 'S', 'LastName': 'Patel', 'Affiliation': 'Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, United States.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Davis', 'Affiliation': 'Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, United States.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Meador', 'Affiliation': 'Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, United States.'}, {'ForeName': 'Puneet', 'Initials': 'P', 'LastName': 'Puri', 'Affiliation': 'Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, United States.'}, {'ForeName': 'Masoumeh', 'Initials': 'M', 'LastName': 'Sikaroodi', 'Affiliation': 'Microbiome Analysis Center, George Mason University, Manassas, VA, United States.'}, {'ForeName': 'Patrick M', 'Initials': 'PM', 'LastName': 'Gillevet', 'Affiliation': 'Microbiome Analysis Center, George Mason University, Manassas, VA, United States.'}]","Hepatology (Baltimore, Md.)",['10.1002/hep.31496'] 2297,32750261,Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™) in premature infants.,"BACKGROUND Immune immaturity may put premature infants at increased risk for infections. DTaP-IPV-Hib-HepB vaccine (Vaxelis™), a hexavalent vaccine studied in >6,800 children, has acceptable safety and immunogenicity profiles generally similar to control vaccines. Here we evaluate safety and immunogenicity of DTaP-IPV-Hib-HepB vaccine in premature infants. METHODS Premature infants were identified using prior medical conditions terms ""premature baby/delivery"" and/or ""low birth weight baby"". Immunogenicity and safety data were summarized across one Phase II and four Phase III randomized, active-comparator-controlled clinical trials (Protocol 004 in Canada [Control: PENTACEL™]; Protocols 005 and 006 in the US [Control: PENTACEL™]; and Protocols 007 and 008 in the EU [Control: INFANRIX™ hexa]) and one Phase III clinical trial in the UK (PRI01C); no formal statistical comparisons were performed. RESULTS Overall, 160 infants were considered premature (DTaP-IPV-Hib-HepB = 111 Control = 49). The incidence of adverse events (AEs) for DTaP-IPV-Hib-HepB was comparable between overall and premature populations for all AEs days 1-15 postvaccination (Overall = 96.3%; Premature = 97.3%;), solicited injection-site AEs days 1-5 postvaccination (Overall = 84.1%; Premature = 75.5%), and solicited systemic AEs days 1-5 postvaccination (Overall = 93.7%; Premature = 94.5%). A high percentage of premature infants mounted protective immune responses to antigens contained in DTaP-IPV-Hib-HepB vaccine. Response rates in preterm infants for all antigens (80-99%) were in a similar range to all infants (80-99%) for both DTaP-IPV-Hib-HepB and control vaccines. CONCLUSIONS DTaP-IPV-Hib-HepB vaccine has a low incidence of AEs, an acceptable safety profile, and elicited satisfactory immune responses in premature infants comparable to the overall study population. These findings support vaccination with DTaP-IPV-Hib-HepB vaccine in healthy premature infants.",2020,A high percentage of premature infants mounted protective immune responses to antigens contained in DTaP-IPV-Hib-HepB vaccine.,"['160 infants were considered premature (DTaP-IPV-Hib-HepB = 111 Control = 49', 'healthy premature infants', 'premature infants', 'Premature infants', '6,800 children']","['DTaP-IPV-Hib-HepB vaccine', 'medical conditions terms ""premature baby/delivery"" and/or ""low birth weight baby', 'EU [Control: INFANRIX™ hexa', 'fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™', 'DTaP-IPV-Hib-HepB vaccine (Vaxelis™']","['Immunogenicity and safety data', 'Response rates', 'Safety and immunogenicity', 'incidence of adverse events (AEs) for DTaP-IPV-Hib-HepB']","[{'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C2716397', 'cui_str': 'diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C2716397', 'cui_str': 'diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C1963897', 'cui_str': 'Low birth weight baby'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0728745', 'cui_str': 'Infanrix'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C4506397', 'cui_str': 'Vaxelis'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2716397', 'cui_str': 'diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine'}]",160.0,0.0309447,A high percentage of premature infants mounted protective immune responses to antigens contained in DTaP-IPV-Hib-HepB vaccine.,"[{'ForeName': 'Marissa B', 'Initials': 'MB', 'LastName': 'Wilck', 'Affiliation': 'Merck & Co., Inc ., Kenilworth, NJ, USA.'}, {'ForeName': 'Z Jin', 'Initials': 'ZJ', 'LastName': 'Xu', 'Affiliation': 'Merck & Co., Inc ., Kenilworth, NJ, USA.'}, {'ForeName': 'Jon E', 'Initials': 'JE', 'LastName': 'Stek', 'Affiliation': 'Merck & Co., Inc ., Kenilworth, NJ, USA.'}, {'ForeName': 'Andrew W', 'Initials': 'AW', 'LastName': 'Lee', 'Affiliation': 'Merck & Co., Inc ., Kenilworth, NJ, USA.'}]",Human vaccines & immunotherapeutics,['10.1080/21645515.2020.1756668'] 2298,32750273,Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults.,"SeVRSV is a replication-competent Sendai virus (SeV)-based vaccine carrying the respiratory syncytial virus (RSV) fusion protein (F) gene. Unmanipulated, non-recombinant SeV is a murine parainfluenza virus type 1 (PIV-1) and serves as a Jennerian vaccine for human PIV-1 (hPIV-1). SeV protects African green monkeys (AGM) from infection after hPIV-1 challenge. The recombinant SeVRSV additionally targets RSV and protects AGM from lower respiratory infections after RSV challenge. The present study is the first to report on the safety, viral genome detection, and immunogenicity following SeVRSV vaccination of healthy adults. Seventeen and four healthy adults received intranasal SeVRSV and PBS, respectively, followed by six months of safety monitoring. Virus genome (in nasal wash) and vaccine-specific antibodies (in sera) were monitored for two and four weeks, respectively, post-vaccination. The vaccine was well-tolerated with only mild to moderate reactions that were also present in the placebo group. No severe reactions occurred. As expected, due to preexisting immunity toward hPIV-1 and RSV in adults, vaccine genome detection was transient. There were minimal antibody responses to SeV and negligible responses to RSV F. Results encourage further studies of SeVRSV with progression toward a clinical trial in seronegative children. ABBREVIATIONS AE-adverse event; SAE-serious adverse event; SeV-Sendai virus; RSV-respiratory syncytial virus; PIV-1-parainfluenza virus-type 1; hPIV-1-human parainfluenza virus-type 1; F-RSV fusion protein; SeVRSV-recombinant SeV carrying the RSV F gene; Ab-antibody; MSW-medically significant wheezing; NOCMC-new onset chronic medical condition, mITT-modified Intent to Treat; ALRI-acute lower respiratory tract infection.",2020,"There were minimal antibody responses to SeV and negligible responses to RSV F. Results encourage further studies of SeVRSV with progression toward a clinical trial in seronegative children. ","['human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults', 'human PIV-1', 'healthy adults', 'SeV protects African green monkeys (AGM) from infection after hPIV-1 challenge']","['Unmanipulated, non-recombinant SeV', 'intranasal SeVRSV and PBS', 'intranasal sendai virus-based vaccine', 'placebo']","['severe reactions', 'Safety and immunogenicity']","[{'cui': 'C1319861', 'cui_str': 'Human parainfluenza viruses'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0035236', 'cui_str': 'Syncytial Virus, Respiratory'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030390', 'cui_str': 'Human parainfluenza virus 1'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0036638', 'cui_str': 'Sendai virus'}, {'cui': 'C0026438', 'cui_str': 'Chlorocebus aethiops'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0036638', 'cui_str': 'Sendai virus'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0033770', 'cui_str': 'Prune belly syndrome'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",21.0,0.0332848,"There were minimal antibody responses to SeV and negligible responses to RSV F. Results encourage further studies of SeVRSV with progression toward a clinical trial in seronegative children. ","[{'ForeName': 'Felicia', 'Initials': 'F', 'LastName': 'Scaggs Huang', 'Affiliation': ""Department of Pediatrics, University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center , Cincinnati, OH, USA.""}, {'ForeName': 'David I', 'Initials': 'DI', 'LastName': 'Bernstein', 'Affiliation': ""Department of Pediatrics, University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center , Cincinnati, OH, USA.""}, {'ForeName': 'Karen S', 'Initials': 'KS', 'LastName': 'Slobod', 'Affiliation': ""Department of Infectious Diseases, Jude Children's Research Hospital , Memphis, TN, USA.""}, {'ForeName': 'Allen', 'Initials': 'A', 'LastName': 'Portner', 'Affiliation': ""Department of Infectious Diseases, Jude Children's Research Hospital , Memphis, TN, USA.""}, {'ForeName': 'Toru', 'Initials': 'T', 'LastName': 'Takimoto', 'Affiliation': ""Department of Infectious Diseases, Jude Children's Research Hospital , Memphis, TN, USA.""}, {'ForeName': 'Charles J', 'Initials': 'CJ', 'LastName': 'Russell', 'Affiliation': ""Department of Infectious Diseases, Jude Children's Research Hospital , Memphis, TN, USA.""}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Meagher', 'Affiliation': ""Children's GMP LLC , Memphis, TN, USA.""}, {'ForeName': 'Bart G', 'Initials': 'BG', 'LastName': 'Jones', 'Affiliation': ""Department of Infectious Diseases, Jude Children's Research Hospital , Memphis, TN, USA.""}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Sealy', 'Affiliation': ""Department of Infectious Diseases, Jude Children's Research Hospital , Memphis, TN, USA.""}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Coleclough', 'Affiliation': ""Department of Infectious Diseases, Jude Children's Research Hospital , Memphis, TN, USA.""}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Branum', 'Affiliation': ""Department of Infectious Diseases, Jude Children's Research Hospital , Memphis, TN, USA.""}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Dickey', 'Affiliation': ""Department of Pediatrics, University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center , Cincinnati, OH, USA.""}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Buschle', 'Affiliation': ""Department of Pediatrics, University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center , Cincinnati, OH, USA.""}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'McNeal', 'Affiliation': ""Department of Pediatrics, University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center , Cincinnati, OH, USA.""}, {'ForeName': 'Mat', 'Initials': 'M', 'LastName': 'Makowski', 'Affiliation': 'The Emmes Company , Rockville, MD, USA.'}, {'ForeName': 'Aya', 'Initials': 'A', 'LastName': 'Nakamura', 'Affiliation': 'The Emmes Company , Rockville, MD, USA.'}, {'ForeName': 'Julia L', 'Initials': 'JL', 'LastName': 'Hurwitz', 'Affiliation': ""Department of Infectious Diseases, Jude Children's Research Hospital , Memphis, TN, USA.""}]",Human vaccines & immunotherapeutics,['10.1080/21645515.2020.1779517'] 2299,32746956,Health literacy and caregiver understanding in the CHD population.,"BACKGROUND CHD is the most common birth defect type, with one-fourth of patients requiring intervention in the first year of life. Caregiver understanding of CHD may vary. Health literacy may be one factor contributing to this variability. METHODS The study occurred at a large, free-standing children's hospital. Recruitment occurred at a free-of-charge CHD camp and during outpatient cardiology follow-up visits. The study team revised the CHD Guided Questions Tool from an eighth- to a sixth-grade reading level. Caregivers of children with CHD completed the ""Newest Vital Sign"" health literacy screen and demographic surveys. Health literacy was categorised as ""high"" (Newest Vital Sign score 4-6) or ""low"" (score 0-3). Caregivers were randomised to read either the original or revised Guided Questions Tool and completed a validated survey measuring understandability and actionability of the Guided Questions Tool. Understandability and actionability data analysis used two-sample t-testing, and within demographic group differences in these parameters were assessed via one-way analysis of variance. RESULTS Eighty-two caregivers participated who were largely well educated with a high income. The majority (79.3%) of participants scored ""high"" for health literacy. No differences in understanding (p = 0.43) or actionability (p = 0.11) of the original and revised Guided Questions Tool were noted. There were no socio-economic-based differences in understandability or actionability (p > 0.05). There was a trend towards improved understanding of the revised tool (p = 0.06). CONCLUSIONS This study demonstrated that readability of the Guided Questions Tool could be improved. Future work is needed to expand the study population and further understand health literacy's impact on the CHD community.",2020,No differences in understanding (p = 0.43) or actionability (p = 0.11) of the original and revised Guided Questions Tool were noted.,"['Eighty-two caregivers participated who were largely well educated with a high income', 'Caregivers of children with CHD completed the ""Newest Vital Sign"" health literacy screen and demographic surveys']",[],"['Health literacy', 'understandability or actionability']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0524327', 'cui_str': 'Well educated'}, {'cui': 'C0948433', 'cui_str': 'High income'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0011296', 'cui_str': 'Demographic Survey'}]",[],"[{'cui': 'C2362527', 'cui_str': 'Health Literacy'}]",82.0,0.0751818,No differences in understanding (p = 0.43) or actionability (p = 0.11) of the original and revised Guided Questions Tool were noted.,"[{'ForeName': 'Megan E', 'Initials': 'ME', 'LastName': 'Rodts', 'Affiliation': ""Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Ndidi I', 'Initials': 'NI', 'LastName': 'Unaka', 'Affiliation': ""Division of Hospital Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Statile', 'Affiliation': 'Department of Pediatrics, University of Cincinnati College Of Medicine, Cincinnati, OH, USA.'}, {'ForeName': 'Nicolas L', 'Initials': 'NL', 'LastName': 'Madsen', 'Affiliation': 'Department of Pediatrics, University of Cincinnati College Of Medicine, Cincinnati, OH, USA.'}]",Cardiology in the young,['10.1017/S1047951120002243'] 2300,32747013,Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.,"OBJECTIVE To examine whether blocking multiple points of the angiogenesis pathway by addition of sorafenib, a multi-kinase inhibitor against VEGFR2/3, Raf, c-Kit, and PDGFR, to bevacizumab would yield clinical activity in ovarian cancer (OvCa). METHODS This phase II study tested bevacizumab plus sorafenib in two cohorts; bevacizumab-naïve and bevacizumab-exposed patients. Bevacizumab (5 mg/kg IV every 2 weeks) was given with sorafenib 200 mg bid 5 days-on/2 days-off. The primary objective was response rate using a Simon two-stage optimal design. Progression-free survival (PFS) and toxicity were the secondary endpoints. Exploratory correlative studies included plasma cytokine concentrations, tissue proteomics and dynamic contrast-enhanced-magnetic resonance imaging (DCE-MRI). RESULTS Between March 2007 and August 2012, 54 women were enrolled, 41 bevacizumab-naive and 13 bevacizumab-prior, with median 5 (2-9) and 6 (5-9) prior systemic therapies, respectively. Nine of 35 (26%) evaluable bevacizumab-naive patients attained partial responses (PR), and 18 had stable disease (SD) ≥ 4 months. No responses were seen in the bevacizumab-prior group and 7 (54%) patients had SD ≥ 4 months, including one exceptional responder with SD of 27 months. The overall median PFS was 5.5 months (95%CI: 4.0-6.8 months). Treatment-related grade 3/4 adverse events (≥5%) included hypertension (17/54 [31%]; grade 3 in 16 patients and grade 4 in one patient) and venous thrombosis or pulmonary embolism (5/54 [9%]; grade 3 in 4 patients and grade 4 in one patient). Pretreatment low IL8 concentration was associated with PFS ≥ 4 months (p = .031). CONCLUSIONS The bevacizumab and sorafenib combination did not meet the pre-specified primary endpoint although some clinical activity was seen in heavily-pretreated bevacizumab-naive OvCa patients with platinum-resistant disease. Anticipated class toxicities required close monitoring and dose modifications.",2020,The overall median PFS was 5.5 months (95%CI: 4.0-6.8 months).,"['recurrent ovarian cancer patients with or without prior-bevacizumab treatment', '54 women were enrolled', 'naive patients attained partial responses (PR), and 18 had stable disease (SD)\xa0≥\xa04\xa0months', 'ovarian cancer (OvCa', 'exposed patients', 'Between March 2007 and August 2012']","['sorafenib', 'Bevacizumab', 'bevacizumab and sorafenib', 'sorafenib 200\xa0mg bid 5\xa0days-on/2\xa0days-off', 'bevacizumab', 'bevacizumab plus sorafenib', '41 bevacizumab-naive and 13 bevacizumab', 'bevacizumab-naïve and bevacizumab']","['Pretreatment low IL8 concentration', 'plasma cytokine concentrations, tissue proteomics and dynamic contrast-enhanced-magnetic resonance imaging (DCE-MRI', 'venous thrombosis or pulmonary embolism', 'overall median PFS', 'clinical activity', 'Progression-free survival (PFS) and toxicity', 'response rate', 'grade 3/4 adverse events', 'hypertension']","[{'cui': 'C0278689', 'cui_str': 'Recurrent ovarian cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0919267', 'cui_str': 'Neoplasm of ovary'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C1516119', 'cui_str': 'sorafenib'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C1677790', 'cui_str': 'sorafenib 200 MG'}, {'cui': 'C0048106', 'cui_str': ""4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate""}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0872252', 'cui_str': 'Proteomics'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0042487', 'cui_str': 'Venous thrombosis'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0442757', 'cui_str': '3/4'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]",54.0,0.0516204,The overall median PFS was 5.5 months (95%CI: 4.0-6.8 months).,"[{'ForeName': 'Jung-Min', 'Initials': 'JM', 'LastName': 'Lee', 'Affiliation': ""Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, United States of America. Electronic address: leej6@mail.nih.gov.""}, {'ForeName': 'Christina M', 'Initials': 'CM', 'LastName': 'Annunziata', 'Affiliation': ""Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, United States of America.""}, {'ForeName': 'John L', 'Initials': 'JL', 'LastName': 'Hays', 'Affiliation': 'Division of Medical Oncology, The Ohio State University James Comprehensive Cancer Center, Columbus, OH, United States of America.'}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Cao', 'Affiliation': 'Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Choyke', 'Affiliation': 'Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.'}, {'ForeName': 'Minshu', 'Initials': 'M', 'LastName': 'Yu', 'Affiliation': ""Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, United States of America.""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'An', 'Affiliation': ""Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, United States of America.""}, {'ForeName': 'Ismail Baris', 'Initials': 'IB', 'LastName': 'Turkbey', 'Affiliation': 'Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.'}, {'ForeName': 'Lori M', 'Initials': 'LM', 'LastName': 'Minasian', 'Affiliation': ""Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, United States of America.""}, {'ForeName': 'Seth M', 'Initials': 'SM', 'LastName': 'Steinberg', 'Affiliation': 'Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, United States of America.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Wright', 'Affiliation': 'Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, United States of America.'}, {'ForeName': 'Elise C', 'Initials': 'EC', 'LastName': 'Kohn', 'Affiliation': ""Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, United States of America.""}]",Gynecologic oncology,['10.1016/j.ygyno.2020.07.031'] 2301,32747208,The impact of a tailored follow-up intervention on comprehensive geriatric assessment in older patients with cancer - a randomised controlled trial.,"PURPOSE Comprehensive Geriatric Assessment (CGA) can identify health problems in older persons. In addition, CGA includes intervention towards the identified problems. With follow up, more problems may be identified and the interventions can be adjusted. We wanted to compare CGA with or without tailored follow-up in a randomised design. PATIENTS AND METHODS Patients 70+ years referred for oncology treatment with four primary tumour sites. Participants were randomised 1:1 to either control group with no follow-up or intervention group with a tailored follow-up by a multidisciplinary team. Primary outcome was adherence to cancer treatment. Secondary outcomes were daily life activities, physical performance and hospitalisation. RESULTS In total, 363 participants were randomised. After randomisation only 301 were planned to receive specific cancer treatment. Median age was 75 years. Among the 301 participants, 52% of control group vs. 61% of intervention group completed treatment. Risk Rate (RR): 1.16 (95% Confidence Interval (CI): 0.95-1.42), p = .14. The impact varied between the included tumour-sites, p < .01. We found no difference in 90 days physical performance or daily life activities between groups. During the study period, 55% of controls vs. 47% in the intervention group were admitted to hospital, RR: 0.86 (95%CI: 0.69-1.07), p = .19. CONCLUSION In frail and vulnerable patients with cancer, a tailored follow-up on CGA showed no differences in ability to complete initially planned cancer treatment. The impact varied between the included tumour sites. We did not find any impact of tailored follow-up on daily life activities, physical performance or hospitalisation.",2020,"Risk Rate (RR): 1.16 (95% Confidence Interval (CI): 0.95-1.42), p = .14.","['older patients with cancer ', 'frail and vulnerable patients with cancer', '363 participants were randomised', 'Median age was 75\u202fyears', 'older persons', 'Patients 70+ years referred for oncology treatment with four primary tumour sites']","['control group with no follow-up or intervention group with a tailored follow-up by a multidisciplinary team', 'CGA', 'tailored follow-up intervention', 'Comprehensive Geriatric Assessment (CGA']","['90\u202fdays physical performance or daily life activities', 'adherence to cancer treatment', 'daily life activities, physical performance or hospitalisation', 'Risk Rate (RR', 'daily life activities, physical performance and hospitalisation']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0475447', 'cui_str': 'Primary tumor site'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0017463', 'cui_str': 'Geriatric screening'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",363.0,0.122336,"Risk Rate (RR): 1.16 (95% Confidence Interval (CI): 0.95-1.42), p = .14.","[{'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Ørum', 'Affiliation': 'Department of Geriatric Medicine, Aarhus University, Denmark. Electronic address: maroer@rm.dk.'}, {'ForeName': 'Stine Vestergaard', 'Initials': 'SV', 'LastName': 'Eriksen', 'Affiliation': 'Department of Oncology, Aarhus University, Denmark. Electronic address: stieri@rm.dk.'}, {'ForeName': 'Merete', 'Initials': 'M', 'LastName': 'Gregersen', 'Affiliation': 'Department of Geriatric Medicine, Aarhus University, Denmark. Electronic address: meregreg@rm.dk.'}, {'ForeName': 'Anni Ravnsbæk', 'Initials': 'AR', 'LastName': 'Jensen', 'Affiliation': 'Department of Oncology, Aarhus University, Denmark. Electronic address: anni.ravnsbaek@auh.rm.dk.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Jensen', 'Affiliation': 'Danish Center for Particle Therapy, Aarhus University, Denmark; Aarhus University, Denmark. Electronic address: Kenneth.Jensen@auh.rm.dk.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Meldgaard', 'Affiliation': 'Department of Oncology, Aarhus University, Denmark; Aarhus University, Denmark. Electronic address: petemeld@rm.dk.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Nordsmark', 'Affiliation': 'Department of Oncology, Aarhus University, Denmark; Aarhus University, Denmark. Electronic address: marianne.nordsmark@rm.dk.'}, {'ForeName': 'Else Marie', 'Initials': 'EM', 'LastName': 'Damsgaard', 'Affiliation': 'Department of Geriatric Medicine, Aarhus University, Denmark; Aarhus University, Denmark. Electronic address: elsedams@rm.dk.'}]",Journal of geriatric oncology,['10.1016/j.jgo.2020.07.011'] 2302,32747213,"Efficacy and safety of a live attenuated influenza vaccine in Chinese healthy children aged 3-17 years in one study center of a randomized, double-blind, placebo-controlled phase 3 clinical trial, 2016/17 season.","BACKGROUND No data on the safety and efficacy of a live attenuated influenza vaccine in China have ever been reported. METHODS At a site of a phase 3 randomized, double-blind, placebo-controlled clinical trial in eastern China, eligible healthy children aged 3-17 years underwent randomization to receive live attenuated vaccine or placebo at a ratio of 1:1. The primary objective of the study was the prevention of laboratory-confirmed influenza illness during the surveillance period, starting on day 15 after vaccination. RESULTS A total of 2000 participants were enrolled, with 998 receiving the vaccine and 1001 receiving placebo. Sixty-four cases of influenza-like illness were observed, of which, 44 were laboratory-confirmed (12 in vaccine group versus 32 in placebo group). Vaccine efficacy was 62.5% (95%CI: 27.6-80.6) against all types of influenza and 63.3% (95%CI: 27.5-81.5) against influenza H3N2 illness. 11 severe adverse events reported (7 in LAIV group versus 4 in placebo group) were all deemed to be non-vaccine-related. Adverse events occurred in 412 (41.3%) participants in the vaccine group versus 389 (38.9%; p = 0.274) participants in the placebo group. Significant increase incidence of fever was observed in participants in the vaccine group, especially in those aged 3-9 years. CONCLUSIONS The live attenuated influenza vaccine showed good efficacy and safety among 3- to 17-year-olds children during the 2016-2017 season at a site in eastern China. Clinical Trial Registry Number: NCT02964065.",2020,Vaccine efficacy was 62.5% (95%CI: 27.6-80.6) against all types of influenza and 63.3% (95%CI: 27.5-81.5) against influenza H3N2 illness.,"['17-year-olds children during the 2016-2017 season at a site in eastern China', 'eastern China, eligible healthy children aged 3-17\xa0years underwent randomization to receive', 'Chinese healthy children aged 3-17\xa0years', '2000 participants were enrolled, with 998 receiving the vaccine and 1001 receiving']","['placebo', 'live attenuated vaccine or placebo', 'live attenuated influenza vaccine']","['11 severe adverse events', 'Adverse events', 'Vaccine efficacy', 'Efficacy and safety', 'efficacy and safety', 'incidence of fever']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C3652556', 'cui_str': 'influenza, live attenuated'}]","[{'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0015967', 'cui_str': 'Fever'}]",2000.0,0.738288,Vaccine efficacy was 62.5% (95%CI: 27.6-80.6) against all types of influenza and 63.3% (95%CI: 27.5-81.5) against influenza H3N2 illness.,"[{'ForeName': 'Shenyu', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, Zhejiang Province, China. Electronic address: sywang@cdc.zj.cn.'}, {'ForeName': 'Yihong', 'Initials': 'Y', 'LastName': 'Zheng', 'Affiliation': ""Chun'an County Center for Disease Control and Prevention, Hangzhou 311700, Zhejiang Province, China. Electronic address: 411035637@qq.com.""}, {'ForeName': 'Xiongyuan', 'Initials': 'X', 'LastName': 'Jin', 'Affiliation': 'Changchun BCHT Biotechnology Co., Changchun 130012, Jilin Province, China. Electronic address: jinxiongyuan@bchtpharm.com.'}, {'ForeName': 'Zhengkai', 'Initials': 'Z', 'LastName': 'Gan', 'Affiliation': 'Xiuzhou District Center for Disease Control and Prevention, Jiaxing 314031, Zhejiang Province, China; Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, Zhejiang Province, China. Electronic address: ganzhengkai@163.com.'}, {'ForeName': 'Yanzhi', 'Initials': 'Y', 'LastName': 'Shao', 'Affiliation': ""Chun'an County Center for Disease Control and Prevention, Hangzhou 311700, Zhejiang Province, China. Electronic address: 39630267@qq.com.""}, {'ForeName': 'Changlin', 'Initials': 'C', 'LastName': 'Zhu', 'Affiliation': 'Changchun BCHT Biotechnology Co., Changchun 130012, Jilin Province, China. Electronic address: zhuchanglin@bchtpharm.com.'}, {'ForeName': 'Xiaosong', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, Zhejiang Province, China. Electronic address: xshu@cdc.zj.cn.'}, {'ForeName': 'Zhenzhen', 'Initials': 'Z', 'LastName': 'Liang', 'Affiliation': 'Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, Zhejiang Province, China. Electronic address: zzliang@cdc.zj.cn.'}, {'ForeName': 'Yingping', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, Zhejiang Province, China. Electronic address: yingpchen@cdc.zj.cn.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Xing', 'Affiliation': 'Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, Zhejiang Province, China. Electronic address: bxing@cdc.zj.cn.'}, {'ForeName': 'Huakun', 'Initials': 'H', 'LastName': 'Lv', 'Affiliation': 'Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, Zhejiang Province, China. Electronic address: hklv@cdc.zj.cn.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Xu', 'Affiliation': 'Changchun BCHT Biotechnology Co., Changchun 130012, Jilin Province, China. Electronic address: xuna@bchtpharm.com.'}]",Vaccine,['10.1016/j.vaccine.2020.07.019'] 2303,32747216,"Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China.","BACKGROUND The immunogenicity and safety of the sequential schedule of Sabin strain-based inactivated poliovirus vaccine (sIPV) and bivalent oral poliovirus vaccine (bOPV) remains poorly understood in Chinese population. METHODS A multi-center, open-label, randomized controlled trial was performed involving 648 healthy infants aged 2 months from Inner Mongolia, Shanxi, and Hebei provinces. These participants were divided into three groups: sIPV-bOPV-bOPV, sIPV-sIPV-bOPV, and sIPV-sIPV-sIPV. Doses were administered sequentially at age 2, 3, and 4 months. Neutralisation assays were tested using sera collected at 2 months and 5 months. RESULTS A total of 569 were included in the per-protocol analysis. The seroconversion rates of poliovirus type 1 and 3 were 100% in all three groups, the seroconversion rate of poliovirus type 2 was 91.53% (173/189) (95% CI: 86.62-95.08) in the sIPV-bOPV-bOPV group, 98.38% (182/185) (95% CI: 95.33-99.66) in the sIPV-sIPV-bOPV group, and 99.49% (194/195) (95% CI: 97.18-99.99) in the sIPV-sIPV-sIPV group. For the seroconversion rate of poliovirus types 1 and 3, the sIPV-bOPV-bOPV and sIPV-sIPV-bOPV groups were non-inferior to the sIPV-sIPV-sIPV group. For the seroconversion rate of poliovirus type 2, the sIPV-sIPV-bOPV group was non-inferior to the sIPV-sIPV-sIPV group, and the sIPV-bOPV-bOPV group was inferior to the sIPV-sIPV-sIPV group. All three groups exhibited good safety, with two serious adverse events reported, that were unrelated to vaccine. CONCLUSIONS In china, a new vaccination schedule that including 2 doses of IPV in the national immunization programs is essential. Trial registration ClinicalTrials.govNCT04054492.",2020,"The seroconversion rates of poliovirus type 1 and 3 were 100% in all three groups, the seroconversion rate of poliovirus type 2 was 91.53% (173/189) (95% CI: 86.62-95.08) in the sIPV-bOPV-bOPV group, 98.38% (182/185) (95% CI: 95.33-99.66) in the sIPV-sIPV-bOPV group, and 99.49% (194/195) (95% CI: 97.18-99.99) in the sIPV-sIPV-sIPV group.","['A total of 569 were included in the per-protocol analysis', 'Chinese population', '648 healthy infants aged 2\xa0months from Inner Mongolia, Shanxi, and Hebei provinces']","['Sabin strain-based inactivated poliovirus vaccine (sIPV) and bivalent oral poliovirus vaccine (bOPV', 'Sabin strain-based inactivated poliovirus vaccination', 'sIPV-bOPV-bOPV, sIPV-sIPV-bOPV, and sIPV-sIPV-sIPV']","['Immunogenicity and safety', 'seroconversion rates of poliovirus type', 'seroconversion rate of poliovirus type 2']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0021515', 'cui_str': 'Inner Mongolia'}]","[{'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0036106', 'cui_str': 'Salk Vaccine'}, {'cui': 'C0032375', 'cui_str': 'Sabin Vaccine'}, {'cui': 'C0206435', 'cui_str': 'Human poliovirus'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0206435', 'cui_str': 'Human poliovirus'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0206433', 'cui_str': 'Human poliovirus 2'}]",648.0,0.0778758,"The seroconversion rates of poliovirus type 1 and 3 were 100% in all three groups, the seroconversion rate of poliovirus type 2 was 91.53% (173/189) (95% CI: 86.62-95.08) in the sIPV-bOPV-bOPV group, 98.38% (182/185) (95% CI: 95.33-99.66) in the sIPV-sIPV-bOPV group, and 99.49% (194/195) (95% CI: 97.18-99.99) in the sIPV-sIPV-sIPV group.","[{'ForeName': 'Shaohong', 'Initials': 'S', 'LastName': 'Yan', 'Affiliation': 'Inner Mongolia Autonomous Region Disease Prevention and Control Center, Huhhot, China.'}, {'ForeName': 'Haiping', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'China National Biotec Group Company Limited, Beijing, China.'}, {'ForeName': 'Zhenguo', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, China.'}, {'ForeName': 'Shaoying', 'Initials': 'S', 'LastName': 'Chang', 'Affiliation': 'Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China.'}, {'ForeName': 'Yanhui', 'Initials': 'Y', 'LastName': 'Xiao', 'Affiliation': 'China National Biotec Group Company Limited, Beijing, China.'}, {'ForeName': 'Linyun', 'Initials': 'L', 'LastName': 'Luo', 'Affiliation': 'China National Biotec Group Company Limited, Beijing, China.'}, {'ForeName': 'Zhaoyong', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Inner Mongolia Autonomous Region Disease Prevention and Control Center, Huhhot, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Sun', 'Affiliation': 'Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China.'}, {'ForeName': 'Yunkai', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Beijing Institute of Biological Products Company Limited, Beijing, China.'}, {'ForeName': 'Xuanwen', 'Initials': 'X', 'LastName': 'Shi', 'Affiliation': 'China National Biotec Group Company Limited, Beijing, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'Inner Mongolia Autonomous Region Disease Prevention and Control Center, Huhhot, China.'}, {'ForeName': 'Yunlong', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': 'Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'Beijing Institute of Biological Products Company Limited, Beijing, China.'}, {'ForeName': 'Shasha', 'Initials': 'S', 'LastName': 'Han', 'Affiliation': 'China National Biotec Group Company Limited, Beijing, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Ma', 'Affiliation': 'Beijing Institute of Biological Products Company Limited, Beijing, China.'}, {'ForeName': 'Xiaoming', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'China National Biotec Group Company Limited, Beijing, China. Electronic address: yangxiaoming@sinopharm.com.'}]",Vaccine,['10.1016/j.vaccine.2020.07.042'] 2304,32747302,Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.,"BACKGROUND Maintenance treatments with fluoropyrimidine alone or combined with bevacizumab after induction chemotherapy are two standard options in first-line metastatic colorectal cancer (mCRC). However, no trial has compared these two maintenance regimens. METHODS BEVAMAINT is a multicenter, open-label, randomized phase III trial comparing fluoropyrimidine alone or plus bevacizumab as maintenance treatment after induction polychemotherapy in mCRC. The primary endpoint is the time-to-treatment failure (TTF), calculated from date of randomization to first radiological progression, death, start of a new chemotherapy regimen (different from induction or maintenance chemotherapy) or end of maintenance treatment without introduction of further chemotherapy. We expect a 2-month TTF improvement from 6 months in the monotherapy arm to 8 months in the combination arm (hazard ratio [HR], 0.75). Based on a two-sided α risk of 5% and a power of 80%, using Schoenfeld method, 379 events are required (planned enrolment, 400 patients). Patients with mCRC, whose disease is measurable according to RECIST 1.1 criteria and controlled (objective response or stable disease) - but remains unresectable - after 4 to 6 months of induction polychemotherapy (doublet or triplet chemotherapy with or without anti-EGFR or bevacizumab), and who have recovered from limiting adverse events of induction polychemotherapy are eligible for randomization. Randomization is stratified according to center, response to induction chemotherapy (objective response vs stable disease), ECOG performance status (0-1 vs 2), maintenance fluoropyrimidine (5-fluorouracil vs capecitabine) and primary tumor status (resected vs not). Capecitabine or bolus and infusional 5-fluorouracil plus folinic acid (simplified LV5FU2 regimen) are both accepted for maintenance chemotherapy, at investigator's discretion. Clinical evaluation, tumor imaging, carcinoembryonic antigen and circulating tumor DNA dosages are planned at enrolment and every 9 weeks. The maintenance treatment will be discontinued in the event of unbearable toxicity, progression or patient refusal. After maintenance discontinuation, reintroduction of induction polychemotherapy is recommended; otherwise a second-line treatment is started. The enrolment has begun in January 2020.",2020,"Randomization is stratified according to center, response to induction chemotherapy (objective response vs stable disease), ECOG performance status (0-1 vs 2), maintenance fluoropyrimidine (5-fluorouracil vs capecitabine) and primary tumor status (resected vs not).","['first-line metastatic colorectal cancer (mCRC', 'metastatic colorectal cancer']","['fluoropyrimidine (5-fluorouracil vs capecitabine', 'fluoropyrimidine plus bevacizumab', 'Capecitabine or bolus and infusional 5-fluorouracil plus folinic acid (simplified LV5FU2 regimen', 'fluoropyrimidine alone or plus bevacizumab', 'fluoropyrimidine alone', 'induction polychemotherapy (doublet or triplet chemotherapy with or without anti-EGFR or bevacizumab', 'fluoropyrimidine alone or combined with bevacizumab']","['time-to-treatment failure (TTF), calculated from date of randomization to first radiological progression, death, start of a new chemotherapy regimen (different from induction or maintenance chemotherapy) or end of maintenance treatment without introduction of further chemotherapy']","[{'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}]","[{'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0013218', 'cui_str': 'Combination Drug Therapy'}, {'cui': 'C0041095', 'cui_str': 'Triplets'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C3494202', 'cui_str': 'Time to Treatment'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0011008', 'cui_str': 'Date'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0392920', 'cui_str': 'Antineoplastic chemotherapy regimen'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0481504', 'cui_str': 'Maintenance Chemotherapy'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",,0.0301699,"Randomization is stratified according to center, response to induction chemotherapy (objective response vs stable disease), ECOG performance status (0-1 vs 2), maintenance fluoropyrimidine (5-fluorouracil vs capecitabine) and primary tumor status (resected vs not).","[{'ForeName': 'Manfredi', 'Initials': 'M', 'LastName': 'Sylvain', 'Affiliation': 'University of Bourgogne Franche-Comté, INSERM U123-1, university hospital Dijon, Gastroenterology unit, 14 rue Paul Gaffarel, 21000 Dijon, France. Electronic address: Sylvain.manfredi@chu-dijon.fr.'}, {'ForeName': 'Turpin', 'Initials': 'T', 'LastName': 'Anthony', 'Affiliation': 'University hospital Claude Hurriez, CHR Lille, France.'}, {'ForeName': 'Malka', 'Initials': 'M', 'LastName': 'David', 'Affiliation': 'Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Barbier', 'Initials': 'B', 'LastName': 'Emilie', 'Affiliation': 'CRGA FFCD, university of Bourgogne Franche-Comté, INSERM U123-1, Dijon, France.'}, {'ForeName': 'Laurent-Puig', 'Initials': 'LP', 'LastName': 'Pierre', 'Affiliation': 'Hôpital Européen Georges-Pompidou HEGP, AP-HP, University Paris Descartes, Paris, France.'}, {'ForeName': 'Zaanan', 'Initials': 'Z', 'LastName': 'Aziz', 'Affiliation': 'Hôpital Européen Georges-Pompidou HEGP, AP-HP, University Paris Descartes, Paris, France.'}, {'ForeName': 'Dahan', 'Initials': 'D', 'LastName': 'Laeticia', 'Affiliation': 'University hospital la Timone, APHM, Marseille, France.'}, {'ForeName': 'Lièvre', 'Initials': 'L', 'LastName': 'Astrid', 'Affiliation': 'University hospital Rennes, France.'}, {'ForeName': 'Phelip', 'Initials': 'P', 'LastName': 'Jean-Marc', 'Affiliation': 'University hospital Saint Etienne, France.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Pierre', 'Affiliation': 'University hospital Rouen, France.'}, {'ForeName': 'Hautefeuille', 'Initials': 'H', 'LastName': 'Vincent', 'Affiliation': 'University hospital Amiens, France.'}, {'ForeName': 'Legoux', 'Initials': 'L', 'LastName': 'Jean-Louis', 'Affiliation': 'General hospital Orléans, France.'}, {'ForeName': 'Lepage', 'Initials': 'L', 'LastName': 'Côme', 'Affiliation': 'University of Bourgogne Franche-Comté, INSERM U123-1, university hospital Dijon, France.'}, {'ForeName': 'Tougeron', 'Initials': 'T', 'LastName': 'David', 'Affiliation': 'University hospital Poitiers, France.'}, {'ForeName': 'Aparicio', 'Initials': 'A', 'LastName': 'Thomas', 'Affiliation': 'University hospital Saint Louis, APHP, Paris, France.'}]",Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,['10.1016/j.dld.2020.06.034'] 2305,32747497,B-type natriuretic peptide and cardiac remodelling after myocardial infarction: a randomised trial.,"OBJECTIVE B-type natriuretic peptide (BNP) has favourable effects on left ventricular remodelling, including antifibrotic and antiapoptotic properties. We tested the hypothesis that infusion of BNP after an acute myocardial infarction would reduce left ventricular systolic and diastolic volumes and improve left ventricular ejection fraction compared with placebo. METHODS A total of 58 patients who underwent successful revascularisation for an acute ST elevation anterior myocardial infarction were randomised to receive 72-hour infusion of BNP at 0.006 µg/kg/min or placebo. Left ventricular end diastolic and systolic volumes and left ventricular ejection fraction were measured at baseline and at 30 days by multigated acquisition scan. Left ventricular infarction size was measured by cardiac MRI. RESULTS BNP infusion led to significantly higher BNP levels and plasma cyclic guanosine monophosphate at 72 hours. No significant difference in change of left ventricular volumes or ejection fraction from baseline to 30 days was observed between groups. Although left ventricular infarction size measured by cardiac MRI was not significantly different between BNP infusion versus placebo (p=0.39), there was a trend towards reduced infarction size in patients with a baseline ejection fraction of <40% (p=0.14). CONCLUSIONS Infusion of BNP in patients with an anterior myocardial infarction did not affect parameters of left ventricular remodelling. Patients treated with BNP who had a baseline left ventricular ejection fraction of <40% had a trend towards reduced left ventricular infarction size compared with placebo. These results do not support the use of intravenous BNP in patients after recent myocardial infarction. TRIAL REGISTRATION NUMBER NCT00573144.",2020,"RESULTS BNP infusion led to significantly higher BNP levels and plasma cyclic guanosine monophosphate at 72 hours.","['myocardial infarction', 'patients with an anterior myocardial infarction', '58 patients who underwent successful revascularisation for an acute ST elevation anterior myocardial infarction']","['BNP infusion versus placebo', 'intravenous BNP', 'BNP', 'placebo']","['BNP levels and plasma cyclic guanosine monophosphate', 'baseline left ventricular ejection fraction', 'infarction size', 'Left ventricular infarction size', 'left ventricular infarction size', 'left ventricular infarction size measured by cardiac MRI', 'change of left ventricular volumes or ejection fraction', 'left ventricular systolic and diastolic volumes and improve left ventricular ejection fraction', 'Left ventricular end diastolic and systolic volumes and left ventricular ejection fraction']","[{'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0340293', 'cui_str': 'Myocardial Infarction, Anterior Wall'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0520886', 'cui_str': 'ST segment elevation'}]","[{'cui': 'C0054015', 'cui_str': 'Nesiritide'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0054015', 'cui_str': 'Nesiritide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0018338', 'cui_str': 'Cyclic guanosine monophosphate'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0021308', 'cui_str': 'Infarct'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0412692', 'cui_str': 'Cardiac MRI'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0444930', 'cui_str': 'End'}]",58.0,0.461985,"RESULTS BNP infusion led to significantly higher BNP levels and plasma cyclic guanosine monophosphate at 72 hours.","[{'ForeName': 'Scott A', 'Initials': 'SA', 'LastName': 'Hubers', 'Affiliation': 'Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA hubers.scott@mayo.edu.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Schirger', 'Affiliation': 'Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'S Jeson', 'Initials': 'SJ', 'LastName': 'Sangaralingham', 'Affiliation': 'Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Burnett', 'Affiliation': 'Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Hodge', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida, USA.'}, {'ForeName': 'Horng H', 'Initials': 'HH', 'LastName': 'Chen', 'Affiliation': 'Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.'}]",Heart (British Cardiac Society),['10.1136/heartjnl-2020-317182'] 2306,32747522,Effect of Fremanezumab on Quality of Life and Productivity in Patients With Chronic Migraine.,"OBJECTIVE To evaluate fremanezumab quarterly or monthly vs placebo on health-related quality of life, health status, patients' global impression of change, and productivity in patients with chronic migraine (CM). METHODS HALO CM was a double-blind, placebo-controlled trial in patients with CM. Patients were randomized 1:1:1 to treatment with fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8), fremanezumab monthly (225 mg at baseline, weeks 4 and 8), or placebo. This manuscript assessed the effect of treatment with fremanezumab on health-related quality of life and productivity using the following prespecified assessments: the Migraine-Specific Quality of Life (MSQoL) questionnaire at baseline, weeks 4, 8, 12; Patient Global Impression of Change (PGIC) questionnaire at weeks 4, 8, 12; EuroQoL 5-dimension, 5-response level (EQ-5D-5L) questionnaire and Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaire at baseline and week 12. RESULTS The full analysis set included 1121 patients: 375 patients with quarterly dosing, 375 with monthly dosing, and 371 with placebo. Fremanezumab quarterly and monthly was associated with significant improvements over placebo in change from baseline mean scores in MSQoL domains (all, p < 0.05) to week 12. At week 12, fremanezumab also showed significant improvements in EQ-5D-5L visual analog scale ( p < 0.05) and PGIC scores ( p < 0.0001); as well as significant reductions from baseline in WPAI:GH scores ( p < 0.01) and presenteeism (impairment while working ; p < 0.05) vs placebo. CONCLUSIONS Fremanezumab quarterly or monthly was associated with improvement over placebo in migraine-specific quality of life, overall health status, patients' global impression of change with treatment, and productivity in patients with CM.",2020,"Fremanezumab quarterly and monthly was associated with significant improvements over placebo in change from baseline mean scores in MSQoL domains (all, p < 0.05) to week 12.","['patients with chronic migraine (CM', 'Patients With Chronic Migraine', '1121 patients: 375 patients with quarterly dosing, 375 with monthly dosing, and 371 with', 'patients with CM']","['fremanezumab', 'fremanezumab quarterly (675 mg at baseline, placebo', 'Fremanezumab', 'fremanezumab quarterly or monthly vs placebo', 'placebo']","[""health-related quality of life, health status, patients' global impression of change, and productivity"", 'Quality of Life and Productivity', 'health-related quality of life and productivity', 'migraine-specific quality of life, overall health status', 'EuroQoL 5-dimension, 5-response level (EQ-5D-5L) questionnaire and Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaire', 'Migraine-Specific Quality of Life (MSQoL) questionnaire', 'PGIC scores', 'WPAI:GH scores', 'Patient Global Impression of Change (PGIC) questionnaire', 'EQ-5D-5L visual analog scale']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1960870', 'cui_str': 'Transformed migraine'}, {'cui': 'C4517745', 'cui_str': '375'}, {'cui': 'C0332179', 'cui_str': 'Trimonthly'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C4549503', 'cui_str': 'fremanezumab'}, {'cui': 'C0332179', 'cui_str': 'Trimonthly'}, {'cui': 'C4517854', 'cui_str': '675'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0033269', 'cui_str': 'Productivity'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",1121.0,0.33054,"Fremanezumab quarterly and monthly was associated with significant improvements over placebo in change from baseline mean scores in MSQoL domains (all, p < 0.05) to week 12.","[{'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Lipton', 'Affiliation': 'Richard B. Lipton, Albert Einstein College of Medicine and Montefiore Headache Center, Bronx, New York, USA Richard.Lipton@einstein.yu.edu.'}, {'ForeName': 'Joshua M', 'Initials': 'JM', 'LastName': 'Cohen', 'Affiliation': 'Richard B. Lipton, Albert Einstein College of Medicine and Montefiore Headache Center, Bronx, New York, USA.'}, {'ForeName': 'Sanjay K', 'Initials': 'SK', 'LastName': 'Gandhi', 'Affiliation': 'Richard B. Lipton, Albert Einstein College of Medicine and Montefiore Headache Center, Bronx, New York, USA.'}, {'ForeName': 'Ronghua', 'Initials': 'R', 'LastName': 'Yang', 'Affiliation': 'Richard B. Lipton, Albert Einstein College of Medicine and Montefiore Headache Center, Bronx, New York, USA.'}, {'ForeName': 'Paul P', 'Initials': 'PP', 'LastName': 'Yeung', 'Affiliation': 'Richard B. Lipton, Albert Einstein College of Medicine and Montefiore Headache Center, Bronx, New York, USA.'}, {'ForeName': 'Dawn C', 'Initials': 'DC', 'LastName': 'Buse', 'Affiliation': 'Richard B. Lipton, Albert Einstein College of Medicine and Montefiore Headache Center, Bronx, New York, USA.'}]",Neurology,['10.1212/WNL.0000000000010000'] 2307,32747544,An objective evaluation of the beholder's response to abstract and figurative art based on construal level theory.,"Does abstract art evoke a different cognitive state than figurative art? To address this question empirically, we bridged art theory and cognitive research and designed an experiment leveraging construal level theory (CLT). CLT is based on experimental data showing that psychologically distant events (i.e., occurring farther away in space or time) are represented more abstractly than closer events. We measured construal level elicited by abstract vs. representational art and asked subjects to assign abstract/representational paintings by the same artist to a situation that was temporally/spatially near or distant. Across three experiments, we found that abstract paintings were assigned to the distant situation significantly more often than representational paintings, indicating that abstract art was evocative of greater psychological distance. Our data demonstrate that different levels of artistic abstraction evoke different levels of mental abstraction and suggest that CLT provides an empirical approach to the analysis of cognitive states evoked by different levels of artistic abstraction.",2020,"Across three experiments, we found that abstract paintings were assigned to the distant situation significantly more often than representational paintings, indicating that abstract art was evocative of greater psychological distance.",[],['CLT'],[],[],"[{'cui': 'C0441889', 'cui_str': 'Levels'}]",[],,0.0375673,"Across three experiments, we found that abstract paintings were assigned to the distant situation significantly more often than representational paintings, indicating that abstract art was evocative of greater psychological distance.","[{'ForeName': 'Celia', 'Initials': 'C', 'LastName': 'Durkin', 'Affiliation': 'Department of Psychology, Columbia University, New York, NY 10027.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Hartnett', 'Affiliation': 'Department of Psychology, Columbia University, New York, NY 10027.'}, {'ForeName': 'Daphna', 'Initials': 'D', 'LastName': 'Shohamy', 'Affiliation': 'Department of Psychology, Columbia University, New York, NY 10027; ds2619@columbia.edu erk5@columbia.edu.'}, {'ForeName': 'Eric R', 'Initials': 'ER', 'LastName': 'Kandel', 'Affiliation': 'Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027; ds2619@columbia.edu erk5@columbia.edu.'}]",Proceedings of the National Academy of Sciences of the United States of America,['10.1073/pnas.2001772117'] 2308,32747876,Investigating the effects of tDCS on Visual Orientation Discrimination Task Performance: 'The possible influence of placebo'.,"The non-invasive neuromodulation technique tDCS offers the promise of a low cost tool for both research and clinical applications in psychology, psychiatry and neuroscience. However, findings regarding its efficacy are often equivocal. A key issue is that the clinical and cognitive applications studied are often complex and thus effects of tDCS are difficult to predict given its known effects on the basic underlying neurophysiology, namely alterations in cortical inhibition-excitation balance. As such, it may be beneficial to assess the effects of tDCS in tasks whose performance has a clear link to cortical inhibition-excitation balance such as the visual orientation discrimination task (ODT). In prior studies in our laboratory no practise effects were found during 2 consecutive runs of the ODT, thus in the current investigation, to examine the effects of tDCS, subjects received 10 minutes of 2mA occipital tDCS (sham, anode, cathode) between a first and second run of ODT. Surprisingly, subjects' performance significantly improved in the second run of ODT compared to the first one regardless of the tDCS stimulation type they received (anodal, cathodal, or sham-tDCS). Possible causes for such an improvement could have been due to either a generic 'placebo' effect of tDCS (as all subjects received some form of tDCS) or an increased delay period between the two runs of ODT of the current study compared to our previous work (10 minutes duration required to administer tDCS as opposed to ~2 minutes in previous studies as a 'break'). As such, we tested these two possibilities with a subsequent experiment in which subjects received 2 minutes or 10 minutes delay between the 2 runs (with no tDCS) or 10 minutes of sham-tDCS. Only sham-tDCS resulted in improved performance thus these data add to a growing literature suggesting that tDCS has powerful placebo effect that may occur even in the absence of active cortical modulation.",2020,"Surprisingly, subjects' performance significantly improved in the second run of ODT compared to the first one regardless of the tDCS stimulation type they received (anodal, cathodal, or sham-tDCS).",[],['tDCS'],[],[],"[{'cui': 'C3850024', 'cui_str': 'tDCS'}]",[],,0.0329876,"Surprisingly, subjects' performance significantly improved in the second run of ODT compared to the first one regardless of the tDCS stimulation type they received (anodal, cathodal, or sham-tDCS).","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'BinDawood', 'Affiliation': 'Department of Psychology, University of Sheffield, Cathedral Court, 1 Vicar Lane, Sheffield UK, S1 2LT.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Dickinson', 'Affiliation': 'Center for Autism Research and Treatment, University of California, Semel Institute for Neuroscience, 760 Westwood Plaza, Suite A7-448, Los Angeles, CA 90095, United States of America.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Aytemur', 'Affiliation': 'Department of Psychology, University of Sheffield, Cathedral Court, 1 Vicar Lane, Sheffield UK, S1 2LT.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Howarth', 'Affiliation': 'Department of Psychology, University of Sheffield, Cathedral Court, 1 Vicar Lane, Sheffield UK, S1 2LT.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Milne', 'Affiliation': 'Department of Psychology, University of Sheffield, Cathedral Court, 1 Vicar Lane, Sheffield UK, S1 2LT.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Jones', 'Affiliation': 'Department of Psychology, University of Sheffield, Cathedral Court, 1 Vicar Lane, Sheffield UK, S1 2LT.'}]",Journal of cognitive enhancement : towards the integration of theory and practice,['10.1007/s41465-019-00154-3'] 2309,32747931,"Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities.","OBJECTIVES To investigate the molecular epidemiology and antimicrobial susceptibility of Clostridioides difficile isolates from patients with C. difficile infection (CDI) from two Phase 3 clinical trials of surotomycin. METHODS In both trials [Protocol MK-4261-005 (NCT01597505) conducted across Europe, North America and Israel; and Protocol MK-4261-006 (NCT01598311) conducted across North America, Asia-Pacific and South America], patients with CDI were randomized (1:1) to receive oral surotomycin (250 mg twice daily) or oral vancomycin (125 mg four times per day) for 10 days. Stool samples were collected at baseline and C. difficile isolates were characterized by restriction endonuclease analysis (REA) and PCR ribotyping. Susceptibility testing was performed by agar dilution, according to CLSI recommendations. RESULTS In total, 1147 patients were included in the microbiological modified ITT population. Of 992 recovered isolates, 922 (92.9%) were typed. There was a high association between REA groups and their corresponding predominant PCR ribotype (RT) for BI, DH, G and CF strains. REA group A showed more diverse PCR RTs. Overall, the most common strain was BI/RT027 (20.3%) followed by Y/RT014/020 (15.0%) and DH/RT106 (7.2%). The BI/RT027 strain was particularly prevalent in Europe (29.9%) and Canada (23.6%), with lower prevalence in the USA (16.8%) and Australia/New Zealand (3.4%). Resistance was most prevalent in the BI/RT027 strain, particularly to metronidazole, vancomycin and moxifloxacin. CONCLUSIONS A wide variation in C. difficile strains, both within and across different geographical regions, was documented by both REA and ribotyping, which showed overall good correlation.",2020,"There was a high association between REA groups and their corresponding predominant PCR ribotype (RT) for BI, DH, G and CF strains.","['patients with C. difficile infection (CDI', '1147 patients were included in the microbiological modified ITT population', 'Europe, North America and Israel; and Protocol MK-4261-006 (NCT01598311) conducted across North America, Asia-Pacific and South America], patients with CDI']","['oral surotomycin', 'oral vancomycin', 'metronidazole, vancomycin and moxifloxacin', 'REA']",['diverse PCR RTs'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0025953', 'cui_str': 'microbiology'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C0022271', 'cui_str': 'Israel'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0003980', 'cui_str': 'Asia'}, {'cui': 'C0037713', 'cui_str': 'South America'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0360373', 'cui_str': 'Vancomycin-containing product in oral dose form'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0042313', 'cui_str': 'Vancomycin'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C0012906', 'cui_str': 'DNA Restriction Enzyme'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}]",1147.0,0.0890204,"There was a high association between REA groups and their corresponding predominant PCR ribotype (RT) for BI, DH, G and CF strains.","[{'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Cheknis', 'Affiliation': 'Edward Hines, Jr. VA Hospital, Hines, IL, USA.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Devaris', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Chesnel', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Suzanne E', 'Initials': 'SE', 'LastName': 'Dale', 'Affiliation': 'ACM Global Laboratories, Rochester, NY, USA.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Nary', 'Affiliation': 'ACM Global Laboratories, Rochester, NY, USA.'}, {'ForeName': 'Susan P', 'Initials': 'SP', 'LastName': 'Sambol', 'Affiliation': 'Edward Hines, Jr. VA Hospital, Hines, IL, USA.'}, {'ForeName': 'Diane M', 'Initials': 'DM', 'LastName': 'Citron', 'Affiliation': 'R.M. Alden Research Laboratory, Culver City, CA, USA.'}, {'ForeName': 'Richard V', 'Initials': 'RV', 'LastName': 'Goering', 'Affiliation': 'Creighton University, Omaha, NE, USA.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Johnson', 'Affiliation': 'Edward Hines, Jr. VA Hospital, Hines, IL, USA.'}]",The Journal of antimicrobial chemotherapy,['10.1093/jac/dkaa297'] 2310,32747973,Casper vs. Closed-Cell Stent : Carotid Artery Stenting Randomized Trial.,"OBJECTIVE The aim of this trial was to compare the efficacy of closed-cell stents with Casper stents during carotid angioplasty stenting (CAS). METHODS This was a randomized superiority trial in which 88 patients were enrolled. The primary end points were the incidence, number, and size of new ischemic brain lesions after CAS under distal embolic protection devices (EPD). The secondary end points included stroke, transient ischemic attack (TIA) and myocardial infarction (MI). Ischemic brain lesions were assessed by a diffusion-weighted magnetic resonance image (DW-MRI). Neurological outcomes were evaluated by means of the National Institutes of Health scale score (NIHSS) and the modified Rankin scale (mRS). RESULTS Compared with closed-cell stents (n = 47), Casper stents (n = 41), resulted in no significant reduction in the incidence (44.7% versus 39%, P = 0.592), number (1.3 ± 1.8 versus 0.9 ± 1.5, p = 0.444), and size (3.9 ± 5.8 mm versus 2.8 ± 4.1 mm, p = 0.353) of new ischemic brain lesions. The global rate of stroke/TIA/MI was (2/88, 2.3%). Two TIA occurred during the hospitalization period, one in each group (1/41, 2.4% vs 1/47, 2.1%). One patient of the Casper group had an asymptomatic in-stent thrombosis. One patient of the control group had a MI (1/47, 2.1%) after discharge. CONCLUSION The Casper stents did not show superiority in the rate of incidence, number and size of new silent ischemic brain lesions detect by DW-MRI when compared to close cell stents during CAS under distal EPD.",2020,"The Casper stents did not show superiority in the rate of incidence, number and size of new silent ischemic brain lesions detect by DW-MRI when compared to close cell stents during CAS under distal EPD.",['88\xa0patients were enrolled'],"['Casper stents', 'closed-cell stents', 'carotid angioplasty stenting (CAS', 'Casper vs. Closed-Cell Stent ', 'closed-cell stents with Casper stents']","['MI', 'Neurological outcomes', 'stroke, transient ischemic attack (TIA) and myocardial infarction (MI', 'global rate of stroke/TIA/MI', 'Ischemic brain lesions', 'National Institutes of Health scale score (NIHSS) and the modified Rankin scale (mRS', 'asymptomatic in-stent thrombosis', 'rate of incidence, number and size of new silent ischemic brain lesions detect by DW-MRI', 'incidence, number, and size of new ischemic brain lesions after CAS under distal embolic protection devices (EPD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C3203476', 'cui_str': 'Carotid angioplasty'}]","[{'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0221505', 'cui_str': 'Lesion of brain'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0443304', 'cui_str': 'Silent'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0028580', 'cui_str': 'Nuclear Magnetic Resonance'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C3203476', 'cui_str': 'Carotid angioplasty'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C2936200', 'cui_str': 'Embolism Protection Devices'}]",,0.238049,"The Casper stents did not show superiority in the rate of incidence, number and size of new silent ischemic brain lesions detect by DW-MRI when compared to close cell stents during CAS under distal EPD.","[{'ForeName': 'José Ricardo', 'Initials': 'JR', 'LastName': 'Vanzin', 'Affiliation': 'Division of Interventional Neuroradiology, Medical School of Passo Fundo, Federal University of South Frontier, Rua Teixeira Soares, 640, Centro, 99080-020, Passo Fundo, RS, Brazil. jrvanzin@gmail.com.'}, {'ForeName': 'Luís Henrique', 'Initials': 'LH', 'LastName': 'de Castro-Afonso', 'Affiliation': 'Division of Interventional Neuroradiology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Moema Nene', 'Initials': 'MN', 'LastName': 'Santos', 'Affiliation': 'Division of Hematology, Medical School of Passo Fundo, Federal University of South Frontier, Passo Fundo, RS, Brazil.'}, {'ForeName': 'Luciano Bambini', 'Initials': 'LB', 'LastName': 'Manzato', 'Affiliation': 'Division of Interventional Neuroradiology, Medical School of Passo Fundo, Federal University of South Frontier, Rua Teixeira Soares, 640, Centro, 99080-020, Passo Fundo, RS, Brazil.'}, {'ForeName': 'Guilherme Seizem', 'Initials': 'GS', 'LastName': 'Nakiri', 'Affiliation': 'Division of Interventional Neuroradiology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Lucas Moretti', 'Initials': 'LM', 'LastName': 'Monsignore', 'Affiliation': 'Division of Interventional Neuroradiology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Felipe Padovani', 'Initials': 'FP', 'LastName': 'Trivelato', 'Affiliation': 'Division of Interventional Neuroradiology, Felício Rocho Hospital, Belo Horizonte, Brazil.'}, {'ForeName': 'Marco Túlio Salles', 'Initials': 'MTS', 'LastName': 'Rezende', 'Affiliation': 'Division of Interventional Neuroradiology, Felício Rocho Hospital, Belo Horizonte, Brazil.'}, {'ForeName': 'Octavio Marques', 'Initials': 'OM', 'LastName': 'Pontes-Neto', 'Affiliation': 'Division of Interventional Neuroradiology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Daniel Giansante', 'Initials': 'DG', 'LastName': 'Abud', 'Affiliation': 'Division of Interventional Neuroradiology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.'}]",Clinical neuroradiology,['10.1007/s00062-020-00937-8'] 2311,32748261,Aerobic endurance training to improve cognition and enhance recovery in schizophrenia: design and methodology of a multicenter randomized controlled trial.,"Even today, patients with schizophrenia often have an unfavorable outcome. Negative symptoms and cognitive deficits are common features in many patients and prevent recovery. In recent years, aerobic endurance training has emerged as a therapeutic approach with positive effects on several domains of patients' health. However, appropriately sized, multicenter randomized controlled trials that would allow better generalization of results are lacking. The exercise study presented here is a multicenter, rater-blind, two-armed, parallel-group randomized clinical trial in patients with clinically stable schizophrenia being conducted at five German tertiary hospitals. The intervention group performs aerobic endurance training on bicycle ergometers three times per week for 40-50 min/session (depending on the intervention week) for a total of 26 weeks, and the control group performs balance and tone training for the same amount of time. Participants are subsequently followed up for 26 weeks. The primary endpoint is all-cause discontinuation; secondary endpoints include psychopathology, cognition, daily functioning, cardiovascular risk factors, and explorative biological measures regarding the underlying mechanisms of exercise. A total of 180 patients will be randomized. With currently 162 randomized participants, our study is the largest trial to date to investigate endurance training in patients with schizophrenia. We hypothesize that aerobic endurance training has beneficial effects on patients' mental and physical health, leading to lower treatment discontinuation rates and improving disease outcomes. The study results will provide a basis for recommending exercise interventions as an add-on therapy in patients with schizophrenia.The study is registered in the International Clinical Trials Database (ClinicalTrials.gov identifier [NCT number]: NCT03466112) and in the German Clinical Trials Register (DRKS-ID: DRKS00009804).",2020,"We hypothesize that aerobic endurance training has beneficial effects on patients' mental and physical health, leading to lower treatment discontinuation rates and improving disease outcomes.","['patients with schizophrenia', 'patients with clinically stable schizophrenia being conducted at five German tertiary hospitals', 'schizophrenia', '180 patients']","['Aerobic endurance training', 'control group performs balance and tone training', 'endurance training', 'aerobic endurance training']","['Negative symptoms and cognitive deficits', 'cause discontinuation; secondary endpoints include psychopathology, cognition, daily functioning, cardiovascular risk factors, and explorative biological measures regarding the underlying mechanisms of exercise']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C4319557', 'cui_str': '180'}]","[{'cui': 'C4704697', 'cui_str': 'Endurance Training'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0009241', 'cui_str': 'Cognitive disorder'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",180.0,0.166193,"We hypothesize that aerobic endurance training has beneficial effects on patients' mental and physical health, leading to lower treatment discontinuation rates and improving disease outcomes.","[{'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Maurus', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nussbaumstrasse 7, 80336, Munich, Germany. Isabel.Maurus@med.uni-muenchen.de.'}, {'ForeName': 'Alkomiet', 'Initials': 'A', 'LastName': 'Hasan', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nussbaumstrasse 7, 80336, Munich, Germany.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Schmitt', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nussbaumstrasse 7, 80336, Munich, Germany.'}, {'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'Roeh', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nussbaumstrasse 7, 80336, Munich, Germany.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Keeser', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nussbaumstrasse 7, 80336, Munich, Germany.'}, {'ForeName': 'Berend', 'Initials': 'B', 'LastName': 'Malchow', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital Göttingen, Göttingen, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Schneider-Axmann', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nussbaumstrasse 7, 80336, Munich, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Hellmich', 'Affiliation': 'Faculty of Medicine, Institute of Medical Statistics and Computational Biology, University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Schmied', 'Affiliation': 'Faculty of Medicine, Clinical Trials Centre Cologne, University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Moritz', 'Initials': 'M', 'LastName': 'Lembeck', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nussbaumstrasse 7, 80336, Munich, Germany.'}, {'ForeName': 'Katriona', 'Initials': 'K', 'LastName': 'Keller-Varady', 'Affiliation': 'Institute of Sports Medicine, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Papazova', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nussbaumstrasse 7, 80336, Munich, Germany.'}, {'ForeName': 'Dusan', 'Initials': 'D', 'LastName': 'Hirjak', 'Affiliation': 'Medical Faculty Mannheim, Central Institute of Mental Health, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Cristina E', 'Initials': 'CE', 'LastName': 'Topor', 'Affiliation': 'Medical Faculty Mannheim, Central Institute of Mental Health, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Walter', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Mohnke', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Bob O', 'Initials': 'BO', 'LastName': 'Vogel', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Wölwer', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University, Duesseldorf, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Schneider', 'Affiliation': 'University Hospital, Heinrich-Heine University, Düsseldorf, Germany.'}, {'ForeName': 'Karsten', 'Initials': 'K', 'LastName': 'Henkel', 'Affiliation': 'Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH, Aachen, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Meyer-Lindenberg', 'Affiliation': 'Medical Faculty Mannheim, Central Institute of Mental Health, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Falkai', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nussbaumstrasse 7, 80336, Munich, Germany.'}]",European archives of psychiatry and clinical neuroscience,['10.1007/s00406-020-01175-2'] 2312,32748293,Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist Clazosentan.,"This study investigated the potential QT liability of the selective endothelin-1 A receptor antagonist clazosentan at a therapeutic (20 mg/h) and supratherapeutic (60 mg/h) intravenous (i.v.) dose. A randomized, placebo- and moxifloxacin-controlled, double-blind, 3-period, crossover study was conducted in 36 healthy subjects receiving clazosentan (20 mg/h followed by 60 mg/h i.v. for 3 h each), placebo (i.v. for 6 h), and moxifloxacin (single oral dose of 400 mg concomitantly with placebo i.v. for 6 h). At least three replicate ECGs were extracted from Holter recordings at predefined time points from 1 h pre-dose to 24 h after end of infusion. Pharmacokinetic blood sampling was performed for concentration/QT analysis (primary endpoint). For moxifloxacin, the lower bound of the 90% confidence interval (CI) of baseline- and placebo-corrected QTcF (ΔΔQTcF) was > 5 ms at its maximum plasma concentration together with a positive slope of the concentration/QT regression line demonstrating assay sensitivity. For clazosentan, time of peak exposure preceded maximum ΔΔQTcF by 4 h indicating delayed QT-prolonging effects leading to invalidity of the concentration/QT analysis. The secondary by-time-point analysis revealed QT liability of clazosentan (i.e., upper bound of 90% CI ∆∆QTcF > 10 ms). Delayed QT prolongation (i.e., hysteresis) was predominantly observed in subjects with nausea and vomiting, potentially caused by vagal reaction and/or decreases in potassium concentration. By contrast, there was no association with other adverse events, food intake, or concomitant medication. In conclusion, clazosentan at therapeutic and supratherapeutic doses has QT liability with hysteresis effects being associated with nausea and vomiting.",2020,"By contrast, there was no association with other adverse events, food intake, or concomitant medication.",['36 healthy subjects receiving clazosentan (20\xa0mg/h followed by 60\xa0mg/h i.v'],"['moxifloxacin', 'moxifloxacin (single oral dose of 400\xa0mg concomitantly with placebo', 'supratherapeutic', 'placebo']","['adverse events, food intake, or concomitant medication', 'Delayed QT prolongation', 'nausea and vomiting', 'potassium concentration', 'QT liability of clazosentan']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C1721268', 'cui_str': 'clazosentan'}, {'cui': 'C0439421', 'cui_str': 'mg/h'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0013470', 'cui_str': 'Eating'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0151878', 'cui_str': 'Prolonged QT interval'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0032821', 'cui_str': 'Potassium'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1721268', 'cui_str': 'clazosentan'}]",36.0,0.136815,"By contrast, there was no association with other adverse events, food intake, or concomitant medication.","[{'ForeName': 'Pierre-Eric', 'Initials': 'PE', 'LastName': 'Juif', 'Affiliation': 'Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123, Allschwil, Switzerland. pierre-eric.juif@idorsia.com.'}, {'ForeName': 'Jasper', 'Initials': 'J', 'LastName': 'Dingemanse', 'Affiliation': 'Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123, Allschwil, Switzerland.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Voors-Pette', 'Affiliation': 'QPS Netherlands B.V., Groningen, The Netherlands.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Ufer', 'Affiliation': 'Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123, Allschwil, Switzerland.'}]",The AAPS journal,['10.1208/s12248-020-00485-6'] 2313,32748303,Kinematic and Somatosensory Gains in Infants with Cerebral Palsy After a Multi-Component Upper-Extremity Intervention: A Randomized Controlled Trial.,"Upper extremity (UE) impairments in infants with cerebral palsy (CP) result from reduced quality of motor experiences and ""noisy"" sensory inputs. We hypothesized that a neuroscience-based multi-component intervention would improve somatosensory processing and motor measures of more-affected (UEs) in infants with CP and asymmetric UE neurologic impairments, while remaining safe for less-affected UEs. Our randomized controlled trial compared infants (6-24 months) with CP receiving intervention (N = 37) versus a waitlisted group (N = 36). Treatment effects tested a direct measurement of reach smoothness (3D-kinematics), a measure of unimanual fine motor function (Bayley unimanual fine motor raw scores), and EEG measures of cortical somatosensory processing. The four-week therapist-directed, parent-administered intervention included daily (1) bimanual play; (2) less-affected UE wearing soft-constraint (6 h/day, electronically-monitored); (3) reach training on more-affected UE; (4) graduated motor-sensory training; and (5) parent education. Waitlist infants received only bimanual play. Effectiveness and safety were tested; z-scores from 54 posttest-matched typically-developing infants provided benchmarks for treatment effects. Intervention and waitlist infants had no pretest differences. Median weekly constraint wear was 38 h; parent-treatment fidelity averaged > 92%. On the more affected side, the intervention significantly increased smoothness of reach (Cohen's d = - 0.90; p < .001) and unimanual fine motor skill (d = 0.35; p = .004). Using unadjusted p values, intervention improved somatosensory processing (d = 0.53; p = .04). All intervention effects referenced well to typically developing children. Safety of the intervention was demonstrated through positive- or non-effects on measurements involving the constrained, less-affected UE and gross motor function; unexpected treatment effects on reach smoothness occurred in less-affected UEs (d =  - 0.85; p = .01). This large clinical trial demonstrated intervention effectiveness and safety for developing sensory and motor systems with improvements in reach smoothness, and developmental abilities.Clinical Trail Registration: ClinicalTrials.gov NCT02567630, registered October 5, 2015.",2020,"On the more affected side, the intervention significantly increased smoothness of reach (Cohen's d = - 0.90; p < .001) and unimanual fine motor skill (d = 0.35; p = .004).","['Infants with Cerebral Palsy', 'infants with cerebral palsy (CP', 'infants with CP and asymmetric UE neurologic impairments', 'infants (6-24\xa0months) with CP receiving intervention (N\u2009=\u200937) versus a waitlisted group (N\u2009=\u200936']","['bimanual play', 'neuroscience-based multi-component intervention', 'parent-administered intervention included daily (1) bimanual play; (2) less-affected UE wearing soft-constraint (6\xa0h/day, electronically-monitored); (3) reach training on more-affected UE; (4) graduated motor-sensory training; and (5) parent education', 'Multi-Component Upper-Extremity Intervention']","['unimanual fine motor function (Bayley unimanual fine motor raw scores), and EEG measures of cortical somatosensory processing', 'reach smoothness', 'somatosensory processing and motor measures', 'Kinematic and Somatosensory Gains', 'unimanual fine motor skill', 'somatosensory processing', 'Effectiveness and safety', 'Upper extremity (UE) impairments', 'smoothness of reach']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0332514', 'cui_str': 'Asymmetry'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0027910', 'cui_str': 'Neurosciences'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0392760', 'cui_str': 'Affecting'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0205358', 'cui_str': 'Soft'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0588053', 'cui_str': 'Graduate'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0562229', 'cui_str': 'Fine motor functions'}, {'cui': 'C0205232', 'cui_str': 'Fine'}, {'cui': 'C0001884', 'cui_str': 'Airway Resistance'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0600169', 'cui_str': 'Kinematics'}, {'cui': 'C0026612', 'cui_str': 'Motor Skills'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}]",,0.0602155,"On the more affected side, the intervention significantly increased smoothness of reach (Cohen's d = - 0.90; p < .001) and unimanual fine motor skill (d = 0.35; p = .004).","[{'ForeName': 'Nathalie L', 'Initials': 'NL', 'LastName': 'Maitre', 'Affiliation': ""Center for Perinatal Research at the Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, USA. Nathalie.maitre@nationwidechildrens.org.""}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Jeanvoine', 'Affiliation': ""Center for Perinatal Research at the Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Yoder', 'Affiliation': 'Department of Special Education, Peabody College of Education and Human Development, Vanderbilt University, Nashville, TN, USA.'}, {'ForeName': 'Alexandra P', 'Initials': 'AP', 'LastName': 'Key', 'Affiliation': 'Department of Hearing and Speech Sciences, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'James C', 'Initials': 'JC', 'LastName': 'Slaughter', 'Affiliation': 'Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Carey', 'Affiliation': ""Center for Perinatal Research at the Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Needham', 'Affiliation': 'Department of Psychology and Human Development, Peabody College, Vanderbilt University, Nashville, TN, USA.'}, {'ForeName': 'Micah M', 'Initials': 'MM', 'LastName': 'Murray', 'Affiliation': 'Department of Hearing and Speech Sciences, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Heathcock', 'Affiliation': 'School of Health and Rehabilitation Sciences, The Ohio State University, Columbus, OH, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Brain topography,['10.1007/s10548-020-00790-5'] 2314,32750431,Protocol for Partner2Lose: A randomized controlled trial to evaluate partner involvement on long-term weight loss.,"BACKGROUND Behavioral interventions produce clinically significant weight reduction, with many participants regaining weight subsequently. Most interventions focus on an individual, but dietary and physical activity behaviors occur with, or are influenced by, domestic partners. According to interdependence theory, couples who approach behavior change as a problem to be tackled together versus independently are more likely to utilize communal coping processes to promote behavior change. We utilized interdependence theory to develop a partner-assisted intervention to increase long-term weight loss. METHODS Community-dwelling individuals (index participants) cohabitating with a partner with 1) overweight and at least one obesity-related comorbidity or 2) obesity are randomized to participate in a standard weight management program alone or with their partner. The weight management program involves biweekly, in-person, group sessions focusing on weight loss for six months, followed by three group sessions and nine telephone calls focusing on weight loss maintenance for twelve months. In the partner-assisted arm, partners participate in half of the group sessions and telephone calls. Couples receive training in principles of cognitive behavioral therapy for couples, including sharing thoughts and feelings and joint problem solving, to increase communal coping. The primary outcome is participant weight loss at 24 months, with caloric intake and moderate-intensity physical activity as secondary outcomes. Partner weight and caloric intake will also be analyzed. Mediation analyses will examine the role of interdependence variables and social support. DISCUSSION This trial will provide knowledge about effective ways to promote long-term weight loss and the role of interdependence constructs in weight loss. Clinical trials identifier: NCT03801174.",2020,"According to interdependence theory, couples who approach behavior change as a problem to be tackled together versus independently are more likely to utilize communal coping processes to promote behavior change.",['Community-dwelling individuals (index participants) cohabitating with a partner with 1) overweight and at least one obesity-related comorbidity or 2) obesity'],"['training in principles of cognitive behavioral therapy', 'standard weight management program alone or with their partner']","['Partner weight and caloric intake', 'participant weight loss at 24\u202fmonths, with caloric intake and moderate-intensity physical activity']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}]","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C4273558', 'cui_str': 'Weight management program'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}]","[{'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.0164121,"According to interdependence theory, couples who approach behavior change as a problem to be tackled together versus independently are more likely to utilize communal coping processes to promote behavior change.","[{'ForeName': 'Corrine I', 'Initials': 'CI', 'LastName': 'Voils', 'Affiliation': 'University of Wisconsin-Madison School of Medicine & Public Health, Department of Surgery, 600 Highland Ave, K6/100 CSC, Madison, WI 53792-1690, USA; William S Middleton Memorial Veterans Hospital, 2500 Overlook Terrace (151), Madison, WI 53705, USA. Electronic address: voils@surgery.wisc.edu.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Shaw', 'Affiliation': 'Duke University School of Nursing, 307 Trent Dr., 1055 Clipp, Durham, NC 27710, USA.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Adler', 'Affiliation': ""Center for Surgery and Public Health, Brigham and Women's Hospital, One Brigham Circle, 1620 Tremont Street Suite 2-016, Boston, MA 02120, USA.""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Jeanes', 'Affiliation': 'University of Wisconsin-Madison School of Medicine & Public Health, Department of Surgery, 600 Highland Ave, K6/100 CSC, Madison, WI 53792-1690, USA.'}, {'ForeName': 'Megan A', 'Initials': 'MA', 'LastName': 'Lewis', 'Affiliation': 'RTI International, 119 S. Main St., Union Trust Bldg., Suite 220, Seattle, WA 98104, USA.'}, {'ForeName': 'Whitney', 'Initials': 'W', 'LastName': 'Sharp', 'Affiliation': 'University of Wisconsin-Madison School of Medicine & Public Health, Department of Surgery, 600 Highland Ave, K6/100 CSC, Madison, WI 53792-1690, USA.'}, {'ForeName': 'Kate A', 'Initials': 'KA', 'LastName': 'Cronin', 'Affiliation': 'University of Wisconsin-Madison School of Medicine & Public Health, Department of Surgery, 600 Highland Ave, K6/100 CSC, Madison, WI 53792-1690, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Hetzel', 'Affiliation': 'University of Wisconsin-Madison School of Medicine & Public Health, Department of Biostatistics and Bioinformatics, 610 Walnut St, WARF 201, Madison, WI 53726, USA.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Mao', 'Affiliation': 'University of Wisconsin-Madison School of Medicine & Public Health, Department of Biostatistics and Bioinformatics, 610 Walnut St, WARF 201, Madison, WI 53726, USA.'}, {'ForeName': 'Heather M', 'Initials': 'HM', 'LastName': 'Johnson', 'Affiliation': ""Boca Raton Regional Hospital, Christine E. Lynn Women's Health & Wellness Institute, 690 Meadows Road, Boca Raton, FL 33486, USA.""}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Elwert', 'Affiliation': 'University of Wisconsin-Madison Department of Sociology, 11800 Observatory Dr, Madison, WI 53706, USA.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Pabich', 'Affiliation': 'University of Wisconsin-Madison School of Medicine & Public Health, Department of Medicine, 1685 Highland Ave Madison, WI 53705-2281, USA.'}, {'ForeName': 'Kara L', 'Initials': 'KL', 'LastName': 'Gavin', 'Affiliation': 'University of Wisconsin-Madison School of Medicine & Public Health, Department of Surgery, 600 Highland Ave, K6/100 CSC, Madison, WI 53792-1690, USA.'}, {'ForeName': 'William S', 'Initials': 'WS', 'LastName': 'Yancy', 'Affiliation': 'Duke University School of Medicine, Department of Medicine, 501 Douglas St., Durham, NC 27705, USA.'}, {'ForeName': 'Laura S', 'Initials': 'LS', 'LastName': 'Porter', 'Affiliation': 'Duke University School of Medicine, Department of Psychiatry and Behavioral Sciences, Box 90399, Durham, NC 27708, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106092'] 2315,32750499,Improving episodic memory: Frontal-midline theta neurofeedback training increases source memory performance.,"Cognitive and neurofeedback training (NFT) studies have demonstrated that training-induced alterations of frontal-midline (FM) theta activity (4-8 Hz) transfer to cognitive control processes. Given that FM theta oscillations are assumed to provide top-down control for episodic memory retrieval, especially for source retrieval, that is, accurate recollection of contextual details of prior episodes, the present study investigated whether FM theta NFT transfers to memory control processes. It was assessed (1) whether FM theta NFT improves source retrieval and modulates its underlying EEG characteristics and (2) whether this transfer extends over two posttests. Over seven NFT sessions, the training group who trained individual FM theta activity showed greater FM theta increase than an active control group who trained randomly chosen frequency bands. The training group showed better source retrieval in a posttraining session performed 13 days after NFT and their performance increases from pre- to both posttraining sessions were predicted by NFT theta increases. Thus, training-induced enhancement of memory control processes seems to protect newly formed memories from proactive interference of previously learned information. EEG analyses revealed that during pretest both groups showed source memory specific theta activity at frontal and parietal sites. Surprisingly, training-induced improvements in source retrieval tended to be accompanied by less prestimulus FM theta activity, which was predicted by NFT theta change for the training but not the control group, suggesting a more efficient use of memory control processes after training. The present findings provide unique evidence for the enhancement of memory control processes by FM theta NFT.",2020,The training group showed better source retrieval in a posttraining session performed 13 days after NFT and their performance increases from pre- to both posttraining sessions were predicted by NFT theta increases.,[],"['FM theta NFT', 'Cognitive and neurofeedback training (NFT']","['FM theta increase', 'source retrieval', 'source memory specific theta activity']",[],"[{'cui': 'C0205123', 'cui_str': 'Coronal'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C2713543', 'cui_str': 'Electroencephalographic biofeedback'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0205123', 'cui_str': 'Coronal'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0449416', 'cui_str': 'Source'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",,0.0178591,The training group showed better source retrieval in a posttraining session performed 13 days after NFT and their performance increases from pre- to both posttraining sessions were predicted by NFT theta increases.,"[{'ForeName': 'Kathrin C J', 'Initials': 'KCJ', 'LastName': 'Eschmann', 'Affiliation': 'Experimental Neuropsychology Unit, Department of Psychology, Saarland University, Saarbrücken, Germany; Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, Cardiff University, Cardiff, United Kingdom. Electronic address: eschmannk@cardiff.ac.uk.'}, {'ForeName': 'Regine', 'Initials': 'R', 'LastName': 'Bader', 'Affiliation': 'Experimental Neuropsychology Unit, Department of Psychology, Saarland University, Saarbrücken, Germany.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Mecklinger', 'Affiliation': 'Experimental Neuropsychology Unit, Department of Psychology, Saarland University, Saarbrücken, Germany.'}]",NeuroImage,['10.1016/j.neuroimage.2020.117219'] 2316,32750502,"Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study).","INTRODUCTION The XELAVIRI study compared application of fluoropyrimidine (FP) and bevacizumab (Bev) followed by sequential escalation to irinotecan (Iri), FP and Bev (arm A) to upfront combination therapy with FP, Iri and Bev (arm B) in patients with metastatic colorectal cancer (mCRC). To elucidate the impact of age on survival, we evaluated efficacy and early mortality in the underlying trial. METHODS Patients were stratified for age in three cohorts (<65 years, 65-74 years and ≥75 years). Survival end-points were expressed by the Kaplan-Meier method and compared by log-rank testing and Cox regression. Objective response and 60-day mortality were evaluated by chi-square testing. RESULTS The efficacy analyses suggest more substantial benefit from upfront combination chemotherapy in younger patients with mCRC. Elderly patients (≥75 years) derived limited benefit from upfront combination chemotherapy, particularly in terms of overall survival. Of 421 randomised patients, 13 patients (3.1%) died within 60 days after treatment initiation with the highest prevalence in elderly patients (1.6% < 65 years, 2.8% 65-74 years and 5.2% ≥ 75 years, p = 0.26). The frequency of 60-day mortality was significantly associated with age (with a maximum of 8.7% in patients aged ≥75 years) in patients undergoing upfront combination therapy (p = 0.027) but not in patients receiving sequential treatment (p = 0.63). CONCLUSION Combination therapy with FP, Iri and Bev does not substantially improve the outcome of patients aged ≥75 years as compared with sequential treatment algorithm. These patients appear to be at a relevant risk for 60-day mortality under Iri-based combination chemotherapy plus Bev.",2020,"CONCLUSION Combination therapy with FP, Iri and Bev does not substantially improve the outcome of patients aged ≥75 years as compared with sequential treatment algorithm.","['patients with metastatic colorectal cancer', 'Elderly patients (≥75 years', 'younger patients with mCRC', 'patients aged ≥75 years', 'Patients were stratified for age in three cohorts (<65 years, 65-74 years and ≥75 years', 'patients with metastatic colorectal cancer (mCRC']","['upfront combination chemotherapy', 'fluoropyrimidine (FP) and bevacizumab (Bev) followed by sequential escalation to irinotecan (Iri), FP and Bev (arm A) to upfront combination therapy with FP, Iri and Bev (arm B']","['Objective response and 60-day mortality', 'frequency of 60-day mortality', 'efficacy and early mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}]","[{'cui': 'C0013218', 'cui_str': 'Combination Drug Therapy'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}, {'cui': 'C0022077', 'cui_str': 'Iris structure'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1279919', 'cui_str': 'Early'}]",421.0,0.107606,"CONCLUSION Combination therapy with FP, Iri and Bev does not substantially improve the outcome of patients aged ≥75 years as compared with sequential treatment algorithm.","[{'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Kurreck', 'Affiliation': 'Charité University Medicine, Department of Hematology, Oncology, and Tumor Immunology (CVK), Berlin, Germany.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Heinemann', 'Affiliation': 'University Hospital Grosshadern, Ludwig Maximilians Universität (LMU), Department of Medical Oncology & Comprehensive Cancer Center, Munich, Germany; German Cancer Consortium (DKTK), DKFZ, Heidelberg, Germany.'}, {'ForeName': 'Ludwig', 'Initials': 'L', 'LastName': 'Fischer von Weikersthal', 'Affiliation': 'Gesundheitszentrum St. Marien, Amberg, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Decker', 'Affiliation': 'Oncological Practice, Ravensburg, Germany.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Kaiser', 'Affiliation': 'Oncological Practice, Landshut, Germany.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Uhlig', 'Affiliation': 'Oncological Practice, Naunhof, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Schenk', 'Affiliation': ""Clinic 'Barmherzige Brüder Regensburg', Regensburg, Germany.""}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Freiberg-Richter', 'Affiliation': 'Oncological Practice, Dresden, Germany.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Peuser', 'Affiliation': 'Oncological Practice am Diakonissenhaus, Leipzig, Germany.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Denzlinger', 'Affiliation': 'Marienhospital, Stuttgart, Germany.'}, {'ForeName': 'Ullrich', 'Initials': 'U', 'LastName': 'Graeven', 'Affiliation': 'Kliniken Maria Hilf GmbH, Mönchengladbach, Germany.'}, {'ForeName': 'Ingo', 'Initials': 'I', 'LastName': 'Schwaner', 'Affiliation': 'Oncological Practice Kurfürstendamm, Berlin, Germany.'}, {'ForeName': 'Arndt', 'Initials': 'A', 'LastName': 'Stahler', 'Affiliation': 'University Hospital Grosshadern, Ludwig Maximilians Universität (LMU), Department of Medical Oncology & Comprehensive Cancer Center, Munich, Germany.'}, {'ForeName': 'Kathrin', 'Initials': 'K', 'LastName': 'Heinrich', 'Affiliation': 'University Hospital Grosshadern, Ludwig Maximilians Universität (LMU), Department of Medical Oncology & Comprehensive Cancer Center, Munich, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Jung', 'Affiliation': 'German Cancer Consortium (DKTK), DKFZ, Heidelberg, Germany; Ludwig Maximilians-University, Department of Pathology, Munich, Germany.'}, {'ForeName': 'Swantje', 'Initials': 'S', 'LastName': 'Held', 'Affiliation': 'ClinAssess GmbH, Leverkusen, Germany.'}, {'ForeName': 'Jobst C', 'Initials': 'JC', 'LastName': 'von Einem', 'Affiliation': 'Charité University Medicine Berlin, Department of Hematology, Oncology, and Tumor Immunology (CCM), Berlin, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Stintzing', 'Affiliation': 'Charité University Medicine Berlin, Department of Hematology, Oncology, and Tumor Immunology (CCM), Berlin, Germany.'}, {'ForeName': 'Clemens', 'Initials': 'C', 'LastName': 'Giessen-Jung', 'Affiliation': 'University Hospital Grosshadern, Ludwig Maximilians Universität (LMU), Department of Medical Oncology & Comprehensive Cancer Center, Munich, Germany.'}, {'ForeName': 'Dominik P', 'Initials': 'DP', 'LastName': 'Modest', 'Affiliation': 'Charité University Medicine, Department of Hematology, Oncology, and Tumor Immunology (CVK), Berlin, Germany. Electronic address: dominik.modest@charite.de.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2020.06.010'] 2317,32750571,Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial.,"INTRODUCTION Venous thromboembolism (VTE) may recur during anticoagulation, but the actual rate is not well established. In a post hoc analysis of the Hokusai-VTE trial we evaluated the risk and determinants of recurrent VTE of patients during anticoagulation with heparin, edoxaban or warfarin. MATERIALS AND METHODS The Hokusai-VTE study showed that in VTE patients edoxaban was non-inferior to warfarin with significantly less bleeding. Treatment duration ranged from 3 to 12 months. The recurrent VTE during anticoagulation period was defined as the VTE which occurred from the date of the first to the last dose (+3 days) of study drug. RESULTS 147 of 8240 patients (1.8%) had a recurrent VTE during anticoagulant treatment. Median duration of anticoagulation was 267 days. 80 (54%) patients recurred within the first 30 days, 39 of those during heparin lead-in. 23 of 147 patients died of pulmonary embolism (PE) during anticoagulation (case fatality rate 15.6%). 13 of those fatalities (57%) occurred during the first 30 days; 4 of those during heparin lead-in. The recurrence risk was numerically lower in patients assigned to edoxaban compared to those assigned to warfarin, particularly beyond 30 days. We observed a trend towards a higher proportion of men, high NT-proBNP levels and obesity at the time of diagnosis among patients with early recurrence and mortality in particular. CONCLUSION The risk of recurrent VTE and PE-related mortality during the time of anticoagulation is low but noteworthy. Further studies are warranted to sharpen the risk profile of VTE patients in order to improve treatment and reduce mortality.",2020,23 of 147 patients died of pulmonary embolism (PE) during anticoagulation (case fatality rate 15.6%).,"['23 of 147 patients died of pulmonary embolism (PE) during anticoagulation (case fatality rate 15.6', '147 of 8240 patients (1.8%) had a recurrent VTE during anticoagulant treatment']","['edoxaban', 'warfarin', 'heparin, edoxaban or warfarin', 'VTE patients edoxaban', 'edoxaban or warfarin']","['Median duration of anticoagulation', 'recurrence risk', 'Recurrent venous thromboembolism', 'bleeding']","[{'cui': 'C1306577', 'cui_str': 'O/E - dead'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0282250', 'cui_str': 'Case fatality rate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C2975435', 'cui_str': 'edoxaban'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]",8240.0,0.0356656,23 of 147 patients died of pulmonary embolism (PE) during anticoagulation (case fatality rate 15.6%).,"[{'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Eichinger', 'Affiliation': 'Dept. of Medicine I, Medical University of Vienna, Austria. Electronic address: sabine.eichinger@meduniwien.ac.at.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Lin', 'Affiliation': 'Daiichi-Sankyo Pharma Development, Basking Ridge, NJ, United States of America.'}, {'ForeName': 'Minggao', 'Initials': 'M', 'LastName': 'Shi', 'Affiliation': 'Daiichi-Sankyo Pharma Development, Basking Ridge, NJ, United States of America.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Grosso', 'Affiliation': 'Daiichi-Sankyo Pharma Development, Basking Ridge, NJ, United States of America.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Kyrle', 'Affiliation': 'Dept. of Medicine I, Medical University of Vienna, Austria.'}]",Thrombosis research,['10.1016/j.thromres.2020.07.028'] 2318,32748394,Setting and techniques for monitoring blood pressure during pregnancy.,"BACKGROUND Regular blood pressure (BP) measurement is crucial for the diagnosis and management of hypertensive disorders in pregnancy, such as pre-eclampsia. BP can be measured in various settings, such as conventional clinics or self-measurement at home, and with different techniques, such as using auscultatory or automated BP devices. It is important to understand the impact of different settings and techniques of BP measurement on important outcomes for pregnant women. OBJECTIVES To assess the effects of setting and technique of BP measurement for diagnosing hypertensive disorders in pregnancy on subsequent maternal and perinatal outcomes, women's quality of life, or use of health service resources. SEARCH METHODS We searched Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) on 22 April 2020, and reference lists of retrieved studies. SELECTION CRITERIA Randomised controlled trials (RCTs) involving pregnant women, using validated BP devices in different settings or using different techniques. DATA COLLECTION AND ANALYSIS Two authors independently extracted data, assessed risk of bias, and used the GRADE approach to assess the certainty of the evidence. MAIN RESULTS Of the 21 identified studies, we included three, and excluded 11; seven were ongoing. Of the three included RCTs (536,607 women), one was a cluster-RCT, with a substantially higher number of participants (536,233 deliveries) than the other two trials, but did not provide data for most of our outcomes. We generally judged the included studies at low risk of bias, however, the certainty of the evidence was low, due to indirectness and imprecision. Meta-analysis was not possible because each study investigated a different comparison. None of the included studies reported our primary outcome of systolic BP greater than or equal to 150 mmHg. None of the studies reported any of these important secondary outcomes: antenatal hospital admissions, neonatal unit length of stay, or neonatal endotracheal intubation and use of mechanical ventilation. Setting of BP measurement: self-measurement versus conventional clinic measurement (one study, 154 women) There were no maternal deaths in either the self-monitoring group or the usual care group. The study did not report perinatal mortality. Self-monitoring may lead to slightly more diagnoses of pre-eclampsia compared with usual care (risk ratio (RR) 1.49, 95% confidence interval (CI) 0.87 to 2.54; 154 women; 1 study; low-certainty evidence) but the wide 95% CI is consistent with possible benefit and possible harm. Self-monitoring may have little to no effect on the likelihood of induction of labour compared with usual care (RR 1.09, 95% CI 0.82 to 1.45; 154 women; 1 study; low-certainty evidence). We are uncertain if self-monitoring BP has any effect on maternal admission to intensive care (RR 1.54, 95% CI 0.06 to 37.25; 154 women; 1 study; low-certainty evidence), stillbirth (RR 2.57, 95% CI 0.13 to 52.63; 154 women; 1 study; low-certainty evidence), neonatal death (RR 1.54, 95% CI 0.06 to 37.25; 154 women; 1 study; low-certainty evidence) or preterm birth (RR 1.15, 95% CI 0.37 to 3.55; 154 women; 1 study; low-certainty evidence), compared with usual care because the certainty of evidence is low and the 95% CI is consistent with appreciable harms and appreciable benefits. Self-monitoring may lead to slightly more neonatal unit admissions compared with usual care (RR 1.53, 95% CI 0.65 to 3.62; 154 women; 1 study; low-certainty evidence) but the wide 95% CI includes the possibility of slightly fewer admissions with self-monitoring. Technique of BP measurement: Korotkoff phase IV (K4, muffling sound) versus Korotkoff phase V (K5, disappearance of sound) to represent diastolic BP (one study, 220 women) There were no maternal deaths in either the K4 or K5 group. There may be little to no difference in the diagnosis of pre-eclampsia between using K4 or K5 for diastolic BP (RR 1.16; 95% CI 0.89 to 1.49; 1 study; 220 women; low-certainty evidence), since the wide 95% CI includes the possibility of more diagnoses with K4. We are uncertain if there is a difference in perinatal mortality between the groups because the quality of evidence is low and the 95% CI is consistent with appreciable harm and appreciable benefit (RR 1.14, 95% CI 0.16 to 7.92; 1 study, 220 women; low-certainty evidence). The trial did not report data on maternal admission to intensive care, induction of labour, stillbirth, neonatal death, preterm birth, or neonatal unit admissions. Technique of BP measurement: CRADLE intervention (CRADLE device, a semi-automated BP monitor with additional features, and an education package) versus usual care (one study, 536,233 deliveries) There may be little to no difference between the use of the CRADLE device and usual care in the number of maternal deaths (adjusted RR 0.80, 95% CI 0.30 to 2.11; 536,233 women; 1 study; low-certainty evidence), but the 95% CI is consistent with appreciable harm and appreciable benefit. The trial did not report pre-eclampsia, induction of labour, perinatal mortality, preterm birth, or neonatal unit admissions. Maternal admission to intensive care and perinatal outcomes (stillbirths and neonatal deaths) were only collected for a small proportion of the women, identified by an outcome not by baseline characteristics, thereby breaking the random allocation. Therefore, any differences between the groups could not be attributed to the intervention, and we did not extract data for these outcomes. AUTHORS' CONCLUSIONS The benefit, if any, of self-monitoring BP in hypertensive pregnancies remains uncertain, as the evidence is limited to one feasibility study. Current practice of using K5 to measure diastolic BP is supported for women with pregnancy hypertension. The benefit, if any, of using the CRADLE device to measure BP in pregnancy remains uncertain, due to the limitations and instability of the trial study design.",2020,"There may be little to no difference in the diagnosis of pre-eclampsia between using K4 or K5 for diastolic BP (RR 1.16; 95% CI 0.89 to 1.49; 1 study; 220 women; low-certainty evidence), since the wide 95% CI includes the possibility of more diagnoses with K4.","['one study, 220 women', 'women with pregnancy hypertension', 'hypertensive pregnancies', '154 women', 'pregnant women']","['setting and technique of BP measurement', 'Regular blood pressure (BP) measurement', 'BP measurement: self-measurement versus conventional clinic measurement', 'Korotkoff phase IV (K4, muffling sound) versus Korotkoff phase V (K5, disappearance of sound) to represent diastolic BP']","['perinatal mortality', 'maternal deaths', 'diastolic BP', 'preterm birth', 'Technique of BP measurement', 'maternal admission to intensive care, induction of labour, stillbirth, neonatal death, preterm birth, or neonatal unit admissions', 'Maternal admission to intensive care and perinatal outcomes (stillbirths and neonatal deaths', 'systolic BP', 'neonatal death', 'pre-eclampsia, induction of labour, perinatal mortality, preterm birth, or neonatal unit admissions', 'antenatal hospital admissions, neonatal unit length of stay, or neonatal endotracheal intubation and use of mechanical ventilation']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0565599', 'cui_str': 'Maternal hypertension'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C5191279', 'cui_str': '154'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}]","[{'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0005824', 'cui_str': 'Blood pressure taking'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}]","[{'cui': 'C0031062', 'cui_str': 'Perinatal Mortality'}, {'cui': 'C0024923', 'cui_str': 'Maternal death'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0005824', 'cui_str': 'Blood pressure taking'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0259787', 'cui_str': 'Induction of labor'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0410916', 'cui_str': 'Newborn death'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0178795', 'cui_str': 'Perinatal period'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C2828394', 'cui_str': 'Antenatal'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}]",154.0,0.236683,"There may be little to no difference in the diagnosis of pre-eclampsia between using K4 or K5 for diastolic BP (RR 1.16; 95% CI 0.89 to 1.49; 1 study; 220 women; low-certainty evidence), since the wide 95% CI includes the possibility of more diagnoses with K4.","[{'ForeName': 'Danielle C', 'Initials': 'DC', 'LastName': 'Ashworth', 'Affiliation': ""Department of Women and Children's Health, King's College London, London, UK.""}, {'ForeName': 'Sophie P', 'Initials': 'SP', 'LastName': 'Maule', 'Affiliation': ""Department of Women and Children's Health, King's College London, London, UK.""}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Stewart', 'Affiliation': ""Cochrane Children and Families Network, c/o Cochrane Pregnancy and Childbirth, Department of Women's and Children's Health, The University of Liverpool, Liverpool, UK.""}, {'ForeName': 'Hannah L', 'Initials': 'HL', 'LastName': 'Nathan', 'Affiliation': ""Department of Women and Children's Health, King's College London, London, UK.""}, {'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Shennan', 'Affiliation': ""Department of Women and Children's Health, King's College London, London, UK.""}, {'ForeName': 'Lucy C', 'Initials': 'LC', 'LastName': 'Chappell', 'Affiliation': ""Department of Women and Children's Health, King's College London, London, UK.""}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD012739.pub2'] 2319,32748404,A cost-effective approach to increasing participation in patient reported outcomes research in cancer: A randomized trial of video invitations.,"Maximizing participation in cancer research is important to improve the validity and generalizability of research findings. We conducted a four-arm randomized controlled trial to test the impact of a novel video invitation on participant response. We invited childhood cancer survivors and parents of survivors <16 years to complete questionnaires. We compared response rates to an invitation letter (control) vs receiving the letter plus a video invitation on a flash-drive presented by a childhood cancer survivor, a pediatric oncologist, or a researcher. We explored factors associated with viewing the video and examined the impact of enclosing the USB on study costs. Overall 54% (634/1164) of questionnaires were returned. Participants who received a video invitation on a USB were more likely to return the questionnaire than those who did not (58% vs 47%, P < 0.001). Participation rate did not significantly differ by video presenter. Forty-seven percent of participants who received a USB reported watching the video, of whom 48% reported that the video influenced their decision to participate. Participants with a lower income (OR = 0.43, 95%CI = 0.25-0.74, P = 0.002) were more likely to report watching the video. Participants who received a video invitation required significantly fewer reminder calls than those who only received a written invitation (mean = 1.6 vs 1.1 calls, P < 0.001), resulting in a 25% recruitment cost-saving for the study. Adding a USB with a video study invitation to recruitment packages is a cost-effective way of improving study participation. This is important in an era of declining study participation and underrepresentation of vulnerable populations in research. This article is protected by copyright. All rights reserved.",2020,"Participants who received a video invitation required significantly fewer reminder calls than those who only received a written invitation (mean = 1.6 vs 1.1 calls, P < 0.001), resulting in a 25% recruitment cost-saving for the study.","['Participants with a lower income (OR\xa0=\xa00.43, 95%CI\xa0', 'childhood cancer survivors and parents of survivors <16\u2009years to complete questionnaires', 'cancer']","['invitation letter (control) vs receiving the letter plus a video invitation', 'novel video invitation', 'video invitations', 'video invitation']","['Participation rate', 'reminder calls']","[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C4505050', 'cui_str': 'Survivors of Childhood Cancer'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]","[{'cui': 'C0282413', 'cui_str': 'Letters as Topic'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0205314', 'cui_str': 'New'}]","[{'cui': 'C1720420', 'cui_str': 'Call'}]",,0.0575472,"Participants who received a video invitation required significantly fewer reminder calls than those who only received a written invitation (mean = 1.6 vs 1.1 calls, P < 0.001), resulting in a 25% recruitment cost-saving for the study.","[{'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Signorelli', 'Affiliation': ""Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.""}, {'ForeName': 'Claire E', 'Initials': 'CE', 'LastName': 'Wakefield', 'Affiliation': ""Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.""}, {'ForeName': 'Jordana K', 'Initials': 'JK', 'LastName': 'McLoone', 'Affiliation': ""Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.""}, {'ForeName': 'Marion K', 'Initials': 'MK', 'LastName': 'Mateos', 'Affiliation': ""Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.""}, {'ForeName': 'Neil K', 'Initials': 'NK', 'LastName': 'Aaronson', 'Affiliation': 'Division of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Ange', 'Initials': 'A', 'LastName': 'Lavoipierre', 'Affiliation': ""Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.""}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Cohn', 'Affiliation': ""Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Alvaro', 'Affiliation': ''}]",International journal of cancer,['10.1002/ijc.33244'] 2320,32748456,Comparison of two case difficulty assessment methods on cohorts of undergraduate dental students - a multi-centre study.,"AIM To compare the educational benefits and user friendliness of two anonymised endodontic case difficulty assessment (CDA) methods. METHODOLOGY A cohort (n = 206) of fourth year undergraduate dental students were recruited from four different Dental Schools and divided randomly into two groups (Group A and B). The participants assessed six test endodontic cases using anonymised versions of the American Association of Endodontists (AAE) case difficulty assessment form (AAE 2006) and EndoApp (Shah & Chong 2018). Group A (n = 107) used the AAE form for assessment of the first three cases, followed by EndoApp for the latter. Group B (n = 99) used EndoApp for the initial three cases and switched to the AAE form for the remainder. Data was collected online and analysed to assess participants' knowledge reinforcement and agreement with the recommendation generated. Statistical analysis was performed using the two-way mixed model ANOVA, Cohen's Kappa (κ) and independent t-tests, with the levels of significance set at P < 0.05. Additionally, participants' feedback and preference for CDA was also gathered. RESULTS There was a significant increase in knowledge reinforcement for the AAE form and EndoApp (P = 0.001) after assessment of the first three test cases. However, this increase was not significant (P = 0.842) between the CDA methods. Overall, the AAE form and EndoApp had slight (κ = 0.176, P < 0.001) and substantial (κ = 0.668, P < 0.001) levels of agreement respectively, and the difference was statistically significant (P < 0.001). Participants' feedback on user friendliness favoured EndoApp for all parameters measured. EndoApp was preferred by 65% of the cohort, whereas only 11% chose the AAE form for CDA. CONCLUSIONS Within the limitations of this study, both the AAE form and EndoApp were beneficial for dental education. EndoApp was reliable in helping with decisions to treat or refer, and combined with user friendliness, it was the preferred choice for CDA.",2020,There was a significant increase in knowledge reinforcement for the AAE form and EndoApp (P = 0.001) after assessment of the first three test cases.,"['A cohort (n = 206) of fourth year undergraduate dental students were recruited from four different Dental Schools', 'cohorts of undergraduate dental students - a multi-centre study']",[],['knowledge reinforcement'],"[{'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0205438', 'cui_str': 'Fourth'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038493', 'cui_str': 'Dental Student'}, {'cui': 'C0036376', 'cui_str': 'Dental School'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],"[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0035007', 'cui_str': 'Psychological Reinforcement'}]",,0.0429236,There was a significant increase in knowledge reinforcement for the AAE form and EndoApp (P = 0.001) after assessment of the first three test cases.,"[{'ForeName': 'P K', 'Initials': 'PK', 'LastName': 'Shah', 'Affiliation': 'Institute of Dentistry, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.'}, {'ForeName': 'H F', 'Initials': 'HF', 'LastName': 'Duncan', 'Affiliation': 'School of Dental Science, Trinity College Dublin, The University of Dublin, Dublin, Ireland.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Abdullah', 'Affiliation': 'Faculty of Dentistry, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'P L', 'Initials': 'PL', 'LastName': 'Tomson', 'Affiliation': 'School of Dentistry, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Murray', 'Affiliation': 'Private Practice, Dublin, Ireland.'}, {'ForeName': 'T M', 'Initials': 'TM', 'LastName': 'Friend', 'Affiliation': 'Institute of Dentistry, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Thomas', 'Affiliation': 'Private Practice, Kent, UK.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Butcher', 'Affiliation': 'Institute of Dentistry, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.'}, {'ForeName': 'B S', 'Initials': 'BS', 'LastName': 'Chong', 'Affiliation': 'Institute of Dentistry, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.'}]",International endodontic journal,['10.1111/iej.13377'] 2321,32748463,EBUS-TBNA vs EUS-B-FNA for diagnosis of undiagnosed mediastinal lymphadenopathy: The TEAM Randomized Controlled Trial.,"BACKGROUND Endobronchial Ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a standard of care modality for the evaluation of mediastinal lymphadenopathy. Transesophageal Bronchoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-B-FNA) wherein one introduces the EBUS bronchoscope through the esophageal route, is also a safe and efficacious diagnostic modality for sampling the mediastinal lymph nodes.The objective of this study was to compare the diagnostic yield and patient comfort with these two available approaches. METHODS We randomized subjects with predominant subcarinal or lower left paratracheal mediastinal lymph node enlargement to eitherEBUS-TBNA or EUS-B-FNA (50 toeach group). Co-Primary objectives were the comparison of adequate and diagnostic aspirates between groups. Key secondary objectives were a comparison of Operator rated cough and Operator rated procedural comfort on Visual Analogue scale (VAS), procedure duration, and complications between the groups. RESULTS Baseline characteristics were comparable between the groups. The proportion of adequate (EBUS-TBNA 46/50; 92% and EUS-B-FNA 48/50;96%, p=0.4) and diagnostic aspirates (EBUS-TBNA 38/50; 76% and EUS-B-FNA 36/50;74%, p=0.4) were similar between the two groups. Operator rated cough was significantly less, and Operator rated patient comfort significantly higher with the EUS-B-FNA approach. Procedure duration was significantly shorter with EUS-B-FNA [18.1(14.4) minutes vs. 16.4 (49.6) minutes, p< 0.001]. Minorcomplications occurred in one patient in the EBUS-TBNA group and none in the EUS-B-FNA group. CONCLUSION During the endosonographic evaluation for undiagnosed mediastinal lymphadenopathy located at predominantly the subcarinal or lower left paratracheal stations, EUS-B-FNA as compared with EBUS-TBNAprovides greater patient comfort with a similar diagnostic yield.",2020,"Operator rated cough was significantly less, and Operator rated patient comfort significantly higher with the EUS-B-FNA approach.","['We randomized subjects with predominant subcarinal or lower left paratracheal mediastinal lymph node enlargement to eitherEBUS-TBNA or EUS-B-FNA (50 toeach group', 'undiagnosed mediastinal lymphadenopathy']","['Endobronchial Ultrasound-guided transbronchial needle aspiration (EBUS-TBNA', 'EBUS-TBNA vs EUS-B-FNA', 'Transesophageal Bronchoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-B-FNA']","['Operator rated cough', 'Procedure duration', 'Minorcomplications', 'comparison of Operator rated cough and Operator rated procedural comfort on Visual Analogue scale (VAS), procedure duration, and complications between the groups']","[{'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0442143', 'cui_str': 'Paratracheal'}, {'cui': 'C0588055', 'cui_str': 'Mediastinal lymph node group'}, {'cui': 'C0020564', 'cui_str': 'Hypertrophy'}, {'cui': 'C0520743', 'cui_str': 'Mediastinal lymphadenopathy'}, {'cui': 'C0522518', 'cui_str': 'Transesophageal approach'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C1510483', 'cui_str': 'Fine needle aspiration biopsy - action'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C3160856', 'cui_str': 'Endobronchial ultrasound'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0442342', 'cui_str': 'Transbronchial approach'}, {'cui': 'C0181959', 'cui_str': 'Aspiration needle'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0520743', 'cui_str': 'Mediastinal lymphadenopathy'}, {'cui': 'C0522518', 'cui_str': 'Transesophageal approach'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C1510483', 'cui_str': 'Fine needle aspiration biopsy - action'}]","[{'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",,0.111372,"Operator rated cough was significantly less, and Operator rated patient comfort significantly higher with the EUS-B-FNA approach.","[{'ForeName': 'Karan', 'Initials': 'K', 'LastName': 'Madan', 'Affiliation': 'Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Saurabh', 'Initials': 'S', 'LastName': 'Mittal', 'Affiliation': 'Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Neha Kawatra', 'Initials': 'NK', 'LastName': 'Madan', 'Affiliation': 'Department of Pathology, VMMC and Safdarjung Hospital, New Delhi, India.'}, {'ForeName': 'Pavan', 'Initials': 'P', 'LastName': 'Tiwari', 'Affiliation': 'Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Deepali', 'Initials': 'D', 'LastName': 'Jain', 'Affiliation': 'Pathology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Sudheer', 'Initials': 'S', 'LastName': 'Arava', 'Affiliation': 'Pathology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Vijay', 'Initials': 'V', 'LastName': 'Hadda', 'Affiliation': 'Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Anant', 'Initials': 'A', 'LastName': 'Mohan', 'Affiliation': 'Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Pramod', 'Initials': 'P', 'LastName': 'Garg', 'Affiliation': 'Gastroenterology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}, {'ForeName': 'Randeep', 'Initials': 'R', 'LastName': 'Guleria', 'Affiliation': 'Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.'}]",The clinical respiratory journal,['10.1111/crj.13244'] 2322,32748572,Retraining and control therapy for pediatric psychogenic non-epileptic seizures.,"OBJECTIVE Our aim was to conduct a pilot randomized controlled trial of a novel cognitive behaviorally based intervention for pediatric PNES called Retraining and Control Therapy (ReACT). METHODS Participants were randomized to receive either eight sessions of ReACT or supportive therapy, and participants completed follow-up visits at 7- and 60-days posttreatment. The primary outcome measure was PNES frequency at 7-days posttreatment. Eligibility criteria included children with video-EEG confirmed PNES and participant/parent or guardian willingness to participate in treatment. Exclusion criteria included substance use, psychosis, and severe intellectual disability. Forty-two patients were assessed for eligibility and 32 were randomized. ReACT aimed to retrain classically conditioned, involuntary PNES by targeting catastrophic symptom expectations and a low sense of control over symptoms using principles of habit reversal. Supportive therapy was based on the assumption that relief from stress or problems can be achieved by discussion with a therapist. RESULTS Twenty-nine participants (M age  = 15.1 years, SD age  = 2.5; 72.2% female; 57.1% Caucasian, 28.6% African American) completed 7-days postprocedures. For PNES frequency, the Wilcoxon Rank Sum test statistic was 273.5 yielding a normal approximation of Z = 4.725 (P < 0.0001), indicating a significant improvement in PNES frequency for ReACT at 7-days posttreatment compared to supportive therapy. Participants with PNES in the 7-days posttreatment were removed from the study for additional treatment, resulting in no 60-day follow-up data for supportive therapy. INTERPRETATION ReACT resulted in significantly greater PNES reduction than supportive therapy, with 100% of patients experiencing no PNES in 7 days after ReACT. Additionally, 82% remained PNES-free for 60 days after ReACT.",2020,"(P < 0.0001), indicating a significant improvement in PNES frequency for ReACT at 7-days posttreatment compared to supportive therapy.","['Eligibility criteria included children with video-EEG confirmed PNES and participant/parent or guardian willingness to participate in treatment', 'Forty-two patients were assessed for eligibility and 32 were randomized', 'Twenty-nine participants (M age \xa0', 'Participants with PNES in the 7-days posttreatment were removed from the study for additional treatment, resulting in no 60-day follow-up data for supportive therapy', '15.1\xa0years, SD age \xa0=\xa02.5; 72.2% female; 57.1% Caucasian, 28.6% African American) completed 7-days postprocedures', 'Participants', 'Exclusion criteria included substance use, psychosis, and severe intellectual disability', 'pediatric psychogenic non-epileptic seizures']","['ReACT or supportive therapy', 'Retraining and control therapy', 'Supportive therapy', 'novel cognitive behaviorally based intervention for pediatric PNES called Retraining and Control Therapy (ReACT']","['PNES frequency at 7-days posttreatment', 'PNES reduction', 'PNES frequency']","[{'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0430801', 'cui_str': 'Video EEG'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C3489398', 'cui_str': 'Peripheral neuroepithelioma'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0023226', 'cui_str': 'Legal guardian'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0450351', 'cui_str': '29'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1292747', 'cui_str': 'Removes from'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332294', 'cui_str': 'Resulting in'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0344211', 'cui_str': 'Support'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C4517679', 'cui_str': '28.6'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0036857', 'cui_str': 'Severe intellectual disability'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C1142430', 'cui_str': 'Psychogenic seizure'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0344211', 'cui_str': 'Support'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C3489398', 'cui_str': 'Peripheral neuroepithelioma'}, {'cui': 'C1720420', 'cui_str': 'Call'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",42.0,0.111421,"(P < 0.0001), indicating a significant improvement in PNES frequency for ReACT at 7-days posttreatment compared to supportive therapy.","[{'ForeName': 'Aaron D', 'Initials': 'AD', 'LastName': 'Fobian', 'Affiliation': 'Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham (UAB), Birmingham, Alabama.'}, {'ForeName': 'Dustin M', 'Initials': 'DM', 'LastName': 'Long', 'Affiliation': 'Department of Biostatistics, University of Alabama at Birmingham (UAB), Birmingham, Alabama.'}, {'ForeName': 'Jerzy P', 'Initials': 'JP', 'LastName': 'Szaflarski', 'Affiliation': 'Departments of Neurology, Neurosurgery and Neurobiology, The UAB Epilepsy Center, University of Alabama at Birmingham (UAB), Birmingham, Alabama.'}]",Annals of clinical and translational neurology,['10.1002/acn3.51138'] 2323,32748579,Comparison of the effects of deep and moderate neuromuscular block on respiratory system compliance and surgical space conditions during robot-assisted laparoscopic radical prostatectomy: a randomized clinical study.,"OBJECTIVE Robot-assisted radical prostatectomy (RARP) requires pneumoperitoneum (Pnp) and a steep head-down position that may disturb respiratory system compliance (C rs ) during surgery. Our aim was to compare the effects of different degrees of neuromuscular block (NMB) on C rs with the same Pnp pressure during RARP. METHODS One hundred patients who underwent RARP were enrolled and randomly allocated to a deep or moderate NMB group with 50 patients in each group. Rocuronium was administered to both groups: in the moderate NMB group to maintain 1-2 responses to train-of-four (TOF) stimulation; and in the deep NMB group to maintain no response to TOF stimulation and 1-2 responses in the post-tetanic count. Pnp pressure in both groups was 10 mmHg (1 mmHg=133.3 Pa). Peak inspiratory pressure (P peak ), mean pressure (P mean ), C rs , and airway resistance (R aw ) were recorded after anesthesia induction and at 0, 30, 60, and 90 min of Pnp and post-Pnp. Surgical space conditions were evaluated after the procedure on a 4-point scale. RESULTS Immediately after the Pnp, P peak , P mean , and R aw significantly increased, while C rs decreased and persisted during Pnp in both groups. The results did not significantly differ between the two groups at any of the time points. There was no difference in surgical space conditions between groups. Body movements occurred in 14 cases in the moderate NMB group and in one case in the deep NMB group, and all occurred during obturator lymphadenectomy. A significant difference between the two groups was observed. CONCLUSIONS Under the same Pnp pressure in RARP, deep and moderate NMBs resulted in similar changes in C rs , and in other respiratory mechanics and surgical space conditions. However, deep NMB significantly reduced body movements during surgery.",2020,The results did not significantly differ between the two groups at any of the time points.,['One hundred patients who underwent RARP'],"['Robot-assisted radical prostatectomy (RARP) requires pneumoperitoneum (Pnp', 'deep or moderate NMB', 'deep and moderate neuromuscular block', 'robot-assisted laparoscopic radical prostatectomy', 'Rocuronium', 'neuromuscular block (NMB']","['Pnp pressure', 'Body movements', 'surgical space conditions', 'Peak inspiratory pressure (P peak ), mean pressure (P mean ), C rs , and airway resistance (R aw ', 'body movements']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}]","[{'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}, {'cui': 'C0032320', 'cui_str': 'Pneumoperitoneum'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0235062', 'cui_str': 'Induction of neuromuscular blockade'}, {'cui': 'C4039115', 'cui_str': 'Robot assisted laparoscopic radical prostatectomy'}, {'cui': 'C0209337', 'cui_str': 'Rocuronium'}]","[{'cui': 'C0032320', 'cui_str': 'Pneumoperitoneum'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0232021', 'cui_str': 'Peak inspiratory pressure'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0445074', 'cui_str': 'Mean pressure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001884', 'cui_str': 'Airway Resistance'}, {'cui': 'C4048282', 'cui_str': 'Airway resistance'}]",100.0,0.0297558,The results did not significantly differ between the two groups at any of the time points.,"[{'ForeName': 'Shao-Jun', 'Initials': 'SJ', 'LastName': 'Zhu', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.'}, {'ForeName': 'Xiao-Lin', 'Initials': 'XL', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Xie', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.'}, {'ForeName': 'Yan-Feng', 'Initials': 'YF', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.'}, {'ForeName': 'Kui-Rong', 'Initials': 'KR', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.'}]",Journal of Zhejiang University. Science. B,['10.1631/jzus.B2000193'] 2324,32748630,Effects of transcranial magnetic stimulation on the performance of the activities of daily living and attention function after stroke: a randomized controlled trial.,"OBJECTIVE We aimed to interrogate the effects of transcranial magnetic stimulation (TMS) on the performance in activities of daily living (ADL) and attention function after stroke. DESIGN Randomized controlled trial. SETTING Inpatient rehabilitation hospital. SUBJECTS We randomized 62 stroke patients with attention dysfunction who were randomly assigned into two groups, and two dropped out from each group. The TMS group ( n  = 29) and a sham group ( n  = 29), whose mean (SD) was 58.12 (6.72) years. A total of 33 (56.9%) patients had right hemisphere lesion while the rest 25 (43.1%) patients had left hemisphere lesion. INTERVENTIONS Patients in the TMS group received 10 Hz, 700 pulses of TMS, while those in the sham group received sham TMS for four weeks. All the participants underwent comprehensive cognitive training. MAIN MEASURES At baseline, and end of the four-week treatment, the performance in the activities of daily living was assessed by Functional Independence Measure (FIM). On the other side, attention dysfunction was screened by Mini-Mental State Examination (MMSE), while the attention function was assessed by the Trail Making Test-A (TMT-A), Digit Symbol Test (DST) and Digital Span Test (DS). RESULTS Our data showed a significant difference in the post-treatment gains in motor of Functional Independence Measure (13.00 SD 1.69 vs 4.21 SD 2.96), cognition of Functional Independence Measure (4.69 SD 1.56 vs 1.52 SD 1.02), total of Functional Independence Measure (17.69 SD 2.36 vs 5.72 SD 3.12), Mini-Mental State Examination (3.07 SD 1.36 vs 1.21 SD 0.62), time taken in Trail Making Test-A (96.67 SD 25.18 vs 44.28 SD 19.45), errors number in Trail Making Test-A (2.72 SD 1.03 vs 0.86 SD 1.03), Digit Symbol Test (3.76 SD 1.09 vs 0.76 SD 0.87) or Digital Span Test (1.69 SD 0.54 vs 0.90 SD 0.72) between the TMS group and the sham group ( P <  0.05). CONCLUSIONS Taken together, we demonstrate that TMS improves the performance in the activities of daily living and attention function in patients with stroke.",2020,"Taken together, we demonstrate that TMS improves the performance in the activities of daily living and attention function in patients with stroke.","['Inpatient rehabilitation hospital', '62 stroke patients with attention dysfunction', 'after stroke', 'patients with stroke']","['TMS', 'comprehensive cognitive training', 'sham TMS', 'TMS group received 10\u2009Hz, 700 pulses of TMS', 'transcranial magnetic stimulation', 'transcranial magnetic stimulation (TMS']","['Trail Making Test-A (TMT-A), Digit Symbol Test (DST) and Digital Span Test (DS', 'cognition of Functional Independence Measure', 'activities of daily living and attention function', 'performance of the activities of daily living and attention function', 'errors number in Trail Making Test-A', 'performance in the activities of daily living', 'Mini-Mental State Examination', 'motor of Functional Independence Measure', 'Digit Symbol Test', 'Digital Span Test', 'activities of daily living (ADL) and attention function', 'Functional Independence Measure (FIM', 'right hemisphere lesion', 'total of Functional Independence Measure']","[{'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0337962', 'cui_str': 'Rehabilitation hospital'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}]","[{'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517862', 'cui_str': '700'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}]","[{'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0040604', 'cui_str': 'Trail making test'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0451172', 'cui_str': 'Functional independence measure'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0228175', 'cui_str': 'Right cerebral hemisphere structure'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",62.0,0.395348,"Taken together, we demonstrate that TMS improves the performance in the activities of daily living and attention function in patients with stroke.","[{'ForeName': 'Yuanwen', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Rehabilitation Medicine, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.'}, {'ForeName': 'Mingyu', 'Initials': 'M', 'LastName': 'Yin', 'Affiliation': 'Department of Rehabilitation Medicine, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Luo', 'Affiliation': 'Department of Rehabilitation Medicine, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Department of Rehabilitation Medicine, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.'}, {'ForeName': 'Shuxian', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': 'Department of Rehabilitation Medicine, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.'}, {'ForeName': 'Cuihuan', 'Initials': 'C', 'LastName': 'Pan', 'Affiliation': 'Department of Rehabilitation Medicine, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Xiquan', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'Department of Rehabilitation Medicine, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.'}]",Clinical rehabilitation,['10.1177/0269215520946386'] 2325,32748649,Daily and near-daily cannabis use is associated with HIV viral load suppression in people living with HIV who use cocaine.,"Disparities remain in HIV viral load (VL) suppression between people living with HIV (PLWH) who use cocaine and those who do not. It is not known how cannabis use affects VL suppression in PLWH who use cocaine. We evaluated the relationship between cannabis use and VL suppression among PLWH who use cocaine. We conducted a secondary data analysis of 119 baseline interviews from a randomized controlled trial in the Bronx, NY (6/2012 to 1/2017). Participants were adult PLWH prescribed antiretrovirals for ≥16 weeks, who endorsed imperfect antiretroviral adherence and used cocaine in the past 30-days. In bivariate and multivariable regression analyses, we examined how cannabis use, is associated with VL suppression among PLWH who use cocaine. Participants were a mean age of 50 years; most were male (64%) and non-Hispanic black (55%). Participants with VL suppression used cocaine less frequently than those with no VL suppression ( p  < 0.01); cannabis use was not significantly different. In regression analysis, compared with no use, daily/near-daily cannabis use was associated with VL suppression (aOR = 4.2, 95% CI: 1.1-16.6, p  < 0.05). Less-frequent cannabis use was not associated with VL suppression. Further investigation is needed to understand how cannabis use impacts HIV outcomes among PLWH who use cocaine.",2020,Participants with VL suppression used cocaine less frequently than those with no VL suppression ( p  < 0.01); cannabis use was not significantly different.,"['119 baseline interviews from a randomized controlled trial in the Bronx, NY (6/2012 to 1/2017', 'Participants were adult PLWH prescribed antiretrovirals for ≥16 weeks, who endorsed imperfect antiretroviral adherence and used cocaine in the past 30-days', 'people living with HIV who use cocaine', 'Participants were a mean age of 50 years; most were male (64%) and non-Hispanic black (55', 'people living with HIV (PLWH) who use cocaine and those who do not']",['cocaine'],['VL suppression'],"[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0599685', 'cui_str': 'Antiretroviral-containing product'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C1299585', 'cui_str': 'Does not'}]","[{'cui': 'C0009170', 'cui_str': 'Cocaine'}]","[{'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}]",,0.0523414,Participants with VL suppression used cocaine less frequently than those with no VL suppression ( p  < 0.01); cannabis use was not significantly different.,"[{'ForeName': 'Deepika E', 'Initials': 'DE', 'LastName': 'Slawek', 'Affiliation': 'Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Arnsten', 'Affiliation': 'Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Sohler', 'Affiliation': 'City University of New York School of Medicine, New York, NY, USA.'}, {'ForeName': 'Chenshu', 'Initials': 'C', 'LastName': 'Zhang', 'Affiliation': 'Montefiore Medical Center, Bronx, NY, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Grossberg', 'Affiliation': 'Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Stein', 'Affiliation': 'Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA.'}, {'ForeName': 'Chinazo O', 'Initials': 'CO', 'LastName': 'Cunningham', 'Affiliation': 'Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA.'}]",AIDS care,['10.1080/09540121.2020.1799922'] 2326,32749096,"A Quality-of-Life Study in Healthy Adults Supplemented with Lentinex® Beta-Glucan of Shiitake Culinary-Medicinal Mushroom, Lentinus edodes (Agaricomycetes).","Lentinus edodes (=Lentinula edodes) is a culinary-medicinal mushroom with a long tradition of use in Asia. The major active substance in L. edodes is a beta-(1-3,1-6)-glucan (lentinan). GlycaNova produces Lentinex®, which contains this beta-glucan from L. edodes mycelia, in a proprietary process that maintains the triple helix molecular structure and high molecular weights. This study was carried out to investigate the effect of Lentinex supplementation on the well-being of adults. We evaluated the effect of Lentinex in healthy adult subjects in a randomized, placebo-controlled, double-blind trial. Sixty-three subjects, randomly allocated to two groups, took orally either 1-2 mL/day Lentinex (1-2 mg beta-glucan) or placebo for four weeks. The participants completed a well-being questionnaire prior to commencing supplementation and again at the end of the in-home study. The results showed an important and statistically significant improvement in well-being over the period in the treated group compared with the placebo group. The degree of improvement in the treated group, including relative to placebo, was higher for subjects who had lower initial well-being than for subjects with higher initial well-being. In conclusion, the lower an individual's initial well-being, the more Lentinex helped.",2020,"The degree of improvement in the treated group, including relative to placebo, was higher for subjects who had lower initial well-being than for subjects with higher initial well-being.","['healthy adult subjects', 'Healthy Adults', 'Sixty-three subjects']","['placebo', 'Lentinex supplementation', 'Lentinex®', 'Lentinex']",[],"[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C4319614', 'cui_str': '63'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]",[],63.0,0.148439,"The degree of improvement in the treated group, including relative to placebo, was higher for subjects who had lower initial well-being than for subjects with higher initial well-being.","[{'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Aldwinckle', 'Affiliation': 'GlycaNova AS, Øraveien Industrial Estate, Øraveien 2, 1630 Gamle Fredrikstad, Norway.'}, {'ForeName': 'Bjorn', 'Initials': 'B', 'LastName': 'Kristiansen', 'Affiliation': 'Department of Bioscience and Biotechnology, University of Strathclyde, Glasgow, Scotland G1 1XW, UK; GlycaNova AS, Øraveien Industrial Estate, Øraveien 2, 1630 Gamle Fredrikstad, Norway.'}]",International journal of medicinal mushrooms,['10.1615/IntJMedMushrooms.2020034208'] 2327,32749173,"Assessing the analgesic efficacy of oral epigallocatechin-3-gallate on epidural catheter analgesia in patients after surgical stabilisation of multiple rib fractures: a prospective double-blind, placebo-controlled clinical trial.","CONTEXT Thoracic trauma results in multiple rib fractures (MRF), and surgical stabilisation of rib fractures (SSRF) can relieve fracture pain. Epigallocatechin-3-gallate (EGCG) is reported to exhibit beneficial effects in bone-related metabolic and differentiation processes. OBJECTIVE To study the clinical effect of EGCG on regional analgesia for pain relief in MRF patients after SSRF. MATERIALS AND METHODS Ninety-seven MRF patients (61 males, 36 females) who were on epidural catheter analgesia after SSRF were recruited. They were randomly divided into: oral EGCG 100 mg (oral grade) twice daily for 10 days and placebo groups. Pain scores, incentive spirometry (IS) volumes, respiratory rate and oxygen saturation (SpO 2 ) were assessed day 10 after SSRF. RESULTS Comparing results from the placebo and EGCG group, in the 10-day intervention course, oral EGCG reduced pain score (8 at base line vs. 4 at end of intervention in EGCG group, p  < 0.05; 4 in EGCG group vs. 6 in placebo group at end of intervention, p  < 0.05), improved IS volume (713 at base line vs. 1072 at end of intervention in EGCG group, p  < 0.05; 1072 in EGCG group vs. 953 in placebo group at end of intervention, p  < 0.05) and respiratory rate (24 at base line vs. 15 at end of intervention in EGCG group, p  < 0.05; 15 in EGCG group vs. 19 in placebo group at end of intervention, p  < 0.05). However, no further enhancing effect on SpO 2 was observed in the EGCG group (0.98 in EGCG group vs. 0.98 in placebo group at end of intervention, p  > 0.05). DISCUSSION AND CONCLUSIONS Although the study is limited by a relatively small sample size and lack of serum factor analysis, the key results and the study design, for the first time, nevertheless pave the way for trials with larger number of patients to understand the effect of EGCG in MRF patients that are undergoing SSRF.",2020,"However, no further enhancing effect on SpO 2 was observed in the EGCG group (0.98 in EGCG group vs. 0.98 in placebo group at end of intervention, p  > 0.05). ","['patients after surgical stabilisation of multiple rib fractures', 'Ninety-seven MRF patients (61 males, 36 females) who were on epidural catheter analgesia after SSRF were recruited', 'MRF patients after SSRF']","['EGCG', 'oral EGCG 100\u2009mg (oral grade) twice daily for 10\u2009days and placebo', 'oral epigallocatechin-3-gallate', 'placebo and EGCG', 'Epigallocatechin-3-gallate (EGCG', 'epidural catheter analgesia', 'placebo']","['pain relief', 'SpO 2', 'oral EGCG reduced pain score', 'analgesic efficacy', 'respiratory rate', 'Pain scores, incentive spirometry (IS) volumes, respiratory rate and oxygen saturation (SpO 2 ', 'IS volume']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0272567', 'cui_str': 'Fracture of multiple ribs'}, {'cui': 'C0439073', 'cui_str': '97'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0179751', 'cui_str': 'Epidural catheter'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0035522', 'cui_str': 'Fracture of rib'}]","[{'cui': 'C0059438', 'cui_str': 'epigallocatechin gallate'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0179751', 'cui_str': 'Epidural catheter'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]","[{'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0059438', 'cui_str': 'epigallocatechin gallate'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0454512', 'cui_str': 'Incentive spirometry'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}]",97.0,0.0849642,"However, no further enhancing effect on SpO 2 was observed in the EGCG group (0.98 in EGCG group vs. 0.98 in placebo group at end of intervention, p  > 0.05). ","[{'ForeName': 'Lihong', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.'}, {'ForeName': 'Weifeng', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.'}, {'ForeName': 'Haiping', 'Initials': 'H', 'LastName': 'You', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.'}, {'ForeName': 'Zhiyuan', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.'}, {'ForeName': 'Liming', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.'}, {'ForeName': 'Hefan', 'Initials': 'H', 'LastName': 'He', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.'}]",Pharmaceutical biology,['10.1080/13880209.2020.1797123'] 2328,32749224,A Web-Based Positive Psychological Intervention to Improve Blood Pressure Control in Spanish-Speaking Hispanic/Latino Adults With Uncontrolled Hypertension: Protocol and Design for the ¡Alégrate! Randomized Controlled Trial.,"BACKGROUND Growing evidence links psychological well-being and resilience with superior cardiac health, but there remains a critical scientific gap about whether (or how) interventions that aim to cultivate psychological well-being reduce cardiac risk. Hispanic/Latino people in the United States have high cardiovascular disease risk and poorly controlled blood pressure (BP) compared with their peers of European ancestry, and they represent a population in need of new and innovative therapeutic approaches. As such, a focused intervention to boost psychological well-being holds promise as a novel therapeutic target for hypertension in Hispanic/Latino adults; to date, however, no research has explored whether a causal link is evident. OBJECTIVE The aim of this paper is to detail the protocol for the ¡Alégrate! (Be Happy!) intervention, a Phase II randomized controlled trial testing initial efficacy in improving BP of a web-based positive psychological intervention designed to boost psychological well-being in Spanish-speaking Hispanic/Latino people with hypertension. METHODS A total of 70 Hispanic/Latino people aged ≥18 years, fluent in Spanish, and with elevated BP (≥140/90 mm Hg) will be recruited in person from a single Federally Qualified Health Center in Chicago. Enrollees will be randomly assigned to 1 of 2 trial arms: (1) web-based positive psychological intervention or (2) an active control condition (eg, 3 times weekly emotion reporting). Our 5-week Spanish-language ¡Alégrate! intervention is web-based and delivers curricular content via didactic instruction, journaling, and assigned at-home practice-all accessed via our website using investigator-purchased tablet computers, with a unique username and password assigned to each enrollee. Targeted skills include noting daily positive events, positive reappraisal of stressful events, effective expression of gratitude, performing acts of kindness, and regular practice of mindfulness and meditation. The primary outcome is improvement in BP, both sitting values and 24-hour ambulatory readings, as measured at baseline and 5 and 12 weeks from baseline. Secondary outcomes include psychological well-being, engagement in healthy behaviors, and circulating levels of inflammatory markers. The outcomes of interest are collected by trained research staff through in-person interviews using the REDCap software. RESULTS Activities of the ¡Alégrate! intervention were funded in August 2017, and data collection is ongoing. We expect to submit trial results for peer-reviewed publications in 2021, soon after recruitment has been concluded and statistical analyses are finalized. CONCLUSIONS Findings will provide evidence on whether interventions to boost psychological well-being and resilience have downstream effects on BP control and cardiovascular health, particularly as they are deployed in the Spanish language with cultural tailoring and via a web-based platform. If effective, we will have an easily disseminatable application that can positively impact well-being profiles and BP control in Hispanic/Latino people, with the possibility of addressing health disparities of this US racial/ethnic minority group. TRIAL REGISTRATION ClinicalTrials.gov NCT03892057; https://clinicaltrials.gov/ct2/show/NCT03892057. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) PRR1-10.2196/17721.",2020,"intervention, a Phase II randomized controlled trial testing initial efficacy in improving BP of a web-based positive psychological intervention designed to boost psychological well-being in Spanish-speaking Hispanic/Latino people with hypertension. ","['Spanish-Speaking Hispanic/Latino Adults With Uncontrolled Hypertension', '70 Hispanic/Latino people aged ≥18 years, fluent in Spanish, and with elevated BP (≥140/90 mm Hg) will be recruited in person from a single Federally Qualified Health Center in Chicago', 'Spanish-speaking Hispanic/Latino people with hypertension', 'hypertension in Hispanic/Latino adults']","['A Web-Based Positive Psychological Intervention', 'web-based positive psychological intervention or (2) an active control condition (eg, 3 times weekly emotion reporting']","['psychological well-being, engagement in healthy behaviors, and circulating levels of inflammatory markers', 'blood pressure (BP', 'Targeted skills include noting daily positive events, positive reappraisal of stressful events, effective expression of gratitude, performing acts of kindness, and regular practice of mindfulness and meditation', 'Blood Pressure Control', 'improvement in BP, both sitting values and 24-hour ambulatory readings']","[{'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1868885', 'cui_str': 'Uncontrolled hypertension'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0008044', 'cui_str': 'Chicago'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}]","[{'cui': 'C0424578', 'cui_str': 'Well in self'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0034754', 'cui_str': 'Reading'}]",,0.23269,"intervention, a Phase II randomized controlled trial testing initial efficacy in improving BP of a web-based positive psychological intervention designed to boost psychological well-being in Spanish-speaking Hispanic/Latino people with hypertension. ","[{'ForeName': 'Rosalba', 'Initials': 'R', 'LastName': 'Hernandez', 'Affiliation': 'School of Social Work, University of Illinois at Urbana-Champaign, Urbana, IL, United States.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Cohn', 'Affiliation': 'Osher Center for Integrative Medicine, University of California, San Francisco, San Francisco, CA, United States.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Hernandez', 'Affiliation': 'Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.'}, {'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Daviglus', 'Affiliation': 'Institute for Minority Health Research, University of Illinois at Chicago College of Medicine, Chicago, IL, United States.'}, {'ForeName': 'Lizet', 'Initials': 'L', 'LastName': 'Martinez', 'Affiliation': 'School of Social Work, University of Illinois at Urbana-Champaign, Urbana, IL, United States.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Martinez', 'Affiliation': 'Department of Psychology, University of Illinois at Chicago, Chicago, IL, United States.'}, {'ForeName': 'Itzel', 'Initials': 'I', 'LastName': 'Martinez', 'Affiliation': 'School of Social Work, University of Illinois at Urbana-Champaign, Urbana, IL, United States.'}, {'ForeName': 'Ramon', 'Initials': 'R', 'LastName': 'Durazo-Arvizu', 'Affiliation': 'Institute for Minority Health Research, University of Illinois at Chicago College of Medicine, Chicago, IL, United States.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Moskowitz', 'Affiliation': 'Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.'}]",JMIR research protocols,['10.2196/17721'] 2329,32749459,"Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial.","AIMS Cardiosphere-derived cells (CDCs) are cardiac progenitor cells that exhibit disease-modifying bioactivity in various models of cardiomyopathy and in previous clinical studies of acute myocardial infarction (MI), dilated cardiomyopathy, and Duchenne muscular dystrophy. The aim of the study was to assess the safety and efficacy of intracoronary administration of allogeneic CDCs in the multicentre, randomized, double-blinded, placebo-controlled, intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR) trial. METHODS AND RESULTS We enrolled patients 4 weeks to 12 months after MI, with left ventricular ejection fraction (LVEF) ≤45% and LV scar size ≥15% of LV mass by magnetic resonance imaging (MRI). A pre-specified interim analysis was performed when 6-month MRI data were available. The trial was subsequently stopped due to the low probability of detecting a significant treatment effect of CDCs based on the primary endpoint. Patients were randomly allocated in a 2:1 ratio to receive CDCs or placebo in the infarct-related artery by stop-flow technique. The primary safety endpoint was the occurrence, during 1-month post-intracoronary infusion, of acute myocarditis attributable to allogeneic CDCs, ventricular tachycardia- or ventricular fibrillation-related death, sudden unexpected death, or a major adverse cardiac event (death or hospitalization for heart failure or non-fatal MI or need for left ventricular assist device or heart transplant). The primary efficacy endpoint was the relative percentage change in infarct size at 12 months post-infusion as assessed by contrast-enhanced cardiac MRI. We randomly allocated 142 eligible patients of whom 134 were treated (90 to the CDC group and 44 to the placebo group). The mean baseline LVEF was 40% and the mean scar size was 22% of LV mass. No primary safety endpoint events occurred. There was no difference in the percentage change from baseline in scar size (P = 0.51) between CDCs and placebo groups at 6 months. Compared with placebo, there were significant reductions in LV end-diastolic volume (P = 0.02), LV end-systolic volume (P = 0.02), and N-terminal pro b-type natriuretic peptide (NT-proBNP) (P = 0.02) at 6 months in CDC-treated patients. CONCLUSION Intracoronary infusion of allogeneic CDCs in patients with post-MI LV dysfunction was safe but did not reduce scar size relative to placebo at 6 months. Nevertheless, the reductions in LV volumes and NT-proBNP reveal disease-modifying bioactivity of CDCs. TRIAL REGISTRATION Clinicaltrials.gov identifier: NCT01458405.",2020,There was no difference in the percentage change from baseline in scar size (P = 0.51) between CDCs and placebo groups at 6 months.,"['142 eligible patients of whom 134 were treated (90 to the CDC group and 44 to the placebo group', 'enrolled patients 4\u2009weeks to 12\u2009months after MI, with left ventricular ejection fraction (LVEF) ≤45% and LV scar size ≥15% of LV mass by magnetic resonance imaging (MRI', 'patients with post-MI LV dysfunction']","['Cardiosphere-derived cells (CDCs', 'placebo', 'CDCs or placebo', 'placebo-controlled, intracoronary ALLogeneic heart STem cells', 'Intracoronary ALLogeneic heart STem cells', 'allogeneic CDCs']","['relative percentage change in infarct size', 'mean baseline LVEF', 'scar size', 'LV volumes and NT-proBNP reveal disease-modifying bioactivity of CDCs', 'scar size relative', 'safety and efficacy', 'mean scar size', 'LV end-systolic volume', 'LV end-diastolic volume', 'occurrence, during 1-month post-intracoronary infusion, of acute myocarditis attributable to allogeneic CDCs, ventricular tachycardia- or ventricular fibrillation-related death, sudden unexpected death, or a major adverse cardiac event (death or hospitalization for heart failure or non-fatal MI or need for left ventricular assist device or heart transplant']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0007670', 'cui_str': 'Centers for Disease Control and Prevention (U.S.)'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0455825', 'cui_str': 'Left ventricular mass'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}]","[{'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0595454', 'cui_str': 'Intracoronary route'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0038250', 'cui_str': 'Stem cell'}]","[{'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0021308', 'cui_str': 'Infarct'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0443289', 'cui_str': 'Revealed'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0595454', 'cui_str': 'Intracoronary route'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0155686', 'cui_str': 'Acute myocarditis'}, {'cui': 'C0042514', 'cui_str': 'Ventricular tachycardia'}, {'cui': 'C0042510', 'cui_str': 'Ventricular fibrillation'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1276802', 'cui_str': 'Sudden'}, {'cui': 'C0277591', 'cui_str': 'Unexpected death'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0085842', 'cui_str': 'Ventricular assist device'}, {'cui': 'C0018823', 'cui_str': 'Transplantation of heart'}]",142.0,0.688567,There was no difference in the percentage change from baseline in scar size (P = 0.51) between CDCs and placebo groups at 6 months.,"[{'ForeName': 'Raj R', 'Initials': 'RR', 'LastName': 'Makkar', 'Affiliation': 'Smidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.'}, {'ForeName': 'Dean J', 'Initials': 'DJ', 'LastName': 'Kereiakes', 'Affiliation': 'The Christ Hospital, Cincinnati, 2139 Auburn Ave, Cincinnati, OH 45219, USA.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Aguirre', 'Affiliation': 'Prairie/St. Johns Hospital, Springfield, 800 E Carpenter St, Springfield, IL 62769, USA.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Kowalchuk', 'Affiliation': 'Sanger Heart & Vascular, Charlotte, 1001 Blythe Blvd Ste 300, Charlotte, NC 28203, USA.'}, {'ForeName': 'Tarun', 'Initials': 'T', 'LastName': 'Chakravarty', 'Affiliation': 'Smidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.'}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Malliaras', 'Affiliation': 'University of Athens, 17 Agiou Thoma street, 11527, Athens, Greece.'}, {'ForeName': 'Gary S', 'Initials': 'GS', 'LastName': 'Francis', 'Affiliation': 'University of Minnesota Heart Care, Minneapolis, 6405 France Ave S, Edina, MN 55435, USA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Povsic', 'Affiliation': 'Duke University Hospital, Durham, 2301 Erwin Rd, Durham, NC 27710, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Schatz', 'Affiliation': 'Scripps Green Hospital, 10666 N Torrey Pines Rd, La Jolla, CA 92037, USA.'}, {'ForeName': 'Jay H', 'Initials': 'JH', 'LastName': 'Traverse', 'Affiliation': 'Minneapolis Heart Institute Foundation, 920 E 28th St Ste 100, Minneapolis, MN 55407, USA.'}, {'ForeName': 'Janice M', 'Initials': 'JM', 'LastName': 'Pogoda', 'Affiliation': 'Capricor Therapeutics, Los Angeles, 8840 Wilshire Blvd Ste 2, Beverly Hills, CA 90211, USA.'}, {'ForeName': 'Rachel R', 'Initials': 'RR', 'LastName': 'Smith', 'Affiliation': 'Capricor Therapeutics, Los Angeles, 8840 Wilshire Blvd Ste 2, Beverly Hills, CA 90211, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Marbán', 'Affiliation': 'Capricor Therapeutics, Los Angeles, 8840 Wilshire Blvd Ste 2, Beverly Hills, CA 90211, USA.'}, {'ForeName': 'Deborah D', 'Initials': 'DD', 'LastName': 'Ascheim', 'Affiliation': 'Capricor Therapeutics, Los Angeles, 8840 Wilshire Blvd Ste 2, Beverly Hills, CA 90211, USA.'}, {'ForeName': 'Mohammad R', 'Initials': 'MR', 'LastName': 'Ostovaneh', 'Affiliation': 'Johns Hopkins University, 3400 N Charles St, Baltimore, MD 21218, USA.'}, {'ForeName': 'João A C', 'Initials': 'JAC', 'LastName': 'Lima', 'Affiliation': 'Johns Hopkins University, 3400 N Charles St, Baltimore, MD 21218, USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'DeMaria', 'Affiliation': 'University of California San Diego Medical Center, 200 W. Arbor Drive, San Diego, CA 92103, USA.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Marbán', 'Affiliation': 'Smidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.'}, {'ForeName': 'Timothy D', 'Initials': 'TD', 'LastName': 'Henry', 'Affiliation': 'Smidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.'}]",European heart journal,['10.1093/eurheartj/ehaa541'] 2330,32749468,Effectiveness of Emotional Memory Reactivation vs Control Memory Reactivation Before Electroconvulsive Therapy in Adult Patients With Depressive Disorder: A Randomized Clinical Trial.,"Importance Although electroconvulsive therapy (ECT) is often effective, approximately half of patients with depression undergoing ECT do not benefit sufficiently, and relapse rates are high. ECT sessions have been shown to weaken reactivated memories. The effect of emotional memory retrieval on cognitive schemas remains unknown. Objective To assess whether emotional memory retrieval just before patients receive ECT sessions weakens underlying cognitive schemas, improves ECT effectiveness, increases ECT response, and reduces relapse rates. Design, Setting, and Participants In this multicenter randomized clinical trial conducted from 2014 to 2018 in the departments of psychiatry in 3 hospitals in the Netherlands, 72 participants were randomized 1:1 to 2 parallel groups to receive either emotional memory reactivation (EMR-ECT) or control memory reactivation (CMR-ECT) interventions before ECT sessions. The Hamilton Depression Rating Scale (HDRS [total score range: 0-52, with 0-7 indicating no depression and ≥24 indicating severe depression]) was used to measure symptoms of depression during and after ECT, with a 6-month follow-up period. Participants were between ages 18 and 70 years with a primary diagnosis of unipolar major depressive disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition, Text Revision) and in whom ECT was indicated. Data analysis was performed from July to November 2019. Interventions EMR-ECT or CMR-ECT interventions prior to ECT sessions. Main Outcomes and Measures Depression scores and relapse rates within 6 months were assessed with the HDRS and analyzed using logistic and linear multiple regression analyses. Results A total of 66 patients (mean [SD] age, 49.3 [12.3] years; 39 [59.1%] women) were randomized to the EMR-ECT group (n = 32) or the CMR-ECT group (n = 34). Regardless of the memory intervention, 42.4% (28 of 66) of patients responded (≥50% decrease of symptom severity on the HDRS). Of patients who responded, 39.3% (11 of 28) relapsed within 6 months. Remission rates (CMR-ECT group, 29.4% [10 of 34] vs EMR-ECT group, 25.0% [8 of 32]; P = .58), mean (SD) HDRS scores after the ECT course (CMR-ECT group, 14.6 [8.6] vs EMR-ECT group, 14.9 [8.8]; P = .88), total mean (SD) number of required ECT sessions for response (CMR-ECT group, 14.9 [7.9] vs EMR-ECT group, 15.6 [7.3]; P = .39), and relapse rates (CMR-ECT group, 46.7% [7 of 15] vs EMR-ECT group, 30.8% [4 of 13]; P = .33) were not significantly altered by the intervention. Conclusions and Relevance Study findings suggest that the EMR-ECT intervention just before patient receipt of ECT for depression did not improve effectiveness, increase speed of response, or reduce relapse rates after the ECT course compared with patients receiving CMR-ECT. Trial Registration Trialregister.nl Identifier: NL4289.",2020,"Regardless of the memory intervention, 42.4% (28 of 66) of patients responded (≥50% decrease of symptom severity on the HDRS).","['Participants were between ages 18 and 70 years with a primary diagnosis of unipolar major depressive disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders', '2014 to 2018 in the departments of psychiatry in 3 hospitals in the Netherlands, 72 participants', 'Adult Patients With Depressive Disorder', '66 patients (mean [SD] age, 49.3 [12.3] years; 39 [59.1%] women']","['Emotional Memory Reactivation vs Control Memory Reactivation', 'electroconvulsive therapy (ECT', 'EMR-ECT', 'CMR-ECT', 'ECT sessions', 'emotional memory retrieval', 'Electroconvulsive Therapy', 'EMR-ECT intervention', 'emotional memory reactivation (EMR-ECT) or control memory reactivation (CMR-ECT) interventions before ECT sessions', 'EMR-ECT or CMR-ECT interventions']","['total mean (SD) number of required ECT sessions for response', 'ECT effectiveness, increases ECT response', 'relapse rates', 'Hamilton Depression Rating Scale (HDRS [total score range', 'mean (SD) HDRS scores', 'speed of response, or reduce relapse rates', 'Remission rates', 'Measures\n\n\nDepression scores and relapse rates']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332137', 'cui_str': 'Principal diagnosis'}, {'cui': 'C0443340', 'cui_str': 'Unipolar'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C1136324', 'cui_str': 'Diagnostic and Statistical Manual of Mental Disorders'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011581', 'cui_str': 'Depressive disorder'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C5191283', 'cui_str': '12.3'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0006802', 'cui_str': 'Cameroon'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C1840333', 'cui_str': 'Hypoparathyroidism, deafness, renal disease syndrome'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",72.0,0.0967269,"Regardless of the memory intervention, 42.4% (28 of 66) of patients responded (≥50% decrease of symptom severity on the HDRS).","[{'ForeName': 'Dominique S', 'Initials': 'DS', 'LastName': 'Scheepens', 'Affiliation': 'Department of Psychiatry, Amsterdam Neuroscience, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Jeroen A', 'Initials': 'JA', 'LastName': 'van Waarde', 'Affiliation': 'Department of Psychiatry, Rijnstate Hospital, Arnhem, the Netherlands.'}, {'ForeName': 'Freek', 'Initials': 'F', 'LastName': 'Ten Doesschate', 'Affiliation': 'Department of Psychiatry, Rijnstate Hospital, Arnhem, the Netherlands.'}, {'ForeName': 'Mirjam', 'Initials': 'M', 'LastName': 'Westra', 'Affiliation': 'Department of Psychiatry, UMC Groningen, University of Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Marijn C W', 'Initials': 'MCW', 'LastName': 'Kroes', 'Affiliation': 'Donders Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Aart H', 'Initials': 'AH', 'LastName': 'Schene', 'Affiliation': 'Donders Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Claudi L H', 'Initials': 'CLH', 'LastName': 'Bockting', 'Affiliation': 'Department of Psychiatry, Amsterdam Neuroscience, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Schoevers', 'Affiliation': 'Department of Psychiatry, UMC Groningen, University of Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Damiaan A J P', 'Initials': 'DAJP', 'LastName': 'Denys', 'Affiliation': 'Department of Psychiatry, Amsterdam Neuroscience, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Henricus G', 'Initials': 'HG', 'LastName': 'Ruhé', 'Affiliation': 'Donders Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Guido A', 'Initials': 'GA', 'LastName': 'van Wingen', 'Affiliation': 'Department of Psychiatry, Amsterdam Neuroscience, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}]",JAMA network open,['10.1001/jamanetworkopen.2020.12389'] 2331,32749474,Correction to Data in Trial of Convalescent Plasma Treatment for COVID-19.,,2020,,[],[],[],[],[],[],,0.0321843,,[],JAMA,['10.1001/jama.2020.13216'] 2332,32749491,Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial.,"Importance Low levels of 25-hydroxyvitamin D have been associated with higher risk for depression later in life, but there have been few long-term, high-dose large-scale trials. Objective To test the effects of vitamin D3 supplementation on late-life depression risk and mood scores. Design, Setting, and Participants There were 18 353 men and women aged 50 years or older in the VITAL-DEP (Vitamin D and Omega-3 Trial-Depression Endpoint Prevention) ancillary study to VITAL, a randomized clinical trial of cardiovascular disease and cancer prevention among 25 871 adults in the US. There were 16 657 at risk for incident depression (ie, no depression history) and 1696 at risk for recurrent depression (ie, depression history but no treatment for depression within the past 2 years). Randomization occurred from November 2011 through March 2014; randomized treatment ended on December 31, 2017, and this was the final date of follow-up. Intervention Randomized assignment in a 2 × 2 factorial design to vitamin D3 (2000 IU/d of cholecalciferol) and fish oil or placebo; 9181 were randomized to vitamin D3 and 9172 were randomized to matching placebo. Main Outcomes and Measures The primary outcomes were the risk of depression or clinically relevant depressive symptoms (total of incident and recurrent cases) and the mean difference in mood scores (8-item Patient Health Questionnaire depression scale [PHQ-8]; score range, 0 points [least symptoms] to 24 points [most symptoms]; the minimal clinically important difference for change in scores was 0.5 points). Results Among the 18 353 randomized participants (mean age, 67.5 [SD, 7.1] years; 49.2% women), the median treatment duration was 5.3 years and 90.5% completed the trial (93.5% among those alive at the end of the trial). Risk of depression or clinically relevant depressive symptoms was not significantly different between the vitamin D3 group (609 depression or clinically relevant depressive symptom events; 12.9/1000 person-years) and the placebo group (625 depression or clinically relevant depressive symptom events; 13.3/1000 person-years) (hazard ratio, 0.97 [95% CI, 0.87 to 1.09]; P = .62); there were no significant differences between groups in depression incidence or recurrence. No significant differences were observed between treatment groups for change in mood scores over time; mean change in PHQ-8 score was not significantly different from zero (mean difference for change in mood scores, 0.01 points [95% CI, -0.04 to 0.05 points]). Conclusions and Relevance Among adults aged 50 years or older without clinically relevant depressive symptoms at baseline, treatment with vitamin D3 compared with placebo did not result in a statistically significant difference in the incidence and recurrence of depression or clinically relevant depressive symptoms or for change in mood scores over a median follow-up of 5.3 years. These findings do not support the use of vitamin D3 in adults to prevent depression. Trial Registration ClinicalTrials.gov Identifiers: NCT01169259 and NCT01696435.",2020,"No significant differences were observed between treatment groups for change in mood scores over time; mean change in PHQ-8 score was not significantly different from zero (mean difference for change in mood scores, 0.01 points [95% CI, -0.04 to 0.05 points]). ","['Among the 18\u202f353 randomized participants (mean age, 67.5 [SD, 7.1] years; 49.2% women', 'Participants\n\n\nThere were 18\u202f353 men and women aged 50 years or older in the VITAL-DEP (Vitamin D and Omega-3 Trial-Depression Endpoint Prevention) ancillary study to VITAL, a randomized clinical trial of cardiovascular disease and cancer prevention among 25\u202f871 adults in the US', 'adults aged 50 years or older without clinically', 'There were 16\u202f657 at risk for incident depression (ie, no depression history) and 1696 at risk for recurrent depression (ie, depression history but no treatment for depression within the past 2 years']","['Long-term Vitamin D3 Supplementation vs Placebo', '25-hydroxyvitamin D', 'vitamin D3 supplementation', 'vitamin D3 (2000 IU/d of cholecalciferol) and fish oil or placebo', 'vitamin D3', 'placebo']","['relevant depressive symptoms', 'late-life depression risk and mood scores', 'Risk of depression or clinically relevant depressive symptoms', 'depression incidence or recurrence', 'Risk of Depression or Clinically Relevant Depressive Symptoms', 'mood scores', 'risk of depression or clinically relevant depressive symptoms (total of incident and recurrent cases) and the mean difference in mood scores (8-item Patient Health Questionnaire depression scale [PHQ-8]; score range, 0 points [least symptoms', 'median treatment duration', 'Mood Scores', 'incidence and recurrence of depression or clinically relevant depressive symptoms', 'PHQ-8 score']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0442732', 'cui_str': 'Vital'}, {'cui': 'C0057472', 'cui_str': '1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0206034', 'cui_str': 'Trials, Randomized Clinical'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0221480', 'cui_str': 'Recurrent depression'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1444637', 'cui_str': 'Past'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0439465', 'cui_str': 'IU/day'}, {'cui': 'C0016157', 'cui_str': 'Fish Oils'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0444921', 'cui_str': 'Duration of treatment'}]",25871.0,0.741621,"No significant differences were observed between treatment groups for change in mood scores over time; mean change in PHQ-8 score was not significantly different from zero (mean difference for change in mood scores, 0.01 points [95% CI, -0.04 to 0.05 points]). ","[{'ForeName': 'Olivia I', 'Initials': 'OI', 'LastName': 'Okereke', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston.'}, {'ForeName': 'Charles F', 'Initials': 'CF', 'LastName': 'Reynolds', 'Affiliation': 'Department of Psychiatry, UPMC and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Mischoulon', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Chang', 'Affiliation': 'Department of Psychiatry, VA Boston Healthcare System, Brockton, Massachusetts.'}, {'ForeName': 'Chirag M', 'Initials': 'CM', 'LastName': 'Vyas', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston.'}, {'ForeName': 'Nancy R', 'Initials': 'NR', 'LastName': 'Cook', 'Affiliation': 'Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Weinberg', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Vadim', 'Initials': 'V', 'LastName': 'Bubes', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Trisha', 'Initials': 'T', 'LastName': 'Copeland', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Georgina', 'Initials': 'G', 'LastName': 'Friedenberg', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'I-Min', 'Initials': 'IM', 'LastName': 'Lee', 'Affiliation': 'Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Julie E', 'Initials': 'JE', 'LastName': 'Buring', 'Affiliation': 'Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'JoAnn E', 'Initials': 'JE', 'LastName': 'Manson', 'Affiliation': ""Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}]",JAMA,['10.1001/jama.2020.10224'] 2333,32749547,Time needed to intubate and suction a manikin prior to instituting positive pressure ventilation: a simulation trial.,"Tracheal suctioning in non-vigorous newborn delivered through meconium-stained amniotic fluid (MSAF) is supposed to delay initiation of positive pressure ventilation (PPV), but the magnitude of such delay is unknown. To compare the time of PPV initiation when performing immediate laryngoscopy with intubation and suctioning vs. performing immediate PPV without intubation in a manikin model. Randomized controlled crossover (AB/BA) trial comparing PPV initiation with or without endotracheal suctioning in a manikin model of non-vigorous neonates born through MSAF. Participants were 20 neonatologists and 20 pediatric residents trained in advanced airway management. Timing of PPV initiation was longer with vs. without endotracheal suctioning in both pediatric residents (mean difference 13 s, 95% confidence interval 8 to 18 s; p < 0.0001) and neonatologists (mean difference 12 s, 95% confidence interval 8 to 16 s; p < 0.0001). The difference in timing of PPV initiation was similar between pediatric residents and neonatologists (mean difference - 1 s, 95% confidence interval - 7 to 6 s; p = 0.85).Conclusions: Performing immediate laryngoscopy with intubation and suctioning was associated with longer-but not clinically relevant-time of initiation of PPV compared with immediate PPV without intubation in a manikin model. While suggesting negligible delay in starting PPV, further studies in a clinical setting are warranted.Registration: clinicaltrial.gov NCT04076189. What is Known: • Management of the non-vigorous newborn delivered through meconium-stained amniotic fluid remains still controversial. • Tracheal suctioning in non-vigorous newborn delivered through meconium-stained amniotic fluid is supposed to delay initiation of positive pressure ventilation, but the magnitude of such delay is unknown. What is New: • Performing immediate ventilation without intubation was associated with shorter-but not clinically relevant-time of initiation of ventilation compared to immediate laryngoscopy with intubation and suctioning in a manikin model. • Further studies in a clinical setting are warranted.",2020,Performing immediate ventilation without intubation was associated with shorter-but not clinically relevant-time of initiation of ventilation compared to immediate laryngoscopy with intubation and suctioning in a manikin model.,"['non-vigorous neonates born through MSAF', 'Participants were 20 neonatologists and 20 pediatric residents trained in advanced airway management']","['Tracheal suctioning', 'meconium-stained amniotic fluid (MSAF', 'PPV initiation with or without endotracheal suctioning', 'intubate and suction a manikin prior to instituting positive pressure ventilation', 'immediate laryngoscopy with intubation and suctioning vs. performing immediate PPV without intubation']","['timing of PPV initiation', 'neonatologists']","[{'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0426209', 'cui_str': 'Amniotic fluid -meconium stain'}, {'cui': 'C0334898', 'cui_str': 'Neonatologist'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0150126', 'cui_str': 'Airway management'}]","[{'cui': 'C2945595', 'cui_str': 'Tracheal'}, {'cui': 'C0038638', 'cui_str': 'Suction drainage'}, {'cui': 'C0426209', 'cui_str': 'Amniotic fluid -meconium stain'}, {'cui': 'C0021778', 'cui_str': 'Intermittent positive pressure ventilation'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C1522653', 'cui_str': 'Intratracheal route'}, {'cui': 'C0024722', 'cui_str': 'Mannequins'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0023072', 'cui_str': 'Laryngoscopy'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0449243', 'cui_str': 'Timing'}, {'cui': 'C0021778', 'cui_str': 'Intermittent positive pressure ventilation'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0334898', 'cui_str': 'Neonatologist'}]",,0.336006,Performing immediate ventilation without intubation was associated with shorter-but not clinically relevant-time of initiation of ventilation compared to immediate laryngoscopy with intubation and suctioning in a manikin model.,"[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Cavallin', 'Affiliation': ', Solagna, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Res', 'Affiliation': 'Department of Women and Children Health, University of Padova, Via Giustiniani, 3, 35128, Padova, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Monfredini', 'Affiliation': 'Fondazione Poliambulanza, Brescia, Italy.'}, {'ForeName': 'Nicoletta', 'Initials': 'N', 'LastName': 'Doglioni', 'Affiliation': 'Department of Women and Children Health, University of Padova, Via Giustiniani, 3, 35128, Padova, Italy.'}, {'ForeName': 'Paolo Ernesto', 'Initials': 'PE', 'LastName': 'Villani', 'Affiliation': 'Fondazione Poliambulanza, Brescia, Italy.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Weiner', 'Affiliation': 'Division of Neonatal-Perinatal Medicine, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Trevisanuto', 'Affiliation': 'Department of Women and Children Health, University of Padova, Via Giustiniani, 3, 35128, Padova, Italy. daniele.trevisanuto@unipd.it.'}]",European journal of pediatrics,['10.1007/s00431-020-03759-5'] 2334,32744859,The role of health anxiety in the experience of perceived stress across the menstrual cycle.,"Background: Hormonal variation throughout the menstrual cycle influences physiological and psychological symptoms, although not for all women. Individual differences in health anxiety (HA) might help to explain the differences in physiological and psychological symptoms and perceived stress observed across women. Design: We examined the moderating role of HA in the relation between menstrual phase and premenstrual symptom severity and perceived stress. Methods: A total of 38 women completed visits in both late luteal and follicular phases, with visit order randomized. Menstrual phase was verified using day-count, a luteinizing hormone test, and progesterone assay. Results: Linear mixed models revealed that women experienced more premenstrual symptoms during the late luteal phase vs. the follicular phase; however, HA did not moderate this effect. There was a significant HA × menstrual cycle phase interaction for perceived stress. During the late luteal phase, women with higher HA reported greater perceived stress compared to women with lower HA. In the follicular phase, women with higher and lower HA reported similar levels of perceived stress. Conclusion: Higher levels of HA may play a role in the experience of perceived stress in specific phases of the menstrual cycle.",2020,There was a significant HA × menstrual cycle phase interaction for perceived stress.,"['38 women completed visits in both late luteal and follicular phases, with visit order randomized']",[],"['health anxiety (HA', 'premenstrual symptoms']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0016434', 'cui_str': 'Menstrual Cycle, Proliferative Phase'}, {'cui': 'C4284072', 'cui_str': 'Order document'}]",[],"[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0232959', 'cui_str': 'Premenstrual symptom'}]",38.0,0.0325567,There was a significant HA × menstrual cycle phase interaction for perceived stress.,"[{'ForeName': 'D R', 'Initials': 'DR', 'LastName': 'Shayani', 'Affiliation': 'Department of Psychiatry, Boston University School of Medicine, Boston, MA, USA.'}, {'ForeName': 'K A', 'Initials': 'KA', 'LastName': 'Arditte Hall', 'Affiliation': 'Department of Psychology & Philosophy, Framingham State University.'}, {'ForeName': 'B C', 'Initials': 'BC', 'LastName': 'Isley', 'Affiliation': 'College of Science, Northeastern University, Boston, MA, USA.'}, {'ForeName': 'K J', 'Initials': 'KJ', 'LastName': 'Rohan', 'Affiliation': 'Department of Psychological Science, University of Vermont, Burlington, VT, USA.'}, {'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'Zvolensky', 'Affiliation': 'Department of Psychology, University of Houston, Houston, TX, USA.'}, {'ForeName': 'Y I', 'Initials': 'YI', 'LastName': 'Nillni', 'Affiliation': 'Department of Psychiatry, Boston University School of Medicine, Boston, MA, USA.'}]","Anxiety, stress, and coping",['10.1080/10615806.2020.1802434'] 2335,32744862,"Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement: Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial.","BACKGROUND Osteoarthritis is a common inflammatory disorder with no disease-modifying therapies. Whether inhibition of interleukin-1β (IL-1β) can reduce the consequences of large joint osteoarthritis is unclear. OBJECTIVE To determine whether IL-1β inhibition with canakinumab reduces incident total hip or knee replacement (THR/TKR). DESIGN Exploratory analysis of a randomized trial. (ClinicalTrials.gov: NCT01327846). SETTING 1091 clinical sites in 39 countries. PARTICIPANTS 10 061 CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) participants. INTERVENTION Random allocation to placebo or canakinumab (50, 150, or 300 mg) subcutaneously once every 3 months. MEASUREMENTS The primary and secondary outcomes were time to first incident THR/TKR and time to first occurrence of an osteoarthritis-related adverse event (AE). Data were obtained through blinded ascertainment of trial clinical and safety databases. RESULTS Median follow-up was 3.7 years. For the individual canakinumab dose groups, compared with placebo, hazard ratios (HRs) for incident THR/TKR during follow-up were 0.60 (95% CI, 0.38 to 0.95) for the 50-mg group, 0.53 (CI, 0.33 to 0.84) for the 150-mg group, and 0.60 (CI, 0.38 to 0.93) for the 300-mg group. Thus, in the pooled canakinumab groups, compared with the placebo group, incidence rates for THR/TKR were 0.31 and 0.54 events per 100 person-years (HR, 0.58 [CI, 0.42 to 0.80]; P  = 0.001), respectively. The HR for the secondary end point of osteoarthritis-related AEs was 0.73 (CI, 0.61 to 0.87). Similar findings were observed in analyses restricted to participants with a history of osteoarthritis. LIMITATION Because the parent trial was not designed to examine the efficacy of IL-1β inhibitors in osteoarthritis, information on structural joint outcomes was not collected. CONCLUSION Findings from this exploratory analysis of a randomized controlled trial support further investigation of IL-1β inhibition for treatment of large joint osteoarthritis. PRIMARY FUNDING SOURCE Novartis Pharmaceuticals.",2020,"Whether inhibition of interleukin-1β (IL-1β) can reduce the consequences of large joint osteoarthritis is unclear. ","['10\xa0061', '1091 clinical sites in 39 countries', 'Incident Hip and Knee Replacement']","['interleukin-1β (IL-1β', 'canakinumab', 'Placebo', 'placebo or canakinumab', 'placebo', 'Interleukin-1β Inhibition']","['hazard ratios (HRs) for incident THR/TKR', 'incidence rates for THR/TKR', 'structural joint outcomes', 'time to first incident THR/TKR and time to first occurrence of an osteoarthritis-related adverse event (AE']","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}]","[{'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C2718773', 'cui_str': 'canakinumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0040005', 'cui_str': 'Threonine'}, {'cui': 'C0206364', 'cui_str': 'Receptor Protein-Tyrosine Kinase'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.513316,"Whether inhibition of interleukin-1β (IL-1β) can reduce the consequences of large joint osteoarthritis is unclear. ","[{'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Schieker', 'Affiliation': 'Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, and Basel, Switzerland, and Ludwig Maximilian University of Munich, Munich, Germany (M.S.).'}, {'ForeName': 'Philip G', 'Initials': 'PG', 'LastName': 'Conaghan', 'Affiliation': 'Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Novartis Institutes for Biomedical Research Leeds Biomedical Research Centre, Leeds, United Kingdom (P.G.C.).'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Mindeholm', 'Affiliation': 'Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, and Basel, Switzerland (L.M., J.P., C.S., H.G., R.R.).'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Praestgaard', 'Affiliation': 'Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, and Basel, Switzerland (L.M., J.P., C.S., H.G., R.R.).'}, {'ForeName': 'Daniel H', 'Initials': 'DH', 'LastName': 'Solomon', 'Affiliation': ""Brigham and Women's Hospital, Boston, Massachusetts (D.H.S., P.M.R.).""}, {'ForeName': 'Celeste', 'Initials': 'C', 'LastName': 'Scotti', 'Affiliation': 'Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, and Basel, Switzerland (L.M., J.P., C.S., H.G., R.R.).'}, {'ForeName': 'Herman', 'Initials': 'H', 'LastName': 'Gram', 'Affiliation': 'Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, and Basel, Switzerland (L.M., J.P., C.S., H.G., R.R.).'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Thuren', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland (T.T.).'}, {'ForeName': 'Ronenn', 'Initials': 'R', 'LastName': 'Roubenoff', 'Affiliation': 'Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, and Basel, Switzerland (L.M., J.P., C.S., H.G., R.R.).'}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Ridker', 'Affiliation': ""Brigham and Women's Hospital, Boston, Massachusetts (D.H.S., P.M.R.).""}]",Annals of internal medicine,['10.7326/M20-0527'] 2336,32744872,Cognitive-behavioral intervention for test anxiety in adolescent students: do benefits extend to school-related wellbeing and clinical anxiety.,"Background and objectives: Cognitive-behavioral interventions have been shown to be effective treatments for test anxiety. Studies on school-aged populations, however, are lacking. Design and methods: In the present study we evaluated a six-session cognitive-behavioral intervention for test anxiety in a sample of secondary school students aged 14-16 years preparing for high-stakes examinations. Furthermore, we extended outcomes to include school-related wellbeing and clinical anxiety. A screening procedure was used to identify highly test anxious persons who were randomly allocated to intervention or wait-list control groups. Results: Test anxiety showed a large reduction following intervention compared to control group participants who showed a moderate reduction. Clinical anxiety showed a small to moderate reduction following intervention compared to control group participants who showed a negligible reduction. The reduction in clinical anxiety was mediated by concurrent reductions in test anxiety. Conclusion: This supports an integrative network approach that deactivating core aspects of anxiety can deactivate associated networks of anxiety symptoms. The intervention showed no impact on school-related wellbeing which increased at a similar rate for both intervention and control group participants. This is likely because test anxiety is just one contributor of many to school-related wellbeing. Implications for school-based treatments are discussed.",2020,A screening procedure was used to identify highly test anxious persons who were randomly allocated to intervention or wait-list control groups. ,"['test anxiety in a sample of secondary school students aged 14-16 years preparing for high-stakes examinations', 'highly test anxious persons', 'adolescent students']","['intervention or wait-list control groups', 'Cognitive-behavioral intervention', 'six-session cognitive-behavioral intervention', 'Cognitive-behavioral interventions']","['school-related wellbeing and clinical anxiety', 'school-related wellbeing', 'clinical anxiety', 'Clinical anxiety']","[{'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0036530', 'cui_str': 'Secondary school'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",,0.0261884,A screening procedure was used to identify highly test anxious persons who were randomly allocated to intervention or wait-list control groups. ,"[{'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Putwain', 'Affiliation': 'School of Education, Liverpool John Moores University, Liverpool, UK.'}, {'ForeName': 'Nathaniel P', 'Initials': 'NP', 'LastName': 'von der Embse', 'Affiliation': 'College of Education, University of South Florida, Tampa, FL, USA.'}]","Anxiety, stress, and coping",['10.1080/10615806.2020.1800656'] 2337,32744919,Effects of Photobiomodulation Therapy and Restriction of Wrist Extensor Blood Flow on Grip: Randomized Clinical Trial.,"Objective : To evaluate the influence of two different photobiomodulation therapy (PBMT) protocols (red 660 nm vs. infrared 830 nm) combined with a blood flow restriction (BFR) training protocol in wrist extensor muscles on handgrip, wrist extension force, and electromyographic behavior [root mean square (RMS)]. Background : PBMT has been widely used to increase muscle performance and recovery in recent clinical trials. However, there is no evidence whether PBMT (red and/or infrared) can promote better results when combined with BFR, a known method to induce better strength gains. Methods : This study was a randomized controlled trial including 58 volunteers allocated into four groups: (1) control (conventional strengthening), (2) BFR (strengthening with BFR), (3) 660 nm (BFR strengthening with 660 nm PBMT-35 mW; 0.05 cm 2 ; 2.10 J, total energy 18.9 J), and (4) 830 nm (BFR strengthening with 830 nm PBMT-32 mW; 0.101 cm 2 ; 1.92 J, total energy 17.2 J). Data were analyzed by using a mixed-effects model, with a 5% significance index. Results : A statistically significant increase was obtained for handgrip strength for the 660 nm group [27.36 ± 2.61 kilogram force (kgF)] compared with the 830 nm group (23.04 ± 3.06 kgF) ( p  = 0.010) and for wrist extensor strength in the 660 nm (7.77 ± 0.58 kgF) and BFR (7.54 ± 0.92 kgF) groups compared with the control group (5.33 ± 0.61 kgF) ( p  = 0.001 and p  = 0.004, respectively). The RMS value for the 660 nm group was significantly higher than control ( p  < 0.0001), BFR ( p  < 0.0001), and the 830 nm group ( p  = 0.0009). Conclusions : The association of PBMT (660 nm) and BFR was effective for increasing handgrip strength of the wrist extensors, associated with an increase in RMS.",2020,"BFR was effective for increasing handgrip strength of the wrist extensors, associated with an increase in RMS.","['Grip', '58 volunteers allocated into four groups: (1']","['BFR', 'control (conventional strengthening), (2) BFR (strengthening with BFR', 'photobiomodulation therapy (PBMT) protocols (red 660\u2009nm vs. infrared 830\u2009nm) combined with a blood flow restriction (BFR) training protocol', 'Photobiomodulation Therapy and Restriction of Wrist Extensor Blood Flow', 'PBMT']","['BFR', 'wrist extensor strength', 'handgrip, wrist extension force, and electromyographic behavior [root mean square (RMS', 'handgrip strength of the wrist extensors', 'RMS value', 'RMS', 'handgrip strength']","[{'cui': 'C0220843', 'cui_str': 'Grasp'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C4019433', 'cui_str': 'Photobiomodulation Therapy'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0332575', 'cui_str': 'Red color'}, {'cui': 'C4517845', 'cui_str': '660'}, {'cui': 'C4517889', 'cui_str': '830'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}]","[{'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",58.0,0.0599809,"BFR was effective for increasing handgrip strength of the wrist extensors, associated with an increase in RMS.","[{'ForeName': 'Vivian Carla', 'Initials': 'VC', 'LastName': 'Florianovicz', 'Affiliation': 'Laboratory of Assessment and Rehabilitation of Locomotor System (LARAL), Postgraduate Program in Rehabilitation Sciences, Federal University of Santa Catarina (UFSC), Araranguá, Brazil.'}, {'ForeName': 'Cleber', 'Initials': 'C', 'LastName': 'Ferraresi', 'Affiliation': 'Postgraduate Program in Biomedical Engineering, Universidade Brasil, São Paulo, Brazil.'}, {'ForeName': 'Heloyse Uliam', 'Initials': 'HU', 'LastName': 'Kuriki', 'Affiliation': 'Laboratory of Assessment and Rehabilitation of Locomotor System (LARAL), Postgraduate Program in Rehabilitation Sciences, Federal University of Santa Catarina (UFSC), Araranguá, Brazil.'}, {'ForeName': 'Alexandre Marcio', 'Initials': 'AM', 'LastName': 'Marcolino', 'Affiliation': 'Laboratory of Assessment and Rehabilitation of Locomotor System (LARAL), Postgraduate Program in Rehabilitation Sciences, Federal University of Santa Catarina (UFSC), Araranguá, Brazil.'}, {'ForeName': 'Rafael Inácio', 'Initials': 'RI', 'LastName': 'Barbosa', 'Affiliation': 'Laboratory of Assessment and Rehabilitation of Locomotor System (LARAL), Postgraduate Program in Rehabilitation Sciences, Federal University of Santa Catarina (UFSC), Araranguá, Brazil.'}]","Photobiomodulation, photomedicine, and laser surgery",['10.1089/photob.2019.4800'] 2338,32744924,Using Levine's conservation model in postpartum care: a randomized controlled trial.,"This randomized controlled trial was conducted with 117 puerperae who were assigned into 2 groups: the intervention group and the control group. While the participants in the intervention group participated in a full program based on the module trainings, the participants in the control group received routine care. There was a significant difference between the women in the intervention and control groups in terms of the variables such as fatigue, sleep, and quality of life. The women in the intervention group experienced less fatigue, and their quality of sleep and quality of life improved considerably. Levine's conservation model enables the provision of the integrative care to women in their postpartum period.",2020,"There was a significant difference between the women in the intervention and control groups in terms of the variables such as fatigue, sleep, and quality of life.","['postpartum care', '117 puerperae who were assigned into 2 groups: the intervention group and the control group']",['control group received routine care'],"['fatigue, sleep, and quality of life', 'fatigue, and their quality of sleep and quality of life']","[{'cui': 'C0032782', 'cui_str': 'Postpartum care'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]",,0.0610909,"There was a significant difference between the women in the intervention and control groups in terms of the variables such as fatigue, sleep, and quality of life.","[{'ForeName': 'Sadiye', 'Initials': 'S', 'LastName': 'Ozcan', 'Affiliation': 'Faculty of Health Science, Yalova University, Yalova, Turkey.'}, {'ForeName': 'Gulsen', 'Initials': 'G', 'LastName': 'Eryilmaz', 'Affiliation': 'Faculty of Nursing, Atatürk University, Erzurum, Turkey.'}]",Health care for women international,['10.1080/07399332.2020.1797038'] 2339,32751370,"Oral Eplerenone Versus Observation in the Management of Acute Central Serous Chorioretinopathy: A Prospective, Randomized Comparative Study.","In this prospective, interventional case-control study, 58 patients with unilateral acute central serous chorioretinopathy (CSCR) were recruited. Patients ≥ 18 years age, presenting with first episodes of acute CSCR, were included. Acute CSCR was defined by the presence of subretinal fluid (SRF) and symptoms for <12 weeks duration with no clinical or imaging features of chronicity. Patients were alternately divided into treatment (Table Eplerenone 50 mg/day for minimum 1 month) and observation groups. Vision, SRF height and subfoveal choroidal thickness (SFCT) were checked at 1-, 2- and 3-months in both eyes of each group. Each group had 29 eyes. Mean age was 40.4 ± 7.1 and 43.3 ± 8.34 years in treatment and observation group, respectively. Mean symptom duration was 6.46 ± 1.45 and 5.87 ± 2.09 weeks, respectively. Vision improvement to 6/6 was seen in 92%, 100% and 100% cases in treatment group and 74%, 86% and 100% in control group at each visit, respectively. Complete SRF resolution in the treatment group was noted in 45%, 55% and 62% cases at each respective monthly visit. In the observation group, complete SRF resolution was noted in 10%, 21% and 31% at 1-, 2- and 3-month visits, respectively. SRF ( p < 0.001) and SFCT ( p < 0.001) reduction was noted in the affected eye of both groups. SFCT was reduced in the fellow eye after treatment ( p = 0.005) compared to the observation group ( p = 0.276). In conclusion, oral eplerenone achieves faster SRF resolution and vision improvement in acute CSCR. Additionally, it shows beneficial effects on the fellow eye.",2020,SFCT was reduced in the fellow eye after treatment ( p = 0.005) compared to the observation group ( p = 0.276).,"['58 patients with unilateral acute central serous chorioretinopathy (CSCR', 'Acute Central Serous Chorioretinopathy', 'Patients ≥ 18 years age, presenting with first episodes of acute CSCR, were included', 'Mean age was 40.4 ± 7.1 and 43.3 ± 8.34 years in treatment and observation group, respectively']","['Oral Eplerenone Versus Observation', 'oral eplerenone']","['Vision, SRF height and subfoveal choroidal thickness (SFCT', 'SFCT', 'SRF resolution and vision improvement', 'Mean symptom duration', 'Complete SRF resolution', 'complete SRF resolution', 'Vision improvement', 'SRF']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0730315', 'cui_str': 'Acute central serous chorioretinopathy'}, {'cui': 'C0730328', 'cui_str': 'Central serous chorioretinopathy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0439615', 'cui_str': 'First episode'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0961485', 'cui_str': 'eplerenone'}, {'cui': 'C0302523', 'cui_str': 'Observation'}]","[{'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C1720732', 'cui_str': 'Subretinal fluid'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0442185', 'cui_str': 'Subfoveal'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0436359', 'cui_str': 'Time symptom lasts'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]",58.0,0.0325964,SFCT was reduced in the fellow eye after treatment ( p = 0.005) compared to the observation group ( p = 0.276).,"[{'ForeName': 'Ramesh', 'Initials': 'R', 'LastName': 'Venkatesh', 'Affiliation': ""Narayana Nethralaya, Department of Retina & Vitreous, 121/C, Chord Road, 1st 'R' Block, Rajaji Nagar, Bengaluru 560010, India.""}, {'ForeName': 'Arpitha', 'Initials': 'A', 'LastName': 'Pereira', 'Affiliation': ""Narayana Nethralaya, Department of Retina & Vitreous, 121/C, Chord Road, 1st 'R' Block, Rajaji Nagar, Bengaluru 560010, India.""}, {'ForeName': 'Chaitra', 'Initials': 'C', 'LastName': 'Jayadev', 'Affiliation': ""Narayana Nethralaya, Department of Retina & Vitreous, 121/C, Chord Road, 1st 'R' Block, Rajaji Nagar, Bengaluru 560010, India.""}, {'ForeName': 'Vishma', 'Initials': 'V', 'LastName': 'Prabhu', 'Affiliation': ""Narayana Nethralaya, Department of Retina & Vitreous, 121/C, Chord Road, 1st 'R' Block, Rajaji Nagar, Bengaluru 560010, India.""}, {'ForeName': 'Aditya', 'Initials': 'A', 'LastName': 'Aseem', 'Affiliation': ""Narayana Nethralaya, Department of Retina & Vitreous, 121/C, Chord Road, 1st 'R' Block, Rajaji Nagar, Bengaluru 560010, India.""}, {'ForeName': 'Kushagra', 'Initials': 'K', 'LastName': 'Jain', 'Affiliation': ""Narayana Nethralaya, Department of Retina & Vitreous, 121/C, Chord Road, 1st 'R' Block, Rajaji Nagar, Bengaluru 560010, India.""}, {'ForeName': 'Bharathi', 'Initials': 'B', 'LastName': 'Bavaharan', 'Affiliation': ""Narayana Nethralaya, Department of Retina & Vitreous, 121/C, Chord Road, 1st 'R' Block, Rajaji Nagar, Bengaluru 560010, India.""}, {'ForeName': 'Naresh Kumar', 'Initials': 'NK', 'LastName': 'Yadav', 'Affiliation': ""Narayana Nethralaya, Department of Retina & Vitreous, 121/C, Chord Road, 1st 'R' Block, Rajaji Nagar, Bengaluru 560010, India.""}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Chhablani', 'Affiliation': 'Department of Medical Retina and Vitreoretinal Surgery, University of Pittsburgh School of Medicine, 203 Lothrop Street, Suite 800, Pittsburg, PA 15213, USA.'}]","Pharmaceuticals (Basel, Switzerland)",['10.3390/ph13080170'] 2340,32751430,Relief Alternatives during Resuscitation: Instructions to Teach Bystanders. A Randomized Control Trial.,"To analyze the quality of resuscitation (CPR) performed by individuals without training after receiving a set of instructions (structured and unstructured/intuitive) from an expert in a simulated context, the specific objective was to design a simple and structured CPR learning method on-site. An experimental study was designed, consisting of two random groups with a post-intervention measurement in which the experimental group (EG) received standardized instructions, and the control group (CG) received intuitive or non-standardized instructions, in a public area simulated scenario. Statistically significant differences were found ( p < 0.0001) between the EG and the CG for variables: time needed to give orders, pauses between chest compressions and ventilations, depth, overall score, chest compression score, and chest recoil. The average depth of the EG was 51.1 mm (SD 7.94) and 42.2 mm (SD 12.04) for the CG. The chest recoil median was 86.32% (IQR 62.36, 98.87) for the EG, and 58.3% (IQR 27.46, 84.33) in the CG. The use of a sequence of simple, short and specific orders, together with observation-based learning makes possible the execution of chest compression maneuvers that are very similar to those performed by rescuers, and allows the teaching of the basic notions of ventilation. The structured order method was shown to be an on-site learning opportunity when faced with the need to maintain high-quality CPR in the presence of an expert resuscitator until the arrival of emergency services.",2020,"Statistically significant differences were found ( p < 0.0001) between the EG and the CG for variables: time needed to give orders, pauses between chest compressions and ventilations, depth, overall score, chest compression score, and chest recoil.",[],"['standardized instructions, and the control group (CG) received intuitive or non-standardized instructions, in a public area simulated scenario']","['chest recoil median', 'average depth of the EG', 'quality of resuscitation (CPR', 'variables: time needed to give orders, pauses between chest compressions and ventilations, depth, overall score, chest compression score, and chest recoil']",[],"[{'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}]","[{'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0035273', 'cui_str': 'Resuscitation'}, {'cui': 'C0007203', 'cui_str': 'Cardiopulmonary resuscitation'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0205142,"Statistically significant differences were found ( p < 0.0001) between the EG and the CG for variables: time needed to give orders, pauses between chest compressions and ventilations, depth, overall score, chest compression score, and chest recoil.","[{'ForeName': 'María José', 'Initials': 'MJ', 'LastName': 'Pujalte-Jesús', 'Affiliation': 'Faculty of Nursing, Universidad Católica de Murcia UCAM, 30107 Murcia, Spain.'}, {'ForeName': 'César', 'Initials': 'C', 'LastName': 'Leal-Costa', 'Affiliation': 'Faculty of Nursing, University of Murcia, 30107 Murcia, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Ruzafa-Martínez', 'Affiliation': 'Faculty of Nursing, University of Murcia, 30107 Murcia, Spain.'}, {'ForeName': 'Antonio Jesús', 'Initials': 'AJ', 'LastName': 'Ramos-Morcillo', 'Affiliation': 'Faculty of Nursing, University of Murcia, 30107 Murcia, Spain.'}, {'ForeName': 'José Luis', 'Initials': 'JL', 'LastName': 'Díaz Agea', 'Affiliation': 'Faculty of Nursing, Catholic University of Murcia, 30107 Murcia, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17155495'] 2341,32751446,Effect of an Integrated Healthcare Program for Korean Rural Older Adults: A Quasi-Experimental Study.,"Studies have been conducted on the development of healthcare programs for older adults in rural areas, not only in Asia but also in Europe and the United States. However, these reports have been limited by largely non-comprehensive results, lack of demand surveys, or programs with no systematic development. The purpose of this study was to develop an integrated healthcare program for rural older adults and investigate the effects of the program. A nonequivalent control group pretest-posttest design was used. Subjects were aged over 65 and lived in the rural community. The integrated healthcare program involved 12 three-hour sessions over 12 weeks. Compared with the control group, the experimental group demonstrated significant differences in both upper extremities strengths (t = 2.74, p = 0.008; t = 2.03, p = 0.047), static balance (z = -2.38, p = 0.017), dynamic balance (t = -4.82, p < 0.001), loneliness (t = -3.02, p = 0.003), and role self-efficacy (t = 2.39, p = 0.020), but no differences for ego integration (t = 1.51, p = 0.137). To improve physical, mental, and social health of the rural older adults, we developed an integrated healthcare program. The program improved physical functions, loneliness, and role self-efficiency of the rural older adults. Therefore, it is recommended that healthcare professionals actively apply this program in primary healthcare institutes and elsewhere.",2020,"Compared with the control group, the experimental group demonstrated significant differences in both upper extremities strengths (t = 2.74, p = 0.008; t = 2.03, p = 0.047), static balance","['rural older adults', 'older adults in rural areas', 'Korean Rural Older Adults', 'Subjects were aged over 65 and lived in the rural community']","['Integrated Healthcare Program', 'integrated healthcare program']","['static balance', 'physical, mental, and social health', 'physical functions, loneliness, and role self-efficiency', 'loneliness', 'upper extremities strengths', 'role self-efficacy', 'dynamic balance']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0086944', 'cui_str': 'Rural Communities'}]","[{'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0023974', 'cui_str': 'Feeling lonely'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}]",,0.0155838,"Compared with the control group, the experimental group demonstrated significant differences in both upper extremities strengths (t = 2.74, p = 0.008; t = 2.03, p = 0.047), static balance","[{'ForeName': 'Hyuk Joon', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Research Institute of Nursing Science, College of Nursing, Jeonbuk National University, Jeonju 54896, Korea.'}, {'ForeName': 'Hye Young', 'Initials': 'HY', 'LastName': 'Kim', 'Affiliation': 'Research Institute of Nursing Science, College of Nursing, Jeonbuk National University, Jeonju 54896, Korea.'}, {'ForeName': 'Youngran', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Research Institute of Nursing Science, College of Nursing, Jeonbuk National University, Jeonju 54896, Korea.'}, {'ForeName': 'Eun', 'Initials': 'E', 'LastName': 'Ko', 'Affiliation': 'Department of Nursing, College of Life Science and Natural Resources, Sunchon National University, Suncheon 57922, Korea.'}]","Healthcare (Basel, Switzerland)",['10.3390/healthcare8030244'] 2342,32751455,Short-Term Resistance Training Supported by Whole-Body Cryostimulation Induced a Decrease in Myostatin Concentration and an Increase in Isokinetic Muscle Strength.,"The study aimed to determine whether combining cryostimulation with resistance training would effectively increase muscle strength, and if so, whether this adaptation would be related to changes in circulating levels of exerkines (i.e., mediators of systemic adaptation to exercise). Twenty-five students completed 12 sessions of resistance training, each followed by either cryostimulation ( n = 15, 3 min exposure at -110 °C) or passive recovery ( n = 10). Prior to and post this intervention, participants performed two eccentric cycling bouts (before and after training). At these points, serum concentrations of muscle damage marker (myoglobin), exerkines (interleukin 6 (IL-6), interleukin 15 (IL-15), irisin, brain-derived neurotrophic factor), hypertrophy-related factors (myostatin, insulin-like growth factor 1), and muscle strength were measured. The applied procedure reduced the physiological burden of the second eccentric cycling bout and myoglobin concentrations only in the group subject to cryostimulation. The same group also exhibited decreased levels of myostatin (from 4.7 ± 1.7 to 3.8 ± 1.8 ng·mL -1 , p < 0.05). A significant and large interaction between the group × time was noted in IL-15 concentration ( p = 0.01, ηp2=0.27). Training and cryostimulation induced a positive and likely significant improvement of isokinetic muscle strength. Altogether, obtained results support the claim that resistance training combined with cold exposure modified muscle strength through modulation of myostatin and IL-15 concentrations.",2020,The applied procedure reduced the physiological burden of the second eccentric cycling bout and myoglobin concentrations only in the group subject to cryostimulation.,[],['resistance training'],"['serum concentrations of muscle damage marker (myoglobin), exerkines (interleukin 6 (IL-6), interleukin 15 (IL-15), irisin, brain-derived neurotrophic factor), hypertrophy-related factors (myostatin, insulin-like growth factor 1), and muscle strength', 'levels of myostatin', 'Myostatin Concentration', 'Isokinetic Muscle Strength', 'isokinetic muscle strength', 'IL-15 concentration']",[],"[{'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage NOS'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0254610', 'cui_str': 'Interleukin 15'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0020564', 'cui_str': 'Hypertrophy'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0538238', 'cui_str': 'GDF8 protein, human'}, {'cui': 'C0021665', 'cui_str': 'Somatomedin C'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",25.0,0.0218574,The applied procedure reduced the physiological burden of the second eccentric cycling bout and myoglobin concentrations only in the group subject to cryostimulation.,"[{'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Jaworska', 'Affiliation': 'Department of Physiology, Gdansk University of Physical Education and Sport, Kazimierza Gorskiego 1, 80-336 Gdansk, Poland.'}, {'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Rodziewicz-Flis', 'Affiliation': 'Department of Physical Therapy and Biological Regeneration, Gdansk University of Physical Education and Sport, Kazimierza Gorskiego 1, 80-336 Gdansk, Poland.'}, {'ForeName': 'Jakub', 'Initials': 'J', 'LastName': 'Kortas', 'Affiliation': 'Department of Sport, Gdansk University of Physical Education and Sport, Kazimierza Gorskiego 1, 80-336 Gdansk, Poland.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Kozłowska', 'Affiliation': 'Department of Physiology, Gdansk University of Physical Education and Sport, Kazimierza Gorskiego 1, 80-336 Gdansk, Poland.'}, {'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Micielska', 'Affiliation': 'Department of Physical Education and Lifelong sports, Poznan University of Physical Education, Krolowej Jadwigi 27/39, 61-871 Poznan, Poland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Babińska', 'Affiliation': 'Department of Endocrinology and Internal Medicine, Medical University, Marii Sklodowskiej-Curie 3, 80-001 Gdansk, Poland.'}, {'ForeName': 'Radosław', 'Initials': 'R', 'LastName': 'Laskowski', 'Affiliation': 'Department of Physiology, Gdansk University of Physical Education and Sport, Kazimierza Gorskiego 1, 80-336 Gdansk, Poland.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Lombardi', 'Affiliation': 'Department of Athletics, Strength and Conditioning, Poznan University of Physical Education, Krolowej Jadwigi 27/39, 61-871 Poznan, Poland.'}, {'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Ziemann', 'Affiliation': 'Department of Athletics, Strength and Conditioning, Poznan University of Physical Education, Krolowej Jadwigi 27/39, 61-871 Poznan, Poland.'}]",International journal of environmental research and public health,['10.3390/ijerph17155496'] 2343,32751487,"A Prospective Clinical Trial of Prolonged Fasting in Healthy Young Males and Females-Effect on Fatigue, Sleepiness, Mood and Body Composition.","Fasting during a long period (17-18 h/day) may affect daily performance. Fatigue is one of important parameters to observe for this effect. This study aimed to determine the effect of Ramadan fasting (RF)-particularly on fatigue in both young males and females. Sleepiness, mood-related symptoms (MRSs) and body composition (BC) were determined, too. Thirty-four young males and females were recruited and performed RF. They were assessed for fatigue, sleepiness, MRS and BC at T1 (one week before RF), T2 (mid of RF), T3 (last days of RF), T4 (one week after RF) and T5 (one month after RF). The assessments were done in the morning, except for fatigue and sleepiness, which were also assessed in the afternoon and evening of T1 to T5. This study observed numerous positive effects to RF. After they began fasting and compared to T1, participants experienced (1) significantly less fatigue; (2) small to large improvement of MRSs; and (3) positive changes relating to BC. RF did not appear to have a significant effect on participants' sleepiness scores. Ultimately, this study illustrates how prolonged fasting, like RF, benefits the youth, particularly by decreasing fatigue, improving MRSs and positively impacting BC.",2020,"After they began fasting and compared to T1, participants experienced (1) significantly less fatigue; (2) small to large improvement of MRSs; and (3) positive changes relating to BC.","['Thirty-four young males and females', 'Healthy Young Males and Females', 'young males and females']",['Ramadan fasting (RF)-particularly'],"['fatigue, sleepiness, MRS and BC', ""participants' sleepiness scores"", 'Fatigue, Sleepiness, Mood and Body Composition', 'fatigue; (2) small to large improvement of MRSs; and (3) positive changes relating to BC', 'Sleepiness, mood-related symptoms (MRSs) and body composition (BC']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",[],"[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",34.0,0.0322455,"After they began fasting and compared to T1, participants experienced (1) significantly less fatigue; (2) small to large improvement of MRSs; and (3) positive changes relating to BC.","[{'ForeName': 'Boya', 'Initials': 'B', 'LastName': 'Nugraha', 'Affiliation': 'Department of Rehabilitation Medicine, Hannover Medical School, 30625 Hannover, Germany.'}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Riat', 'Affiliation': 'Department of Rehabilitation Medicine, Hannover Medical School, 30625 Hannover, Germany.'}, {'ForeName': 'Samaneh Khoshandam', 'Initials': 'SK', 'LastName': 'Ghashang', 'Affiliation': 'Department of Rehabilitation Medicine, Hannover Medical School, 30625 Hannover, Germany.'}, {'ForeName': 'Luqman', 'Initials': 'L', 'LastName': 'Eljurnazi', 'Affiliation': 'Department of Rehabilitation Medicine, Hannover Medical School, 30625 Hannover, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Gutenbrunner', 'Affiliation': 'Department of Rehabilitation Medicine, Hannover Medical School, 30625 Hannover, Germany.'}]",Nutrients,['10.3390/nu12082281'] 2344,32751514,The Use of Bispectral Index Monitoring Does Not Change Intraoperative Exposure to Volatile Anesthetics in Children.,"The exposure of infants and children to volatile anesthetics, such as sevoflurane, has been a topic of concern with respect to the potential risk for long term neurocognitive effects. The primary objective of this study was to determine whether the perioperative utilization of Bispectral Index (BIS) monitoring alters the sevoflurane delivery and exposure to children. This is a prospective randomized trial of two groups of healthy ambulatory day surgery patients (2 to 12 years). The patients in both groups had the BIS applied soon after the induction of general anesthesia, but only the anesthesiologists in the group randomized to BIS visible were able to see the BIS values. All of the patients received general anesthesia with sevoflurane. This study found no difference in the overall exposure to sevoflurane between both groups (mean end-tidal sevoflurane level of 1.8 in both groups, P = 084). The duration of time in the recovery room, the time to meet discharge criteria, the Pediatric Agitation Emergence Delirium (PAED) scores and the Face, Legs, Activity, Cry, Consolability (FLACC) scores were not statistically different between the groups. The application and utilization of intraoperative BIS monitoring does not alter the sevoflurane administration nor the discharge readiness nor the recovery profile in healthy ambulatory children.",2020,The application and utilization of intraoperative BIS monitoring does not alter the sevoflurane administration nor the discharge readiness nor the recovery profile in healthy ambulatory children.,"['healthy ambulatory children', 'two groups of healthy ambulatory day surgery patients (2 to 12 years', 'Children', 'children']","['general anesthesia with sevoflurane', 'sevoflurane', 'Bispectral Index (BIS']","['duration of time in the recovery room, the time to meet discharge criteria, the Pediatric Agitation Emergence Delirium (PAED) scores and the Face, Legs, Activity, Cry, Consolability (FLACC) scores']","[{'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0282046', 'cui_str': 'Day Surgery'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C1301882', 'cui_str': 'Bispectral index'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0034871', 'cui_str': 'Postoperative anesthesia care unit'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0920253', 'cui_str': 'Agitated Emergence'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0010399', 'cui_str': 'Crying'}]",,0.0247457,The application and utilization of intraoperative BIS monitoring does not alter the sevoflurane administration nor the discharge readiness nor the recovery profile in healthy ambulatory children.,"[{'ForeName': 'Cornelius A', 'Initials': 'CA', 'LastName': 'Sullivan', 'Affiliation': ""Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.""}, {'ForeName': 'Chinyere', 'Initials': 'C', 'LastName': 'Egbuta', 'Affiliation': ""Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA 02115, USA.""}, {'ForeName': 'Raymond S', 'Initials': 'RS', 'LastName': 'Park', 'Affiliation': ""Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA 02115, USA.""}, {'ForeName': 'Karina', 'Initials': 'K', 'LastName': 'Lukovits', 'Affiliation': ""Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA 02115, USA.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cavanaugh', 'Affiliation': 'Boston Biostatistical Consulting, North Reading, MA 01864, USA.'}, {'ForeName': 'Keira P', 'Initials': 'KP', 'LastName': 'Mason', 'Affiliation': ""Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.""}]",Journal of clinical medicine,['10.3390/jcm9082437'] 2345,32751515,"Effects of 24-Week Exergame Intervention on the Gray Matter Volume of Different Brain Structures in Women with Fibromyalgia: A Single-Blind, Randomized Controlled Trial.","BACKGROUND Exergame-induced changes in the volume of brain gray matter have not been studied in fibromyalgia (FM). This study evaluates the effects of a 24-week exergame-based intervention on the gray matter volume of different brain structures in patients with FM through magnetic resonance imaging (MRI). METHODS A total of 25 FM patients completed 24 weeks of intervention program, and another 25 FM patients did not receive any intervention. T1-weighted MRI was used to assess brain volume, and FreeSurfer software was used to segment the brain regions. RESULTS No significant effects on gray matter volume of different structures and total gray matter were found. CONCLUSIONS FM patients did not show significant changes in gray matter brain volume between the control and experimental groups after 24 weeks. FM patients showed significant relationships between peak oxygen consumption (pVO2) and the left and right regions of the hippocampus and the left and right regions of the amygdala.",2020,FM patients showed significant relationships between peak oxygen consumption (pVO2) and the left and right regions of the hippocampus and the left and right regions of the amygdala.,"['Women with Fibromyalgia', 'patients with FM through magnetic resonance imaging (MRI']","['24-Week Exergame Intervention', 'FM', '24-week exergame-based intervention']","['gray matter brain volume', 'Gray Matter Volume of Different Brain Structures', 'gray matter volume of different structures and total gray matter', 'peak oxygen consumption (pVO2) and the left and right regions of the hippocampus and the left and right regions of the amygdala']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0002708', 'cui_str': 'Amygdaloid structure'}]",25.0,0.0602159,FM patients showed significant relationships between peak oxygen consumption (pVO2) and the left and right regions of the hippocampus and the left and right regions of the amygdala.,"[{'ForeName': 'Juan Luis', 'Initials': 'JL', 'LastName': 'Leon-Llamas', 'Affiliation': 'Physical Activity and Quality of Life Research Group (AFYCAV), Faculty of Sport Science, University of Extremadura, 10003 Cáceres, Spain.'}, {'ForeName': 'Santos', 'Initials': 'S', 'LastName': 'Villafaina', 'Affiliation': 'Physical Activity and Quality of Life Research Group (AFYCAV), Faculty of Sport Science, University of Extremadura, 10003 Cáceres, Spain.'}, {'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Murillo-Garcia', 'Affiliation': 'Physical Activity and Quality of Life Research Group (AFYCAV), Faculty of Sport Science, University of Extremadura, 10003 Cáceres, Spain.'}, {'ForeName': 'Francisco Javier', 'Initials': 'FJ', 'LastName': 'Dominguez-Muñoz', 'Affiliation': 'Physical Activity and Quality of Life Research Group (AFYCAV), Faculty of Sport Science, University of Extremadura, 10003 Cáceres, Spain.'}, {'ForeName': 'Narcis', 'Initials': 'N', 'LastName': 'Gusi', 'Affiliation': 'Physical Activity and Quality of Life Research Group (AFYCAV), Faculty of Sport Science, University of Extremadura, 10003 Cáceres, Spain.'}]",Journal of clinical medicine,['10.3390/jcm9082436'] 2346,32751720,"Effect of a Six-Week Core Conditioning as a Warm-Up Exercise in Physical Education Classes on Physical Fitness, Movement Capability, and Balance in School-Aged Children.","Whether the implementation of feasible, equipment-free, and simple core exercises in warm-up routines in physical education classes for school-aged children is beneficial remains unclear. Therefore, this study investigated the effects of a core conditioning in the warm-up routine of physical education classes on trunk muscular endurance, movement capability, and flexibility in this population. In these pre- and post-test control group experiments, 52 healthy, school-aged children (aged 10-11 years) were cluster randomized allocated to either the dynamic core exercise (DCE) group or general physical education (GPE) group. The DCE group performed a 10-min core exercise routine twice per week for six consecutive weeks; the GPE group performed traditional physical education warm-up exercises regularly. The children were assessed by conducting the trunk muscular endurance test (i.e., dynamic curl-up, static curl-up, plank, and lateral plank), functional movement screen (FMS), and single-leg balance test before and after the intervention. At the end of the intervention, the DCE group demonstrated a significant effect on trunk muscular endurance, movement capability (i.e., FMS scores), flexibility, and balance (each p < 0.001, effect size: 0.38-1.3). Furthermore, the DCE group showed significant improvements in all outcome measurements compared with the GPE group ( p < 0.05, effect size: 0.29-1.68). These data may provide a reference for incorporating additional core stability exercises in the warm-up routine of physical education classes in school-aged children in the future.",2020,"Furthermore, the DCE group showed significant improvements in all outcome measurements compared with the GPE group ( p < 0.05, effect size: 0.29-1.68).","['School-Aged Children', 'school-aged children', '52 healthy, school-aged children (aged 10-11 years']","['dynamic core exercise (DCE) group or general physical education (GPE', 'GPE group performed traditional physical education warm-up exercises regularly', 'DCE', 'GPE']","['trunk muscular endurance, movement capability, and flexibility', 'Physical Fitness, Movement Capability, and Balance', 'trunk muscular endurance, movement capability (i.e., FMS scores), flexibility, and balance']","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031805', 'cui_str': 'Education, Physical'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C2350169', 'cui_str': 'Warming-Up Exercise'}]","[{'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",52.0,0.036687,"Furthermore, the DCE group showed significant improvements in all outcome measurements compared with the GPE group ( p < 0.05, effect size: 0.29-1.68).","[{'ForeName': 'Nai-Jen', 'Initials': 'NJ', 'LastName': 'Chang', 'Affiliation': 'Department of Sports Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.'}, {'ForeName': 'I-Hsien', 'Initials': 'IH', 'LastName': 'Tsai', 'Affiliation': 'Department of Sports Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.'}, {'ForeName': 'Chia-Lun', 'Initials': 'CL', 'LastName': 'Lee', 'Affiliation': 'Center for Physical and Health Education, National Sun Yat-sen University, Kaohsiung 804, Taiwan.'}, {'ForeName': 'Chun-Hao', 'Initials': 'CH', 'LastName': 'Liang', 'Affiliation': 'Department of Sports Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.'}]",International journal of environmental research and public health,['10.3390/ijerph17155517'] 2347,32751779,The First Human Clinical Trial on the Skin Depigmentation Efficacy of Glycinamide Hydrochloride.,"A previous study identified certain low molecular anti-melanogenic peptides that share a common sequence with α-melanocyte stimulating hormone (MSH) and end with a glycinamide moiety. Glycinamide itself also showed anti-melanogenic activity in cell-based assays, but neither glycine nor acetyl glycinamide were active, which indicated a special structure and activity relationship. The aim of this study was to examine the skin depigmentation efficacy of glycinamide hydrochloride in human subjects. The primary skin irritation potential of glycinamide hydrochloride was evaluated by patch testing in 30 human subjects. The skin depigmentation efficacy of glycinamide hydrochloride was evaluated in a double-blinded clinical test in 21 human subjects. The test product and a control product were applied to designated sites on the right or left side of the face twice daily for eight weeks. Skin color parameters, i.e., the melanin index, the L* value (representing skin lightness), a* value (redness), and b* value (yellowness) were measured using instruments. The individual topology angle (ITA o , representing skin color) was calculated from L* and b values. The degree of skin pigmentation was visually assessed by two testers. The primary skin irritation test showed that a solution containing glycinamide hydrochloride up to 10% did not induce any adverse skin responses. In the efficacy test, the test product significantly reduced the melanin index, and increased L* value and ITA o after two weeks of application relative to the baseline value at the start of the test. It also significantly lowered the degree of pigmentation after 6 weeks of application, relative to the baseline value. Differences in the melanin index, L* value, ITA o and the degree of pigmentation between the test and control groups became statistically significant after six weeks or eight weeks of application. No signs of skin irritation were observed during the efficacy test. The present study suggests that glycinamide hydrochloride has great potential to be used in the control of skin hyperpigmentation.",2020,"In the efficacy test, the test product significantly reduced the melanin index, and increased L* value and ITA o after two weeks of application relative to the baseline value at the start of the test.","['30 human subjects', 'human subjects', '21 human subjects']","['glycinamide hydrochloride', 'Glycinamide Hydrochloride']","['adverse skin responses', 'skin irritation', 'melanin index, L* value, ITA o and the degree of pigmentation', 'melanin index, the L* value (representing skin lightness), a* value (redness), and b* value (yellowness', 'degree of skin pigmentation', 'individual topology angle (ITA o , representing skin color', 'degree of pigmentation', 'melanin index, and increased L* value and ITA o', 'skin depigmentation efficacy']","[{'cui': 'C0080105', 'cui_str': 'Human Subjects'}]","[{'cui': 'C0061596', 'cui_str': 'glycine amide'}]","[{'cui': 'C0312646', 'cui_str': 'Finding related to response to skin test'}, {'cui': 'C0152030', 'cui_str': 'Skin irritation'}, {'cui': 'C0025196', 'cui_str': 'Melanin'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0022275', 'cui_str': 'Italian language'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0031911', 'cui_str': 'Pigmentation'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0037290', 'cui_str': 'Skin pigmentation'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0002812', 'cui_str': 'Regional Anatomy'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0262977', 'cui_str': 'Achromia of skin'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",30.0,0.0168457,"In the efficacy test, the test product significantly reduced the melanin index, and increased L* value and ITA o after two weeks of application relative to the baseline value at the start of the test.","[{'ForeName': 'Yong Chool', 'Initials': 'YC', 'LastName': 'Boo', 'Affiliation': 'Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Korea.'}, {'ForeName': 'Da Jung', 'Initials': 'DJ', 'LastName': 'Jo', 'Affiliation': 'Dermapro Skin Research Center, Dermapro Ltd., Seoul 06684, Korea.'}, {'ForeName': 'Chang Min', 'Initials': 'CM', 'LastName': 'Oh', 'Affiliation': 'Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Korea.'}, {'ForeName': 'Shin Young', 'Initials': 'SY', 'LastName': 'Lee', 'Affiliation': 'Ruby Crown Co., Ltd., Suite 505, Korea Mediventure Center, 76 Dongnae-ro, Dong-gu, Daegu 41061, Korea.'}, {'ForeName': 'Young Mi', 'Initials': 'YM', 'LastName': 'Kim', 'Affiliation': 'Ruby Crown Co., Ltd., Suite 505, Korea Mediventure Center, 76 Dongnae-ro, Dong-gu, Daegu 41061, Korea.'}]",Biomedicines,['10.3390/biomedicines8080257'] 2348,32751788,Casein Protein Processing Strongly Modulates Post-Prandial Plasma Amino Acid Responses In Vivo in Humans.,"Micellar casein is characterized as a slowly digestible protein source, and its structure can be modulated by various food processing techniques to modify its functional properties. However, little is known about the impact of such modifications on casein protein digestion and amino acid absorption kinetics and the subsequent post-prandial plasma amino acid responses. In the present study, we determined post-prandial aminoacidemia following ingestion of isonitrogenous amounts of casein protein (40 g) provided as micellar casein (Mi-CAS), calcium caseinate (Ca-CAS), or cross-linked sodium caseinate (XL-CAS). Fifteen healthy, young men (age: 26 ± 4 years, BMI: 23 ± 1 kg·m -2 ) participated in this randomized cross-over study and ingested 40 g Mi-Cas, Ca-CAS, and XL-CAS protein, with a ~1 week washout between treatments. On each trial day, arterialized blood samples were collected at regular intervals during a 6 h post-prandial period to assess plasma amino acid concentrations using ultra-performance liquid chromatography. Plasma amino acid concentrations were higher following the ingestion of XL-CAS when compared to Mi-CAS and Ca-CAS from t = 15 to 90 min (all p < 0.05). Plasma amino acid concentrations were higher following ingestion of Mi-CAS compared to Ca-CAS from t = 30 to 45 min (both p < 0.05). Plasma total amino acids iAUC were higher following the ingestion of XL-CAS when compared to Ca-CAS (294 ± 63 vs. 260 ± 75 mmol·L -1 , p = 0.006), with intermediate values following Mi-CAS ingestion (270 ± 63 mmol·L -1 , p > 0.05). In conclusion, cross-linked sodium caseinate is more rapidly digested when compared to micellar casein and calcium caseinate. Protein processing can strongly modulate the post-prandial rise in plasma amino acid bioavailability in vivo in humans.",2020,Plasma amino acid concentrations were higher following the ingestion of XL-CAS when compared to Mi-CAS and Ca-CAS from t = 15 to 90 min (all p < 0.05).,"['Fifteen healthy, young men (age: 26 ± 4 years, BMI: 23 ± 1 kg·m -2 ) participated in this randomized cross-over study and ingested 40 g', 'Humans']","['Micellar casein', 'casein protein (40 g) provided as micellar casein (Mi-CAS), calcium caseinate (Ca-CAS), or cross-linked sodium caseinate (XL-CAS']","['Plasma amino acid concentrations', 'Plasma total amino acids iAUC']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0007332', 'cui_str': 'Caseins'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0301465', 'cui_str': 'Calcium caseinate'}, {'cui': 'C0332220', 'cui_str': 'Cross-linking'}, {'cui': 'C0037488', 'cui_str': 'Sodium Caseinate'}, {'cui': 'C0750927', 'cui_str': 'Developmental verbal dyspraxia'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",,0.0254113,Plasma amino acid concentrations were higher following the ingestion of XL-CAS when compared to Mi-CAS and Ca-CAS from t = 15 to 90 min (all p < 0.05).,"[{'ForeName': 'Jorn', 'Initials': 'J', 'LastName': 'Trommelen', 'Affiliation': 'NUTRIM School of Nutrition and Translation Research in Metabolism, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands.'}, {'ForeName': 'Michelle E G', 'Initials': 'MEG', 'LastName': 'Weijzen', 'Affiliation': 'NUTRIM School of Nutrition and Translation Research in Metabolism, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands.'}, {'ForeName': 'Janneau', 'Initials': 'J', 'LastName': 'van Kranenburg', 'Affiliation': 'NUTRIM School of Nutrition and Translation Research in Metabolism, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands.'}, {'ForeName': 'Renate A', 'Initials': 'RA', 'LastName': 'Ganzevles', 'Affiliation': 'FrieslandCampina, Stationsplein 4, 3818 LE Amstersfoort, The Netherlands.'}, {'ForeName': 'Milou', 'Initials': 'M', 'LastName': 'Beelen', 'Affiliation': 'NUTRIM School of Nutrition and Translation Research in Metabolism, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands.'}, {'ForeName': 'Lex B', 'Initials': 'LB', 'LastName': 'Verdijk', 'Affiliation': 'NUTRIM School of Nutrition and Translation Research in Metabolism, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands.'}, {'ForeName': 'Luc J C', 'Initials': 'LJC', 'LastName': 'van Loon', 'Affiliation': 'NUTRIM School of Nutrition and Translation Research in Metabolism, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands.'}]",Nutrients,['10.3390/nu12082299'] 2349,32752023,Title: Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy.,"We investigated whether responses to as-needed intravitreal aflibercept injections (IAIs) for polypoidal choroidal vasculopathy (PCV) differed among patients based upon drusen characteristics in fellow eyes. 110 eyes from 110 patients with PCV received 3 monthly IAI and thereafter Pro re nata (PRN) IAI over 12 months. Patients were classified into 4 groups depending on fellow eye findings. Group 1 (n = 16): pachydrusen; Group 2 (n = 45): no drusen; Group 3 (n = 35): soft drusen; Group4 (n = 14) PCV/scarring. Best-corrected visual acuity improved at 12 months in all groups, but not significantly in Group 1 and Group 4; however, visual improvement was similar among the groups after adjusting baseline confounders. Group 1 had a significantly lower percentage of eyes needing retreatment (all p < 0.001; Group 1: 16.7%; Group 2: 50.8%; Group 3: 80%; Group 4: 85.7%). The mean number of retreatments was least in Group 1 among the groups (all p -value < 0.003; Group 1: 0.50 ± 1.32; Group 2: 1.73 ± 2.08; Group 3:2.71 ± 1.99; Group 3: 2.71 ± 2.16). Patients with pachydrusen in fellow eyes were less likely to require additional IAI following the loading dose and may be ideal candidates for aflibercept monotherapy in their first year.",2020,Group 1 had a significantly lower percentage of eyes needing retreatment (all p < 0.001; Group 1: 16.7%; Group 2: 50.8%; Group 3: 80%; Group 4: 85.7%).,"['110 eyes from 110 patients with PCV received 3 monthly IAI and thereafter Pro re nata', 'Patients with Polypoidal Choroidal Vasculopathy', 'Patients with pachydrusen in fellow eyes', 'Title']","['Aflibercept Monotherapy', 'intravitreal aflibercept injections (IAIs']","['Best-corrected visual acuity', 'visual improvement', 'percentage of eyes needing retreatment', 'mean number of retreatments']","[{'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1504336', 'cui_str': 'Polypoidal choroidal vasculopathy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0067792', 'cui_str': 'N-acetyltryptophanamide'}]","[{'cui': 'C1134659', 'cui_str': 'aflibercept'}, {'cui': 'C1517572', 'cui_str': 'Intravitreal route'}, {'cui': 'C4050106', 'cui_str': 'aflibercept Injection'}]","[{'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0376495', 'cui_str': 'Retreatments'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",110.0,0.0328223,Group 1 had a significantly lower percentage of eyes needing retreatment (all p < 0.001; Group 1: 16.7%; Group 2: 50.8%; Group 3: 80%; Group 4: 85.7%).,"[{'ForeName': 'Yoshiko', 'Initials': 'Y', 'LastName': 'Fukuda', 'Affiliation': 'Departments of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo 409-3898, Yamanashi, Japan.'}, {'ForeName': 'Yoichi', 'Initials': 'Y', 'LastName': 'Sakurada', 'Affiliation': 'Departments of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo 409-3898, Yamanashi, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Sugiyama', 'Affiliation': 'Departments of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo 409-3898, Yamanashi, Japan.'}, {'ForeName': 'Seigo', 'Initials': 'S', 'LastName': 'Yoneyama', 'Affiliation': 'Departments of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo 409-3898, Yamanashi, Japan.'}, {'ForeName': 'Mio', 'Initials': 'M', 'LastName': 'Matsubara', 'Affiliation': 'Departments of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo 409-3898, Yamanashi, Japan.'}, {'ForeName': 'Wataru', 'Initials': 'W', 'LastName': 'Kikushima', 'Affiliation': 'Departments of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo 409-3898, Yamanashi, Japan.'}, {'ForeName': 'Naohiko', 'Initials': 'N', 'LastName': 'Tanabe', 'Affiliation': 'Departments of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo 409-3898, Yamanashi, Japan.'}, {'ForeName': 'Ravi', 'Initials': 'R', 'LastName': 'Parikh', 'Affiliation': 'Department of Ophthalmology, School of Medicine, New York University, New York, NY 10016, USA.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Kashiwagi', 'Affiliation': 'Departments of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo 409-3898, Yamanashi, Japan.'}]",Journal of clinical medicine,['10.3390/jcm9082459'] 2350,32752026,Improving Breastfeeding by Empowering Mothers in Vietnam: A Randomised Controlled Trial of a Mobile App.,"Breastfeeding provides benefits to the infant and mother; however, the rates of breastfeeding, particularly exclusive breastfeeding, remain below optimal levels in many Asian countries. The aim of this study is to review the benefits of breastfeeding to mothers and infants and current rates of breastfeeding in Vietnam, and to evaluate the effectiveness of a mobile application on exclusive breastfeeding among mothers in Vietnam. A two-arm, parallel triple-blinded randomised controlled trial will be conducted among 1000 mothers in Hanoi City, Vietnam, during 2020-2021. Eligible participants are pregnant women who will seek antenatal care from health facilities at 24-36 weeks of gestation and plan to deliver at two participating hospitals, own a smartphone, and carry a singleton foetus. Permuted-block randomisation method stratified by maternal age, education and parity will be used to ensure an equal number of participants in each group. A smartphone app will be developed to deliver breastfeeding and non-breastfeeding information to the intervention and control group, respectively. Data will be collected at baseline, before hospital discharge, and at 1, 4, and 6 months postpartum. This study envisages demonstrating whether a smartphone-based intervention can be effective at improving breastfeeding in Vietnam. Trials registration: ACTRN12619000531112.",2020,"Permuted-block randomisation method stratified by maternal age, education and parity will be used to ensure an equal number of participants in each group.","['1000 mothers in Hanoi City, Vietnam, during 2020-2021', 'Eligible participants are pregnant women who will seek antenatal care from health facilities at 24-36 weeks of gestation and plan to deliver at two participating hospitals, own a smartphone, and carry a singleton foetus', 'Empowering Mothers in Vietnam', 'mothers in Vietnam']",['smartphone-based intervention'],[],"[{'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0042658', 'cui_str': 'Vietnam'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}, {'cui': 'C0562342', 'cui_str': 'Empowered'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.142532,"Permuted-block randomisation method stratified by maternal age, education and parity will be used to ensure an equal number of participants in each group.","[{'ForeName': 'Thi Thuy Duong', 'Initials': 'TTD', 'LastName': 'Doan', 'Affiliation': 'Faculty of Social Sciences, Behavior and Health Education, Hanoi University of Public Health, 1A Duc Thang Street, Bac Tu Liem District, Hanoi 10000, Vietnam.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Binns', 'Affiliation': 'School of Public Health, Curtin University, Bentley, WA 6102, Australia.'}, {'ForeName': 'Ngoc Minh', 'Initials': 'NM', 'LastName': 'Pham', 'Affiliation': 'School of Public Health, Curtin University, Bentley, WA 6102, Australia.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'School of Public Health, Curtin University, Bentley, WA 6102, Australia.'}, {'ForeName': 'Thi Phuong Hoa', 'Initials': 'TPH', 'LastName': 'Dinh', 'Affiliation': 'Faculty of Social Sciences, Behavior and Health Education, Hanoi University of Public Health, 1A Duc Thang Street, Bac Tu Liem District, Hanoi 10000, Vietnam.'}, {'ForeName': 'Thi Thu Ha', 'Initials': 'TTH', 'LastName': 'Bui', 'Affiliation': 'Faculty of Social Sciences, Behavior and Health Education, Hanoi University of Public Health, 1A Duc Thang Street, Bac Tu Liem District, Hanoi 10000, Vietnam.'}, {'ForeName': 'Trung Chuyen', 'Initials': 'TC', 'LastName': 'Tran', 'Affiliation': 'Faculty of Information Technology, Department of Hanoi University of Mining and Geology, 18 Vien Street-Bac Tu Liem District, Hanoi 10000, Vietnam.'}, {'ForeName': 'Xuan Hoai', 'Initials': 'XH', 'LastName': 'Nguyen', 'Affiliation': 'Faculty of IT, Ho Chi Minh University of Technology (HUTECH), Ho Chi Minh 700000, Vietnam.'}, {'ForeName': 'Roslyn', 'Initials': 'R', 'LastName': 'Giglia', 'Affiliation': 'Foodbank Perth Airport, Perth, WA 6105, Australia.'}, {'ForeName': 'Fenglian', 'Initials': 'F', 'LastName': 'Xu', 'Affiliation': 'Data Analysis & Surgical Outcomes Unit (DASO), Royal North Shore Hospital, St Leonards, NSW 2065, Australia.'}, {'ForeName': 'Andy', 'Initials': 'A', 'LastName': 'Lee', 'Affiliation': 'Faculty of Social Sciences, Behavior and Health Education, Hanoi University of Public Health, 1A Duc Thang Street, Bac Tu Liem District, Hanoi 10000, Vietnam.'}]",International journal of environmental research and public health,['10.3390/ijerph17155552'] 2351,32752077,Parental Opinion about the Low FODMAP Diet in Dietary Treatment of Children with Functional Abdominal Pain.,"The aim of this study was primarily to evaluate differences between parental opinion about the diet and overall changes in children's symptoms of functional abdominal pain (FAP) during the low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet and National Institute for Health and Care Excellence (NICE) diet. Secondly, this paper examined the agreement between parental perception of children's symptoms and children's self-assessment of symptoms during the diet in both treatment groups. Twenty-seven children with diagnosed functional abdominal pain (FAP) were randomized to one of two group, receiving the low FODMAP diet or the diet based on NICE guidelines. Children reported gastrointestinal symptoms at baseline and during the diet. At the end of the intervention, parents assessed their children's diet and symptoms changes, using Likert scales. The agreement between parental and children assessments of gastrointestinal symptoms was defined as the percentage of compatible answers. In the low FODMAP group a significantly lower percentage of parents (38%) declared that it was easy to follow the diet, compared to the NICE group (57%), ( p = 0.017). A high percentage of parents in both groups reported improvement in all symptoms of children during dietary intervention. A high level of agreement was also observed between parental and children's self-assessment of abdominal pain intensity and frequency. Our research suggests that in parental opinion the low FODMAP diet is as effective as the diet based on NICE guidelines in children with FAP. However, the low FODMAP diet may seem more difficult to follow, and this may have had an impact on the effectiveness and acceptability of the FODMAP diet by children.",2020,A high level of agreement was also observed between parental and children's self-assessment of abdominal pain intensity and frequency.,"['children with FAP', 'Children with Functional Abdominal Pain', 'Twenty-seven children with diagnosed functional abdominal pain (FAP']","['low FODMAP diet or the diet based on NICE guidelines', 'Low FODMAP Diet']","['functional abdominal pain (FAP', 'gastrointestinal symptoms']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1609533', 'cui_str': 'Functional abdominal pain'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0028959', 'cui_str': 'Oligosaccharide'}, {'cui': 'C0012611', 'cui_str': 'Disaccharide'}, {'cui': 'C0026492', 'cui_str': 'Monosaccharide'}, {'cui': 'C0071629', 'cui_str': 'polyol'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}]","[{'cui': 'C1609533', 'cui_str': 'Functional abdominal pain'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}]",27.0,0.0139782,A high level of agreement was also observed between parental and children's self-assessment of abdominal pain intensity and frequency.,"[{'ForeName': 'Katarzyna Mirosława', 'Initials': 'KM', 'LastName': 'Boradyn', 'Affiliation': 'Department of Human Nutrition, Faculty of Food Sciences, University of Warmia and Mazury in Olsztyn, Słoneczna 45F, 10-718 Olsztyn, Poland.'}, {'ForeName': 'Elżbieta', 'Initials': 'E', 'LastName': 'Jarocka-Cyrta', 'Affiliation': 'Department of Pediatrics, Gastroenterology and Nutrition, Faculty of Medicine Collegium Medicum, University of Warmia and Mazury in Olsztyn, Żołnierska 18A, 10-561 Olsztyn, Poland.'}, {'ForeName': 'Katarzyna Eufemia', 'Initials': 'KE', 'LastName': 'Przybyłowicz', 'Affiliation': 'Department of Human Nutrition, Faculty of Food Sciences, University of Warmia and Mazury in Olsztyn, Słoneczna 45F, 10-718 Olsztyn, Poland.'}, {'ForeName': 'Małgorzata', 'Initials': 'M', 'LastName': 'Obara-Gołębiowska', 'Affiliation': 'Department of Clinical, Developmental and Educational Psychology, Faculty of Social Sciences, University of Warmia and Mazury in Olsztyn, Prawocheńskiego 13, 10-447 Olsztyn, Poland.'}]",International journal of environmental research and public health,['10.3390/ijerph17155554'] 2352,32752178,Lactobacillus plantarum PS128 Improves Physiological Adaptation and Performance in Triathletes through Gut Microbiota Modulation.,"A triathlon is an extremely high-intensity exercise and a challenge for physiological adaptation. A triathlete's microbiome might be modulated by diet, age, medical treatments, lifestyle, and exercise, thereby maintaining aerobiosis and optimum health and performance. Probiotics, prebiotics, and synbiotics have been reported to have health-promoting activities (e.g., immunoregulation and cancer prevention). However, few studies have addressed how probiotics affect the microbiota of athletes and how this translates into functional activities. In our previous study, we found that Lactobacillus plantarum PS128 could ameliorate inflammation and oxidative stress, with improved exercise performance. Thus, here we investigate how the microbiota of triathletes are altered by L. plantarum PS128 supplementation, not only for exercise performance but also for possible physiological adaptation. The triathletes were assigned to two groups: an L. plantarum 128 supplement group (LG, 3 × 10 10 colony-forming units (CFU)/day) and a placebo group (PG). Both groups continued with their regular exercise training for the next 4 weeks. The endurance performance, body composition, biochemistries, blood cells, microbiota, and associated metabolites were further investigated. PS128 significantly increased the athletes' endurance, by about 130% as compared to the PG group, but there was no significant difference in maximal oxygen consumption (VO 2 max) and composition between groups. The PS128 supplementation (LG) modulated the athlete's microbiota with both significant decreases ( Anaerotruncus , Caproiciproducens , Coprobacillus , Desulfovibrio , Dielma , Family_XIII , Holdemania , and Oxalobacter ) and increases ( Akkermansia , Bifidobacterium , Butyricimonas , and Lactobacillus ), and the LG showed lower diversity when compared to the PG. Also, the short-chain fatty acids (SCFAs; acetate, propionate, and butyrate) of the LG were significantly higher than the PG, which might be a result of a modulation of the associated microbiota. In conclusion, PS128 supplementation was associated with an improvement on endurance running performance through microbiota modulation and related metabolites, but not in maximal oxygen uptake.",2020,"The PS128 supplementation (LG) modulated the athlete's microbiota with both significant decreases ( Anaerotruncus , Caproiciproducens , Coprobacillus , Desulfovibrio , Dielma , Family_XIII , Holdemania , and Oxalobacter ) and increases ( Akkermansia , Bifidobacterium , Butyricimonas , and Lactobacillus ), and the LG showed lower diversity when compared to the PG.",['Triathletes through Gut Microbiota Modulation'],"['Lactobacillus plantarum PS128', 'regular exercise training', 'PS128 supplementation', 'L. plantarum 128 supplement group (LG, 3 × 10 10 colony-forming units (CFU)/day) and a placebo']","[' Anaerotruncus , Caproiciproducens , Coprobacillus , Desulfovibrio , Dielma , Family_XIII , Holdemania , and Oxalobacter ) and increases ( Akkermansia , Bifidobacterium , Butyricimonas , and Lactobacillus ', 'inflammation and oxidative stress', 'maximal oxygen uptake', 'endurance performance, body composition, biochemistries, blood cells, microbiota, and associated metabolites', 'maximal oxygen consumption (VO 2 max) and composition', ""athletes' endurance"", 'endurance running performance', 'PS128', 'exercise performance']","[{'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}]","[{'cui': 'C0317608', 'cui_str': 'Lactobacillus plantarum'}, {'cui': 'C0582191', 'cui_str': 'Regular exercise'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C1231534', 'cui_str': 'Curtobacterium plantarum'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439158', 'cui_str': 'colonies'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1493608', 'cui_str': 'Anaerotruncus'}, {'cui': 'C1046489', 'cui_str': 'Genus Coprobacillus'}, {'cui': 'C0011731', 'cui_str': 'Desulfovibrio'}, {'cui': 'C1022647', 'cui_str': 'Holdemania'}, {'cui': 'C0317924', 'cui_str': 'Oxalobacter'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1490589', 'cui_str': 'Akkermansia'}, {'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}, {'cui': 'C0022938', 'cui_str': 'Lactobacillus'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0005477', 'cui_str': 'Biochemistry'}, {'cui': 'C0005773', 'cui_str': 'Blood cell'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.0287401,"The PS128 supplementation (LG) modulated the athlete's microbiota with both significant decreases ( Anaerotruncus , Caproiciproducens , Coprobacillus , Desulfovibrio , Dielma , Family_XIII , Holdemania , and Oxalobacter ) and increases ( Akkermansia , Bifidobacterium , Butyricimonas , and Lactobacillus ), and the LG showed lower diversity when compared to the PG.","[{'ForeName': 'Wen-Ching', 'Initials': 'WC', 'LastName': 'Huang', 'Affiliation': 'Department of Exercise and Health Science, National Taipei University of Nursing and Health Sciences, Taipei 11219, Taiwan.'}, {'ForeName': 'Chun-Hsu', 'Initials': 'CH', 'LastName': 'Pan', 'Affiliation': 'Ph.D. Program in Biotechnology Research and Development, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan.'}, {'ForeName': 'Chen-Chan', 'Initials': 'CC', 'LastName': 'Wei', 'Affiliation': 'Department of Aquatic Sport, University of Taipei, Taipei 11153, Taiwan.'}, {'ForeName': 'Hui-Yu', 'Initials': 'HY', 'LastName': 'Huang', 'Affiliation': 'Graduate Institute of Metabolism and Obesity Sciences, Taipei Medical University, Taipei 11031, Taiwan.'}]",Nutrients,['10.3390/nu12082315'] 2353,32752228,Benefits of Brief Group Cognitive Behavioral Therapy in Reducing Diabetes-Related Distress and HbA1c in Uncontrolled Type 2 Diabetes Mellitus Patients in Thailand.,"This study evaluated the short-term efficacy of brief group cognitive behavioral therapy (BG-CBT) in reducing diabetes-related distress (DRD), lowering hemoglobin A1c (HbA1c), improving food consumption behavior, increasing physical activity, and improving medication adherence behavior. A quasi-experimental pretest/post-test design with follow-up assessments was used with an experimental and a control group. Participants were patients with uncontrolled type 2 diabetes mellitus (T2DM) and moderate or high diabetes-related distress recruited from the Diabetes Mellitus Clinic of Hang Dong Hospital, Chiang Mai, Thailand. Fifty-six eligible participants were purposively selected and enrolled, then randomly assigned to either the BG-CBT group or the control group. The BG-CBT group received six brief weekly sessions of cognitive behavioral group therapy, while the control group received conventional care. Baseline data were collected at week 0 (pretest) and at week 6 (post-test), including food consumption behavior, physical activity, and adherence to medication regimes, as well as a blood examination to determine levels of HbA1c at the week 12 follow-up. DRD was assessed using the Diabetes Distress Scale (DDS-17) and analyzed using descriptive statistics, including pair t-test and independence t-test results. The BG-CBT had a significant effect on the amelioration of diabetes distress, improvement of food consumption behavior, and reduction of HbA1c levels, demonstrating the effectiveness of BG-CBT in maintaining diabetes control in people with T2DM-related distress.",2020,"The BG-CBT had a significant effect on the amelioration of diabetes distress, improvement of food consumption behavior, and reduction of HbA1c levels, demonstrating the effectiveness of BG-CBT in maintaining diabetes control in people with T2DM-related distress.","['Participants were patients with uncontrolled type 2 diabetes mellitus (T2DM) and moderate or high diabetes-related distress recruited from the Diabetes Mellitus Clinic of Hang Dong Hospital, Chiang Mai, Thailand', 'Uncontrolled Type 2 Diabetes Mellitus Patients in Thailand', 'Fifty-six eligible participants']","['brief group cognitive behavioral therapy (BG-CBT', 'cognitive behavioral group therapy, while the control group received conventional care', 'BG-CBT', 'Brief Group Cognitive Behavioral Therapy']","['diabetes-related distress (DRD), lowering hemoglobin A1c (HbA1c), improving food consumption behavior, increasing physical activity, and improving medication adherence behavior', 'Diabetes Distress Scale (DDS-17', 'DRD', 'amelioration of diabetes distress, improvement of food consumption behavior, and reduction of HbA1c levels', 'food consumption behavior, physical activity, and adherence to medication regimes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0544691', 'cui_str': 'Hanging'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0026914', 'cui_str': 'Mycobacterium avium-intracellulare'}, {'cui': 'C0039725', 'cui_str': 'Thailand'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0033971', 'cui_str': 'Group psychotherapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C4039165', 'cui_str': 'Increased physical activity'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0010980', 'cui_str': 'Dapsone'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0474680', 'cui_str': 'Hemoglobin A1c measurement'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",56.0,0.0198252,"The BG-CBT had a significant effect on the amelioration of diabetes distress, improvement of food consumption behavior, and reduction of HbA1c levels, demonstrating the effectiveness of BG-CBT in maintaining diabetes control in people with T2DM-related distress.","[{'ForeName': 'Kongprai', 'Initials': 'K', 'LastName': 'Tunsuchart', 'Affiliation': 'Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'ForeName': 'Peerasak', 'Initials': 'P', 'LastName': 'Lerttrakarnnon', 'Affiliation': 'Department of Family Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'ForeName': 'Kriengkrai', 'Initials': 'K', 'LastName': 'Srithanaviboonchai', 'Affiliation': 'Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'ForeName': 'Surinporn', 'Initials': 'S', 'LastName': 'Likhitsathian', 'Affiliation': 'Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'ForeName': 'Sombat', 'Initials': 'S', 'LastName': 'Skulphan', 'Affiliation': 'Department of Psychiatric Nursing, Faculty of Nursing, Chiang Mai University, Chiang Mai 50200, Thailand.'}]",International journal of environmental research and public health,['10.3390/ijerph17155564'] 2354,32752234,The Effectiveness of Individual or Group Physiotherapy in the Management of Sub-Acromial Impingement: A Randomised Controlled Trial and Health Economic Analysis.,"Background : Shoulder pain is common in primary care. The management of subacromial impingement (SAI) can include corticosteroid injections and physiotherapy. Physiotherapy can be on an individual or group basis. Aim : To examine the clinical effectiveness and make an economic analysis of individual versus group physiotherapy, following corticosteroid injection for SAI. Design and Setting : A single-blind, open-label, randomised equivalence study comparing group and individual physiotherapy. Patients referred by local general practitioners and physiotherapists were considered for inclusion. Method : Patients were randomised to individual or group physiotherapy groups, and all received corticosteroid injection before physiotherapy. The primary outcome measure was shoulder pain and disability index (SPADI) at 26 weeks. An economic analysis was conducted. Results and Conclusion : 136 patients were recruited, 68 randomised to each group. Recruitment was 68% of the target 200 participants. SPADI (from baseline to 26 weeks) demonstrated a difference (SE) in mean change between groups of -0.43 (5.7) ( p -value = 0.050001), and the TOST (two-one-sided test for equivalence) 90% CI for this difference was (-10.0 to 9.14). This was borderline. In a secondary analysis using inputted data, patients without SPADI at week 26 were analysed by carrying forward scores at week 12 (mean difference (95% CI) = -0.14 (-7.5 to 7.3), p -value = 0.014). There is little difference in outcome at 26 weeks. Group physiotherapy was cheaper to deliver per patient (£252 versus £84). Group physiotherapy for SAI produces similar clinical outcomes to individual physiotherapy with potential cost savings. Due to low recruitment to our study, firm conclusions are difficult and further research is required to give a definitive answer to this research question. (NCT Clinical Trial Registration Number NCT04058522).",2020,Group physiotherapy was cheaper to deliver per patient (£252 versus £84).,"['Sub-Acromial Impingement', '136 patients were recruited, 68 randomised to each group', 'Patients referred by local general practitioners and physiotherapists were considered for inclusion']","['corticosteroid injection before physiotherapy', 'subacromial impingement (SAI', 'Individual or Group Physiotherapy', 'corticosteroid injections and physiotherapy']","['shoulder pain and disability index (SPADI', 'TOST', 'SPADI']","[{'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0553514', 'cui_str': 'Referral source'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}]","[{'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0376685', 'cui_str': 'Impingement syndrome of shoulder region'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4704938', 'cui_str': 'Group Physiotherapy'}]","[{'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.232029,Group physiotherapy was cheaper to deliver per patient (£252 versus £84).,"[{'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Ryans', 'Affiliation': 'General Practice Elective Care Service (MSK), Eastern GP Federations, Belfast, BT8 7AR, Ireland.'}, {'ForeName': 'Rhona', 'Initials': 'R', 'LastName': 'Galway', 'Affiliation': 'Rheumatology Department, South Eastern Health and Social Services Trust, Dundonald BT16 1RH, Ireland.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Harte', 'Affiliation': 'School of Health Sciences, Ulster University, Belfast BT37 0QB, Ireland.'}, {'ForeName': 'Rejina', 'Initials': 'R', 'LastName': 'Verghis', 'Affiliation': 'Northern Ireland Clinical Trials Unit, Belfast BT12 6BA, Ireland.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Agus', 'Affiliation': 'Northern Ireland Clinical Trials Unit, Belfast BT12 6BA, Ireland.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Heron', 'Affiliation': ""Department of General Practice, Queen's University Belfast, Belfast BT7 1NN, UK.""}, {'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'McKane', 'Affiliation': 'Rheumatology Department, South Eastern Health and Social Services Trust, Dundonald BT16 1RH, Ireland.'}]",International journal of environmental research and public health,['10.3390/ijerph17155565'] 2355,32752282,"Effects of Depressive Symptoms, Feelings, and Interoception on Reward-Based Decision-Making: Investigation Using Reinforcement Learning Model.","BACKGROUND In this study, we examined the relationships between reward-based decision-making in terms of learning rate, memory rate, exploration rate, and depression-related subjective emotional experience, in terms of interoception and feelings, to understand how reward-based decision-making is impaired in depression. METHODS In all, 52 university students were randomly assigned to an experimental group and a control group. To manipulate interoception, the participants in the experimental group were instructed to tune their internal somatic sense to the skin-conductance-response waveform presented on a display. The participants in the control group were only instructed to stay relaxed. Before and after the manipulation, the participants completed a probabilistic reversal-learning task to assess reward-based decision-making using reinforcement learning modeling. Similarly, participants completed a probe-detection task, a heartbeat-detection task, and self-rated scales. RESULTS The experimental manipulation of interoception was not successful. In the baseline testing, reinforcement learning modeling indicated a marginally-significant correlation between the exploration rate and depressive symptoms. However, the exploration rate was significantly associated with lower interoceptive attention and higher depressive feeling. CONCLUSIONS The findings suggest that situational characteristics may be closely involved in reward exploration and highlight the clinically-meaningful possibility that intervention for affective processes may impact reward-based decision-making in those with depression.",2020,"Before and after the manipulation, the participants completed a probabilistic reversal-learning task to assess reward-based decision-making using reinforcement learning modeling.",['52 university students'],"['tune their internal somatic sense to the skin-conductance-response waveform presented on a display', 'probabilistic reversal-learning task to assess reward-based decision-making using reinforcement learning modeling']","['lower interoceptive attention and higher depressive feeling', 'exploration rate and depressive symptoms', 'learning rate, memory rate, exploration rate, and depression-related subjective emotional experience', 'probe-detection task, a heartbeat-detection task, and self-rated scales']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C1257909', 'cui_str': 'Diploid Cell'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0450448', 'cui_str': 'Waveforms'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0035375', 'cui_str': 'Reversal Learning'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0035007', 'cui_str': 'Psychological Reinforcement'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C1280903', 'cui_str': 'Exploration procedure'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0425583', 'cui_str': 'Heart beat'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.0546274,"Before and after the manipulation, the participants completed a probabilistic reversal-learning task to assess reward-based decision-making using reinforcement learning modeling.","[{'ForeName': 'Hiroyoshi', 'Initials': 'H', 'LastName': 'Ogishima', 'Affiliation': 'Graduate School of Human Sciences, Waseda University, 359-1192 Saitama, Japan.'}, {'ForeName': 'Shunta', 'Initials': 'S', 'LastName': 'Maeda', 'Affiliation': 'Graduate School of Education, Tohoku University, 980-8576 Miyagi, Japan.'}, {'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Tanaka', 'Affiliation': ""Faculty of Humanities, Wayo Women's University, 272-8533 Chiba, Japan.""}, {'ForeName': 'Hironori', 'Initials': 'H', 'LastName': 'Shimada', 'Affiliation': 'Faculty of Human Sciences, Waseda University, 359-1192 Saitama, Japan.'}]",Brain sciences,['10.3390/brainsci10080508'] 2356,32752306,Thermotherapy Plus Neck Stabilization Exercise for Chronic Nonspecific Neck Pain in Elderly: A Single-Blinded Randomized Controlled Trial.,"Neck pain is a serious problem for public health. This study aimed to compare the effects of thermotherapy plus neck stabilization exercise versus neck stabilization exercise alone on pain, neck disability, muscle properties, and alignment of the neck and shoulder in the elderly with chronic nonspecific neck pain. This study is a single-blinded randomized controlled trial. Thirty-five individuals with chronic nonspecific neck pain were randomly allocated to intervention ( n = 18) or control ( n = 17) groups. The intervention group received thermotherapy with a salt-pack for 30 min and performed a neck stabilization exercise for 40 min twice a day for 5 days (10 sessions). The control group performed a neck stabilization exercise at the same time points. Pain intensity, pain pressure threshold (PPT), neck disability index, muscle properties, and alignment of the neck and shoulder were evaluated before and after the intervention. Significant time and group interactions were observed for pain at rest ( p < 0.001) and during movement ( p < 0.001), and for PPT at the upper-trapezius ( p < 0.001), levator-scapula ( p = 0.003), and splenius-capitis ( p = 0.001). The disability caused by neck pain also significantly changed between groups over time ( p = 0.005). In comparison with the control group, the intervention group showed significant improvements in muscle properties for the upper-trapezius (tone, p = 0.021; stiffness, p = 0.017), levator-scapula (stiffness, p = 0.025; elasticity, p = 0.035), and splenius-capitis (stiffness, p = 0.012), and alignment of the neck ( p = 0.016) and shoulder ( p < 0.001) over time. These results recommend the clinical use of salt pack thermotherapy in addition to neck stabilization exercise as a complementary intervention for chronic nonspecific neck pain control.",2020,"Significant time and group interactions were observed for pain at rest ( p < 0.001) and during movement ( p < 0.001), and for PPT at the upper-trapezius ( p < 0.001), levator-scapula ( p = 0.003), and splenius-capitis ( p = 0.001).","['elderly with chronic nonspecific neck pain', 'chronic nonspecific neck pain control', 'Thirty-five individuals with chronic nonspecific neck pain', 'Chronic Nonspecific Neck Pain in Elderly']","['thermotherapy plus neck stabilization exercise versus neck stabilization exercise alone', 'neck stabilization exercise', 'Thermotherapy Plus Neck Stabilization Exercise', 'thermotherapy with a salt-pack for 30 min and performed a neck stabilization exercise']","['pain, neck disability, muscle properties, and alignment of the neck and shoulder', 'Pain intensity, pain pressure threshold (PPT), neck disability index, muscle properties, and alignment of the neck and shoulder', 'muscle properties for the upper-trapezius', 'pain at rest', 'disability caused by neck pain', 'levator-scapula']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0020548', 'cui_str': 'Thermotherapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0036140', 'cui_str': 'Salts'}, {'cui': 'C0184967', 'cui_str': 'Insertion of pack'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0231493', 'cui_str': 'Muscle property'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0224361', 'cui_str': 'Structure of trapezius muscle'}, {'cui': 'C0234253', 'cui_str': 'Rest pain'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0036277', 'cui_str': 'Bone structure of scapula'}]",35.0,0.064528,"Significant time and group interactions were observed for pain at rest ( p < 0.001) and during movement ( p < 0.001), and for PPT at the upper-trapezius ( p < 0.001), levator-scapula ( p = 0.003), and splenius-capitis ( p = 0.001).","[{'ForeName': 'Ho-Jin', 'Initials': 'HJ', 'LastName': 'Shin', 'Affiliation': 'Department of Health Science, Gachon University Graduate School, Incheon 21936, Korea.'}, {'ForeName': 'Sung-Hyeon', 'Initials': 'SH', 'LastName': 'Kim', 'Affiliation': 'Department of Health Science, Gachon University Graduate School, Incheon 21936, Korea.'}, {'ForeName': 'Suk-Chan', 'Initials': 'SC', 'LastName': 'Hahm', 'Affiliation': 'Graduate School of Integrative Medicine, CHA University, Seongnam 13488, Korea.'}, {'ForeName': 'Hwi-Young', 'Initials': 'HY', 'LastName': 'Cho', 'Affiliation': 'Department of Health Science, Gachon University Graduate School, Incheon 21936, Korea.'}]",International journal of environmental research and public health,['10.3390/ijerph17155572'] 2357,32752597,Educational Intervention Based on the Health Belief Model to Modify Risk Factors of Cardiovascular Disease in Police Officers in Iran: A Quasi-experimental Study.,"OBJECTIVES Police officers may be at a greater risk for cardiovascular disease (CVD) than the general population due to their highstress occupation. This study evaluated how an educational program based on the health belief model (HBM) may protect police officers from developing CVD. METHODS In this single-group experimental study, 58 police officers in Iran participated in a 5-week intervention based on HBM principles. Outcomes included changes in scores on an HBM scale, time spent on moderate to vigorous physical activity (International Physical Activity Questionnaire), body mass index (BMI), blood lipid profile, blood glucose, and blood pressure. The intervention consisted of 5 HBM-based educational sessions. Follow-up was conducted at 3 months post-intervention. The paired t-test was used to examine differences between baseline and follow-up scores. RESULTS All aspects of the HBM scale improved between baseline and follow-up (p<0.05), except the cues to action subscale. Self-efficacy and preventive behaviors improved the most. BMI decreased from 26.7±2.9 kg/m2 at baseline to 25.8±2.4 kg/m2 at follow-up. All components of the lipid profile, including triglycerides, cholesterol, high-density lipoprotein, and low-density lipoprotein, showed significant improvements post-intervention. Blood glucose and blood pressure also decreased, but not significantly. Nearly 25% of participants who were not physically active at baseline increased their physical activity above or beyond the healthy threshold. CONCLUSIONS A relatively brief educational intervention based on HBM principles led to a significant improvement in CVD risk factors among police officers. Further research is needed to corroborate the effectiveness of this intervention.",2020,"All aspects of the HBM scale improved between baseline and follow-up (p<0.05), except the cues to action subscale.","['Police Officers in Iran', '58 police officers in Iran participated in a 5-week intervention based on HBM principles']","['5 HBM-based educational sessions', 'Educational Intervention']","['CVD risk factors', 'physical activity', 'BMI', 'triglycerides, cholesterol, high-density lipoprotein, and low-density lipoprotein', 'Blood glucose and blood pressure', 'Self-efficacy and preventive behaviors', 'HBM scale', 'HBM scale, time spent on moderate to vigorous physical activity (International Physical Activity Questionnaire), body mass index (BMI), blood lipid profile, blood glucose, and blood pressure']","[{'cui': 'C0086825', 'cui_str': 'Policeman'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C3714363', 'cui_str': 'Health belief model'}]","[{'cui': 'C3714363', 'cui_str': 'Health belief model'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0204169', 'cui_str': 'Preventive dental procedure'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C3714363', 'cui_str': 'Health belief model'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}]",58.0,0.0197036,"All aspects of the HBM scale improved between baseline and follow-up (p<0.05), except the cues to action subscale.","[{'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Saffari', 'Affiliation': 'Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences Tehran, Iran.'}, {'ForeName': 'Hormoz', 'Initials': 'H', 'LastName': 'Sanaeinasab', 'Affiliation': 'Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences Tehran, Iran.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Jafarzadeh', 'Affiliation': 'Health Education Department, Faculty of Health, Baqiyatallah University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mojtaba', 'Initials': 'M', 'LastName': 'Sepandi', 'Affiliation': 'Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences Tehran, Iran.'}, {'ForeName': 'Keisha-Gaye N', 'Initials': 'KN', 'LastName': ""O'Garo"", 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Harold G', 'Initials': 'HG', 'LastName': 'Koenig', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Amir H', 'Initials': 'AH', 'LastName': 'Pakpour', 'Affiliation': 'Social Determinants of Health Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.'}]",Journal of preventive medicine and public health = Yebang Uihakhoe chi,['10.3961/jpmph.20.095'] 2358,32752904,Peptide vaccine with glucopyranosyl lipid A-stable oil-in-water emulsion for patients with resected melanoma.,"Aim: We tested the safety and immunogenicity of a novel vaccine in patients with resected high-risk melanoma. Patients & methods: HLA-A2-positive patients with resected Stage II-IV melanoma were randomized to receive up to three vaccinations of melanoma-associated peptide (MART-1a) combined with a stable oil-in-water emulsion (SE) either with the Toll-like receptor 4 agonist glucopyranosyl lipid A (GLA-SE-Schedule 1) or alone (SE-Schedule 2). Safety and immunogenicity of the vaccines were monitored. Results:  A total of 23 patients were registered. No treatment-related grade 3 or higher adverse events were observed. Increases in MART-1a-specific T cells were seen in 70 and 63% of Schedule 1 and Schedule 2 patients, respectively. Conclusion: Both vaccine schedules were well-tolerated and resulted in an increase in MART-1a-specific T cells. Clinical Trial registration: NCT02320305 (ClinicalTrials.gov).",2020,"Increases in MART-1a-specific T cells were seen in 70 and 63% of Schedule 1 and Schedule 2 patients, respectively. ","['A total of\xa023 patients were registered', 'Patients & methods: HLA-A2-positive patients with resected Stage II-IV melanoma', 'patients with resected high-risk melanoma', 'patients with resected melanoma']","['agonist glucopyranosyl lipid A (GLA-SE-Schedule 1) or alone (SE-Schedule 2', 'novel vaccine', 'Peptide vaccine with glucopyranosyl lipid A-stable oil-in-water emulsion', 'melanoma-associated peptide (MART-1a) combined with a\xa0stable\xa0oil-in-water emulsion (SE) either with the Toll-like receptor 4']","['adverse events', 'MART-1a-specific T cells', 'Safety and immunogenicity', 'safety and immunogenicity']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0019733', 'cui_str': 'HLA-A2 antigen'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]","[{'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C4276833', 'cui_str': 'glucopyranosyl lipid-A'}, {'cui': 'C0061078', 'cui_str': 'gamolenic acid'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0599934', 'cui_str': 'Peptide Vaccines'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0014020', 'cui_str': 'Emulsions'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1321919', 'cui_str': 'TLR4 protein, human'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",23.0,0.454163,"Increases in MART-1a-specific T cells were seen in 70 and 63% of Schedule 1 and Schedule 2 patients, respectively. ","[{'ForeName': 'Eric P', 'Initials': 'EP', 'LastName': 'Grewal', 'Affiliation': 'Mayo Clinic Rochester, Division of Medical Oncology, 200 First Street SW, Rochester, MN 55905, USA.'}, {'ForeName': 'Courtney L', 'Initials': 'CL', 'LastName': 'Erskine', 'Affiliation': 'Department of Immunology, 200 First Street SW, Rochester, MN 55905, USA.'}, {'ForeName': 'Wendy K', 'Initials': 'WK', 'LastName': 'Nevala', 'Affiliation': 'Division of Oncology Research, 200 First Street SW, Rochester, MN 55905, USA.'}, {'ForeName': 'Jacob B', 'Initials': 'JB', 'LastName': 'Allred', 'Affiliation': 'Department of Biostatistics & Informatics, 200 First Street SW, Rochester, MN 55905, USA.'}, {'ForeName': 'Carrie A', 'Initials': 'CA', 'LastName': 'Strand', 'Affiliation': 'Department of Biostatistics & Informatics, 200 First Street SW, Rochester, MN 55905, USA.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Kottschade', 'Affiliation': 'Mayo Clinic Rochester, Division of Medical Oncology, 200 First Street SW, Rochester, MN 55905, USA.'}, {'ForeName': 'Robert R', 'Initials': 'RR', 'LastName': 'McWilliams', 'Affiliation': 'Mayo Clinic Rochester, Division of Medical Oncology, 200 First Street SW, Rochester, MN 55905, USA.'}, {'ForeName': 'Roxana S', 'Initials': 'RS', 'LastName': 'Dronca', 'Affiliation': 'Department of Hematology/Oncology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA.'}, {'ForeName': 'Adam J', 'Initials': 'AJ', 'LastName': 'Yakovich', 'Affiliation': 'Immune Design, Inc., 1616 Eastlake Ave E #310, Seattle, WA 98102, USA.'}, {'ForeName': 'Svetomir N', 'Initials': 'SN', 'LastName': 'Markovic', 'Affiliation': 'Mayo Clinic Rochester, Division of Medical Oncology, 200 First Street SW, Rochester, MN 55905, USA.'}, {'ForeName': 'Matthew S', 'Initials': 'MS', 'LastName': 'Block', 'Affiliation': 'Mayo Clinic Rochester, Division of Medical Oncology, 200 First Street SW, Rochester, MN 55905, USA.'}]",Immunotherapy,['10.2217/imt-2020-0085'] 2359,32752932,Development of a novel zolmitriptan intracutaneous microneedle system (Qtrypta™) for the acute treatment of migraine.,"M207 is an investigational intracutaneous microneedle therapeutic system for nonoral zolmitriptan delivery. In a Phase I trial, M207 provided faster absorption with a higher 2 h exposure than oral zolmitriptan. In the pivotal trial evaluating efficacy, tolerability and safety in moderate-to-severe migraine attacks, M207 3.8 mg was superior to placebo in providing freedom from headache pain (42 vs 14%) and freedom from most bothersome symptom (68 vs 43%) 2 h post-dose. Treatment-emergent adverse events were mild and transient and most commonly concerned the application site. In post hoc analyses: pain freedom was sustained in approximately 1/3 of patients; efficacy was observed in migraine headaches that are typically more difficult to treat.",2020,In post hoc analyses: pain freedom was sustained in approximately 1/3 of patients; efficacy was observed in migraine headaches that are typically more difficult to treat.,[],"['oral zolmitriptan', 'zolmitriptan intracutaneous microneedle system (Qtrypta™', 'placebo']","['pain freedom', 'headache pain', 'efficacy, tolerability and safety']",[],"[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0528166', 'cui_str': 'zolmitriptan'}, {'cui': 'C1522475', 'cui_str': 'Intradermal route'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0345793,In post hoc analyses: pain freedom was sustained in approximately 1/3 of patients; efficacy was observed in migraine headaches that are typically more difficult to treat.,"[{'ForeName': 'Alan M', 'Initials': 'AM', 'LastName': 'Rapoport', 'Affiliation': 'The David Geffen School of Medicine at UCLA in Los Angeles, CA\xa090095, USA.'}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Ameri', 'Affiliation': 'Zosano Pharma, 34790 Ardentech Court, Fremont, CA 94555, USA.'}, {'ForeName': 'Hayley', 'Initials': 'H', 'LastName': 'Lewis', 'Affiliation': 'Zosano Pharma, 34790 Ardentech Court, Fremont, CA 94555, USA.'}, {'ForeName': 'Donald J', 'Initials': 'DJ', 'LastName': 'Kellerman', 'Affiliation': 'Zosano Pharma, 34790 Ardentech Court, Fremont, CA 94555, USA.'}]",Pain management,['10.2217/pmt-2020-0041'] 2360,32753043,Application of multidirectional stitching technology in a laparoscopic suturing instructional program: a randomized controlled trial.,"BACKGROUND Surgeon suturing technology plays a pivotal role in patient recovery after laparoscopic surgery. Intracorporal suturing and knot tying in minimally invasive surgery are particularly challenging and represent a key skill for advanced procedures. In this study, we compared the application of multidirectional stitching technology with application of the traditional method in a laparoscopic suturing instructional program. METHODS We selected forty residents within two years of graduation to assess the specialized teaching of laparoscopic suturing with laparoscopic simulators. The forty students were randomly divided into two groups, a control group and an experimental group, with twenty students in each group. The control group was scheduled to learn the traditional suture method, and the experimental group applied multidirectional stitching technology. The grades for suturing time, thread length, accuracy of needle entry, stability of the knot, tissue integrity, and tightness of the tissue before and after the training program were calculated. RESULTS There was no significant difference between the two groups before the learning intervention. After the program, both groups significantly improved in each subject. There were significant differences between the control group and the experimental group in suture time (P = 0.001), accuracy of needle entry and exit (P = 0.035), and whether the suture tissue had cracks (P = 0.030). However, the two groups showed non-significant differences in thread length (P = 0.093), stablity of the knot (P = 0.241), or tightness of the tissue (P = 0.367). CONCLUSIONS Multidirectional stitching technology improves the efficiency and effectiveness of traditional laparoscopic suture instructional programs. It might be a practicable, novel training method for acquiring proficiency in manual laparoscopic skills in a training setting.",2020,"There were significant differences between the control group and the experimental group in suture time (P = 0.001), accuracy of needle entry and exit (P = 0.035), and whether the suture tissue had cracks (P = 0.030).","['forty residents within two years of graduation to assess the specialized teaching of laparoscopic suturing with laparoscopic simulators', 'patient recovery after laparoscopic surgery', 'forty students']","['learn the traditional suture method, and the experimental group applied multidirectional stitching technology', 'multidirectional stitching technology', 'Intracorporal suturing and knot tying']","['thread length', 'suture time', 'suturing time, thread length, accuracy of needle entry, stability of the knot, tissue integrity, and tightness of the tissue', 'efficiency and effectiveness', 'accuracy of needle entry and exit', 'tightness of the tissue', 'stablity of the knot']","[{'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0560032', 'cui_str': 'knot'}]","[{'cui': 'C4319672', 'cui_str': 'Thread'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0560032', 'cui_str': 'knot'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0439816', 'cui_str': 'Tightness sensation quality'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0337094', 'cui_str': 'Exit'}]",40.0,0.0211181,"There were significant differences between the control group and the experimental group in suture time (P = 0.001), accuracy of needle entry and exit (P = 0.035), and whether the suture tissue had cracks (P = 0.030).","[{'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': ""Department of Obstetrics and Gynaecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.""}, {'ForeName': 'Qiong', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': ""Department of Obstetrics and Gynaecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.""}, {'ForeName': 'Jia-Ning', 'Initials': 'JN', 'LastName': 'Hu', 'Affiliation': 'The Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Shen', 'Affiliation': ""Department of Obstetrics and Gynaecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.""}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Xia', 'Affiliation': ""Department of Obstetrics and Gynaecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.""}, {'ForeName': 'Lin-Zhi', 'Initials': 'LZ', 'LastName': 'Yan', 'Affiliation': ""Department of Obstetrics and Gynaecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.""}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ""Department of Obstetrics and Gynaecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.""}, {'ForeName': 'Xiu-Jie', 'Initials': 'XJ', 'LastName': 'Zhu', 'Affiliation': ""Department of Obstetrics and Gynaecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.""}, {'ForeName': 'Wen-Ju', 'Initials': 'WJ', 'LastName': 'Li', 'Affiliation': ""Department of Obstetrics and Gynaecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.""}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': ""Department of Obstetrics and Gynaecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.""}, {'ForeName': 'Qiong', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': ""Department of Obstetrics and Gynaecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China. joan_zhang2002@sina.com.""}]",BMC medical education,['10.1186/s12909-020-02146-w'] 2361,32753063,"Comparison of preemptive paracetamol, paracetamol-diclofenac & paracetamol-tramadol combination on postoperative pain after elective abdominal surgery under general anesthesia, Ethiopia: a randomized control trial study, 2018.","BACKGROUND In the practice of postoperative pain management, pain is still poorly managed in low resource setting where the practice of epidural and opioid free analgesia is impractical. There has been a recent trend of combining different drugs and concept of preemptive analgesia but the therapeutic superiority remains understudied for postoperative pain management. The aim of this study is to assess postoperative analgesic effect of preemptive Paracetamol, Paracetamol-diclofenac and Paracetamol-tramadol combination in patients undergoing laparotomy surgery. METHODS Three-arm, randomized control trial study conducted on 63 patients undergone laparotomy surgery; group-P (paracetamol 1 g), group-PD (1 g + diclofenac 75 mg) and group-PT (paracetamol 1 g + tramadol 100 mg). The Numerical Rating Scale (NRS) pain rating system was used for this study. The primary endpoint of the study was total amount of analgesia consumption. Post-operative analgesic therapy [intravenous tramadol, 50 mg] were provided when patients complain of pain (request medication) or a numeric rating scale ≥4 was recorded. Secondary endpoint of the study were the time of first analgesic request and the intensity of the pain during 24 h post-op follow up period. Parametric data were analyzed using (ANOVA) and nonparametric data analyzed by Kuruska-Wallis H rank test. Chi-square test used for categorical variable. Statistical significance were sated at p value < 0.05 with a power of 80%. RESULTS The mean total tramadol consumption was significant higher in paracetamol group 250 ± 79.06 mg compared to paracetamol-diclofenac (173.81 ± 87.49 mg p = 0. 008) and paracetamol-tramadol (154.76 ± 70.54 mg p = 0. 001) group. Time to first analgesic request was significantly shorter within paracetamol group (87.62 ± 20.95 min) compared to paracetamol-diclofenac (103.01 ± 23.53 min p = 0.029) and paracetamol-tramadol (144.05 ± 14.72 min p < 0.001) group. There was statistically significant difference at 4th, 6th and 8th hour showing lower median pain score in paracetamol-tramadol group compared to paracetamol group. CONCLUSION Preemptive combination of paracetamol-tramadol and paracetamol-diclofenac reduce total tramadol consumption and prolongs time to first analgesic request compared to paracetamol alone in patients undergoing laparotomy surgery. TRIAL REGISTRATION The study was retrospectively registered on 07 July 2019 at Pan African Clinical Trial Registry with the identification number of PACTR201908890749145 . It was accepted on 14 August 2019.",2020,Time to first analgesic request was significantly shorter within paracetamol group (87.62 ± 20.95 min) compared to paracetamol-diclofenac (103.01 ± 23.53 min p = 0.029) and paracetamol-tramadol (144.05 ± 14.72 min p < 0.001) group.,"['07 July 2019 at Pan African Clinical Trial Registry with the identification number of PACTR201908890749145 ', 'postoperative pain after elective abdominal surgery under general anesthesia, Ethiopia', '63 patients undergone', 'patients undergoing laparotomy surgery']","['Post-operative analgesic therapy [intravenous tramadol', 'paracetamol-tramadol', 'paracetamol-tramadol and paracetamol-diclofenac', 'laparotomy surgery; group-P (paracetamol 1\u2009g), group-PD (1\u2009g\u2009+\u2009diclofenac 75\u2009mg) and group-PT (paracetamol 1\u2009g\u2009+\u2009tramadol', 'preemptive Paracetamol, Paracetamol-diclofenac and Paracetamol-tramadol combination', 'preemptive paracetamol, paracetamol-diclofenac & paracetamol-tramadol combination', 'paracetamol-diclofenac', 'paracetamol']","['median pain score', 'Time to first analgesic request', 'complain of pain (request medication) or a numeric rating scale ≥4', 'time of first analgesic request and the intensity of the pain', 'Numerical Rating Scale (NRS) pain rating system', 'mean total tramadol consumption', 'total tramadol consumption and prolongs time to first analgesic request', 'total amount of analgesia consumption', 'postoperative analgesic effect']","[{'cui': 'C0030266', 'cui_str': 'Panama'}, {'cui': 'C0027567', 'cui_str': 'African race'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C1300638', 'cui_str': 'Identification number'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0015024', 'cui_str': 'Ethiopia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023038', 'cui_str': 'Laparotomy'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0412784', 'cui_str': 'Analgesic technique'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0040610', 'cui_str': 'Tramadol'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C1169987', 'cui_str': 'tramadol and paracetamol'}, {'cui': 'C0012091', 'cui_str': 'Diclofenac'}, {'cui': 'C0023038', 'cui_str': 'Laparotomy'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0441849', 'cui_str': 'Group P'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0420259', 'cui_str': 'Analgesics requested'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0420258', 'cui_str': 'Medication requested'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040610', 'cui_str': 'Tramadol'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}]",63.0,0.0570596,Time to first analgesic request was significantly shorter within paracetamol group (87.62 ± 20.95 min) compared to paracetamol-diclofenac (103.01 ± 23.53 min p = 0.029) and paracetamol-tramadol (144.05 ± 14.72 min p < 0.001) group.,"[{'ForeName': 'Zemedu', 'Initials': 'Z', 'LastName': 'Aweke', 'Affiliation': 'Department of Anesthesia, College of Medicine and Health Sciences, Dilla University, Dilla, Ethiopia.'}, {'ForeName': 'Fetene', 'Initials': 'F', 'LastName': 'Seyoum', 'Affiliation': 'Department of Anesthesia, College of Medicine and Health Sciences, Dilla University, Dilla, Ethiopia.'}, {'ForeName': 'Tewoderos', 'Initials': 'T', 'LastName': 'Shitemaw', 'Affiliation': 'Department of Anesthesia, Kotebe Metropolitan University, Menelik II Medical & Health Science College, Addis Ababa, Ethiopia. tewoderosshitemaw@gmail.com.'}, {'ForeName': 'Derartu Neme', 'Initials': 'DN', 'LastName': 'Doba', 'Affiliation': 'Department of Anesthesia, College of Medicine and Health Sciences, Dilla University, Dilla, Ethiopia.'}]",BMC anesthesiology,['10.1186/s12871-020-01115-6'] 2362,32753064,A comparison of intraoperative goal-directed intravenous administration of crystalloid versus colloid solutions on the postoperative maximum N-terminal pro brain natriuretic peptide in patients undergoing moderate- to high-risk noncardiac surgery.,"BACKGROUND N-terminal pro brain natriuretic peptide (NT-proBNP) and troponin T are released during myocardial wall stress and/or ischemia and are strong predictors for postoperative cardiovascular complications. However, the relative effects of goal-directed, intravenous administration of crystalloid compared to colloid solutions on NT-proBNP and troponin T, especially in relatively healthy patients undergoing moderate- to high-risk noncardiac surgery, remains unclear. Thus, we evaluated in this sub-study the effect of a goal-directed crystalloid versus a goal-directed colloid fluid regimen on postoperative maximum NT-proBNP concentration. We further evaluated the incidence of myocardial injury after noncardiac surgery (MINS) between both study groups. METHODS Thirty patients were randomly assigned to receive additional intravenous fluid boluses of 6% hydroxyethyl starch 130/0.4 and 30 patients to receive lactated Ringer's solution. Intraoperative fluid management was guided by oesophageal Doppler-according to a previously published algorithm. The primary outcome were differences in postoperative maximum NT-proBNP (maxNT-proBNP) between both groups. As our secondary outcome we evaluated the incidence of MINS between both study groups. We defined maxNT-proBNP as the maximum value measured within 2 h after surgery and on the first and second postoperative day. RESULTS In total 56 patients were analysed. There was no significant difference in postoperative maximum NT-proBNP between the colloid group (258.7 ng/L (IQR 199.4 to 782.1)) and the crystalloid group (440.3 ng/L (IQR 177.9 to 691.2)) during the first 2 postoperative days (P = 0.29). Five patients in the colloid group and 7 patients in the crystalloid group developed MINS (P = 0.75). CONCLUSIONS Based on this relatively small study goal-directed colloid administration did not decrease postoperative maxNT-proBNP concentration as compared to goal-directed crystalloid administration. TRIAL REGISTRATION ClinicalTrials.gov ( NCT01195883 ) Registered on 6th September 2010.",2020,There was no significant difference in postoperative maximum NT-proBNP between the colloid group (258.7 ng/L (IQR 199.4 to 782.1)) and the crystalloid group (440.3 ng/L (IQR 177.9 to 691.2)) during the first 2 postoperative days (P = 0.29).,"['relatively healthy patients undergoing moderate- to high-risk noncardiac surgery', 'Thirty patients', 'In total 56 patients were analysed', 'patients undergoing moderate- to high-risk noncardiac surgery']","['additional intravenous fluid boluses of 6% hydroxyethyl starch', 'crystalloid', 'crystalloid versus colloid solutions', ""lactated Ringer's solution""]","['postoperative maxNT-proBNP concentration', 'postoperative maximum NT-proBNP concentration', 'postoperative maximum NT-proBNP (maxNT-proBNP', 'incidence of MINS', 'postoperative maximum NT-proBNP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C1289919', 'cui_str': 'Intravenous fluid'}, {'cui': 'C0020352', 'cui_str': 'Hetastarch'}, {'cui': 'C0056562', 'cui_str': 'Crystalloid'}, {'cui': 'C0009361', 'cui_str': 'Colloids'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0073385', 'cui_str': ""Lactated Ringer's Solution""}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439232', 'cui_str': 'min'}]",56.0,0.304933,There was no significant difference in postoperative maximum NT-proBNP between the colloid group (258.7 ng/L (IQR 199.4 to 782.1)) and the crystalloid group (440.3 ng/L (IQR 177.9 to 691.2)) during the first 2 postoperative days (P = 0.29).,"[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Reiterer', 'Affiliation': 'Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Kabon', 'Affiliation': 'Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria. barbara.kabon@meduniwien.ac.at.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Taschner', 'Affiliation': 'Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Zotti', 'Affiliation': 'Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Kurz', 'Affiliation': 'Department of Outcomes Research and General Anaesthesiology, Anaesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Edith', 'Initials': 'E', 'LastName': 'Fleischmann', 'Affiliation': 'Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}]",BMC anesthesiology,['10.1186/s12871-020-01104-9'] 2363,32753113,[Efficacy of different doses and timing of tranexamic acid in major orthopedic surgeries: a randomized trial].,"BACKGROUND Tranexamic acid was studied in four different dosage regimens and their efficacy was compared for perioperative blood loss reduction, blood transfusion requirements and deep vein thrombosis (DVT) complication. METHODS Two hundred patients undergoing major orthopedic procedures were divided into five groups containing 40 each: placebo, low dose (bolus 10mg.kg -1 ), low dose+maintenance (bolus 10mg.kg -1 +maintenance 1mg.kg -1 .hr -1 ), high dose (bolus 30mg.kg -1 ) and high dose+maintenance (bolus 30mg.kg -1 +maintenance 3mg.kg -1 .hr -1 ). Surgical blood loss was measured intraoperatively and drains collection in the first 24 hours postoperative period. Blood transfusion was done when hematocrit falls less than 25%. DVT screening was done in the postoperative period. RESULTS The intraoperative blood loss was 440±207.54mL in the placebo group, 412.5±208.21mL in the low dose group, 290±149.6ml in the low dose plus maintenance group, 332.5±162.33mL in the high dose group and 240.7±88.15mL in the high dose maintenance group (p <0.001). The reduction in postoperative blood loss in the drain for the first 24hours was 80±44.44mL in the placebo group, 89.88±44.87mL in the low dose group, 56.7±29.12mL in the low dose plus maintenance group, 77.9±35.74mL in the high dose group and 46.7±19.9mL in the high dose maintenance group (p <0.001). DVT was not encountered in any patient. CONCLUSION Tranexamic acid was most effective in reducing surgical blood loss and blood transfusion requirements in a low dose+maintenance group.",2020,"The reduction in postoperative blood loss in the drain for the first 24hours was 80±44.44mL in the placebo group, 89.88±44.87mL in the low dose group, 56.7±29.12mL in the low dose plus maintenance group, 77.9±35.74mL in the high dose group and 46.7±19.9mL in the high dose maintenance group (p <0.001).","['major orthopedic surgeries', 'Two hundred patients undergoing major orthopedic procedures']","['placebo', 'placebo, low dose (bolus 10mg.kg -1 ), low dose+maintenance (bolus 10mg.kg -1 ', 'tranexamic acid', 'Tranexamic acid']","['DVT', 'surgical blood loss and blood transfusion requirements', 'postoperative blood loss', 'perioperative blood loss reduction, blood transfusion requirements and deep vein thrombosis (DVT) complication', 'Surgical blood loss', 'Blood transfusion', 'intraoperative blood loss']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0524852', 'cui_str': 'Orthopaedic procedure'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}]","[{'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0079027', 'cui_str': 'Intraoperative hemorrhage'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0032788', 'cui_str': 'Postoperative hemorrhage'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}]",200.0,0.255206,"The reduction in postoperative blood loss in the drain for the first 24hours was 80±44.44mL in the placebo group, 89.88±44.87mL in the low dose group, 56.7±29.12mL in the low dose plus maintenance group, 77.9±35.74mL in the high dose group and 46.7±19.9mL in the high dose maintenance group (p <0.001).","[{'ForeName': 'Ravi', 'Initials': 'R', 'LastName': 'Saravanan', 'Affiliation': 'SRM Medical College Hospital and Research Centre, Department of Anaesthesia, Tamilnadu, India.'}, {'ForeName': 'Rajagopalan', 'Initials': 'R', 'LastName': 'Venkatraman', 'Affiliation': 'SRM Medical College Hospital and Research Centre, Department of Anaesthesia, Tamilnadu, India. Electronic address: drvenkat94@gmail.com.'}, {'ForeName': 'Krishnamoorthy', 'Initials': 'K', 'LastName': 'Karthik', 'Affiliation': 'SRM Medical College Hospital and Research Centre, Department of Anaesthesia, Tamilnadu, India.'}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Pushparani', 'Affiliation': 'SRM Medical College Hospital and Research Centre, Department of Anaesthesia, Tamilnadu, India.'}]",Revista brasileira de anestesiologia,['10.1016/j.bjan.2020.03.013'] 2364,32753258,"Effects of an information booklet on patient anxiety and satisfaction with information in magnetic resonance imaging: A randomized, single-blind, placebo-controlled trial.","INTRODUCTION Magnetic resonance imaging (MRI) is an important modality in diagnostics and treatment follow-up. However, MRI can be perceived as unpleasant even though the examination is non-invasive. Patients' knowledge of the MRI procedure is usually scarce, which may enhance patient anxiety at examination. We investigated the effects on anxiety and satisfaction with an information booklet on MRI compared to a placebo booklet delivered to adult patients prior to their first MRI examination. METHODS This randomized, single-blind, placebo-controlled trial included 197 patients. The intervention group (n = 95) received a booklet about MRI prior to the examination, whereas the control group (n = 102) received a placebo booklet of the same size and layout but containing general information. The State Trait Anxiety Inventory with supplementary questions from the Quality from the Patient's Perspective questionnaire were used as patient-reported outcome measures. RESULTS Anxiety did not differ between the groups, either prior to MRI or during the examination, but those who received the placebo booklet were at higher risk of experiencing high anxiety prior to the MRI examination (odds ratio 2.64; P = 0.029). The intervention group was more satisfied with the information received (P = 0.044), and a majority of participants in both groups (≥87%) considered it important to obtain information on the MRI procedure. CONCLUSION Written MRI information decreases the risk of high anxiety levels before MRI and improves patient satisfaction with the information. Further research is needed to investigate whether written information prior to MRI is beneficial not only from the perspective of the patient but may also be cost-effective. IMPLICATIONS FOR PRACTICE Written MRI information prior to the examination is recommended in radiography care.",2020,"The intervention group was more satisfied with the information received (P = 0.044), and a majority of participants in both groups (≥87%) considered it important to obtain information on the MRI procedure. ","['197 patients', 'adult patients prior to their first MRI examination']","['Magnetic resonance imaging (MRI', 'information booklet', 'placebo booklet', 'booklet about MRI', 'placebo booklet of the same size and layout but containing general information', 'placebo']","['anxiety and satisfaction', 'Anxiety', 'State Trait Anxiety Inventory', 'patient anxiety and satisfaction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",197.0,0.0738261,"The intervention group was more satisfied with the information received (P = 0.044), and a majority of participants in both groups (≥87%) considered it important to obtain information on the MRI procedure. ","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Bolejko', 'Affiliation': 'Department of Translational Medicine, Department of Medical Imaging and Physiology, Lund University, Skåne University Hospital, Carl Bertil Laurells gata 9, 205 02, Malmö, Sweden. Electronic address: anetta.bolejko@med.lu.se.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Hagell', 'Affiliation': 'The PRO-CARE Group, Faculty of Health Sciences, Kristianstad University, Elmetorpsvägen 15, 291 88, Kristianstad, Sweden. Electronic address: peter.hagell@hkr.se.'}]","Radiography (London, England : 1995)",['10.1016/j.radi.2020.07.011'] 2365,32753268,Differences in Thromboembolic Complications Between Paroxysmal and Persistent Atrial Fibrillation Patients Following Electrical Cardioversion (From the ENSURE-AF Study).,"It is unclear if patients with paroxysmal atrial fibrillation (AF) and persistent AF have different outcomes following electrical cardioversion (ECV). ENSURE-AF-a multicenter, prospective, randomized, open-label, blinded-endpoint evaluation trial-compared once-daily edoxaban 60 mg with enoxaparin-warfarin in 2,199 subjects undergoing ECV of nonvalvular AF (NCT02072434). Patients received ≥3 weeks of proper anticoagulation or transesophageal echocardiogram before ECV paroxysmal AF was defined as AF with spontaneous conversion of duration of <7 days; persistent AF was defined as AF lasting ≥7 days without spontaneous conversion. Clinical characteristics and outcomes were compared between subjects based on type of AF present at baseline. In total, 415 subjects had paroxysmal AF; 1,777 had persistent AF. Patients with paroxysmal AF were older (65.8 ± 10.3 vs 63.9 ± 10.5, p = 0.001) with more hypertension (82.7% vs 77.2%, p = 0.01) versus persistent AF patients. Congestive heart failure was more common in persistent AF (46.7%) versus paroxysmal AF (31.3%, p <0.0001). CHA 2 DS 2 -VASc (score >2: 52.0% vs 49.5%, p = 0.4375) and prior myocardial infarction (6.5% vs 6.8%, p = 0.91) did not significantly differ between groups. After ECV, primary endpoint events were numerically higher in paroxysmal AF versus persistent AF (1.5% vs 0.6%, p = 0.0571), approaching statistical significance. Of note, myocardial infarction was observed in paroxysmal AF (n = 4 vs 0), whereas persistent AF was accompanied by stroke (n = 0 vs 5; p <0.05). In conclusion, patients with paroxysmal AF had more frequent major cardiovascular events than patients with persistent AF. Composite event rates were driven mainly by myocardial infarction in patients with paroxysmal AF and by stroke in those with persistent AF. Overall, the absolute number of events was low after ECV under anticoagulation.",2020,"(score >2: 52.0% vs 49.5%, p = 0.4375) and prior myocardial infarction (6.5% vs 6.8%, p = 0.91) did not significantly differ between groups.","['2,199 subjects undergoing ECV of nonvalvular AF (NCT02072434', '415 subjects had paroxysmal AF; 1,777 had persistent AF', 'patients with paroxysmal atrial fibrillation (AF']","['electrical cardioversion (ECV', 'edoxaban', 'enoxaparin-warfarin', 'Electrical Cardioversion']","['paroxysmal AF', 'CHA 2 DS 2 -VASc', 'paroxysmal AF versus persistent AF', 'Congestive heart failure', 'prior myocardial infarction', 'myocardial infarction', 'Thromboembolic Complications', 'frequent major cardiovascular events', 'Composite event rates', 'hypertension']","[{'cui': 'C0013778', 'cui_str': 'Cardioversion'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C4517772', 'cui_str': '415'}, {'cui': 'C0235480', 'cui_str': 'Paroxysmal atrial fibrillation'}, {'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0013778', 'cui_str': 'Cardioversion'}, {'cui': 'C2975435', 'cui_str': 'edoxaban'}, {'cui': 'C0206460', 'cui_str': 'Enoxaparin'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}]","[{'cui': 'C0235480', 'cui_str': 'Paroxysmal atrial fibrillation'}, {'cui': 'C0574369', 'cui_str': 'Chamorro language'}, {'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0155668', 'cui_str': 'Old myocardial infarction'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]",2199.0,0.0283141,"(score >2: 52.0% vs 49.5%, p = 0.4375) and prior myocardial infarction (6.5% vs 6.8%, p = 0.91) did not significantly differ between groups.","[{'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Goette', 'Affiliation': 'St. Vincenz-Hospital, Paderborn, Germany; Working Group: Molecular Electrophysiology, University Hospital Magdeburg, Magdeburg, Germany. Electronic address: andreas.goette@vincenz.de.'}, {'ForeName': 'Gregory Y H', 'Initials': 'GYH', 'LastName': 'Lip', 'Affiliation': 'Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Jin', 'Affiliation': 'Daiichi Sankyo, Inc., Basking Ridge, New Jersey.'}, {'ForeName': 'Hein', 'Initials': 'H', 'LastName': 'Heidbuchel', 'Affiliation': 'Antwerp University and University Hospital, Cardiology, Antwerp, Belgium.'}, {'ForeName': 'Aron-Ariel', 'Initials': 'AA', 'LastName': 'Cohen', 'Affiliation': 'Hôpital Saint Antoine, Hôpital Tenon, Paris, France; Université Pierre et Marie Curie (Paris VI), Paris, France.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Ezekowitz', 'Affiliation': 'Department of Cardiovascular Medicine, Sidney Kimmel Jefferson Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania; Lankenau Medical Center, Broomall, Pennsylvania.'}, {'ForeName': 'Jose Luis', 'Initials': 'JL', 'LastName': 'Merino', 'Affiliation': 'Arrhythmia and Robotic Electrophysiology Unit, Hospital Universitario La Paz, Universidad Europea, Madrid, Spain.'}]",The American journal of cardiology,['10.1016/j.amjcard.2020.06.046'] 2366,32753300,Bariatric surgery in the elderly: a randomized prospective study comparing safety of sleeve gastrectomy and Roux-en-Y gastric bypass (BASE Trial).,"BACKGROUND The aging population along with the obesity epidemic has increased the number of older patients undergoing bariatric surgery. Nevertheless, there is still conflicting data regarding surgical safety in this population. OBJECTIVES The aim of this study was to compare the surgical morbidity of laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB) for older patients. SETTING University hospital, São Paulo, Brazil. METHODS We performed a prospective randomized clinical trial from September 2017 to May 2019. Obese patients aged ≥65 years were randomized to LSG or LRYGB. Data collection included demographic information, body mass index (BMI), and co-morbidities. We assessed readmission, postoperative complications, and mortality. Complications were scored according to Clavien-Dindo classification. RESULTS A total of 36 patients, with a BMI between 35.5 and 52.8 kg/m 2 were randomized to either LSG (18 patients) or LRYGB (18 patients). The overall complication rate was similar between LSG and LRYGB (3 versus 7, P = .13). Severe complication was more prevalent in LRYGB patients but had no statistically significant difference (0 versus 3, P = .07). Each group had 1 readmission and there was no mortality in 90-day follow-up. CONCLUSIONS Morbidity and mortality rates of bariatric surgery are low in elderly obese patients. Despite not statistically significant, LSG had a lower rate of severe complications compared with LRYGB in this population setting.",2020,"The overall complication rate was similar between LSG and LRYGB (3 versus 7, P = .13).","['September 2017 to May 2019', 'older patients', 'elderly obese patients', 'Bariatric surgery in the elderly', '36 patients, with a BMI between 35.5 and 52.8 kg/m 2', 'older patients undergoing bariatric surgery', 'University hospital, São Paulo, Brazil', 'Obese patients aged ≥65 years']","['LSG or LRYGB', 'laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB', 'sleeve gastrectomy and Roux-en-Y gastric bypass', 'bariatric surgery', 'LSG']","['surgical morbidity', 'readmission, postoperative complications, and mortality', 'demographic information, body mass index (BMI), and co-morbidities', 'overall complication rate', 'Morbidity and mortality rates', 'severe complications', 'Severe complication']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1456587', 'cui_str': 'Metabolic surgery'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0399839', 'cui_str': 'Bypass gastrojejunostomy'}, {'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}, {'cui': 'C1456587', 'cui_str': 'Metabolic surgery'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",36.0,0.116361,"The overall complication rate was similar between LSG and LRYGB (3 versus 7, P = .13).","[{'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Pajecki', 'Affiliation': 'Bariatric and Metabolic Surgery Unit, Discipline of Digestive Surgery, University of Sao Paulo Medical School, Sao Paulo, Brazil.'}, {'ForeName': 'Anna Carolina Batista', 'Initials': 'ACB', 'LastName': 'Dantas', 'Affiliation': 'Bariatric and Metabolic Surgery Unit, Discipline of Digestive Surgery, University of Sao Paulo Medical School, Sao Paulo, Brazil. Electronic address: carolbatista.med@gmail.com.'}, {'ForeName': 'Ana Lumi', 'Initials': 'AL', 'LastName': 'Kanaji', 'Affiliation': 'Division of Geriatrics, Department of Internal Medicine, University of Sao Paulo Medical School, Sao Paulo, Brazil.'}, {'ForeName': 'Daniel Riccioppo Cerqueira Ferreira', 'Initials': 'DRCF', 'LastName': 'de Oliveira', 'Affiliation': 'Bariatric and Metabolic Surgery Unit, Discipline of Digestive Surgery, University of Sao Paulo Medical School, Sao Paulo, Brazil.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'de Cleva', 'Affiliation': 'Bariatric and Metabolic Surgery Unit, Discipline of Digestive Surgery, University of Sao Paulo Medical School, Sao Paulo, Brazil.'}, {'ForeName': 'Marco Aurelio', 'Initials': 'MA', 'LastName': 'Santo', 'Affiliation': 'Bariatric and Metabolic Surgery Unit, Discipline of Digestive Surgery, University of Sao Paulo Medical School, Sao Paulo, Brazil.'}]",Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery,['10.1016/j.soard.2020.05.030'] 2367,32749733,Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.,"AIM To estimate the cost-effectiveness of dapagliflozin added to standard therapy, versus standard therapy only, in patients with heart failure (HF) with reduced ejection fraction, from the perspective of UK, German, and Spanish payers. METHODS AND RESULTS A lifetime Markov model was built to estimate outcomes in patients with HFrEF. Health states were defined by Kansas City Cardiomyopathy Total Symptom Score, type 2 diabetes and worsening HF events. The incidence of worsening HF and all-cause mortality was estimated using negative binomial regression models and parametric survival analysis, respectively. Direct healthcare costs (2019 British pounds/Euro) and patient-reported outcomes (EQ-5D) were sourced from the existing literature and the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF), respectively; the median duration of follow-up in DAPA-HF was 18.2 months (range: 0-27.8). Future costs and effects were discounted at 3.0% for the Spanish and German analyses and 3.5% for the UK analysis. In the UK setting, treatment with dapagliflozin was estimated to increase life-years and quality-adjusted life-years (QALYs) from 5.62 to 6.20 (+0.58) and 4.13 to 4.61 (+0.48), respectively, and reduce lifetime hospitalisations for HF (925 and 820 events per 1,000 patients for placebo and dapagliflozin, respectively). Similar results were obtained for Germany and Spain. The incremental cost-effectiveness ratios were £5,822, €5,379 and €9,406/QALY in the UK, Germany and Spain, respectively. In probabilistic sensitivity analyses, more than 90% of simulations were cost-effective at a willingness-to-pay threshold of £20,000/QALY in UK and €20,000/QALY in Germany and Spain. CONCLUSION Dapagliflozin is likely to be a cost-effective treatment for HFrEF in the UK, German and Spanish healthcare systems. This article is protected by copyright. All rights reserved.",2020,"The incremental cost-effectiveness ratios were £5,822, €5,379 and €9,406/QALY in the UK, Germany and Spain, respectively.","['heart failure with reduced ejection fraction', 'patients with HFrEF', 'patients with heart failure (HF) with reduced ejection fraction, from the perspective of UK, German, and Spanish payers', '925 and 820 events per 1,000 patients for']","['Dapagliflozin', 'dapagliflozin', 'placebo and dapagliflozin']","['incremental cost-effectiveness ratios', 'Direct healthcare costs', 'Kansas City Cardiomyopathy Total Symptom Score, type 2 diabetes and worsening HF events', 'cost-effective', 'increase life-years and quality-adjusted life-years (QALYs', 'cost-effectiveness', 'lifetime hospitalisations for HF ', 'incidence of worsening HF and all-cause mortality']","[{'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C4517904', 'cui_str': '925'}, {'cui': 'C0441471', 'cui_str': 'Event'}]","[{'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0085552', 'cui_str': 'Health Costs'}, {'cui': 'C0022497', 'cui_str': 'Kansas'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0878544', 'cui_str': 'Cardiomyopathy'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",,0.0421322,"The incremental cost-effectiveness ratios were £5,822, €5,379 and €9,406/QALY in the UK, Germany and Spain, respectively.","[{'ForeName': 'Phil', 'Initials': 'P', 'LastName': 'McEwan', 'Affiliation': 'Health Economics and Outcomes Research Ltd, Cardiff, UK.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Darlington', 'Affiliation': 'Health Economics and Outcomes Research Ltd, Cardiff, UK.'}, {'ForeName': 'John J V', 'Initials': 'JJV', 'LastName': 'McMurray', 'Affiliation': 'University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Pardeep S', 'Initials': 'PS', 'LastName': 'Jhund', 'Affiliation': 'University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Kieran F', 'Initials': 'KF', 'LastName': 'Docherty', 'Affiliation': 'University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Böhm', 'Affiliation': 'Department of Medicine, Saarland University Hospital, Homburg, Saar, Germany.'}, {'ForeName': 'Mark C', 'Initials': 'MC', 'LastName': 'Petrie', 'Affiliation': 'University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Klas', 'Initials': 'K', 'LastName': 'Bergenheim', 'Affiliation': 'AstraZeneca, CVRM Biopharmaceutical, Gothenburg, Sweden.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Qin', 'Affiliation': 'AstraZeneca, CVRM Biopharmaceutical, Gaithersburg, USA.'}]",European journal of heart failure,['10.1002/ejhf.1978'] 2368,32744951,Exploring the effects of visual and literary arts interventions on psychosocial well-being of diverse older adults: a mixed methods pilot study.,"BACKGROUND Engagement in the arts may have health benefits for older adults. Most research has focused on music and dance; less is known about the benefits of other arts interventions. The purpose of this study was to examine the effects of visual (ceramics and collage) and literary arts (storytelling and writing) on well-being. METHODS We used mixed methods to examine the effects of a 12-week visual or literary arts intervention on well-being. Adults age 55 and over from four housing sites were assigned to start an intervention immediately (intervention) or wait 12 weeks (controls). The study included pre/post-test measures of well-being and focus groups about perceived benefits. RESULTS Compared to controls, participants in the ceramics intervention had significant improvements in interest in life and mastery, while no changes were observed after the storytelling intervention. Seven psychosocial benefits were identified . CONCLUSIONS Participation in visual and literary arts for older adults was associated with well-being media.",2020,"Compared to controls, participants in the ceramics intervention had significant improvements in interest in life and mastery, while no changes were observed after the storytelling intervention.","['diverse older adults', 'Adults age 55 and over from four housing sites', 'older adults']","['visual and literary arts interventions', 'visual or literary arts intervention', 'visual (ceramics and collage) and literary arts (storytelling and writing']",['life and mastery'],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0020056', 'cui_str': 'Housed'}, {'cui': 'C0205145', 'cui_str': 'Site'}]","[{'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0007742', 'cui_str': 'Ceramic'}, {'cui': 'C0018582', 'cui_str': 'Handwriting'}]","[{'cui': 'C0376558', 'cui_str': 'Life'}]",7.0,0.0467071,"Compared to controls, participants in the ceramics intervention had significant improvements in interest in life and mastery, while no changes were observed after the storytelling intervention.","[{'ForeName': 'Julene K', 'Initials': 'JK', 'LastName': 'Johnson', 'Affiliation': 'Institute for Health & Aging, University of California , San Francisco, CA, USA.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Carpenter', 'Affiliation': 'EngAGE, Inc ., Los Angeles, CA, USA.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Goodhart', 'Affiliation': 'EngAGE, Inc ., Los Angeles, CA, USA.'}, {'ForeName': 'Anita L', 'Initials': 'AL', 'LastName': 'Stewart', 'Affiliation': 'Institute for Health & Aging, University of California , San Francisco, CA, USA.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'du Plessis', 'Affiliation': 'Institute for Health & Aging, University of California , San Francisco, CA, USA.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Coaston', 'Affiliation': 'School of Nursing, University of California , San Francisco, CA, USA.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Clark', 'Affiliation': 'School of Nursing, University of California , San Francisco, CA, USA.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Lazar', 'Affiliation': 'Department of Epidemiology and Biostatistics, University of California , San Francisco, CA, USA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Chapline', 'Affiliation': 'New Art Horizons , Pacifica, CA, USA.'}]",Arts & health,['10.1080/17533015.2020.1802603'] 2369,32744999,A drug-coated balloon treatment for urethral stricture disease: Two-year results from the ROBUST I study.,"INTRODUCTION Mechanical balloon dilation and direct visualization internal urethrotomy (DVIU) are the most widely used treatments for urethral stricture disease in the U.S., but recurrence rates are high, especially after re-treatment. This study investigates the safety and efficacy of the Optilume™ paclitaxel-coated balloon for the treatment of recurrent strictures. METHODS Men with recurrent bulbar strictures ≤2 cm with 1-4 prior endoscopic treatments were treated with the Optilume™ drug-coated balloon. Patients were evaluated within 14 days, three, six, 12, and 24 months post-treatment. The primary safety endpoint was serious urinary adverse events. The primary efficacy endpoint was ≥50% improvement in International Prostate Symptom Score (IPSS) at 24 months. Secondary outcomes included quality of life, erectile function, flow rate, and post-void residual urine volume. RESULTS A total of 53 subjects were enrolled and treated; 46 completed the 24-month followup. Forty-three percent of men had undergone >1 previous dilations, with a mean of 1.7 prior dilations. There were no serious adverse events related to treatment at two years. Success was achieved in 32/46 (70%), and baseline IPSS improved from a mean of 25.2 to 6.9 at 24 months (p<0.0001). Quality of life, flow rate, and post-void residual urine volumes improved significantly from baseline. There was no impact on erectile function. CONCLUSIONS Two-year data indicates the Optilume™ paclitaxel-coated balloon is safe for the treatment of recurrent bulbar urethral strictures. Early efficacy results are encouraging and support further followup of these men through five years, as well as further investigation with a randomized trial.",2020,There were no serious adverse events related to treatment at two years.,"['recurrent bulbar urethral strictures', 'urethral stricture disease', 'A total of 53 subjects were enrolled and treated; 46 completed the 24-month followup', 'recurrent strictures', 'Men with recurrent bulbar strictures ≤2 cm with 1-4 prior endoscopic treatments', 'Forty-three percent of men had undergone >1 previous dilations, with a mean of 1.7 prior dilations']","['Optilume™ paclitaxel-coated balloon', 'Mechanical balloon dilation and direct visualization internal urethrotomy (DVIU', 'paclitaxel-coated balloon', 'Optilume™ drug-coated balloon']","['Success', 'quality of life, erectile function, flow rate, and post-void residual urine volume', 'Quality of life, flow rate, and post-void residual urine volumes', 'serious urinary adverse events', 'erectile function', 'baseline IPSS', 'safety and efficacy', 'serious adverse events', 'International Prostate Symptom Score (IPSS']","[{'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0041974', 'cui_str': 'Urethral stenosis'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1261287', 'cui_str': 'Stenosis'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0450368', 'cui_str': '43'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C4280965', 'cui_str': 'Greater than one'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4517512', 'cui_str': '1.7'}]","[{'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0565436', 'cui_str': 'Internal urethrotomy'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0453946', 'cui_str': 'Coat'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030847', 'cui_str': 'Penile erection'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0042034', 'cui_str': 'Micturition'}, {'cui': 'C0429774', 'cui_str': 'Residual urine volume'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1998280', 'cui_str': 'International prostate symptom score'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",53.0,0.0294462,There were no serious adverse events related to treatment at two years.,"[{'ForeName': 'Rachel A', 'Initials': 'RA', 'LastName': 'Mann', 'Affiliation': 'Department of Urology, University of Minnesota, Minneapolis, MN, United States.'}, {'ForeName': 'Ramón', 'Initials': 'R', 'LastName': 'Virasoro', 'Affiliation': 'Department of Urology, Eastern Virginia Medical School, Norfolk, VA, United States.'}, {'ForeName': 'Jessica M', 'Initials': 'JM', 'LastName': 'DeLong', 'Affiliation': 'Department of Urology, Eastern Virginia Medical School, Norfolk, VA, United States.'}, {'ForeName': 'Rafael E', 'Initials': 'RE', 'LastName': 'Estrella', 'Affiliation': 'Clinica Union Medica, Santiago de los Caballeros, Dominican Republic.'}, {'ForeName': 'Merycarla', 'Initials': 'M', 'LastName': 'Pichardo', 'Affiliation': 'URUS, Santo Domingo, Dominican Republic.'}, {'ForeName': 'Ramón Rodríguez', 'Initials': 'RR', 'LastName': 'Lay', 'Affiliation': 'Urology Royal Center Panamá City, Panamá.'}, {'ForeName': 'Gustavo', 'Initials': 'G', 'LastName': 'Espino', 'Affiliation': 'Centro Especializado San Fernando, Panamá City, Panamá.'}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Roth', 'Affiliation': 'Department of Urology, University of Minnesota, Minneapolis, MN, United States.'}, {'ForeName': 'Sean P', 'Initials': 'SP', 'LastName': 'Elliott', 'Affiliation': 'Department of Urology, University of Minnesota, Minneapolis, MN, United States.'}]",Canadian Urological Association journal = Journal de l'Association des urologues du Canada,['10.5489/cuaj.6661'] 2370,32745000,Comparison of a magnetic retrieval device vs. flexible cystoscopy for removal of ureteral stents in renal transplant patients: A randomized controlled trial.,"INTRODUCTION Placement of a ureteral stent at the time of renal transplantation can reduce complications when compared to non-stented anastomoses. Removal by flexible cystoscopy can be associated with discomfort, risk for infection, and high costs. New magnetic stents offer a means of bypassing cystoscopy by use of a magnetic retrieval device. Our objective was to compare clinical and cost-related outcomes of conventional and magnetic stents in patients undergoing deceased donor renal transplantation. METHODS Patients were randomized to receive either a conventional or a Black-Star ® magnetic stent. Clinical, procedural, and cost outcomes were assessed, and the Ureteral Stent Symptom Questionnaire (USSQ) was administered with the stent in situ and after stent removal. All variables were compared between groups. RESULTS Forty-one patients were randomized to conventional (n=19) or Black-Star (n=22) stent. The total time for stent removal under cystoscopy was significantly longer compared to Black-Star removal (6.67±2.47 and 4.80±2.21 minutes, respectively; p=0.019). No differences were found in the USSQ domains between groups. Rates of urinary tract infections and surgical complications between groups were similar. Stent removal was well-tolerated in both groups. Black-Star stent use resulted in a cost savings of $304.02 Canadian dollars (CAD) per case. CONCLUSIONS USSQ scores suggest that stent removal with the Black-Star magnetic stent is as equally well-tolerated as flexible cystoscopy by renal transplant patients. Black-Star stent removal was significantly faster than conventional stents. No differences in discomfort, infection rate, or complication rate were found. Use of the Black-Star stent resulted in an estimated annual savings of $27 360 CAD at our centre.",2020,"No differences in discomfort, infection rate, or complication rate were found.","['Forty-one patients were randomized to conventional (n=19) or Black-Star (n=22) stent', 'renal transplant patients', 'patients undergoing deceased donor renal transplantation', 'Patients']","['magnetic retrieval device vs. flexible cystoscopy', 'conventional or a Black-Star ® magnetic stent', 'conventional and magnetic stents', 'Black-Star stent']","['discomfort, infection rate, or complication rate', 'cost savings', 'Clinical, procedural, and cost outcomes', 'Rates of urinary tract infections and surgical complications', 'total time for stent removal under cystoscopy', 'Ureteral Stent Symptom Questionnaire (USSQ', 'Black-Star stent removal']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0282064', 'cui_str': 'Stars, Celestial'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0730392', 'cui_str': 'Donor renal transplantation'}]","[{'cui': 'C0024488', 'cui_str': 'Magnetics'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0577992', 'cui_str': 'Flexible cystoscopy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0282064', 'cui_str': 'Stars, Celestial'}, {'cui': 'C0038257', 'cui_str': 'Stent'}]","[{'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0085550', 'cui_str': 'Cost Savings'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0522778', 'cui_str': 'Removal of stent'}, {'cui': 'C0010702', 'cui_str': 'Cystoscopy'}, {'cui': 'C0183518', 'cui_str': 'Ureteric stent'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0282064', 'cui_str': 'Stars, Celestial'}]",41.0,0.143266,"No differences in discomfort, infection rate, or complication rate were found.","[{'ForeName': 'Anil', 'Initials': 'A', 'LastName': 'Kapoor', 'Affiliation': 'Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Akerman', 'Affiliation': 'Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'C L Wong', 'Affiliation': 'Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Gaurav', 'Initials': 'G', 'LastName': 'Vasisth', 'Affiliation': 'Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Fadil', 'Initials': 'F', 'LastName': 'Hassan', 'Affiliation': 'Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Tajzler', 'Affiliation': 'Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Piercey', 'Affiliation': 'Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Jen', 'Initials': 'J', 'LastName': 'Hoogenes', 'Affiliation': 'Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Shahid', 'Initials': 'S', 'LastName': 'Lambe', 'Affiliation': 'Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada.'}]",Canadian Urological Association journal = Journal de l'Association des urologues du Canada,['10.5489/cuaj.6684'] 2371,32745003,Daily use of a muscle pump activator device reduces duration of hospitalization and improves early graft outcomes post-kidney transplantation: A randomized controlled trial.,"INTRODUCTION Kidney and simultaneous pancreas-kidney (SPK) transplant recipients can have prolonged postoperative hospitalization due to edema. Thrombo-embolic-deterrent (TED) stockings with intermittent pneumatic compression devices (TED+IPC) have been used to improve venous return during the perioperative period. The objective of this trial was to evaluate the effects of TED+IPC vs. muscle pump activator (MPA) devices on factors that could reduce postoperative complications and duration of hospitalization. METHODS In this single-center, prospective, randomized, controlled trial, 221 kidney and SPK transplant recipients were randomized to either wearing TED+IPC or MPA for six days postoperatively. Groups were compared with respect to postoperative urine output, lower limb edema, weight, days in hospital, mobility, serum creatinine, delayed graft function, need for dialysis, and lower extremity blood flow. RESULTS Patients in the MPA group had significantly higher urine output and less increase in mid-calf leg circumference and weight gain compared to the TED+IPC group (p=0.003, p=0.001, and p=0.003, respectively). The MPA group also experienced shorter hospitalization (p=0.038), higher femoral vein velocity (p=0.001), and took more steps (p=0.009). Incidence of delayed graft function (p=0.72) and number of dialysis runs (p=0.39) was not different between study groups. Subgroup analysis of primary endpoints in donation after cardiac death recipients and SPK recipients did not yield any significance between the study arms. CONCLUSIONS Postoperative use of the MPA device increases urine output, decreases leg edema, minimizes weight gain, and decreases duration of hospitalization after kidney transplantation. A larger and longer-term trial is needed to evaluate the impact on graft function.",2020,"RESULTS Patients in the MPA group had significantly higher urine output and less increase in mid-calf leg circumference and weight gain compared to the TED+IPC group (p=0.003, p=0.001, and p=0.003, respectively).","['post-kidney transplantation', '221 kidney and SPK transplant recipients']","['TED+IPC', 'TED+IPC vs. muscle pump activator (MPA) devices', 'wearing TED+IPC or MPA', 'muscle pump activator device', 'Thrombo-embolic-deterrent (TED) stockings with intermittent pneumatic compression devices (TED+IPC']","['higher femoral vein velocity', 'duration of hospitalization', 'urine output, decreases leg edema, minimizes weight gain', 'mid-calf leg circumference and weight gain', 'Incidence of delayed graft function', 'number of dialysis runs', 'urine output', 'postoperative urine output, lower limb edema, weight, days in hospital, mobility, serum creatinine, delayed graft function, need for dialysis, and lower extremity blood flow', 'postoperative complications and duration of hospitalization', 'shorter hospitalization', 'duration of hospitalization and improves early graft outcomes']","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0030274', 'cui_str': 'Pancreatic structure'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0445269', 'cui_str': 'Socks'}, {'cui': 'C1449835', 'cui_str': 'Intermittent pneumatic compression device'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0015809', 'cui_str': 'Femoral vein structure'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0235886', 'cui_str': 'Leg edema'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0230445', 'cui_str': 'Structure of calf of leg'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C1566590', 'cui_str': 'Delayed graft function'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0239340', 'cui_str': 'Edema of lower extremity'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",221.0,0.198957,"RESULTS Patients in the MPA group had significantly higher urine output and less increase in mid-calf leg circumference and weight gain compared to the TED+IPC group (p=0.003, p=0.001, and p=0.003, respectively).","[{'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Xie', 'Affiliation': ""Departments of Surgery, Schulich School of Medicine & Dentistry, St. Joseph's Hospital, London, ON, Canada.""}, {'ForeName': 'Max A', 'Initials': 'MA', 'LastName': 'Levine', 'Affiliation': ""Departments of Surgery, Schulich School of Medicine & Dentistry, St. Joseph's Hospital, London, ON, Canada.""}, {'ForeName': 'Shahid', 'Initials': 'S', 'LastName': 'Aquil', 'Affiliation': ""Departments of Surgery, Schulich School of Medicine & Dentistry, St. Joseph's Hospital, London, ON, Canada.""}, {'ForeName': 'Katharine', 'Initials': 'K', 'LastName': 'Pacoli', 'Affiliation': 'Matthew Mailing Centre for Translational Transplant Studies, London Health Sciences Centre, London, ON, Canada.'}, {'ForeName': 'Rafid', 'Initials': 'R', 'LastName': 'Al-Ogaili', 'Affiliation': ""Departments of Surgery, Schulich School of Medicine & Dentistry, St. Joseph's Hospital, London, ON, Canada.""}, {'ForeName': 'Patrick P', 'Initials': 'PP', 'LastName': 'Luke', 'Affiliation': ""Departments of Surgery, Schulich School of Medicine & Dentistry, St. Joseph's Hospital, London, ON, Canada.""}, {'ForeName': 'Alp', 'Initials': 'A', 'LastName': 'Sener', 'Affiliation': ""Departments of Surgery, Schulich School of Medicine & Dentistry, St. Joseph's Hospital, London, ON, Canada.""}]",Canadian Urological Association journal = Journal de l'Association des urologues du Canada,['10.5489/cuaj.6487'] 2372,32745019,Using a Nurse-Led Telehealth Intervention to Improve Fasting Glucose Levels in Patients With Uncontrolled Type 2 Diabetes Undergoing a Surgical Intervention.,"BACKGROUND Uncontrolled diabetes during the perioperative period can result in a variety of adverse postoperative outcomes. OBJECTIVE Evaluate a nurse-led telehealth preoperative intervention to improve glycemic control. METHODS Provide telehealth diabetes education prior to surgery and evaluate time spent and pre-/post-glucose levels. Between-group differences were used to assess glycemic control. RESULTS There was no significant difference in scores for those who received the telephone intervention ( M = 167.71, SD = 59.9) and those who did not receive the intervention ( M = 171.44, SD = 54.9; t (44) = 0.220, p = .82, two-tailed). The magnitude of the differences in the means was very small (Cohen's d = 0.03). There was a reduction in pre- and post-glucose levels for both groups. CONCLUSIONS Although the findings were not statistically significant, there may be some clinical significance. IMPLICATIONS FOR NURSING The clinical significance has implications for nursing due to participants choosing to delay surgery and potentially preventing adverse outcomes.",2018,"There was a reduction in pre- and post-glucose levels for both groups. ",['Patients With Uncontrolled Type 2 Diabetes Undergoing a Surgical Intervention'],"['Nurse-Led Telehealth Intervention', 'nurse-led telehealth preoperative intervention']","['time spent and pre-/post-glucose levels', 'glycemic control', 'pre- and post-glucose levels', 'Fasting Glucose Levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}]",,0.0283856,"There was a reduction in pre- and post-glucose levels for both groups. ","[{'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Mott', 'Affiliation': 'West Virginia University, School of Nursing, Morgantown, West Virginia cmott@hsc.wvu.edu.'}, {'ForeName': 'Kendra', 'Initials': 'K', 'LastName': 'Barker', 'Affiliation': 'West Virginia University, School of Nursing, Morgantown, West Virginia.'}, {'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Schwertfeger', 'Affiliation': 'West Virginia University, School of Nursing, Morgantown, West Virginia.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Mallow', 'Affiliation': 'West Virginia University, School of Nursing, Morgantown, West Virginia.'}]",Journal of doctoral nursing practice,['10.1891/2380-9418.11.2.126'] 2373,32745170,p16/ki67 and E6/E7 mRNA accuracy and prognostic value in triaging HPV DNA-positive women.,"BACKGROUND The study presents cross-sectional accuracy of E6/E7 mRNA detection and p16/ki67 dual staining, alone or in combination with cytology and HPV16/18 genotyping, as triage test in HPV DNA-positive women and their impact on CIN2+ overdiagnosis. METHODS Women aged 25-64 were recruited. HPV DNA-positives were triaged with cytology and tested for E6/E7 mRNA and p16/ki67. Cytology positives were referred to colposcopy, while negatives were randomised to immediate colposcopy or to one-year HPV retesting. Lesions found within 24 months since recruitment were included. All p-values were two-sided. RESULTS 40,509 women were recruited and 3147 (7.8%) tested HPV DNA-positive; 174 CIN2+ were found: sensitivity was 61.0% (95% CI = 53.6 to 68.0), 94.4% (95% CI = 89.1 to 97.3), and 75.2% (95% CI = 68.1 to 81.6) for cytology, E6/E7 mRNA, and p16/ki67, respectively. Immediate referral was 25.6%, 66.8%, and 28.3%, respectively. Overall referral was 65.3%, 78.3%, and 63.3%. Cytology or p16/ki67 when combined with HPV16/18 typing reached higher sensitivity with a small impact on referral. Among the 2306 HPV DNA-positive/cytology-negative women, relative CIN2+ detection in those randomized at 1-year retesting vs. immediate colposcopy suggests a -28% CIN2+ regression (95% CI = -57% to + 20%); regression was higher in E6/E7 mRNA-negatives (pinteraction =.29). HPV clearance at 1 year in E6/E7 mRNA and in p16/ki67 negatives was about 2 times higher than in positive women (Pinteraction < .001 for both). CONCLUSIONS p16/ki67 showed good performance as triage test. E6/E7 mRNA showed the highest sensitivity, at the price of too high a positivity rate to be efficient for triage. However, when negative, it showed a good prognostic value for clearance and CIN2+ regression.",2020,"HPV clearance at 1 year in E6/E7 mRNA and in p16/ki67 negatives was about 2 times higher than in positive women (Pinteraction < .001 for both). ","['Women aged 25-64 were recruited', '40,509 women', 'triaging HPV DNA-positive women']","['E6/E7 mRNA detection and p16/ki67 dual staining, alone or in combination with cytology and HPV16/18 genotyping']","['Immediate referral', 'sensitivity', 'relative CIN2+ detection', 'Overall referral', 'p16/ki67 negatives', 'highest sensitivity', 'HPV clearance']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3872595', 'cui_str': 'Human papillomavirus DNA'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]","[{'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0487602', 'cui_str': 'Staining method'}, {'cui': 'C0010818', 'cui_str': 'Cytology'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0349459', 'cui_str': 'Cervical intraepithelial neoplasia grade 2'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}]",40509.0,0.212199,"HPV clearance at 1 year in E6/E7 mRNA and in p16/ki67 negatives was about 2 times higher than in positive women (Pinteraction < .001 for both). ","[{'ForeName': 'Paolo Giorgi', 'Initials': 'PG', 'LastName': 'Rossi', 'Affiliation': 'Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, via Amendola, 2, Reggio Emilia, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Carozzi', 'Affiliation': 'ISPRO Oncological Network, Prevention and Research Institute, Regional Laboratory of Cancer Prevention Unit, Via Cosimo Il Vecchio, 2, Florence, Italy.'}, {'ForeName': 'Guglielmo', 'Initials': 'G', 'LastName': 'Ronco', 'Affiliation': 'Center for Cancer Epidemiology and Prevention (CPO), corso Bramante, 88, Turin, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Allia', 'Affiliation': 'Center for Cervical Cancer Screening, City of Health and Science Hospital, Via Camillo Benso di Cavour, 31, Turin, Italy.'}, {'ForeName': 'Simonetta', 'Initials': 'S', 'LastName': 'Bisanzi', 'Affiliation': 'ISPRO Oncological Network, Prevention and Research Institute, Regional Laboratory of Cancer Prevention Unit, Via Cosimo Il Vecchio, 2, Florence, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Gillio-Tos', 'Affiliation': 'Unit of Cancer Epidemiology and Center for Cancer Prevention (CPO), City of Health and Science Hospital, Via Santena, 7, Turin, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'De Marco', 'Affiliation': 'Center for Cervical Cancer Screening, City of Health and Science Hospital, Via Camillo Benso di Cavour, 31, Turin, Italy.'}, {'ForeName': 'Raffaella', 'Initials': 'R', 'LastName': 'Rizzolo', 'Affiliation': 'Center for Cancer Epidemiology and Prevention (CPO), corso Bramante, 88, Turin, Italy.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Gustinucci', 'Affiliation': 'Laboratorio Unico di Screening USL Umbria1, Via XIV settembre, 75, Perugia, Italy.'}, {'ForeName': 'Annarosa', 'Initials': 'A', 'LastName': 'Del Mistro', 'Affiliation': 'Istituto Oncologico Veneto IOV - IRCCS, Via Gattamelata, 64, Padua, Italy.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Frayle', 'Affiliation': 'Istituto Oncologico Veneto IOV - IRCCS, Via Gattamelata, 64, Padua, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Confortini', 'Affiliation': 'ISPRO Oncological Network, Prevention and Research Institute, Regional Laboratory of Cancer Prevention Unit, Via Cosimo Il Vecchio, 2, Florence, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Iossa', 'Affiliation': 'ISPRO Oncological Network, prevention and research Institute, Screening Unit, Via Cosimo Il Vecchio, 2, Florence, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Cesarini', 'Affiliation': 'Laboratorio Unico di Screening USL Umbria1, Via XIV settembre, 75, Perugia, Italy.'}, {'ForeName': 'Simonetta', 'Initials': 'S', 'LastName': 'Bulletti', 'Affiliation': 'Laboratorio Unico di Screening USL Umbria1, Via XIV settembre, 75, Perugia, Italy.'}, {'ForeName': 'Basilio', 'Initials': 'B', 'LastName': 'Passamonti', 'Affiliation': 'Laboratorio Unico di Screening USL Umbria1, Via XIV settembre, 75, Perugia, Italy.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Gori', 'Affiliation': 'Istituto Oncologico Veneto IOV - IRCCS, Via Gattamelata, 64, Padua, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Toniolo', 'Affiliation': 'ULSS6, Via S. Fermo, 10, 35042, Este, Padua, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Barca', 'Affiliation': 'Assessorato alla Salute, Regione Lazio, Via R. Raimondi Garibaldi, 7, Rome, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Bonvicini', 'Affiliation': 'Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, via Amendola, 2, Reggio Emilia, Italy.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Mancuso', 'Affiliation': 'Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, via Amendola, 2, Reggio Emilia, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Venturelli', 'Affiliation': 'Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, via Amendola, 2, Reggio Emilia, Italy.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Benevolo', 'Affiliation': 'IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi, 53, Rome, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of the National Cancer Institute,['10.1093/jnci/djaa105'] 2374,32745227,Osseous Integration of the Central Peg of an All-Polyethylene Glenoid With 3 Different Surgical Techniques.,"All-polyethylene glenoid components designed for osseous integration of the central peg can be placed with no graft (NG), autogenous bone graft (ABG), or demineralized bone matrix (DBM). The purpose of this study was to compare osseous integration with these 3 techniques. A randomized controlled trial was performed of 153 total shoulder arthroplasties using a pegged allpolyethylene glenoid component designed for osseous integration. Central peg treatment included NG, ABG, or DBM. The primary outcome was central peg osseous integration defined as bone presence between the central fins 1 year postoperatively. Central osseous integration was observed in 90% of cases treated with ABG, 68% of cases treated with DBM, and 68% of cases treated with NG (P=.022). Postoperative Wirth grading revealed radiolucency around the central peg (grade 1) in 2.4% of cases with ABG, 5.4% of cases with DBM, and 9.8% of cases with NG (P=.134). At short-term follow-up, osseous integration of the central peg of an all-polyethylene glenoid designed for bony growth between the central fins appears to be highest when treating the central peg with ABG compared with leaving the central peg untreated or using DBM. [Orthopedics. 2020;43(x):xx-xx.].",2020,"Postoperative Wirth grading revealed radiolucency around the central peg (grade 1) in 2.4% of cases with ABG, 5.4% of cases with DBM, and 9.8% of cases with NG (P=.134).",['153 total shoulder arthroplasties using a pegged allpolyethylene glenoid component designed for osseous integration'],['DBM'],"['NG, ABG, or DBM', 'Central osseous integration', 'central peg osseous integration defined as bone presence between the central fins 1 year postoperatively']","[{'cui': 'C0186657', 'cui_str': 'Total shoulder replacement'}, {'cui': 'C0032478', 'cui_str': 'Polyethylene Glycol 400'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}]","[{'cui': 'C0005962', 'cui_str': 'Bone matrix'}]","[{'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0440800', 'cui_str': 'Autogenous bone graft'}, {'cui': 'C0005962', 'cui_str': 'Bone matrix'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0032478', 'cui_str': 'Polyethylene Glycol 400'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0016132', 'cui_str': 'Finland'}, {'cui': 'C0439234', 'cui_str': 'year'}]",153.0,0.0247273,"Postoperative Wirth grading revealed radiolucency around the central peg (grade 1) in 2.4% of cases with ABG, 5.4% of cases with DBM, and 9.8% of cases with NG (P=.134).","[{'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Denard', 'Affiliation': ''}, {'ForeName': 'Reuben', 'Initials': 'R', 'LastName': 'Gobezie', 'Affiliation': ''}, {'ForeName': 'Justin W', 'Initials': 'JW', 'LastName': 'Griffin', 'Affiliation': ''}, {'ForeName': 'Anthony A', 'Initials': 'AA', 'LastName': 'Romeo', 'Affiliation': ''}, {'ForeName': 'Evan', 'Initials': 'E', 'LastName': 'Lederman', 'Affiliation': ''}]",Orthopedics,['10.3928/01477447-20200721-04'] 2375,32745229,Gravity-Assisted Passive Flexion in Total Knee Arthroplasty Recovery.,"This study examined the use of gravity-assisted passive flexion (GAP-FLEX) for perioperative total knee arthroplasty (TKA) recovery. The main questions associated with this technique were: (1) Can GAP-FLEX improve patient recovery of range of motion after TKA? (2) Does GAP-FLEX reduce patient time and effort associated with therapy compared with continuous passive motion (CPM)? (3) Does GAP-FLEX reduce overall episodic care cost? A prospective, randomized multicenter study was conducted. Two senior surgeons used identical surgical approach, prosthesis, and postoperative management protocols. Patients consenting to the study were randomly assigned to either standard of care (CPM) or GAP-FLEX groups. Active flexion range of motion (ROM) was measured via goniometer with a primary endpoint established at 4 weeks after surgery. Secondary endpoints included pain and functional mobility. A total of 27 patients completed the study. Average ROM in the GAP-FLEX sample was 8.4° greater than the CPM sample (P=.009) at study endpoint. The GAP-FLEX patients achieved greater postoperative ROM within 2 days and maintained an improvement over CPM to study endpoint. Eighty-five percent (11 of 13) of GAP-FLEX patients achieved or surpassed their baseline ROM by study endpoint, compared with 50% (7 of 14) of CPM patients. These improvements occurred while requiring 90% less therapy time on device compared with the CPM patients. Patients did not report any statistically different pain levels but did exhibit higher functional mobility at endpoint (P=.026). [Orthopedics. 2020;43(x):xx-xx.].",2020,Average ROM in the GAP-FLEX sample was 8.4° greater than the CPM sample (P=.009) at study endpoint.,"['27 patients completed the study', 'Total Knee Arthroplasty Recovery', 'Patients consenting to the study']","['GAP-FLEX', 'gravity-assisted passive flexion (GAP-FLEX', 'Gravity-Assisted Passive Flexion', 'standard of care (CPM) or GAP-FLEX groups']","['Average ROM', 'pain and functional mobility', 'pain levels', 'Active flexion range of motion (ROM', 'functional mobility', 'postoperative ROM']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C2711213', 'cui_str': 'Consented'}]","[{'cui': 'C0282189', 'cui_str': 'Gravity'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0079991', 'cui_str': 'Passive movement'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]",2.0,0.0415538,Average ROM in the GAP-FLEX sample was 8.4° greater than the CPM sample (P=.009) at study endpoint.,"[{'ForeName': 'Frank A', 'Initials': 'FA', 'LastName': 'Buttacavoli', 'Affiliation': ''}]",Orthopedics,['10.3928/01477447-20200721-09'] 2376,32745244,The effect of preoperative anxiety on phenylephrine dose during cesarean delivery: an open controlled one-arm clinical trial.,"BACKGROUND We performed an open controlled one-arm clinical trial to assess whether pre-operative anxiety influences phenylephrine dosage required to maintain normotension during cesarean section under spinal anesthesia. METHODS Ninety-four parturients undergoing elective cesarean delivery under spinal anesthesia were included. Anxiety levels were measured using a verbal numerical scale anxiety score (0-10). Phenylephrine infusion to prevent hypotension was adjusted by a standard algorithm. The primary outcome was total phenylephrine dose. Linear uni- and multivariate regressions were performed to assess the relationship between preoperative anxiety and the outcome. p<0.05 was considered statistically significant. RESULTS We found no association between preoperative anxiety and phenylephrine dosage (R 2 =0.05). Taking the number of attempts for spinal anesthesia and surgical time into account did not lead to a significant improvement of the regression model. CONCLUSION In conclusion, we did not find a large independent effect of preoperative anxiety on phenylephrine dose required to maintain normotension in our cohort. We believe that spinal hypotension and phenylephrine dose requirement are multifactorial and anxiety is only one of the factors in this complex interaction.",2020,"Taking the number of attempts for spinal anesthesia and surgical time into account did not lead to a significant improvement of the regression model. ",['Ninety-four parturients undergoing elective cesarean delivery under spinal anesthesia were included'],"['Phenylephrine', 'phenylephrine']","['Anxiety levels', 'hypotension', 'verbal numerical scale anxiety score', 'total phenylephrine dose']","[{'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0031469', 'cui_str': 'Phenylephrine'}]","[{'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0031469', 'cui_str': 'Phenylephrine'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]",94.0,0.0711361,"Taking the number of attempts for spinal anesthesia and surgical time into account did not lead to a significant improvement of the regression model. ","[{'ForeName': 'Eran', 'Initials': 'E', 'LastName': 'Danon', 'Affiliation': 'Department of Anesthesiology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Heesen', 'Affiliation': 'Faculty of Medicine, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Orbach-Zinger', 'Affiliation': 'Department of Anesthesiology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.'}, {'ForeName': 'Evgeniya', 'Initials': 'E', 'LastName': 'Kornilov', 'Affiliation': 'Department of Anesthesiology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.'}, {'ForeName': 'Ariel', 'Initials': 'A', 'LastName': 'Ronen', 'Affiliation': 'Department of Anesthesiology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.'}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Weiniger', 'Affiliation': 'Division of Anesthesia, Critical Care and Pain, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Leonid', 'Initials': 'L', 'LastName': 'Eidelman', 'Affiliation': 'Department of Anesthesiology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13683'] 2377,30168905,"Characterizing the Sources of Pharmacokinetic Variability for TAK-117 (Serabelisib), an Investigational Phosphoinositide 3-Kinase Alpha Inhibitor: A Clinical Biopharmaceutics Study to Inform Development Strategy.","TAK-117 (also known as MLN1117 or serabelisib) is an orally available inhibitor of phosphoinositide 3-kinase alpha being developed for treatment of solid tumors. This clinical study in healthy subjects assessed the relative bioavailability of a TAK-117 tablet compared with a capsule formulation (part 1) and the effect of food (part 2) and intragastric pH modulation (part 3) on TAK-117 pharmacokinetics. In part 1, subjects received single doses of 900 mg TAK-117 under fasting conditions as capsules and tablets on 2 different occasions in random order. In part 2, subjects received a single dose of 600 mg TAK-117 under fed (high-fat meal) or fasted conditions on 2 different occasions in random order. In part 3, subjects received a single dose of 900 mg TAK-117 alone and in combination with lansoprazole in a fixed sequence. Blood samples were collected up to 72 hours after each TAK-117 dose. The geometric mean ratios (90% confidence intervals) for the area under the TAK-117 plasma concentration-time curves were 1.53 (0.93-2.51) for tablets versus capsules, 1.50 (1.00-2.25) for fed versus fasted, and 0.02 (0.01-0.04) for TAK-117 plus lansoprazole compared with TAK-117 alone. The most common adverse event was nausea, the incidence of which was reduced when TAK-117 was administered with food despite the increased systemic exposure. The incidence of all adverse events was reduced when TAK-117 was administered with lansoprazole, which was consistent with the substantial reduction in bioavailability. Intersubject variability of TAK-117 was high. Careful management of intragastric pH-modulatory concomitant medications and food intake may be required.",2019,"The incidence of all adverse events was reduced when TAK-117 was administered with lansoprazole, which was consistent with the substantial reduction in bioavailability.",['healthy subjects'],"['TAK-117 alone and in combination with lansoprazole', 'TAK-117', 'lansoprazole', 'TAK-117 plus lansoprazole']","['Blood samples', 'systemic exposure', 'geometric mean ratios', 'relative bioavailability', 'bioavailability', 'incidence of all adverse events', 'TAK-117 plasma concentration-time curves']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C4054273', 'cui_str': 'TAK-117'}, {'cui': 'C0050940', 'cui_str': 'lansoprazole'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4054273', 'cui_str': 'TAK-117'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}]",,0.101669,"The incidence of all adverse events was reduced when TAK-117 was administered with lansoprazole, which was consistent with the substantial reduction in bioavailability.","[{'ForeName': 'Chirag G', 'Initials': 'CG', 'LastName': 'Patel', 'Affiliation': 'Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.'}, {'ForeName': 'Lakshmi', 'Initials': 'L', 'LastName': 'Rangachari', 'Affiliation': 'Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Patti', 'Affiliation': 'Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.'}, {'ForeName': 'Celina', 'Initials': 'C', 'LastName': 'Griffin', 'Affiliation': 'Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.'}, {'ForeName': 'Yaping', 'Initials': 'Y', 'LastName': 'Shou', 'Affiliation': 'Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.'}, {'ForeName': 'Karthik', 'Initials': 'K', 'LastName': 'Venkatakrishnan', 'Affiliation': 'Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.613'] 2378,30473390,Challenges in implementing and assessing outcomes of school start time change in the UK: experience of the Oxford Teensleep study.,"OBJECTIVE Later school start times for adolescents have been implemented in the US and associated benefits found, although no randomised controlled trials (RCT) have been undertaken. The objective of this study was to evaluate the impact of two school interventions in the UK, a delayed start time and a sleep education programme, on students' academic performance, sleep outcomes and health-related quality of life. METHODS The study had an RCT design to enable an investigation into the differential effects of two interventions or a combination of both: schools were to delay their start time to 10:00am and/or provide a classroom-based sleep education programme. The recruitment target was 100 state (non-fee-paying) secondary schools. Participants were to be students in Year 10/11 (14-16-year-olds). RESULTS Despite much media coverage, only two schools volunteered to take part in the RCT. The main challenges faced in recruitment fell under three categories: research design, school, and project-specific issues. The delayed start time and prospect of randomisation to this intervention were the overwhelming reasons cited for not taking part. Facilitators and barriers to research were identified. Recommendations include carrying out a feasibility study prior to a main trial, allowing adequate time for recruitment, involving stakeholders throughout the decision-making process, incorporating independent (fee-paying) schools in recruitment, focusing on students not taking important examinations or involving an older year group with greater independence. CONCLUSION The Teensleep study provides supporting evidence that evaluating the effects of a change in school start times through an RCT is unfeasible in the UK.",2019,The study had an RCT design to enable an investigation into the differential effects of two interventions or a combination of both: schools were to delay their start time to 10:00am and/or provide a classroom-based sleep education programme.,"['Participants were to be students in Year 10/11 (14-16-year-olds', 'students not taking important examinations or involving an older year group with greater independence']",[],"[""students' academic performance, sleep outcomes and health-related quality of life""]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205393', 'cui_str': 'Most'}]",[],"[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0036373', 'cui_str': 'Academic Test Performance'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.0390391,The study had an RCT design to enable an investigation into the differential effects of two interventions or a combination of both: schools were to delay their start time to 10:00am and/or provide a classroom-based sleep education programme.,"[{'ForeName': 'Gaby', 'Initials': 'G', 'LastName': 'Illingworth', 'Affiliation': 'Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, UK. Electronic address: gaby.illingworth@ndcn.ox.ac.uk.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Sharman', 'Affiliation': 'Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, UK.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Jowett', 'Affiliation': 'Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, UK; Department of Psychology, Royal Holloway, University of London, UK.'}, {'ForeName': 'Christopher-James', 'Initials': 'CJ', 'LastName': 'Harvey', 'Affiliation': 'Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, UK.'}, {'ForeName': 'Russell G', 'Initials': 'RG', 'LastName': 'Foster', 'Affiliation': 'Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, UK.'}, {'ForeName': 'Colin A', 'Initials': 'CA', 'LastName': 'Espie', 'Affiliation': 'Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, UK.'}]",Sleep medicine,['10.1016/j.sleep.2018.10.021'] 2379,30698114,Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder.,"BACKGROUND For patients with major depressive disorder (MDD) experiencing side-effects or non-response to their first antidepressant, little is known regarding the effect of switching between a tricyclic antidepressant (TCA) and a selective serotonin reuptake inhibitor (SSRI).AimsTo compare the switch between the TCA nortriptyline and the SSRI escitalopram. METHOD Among 811 adults with MDD treated with nortriptyline or escitalopram for up to 12 weeks, 108 individuals switched from nortriptyline to escitalopram or vice versa because of side-effects or non-response (trial registration: EudraCT No.2004-001723-38 (https://eudract.ema.europa.eu/) and ISRCTN No.03693000 (http://www.controlled-trials.com)). Patients were followed for up to 26 weeks after switching and response was measured with the Montgomery-Åsberg Depression Rating scale (MADRS). We performed adjusted mixed-effects linear regression models with full information maximum likelihood estimation reporting β-coefficients with 95% CIs. RESULTS Switching antidepressants resulted in a significant decrease in MADRS scores. This was present for switchers from escitalopram to nortriptyline (n = 36, β = -0.38, 95% CI -0.51 to -0.25, P<0.001) and from nortriptyline to escitalopram (n = 72, β = -0.34, 95% CI -0.41 to -0.26, P<0.001). Both switching options resulted in significant improvement among individuals who switched because of non-response or side-effects. The results were supported by analyses on other rating scales and symptom dimensions. CONCLUSIONS These results suggest that switching from a TCA to an SSRI or vice versa after non-response or side-effects to the first antidepressant may be a viable approach to achieve response among patients with MDD.Declarations of interestK.J.A. holds an Alberta Centennial Addiction and Mental Health Research Chair, funded by the Government of Alberta. K.J.A. has been a member of various advisory boards, received consultancy fees and honoraria, and has received research grants from various companies including Johnson and Johnson Pharmaceuticals Research and Development and Bristol-Myers Squibb Pharmaceuticals Limited. D.S. has served on advisory boards for, and received unrestricted grants from, Lundbeck and AstraZeneca. A.F. and P.M. have received honoraria for participating in expert panels for Lundbeck and GlaxoSmithKline.",2019,"β = -0.34, 95% CI -0.41 to -0.26, P<0.001).","['811 adults with MDD treated with', 'patients with major depressive disorder (MDD', 'patients with major depressive disorder']","['nortriptyline or escitalopram', 'nortriptyline and escitalopram', 'nortriptyline']","['MADRS scores', 'rating scales and symptom dimensions', 'Montgomery-Åsberg Depression Rating scale (MADRS']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0028420', 'cui_str': 'Nortriptyline'}, {'cui': 'C1099456', 'cui_str': 'Escitalopram'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C2960593', 'cui_str': 'Montgomery-Åsberg depression rating scale'}]",811.0,0.0681229,"β = -0.34, 95% CI -0.41 to -0.26, P<0.001).","[{'ForeName': 'Ole', 'Initials': 'O', 'LastName': 'Köhler-Forsberg', 'Affiliation': 'Psychosis Research Unit,Aarhus University Hospital - Psychiatry;Department of Clinical Medicine,Aarhus University;and iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research,Denmark.'}, {'ForeName': 'Erik Roj', 'Initials': 'ER', 'LastName': 'Larsen', 'Affiliation': 'Chief Physician,Department of Psychiatry,Psychiatry in the Region of Southern Denmark,Institute of Clinical Research,Research Unit of Psychiatry,University of Southern Denmark,Denmark.'}, {'ForeName': 'Henriette N', 'Initials': 'HN', 'LastName': 'Buttenschøn', 'Affiliation': 'Associate Professor,iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research;and Translational Neuropsychiatry Unit,Department of Clinical Medicine,Aarhus University,Denmark.'}, {'ForeName': 'Marcella', 'Initials': 'M', 'LastName': 'Rietschel', 'Affiliation': 'Professor,Central Institute of Mental Health,Department of Genetic Epidemiology in Psychiatry,Medical Faculty Mannheim/Heidelberg University,Germany.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Hauser', 'Affiliation': 'Professor,Laboratory of Psychiatric Genetics,Department of Psychiatry,Poznan University of Medical Sciences,Poland.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Souery', 'Affiliation': 'Professor,Laboratoire de Psychologie Médicale,Université Libre de Bruxelles;Psy Pluriel - Centre Européen de Psychologie Médicale,Belgium.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Maier', 'Affiliation': 'Professor,Department of Psychiatry,University of Bonn,Germany.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Farmer', 'Affiliation': ""Professor,Social, Genetic and Developmental Psychiatry Centre,Institute of Psychiatry, Psychology and Neuroscience,King's College London,UK.""}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'McGuffin', 'Affiliation': ""Professor,Social, Genetic and Developmental Psychiatry Centre,Institute of Psychiatry, Psychology and Neuroscience,King's College London,UK.""}, {'ForeName': 'Katherine J', 'Initials': 'KJ', 'LastName': 'Aitchison', 'Affiliation': 'Professor,University of Alberta,Canada.'}, {'ForeName': 'Rudolf', 'Initials': 'R', 'LastName': 'Uher', 'Affiliation': ""Professor,Social, Genetic and Developmental Psychiatry Centre,Institute of Psychiatry,Psychology and Neuroscience,King's College London,UK;and Department of Psychiatry,Dalhousie University,Canada.""}, {'ForeName': 'Ole', 'Initials': 'O', 'LastName': 'Mors', 'Affiliation': 'Professor,Psychosis Research Unit,Aarhus University Hospital - Psychiatry;Department of Clinical Medicine,Aarhus University;and iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research,Denmark.'}]",The British journal of psychiatry : the journal of mental science,['10.1192/bjp.2018.302'] 2380,31034619,The role of therapist MI skill and client change talk class membership predicting dual alcohol and sex risk outcomes.,"OBJECTIVE We investigated the technical model of motivational interviewing (MI) in a dual-outcome intervention (i.e., alcohol, sexual risk; N = 164; 57% female). METHOD We identified latent classes of client change statements, based on the proportion of change talk (CT) over the session. We then examined whether outcomes were related to CT class, and whether the relations between MI skill and outcomes varied by CT class. RESULTS We found three classes of alcohol-CT and two classes of sexual risk-CT. While CT class membership did not predict outcomes directly, greater therapist MI-consistent skill was associated with fewer heavy drinking days in the increasing alcohol-CT class. For sexual risk outcomes, therapist MI-consistent skill was associated with reduced odds of condomless sex for the low sexual risk-CT class. CONCLUSIONS The relation of therapist MI consistency to outcomes appears to be a function of client CT during the session.",2019,"For sexual risk outcomes, therapist MI-consistent skill was associated with reduced odds of condomless sex for the low sexual risk-CT class. ",[],"['motivational interviewing (MI', 'therapist MI skill and client change talk class membership']",[],[],"[{'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0456387', 'cui_str': 'Class'}]",[],,0.0115664,"For sexual risk outcomes, therapist MI-consistent skill was associated with reduced odds of condomless sex for the low sexual risk-CT class. ","[{'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Janssen', 'Affiliation': 'Department of Behavioral and Social Sciences, Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, Rhode Island.'}, {'ForeName': 'Molly', 'Initials': 'M', 'LastName': 'Magill', 'Affiliation': 'Department of Behavioral and Social Sciences, Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, Rhode Island.'}, {'ForeName': 'Nadine R', 'Initials': 'NR', 'LastName': 'Mastroleo', 'Affiliation': 'Community Research and Action, Binghamton University College of Community and Public Affairs, Binghamton, New York.'}, {'ForeName': 'M Barton', 'Initials': 'MB', 'LastName': 'Laws', 'Affiliation': 'Department of Health Services, Center for Gerontology and Healthcare Research, Policy and Practice, Brown University School of Public Health, Providence, Rhode Island.'}, {'ForeName': 'Chanelle J', 'Initials': 'CJ', 'LastName': 'Howe', 'Affiliation': 'Department of Epidemiology, Centers for Epidemiology and Environmental Health, Brown University School of Public Health, Providence, Rhode Island.'}, {'ForeName': 'Justin W', 'Initials': 'JW', 'LastName': 'Walthers', 'Affiliation': 'Department of Behavioral and Social Sciences, Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, Rhode Island.'}, {'ForeName': 'Peter M', 'Initials': 'PM', 'LastName': 'Monti', 'Affiliation': 'Department of Behavioral and Social Sciences, Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, Rhode Island.'}, {'ForeName': 'Christopher W', 'Initials': 'CW', 'LastName': 'Kahler', 'Affiliation': 'Department of Behavioral and Social Sciences, Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, Rhode Island.'}]",Journal of clinical psychology,['10.1002/jclp.22798'] 2381,31367741,Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice.,"BACKGROUND Early clinical response (ECR) is a new endpoint to determine whether a drug should be approved for community-acquired bacterial pneumonia in the United States. The Omadacycline for Pneumonia Treatment In the Community (OPTIC) phase III study demonstrated noninferiority of omadacycline to moxifloxacin using this endpoint. This study describes the performance of the ECR endpoint and clinical stability relative to a posttreatment evaluation (PTE) of clinical success. METHODS ECR was defined as symptom improvement 72-120 hours after the first dose of study drug (ECR window), no use of rescue antibiotics, and patient survival. Clinical success at PTE was an investigator assessment of success. Clinical stability was defined based on vital sign stabilization, described in the American Thoracic Society and Infectious Diseases Society of America community-acquired pneumonia treatment guidelines. RESULTS During the ECR window, ECR was achieved in 81.1% and 82.7% of omadacycline and moxifloxacin patients, respectively. Similar numbers of patients achieved clinical stability in each treatment group (omadacycline 74.6%, moxifloxacin 77.6%). The proportion of patients with improved symptoms who were considered clinically stable increased across the ECR window (69.2-77.6% for omadacycline; 68.0-79.7% for moxifloxacin). There was high concordance (>70%) and high positive predictive value (>90%) of ECR and clinical stability with overall clinical success at PTE. CONCLUSIONS Omadacycline was noninferior to moxifloxacin, based on a new ECR endpoint. Clinical stability was similarly high when measured in the same time frame as ECR. Both ECR and clinical stability showed high concordance and high positive predictive value with clinical success at PTE. CLINICAL TRIALS REGISTRATION NCT02531438.",2019,"There was high concordance (>70%) and high positive predictive value (>90%) of ECR and clinical stability with overall clinical success at PTE. ",['Community-acquired Bacterial Pneumonia'],['moxifloxacin'],"['Clinical stability', 'ECR window', 'clinical stability']","[{'cui': 'C0456394', 'cui_str': 'Community acquired'}, {'cui': 'C0004626', 'cui_str': 'Bacterial pneumonia'}]","[{'cui': 'C0536495', 'cui_str': 'moxifloxacin'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0557702', 'cui_str': 'Window'}]",,0.0670521,"There was high concordance (>70%) and high positive predictive value (>90%) of ECR and clinical stability with overall clinical success at PTE. ","[{'ForeName': 'Julio A', 'Initials': 'JA', 'LastName': 'Ramirez', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of Louisville, Kentucky.'}, {'ForeName': 'Evan', 'Initials': 'E', 'LastName': 'Tzanis', 'Affiliation': 'Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania.'}, {'ForeName': 'Marla', 'Initials': 'M', 'LastName': 'Curran', 'Affiliation': 'Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Noble', 'Affiliation': 'Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania.'}, {'ForeName': 'Surya', 'Initials': 'S', 'LastName': 'Chitra', 'Affiliation': 'Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Manley', 'Affiliation': 'Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania.'}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Kirsch', 'Affiliation': 'Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania.'}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'McGovern', 'Affiliation': 'Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciz397'] 2382,31383692,"Relative importance of prenatal and postnatal determinants of stunting: data mining approaches to the MINIMat cohort, Bangladesh.","INTRODUCTION WHO has set a goal to reduce the prevalence of stunted child growth by 40% by the year 2025. To reach this goal, it is imperative to establish the relative importance of risk factors for stunting to deliver appropriate interventions. Currently, most interventions take place in late infancy and early childhood. This study aimed to identify the most critical prenatal and postnatal determinants of linear growth 0-24 months and the risk factors for stunting at 2 years, and to identify subgroups with different growth trajectories and levels of stunting at 2 years. METHODS Conditional inference tree-based methods were applied to the extensive Maternal and Infant Nutrition Interventions in Matlab trial database with 309 variables of 2723 children, their parents and living conditions, including socioeconomic, nutritional and other biological characteristics of the parents; maternal exposure to violence; household food security; breast and complementary feeding; and measurements of morbidity of the mothers during pregnancy and repeatedly of their children up to 24 months of age. Child anthropometry was measured monthly from birth to 12 months, thereafter quarterly to 24 months. RESULTS Birth length and weight were the most critical factors for linear growth 0-24 months and stunting at 2 years, followed by maternal anthropometry and parental education. Conditions after birth, such as feeding practices and morbidity, were less strongly associated with linear growth trajectories and stunting at 2 years. CONCLUSION The results of this study emphasise the benefit of interventions before conception and during pregnancy to reach a substantial reduction in stunting.",2019,"Conditions after birth, such as feeding practices and morbidity, were less strongly associated with linear growth trajectories and stunting at 2 years. ","['Matlab trial database with 309 variables of 2723 children, their parents and living conditions, including socioeconomic, nutritional and other biological characteristics of the parents; maternal exposure to violence; household food security; breast and complementary feeding; and measurements of morbidity of the mothers during pregnancy and repeatedly of their children up to 24 months of age']",[],"['Birth length and weight', 'Child anthropometry']","[{'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0037464', 'cui_str': 'Factors, Socioeconomic'}, {'cui': 'C0243033', 'cui_str': 'Maternal Exposure'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C3178753', 'cui_str': 'Food Security'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0038847', 'cui_str': 'Complementary Feeding'}, {'cui': 'C0347984', 'cui_str': 'During'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0001779', 'cui_str': 'Age'}]",[],"[{'cui': 'C0419415', 'cui_str': 'Birth length'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}]",2723.0,0.0246863,"Conditions after birth, such as feeding practices and morbidity, were less strongly associated with linear growth trajectories and stunting at 2 years. ","[{'ForeName': 'Pernilla', 'Initials': 'P', 'LastName': 'Svefors', 'Affiliation': ""Women's and Children's Health, Uppsala Universitet, Uppsala, Sweden pernilla.svefors@kbh.uu.se.""}, {'ForeName': 'Oleg', 'Initials': 'O', 'LastName': 'Sysoev', 'Affiliation': 'Department of Computer and Information Sciences, Linkopings universitet, Linkoping, Sweden.'}, {'ForeName': 'Eva-Charlotte', 'Initials': 'EC', 'LastName': 'Ekstrom', 'Affiliation': ""Women's and Children's Health, Uppsala Universitet, Uppsala, Sweden.""}, {'ForeName': 'Lars Ake', 'Initials': 'LA', 'LastName': 'Persson', 'Affiliation': 'Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Shams E', 'Initials': 'SE', 'LastName': 'Arifeen', 'Affiliation': 'Maternal and Child Health Division, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.'}, {'ForeName': 'Ruchira T', 'Initials': 'RT', 'LastName': 'Naved', 'Affiliation': 'Health System and Population Studies Division, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.'}, {'ForeName': 'Anisur', 'Initials': 'A', 'LastName': 'Rahman', 'Affiliation': 'Maternal and Child Health Division, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.'}, {'ForeName': 'Ashraful Islam', 'Initials': 'AI', 'LastName': 'Khan', 'Affiliation': 'Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.'}, {'ForeName': 'Katarina', 'Initials': 'K', 'LastName': 'Selling', 'Affiliation': ""Women's and Children's Health, Uppsala Universitet, Uppsala, Sweden.""}]",BMJ open,['10.1136/bmjopen-2018-025154'] 2383,32753561,"Trends and survival outcomes of robotic, laparoscopic, and open surgery for stage II uterine cancer.","INTRODUCTION A recent randomized clinical trial showed that minimally invasive surgery led to poorer survival compared with open surgery in early stage cervical cancer. We determined the trends in adoption of minimally invasive surgery and 5-year overall survival outcomes after open, laparoscopic-assisted, and robotic-assisted hysterectomy for stage II uterine cancer with cervical stromal involvement. METHODS Data for patients with stage II uterine cancer were acquired from the National Cancer Database from 2010 to 2015. χ 2 testing, Kaplan-Meier methods, and Cox models were used for statistical analyses. RESULTS Of 2949 patients, 44.3% underwent open hysterectomy, 13.9% underwent laparoscopic hysterectomy, and 41.8% underwent robotic hysterectomy. The proportion of robotic cases increased from 26.8% in 2010 to 48.3% in 2015 (annual percent change 10.1%), with a decrease in open hysterectomy from 63.3% to 34.3% (annual percent change -12.5%). The overall 5-year survival was 77.6% in robotic, 76.8% in laparoscopic, and 72.5% in open hysterectomy (p=0.045); however, after adjusting for known prognostic factors, robotic (HR 1.00, 95% CI 0.82 to 1.21; p=0.97) and laparoscopic hysterectomy (HR 1.09, 95% CI 0.83 to 1.44; p=0.54) did not portend for improved survival compared with open hysterectomy. Black women (HR 1.59, 95% CI 1.25 to 2.02; p<0.001) and individuals with co-morbidities (HR 1.45, 95% CI 1.21 to 1.75, p<0.001) had worse adjusted survival and the highest rates of open hysterectomy. CONCLUSION The use of minimally invasive surgery for stage II uterine cancer has increased over time, with comparable adjusted 5-year survival after robotic or laparoscopic hysterectomy compared with open hysterectomy. Black women and those with co-morbidities had lowest rates of minimally invasive surgery and the poorest adjusted survival.",2020,"The use of minimally invasive surgery for stage II uterine cancer has increased over time, with comparable adjusted 5-year survival after robotic or laparoscopic hysterectomy compared with open hysterectomy.","['early stage cervical cancer', 'Of 2949 patients, 44.3% underwent', 'stage II uterine cancer', 'stage II uterine cancer with cervical stromal involvement', 'patients with stage II uterine cancer were acquired from the National Cancer Database from 2010 to 2015']","['open hysterectomy', 'laparoscopic hysterectomy', 'laparoscopic-assisted, and robotic-assisted hysterectomy', 'robotic hysterectomy', 'minimally invasive surgery', 'robotic, laparoscopic, and open surgery']","['5-year survival', 'overall 5-year survival', 'open hysterectomy', 'poorer survival', 'survival', 'laparoscopic hysterectomy', 'adjusted survival', 'proportion of robotic cases', '5-year overall survival outcomes', 'individuals with co-morbidities']","[{'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0278799', 'cui_str': 'Endometrial cancer stage II'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0439661', 'cui_str': 'Acquired'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}]","[{'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0282624', 'cui_str': 'Procedures, Minimally Invasive Surgical'}, {'cui': 'C0348025', 'cui_str': 'Open approach'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}]",2949.0,0.377133,"The use of minimally invasive surgery for stage II uterine cancer has increased over time, with comparable adjusted 5-year survival after robotic or laparoscopic hysterectomy compared with open hysterectomy.","[{'ForeName': 'Mary Kathryn', 'Initials': 'MK', 'LastName': 'Abel', 'Affiliation': 'School of Medicine, University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'John K', 'Initials': 'JK', 'LastName': 'Chan', 'Affiliation': 'Division of Gynecologic Oncology, Palo Alto Medical Foundation, California Pacific Medical Center, Sutter Health, San Francisco, California, USA chanjohn@sutterhealth.org.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Chow', 'Affiliation': 'Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California, USA.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Darcy', 'Affiliation': 'Gynecologic Cancer Center of Excellence, Department of Obstetrics & Gynecology, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.'}, {'ForeName': 'Chunqiao', 'Initials': 'C', 'LastName': 'Tian', 'Affiliation': 'Gynecologic Cancer Center of Excellence, Department of Obstetrics & Gynecology, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.'}, {'ForeName': 'Daniel S', 'Initials': 'DS', 'LastName': 'Kapp', 'Affiliation': 'Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California, USA.'}, {'ForeName': 'Amandeep K', 'Initials': 'AK', 'LastName': 'Mann', 'Affiliation': 'Division of Gynecologic Oncology, Palo Alto Medical Foundation Research Institute, Palo Alto, California, USA.'}, {'ForeName': 'Cheng-I', 'Initials': 'CI', 'LastName': 'Liao', 'Affiliation': 'Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.'}]",International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,['10.1136/ijgc-2020-001646'] 2384,32753571,Are There Lower Complication Rates with Bidirectional Barbed Suture in Total Knee Arthroplasty Incision Closure? A Randomized Clinical Trial.,"BACKGROUND The use of barbed suture in total knee arthroplasty (TKA) remains controversial. We performed a prospective study to investigate the clinical outcomes of bidirectional barbed suture for incision closure in TKA. MATERIAL AND METHODS We conducted a single-center, randomized controlled trial to determine the efficiency and safety of barbed suture in TKA at our institution between December 2017 and April 2019. Eligible patients were randomly assigned to different suture methods for skin closure. Randomization was conducted via computerized randomization list. Our primary endpoint was the incidence of wound complications within 3 months of surgery. This trial was registered at ClinicalTrials.gov, number ChiCTR-IPR-17013677. RESULTS A total of 582 patients were enrolled, consisting of 193 who received full-layer barbed suture (group A), 195 who received barbed suturing of the joint capsule (group B), and 194 who received suturing of the joint capsule by traditional absorbable suture (group C). The incidence of incision complications in group A (19.7%) was significantly higher than that in group B (7.2%) and C (9.3%) (P<0.0125). The incidence rate for incision complications in group B was similar to that in group C (P>0.0125). The time for incision closure in groups A (13.5±2.0 min) and B (16.1±1.9 min) was significantly shorter than that in group C (25.0±2.0 min) (P<0.001). CONCLUSIONS The use of full-thickness bidirectional barbed suture for incision closure after TKA may increase postoperative incision complications, and therefore is not recommended. However, the use of barbed suture for the joint capsule has shown effectiveness, reducing suture time with no increase in incision complications.",2020,The incidence rate for incision complications in group B was similar to that in group C (P>0.0125).,"['total knee arthroplasty (TKA', 'at our institution between December 2017 and April 2019', 'Eligible patients', '582 patients were enrolled, consisting of 193 who received']","['barbed suturing of the joint capsule', 'suturing of the joint capsule by traditional absorbable suture', 'bidirectional barbed suture for incision closure in TKA', 'suture methods for skin closure', 'barbed suture', 'Bidirectional Barbed Suture', 'full-thickness bidirectional barbed suture for incision closure after TKA', 'barbed suture in TKA', 'full-layer barbed suture']","['suture time', 'efficiency and safety', 'incidence rate for incision complications', 'incidence of wound complications', 'incision complications', 'postoperative incision complications', 'time for incision closure', 'incidence of incision complications', 'Complication Rates']","[{'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}]","[{'cui': 'C0206207', 'cui_str': 'Structure of articular capsule'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0461643', 'cui_str': 'Absorbable suture'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0439809', 'cui_str': 'Full thickness'}]","[{'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}]",582.0,0.205795,The incidence rate for incision complications in group B was similar to that in group C (P>0.0125).,"[{'ForeName': 'Shuo', 'Initials': 'S', 'LastName': 'Feng', 'Affiliation': 'Department of Orthopedic Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China (mainland).'}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Orthopedic Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China (mainland).'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Zhang', 'Affiliation': 'Postgraduate Department, Harbin Medical University, Harbin, Heilongjiang, China (mainland).'}, {'ForeName': 'Zhi', 'Initials': 'Z', 'LastName': 'Yang', 'Affiliation': 'Department of Orthopedic Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China (mainland).'}, {'ForeName': 'Xiang-Yang', 'Initials': 'XY', 'LastName': 'Chen', 'Affiliation': 'Department of Orthopedic Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China (mainland).'}, {'ForeName': 'Guo-Chun', 'Initials': 'GC', 'LastName': 'Zha', 'Affiliation': 'Department of Orthopedic Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China (mainland).'}]",Medical science monitor : international medical journal of experimental and clinical research,['10.12659/MSM.922783'] 2385,32753637,Effects of L-theanine-caffeine combination on sustained attention and inhibitory control among children with ADHD: a proof-of-concept neuroimaging RCT.,"We examined the acute effects of L-theanine, caffeine and their combination on sustained attention, inhibitory control and overall cognition in boys with attention deficit hyperactivity disorder (ADHD). L-Theanine (2.5 mg/kg), caffeine (2.0 mg/kg), their combination and a placebo were administered in a randomized four-way repeated-measures crossover with washout, to five boys (8-15 years) with ADHD. Functional magnetic resonance imaging (fMRI) was performed during a Go/NoGo task and a Stop-signal task ~ 1 h post-dose. NIH Cognition Toolbox was administered ~ 2 h post-dose. Treatment vs. placebo effects were examined in multi-level mixed-effects models. L-Theanine improved total cognition composite in NIH Cognition Toolbox (p = 0.040) vs. placebo. Caffeine worsened and L-theanine had a trend of worsening inhibitory control (i.e. increased Stop-signal reaction time; p = 0.031 and p = 0.053 respectively). L-Theanine-caffeine combination improved total cognition composite (p = 0.041), d-prime in the Go/NoGo task (p = 0.033) and showed a trend of improvement of inhibitory control (p = 0.080). L-Theanine-caffeine combination was associated with decreased task-related reactivity of a brain network associated with mind wandering (i.e. default mode network). L-Theanine-caffeine combination may be a potential therapeutic option for ADHD-associated impairments in sustained attention, inhibitory control and overall cognitive performance.",2020,L-Theanine improved total cognition composite in NIH Cognition Toolbox (p = 0.040) vs. placebo.,"['children with ADHD', 'boys with attention deficit hyperactivity disorder (ADHD']","['L-Theanine-caffeine combination', 'L-Theanine-caffeine', 'caffeine', 'Caffeine', 'L-Theanine', 'Functional magnetic resonance imaging (fMRI', 'L-theanine-caffeine combination', 'L-theanine, caffeine and their combination', 'placebo']","['worsening inhibitory control', 'total cognition composite', 'total cognition composite in NIH Cognition Toolbox', 'sustained attention and inhibitory control']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0870221', 'cui_str': 'Male child'}]","[{'cui': 'C0076380', 'cui_str': 'theanine'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0027468', 'cui_str': 'United States National Institutes of Health'}, {'cui': 'C0589099', 'cui_str': 'Sustained attention'}]",,0.0661708,L-Theanine improved total cognition composite in NIH Cognition Toolbox (p = 0.040) vs. placebo.,"[{'ForeName': 'Chanaka N', 'Initials': 'CN', 'LastName': 'Kahathuduwa', 'Affiliation': 'Department of Laboratory Sciences and Primary Care, School of Health Professions, Texas Tech University Health Sciences Center, 3601 4th Street, Lubbock, TX, USA. chanaka.kahathuduwa@ttuhsc.edu.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Wakefield', 'Affiliation': 'Department of Psychiatry, School of Medicine, Texas Tech University Health Sciences Center, 3601 4th Street, Lubbock, TX, USA.'}, {'ForeName': 'Blake D', 'Initials': 'BD', 'LastName': 'West', 'Affiliation': 'Department of Human Development and Family Studies, College of Human Sciences, Texas Tech University, Lubbock, TX, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Blume', 'Affiliation': 'Department of Human Development and Family Studies, College of Human Sciences, Texas Tech University, Lubbock, TX, USA.'}, {'ForeName': 'Tharaka L', 'Initials': 'TL', 'LastName': 'Dassanayake', 'Affiliation': 'Department of Physiology, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka.'}, {'ForeName': 'Vajira S', 'Initials': 'VS', 'LastName': 'Weerasinghe', 'Affiliation': 'Department of Physiology, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Mastergeorge', 'Affiliation': 'Department of Human Development and Family Studies, College of Human Sciences, Texas Tech University, Lubbock, TX, USA.'}]",Scientific reports,['10.1038/s41598-020-70037-7'] 2386,32753750,Transcriptomic profile of adverse neurodevelopmental outcomes after neonatal encephalopathy.,"A rapid and early diagnostic test to identify the encephalopathic babies at risk of adverse outcome may accelerate the development of neuroprotectants. We examined if a whole blood transcriptomic signature measured soon after birth, predicts adverse neurodevelopmental outcome eighteen months after neonatal encephalopathy. We performed next generation sequencing on whole blood ribonucleic acid obtained within six hours of birth from the first 47 encephalopathic babies recruited to the Hypothermia for Encephalopathy in Low and middle-income countries (HELIX) trial. Two infants with blood culture positive sepsis were excluded, and the data from remaining 45 were analysed. A total of 855 genes were significantly differentially expressed between the good and adverse outcome groups, of which RGS1 and SMC4 were the most significant. Biological pathway analysis adjusted for gender, trial randomisation allocation (cooling therapy versus usual care) and estimated blood leukocyte proportions revealed over-representation of genes from pathways related to melatonin and polo-like kinase in babies with adverse outcome. These preliminary data suggest that transcriptomic profiling may be a promising tool for rapid risk stratification in neonatal encephalopathy. It may provide insights into biological mechanisms and identify novel therapeutic targets for neuroprotection.",2020,"A total of 855 genes were significantly differentially expressed between the good and adverse outcome groups, of which RGS1 and SMC4 were the most significant.","['Two infants with blood culture positive sepsis', 'neonatal encephalopathy', '47 encephalopathic babies recruited to the Hypothermia for Encephalopathy in Low and middle-income countries (HELIX) trial']",[],[],"[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0740299', 'cui_str': 'Blood culture positive for microorganism'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0235820', 'cui_str': 'Neonatal encephalopathy'}, {'cui': 'C0020672', 'cui_str': 'Hypothermia'}, {'cui': 'C0085584', 'cui_str': 'Encephalopathy'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],[],2.0,0.128731,"A total of 855 genes were significantly differentially expressed between the good and adverse outcome groups, of which RGS1 and SMC4 were the most significant.","[{'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Montaldo', 'Affiliation': 'Department of Brain Sciences, Centre for Perinatal Neuroscience, Imperial College London, London, UK. p.montaldo@imperial.ac.uk.'}, {'ForeName': 'Aubrey', 'Initials': 'A', 'LastName': 'Cunnington', 'Affiliation': 'Paediatric Infectious Diseases, Department of Infectious Diseases, Imperial College London, London, UK.'}, {'ForeName': 'Vania', 'Initials': 'V', 'LastName': 'Oliveira', 'Affiliation': 'Department of Brain Sciences, Centre for Perinatal Neuroscience, Imperial College London, London, UK.'}, {'ForeName': 'Ravi', 'Initials': 'R', 'LastName': 'Swamy', 'Affiliation': 'Department of Brain Sciences, Centre for Perinatal Neuroscience, Imperial College London, London, UK.'}, {'ForeName': 'Prathik', 'Initials': 'P', 'LastName': 'Bandya', 'Affiliation': 'Neonatal Medicine, Indira Gandhi Institute of Child Health, Bangalore, Karnataka, India.'}, {'ForeName': 'Stuti', 'Initials': 'S', 'LastName': 'Pant', 'Affiliation': 'Department of Brain Sciences, Centre for Perinatal Neuroscience, Imperial College London, London, UK.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Lally', 'Affiliation': 'Department of Brain Sciences, Centre for Perinatal Neuroscience, Imperial College London, London, UK.'}, {'ForeName': 'Phoebe', 'Initials': 'P', 'LastName': 'Ivain', 'Affiliation': 'Department of Brain Sciences, Centre for Perinatal Neuroscience, Imperial College London, London, UK.'}, {'ForeName': 'Josephine', 'Initials': 'J', 'LastName': 'Mendoza', 'Affiliation': 'Department of Brain Sciences, Centre for Perinatal Neuroscience, Imperial College London, London, UK.'}, {'ForeName': 'Gaurav', 'Initials': 'G', 'LastName': 'Atreja', 'Affiliation': 'Department of Brain Sciences, Centre for Perinatal Neuroscience, Imperial College London, London, UK.'}, {'ForeName': 'Vadakepat', 'Initials': 'V', 'LastName': 'Padmesh', 'Affiliation': 'Neonatal Medicine, Institute of Obstetrics and Gynaecology, Madras Medical College, Chennai, Tamil Nadu, India.'}, {'ForeName': 'Mythili', 'Initials': 'M', 'LastName': 'Baburaj', 'Affiliation': 'Neonatal Medicine, Institute of Obstetrics and Gynaecology, Madras Medical College, Chennai, Tamil Nadu, India.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Sebastian', 'Affiliation': 'Neonatal Medicine, Institute of Child Health, Madras Medical College, Tamil Nadu, Chennai, India.'}, {'ForeName': 'Indiramma', 'Initials': 'I', 'LastName': 'Yasashwi', 'Affiliation': 'Neonatal Medicine, Indira Gandhi Institute of Child Health, Bangalore, Karnataka, India.'}, {'ForeName': 'Chinnathambi', 'Initials': 'C', 'LastName': 'Kamalarathnam', 'Affiliation': 'Neonatal Medicine, Institute of Obstetrics and Gynaecology, Madras Medical College, Chennai, Tamil Nadu, India.'}, {'ForeName': 'Rema', 'Initials': 'R', 'LastName': 'Chandramohan', 'Affiliation': 'Neonatal Medicine, Institute of Obstetrics and Gynaecology, Madras Medical College, Chennai, Tamil Nadu, India.'}, {'ForeName': 'Sundaram', 'Initials': 'S', 'LastName': 'Mangalabharathi', 'Affiliation': 'Neonatal Medicine, Institute of Obstetrics and Gynaecology, Madras Medical College, Chennai, Tamil Nadu, India.'}, {'ForeName': 'Kumutha', 'Initials': 'K', 'LastName': 'Kumaraswami', 'Affiliation': 'Neonatal Medicine, Institute of Obstetrics and Gynaecology, Madras Medical College, Chennai, Tamil Nadu, India.'}, {'ForeName': 'Shobha', 'Initials': 'S', 'LastName': 'Kumar', 'Affiliation': 'Neonatal Medicine, Institute of Obstetrics and Gynaecology, Madras Medical College, Chennai, Tamil Nadu, India.'}, {'ForeName': 'Naveen', 'Initials': 'N', 'LastName': 'Benakappa', 'Affiliation': 'Neonatal Medicine, Indira Gandhi Institute of Child Health, Bangalore, Karnataka, India.'}, {'ForeName': 'Swati', 'Initials': 'S', 'LastName': 'Manerkar', 'Affiliation': 'Neonatal Medicine, Sion Medical College, Mumbai, India.'}, {'ForeName': 'Jayashree', 'Initials': 'J', 'LastName': 'Mondhkar', 'Affiliation': 'Neonatal Medicine, Sion Medical College, Mumbai, India.'}, {'ForeName': 'Vinayagam', 'Initials': 'V', 'LastName': 'Prakash', 'Affiliation': 'Neonatal Medicine, Institute of Obstetrics and Gynaecology, Madras Medical College, Chennai, Tamil Nadu, India.'}, {'ForeName': 'Mohammed', 'Initials': 'M', 'LastName': 'Sajjid', 'Affiliation': 'Neonatal Medicine, Institute of Obstetrics and Gynaecology, Madras Medical College, Chennai, Tamil Nadu, India.'}, {'ForeName': 'Arasar', 'Initials': 'A', 'LastName': 'Seeralar', 'Affiliation': 'Neonatal Medicine, Institute of Child Health, Madras Medical College, Tamil Nadu, Chennai, India.'}, {'ForeName': 'Ismat', 'Initials': 'I', 'LastName': 'Jahan', 'Affiliation': 'Neonatal Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.'}, {'ForeName': 'Sadeka Choudhury', 'Initials': 'SC', 'LastName': 'Moni', 'Affiliation': 'Neonatal Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.'}, {'ForeName': 'Mohammod', 'Initials': 'M', 'LastName': 'Shahidullah', 'Affiliation': 'Neonatal Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.'}, {'ForeName': 'Radhika', 'Initials': 'R', 'LastName': 'Sujatha', 'Affiliation': 'Neonatal Medicine, Government Medical College, Thiruvananthapuram, Kerala, India.'}, {'ForeName': 'Manigandan', 'Initials': 'M', 'LastName': 'Chandrasekaran', 'Affiliation': 'Department of Brain Sciences, Centre for Perinatal Neuroscience, Imperial College London, London, UK.'}, {'ForeName': 'Siddarth', 'Initials': 'S', 'LastName': 'Ramji', 'Affiliation': 'Neonatal Medicine, Maulana Azad Medical College, New Delhi, Delhi, India.'}, {'ForeName': 'Seetha', 'Initials': 'S', 'LastName': 'Shankaran', 'Affiliation': 'Neonatal-Perinatal Medicine, Wayne State University, Detroit, MI, USA.'}, {'ForeName': 'Myrsini', 'Initials': 'M', 'LastName': 'Kaforou', 'Affiliation': 'Paediatric Infectious Diseases, Department of Infectious Diseases, Imperial College London, London, UK.'}, {'ForeName': 'Jethro', 'Initials': 'J', 'LastName': 'Herberg', 'Affiliation': 'Paediatric Infectious Diseases, Department of Infectious Diseases, Imperial College London, London, UK.'}, {'ForeName': 'Sudhin', 'Initials': 'S', 'LastName': 'Thayyil', 'Affiliation': 'Department of Brain Sciences, Centre for Perinatal Neuroscience, Imperial College London, London, UK.'}]",Scientific reports,['10.1038/s41598-020-70131-w'] 2387,32421785,Prognostic Value of Masked Uncontrolled Hypertension Defined by Different Ambulatory Blood Pressure Criteria.,"BACKGROUND Masked uncontrolled hypertension (MUCH), that is, nonhypertensive clinic but high out-of-office blood pressure (BP) in treated patients is at increased cardiovascular risk than controlled hypertension (CH), that is, nonhypertensive clinic and out-of-office BP. Using ambulatory BP, MUCH can be defined as daytime and/or nighttime and/or 24-hour BP above thresholds. It is unclear whether different definitions of MUCH have similar prognostic information. This study assessed the prognostic value of MUCH defined by different ambulatory BP criteria. METHODS Cardiovascular events were evaluated in 738 treated hypertensive patients with nonhypertensive clinic BP. Among them, participants were classified as having CH or daytime MUCH (BP ≥135/85 mm Hg) regardless of nighttime BP (group 1), nighttime MUCH (BP ≥120/70 mm Hg) regardless of daytime BP (group 2), 24-hour MUCH (BP ≥130/80 mm Hg) regardless of daytime or nighttime BP (group 3), daytime MUCH only (group 4), nighttime MUCH only (group 5), and daytime + nighttime MUCH (group 6). RESULTS We detected 215 (29%), 357 (48.5%), 275 (37%), 42 (5.5%),184 (25%) and 173 (23.5%) patients with MUCH from group 1 to 6, respectively. During the follow-up (10 ± 5 years), 148 events occurred in patients with CH and MUCH. After adjustment for covariates, compared with patients with CH, the adjusted hazard ratio (95% confidence interval) for cardiovascular events was 2.01 (1.45-2.79), 1.53 (1.09-2.15), 1.69 (1.22-2.34), 1.52 (0.80-2.91), 1.15 (0.74-1.80), and 2.29 (1.53-3.42) from group 1 to 6, respectively. CONCLUSIONS The prognostic impact of MUCH defined according to various ambulatory BP definitions may be different.",2020,"After adjustment for covariates, compared with patients with CH, the adjusted hazard ratio (95% confidence interval) for cardiovascular events was 2.01 (1.45-2.79), 1.53 (1.09-2.15), 1.69 (1.22-2.34), 1.52 (0.80-2.91), 1.15 (0.74-1.80), and 2.29 (1.53-3.42) from group 1 to 6, respectively. ",['738 treated hypertensive patients with nonhypertensive clinic BP'],[],"['cardiovascular events', 'nighttime MUCH (BP ≥120/70 mm Hg) regardless of daytime BP', '24-hour MUCH (BP ≥130/80 mm Hg) regardless of daytime or nighttime BP', 'daytime and/or nighttime and/or 24-hour BP above thresholds']","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]",[],"[{'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C1868885', 'cui_str': 'Uncontrolled hypertension'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C1282173', 'cui_str': '24 hour blood pressure'}, {'cui': 'C0443129', 'cui_str': 'Above threshold'}]",738.0,0.0362822,"After adjustment for covariates, compared with patients with CH, the adjusted hazard ratio (95% confidence interval) for cardiovascular events was 2.01 (1.45-2.79), 1.53 (1.09-2.15), 1.69 (1.22-2.34), 1.52 (0.80-2.91), 1.15 (0.74-1.80), and 2.29 (1.53-3.42) from group 1 to 6, respectively. ","[{'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Coccina', 'Affiliation': 'Department of Medical, Oral and Biotechnological Sciences, University ""Gabriele d\'Annunzio"", Chieti-Pescara, Chieti, Italy.'}, {'ForeName': 'Anna M', 'Initials': 'AM', 'LastName': 'Pierdomenico', 'Affiliation': 'Department of Medicine and Aging Sciences, University ""Gabriele d\'Annunzio"", Chieti-Pescara, Chieti, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Cuccurullo', 'Affiliation': 'Department of Medicine and Aging Sciences, University ""Gabriele d\'Annunzio"", Chieti-Pescara, Chieti, Italy.'}, {'ForeName': 'Jacopo', 'Initials': 'J', 'LastName': 'Pizzicannella', 'Affiliation': 'Department of Medical, Oral and Biotechnological Sciences, University ""Gabriele d\'Annunzio"", Chieti-Pescara, Chieti, Italy.'}, {'ForeName': 'Rosalinda', 'Initials': 'R', 'LastName': 'Madonna', 'Affiliation': 'Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Oriana', 'Initials': 'O', 'LastName': 'Trubiani', 'Affiliation': 'Department of Medical, Oral and Biotechnological Sciences, University ""Gabriele d\'Annunzio"", Chieti-Pescara, Chieti, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Cipollone', 'Affiliation': 'Department of Medicine and Aging Sciences, University ""Gabriele d\'Annunzio"", Chieti-Pescara, Chieti, Italy.'}, {'ForeName': 'Sante D', 'Initials': 'SD', 'LastName': 'Pierdomenico', 'Affiliation': 'Department of Medical, Oral and Biotechnological Sciences, University ""Gabriele d\'Annunzio"", Chieti-Pescara, Chieti, Italy.'}]",American journal of hypertension,['10.1093/ajh/hpaa078'] 2388,31481364,Improving cardiovascular disease risk communication in NHS Health Checks: a qualitative study.,"OBJECTIVE The NHS Health Check programme is a public screening and prevention initiative in England to detect early signs of cardiovascular ill health among healthy adults. We aimed to explore patient perspectives and experiences of a personalised Risk Report designed to improve cardiovascular risk communication in the NHS Health Check. DESIGN AND SETTING This is a qualitative study with NHS Health Check attendees in three general practices in the London Borough of Newham. INTERVENTION AND PARTICIPANTS A personalised Risk Report for the NHS Health Check was developed to improve communication of results and advice. The Risk Report was embedded in the electronic health record, printed with auto-filled results and used as a discussion aid during the NHS Health Check, and was a take-home record of information and advice on risk reduction for the attendees. 18 purposively sampled socially diverse participants took part in semistructured interviews, which were analysed thematically. RESULTS For most participants, the NHS Health Check was an opportunity for reassurance and assessment, and the Risk Report was an enduring record that supported risk understanding, with impact beyond the individual. For a minority, ambivalence towards the Risk Report occurred in the context of attending for other reasons, and risk and lifestyle advice were not internalised or acted on. CONCLUSION Our findings demonstrate the potential of a personalised Risk Report as a useful intervention in NHS Health Checks for enhancing patient understanding of cardiovascular risk and strategies for risk reduction. Also highlighted are the challenges that must be overcome to ensure transferability of these benefits to diverse patient groups. TRIAL REGISTRATION NUMBER NCT02486913.",2019,Our findings demonstrate the potential of a personalised Risk Report as a useful intervention in NHS Health Checks for enhancing patient understanding of cardiovascular risk and strategies for risk reduction.,"['NHS Health Checks', 'healthy adults', 'NHS Health Check attendees in three general practices in the London Borough of Newham', '18 purposively sampled']",[],['cardiovascular risk communication'],"[{'cui': 'C0796085', 'cui_str': 'Nance-Horan syndrome'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1283174', 'cui_str': 'Checking - action'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0015607', 'cui_str': 'Family practice'}, {'cui': 'C0023973', 'cui_str': 'London'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]",[],"[{'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0009452', 'cui_str': 'Communication'}]",18.0,0.0227107,Our findings demonstrate the potential of a personalised Risk Report as a useful intervention in NHS Health Checks for enhancing patient understanding of cardiovascular risk and strategies for risk reduction.,"[{'ForeName': 'Meredith K D', 'Initials': 'MKD', 'LastName': 'Hawking', 'Affiliation': 'Centre for Primary Care and Public Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Timmis', 'Affiliation': 'NIHR Cardiovascular Biomedical Research Unit, Barts Heart Centre, London, UK.'}, {'ForeName': 'Fae', 'Initials': 'F', 'LastName': 'Wilkins', 'Affiliation': 'Centre for Primary Care and Public Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.'}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Potter', 'Affiliation': 'Centre for Primary Care and Public Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Robson', 'Affiliation': 'Centre for Primary Care and Public Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK j.robson@qmul.ac.uk.'}]",BMJ open,['10.1136/bmjopen-2018-026058'] 2389,31511069,Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.,"BACKGROUND There is strong evidence that immunotherapy-mediated tumor rejection can be driven by tumor-specific CD8+ T cells reinvigorated to recognize neoantigens derived from tumor somatic mutations. Thus, the frequencies or characteristics of tumor-reactive, mutation-specific CD8+ T cells could be used as biomarkers of an anti-tumor response. However, such neoantigen-specific T cells are difficult to reliably identify due to their low frequency in peripheral blood and wide range of potential epitope specificities. METHODS Peripheral blood mononuclear cells (PBMC) from 14 non-small cell lung cancer (NSCLC) patients were collected pre- and post-treatment with the anti-PD-L1 antibody atezolizumab. Using whole exome sequencing and RNA sequencing we identified tumor neoantigens that are predicted to bind to major histocompatibility complex class I (MHC-I) and utilized mass cytometry, together with cellular 'barcoding', to profile immune cells from patients with objective response to therapy (n = 8) and those with progressive disease (n = 6). In parallel, a highly-multiplexed combinatorial tetramer staining was used to screen antigen-specific CD8+ T cells in peripheral blood for 782 candidate tumor neoantigens and 71 known viral-derived control peptide epitopes across all patient samples. RESULTS No significant treatment- or response associated phenotypic difference were measured in bulk CD8+ T cells. Multiplexed peptide-MHC multimer staining detected 20 different neoantigen-specific T cell populations, as well as T cells specific for viral control antigens. Not only were neoantigen-specific T cells more frequently detected in responding patients, their phenotypes were also almost entirely distinct. Neoantigen-specific T cells from responder patients typically showed a differentiated effector phenotype, most like Cytomegalovirus (CMV) and some types of Epstein-Barr virus (EBV)-specific CD8+ T cells. In contrast, more memory-like phenotypic profiles were observed for neoantigen-specific CD8+ T cells from patients with progressive disease. CONCLUSION This study demonstrates that neoantigen-specific T cells can be detected in peripheral blood in non-small cell lung cancer (NSCLC) patients during anti-PD-L1 therapy. Patients with an objective response had an enrichment of neoantigen-reactive T cells and these cells showed a phenotype that differed from patients without a response. These findings suggest the ex vivo identification, characterization, and longitudinal follow-up of rare tumor-specific differentiated effector neoantigen-specific T cells may be useful in predicting response to checkpoint blockade. TRIAL REGISTRATION POPLAR trial NCT01903993 .",2019,"Neoantigen-specific T cells from responder patients typically showed a differentiated effector phenotype, most like Cytomegalovirus (CMV) and some types of Epstein-Barr virus (EBV)-specific CD8+ T cells.","['Peripheral blood mononuclear cells (PBMC) from 14 non-small cell lung cancer (NSCLC) patients were', 'patients with objective response to therapy (n\xa0=\u20098) and those with progressive disease (n\xa0=\u20096', 'patients with progressive disease']",['collected pre- and post-treatment with the anti-PD-L1 antibody atezolizumab'],"['neoantigen-specific T cells', 'bulk CD8+ T cells', 'memory-like phenotypic profiles', 'enrichment of neoantigen-reactive T cells']","[{'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C4055433', 'cui_str': 'atezolizumab'}]","[{'cui': 'C0312555', 'cui_str': 'Neoantigen'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0242629', 'cui_str': 'Lymphocyte positive for CD8 antigen'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0205332', 'cui_str': 'Reactive'}]",,0.0559435,"Neoantigen-specific T cells from responder patients typically showed a differentiated effector phenotype, most like Cytomegalovirus (CMV) and some types of Epstein-Barr virus (EBV)-specific CD8+ T cells.","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Fehlings', 'Affiliation': 'immunoSCAPE Pte Ltd, Singapore, Singapore.'}, {'ForeName': 'Suchit', 'Initials': 'S', 'LastName': 'Jhunjhunwala', 'Affiliation': 'Genentech, 1 DNA way, South San Francisco, CA, 94080, USA.'}, {'ForeName': 'Marcin', 'Initials': 'M', 'LastName': 'Kowanetz', 'Affiliation': 'Genentech, 1 DNA way, South San Francisco, CA, 94080, USA.'}, {'ForeName': 'William E', 'Initials': 'WE', 'LastName': ""O'Gorman"", 'Affiliation': 'Genentech, 1 DNA way, South San Francisco, CA, 94080, USA.'}, {'ForeName': 'Priti S', 'Initials': 'PS', 'LastName': 'Hegde', 'Affiliation': 'Genentech, 1 DNA way, South San Francisco, CA, 94080, USA.'}, {'ForeName': 'Hermi', 'Initials': 'H', 'LastName': 'Sumatoh', 'Affiliation': 'immunoSCAPE Pte Ltd, Singapore, Singapore.'}, {'ForeName': 'Boon Heng', 'Initials': 'BH', 'LastName': 'Lee', 'Affiliation': 'immunoSCAPE Pte Ltd, Singapore, Singapore.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Nardin', 'Affiliation': 'immunoSCAPE Pte Ltd, Singapore, Singapore.'}, {'ForeName': 'Etienne', 'Initials': 'E', 'LastName': 'Becht', 'Affiliation': 'Agency for Science, Technology and Research (A*STAR), Singapore Immunology Network (SIgN), Singapore, Singapore.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Flynn', 'Affiliation': 'Genentech, 1 DNA way, South San Francisco, CA, 94080, USA.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Ballinger', 'Affiliation': 'immunoSCAPE Pte Ltd, Singapore, Singapore.'}, {'ForeName': 'Evan W', 'Initials': 'EW', 'LastName': 'Newell', 'Affiliation': 'immunoSCAPE Pte Ltd, Singapore, Singapore.'}, {'ForeName': 'Mahesh', 'Initials': 'M', 'LastName': 'Yadav', 'Affiliation': 'Genentech, 1 DNA way, South San Francisco, CA, 94080, USA. yadav.mahesh@gene.com.'}]",Journal for immunotherapy of cancer,['10.1186/s40425-019-0695-9'] 2390,31605877,Lifestyle factors modulate postprandial hypertriglyceridemia: From the CORDIOPREV study.,"BACKGROUND AND AIMS Recent evidence suggests that postprandial hypertriglyceridemia (PPT) is associated with the incidence of CVD. Several non-modifiable factors (genetics, age, gender) and lifestyle factors (physical activity, smoking, regular alcohol) have shown their ability to modulate PPT. We evaluate the influence of regular alcohol intake, physical activity and smoking habit modulating PPT in the CORDIOPREV study (NCT00924937). METHODS 1002 patients were subject to an oral fat load test meal and serial blood samples were drawn at 0, 1, 2, 3 and 4 h during postprandial state. A PPT concentration above 2.5 mmol/L (220 mg/dL) at any time point has been established as a detrimental response. Alcohol consumption was defined as non-drinkers, moderate and severe intake; regular physical activity exceeding than or lower than 1000 MET/week; smoking habit was classified in current, never, recent ex-smokers and long-term ex-smokers. RESULTS The prevalence of undesirable PPT response was 68% in current, 58% in recent ex-smokers, 49% in long-term ex-smokers and 48% in never smokers (p < 0.001). Current and recent ex-smokers displayed higher PPT response as well as a greater area under the curve (AUC) and higher incremental (iAUC) of triglycerides (TG) compared with long-term ex-smokers and never smokers (p < 0.05), without differences among these subgroups. No differences were observed in the magnitude of PPT according to regular physical activity or alcohol intake habits. CONCLUSIONS Smoking is an independent risk factor modulating the magnitude of PPT. However, after tobacco cessation, ex-smokers show a progressive decrease on their PPT to reach levels similar to those of never smokers.",2019,"Current and recent ex-smokers displayed higher PPT response as well as a greater area under the curve (AUC) and higher incremental (iAUC) of triglycerides (TG) compared with long-term ex-smokers and never smokers (p < 0.05), without differences among these subgroups.",['1002 patients'],[],"['postprandial hypertriglyceridemia', 'greater area under the curve (AUC) and higher incremental (iAUC) of triglycerides (TG', 'prevalence of undesirable PPT response', 'regular physical activity or alcohol intake habits', 'PPT response', 'Alcohol consumption']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]",[],"[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0020557', 'cui_str': 'Hypertriglyceridemia'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0032334', 'cui_str': 'podofilox'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0018464', 'cui_str': 'Habits'}]",1002.0,0.0132182,"Current and recent ex-smokers displayed higher PPT response as well as a greater area under the curve (AUC) and higher incremental (iAUC) of triglycerides (TG) compared with long-term ex-smokers and never smokers (p < 0.05), without differences among these subgroups.","[{'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Leon-Acuña', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Córdoba, Spain.'}, {'ForeName': 'Jose D', 'Initials': 'JD', 'LastName': 'Torres-Peña', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Córdoba, Spain.'}, {'ForeName': 'Juan F', 'Initials': 'JF', 'LastName': 'Alcala-Diaz', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Córdoba, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Vals-Delgado', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Córdoba, Spain.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Roncero-Ramos', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Córdoba, Spain.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Yubero-Serrano', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Córdoba, Spain.'}, {'ForeName': 'Francisco J', 'Initials': 'FJ', 'LastName': 'Tinahones', 'Affiliation': 'CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Córdoba, Spain; Endocrinology and Nutrition Unit, Biomedical Research Institute of Malaga (IBIMA), Virgen de la Victoria University Hospital, Malaga, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Castro-Clerico', 'Affiliation': 'Biochemistry Laboratory and Reina Sofia University Hospital, Cordoba, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Delgado-Lista', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Córdoba, Spain.'}, {'ForeName': 'Jose M', 'Initials': 'JM', 'LastName': 'Ordovas', 'Affiliation': 'Nutrition and Genomics Laboratory, J.M.-US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA; IMDEA Alimentación, Madrid, Spain; CNIC, Madrid, Spain.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Lopez-Miranda', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Córdoba, Spain.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Perez-Martinez', 'Affiliation': 'Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Córdoba, Spain. Electronic address: pabloperez@uco.es.'}]",Atherosclerosis,['10.1016/j.atherosclerosis.2019.09.025'] 2391,32745493,Optimal timing of postoperative patient telephone calls after Mohs micrographic surgery: A randomized controlled trial.,,2020,,['postoperative patient telephone calls after Mohs micrographic surgery'],[],[],"[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0079850', 'cui_str': 'Mohs surgery'}]",[],[],,0.218998,,"[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Bednarek', 'Affiliation': 'Department of Dermatology, University of Missouri, Columbia MO. Electronic address: rbednare11@gmail.com.'}, {'ForeName': 'Cory', 'Initials': 'C', 'LastName': 'Jonak', 'Affiliation': 'University of Missouri School of Medicine, Columbia MO.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Golda', 'Affiliation': 'Department of Dermatology, University of Missouri, Columbia MO.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.07.106'] 2392,32745532,"Double high-level disinfection versus liquid chemical sterilization for reprocessing of duodenoscopes used for ERCP: a prospective, randomized study.","BACKGROUND AND AIMS The potential for transmission of pathogenic organisms is a problem inherent to the current reusable duodenoscope design. Recent outbreaks of multidrug resistant pathogenic organisms transmitted via duodenoscopes has brought to light the urgency of this problem. Microbiological culturing of duodenoscopes and reprocessing with repeat high-level disinfection or liquid chemical sterilization have been offered as supplemental measures to enhance duodenoscope reprocessing by the U.S. Food and Drug Administration (FDA). This study aims to compare the efficacy of reprocessing duodenoscopes with double high-level disinfection (DHLD) versus liquid chemical sterilization (LCS). METHODS We prospectively evaluated 2 different modalities of duodenoscope reprocessing from October 23, 2017 to September 24, 2018. Eligible duodenoscopes were randomly segregated to be reprocessed by either DHLD or LCS. Duodenoscopes were randomly cultured after reprocessing for surveillance based on an internal protocol. RESULTS During the study time period, there were 878 postreprocessing surveillance cultures (453 in the DHLD group and 425 in the LCS group). Of all of the cultures, 17 were positive for any organism (1.9%). There was no significant difference of positive cultures when comparing the duodenoscopes undergoing DHLD (8 positive cultures, 1.8%) to duodenoscopes undergoing LCS (9 positive cultures, 2.1%, p=0.8). Both groups had 2 cultures that grew high-concern organisms (0.5% vs. 0.5%, p=1.0). No multi-drug resistant organisms (MDRO), including carbapenem-resistant enterobacteriaceae (CRE), were detected. CONCLUSIONS DHLD and LCS both resulted in a low rate of positive cultures, both for all organisms and for high-concern organisms, but neither process completely eliminated positive cultures from duodenoscopes reprocessed with 2 different supplemental reprocessing strategies.",2020,"There was no significant difference of positive cultures when comparing the duodenoscopes undergoing DHLD (8 positive cultures, 1.8%) to duodenoscopes undergoing LCS (9 positive cultures, 2.1%, p=0.8).","['878 postreprocessing surveillance cultures (453 in the DHLD group and 425 in the LCS group', 'Eligible duodenoscopes', 'duodenoscope reprocessing from October 23, 2017 to September 24, 2018']","['Double high-level disinfection versus liquid chemical sterilization', 'duodenoscopes and reprocessing with repeat high-level disinfection or liquid chemical sterilization', 'DHLD or LCS', 'reprocessing duodenoscopes with double high-level disinfection (DHLD) versus liquid chemical sterilization (LCS']",['positive cultures'],"[{'cui': 'C0201227', 'cui_str': 'Surveillance culture'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0012683', 'cui_str': 'Disinfection'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3844105', 'cui_str': '425'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0220806', 'cui_str': 'Chemical'}, {'cui': 'C0038280', 'cui_str': 'Sterilization'}, {'cui': 'C0180565', 'cui_str': 'Duodenoscope'}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0012683', 'cui_str': 'Disinfection'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0220806', 'cui_str': 'Chemical'}, {'cui': 'C0038280', 'cui_str': 'Sterilization'}, {'cui': 'C0180565', 'cui_str': 'Duodenoscope'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0010453', 'cui_str': 'Culture'}]",,0.0851591,"There was no significant difference of positive cultures when comparing the duodenoscopes undergoing DHLD (8 positive cultures, 1.8%) to duodenoscopes undergoing LCS (9 positive cultures, 2.1%, p=0.8).","[{'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Gromski', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: mgromski@iu.edu.'}, {'ForeName': 'Marnie S', 'Initials': 'MS', 'LastName': 'Sieber', 'Affiliation': 'Infection Prevention, IU Health, Indianapolis, IN, USA.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Sherman', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.'}, {'ForeName': 'Douglas K', 'Initials': 'DK', 'LastName': 'Rex', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.'}]",Gastrointestinal endoscopy,['10.1016/j.gie.2020.07.057'] 2393,32745830,A randomised trial comparing a brief online delivery of mindfulness-plus-values versus values only for symptoms of depression: Does baseline severity matter?,"BACKGROUND Acceptance/mindfulness-based interventions often focus on (a) developing dispositional mindfulness and (b) pursuing personally meaningful and valued activities. Acceptance/mindfulness-based interventions can reduce depression, but little is known about the combined effects of components or the influence of baseline variables on outcomes. This study tested whether practicing a brief (10-min) mindfulness meditation over a 2-week period followed by a single values session (mindfulness+values) was more effective than values alone (values only) in reducing symptoms of depression. The study was delivered online and modules were fully self-help (i.e., no therapist contact). METHODS 206 participants (M age =23.4 years, SD=6.53) with elevated depression scores (DASS-depression ≥ 10) were randomised to: mindfulness+values condition or a 2-week wait period followed by the values session (i.e., values only condition). Symptoms of depression were assessed at baseline, after the 2-week mindfulness practice/wait period, and 1-week following the values session. RESULTS Reductions in depression and recovery rates were significantly greater following mindfulness+values than values only. Baseline severity affected outcomes: mindfulness+values was significantly more beneficial than values only for individuals with high baseline levels of depression. Outcomes did not differ for those with low levels of depression. Rates of deterioration were higher than expected for values only participants. LIMITATIONS Conclusions are preliminary and tentative due to no follow-up period and a small sample. Drop-out was high (50%) and findings cannot be assumed to generalise to treatment seeking or more diverse samples. CONCLUSIONS Tentatively, results suggest mindfulness+values can significantly reduce depression, especially for individuals with higher baseline depression.",2020,Baseline severity affected outcomes: mindfulness+values was significantly more beneficial than values only for individuals with high baseline levels of depression.,"['206 participants (M age =23.4 years, SD=6.53) with elevated depression scores (DASS-depression ≥ 10']","['mindfulness-plus-values', 'practicing a brief (10-min) mindfulness meditation']","['Symptoms of depression', 'Rates of deterioration', 'depression and recovery rates']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517655', 'cui_str': '23.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1832594', 'cui_str': 'Verloes Bourguignon syndrome'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0439232', 'cui_str': 'min'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",206.0,0.0678318,Baseline severity affected outcomes: mindfulness+values was significantly more beneficial than values only for individuals with high baseline levels of depression.,"[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Kingston', 'Affiliation': 'Royal Holloway University of London Egham Hill Egham, Bowyer Building, Surrey TW20 0EX, United Kingdom. Electronic address: Jessica.kingston@rhul.ac.uk.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Becker', 'Affiliation': 'Royal Holloway University of London Egham Hill Egham, Bowyer Building, Surrey TW20 0EX, United Kingdom.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Woeginger', 'Affiliation': 'Royal Holloway University of London Egham Hill Egham, Bowyer Building, Surrey TW20 0EX, United Kingdom.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Ellett', 'Affiliation': 'Royal Holloway University of London Egham Hill Egham, Bowyer Building, Surrey TW20 0EX, United Kingdom.'}]",Journal of affective disorders,['10.1016/j.jad.2020.07.087'] 2394,32745891,Automatic Imitation in Comorbid PTSD & Alcohol Use Disorder and Controls: an RCT of Intranasal Oxytocin.,"INTRODUCTION Mimicking movements of others makes both the imitating and imitated partners feel closer. Oxytocin may increase focus on others and has been shown to increase automatic imitation in healthy controls (HC). However, this has not been replicated, and oxytocin's effects on automatic imitation have not been demonstrated in clinical populations. This study attempts to replicate effects on HC and examine effects on people with comorbid posttraumatic stress disorder and alcohol use disorder (PTSD-AUD). METHODS Fifty-four males with PTSD-AUD and 43 male HC received three intranasal treatment conditions (placebo, oxytocin 20 International Units (IU), and oxytocin 40 IU) in a randomized order, across three separate testing days, as part of a double-blind, crossover parent study. At 135 min post-administration, each performed the imitation-inhibition task, which quantifies automatic imitation as the congruency effect (CE). After exclusions, the final analyzed data set included 49 participants with PTSD-AUD and 38 HC. RESULTS In HC, oxytocin 20 IU demonstrated a statistically significant increase in CE, and 40 IU showed a trend-level increase. In PTSD-AUD, oxytocin did not significantly increase CE. Post-hoc analysis showed the PTSD-AUD group had higher CE than HC on placebo visits. DISCUSSION Our data suggest PTSD-AUD is associated with higher automatic imitation than HC in the absence of oxytocin administration. We successfully replicated findings that oxytocin increases automatic imitation in HC. This demonstrates an unconscious motor effect induced by oxytocin, likely relevant to more complex forms of imitative movements, which have the potential to improve social connection. We did not find a significant effect of oxytocin on automatic imitation in PTSD-AUD. Future research should examine imitation in both sexes, at peak oxytocin levels, and on increasingly complex forms of imitation.",2020,"In HC, oxytocin 20 IU demonstrated a statistically significant increase in CE, and 40 IU showed a trend-level increase.","['49 participants with PTSD-AUD and 38 HC', 'Fifty-four males with PTSD-AUD and 43 male HC', 'people with comorbid posttraumatic stress disorder and alcohol use disorder (PTSD-AUD', 'healthy controls (HC']","['intranasal treatment conditions (placebo, oxytocin 20 International Units (IU), and oxytocin 40 IU', 'oxytocin', 'Intranasal Oxytocin', 'Oxytocin']","['CE', 'automatic imitation']","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0439453', 'cui_str': 'IU'}]","[{'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0205554', 'cui_str': 'Automated'}]",49.0,0.0522705,"In HC, oxytocin 20 IU demonstrated a statistically significant increase in CE, and 40 IU showed a trend-level increase.","[{'ForeName': 'Tyler E', 'Initials': 'TE', 'LastName': 'Morrison', 'Affiliation': 'Department of Psychiatry at University of California San Francisco School of Medicine, 401 Parnassus Ave (Box 0984 RTP), San Francisco, CA, 94143, USA. Electronic address: morrisont@gmail.com.'}, {'ForeName': 'Lize', 'Initials': 'L', 'LastName': 'De Coster', 'Affiliation': 'Department of Psychiatry at University of California San Francisco School of Medicine, 401 Parnassus Ave (Box 0984 RTP), San Francisco, CA, 94143, USA; VA San Francisco Healthcare System, 4150 Clement St (116C-1), San Francisco, CA, 94121, USA. Electronic address: lize.decoster@gmail.com.'}, {'ForeName': 'Christopher S', 'Initials': 'CS', 'LastName': 'Stauffer', 'Affiliation': 'VA San Francisco Healthcare System, 4150 Clement St (116C-1), San Francisco, CA, 94121, USA. Electronic address: Christopher.Stauffer@ucsf.edu.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Wen', 'Affiliation': 'VA San Francisco Healthcare System, 4150 Clement St (116C-1), San Francisco, CA, 94121, USA. Electronic address: jin.wen2100@gmail.com.'}, {'ForeName': 'Elnaz', 'Initials': 'E', 'LastName': 'Ahmadi', 'Affiliation': 'VA San Francisco Healthcare System, 4150 Clement St (116C-1), San Francisco, CA, 94121, USA. Electronic address: elnaz.ahmadi@gmail.com.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Delucchi', 'Affiliation': 'Department of Psychiatry at University of California San Francisco School of Medicine, 401 Parnassus Ave (Box 0984 RTP), San Francisco, CA, 94143, USA. Electronic address: Kevin.Delucchi@ucsf.edu.'}, {'ForeName': 'Aoife', 'Initials': 'A', 'LastName': ""O'Donovan"", 'Affiliation': 'Department of Psychiatry at University of California San Francisco School of Medicine, 401 Parnassus Ave (Box 0984 RTP), San Francisco, CA, 94143, USA; VA San Francisco Healthcare System, 4150 Clement St (116C-1), San Francisco, CA, 94121, USA. Electronic address: Aoife.ODonovan@ucsf.edu.'}, {'ForeName': 'Josh', 'Initials': 'J', 'LastName': 'Woolley', 'Affiliation': 'Department of Psychiatry at University of California San Francisco School of Medicine, 401 Parnassus Ave (Box 0984 RTP), San Francisco, CA, 94143, USA; VA San Francisco Healthcare System, 4150 Clement St (116C-1), San Francisco, CA, 94121, USA. Electronic address: Josh.Woolley@ucsf.edu.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2020.104787'] 2395,32745945,"Chasing the desire: An investigation on the role of craving, time perspective, and alcohol use in adolescent gambling.","Chasing, or continuing to gamble to recoup losses, is a behavioral marker and a diagnostic criterion for gambling disorder. Research on chasing has focused mainly on adults, whereas the analysis of chasing behavior among adolescents has not received empirical attention in the gambling literature. The aim of the present study was to first investigate the interplay between chasing behavior, craving, temporal perspective, alcohol use, and gambling severity among Italian adolescents. Three hundred and sixty-four adolescents took part in the study. Participants completed the South Oaks Gambling Screen Revised for Adolescents (SOGS-RA), the Gambling Craving Scale (GACS), the 14-item Consideration of Future Consequences scale (CFC-14), the Alcohol Use Disorders Identification Test (AUDIT), and performed a computerized task assessing chasing behavior. Participants were randomly assigned to the control and the loss condition of the computerized task. Results indicated that the choice to continue playing, as well as chasing frequency did not vary as a function of experimental condition. Hierarchical logistic and linear regression analyses revealed that the decision to chase depended mostly on craving, whereas chasing propensity was affected by craving and alcohol misuse. Notably, gambling severity did not predict either the decision to chase, or the chasing persistence. The present study contributes important findings to the gambling literature, highlighting the role of craving alcohol use in facilitating the inability to stop within-sessions gambling among adolescents. These findings may provide evidence that nonchasers and chasers represent two different types of gamblers, and that the difference may be useful for targeting more effective therapies.",2020,"Participants completed the South Oaks Gambling Screen Revised for Adolescents (SOGS-RA), the Gambling Craving Scale (GACS), the 14-item Consideration of Future Consequences scale (CFC-14), the Alcohol Use Disorders Identification Test (AUDIT), and performed a computerized task assessing chasing behavior.","['Chasing the desire', 'Three hundred and sixty-four adolescents took part in the study', 'Italian adolescents', 'adolescent gambling']",[],"['South Oaks Gambling Screen Revised for Adolescents (SOGS-RA), the Gambling Craving Scale (GACS']","[{'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0022275', 'cui_str': 'Italian language'}, {'cui': 'C0016995', 'cui_str': 'Gambling'}]",[],"[{'cui': 'C0330302', 'cui_str': 'Genus Quercus'}, {'cui': 'C0016995', 'cui_str': 'Gambling'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",364.0,0.0202985,"Participants completed the South Oaks Gambling Screen Revised for Adolescents (SOGS-RA), the Gambling Craving Scale (GACS), the 14-item Consideration of Future Consequences scale (CFC-14), the Alcohol Use Disorders Identification Test (AUDIT), and performed a computerized task assessing chasing behavior.","[{'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Cosenza', 'Affiliation': 'Department of Psychology, Università degli studi della Campania ""Luigi Vanvitelli"", Viale Ellittico, 31, 81100 Caserta, Italy. Electronic address: marina.cosenza@unicampania.it.'}, {'ForeName': 'Olimpia', 'Initials': 'O', 'LastName': 'Matarazzo', 'Affiliation': 'Department of Psychology, Università degli studi della Campania ""Luigi Vanvitelli"", Viale Ellittico, 31, 81100 Caserta, Italy. Electronic address: olimpia.matarazzo@unicampania.it.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Ciccarelli', 'Affiliation': 'Department of Psychology, Università degli studi della Campania ""Luigi Vanvitelli"", Viale Ellittico, 31, 81100 Caserta, Italy. Electronic address: maria.ciccarelli@unicampania.it.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Nigro', 'Affiliation': 'Department of Psychology, Università degli studi della Campania ""Luigi Vanvitelli"", Viale Ellittico, 31, 81100 Caserta, Italy. Electronic address: giovanna.nigro@unicampania.it.'}]",Addictive behaviors,['10.1016/j.addbeh.2020.106566'] 2396,32745964,"Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03).","BACKGROUND There is a lack of large-scale randomised data evaluating the impact of sex and age in patients undergoing chemotherapy followed by potentially curative surgery for oesophagogastric cancer. PATIENTS AND METHODS Individual patient data from four prospective randomised controlled trials were pooled using a two-stage meta-analysis. For survival analysis, hazard ratios (HRs) were calculated for patients aged <70 and ≥ 70 years, as well as between males and females. Mandard tumour regression grade (TRG) and, ≥grade III toxicities were compared using logistic regression models to calculate odds ratios. All analyses were adjusted for the type of chemotherapy received. RESULTS 3265 patients were included for survival analysis (2668 [82%] male, 597 [18%] female; 2627 (80%) <70 years, 638 (20%) ≥70 years). A significant improvement in overall survival (OS) (HR: 0.78; p < 0.001) and disease-specific survival (DSS) (HR: 0.78; p < 0.001) was observed in females compared with males. No significant differences in OS (HR: 1.11; p = 0.045) or DSS (HR: 1.01; p = 0.821) were observed in older patients compared with younger patients. For patients who underwent resection, older patients (15% vs 10%; p = 0.03) and female patients (14% vs 10%, p = 0.10) were more likely to achieve favourable Mandard TRG scores. Females experienced significantly more ≥grade III nausea (10% vs 5%; p≤0.001), vomiting (10% vs 4%; p≤0.001) and diarrhoea (9% vs 4%; p≤0.001) than males. CONCLUSIONS In this large pooled analysis using prospective randomised trial data, females had significantly improved survival while experiencing more gastrointestinal toxicities. Older patients achieved comparable survival to younger patients and thus, dependent on fitness, should be offered the same treatment paradigm.",2020,A significant improvement in overall survival (OS) (HR: 0.78; p < 0.001) and disease-specific survival (DSS) (HR: 0.78; p < 0.001) was observed in females compared with males.,"['Older patients', '3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03', 'localised oesophagogastric cancer', 'patients undergoing chemotherapy followed by potentially curative surgery for oesophagogastric cancer', '3265 patients were included for survival analysis (2668 [82%] male, 597 [18%] female; 2627 (80%) <70 years, 638 (20%) ≥70 years']",[],"['chemotherapy efficacy, toxicity and survival', '≥grade III nausea', 'Mandard tumour regression grade (TRG) and, ≥grade III toxicities', 'favourable Mandard TRG scores', 'diarrhoea', 'survival', 'gastrointestinal toxicities', 'vomiting', 'disease-specific survival (DSS', 'overall survival (OS', 'For survival analysis, hazard ratios (HRs']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0024460', 'cui_str': 'Magic'}, {'cui': 'C0475468', 'cui_str': 'Esophagogastric'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0038953', 'cui_str': 'Analysis, Survival'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}]",[],"[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0684321', 'cui_str': 'Regression - mental defense mechanism'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C1142499', 'cui_str': 'Gastrointestinal toxicity'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038953', 'cui_str': 'Analysis, Survival'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",3265.0,0.254262,A significant improvement in overall survival (OS) (HR: 0.78; p < 0.001) and disease-specific survival (DSS) (HR: 0.78; p < 0.001) was observed in females compared with males.,"[{'ForeName': 'Avani', 'Initials': 'A', 'LastName': 'Athauda', 'Affiliation': 'Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, United Kingdom.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Nankivell', 'Affiliation': 'Medical Research Council Clinical Trials Unit at University College London, 90 High Holborn, Second Floor, London, WC1V 6LJ, United Kingdom.'}, {'ForeName': 'Ruth E', 'Initials': 'RE', 'LastName': 'Langley', 'Affiliation': 'Medical Research Council Clinical Trials Unit at University College London, 90 High Holborn, Second Floor, London, WC1V 6LJ, United Kingdom.'}, {'ForeName': 'Derek', 'Initials': 'D', 'LastName': 'Alderson', 'Affiliation': 'Department of Surgery, Queen Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham, B15 2WB, United Kingdom.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Allum', 'Affiliation': 'Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, United Kingdom.'}, {'ForeName': 'Heike I', 'Initials': 'HI', 'LastName': 'Grabsch', 'Affiliation': ""Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands; Pathology and Data Analytics, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, LS9 7TF, United Kingdom.""}, {'ForeName': 'Naureen', 'Initials': 'N', 'LastName': 'Starling', 'Affiliation': 'Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, United Kingdom.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Chau', 'Affiliation': 'Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, United Kingdom.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cunningham', 'Affiliation': 'Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, United Kingdom. Electronic address: david.cunningham@rmh.nhs.uk.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2020.06.005'] 2397,32746071,Skill-oriented and Performance-driven Adaptive Curricula for Training in Robot-Assisted Surgery using Simulators: a Feasibility Study.,"Virtual Reality (VR) simulators represent a remarkable educational opportunity in order to acquire and refine surgical practical skills. Nevertheless, there exists no consensus regarding a standard curriculum of simulation-based training. This study introduces an automatic, adaptive curriculum where the training session is real-time scheduled on the basis of the trainee's performances. An experimental study using the master console of the da Vinci Research Kit (Intuitive Surgical Inc., Sunnyvale, US) was carried out to test this approach. Tasks involving fundamental skills of robotic surgery were designed and simulated in VR. Twelve participants without medical background along with twelve medical residents were randomly and equally divided into two groups: a control group, self-managing the training session, and an experimental group, undergoing the proposed adaptive training. The performances of the experimental users were significantly better with respect to the ones of the control group after training (non-medical: p<0.01; medical: p=0.02). The analysis of the learning of the involved surgical skills highlighted how the adaptive training managed to better identify and compensate for the trainee's gaps. This trend was analogous in the non-medical and medical populations. No significant difference was identified between these classes in the baseline assessment: this underlines that robotic surgical devices require specific training before clinical practice.",2020,The performances of the experimental users were significantly better with respect to the ones of the control group after training (non-medical: p<0.01; medical: p=0.02).,['Twelve participants without medical background along with twelve medical residents'],"['Virtual Reality (VR) simulators', 'Skill-oriented and Performance-driven Adaptive Curricula for Training in Robot-Assisted Surgery using Simulators', 'control group, self-managing the training session, and an experimental group, undergoing the proposed adaptive training']",[],"[{'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",[],12.0,0.0124593,The performances of the experimental users were significantly better with respect to the ones of the control group after training (non-medical: p<0.01; medical: p=0.02).,"[{'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Mariani', 'Affiliation': ''}, {'ForeName': 'Edoardo', 'Initials': 'E', 'LastName': 'Pellegrini', 'Affiliation': ''}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'De Momi', 'Affiliation': ''}]",IEEE transactions on bio-medical engineering,['10.1109/TBME.2020.3011867'] 2398,32746432,"Feasibility, Acceptability, and Exploratory Outcomes of Acceptance and Commitment Therapy for Binge Eating Symptoms in Veterans: A Preliminary Clinic-Based Study.","Overweight and obesity are disabling problems for veterans and place a heavy toll on their physical and mental health. Acceptance and commitment therapy (ACT) is an empirically supported intervention that shows promise in improving binge eating, weight, and psychological functioning. This preliminary study evaluated the feasibility and acceptability of an 8-week ACT group intervention for binge eating in veterans ( N = 85) who were overweight or obese and explored preliminary intervention effects on binge eating and physical and mental health functioning. Veterans were predominantly male (86.7%) with an average age of 58 years, and 65% endorsed clinically significant binge eating. Qualitative results indicated the majority of veterans found the intervention useful. Baseline to post-treatment comparisons found significant reductions in binge eating symptoms, depression, global psychological distress, and body mass index, as well as improvement in functioning. Findings suggest implementing ACT for binge eating in veterans is feasible and deserves further exploration, addressing binge eating and weight control. Future studies should examine ACT for this population in a randomized controlled trial.",2018,"Baseline to post-treatment comparisons found significant reductions in binge eating symptoms, depression, global psychological distress, and body mass index, as well as improvement in functioning.","['binge eating in veterans ( N = 85) who were overweight or obese and explored preliminary intervention effects on binge eating and physical and mental health functioning', 'Binge Eating Symptoms in Veterans', 'Veterans were predominantly male (86.7%) with an average age of 58 years, and 65% endorsed clinically significant binge eating']","['Acceptance and commitment therapy (ACT', 'ACT group intervention', 'Acceptance and Commitment Therapy']","['binge eating symptoms, depression, global psychological distress, and body mass index']","[{'cui': 'C0006370', 'cui_str': 'Binge Eating'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0439611', 'cui_str': 'Preliminary'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0750502', 'cui_str': 'Significant'}]","[{'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}, {'cui': 'C0029917', 'cui_str': 'Outpatient Commitment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1527374', 'cui_str': 'Group Therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0006370', 'cui_str': 'Binge Eating'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",,0.0477867,"Baseline to post-treatment comparisons found significant reductions in binge eating symptoms, depression, global psychological distress, and body mass index, as well as improvement in functioning.","[{'ForeName': 'Jessica Gundy', 'Initials': 'JG', 'LastName': 'Cuneo', 'Affiliation': 'Department of Psychiatry, University of California, San Diego, La Jolla, California jgundycuneo@ucsd.edu.'}, {'ForeName': 'Kathryn M', 'Initials': 'KM', 'LastName': 'Godfrey', 'Affiliation': 'San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, California.'}, {'ForeName': 'Lisa Johnson', 'Initials': 'LJ', 'LastName': 'Wright', 'Affiliation': 'VA Northern California Healthcare System, Oakland, California.'}, {'ForeName': 'Autumn', 'Initials': 'A', 'LastName': 'Backhaus', 'Affiliation': 'VA San Diego Healthcare System, San Diego, California.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Miggantz', 'Affiliation': 'Veterans Medical Research Foundation, San Diego, California.'}, {'ForeName': 'Niloofar', 'Initials': 'N', 'LastName': 'Afari', 'Affiliation': 'Department of Psychiatry, University of California, San Diego, La Jolla, California.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.32.3.155'] 2399,32746473,Erratum: Nasogastric versus Orogastric Bolus Tube Feeding in Preterm Infants: Pilot Randomized Clinical Trial.,,2020,,['Preterm Infants'],['Erratum: Nasogastric versus Orogastric Bolus Tube Feeding'],[],"[{'cui': 'C0021294', 'cui_str': 'Premature infant'}]","[{'cui': 'C0694637', 'cui_str': 'Nasogastric route'}, {'cui': 'C0450104', 'cui_str': 'Orogastric'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}]",[],,0.138694,,"[{'ForeName': 'Ahmed Tawfik', 'Initials': 'AT', 'LastName': 'Badran', 'Affiliation': 'Department of Pediatrics, SUNY Downstate Health Sciences University, Brooklyn, New York.'}, {'ForeName': 'Menna', 'Initials': 'M', 'LastName': 'Hashish', 'Affiliation': ""Neonatal Intensive Care Unit, Mansoura University Children's Hospital, Mansoura, Egypt.""}, {'ForeName': 'Alaa', 'Initials': 'A', 'LastName': 'Ali', 'Affiliation': 'Department of Pediatrics, National Research Center, Cairo, Egypt.'}, {'ForeName': 'Mohamed Ahmed', 'Initials': 'MA', 'LastName': 'Shokeir', 'Affiliation': ""Department of Pediatrics, Mansoura University Children's Hospital, Mansoura, Egypt.""}, {'ForeName': 'Abdelaziz', 'Initials': 'A', 'LastName': 'Shaaban', 'Affiliation': ""Neonatal Intensive Care Unit, Mansoura University Children's Hospital, Mansoura, Egypt.""}]",American journal of perinatology,['10.1055/s-0040-1714720'] 2400,32746598,[Effects of desflurane and sevoflurane anesthesia on postoperative recovery after long-term tumor surgery].,"Objective: To analyze the effects of desflurane and sevoflurane anesthesia on postoperative recovery after long lasting tumor surgery. Methods: One hundred and sixty patients undergoing endoscopic radical esophagectomy and gastrectomy (80 cases of each surgical type) from November 2019 to March 2020 at Henan Cancer Hospital, were randomized into 4 groups( n= 40): group CS (esophageal cancer+sevoflurane anesthesia), group DS (esophageal cancer+desflurane anesthesia),group CW (stomach cancer+sevoflurane anesthesia) and group DW (gastric cancer+desflurane anesthesia). General anesthesia was induced by intravenous agents in all four groups, which were maintained by inhaled anesthetic during the operation. The mean arterial pressure (MAP), heart rate (HR), and surplus pulse O(2) (SpO(2)) immediately before induction (T(1)), the moment of operation begin (T(2)), operation end (T(3)) and extubation (T(4)) were recorded. Also, the duration required for inhalation anesthetic alveolar concentration reaching 0.5 minimum alveolar concentration (MAC) during induction, the alveolar anesthetic concentration at the beginning of the operation, the duration required for XMAC (patients specific alveolar concentration) declining to 0.5 MAC on recovery period, and the duration of alveolar concentration of 0.5 MAC declining to 0.2 MAC were determined. Additionally, the durations of spontaneous breathing recovery, eyes opening, extubation and recovery of consciousness were recorded. Finally, restlessness score (RS) during recovery period was used to evaluate postoperative agitation. Results: Compared with group CS and group CW, no significant differences in MAP, HR, SpO(2) in group DS and group DW at T(1) to T(4) were found (all P> 0.05). The durations required for inhalation anesthetic alveolar concentration reaching 0.5 MAC were (5.6±1.3), (5.8±2.1), (3.5±1.5) and (3.8±1.0) min in group CS, group CW, group DS and group DW, where the durations in group DS and group DW were significantly shorter than those in group CS and group CW ( F= 32.538, P< 0.05). The durations of alveolar concentration of 0.5 MAC declining to 0.2 MAC were (6.4±2.2), (7.0±1.5), (4.2±2.2) and (4.1±1.5) min in group CS, group CW, group DS and group DW, and the durations in group DS and group DW were significantly shortened as compared with group CS and group CW ( F= 42.113, P< 0.05). Compared with group CS and group CW, group DS and group DW required significantly shorter time for spontaneous breathing recovery, eye opening,extubation, and directional force recovery after operation (all P< 0.05). Conclusions: Both desflurane and sevoflurane anesthesia can achieve satisfactory anesthesia depth during long lasting tumor surgery. Desflurane can shorten the recovery time and early extubation, and improve the quality of recovery.",2020,"Compared with group CS and group CW, no significant differences in MAP, HR, SpO(2) in group DS and group DW at T(1) to T(4) were found (all P> 0.05).","['80 cases of each surgical type) from November 2019 to March 2020 at Henan Cancer Hospital', 'after long-term tumor surgery', 'One hundred and sixty patients undergoing']","['CS (esophageal cancer+sevoflurane anesthesia), group DS (esophageal cancer+desflurane anesthesia),group CW (stomach cancer+sevoflurane anesthesia) and group DW (gastric cancer+desflurane anesthesia', 'desflurane and sevoflurane anesthesia', 'endoscopic radical esophagectomy and gastrectomy', 'Desflurane']","['duration of alveolar concentration', 'durations required for inhalation anesthetic alveolar concentration reaching 0.5 MAC', 'restlessness score (RS', 'postoperative recovery', 'duration required for inhalation anesthetic alveolar concentration reaching 0.5 minimum alveolar concentration (MAC) during induction, the alveolar anesthetic concentration', 'MAP, HR, SpO(2', 'shorter time for spontaneous breathing recovery, eye opening,extubation, and directional force recovery', 'recovery time and early extubation', 'durations of alveolar concentration of 0.5 MAC declining to 0.2 MAC', 'satisfactory anesthesia depth', 'mean arterial pressure (MAP), heart rate (HR), and surplus pulse O(2) (SpO(2)) immediately before induction (T(1)), the moment of operation begin (T(2)), operation end (T(3)) and extubation (T(4', 'quality of recovery', 'durations of spontaneous breathing recovery, eyes opening, extubation and recovery of consciousness']","[{'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0019999', 'cui_str': 'Cancer hospital'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0063252', 'cui_str': 'desflurane'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0302912', 'cui_str': 'Radical'}, {'cui': 'C0085198', 'cui_str': 'Esophagectomy'}, {'cui': 'C0017118', 'cui_str': 'Gastrectomy'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0009545', 'cui_str': 'Active C5b6789'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0024779', 'cui_str': 'Maps'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0009791', 'cui_str': 'Consciousness related finding'}]",160.0,0.01659,"Compared with group CS and group CW, no significant differences in MAP, HR, SpO(2) in group DS and group DW at T(1) to T(4) were found (all P> 0.05).","[{'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Bai', 'Affiliation': 'Department of Anesthesiology, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.'}, {'ForeName': 'C S', 'Initials': 'CS', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.'}, {'ForeName': 'X H', 'Initials': 'XH', 'LastName': 'Lu', 'Affiliation': 'Department of Anesthesiology, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesiology, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.'}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Miao', 'Affiliation': 'Department of Anesthesiology, Cancer Hospital, Fudan University, Shanghai 200032, China.'}]",Zhonghua yi xue za zhi,['10.3760/cma.j.cn112137-20200422-01273'] 2401,32746602,[Efficacy of thymectomy in patients with non-thymoma myasthenia gravis].,"Objective: To compare the efficacy between thymectomy plus prednisone and prednisone alone in patients with non-thymoma myasthenia gravis (MG). Methods: Thirty generalized MG patients without thymoma who underwent thymectomy were collected as the operation group, and thirty-nine patients without thymectomy who were treated with prednisone alone were matched as the control group. The start point was the enrollment time and the endpoint event was the ""clinical remission"" (including complete stabilization remission, drug remission, and poor performance). The survival curve was used to analyze the difference of endpoint event time between the two groups. Besides, a 12-month follow-up study was conducted to compare relevant clinical indicators between the two groups. Results: There was no significant difference in the occurrence time of endpoint events between the two groups ( P= 0.614). After 6-month follow-up, no significant differences were found in clinical remission rate, the dosage of pyridostigmine bromide and prednisone, the peak dosage of prednisone, the use of other immunosuppressive medications and the rate of hospitalization for exacerbation of disease between the two groups (all P> 0.05). After 12-month follow-up, the dosage of prednisone and pyridostigmine in the operation group was significantly lower than that in the control group (5(0,10)mg/d vs 7.5(5,10)mg/d and 30(0,105)mg/d vs 90(15,180)mg/d; P= 0.038, 0.032). Conclusion: In patients with mild to moderate non-thymoma generalized MG, thymectomy does not achieve faster remission, but it does reduce the long-term dosage of prednisone and bromopyrazine.",2020,There was no significant difference in the occurrence time of endpoint events between the two groups ( P= 0.614).,"['Thirty generalized MG patients without thymoma who underwent thymectomy were collected as the operation group, and thirty-nine patients without thymectomy who were treated with', 'patients with non-thymoma myasthenia gravis', 'patients with non-thymoma myasthenia gravis (MG']","['prednisone', 'thymectomy', 'prednisone and pyridostigmine', 'thymectomy plus prednisone and prednisone alone', 'pyridostigmine bromide and prednisone']","['clinical remission"" (including complete stabilization remission, drug remission, and poor performance', 'survival curve', 'rate of hospitalization for exacerbation of disease', 'occurrence time of endpoint events', 'clinical remission rate']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040100', 'cui_str': 'Thymoma'}, {'cui': 'C0040071', 'cui_str': 'Excision of thymus'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3816447', 'cui_str': '39'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0026896', 'cui_str': 'Myasthenia gravis'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0040071', 'cui_str': 'Excision of thymus'}, {'cui': 'C0034261', 'cui_str': 'Pyridostigmine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0034262', 'cui_str': 'Pyridostigmine bromide'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0235874', 'cui_str': 'Condition aggravated'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",39.0,0.0160311,There was no significant difference in the occurrence time of endpoint events between the two groups ( P= 0.614).,"[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': ""Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China [Yang Song is now working at the Department of Neurology, the Third Affiliated Hospital of Soochow University (Changzhou First People's Hospital), Changzhou 213003, China].""}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Huan', 'Affiliation': 'Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Yan', 'Affiliation': 'Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Song', 'Affiliation': 'Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China.'}, {'ForeName': 'S S', 'Initials': 'SS', 'LastName': 'Luo', 'Affiliation': 'Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China.'}, {'ForeName': 'J H', 'Initials': 'JH', 'LastName': 'Lu', 'Affiliation': 'Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China.'}, {'ForeName': 'C B', 'Initials': 'CB', 'LastName': 'Zhao', 'Affiliation': 'Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China.'}]",Zhonghua yi xue za zhi,['10.3760/cma.j.cn112137-20191206-02664'] 2402,32746668,Study protocol: Effectiveness of dual-mobility cups compared with uni-polar cups for preventing dislocation after primary total hip arthroplasty in elderly patients - design of a randomized controlled trial nested in the Dutch Arthroplasty Registry.,"Background and purpose - Dislocation is the leading reason for early revision surgery after total hip arthroplasty (THA). The dual-mobility (DM) cup was developed to provide more stability and mechanically reduce the risk of dislocation. Despite the increased use of DM cups, high-quality evidence of their (cost-)effectiveness is lacking. The primary objective of this randomized controlled trial (RCT) is to investigate whether there is a difference in the number of hip dislocations following primary THA, using the posterolateral approach, with a DM cup compared with a unipolar (UP) cup in elderly patients 1 year after surgery. Secondary outcomes include the number of revision surgeries, patient-reported outcome measures (PROMs), and cost-effectiveness.Methods and analysis - This is a prospective multicenter nationwide, single-blinded RCT nested in the Dutch Arthroplasty Registry. Patients ≥ 70 years old, undergoing elective primary THA using the posterolateral approach, will be eligible. After written informed consent, 1,100 participants will be randomly allocated to the intervention or control group. The intervention group receives a THA with a DM cup and the control group a THA with a UP cup. PROMs are collected preoperatively, and 3 months, 1 and 2 years postoperatively. Primary outcome is the difference in number of dislocations between the UP and DM cup within 1 year, reported in the registry (revisions), or by the patients (closed or open reduction). Data will be analyzed using multilevel models as appropriate for each outcome (linear/logistic/survival). An economic evaluation will be performed from the healthcare and societal perspective, for dislocation and quality adjusted life years (QALYs).Trial registration - This RCT is registered at www.clinicaltrials.gov with identification number NCT04031820.",2020,"An economic evaluation will be performed from the healthcare and societal perspective, for dislocation and quality adjusted life years (QALYs).Trial registration - This RCT is registered at www.clinicaltrials.gov with identification number NCT04031820.","['Dutch Arthroplasty Registry', 'dislocation after primary total hip arthroplasty in elderly patients - design', 'elderly patients 1 year after surgery', 'Patients ≥ 70 years old, undergoing elective primary THA using the posterolateral approach, will be eligible', 'early revision surgery after total hip arthroplasty (THA']","['dual-mobility cups compared with uni-polar cups', 'THA with a DM cup and the control group a THA with a UP cup']","['number of dislocations between the UP and DM cup within 1 year, reported in the registry (revisions), or by the patients (closed or open reduction', 'number of revision surgeries, patient-reported outcome measures (PROMs), and cost-effectiveness']","[{'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0003893', 'cui_str': 'Arthroplasty'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0012691', 'cui_str': 'Dislocation'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0039245', 'cui_str': 'Tacrine'}, {'cui': 'C0587271', 'cui_str': 'Posterolateral approach'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0220647', 'cui_str': 'Carcinoma of unknown primary'}, {'cui': 'C3853222', 'cui_str': 'Sea urchin - dietary'}, {'cui': 'C0039245', 'cui_str': 'Tacrine'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0012691', 'cui_str': 'Dislocation'}, {'cui': 'C0220647', 'cui_str': 'Carcinoma of unknown primary'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0185373', 'cui_str': 'Open reduction of fracture'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C4277735', 'cui_str': 'Patient Reported Outcome Measures'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",1100.0,0.179307,"An economic evaluation will be performed from the healthcare and societal perspective, for dislocation and quality adjusted life years (QALYs).Trial registration - This RCT is registered at www.clinicaltrials.gov with identification number NCT04031820.","[{'ForeName': 'Loes W A H', 'Initials': 'LWAH', 'LastName': 'Van Beers', 'Affiliation': 'OLVG, Amsterdam.'}, {'ForeName': 'Bart C H', 'Initials': 'BCH', 'LastName': 'Van Der Wal', 'Affiliation': 'University Medical Center Utrecht, Utrecht.'}, {'ForeName': 'Tess Glastra', 'Initials': 'TG', 'LastName': 'Van Loon', 'Affiliation': 'OLVG, Amsterdam.'}, {'ForeName': 'Dirk Jan F', 'Initials': 'DJF', 'LastName': 'Moojen', 'Affiliation': 'OLVG, Amsterdam.'}, {'ForeName': 'Marieke F', 'Initials': 'MF', 'LastName': 'Van Wier', 'Affiliation': 'OLVG, Amsterdam.'}, {'ForeName': 'Amanda D', 'Initials': 'AD', 'LastName': 'Klaassen', 'Affiliation': 'OLVG, Amsterdam.'}, {'ForeName': 'Nienke W', 'Initials': 'NW', 'LastName': 'Willigenburg', 'Affiliation': 'OLVG, Amsterdam.'}, {'ForeName': 'Rudolf W', 'Initials': 'RW', 'LastName': 'Poolman', 'Affiliation': 'OLVG, Amsterdam.'}]",Acta orthopaedica,['10.1080/17453674.2020.1798658'] 2403,32746728,Trunk muscle activity during different types of low weighted squat exercises in normal and forefoot standing conditions.,"Squats are considered a useful basic exercise for trunk muscle activation. To gain knowledge about trunk muscle activity patterns depending on the barbell position in beginners, we examined squats with low weights in the back, front, and overhead position. METHODS Twelve healthy adults (6 women/6 men, age: 29.1 (SD 8.0) y, height: 173.4 (6.9) cm, body mass: 70.1 (9.1) kg) randomly performed the three barbell squats in normal and in forefoot standing. Surface electromyography from external (EO) and internal oblique, rectus abdominis, and erector spinae (ES) was recorded. The centre of pressure path length (CoP) and the motion of the lumbar spine were captured. RESULTS The overhead squat revealed the highest percent muscle activity, where EO (p = 0.009) and ES (p = 0.03) showed the greatest activity. Forefoot standing did not change overall trunk muscle activities (.05< Hedges' g <.29, 0.17 < p < 0.95) although longer CoP path length (.45 < g < 1.3, p < 0.05) was measured. CONCLUSIONS Squat exercises with low weight are useful to activate trunk muscles. Activity increases with the difficulty of the squat by frontal or overhead loading, but not by standing on the forefoot. The low weighted squat can target well core muscle activity in training with beginners or in rehabilitation.",2020,Forefoot standing did not change overall trunk muscle activities (.05,"['Twelve healthy adults (6 women/6 men, age: 29.1 (SD 8.0']","['Squat exercises', 'low weighted squat exercises']","['longer CoP path length', 'Surface electromyography from external (EO) and internal oblique, rectus abdominis, and erector spinae (ES', 'Trunk muscle activity', 'pressure path length (CoP) and the motion of the lumbar spine', 'overall trunk muscle activities']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0430815', 'cui_str': 'Surface EMG'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0224376', 'cui_str': 'Internal Oblique Muscle'}, {'cui': 'C0224301', 'cui_str': 'Structure of erector spinae muscle'}, {'cui': 'C0581755', 'cui_str': 'Skeletal muscle structure of trunk'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0024091', 'cui_str': 'Bone structure of lumbar vertebra'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",12.0,0.0204557,Forefoot standing did not change overall trunk muscle activities (.05,"[{'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Roth', 'Affiliation': 'Department of Sport, Exercise and Health, University of Basel , Basel, Switzerland.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Donath', 'Affiliation': 'Department of Interventions Research in Exercise Training, German Sport University Cologne , Cologne, Germany.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Faude', 'Affiliation': 'Department of Sport, Exercise and Health, University of Basel , Basel, Switzerland.'}, {'ForeName': 'Andrew G', 'Initials': 'AG', 'LastName': 'Cresswell', 'Affiliation': 'School of Human Movement and Nutrition Sciences, The University of Queensland , Brisbane, Australia.'}]",Journal of sports sciences,['10.1080/02640414.2020.1800358'] 2404,32746730,Improving parent-child interactions in maltreating families with the Attachment Video-feedback Intervention: Parental childhood trauma as a moderator of treatment effects.,"Research is demonstrating the effectiveness of attachment-based interventions for maltreating families. However, parents' own traumatic childhood experiences may interfere with treatment effects. The current study investigated in a sample of maltreating families whether effects of the Attachment Video-feedback Intervention (AVI) on parent-child interactive quality were moderated by parental childhood trauma. Families were randomized to receive AVI ( n = 29) or a Psychoeducative intervention (PI; n = 19), or they were in anon-randomized comparison group (RS; n = 40). Parents filled out the Childhood Trauma Questionnaire and videotapes of parent-child interactions were coded for interactive quality. Parents who received AVI showed improved parent-child interactive quality compared to parents in PI and RS groups. However, parents with more severe levels of childhood trauma showed less improvements. Future research should explore whether clinical attention with a specific focus on trauma would increase treatement effects.",2020,Parents who received AVI showed improved parent-child interactive quality compared to parents in PI and RS groups.,[],"['Attachment Video-feedback Intervention (AVI', 'AVI', 'Psychoeducative intervention']","['parent-child interactive quality', 'Childhood Trauma Questionnaire and videotapes of parent-child interactions']",[],"[{'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}]",,0.0424963,Parents who received AVI showed improved parent-child interactive quality compared to parents in PI and RS groups.,"[{'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'van der Asdonk', 'Affiliation': 'Institute of Education and Child Studies, Leiden University , Leiden, the Netherlands.'}, {'ForeName': 'Chantal', 'Initials': 'C', 'LastName': 'Cyr', 'Affiliation': 'Institute of Education and Child Studies, Leiden University , Leiden, the Netherlands.'}, {'ForeName': 'Lenneke', 'Initials': 'L', 'LastName': 'Alink', 'Affiliation': 'Université du Québec à Montréal , Montréal, Canada.'}]",Attachment & human development,['10.1080/14616734.2020.1799047'] 2405,32746734,Virtual Reality as Distraction Analgesia for Office-Based Procedures: A Randomized Crossover-Controlled Trial.,"OBJECTIVE The purpose of this study was to explore the use of immersive and interactive virtual reality (VR) for analgesia, anxiety reduction, and overall satisfaction in patients undergoing outpatient postoperative debridements. STUDY DESIGN Randomized crossover-controlled trial. SETTING Academic outpatient clinic. SUBJECTS AND METHODS Adult patients who had functional endoscopic sinus surgery and skull base surgery and were undergoing office-based postoperative nasal endoscopy and debridement were recruited and followed for 2 consecutive office visits. Participants were randomized to receive either the control or experimental analgesia for the first postoperative visit (PO1) and crossed over into the opposite treatment arm during the second postoperative visit (PO2). Outcomes included procedural pain, anxiety and satisfaction scores, procedural time, and reflexive head movements per minute (RHM). RESULTS Eighty-two participants were recruited. At PO1, 39 received standard analgesia, and 43 received an immersive VR experience. At PO1, the VR group experienced significantly less anxiety ( P = .043) and fewer RHM ( P = .00016) than the control group. At PO2, the VR group experienced significantly fewer RHM ( P = .0002). At PO2, patients who received the experimental treatment after initially receiving the control treatment had significantly decreased pain, anxiety, and RHM. This effect was not seen in the second group. Overall, 69.51% of patients felt that the VR treatment was better; 19.51% thought that it was the same; and 9.76% found it to be worse. CONCLUSION VR technology holds promise as a nonpharmacologic analgesic and anxiolytic intervention for otolaryngology office-based procedures. Further study of VR use in other procedures is warranted. LEVEL OF EVIDENCE 1, randomized controlled trial.",2020,"At PO1, the VR group experienced significantly less anxiety ( P = .043) and fewer RHM ( P = .00016) than the control group.","['Eighty-two participants were recruited', 'Adult patients who had functional endoscopic sinus surgery and skull base surgery and were undergoing office-based postoperative nasal endoscopy and debridement were recruited and followed for 2 consecutive office visits', 'Academic outpatient clinic', 'Office-Based Procedures', 'patients undergoing outpatient postoperative debridements']","['standard analgesia, and 43 received an immersive VR experience', 'immersive and interactive virtual reality (VR', 'control or experimental analgesia for the first postoperative visit (PO1) and crossed over into the opposite treatment arm during the second postoperative visit (PO2']","['anxiety', 'pain, anxiety, and RHM', 'analgesia, anxiety reduction, and overall satisfaction', 'procedural pain, anxiety and satisfaction scores, procedural time, and reflexive head movements per minute (RHM', 'RHM']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442968', 'cui_str': 'Functional endoscopic sinus surgery'}, {'cui': 'C0149543', 'cui_str': 'Base of skull structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0189024', 'cui_str': 'Endoscopy of nose'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0028900', 'cui_str': 'Office visit'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0580703', 'cui_str': 'Postoperative visit'}, {'cui': 'C0010366', 'cui_str': 'Genetic crossing over'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0202155', 'cui_str': 'Oxygen measurement, partial pressure, arterial'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0376591', 'cui_str': 'Head Movements'}, {'cui': 'C0702093', 'cui_str': '/minute'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0150135', 'cui_str': 'Alleviating anxiety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1619712', 'cui_str': 'Procedural pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",82.0,0.0745387,"At PO1, the VR group experienced significantly less anxiety ( P = .043) and fewer RHM ( P = .00016) than the control group.","[{'ForeName': 'Mingyang L', 'Initials': 'ML', 'LastName': 'Gray', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'David Y', 'Initials': 'DY', 'LastName': 'Goldrich', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'McKee', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Madeleine', 'Initials': 'M', 'LastName': 'Schaberg', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Del Signore', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Satish', 'Initials': 'S', 'LastName': 'Govindaraj', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Alfred Marc', 'Initials': 'AM', 'LastName': 'Iloreta', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}]",Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery,['10.1177/0194599820942215'] 2406,32746736,Yoga Meditation Enhances Proprioception and Balance in Individuals Diagnosed With Parkinson's Disease.,"This study compared the effectiveness of two proprioceptive exercise programs for persons diagnosed with Parkinson's disease (PD). Thirty-three patients with mild to moderate PD were randomly assigned to a yoga meditation program (YoMed) or to an established proprioceptive training program (PRO). Both interventions included twice weekly sessions (45 minutes each), spanning a 12-week period. Outcome measures included: joint position sense (JPS 45 °, JPS 55 °, JPS 65 °) and joint kinesthesia (JK Flex and JK Ext ), the Tinetti Balance Assessment Tool (TIN), Falls Efficacy Scale (FES), Balance Error Scoring System (BESS), dynamic posturography (DMA and TIME) and the Timed Up-and-Go Test (TUG). Test administrators were blinded to group affiliation. Significant between-group differences favoring the YoMed group were observed for TIN ( p  = 0.01, d  = 0.77) and JK Flex ( p  = 0.05, d  = -0.72). DMA and TIME scores significantly improved for both groups, and no adverse events were reported. These findings indicate that the YoMed program is safe and effective for patients with PD. Researchers should continue to examine the clinical efficacy of mind-body techniques to improve movement control and body awareness in this population.",2020,Researchers should continue to examine the clinical efficacy of mind-body techniques to improve movement control and body awareness in this population.,"[""persons diagnosed with Parkinson's disease (PD"", ""Individuals Diagnosed With Parkinson's Disease"", 'patients with PD', 'Thirty-three patients with mild to moderate PD']","['Yoga Meditation', 'YoMed program', 'yoga meditation program (YoMed) or to an established proprioceptive training program (PRO', 'proprioceptive exercise programs']","['joint position sense (JPS 45 °, JPS 55 °, JPS 65 °) and joint kinesthesia (JK Flex and JK Ext ), the Tinetti Balance Assessment Tool (TIN), Falls Efficacy Scale (FES), Balance Error Scoring System (BESS), dynamic posturography (DMA and TIME) and the Timed Up-and-Go Test (TUG', 'DMA and TIME scores', 'adverse events']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0454280', 'cui_str': 'Proprioceptive exercises'}]","[{'cui': 'C0423561', 'cui_str': 'Joint position sense'}, {'cui': 'C0345893', 'cui_str': 'Juvenile polyposis syndrome'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0022701', 'cui_str': 'Sense of position and movement, function'}, {'cui': 'C0015306', 'cui_str': 'Multiple congenital exostosis'}, {'cui': 'C1960377', 'cui_str': 'Assessment of sense of balance'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0919611', 'cui_str': 'Posturography'}, {'cui': 'C0013013', 'cui_str': 'Commonwealth of Dominica'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",33.0,0.0127641,Researchers should continue to examine the clinical efficacy of mind-body techniques to improve movement control and body awareness in this population.,"[{'ForeName': 'Nicholas P', 'Initials': 'NP', 'LastName': 'Cherup', 'Affiliation': 'Laboratory of Neuromuscular Research and Active Aging, Department of Kinesiology and Sport Sciences, University of Miami.'}, {'ForeName': 'Keri L', 'Initials': 'KL', 'LastName': 'Strand', 'Affiliation': 'Laboratory of Neuromuscular Research and Active Aging, Department of Kinesiology and Sport Sciences, University of Miami.'}, {'ForeName': 'Lucrezia', 'Initials': 'L', 'LastName': 'Lucchi', 'Affiliation': 'Laboratory of Neuromuscular Research and Active Aging, Department of Kinesiology and Sport Sciences, University of Miami.'}, {'ForeName': 'Savannah V', 'Initials': 'SV', 'LastName': 'Wooten', 'Affiliation': 'Laboratory of Neuromuscular Research and Active Aging, Department of Kinesiology and Sport Sciences, University of Miami.'}, {'ForeName': 'Corneliu', 'Initials': 'C', 'LastName': 'Luca', 'Affiliation': 'Miller School of Medicine, Soffer Clinical Research Center, University of Miami.'}, {'ForeName': 'Joseph F', 'Initials': 'JF', 'LastName': 'Signorile', 'Affiliation': 'Laboratory of Neuromuscular Research and Active Aging, Department of Kinesiology and Sport Sciences, University of Miami.'}]",Perceptual and motor skills,['10.1177/0031512520945085'] 2407,32754522,The study of placentrex and hydrocortisone as an adjunct treatment in oral submucous fibrosis.,"Background Submucous fibrosis with a high incidence rate in the Indian subcontinent is a devastating disease affecting the oral cavity and oropharynx. Aims and Objective To evaluate the efficacy of injection placentrex and injection hydrocortisone in oral submucous fibrosis patients in increasing mouth opening, burning sensation, and improve the mucosal lining. Materials and Methods We recruited 60 patients with Stage II and Stage III of the ailment, who were randomly divided into Group A and Group B. They were administered submucosal injections of hydrocortisone and placentrex along with physiotherapy and oral iron, nutrients, and B-carotene supplements over a period of 2 months. Interpretations and Results The pinnacle rate of the incidence was found in the age group of 30 to 40 years among both the genders. Statistically significant difference ( P = 0.0001), that is, 5.19 ± 1.33 in Group A and 11.69 ± 1.26 mm in Group B was noted in the mean mouth opening values. Statistically significant difference in burning sensation was noted to be better in Group A than in Group B. Discussion and Conclusion Overall hydrocortisone seems to be a better regimen for improving the mucosal health and increasing the mouth opening as compared to placentrix regimen. Although Placentrex is better than hydrocortisone in reducing burning sensation.",2020,The pinnacle rate of the incidence was found in the age group of 30 to 40 years among both the genders.,"['oral submucous fibrosis', 'oral submucous fibrosis patients', '60 patients with Stage II and Stage III of the ailment']","['Placentrex', 'hydrocortisone', 'injection placentrex and injection hydrocortisone', 'placentrex and hydrocortisone', 'hydrocortisone and placentrex along with physiotherapy and oral iron, nutrients, and B-carotene supplements']","['pinnacle rate of the incidence', 'mean mouth opening values', 'mucosal health', 'burning sensation']","[{'cui': 'C0029172', 'cui_str': 'Oral submucosal fibrosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0221423', 'cui_str': 'Illness'}]","[{'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0696105', 'cui_str': 'Beta carotene level'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0240379', 'cui_str': 'Open mouth'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0026724', 'cui_str': 'Mucosal'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0085624', 'cui_str': 'Burning sensation'}]",60.0,0.0736323,The pinnacle rate of the incidence was found in the age group of 30 to 40 years among both the genders.,"[{'ForeName': 'Parag', 'Initials': 'P', 'LastName': 'Kisave', 'Affiliation': 'Consultant Oral and Maxillofacial Surgeon, Mangalmurti Multi Speciality Dental Clinic, Natepute, Maharashtra, India.'}, {'ForeName': 'Vijay', 'Initials': 'V', 'LastName': 'Shekhar', 'Affiliation': 'Conservative Dentistry and Endodontics, Government Dental Surgeon, PHC Sampatchak, Patna, Bihar, India.'}, {'ForeName': 'Prasoon S', 'Initials': 'PS', 'LastName': 'Babu', 'Affiliation': 'Consultant Oral and Maxillofacial Surgeon, Smilecraft Dental Studio, Yelahanka New Town, Banglore, Karnataka, India.'}, {'ForeName': 'Syed W U', 'Initials': 'SWU', 'LastName': 'Hussaini', 'Affiliation': 'Intern, Sri Sai College of Dental Surgery, Vikarabad, Telangana, India.'}, {'ForeName': 'Rishabh', 'Initials': 'R', 'LastName': 'Bhanot', 'Affiliation': 'Consultant Oral and Maxillofacial Surgeon, Jyoti Kendra General Hospital, Ludhiana, Punjab, India.'}, {'ForeName': 'Abhinav', 'Initials': 'A', 'LastName': 'Kumar', 'Affiliation': 'Departments of Oral and Maxillofacial Surgery, Dr. H.S.R.S.M Dental College and Hospital, Hingoli, Maharashtra, India.'}, {'ForeName': 'Rahul V C', 'Initials': 'RVC', 'LastName': 'Tiwari', 'Affiliation': 'Consultant Oral and Maxillofacial Surgeon, Clove Dental and Omni Hospitals, Visakhapatnam, Andhra Pradesh, India.'}]",Journal of family medicine and primary care,['10.4103/jfmpc.jfmpc_268_20'] 2408,32754559,"The Acceptability and Feasibility of a Preschool Intervention Targeting Motor, Social, and Emotional Development.","Background: Children and youth are facing three major challenges: (1) poor mental health, (2) physical inactivity, and (3) lack of school readiness. Fundamental movement skills (FMS) and social-emotional learning (SEL) are two developmental domains that are associated with each of these challenges. Currently, there is little focus on interventions that target both FMS and SEL. Thus, the purposes of this study were to: (1) examine the acceptability and feasibility of an FMS and SEL program ( Move 2 Smile ) and (2) assess the impact of Move 2 Smile on FMS and SEL in children. Methods: An exploratory, pilot study using a within-subjects design was conducted. Descriptive statistics were computed to assess the acceptability and feasibility of the Move 2 Smile program. Changes in FMS and SEL were analyzed using a paired sample t -test. A focus group was conducted with parents to gain feedback after the program ended. Results: Eleven children (four girls; M age = 50.56 months, SD = 8.63) participated, with families attending 80% of the sessions. The children and parents rated the enjoyment of the program 4.1/5 and 4.7/5, respectively. The instructor rated the children's perceived enjoyment 4.6/5 and feasibility of the sessions 4.7/5. Parents engaged in the FMS take-home activities once per week and the SEL activities three times per week. The intervention had a non-significant small to medium effect on FMS ( d z = 0.42, p = 0.19), a significant large effect on social skills ( d z = 1.38, p = 0.001) and emotion expressiveness ( d z = 0.79, p = 0.03), and a non-significant small to medium effect on emotion knowledge ( d z = 0.58, p = 0.10) and emotion regulation ( d z = 0.44, p = 0.17). The results from the focus group suggest that parents and children enjoyed the program and that the program was useful and effective at impacting FMS and SEL. Conclusions: This intervention is one of the first to intentionally target both FMS and SEL. Children, parents, and instructors deemed this program as acceptable and feasible. These preliminary findings warrant future evaluations of Move 2 Smile , including a randomized controlled trial.",2020,"The intervention had a non-significant small to medium effect on FMS ( d z = 0.42, p = 0.19), a significant large effect on social skills ( d z = 1.38, p = 0.001) and emotion expressiveness ( d z = 0.79, p = 0.03), and a non-significant small to medium effect on emotion knowledge ( d z = 0.58, p = 0.10) and emotion regulation ( d z = 0.44, p = 0.17).","['Eleven children (four girls; M age = 50.56 months, SD = 8.63', 'children']","['FMS and SEL program', 'Preschool Intervention Targeting Motor, Social, and Emotional Development', 'Fundamental movement skills (FMS) and social-emotional learning (SEL']","['emotion regulation', 'emotion knowledge', 'FMS and SEL', 'social skills', 'FMS', 'emotion expressiveness']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0574702', 'cui_str': 'Selkup language'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0582589', 'cui_str': 'Emotional learning'}]","[{'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0574702', 'cui_str': 'Selkup language'}, {'cui': 'C0679005', 'cui_str': 'Social Abilities'}]",11.0,0.0271233,"The intervention had a non-significant small to medium effect on FMS ( d z = 0.42, p = 0.19), a significant large effect on social skills ( d z = 1.38, p = 0.001) and emotion expressiveness ( d z = 0.79, p = 0.03), and a non-significant small to medium effect on emotion knowledge ( d z = 0.58, p = 0.10) and emotion regulation ( d z = 0.44, p = 0.17).","[{'ForeName': 'Maeghan E', 'Initials': 'ME', 'LastName': 'James', 'Affiliation': 'Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Chloe', 'Initials': 'C', 'LastName': 'Bedard', 'Affiliation': 'Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Bremer', 'Affiliation': 'Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Cairney', 'Affiliation': 'School of Human Movement and Nutrition Sciences, University of Queensland, St Lucia, QLD, Australia.'}]",Frontiers in pediatrics,['10.3389/fped.2020.00319'] 2409,32106733,"Greater early migration of a short-stem total hip arthroplasty is not associated with an increased risk of osseointegration failure: 5th-year results from a prospective RSA study with 39 patients, a follow-up study.","Background and purpose - Short-stem hip arthroplasty has been a viable alternative to standard stems for the treatment of hip osteoarthritis for over 10 years. This study assessed whether a correlation existed between a greater initial increase in implant migration and inferior clinical outcomes at 5 years postoperatively. Results on these patients after 2 years have been published previously.Patients and methods - Radiostereometry and clinical scoring were undertaken after surgery and at 3, 6, 12, and 24 months, and 5 years postoperatively. The migration and the clinical outcomes data from the patients with initial migrations at 3 months above the 75th percentile (≥ 75% group) were compared with those with migrations at 3 months of less than the 75th percentile (< 75% group).Results - Between 3 months and 5 years after surgery, the mean resultant implant migrations were 0.40 mm (SD 0.32) in the ≥ 75% group and 0.39 mm (SD 0.25) in the < 75% group. The mean Harris Hip Scores and SF-36 physical scores at 5 years postoperatively were 100 (SD 0.4) and 44 (SD 12), respectively, for the ≥ 75% group and 99 (SD 2) and 50 (SD 10), respectively, for the < 75% group. The differences between the patient groups were not statistically significant.Interpretation - There was no correlation between a greater initial migration and inferior clinical outcomes at 5 years postoperatively. Despite a greater initial migration, there were no risks of early aseptic loosening and inferior midterm clinical outcomes associated with a short-stem implant with a primary metaphyseal anchorage.",2020,The mean Harris Hip Scores and SF-36 physical scores at 5 years postoperatively were 100,[],[],"['mean Harris Hip Scores and SF-36 physical scores', 'risk of osseointegration failure', 'implant migration and inferior clinical outcomes', 'initial migration and inferior clinical outcomes', 'mean resultant implant migrations']",[],[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2919875', 'cui_str': 'Harris hip score'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0079949', 'cui_str': 'Osseointegration'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0237731', 'cui_str': 'Human Migration'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205265', 'cui_str': 'Initial'}]",,0.0358258,The mean Harris Hip Scores and SF-36 physical scores at 5 years postoperatively were 100,"[{'ForeName': 'Thilo', 'Initials': 'T', 'LastName': 'Floerkemeier', 'Affiliation': 'Department of Orthopaedic Surgery, Hannover Medical School, Germany;'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Budde', 'Affiliation': 'Department of Orthopaedic Surgery, Hannover Medical School, Germany;'}, {'ForeName': 'Gabriela V', 'Initials': 'GV', 'LastName': 'Lewinski', 'Affiliation': 'Department of Orthopaedic Surgery, Hannover Medical School, Germany;'}, {'ForeName': 'Henning', 'Initials': 'H', 'LastName': 'Windhagen', 'Affiliation': 'Department of Orthopaedic Surgery, Hannover Medical School, Germany;'}, {'ForeName': 'Christof', 'Initials': 'C', 'LastName': 'HurSchler', 'Affiliation': 'Laboratory for Biomechanics and Biomaterials, Hannover Medical School.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Schwarze', 'Affiliation': 'Laboratory for Biomechanics and Biomaterials, Hannover Medical School.'}]",Acta orthopaedica,['10.1080/17453674.2020.1732749'] 2410,32746775,Efficacy and safety of erenumab in women with a history of menstrual migraine.,"BACKGROUND We performed a post hoc, subgroup analysis of a phase 3, randomized, double-blind, placebo-controlled study of erenumab for prevention of episodic migraine (STRIVE) to determine the efficacy and safety of erenumab in women with self-reported menstrual migraine. METHODS Patients received placebo, erenumab 70 mg, or erenumab 140 mg subcutaneously once monthly during the 6-month double-blind treatment phase of STRIVE. Women who reported history of menstrual migraine and who were ≤ 50 years old were included in the analysis. Endpoints were change from baseline in monthly migraine days (MMD) and monthly acute migraine-specific medication days (MSMD; among patients who took acute migraine-specific medications at baseline), proportion of patients achieving ≥ 50% reduction from baseline in MMD, and incidence of adverse events. RESULTS Among 814 women enrolled in STRIVE, 232 (28.5%) reported a history of menstrual migraine and were ≤ 50 years old. Of the 232 patients, 214 (92%) had a baseline MMD > 5, suggesting a high proportion of women with attacks outside of the 5-day perimenstrual window (2 days before and 3 days after the start of menstruation). Information on ""migraine days"" includes (and does not discriminate between) perimenstrual and intermenstrual migraine attacks. Between-group differences from placebo over months 4-6 for erenumab 70 mg and 140 mg were - 1.8 (P = 0.001) and - 2.1 (P < 0.001) days for MMD and - 1.6 (P = 0.002) and - 2.4 (P < 0.001) days for acute MSMD, respectively. The odds of having a ≥ 50% reduction from baseline in MMD over months 4-6 were 2.2 (P = 0.024) and 2.8 (P = 0.002) times greater for erenumab 70 mg and 140 mg, respectively, than for placebo. Erenumab had an overall safety profile comparable to placebo. CONCLUSION Data from this subgroup analysis of women with menstrual migraine are consistent with data from the overall STRIVE episodic migraine population, supporting the efficacy and safety of erenumab in women who experience menstrual migraine. TRIAL REGISTRATION ClinicalTrials.gov, NCT02456740. Registered 28 May 2015.",2020,"Between-group differences from placebo over months 4-6 for erenumab 70 mg and 140 mg were - 1.8 (P = 0.001) and - 2.1 (P < 0.001) days for MMD and - 1.6 (P = 0.002) and - 2.4 (P < 0.001) days for acute MSMD, respectively.","['women with menstrual migraine', 'Women who reported history of menstrual migraine and who were\u2009≤\u200950\u2009years old were included in the analysis', '814 women enrolled in STRIVE, 232 (28.5%) reported a history of menstrual migraine and were\u2009≤\u200950\u2009years old', 'women with a history of menstrual migraine', 'women with self-reported menstrual migraine', 'women who experience menstrual migraine']","['erenumab', 'placebo, erenumab 70\u2009mg, or erenumab 140\u2009mg subcutaneously', 'placebo']","['overall safety profile', 'Efficacy and safety', 'monthly migraine days (MMD) and monthly acute migraine-specific medication days (MSMD']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0269226', 'cui_str': 'Menstrual migraine'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C4517678', 'cui_str': '28.5'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]","[{'cui': 'C4542165', 'cui_str': 'erenumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4319553', 'cui_str': '140'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1740836', 'cui_str': 'Acute migraine'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]",814.0,0.544437,"Between-group differences from placebo over months 4-6 for erenumab 70 mg and 140 mg were - 1.8 (P = 0.001) and - 2.1 (P < 0.001) days for MMD and - 1.6 (P = 0.002) and - 2.4 (P < 0.001) days for acute MSMD, respectively.","[{'ForeName': 'Jelena M', 'Initials': 'JM', 'LastName': 'Pavlovic', 'Affiliation': 'Department of Neurology, Montefiore Headache Center, 1300 Morris Park Avenue, Van Etten 3C9, Bronx, NY, 10461, USA. jpavlovi@montefiore.org.'}, {'ForeName': 'Koen', 'Initials': 'K', 'LastName': 'Paemeleire', 'Affiliation': 'Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Göbel', 'Affiliation': 'Kiel Migraine and Headache Center, Kiel, Germany.'}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Bonner', 'Affiliation': 'Mercy Clinic Neurology, St Louis, MO, USA.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Rapoport', 'Affiliation': 'The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Risa', 'Initials': 'R', 'LastName': 'Kagan', 'Affiliation': 'Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Zhang', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Hernan', 'Initials': 'H', 'LastName': 'Picard', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Daniel D', 'Initials': 'DD', 'LastName': 'Mikol', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}]",The journal of headache and pain,['10.1186/s10194-020-01167-6'] 2411,32746799,Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH).,"BACKGROUND Hematopoietic cell transplantation (HCT) is a curative option for a growing number of patients with hematologic diseases and malignancies. However, HCT-related factors, such as total body irradiation used for conditioning, graft-versus-host disease, and prolonged exposure to immunosuppressive therapy, result in very high risk for melanoma and non-melanoma skin cancer (NMSC). In fact, skin cancer is the most common subsequent neoplasm in HCT survivors, tending to develop at a time when survivors' follow-up care has largely transitioned to the primary care setting. The goal of this study is to increase skin cancer screening rates among HCT survivors through patient-directed activation alone or in combination with physician-directed activation. The proposed intervention will identify facilitators of and barriers to risk-based screening in this population and help reduce the burden of cancer-related morbidity after HCT. METHODS/DESIGN 720 HCT survivors will be enrolled in this 12-month randomized controlled trial. This study uses a comparative effectiveness design comparing (1) patient activation and education (PAE, N = 360) including text messaging and print materials to encourage and motivate skin examinations; (2) PAE plus primary care physician activation (PAE + Phys, N = 360) adding print materials for the physician on the HCT survivors' increased risk of skin cancer and importance of conducting a full-body skin exam. Patients on the PAE + Phys arm will be further randomized 1:1 to the teledermoscopy (PAE + Phys+TD) adding physician receipt of a portable dermatoscope to upload images of suspect lesions for review by the study dermatologist and an online course with descriptions of dermoscopic images for skin cancers. DISCUSSION When completed, this study will provide much-needed information regarding strategies to improve skin cancer detection in other high-risk (e.g. radiation-exposed) cancer survivor populations, and to facilitate screening and management of other late effects (e.g. cardiovascular, endocrine) in HCT survivors. TRIAL REGISTRATION ClinicalTrials.gov, NCT04358276 . Registered 24 April 2020.",2020,"Patients on the PAE + Phys arm will be further randomized 1:1 to the teledermoscopy (PAE + Phys+TD) adding physician receipt of a portable dermatoscope to upload images of suspect lesions for review by the study dermatologist and an online course with descriptions of dermoscopic images for skin cancers. ","['720 HCT survivors', 'patients with hematologic diseases and malignancies', 'hematopoietic cell transplantation survivors']","['HCT survivors through patient-directed activation alone or in combination with physician-directed activation', 'patient activation and education (PAE, N\u2009=\u2009360) including text messaging and print materials to encourage and motivate skin examinations; (2) PAE plus primary care physician activation (PAE\u2009+\u2009Phys, N\u2009=\u2009360) adding print materials for the physician on the HCT survivors', 'Hematopoietic cell transplantation (HCT', 'Technology-enabled activation of skin cancer screening', 'teledermoscopy (PAE\u2009+\u2009Phys+TD']","['risk of skin cancer and importance of conducting a full-body skin exam', 'skin cancer screening rates']","[{'cui': 'C4517865', 'cui_str': '720'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018939', 'cui_str': 'Disorder of hematopoietic system'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]","[{'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C3853034', 'cui_str': 'Patient Activation'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0034036', 'cui_str': 'Printed material'}, {'cui': 'C0436149', 'cui_str': 'Examination of skin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0033131', 'cui_str': 'Primary care physician'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0562342', 'cui_str': 'Empowered'}, {'cui': 'C0007114', 'cui_str': 'Malignant neoplasm of skin'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0007114', 'cui_str': 'Malignant neoplasm of skin'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0436149', 'cui_str': 'Examination of skin'}, {'cui': 'C2919584', 'cui_str': 'Screening for malignant neoplasm of skin'}]",,0.0260647,"Patients on the PAE + Phys arm will be further randomized 1:1 to the teledermoscopy (PAE + Phys+TD) adding physician receipt of a portable dermatoscope to upload images of suspect lesions for review by the study dermatologist and an online course with descriptions of dermoscopic images for skin cancers. ","[{'ForeName': 'Saro H', 'Initials': 'SH', 'LastName': 'Armenian', 'Affiliation': 'Department of Population Sciences, City of Hope, 1500, East Duarte Road, Duarte, CA, 91010-3000, USA. sarmenian@coh.org.'}, {'ForeName': 'Lanie', 'Initials': 'L', 'LastName': 'Lindenfeld', 'Affiliation': 'Department of Population Sciences, City of Hope, 1500, East Duarte Road, Duarte, CA, 91010-3000, USA.'}, {'ForeName': 'Aleksi', 'Initials': 'A', 'LastName': 'Iukuridze', 'Affiliation': 'Department of Population Sciences, City of Hope, 1500, East Duarte Road, Duarte, CA, 91010-3000, USA.'}, {'ForeName': 'Meagan', 'Initials': 'M', 'LastName': 'Echevarria', 'Affiliation': 'Department of Population Sciences, City of Hope, 1500, East Duarte Road, Duarte, CA, 91010-3000, USA.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Bebel', 'Affiliation': 'Department of Population Sciences, City of Hope, 1500, East Duarte Road, Duarte, CA, 91010-3000, USA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Coleman', 'Affiliation': 'Department of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.'}, {'ForeName': 'Ryotaro', 'Initials': 'R', 'LastName': 'Nakamura', 'Affiliation': 'Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.'}, {'ForeName': 'Farah', 'Initials': 'F', 'LastName': 'Abdullah', 'Affiliation': 'Department of Surgery, City of Hope, Duarte, CA, USA.'}, {'ForeName': 'Badri', 'Initials': 'B', 'LastName': 'Modi', 'Affiliation': 'Department of Surgery, City of Hope, Duarte, CA, USA.'}, {'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': 'Oeffinger', 'Affiliation': 'Department of Medicine, Community and Family Medicine and Population Health Sciences, Duke Cancer Institution, Duke, North Carolina, USA.'}, {'ForeName': 'Karen M', 'Initials': 'KM', 'LastName': 'Emmons', 'Affiliation': 'Department of Social and Behavioral Sciences, Harvard TH Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Ashfaq A', 'Initials': 'AA', 'LastName': 'Marghoob', 'Affiliation': 'Department of Dermatology, Memorial-Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Alan C', 'Initials': 'AC', 'LastName': 'Geller', 'Affiliation': 'Department of Social and Behavioral Sciences, Harvard TH Chan School of Public Health, Boston, MA, USA.'}]",BMC cancer,['10.1186/s12885-020-07232-2'] 2412,32433709,Environmental exposure to lead and cadmium and hearing loss in Chinese adults: A case-control study.,"Hearing loss is the second most common nonfatal problem affecting the Chinese population. Historical studies have suggested an association between exposure to heavy metals, such as cadmium and lead, and hearing loss. Few studies have investigated this relationship in the general population in China. We conducted a case-control study with 1008 pairs of participants from a cross-sectional epidemiological survey conducted in Zhejiang Province. A self-designed questionnaire was adopted to collect information on demographics, chronic diseases, lifestyles and environmental noise. Pure-tone averages of hearing thresholds at frequencies of 0.5, 1, 2, and 4 kHz were computed. Blood lead and cadmium levels were analyzed with an atomic absorption spectrometer. After adjusting for all other potential confounding factors, compared with the lowest blood cadmium quartile (0.00-0.53 μg/L), blood cadmium quartile 2 (0.54-0.92 μg/L), quartile 3 (0.93-1.62 μg/L) and quartile 4 (1.63-57.81 μg/L) exhibited significantly elevated risks for hearing loss, with odds ratios of 1.932 (95% CI: 1.356-2.751), 2.036 (95% CI: 1.423-2.914) and 1.495 (95% CI: 1.048-2.133), respectively (P-trend<0.001). However, an association of lead with hearing loss was not found. Young age (less than 60 years), male sex and current smoking were associated with increased blood cadmium concentration. Additionally, a positive association between blood cadmium and lead concentrations was found. Therefore, we conclude that exposure to environmental cadmium may be a risk factor for hearing loss among the general population in China.",2020,"Young age (less than 60 years), male sex and current smoking were associated with increased blood cadmium concentration.","['Chinese adults', 'general population in China', '1008 pairs of participants from a cross-sectional epidemiological survey conducted in Zhejiang Province', 'Young age (less than 60 years), male sex and current smoking']",[],"['lowest blood cadmium quartile', 'Blood lead and cadmium levels', 'blood cadmium concentration', 'hearing loss', 'blood cadmium and lead concentrations', 'Hearing loss']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0014507', 'cui_str': 'Epidemiology'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}]",[],"[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0855870', 'cui_str': 'Blood cadmium'}, {'cui': 'C0853362', 'cui_str': 'Blood lead'}, {'cui': 'C0202347', 'cui_str': 'Cadmium measurement, urine'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0011053', 'cui_str': 'Deafness'}, {'cui': 'C0023175', 'cui_str': 'Lead'}]",1008.0,0.0472356,"Young age (less than 60 years), male sex and current smoking were associated with increased blood cadmium concentration.","[{'ForeName': 'Da-Hui', 'Initials': 'DH', 'LastName': 'Wang', 'Affiliation': 'Medical School, Hangzhou Normal University, Hangzhou, Zhejiang, PR China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Xu', 'Affiliation': 'Medical School, Hangzhou Normal University, Hangzhou, Zhejiang, PR China.'}, {'ForeName': 'Yi-Hua', 'Initials': 'YH', 'LastName': 'Zheng', 'Affiliation': ""Jiangshan People's Hospital, Jiangshan, Zhejiang, PR China.""}, {'ForeName': 'Dong-Sheng', 'Initials': 'DS', 'LastName': 'Gu', 'Affiliation': ""Hospital of Zhejiang Provincial Headquarters of the Chinese People's Armed Police Force, Jiaxing, Zhejiang, PR China.""}, {'ForeName': 'Ya-Jun', 'Initials': 'YJ', 'LastName': 'Zhu', 'Affiliation': 'Medical School, Hangzhou Normal University, Hangzhou, Zhejiang, PR China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Ren', 'Affiliation': 'Medical School, Hangzhou Normal University, Hangzhou, Zhejiang, PR China.'}, {'ForeName': 'Shi-Chang', 'Initials': 'SC', 'LastName': 'Wang', 'Affiliation': 'Medical School, Hangzhou Normal University, Hangzhou, Zhejiang, PR China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Medical School, Hangzhou Normal University, Hangzhou, Zhejiang, PR China.'}, {'ForeName': 'Liang-Wen', 'Initials': 'LW', 'LastName': 'Xu', 'Affiliation': 'Medical School, Hangzhou Normal University, Hangzhou, Zhejiang, PR China.'}]",PloS one,['10.1371/journal.pone.0233165'] 2413,32556055,Mechanical evaluation of tibial fixation of the hamstring tendon in anterior cruciate ligament double-bundle reconstruction with and without interference screws.,"OBJECTIVE The objective of this study was to compare two postero-lateral bundle (PLB) tibial fixation techniques for the reconstruction of the anterior cruciate ligament with double bundle: a technique without the use of an interference screw, preserving the native tibial insertion of the tendons of the gracilis and semitendineous muscles, and a technique with the use of an interference screw and without preserving the insertion of the tendons. METHODS A comparative study was conducted in cadavers with a universal mechanical test machine. In total, 23 cadaver knees were randomized for tibial fixation of the PLB using the two techniques: Maintaining the tibial insertion of the tendons during reconstruction, without the use of an interference screw (group A, 11 cases); and fixating the graft with an interference screw, without maintaining the insertion of the tendons (group B, 12 cases). A continuous traction was performed (20 mm/min) in the same direction as the produced tunnel, and force (N), elongation (mm), rigidity (N/mm), and tension (N/mm2) were objectively determined in each group. RESULTS Group A exhibited a maximum force (MF) of 315.4±124.7 N; maximum tension of 13.57±3.65 N/mm2; maximum elongation of 19.73±4.76 mm; force at the limit of proportionality (FLP) of 240.6±144.0 N; and an elongation at the limit of proportionality of 14.37±6.58 mm. Group B exhibited a MF of 195.7±71.8 N; maximum tension of 8.8±3.81 N/mm2; maximum elongation of 15.3±10.73 mm; FLP of 150.1±68.7 N; and an elongation at the limit of proportionality of 6.86±2.42 mm. When comparing the two groups, significant differences were observed in the variables of maximum force (p=0.016), maximum tension (p=0.019), maximum elongation (p=0.007), and elongation at the limit of proportionality (p=0.003). CONCLUSION The use of the native insertion of the semitendineous and gracilis tendons, without an additional fixation device, presented mechanical superiority over their fixation with interference screws.",2020,"When comparing the two groups, significant differences were observed in the variables of maximum force (p=0.016), maximum tension (p=0.019), maximum elongation (p=0.007), and elongation at the limit of proportionality (p=0.003). ","['cadavers with a universal mechanical test machine', 'anterior cruciate ligament with double bundle', '23 cadaver knees']","['interference screw (group A, 11 cases); and fixating the graft with an interference screw, without maintaining the insertion of the tendons', 'anterior cruciate ligament double-bundle reconstruction with and without interference screws', 'Mechanical evaluation of tibial fixation of the hamstring tendon', 'postero-lateral bundle (PLB) tibial fixation techniques']","['maximum force (MF', 'variables of maximum force', 'maximum tension', 'maximum elongation']","[{'cui': 'C0006629', 'cui_str': 'Cadaver'}, {'cui': 'C0175671', 'cui_str': 'Universal'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0336779', 'cui_str': 'Machine'}, {'cui': 'C0078960', 'cui_str': 'Structure of anterior cruciate ligament of knee joint'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}]","[{'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0005975', 'cui_str': 'Bone screw'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0039508', 'cui_str': 'Tendon structure'}, {'cui': 'C0078960', 'cui_str': 'Structure of anterior cruciate ligament of knee joint'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0040184', 'cui_str': 'Bone structure of tibia'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C1267157', 'cui_str': 'Hamstring Tendons'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0233494', 'cui_str': 'Tension'}]",,0.0548917,"When comparing the two groups, significant differences were observed in the variables of maximum force (p=0.016), maximum tension (p=0.019), maximum elongation (p=0.007), and elongation at the limit of proportionality (p=0.003). ","[{'ForeName': 'Anderson de Aquino', 'Initials': 'AA', 'LastName': 'Santos', 'Affiliation': 'Departamento de Ortopedia e Traumatologia, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Carneiro-Filho', 'Affiliation': 'Departamento de Ortopedia e Traumatologia, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Roberto Freire da Mota E', 'Initials': 'RFDME', 'LastName': 'Albuquerque', 'Affiliation': 'Instituto de Ortopedia e Traumatologia (IOT), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'João Paulo Freire Martins de', 'Initials': 'JPFM', 'LastName': 'Moura', 'Affiliation': 'Departamento de Ortopedia e Traumatologia, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Carlos Eduardo', 'Initials': 'CE', 'LastName': 'Franciozi', 'Affiliation': 'Departamento de Ortopedia e Traumatologia, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Marcus Vinícius Malheiros', 'Initials': 'MVM', 'LastName': 'Luzo', 'Affiliation': 'Departamento de Ortopedia e Traumatologia, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, SP, BR.'}]","Clinics (Sao Paulo, Brazil)",['10.6061/clinics/2020/e1123'] 2414,32702892,Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.,"Lefamulin is a novel pleuromutilin antibiotic with potent in vitro activity against key community-acquired bacterial pneumonia (CABP) pathogens. However, the clinical efficacy and safety of lefamulin for treating CABP remains unclear.An integrated analysis of 2 phase III trials investigating the clinical efficacy and safety of lefamulin vs moxifloxacin in the treatment of CABP was conducted.A total of 1289 patients (lefamulin group: 646 and moxifloxacin group: 643) were included in this analysis. The early clinical response rate was 89.3% and 90.5% among lefamulin and moxifloxacin group, respectively. Lefamulin was noninferior to moxifloxacin (89.3% vs 90.5%, RR: 0.99, 95% CI: 0.95-1.02, I = 0%). In terms of clinical response at test of cure, no significant difference was observed between the lefamulin and moxifloxacin groups (for modified intention to treat population, RR: 0.98, 95% CI: 0.94-1.02, I = 0%; for clinically evaluable population, RR: 0.96, 95% CI: 0.93-1.00, I = 0%). In the subgroup analysis, the early clinical response rate at early clinical assessment and clinical response rate at test of cure of lefamulin was similar to that of moxifloxacin across different subgpopulations and all baseline CABP pathogens. Lefamulin was associated with a similar risk of adverse events as moxifloxacin.Clinical efficacy and tolerability for lefamulin in the treatment of CABP were similar to those for moxifloxacin.",2020,Clinical efficacy and tolerability for lefamulin in the treatment of CABP were similar to those for moxifloxacin.,"['1289 patients (lefamulin group: 646 and moxifloxacin group: 643', 'community-acquired bacterial pneumonia']","['Lefamulin', 'Lefamulin vs moxifloxacin', 'lefamulin vs moxifloxacin', 'lefamulin', 'moxifloxacin']","['clinical response rate', 'early clinical response rate at early clinical assessment and clinical response rate', 'Clinical efficacy and tolerability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C0456394', 'cui_str': 'Community acquired'}, {'cui': 'C0004626', 'cui_str': 'Bacterial pneumonia'}]","[{'cui': 'C0536495', 'cui_str': 'moxifloxacin'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}]",1289.0,0.0849793,Clinical efficacy and tolerability for lefamulin in the treatment of CABP were similar to those for moxifloxacin.,"[{'ForeName': 'Hung-Jen', 'Initials': 'HJ', 'LastName': 'Tang', 'Affiliation': 'aDepartment of Medicine, Chi Mei Medical Center bDepartment of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan.'}, {'ForeName': 'Jui-Hsiang', 'Initials': 'JH', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Chih-Cheng', 'Initials': 'CC', 'LastName': 'Lai', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021223'] 2415,31887537,Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.,"BACKGROUND Cabozantinib improved progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) compared with everolimus in patients with advanced renal cell carcinoma (RCC) after prior antiangiogenic therapy in the phase III METEOR trial (NCT01865747). Limited data are available on the use of targeted therapies in older patients with advanced RCC. METHODS Efficacy and safety in METEOR were retrospectively analysed for three age subgroups: <65 (n = 394), 65-74 (n = 201) and ≥75 years (n = 63). RESULTS PFS, OS and ORR were improved with cabozantinib compared with everolimus in all age subgroups. The PFS hazard ratios (HRs) were 0.53 (95% confidence interval [CI]: 0.41-0.68), 0.53 (95% CI: 0.37-0.77) and 0.38 (95% CI: 0.18-0.79) for <65, 65-74 and ≥75 years, respectively, and the OS HRs were 0.72 (95% CI: 0.54-0.95), 0.66 (95% CI: 0.44-0.99) and 0.57 (95% CI: 0.28-1.14). The ORR for cabozantinib versus everolimus was 15% vs 5%, 21% vs 2% and 19% vs 0%, respectively. No significant differences were observed in PFS or OS with age as a categorical or continuous variable. Grade III/IV adverse events (AEs) were generally consistent across subgroups, although fatigue, hypertension and hyponatraemia occurred more frequently in older patients treated with cabozantinib. Dose reductions to manage AEs were more frequent in patients receiving cabozantinib than in those receiving everolimus. Dose reductions and treatment discontinuation due to AEs were more frequent in older patients in both treatment groups. CONCLUSIONS Cabozantinib improved PFS, OS and ORR compared with everolimus in previously treated patients with advanced RCC, irrespective of age group, supporting use in all age categories. Proactive dose modification and supportive care may help to mitigate AEs in older patients while maintaining efficacy.",2020,"RESULTS PFS, OS and ORR were improved with cabozantinib compared with everolimus in all age subgroups.","['patients with advanced renal cell carcinoma', 'three age subgroups: <65 (n\xa0=\xa0394), 65-74 (n\xa0=\xa0201) and ≥75 years (n\xa0=\xa063', 'patients with advanced renal cell carcinoma (RCC) after prior', 'older patients', 'older patients with advanced RCC']","['everolimus', 'antiangiogenic therapy', 'cabozantinib versus everolimus']","['PFS, OS\xa0and ORR', 'fatigue, hypertension and hyponatraemia', 'PFS hazard ratios (HRs', 'progression-free survival (PFS), overall survival (OS) and objective response rate (ORR', 'ORR', 'PFS or OS', 'PFS, OS and ORR', 'Grade III/IV adverse events (AEs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007134', 'cui_str': 'Renal cell carcinoma'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C2363719', 'cui_str': 'Antiangiogenic therapy'}, {'cui': 'C3181682', 'cui_str': 'cabozantinib'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0020625', 'cui_str': 'Hyponatremia'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205617', 'cui_str': 'Poorly differentiated'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.167333,"RESULTS PFS, OS and ORR were improved with cabozantinib compared with everolimus in all age subgroups.","[{'ForeName': 'Frede', 'Initials': 'F', 'LastName': 'Donskov', 'Affiliation': 'Aarhus University Hospital, Aarhus, Denmark. Electronic address: Frede.Donskov@auh.rm.dk.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Motzer', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Voog', 'Affiliation': 'Centre Jean Bernard Clinique Victor Hugo, Le Mans, France.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Hovey', 'Affiliation': 'Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Randwick, Australia.'}, {'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Grüllich', 'Affiliation': 'National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Louise M', 'Initials': 'LM', 'LastName': 'Nott', 'Affiliation': 'Royal Hobart Hospital, Hobart, Australia.'}, {'ForeName': 'Katharine', 'Initials': 'K', 'LastName': 'Cuff', 'Affiliation': 'Princess Alexandra Hospital, Woolloongabba, Australia.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Gil', 'Affiliation': 'Institute Jules Bordet, Brussels, Belgium.'}, {'ForeName': 'Niels Viggo', 'Initials': 'NV', 'LastName': 'Jensen', 'Affiliation': 'Odense Universitetshospital, Odense, Denmark.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Chevreau', 'Affiliation': 'Institut Universitaire Du Cancer Toulouse, Toulouse, France.'}, {'ForeName': 'Sylvie', 'Initials': 'S', 'LastName': 'Negrier', 'Affiliation': 'Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Depenbusch', 'Affiliation': 'Onkologische Schwerpunktpraxis Gütersloh, Gütersloh, Germany.'}, {'ForeName': 'Lothar', 'Initials': 'L', 'LastName': 'Bergmann', 'Affiliation': 'Universitätsklinik Frankfurt Hospital, Frankfurt, Germany.'}, {'ForeName': 'Izzy', 'Initials': 'I', 'LastName': 'Cornelio', 'Affiliation': 'Exelixis, Alameda, CA, USA.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Champsaur', 'Affiliation': 'Exelixis, Alameda, CA, USA.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Escudier', 'Affiliation': 'Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Sumanta', 'Initials': 'S', 'LastName': 'Pal', 'Affiliation': 'City of Hope National Medical Center, Duarte, CA, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Powles', 'Affiliation': 'Barts Cancer Institute, Queen Mary University of London, London, UK.'}, {'ForeName': 'Toni K', 'Initials': 'TK', 'LastName': 'Choueiri', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA, USA.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.10.032'] 2416,31255494,Blood amyloid levels and risk of dementia in the Ginkgo Evaluation of Memory Study (GEMS): A longitudinal analysis.,"INTRODUCTION Both high or low plasma amyloid levels have been associated with risk of dementia in nondemented subjects. METHODS We examined baseline plasma β-amyloid (Aβ) levels in relationship to incident dementia during a period of 8.5 years in 2840 subjects age >75 years; 2381 were cognitively normal (CN) and 450 mild cognitive impairment. RESULTS Increased plasma Aβ1-40 and Aβ1-42 levels were associated with gender (women), age, low education, creatinine levels, history of stroke, and hypertension. CN participants who developed dementia had lower levels of Aβ1-42 and Aβ1-42/Aβ1-40 ratio compared with those who did not. Aβ levels did not predict dementia in mild cognitive impairment participants. DISCUSSION There was an inverse association between Aβ1-42 and Aβ1-42/Aβ1-40 ratio to risk of dementia in CN participants. Cerebral and cardiovascular disease and renal function are important determinants of increased Aβ levels and must be considered in evaluations of relationship of plasma Aβ and subsequent risk of dementia.",2019,CN participants who developed dementia had lower levels of Aβ1-42 and Aβ1-42/Aβ1-40 ratio compared with those who did not.,"['mild cognitive impairment participants', 'incident dementia during a period of 8.5\xa0years in 2840 subjects age >75 years; 2381 were cognitively normal (CN) and 450 mild cognitive impairment']",['Memory Study (GEMS'],"['baseline plasma β-amyloid (Aβ) levels', 'Blood amyloid levels and risk of dementia']","[{'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C4517877', 'cui_str': '8.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C3844104', 'cui_str': '450'}]","[{'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0445501', 'cui_str': 'Gem'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0002716', 'cui_str': 'Amyloid Substance'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}]",2840.0,0.0827322,CN participants who developed dementia had lower levels of Aβ1-42 and Aβ1-42/Aβ1-40 ratio compared with those who did not.,"[{'ForeName': 'Oscar L', 'Initials': 'OL', 'LastName': 'Lopez', 'Affiliation': 'Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA; Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: lopezol@upmc.edu.'}, {'ForeName': 'Yuefang', 'Initials': 'Y', 'LastName': 'Chang', 'Affiliation': 'Department of Neurosurgery, University of Pittsburgh, Pittsburgh, PA, USA; Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Diane G', 'Initials': 'DG', 'LastName': 'Ives', 'Affiliation': 'Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Beth E', 'Initials': 'BE', 'LastName': 'Snitz', 'Affiliation': 'Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Annette L', 'Initials': 'AL', 'LastName': 'Fitzpatrick', 'Affiliation': 'Department of Family Medicine, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Michelle C', 'Initials': 'MC', 'LastName': 'Carlson', 'Affiliation': 'Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Stephen R', 'Initials': 'SR', 'LastName': 'Rapp', 'Affiliation': 'Department of Psychiatry and Behavioral Medicine, Wake Forest University, Winston-Salem, NC, USA.'}, {'ForeName': 'Jeffrey D', 'Initials': 'JD', 'LastName': 'Williamson', 'Affiliation': ""Department of Medicine and the Sticht Center for Healthy Aging and Alzheimer's Prevention, Wake Forest University, Winston-Salem, NC, USA.""}, {'ForeName': 'Russell P', 'Initials': 'RP', 'LastName': 'Tracy', 'Affiliation': 'Department of Pathology, University of Vermont, Colchester, VT, USA; Department of Biochemistry, University of Vermont, Colchester, VT, USA.'}, {'ForeName': 'Steven T', 'Initials': 'ST', 'LastName': 'DeKosky', 'Affiliation': 'Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, FL, USA; Department of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Lewis H', 'Initials': 'LH', 'LastName': 'Kuller', 'Affiliation': 'Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.'}]",Alzheimer's & dementia : the journal of the Alzheimer's Association,['10.1016/j.jalz.2019.04.008'] 2417,32754926,Note on the role of the placebo group in the short-term and long-term hazard ratio model.,,2020,,[],['placebo'],[],[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.0833684,,"[{'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Flandre', 'Affiliation': ""INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Paris, France.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': ""O'Quigley"", 'Affiliation': 'INSERM, Sorbonne Université, LPSM, Sorbonne University, Paris, France.'}]",Statistics in medicine,['10.1002/sim.8424'] 2418,32755035,CALIBRATE: A Phase 2 Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.,"OBJECTIVES To assess safety and mechanism of action, and generate preliminary efficacy data on rituximabfollowed by belimumab for refractory lupus nephritis. METHODS Forty three participants with recurrent or refractory lupus nephritis were treated with rituximab, cyclophosphamide, and glucocorticoids, followed by randomization to belimumab infusions (RCB) until Week 48, or no infusion (RC) in a multicenter, randomized, open label clinical trial. Patients were followed until Week 96. Total and autoreactive B cell subsets were analyzed by flow cytometry. RESULTS Addition of belimumab did not increase the incidence of adverse events. At Week 48, complete or partial renal response occurred in 11/21 (52%) in those receiving belimumab, versus 9/22 (41%) in those that did not (p=0.452). LN was the major reason for treatment failure. B cell depletion occurred in both groups, but B cells remained lower in those receiving belimumab (Week 60: Geom. Mean=53 cells/μL vs. 11, p=0.0012). The percentage of total and autoreactive transitional B cells increased from baseline to Week 48 in both groups, however the percentage of total and autoreactive naïve B cells (p=0.0349) decreased in the belimumab group, consistent with impaired maturation of naïve B cells and enhanced censoring of autoreactive B cells. CONCLUSION The addition of belimumab to rituximab and cyclophosphamide was safe. This regimen diminished maturation of transitional to naïve B cells during B cell reconstitution and enhanced negative selection of autoreactive B cells. The combination did not improve clinical efficacy compared to B cell depletion alone.",2020,"The percentage of total and autoreactive transitional B cells increased from baseline to Week 48 in both groups, however the percentage of total and autoreactive naïve B cells (p=0.0349) decreased in the belimumab group, consistent with impaired maturation of naïve B cells and enhanced censoring of autoreactive B cells. ","['Forty three participants with recurrent or refractory lupus nephritis were treated with', 'Lupus Nephritis']","['Rituximab Plus Cyclophosphamide', 'rituximabfollowed', 'rituximab and cyclophosphamide', 'CALIBRATE', 'rituximab, cyclophosphamide, and glucocorticoids, followed by randomization to belimumab infusions (RCB) until Week 48, or no infusion (RC']","['maturation of naïve B cells and enhanced censoring of autoreactive B cells', 'clinical efficacy', 'percentage of total and autoreactive transitional B cells', 'B cell depletion', 'complete or partial renal response', 'Total and autoreactive B cell subsets', 'incidence of adverse events', 'percentage of total and autoreactive naïve B cells']","[{'cui': 'C0450368', 'cui_str': '43'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0024143', 'cui_str': 'SLE glomerulonephritis syndrome'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C1723401', 'cui_str': 'belimumab'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0004561', 'cui_str': 'B lymphocyte'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1512631', 'cui_str': 'Immature B-Lymphocytes'}, {'cui': 'C0333668', 'cui_str': 'Depletion'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0079004', 'cui_str': 'B-Cell Subsets'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",43.0,0.0654134,"The percentage of total and autoreactive transitional B cells increased from baseline to Week 48 in both groups, however the percentage of total and autoreactive naïve B cells (p=0.0349) decreased in the belimumab group, consistent with impaired maturation of naïve B cells and enhanced censoring of autoreactive B cells. ","[{'ForeName': 'Yemil', 'Initials': 'Y', 'LastName': 'Atisha-Fregoso', 'Affiliation': 'Feinstein Institute for Medical Research, Center for Autoimmune, Musculoskeletal and Hematopoetic Diseases, Manhasset, New York, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Malkiel', 'Affiliation': 'Feinstein Institute for Medical Research, Center for Autoimmune, Musculoskeletal and Hematopoetic Diseases, Manhasset, New York, USA.'}, {'ForeName': 'Kristina M', 'Initials': 'KM', 'LastName': 'Harris', 'Affiliation': 'Immune Tolerance Network, Bethesda, Maryland, USA.'}, {'ForeName': 'Margie', 'Initials': 'M', 'LastName': 'Byron', 'Affiliation': 'RHO, Durham, North Carolina, USA.'}, {'ForeName': 'Linna', 'Initials': 'L', 'LastName': 'Ding', 'Affiliation': 'National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.'}, {'ForeName': 'Sai', 'Initials': 'S', 'LastName': 'Kanaparthi', 'Affiliation': 'Immune Tolerance Network, Bethesda, Maryland, USA.'}, {'ForeName': 'William T', 'Initials': 'WT', 'LastName': 'Barry', 'Affiliation': 'RHO, Durham, North Carolina, USA.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Gao', 'Affiliation': 'National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Ryker', 'Affiliation': '1155 Battery Street, San Francisco, California, USA, San Francisco.'}, {'ForeName': 'Patti', 'Initials': 'P', 'LastName': 'Tosta', 'Affiliation': 'Immune Tolerance Network, Bethesda, Maryland, USA.'}, {'ForeName': 'Anca D', 'Initials': 'AD', 'LastName': 'Askanase', 'Affiliation': 'Columbia University Medical Center, Internal Medicine, Division of Rheumatology, New York, New York, USA.'}, {'ForeName': 'Susan A', 'Initials': 'SA', 'LastName': 'Boackle', 'Affiliation': 'University of Colorado, Denver, Colorado, USA.'}, {'ForeName': 'W Winn', 'Initials': 'WW', 'LastName': 'Chatham', 'Affiliation': 'UAB, Medicine/Rheumatology, FOT 858 1720 2nd Ave S, Birmingham, Alabama, USA.'}, {'ForeName': 'Diane L', 'Initials': 'DL', 'LastName': 'Kamen', 'Affiliation': 'Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, South Carolina, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Karp', 'Affiliation': 'UT Southwestern Medical Center, Rheumatic Diseases Division, Dallas, Texas, USA.'}, {'ForeName': 'Kyriakos A', 'Initials': 'KA', 'LastName': 'Kirou', 'Affiliation': 'Hospital for Special Surgery, Rheumatology, New York, New York, USA.'}, {'ForeName': 'S Sam', 'Initials': 'SS', 'LastName': 'Lim', 'Affiliation': 'Emory University, Division of Rheumatology, Atlanta, Georgia, USA.'}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Marder', 'Affiliation': 'Medical Center of Aurora, Aurora, Colorado, USA.'}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'McMahon', 'Affiliation': 'UCLA, Rheumatology, 1000 Veteran Ave 32-59, Box 951670, Los Angeles, California, USA.'}, {'ForeName': 'Samir V', 'Initials': 'SV', 'LastName': 'Parikh', 'Affiliation': 'The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.'}, {'ForeName': 'William F', 'Initials': 'WF', 'LastName': 'Pendergraft', 'Affiliation': 'University of North Carolina Kidney Center, Division of Nephrology and Hypertension, Chapel Hill, North Carolina, USA.'}, {'ForeName': 'Amber S', 'Initials': 'AS', 'LastName': 'Podoll', 'Affiliation': 'University of Colorado, Denver, Colorado, USA.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Saxena', 'Affiliation': 'NYU School of Medicine, New York, New York, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Wofsy', 'Affiliation': 'Russell/Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Betty', 'Initials': 'B', 'LastName': 'Diamond', 'Affiliation': 'The Feinstein Institute for Medical Research North Shore, Autoimmune, Musculoskeletal and Hematopoietic Diseases, 350 Community Drive, Manhasset, New York, USA.'}, {'ForeName': 'Dawn E', 'Initials': 'DE', 'LastName': 'Smilek', 'Affiliation': 'Immune Tolerance Network, San Francisco, California, USA, Bethesda.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Aranow', 'Affiliation': 'Feinstein Institute for Medical Research, Manhasset, New York, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': ""Dall'Era"", 'Affiliation': 'Yale University School of Medicine, Dept. of Medicine, Section of Rheumatology, New Haven, Connecticut, USA.'}]","Arthritis & rheumatology (Hoboken, N.J.)",['10.1002/art.41466'] 2419,32755065,A new surgical approach of direct perineal wound full-thick closure for perineal wound of abdominoperineal resection for rectal carcinoma: A prospective cohort trial.,"Perineal wound complications after APR have high morbidity in the colorectal surgical department. Although some approaches have been figured out to solve this clinical focus, the outcomes are still not satisfied. Herein, this prospective comparative clinical trial has been designed to evaluate a new surgical procedure of direct perineal wound full-thick closure (DPWC), compared with conventional perineal wound closure (CPWC), with hopes of making wound healing with less complications. In addition, an evaluation of an incision negative wound pressure therapy, as another focus in this field, was also analysed in the DPWC group. A total of 44 participants in our department were recruited from March 2018 to March 2020, divided into two groups randomly, CPWC group and DPWC group. The patients' characteristics, such as age, gender, BMI, smoking, alcohol consumption, comorbidities, CEA level, and high-risk of invasion, were recorded without statistical significance between the CPWC group and DPWC group. After the same standard abdominal phase, these two groups were performed in different perineal phases. And then, operative and postoperative outcomes were analysed with different statistical methods. Data on wound healing time and length of stay in the DPWC group were shorter than those in the CPWC group (P < .05). Furthermore, cases of wound infection within 30 days in the DPWC group were also less than that in the CPWC group (P < .05). However, no difference was found between the incisional negative pressure wound therapy assisted group (NPA group) and non- incisional negative pressure wound therapy assisted group (non-NPA group). During this study, hypoalbuminemia, as an independent high-risk factor, impacted perineal wound healing. (P = .0271) In conclusion, DPWC is a new surgical approach, which can lead to a better outcome than DPWC, and it can be another surgical procedure for clinicians. In addition, hypoalbuminemia should be interfered for avoiding perineal wound complications.",2020,Data on wound healing time and length of stay in the DPWC group were shorter than those in the CPWC group (P < .05).,"['44 participants in our department were recruited from March 2018 to March 2020', 'rectal carcinoma']","['abdominoperineal resection', 'direct perineal wound full-thick closure', 'CPWC group and DPWC', 'conventional perineal wound closure (CPWC', 'direct perineal wound full-thick closure (DPWC', 'DPWC', 'CPWC']","['Perineal wound complications', 'wound infection', 'wound healing time and length of stay']","[{'cui': 'C0007113', 'cui_str': 'Rectal cancer'}]","[{'cui': 'C2004459', 'cui_str': 'Abdominoperineal resection'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0031066', 'cui_str': 'Perineal'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0450015', 'cui_str': 'Method of wound closure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0031066', 'cui_str': 'Perineal'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0043241', 'cui_str': 'Local infection of wound'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}]",44.0,0.0218492,Data on wound healing time and length of stay in the DPWC group were shorter than those in the CPWC group (P < .05).,"[{'ForeName': 'Yong-Ping', 'Initials': 'YP', 'LastName': 'Yang', 'Affiliation': 'The Department of General Surgery, the Second Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Ling-Yun', 'Initials': 'LY', 'LastName': 'Yu', 'Affiliation': 'The Department of Ear Nose and Throat Surgery, the First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': 'The Department of General Surgery, the Second Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Mu', 'Affiliation': 'The Department of General Surgery, the Second Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Jian-Nan', 'Initials': 'JN', 'LastName': 'Li', 'Affiliation': 'The Department of General Surgery, the Second Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Feng-Jia', 'Initials': 'FJ', 'LastName': 'Shang', 'Affiliation': 'The Department of General Surgery, the Second Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Xian-Feng', 'Initials': 'XF', 'LastName': 'Wu', 'Affiliation': 'The Department of General Surgery, the Second Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Tong-Jun', 'Initials': 'TJ', 'LastName': 'Liu', 'Affiliation': 'The Department of General Surgery, the Second Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': 'The Department of General Surgery, the Second Hospital of Jilin University, Changchun, China.'}]",International wound journal,['10.1111/iwj.13470'] 2420,32755086,A randomised trial comparing the Ambu® Aura-i TM and the Ambu® Aura Gain TM laryngeal mask as conduit for tracheal intubation in children.,"BACKGROUND The Ambu Aura Gain is a newer second-generation supraglottic airway device designed for fibreoptic bronchoscopy (FOB)-guided tracheal intubation. METHODS 57 patients between 18 months and 6 years of age were randomized to receive either the Ambu Aura-I (n:29) or the Ambu Aura Gain (n:28). Primary endpoint was the time for intubation. Secondary endpoints were the time and number of attempts for device insertion, the feasibility of FOB-guided intubation, the oropharyngeal leak pressure (OLP) the fibreoptic grade of laryngeal view and possible complications. RESULTS No difference was found in the time for intubation, the time for device insertion or the fibreoptic grade of laryngeal view. First-attempt device insertion was successful in all (n= 28) patients with Aura Gain (100%) and in 27 (97%) with Aura-i. In the Aura-i group one insertion failed. A significant difference in successful intubation was seen between the Aura-i and the Aura Gain (79% vs 100%, respectively, p=0,0011). Also found was a significant difference in the mean OLP (SD) between the Ambu Aura-i and the Ambu Aura Gain (18 (3) vs 20 (3) cm H2O, respectively; mean difference [MD] - 2 cmH2 O; P = 0.005). CONCLUSIONS The Ambu Aura Gain served as a reliable device for FOB-guided tracheal intubation. Even if the time for intubation, when intubation was possible did not differ, the Aura-i showed only 79% intubation success, making it a doubtful device for FOB-guided tracheal intubation in cases of emergency and severe hypoxemia in small children.",2020,"No difference was found in the time for intubation, the time for device insertion or the fibreoptic grade of laryngeal view.","['57 patients between 18 months and 6 years of age', 'children']","['Ambu® Aura-i TM and the Ambu® Aura Gain TM laryngeal mask', 'Ambu Aura-I (n:29) or the Ambu Aura Gain (n:28', 'fibreoptic bronchoscopy (FOB)-guided tracheal intubation']","['Aura Gain', 'time for intubation, the time for device insertion or the fibreoptic grade of laryngeal view', 'time and number of attempts for device insertion, the feasibility of FOB-guided intubation, the oropharyngeal leak pressure (OLP) the fibreoptic grade of laryngeal view and possible complications', 'mean OLP (SD', 'successful intubation', 'Ambu Aura Gain', 'time for intubation', 'mean difference [MD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0236018', 'cui_str': 'Aura'}, {'cui': 'C0162645', 'cui_str': 'Laryngeal mask'}, {'cui': 'C0189391', 'cui_str': 'Fiberoptic bronchoscopy'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}]","[{'cui': 'C0236018', 'cui_str': 'Aura'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0023078', 'cui_str': 'Laryngeal'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0189391', 'cui_str': 'Fiberoptic bronchoscopy'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0521367', 'cui_str': 'Oropharyngeal structure'}, {'cui': 'C0332234', 'cui_str': 'Leaking'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0332149', 'cui_str': 'Possible'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1272703', 'cui_str': 'Successful'}]",57.0,0.105518,"No difference was found in the time for intubation, the time for device insertion or the fibreoptic grade of laryngeal view.","[{'ForeName': 'Lukas', 'Initials': 'L', 'LastName': 'Gasteiger', 'Affiliation': 'Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria - lukas.gasteiger@tirol-kliniken.'}, {'ForeName': 'Elgar', 'Initials': 'E', 'LastName': 'Oswald', 'Affiliation': 'Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Keplinger', 'Affiliation': 'Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Putzer', 'Affiliation': 'Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Luger', 'Affiliation': 'Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Neururer', 'Affiliation': 'Department of Medical Statistics, Informatics and Health Economics, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Keller', 'Affiliation': 'Department of Anaesthesiology, Schulthess Klinik, Zürich, Switzerland.'}, {'ForeName': 'Berthold', 'Initials': 'B', 'LastName': 'Moser', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Spital Limmattal, Schlieren, Switzerland.'}]",Minerva anestesiologica,['10.23736/S0375-9393.20.14422-5'] 2421,32755100,Investigating the preventive effect of vitamins C and E on preeclampsia in nulliparous pregnant women.,"Objectives Preeclampsia is a hypertensive disorder associated with pregnancy and is the leading cause of both maternal and neonatal morbidity and mortality. Recent reports suggest that free radical-induced endothelial cell injury might be an etiologic factor in the pathogenesis of preeclampsia. The aim of this study was to determine the protective effects of vitamins C and E for the prevention of preeclampsia. Methods This clinical trial was conducted in the year 2018 in the clinical centers of Lorestan University of Medical Sciences. One hundred and sixty nulliparous women aged 18-38 years without any risk factors for preeclampsia were divided into two groups. The first group received a 400-IU/day dose of vitamin E orally and a 1000-mg/day dose of vitamin C with iron tablets during 20-24 weeks of pregnancy, while the control group received only iron tablets. Finally, the data were analyzed using descriptive statistics and frequency distribution tables. Results The incidence of preeclampsia in the control group was 17.5% and in the intervention group was 5%, which was significantly different. The mean systolic pressures before and after intervention were 99.43 ± 7.8 and 12.44 ± 19.1, respectively, in the control group, and 99.3 ± 8.3 and 106.12 ± 13.25, respectively, in the intervention group (P < 0.001). The mean diastolic pressures before and after intervention in the control group were 62.7 ± 13.6 and 62.7 ± 4.7 (P < 0.001), respectively. Conclusion The results of this study show that vitamins C and E have protective effects against preeclampsia by alleviating the overall blood pressure.",2020,"The incidence of preeclampsia in the control group was 17.5% and in the intervention group was 5%, which was significantly different.","['One hundred and sixty nulliparous women aged 18-38 years without any risk factors for preeclampsia', 'year 2018 in the clinical centers of Lorestan University of Medical Sciences', 'nulliparous pregnant women']","['vitamin C with iron tablets', 'vitamin E', 'control group received only iron tablets', 'vitamins C and E']","['overall blood pressure', 'incidence of preeclampsia', 'mean diastolic pressures', 'mean systolic pressures']","[{'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0425979', 'cui_str': 'Nulliparous'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}]","[{'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",160.0,0.108325,"The incidence of preeclampsia in the control group was 17.5% and in the intervention group was 5%, which was significantly different.","[{'ForeName': 'Nahid', 'Initials': 'N', 'LastName': 'Lorzadeh', 'Affiliation': 'Gynecology Department, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.'}, {'ForeName': 'Yasaman', 'Initials': 'Y', 'LastName': 'Kazemirad', 'Affiliation': 'Faculty of Dentistry, Biruni University, Istanbul, Turkey.'}, {'ForeName': 'Nastran', 'Initials': 'N', 'LastName': 'Kazemirad', 'Affiliation': 'Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}]",Journal of perinatal medicine,['10.1515/jpm-2019-0469'] 2422,32755104,Effects of oral alcohol administration on heat pain threshold and ratings of supra-threshold stimuli.,"Background and aims Evidence for analgesic effects of oral alcohol consumption on heat pain has recently been documented in a placebo-controlled, randomized and double-blind design. We aimed at further investigating these effects and now set the focus on pain threshold and the ratings of supra-threshold pain to cover most of the pain range. Moreover, we now firstly evaluated sex differences in these effects. Methods We investigated 41 healthy participants (22 females) in a randomized, double-blind and placebo-controlled design and targeted two different moderate breath-alcohol levels of 0.06% and 0.08%. Before and after an alcoholic or placebo drink, contact heat was applied at the forearm. Subjects evaluated pain threshold (method of adjustment) and rated pain intensity and pain unpleasantness of supra-threshold stimuli (intensity: threshold +3 °C; duration: 5 s). Results Analgesic effects taking the form of increased pain thresholds were found after both alcohol doses, surprisingly with more pronounced effects for the lower dose. While the high alcohol dose exerted small analgesic effects on pain intensity ratings (i.e. decrease), slightly increased ratings of pain intensity and pain unpleasantness after the low alcohol dose rather suggest pain enhancement. Alcohol did not affect intensity vs. unpleasantness ratings differentially. We found no evidence for sex differences in any of these effects. Conclusions Overall, acute alcohol effects on pain were subtle. Our findings suggest that while low alcohol doses already exert analgesic effects on pain threshold, stronger doses are required for pain reduction on supra-threshold pain levels. Furthermore, sex differences could not be detected within our experimental paradigm but should be further explored in future research. Implications Analgesic effects of sub-toxic alcohol doses - as normally occurring during social drinking - might be weak; however, susceptibility to pain relieving effects of alcohol might be a risk factor for the use of alcohol as self-medication in acute pain states.",2020,"While the high alcohol dose exerted small analgesic effects on pain intensity ratings (i.e. decrease), slightly increased ratings of pain intensity and pain unpleasantness after the low alcohol dose rather suggest pain enhancement.",['41 healthy participants (22 females'],"['oral alcohol', 'oral alcohol consumption', 'placebo']","['pain thresholds', 'heat pain threshold and ratings of supra-threshold stimuli', 'pain threshold (method of adjustment) and rated pain intensity and pain unpleasantness of supra-threshold stimuli', 'pain intensity ratings', 'ratings of pain intensity and pain unpleasantness']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0449310', 'cui_str': 'Method of adjustment'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",41.0,0.229809,"While the high alcohol dose exerted small analgesic effects on pain intensity ratings (i.e. decrease), slightly increased ratings of pain intensity and pain unpleasantness after the low alcohol dose rather suggest pain enhancement.","[{'ForeName': 'Eva Susanne', 'Initials': 'ES', 'LastName': 'Capito', 'Affiliation': 'Physiological Psychology, University of Bamberg, Markusplatz 3, 96045 Bamberg, Germany, Phone: +49 951 863-1847.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Lautenbacher', 'Affiliation': 'Physiological Psychology, University of Bamberg, Bamberg, Germany.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Wolstein', 'Affiliation': 'Pathopsychology, University of Bamberg, Bamberg, Germany.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Horn-Hofmann', 'Affiliation': 'Physiological Psychology, University of Bamberg, Bamberg, Germany.'}]",Scandinavian journal of pain,['10.1515/sjpain-2019-0144'] 2423,32749863,Treatment With Oral Versus Intravenous Acetaminophen in Elderly Trauma Patients With Rib Fractures: A Prospective Randomized Trial.,"BACKGROUND Rib fractures are common injuries among traumatically injured patients, and elderly patients with rib fractures are at increased risk for adverse events and death. The purpose of this study was to determine if oral Per os (PO) acetaminophen is as effective as intravenous (IV) acetaminophen in treating the pain associated with rib fractures. METHODS We performed a single-center, randomized, placebo-controlled, double-blinded study. Trauma patients who were ≥65 years old and had ≥1 rib fracture were included in this study. Patients were randomized into IV acetaminophen and oral placebo (n = 63) or IV placebo and oral solution acetaminophen (n = 75) groups. The primary outcome was a mean reduction in pain score at 24 hours, and secondary outcomes included opioid use, intensive care unit (ICU) length of stay (LOS), hospital LOS, hospital mortality, the difference in incentive spirometry, and development of pneumonia. RESULTS Among the 138 patients included, there was no statistically significant difference between the 2 study groups in a mean reduction in pain score at 24 hours after injury (PO: 3.24, IV: 2.49; P = .230). Opioid pain medication use was equivalent between groups ( P = .212), and there was no significant difference in hospital mortality rate between groups ( P = .827). There was no statistically significant difference in ICU LOS, hospital LOS, or development of pneumonia. DISCUSSION In elderly trauma patients (age ≥65 years) with 1 or more rib fractures, PO acetaminophen is equivalent to IV acetaminophen for pain control, with no difference in morbidity or mortality. Oral acetaminophen should be preferentially used over IV acetaminophen when treating the elderly trauma patient with rib fractures.",2020,"Among the 138 patients included, there was no statistically significant difference between the 2 study groups in a mean reduction in pain score at 24 hours after injury (PO: 3.24, IV: 2.49; P = .230).","['elderly trauma patient with rib fractures', 'elderly trauma patients (age ≥65 years) with 1 or more rib fractures', 'Trauma patients who were ≥65 years old and had ≥1 rib fracture', '138 patients', 'Elderly Trauma Patients With Rib Fractures', 'traumatically injured patients, and elderly patients with rib fractures']","['PO acetaminophen', 'oral Per os (PO) acetaminophen', 'Oral Versus Intravenous Acetaminophen', 'placebo and oral solution acetaminophen', 'acetaminophen and oral placebo', 'acetaminophen', 'Oral acetaminophen', 'placebo']","['hospital mortality rate', 'morbidity or mortality', 'opioid use, intensive care unit (ICU) length of stay (LOS), hospital LOS, hospital mortality, the difference in incentive spirometry, and development of pneumonia', 'mean reduction in pain score', 'ICU LOS, hospital LOS, or development of pneumonia', 'pain score', 'Opioid pain medication use']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035522', 'cui_str': 'Fracture of rib'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1527415', 'cui_str': 'Oral route'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0991536', 'cui_str': 'Oral solution'}]","[{'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0454512', 'cui_str': 'Incentive spirometry'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}]",138.0,0.177722,"Among the 138 patients included, there was no statistically significant difference between the 2 study groups in a mean reduction in pain score at 24 hours after injury (PO: 3.24, IV: 2.49; P = .230).","[{'ForeName': 'Andrew C', 'Initials': 'AC', 'LastName': 'Antill', 'Affiliation': '21823 Department of Surgery, University of Tennessee Medical Center, Knoxville, TN, USA.'}, {'ForeName': 'Sarah W', 'Initials': 'SW', 'LastName': 'Frye', 'Affiliation': 'Department of Pharmacy, Spartanburg Medical Center, SC, USA.'}, {'ForeName': 'James C', 'Initials': 'JC', 'LastName': 'McMillen', 'Affiliation': 'Department of Pharmacy, University of Tennessee Medical Center, Knoxville, TN, USA.'}, {'ForeName': 'James C', 'Initials': 'JC', 'LastName': 'Haynes', 'Affiliation': 'Department of Surgery, WellStar North Fulton Hospital, Roswell, GA, USA.'}, {'ForeName': 'Benjamin R', 'Initials': 'BR', 'LastName': 'Ford', 'Affiliation': 'Department of Surgery, Roper Saint Francis Healthcare, Charleston, SC, USA.'}, {'ForeName': 'Reagan W', 'Initials': 'RW', 'LastName': 'Bollig', 'Affiliation': '21823 Department of Surgery, University of Tennessee Medical Center, Knoxville, TN, USA.'}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Daley', 'Affiliation': '21823 Department of Surgery, University of Tennessee Medical Center, Knoxville, TN, USA.'}]",The American surgeon,['10.1177/0003134820940268'] 2424,32749877,"Understanding of Perceived Infectiousness and Its Influence on Sexual Behavior Among Individuals With Acute HIV Infection in Lilongwe, Malawi (HPTN 062).","We implemented HPTN 062, an acceptability and feasibility study of a motivational-interviewing (MI) intervention to reduce HIV transmission among individuals with acute HIV infection (AHI) in Lilongwe, Malawi. Participants were randomly assigned to receive either brief education or the MI intervention over 24 weeks; all participants received the same messages about AHI. We used mixed methods to assess participants' understanding of the association between AHI and viral load, and its connection to sexual behavior at 8 weeks. While most participants understood key aspects of AHI, MI-intervention participants gave substantially more detailed descriptions of their understanding. Nearly all participants, regardless of study arm, understood that they were highly infectious and would be very likely to transmit HIV after unprotected sex during AHI. Our findings suggest that messages about AHI delivered during the period of AHI are likely beneficial for ensuring that those with AHI understand their level of infectiousness and its association with forward transmission.",2020,"Nearly all participants, regardless of study arm, understood that they were highly infectious and would be very likely to transmit HIV after unprotected sex during AHI.","['Individuals With Acute HIV Infection in Lilongwe, Malawi', 'individuals with acute HIV infection (AHI) in Lilongwe, Malawi']","['brief education or the MI intervention', 'motivational-interviewing (MI) intervention']",['Sexual Behavior'],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0343752', 'cui_str': 'Acute HIV infection'}, {'cui': 'C0024548', 'cui_str': 'Malawi'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0036864', 'cui_str': 'Sexual behavior'}]",,0.0351249,"Nearly all participants, regardless of study arm, understood that they were highly infectious and would be very likely to transmit HIV after unprotected sex during AHI.","[{'ForeName': 'Tiarney D', 'Initials': 'TD', 'LastName': 'Ritchwood', 'Affiliation': 'Department of Family Medicine and Community Health, School of Medicine, Duke University, Durham, North Carolina.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Massa', 'Affiliation': 'UNC Project Lilongwe, Lilongwe, Malawi.'}, {'ForeName': 'Gift', 'Initials': 'G', 'LastName': 'Kamanga', 'Affiliation': 'FHI 360, Lilongwe, Malawi.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Pettifor', 'Affiliation': 'Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Irving', 'Initials': 'I', 'LastName': 'Hoffman', 'Affiliation': 'Division of Infectious Diseases, University of North Carolina at Chapel Hill.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Corneli', 'Affiliation': 'Department of Population Health Sciences, School of Medicine, Duke University, and the Duke Clinical Research Institute, Duke University.'}]",AIDS education and prevention : official publication of the International Society for AIDS Education,['10.1521/aeap.2020.32.3.260'] 2425,32755831,"An android smartphone-based randomized intervention improves the quality of life in patients with type 2 diabetes in Mysore, Karnataka, India.","BACKGROUND AND AIMS Associated with severe complications and morbidity, Diabetes Mellitus is a significant public health burden. The need for regular monitoring and adherence to treatment and lifestyle changes have a high impact on the quality of life of the patients. This study attempts to assess the effect of smartphone-based lifestyle modification intervention in the quality of life of patients with type 2 Diabetes through a randomized filed trial. METHODS A randomized field trial was performed among the patients attending the outpatient department of a tertiary care hospital in Mysuru city. A mobile application named DIAGURU, mainly focusing on the lifestyle modification and medication management was used for a period of 6 months from April 2019 to September 2019 by 150 patients in the intervention group while another 150 participants served as controls. The quality of life was assessed using the WHO QOL BREF questionnaire at the beginning of the study and after six months. RESULTS The change in the quality of life in a positive direction was significantly higher in the intervention group compared to the non-intervention group after six months. The differences in the change in scores of quality of life of participants recruited in intervention and non-intervention groups were statistically significant in all the four domains after the intervention with a p value < 0.001. CONCLUSION The evidence generated in this study suggest that such technological approaches can be used as a public health measure to improve the quality of life of patients with type 2 Diabetes Mellitus.",2020,The change in the quality of life in a positive direction was significantly higher in the intervention group compared to the non-intervention group after six months.,"['patients with type 2 diabetes in Mysore, Karnataka, India', 'patients with type 2 Diabetes Mellitus', 'patients attending the outpatient department of a tertiary care hospital in Mysuru city', 'patients with type 2 Diabetes']","['smartphone-based lifestyle modification intervention', 'android smartphone-based randomized intervention']","['quality of life', 'quality of life in a positive direction', 'WHO QOL BREF questionnaire', 'scores of quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0337954', 'cui_str': 'Tertiary care hospital'}, {'cui': 'C0008848', 'cui_str': 'Cities'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0336541', 'cui_str': 'Android'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0439755', 'cui_str': 'Directions'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0470927,The change in the quality of life in a positive direction was significantly higher in the intervention group compared to the non-intervention group after six months.,"[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Sunil Kumar', 'Affiliation': 'Department of Community Medicine, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru, India.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Prakash', 'Affiliation': 'Department of Community Medicine, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru, India.'}, {'ForeName': 'B J', 'Initials': 'BJ', 'LastName': 'Subhash Chandra', 'Affiliation': 'Department of General Medicine, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru, India.'}, {'ForeName': 'Padma Shrinivas', 'Initials': 'PS', 'LastName': 'Kadkol', 'Affiliation': 'Department of Information Science & Engineering, JSS S&T University (Formally SJCE), Mysuru, India.'}, {'ForeName': 'Vanishri', 'Initials': 'V', 'LastName': 'Arun', 'Affiliation': 'Department of Information Science & Engineering, JSS S&T University (Formally SJCE), Mysuru, India.'}, {'ForeName': 'Jose Jom', 'Initials': 'JJ', 'LastName': 'Thomas', 'Affiliation': 'Department of Community Medicine, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru, India. Electronic address: josejom031@gmail.com.'}]",Diabetes & metabolic syndrome,['10.1016/j.dsx.2020.07.025'] 2426,32755838,"Impact of patient education on KAP, medication adherence and therapeutic outcomes of metformin versus insulin therapy in patients with gestational diabetes: A Hospital based pilot study in South India.","BACKGROUND AND AIM The study assessed the impact of continuous patient education on Knowledge, Attitude, Practice (KAP), medication adherence and extent of glycemic control in pregnant women with gestational diabetes on insulin or metformin therapy. METHODS 81 women with gestational diabetes (37 on insulin and 44 on metformin) were assessed for KAP using a validated questionnaire and medication adherence using the 8-items Morisky medication adherence scale, fasting, and postprandial blood glucose levels at the baseline and after two education sessions on drug therapy at one and three months intervals. The difference in mean KAP, medication adherence scores, fasting, and postprandial blood glucose levels and the extent of glycemic control with insulin or metformin therapy were assessed statistically. RESULTS There was a highly significant difference in the mean KAP, medication adherence scores, fasting and postprandial blood glucose levels from baseline to follow-up after three months, (P < 0.0001) indicating that continuous patient education had a positive impact on their KAP, medication adherence, blood glucose levels. CONCLUSION The study identified that continuous patient education improved their knowledge and practice of medication adherence which reflected on lowered fasting and postprandial blood glucose levels. Glycemic control was found to be the same with metformin and insulin in gestational diabetes.",2020,"There was a highly significant difference in the mean KAP, medication adherence scores, fasting and postprandial blood glucose levels from baseline to follow-up after three months, (P < 0.0001) indicating that continuous patient education had a positive impact on their KAP, medication adherence, blood glucose levels. ","['patients with gestational diabetes', '81 women with gestational diabetes (37 on insulin and 44 on', 'pregnant women with gestational diabetes on insulin or metformin therapy', 'South India']","['metformin and insulin', 'metformin', 'metformin versus insulin therapy']","['Morisky medication adherence scale, fasting, and postprandial blood glucose levels', 'Knowledge, Attitude, Practice (KAP), medication adherence and extent of glycemic control', 'KAP, medication adherence, blood glucose levels', 'lowered fasting and postprandial blood glucose levels', 'knowledge and practice of medication adherence', 'mean KAP, medication adherence scores, fasting, and postprandial blood glucose levels and the extent of glycemic control with insulin or metformin therapy', 'mean KAP, medication adherence scores, fasting and postprandial blood glucose levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439671', 'cui_str': 'Gestational'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0021201', 'cui_str': 'India'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0439792', 'cui_str': 'Extent'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",81.0,0.0210953,"There was a highly significant difference in the mean KAP, medication adherence scores, fasting and postprandial blood glucose levels from baseline to follow-up after three months, (P < 0.0001) indicating that continuous patient education had a positive impact on their KAP, medication adherence, blood glucose levels. ","[{'ForeName': 'Sneha', 'Initials': 'S', 'LastName': 'Krishnakumar', 'Affiliation': 'Sri Ramachandra Institute of Higher Education and Research (Deemed to Be University), India.'}, {'ForeName': 'Yeswanth', 'Initials': 'Y', 'LastName': 'Govindarajulu', 'Affiliation': 'Sri Ramachandra Hospital, Sri Ramachandra Institute of Higher Education and Research (Deemed to Be University), India.'}, {'ForeName': 'Usha', 'Initials': 'U', 'LastName': 'Vishwanath', 'Affiliation': 'Department of Obstetrics and Gynecology, Sri Ramachandra Institute of Higher Education and Research (Deemed to Be University), India.'}, {'ForeName': 'Vanitha Rani', 'Initials': 'VR', 'LastName': 'Nagasubramanian', 'Affiliation': 'Department of Pharmacy Practice, Sri Ramachandra Institute of Higher Education and Research (Deemed to Be University), Porur, Chennai, Tamil Nadu, India. Electronic address: vanitharani.n@sriramachandra.edu.in.'}, {'ForeName': 'Thennarasu', 'Initials': 'T', 'LastName': 'Palani', 'Affiliation': 'Department of Pharmacy Practice, Sri Ramachandra Institute of Higher Education and Research (Deemed to Be University), Porur, Chennai, Tamil Nadu, India.'}]",Diabetes & metabolic syndrome,['10.1016/j.dsx.2020.07.026'] 2427,32755889,User Perception of a Smartphone App to Promote Physical Activity Through Active Transportation: Inductive Qualitative Content Analysis Within the Smart City Active Mobile Phone Intervention (SCAMPI) Study.,"BACKGROUND Physical inactivity is globally recognized as a major risk factor for morbidity, particularly the incidence of noncommunicable diseases. Increasing physical activity (PA) is therefore a public health priority. Engaging in active transportation (AT) is a viable approach for promoting daily PA levels. Mobile health interventions enable the promotion of AT to a larger population. The Smart City Active Mobile Phone Intervention (SCAMPI) study was a randomized controlled trial designed to evaluate the ability of a behavior change program delivered via a smartphone app to motivate participants to increase their PA by engaging in AT. OBJECTIVE This qualitative study aims to examine the acceptance and user experience of the app promoting AT that was used in the SCAMPI trial (the TRavelVU Plus app). METHODS A total of 17 residents of Stockholm County (13 women; age range 25-61 years) who completed the 3-month app-based behavioral change program (delivered through the TRavelVU Plus app) in the SCAMPI randomized controlled trial during 2018 agreed to participate in a semistructured telephone-based interview. These participants were well representative of the whole intervention group (n=127) in terms of baseline characteristics such as age, sex, and area of residence. The interviews were audiorecorded, transcribed verbatim, and analyzed using an inductive qualitative content analysis. RESULTS The content analysis revealed 2 themes and 4 subcategories. The first theme, ""main motivators: monitoring and messages,"" highlighted that monitoring AT and being able to set weekly goals using the app were the primary motivators reported by study participants. The second theme, ""acceptable but modifiable,"" reflects that the app was well accepted and effectively encouraged many participants to use more AT. Nevertheless, there were functions in the app that require modification. For example, while the semiautomated travel tracking feature was appreciated, participants found it time-consuming and unreliable at times. CONCLUSIONS This study contributes novel insight into adults' experiences of using a mobile app to promote the use of AT. The results showed that the app was well accepted and that self-monitoring and goal setting were the main motivators to engage in more AT. The semiautomated tracking of AT was appreciated; however, it was also reported to be energy- and time-consuming when it failed to work. Thus, this feature should be improved going forward. TRIAL REGISTRATION ClinicalTrials.gov NCT03086837; https://clinicaltrials.gov/ct2/show/NCT03086837. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR2-10.1186/s12889-018-5658-4.",2020,"These participants were well representative of the whole intervention group (n=127) in terms of baseline characteristics such as age, sex, and area of residence.","['participants were well representative of the whole intervention group (n=127) in terms of baseline characteristics such as age, sex, and area of residence', '17 residents of Stockholm County (13 women; age range 25-61 years) who completed the 3-month app-based behavioral change program (delivered through the TRavelVU Plus app) in the SCAMPI randomized controlled trial during 2018 agreed to participate in a semistructured telephone-based interview']",['Engaging in active transportation (AT'],[],"[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0235048', 'cui_str': 'Smarting pain'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}]","[{'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0040756', 'cui_str': 'Transportation'}]",[],,0.0680044,"These participants were well representative of the whole intervention group (n=127) in terms of baseline characteristics such as age, sex, and area of residence.","[{'ForeName': 'Anna-Karin', 'Initials': 'AK', 'LastName': 'Lindqvist', 'Affiliation': 'Division of Health, Medicine and Rehabilitation, Department of Health Sciences, Luleå University of Technology, Luleå, Sweden.'}, {'ForeName': 'Stina', 'Initials': 'S', 'LastName': 'Rutberg', 'Affiliation': 'Division of Health, Medicine and Rehabilitation, Department of Health Sciences, Luleå University of Technology, Luleå, Sweden.'}, {'ForeName': 'Emmie', 'Initials': 'E', 'LastName': 'Söderström', 'Affiliation': 'Department of Health, Medical and Caring Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Ek', 'Affiliation': 'Department of Clinical Science Intervention and Technology, Karolinska Institutet, Huddinge, Sweden.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Alexandrou', 'Affiliation': 'Department of Health, Medical and Caring Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Ralph', 'Initials': 'R', 'LastName': 'Maddison', 'Affiliation': 'Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Melbourne, Australia.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Löf', 'Affiliation': 'Department of Health, Medical and Caring Sciences, Linköping University, Linköping, Sweden.'}]",JMIR mHealth and uHealth,['10.2196/19380'] 2428,32755890,Effects of Alternative Offers of Screening Sigmoidoscopy and Colonoscopy on Utilization and Yield of Endoscopic Screening for Colorectal Neoplasms: Protocol of the DARIO Randomized Trial.,"BACKGROUND Flexible sigmoidoscopy and colonoscopy are recommended screening options for colorectal cancer (CRC). Despite colonoscopy being offered for CRC screening in Germany, the uptake of this offer has been very limited. OBJECTIVE The objective of this study was to assess the potential for increasing use of endoscopic CRC screening and the detection of advanced colorectal neoplasms by offering the choice between use of flexible sigmoidoscopy and colonoscopy. METHODS The DARIO study includes a cross-sectional study (part I), followed by a prospective 2-arm randomized controlled intervention trial (part II) with an associated biobank study (part III). Participation is possible in part I of the DARIO study only, parts I and II, or all 3 study parts. After obtaining informed consent from the municipalities, 12,000 people, aged 50-54 years, from the Rhine-Neckar region in Germany were randomly selected from residential lists of the responsible population registries and invited to complete a standardized questionnaire to investigate the nature, frequency, timing, and results of previous CRC screening and eventual diagnostic colonoscopies. In study part II participants from study part I with no colonoscopy in the preceding 5 years are randomized into 2 arms: arm A offering screening colonoscopy only, and arm B offering both options, either screening colonoscopy or screening sigmoidoscopy. The primary endpoint is the proportion of participants in whom colorectal neoplasms >0.5 cm are detected and removed at screening endoscopy. The secondary endpoints are the detection rate of any neoplasm and use of any endoscopic screening. Part III of the study will use samples from participants in study part II to construct a liquid and tissue biobank for the evaluation of less invasive methods of early detection of colon cancer and for the more detailed characterization of the detected neoplasms. Blood, urine, stool, and saliva samples are taken before the endoscopy. Tissue samples are obtained from the neoplasms removed during endoscopy. RESULTS A total of 10,568 from 12,000 randomly selected women and men aged 50-54 years living in the Rhine-Neckar-Region of Germany have been invited for participation. The remaining 1432 (11.93%) could not be invited because they reached the age of 55 at the time of contact. Of those invited, 2785/10,568 (26.35%) participated in study part I; 53.60% (1493/2785) of these participants were female. Study parts II and III are ongoing. CONCLUSIONS This study will answer the question if alternative offers of either screening sigmoidoscopy or screening colonoscopy will increase utilization and effectiveness of endoscopic CRC screening compared with an exclusive offer of screening colonoscopy. In addition, alternative noninvasive screening tests will be developed and validated. TRIAL REGISTRATION German Clinical Trials Register DRKS00018932; https://www.drks.de/drks_web/navigate.do? navigationId=trial.HTML&TRIAL_ID=DRKS00018932. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/17516.",2020,"After obtaining informed consent from the municipalities, 12,000 people, aged 50-54 years, from the Rhine-Neckar region in Germany were randomly selected from residential lists of the responsible population registries and invited to complete a standardized questionnaire to investigate the nature, frequency, timing, and results of previous CRC screening and eventual diagnostic colonoscopies.","['A total of 10,568 from 12,000 randomly selected women and men aged 50-54 years living in the Rhine-Neckar-Region of Germany have been invited for participation', 'Of those invited, 2785/10,568 (26.35%) participated in study part I; 53.60% (1493/2785) of these participants were female', '12,000 people, aged 50-54 years, from the Rhine-Neckar region in Germany', 'Colorectal Neoplasms', 'colorectal cancer (CRC', 'In study part II participants from study part I with no colonoscopy in the preceding 5 years']","['endoscopic CRC screening', 'screening colonoscopy only, and arm B offering both options, either screening colonoscopy or screening sigmoidoscopy', 'screening sigmoidoscopy or screening colonoscopy', 'Flexible sigmoidoscopy and colonoscopy', 'flexible sigmoidoscopy and colonoscopy', 'Screening Sigmoidoscopy and Colonoscopy']","['Blood, urine, stool, and saliva samples', 'detection rate of any neoplasm and use of any endoscopic screening', 'proportion of participants in whom colorectal neoplasms >0.5 cm are detected and removed at screening endoscopy']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009404', 'cui_str': 'Neoplasm of large intestine'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0332152', 'cui_str': 'Before'}]","[{'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0037075', 'cui_str': 'Sigmoidoscopy'}, {'cui': 'C0016234', 'cui_str': 'Flexible fiberoptic sigmoidoscopy'}]","[{'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0009404', 'cui_str': 'Neoplasm of large intestine'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C1883720', 'cui_str': 'Removes'}]",12000.0,0.0559897,"After obtaining informed consent from the municipalities, 12,000 people, aged 50-54 years, from the Rhine-Neckar region in Germany were randomly selected from residential lists of the responsible population registries and invited to complete a standardized questionnaire to investigate the nature, frequency, timing, and results of previous CRC screening and eventual diagnostic colonoscopies.","[{'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Schrotz-King', 'Affiliation': 'Division of Preventive Oncology, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hoffmeister', 'Affiliation': 'Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Sauer', 'Affiliation': 'Interdisciplinary Endoscopy Center (IEZ), Heidelberg University Hospital, Heidelberg, Germany.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Schaible', 'Affiliation': 'Interdisciplinary Endoscopy Center (IEZ), Heidelberg University Hospital, Heidelberg, Germany.'}, {'ForeName': 'Hermann', 'Initials': 'H', 'LastName': 'Brenner', 'Affiliation': 'Division of Preventive Oncology, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.'}]",JMIR research protocols,['10.2196/17516'] 2429,32755927,Cognitive Dissonance About Thought-Action Fusion Beliefs Improves and Maintains the Effects of Thought-Action Fusion-Specific Psychoeducation.,"The effects of psychoeducation on thought-action fusion (TAF) beliefs are understudied. We tested whether adding mock electroencephalography (EEG)-based computer trials that induce cognitive dissonance about TAF beliefs, prior to TAF-specific psychoeducation, would enhance and maintain the reduction of TAF beliefs. An unselected sample of 140 Singaporean undergraduates (89 females, 51 males) was randomly assigned to a combined intervention, TAF-specific psychoeducation-only, or control group. Self-report measures of TAF beliefs and cognitive dissonance about TAF beliefs were administered 4 times in the initial session, and once at 1-month follow-up. Findings included the following: (a) greatest cognitive dissonance about TAF beliefs in the initial session with the combined intervention; (b) greater reduction in TAF beliefs in the initial session in both intervention groups, compared with the control group; and (c) incremental reduction in TAF beliefs in the initial session and maintenance at 1-month follow-up with the combined intervention. Cognitive dissonance should be investigated extensively in other aspects of cognitive behavioral therapy (CBT) procedures for TAF beliefs (e.g., behavioral experiments, exposure, and response prevention) to determine whether it contributes to therapeutic change with these techniques. Our combined intervention procedure should also be examined for relevant psychopathology (e.g., obsessive-compulsive symptoms).",2016,"Self-report measures of TAF beliefs and cognitive dissonance about TAF beliefs were administered 4 times in the initial session, and once at 1-month follow-up.","['140 Singaporean undergraduates (89 females, 51 males']","['combined intervention, TAF-specific psychoeducation-only, or control group', 'cognitive behavioral therapy (CBT', 'mock electroencephalography (EEG)-based computer trials']","['TAF beliefs', 'cognitive dissonance about TAF beliefs', 'TAF beliefs and cognitive dissonance about TAF beliefs']","[{'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0039869', 'cui_str': 'Thinking'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0562577', 'cui_str': 'Mocking'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0039869', 'cui_str': 'Thinking'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0009242', 'cui_str': 'Cognitive Dissonance'}]",140.0,0.0142133,"Self-report measures of TAF beliefs and cognitive dissonance about TAF beliefs were administered 4 times in the initial session, and once at 1-month follow-up.","[{'ForeName': 'Terence H W', 'Initials': 'THW', 'LastName': 'Ching', 'Affiliation': 'University of Connecticut, Department of Psychological Sciences terence.ching@uconn.edu.'}, {'ForeName': 'Catherine S', 'Initials': 'CS', 'LastName': 'Tang', 'Affiliation': 'National University of Singapore, Department of Psychology.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.30.4.235'] 2430,32755941,Evaluation of Inference-Based Therapy (Doubt Therapy) as a Self-Help Tool for Obsessive-Compulsive Disorder.,"INTRODUCTION Inference-based therapy (IBT) is a novel therapeutic approach aimed at reducing obsessive-compulsive symptoms. For this study, the original therapist-guided protocol was adapted for self-help administration. METHOD Fifty patients with obsessive-compulsive disorder who had been recruited via specialized online fora were randomly allocated to either IBT or a wait-list control condition. At baseline and 4 weeks later, questionnaires tapping into psychopathology, quality of life, and faulty reasoning were administered. RESULTS The completion rate was acceptable (74%) and not significantly different across groups. Relative to controls, patients in the IBT group showed modest but significant symptom decline on obsessions (Yale-Brown Obsessive-Compulsive Scale [Y-BOCS] self-report and Obsessive-Compulsive Inventory-Revised [OCI-R]) and washing compulsions (OCI-R) across time. No significant differences emerged for depression, quality of life, and inferential confusion. Ratings at the post-assessment suggest that the training was well accepted among patients. Test-retest reliability was high indicating good quality of the data. DISCUSSION This study confirms prior research suggesting that IBT is effective as a stand-alone technique. Follow-up studies are needed to elucidate the long-term effects of the training and whether positive effects are maintained if IBT is introduced as an add-on to standard treatment (i.e., cognitive behavioral therapy/medication).",2015,"No significant differences emerged for depression, quality of life, and inferential confusion.",['Fifty patients with obsessive-compulsive disorder who had been recruited via specialized online fora'],"['IBT', 'IBT or a wait-list control condition', 'Inference-Based Therapy (Doubt Therapy', 'Inference-based therapy (IBT']","['completion rate', 'questionnaires tapping into psychopathology, quality of life, and faulty reasoning', 'depression, quality of life, and inferential confusion', 'symptom decline on obsessions (Yale-Brown Obsessive-Compulsive Scale [Y-BOCS] self-report and Obsessive-Compulsive Inventory-Revised [OCI-R]) and washing compulsions (OCI-R']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028768', 'cui_str': 'Obsessive-compulsive disorder'}, {'cui': 'C0205555', 'cui_str': 'Special'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0034115', 'cui_str': 'Centesis'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1280014', 'cui_str': 'Faulty'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0009676', 'cui_str': 'Confusional state'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0233697', 'cui_str': 'Obsessional thoughts'}, {'cui': 'C0155339', 'cui_str': ""Brown's tendon sheath syndrome""}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C3472214', 'cui_str': 'Obsessive compulsive inventory'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0684043', 'cui_str': 'Occitan language'}, {'cui': 'C1547959', 'cui_str': 'Wash'}, {'cui': 'C0600104', 'cui_str': 'Compulsive behavior'}]",50.0,0.0298507,"No significant differences emerged for depression, quality of life, and inferential confusion.","[{'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Moritz', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Germany moritz@uke.uni-hamburg.de.'}, {'ForeName': 'Chantal', 'Initials': 'C', 'LastName': 'Dietl', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Germany.'}, {'ForeName': 'Jan Felix', 'Initials': 'JF', 'LastName': 'Kersten', 'Affiliation': 'Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Germany.'}, {'ForeName': 'Frederick', 'Initials': 'F', 'LastName': 'Aardema', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Germany.'}, {'ForeName': 'Kieron', 'Initials': 'K', 'LastName': ""O'Connor"", 'Affiliation': 'Mental Health University Institute of Montreal, University of Montreal, Québec, Canada.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.29.4.315'] 2431,32756053,Randomised Controlled Trial Evaluating Active versus Passive Waiting for Speech-Language Pathology.,"INTRODUCTION High demand for speech-language pathology means children sometimes wait over 12 months for services, missing out on timely support. Waiting can be a time of stress, concern, and powerlessness for caregivers. Provision of information via a website may support families and encourage active waiting. OBJECTIVE The aim of this study was to compare children's speech, intelligibility, language, and literacy outcomes, and caregivers' satisfaction and empowerment in active versus passive waiting conditions. METHODS Ninety-seven preschool-aged children referred to a community health speech-language pathology service in Australia were screened for eligibility. Eligible children (n =42) with speech/language difficulties were randomly allocated to: (a) active waiting (provision of a purpose-built website; n = 20), or (b) passive waiting (control group; n = 22). Pre- and post-assessments (after 6 months on a waiting list) were completed with children and caregivers by a speech-language pathologist blinded to group allocations. RESULTS Intention to treat (n =36) and per-protocol analyses (n =30) were conducted to measure group differences in child and caregiver outcomes at post-assessment using one-way ANCOVA, controlling for baseline scores. There were no statistically significant differences between groups for children's speech, intelligibility, language, and literacy, or caregivers' empowerment and satisfaction. Children in both groups made minimal gains over 6 months. CONCLUSIONS Provision of an active waiting website did not lead to statistically significant change in child or caregiver outcomes, and children in both groups made little progress over a 6-month period. Early speech-language pathology intervention delivered with appropriate dosage is needed to optimise children's outcomes. Until timely and effective speech-language pathology intervention can be provided for all who need it, provision of early assessments may be beneficial. There remains a need for effective ways to support children and families on waiting lists.",2020,"There were no statistically significant differences between groups for children's speech, intelligibility, language, and literacy, or caregivers' empowerment and satisfaction.","['Ninety-seven preschool-aged children referred to a community health speech-language pathology service in Australia were screened for eligibility', 'Eligible children (n =42) with speech/language difficulties']",['Pre- and post-assessments '],"[""children's speech, intelligibility, language, and literacy outcomes, and caregivers' satisfaction and empowerment in active versus passive waiting conditions"", ""children's speech, intelligibility, language, and literacy, or caregivers' empowerment and satisfaction""]","[{'cui': 'C0439073', 'cui_str': '97'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0037825', 'cui_str': 'Pathology, Speech-Language'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0564213', 'cui_str': 'Difficulty using language'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0589416', 'cui_str': 'Intelligibility'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0679959', 'cui_str': 'Empowerment'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]",30.0,0.0965534,"There were no statistically significant differences between groups for children's speech, intelligibility, language, and literacy, or caregivers' empowerment and satisfaction.","[{'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'McGill', 'Affiliation': 'Charles Sturt University, Bathurst, New South Wales, Australia, nmcgill@csu.edu.au.'}, {'ForeName': 'Sharynne', 'Initials': 'S', 'LastName': 'McLeod', 'Affiliation': 'Charles Sturt University, Bathurst, New South Wales, Australia.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Ivory', 'Affiliation': 'Charles Sturt University, Bathurst, New South Wales, Australia.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Davis', 'Affiliation': 'Western NSW Local Health District, Bathurst, New South Wales, Australia.'}, {'ForeName': 'Katrina', 'Initials': 'K', 'LastName': 'Rohr', 'Affiliation': 'Western NSW Local Health District, Bathurst, New South Wales, Australia.'}]",Folia phoniatrica et logopaedica : official organ of the International Association of Logopedics and Phoniatrics (IALP),['10.1159/000508830'] 2432,32756067,Feasibility of a Cognitive Training Game in Parkinson's Disease: The Randomized Parkin'Play Study.,"Cognitive training (CT) shows modest positive effects on cognitive function in patients with Parkinson's disease (PD). Gamification may enhance adherence to traditional CT, but this has not been studied yet. Here, we investigated the feasibility of a gamified CT. We performed a randomized controlled trial including PD patients with mild cognitive impairment. Participants were randomly allocated to a 12-week home-based gamified CT intervention or waiting-list control group. Assessments were performed at baseline and at weeks 12 and 24. Forty-one patients were included (21 intervention and 20 waiting-list controls). Sixty-three percent of the intervention group trained >50% of the recommended sessions, while 81% voluntarily continued training after 12 weeks. After 24 weeks, 87.5% graded the game to be satisfactory. Global cognition scores improved after 24 weeks. Home-based gamified CT shows acceptable feasibility in patients with PD, and we observed preliminary indications for efficacy. Larger trials are needed to establish this efficacy.",2020,Global cognition scores improved after 24 weeks.,"[""patients with Parkinson's disease (PD"", ""Parkinson's Disease"", 'PD patients with mild cognitive impairment', 'patients with PD', 'Forty-one patients were included (21 intervention and 20 waiting-list controls']","['gamified CT', 'Cognitive Training Game', '12-week home-based gamified CT intervention or waiting-list control group', 'Cognitive training (CT']","['cognitive function', 'Global cognition scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",41.0,0.0472378,Global cognition scores improved after 24 weeks.,"[{'ForeName': 'Sjors C F', 'Initials': 'SCF', 'LastName': 'van de Weijer', 'Affiliation': 'Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands, sjors.vande.weijer@mumc.nl.'}, {'ForeName': 'Annelien A', 'Initials': 'AA', 'LastName': 'Duits', 'Affiliation': 'Department of Psychiatry and Psychology, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Bastiaan R', 'Initials': 'BR', 'LastName': 'Bloem', 'Affiliation': 'Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'Nienke M', 'Initials': 'NM', 'LastName': 'de Vries', 'Affiliation': 'Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'Roy P C', 'Initials': 'RPC', 'LastName': 'Kessels', 'Affiliation': 'Department of Medical Psychology, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Köhler', 'Affiliation': 'School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Gerrit', 'Initials': 'G', 'LastName': 'Tissingh', 'Affiliation': 'Department of Neurology, Zuyderland Medical Center, Heerlen, The Netherlands.'}, {'ForeName': 'Mark L', 'Initials': 'ML', 'LastName': 'Kuijf', 'Affiliation': 'Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands.'}]",European neurology,['10.1159/000509685'] 2433,32756069,Treatment of Pemphigus Vulgaris and Foliaceus with Adjuvant Rituximab Compared to Immunosuppression Alone: Real-Life Experience.,"INTRODUCTION In a randomized prospective trial, adjuvant rituximab was more efficacious than corticosteroids alone in the treatment of pemphigus; however, real-life data are limited. Rituximab treatment for pemphigus has only recently been introduced to the Israeli health basket. Previously, patients received rituximab if they paid out of pocket or through private insurance, separating patients into 2 treatment groups, mostly based on economic capability. METHODS A retrospective cohort study of the 12-month clinical response of pemphigus vulgaris/foliaceus patients. We compared patients after a single cycle (1,000 mg on days 0 and 15 or weekly 375 mg/m2 for 4 weeks) of adjuvant rituximab with systemic corticosteroids ± steroid-sparing agents, to patients who were prescribed rituximab, could not obtain it, and received systemic corticosteroids ± steroid-sparing agents. RESULTS Forty-five patients were included (adjuvant rituximab, n = 29; immunosuppression alone, n = 16). At baseline, rituximab patients had a higher mean pemphigus disease area index (PDAI) (p = 0.07) and higher mean daily dosages of prednisone (1.51 vs. 1.16 mg/kg, p = 0.39). All patients but 1 in the rituximab group continued systemic steroids, and 31% in the rituximab group versus 50% in the immunosuppression-alone group received systemic adjuvants. At 12 months, partial or complete remission rates (on or off maximum 40 mg/day prednisone equivalent) were nonsignificantly higher in the rituximab group (62 vs. 50%, p = 0.53); however, patients on rituximab showed faster remissions (3.4 ± 1.9 vs. 5.9 ± 3.6 months; p = 0.03) with a trend for a greater PDAI reduction (p = 0.051). Adverse events were comparable. CONCLUSIONS In this real-life study, a single cycle of rituximab achieved more remissions and sooner compared to conventional immunosuppression, but the differences were not significant, probably due to a small sample size and severe baseline disease in the rituximab group. Future real-life studies on larger groups are needed.",2020,"At baseline, rituximab patients had a higher mean pemphigus disease area index (PDAI) (p = 0.07) and higher mean daily dosages of prednisone (1.51 vs. 1.16 mg/kg, p = 0.39).","['pemphigus vulgaris/foliaceus patients', 'Forty-five patients were included (adjuvant rituximab, n = 29; immunosuppression alone, n = 16']","['prednisone', 'adjuvant rituximab with systemic corticosteroids ± steroid-sparing agents, to patients who were prescribed rituximab, could not obtain it, and received systemic corticosteroids ± steroid-sparing agents', 'Pemphigus Vulgaris and Foliaceus with Adjuvant Rituximab', 'systemic adjuvants', 'adjuvant rituximab', 'Rituximab', 'rituximab']","['mean pemphigus disease area index (PDAI', 'Adverse events', 'PDAI reduction', 'systemic steroids', 'partial or complete remission rates', 'faster remissions']","[{'cui': 'C0030809', 'cui_str': 'Pemphigus vulgaris'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0021079', 'cui_str': 'Immunosuppressive therapy'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C1843661', 'cui_str': 'Spastic Paraplegia, Ataxia, And Mental Retardation'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0030809', 'cui_str': 'Pemphigus vulgaris'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0030807', 'cui_str': 'Pemphigus'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}]",45.0,0.0630591,"At baseline, rituximab patients had a higher mean pemphigus disease area index (PDAI) (p = 0.07) and higher mean daily dosages of prednisone (1.51 vs. 1.16 mg/kg, p = 0.39).","[{'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Snast', 'Affiliation': 'Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel, Snastigor@gmail.com.'}, {'ForeName': 'Liron', 'Initials': 'L', 'LastName': 'Spitzer', 'Affiliation': 'Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Emmilia', 'Initials': 'E', 'LastName': 'Hodak', 'Affiliation': 'Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.'}, {'ForeName': 'Assi', 'Initials': 'A', 'LastName': 'Levi', 'Affiliation': 'Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Mimouni', 'Affiliation': 'Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.'}, {'ForeName': 'Yael A', 'Initials': 'YA', 'LastName': 'Leshem', 'Affiliation': 'Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.'}]","Dermatology (Basel, Switzerland)",['10.1159/000508788'] 2434,32756078,The effect of Sancai powder on glycemic variability of type 2 diabetes in the elderly: A randomized controlled trial.,"BACKGROUND Type 2 diabetes is a kind of metabolic disease. Its clinical characteristic is hyperglycemia. Recently, more and more elderly people suffer from type 2 diabetes, and the glycemic variability of the elderly is greater. In addition, blood sugar variation is more likely to cause diabetes complications than simple hyperglycemia. Sancai podwer (SC) is based on the theory of traditional Chinese medicine and gradually formed in the summary of clinical experience. It has the effect of lowering blood sugar and alleviating clinical symptoms of diabetes. But the existing evidence of its efficacy on glycemic variability is insufficient. So, in our study, the randomized controlled trials will be used as a research method to explore the effects of SC on glycemic variability of type 2 diabetes. METHOD We will use randomized controlled experiments based on the recommended diagnostic criteria, inclusion and exclusion criteria. A total of 60 elderly patients with type 2 diabetes will be randomly divided into treatment group and control group, 30 cases in each group. The control group will receive conventional western medicine and the intervention group will receive SC combined with western medicine. The standard deviation and coefficient of variation of blood glucose level will be used as evaluation indexes. DISCUSSION This study can provide evidence for the clinical efficacy and safety of SC in elderly patients with type 2 diabetes mellitus. TRIAL REGISTRATION This study is registered on the Chinese Clinical Trial Registry: ChiCTR2000032611.",2020,Sancai podwer (SC) is based on the theory of traditional Chinese medicine and gradually formed in the summary of clinical experience.,"['type 2 diabetes in the elderly', 'elderly patients with type 2 diabetes mellitus', '60 elderly patients with type 2 diabetes']","['Sancai podwer (SC', 'Sancai powder', 'conventional western medicine and the intervention group will receive SC combined with western medicine', 'SC']","['standard deviation and coefficient of variation of blood glucose level', 'glycemic variability']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C0032861', 'cui_str': 'Powder'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}]",60.0,0.0609136,Sancai podwer (SC) is based on the theory of traditional Chinese medicine and gradually formed in the summary of clinical experience.,"[{'ForeName': 'Dongqi', 'Initials': 'D', 'LastName': 'Zhou', 'Affiliation': 'Hospital of Chengdu University of Traditional Chinese Medicine.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Hospital of Chengdu University of Traditional Chinese Medicine.'}, {'ForeName': 'Xuke', 'Initials': 'X', 'LastName': 'Han', 'Affiliation': 'Hospital of Chengdu University of Traditional Chinese Medicine.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': 'Hospital of Chengdu University of Traditional Chinese Medicine.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Zeng', 'Affiliation': 'Hospital of Chengdu University of Traditional Chinese Medicine.'}, {'ForeName': 'Weiwei', 'Initials': 'W', 'LastName': 'Yu', 'Affiliation': 'Hospital of Chengdu University of Traditional Chinese Medicine.'}, {'ForeName': 'Lisha', 'Initials': 'L', 'LastName': 'Sun', 'Affiliation': 'Hospital of Chengdu University of Traditional Chinese Medicine.'}, {'ForeName': 'Qiu', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'Hospital of Chengdu University of Traditional Chinese Medicine.'}]",Medicine,['10.1097/MD.0000000000020750'] 2435,32756081,Study on preventing adverse events in neonates (SEPREVEN): A stepped-wedge randomised controlled trial to reduce adverse event rates in the NICU.,"INTRODUCTION Adverse events (AE) in care are recognized as a leading cause of mortality and injury in patients. Improving patients' safety is difficult to achieve. Therefore, innovative research strategies are needed to identify errors in subgroups of patients and related severity of outcomes as well as reliably measured efficiency of reproducible strategies to improve safety. This trial aims to evaluate the impact of a combined multiprofessional education program on the rate of AE in neonatal intensive care units (NICUs). METHODS AND ANALYSIS This is a stepped-wedge cluster randomised controlled trial with 3 clusters each containing 4 units. The study time period will be 20 months. The education program will be implemented within each cluster following a random sequence with a control period, a 4-month transition period and a post-educational intervention period. Eligibility criteria: for clusters: 6 NICUs from Ile-de-France and 6 NICUs from different regions in France; for patients: in-hospital during the study period (November 23, 2015 and November 2, 2017 [inclusion start dates varying by unit]) in one of the 12 NICUs; corrected gestational age ≤42 weeks upon admission; hospitalization period >2 days; and parents informed and not opposed to the use of their newborn's data. A routine occurrence reporting of medical errors and their consequence will take place during the entire study period. The intervention will combine an education to implement a standardized root cause analysis method, creation of bundles (insertion, daily goals, maintenance bundles) to prevent catheter-associated blood-stream infection and a poster to prevent extravasation injuries. OUTCOME We hypothesize a reduction from 60 (control) to 50 (intervention) AE/1000 patient-days. The primary outcome will be the rate of AE/1000 patient-days in the NICU. TRIAL REGISTRATION NUMBER NCT02598609, trial registered November 6, 2015. https://clinicaltrials.gov/ct2/show/NCT02598609. ETHICS AND DISSEMINATION Study approved by the regional ethic committee CPP Ile-de-France III (no 2014-A01751-46). The results will be published in peer-reviewed journals.",2020,"This trial aims to evaluate the impact of a combined multiprofessional education program on the rate of AE in neonatal intensive care units (NICUs). ","[""Eligibility criteria: for clusters: 6 NICUs from Ile-de-France and 6 NICUs from different regions in France; for patients: in-hospital during the study period (November 23, 2015 and November 2, 2017 [inclusion start dates varying by unit]) in one of the 12 NICUs; corrected gestational age ≤42 weeks upon admission; hospitalization period >2 days; and parents informed and not opposed to the use of their newborn's data"", 'neonates (SEPREVEN', 'neonatal intensive care units (NICUs']",['combined multiprofessional education program'],"['adverse event rates', 'rate of AE', 'rate of AE/1000\u200apatient-days in the NICU', 'adverse events']","[{'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0022192', 'cui_str': 'Isoleucine'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0011008', 'cui_str': 'Date'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0700287', 'cui_str': 'Informing'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}]",,0.170506,"This trial aims to evaluate the impact of a combined multiprofessional education program on the rate of AE in neonatal intensive care units (NICUs). ","[{'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Caeymaex', 'Affiliation': 'Faculty of Health and CEDITEC, University Paris East Creteil.'}, {'ForeName': 'Cecile', 'Initials': 'C', 'LastName': 'Lebeaux', 'Affiliation': 'Neonatal Intensive Care Unit, Centre Hospitalier Intercommunal de Creteil.'}, {'ForeName': 'Jean Christophe', 'Initials': 'JC', 'LastName': 'Roze', 'Affiliation': 'Pediatric Intensive Care Unit Nantes, University Hospital Centre Nantes, Pays de la Loire.'}, {'ForeName': 'Claude', 'Initials': 'C', 'LastName': 'Danan', 'Affiliation': 'Neonatal Intensive Care Unit, Centre Hospitalier Intercommunal de Creteil.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Reynaud', 'Affiliation': 'Association SOS Prema, Boulogne Billancourt.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Jung', 'Affiliation': 'Clinical Research Center (CRC), Centre Hospitalier Intercommunal de Creteil, Créteil.'}, {'ForeName': 'Etienne', 'Initials': 'E', 'LastName': 'Audureau', 'Affiliation': 'Faculty of Health and CEDITEC, University Paris East Creteil.'}]",Medicine,['10.1097/MD.0000000000020912'] 2436,32756091,A randomized controlled clinical trial study protocol of Liuwei Dihuang pills in the adjuvant treatment of diabetic kidney disease.,"INTRODUCTION A large number of patients with diabetic kidney disease (DKD) approach traditional Chinese medicine (TCM) owing to discontent with standard treatments. Based on TCM theory and clinical experience, the syndrome of kidney yin deficiency is a common type of DKD. Liuwei Dihuang pills (LDPs) is a common prescription of a Chinese herbal formula for patients presenting this syndrome of DKD. However, well-established data supporting the efficacy and safety of LDP in DKD treatment are lacking. METHODS We have designed a double-blind, placebo-controlled, randomized trial. After a 2-week run-in period, 124 eligible participants with DKD will be assigned to either the experimental or the control group in a 1:1 ratio. Patients in the experimental group will receive LDP, while patients in the control group will receive a matched placebo. As the basic treatment in the 2 groups, metformin hydrochloride sustained-release tablets, for blood glucose control, and irbesartan tablets, for blood pressure regulation, will be provided. All participants will undergo 4 weeks of treatment and 12 weeks of follow-up. The primary outcome is the change in 24 hours urinary protein levels, measured from the baseline to the end of the treatment phase (week 24). The secondary outcomes to be assessed include the change in serum creatinine and estimated glomerular filtration rate, urinary albumin excretion rate, improvement of TCM syndromes and symptoms, fasting blood glucose and postprandial 2-hour blood glucose, blood lipids (total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol, from baseline to weeks 12 and 24. DISCUSSION The results of this study will provide high-quality evidence of the effects of LDP in DKD treatment, which will provide an alternative treatment strategy in patients with DKD.",2020,"The primary outcome is the change in 24 hours urinary protein levels, measured from the baseline to the end of the treatment phase (week 24).","['patients presenting this syndrome of DKD', 'patients with diabetic kidney disease (DKD) approach traditional Chinese medicine (TCM', '124 eligible participants with DKD', 'diabetic kidney disease', 'patients with DKD']","['Liuwei Dihuang pills', 'Liuwei Dihuang pills (LDPs', 'metformin hydrochloride', 'LDP', 'placebo']","['change in 24\u200ahours urinary protein levels', 'blood glucose control, and irbesartan tablets, for blood pressure regulation', 'change in serum creatinine and estimated glomerular filtration rate, urinary albumin excretion rate, improvement of TCM syndromes and symptoms, fasting blood glucose and postprandial 2-hour blood glucose, blood lipids (total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0011881', 'cui_str': 'Kidney disorder due to diabetes mellitus'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C4517553', 'cui_str': '124'}]","[{'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0770893', 'cui_str': 'Metformin hydrochloride'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0428479', 'cui_str': 'Protein level - finding'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1244726', 'cui_str': 'irbesartan Oral Tablet'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0585937', 'cui_str': 'Albumin excretion rate measurement'}, {'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C1292425', 'cui_str': '2 hours'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}]",124.0,0.149074,"The primary outcome is the change in 24 hours urinary protein levels, measured from the baseline to the end of the treatment phase (week 24).","[{'ForeName': 'Tingting', 'Initials': 'T', 'LastName': 'Liao', 'Affiliation': 'Department of Endocrinology.'}, {'ForeName': 'Keni', 'Initials': 'K', 'LastName': 'Zhao', 'Affiliation': 'Department of Respiratory Medicine.'}, {'ForeName': 'Qun', 'Initials': 'Q', 'LastName': 'Huang', 'Affiliation': 'Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.'}, {'ForeName': 'Shiyun', 'Initials': 'S', 'LastName': 'Tang', 'Affiliation': 'Department of Endocrinology.'}, {'ForeName': 'Keling', 'Initials': 'K', 'LastName': 'Chen', 'Affiliation': 'Department of Respiratory Medicine.'}, {'ForeName': 'Chunguang', 'Initials': 'C', 'LastName': 'Xie', 'Affiliation': 'Department of Endocrinology.'}, {'ForeName': 'Chuantao', 'Initials': 'C', 'LastName': 'Zhang', 'Affiliation': 'Department of Respiratory Medicine.'}, {'ForeName': 'Wenfan', 'Initials': 'W', 'LastName': 'Gan', 'Affiliation': 'Department of Respiratory Medicine.'}]",Medicine,['10.1097/MD.0000000000021137'] 2437,32756138,A study on the effectiveness of pharmacopuncture for chronic neck pain: A protocol for a pragmatic randomized controlled trial.,"BACKGROUND Neck pain is a common musculoskeletal disorder that impacts individuals' daily life, and might sometimes lead to disability and increased medical costs. Pharmacopuncture combines acupuncture with herbal medicine, in which herbal extracts are administered on the acupoints. We designed a pragmatic randomized controlled trial (RCT) to compare the effectiveness of pharmacopuncture and physical therapy as a treatment for chronic neck pain. METHODS This study is a 2-armed, parallel, multi-center RCT. The participants will be randomly assigned to pharmacopuncture or physical therapy group to receive their respective 8-session treatments for 4 weeks. The primary outcome is the visual analogue scale of neck pain. Secondary outcomes is the Northwick Park questionnaire, visual analogue scale of radiating arm pain, numeric rating scale of the neck and arm bothersomeness, neck disability index, patient global impression of change, short form-12 health survey version 2, and 5-level EuroQol-5 dimension. DISCUSSION This is a protocol for a pragmatic RCT that would attempt to present evidence conducive to clinical decision or policy-making by investigating the effectiveness of pharmacopuncture therapy, a widely used approach in Korean medicine clinical practice, in comparison to the standard therapy.",2020,"Secondary outcomes is the Northwick Park questionnaire, visual analogue scale of radiating arm pain, numeric rating scale of the neck and arm bothersomeness, neck disability index, patient global impression of change, short form-12 health survey version 2, and 5-level EuroQol-5 dimension. ",['chronic neck pain'],"['pharmacopuncture and physical therapy', 'Pharmacopuncture combines acupuncture with herbal medicine', 'pharmacopuncture', 'pharmacopuncture or physical therapy group to receive their respective 8-session treatments']","['Northwick Park questionnaire, visual analogue scale of radiating arm pain, numeric rating scale of the neck and arm bothersomeness, neck disability index, patient global impression of change, short form-12 health survey version 2, and 5-level EuroQol-5 dimension', 'visual analogue scale of neck pain']","[{'cui': 'C0746815', 'cui_str': 'Chronic neck pain'}]","[{'cui': 'C4279921', 'cui_str': 'Pharmacopuncture'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0025125', 'cui_str': 'Herbs, Medicinal'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0237771', 'cui_str': 'Parks, Recreational'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0332301', 'cui_str': 'Radiating to'}, {'cui': 'C0239377', 'cui_str': 'Pain in upper limb'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0456951', 'cui_str': 'Level 5'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}]",,0.194569,"Secondary outcomes is the Northwick Park questionnaire, visual analogue scale of radiating arm pain, numeric rating scale of the neck and arm bothersomeness, neck disability index, patient global impression of change, short form-12 health survey version 2, and 5-level EuroQol-5 dimension. ","[{'ForeName': 'Kyoung Sun', 'Initials': 'KS', 'LastName': 'Park', 'Affiliation': 'Jaseng Hospital of Korean Medicine.'}, {'ForeName': 'Yoon Jae', 'Initials': 'YJ', 'LastName': 'Lee', 'Affiliation': 'Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Gangnam-gu, Seoul, Republic of Korea.'}, {'ForeName': 'Jinho', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Jaseng Hospital of Korean Medicine.'}, {'ForeName': 'In-Hyuk', 'Initials': 'IH', 'LastName': 'Ha', 'Affiliation': 'Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Gangnam-gu, Seoul, Republic of Korea.'}]",Medicine,['10.1097/MD.0000000000021406'] 2438,32756146,Evaluation of protective equipment for the reduction of radiation exposure to physicians performing fluoroscopically guided lumbar transforaminal epidural steroid injections: A randomized controlled trial.,"BACKGROUND Spine interventionists frequently employ fluoroscopy to guide injection procedures. The increase in fluoroscopically guided procedures in recent years has led to a growing concern about radiation exposure. A new method of covering the C-arm tube with a lead apron has been suggested to reduce radiation exposure. This study aimed to compare the radiation exposure when performing lumbar transforaminal epidural steroid injections (TFESIs) using this new method to a control group. METHODS A total of 200 patients who underwent lumbar TFESIs by a single physician were recruited. Patients were divided into 2 groups, the new method group (group A) and the control group (group C), and the amount of radiation exposure was compared. The dosimetry badge locations were marked as outside of apron, inside of apron, outside of thyroid collar, inside of thyroid collar, ring, and glasses. RESULTS The cumulative dose equivalents of all the measurement sites were reduced in group A compared with group C, and the most reduced site was inside the thyroid collar. CONCLUSIONS Covering the C-arm tube with a lead apron can be effective in reducing the cumulative radiation exposure when performing fluoroscopically guided TFESIs.",2020,"The cumulative dose equivalents of all the measurement sites were reduced in group A compared with group C, and the most reduced site was inside the thyroid collar. ","['200 patients who underwent lumbar TFESIs by a single physician were recruited', 'physicians performing fluoroscopically guided lumbar transforaminal epidural steroid injections']","['lumbar transforaminal epidural steroid injections (TFESIs', 'protective equipment']",['cumulative dose equivalents'],"[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0196394', 'cui_str': 'Epidural steroid injection'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0181090', 'cui_str': 'Guide'}]","[{'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0196394', 'cui_str': 'Epidural steroid injection'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}]","[{'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0205163', 'cui_str': 'Equal'}]",200.0,0.026103,"The cumulative dose equivalents of all the measurement sites were reduced in group A compared with group C, and the most reduced site was inside the thyroid collar. ","[{'ForeName': 'Won-Joong', 'Initials': 'WJ', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, School of Medicine, Ewha Womans University, Ewha Womans University Mokdong Hospital, Yangcheon-gu.'}, {'ForeName': 'Seung Hee', 'Initials': 'SH', 'LastName': 'Yoo', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, School of Medicine, Ewha Womans University, Ewha Womans University Mokdong Hospital, Yangcheon-gu.'}, {'ForeName': 'Hahck Soo', 'Initials': 'HS', 'LastName': 'Park', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, School of Medicine, Ewha Womans University, Ewha Womans University Seoul Hospital, Gangseo-gu, Seoul, Republic of Korea.'}]",Medicine,['10.1097/MD.0000000000021424'] 2439,32756160,The role of acupotomy in treatment of patients with lumbar spinal stenosis: A protocol for a randomized study.,"BACKGROUND Currently, there is some clinical evidence supporting the use of acupuncture in alleviating pain and dysfunction in patients with lumbar spinal stenosis (LSS). However, the question of whether acupuncture could be efficacious for ageing patients remains unanswered. We designed a randomized controlled study to evaluate the safety and feasibility of acupuncture for participants with symptomatic LSS. METHODS This study is a randomized, single-blind, noninferiority trial. This clinical trial was approved by the Linyi Cancer Hospital. We received informed consent from all patients before surgery. In preparing this report, we adhered to the Consolidated Standards of Reporting Trials guidelines. We randomized consented study participants on a 1:1 ratio to one of two study groups (acupuncture and control groups) using a computer-generated list of random numbers in varying block sizes. Three outcome measures were selected to evaluate the effectiveness and safety of the treatment: visual analogue score and Oswestry disability index, and complicatins. A P < .05 was regarded as statistically significant. RESULTS The hypothesis was that the acupuncture group would achieve acceptable clinical outcomes as compared to the control group in LSS. TRIAL REGISTRATION This study protocol was registered in Research Registry (researchregistry5744).",2020,"Three outcome measures were selected to evaluate the effectiveness and safety of the treatment: visual analogue score and Oswestry disability index, and complicatins.","['participants with symptomatic LSS', 'patients with lumbar spinal stenosis', 'patients with lumbar spinal stenosis (LSS']","['acupotomy', 'acupuncture']","['safety and feasibility', 'effectiveness and safety of the treatment: visual analogue score and Oswestry disability index, and complicatins']","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0158288', 'cui_str': 'Spinal stenosis of lumbar region'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4505457', 'cui_str': 'Acupotomy'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}]",,0.193331,"Three outcome measures were selected to evaluate the effectiveness and safety of the treatment: visual analogue score and Oswestry disability index, and complicatins.","[{'ForeName': 'Yuqin', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Rehabilitation, Linyi Central Hospital.'}, {'ForeName': 'Huaihua', 'Initials': 'H', 'LastName': 'Song', 'Affiliation': ""Department of Obstetrics and Gynecology, The third People's Hospital of Linyi.""}, {'ForeName': 'Mingyu', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': 'Department of Neurology, Linyi Central Hospital.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Xu', 'Affiliation': 'Department of Bone Oncology, Linyi Cancer Hospital, Shandong, China.'}]",Medicine,['10.1097/MD.0000000000021444'] 2440,32756176,"Effects of Yangxinshi tablet on exercise tolerance in patients with coronary heart disease: A protocol of randomized, double-blind, placebo-controlled, and multi-center trial.","BACKGROUND Exercise intolerance is very common in patients with coronary heart disease (CHD). Although some researches confirming the validation of traditional Chinese medicine (TCM) on CHD treatment, the effect of TCM on improving the exercise tolerance of patients with CHD remains unclear so far. Our trial is to investigate whether the Yangxinshi (YXS) tablet can improve exercise tolerance as well as the quality of life among CHD patients. METHODS It is a randomized, double-blind, placebo-controlled, multi-center trial. A total of 90 patients with CHD from 3 hospitals in China will be enrolled and randomly assigned to one of 2 groups: YXS group, N = 45; placebo group, N = 45. The 2 groups will simultaneously receive standardized western medicine and exercise-based cardiac rehabilitation program for 12 weeks. The primary outcome measure is the exercise capacity, which will be evaluated by the cardiopulmonary exercise test and 6-minute walking test. The 2nd outcomes include symptom improvement, psychologic issues, laboratory tests, side effects, and adverse events. DISCUSSION To our knowledge, it is the 1st randomized controlled trial to evaluate the effect of TCM YXS tablet on exercise tolerance in patients with CHD. The results will provide more evidence for future studies in this area. TRIAL REGISTRATION This study protocol was registered in Research Registry (researchregistry5752).",2020,"Our trial is to investigate whether the Yangxinshi (YXS) tablet can improve exercise tolerance as well as the quality of life among CHD patients. ","['90 patients with CHD from 3 hospitals in China', 'patients with coronary heart disease (CHD', 'patients with coronary heart disease', 'CHD patients', 'patients with CHD']","['Yangxinshi (YXS) tablet', 'Yangxinshi tablet', 'TCM', 'TCM YXS tablet', 'YXS group, N\u200a=\u200a45; placebo', 'standardized western medicine and exercise-based cardiac rehabilitation program', 'traditional Chinese medicine (TCM', 'placebo']","['symptom improvement, psychologic issues, laboratory tests, side effects, and adverse events', 'exercise tolerance', 'exercise capacity, which will be evaluated by the cardiopulmonary exercise test and 6-minute walking test']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C4742319', 'cui_str': 'Yangxinshi tablet'}, {'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C4742318', 'cui_str': 'Yangxinshi'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0022885', 'cui_str': 'Laboratory procedure'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary exercise test'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",90.0,0.531614,"Our trial is to investigate whether the Yangxinshi (YXS) tablet can improve exercise tolerance as well as the quality of life among CHD patients. ","[{'ForeName': 'Sisi', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': 'Cardiovascular and Cardiac Rehabilitation Department, First Affiliated Hospital of Changchun Chinese Medicine University, Changchun City, Jilin Province.'}, {'ForeName': 'Congying', 'Initials': 'C', 'LastName': 'Liang', 'Affiliation': 'Cardiovascular and Cardiac Rehabilitation Department, First Affiliated Hospital of Changchun Chinese Medicine University, Changchun City, Jilin Province.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Cardiovascular and Cardiac Rehabilitation Department, First Affiliated Hospital of Changchun Chinese Medicine University, Changchun City, Jilin Province.'}, {'ForeName': 'Zhijia', 'Initials': 'Z', 'LastName': 'Zhao', 'Affiliation': 'Cardiovascular and Cardiac Rehabilitation Department, First Affiliated Hospital of Changchun Chinese Medicine University, Changchun City, Jilin Province.'}, {'ForeName': 'Jiaojiao', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ""Operating Room Department, Feicheng Mining Bureau Central Hospital, Tai'an City, Shandong Province, China.""}, {'ForeName': 'Xiaoping', 'Initials': 'X', 'LastName': 'Meng', 'Affiliation': 'Cardiovascular and Cardiac Rehabilitation Department, First Affiliated Hospital of Changchun Chinese Medicine University, Changchun City, Jilin Province.'}]",Medicine,['10.1097/MD.0000000000021485'] 2441,32750305,Ischemic Preconditioning Improves Microvascular Endothelial Function in Remote Vasculature by Enhanced Prostacyclin Production.,"BACKGROUND The mechanisms underlying the effect of preconditioning on remote microvasculature remains undisclosed. The primary objective was to document the remote effect of ischemic preconditioning on microvascular function in humans. The secondary objective was to test if exercise also induces remote microvascular effects. METHODS AND RESULTS A total of 12 healthy young men and women participated in 2 experimental days in a random counterbalanced order. On one day the participants underwent 4×5 minutes of forearm ischemic preconditioning, and on the other day they completed 4×5 minutes of hand-grip exercise. On both days, catheters were placed in the brachial and femoral artery and vein for infusion of acetylcholine, sodium nitroprusside, and epoprostenol. Vascular conductance was calculated from blood flow measurements with ultrasound Doppler and arterial and venous blood pressures. Ischemic preconditioning enhanced ( P <0.05) the remote vasodilator response to intra-arterial acetylcholine in the leg at 5 and 90 minutes after application. The enhanced response was associated with a 6-fold increase ( P <0.05) in femoral venous plasma prostacyclin levels and with a transient increase ( P <0.05) in arterial plasma levels of brain-derived neurotrophic factor and vascular endothelial growth factor. In contrast, hand-grip exercise did not influence remote microvascular function. CONCLUSIONS These findings demonstrate that ischemic preconditioning of the forearm improves remote microvascular endothelial function and suggest that one of the underlying mechanisms is a humoral-mediated potentiation of prostacyclin formation.",2020,Ischemic preconditioning enhanced ( P <0.05) the remote vasodilator response to intra-arterial acetylcholine in the leg at 5 and 90 minutes after application.,"['12 healthy young men and women participated in 2 experimental days in a random counterbalanced order', 'humans']","['acetylcholine, sodium nitroprusside, and epoprostenol', 'ischemic preconditioning', 'forearm ischemic preconditioning, and on the other day they completed 4×5\xa0minutes of hand-grip exercise', 'Ischemic Preconditioning']","['microvascular function', 'blood flow measurements with ultrasound Doppler and arterial and venous blood pressures', 'arterial plasma levels of brain-derived neurotrophic factor and vascular endothelial growth factor', 'femoral venous plasma prostacyclin levels', 'remote microvascular function', 'Microvascular Endothelial Function', 'Vascular conductance', 'remote vasodilator response', 'remote microvascular effects']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0001041', 'cui_str': 'Acetylcholine'}, {'cui': 'C0037533', 'cui_str': 'Sodium nitroprusside'}, {'cui': 'C0033567', 'cui_str': 'Epoprostenol'}, {'cui': 'C0376466', 'cui_str': 'Ischemic Pre-Conditioning'}, {'cui': 'C0016536', 'cui_str': 'Forearm structure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C1293900', 'cui_str': 'Hand grip'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0005776', 'cui_str': 'Circulatory function tests'}, {'cui': 'C0162481', 'cui_str': 'Doppler ultrasound'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0042486', 'cui_str': 'Venous pressure'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C3838734', 'cui_str': 'Venous plasma'}, {'cui': 'C0033567', 'cui_str': 'Epoprostenol'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0042402', 'cui_str': 'Vasodilator agent'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",12.0,0.0531349,Ischemic preconditioning enhanced ( P <0.05) the remote vasodilator response to intra-arterial acetylcholine in the leg at 5 and 90 minutes after application.,"[{'ForeName': 'Nicolai', 'Initials': 'N', 'LastName': 'Rytter', 'Affiliation': 'Section of Integrative Physiology Department of Nutrition, Exercise and Sports University of Copenhagen Denmark.'}, {'ForeName': 'Howard', 'Initials': 'H', 'LastName': 'Carter', 'Affiliation': 'Section of Integrative Physiology Department of Nutrition, Exercise and Sports University of Copenhagen Denmark.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Piil', 'Affiliation': 'Section of Integrative Physiology Department of Nutrition, Exercise and Sports University of Copenhagen Denmark.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Sørensen', 'Affiliation': 'Section of Integrative Physiology Department of Nutrition, Exercise and Sports University of Copenhagen Denmark.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Ehlers', 'Affiliation': 'Section of Integrative Physiology Department of Nutrition, Exercise and Sports University of Copenhagen Denmark.'}, {'ForeName': 'Frederik', 'Initials': 'F', 'LastName': 'Holmegaard', 'Affiliation': 'Section of Integrative Physiology Department of Nutrition, Exercise and Sports University of Copenhagen Denmark.'}, {'ForeName': 'Christoffer', 'Initials': 'C', 'LastName': 'Tuxen', 'Affiliation': 'Section of Integrative Physiology Department of Nutrition, Exercise and Sports University of Copenhagen Denmark.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Jones', 'Affiliation': 'Research Institute for Sport and Exercise Sciences Liverpool John Moores University Liverpool United Kingdom.'}, {'ForeName': 'Dick', 'Initials': 'D', 'LastName': 'Thijssen', 'Affiliation': 'Research Institute for Sport and Exercise Sciences Liverpool John Moores University Liverpool United Kingdom.'}, {'ForeName': 'Lasse', 'Initials': 'L', 'LastName': 'Gliemann', 'Affiliation': 'Section of Integrative Physiology Department of Nutrition, Exercise and Sports University of Copenhagen Denmark.'}, {'ForeName': 'Ylva', 'Initials': 'Y', 'LastName': 'Hellsten', 'Affiliation': 'Section of Integrative Physiology Department of Nutrition, Exercise and Sports University of Copenhagen Denmark.'}]",Journal of the American Heart Association,['10.1161/JAHA.120.016017'] 2442,32750310,Associations of Left Ventricular Structure and Function With Blood Pressure in Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.,"Background Data on the association of systolic and diastolic blood pressure with the structure and function of failing hearts with preserved ejection fraction (EF) are sparse. Methods and Results This analysis included 935 patients with heart failure (49.4% women; mean age, 69.9 years) with preserved EF (≥45%) enrolled in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial before initiation of randomized therapy. Left ventricular (LV) structure (dimensions, wall thickness, and mass index), diastolic function (left atrial volume index, transmitral blood flow, and mitral annular velocities), and systolic function (EF and longitudinal strain) were assessed echocardiographically. In multivariable-adjusted analyses, association sizes expressed per 1-SD (14.8-mm Hg) increment in systolic blood pressure were 0.020 cm ( P =0.003) and 0.018 cm ( P =0.004) for LV septal and posterior wall thickness, respectively, and 2.42 mg/m 2 ( P =0.018) for LV mass index. The corresponding associations with diastolic blood pressure were nonsignificant ( P ≥0.067). In similarly adjusted analyses, the association sizes expressed per 1-SD (10.7-mm Hg) increment in diastolic blood pressure were -0.15 for E/A ( P <0.001), -0.76 for E/e' ( P =0.006), and -0.62% for EF ( P =0.024). These findings were consistent, if models including systolic blood pressure were additionally adjusted for diastolic blood pressure and vice versa, albeit that the relation of EF with diastolic blood pressure weakened (-0.54%; P =0.10). Conclusions In diastolic heart failure, LV wall thickness and LV mass index increased with higher systolic blood pressure, but not with higher diastolic blood pressure, whereas functional measures reflecting diastolic LV function decreased with higher diastolic blood pressure, independent of systolic blood pressure. These observations highlight the importance of controlling both systolic and diastolic blood pressure as modifiable risk factors to reduce the risk of LV remodeling and diastolic LV dysfunction.",2020,"In diastolic heart failure, LV wall thickness and LV mass index increased with higher systolic blood pressure, but not with higher diastolic blood pressure, whereas functional measures reflecting diastolic LV function decreased with higher diastolic blood pressure, independent of systolic blood pressure.","['935 patients with heart failure (49.4% women; mean age, 69.9\xa0years) with preserved EF (≥45%) enrolled in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an', 'Heart Failure']","['Preserved Ejection Fraction', 'Aldosterone Antagonist']","['diastolic LV function', 'LV septal and posterior wall thickness', 'diastolic heart failure, LV wall thickness and LV mass index', 'systolic and diastolic blood pressure', 'systolic blood pressure', 'diastolic blood pressure', 'diastolic blood pressure and vice versa', 'Left ventricular (LV) structure (dimensions, wall thickness, and mass index), diastolic function (left atrial volume index, transmitral blood flow, and mitral annular velocities), and systolic function (EF and longitudinal strain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}]","[{'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0002007', 'cui_str': 'Aldosterone receptor antagonist-containing product'}]","[{'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0080310', 'cui_str': 'Left ventricular function'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0442004', 'cui_str': 'Septal'}, {'cui': 'C0227701', 'cui_str': 'Structure of posterior wall of urinary bladder'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C1135196', 'cui_str': 'Diastolic heart failure'}, {'cui': 'C0205380', 'cui_str': 'Walled'}, {'cui': 'C0455825', 'cui_str': 'Left ventricular mass'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0018792', 'cui_str': 'Atrial structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0521164', 'cui_str': 'Annular shape'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}]",935.0,0.0265293,"In diastolic heart failure, LV wall thickness and LV mass index increased with higher systolic blood pressure, but not with higher diastolic blood pressure, whereas functional measures reflecting diastolic LV function decreased with higher diastolic blood pressure, independent of systolic blood pressure.","[{'ForeName': 'Fang-Fei', 'Initials': 'FF', 'LastName': 'Wei', 'Affiliation': 'Department of Cardiology the First Affiliated Hospital of Sun Yat-Sen University Guangzhou Guangdong, China.'}, {'ForeName': 'Ruicong', 'Initials': 'R', 'LastName': 'Xue', 'Affiliation': 'Department of Cardiology the First Affiliated Hospital of Sun Yat-Sen University Guangzhou Guangdong, China.'}, {'ForeName': 'Lutgarde', 'Initials': 'L', 'LastName': 'Thijs', 'Affiliation': 'Studies Coordinating Centre Research Unit Hypertension and Cardiovascular Epidemiology Department of Cardiovascular Sciences University of Leuven Belgium.'}, {'ForeName': 'Weihao', 'Initials': 'W', 'LastName': 'Liang', 'Affiliation': 'Department of Cardiology the First Affiliated Hospital of Sun Yat-Sen University Guangzhou Guangdong, China.'}, {'ForeName': 'Marvin', 'Initials': 'M', 'LastName': 'Owusu-Agyeman', 'Affiliation': 'Department of Cardiology the First Affiliated Hospital of Sun Yat-Sen University Guangzhou Guangdong, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'He', 'Affiliation': 'Department of Cardiology the First Affiliated Hospital of Sun Yat-Sen University Guangzhou Guangdong, China.'}, {'ForeName': 'Jan A', 'Initials': 'JA', 'LastName': 'Staessen', 'Affiliation': 'Studies Coordinating Centre Research Unit Hypertension and Cardiovascular Epidemiology Department of Cardiovascular Sciences University of Leuven Belgium.'}, {'ForeName': 'Yugang', 'Initials': 'Y', 'LastName': 'Dong', 'Affiliation': 'Department of Cardiology the First Affiliated Hospital of Sun Yat-Sen University Guangzhou Guangdong, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Department of Cardiology the First Affiliated Hospital of Sun Yat-Sen University Guangzhou Guangdong, China.'}]",Journal of the American Heart Association,['10.1161/JAHA.119.016009'] 2443,32750332,The effect of oxytocin on pupil response to naturalistic dynamic facial expressions.,"The neuropeptide oxytocin (OT) has been found to play an important role in a variety of social behaviours and social cognition in particular. The social salience hypothesis of OT suggests that OT shifts attention towards socially relevant stimuli, which offers an explanation for improvements on social cognition measures following OT administration. Pupil dilation occurs with increasing attentional resource allocation and previous research has found that OT administration led to an increase in pupil diameter in response to social stimuli relative to placebo (PL), thereby suggesting increased social attention. The current study aimed to investigate the effects of OT on pupillary responses to more naturalistic social stimuli in a larger sample. Ninety-four male participants took part in the double-blind, placebo controlled, mixed-design study, in which they self-administered either an OT or PL nasal spray before viewing naturalistic dynamic facial expressions of emotion (happy, sad, fear and anger). Contrary to prediction, there was no effect of OT administration on pupil diameter. The results are discussed in light of the social salience hypothesis and with reference to the methodological differences between studies.",2020,"Pupil dilation occurs with increasing attentional resource allocation and previous research has found that OT administration led to an increase in pupil diameter in response to social stimuli relative to placebo (PL), thereby suggesting increased social attention.",['Ninety-four male participants took part in the double-blind'],"['OT', 'oxytocin', 'OT or PL nasal spray', 'neuropeptide oxytocin (OT', 'placebo']","['social cognition measures', 'pupil response to naturalistic dynamic facial expressions', 'emotion (happy, sad, fear and anger']","[{'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0461725', 'cui_str': 'Nasal spray'}, {'cui': 'C0027895', 'cui_str': 'Neuropeptide'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0034121', 'cui_str': 'Pupil structure'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0085159', 'cui_str': 'Seasonal affective disorder'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0002957', 'cui_str': 'Feeling angry'}]",94.0,0.0408089,"Pupil dilation occurs with increasing attentional resource allocation and previous research has found that OT administration led to an increase in pupil diameter in response to social stimuli relative to placebo (PL), thereby suggesting increased social attention.","[{'ForeName': 'Daniel T', 'Initials': 'DT', 'LastName': 'Burley', 'Affiliation': 'Cardiff University Centre for Human Developmental Science, School of Psychology, Cardiff University, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Daughters', 'Affiliation': 'Neuroscience and Mental Health Research Institute, Cardiff University, United Kingdom of Great Britain and Northern Ireland. Electronic address: k.daughters@bangor.ac.uk.'}]",Hormones and behavior,['10.1016/j.yhbeh.2020.104837'] 2444,32750373,Cardiac rehabilitation for patients treated for atrial fibrillation with ablation has long-term effects: 12 and 24 month follow-up results from the randomized CopenHeartRFA trial.,"OBJECTIVE To assess outcomes at 12 and 24 months following participation in a multidisciplinary cardiac rehabilitation program plus usual care compared with usual care alone for patients treated for atrial fibrillation with catheter ablation. DESIGN Long-term follow-up on the randomized CopenHeartRFA trial. STETTING Patients were enrolled and outcome assessed at the hospital and the intervention were carried out at the hospital or at local rehabilitation centers. PARTICIPANTS Patients treated for atrial fibrillation with catheter ablation included in the CopenHeartRFA trial. INTERVENTIONS A six months cardiac rehabilitation program consisting of physical exercise and psycho-educational consultations plus usual care or usual care alone. MAIN OUTCOME MEASURES Physical capacity was measured by peak oxygen uptake (VO 2 peak) at 12 months and patient-reported outcomes on perceived health, anxiety and depression were collected at by validated questionnaires at 12 and 24 months. Information on hospital admissions and mortality was collected through national registers up to 24 months. RESULTS Mean VO2 peak was higher at 12 months in the cardiac rehabilitation group (cardiac rehabilitation group: 25.82 ml/kg/min vs. usual care group, 22.43 ml/kg/min, p=0.003). A lower; proportion of patients had high levels of anxiety at 24 months in the cardiac rehabilitation group; compared to usual care (12% vs 24%, p=0.004). There was no difference in mortality or hospital; admissions at 24 months between groups. CONCLUSIONS This long-term follow-up of a comprehensive multidisciplinary cardiac rehabilitation program for patients treated for atrial fibrillation with catheter ablation found sustained improvements with respect to physical capacity and anxiety compared to usual care but no difference on mortality or hospital admission.",2020,"A lower; proportion of patients had high levels of anxiety at 24 months in the cardiac rehabilitation group; compared to usual care (12% vs 24%, p=0.004).","['patients treated for atrial fibrillation with catheter ablation', 'Patients treated for atrial fibrillation with catheter ablation included in the CopenHeartRFA trial', 'Patients were enrolled and outcome assessed at the hospital and the intervention were carried out at the hospital or at local rehabilitation centers', 'patients treated for atrial fibrillation with']","['catheter ablation', 'physical exercise and psycho-educational consultations plus usual care or usual care alone', 'multidisciplinary cardiac rehabilitation program plus usual care compared with usual care alone', 'Cardiac rehabilitation']","['mortality or hospital admission', 'anxiety', 'Mean VO2 peak', 'peak oxygen uptake', 'mortality or hospital; admissions', 'perceived health, anxiety and depression', 'hospital admissions and mortality', 'physical capacity and anxiety', 'Physical capacity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0162563', 'cui_str': 'Cardiac ablation'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0034993', 'cui_str': 'Centers, Rehabilitation'}]","[{'cui': 'C0162563', 'cui_str': 'Cardiac ablation'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0667627', 'cui_str': 'bis(kojato)oxovanadium(IV)'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",,0.0630477,"A lower; proportion of patients had high levels of anxiety at 24 months in the cardiac rehabilitation group; compared to usual care (12% vs 24%, p=0.004).","[{'ForeName': 'Signe Stelling', 'Initials': 'SS', 'LastName': 'Risom', 'Affiliation': 'Centre for Cardiac, Vascular, Pulmonary and Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Denmark; Institute of Nursing and Nutrition, University College Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: signe.stelling.risom@regionh.dk.'}, {'ForeName': 'Ann-Dorthe', 'Initials': 'AD', 'LastName': 'Zwisler', 'Affiliation': 'Centre for Cardiac, Vascular, Pulmonary and Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Denmark; Danish Knowledge Centre for Rehabilitation and Palliation, University of Southern Denmark and University hospital Odense, Denmark.'}, {'ForeName': 'Kirstine Lærum', 'Initials': 'KL', 'LastName': 'Sibilitz', 'Affiliation': 'Centre for Cardiac, Vascular, Pulmonary and Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Denmark.'}, {'ForeName': 'Trine Bernholdt', 'Initials': 'TB', 'LastName': 'Rasmussen', 'Affiliation': 'Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Cardiology, Herlev and Gentofte University Hospital, Hellerup, Denmark.'}, {'ForeName': 'Rod Stephen', 'Initials': 'RS', 'LastName': 'Taylor', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark; Institute of Health Research, University of Exeter Medical School, Exeter, UK; Institute of Health and Well Being, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Lau Caspar', 'Initials': 'LC', 'LastName': 'Thygesen', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.'}, {'ForeName': 'Trine Stougaard', 'Initials': 'TS', 'LastName': 'Madsen', 'Affiliation': 'Institute of Nursing and Nutrition, University College Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Jesper Hastrup', 'Initials': 'JH', 'LastName': 'Svendsen', 'Affiliation': 'Centre for Cardiac, Vascular, Pulmonary and Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; The Danish National Research Foundation Centre for Cardiac Arrhythmia (DARC), Copenhagen, Denmark.'}, {'ForeName': 'Selina Kikkenborg', 'Initials': 'SK', 'LastName': 'Berg', 'Affiliation': 'Centre for Cardiac, Vascular, Pulmonary and Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.'}]",Archives of physical medicine and rehabilitation,['10.1016/j.apmr.2020.06.026'] 2445,32750393,Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial.,"BACKGROUNDS Data on optimal antiplatelet therapy in patients undergoing stenting of the proximal left anterior descending artery (LAD) are limited. METHODS This is a post-hoc analysis of the GLOBAL LEADERS trial, a prospective, multi-center, randomized controlled trial, comparing the experimental strategy (1-month dual anti-platelet therapy [DAPT] followed by 23-month ticagrelor monotherapy) with the reference regimen (12-month DAPT followed by 12-month aspirin monotherapy) in relation to stenting of the proximal LAD. The primary endpoint was the composite of all-cause death or new Q-wave myocardial infarction (MI) and key secondary safety endpoint was Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at two years. RESULTS Among 15,845 patients included in the analysis, 3823 (23.9%) patients underwent stenting of the proximal LAD, while 12,022 (75.2%) did not. In the proximal LAD stenting group, there was no significant difference in the risk of the primary endpoint between the two antiplatelet strategies (3.38% vs. 3.93%; hazard ratio [HR]:0.86; 95% CI:0.62-1.20; P interaction  = 0.951). However, the risk of any MI (2.63% vs. 3.88%; HR:0.68; 95% CI:0.47-0.97; P interaction  = 0.015) and any revascularization (7.84% vs. 9.94%; HR:0.78; 95% CI:0.63-0.97; P interaction  = 0.058) was significantly lower in the experimental strategy group, while demonstrating a similar risk of BARC type 3 or 5 bleeding between the two antiplatelet strategies (1.93% vs. 1.99%; HR:0.98; 95% CI:0.62-1.54; P interaction  = 0.981). CONCLUSIONS The present study showed patients having stenting to the proximal LAD could potentially benefit from the experimental strategy with lower ischaemic events without a trade-off in major bleeding at two years.",2020,"In the proximal LAD stenting group, there was no significant difference in the risk of the primary endpoint between the two antiplatelet strategies (3.38% vs. 3.93%; hazard ratio [HR]:0.86; 95% CI:0.62-1.20; P interaction  = 0.951).","['patients having stenting to the proximal LAD', 'patients undergoing proximal LAD stenting', 'patients undergoing stenting of the proximal left anterior descending artery (LAD', '15,845 patients included in the analysis, 3823 (23.9%) patients underwent stenting of the proximal LAD, while 12,022 (75.2%) did not']","['dual anti-platelet therapy [DAPT', 'aspirin monotherapy', 'ticagrelor monotherapy']","['risk of any MI', 'Efficacy and safety', 'composite of all-cause death or new Q-wave myocardial infarction (MI) and key secondary safety endpoint was Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at two years']","[{'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0226032', 'cui_str': 'Structure of anterior descending branch of left coronary artery'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1299585', 'cui_str': 'Does not'}]","[{'cui': 'C5197905', 'cui_str': 'Dual Anti-Platelet Therapy'}, {'cui': 'C0634829', 'cui_str': '1,2-dilinolenoyl-3-(4-aminobutyryl)propane-1,2,3-triol'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0429089', 'cui_str': 'Electrocardiogram Q waves'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0441731', 'cui_str': 'Type 3'}, {'cui': 'C0439234', 'cui_str': 'year'}]",15845.0,0.0682053,"In the proximal LAD stenting group, there was no significant difference in the risk of the primary endpoint between the two antiplatelet strategies (3.38% vs. 3.93%; hazard ratio [HR]:0.86; 95% CI:0.62-1.20; P interaction  = 0.951).","[{'ForeName': 'Kuniaki', 'Initials': 'K', 'LastName': 'Takahashi', 'Affiliation': 'Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Rutao', 'Initials': 'R', 'LastName': 'Wang', 'Affiliation': 'Depatment of Cardiology, Radboud University, Nijmegen, the Netherlands.'}, {'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Kawashima', 'Affiliation': 'Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Mariusz', 'Initials': 'M', 'LastName': 'Tomaniak', 'Affiliation': 'Department of Cardiology, Erasmus Medical University Center, Thorax Centre, Rotterdam, the Netherlands.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Gao', 'Affiliation': 'Depatment of Cardiology, Radboud University, Nijmegen, the Netherlands.'}, {'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Ono', 'Affiliation': 'Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Hironori', 'Initials': 'H', 'LastName': 'Hara', 'Affiliation': 'Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Joanna J', 'Initials': 'JJ', 'LastName': 'Wykrzykowska', 'Affiliation': 'Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Robbert J', 'Initials': 'RJ', 'LastName': 'de Winter', 'Affiliation': 'Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Nikos', 'Initials': 'N', 'LastName': 'Werner', 'Affiliation': 'Department of Medicine II, Heart Center, University Hospital Bonn, Bonn, Germany.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Teiger', 'Affiliation': 'University Hospital Henri Mondor, Créteil, France.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Almeida', 'Affiliation': 'Hospital de Santa Cruz, Lisbon, Portugal.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Barraud', 'Affiliation': 'Clinique des Dômes, Clermont-Ferrand, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Lantelme', 'Affiliation': 'Hôpital de la Croix-Rousse, Lyon, France.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Barlis', 'Affiliation': ""Northern Hospital, Epping, Australia; St. Vincent's Heart Centre, Fitzroy, Australia.""}, {'ForeName': 'Scot', 'Initials': 'S', 'LastName': 'Garg', 'Affiliation': 'Royal Blackburn Hospital, Blackburn, United Kingdom.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Hamm', 'Affiliation': 'University of Giessen, Kerckhoff Heartand Thorax Center, Bad Nauheim, Germany.'}, {'ForeName': 'Philippe Gabriel', 'Initials': 'PG', 'LastName': 'Steg', 'Affiliation': 'FACT (French Alliance for Cardiovascular Trials), Université Paris-Diderot, Paris, France.'}, {'ForeName': 'Yoshinobu', 'Initials': 'Y', 'LastName': 'Onuma', 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Vranckx', 'Affiliation': 'Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa, Ziekenhuis, Hasselt, Belgium, Faculty of Medicine and Life Sciences, University of Hasselt, Hasselt, Belgium.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Windecker', 'Affiliation': 'Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Valgimigli', 'Affiliation': 'Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Patrick W', 'Initials': 'PW', 'LastName': 'Serruys', 'Affiliation': 'Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland. Electronic address: patrick.w.j.c.serruys@gmail.com.'}]",International journal of cardiology,['10.1016/j.ijcard.2020.07.042'] 2446,32750572,Clinical outcomes from the texting for relapse prevention (T4RP) in schizophrenia and schizoaffective disorder study.,"This 6 month randomized control trial investigated whether a novel text-messaging program impacted targeted clinical outcomes in patients with schizophrenia and schizoaffective disorder (SAD). Forty patients were enrolled and completed baseline, 3-month and 6-month assessments. The intervention group received daily symptom check-in text messages, plus, a medication reminder or, inspirational quote text. The control group had treatment as usual. At 6 months the Positive and Negative Syndrome Scale mean positive score was significantly lower and injectable medication compliance was significantly higher in the intervention group. Recovery scores were significantly higher at 3 months. Results suggest that this program may benefit individuals with schizophrenia/SAD who use text messaging. Further investigation in a larger sample appears warranted.",2020,At 6 months the Positive and Negative Syndrome Scale mean positive score was significantly lower and injectable medication compliance was significantly higher in the intervention group.,"['patients with schizophrenia and schizoaffective disorder (SAD', 'Forty patients were enrolled and completed baseline, 3-month and 6-month assessments']","['texting for relapse prevention (T4RP', 'daily symptom check-in text messages, plus, a medication reminder or, inspirational quote text', 'novel text-messaging program']","['Recovery scores', 'injectable medication compliance', 'Positive and Negative Syndrome Scale mean positive score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0036337', 'cui_str': 'Schizoaffective disorder'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0679867', 'cui_str': 'Relapse prevention'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1283174', 'cui_str': 'Checking - action'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0451383', 'cui_str': 'Positive and negative syndrome scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]",40.0,0.0323144,At 6 months the Positive and Negative Syndrome Scale mean positive score was significantly lower and injectable medication compliance was significantly higher in the intervention group.,"[{'ForeName': 'Bernadette A', 'Initials': 'BA', 'LastName': 'Cullen', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA; Department of Mental Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Electronic address: bcullen@jhmi.edu.'}, {'ForeName': 'Katrina', 'Initials': 'K', 'LastName': 'Rodriguez', 'Affiliation': 'Department of Mental Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'William W', 'Initials': 'WW', 'LastName': 'Eaton', 'Affiliation': 'Department of Mental Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Ramin', 'Initials': 'R', 'LastName': 'Mojtabai', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA; Department of Mental Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'Von Mach', 'Affiliation': ""Ann & Robert H. Lurie Children's Hospital of Chicago, USA.""}, {'ForeName': 'Michele L', 'Initials': 'ML', 'LastName': 'Ybarra', 'Affiliation': 'Department of Mental Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; Center for Innovative Public Health Research, San Clemente, California, USA.'}]",Psychiatry research,['10.1016/j.psychres.2020.113346'] 2447,32750626,Association of patient preferences on medication discussion in hypertension: Results from a randomized clinical trial.,"Patient-centered care has received significant attention and is an integral component of high-quality healthcare. While it is often assumed that most prefer a patient-centered role orientation, such preferences exist along a continuum with some patients preferring a more provider-centered role. The present study examines patient preference data from a randomized clinical trial designed to test the efficacy of a patient activation intervention to promote thiazide prescribing for veteran patients with uncontrolled hypertension. Patient preferences for involvement in healthcare were assessed using the 9-item Sharing subscale of the Patient-Practitioner Orientation Scale (PPOS). The primary aim was to examine differences in discussion of thiazide use in the clinical encounter by those scoring high versus low on the PPOS. Five hundred ninety-five veteran patients were randomized to either one of three intervention groups or a usual care control group. The adjusted odds ratios (OR) for the three intervention groups relative to the control group indicated that thiazide discussion increased as a function of intervention intensity across both high and low PPOS groups. ORs for the most intensive intervention group were 3.72 (95% CI = 1.61-8.65, p < .01) for high PPOS patients and 6.71 (95% CI = 2.59-10.67, p < .001) for low PPOS patients. Results suggest that this patient activation intervention is effective for veteran patients representing a range of preferred involvement. Consideration of such preferences may be useful in tailoring future interventions in the healthcare context.",2020,"ORs for the most intensive intervention group were 3.72 (95% CI = 1.61-8.65, p < .01) for high PPOS patients and 6.71 (95% CI = 2.59-10.67, p < .001) for low PPOS patients.","['Five hundred ninety-five veteran patients', 'veteran patients with uncontrolled hypertension', 'hypertension']","['patient activation intervention', 'thiazide prescribing', 'thiazide', 'activation intervention', 'usual care control group']","['9-item Sharing subscale of the Patient-Practitioner Orientation Scale (PPOS', 'adjusted odds ratios (OR', 'function of intervention intensity']","[{'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C4517906', 'cui_str': '95'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1868885', 'cui_str': 'Uncontrolled hypertension'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]","[{'cui': 'C3853034', 'cui_str': 'Patient Activation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0012802', 'cui_str': 'Thiazide diuretic'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0029266', 'cui_str': 'Orientation'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}]",595.0,0.0335965,"ORs for the most intensive intervention group were 3.72 (95% CI = 1.61-8.65, p < .01) for high PPOS patients and 6.71 (95% CI = 2.59-10.67, p < .001) for low PPOS patients.","[{'ForeName': 'M Bryant', 'Initials': 'MB', 'LastName': 'Howren', 'Affiliation': 'Center for Access Delivery Research & Evaluation (CADRE), VA Iowa City Healthcare System, Iowa City, IA, USA; Department of Behavioral Sciences & Social Medicine, College of Medicine, Florida State University, Tallahassee, FL, USA. Electronic address: matthew.howren@med.fsu.edu.'}, {'ForeName': 'Mark W', 'Initials': 'MW', 'LastName': 'Vander Weg', 'Affiliation': 'Center for Access Delivery Research & Evaluation (CADRE), VA Iowa City Healthcare System, Iowa City, IA, USA; Division of General Internal Medicine, The University of Iowa Carver College of Medicine, Iowa City, IA, USA; Department of Psychological & Brain Sciences, The University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Alan J', 'Initials': 'AJ', 'LastName': 'Christensen', 'Affiliation': 'Department of Psychology, East Carolina University, Greenville, NC, USA.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Kaboli', 'Affiliation': 'Center for Access Delivery Research & Evaluation (CADRE), VA Iowa City Healthcare System, Iowa City, IA, USA; Division of General Internal Medicine, The University of Iowa Carver College of Medicine, Iowa City, IA, USA.'}]",Social science & medicine (1982),['10.1016/j.socscimed.2020.113244'] 2448,32750703,Proton Therapy Reduces the Likelihood of High-Grade Radiation-Induced Lymphopenia in Glioblastoma Patients: Phase II Randomized Study of Protons vs. Photons.,"BACKGROUND We investigated differences in radiation-induced grade 3+ lymphopenia (G3+L), defined as an absolute lymphocyte count (ALC) nadir of <500 cells/µL, after proton therapy (PT) or X-ray (photon) therapy (XRT) for patients with glioblastoma (GBM). METHODS Patients enrolled in a randomized phase II trial received PT (n=28) or XRT (n=56), concomitantly with temozolomide. ALC was measured before, weekly during, and within 1 month after radiotherapy. Whole-brain mean dose (WBMD) and brain dose-volume indices were extracted from planned dose distributions. Univariate and multivariate logistic regression analyses were used to identify independent predictive variables. The resulting model was evaluated using receiver operating characteristic (ROC) curve analysis. RESULTS Rates of G3+L were lower in men (7/47 [15%] vs. women (19/37 [51%], P<0.001)), and for PT (4/28 [14%] vs. XRT (22/56 [39%], P=0.024)). G3+L was significantly associated with baseline ALC, WBMD, and brain volumes receiving 5‒40 Gy(RBE) or higher (i.e., V5 through V40). Stepwise multivariate logistic regression analysis identified being female (odds ratio [OR] 6.2, 05% confidence interval [CI] 1.95‒22.4, P=0.003), baseline ALC (OR 0.18, 95% CI 0.05‒0.51, P=0.003) and whole brain V20 (OR 1.07, 95% CI 1.03‒1.13, P=0.002) as the strongest predictors. ROC analysis yielded an area under the curve of 0.86 (95% CI 0.79-0.94) for the final G3+L prediction model. CONCLUSIONS Sex, baseline ALC, and whole brain V20 were the strongest predictors of G3+L for patients with GBM treated with radiation and temozolomide. PT reduced brain volumes receiving low and intermediate doses and, consequently, reduced G3+L.",2020,"PT reduced brain volumes receiving low and intermediate doses and, consequently, reduced G3+L.","['Glioblastoma Patients', 'Patients enrolled', 'patients with glioblastoma (GBM']","['temozolomide', 'proton therapy (PT) or X-ray (photon) therapy (XRT', 'PT', 'Proton Therapy', 'XRT', 'Protons vs. Photons']","['Rates of G3+L', 'baseline ALC', 'baseline ALC, WBMD, and brain volumes receiving 5‒40 Gy(RBE', 'ALC']","[{'cui': 'C0017636', 'cui_str': 'Glioblastoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0076080', 'cui_str': 'temozolomide'}, {'cui': 'C0436226', 'cui_str': 'Proton therapy'}, {'cui': 'C0043308', 'cui_str': 'X-ray treatment'}, {'cui': 'C0033727', 'cui_str': 'Proton'}, {'cui': 'C0086805', 'cui_str': 'Photon'}]","[{'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0024312', 'cui_str': 'Lymphocytopenia'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C3544087', 'cui_str': 'Absolute lymphocyte count'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",,0.096417,"PT reduced brain volumes receiving low and intermediate doses and, consequently, reduced G3+L.","[{'ForeName': 'Radhe', 'Initials': 'R', 'LastName': 'Mohan', 'Affiliation': 'Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Amy Y', 'Initials': 'AY', 'LastName': 'Liu', 'Affiliation': 'Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Brown', 'Affiliation': 'Department of Radiation Oncology, Mayo Clinic Hospital, Rochester MN.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Mahajan', 'Affiliation': 'Department of Radiation Oncology, Mayo Clinic Hospital, Rochester MN.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Dinh', 'Affiliation': 'Millennium Physicians Radiation Oncology, The Woodlands, TX.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Chung', 'Affiliation': 'Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'McAvoy', 'Affiliation': 'Department of Radiation Oncology, University of Maryland, Baltimore MD.'}, {'ForeName': 'Mary Frances', 'Initials': 'MF', 'LastName': 'McAleer', 'Affiliation': 'Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Steven H', 'Initials': 'SH', 'LastName': 'Lin', 'Affiliation': 'Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Amol J', 'Initials': 'AJ', 'LastName': 'Ghia', 'Affiliation': 'Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Cong', 'Initials': 'C', 'LastName': 'Zhu', 'Affiliation': 'Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Erik P', 'Initials': 'EP', 'LastName': 'Sulman', 'Affiliation': 'Department of Radiation Oncology, NYU Grossman School of Medicine, New York, NY.'}, {'ForeName': 'John F', 'Initials': 'JF', 'LastName': 'de Groot', 'Affiliation': 'Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Amy B', 'Initials': 'AB', 'LastName': 'Heimberger', 'Affiliation': 'Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'McGovern', 'Affiliation': 'Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Clemens', 'Initials': 'C', 'LastName': 'Grassberger', 'Affiliation': 'Department of Radiation Oncology, Massachusetts General Hospital, Boston MA.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Shih', 'Affiliation': 'Department of Radiation Oncology, Massachusetts General Hospital, Boston MA.'}, {'ForeName': 'Susannah', 'Initials': 'S', 'LastName': 'Ellsworth', 'Affiliation': 'Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Grosshans', 'Affiliation': 'Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.'}]",Neuro-oncology,['10.1093/neuonc/noaa182'] 2449,32750714,The Effect of Business Internships Model and Employment on Enhancing the Independence of Young Adults With Significant Impact From Autism.,This article presents findings from a multisite randomized clinical trial measuring the impact of employment on independence in 18 to 22 year old youth with significant impact from autism spectrum disorder (ASD). The treatment condition was Project SEARCH plus ASD Supports (PS+ASD) where 73.4% of participants gained competitive integrated employment (CIE) within 1 year of graduation compared to control participants who acquired CIE at 17%. Within group analysis revealed that PS+ASD participants demonstrated improvement in all domains whereas control group participants demonstrated improvement in one domain only. Between groups analysis indicated that participants in PS+ASD demonstrated nominally better rates of improvement than control group participants at graduation and 1-year follow-up. Results provide evidence that employment provides therapeutic benefits to individuals with ASD.,2020,Within group analysis revealed that PS+ASD participants demonstrated improvement in all domains whereas control group participants demonstrated improvement in one domain only.,"['individuals with ASD', '18 to 22 year old youth with significant impact from autism spectrum disorder (ASD', 'Young Adults With Significant Impact From Autism']",['Business Internships Model and Employment'],[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}]","[{'cui': 'C0085936', 'cui_str': 'Business'}, {'cui': 'C0237690', 'cui_str': 'Internship'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0014003', 'cui_str': 'Employment'}]",[],,0.112685,Within group analysis revealed that PS+ASD participants demonstrated improvement in all domains whereas control group participants demonstrated improvement in one domain only.,"[{'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Schall', 'Affiliation': 'Carol Schall, Adam P. Sima, Lauren Avellone, Paul Wehman, Jennifer McDonough, and Alecia Brown, Virginia Commonwealth University.'}, {'ForeName': 'Adam P', 'Initials': 'AP', 'LastName': 'Sima', 'Affiliation': 'Carol Schall, Adam P. Sima, Lauren Avellone, Paul Wehman, Jennifer McDonough, and Alecia Brown, Virginia Commonwealth University.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Avellone', 'Affiliation': 'Carol Schall, Adam P. Sima, Lauren Avellone, Paul Wehman, Jennifer McDonough, and Alecia Brown, Virginia Commonwealth University.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Wehman', 'Affiliation': 'Carol Schall, Adam P. Sima, Lauren Avellone, Paul Wehman, Jennifer McDonough, and Alecia Brown, Virginia Commonwealth University.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'McDonough', 'Affiliation': 'Carol Schall, Adam P. Sima, Lauren Avellone, Paul Wehman, Jennifer McDonough, and Alecia Brown, Virginia Commonwealth University.'}, {'ForeName': 'Alecia', 'Initials': 'A', 'LastName': 'Brown', 'Affiliation': 'Carol Schall, Adam P. Sima, Lauren Avellone, Paul Wehman, Jennifer McDonough, and Alecia Brown, Virginia Commonwealth University.'}]",Intellectual and developmental disabilities,['10.1352/1934-9556-58.4.301'] 2450,32750730,"Efficacy of post-operative oral metronidazole for haemorrhoidectomy pain: a randomised double-blind, placebo-controlled trial.","AIM To examine the efficacy of oral metronidazole in reducing post-haemorrhoidectomy pain versus placebo. METHOD Forty patients were randomised to either metronidazole and standard care or placebo and standard care (21 metronidazole, 19 placebo) in a double-blinded, randomised controlled trial. The main outcome measure was post-haemorrhoidectomy pain scores over twenty-one days, measured on a ten-point Likert scale. RESULTS There were no significant differences between groups with regards to age, gender, smoking status, self-reported general health or quality of life, haemorrhoid-related pain, haemorrhoid-related impact on quality of life, reported satisfaction with surgery, experience of surgery, median overall pain score, or likelihood of recommending surgery to others. For reported median worst pain scores and defaecation-related pain, a trend to significance was identified between groups on days 16 and 18-21 with the metronidazole group reporting less pain. However, these differences were not significant when pre-specified Bonferroni correction criteria were used. Using multilevel mixed effects modelling, the impact of time on median worst pain score was identified to be highly significant (p<0.0001) whereas treatment allocation (placebo versus metronidazole) did not significantly affect the improvement in patients' reported pain (p=0.8837). CONCLUSION Our data do not support the hypothesis that post-operative metronidazole has a clinically meaningful effect on post-haemorrhoidectomy pain. This study adds to the previous literature, and implies that it should not be routinely used as an analgesic adjunct.",2020,"For reported median worst pain scores and defaecation-related pain, a trend to significance was identified between groups on days 16 and 18-21 with the metronidazole group reporting less pain.","['haemorrhoidectomy pain', 'Forty patients']","['placebo', 'metronidazole', 'metronidazole and standard care or placebo and standard care (21 metronidazole, 19 placebo', 'post-operative oral metronidazole']","['quality of life, reported satisfaction with surgery, experience of surgery, median overall pain score, or likelihood of recommending surgery to others', 'post-haemorrhoidectomy pain scores', 'pain', 'median worst pain score', 'median worst pain scores and defaecation-related pain']","[{'cui': 'C0019108', 'cui_str': 'Hemorrhoidectomy'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0360345', 'cui_str': 'Metronidazole-containing product in oral dose form'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0019108', 'cui_str': 'Hemorrhoidectomy'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0011135', 'cui_str': 'Defecation'}]",40.0,0.678707,"For reported median worst pain scores and defaecation-related pain, a trend to significance was identified between groups on days 16 and 18-21 with the metronidazole group reporting less pain.","[{'ForeName': 'Bruce D', 'Initials': 'BD', 'LastName': 'Wilkie', 'Affiliation': 'Department of Surgery, Eastern Health, 8 Arnold St Box Hill, Melbourne, Australia.'}, {'ForeName': 'Raaj', 'Initials': 'R', 'LastName': 'Chandra', 'Affiliation': 'Department of Surgery, Eastern Health, 8 Arnold St Box Hill, Melbourne, Australia.'}, {'ForeName': 'Jonathon', 'Initials': 'J', 'LastName': 'Chua', 'Affiliation': 'Department of Surgery, Eastern Health, 8 Arnold St Box Hill, Melbourne, Australia.'}, {'ForeName': 'David Cs', 'Initials': 'DC', 'LastName': 'Lam', 'Affiliation': 'Department of Surgery, Eastern Health, 8 Arnold St Box Hill, Melbourne, Australia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Paratz', 'Affiliation': ""St Vincent's Hospital Melbourne, 41 Victoria Parade Fitzroy, Melbourne, Australia.""}, {'ForeName': 'Vinna', 'Initials': 'V', 'LastName': 'An', 'Affiliation': 'Department of Surgery, Eastern Health, 8 Arnold St Box Hill, Melbourne, Australia.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Keck', 'Affiliation': 'Department of Surgery, Eastern Health, 8 Arnold St Box Hill, Melbourne, Australia.'}]",Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland,['10.1111/codi.15291'] 2451,32751161,"Neurologic Safety of Etomidate-Based Sedation during Upper Endoscopy in Patients with Liver Cirrhosis Compared with Propofol: A Double-Blind, Randomized Controlled Trial.","(1) Background: Although etomidate-based sedation is an effective and safe protocol in endoscopic procedures, there is a lack of evidence regarding the safety of etomidate in patients with liver cirrhosis (LC). This study aimed to compare the neurologic safety and efficacy of etomidate and propofol for endoscopic sedation in patients with LC. (2) Methods: From December 2017 to December 2019, consecutive cirrhotic patients who underwent sedative endoscopy using either etomidate or propofol were randomly recruited. The primary endpoint was the number connection test (NCT), and the secondary endpoints included factors for the safety of sedatives during endoscopy. (3) Results: 63 patients were enrolled in each of the etomidate and propofol groups. The NCT times were significantly lower in the etomidate group than in the propofol group. Furthermore, severe or very severe degree of encephalopathy was higher in the propofol group but was not significantly different. Pharmacological properties and the overall incidence of respiratory and cardiovascular events did not differ significantly between the groups. (4) Conclusion: Etomidate-based sedation exacerbates neither subclinical nor overt hepatic encephalopathy. It guarantees efficacies similar to those of propofol regarding rapid sedation, fast recovery, and early discharge, with no increased risk of adverse respiratory or cardiovascular events in patients with LC.",2020,Pharmacological properties and the overall incidence of respiratory and cardiovascular events did not differ significantly between the groups.,"['patients with LC', '63 patients were enrolled in each of the etomidate and propofol groups', 'Patients with Liver Cirrhosis', 'patients with liver cirrhosis (LC', 'From December 2017 to December 2019, consecutive cirrhotic patients who underwent sedative endoscopy using either']","['etomidate', 'etomidate-based sedation', 'Etomidate-Based Sedation', 'Propofol', 'Etomidate-based sedation', 'etomidate or propofol', 'propofol', 'etomidate and propofol']","['safety of sedatives during endoscopy', 'neurologic safety and efficacy', 'Neurologic Safety', 'overall incidence of respiratory and cardiovascular events', 'risk of adverse respiratory or cardiovascular events', 'severe or very severe degree of encephalopathy', 'NCT times', 'rapid sedation, fast recovery, and early discharge', 'number connection test (NCT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}, {'cui': 'C0015131', 'cui_str': 'Etomidate'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439686', 'cui_str': 'Cirrhotic'}, {'cui': 'C0020592', 'cui_str': 'HYPNOTICS AND SEDATIVES'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}]","[{'cui': 'C0015131', 'cui_str': 'Etomidate'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0020592', 'cui_str': 'HYPNOTICS AND SEDATIVES'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C3641272', 'cui_str': 'Very severe'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0085584', 'cui_str': 'Encephalopathy'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0449379', 'cui_str': 'Connection'}, {'cui': 'C0429928', 'cui_str': 'Test time'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",63.0,0.16516,Pharmacological properties and the overall incidence of respiratory and cardiovascular events did not differ significantly between the groups.,"[{'ForeName': 'Jang Han', 'Initials': 'JH', 'LastName': 'Jung', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong-si 18450, Gyeonggi-do, Korea.'}, {'ForeName': 'Bomi', 'Initials': 'B', 'LastName': 'Hyun', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong-si 18450, Gyeonggi-do, Korea.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong-si 18450, Gyeonggi-do, Korea.'}, {'ForeName': 'Dong Hee', 'Initials': 'DH', 'LastName': 'Koh', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong-si 18450, Gyeonggi-do, Korea.'}, {'ForeName': 'Jung Hee', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong-si 18450, Gyeonggi-do, Korea.'}, {'ForeName': 'Se Woo', 'Initials': 'SW', 'LastName': 'Park', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong-si 18450, Gyeonggi-do, Korea.'}]",Journal of clinical medicine,['10.3390/jcm9082424'] 2452,32751162,"Carbohydrate Mouth Rinse Mitigates Mental Fatigue Effects on Maximal Incremental Test Performance, but Not in Cortical Alterations.","Detrimental mental fatigue effects on exercise performance have been documented in constant workload and time trial exercises, but effects on a maximal incremental test (MIT) remain poorly investigated. Mental fatigue-reduced exercise performance is related to an increased effort sensation, likely due to a reduced prefrontal cortex (PFC) activation and inhibited spontaneous behavior. Interestingly, only a few studies verified if centrally active compounds may mitigate such effects. For example, carbohydrate (CHO) mouth rinse potentiates exercise performance and reduces effort sensation, likely through its effects on PFC activation. However, it is unknown if this centrally mediated effect of CHO mouth rinse may mitigate mental fatigue-reduced exercise performance. After a proof-of-principle study, showing a mental fatigue-reduced MIT performance, we observed that CHO mouth rinse mitigated MIT performance reductions in mentally fatigued cyclists, regardless of PFC alterations. When compared to placebo, mentally fatigued cyclists improved MIT performance by 2.24-2.33% when rinsing their mouth with CHO during MIT. However, PFC and motor cortex activation during MIT in both CHO and placebo mouth rinses were greater than in mental fatigue. Results showed that CHO mouth rinse mitigated the mental fatigue-reduced MIT performance, but challenged the role of CHO mouth rinse on PFC and motor cortex activation.",2020,"When compared to placebo, mentally fatigued cyclists improved MIT performance by 2.24-2.33% when rinsing their mouth with CHO during MIT.",['mentally fatigued cyclists'],['placebo'],"['mental fatigue-reduced MIT performance', 'Mental fatigue-reduced exercise performance', 'MIT performance reductions', 'MIT performance', 'PFC and motor cortex activation']","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0015676', 'cui_str': 'Mental fatigue'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0026607', 'cui_str': 'Motor cortex'}]",,0.0691881,"When compared to placebo, mentally fatigued cyclists improved MIT performance by 2.24-2.33% when rinsing their mouth with CHO during MIT.","[{'ForeName': 'Cayque', 'Initials': 'C', 'LastName': 'Brietzke', 'Affiliation': 'Exercise Psychophysiology Research Group, School of Arts, Sciences and Humanities, University of São Paulo, São Paulo 05508-060, Brazil.'}, {'ForeName': 'Paulo Estevão', 'Initials': 'PE', 'LastName': 'Franco-Alvarenga', 'Affiliation': 'Exercise Psychophysiology Research Group, School of Arts, Sciences and Humanities, University of São Paulo, São Paulo 05508-060, Brazil.'}, {'ForeName': 'Raul', 'Initials': 'R', 'LastName': 'Canestri', 'Affiliation': 'Exercise Psychophysiology Research Group, School of Arts, Sciences and Humanities, University of São Paulo, São Paulo 05508-060, Brazil.'}, {'ForeName': 'Márcio Fagundes', 'Initials': 'MF', 'LastName': 'Goethel', 'Affiliation': 'Exercise Psychophysiology Research Group, School of Arts, Sciences and Humanities, University of São Paulo, São Paulo 05508-060, Brazil.'}, {'ForeName': 'Ítalo', 'Initials': 'Í', 'LastName': 'Vínicius', 'Affiliation': 'Exercise Psychophysiology Research Group, School of Arts, Sciences and Humanities, University of São Paulo, São Paulo 05508-060, Brazil.'}, {'ForeName': 'Vitor de Salles', 'Initials': 'VS', 'LastName': 'Painelli', 'Affiliation': 'Exercise Psychophysiology Research Group, School of Arts, Sciences and Humanities, University of São Paulo, São Paulo 05508-060, Brazil.'}, {'ForeName': 'Tony Meireles', 'Initials': 'TM', 'LastName': 'Santos', 'Affiliation': 'Physical Education Program, Research Center for Performance and Health, Federal University of Pernambuco, Recife 52071-030, Brazil.'}, {'ForeName': 'Florentina Johanna', 'Initials': 'FJ', 'LastName': 'Hettinga', 'Affiliation': 'Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle NE1 8ST, UK.'}, {'ForeName': 'Flávio Oliveira', 'Initials': 'FO', 'LastName': 'Pires', 'Affiliation': 'Exercise Psychophysiology Research Group, School of Arts, Sciences and Humanities, University of São Paulo, São Paulo 05508-060, Brazil.'}]",Brain sciences,['10.3390/brainsci10080493'] 2453,32751170,Postprandial Metabolic Response to Rapeseed Protein in Healthy Subjects.,"Plant proteins have become increasingly important for ecological reasons. Rapeseed is a novel source of plant proteins with high biological value, but its metabolic impact in humans is largely unknown. A randomized, controlled intervention study including 20 healthy subjects was conducted in a crossover design. All participants received a test meal without additional protein or with 28 g of rapeseed protein isolate or soy protein isolate (control). Venous blood samples were collected over a 360-min period to analyze metabolites; satiety was assessed using a visual analog scale. Postprandial levels of lipids, urea, and amino acids increased following the intake of both protein isolates. The postprandial insulin response was lower after consumption of the rapeseed protein than after intake of the soy protein ( p < 0.05), whereas the postmeal responses of glucose, lipids, interleukin-6, minerals, and urea were comparable between the two protein isolates. Interestingly, the rapeseed protein exerted stronger effects on postprandial satiety than the soy protein ( p < 0.05). The postmeal metabolism following rapeseed protein intake is comparable with that of soy protein. The favorable effect of rapeseed protein on postprandial insulin and satiety makes it a valuable plant protein for human nutrition.",2020,"Interestingly, the rapeseed protein exerted stronger effects on postprandial satiety than the soy protein ( p < 0.05).","['20 healthy subjects', 'Healthy Subjects']","['rapeseed protein', 'test meal without additional protein or with 28 g of rapeseed protein isolate or soy protein isolate (control']","['postprandial insulin response', 'Venous blood samples', 'postprandial satiety', 'Postprandial Metabolic Response', 'postmeal responses of glucose, lipids, interleukin-6, minerals, and urea', 'Postprandial levels of lipids, urea, and amino acids']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0034670', 'cui_str': 'Brassica rapa'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C3164740', 'cui_str': '28 gauge'}, {'cui': 'C0205409', 'cui_str': 'Isolated'}, {'cui': 'C0677666', 'cui_str': 'soy protein isolate'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0444255', 'cui_str': 'Venous blood specimen'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0041942', 'cui_str': 'Urea'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}]",20.0,0.0127271,"Interestingly, the rapeseed protein exerted stronger effects on postprandial satiety than the soy protein ( p < 0.05).","[{'ForeName': 'Christin', 'Initials': 'C', 'LastName': 'Volk', 'Affiliation': 'Institute of Agricultural and Nutritional Sciences, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.'}, {'ForeName': 'Corinna', 'Initials': 'C', 'LastName': 'Brandsch', 'Affiliation': 'Institute of Agricultural and Nutritional Sciences, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.'}, {'ForeName': 'Ulf', 'Initials': 'U', 'LastName': 'Schlegelmilch', 'Affiliation': 'Institute of Agricultural and Nutritional Sciences, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Wensch-Dorendorf', 'Affiliation': 'Institute of Agricultural and Nutritional Sciences, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Hirche', 'Affiliation': 'Institute of Agricultural and Nutritional Sciences, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Simm', 'Affiliation': 'Department of Cardiac Surgery, University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.'}, {'ForeName': 'Osama', 'Initials': 'O', 'LastName': 'Gargum', 'Affiliation': 'Department of Cardiac Surgery, University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Wiacek', 'Affiliation': 'Institute of Food Hygiene, University Leipzig, 04103 Leipzig, Germany.'}, {'ForeName': 'Peggy G', 'Initials': 'PG', 'LastName': 'Braun', 'Affiliation': 'Institute of Food Hygiene, University Leipzig, 04103 Leipzig, Germany.'}, {'ForeName': 'Johannes F', 'Initials': 'JF', 'LastName': 'Kopp', 'Affiliation': 'Institute of Nutritional Science, University of Potsdam, 14558 Nuthetal, Germany.'}, {'ForeName': 'Tanja', 'Initials': 'T', 'LastName': 'Schwerdtle', 'Affiliation': 'Institute of Nutritional Science, University of Potsdam, 14558 Nuthetal, Germany.'}, {'ForeName': 'Hendrik', 'Initials': 'H', 'LastName': 'Treede', 'Affiliation': 'Department of Cardiac Surgery, University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.'}, {'ForeName': 'Gabriele I', 'Initials': 'GI', 'LastName': 'Stangl', 'Affiliation': 'Institute of Agricultural and Nutritional Sciences, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.'}]",Nutrients,['10.3390/nu12082270'] 2454,32751204,HRV-Guided Training for Professional Endurance Athletes: A Protocol for a Cluster-Randomized Controlled Trial.,"Physiological training responses depend on sympathetic (SNS) and parasympathetic nervous system (PNS) balance. This activity can be measured using heart rate variability (HRV). Such a measurement method can favor individualized training planning to improve athletes' performance. Recently, HRV-guided training has been implemented both on professional and amateur sportsmen and sportswomen with varied results. There is a dearth of studies involving professional endurance athletes following a defined HRV-guided training protocol. The objectives of the proposed protocol are: (i) to determine changes in the performance of high-level athletes after following an HRV-guided or a traditional training period and (ii) to determine differences in the athletes' performance after following both training protocols. This will be a 12-week cluster-randomized controlled protocol in which professional athletes will be assigned to an HRV-based training group (HRV-G) or a traditional-based training group (TRAD-G). TRAD-G will train according to a predefined training program. HRV-G training will depend on the athletes' daily HRV. The maximal oxygen uptake (VO 2max ) attained in an incremental treadmill test will be considered as the primary outcome. It is expected that this HRV-guided training protocol will improve functional performance in the high-level athletes, achieving better results than a traditional training method, and thus providing a good strategy for coaches of high-level athletes.",2020,"Recently, HRV-guided training has been implemented both on professional and amateur sportsmen and sportswomen with varied results.","['professional endurance athletes', 'professional athletes', 'Professional Endurance Athletes']","['HRV-based training group (HRV-G) or a traditional-based training group (TRAD-G', 'HRV-G training', 'HRV-Guided Training']","['TRAD', 'functional performance', 'maximal oxygen uptake (VO 2max ', 'sympathetic (SNS) and parasympathetic nervous system (PNS) balance', 'heart rate variability (HRV']","[{'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0181090', 'cui_str': 'Guide'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0030510', 'cui_str': 'Parasympathetic nervous system structure'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}]",,0.0470006,"Recently, HRV-guided training has been implemented both on professional and amateur sportsmen and sportswomen with varied results.","[{'ForeName': 'María', 'Initials': 'M', 'LastName': 'Carrasco-Poyatos', 'Affiliation': 'Department of Education, Health and Public Administration Research Center, University of Almeria, 04120 Almeria, Spain.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'González-Quílez', 'Affiliation': 'Department of Education, University of Almeria, 04120 Almeria, Spain.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Martínez-González-Moro', 'Affiliation': 'Department of Physiotherapy, Physical Exercise and Human Performance Research Group, University of Murcia, 30001 Murcia, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Granero-Gallegos', 'Affiliation': 'Department of Education, Health and Public Administration Research Center, University of Almeria, 04120 Almeria, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17155465'] 2455,32756878,Dorsolateral prefrontal cortex response to negative tweets relates to executive functioning.,"Cognitive performance can become impaired when a stimulus evokes an emotional response. Social media often elicits emotional reactions, but, despite social media's ubiquity, cognitive and neural consequences of exposure to negative online content are relatively unknown. Fifty-seven human adults (18-29 years; 38 female) who identified with at least one historically-marginalized group performed a novel 'Tweet Task'. While undergoing functional magnetic resonance imaging, participants completed a spatial reasoning task before and after reading a set of actual tweets. Participants were randomly assigned to read negative, discriminatory tweets from President Trump (Negative Condition) or neutral tweets (Neutral Condition). Participants in the Negative Condition reported worsening affect and demonstrated performance interference post-tweet compared to those in the Neutral Condition. Affect post-tweet was associated with parametric reductions in left dorsolateral prefrontal cortex, which predicted variance in performance beyond elicited negative affect. Performance effects were demonstrated on an unrelated spatial reasoning task suggesting that engaging with negative, emotionally-arousing content on social media can have deleterious effects on executive functioning in non-social domains.",2020,Participants in the Negative Condition reported worsening affect and demonstrated performance interference post-tweet compared to those in the Neutral Condition.,"[""Fifty-seven human adults (18-29\xa0years; 38 female) who identified with at least one historically-marginalized group performed a novel 'Tweet Task""]","['functional magnetic resonance imaging', 'read negative, discriminatory tweets from President Trump (Negative Condition) or neutral tweets (Neutral Condition']","['Performance effects', 'Cognitive performance']","[{'cui': 'C4517815', 'cui_str': '57'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205314', 'cui_str': 'New'}]","[{'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C1280500', 'cui_str': 'Effect'}]",57.0,0.0229807,Participants in the Negative Condition reported worsening affect and demonstrated performance interference post-tweet compared to those in the Neutral Condition.,"[{'ForeName': 'Sarah M', 'Initials': 'SM', 'LastName': 'Tashjian', 'Affiliation': 'Department of Psychology, University of California, Los Angeles, Los Angeles, CA 90095, USA.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Galván', 'Affiliation': 'Department of Psychology, University of California, Los Angeles, Los Angeles, CA 90095, USA.'}]",Social cognitive and affective neuroscience,['10.1093/scan/nsaa101'] 2456,32756916,Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines.,"Importance The 2018 American Heart Association/American College of Cardiology (AHA/ACC) cholesterol management guidelines identified 2 distinct groups of patients with atherosclerotic cardiovascular disease (ASCVD) prompting different treatment recommendations. Objective To investigate whether the addition of high-sensitivity troponin (hsTn) testing to guideline-derived ASCVD risk can improve risk classification and downstream treatment recommendations. Design, Setting, and Participants A prospective cohort biomarker substudy was performed that included 8635 patients enrolled in the Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Patients were assigned to risk groups of either very high-risk ASCVD or lower-risk ASCVD based on their cardiovascular history and comorbidities, in line with the 2018 AHA/ACC cholesterol management guidelines criteria. Patients were also classified on the basis of hsTnI level (ARCHITECT assay; Abbott) using cut points of 2 ng/L (limit of detection) and 6 ng/L (risk threshold), followed by joint classification on the basis of clinical features and hsTnI level. The setting was a nested prospective cohort study in a completed multinational trial. Participants were all patients who had a myocardial infarction 1 to 3 years before enrollment, were at least 50 years of age, and had at least 1 high-risk feature. The study dates were October 2010 to December 2014. The dates of analysis were June 2019 to January 2020. Main Outcomes and Measures The primary end point was a composite of cardiovascular death, myocardial infarction, or stroke. Results Among 8635 patients enrolled in the PEGASUS-TIMI 54 trial, the median age was 65 years (interquartile range, 58-71 years), and 6614 (76.6%) were men; 8340 (96.6%) were White individuals and 176 (2.0%) were Black individuals. Patients meeting clinical criteria for the very high-risk ASCVD group had a primary end point 3-year event rate of 8.8% compared with 5.0% in the lower-risk ASCVD group (hazard ratio, 2.01; 95% CI, 1.58-2.57; P < .001). When patients in the very high-risk ASCVD group were further risk stratified by hsTnI level, 614 of 6789 patients (9.0%) with an undetectable hsTnI level had a 3-year event rate of 2.7% (<1% per year), which was less than the overall rate in the lower-risk ASCVD group. Analogously, in the lower-risk ASCVD group, 417 of 1846 patients (22.6%) with an hsTnI level exceeding 6 ng/L had an event rate of 9.1%, comparable to the overall rate in the very high-risk ASCVD group. The addition of hsTnI to guideline-derived ASCVD risk led to a net reclassification index at event rate of 0.15 (95% CI, 0.10-0.21). Overall, use of hsTnI reclassified 1031 of 8635 patients (11.9%) (1 in 11 with very high-risk ASCVD and 1 in 4 with lower-risk ASCVD). Conclusions and Relevance The findings of this cohort substudy suggest that a strategy incorporating hsTn into a guideline-derived ASCVD risk algorithm provides enhanced risk stratification and reclassifies 11.9% of patients into a more appropriate risk group. This application of hsTn testing might be used to optimize the care of patients with ASCVD.",2020,"Overall, use of hsTnI reclassified 1031 of 8635 patients (11.9%) (1 in 11 with very high-risk ASCVD and 1 in 4 with lower-risk ASCVD). ","['2018 American Heart Association/American College of Cardiology (AHA/ACC) cholesterol management guidelines identified 2 distinct groups of patients with atherosclerotic cardiovascular disease (ASCVD', '8635 patients enrolled in the PEGASUS-TIMI 54 trial, the median age was 65 years (interquartile range, 58-71 years), and 6614 (76.6%) were men; 8340 (96.6%) were White individuals and 176 (2.0%) were Black individuals', '8635 patients enrolled in the Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using', 'Participants were all patients who had a myocardial infarction 1 to 3 years before enrollment, were at least 50 years of age, and had at least 1 high-risk feature', 'patients with ASCVD', 'Patients were assigned to risk groups of either very high-risk ASCVD or lower-risk ASCVD based on their cardiovascular history and comorbidities, in line with the 2018 AHA/ACC cholesterol management guidelines criteria']","['Ticagrelor', 'High-Sensitivity Troponin', 'Placebo', 'Aspirin-Thrombolysis']","['3-year event rate', 'overall rate', 'composite of cardiovascular death, myocardial infarction, or stroke']","[{'cui': 'C0002458', 'cui_str': 'American Heart Association'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}, {'cui': 'C0050451', 'cui_str': 'acetohydroxamic acid'}, {'cui': 'C0175754', 'cui_str': 'Agenesis of corpus callosum'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0155668', 'cui_str': 'Old myocardial infarction'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0442804', 'cui_str': 'Very high'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0041199', 'cui_str': 'Troponin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]",8635.0,0.0553127,"Overall, use of hsTnI reclassified 1031 of 8635 patients (11.9%) (1 in 11 with very high-risk ASCVD and 1 in 4 with lower-risk ASCVD). ","[{'ForeName': 'Nicholas A', 'Initials': 'NA', 'LastName': 'Marston', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Marc P', 'Initials': 'MP', 'LastName': 'Bonaca', 'Affiliation': 'Colorado Prevention Center (CPC) Clinical Research, Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora.'}, {'ForeName': 'Petr', 'Initials': 'P', 'LastName': 'Jarolim', 'Affiliation': ""Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Erica L', 'Initials': 'EL', 'LastName': 'Goodrich', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': ""Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Philippe G', 'Initials': 'PG', 'LastName': 'Steg', 'Affiliation': 'Division of Cardiology, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Cohen', 'Affiliation': 'Newark Beth Israel Medical Center, Rutgers New Jersey Medical School, Newark.'}, {'ForeName': 'Robert F', 'Initials': 'RF', 'LastName': 'Storey', 'Affiliation': 'Division of Cardiology, The University of Sheffield, Sheffield, United Kingdom.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Johanson', 'Affiliation': 'AstraZeneca R&D, Gothenburg, Sweden.'}, {'ForeName': 'Stephen D', 'Initials': 'SD', 'LastName': 'Wiviott', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Braunwald', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Marc S', 'Initials': 'MS', 'LastName': 'Sabatine', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Morrow', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}]",JAMA cardiology,['10.1001/jamacardio.2020.2981'] 2457,32756930,Effect of Spinal Manipulative and Mobilization Therapies in Young Adults With Mild to Moderate Chronic Low Back Pain: A Randomized Clinical Trial.,"Importance Low back pain (LBP) is one of the most common reasons for seeking medical care. Manual therapy is a common treatment of LBP, yet few studies have directly compared the effectiveness of thrust (spinal manipulation) vs nonthrust (spinal mobilization) techniques. Objective To evaluate the comparative effectiveness of spinal manipulation and spinal mobilization at reducing pain and disability compared with a placebo control group (sham cold laser) in a cohort of young adults with chronic LBP. Design, Setting, and Participants This single-blinded (investigator-blinded), placebo-controlled randomized clinical trial with 3 treatment groups was conducted at the Ohio Musculoskeletal and Neurological Institute at Ohio University from June 1, 2013, to August 31, 2017. Of 4903 adult patients assessed for eligibility, 4741 did not meet inclusion criteria, and 162 patients with chronic LBP qualified for randomization to 1 of 3 treatment groups. Recruitment began on June 1, 2013, and the primary completion date was August 31, 2017. Data were analyzed from September 1, 2017, to January 20, 2020. Interventions Participants received 6 treatment sessions of (1) spinal manipulation, (2) spinal mobilization, or (3) sham cold laser therapy (placebo) during a 3-week period. Main Outcomes and Measures Coprimary outcome measures were the change from baseline in Numerical Pain Rating Scale (NPRS) score over the last 7 days and the change in disability assessed with the Roland-Morris Disability Questionnaire (scores range from 0 to 24, with higher scores indicating greater disability) 48 to 72 hours after completion of the 6 treatments. Results A total of 162 participants (mean [SD] age, 25.0 [6.2] years; 92 women [57%]) with chronic LBP (mean [SD] NPRS score, 4.3 [2.6] on a 1-10 scale, with higher scores indicating greater pain) were randomized. Fifty-four participants were randomized to the spinal manipulation group, 54 to the spinal mobilization group, and 54 to the placebo group. There were no significant group differences for sex, age, body mass index, duration of LBP symptoms, depression, fear avoidance, current pain, average pain over the last 7 days, and self-reported disability. At the primary end point, there was no significant difference in change in pain scores between spinal manipulation and spinal mobilization (0.24 [95% CI, -0.38 to 0.86]; P = .45), spinal manipulation and placebo (-0.03 [95% CI, -0.65 to 0.59]; P = .92), or spinal mobilization and placebo (-0.26 [95% CI, -0.38 to 0.85]; P = .39). There was no significant difference in change in self-reported disability scores between spinal manipulation and spinal mobilization (-1.00 [95% CI, -2.27 to 0.36]; P = .14), spinal manipulation and placebo (-0.07 [95% CI, -1.43 to 1.29]; P = .92) or spinal mobilization and placebo (0.93 [95% CI, -0.41 to 2.29]; P = .17). Conclusions and Relevance In this randomized clinical trial, neither spinal manipulation nor spinal mobilization appeared to be effective treatments for mild to moderate chronic LBP. Trial Registration ClinicalTrials.gov Identifier: NCT01854892.",2020,"There were no significant group differences for sex, age, body mass index, duration of LBP symptoms, depression, fear avoidance, current pain, average pain over the last 7 days, and self-reported disability.","['3 treatment groups was conducted at the Ohio Musculoskeletal and Neurological Institute at Ohio University from June 1, 2013, to August 31, 2017', 'Young Adults', 'A total of 162 participants (mean [SD] age, 25.0 [6.2] years; 92 women [57%]) with chronic LBP (mean [SD] NPRS score, 4.3 [2.6] on a 1-10 scale, with higher scores indicating greater pain', 'young adults with chronic LBP', 'Fifty-four participants', '4903 adult patients assessed for eligibility, 4741 did not meet inclusion criteria, and 162 patients with chronic LBP qualified for randomization to 1 of 3 treatment groups', 'With Mild to Moderate Chronic Low Back Pain']","['Spinal Manipulative and Mobilization Therapies', 'spinal manipulation', '6 treatment sessions of (1) spinal manipulation, (2) spinal mobilization, or (3) sham cold laser therapy (placebo', 'spinal manipulation and spinal mobilization', 'placebo control group (sham cold laser', 'placebo']","['Numerical Pain Rating Scale (NPRS) score over the last 7 days and the change in disability assessed with the Roland-Morris Disability Questionnaire (scores range', 'spinal manipulation', 'change in self-reported disability scores between spinal manipulation and spinal mobilization', 'pain and disability', 'pain scores between spinal manipulation and spinal mobilization', 'sex, age, body mass index, duration of LBP symptoms, depression, fear avoidance, current pain, average pain over the last 7 days, and self-reported disability', 'spinal mobilization']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0028905', 'cui_str': 'Ohio'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C5191360', 'cui_str': '162'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517820', 'cui_str': '6.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4517759', 'cui_str': '4.3'}, {'cui': 'C4517633', 'cui_str': '2.6'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}]","[{'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0524864', 'cui_str': 'Haematopoietic stem cell mobilisation'}, {'cui': 'C0086586', 'cui_str': 'Manipulation of spine'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0086586', 'cui_str': 'Manipulation of spine'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0521116', 'cui_str': 'Current'}]",4903.0,0.399355,"There were no significant group differences for sex, age, body mass index, duration of LBP symptoms, depression, fear avoidance, current pain, average pain over the last 7 days, and self-reported disability.","[{'ForeName': 'James S', 'Initials': 'JS', 'LastName': 'Thomas', 'Affiliation': 'Department of Physical Therapy, Virginia Commonwealth University, Richmond.'}, {'ForeName': 'Brian C', 'Initials': 'BC', 'LastName': 'Clark', 'Affiliation': 'Ohio Musculoskeletal and Neurological Institute, Ohio University, Athens.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Russ', 'Affiliation': 'Division of Physical Therapy, Ohio University School of Rehabilitation and Communication Sciences, Athens.'}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'France', 'Affiliation': 'Ohio Musculoskeletal and Neurological Institute, Ohio University, Athens.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Ploutz-Snyder', 'Affiliation': 'Applied Biostatistics Laboratory, University of Michigan School of Nursing, Ann Arbor.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Corcos', 'Affiliation': 'Feinberg School of Medicine, Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, Illinois.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA network open,['10.1001/jamanetworkopen.2020.12589'] 2458,32757065,Effect of carbohydrate-protein supplementation on endurance training adaptations.,"PURPOSE To examine the influence of post-exercise protein feeding upon the adaptive response to endurance exercise training. METHODS In a randomised parallel group design, 25 healthy men and women completed 6 weeks of endurance exercise training by running on a treadmill for 30-60 min at 70-75% maximal oxygen uptake (VO 2max ) 4 times/week. Participants ingested 1.6 g per kilogram of body mass (g kg BM -1 ) of carbohydrate (CHO) or an isocaloric carbohydrate-protein solution (CHO-P; 0.8 g carbohydrate kg BM -1  + 0.8 g protein kg BM -1 ) immediately and 1 h post-exercise. Expired gas, blood and muscle biopsy samples were taken at baseline and follow-up. RESULTS Exercise training improved VO 2max in both groups (p ≤ 0.001), but this increment was not different between groups either in absolute terms or relative to body mass (0.2 ± 0.2 L min -1 and 3.0 ± 2 mL kg -1  min -1 , respectively). No change occurred in plasma albumin concentration from baseline to follow-up with CHO-P (4.18 ± 0.18 to 4.23 ± 0.17 g dL -1 ) or CHO (4.17 ± 0.17 to 4.12 ± 0.22 g dL -1 ; interaction: p > 0.05). Mechanistic target of rapamycin (mTOR) gene expression was up-regulated in CHO-P (+ 46%; p = 0.025) relative to CHO (+ 4%) following exercise training. CONCLUSION Post-exercise protein supplementation up-regulated the expression of mTOR in skeletal muscle over 6 weeks of endurance exercise training. However, the magnitude of improvement in VO 2max was similar between groups.",2020,"RESULTS Exercise training improved VO 2max in both groups (p ≤ 0.001), but this increment was not different between groups either in absolute terms or relative to body mass (0.2 ± 0.2 ",['25 healthy men and women completed 6\xa0weeks of'],"['endurance exercise training by running on a treadmill for 30-60\xa0min at 70-75% maximal oxygen uptake', 'endurance exercise training', 'carbohydrate (CHO', 'carbohydrate-protein supplementation', 'isocaloric carbohydrate-protein solution (CHO-P; 0.8\xa0g carbohydrate kg', 'L']","['BM -1', 'plasma albumin concentration', 'VO 2max', 'Mechanistic target of rapamycin (mTOR) gene expression', 'endurance training adaptations', 'Expired gas, blood and muscle biopsy samples']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0419120', 'cui_str': 'Muscular endurance development exercise'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0054889', 'cui_str': 'CAV protocol'}, {'cui': 'C0770246', 'cui_str': 'Protein supplementation'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C4517481', 'cui_str': '0.8'}]","[{'cui': 'C0857876', 'cui_str': 'Plasma albumin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1307407', 'cui_str': 'FRAP1 protein, human'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C4704697', 'cui_str': 'Endurance Training'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0017110', 'cui_str': 'Gas'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0587033', 'cui_str': 'Muscle biopsy sample'}]",25.0,0.046735,"RESULTS Exercise training improved VO 2max in both groups (p ≤ 0.001), but this increment was not different between groups either in absolute terms or relative to body mass (0.2 ± 0.2 ","[{'ForeName': 'Abdullah F', 'Initials': 'AF', 'LastName': 'Alghannam', 'Affiliation': 'Lifestyle and Health Research Center, Health Sciences Research Center, Princess Nourah Bint Abdulrahman University, Riyadh, 84428, Saudi Arabia. AFAlghannam@pnu.edu.sa.'}, {'ForeName': 'Iain', 'Initials': 'I', 'LastName': 'Templeman', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'Joel E', 'Initials': 'JE', 'LastName': 'Thomas', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'Dawid', 'Initials': 'D', 'LastName': 'Jedrzejewski', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Griffiths', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Lemon', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Byers', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Reeves', 'Affiliation': 'Department of Life Sciences, University of Roehampton, London, SW15 4JD, UK.'}, {'ForeName': 'Javier T', 'Initials': 'JT', 'LastName': 'Gonzalez', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'Dylan', 'Initials': 'D', 'LastName': 'Thompson', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Bilzon', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}, {'ForeName': 'Kostas', 'Initials': 'K', 'LastName': 'Tsintzas', 'Affiliation': ""School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK.""}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Betts', 'Affiliation': 'Department for Health, University of Bath, Bath, BA2 7AY, UK.'}]",European journal of applied physiology,['10.1007/s00421-020-04450-1'] 2459,32757075,Effect of mixed chlorhexidine and hydrogen peroxide mouthrinses on developing plaque and stain in gingivitis patients: a randomized clinical trial.,"AIMS To evaluate the effects of mixed chlorhexidine (CHX)/hydrogen peroxide (H 2 O 2 ) mouthrinses compared with CHX mouthrinse alone on plaque, tooth stain, and gingivitis. MATERIALS AND METHODS This study was a double-blind, randomized two group parallel experiment, using a 14-day non-brushing half-mouth model. The test group was randomly assigned to the mixed 0.12% CHX and 1.5% H 2 O 2 mouthrinse, whereas the control group used 0.12% CHX. Sixty healthy volunteers were enrolled in the study and received scaling and polishing 2 weeks prior to the experiment and then rinsed with the allocated mouthrinses twice daily for 2 weeks. The plaque, stain, and gingivitis scores were evaluated and recorded by a calibrated investigator. RESULTS Fifty-two subjects completed the study (CHX + H 2 O 2 n = 25/CHX n = 27). There were significant differences between the control and test groups for plaque index (CHX 0.64 ± 0.41 vs. CHX + H 2 O 2 0.46 ± 0.36, p = 0.035) and stain intensity at proximal areas (CHX 0.26 ± 0.36 vs. CHX + H 2 O 2 0.09 ± 0.14, p = 0.019) at the end of the experimental non-brushing side. However, the gingival indices did not differ significantly (CHX 0.61 ± 0.34 vs. CHX + H 2 O 2 0.62 ± 0.31, p = 0.938) between groups. CONCLUSIONS In the absence of oral hygiene practice, the mixed CHX + H 2 O 2 mouthrinse was slightly superior in reducing plaque scores and stain compared with CHX alone. CLINICAL RELEVANCE The clinical effectiveness of CHX + H 2 O 2 is comparable with CHX mouthwash alone. Therefore, the use of the mixed mouthrinse is beneficial compared with CHX for minimizing biofilm and tooth staining.",2020,"There were significant differences between the control and test groups for plaque index (CHX 0.64 ± 0.41 vs. CHX + H 2 O 2 0.46 ± 0.36, p = 0.035) and stain intensity at proximal areas (CHX 0.26 ± 0.36 vs. CHX + H 2 O 2 0.09 ± 0.14, p = 0.019) at the end of the experimental non-brushing side.","['Fifty-two subjects', 'gingivitis patients', 'Sixty healthy volunteers']","['mixed chlorhexidine (CHX)/hydrogen peroxide', 'control group used 0.12% CHX', 'CHX', 'CHX mouthrinse', 'mixed chlorhexidine and hydrogen peroxide mouthrinses']","['stain intensity', 'plaque, stain, and gingivitis scores', 'plaque, tooth stain, and gingivitis', 'gingival indices', 'plaque scores', 'plaque index']","[{'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0008684', 'cui_str': 'Chronic gingivitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C0031180', 'cui_str': 'Peroxide'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517426', 'cui_str': '0.12'}, {'cui': 'C0020281', 'cui_str': 'Hydrogen Peroxide'}]","[{'cui': 'C0038128', 'cui_str': 'Stain'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0040434', 'cui_str': 'Staining of tooth'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}]",60.0,0.0421599,"There were significant differences between the control and test groups for plaque index (CHX 0.64 ± 0.41 vs. CHX + H 2 O 2 0.46 ± 0.36, p = 0.035) and stain intensity at proximal areas (CHX 0.26 ± 0.36 vs. CHX + H 2 O 2 0.09 ± 0.14, p = 0.019) at the end of the experimental non-brushing side.","[{'ForeName': 'Kamolchanok', 'Initials': 'K', 'LastName': 'Kamolnarumeth', 'Affiliation': 'Department of Periodontology, Faculty of Dentistry, Chulalongkorn University, 34 Henri Dunant Road, Pathumwan, Bangkok, 10330, Thailand.'}, {'ForeName': 'Jedtanut', 'Initials': 'J', 'LastName': 'Thussananutiyakul', 'Affiliation': 'Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Pholthanik', 'Initials': 'P', 'LastName': 'Lertchwalitanon', 'Affiliation': 'Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Piboon', 'Initials': 'P', 'LastName': 'Rungtanakiat', 'Affiliation': 'Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Widhunya', 'Initials': 'W', 'LastName': 'Mathurasai', 'Affiliation': 'Department of Pharmacology, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Sireerat', 'Initials': 'S', 'LastName': 'Sooampon', 'Affiliation': 'Department of Pharmacology, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Sirikarn P', 'Initials': 'SP', 'LastName': 'Arunyanak', 'Affiliation': 'Department of Periodontology, Faculty of Dentistry, Chulalongkorn University, 34 Henri Dunant Road, Pathumwan, Bangkok, 10330, Thailand. phothikhuns@gmail.com.'}]",Clinical oral investigations,['10.1007/s00784-020-03470-7'] 2460,32757086,Effect of closed loop stimulation versus accelerometer on outcomes with cardiac resynchronization therapy: the CLASS trial.,"PURPOSE Chronotropic incompetence (CI) in patients with heart failure is common and associated with impaired exercise intolerance and adverse outcomes. This study sought to determine the effects of closed loop stimulation (CLS) rate-adaptive pacing on functional capacity in patients with heart failure with reduced ejection fraction (HFrEF) and CI implanted with cardiac resynchronization therapy (CRT) devices. METHODS A randomized, blinded, cross-over designed trial enrolled patients with HFrEF and CI implanted with a Biotronik CRT-D to complete a quality of life questionnaire, 6-min walk distance (6MWD), and cardiopulmonary exercise testing after two programmed periods: 1-week period of CLS and 1-week period of standard accelerometer (DDDR). RESULTS Nine patients (6 males, mean age 71.4 years, 7 with New York Heart Association Class III, mean ejection fraction 39 ± 8%) were enrolled. Quality of life trended higher in CLS as compared to DDDR (550.8 ± 123.9 vs 489.3 ± 164.9, p = 0.06). There were no differences between CLS and DDDR in 6MWD (293.1 ± 90.2 m vs 315.1 ± 95.5 m, p = 0.52), peak heart rate (HR) 110.7 ± 14.7 bpm vs 109.7 bpm ± 14.1, p = 0.67), or peak VO2 (12.3 ± 4.9 ml/kg/min vs 12.9 ± 5.9, p = 0.47). As tests were submaximal as indicated by low respiratory exchange ratios (0.98 ± 0.11 vs 1.0 ± 0.8, p = 0.35), VE/VCO 2 slope also showed no difference between CLS and DDDR (35.8 ± 5.6 vs 35.4 ± 5.7, p = 0.65). Five patients (56%) preferred CLS programming (p = 1.0). CONCLUSIONS In patients with HFrEF and CI implanted with a CRT-D, peak HR, peak VO2, and 6MWD were equivalent, while there was a trend toward improved quality of life in CLS as compared to DDDR. CLINICAL TRIAL REGISTRATION URL: https://www.clinicaltrials.gov . Unique identifier: NCT02693262.",2020,"Quality of life trended higher in CLS as compared to DDDR (550.8 ± 123.9 vs 489.3 ± 164.9, p = 0.06).","['patients with heart failure with reduced ejection fraction (HFrEF) and CI implanted with cardiac resynchronization therapy (CRT) devices', 'patients with heart failure', 'trial enrolled patients with HFrEF and CI implanted with a Biotronik CRT-D to complete a quality of life questionnaire, 6-min walk distance (6MWD), and cardiopulmonary exercise testing after two programmed periods: 1-week period of', 'Nine patients (6 males, mean age 71.4\xa0years, 7 with New York Heart Association Class III, mean ejection fraction 39\u2009±\u20098%) were enrolled']","['CLS and 1-week period of standard accelerometer (DDDR', 'closed loop stimulation versus accelerometer', 'closed loop stimulation (CLS) rate-adaptive pacing']","['CLS and DDDR in 6MWD', 'CLS and DDDR', 'quality of life in CLS', 'Quality of life', 'peak heart rate', 'peak HR, peak VO2, and 6MWD', 'peak VO2']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}, {'cui': 'C1997984', 'cui_str': 'Chronotropic incompetence'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C1167956', 'cui_str': 'Cardiac resynchronisation therapy'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary exercise test'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1442452', 'cui_str': 'One week'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0441887', 'cui_str': 'Class 3'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}]","[{'cui': 'C0443183', 'cui_str': 'Closed loop'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C1442452', 'cui_str': 'One week'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0445022', 'cui_str': 'Loop'}, {'cui': 'C0562458', 'cui_str': 'Pacing up and down'}]","[{'cui': 'C0443183', 'cui_str': 'Closed loop'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0667627', 'cui_str': 'bis(kojato)oxovanadium(IV)'}]",,0.0638195,"Quality of life trended higher in CLS as compared to DDDR (550.8 ± 123.9 vs 489.3 ± 164.9, p = 0.06).","[{'ForeName': 'Jonathan C', 'Initials': 'JC', 'LastName': 'Hsu', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of California, San Diego, 9452 Medical Center Dr., La Jolla, CA, 92037, USA. Jonathan.Hsu@ucsd.edu.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Darden', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of California, San Diego, 9452 Medical Center Dr., La Jolla, CA, 92037, USA.'}, {'ForeName': 'Maylene', 'Initials': 'M', 'LastName': 'Alegre', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of California, San Diego, 9452 Medical Center Dr., La Jolla, CA, 92037, USA.'}, {'ForeName': 'Ulrika', 'Initials': 'U', 'LastName': 'Birgersdotter-Green', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of California, San Diego, 9452 Medical Center Dr., La Jolla, CA, 92037, USA.'}, {'ForeName': 'Gregory K', 'Initials': 'GK', 'LastName': 'Feld', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of California, San Diego, 9452 Medical Center Dr., La Jolla, CA, 92037, USA.'}, {'ForeName': 'Kurt S', 'Initials': 'KS', 'LastName': 'Hoffmayer', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of California, San Diego, 9452 Medical Center Dr., La Jolla, CA, 92037, USA.'}, {'ForeName': 'Frederick', 'Initials': 'F', 'LastName': 'Han', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of California, San Diego, 9452 Medical Center Dr., La Jolla, CA, 92037, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Krummen', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of California, San Diego, 9452 Medical Center Dr., La Jolla, CA, 92037, USA.'}, {'ForeName': 'Farshad', 'Initials': 'F', 'LastName': 'Raissi', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of California, San Diego, 9452 Medical Center Dr., La Jolla, CA, 92037, USA.'}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Ho', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of California, San Diego, 9452 Medical Center Dr., La Jolla, CA, 92037, USA.'}, {'ForeName': 'Pam R', 'Initials': 'PR', 'LastName': 'Taub', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of California, San Diego, 9452 Medical Center Dr., La Jolla, CA, 92037, USA.'}, {'ForeName': 'Marcus A', 'Initials': 'MA', 'LastName': 'Urey', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of California, San Diego, 9452 Medical Center Dr., La Jolla, CA, 92037, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Adler', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of California, San Diego, 9452 Medical Center Dr., La Jolla, CA, 92037, USA.'}]",Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing,['10.1007/s10840-020-00829-4'] 2461,32757218,Changes of Laryngeal and Extralaryngeal Symptoms and Findings in Laryngopharyngeal Reflux Patients.,"OBJECTIVES/HYPOTHESIS To assess the evolution of laryngeal and extralaryngeal symptoms and findings of laryngopharyngeal reflux (LPR) throughout a 3-month to 9-month treatment. STUDY DESIGN Prospective Controlled Study. METHODS One hundred twenty-seven LPR patients and 123 healthy individuals were enrolled from four European hospitals. Patients were managed with a 3-month personalized treatment considering the LPR characteristics at the impedance-pH monitoring. Regarding the clinical therapeutic response, treatment was adapted for 3 to 6 additional months. Symptoms and findings were assessed throughout the therapeutic course with the Reflux Symptom Score (RSS) and the short version of the Reflux Sign Assessment (sRSA). The relationship between patient and reflux characteristics, symptoms, and findings was assessed. RESULTS One hundred twenty-one LPR patients completed the study. LPR patients exhibited more laryngeal and extralaryngeal symptoms and findings than healthy individuals. RSS significantly improved from baseline to 6 weeks posttreatment and continued to improve from 3 months to 6 months posttreatment. sRSA significantly improved from baseline to 3 months posttreatment. No further improvement was noted at 6 months posttreatment for pharyngeal and oral findings. Laryngeal findings continued to improve from 3 months to 6 months posttreatment. There was a significant association between patient stress level and RSS (P = .045). At 3 months posttreatment, 28.1% of patients had high or complete response, whereas 47.1% required 6 months or 9 months of treatment. Overall, 24.8% of patients had an LPR chronic course. CONCLUSIONS Laryngeal and extralaryngeal symptoms and findings significantly improved throughout treatment in LPR patients. The improvement of laryngeal findings was slower. Regarding the low prevalence of some digestive or otolaryngological symptoms, a short version of the RSS could be developed. LEVEL OF EVIDENCE 3 Laryngoscope, 2020.",2020,"At 3 months posttreatment, 28.1% of patients had high or complete response, whereas 47.1% required 6 months or 9 months of treatment.","['One hundred twenty-seven LPR patients and 123 healthy individuals were enrolled from four European hospitals', 'Laryngopharyngeal Reflux Patients', 'One hundred twenty-one LPR patients completed the study', 'LPR patients']",['LPR'],"['therapeutic course with the Reflux Symptom Score (RSS) and the short version of the Reflux Sign Assessment (sRSA', 'sRSA', 'patient stress level and RSS', 'LPR chronic course', 'laryngeal findings', 'RSS', 'high or complete response', 'laryngeal and extralaryngeal symptoms', 'evolution of laryngeal and extralaryngeal symptoms and findings of laryngopharyngeal reflux (LPR']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C1168250', 'cui_str': 'Laryngopharyngeal reflux'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C1168250', 'cui_str': 'Laryngopharyngeal reflux'}]","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C4317146', 'cui_str': 'Acid reflux'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}, {'cui': 'C1168250', 'cui_str': 'Laryngopharyngeal reflux'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0023078', 'cui_str': 'Laryngeal'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0015219', 'cui_str': 'Biological Evolution'}]",127.0,0.0490684,"At 3 months posttreatment, 28.1% of patients had high or complete response, whereas 47.1% required 6 months or 9 months of treatment.","[{'ForeName': 'Jérôme R', 'Initials': 'JR', 'LastName': 'Lechien', 'Affiliation': 'Laryngopharyngeal Reflux Study Group of Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.'}, {'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Bobin', 'Affiliation': 'Laryngopharyngeal Reflux Study Group of Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.'}, {'ForeName': 'Vinciane', 'Initials': 'V', 'LastName': 'Muls', 'Affiliation': 'Laryngopharyngeal Reflux Study Group of Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.'}, {'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Mouawad', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Lille University Hospital Center, Lille University 2, Lille, France.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Dapri', 'Affiliation': 'Laryngopharyngeal Reflux Study Group of Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.'}, {'ForeName': 'Didier', 'Initials': 'D', 'LastName': 'Dequanter', 'Affiliation': 'Laryngopharyngeal Reflux Study Group of Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.'}, {'ForeName': 'Mihaela', 'Initials': 'M', 'LastName': 'Horoi', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Saint-Pierre University Hospital Center, Free University of Brussels, Université Libre de Bruxelles (ULB), Brussels, Belgium.'}, {'ForeName': 'Marie-Paule', 'Initials': 'MP', 'LastName': 'Thill', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Saint-Pierre University Hospital Center, Free University of Brussels, Université Libre de Bruxelles (ULB), Brussels, Belgium.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Rodriguez Ruiz', 'Affiliation': 'Laryngopharyngeal Reflux Study Group of Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Saussez', 'Affiliation': 'Laryngopharyngeal Reflux Study Group of Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.'}]",The Laryngoscope,['10.1002/lary.28962'] 2462,32757387,Immediate versus delayed temporization at posterior single implant sites: A randomized controlled trial.,"AIMS We conducted a randomized controlled trial to assess the clinical outcomes of two loading protocols involving either immediate or delayed prosthetic temporization of single implants placed at posterior, healed sites. MATERIALS AND METHODS Forty-nine patients in need of single implants at premolar or molar sites were randomized to receive a temporary crown either immediately after implant placement or three months later. Randomization was stratified by sex, implant location (premolar/molar) and arch (maxilla/mandible). Final implant screw-retained Zirconia crowns with angulated screw channels were delivered at 5 months after surgery. Radiographic bone levels (primary outcome), peri-implant mucosal margin levels, and peri-implant probing depths were recorded at baseline, 6 months, and 12 months after surgery. RESULTS Both treatment arms showed similar patterns of soft tissue and bone remodeling from the implant platform over 12 months [mean bone level change 1.6 mm (SD 1.0mm) in the delayed, and 1.2 mm (SD 1.3mm) in the immediate temporization group], with the majority of changes occurring within the first 6 months. CONCLUSIONS Immediate or delayed temporization of single implants placed at posterior healed sites resulted in largely similar 1-year outcomes with respect to peri-implant bone levels and soft tissue changes.",2020,"CONCLUSIONS Immediate or delayed temporization of single implants placed at posterior healed sites resulted in largely similar 1-year outcomes with respect to peri-implant bone levels and soft tissue changes.",['Forty-nine patients in need of single implants at premolar or molar sites'],[],"['soft tissue and bone remodeling', 'Radiographic bone levels (primary outcome), peri-implant mucosal margin levels, and peri-implant probing depths']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C1704302', 'cui_str': 'Structure of premolar tooth'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0205145', 'cui_str': 'Site'}]",[],"[{'cui': 'C0225317', 'cui_str': 'Soft tissue'}, {'cui': 'C0085268', 'cui_str': 'Bone remodeling'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0026724', 'cui_str': 'Mucosal'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}]",49.0,0.220279,"CONCLUSIONS Immediate or delayed temporization of single implants placed at posterior healed sites resulted in largely similar 1-year outcomes with respect to peri-implant bone levels and soft tissue changes.","[{'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Division of Periodontics, Section of Oral, Diagnostic and Rehabilitation Sciences, College of Dental Medicine, New York, United States.'}, {'ForeName': 'Gila', 'Initials': 'G', 'LastName': 'Lerman', 'Affiliation': 'Division of Periodontics, Section of Oral, Diagnostic and Rehabilitation Sciences, College of Dental Medicine, New York, United States.'}, {'ForeName': 'Nurit', 'Initials': 'N', 'LastName': 'Bittner', 'Affiliation': 'Division of Prosthodontics, Section of Oral, Diagnostic and Rehabilitation Sciences, College of Dental Medicine, New York, United States.'}, {'ForeName': 'Weijia', 'Initials': 'W', 'LastName': 'Fan', 'Affiliation': 'Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, United States.'}, {'ForeName': 'Evanthia', 'Initials': 'E', 'LastName': 'Lalla', 'Affiliation': 'Division of Periodontics, Section of Oral, Diagnostic and Rehabilitation Sciences, College of Dental Medicine, New York, United States.'}, {'ForeName': 'Panos N', 'Initials': 'PN', 'LastName': 'Papapanou', 'Affiliation': 'Division of Periodontics, Section of Oral, Diagnostic and Rehabilitation Sciences, College of Dental Medicine, New York, United States.'}]",Journal of clinical periodontology,['10.1111/jcpe.13354'] 2463,32757413,Non-motor symptoms in Parkinson´s disease are reduced by nabilone.,"OBJECTIVE To assess the efficacy and safety of nabilone, a synthetic tetrahydrocannabinol analogue, as a treatment for non-motor symptoms (NMS) in Parkinson´s Disease (PD). METHODS This was a phase II placebo-controlled, double-blind, parallel-group, enriched enrollment randomized withdrawal trial at the Medical University Innsbruck. A random sample of 47 PD patients with stable motor disease and disturbing NMS defined by a score of ≥4 points on the Movement Disorder Society-Unified PD Rating Scale-I (MDS-UPDRS-I) underwent open-label nabilone titration (0.25mg once daily-1mg twice daily, Phase 1). Responders were randomized 1:1 to continue with nabilone or switch to placebo for four weeks (Phase 2). The primary efficacy criterion was the change of the MDS-UPDRS-I between randomization and week four. Safety was analyzed in all patients who received at least one nabilone dose. RESULTS Between October 2017 and July 2019, 19 patients received either nabilone (median dose=0.75mg) or placebo. At week four, mean change of the MDS-UPDRS-I was 2.63 (95%CI 1.53-3.74, p=0.002, effect size=1.15) in the placebo versus 1.00 (95%CI -0.16-2.16, p=0.280, effect size=0.42) in the nabilone-group (difference:1.63, 95%CI 0.09-3.18, p=0.030, effect size=0.66). Seventy-seven percent of patients had adverse events (AEs) during open-label titration, most of them were transient. In the double-blind phase, similar proportions of patients in each group had AEs (42% placebo-group, 32% nabilone-group). There were no serious AEs. INTERPRETATION Our results highlight the potential efficacy of nabilone for PD patients with disturbing NMS, which appears to be driven by positive effects on anxious mood and night-time sleep problems. TRIAL REGISTRY ClinicalTrials.gov (NCT03769896) and EudraCT (2017-000192-86) This article is protected by copyright. All rights reserved.",2020,"I was 2.63 (95%CI 1.53-3.74, p=0.002, effect","['Between October 2017 and July 2019', '47 PD patients with stable motor disease and disturbing NMS defined by a score of ≥4 points on the Movement Disorder Society-Unified PD Rating Scale-I (MDS-UPDRS-I) underwent', '2017-000192-86', 'non-motor symptoms (NMS) in Parkinson´s Disease (PD']","['nabilone or switch to placebo', 'open-label nabilone titration', 'EudraCT', 'placebo']","['Safety', 'effect', 'mean change of the MDS-UPDRS', 'adverse events (AEs', 'change of the MDS-UPDRS']","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026650', 'cui_str': 'Movement disorder'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}]","[{'cui': 'C0068333', 'cui_str': 'nabilone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0162621', 'cui_str': 'Titration method'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.706771,"I was 2.63 (95%CI 1.53-3.74, p=0.002, effect","[{'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Peball', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Krismer', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Hans-Günther', 'Initials': 'HG', 'LastName': 'Knaus', 'Affiliation': 'Department for Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Peter-Mayr Straße 1, 6020, Innsbruck, Austria.'}, {'ForeName': 'Atbin', 'Initials': 'A', 'LastName': 'Djamshidian', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Werkmann', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Federico', 'Initials': 'F', 'LastName': 'Carbone', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Ellmerer', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Heim', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Kathrin', 'Initials': 'K', 'LastName': 'Marini', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Dora', 'Initials': 'D', 'LastName': 'Valent', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Georg', 'Initials': 'G', 'LastName': 'Goebel', 'Affiliation': 'Department of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University, Schöpfstraße 41/1, 6020, Innsbruck, Austria.'}, {'ForeName': 'Hanno', 'Initials': 'H', 'LastName': 'Ulmer', 'Affiliation': 'Department of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University, Schöpfstraße 41/1, 6020, Innsbruck, Austria.'}, {'ForeName': 'Heike', 'Initials': 'H', 'LastName': 'Stockner', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Gregor K', 'Initials': 'GK', 'LastName': 'Wenning', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Raphaela', 'Initials': 'R', 'LastName': 'Stolz', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Krejcy', 'Affiliation': 'AOP Orphan Pharmaceuticals AG, Wilhelminenstraße 91, 1160, Vienna, Austria.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Poewe', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Seppi', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Annals of neurology,['10.1002/ana.25864'] 2464,32757418,The efficacy of administrating a sweet tasting solution for reducing the pain related to dental injections in children: A Randomized Controlled Trial.,"BACKGROUND Anesthetic injections are an unpleasant experience for children in the dental office. Oral intake of sweet substances by newborns has been shown to be effective in reducing pain. AIM The purpose of this study was to determine whether a prior administration of a sweet-tasting solution has an effect on dental injection pain. DESIGN A total 60 healthy children needing bilateral maxillary primary canine extraction were included in this split mouth randomized clinical trial. In the test side, dental injection (local infiltration) was applied after the patient received a sweet tasting solution, while in the control side sterile water was administered. The patients' demographic characteristics, body mass index (BMI) and sweet taste preference were recorded. Pain perception during injection was measured using visual analogue scale (VAS) and sound, eye, body movement (SEM). RESULTS Mean VAS (28.30±6.43) and SEM (2.14±0.78) in the test side were lower than the control side (45.80±7.17 and 2.95±1.00). It was shown that higher BMI was associated with reduction in the analgesic effect while the individual's tendency to sweetness increased pain reduction. CONCLUSIONS Sweet taste administration before dental injections in children helps to control the associated pain. This effect is influenced by the individual's sweet taste tendency and BMI.",2020,"It was shown that higher BMI was associated with reduction in the analgesic effect while the individual's tendency to sweetness increased pain reduction. ","['children in the dental office', '60 healthy children needing bilateral maxillary primary canine extraction', 'children']","['sweet tasting solution', 'sweet-tasting solution']","['pain reduction', 'Pain perception', 'visual analogue scale (VAS) and sound, eye, body movement (SEM', 'demographic characteristics, body mass index (BMI) and sweet taste preference', 'Mean VAS ']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011386', 'cui_str': 'Dental Office'}, {'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0010482', 'cui_str': 'Structure of canine tooth'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}]","[{'cui': 'C0085077', 'cui_str': 'Acute febrile neutrophilic dermatosis'}, {'cui': 'C0037633', 'cui_str': 'Solution'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0858600', 'cui_str': 'Taste sweet'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",60.0,0.181686,"It was shown that higher BMI was associated with reduction in the analgesic effect while the individual's tendency to sweetness increased pain reduction. ","[{'ForeName': 'Faezeh', 'Initials': 'F', 'LastName': 'Ghaderi', 'Affiliation': 'DMD, MSc in Pediatric Dentistry, Department of Pediatric Dentistry, School of Dentistry, Shiraz University of Medical Science, Shiraz, Fars, Iran.'}, {'ForeName': 'Mahboobe', 'Initials': 'M', 'LastName': 'Ahmadbeigi', 'Affiliation': 'DMD, Dental research committee, Shaherkord University of Medical Sciences, School of Dentistry, Shahrekord, chaharmahal bakhtiari, Iran.'}, {'ForeName': 'Mehrdad', 'Initials': 'M', 'LastName': 'Vossoughi', 'Affiliation': 'PhD in Statistical Sciences, Oral and Dental Disease Research Center, Department of Dental Public Health, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Fars, Iran.'}, {'ForeName': 'Ahmadreza', 'Initials': 'A', 'LastName': 'Sardarian', 'Affiliation': 'DMD, MSc in Orthodontics, Orthodontic Research Center, Department of Orthodontics, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Fars, Iran.'}]",International journal of paediatric dentistry,['10.1111/ipd.12697'] 2465,32750760,"Efficacy of Buspirone Augmentation of Escitalopram in Patients with Major Depressive Disorder with and without Atypical Features: A Randomized, 8 Week, Multicenter, Open-Label Clinical Trial.","OBJECTIVE This study investigated the treatment response and cognitive enhancement effects of buspirone augmentation of escitalopram in patients with major depressive disorder (MDD), according to atypical feature subtypes of MDD. METHODS An 8 week, randomized, parallel-controlled, open-label study was conducted. The Columbia Atypical Depression Diagnostic Scale was administered to evaluate atypical features. Patients were assigned randomly to the buspirone augmentation or non-buspirone groups. Symptom severity and cognitive function were evaluated using the 17-item Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Beck Depression Inventory, Beck Anxiety Inventory, digit span test, word fluency test, and Trail Making Tests A and B. RESULTS A total of 89 patients were recruited. There were no significant differences in the measures between the groups; however, among the MDD patients without atypical features, the digit span and word fluency tests were improved by treatment. In the MDD patients without atypical features, the buspirone augmentation group showed a significant improvement on the digit span test compared to the non-buspirone group. CONCLUSION Buspirone augmentation did not demonstrate significant benefits in MDD patients; however, buspirone augmentation showed greater efficacy for the improvement of cognitive function in MDD patients without atypical features. Our study suggests that atypical features are an important factor for cognitive enhancement in buspirone augmentation treatment in patients with MDD.",2020,"In the MDD patients without atypical features, the buspirone augmentation group showed a significant improvement on the digit span test compared to the non-buspirone group. ","['MDD patients', 'patients with MDD', 'patients with major depressive disorder (MDD', 'A total of 89 patients were recruited', 'Patients with Major Depressive Disorder with and without Atypical Features']","['buspirone augmentation of escitalopram', 'Buspirone Augmentation of Escitalopram', 'buspirone augmentation or non-buspirone']","['digit span and word fluency tests', 'cognitive function', 'Symptom severity and cognitive function', 'digit span test', '17-item Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Beck Depression Inventory, Beck Anxiety Inventory, digit span test, word fluency test, and Trail Making Tests A and B', 'Columbia Atypical Depression Diagnostic Scale']","[{'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205182', 'cui_str': 'Atypical'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]","[{'cui': 'C0006462', 'cui_str': 'Buspirone'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C1099456', 'cui_str': 'Escitalopram'}]","[{'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory'}, {'cui': 'C0040604', 'cui_str': 'Trail making test'}, {'cui': 'C0154437', 'cui_str': 'Atypical depressive disorder'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]",89.0,0.0151867,"In the MDD patients without atypical features, the buspirone augmentation group showed a significant improvement on the digit span test compared to the non-buspirone group. ","[{'ForeName': 'Cheolmin', 'Initials': 'C', 'LastName': 'Shin', 'Affiliation': 'Department of Psychiatry, Korea University College of Medicine, Korea University Ansan Hospital, Ansan, Republic of Korea.'}, {'ForeName': 'Young-Hoon', 'Initials': 'YH', 'LastName': 'Ko', 'Affiliation': 'Department of Psychiatry, Korea University College of Medicine, Korea University Ansan Hospital, Ansan, Republic of Korea.'}, {'ForeName': 'Se-Hoon', 'Initials': 'SH', 'LastName': 'Shim', 'Affiliation': 'Department of Psychiatry, Soonchunhyang University College of Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea.'}, {'ForeName': 'Ji Sun', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': 'Department of Psychiatry, Soonchunhyang University College of Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea.'}, {'ForeName': 'Kyoung-Sae', 'Initials': 'KS', 'LastName': 'Na', 'Affiliation': 'Department of Psychiatry, Gachon University College of Medicine, Gil Medical Center, Incheon, Republic of Korea.'}, {'ForeName': 'Sang-Woo', 'Initials': 'SW', 'LastName': 'Hahn', 'Affiliation': 'Department of Psychiatry, Soonchunhyang University College of Medicine, Soonchunhyang University Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Seung-Hwan', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Department of Psychiatry, Inje University Ilsan Paik Hospital, Goyang, Republic of Korea.'}]",Psychiatry investigation,['10.30773/pi.2020.0017'] 2466,32750990,Evaluating an Outpatient Diabetes Program Telephone Follow-Up Process on Glycosylated Hemoglobin Levels.,"Purpose: The purpose of this study was to determine if increased frequency of telephone contact immediately following diabetes self-management education (DSME) impacts improvements in A1C levels versus routine telephone follow-up. Methods: This study used a quasi-experimental design consisting of a control group ( n = 30) who received routine follow-up (1 telephone call 4-6 weeks after DSME class completion) and an intervention group ( n = 26) who received an average of 5 telephone calls over a 3-month period following DSME. Participants were obtained from an outpatient diabetes education program assoctiated with a large urban health care system. Results: Most participants were female, White, with the average age of 57.2 years ( SD = 14.1). Preintervention A1C levels ranged from 6.5% to 14.3%, whereas postintervention A1C levels ranged from 5.2% to 13.6%. There was significant improvement in A1C levels for both the intervention and the control groups. However, no statistically significant difference in A1C change scores was found between the groups. Sixty percent of the control group participants had post-A1C levels below 7% compared to 54% of the intervention group. Increased telephone contact was associated with A1C reductions, although this relationship was not statistically significant. Conclusions: This study demonstrated that A1C reductions can occur with either frequency of telephone follow-up. The diabetes educator should evaluate the telephone follow-up needs of each DSME participant to support his or her diabetes self-management success.",2016,There was significant improvement in A1C levels for both the intervention and the control groups.,"['Participants were obtained from an outpatient diabetes education program assoctiated with a large urban health care system', 'Most participants were female, White, with the average age of 57.2 years ( SD = 14.1']","['diabetes self-management education (DSME', 'control group ( n = 30) who received routine follow-up (1 telephone call 4-6 weeks after DSME class completion) and an intervention group ( n = 26) who received an average of 5 telephone calls']","['Preintervention A1C levels', 'A1C change scores', 'postintervention A1C levels', 'post-A1C levels', 'Glycosylated Hemoglobin Levels', 'A1C levels']","[{'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0041933', 'cui_str': 'Urban Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1319140', 'cui_str': 'Diabetes self-management behavior'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1720420', 'cui_str': 'Call'}]","[{'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}]",,0.0150687,There was significant improvement in A1C levels for both the intervention and the control groups.,"[{'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Niemczewski', 'Affiliation': 'Norton Audubon Hospital, Bellarmine University School of Nursing, Louisville, Kentucky joan.niemczewski@nortonhealthcare.org.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Polivka', 'Affiliation': 'University of Louisville School of Nursing, Louisville, Kentucky.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Clark', 'Affiliation': 'Norton Healthcare Institute for Nursing, University of Louisville School of Nursing, Louisville, Kentucky.'}]",Journal of doctoral nursing practice,['10.1891/2380-9418.9.2.199'] 2467,32750997,The Effect of a Comprehensive Provider and Patient Intervention to Improve Blood Pressure Control.,"Purpose: To examine the comprehensive provider and patient intervention (CPPI) compared to usual care (UC) on blood pressure control among newly diagnosed hypertensive patients treated in a nurse practitioner practice. Data Sources: CPPI included provider and patient education, electronic health record messages about the guidelines of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, Treatment of High Blood Pressure (JNC-7), and patient counseling. Blood pressure control (intervention group; CPPI) was assessed and compared to levels of newly diagnosed patients prior to the intervention (usual care group; UC). One-way analysis of variance (ANOVA) tested for between-group differences and independent samples t test tested for within-group differences in blood pressure readings measured at initial visit and 12-week follow-up visit. Conclusions: There were no significant differences between the groups for mean blood pressure on Weeks 1 and 12. Patients in CPPI showed slightly greater improvement in blood pressure classification compared to UC. Follow-up phone calls allowed for identification of barriers for adherence with follow-up appointments. Implications for Practice: JNC-7 provides an evidence-based approach to diagnosis and management of hypertension. Understanding patient barriers to adherence with treatment may lead to more effective programs that address individual patient needs.",2016,There were no significant differences between the groups for mean blood pressure on Weeks 1 and 12.,['newly diagnosed hypertensive patients treated in a nurse practitioner practice'],"['JNC-7', 'Comprehensive Provider and Patient Intervention', 'comprehensive provider and patient intervention (CPPI', 'Blood pressure control (intervention group; CPPI', 'usual care (UC']","['blood pressure readings', 'blood pressure control', 'blood pressure classification', 'mean blood pressure', 'Blood Pressure Control']","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0028657', 'cui_str': 'Nurse practitioner'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}]",,0.0227653,There were no significant differences between the groups for mean blood pressure on Weeks 1 and 12.,"[{'ForeName': 'Kimberly A', 'Initials': 'KA', 'LastName': 'Keser', 'Affiliation': 'Saint Louis University School of Nursing, Missouri kkeser@ymail.com.'}, {'ForeName': 'Rebecca A', 'Initials': 'RA', 'LastName': 'Lorenz', 'Affiliation': 'Saint Louis University School of Nursing, Missouri.'}]",Journal of doctoral nursing practice,['10.1891/2380-9418.9.1.4'] 2468,32751064,"Effects of Mulligan Mobilization and Low-Level Laser Therapy on Physical Disability, Pain, and Range of Motion in Patients with Chronic Low Back Pain: A Pilot Randomized Controlled Trial.","This study aimed to determine the combined treatment effects of Mulligan sustained natural apophyseal glides (SNAGs) and low-level laser therapy (LLLT) on function, pain, and range of motion (ROM) in patients with chronic low back pain. A total of 49 adults participated in this study and were randomly divided into three groups (SNAGs with LLLT group, SNAGs group, and control group). The participants in the SNAGs with LLLT group received SNAGs for 10 min, LLLT for 10 min, and electrotherapy for 10 min. The SNAGs group received SNAGs for 10 min and electrotherapy for 20 min. The control group received electrotherapy for 30 min. All participants received the assigned treatment for 30 min a day, 3 times a week, for 4 weeks. We used the visual analogue scale (VAS) to measure pain, the modified-modified Schober test (MMST) to measure ROM, and the Roland Morris disability questionnaire (RMDQ) to measure physical disability. Compared to the pre-intervention values, the VAS and MMST scores significantly increased after the intervention in the SNAGs with LLLT group ( p = 0.000) and the SNAGs group ( p = 0.000). The RMDQ score significantly improved in the SNAGs with LLLT ( p = 0.000), SNAGs ( p = 0.000) and control ( p = 0.025) group after the intervention. The inter-group differences were greater for the SNAGs with LLLT and SNAGs groups than for the control group ( p = 0.001), and the difference was greater for the SNAGs with LLLT than for the SNAGs ( p = 0.001) with respect to the VAS, MMST, and RMDQ scores. These results indicate that significant improvement in pain, function, and ROM may be achieved by a combination of SNAGs and LLLT to treat chronic low back pain.",2020,"The RMDQ score significantly improved in the SNAGs with LLLT ( p = 0.000), SNAGs ( p = 0.000) and control ( p = 0.025) group after the intervention.","['Patients with Chronic Low Back Pain', '49 adults', 'patients with chronic low back pain']","['Mulligan sustained natural apophyseal glides (SNAGs) and low-level laser therapy (LLLT', 'Mulligan Mobilization and Low-Level Laser Therapy', 'electrotherapy', 'LLLT']","['VAS, MMST, and RMDQ scores', 'pain, function, and ROM', 'VAS and MMST scores', 'function, pain, and range of motion (ROM', 'RMDQ score', 'visual analogue scale (VAS) to measure pain, the modified-modified Schober test (MMST) to measure ROM, and the Roland Morris disability questionnaire (RMDQ) to measure physical disability', 'Physical Disability, Pain, and Range of Motion']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0205296', 'cui_str': 'Natural'}, {'cui': 'C0336966', 'cui_str': 'Gliding'}, {'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0013787', 'cui_str': 'Electrotherapy'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0430750', 'cui_str': 'Modified Schober test'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0520817', 'cui_str': 'Physical handicap'}]",49.0,0.0393352,"The RMDQ score significantly improved in the SNAGs with LLLT ( p = 0.000), SNAGs ( p = 0.000) and control ( p = 0.025) group after the intervention.","[{'ForeName': 'U-Hyeok', 'Initials': 'UH', 'LastName': 'Seo', 'Affiliation': 'Graduate School of Physical Therapy, Sahmyook University, Seoul 01795, Korea.'}, {'ForeName': 'Jung-Hee', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Department of Physical Therapy, Andong Science College, Andong 36616, Korea.'}, {'ForeName': 'Byoung-Hee', 'Initials': 'BH', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Therapy, Sahmyook University, Seoul 01795, Korea.'}]","Healthcare (Basel, Switzerland)",['10.3390/healthcare8030237'] 2469,32751219,"The Effect of High Polyphenol Extra Virgin Olive Oil on Blood Pressure and Arterial Stiffness in Healthy Australian Adults: A Randomized, Controlled, Cross-Over Study.","Extra virgin olive oil (EVOO) is suggested to be cardioprotective, partly due to its high phenolic content. We investigated the effect of extra virgin high polyphenol olive oil (HPOO) versus low polyphenol olive oil (LPOO) on blood pressure (BP) and arterial stiffness in healthy Australian adults. In a double-blind, randomized, controlled cross-over trial, 50 participants (age 38.5 ± 13.9 years, 66% female) were randomized to consume 60 mL/day of either HPOO (360 mg/kg polyphenols) or LPOO (86 mg/kg polyphenols) for three weeks. Following a two-week washout period, participants crossed over to consume the alternate oil. Anthropometric data, peripheral BP, central BP and arterial stiffness were measured at baseline and follow up. No significant differences were observed in the changes from baseline to follow up between the two treatments. However, a significant decrease in peripheral and central systolic BP (SBP) by 2.5 mmHg (95% CI: -4.7 to -0.3) and 2.7 mmHg (95% CI: -4.7 to -0.6), respectively, was observed after HPOO consumption. Neither olive oil changed diastolic BP (DBP) or measures of arterial stiffness. The reductions in SBP after HPOO consumption provide evidence for a potentially widely accessible dietary intervention to prevent cardiovascular disease in a multiethnic population. Longer intervention studies and/or higher doses of EVOO polyphenols are warranted to elucidate the potential effect on DBP and arterial stiffness.",2020,"However, a significant decrease in peripheral and central systolic BP (SBP) by 2.5 mmHg (95% CI: -4.7 to -0.3) and 2.7 mmHg (95% CI: -4.7 to -0.6), respectively, was observed after HPOO consumption.","['healthy Australian adults', '50 participants (age 38.5 ± 13.9 years, 66% female', 'Healthy Australian Adults']","['HPOO (360 mg/kg polyphenols) or LPOO', 'extra virgin high polyphenol olive oil (HPOO) versus low polyphenol olive oil (LPOO', 'Extra virgin olive oil (EVOO', 'EVOO polyphenols', 'High Polyphenol Extra Virgin Olive Oil']","['peripheral and central systolic BP (SBP', 'diastolic BP (DBP) or measures of arterial stiffness', 'blood pressure (BP) and arterial stiffness', 'Anthropometric data, peripheral BP, central BP and arterial stiffness', 'Blood Pressure and Arterial Stiffness']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517562', 'cui_str': '13.9'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0071649', 'cui_str': 'Polyphenol'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0555061', 'cui_str': 'Virgin'}]","[{'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}]",50.0,0.270672,"However, a significant decrease in peripheral and central systolic BP (SBP) by 2.5 mmHg (95% CI: -4.7 to -0.3) and 2.7 mmHg (95% CI: -4.7 to -0.6), respectively, was observed after HPOO consumption.","[{'ForeName': 'Katerina', 'Initials': 'K', 'LastName': 'Sarapis', 'Affiliation': 'Department of Dietetics, Nutrition and Sport, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne 3086, Australia.'}, {'ForeName': 'Colleen J', 'Initials': 'CJ', 'LastName': 'Thomas', 'Affiliation': 'Department of Physiology, Anatomy and Microbiology, School of Life Sciences, La Trobe University, Melbourne 3086, Australia.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Hoskin', 'Affiliation': 'Department of Dietetics, Nutrition and Sport, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne 3086, Australia.'}, {'ForeName': 'Elena S', 'Initials': 'ES', 'LastName': 'George', 'Affiliation': 'Department of Dietetics, Nutrition and Sport, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne 3086, Australia.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Marx', 'Affiliation': 'Department of Dietetics, Nutrition and Sport, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne 3086, Australia.'}, {'ForeName': 'Hannah L', 'Initials': 'HL', 'LastName': 'Mayr', 'Affiliation': 'School of Allied Health, Human Services and Sport, La Trobe University, Melbourne 3086, Australia.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Kennedy', 'Affiliation': 'Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne 3122, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Pipingas', 'Affiliation': 'Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne 3122, Australia.'}, {'ForeName': 'Jane C', 'Initials': 'JC', 'LastName': 'Willcox', 'Affiliation': 'Department of Dietetics, Nutrition and Sport, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne 3086, Australia.'}, {'ForeName': 'Luke A', 'Initials': 'LA', 'LastName': 'Prendergast', 'Affiliation': 'Department of Mathematics and Statistics, School of Engineering and Mathematical Sciences, La Trobe University, Melbourne 3086, Australia.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Itsiopoulos', 'Affiliation': 'School of Allied Health, Human Services and Sport, La Trobe University, Melbourne 3086, Australia.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Moschonis', 'Affiliation': 'Department of Dietetics, Nutrition and Sport, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne 3086, Australia.'}]",Nutrients,['10.3390/nu12082272'] 2470,32751269,Effect of Varying Molecular Weight of Oat β-Glucan Taken just before Eating on Postprandial Glycemic Response in Healthy Humans.,"To see if the molecular weight (MW) and viscosity of oat β-glucan (OBG) when taken before eating determine its effect on postprandial glycemic responses (PPRG), healthy overnight-fasted subjects ( n = 16) were studied on eight separate occasions. Subjects consumed 200 mL water alone (Control) or with 4 g OBG varying in MW and viscosity followed, 2-3 min later, by 113 g white-bread. Blood was taken fasting and at 15, 30, 45, 60, 90, and 120 min after starting to eat. None of the OBG treatments differed significantly from the Control for the a-priori primary endpoint of glucose peak-rise or secondary endpoint of incremental area-under-the-curve (iAUC) over 0-120 min. However, significant differences from the Control were seen for glucose iAUC over 0-45 min and time to peak (TTP) glucose. Lower log(MW) and log(viscosity) were associated with higher iAUC 0-45 ( p < 0.001) and shorter TTP ( p < 0.001). We conclude that when 4 g OBG is taken as a preload, reducing MW does not affect glucose peak rise or iAUC0-120, but rather accelerates the rise in blood glucose and reduces the time it takes glucose to reach the peak. However, this is based on post-hoc calculation of iAUC0-45 and TTP and needs to be confirmed in a subsequent study.",2020,None of the OBG treatments differed significantly from the Control for the a-priori primary endpoint of glucose peak-rise or secondary endpoint of incremental area-under-the-curve (iAUC) over 0-120 min.,"['Healthy Humans', 'healthy overnight-fasted subjects ( n = 16']","['Varying Molecular Weight of Oat β-Glucan Taken just before Eating', '200 mL water alone (Control) or with 4 g OBG varying in MW and viscosity']","['molecular weight (MW) and viscosity of oat β-glucan (OBG', 'shorter TTP', 'blood glucose', 'Lower log(MW) and log(viscosity', 'postprandial glycemic responses (PPRG', 'glucose peak-rise or secondary endpoint of incremental area-under-the-curve (iAUC', 'Postprandial Glycemic Response', 'glucose iAUC over 0-45 min and time to peak (TTP) glucose']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0439583', 'cui_str': 'Overnight'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}]","[{'cui': 'C0026385', 'cui_str': 'Molecular Weight'}, {'cui': 'C0028753', 'cui_str': 'Oats'}, {'cui': 'C0017692', 'cui_str': 'Glucan (BO)'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0042784', 'cui_str': 'Viscosity'}]","[{'cui': 'C0026385', 'cui_str': 'Molecular Weight'}, {'cui': 'C0042784', 'cui_str': 'Viscosity'}, {'cui': 'C0028753', 'cui_str': 'Oats'}, {'cui': 'C0017692', 'cui_str': 'Glucan (BO)'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0034155', 'cui_str': 'Thrombotic thrombocytopenic purpura'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",16.0,0.0204447,None of the OBG treatments differed significantly from the Control for the a-priori primary endpoint of glucose peak-rise or secondary endpoint of incremental area-under-the-curve (iAUC) over 0-120 min.,"[{'ForeName': 'Thomas M S', 'Initials': 'TMS', 'LastName': 'Wolever', 'Affiliation': 'INQUIS Clinical Research, Ltd. (formerly GI Labs), Toronto, ON M5C 2N8, Canada.'}, {'ForeName': 'Outi', 'Initials': 'O', 'LastName': 'Mattila', 'Affiliation': 'VTT Technical Research Centre of Finland Ltd., 1000 Espoo, Finland.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Rosa-Sibakov', 'Affiliation': 'VTT Technical Research Centre of Finland Ltd., 1000 Espoo, Finland.'}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Tosh', 'Affiliation': 'School of Nutrition Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada.'}, {'ForeName': 'Alexandra L', 'Initials': 'AL', 'LastName': 'Jenkins', 'Affiliation': 'INQUIS Clinical Research, Ltd. (formerly GI Labs), Toronto, ON M5C 2N8, Canada.'}, {'ForeName': 'Adish', 'Initials': 'A', 'LastName': 'Ezatagha', 'Affiliation': 'INQUIS Clinical Research, Ltd. (formerly GI Labs), Toronto, ON M5C 2N8, Canada.'}, {'ForeName': 'Ruedi', 'Initials': 'R', 'LastName': 'Duss', 'Affiliation': 'DSM Nutritional Products Ltd., R&D Human Nutrition and Health, 4002 Basel, Switzerland.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Steinert', 'Affiliation': 'DSM Nutritional Products Ltd., R&D Human Nutrition and Health, 4002 Basel, Switzerland.'}]",Nutrients,['10.3390/nu12082275'] 2471,32751340,The Effect of Gaseous Ozone Therapy in Conjunction with Periodontal Treatment on Glycated Hemoglobin Level in Subjects with Type 2 Diabetes Mellitus: An Unmasked Randomized Controlled Trial.,"BACKGROUND It is established that inflammation is involved in the pathogenesis of Type 2 Diabetes Mellitus (T2DM) by promoting insulin resistance and impaired beta cell function in the pancreas. Among the hypothesized independent risk factors implicated in the pathogenetic basis of disease, periodontal infection has been proposed to promote an amplification of the magnitude of the advanced glycation end product (AGE)-mediated upregulation of cytokine synthesis and secretion. These findings suggest an interrelationship between periodontal disease and type 2 diabetes, describing poor metabolic control in subjects with periodontitis as compared to nondiabetic subjects and more severe periodontitis in subjects with T2DM as compared to a healthy population, with a significant positive correlation between periodontal inflammatory parameters and glycated hemoglobin level. Results from clinical trials show that periodontal treatment is able to improve glycemic control in subjects with diabetes. Many therapeutic strategies have been developed to improve periodontal conditions in conjunction with conventional treatment, among which ozone (O 3 ) is of specific concern. The principal aim of this trial was to compare the clinical effectiveness of an intensive periodontal intervention consisting of conventional periodontal treatment in conjunction with ozone gas therapy in reducing glycated hemoglobin level in type 2 diabetic patients and standard periodontal treatment. METHODS This study was a 12-month unmasked randomized trial and included 100 patients aged 40-74 years older, with type 2 diabetes mellitus diagnosed. All the patients received conventional periodontal treatment, or periodontal treatment in conjunction with ozone gas therapy in a randomly assigned order (1:1). The primary outcome was a clinical measure of glycated hemoglobin level at 3, 6, 9 and 12 months from randomization. Secondary outcomes were changes in periodontal inflammatory parameters. RESULTS At 12 months, the periodontal treatment in conjunction with ozone gas therapy did not show significant differences than standard therapy in decreasing glycated hemoglobin (HbA1C) level and the lack of significant differences in balance is evident. CONCLUSIONS Although the change was not significant, periodontal treatment in conjunction with the gaseous ozone therapy tended to reduce the levels of glycated hemoglobin. The study shows a benefit with ozone therapy as compared to traditional periodontal treatment.",2020,"At 12 months, the periodontal treatment in conjunction with ozone gas therapy did not show significant differences than standard therapy in decreasing glycated hemoglobin (HbA1C) level and the lack of significant differences in balance is evident. ","['Subjects with Type 2 Diabetes Mellitus', 'type 2 diabetic patients and standard periodontal treatment', 'subjects with diabetes', '100 patients aged 40-74 years older, with type 2 diabetes mellitus diagnosed']","['intensive periodontal intervention', 'ozone therapy', 'conventional periodontal treatment', 'ozone gas therapy', 'conventional periodontal treatment, or periodontal treatment in conjunction with ozone gas therapy', 'Periodontal Treatment', 'Gaseous Ozone Therapy']","['glycated hemoglobin level', 'glycated hemoglobin (HbA1C) level', 'changes in periodontal inflammatory parameters', 'severe periodontitis', 'Glycated Hemoglobin Level', 'clinical measure of glycated hemoglobin level', 'levels of glycated hemoglobin', 'glycemic control']","[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4727847', 'cui_str': 'Ozone therapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030106', 'cui_str': 'Ozone'}, {'cui': 'C0017110', 'cui_str': 'Gas'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0031099', 'cui_str': 'Periodontitis'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",100.0,0.0391699,"At 12 months, the periodontal treatment in conjunction with ozone gas therapy did not show significant differences than standard therapy in decreasing glycated hemoglobin (HbA1C) level and the lack of significant differences in balance is evident. ","[{'ForeName': 'Biagio', 'Initials': 'B', 'LastName': 'Rapone', 'Affiliation': 'Department of Basic Medical Sciences, Neurosciences and Sense Organs, ""Aldo Moro"" University of Bari, 70121 Bari, Italy.'}, {'ForeName': 'Elisabetta', 'Initials': 'E', 'LastName': 'Ferrara', 'Affiliation': 'Complex Operative Unit of Odontostomatology, Hospital S.S. Annunziata, 66100 Chieti, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Corsalini', 'Affiliation': 'Interdisciplinary Department of Medicine, University of Bari, 70121 Bari, Italy.'}, {'ForeName': 'Ilaria', 'Initials': 'I', 'LastName': 'Converti', 'Affiliation': 'Department of Emergency and Organ Transplantation, Division of Plastic and Reconstructive Surgery, ""Aldo Moro"" University of Bari, 70121 Bari, Italy.'}, {'ForeName': 'Felice Roberto', 'Initials': 'FR', 'LastName': 'Grassi', 'Affiliation': 'Department of Basic Medical Sciences, Neurosciences and Sense Organs, ""Aldo Moro"" University of Bari, 70121 Bari, Italy.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Santacroce', 'Affiliation': 'Ionian Department (DJSGEM), ""Aldo Moro"" University of Bari, 70121 Bari, Italy.'}, {'ForeName': 'Skender', 'Initials': 'S', 'LastName': 'Topi', 'Affiliation': 'Department of Clinical Disciplines, School of Technical Medical Sciences, University A. Xhuvani, 3001 Elbasan, Albania.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Gnoni', 'Affiliation': 'Department of Basic Medical Sciences, Neurosciences and Sense Organs, ""Aldo Moro"" University of Bari, 70121 Bari, Italy.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Scacco', 'Affiliation': 'Department of Basic Medical Sciences, Neurosciences and Sense Organs, ""Aldo Moro"" University of Bari, 70121 Bari, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Scarano', 'Affiliation': 'Department of Oral Science, Nano and Biotechnology and CeSi-Met University of Chieti-Pescara, 66100 Chieti, Italy.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Delvecchio', 'Affiliation': ""Department of Metabolic and Genetic Diseases, Giovanni XXIII Children's Hospital, 70126 Bari, Italy.""}]",International journal of environmental research and public health,['10.3390/ijerph17155467'] 2472,32751341,Enhancing Memory for Relationship Actions by Transcranial Direct Current Stimulation of the Superior Temporal Sulcus.,"We examine the effect of transcranial direct current stimulation (tDCS) of right superior temporal sulcus (rSTS) in memorization of approach/avoidance relationship-action sentences; for example, ""Alejandro accepted/rejected Marta in his group."" Sixty-five university students participated in a tDCS study, in which a between-subjects design was adopted. Sixty-four participants were also given the behavioral approach system (BAS) and behavioral inhibition system (BIS) scales. Participants were subjected to 20 min of stimulation: anodal (N = 24), cathodal (N = 21), or sham (N = 20); subsequently, they were given a list of 40 sentences (half approach and half avoidance) and told to try to memorize them. Finally, they performed a changed/same memory task (half the sentences were the ""same"" and half were ""changed""). Previously, we had examined performance in the memory task without tDCS with another group of participants (N = 20). We found that anodal stimulation improved d' index of discriminability (hits-false alarms) compared to sham and cathodal conditions for both approach and avoidance sentences. Moreover, the comparison between anodal and task-alone performance showed that stimulation improved d' index of approach sentences more, as task-alone performance showed better discrimination for avoidance than for approach. Likewise, we explored a potential modulation of tDCS effect by (BAS) and (BIS) traits. We found that d' index improvement in anodal stimulation condition only benefited low BAS and low BIS participants. Implications of these results are discussed in the context of rSTS function in encoding and memorizing verbally described intentional relationship-actions and the role of individual differences on modulating tDCS effect.",2020,We found that anodal stimulation improved d' index of discriminability (hits-false alarms) compared to sham and cathodal conditions for both approach and avoidance sentences.,"[' Sixty-five university students participated in a tDCS study, in which a between-subjects design was adopted']",['transcranial direct current stimulation (tDCS) of right superior temporal sulcus (rSTS'],"[""anodal stimulation improved d' index of discriminability"", 'tDCS effect by (BAS) and (BIS) traits', 'behavioral approach system (BAS) and behavioral inhibition system (BIS) scales']","[{'cui': 'C0450385', 'cui_str': '65'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0425382', 'cui_str': 'Adopted'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0228237', 'cui_str': 'Structure of superior temporal sulcus'}]","[{'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",64.0,0.0287025,We found that anodal stimulation improved d' index of discriminability (hits-false alarms) compared to sham and cathodal conditions for both approach and avoidance sentences.,"[{'ForeName': 'Hipólito', 'Initials': 'H', 'LastName': 'Marrero', 'Affiliation': 'Departamento de Psicología Cognitiva, Social y organizacional, Universidad de La Laguna, 38071 San Cristóbal de La Laguna, Spain.'}, {'ForeName': 'Sara Nila', 'Initials': 'SN', 'LastName': 'Yagual', 'Affiliation': 'Departamento de Psicología Cognitiva, Social y organizacional, Universidad de La Laguna, 38071 San Cristóbal de La Laguna, Spain.'}, {'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'García-Marco', 'Affiliation': 'Departamento de Psicología Cognitiva, Social y organizacional, Universidad de La Laguna, 38071 San Cristóbal de La Laguna, Spain.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Gámez', 'Affiliation': 'Departamento de Psicología Cognitiva, Social y organizacional, Universidad de La Laguna, 38071 San Cristóbal de La Laguna, Spain.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Beltrán', 'Affiliation': 'Departamento de Psicología Cognitiva, Social y organizacional, Universidad de La Laguna, 38071 San Cristóbal de La Laguna, Spain.'}, {'ForeName': 'Jose Miguel', 'Initials': 'JM', 'LastName': 'Díaz', 'Affiliation': 'Departamento de Psicología Cognitiva, Social y organizacional, Universidad de La Laguna, 38071 San Cristóbal de La Laguna, Spain.'}, {'ForeName': 'Mabel', 'Initials': 'M', 'LastName': 'Urrutia', 'Affiliation': 'Instituto Universitario de Neurociencias de la Universidad de La Laguna, 38071 San Cristóbal de La Laguna, Spain.'}]",Brain sciences,['10.3390/brainsci10080497'] 2473,32751522,"Response of Vitamin D after Magnesium Intervention in a Postmenopausal Population from the Province of Granada, Spain.","Menopause is a stage of hormonal imbalance in women which, in addition to other physiopathological consequences, poses a risk of deficiency of key micronutrients such as magnesium and vitamin D. A study was made of the influence of a magnesium intervention upon vitamin D status in a postmenopausal population from the province of Granada (Spain). Fifty-two healthy postmenopausal women between 44-76 years of age were included. Two randomized groups-placebo and magnesium (500 mg/day)-were treated during eight weeks. Nutrient intake was assessed using questionnaires based on 72-h recall. Vitamin D was analyzed by liquid chromatography-tandem mass spectrometry. Baseline vitamin D proved deficient in over 80% of the subjects. The administration of magnesium resulted in significantly increased vitamin D levels in the intervention group versus the controls ( p < 0.05). Magnesium supplementation improved vitamin D status in the studied postmenopausal women.",2020,The administration of magnesium resulted in significantly increased vitamin D levels in the intervention group versus the controls ( p < 0.05).,"['Postmenopausal Population from the Province of Granada, Spain', 'postmenopausal population from the province of Granada (Spain', 'studied postmenopausal women', 'Fifty-two healthy postmenopausal women between 44-76 years of age were included']","['Baseline vitamin D', 'Vitamin D', 'Magnesium Intervention', 'Magnesium supplementation', 'magnesium intervention', 'placebo and magnesium', 'magnesium']","['vitamin D levels', 'Nutrient intake', 'vitamin D status']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1096534', 'cui_str': 'Magnesium supplement therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",52.0,0.285171,The administration of magnesium resulted in significantly increased vitamin D levels in the intervention group versus the controls ( p < 0.05).,"[{'ForeName': 'Héctor', 'Initials': 'H', 'LastName': 'Vázquez-Lorente', 'Affiliation': 'Department of Physiology, School of Pharmacy, Institute of Nutrition and Food Technology ""José Mataix"", University of Granada, 18071 Granada, Spain.'}, {'ForeName': 'Lourdes', 'Initials': 'L', 'LastName': 'Herrera-Quintana', 'Affiliation': 'Department of Physiology, School of Pharmacy, Institute of Nutrition and Food Technology ""José Mataix"", University of Granada, 18071 Granada, Spain.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Molina-López', 'Affiliation': 'Department of Physical Education and Sports, Faculty of Education, Psychology and Sports Sciences, University of Huelva, 21007 Huelva, Spain.'}, {'ForeName': 'Yenifer', 'Initials': 'Y', 'LastName': 'Gamarra-Morales', 'Affiliation': 'Department of Physiology, School of Pharmacy, Institute of Nutrition and Food Technology ""José Mataix"", University of Granada, 18071 Granada, Spain.'}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'López-González', 'Affiliation': 'Department of Physiology, School of Pharmacy, Institute of Nutrition and Food Technology ""José Mataix"", University of Granada, 18071 Granada, Spain.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Miralles-Adell', 'Affiliation': 'Department of Physiology, School of Pharmacy, Institute of Nutrition and Food Technology ""José Mataix"", University of Granada, 18071 Granada, Spain.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Planells', 'Affiliation': 'Department of Physiology, School of Pharmacy, Institute of Nutrition and Food Technology ""José Mataix"", University of Granada, 18071 Granada, Spain.'}]",Nutrients,['10.3390/nu12082283'] 2474,32751640,Short-Term Compound Training on Physical Performance in Young Soccer Players.,"This study aimed to investigate the effects of a five-week compound training (with strength and plyometric exercises performed on separate days) on sprint, change of direction, and vertical jump in young soccer players. Eighteen novices in strength and plyometric training were assigned to either a compound training (CMPT) or a control condition (CNT). Both groups trained three times per week. One session was dedicated to soccer-specific drills. The other two weekly sessions were dedicated to circuit-based training routines employing on one-day strength exercises and on the other day plyometric exercises in the CMPT group. At the same time, the CNT group performed two weekly soccer-specific training sessions. All players were tested by 15-m sprint, change-of-direction and acceleration test (CODAT), squat jump, and countermovement jump with arms swing tests. CMPT group improved CODAT, squat jump and countermovement jump to a higher extent compared to CNT group (large vs small or trivial effects, p < 0.05), while both groups had similar 15-m sprint performance ( p > 0.05). These results support the use of compound training to improve change of direction and vertical jump performances in young novice soccer players, which are unfamiliar with structured and advanced strength and plyometric training.",2020,"CMPT group improved CODAT, squat jump and countermovement jump to a higher extent compared to CNT group (large vs small or trivial effects, p < 0.05), while both groups had similar 15-m sprint performance ( p > 0.05).","['Eighteen novices in strength and plyometric training', 'young soccer players', 'Young Soccer Players', 'young novice soccer players']","['compound training (CMPT) or a control condition (CNT', 'five-week compound training (with strength and plyometric exercises', 'CMPT', 'CNT', 'Short-Term Compound Training']","['15-m sprint, change-of-direction and acceleration test (CODAT), squat jump, and countermovement jump with arms swing tests', 'change of direction and vertical jump performances', '15-m sprint performance', 'Physical Performance', 'CODAT, squat jump and countermovement jump']","[{'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C3178799', 'cui_str': 'Plyometric Drill'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}]","[{'cui': 'C0205198', 'cui_str': 'Compound'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C3178799', 'cui_str': 'Plyometric Drill'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]","[{'cui': 'C1442447', 'cui_str': 'Fifteen minutes'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439755', 'cui_str': 'Directions'}, {'cui': 'C0000894', 'cui_str': 'Acceleration'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",,0.00854369,"CMPT group improved CODAT, squat jump and countermovement jump to a higher extent compared to CNT group (large vs small or trivial effects, p < 0.05), while both groups had similar 15-m sprint performance ( p > 0.05).","[{'ForeName': 'Athos', 'Initials': 'A', 'LastName': 'Trecroci', 'Affiliation': 'Department of Biomedical Sciences for Health, Università degli Studi di Milano, 20129 Milan, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Duca', 'Affiliation': 'Department of Biomedical Sciences for Health, Università degli Studi di Milano, 20129 Milan, Italy.'}, {'ForeName': 'Damiano', 'Initials': 'D', 'LastName': 'Formenti', 'Affiliation': 'Department of Biotechnology and Life Sciences (DBSV), University of Insubria, 21100 Varese, Italy.'}, {'ForeName': 'Giampietro', 'Initials': 'G', 'LastName': 'Alberti', 'Affiliation': 'Department of Biomedical Sciences for Health, Università degli Studi di Milano, 20129 Milan, Italy.'}, {'ForeName': 'F Marcello', 'Initials': 'FM', 'LastName': 'Iaia', 'Affiliation': 'Department of Biomedical Sciences for Health, Università degli Studi di Milano, 20129 Milan, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Longo', 'Affiliation': 'Department of Biomedical Sciences for Health, Università degli Studi di Milano, 20129 Milan, Italy.'}]","Sports (Basel, Switzerland)",['10.3390/sports8080108'] 2475,32751650,The Evaluation of a Mind-Body Intervention (MBT-T) for Stress Reduction in Academic Settings: A Pilot Study.,"This study is aimed at evaluating the outcomes of mind-body transformation therapy (MBT-T), previously known as the creative psychosocial genomic healing experience© (CPGHE). The intervention was aimed at reducing the perceived level of stress in two non-clinical groups of students with different educational levels and different expertise in the domain of well-being. Whereas participants from the first group were first-year university students, participants from the second group were students attending a post-graduate program in psychotherapy. All participants ( n = 159) were exposed to a single session of MBT-T, each group in a separate session. The results of two paired-samples t -tests, conducted separately on the two samples, showed that there was a statistically significant reduction in the participants' perceived level of stress between pre- and post-intervention states in both samples (t 88 = 5.39, p < 0.001; t 53 = 4.56, p < 0.001 respectively). The results, therefore, showed that a single session of MBT-T was beneficial in reducing the perceived level of stress in both first-year university students and students attending a post-graduate program in psychotherapy, regardless of educational level and expertise in the domain of well-being.",2020,The intervention was aimed at reducing the perceived level of stress in two non-clinical groups of students with different educational levels and different expertise in the domain of well-being.,"['Whereas participants from the first group were first-year university students, participants from the second group were students attending a post-graduate program in psychotherapy', 'All participants ( n = 159']","['Mind-Body Intervention (MBT-T', 'mind-body transformation therapy (MBT-T']","['perceived level of stress', 'level of stress']","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0588053', 'cui_str': 'Graduate'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0033968', 'cui_str': 'Psychotherapy'}]","[{'cui': 'C1513305', 'cui_str': 'Mind-Body Medicine'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C3714584', 'cui_str': 'Transformation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}]",159.0,0.0234047,The intervention was aimed at reducing the perceived level of stress in two non-clinical groups of students with different educational levels and different expertise in the domain of well-being.,"[{'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Cozzolino', 'Affiliation': 'Department of Humanities, Philosophy and Education, University of Salerno, 84084 Fisciano, Italy.'}, {'ForeName': 'Deborah R', 'Initials': 'DR', 'LastName': 'Vivo', 'Affiliation': 'Department of Humanities, Philosophy and Education, University of Salerno, 84084 Fisciano, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Girelli', 'Affiliation': 'Department of Humanities, Philosophy and Education, University of Salerno, 84084 Fisciano, Italy.'}, {'ForeName': 'Pierpaolo', 'Initials': 'P', 'LastName': 'Limone', 'Affiliation': 'Department of Humanities, Literature, Cultural Heritage, Education Sciences, University of Foggia, 71122 Foggia, Italy.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Celia', 'Affiliation': 'Department of Humanities, Literature, Cultural Heritage, Education Sciences, University of Foggia, 71122 Foggia, Italy.'}]","Behavioral sciences (Basel, Switzerland)",['10.3390/bs10080124'] 2476,32751676,"Effect of an Enhanced Self-Care Protocol on Lymphedema Status among People Affected by Moderate to Severe Lower-Limb Lymphedema in Bangladesh, a Cluster Randomized Controlled Trial.","BACKGROUND Lymphatic filariasis (LF) is a major cause of lymphedema, affecting over 16 million people globally. A daily, hygiene-centered self-care protocol is recommended and effective in reducing acute attacks caused by secondary infections. It may also reverse lymphedema status in early stages, but less so as lymphedema advances. Lymphatic stimulating activities such as self-massage and deep-breathing have proven beneficial for cancer-related lymphedema, but have not been tested in LF-settings. Therefore, an enhanced self-care protocol was trialed among people affected by moderate to severe LF-related lymphedema in northern Bangladesh. METHODS Cluster randomization was used to allocate participants to either standard- or enhanced-self-care groups. Lymphedema status was determined by lymphedema stage, mid-calf circumference, and mid-calf tissue compressibility. RESULTS There were 71 patients in each group and at 24 weeks, both groups had experienced significant improvement in lymphedema status and reduction in acute attacks. There was a significant and clinically relevant between-group difference in mid-calf tissue compressibility with the biggest change observed on legs affected by severe lymphedema in the enhanced self-care group (∆ 21.5%, -0.68 (-0.91, -0.45), p < 0.001). CONCLUSION This study offers the first evidence for including lymphatic stimulating activities in recommended self-care for people affected by moderate and severe LF-related lymphedema.",2020,"There were 71 patients in each group and at 24 weeks, both groups had experienced significant improvement in lymphedema status and reduction in acute attacks.","['Lymphedema Status among People Affected by Moderate to Severe Lower-Limb Lymphedema in Bangladesh', 'people affected by moderate and severe LF-related lymphedema', 'people affected by moderate to severe LF-related lymphedema in northern Bangladesh']","['Enhanced Self-Care Protocol', 'standard- or enhanced-self-care groups']","['lymphedema status and reduction in acute attacks', 'mid-calf tissue compressibility', 'Lymphedema status', 'severe lymphedema']","[{'cui': 'C0024236', 'cui_str': 'Lymphedema'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0013884', 'cui_str': 'Lymphatic filariasis'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}]","[{'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0024236', 'cui_str': 'Lymphedema'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0004063', 'cui_str': 'Assault'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0230445', 'cui_str': 'Structure of calf of leg'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",71.0,0.0790095,"There were 71 patients in each group and at 24 weeks, both groups had experienced significant improvement in lymphedema status and reduction in acute attacks.","[{'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Douglass', 'Affiliation': 'Centre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.'}, {'ForeName': 'Hayley', 'Initials': 'H', 'LastName': 'Mableson', 'Affiliation': 'Centre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Martindale', 'Affiliation': 'Centre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.'}, {'ForeName': 'Sanya Tahmina', 'Initials': 'ST', 'LastName': 'Jhara', 'Affiliation': 'Filariasis Elimination and STH Control Program, Ministry of Health and Family Welfare, Dhaka 1000, Bangladesh.'}, {'ForeName': 'Mohammad Jahirul', 'Initials': 'MJ', 'LastName': 'Karim', 'Affiliation': 'Filariasis Elimination and STH Control Program, Ministry of Health and Family Welfare, Dhaka 1000, Bangladesh.'}, {'ForeName': 'Muhammad Mujibur', 'Initials': 'MM', 'LastName': 'Rahman', 'Affiliation': 'Filariasis Elimination and STH Control Program, Ministry of Health and Family Welfare, Dhaka 1000, Bangladesh.'}, {'ForeName': 'Abdullah Al', 'Initials': 'AA', 'LastName': 'Kawsar', 'Affiliation': 'Filariasis Elimination and STH Control Program, Ministry of Health and Family Welfare, Dhaka 1000, Bangladesh.'}, {'ForeName': 'Abul', 'Initials': 'A', 'LastName': 'Khair', 'Affiliation': 'Filariasis Elimination and STH Control Program, Ministry of Health and Family Welfare, Dhaka 1000, Bangladesh.'}, {'ForeName': 'Asm Sultan', 'Initials': 'AS', 'LastName': 'Mahmood', 'Affiliation': 'Filariasis Elimination and STH Control Program, Ministry of Health and Family Welfare, Dhaka 1000, Bangladesh.'}, {'ForeName': 'Akm Fazlur', 'Initials': 'AF', 'LastName': 'Rahman', 'Affiliation': 'Centre for Injury Prevention and Research Bangladesh, Dhaka 1206, Bangladesh.'}, {'ForeName': 'Salim Mahmud', 'Initials': 'SM', 'LastName': 'Chowdhury', 'Affiliation': 'Centre for Injury Prevention and Research Bangladesh, Dhaka 1206, Bangladesh.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'College of Medicine and Public Health, Flinders University, Bedford Park SA 5042, Australia.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Betts', 'Affiliation': 'Centre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Taylor', 'Affiliation': 'Centre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Kelly-Hope', 'Affiliation': 'Centre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.'}]",Journal of clinical medicine,['10.3390/jcm9082444'] 2477,32751812,Does A Multiple-Sport Intervention Based on the TGfU Pedagogical Model for Physical Education Increase Physical Fitness in Primary School Children?,"Teaching Games for Understanding (TGfU) is one of the pedagogical models used for increasing health through physical education (PE), being associated with several psychological benefits. However, only few studies have studied the effect of TGfU on physical fitness. This study aims at assessing the changes in students' physical fitness after a six-month TGfU-based program with primary school children. A total of eight schools from the state of Sonora (Mexico) were randomly distributed into experimental (EG) and control group (CG). The final sample consisted of 188 pupils (100 boys, 88 girls; age = 10.22 ± 0.76 years) from the 5th and 6th grade. Employing a quasi-experimental design, physical fitness was assessed by means of the Eurofit test battery. At post-test, EG obtained significantly higher scores than CG in flexibility, abdominals, speed ( p < 0.001), handgrip ( p = 0.002), low-limb power ( p = 0.032), and cardiorespiratory fitness ( p = 0.048). Our findings suggest that TGfU can be a valid alternative to traditional methodologies not only when the aim of a PE unit is to stimulate the cognitive domain, but also for the development of physical fitness attributes that may help pupils develop in a comprehensive manner.",2020,"At post-test, EG obtained significantly higher scores than CG in flexibility, abdominals, speed ( p < 0.001), handgrip ( p = 0.002), low-limb power ( p = 0.032), and cardiorespiratory fitness ( p = 0.048).","['Primary School Children', ""students' physical fitness after a six-month TGfU-based program with primary school children"", 'A total of eight schools from the state of Sonora (Mexico', '188 pupils (100 boys, 88 girls; age = 10.22 ± 0.76 years) from the 5th and 6th grade']",[],"['low-limb power', 'cardiorespiratory fitness']","[{'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0025885', 'cui_str': 'Mexico'}, {'cui': 'C0034121', 'cui_str': 'Pupil structure'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205439', 'cui_str': 'Fifth'}, {'cui': 'C0441800', 'cui_str': 'Grade'}]",[],"[{'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}]",188.0,0.0104797,"At post-test, EG obtained significantly higher scores than CG in flexibility, abdominals, speed ( p < 0.001), handgrip ( p = 0.002), low-limb power ( p = 0.032), and cardiorespiratory fitness ( p = 0.048).","[{'ForeName': 'Armando', 'Initials': 'A', 'LastName': 'Cocca', 'Affiliation': 'Department of Sport Science, University of Innsbruck, Fürstenweg 185, 6020 Innsbruck, Austria.'}, {'ForeName': 'Jovanny Edmundo', 'Initials': 'JE', 'LastName': 'Carbajal Baca', 'Affiliation': 'Degree in Sport Training, State University of Sonora, Boulevard Rosales 189, Colonia Centro, 83079 Hermosillo, Mexico.'}, {'ForeName': 'Germán', 'Initials': 'G', 'LastName': 'Hernández Cruz', 'Affiliation': 'School of Sport Organization, Autonomous University of Nuevo Leon, Ciudad Universitaria s/n, 66455 San Nicolás de los Garza, Mexico.'}, {'ForeName': 'Michaela', 'Initials': 'M', 'LastName': 'Cocca', 'Affiliation': 'School of Sport Organization, Autonomous University of Nuevo Leon, Ciudad Universitaria s/n, 66455 San Nicolás de los Garza, Mexico.'}]",International journal of environmental research and public health,['10.3390/ijerph17155532'] 2478,32751813,"Effect of Functional Progressive Resistance Exercise on Lower Extremity Structure, Muscle Tone, Dynamic Balance and Functional Ability in Children with Spastic Cerebral Palsy.","The purpose of this study was to investigate the effects of functional progressive resistance exercise (FPRE) on muscle tone, dynamic balance and functional ability in children with spastic cerebral palsy. Twenty-five subjects were randomized into two groups: the FPRE group ( n = 13) and the control group ( n = 12). The experimental group participated in an FPRE program for 30 min per day, three times per week for six weeks. Knee extensor strength, rehabilitative ultrasound imaging (RUSI), muscle tone, dynamic balance, and functional ability was evaluated. The results showed statistically significant time × group interaction effects on the dominant side for knee extensor strength and cross-sectional area (CSA) in RUSI ( p < 0.05). On both sides for thickness of the quadriceps (TQ) in RUSI, muscle tone and dynamic balance were statistically significant time × group interaction effects ( p < 0.05). Additionally, knee extensor strength, CSA, TQ in RUS, muscle tone, dynamic balance and gross motor function measure (GMFM) in functional ability were significantly increased between pre- and post-intervention within the FPRE group ( p < 0.05). The results suggest that FPRE is both feasible and beneficial for improving muscle tone, dynamic balance and functional ability in children with spastic cerebral palsy.",2020,The results showed statistically significant time × group interaction effects on the dominant side for knee extensor strength and cross-sectional area (CSA) in RUSI ( p < 0.05).,"['Children with Spastic Cerebral Palsy', 'children with spastic cerebral palsy', 'Twenty-five subjects']","['FPRE', 'FPRE program', 'Functional Progressive Resistance Exercise', 'functional progressive resistance exercise (FPRE']","['Knee extensor strength, rehabilitative ultrasound imaging (RUSI), muscle tone, dynamic balance, and functional ability', 'thickness of the quadriceps (TQ) in RUSI, muscle tone and dynamic balance', 'muscle tone, dynamic balance and functional ability', 'knee extensor strength, CSA, TQ in RUS, muscle tone, dynamic balance and gross motor function measure (GMFM) in functional ability', 'Lower Extremity Structure, Muscle Tone, Dynamic Balance and Functional Ability', 'knee extensor strength and cross-sectional area (CSA) in RUSI']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0338596', 'cui_str': 'Spastic cerebral palsy'}, {'cui': 'C3715062', 'cui_str': '25'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0026841', 'cui_str': 'Muscle Tension'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0010592', 'cui_str': 'Cyclosporine'}, {'cui': 'C0035967', 'cui_str': 'Russian language'}, {'cui': 'C0677549', 'cui_str': 'Gross motor functions'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]",25.0,0.012935,The results showed statistically significant time × group interaction effects on the dominant side for knee extensor strength and cross-sectional area (CSA) in RUSI ( p < 0.05).,"[{'ForeName': 'Hye-Jin', 'Initials': 'HJ', 'LastName': 'Cho', 'Affiliation': 'Graduate School of Physical Therapy, Sahmyook University, Seoul 01795, Korea.'}, {'ForeName': 'Byoung-Hee', 'Initials': 'BH', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Therapy, Sahmyook University, Seoul 01795, Korea.'}]","Children (Basel, Switzerland)",['10.3390/children7080085'] 2479,32751954,Distinguishing and Biochemical Phenotype Analysis of Epilepsy Patients Using a Novel Serum Profiling Platform.,"Diagnosis of non-symptomatic epilepsy includes a history of two or more seizures and brain imaging to rule out structural changes like trauma, tumor, infection. Such analysis can be problematic. It is important to develop capabilities to help identify non-symptomatic epilepsy in order to better monitor and understand the condition. This understanding could lead to improved diagnostics and therapeutics. Serum mass peak profiling was performed using electrospray ionization mass spectrometry (ESI-MS). A comparison of sera mass peaks between epilepsy and control groups was performed via leave one [serum sample] out cross-validation (LOOCV). MS/MS peptide analysis was performed on serum mass peaks to compare epilepsy patient and control groups. LOOCV identified significant differences between the epilepsy patient group and control group ( p = 10 -22 ). This value became non-significant ( p = 0.10) when the samples were randomly allocated between the groups and reanalyzed by LOOCV. LOOCV was thus able to distinguish a non-symptomatic epilepsy patient group from a control group based on physiological differences and underlying phenotype. MS/MS was able to identify potential peptide/protein changes involved in this epilepsy versus control comparison, with 70% of the top 100 proteins indicating overall neurologic function. Specifically, peptide/protein sera changes suggested neuro-inflammatory, seizure, ion-channel, synapse, and autoimmune pathways changing between epilepsy patients and controls.",2020,LOOCV was thus able to distinguish a non-symptomatic epilepsy patient group from a control group based on physiological differences and underlying phenotype.,[],['LOOCV'],['overall neurologic function'],[],"[{'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C1550100', 'cui_str': 'Serum specimen'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0027767', 'cui_str': 'Nervous system function'}]",,0.0168631,LOOCV was thus able to distinguish a non-symptomatic epilepsy patient group from a control group based on physiological differences and underlying phenotype.,"[{'ForeName': 'Jay S', 'Initials': 'JS', 'LastName': 'Hanas', 'Affiliation': 'Department of Biochemistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.'}, {'ForeName': 'James R S', 'Initials': 'JRS', 'LastName': 'Hocker', 'Affiliation': 'Department of Biochemistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Vannarath', 'Affiliation': 'Department of Biochemistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.'}, {'ForeName': 'Betcy', 'Initials': 'B', 'LastName': 'Evangeline', 'Affiliation': 'Department of Neurological Sciences, Christian Medical College, Vellore 632004, India.'}, {'ForeName': 'Vasudevan', 'Initials': 'V', 'LastName': 'Prabhakaran', 'Affiliation': 'Department of Neurological Sciences, Christian Medical College, Vellore 632004, India.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Oommen', 'Affiliation': 'Department of Neurological Sciences, Christian Medical College, Vellore 632004, India.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Couch', 'Affiliation': 'Department of Neurology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Anderson', 'Affiliation': 'Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.'}, {'ForeName': 'Vedantam', 'Initials': 'V', 'LastName': 'Rajshekhar', 'Affiliation': 'Department of Neurological Sciences, Christian Medical College, Vellore 632004, India.'}, {'ForeName': 'Hélène', 'Initials': 'H', 'LastName': 'Carabin', 'Affiliation': 'Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Drevets', 'Affiliation': 'Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.'}]",Brain sciences,['10.3390/brainsci10080504'] 2480,32752021,Effectiveness of Different Front-of-Pack Nutrition Labels among Italian Consumers: Results from an Online Randomized Controlled Trial.,"In Italy, discussions are currently ongoing to implement a front-of-pack nutrition label (FoPL) while a growing number of European countries are adopting the Nutri-Score. The effectiveness of the Nutri-Score among Italian consumers requires further investigation. This study compared five FoPLs among Italian participants (Health Star Rating system, multiple traffic lights, Nutri-Score, reference intakes, warning symbol) in terms of food choices and understanding of the labels by consumers. In 2019, 1032 Italian consumers completed an online survey in which they were asked to select one product they would likely purchase from a set of three foods with different nutrient profiles and then classify the products within the set according to their nutritional quality, first with no label and then with one of the five FoPLs on the pack. While no significant difference across labels was observed for food choices, the Nutri-Score demonstrated the highest overall performance in helping consumers to correctly rank the products according to their nutritional quality compared to the reference intakes (OR = 2.18 (1.50-3.17), p -value < 0.0001). Our results provide new insights on the effectiveness of the Nutri-Score, which would be a relevant tool to inform Italian consumers on the nutritional quality of food products.",2020,"While no significant difference across labels was observed for food choices, the Nutri-Score demonstrated the highest overall performance in helping consumers to correctly rank the products according to their nutritional quality compared to the reference intakes (OR = 2.18 (1.50-3.17), p -value < 0.0001).","['Italian participants (Health Star Rating system, multiple traffic lights, Nutri-Score, reference intakes, warning symbol', 'In 2019, 1032 Italian consumers completed an online survey', 'Italian Consumers']",['Different Front-of-Pack Nutrition Labels'],[],"[{'cui': 'C0022275', 'cui_str': 'Italian language'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0282064', 'cui_str': 'Stars, Celestial'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0442664', 'cui_str': 'Traffic light'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]","[{'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0184967', 'cui_str': 'Insertion of pack'}, {'cui': 'C0028711', 'cui_str': 'Nutrition Labeling'}]",[],,0.0519772,"While no significant difference across labels was observed for food choices, the Nutri-Score demonstrated the highest overall performance in helping consumers to correctly rank the products according to their nutritional quality compared to the reference intakes (OR = 2.18 (1.50-3.17), p -value < 0.0001).","[{'ForeName': 'Morgane', 'Initials': 'M', 'LastName': 'Fialon', 'Affiliation': 'Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Cnam, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), 93000 Bobigny, France.'}, {'ForeName': 'Manon', 'Initials': 'M', 'LastName': 'Egnell', 'Affiliation': 'Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Cnam, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), 93000 Bobigny, France.'}, {'ForeName': 'Zenobia', 'Initials': 'Z', 'LastName': 'Talati', 'Affiliation': 'School of Psychology, Curtin University, Kent St, Bentley, WA 6102, Australia.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Galan', 'Affiliation': 'Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Cnam, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), 93000 Bobigny, France.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Dréano-Trécant', 'Affiliation': 'Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Cnam, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), 93000 Bobigny, France.'}, {'ForeName': 'Mathilde', 'Initials': 'M', 'LastName': 'Touvier', 'Affiliation': 'Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Cnam, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), 93000 Bobigny, France.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Pettigrew', 'Affiliation': 'The George Institute for Global Health, Newtown, Sydney 2042, Australia.'}, {'ForeName': 'Serge', 'Initials': 'S', 'LastName': 'Hercberg', 'Affiliation': 'Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Cnam, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), 93000 Bobigny, France.'}, {'ForeName': 'Chantal', 'Initials': 'C', 'LastName': 'Julia', 'Affiliation': 'Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Cnam, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), 93000 Bobigny, France.'}]",Nutrients,['10.3390/nu12082307'] 2481,32579403,Comparison of 18 F-FDG PET-MR and fecal biomarkers in the assessment of disease activity in patients with ulcerative colitis.,"OBJECTIVE To compare the diagnostic performance of fecal biomarkers and 18 F-fludeoxyglucose ( 18 F-FDG) positron emmision tomography-MR (PET-MR) in the assessment of disease activity in patients with ulcerative colitis. METHODS This study was conducted under the framework of a single-center clinical trial (clinicaltrials.gov [NCT03781284]). N = 50 participants were enrolled. Fecal samples were collected before bowel preparation. All patients underwent whole-body 18 F-FDG PET-MR followed by ileocolonoscopy within 24 h. Diagnostic performance of five fecal biomarkers (calprotectin, lactoferrin, polymorphonuclear leukocyte elastase, S100A12 and eosinophil-derived neurotoxin), MR morphological parameters (MRmorph), diffusion-weighted imaging and PET in detecting active disease determined by Rachmilewitz endoscopic activity index (EAI) were evaluated and compared with each other. Correlations between fecal biomarkers, PET and endoscopy were calculated. RESULTS According to EAI, n = 38 patients presented with endoscopically active disease (16 mild, 19 moderate and 3 severe). All five biomarkers, PET and MRmorph could differentiate endoscopically active disease from endoscopic remission without significant difference regarding their operating characteristics (accuracies between 0.673 for calprotectin and 0.898 for lactoferrin). In predicting endoscopically moderate to severe disease, PET showed the highest diagnostic performance (accuracy = 0.857) compared to calprotectin and lactoferrin (accuracy = 0.633 and 0.735). PET had also the strongest correlation with endoscopy (ρ = 0.685, p < 0.001), while within fecal biomarkers the levels of lactoferrin and eosinophil-derived neurotoxin correlated significantly with EAI (ρ = 0.423 and 0.528, both p < 0.05). CONCLUSION Both fecal biomarkers and PET-MR were excellent non-invasive diagnostic tools in the assessment of disease activity in ulcerative colitis. ADVANCES IN KNOWLEDGE Both fecal biomarkers and PET-MR parameters are able to predict endoscopically active disease with comparable diagnostic performance. PET had the highest correlation with endoscopy and outperformed fecal biomarkers in differentiating moderate to severe from mild disease.",2020,"Both fecal biomarkers and PET-MR were excellent non-invasive diagnostic tools in the assessment of disease activity in ulcerative colitis. ","['38 patients presented with endoscopically active disease (16 mild, 19 moderate and 3 severe', '50 participants were enrolled', 'patients with ulcerative colitis']","['fecal biomarkers and 18 F-fludeoxyglucose ( 18 F-FDG) positron emmision tomography-MR (PET-MR', 'ileocolonoscopy']","['S100A12 and eosinophil-derived neurotoxin), MR morphological parameters (MRmorph), diffusion-weighted imaging and PET in detecting active disease determined by Rachmilewitz endoscopic activity index (EAI', 'highest diagnostic performance', 'levels of lactoferrin and eosinophil-derived neurotoxin']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}]","[{'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0302995', 'cui_str': 'Fluorine-18'}, {'cui': 'C0046056', 'cui_str': 'Fluorodeoxyglucose F18'}, {'cui': 'C0032744', 'cui_str': 'Positive beta particle'}, {'cui': 'C0040395', 'cui_str': 'Diagnostic tomography'}, {'cui': 'C0031268', 'cui_str': 'Companion Animals'}]","[{'cui': 'C0389073', 'cui_str': 'S100A12 protein, human'}, {'cui': 'C0059409', 'cui_str': 'Eosinophil Protein X'}, {'cui': 'C0543482', 'cui_str': 'morphology'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0598801', 'cui_str': 'Diffusion weighted magnetic resonance imaging'}, {'cui': 'C0031268', 'cui_str': 'Companion Animals'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0022942', 'cui_str': 'Lactoferrin'}]",50.0,0.139443,"Both fecal biomarkers and PET-MR were excellent non-invasive diagnostic tools in the assessment of disease activity in ulcerative colitis. ","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147 Essen, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Khamou', 'Affiliation': 'Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147 Essen, Germany.'}, {'ForeName': 'Benedikt Michael', 'Initials': 'BM', 'LastName': 'Schaarschmidt', 'Affiliation': 'Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147 Essen, Germany.'}, {'ForeName': 'Lale', 'Initials': 'L', 'LastName': 'Umutlu', 'Affiliation': 'Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147 Essen, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Forsting', 'Affiliation': 'Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147 Essen, Germany.'}, {'ForeName': 'Aydin', 'Initials': 'A', 'LastName': 'Demircioglu', 'Affiliation': 'Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147 Essen, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Haubold', 'Affiliation': 'Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147 Essen, Germany.'}, {'ForeName': 'Anna Katharina', 'Initials': 'AK', 'LastName': 'Koch', 'Affiliation': 'Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, Am Deimelsberg 34a, 45276 Essen, Germany.'}, {'ForeName': 'Nils-Martin', 'Initials': 'NM', 'LastName': 'Bruckmann', 'Affiliation': 'Department of Diagnostic and Interventional Radiology, University Hospital Dusseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany.'}, {'ForeName': 'Lino Morris', 'Initials': 'LM', 'LastName': 'Sawicki', 'Affiliation': 'Department of Diagnostic and Interventional Radiology, University Hospital Dusseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Herrmann', 'Affiliation': 'Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147 Essen, Germany.'}, {'ForeName': 'James Hunter', 'Initials': 'JH', 'LastName': 'Boone', 'Affiliation': 'Research and Development, TechLab, INC., 2001 Kraft Drive, Blacksburg, USA.'}, {'ForeName': 'Jost', 'Initials': 'J', 'LastName': 'Langhorst', 'Affiliation': 'Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, Am Deimelsberg 34a, 45276 Essen, Germany.'}]",The British journal of radiology,['10.1259/bjr.20200167'] 2482,31712617,Polygenic burden associated to oligodendrocyte precursor cells and radial glia influences the hippocampal volume changes induced by aerobic exercise in schizophrenia patients.,"Hippocampal volume decrease is a structural hallmark of schizophrenia (SCZ), and convergent evidence from postmortem and imaging studies suggests that it may be explained by changes in the cytoarchitecture of the cornu ammonis 4 (CA4) and dentate gyrus (DG) subfields. Increasing evidence indicates that aerobic exercise increases hippocampal volume in CA subfields and improves cognition in SCZ patients. Previous studies showed that the effects of exercise on the hippocampus might be connected to the polygenic burden of SCZ risk variants. However, little is known about cell type-specific genetic contributions to these structural changes. In this secondary analysis, we evaluated the modulatory role of cell type-specific SCZ polygenic risk scores (PRS) on volume changes in the CA1, CA2/3, and CA4/DG subfields over time. We studied 20 multi-episode SCZ patients and 23 healthy controls who performed aerobic exercise, and 21 multi-episode SCZ patients allocated to a control intervention (table soccer) for 3 months. Magnetic resonance imaging-based assessments were performed with FreeSurfer at baseline and after 3 months. The analyses showed that the polygenic burden associated with oligodendrocyte precursor cells (OPC) and radial glia (RG) significantly influenced the volume changes between baseline and 3 months in the CA4/DG subfield in SCZ patients performing aerobic exercise. A higher OPC- or RG-associated genetic risk burden was associated with a less pronounced volume increase or even a decrease in CA4/DG during the exercise intervention. We hypothesize that SCZ cell type-specific polygenic risk modulates the aerobic exercise-induced neuroplastic processes in the hippocampus.",2019,A higher OPC- or RG-associated genetic risk burden was associated with a less pronounced volume increase or even a decrease in CA4/DG during the exercise intervention.,"['schizophrenia patients', '20 multi-episode SCZ patients and 23 healthy controls who performed aerobic exercise, and 21 multi-episode SCZ patients allocated to a', 'SCZ patients']","['control intervention (table soccer', 'aerobic exercise']","['modulatory role of cell type-specific SCZ polygenic risk scores (PRS) on volume changes in the CA1, CA2/3, and CA4/DG subfields over time', 'CA4/DG', 'oligodendrocyte precursor cells (OPC) and radial glia (RG']","[{'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0039224', 'cui_str': 'Table'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}]","[{'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0694598', 'cui_str': 'CA1 Field of Hippocampus'}, {'cui': 'C3887642', 'cui_str': 'Hippocampus Proper'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C4505105', 'cui_str': 'Oligodendrocyte Precursors'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0027836', 'cui_str': 'Glia'}]",20.0,0.063119,A higher OPC- or RG-associated genetic risk burden was associated with a less pronounced volume increase or even a decrease in CA4/DG during the exercise intervention.,"[{'ForeName': 'Sergi', 'Initials': 'S', 'LastName': 'Papiol', 'Affiliation': 'Department of Psychiatry, University Hospital, Nussbaumstrasse 7, 80336, Munich, Germany. sergi.papiol@med.uni-muenchen.de.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Keeser', 'Affiliation': 'Department of Psychiatry, University Hospital, Nussbaumstrasse 7, 80336, Munich, Germany.'}, {'ForeName': 'Alkomiet', 'Initials': 'A', 'LastName': 'Hasan', 'Affiliation': 'Department of Psychiatry, University Hospital, Nussbaumstrasse 7, 80336, Munich, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Schneider-Axmann', 'Affiliation': 'Department of Psychiatry, University Hospital, Nussbaumstrasse 7, 80336, Munich, Germany.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Raabe', 'Affiliation': 'Department of Psychiatry, University Hospital, Nussbaumstrasse 7, 80336, Munich, Germany.'}, {'ForeName': 'Franziska', 'Initials': 'F', 'LastName': 'Degenhardt', 'Affiliation': 'Institute of Human Genetics, University of Bonn, Bonn, Germany.'}, {'ForeName': 'Moritz J', 'Initials': 'MJ', 'LastName': 'Rossner', 'Affiliation': 'Department of Psychiatry, University Hospital, Nussbaumstrasse 7, 80336, Munich, Germany.'}, {'ForeName': 'Heike', 'Initials': 'H', 'LastName': 'Bickeböller', 'Affiliation': 'Department of Genetic Epidemiology, University Medical Center, Georg-August-Universität Göttingen, Humboldtallee 32, 37073, Göttingen, Germany.'}, {'ForeName': 'Ludovico', 'Initials': 'L', 'LastName': 'Cantuti-Castelvetri', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen Str. 17, 81377, Munich, Germany.'}, {'ForeName': 'Mikael', 'Initials': 'M', 'LastName': 'Simons', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen Str. 17, 81377, Munich, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Wobrock', 'Affiliation': 'Department of Psychiatry and Psychotherapy, County Hospitals Darmstadt-Dieburg, Krankenhausstrasse 7, 64823, Groß-Umstadt, Germany.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Schmitt', 'Affiliation': 'Department of Psychiatry, University Hospital, Nussbaumstrasse 7, 80336, Munich, Germany.'}, {'ForeName': 'Berend', 'Initials': 'B', 'LastName': 'Malchow', 'Affiliation': 'Department of Psychiatry, University Hospital, Nussbaumstrasse 7, 80336, Munich, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Falkai', 'Affiliation': 'Department of Psychiatry, University Hospital, Nussbaumstrasse 7, 80336, Munich, Germany.'}]",Translational psychiatry,['10.1038/s41398-019-0618-z'] 2483,32753339,Less Is More: The Impact of Deprescribing Psychotropic Drugs on Behavioral and Psychological Symptoms and Daily Functioning in Nursing Home Patients. Results From the Cluster-Randomized Controlled COSMOS Trial.,"OBJECTIVE To investigate the impact of medication reviews using collegial mentoring and systematic clinical evaluation on psychotropic prescriptions, behavioral and psychological symptoms of dementia (BPSD), and activities of daily living (ADL). DESIGN Four-month multicenter, multicomponent, cluster-randomized, single-blinded controlled trial. SETTING Thirty-three Norwegian nursing homes including 67 nursing home wards (clusters). PARTICIPANTS A total of 723 enrolled patients, of which 428 participated in the study; 217 were randomized to the intervention and 211 to care as usual (control). INTERVENTION The COSMOS intervention consisted of Communication, Systematic pain management, Medication reviews, Organization of activities, and Safety. During medication review, the nursing home physician evaluated treatment with colleagues systematically using the results from validated clinical assessments. MEASUREMENTS Mean changes from baseline to month 4 in the number of prescribed psychotropic drugs (antipsychotics, anxiolytics, hypnotics or sedatives, antidepressants, and antidementia drugs); Neuropsychiatric Inventory Nursing Home Version (NPI-NH) and Cornell Scale of Depression in Dementia (CSDD); Lawton and Brody's Physical Self Maintenance Scale (PSMS). RESULTS Compared to control, the mean change in prescribed psychotropic drugs was reduced both in total and regular number, while mean changes in NPI-NH and CSDD scores did not differ between the groups. Mean change in PSMS showed improvement in the intervention group, and deterioration in the control group. CONCLUSION Medication reviews using collegial mentoring and systematic clinical evaluation led to safe deprescribing, as the reductions in psychotropic drug use did not negatively affect BPSD, while ADL improved.",2020,"Mean change in PSMS showed improvement in the intervention group, and deterioration in the control group. ","['A total of 723 enrolled patients, of which 428 participated in the study; 217 were randomized to the intervention and 211 to care as usual (control', 'Nursing Home Patients', 'Thirty-three Norwegian nursing homes including 67 nursing home wards (clusters']",[],"['Mean change in PSMS', ""number of prescribed psychotropic drugs (antipsychotics, anxiolytics, hypnotics or sedatives, antidepressants, and antidementia drugs); Neuropsychiatric Inventory Nursing Home Version (NPI-NH) and Cornell Scale of Depression in Dementia (CSDD); Lawton and Brody's Physical Self Maintenance Scale (PSMS"", 'psychotropic prescriptions, behavioral and psychological symptoms of dementia (BPSD), and activities of daily living (ADL', 'NPI-NH and CSDD scores', 'Behavioral and Psychological Symptoms and Daily Functioning']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517866', 'cui_str': '723'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517775', 'cui_str': '428'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517646', 'cui_str': '217'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0028424', 'cui_str': 'Norwegian language'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1275588', 'cui_str': 'Physical self maintenance scale'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0033978', 'cui_str': 'Psychotherapeutic agent'}, {'cui': 'C0040615', 'cui_str': 'Antipsychotic agent'}, {'cui': 'C0040616', 'cui_str': 'Anxiolytic agent'}, {'cui': 'C0020591', 'cui_str': 'Hypnotic agent'}, {'cui': 'C0020592', 'cui_str': 'HYPNOTICS AND SEDATIVES'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C4285807', 'cui_str': 'Behavioral and psychological symptoms of dementia'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0233397', 'cui_str': 'Psychological symptom'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",723.0,0.0755198,"Mean change in PSMS showed improvement in the intervention group, and deterioration in the control group. ","[{'ForeName': 'Marie H', 'Initials': 'MH', 'LastName': 'Gedde', 'Affiliation': 'Centre for Elderly and Nursing Home Medicine, Department of Global Public Health and Primary Care, Faculty of Medicine, University of Bergen, Bergen, Norway; Haraldsplass Deaconess Hospital, Bergen, Norway. Electronic address: marie.gedde@uib.no.'}, {'ForeName': 'Bettina S', 'Initials': 'BS', 'LastName': 'Husebo', 'Affiliation': 'Centre for Elderly and Nursing Home Medicine, Department of Global Public Health and Primary Care, Faculty of Medicine, University of Bergen, Bergen, Norway; Municipality of Bergen, Bergen, Norway.'}, {'ForeName': 'Janne', 'Initials': 'J', 'LastName': 'Mannseth', 'Affiliation': 'Section for Epidemiology and Medical Statistic, Department of Global Public Health and Primary Care, Faculty of Medicine, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Reidun L S', 'Initials': 'RLS', 'LastName': 'Kjome', 'Affiliation': 'Centre for Pharmacy/Department for Global Public Health and Primary Care, Faculty of Medicine, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Mala', 'Initials': 'M', 'LastName': 'Naik', 'Affiliation': 'Haraldsplass Deaconess Hospital, Bergen, Norway; Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Line I', 'Initials': 'LI', 'LastName': 'Berge', 'Affiliation': 'Centre for Elderly and Nursing Home Medicine, Department of Global Public Health and Primary Care, Faculty of Medicine, University of Bergen, Bergen, Norway; NKS Olaviken Gerontopsychiatric Hospital, Bergen, Norway.'}]",The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,['10.1016/j.jagp.2020.07.004'] 2484,32753348,Oxidation of dietary linoleate occurs to a greater extent than dietary palmitate in vivo in humans.,"BACKGROUND It has been suggested that dietary polyunsaturated fatty acids (PUFA) are partitioned into oxidation pathways to a greater extent than dietary saturated fatty acids (SFA). Whilst this has been demonstrated in animal models, evidence in humans is lacking. The potential divergence in the metabolic fate of these dietary fatty acids (FA) may explain some of the reported differences in ectopic fat deposition with SFA and PUFA enriched diets. AIMS To compare whole-body oxidation of dietary palmitate and linoleate after consumption of a single test meal. METHODS In a randomized, crossover design 24 healthy volunteers (12 males and 12 females, matched for age and BMI) underwent two study days separated by 2-week washout period. During each study day participants consumed a standardized test meal which contained [U 13 C]palmitate or [U 13 C]linoleate. Blood and breath samples were collected over the 6 h postprandial period and the 13 C enrichment in breath CO 2 samples and plasma lipid fractions was determined. RESULTS Appearance of 13 C in expired CO 2 was significantly (p < 0.05) increased after consumption of the meal containing [U 13 C]linoleate compared to the meal containing [U 13 C]palmitate. The recovery of tracer was 8.9 ± 1.2% [U 13 C]linoleate vs. 5.6 ± 0.4% [U 13 C]palmitate (p < 0.05). The incorporation of 13 C from [U 13 C]palmitate was greater in plasma triacylglycerol and non-esterified fatty acids than [U 13 C]linoleate, whereas the incorporation of 13 C from [U 13 C]linoleate was greater than [U 13 C]palmitate in plasma phospholipids. Although 13 CO 2 was significantly (p < 0.05) higher in females compared to males after consumption of [U 13 C]palmitate, there was no difference in 13 CO 2 between sexes after consumption of [U 13 C]linoleate. CONCLUSIONS We demonstrate that whole-body oxidation of dietary linoleate is comparatively higher than that of dietary palmitate in humans following consumption of a single mixed-test meal. We found indications of sexual dimorphism for dietary palmitate but not dietary linoleate. STUDY REGISTRATION http://www.clinicaltrials.org/ ID number NCT03587753.",2020,"RESULTS Appearance of 13 C in expired CO 2 was significantly (p < 0.05) increased after consumption of the meal containing [U 13 C]linoleate compared to the meal containing [U 13 C]palmitate.","['24 healthy volunteers (12 males and 12 females, matched for age and BMI']","['dietary polyunsaturated fatty acids (PUFA', 'dietary palmitate and linoleate', 'dietary palmitate']","['recovery of tracer', 'Blood and breath samples', 'plasma triacylglycerol and non-esterified fatty acids']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0030233', 'cui_str': 'Hexadecanoates'}, {'cui': 'C0220871', 'cui_str': 'linoleate'}]","[{'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0225386', 'cui_str': 'Breath'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0369212', 'cui_str': 'Esterified fatty acid'}]",24.0,0.0206381,"RESULTS Appearance of 13 C in expired CO 2 was significantly (p < 0.05) increased after consumption of the meal containing [U 13 C]linoleate compared to the meal containing [U 13 C]palmitate.","[{'ForeName': 'Siôn A', 'Initials': 'SA', 'LastName': 'Parry', 'Affiliation': 'Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford, UK.'}, {'ForeName': 'Fredrik', 'Initials': 'F', 'LastName': 'Rosqvist', 'Affiliation': 'Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford, UK; Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Cornfield', 'Affiliation': 'Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford, UK.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Barrett', 'Affiliation': 'Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford, UK.'}, {'ForeName': 'Leanne', 'Initials': 'L', 'LastName': 'Hodson', 'Affiliation': 'Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford, UK; Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK. Electronic address: leanne.hodson@ocdem.ox.ac.uk.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.07.013'] 2485,32753414,Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al .,,2020,,['systemic lupus erythematosus'],"['subcutaneous belimumab and long-term antimalarial treatment', 'belimumab treatment', 'placebo']",['antiphospholipid antibodies levels'],"[{'cui': 'C0024141', 'cui_str': 'Systemic lupus erythematosus'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C1723401', 'cui_str': 'belimumab'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0003374', 'cui_str': 'Antimalarial'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0162595', 'cui_str': 'Anti-phospholipid antibody'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.470362,,"[{'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Bettiol', 'Affiliation': 'Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Firenze, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Pregnolato', 'Affiliation': 'Experimental Laboratory of Immuno-rheumatology, Istituto Auxologico Italiano, IRCCS, Cusano Milanino, Italy.'}, {'ForeName': 'Savino', 'Initials': 'S', 'LastName': 'Sciascia', 'Affiliation': 'Dipartimento di Malattie Rare, Immunologiche, Ematologiche ed Immunoematologiche, Centro di Ricerche di Immunopatologia e Documentazione su Malattie Rare, Struttura Complessa a Direzione Universitaria di Immunologia Clinica, Ospedale Torino Nord Emergenza San G. Bosco ed Università di Torino, Torino, Italy.'}, {'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Emmi', 'Affiliation': 'Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy giacomo.emmi@unifi.it.'}, {'ForeName': 'Domenico', 'Initials': 'D', 'LastName': 'Prisco', 'Affiliation': 'Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy.'}, {'ForeName': 'Pier Luigi', 'Initials': 'PL', 'LastName': 'Meroni', 'Affiliation': 'Experimental Laboratory of Immuno-rheumatology, Istituto Auxologico Italiano, IRCCS, Cusano Milanino, Italy.'}]",Annals of the rheumatic diseases,['10.1136/annrheumdis-2020-218377'] 2486,32753416,Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al ' by Bettiol et al .,,2020,,['systemic lupus erythematosus'],"['subcutaneous belimumab and long-term antimalarial treatment', 'belimumab treatment', 'placebo']",['antiphospholipid antibodies levels'],"[{'cui': 'C0024141', 'cui_str': 'Systemic lupus erythematosus'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C1723401', 'cui_str': 'belimumab'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0003374', 'cui_str': 'Antimalarial'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0162595', 'cui_str': 'Anti-phospholipid antibody'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.398275,,"[{'ForeName': 'Katerina', 'Initials': 'K', 'LastName': 'Chatzidionysiou', 'Affiliation': '1st Department of Propaedeutic and Internal Medicine, Joint Rheumatology Program, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Attica, Greece.'}, {'ForeName': 'Evangelia', 'Initials': 'E', 'LastName': 'Samoli', 'Affiliation': 'Department of Hygiene, Epidemiology, and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Petros P', 'Initials': 'PP', 'LastName': 'Sfikakis', 'Affiliation': '1st Department of Propaedeutic and Internal Medicine, Joint Rheumatology Program, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Attica, Greece.'}, {'ForeName': 'Maria G', 'Initials': 'MG', 'LastName': 'Tektonidou', 'Affiliation': '1st Department of Propaedeutic and Internal Medicine, Joint Rheumatology Program, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Attica, Greece mtektonidou@gmail.com.'}]",Annals of the rheumatic diseases,['10.1136/annrheumdis-2020-218444'] 2487,32753452,FIRST-line support for assistance in breathing in children (FIRST-ABC): a master protocol of two randomised trials to evaluate the non-inferiority of high-flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in paediatric critical care.,"INTRODUCTION Even though respiratory support is a common intervention in paediatric critical care, there is no randomised controlled trial (RCT) evidence regarding the effectiveness of two commonly used modes of non-invasive respiratory support (NRS), continuous positive airway pressure (CPAP) and high-flow nasal cannula therapy (HFNC). FIRST-line support for assistance in breathing in children is a master protocol of two pragmatic non-inferiority RCTs to evaluate the clinical and cost-effectiveness of HFNC (compared with CPAP) as the first-line mode of support in critically ill children. METHODS AND ANALYSIS We will recruit participants over a 30-month period at 25 UK paediatric critical care units (paediatric intensive care units/high-dependency units). Patients are eligible if admitted/accepted for admission, aged >36 weeks corrected gestational age and <16 years, and assessed by the treating clinician to require NRS for an acute illness (step-up RCT) or within 72 hours of extubation following a period of invasive ventilation (step-down RCT). Due to the emergency nature of the treatment, written informed consent will be deferred to after randomisation. Randomisation will occur 1:1 to CPAP or HFNC, stratified by site and age (<12 vs ≥12 months). The primary outcome is time to liberation from respiratory support for a continuous period of 48 hours. A total sample size of 600 patients in each RCT will provide 90% power with a type I error rate of 2.5% (one sided) to exclude the prespecified non-inferiority margin of HR of 0.75. Primary analyses will be undertaken separately in each RCT in both the intention-to-treat and per-protocol populations. ETHICS AND DISSEMINATION This master protocol received favourable ethical opinion from National Health Service East of England-Cambridge South Research Ethics Committee (reference: 19/EE/0185) and approval from the Health Research Authority (reference: 260536). Results will be disseminated via publications in peer-reviewed medical journals and presentations at national and international conferences. TRIAL REGISTRATION NUMBER ISRCTN60048867.",2020,"Randomisation will occur 1:1 to CPAP or HFNC, stratified by site and age (<12 vs ≥12 months).","['600 patients in each', 'participants over a 30-month period at 25 UK paediatric critical care units (paediatric intensive care units/high-dependency units', 'Patients are eligible if admitted/accepted for admission, aged >36 weeks corrected gestational age and <16 years, and assessed by the treating clinician to require NRS for an acute illness (step-up RCT) or within 72\u2009hours of extubation following a period of invasive ventilation (step-down RCT', 'critically ill children']","['RCT', 'FIRST-line support', 'high-flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP', 'HFNC']",['time to liberation from respiratory support for a continuous period of 48\u2009hours'],"[{'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0021710', 'cui_str': 'Pediatric intensive care unit'}, {'cui': 'C1627345', 'cui_str': 'Stepdown unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0454366', 'cui_str': 'Step ups'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannulae'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0439586', 'cui_str': '48 hours'}]",,0.253144,"Randomisation will occur 1:1 to CPAP or HFNC, stratified by site and age (<12 vs ≥12 months).","[{'ForeName': 'Alvin', 'Initials': 'A', 'LastName': 'Richards-Belle', 'Affiliation': 'Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Davis', 'Affiliation': 'Paediatric Intensive Care, Bristol Royal Hospital for Children, Bristol, UK.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Drikite', 'Affiliation': 'Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Feltbower', 'Affiliation': 'Leeds Institute for Data Analytics, University of Leeds, Leeds, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Grieve', 'Affiliation': 'Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Harrison', 'Affiliation': 'Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, UK.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Lester', 'Affiliation': 'Parent representative, Sussex, UK.'}, {'ForeName': 'Kevin P', 'Initials': 'KP', 'LastName': 'Morris', 'Affiliation': ""Paediatric Intensive Care Unit, Birmingham Women's and Children's Hospitals NHS Foundation Trust, Birmingham, UK.""}, {'ForeName': 'Paul R', 'Initials': 'PR', 'LastName': 'Mouncey', 'Affiliation': 'Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, UK.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Peters', 'Affiliation': 'Paediatric Intensive Care Unit, Great Ormond Street Hospital For Children NHS Trust, London, UK.'}, {'ForeName': 'Kathryn M', 'Initials': 'KM', 'LastName': 'Rowan', 'Affiliation': 'Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, UK.'}, {'ForeName': 'Zia', 'Initials': 'Z', 'LastName': 'Sadique', 'Affiliation': 'Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Lyvonne N', 'Initials': 'LN', 'LastName': 'Tume', 'Affiliation': 'School of Health and Society, University of Salford, Salford, Greater Manchester, UK.'}, {'ForeName': 'Padmanabhan', 'Initials': 'P', 'LastName': 'Ramnarayan', 'Affiliation': ""Children's Acute Transport Service, Great Ormond Street Hospital For Children NHS Trust, London, UK p.ramnarayan@gosh.nhs.uk.""}]",BMJ open,['10.1136/bmjopen-2020-038002'] 2488,32753522,The Effect of Mobile Text Messages and a Novel Floss Holder on Gingival Health: A randomized control trial.,"Purpose: The purpose of this study was to evaluate the effects of using mobile text messages and a novel floss holder as compared to finger flossing or the novel floss holder alone, on the psychological, behavioral, and clinical parameters of patients with gingivitis. Methods: A total 165 adults were assessed for eligibility and 144 met the criteria for randomization into three groups: Finger Floss (FF, n=43), Novel Floss Holder (NFH, n= 40), and Novel Floss Holder plus Text Messages (NFH+TM, n= 61) following a dental hygiene consultation appointment. Gingival bleeding points were measured on probing (BOMP) at baseline and four months later by a calibrated dental hygienist, blinded to the experimental groups. Participants also self-reported their oral hygiene behaviors, and indicated psychological determinants of behavior change prior to the dental hygiene consultation and at four months. Descriptive statistics and repeated measures analysis of variance (ANOVA) were used to compare groups over time. Results: Two subjects dropped out of the study making the total number of participants 142. At the four month follow-up, the NFH group and the NFH+TM groups demonstrated significantly higher levels of self-reported flossing, action self-efficacy, intention, action planning, and action control. The NFH+TM group showed lower levels of bleeding and higher levels of oral hygiene and recovery self-efficacy than the other groups, in addition to higher levels of maintenance self-efficacy as compared to the FF group. Conclusions: The use of a novel floss holder, NFH, was shown to improve the behavioral and psychological determinants of periodontal health four months after introduction of the device. However the clinical measures of BOMP only improved significantly when used in conjunction with text messages (NFH+TM). The use of a consciousness awareness technique,TMs, in combination with a novel device, may help patients to reach therapeutic objectives and contribute to the management of periodontal pathologies such as gingivitis.",2020,"The NFH+TM group showed lower levels of bleeding and higher levels of oral hygiene and recovery self-efficacy than the other groups, in addition to higher levels of maintenance self-efficacy as compared to the FF group.","['on Gingival Health', 'Two subjects dropped out of the study making the total number of participants 142', 'patients with gingivitis', 'total 165 adults were assessed for eligibility and 144 met the criteria for randomization into three groups: Finger Floss (FF, n=43']","['NFH+TM', 'dental hygiene consultation appointment', 'Novel Floss Holder (NFH, n= 40), and Novel Floss Holder plus Text Messages (NFH+TM, n', 'NFH', 'mobile text messages', 'Mobile Text Messages and a Novel Floss Holder']","['levels of self-reported flossing, action self-efficacy, intention, action planning, and action control', 'Gingival bleeding points', 'BOMP', 'oral hygiene behaviors', 'levels of bleeding and higher levels of oral hygiene and recovery self-efficacy', 'maintenance self-efficacy']","[{'cui': 'C0017562', 'cui_str': 'Gingival structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0016129', 'cui_str': 'Digit of hand structure'}]","[{'cui': 'C0029164', 'cui_str': 'Dental Hygiene'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C1551377', 'cui_str': 'Holder'}, {'cui': 'C0332123', 'cui_str': 'No family history of'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0017565', 'cui_str': 'Bleeding gums'}, {'cui': 'C0053926', 'cui_str': 'BOMP protocol'}, {'cui': 'C0029164', 'cui_str': 'Dental Hygiene'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}]",165.0,0.0182216,"The NFH+TM group showed lower levels of bleeding and higher levels of oral hygiene and recovery self-efficacy than the other groups, in addition to higher levels of maintenance self-efficacy as compared to the FF group.","[{'ForeName': 'Mário-Rui', 'Initials': 'MR', 'LastName': 'Araújo', 'Affiliation': ''}, {'ForeName': 'Maria-João', 'Initials': 'MJ', 'LastName': 'Alvarez', 'Affiliation': ''}, {'ForeName': 'Cristina A', 'Initials': 'CA', 'LastName': 'Godinho', 'Affiliation': ''}]",Journal of dental hygiene : JDH,[] 2489,32753545,Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.,"Treatment of metastatic melanoma with autologous tumor infiltrating lymphocytes (TILs) is currently applied in several centers. Robust and remarkably consistent overall response rates, of around 50% of treated patients, have been observed across hospitals, including a substantial fraction of durable, complete responses. PURPOSE Execute a phase I/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized phase III trial. EXPERIMENTAL Ten patients were treated with TIL therapy. Infusion products and peripheral blood samples were phenotypically characterized and neoantigen reactivity was assessed. Here, we present long-term clinical outcome and translational data on neoantigen reactivity of the T cell products. RESULTS Five out of 10 patients, who were all anti-PD-1 naïve at time of treatment, showed an objective clinical response, including two patients with a complete response that are both ongoing for more than 7 years. Immune monitoring demonstrated that neoantigen-specific T cells were detectable in TIL infusion products from three out of three patients analyzed. For six out of the nine neoantigen-specific T cell responses detected in these TIL products, T cell response magnitude increased significantly in the peripheral blood compartment after therapy, and neoantigen-specific T cells were detectable for up to 3 years after TIL infusion. CONCLUSION The clinical results from this study confirm the robustness of TIL therapy in metastatic melanoma and the potential role of neoantigen-specific T cell reactivity. In addition, the data from this study supported the rationale to initiate an ongoing multicenter phase III TIL trial.",2020,Immune monitoring demonstrated that neoantigen-specific T cells were detectable in TIL infusion products from three out of three patients analyzed.,"['metastatic melanoma', 'metastatic melanoma at the Netherlands Cancer Institute', 'metastatic melanoma with autologous tumor infiltrating lymphocytes (TILs']",['TIL therapy'],"['neoantigen-specific T cells', 'overall response rates']","[{'cui': 'C0278883', 'cui_str': 'Metastatic melanoma'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0079722', 'cui_str': 'Tumor-Infiltrating Lymphocytes'}]","[{'cui': 'C0280661', 'cui_str': 'TIL therapy'}]","[{'cui': 'C0312555', 'cui_str': 'Neoantigen'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",2.0,0.0473248,Immune monitoring demonstrated that neoantigen-specific T cells were detectable in TIL infusion products from three out of three patients analyzed.,"[{'ForeName': 'Joost H', 'Initials': 'JH', 'LastName': 'van den Berg', 'Affiliation': 'BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Bianca', 'Initials': 'B', 'LastName': 'Heemskerk', 'Affiliation': 'Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Nienke', 'Initials': 'N', 'LastName': 'van Rooij', 'Affiliation': 'Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Gomez-Eerland', 'Affiliation': 'Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Samira', 'Initials': 'S', 'LastName': 'Michels', 'Affiliation': 'Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Maaike', 'Initials': 'M', 'LastName': 'van Zon', 'Affiliation': 'BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Renate', 'Initials': 'R', 'LastName': 'de Boer', 'Affiliation': 'BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Noor A M', 'Initials': 'NAM', 'LastName': 'Bakker', 'Affiliation': 'BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Annelies', 'Initials': 'A', 'LastName': 'Jorritsma-Smit', 'Affiliation': 'Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Marit M', 'Initials': 'MM', 'LastName': 'van Buuren', 'Affiliation': 'Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Pia', 'Initials': 'P', 'LastName': 'Kvistborg', 'Affiliation': 'Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Hergen', 'Initials': 'H', 'LastName': 'Spits', 'Affiliation': 'AIMM Therapeutics, Amsterdam, The Netherlands.'}, {'ForeName': 'Remko', 'Initials': 'R', 'LastName': 'Schotte', 'Affiliation': 'AIMM Therapeutics, Amsterdam, The Netherlands.'}, {'ForeName': 'Henk', 'Initials': 'H', 'LastName': 'Mallo', 'Affiliation': 'Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Karger', 'Affiliation': 'Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Joris A', 'Initials': 'JA', 'LastName': 'van der Hage', 'Affiliation': 'Department of Surgery, Leiden Universitair Medisch Centrum, Leiden, Zuid-Holland, The Netherlands.'}, {'ForeName': 'Michel W J M', 'Initials': 'MWJM', 'LastName': 'Wouters', 'Affiliation': 'Surgical Oncology, Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, The Netherlands.'}, {'ForeName': 'Loes M', 'Initials': 'LM', 'LastName': 'Pronk', 'Affiliation': 'Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Marnix H', 'Initials': 'MH', 'LastName': 'Geukes Foppen', 'Affiliation': 'Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Christian U', 'Initials': 'CU', 'LastName': 'Blank', 'Affiliation': 'Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, The Netherlands.'}, {'ForeName': 'Jos H', 'Initials': 'JH', 'LastName': 'Beijnen', 'Affiliation': 'Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Bastiaan', 'Initials': 'B', 'LastName': 'Nuijen', 'Affiliation': 'Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Ton N', 'Initials': 'TN', 'LastName': 'Schumacher', 'Affiliation': 'Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'John B A G', 'Initials': 'JBAG', 'LastName': 'Haanen', 'Affiliation': 'Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands j.haanen@nki.nl.'}]",Journal for immunotherapy of cancer,['10.1136/jitc-2020-000848'] 2490,32753780,Pulsed ND:YAG laser combined with progressive pressure release in the treatment of cervical myofascial pain syndrome: a randomized control trial.,"[Purpose] To investigate the effect of pulsed Nd:YAG laser combined with the progressive pressure release technique (PPRT) and exercises in the treatment of myofascial trigger points (MTrPs) in patients with myofascial pain syndrome (MPS). [Participants and Methods] A total of 50 patients with MTrPs in the upper trapezius muscle participated in the study. The patients were randomly assigned to two groups and treated with laser plus PPRT (Laser + PPRT group) or placebo laser and exercises (PL + PPRT group). The laser was applied for eight MTrPs with a 50 J/point. PPRT was applied for 30 seconds for each point. Exercises included strengthening and stretching exercises applied three times per week for four weeks. A visual analogue scale (VAS) and pressure pain threshold (PPT) were used to measure pain and pain threshold, respectively. A cervical range of motion device (CROM) was used to measure the cervical range of motion. [Results] Both treatment groups showed significant improvement in CROM, PPT, and VAS post-treatment with a more significant effect in the Laser + PPRT group compared to the PL + PPRT group. [Conclusion] PPRT and exercises alone or that in combination with laser therapy were effective in the treatment of active MTrPs in patients with MPS.",2020,"Both treatment groups showed significant improvement in CROM, PPT, and VAS post-treatment with a more significant effect in the Laser + PPRT group compared to the PL + PPRT group.","['patients with myofascial pain syndrome (MPS', 'patients with MPS', '50 patients with MTrPs in the upper trapezius muscle participated in the study', 'Participants and Methods', 'cervical myofascial pain syndrome']","['Pulsed ND:YAG laser combined with progressive pressure release', 'PPRT', 'motion device (CROM', 'pulsed Nd:YAG laser combined with the progressive pressure release technique (PPRT) and exercises', 'laser therapy', 'laser plus PPRT (Laser + PPRT group) or placebo laser and exercises (PL + PPRT group', 'PL + PPRT']","['CROM, PPT, and VAS', 'A visual analogue scale (VAS) and pressure pain threshold (PPT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0458343', 'cui_str': 'Trigger point'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0224361', 'cui_str': 'Structure of trapezius muscle'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0458110', 'cui_str': 'Myofascial pain syndrome of neck'}]","[{'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0392276', 'cui_str': 'Neodymium-YAG laser'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",50.0,0.0218477,"Both treatment groups showed significant improvement in CROM, PPT, and VAS post-treatment with a more significant effect in the Laser + PPRT group compared to the PL + PPRT group.","[{'ForeName': 'Mohamed Salaheldein', 'Initials': 'MS', 'LastName': 'Alayat', 'Affiliation': 'Faculty of Applied Medical Science, Umm Al-Qura University: 4888 Bathaa Qurish, Mecca 21955, Saudi Arabia.'}, {'ForeName': 'Kadrya Hosney', 'Initials': 'KH', 'LastName': 'Battecha', 'Affiliation': 'Faculty of Applied Medical Science, Umm Al-Qura University: 4888 Bathaa Qurish, Mecca 21955, Saudi Arabia.'}, {'ForeName': 'Ahmed Mohamed', 'Initials': 'AM', 'LastName': 'ELsodany', 'Affiliation': 'Faculty of Applied Medical Science, Umm Al-Qura University: 4888 Bathaa Qurish, Mecca 21955, Saudi Arabia.'}, {'ForeName': 'Mohamed Ibrahim', 'Initials': 'MI', 'LastName': 'Ali', 'Affiliation': 'Faculty of Applied Medical Science, Umm Al-Qura University: 4888 Bathaa Qurish, Mecca 21955, Saudi Arabia.'}]",Journal of physical therapy science,['10.1589/jpts.32.422'] 2491,32753845,Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects.,"Purpose Glimepiride, an FDA-approved oral hypoglycemic drug, is a long-acting sulfonylurea (SU), used for treating type 2 diabetes. The study aimed to evaluate the bioequivalence and safety profiles of two different formulations of glimepiride 1 mg from two different manufactures in healthy Chinese subjects in the fasting and fed state in order to acquire adequate pharmacokinetic evidence for registration approval of the test formulation. Patients and Methods This study is an open-label, two-period, two-sequence, randomized, two-way crossover pharmacokinetic study in healthy Chinese subjects in the fasting and fed state. Seventy-two subjects were randomly assigned to the fasting group and the fed group (n=36 each). We collected blood samples, 24-h post drug administration. The plasma concentration of glimepiride was assessed using HPLC coupled with mass spectrometry. The following parameters were evaluated: AUC 0-inf , AUC 0-last , C max , t 1⁄2 , T max , and λ z . Safety was determined based on the occurrence of adverse events (AEs) and laboratory examinations (biochemistry, hematology, and urinalysis) throughout the entire study period. Results The geometric mean ratios (GMR) amongst the two glimepiride formulations for the primary pharmacokinetic parameters, ie, AUC 0-inf , AUC 0-last , and C max as well as the corresponding 90% CIs, were all within the range of 80.00-125.00% in the fasting and fed state. The safety profile for both treatments was comparable. Conclusion PK analysis revealed that the test and reference formulations of glimepiride were bioequivalent and well tolerated in healthy Chinese subjects. Chinese Clinical Trials Registry identifier: CTR20171121. Clinical Trial Registration Number CTR20171121.",2020,"Conclusion PK analysis revealed that the test and reference formulations of glimepiride were bioequivalent and well tolerated in healthy Chinese subjects.","['healthy Chinese subjects in the fasting and fed state', 'Chinese Subjects', 'Seventy-two subjects', 'healthy Chinese subjects']","['Glimepiride', 'glimepiride']","['plasma concentration of glimepiride', 'AUC 0-inf , AUC 0-last , and C max as well as the corresponding 90% CIs', 'AUC 0-inf , AUC 0-last , C max , t 1⁄2 , T max , and λ z ', 'safety profile', 'occurrence of adverse events (AEs) and laboratory examinations (biochemistry, hematology, and urinalysis', 'geometric mean ratios (GMR']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C4319632', 'cui_str': '72'}]","[{'cui': 'C0061323', 'cui_str': 'glimepiride'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0061323', 'cui_str': 'glimepiride'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0007099', 'cui_str': 'Carcinoma in situ'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0260877', 'cui_str': 'Laboratory examination'}, {'cui': 'C0005477', 'cui_str': 'Biochemistry'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0042014', 'cui_str': 'Urinalysis'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",72.0,0.0384198,"Conclusion PK analysis revealed that the test and reference formulations of glimepiride were bioequivalent and well tolerated in healthy Chinese subjects.","[{'ForeName': 'Gehang', 'Initials': 'G', 'LastName': 'Ju', 'Affiliation': ""School of Pharmacy Lanzhou University, Lanzhou University, Lanzhou, People's Republic of China.""}, {'ForeName': 'Keyu', 'Initials': 'K', 'LastName': 'Yan', 'Affiliation': ""School of Pharmacy Lanzhou University, Lanzhou University, Lanzhou, People's Republic of China.""}, {'ForeName': 'Youwei', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': ""Research Institute, Shandong Xinhua Pharmaceutical Company Limited, Shandong, People's Republic of China.""}, {'ForeName': 'Shilin', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': ""The Department of Analysis, Chengdu Fanweixi Pharmaceutical Technology Company, Limited, Chengdu, People's Republic of China.""}, {'ForeName': 'Zhonghui', 'Initials': 'Z', 'LastName': 'Zheng', 'Affiliation': ""Research Institute, Shandong Xinhua Pharmaceutical Company Limited, Shandong, People's Republic of China.""}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Qiu', 'Affiliation': ""Phase I Clinical Unit, Lanzhou University Second Hospital, Lanzhou, People's Republic of China.""}]","Drug design, development and therapy",['10.2147/DDDT.S249355'] 2492,32753849,Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire.,"Introduction Understanding patients' preferences for long-acting injectable (LAI) or oral antipsychotics (pills) could help reduce potential barriers to LAI use in schizophrenia. Methods Post hoc analyses were conducted from a double-blind, randomized, non-inferiority study (NCT01515423) of 3-monthly vs 1-monthly paliperidone palmitate in patients with schizophrenia. Data from the Medication Preference Questionnaire, administered on day 1 (baseline; open-label stabilization phase), were analyzed. The questionnaire includes four sets of items: 1) reasons for general treatment preference based on goals/outcomes and preference for LAI vs pills based on 2) personal experience, 3) injection-site (deltoid vs gluteal), 4) dosing frequency (3-monthly vs 1-monthly). A logistic regression analysis was performed to assess the effect of baseline variables on preference (LAIs or pills). Results Data from 1402 patients were available for analysis. Patients who preferred LAIs recognized these outcomes as important: ""I feel more healthy"" (57%), ""I can get back to my favorite activities"" (56%), ""I don't have to think about taking my medicines"" (54%). Most common reasons for medication preference (LAI vs pills) were: ""LAIs/pills are easier for me"" (67% vs 18%), ""more in control/don't have to think about taking medicine"" (64% vs 14%), ""less pain/sudden symptoms"" (38% vs 18%) and ""less embarrassed"" (0% vs 46%). Majority of patients (59%) preferred deltoid over gluteal injections (reasons: faster administration [63%], easier [51%], less embarrassing [44%]). In total, 50% of patients preferred 3-monthly over 1-monthly (38%) or every day (3%) dosing citing reasons: fewer injections [96%], fewer injections are less painful [84%], and fewer doctor visits [80%]. From logistic regression analysis, 77% of patients preferred LAI over pills; culture and race appeared to play a role in this preference. Conclusion Patients who preferred LAI antipsychotics prioritized self-empowerment and quality-of-life-related goals. When given the option, patients preferred less-frequent, quarterly injections over monthly injections and daily oral medications.",2020,"From logistic regression analysis, 77% of patients preferred LAI over pills; culture and race appeared to play a role in this preference. ","['patients with schizophrenia', '1402 patients were available for analysis']","['long-acting injectable (LAI) or oral antipsychotics (pills', 'paliperidone palmitate']","['doctor visits', 'less pain/sudden symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0040615', 'cui_str': 'Antipsychotic agent'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C2719626', 'cui_str': 'Paliperidone palmitate'}]","[{'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1276802', 'cui_str': 'Sudden'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",1402.0,0.082721,"From logistic regression analysis, 77% of patients preferred LAI over pills; culture and race appeared to play a role in this preference. ","[{'ForeName': 'Clifton', 'Initials': 'C', 'LastName': 'Blackwood', 'Affiliation': 'Penn State University, Abington, PA, USA.'}, {'ForeName': 'Panna', 'Initials': 'P', 'LastName': 'Sanga', 'Affiliation': 'Department of Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Isaac', 'Initials': 'I', 'LastName': 'Nuamah', 'Affiliation': 'Clinical Biostatistics, Janssen Research & Development, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Keenan', 'Affiliation': 'Health Economics and Market Access, Janssen Research & Development, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Arun', 'Initials': 'A', 'LastName': 'Singh', 'Affiliation': 'Department of Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Maju', 'Initials': 'M', 'LastName': 'Mathews', 'Affiliation': 'Department of Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Srihari', 'Initials': 'S', 'LastName': 'Gopal', 'Affiliation': 'Department of Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA.'}]",Patient preference and adherence,['10.2147/PPA.S251812'] 2493,32753850,"Measurement of the Quality of Life of Prolanis Hypertension Patients in Sixteen Primary Healthcare Centers in Pandeglang District, Banten Province, Indonesia, Using EQ-5D-5L Instrument.","Introduction The prevalence of hypertension in Indonesia is increasing, not least in some peripheral areas, including in Pandeglang District, Banten Province. The government of Indonesia, through the Social Health Insurance Administration Body (BPJS Kesehatan) has launched a chronic disease management program (Prolanis) to achieve more optimal results in treating patients with chronic diseases, including hypertension. Objective This study aimed to measure the quality of life of Prolanis hypertension patients at the primary healthcare centers (PHCs) using EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) instrument and taking pharmacists' counseling intervention into account. This study was conducted in 96 Prolanis patients, consisting of 48 patients from 8 PHCs who did not receive pharmacists' counseling intervention (control group) and 48 other patients from 8 different PHCs who received 4 times intervention (intervention group). This study was conducted in a period of 3 months (June-August 2019) in 16 sub-districts of Pandeglang District. Methods An experimental study design was applied by considering a purposive sampling method. Patients' quality of life were measured by using EQ-5D-5L instrument and its Indonesian value set. For data analysis, we applied the Kruskal-Wallis, Mann-Whitney, Wilcoxon, and Binomial tests to investigate the differences of patients' quality of life in both groups of control and intervention. Results and Conclusions The results showed that the average utility value of the intervention group experienced an improvement at each meeting (m1 = 51.25%; m2 = 66.25%; m3 = 84.17%; and m4 = 91.67%), while the control group experienced a lower and more fluctuative improvement than the intervention group (m1 = 65.42%; m2 = 70.42%; m3 = 80.42%; and m4 = 76.67%). The same results also occurred in the average value of visual analogue scale (VAS). There was a better improvement in the intervention group than in the control group. Clinical Trial Registration Number 62/UN6.KEP/EC/2019.",2020,"There was a better improvement in the intervention group than in the control group. ","['Prolanis Hypertension Patients in Sixteen Primary Healthcare Centers in Pandeglang District, Banten Province, Indonesia, Using EQ-5D-5L Instrument', 'patients with chronic diseases, including hypertension', ""96 Prolanis patients, consisting of 48 patients from 8 PHCs who did not receive pharmacists' counseling intervention (control group) and 48 other patients from 8 different PHCs who received 4 times intervention (intervention group"", 'Prolanis hypertension patients at the primary healthcare centers (PHCs) using', 'period of 3 months (June-August 2019) in 16 sub-districts of Pandeglang District']","[""EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) instrument and taking pharmacists' counseling intervention""]","['quality of life', ""Patients' quality of life"", 'fluctuative improvement', 'Quality of Life', 'average utility value', 'average value of visual analogue scale (VAS']","[{'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0021247', 'cui_str': 'Indonesia'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0456951', 'cui_str': 'Level 5'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}]","[{'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0456951', 'cui_str': 'Level 5'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",96.0,0.0230107,"There was a better improvement in the intervention group than in the control group. ","[{'ForeName': '', 'Initials': '', 'LastName': 'Yusransyah', 'Affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, West Java, Indonesia.'}, {'ForeName': 'Eli', 'Initials': 'E', 'LastName': 'Halimah', 'Affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, West Java, Indonesia.'}, {'ForeName': 'Auliya A', 'Initials': 'AA', 'LastName': 'Suwantika', 'Affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, West Java, Indonesia.'}]",Patient preference and adherence,['10.2147/PPA.S249085'] 2494,32753856,Evaluation of an Education Strategy versus Usual Care to Implement the STEADI Algorithm in Primary Care Clinics in an Academic Medical Center.,"Background Although falls are the leading cause of morbidity and mortality in the US in the older adult population, there is little information regarding implementation of evidence-based fall prevention guidelines within primary care settings. The objective of this study was to address this gap in the literature by determining the effectiveness of the use of education and written materials as implementation strategies. Methods Using a prospective, mixed methods, controlled before-and-after study design, we studied the effect of the Stopping Elderly Accidents, Deaths, and Injuries (STEADI) education and written materials on knowledge and intention to use in primary care clinics as well as test the screening, assessment, and intervention behaviors. This manuscript details the quantitative findings of the study, using STEADI Knowledge Test, Continuing Professional Development (CPD) Reaction Questionnaire, and EMR Reports. We compared data between the study arms (usual implementation versus education implementation) using descriptive statistics, paired t -tests, and factorial ANOVAs. Results In total, data from 29 primary care staff, including physicians, APRNs, RNs, and medical assistants, were analyzed. Although we found a statistically significant difference within the education arm between immediate pretests and posttests/surveys mean scores, there was no statistically significant difference between the study arms' knowledge, intent to use STEADI, or use behaviors. The pre/immediate post education mean knowledge score increased by 1.19 (p= 0.02) and the pre/immediate post education intent to use mean increased by 0.64 (p 0.01). There was no statistically significant change between the study arms over time. Conclusion Educational strategies, particularly written materials and an online module, did not increase the long-term use of the STEADI toolkit. Implementation research is needed to identify the strategies that are most effective for promoting the adoption of STEADI in primary care.",2020,The pre/immediate post education mean knowledge score increased by 1.19 (p= 0.02) and the pre/immediate post education intent to use mean increased by 0.64 (p 0.01).,"['older adult population', 'in Primary Care Clinics in an Academic Medical Center']",['Education Strategy versus Usual Care to Implement the STEADI Algorithm'],"[' knowledge, intent to use STEADI, or use behaviors', 'pre/immediate post education mean knowledge score']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0450446', 'cui_str': 'Stops'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0000924', 'cui_str': 'Accident'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0450446', 'cui_str': 'Stops'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0000924', 'cui_str': 'Accident'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0275703,The pre/immediate post education mean knowledge score increased by 1.19 (p= 0.02) and the pre/immediate post education intent to use mean increased by 0.64 (p 0.01).,"[{'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Urban', 'Affiliation': 'College of Nursing, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.'}, {'ForeName': 'Patricia B', 'Initials': 'PB', 'LastName': 'Wright', 'Affiliation': 'College of Nursing, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.'}, {'ForeName': 'Amy L', 'Initials': 'AL', 'LastName': 'Hester', 'Affiliation': 'College of Nursing, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.'}, {'ForeName': 'Geoffrey', 'Initials': 'G', 'LastName': 'Curran', 'Affiliation': 'College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.'}, {'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Rojo', 'Affiliation': 'College of Nursing, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.'}, {'ForeName': 'Pao-Feng', 'Initials': 'PF', 'LastName': 'Tsai', 'Affiliation': 'School of Nursing, Auburn University, Auburn, Alabama, USA.'}]",Clinical interventions in aging,['10.2147/CIA.S256416'] 2495,32753864,"The Effects of Silver, Zinc Oxide, and Titanium Dioxide Nanoparticles Used as Dentin Pretreatments on the Microshear Bond Strength of a Conventional Glass Ionomer Cement to Dentin.","Aim This study was conducted to evaluate the effects of three nanoparticle solutions used as dentin pretreatments on the microshear bond strength (µSBS) of a conventional glass ionomer cement (GIC) to dentin. Materials and Methods Ninety intact human molars were used after sectioning their occlusal surfaces to expose flat dentin surfaces. The specimens were randomly assigned to nine groups (n = 10). Group A was the control group (without using the cavity disinfectant). In groups B, C, D, and E, the prepared dentin surfaces were treated with 1 cc 2% chlorhexidine (CHX), 0.1% silver nanoparticle (SNP), 0.1% titanium dioxide nanoparticle (TNP), and 0.1% zinc oxide nanoparticle (ZNP) solutions for 1 minute, respectively, before applying the conditioner. CHX, SNPs, TNPs, and ZNPs were applied for 1 minute after applying the conditioner in groups F, G, H, and I, respectively. The specimens were restored with a conventional GIC and underwent µSBS testing after 24 hours. The data were analyzed using the one-way analysis of variance and Tukey's test (p=0.05). Results The applications of the nanoparticles (SNP, TNP, and ZNP) after the conditioner were associated with significantly greater µSBS values compared to that of the control group (p values < 0.05). Significantly higher µSBS values were observed when TNP or ZNP was applied after the conditioner compared to their applications before the conditioner (p values < 0.05). The highest µSBS values were observed when TNP was applied after the conditioner. Conclusion Dentin pretreatment with the nanoparticles after applying the conditioner enhanced the bond strength of the GIC to dentin compared with the control group. The best results were obtained for the TNPs applied after the conditioner.",2020,Significantly higher µSBS values were observed when TNP or ZNP was applied after the conditioner compared to their applications before the conditioner (p values < 0.05).,[],"['Silver, Zinc Oxide, and Titanium Dioxide Nanoparticles', 'chlorhexidine (CHX), 0.1% silver nanoparticle (SNP), 0.1% titanium dioxide nanoparticle (TNP), and 0.1% zinc oxide nanoparticle (ZNP) solutions', 'TNP', 'TNP or ZNP']","['µSBS values', 'highest µSBS values', 'microshear bond strength (µSBS', 'bond strength', 'CHX, SNPs, TNPs, and ZNPs']",[],"[{'cui': 'C0037125', 'cui_str': 'silver'}, {'cui': 'C0043491', 'cui_str': 'Zinc Oxide'}, {'cui': 'C0076733', 'cui_str': 'titanium dioxide'}, {'cui': 'C1450054', 'cui_str': 'Nanoparticles'}, {'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C0037633', 'cui_str': 'Solution'}]","[{'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0028758', 'cui_str': 'Bonding (Psychology)'}, {'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C0752046', 'cui_str': 'Single Nucleotide Polymorphism'}, {'cui': 'C0272137', 'cui_str': 'Polyagglutinable erythrocyte syndrome'}, {'cui': 'C0724447', 'cui_str': 'ZNP'}]",,0.0156017,Significantly higher µSBS values were observed when TNP or ZNP was applied after the conditioner compared to their applications before the conditioner (p values < 0.05).,"[{'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Jowkar', 'Affiliation': 'Oral and Dental Disease Research Center, Department of Operative Dentistry, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Fattah', 'Affiliation': 'Oral and Dental Disease Research Center, Department of Operative Dentistry, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Saeedreza', 'Initials': 'S', 'LastName': 'Ghanbarian', 'Affiliation': 'Department of Operative Dentistry, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Shafiei', 'Affiliation': 'Oral and Dental Disease Research Center, Department of Operative Dentistry, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",International journal of nanomedicine,['10.2147/IJN.S262664'] 2496,32753874,Cardiovascular Protection Variables Based on Exercise Intensity in Stable Coronary Heart Disease Patients After Coronary Stenting: A Comparative Study.,"Purpose Our study aimed at determining and comparing the mechanism of cardiovascular protection variables in moderate-intensity continuous training (MICT) and high-intensity interval training (HIIT) in patients with stable coronary heart disease (CHD) after coronary stenting. Participants and Methods This experimental study used the same subject and cross-over design, involving eleven stable CHD patients after coronary stenting. These were randomly divided into two groups; MICT for 29 minutes at 50-60% heart rate reserve and HIIT with 4x4 minute intervals at 60-80% heart rate reserve, each followed by three minutes of active recovery at 40-50% heart rate reserve. These were conducted three times a week for two weeks. The participants' levels of adrenaline, noradrenaline, endothelial nitric oxide synthase (eNOS), extracellular superoxide dismutase (EC-SOD) activity assayed, and flow-mediated dilatation (FMD) were examined before and after treatments were completed. Results The HIIT significantly increased the levels of noradrenaline and eNOS compared with MICT (p<0.05). Also, HIIT was better in maintaining EC-SOD activity and FMD compared with MICT (p<0.05). Through the noradrenalin pathway, HIIT had a direct and significant effect on eNOS and FMD (p<0.05) but MICT, through the noradrenaline pathways, had a direct and significant effect on eNOS (p<0.05), and through the EC-SOD activity pathways had a direct and significant effect on FMD (p<0.05). MICT reduced EC-SOD activity and also decreased the FMD value. Conclusion HIIT is superior to MICT in increasing cardiovascular protection by increasing the concentrations of noradrenalin and eNOS, maintaining EC-SOD activity, and FMD in stable CHD patients after coronary stenting.",2020,The HIIT significantly increased the levels of noradrenaline and eNOS compared with MICT (p<0.05).,"['eleven stable CHD patients after coronary stenting', 'stable CHD patients after coronary stenting', 'Stable Coronary Heart Disease Patients', 'Participants and Methods', 'patients with stable coronary heart disease (CHD) after coronary stenting', 'moderate']","['MICT', 'intensity continuous training (MICT) and high-intensity interval training (HIIT']","['FMD value', 'eNOS and FMD', 'maintaining EC-SOD activity and FMD', 'adrenaline, noradrenaline, endothelial nitric oxide synthase (eNOS), extracellular superoxide dismutase (EC-SOD) activity assayed, and flow-mediated dilatation (FMD', 'levels of noradrenaline and eNOS', 'concentrations of noradrenalin and eNOS, maintaining EC-SOD activity, and FMD', 'MICT reduced EC-SOD activity']","[{'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}]","[{'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}]","[{'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0002940', 'cui_str': 'Aneurysm'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0669365', 'cui_str': 'NOS3 protein, human'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0521119', 'cui_str': 'Extracellular'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",11.0,0.0275147,The HIIT significantly increased the levels of noradrenaline and eNOS compared with MICT (p<0.05).,"[{'ForeName': 'Dyana', 'Initials': 'D', 'LastName': 'Sarvasti', 'Affiliation': 'Department of Internal Medicine, Faculty of Medicine Widya Mandala Catholic University, Surabaya, Indonesia.'}, {'ForeName': 'Isabella', 'Initials': 'I', 'LastName': 'Lalenoh', 'Affiliation': 'Department of Cardiology, Siloam Hospital TB Simatupang, Jakarta, Indonesia.'}, {'ForeName': 'Emanoel', 'Initials': 'E', 'LastName': 'Oepangat', 'Affiliation': 'Department of Cardiology, Siloam Hospital TB Simatupang, Jakarta, Indonesia.'}, {'ForeName': 'Budhi Setianto', 'Initials': 'BS', 'LastName': 'Purwowiyoto', 'Affiliation': 'Department of Cardiology and Vascular Medicine, Faculty of Medicine University of Indonesia National Cardiovascular Center Harapan Kita, Jakarta, Indonesia.'}, {'ForeName': 'Anwar', 'Initials': 'A', 'LastName': 'Santoso', 'Affiliation': 'Department of Cardiology and Vascular Medicine, Faculty of Medicine University of Indonesia National Cardiovascular Center Harapan Kita, Jakarta, Indonesia.'}, {'ForeName': 'Rochmad', 'Initials': 'R', 'LastName': 'Romdoni', 'Affiliation': 'Department of Cardiology and Vascular Medicine, Faculty of Medicine Airlangga University - Dr. Soetomo District General Hospital, Surabaya, Indonesia.'}]",Vascular health and risk management,['10.2147/VHRM.S259190'] 2497,32753923,Therapeutic Effects of Garlic on Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients: A Randomized Clinical Trial.,"Background and Aims Emerging evidence suggests that garlic ( Allium sativum L.) and its bioactive components can mitigate hepatic steatosis by the modulation of hepatic lipid metabolism. We aimed to assess the efficacy of the garlic administration on hepatic steatosis in patients with NAFLD. Patients and Methods This clinical trial was conducted on adult patients with ultrasound-diagnosed NAFLD. Eligible participants were randomly assigned, with the use of the stratified blocked procedure, to receive 800 mg garlic or placebo for 15 weeks. The primary outcome was the improvement in the hepatic steatosis diagnosed by ultrasound technique after 15 weeks of intervention. Results A total of 110 patients underwent randomization, and 98 patients completed the trial. Twenty-four (51.1%) patients in the garlic group achieved improvement in the hepatic steatosis compared to eight (15.7%) patients in the placebo group with the relative risk of 5.6 (95% CI: 2.17 to 14.5; P=0.001), which remained significant after adjusting for baseline value of hepatic steatosis. There were significant reductions in weight and serum ALT, AST, FBS, Hb A1C, total cholesterol, LDL-cholesterol, and TG concentration with the garlic intake compared to placebo (P<0.05). The results were also significant after adjusting for weight change, energy intake, and physical activity. No serious adverse effects were observed with the garlic intake. Conclusion The intake of garlic powder was accompanied by a significant improvement in the hepatic steatosis and comorbidity related to this condition among subjects with NAFLD.",2020,"There were significant reductions in weight and serum ALT, AST, FBS, Hb A1C, total cholesterol, LDL-cholesterol, and TG concentration with the garlic intake compared to placebo (P<0.05).","['Eligible participants', '110 patients underwent randomization, and 98 patients completed the trial', 'adult patients with ultrasound-diagnosed NAFLD', 'patients with NAFLD', 'Nonalcoholic Fatty Liver Disease Patients']","['Garlic', 'garlic ( Allium sativum L', 'garlic or placebo', 'garlic administration', 'placebo']","['hepatic steatosis and comorbidity', 'hepatic steatosis', 'weight and serum ALT, AST, FBS, Hb A1C, total cholesterol, LDL-cholesterol, and TG concentration with the garlic intake', 'hepatic steatosis diagnosed by ultrasound technique', 'weight change, energy intake, and physical activity', 'Hepatic Steatosis', 'serious adverse effects']","[{'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}]","[{'cui': 'C0331590', 'cui_str': 'Allium ameloprasum'}, {'cui': 'C0993630', 'cui_str': 'Garlic'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0015695', 'cui_str': 'Fatty Liver'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0036828', 'cui_str': 'SGPT'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C3495427', 'cui_str': 'Fanconi-Bickel Syndrome'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0331590', 'cui_str': 'Allium ameloprasum'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",110.0,0.339699,"There were significant reductions in weight and serum ALT, AST, FBS, Hb A1C, total cholesterol, LDL-cholesterol, and TG concentration with the garlic intake compared to placebo (P<0.05).","[{'ForeName': 'Davood', 'Initials': 'D', 'LastName': 'Soleimani', 'Affiliation': 'Nutritional Sciences Department, School of Nutrition Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Zamzam', 'Initials': 'Z', 'LastName': 'Paknahad', 'Affiliation': 'Department of Clinical Nutrition, School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Mohammad Hossein', 'Initials': 'MH', 'LastName': 'Rouhani', 'Affiliation': 'Department of Community Nutrition, School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.'}]","Diabetes, metabolic syndrome and obesity : targets and therapy",['10.2147/DMSO.S254555'] 2498,32754110,"Efficacy of Tasimelteon (HETLIOZ®) in the Treatment of Jet Lag Disorder Evaluated in an 8-h Phase Advance Model; a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.","Background: Most travelers experience Jet Lag Disorder (JLD) symptoms due to misalignment of their circadian rhythms with respect to the new time zone. We assessed the efficacy and safety of tasimelteon (HETLIOZ®) in healthy participants using a laboratory model of JLD induced by an 8-h phase advance of the sleep-wake cycle (JET8 Study). We hypothesized that tasimelteon treatment in participants experiencing JLD would cause increased sleep time, increased next-day alertness, and reduced next-day sleepiness. Methods: We undertook a randomized, double-blind, placebo-controlled trial in 12 US clinical research sleep centers. We screened healthy adults ages 18-73 years, who were eligible for the randomization phase of JET8 if they typically went to bed between 21:00 and 01:00, slept between 7 and 9 h each night, and slept at a consistent bedtime. We used block randomization stratified by site to assign participants (1:1) to receive a single oral dose of tasimelteon (20 mg) or placebo 30 min before their 8-h phase-advanced bedtime. The primary endpoint was Total Sleep Time in the first 2/3 of the night (TST 2/3 ), which was measured by polysomnography during the 8-h sleep episode, and assessed in the intent-to-treat population. The trial is completed and registered with ClinicalTrials.gov, NCT03373201. Results: Between October 16, 2017 and January 17, 2018, we screened 607 healthy participants for JET8, of whom 320 (53%) were assigned to receive tasimelteon ( n = 160) or placebo ( n = 160). Tasimelteon treatment increased TST 2/3 (primary endpoint) by 60.3 min (95%CI 44.0 to 76.7, P < 0.0001) and whole night TST by 85.5 min (95% CI 64.3 to 106.6, P < 0.0001), improved next day alertness, next day sleepiness, and shortened latency to persistent sleep by -15.1 min (95% CI -26.2 to -4.0, P = 0.0081). Conclusion: A single dose of tasimelteon improves the primary symptoms of JLD, including nighttime insomnia and next day functioning among participants in a laboratory model of JLD simulating eastward trans-meridian travel by inducing an 8-h phase advance of the sleep-wake cycle.",2020,"Tasimelteon treatment increased TST 2/3 (primary endpoint) by 60.3 min (95%CI 44.0 to 76.7, P < 0.0001) and whole night TST by 85.5 min (95% CI 64.3 to 106.6, P < 0.0001), improved next day alertness, next day sleepiness, and shortened latency to persistent sleep by -15.1 min (95% CI -26.2 to -4.0, P = 0.0081). ","['screened healthy adults ages 18-73 years, who were eligible for the randomization phase of JET8 if they typically went to bed between 21:00 and 01:00, slept between 7 and 9 h each night, and slept at a consistent bedtime', '607 healthy participants for JET8, of whom 320 (53', '12 US clinical research sleep centers', 'healthy participants using a laboratory model of JLD induced by an 8-h phase advance of the sleep-wake cycle (JET8 Study', 'Results: Between October 16, 2017 and January 17, 2018']","['tasimelteon (HETLIOZ®', 'Placebo', 'Tasimelteon (HETLIOZ®', 'placebo']","['Total Sleep Time', 'efficacy and safety', 'primary symptoms of JLD, including nighttime insomnia and next day functioning', 'whole night TST', 'sleep time, increased next-day alertness, and reduced next-day sleepiness', 'next day alertness, next day sleepiness, and shortened latency to persistent sleep']","[{'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C1457900', 'cui_str': 'Each'}, {'cui': 'C0521112', 'cui_str': 'Bedtime'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4517711', 'cui_str': '320'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0442696', 'cui_str': 'Waking'}, {'cui': 'C0678226', 'cui_str': 'Due to'}]","[{'cui': 'C1313052', 'cui_str': 'tasimelteon'}, {'cui': 'C3817353', 'cui_str': 'Hetlioz'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0041290', 'cui_str': 'Delayed hypersensitivity skin test for tuberculin PPD'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}, {'cui': 'C0242465', 'cui_str': 'Response Latency'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}]",607.0,0.606965,"Tasimelteon treatment increased TST 2/3 (primary endpoint) by 60.3 min (95%CI 44.0 to 76.7, P < 0.0001) and whole night TST by 85.5 min (95% CI 64.3 to 106.6, P < 0.0001), improved next day alertness, next day sleepiness, and shortened latency to persistent sleep by -15.1 min (95% CI -26.2 to -4.0, P = 0.0081). ","[{'ForeName': 'Christos M', 'Initials': 'CM', 'LastName': 'Polymeropoulos', 'Affiliation': 'Vanda Pharmaceuticals Inc., Washington, CA, United States.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Mohrman', 'Affiliation': 'Vanda Pharmaceuticals Inc., Washington, CA, United States.'}, {'ForeName': 'Madison S', 'Initials': 'MS', 'LastName': 'Keefe', 'Affiliation': 'Vanda Pharmaceuticals Inc., Washington, CA, United States.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Brzezynski', 'Affiliation': 'Vanda Pharmaceuticals Inc., Washington, CA, United States.'}, {'ForeName': 'Jingyuan', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Vanda Pharmaceuticals Inc., Washington, CA, United States.'}, {'ForeName': 'Lydia S', 'Initials': 'LS', 'LastName': 'Prokosch', 'Affiliation': 'Vanda Pharmaceuticals Inc., Washington, CA, United States.'}, {'ForeName': 'Vasilios M', 'Initials': 'VM', 'LastName': 'Polymeropoulos', 'Affiliation': 'Vanda Pharmaceuticals Inc., Washington, CA, United States.'}, {'ForeName': 'Changfu', 'Initials': 'C', 'LastName': 'Xiao', 'Affiliation': 'Vanda Pharmaceuticals Inc., Washington, CA, United States.'}, {'ForeName': 'Gunther', 'Initials': 'G', 'LastName': 'Birznieks', 'Affiliation': 'Vanda Pharmaceuticals Inc., Washington, CA, United States.'}, {'ForeName': 'Mihael H', 'Initials': 'MH', 'LastName': 'Polymeropoulos', 'Affiliation': 'Vanda Pharmaceuticals Inc., Washington, CA, United States.'}]",Frontiers in neurology,['10.3389/fneur.2020.00611'] 2499,32754150,Iron Deficiency Anemia at Time of Vaccination Predicts Decreased Vaccine Response and Iron Supplementation at Time of Vaccination Increases Humoral Vaccine Response: A Birth Cohort Study and a Randomized Trial Follow-Up Study in Kenyan Infants.,"Background: Iron deficiency may impair adaptive immunity and is common among African infants at time of vaccination. Whether iron deficiency impairs vaccine response and whether iron supplementation improves humoral vaccine response is uncertain. Methods: We performed two studies in southern coastal Kenya. In a birth cohort study, we followed infants to age 18 mo and assessed whether anemia or iron deficiency at time of vaccination predicted vaccine response to three-valent oral polio, diphtheria-tetanus-whole cell pertussis- Haemophilus influenzae type b vaccine, ten-valent pneumococcal-conjugate vaccine and measles vaccine. Primary outcomes were anti-vaccine-IgG and seroconversion at age 24 wk and 18 mo. In a randomized trial cohort follow-up, children received a micronutrient powder (MNP) with 5 mg iron daily or a MNP without iron for 4 mo starting at age 7.5 mo and received measles vaccine at 9 and 18 mo; primary outcomes were anti-measles IgG, seroconversion and avidity at age 11.5 mo and 4.5 y. Findings: In the birth cohort study, 573 infants were enrolled and 303 completed the study. Controlling for sex, birthweight, anthropometric indices and maternal antibodies, hemoglobin at time of vaccination was the strongest positive predictor of: (A) anti-diphtheria and anti-pertussis-IgG at 24 wk ( p = 0.0071, p = 0.0339) and 18 mo ( p = 0.0182, p = 0.0360); (B) anti-pertussis filamentous hemagglutinin-IgG at 24 wk ( p = 0.0423); and (C) anti-pneumococcus 19 IgG at 18 mo ( p = 0.0129). Anemia and serum transferrin receptor at time of vaccination were the strongest predictors of seroconversion against diphtheria ( p = 0.0484, p = 0.0439) and pneumococcus 19 at 18 mo ( p = 0.0199, p = 0.0327). In the randomized trial, 155 infants were recruited, 127 and 88 were assessed at age 11.5 mo and 4.5 y. Compared to infants that did not receive iron, those who received iron at time of vaccination had higher anti-measles-IgG ( p = 0.0415), seroconversion ( p = 0.0531) and IgG avidity ( p = 0.0425) at 11.5 mo. Interpretation: In Kenyan infants, anemia and iron deficiency at time of vaccination predict decreased response to diphtheria, pertussis and pneumococcal vaccines. Primary response to measles vaccine may be increased by iron supplementation at time of vaccination. These findings argue that correction of iron deficiency during early infancy may improve vaccine response.",2020,"Anemia and serum transferrin receptor at time of vaccination were the strongest predictors of seroconversion against diphtheria ( p = 0.0484, p = 0.0439) and pneumococcus 19 at 18 mo ( p = 0.0199, p = 0.0327).","['573 infants were enrolled and 303 completed the study', '155 infants were recruited, 127 and 88 were assessed at age 11.5 mo and 4.5 y', 'African infants at time of vaccination', 'southern coastal Kenya', 'infants to age 18 mo and assessed whether anemia or iron deficiency at time of vaccination predicted vaccine response to three-valent oral polio', 'Kenyan Infants']","['iron supplementation', 'Humoral Vaccine Response', 'micronutrient powder (MNP) with 5 mg iron daily or a MNP without iron for 4 mo starting at age 7.5 mo and received measles vaccine', 'diphtheria-tetanus-whole cell pertussis- Haemophilus influenzae type b vaccine, ten-valent pneumococcal-conjugate vaccine and measles vaccine']","['Anemia and serum transferrin receptor', 'IgG avidity', 'humoral vaccine response', 'anti-vaccine-IgG and seroconversion', 'sex, birthweight, anthropometric indices and maternal antibodies, hemoglobin at time of vaccination', 'seroconversion']","[{'cui': 'C4708164', 'cui_str': '573'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517534', 'cui_str': '11.5'}, {'cui': 'C3844009', 'cui_str': '4.5'}, {'cui': 'C0027567', 'cui_str': 'African race'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032371', 'cui_str': 'Acute poliomyelitis'}, {'cui': 'C0337839', 'cui_str': 'Kenyans'}]","[{'cui': 'C3537005', 'cui_str': 'Iron supplement therapy'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0040577', 'cui_str': 'Trace element'}, {'cui': 'C0032861', 'cui_str': 'Powder'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0282245', 'cui_str': 'Northern Mariana Islands'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C0012546', 'cui_str': 'Diphtheria'}, {'cui': 'C0039614', 'cui_str': 'Tetanus'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0031237', 'cui_str': 'Pertussis Vaccine'}, {'cui': 'C0062086', 'cui_str': 'Haemophilus influenzae Type b vaccine'}, {'cui': 'C1579319', 'cui_str': 'Pneumococcal conjugate vaccine'}]","[{'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0428545', 'cui_str': 'Serum transferrin measurement'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0729663', 'cui_str': 'Maternal antibody'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",573.0,0.243708,"Anemia and serum transferrin receptor at time of vaccination were the strongest predictors of seroconversion against diphtheria ( p = 0.0484, p = 0.0439) and pneumococcus 19 at 18 mo ( p = 0.0199, p = 0.0327).","[{'ForeName': 'Nicole U', 'Initials': 'NU', 'LastName': 'Stoffel', 'Affiliation': 'Department of Health Sciences and Technology, Institute of Food, Nutrition and Health, Laboratory of Human Nutrition, ETH Zürich, Zurich, Switzerland.'}, {'ForeName': 'Mary A', 'Initials': 'MA', 'LastName': 'Uyoga', 'Affiliation': 'Department of Health Sciences and Technology, Institute of Food, Nutrition and Health, Laboratory of Human Nutrition, ETH Zürich, Zurich, Switzerland.'}, {'ForeName': 'Francis M', 'Initials': 'FM', 'LastName': 'Mutuku', 'Affiliation': 'Department of Environment and Health Sciences, Technical University Mombasa, Mombasa, Kenya.'}, {'ForeName': 'Joe N', 'Initials': 'JN', 'LastName': 'Frost', 'Affiliation': 'MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom.'}, {'ForeName': 'Edith', 'Initials': 'E', 'LastName': 'Mwasi', 'Affiliation': 'Pediatrics Department, Msambweni County Referral Hospital, Msambweni, Kenya.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Paganini', 'Affiliation': 'Department of Health Sciences and Technology, Institute of Food, Nutrition and Health, Laboratory of Human Nutrition, ETH Zürich, Zurich, Switzerland.'}, {'ForeName': 'Fiona R M', 'Initials': 'FRM', 'LastName': 'van der Klis', 'Affiliation': 'Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, Netherlands.'}, {'ForeName': 'Indu J', 'Initials': 'IJ', 'LastName': 'Malhotra', 'Affiliation': 'Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, OH, United States.'}, {'ForeName': 'A Desiráe', 'Initials': 'AD', 'LastName': 'LaBeaud', 'Affiliation': ""Division of Infectious Diseases, Department of Pediatrics, Lucille Packard Children's Hospital at Stanford School of Medicine, Stanford, CA, United States.""}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Ricci', 'Affiliation': 'Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Karanja', 'Affiliation': 'Department of Medical Epidemiology, College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.'}, {'ForeName': 'Hal', 'Initials': 'H', 'LastName': 'Drakesmith', 'Affiliation': 'MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom.'}, {'ForeName': 'Charles H', 'Initials': 'CH', 'LastName': 'King', 'Affiliation': 'Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, OH, United States.'}, {'ForeName': 'Michael B', 'Initials': 'MB', 'LastName': 'Zimmermann', 'Affiliation': 'Department of Health Sciences and Technology, Institute of Food, Nutrition and Health, Laboratory of Human Nutrition, ETH Zürich, Zurich, Switzerland.'}]",Frontiers in immunology,['10.3389/fimmu.2020.01313'] 2500,32754229,Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial.,"Background Cancer trials involving multiple treatment lines substantially increase our understanding of therapeutic strategies. However, even when the primary end-point of these studies is progression-free survival (PFS), their statistical analysis usually focuses on each line separately, or does not consider repeated events, thus missing potentially relevant information. Consequently, the evaluation of the effectiveness of treatment strategies is highly impaired. Methods We evaluated the potentially different effect of bevacizumab (B) administered for the first- or second-line treatment of metastatic colorectal cancer (mCRC) in the ITACa (Italian Trial in Advanced Colorectal Cancer) randomized trial. The ITACa trial consisted of two arms: first-line chemotherapy (CT)+B followed by second-line CT alone versus first-line CT alone followed by second-line CT+B or CT+B+cetuximab according to KRAS status. Cox models for repeated disease progression were performed, and potential selection bias was adjusted using the inverse probability of censoring weighting method. Hazard ratios (HR) [95% confidence interval (CI)] for PFS (primary endpoint) were reported. Results The overall effect of B across the two lines resulted in a HR = 0.80 (95% CI 0.68-0.95, p  = 0.008). Evaluating the differential effect of B in first- and second-line, the addition of B to first-line chemotherapy (CT) produced a 10% risk reduction (HR = 0.90, 95% CI 0.72-1.12, p  = 0.340) versus CT alone; B added to second-line CT produced a 36% risk reduction (HR = 0.64, 95% CI 0.49-0.84, p  = 0.0011) versus CT alone. Conclusion Our results seem to suggest that B confers a PFS advantage when administered in combination with second-line chemotherapy, which could help to improve current international guidelines on optimal sequential treatment strategies.",2020,"The overall effect of B across the two lines resulted in a HR = 0.80 (95% CI 0.68-0.95, p  = 0.008).","['metastatic colorectal cancer', 'metastatic colorectal cancer (mCRC) in the ITACa (Italian Trial in Advanced Colorectal Cancer']","['B to first-line chemotherapy (CT', 'bevacizumab (B', 'first-line chemotherapy (CT)+B followed by second-line CT alone versus first-line CT alone followed by second-line CT+B or CT+B+cetuximab', 'bevacizumab']","['progression-free survival (PFS', 'Hazard ratios (HR']","[{'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0022275', 'cui_str': 'Italian language'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}]","[{'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0205436', 'cui_str': 'Second'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.0649974,"The overall effect of B across the two lines resulted in a HR = 0.80 (95% CI 0.68-0.95, p  = 0.008).","[{'ForeName': 'Elisabetta', 'Initials': 'E', 'LastName': 'Petracci', 'Affiliation': 'Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Emanuela', 'Initials': 'E', 'LastName': 'Scarpi', 'Affiliation': 'Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, via Piero Maroncelli 40, Meldola, 47014, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Passardi', 'Affiliation': 'Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Annibale', 'Initials': 'A', 'LastName': 'Biggeri', 'Affiliation': 'Department of Statistics, Informatics and Applications ""G. Parenti"", University of Florence, Florence, Italy.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Milandri', 'Affiliation': 'Oncology Unit, S. Giuseppe Hospital, Empoli, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Vecchia', 'Affiliation': 'Department of Pharmacy, Guglielmo da Saliceto Hospital, Piacenza, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Gelsomino', 'Affiliation': 'Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Tassinari', 'Affiliation': 'Department of Oncology, Infermi Hospital, Rimini, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Tamberi', 'Affiliation': 'Medical Oncology Unit, Department of Oncology and Hematology, Degli Infermi Hospital, Faenza, Italy.'}, {'ForeName': 'Ilaria', 'Initials': 'I', 'LastName': 'Bernardini', 'Affiliation': 'Oncology Department, Ramazzini Hospital, Carpi, Italy.'}, {'ForeName': 'Caterina', 'Initials': 'C', 'LastName': 'Accettura', 'Affiliation': 'Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy.'}, {'ForeName': 'Giovanni Luca', 'Initials': 'GL', 'LastName': 'Frassineti', 'Affiliation': 'Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Dino', 'Initials': 'D', 'LastName': 'Amadori', 'Affiliation': 'Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Oriana', 'Initials': 'O', 'LastName': 'Nanni', 'Affiliation': 'Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}]",Therapeutic advances in medical oncology,['10.1177/1758835920937427'] 2501,32754349,Comparison of postoperative cognitive dysfunction with the use of propofol versus desflurane in patients undergoing surgery for clipping of aneurysm after subarachnoid hemorrhage.,"Background Cerebral aneurysm rupture is a distinct entity among various causes of cerebrovascular accident. Despite the current concept of early surgical clipping to prevent consequences of ruptured aneurysm in good grade subarachnoid hemorrhage patients, 40-50% have postoperative cognitive dysfunction (POCD) on a long- term basis. Here, we compared the effect of two commonly used anesthetic agents on cognitive function following cerebral aneurysmal surgery, i.e., propofol and desflurane. Methods We conducted a prospective double-blind clinical study in 70 patients who were randomized to receive maintenance anesthetic agents either propofol or desflurane. The cognitive functions of patients were studied at the time of the discharge from a hospital or at 2 weeks following surgery whichever was early using the Hindi version of the Montreal Cognitive Assessment scale. The hemodynamic parameters, brain relaxation score at the different time intervals, were also studied. Results There was no difference between the two anesthetic agents in terms of incidence of POCD (65.4% vs. 82.6%, P > 0.05) at the time of discharge or at 2 weeks following surgery. The mean POCD score in propofol and desflurane group was 22.81 ± 4.45 and 19.09 ± 5.66 which was statistically significant ( P -value-0.01). The scores for domains of executive function, attention, and orientation were better with propofol group than desflurane group. Intraoperative hemodynamics and brain relaxation scores were similar in both groups. Conclusion A significant number of patients undergoing aneurysmal neck surgery experienced POCD although incidence remained similar in both groups. However, it appears that mean cognitive score and certain domains of cognitive functions especially the executive function, attention, and orientation were better preserved with the use of propofol when compared to desflurane at the time of discharge or on 2 weeks following surgery whichever was early.",2020,"The scores for domains of executive function, attention, and orientation were better with propofol group than desflurane group.","['patients undergoing surgery for clipping of aneurysm after subarachnoid hemorrhage', '70 patients who were randomized to receive']","['propofol and desflurane', 'propofol versus desflurane', 'maintenance anesthetic agents either propofol or desflurane', 'desflurane', 'propofol']","['scores for domains of executive function, attention, and orientation', 'Intraoperative hemodynamics and brain relaxation scores', 'mean POCD score', 'cognitive function', 'postoperative cognitive dysfunction (POCD', 'incidence of POCD', 'hemodynamic parameters, brain relaxation score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0002940', 'cui_str': 'Aneurysm'}, {'cui': 'C0038525', 'cui_str': 'Subarachnoid hemorrhage'}]","[{'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0063252', 'cui_str': 'desflurane'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0002932', 'cui_str': 'Anesthetic'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0029266', 'cui_str': 'Orientation'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4721773', 'cui_str': 'Postoperative cognitive dysfunction'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",70.0,0.0554525,"The scores for domains of executive function, attention, and orientation were better with propofol group than desflurane group.","[{'ForeName': 'Nanish', 'Initials': 'N', 'LastName': 'Sharma', 'Affiliation': 'Department of Anesthesia, Dr. Rajendra Prasad Medical College, Kangra, Himachal Pradesh, India.'}, {'ForeName': 'Jyotsna', 'Initials': 'J', 'LastName': 'Wig', 'Affiliation': 'Departments of Anaesthesia and Intensive Care, Chandigarh, India.'}, {'ForeName': 'Shalvi', 'Initials': 'S', 'LastName': 'Mahajan', 'Affiliation': 'Departments of Anaesthesia and Intensive Care, Chandigarh, India.'}, {'ForeName': 'Rajeev', 'Initials': 'R', 'LastName': 'Chauhan', 'Affiliation': 'Departments of Anaesthesia and Intensive Care, Chandigarh, India.'}, {'ForeName': 'Manju', 'Initials': 'M', 'LastName': 'Mohanty', 'Affiliation': 'Departments of Neurosurgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Hemant', 'Initials': 'H', 'LastName': 'Bhagat', 'Affiliation': 'Departments of Anaesthesia and Intensive Care, Chandigarh, India.'}]",Surgical neurology international,['10.25259/SNI_70_2020'] 2502,32755396,"Electrical Posterior Box Isolation in Persistent Atrial Fibrillation Changed to Paroxysmal Atrial Fibrillation: A Multi-center, Prospective, Randomized Study (PEACEFUL).","Background - Persistent atrial fibrillation (PeAF) can change to paroxysmal AF (PAF) after antiarrhythmic drug (AAD) medication and cardioversion. We investigated whether electrical posterior box isolation (POBI) may improve rhythm outcome of catheter ablation in those patient group. Methods - We prospectively randomized 114 patients with PeAF to PAF (male 75%, 59.8 ± 9.9 years old) to circumferential pulmonary vein isolation (CPVI) alone group (n=57) and additional POBI group (n=57). Primary endpoint was AF recurrence after a single procedure, and secondary endpoints were recurrence pattern, cardioversion rate, and response to AADs. Results - After a mean follow-up of 23.8±10.2 months, the clinical recurrence rate did not significantly differ between the CPVI alone and additional POBI group (31.6% vs. 28.1%, p=0.682; log rank p=0.729). The recurrences as atrial tachycardias (5.3% vs. 12.3%, p=0.134) and cardioversion rates (5.3% vs. 10.5%, p=0.250) were not significantly different between the CPVI and POBI group. At the final follow-up, sinus rhythm was maintained without antiarrhythmic drug in 52.6% of CPVI group and 59.6% of POBI group (p=0.450). No significant difference was found in major complication rates between the two groups (5.3% vs. 1.8%, p=0.618), but the total ablation time was significantly longer in POBI group (4187±952 sec vs. 5337±1517 sec, p<0.001). Conclusions - In patients with persistent AF converted to paroxysmal AF by AAD, the addition of POBI to CPVI did not improve the rhythm outcome of catheter ablation nor influence overall safety, while leading to longer ablation time.",2020,"The recurrences as atrial tachycardias (5.3% vs. 12.3%, p=0.134) and cardioversion rates (5.3% vs. 10.5%, p=0.250) were not significantly different between the CPVI and POBI group.","['Paroxysmal Atrial Fibrillation', '114 patients with PeAF to PAF (male 75%, 59.8 ± 9.9 years old) to circumferential pulmonary vein isolation (CPVI) alone group (n=57) and additional POBI group (n=57']","['Electrical Posterior Box Isolation', 'electrical posterior box isolation (POBI', ' - Persistent atrial fibrillation (PeAF']","['clinical recurrence rate', 'rhythm outcome of catheter ablation', 'recurrences as atrial tachycardias', 'recurrence pattern, cardioversion rate, and response to AADs', 'cardioversion rates', 'major complication rates', 'AF recurrence', 'total ablation time']","[{'cui': 'C0235480', 'cui_str': 'Paroxysmal atrial fibrillation'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032172', 'cui_str': 'Platelet activating factor'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205113', 'cui_str': 'Circumferential'}, {'cui': 'C3544330', 'cui_str': 'Pulmonary vein isolation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0006080', 'cui_str': 'Boxing'}, {'cui': 'C0037421', 'cui_str': 'Social isolation'}, {'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0162563', 'cui_str': 'Cardiac ablation'}, {'cui': 'C0030587', 'cui_str': 'Atrial paroxysmal tachycardia'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0013778', 'cui_str': 'Cardioversion'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",114.0,0.0438541,"The recurrences as atrial tachycardias (5.3% vs. 12.3%, p=0.134) and cardioversion rates (5.3% vs. 10.5%, p=0.250) were not significantly different between the CPVI and POBI group.","[{'ForeName': 'Hui-Nam', 'Initials': 'HN', 'LastName': 'Pak', 'Affiliation': 'Yonsei University Health System, Seoul, Republic of Korea.'}, {'ForeName': 'Junbeom', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': 'Ewha Womans University, Seoul, Republic of Korea.'}, {'ForeName': 'Je-Wook', 'Initials': 'JW', 'LastName': 'Park', 'Affiliation': 'Yonsei University Health System, Seoul, Republic of Korea.'}, {'ForeName': 'Song-Yi', 'Initials': 'SY', 'LastName': 'Yang', 'Affiliation': 'Yonsei University Health System, Seoul, Republic of Korea.'}, {'ForeName': 'Hee Tae', 'Initials': 'HT', 'LastName': 'Yu', 'Affiliation': 'Yonsei University Health System, Seoul, Republic of Korea.'}, {'ForeName': 'Tae-Hoon', 'Initials': 'TH', 'LastName': 'Kim', 'Affiliation': 'Yonsei University Health System, Seoul, Republic of Korea.'}, {'ForeName': 'Jae-Sun', 'Initials': 'JS', 'LastName': 'Uhm', 'Affiliation': 'Yonsei University Health System, Seoul, Republic of Korea.'}, {'ForeName': 'Jong-Il', 'Initials': 'JI', 'LastName': 'Choi', 'Affiliation': 'Korea University Cardiovascular Center, Seoul, Republic of Korea.'}, {'ForeName': 'Boyoung', 'Initials': 'B', 'LastName': 'Joung', 'Affiliation': 'Yonsei University Health System, Seoul, Republic of Korea.'}, {'ForeName': 'Moon-Hyoung', 'Initials': 'MH', 'LastName': 'Lee', 'Affiliation': 'Yonsei University Health System, Seoul, Republic of Korea.'}, {'ForeName': 'Young-Hoon', 'Initials': 'YH', 'LastName': 'Kim', 'Affiliation': 'Korea University Cardiovascular Center, Seoul, Republic of Korea.'}, {'ForeName': 'Jaemin', 'Initials': 'J', 'LastName': 'Shim', 'Affiliation': 'Korea University Cardiovascular Center, Seoul, Republic of Korea.'}]",Circulation. Arrhythmia and electrophysiology,['10.1161/CIRCEP.120.008531'] 2503,32755413,Preconception Blood Pressure and Its Change Into Early Pregnancy: Early Risk Factors for Preeclampsia and Gestational Hypertension.,"Preeclampsia and gestational hypertension are common complications of pregnancy associated with significant maternal and infant morbidity. Despite extensive research evaluating risk factors during pregnancy, most women who develop a hypertensive disorder of pregnancy are not considered high-risk and strategies for prevention remain elusive. We evaluated preconception blood pressure and its change into early pregnancy as novel risk markers for development of a hypertensive disorder of pregnancy. The EAGeR (Effects of Aspirin in Gestation and Reproduction) trial (2007-2011) randomized 1228 healthy women with a history of pregnancy loss to preconception-initiated low-dose aspirin versus placebo and followed participants for up to 6 menstrual cycles attempting pregnancy and throughout pregnancy if they became pregnant. Blood pressure was measured during preconception and throughout early gestation. The primary outcomes, preterm preeclampsia, term preeclampsia, and gestational hypertension, were abstracted from medical records. Among 586 women with a pregnancy >20 weeks' gestation, preconception blood pressure levels were higher for preterm preeclampsia (87.3±6.7 mm Hg mean arterial pressure), term preeclampsia (88.3±9.8 mm Hg), and gestational hypertension (87.9±9.1 mm Hg) as compared with no hypertensive disorder of pregnancy (83.9±8.6 mm Hg). Change in blood pressure from preconception into very early pregnancy was associated with development of preeclampsia (relative risk, 1.13 [95% CI, 1.02-1.25] per 2 mm Hg increase in mean arterial pressure at 4 weeks' gestation), particularly preterm preeclampsia (relative risk, 1.21 [95% CI, 1.01-1.45]). Randomization to aspirin did not alter blood pressure trajectory or risk of hypertension in pregnancy. Preconception blood pressure and longitudinal changes during early pregnancy are underexplored but crucial windows in the detection and prevention of hypertensive disorders of pregnancy. Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00467363.",2020,Randomization to aspirin did not alter blood pressure trajectory or risk of hypertension in pregnancy.,"['1228 healthy women with a history of pregnancy loss to preconception-initiated low-dose', ""586 women with a pregnancy >20 weeks' gestation, preconception blood pressure levels were higher for preterm preeclampsia (87.3±6.7 mm Hg mean arterial pressure), term preeclampsia (88.3±9.8 mm Hg), and gestational hypertension (87.9±9.1 mm Hg) as compared with no hypertensive disorder of pregnancy (83.9±8.6 mm Hg"", 'and followed participants for up to 6 menstrual cycles attempting pregnancy and throughout pregnancy if they became pregnant']","['Aspirin', 'aspirin', 'aspirin versus placebo']","['blood pressure trajectory or risk of hypertension in pregnancy', 'blood pressure', 'mean arterial pressure', 'Blood pressure', 'preterm preeclampsia', 'preterm preeclampsia, term preeclampsia, and gestational hypertension', 'Preeclampsia and gestational hypertension']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032967', 'cui_str': 'H/O: pregnancy'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0341934', 'cui_str': 'Transient hypertension of pregnancy'}, {'cui': 'C0852260', 'cui_str': 'Hypertension associated disorders of pregnancy'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0025329', 'cui_str': 'Normal menstrual cycle'}, {'cui': 'C0549206', 'cui_str': 'Pregnant'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0565599', 'cui_str': 'Maternal hypertension'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0341934', 'cui_str': 'Transient hypertension of pregnancy'}]",1228.0,0.253145,Randomization to aspirin did not alter blood pressure trajectory or risk of hypertension in pregnancy.,"[{'ForeName': 'Carrie J', 'Initials': 'CJ', 'LastName': 'Nobles', 'Affiliation': 'From the Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (C.J.N., P.M., S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).'}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Mendola', 'Affiliation': 'From the Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (C.J.N., P.M., S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).'}, {'ForeName': 'Sunni L', 'Initials': 'SL', 'LastName': 'Mumford', 'Affiliation': 'From the Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (C.J.N., P.M., S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Silver', 'Affiliation': 'Obstetrics and Gynecology, School of Medicine, University of Utah (R.M.S.).'}, {'ForeName': 'Keewan', 'Initials': 'K', 'LastName': 'Kim', 'Affiliation': 'From the Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (C.J.N., P.M., S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).'}, {'ForeName': 'Victoria C', 'Initials': 'VC', 'LastName': 'Andriessen', 'Affiliation': 'From the Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (C.J.N., P.M., S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Connell', 'Affiliation': 'From the Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (C.J.N., P.M., S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).'}, {'ForeName': 'Lindsey', 'Initials': 'L', 'LastName': 'Sjaarda', 'Affiliation': 'From the Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (C.J.N., P.M., S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).'}, {'ForeName': 'Neil J', 'Initials': 'NJ', 'LastName': 'Perkins', 'Affiliation': 'From the Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (C.J.N., P.M., S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).'}, {'ForeName': 'Enrique F', 'Initials': 'EF', 'LastName': 'Schisterman', 'Affiliation': 'From the Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (C.J.N., P.M., S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).'}]","Hypertension (Dallas, Tex. : 1979)",['10.1161/HYPERTENSIONAHA.120.14875'] 2504,32755419,Blast exposure results in tau and neurofilament light chain changes in peripheral blood.,"OBJECTIVES To evaluate how blast exposure impacts peripheral biomarkers. in military personnel enrolled in 10-day blast training. METHODS On day 7, 21 military personnel experienced peak overpressure <2 pounds per square inch (psi); while 29 military personnel experienced peak overpressure ≥5 psi. Blood samples were collected each day to measure changes in amyloid beta (Aβ), neurofilament light chain (NFL), and tau concentrations. RESULTS Within 24 hours following exposure ≥5 psi, the ≥5 psi group had lower Aβ42 ( p = .004) and NFL ( p < .001) compared to the <2 psi group and lower Aβ42 (9.35%) and NFL (22.01%) compared to baseline. Twenty-four hours after ≥5 psi exposure, the ≥5 psi group had lower tau ( p < .001) and NFL ( p < .001) compared to the <2 psi group and baseline. Seventy-two hours after exposure ≥5 psi, tau increased in the ≥5 psi group compared to the <2 psi group ( p = .02) and baseline. The tau:Aβ42 ratio 24 hours after blast ( p = .012), and the Aβ40:Aβ42 ratio 48 hours after blast ( p = .04) differed in the ≥5 psi group compared to the <2 psi group. CONCLUSIONS These findings provide an initial report of acute alterations in biomarker concentrations following blast exposure.",2020,"The tau:Aβ42 ratio 24 hours after blast ( p = .012), and the Aβ40:Aβ42 ratio 48 hours after blast ( p = .04) differed in the ≥5 psi group compared to the <2 psi group. ",['military personnel enrolled in 10-day blast training'],[],"['peripheral blood', 'neurofilament light chain (NFL), and tau concentrations', 'NFL', 'amyloid beta ']","[{'cui': 'C0026126', 'cui_str': 'Military personnel'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0337026', 'cui_str': 'Blast'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",[],"[{'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0027834', 'cui_str': 'Neurofilaments'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0002716', 'cui_str': 'Amyloid Substance'}, {'cui': 'C0330390', 'cui_str': 'Beta'}]",,0.0370886,"The tau:Aβ42 ratio 24 hours after blast ( p = .012), and the Aβ40:Aβ42 ratio 48 hours after blast ( p = .04) differed in the ≥5 psi group compared to the <2 psi group. ","[{'ForeName': 'Katie A', 'Initials': 'KA', 'LastName': 'Edwards', 'Affiliation': 'National Institute of Nursing Research, National Institutes of Health , Bethesda, MD, USA.'}, {'ForeName': 'Jacqueline J', 'Initials': 'JJ', 'LastName': 'Leete', 'Affiliation': 'National Institute of Nursing Research, National Institutes of Health , Bethesda, MD, USA.'}, {'ForeName': 'Anna E', 'Initials': 'AE', 'LastName': 'Tschiffely', 'Affiliation': 'Department of Neurotrauma, Naval Medical Research Center , Silver Spring, MD, USA.'}, {'ForeName': 'Candace Y', 'Initials': 'CY', 'LastName': 'Moore', 'Affiliation': 'National Institute of Nursing Research, National Institutes of Health , Bethesda, MD, USA.'}, {'ForeName': 'Kristine C', 'Initials': 'KC', 'LastName': 'Dell', 'Affiliation': 'Department of Psychology, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Jonathan K', 'Initials': 'JK', 'LastName': 'Statz', 'Affiliation': 'Henry M. Jackson Foundation, Bethesda, MD, USA.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Carr', 'Affiliation': 'Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA.'}, {'ForeName': 'Peter B', 'Initials': 'PB', 'LastName': 'Walker', 'Affiliation': 'Joint Artificial Intelligence Center, Arlington, VA, USA.'}, {'ForeName': 'Matthew L', 'Initials': 'ML', 'LastName': 'LoPresti', 'Affiliation': 'Center for Military Psychiatry & Neuroscience, Walter Reed Army Institute of Research, Silver Spring, , MD, USA.'}, {'ForeName': 'Stephen T', 'Initials': 'ST', 'LastName': 'Ahlers', 'Affiliation': 'Operational & Undersea Medicine Directorate, Naval Medical Research Center, Silver Spring, MD, USA.'}, {'ForeName': 'Angela M', 'Initials': 'AM', 'LastName': 'Yarnell', 'Affiliation': 'Operational & Undersea Medicine Directorate, Naval Medical Research Center, Silver Spring, MD, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Gill', 'Affiliation': 'National Institute of Nursing Research, National Institutes of Health , Bethesda, MD, USA.'}]",Brain injury,['10.1080/02699052.2020.1797171'] 2505,32755427,"Continuous walking and time- and intensity-matched interval walking: Cardiometabolic demand and post-exercise enjoyment in insufficiently active, healthy adults.","We compared cardiometabolic demand and post-exercise enjoyment between continuous walking (CW) and time- and intensity-matched interval walking (IW) in insufficiently active adults. Sixteen individuals (13 females and three males, age 25.3 ± 11.1 years) completed one CW and one IW session lasting 30 min in a randomised-counterbalanced design. For CW, participants walked at a mean intensity of 65-70% predicted maximum heart rate (HR max ). For IW, participants alternated between 3 min at 80% HR max and 2 min at 50% HR max . Expired gas was measured throughout each protocol. Participants rated post-exercise enjoyment following each protocol. Mean HR and V̇O 2 showed small positive differences in IW vs. CW (2, 95%CL 0, 4 beat.min -1 ; d = 0.23, 95%CL 0.06, 0.41 and 1.4, 95%CL 1.2 ml.kg -1 .min -1 , d = 0.36, 95%CL 0.05, 0.65, respectively). There was a medium positive difference in overall kcal expenditure in IW vs. CW (25, 95%CL 7 kcal, d = 0.58, 95%CL 0.33, 0.82). Post-exercise enjoyment was moderately greater following IW vs. CW (9.1, 95%CL 1.4, 16.8 AU, d = 0.62, 95%CL 0.06, 0.90), with 75% of participants reporting IW as more enjoyable. Interval walking elicits meaningfully greater energy expenditure and is more enjoyable than CW in insufficiently active, healthy adults.",2020,"Post-exercise enjoyment was moderately greater following IW vs. CW (9.1, 95%CL 1.4, 16.8 AU, d = 0.62, 95%CL 0.06, 0.90), with 75% of participants reporting IW as more enjoyable.","['insufficiently active, healthy adults', 'Sixteen individuals (13 females and three males, age 25.3\xa0±\xa011.1\xa0years', 'healthy adults', 'insufficiently active adults']","['Interval walking elicits meaningfully greater energy expenditure', '95%CL', 'Continuous walking and time- and intensity-matched interval walking: Cardiometabolic demand and post-exercise enjoyment', 'cardiometabolic demand and post-exercise enjoyment between continuous walking (CW) and time- and intensity-matched interval walking (IW']","['maximum heart rate (HR max ', 'Post-exercise enjoyment', 'Mean HR and V̇O', 'overall kcal expenditure']","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0449265', 'cui_str': 'Elicited by'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1979962', 'cui_str': 'After exercise'}, {'cui': 'C0679105', 'cui_str': 'Pleasure'}]","[{'cui': 'C0744679', 'cui_str': 'Maximum heart rate'}, {'cui': 'C1979962', 'cui_str': 'After exercise'}, {'cui': 'C0679105', 'cui_str': 'Pleasure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0015316', 'cui_str': 'Expenditures'}]",,0.332494,"Post-exercise enjoyment was moderately greater following IW vs. CW (9.1, 95%CL 1.4, 16.8 AU, d = 0.62, 95%CL 0.06, 0.90), with 75% of participants reporting IW as more enjoyable.","[{'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Francis', 'Affiliation': 'Edinburgh Medical School, The University of Edinburgh , Edinburgh, UK.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Williamson', 'Affiliation': 'Edinburgh Medical School, The University of Edinburgh , Edinburgh, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Kelly', 'Affiliation': 'Physical Activity for Health Research Centre, The University of Edinburgh , Edinburgh, UK.'}, {'ForeName': 'Shaun M', 'Initials': 'SM', 'LastName': 'Phillips', 'Affiliation': 'Human Performance Science Research Group, The University of Edinburgh , Edinburgh, UK.'}]",Journal of sports sciences,['10.1080/02640414.2020.1803717'] 2506,32755526,Septic Shock: A Genomewide Association Study and Polygenic Risk Score Analysis.,"Previous genetic association studies have failed to identify loci robustly associated with sepsis, and there have been no published genetic association studies or polygenic risk score analyses of patients with septic shock, despite evidence suggesting genetic factors may be involved. We systematically collected genotype and clinical outcome data in the context of a randomized controlled trial from patients with septic shock to enrich the presence of disease-associated genetic variants. We performed genomewide association studies of susceptibility and mortality in septic shock using 493 patients with septic shock and 2442 population controls, and polygenic risk score analysis to assess genetic overlap between septic shock risk/mortality with clinically relevant traits. One variant, rs9489328, located in AL589740.1 noncoding RNA, was significantly associated with septic shock (p = 1.05 × 10-10); however, it is likely a false-positive. We were unable to replicate variants previously reported to be associated (p < 1.00 × 10-6 in previous scans) with susceptibility to and mortality from sepsis. Polygenic risk scores for hematocrit and granulocyte count were negatively associated with 28-day mortality (p = 3.04 × 10-3; p = 2.29 × 10-3), and scores for C-reactive protein levels were positively associated with susceptibility to septic shock (p = 1.44 × 10-3). Results suggest that common variants of large effect do not influence septic shock susceptibility, mortality and resolution; however, genetic predispositions to clinically relevant traits are significantly associated with increased susceptibility and mortality in septic individuals.",2020,"Polygenic risk scores for hematocrit and granulocyte count were negatively associated with 28-day mortality (p = 3.04 × 10-3; p = 2.29 × 10-3), and scores for C-reactive protein levels were positively associated with susceptibility to septic shock (p = 1.44 × 10-3).","['patients with septic shock to enrich the presence of disease-associated genetic variants', 'Septic Shock', '493 patients with septic shock and 2442 population controls, and polygenic risk score analysis to assess genetic overlap between septic shock risk/mortality with clinically relevant traits']",[],"['septic shock', 'Polygenic risk scores for hematocrit and granulocyte count', 'susceptibility and mortality', '28-day mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036983', 'cui_str': 'Septic shock'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0017296', 'cui_str': 'Gene therapy'}, {'cui': 'C0205419', 'cui_str': 'Variant'}, {'cui': 'C0032662', 'cui_str': 'Population Control'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0185027', 'cui_str': 'Imbrication'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",[],"[{'cui': 'C0036983', 'cui_str': 'Septic shock'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}, {'cui': 'C0857490', 'cui_str': 'Granulocyte count'}, {'cui': 'C0012655', 'cui_str': 'Diathesis'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",,0.431108,"Polygenic risk scores for hematocrit and granulocyte count were negatively associated with 28-day mortality (p = 3.04 × 10-3; p = 2.29 × 10-3), and scores for C-reactive protein levels were positively associated with susceptibility to septic shock (p = 1.44 × 10-3).","[{'ForeName': 'Shannon', 'Initials': 'S', 'LastName': ""D'Urso"", 'Affiliation': 'The University of Queensland Diamantina Institute, University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Dorrilyn', 'Initials': 'D', 'LastName': 'Rajbhandari', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Peach', 'Affiliation': 'The University of Queensland Diamantina Institute, University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'de Guzman', 'Affiliation': 'Australian Translational Genomics Centre, Queensland University of Technology, Brisbane, Australia.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Medland', 'Affiliation': 'QIMR Berghofer Medical Research Institute, Brisbane, Australia.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Gordon', 'Affiliation': 'QIMR Berghofer Medical Research Institute, Brisbane, Australia.'}, {'ForeName': 'Nicholas G', 'Initials': 'NG', 'LastName': 'Martin', 'Affiliation': 'QIMR Berghofer Medical Research Institute, Brisbane, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Symen', 'Initials': 'S', 'LastName': 'Ligthart', 'Affiliation': 'Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Matthew A', 'Initials': 'MA', 'LastName': 'Brown', 'Affiliation': ""Guy's & St Thomas' NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, London, England.""}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Powell', 'Affiliation': 'Garvan-Weizmann Centre for Cellular Genomics, Garvan Institute, Sydney, Australia.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'McArthur', 'Affiliation': 'Department of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealand.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Rhodes', 'Affiliation': ""Department of Adult Critical Care, St George's University Hospitals NHS Foundation Trust and St George's University of London, London, UK.""}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Meyer', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Finfer', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Myburgh', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia.'}, {'ForeName': 'Antje', 'Initials': 'A', 'LastName': 'Blumenthal', 'Affiliation': 'The University of Queensland Diamantina Institute, University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Cohen', 'Affiliation': ""Royal Brisbane and Women's Hospital, Brisbane, Australia.""}, {'ForeName': 'Balasubramanian', 'Initials': 'B', 'LastName': 'Venkatesh', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Cuellar-Partida', 'Affiliation': 'The University of Queensland Diamantina Institute, University of Queensland, Brisbane, Australia.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Evans', 'Affiliation': 'The University of Queensland Diamantina Institute, University of Queensland, Brisbane, Australia.'}]",Twin research and human genetics : the official journal of the International Society for Twin Studies,['10.1017/thg.2020.60'] 2507,32755632,Training Community Therapists to Deliver a Mental Health Intervention for Autism Spectrum Disorder: Changes in Caregiver Outcomes and Mediating Role on Child Outcomes.,"OBJECTIVE This study examines the impact of training therapists to deliver An Individualized Mental Health Intervention for autism spectrum disorder (ASD) (AIM HI) for children with autism spectrum disorder on caregiver outcomes and the mediating role of changes in caregiver outcomes on child outcomes. METHOD Data were drawn from a cluster randomized trial conducted in 29 publicly-funded mental health programs randomized to receive AIM HI training or usual care. Therapists were recruited from enrolled programs and child/caregiver participants enrolled from therapists' caseloads. Participants included 202 caregivers of children aged 5 to 13 with autism spectrum disorder. Caregiver strain and sense of competence were assessed at baseline and 6 month post baseline. Child behaviors were assessed at baseline and 6, 12, and 18 months post baseline. Therapist delivery of evidence-based intervention strategies were assessed between baseline and 6 months. RESULTS A significant training effect was observed for caregiver sense of competence, with AIM HI caregivers reporting significantly greater improvement relative to usual care. There was no significant training effect for caregiver strain. Observer-rated therapist delivery of evidence-based interventions strategies over 6 months mediated training effects for sense of competence at 6 months. Changes in sense of competence from baseline to 6 months was associated with reduced child challenging behaviors at 6 months and mediated child outcomes at 12 and 18 months. CONCLUSION Combined with research demonstrating effectiveness of therapist AIM HI training on child outcomes, this study provides further evidence of the positive impact of training community therapists in the AIM HI intervention.",2020,"Changes in sense of competence from baseline to 6 months was associated with reduced child challenging behaviors at 6 months and mediated child outcomes at 12 and 18 months. ","['children with autism spectrum disorder', 'Autism', 'Participants included 202 caregivers of children aged 5 to 13 with autism spectrum disorder', 'autism spectrum disorder (ASD', ""Therapists were recruited from enrolled programs and child/caregiver participants enrolled from therapists' caseloads"", 'Data were drawn from a cluster randomized trial conducted in 29 publicly-funded mental health programs']","['Mental Health Intervention', 'HI training or usual care', 'therapist AIM HI training', 'training therapists to deliver An Individualized Mental Health Intervention']","['Caregiver strain and sense of competence', 'Child behaviors', 'caregiver sense of competence']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0013113', 'cui_str': 'Drawings'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0016820', 'cui_str': 'Funds'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C2744535', 'cui_str': 'CD69 protein, human'}]","[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0008065', 'cui_str': 'Behavior, Child'}]",202.0,0.180546,"Changes in sense of competence from baseline to 6 months was associated with reduced child challenging behaviors at 6 months and mediated child outcomes at 12 and 18 months. ","[{'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Brookman-Frazee', 'Affiliation': ""Child and Adolescent Services Research Center, San Diego, California; University of California, San Diego; Rady Children's Hospital, San Diego, California.""}, {'ForeName': 'Colby', 'Initials': 'C', 'LastName': 'Chlebowski', 'Affiliation': 'Child and Adolescent Services Research Center, San Diego, California; University of California, San Diego. Electronic address: cchlebowski@health.ucsd.edu.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Villodas', 'Affiliation': 'Child and Adolescent Services Research Center, San Diego, California; San Diego State University, California.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Roesch', 'Affiliation': 'San Diego State University, California.'}, {'ForeName': 'Kassandra', 'Initials': 'K', 'LastName': 'Martinez', 'Affiliation': 'Child and Adolescent Services Research Center, San Diego, California; SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, California.'}]",Journal of the American Academy of Child and Adolescent Psychiatry,['10.1016/j.jaac.2020.07.896'] 2508,32755695,Pharmacokinetics of fluoride in human adults: The effect of exercise.,"The literature is sparse in terms of the effect of exercise on the pharmacokinetics of fluoride (F) in humans. In a 4-treatment repeated measures cross-over study, we investigated F pharmacokinetics following no exercise (control) and three exercise intensity conditions (light, moderate and vigorous) in healthy adults. At a pre-experimental session, 8 participants (18-30y) residing in a non-fluoridated-area, underwent a VO 2 max test to guide the three exercise intensities for the experimental sessions. Participants were on a F-free regime one week before and throughout the four experimental weeks. We measured urinary F excretion (UFE), maximum plasma concentration (Cmax), lag time of Cmax (Tmax), and Area Under the Curve (AUC) for plasma F concentration against time, following F ingestion then no, light, moderate and vigorous exercise. Results showed no statistically significant difference in Tmax among all sessions; whereas Cmax for moderate exercise (226.2 ng/ml) was significantly higher than for no (27.0 ng/ml; p < 0.001), light (105.6 ng/ml; p = 0.016) and vigorous (94.2 ng/ml; p = 0.008) exercise. Mean AUC over 0-90 min following F ingestion was also significantly higher in moderate exercise than for no (p < 0.001), light (p = 0.004) and vigorous (p = 0.001) exercise. Mean UFE over 0-14h was 638.8, 718.7, 574.6 and 450.5  μg for no, light, moderate and vigorous exercise, with no statistically significant differences among different sessions. In conclusion, this human experimental study suggests that moderate exercise may increase the fraction of F absorbed systemically which is therefore available to produce a biological effect. Future studies should be conducted with larger samples, different age groups and using different F doses.",2020,"Mean AUC over 0-90 min following F ingestion was also significantly higher in moderate exercise than for no (p < 0.001), light (p = 0.004) and vigorous (p = 0.001) exercise.","['healthy adults', 'human adults', 'humans']","['no exercise (control) and three exercise intensity conditions (light, moderate and vigorous', 'fluoride']","['Cmax for moderate exercise', 'urinary F excretion (UFE), maximum plasma concentration (Cmax), lag time of Cmax (Tmax), and Area Under the Curve (AUC) for plasma F concentration against time, following F ingestion then no, light, moderate and vigorous exercise', 'Mean AUC', 'Tmax', 'Mean UFE']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0016327', 'cui_str': 'Fluoride'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",,0.0384832,"Mean AUC over 0-90 min following F ingestion was also significantly higher in moderate exercise than for no (p < 0.001), light (p = 0.004) and vigorous (p = 0.001) exercise.","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Mahmood', 'Affiliation': 'School of Health and Life Sciences, Teesside University, Middlesbrough, UK.'}, {'ForeName': 'Liane B', 'Initials': 'LB', 'LastName': 'Azevedo', 'Affiliation': 'School of Human and Health Sciences, University of Huddersfield, Huddersfield, UK.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Maguire', 'Affiliation': 'School of Dental Sciences, Faculty of Medical Sciences, Newcastle University, Newcastle-upon-Tyne, UK.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Buzalaf', 'Affiliation': 'Bauru Dental School, University of Sao Paulo, Brazil.'}, {'ForeName': 'Fatemeh Vida', 'Initials': 'FV', 'LastName': 'Zohoori', 'Affiliation': 'School of Health and Life Sciences, Teesside University, Middlesbrough, UK. Electronic address: v.zohoori@tees.ac.uk.'}]",Chemosphere,['10.1016/j.chemosphere.2020.127796'] 2509,32760476,Short-term Haematological Parameters Following Surgical Removal of Mandibular Third Molars with Different Doses of Methylprednisolone Compared with Placebo. A Randomized Controlled Trial.,"Objectives To evaluate the influence of a single intraoperative injection of methylprednisolone on short-term haematological parameters following surgical removal of mandibular third molars. Material and Methods Fifty-two patients with indications for surgical removal of bilateral impacted mandibular third molars were included in a randomized, split-mouth and double-blinded study design. Each molar were randomly allocated into one of following four groups: 20 mg methylprednisolone, 30 mg methylprednisolone, 40 mg methylprednisolone and placebo. Peripheral blood samples were obtained before and three days after surgery. Haematological parameters involving haemoglobin, white blood cell count and C-reactive protein (CRP) were evaluated and expressed as mean changes. Level of significance was 0.05. Furthermore, outcomes were correlated for age, sex, smoking and time of surgery. Results There were no significant differences in postoperative haematological parameters with different doses of methylprednisolone compared with placebo. Peripheral blood samples revealed decreased level of haemoglobin and increased level of leucocytes and CRP in each group. Smokers displayed a significant lower level of haemoglobin and CRP compared with non-smokers (P < 0.05) and level of eosinophils decreased significantly with increasing age (P < 0.05). Conclusions This study indicates that a single intraoperative injection of methylprednisolone seems not to cause suppression of short-term haematological parameters compared with placebo following surgical removal of mandibular third molars.",2020,"Smokers displayed a significant lower level of haemoglobin and CRP compared with non-smokers (P < 0.05) and level of eosinophils decreased significantly with increasing age (P < 0.05). ","['Material and Methods\n\n\nFifty-two patients with indications for surgical removal of bilateral impacted mandibular third molars', 'surgical removal of mandibular third molars']","['methylprednisolone and placebo', 'Placebo', 'methylprednisolone', 'Methylprednisolone', 'placebo']","['Peripheral blood samples', 'Haematological parameters involving haemoglobin, white blood cell count and C-reactive protein (CRP', 'level of haemoglobin and CRP', 'level of eosinophils', 'level of haemoglobin and increased level of leucocytes and CRP', 'postoperative haematological parameters']","[{'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026369', 'cui_str': 'Structure of wisdom tooth'}]","[{'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0023516', 'cui_str': 'Leukocyte'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]",52.0,0.267727,"Smokers displayed a significant lower level of haemoglobin and CRP compared with non-smokers (P < 0.05) and level of eosinophils decreased significantly with increasing age (P < 0.05). ","[{'ForeName': 'Marie Kjærgaard', 'Initials': 'MK', 'LastName': 'Larsen', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Aalborg University HospitalDenmark.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Kofod', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Rigshospitalet, Copenhagen University HospitalDenmark.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Duch', 'Affiliation': 'Clinical unit of Biostatistics, Aalborg University Hospital, AalborgDenmark.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Starch-Jensen', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Aalborg University HospitalDenmark.'}]",Journal of oral & maxillofacial research,['10.5037/jomr.2020.11203'] 2510,32760479,The Efficacy of Soprolife ® in Detecting in Vitro Remineralization of Early Caries Lesions.,"Objectives This randomized controlled in vitro 4-arm trial study aimed to evaluate the efficacy of SoproLife ® in detecting and quantifying in vitro remineralization with early caries lesions. Material and Methods Sixty human teeth were randomly assigned into four equal groups. Groups 1 and 2 were prophylactically cleaned; groups 3 and 4 were not. Group 1 received treatment with MI Varnish ® and Recaldent™ for 30 days. Group 2 was treated similarly, but without MI Varnish ® . Group 3 was treated as 1 and Group 4 as 2. Mineral composition was obtained using scanning electron microscopy with energy dispersive X-ray analysis SoproLife ® camera images on the occlusal surfaces were analysed for grey value distribution and difference in mean intensity values (DI). Paired t-test and Mann-Whitney-U test were used for intragroup comparison between baseline and T1. Kruskal-Wallis followed by Mann-Whitney-U tests were used for inter-group comparisons at T1. Results All groups exhibited a significant increase in calcium content and calcium-to-phosphorus ratio (P < 0.05), except Group 4 (Group 1 showed the greatest increase, then Groups 3 and 2). Grey intensity values decreased in all groups (P < 0.05). Group 1 showed the greatest change in DI (16.82 [SD 12.07]), followed by Group 3 (12.46 [SD 9.41]), 2 (10.45 [SD 7.76]), and 4 (6.46 [SD 6.21]). The difference in DI was different between the compared groups (P = 0.038); Groups 1 and 3 exhibited a greater DI compared with 4 (P < 0.01). Conclusions Within the limitations of this study, SoproLife ® is effective for early detection and for longitudinally monitoring the remineralization after Recaldent™ therapy.",2020,"All groups exhibited a significant increase in calcium content and calcium-to-phosphorus ratio (P < 0.05), except Group 4 (Group 1 showed the greatest increase, then Groups 3 and 2).","['Vitro Remineralization of Early Caries Lesions', 'Material and Methods\n\n\nSixty human teeth']","['Soprolife ®', 'MI Varnish ® and Recaldent™ for 30 days', 'SoproLife ®']","['calcium content and calcium-to-phosphorus ratio', 'Grey intensity values', 'mean intensity values (DI', 'Mineral composition', 'greatest change in DI']","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}]","[{'cui': 'C0042359', 'cui_str': 'Varnish'}, {'cui': 'C1120339', 'cui_str': 'Recaldent'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0031705', 'cui_str': 'Phosphorus'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1269776', 'cui_str': 'Gray color'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",60.0,0.0482363,"All groups exhibited a significant increase in calcium content and calcium-to-phosphorus ratio (P < 0.05), except Group 4 (Group 1 showed the greatest increase, then Groups 3 and 2).","[{'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Zeitouny', 'Affiliation': 'Department of Restorative and Esthetic, Faculty of dentistry, Lebanese University, HadathLebanon.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Cuisinier', 'Affiliation': 'Laboratoire Bioingénieurie et Nanosciences (LBN), Université de Montpellier, MontpellierFrance.'}, {'ForeName': 'Hervé', 'Initials': 'H', 'LastName': 'Tassery', 'Affiliation': 'Laboratoire Bioingénieurie et Nanosciences (LBN), Université de Montpellier, MontpellierFrance.'}, {'ForeName': 'Hussein', 'Initials': 'H', 'LastName': 'Fayyad-Kazan', 'Affiliation': 'Laboratory of Cancer Biology and Molecular Immunology, Faculty of Sciences I, Lebanese University, HadathLebanon.'}]",Journal of oral & maxillofacial research,['10.5037/jomr.2020.11206'] 2511,32753940,"Analgesic Effect of Ultrasound-Guided Preoperative Unilateral Lateral Quadratus Lumborum Block for Laparoscopic Nephrectomy: A Randomized, Double-Blinded, Controlled Trial.","Purpose The quadratus lumborum block (QLB) is a relatively new regional analgesic technique that could provide analgesia to the abdominal wall and reduce postoperative opioid consumption. We investigated the opioid-sparing effect of a unilateral lateral QLB in laparoscopic nephrectomy. Patients and Methods A total of 60 patients undergoing laparoscopic nephrectomy were included in the study. Patients were randomized into two groups as QLB and control group. QLB group received QLB with 25mL 0.25% ropivacaine, and the control group received 25mL 0.9% saline at anterolateral border of quadratus lumborum muscle preoperatively. Opioid consumption and the pain intensity at rest and on movement were measured at 2nd, 6th, 24th, and 48th hour postoperatively. We also assessed the time to first flatus to measure the extent of paralytic ileus and the quality of recovery-15 (QoR-15) questionnaire. Results Postoperative opioid consumption was significantly lower in the QLB group than in the control group at 6, 24, and 48h after surgery ( P < 0.05). The pain intensity at rest and on movement was significantly lower in the QLB group than in the control group during the first 24 hours after surgery ( P < 0.05). The incidence of postoperative nausea and vomiting, time to first flatus, and QoR-15 score did not show significant differences. Conclusion Preoperative unilateral QLB successfully decreased postoperative pain and opioid consumption after laparoscopic nephrectomy and could be an option for analgesia after laparoscopic nephrectomy.",2020,The pain intensity at rest and on movement was significantly lower in the QLB group than in the control group during the first 24 hours after surgery ( P < 0.05).,"['Patients and Methods\n\n\nA total of 60 patients undergoing', 'Laparoscopic Nephrectomy']","['QLB', 'unilateral lateral QLB', 'Ultrasound-Guided Preoperative Unilateral Lateral Quadratus Lumborum Block', 'laparoscopic nephrectomy', '25mL 0.9% saline', 'QLB with 25mL 0.25% ropivacaine', 'quadratus lumborum block (QLB']","['postoperative nausea and vomiting, time to first flatus, and QoR-15 score', 'pain intensity at rest and on movement', 'paralytic ileus and the quality of recovery-15 (QoR-15) questionnaire', 'Postoperative opioid consumption', 'Opioid consumption and the pain intensity', 'postoperative pain and opioid consumption']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0027695', 'cui_str': 'Kidney excision'}]","[{'cui': 'C0224380', 'cui_str': 'Structure of quadratus lumborum muscle'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0027695', 'cui_str': 'Kidney excision'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C4517443', 'cui_str': '0.25'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}]","[{'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0443144', 'cui_str': 'At rest'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0030446', 'cui_str': 'Paralytic ileus'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}]",60.0,0.159924,The pain intensity at rest and on movement was significantly lower in the QLB group than in the control group during the first 24 hours after surgery ( P < 0.05).,"[{'ForeName': 'Kyung-Hwa', 'Initials': 'KH', 'LastName': 'Kwak', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kyungpook National University Chilgok Hospital, Kyungpook National University School of Medicine, Daegu, Korea.'}, {'ForeName': 'Seung Ik', 'Initials': 'SI', 'LastName': 'Baek', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kyungpook National University Chilgok Hospital, Kyungpook National University School of Medicine, Daegu, Korea.'}, {'ForeName': 'Jay Kyoung', 'Initials': 'JK', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kyungpook National University Chilgok Hospital, Kyungpook National University School of Medicine, Daegu, Korea.'}, {'ForeName': 'Tae-Hwan', 'Initials': 'TH', 'LastName': 'Kim', 'Affiliation': 'Department of Urology, Kyungpook National University Chilgok Hospital, Kyungpook National University School of Medicine, Daegu, Korea.'}, {'ForeName': 'Jinseok', 'Initials': 'J', 'LastName': 'Yeo', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kyungpook National University Chilgok Hospital, Kyungpook National University School of Medicine, Daegu, Korea.'}]",Journal of pain research,['10.2147/JPR.S257466'] 2512,32753943,Effects of Trigger Point Dry Needling on Neuromuscular Performance and Pain of Individuals Affected by Patellofemoral Pain: A Randomized Controlled Trial.,"Purpose To investigate the effects of trigger point dry needling (TrP-DN) on exercise-induced patellofemoral pain syndrome (PFPS). Patients and Methods In this randomized, single-blind, parallel-group trial, 50 patients with PFPS were randomly allocated to the following two groups: the TrP-DN group (n = 25) and the Sham needling group (n = 25). Patients in both groups were asked to perform a stretching exercise of the quadriceps daily after needling. The needling group received a single session of TrP-DN to trigger points (TrPs) in the vastus medialis oblique (VMO), vastus lateralis (VL), and rectus femoris muscles (once a week for 6 weeks), and the Sham group received placebo needling. Visual analogue scale (VAS) for pain intensity and Kujala questionnaire for the functional status were assessed before treatment, 3 and 6 weeks after treatment, and at the 3-month follow-up. The ratio of the myoelectric amplitude of the vastus medialis oblique and vastus lateralis muscles (VMO/VL) was assessed before treatment and 6 weeks after treatment. Results There was no significant difference in the general data between the two groups. The VAS scores and Kujala scores in the TrP-DN group were significantly improved and increased at the 3-week treatment visit, 6-week treatment visit, and 3-month follow-up compared to the scores before treatment; and the scores in the Sham group were only significantly improved at the 3-week treatment visit, and 6-week treatment visit. VAS scores in the TrP-DN group were significantly lower and Kujala scores were significantly higher at the 6-week treatment visit and the 3-month follow-up compared to those in the Sham group. The VMO/VL ratio in the TrP-DN group was significantly increased at the 6-week treatment visit compared to that before treatment. Conclusion TrP-DN at the quadriceps combined with stretch can reduce the pain, and improves the clinical symptoms and function, the VMO/VL ratio, and the coordination of VMO and VL in patients with PFPS.",2020,"The VMO/VL ratio in the TrP-DN group was significantly increased at the 6-week treatment visit compared to that before treatment. ","['patients with PFPS', '50 patients with PFPS', 'exercise-induced patellofemoral pain syndrome (PFPS', 'Individuals Affected by Patellofemoral Pain']","['trigger point dry needling (TrP-DN', 'single session of TrP-DN to trigger points (TrPs', 'stretching exercise', 'Sham needling group', 'TrP-DN', 'Trigger Point Dry Needling', 'placebo needling']","['VAS scores and Kujala scores', 'ratio of the myoelectric amplitude of the vastus medialis oblique and vastus lateralis muscles (VMO/VL', 'Visual analogue scale (VAS) for pain intensity and Kujala questionnaire for the functional status', 'Kujala scores', 'VMO/VL ratio', 'clinical symptoms and function, the VMO/VL ratio, and the coordination of VMO and VL', 'Neuromuscular Performance and Pain', 'VAS scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0877149', 'cui_str': 'Patellofemoral pain syndrome'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0458343', 'cui_str': 'Trigger point'}, {'cui': 'C0394648', 'cui_str': 'Dry needle acupuncture'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0011682', 'cui_str': 'Desiccation - action'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0600080', 'cui_str': 'Stretching exercises'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0224445', 'cui_str': 'Structure of vastus medialis muscle'}, {'cui': 'C0205315', 'cui_str': 'Oblique'}, {'cui': 'C0224444', 'cui_str': 'Structure of vastus lateralis muscle'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",50.0,0.0364052,"The VMO/VL ratio in the TrP-DN group was significantly increased at the 6-week treatment visit compared to that before treatment. ","[{'ForeName': 'Yan-Tao', 'Initials': 'YT', 'LastName': 'Ma', 'Affiliation': ""Department of Pain Management, Huadong Hospital Affiliated to Fudan University, Shanghai, People's Republic of China.""}, {'ForeName': 'Li-Hui', 'Initials': 'LH', 'LastName': 'Li', 'Affiliation': ""Department of Sport Rehabilitation, School of Kinesiology, Shanghai University of Sport, Shanghai, People's Republic of China.""}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Han', 'Affiliation': ""Department of Pain Management, Huadong Hospital Affiliated to Fudan University, Shanghai, People's Republic of China.""}, {'ForeName': 'Xiao-Lei', 'Initials': 'XL', 'LastName': 'Wang', 'Affiliation': ""Department of Pain Management, Huadong Hospital Affiliated to Fudan University, Shanghai, People's Republic of China.""}, {'ForeName': 'Pei-Yu', 'Initials': 'PY', 'LastName': 'Jia', 'Affiliation': ""Department of Pain Management, Huadong Hospital Affiliated to Fudan University, Shanghai, People's Republic of China.""}, {'ForeName': 'Qiang-Min', 'Initials': 'QM', 'LastName': 'Huang', 'Affiliation': ""Department of Sport Rehabilitation, School of Kinesiology, Shanghai University of Sport, Shanghai, People's Republic of China.""}, {'ForeName': 'Yong-Jun', 'Initials': 'YJ', 'LastName': 'Zheng', 'Affiliation': ""Department of Pain Management, Huadong Hospital Affiliated to Fudan University, Shanghai, People's Republic of China.""}]",Journal of pain research,['10.2147/JPR.S240376'] 2513,32753945,Platelet-Rich Plasma-Derived Growth Factor vs Hyaluronic Acid Injection in the Individuals with Knee Osteoarthritis: A One Year Randomized Clinical Trial.,"Objective In this study, we aimed at performing a comparison between intra-articular injections of PRP-derived growth factor (PGRF) and hyaluronic acid regarding their effect on pain and patient's function in knee osteoarthritis, as well as their safety profiles. Methods During our single-masked randomized clinical trial, the candidates with symptomatic knee osteoarthritis received two intra-articular injections of PRGF with 3 weeks apart or received three weekly injections of HA. The mean improvements from before treatment until the second, sixth, and twelfth months post-intervention in scores obtained by visual analog scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Lequesne index were our primary outcomes. Results A total of 102 candidates were finally included in the study. Patients' mean age was 57.08±7.3 years old in the PRGF group compared to the mean age of 58.63±7.09 years old in HA patients. In the PRGF group, total WOMAC index decreased from 41.96±11.71 to 27.10±12.3 (P = 0.02), and from 39.71±10.4 to 32.41±11.8 in the HA group after 12 months (P > 0.05). Regarding the Lequesne index, pain, ADL, and global scores significantly decreased after 12 months in the PRGF group compared to the HA group (P<0.001). There was also a meaningful higher rate of satisfaction in the PRGF group compared to the HA group after 12 months of treatment (P<0.001). Conclusion Besides significantly higher satisfaction belonging to the PRGF group, there was a statistically significant improvement in VAS score and global, pain, and ADL score of Lequesne by passing 12 months from injection in PRGF compared to HA.",2020,"Regarding the Lequesne index, pain, ADL, and global scores significantly decreased after 12 months in the PRGF group compared to the HA group (P<0.001).","['Individuals with Knee Osteoarthritis', 'A total of 102 candidates were finally included in the study', ""Patients' mean age was 57.08±7.3 years old in the PRGF group compared to the mean age of 58.63±7.09 years old in HA patients"", 'candidates with symptomatic knee osteoarthritis']","['PRP-derived growth factor (PGRF) and hyaluronic acid', 'PRGF', 'Platelet-Rich Plasma-Derived Growth Factor vs Hyaluronic Acid Injection']","['total WOMAC index', 'VAS score and global, pain, and ADL score of Lequesne', 'rate of satisfaction', 'Lequesne index, pain, ADL, and global scores', 'visual analog scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Lequesne index']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}]","[{'cui': 'C0032027', 'cui_str': 'Pityriasis rubra pilaris'}, {'cui': 'C0018284', 'cui_str': 'Growth factor'}, {'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}, {'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C3472647', 'cui_str': 'Western Ontario and McMaster Universities osteoarthritis index'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451868', 'cui_str': 'Localized osteoporosis - Lequesne'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0451257', 'cui_str': 'Lequesne index'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",102.0,0.0578254,"Regarding the Lequesne index, pain, ADL, and global scores significantly decreased after 12 months in the PRGF group compared to the HA group (P<0.001).","[{'ForeName': 'Seyed Ahmad', 'Initials': 'SA', 'LastName': 'Raeissadat', 'Affiliation': 'Physical Medicine and Rehabilitation Research Center, Clinical Research Development Center of Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Azadeh', 'Initials': 'A', 'LastName': 'Gharooee Ahangar', 'Affiliation': 'Department of Orthopedic Surgery, Zanjan University of Medical Sciences, Zanjan, Iran.'}, {'ForeName': 'Seyed Mansoor', 'Initials': 'SM', 'LastName': 'Rayegani', 'Affiliation': 'Physical Medicine and Rehabilitation Research Center, Clinical Research Development Center of Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammadreza', 'Initials': 'M', 'LastName': 'Minator Sajjadi', 'Affiliation': 'Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Adel', 'Initials': 'A', 'LastName': 'Ebrahimpour', 'Affiliation': 'Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Pegah', 'Initials': 'P', 'LastName': 'Yavari', 'Affiliation': 'Physical Medicine and Rehabilitation Research Center, Clinical Research Development Center of Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}]",Journal of pain research,['10.2147/JPR.S210715'] 2514,32754093,Effects of Viewing Cute Pictures on Quiet Eye Duration and Fine Motor Task Performance.,"We investigated if viewing cute pictures could improve fine motor skills and prolong quiet eye (QE) duration. QE is a gaze phenomenon, and its duration (i.e., the period between fixation onset preceding a critical movement and fixation offset) is thought to represent attention control. As it has been reported that QE duration is longer for expert athletes than for novice athletes in various sports and becomes shorter even for experts who choke under pressure during games, resulting in performance deterioration, QE prolongation is important to prevent choking under pressure. Separately, several studies have confirmed that viewing cute pictures can induce focal attention, thus improving performance in fine motor tasks. We hypothesized that viewing cute pictures may modulate attention control and prolong QE duration. We also tested if the beneficial effects of viewing cute pictures could be obtained in a high-pressure situation in which participant performance was evaluated by an experimenter. We used a fine-motor task requiring participants to use a pair of tweezers to remove 12 small pieces from holes in a game board. We randomly assigned participants to either the baby-animal pictures group or the adult-animal pictures group, based on pictures viewed prior to the task. Participants executed the task in a pre-test, post-test, and pressure test. In both the post-test and the pressure test, participants viewed seven photographs of either baby animals or adult animals before execution of the task. In accordance with previous research, task precision increased after viewing pictures of baby animals in both the post-test and pressure test. Furthermore, QE duration was also prolonged after viewing cute pictures in the post-test, but not in the pressure test. Neither performance improvement nor QE prolongation was found after viewing pictures of adult animals. These results suggested that simply viewing cute pictures could prolong QE duration without pressure and might provide a beneficial effect on performance, even in a high-pressure situation.",2020,"Furthermore, QE duration was also prolonged after viewing cute pictures in the post-test, but not in the pressure test.",[],"['baby-animal pictures group or the adult-animal pictures group, based on pictures viewed prior to the task', 'QE', 'fine-motor task requiring participants to use a pair of tweezers to remove 12 small pieces from holes in a game board', 'Viewing Cute Pictures']","['QE prolongation', 'Quiet Eye Duration and Fine Motor Task Performance', 'task precision', 'QE duration', 'fine motor skills and prolong quiet eye (QE) duration']",[],"[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0003062', 'cui_str': 'Kingdom Animalia'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0439654', 'cui_str': 'Quiet'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205232', 'cui_str': 'Fine'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0184187', 'cui_str': 'Tweezer'}, {'cui': 'C1883720', 'cui_str': 'Removes'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}]","[{'cui': 'C0439654', 'cui_str': 'Quiet'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205232', 'cui_str': 'Fine'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0026612', 'cui_str': 'Motor Skills'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}]",,0.0637155,"Furthermore, QE duration was also prolonged after viewing cute pictures in the post-test, but not in the pressure test.","[{'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Yoshikawa', 'Affiliation': 'Faculty of Sport Sciences, Waseda University, Saitama, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Nittono', 'Affiliation': 'Graduate School of Human Sciences, Osaka University, Osaka, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Masaki', 'Affiliation': 'Faculty of Sport Sciences, Waseda University, Saitama, Japan.'}]",Frontiers in psychology,['10.3389/fpsyg.2020.01565'] 2515,32754431,Comparative Analgesic Effects of Intradermal and Subdermal Injection of Sterile Water on Active Labor Pain.,"Background The labor pain is one of the factors encouraging pregnant women for cesarean section delivery. Recently, intradermal and subdermal injection of distilled water has shown to be effective in improving this pain. Objectives The present study aimed to determine which method has a greater impact on labor pain reduction. Methods In this double-blind, randomized clinical trial, 121 nulliparous women with a gestational age of ≥ 37 weeks were randomly divided into three groups: (1) 0.5 cc sterile water injection subdermally at four sacral points with insulin needles (n = 40); (2) 0.5 cc sterile water injection intradermally (n = 39); and (3) needle contact with the mentioned points as the placebo (n = 42). Before the intervention, the VAS score was measured for labor pain, and it was repeated 10, 30, 60, and 90 min after the intervention. The results were compared between the three groups. Results Before the intervention, the mean VAS pain score had no significant difference between the three groups. However, 30, 60, and 90 min after the intervention, the mean pain score was significantly lower in the intradermal and subdermal injection groups than in the control group (P = 0.001); however, the difference between the intradermal and subdermal injection groups was not significant. Conclusions The injection of distilled water by either intradermal or subdermal method was associated with a significant reduction in the pain score during labor, but there was no difference between these two methods in terms of decreasing labor pain. As sterile water injection is a safe, effective, and low-cost method, it is proposed to increase the knowledge of midwives and obstetricians about this method.",2020,"However, 30, 60, and 90 min after the intervention, the mean pain score was significantly lower in the intradermal and subdermal injection groups than in the control group (P = 0.001); however, the difference between the intradermal and subdermal injection groups was not significant. ","['pregnant women for cesarean section delivery', '121 nulliparous women with a gestational age of ≥ 37 weeks']","['0.5 cc sterile water injection subdermally at four sacral points with insulin needles', 'Intradermal and Subdermal Injection of Sterile Water', 'placebo']","['labor pain reduction', 'mean VAS pain score', 'VAS score', 'Active Labor Pain', 'labor pain', 'mean pain score', 'pain score']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0425979', 'cui_str': 'Nulliparous'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C1163679', 'cui_str': 'Water 1 g/mL solution for injection'}, {'cui': 'C0036037', 'cui_str': 'Bone structure of sacrum'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C1522475', 'cui_str': 'Intradermal route'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0359299', 'cui_str': 'sterile water'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0474368', 'cui_str': 'Labor pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0233081', 'cui_str': 'Normal labor'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",121.0,0.0571914,"However, 30, 60, and 90 min after the intervention, the mean pain score was significantly lower in the intradermal and subdermal injection groups than in the control group (P = 0.001); however, the difference between the intradermal and subdermal injection groups was not significant. ","[{'ForeName': 'Fariba', 'Initials': 'F', 'LastName': 'Almassinokiani', 'Affiliation': 'Minimally Invasive Surgery Research Center, Pain Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.'}, {'ForeName': 'Nasim', 'Initials': 'N', 'LastName': 'Ahani', 'Affiliation': 'Shahid Akbarabadi Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran.'}, {'ForeName': 'Peyman', 'Initials': 'P', 'LastName': 'Akbari', 'Affiliation': 'Tehran University of Medical Sciences (TUMS), Tehran, Iran.'}, {'ForeName': 'Poupak', 'Initials': 'P', 'LastName': 'Rahimzadeh', 'Affiliation': 'Pain Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Akbari', 'Affiliation': 'Burn Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Sharifzadeh', 'Affiliation': 'Shahid Akbarabadi Clinical Research Development Unit (ShACRDU), Shahid Akbarabadi Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran.'}]",Anesthesiology and pain medicine,['10.5812/aapm.99867'] 2516,32754432,Effect of Peribulbar Anesthesia with and Without Adrenaline on Retinal Thickness in Patients Undergoing Elective Cataract Surgery.,"Background The toxic effect of local anesthesia on the retina has been previously investigated in animal studies but not in humans. Objectives The objective of this study was to clarify the effect of local anesthesia with lidocaine versus local anesthesia with lidocaine with extra administration of adrenaline on the retinal layer thickness measured by optical coherence tomography (OCT) in patients indicated for elective cataract surgery. Methods This is a randomized controlled trial conducted on 60 patients indicated for elective cataract surgery under local anesthesia with lidocaine. Thirty participants received local anesthesia with lidocaine 2% with extra administration of adrenaline (adrenaline group), and 30 participants received local anesthesia with lidocaine 2% only (control group). The retinal thickness was measured for all participants preoperatively and one week postoperatively using OCT. Results The OCT findings showed statistically significant decreases postoperatively in superior (P value = 0.028), inferior (P value = 0.017), and average (P value = 0.021) retinal thickness in the adrenaline group. Moreover, there were statistically significant decreases postoperatively in superior (P value = 0.032), inferior (P value = 0.046), and average (P value = 0.028) retinal thickness in the control group. Comparing the adrenaline and control groups for the OCT findings, there was no statistically significant difference between the groups regarding the decreases in superior (P value = 0.325), inferior (P value = 0.642), and average (P value = 0.291) retinal thickness. Conclusions Local anesthesia with lidocaine significantly decreased the retinal thickness. The extra administration of adrenaline to lidocaine did not affect the post-anesthetic changes in the retinal thickness.",2020,"The OCT findings showed statistically significant decreases postoperatively in superior (P value = 0.028), inferior (P value = 0.017), and average (P value = 0.021) retinal thickness in the adrenaline group.","['Thirty participants received', 'patients indicated for elective cataract surgery', 'Patients Undergoing Elective Cataract Surgery', '60 patients indicated for elective cataract surgery under local anesthesia with']","['lidocaine', 'adrenaline (adrenaline', 'adrenaline', 'optical coherence tomography (OCT', 'Peribulbar Anesthesia with and Without Adrenaline', 'local anesthesia with lidocaine']","['Retinal Thickness', 'retinal thickness', 'retinal layer thickness']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C1720162', 'cui_str': 'Under local anesthesia'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0920367', 'cui_str': 'Optical coherence tomography'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}]","[{'cui': 'C0035298', 'cui_str': 'Retinal structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}]",60.0,0.0397973,"The OCT findings showed statistically significant decreases postoperatively in superior (P value = 0.028), inferior (P value = 0.017), and average (P value = 0.021) retinal thickness in the adrenaline group.","[{'ForeName': 'Wael', 'Initials': 'W', 'LastName': 'Fathy', 'Affiliation': 'Department of Anaesthesia, Beni-Suef University, Beni-Suef, Egypt.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Taha', 'Affiliation': 'Department of Ophthalmology, Beni-Suef University, Beni-Suef, Egypt.'}, {'ForeName': 'Sahar', 'Initials': 'S', 'LastName': 'Ibrahim', 'Affiliation': 'Department of Ophthalmology, Beni-Suef University, Beni-Suef, Egypt.'}]",Anesthesiology and pain medicine,['10.5812/aapm.100138'] 2517,32754434,Minimal Inflation Tourniquet Pressure Using Induced Hypotension with Limb Occlusion Pressure Determination or Arterial Occlusion Pressure Estimation in Upper Limb Surgery: A Randomized Double-Blinded Comparative Study.,"Objectives This study compared the efficacy and safety of minimal tourniquet pressure using either determined limb occlusion pressure (LOP) or estimated arterial occlusion pressure (AOP) for elective upper limb surgeries. Methods Forty patients undergone elective upper limb surgery under general hypotensive anesthesia were randomized into groups A and B, where tourniquet pressure was calculated using AOP estimation for group A and LOP determination for group B. AOP, LOP, the time needed to estimate the AOP and determine the LOP and set the tourniquet inflation pressure, tourniquet inflation pressure, initial and maximal systolic blood pressure, heart rate, intraoperative fentanyl requirement, arm circumference, and tourniquet time were recorded. Tourniquet performance was assessed, and signs of tourniquet-related complications were noticed. Results Systolic arterial blood pressure was comparable between the groups. Less time was recorded for measuring AOP or LOP and set the minimal inflation pressure (in second) in group A than in group B (62 ± 2 for group A vs. 120 ± 3 for group B; P < 0.001). The estimated AOP in group A was significantly higher than the determined LOP in group B (118 ± 2 vs. 91 ± 2; P < 0.001). Tourniquet inflation pressures were not significantly different between the groups. Tourniquet performance was excellent or good in all patients in both groups. Conclusions Arterial occlusion pressure estimation or LOP determination methods to set the tourniquet inflation pressure with hypotensive anesthesia can provide effective minimal inflation pressure and satisfactory surgical field for upper extremity surgeries without tourniquet-related complications.",2020,Tourniquet inflation pressures were not significantly different between the groups.,"['elective upper limb surgeries', 'Upper Limb Surgery', 'Forty patients undergone elective upper limb surgery under general hypotensive anesthesia']","['LOP', 'Minimal Inflation Tourniquet Pressure Using Induced Hypotension with Limb Occlusion Pressure Determination or Arterial Occlusion Pressure Estimation', 'minimal tourniquet pressure using either determined limb occlusion pressure (LOP) or estimated arterial occlusion pressure (AOP']","['Tourniquet performance', 'AOP or LOP and set the minimal inflation pressure', 'Systolic arterial blood pressure', 'Tourniquet inflation pressures', 'tourniquet inflation pressure, tourniquet inflation pressure, initial and maximal systolic blood pressure, heart rate, intraoperative fentanyl requirement, arm circumference, and tourniquet time']","[{'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}]","[{'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0021398', 'cui_str': 'Economic Inflation'}, {'cui': 'C0040519', 'cui_str': 'Tourniquet'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0264995', 'cui_str': 'Occlusion of artery'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}]","[{'cui': 'C0040519', 'cui_str': 'Tourniquet'}, {'cui': 'C0264995', 'cui_str': 'Occlusion of artery'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0021398', 'cui_str': 'Economic Inflation'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C1272641', 'cui_str': 'Systemic arterial pressure'}, {'cui': 'C0428725', 'cui_str': 'Tourniquet inflation pressure'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0428724', 'cui_str': 'Duration of tourniquet inflation'}]",40.0,0.0711845,Tourniquet inflation pressures were not significantly different between the groups.,"[{'ForeName': 'Samaa A', 'Initials': 'SA', 'LastName': 'Kasem', 'Affiliation': 'Department of Anesthesia Surgical Intensive Care and Pain Managment, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.'}, {'ForeName': 'Ashraf Abd Elmawgood', 'Initials': 'AAE', 'LastName': 'Bassiouny', 'Affiliation': 'Anesthesia Department, Faculty of Medicine, Cairo University, Giza, Egypt.'}, {'ForeName': 'Doaa Abu Elkassim', 'Initials': 'DAE', 'LastName': 'Rashwan', 'Affiliation': 'Department of Anesthesia Surgical Intensive Care and Pain Managment, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.'}, {'ForeName': 'Mahmoud Hussein', 'Initials': 'MH', 'LastName': 'Bahr', 'Affiliation': 'Department of Anesthesia Surgical Intensive Care and Pain Managment, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.'}]",Anesthesiology and pain medicine,['10.5812/aapm.102124'] 2518,32754458,ADENOTONSILLECTOMY: CARE GIVERS' RECALL OF INFORMATION ON RISKS PROVIDED DURING INFORMED CONSENT PROCESS.,"Background ""Informed consent"" for surgery has been widely researched; however, there is no local data on surgical risk recall by care givers' (usually a parent) of children undergoing adenotonsillectomy (Ts &A). Aim and Objective This study evaluated care givers' recall of the surgical risks for Ts&A after verbal explanation compared to combined verbal and written explanation in the informed consent process. Design of the Study This was a prospective randomized comparative study of fifty parents/guardians of patients undergoing tonsillectomy and adenoidectomy for obstructive sleep disorders. Setting The E.N. T. Unit, Korle Bu Teaching Hospital, Accra, Ghana. Materials and Methods Parents/guardians of children were randomized to only verbal explanation or combined verbal and written explanations prior to signing informed consent a day before their wards' operation. Recall of surgical risks explained in the informed consent procedure was evaluated two days postoperatively. The rates of surgical risk recall for the two groups were analysed and compared. Results There were no significant differences in the demographic characteristics of the parents/guardians. The overall recall rate for surgical risks for the whole group was 46.0%. The surgical risk recall rate for the verbal explanation group, 44.4% was not significantly different from that for the combined verbal and written explanation group, 47.2% (p=0.624). There was a weak but significant positive correlation between risk recall scores and parental level of education (Spearman r s =0.306; p = 0.015). Conclusion Among parents/guardians whose children were undergoing adenotonsillectomy, combining written explanation with verbal explanation in the informed consent process did not significantly improve postoperative surgical risks recall rate when compared with only verbal explanation. The overall risk recall rate was 46.0%. A study with larger sample sizes is recommended to confirm these findings.",2018,"The surgical risk recall rate for the verbal explanation group, 44.4% was not significantly different from that for the combined verbal and written explanation group, 47.2% (p=0.624).","['children undergoing adenotonsillectomy (Ts &A', 'fifty parents/guardians of patients undergoing', 'parents/guardians whose children were undergoing', 'for obstructive sleep disorders']","['tonsillectomy and adenoidectomy', 'verbal explanation or combined verbal and written explanations prior to signing informed consent', 'adenotonsillectomy']","['overall risk recall rate', 'surgical risk recall rate', 'overall recall rate for surgical risks', 'Recall of surgical risks', 'postoperative surgical risks recall rate', 'risk recall scores and parental level of education', 'rates of surgical risk recall']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0193959', 'cui_str': 'Tonsillectomy and adenoidectomy'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0023226', 'cui_str': 'Legal guardian'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0851578', 'cui_str': 'Sleep disorder'}]","[{'cui': 'C0193959', 'cui_str': 'Tonsillectomy and adenoidectomy'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0013621', 'cui_str': 'Education'}]",50.0,0.0281593,"The surgical risk recall rate for the verbal explanation group, 44.4% was not significantly different from that for the combined verbal and written explanation group, 47.2% (p=0.624).","[{'ForeName': 'E D', 'Initials': 'ED', 'LastName': 'Kitcher', 'Affiliation': 'E.N.T. Unit, Department of Surgery, Korle Bu Teaching Hospital, P.O. Box 77, Korle Bu, Accra, Ghana.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Searyoh', 'Affiliation': 'E.N.T. Unit, Department of Surgery, Korle Bu Teaching Hospital, P.O. Box 77, Korle Bu, Accra, Ghana.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Abaidoo', 'Affiliation': 'Department of Surgery, Ophthalmology Unit, University of Ghana Medical School, P.O. Box 4236, Accra, Ghana.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Siale', 'Affiliation': 'E.N.T. Unit, Department of Surgery, Korle Bu Teaching Hospital, P.O. Box 77, Korle Bu, Accra, Ghana.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Sackitey', 'Affiliation': 'E.N.T. Unit, Department of Surgery, Korle Bu Teaching Hospital, P.O. Box 77, Korle Bu, Accra, Ghana.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Nyamekye', 'Affiliation': 'E.N.T. Unit, Department of Surgery, Korle Bu Teaching Hospital, P.O. Box 77, Korle Bu, Accra, Ghana.'}]",Journal of the West African College of Surgeons,[] 2519,32754489,Study of the role of regular physical activity on promoting hedonism and eudaimonia in breast cancer survivors.,"Background Individuals who have completed cancer treatment may have psychological and physical challenges. Participating in regular physical activity is considered as one of the most important factors for improving postcancer experience. Aims The aim of this study was to examine the effect of participating in physical activities on hedonism and eudaimonia among breast cancer survivors. Methods The research method was a semi-experimental design in the form of time-series using two experimental and control groups. 42 breast cancer survivors participated in this study in Urmia. Data using motives for activation of hedonism and eudiamonia (HEMA) were gathered before the intervention program (pre-test), at the end of intervention (the first post-test), and two weeks after the first post-test (the second post-test). For data analysis, descriptive and inferential statistics (T-test, Chi-square, and repeated measures ANOVA) were used. Result Repeated measures ANOVA analysis in the three different periods of pre-test, post-test, and a month later post-test showed that changes in the mean score of hedonism and eudaimonia motivation were not similar in the two groups and indicated the improvement of dialysis adequacy in the intervention group compared with the control group. Conclusion Generally, the results showed that participating in regular physical activity is an effective intervention on enhancing the motives for hedonism and eduaimonia in breast cancer survivors.",2020,"Generally, the results showed that participating in regular physical activity is an effective intervention on enhancing the motives for hedonism and eduaimonia in breast cancer survivors.","['breast cancer survivors', '42 breast cancer survivors participated in this study in Urmia']",['regular physical activity'],"['activation of hedonism and eudiamonia (HEMA', 'dialysis adequacy', 'mean score of hedonism and eudaimonia motivation']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0018867', 'cui_str': 'Hedonism'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}]",42.0,0.0195117,"Generally, the results showed that participating in regular physical activity is an effective intervention on enhancing the motives for hedonism and eduaimonia in breast cancer survivors.","[{'ForeName': 'Arezou', 'Initials': 'A', 'LastName': 'Kiani', 'Affiliation': 'Neurophysiology Research Center, Urmia University of Medical Sciences, Urmia, Iran.'}, {'ForeName': 'Behzad', 'Initials': 'B', 'LastName': 'Behzadnia', 'Affiliation': 'Neurophysiology Research Center, Urmia University of Medical Sciences, Urmia, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Jafarizadeh', 'Affiliation': 'Patient Safety Research Center, Urmia University of Medical Sciences, Urmia, Iran.'}]",Journal of family medicine and primary care,['10.4103/jfmpc.jfmpc_331_20'] 2520,32369830,Quality performance and associated factors in Swiss diabetes care - A cross-sectional study.,"INTRODUCTION Quality indicators and pay-for-performance schemes aim to improve processes and outcomes in clinical practice. However, general practitioner and patient characteristics influence quality indicator performance. In Switzerland, no data on the pay-for-performance approach exists and the use of quality indicators has been marginal. The aim of this study was to describe quality indicator performance in diabetes care in Swiss primary care and to analyze associations of practice, general practitioner and patient covariates with quality indicator performance. METHODS For this cross-sectional study, we used medical routine data from an electronic medical record database. Data from 71 general practitioners and all their patients with diabetes were included. Starting in July 2018, we retrieved 12-month retrospective data about practice, general practitioner and patient characteristics, laboratory values, comorbidities and co-medication. Based on this data, we assessed quality indicator performance of process and intermediate outcomes for glycated hemoglobin, blood pressure, cholesterol and associations of practice, general practitioner and patient characteristics with individual and cumulative quality indicator performance. We calculated odds ratios (OR) and 95% confidence intervals (CI) using regression methods. RESULTS We assessed 3,383 patients with diabetes (57% male, mean age 68.3 years). On average, patients fulfilled 3.56 (standard deviation: 1.89) quality indicators, whereas 17.2% of the patients fulfilled all six quality indicators. On practice and general practitioner level, we found no associations with cumulative quality indicator performance. On patient level, gender (ref = male) (OR: 0.83, CI: 0.78-0.88), number of treating general practitioners (OR: 0.94, CI: 0.91-0.97), number of comorbidities (OR: 1.43, CI: 1.38-1.47) and number of consultations (OR: 1.02, CI: 1.02-1.02) were associated with cumulative quality indicator performance. CONCLUSION The influence of practice, general practitioner and patient characteristics on quality indicator performance was surprisingly small and room for improvement in quality indicator performance of Swiss general practitioners seems to exist in diabetes care.",2020,"The influence of practice, general practitioner and patient characteristics on quality indicator performance was surprisingly small and room for improvement in quality indicator performance of Swiss general practitioners seems to exist in diabetes care.","['Swiss general practitioners', '3,383 patients with diabetes (57% male, mean age 68.3 years', '71 general practitioners and all their patients with diabetes were included', 'diabetes care in Swiss primary care']",[],"['glycated hemoglobin, blood pressure, cholesterol and associations of practice, general practitioner and patient characteristics with individual and cumulative quality indicator performance', 'number of comorbidities', 'cumulative quality indicator performance', 'number of treating general practitioners', 'Quality performance', 'quality indicator performance']","[{'cui': 'C0241315', 'cui_str': 'Swiss'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}]",[],"[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]",3383.0,0.148476,"The influence of practice, general practitioner and patient characteristics on quality indicator performance was surprisingly small and room for improvement in quality indicator performance of Swiss general practitioners seems to exist in diabetes care.","[{'ForeName': 'Rahel', 'Initials': 'R', 'LastName': 'Meier', 'Affiliation': 'Institute of Primary Care, University of Zurich and University Hospital Zurich, Zürich, Switzerland.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Valeri', 'Affiliation': 'Institute of Primary Care, University of Zurich and University Hospital Zurich, Zürich, Switzerland.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Senn', 'Affiliation': 'Institute of Primary Care, University of Zurich and University Hospital Zurich, Zürich, Switzerland.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Rosemann', 'Affiliation': 'Institute of Primary Care, University of Zurich and University Hospital Zurich, Zürich, Switzerland.'}, {'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Chmiel', 'Affiliation': 'Institute of Primary Care, University of Zurich and University Hospital Zurich, Zürich, Switzerland.'}]",PloS one,['10.1371/journal.pone.0232686'] 2521,29334322,Plasma brain-derived neurotrophic factor (pBDNF) and executive dysfunctions in patients with major depressive disorder.,"Objectives: Executive dysfunctions are frequently seen in patients with major depressive disorder (MDD) and normalise in many cases during effective antidepressant therapy. This study investigated whether a normalisation of executive dysfunctions during antidepressant treatment correlates with or can be predicted by clinical parameters or levels of brain-derived neurotrophic factor (BDNF). Methods: In 110 MDD patients with executive dysfunctions (percentile <16), executive functions and plasma BDNF levels were analysed at baseline, and days 14 and 56 of an antidepressant treatment. BDNF exon IV and P11 methylation status was studied at baseline. Results: Eighty patients (73%) experienced a normalisation of executive dysfunctions, while 30 (27%) suffered from persistent dysfunctions until day 56. Patients with persistent dysfunctions had significantly higher HAMD scores at days 14 and 56, and lower plasma BDNF levels at each time point than patients with a normalisation of dysfunctions ( F 1 = 10.18; P  = 0.002). This was seen for verbal fluency, but not processing speed. BDNF exon IV and p11 promoter methylation was not associated with test performance. Conclusions: Our results corroborate a concomitant amelioration of executive dysfunctions with successful antidepressant therapy and support a role of BDNF in the neural mechanisms underlying the normalisation of executive dysfunctions in MDD. ClinicalTrials.gov number: NCT00974155; EudraCT: 2008-008280-96.",2019,"Patients with persistent dysfunctions had significantly higher HAMD scores at days 14 and 56, and lower plasma BDNF levels at each time point than patients with a normalisation of dysfunctions ( F 1 = 10.18; P  = 0.002).","['Eighty patients (73', '110 MDD patients with executive dysfunctions (percentile <16', 'patients with major depressive disorder (MDD', 'patients with major depressive disorder']",[],"['HAMD scores', 'verbal fluency', 'BDNF exon IV and P11 methylation status', 'executive functions and plasma BDNF levels', 'normalisation of executive dysfunctions', 'plasma BDNF levels', 'Plasma brain-derived neurotrophic factor (pBDNF) and executive dysfunctions']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C1269683', 'cui_str': 'Major depressive disorder'}, {'cui': 'C2748208', 'cui_str': 'Executive dysfunction'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}]",[],"[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0015295', 'cui_str': 'Exons'}, {'cui': 'C0673066', 'cui_str': 'P11 (CBL)'}, {'cui': 'C0025723', 'cui_str': 'Methylation'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2748208', 'cui_str': 'Executive dysfunction'}]",110.0,0.0632184,"Patients with persistent dysfunctions had significantly higher HAMD scores at days 14 and 56, and lower plasma BDNF levels at each time point than patients with a normalisation of dysfunctions ( F 1 = 10.18; P  = 0.002).","[{'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Wagner', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, Germany.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Kayser', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Engelmann', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, Germany.'}, {'ForeName': 'Konrad F', 'Initials': 'KF', 'LastName': 'Schlicht', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, Germany.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Dreimüller', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, Germany.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Tüscher', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, Germany.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Müller-Dahlhaus', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, Germany.'}, {'ForeName': 'Dieter F', 'Initials': 'DF', 'LastName': 'Braus', 'Affiliation': 'Department of Psychiatry and Psychotherapy, HELIOS Dr. Horst-Schmidt-Kliniken, Wiesbaden, Germany.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Tadić', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, Germany.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Neyazi', 'Affiliation': 'Molecular Neuroscience Laboratory, Department of Psychiatry, Social psychiatry and Psychotherapy, Hannover Medical School (MHH), Hannover, Germany.'}, {'ForeName': 'Helge', 'Initials': 'H', 'LastName': 'Frieling', 'Affiliation': 'Molecular Neuroscience Laboratory, Department of Psychiatry, Social psychiatry and Psychotherapy, Hannover Medical School (MHH), Hannover, Germany.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Lieb', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, Germany.'}]",The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry,['10.1080/15622975.2018.1425478'] 2522,30239650,Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade.,"BACKGROUND The C-C chemokine receptor Type 5 (CCR5) is a key receptor for human immunodeficiency virus type 1 (HIV-1) entry into T-cells and a variant allele, CCR5 delta-32, is associated with decreased viral replication and disease progression. Active HIV-1 replication is highly associated with accelerated rates of hepatic fibrosis. We postulated that CCR5 plays a role in the development of hepatic fibrosis and evaluated the longitudinal effect of natural or drug-induced CCR5 mutation and blockade on biomarkers of liver fibrosis in HIV-1 patients. METHODS To accomplish this goal, we examined 2 distinct cohorts. First, we evaluated fibrosis markers in the Multicenter Hemophilia Cohort Studies (MHCS), which included subjects with HIV and hepatitis C virus (HCV) coinfection with the CCR5 delta-32 allele. We also evaluated an HIV-1 infected cohort that was treated with a dual CCR5/CCR2 antagonist, cenicriviroc. The enhanced liver fibrosis (ELF) index was validated against liver histology obtained from HCV/HIV and HCV patients and demonstrated strong correlation with fibrosis stage. RESULTS In both the MHCS patients and patients treated with cenicriviroc, CCR5 mutation or blockade was associated with a significant decrease in the ELF index. Among the patients with the delta-32 allele, the ELF index rate significantly decreased in sequential samples as compared to CCR5 wild-type patients (P = .043). This was not observed in control subjects treated with efavirenz nor with a lower dose of 100 mg cenicriviroc. CONCLUSION These findings suggest that hepatic fibrosis in HIV-1 infected patients can be modulated by the mutation of CCR5 and/or use of CCR5/CCR2 blockade agents. CLINICAL TRIALS REGISTRATION NCT01338883.",2019,"The enhanced liver fibrosis (ELF) index was validated against liver histology obtained from HCV/HIV and HCV patients and demonstrated strong correlation with fibrosis stage. ","['Multicenter Hemophilia Cohort Studies (MHCS), which included subjects with HIV and hepatitis C virus (HCV) coinfection with the CCR5 delta-32 allele', 'HIV-1 patients']","['efavirenz', 'MHCS', 'dual CCR5/CCR2 antagonist, cenicriviroc']","['Hepatic Fibrosis Biomarkers', 'ELF index', 'ELF index rate', 'enhanced liver fibrosis (ELF) index']","[{'cui': 'C0019069', 'cui_str': 'Hereditary factor VIII deficiency disease'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0079500', 'cui_str': 'Hepacivirus'}, {'cui': 'C0275524', 'cui_str': 'Mixed infectious disease'}, {'cui': 'C0282554', 'cui_str': 'Cytokines, Chemotactic'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0457499', 'cui_str': 'Type 5'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0002085', 'cui_str': 'Genetic alleles'}, {'cui': 'C0019704', 'cui_str': 'Human immunodeficiency virus type I'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0674428', 'cui_str': 'efavirenz'}, {'cui': 'C0019069', 'cui_str': 'Hereditary factor VIII deficiency disease'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0282554', 'cui_str': 'Cytokines, Chemotactic'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}]","[{'cui': 'C0239946', 'cui_str': 'Hepatic fibrosis'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.0271714,"The enhanced liver fibrosis (ELF) index was validated against liver histology obtained from HCV/HIV and HCV patients and demonstrated strong correlation with fibrosis stage. ","[{'ForeName': 'Kenneth E', 'Initials': 'KE', 'LastName': 'Sherman', 'Affiliation': 'University of Cincinnati College of Medicine, Ohio.'}, {'ForeName': 'Enass', 'Initials': 'E', 'LastName': 'Abdel-Hameed', 'Affiliation': 'University of Cincinnati College of Medicine, Ohio.'}, {'ForeName': 'Susan D', 'Initials': 'SD', 'LastName': 'Rouster', 'Affiliation': 'University of Cincinnati College of Medicine, Ohio.'}, {'ForeName': 'Mohamed Tarek M', 'Initials': 'MTM', 'LastName': 'Shata', 'Affiliation': 'University of Cincinnati College of Medicine, Ohio.'}, {'ForeName': 'Jason T', 'Initials': 'JT', 'LastName': 'Blackard', 'Affiliation': 'University of Cincinnati College of Medicine, Ohio.'}, {'ForeName': 'Parham', 'Initials': 'P', 'LastName': 'Safaie', 'Affiliation': 'University of Cincinnati College of Medicine, Ohio.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Kroner', 'Affiliation': 'Research Triangle Institute, Philadelphia, Pennsylvania.'}, {'ForeName': 'Liliana', 'Initials': 'L', 'LastName': 'Preiss', 'Affiliation': 'Research Triangle Institute, Philadelphia, Pennsylvania.'}, {'ForeName': 'Paul S', 'Initials': 'PS', 'LastName': 'Horn', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, Ohio.""}, {'ForeName': 'Shyam', 'Initials': 'S', 'LastName': 'Kottilil', 'Affiliation': 'University of Maryland, Baltimore.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciy807'] 2523,30561227,Association of aldosterone synthase CYP11B2 (-344C/T) gene polymorphism with essential hypertension and left ventricular hypertrophy in the Egyptian population.,"Background and Objectives : Essential hypertension is a complex progressive cardiovascular disorder. Renin-angiotensin aldosterone system (RAAS) plays a major role in blood pressure regulation. Aldosterone, synthesized in the adrenal cortex by aldosterone synthase is encoded by the CYP11B2 gene. This case-control study was aiming to investigate the relationship between the aldosterone synthase gene ( CYP11B2 ) biallelic polymorphism in the promoter at position -344 (-344C/T) with essential hypertension and left ventricular hypertrophy in the Egyptian population. Methods : This study was conducted on 100 hypertensive patients (group I) and 50 healthy control subjects (group II). Serum aldosterone, plasma renin, ARR levels were investigated. Echocardiography was done to evaluate LV dimensions. Genotyping of the CYP11B2 gene was performed by PCR/RFLP confirmed by direct sequencing. Results : Our study revealed that CYP11B2 (-344T) allele was significantly higher than (-344C) allele in hypertensive patients as compared to healthy control (OR-2.51; 95% CI:1.3-3.5; P = 0.002) and -344TT genotype was associated with increased LVMI as compared with -344CC genotype (P = 0.001). Conclusion : A Significant association was observed between the CYP11B2 (-344C/T) polymorphism and -344T allele and essential hypertension in the Egyptian population. Also, we found that the CYP11B2 -3 44C/T polymorphism and -344T allele are associated with left ventricular hypertrophy which may predispose to cardiovascular complications of hypertension.",2019,A Significant association was observed between the CYP11B2 (-344C/T) polymorphism and -344T allele and essential hypertension in the Egyptian population.,['100 hypertensive patients (group I) and 50 healthy control subjects (group II'],"['Aldosterone', 'Renin-angiotensin aldosterone system (RAAS', 'aldosterone synthase CYP11B2 (-344C/T']","['CYP11B2 (-344C/T) polymorphism and -344T allele and essential hypertension', 'Serum aldosterone, plasma renin, ARR levels']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441843', 'cui_str': 'Group I'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0002006', 'cui_str': 'Aldosterone'}, {'cui': 'C0086907', 'cui_str': 'Renin-Angiotensin-Aldosterone System'}, {'cui': 'C0075233', 'cui_str': 'Aldosterone Synthase'}]","[{'cui': 'C0075233', 'cui_str': 'Aldosterone Synthase'}, {'cui': 'C0032529', 'cui_str': 'Genetic polymorphism'}, {'cui': 'C0002085', 'cui_str': 'Genetic alleles'}, {'cui': 'C0085580', 'cui_str': 'Essential hypertension'}, {'cui': 'C0428395', 'cui_str': 'Aldosterone measurement, serum'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0035094', 'cui_str': 'Renin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",100.0,0.0257014,A Significant association was observed between the CYP11B2 (-344C/T) polymorphism and -344T allele and essential hypertension in the Egyptian population.,"[{'ForeName': 'Muhammad Tarek', 'Initials': 'MT', 'LastName': 'Abdel Ghafar', 'Affiliation': 'Departments of Clinical pathology, Faculty of Medicine, Tanta University, Tanta, Egypt.'}]","Clinical and experimental hypertension (New York, N.Y. : 1993)",['10.1080/10641963.2018.1557679'] 2524,31533195,The Contribution of Lipids to the Interindividual Response of Vitamin K Biomarkers to Vitamin K Supplementation.,"SCOPE A better understanding of factors contributing to interindividual variability in biomarkers of vitamin K can enhance the understanding of the equivocal role of vitamin K in cardiovascular disease. Based on the known biology of phylloquinone, the major form of vitamin K, it is hypothesized that plasma lipids contribute to the variable response of biomarkers of vitamin K metabolism to phylloquinone supplementation. METHODS AND RESULTS The association of plasma lipids and 27 lipid-related genetic variants with the response of biomarkers of vitamin K metabolism is examined in a secondary analysis of data from a 3-year phylloquinone supplementation trial in men (n = 66) and women (n = 85). Year 3 plasma triglycerides (TG), but not total cholesterol, LDL-cholesterol, or HDL-cholesterol, are associated with the plasma phylloquinone response (men: β = 1.01, p < 0.001, R 2  = 0.34; women: β = 0.61, p = 0.008, R 2  = 0.11; sex interaction p = 0.077). Four variants and the TG-weighted genetic risk score are associated with the plasma phylloquinone response in men only. Plasma lipids are not associated with changes in biomarkers of vitamin K function (undercarboxylated osteocalcin and matrix gla protein) in either sex. CONCLUSION Plasma TG are an important determinant of the interindividual response of plasma phylloquinone to phylloquinone supplementation, but changes in biomarkers of vitamin K carboxylation are not influenced by lipids.",2019,"Plasma lipids are not associated with changes in biomarkers of vitamin K function (undercarboxylated osteocalcin and matrix gla protein) in either sex. ",['trial in men (n\xa0= 66) and women (n\xa0= 85'],['phylloquinone supplementation'],"['total cholesterol, LDL-cholesterol, or HDL-cholesterol', 'Year 3 plasma triglycerides (TG', 'vitamin K function (undercarboxylated osteocalcin and matrix gla protein', 'plasma phylloquinone response']","[{'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0031862', 'cui_str': 'Vitamin K 1'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol in high density lipoprotein subfraction 2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0583329', 'cui_str': 'Plasma triglyceride measurement'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0042878', 'cui_str': 'Vitamin K'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0029419', 'cui_str': 'Osteocalcin'}, {'cui': 'C0065752', 'cui_str': 'matrix Gla protein'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0031862', 'cui_str': 'Vitamin K 1'}]",,0.0446526,"Plasma lipids are not associated with changes in biomarkers of vitamin K function (undercarboxylated osteocalcin and matrix gla protein) in either sex. ","[{'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Kelly', 'Affiliation': 'Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, 02111, USA.'}, {'ForeName': 'Jose M', 'Initials': 'JM', 'LastName': 'Ordovas', 'Affiliation': 'Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, 02111, USA.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Matuszek', 'Affiliation': 'Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, 02111, USA.'}, {'ForeName': 'Caren E', 'Initials': 'CE', 'LastName': 'Smith', 'Affiliation': 'Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, 02111, USA.'}, {'ForeName': 'Gordon S', 'Initials': 'GS', 'LastName': 'Huggins', 'Affiliation': 'Molecular Cardiology Research Institute Center for Translational Genomics, Tufts Medical Center and Tufts University, Boston, MA, 02111, USA.'}, {'ForeName': 'Hassan S', 'Initials': 'HS', 'LastName': 'Dashti', 'Affiliation': 'Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.'}, {'ForeName': 'Reiko', 'Initials': 'R', 'LastName': 'Ichikawa', 'Affiliation': 'Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, 02111, USA.'}, {'ForeName': 'Sarah L', 'Initials': 'SL', 'LastName': 'Booth', 'Affiliation': 'Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, 02111, USA.'}]",Molecular nutrition & food research,['10.1002/mnfr.201900399'] 2525,31611625,The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial.,"Disease factors such as tumor burden and molecular risk affect myeloma patient outcomes as well as patient factors that impact the capacity to deliver treatment. How the relative importance of these factors changes with patient age has not previously been investigated comprehensively. We analyzed data from 3894 patients of all ages uniformly treated in a large clinical trial of myeloma patients, Myeloma XI. Even with novel therapeutic approaches progression-free survival (PFS) and overall survival (OS) are affected by age with a stepwise reduction in PFS and OS with each decade increase. Renal function deteriorated with increasing age whilst the frequency of t(4;14) and del(17p) decreased and gain(1q) increased. The relative contribution of performance status, international staging score and molecular risk to progression-free and overall survival varied by age group. Molecular events have a larger effect on outcome in younger patients with their relative contribution diminishing in the elderly. Performance status is important for patient outcome at all ages suggesting that physical frailty may be a more important predictor of outcome than age itself. Significant differences in the factors driving patient outcomes at different ages are important to consider as we design disease segmentation strategies to deliver personalized treatment approaches.",2020,"The relative contribution of performance status, international staging score and molecular risk to progression-free and overall survival varied by age group.","['myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial', 'younger patients with their relative contribution diminishing in the elderly', '3894 patients of all ages uniformly treated in a large clinical trial of myeloma patients, Myeloma XI']",[],"['relative contribution of performance status, international staging score and molecular risk to progression-free and overall survival', 'progression-free survival (PFS) and overall survival (OS']","[{'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0549177', 'cui_str': 'Large'}]",[],"[{'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0332305', 'cui_str': 'With staging'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",,0.0547204,"The relative contribution of performance status, international staging score and molecular risk to progression-free and overall survival varied by age group.","[{'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Pawlyn', 'Affiliation': 'The Institute of Cancer Research, London, UK. charlotte.pawlyn@icr.ac.uk.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cairns', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Kaiser', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Striha', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Jones', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Vallari', 'Initials': 'V', 'LastName': 'Shah', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Jenner', 'Affiliation': 'University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Drayson', 'Affiliation': 'Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Owen', 'Affiliation': ""Haematological Malignancy Diagnostic Service (HMDS), St James's University Hospital, Leeds, UK.""}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Gregory', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Cook', 'Affiliation': 'Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.'}, {'ForeName': 'Gareth', 'Initials': 'G', 'LastName': 'Morgan', 'Affiliation': 'Perlmutter Cancer Center, NYU Langone Health, New York, UK.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Jackson', 'Affiliation': 'Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Faith', 'Initials': 'F', 'LastName': 'Davies', 'Affiliation': 'Perlmutter Cancer Center, NYU Langone Health, New York, UK.'}]",Leukemia,['10.1038/s41375-019-0595-5'] 2526,32760848,"Double blind, randomised trial to compare efficacy of escitalopram versus citalopram for interferon induced depression in hepatitis C patients.","Objectives The objective of the study was to compare the two antidepressant drugs citalopram and escitalopram on the basis of efficacy in depressed patients of Hepatitis C patients receiving interferons. Methods In this double blind randomized trial, the hepatitis C patients visited National institute of liver and Gastro intestinal diseases (NILGID), Dow University Hospital, were screened for depression before starting treatment with interferons. The Institutional review board approval was obtained and its letter reference no.is: IRB-682/DUHS/Approval/2016/169. Patients with previous history of depression were excluded from the study. The patients who started with Interferon therapy were assessed for depression on baseline and then on each visit. Those who developed depression were randomly assigned to receive either citalopram or escitalopram. Treatment groups were assessed with depression scale each time they visit the clinic. Two antidepressants were compared for their efficacy at an interval of 4 weeks, 8weeks and then 12 weeks. Results In the current study 80 patients were randomized to receive either citalopram or escitalopram. The study outcome was better in patients treated with escitalopram. The mean change in depression score from baseline to the end of the study was greater in escitalopram group i.e. 10.41 as compared to citalopram group i.e. 14.17. The difference in depression score was also calculated as 4.28 and.3.76 (p < 0.001) for both the drugs at week 8 and week 12 respectively, which was statistically significant. Difference in depression score were also calculated for gender 0.576 (p = 0.497) and age 0.950 (p = 0.265), which were found to be non-significant, statistically. Conclusion The results demonstrated superiority of escitalopram over citalopram, the drug is twice as potent as the racemic mixture. Additionally the drug is well tolerated and exhibited better effects. Escitalopram proved to be a safer alternative to citalopram.",2020,The mean change in depression score from baseline to the end of the study was greater in escitalopram group i.e. 10.41 as compared to citalopram group i.e. 14.17.,"['80 patients', 'depressed patients of Hepatitis C patients receiving interferons', 'hepatitis C patients visited National institute of liver and Gastro intestinal diseases (NILGID), Dow University Hospital, were screened for depression before starting treatment with interferons', 'Patients with previous history of depression were excluded from the study', 'hepatitis C patients']","['citalopram', 'escitalopram', 'escitalopram versus citalopram', 'citalopram or escitalopram', 'Interferon therapy']","['depression score', 'mean change in depression score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0344315', 'cui_str': 'Depressed mood'}, {'cui': 'C0019196', 'cui_str': 'Viral hepatitis C'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0021831', 'cui_str': 'Disorder of intestine'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0455503', 'cui_str': 'H/O: depression'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0008845', 'cui_str': 'Citalopram'}, {'cui': 'C1099456', 'cui_str': 'Escitalopram'}, {'cui': 'C0279030', 'cui_str': 'Interferon therapy'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",2.0,0.288658,The mean change in depression score from baseline to the end of the study was greater in escitalopram group i.e. 10.41 as compared to citalopram group i.e. 14.17.,"[{'ForeName': 'Uzma', 'Initials': 'U', 'LastName': 'Shakeel', 'Affiliation': 'Department of Pharmacology, Faculty of Pharmaceutical Sciences, Dow College of Pharmacy, Dow University of Health Sciences, Pakistan.'}, {'ForeName': 'Sumbul', 'Initials': 'S', 'LastName': 'Shamim', 'Affiliation': 'Department of Pharmacology, Faculty of Pharmaceutical Sciences, Dow College of Pharmacy, Dow University of Health Sciences, Pakistan.'}, {'ForeName': 'Zahid', 'Initials': 'Z', 'LastName': 'Azam', 'Affiliation': 'National Institute of Liver and Gastro intestinal Diseases, Dow University Hospital, Dow University of Health Sciences, Pakistan.'}, {'ForeName': 'Hafiz Muhammad', 'Initials': 'HM', 'LastName': 'Arshad', 'Affiliation': 'Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Dow College of Pharmacy, Dow University of Health Sciences, Pakistan.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Asgher', 'Affiliation': 'Department of Pharmacology, Faculty of Pharmaceutical Sciences, Dow College of Pharmacy, Dow University of Health Sciences, Pakistan.'}]",Contemporary clinical trials communications,['10.1016/j.conctc.2020.100622'] 2527,32760865,Provision of free nicotine replacement therapy to parental smokers in the pediatric emergency setting.,"INTRODUCTION Although the administration of free Nicotine Replacement Therapy (NRT) is effective in helping smokers quit, the feasibility, acceptability and safety of this practice have not been examined in the emergency setting of the pediatric emergency department (PED) or urgent care (UC). We examined the characteristics of parental smokers who were interested and eligible for free NRT during their child's emergency visit and the uptake, usage, and associated side effects of NRT use. METHODS We analyzed data from 377 parental smokers who were randomized to receive cessation counseling and free NRT as part of an emergency visit-based randomized controlled trial. Parents interested in NRT were screened for medical contraindications; eligible parents were given a 6-week supply of NRT patches or lozenges during their child's emergency visit and offered another supply 6 weeks later. We conducted Wilcoxon rank-sum tests and chi-squared tests to address our main study objective. RESULTS The majority of parents were female (87.5%), non-Hispanic Black (52.5%), and mean (SD) age was 33.1 (8.2) years. A total of 252 (66.8%) parents were interested in receiving NRT. Compared to uninterested parents, interested parents were more likely to: be older [33.6 (8.2) vs 31.9 (8.2), years]; be non-Hispanic Black (54.0% vs 49.6%); have older children [5.5 (5.0) vs 4.2 (4.6)]; have a higher readiness to quit [7.0 (2.4) vs 5.2 (2.6)]; and have a child being evaluated in UC compared to the PED (72.4% vs 56.5%). A total of 53 (21%) interested parents had >1 NRT contraindications. At 6 weeks, 94 (79.0%) parents reported some ≥NRT usage and 50 (53.2%) requested an additional 6-week supply. There were no serious adverse events and 5 (5.3%) reported minor side effects. CONCLUSIONS Parental smokers in the emergency setting are interested in receiving free NRT, the majority use it, and use is not associated with adverse side effects. The emergency visit may be an optimal time to offer NRT to parental smokers.",2020,"There were no serious adverse events and 5 (5.3%) reported minor side effects. ","['parental smokers in the pediatric emergency setting', '377 parental smokers', 'The majority of parents were female (87.5%), non-Hispanic Black (52.5%), and mean (SD) age was 33.1 (8.2) years', ""parental smokers who were interested and eligible for free NRT during their child's emergency visit and the uptake, usage, and associated side effects of NRT use""]","['cessation counseling and free NRT', 'Nicotine Replacement Therapy (NRT', 'NRT patches or lozenges', 'nicotine replacement therapy']","['serious adverse events', 'non-Hispanic Black']","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517896', 'cui_str': '87.5'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C4517802', 'cui_str': '52.5'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C1278444', 'cui_str': 'Nicotine replacement therapy'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0457083', 'cui_str': 'Usage'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C1278444', 'cui_str': 'Nicotine replacement therapy'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0991564', 'cui_str': 'Lozenge'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}]",,0.0462741,"There were no serious adverse events and 5 (5.3%) reported minor side effects. ","[{'ForeName': 'E Melinda', 'Initials': 'EM', 'LastName': 'Mahabee-Gittens', 'Affiliation': ""Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, United States.""}, {'ForeName': 'Ashley L', 'Initials': 'AL', 'LastName': 'Merianos', 'Affiliation': 'School of Human Services, University of Cincinnati, Cincinnati, United States.'}, {'ForeName': 'Meredith E', 'Initials': 'ME', 'LastName': 'Tabangin', 'Affiliation': ""Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, United States.""}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Stone', 'Affiliation': ""Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, United States.""}, {'ForeName': 'Judith S', 'Initials': 'JS', 'LastName': 'Gordon', 'Affiliation': 'College of Nursing, University of Arizona, Tucson, United States.'}, {'ForeName': 'Jane C', 'Initials': 'JC', 'LastName': 'Khoury', 'Affiliation': ""Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, United States.""}]",Tobacco prevention & cessation,['10.18332/tpc/119125'] 2528,32760888,"The improvement in aerobic capacity, disease activity, and function in patients with rheumatoid arthritis following cardiac rehabilitation program: A single-center, controlled study.","Objectives This study aims to evaluate the effect of cardiac rehabilitation (CR) on disease activity, functional status, fitness, and modified cardiovascular disease (CVD) risk factors in patients with rheumatoid arthritis (RA) with a moderate disease activity. Patients and methods This single-center, controlled study included a total of 60 female RA patients (mean age 57.5 years; range, 50 to 64 years) with moderate disease activity according to the Disease Activity Score-28 (DAS28) between January 2014 and June 2015. The patients were divided into two equal groups as those receiving CR program (n=30) and those receiving home exercise program (HEP; n=30). The patients were evaluated at baseline, at Weeks 10 and 24 using exercise tolerance test (i.e., The Metabolic Equivalent of Task [MET] and maximal oxygen uptake [VO2 max]), Six-Minute Walk Test (6MWT), DAS28, Health Assessment Questionnaire (HAQ), modified Systematic Coronary Risk Evaluation (mSCORE), Short Form Health Survey-36 (SF-36), and Beck Depression Inventory (BDI). Results There was a significant improvement in the VO2 max (p<0.001), MET (p<0.001), DAS28 (p<0.001), HAQ (p<0.001), BDI (p=0.005), SF-36 physical function (p=0.039), pain (p<0.001) and vitality subscale scores (p=0.008), and 6MWT (p<0.001), after the initial and repetitive exercise programs in the CR group compared to the HEP group. At the end of Week 24, full compliance with HEP was higher in the patients with CR group, compared to the HEP group (p<0.001). There was no significant effect of supervised exercise program on the mSCORE, although systolic blood pressure (p=0.033) and resting heart rate (p=0.049) were significantly improved in the CR group versus HEP group. Conclusion Based on our study results, supervised exercise program cannot reduce CVD risk as assessed by the mSCORE, although it improves physical fitness, disease activity, and functional outcomes which may reduce traditional CVD risk factors in patients with RA.",2020,"There was a significant improvement in the VO2 max (p<0.001), MET (p<0.001), DAS28 (p<0.001), HAQ (p<0.001), BDI (p=0.005), SF-36 physical function (p=0.039), pain (p<0.001) and vitality subscale scores (p=0.008), and 6MWT (p<0.001), after the initial and repetitive exercise programs in the CR group compared to the HEP group.","['60 female RA patients (mean age 57.5 years; range, 50 to 64 years) with moderate disease activity according to the Disease Activity Score-28 (DAS28) between January 2014 and June 2015', 'patients with rheumatoid arthritis following cardiac rehabilitation program', 'patients with rheumatoid arthritis (RA) with a moderate disease activity', 'patients with RA']","['supervised exercise program', 'cardiac rehabilitation (CR', 'home exercise program (HEP', 'CR program']","['Metabolic Equivalent of Task [MET] and maximal oxygen uptake [VO2 max]), Six-Minute Walk Test (6MWT), DAS28, Health Assessment Questionnaire (HAQ), modified Systematic Coronary Risk Evaluation (mSCORE), Short Form Health Survey-36 (SF-36), and Beck Depression Inventory (BDI', 'VO2 max', 'disease activity, functional status, fitness, and modified cardiovascular disease (CVD) risk factors', 'DAS28 (p<0.001), HAQ (p<0.001), BDI', 'SF-36 physical function', 'resting heart rate', 'aerobic capacity, disease activity, and function', 'full compliance with HEP', 'CVD risk', 'physical fitness, disease activity, and functional outcomes', 'systolic blood pressure', 'pain (p<0.001) and vitality subscale scores', 'traditional CVD risk factors']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program'}]","[{'cui': 'C2983100', 'cui_str': 'Metabolic equivalent of task'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0667627', 'cui_str': 'bis(kojato)oxovanadium(IV)'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C0451208', 'cui_str': 'Health assessment questionnaire'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1821417', 'cui_str': 'Resting heart rate'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0459443', 'cui_str': 'Subscale score'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}]",60.0,0.0254049,"There was a significant improvement in the VO2 max (p<0.001), MET (p<0.001), DAS28 (p<0.001), HAQ (p<0.001), BDI (p=0.005), SF-36 physical function (p=0.039), pain (p<0.001) and vitality subscale scores (p=0.008), and 6MWT (p<0.001), after the initial and repetitive exercise programs in the CR group compared to the HEP group.","[{'ForeName': 'Hülya', 'Initials': 'H', 'LastName': 'Peynirci Cerşit', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey.'}, {'ForeName': 'İlker', 'Initials': 'İ', 'LastName': 'Yağcı', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey.'}, {'ForeName': 'Sinan', 'Initials': 'S', 'LastName': 'Cerşit', 'Affiliation': 'Department of Cardiology, Istanbul Kartal Koşuyolu Yüksek Ihtisas Training and Research Hospital, Istanbul, Turkey.'}]",Turkish journal of physical medicine and rehabilitation,['10.5606/tftrd.2020.3250'] 2529,32760890,"Effectiveness of pulsed electromagnetic field therapy on pain, functional status, and quality of life in patients with chronic non-specific neck pain: A prospective, randomized-controlled study.","Objectives The aim of this study was to evaluate whether pulsed electromagnetic field (PEMF) therapy when applied in addition to a conventional physical therapy program would provide any further benefits in reducing pain and functional limitation in patients with chronic non-specific neck pain. Patients and methods This double-blind, prospective, randomized, placebo-controlled study included a total of 63 patients (15 males, 48 females; mean age 45.1; range, 25 to 59 years) with a complaint of mechanical neck pain between January 2016 and September 2016. The patients were divided into two groups as PEMF therapy group (n=33) and control group (n=30). A total of 15 sessions of conventional physical therapy program were applied to both groups for a total of three weeks. In addition, the active group received 20-min PEMF and the control group received 20-min sham PEMF. The patients were evaluated at baseline and after treatment. The therapeutic effect was evaluated using the visual analog scale (VAS), Neck Pain Disability Scale (NPDS), Short Form-36 (SF-36), and Physician Global Assessment (PGA). Results At baseline, two groups were similar in terms of the demographic and clinical characteristics (p>0.05). There were significant improvements in the VAS, NPDS, SF-36, and physician global assessment after treatment in both groups. However, the PEMF group was not found to be superior to the sham group in terms of improvements in the outcome parameters. Conclusion Our study findings indicate that PEMF therapy is safe in patients with chronic non-specific neck pain. However, it does not provide further improvement in pain and functionality when applied in addition to a conventional physical therapy.",2020,"There were significant improvements in the VAS, NPDS, SF-36, and physician global assessment after treatment in both groups.","['patients with chronic non-specific neck pain', '63 patients (15 males, 48 females; mean age 45.1; range, 25 to 59 years) with a complaint of mechanical neck pain between January 2016 and September 2016']","['PEMF therapy', '20-min PEMF and the control group received 20-min sham PEMF', 'PEMF', 'conventional physical therapy program', 'pulsed electromagnetic field (PEMF) therapy', 'pulsed electromagnetic field therapy', 'placebo']","['pain and functional limitation', 'VAS, NPDS, SF-36, and physician global assessment', 'visual analog scale (VAS), Neck Pain Disability Scale (NPDS), Short Form-36 (SF-36), and Physician Global Assessment (PGA', 'pain, functional status, and quality of life', 'pain and functionality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205370', 'cui_str': 'Non-specific'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0277786', 'cui_str': 'Complaint'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}]","[{'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0013835', 'cui_str': 'Electromagnetic Fields'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",63.0,0.040432,"There were significant improvements in the VAS, NPDS, SF-36, and physician global assessment after treatment in both groups.","[{'ForeName': 'Merve', 'Initials': 'M', 'LastName': 'Karakaş', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Ankara University Faculty of Medicine, Ankara, Turkey.'}, {'ForeName': 'Haydar', 'Initials': 'H', 'LastName': 'Gök', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Ankara University Faculty of Medicine, Ankara, Turkey.'}]",Turkish journal of physical medicine and rehabilitation,['10.5606/tftrd.2020.5169'] 2530,32760898,A comparison of application frequency of physical therapy modalities in patients with chronic mechanical low back pain.,"Objectives This study aims to evaluate the effects of physical therapy modalities five days a week versus twice a week with a three-day interval on pain, depression, and functional disability in patients with chronic mechanical low back pain. Patients and methods Between June 2018 and November 2018, a total of 60 patients (39 females, 21 males; mean age 41.0±6.8 years; range, 25 to 55 years) with chronic mechanical low back pain were included. The patients were divided into two groups: Group 1 (n=30) received physical therapy five days a week for a total of 15 sessions, while Group 2 (n=30) received physical therapy twice a week with a three-day interval for a total of six sessions. Per protocol, all patients were applied hot pack for 20 min, followed by conventional transcutaneous electrical nerve stimulation (TENS) for 20 min and therapeutic ultrasound (US) for 10 min in each session. All patients were given exercise training and were instructed to do twice a day up to four weeks after the completion of physical therapy sessions. The severity of low back pain was evaluated using the visual analog scale (VAS), the severity of depression using the Beck Depression Inventory (BDI), and functional disability using the Oswestry Disability Index (ODI). All patients were evaluated before and after physical therapy and at four weeks. The results were compared between the groups. Results There was no statistically significant difference in the age, gender, body mass index, occupation, VAS, BDI, and ODI scores at the time of randomization (p>0.05). Intra-group analysis showed a significant improvement in all parameters after physical therapy compared to pre-treatment values and at four weeks compared to the post-treatment values (p<0.001). The differences of changes were used for the inter- group analysis which revealed a difference of change in favor of improvement was significantly higher in Group 2 than Group 1 (p<0.001). There was no significant difference between the post-treatment values and values at four weeks (p>0.05). Conclusion Our study results suggest that both physical therapy modalities applied five days week and twice a week are effective in pain, depression, and functional disability. However, physical therapy protocol applied twice a week yields more improvement, indicating that it is more advantageous with less cost and lost workdays.",2020,Intra-group analysis showed a significant improvement in all parameters after physical therapy compared to pre-treatment values and at four weeks compared to the post-treatment values (p<0.001).,"['Patients and methods\n\n\nBetween June 2018 and November 2018, a total of 60 patients (39 females, 21 males; mean age 41.0±6.8 years; range, 25 to 55 years) with chronic mechanical low back pain were included', 'patients with chronic mechanical low back pain']","['exercise training', 'physical therapy modalities', 'conventional transcutaneous electrical nerve stimulation (TENS) for 20 min and therapeutic ultrasound (US', 'physical therapy']","['visual analog scale (VAS), the severity of depression using the Beck Depression Inventory (BDI), and functional disability using the Oswestry Disability Index (ODI', 'age, gender, body mass index, occupation, VAS, BDI, and ODI scores', 'severity of low back pain', 'pain, depression, and functional disability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0423682', 'cui_str': 'Mechanical low back pain'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0394678', 'cui_str': 'Conventional transcutaneous electrical nerve stimulation'}, {'cui': 'C0040654', 'cui_str': 'Percutaneous electrical nerve stimulation'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0041620', 'cui_str': 'Therapeutic ultrasound'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C2960603', 'cui_str': 'Oswestry disability index score'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",60.0,0.0134899,Intra-group analysis showed a significant improvement in all parameters after physical therapy compared to pre-treatment values and at four weeks compared to the post-treatment values (p<0.001).,"[{'ForeName': 'Turgay', 'Initials': 'T', 'LastName': 'Altınbilek', 'Affiliation': 'Specialist of Physical Medicine and Rehabilitation, Private Office, Istanbul, Turkey.'}, {'ForeName': 'Sadiye', 'Initials': 'S', 'LastName': 'Murat', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Istanbul Medeniyet University Göztepe Training and Research Hospital, Istanbul, Turkey.'}]",Turkish journal of physical medicine and rehabilitation,['10.5606/tftrd.2020.4192'] 2531,30641036,Effects of mild traumatic brain injury and post-traumatic stress disorder on resting-state default mode network connectivity.,"Mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) are common outcomes for service members. Abnormal connectivity within neural networks has been reported in the resting brain of mTBI and PTSD patients, respectively; however, the potential role of PTSD in changes to neural networks following injury has not been studied in detail. Using a data-driven approach, the present analysis aimed to elucidate resting state functional connectivity in the default mode network (DMN) in those with mTBI only and those with comorbid mTBI and PTSD. A secondary analysis focused on distinct contributions by the anterior and posterior DMN components. Group-level independent component analysis was used to identify the DMN, and a dual-regression method was utilized to measure connectivity within the overall network and its anterior (medial prefrontal cortex) and posterior (posterior cingulate cortex) nodes. Connectivity within the overall DMN was significantly higher for the mTBI only group (p = 0.001), as compared to controls and mTBI + PTSD. For all subjects with mTBI, network connectivity correlated inversely with PTSD checklist score (p < 0.05). Additionally, distinct associations (p < 0.05) between medial prefrontal cortex connectivity and PTSD symptoms and, separately, posterior cingulate cortex connectivity and mTBI-related cognitive deficits were found. To our knowledge, this is the first study to report a differential relationship between DMN components and both post-traumatic symptoms and cognitive outcomes.",2019,"Connectivity within the overall DMN was significantly higher for the mTBI only group (p = 0.001), as compared to controls and mTBI + PTSD.",['Mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD'],[],"['Connectivity within the overall DMN', 'medial prefrontal cortex connectivity and PTSD symptoms and, separately, posterior cingulate cortex connectivity and mTBI-related cognitive deficits', 'PTSD checklist score']","[{'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}]",[],"[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0175191', 'cui_str': 'Posterior Cingulate Gyri'}, {'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0009241', 'cui_str': 'Cognitive disorder'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.023269,"Connectivity within the overall DMN was significantly higher for the mTBI only group (p = 0.001), as compared to controls and mTBI + PTSD.","[{'ForeName': 'Priya', 'Initials': 'P', 'LastName': 'Santhanam', 'Affiliation': 'Lovelace Biomedical Research, Albuquerque, NM, United States. Electronic address: psanthanam@lrri.org.'}, {'ForeName': 'Steffanie H', 'Initials': 'SH', 'LastName': 'Wilson', 'Affiliation': 'The Emmes Corporation, Rockville, MD, United States.'}, {'ForeName': 'Terrence R', 'Initials': 'TR', 'LastName': 'Oakes', 'Affiliation': 'School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States.'}, {'ForeName': 'Lindell K', 'Initials': 'LK', 'LastName': 'Weaver', 'Affiliation': 'Division of Hyperbaric Medicine, Intermountain Medical Center, Murray, UT, United States; Division of Hyperbaric Medicine, Intermountain LDS Hospital, Salt Lake City, UT, United States; Department of Medicine, University of Utah, School of Medicine, Salt Lake, UT, United States.'}]",Brain research,['10.1016/j.brainres.2019.01.015'] 2532,30818971,Animal-assisted activity improves social behaviors in psychiatrically hospitalized youth with autism.,"There is preliminary research suggesting that animal-assisted activities can improve social interactions of children with autism spectrum disorder. This pilot study sought to investigate the benefits of animal-assisted activities with dogs and psychiatrically hospitalized youth with autism spectrum disorder. Participants were recruited from a specialized inpatient psychiatric hospital unit for youth with autism spectrum disorder and other developmental disabilities. Utilizing a crossover design, participants served as their own control by engaging in two 10-min conditions: an experimental dog and handler interaction (animal-assisted activities) and a novel toy and handler control (control). Of the 142 youth aged 6--8 years screened for participation, 47 completed both conditions. Participants' behavioral data were captured via video and coded using the Observation of Human-Animal Interaction for Research, a tool specifically developed to capture human behavioral interactions in the presence of animals. Overall, social-communication behaviors significantly improved in the animal-assisted activities experimental condition compared to the control condition ( p  = 0.0001). Specifically, participants in the animal-assisted activities experimental condition displayed more positive emotional facial expressions ( p  ⩽ 0.0001), talking ( p  = 0.0408), use of gestures ( p  = 0.032), and looking at both adults and peers ( p  ⩽ 0.0001). In addition, a higher frequency of constant motion ( p  = 0.003) was observed in the animal-assisted activities experimental condition. Results suggest that animal-assisted activities with a dog may promote social-communication behaviors in psychiatrically hospitalized youth with autism spectrum disorder. Given the fact that social and communication behaviors can facilitate treatment engagement for this population, we recommend future studies examine how such improvements can positively affect the psychiatric treatment of this population.",2019,"Specifically, participants in the animal-assisted activities experimental condition displayed more positive emotional facial expressions ( p  ⩽ 0.0001), talking ( p  = 0.0408), use of gestures ( p  = 0.032), and looking at both adults and peers ( p  ⩽ 0.0001).","['142 youth aged 6--8\u2009years screened for participation, 47 completed both conditions', 'children with autism spectrum disorder', 'Participants were recruited from a specialized inpatient psychiatric hospital unit for youth with autism spectrum disorder and other developmental disabilities', 'psychiatrically hospitalized youth with autism spectrum disorder', 'dogs and psychiatrically hospitalized youth with autism spectrum disorder', 'psychiatrically hospitalized youth with autism']","['Animal-assisted activity', 'animal-assisted activities', 'control by engaging in two 10-min conditions: an experimental dog and handler interaction (animal-assisted activities) and a novel toy and handler control (control']","['social behaviors', 'frequency of constant motion', 'positive emotional facial expressions', 'social-communication behaviors', 'Overall, social-communication behaviors', 'social interactions']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0748064', 'cui_str': 'Psychiatric in-patient'}, {'cui': 'C0019988', 'cui_str': 'Hospital Units'}, {'cui': 'C0008073', 'cui_str': 'Developmental disorder'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0012984', 'cui_str': 'Canis lupus familiaris'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}]","[{'cui': 'C0003062', 'cui_str': 'Kingdom Animalia'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332298', 'cui_str': 'Controlled by'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0012984', 'cui_str': 'Canis lupus familiaris'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0040565', 'cui_str': 'Toy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0037397', 'cui_str': 'Social behavior'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0037420', 'cui_str': 'Interaction with others'}]",142.0,0.0654835,"Specifically, participants in the animal-assisted activities experimental condition displayed more positive emotional facial expressions ( p  ⩽ 0.0001), talking ( p  = 0.0408), use of gestures ( p  = 0.032), and looking at both adults and peers ( p  ⩽ 0.0001).","[{'ForeName': 'Monique M', 'Initials': 'MM', 'LastName': 'Germone', 'Affiliation': '1 University of Colorado, USA.'}, {'ForeName': 'Robin L', 'Initials': 'RL', 'LastName': 'Gabriels', 'Affiliation': '1 University of Colorado, USA.'}, {'ForeName': 'Noémie A', 'Initials': 'NA', 'LastName': 'Guérin', 'Affiliation': '3 Purdue University, USA.'}, {'ForeName': 'Zhaoxing', 'Initials': 'Z', 'LastName': 'Pan', 'Affiliation': '1 University of Colorado, USA.'}, {'ForeName': 'Tiffany', 'Initials': 'T', 'LastName': 'Banks', 'Affiliation': ""2 Children's Hospital Colorado, USA.""}, {'ForeName': 'Marguerite E', 'Initials': 'ME', 'LastName': ""O'Haire"", 'Affiliation': '3 Purdue University, USA.'}]",Autism : the international journal of research and practice,['10.1177/1362361319827411'] 2533,30875548,Using data to solve problems: Children reason flexibly in response to different kinds of evidence.,"This study examined children's (5- to 9-year-olds, N = 363) abilities to use information seeking and explanation to solve problems using conclusive or inconclusive (i.e., consistent, inconsistent, or ambiguous) evidence. Results demonstrated that inconsistent and ambiguous evidence, not consistent evidence, motivate more requests for information than conclusive evidence. In addition, children's explanations were flexible in response to evidence; explanations based on transitive inference were more likely to be associated with an accurate conclusion than other explanation types. Children's requests for additional information in response to inconclusive evidence increased with age, as did their problem-solving accuracy. The data demonstrate that children's capacity to use information seeking and explanation develop in tandem as tools for problem solving.",2019,"Children's requests for additional information in response to inconclusive evidence increased with age, as did their problem-solving accuracy.","[""children's (5- to 9-year-olds, N\u202f=\u202f363) abilities to use information seeking and explanation to solve problems using conclusive or inconclusive (i.e., consistent, inconsistent, or ambiguous) evidence""]",[],[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0033211', 'cui_str': 'Problem solving'}, {'cui': 'C0205258', 'cui_str': 'Indeterminate'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C0442809', 'cui_str': 'Inconsistent'}, {'cui': 'C3539086', 'cui_str': 'Ambiguous'}]",[],[],,0.0452807,"Children's requests for additional information in response to inconclusive evidence increased with age, as did their problem-solving accuracy.","[{'ForeName': 'Justin T A', 'Initials': 'JTA', 'LastName': 'Busch', 'Affiliation': 'Department of Psychology, The University of Texas at Austin, Austin, TX 78712, USA. Electronic address: justin.ta.busch@utexas.edu.'}, {'ForeName': 'Cristine H', 'Initials': 'CH', 'LastName': 'Legare', 'Affiliation': 'Department of Psychology, The University of Texas at Austin, Austin, TX 78712, USA.'}]",Journal of experimental child psychology,['10.1016/j.jecp.2019.01.007'] 2534,30948491,Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial.,,2019,,['older patients with acute myeloid leukemia'],['Myeloablative conditioning using timed-sequential busulfan plus fludarabine'],[],"[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}]","[{'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0006463', 'cui_str': 'Busulfan'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0059985', 'cui_str': 'fludarabine'}]",[],,0.0125012,,"[{'ForeName': 'Rohtesh S', 'Initials': 'RS', 'LastName': 'Mehta', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Bassett', 'Affiliation': 'Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Olson', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Julianne', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Sairah', 'Initials': 'S', 'LastName': 'Ahmed', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Amin M', 'Initials': 'AM', 'LastName': 'Alousi', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Anderlini', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Gheath', 'Initials': 'G', 'LastName': 'Al-Atrash', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Qaiser', 'Initials': 'Q', 'LastName': 'Bashir', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Stefan O', 'Initials': 'SO', 'LastName': 'Ciurea', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Chitra M', 'Initials': 'CM', 'LastName': 'Hosing', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Jin S', 'Initials': 'JS', 'LastName': 'Im', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Partow', 'Initials': 'P', 'LastName': 'Kebriaei', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Issa', 'Initials': 'I', 'LastName': 'Khouri', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Marin', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'Molldrem', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Yago', 'Initials': 'Y', 'LastName': 'Nieto', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Betul', 'Initials': 'B', 'LastName': 'Oran', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Katayoun', 'Initials': 'K', 'LastName': 'Rezvani', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Muzaffar H', 'Initials': 'MH', 'LastName': 'Qazilbash', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Samer A', 'Initials': 'SA', 'LastName': 'Srour', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Elizabeth J', 'Initials': 'EJ', 'LastName': 'Shpall', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Borje S', 'Initials': 'BS', 'LastName': 'Andersson', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Champlin', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy.'}, {'ForeName': 'Uday R', 'Initials': 'UR', 'LastName': 'Popat', 'Affiliation': 'Department of Stem Cell Transplantation and Cellular Therapy upopat@mdanderson.org.'}]",Haematologica,['10.3324/haematol.2018.214429'] 2535,31418538,Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy-Induced Nausea and Vomiting.,"Population pharmacokinetics of rolapitant and its active metabolite M19 were studied in 482 patients receiving this neurokinin-1 receptor antagonist in combination with a 5-hydroxytryptamine-3 receptor antagonist and dexamethasone for prevention of chemotherapy-induced nausea and vomiting (CINV). Patients received a single dose of rolapitant (range, 9-180 mg) before administration of moderately or highly emetogenic chemotherapy. Population pharmacokinetic analysis was performed via nonlinear mixed-effects modeling. Rolapitant pharmacokinetics was best characterized by a 2-compartment model. Population typical values were estimated to be 0.962 L/h for apparent oral clearance and 214 L for central compartment volume of distribution. The intercompartment clearance and peripheral compartment volume of distribution was estimated to be 2.79 L/h and 164 L, respectively. Metabolite M19 pharmacokinetics was described by a 1-compartment model with an apparent metabolite clearance of 1.83 L/h. Intersubject variability was moderate for pharmacokinetics parameters. Weight positively correlated with central compartment volume of distribution and peripheral compartment volume of distribution but not with apparent oral clearance. No other demographic, clinical, or pathophysiologic covariates, including liver and renal function, influenced rolapitant pharmacokinetics. A slight positive trend was observed between rolapitant exposure and efficacy (ie, complete response defined as no emesis and no use of rescue medication) in the delayed phase of CINV (>24-120 hours after chemotherapy). This further supports the 180-mg dose of rolapitant in CINV patients. In summary, this validated population pharmacokinetic model satisfactorily describes pharmacokinetics of rolapitant and M19 in patients with CINV. These results support the recommendation that no dose adjustment for patient variables investigated is necessary.",2019,Metabolite M19 pharmacokinetics was described by a 1-compartment model with an apparent metabolite clearance of 1.83 L/h.,"['patients with CINV', 'for prevention of chemotherapy-induced nausea and vomiting (CINV', 'CINV patients', 'Patients', '482 patients receiving this neurokinin-1 receptor antagonist in combination with a']","['5-hydroxytryptamine-3 receptor antagonist and dexamethasone', 'single dose of rolapitant (range, 9-180\xa0mg) before administration of moderately or highly emetogenic chemotherapy']","['demographic, clinical, or pathophysiologic covariates, including liver and renal function, influenced rolapitant pharmacokinetics', 'rolapitant exposure and efficacy (ie, complete response defined as no emesis and no use of rescue medication', 'Metabolite M19 pharmacokinetics', 'Nausea and Vomiting', 'intercompartment clearance and peripheral compartment volume of distribution']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0401160', 'cui_str': 'Chemotherapy-induced nausea and vomiting'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C3543440', 'cui_str': 'Neurokinin 1 receptor antagonist'}]","[{'cui': 'C0360055', 'cui_str': '5-HT3 receptor antagonist'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C3273719', 'cui_str': 'rolapitant'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0013973', 'cui_str': 'Emetic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C3273719', 'cui_str': 'rolapitant'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}]",482.0,0.039688,Metabolite M19 pharmacokinetics was described by a 1-compartment model with an apparent metabolite clearance of 1.83 L/h.,"[{'ForeName': 'Xiaodong', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'TESARO Inc., Waltham, Massachusetts, USA.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'TESARO Inc., Waltham, Massachusetts, USA.'}, {'ForeName': 'Zhi-Yi', 'Initials': 'ZY', 'LastName': 'Zhang', 'Affiliation': 'TESARO Inc., Waltham, Massachusetts, USA.'}, {'ForeName': 'Vikram', 'Initials': 'V', 'LastName': 'Kansra', 'Affiliation': 'TESARO Inc., Waltham, Massachusetts, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.733'] 2536,32755904,"Effects of a 12-Week Mindfulness, Compassion, and Loving Kindness Program on Chronic Depression: A Pilot Within-Subjects Wait-List Controlled Trial.","In this pilot study, N = 11 patients suffering from chronic depression were treated in a 12-week group program consisting of basic mindfulness exercises from Mindfulness-Based Cognitive Therapy and compassion exercises from Compassion Focused Therapy and Loving Kindness Meditation. In a 3-month waiting period prior to treatment, depression symptoms both in self-report and clinician rating did not change significantly. After treatment, depression severity was significantly reduced. After a 3-month follow-up, the symptoms further improved, with almost large effect sizes being observed in primary outcome measures.Changes in emotion regulation styles reflected by a significant increase in acceptance and significant decrease in suppression of emotions were observed at follow-up. Rumination about oneself was also significantly reduced at follow-up. Compassionate love and mindfulness were increased at follow-up, no effects were found on the Self-Compassion Scale and the Rosenberg Self-Esteem Scale. Given further confirming studies for this approach, it might improve treatment options for patients suffering from chronic depression.",2016,"Compassionate love and mindfulness were increased at follow-up, no effects were found on the Self-Compassion Scale and the Rosenberg Self-Esteem Scale.","['N = 11 patients suffering from chronic depression', 'patients suffering from chronic depression']","['12-Week Mindfulness, Compassion, and Loving Kindness Program', 'basic mindfulness exercises from Mindfulness-Based Cognitive Therapy and compassion exercises from Compassion Focused Therapy and Loving Kindness Meditation']","['suppression of emotions', 'Rumination about oneself', 'acceptance', 'depression symptoms both in self-report and clinician rating', 'Changes in emotion regulation styles', 'Chronic Depression', 'depression severity', 'Self-Compassion Scale and the Rosenberg Self-Esteem Scale']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0581391', 'cui_str': 'Chronic depression'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0024028', 'cui_str': 'Love'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0581391', 'cui_str': 'Chronic depression'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0582666', 'cui_str': 'Rosenberg self-esteem scale'}]",11.0,0.011618,"Compassionate love and mindfulness were increased at follow-up, no effects were found on the Self-Compassion Scale and the Rosenberg Self-Esteem Scale.","[{'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Graser', 'Affiliation': 'Goethe University, Department of Clinical Psychology and Psychotherapy, Frankfurt, Germany graser@psych.uni-frankfurt.de graser.johannes@gmail.com.'}, {'ForeName': 'Volkmar', 'Initials': 'V', 'LastName': 'Höfling', 'Affiliation': 'Goethe University, Department of Clinical Psychology and Psychotherapy, Frankfurt, Germany.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Weβlau', 'Affiliation': 'Goethe University, Department of Clinical Psychology and Psychotherapy, Frankfurt, Germany.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Mendes', 'Affiliation': 'Goethe University, Department of Clinical Psychology and Psychotherapy, Frankfurt, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Stangier', 'Affiliation': 'Goethe University, Department of Clinical Psychology and Psychotherapy, Frankfurt, Germany.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.30.1.35'] 2537,32755908,"Does the Theoretical Perspective of Exposure Framing Matter? Acceptance, Fear Reduction/Cognitive Reappraisal, and Values-Framing of Exposure for Social Anxiety.","Exposure-based therapy represents a first line treatment for anxiety disorders, but it is often underused. One target for improving client engagement is manipulating the theoretical perspective from which exposure is framed. Ninety-six adults with elevated social anxiety were enrolled in a two-session exposure therapy intervention. Participants were randomized to one of four conditions: (a) fear reduction/cognitive reappraisal , (b) acceptance , (c) personal values , or (d) experimental control The first three included brief psychoeducation and condition-specific experiential exercises and rationale; all four included in-session speech exposure and between-session exposure for homework. Results revealed that compared to the experimental control, the three active conditions reported significantly higher treatment credibility, initial in-vivo exposure engagement, and improvement in social anxiety symptoms. The three active conditions showed few differences among themselves. This study demonstrates that a brief exposure intervention using a credible rationale led to initial engagement in exposure therapy and improvement in social anxiety symptoms.",2016,"Results revealed that compared to the experimental control, the three active conditions reported significantly higher treatment credibility, initial in-vivo exposure engagement, and improvement in social anxiety symptoms.",['Ninety-six adults with elevated social anxiety'],"['fear reduction/cognitive reappraisal , (b) acceptance , (c) personal values , or (d) experimental control', 'brief psychoeducation and condition-specific experiential exercises and rationale; all four included in-session speech exposure and between-session exposure for homework']","['Acceptance, Fear Reduction/Cognitive Reappraisal, and Values-Framing of Exposure for Social Anxiety', 'social anxiety symptoms', 'treatment credibility, initial in-vivo exposure engagement']","[{'cui': 'C4319625', 'cui_str': '96'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0424166', 'cui_str': 'Social fear'}]","[{'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0589414', 'cui_str': 'Homework'}]","[{'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0080089', 'cui_str': 'Reading Frames'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}]",96.0,0.00756492,"Results revealed that compared to the experimental control, the three active conditions reported significantly higher treatment credibility, initial in-vivo exposure engagement, and improvement in social anxiety symptoms.","[{'ForeName': 'Ellen J', 'Initials': 'EJ', 'LastName': 'Bluett', 'Affiliation': 'Department of Psychology, Utah State University.'}, {'ForeName': 'Lauren L', 'Initials': 'LL', 'LastName': 'Landy', 'Affiliation': 'Department of Psychology and Neuroscience, University of Colorado Boulder.'}, {'ForeName': 'Michel P', 'Initials': 'MP', 'LastName': 'Twohig', 'Affiliation': 'Department of Psychology, Utah State University.'}, {'ForeName': 'Joanna J', 'Initials': 'JJ', 'LastName': 'Arch', 'Affiliation': 'Department of Psychology and Neuroscience, University of Colorado Boulder.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.30.2.77'] 2538,32755912,Two Interventions Decrease Anxiety Sensitivity Among High Anxiety Sensitive Women: Could Physical Exercise Be the Key?,"A brief group-based cognitive behavioral therapy (CBT), with running as an interoceptive exposure (IE) component, was effective in reducing anxiety sensitivity (AS) levels in undergraduate women (Watt, Stewart, Lefaivre, & Uman, 2006). This study investigated whether the CBT/IE intervention would result in decreases in AS and emotional distress that would be maintained over 14 weeks. Female undergraduates, high ( n = 81) or low ( n = 73) in AS, were randomized to 3-day CBT plus forty-two 10-min running IE trials ( n = 83) or 3-day health education control (HEC) with interactive discussions and problem solving on exercise, nutrition, and sleep ( n = 71). The CBT/IE intervention led to decreases in AS, depression, and stress symptoms for high AS participants, which were maintained at 14 weeks. Unexpectedly, HEC participants experienced similar and lasting decreases in AS, depression, and anxiety symptoms. Furthermore, there were no post-intervention differences between CBT/IE and HEC participants in any of the outcomes. Low AS participants experienced few sustained changes. Clinical implications and the possible role of aerobic exercise in explaining outcomes of both interventions are discussed.",2016,"Furthermore, there were no post-intervention differences between CBT/IE and HEC participants in any of the outcomes.","['undergraduate women (Watt, Stewart, Lefaivre, & Uman, 2006', 'Female undergraduates, high ( n = 81) or low ( n = 73) in AS', 'High Anxiety Sensitive Women']","['A brief group-based cognitive behavioral therapy (CBT), with running as an interoceptive exposure (IE) component', '3-day health education control (HEC) with interactive discussions and problem solving on exercise, nutrition, and sleep', 'CBT/IE intervention', 'aerobic exercise']","['AS, depression, and anxiety symptoms', 'anxiety sensitivity (AS) levels', 'Anxiety Sensitivity', 'AS, depression, and stress symptoms', 'AS and emotional distress']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439261', 'cui_str': 'watt'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}, {'cui': 'C0033211', 'cui_str': 'Problem solving'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0700361', 'cui_str': 'Emotional distress'}]",,0.0784265,"Furthermore, there were no post-intervention differences between CBT/IE and HEC participants in any of the outcomes.","[{'ForeName': 'Brigitte C', 'Initials': 'BC', 'LastName': 'Sabourin', 'Affiliation': 'Department of Clinical Health Psychology, University of Manitoba, Canada.'}, {'ForeName': 'Margo C', 'Initials': 'MC', 'LastName': 'Watt', 'Affiliation': 'Department of Psychology, St. Francis Xavier University, Canada.'}, {'ForeName': 'Olav E', 'Initials': 'OE', 'LastName': 'Krigolson', 'Affiliation': 'Neuroeconomics Laboratory, University of Victoria, Canada.'}, {'ForeName': 'Sherry H', 'Initials': 'SH', 'LastName': 'Stewart', 'Affiliation': 'Department of Psychiatry and Department of Psychology and Neuroscience, Dalhousie University, Canada.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.30.2.131'] 2539,32755922,Social Anxiety and Misinterpretation of the Five Facet Mindfulness Questionnaire Describe Subscale.,"The Five Facet Mindfulness Questionnaire is a widely used measure assessing 5 aspects of mindfulness. The Describe subscale is intended to assess the ability to put one's inner experience into words for one's own understanding, but subscale items contain language that may be ambiguous in that regard. The current study investigated whether social anxiety is associated with a tendency to misinterpret Describe items as referring to describing one's experiences to others rather than oneself. Participants were randomized to receive one of 3 versions of the Describe subscale: the original version or one of two variants orienting participants to describe inner experience for self-communication or interpersonal communication. Social anxiety was negatively associated with Describe scores for the Standard Describe subscale and the interpersonal communication variant, but not for the self-communication variant. Results suggest that high levels of social anxiety are associated with misinterpretation of statements on the Describe subscale as probing for interpersonal communication.",2016,"Social anxiety was negatively associated with Describe scores for the Standard Describe subscale and the interpersonal communication variant, but not for the self-communication variant.",[],['Describe subscale: the original version or one of two variants orienting participants to describe inner experience for self-communication or interpersonal communication'],"['social anxiety', 'Social anxiety', 'Social Anxiety and Misinterpretation of the Five Facet Mindfulness Questionnaire Describe Subscale']",[],"[{'cui': 'C0205313', 'cui_str': 'Original'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0205419', 'cui_str': 'Variant'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0086792', 'cui_str': 'Personal Communication'}]","[{'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0222679', 'cui_str': 'Structure of articular surface of bone'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.0104318,"Social anxiety was negatively associated with Describe scores for the Standard Describe subscale and the interpersonal communication variant, but not for the self-communication variant.","[{'ForeName': 'Dane', 'Initials': 'D', 'LastName': 'Jensen', 'Affiliation': 'Psychology Department, Temple University, Philadelphia, Pennsylvania.'}, {'ForeName': 'Laura C', 'Initials': 'LC', 'LastName': 'Bruce', 'Affiliation': 'Psychology Department, Temple University, Philadelphia, Pennsylvania.'}, {'ForeName': 'Richard G', 'Initials': 'RG', 'LastName': 'Heimberg', 'Affiliation': 'Psychology Department, Temple University, Philadelphia, Pennsylvania heimberg@temple.edu.'}, {'ForeName': 'Lindsey M', 'Initials': 'LM', 'LastName': 'Matt', 'Affiliation': 'Psychology Department of Kent State University, Kent, Ohio.'}, {'ForeName': 'Amanda S', 'Initials': 'AS', 'LastName': 'Morrison', 'Affiliation': 'Psychology Department of Stanford University, Stanford, California.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.30.3.168'] 2540,32755924,An Initial Test of Reconsolidation in Disgust-Related Learning and Extinction.,"This study examines whether the spacing of a single unreinforced retrieval trial relative to extinction learning allows for ""rewriting"" the original disgust association, thereby preventing the return of disgust using a paradigm that employs disgust-relevant unconditioned stimuli (US). During conditioning, disgusting US were paired with a color square that served as the conditioned stimuli (CS). Participants ( n = 54) then returned to the lab 24 hours later and received a ""reactivation"" intervention which consisted of one unpaired presentation of the CS+. Participants were then randomized to receive extinction trials either 10 min (Group A) or 6 hours (Group B) after reactivation. A third control group (Group C) did not receive the reactivation manipulation before extinction. Participants returned 24 hours later for additional extinction trials and at a 1-month follow-up for disgust reinstatement. Although the paradigm resulted in participants evaluating the CS+ as significantly more unpleasant after being associated with a disgust-relevant US, extinction learning within the reconsolidation window did not influence self-reported reduction or return of disgust. However, there was some evidence suggesting that those who received reactivation (Groups A and B), regardless of timing, evaluated the CS+ as less unpleasant after extinction relative to acquisition, whereas this pattern was not observed among those who did not receive reactivation (Group C). The implications of these findings for anxiety-related disorders in which disgust has been implicated will be discussed.",2016,A third control group (Group C) did not receive the reactivation manipulation before extinction.,[],"['reactivation"" intervention']",[],[],"[{'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],1.0,0.0204772,A third control group (Group C) did not receive the reactivation manipulation before extinction.,"[{'ForeName': 'Bunmi', 'Initials': 'B', 'LastName': 'Olatunji', 'Affiliation': 'Vanderbilt University, Nashville, Tennessee.'}, {'ForeName': 'Shivali', 'Initials': 'S', 'LastName': 'Sarawgi', 'Affiliation': 'Vanderbilt University, Nashville, Tennessee.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Viar-Paxton', 'Affiliation': 'Vanderbilt University, Nashville, Tennessee.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.30.3.190'] 2541,32756094,"Pureed diets containing a gelling agent to reduce the risk of aspiration in elderly patients with moderate to severe dysphagia: A randomized, crossover trial.","GOALS The aim of this study was to evaluate the effectiveness of adding a gelling agent to pureed diets to prevent aspiration pneumonia in elderly patients with moderate to severe dysphagia. BACKGROUND Pureed diets are often used to reduce aspiration in patients with dysphagia. However, the ideal texture of a pureed diet to prevent aspiration pneumonia remains unclear. MATERIALS AND METHODS We prospectively conducted a randomized, crossover trial of pureed rice with or without a gelling agent in patients with moderate to severe dysphagia (ClincialTrials.gov number, NCT03163355). The primary outcome measure was pharyngeal residuals using an endoscopic scoring system. The secondary outcome was the sense of material remaining in the throat following swallowing. RESULTS Sixty two patients (58% men), mean age 83 ± 9 years with moderate to severe dysphagia were included. Residuals in the throat were significantly less likely with pureed rice with than without the gelling agent (median cyclic ingestion score (range); 1 (0-4) vs 2 (0-4); P = .001). Irrespective of the presence or absence of the gelling agent, the sense of material remaining in the throat was significantly less frequent in older patients (87 ± 7.6 vs 75 ± 9.1 years, P < .01; 86 ± 7.3 vs 75 ± 8.6 years, P < .01). CONCLUSIONS Pureed diets containing a gelling agent may reduce the risk of aspiration pneumonia possibly by decreasing pharyngeal residues in elderly patients with moderate to severe dysphagia.",2020,Residuals in the throat were significantly less likely with pureed rice with than without the gelling agent (median cyclic ingestion score (range); 1 (0-4) vs 2 (0-4); P = .001).,"['patients with dysphagia', 'Sixty two patients (58% men), mean age 83\u200a±\u200a9 years with moderate to severe dysphagia were included', 'elderly patients with moderate to severe dysphagia', 'patients with moderate to severe dysphagia (ClincialTrials.gov number, NCT03163355']","['gelling agent to pureed diets', 'Pureed diets containing a gelling agent']","['pharyngeal residuals using an endoscopic scoring system', 'sense of material remaining in the throat following swallowing']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C4517835', 'cui_str': '62'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0237753', 'cui_str': 'Number'}]","[{'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0452392', 'cui_str': 'Pureed diet'}, {'cui': 'C0332256', 'cui_str': 'Containing'}]","[{'cui': 'C0031354', 'cui_str': 'Pharyngeal structure'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}]",,0.0556869,Residuals in the throat were significantly less likely with pureed rice with than without the gelling agent (median cyclic ingestion score (range); 1 (0-4) vs 2 (0-4); P = .001).,"[{'ForeName': 'Reiko', 'Initials': 'R', 'LastName': 'Kyodo', 'Affiliation': 'Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Kudo', 'Affiliation': 'Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Horiuchi', 'Affiliation': 'Digestive Disease Center.'}, {'ForeName': 'Torao', 'Initials': 'T', 'LastName': 'Sakamoto', 'Affiliation': 'Department of Rehabilitation, Showa Inan General Hospital, Komagane, Japan.'}, {'ForeName': 'Toshiaki', 'Initials': 'T', 'LastName': 'Shimizu', 'Affiliation': 'Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo.'}]",Medicine,['10.1097/MD.0000000000021165'] 2542,32756101,Protocol paper for the Movimente school-based program: A cluster-randomized controlled trial targeting physical activity and sedentary behavior among Brazilian adolescents.,"BACKGROUND A better understanding of how multicomponent school-based interventions work and their effects on health and education outcomes are needed. This paper described the methods of the Movimente Program, a school-based intervention that aims to increase physical activity (PA) and decrease sedentary behavior (SB) among Brazilian students. METHODS This is a cluster randomized controlled trial with adolescents from 7th to 9th grade in public schools from Florianopolis, Southern Brazil. After agreement, 6 schools were randomly selected to intervention or control groups (3 schools each), and all eligible students were invited to the study. The Movimente intervention program was performed during a school year and included 3 main components: Teacher training (including face-to-face meeting, social media platform, and handbook with lesson plans); improvements in the PA environment in school; and educational strategies. Control schools continued with their traditional schedule. Baseline (March/April 2017), postintervention (November/December 2017), and maintenance (June/July 2018) evaluations included PA and SB as primary outcomes (assessed by self-report and accelerometry). Secondary outcomes included psychosocial factors related to PA and SB (e.g., social support and self-efficacy), as well as health (e.g., quality of life and nutritional status) and education (e.g., academic achievement) outcomes. A program evaluation was performed based on the RE-AIM framework. Participants, intervention staffs, and evaluators were not blinded to group assignment, but a standardized evaluation protocol was applied independently of the trial allocation. RESULTS Statistical analyses will include a multilevel approach for repeated measurements and mediation analysis. Any side effects of the intervention will be recorded. The sample size close to that expected (n = 1090) was reached (n = 999). The results of this trial will involve valuable information about the effect and the evaluation of a multicomponent intervention carried out in a middle-income country. CONCLUSION By creating opportunities for adolescents to be active at school using multicomponent strategies, the Movimente program has the potential to enhance students health and academic performance which may encourage the school community (e.g., teachers, principals) to adopt the program. Also, this trial will provide evidence for practitioners, policy makers, and researchers on how multicomponent program may be implemented in a school setting. TRIAL REGISTRATION The trial is registered at the Clinical Trial Registry (Trial ID: NCT02944318; date of registration: 18 October 2016).",2020,"Participants, intervention staffs, and evaluators were not blinded to group assignment, but a standardized evaluation protocol was applied independently of the trial allocation. ","['Brazilian adolescents', 'adolescents from 7th to 9th grade in public schools from Florianopolis, Southern Brazil', '6 schools were randomly selected to intervention or control groups (3 schools each), and all eligible students were invited to the study', 'Movimente school-based program', 'Brazilian students']","['Movimente intervention program was performed during a school year and included 3 main components: Teacher training (including face-to-face meeting, social media platform, and handbook with lesson plans']","['physical activity (PA) and decrease sedentary behavior (SB', 'psychosocial factors related to PA and SB (e.g., social support and self-efficacy), as well as health (e.g., quality of life and nutritional status) and education (e.g., academic achievement) outcomes']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0557800', 'cui_str': 'Public school'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C4082803', 'cui_str': 'Teacher Training'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}, {'cui': 'C3179065', 'cui_str': 'Social Medium'}, {'cui': 'C0596654', 'cui_str': 'Handbooks'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C1532253', 'cui_str': 'Sedentary lifestyle'}, {'cui': 'C0033963', 'cui_str': 'Psychosocial Factors'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0013658', 'cui_str': 'Educational achievement'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",6.0,0.0468859,"Participants, intervention staffs, and evaluators were not blinded to group assignment, but a standardized evaluation protocol was applied independently of the trial allocation. ","[{'ForeName': 'Kelly Samara', 'Initials': 'KS', 'LastName': 'Silva', 'Affiliation': 'Department of Physical Education, Research Centre in Physical Activity and Health, Sport Centre, Federal University of Santa Catarina, Florianopolis.'}, {'ForeName': 'Jaqueline Aragoni da', 'Initials': 'JAD', 'LastName': 'Silva', 'Affiliation': 'Department of Physical Education, Research Centre in Physical Activity and Health, Sport Centre, Federal University of Santa Catarina, Florianopolis.'}, {'ForeName': 'Valter Cordeiro', 'Initials': 'VC', 'LastName': 'Barbosa Filho', 'Affiliation': 'Federal Institute of Education, Science and Technology of Ceara, Aracati, Brazil.'}, {'ForeName': 'Priscila Cristina Dos', 'Initials': 'PCD', 'LastName': 'Santos', 'Affiliation': 'Department of Physical Education, Research Centre in Physical Activity and Health, Sport Centre, Federal University of Santa Catarina, Florianopolis.'}, {'ForeName': 'Pablo Magno da', 'Initials': 'PMD', 'LastName': 'Silveira', 'Affiliation': 'Department of Physical Education, Research Centre in Physical Activity and Health, Sport Centre, Federal University of Santa Catarina, Florianopolis.'}, {'ForeName': 'Marcus V V', 'Initials': 'MVV', 'LastName': 'Lopes', 'Affiliation': 'Department of Physical Education, Research Centre in Physical Activity and Health, Sport Centre, Federal University of Santa Catarina, Florianopolis.'}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Salmon', 'Affiliation': 'Institute for Physical Activity and Nutrition, Faculty of Health, Deakin University, Victoria, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021233'] 2543,32756124,A randomized study protocol of microendoscopic versus open discectomy in treatment of lumbar disc herniation.,"BACKGROUND Lumbar disk herniation (LDH) is one of the main causes of discogenic low back pain. However, the evidence comparing different approaches for discectomy has lacked definitive conclusions, with conflicting results regarding the benefit of minimally invasive versus open techniques for LDH. We are now conducting a randomized controlled trial to figure out whether or not microendoscopic discectomy yields better clinical outcomes and causes less surgical trauma than open surgery. METHODS This prospective, randomized, single-blind, controlled, superiority clinical trial was approved by the institutional review board in the People's Hospital of Jianyang City. The conduct of this study followed the Declaration of Helsinki principles and the reporting of this study adhered to the Consolidated Standards of Reporting Trials guidelines for randomized controlled trials. Subjects were randomized into 2 groups as follows: open surgery and microendoscopic group. The outcomes included pain score, functional outcome, satisfaction rate, radiological outcomes, and complications. The statistical analyses in this study were performed using the Statistical Package for the Social Sciences 20.0 software. P < .05 was accepted as statistically significant. RESULTS The hypothesis was that the open technique would achieve similar clinical outcomes as compared to the microendoscopic technique in LDH. TRIAL REGISTRATION This study protocol was registered in Research Registry (researchregistry5708).",2020,"We are now conducting a randomized controlled trial to figure out whether or not microendoscopic discectomy yields better clinical outcomes and causes less surgical trauma than open surgery. ","['lumbar disc herniation', ""People's Hospital of Jianyang City""]","['open surgery and microendoscopic group', 'microendoscopic versus open discectomy']","['pain score, functional outcome, satisfaction rate, radiological outcomes, and complications']","[{'cui': 'C0281899', 'cui_str': 'Prolapsed lumbar intervertebral disc'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008848', 'cui_str': 'Cities'}]","[{'cui': 'C0348025', 'cui_str': 'Open approach'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0206078', 'cui_str': 'Discectomy of spine'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",,0.132044,"We are now conducting a randomized controlled trial to figure out whether or not microendoscopic discectomy yields better clinical outcomes and causes less surgical trauma than open surgery. ","[{'ForeName': 'Yunlong', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': ""Department of Orthopaedics, The People's Hospital of Leshan.""}, {'ForeName': 'Zhiqiang', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Department of Orthopedics, the Affiliated Hospital of Southwest Medical University.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Lei', 'Affiliation': 'Department of Orthopedics, the Affiliated Hospital of Southwest Medical University.'}, {'ForeName': 'Kan', 'Initials': 'K', 'LastName': 'Xie', 'Affiliation': ""Department of Orthopaedics, The People's Hospital of Leshan.""}, {'ForeName': 'Xufeng', 'Initials': 'X', 'LastName': 'Jia', 'Affiliation': ""Department of Orthopedics, The People's Hospital of Jianyang City, Sichuan Province, China.""}]",Medicine,['10.1097/MD.0000000000021361'] 2544,32756135,Analgesic effect of extracorporeal shock-wave therapy for frozen shoulder: A randomized controlled trial protocol.,"BACKGROUND Till date only a few studies have reported the efficacy and clinical improvements obtained by extracorporeal shock-wave therapy (ESWT) on frozen shoulder. Limited by small number of studies and insufficient outcomes, it is important and necessary to conduct a new randomized controlled trial. The purpose of the present study is to determine whether ESWT could be more effective than oral steroid in treatment of frozen shoulder. METHODS This randomized, single-blind, superiority clinical trial was approved by the institutional review board in The Third People's Hospital of Linyi. The inclusion criteria were patients aged >18 years with shoulder pain and restriction in range of motion. A symptom duration >3 months was required, with no radiographic findings on anteroposterior shoulder plain radiographs except for osteoporosis. Group 1 patients were given 30 mg of oral prednisolone daily for 2 weeks as a single morning dose and then 15 mg daily for another 2 weeks. Group 2 patients received 3 sessions of ESWT on the first, 14th, and 28th days. The primary outcome measure was shoulder pain score. The secondary outcomes included Disabilities of the Arm, Shoulder, and Hand score, range of motion, satisfaction rate, and complications. RESULTS It was hypothesized that there would be a significant difference between ESWT and control groups in improving shoulder pain and functions in frozen shoulder. TRIAL REGISTRATION This study protocol was registered in Research Registry (researchregistry5736).",2020,"The secondary outcomes included Disabilities of the Arm, Shoulder, and Hand score, range of motion, satisfaction rate, and complications. ","[""Third People's Hospital of Linyi"", 'frozen shoulder', 'patients aged >18 years with shoulder pain and restriction in range of motion']","['oral prednisolone', 'extracorporeal shock-wave therapy', 'ESWT', 'extracorporeal shock-wave therapy (ESWT']","['Analgesic effect', 'shoulder pain score', 'shoulder pain and functions', 'Disabilities of the Arm, Shoulder, and Hand score, range of motion, satisfaction rate, and complications']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0311223', 'cui_str': 'Adhesive capsulitis of shoulder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0460094', 'cui_str': 'Within reference range'}, {'cui': 'C0026597', 'cui_str': 'Motion'}]","[{'cui': 'C0358513', 'cui_str': 'Prednisolone-containing product in oral dose form'}, {'cui': 'C1737238', 'cui_str': 'Extracorporeal shock wave therapy'}]","[{'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",,0.190963,"The secondary outcomes included Disabilities of the Arm, Shoulder, and Hand score, range of motion, satisfaction rate, and complications. ","[{'ForeName': 'Han-Yong', 'Initials': 'HY', 'LastName': 'Qiao', 'Affiliation': 'Department of Special Inspection.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Xin', 'Affiliation': ""Department of Pathology, The Third People's Hospital of Linyi, Shandong, 276023, China.""}, {'ForeName': 'Shao-Lan', 'Initials': 'SL', 'LastName': 'Wu', 'Affiliation': 'Department of Special Inspection.'}]",Medicine,['10.1097/MD.0000000000021399'] 2545,32756479,Effects of Ramadan Intermittent Fasting on Gut Hormones and Body Composition in Males with Obesity.,"We studied the effects of Ramadan intermittent fasting (RIF) on gut hormones (leptin, glucagon-like peptide-1 (GLP-1), peptide YY (PYY), cholecystokinin (CCK), and ghrelin) in males with obesity. Thirty sedentary males were randomly allocated to either an experimental group (EG, n = 15) or a control group (CG, n = 15). The EG group completed their Ramadan fasting rituals (30 days), whereas the CG continued with their normal daily habits. Blood samples were collected at four time points: 24 h before the start of Ramadan (T0), on the 15th day of Ramadan (T1), the day after the end of Ramadan (T2) and 21 days after Ramadan (T3). There were significant pre-to-post improvements for leptin ( p = 0.01, d = 1.52), GLP-1 ( p = 0.022, d = 0.75), PYY ( p = 0.031, d = 0.69) and CCK ( p = 0.027, d = 0.81) in the EG, with no interaction effect for ghrelin ( p = 0.74; d = 0.008). No significant changes ( p > 0.05) occurred in plasma volume variations (ΔPV) after RIF in both EG (-0.03 ± 0.01%) and CG (0.06 ± 0.07%). RIF represents an effective strategy to modify appetite-regulating hormones, leading to improved body composition indices and reduced obesity.",2020,"There were significant pre-to-post improvements for leptin ( p = 0.01, d = 1.52), GLP-1 ( p = 0.022, d = 0.75), PYY ( p = 0.031, d = 0.69) and CCK ( p = 0.027, d = 0.81) in the EG, with no interaction effect for ghrelin ( p = 0.74; d = 0.008).","['Males with Obesity', 'Thirty sedentary males', 'males with obesity']","['Ramadan Intermittent Fasting', 'Ramadan intermittent fasting (RIF']","['plasma volume variations (ΔPV', 'Gut Hormones and Body Composition', 'leptin', 'Blood samples', 'GLP-1', 'GLP-1), peptide YY (PYY), cholecystokinin (CCK), and ghrelin', 'gut hormones (leptin, glucagon-like peptide-1']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}]","[{'cui': 'C4704881', 'cui_str': 'Intermittent Fasting'}]","[{'cui': 'C0032127', 'cui_str': 'Blood plasma volume'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0070358', 'cui_str': 'Peptide YY'}, {'cui': 'C0008328', 'cui_str': 'Cholecystokinin'}, {'cui': 'C0911014', 'cui_str': 'Ghrelin'}]",30.0,0.0168911,"There were significant pre-to-post improvements for leptin ( p = 0.01, d = 1.52), GLP-1 ( p = 0.022, d = 0.75), PYY ( p = 0.031, d = 0.69) and CCK ( p = 0.027, d = 0.81) in the EG, with no interaction effect for ghrelin ( p = 0.74; d = 0.008).","[{'ForeName': 'Hassane', 'Initials': 'H', 'LastName': 'Zouhal', 'Affiliation': 'Laboratoire Mouvement, Sport, Santé (M2S)-EA 1274, Université Rennes, F-35000 Rennes, France.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Bagheri', 'Affiliation': 'Department of Exercise Physiology, University of Isfahan, Isfahan 8174673441, Iran.'}, {'ForeName': 'Raoua', 'Initials': 'R', 'LastName': 'Triki', 'Affiliation': 'ISSEP Ksar Said, University of La Manouba, Tunis 2000, Tunisia.'}, {'ForeName': 'Ayoub', 'Initials': 'A', 'LastName': 'Saeidi', 'Affiliation': 'Department of Physical Education, Damghan Branch, Islamic Azad University, Damghan 3671637849, Iran.'}, {'ForeName': 'Alexei', 'Initials': 'A', 'LastName': 'Wong', 'Affiliation': 'Department of Health and Human Performance, Marymount University, Arlington, VA 22207, USA.'}, {'ForeName': 'Anthony C', 'Initials': 'AC', 'LastName': 'Hackney', 'Affiliation': 'Department of Exercise & Sport Science, University of North Carolina, Chapel Hill, NC 27599, USA.'}, {'ForeName': 'Ismail', 'Initials': 'I', 'LastName': 'Laher', 'Affiliation': 'Department of Anesthesiology, Pharmacology and Therapeutics, The University of British Columbia, Vancouver, BC V6T 1Z4, Canada.'}, {'ForeName': 'Katsuhiko', 'Initials': 'K', 'LastName': 'Suzuki', 'Affiliation': 'Faculty of Sport Sciences, Waseda University, Tokorozawa 359-1192, Japan.'}, {'ForeName': 'Abderraouf', 'Initials': 'A', 'LastName': 'Ben Abderrahman', 'Affiliation': 'ISSEP Ksar Said, University of La Manouba, Tunis 2000, Tunisia.'}]",International journal of environmental research and public health,['10.3390/ijerph17155600'] 2546,32756485,Schoolteachers' Knowledge of Attention-Deficit/Hyperactivity Disorder-Current Status and Effectiveness of Knowledge Improvement Program: A Randomized Controlled Trial.,"BACKGROUND Adequately knowledgeable schoolteachers can play an essential role in early detection and proper treatment of children with attention-deficit/hyperactivity disorder (ADHD) at school. OBJECTIVES To assess the schoolteachers' knowledge of ADHD and to evaluate the effectiveness of the ADHD knowledge improvement program. METHODS A randomized controlled trial study design was followed on 100 primary school teachers from Abha City, Saudi Arabia. Teachers were randomly selected and allocated into trial and control groups. A self-administered questionnaire was used to evaluate teachers' knowledge about ADHD. After the baseline assessment, participants in the trial group received a two-day ADHD knowledge improvement program. Teachers' knowledge about ADHD was reassessed using the same questionnaire immediately after finishing the intervention program and after three months in both groups. RESULTS Only 16% and 22% of trial and control groups, respectively, showed adequate baseline knowledge about ADHD. Teachers' main sources of information about ADHD were the internet (67%), friends (47%), TV (34%), and reading books (23%). Knowledge of teachers in the trial group significantly improved immediately after the intervention. After three months, these knowledge benefits slightly declined but remained more adequate than those of teachers in the control group. The logistic regression model revealed that being a participant in the trial group and of higher qualification were associated with significant improvement in teachers' retained knowledge on ADHD ( p < 0.001 and p = 0.050, respectively). CONCLUSIONS The majority of male primary school teachers in Abha City, Saudi Arabia, have inadequate knowledge about ADHD. Applying a knowledge improvement program can substantially improve their knowledge of ADHD. Consideration should be given to the integration of ADHD knowledge improvement program into teachers' educational programs.",2020,"Teachers' main sources of information about ADHD were the internet (67%), friends (47%), TV (34%), and reading books (23%).","['male primary school teachers in Abha City, Saudi Arabia', '100 primary school teachers from Abha City, Saudi Arabia', 'children with attention-deficit/hyperactivity disorder (ADHD) at school']",['Knowledge Improvement Program'],"[""teachers' retained knowledge on ADHD""]","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0036243', 'cui_str': 'Saudi Arabia'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0036375', 'cui_str': 'School'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}]",100.0,0.0228989,"Teachers' main sources of information about ADHD were the internet (67%), friends (47%), TV (34%), and reading books (23%).","[{'ForeName': 'Abdullah M', 'Initials': 'AM', 'LastName': 'Alshehri', 'Affiliation': 'Joint Program of Saudi Board in Community Medicine, Southern Region 61421, Saudi Arabia.'}, {'ForeName': 'Shehata F', 'Initials': 'SF', 'LastName': 'Shehata', 'Affiliation': 'Department of Family and Community Medicine, College of Medicine, King Khalid University, Abha 61421, Saudi Arabia.'}, {'ForeName': 'Khalid M', 'Initials': 'KM', 'LastName': 'Almosa', 'Affiliation': 'Community Medicine Consultant, Joint Program of Saudi Board in Community Medicine, Southern Region 61421, Saudi Arabia.'}, {'ForeName': 'Nabil J', 'Initials': 'NJ', 'LastName': 'Awadalla', 'Affiliation': 'Department of Family and Community Medicine, College of Medicine, King Khalid University, Abha 61421, Saudi Arabia.'}]",International journal of environmental research and public health,['10.3390/ijerph17155605'] 2547,32756488,Antidepressant Effect of Shaded White Leaf Tea Containing High Levels of Caffeine and Amino Acids.,"The young leaves of green tea become lighter in color than usual when protected from sunlight by a shading net for about two weeks while growing. These leaves are called ""shaded white leaf tea"" or SWLT. In the eluate of SWLT, the amount of amino acids (361 mg/L) was significantly higher than that in regular tea (53.5 mg/L). Since theanine and arginine, the first and second most abundant amino acids in SWLT, have significant antistress effects, we examined the antistress effect of SWLT on humans. SWLT or placebo green tea (3 g) was eluted with room-temperature water (500 mL). Participants consumed the tea for one week prior to pharmacy practice and continued for 10 days in the practice period. The state-trait anxiety inventory, an anxiety questionnaire, tended to be scored lower in the SWLT group than the placebo, but other stress markers showed no differences. The effect of the difference in SWLT components examined with mice showed that aspartic acid and asparagine, which are abundant in SWLT, counteracted the antistress effects of theanine and arginine. Large amounts of caffeine also interfered with SWLT's antistress effect. Thus, SWLT, which is high in caffeine and amino acids, suppressed depressant behavior in mice.",2020,"In the eluate of SWLT, the amount of amino acids (361 mg/L) was significantly higher than that in regular tea (53.5 mg/L).",[],"['Caffeine and Amino Acids', 'caffeine', 'Shaded White Leaf Tea', 'SWLT or placebo green tea', 'amino acids', 'placebo']","['state-trait anxiety inventory, an anxiety questionnaire']",[],"[{'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0242724', 'cui_str': 'Leaves'}, {'cui': 'C0039400', 'cui_str': 'Tea'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1384640', 'cui_str': 'Green tea'}]","[{'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.0461238,"In the eluate of SWLT, the amount of amino acids (361 mg/L) was significantly higher than that in regular tea (53.5 mg/L).","[{'ForeName': 'Keiko', 'Initials': 'K', 'LastName': 'Unno', 'Affiliation': 'Tea Science Center, Graduate Division of Nutritional and Environmental Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Furushima', 'Affiliation': 'Department of Drug Evaluation & Informatics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.'}, {'ForeName': 'Yuzuki', 'Initials': 'Y', 'LastName': 'Nomura', 'Affiliation': 'Department of Drug Evaluation & Informatics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Yamada', 'Affiliation': 'Department of Drug Evaluation & Informatics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.'}, {'ForeName': 'Kazuaki', 'Initials': 'K', 'LastName': 'Iguchi', 'Affiliation': 'Department of Neurophysiology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.'}, {'ForeName': 'Kyoko', 'Initials': 'K', 'LastName': 'Taguchi', 'Affiliation': 'Tea Science Center, Graduate Division of Nutritional and Environmental Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.'}, {'ForeName': 'Toshikazu', 'Initials': 'T', 'LastName': 'Suzuki', 'Affiliation': 'Tea Research Center, Shizuoka Prefectural Research Institute of Agriculture and Forestry, Kikugawa, Shizuoka 439-0002, Japan.'}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Ozeki', 'Affiliation': 'Nutrition Division, R&D Group, Taiyo Kagaku Co., Ltd., Yokkaichi, Mie 510-0844, Japan.'}, {'ForeName': 'Yoriyuki', 'Initials': 'Y', 'LastName': 'Nakamura', 'Affiliation': 'Tea Science Center, Graduate Division of Nutritional and Environmental Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.'}]","Molecules (Basel, Switzerland)",['10.3390/molecules25153550'] 2548,32756520,Combination Preemptive Peripheral Nerve Block in Limb Surgery. A Prospective Study.,"Background and objectives : Patients often suffer from moderate to severe pain during the early recovery period in orthopedic surgery. We investigated the impact of a single-shot preoperative peripheral nerve block (PNB) on post-anesthesia recovery parameters and interleukin (IL)-6 level during limb surgery. Materials and Methods: A prospective randomized controlled study was conducted, and patients scheduled for limb surgery were recruited. Sixty patients were randomly assigned to either the PNB group or control group, who received morphine as a primary analgesic. The peak verbal numeric rating scale (NRS) score in the post-anesthesia care unit (PACU) was evaluated as a primary outcome. We also recorded rescue analgesics requirement and wake-up time from anesthesia in the PACU. In addition, the change of plasma IL-6 level after incision was measured. Results : Fifty-two patients completed the study, 27 and 25 cases in the PNB and control group, respectively. Preemptive PNB significantly reduced peak NRS score in the PACU compared to control group. Lower rescue analgesics requirement and rapid wake-up from anesthesia were also noted in PNB group. The IL-6 concentration increased less in the PNB group at 2 h after incision. Conclusions : Preemptive PNB attenuates IL-6 expression 2 h after incision and improves pain management in the PACU. PNB was considered as an essential part of pain management in limb surgery.",2020,The IL-6 concentration increased less in the PNB group at 2 h after incision. ,"['Fifty-two patients completed the study, 27 and 25 cases in the PNB and control group, respectively', 'Limb Surgery', 'patients scheduled for limb surgery were recruited', 'Sixty patients', ' and objectives : Patients often suffer from moderate to severe pain during the early recovery period in orthopedic surgery']","['PNB', 'Preemptive PNB', 'single-shot preoperative peripheral nerve block (PNB', 'morphine']","['peak NRS score', 'plasma IL-6 level', 'pain management', 'Lower rescue analgesics requirement and rapid wake-up from anesthesia', 'IL-6 concentration', 'peak verbal numeric rating scale (NRS) score']","[{'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0198807', 'cui_str': 'Peripheral block anesthesia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}]","[{'cui': 'C0198807', 'cui_str': 'Peripheral block anesthesia'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0442696', 'cui_str': 'Waking'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",60.0,0.0627649,The IL-6 concentration increased less in the PNB group at 2 h after incision. ,"[{'ForeName': 'I-Cheng', 'Initials': 'IC', 'LastName': 'Lu', 'Affiliation': 'Department of Anesthesiology, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.'}, {'ForeName': 'Shu-Hung', 'Initials': 'SH', 'LastName': 'Huang', 'Affiliation': 'Department of Surgery, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.'}, {'ForeName': 'David Vi', 'Initials': 'DV', 'LastName': 'Lu', 'Affiliation': 'Department of Anesthesiology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung 812, Taiwan.'}, {'ForeName': 'Chun Dan', 'Initials': 'CD', 'LastName': 'Hsu', 'Affiliation': 'Department of Anesthesiology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung 812, Taiwan.'}, {'ForeName': 'Sheng Hua', 'Initials': 'SH', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesiology, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.'}]","Medicina (Kaunas, Lithuania)",['10.3390/medicina56080388'] 2549,32756564,The effect of hydration status on plasma FGF21 concentrations in humans: A subanalysis of a randomised crossover trial.,"AIM Fibroblast growth factor 21 (FGF21) has recently been implicated in thirst in rodent models. The mechanisms for this are currently uncertain, and it is unclear whether hydration status can alter FGF21 concentrations, potentially providing an additional mechanism by which hypohydration induces thirst. The aim of this study is therefore to understand whether hydration status can alter circulating FGF21 in humans. METHODS Using a heat tent and fluid restriction, we induced hypohydration (1.9% body mass loss) in 16 healthy participants (n = 8 men), and compared their glycaemic regulation to a rehydration protocol (heat tent and fluid replacement) in a randomised crossover design. RESULTS After the hypohydration procedure, urine specific gravity, urine and serum osmolality, and plasma copeptin (as a marker for arginine vasopressin) increased as expected, with no change after the rehydration protocol. In the fasted state, the median paired difference in plasma FGF21 concentrations from the rehydrated to hypohydrated trial arm was -37 (interquartile range -125, 10) pg∙mL-1(P = 0.278), with average concentrations being 458 ± 462 pg∙mL-1 after hypohydration and 467 ± 438 pg∙mL-1 after rehydration; mean difference -9 ± 173 pg∙mL-1. CONCLUSION To our knowledge, these are the first causal data in humans investigating hydration and FGF21, demonstrating that an acute bout of hypohydration does not impact fasted plasma FGF21 concentrations. These data may suggest that whilst previous research has found FGF21 administration can induce thirst and drinking behaviours, a physiological state implicated in increased thirst (hypohydration) does not appear to impact plasma FGF21 concentrations in humans.",2020,FGF21 concentrations from the rehydrated to hypohydrated trial arm was -37,"['16 healthy participants (n = 8 men', 'humans']","['hydration status', 'rehydration protocol (heat tent and fluid replacement', 'Fibroblast growth factor 21 (FGF21']","['FGF21 concentrations', 'urine specific gravity, urine and serum osmolality, and plasma copeptin (as a marker for arginine vasopressin', 'plasma FGF21 concentrations', 'plasma']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C1321013', 'cui_str': 'Hydration status'}, {'cui': 'C0034997', 'cui_str': 'Rehydration therapy'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0677506', 'cui_str': 'Tent'}, {'cui': 'C0521302', 'cui_str': 'Body fluid replacement'}, {'cui': 'C0972232', 'cui_str': 'fibroblast growth factor 21'}]","[{'cui': 'C0972232', 'cui_str': 'fibroblast growth factor 21'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0202517', 'cui_str': 'Urinalysis, specific gravity measurement'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0202151', 'cui_str': 'Osmolality measurement, serum'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0056279', 'cui_str': 'copeptins'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0003779', 'cui_str': 'Argipressin'}]",16.0,0.122116,FGF21 concentrations from the rehydrated to hypohydrated trial arm was -37,"[{'ForeName': 'Harriet A', 'Initials': 'HA', 'LastName': 'Carroll', 'Affiliation': 'Department for Health, University of Bath, Bath, United Kingdom.'}, {'ForeName': 'Yung-Chih', 'Initials': 'YC', 'LastName': 'Chen', 'Affiliation': 'Department of Physical Education, National Taiwan Normal University, Taipei, Taiwan.'}, {'ForeName': 'Iain', 'Initials': 'I', 'LastName': 'Templeman', 'Affiliation': 'Department for Health, University of Bath, Bath, United Kingdom.'}, {'ForeName': 'Lewis J', 'Initials': 'LJ', 'LastName': 'James', 'Affiliation': 'School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, United Kingdom.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Betts', 'Affiliation': 'Department for Health, University of Bath, Bath, United Kingdom.'}, {'ForeName': 'William V', 'Initials': 'WV', 'LastName': 'Trim', 'Affiliation': 'Department for Health, University of Bath, Bath, United Kingdom.'}]",PloS one,['10.1371/journal.pone.0235557'] 2550,32761422,Efficacy of intravenous tranexamic acid administration in revision hip arthroplasty.,"BACKGROUND This study aimed to evaluate the efficiency of constant dose intravenous administration of tranexamic acid (TXA) in reducing postoperative blood loss, hemoglobin (Hb) concentration, and the number of transfusions in revision hip arthroplasty (RHA). METHODS The study included 145 consecutive patients who had undergone RHA: a TXA group (75 patients) who received two doses of TXA (1.0 g 15 min before skin incision and 1.0 g during wound closure) and a no-TXA group (70 patients). Percentage blood loss and quantitative blood loss were calculated. RESULTS The percentage blood loss (23.82 ± 10.6% vs. 39.17 ± 15.1%; P < 0.001), Hb drop (2.9 ± 1.14 g/dL vs. 4.22 ± 1.4 g/dL; P < 0.001), and total blood loss (1030 ± 477 mL vs. 1736 ± 761 mL; P < 0.001) were significantly lower in the TXA group than in the no-TXA group on postoperative day 1. Percentage blood loss (37.5 ± 10.4% vs. 43.1 ± 12.5%; P < 0.01), Hb drop (4.64 ± 1.5 g/dL vs. 5.22 ± 1.6 g/dL; P < 0.01) and total blood loss (1639 ± 543 mL vs. 1908 ± 681 mL; P = 0.02) were significantly lower in the TXA group than in the no-TXA group on the 5th postoperative day. The blood transfusion requirements were lower in the TXA group than those in the no-TXA group (30.7% vs. 71.4% of patients; P < 0.001), with a lower transfusion per patient ratio of 0.55 in the TXA group and 1.4 in the no-TXA group. No postoperative complications were associated with TXA administration, including deep-vein thrombosis and pulmonary embolism. CONCLUSION Administration of TXA is an effective method to reduce perioperative blood loss, Hb drop and the number of transfusions in RHA.",2020,"The percentage blood loss (23.82 ± 10.6% vs. 39.17 ± 15.1%; P < 0.001), Hb drop (2.9 ± 1.14 g/dL vs. 4.22 ± 1.4 g/dL; P < 0.001), and total blood loss (1030 ± 477 mL vs. 1736 ± 761 mL; P < 0.001) were significantly lower in the TXA group than in the no-TXA group on postoperative day 1.","['145 consecutive patients who had undergone RHA: a\xa0TXA group (75\xa0patients) who received two doses of', 'revision hip arthroplasty']","['TXA (1.0\u202fg 15\u202fmin before skin incision and 1.0\u202fg during wound closure) and a\xa0no-TXA', 'tranexamic acid (TXA', 'tranexamic acid', 'TXA']","['postoperative blood loss, hemoglobin (Hb) concentration', 'total blood loss', 'percentage blood loss', 'blood transfusion requirements', 'deep-vein thrombosis and pulmonary embolism', 'postoperative complications', 'perioperative blood loss', 'Percentage blood loss and quantitative blood loss', 'Percentage blood loss']","[{'cui': 'C4517577', 'cui_str': '145'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0459480', 'cui_str': 'Revision of hip arthroplasty'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0191279', 'cui_str': 'Incision of skin'}, {'cui': 'C0450015', 'cui_str': 'Method of wound closure'}]","[{'cui': 'C0032788', 'cui_str': 'Postoperative hemorrhage'}, {'cui': 'C1318517', 'cui_str': 'Hemoglobin concentration, dipstick - finding'}, {'cui': 'C0232100', 'cui_str': 'Exsanguination'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}]",145.0,0.0575864,"The percentage blood loss (23.82 ± 10.6% vs. 39.17 ± 15.1%; P < 0.001), Hb drop (2.9 ± 1.14 g/dL vs. 4.22 ± 1.4 g/dL; P < 0.001), and total blood loss (1030 ± 477 mL vs. 1736 ± 761 mL; P < 0.001) were significantly lower in the TXA group than in the no-TXA group on postoperative day 1.","[{'ForeName': 'Dariusz', 'Initials': 'D', 'LastName': 'Grzelecki', 'Affiliation': 'Department of Orthopedics and Rheumoorthopedics, Professor Adam Gruca Teaching Hospital, Centre of Postgraduate Medical Education, Konarskiego\xa013, 05-400, Otwock, Poland. dariuszgrzelecki@gmail.com.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Dudek', 'Affiliation': 'Department of Orthopedics and Rheumoorthopedics, Professor Adam Gruca Teaching Hospital, Centre of Postgraduate Medical Education, Konarskiego\xa013, 05-400, Otwock, Poland.'}, {'ForeName': 'Tomasz', 'Initials': 'T', 'LastName': 'Okoń', 'Affiliation': 'Department of Orthopedics and Rheumoorthopedics, Professor Adam Gruca Teaching Hospital, Centre of Postgraduate Medical Education, Konarskiego\xa013, 05-400, Otwock, Poland.'}, {'ForeName': 'Dariusz', 'Initials': 'D', 'LastName': 'Marczak', 'Affiliation': 'Department of Orthopedics and Rheumoorthopedics, Professor Adam Gruca Teaching Hospital, Centre of Postgraduate Medical Education, Konarskiego\xa013, 05-400, Otwock, Poland.'}, {'ForeName': 'Bartłomiej', 'Initials': 'B', 'LastName': 'Kordasiewicz', 'Affiliation': 'Department of Traumatology and Orthopedic Surgery, Professor Adam Gruca Teaching Hospital, Centre of Postgraduate Medical Education, Konarskiego\xa013, 05-400, Otwock, Poland.'}, {'ForeName': 'Marcin', 'Initials': 'M', 'LastName': 'Sibiński', 'Affiliation': 'Clinic of Orthopedics and Pediatric Orthopedics, Medical University of Łódź, Pomorska 251, 92-213, Łódź, Poland.'}, {'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Kowalczewski', 'Affiliation': 'Department of Orthopedics and Rheumoorthopedics, Professor Adam Gruca Teaching Hospital, Centre of Postgraduate Medical Education, Konarskiego\xa013, 05-400, Otwock, Poland.'}]",Der Orthopade,['10.1007/s00132-020-03959-9'] 2551,32761473,Combined pars plana vitrectomy (PPV) and phacoemulsification (phaco) versus PPV and deferred phaco for phakic patients with full-thickness macular hole (FTMH) and no significant cataract at baseline: 1-year outcomes of a randomized trial combined PPV/phaco vs PPV/deferred phaco for MH.,"PURPOSE To compare functional and anatomic outcomes of combined pars plana vitrectomy (PPV) and phacoemulsification (phaco) versus PPV and deferred phaco in patients with full-thickness macular hole (FTMH) and no significant cataract. METHODS Thirty-four patients were randomized to group 1 (combined PPV/phaco) and 34 to group 2 (PPV/deferred phaco). Group 2 patients could undergo phaco any time after FTMH surgery if significant cataract developed. RESULTS Sixty-five patients (33 group 1 and 32 group 2) completed the 12-month visit. Mean ± SEM logMAR best-corrected visual acuity (BCVA) was 0.92 ± 0.04 and 0.90 ± 0.04 at baseline and improved significantly to 0.60 ± 0.05 and 0.58 ± 0.05 at month 12 (p < 0.0001) in groups 1 and 2, respectively. There was no significant difference between the groups in mean BCVA at baseline or at month 12. Mean macular sensitivity (dB) was 18.22 ± 0.93 and 16.72 ± 0.93 at baseline and increased to 21.13 ± 0.86 and 21.07 ± 0.85 in groups 1 and 2, respectively (p < 0.05) with no significant difference between the groups (p = 0.449) at month 12. FTMH closure rate was 73% and 75% in groups 1 and 2, respectively (p = 0.834). CONCLUSION Among patients with FTMH and no significant cataract at baseline, combined PPV/phaco was associated with similar BCVA, microperimetry, and FTMH closure outcomes at 1-year compared with PPV/deferred phaco. TRIAL REGISTRATION ( clinicaltrials.gov.br ): Ensaios clínicos brasileiros: RBR-3wmd9s; UTN number: U1111-1190-5013; Plataforma Brasil CAAE number: 50455415.3.0000.5440; IRB number: 1.433.000.",2020,"FTMH closure rate was 73% and 75% in groups 1 and 2, respectively (p = 0.834). ","['phakic patients with full-thickness macular hole (FTMH', 'Thirty-four patients', 'patients with full-thickness macular hole (FTMH) and no significant cataract']","['PPV/phaco) and 34 to group 2 (PPV/deferred phaco', 'combined pars plana vitrectomy (PPV) and phacoemulsification (phaco) versus PPV and deferred phaco', 'Combined pars plana vitrectomy (PPV) and phacoemulsification (phaco) versus PPV and deferred phaco', 'PPV/phaco vs PPV/deferred phaco for MH']","['mean BCVA', 'Mean macular sensitivity (dB', 'FTMH closure rate', 'Mean ± SEM logMAR best-corrected visual acuity (BCVA', 'similar BCVA, microperimetry, and FTMH closure outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2733564', 'cui_str': 'Full thickness hole of macula lutea'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}]","[{'cui': 'C0563537', 'cui_str': 'Mechanical vitrectomy by pars plana approach'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C2733564', 'cui_str': 'Full thickness hole of macula lutea'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0262878', 'cui_str': 'Scanning electron microscope'}, {'cui': 'C1690532', 'cui_str': 'Best corrected visual acuity'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",34.0,0.084077,"FTMH closure rate was 73% and 75% in groups 1 and 2, respectively (p = 0.834). ","[{'ForeName': 'Karlos Ítalo S', 'Initials': 'KÍS', 'LastName': 'Viana', 'Affiliation': 'Ophthalmology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Camila T', 'Initials': 'CT', 'LastName': 'Gordilho', 'Affiliation': 'Ophthalmology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Felipe P P', 'Initials': 'FPP', 'LastName': 'Almeida', 'Affiliation': 'Ophthalmology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Marcelo M', 'Initials': 'MM', 'LastName': 'Esperandio', 'Affiliation': 'Ophthalmology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Lucena', 'Affiliation': 'Ophthalmology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Denny M', 'Initials': 'DM', 'LastName': 'Garcia', 'Affiliation': 'Ophthalmology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Ingrid U', 'Initials': 'IU', 'LastName': 'Scott', 'Affiliation': 'Departments of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.'}, {'ForeName': 'André M V', 'Initials': 'AMV', 'LastName': 'Messias', 'Affiliation': 'Ophthalmology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Jorge', 'Affiliation': 'Ophthalmology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil. rjorge@fmrp.usp.br.'}]",Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,['10.1007/s00417-020-04731-7'] 2552,32761487,Beneficial Effects of Baduanjin Exercise on Left Ventricular Remodelling in Patients after Acute Myocardial Infarction: an Exploratory Clinical Trial and Proteomic Analysis.,"BACKGROUND The beneficial effects of physical exercise on cardiac remodelling improvement after myocardial infarction have already been suggested. However, the results of previous clinical trials have not been consistent. Moreover, the putative molecular mechanisms leading to the clinically observed effects of physical exercise still remain elusive. AIM We aimed to evaluate whether the well-defined and strictly controlled traditional Chinese Qigong Baduanjin exercise (BE) would attenuate the adverse left ventricular (LV) remodelling in patients with ST-elevation myocardial infarction (STEMI). METHODS A total of 110 clinically stable STEMI patients, following successful revascularization of their infarcted coronary arteries, were randomized and enrolled in two groups: 56 were subjected to a 12-week BE-based cardiac rehabilitation programme (BE group), and the remaining 54 were exposed to the usual physical exercise (control group) for the same time period. The primary outcome was the change from baseline to 6 months in the echocardiographic LV end-diastolic volume index (ΔLVEDVi). Proteomic analysis was also performed to uncover associated mechanisms. RESULTS Compared with the control group, the BE group showed significantly lower ΔLVEDVi (-5.1 ± 1.1 vs. 0.3 ± 1.2 mL/m 2 , P < 0.01). Proteomic analysis revealed BE-induced variations in the expression of 80 proteins linked to regulation the of metabolic process, immune process, and extracellular matrix reorganization. Furthermore, correlation analyses between the validated serum proteomes and primary endpoint demonstrated a positive association between ΔLVEDVi and MMP-9 expression, but a negative correlation between ΔLVEDVi and CXCL1 expression. CONCLUSION This is the first study indicating that BE in STEMI patients can alleviate adverse LV remodelling associated with beneficial energy metabolism adaptation, inflammation curbing, and extracellular matrix organization adjustment.",2020,"Proteomic analysis revealed BE-induced variations in the expression of 80 proteins linked to regulation the of metabolic process, immune process, and extracellular matrix reorganization.","['Patients after Acute Myocardial Infarction', 'A total of 110 clinically stable STEMI patients, following successful revascularization of their infarcted coronary arteries', 'patients with ST-elevation myocardial infarction (STEMI']","['BE-based cardiac rehabilitation programme (BE group), and the remaining 54 were exposed to the usual physical exercise (control group', 'well-defined and strictly controlled traditional Chinese Qigong Baduanjin exercise (BE', 'Baduanjin Exercise', 'physical exercise']","['adverse left ventricular (LV) remodelling', 'ΔLVEDVi', 'ΔLVEDVi and MMP-9 expression', 'change from baseline to 6\xa0months in the echocardiographic LV end-diastolic volume index (ΔLVEDVi', 'Left Ventricular Remodelling']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C1303258', 'cui_str': 'Acute ST segment elevation myocardial infarction'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0205042', 'cui_str': 'Coronary artery structure'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0442825', 'cui_str': 'Well defined'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0282077', 'cui_str': 'Qigong'}]","[{'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0165519', 'cui_str': 'Gelatinase B'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0455833', 'cui_str': 'Left ventricular end-diastolic cavity size'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0600519', 'cui_str': 'Ventricular remodelling'}]",110.0,0.0549444,"Proteomic analysis revealed BE-induced variations in the expression of 80 proteins linked to regulation the of metabolic process, immune process, and extracellular matrix reorganization.","[{'ForeName': 'Shuai', 'Initials': 'S', 'LastName': 'Mao', 'Affiliation': 'State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.'}, {'ForeName': 'Xiaoxuan', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.'}, {'ForeName': 'Minggui', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': 'State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.'}, {'ForeName': 'Chuyang', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Biological Resource Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China.'}, {'ForeName': 'Qubo', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'Biological Resource Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China.'}, {'ForeName': 'Liheng', 'Initials': 'L', 'LastName': 'Guo', 'Affiliation': 'State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.'}, {'ForeName': 'Minzhou', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. minzhouzhang@aliyun.com.'}, {'ForeName': 'Aleksander', 'Initials': 'A', 'LastName': 'Hinek', 'Affiliation': 'Translational Medicine, Hospital for Sick Children, Toronto, M5G 0A4, Canada.'}]",Cardiovascular drugs and therapy,['10.1007/s10557-020-07047-0'] 2553,32756180,Th17/Treg imbalance in patients with severe acute pancreatitis: Attenuated by high-volume hemofiltration treatment.,"BACKGROUND To investigate the effect of high-volume hemofiltration (HVHF) on Th17/Treg imbalance in patients with severe acute pancreatitis (SAP). METHODS Forty-two patients with SAP were randomly received 24 hours of continuous HVHF (n = 21) or without HVHF (n = 21). At day 28, all 42 patients were divided into survival group (n = 32) and non-survival group (n = 10). Venous blood samples collected at 0, 6, 12, and 24 hours during HVHF treatment (or equivalent time in non-HVHF group) were assessed by flow cytometry to detect Th17 and Treg cells. Concentrations of IL-6, IL-17, IL-10, and TGF-β1 were detected by enzyme-linked immunosorbent assay. RESULTS Th17%, Treg%, Th17/Treg, and levels of related cytokines were significantly higher in SAP patients than healthy controls (P < .05), and these changes were more pronounced in SAP patients with multiple organ failure than those with single organ failure (P < .05). After HVHF treatment, Th17%, Treg%, Th17/Treg, IL-6, IL-17, and IL-10 significantly reduced (P < .05), while there were no significant changes in non-HVHF group (P > .05). In addition, acute physiology and chronic health evaluation II and sequential organ failure assessment scores decreased markedly after HVHF treatment. Baselines of Th17%, Treg%, Th17/Treg, and related cytokines were significantly higher in non-survival group than survival group. Both acute physiology and chronic health evaluation I score and IL-6 level were positively correlated with Th17% before and after HVHF treatment (P < .01). CONCLUSIONS Th17/Treg imbalance is present in SAP and may be correlated with its severity and prognosis. HVHF effectively attenuates the Th17/Treg imbalance in SAP patients. The beneficial effect of HVHF on Th17/Treg imbalance is possibly associated with removing excess inflammatory mediators.",2020,"After HVHF treatment, Th17%, Treg%, Th17/Treg, IL-6, IL-17, and IL-10 significantly reduced (P < .05), while there were no significant changes in non-HVHF group (P > .05).","['Forty-two patients with SAP', 'patients with severe acute pancreatitis', 'SAP patients', 'patients with severe acute pancreatitis (SAP']","['high-volume hemofiltration (HVHF', 'HVHF', 'continuous HVHF (n\u200a=\u200a21) or without HVHF']","['Treg%, Th17/Treg, and levels of related cytokines', 'acute physiology and chronic health evaluation I score and IL-6 level', 'Treg%, Th17/Treg, IL-6, IL-17, and IL-10', 'Th17/Treg imbalance', 'Concentrations of IL-6, IL-17, IL-10, and TGF-β1', 'acute physiology and chronic health evaluation II and sequential organ failure assessment scores', 'Treg%, Th17/Treg, and related cytokines']","[{'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0001339', 'cui_str': 'Acute pancreatitis'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0019014', 'cui_str': 'Hemofiltration'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0243030', 'cui_str': 'Acute physiology and chronic health evaluation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0384648', 'cui_str': 'Interleukin 17'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040691', 'cui_str': 'Transforming Growth Factor'}, {'cui': 'C0243028', 'cui_str': 'Acute physiology and chronic health evaluation II'}, {'cui': 'C3494459', 'cui_str': 'Sequential organ failure assessment score'}]",42.0,0.0236775,"After HVHF treatment, Th17%, Treg%, Th17/Treg, IL-6, IL-17, and IL-10 significantly reduced (P < .05), while there were no significant changes in non-HVHF group (P > .05).","[{'ForeName': 'Jiguang', 'Initials': 'J', 'LastName': 'Guo', 'Affiliation': ""Department of Nephrology,People's Hospital of Rongchang District.""}, {'ForeName': 'Zhen', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Department of Nephrology, Yongchuan Hospital of Chongqing Medical University.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Tang', 'Affiliation': 'Department of Nephrology, Yongchuan Hospital of traditional Chinese Medicine, Chongqing, China.'}, {'ForeName': 'Jianbin', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Nephrology, Yongchuan Hospital of Chongqing Medical University.'}]",Medicine,['10.1097/MD.0000000000021491'] 2554,32756204,A study on respiratory management in acute postoperative period by nasal high flow for patients undergoing surgery under general anesthesia.,"In head and neck surgery where the oropharyngeal area is the operative field, postoperative respiratory depression and upper airway obstruction are common. Therefore, supplemental oxygen is administered to prevent severe postoperative early hypoxemia. However, a high concentration of oxygen increases the likelihood of secondary complications, such as carbon dioxide (CO2) narcosis. Nasal high-flow (NHF) therapy generates high flows (≤60 L/min) of heated and humidified gas delivered via nasal cannula and provides respiratory support by generating positive airway pressure, clearance of dead space and reduction of work of breathing. This study aims to determine whether the postoperative hypoxemia and hypercapnia can be prevented by NHF without the requirement of supplemental oxygen. The study will recruit adult patients undergoing planned oral surgery under general anesthesia at Nagasaki University Hospital. It is a randomized parallel group comparative study with 3 groups: NHF with room air only and no supplemental oxygen, no respiratory support, and face mask oxygen administration. The study protocol will begin at the time that the patient is returned to the general ward and will finish 3 hours later. The primary endpoint is the time-weighted average of transcutaneous O2 over the 180 minutes and secondary endpoints are the time-weighted average of transcutaneous CO2 (tcpCO2), SpO2, and respiratory rate, incidence rate of marked hypercapnia (tcpCO2 ≥60 mm Hg for 5 minutes or longer), incidence rate of moderate hypercapnia (tcpCO2 ≥50 mm Hg for 5 minutes or longer) and the percentage of time that SpO2 is <90%. Included also is a group in which the postoperative management is performed only by spontaneous breathing without performing respiratory support such as oxygen administration, to investigate the efficacy and necessity of conventional oxygen administration. This exploratory study will investigate the use of NHF without supplemental oxygen as an effective respiratory support during the acute postoperative period. TRIAL REGISTRATION:: The study was registered the jRCTs072200018. URL https://jrct.niph.go.jp/latest-detail/jRCTs072200018.",2020,"Nasal high-flow (NHF) therapy generates high flows (≤60 L/min) of heated and humidified gas delivered via nasal cannula and provides respiratory support by generating positive airway pressure, clearance of dead space and reduction of work of breathing.","['patients undergoing surgery under general anesthesia', 'adult patients undergoing planned oral surgery under general anesthesia at Nagasaki University Hospital']","['Nasal high-flow (NHF) therapy', 'NHF without supplemental oxygen', 'NHF with room air only and no supplemental oxygen, no respiratory support, and face mask oxygen administration']","['carbon dioxide (CO2) narcosis', 'positive airway pressure, clearance of dead space and reduction of work of breathing', 'time-weighted average of transcutaneous O2', 'time-weighted average of transcutaneous CO2 (tcpCO2), SpO2, and respiratory rate, incidence rate of marked hypercapnia (tcpCO2 ≥60 mm Hg for 5 minutes or longer), incidence rate of moderate hypercapnia (tcpCO2 ≥50 mm Hg for 5 minutes or longer) and the percentage of time that SpO2']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0038908', 'cui_str': 'Oral surgery'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}]","[{'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}]","[{'cui': 'C0221340', 'cui_str': 'Carbon dioxide narcosis'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0043229', 'cui_str': 'Work of Breathing'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0020440', 'cui_str': 'Hypercapnia'}, {'cui': 'C1318131', 'cui_str': 'TcPCO2'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0439165', 'cui_str': 'Percent'}]",,0.0988491,"Nasal high-flow (NHF) therapy generates high flows (≤60 L/min) of heated and humidified gas delivered via nasal cannula and provides respiratory support by generating positive airway pressure, clearance of dead space and reduction of work of breathing.","[{'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Kurata', 'Affiliation': 'Department of Dental Anesthesiology.'}, {'ForeName': 'Gaku', 'Initials': 'G', 'LastName': 'Mishima', 'Affiliation': 'Department of Dental Anesthesiology.'}, {'ForeName': 'Motohiro', 'Initials': 'M', 'LastName': 'Sekino', 'Affiliation': 'Division of Intensive Care.'}, {'ForeName': 'Shuntaro', 'Initials': 'S', 'LastName': 'Sato', 'Affiliation': 'Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.'}, {'ForeName': 'Maximilian', 'Initials': 'M', 'LastName': 'Pinkham', 'Affiliation': 'Fisher and Paykel Healthcare Ltd, Auckland, New Zealand.'}, {'ForeName': 'Stanislav', 'Initials': 'S', 'LastName': 'Tatkov', 'Affiliation': 'Fisher and Paykel Healthcare Ltd, Auckland, New Zealand.'}, {'ForeName': 'Takao', 'Initials': 'T', 'LastName': 'Ayuse', 'Affiliation': 'Department of Dental Anesthesiology.'}]",Medicine,['10.1097/MD.0000000000021537'] 2555,32756299,Nutritional Supplementation Concurrent with Nutrition Education Accelerates the Wound Healing Process in Patients with Diabetic Foot Ulcers.,"Trials on nutritional supplements for the treatment of diabetic foot ulcer (DFU) have only evaluated the effects of supplementation with specific nutrients. Additionally, nutrition education has not been a systematic part of these studies. The aim of this study was to evaluate the effects of a nutrient-dense formula combined with nutrition education on wound healing in DFU patients. Twenty-nine patients were randomly assigned to the treatment group ( n = 15) receiving two servings of supplements daily plus nutrition education or control group ( n = 14) that received the standard of care but no additional nutritional or educational intervention. Both groups were followed for a maximum of 12 weeks. Wound healing, as measured by planimetry, was examined at baseline and every four weeks until complete wound closure or up to 12 weeks. There were no significant differences between groups for BMI, age, duration of diabetes, wound age estimation, or wound area at baseline. The treatment group experienced a faster wound healing rate (6.43 mm 2 /week more reduction in the wound area) than the control group. The mean reduction in the wound area during the first four weeks of the study was almost 13-fold greater in the treatment group compared to the control group (18.0 mm 2 /week vs. 1.4 mm 2 /week, respectively). Our findings showed that nutrition supplementation plus nutrition education significantly accelerated wound healing in DFU patients compared to those who just received a standard-of-care regimen.",2020,The treatment group experienced a faster wound healing rate (6.43 mm 2 /week more reduction in the wound area) than the control group.,"['diabetic foot ulcer (DFU', 'Patients with Diabetic Foot Ulcers', 'Twenty-nine patients', 'DFU patients']","['two servings of supplements daily plus nutrition education or control group ( n = 14) that received the standard of care but no additional nutritional or educational intervention', 'nutritional supplements', 'nutrient-dense formula combined with nutrition education', 'Nutritional Supplementation Concurrent with Nutrition Education', 'nutrition supplementation plus nutrition education']","['wound healing rate', 'Wound healing', 'wound healing', 'Wound Healing Process', 'mean reduction in the wound area', 'BMI, age, duration of diabetes, wound age estimation, or wound area']","[{'cui': 'C1456868', 'cui_str': 'Diabetic foot ulcer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0450351', 'cui_str': '29'}]","[{'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0439794', 'cui_str': 'Dense'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}]",29.0,0.0302014,The treatment group experienced a faster wound healing rate (6.43 mm 2 /week more reduction in the wound area) than the control group.,"[{'ForeName': 'Raedeh', 'Initials': 'R', 'LastName': 'Basiri', 'Affiliation': 'Department of Nutrition Food and Exercise Sciences, Florida State University, Tallahassee, FL 32306, USA.'}, {'ForeName': 'Maria T', 'Initials': 'MT', 'LastName': 'Spicer', 'Affiliation': 'Department of Nutrition Food and Exercise Sciences, Florida State University, Tallahassee, FL 32306, USA.'}, {'ForeName': 'Cathy W', 'Initials': 'CW', 'LastName': 'Levenson', 'Affiliation': 'Department of Biomedical Sciences, College of Medicine, Florida State University, Tallahassee, FL 32306, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Ormsbee', 'Affiliation': 'Department of Nutrition Food and Exercise Sciences, Florida State University, Tallahassee, FL 32306, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Ledermann', 'Affiliation': 'Department of Family and Child Sciences, Florida State University, Tallahassee, FL 32306, USA.'}, {'ForeName': 'Bahram H', 'Initials': 'BH', 'LastName': 'Arjmandi', 'Affiliation': 'Department of Nutrition Food and Exercise Sciences, Florida State University, Tallahassee, FL 32306, USA.'}]",Biomedicines,['10.3390/biomedicines8080263'] 2556,32756313,Energy Intake and Satiety Responses of Eggs for Breakfast in Overweight and Obese Adults-A Crossover Study.,"The type of food eaten for breakfast may determine the amount of food consumed at the next meal. This may be important when considering dietary advice for overweight and obese individuals who are trying to lose weight. The aim of the study was to investigate the energy intake and subjective sensations of hunger using a visual analogue scale (VAS) of a breakfast meal of eggs compared with a breakfast meal of cereal in overweight Australian adults. In a cross-over study, participants attended the University of South Australia's Clinical Trial Facility on two separate days, one week apart. On each day participants consumed one of two isoenergetic breakfasts (1800 kJ), either eggs and toast or cereal with milk and orange juice. Fifty overweight or obese participants, 44 ± 21 years, 86 ± 14 kg, with a body mass index (BMI) of 31 ± 4 kg/m 2 completed both study visits. Energy intake following the egg breakfast was significantly reduced compared with the cereal breakfast (4518 vs. 5283 kJ, p = 0.001). BMI and gender were unrelated to these effects. The sensation of hunger was less after the egg breakfast ( p = 0.028 for diet by time interaction) and returned more quickly after the cereal breakfast. There were no effects of gender or age. Energy intake was reduced at an ad libitum lunch meal 4 hours after a breakfast meal containing eggs. The findings suggest that satiety responses of overweight and obese are not different to non-obese participants as our study confirms findings from studies conducted in different populations. Determining which foods may help overweight and obese individuals manage their food intake is important for diet planning.",2020,The sensation of hunger was less after the egg breakfast ( p = 0.028 for diet by time interaction) and returned more quickly after the cereal breakfast.,"[""participants attended the University of South Australia's"", 'Eggs for Breakfast in Overweight and Obese Adults', 'overweight Australian adults', 'overweight and obese individuals who are trying to lose weight', 'Fifty overweight or obese participants, 44 ± 21 years, 86 ± 14 kg, with a body mass index (BMI) of 31 ± 4 kg/m 2 completed both study visits']","['hunger using a visual analogue scale (VAS) of a breakfast meal of eggs compared with a breakfast meal of cereal', 'isoenergetic breakfasts (1800 kJ), either eggs and toast or cereal with milk and orange juice']","['Energy intake', 'sensation of hunger', 'Energy Intake and Satiety Responses']","[{'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0037715', 'cui_str': 'South Australia'}, {'cui': 'C0013710', 'cui_str': 'Eggs (edible)'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0013710', 'cui_str': 'Eggs (edible)'}, {'cui': 'C0007757', 'cui_str': 'Cereal'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0452458', 'cui_str': 'Orange juice'}]","[{'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0036240', 'cui_str': 'Satiety Response'}]",,0.0627151,The sensation of hunger was less after the egg breakfast ( p = 0.028 for diet by time interaction) and returned more quickly after the cereal breakfast.,"[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'B Keogh', 'Affiliation': 'UniSA Clinical and Health Sciences, University of South Australia, Adelaide SA 5000, Australia.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'M Clifton', 'Affiliation': 'UniSA Clinical and Health Sciences, University of South Australia, Adelaide SA 5000, Australia.'}]",International journal of environmental research and public health,['10.3390/ijerph17155583'] 2557,32756643,"Effects of probiotic therapy on cardio-metabolic parameters and autonomic modulation in hypertensive women: a randomized, triple-blind, placebo-controlled trial.","BACKGROUND AND AIMS We assessed the effects of probiotic therapy for 8 weeks on cardiometabolic variables and autonomic function in women medically diagnosed with arterial hypertension. METHODS AND RESULTS Forty women with arterial hypertension, 20-50 years, were assigned to two groups in this randomized, triple-blind, placebo-controlled clinical trial. Patients in the probiotic group received a daily sachet containing Lactobacillus para casei LPC-37, Lactobacillus rhamnosus HN001, Lactobacillus acidophilus NCFM, and Bifidobacterium lactis HN019 (109 CFU of each strain) for 8 weeks. Patients in the placebo group received identical sachets with polydextrose (1 g day-1, for 8 weeks). Anthropometric, BP, electrocardiogram, biochemical measurements, fecal microbiota composition, and glucose hydrogen breath test were assessed at baseline and after 8 weeks intervention. Anthropometric variables (weight, BMI, and waist circumference) were similar between the two groups (p > 0.05). Probiotic supplementation significantly reduced fasting glucose (change -10.3 mg dL-1, p < 0.05) and cholesterol levels (change -23.6 mg dL-1, p < 0.05), and increased the HDL-cholesterol (change 6.5 mg dL-1, p < 0.05) compared with the baseline condition. Probiotic supplementation lowered, although without statistical significance, systolic BP by about 5 mmHg and diastolic BP by about 2 mmHg in hypertensive women. Lastly, probiotic administration reduced the low frequency (LF) oscillation and LF/high frequency (HF) ratio (p < 0.05) in the frequency domain of heart rate variability, suggesting an improvement in autonomic modulation. CONCLUSION Probiotic therapy for 8 weeks reduced fasting glucose levels, and improved the lipid profile and autonomic modulation in hypertensive women.",2020,"Probiotic supplementation significantly reduced fasting glucose (change -10.3 mg dL-1, p < 0.05) and cholesterol levels (change -23.6 mg dL-1, p < 0.05), and increased the HDL-cholesterol (change 6.5 mg dL-1, p < 0.05) compared with the baseline condition.","['women medically diagnosed with arterial hypertension', 'Forty women with arterial hypertension, 20-50 years', 'hypertensive women']","['probiotic therapy', 'identical sachets with polydextrose', 'Probiotic supplementation', 'Probiotic therapy', 'daily sachet containing Lactobacillus para casei LPC-37, Lactobacillus rhamnosus', 'placebo']","['cardiometabolic variables and autonomic function', 'cholesterol levels', 'fasting glucose levels', 'lipid profile and autonomic modulation', 'fasting glucose', 'diastolic BP', 'Anthropometric, BP, electrocardiogram, biochemical measurements, fecal microbiota composition, and glucose hydrogen breath test', 'autonomic modulation', 'HDL-cholesterol', 'HN001, Lactobacillus acidophilus NCFM, and Bifidobacterium lactis HN019 ', 'systolic BP', 'Anthropometric variables (weight, BMI, and waist circumference', 'low frequency (LF) oscillation and LF/high frequency (HF) ratio', 'cardio-metabolic parameters and autonomic modulation']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}]","[{'cui': 'C2242626', 'cui_str': 'Probiotic therapy'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C2348127', 'cui_str': 'Sachet - unit of product usage'}, {'cui': 'C0071545', 'cui_str': 'polydextrose'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0022938', 'cui_str': 'Lactobacillus'}, {'cui': 'C0030563', 'cui_str': 'Parity'}, {'cui': 'C0317597', 'cui_str': 'Lactobacillus casei rhamnosus'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0344439', 'cui_str': 'Hydrogen breath test'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol in high density lipoprotein subfraction 2'}, {'cui': 'C0022939', 'cui_str': 'Lactobacillus acidophilus'}, {'cui': 'C1001866', 'cui_str': 'Bifidobacterium animalis'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0205213', 'cui_str': 'Low frequency'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",40.0,0.218213,"Probiotic supplementation significantly reduced fasting glucose (change -10.3 mg dL-1, p < 0.05) and cholesterol levels (change -23.6 mg dL-1, p < 0.05), and increased the HDL-cholesterol (change 6.5 mg dL-1, p < 0.05) compared with the baseline condition.","[{'ForeName': 'Larissa de Fátima', 'Initials': 'LF', 'LastName': 'Romão da Silva', 'Affiliation': 'Department of Nutrition, Health Sciences Center, Federal University of Paraiba, João Pessoa, Brazil. jose_luiz_61@hotmail.com jose.luiz@academico.ufpb.br.'}, {'ForeName': 'Yohanna', 'Initials': 'Y', 'LastName': 'de Oliveira', 'Affiliation': 'Department of Nutrition, Health Sciences Center, Federal University of Paraiba, João Pessoa, Brazil. jose_luiz_61@hotmail.com jose.luiz@academico.ufpb.br.'}, {'ForeName': 'Evandro Leite', 'Initials': 'EL', 'LastName': 'de Souza', 'Affiliation': 'Department of Nutrition, Health Sciences Center, Federal University of Paraiba, João Pessoa, Brazil. jose_luiz_61@hotmail.com jose.luiz@academico.ufpb.br.'}, {'ForeName': 'Micaelle Oliveira', 'Initials': 'MO', 'LastName': 'de Luna Freire', 'Affiliation': 'Biotechnology Center, Federal University of Paraíba, João Pessoa, Brazil.'}, {'ForeName': 'Valdir de Andrade', 'Initials': 'VA', 'LastName': 'Braga', 'Affiliation': 'Biotechnology Center, Federal University of Paraíba, João Pessoa, Brazil.'}, {'ForeName': 'Marciane', 'Initials': 'M', 'LastName': 'Magnani', 'Affiliation': 'Department of Food Engineering, Technology Center, Federal University of Paraíba, Joao Pessoa, Brazil.'}, {'ForeName': 'José Luiz', 'Initials': 'JL', 'LastName': 'de Brito Alves', 'Affiliation': 'Department of Nutrition, Health Sciences Center, Federal University of Paraiba, João Pessoa, Brazil. jose_luiz_61@hotmail.com jose.luiz@academico.ufpb.br.'}]",Food & function,['10.1039/d0fo01661f'] 2558,32756661,"Effects of plant oils with different fatty acid composition on cardiovascular risk factors in moderately hypercholesteremic Chinese adults: a randomized, double-blinded, parallel-designed trial.","OBJECTIVES Plant oil for cooking typically provides 40% to 50% of dietary fat, 65% of linoleic acid, 44% of α-linolenic acid and 41% of oleic acid in the Chinese diet. However, the comparative effects of fatty acids derived from plant oil on cardiovascular risk factors in Chinese are still inconclusive. Hence, the aim of this study is to investigate whether cardiovascular risk factors are altered depending on various types of plant oils such as peanut oil rich in oleic acid, corn oil rich in linoleic acid, and blend oil fortified by α-linolenic acid. DESIGN A randomized, double-blinded, parallel-designed trial. SETTING The First and the Second Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. PARTICIPANTS A total of 251 volunteers with fasting blood total cholesterol between 5.13 and 8.00 mmol L-1 were enrolled. INTERVENTION Volunteers received peanut oil, corn oil or blend oil to use for cooking for one year. MAIN OUTCOME MEASURES The erythrocyte membrane fatty acid composition, fasting plasma lipids, glucose and insulin concentrations and high sensitivity C-reactive protein (hsCRP) levels were measured before, during and after the intervention. The level of α-linolenic acid in erythrocyte membranes was significantly increased in the blend oil group after the intervention (P < 0.001). The level of other fatty acids did not show any statistically significant differences between the three groups. No significant differences were observed in the concentrations of fasting plasma lipids, hsCRP, glucose, and insulin among the three groups using different types of plant oils. CONCLUSIONS The results suggest that although ingesting cooking oil with different fatty acid composition for one year could change erythrocyte membrane fatty acid compositions, it did not significantly modify cardiovascular risk factors in moderately hypercholesteremic people.",2020,The level of α-linolenic acid in erythrocyte membranes was significantly increased in the blend oil group after the intervention (P < 0.001).,"['moderately hypercholesteremic Chinese adults', 'A total of 251 volunteers with fasting blood total cholesterol between 5.13 and 8.00 mmol L-1 were enrolled', 'moderately hypercholesteremic people']","['linoleic acid', 'oleic acid', 'plant oils with different fatty acid composition', 'fatty acids derived from plant oil', 'peanut oil, corn oil or blend oil to use for cooking for one year']","['concentrations of fasting plasma lipids, hsCRP, glucose, and insulin', 'level of other fatty acids', 'level of α-linolenic acid in erythrocyte membranes', 'cardiovascular risk factors', 'erythrocyte membrane fatty acid composition, fasting plasma lipids, glucose and insulin concentrations and high sensitivity C-reactive protein (hsCRP) levels']","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0761050', 'cui_str': '(GVGVP)251'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0600472', 'cui_str': 'L1 Elements'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0023749', 'cui_str': 'Linoleic acid'}, {'cui': 'C0028928', 'cui_str': '9 cis-octadecenoic acid'}, {'cui': 'C0032085', 'cui_str': 'Plant oil'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0052300', 'cui_str': 'Peanut Oil'}, {'cui': 'C0010029', 'cui_str': 'Corn Oil'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0335326', 'cui_str': 'Cookery'}, {'cui': 'C4082117', 'cui_str': 'One year'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C1278073', 'cui_str': 'Plasma lipid measurement'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0051405', 'cui_str': 'alpha-Linolenic Acid'}, {'cui': 'C0014780', 'cui_str': 'Erythrocyte Cytoskeleton'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}]",251.0,0.149744,The level of α-linolenic acid in erythrocyte membranes was significantly increased in the blend oil group after the intervention (P < 0.001).,"[{'ForeName': 'Chao-Gang', 'Initials': 'CG', 'LastName': 'Chen', 'Affiliation': 'Department of Clinical Nutrition, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510012, P. R. China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Wang', 'Affiliation': 'Guangdong Provincial Institute of Public Health, Guangzhou 511430, P. R. China.'}, {'ForeName': 'Zhe-Qing', 'Initials': 'ZQ', 'LastName': 'Zhang', 'Affiliation': 'Department of Nutrition and Food Hygiene, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, P. R. China.'}, {'ForeName': 'Yan-Bin', 'Initials': 'YB', 'LastName': 'Ye', 'Affiliation': 'Department of Clinical Nutrition, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, P. R. China.'}, {'ForeName': 'Shu-Yu', 'Initials': 'SY', 'LastName': 'Zhuo', 'Affiliation': 'Department of Clinical Nutrition, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, P. R. China.'}, {'ForeName': 'Quan', 'Initials': 'Q', 'LastName': 'Zhou', 'Affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Guangzhou Medical University, Guangzhou 510182, P. R. China.'}, {'ForeName': 'Yu-Ming', 'Initials': 'YM', 'LastName': 'Chen', 'Affiliation': 'Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, P. R. China.'}, {'ForeName': 'Yi-Xiang', 'Initials': 'YX', 'LastName': 'Su', 'Affiliation': 'Department of Nutrition, Guangdong Provincial Key Laboratory of Food, School of Public Health, Sun Yat-Sen University, Guangzhou 510080, P. R. China. suyx@mail.sysu.edu.cn.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Zhang', 'Affiliation': 'Food Safety and Health Research Center, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, P. R. China. cnzhangbo@126.com.'}]",Food & function,['10.1039/d0fo00875c'] 2559,32756788,Changes in anterior segment parameters following insertion of ExPRESS mini glaucoma implant vs. trabeculectomy.,"PURPOSE To compare changes in anterior segment parameters following ExPRESS Mini Glaucoma Shunt surgery vs. trabeculectomy using the Pentacam rotating Scheimpflug camera. METHODS In this prospective, comparative study, 27 patients with glaucoma treated at the Rabin Medical Center from 2009 to 2013 were enrolled in this prospective comparative study: 19 participants (19 eyes) underwent ExPRESS shunt implantation and 12 (13 eyes) underwent trabeculectomy. Changes in anterior chamber parameters at postoperative day 1 and postoperative month 3 were evaluated on Scheimpflug images. RESULTS Intraocular pressure decreased significantly from baseline in both groups. The decrease in both groups was similar at postoperative month 3 (p=0.82). ExPRESS surgery caused a transient increase in posterior corneal astigmatism (p=0.008) and a transient decrease in anterior chamber depth (p=0.016) and volume (p=0.006) on postoperative day 1. At postoperative month 3, these parameters were no longer statistically significant (p=0.65, p=0.51, and p=0.57 respectively). Trabeculectomy caused a transient increase in anterior and posterior corneal astigmatism on postoperative day 1 (p=0.003 and p=0.005, respectively), which were not evident at postoperative month 3 (p=1.0 and p=1.0, respectively). At postoperative month 3, both ExPRESS and trabeculectomy showed similar changes in anterior chamber parameters. CONCLUSIONS Both ExPRESS mini glaucoma implant and trabeculectomy significantly decreased intraocular pressure and had transient effects on anterior segment parameters, with minor differences between the methods.",2020,"Both ExPRESS mini glaucoma implant and trabeculectomy significantly decreased intraocular pressure and had transient effects on anterior segment parameters, with minor differences between the methods.",['27 patients with glaucoma treated at the Rabin Medical Center from 2009 to 2013 were enrolled in this prospective comparative study: 19 participants (19 eyes) underwent'],"['ExPRESS shunt implantation', 'insertion of ExPRESS mini glaucoma implant vs. trabeculectomy', 'Trabeculectomy', 'trabeculectomy', 'ExPRESS Mini Glaucoma Shunt surgery vs. trabeculectomy']","['anterior and posterior corneal astigmatism', 'anterior chamber depth', 'anterior chamber parameters', 'posterior corneal astigmatism', 'Intraocular pressure', 'intraocular pressure']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0009491', 'cui_str': 'Comparative Studies'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}]","[{'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0542331', 'cui_str': 'Shunt'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0040574', 'cui_str': 'Trabeculoplasty'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0339682', 'cui_str': 'Regular astigmatism - corneal'}, {'cui': 'C0429492', 'cui_str': 'Depth of anterior chamber'}, {'cui': 'C0003151', 'cui_str': 'Anterior chamber of eye structure'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}]",27.0,0.0158855,"Both ExPRESS mini glaucoma implant and trabeculectomy significantly decreased intraocular pressure and had transient effects on anterior segment parameters, with minor differences between the methods.","[{'ForeName': 'Eitan', 'Initials': 'E', 'LastName': 'Livny', 'Affiliation': 'Departmens of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.'}, {'ForeName': ""Na'ama"", 'Initials': 'N', 'LastName': 'Hammel', 'Affiliation': 'Departmens of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Mimouni', 'Affiliation': 'Department of Ophthalmology, Rambam Health Care Campus, Haifa, Israel.'}, {'ForeName': 'Moshe', 'Initials': 'M', 'LastName': 'Lusky', 'Affiliation': 'Departmens of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Kaiserman', 'Affiliation': 'Department of Ophthalmology, Barzilai Medical Center, Ashkelon, Israel.'}, {'ForeName': 'Irit', 'Initials': 'I', 'LastName': 'Bahar', 'Affiliation': 'Departmens of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.'}]",Arquivos brasileiros de oftalmologia,['10.5935/0004-2749.20200040'] 2560,32756825,Effectiveness of a handmade shell-based substrate for the breeding of Biomphalaria glabrata under laboratory conditions.,"Efficient snail production is essential for the proper maintenance of the Schistosoma mansoni life cycle in the laboratory. In order to improve the breeding of Biomphalaria glabrata under laboratory conditions, this study aimed to demonstrate the effectiveness of a handmade shell-based substrate on the physiological performance of B. glabrata. The shells used to make the substrate were cleaned, sterilized and macerated until a powder was obtained (yield of 92.3%). B. glabrata specimens were randomly assigned to three treatment groups: negative control group (NCG) exposed to a clay-only substrate; a positive control group (PCG) containing clay, oyster flour and calcium carbonate; and the test group (TG) with the shell-based substrate and clay. B. glabrata bred in the test group showed improved growth, sexual maturity, fertility, mortality rate, and shell morphology when compared to the NCG, and similar to the PCG. Therefore, the shell-based substrate proved to be efficient and has a low cost for the breeding of B. glabrata.",2020,"B. glabrata bred in the test group showed improved growth, sexual maturity, fertility, mortality rate, and shell morphology when compared to the NCG, and similar to the PCG.",['B. glabrata specimens'],"['handmade shell-based substrate', 'negative control group (NCG) exposed to a clay-only substrate; a positive control group (PCG) containing clay, oyster flour and calcium carbonate; and the test group (TG) with the shell-based substrate and clay']","['improved growth, sexual maturity, fertility, mortality rate, and shell morphology']","[{'cui': 'C0319899', 'cui_str': 'Candida glabrata'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0030104', 'cui_str': 'Oyster'}, {'cui': 'C0016260', 'cui_str': 'Flour'}, {'cui': 'C0006681', 'cui_str': 'Calcium Carbonate'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0233891', 'cui_str': 'Finding related to maturity of sexuality'}, {'cui': 'C0015895', 'cui_str': 'Ability to conceive'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0332437', 'cui_str': 'Associated morphology'}]",,0.016931,"B. glabrata bred in the test group showed improved growth, sexual maturity, fertility, mortality rate, and shell morphology when compared to the NCG, and similar to the PCG.","[{'ForeName': 'João Gustavo Mendes', 'Initials': 'JGM', 'LastName': 'Rodrigues', 'Affiliation': 'Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.'}, {'ForeName': 'Maria Gabriela Sampaio', 'Initials': 'MGS', 'LastName': 'Lira', 'Affiliation': 'Departamento de Patologia, Centro de Ciências Biológicas e da Saúde, Universidade Federal do Maranhão, São Luís, Maranhão, Brazil.'}, {'ForeName': 'Ranielly Araújo', 'Initials': 'RA', 'LastName': 'Nogueira', 'Affiliation': 'Departamento de Patologia, Centro de Ciências Biológicas e da Saúde, Universidade Federal do Maranhão, São Luís, Maranhão, Brazil.'}, {'ForeName': 'Gleycka Cristine Carvalho', 'Initials': 'GCC', 'LastName': 'Gomes', 'Affiliation': 'Departamento de Patologia, Centro de Ciências Biológicas e da Saúde, Universidade Federal do Maranhão, São Luís, Maranhão, Brazil.'}, {'ForeName': 'Irlla Correia Lima', 'Initials': 'ICL', 'LastName': 'Licá', 'Affiliation': 'Departamento de Patologia, Centro de Ciências Biológicas e da Saúde, Universidade Federal do Maranhão, São Luís, Maranhão, Brazil.'}, {'ForeName': 'Davi', 'Initials': 'D', 'LastName': 'Viegas-Melo', 'Affiliation': 'Laboratório de Parasitologia Humana, Departamento de Química e Biologia, Universidade Estadual do Maranhão, São Luís, Maranhão, Brazil.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Teles-Reis', 'Affiliation': 'Laboratório de Parasitologia Humana, Departamento de Química e Biologia, Universidade Estadual do Maranhão, São Luís, Maranhão, Brazil.'}, {'ForeName': 'Guilherme Silva', 'Initials': 'GS', 'LastName': 'Miranda', 'Affiliation': 'Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.'}, {'ForeName': 'Nêuton', 'Initials': 'N', 'LastName': 'Silva-Souza', 'Affiliation': 'Laboratório de Parasitologia Humana, Departamento de Química e Biologia, Universidade Estadual do Maranhão, São Luís, Maranhão, Brazil.'}]",Revista do Instituto de Medicina Tropical de Sao Paulo,['10.1590/s1678-9946202062055'] 2561,32756944,Analysis of the Effects of Isotretinoin on Rhinoplasty Patients.,"BACKGROUND While the number of cosmetic surgeries performed per year continues to increase, many candidates have skin problems. Thick-skinned rhinoplasty patients are a real challenge for surgeons. Fear of performing surgery in patients with history of isotretinoin use is another concern. OBJECTIVES The present research was an attempt to study the effects of perioperative isotretinoin on rhinoplasty patient outcomes. METHODS This research was conducted on 303 rhinoplasty patients in the control and experimental groups from 2012 to 2015. The experimental group patients were requested to consume isotretinoin from two weeks before surgery to two months following the surgery. A comparison was made between the two groups one, three, six, and 12 months after the surgery. RESULTS Statistical tests indicated that satisfaction of patients of the experimental group in the first and third months following the surgery was significantly higher than the control group (p<0.01). Examination of the nose suggests a lack of evidence of soft tissue repair disturbance and cartilaginous deformities. Nine patients from the experimental group needed revision surgery during the study period and the reason for none of the revision surgeries was logically related to intake of isotretinoin. CONCLUSIONS Results of this research suggest that isotretinoin cause no evident disturbance to the recovery of rhinoplastic incisions and internal nose structures. Moreover, none of the members of the experimental group showed hypertrophic tissues and cartilaginous deformities, and the repair was satisfactory similar to the control group. However, patients receiving isotretinoin were more satisfied with their operation outcomes with less skin problems.",2020,"RESULTS Statistical tests indicated that satisfaction of patients of the experimental group in the first and third months following the surgery was significantly higher than the control group (p<0.01).","['patients with history of isotretinoin', 'Rhinoplasty Patients', '303 rhinoplasty patients in the control and experimental groups from 2012 to 2015']",[],"['hypertrophic tissues and cartilaginous deformities', 'revision surgery']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0022265', 'cui_str': 'Isotretinoin'}, {'cui': 'C0035467', 'cui_str': 'Rhinoplasty'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",[],"[{'cui': 'C0020564', 'cui_str': 'Hypertrophy'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0007301', 'cui_str': 'Cartilage tissue'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}]",303.0,0.0267328,"RESULTS Statistical tests indicated that satisfaction of patients of the experimental group in the first and third months following the surgery was significantly higher than the control group (p<0.01).","[{'ForeName': 'Shahriyar', 'Initials': 'S', 'LastName': 'Yahyavi', 'Affiliation': ''}, {'ForeName': 'Hesam', 'Initials': 'H', 'LastName': 'Jahandideh', 'Affiliation': 'Otolaryngology, Firoozgar Hospital, ENT and Head and Neck Research Center and Department, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Izadi', 'Affiliation': ''}, {'ForeName': 'Hamidreza', 'Initials': 'H', 'LastName': 'Paknejad', 'Affiliation': ''}, {'ForeName': 'Niousha', 'Initials': 'N', 'LastName': 'Kordbache', 'Affiliation': ''}, {'ForeName': 'Sanaz', 'Initials': 'S', 'LastName': 'Taherzade', 'Affiliation': ''}]",Aesthetic surgery journal,['10.1093/asj/sjaa219'] 2562,32757038,"Efficacy of Rhino-Protect ointment after endoscopic sinus surgery: a prospective, randomized, multicenter study.","OBJECTIVE Blocking airflow into the sinonasal cavity after surgery may help to keep the cavity moist and thus decrease postoperative crusting. Here we investigated the efficacy of Rhino-Protect ointment following endoscopic sinus surgery (ESS). SUBJECTS AND METHODS A total of 93 patients with chronic rhinosinusitis who underwent identical ESS were enrolled. After surgery, all patients were instructed to perform nasal saline irrigation and deliver a nasal spray to each nostril, then to apply Rhino-Protect ointment to one nostril only; the other nostril served as a control. Subjective symptoms, postoperative Lund-Kennedy (LK) endoscopic scores, and adverse reactions 14 and 28 days after treatment were evaluated. RESULTS The Rhino-Protect ointment significantly reduced pain (p = 0.015 at 28 days), dryness (p = 0.009 at 14 days and p = 0.045 at 28 days), and crusting (p = 0.047 at 14 days), and was associated with significantly lower LK scores 14 and 28 days after treatment (p = 0.037 and p = 0.007, respectively). Statistically significant differences were noted in the LK edema subscore at 14 days (p = 0.043) and in LK crusting subscores at 14 and 28 days (p = 0.005 and p = 0.006, respectively). No patient reported any serious adverse event associated with Rhino-Protect use. CONCLUSION Applying Rhino-Protect after ESS significantly reduced the formation of edema and crusts, leading to improving the patients' discomfort for pain, dryness, and crust.",2020,"The Rhino-Protect ointment significantly reduced pain (p = 0.015 at 28 days), dryness (p = 0.009 at 14 days and p = 0.045 at 28 days), and crusting (p = 0.047 at 14 days), and was associated with significantly lower LK scores 14 and 28 days after treatment (p = 0.037 and p = 0.007, respectively).","['endoscopic sinus surgery', '93 patients with chronic rhinosinusitis who underwent identical ESS were enrolled']","['Rhino-Protect ointment', 'endoscopic sinus surgery (ESS', 'nasal saline irrigation and deliver a nasal spray to each nostril, then to apply Rhino-Protect ointment to one nostril only; the other nostril served as a control']","['dryness', 'crusting', 'reduced pain', 'Subjective symptoms, postoperative Lund-Kennedy (LK) endoscopic scores, and adverse reactions', 'LK crusting subscores', 'LK scores', ""formation of edema and crusts, leading to improving the patients' discomfort for pain, dryness, and crust"", 'LK edema subscore']","[{'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0748725', 'cui_str': 'Sinus operation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205280', 'cui_str': 'Identical'}]","[{'cui': 'C0028912', 'cui_str': 'Ointment'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0748725', 'cui_str': 'Sinus operation'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0461725', 'cui_str': 'Nasal spray'}, {'cui': 'C0595944', 'cui_str': 'Both anterior nares'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0685682', 'cui_str': 'Single naris'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205204', 'cui_str': 'Crust'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}]",93.0,0.0312722,"The Rhino-Protect ointment significantly reduced pain (p = 0.015 at 28 days), dryness (p = 0.009 at 14 days and p = 0.045 at 28 days), and crusting (p = 0.047 at 14 days), and was associated with significantly lower LK scores 14 and 28 days after treatment (p = 0.037 and p = 0.007, respectively).","[{'ForeName': 'Kyu-Sup', 'Initials': 'KS', 'LastName': 'Cho', 'Affiliation': 'Department of Otorhinolaryngology and Biomedical Research Institute, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Republic of Korea.'}, {'ForeName': 'Soo Whan', 'Initials': 'SW', 'LastName': 'Kim', 'Affiliation': ""Department of Otorhinolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea.""}, {'ForeName': 'Jin Kook', 'Initials': 'JK', 'LastName': 'Kim', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Konkuk University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Chang-Hoon', 'Initials': 'CH', 'LastName': 'Kim', 'Affiliation': 'Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea. entman@yuhs.ac.'}]",European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,['10.1007/s00405-020-06265-4'] 2563,32757049,Effect of high-fat diet on the pharmacokinetics and safety of flumatinib in healthy Chinese subjects.,"PURPOSE To evaluate the effect of a high-fat diet on the pharmacokinetics and safety of flumatinib mesylate tablets in healthy Chinese subjects. METHODS This study was a randomized, open-label, single-dose, two-period crossover trial in which subjects were randomly assigned to take 400 mg of flumatinib mesylate after a high-fat diet or a fasted state. After a 14-day washout period, the two groups were administered flumatinib mesylate under opposite conditions. Blood samples were collected at baseline 0 and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, and 96 h, respectively. Plasma concentrations of flumatinib and its metabolites (M1 and M3) were analyzed using liquid chromatography-mass spectrometry. Pharmacokinetic parameters were calculated using the non-compartmental module of the Phoenix WinNonlin Version 7.0 software. BE module of WinNonLin was used for statistical analysis of AUC 0-t , AUC 0-∞ and C max in plasma. RESULTS Twelve healthy subjects, half male and half female, were enrolled. One subject withdrew due to a treatment-emergent adverse event. Eleven subjects were administered drugs on fasting and 12 were administered drugs after a high-fat diet. On high-fat diet/fasting, the least square geometric mean (LSGM) ratios of flumatinib, M1, M3, and their 90% confidence interval (CI) were as follows: for flumatinib, C max , AUC 0-t and AUC 0-∞ were 281.65% (225.80-351.31%), 167.43% (143.92-194.79%), and 166.87% (143.47-194.09%); for M1, C max , AUC 0-t , and AUC 0-∞ were 188.59% (145.29-244.79), 163.94% (149.11-180.24%), and 164.48% (150.36-179.94%); for M3, C max , AUC 0-t , and AUC 0-∞ were 63.47% (54.02-74.57%), 85.23% (74.72-97.22%), and 96.73% (86.63-108.02%). CONCLUSION Among the subjects, oral administration of 400 mg of flumatinib was safe and well tolerated. High-fat diet significantly increases the exposure to flumatinib, therefore, fasting may be recommended. CLINICAL TRIAL REGISTRATION The study was registered at chictr.org Identifier: ChiCTR-IIR-17013179.",2020,"AUC 0-∞ were 63.47% (54.02-74.57%), 85.23% (74.72-97.22%), and 96.73% (86.63-108.02%). ","['Eleven subjects were administered drugs on fasting and 12 were administered drugs after a high-fat diet', 'healthy Chinese subjects', 'Twelve healthy subjects, half male and half female, were enrolled']","['WinNonLin', 'high-fat diet', 'oral administration of 400\xa0mg of flumatinib', 'flumatinib mesylate tablets', 'flumatinib mesylate']","['least square geometric mean (LSGM) ratios of flumatinib, M1, M3, and their 90% confidence interval (CI', 'Plasma concentrations of flumatinib and its metabolites (M1 and M3', 'pharmacokinetics and safety of flumatinib', 'Blood samples', 'AUC 0-t and AUC 0-∞', 'safe and well tolerated', 'Pharmacokinetic parameters']","[{'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0521974', 'cui_str': 'High fat diet'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0521974', 'cui_str': 'High fat diet'}, {'cui': 'C0001563', 'cui_str': 'Medication administration: oral'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0025619', 'cui_str': 'Mesilates'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}]","[{'cui': 'C0023189', 'cui_str': 'Analysis, Least-Squares'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0009667', 'cui_str': 'Confidence Intervals'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",12.0,0.0595274,"AUC 0-∞ were 63.47% (54.02-74.57%), 85.23% (74.72-97.22%), and 96.73% (86.63-108.02%). ","[{'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Kuang', 'Affiliation': 'Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Hui-Ling', 'Initials': 'HL', 'LastName': 'Song', 'Affiliation': 'Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Guo-Ping', 'Initials': 'GP', 'LastName': 'Yang', 'Affiliation': 'Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Pei', 'Affiliation': 'Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Xiao-Yan', 'Initials': 'XY', 'LastName': 'Yang', 'Affiliation': 'Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Ye', 'Affiliation': 'Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Shuang', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': 'Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Shu-Ting', 'Initials': 'ST', 'LastName': 'Wu', 'Affiliation': 'Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Can', 'Initials': 'C', 'LastName': 'Guo', 'Affiliation': 'Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Qing-Nan', 'Initials': 'QN', 'LastName': 'He', 'Affiliation': 'Research Center for Drug Clinical Evaluation of Central, Central South University, Changsha, Hunan, China. heqn2629@163.com.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China. cellahuang1988@163.com.'}]",Cancer chemotherapy and pharmacology,['10.1007/s00280-020-04117-w'] 2564,32757060,"Examining potential effects of arousal, valence, and likability of music on visually induced motion sickness.","The present study investigated how valence, arousal, and subjective liking of music affect visually induced motion sickness (VIMS). VIMS is a common side effect when interacting with virtual environments, resulting in discomfort, dizziness, and/or nausea. Music has previously been shown to reduce VIMS, but the precise nature of this effect remains unknown. Eighty participants watched a video of a bicycle ride filmed from a first-person perspective. First, participants (n = 40) were randomly assigned to one of four groups that listened to pre-selected, classical music excerpts varying in valence and arousal (happy, peaceful, agitated, sad) while watching the video. Second, the level of subjective liking of music was maximized by asking participants to select their favourite music (n = 20), which was then played during the video. A control group (n = 20) watched the video without music. VIMS was measured using the Fast Motion Sickness Scale (FMS) and the Simulator Sickness Questionnaire (SSQ). No effects of valence or arousal on VIMS symptoms were found. Instead, we found that VIMS was significantly reduced when music liking was maximized: Participants who listened to their favourite music reported less VIMS compared to those who did not listen to music at all or to pre-selected music that they liked less. Music that is highly liked can, under certain circumstances, successfully reduce VIMS. These effects appear to be independent of the valence and arousal characteristics of the music.",2020,VIMS was measured using the Fast Motion Sickness Scale (FMS) and the Simulator Sickness Questionnaire (SSQ).,"['Eighty participants watched a video of a bicycle ride filmed from a first-person perspective', 'participants (n\u2009=\u200940']","['VIMS', 'listened to pre-selected, classical music excerpts varying in valence and arousal (happy, peaceful, agitated, sad) while watching the video', 'video without music']","['level of subjective liking of music', 'music liking', 'valence or arousal on VIMS symptoms', 'valence, arousal, and subjective liking of music affect visually induced motion sickness (VIMS', 'VIMS', 'Fast Motion Sickness Scale (FMS) and the Simulator Sickness Questionnaire (SSQ', 'discomfort, dizziness, and/or nausea']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0577368', 'cui_str': 'Does ride a bicycle'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0026603', 'cui_str': 'Motion sickness'}, {'cui': 'C0004309', 'cui_str': 'Auditory Perception'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0681251', 'cui_str': 'Classical Music'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0085159', 'cui_str': 'Seasonal affective disorder'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0026867', 'cui_str': 'Music'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0026603', 'cui_str': 'Motion sickness'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",80.0,0.245755,VIMS was measured using the Fast Motion Sickness Scale (FMS) and the Simulator Sickness Questionnaire (SSQ).,"[{'ForeName': 'Katlyn', 'Initials': 'K', 'LastName': 'Peck', 'Affiliation': 'Department of Psychology, Ryerson University, Toronto, ON, Canada.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Russo', 'Affiliation': 'Department of Psychology, Ryerson University, Toronto, ON, Canada.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Campos', 'Affiliation': 'KITE-Toronto Rehabilitation Institute, University Health Network, 550 University Avenue, Toronto, ON, M5G 2A2, Canada.'}, {'ForeName': 'Behrang', 'Initials': 'B', 'LastName': 'Keshavarz', 'Affiliation': 'Department of Psychology, Ryerson University, Toronto, ON, Canada. behrang.keshavarz@uhn.ca.'}]",Experimental brain research,['10.1007/s00221-020-05871-2'] 2565,32757247,Isobutylamido thiazolyl resorcinol for prevention of UVB-induced hyperpigmentation.,"BACKGROUND Isobutylamido thiazolyl resorcinol (ITR, Thiamidol ® ) has been proposed as a potent tyrosinase inhibitor. A formulation containing ITR has recently shown promising efficacy for the treatment of some hyperpigmentary conditions. OBJECTIVES This study aimed to evaluate the efficacy and safety of ITR in the prevention of ultraviolet (UV)-induced hyperpigmentation in human skin. MATERIALS AND METHODS We performed a randomized, single-blinded, pilot study in 30 healthy participants. One arm was randomly assigned to receive an ITR-containing product for three weeks. Three hyperpigmented spots were induced by UVB irradiation on both arms after 3 weeks of ITR application. Outcome evaluations included measuring mean lightness index (*L) obtained by colorimeter, hyperpigmentation scores by visual analog scale (VAS), and adverse effects. RESULTS Both experimental sides showed no significant difference in terms of skin lightening after ITR application. However, the ITR-treated sides showed a statistically significant lower mean lightness index compared to control after an induction with UVB. In addition, the ITR-treated sides had an earlier improvement and resumed the normal skin color after 3 weeks post-UVB induction. A clinical evaluation by a blinded nontreating physician and subjects was more favorable on the ITR-treated side than the control side (P < .05). No significant side effect was noted. CONCLUSIONS ITR is an effective agent in the prevention of pigmentary change from UVB irradiation and may serve as a promising agent for preventing other hyperpigmentary conditions.",2020,"However, the ITR-treated sides showed a statistically significant lower mean lightness index compared to control after an induction with UVB.","['human skin', '30 healthy participants']",['ITR'],"['normal skin color', 'mean lightness index', 'mean lightness index (*L) obtained by colorimeter, hyperpigmentation scores by visual analog scale (VAS), and adverse effects', 'side effect', 'skin lightening']","[{'cui': 'C3859811', 'cui_str': 'human skin preparation'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]",[],"[{'cui': 'C0558145', 'cui_str': 'Skin appearance normal'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0162834', 'cui_str': 'Hyperpigmentation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C1868997', 'cui_str': 'Skin lightening'}]",30.0,0.0429408,"However, the ITR-treated sides showed a statistically significant lower mean lightness index compared to control after an induction with UVB.","[{'ForeName': 'Vasanop', 'Initials': 'V', 'LastName': 'Vachiramon', 'Affiliation': 'Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Chaninan', 'Initials': 'C', 'LastName': 'Kositkuljorn', 'Affiliation': 'Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Kanchana', 'Initials': 'K', 'LastName': 'Leerunyakul', 'Affiliation': 'Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Kumutnart', 'Initials': 'K', 'LastName': 'Chanprapaph', 'Affiliation': 'Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13615'] 2566,32757272,Vibration improves gait biomechanics linked to post-traumatic knee osteoarthritis following anterior cruciate ligament injury.,"Anterior cruciate ligament reconstruction (ACLR) incurs a high risk of post-traumatic knee osteoarthritis (PTOA). Aberrant gait biomechanics contribute to PTOA and are attributable in part to quadriceps dysfunction. Vibration improves quadriceps function following ACLR, but its effects on gait biomechanics are unknown. The purpose of this study was to evaluate the effects of whole body vibration (WBV) and local muscle vibration (LMV) on gait biomechanics in individuals with ACLR. Seventy-five volunteers (time since ACLR 27±16 mo) were randomized to WBV, LMV, or Control interventions. Walking biomechanics were assessed prior to and following a single exposure to the interventions. Outcomes included pre-post change scores in the ACLR limb for the peak vertical ground reaction force (vGRF) and its loading rate, peak internal knee extension (KEM) and abduction (KAM) moments, and peak knee flexion and varus angles. LMV produced a significant decrease in the vGRF loading rate (-3.6 BW/s) that was greater than the changes in the WBV (-0.3 BW/s) and Control (0.5 BW/s) groups. Additionally, WBV produced an increase in the peak KEM (0.27 %BW*Ht) that was greater than the change in the Control group (-0.17 %BW*Ht) but not the LMV group (0.01 %BW*Ht). Lower KEM and greater loading rates have been linked to declines in joint health following ACLR. WBV acutely increased the peak KEM and LMV decreased loading rates. These data suggest that vibration has the potential to mitigate aberrant gait biomechanics, and may represent an effective approach for reducing PTOA risk following ACLR. This article is protected by copyright. All rights reserved.",2020,"Outcomes included pre-post change scores in the ACLR limb for the peak vertical ground reaction force (vGRF) and its loading rate, peak internal knee extension (KEM) and abduction (KAM) moments, and peak knee flexion and varus angles.","['anterior cruciate ligament injury', 'Seventy-five volunteers (time since ACLR 27±16 mo', 'individuals with ACLR']","['Anterior cruciate ligament reconstruction (ACLR', 'whole body vibration (WBV) and local muscle vibration (LMV', 'Vibration', 'LMV', 'WBV, LMV, or Control interventions']","['vGRF loading rate', 'peak KEM', 'Walking biomechanics', 'ACLR limb for the peak vertical ground reaction force (vGRF) and its loading rate, peak internal knee extension (KEM) and abduction (KAM) moments, and peak knee flexion and varus angles', 'quadriceps function', 'peak KEM and LMV decreased loading rates', 'gait biomechanics']","[{'cui': 'C1456574', 'cui_str': 'Injury of anterior cruciate ligament'}, {'cui': 'C4319621', 'cui_str': '75'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0016928', 'cui_str': 'Gait'}]",75.0,0.0187686,"Outcomes included pre-post change scores in the ACLR limb for the peak vertical ground reaction force (vGRF) and its loading rate, peak internal knee extension (KEM) and abduction (KAM) moments, and peak knee flexion and varus angles.","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Troy Blackburn', 'Affiliation': 'Department of Exercise and Sport Science.'}, {'ForeName': 'Darin A', 'Initials': 'DA', 'LastName': 'Padua', 'Affiliation': 'Department of Exercise and Sport Science.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Pietrosimone', 'Affiliation': 'Department of Exercise and Sport Science.'}, {'ForeName': 'Todd A', 'Initials': 'TA', 'LastName': 'Schwartz', 'Affiliation': 'Department of Biostatistics, University of North Carolina at Chapel Hill.'}, {'ForeName': 'Jeffrey T', 'Initials': 'JT', 'LastName': 'Spang', 'Affiliation': 'Department of Orthopaedics.'}, {'ForeName': 'Jonathan S', 'Initials': 'JS', 'LastName': 'Goodwin', 'Affiliation': 'Department of Physical Therapy, Elon University.'}, {'ForeName': 'Derek R', 'Initials': 'DR', 'LastName': 'Dewig', 'Affiliation': 'Program in Human Movement Science.'}, {'ForeName': 'Chris D', 'Initials': 'CD', 'LastName': 'Johnston', 'Affiliation': 'Program in Human Movement Science.'}]",Journal of orthopaedic research : official publication of the Orthopaedic Research Society,['10.1002/jor.24821'] 2567,32757302,A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.,"BACKGROUND Inhibition of the programmed cell death protein 1 (PD-1) pathway has demonstrated clinical benefit in metastatic urothelial cancer (mUC); however, response rates of 15% to 26% highlight the need for more effective therapies. Bruton tyrosine kinase (BTK) inhibition may suppress myeloid-derived suppressor cells (MDSCs) and improve T-cell activation. METHODS The Randomized Phase 2 Trial of Acalabrutinib and Pembrolizumab Immunotherapy Dual Checkpoint Inhibition in Platinum-Resistant Metastatic Urothelial Carcinoma (RAPID CHECK; also known as ACE-ST-005) was a randomized phase 2 trial evaluating the PD-1 inhibitor pembrolizumab with or without the BTK inhibitor acalabrutinib for patients with platinum-refractory mUC. The primary objectives were safety and objective response rates (ORRs) according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Immune profiling was performed to analyze circulating monocytic MDSCs and T cells. RESULTS Seventy-five patients were treated with pembrolizumab (n = 35) or pembrolizumab plus acalabrutinib (n = 40). The ORR was 26% with pembrolizumab (9% with a complete response [CR]) and 20% with pembrolizumab plus acalabrutinib (10% with a CR). The grade 3/4 adverse events (AEs) that occurred in ≥15% of the patients were anemia (20%) with pembrolizumab and fatigue (23%), increased alanine aminotransferase (23%), urinary tract infections (18%), and anemia (18%) with pembrolizumab plus acalabrutinib. One patient treated with pembrolizumab plus acalabrutinib had high MDSCs at the baseline, which significantly decreased at week 7. Overall, MDSCs were not correlated with a clinical response, but some subsets of CD8+ T cells did increase during the combination treatment. CONCLUSIONS Both treatments were generally well tolerated, although serious AE rates were higher with the combination. Acalabrutinib plus pembrolizumab did not improve the ORR, PFS, or OS in comparison with pembrolizumab alone in mUC. Baseline and on-treatment peripheral monocytic MDSCs were not different in the treatment cohorts. Proliferating CD8+ T-cell subsets increased during treatment, particularly in the combination cohort. Ongoing studies are correlating these peripheral immunome findings with tissue-based immune cell infiltration.",2020,"Acalabrutinib plus pembrolizumab did not improve the ORR, PFS, or OS in comparison with pembrolizumab alone in mUC.","['Platinum-Resistant Metastatic Urothelial Carcinoma (RAPID CHECK', 'Seventy-five patients were treated with', 'patients with platinum-resistant metastatic urothelial cancer', 'patients with platinum-refractory mUC', 'metastatic urothelial cancer (mUC']","['Acalabrutinib and Pembrolizumab Immunotherapy Dual Checkpoint Inhibition', 'pembrolizumab and acalabrutinib', 'Acalabrutinib plus pembrolizumab', 'pembrolizumab plus acalabrutinib', 'pembrolizumab']","['urinary tract infections', 'progression-free survival (PFS) and overall survival (OS', 'circulating monocytic MDSCs and T cells', 'safety and objective response rates (ORRs', 'grade 3/4 adverse events (AEs', 'serious AE rates', 'ORR, PFS, or OS', 'alanine aminotransferase', 'ORR', 'Proliferating CD8+ T-cell subsets', 'anemia', 'CD8+ T cells']","[{'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C4288754', 'cui_str': 'Metastatic urothelial carcinoma'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C1283174', 'cui_str': 'Checking - action'}, {'cui': 'C4319621', 'cui_str': '75'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}]","[{'cui': 'C4078312', 'cui_str': 'acalabrutinib'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C1155874', 'cui_str': 'Cell Cycle Checkpoints'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0026473', 'cui_str': 'Monocyte'}, {'cui': 'C4277543', 'cui_str': 'MDSCs'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0442757', 'cui_str': '3/4'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0242629', 'cui_str': 'Lymphocyte positive for CD8 antigen'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}]",75.0,0.101506,"Acalabrutinib plus pembrolizumab did not improve the ORR, PFS, or OS in comparison with pembrolizumab alone in mUC.","[{'ForeName': 'Tian', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Harrison', 'Affiliation': 'Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Peter H', 'Initials': 'PH', 'LastName': ""O'Donnell"", 'Affiliation': 'University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Ajjai S', 'Initials': 'AS', 'LastName': 'Alva', 'Affiliation': 'University of Michigan Medical Center, Ann Arbor, Michigan.'}, {'ForeName': 'Noah M', 'Initials': 'NM', 'LastName': 'Hahn', 'Affiliation': 'Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Leonard J', 'Initials': 'LJ', 'LastName': 'Appleman', 'Affiliation': 'University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Cetnar', 'Affiliation': 'Oregon Health and Science University Center for Health, Portland, Oregon.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Burke', 'Affiliation': 'Rocky Mountain Cancer Centers, Aurora, Colorado.'}, {'ForeName': 'Mark T', 'Initials': 'MT', 'LastName': 'Fleming', 'Affiliation': 'Virginia Oncology Associates, Norfolk, Virginia.'}, {'ForeName': 'Matthew I', 'Initials': 'MI', 'LastName': 'Milowsky', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Mortazavi', 'Affiliation': 'Ohio State University Comprehensive Cancer Center, Columbus, Ohio.'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Shore', 'Affiliation': 'Carolina Urologic Research Center, Myrtle Beach, South Carolina.'}, {'ForeName': 'Guru P', 'Initials': 'GP', 'LastName': 'Sonpavde', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, Massachusetts.'}, {'ForeName': 'Emmett V', 'Initials': 'EV', 'LastName': 'Schmidt', 'Affiliation': 'Merck & Co, Inc, North Wales, Pennsylvania.'}, {'ForeName': 'Bojena', 'Initials': 'B', 'LastName': 'Bitman', 'Affiliation': 'Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.'}, {'ForeName': 'Veerendra', 'Initials': 'V', 'LastName': 'Munugalavadla', 'Affiliation': 'Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.'}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Izumi', 'Affiliation': 'Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.'}, {'ForeName': 'Priti', 'Initials': 'P', 'LastName': 'Patel', 'Affiliation': 'Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Staats', 'Affiliation': 'Division of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Cliburn', 'Initials': 'C', 'LastName': 'Chan', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Kent J', 'Initials': 'KJ', 'LastName': 'Weinhold', 'Affiliation': 'Division of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'George', 'Affiliation': 'Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.'}]",Cancer,['10.1002/cncr.33067'] 2568,32757311,Socket shield technique vs conventional immediate implant placement with immediate temporization. Randomized clinical trial.,"BACKGROUND Alveolar bone resorption and labial bone plate reduction follow teeth extraction due to the deficiency of blood supply, derived from the loss of periodontal ligaments, and hence the socket shield technique was introduced to preserve the periodontal ligaments related perfusion. PURPOSE The study aimed to compare the vertical and horizontal changes of the buccal cortical bone plates, encountered after utilizing the socket shield technique with immediate temporization vs an immediate implant placement with immediate temporization, and analyzing the differences of the implant stability and pink esthetic score evaluation between both techniques. MATERIALS AND METHODS A total of 40 dental implants were placed in the maxillary esthetic zone, 20 implants were placed using the socket shield technique with immediate temporization; the study group and 20 implants were placed immediately with immediate temporization; the control group. All patients received immediate and 6 months postoperative CBCT to assess the dimensional changes in the labial bone plates. Implant stability quotients (ISQs) and pink esthetic scores were measured at the time of implant placement and 6 months postoperatively. RESULTS The horizontal bone loss; ranged from 0 to0.26 (0.15) mm and 0.03 to0.44 (0.32) mm for the study and control groups, respectively. The vertical bone loss; ranged from 0.11 to 0.55 (0.31) mm and 0.25 to 1.51 (0.7) mm for the study and control groups, respectively. The ISQ for the study group increased from 68.6 ± 3.81 to 76.7 ± 3.49, while in the control group it increased from 66.4 ± 5.64 to 75 ± 4.4. PES for the study group increased from 11 to 12, while in the control group it decreased from 13 to 9. CONCLUSION The socket shield technique with immediate temporization is a reliable method to reduce the labial bone loss following teeth extraction. However, further studies are required to investigate the effect of grafting the jumping gaps, to evaluate the graft contribution in further reduction of the bone loss.",2020,"RESULTS The horizontal bone loss; ranged from 0 to0.26 (0.15) mm and 0.03 to0.44 (0.32) mm for the study and control groups, respectively.",['40 dental implants'],['Socket shield technique vs conventional immediate implant placement with immediate temporization'],"['labial bone loss', 'Implant stability quotients (ISQs) and pink esthetic scores', 'implant stability and pink esthetic score evaluation', 'vertical bone loss', 'horizontal bone loss']","[{'cui': 'C0011370', 'cui_str': 'Dental implantation'}]","[{'cui': 'C0224517', 'cui_str': 'Gomphosis structure'}, {'cui': 'C0183251', 'cui_str': 'Shield'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0011414', 'cui_str': 'Dental Restorations, Temporary'}]","[{'cui': 'C0023759', 'cui_str': 'Lip structure'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0332585', 'cui_str': 'Pink color'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0205126', 'cui_str': 'Horizontal'}]",,0.0354084,"RESULTS The horizontal bone loss; ranged from 0 to0.26 (0.15) mm and 0.03 to0.44 (0.32) mm for the study and control groups, respectively.","[{'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Abd-Elrahman', 'Affiliation': 'Department of Oral Implantology, Cairo University, Giza, Egypt.'}, {'ForeName': 'Mostafa', 'Initials': 'M', 'LastName': 'Shaheen', 'Affiliation': 'Department of Oral Implantology, Cairo University, Giza, Egypt.'}, {'ForeName': 'Niveen', 'Initials': 'N', 'LastName': 'Askar', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Cairo University, Giza, Egypt.'}, {'ForeName': 'Mohammed', 'Initials': 'M', 'LastName': 'Atef', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Cairo University, Giza, Egypt.'}]",Clinical implant dentistry and related research,['10.1111/cid.12938'] 2569,32757317,The Effect of Vitamin D Administration on Vitamin D Status and Respiratory Morbidity in Late Premature Infants.,"OBJECTIVE To assess whether increment of vitamin D daily intake results in improved serum 25 (OH) vitamin D levels and reduced respiratory morbidity in premature infants. METHODS A randomized double-blind clinical pilot trial, including preterm infants born at 32+6 to 36+6 weeks of gestation. The control group received 400 IU of cholecalciferol daily compared to 800 IU daily in the intervention group. Levels of 25 (OH) vitamin D were measured at birth, 6 and 12 months of age. Respiratory morbidity was followed until 1 year of age. RESULTS Fifty subjects were recruited during the study period; the median measured 25 (OH) vitamin D levels in the control vs. intervention groups were: 26.5 vs. 34 nmol/L (p-value 0.271) at birth, 99 vs. 75.5 nmol/L (p-value 0.008) at 6 months and 72.5 vs. 75 nmol/L (p-value 0.95) at 12 months of age. Infants with insufficient vitamin D (< 75 nmol/L) levels had higher respiratory morbidity. Serum vitamin 25 (OH) D is a fair predictor for respiratory symptoms (AUC 0.697, 95%CI 0.509-0.885, p-value 0.047) and for recorded acute respiratory illnesses (AUC 0.745, 95%CI 0.569-0.922, p-value 0.012). CONCLUSION Doubling the daily intake of vitamin D in premature infants did not increase serum 25 (OH) vitamin D level, due to poor compliance in the intervention group. We found an inverse association between serum 25 (OH) vitamin D and respiratory symptoms, indicating vitamin D deficiency is a fair predictor for respiratory morbidity. This article is protected by copyright. All rights reserved.",2020,"Serum vitamin 25 (OH) D is a fair predictor for respiratory symptoms (AUC 0.697, 95%CI 0.509-0.885, p-value 0.047) and for recorded acute respiratory illnesses (AUC 0.745, 95%CI 0.569-0.922, p-value 0.012). ","['Late Premature Infants', 'premature infants', 'preterm infants born at 32+6 to 36+6 weeks of gestation', 'Fifty subjects']","['vitamin D daily intake', 'Vitamin D', 'vitamin D', '400 IU of cholecalciferol']","['respiratory morbidity', 'serum 25 (OH) vitamin D and respiratory symptoms', 'Serum vitamin 25 (OH) D', 'serum 25 (OH) vitamin D levels', 'Respiratory morbidity', 'Levels of 25 (OH) vitamin D', 'serum 25 (OH) vitamin D level', 'Vitamin D Status and Respiratory Morbidity', 'acute respiratory illnesses', 'median measured 25 (OH) vitamin D levels']","[{'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C3816746', 'cui_str': '400'}]","[{'cui': 'C1301752', 'cui_str': 'Respiratory morbidity'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0037090', 'cui_str': 'Respiratory symptom'}, {'cui': 'C0428581', 'cui_str': 'Serum vitamin A measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",50.0,0.319027,"Serum vitamin 25 (OH) D is a fair predictor for respiratory symptoms (AUC 0.697, 95%CI 0.509-0.885, p-value 0.047) and for recorded acute respiratory illnesses (AUC 0.745, 95%CI 0.569-0.922, p-value 0.012). ","[{'ForeName': 'Golan-Tripto', 'Initials': 'GT', 'LastName': 'Inbal', 'Affiliation': 'Department of Pediatrics, Soroka University Medical Center, Beer Sheva, Israel.'}, {'ForeName': 'Bistritzer', 'Initials': 'B', 'LastName': 'Jacob', 'Affiliation': 'Department of Pediatrics, Soroka University Medical Center, Beer Sheva, Israel.'}, {'ForeName': 'Loewenthal', 'Initials': 'L', 'LastName': 'Neta', 'Affiliation': 'Department of Pediatrics, Soroka University Medical Center, Beer Sheva, Israel.'}, {'ForeName': 'Staretz-Chacham', 'Initials': 'SC', 'LastName': 'Orna', 'Affiliation': 'Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.'}, {'ForeName': 'Dizitzer', 'Initials': 'D', 'LastName': 'Yotam', 'Affiliation': 'Clinical Research Center, Soroka University Medical Center, Beer Sheva, Israel.'}, {'ForeName': 'Goldbart', 'Initials': 'G', 'LastName': 'Aviv', 'Affiliation': 'Department of Pediatrics, Soroka University Medical Center, Beer Sheva, Israel.'}]",Pediatric pulmonology,['10.1002/ppul.25006'] 2570,32761987,Remote skin self-examination training of melanoma survivors and their skin check partners: A randomized trial and comparison with in-person training.,"BACKGROUND Compared with other cancers, melanoma has the longest delays measured as the median time to patient presentation for care from symptom onset. Time to presentation for care is a key determinant of outcomes, including disease stage, prognosis, and treatment. METHODS Melanoma survivors with localized disease and their skin check partners enrolled in two sequential randomized control trials of skin self-examination (SSE) training. In Phase 1, the pair read a workbook in the office and had quarterly total body skin examinations with a study dermatologist. In Phase 2, materials were mailed to pairs, whose surveillance was with a community physician. SSE knowledge, performance (frequency and extent), and identification of concerning moles were compared between phases. RESULTS Among 341 patients, 197 received the workbook and the others were controls. Knowledge in performing SSE was higher for the workbook relative to controls in both phases. The SSE frequency ranged from 2.38 to 5.97 times in 9 months. Patients randomized to the workbook in both phases performed significantly more SSE than controls at 9 months (P < .05). In both phases, trained survivors performed significantly more SSEs on the scalp than controls at 9 and 18 months (P < .05). Phase 1 survivors performed significantly more SSEs on the abdomen, buttocks, and soles of the feet than controls, but this did not occur in Phase 2. Finally, in both phases, survivors trained with the workbook resulted in greater detection of suspicious lesions and melanomas. CONCLUSIONS These findings justify the benefits of remote SSE training for patients as an adjunct to provider-administered screening.",2020,Patients randomized to the workbook in both phases performed significantly more SSE than controls at 9 months (P < .05).,"['341 patients, 197 received the workbook and the others were controls', 'Melanoma survivors with localized disease and their skin check partners', 'melanoma survivors and their skin check partners']","['remote SSE training', 'Remote skin self-examination training', 'skin self-examination (SSE) training']","['SSEs on the abdomen, buttocks, and soles of the feet', 'detection of suspicious lesions and melanomas', 'SSE knowledge, performance (frequency and extent), and identification of concerning moles', 'SSE']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0277565', 'cui_str': 'Local disease'}, {'cui': 'C1283174', 'cui_str': 'Checking - action'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}]","[{'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C1444170', 'cui_str': 'Skin self-examination'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0006497', 'cui_str': 'Buttock structure'}, {'cui': 'C0205208', 'cui_str': 'Solid'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C1444170', 'cui_str': 'Skin self-examination'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0439792', 'cui_str': 'Extent'}, {'cui': 'C0020792', 'cui_str': 'Identification - mental defense mechanism'}, {'cui': 'C0027960', 'cui_str': 'Nevi'}]",341.0,0.0264083,Patients randomized to the workbook in both phases performed significantly more SSE than controls at 9 months (P < .05).,"[{'ForeName': 'June K', 'Initials': 'JK', 'LastName': 'Robinson', 'Affiliation': 'Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Racheal', 'Initials': 'R', 'LastName': 'Reavy', 'Affiliation': 'Biobehavioral Health and Prevention Research Center, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Kimberly A', 'Initials': 'KA', 'LastName': 'Mallett', 'Affiliation': 'Biobehavioral Health and Prevention Research Center, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Rob', 'Initials': 'R', 'LastName': 'Turrisi', 'Affiliation': 'Biobehavioral Health and Prevention Research Center, The Pennsylvania State University, University Park, PA, USA.'}]",Cancer medicine,['10.1002/cam4.3299'] 2571,32762012,Quality of life and patient satisfaction after implant-based breast reconstruction with or without acellular dermal matrix: randomized clinical trial.,"BACKGROUND Acellular dermal matrix (ADM) in implant-based breast reconstructions (IBBRs) aims to improve cosmetic outcomes. Six-month data are presented from a randomized trial evaluating whether IBBR with ADM provides higher health-related quality of life (HRQoL) and patient-reported cosmetic outcomes compared with conventional IBBR without ADM. METHODS In this multicentre open-label RCT, women with breast cancer planned for mastectomy with immediate IBBR in four centres in Sweden and one in the UK were allocated randomly (1 : 1) to IBBR with or without ADM. HRQoL, a secondary endpoint, was measured as patient-reported outcome measures (PROMs) using three validated instruments (EORTC-QLQC30, QLQ-BR23, QLQ-BRR26) at baseline and 6 months. RESULTS Between 24 April 2014 and 10 May 2017, 135 women were enrolled, of whom 64 with and 65 without ADM were included in the final analysis. At 6 months after surgery, patient-reported HRQoL, measured with generic QLQ-C30 or breast cancer-specific QLQ-BR23, was similar between the groups. For patient-reported cosmetic outcomes, two subscale items, cosmetic outcome (8·66, 95 per cent c.i. 0·46 to 16·86; P = 0·041) and problems finding a well-fitting bra (-13·21, -25·54 to -0·89; P = 0·038), yielded higher scores in favour of ADM, corresponding to a small to moderate clinical difference. None of the other 27 domains measured showed any significant differences between the groups. CONCLUSION IBBR with ADM was not superior in terms of higher levels of HRQoL compared with IBBR without ADM. Although two subscale items of patient-reported cosmetic outcomes favoured ADM, the majority of cosmetic items showed no significant difference between treatments at 6 months. Registration number: NCT02061527 ( www.clinicaltrials.gov).",2020,"Although two subscale items of patient-reported cosmetic outcomes favoured ADM, the majority of cosmetic items showed no significant difference between treatments at 6 months.","['women with breast cancer planned for mastectomy with immediate IBBR in four centres in Sweden and one in the UK', 'Between 24 April 2014 and 10 May 2017', '135 women were enrolled, of whom 64 with and 65 without ADM were included in the final analysis']","['Acellular dermal matrix (ADM', 'IBBR with or without ADM', 'IBBR with ADM', 'implant-based breast reconstruction with or without acellular dermal matrix']","['health-related quality of life (HRQoL', 'Quality of life and patient satisfaction', 'generic QLQ-C30 or breast cancer-specific QLQ-BR23', 'validated instruments (EORTC-QLQC30, QLQ-BR23, QLQ-BRR26', 'problems finding a well-fitting bra ']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0024881', 'cui_str': 'Mastectomy'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C3494272', 'cui_str': 'Acellular Dermal Matrix'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C3494272', 'cui_str': 'Acellular Dermal Matrix'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0085076', 'cui_str': 'Mammoplasty'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0036572', 'cui_str': 'Seizure'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}]",135.0,0.156471,"Although two subscale items of patient-reported cosmetic outcomes favoured ADM, the majority of cosmetic items showed no significant difference between treatments at 6 months.","[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Lohmander', 'Affiliation': 'Department of Breast and Endocrine Surgery, Section of Breast Surgery, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Lagergren', 'Affiliation': 'Department of Surgery, Breast Centre, Capio St Görans Hospital, Stockholm, Sweden.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Johansson', 'Affiliation': 'Department of Oncology-Pathology, Cancer Centre, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'P G', 'Initials': 'PG', 'LastName': 'Roy', 'Affiliation': 'Department of Breast Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Frisell', 'Affiliation': 'Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Brandberg', 'Affiliation': 'Department of Oncology-Pathology, Cancer Centre, Karolinska Institutet, Stockholm, Sweden.'}]",BJS open,['10.1002/bjs5.50324'] 2572,32762030,"Evaluation of the effect of Silybum marianum extract on menopausal symptoms: A randomized, double-blind placebo-controlled trial.","The tendency to use herbs to manage menopausal symptoms has increased in recent years. The purpose of this study was to evaluate the effect of Silybum marianum (L.) compared with placebo in women with hot flashes. Eighty women were randomly allocated into two equal groups (S. marianum extract [400 mg/d] or placebo capsules). Hot flashes frequency and severity were evaluated in 12 weeks with the Greene Climacteric Scale (GCS) and the Hot Flash Related Daily Interference Scale (HFRDIS). The data were analyzed in SPSS software using t-test, Mann-Whitney, chi-square test and repeated measure analysis. Hot flashes frequency and severity decreased from 4.32 ± 0.20/day to 1.31 ± 0.15/day and from 5.25 ± 0.22 to 1.62 ± 0.08, respectively, during the study in test group (p < .001) which were significantly better than effects of placebo in all steps of study (p < .001). Significant decreases in GCS and HFRDIS scores were also detected in S. marianum group compared with placebo after 4, 8 and 12 weeks (p < .001). The results showed that S. marianum can decrease frequency and severity of hot flashes significantly. Considering the safety and high consumption of this herbal medicine worldwide, its use in women with menopausal symptoms can be helpful.",2020,"Significant decreases in GCS and HFRDIS scores were also detected in S. marianum group compared with placebo after 4, 8 and 12 weeks (p < .001).","['women with menopausal symptoms', 'women with hot flashes', 'Eighty women']","['Silybum marianum extract', 'Silybum marianum (L', 'marianum extract [400\u2009mg/d] or placebo', 'placebo']","['GCS and HFRDIS scores', 'Greene Climacteric Scale (GCS) and the Hot Flash Related Daily Interference Scale (HFRDIS', 'frequency and severity of hot flashes', 'Hot flashes frequency and severity', 'menopausal symptoms']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0236075', 'cui_str': 'Menopausal symptom'}, {'cui': 'C0600142', 'cui_str': 'Menopausal flushing'}, {'cui': 'C3816958', 'cui_str': '80'}]","[{'cui': 'C0937640', 'cui_str': 'Milk thistle extract'}, {'cui': 'C0331428', 'cui_str': 'Silybum marianum'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0008943', 'cui_str': 'Change of Life'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0600142', 'cui_str': 'Menopausal flushing'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0236075', 'cui_str': 'Menopausal symptom'}]",80.0,0.235785,"Significant decreases in GCS and HFRDIS scores were also detected in S. marianum group compared with placebo after 4, 8 and 12 weeks (p < .001).","[{'ForeName': 'Zohreh', 'Initials': 'Z', 'LastName': 'Saberi', 'Affiliation': 'Department of Persian Medicine, School of Persian Medicine, Babol University of Medical Sciences, Babol, Iran.'}, {'ForeName': 'Narjes', 'Initials': 'N', 'LastName': 'Gorji', 'Affiliation': 'Traditional Medicine and History of Medical Sciences Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Memariani', 'Affiliation': 'Traditional Medicine and History of Medical Sciences Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.'}, {'ForeName': 'Reihaneh', 'Initials': 'R', 'LastName': 'Moeini', 'Affiliation': 'Traditional Medicine and History of Medical Sciences Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.'}, {'ForeName': 'Hoda', 'Initials': 'H', 'LastName': 'Shirafkan', 'Affiliation': 'Health Research Institute, Babol University of Medical Sciences, Babol, Iran.'}, {'ForeName': 'Mania', 'Initials': 'M', 'LastName': 'Amiri', 'Affiliation': 'Infertility and Reproductive Health Research Center, Health Research Institute & Clinical Research, PCOs Clinic, Babol University of Medical Science, Babol, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.6789'] 2573,32762109,Automated pulse wave velocity assessment using a professional oscillometric office blood pressure monitor.,"Carotid-femoral pulse wave velocity (cfPWV) is the gold standard method for assessing arterial stiffness. This study evaluated automated brachial-ankle PWV (baPWV) taken by a professional oscillometric blood pressure monitor (Microlife WatchBP Office Vascular) versus reference cfPWV (Complior device). Subjects recruited from a hypertension outpatient clinic had duplicate baPWV and cfPWV measurements (randomized crossover design) and carotid ultrasonography. Of 102 subjects recruited, 101 had valid baPWV measurements. Four subjects were excluded and 97 were analyzed (age 58.3 ± 11.4 years, men 70%, hypertensives 76%, diabetics 17%, cardiovascular disease 10%, smokers 23%). The mean difference between baPWV (13.1 ± 1.8 m/s) and cfPWV (9.1 ± 1.8 m/s) was 4.0 ± 1.4 m/s (P < .01) with close association between them (r = 0.70, P < .01). baPWV and cfPWV were correlated with age (r 0.54/0.49 respectively), systolic blood pressure (0.45/0.50), carotid intima-media thickness (0.31/0.44), and carotid distensibility coefficient (-0.47/-0.34) (all P < .05; no difference between the two methods, z test). There was reasonable agreement (77%) between the two methods in identifying subjects at the top quartile of their distributions (kappa 0.39, P < .01). The areas under the receiver operating characteristic curves for the identification of carotid plaques were comparable for cfPWV and baPWV (0.79 and 0.74 respectively, P = NS). Automated baPWV measurement by a professional oscillometric blood pressure monitor is feasible and observer-independent. baPWV values differ from those by cfPWV, yet they are closely correlated, have reasonable agreement in detecting increased arterial stiffness and give similar associations with carotid stiffness and atherosclerosis.",2020,"The areas under the receiver operating characteristic curves for the identification of carotid plaques were comparable for cfPWV and baPWV (0.79 and 0.74 respectively, P = NS).","['102 subjects recruited, 101 had valid baPWV measurements', 'Four subjects were excluded and 97 were analyzed (age 58.3\xa0±\xa011.4\xa0years, men 70%, hypertensives 76%, diabetics 17%, cardiovascular disease 10%, smokers 23', 'Subjects recruited from a hypertension outpatient clinic had duplicate baPWV and cfPWV measurements (randomized crossover design) and']","['carotid ultrasonography', 'Carotid-femoral pulse wave velocity (cfPWV', 'automated brachial-ankle PWV (baPWV) taken by a professional oscillometric blood pressure monitor (Microlife WatchBP Office Vascular) versus reference cfPWV (Complior device']","['cfPWV and baPWV', 'systolic blood pressure (0.45/0.50), carotid intima-media thickness', 'baPWV values', 'carotid distensibility coefficient', 'baPWV and cfPWV']","[{'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517533', 'cui_str': '11.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C5197774', 'cui_str': 'Carotid-Femoral Pulse Wave Velocities'}, {'cui': 'C0242817', 'cui_str': 'Crossover Design'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C5197774', 'cui_str': 'Carotid-Femoral Pulse Wave Velocities'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0005825', 'cui_str': 'Sphygmomanometers, Continuous'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C5197774', 'cui_str': 'Carotid-Femoral Pulse Wave Velocities'}, {'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0162864', 'cui_str': 'Tunica intima'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",4.0,0.0770067,"The areas under the receiver operating characteristic curves for the identification of carotid plaques were comparable for cfPWV and baPWV (0.79 and 0.74 respectively, P = NS).","[{'ForeName': 'Anastasios', 'Initials': 'A', 'LastName': 'Kollias', 'Affiliation': 'Hypertension Center STRIDE-7, National and Kapodistrian University of Athens , School of Medicine, Third Department of Medicine, Sotiria Hospital, Athens, Greece.'}, {'ForeName': 'Konstantinos G', 'Initials': 'KG', 'LastName': 'Kyriakoulis', 'Affiliation': 'Hypertension Center STRIDE-7, National and Kapodistrian University of Athens , School of Medicine, Third Department of Medicine, Sotiria Hospital, Athens, Greece.'}, {'ForeName': 'Areti', 'Initials': 'A', 'LastName': 'Gravvani', 'Affiliation': 'Hypertension Center STRIDE-7, National and Kapodistrian University of Athens , School of Medicine, Third Department of Medicine, Sotiria Hospital, Athens, Greece.'}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Anagnostopoulos', 'Affiliation': 'Hypertension Center STRIDE-7, National and Kapodistrian University of Athens , School of Medicine, Third Department of Medicine, Sotiria Hospital, Athens, Greece.'}, {'ForeName': 'George S', 'Initials': 'GS', 'LastName': 'Stergiou', 'Affiliation': 'Hypertension Center STRIDE-7, National and Kapodistrian University of Athens , School of Medicine, Third Department of Medicine, Sotiria Hospital, Athens, Greece.'}]","Journal of clinical hypertension (Greenwich, Conn.)",['10.1111/jch.13966'] 2574,32757569,Teaching sarcasm: Evaluating metapragmatic training for typically developing children.,"Sarcasm is a common form of social language but one that can be challenging for children to understand. We investigated whether training can enhance children's ability to understand sarcasm. Participants were 111 five- to six- year-olds, assigned to either the training or control condition. In both conditions, children were first shown a series of puppet shows. Each puppet show ended with a sarcastic or literal remark. After each show children were asked about speaker belief, intent, and humour. Children's responses were used to estimate their pretraining sarcasm understanding. In the training condition, children were taught what sarcasm was and what cues to look for as they interacted with the researcher over a set of stories where characters made either sarcastic or literal remarks. In the control condition children read a nonsarcastic storybook with the researcher. Children's understanding of sarcasm was then reassessed using another series of puppet shows. For children who were not already proficient in sarcasm understanding, training was associated with more accurate speaker belief and intent responses and more accurate sarcasm detection. Training was not related to children's speaker humour responses. Thus, the findings of the present study provide evidence that aspects of children's sarcasm understanding can be enhanced through training. The training paradigm could be developed further to test its effectiveness in other populations who struggle with sarcasm understanding, and to help refine theories of irony development. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"For children who were not already proficient in sarcasm understanding, training was associated with more accurate speaker belief and intent responses and more accurate sarcasm detection.","['Participants were 111 five- to six- year-olds', 'typically developing children']","['metapragmatic training', 'training or control condition']",['accurate speaker belief and intent responses and more accurate sarcasm detection'],"[{'cui': 'C2003373', 'cui_str': 'AM 111'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}]",,0.020189,"For children who were not already proficient in sarcasm understanding, training was associated with more accurate speaker belief and intent responses and more accurate sarcasm detection.","[{'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Lee', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Sidhu', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Penny M', 'Initials': 'PM', 'LastName': 'Pexman', 'Affiliation': 'Department of Psychology.'}]",Canadian journal of experimental psychology = Revue canadienne de psychologie experimentale,['10.1037/cep0000228'] 2575,32757577,Development of a cognitive behavioral therapy with integrated mindfulness for Latinx immigrants with co-occurring disorders: Analysis of intermediary outcomes.,"Objectives: Transdiagnostic interventions have been increasingly used in the management of a variety of mental health and substance use conditions, and in the context of chronic stress. We discuss the development and evaluation of the Integrated Intervention for Dual Problems and Early Action (IIDEA), a 10-session manualized intervention that includes cognitive therapy and mindfulness practice designed to improve symptoms of anxiety, depression, posttraumatic stress, and co-occurring substance use problems. Methods: In this secondary analysis of a randomized-controlled trial of IIDEA conducted with an international sample of immigrant Latinx in the United States and Spain, we evaluate intermediate outcomes-mindful awareness, working alliance with clinician and illness self-management-and integrate statistical findings with results from qualitative interviews with participants. Results: The IIDEA intervention group showed higher levels of mindful awareness, illness self-management, and working alliance over an enhanced treatment as usual control group (usual treatment plus scheduled assessments) and qualitative data offer insights into the importance of therapeutic alliance and integration of mindfulness practice with cognitive therapy management skills. Conclusions: Findings suggest that skills related to the studied intermediary outcomes can be helpful for Latinx immigrants experiencing circumstances of ongoing exposure to adversity and traumatic stress. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"The IIDEA intervention group showed higher levels of mindful awareness, illness self-management, and working alliance over an enhanced treatment as usual control group (usual treatment plus scheduled assessments) and qualitative data offer insights into the importance of therapeutic alliance and integration of mindfulness practice with cognitive therapy management skills. ","['IIDEA conducted with an international sample of immigrant Latinx in the United States and Spain', 'Latinx immigrants with co-occurring disorders']","['Transdiagnostic interventions', 'cognitive behavioral therapy with integrated mindfulness']","['levels of mindful awareness, illness self-management, and working alliance', 'symptoms of anxiety, depression, posttraumatic stress, and co-occurring substance use problems']","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0282163', 'cui_str': 'Immigrant'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0033213', 'cui_str': 'Problem'}]",,0.0352784,"The IIDEA intervention group showed higher levels of mindful awareness, illness self-management, and working alliance over an enhanced treatment as usual control group (usual treatment plus scheduled assessments) and qualitative data offer insights into the importance of therapeutic alliance and integration of mindfulness practice with cognitive therapy management skills. ","[{'ForeName': 'Lisa R', 'Initials': 'LR', 'LastName': 'Fortuna', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of California, San Francisco.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Falgas-Bague', 'Affiliation': 'Disparities Research Unit, Department of Medicine, Massachusetts General Hospital.'}, {'ForeName': 'Zorangelí', 'Initials': 'Z', 'LastName': 'Ramos', 'Affiliation': 'Disparities Research Unit, Department of Medicine, Massachusetts General Hospital.'}, {'ForeName': 'Michelle V', 'Initials': 'MV', 'LastName': 'Porche', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of California, San Francisco.'}, {'ForeName': 'Margarita', 'Initials': 'M', 'LastName': 'Alegría', 'Affiliation': 'Disparities Research Unit, Department of Medicine, Massachusetts General Hospital.'}]","Psychological trauma : theory, research, practice and policy",['10.1037/tra0000949'] 2576,32757595,Increasing cessation motivation and treatment engagement among smokers in pain: A pilot randomized controlled trial.,"Tobacco smokers with co-occurring pain report greater difficulty quitting, face unique cessation challenges, and may benefit from targeted smoking interventions. We developed and tested a brief motivational intervention aimed at increasing knowledge of pain-smoking interrelations, motivation to quit, and cessation treatment engagement among smokers in pain. Nontreatment seeking daily cigarette smokers with chronic pain (N = 76, 57.9% women, 52.6% White) were randomized to the targeted or ask, advise, refer (AAR) intervention. The targeted intervention included personalized feedback and pain-smoking psychoeducation to help participants develop discrepancy between continued smoking and desired pain outcomes. At postintervention, the targeted intervention (vs. AAR) increased knowledge of pain-smoking interrelations and several indices of motivation to quit smoking (ps < .01). Participants who received the targeted intervention were also more likely to accept information about and report intention to engage evidence-based cessation treatments (ps < .05). Increased knowledge of pain-smoking interrelations mediated postintervention effects on motivation to quit and willingness to learn about treatments. At 1-month follow up, gains in knowledge of pain-smoking interrelations were maintained (p = .009). Participants who received the targeted intervention were more likely to report having subsequently engaged cessation treatment (p = .019), but this was not mediated by increased knowledge of pain-smoking interrelations. Smokers with chronic pain may benefit from targeted interventions that address smoking in the context of pain. Smokers in pain may become increasingly motivated to quit and engage cessation treatment as they become aware of how smoking may exacerbate their pain. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"Participants who received the targeted intervention were more likely to report having subsequently engaged cessation treatment (p = .019), but this was not mediated by increased knowledge of pain-smoking interrelations.","['Nontreatment seeking daily cigarette smokers with chronic pain (N = 76, 57.9% women, 52.6% White', 'Tobacco smokers with co-occurring pain report greater difficulty quitting', 'Smokers with chronic pain', 'smokers in pain']",['personalized feedback and pain-smoking psychoeducation'],"['gains in knowledge of pain-smoking interrelations', 'knowledge of pain-smoking interrelations', 'knowledge of pain-smoking interrelations and several indices of motivation to quit smoking']","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0337667', 'cui_str': 'Cigarette smoker'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C4505217', 'cui_str': 'Smokers, Tobacco'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}]","[{'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}]",,0.0267168,"Participants who received the targeted intervention were more likely to report having subsequently engaged cessation treatment (p = .019), but this was not mediated by increased knowledge of pain-smoking interrelations.","[{'ForeName': 'Emily L', 'Initials': 'EL', 'LastName': 'Zale', 'Affiliation': 'Department of Psychology, Binghamton University.'}, {'ForeName': 'Stephen A', 'Initials': 'SA', 'LastName': 'Maisto', 'Affiliation': 'Department of Psychology, Syracuse University.'}, {'ForeName': 'Martin J', 'Initials': 'MJ', 'LastName': 'De Vita', 'Affiliation': 'Department of Psychology, Syracuse University.'}, {'ForeName': 'W Michael', 'Initials': 'WM', 'LastName': 'Hooten', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, Mayo Clinic College of Medicine.'}, {'ForeName': 'Joseph W', 'Initials': 'JW', 'LastName': 'Ditre', 'Affiliation': 'Department of Psychology, Syracuse University.'}]",Experimental and clinical psychopharmacology,['10.1037/pha0000424'] 2577,32757625,Trajectories and associations between depression and physical activity in patients with cardiovascular disease during participation in an internet-based cognitive behavioural therapy programme.,"BACKGROUND There is a lack of knowledge about internet-based cognitive behavioural therapy in patients with cardiovascular disease, and its effects on depressive symptoms and physical activity. AIM To examine trajectories of depressive symptoms and physical activity, and to explore if these trajectories are linked with the delivery of internet-based cognitive behavioural therapy. METHODS A secondary-analysis of data collected in a randomised controlled trial that evaluated the effects of a 9-week internet-based cognitive behavioural therapy programme compared to an online discussion forum on depressive symptoms in cardiovascular disease patients. Data were collected at baseline, once weekly during the 9-week intervention period and at the 9-week follow-up. The Montgomery Åsberg depression rating scale - self-rating (MADRS-S) was used to measure depressive symptoms. Two modified items from the physical activity questionnaire measuring frequency and length of physical activity were merged to form a physical activity factor. RESULTS After 2 weeks the internet-based cognitive behavioural therapy group had a temporary worsening in depressive symptoms. At 9-week follow-up, depressive symptoms ( P <0.001) and physical activity ( P =0.02) had improved more in the internet-based cognitive behavioural therapy group. Only in the internet-based cognitive behavioural therapy group, was a significant correlation ( r =-0.39, P =0.002) between changes in depressive symptoms and changes in physical activity found. Structural equation analyses revealed that internet-based cognitive behavioural therapy decreased depressive symptoms, and that a decrease in depression, in turn, resulted in an increase in physical activity. CONCLUSIONS Internet-based cognitive behavioural therapy was more effective than an online discussion forum to decrease depressive symptoms and increase physical activity. Importantly, a decrease in depressive symptoms needs to precede an increase in physical activity.",2020,"CONCLUSIONS Internet-based cognitive behavioural therapy was more effective than an online discussion forum to decrease depressive symptoms and increase physical activity.","['cardiovascular disease patients', 'patients with cardiovascular disease', 'patients with cardiovascular disease during participation in an internet-based cognitive behavioural therapy programme']","['Internet-based cognitive behavioural therapy', '9-week internet-based cognitive behavioural therapy programme', 'internet-based cognitive behavioural therapy']","['depressive symptoms and changes in physical activity', 'physical activity', 'depressive symptoms and increase physical activity', 'Montgomery Åsberg depression rating scale - self-rating (MADRS-S', 'physical activity questionnaire measuring frequency and length of physical activity', 'depressive symptoms']","[{'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0851408', 'cui_str': 'Changes in physical activity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4039165', 'cui_str': 'Increased physical activity'}, {'cui': 'C2960593', 'cui_str': 'Montgomery-Åsberg depression rating scale'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C1444754', 'cui_str': 'Length'}]",,0.0448648,"CONCLUSIONS Internet-based cognitive behavioural therapy was more effective than an online discussion forum to decrease depressive symptoms and increase physical activity.","[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Johansson', 'Affiliation': 'Department of Health, Medicine and Caring Sciences, Linköping University, Sweden.'}, {'ForeName': 'Erland', 'Initials': 'E', 'LastName': 'Svensson', 'Affiliation': 'Swedish Defense Research Agency, Sweden.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Andersson', 'Affiliation': 'Department of Behavioural Sciences and Learning, Linköping University, Sweden.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Lundgren', 'Affiliation': 'Department of Health, Medicine and Caring Sciences, Linköping University, Sweden.'}]",European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology,['10.1177/1474515120947250'] 2578,32757626,Reply to 'Comments on Effectiveness of acupuncture vs. core stability training in balance and functional capacity of women with fibromyalgia: A randomized controlled trial'.,,2020,,['women with fibromyalgia'],['acupuncture vs. core stability training'],[],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",[],,0.287529,,"[{'ForeName': 'Elisa María', 'Initials': 'EM', 'LastName': 'Garrido-Ardila', 'Affiliation': 'ADOLOR Research group, Department of Medical-Surgical Therapy, Medicine Faculty, Physiotherapy Field, Extremadura University, Badajoz, Spain.'}]",Clinical rehabilitation,['10.1177/0269215520945656'] 2579,32757628,"Comments on ""Effectiveness of acupuncture vs. core stability training in balance and functional capacity of women with fibromyalgia: a randomized controlled trial"".",,2020,,['women with fibromyalgia'],['acupuncture vs. core stability training'],[],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",[],,0.341993,,"[{'ForeName': 'Xiaoman', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Radiology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Pengfei', 'Initials': 'P', 'LastName': 'Rong', 'Affiliation': 'Department of Radiology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.'}]",Clinical rehabilitation,['10.1177/0269215520945663'] 2580,32757427,Use of an audit with feedback implementation strategy to promote medication error reporting by nurses.,"AIMS AND OBJECTIVES To outline the development and effect of an audit with feedback implementation strategy that intended to increase the rate of voluntary medication error reporting by nurses. BACKGROUND Medication errors are a serious global health issue. Audit with feedback is a widely-used implementation strategy that has potential to modify nurses' reporting behaviour and improve medication error reporting rates. DESIGN Quasi-experimental implementation study (fulfilling the TIDieR checklist) with two pairs of matched wards at a private hospital in Australia was conducted from March 2015-September 2016. One ward from each pair was randomised to either the intervention or control group. METHOD Nurses within intervention wards received audit with feedback on a quarterly basis over a 12-month implementation period. Control wards underwent quarterly audits only (without feedback). Feedback consisted of a one-page infographic poster, with content based on medication error data obtained from audits and the hospitals' risk management system (RiskMan). The primary outcome - rate of medication errors reported per month - was determined in both groups at pre-implementation, implementation, and post-implementation phases. Differences between groups were compared using generalised linear mixed models with Poisson distribution and log link. RESULTS A non-significant intervention effect was found for rate of medication errors reported per month. Interestingly, when combining data from both groups, a significant increasing time trend was observed for medication errors reported per month across pre-implementation and implementation phases (80% increase). CONCLUSIONS The audit with feedback strategy developed in the present study did not effectively influence the voluntary reporting of medication errors by nurses. RELEVANCE TO CLINICAL PRACTICE Despite the lack of intervention effects, the use of a published checklist to optimise the reporting quality of this study will contribute to the field by furthering the understanding of how to enhance audit with feedback implementation strategies for nurses.",2020,"Audit with feedback is a widely-used implementation strategy that has potential to modify nurses' reporting behaviour and improve medication error reporting rates. ","['Nurses within intervention wards received audit with feedback on a quarterly basis over a 12-month implementation period', 'Quasi-experimental implementation study (fulfilling the TIDieR checklist) with two pairs of matched wards at a private hospital in Australia was conducted from March 2015-September 2016']",[],"['rate of medication errors', ' rate of medication errors reported per month ']","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0450985', 'cui_str': 'Alcohol use disorders identification test'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0332179', 'cui_str': 'Trimonthly'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0033173', 'cui_str': 'Private hospital'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]",[],"[{'cui': 'C0025115', 'cui_str': 'Medication error'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",,0.0347824,"Audit with feedback is a widely-used implementation strategy that has potential to modify nurses' reporting behaviour and improve medication error reporting rates. ","[{'ForeName': 'Alison M', 'Initials': 'AM', 'LastName': 'Hutchinson', 'Affiliation': 'Deakin University, Geelong, School of Nursing & Midwifery, Centre for Quality & Patient Safety, Institute for Health Transformation, Faculty of Health, Victoria, 3220, Australia.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Brotto', 'Affiliation': 'Deakin University, Geelong, School of Nursing & Midwifery, Centre for Quality & Patient Safety, Institute for Health Transformation, Faculty of Health, Victoria, 3220, Australia.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Chapman', 'Affiliation': 'Deakin University, Geelong, School of Nursing & Midwifery, Centre for Quality & Patient Safety, Institute for Health Transformation, Faculty of Health, Victoria, 3220, Australia.'}, {'ForeName': 'Anne E', 'Initials': 'AE', 'LastName': 'Sales', 'Affiliation': 'Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Mohammadreza', 'Initials': 'M', 'LastName': 'Mohebbi', 'Affiliation': 'Biostatistics Unit, Faculty of Health, Deakin University, Geelong, Victoria, 3220, Australia.'}, {'ForeName': 'Tracey K', 'Initials': 'TK', 'LastName': 'Bucknall', 'Affiliation': 'Deakin University, Geelong, School of Nursing & Midwifery, Centre for Quality & Patient Safety, Institute for Health Transformation, Faculty of Health, Victoria, 3220, Australia.'}]",Journal of clinical nursing,['10.1111/jocn.15447'] 2581,32757437,"Collaborative Care for the Wearable Cardioverter Defibrillator Patient: Getting the Patient and Medical Team ""Vested and Active"".","Patients with a reduced ejection fraction of 35% or less and a history of myocardial infarction are at increased risk of sudden cardiac death (SCD). These patients have a class I indication for an implantable cardioverter-defibrillator after allowing time for medical therapy optimization and potential cardiac recovery. The rates of SCD are highest in this ""gap"" period early after a cardiac event, and the wearable cardioverter-defibrillator (WCD) is an intervention that can be used to protect against SCD during this time period. There has been a clinical trial that randomized patients with a reduced ejection fraction at the time of myocardial infarction to a WCD versus control. Results of the trial showed no statistically significant difference in the primary endpoint of SCD. There are many intricacies to the interpretation of the trial, including the importance of patient adherence to WCD therapy, which is affected by the patient experience and psychological factors. Patients with a new cardiomyopathy are affected by a mix of psychological factors, including the feeling of safety and protection from a WCD contrasted by the WCD providing a reminder of awareness and fear of ventricular arrhythmias and SCD. Beyond the capabilities of a WCD to defibrillate a life-threatening ventricular arrhythmia, the device can also provide activity and heart failure diagnostics monitoring. Patients need to be engaged in shared decision-making conversations about a WCD, so that patients can make a decision based on their own values construct, ultimately increasing adherence among the patients that want a WCD. This article is protected by copyright. All rights reserved.",2020,Results of the trial showed no statistically significant difference in the primary endpoint of SCD.,"['Wearable Cardioverter Defibrillator Patient', 'Patients with a reduced ejection fraction of 35% or less and a history of myocardial infarction']",['implantable cardioverter-defibrillator'],"['rates of SCD', 'SCD', 'risk of sudden cardiac death (SCD']","[{'cui': 'C0180307', 'cui_str': 'Defibrillator'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C1275835', 'cui_str': 'History of myocardial infarction'}]","[{'cui': 'C0162589', 'cui_str': 'Implantable defibrillator'}]","[{'cui': 'C0085298', 'cui_str': 'Sudden cardiac death'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",,0.0436581,Results of the trial showed no statistically significant difference in the primary endpoint of SCD.,"[{'ForeName': 'Samuel F', 'Initials': 'SF', 'LastName': 'Sears', 'Affiliation': 'Department of Psychology, East Carolina University, Greenville, North Carolina, USA.'}, {'ForeName': 'Connor', 'Initials': 'C', 'LastName': 'Tripp', 'Affiliation': 'Department of Psychology, East Carolina University, Greenville, North Carolina, USA.'}, {'ForeName': 'Nichelle L', 'Initials': 'NL', 'LastName': 'Huber', 'Affiliation': 'Department of Psychology, East Carolina University, Greenville, North Carolina, USA.'}, {'ForeName': 'Saleen', 'Initials': 'S', 'LastName': 'Khan', 'Affiliation': 'Department of Cardiovascular Sciences, East Carolina University, Greenville, North Carolina, USA.'}, {'ForeName': 'Rajasekhar', 'Initials': 'R', 'LastName': 'Nekkanti', 'Affiliation': 'Department of Cardiovascular Sciences, East Carolina University, Greenville, North Carolina, USA.'}, {'ForeName': 'Ashley E', 'Initials': 'AE', 'LastName': 'Burch', 'Affiliation': 'Department of Psychology, East Carolina University, Greenville, North Carolina, USA.'}, {'ForeName': 'Sean D', 'Initials': 'SD', 'LastName': 'Pokorney', 'Affiliation': 'Division of Cardiology, Duke University, Durham, North Carolina, USA.'}]",Journal of cardiovascular electrophysiology,['10.1111/jce.14708'] 2582,32757479,Capsaicin combined with ice stimulation improves swallowing function in patients with dysphagia after stroke: a randomized controlled trial.,"BACKGROUND Dysphagia is a common condition after stroke and it's associated with many complications. Early and effective treatments are essential to the prognosis of patients with dysphagia. We aimed to evaluate the effects and safety of capsaicin combined with ice stimulation in patients with dysphagia after stroke. METHODS Patients with dysphagia admitted to our hospital from December 2017 to December 2019 were included. The control group received the ice stimulation, and the experimental group received the combined capsaicin and ice stimulation. The grade of water swallowing test (WST), Standard Swallowing Assessment (SSA) scores and the serum substance P level were compared between control (ice only) and experimental group(capsaicin plus ice). RESULTS No differences before treatment, and significance following treatment in each group (before and after) and between groups (capsaicin plus ice vs ice only) were found(all p>0.05); the SSA scores were significantly reduced after intervention for both groups(all p<0.001), and after intervention, SSA score in experimental group was significantly less than that of control group(p<0.001). After intervention, the number of patients graded as WST level I-II in experimental group was significantly more than that of control group(p<0.001); the serum substance P level was significantly increased after intervention for both groups (all p<0.05), and after intervention, the serum substance P level in experimental group was significantly higher than that of control group(p=0.007). CONCLUSIONS The combined use of capsaicin with ice stimulation is beneficial to the recovery of swallowing function of patients with dysphagia, which should be included into the clinical practice.",2020,"The grade of water swallowing test (WST), Standard Swallowing Assessment (SSA) scores and the serum substance P level were compared between control (ice only) and experimental group(capsaicin plus ice). ","['patients with dysphagia', 'patients with dysphagia after stroke', 'Patients with dysphagia admitted to our hospital from December 2017 to December 2019 were included']","['combined capsaicin and ice stimulation', 'capsaicin combined with ice stimulation', 'capsaicin with ice stimulation', 'Capsaicin combined with ice stimulation']","['serum substance P level', 'swallowing function', 'SSA score', 'grade of water swallowing test (WST), Standard Swallowing Assessment (SSA) scores and the serum substance P level', 'SSA scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0006931', 'cui_str': 'Capsaicin'}, {'cui': 'C0020746', 'cui_str': 'Ice'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0038585', 'cui_str': 'Substance P'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.027652,"The grade of water swallowing test (WST), Standard Swallowing Assessment (SSA) scores and the serum substance P level were compared between control (ice only) and experimental group(capsaicin plus ice). ","[{'ForeName': 'Feifei', 'Initials': 'F', 'LastName': 'Cui', 'Affiliation': 'Department of Neurosurgery, the First Affiliated Hospital of Soochow University.'}, {'ForeName': 'Qingmei', 'Initials': 'Q', 'LastName': 'Yin', 'Affiliation': 'Department of Neurosurgery, the First Affiliated Hospital of Soochow University.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Wu', 'Affiliation': 'Department of Neurosurgery, the First Affiliated Hospital of Soochow University.'}, {'ForeName': 'Meifen', 'Initials': 'M', 'LastName': 'Shen', 'Affiliation': 'Department of Neurosurgery, the First Affiliated Hospital of Soochow University.'}, {'ForeName': 'Yijie', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Neurosurgery, the First Affiliated Hospital of Soochow University.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Ma', 'Affiliation': 'Department of Neurosurgery, the First Affiliated Hospital of Soochow University.'}, {'ForeName': 'Haiying', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Neurosurgery, the First Affiliated Hospital of Soochow University.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Shen', 'Affiliation': 'Department of Neurosurgery, the First Affiliated Hospital of Soochow University.'}]",Journal of oral rehabilitation,['10.1111/joor.13068'] 2583,32068424,Effects of modifying interpretation bias on transdiagnostic repetitive negative thinking.,"OBJECTIVE Repetitive negative thinking (RNT; e.g., worry and rumination) is common across emotional disorders, as is the tendency to generate negative interpretations (interpretation bias). Ameliorating negative interpretations via cognitive bias modification of interpretations (CBM-I) reduces worry/rumination, and improves mood in people diagnosed with generalized anxiety disorder (GAD) or depression. We investigated whether these findings generalize to high worry or rumination populations, irrespective of diagnosis, and whether effects are increased by enhancing emotional engagement with training with active generation of positive resolutions of ambiguity and imagery. METHOD Community volunteers with excessive worry and/or rumination, who were above clinical cut-off on anxiety and/or depression measures, were allocated to an active control condition ( n = 54), interpretation training condition with prior activation of RNT (CBM_RNT; n = 54), or training condition augmented with positive outcome generation and imagery (CBM_ENH; n = 53). Interpretation bias, RNT, and mood were assessed before and following 10 Internet-based sessions completed within a 1-month period. RNT and mood questionnaires were also completed at 1-month follow-up. RESULTS After training, both forms of CBM-I (vs. control) facilitated more positive interpretations and reduced negative intrusions during a worry task. At 1-month follow-up, anxiety, depression, RNT, and worry in the past week were lower in the CBM-I than control conditions, but not rumination or trait worry. Compared with standard CBM-I, the augmented form facilitated more positive interpretations, reduced negative intrusions after training, and reduced trait rumination at 1-month follow-up, but it did not augment effects on trait worry, anxiety or depression. CONCLUSIONS Interpretation bias maintains transdiagnostic RNT and Internet-based CBM-I can reduce longer-term RNT. (PsycINFO Database Record (c) 2020 APA, all rights reserved).",2020,"Compared with standard CBM-I, the augmented form facilitated more positive interpretations, reduced negative intrusions after training, and reduced trait rumination at 1-month follow-up, but it did not augment effects on trait worry, anxiety or depression. ","['Community volunteers with excessive worry and/or rumination, who were above clinical cut-off on anxiety and/or depression measures', 'people diagnosed with generalized anxiety disorder (GAD) or depression']","['active control condition ( n = 54), interpretation training condition with prior activation of RNT (CBM_RNT; n = 54), or training condition augmented with positive outcome generation and imagery (CBM_ENH; n = 53']","['RNT and mood questionnaires', 'trait worry, anxiety or depression', 'trait rumination', 'positive interpretations and reduced negative intrusions', 'anxiety, depression, RNT, and worry']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0442802', 'cui_str': 'Excessive'}, {'cui': 'C0233481', 'cui_str': 'Worried'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0000925', 'cui_str': 'Incised wound'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0459471', 'cui_str': 'Interpretation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0424134', 'cui_str': 'Pessimistic'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}]","[{'cui': 'C0424134', 'cui_str': 'Pessimistic'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0233481', 'cui_str': 'Worried'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0459471', 'cui_str': 'Interpretation'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0205160', 'cui_str': 'Negative'}]",,0.0463741,"Compared with standard CBM-I, the augmented form facilitated more positive interpretations, reduced negative intrusions after training, and reduced trait rumination at 1-month follow-up, but it did not augment effects on trait worry, anxiety or depression. ","[{'ForeName': 'Colette R', 'Initials': 'CR', 'LastName': 'Hirsch', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London.""}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Krahé', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London.""}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Whyte', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London.""}, {'ForeName': 'Livia', 'Initials': 'L', 'LastName': 'Bridge', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London.""}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Loizou', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London.""}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Norton', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London.""}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Mathews', 'Affiliation': 'Department of Psychology, University of California, Davis.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000455'] 2584,31509824,Mindfulness-Based Therapy Regulates Brain Connectivity in Major Depression.,,2019,,['Major Depression'],['Mindfulness-Based Therapy'],[],"[{'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",[],,0.0112075,,"[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lifshitz', 'Affiliation': 'Integrated Program in Neuroscience, McGill University, Montreal, Québec, Canada, lifshitz@stanford.edu.'}, {'ForeName': 'Matthew D', 'Initials': 'MD', 'LastName': 'Sacchet', 'Affiliation': 'Center for Depression, Anxiety, and Stress Research, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA.'}, {'ForeName': 'Julia M', 'Initials': 'JM', 'LastName': 'Huntenburg', 'Affiliation': 'Max Planck Research Group for Neuroanatomy & Connectivity, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Thiery', 'Affiliation': 'Department of Psychology, Université de Montréal, Montreal, Québec, Canada.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Fan', 'Affiliation': 'Department of Psychology and Neurosciences, Leibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany.'}, {'ForeName': 'Matti', 'Initials': 'M', 'LastName': 'Gärtner', 'Affiliation': 'Clinic for Psychiatry and Psychotherapy, Charité University Medicine Berlin, Berlin, Germany.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Grimm', 'Affiliation': 'Clinic for Psychiatry and Psychotherapy, Charité University Medicine Berlin, Berlin, Germany.'}, {'ForeName': 'Emilia', 'Initials': 'E', 'LastName': 'Winnebeck', 'Affiliation': 'Clinic for Psychiatry and Psychotherapy, Charité University Medicine Berlin, Berlin, Germany.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Fissler', 'Affiliation': 'Clinic for Psychiatry and Psychotherapy, Charité University Medicine Berlin, Berlin, Germany.'}, {'ForeName': 'Titus A', 'Initials': 'TA', 'LastName': 'Schroeter', 'Affiliation': 'Dahlem Institute for Neuroimaging of Emotion, Freie Universität, Berlin, Germany.'}, {'ForeName': 'Daniel S', 'Initials': 'DS', 'LastName': 'Margulies', 'Affiliation': 'Centre National de la Recherche Scientifique (CNRS) UMR 7225, Frontlab, Institut du Cerveau et de la Moelle Épinière, Paris, France.'}, {'ForeName': 'Thorsten', 'Initials': 'T', 'LastName': 'Barnhofer', 'Affiliation': 'School of Psychology, University of Surrey, Guildford, United Kingdom.'}]",Psychotherapy and psychosomatics,['10.1159/000501170'] 2585,32755237,Prospective Randomized Evaluation of Local Injection of Allogeneic Growth Factors in Plantar Fasciitis.,"BACKGROUND The aim of this study was to evaluate the efficacy and safety of injection of allogeneic growth factors in patients with plantar fasciitis. METHODS This study included 150 patients who were randomly divided into 2 equal groups; the patients were locally injected with allogeneic growth factors (GFs) (treatment group) or with saline 0.9% (control group). The patients were assessed using visual analog scale (VAS) and Foot Function Index-Revised short form (FFI-Rs) scores preinjection and 1, 3, 6, and 12 months postinjection. The patients were questioned about their satisfaction. Any adverse effects were recorded. RESULTS At baseline, there was no significant difference between both groups regarding the mean VAS and FFI-Rs scores. At 3-month follow-up, the reduction in mean VAS score was 87% in the treatment group and 55% in the control group ( P < .001), and the reduction in mean FFI-Rs score was 62% in the treatment group and 40% in the control group ( P < .001). Treatment group and study visit were significant factors affecting both VAS and FFI-Rs scores. Overall, 92% were satisfied in the treatment group, and 78.2% in the control group. Postinjection pain occurred in 5 patients in the treatment group. CONCLUSION This study provides Level I evidence regarding the efficacy and safety of allogeneic GF injection in patients with plantar fasciitis. However, additional studies are needed to evaluate their adverse effects, immunogenicity, and microbiological safety. LEVEL OF EVIDENCE Level I, prospective randomized controlled case series.",2020,"At baseline, there was no significant difference between both groups regarding the mean VAS and FFI-Rs scores.","['patients with plantar fasciitis', 'Plantar Fasciitis', '150 patients who were randomly divided into 2 equal groups; the patients were locally injected with']","['Local Injection of Allogeneic Growth Factors', 'allogeneic growth factors', 'allogeneic GF injection', 'allogeneic growth factors (GFs) (treatment group) or with saline 0.9% (control group']","['mean FFI-Rs score', 'Postinjection pain', 'visual analog scale (VAS) and Foot Function Index-Revised short form (FFI-Rs) scores preinjection', 'efficacy and safety', 'VAS and FFI-Rs scores', 'mean VAS score', 'adverse effects, immunogenicity, and microbiological safety', 'adverse effects', 'mean VAS and FFI-Rs scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0149756', 'cui_str': 'Plantar fasciitis'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1720154', 'cui_str': 'Inject'}]","[{'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0018284', 'cui_str': 'Growth factor'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C4068881', 'cui_str': '0.9'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0206042', 'cui_str': 'Fatal familial insomnia'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C4706287', 'cui_str': 'Foot Function Index'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0025953', 'cui_str': 'microbiology'}]",150.0,0.0365172,"At baseline, there was no significant difference between both groups regarding the mean VAS and FFI-Rs scores.","[{'ForeName': 'Mahmoud Ibrahim', 'Initials': 'MI', 'LastName': 'Kandil', 'Affiliation': 'Orthopedic Surgery, Department of Orthopaedics and Traumatology, Faculty of Medicine, Benha University, Benha, Qalyubia, Egypt.'}, {'ForeName': 'Eslam Abdelshafi', 'Initials': 'EA', 'LastName': 'Tabl', 'Affiliation': 'Orthopedic Surgery, Department of Orthopaedics and Traumatology, Faculty of Medicine, Benha University, Benha, Qalyubia, Egypt.'}, {'ForeName': 'Adel Samy', 'Initials': 'AS', 'LastName': 'Elhammady', 'Affiliation': 'Orthopedic Surgery, Department of Orthopaedics and Traumatology, Faculty of Medicine, Benha University, Benha, Qalyubia, Egypt.'}]",Foot & ankle international,['10.1177/1071100720939066'] 2586,32755254,Degree of Blood Pressure Control and Incident Diabetes Mellitus in Chinese Adults With Hypertension.,"Background The association between blood pressure (BP) control and incident diabetes mellitus remains unknown. We aim to investigate the association between degree of time-averaged on-treatment systolic blood pressure (SBP) control and incident diabetes mellitus in hypertensive adults. Methods and Results A total of 14 978 adults with hypertension without diabetes mellitus at baseline were included from the CSPPT (China Stroke Primary Prevention Trial). Participants were randomized double-masked to daily enalapril 10 mg and folic acid 0.8 mg or enalapril 10 mg alone. BP measurements were taken every 3 months after randomization. The primary outcome was incident diabetes mellitus, defined as physician-diagnosed diabetes mellitus, or use of glucose-lowering drugs during follow-up, or fasting glucose ≥126 mg/dL at the exit visit. Over a median of 4.5 years, a significantly higher risk of incident diabetes mellitus was found in participants with time-averaged on-treatment SBP 130 to <140 mm Hg (10.3% versus 7.4%; odds ratio [OR], 1.37; 95% CI, 1.15‒1.64), compared with those with SBP 120 to <130 mm Hg. Moreover, the risk of incident diabetes mellitus increased by 24% (OR, 1.24; 95% CI, 1.00‒1.53) and the incidence of regression to normal fasting glucose (<100 mg/dL) decreased by 29% (OR, 0.71; 95% CI, 0.57‒0.89) in participants with intermediate BP control (SBP/diastolic blood pressure, 130 to <140 and/or 80 to <90 mm Hg), compared with those with a tight BP control of <130/<80 mm Hg. Similar results were found when the time-averaged BP were calculated using the BP measurements during the first 6- or 24-month treatment period, or in the analysis using propensity scores. Conclusions In this non-diabetic, hypertensive population, SBP control in the range of 120 to <130 mm Hg, compared with the 130 to <140 mm Hg, was associated with a lower risk of incident diabetes mellitus.",2020,"Hg (10.3% versus 7.4%; odds ratio [OR], 1.37; 95% CI, 1.15‒1.64), compared with those with SBP 120 to <130 mm Hg.","['hypertensive adults', 'Chinese Adults With Hypertension', 'A total of 14\xa0978 adults with hypertension without diabetes mellitus at baseline were included from the CSPPT (China Stroke Primary Prevention Trial']","['time-averaged on-treatment systolic blood pressure (SBP) control', 'enalapril 10\xa0mg and folic acid 0.8\xa0mg or enalapril 10\xa0mg alone']","['BP measurements', 'incidence of regression to normal fasting glucose', 'incident diabetes mellitus, defined as physician-diagnosed diabetes mellitus, or use of glucose-lowering drugs during follow-up, or fasting glucose ≥126', 'Degree of Blood Pressure Control and Incident Diabetes Mellitus', 'blood pressure (BP) control and incident diabetes mellitus', 'risk of incident diabetes mellitus', 'time-averaged BP']","[{'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0033144', 'cui_str': 'Primary prevention'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0014025', 'cui_str': 'Enalapril'}, {'cui': 'C0986173', 'cui_str': 'Folic Acid 0.8 MG'}]","[{'cui': 'C0005824', 'cui_str': 'Blood pressure taking'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0684321', 'cui_str': 'Regression - mental defense mechanism'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C4301973', 'cui_str': 'Average blood pressure'}]",14978.0,0.11366,"Hg (10.3% versus 7.4%; odds ratio [OR], 1.37; 95% CI, 1.15‒1.64), compared with those with SBP 120 to <130 mm Hg.","[{'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'National Clinical Research Center for Kidney Disease State Key Laboratory for Organ Failure Research Division of Nephrology Nanfang HospitalSouthern Medical University Guangzhou China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Nie', 'Affiliation': 'National Clinical Research Center for Kidney Disease State Key Laboratory for Organ Failure Research Division of Nephrology Nanfang HospitalSouthern Medical University Guangzhou China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiology Peking University First Hospital Beijing China.'}, {'ForeName': 'Jianping', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Cardiology Peking University First Hospital Beijing China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Liang', 'Affiliation': 'National Clinical Research Center for Kidney Disease State Key Laboratory for Organ Failure Research Division of Nephrology Nanfang HospitalSouthern Medical University Guangzhou China.'}, {'ForeName': 'Guobao', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'National Clinical Research Center for Kidney Disease State Key Laboratory for Organ Failure Research Division of Nephrology Nanfang HospitalSouthern Medical University Guangzhou China.'}, {'ForeName': 'Jianwei', 'Initials': 'J', 'LastName': 'Tian', 'Affiliation': 'National Clinical Research Center for Kidney Disease State Key Laboratory for Organ Failure Research Division of Nephrology Nanfang HospitalSouthern Medical University Guangzhou China.'}, {'ForeName': 'Chengzhang', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Shenzhen Evergreen Medical Institute Shenzhen China.'}, {'ForeName': 'Binyan', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': 'Institute of Biomedicine Anhui Medical University Hefei China.'}, {'ForeName': 'Yimin', 'Initials': 'Y', 'LastName': 'Cui', 'Affiliation': 'Department of Pharmacy Peking University First Hospital Beijing China.'}, {'ForeName': 'Xiaobin', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Population, Family and Reproductive Health Johns Hopkins University Bloomberg School of Public Health Baltimore MD.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Huo', 'Affiliation': 'Department of Cardiology Peking University First Hospital Beijing China.'}, {'ForeName': 'Xiping', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': 'National Clinical Research Center for Kidney Disease State Key Laboratory for Organ Failure Research Division of Nephrology Nanfang HospitalSouthern Medical University Guangzhou China.'}, {'ForeName': 'Fan Fan', 'Initials': 'FF', 'LastName': 'Hou', 'Affiliation': 'National Clinical Research Center for Kidney Disease State Key Laboratory for Organ Failure Research Division of Nephrology Nanfang HospitalSouthern Medical University Guangzhou China.'}, {'ForeName': 'Xianhui', 'Initials': 'X', 'LastName': 'Qin', 'Affiliation': 'National Clinical Research Center for Kidney Disease State Key Laboratory for Organ Failure Research Division of Nephrology Nanfang HospitalSouthern Medical University Guangzhou China.'}]",Journal of the American Heart Association,['10.1161/JAHA.120.017015'] 2587,32755265,Randomized Controlled Trial: Cognitive-Narrative Therapy for IPV Victims.,"The objective is to test the efficacy of cognitive-narrative therapy in the treatment of depression, post-traumatic stress disorder (PTSD), complex posttraumatic stress disorder (CPTSD) and borderline symptoms on a sample of women who suffered from intimate partner violence (IPV). Trial design is a longitudinal randomized controlled trial with a sample of 19 battered women allocated in two groups, a control group and treatment group, assessed twice at baseline before intervention, and at follow-up. The outcome measures were the Patient Health Questionnaire, International Trauma Questionnaire, PTSD and CPTSD Diagnostic Interview Schedule for International Classification of Diseases (ICD)-11, Conjugal Violence Exposure Scale (CVES), Life Events Checklist and Intervention Program Satisfaction Assessment Instrument. The treatment group received a four-session cognitive-narrative manualized intervention. There were no statistically significant differences between groups at baseline and follow-up, however, positive effect sizes ranging between 0.04 and 0.43 were found in depression, PTSD, and borderline, as well in some CPTSD dimensions when analyzing baseline-follow-up deltas between groups. There was also a negative effect size of -0.28 in the CPTSD total. This intervention is effective in the treatment of depression, PTSD and borderline and is an important tool in the treatment of these disorders.",2020,"The outcome measures were the Patient Health Questionnaire, International Trauma Questionnaire, PTSD and CPTSD Diagnostic Interview Schedule for International Classification of Diseases (ICD)-11, Conjugal Violence Exposure Scale (CVES), Life Events Checklist and Intervention Program Satisfaction Assessment Instrument.","['19 battered women', 'IPV Victims', 'women who suffered from intimate partner violence (IPV']","['four-session cognitive-narrative manualized intervention', 'Cognitive-Narrative Therapy', 'cognitive-narrative therapy']","['Patient Health Questionnaire, International Trauma Questionnaire, PTSD and CPTSD Diagnostic Interview Schedule for International Classification of Diseases (ICD)-11, Conjugal Violence Exposure Scale (CVES), Life Events Checklist and Intervention Program Satisfaction Assessment Instrument']","[{'cui': 'C0242810', 'cui_str': 'Battered Woman'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C1135957', 'cui_str': 'Narration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3494322', 'cui_str': 'Narrative Therapy'}]","[{'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C2733207', 'cui_str': 'Complex posttraumatic stress disorder'}, {'cui': 'C0451119', 'cui_str': 'Diagnostic interview schedule'}, {'cui': 'C0870733', 'cui_str': 'International Statistical Classification of Diseases and Related Health Problems'}, {'cui': 'C0814549', 'cui_str': 'Violence Exposure'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0557155', 'cui_str': 'Life event observable'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}]",19.0,0.0430683,"The outcome measures were the Patient Health Questionnaire, International Trauma Questionnaire, PTSD and CPTSD Diagnostic Interview Schedule for International Classification of Diseases (ICD)-11, Conjugal Violence Exposure Scale (CVES), Life Events Checklist and Intervention Program Satisfaction Assessment Instrument.","[{'ForeName': 'André', 'Initials': 'A', 'LastName': 'Moreira', 'Affiliation': 'Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Gandra, Portugal.'}, {'ForeName': 'Ana Cristina', 'Initials': 'AC', 'LastName': 'Moreira', 'Affiliation': 'Associação para o Desenvolvimento da Figueira, Penafiel, Portugal.'}, {'ForeName': 'José Carlos', 'Initials': 'JC', 'LastName': 'Rocha', 'Affiliation': 'Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Gandra, Portugal.'}]",Journal of interpersonal violence,['10.1177/0886260520943719'] 2588,32755273,The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers.,"BACKGROUND Cannabidiol has potential therapeutic benefits for people with psychiatric disorders characterised by reward function impairment. There is existing evidence that cannabidiol may influence some aspects of reward processing. However, it is unknown whether cannabidiol acutely affects brain function underpinning reward anticipation and feedback. HYPOTHESES We predicted that cannabidiol would augment brain activity associated with reward anticipation and feedback. METHODS We administered a single 600 mg oral dose of cannabidiol and matched placebo to 23 healthy participants in a double-blind, placebo-controlled, repeated-measures design. We employed the monetary incentive delay task during functional magnetic resonance imaging to assay the neural correlates of reward anticipation and feedback. We conducted whole brain analyses and region-of-interest analyses in pre-specified reward-related brain regions. RESULTS The monetary incentive delay task elicited expected brain activity during reward anticipation and feedback, including in the insula, caudate, nucleus accumbens, anterior cingulate and orbitofrontal cortex. However, across the whole brain, we did not find any evidence that cannabidiol altered reward-related brain activity. Moreover, our Bayesian analyses showed that activity in our regions-of-interest was similar following cannabidiol and placebo. Additionally, our behavioural measures of motivation for reward did not show a significant difference between cannabidiol and placebo. DISCUSSION Cannabidiol did not acutely affect the neural correlates of reward anticipation and feedback in healthy participants. Future research should explore the effects of cannabidiol on different components of reward processing, employ different doses and administration regimens, and test its reward-related effects in people with psychiatric disorders.",2020,"However, across the whole brain, we did not find any evidence that cannabidiol altered reward-related brain activity.","['healthy volunteers', '23 healthy participants', 'people with psychiatric disorders', 'healthy participants', 'people with psychiatric disorders characterised by reward function impairment']","['single 600 mg oral dose of cannabidiol and matched placebo', 'placebo']","['brain activity during reward anticipation and feedback, including in the insula, caudate, nucleus accumbens, anterior cingulate and orbitofrontal cortex']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0006863', 'cui_str': 'Cannabidiol'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0443158', 'cui_str': 'Brain activity'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0021640', 'cui_str': 'Insular structure'}, {'cui': 'C0007610', 'cui_str': 'Nucleus'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate Gyrus'}, {'cui': 'C0152301', 'cui_str': 'Structure of orbital gyrus'}]",23.0,0.374604,"However, across the whole brain, we did not find any evidence that cannabidiol altered reward-related brain activity.","[{'ForeName': 'Will', 'Initials': 'W', 'LastName': 'Lawn', 'Affiliation': 'Clinical Psychopharmacology Unit, University College London, London, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Hill', 'Affiliation': 'Translational Psychiatry Research Group, University College London, London, UK.'}, {'ForeName': 'Chandni', 'Initials': 'C', 'LastName': 'Hindocha', 'Affiliation': 'Clinical Psychopharmacology Unit, University College London, London, UK.'}, {'ForeName': 'Jocelyn', 'Initials': 'J', 'LastName': 'Yim', 'Affiliation': 'Translational Psychiatry Research Group, University College London, London, UK.'}, {'ForeName': 'Yumeya', 'Initials': 'Y', 'LastName': 'Yamamori', 'Affiliation': 'Translational Psychiatry Research Group, University College London, London, UK.'}, {'ForeName': 'Gus', 'Initials': 'G', 'LastName': 'Jones', 'Affiliation': 'Translational Psychiatry Research Group, University College London, London, UK.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Walker', 'Affiliation': 'Translational Psychiatry Research Group, University College London, London, UK.'}, {'ForeName': 'Sebastian F', 'Initials': 'SF', 'LastName': 'Green', 'Affiliation': 'Translational Psychiatry Research Group, University College London, London, UK.'}, {'ForeName': 'Matthew B', 'Initials': 'MB', 'LastName': 'Wall', 'Affiliation': 'Clinical Psychopharmacology Unit, University College London, London, UK.'}, {'ForeName': 'Oliver D', 'Initials': 'OD', 'LastName': 'Howes', 'Affiliation': 'Psychiatric Imaging Group, Imperial College London, London, UK.'}, {'ForeName': 'H Valerie', 'Initials': 'HV', 'LastName': 'Curran', 'Affiliation': 'Clinical Psychopharmacology Unit, University College London, London, UK.'}, {'ForeName': 'Tom P', 'Initials': 'TP', 'LastName': 'Freeman', 'Affiliation': 'Clinical Psychopharmacology Unit, University College London, London, UK.'}, {'ForeName': 'Michael Ap', 'Initials': 'MA', 'LastName': 'Bloomfield', 'Affiliation': 'Clinical Psychopharmacology Unit, University College London, London, UK.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881120944148'] 2589,32755372,Normoxic management of cardiopulmonary bypass reduces myocardial oxidative stress in adult patients undergoing coronary artery bypass graft surgery.,"INTRODUCTION We aimed to investigate whether normoxic cardiopulmonary bypass would limit myocardial oxidative stress in adults undergoing coronary artery bypass grafting. METHODS Patients scheduled to undergo elective isolated on-pump coronary artery bypass grafting were randomized to normoxia and hyperoxia groups. The normoxia group received 35% oxygen during anesthetic induction, 35% during hypothermic bypass, and 45% during rewarming. The hyperoxia group received 70%, 50%, and 70% oxygen, respectively. Coronary sinus blood samples were taken prior to initiation of cardiopulmonary bypass and after reperfusion for myocardial total oxidant and antioxidant status measurements. The primary endpoint was myocardial total oxidant status. Secondary endpoints were myocardial total antioxidant status and length of intensive care unit and hospital stay. RESULTS Forty-eight patients were included. Twenty-two received normoxic management. Mean ± standard deviation of age was 58 ± 9.07 years. Groups were balanced in terms of demographics, risk factors, and operative data. Myocardial total oxidant status was significantly lower in the normoxia group following reperfusion (p = 0.03). There was no statistically significant difference regarding myocardial total antioxidant status and length of intensive care unit and hospital stay (p = 0.08, p = 0.82, and p = 0.54, respectively). CONCLUSIONS Normoxic cardiopulmonary bypass is associated with reduced myocardial oxidative stress compared to hyperoxic cardiopulmonary bypass in adult coronary artery bypass patients.",2020,"There was no statistically significant difference regarding myocardial total antioxidant status and length of intensive care unit and hospital stay (p = 0.08, p = 0.82, and p = 0.54, respectively). ","['Forty-eight patients were included', 'adult coronary artery bypass patients', 'Patients scheduled to undergo elective isolated on-pump coronary artery bypass grafting were randomized to normoxia and hyperoxia groups', 'adult patients undergoing coronary artery bypass graft surgery', 'adults undergoing coronary artery bypass grafting']","['hyperoxic cardiopulmonary bypass', 'normoxic management', 'normoxic cardiopulmonary bypass', 'cardiopulmonary bypass', 'Normoxic cardiopulmonary bypass']","['myocardial total oxidant status', 'myocardial oxidative stress', 'myocardial total antioxidant status and length of intensive care unit and hospital stay', 'Myocardial total oxidant status']","[{'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0205409', 'cui_str': 'Isolated'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0242706', 'cui_str': 'Hyperoxia'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0085403', 'cui_str': 'Oxidizing Agents'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",48.0,0.0305002,"There was no statistically significant difference regarding myocardial total antioxidant status and length of intensive care unit and hospital stay (p = 0.08, p = 0.82, and p = 0.54, respectively). ","[{'ForeName': 'Ahmet Can', 'Initials': 'AC', 'LastName': 'Topcu', 'Affiliation': 'Department of Cardiovascular Surgery, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Bolukcu', 'Affiliation': 'Department of Cardiovascular Surgery, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Kamile', 'Initials': 'K', 'LastName': 'Ozeren', 'Affiliation': 'Department of Cardiovascular Surgery, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Tugba', 'Initials': 'T', 'LastName': 'Kavasoglu', 'Affiliation': 'Department of Anesthesiology and Reanimation, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Ilyas', 'Initials': 'I', 'LastName': 'Kayacioglu', 'Affiliation': 'Department of Cardiovascular Surgery, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.'}]",Perfusion,['10.1177/0267659120946733'] 2590,32755441,"Cluster randomised controlled trial of a problem-solving, Story-bridge mental health literacy programme for improving Ghanaian community leaders' knowledge of depression.","BACKGROUND Low levels of mental health literacy about depression in the community impact negatively on attitudes towards people with the disorder and their help-seeking. AIMS The aim of this study was to assess the effectiveness of a problem-solving, Story-bridge mental health literacy programme, in improving community leaders' knowledge about helpful interventions for, and recognition of, depression. METHODS A cluster randomised controlled trial involving 140 assembly members, intervention ( n  = 70) and control ( n  = 70) groups. The intervention group received a three-hour mental health literacy programme. The control group received a plain language basic brochure about mental health issues. Data were collected at baseline and 12-week follow-up. RESULTS The intervention group demonstrated greater improvement in knowledge about helpful interventions for, and recognition of, depression compared to the control group at follow-up; however, the differences in both measures were small and not statistically significant. CONCLUSION The programme has the potential to improve participants' knowledge about helpful interventions for, and recognition of, depression. Positive outcomes have public mental health implications as they might enhance early help-seeking and contribute to better outcomes for individuals with mental health problems. TRIAL REGISTRATION ACTRN12617000033347. Date of registration - 9 January 2017.",2020,"The intervention group demonstrated greater improvement in knowledge about helpful interventions for, and recognition of, depression compared to the control group at follow-up; however, the differences in both measures were small and not statistically significant. ","['individuals with mental health problems', '140 assembly members, intervention ( n \u2009=\u200970) and control ( n \u2009=\u200970) groups']","['three-hour mental health literacy programme', 'problem-solving, Story-bridge mental health literacy programme', 'plain language basic brochure about mental health issues']","['knowledge about helpful interventions for, and recognition of, depression']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1446377', 'cui_str': 'Mental health problem'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0033211', 'cui_str': 'Problem solving'}, {'cui': 'C0221821', 'cui_str': 'Dental bridge'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0033213', 'cui_str': 'Problem'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",140.0,0.114708,"The intervention group demonstrated greater improvement in knowledge about helpful interventions for, and recognition of, depression compared to the control group at follow-up; however, the differences in both measures were small and not statistically significant. ","[{'ForeName': 'Yaw Amankwa', 'Initials': 'YA', 'LastName': 'Arthur', 'Affiliation': 'Discipline of Nursing and Midwifery, Institute for Health and Sport, Victoria University, Melbourne, Australia.'}, {'ForeName': 'Gayelene H', 'Initials': 'GH', 'LastName': 'Boardman', 'Affiliation': 'Discipline of Nursing and Midwifery, Institute for Health and Sport, Victoria University, Melbourne, Australia.'}, {'ForeName': 'Amy J', 'Initials': 'AJ', 'LastName': 'Morgan', 'Affiliation': 'Centre for Mental Health, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Terence V', 'Initials': 'TV', 'LastName': 'McCann', 'Affiliation': 'Turning Point, Eastern Health, Melbourne, Australia.'}]","Journal of mental health (Abingdon, England)",['10.1080/09638237.2020.1793122'] 2591,32755482,Metastatic Pancreatic Cancer: ASCO Guideline Update.,"PURPOSE The aim of this work was to provide an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options after first-line treatment. METHODS ASCO convened an Expert Panel and conducted a systematic review to update guideline recommendations for second-line therapy for metastatic pancreatic cancer. RESULTS One randomized controlled trial of olaparib versus placebo, one report on phase I and II studies of larotrectinib, and one report on phase I and II studies of entrectinib met the inclusion criteria and inform the guideline update. RECOMMENDATIONS New or updated recommendations for germline and somatic testing for microsatellite instability high/mismatch repair deficiency, BRCA mutations, and TRK alterations are provided for all treatment-eligible patients to select patients for recommended therapies, including pembrolizumab, olaparib, larotrectinib, or entrectinib, or potential clinical trials. The Expert Panel continues to endorse the remaining recommendations for second-line chemotherapy, as well as other recommendations related to treatment, follow-up, and palliative care from the 2018 version of this guideline. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.",2020,"The Expert Panel continues to endorse the remaining recommendations for second-line chemotherapy, as well as other recommendations related to treatment, follow-up, and palliative care from the 2018 version of this guideline.","['metastatic pancreatic cancer', 'Metastatic Pancreatic Cancer']","['ASCO guideline', 'olaparib versus placebo']",[],"[{'cui': 'C0346976', 'cui_str': 'Secondary malignant neoplasm of pancreas'}]","[{'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C2316164', 'cui_str': 'olaparib'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.0240255,"The Expert Panel continues to endorse the remaining recommendations for second-line chemotherapy, as well as other recommendations related to treatment, follow-up, and palliative care from the 2018 version of this guideline.","[{'ForeName': 'Davendra P S', 'Initials': 'DPS', 'LastName': 'Sohal', 'Affiliation': 'University of Cincinnati, Cincinnati, OH.'}, {'ForeName': 'Erin B', 'Initials': 'EB', 'LastName': 'Kennedy', 'Affiliation': 'American Society of Clinical Oncology, Alexandria, VA.'}, {'ForeName': 'Pelin', 'Initials': 'P', 'LastName': 'Cinar', 'Affiliation': 'University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Conroy', 'Affiliation': 'Université de Lorraine and Institut de Cancérologie de Lorraine, Lorraine, France.'}, {'ForeName': 'Mehmet S', 'Initials': 'MS', 'LastName': 'Copur', 'Affiliation': 'Morrison Cancer Center, Hastings, NE.'}, {'ForeName': 'Christopher H', 'Initials': 'CH', 'LastName': 'Crane', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Garrido-Laguna', 'Affiliation': 'Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'Michelle W', 'Initials': 'MW', 'LastName': 'Lau', 'Affiliation': 'Phoenix VA Medical Center, Phoenix, AZ.'}, {'ForeName': 'Tyler', 'Initials': 'T', 'LastName': 'Johnson', 'Affiliation': 'Stanford University, Palo Alto, CA.'}, {'ForeName': 'Smitha', 'Initials': 'S', 'LastName': 'Krishnamurthi', 'Affiliation': 'Cleveland Clinic, Cleveland, OH.'}, {'ForeName': 'Cassadie', 'Initials': 'C', 'LastName': 'Moravek', 'Affiliation': 'Pancreatic Cancer Action Network, Manhattan Beach, CA.'}, {'ForeName': 'Eileen M', 'Initials': 'EM', 'LastName': ""O'Reilly"", 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Philip A', 'Initials': 'PA', 'LastName': 'Philip', 'Affiliation': 'Barbara Ann Karmanos Cancer Institute, Farmington Hills, MI.'}, {'ForeName': 'Shubham', 'Initials': 'S', 'LastName': 'Pant', 'Affiliation': 'MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Manish A', 'Initials': 'MA', 'LastName': 'Shah', 'Affiliation': 'New York Presbyterian/Weill Cornell Medical Center, New York, NY.'}, {'ForeName': 'Vaibhav', 'Initials': 'V', 'LastName': 'Sahai', 'Affiliation': 'University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Hope E', 'Initials': 'HE', 'LastName': 'Uronis', 'Affiliation': 'Duke University, Durham, NC.'}, {'ForeName': 'Neeha', 'Initials': 'N', 'LastName': 'Zaidi', 'Affiliation': 'Johns Hopkins Medicine, Baltimore, MD.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Laheru', 'Affiliation': 'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.20.01364'] 2592,32755488,"Can We Eliminate Opioid Medications for Postoperative Pain Control? A Prospective, Surgeon-Blinded, Randomized Controlled Trial in Knee Arthroscopic Surgery.","BACKGROUND Orthopaedic surgeons have a responsibility to develop responsible opioid practices. Growing evidence has helped define an optimal number of opioids to prescribe after surgical procedures, but little evidence-based guidance exists to support specific practice patterns to decrease opioid utilization. HYPOTHESIS After knee arthroscopic surgery with partial meniscectomy, patients who were provided a prescription for opioids and instructed to only fill the prescription if absolutely necessary for pain control would take fewer opioids than patients with opioids automatically included as part of a multimodal approach to pain control prescribed at discharge. STUDY DESIGN Randomized controlled trial; Level of evidence, 2. METHODS Patients undergoing arthroscopic partial meniscectomy were provided multimodal pain control with aspirin, acetaminophen, and naproxen and randomized to receive oxycodone as either included with their multimodal pain medications (group 1) or given an optional prescription to fill (group 2). Patients were contacted at time points up to 1 month after surgery to assess opioid utilization and medication side effects. The mean number of tablets utilized was the primary outcome measure, with a 50% reduction defined as a successful outcome. RESULTS A total of 105 patients were initially enrolled, and 95 (91%; 48 in group 1 and 47 in group 2) successfully completed the study. There was no significant reduction in the number of tablets utilized between groups 1 and 2 (3.5 vs 4.5, respectively; P = .45), days that opioids were required (2.2 vs 3.2, respectively; P = .20), or postoperative pain at any time point. The group with the option to fill their prescription had significantly fewer unused tablets remaining than the group with opioids included as part of the multimodal pain control regimen (75% of potentially prescribed tablets vs 82% of prescribed tablets; P < .001). Overall, 37% of patients did not require any opioids after surgery, and 86% used ≤8 tablets. CONCLUSION Patients required a minimal number of opioids after knee arthroscopic surgery with partial meniscectomy. There was no difference in the number of tablets utilized whether the opioid prescription was included in a multimodal pain control regimen or patients were given an option to fill the prescription. Offering optional opioid prescriptions in the setting of a multimodal approach to pain control can significantly reduce the number of unused opioids circulating in the community. REGISTRATION NCT03876743 (ClinicalTrials.gov identifier).",2020,There was no difference in the number of tablets utilized whether the opioid prescription was included in a multimodal pain control regimen or patients were given an option to fill the prescription.,"['Patients undergoing arthroscopic partial meniscectomy were provided multimodal pain control with', 'After knee arthroscopic surgery with partial meniscectomy, patients who were provided a prescription for opioids and instructed to only fill the prescription if absolutely necessary for pain control would take fewer opioids than patients with opioids automatically included as part of a multimodal approach to pain control prescribed at discharge', 'A total of 105 patients were initially enrolled, and 95 (91%; 48 in group 1 and 47 in group 2) successfully completed the study', 'Patients required a minimal number of opioids after knee arthroscopic surgery with partial meniscectomy', 'Knee Arthroscopic Surgery']","['aspirin, acetaminophen, and naproxen', 'oxycodone as either included with their multimodal pain medications (group 1) or given an optional prescription to fill']","['multimodal pain control regimen', 'number of tablets utilized', 'postoperative pain', 'successful outcome', 'opioid utilization and medication side effects', 'mean number of tablets utilized']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0187901', 'cui_str': 'Chondrectomy of semilunar cartilage of knee'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C4082765', 'cui_str': 'Arthroscopic knee operation'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0205388', 'cui_str': 'Few'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C3871203', 'cui_str': 'At discharge'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0237753', 'cui_str': 'Number'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0027396', 'cui_str': 'Naproxen'}, {'cui': 'C0030049', 'cui_str': 'Oxycodone'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}]","[{'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0041755', 'cui_str': 'Adverse reaction to drug'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",105.0,0.268241,There was no difference in the number of tablets utilized whether the opioid prescription was included in a multimodal pain control regimen or patients were given an option to fill the prescription.,"[{'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Hartwell', 'Affiliation': 'Department of Orthopaedic Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.'}, {'ForeName': 'Ryan S', 'Initials': 'RS', 'LastName': 'Selley', 'Affiliation': 'Department of Orthopaedic Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Terry', 'Affiliation': 'Department of Orthopaedic Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.'}, {'ForeName': 'Vehniah K', 'Initials': 'VK', 'LastName': 'Tjong', 'Affiliation': 'Department of Orthopaedic Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.'}]",The American journal of sports medicine,['10.1177/0363546520941861'] 2593,32755496,A Comparison of Speech Amplification and Personal Communication Devices for Hypophonia.,"Purpose This study compared the performance of three amplification devices hypothesized to improve speech communication in individuals with hypophonia (HP), as well as to identify individuals' device preferences. Method Twenty-two individuals with HP and their primary communication partners participated in a cross-over design study comparing three different speech amplification devices: a wired portable amplifier (Device A), a wireless stationary amplifier (Device B), and a one-way personal communication system (Device C). Participants attended one laboratory visit followed by 1-week trial periods with each device. At the first visit, HP participants completed speech tasks with and without the devices, in quiet and in noise. Following the in-laboratory test period, participants trialed each device at home for approximately 1 week per device. Following completion of the study, participants indicated whether or not they would like to continue using a device. Results Overall, in the presence of noise, all three devices demonstrated significant improvements in speech-to-noise levels and speech intelligibility compared to no device. A clear device hierarchy emerged such that the personal communication device (Device C) was associated with significantly better speech outcomes compared to the other two devices. The majority of participants elected to continue using a device at the completion of the study. Device preferences, however, did not clearly reflect the objective device hierarchy that was found for the objective speech measures. Each of the three devices was selected as a preferred device by at least three participants at the completion of the study. Conclusion Results from this study demonstrated clear differences in device performance in three distinct forms of amplification devices for individuals with HP. Findings suggest that amplification device use may be beneficial for this clinical population and underscore the potential to improve device availability and device selection criteria in future research. Supplemental Material https://doi.org/10.23641/asha.12735875.",2020,A clear device hierarchy emerged such that the personal communication device (Device C) was associated with significantly better speech outcomes compared to the other two devices.,"['individuals with HP', 'Method Twenty-two individuals with HP and their primary communication partners', 'individuals with hypophonia (HP']","['speech amplification devices: a wired portable amplifier (Device A), a wireless stationary amplifier (Device B), and a one-way personal communication system (Device C']","['device performance', 'speech-to-noise levels and speech intelligibility']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0521007', 'cui_str': 'Hypophonia'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}]","[{'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0002684', 'cui_str': 'Electronic Amplifiers'}, {'cui': 'C0439835', 'cui_str': 'Stationary'}, {'cui': 'C0086792', 'cui_str': 'Personal Communication'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0037824', 'cui_str': 'Speech Intelligibility'}]",22.0,0.148665,A clear device hierarchy emerged such that the personal communication device (Device C) was associated with significantly better speech outcomes compared to the other two devices.,"[{'ForeName': 'Thea', 'Initials': 'T', 'LastName': 'Knowles', 'Affiliation': 'Department of Communicative Disorders and Sciences, University at Buffalo, NY.'}, {'ForeName': 'Scott G', 'Initials': 'SG', 'LastName': 'Adams', 'Affiliation': 'School of Communication Sciences and Disorders, Western University, London, Ontario, Canada.'}, {'ForeName': 'Allyson', 'Initials': 'A', 'LastName': 'Page', 'Affiliation': 'School of Communication Sciences and Disorders, Western University, London, Ontario, Canada.'}, {'ForeName': 'Daryn', 'Initials': 'D', 'LastName': 'Cushnie-Sparrow', 'Affiliation': 'School of Communication Sciences and Disorders, Western University, London, Ontario, Canada.'}, {'ForeName': 'Mandar', 'Initials': 'M', 'LastName': 'Jog', 'Affiliation': 'Department of Clinical Neurological Sciences, University Hospital, London, Ontario, Canada.'}]","Journal of speech, language, and hearing research : JSLHR",['10.1044/2020_JSLHR-20-00085'] 2594,32755802,Distance to white matter trajectories is associated with treatment response to internal capsule deep brain stimulation in treatment-refractory depression.,"BACKGROUND Deep brain stimulation (DBS) is an innovative treatment for treatment-refractory depression. DBS is usually targeted at specific anatomical landmarks, with patients responding to DBS in approximately 50% of cases. Attention has recently shifted to white matter tracts to explain DBS response, with initial open-label trials targeting white matter tracts yielding much higher response rates (>70%). OBJECTIVE/HYPOTHESIS Our aim was to associate distance to individual white matter tracts around the stimulation target in the ventral anterior limb of the internal capsule to treatment response. METHODS We performed diffusion magnetic resonance tractography of the superolateral branch of the medial forebrain bundle and the anterior thalamic radiation in fourteen patients that participated in our randomized clinical trial. We combined the tract reconstructions with the postoperative images to identify the DBS leads and estimated the distance between tracts and leads, which we subsequently associated with treatment response. RESULTS Stimulation closer to both tracts was significantly correlated to a larger symptom decrease (r = 0.61, p = 0.02), suggesting that stimulation more proximal to the tracts was beneficial. Biophysical modelling indicated that 37.5% of tracts were even outside the volume of activated tissue. There was no difference in lead placement with respect to anatomical landmarks, which could mean that differences in treatment response were driven by individual differences in white matter anatomy. CONCLUSIONS Our results suggest that deep brain stimulation of the ventral anterior limb of the internal capsule could benefit from targeting white matter bundles. We recommend acquiring diffusion magnetic resonance data for each individual patient.",2020,"RESULTS Stimulation closer to both tracts was significantly correlated to a larger symptom decrease (r = 0.61, p = 0.02), suggesting that stimulation more proximal to the tracts was beneficial.",['fourteen patients that participated in our randomized clinical trial'],"['DBS', 'Deep brain stimulation (DBS', 'diffusion magnetic resonance tractography of the superolateral branch of the medial forebrain bundle and the anterior thalamic radiation']",['lead placement'],"[{'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206034', 'cui_str': 'Trials, Randomized Clinical'}]","[{'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C0028580', 'cui_str': 'Nuclear Magnetic Resonance'}, {'cui': 'C1253959', 'cui_str': 'Branch of'}, {'cui': 'C0025055', 'cui_str': 'Structure of median forebrain bundle'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0039729', 'cui_str': 'Thalamic structure'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}]","[{'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]",,0.085274,"RESULTS Stimulation closer to both tracts was significantly correlated to a larger symptom decrease (r = 0.61, p = 0.02), suggesting that stimulation more proximal to the tracts was beneficial.","[{'ForeName': 'Luka C', 'Initials': 'LC', 'LastName': 'Liebrand', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Meibergdreef 9, Amsterdam, Netherlands; Amsterdam UMC, University of Amsterdam, Department of Biomedical Engineering and Physics, Meibergdreef 9, Amsterdam, Netherlands; Amsterdam Brain and Cognition, Nieuwe Achtergracht 129 B, Amsterdam, Netherlands. Electronic address: L.C.Liebrand@amsterdamumc.nl.'}, {'ForeName': 'Samuel J', 'Initials': 'SJ', 'LastName': 'Natarajan', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Meibergdreef 9, Amsterdam, Netherlands; Amsterdam Brain and Cognition, Nieuwe Achtergracht 129 B, Amsterdam, Netherlands.'}, {'ForeName': 'Matthan W A', 'Initials': 'MWA', 'LastName': 'Caan', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Department of Biomedical Engineering and Physics, Meibergdreef 9, Amsterdam, Netherlands.'}, {'ForeName': 'P Richard', 'Initials': 'PR', 'LastName': 'Schuurman', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Department of Neurosurgery, Meibergdreef 9, Amsterdam, Netherlands.'}, {'ForeName': 'Pepijn', 'Initials': 'P', 'LastName': 'van den Munckhof', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Department of Neurosurgery, Meibergdreef 9, Amsterdam, Netherlands.'}, {'ForeName': 'Bart', 'Initials': 'B', 'LastName': 'de Kwaasteniet', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Meibergdreef 9, Amsterdam, Netherlands; Amsterdam Brain and Cognition, Nieuwe Achtergracht 129 B, Amsterdam, Netherlands.'}, {'ForeName': 'Judy', 'Initials': 'J', 'LastName': 'Luigjes', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Meibergdreef 9, Amsterdam, Netherlands; Amsterdam Brain and Cognition, Nieuwe Achtergracht 129 B, Amsterdam, Netherlands.'}, {'ForeName': 'Isidoor O', 'Initials': 'IO', 'LastName': 'Bergfeld', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Meibergdreef 9, Amsterdam, Netherlands; Amsterdam Brain and Cognition, Nieuwe Achtergracht 129 B, Amsterdam, Netherlands.'}, {'ForeName': 'Damiaan', 'Initials': 'D', 'LastName': 'Denys', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Meibergdreef 9, Amsterdam, Netherlands; Amsterdam Brain and Cognition, Nieuwe Achtergracht 129 B, Amsterdam, Netherlands; Netherlands Institute for Neuroscience, Royal Academy of Arts and Sciences, Meibergdreef 47, Amsterdam, Netherlands.'}, {'ForeName': 'Guido A', 'Initials': 'GA', 'LastName': 'van Wingen', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Meibergdreef 9, Amsterdam, Netherlands; Amsterdam Brain and Cognition, Nieuwe Achtergracht 129 B, Amsterdam, Netherlands.'}]",NeuroImage. Clinical,['10.1016/j.nicl.2020.102363'] 2595,30714205,Complications of nonionizing radiofrequency on divided attention.,"Exposure to electromagnetic fields is considered as a potential hazard for biological systems. The objective of our investigation is the study of probable consequences of radiofrequency electromagnetic fields from Wi-Fi router devices on the short-term memory, and attention's levels. A population consisting of 312 female college students (14 to 17 years old) was elected by cluster random sampling. Teenagers were divided into two groups of control group (Wi-Fi nonusers; n = 138), and experiment group (Wi-Fi users; n = 174). Both groups have been examined using short-term memory tests; selective attention, and also divided attention tests. According to the results, there was no significant difference between using Wi-Fi router devices on levels of selective attentions and short-term memory of the sample students with the control group. However, analyses revealed that there is a significant correlation between the use of Wi-Fi routers and declining levels of divided attentions. Our investigation has demonstrated the adverse consequences of 2.4-2.48 GHz radiofrequency electromagnetic fields of Wi-Fi router devices on divided attention levels of female university students that should be mentioned as a technological risk factor and taken into account by healthcare organizations.",2019,"According to the results, there was no significant difference between using Wi-Fi router devices on levels of selective attentions and short-term memory of the sample students with the control group.","['female university students', '312 female college students (14 to 17 years old']","['radiofrequency electromagnetic fields from Wi-Fi router devices', 'nonionizing radiofrequency']",['levels of selective attentions and short-term memory'],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C4517706', 'cui_str': '312'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0013835', 'cui_str': 'Electromagnetic Fields'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0233421', 'cui_str': 'Selective inattention'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}]",,0.0170142,"According to the results, there was no significant difference between using Wi-Fi router devices on levels of selective attentions and short-term memory of the sample students with the control group.","[{'ForeName': 'Kourosh', 'Initials': 'K', 'LastName': 'Bamdad', 'Affiliation': 'Department of Biology, Payame Noor University (PNU), Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Adel', 'Affiliation': 'Department of Biology, Payame Noor University (PNU), Iran.'}, {'ForeName': 'Masoomeh', 'Initials': 'M', 'LastName': 'Esmaeili', 'Affiliation': 'Department of Psychology, Payame Noor University (PNU), Iran.'}]",Journal of cellular biochemistry,['10.1002/jcb.28343'] 2596,30811685,High Postural Sway Is an Independent Risk Factor for Osteoporotic Fractures but Not for Mortality in Elderly Women.,"The aim of this prospective cohort study was to investigate the independent effect of postural sway on overall fracture and osteoporotic fracture risk after controlling for other established fracture risk factors. As a secondary outcome, mortality was also investigated. The study sample is a stratified random sample of 1568 women born between 1932 and 1941, residing in Kuopio province, eastern Finland. Fracture data were obtained through study questionnaires and verified through hospital records. Mortality data were verified through the National Registry. Using static posturography, postural sway was recorded for 1568 women at the fifth year of follow-up in 1994 through 1997. Mediolateral (ML), anteroposterior (AP), and total sway parameters were used for analysis. Mean follow-up time for any fractures, osteoporotic fractures, and mortality was 10.6, 11.4, and 17.5 years, respectively. After adjustment, subjects in the highest quartile of ML sway (HR, 2.0; 95% CI, 1.5 to 2.8) and total sway (HR, 1.6; 95% CI, 1.2 to 2.2) had a higher risk for any fracture. Osteoporotic fracture risk was also higher in the fourth quartile of ML sway (HR, 1.9; 95% CI, 1.1 to 3.0) and total sway (HR, 1.7; 95% CI, 1.0 to 2.8). The models were adjusted for fracture risk assessment tool risk factors and leg-extension strength. Further, women having both lowest bone density and highest postural sway were at 4.9 (95% CI, 2.6 to 9.5) times higher risk of overall fracture and 11.8 (95% CI, 2.7 to 51.3) times higher risk for osteoporotic fracture in comparison with subjects having highest bone density and lowest postural sway. The association between postural sway and mortality was not significant after adjustment. In conclusion, high postural sway is an independent risk factor for any fractures as well as for osteoporotic fractures. A combination of low bone density and high postural sway poses even higher fracture risk than either factor alone. Postural sway does not predict mortality independently. © 2019 American Society for Bone and Mineral Research.",2019,"Osteoporotic fracture risk was also higher in the fourth quartile of ML sway (HR, 1.9; 95% CI, 1.1 to 3.0) and total sway (HR, 1.7; 95% CI, 1.0 to 2.8).","['Elderly Women', '1568 women born between 1932 and 1941, residing in Kuopio province, eastern Finland', '1568 women at the fifth year of follow-up in 1994 through 1997', '© 2019 American Society for Bone and Mineral Research']","['High Postural Sway', 'postural sway']","['Mortality data', 'bone density and highest postural sway', 'Osteoporotic fracture risk', 'total sway', 'mortality', 'overall fracture and osteoporotic fracture risk', 'postural sway and mortality', 'Mediolateral (ML), anteroposterior (AP), and total sway parameters', 'Mean follow-up time for any fractures, osteoporotic fractures, and mortality']","[{'cui': 'C0524338', 'cui_str': 'Elderly woman'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0016132', 'cui_str': 'Finland'}, {'cui': 'C0205439', 'cui_str': 'Fifth'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0730225', 'cui_str': '1997'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205278', 'cui_str': 'Postural'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0521170', 'cui_str': 'Osteoporotic fracture'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0441992', 'cui_str': 'Mediolateral'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",1568.0,0.0408833,"Osteoporotic fracture risk was also higher in the fourth quartile of ML sway (HR, 1.9; 95% CI, 1.1 to 3.0) and total sway (HR, 1.7; 95% CI, 1.0 to 2.8).","[{'ForeName': 'Sarang Latif', 'Initials': 'SL', 'LastName': 'Qazi', 'Affiliation': 'Kuopio Musculoskeletal Research Unit (KMRU), University of Eastern Finland, Kuopio, Finland.'}, {'ForeName': 'Joonas', 'Initials': 'J', 'LastName': 'Sirola', 'Affiliation': 'Kuopio Musculoskeletal Research Unit (KMRU), University of Eastern Finland, Kuopio, Finland.'}, {'ForeName': 'Heikki', 'Initials': 'H', 'LastName': 'Kröger', 'Affiliation': 'Kuopio Musculoskeletal Research Unit (KMRU), University of Eastern Finland, Kuopio, Finland.'}, {'ForeName': 'Risto', 'Initials': 'R', 'LastName': 'Honkanen', 'Affiliation': 'Kuopio Musculoskeletal Research Unit (KMRU), University of Eastern Finland, Kuopio, Finland.'}, {'ForeName': 'Masoud', 'Initials': 'M', 'LastName': 'Isanejad', 'Affiliation': 'Kuopio Musculoskeletal Research Unit (KMRU), University of Eastern Finland, Kuopio, Finland.'}, {'ForeName': 'Olavi', 'Initials': 'O', 'LastName': 'Airaksinen', 'Affiliation': 'Department of Physical and Rehabilitation Medicine, Kuopio University Hospital, Kuopio, Finland.'}, {'ForeName': 'Toni', 'Initials': 'T', 'LastName': 'Rikkonen', 'Affiliation': 'Kuopio Musculoskeletal Research Unit (KMRU), University of Eastern Finland, Kuopio, Finland.'}]",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,['10.1002/jbmr.3664'] 2597,31228015,Cost-Effectiveness of a Psycho-Educational Intervention Targeting Fear of Cancer Recurrence in People Treated for Early-Stage Melanoma.,"OBJECTIVE This study aimed to evaluate the cost effectiveness of a newly developed psycho-educational intervention to reduce fear of cancer recurrence (FCR) in early-stage melanoma patients. METHODS A within-trial cost-effectiveness and cost-utility analysis was conducted from the Australian health system perspective using data from linked Medicare records. Outcomes included FCR, measured with the severity subscale of the FCR Inventory; quality-adjusted life years (QALYs) measured using the preference-based instrument, Assessment of Quality of Life-8 Dimensions (AQoL-8D) and 12-month survival. An incremental cost-effectiveness ratio (ICER) was calculated for two economic outcomes: (1) cost per additional case of 'high' FCR avoided and (2) cost per QALY gained. Means and 95% CIs around the ICER were generated from non-parametric bootstrapping with 1000 replications. RESULTS A total of 151 trial participants were included in the economic evaluation. The mean cost of the psycho-educational intervention was AU$1614 per participant, including intervention development costs. The ICER per case of high FCR avoided was AU$12,903. The cost-effectiveness acceptability curve demonstrated a 78% probability of the intervention being cost effective relative to the control at a threshold of AU$50,000 per extra person avoiding FCR. The ICER per QALY gained was AU$116,126 and the probability of the intervention being cost effective for this outcome was 36% at a willingness to pay of AU$50,000 per QALY. CONCLUSION The psycho-educational intervention reduced FCR at 12 months for people at high risk of developing another melanoma and may represent good value for money. For the QALY outcome, the psycho-educational intervention is unlikely to be cost effective at standard government willingness-to-pay levels. The trial was prospectively registered in the Australian and New Zealand Clinical Trials Registry (CTRN12613000304730).",2019,"For the QALY outcome, the psycho-educational intervention is unlikely to be cost effective at standard government willingness-to-pay levels.","['People Treated for Early-Stage Melanoma', 'early-stage melanoma patients', 'A total of 151 trial participants were included in the economic evaluation']","['psycho-educational intervention', 'Psycho-Educational Intervention']","[""cost per additional case of 'high' FCR avoided and (2) cost per QALY gained"", 'FCR, measured with the severity subscale of the FCR Inventory; quality-adjusted life years (QALYs) measured using the preference-based instrument, Assessment of Quality of Life-8 Dimensions (AQoL-8D) and 12-month survival', 'mean cost of the psycho-educational intervention', 'fear of cancer recurrence (FCR', 'Cost-Effectiveness', 'cost-effectiveness acceptability', 'cost effectiveness', 'Cancer Recurrence', 'incremental cost-effectiveness ratio (ICER']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0150099', 'cui_str': 'Economic Evaluation'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0233705', 'cui_str': 'Fear of getting cancer'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0281588', 'cui_str': 'Assessment of quality of life'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.162018,"For the QALY outcome, the psycho-educational intervention is unlikely to be cost effective at standard government willingness-to-pay levels.","[{'ForeName': 'Mbathio', 'Initials': 'M', 'LastName': 'Dieng', 'Affiliation': 'NHMRC Clinical Trials Centre, The University of Sydney, Medical Foundation Building, Level 6, 92-94 Parramatta Rd, Camperdown, NSW, 2050, Australia. mbathio.dieng@ctc.usyd.edu.au.'}, {'ForeName': 'Nikita', 'Initials': 'N', 'LastName': 'Khanna', 'Affiliation': 'NHMRC Clinical Trials Centre, The University of Sydney, Medical Foundation Building, Level 6, 92-94 Parramatta Rd, Camperdown, NSW, 2050, Australia.'}, {'ForeName': 'Nadine A', 'Initials': 'NA', 'LastName': 'Kasparian', 'Affiliation': ""School of Women's and Children's Health, Faculty of Medicine, The University of New South Wales, Kensington, Sydney, NSW, Australia.""}, {'ForeName': 'Daniel S J', 'Initials': 'DSJ', 'LastName': 'Costa', 'Affiliation': 'Pain Management Research Institute, Royal North Shore Hospital, The University of Sydney, Camperdown, Sydney, NSW, Australia.'}, {'ForeName': 'Phyllis N', 'Initials': 'PN', 'LastName': 'Butow', 'Affiliation': 'Psycho-oncology Co-operative Research Group, School of Psychology, The University of Sydney, Camperdown, Sydney, NSW, Australia.'}, {'ForeName': 'Scott W', 'Initials': 'SW', 'LastName': 'Menzies', 'Affiliation': 'Sydney Melanoma Diagnostic Centre, Sydney Cancer Centre, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Sydney, NSW, 2050, Australia.'}, {'ForeName': 'Graham J', 'Initials': 'GJ', 'LastName': 'Mann', 'Affiliation': 'Melanoma Institute Australia, and Centre for Cancer Research, Westmead Institute for Medical Research, The University of Sydney, Camperdown, Sydney, NSW, Australia.'}, {'ForeName': 'Anne E', 'Initials': 'AE', 'LastName': 'Cust', 'Affiliation': 'Cancer Epidemiology and Prevention Research and Melanoma Institute Australia, Sydney School of Public Health, The University of Sydney, Camperdown, Sydney, NSW, Australia.'}, {'ForeName': 'Rachael L', 'Initials': 'RL', 'LastName': 'Morton', 'Affiliation': 'NHMRC Clinical Trials Centre and Melanoma Institute Australia, The University of Sydney, Camperdown, Sydney, NSW, Australia.'}]",Applied health economics and health policy,['10.1007/s40258-019-00483-6'] 2598,32757824,Preventing Type 2 Diabetes Among Midlife Women: A Feasibility Study Comparing a Combined Sleep and Lifestyle Intervention With a Standard Lifestyle Intervention.,"PURPOSE The purpose of this pilot study was to evaluate the feasibility, acceptability, and initial efficacy of adding a sleep extension intervention to a well-established diabetes prevention intervention among midlife women with short sleep duration at risk for type 2 diabetes. METHODS For this 2-group comparative design, 26 women with prediabetes or metabolic syndrome and sleep duration <7 hours were recruited from the community to participate in an 8-session diet and physical activity lifestyle intervention alone (L-alone) or L-alone plus a behavioral sleep intervention (L+Sleep). Body mass index (BMI), waist circumference, and other outcomes were compared at baseline and 3 and 6 months using analysis of covariance. RESULTS Incorporating a sleep intervention into lifestyle changes proved feasible and acceptable to midlife women at risk for type 2 diabetes. Significant decreases in BMI and waist circumference over time were observed in both groups, but comparative efficacy of L+Sleep versus L-alone yielded few group differences. Exploratory analysis indicated that women who increased their sleep to ≥7 h/night, regardless of group assignment, lost more weight than women who continued to report sleeping <7 h/night. CONCLUSION Adding sleep extension to a lifestyle change intervention proved feasible and satisfactory to participants, but initial efficacy did not differentiate the 2 intervention groups.",2020,"Adding sleep extension to a lifestyle change intervention proved feasible and satisfactory to participants, but initial efficacy did not differentiate the 2 intervention groups.","['midlife women at risk for type 2 diabetes', 'midlife women with short sleep duration at risk for type 2 diabetes', 'Midlife Women', '26 women with prediabetes or metabolic syndrome and sleep duration <7 hours were recruited from the community to participate in an']","['8-session diet and physical activity lifestyle intervention alone (L-alone) or L-alone plus a behavioral sleep intervention (L+Sleep', 'lifestyle change intervention', 'sleep intervention', 'Combined Sleep and Lifestyle Intervention', 'sleep extension intervention to a well-established diabetes prevention intervention', 'L+Sleep']","['feasibility, acceptability, and initial efficacy', 'BMI and waist circumference', 'Body mass index (BMI), waist circumference, and other outcomes']","[{'cui': 'C0026062', 'cui_str': 'Middle-age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0424574', 'cui_str': 'Duration of sleep'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",26.0,0.0198206,"Adding sleep extension to a lifestyle change intervention proved feasible and satisfactory to participants, but initial efficacy did not differentiate the 2 intervention groups.","[{'ForeName': 'Catherine A', 'Initials': 'CA', 'LastName': 'Chesla', 'Affiliation': 'Department of Family Health Care Nursing, University of California, San Francisco, California.'}, {'ForeName': 'Caryl', 'Initials': 'C', 'LastName': 'Gay', 'Affiliation': 'Department of Family Health Care Nursing, University of California, San Francisco, California.'}, {'ForeName': 'Laurie', 'Initials': 'L', 'LastName': 'Bauer', 'Affiliation': 'Department of Social and Behavioral Sciences, University of California, San Francisco, California.'}, {'ForeName': 'Melinda Sarmiento', 'Initials': 'MS', 'LastName': 'Bender', 'Affiliation': 'Department of Family Health Care Nursing, University of California, San Francisco, California.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Lee', 'Affiliation': 'Department of Family Health Care Nursing, University of California, San Francisco, California.'}]",The Diabetes educator,['10.1177/0145721720943128'] 2599,32757825,"Strong Men, Strong Communities: Design of a Randomized Controlled Trial of a Diabetes Prevention Intervention for American Indian and Alaska Native Men.","Type 2 diabetes is a serious global epidemic that disproportionately affects disadvantaged populations. American Indians and Alaska Natives (AIs/ANs) have the highest rates of diabetes in the nation with a prevalence of 14.7% in 2018, more than twice that of non-Hispanic Whites. AI/AN men have the highest prevalence of diagnosed type 2 diabetes (14.5%) compared to non-Hispanic Black (11.4%), non-Hispanic Asian (10.0%), and non-Hispanic White (8.6%) men. Several landmark clinical trials have shown that lifestyle interventions can effectively prevent or delay the onset of diabetes among those at risk, including in AIs/ANs. Despite positive outcomes for AIs/ANs in these studies, very few were men. To date, there have been no concerted efforts to recruit and retain AI/AN men in interventions that promote weight loss and healthy lifestyles to prevent diabetes, and they remain underrepresented in these types of studies. This article describes the design and methods of the first randomized controlled trial of a diabetes prevention program with a study sample comprised entirely of AI/AN men. Research to date has demonstrated suboptimal patterns of recruitment and retention of AI/AN men, resulting in their virtual absence in health and intervention research. Effective methods to recruit and retain AI/AN men, and potential benefit gained from participation in diabetes prevention research, are unknown for this population who experience a high prevalence of type 2 diabetes. The study design presented in this article offers promising insights to help remedy these important shortcomings in the science of recruitment and retention of AI/AN men in research.",2020,"AN men have the highest prevalence of diagnosed type 2 diabetes (14.5%) compared to non-Hispanic Black (11.4%), non-Hispanic Asian (10.0%), and non-Hispanic White (8.6%) men.","['AN men have the highest prevalence of diagnosed type 2 diabetes (14.5%) compared to non-Hispanic Black (11.4%), non-Hispanic Asian (10.0%), and non-Hispanic White (8.6%) men', 'diabetes prevention program with a study sample comprised entirely of AI/AN men', 'American Indian and Alaska Native Men']",['Diabetes Prevention Intervention'],[],"[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C4517533', 'cui_str': '11.4'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C4517879', 'cui_str': '8.6'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0682125', 'cui_str': 'Native Alaskians'}]","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.0537682,"AN men have the highest prevalence of diagnosed type 2 diabetes (14.5%) compared to non-Hispanic Black (11.4%), non-Hispanic Asian (10.0%), and non-Hispanic White (8.6%) men.","[{'ForeName': ""Ka'imi"", 'Initials': 'K', 'LastName': 'Sinclair', 'Affiliation': 'College of Nursing, Initiative for Research and Education to Advance Community Health (IREACH), Washington State University, Seattle, WA, USA.'}, {'ForeName': 'Cara', 'Initials': 'C', 'LastName': 'Carty', 'Affiliation': 'Initiative for Research and Education to Advance Community Health (IREACH), Washington State University, Seattle, WA, USA.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Gonzales', 'Affiliation': 'Portland State University-Oregon Health Sciences University Joint School of Public Health, Portland, OR, USA.'}, {'ForeName': 'Cassandra', 'Initials': 'C', 'LastName': 'Nikolaus', 'Affiliation': 'Initiative for Research and Education to Advance Community Health (IREACH), Washington State University, Seattle, WA, USA.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Gillespie', 'Affiliation': 'Initiative for Research and Education to Advance Community Health (IREACH), Washington State University, Seattle, WA, USA.'}, {'ForeName': 'Dedra', 'Initials': 'D', 'LastName': 'Buchwald', 'Affiliation': 'Initiative for Research and Education to Advance Community Health (IREACH), Washington State University, Seattle, WA, USA.'}]",American journal of men's health,['10.1177/1557988320945457'] 2600,32757835,OPT-In For Life: A Mobile Technology-Based Intervention to Improve HIV Care Continuum for Young Adults Living With HIV.,"Young adults living with HIV (YALH) have lower rates of retention in care and HIV viral suppression. Multiple barriers exist to engage YALH in care. We developed and implemented a multifaceted, mobile application-based intervention, ""OPT-In for Life,"" by targeting YALH to encourage retention in care and eventually viral suppression. The app integrated multiple user-friendly features for YALH to manage their HIV care, including a two-way secure messaging function, HIV-related laboratory results, and appointment or medication reminders. We recruited 92 YALH who were 18 to 34 years old and were newly diagnosed with HIV, had a history of falling out of care, or had a detectable HIV viral load into this intervention. Study participants used the app to manage their HIV care and to communicate and interact with their HIV care team. During the intervention period, the retention rate among our study participants increased from 41.3% at baseline to 78.6% at 6-month follow-up, maintained at 12-month follow-up (79.8%), and slightly decreased to 73.4% at 18-month follow-up but it was still significantly higher than the baseline retention rate ( p < .0001). The viral suppression rate (HIV RNA <200 copies/ml) increased from 64.1% at baseline to about 85% at 6-month and at 12-month follow-up and reached 91.4% at 18-month ( p = .0002) among participants who were retained in care. Our study demonstrated using a HIPAA-compliant mobile application as an effective intervention to engage YALH in care. This mobile technology-based intervention can be incorporated into routine clinical practice to improve HIV care continuum.",2020,The viral suppression rate (HIV RNA <200 copies/ml) increased from 64.1% at baseline to about 85% at 6-month and at 12-month follow-up and reached 91.4% at 18-month ( p = .0002) among participants who were retained in care.,"['Young adults living with HIV (YALH', 'We recruited 92 YALH who were 18 to 34 years old and were newly diagnosed with HIV, had a history of falling out of care, or had a detectable HIV viral load into this intervention', 'Young Adults Living With HIV', 'Study participants used the app to manage their HIV care and to communicate and interact with their HIV care team']",['Mobile Technology-Based Intervention'],"['retention rate', 'viral suppression rate']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C1561668', 'cui_str': 'History of fall'}, {'cui': 'C0439787', 'cui_str': 'Out'}, {'cui': 'C1168369', 'cui_str': 'HIV viral load'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}]",,0.0297418,The viral suppression rate (HIV RNA <200 copies/ml) increased from 64.1% at baseline to about 85% at 6-month and at 12-month follow-up and reached 91.4% at 18-month ( p = .0002) among participants who were retained in care.,"[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'Zurlo', 'Affiliation': 'Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Du', 'Affiliation': 'Pennsylvania State University, Hershey, PA, USA.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Haynos', 'Affiliation': 'Pennsylvania State University, Hershey, PA, USA.'}, {'ForeName': 'Verbenia', 'Initials': 'V', 'LastName': 'Collins', 'Affiliation': 'Pennsylvania State University, Hershey, PA, USA.'}, {'ForeName': 'Tarek', 'Initials': 'T', 'LastName': 'Eshak', 'Affiliation': 'Pennsylvania State University, Hershey, PA, USA.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Whitener', 'Affiliation': 'Pennsylvania State University, Hershey, PA, USA.'}]",Health promotion practice,['10.1177/1524839920936247'] 2601,32757870,Healing of erosions in rheumatoid arthritis remains elusive: results with 24 months of the anabolic agent teriparatide.,"OBJECTIVE Erosion healing in rheumatoid arthritis (RA) is difficult to demonstrate. This extension study aimed to determine whether 2 years of teriparatide (TPTD) produces erosion healing. METHOD Subjects in a previous 12 month randomized controlled trial of TPTD in RA were invited to receive 12 additional months of open-label TPTD. Eleven of the 24 original subjects were enrolled in the extension study, six of whom received TPTD in the final 12 months only. Subjects receiving 24 months of TPTD were assessed for reduction in erosion volume from baseline using computed tomography. We also compared erosion volumes between 12 and 24 months of TPTD. Large erosions in subjects receiving TPTD for 24 months were examined for volume change. RESULTS In the six patients who received 24 months of TPTD, there was no significant change in erosion volume at the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints compared with baseline. The six subjects who received 24 months of TPTD had similar changes in erosion volume to the five who received 12 months of TPTD, in MCP (p = 0.17) and PIP (p = 0.63) joints. Assessment of large erosions in those receiving TPTD for 24 months showed no evidence of erosion healing. CONCLUSION While this extension study was too small to be conclusive, we observed no evidence of reduction in erosion volume with the addition of TPTD for 24 months in subjects with RA in whom disease activity was controlled on a tumour necrosis factor inhibitor. This is consistent with our negative findings at 12 months.",2020,"The six subjects who received 24 months of TPTD had similar changes in erosion volume to the five who received 12 months of TPTD, in MCP (p = 0.17) and PIP (p = 0.63) joints.","['Subjects in a previous 12\xa0month randomized controlled trial of TPTD in RA', 'rheumatoid arthritis (RA', 'Eleven of the 24 original subjects were enrolled in the extension study, six of whom received TPTD in the final 12\xa0months only']","['TPTD', 'open-label TPTD', 'teriparatide (TPTD', 'anabolic agent teriparatide']","['erosion volumes', 'Healing of erosions', 'erosion volume', 'erosion volume at the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints', 'erosion healing', 'Large erosions']","[{'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0070093', 'cui_str': 'Teriparatide'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0205313', 'cui_str': 'Original'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}]","[{'cui': 'C0070093', 'cui_str': 'Teriparatide'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C1258800', 'cui_str': 'Anabolic Agents'}]","[{'cui': 'C0333307', 'cui_str': 'Superficial ulcer'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0549177', 'cui_str': 'Large'}]",24.0,0.0279013,"The six subjects who received 24 months of TPTD had similar changes in erosion volume to the five who received 12 months of TPTD, in MCP (p = 0.17) and PIP (p = 0.63) joints.","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Duryea', 'Affiliation': ""Department of Radiology, Brigham and Women's Hospital , Boston, MA, USA.""}, {'ForeName': 'E M', 'Initials': 'EM', 'LastName': 'Gravallese', 'Affiliation': 'Division of Rheumatology, University of Massachusetts Medical School , Worcester, MA, USA.'}, {'ForeName': 'J R', 'Initials': 'JR', 'LastName': 'Wortman', 'Affiliation': ""Department of Radiology, Brigham and Women's Hospital , Boston, MA, USA.""}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Xu', 'Affiliation': ""Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital , Boston, MA, USA.""}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Lu', 'Affiliation': ""Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital , Boston, MA, USA.""}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Kay', 'Affiliation': 'Division of Rheumatology, University of Massachusetts Medical School , Worcester, MA, USA.'}, {'ForeName': 'D H', 'Initials': 'DH', 'LastName': 'Solomon', 'Affiliation': ""Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital , Boston, MA, USA.""}]",Scandinavian journal of rheumatology,['10.1080/03009742.2020.1772362'] 2602,32758135,Outpatient psychotherapy for home-living vulnerable older adults with depression: study protocol of the PSY-CARE trial.,"BACKGROUND There is a need to improve psychotherapeutic approaches to treatment for vulnerable older adults with depression in terms of both clinical practice and health care supply. Against this background, PSY-CARE is testing the feasibility and effectiveness of outpatient psychotherapy for home-living older adults in need of care with depression in Berlin, Germany, and neighboring suburban areas. METHODS In a two-arm single-center pragmatic randomized controlled trial (RCT), manual-guided outpatient psychotherapy will be compared to brief psychosocial counseling. The study population will be compromised of older adults with clinically significant depressive symptoms who have a long-term care grade, as assessed by the German compulsory state nursing care insurance. In the intervention group, individual cognitive-behavioral psychotherapy tailored to the specific needs of this population will be offered by residential psychotherapists as part of the regular healthcare service. In the active control group, participants will receive individual psychosocial telephone counselling and a self-help guide. The planned sample size is N = 130 (n = 65 participants per group). The reduction of depressive symptoms (primary outcome) as well as the maintaining of activities of daily living, quality of life, and functioning will be assessed with questionnaires provided at baseline, after the end of the intervention and after three months. Feasibility and process evaluation will be conducted qualitatively based on documentation and interviews with psychotherapists, gatekeepers and the participants. DISCUSSION PSY-CARE investigates the potentials and limitations of providing outpatient psychotherapeutic treatment meeting the demands of vulnerable home-living older adults with depression under the real conditions of the health care system. The study will provide practical implications to improve access to and quality of outpatient psychotherapy for this poorly supplied population. TRIAL REGISTRATION The trial is registered at ISRCTN55646265 ; February 15, 2019.",2020,"The reduction of depressive symptoms (primary outcome) as well as the maintaining of activities of daily living, quality of life, and functioning will be assessed with questionnaires provided at baseline, after the end of the intervention and after three months.","['home-living older adults in need of care with depression in Berlin, Germany, and neighboring suburban areas', 'vulnerable older adults with depression', 'older adults with clinically significant depressive symptoms who have a long-term care grade, as assessed by the German compulsory state nursing care insurance', 'home-living vulnerable older adults with depression']","['individual psychosocial telephone counselling and a self-help guide', 'manual-guided outpatient psychotherapy', 'outpatient psychotherapy', 'Outpatient psychotherapy', 'individual cognitive-behavioral psychotherapy']","['maintaining of activities of daily living, quality of life, and functioning will be assessed with questionnaires', 'reduction of depressive symptoms']","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0005125', 'cui_str': 'Berlin'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C1553702', 'cui_str': 'Neighbor'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0028678', 'cui_str': 'nursing'}, {'cui': 'C0021672', 'cui_str': 'Insurance'}]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1283220', 'cui_str': 'Guide help'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}]","[{'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",,0.119432,"The reduction of depressive symptoms (primary outcome) as well as the maintaining of activities of daily living, quality of life, and functioning will be assessed with questionnaires provided at baseline, after the end of the intervention and after three months.","[{'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Gellert', 'Affiliation': 'Institute for Medical Sociology and Rehabilitation Science, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany. paul.gellert@charite.de.'}, {'ForeName': 'Ann-Kristin', 'Initials': 'AK', 'LastName': 'Beyer', 'Affiliation': 'Institute for Medical Sociology and Rehabilitation Science, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Tegeler', 'Affiliation': 'MSB Medical School Berlin, Department of Psychology, Rüdesheimer Str. 50, 14197, Berlin, Germany.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Vathke', 'Affiliation': 'MSB Medical School Berlin, Department of Psychology, Rüdesheimer Str. 50, 14197, Berlin, Germany.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Nordheim', 'Affiliation': 'Institute for Medical Sociology and Rehabilitation Science, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.'}, {'ForeName': 'Adelheid', 'Initials': 'A', 'LastName': 'Kuhlmey', 'Affiliation': 'Institute for Medical Sociology and Rehabilitation Science, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.'}, {'ForeName': 'Eva-Marie', 'Initials': 'EM', 'LastName': 'Kessler', 'Affiliation': 'MSB Medical School Berlin, Department of Psychology, Rüdesheimer Str. 50, 14197, Berlin, Germany.'}]",BMC geriatrics,['10.1186/s12877-020-01661-1'] 2603,32758147,Implementation of a complex intervention to improve participation in older people with joint contractures living in nursing homes: a process evaluation of a cluster-randomised pilot trial.,"BACKGROUND Joint contractures in frail older people are associated with serious restrictions in participation. We developed the Participation Enabling CAre in Nursing (PECAN) intervention, a complex intervention to enable nurses to promote participation in nursing home residents with joint contractures. The aim of this study was to examine the feasibility of the implementation strategy and to identify enablers and barriers for a successful implementation. METHODS The implementation of PECAN was investigated in a 6-month pilot cluster-randomised controlled trial (c-RCT). As a key component of the implementation strategy, nominated nurses were trained as facilitators in a one-day workshop and supported by peer-mentoring (visit, telephone counselling). A mixed-methods approach was conducted in conjunction with the pilot trial and guided by a framework for process evaluations of c-RCTs. Data were collected using standardised questionnaires (nursing staff), documentation forms, problem-centred qualitative interviews (facilitators, therapists, social workers, relatives, peer-mentors), and a group discussion (facilitators). A set of predefined criteria on the nursing home level was examined. Quantitative data were analysed using descriptive statistics. Qualitative data were analysed using directed content analysis. RESULTS Seven nursing homes (n = 4 intervention groups, n = 3 control groups) in two regions of Germany took part in the study. Facilitators responded well to the qualification measures (workshop participation: 14/14; workshop rating: ""good""; peer-mentor visit participation: 10/14). The usage of peer-mentoring via telephone varied (one to seven contacts per nursing home). Our implementation strategy was not successful in connection with supplying the intervention to all the nurses. The clear commitment of the entire nursing home and the respect for the expertise of different healthcare professionals were emphasised as enablers, whereas a lack of impact on organisational conditions and routines and a lack of time and staff competence were mentioned as barriers. CONCLUSION The PECAN intervention was delivered as planned to the facilitators but was unable to produce comprehensive changes in the nursing homes and subsequently for the residents. Strategies to systematically include the management and the nursing team from the beginning are needed to support the facilitators during implementation in the main trial. TRIAL REGISTRATION German clinical trials register, DRKS00010037 . Registered 12 February 2016.",2020,The PECAN intervention was delivered as planned to the facilitators but was unable to produce comprehensive changes in the nursing homes and subsequently for the residents.,"['frail older people', 'older people with joint contractures living in nursing homes', 'nursing home residents with joint contractures']","['Participation Enabling CAre in Nursing (PECAN) intervention', 'complex intervention']",[],"[{'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009918', 'cui_str': 'Contracture of joint'}, {'cui': 'C0425205', 'cui_str': 'Lives in a nursing home'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}]","[{'cui': 'C0562342', 'cui_str': 'Empowered'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}]",[],,0.0477284,The PECAN intervention was delivered as planned to the facilitators but was unable to produce comprehensive changes in the nursing homes and subsequently for the residents.,"[{'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Klingshirn', 'Affiliation': 'Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-Universität München, Marchioninistr 17, 81377, Munich, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Müller', 'Affiliation': 'Faculty of Applied Health and Social Sciences, Rosenheim Technical University of Applied Sciences, Hochschulstraße 1, 83024, Rosenheim, Germany.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Beutner', 'Affiliation': 'Institute for Health and Nursing Sciences, Medical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Straße 8, 06112, Halle (Saale), Germany.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Hirt', 'Affiliation': 'Institute for Health and Nursing Sciences, Medical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Straße 8, 06112, Halle (Saale), Germany.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Strobl', 'Affiliation': 'Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-Universität München, Marchioninistr 17, 81377, Munich, Germany.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Grill', 'Affiliation': 'Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-Universität München, Marchioninistr 17, 81377, Munich, Germany.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Meyer', 'Affiliation': 'Institute for Health and Nursing Sciences, Medical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Straße 8, 06112, Halle (Saale), Germany.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Saal', 'Affiliation': 'Institute for Health and Nursing Sciences, Medical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Straße 8, 06112, Halle (Saale), Germany. susanne.saal@uk-halle.de.'}]",BMC geriatrics,['10.1186/s12877-020-01655-z'] 2604,32758152,A randomized crossover trial to assess therapeutic efficacy and cost reduction of acid ursodeoxycholic manufactured by the university hospital for the treatment of primary biliary cholangitis.,"BACKGROUND Health care costs are growing faster than the rest of the global economy, according to the World Health Organization (WHO). Countries' health expenditures include paying for general medicine, diagnostic procedures, hospitalizations and surgeries, as well as medications and prescribed treatment. Primary biliary cholangitis (PBC) is a rare autoimmune liver disease and the first line available treatment is ursodeoxycholic acid (UDCA), however, direct and indirect treatment costs are expensive. Main aim of this trial was to assess if the therapeutic efficacy of UDCA manufactured by the university hospital is equivalent to that of standard UDCA and treatment cost reduction in patients with PBC. METHODS It is a prospective, interventional, randomized, and crossover study in patients diagnosed with PBC. UDCA 300 mg tablets and capsules were developed and manufactured by the university hospital. Thirty patients under treatment with standard UDCA, in stable doses were randomized in sequence A and B, 15 patients in each arm. The groups were treated for 12 weeks and after, the UDCA formulation was changed, following for another 12 weeks of continuous therapy (tablets and capsules / capsules and tablets). Laboratory tests were performed at time T0 (beginning of treatment), T1 (at the 12 week-therapy, before the crossing-over) and T2 (end of treatment). The evaluation was done by comparing the hepatic parameters ALP, GGT, ALT, AST and total bilirubin, also considering the adverse events. The comparison of costs was based on price of the manufactured UDCA and standard UDCA price of the hospital. RESULTS Hospital reduced 66.1% the PBC treatment costs using manufactured UDCA. There were no differences in the biochemical parameters between sequence (A and B) and tablets or capsules of UDCA formulations applied in the treatment of PBC. CONCLUSIONS The study showed that there was no significant difference between manufactured UDCA (capsule and tablet) and standard UDCA. Hospital reduced the PBC treatment costs using the manufactured UDCA by the university hospital. TRIAL REGISTRATION ClinicalTrials.gov: NCT03489889 retrospectively registered on January 12th, 2018; Ethics Committee approved the study (ID: 1.790.088) on October 25th, 2016.",2020,"There were no differences in the biochemical parameters between sequence (A and B) and tablets or capsules of UDCA formulations applied in the treatment of PBC. ","['Primary biliary cholangitis (PBC', 'primary biliary cholangitis', 'Thirty patients under treatment with', 'patients diagnosed with PBC', 'patients with PBC']","['acid ursodeoxycholic manufactured', 'UDCA', 'ursodeoxycholic acid (UDCA', 'standard UDCA']","['hepatic parameters ALP, GGT, ALT, AST and total bilirubin', 'manufactured UDCA (capsule and tablet) and standard UDCA']","[{'cui': 'C0008312', 'cui_str': 'Primary biliary cholangitis'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0042105', 'cui_str': 'ursodeoxycholic acid'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0017040', 'cui_str': 'Gamma-glutamyltransferase'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin'}, {'cui': 'C0042105', 'cui_str': 'ursodeoxycholic acid'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0038137', 'cui_str': 'standards'}]",30.0,0.0305846,"There were no differences in the biochemical parameters between sequence (A and B) and tablets or capsules of UDCA formulations applied in the treatment of PBC. ","[{'ForeName': 'Larissa Akeme', 'Initials': 'LA', 'LastName': 'Nakano', 'Affiliation': 'Department of Gastroenterology, Division of Clinical Gastroenterology and Hepatology, Hospital das Clinicas, University of São Paulo School of Medicine, Av. Dr. Enéas Carvalho de Aguiar, 255, ICHC, 9th Floor, office 9159, São Paulo, SP 05403-000, Brazil.'}, {'ForeName': 'Eduardo Luiz Rachid', 'Initials': 'ELR', 'LastName': 'Cançado', 'Affiliation': 'Department of Gastroenterology, Division of Clinical Gastroenterology and Hepatology, Hospital das Clinicas, University of São Paulo School of Medicine, Av. Dr. Enéas Carvalho de Aguiar, 255, ICHC, 9th Floor, office 9159, São Paulo, SP 05403-000, Brazil.'}, {'ForeName': 'Cleuber Esteves', 'Initials': 'CE', 'LastName': 'Chaves', 'Affiliation': 'Division of Pharmacy of Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, Brazil.'}, {'ForeName': 'Maria Cristina Vaz', 'Initials': 'MCV', 'LastName': 'Madeira', 'Affiliation': 'Division of Pharmacy of Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, Brazil.'}, {'ForeName': 'Jéssica Toshie', 'Initials': 'JT', 'LastName': 'Katayose', 'Affiliation': 'Division of Pharmacy of Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, Brazil.'}, {'ForeName': 'Mariana Akemi', 'Initials': 'MA', 'LastName': 'Nabeshima', 'Affiliation': 'Department of Gastroenterology, Division of Clinical Gastroenterology and Hepatology, Hospital das Clinicas, University of São Paulo School of Medicine, Av. Dr. Enéas Carvalho de Aguiar, 255, ICHC, 9th Floor, office 9159, São Paulo, SP 05403-000, Brazil.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Fossaluza', 'Affiliation': 'Institute of Mathematics and Statistics, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Gabriela Guimarães', 'Initials': 'GG', 'LastName': 'Uhrigshardt', 'Affiliation': 'Institute of Mathematics and Statistics, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Liting', 'Affiliation': 'Institute of Mathematics and Statistics, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Vanusa Barbosa', 'Initials': 'VB', 'LastName': 'Pinto', 'Affiliation': 'Division of Pharmacy of Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, Brazil.'}, {'ForeName': 'Flair José', 'Initials': 'FJ', 'LastName': 'Carrilho', 'Affiliation': 'Department of Gastroenterology, Division of Clinical Gastroenterology and Hepatology, Hospital das Clinicas, University of São Paulo School of Medicine, Av. Dr. Enéas Carvalho de Aguiar, 255, ICHC, 9th Floor, office 9159, São Paulo, SP 05403-000, Brazil.'}, {'ForeName': 'Suzane Kioko', 'Initials': 'SK', 'LastName': 'Ono', 'Affiliation': 'Department of Gastroenterology, Division of Clinical Gastroenterology and Hepatology, Hospital das Clinicas, University of São Paulo School of Medicine, Av. Dr. Enéas Carvalho de Aguiar, 255, ICHC, 9th Floor, office 9159, São Paulo, SP 05403-000, Brazil. suzane.ono@fm.usp.br.'}]",BMC gastroenterology,['10.1186/s12876-020-01399-5'] 2605,32758173,Prophylactic endovascular balloon occlusion of the aorta in cases of placenta accreta spectrum during caesarean section: points from the anaesthesiologist's perspective.,"BACKGROUND The placenta accreta spectrum (PAS) is a severe complication of pregnancy and is associated with massive haemorrhage, hysterectomy, and even perinatal maternal-foetal death. Prophylactic abdominal aortic balloon occlusion (PAABO) is a novel and efficient therapy for these patients. The aim of this study was to investigate the benefits, potential risks, and characteristics of anaesthesia management. METHODS A total of 48 parturients with PAS were enrolled and divided into two groups. Group A (n = 25) received PAABO, and Group B (n = 23) underwent a normal operative procedure. The characteristics of the general parameters, anaesthesia, and operative procedure were noted. Data on vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) during the operation were recorded. Before and after the procedure, hepatic and renal function and lactate dehydrogenase (LDH) were also measured. RESULTS The characteristics of the groups were comparable. PAABO significantly reduced estimated blood loss, which was ≥ 1000 ml. Drastic fluctuations in SBP, DBP and HR were observed during inflation and deflation in Group B. After the operation, increased LDH and glutamic oxaloacetic transaminase (GOT) were observed in both groups, and increased glutamic-pyruvic transaminase (GTP) was observed in Group B. CONCLUSIONS PAABO reduced perioperative blood loss and the risk of hysterectomy among parturients with PAS. Sophisticated anaesthetic management should be implemented to prevent or reduce perioperative complications and address internal disorders that are caused by massive blood loss.",2020,"After the operation, increased LDH and glutamic oxaloacetic transaminase (GOT) were observed in both groups, and increased glutamic-pyruvic transaminase (GTP) was observed in Group B. CONCLUSIONS PAABO reduced perioperative blood loss and the risk of hysterectomy among parturients with PAS.","['48 parturients with PAS', 'parturients with PAS']","['normal operative procedure', 'Prophylactic abdominal aortic balloon occlusion (PAABO', 'Prophylactic endovascular balloon occlusion']","['glutamic-pyruvic transaminase (GTP', 'systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR', 'perioperative blood loss', 'blood loss', 'LDH and glutamic oxaloacetic transaminase (GOT', 'hepatic and renal function and lactate dehydrogenase (LDH', 'Drastic fluctuations in SBP, DBP and HR']","[{'cui': 'C0032044', 'cui_str': 'Placenta accreta'}]","[{'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0003483', 'cui_str': 'Aortic'}, {'cui': 'C0887842', 'cui_str': 'Balloon Occlusion'}]","[{'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0022917', 'cui_str': 'Lactate dehydrogenase'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0231239', 'cui_str': 'Fluctuation'}]",48.0,0.0659271,"After the operation, increased LDH and glutamic oxaloacetic transaminase (GOT) were observed in both groups, and increased glutamic-pyruvic transaminase (GTP) was observed in Group B. CONCLUSIONS PAABO reduced perioperative blood loss and the risk of hysterectomy among parturients with PAS.","[{'ForeName': 'Haijuan', 'Initials': 'H', 'LastName': 'Zhu', 'Affiliation': 'Department of Anaesthesiology, Anhui Women and Child Health Care Hospital, 230601, Hefei, China.'}, {'ForeName': 'Shengyou', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Department of Anaesthesiology, Anhui Women and Child Health Care Hospital, 230601, Hefei, China.'}, {'ForeName': 'Jingfa', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': 'Department of Anaesthesiology, Anhui Women and Child Health Care Hospital, 230601, Hefei, China.'}, {'ForeName': 'Lamei', 'Initials': 'L', 'LastName': 'Yao', 'Affiliation': 'Department of Anaesthesiology, Anhui Women and Child Health Care Hospital, 230601, Hefei, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Anaesthesiology, Anhui Women and Child Health Care Hospital, 230601, Hefei, China.'}, {'ForeName': 'Hongbo', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Department of Obstetrics and Gynecology, Anhui Women and Child Health Care Hospital, 230601, Hefei, China.'}, {'ForeName': 'Xiangdong', 'Initials': 'X', 'LastName': 'Fang', 'Affiliation': 'Department of Anaesthesiology, Anhui Women and Child Health Care Hospital, 230601, Hefei, China. 35880762@qq.com.'}]",BMC pregnancy and childbirth,['10.1186/s12884-020-03136-y'] 2606,32758205,Correction to: Routine versus on demand removal of the syndesmotic screw; a protocol for an international randomised controlled trial (RODEO-trial).,An amendment to this paper has been published and can be accessed via the original article.,2020,An amendment to this paper has been published and can be accessed via the original article.,[],['syndesmotic screw'],[],[],"[{'cui': 'C0005975', 'cui_str': 'Bone screw'}]",[],,0.118978,An amendment to this paper has been published and can be accessed via the original article.,"[{'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'Dingemans', 'Affiliation': 'Department of Surgery, Trauma Unit, Academic Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands.'}, {'ForeName': 'M F N', 'Initials': 'MFN', 'LastName': 'Birnie', 'Affiliation': 'Department of Surgery, Trauma Unit, Academic Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands.'}, {'ForeName': 'F R K', 'Initials': 'FRK', 'LastName': 'Sanders', 'Affiliation': 'Department of Surgery, Trauma Unit, Academic Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands.'}, {'ForeName': 'M P J', 'Initials': 'MPJ', 'LastName': 'van den Bekerom', 'Affiliation': 'Department of Orthopedic Surgery, OLVG, P.O. Box 95500, 1090 HM, Amsterdam, The Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Backes', 'Affiliation': 'Department of Surgery, Trauma Unit, Academic Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'van Beeck', 'Affiliation': 'Department of Public Health, Erasmus MC, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.'}, {'ForeName': 'F W', 'Initials': 'FW', 'LastName': 'Bloemers', 'Affiliation': 'Department of Surgery, Trauma Unit, VU University Medical Centre, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'van Dijkman', 'Affiliation': 'Department of Surgery, Flevo Hospital, P.O. Box 3005, 1300 EG, Almere, The Netherlands.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Flikweert', 'Affiliation': 'Department of Surgery, Deventer Hospital, P.O. Box 5001, 7400 GC, Deventer, The Netherlands.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Haverkamp', 'Affiliation': 'Department of Surgery, Slotervaart Hospital, P.O. Box 90440, 1006 BK, Amsterdam, The Netherlands.'}, {'ForeName': 'H R', 'Initials': 'HR', 'LastName': 'Holtslag', 'Affiliation': 'Department of Surgery, Trauma Unit, Academic Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Hoogendoorn', 'Affiliation': 'Department of Surgery, Haaglanden MC, P.O. Box 432, 2501 CK, The Hague, The Netherlands.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Joosse', 'Affiliation': 'Department of Surgery, Noordwest Hospital Group, P.O. Box 501, 1815 JD, Alkmaar, The Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Parkkinen', 'Affiliation': 'Department of Orthopaedics and Traumatology, Helsinki University Hospital, Topeliuksenkatu 5, 00260, Helsinki, Finland.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Roukema', 'Affiliation': 'Department of Surgery, Maasstad Hospital, P.O. Box 9100, 3007 AC, Rotterdam, The Netherlands.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Sosef', 'Affiliation': 'Department of Surgery, Spaarne Hospital, P.O. Box 770, 2130 AT, Hoofddorp, The Netherlands.'}, {'ForeName': 'B A', 'Initials': 'BA', 'LastName': 'Twigt', 'Affiliation': 'Department of Surgery, BovenIJ Hospital, P.O. Box 37610, 1030 BD, Amsterdam, The Netherlands.'}, {'ForeName': 'R N', 'Initials': 'RN', 'LastName': 'van Veen', 'Affiliation': 'Department of Surgery, OLVG, P.O. Box 95500, 1090 HM, Amsterdam, The Netherlands.'}, {'ForeName': 'A H', 'Initials': 'AH', 'LastName': 'van der Veen', 'Affiliation': 'Department of Surgery, Catharina Hospital, P.O. Box 1350, 5602 ZA, Eindhoven, The Netherlands.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Vermeulen', 'Affiliation': 'Department of Surgery, Spaarne Hospital, P.O. Box 770, 2130 AT, Hoofddorp, The Netherlands.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Winkelhagen', 'Affiliation': 'Department of Surgery, Westfries Hospital, P.O. Box 600, 1620 AR, Hoorn, The Netherlands.'}, {'ForeName': 'B C', 'Initials': 'BC', 'LastName': 'van der Zwaard', 'Affiliation': ""Department of Orthopaedics, Jeroen Bosch Hospital, P.O. Box 90153, 5200 ME, 's-Hertogenbosch, The Netherlands.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'van Dieren', 'Affiliation': 'Department of Surgery, Trauma Unit, Academic Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands.'}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Goslings', 'Affiliation': 'Department of Orthopedic Surgery, OLVG, P.O. Box 95500, 1090 HM, Amsterdam, The Netherlands.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Schepers', 'Affiliation': 'Department of Surgery, Trauma Unit, Academic Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands. t.schepers@amc.nl.'}]",BMC musculoskeletal disorders,['10.1186/s12891-020-03516-7'] 2607,32758407,Surgical Closure of Atrial Septal Defects in Young Children-A Review of Anesthesia Care in Sternotomy and Thoracotomy Approaches.,"OBJECTIVES To review and compare the anesthetic management of atrial septal defect (ASD) closures via mini lateral thoracotomy and sternotomy approaches. DESIGN Retrospective analysis. SETTING Single- center pediatric quaternary care hospital. PARTICIPANTS Patients aged <8 years of age undergoing ASD closure. INTERVENTION None. MEASUREMENTS AND MAIN RESULTS Outcome measures included anesthetic technique, total amount and type of analgesics, pain scores, procedure duration, complications, blood transfusion requirements, and duration of stay. Each group had 15 patients. All patients in the sternotomy group received 0.25% bupivacaine subcutaneous infiltration. Eleven of the 15 thoracotomy patients received a fascial plane block, including serratus anterior and erector spinae blocks, and 3 received subcutaneous infiltration. There was no difference in opioid consumption intraoperatively or in the first 24 hours after surgery (0.28 ± 0.24 mg/kg morphine equivalents in thoracotomy group and 0.21 ± 0.12 mg/kg in sternotomy group). Duration of procedure and cardiopulmonary bypass duration were longer in the thoracotomy group. There was no difference in cross-clamp duration between groups. There was no difference in intensive care unit or hospital stay. CONCLUSIONS The authors reviewed perioperative pain management strategies used in surgical ASD closures. Different fascial plane blocks were used. This study has paved way to design a randomized control trial to compare various regional techniques for cardiac surgeries and identified opportunities for improved pain assessment scoring in children after cardiac surgery.",2020,"There was no difference in intensive care unit or hospital stay. ","['Patients aged <8 years of age undergoing ASD closure', 'Single- center pediatric quaternary care hospital', 'Young Children', 'children after cardiac surgery', 'Eleven of the 15 thoracotomy patients']","['bupivacaine subcutaneous infiltration', 'atrial septal defect (ASD) closures via mini lateral thoracotomy and sternotomy approaches', 'fascial plane block, including serratus anterior and erector spinae blocks, and 3 received subcutaneous infiltration']","['Duration of procedure and cardiopulmonary bypass duration', 'anesthetic technique, total amount and type of analgesics, pain scores, procedure duration, complications, blood transfusion requirements, and duration of stay', 'opioid consumption', 'intensive care unit or hospital stay', 'cross-clamp duration']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0189965', 'cui_str': 'Atrioseptoplasty'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0039991', 'cui_str': 'Chest wall incision'}]","[{'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0018817', 'cui_str': 'Atrial septal defect'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0039991', 'cui_str': 'Chest wall incision'}, {'cui': 'C0185792', 'cui_str': 'Sternotomy'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0015641', 'cui_str': 'Fascial'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0224349', 'cui_str': 'Structure of serratus anterior muscle'}, {'cui': 'C0224301', 'cui_str': 'Structure of erector spinae muscle'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0175721', 'cui_str': 'Clamp'}]",,0.063648,"There was no difference in intensive care unit or hospital stay. ","[{'ForeName': 'Niveditha', 'Initials': 'N', 'LastName': 'Karuppiah', 'Affiliation': 'Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Canada.'}, {'ForeName': 'Carolyne', 'Initials': 'C', 'LastName': 'Pehora', 'Affiliation': 'Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Canada.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Haller', 'Affiliation': 'Division of Cardiovascular Surgery, The Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Taylor', 'Affiliation': 'Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Canada; University of Toronto, Toronto, Canada. Electronic address: katherine.taylor@sickkids.ca.'}]",Journal of cardiothoracic and vascular anesthesia,['10.1053/j.jvca.2020.07.023'] 2608,32760598,Effects of live and video simulation on clinical reasoning performance and reflection.,"Introduction In recent years, researchers have recognized the need to examine the relative effectiveness of different simulation approaches and the experiences of physicians operating within such environments. The current study experimentally examined the reflective judgments, cognitive processing, and clinical reasoning performance of physicians across live and video simulation environments. Methods Thirty-eight physicians were randomly assigned to a live scenario or video case condition. Both conditions encompassed two components: (a) patient encounter and (b) video reflection activity. Following the condition-specific patient encounter (i.e., live scenario or video), the participants completed a Post Encounter Form (PEF), microanalytic questions, and a mental effort question. Participants were then instructed to re-watch the video (i.e., video condition) or a video recording of their live patient encounter (i.e., live scenario) while thinking aloud about how they came to the diagnosis and management plan. Results Although significant differences did not emerge across all measures, physicians in the live scenario condition exhibited superior performance in clinical reasoning (i.e., PEF) and a distinct profile of reflective judgments and cognitive processing. Generally, the live condition participants focused more attention on aspects of the clinical reasoning process and demonstrated higher level cognitive processing than the video group. Conclusions The current study sheds light on the differential effects of live scenario and video simulation approaches. Physicians who engaged in live scenario simulations outperformed and showed a distinct pattern of cognitive reactions and judgments compared to physicians who practiced their clinical reasoning via video simulation. Additionally, the current study points to the potential advantages of video self-reflection following live scenarios while also shedding some light on the debate regarding whether video-guided reflection, specifically, is advantageous. The utility of context-specific, micro-level assessments that incorporate multiple methods as physicians complete different parts of clinical tasks is also discussed.",2020,Physicians who engaged in live scenario simulations outperformed and showed a distinct pattern of cognitive reactions and judgments compared to physicians who practiced their clinical reasoning via video simulation.,['Methods\n\n\nThirty-eight physicians'],"['video recording of their live patient encounter (i.e., live scenario) while thinking aloud about how they came to the diagnosis and management plan', 'live and video simulation', 'live scenario or video case condition']","['level cognitive processing', 'clinical reasoning performance and reflection']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0450361', 'cui_str': '38'}, {'cui': 'C0031831', 'cui_str': 'Physician'}]","[{'cui': 'C0042650', 'cui_str': 'Audiovisual Recording'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0205115', 'cui_str': 'Afferent'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}]",38.0,0.0400202,Physicians who engaged in live scenario simulations outperformed and showed a distinct pattern of cognitive reactions and judgments compared to physicians who practiced their clinical reasoning via video simulation.,"[{'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': 'Cleary', 'Affiliation': 'Rutgers, The State University of New Jersey, New Brunswick, USA.'}, {'ForeName': 'Alexis', 'Initials': 'A', 'LastName': 'Battista', 'Affiliation': 'Center for Health Professions Education, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814-4712 USA.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Konopasky', 'Affiliation': 'Center for Health Professions Education, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814-4712 USA.'}, {'ForeName': 'Divya', 'Initials': 'D', 'LastName': 'Ramani', 'Affiliation': 'Center for Health Professions Education, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814-4712 USA.'}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Durning', 'Affiliation': 'Center for Health Professions Education, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814-4712 USA.'}, {'ForeName': 'Anthony R', 'Initials': 'AR', 'LastName': 'Artino', 'Affiliation': 'Department of Health, Human Function, and Rehabilitation Sciences, The George Washington University School of Medicine and Health Sciences, Washington, USA.'}]","Advances in simulation (London, England)",['10.1186/s41077-020-00133-1'] 2609,32760602,"Effect of Two Different Doses of Dexmedetomidine as Adjuvant in Bupivacaine Induced Subarachnoid Block for Elective Abdominal Hysterectomy Operations: A Prospective, Double-blind, Randomized Controlled Study.",[This retracts the article DOI: 10.5001/omj.2015.52.].,2020,[This retracts the article DOI: 10.5001/omj.2015.52.].,['Elective Abdominal Hysterectomy Operations'],"['Dexmedetomidine', 'Bupivacaine']",[],"[{'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0404077', 'cui_str': 'Abdominal hysterectomy'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]",[],,0.32909,[This retracts the article DOI: 10.5001/omj.2015.52.].,[],Oman medical journal,['10.5001/omj.2020.76'] 2610,32760614,Safety and Efficacy of Blood Flow Restriction Therapy after Operative Management of Distal Radius Fractures: A Randomized Controlled Study.,"Background  Blood flow restriction (BFR) therapy is an emerging addition to rehabilitative programs that allows patients to increase strength at lower loads over shorter time periods. Therefore, we conducted a study to evaluate the safety and efficacy of a rehabilitation program using BFR to a traditional rehabilitation protocol following operative fixation of distal radius fractures. Methods  A randomized controlled study was conducted comparing a standardized rehabilitation protocol alone to a combined protocol with the use of BFR therapy in patients treated with volar plate fixation following a displaced distal radius fracture. The same exercises done in the control group were performed by the BFR group with a restrictive tourniquet in place. Patients were followed with serial radiographs to ensure fracture stability. Outcome measures included wrist range of motion, grip strength, pinch strength, visual analog scale (VAS) pain scores at rest and during activity, patient rated wrist evaluation scores (PRWE), and disabilities of the arm, shoulder, and hand scores. Results  Nine patients were randomized and enrolled within the BFR group ( n  = 5) and control ( n  = 4) groups. Patients within the BFR group had a significantly greater reduction in pain with activity over the course of the rehabilitation program. Additionally, the BFR group had a significant improvement in PRWE scores during the 8-week rehabilitation program. There was no difference in radiographic measures after initiation of BFR, and all patients tolerated therapy without noted complications. Conclusion  BFR therapy is safe and well tolerated after operatively treated distal radius fractures. The addition of BFR therapy can result in quicker reduction in pain with activity and improvement in patient disability when used early following operative management of a distal radius fracture. Level of Evidence  This is a Level 1, prognostic study.",2020,"Outcome measures included wrist range of motion, grip strength, pinch strength, visual analog scale (VAS) pain scores at rest and during activity, patient rated wrist evaluation scores (PRWE), and disabilities of the arm, shoulder, and hand scores. ","['Distal Radius Fractures', 'patients treated with volar plate fixation following a displaced distal radius fracture']","['rehabilitation program using BFR', 'BFR therapy', ' \u2003Blood flow restriction (BFR) therapy', 'Blood Flow Restriction Therapy', 'BFR group with a restrictive tourniquet in place']","['radiographic measures', 'PRWE scores', 'wrist range of motion, grip strength, pinch strength, visual analog scale (VAS) pain scores at rest and during activity, patient rated wrist evaluation scores (PRWE), and disabilities of the arm, shoulder, and hand scores', 'Level of Evidence', 'safety and efficacy', 'pain with activity', 'safe and well tolerated']","[{'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0443349', 'cui_str': 'Volar'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0012727', 'cui_str': 'Displacement'}]","[{'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0040519', 'cui_str': 'Tourniquet'}, {'cui': 'C0442504', 'cui_str': 'Place'}]","[{'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0575717', 'cui_str': 'Wrist joint - range of movement'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C1720876', 'cui_str': 'Pinch Strength'}, {'cui': 'C2732809', 'cui_str': 'Visual analog scale pain score'}, {'cui': 'C0443144', 'cui_str': 'At rest'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",9.0,0.0272854,"Outcome measures included wrist range of motion, grip strength, pinch strength, visual analog scale (VAS) pain scores at rest and during activity, patient rated wrist evaluation scores (PRWE), and disabilities of the arm, shoulder, and hand scores. ","[{'ForeName': 'Nicole M', 'Initials': 'NM', 'LastName': 'Sgromolo', 'Affiliation': 'Department of Orthopaedic Surgery, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, Texas.'}, {'ForeName': 'Jill M', 'Initials': 'JM', 'LastName': 'Cancio', 'Affiliation': 'Department of Rehabilitation Medicine, Center for the Intrepid, Brooke Army Medical Center, San Antonio Military Medical Center, JBSA Ft. Sam Houston, San Antonio, Texas.'}, {'ForeName': 'Peter C', 'Initials': 'PC', 'LastName': 'Rhee', 'Affiliation': 'Division of Hand Surgery, Mayo Clinic, Rochester, Minnesota.'}]",Journal of wrist surgery,['10.1055/s-0040-1712504'] 2611,32760749,"Effects of Internet Cognitive-Behavioral Therapy on Depressive Symptoms and Surrogates of Cardiovascular Risk in Human Immunodeficiency Virus: A Pilot, Randomized, Controlled Trial.","Background Depression is associated with an increased risk of cardiovascular disease in human immunodeficiency virus (HIV). We hypothesized that reducing depressive symptoms would improve HIV-related cardiovascular risk. Methods We conducted a single-center, randomized (1:1), controlled, parallel-group, assessor-blinded, pilot trial comparing Beating the Blues US (BtB)-an evidence-based, 8-session, internet cognitive-behavioral therapy for depression-with usual care (UC) in HIV-positive participants receiving virologically suppressive antiretroviral therapy and with Patient Health Questionnaire (PHQ)-9 scores ≥10. The primary endpoint was change in brachial artery flow-mediated dilation (FMD) at 12 weeks. Secondary endpoints were FMD change at 24 weeks and inflammation, coagulation, and metabolic biomarker changes at 12 and 24 weeks. Results Fifty-four participants were randomized (27 in each arm). Mean reductions in PHQ-9 scores were significantly greater with BtB versus UC at 12 weeks (-5.60 vs -1.52; P  = .007) and 24 weeks (-6.00 vs -1.38; P  = .008); reductions in the Hopkins Symptom Checklist Depression Scale-20 scores were also significantly greater with BtB versus UC at 24 weeks (-0.72 vs -0.35; P  = .029). Changes in FMD between arms were not significantly different at 12 or 24 weeks. Significantly larger reductions in soluble (s)CD14 and sCD163 with BtB versus UC were found at 12 and 24 weeks, respectively. Conclusions Compared with UC, internet cognitive-behavioral therapy using BtB resulted in greater improvements in depressive symptoms and monocyte activation markers but did not improve FMD in this pilot trial. These data support performing larger studies to determine the potential salutatory effects of behavioral therapies for depression on HIV-related inflammation.",2020,"Compared with UC, internet cognitive-behavioral therapy using BtB resulted in greater improvements in depressive symptoms and monocyte activation markers but did not improve FMD in this pilot trial.","['human immunodeficiency virus (HIV', 'Human Immunodeficiency Virus', 'HIV-positive participants receiving virologically suppressive antiretroviral therapy and with Patient Health Questionnaire (PHQ)-9 scores\u2005≥10']","['UC, internet cognitive-behavioral therapy using BtB', 'Blues US (BtB)-an evidence-based, 8-session, internet cognitive-behavioral therapy for depression-with usual care (UC', 'Internet Cognitive-Behavioral Therapy']","['Depressive Symptoms and Surrogates of Cardiovascular Risk', 'FMD change at 24 weeks and inflammation, coagulation, and metabolic biomarker changes', 'change in brachial artery flow-mediated dilation (FMD', 'Changes in FMD', 'Mean reductions in PHQ-9 scores', 'depressive symptoms and monocyte activation markers', 'Hopkins Symptom Checklist Depression Scale-20 scores', 'soluble (s)CD14 and sCD163 with BtB versus UC']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0019699', 'cui_str': 'HIV positive'}, {'cui': 'C0205367', 'cui_str': 'Suppressive'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C1260957', 'cui_str': 'Blue color'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0006087', 'cui_str': 'Structure of brachial artery'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026473', 'cui_str': 'Monocyte'}, {'cui': 'C0451524', 'cui_str': 'Symptom checklist'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0108768', 'cui_str': 'Lymphocyte antigen CD14'}, {'cui': 'C1260957', 'cui_str': 'Blue color'}]",54.0,0.343377,"Compared with UC, internet cognitive-behavioral therapy using BtB resulted in greater improvements in depressive symptoms and monocyte activation markers but did not improve FMD in this pilot trial.","[{'ForeName': 'Samir K', 'Initials': 'SK', 'LastName': 'Gupta', 'Affiliation': 'Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA.'}, {'ForeName': 'James E', 'Initials': 'JE', 'LastName': 'Slaven', 'Affiliation': 'Department of Biostatistics, Indiana University School of Public Health, Indianapolis, Indiana, USA.'}, {'ForeName': 'Ziyue', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Department of Biostatistics, Indiana University School of Public Health, Indianapolis, Indiana, USA.'}, {'ForeName': 'Brittanny M', 'Initials': 'BM', 'LastName': 'Polanka', 'Affiliation': 'Department of Psychology, Indiana University-Purdue University-Indianapolis (IUPUI), Indianapolis, Indiana, USA.'}, {'ForeName': 'Matthew S', 'Initials': 'MS', 'LastName': 'Freiberg', 'Affiliation': 'Cardiovascular Medicine Division, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Jesse C', 'Initials': 'JC', 'LastName': 'Stewart', 'Affiliation': 'Department of Psychology, Indiana University-Purdue University-Indianapolis (IUPUI), Indianapolis, Indiana, USA.'}]",Open forum infectious diseases,['10.1093/ofid/ofaa280'] 2612,32760817,Structured Water Dance Intervention (SWAN) for adults with profound intellectual and multiple disabilities: study protocol.,"Background People with profound intellectual and multiple disabilities (PIMD) have a combination of severe intellectual disability, extensive physical impairment, sensory impairments and medical health problems. There is, however, a lack of evidence-based physical and health-promoting interventions for people with PIMD. Objective Structured Water Dance Intervention (SWAN) is a new method developed to fill this gap. This paper reports a protocol for an intervention study which aims to evaluate SWAN with regard to its effects on physiological, psychological and social health-related variables as well as its cost-effectiveness and potential for implementation in health care. Methods The evaluation of SWAN is performed in a multi-center randomized crossover study. Data is collected through cortisol measurement, physiological assessments, proxy ratings, video observations and interviews. Conclusions This is the first attempt to evaluate rigorously an innovative intervention for people with PIMD, a group that is rarely considered for health promotion interventions. This study will provide important information about the efficacy, cost-effectiveness and potential to implement SWAN in health care.",2020,"This is the first attempt to evaluate rigorously an innovative intervention for people with PIMD, a group that is rarely considered for health promotion interventions.","['people with PIMD', '\n\n\nPeople with profound intellectual and multiple disabilities (PIMD', 'adults with profound intellectual and multiple disabilities']","['Structured Water Dance Intervention (SWAN', 'Objective\n\n\nStructured Water Dance Intervention (SWAN']",[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439808', 'cui_str': 'Profound'}, {'cui': 'C0935560', 'cui_str': 'Multiple disability'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0010963', 'cui_str': 'Dance'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018017', 'cui_str': 'Goal'}]",[],,0.0837084,"This is the first attempt to evaluate rigorously an innovative intervention for people with PIMD, a group that is rarely considered for health promotion interventions.","[{'ForeName': 'Lars-Olov', 'Initials': 'LO', 'LastName': 'Lundqvist', 'Affiliation': 'University Health Care Research Center, Faculty of Medicine and Health, Örebro University, SE 70182, Örebro, Sweden.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Matérne', 'Affiliation': 'University Health Care Research Center, Faculty of Medicine and Health, Örebro University, SE 70182, Örebro, Sweden.'}, {'ForeName': 'Anette', 'Initials': 'A', 'LastName': 'Granberg', 'Affiliation': 'University Health Care Research Center, Faculty of Medicine and Health, Örebro University, SE 70182, Örebro, Sweden.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Frank', 'Affiliation': 'University Health Care Research Center, Faculty of Medicine and Health, Örebro University, SE 70182, Örebro, Sweden.'}, {'ForeName': 'Patrik', 'Initials': 'P', 'LastName': 'Arvidsson', 'Affiliation': 'Region Gävleborg, Centre for Research & Development, Uppsala University/Region Gävleborg, 806 33, Gävle, Sweden.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Duberg', 'Affiliation': 'University Health Care Research Center, Faculty of Medicine and Health, Örebro University, SE 70182, Örebro, Sweden.'}]",Heliyon,['10.1016/j.heliyon.2020.e04242'] 2613,32760832,Randomized feasibility trial to assess tolerance and clinical effects of lithium in progressive multiple sclerosis.,"Background Disability accumulation in progressive multiple sclerosis (MS) results from inflammatory and neurodegenerative mechanisms. In animal models of MS, lithium acts to reduce inflammatory demyelination, and in models of neurodegenerative diseases, lithium also slows neuronal death. Prospective studies of lithium in MS patients have not been previously undertaken. Objective To determine the tolerance and feasibility of using low-dose (150-300 mg/daily) lithium as a pharmaceutical intervention in a cohort of subjects with progressive MS, and to gauge preliminary effects of lithium on change in brain volume over time. Methods Patients with primary or secondary progressive MS were recruited into a 2-year, single-blind crossover trial in which subjects were randomly assigned to take lithium in year 1 or 2. The primary outcomes of interest were tolerance of lithium and percentage brain volume change (PBVC) on vs. off lithium. Secondary outcomes included relapse rates, disability changes, and self-report scales assessing fatigue, mood, and quality of life (QOL). Results Of 24 screened patients, 23 were randomized to take lithium during year 1 (n = 11) or 2 (n = 12). Two subjects discontinued the trial due to lithium side effects. Other reasons for discontinuation included personal reasons (n = 2), worsening MS (n = 1), and development of multiple myeloma (n = 1). For the 17 who completed the trial, change in PBVC on lithium (+0.107) did not significantly differ from the observation period (-0.355, p = 0.346). Disability measured by Expanded Disability Status Scale and MS Functional Composite did not differ by lithium treatment status. On patient reported measures of mental well-being, subjects reported fewer depressive symptoms on the Beck Depression Inventory (12.3 vs. 15.8, p = 0.016) and more favorably on the mental domains of the MSQOL inventory (56.7 vs. 52.4, p = 0.028). Conclusions Low-dose lithium is well tolerated in persons with MS. Taking lithium did not result in differences in PBVC, relapses, or disability, but conclusions were limited by study design and sample size. Despite concern for lithium-associated neurological side effects, subjects taking lithium did not report worsened fatigue or physical well-being. On measures of mood and mental health QOL, subjects scored more favorably while taking lithium. Clinicaltrialsgov identifier NCT01259388.",2020,"Secondary outcomes included relapse rates, disability changes, and self-report scales assessing fatigue, mood, and quality of life (QOL). ","['progressive multiple sclerosis (MS', 'persons with MS', 'MS patients', '24 screened patients', 'progressive multiple sclerosis', 'Methods\n\n\nPatients with primary or secondary progressive MS']","['low-dose (150-300 mg/daily) lithium', 'lithium']","['Disability measured by Expanded Disability Status Scale and MS Functional Composite', 'tolerance of lithium and percentage brain volume change (PBVC) on vs. off lithium', 'mood and mental health QOL', 'PBVC, relapses, or disability', 'depressive symptoms on the Beck Depression Inventory', 'relapse rates, disability changes, and self-report scales assessing fatigue, mood, and quality of life (QOL', 'PBVC on lithium']","[{'cui': 'C1095979', 'cui_str': 'Progressive multiple sclerosis'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0751965', 'cui_str': 'Secondary progressive multiple sclerosis'}]","[{'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0023870', 'cui_str': 'Lithium'}]","[{'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0023870', 'cui_str': 'Lithium'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0240220', 'cui_str': 'On lithium'}]",,0.0634461,"Secondary outcomes included relapse rates, disability changes, and self-report scales assessing fatigue, mood, and quality of life (QOL). ","[{'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Rinker', 'Affiliation': 'Department of Neurology, University of Alabama at Birmingham, 1720 7 Avenue South, Birmingham, AL, 35294, USA.'}, {'ForeName': 'William R', 'Initials': 'WR', 'LastName': 'Meador', 'Affiliation': 'Department of Neurology, University of Alabama at Birmingham, 1720 7 Avenue South, Birmingham, AL, 35294, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'King', 'Affiliation': 'Birmingham VA Medical Center, 700 19 Street South, Birmingham, AL, 35233, USA.'}]",Heliyon,['10.1016/j.heliyon.2020.e04528'] 2614,32760847,"Effects of a chlorhexidine mouthwash on clinical parameters of gingivitis, dental plaque and oral polymorphonuclear leukocytes [PMN].","Histological features of oral inflammation include infiltration of polymorphonuclear leukocytes [PMN], however studies have not examined the effects of interventions mitigating inflammation on oral PMN. Methods : This double-blind clinical study examined the effects of rinsing with mouthwashes formulated with chlorhexidine [CHX], an ingredient widely utilized in the dental clinic in comparison to a control on oral PMN representing a novel measure of inflammation. A concurrent evaluation of dental plaque and gingival inflammation using widely accepted clinical indices was included in the study. The study enrolled adult subjects providing informed consent, met study criteria and registered gingival index scores of 1.0 or more at the screening visit. Subjects [n = 90; age range 19-58 years] completed a washout phase prior to baseline evaluations for PMN and clinical assessments for dental plaque and gingivitis. Treatments [CHX or a control mouthwash] were randomly assigned to subjects for twice-daily use for the next two weeks. Post-treatment evaluations similar to baseline were conducted after one and two week use of assigned treatment. Results : At baseline, no statistically significant differences between treatment groups for PMN or clinical indices for dental plaque or gingivitis were noted. Rinsing with CHX demonstrated significant reductions for PMN and dental plaque, gingivitis in comparison to the control group. After one and two week use of CHX, PMN demonstrated a 35.9% and 54.9% reduction respectively in comparison to the control group representing significant differences [p < 0.05]. At the one and two week post-treatment evaluations, rinsing with CHX demonstrated 15% and 25% reductions in gingivitis respectively and were significantly different from the control [p < 0.05]. Rinsing with CHX also demonstrated significant reductions in dental plaque of 15% and 19% at the one and two-week post-treatment evaluations respectively in comparison to the control [p < 0.05]. The CHX group also demonstrated reductions in interproximal scores and registered the lowest frequency of gingival index or dental plaque scores on all oral surfaces. Conclusions: Results outline an objective approach to evaluate oral inflammation demonstrating a large and sustained reduction in oral PMN by CHX with these outcomes numerically higher than a clinical index evaluating gingivitis.",2020,"Rinsing with CHX demonstrated significant reductions for PMN and dental plaque, gingivitis in comparison to the control group.","['enrolled adult subjects providing informed consent, met study criteria and registered gingival index scores of 1.0 or more at the screening visit', 'Subjects [n\u202f=\u202f90; age range 19-58 years']","['CHX', 'CHX or a control mouthwash', 'chlorhexidine mouthwash', 'chlorhexidine [CHX']","['PMN or clinical indices for dental plaque or gingivitis', 'gingival index or dental plaque scores', 'gingivitis', 'PMN and dental plaque, gingivitis', 'interproximal scores', 'dental plaque', 'clinical parameters of gingivitis, dental plaque and oral polymorphonuclear leukocytes [PMN']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0026647', 'cui_str': 'Oromucosal solution for gargle'}, {'cui': 'C0352155', 'cui_str': 'Chlorhexidine Mouthwash'}, {'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}]","[{'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C0429153', 'cui_str': 'Dental plaque score'}, {'cui': 'C0008684', 'cui_str': 'Chronic gingivitis'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]",90.0,0.0199941,"Rinsing with CHX demonstrated significant reductions for PMN and dental plaque, gingivitis in comparison to the control group.","[{'ForeName': 'Prem K', 'Initials': 'PK', 'LastName': 'Sreenivasan', 'Affiliation': 'Department of Oral Biology, Rutgers School of Dental Medicine, Colgate-Palmolive, Piscataway, NJ, USA.'}, {'ForeName': 'Kakarla V V', 'Initials': 'KVV', 'LastName': 'Prasad', 'Affiliation': 'Department of Public Health Dentistry, SDM Dental College and Hospital, Dharwad, India.'}]",Contemporary clinical trials communications,['10.1016/j.conctc.2019.100473'] 2615,32760891,Pain-diminishing and quality of life-related outcomes of Kinesio taping in patients on non-steroidal anti-inflammatory drug therapy for post-thoracotomy pain syndrome.,"Objectives This study aims to evaluate pain-diminishing and quality of life-related outcomes of Kinesio taping in patients on non-steroidal anti-inflammatory drug (NSAID) therapy for post-thoracotomy pain syndrome (PTPS). Patients and methods Between February 2016 and May 2017, a total 60 patients (39 males, 21 females; median age 43.5 years; range, 18 to 76 years) with PTPS were included in this single-center, prospective, randomized study. The patients were randomized into two groups based on five-day pain management protocol including NSAIDs per se (NSAID group; n=30) and NSAIDs plus Kinesio taping (NSAID-KT group; n=30) groups. Pain intensity (via visual pain scale [VAS]), neuropathic pain (Leeds Assessment of Neuropathic Symptoms and Signs [LANSS] Pain Scale), major chronic pain symptoms (via Short-Form McGill Pain Questionnaire [SF-MPQ-2]), and quality of life (via Nottingham Health Profile [NHP]) were assessed before and after five-day treatment period. Results In both NSAID and NSAID-KT groups, treatment was associated with a significant decrease in the VAS-pain (p<0.001), LANSS Pain Scale scores (from median 8.0 to 3.0 and from median 18.5 to 15.0, respectively, p<0.001 for each), SF-MPQ scores (p<0.001), and physical mobility and pain domains of NHS (p<0.001 for each). Conclusion In conclusion, our study findings indicate no additional benefit of KT application on further amelioration of long-term PTPS in patients under NSAID analgesia. Both NSAID and NSAID-KT treatments produced a significant improvement in the VAS, LANSS, SF-MPQ scores, and in the quality of life after five-day treatment.",2020,"Both NSAID and NSAID-KT treatments produced a significant improvement in the VAS, LANSS, SF-MPQ scores, and in the quality of life after five-day treatment.","['patients under NSAID analgesia', 'Patients and methods\n\n\nBetween February 2016 and May 2017, a total 60 patients (39 males, 21 females; median age 43.5 years; range, 18 to 76 years) with PTPS', 'patients on non-steroidal anti-inflammatory drug (NSAID) therapy for post-thoracotomy pain syndrome (PTPS', 'patients on non-steroidal anti-inflammatory drug therapy for post-thoracotomy pain syndrome']","['Kinesio taping', 'KT application', 'pain management protocol including NSAIDs per se (NSAID group; n=30) and NSAIDs plus Kinesio taping (NSAID-KT group']","['quality of life', 'VAS-pain', 'Pain-diminishing and quality of life-related outcomes', 'LANSS Pain Scale scores', 'SF-MPQ scores (p<0.001), and physical mobility and pain domains of NHS', 'pain-diminishing and quality of life-related outcomes', 'VAS, LANSS, SF-MPQ scores', 'Pain intensity (via visual pain scale [VAS]), neuropathic pain (Leeds Assessment of Neuropathic Symptoms and Signs [LANSS] Pain Scale), major chronic pain symptoms (via Short-Form McGill Pain Questionnaire [SF-MPQ-2]), and quality of life (via Nottingham Health Profile [NHP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0406844', 'cui_str': 'Post-thoracotomy pain syndrome'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0796085', 'cui_str': 'Nance-Horan syndrome'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0027796', 'cui_str': 'Neuralgia'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0457972', 'cui_str': 'Short form McGill pain questionnaire'}, {'cui': 'C0451339', 'cui_str': 'Nottingham health profile'}]",,0.079542,"Both NSAID and NSAID-KT treatments produced a significant improvement in the VAS, LANSS, SF-MPQ scores, and in the quality of life after five-day treatment.","[{'ForeName': 'Hülya', 'Initials': 'H', 'LastName': 'Kurt Saruhan', 'Affiliation': ''}, {'ForeName': 'Murat', 'Initials': 'M', 'LastName': 'Toprak', 'Affiliation': ''}]",Turkish journal of physical medicine and rehabilitation,['10.5606/tftrd.2020.4068'] 2616,32760892,"The effect of mirror therapy on lower extremity motor function and ambulation in post-stroke patients: A prospective, randomized-controlled study.","Objectives This study aims to evaluate the effects of mirror therapy (MT) on lower extremity motor function and ambulation in post-stroke patients. Patients and methods A total of 42 post-stroke patients (25 males, 17 females; mean age 58 years; range, 32 to 71 years) were included. All patients were randomly divided into two groups as the control group (n=21) receiving a conventional rehabilitation program for four weeks (60 to 120 min/day for five days a week) and as the MT group (n=21) receiving MT for 30 min in each session in addition to the conventional rehabilitation program. The Brunnstrom stages of stroke recovery, Functional Independence Measure (FIM), Berg Balance Scale (BBS) and Motricity Index (MI) scores, six-minute walking test (6MWT), Functional Ambulation Category (FAC), and the degree of ankle plantar flexion spasticity using the Modified Ashworth Scale (MAS) were evaluated at baseline (Day 0), at post-treatment (Week 4), and eight weeks after the end of treatment (Week 12). Results There were significant differences in all parameters between the groups, except for the degree of ankle plantar flexion spasticity, and in all time points between Week 0 and 4 and between Week 0 and 12 (p<0.05). Conclusion These results suggest that MT in addition to conventional rehabilitation program yields a greater improvement in the lower extremity motor function and ambulation, which sustains for a short period of time after the treatment.",2020,"There were significant differences in all parameters between the groups, except for the degree of ankle plantar flexion spasticity, and in all time points between Week 0 and 4 and between Week 0 and 12 (p<0.05). ","['A total of 42 post-stroke patients (25 males, 17 females; mean age 58 years; range, 32 to 71 years) were included', 'post-stroke patients']","['mirror therapy', 'MT', 'control group (n=21) receiving a conventional rehabilitation program', 'MT group (n=21) receiving MT for 30 min in each session in addition to the conventional rehabilitation program', 'mirror therapy (MT']","['lower extremity motor function and ambulation', 'degree of ankle plantar flexion spasticity', 'Brunnstrom stages of stroke recovery, Functional Independence Measure (FIM), Berg Balance Scale (BBS) and Motricity Index (MI) scores, six-minute walking test (6MWT), Functional Ambulation Category (FAC), and the degree of ankle plantar flexion spasticity using the Modified Ashworth Scale (MAS']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0181868', 'cui_str': 'Mirror'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C1527374', 'cui_str': 'Group Therapy'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0231784', 'cui_str': 'Plantar flexion'}, {'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0451172', 'cui_str': 'Functional independence measure'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C0451322', 'cui_str': 'Motricity index'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C4707572', 'cui_str': 'Modified Ashworth Scale'}]",,0.0203403,"There were significant differences in all parameters between the groups, except for the degree of ankle plantar flexion spasticity, and in all time points between Week 0 and 4 and between Week 0 and 12 (p<0.05). ","[{'ForeName': 'Hatice', 'Initials': 'H', 'LastName': 'İkizler May', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Antalya Atatürk State Hospital, Antalya, Turkey.'}, {'ForeName': 'Şenay', 'Initials': 'Ş', 'LastName': 'Özdolap', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey.'}, {'ForeName': 'Alper', 'Initials': 'A', 'LastName': 'Mengi', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Gaziosmanpaşa Taksim Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Selda', 'Initials': 'S', 'LastName': 'Sarıkaya', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey.'}]",Turkish journal of physical medicine and rehabilitation,['10.5606/tftrd.2020.2719'] 2617,32760894,The efficacy of transcutaneous electrical nerve stimulation therapy in pain control after cesarean section delivery associated with uterine contractions and abdominal incision.,"Objectives This study aims to investigate the effects of transcutaneous electrical nerve stimulation (TENS) therapy on the intensity of pain associated with uterine contractions and abdominal incision in patients undergoing cesarean section (C-section) delivery. Patients and methods This single-blind, prospective, randomized-controlled study included a total of 90 female patients (mean age 30.5 years; range, 25 to 36 years) who had a scheduled C-section delivery between November 2017 and April 2018. Forty-five postpartum patients were randomly assigned into the treatment group (Group 1) and TENS electrodes were placed below and above the abdominal incision. The control group (n=45) consisted of 45 patients who had a scheduled C-section (Group 2) (n=45) and received routine follow-up care. The Visual Numeric Scale (VNS) scores were obtained separately for abdominal, low back, and groin pain at baseline (within 1 h after C-section before the TENS replacement), at postpartum 2, 6, 24, and 48 h. In addition to instant scoring, the percentages of change in pain scores from baseline were also calculated for each time points. Results Data of a total of 87 patients were analyzed. No statistically significant difference was found in the baseline VNS scores measured in any body regions between the groups (p>0.05). However, there was a statistically significant difference in the instant VNS scores for abdominal pain at 2, 6, 24, and 48 h in favor of Group 1 (p<0.05). No significant differences were found in the instant VNS scores for low back and groin pain (p>0.05). The comparison of changes in pain scores from baseline (% change) over time between the groups revealed a statistically significant difference in favor of Group 1 in all VNS scores for abdominal, low back, and groin pain at 2, 6, 24, and 48 h (p<0.05). Conclusion Our study results suggest that TENS is an effective and safe non-invasive, non-pharmacological treatment modality. It may be preferred as an alternative method in pain control in postpartum women after C-section delivery.",2020,No statistically significant difference was found in the baseline VNS scores measured in any body regions between the groups (p>0.05).,"['Forty-five postpartum patients', '45 patients who had a scheduled C-section (Group 2) (n=45) and received', 'pain control after cesarean section delivery associated with uterine contractions and abdominal incision', 'patients undergoing cesarean section (C-section) delivery', '90 female patients (mean age 30.5 years; range, 25 to 36 years) who had a scheduled C-section delivery between November 2017 and April 2018']","['TENS', 'TENS electrodes were placed below and above the abdominal incision', 'transcutaneous electrical nerve stimulation therapy', 'routine follow-up care', 'transcutaneous electrical nerve stimulation (TENS) therapy']","['pain scores', 'abdominal, low back, and groin pain', 'instant VNS scores for low back and groin pain', 'Visual Numeric Scale (VNS) scores', 'VNS scores for abdominal, low back, and groin pain', 'baseline VNS scores', 'instant VNS scores for abdominal pain']","[{'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0042130', 'cui_str': 'Uterine contraction'}, {'cui': 'C0198488', 'cui_str': 'Abdomen incision'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0040654', 'cui_str': 'Percutaneous electrical nerve stimulation'}, {'cui': 'C0013812', 'cui_str': 'Electrode'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0198488', 'cui_str': 'Abdomen incision'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C3899107', 'cui_str': 'Follow-Up Care'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0239783', 'cui_str': 'Inguinal pain'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}]",87.0,0.0626458,No statistically significant difference was found in the baseline VNS scores measured in any body regions between the groups (p>0.05).,"[{'ForeName': 'Işıl', 'Initials': 'I', 'LastName': 'Kasapoğlu', 'Affiliation': 'Department of Obstetrics and Gynecology, Uludağ University School of Medicine, Bursa, Turkey.'}, {'ForeName': 'Meliha', 'Initials': 'M', 'LastName': 'Kasapoğlu Aksoy', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, University of Health Sciences, Bursa Yüksek Ihtisas Training and Research Hospital, Bursa, Turkey.'}, {'ForeName': 'Bilge', 'Initials': 'B', 'LastName': 'Çetinkaya Demir', 'Affiliation': 'Department of Obstetrics and Gynecology, Uludağ University School of Medicine, Bursa, Turkey.'}, {'ForeName': 'Lale', 'Initials': 'L', 'LastName': 'Altan', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Uludağ University School of Medicine, Bursa, Turkey.'}]",Turkish journal of physical medicine and rehabilitation,['10.5606/tftrd.2020.3225'] 2618,32760896,Comparison of mobilization with supervised exercise for patients with subacromial impingement syndrome.,"Objectives This study aims to investigate the effects of joint mobilization with supervised exercise in patients with subacromial impingement syndrome (SAIS). Patients and methods This prospective, randomized-controlled study included a total of 40 patients (18 males, 22 females; mean age 43.52 years; range, 27 to 67 years) with SAIS of more than six weeks between June 2014 and June 2015. The patients were randomly allocated into two groups: Group 1 (n=20) received joint mobilization and neuromuscular electrical stimulation and Group 2 (n=20) received a supervised exercise program and neuromuscular electrical stimulation. The outcome measures included the range of motion, pain intensity, the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire, American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form-patient self-report section, Short Form-36, and Global Rating of Change Questionnaire. Pain was evaluated using the visual analog scale (VAS). Results In both groups, the mean VAS scores significantly decreased and the range of motion significantly increased after treatment (p<0.05). Both joint mobilization and supervised exercise combined with neuromuscular electrical stimulation led to a significant improvement in function in patients with SAIS (p<0.05), although it did not significantly differ between the groups (p>0.05). Patient satisfaction with treatment was similar in both groups (p=0.28). Conclusion Based on our study results, mobilization and supervised exercise yield comparable outcomes in patients with SAIS.",2020,"Both joint mobilization and supervised exercise combined with neuromuscular electrical stimulation led to a significant improvement in function in patients with SAIS (p<0.05), although it did not significantly differ between the groups (p>0.05).","['patients with subacromial impingement syndrome (SAIS', 'patients with SAIS', 'patients with subacromial impingement syndrome', '40 patients (18 males, 22 females; mean age 43.52 years; range, 27 to 67 years) with SAIS of more than six weeks between June 2014 and June 2015', 'patients with SAIS (p<0.05']","['joint mobilization with supervised exercise', 'supervised exercise combined with neuromuscular electrical stimulation', 'mobilization with supervised exercise', 'joint mobilization and neuromuscular electrical stimulation and Group 2 (n=20) received a supervised exercise program and neuromuscular electrical stimulation']","['Patient satisfaction', 'visual analog scale (VAS', 'Pain', 'mean VAS scores', 'range of motion, pain intensity, the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire, American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form-patient self-report section, Short Form-36, and Global Rating of Change Questionnaire', 'range of motion']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0376685', 'cui_str': 'Impingement syndrome of shoulder region'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0231588', 'cui_str': 'Physiatric mobilization of joint'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",40.0,0.0580416,"Both joint mobilization and supervised exercise combined with neuromuscular electrical stimulation led to a significant improvement in function in patients with SAIS (p<0.05), although it did not significantly differ between the groups (p>0.05).","[{'ForeName': 'Ferit', 'Initials': 'F', 'LastName': 'Pekgöz', 'Affiliation': 'Division of Physical Therapy and Rehabilitation, Istanbul Medipol University, Institute of Health Sciences, Istanbul, Turkey.'}, {'ForeName': 'Hanifegül', 'Initials': 'H', 'LastName': 'Taşkıran', 'Affiliation': 'Division of Physical Therapy and Rehabilitation, Istanbul Aydın University, Faculty of Health Sciences, Istanbul, Turkey.'}, {'ForeName': 'Ebru', 'Initials': 'E', 'LastName': 'Kaya Mutlu', 'Affiliation': 'Division of Physical Therapy and Rehabilitation, Istanbul University, Faculty of Health Sciences, Istanbul, Turkey.'}, {'ForeName': 'Ayçe', 'Initials': 'A', 'LastName': 'Atalay', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Acıbadem University, Faculty of Medicine, Istanbul, Turkey.'}, {'ForeName': 'Reyhan', 'Initials': 'R', 'LastName': 'Çeliker', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Acıbadem University, Faculty of Medicine, Istanbul, Turkey.'}]",Turkish journal of physical medicine and rehabilitation,['10.5606/tftrd.2020.3649'] 2619,32761160,Effects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment: A Randomized Clinical Trial.,"Importance Observational studies have suggested that angiotensin receptor blockers are associated with a unique cognitive protection. It is unclear if this is due to reduced blood pressure (BP) or angiotensin receptors type 1 blockade. Objective To determine neurocognitive effects of candesartan vs lisinopril in older adults with mild cognitive impairment (MCI). Design, Setting, and Participants This randomized clinical trial included participants aged 55 years or older with MCI and hypertension. Individuals were withdrawn from prior antihypertensive therapy and randomized in a 1 to 1 ratio to candesartan or lisinopril from June 2014 to December 2018. Participants underwent cognitive assessments at baseline and at 6 and 12 months. Brain magnetic resonance images were obtained at baseline and 12 months. This intent-to-treat study was double-blind and powered for a sample size accounting for 20% dropout. Data were analyzed from May to October 2019. Interventions Escalating doses of oral candesartan (up to 32 mg) or lisinopril (up to 40 mg) once daily. Open-label antihypertensive drug treatments were added as needed to achieve BP less than 140/90 mm Hg. Main Outcomes and Measures The primary outcome was executive function (measured using the Trail Making Test, Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research tool) and secondary outcomes were episodic memory (measured using the Hopkins Verbal Learning Test-Revised) and microvascular brain injury reflected by magnetic resonance images of white matter lesions. Results Among 176 randomized participants (mean [SD] age, 66.0 [7.8] years; 101 [57.4%] women; 113 [64.2%] African American), 87 were assigned to candesartan and 89 were assigned to lisinopril. Among these, 141 participants completed the trial, including 77 in the candesartan group and 64 in the lisinopril group. Although the lisinopril vs candesartan groups achieved similar BP (12-month mean [SD] systolic BP: 130 [17] mm Hg vs 134 [20] mm Hg; P = .20; 12-month mean [SD] diastolic BP: 77 [10] mm Hg vs 78 [11] mm Hg; P = .52), candesartan was superior to lisinopril on the primary outcome of executive function measured by Trail Making Test Part B (effect size [ES] = -12.8 [95% CI, -22.5 to -3.1]) but not Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research score (ES = -0.03 [95% CI, -0.08 to 0.03]). Candesartan was also superior to lisinopril on the secondary outcome of Hopkins Verbal Learning Test-Revised delayed recall (ES = 0.4 [95% CI, 0.02 to 0.8]) and retention (ES = 5.1 [95% CI, 0.7 to 9.5]). Conclusions and Relevance These findings suggest that in older adults with MCI, 1-year treatment with candesartan had superior neurocognitive outcomes compared with lisinopril. These effects are likely independent of the BP-lowering effect of candesartan. Trial Registration ClinicalTrials.gov Identifier: NCT01984164.",2020,", candesartan was superior to lisinopril on the primary outcome of executive function measured by Trail Making Test Part B (effect size [ES] = -12.8","['older adults with MCI', 'participants aged 55 years or older with MCI and hypertension', '176 randomized participants (mean [SD] age', '141 participants completed the trial, including 77 in the candesartan group and 64 in the lisinopril group', 'Hg vs 134 [20', 'Older Adults With Executive Mild Cognitive Impairment', 'older adults with mild cognitive impairment (MCI', '66.0 [7.8] years; 101 [57.4%] women; 113 [64.2%] African American']","['lisinopril vs candesartan', 'oral candesartan', 'Candesartan', 'candesartan or lisinopril', 'angiotensin receptor blockers', 'Candesartan vs Lisinopril', 'candesartan', 'candesartan vs lisinopril', 'lisinopril']","['SD] diastolic BP', 'Neurocognitive Function', 'executive function (measured using the Trail Making Test, Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research tool) and secondary outcomes were episodic memory (measured using the Hopkins Verbal Learning Test-Revised) and microvascular brain injury reflected by magnetic resonance images of white matter lesions', 'executive function measured by Trail Making Test Part B (effect size [ES', 'Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research score', 'Hopkins Verbal Learning Test-Revised delayed recall', 'blood pressure (BP', 'superior neurocognitive outcomes']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0717550', 'cui_str': 'candesartan'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0065374', 'cui_str': 'Lisinopril'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0085756', 'cui_str': 'African American'}]","[{'cui': 'C0065374', 'cui_str': 'Lisinopril'}, {'cui': 'C0717550', 'cui_str': 'candesartan'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0034787', 'cui_str': 'Angiotensin receptor'}]","[{'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}, {'cui': 'C0042531', 'cui_str': 'Verbal learning'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}, {'cui': 'C0558058', 'cui_str': 'Reflecting'}, {'cui': 'C0028580', 'cui_str': 'Nuclear Magnetic Resonance'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C2752009', 'cui_str': 'White matter lesion'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C1282910', 'cui_str': 'Upper'}]",176.0,0.234526,", candesartan was superior to lisinopril on the primary outcome of executive function measured by Trail Making Test Part B (effect size [ES] = -12.8","[{'ForeName': 'Ihab', 'Initials': 'I', 'LastName': 'Hajjar', 'Affiliation': 'Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Okafor', 'Affiliation': 'Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Darius', 'Initials': 'D', 'LastName': 'McDaniel', 'Affiliation': 'Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Malik', 'Initials': 'M', 'LastName': 'Obideen', 'Affiliation': 'Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Dee', 'Affiliation': 'Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Shokouhi', 'Affiliation': 'Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Arshed A', 'Initials': 'AA', 'LastName': 'Quyyumi', 'Affiliation': 'Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Allan', 'Initials': 'A', 'LastName': 'Levey', 'Affiliation': 'Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Felicia', 'Initials': 'F', 'LastName': 'Goldstein', 'Affiliation': 'Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.'}]",JAMA network open,['10.1001/jamanetworkopen.2020.12252'] 2620,32761174,"Effects of a Water, Sanitation and Hygiene Mobile Health Program on Diarrhea and Child Growth in Bangladesh: A Cluster-Randomized Controlled Trial of the CHoBI7 Mobile Health Program.","BACKGROUND The Cholera-Hospital-Based-Intervention-for-7-days (CHoBI7) mobile health (mHealth) program was a cluster-randomized controlled trial of diarrhea patient households conducted in Dhaka, Bangladesh. METHODS Patients were block-randomized to three arms: standard recommendation on oral rehydration solution use; health facility delivery of CHoBI7 plus mHealth (no home visits); and health facility delivery of CHoBI7 plus two home visits and mHealth. The primary outcome was reported diarrhea in the past two weeks collected monthly for 12 months. The secondary outcomes were stunting, underweight, and wasting at a 12 month follow-up. Analysis was intention-to-treat. The trial is registered at ClinicalTrials.gov (NCT04008134). RESULTS Between December 4, 2016 and April 26, 2018, 2626 participants in 769 households were randomly allocated to three arms: 849 participants to standard message, 886 to mHealth with no home visits, and 891 to mHealth with two home visits. Children under five years had significantly lower 12-month diarrhea prevalence in both the mHealth with two home visits arm (Prevalence Ratio(PR): 0.73 (95% Confidence Interval(CI): 0.61, 0.87)) and the mHealth with no home visits arm (PR: 0.82 (95% CI: 0.69, 0.97)). Children under 2 years were significantly less likely to be stunted in both the mHealth with two home visits arm (33% vs. 45%, Odds Ratio(OR): 0.55, 95% CI: 0.31, 0.97) and the mHealth with no home visits arm (32% vs. 45%, OR: 0.54, 95% CI: 0.31, 0.96) compared to children in the standard message arm. CONCLUSION The CHoBI7 mHealth program lowered pediatric diarrhea and stunting among diarrhea patient households.",2020,"Children under five years had significantly lower 12-month diarrhea prevalence in both the mHealth with two home visits arm (Prevalence Ratio(PR): 0.73 (95% Confidence Interval(CI): 0.61, 0.87)) and the mHealth with no home visits arm (PR: 0.82 (95% CI: 0.69, 0.97)).","['Patients were block-randomized to three arms', 'Between December 4, 2016 and April 26, 2018', 'Diarrhea and Child Growth in Bangladesh', 'diarrhea patient households conducted in Dhaka, Bangladesh', '2626 participants in 769 households were randomly allocated to three arms: 849 participants to standard message, 886 to mHealth with no home visits, and 891 to mHealth with two home visits']","['Cholera-Hospital-Based-Intervention-for-7-days (CHoBI7) mobile health (mHealth) program', 'Water, Sanitation and Hygiene Mobile Health Program', 'standard recommendation on oral rehydration solution use; health facility delivery of CHoBI7 plus mHealth (no home visits); and health facility delivery of CHoBI7 plus two home visits and mHealth']","['pediatric diarrhea and stunting', 'diarrhea', '12-month diarrhea prevalence', 'stunting, underweight, and wasting']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}]","[{'cui': 'C0008354', 'cui_str': 'Cholera'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0036172', 'cui_str': 'Sanitation'}, {'cui': 'C0020405', 'cui_str': 'Hygiene'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0078516', 'cui_str': 'World Health Organization oral rehydration solution'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}]","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0018273', 'cui_str': 'Growth disorder'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C0006625', 'cui_str': 'Cachexia'}]",769.0,0.179197,"Children under five years had significantly lower 12-month diarrhea prevalence in both the mHealth with two home visits arm (Prevalence Ratio(PR): 0.73 (95% Confidence Interval(CI): 0.61, 0.87)) and the mHealth with no home visits arm (PR: 0.82 (95% CI: 0.69, 0.97)).","[{'ForeName': 'Christine Marie', 'Initials': 'CM', 'LastName': 'George', 'Affiliation': 'Department of International Health, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Shirajum', 'Initials': 'S', 'LastName': 'Monira', 'Affiliation': 'International Centre for Diarrhoeal Disease Research,\xa0Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Fatema', 'Initials': 'F', 'LastName': 'Zohura', 'Affiliation': 'International Centre for Diarrhoeal Disease Research,\xa0Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Elizabeth D', 'Initials': 'ED', 'LastName': 'Thomas', 'Affiliation': 'Department of International Health, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'M Tasdik', 'Initials': 'MT', 'LastName': 'Hasan', 'Affiliation': 'International Centre for Diarrhoeal Disease Research,\xa0Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Tahmina', 'Initials': 'T', 'LastName': 'Parvin', 'Affiliation': 'International Centre for Diarrhoeal Disease Research,\xa0Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Khaled', 'Initials': 'K', 'LastName': 'Hasan', 'Affiliation': 'Department of International Health, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Mahamud-Ur', 'Initials': 'MU', 'LastName': 'Rashid', 'Affiliation': 'International Centre for Diarrhoeal Disease Research,\xa0Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Nowshin', 'Initials': 'N', 'LastName': 'Papri', 'Affiliation': 'International Centre for Diarrhoeal Disease Research,\xa0Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Aminul', 'Initials': 'A', 'LastName': 'Islam', 'Affiliation': 'International Centre for Diarrhoeal Disease Research,\xa0Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Zillur', 'Initials': 'Z', 'LastName': 'Rahman', 'Affiliation': 'International Centre for Diarrhoeal Disease Research,\xa0Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Raisa', 'Initials': 'R', 'LastName': 'Rafique', 'Affiliation': 'International Centre for Diarrhoeal Disease Research,\xa0Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Sazzadul', 'Initials': 'S', 'LastName': 'Islam Bhuyian', 'Affiliation': 'International Centre for Diarrhoeal Disease Research,\xa0Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Saxton', 'Affiliation': 'Department of International Health, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Labrique', 'Affiliation': 'Department of International Health, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Alland', 'Affiliation': 'Department of International Health, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Indrajeet', 'Initials': 'I', 'LastName': 'Barman', 'Affiliation': 'International Centre for Diarrhoeal Disease Research,\xa0Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Fatema Tuz', 'Initials': 'FT', 'LastName': 'Jubyda', 'Affiliation': 'Department of International Health, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Farzana', 'Initials': 'F', 'LastName': 'Afroze', 'Affiliation': 'International Centre for Diarrhoeal Disease Research,\xa0Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Marzia', 'Initials': 'M', 'LastName': 'Sultana', 'Affiliation': 'International Centre for Diarrhoeal Disease Research,\xa0Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Fatema-Tuz', 'Initials': 'FT', 'LastName': 'Johura', 'Affiliation': 'International Centre for Diarrhoeal Disease Research,\xa0Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Md Abul Hasem', 'Initials': 'MAH', 'LastName': 'Khan', 'Affiliation': 'Bangladesh Ministry of Health and Family Welfare, Dhaka, Bangladesh.'}, {'ForeName': 'Sanya', 'Initials': 'S', 'LastName': 'Tahmina', 'Affiliation': 'Bangladesh Ministry of Health and Family Welfare, Dhaka, Bangladesh.'}, {'ForeName': 'Farzana', 'Initials': 'F', 'LastName': 'Munmun', 'Affiliation': 'Bangladesh Ministry of Health and Family Welfare, Dhaka, Bangladesh.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Sack', 'Affiliation': 'Department of International Health, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Perin', 'Affiliation': 'Department of International Health, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Munirul', 'Initials': 'M', 'LastName': 'Alam', 'Affiliation': 'International Centre for Diarrhoeal Disease Research,\xa0Bangladesh, Dhaka, Bangladesh.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciaa754'] 2621,32761191,"Efficacy of Ketogenic Diet, Modified Atkins Diet, and Low Glycemic Index Therapy Diet Among Children With Drug-Resistant Epilepsy: A Randomized Clinical Trial.","Importance The ketogenic diet (KD) has been used successfully to treat children with drug-resistant epilepsy. Data assessing the efficacy of the modified Atkins diet (MAD) and low glycemic index therapy (LGIT) diet compared with the KD are scarce. Objective To determine whether the MAD and LGIT diet are noninferior to the KD among children with drug-resistant epilepsy. Design, Setting, and Participants One hundred seventy children aged between 1 and 15 years who had 4 or more seizures per month, had not responded to 2 or more antiseizure drugs, and had not been treated previously with the KD, MAD, or LGIT diet were enrolled between April 1, 2016, and August 20, 2017, at a tertiary care referral center in India. Exposures Children were randomly assigned to receive the KD, MAD, or LGIT diet as additions to ongoing therapy with antiseizure drugs. Main Outcomes and Measures Primary outcome was percentage change in seizure frequency after 24 weeks of dietary therapy in the MAD cohort compared with the KD cohort and in the LGIT diet cohort compared with the KD cohort. The trial was powered to assess noninferiority of the MAD and LGIT diet compared with the KD with a predefined, noninferiority margin of -15 percentage points. Intention-to-treat analysis was used. Results One hundred fifty-eight children completed the trial: KD (n = 52), MAD (n = 52), and LGIT diet (n = 54). Intention-to-treat analysis showed that, after 24 weeks of intervention, the median (interquartile range [IQR]) change in seizure frequency (KD: -66%; IQR, -85% to -38%; MAD: -45%; IQR, -91% to -7%; and LGIT diet: -54%; IQR, -92% to -19%) was similar among the 3 arms (P = .39). The median difference, per intention-to-treat analysis, in seizure reduction between the KD and MAD arms was -21 percentage points (95% CI, -29 to -3 percentage points) and between the KD and LGIT arms was -12 percentage points (95% CI, -21 to 7 percentage points), with both breaching the noninferiority margin of -15 percentage points. Treatment-related adverse events were similar between the KD (31 of 55 [56.4%]) and MAD (33 of 58 [56.9%]) arms but were significantly less in the LGIT diet arm (19 of 57 [33.3%]). Conclusions and Relevance Neither the MAD nor the LGIT diet met the noninferiority criteria. However, the results of this study for the LGIT diet showed a balance between seizure reduction and relatively fewer adverse events compared with the KD and MAD. These potential benefits suggest that the risk-benefit decision with regard to the 3 diet interventions needs to be individualized. Trial Registration ClinicalTrials.gov Identifier: NCT02708030.",2020,Treatment-related adverse events were similar between the KD (31 of 55 [56.4%]) and MAD (33 of 58 [56.9%]) arms,"['children with drug-resistant epilepsy', 'Participants\n\n\nOne hundred seventy children aged between 1 and 15 years who had 4 or more seizures per month, had not responded to 2 or more antiseizure drugs, and had not been treated previously with the KD, MAD, or LGIT diet were enrolled between April 1, 2016, and August 20, 2017, at a tertiary care referral center in India', 'One hundred fifty-eight children completed the trial: KD (n\u2009=\u200952), MAD (n\u2009=\u200952), and', 'Exposures\n\n\nChildren', 'Children With Drug-Resistant Epilepsy']","['LGIT diet', 'Ketogenic Diet, Modified Atkins Diet, and Low Glycemic Index Therapy Diet', 'MAD and LGIT diet', 'modified Atkins diet (MAD) and low glycemic index therapy (LGIT) diet', 'ketogenic diet (KD', 'KD, MAD, or LGIT diet as additions to ongoing therapy with antiseizure drugs']","['seizure frequency', 'adverse events', 'MAD', 'median difference, per intention-to-treat analysis, in seizure reduction']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1096063', 'cui_str': 'Refractory epilepsy'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0259972', 'cui_str': 'Ketogenic diet'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0259972', 'cui_str': 'Ketogenic diet'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0149775', 'cui_str': 'Fit frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",170.0,0.11082,Treatment-related adverse events were similar between the KD (31 of 55 [56.4%]) and MAD (33 of 58 [56.9%]) arms,"[{'ForeName': 'Vishal', 'Initials': 'V', 'LastName': 'Sondhi', 'Affiliation': 'Center of Excellence & Advanced Research on Childhood Neurodevelopmental Disorders, Child Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Anuja', 'Initials': 'A', 'LastName': 'Agarwala', 'Affiliation': 'Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Ravindra M', 'Initials': 'RM', 'LastName': 'Pandey', 'Affiliation': 'Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Biswaroop', 'Initials': 'B', 'LastName': 'Chakrabarty', 'Affiliation': 'Center of Excellence & Advanced Research on Childhood Neurodevelopmental Disorders, Child Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Prashant', 'Initials': 'P', 'LastName': 'Jauhari', 'Affiliation': 'Center of Excellence & Advanced Research on Childhood Neurodevelopmental Disorders, Child Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Rakesh', 'Initials': 'R', 'LastName': 'Lodha', 'Affiliation': 'Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Gurudyal S', 'Initials': 'GS', 'LastName': 'Toteja', 'Affiliation': 'Scientist H & Head (Nutrition), Indian Council of Medical Research, New Delhi, India.'}, {'ForeName': 'Shobha', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'Center of Excellence & Advanced Research on Childhood Neurodevelopmental Disorders, Child Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Vinod K', 'Initials': 'VK', 'LastName': 'Paul', 'Affiliation': 'Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Kossoff', 'Affiliation': 'Department of Neurology, Johns Hopkins Hospital, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Sheffali', 'Initials': 'S', 'LastName': 'Gulati', 'Affiliation': 'Center of Excellence & Advanced Research on Childhood Neurodevelopmental Disorders, Child Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.'}]",JAMA pediatrics,['10.1001/jamapediatrics.2020.2282'] 2622,32761194,Erratum to: Pilot Randomized Controlled Trial of a Novel Smoking Cessation App Designed for Individuals With Co-Occurring Tobacco Dependence and Serious Mental Illness.,,2020,,['Individuals With Co-Occurring Tobacco Dependence and Serious Mental Illness'],['Novel Smoking Cessation App'],[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0040332', 'cui_str': 'Tobacco dependence syndrome'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}]",[],,0.0996597,,"[{'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Vilardaga', 'Affiliation': ''}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Rizo', 'Affiliation': ''}, {'ForeName': 'Paige E', 'Initials': 'PE', 'LastName': 'Palenski', 'Affiliation': ''}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Mannelli', 'Affiliation': ''}, {'ForeName': 'Jason A', 'Initials': 'JA', 'LastName': 'Oliver', 'Affiliation': ''}, {'ForeName': 'Francis J', 'Initials': 'FJ', 'LastName': 'McClernon', 'Affiliation': ''}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntaa125'] 2623,32761276,Patellar denervation does not reduce post-operative anterior knee pain after primary total knee arthroplasty with patellar resurfacing.,"PURPOSE Anterior knee pain (AKP) is a frequent symptom after a total knee arthroplasty (TKA). Patellar denervation (PD) has been put forth as a technique to reduce this pain; however, its effects have not been assessed in combination with patellar resurfacing. The aim of this study is to evaluate the effect of PD on AKP and functional outcomes after TKA with patellar resurfacing. METHODS A prospective study was designed that included patients scheduled for TKA with patellar resurfacing. The 202 recruited patients were randomized into either the PD group or the non-denervation group [mean age 72.7 years (SD 8.2); 119 (70.4%) women and 50 (29.6%) men; average body mass index 31.4 kg/m 2 (SD 4.9)]. Pressure pain threshold (PPT) assessed by pressure algometry (PA), visual analogue scale(VAS), patellofemoral Feller score and the Knee Society Scores (KSS) were recorded preoperatively and at the 1-year follow-up. RESULTS 169 patients were included in data analysis. At the 1-year follow-up, there were mild differences between denervation and non-denervation group in PPT value (494.4 kPa vs. 552.3 kPa, p = 0.047) and in VAS at stairs (2.9 vs. 1.5, p = 0.003) in favour of the non-denervation group. There was no difference in the improvement between groups in patellofemoral Feller score and KSS, but slightly higher improvement in non-denervation group in PPT (94.1 kPa vs. 160 kPa, p = 0.047), VAS walking (5.3 vs. 6.2, p = 0.041) and VAS at stairs (4.6 vs. 5.7, p = 0.022). CONCLUSION Patellar denervation does not improve AKP and clinical outcomes in primary TKA with patellar resurfacing compared to patellar replacement without denervation. PD cannot be recommended when patellar replacement is performed in TKA. LEVEL OF EVIDENCE II.",2020,"There was no difference in the improvement between groups in patellofemoral Feller score and KSS, but slightly higher improvement in non-denervation group in PPT (94.1 kPa vs. 160 kPa, p = 0.047), VAS walking (5.3 vs. 6.2, p = 0.041) and VAS at stairs (4.6 vs. 5.7, p = 0.022). ","['total knee arthroplasty (TKA', '202 recruited patients were randomized into either the PD group or the non-denervation group [mean age 72.7\xa0years (SD 8.2); 119 (70.4%) women and 50 (29.6%) men; average body mass index 31.4\xa0kg/m 2 (SD 4.9', '169 patients were included in data analysis', 'primary total knee arthroplasty with patellar resurfacing', 'included patients scheduled for TKA with patellar resurfacing']","['PD', 'TKA with patellar resurfacing', 'Patellar denervation (PD', 'patellar resurfacing']","['patellofemoral Feller score and KSS', 'VAS walking', 'AKP and clinical outcomes', 'Pressure pain threshold (PPT) assessed by pressure algometry (PA), visual analogue scale(VAS), patellofemoral Feller score and the Knee Society Scores (KSS', 'VAS at stairs']","[{'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030647', 'cui_str': 'Bone structure of patella'}, {'cui': 'C0011307', 'cui_str': 'Denervation - action'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}]","[{'cui': 'C0030647', 'cui_str': 'Bone structure of patella'}, {'cui': 'C0011307', 'cui_str': 'Denervation - action'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0022541', 'cui_str': 'Kearns-Sayre syndrome'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0409326', 'cui_str': 'Anterior knee pain'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0037455', 'cui_str': 'Societies'}]",202.0,0.0882839,"There was no difference in the improvement between groups in patellofemoral Feller score and KSS, but slightly higher improvement in non-denervation group in PPT (94.1 kPa vs. 160 kPa, p = 0.047), VAS walking (5.3 vs. 6.2, p = 0.041) and VAS at stairs (4.6 vs. 5.7, p = 0.022). ","[{'ForeName': 'Nerea', 'Initials': 'N', 'LastName': 'Goicoechea', 'Affiliation': 'Department of Orthopaedic Surgery, Parc de Salut Mar, Hospital de la Esperanza, Universitat Autònoma de Barcelona, Sant Josep de la Muntanya 12, 08024, Barcelona, Spain. 62225@parcdesalutmar.cat.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Hinarejos', 'Affiliation': 'Department of Orthopaedic Surgery, Parc de Salut Mar, Hospital de la Esperanza, Universitat Autònoma de Barcelona, Sant Josep de la Muntanya 12, 08024, Barcelona, Spain.'}, {'ForeName': 'Raul', 'Initials': 'R', 'LastName': 'Torres-Claramunt', 'Affiliation': 'Department of Orthopaedic Surgery, Parc de Salut Mar, Hospital de la Esperanza, Universitat Autònoma de Barcelona, Sant Josep de la Muntanya 12, 08024, Barcelona, Spain.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Leal-Blanquet', 'Affiliation': 'Department of Orthopaedic Surgery, Parc de Salut Mar, Hospital de la Esperanza, Universitat Autònoma de Barcelona, Sant Josep de la Muntanya 12, 08024, Barcelona, Spain.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Sánchez-Soler', 'Affiliation': 'Department of Orthopaedic Surgery, Parc de Salut Mar, Hospital de la Esperanza, Universitat Autònoma de Barcelona, Sant Josep de la Muntanya 12, 08024, Barcelona, Spain.'}, {'ForeName': 'Joan Carles', 'Initials': 'JC', 'LastName': 'Monllau', 'Affiliation': 'Department of Orthopaedic Surgery, Parc de Salut Mar, Hospital de la Esperanza, Universitat Autònoma de Barcelona, Sant Josep de la Muntanya 12, 08024, Barcelona, Spain.'}]","Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA",['10.1007/s00167-020-06164-5'] 2624,32758684,Is it worth using low-cost glass ionomer cements for occlusal ART restorations in primary molars? 2-year survival and cost analysis of a Randomized clinical trial.,"OBJECTIVE To evaluate the 2-year survival rate and the cost-effectiveness of Atraumatic Restorative Treatment (ART) using three different glass ionomer cements (GICs) for restoring occlusal dentin caries lesions in primary molars. METHODS 150 4-8-year-old children were selected, randomly allocated and treated in school tables according to the restorative material: Fuji IX Gold Label (GC Corp), Vitro Molar (nova DFL) and Maxxion R (FGM), the latter two being low-cost brands. Materials and professionals' costs were considered to analyse baseline total cost, and from this the cumulative cost of each treatment was calculated. Restoration assessments were performed after 2, 6, 12 and 24 months by an independent calibrated examiner. Restoration survival was estimated using Kaplan-Meier survival analysis and Cox regression was used to test association with clinical factors. Bootstrap regression (1,000 replications) compared material´s cost over time and Monte-Carlo simulation was used to build cost-effectiveness scatter plots. RESULTS The overall survival rate of occlusal ART restorations after 2 years was 53% (Fuji IX = 72.7%; Vitro Molar = 46.5%; Maxxion R = 39.6%). Restorations performed with Vitro Molar and Maxxion R were more likely to fail when compared to Fuji IX. At baseline, Fuji IX was the more expensive option (p < 0.001), however, considering the simulation of accumulated cost caused by failures until 2-year evaluation, no difference was found between the groups. CONCLUSIONS After 2 years' follow up, restorations performed with Fuji IX proved to be superior in terms of survival, with a similar overall cost, when compared to low-cost glass ionomers cements (Vitro Molar and Maxxion R).",2020,"After 2 years' follow up, restorations performed with Fuji IX proved to be superior in terms of survival, with a similar overall cost, when compared to low-cost glass ionomers cements (Vitro Molar and Maxxion R).","['150 4-8-year-old children', 'primary molars']","['glass ionomer cements (GICs', 'restorative material: Fuji IX Gold Label (GC Corp), Vitro Molar (nova DFL) and Maxxion R (FGM', 'Atraumatic Restorative Treatment (ART', 'Fuji IX']","['overall survival rate of occlusal ART restorations', 'Restoration survival', '2-year survival rate']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}]","[{'cui': 'C0017597', 'cui_str': 'Glass-ionomer dental material'}, {'cui': 'C0182981', 'cui_str': 'Dental restorative material'}, {'cui': 'C0671561', 'cui_str': 'fuji IX'}, {'cui': 'C0018026', 'cui_str': 'Gold'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C3529286', 'cui_str': 'Maxxion'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0447303', 'cui_str': 'Structure of occlusal surface of tooth'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0439234', 'cui_str': 'year'}]",,0.0977731,"After 2 years' follow up, restorations performed with Fuji IX proved to be superior in terms of survival, with a similar overall cost, when compared to low-cost glass ionomers cements (Vitro Molar and Maxxion R).","[{'ForeName': 'Isabel Cristina', 'Initials': 'IC', 'LastName': 'Olegário', 'Affiliation': 'Department of Public and Child Dental Health, Dublin Dental University Hospital, University of Dublin, Trinity College, Dublin, Ireland; Department of Paediatric Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Nathalia de Miranda', 'Initials': 'NM', 'LastName': 'Ladewig', 'Affiliation': 'Department of Paediatric Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Hesse', 'Affiliation': 'Department of Cariology, Endodontics and Pedodontology, Academic Centre for Dentistry Amsterdam (ACTA), Amsterdam, the Netherlands.'}, {'ForeName': 'Clarissa Calil', 'Initials': 'CC', 'LastName': 'Bonifácio', 'Affiliation': 'Department of Cariology, Endodontics and Pedodontology, Academic Centre for Dentistry Amsterdam (ACTA), Amsterdam, the Netherlands.'}, {'ForeName': 'Mariana Minatel', 'Initials': 'MM', 'LastName': 'Braga', 'Affiliation': 'Department of Paediatric Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'José Carlos Pettorossi', 'Initials': 'JCP', 'LastName': 'Imparato', 'Affiliation': 'Department of Paediatric Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Fausto Medeiros', 'Initials': 'FM', 'LastName': 'Mendes', 'Affiliation': 'Department of Paediatric Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Daniela Prócida', 'Initials': 'DP', 'LastName': 'Raggio', 'Affiliation': 'Department of Paediatric Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil. Electronic address: danielar@usp.br.'}]",Journal of dentistry,['10.1016/j.jdent.2020.103446'] 2625,32758689,"SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial.","BACKGROUND The anti-viral effects of Novaferon, a potent antiviral protein drug on COVID-19 was evaluated in laboratory, and in a randomized, open-label, parallel group trial. METHODS In laboratory, the inhibition of Novaferon on viral replication in cells infected with SARS-CoV-2, and on prevention of SARS-CoV-2 entry into healthy cells was determined. Antiviral effects of Novaferon in COVID-19 patients with treatment of Novaferon, Novaferon plus Lopinavir/Ritonavir, or Lopinavir/Ritonavir were evaluated. The primary endpoint was the SARS-CoV-2 clearance rates on day 6 of treatment, and the secondary endpoint was the time to SARS-CoV-2 clearance. RESULTS Novaferon inhibited the viral replication (EC 50  = 1.02 ng/ml), and prevented viral infection (EC 50  = 0.10 ng/ml). Results from the 89 enrolled COVID-19 patients showed that both Novaferon and Novaferon plus Lopinavir/Ritonavir groups had significantly higher viral clearance rates on day 6than Lopinavir/Ritonavir group (50.0% vs.24.1%, p = 0.0400, and 60.0% vs.24.1%, p = 0.0053). Median time to viral clearance were 6 days, 6 days, and 9 days for three groups respectively, a 3-dayreductionin both Novaferon and Novaferon plus Lopinavir/Ritonavir groups compared with Lopinavir/Ritonavir group. CONCLUSIONS Novaferon exhibited anti-SARS-CoV-2 effects in vitro and in COVID-19 patients. These data justified the further evaluation of Novaferon. TRIAL REGISTRATION NUMBER number ChiCTR2000029496at the Chinese Clinical Trial Registry (http://www.chictr.org.cn/).",2020,"RESULTS Novaferon inhibited the viral replication (EC 50  = 1.02 ng/ml), and prevented viral infection (EC 50  = 0.10 ng/ml).","['COVID-19 patients with treatment of Novaferon', 'COVID-19 Patients with Novaferon Treatment']","['Lopinavir/Ritonavir', 'Novaferon plus Lopinavir/Ritonavir, or Lopinavir/Ritonavir', 'Novaferon', '6than Lopinavir/Ritonavir']","['viral infection', 'SARS-CoV-2 Clearance', 'Median time to viral clearance', 'viral replication', 'SARS-CoV-2 clearance rates', 'time to SARS-CoV-2 clearance', 'viral clearance rates']","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C3273451', 'cui_str': 'Novaferon'}]","[{'cui': 'C0939237', 'cui_str': 'lopinavir and ritonavir'}, {'cui': 'C3273451', 'cui_str': 'Novaferon'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0042769', 'cui_str': 'Viral disease'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0042774', 'cui_str': 'Virus Replication'}, {'cui': 'C0025515', 'cui_str': 'Metabolic clearance rate'}]",89.0,0.111733,"RESULTS Novaferon inhibited the viral replication (EC 50  = 1.02 ng/ml), and prevented viral infection (EC 50  = 0.10 ng/ml).","[{'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Zheng', 'Affiliation': 'Department of Infectious Diseases, The First Hospital of Changsha, Changsha, China.'}, {'ForeName': 'Yanwen', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Zhiguo', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': 'Department of Respiratory Medicine, The First Hospital of Changsha, Changsha, China.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Ye', 'Affiliation': 'National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.'}, {'ForeName': 'Baoying', 'Initials': 'B', 'LastName': 'Huang', 'Affiliation': 'National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.'}, {'ForeName': 'Yaxiong', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': 'Department of Infectious Diseases, The First Hospital of Changsha, Changsha, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': 'Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Zuo', 'Affiliation': 'Department of Intensive Care Unit, The First Hospital of Changsha, Changsha, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Tan', 'Affiliation': 'Department of Pediatrics, The First Hospital of Changsha, Changsha, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Xie', 'Affiliation': 'Department of Internal Medicine, The First Hospital of Changsha, Changsha, China.'}, {'ForeName': 'Peihua', 'Initials': 'P', 'LastName': 'Niu', 'Affiliation': 'National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.'}, {'ForeName': 'Wenlong', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Peng', 'Affiliation': 'Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Zhou', 'Affiliation': 'Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Chunlin', 'Initials': 'C', 'LastName': 'Cai', 'Affiliation': 'Department of Infectious Diseases, The First Hospital of Changsha, Changsha, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Tang', 'Affiliation': 'Department of Infectious Diseases, The First Hospital of Changsha, Changsha, China.'}, {'ForeName': 'Xinqiang', 'Initials': 'X', 'LastName': 'Xiao', 'Affiliation': 'Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Zhiguang', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': 'Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, National Clinical Research Center for Metabolic Diseases, the Second Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Yongfang', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': 'Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China. Electronic address: jiangyongfang@csu.edu.cn.'}, {'ForeName': 'Yuanlin', 'Initials': 'Y', 'LastName': 'Xie', 'Affiliation': 'Department of Infectious Diseases, The First Hospital of Changsha, Changsha, China. Electronic address: 1286779459@qq.com.'}, {'ForeName': 'Wenjie', 'Initials': 'W', 'LastName': 'Tan', 'Affiliation': 'National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. Electronic address: tanwj@ivdc.chinacdc.cn.'}, {'ForeName': 'Guozhong', 'Initials': 'G', 'LastName': 'Gong', 'Affiliation': 'Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China. Electronic address: gongguozhong@csu.edu.cn.'}]",International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,['10.1016/j.ijid.2020.07.053'] 2626,32759074,Auricular acupuncture for the treatment of nonepileptic seizures: A pilot study.,"OBJECTIVE The aim of this pilot study was to examine the safety and tolerability of an eight-week treatment of twice weekly auricular acupuncture as a therapeutic intervention for the treatment of psychogenic nonepileptic seizures (PNES). The secondary aim was to determine if auricular acupuncture was effective at reducing PNES event frequency. Psychogenic nonepileptic seizures are as common as multiple sclerosis and are highly resistant to intervention. Unfortunately, there is no standard of care therapy, although mental health treatment referrals are commonly made. Acupuncture is felt to be a safe and cost-effective treatment for many diseases and symptoms including mental health disorders such as posttraumatic stress disorder (PTSD), anxiety, and conversion disorders. We propose to examine auricular acupuncture as a treatment for PNES. METHODS A single-center, 16-week trial of auricular acupuncture was designed: a four-week baseline period, followed by an eight-week active treatment period during which subjects received twice weekly auricular acupuncture, then followed by a four-week washout period. Tolerability was defined as completion of 12 of 16 treatments. Successful compliance with seizure diary was defined as >80%, or 100 of 120 days completed. Safety profile was established and seizure count per week was also calculated. RESULTS A total of 29 subjects enrolled from a consecutive sample of 73 PNES diagnoses discharging from our epilepsy unit. Twenty-two subjects entered the study with 91% completing more than 12 of 16 treatments, 91% meeting the endpoint of completing >80% of diary entries. Adverse events were mild, and only two subjects were withdrawn due to increased PNES frequency. Although short-term in design, using one-way repeated measures analysis of variance (ANOVA), we observed a statistically significant reduction in seizure count from baseline at treatment month one, treatment month two, and at the washout period (p = 0.0083). Eleven of 12 subjects (52.3%) who received at least one treatment recorded a 50% frequency reduction. Three of 21 subjects (14%) were PNES-free at the end of the study. SIGNIFICANCE Auricular acupuncture is well-tolerated in a population with PNES and exhibits similar event frequency reductions as cognitive behavioral therapy (CBT). We believe that this is the first literature report examining auricular acupuncture for the treatment of PNES.",2020,"SIGNIFICANCE Auricular acupuncture is well-tolerated in a population with PNES and exhibits similar event frequency reductions as cognitive behavioral therapy (CBT).","['psychogenic nonepileptic seizures (PNES', 'Twenty-two subjects entered the study with 91% completing more than 12 of 16 treatments, 91% meeting the endpoint of completing >80% of diary entries', 'nonepileptic seizures', 'A total of 29 subjects enrolled from a consecutive sample of 73 PNES diagnoses discharging from our epilepsy unit', 'Three of 21 subjects (14%) were PNES-free at the end of the study']","['auricular acupuncture', 'Acupuncture', 'Auricular acupuncture']","['Adverse events', 'Psychogenic nonepileptic seizures', 'safety and tolerability', 'Tolerability', 'seizure count']","[{'cui': 'C0458006', 'cui_str': 'Psychogenic'}, {'cui': 'C3495874', 'cui_str': 'Non-Epileptic Seizures'}, {'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0444930', 'cui_str': 'End'}]","[{'cui': 'C0752217', 'cui_str': 'Ear Acupuncture'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0458006', 'cui_str': 'Psychogenic'}, {'cui': 'C3495874', 'cui_str': 'Non-Epileptic Seizures'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0439157', 'cui_str': 'counts'}]",29.0,0.0284195,"SIGNIFICANCE Auricular acupuncture is well-tolerated in a population with PNES and exhibits similar event frequency reductions as cognitive behavioral therapy (CBT).","[{'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Maa', 'Affiliation': 'Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, United States of America; University of Colorado, 12401 E. 17th Avenue Mail Stop F782, Aurora, CO 80045, United States of America. Electronic address: Edward.maa@dhha.org.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Applegate', 'Affiliation': 'St. Joseph Hospital, 1375 E. 19th Avenue, Denver, CO 80218, United States of America. Electronic address: Matt.Applegate@sclhealth.org.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Keniston', 'Affiliation': 'University of Colorado, 12401 E. 17th Avenue Mail Stop F782, Aurora, CO 80045, United States of America. Electronic address: Angela.keniston@cuanschutz.edu.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2020.107329'] 2627,32759079,"Corrections to ""Audomni: Super-Scale Sensory Supplementation to Increase the Mobility of Blind and Low-Vision Individuals-A Pilot Study"".",,2020,,[],[],['Mobility of Blind and Low-Vision'],[],[],"[{'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0042798', 'cui_str': 'Dim vision'}]",,0.0236417,,"[{'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Isaksson', 'Affiliation': ''}, {'ForeName': 'Tomas', 'Initials': 'T', 'LastName': 'Jansson', 'Affiliation': ''}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Nilsson', 'Affiliation': ''}]",IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society,['10.1109/TNSRE.2020.3002048'] 2628,32759096,Short-term outcome of Polytetrafluoroethylene Membrane Valve versus Transannular Pericardial patch Reconstruction of Right Ventricular Outflow Tract in Tetralogy of Fallot : a Randomized Controlled Trial.,"INTRODUCTION Reconstruction of right ventricular outflow tract during primary repair of tetralogy of Fallot often requires the placement of a transannular patch which results in pulmonary regurgitation (PR). We compared the short-term outcomes of bicuspid polytetrafluoroethylene membrane valve versus transannular pericardial patch reconstruction of the right ventricular outflow tract. METHODS Thirty consecutive patients undergoing primary repair of tetralogy of Fallot were randomly allocated to two groups - polytetrafluoroethylene valve (PTFEV) group (n=15) and transannular pericardial patch (TAP) group (n=15). The two groups had similar preoperative demographic characteristics. We compared the short-term clinical and echocardiographic outcomes between these groups. The transthoracic echocardiographic follow-up was performed at one week, one month and six months after surgery. RESULTS The PTFEV group had significantly lower central venous pressure in the immediate postoperative period compared to the TAP group (7.60±2.06 vs. 10.13±1.73, P=0.002). Extubation time was significantly shorter in the PTFEV group compared to the TAP group (12.93±7.55 hrs vs. 22.23±15.11 hrs, P=0.04). PR in the PTFEV group was absent in five patients at 24 hours post-surgery. At the study endpoint, PR was absent in six, trivial in one and mild in eight patients in the PTFEV group compared to TAP group, where all 15 patients had severe PR. CONCLUSION The bicuspid polytetrafluoroethylene membrane valves significantly decrease the central venous pressure in the immediate postoperative period, facilitate early extubation and, thus, prevent ventilator-related comorbidities. They achieve a high degree of pulmonary competence and do not increase the right ventricular outflow tract gradient in short-term follow-up.",2020,"Extubation time was significantly shorter in the PTFEV group compared to the TAP group (12.93±7.55 hrs vs. 22.23±15.11 hrs, P=0.04).","['Thirty consecutive patients undergoing primary repair of tetralogy of Fallot', 'Tetralogy of Fallot ']","['transannular pericardial patch (TAP', 'polytetrafluoroethylene valve (PTFEV', 'Polytetrafluoroethylene Membrane Valve versus Transannular Pericardial patch Reconstruction of Right Ventricular Outflow Tract', 'TAP', 'PTFEV', 'bicuspid polytetrafluoroethylene membrane valve versus transannular pericardial patch reconstruction']","['severe PR', 'Extubation time', 'right ventricular outflow tract gradient', 'central venous pressure']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0397326', 'cui_str': 'Repair of tetralogy of Fallot'}, {'cui': 'C0039685', 'cui_str': 'Tetralogy of Fallot'}]","[{'cui': 'C0581772', 'cui_str': 'Transannular'}, {'cui': 'C0440774', 'cui_str': 'Pericardial patch'}, {'cui': 'C0034115', 'cui_str': 'Centesis'}, {'cui': 'C0032611', 'cui_str': 'Polytetrafluoroethylene'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0225892', 'cui_str': 'Structure of outflow tract of right ventricle'}, {'cui': 'C0005373', 'cui_str': 'Bicuspid'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0034088', 'cui_str': 'Pulmonic valve regurgitation'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0225892', 'cui_str': 'Structure of outflow tract of right ventricle'}, {'cui': 'C0199666', 'cui_str': 'Measurement of central venous pressure'}]",30.0,0.019597,"Extubation time was significantly shorter in the PTFEV group compared to the TAP group (12.93±7.55 hrs vs. 22.23±15.11 hrs, P=0.04).","[{'ForeName': 'Sanjib', 'Initials': 'S', 'LastName': 'Rawat', 'Affiliation': 'Institute of Medical Education and Research Department of Cardiovascular and Thoracic Surgery Chandigarh India Department of Cardiovascular and Thoracic Surgery, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.'}, {'ForeName': 'Vivek', 'Initials': 'V', 'LastName': 'Jaswal', 'Affiliation': 'Institute of Medical Education and Research Department of Cardiovascular and Thoracic Surgery Chandigarh India Department of Cardiovascular and Thoracic Surgery, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.'}, {'ForeName': 'Shyam Kumar Singh', 'Initials': 'SKS', 'LastName': 'Thingnam', 'Affiliation': 'Institute of Medical Education and Research Department of Cardiovascular and Thoracic Surgery Chandigarh India Department of Cardiovascular and Thoracic Surgery, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.'}, {'ForeName': 'Harkant', 'Initials': 'H', 'LastName': 'Singh', 'Affiliation': 'Institute of Medical Education and Research Department of Cardiovascular and Thoracic Surgery Chandigarh India Department of Cardiovascular and Thoracic Surgery, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.'}, {'ForeName': 'Sachin', 'Initials': 'S', 'LastName': 'Mahajan', 'Affiliation': 'Institute of Medical Education and Research Department of Cardiovascular and Thoracic Surgery Chandigarh India Department of Cardiovascular and Thoracic Surgery, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.'}, {'ForeName': 'Reuben Lamiaki', 'Initials': 'RL', 'LastName': 'Kynta', 'Affiliation': 'Institute of Medical Education and Research Department of Cardiovascular and Thoracic Surgery Chandigarh India Department of Cardiovascular and Thoracic Surgery, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.'}, {'ForeName': 'Goverdhan Dutt', 'Initials': 'GD', 'LastName': 'Puri', 'Affiliation': 'Institute of Medical Education and Research Department of Anaesthesia and Critical Care Chandigarh India Department of Anaesthesia and Critical Care, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.'}, {'ForeName': 'Manoj Kumar', 'Initials': 'MK', 'LastName': 'Rohit', 'Affiliation': 'Institute of Medical Education and Research Department of Cardiology Chandigarh India Department of Cardiology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.'}]",Brazilian journal of cardiovascular surgery,['10.21470/1678-9741-2020-0059'] 2629,32759165,"Preliminary Results on Acceptance, Feasibility, and Subjective Efficacy of the Add-On Group Intervention Metacognitive Training for Borderline Patients.","OBJECTIVE The add-on intervention ""metacognitive training for borderline patients (B-MCT)"" targets cognitive biases in patients with borderline personality disorder (BPD). We aimed to evaluate acceptance, feasibility, and subjective use of this group intervention. METHODS Forty-eight inpatients with BPD were randomly assigned to 8 sessions of B-MCT versus an active control intervention (progressive muscle relaxation). Subjective use was assessed after 4 weeks. RESULTS B-MCT yielded significantly superior scores relative to the control group on several parameters, for example, use, fun, recommendation, and subjective improvements in symptomatology and cognitive abilities (e.g., perspective taking). CONCLUSIONS The trial provides preliminary evidence for the acceptance and feasibility of metacognitive training in BPD. However, randomized controlled trials with larger samples and symptomatic outcomes are needed to investigate the specific impact of B-MCT on psychopathology and cognition.",2015,"RESULTS B-MCT yielded significantly superior scores relative to the control group on several parameters, for example, use, fun, recommendation, and subjective improvements in symptomatology and cognitive abilities (e.g., perspective taking). ","['patients with borderline personality disorder (BPD', 'Forty-eight inpatients with BPD', 'Borderline Patients']","['metacognitive training', 'MCT versus an active control intervention (progressive muscle relaxation', 'intervention ""metacognitive training']","['Acceptance, Feasibility, and Subjective Efficacy', 'symptomatology and cognitive abilities (e.g., perspective taking']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006012', 'cui_str': 'Borderline personality disorder'}, {'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0026687', 'cui_str': 'Mucociliary clearance'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0454043', 'cui_str': 'Jacobson technique'}]","[{'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C1515187', 'cui_str': 'Take'}]",48.0,0.0319838,"RESULTS B-MCT yielded significantly superior scores relative to the control group on several parameters, for example, use, fun, recommendation, and subjective improvements in symptomatology and cognitive abilities (e.g., perspective taking). ","[{'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Schilling', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Asklepios Clinic Nord-Wandsbek, Hamburg, Germany l.schilling@asklepios.com.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Moritz', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Asklepios Clinic Nord-Wandsbek, Hamburg, Germany.'}, {'ForeName': 'Ulf', 'Initials': 'U', 'LastName': 'Köther', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Nagel', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Asklepios Clinic Nord-Wandsbek, Hamburg, Germany.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.29.2.153'] 2630,32759193,Prevention of Benign Paroxysmal Positional Vertigo with Vit D Supplementation: A Randomized Trial.,"OBJECTIVE To assess the effect of vitamin D and calcium supplementation in preventing recurrences of benign paroxysmal positional vertigo (BPPV). METHODS We performed an investigator-initiated, blinded-outcome-assessor, parallel, multicenter, randomized controlled trial in 8 hospitals between December 2013 and May 2017. Patients with confirmed BPPV were randomly assigned to the intervention (n=518) or the observation (n=532) group after a successful treatment with canalith repositioning maneuvers. The primary outcome was the annual recurrence rate (ARR). Patients in the intervention group had taken vitamin D 400 IU and 500 mg of calcium carbonate twice a day for one year when serum vitamin D level was lower than 20 ng/ml. Patients in the observation group were assigned to follow-ups without further vitamin D evaluation or supplementation. RESULTS The intervention group showed a reduction in the ARR [0.83 (95% CI: 0.74-0.92) vs. 1.10 (95% CI: 1.00-1.19) recurrences per one-person year] with an incidence rate ratio of 0.76 (95% CI: 0.66-0.87, p <0.001) and an absolute rate ratio of -0.27 (-0.40 to -0.14) from intention to treat analysis. The number needed to treat was 3.70 (95% CI: 2.50-7.14). The proportion of patients with recurrence was also lower in the intervention than in the observation group (37.8 vs. 46.7%, p =0.005). CONCLUSIONS Supplementation of vitamin D and calcium may be considered in patients with frequent attacks of BPPV, especially when serum vitamin D is subnormal. CLASSIFICATION OF EVIDENCE This study provides Class III evidence that for patients with BPPV, vitamin D and calcium supplementation reduces recurrences of BPPV.",2020,The intervention group showed a reduction in the ARR [0.83,"['8 hospitals between December 2013 and May 2017', 'patients with frequent attacks of BPPV', 'Patients with confirmed BPPV', 'patients with BPPV']","['vitamin D 400 IU and 500 mg of calcium carbonate', 'Vit D Supplementation', 'vitamin D evaluation or supplementation', 'canalith repositioning maneuvers', 'vitamin D and calcium', 'vitamin D and calcium supplementation']","['proportion of patients with recurrence', 'absolute rate ratio', 'serum vitamin D level', 'annual recurrence rate (ARR', 'recurrences of benign paroxysmal positional vertigo (BPPV']","[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0004063', 'cui_str': 'Assault'}, {'cui': 'C0155502', 'cui_str': 'Benign paroxysmal positional vertigo'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0006681', 'cui_str': 'Calcium Carbonate'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0556030', 'cui_str': 'Repositioning'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C1096745', 'cui_str': 'Calcium supplement therapy'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0428586', 'cui_str': 'Serum vitamin D measurement'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0155502', 'cui_str': 'Benign paroxysmal positional vertigo'}]",8.0,0.503458,The intervention group showed a reduction in the ARR [0.83,"[{'ForeName': 'Seong-Hae', 'Initials': 'SH', 'LastName': 'Jeong', 'Affiliation': 'Department of Neurology, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea.'}, {'ForeName': 'Ji-Soo', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': 'Department of Neurology, Seoul National University College of Medicine, Seoul, Korea jisookim@snu.ac.kr.'}, {'ForeName': 'Hyo-Jung', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Research Administration Team, Seoul National University Bundang Hospital, Seongnam, Korea.'}, {'ForeName': 'Jeong-Yoon', 'Initials': 'JY', 'LastName': 'Choi', 'Affiliation': 'Dizziness Center, Seoul National University Bundang Hospital, Seongnam, Korea.'}, {'ForeName': 'Ja-Won', 'Initials': 'JW', 'LastName': 'Koo', 'Affiliation': 'Dizziness Center, Seoul National University Bundang Hospital, Seongnam, Korea.'}, {'ForeName': 'Kwang-Dong', 'Initials': 'KD', 'LastName': 'Choi', 'Affiliation': 'Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine, Pusan, Korea.'}, {'ForeName': 'Ji-Yun', 'Initials': 'JY', 'LastName': 'Park', 'Affiliation': 'Department of Neurology, Ulsan University College of Medicine, Ulsan University Hospital, Ulsan, Korea.'}, {'ForeName': 'Seung-Han', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Department of Neurology, Chonnam National University Medical School, Gwangju, Korea.'}, {'ForeName': 'Seo-Young', 'Initials': 'SY', 'LastName': 'Choi', 'Affiliation': 'Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine, Pusan, Korea.'}, {'ForeName': 'Sun-Young', 'Initials': 'SY', 'LastName': 'Oh', 'Affiliation': 'Department of Neurology, Chonbuk National University School of Medicine, Jeonju, Korea.'}, {'ForeName': 'Tae-Ho', 'Initials': 'TH', 'LastName': 'Yang', 'Affiliation': 'Department of Neurology, Chonbuk National University School of Medicine, Jeonju, Korea.'}, {'ForeName': 'Jae Han', 'Initials': 'JH', 'LastName': 'Park', 'Affiliation': 'Department of Neurology, School of Medicine, Catholic University of Daegu, Daegu, Korea.'}, {'ForeName': 'Ileok', 'Initials': 'I', 'LastName': 'Jung', 'Affiliation': 'Department of Neurology, Korea University Ansan Hospital, Ansan, Korea.'}, {'ForeName': 'Soyeon', 'Initials': 'S', 'LastName': 'Ahn', 'Affiliation': 'Medical Research Collaborating Center, Seoul National University Bundang Hospital, Seongnam, Korea.'}, {'ForeName': 'Sooyeon', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Medical Research Collaborating Center, Seoul National University Bundang Hospital, Seongnam, Korea.'}]",Neurology,['10.1212/WNL.0000000000010343'] 2631,32759203,Randomized controlled trial in support of Vitamin D and calcium supplementation for BPPV.,,2020,,[],['Vitamin D and calcium supplementation'],[],[],"[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C1096745', 'cui_str': 'Calcium supplement therapy'}]",[],,0.374233,,"[{'ForeName': 'Robin T', 'Initials': 'RT', 'LastName': 'Bigelow', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA rbigelow@jhmi.edu.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Carey', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.'}]",Neurology,['10.1212/WNL.0000000000010349'] 2632,32759229,Effects of synbiotic supplementation on the components of metabolic syndrome in military personnel: a double-blind randomised controlled trial.,"INTRODUCTION Metabolic syndrome comprises a set of risk factors for chronic diseases including abdominal obesity, increased fasting blood glucose (FBG), altered lipid profile and elevated blood pressure (BP). Due to high prevalence of metabolic syndrome and its complications in the military personnel, the relevant problems should be identified and controlled. Therefore, the present study was conducted to determine the effect of synbiotic supplements on the components of metabolic syndrome in the military personnel with metabolic syndrome. METHODOLOGY Sixty military personnel with metabolic syndrome were included in this double-blind randomised controlled clinical trial. During the intervention, they were asked to consume one capsule of synbiotic supplement or placebo per day for 8 weeks. Body Mass Index (BMI), waist circumference, BP, FBG and lipid profile were measured before and after the intervention. RESULTS The results of the study showed that the synbiotic supplementation had a large significant adjusted effect on the BMI (Cohen's d=0.82 (95% CI 0.29 to 1.34)). It also had a medium significant adjusted effect on the FBG (Cohen's d=0.52 (95% CI 0.004 to 1.03)) as well as triglyceride (Cohen's d=0.65 (95% CI 0.13 to 1.17)). CONCLUSION Findings of the study revealed that synbiotic supplementation may lead to a significant improvement in the BMI, triglyceride and FBG levels in the military personnel. Thus, consumption of synbiotic supplements is recommended as an adjuvant therapy in the military personnel with metabolic syndrome.",2020,"It also had a medium significant adjusted effect on the FBG (Cohen's d=0.52 (95% CI 0.004 to 1.03)) as well as triglyceride (Cohen's d=0.65 (95% CI 0.13 to 1.17)). ","['military personnel with metabolic syndrome', 'Sixty military personnel with metabolic syndrome', 'military personnel']","['synbiotic supplements', 'synbiotic supplementation', 'synbiotic supplement or placebo']","['FBG', 'fasting blood glucose (FBG), altered lipid profile and elevated blood pressure (BP', 'BMI', 'Body Mass Index (BMI), waist circumference, BP, FBG and lipid profile', 'BMI, triglyceride and FBG levels', 'triglyceride', 'metabolic syndrome']","[{'cui': 'C0026126', 'cui_str': 'Military personnel'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}]","[{'cui': 'C2936470', 'cui_str': 'Synbiotics'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}]",60.0,0.274207,"It also had a medium significant adjusted effect on the FBG (Cohen's d=0.52 (95% CI 0.004 to 1.03)) as well as triglyceride (Cohen's d=0.65 (95% CI 0.13 to 1.17)). ","[{'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Parastouei', 'Affiliation': 'Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Saeidipoor', 'Affiliation': 'Department of Nutrition and Food Hygiene, Faculty of Health, Baqiyatallah University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Sepandi', 'Affiliation': 'Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Abbaszadeh', 'Affiliation': 'Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Taghdir', 'Affiliation': 'Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran mtaghdir@bmsu.ac.ir.'}]",BMJ military health,['10.1136/bmjmilitary-2020-001459'] 2633,32759239,"Efficacy of biofeedback, repetitive transcranial magnetic stimulation and pelvic floor muscle training for female neurogenic bladder dysfunction after spinal cord injury: a study protocol for a randomised controlled trial.","INTRODUCTION Neurogenic bladder dysfunction is prevalent in female patients with spinal cord injury (SCI), and previous guidelines have recommended pelvic floor muscle training (PFMT) for first-line conservative treatment. However, the actual regimen of PFMT varies widely and the single treatment does not satisfy the need of some patients. Therefore, this study aims to provide a detailed rationale and methodology for comparing the effectiveness of PFMT, biofeedback and repetitive transcranial magnetic stimulation (rTMS) as adjunct treatments for neurogenic bladder dysfunction. METHODS AND ANALYSIS This trial is a single-centre randomised controlled trial for female patients with urinary incontinence (UI) in phase of chronic SCI. Eligible participants will be randomised to one of four arms: (1) PFMT, (2) PFMT with biofeedback, (3) PFMT and rTMS and (4) PFMT with biofeedback and rTMS. There will be 44 participants in each arm and all the subjects will undergo 20 treatment sessions, five times a week for 4 weeks. The outcomes will be evaluated at 4 weeks, 3 months and 6 months after randomisation. The primary outcome is the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form, and the secondary outcomes include bladder diary, pelvic floor muscle function and the International Spinal Cord Injury Quality of Life Basic Data Set. ETHICS AND DISSEMINATION The Clinical Research and Biomedical Ethics Committee of the West China Hospital, Sichuan University has approved this trial and the approval number is 2019-885. All participants will be provided written informed consent after verification of the eligibility criteria. The results of this study will be accessible in peer-reviewed publications and be presented at academic conferences. TRIAL REGISTRATION NUMBER Chinese Clinical Trial Registry (ChiCTR1900026126).",2020,"The primary outcome is the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form, and the secondary outcomes include bladder diary, pelvic floor muscle function and the International Spinal Cord Injury Quality of Life Basic Data Set. ","['female patients with spinal cord injury (SCI', 'female neurogenic bladder dysfunction after spinal cord injury', 'female patients with urinary incontinence (UI) in phase of chronic SCI']","['biofeedback, repetitive transcranial magnetic stimulation and pelvic floor muscle training', 'PFMT, biofeedback and repetitive transcranial magnetic stimulation (rTMS', 'PFMT, (2) PFMT with biofeedback, (3) PFMT and rTMS and (4) PFMT with biofeedback and rTMS', 'PFMT']","['International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form, and the secondary outcomes include bladder diary, pelvic floor muscle function and the International Spinal Cord Injury Quality of Life Basic Data Set']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0005697', 'cui_str': 'Neurogenic bladder'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}]","[{'cui': 'C0005491', 'cui_str': 'Biofeedback procedure'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C4087139', 'cui_str': 'Pelvic floor muscle training'}]","[{'cui': 'C4544471', 'cui_str': 'International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0430970', 'cui_str': 'Urinary frequency volume chart'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0231484', 'cui_str': 'Muscle function'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0150098', 'cui_str': 'Data Set'}]",,0.208539,"The primary outcome is the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form, and the secondary outcomes include bladder diary, pelvic floor muscle function and the International Spinal Cord Injury Quality of Life Basic Data Set. ","[{'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': 'Department of Rehabilitation Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China.'}, {'ForeName': 'Chenying', 'Initials': 'C', 'LastName': 'Fu', 'Affiliation': 'State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Department of Rehabilitation Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Xiong', 'Affiliation': 'Department of Rehabilitation Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China.'}, {'ForeName': 'Lihong', 'Initials': 'L', 'LastName': 'Peng', 'Affiliation': 'Department of Rehabilitation Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China.'}, {'ForeName': 'Zejun', 'Initials': 'Z', 'LastName': 'Liang', 'Affiliation': 'Department of Rehabilitation Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Rehabilitation Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China.'}, {'ForeName': 'Chengqi', 'Initials': 'C', 'LastName': 'He', 'Affiliation': 'Department of Rehabilitation Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China.'}, {'ForeName': 'Quan', 'Initials': 'Q', 'LastName': 'Wei', 'Affiliation': 'Department of Rehabilitation Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China weiquan@scu.edu.cn.'}]",BMJ open,['10.1136/bmjopen-2019-034582'] 2634,32759361,"Reducing Inpatient Hypoglycemia in the General Wards Using Real-Time Continuous Glucose Monitoring: The Glucose Telemetry System, a Randomized Clinical Trial.","OBJECTIVE Use of real-time continuous glucose monitoring (RT-CGM) systems in the inpatient setting is considered investigational. The objective of this study was to evaluate whether RT-CGM, using the glucose telemetry system (GTS), can prevent hypoglycemia in the general wards. RESEARCH DESIGN AND METHODS In a randomized clinical trial, insulin-treated patients with type 2 diabetes at high risk for hypoglycemia were recruited. Participants were randomized to RT-CGM/GTS or point-of-care (POC) blood glucose testing. The primary outcome was difference in inpatient hypoglycemia. RESULTS Seventy-two participants were included in this interim analysis, 36 in the RT-CGM/GTS group and 36 in the POC group. The RT-CGM/GTS group experienced fewer hypoglycemic events (<70 mg/dL) per patient (0.67 [95% CI 0.34-1.30] vs. 1.69 [1.11-2.58], P = 0.024), fewer clinically significant hypoglycemic events (<54 mg/dL) per patient (0.08 [0.03-0.26] vs. 0.75 [0.51-1.09], P = 0.003), and a lower percentage of time spent below range <70 mg/dL (0.40% [0.18-0.92%] vs. 1.88% [1.26-2.81%], P = 0.002) and <54 mg/dL (0.05% [0.01-0.43%] vs. 0.82% [0.47-1.43%], P = 0.017) compared with the POC group. No differences in nocturnal hypoglycemia, time in range 70-180 mg/dL, and time above range >180-250 mg/dL and >250 mg/dL were found between the groups. The RT-CGM/GTS group had no prolonged hypoglycemia compared with 0.20 episodes <54 mg/dL and 0.40 episodes <70 mg/dL per patient in the POC group. CONCLUSIONS RT-CGM/GTS can decrease hypoglycemia among hospitalized high-risk insulin-treated patients with type 2 diabetes.",2020,"The RT-CGM/GTS group experienced fewer hypoglycemic events (<70 mg/dL) per patient (0.67 [95% CI 0.34-1.30] vs. 1.69 [1.11-2.58], P = 0.024), fewer clinically significant hypoglycemic events (<54 mg/dL) per patient (0.08 [0.03-0.26] vs. 0.75 [0.51-1.09], P = 0.003), and a lower percentage of time spent below range <70 mg/dL (0.40% [0.18-0.92%] vs. 1.88% [1.26-2.81%], P = 0.002) and <54 mg/dL (0.05% [0.01-0.43%] vs. 0.82% [0.47-1.43%], P = 0.017) compared with the POC group.","['treated patients with type 2 diabetes at high risk for hypoglycemia were recruited', 'Seventy-two participants were included in this interim analysis, 36 in the RT-CGM/GTS group and 36 in the POC group']","['RT-CGM', 'RT-CGM/GTS or point-of-care (POC) blood glucose testing', 'insulin', 'RT-CGM/GTS', 'glucose telemetry system (GTS', 'real-time continuous glucose monitoring (RT-CGM']","['nocturnal hypoglycemia', 'hypoglycemia', 'inpatient hypoglycemia', 'prolonged hypoglycemia', 'Inpatient Hypoglycemia', 'hypoglycemic events']","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C4319632', 'cui_str': '72'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0039451', 'cui_str': 'Telemetry'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0282664', 'cui_str': 'Point-of-Care'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0039451', 'cui_str': 'Telemetry'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0282664', 'cui_str': 'Point-of-Care'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}]","[{'cui': 'C0342315', 'cui_str': 'Nocturnal hypoglycemia'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic agent'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",72.0,0.0730647,"The RT-CGM/GTS group experienced fewer hypoglycemic events (<70 mg/dL) per patient (0.67 [95% CI 0.34-1.30] vs. 1.69 [1.11-2.58], P = 0.024), fewer clinically significant hypoglycemic events (<54 mg/dL) per patient (0.08 [0.03-0.26] vs. 0.75 [0.51-1.09], P = 0.003), and a lower percentage of time spent below range <70 mg/dL (0.40% [0.18-0.92%] vs. 1.88% [1.26-2.81%], P = 0.002) and <54 mg/dL (0.05% [0.01-0.43%] vs. 0.82% [0.47-1.43%], P = 0.017) compared with the POC group.","[{'ForeName': 'Lakshmi G', 'Initials': 'LG', 'LastName': 'Singh', 'Affiliation': 'Division of Endocrinology, Baltimore Veterans Affairs Medical Center, Baltimore, MD.'}, {'ForeName': 'Medha', 'Initials': 'M', 'LastName': 'Satyarengga', 'Affiliation': 'Center for Diabetes and Endocrinology, University of Maryland Shore Regional Health, Easton, MD.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Marcano', 'Affiliation': 'Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD.'}, {'ForeName': 'William H', 'Initials': 'WH', 'LastName': 'Scott', 'Affiliation': 'Division of Endocrinology, Baltimore Veterans Affairs Medical Center, Baltimore, MD.'}, {'ForeName': 'Lillian F', 'Initials': 'LF', 'LastName': 'Pinault', 'Affiliation': 'Division of Endocrinology, Baltimore Veterans Affairs Medical Center, Baltimore, MD.'}, {'ForeName': 'Zhaoyong', 'Initials': 'Z', 'LastName': 'Feng', 'Affiliation': 'Pharmaceutical Research Computing, Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Sorkin', 'Affiliation': 'Baltimore Veterans Affairs Medical Center Geriatric Research, Education, and Clinical Center, Baltimore, MD.'}, {'ForeName': 'Guillermo E', 'Initials': 'GE', 'LastName': 'Umpierrez', 'Affiliation': 'Division of Endocrinology, Metabolism, and Lipids, Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'Elias K', 'Initials': 'EK', 'LastName': 'Spanakis', 'Affiliation': 'Division of Endocrinology, Baltimore Veterans Affairs Medical Center, Baltimore, MD ispanakis@som.umaryland.edu.'}]",Diabetes care,['10.2337/dc20-0840'] 2635,32759439,Efficacy of pectoral nerve block type II versus thoracic paravertebral block for analgesia in breast cancer surgery.,"OBJECTIVE The aim: to compare the efficacy of pectoral nerve block type II and thoracic paravertebral block for analgesia during and after breast cancer surgery. PATIENTS AND METHODS Materials and methods: Sixty adult women were undergoing unilateral radical mastectomy or quadrantectomy with axillary dissection. Patients were randomized to receive either pectoral nerve block with ropivacaine 0.375% 30 ml or thoracic paravertebral block with ropivacaine 0.5% 20 ml. Evaluated variables included pain intensity at 0, 2, 4, 6, 12, 18 and 24 hours, intraoperative fentanyl, 24-hour postoperative opioid (promedol) and nonopioid (ketoprofen) consumption, the time to first rescue analgesia. RESULTS Results: There were no statistically significant differences between pectoral block and paravertebral block groups in intraoperative fentanyl consumption 2,2 (1,81-2,81) vs 1,9 (1,63-2,25) mcg/kg/hour (Р>0,05) and in the pain intensity during the first 24 hours after operation. The mean postoperative 24-hour promedol and ketoprofen consumption was 4,0 (±8,14) mgvs 5,0 (±8,85) mg (Р>0,05) and 66,7 (±66,09) mgvs 95,8 (±90,78) mg (Р>0,05) in the pectoral and paravertebral block groups respectively. Time to the first analgesia request was longer in pectoral block group - 540 (455,0-600,0) min vs 515 (265,0-650,0) min (Р>0,05). There were no complications after pectoral blocks and 2 complications after paravertebral blocks. CONCLUSION Conclusions: in breast cancer surgery pectoral nerve blocktype II can provide postoperative analgesia comparable to thoracic paravertebral block with lower complications rate.",2020,"There were no statistically significant differences between pectoral block and paravertebral block groups in intraoperative fentanyl consumption 2,2 (1,81-2,81)","[' Sixty adult women were undergoing', 'breast cancer surgery']","['pectoral nerve block type II and thoracic paravertebral block', 'pectoral nerve block with ropivacaine 0.375% 30 ml or thoracic paravertebral block with ropivacaine', 'pectoral nerve block type II versus thoracic paravertebral block', 'unilateral radical mastectomy or quadrantectomy with axillary dissection']","['pain intensity', 'intraoperative fentanyl, 24-hour postoperative opioid (promedol) and nonopioid (ketoprofen) consumption, the time to first rescue analgesia', 'mean postoperative 24-hour promedol and ketoprofen consumption']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0205967', 'cui_str': 'Pectoral Nerves'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0442150', 'cui_str': 'Paravertebral'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C4517455', 'cui_str': '0.375'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0024884', 'cui_str': 'Radical mastectomy'}, {'cui': 'C0337354', 'cui_str': 'Quadrantectomy of breast'}, {'cui': 'C0193867', 'cui_str': 'Excision of axillary lymph nodes'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0242937', 'cui_str': 'Non-opioid analgesic'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0033400', 'cui_str': 'Dimethylmeperidine'}, {'cui': 'C0022635', 'cui_str': 'Ketoprofen'}]",60.0,0.0664339,"There were no statistically significant differences between pectoral block and paravertebral block groups in intraoperative fentanyl consumption 2,2 (1,81-2,81)","[{'ForeName': 'Volodymyr V', 'Initials': 'VV', 'LastName': 'Martsiniv', 'Affiliation': 'Shupyk National Medical Academy Of Postgraduate Education, Kyiv, Ukraine, Feofaniya Clinical Hospital Of State Management Of Affairs, Kyiv, Ukraine.'}, {'ForeName': 'Oleg A', 'Initials': 'OA', 'LastName': 'Loskutov', 'Affiliation': 'Shupyk National Medical Academy Of Postgraduate Education, Kyiv, Ukraine.'}, {'ForeName': 'Andriy M', 'Initials': 'AM', 'LastName': 'Strokan', 'Affiliation': 'Shupyk National Medical Academy Of Postgraduate Education, Kyiv, Ukraine, Feofaniya Clinical Hospital Of State Management Of Affairs, Kyiv, Ukraine.'}, {'ForeName': 'Mihaylo V', 'Initials': 'MV', 'LastName': 'Bondar', 'Affiliation': 'Shupyk National Medical Academy Of Postgraduate Education, Kyiv, Ukraine.'}]","Wiadomosci lekarskie (Warsaw, Poland : 1960)",[] 2636,32759484,Kohn-Sham equations with functionals from the strictly-correlated regime: Investigation with a spectral renormalization method.,"We re-adapt a spectral renormalization method, introduced in nonlinear optics, to solve the Kohn- Sham (KS) equations of density functional theory (DFT), with a focus on functionals based on the strictly-correlated electrons (SCE) regime, which are particularly challenging to converge. Important aspects of the method are: (i) the eigenvalues and the density are computed simultaneously; (ii) it converges using randomized initial guesses; (iii) easy to implement. Using this method we could converge for the first time the Kohn-Sham equations with functionals that include the next leading term in the strong-interaction limit of density functional theory, the so called zero-point energy (ZPE) functional as well as with an interaction-strength-interpolation (ISI) functional that includes both the exact SCE and ZPE terms. This work is the first building block for future studies on quantum systems confined in low dimensions with different statistics and long-range repulsions, such as localization properties of fermions and bosons with strong long-range repulsive interactions in the presence of a random external potential.",2020,"Using this method we could converge for the first time the Kohn-Sham equations with functionals that include the next leading term in the strong-interaction limit of density functional theory, the so called zero-point energy (ZPE) functional as well as with an interaction-strength-interpolation (ISI) functional that includes both the exact SCE and ZPE terms.",[],['Kohn- Sham (KS) equations of density functional theory (DFT'],[],[],"[{'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C4704758', 'cui_str': 'KS-DFT'}]",[],,0.0217531,"Using this method we could converge for the first time the Kohn-Sham equations with functionals that include the next leading term in the strong-interaction limit of density functional theory, the so called zero-point energy (ZPE) functional as well as with an interaction-strength-interpolation (ISI) functional that includes both the exact SCE and ZPE terms.","[{'ForeName': 'Juri', 'Initials': 'J', 'LastName': 'Grossi', 'Affiliation': 'Vrije Universiteit Amsterdam Faculteit der Exacte Wetenschappen, Amsterdam, 1081 HV, NETHERLANDS.'}, {'ForeName': 'Ziad', 'Initials': 'Z', 'LastName': 'Musslimani', 'Affiliation': 'Florida State University, Tallahassee, Florida, 32306-1058, UNITED STATES.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Seidl', 'Affiliation': 'Vrije Universiteit Amsterdam Faculteit der Exacte Wetenschappen, Amsterdam, NETHERLANDS.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Gori-Giorgi', 'Affiliation': 'Vrije Universiteit Amsterdam, Amsterdam, 1081 HV, NETHERLANDS.'}]",Journal of physics. Condensed matter : an Institute of Physics journal,['10.1088/1361-648X/abace2'] 2637,32759543,Concomitant Use of Rosuvastatin and Eicosapentaenoic Acid Significantly Prevents Native Coronary Atherosclerotic Progression in Patients With In-Stent Neoatherosclerosis.,"BACKGROUND In-stent neoatherosclerosis (NA) is a risk for future cardiovascular events through atherosclerotic progression in non-stented lesions. Using optical coherence tomography, this study assessed the efficacy of intensive therapy with 10 mg/day rosuvastatin plus 1,800 mg/day eicosapentaenoic acid (EPA) vs. standard 2.5 mg/day rosuvastatin therapy on native coronary plaques in patients with NA.Methods and Results:This was a subgroup analysis of the randomized LINK-IT trial, which was designed to compare changes in the lipid index in NA between intensive and standard therapy for 12 months. In all, 42 patients with native coronary plaques and NA were assessed. Compared with standard therapy, intensive therapy resulted in greater decreases in serum low-density lipoprotein cholesterol concentrations and greater increases in serum 18-hydroxyeicosapentaenoic acid concentrations, with significantly greater decreases in the lipid index and macrophage grade in both NA (-24 vs. 217 [P<0.001] and -15 vs. 24 [P<0.001], respectively) and native coronary plaques (-112 vs. 29 [P<0.001] and -17 vs. 1 [P<0.001], respectively) following intensive therapy. Although there was a greater increase in the macrophage grade in NA than in native coronary plaques in the standard therapy group, in the intensive therapy group there were comparable reductions in macrophage grade between NA and native coronary plaques. CONCLUSIONS Compared with standard therapy, intensive therapy prevented atherosclerotic progression more effectively in native coronary plaques in patients with NA.",2020,"Compared with standard therapy, intensive therapy resulted in greater decreases in serum low-density lipoprotein cholesterol concentrations and greater increases in serum 18-hydroxyeicosapentaenoic acid concentrations, with significantly greater decreases in the lipid index and macrophage grade in both NA (-24 vs. 217 [P<0.001] and -15 vs. 24 [P<0.001], respectively) and native coronary plaques (-112 vs. 29 [P<0.001] and -17 vs. 1 [P<0.001], respectively) following intensive therapy.","['patients with NA.Methods\u2004and\u2004Results', 'Patients', '42 patients with native coronary plaques and NA', 'patients with NA']","['standard therapy, intensive therapy', 'intensive therapy with 10 mg/day rosuvastatin plus 1,800 mg/day eicosapentaenoic acid (EPA) vs. standard 2.5 mg/day rosuvastatin therapy', 'Rosuvastatin and Eicosapentaenoic Acid', 'stent neoatherosclerosis (NA']","['Native Coronary Atherosclerotic Progression', 'lipid index and macrophage grade', 'macrophage grade', 'native coronary plaques', 'serum low-density lipoprotein cholesterol concentrations', 'serum 18-hydroxyeicosapentaenoic acid concentrations']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0079891', 'cui_str': 'Indigenous Population'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}]","[{'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic acid'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0038257', 'cui_str': 'Stent'}]","[{'cui': 'C0079891', 'cui_str': 'Indigenous Population'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0024432', 'cui_str': 'Macrophage'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C3251952', 'cui_str': '18(R)-hydroxyeicosapentaenoic acid'}]",42.0,0.0534448,"Compared with standard therapy, intensive therapy resulted in greater decreases in serum low-density lipoprotein cholesterol concentrations and greater increases in serum 18-hydroxyeicosapentaenoic acid concentrations, with significantly greater decreases in the lipid index and macrophage grade in both NA (-24 vs. 217 [P<0.001] and -15 vs. 24 [P<0.001], respectively) and native coronary plaques (-112 vs. 29 [P<0.001] and -17 vs. 1 [P<0.001], respectively) following intensive therapy.","[{'ForeName': 'Yoichiro', 'Initials': 'Y', 'LastName': 'Sugizaki', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.'}, {'ForeName': 'Hiromasa', 'Initials': 'H', 'LastName': 'Otake', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Kuroda', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Kawamori', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.'}, {'ForeName': 'Takayoshi', 'Initials': 'T', 'LastName': 'Toba', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Nagasawa', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.'}, {'ForeName': 'Ryo', 'Initials': 'R', 'LastName': 'Takeshige', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.'}, {'ForeName': 'Shinsuke', 'Initials': 'S', 'LastName': 'Nakano', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.'}, {'ForeName': 'Yoichiro', 'Initials': 'Y', 'LastName': 'Matsuoka', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.'}, {'ForeName': 'Kosuke', 'Initials': 'K', 'LastName': 'Tanimura', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Takahashi', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Fukuyama', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.'}, {'ForeName': 'Ken-Ichi', 'Initials': 'KI', 'LastName': 'Hirata', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.'}]",Circulation journal : official journal of the Japanese Circulation Society,['10.1253/circj.CJ-20-0199'] 2638,32759599,The effects of acute and chronic inflammation on the dynamics of fluid shift of Ringer's solution and hemodynamics during surgery.,"The aim of this study was to investigate the influences of acute and chronic inflammation on the dynamics of fluid shift of Ringer's solution and hemodynamics in patients during surgery. Thirty-seven patients with ASA grade I-II were enrolled and allocated to two study groups according to the type of disease and operation and inflammation, including patients undergoing emergency appendectomy (Acute group, n = 19) and patients undergoing elective cholecystectomy (Chronic group, n = 18). All of the patients were administered 15 mL/kg of RL at a constant rate over 35 mins before the induction of anesthesia. Plasma dilution (PD), volume expansion (VE), volume expansion efficiency (VEE), and extravascular volume (EVV) were calculated based on the concentration of hemoglobin within 2 hrs post-infusion. Heart rate (HR), arterial blood pressure and urine output were also recorded. PD and VE peaked at the end of infusion, while VEE peaked at the beginning of infusion in all of the patients. After infusion, PD, VE and VEE in the Acute group were all higher than those in the Chronic group (P < 0.05). PD and VE were higher during anesthesia or surgery than during awake or non-surgery (P < 0.001). The mean arterial pressure (MAP) and diastolic pressure (DBP) in the Acute group were significantly lower (P < 0.001) and HR was significantly higher (P < 0.001) than in the Chronic group during the study periods. It was suggested that patients with acute inflammation be treated with individualized fluid therapy during surgery.",2020,PD and VE were higher during anesthesia or surgery than during awake or non-surgery (P < 0.001).,"['Thirty-seven patients with ASA grade I-II', 'patients undergoing emergency appendectomy (Acute group, n = 19) and patients undergoing elective cholecystectomy (Chronic group, n = 18', 'patients with acute inflammation be treated with', 'patients during surgery']",['individualized fluid therapy'],"['HR', 'Plasma dilution (PD), volume expansion (VE), volume expansion efficiency (VEE), and extravascular volume (EVV', 'PD and VE', 'mean arterial pressure (MAP) and diastolic pressure (DBP', 'PD, VE and VEE', 'Heart rate (HR), arterial blood pressure and urine output']","[{'cui': 'C4319569', 'cui_str': '37'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C0399997', 'cui_str': 'Emergency appendectomy'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0008320', 'cui_str': 'Cholecystectomy'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0333361', 'cui_str': 'Acute inflammation'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0016286', 'cui_str': 'Therapy, Fluid'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0079240', 'cui_str': 'Dilution'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C1272641', 'cui_str': 'Systemic arterial pressure'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}]",37.0,0.0530746,PD and VE were higher during anesthesia or surgery than during awake or non-surgery (P < 0.001).,"[{'ForeName': 'Xiuzhen', 'Initials': 'X', 'LastName': 'Lei', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital, College of Medicine, Zhejiang University.'}, {'ForeName': 'Manli', 'Initials': 'M', 'LastName': 'An', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital, College of Medicine, Zhejiang University.'}, {'ForeName': 'Yulong', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital, College of Medicine, Zhejiang University.'}, {'ForeName': 'Shenghua', 'Initials': 'S', 'LastName': 'Yi', 'Affiliation': ""Department of Anesthesiology and Clinical Research Center, Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University).""}, {'ForeName': 'Yeke', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital, College of Medicine, Zhejiang University.'}, {'ForeName': 'Hu', 'Initials': 'H', 'LastName': 'Shuangyan', 'Affiliation': ""Department of Anesthesiology and Clinical Research Center, Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University).""}, {'ForeName': 'Yuhong', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ""Department of Anesthesiology and Clinical Research Center, Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University).""}, {'ForeName': 'Shengmei', 'Initials': 'S', 'LastName': 'Zhu', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital, College of Medicine, Zhejiang University.'}]",Biological & pharmaceutical bulletin,['10.1248/bpb.b19-00631'] 2639,30919997,Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment.,"Although treat-to-target strategies are being discussed in osteoporosis, there is little evidence of what the target should be to reduce fracture risk maximally. We investigated the relationship between total hip BMD T-score and the incidence of nonvertebral fracture in women who received up to 10 years of continued denosumab therapy in the FREEDOM (3 years) study and its long-term Extension (up to 7 years) study. We report the percentages of women who achieved a range of T-scores at the total hip or femoral neck over 10 years of denosumab treatment (1343 women completed 10 years of treatment). The incidence of nonvertebral fractures was lower with higher total hip T-score. This relationship plateaued at a T-score between -2.0 and -1.5 and was independent of age and prevalent vertebral fractures, similar to observations in treatment-naïve subjects. Reaching a specific T-score during denosumab treatment was dependent on the baseline T-score, with higher T-scores at baseline more likely to result in higher T-scores at each time point during the study. Our findings highlight the importance of follow-up BMD measurements in patients receiving denosumab therapy because BMD remains a robust indicator of fracture risk. These data support the notion of a specific T-score threshold as a practical target for therapy in osteoporosis. © 2019 The Authors Journal of Bone and Mineral Research published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research (ASBMR).",2019,The incidence of nonvertebral fractures was lower with higher total hip T-score.,"['women who achieved a range of T-scores at the total hip or femoral neck over 10 years of denosumab treatment (1343 women completed 10 years of treatment', 'women who received up to 10 years of continued denosumab therapy in the FREEDOM (3 years) study and its long-term Extension (up to 7 years) study', '2019']",[],"['nonvertebral fractures', 'Bone Mineral Density T-Score and Nonvertebral Fracture Risk', 'total hip BMD T-score and the incidence of nonvertebral fracture']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C3854607', 'cui_str': 'T score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0015815', 'cui_str': 'Structure of neck of femur'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1690432', 'cui_str': 'denosumab'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C3839270', 'cui_str': 'Denosumab therapy'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0231448', 'cui_str': 'Extension'}]",[],"[{'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C3854607', 'cui_str': 'T score'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",,0.0238398,The incidence of nonvertebral fractures was lower with higher total hip T-score.,"[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Ferrari', 'Affiliation': 'Geneva University Hospital, Geneva, Switzerland.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Libanati', 'Affiliation': 'UCB Pharma, Brussels, Belgium.'}, {'ForeName': 'Celia Jow Fang', 'Initials': 'CJF', 'LastName': 'Lin', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Brown', 'Affiliation': 'Laval University and CHU de Québec Research Centre, Quebec City, QC, Canada.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Cosman', 'Affiliation': 'Columbia University, NY, USA.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Czerwiński', 'Affiliation': 'Krakow Medical Center, Krakow, Poland.'}, {'ForeName': 'L H', 'Initials': 'LH', 'LastName': 'de Gregόrio', 'Affiliation': 'Center for Clinical and Basic Research - Brasil, Rio de Janeiro, Brazil.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Malouf-Sierra', 'Affiliation': 'Universitat Autònoma de Barcelona, Barcelona, Spain.'}, {'ForeName': 'J-Y', 'Initials': 'JY', 'LastName': 'Reginster', 'Affiliation': 'University of Liège, Liège, Belgium.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Wang', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'R B', 'Initials': 'RB', 'LastName': 'Wagman', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'E M', 'Initials': 'EM', 'LastName': 'Lewiecki', 'Affiliation': 'New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA.'}]",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,['10.1002/jbmr.3722'] 2640,32761047,Skeletal and dentoalveolar effects using tooth-borne and tooth-bone-borne RME appliances: a randomized controlled trial with 1-year follow-up.,"OBJECTIVES To evaluate and compare the skeletal and dentoalveolar effects of tooth-borne (TB) and tooth-bone-borne (TBB) rapid maxillary expansion (RME). MATERIALS AND METHODS Fifty-two consecutive patients who met the eligibility criteria were recruited and allocated to either the TB group, mean age 9.3 years [standard deviation (SD) 1.3], or the TBB group, mean age 9.5 years (SD 1.2). Cone-beam computed tomography (CBCT) records and plaster models were taken before (T0), directly after (T1), and 1 year after expansion (T2). Dentoalveolar and skeletal measurements were made on the CBCT images. The dental expansion was also measured on the plaster models. RANDOMIZATION Participants were randomly allocated in blocks of different sizes using the concealed allocation principle in a 1:1 ratio. The randomization list was also stratified by sex to ensure homogeneity between groups. BLINDING Due to clinical limitations, only the outcomes assessors were blinded to the groups to which the patients were allocated. RESULTS Skeletal expansion in the midpalatal suture and at the level of the nasal cavity was significantly higher in the TBB group. However, the magnitude of the expansion in the midpalatal suture was around 1 mm [95 per cent confidence interval (CI) 0.5-1.7, P = 0.001] more and perhaps not clinically significant. The magnitude of the expansion at the level of the nasal cavity was almost two times higher in the TBB group (95 per cent CI 0.7-2.6, P = 0.001). The dental expansion, alveolar bending, tipping of the molars, and stability 1 year post-expansion did not show any statistically significant differences between the groups. The actual direct cost of the treatment for the TBB group was approximately €300 higher than TB group. LIMITATIONS Double blinding was not possible due to the clinical limitations. CONCLUSIONS In young preadolescents with constricted maxilla and no signs of upper airway obstruction, it seems that conventional TB RME achieves the same clinical results with good stability 1 year post-expansion at lower cost. TRIAL REGISTRATION The trial was not registered.",2020,"The dental expansion, alveolar bending, tipping of the molars, and stability 1 year post-expansion did not show any statistically significant differences between the groups.","['Fifty-two consecutive patients who met the eligibility criteria were recruited and allocated to either the TB group, mean age 9.3 years [standard deviation (SD) 1.3], or the TBB group, mean age 9.5 years (SD 1.2']","['conventional TB RME', 'tooth-borne (TB) and tooth-bone-borne (TBB) rapid maxillary expansion (RME', 'Cone-beam computed tomography (CBCT', 'tooth-borne and tooth-bone-borne RME appliances']","['actual direct cost', 'level of the nasal cavity', 'Dentoalveolar and skeletal measurements']","[{'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C4517499', 'cui_str': '1.3'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C4517899', 'cui_str': '9.5'}, {'cui': 'C4068880', 'cui_str': '1.2'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0600288', 'cui_str': 'Maxillary Expansion'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C1956110', 'cui_str': 'Cone beam CT'}, {'cui': 'C0441424', 'cui_str': 'Rapid maxillary expansion appliance'}]","[{'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0027423', 'cui_str': 'Nasal cavity structure'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",52.0,0.110434,"The dental expansion, alveolar bending, tipping of the molars, and stability 1 year post-expansion did not show any statistically significant differences between the groups.","[{'ForeName': 'Farhan', 'Initials': 'F', 'LastName': 'Bazargani', 'Affiliation': 'Department of Orthodontics, Postgraduate Dental Education Center, Örebro, Sweden.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Lund', 'Affiliation': 'Institute of Odontology, Sahlgrenska Academy, Department of Oral and Maxillofacial Radiology, University of Gothenburg, Göteborg, Sweden.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Magnuson', 'Affiliation': 'Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Sweden.'}, {'ForeName': 'Björn', 'Initials': 'B', 'LastName': 'Ludwig', 'Affiliation': 'Private Orthodontic Office, Traben-Trarbach, Germany.'}]",European journal of orthodontics,['10.1093/ejo/cjaa040'] 2641,32761069,Economic Evaluation of Sedative Deprescribing in Older Adults by Community Pharmacists.,"BACKGROUND Sedative use in older adults increases the risk of falls, fractures, and hospitalizations. The D-PRESCRIBE (Developing Pharmacist-Led Research to Educate and Sensitize Community Residents to the Inappropriate Prescriptions Burden in the Elderly), pragmatic randomized clinical trial demonstrated that community-based, pharmacist-led education delivered simultaneously to older adults and their primary care providers reduce the use of sedatives by 43% over 6 months. However, the associated health benefits and cost savings have yet to be described. This study evaluates the cost-effectiveness of the D-PRESCRIBE intervention compared to usual care for reducing the use of potentially inappropriate sedatives among older adults. METHODS A cost-utility analysis from the public health care perspective of Canada estimated the costs and quality-adjusted life-years (QALYs) associated with the D-PRESCRIBE intervention compared to usual care over a 1-year time horizon. Transition probabilities, intervention effectiveness, utility, and costs were derived from the literature. Probabilistic analyses were performed using a decision tree and Markov model to estimate the incremental cost-effectiveness ratio. RESULTS Compared to usual care, pharmacist-led deprescribing is less costly (-$1392.05 CAD) and more effective (0.0769 QALYs). Using common willingness-to-pay (WTP) thresholds of $50 000 and $100 000, D-PRESCRIBE was the optimal strategy. Scenario analysis indicated the cost-effectiveness of D-PRESCRIBE is sensitive to the rate of deprescribing. CONCLUSIONS Community pharmacist-led deprescribing of sedatives is cost-effective, leading to greater quality-of-life and harm reduction among older adults. As the pharmacist's scope of practice expands, consideration should be given to interprofessional models of remuneration for quality prescribing and deprescribing services.",2020,"Compared to usual care, pharmacist-led deprescribing is less costly (-$1392.05 CAD) and more effective (0.0769 QALYs).","['Older Adults by Community Pharmacists', 'older adults']",['Sedative Deprescribing'],"['Transition probabilities, intervention effectiveness, utility, and costs']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0402003', 'cui_str': 'Community pharmacist'}]","[{'cui': 'C0020592', 'cui_str': 'HYPNOTICS AND SEDATIVES'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",,0.034788,"Compared to usual care, pharmacist-led deprescribing is less costly (-$1392.05 CAD) and more effective (0.0769 QALYs).","[{'ForeName': 'Justin P', 'Initials': 'JP', 'LastName': 'Turner', 'Affiliation': 'Faculty of Pharmacy, Université de Montréal, Québec, Canada.'}, {'ForeName': 'Chiranjeev', 'Initials': 'C', 'LastName': 'Sanyal', 'Affiliation': 'Canadian Pharmacists Association, Ottawa, Ontario, Canada.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Martin', 'Affiliation': 'Faculty of Pharmacy, Université de Montréal, Québec, Canada.'}, {'ForeName': 'Cara', 'Initials': 'C', 'LastName': 'Tannenbaum', 'Affiliation': 'Faculty of Pharmacy, Université de Montréal, Québec, Canada.'}]","The journals of gerontology. Series A, Biological sciences and medical sciences",['10.1093/gerona/glaa180'] 2642,32761068,Guidelines for the Management of Severe Traumatic Brain Injury: 2020 Update of the Decompressive Craniectomy Recommendations.,"When the fourth edition of the Brain Trauma Foundation's Guidelines for the Management of Severe Traumatic Brain Injury were finalized in late 2016, it was known that the results of the RESCUEicp (Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension) randomized controlled trial of decompressive craniectomy would be public after the guidelines were released. The guideline authors decided to proceed with publication but to update the decompressive craniectomy recommendations later in the spirit of ""living guidelines,"" whereby topics are updated more frequently, and between new editions, when important new evidence is published. The update to the decompressive craniectomy chapter presented here integrates the findings of the RESCUEicp study as well as the recently published 12-mo outcome data from the DECRA (Decompressive Craniectomy in Patients With Severe Traumatic Brain Injury) trial. Incorporation of these publications into the body of evidence led to the generation of 3 new level-IIA recommendations; a fourth previously presented level-IIA recommendation remains valid and has been restated. To increase the utility of the recommendations, we added a new section entitled Incorporating the Evidence into Practice. This summary of expert opinion provides important context and addresses key issues for practitioners, which are intended to help the clinician utilize the available evidence and these recommendations. The full guideline can be found at: https://braintrauma.org/guidelines/guidelines-for-the-management-of-severe-tbi-4th-ed#/.",2020,"When the fourth edition of the Brain Trauma Foundation's Guidelines for the Management of Severe Traumatic Brain Injury were finalized in late 2016, it was known that the results of the RESCUEicp (Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension) randomized controlled trial of decompressive craniectomy would be public after the guidelines were released.",['Patients With Severe Traumatic Brain Injury) trial'],"['DECRA (Decompressive Craniectomy', 'decompressive craniectomy']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C2717817', 'cui_str': 'Decompressive craniectomy'}]",[],,0.0441026,"When the fourth edition of the Brain Trauma Foundation's Guidelines for the Management of Severe Traumatic Brain Injury were finalized in late 2016, it was known that the results of the RESCUEicp (Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension) randomized controlled trial of decompressive craniectomy would be public after the guidelines were released.","[{'ForeName': 'Gregory W J', 'Initials': 'GWJ', 'LastName': 'Hawryluk', 'Affiliation': 'Section of Neurosurgery, GB1-Health Sciences Centre, University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Andres M', 'Initials': 'AM', 'LastName': 'Rubiano', 'Affiliation': 'INUB-MEDITECH Research Group, Universidad El Bosque, Bogota, Colombia.'}, {'ForeName': 'Annette M', 'Initials': 'AM', 'LastName': 'Totten', 'Affiliation': 'Oregon Health & Science University, Portland, Oregon.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': ""O'Reilly"", 'Affiliation': 'Oregon Health & Science University, Portland, Oregon.'}, {'ForeName': 'Jamie S', 'Initials': 'JS', 'LastName': 'Ullman', 'Affiliation': 'Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Bratton', 'Affiliation': 'University of Utah, Salt Lake City, Utah.'}, {'ForeName': 'Randall', 'Initials': 'R', 'LastName': 'Chesnut', 'Affiliation': 'University of Washington, Seattle, Washington.'}, {'ForeName': 'Odette A', 'Initials': 'OA', 'LastName': 'Harris', 'Affiliation': 'Stanford University, Stanford, California.'}, {'ForeName': 'Niranjan', 'Initials': 'N', 'LastName': 'Kissoon', 'Affiliation': 'University of British Columbia, Vancouver, British Columbia.'}, {'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Shutter', 'Affiliation': 'University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Tasker', 'Affiliation': ""Harvard Medical School & Boston Children's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Monica S', 'Initials': 'MS', 'LastName': 'Vavilala', 'Affiliation': 'University of Washington, Seattle, Washington.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Wilberger', 'Affiliation': 'Drexel University, Pittsburgh, Pennsylvania.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Wright', 'Affiliation': 'Emory University, Atlanta, Georgia.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Lumba-Brown', 'Affiliation': 'Stanford University, Stanford, California.'}, {'ForeName': 'Jamshid', 'Initials': 'J', 'LastName': 'Ghajar', 'Affiliation': 'Stanford University, Stanford, California.'}]",Neurosurgery,['10.1093/neuros/nyaa278'] 2643,32761109,Transfer and retention of oculomotor alignment rehabilitation training.,"Ocular alignment defects such as strabismus affect around 5% of people and are associated with binocular vision impairments. Current nonsurgical treatments are controversial and have high levels of recidivism. In this study, we developed a rehabilitation method for ocular alignment training and examined the rate of learning, transfer to untrained alignments, and retention over time. Ocular alignment was controlled with a real-time dichoptic feedback paradigm where a static fixation target and white gaze-contingent ring were presented to the dominant eye and a black gaze-contingent ring with no fixation target was presented to the nondominant eye. Observers were required to move their eyes to center the rings on the target, with real-time feedback provided by the size of the rings. Offsetting the ring of the nondominant temporal or nasal visual field required convergent or divergent ocular deviation, respectively, to center the ring on the fixation target. Learning was quantified as the time taken to achieve target deviation of 2° (easy, E) or 4° (hard, H) for convergence (CE, CH) or divergence (DE, DH) over 40 trials. Thirty-two normally sighted observers completed two training sequences separated by one week. Subjects were randomly assigned to a training sequence: CE-CH-DE, CH-CE-DE, DE-DH-CE, or DH-DE-CE. The results showed that training was retained over the course of approximately one week across all conditions. Training on an easy deviation angle transferred to untrained hard angles within convergence or divergence but not between these directions. We conclude that oculomotor alignment can be rapidly trained, retained, and transferred with a feedback-based dichoptic paradigm. Feedback-based oculomotor training may therefore provide a noninvasive method for the rehabilitation of ocular alignment defects.",2020,"Learning was quantified as the time taken to achieve target deviation of 2° (easy, E) or 4° (hard, H) for convergence (CE, CH) or divergence (DE, DH) over 40 trials.",[],"['Feedback-based oculomotor training', 'static fixation target and white gaze-contingent ring were presented to the dominant eye and a black gaze-contingent ring with no fixation target', 'training sequence: CE-CH-DE, CH-CE-DE, DE-DH-CE, or DH-DE-CE', 'oculomotor alignment rehabilitation training']","['rate of learning, transfer to untrained alignments, and retention over time']",[],"[{'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0553544', 'cui_str': 'Gaze'}, {'cui': 'C0521164', 'cui_str': 'Annular shape'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0004793', 'cui_str': 'Base sequence'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",,0.0149007,"Learning was quantified as the time taken to achieve target deviation of 2° (easy, E) or 4° (hard, H) for convergence (CE, CH) or divergence (DE, DH) over 40 trials.","[{'ForeName': 'Kerri', 'Initials': 'K', 'LastName': 'Walter', 'Affiliation': 'Northeastern University, Boston, MA, USA.'}, {'ForeName': 'Yesenia', 'Initials': 'Y', 'LastName': 'Taveras-Cruz', 'Affiliation': 'Northeastern University, Boston, MA, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Bex', 'Affiliation': 'Northeastern University, Boston, MA, USA.'}]",Journal of vision,['10.1167/jov.20.8.9'] 2644,32761130,Corrigendum to: A Randomized Clinical Trial to Compare Plasmodium falciparum Gametocytemia and Infectivity After Blood-Stage or Mosquito Bite-Induced Controlled Malaria Infection.,,2020,,[],[],[],[],[],[],,0.050869,,"[{'ForeName': 'Manon', 'Initials': 'M', 'LastName': 'Alkema', 'Affiliation': 'Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Isaie J', 'Initials': 'IJ', 'LastName': 'Reuling', 'Affiliation': 'Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Gerdie M', 'Initials': 'GM', 'LastName': 'de Jong', 'Affiliation': 'Department of Medical Microbiology and Infectious Diseases, University Medical Center Rotterdam, Rotterdam, the Netherlands.'}, {'ForeName': 'Kjerstin', 'Initials': 'K', 'LastName': 'Lanke', 'Affiliation': 'Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Luc E', 'Initials': 'LE', 'LastName': 'Coffeng', 'Affiliation': 'Department of Public Health, University Medical Center Rotterdam, Rotterdam, the Netherlands.'}, {'ForeName': 'Geert-Jan', 'Initials': 'GJ', 'LastName': 'van Gemert', 'Affiliation': 'Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Marga', 'Initials': 'M', 'LastName': 'van de Vegte-Bolmer', 'Affiliation': 'Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Quirijn', 'Initials': 'Q', 'LastName': 'de Mast', 'Affiliation': 'Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Reinout', 'Initials': 'R', 'LastName': 'van Crevel', 'Affiliation': 'Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Ivinson', 'Affiliation': 'PATH Malaria Vaccine Initiative, Washington, DC, USA.'}, {'ForeName': 'Christian F', 'Initials': 'CF', 'LastName': 'Ockenhouse', 'Affiliation': 'PATH Malaria Vaccine Initiative, Washington, DC, USA.'}, {'ForeName': 'James S', 'Initials': 'JS', 'LastName': 'McCarthy', 'Affiliation': 'Clinical Tropical Medicine Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Sauerwein', 'Affiliation': 'Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Katharine A', 'Initials': 'KA', 'LastName': 'Collins', 'Affiliation': 'Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Teun', 'Initials': 'T', 'LastName': 'Bousema', 'Affiliation': 'Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.'}]",The Journal of infectious diseases,['10.1093/infdis/jiaa428'] 2645,32761316,Using automated pump-delivery devices to reduce the incidence of excessive fluid administration during pediatric dental surgery: a randomized-controlled trial.,"PURPOSE The harms caused by excessive perioperative intravenous (IV) fluid administration are both well recognized and avoidable. The purpose of this study was to compare the incidence of excess intraoperative fluid administration in pediatric dental surgery patients when either an automated pump-delivery device or a manual gravity-drip device is used. METHODS We randomly assigned American Society of Anesthesiologists physical status I and II pediatric dental surgery patients to receive IV fluid via either a manual gravity-drip or automated pump-delivery device. Prior to each case, the attending anesthesiologist determined the target volume of maintenance IV fluid to be administered based on patient weight, estimated fluid deficits, and expected case length. The intraoperative IV fluid delivered was determined at the end of the case by the change in the IV bag weight. The primary outcome was the proportion of procedures that delivered ≥ 10% of the target IV fluid volume. RESULTS We recruited 105 children aged two to 12 yr (n = 49 in the automated pump-delivery device; n = 53 in the manual gravity-drip device). The proportion of excessive fluid administration was 8/49 (16%) in the automated pump-delivery device group compared with 33/53 (62%) in the gravity-drip group (relative risk of excessive fluid administration, 0.26; 95% confidence interval, 0.13 to 0.51; P < 0.001). CONCLUSION Intraoperative fluid administration using an automated pump-delivery device decreased the incidence of excessive IV fluid administration in pediatric dental surgery patients. TRIAL REGISTRATION www.clinicaltrials.gov (NCT03312452); registered 17 October 2017.",2020,"CONCLUSION Intraoperative fluid administration using an automated pump-delivery device decreased the incidence of excessive IV fluid administration in pediatric dental surgery patients. ","['I and II pediatric dental surgery patients', 'pediatric dental surgery', 'pediatric dental surgery patients', '105 children aged two to 12 yr (n = 49 in the automated pump-delivery device; n = 53 in the manual gravity-drip device']","['IV fluid via either a manual gravity-drip or automated pump-delivery device', 'automated pump-delivery device or a manual gravity-drip device']","['proportion of excessive fluid administration', 'proportion of procedures that delivered ≥ 10% of the target IV fluid volume']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0204324', 'cui_str': 'Dental surgical procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0282189', 'cui_str': 'Gravity'}, {'cui': 'C0452837', 'cui_str': 'Dripping'}]","[{'cui': 'C1289919', 'cui_str': 'Intravenous fluid'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0282189', 'cui_str': 'Gravity'}, {'cui': 'C0452837', 'cui_str': 'Dripping'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0442802', 'cui_str': 'Excessive'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1289919', 'cui_str': 'Intravenous fluid'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",105.0,0.554494,"CONCLUSION Intraoperative fluid administration using an automated pump-delivery device decreased the incidence of excessive IV fluid administration in pediatric dental surgery patients. ","[{'ForeName': 'Duncan E', 'Initials': 'DE', 'LastName': 'Bowes', 'Affiliation': 'Department of Anesthesiology, Perioperative Medicine and Pain Management, Royal University Hospital, University of Saskatchewan, G525-103 Hospital Drive, Saskatoon, SK, S7N 0W8, Canada. Duncan.Bowes@usask.ca.'}, {'ForeName': 'Jonathan J', 'Initials': 'JJ', 'LastName': 'Gamble', 'Affiliation': 'Department of Anesthesiology, Perioperative Medicine and Pain Management, Royal University Hospital, University of Saskatchewan, G525-103 Hospital Drive, Saskatoon, SK, S7N 0W8, Canada.'}, {'ForeName': 'Jagmeet S', 'Initials': 'JS', 'LastName': 'Bajwa', 'Affiliation': 'Department of Anesthesiology, Perioperative Medicine and Pain Management, Royal University Hospital, University of Saskatchewan, G525-103 Hospital Drive, Saskatoon, SK, S7N 0W8, Canada.'}]",Canadian journal of anaesthesia = Journal canadien d'anesthesie,['10.1007/s12630-020-01776-4'] 2646,32761337,"Efficacy and Safety of Guilingji Capsules () for Treating Mild-to-Moderate Cognitive Impairment: Study Protocol for A Randomized, Double-Blind, Positive-Controlled, Multicenter and Noninferiority Trial.","BACKGROUND The incidence of cognitive impairment (CI) is gradually increasing, which has attracted more attention from medical researchers worldwide. Definitive mechanisms of pathogenesis remain elusive, and there are few medications that have been proven effective for CI. The utilization of Chinese herbal medicine has shown positive therapeutic effects for a broad spectrum of diseases, including CI. OBJECTIVE The purpose of this study is to evaluate the safety and efficacy of Guilingji Capsules (GLJC, ) in treating mild-to-moderate CI with Shen (Kidney) and marrow deficiency syndrome. METHODS This is a randomized, double-blind, positive-controlled, multicenter clinical trial with a noninferiority design that included 348 participants randomly divided into an experimental arm and an active comparator arm. Individuals in the experimental arm (174 cases) took 0.6 g of GLJC once a day and 19.2 mg of Gingko biloba extract mimetic 3 times a day. Individuals in the active comparator arm (174 cases) took 0.6 g of GLJC mimetic once a day and 19.2 mg of Gingko biloba extract in tablet form 3 times a day. The intervention period included two sessions over 24 weeks. The primary outcome be the effectiveness of GLJC on cognitive improvement after 24 weeks of treatment, which was defined as an increase in the Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) Scale. The secondary outcomes were improvement in independence, daily living ability, and Chinese medicine (CM) syndrome, which were measured with the Alzheimer's disease Rating Scale-Cognitive Project (ADAS-Cog), Clinical Dementia Rating (CDR) Total Score, Activities of Daily Living (ADL) Total Score and the Chinese Medicine Symptom Scale (CM-SS), respectively. Serum acetylcholine, acetylcholinesterase, bax and bcl-2 were monitored to explore the mechanism of GLJC on CI. In addition, safety measures, including vital signs, electrocardiography, laboratory indicators (full blood count, kidney and liver function tests, routine urine test and routine stool test) and adverse events, were also recorded. DISCUSSION The purpose of this trial is to evaluate the efficacy and safety of GLJC in patients with mild-to-moderate CI with kidney and marrow deficiency syndrome. If successful, the results would provide a viable treatment for patients with mild-to-moderate CI. (Clinical Trials.gov. ID: NCT03647384. Registered on 23 August 2018).",2020,Individuals in the active comparator arm (174 cases) took 0.6 g of GLJC mimetic once a day and 19.2 mg of Gingko biloba extract in tablet form 3 times a day.,"['treating mild-to-moderate CI with Shen (Kidney) and marrow deficiency syndrome', 'Treating Mild-to-Moderate Cognitive Impairment', '348 participants randomly divided into an experimental arm and an active comparator arm', 'patients with mild-to-moderate CI', 'patients with mild-to-moderate CI with kidney and marrow deficiency syndrome']","['GLJC', 'Gingko biloba extract mimetic', 'Gingko biloba extract', 'Guilingji Capsules (GLJC, ', 'Guilingji Capsules ', 'GLJC mimetic']","['Efficacy and Safety', 'safety measures, including vital signs, electrocardiography, laboratory indicators (full blood count, kidney and liver function tests, routine urine test and routine stool test) and adverse events', 'effectiveness of GLJC on cognitive improvement', 'efficacy and safety', ""improvement in independence, daily living ability, and Chinese medicine (CM) syndrome, which were measured with the Alzheimer's disease Rating Scale-Cognitive Project (ADAS-Cog), Clinical Dementia Rating (CDR) Total Score, Activities of Daily Living (ADL) Total Score and the Chinese Medicine Symptom Scale (CM-SS"", 'Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) Scale', 'Serum acetylcholine, acetylcholinesterase, bax and bcl-2']","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0005953', 'cui_str': 'Bone marrow structure'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C4517733', 'cui_str': '348'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}]","[{'cui': 'C0330206', 'cui_str': 'Ginkgo biloba'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0009555', 'cui_str': 'Complete blood count'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0023901', 'cui_str': 'Hepatic function panel'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0042014', 'cui_str': 'Urinalysis'}, {'cui': 'C0201811', 'cui_str': 'Screening for occult blood in feces'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C0451074', 'cui_str': 'Clinical dementia rating scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0001041', 'cui_str': 'Acetylcholine'}, {'cui': 'C0001044', 'cui_str': 'Acetylcholinesterase'}, {'cui': 'C0219474', 'cui_str': 'Bax Protein'}, {'cui': 'C0376515', 'cui_str': 'bcl-2 Genes'}]",348.0,0.412579,Individuals in the active comparator arm (174 cases) took 0.6 g of GLJC mimetic once a day and 19.2 mg of Gingko biloba extract in tablet form 3 times a day.,"[{'ForeName': 'Nan-Yang', 'Initials': 'NY', 'LastName': 'Liu', 'Affiliation': 'Department of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Pei', 'Affiliation': 'Department of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.'}, {'ForeName': 'Mei-Xia', 'Initials': 'MX', 'LastName': 'Liu', 'Affiliation': 'Department of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.'}, {'ForeName': 'Long-Tao', 'Initials': 'LT', 'LastName': 'Liu', 'Affiliation': 'Department of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.'}, {'ForeName': 'Chang-Geng', 'Initials': 'CG', 'LastName': 'Fu', 'Affiliation': 'Department of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. xyhplihao1965@126.com.'}, {'ForeName': 'Ke-Ji', 'Initials': 'KJ', 'LastName': 'Chen', 'Affiliation': 'Department of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. keji_chen@yahoo.com.'}]",Chinese journal of integrative medicine,['10.1007/s11655-020-2723-5'] 2647,32761372,ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute coronary syndrome: CARTHaGE-ACS trial.,"BACKGROUND Diabetes is associated with a high rate of events after acute coronary syndrome. It was recently reported that once-daily aspirin might not provide stable biological efficacy in patients with diabetes. AIMS We sought to compare the biological efficacy of aspirin given once a day versus aspirin divided twice per day in a population of diabetic patients with non-ST elevation acute coronary syndrome (NSTE-ACS) as assessed by the thrombin generation test. METHODS We performed an open-label single-blind randomized study including 59 consecutive diabetic patients admitted for NSTE-ACS. Patients were randomly treated with aspirin 100 mg once a day (GA100; n = 20), aspirin 160 mg once a day (GA160; n = 19) or aspirin 100 mg twice a day (G2A100; n = 20). The primary endpoint was endogenous thrombin potential (ETP) at discharge and after 6 months. RESULTS The mean age of our patients was 61.5 ± 9 years, and 73% were male. The baseline characteristics were comparable between the three groups. In the GA100 group, there was no significant effect on ETP variation at 6 months (1150.46 ± 504.84 vs. 1087.63 ± 454.18; p = 0.794). An increase in aspirin dose with a second daily administration of 100 mg was associated with a significant reduction in ETP at 6 months (1004.87 ± 196.2 vs. 1233.63 ± 333.5; p = 0.003). A nonsignificant decrease in ETP was seen in the GA160 group (from 1173.8 ± 388.07 to 1053.64 ± 269.93 at 6 months, p = 0.117). CONCLUSION Only the twice-daily aspirin regimen led to better control of hypercoagulability in NSTE-ACS diabetic patients. However, no thrombin generation normalization was reported.",2020,"In the GA100 group, there was no significant effect on ETP variation at 6 months (1150.46 ± 504.84 vs. 1087.63 ± 454.18; p = 0.794).","['patients with diabetes', 'diabetic patients with non-ST elevation', '59 consecutive diabetic patients admitted for NSTE-ACS', 'The mean age of our patients was 61.5\u2009±\u20099\xa0years, and 73% were male', 'NSTE-ACS diabetic patients', 'diabEtic patients with acute coronary syndrome']","['aspirin 160\xa0mg once a day (GA160; n\u2009=\u200919) or aspirin', 'aspirin']","['thrombin generation normalization', 'ETP variation', 'control of hypercoagulability', 'ETP', 'endogenous thrombin potential (ETP) at discharge and after 6 months', 'biological efficacy', 'THrombin generation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0520886', 'cui_str': 'ST segment elevation'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}]","[{'cui': 'C0040018', 'cui_str': 'Thrombin'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0205227', 'cui_str': 'Endogenous'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0398623', 'cui_str': 'Thrombophilia'}, {'cui': 'C3871203', 'cui_str': 'At discharge'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",59.0,0.0963132,"In the GA100 group, there was no significant effect on ETP variation at 6 months (1150.46 ± 504.84 vs. 1087.63 ± 454.18; p = 0.794).","[{'ForeName': 'Amine', 'Initials': 'A', 'LastName': 'Boussofara', 'Affiliation': 'Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.'}, {'ForeName': 'Lobna', 'Initials': 'L', 'LastName': 'Laroussi', 'Affiliation': 'Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia. lobna_laroussi@hotmail.com.'}, {'ForeName': 'Hela', 'Initials': 'H', 'LastName': 'Baccouche', 'Affiliation': 'Faculty of Medicine of Tunis- Tunis University El Manar, Tunis, Tunisia.'}, {'ForeName': 'Emna', 'Initials': 'E', 'LastName': 'Bennour', 'Affiliation': 'Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.'}, {'ForeName': 'Sami', 'Initials': 'S', 'LastName': 'Kasbaoui', 'Affiliation': 'Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.'}, {'ForeName': 'Hbib', 'Initials': 'H', 'LastName': 'Triki', 'Affiliation': 'Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.'}, {'ForeName': 'Ibn El Haj', 'Initials': 'EH', 'LastName': 'Zied', 'Affiliation': 'Faculty of Medicine of Tunis- Tunis University El Manar, Tunis, Tunisia.'}, {'ForeName': 'Ikram', 'Initials': 'I', 'LastName': 'Kammoun', 'Affiliation': 'Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.'}, {'ForeName': 'Afef Ben', 'Initials': 'AB', 'LastName': 'Halima', 'Affiliation': 'Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.'}, {'ForeName': 'Faouzi', 'Initials': 'F', 'LastName': 'Addad', 'Affiliation': 'Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Marrakchi', 'Affiliation': 'Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.'}, {'ForeName': 'Neila Ben', 'Initials': 'NB', 'LastName': 'Romdhane', 'Affiliation': 'Faculty of Medicine of Tunis- Tunis University El Manar, Tunis, Tunisia.'}, {'ForeName': 'Salem', 'Initials': 'S', 'LastName': 'Kachboura', 'Affiliation': 'Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.'}]",European journal of clinical pharmacology,['10.1007/s00228-020-02969-y'] 2648,32761373,One anastomosis gastric bypass vs. Roux-en-Y gastric bypass: a 5-year follow-up prospective randomized trial.,"BACKGROUND One anastomosis gastric bypass (OAGB) is a relatively novel technique with excellent outcomes, comparable to most accepted procedures. Our aim was to compare OAGB and Roux-en-Y gastric bypass (RYGB) in terms of percent of excess weight lost (%EWL) and resolution of comorbidities. METHODS Thirty-three patients were randomly assigned (1:2) to two groups (OAGB = 9 and RYGB = 24). Patients were analyzed prospectively. RESULTS The 5-year follow-up was 85% (28 patients). Both groups were comparable preoperatively in age, weight, body mass index (BMI), and excess weight. One intraoperative complication in OAGB group and no major postoperative complications for both groups were recorded. Progressive decrease in weight, BMI, and %EWL was observed at 1, 6, 12 months, and 5 years, with no differences between groups. Regarding comorbidities, we registered complete remission in type 2 diabetes mellitus (T2DM), insulin resistance, and dyslipidemia with OAGB. RYGB group reported complete remission in T2DM, insulin resistance, dyslipidemia, and gastroesophageal reflux disease (GERD). Mean operative time were 113.3 min ± 41.2 and 143.7 min ± 21.85 for OAGB and RYGB respectively. Mean number of reloads used was 5 for OAGB and 7 for RYGB, which demands further investigations. Postoperative pain was significantly higher in RYGB group. Hospital stay was 3 days for both groups. CONCLUSION At 5-year follow-up, patients of both techniques achieved similar outcomes in terms of %EWL and resolution of comorbidities, without early or mid-term major complications and no mortality. OAGB demonstrated less use of surgical stapling and unexplainably less postoperative pain compared to RYGB.",2020,Mean operative time were 113.3 min ± 41.2 and 143.7 min ± 21.85 for OAGB and RYGB respectively.,['Thirty-three patients'],"['OAGB', 'anastomosis gastric bypass vs. Roux-en-Y gastric bypass', 'OAGB and Roux-en-Y gastric bypass (RYGB', 'anastomosis gastric bypass (OAGB']","['Mean operative time', 'postoperative pain', 'postoperative complications', 'complete remission in T2DM, insulin resistance, dyslipidemia, and gastroesophageal reflux disease (GERD', 'Hospital stay', 'weight, BMI, and %EWL', 'Postoperative pain', 'EWL and resolution of comorbidities, without early or mid-term major complications and no mortality']","[{'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0332853', 'cui_str': 'Anastomosis'}, {'cui': 'C0017125', 'cui_str': 'Bypass of stomach'}, {'cui': 'C0399839', 'cui_str': 'Bypass gastrojejunostomy'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemia'}, {'cui': 'C0017168', 'cui_str': 'Gastroesophageal reflux disease'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",33.0,0.0286641,Mean operative time were 113.3 min ± 41.2 and 143.7 min ± 21.85 for OAGB and RYGB respectively.,"[{'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Level', 'Affiliation': 'Universidad Central de Venezuela, Hospital Dr. Miguel Pérez Carreño, General Surgery Service I, Caracas, Venezuela. levelluis@yahoo.com.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Rojas', 'Affiliation': 'Hospital Dr. Miguel Pérez Carreño, General Surgery Service I, Caracas, Venezuela.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Piñango', 'Affiliation': 'Hospital Dr. Miguel Pérez Carreño, General Surgery Service I, Caracas, Venezuela.'}, {'ForeName': 'Yubisay', 'Initials': 'Y', 'LastName': 'Avariano', 'Affiliation': 'Hospital Dr. Miguel Pérez Carreño, General Surgery Service I, Caracas, Venezuela.'}]",Langenbeck's archives of surgery,['10.1007/s00423-020-01949-1'] 2649,32761611,The effect of trimodal prehabilitation on the physical and psychological health of patients undergoing colorectal surgery: a randomised clinical trial.,"prehabilitation aims to increase the endurance capacity of patients who are awaiting major surgery. However, there are no studies investigating the implementation of this demanding and expensive intervention in low-income countries. This study aimed to assess the impact of a 4-week trimodal prehabilitation program on the physical and psychological health of patients waiting for colorectal surgery compared with a control group managed according to enhanced recovery after surgery principles supplemented by nutritional care. This study was a single-centre, randomised controlled trial. The primary outcome measures for the physical aspects were 6-minute walking distance (6MWD) and incentive spirometry, whereas the psychological elements were measured using the 36-item short form survey questionnaire and the hospital anxiety and depression score. In total, data from 149 patients were analysed (77 in the prehabilitation group and 72 in the control group). At the time of surgery, patients in the prehabilitation group had improved 6MWD and incentive spirometry compared with the control group (median (IQR [range]) percentage improvement 131% (112-173 [68-376]) vs. 107% (99-120 [63-163]); p < 0.001 and 113% (100-125 [75-200]) vs. 100% (100-112 [86-167]); p < 0.001 respectively). Patients in the prehabilitation group also had reduced anxiety scores compared with the control group (mean (SD) anxiety score (4 (3) vs. 5 (3) respectively; p = 0.032). However, these effects did not translate into improvements in postoperative mortality and morbidity, or a reduction in duration of hospital stay. Trimodal (physical, emotional and nutritional) prehabilitation is able to improve functional status as well as some parameters of emotional and physical well-being of patients waiting for colorectal surgery.",2020,"However, these effects did not translate into improvements in postoperative mortality and morbidity, or a reduction in duration of hospital stay.","['patients undergoing colorectal surgery', 'patients who are awaiting major surgery', '149 patients were analysed (77 in the prehabilitation group and 72 in the control group', 'patients waiting for colorectal surgery']","['trimodal prehabilitation program', 'trimodal prehabilitation']","['physical aspects were 6-minute walking distance (6MWD) and incentive spirometry, whereas the psychological elements were measured using the 36-item short form survey questionnaire and the hospital anxiety and depression score', 'reduced anxiety scores', 'postoperative mortality and morbidity', 'endurance capacity', 'anxiety score', '6MWD and incentive spirometry', 'duration of hospital stay']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009369', 'cui_str': 'Colorectal surgery'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C5191071', 'cui_str': '149'}, {'cui': 'C5192101', 'cui_str': 'Prehabilitation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0542399', 'cui_str': 'Patient waiting for'}]","[{'cui': 'C5192101', 'cui_str': 'Prehabilitation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0444858', 'cui_str': 'AM 6'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0454512', 'cui_str': 'Incentive spirometry'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0013879', 'cui_str': 'Chemical element'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0150135', 'cui_str': 'Alleviating anxiety'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",149.0,0.100995,"However, these effects did not translate into improvements in postoperative mortality and morbidity, or a reduction in duration of hospital stay.","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Fulop', 'Affiliation': '1st Department of Surgery, Semmelweis University, Budapest, Hungary.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Lakatos', 'Affiliation': 'Department of Surgery, St. Borbala Hospital, Tatabanya, Hungary.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Susztak', 'Affiliation': 'Department of Surgery, St. Borbala Hospital, Tatabanya, Hungary.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Szijarto', 'Affiliation': '1st Department of Surgery, Semmelweis University, Budapest, Hungary.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Banky', 'Affiliation': 'Department of Surgery, St. Borbala Hospital, Tatabanya, Hungary.'}]",Anaesthesia,['10.1111/anae.15215'] 2650,32761620,Diagnostic work-up including CD203c-based basophil activation test in immediate hypersensitivity due to metronidazole and ornidazole and evaluation of cross-reactivity in between.,"BACKGROUND Little is known about the diagnostic approaches for immediate hypersensitivity reactions (IHRs) due to 5-nitroimidazole antibiotics. The aim was to evaluate the usefulness of in vivo tests and basophil activation test (BAT) for the diagnosis of IHRs due metronidazole and ornidazole and to determine possible cross reactivity in between. METHODS Forty-nine patients with a clear history of IHRs due to these drugs and 20 healthy subjects who were known to tolerate these drugs were included. Skin tests (STs), and single-blind placebo-controlled drug provocation tests (SBPCDPTs) were performed with both drugs whereas BAT was applied only with the culprit drug. RESULTS The most and least common reaction types were urticaria/angioedema (34.7%) and anaphylaxis (14.3%), respectively. SBPCDPTs were positive in 15 out of 47 patients, only 7 had positive STs. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of STs for metronidazole/ornidazole were 33.3%/16.6, 94.2%/97.3, 60%/50 and 84.6%/88.1, respectively. BAT was positive in 12 out of 15 patients and negative in 10 control subjects, giving a sensitivity rate of 71.4% (CI, 29.0-96.3%) for metronidazole and 83.3% (CI, 35.8-99.5%) for ornidazole. The optimal concentration of both drugs for BAT was determined as 5 mg/ml. No cross-reactivity among two drugs was observed according to in vivo tests. CONCLUSIONS Our study showed that SBPCDPT and BAT are both useful diagnostic tools for IHRs due to 5-nitroimidazole antibiotics and can be used as supplementary to each other. No cross-reactivity between metronidazole and ornidazole in IHRs exits.",2020,"The most and least common reaction types were urticaria/angioedema (34.7%) and anaphylaxis (14.3%), respectively.",['Forty-nine patients with a clear history of IHRs due to these drugs and 20 healthy subjects who were known to tolerate these drugs were included'],"['metronidazole', 'SBPCDPT and BAT', 'basophil activation test (BAT', 'Skin tests (STs), and single-blind placebo-controlled drug provocation tests (SBPCDPTs']","['sensitivity rate', 'urticaria/angioedema', 'Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of STs for metronidazole/ornidazole', 'BAT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0020523', 'cui_str': 'IgE-mediated allergic disorder'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0004827', 'cui_str': 'Basophils'}, {'cui': 'C0201781', 'cui_str': 'Activation test'}, {'cui': 'C0037296', 'cui_str': 'Hypersensitivity skin testing'}, {'cui': 'C0242570', 'cui_str': 'Single-Masked Study'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0013168', 'cui_str': 'Drug Control'}, {'cui': 'C0449428', 'cui_str': 'Provocation'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0042109', 'cui_str': 'Urticaria'}, {'cui': 'C0002994', 'cui_str': 'Angioedema'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0037296', 'cui_str': 'Hypersensitivity skin testing'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0029274', 'cui_str': 'Ornidazole'}, {'cui': 'C0004827', 'cui_str': 'Basophils'}, {'cui': 'C0201781', 'cui_str': 'Activation test'}]",49.0,0.0301092,"The most and least common reaction types were urticaria/angioedema (34.7%) and anaphylaxis (14.3%), respectively.","[{'ForeName': 'Şengül', 'Initials': 'Ş', 'LastName': 'Beyaz', 'Affiliation': 'Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Nilgün', 'Initials': 'N', 'LastName': 'Akdeniz', 'Affiliation': 'Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Abdullah', 'Initials': 'A', 'LastName': 'Yılmaz', 'Affiliation': 'Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Semra', 'Initials': 'S', 'LastName': 'Demir', 'Affiliation': 'Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Nida', 'Initials': 'N', 'LastName': 'Öztop', 'Affiliation': 'Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Bahauddin', 'Initials': 'B', 'LastName': 'Çolakoğlu', 'Affiliation': 'Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Suna', 'Initials': 'S', 'LastName': 'Büyüköztürk', 'Affiliation': 'Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Günnur', 'Initials': 'G', 'LastName': 'Deniz', 'Affiliation': 'Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Aslı', 'Initials': 'A', 'LastName': 'Gelincik', 'Affiliation': 'Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}]",Allergy,['10.1111/all.14542'] 2651,32761638,Increasing cardiovascular medication adherence: A medical research council complex mhealth intervention mixed-methods feasibility study to inform global practice.,"AIMS To evaluate a mHealth intervention to increase medication adherence among Iranian coronary heart disease patients. DESIGN Quantitative-dominant mixed-methods study. DATA SOURCE Iranian coronary heart disease patients' responses and most recent clinical documents as well as responses from Iranian cardiac nurses who participated in this study. METHODS The study was conducted between September 2015-April 2016 drawing on the Medical Research Council's Framework. Phase one comprised of a patients' survey and focus groups with cardiac nurses. The automated short message service reminder was piloted in phase two. We recruited 78 patients and randomized to receive either 12-week daily reminders or usual care. The primary outcome was the effect on medication adherence; secondary outcomes were self-efficacy, ejection fraction, functional capacity, readmission rate and quality of life. RESULTS Feasibility was evidenced by high ownership of mobile phones and high interest in receiving reminders. Participants in the intervention group showed significantly higher medication adherence compared with the control group. CONCLUSION The mHealth intervention was well accepted and feasible with early evidence of effectiveness that needs to be confirmed in a fully powered future randomized clinical trial.",2020,"Participants in the intervention group showed significantly higher medication adherence compared with the control group. ","[""September 2015-April 2016 drawing on the Medical Research Council's Framework"", 'Iranian cardiac nurses who participated in this study', '78 patients', 'Iranian coronary heart disease patients']","['12-week daily reminders or usual care', 'mHealth intervention']","['medication adherence; secondary outcomes were self-efficacy, ejection fraction, functional capacity, readmission rate and quality of life', 'cardiovascular medication adherence', 'medication adherence']","[{'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0013113', 'cui_str': 'Drawings'}, {'cui': 'C0079816', 'cui_str': 'Research, Medical'}, {'cui': 'C3887625', 'cui_str': 'Coronary care nurse'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0007220', 'cui_str': 'Cardiovascular agent'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",78.0,0.0982752,"Participants in the intervention group showed significantly higher medication adherence compared with the control group. ","[{'ForeName': 'Sahar', 'Initials': 'S', 'LastName': 'Khonsari', 'Affiliation': 'School of Health in Social Science, The University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Chandler', 'Affiliation': 'School of Health in Social Science, The University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Parker', 'Affiliation': 'Usher Institute, The University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Aisha', 'Initials': 'A', 'LastName': 'Holloway', 'Affiliation': 'School of Health in Social Science, The University of Edinburgh, Edinburgh, UK.'}]",Journal of advanced nursing,['10.1111/jan.14465'] 2652,32761890,Two-year outcomes after percutaneous coronary intervention with drug-eluting stents or bare-metal stents in elderly patients with coronary artery disease.,"OBJECTIVES Report the results at 2 years of the patients included in the SENIOR trial. BACKGROUND Patients above 75 years of age represent a fast-growing population in the cathlab. In the SENIOR trial, patients treated by percutaneous coronary intervention (PCI) with drug eluting stent (DES) and a short duration of P2Y12 inhibitor (1 and 6 months for stable and unstable coronary syndromes, respectively) compared with bare metal stents (BMS) was associated with a 29% reduction in the rate of all-cause mortality, myocardial infarction (MI), stroke, and ischaemia-driven target lesion revascularization (ID-TLR) at 1 year. The results at 2 years are reported here. METHODS AND RESULTS We randomly assigned 1,200 patients (596[50%] to the DES group and 604[50%] to the BMS group). At 2 years, the composite endpoint of all-cause mortality, MI, stroke and ID-TLR had occurred in 116 (20%) patients in the DES group and 131 (22%) patients in the BMS group (RR 0.90 [95%CI 0.72-1.13], p = .37). IDTLR occurred in 14 (2%) patients in the DES group and 41 (7%) patients in the BMS group (RR 0.35 [95%CI 0.16-0.60], p = .0002). Major bleedings (BARC 3-5) occurred in 27(5%) patients in both groups (RR 1.00, [95%CI 0.58-1.75], p = .99). Stent thrombosis rates were low and similar between DES and BMS (0.8 vs 1.3%, (RR 0.52 [95%CI 0.01-1.95], p = .27). CONCLUSION Among elderly PCI patients, a strategy combining a DES together with a short duration of DAPT is associated with a reduction in revascularization up to 2 years compared with BMS with very few late events and without any increased in bleeding complications or stent thrombosis.",2020,"Stent thrombosis rates were low and similar between DES and BMS (0.8 vs 1.3%, (RR 0.52","['2 years of the patients included in the SENIOR trial', 'elderly PCI patients', 'Patients above 75\u2009years of age represent a fast-growing population in the cathlab', 'elderly patients with coronary artery disease']","['DES', 'percutaneous coronary intervention with drug-eluting stents or bare-metal stents', 'bare metal stents (BMS', 'percutaneous coronary intervention (PCI) with drug eluting stent (DES']","['Stent thrombosis rates', 'bleeding complications or stent thrombosis', 'Major bleedings', 'TLR', 'rate of all-cause mortality, myocardial infarction (MI), stroke, and ischaemia-driven target lesion revascularization (ID-TLR', 'composite endpoint of all-cause mortality, MI, stroke and ID', 'IDTLR', 'DES and BMS']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}]","[{'cui': 'C1322815', 'cui_str': 'Drug eluting stent'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C2825200', 'cui_str': 'Bare metal stent'}]","[{'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0014742', 'cui_str': 'Erythema multiforme'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1322815', 'cui_str': 'Drug eluting stent'}, {'cui': 'C2825200', 'cui_str': 'Bare metal stent'}]",1200.0,0.0960011,"Stent thrombosis rates were low and similar between DES and BMS (0.8 vs 1.3%, (RR 0.52","[{'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Lafont', 'Affiliation': 'Cardiology Department Hôpital Cochin, Assistance Publique-Hôpitaux de Paris and, Université de Paris, Paris, France.'}, {'ForeName': 'Peter R', 'Initials': 'PR', 'LastName': 'Sinnaeve', 'Affiliation': 'Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Cuisset', 'Affiliation': 'Cardiology Department, Centre Hospitalier Universitaire Timone, Marseille, France.'}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Cook', 'Affiliation': 'Cardiology Department, University and Hospital Fribourg, Fribourg, Switzerland.'}, {'ForeName': 'Giorgios', 'Initials': 'G', 'LastName': 'Sideris', 'Affiliation': 'Cardiology Department Service de Cardiologie-Institut national de la santé et de la recherche médicale U942, Hôpital Lariboisiere, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, Paris, France.'}, {'ForeName': 'Sasko', 'Initials': 'S', 'LastName': 'Kedev', 'Affiliation': 'Cardiology Department, University St Cyril and Methodius, Skopje, Macedonia.'}, {'ForeName': 'Didier', 'Initials': 'D', 'LastName': 'Carrie', 'Affiliation': 'Service de Cardiologie, Centre hospitalier universitaire Toulouse Rangueil, Université Paul Sabatier, Toulouse, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Hovasse', 'Affiliation': 'Institut Cardiovasculaire Paris-Sud, Ramsay Générale de Santé, Massy, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Garot', 'Affiliation': 'Institut Cardiovasculaire Paris-Sud, Ramsay Générale de Santé, Massy, France.'}, {'ForeName': 'Rami', 'Initials': 'R', 'LastName': 'El Mahmoud', 'Affiliation': 'Hôpital Ambroise Paré Assistance Publique-Hôpitaux de Paris, Université Versailles-Saint Quentin en Yvelines, Versailles, France.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Spaulding', 'Affiliation': 'Service de Cardiologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Université de Paris and Sudden Death Expert Center, Institut national de la santé et de la recherche médicale U990, Paris, France.'}, {'ForeName': 'Gérard', 'Initials': 'G', 'LastName': 'Helft', 'Affiliation': 'Institut de Cardiologie, Hôpital Pitié-Salpétrière, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie et Institut hospitalo-universitaire, Institute of Cardiometabolism and Nutrition, Hôpital Pitié-Salpétrière, Paris, France.'}, {'ForeName': 'José F', 'Initials': 'JF', 'LastName': 'Diaz Fernandez', 'Affiliation': 'Cardiology department, Juan Ramón Jiménez University Hospital, Huelva, Spain.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Brugaleta', 'Affiliation': ""Cardiovascular Institute, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.""}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Pinar-Bermudez', 'Affiliation': 'Cardiology department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.'}, {'ForeName': 'Josepa Mauri', 'Initials': 'JM', 'LastName': 'Ferre', 'Affiliation': 'Cardiology department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Commeau', 'Affiliation': 'Département de Cardiologie Interventionnelle, Polyclinique Les Fleurs, France.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Teiger', 'Affiliation': 'Service de Cardiologie, Hôpital Henri Mondor Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France.'}, {'ForeName': 'Kris', 'Initials': 'K', 'LastName': 'Bogaerts', 'Affiliation': 'Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Department of Public Health and Primary Care, Katholieke Universiteit Leuven, Leuven, Belgium, and Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), University Hasselt, Hasselt, Belgium.'}, {'ForeName': 'Manel', 'Initials': 'M', 'LastName': 'Sabate', 'Affiliation': ""Interventional Cardiology Unit, Cardiovascular Institute, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.""}, {'ForeName': 'Marie Claude', 'Initials': 'MC', 'LastName': 'Morice', 'Affiliation': 'CERC (Cardiovascular European Research Center), Massy, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Varenne', 'Affiliation': 'Cardiology Department Hôpital Cochin, Assistance Publique-Hôpitaux de Paris and, Université de Paris, Paris, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,['10.1002/ccd.29159'] 2653,32761909,Topical phenytoin effects on palatal wound healing.,"BACKGROUND The clinical benefits of autogenous soft tissue grafts are countered by donor site morbidity. The aim of this prospective split-mouth clinical trial is to assess clinical, histological and patient outcomes following topical phenytoin (PHT) treatment of experimental palatal wounds. MATERIAL AND METHODS Systemically healthy adults were recruited. One 6 mm diameter wound (posterior) and one 4 mm diameter wound (anterior), each 1-1.5 mm deep, were created on both sides of the palate. Wounds on one randomly chosen side received 10% phenytoin USP and contralateral wounds received carrier alone. Biopsies were harvested from anterior wounds (Day 1 or Day 5) and were routinely processed for histology. Posterior wounds were left undisturbed to clinically evaluate healing (using photographs and Healing Score Index) on Days 1, 5, 14 and 21. Questionnaires were used to assess patient-centred outcomes. Data analysis was performed using generalized logistic and generalized linear mixed models. RESULTS 20 participants completed all visits. 30% of participants reported more pain on control side than the PHT side at Day 1 (p = 0.014). PHT treated sites were more likely to not exhibit swelling (OR = 9.35; p = 0.009) and to not experience pain on palpation (OR = 6.278; p = 0.007). PHT significantly and time-dependently affected granulation tissue appearance (p = 0.004). Histologically, there were no significant differences between control and PHT, at any time point (p≥0.853). CONCLUSIONS The results of the present study, the first one to report on topical PHT as palatal wound treatment, suggest that PHT application on palatal wounds could result in improved healing outcomes. This article is protected by copyright. All rights reserved.",2020,PHT treated sites were more likely to not exhibit swelling (OR = 9.35; p = 0.009) and to not experience pain on palpation (OR = 6.278; p = 0.007).,"['experimental palatal wounds', '20 participants completed all visits', 'Systemically healthy adults were recruited']","['topical phenytoin (PHT', 'phenytoin USP and contralateral wounds received carrier alone', 'Topical phenytoin']","['pain on control side', 'healing outcomes', 'granulation tissue appearance', 'palatal wound healing']","[{'cui': 'C0700374', 'cui_str': 'Palatal'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0031507', 'cui_str': 'Phenytoin'}, {'cui': 'C0441988', 'cui_str': 'Contralateral'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0007294', 'cui_str': 'Genetic disorder carrier'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0018180', 'cui_str': 'Granulation tissue'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0700374', 'cui_str': 'Palatal'}]",1.0,0.0375099,PHT treated sites were more likely to not exhibit swelling (OR = 9.35; p = 0.009) and to not experience pain on palpation (OR = 6.278; p = 0.007).,"[{'ForeName': 'Anuja', 'Initials': 'A', 'LastName': 'Doshi', 'Affiliation': 'Division of Periodontology, College of Dentistry, The Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'James W', 'Initials': 'JW', 'LastName': 'McAuley', 'Affiliation': 'College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Dimitris N', 'Initials': 'DN', 'LastName': 'Tatakis', 'Affiliation': 'Division of Periodontology, College of Dentistry, The Ohio State University, Columbus, Ohio, USA.'}]",Journal of periodontology,['10.1002/JPER.20-0340'] 2654,32761955,"Double-Blind, Randomized, Placebo-Controlled Trial of DA-9701 in Parkinson's Disease: PASS-GI Study.","OBJECTIVES This study aimed to assess the efficacy of DA-9701 on gastrointestinal symptom-related quality of life in patients with Parkinson's disease on stable dopaminergic medications. METHODS This multicenter, double-blind, placebo-controlled, phase 4 trial included a total of 144 patients with Parkinson's disease with gastrointestinal dysfunctions based on predefined criteria. Participants were randomized to take either DA-9701 or placebo for 4 weeks, and then both groups were administered DA-9701 for an additional 8 weeks while antiparkinsonian medications were unchanged. The primary outcome measure was gastrointestinal symptoms and related quality-of-life changes assessed on the Korean Nepean dyspepsia index after 4 and 12 weeks of therapy. We also evaluated the impact of DA-9701 therapy on parkinsonian motor symptoms at each time point. RESULTS The gastrointestinal symptom-related quality-of-life score significantly improved in the DA-9701-treated group compared with the placebo-treated group after 4weeks (adjusted P = 0.012 by linear mixed effect model analysis). The overall gastrointestinal symptom and dyspepsia sum scores improved at 12 weeks after intervention in the DA-9701-first treated group (adjusted P = 0.002 and 0.014, respectively) and also in the placebo-first treated group (adjusted P = 0.019 and 0.039) compared with the baseline. Parkinsonian motor severity was not significantly affected by DA-9701 treatment in both groups at 4 and 12 weeks after intervention. There were no drug-related serious adverse events throughout the trial. CONCLUSIONS DA-9701 therapy improved gastrointestinal symptom-related quality of life, and 12 weeks of daily administration can relieve the overall severity of gastrointestinal symptoms in patients with Parkinson's disease without affecting motor symptoms. (Clinical trial identifier: NCT02775591.) © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC. on behalf of International Parkinson and Movement Disorder Society.",2020,Parkinsonian motor severity was not significantly affected by DA-9701 treatment in both groups at 4 and 12 weeks after intervention.,"[""patients with Parkinson's disease on stable dopaminergic medications"", '2020', ""Parkinson's Disease"", ""patients with Parkinson's disease without affecting motor symptoms"", ""144 patients with Parkinson's disease with gastrointestinal dysfunctions based on predefined criteria""]","['Placebo', 'DA-9701 therapy', 'DA-9701 or placebo', 'DA-9701', 'placebo']","['gastrointestinal symptom-related quality of life', 'parkinsonian motor symptoms', 'overall gastrointestinal symptom and dyspepsia sum scores', 'gastrointestinal symptoms and related quality-of-life changes assessed on the Korean Nepean dyspepsia index', 'Parkinsonian motor severity', 'gastrointestinal symptom-related quality-of-life score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0178601', 'cui_str': 'Dopamine receptor agonist'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2606904', 'cui_str': 'DA-9701'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0013395', 'cui_str': 'Indigestion'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",144.0,0.454535,Parkinsonian motor severity was not significantly affected by DA-9701 treatment in both groups at 4 and 12 weeks after intervention.,"[{'ForeName': 'Ji-Hyun', 'Initials': 'JH', 'LastName': 'Choi', 'Affiliation': 'Department of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Jee-Young', 'Initials': 'JY', 'LastName': 'Lee', 'Affiliation': 'Department of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Jin Whan', 'Initials': 'JW', 'LastName': 'Cho', 'Affiliation': 'Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Seong-Beom', 'Initials': 'SB', 'LastName': 'Koh', 'Affiliation': 'Department of Neurology, Korea University Guro Hospital, Seoul, South Korea.'}, {'ForeName': 'Young Soon', 'Initials': 'YS', 'LastName': 'Yang', 'Affiliation': 'Department of Neurology, National Neuroscience Institute, Singapore, Singapore.'}, {'ForeName': 'Dalla', 'Initials': 'D', 'LastName': 'Yoo', 'Affiliation': 'Department of Neurology, Kyung Hee University Hospital, Seoul, South Korea.'}, {'ForeName': 'Cheol-Min', 'Initials': 'CM', 'LastName': 'Shin', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.'}, {'ForeName': 'Hee Tae', 'Initials': 'HT', 'LastName': 'Kim', 'Affiliation': 'Department of Neurology, Hanyang University Medical Center, Seoul, South Korea.'}]",Movement disorders : official journal of the Movement Disorder Society,['10.1002/mds.28219'] 2655,32761980,Sceletium tortuosum (Zembrin ® ) ameliorates experimentally induced anxiety in healthy volunteers.,"OBJECTIVE To investigate the anxiolytic properties of a standardized extract of Sceletium tortuosum (trademarked-Zembrin ® ). METHODS Two studies utilized a placebo-controlled, double-blind, between-subject experimental design to investigate the effects of a single dose of Sceletium tortuosum (25 mg, Zembrin ® ) on laboratory stress/anxiety responding in 20 young healthy volunteers. To elicit feelings of stress/anxiety, participants completed 20 min of the multitasking framework in study 1 and a 5-min simulated public speaking task in study 2. Study 1 measured subjective experiences of mood at baseline, prestress induction, and poststress induction. Study 2 measured subjective experiences of anxiety and physiological indicators of stress (heart rate [HR] and galvanic skin response) at baseline, prestress induction, during stress induction, and poststress induction. RESULTS A series of analysis of covariances (baseline entered as the covariate) revealed no treatment effect in study 1; however, study 2 revealed subjective anxiety levels to be significantly lower in the Zembrin ® group at the prestress induction point and a significant interaction between treatment and time on HR. Taken together, results indicate that a single dose of Zembrin ® can ameliorate laboratory stress/anxiety responding in healthy volunteers. CONCLUSION We provide the first tentative behavioral evidence to support the anxiolytic properties of Sceletium tortuosum (25 mg Zembrin ® ).",2020,"A series of analysis of covariances (baseline entered as the covariate) revealed no treatment effect in study 1; however, study 2 revealed subjective anxiety levels to be significantly lower in the Zembrin ® group at the prestress induction point and a significant interaction between treatment and time on HR.","['20 young healthy volunteers', 'healthy volunteers']","['Sceletium tortuosum (25 mg, Zembrin ® ', 'Zembrin ®', 'Sceletium tortuosum (Zembrin ® ', 'placebo']","['subjective experiences of anxiety and physiological indicators of stress (heart rate [HR] and galvanic skin response) at baseline, prestress induction, during stress induction, and poststress induction', 'subjective experiences of mood at baseline, prestress induction, and poststress induction', 'subjective anxiety levels']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0016989', 'cui_str': 'Galvanic skin response'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}]",20.0,0.0616753,"A series of analysis of covariances (baseline entered as the covariate) revealed no treatment effect in study 1; however, study 2 revealed subjective anxiety levels to be significantly lower in the Zembrin ® group at the prestress induction point and a significant interaction between treatment and time on HR.","[{'ForeName': 'Jonathon', 'Initials': 'J', 'LastName': 'Reay', 'Affiliation': 'Department of Psychology, School of Social Sciences, Humanities & Law, Teesside University, Middlesbrough, UK.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Wetherell', 'Affiliation': 'Department of Psychology, Stress Research Group, Northumbria University, Newcastle-upon-Tyne, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Morton', 'Affiliation': 'Department of Psychology, Stress Research Group, Northumbria University, Newcastle-upon-Tyne, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Lillis', 'Affiliation': 'Department of Psychology, School of Social Sciences, Humanities & Law, Teesside University, Middlesbrough, UK.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Badmaev', 'Affiliation': 'American Medical Holdings Inc., New York, New York, USA.'}]",Human psychopharmacology,['10.1002/hup.2753'] 2656,32760247,Vitamin B 12 Supplementation and NT-proBNP Levels in COPD Patients: A Secondary Analysis of a Randomized and Controlled Study in Rehabilitation.,"Purpose There is evidence of complex interaction between vitamin B 12 (vB 12 ) level, hyperhomocysteinemia (HyCy), and natriuretic peptide secretion. Exercise training could also modulate such interaction. In this secondary analysis of a Randomized Clinical Trial performed in a chronic obstructive pulmonary disease (COPD) rehabilitation setting, our primary objective was to investigate the interaction between vB 12 supplementation, exercise training, and changes in NT-proBNP levels after 8 weeks of intervention. Secondary objectives were to explore the correlations between acute changes in NT-proBNP levels with (i) acute exercise and (ii) oxygen uptake ( V 'O 2 ) kinetics during rest-to-exercise transition. Methods Thirty-two subjects with COPD were randomized into four groups: Rehabilitation+vB 12 ( n = 8), Rehabilitation ( n = 8), vB 12 ( n = 8), or Maltodextrin( n = 8). They were evaluated at baseline and after 8 weeks, during resting and immediately after maximal exercise constant work-rate tests (CWTs, T lim), for NT-proBNP plasmatic levels. Results After interaction analysis, the supplementation with vB 12 significantly changed the time course of NT-proBNP responses during treatment ( p = 0.048). However, the final analysis could not support a significant change in NT-proBNP levels owing to high-intensity constant work-rate exercise ( p -value > 0.05). There was a statistically significant correlation between V 'O 2 time constant and ΔNT-proBNP values ( T lim - rest) at baseline ( p = 0.049) and 2 months later ( p = 0.015), considering all subjects ( n = 32). Conclusion We conclude that vB 12 supplementation could modulate NT-proBNP secretion. Moreover, possibly, the slower the initial V 'O 2 adjustments toward a steady-state during rest-to-exercise transitions, the more severe the ventricular chamber volume/pressure stress recruitment, expressed through higher NT-proBNP secretion in subjects with larger V 'O 2 time constants, despite unchanged final acute exercise-induced neurohormone secretion.",2020,"There was a statistically significant correlation between V 'O 2 time constant and ΔNT-proBNP values ( T lim - rest) at baseline ( p = 0.049) and 2 months later ( p = 0.015), considering all subjects ( n = 32). ","['chronic obstructive pulmonary disease (COPD) rehabilitation setting', 'Methods\n\n\nThirty-two subjects with COPD', 'COPD Patients']","['Maltodextrin', 'Vitamin B 12 Supplementation and NT-proBNP Levels', 'Exercise training']","[""acute changes in NT-proBNP levels with (i) acute exercise and (ii) oxygen uptake ( V 'O 2 ) kinetics during rest-to-exercise transition"", 'time course of NT-proBNP responses', 'NT-proBNP levels', 'maximal exercise constant work-rate tests (CWTs, T lim), for NT-proBNP plasmatic levels', 'vitamin B 12 (vB 12 ) level, hyperhomocysteinemia (HyCy), and natriuretic peptide secretion', 'NT-proBNP secretion', ""V 'O 2 time constant and ΔNT-proBNP values""]","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0042845', 'cui_str': 'Vitamin B 12'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4279937', 'cui_str': 'Acute Exercise'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449247', 'cui_str': 'Time course'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449205', 'cui_str': 'LIM'}, {'cui': 'C0042845', 'cui_str': 'Vitamin B 12'}, {'cui': 'C0598608', 'cui_str': 'Hyperhomocysteinemia'}, {'cui': 'C1144709', 'cui_str': 'Natriuretic Peptide Hormones'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",32.0,0.0602222,"There was a statistically significant correlation between V 'O 2 time constant and ΔNT-proBNP values ( T lim - rest) at baseline ( p = 0.049) and 2 months later ( p = 0.015), considering all subjects ( n = 32). ","[{'ForeName': 'Fernanda Viana', 'Initials': 'FV', 'LastName': 'Paulin', 'Affiliation': 'Laboratory of Respiratory Pathophysiology, Respiratory Division, Department of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, Brazil.'}, {'ForeName': 'Leandro Steinhorst', 'Initials': 'LS', 'LastName': 'Goelzer', 'Affiliation': 'Laboratory of Respiratory Pathophysiology, Respiratory Division, Department of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, Brazil.'}, {'ForeName': 'Paulo de Tarso', 'Initials': 'PT', 'LastName': 'Müller', 'Affiliation': 'Laboratory of Respiratory Pathophysiology, Respiratory Division, Department of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, Brazil.'}]",Frontiers in neuroscience,['10.3389/fnins.2020.00740'] 2657,32760263,ABBaH: Activity Breaks for Brain Health. A Protocol for a Randomized Crossover Trial.,"Introduction : Extended periods of sitting may have detrimental effects on brain health. However, the effects of breaking up prolonged sedentary periods with frequent, short physical activity bouts on mechanisms to improve brain health remain unclear. Therefore, this study aims to investigate the immediate effects of uninterrupted sitting and frequent, short bouts of physical activity on cerebral blood flow and cognitive function in the prefrontal cortex in middle-aged adults. Methods : This is a protocol article to describe a randomized crossover study. We will collect data from 13 healthy adults, aged between 40 and 60 years old, with a body mass index <35 kg/m 2 . Participants will be required to come into the laboratory on three occasions, sit for 3 h, and perform a different type of break for 3 min every 30 min at each visit in a random order, being either: (1) a social break; (2) brisk walk on a treadmill; or (3) simple resistance activities. Before and after each experimental condition, cerebral blood flow (primary outcome) will be measured using functional near-infrared spectroscopy (fNIRS), with short-separation channels, and working memory (1-, 2-, and 3-back on the computer) will be assessed. The following additional secondary outcomes will be collected: psychological factors (questionnaires); arterial stiffness; salivary cortisol levels; and blood glucose levels. Conclusion : The results from this randomized crossover study will determine the effects of uninterrupted sitting and frequent, short bouts of physical activity on cerebral blood flow and cognitive performance. Publication of this study protocol emphasizes the importance of registration and publication of protocols in the field of sedentary behavior research.",2020,"Before and after each experimental condition, cerebral blood flow (primary outcome) will be measured using functional near-infrared spectroscopy (fNIRS), with short-separation channels, and working memory (","['middle-aged adults', '13 healthy adults, aged between 40 and 60 years old, with a body mass index <35 kg/m 2 ']","['uninterrupted sitting and frequent, short bouts of physical activity', 'social break; (2) brisk walk on a treadmill; or (3) simple resistance activities']","['cerebral blood flow and cognitive function', 'collected: psychological factors (questionnaires); arterial stiffness; salivary cortisol levels; and blood glucose levels', 'cerebral blood flow and cognitive performance', 'cerebral blood flow']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0443162', 'cui_str': 'Brisk'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]","[{'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0033898', 'cui_str': 'Factors, Psychological'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}]",13.0,0.0596352,"Before and after each experimental condition, cerebral blood flow (primary outcome) will be measured using functional near-infrared spectroscopy (fNIRS), with short-separation channels, and working memory (","[{'ForeName': 'Emerald G', 'Initials': 'EG', 'LastName': 'Heiland', 'Affiliation': 'The Swedish School of Sport and Health Sciences (GIH), Stockholm, Sweden.'}, {'ForeName': 'Örjan', 'Initials': 'Ö', 'LastName': 'Ekblom', 'Affiliation': 'The Swedish School of Sport and Health Sciences (GIH), Stockholm, Sweden.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Tarassova', 'Affiliation': 'The Swedish School of Sport and Health Sciences (GIH), Stockholm, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Fernström', 'Affiliation': 'The Swedish School of Sport and Health Sciences (GIH), Stockholm, Sweden.'}, {'ForeName': 'Coralie', 'Initials': 'C', 'LastName': 'English', 'Affiliation': 'School of Health Sciences and Priority Research Centre for Stroke and Brain Injury, University of Newcastle, Newcastle, NSW, Australia.'}, {'ForeName': 'Maria M', 'Initials': 'MM', 'LastName': 'Ekblom', 'Affiliation': 'The Swedish School of Sport and Health Sciences (GIH), Stockholm, Sweden.'}]",Frontiers in human neuroscience,['10.3389/fnhum.2020.00273'] 2658,32760267,Heart Rate Variability Mainly Relates to Cognitive Executive Functions and Improves Through Exergame Training in Older Adults: A Secondary Analysis of a 6-Month Randomized Controlled Trial.,"Heart rate variability (HRV) mirrors autonomic nervous system activities and might serve as a parameter to monitor health status in older adults. However, it is currently unknown which functional health measures, including cognitive, physical, and gait performance parameters, are most strongly related to HRV indices. This knowledge would enable implementing HRV assessments into health monitoring routines and training planning for older adults. Simultaneous cognitive-motor and exergame training may be effective to improve HRV indices but has not been investigated yet. Eighty-nine healthy older adults (≥70 years of age) were randomized into three groups: (1) virtual reality video game dancing, i.e., exergaming (DANCE); (2) treadmill walking with simultaneous verbal memory training (MEMORY); or (3) treadmill walking only (PHYS). Strength and balance exercises complemented each program. Over 6 months, two weekly 1-h training sessions were performed. HRV indices (standard deviation of N-N intervals, SDNN; root mean square of successive R-R interval differences, RMSSD; and absolute power of high-frequency band (0.15-0.4 Hz), HF power) and various measures of cognitive, physical, and gait performance were assessed at baseline and after 3 months and 6 months. Multiple linear regression analyses with planned comparisons were calculated. At baseline, 8-12% of HRV variance was significantly explained by cognitive executive functions and leg strength (inversely related). Verbal long-term memory, aerobic and functional fitness, and gait performance did not contribute to the model (SDNN: R 2 = 0.082, p = 0.016; RMSSD: R 2 = 0.121, p = 0.013; HF power: R 2 = 0.119, p = 0.015). After 6 months, DANCE improved HRV indices, while MEMORY and PHYS did not (time × intervention interactions: first-contrast DANCE/MEMORY vs. PHYS: SDNN p = 0.014 one-tailed, Δ R 2 = 0.020 and RMSSD p = 0.052 one-tailed (trend), Δ R 2 = 0.007; second-contrast DANCE vs. MEMORY: SDNN p = 0.002 one-tailed, Δ R 2 = 0.035, RMSSD p = 0.017 one-tailed, Δ R 2 = 0.012, and HF power p = 0.011 one-tailed, Δ R 2 = 0.013). We conclude that mainly cognitive executive functions are associated with HRV indices and that exergame training improves global and parasympathetic autonomic nervous system activities in older adults. Periodic assessments of HRV in older citizens could be particularly beneficial to monitor cognitive health and provide indications for preventative exercise measures.",2020,"Verbal long-term memory, aerobic and functional fitness, and gait performance did not contribute to the model (SDNN: R 2 = 0.082, ","['Older Adults', 'older adults', 'Eighty-nine healthy older adults (≥70 years of age']","['virtual reality video game dancing, i.e., exergaming (DANCE); (2) treadmill walking with simultaneous verbal memory training (MEMORY); or (3) treadmill walking only (PHYS', 'exergame training', 'Simultaneous cognitive-motor and exergame training']","['Cognitive Executive Functions', 'Verbal long-term memory, aerobic and functional fitness, and gait performance', 'HRV indices (standard deviation of N-N intervals, SDNN; root mean square of successive R-R interval differences, RMSSD; and absolute power of high-frequency', 'global and parasympathetic autonomic nervous system activities', 'HRV indices', 'Heart Rate Variability', 'cognitive executive functions and leg strength', 'HF power) and various measures of cognitive, physical, and gait performance', 'HRV indices, while MEMORY and PHYS']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0042649', 'cui_str': 'Video Games'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0729377', 'cui_str': 'Memory skills training'}]","[{'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0423909', 'cui_str': 'Long-term memory performance'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0729377', 'cui_str': 'Memory skills training'}]",89.0,0.0162505,"Verbal long-term memory, aerobic and functional fitness, and gait performance did not contribute to the model (SDNN: R 2 = 0.082, ","[{'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Eggenberger', 'Affiliation': 'Empa, Swiss Federal Laboratories for Materials Science and Technology, Laboratory for Biomimetic Membranes and Textiles, St. Gallen, Switzerland.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Annaheim', 'Affiliation': 'Empa, Swiss Federal Laboratories for Materials Science and Technology, Laboratory for Biomimetic Membranes and Textiles, St. Gallen, Switzerland.'}, {'ForeName': 'Kerstin A', 'Initials': 'KA', 'LastName': 'Kündig', 'Affiliation': 'Empa, Swiss Federal Laboratories for Materials Science and Technology, Laboratory for Biomimetic Membranes and Textiles, St. Gallen, Switzerland.'}, {'ForeName': 'René M', 'Initials': 'RM', 'LastName': 'Rossi', 'Affiliation': 'Empa, Swiss Federal Laboratories for Materials Science and Technology, Laboratory for Biomimetic Membranes and Textiles, St. Gallen, Switzerland.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Münzer', 'Affiliation': 'Geriatrische Klinik St. Gallen, St. Gallen, Switzerland.'}, {'ForeName': 'Eling D', 'Initials': 'ED', 'LastName': 'de Bruin', 'Affiliation': 'Department of Health Sciences and Technology, Institute of Human Movement Sciences and Sport, ETH Zurich, Zurich, Switzerland.'}]",Frontiers in aging neuroscience,['10.3389/fnagi.2020.00197'] 2659,32760296,Promoting Mental Health and Psychological Thriving in University Students: A Randomized Controlled Trial of Three Well-Being Interventions.,"This study aimed to address the decline in mental health on U.S. university campuses by examining the effects of three interventions. University students suffer from high levels of anxiety, depression, and suicide. Counseling centers on university campuses are struggling to meet increased demand. The cost to students and universities could be buffered by offering preventative, psychoeducational, and skill-building training programs that promote mental health and psychological thriving. To date, the research literature has not yielded systematically evaluated and recommendable preventative mental health and well-being programs for university students. In a registered, randomized controlled trial, 131 university students were either placed in a non-intervention control group ( N = 47) or received training in one of three 30-hour, eight-week semester-long well-being programs: SKY Campus Happiness (""SKY""; N = 29), Foundations of Emotional Intelligence (""EI""; N = 21) or Mindfulness-Based Stress Reduction (""MBSR""; N = 34). Compared to the control group and controlling for variance of baseline measurements and multiple comparisons, SKY Campus Happiness showed the greatest impact, benefiting six outcomes: depression, stress, mental health, mindfulness, positive affect and social connectedness. EI benefited one outcome: mindfulness. The MBSR group showed no change. Delivering SKY or EI to university students may be a cost-effective and efficient way to proactively and preventatively address mental health for university students and reduce the financial strain on universities.",2020,"Compared to the control group and controlling for variance of baseline measurements and multiple comparisons, SKY Campus Happiness showed the greatest impact, benefiting six outcomes: depression, stress, mental health, mindfulness, positive affect and social connectedness.","['University students suffer from high levels of anxiety, depression, and suicide', '131 university students', 'University Students', 'university students']","['placed in a non-intervention control group ( N = 47) or received training in one of three 30-hour, eight-week semester-long well-being programs: SKY Campus Happiness (""SKY""; N = 29), Foundations of Emotional Intelligence (""EI""; N = 21) or Mindfulness-Based Stress Reduction']","['benefiting six outcomes: depression, stress, mental health, mindfulness, positive affect and social connectedness']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0038661', 'cui_str': 'Suicide'}]","[{'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0301560', 'cui_str': 'Ski'}, {'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0016617', 'cui_str': 'Foundations'}, {'cui': 'C1510539', 'cui_str': 'Emotional Intelligence'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]","[{'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0001721', 'cui_str': 'Affect'}]",131.0,0.0380405,"Compared to the control group and controlling for variance of baseline measurements and multiple comparisons, SKY Campus Happiness showed the greatest impact, benefiting six outcomes: depression, stress, mental health, mindfulness, positive affect and social connectedness.","[{'ForeName': 'Emma M', 'Initials': 'EM', 'LastName': 'Seppälä', 'Affiliation': 'Yale Child Study Center & Yale Center for Emotional Intelligence, Yale University, New Haven, CT, United States.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Bradley', 'Affiliation': 'Yale Child Study Center & Yale Center for Emotional Intelligence, Yale University, New Haven, CT, United States.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Moeller', 'Affiliation': 'Department of Education, Leipzig University, Leipzig, Germany.'}, {'ForeName': 'Leilah', 'Initials': 'L', 'LastName': 'Harouni', 'Affiliation': 'Yale Child Study Center & Yale Center for Emotional Intelligence, Yale University, New Haven, CT, United States.'}, {'ForeName': 'Dhruv', 'Initials': 'D', 'LastName': 'Nandamudi', 'Affiliation': 'Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'Marc A', 'Initials': 'MA', 'LastName': 'Brackett', 'Affiliation': 'Yale Child Study Center & Yale Center for Emotional Intelligence, Yale University, New Haven, CT, United States.'}]",Frontiers in psychiatry,['10.3389/fpsyt.2020.00590'] 2660,32767145,Prospective randomized controlled trial on comparison of standard CO 2 pressure pneumoperitoneum insufflator versus AirSeal®.,"BACKGROUND AirSeal® is a valve-free insufflation system that enables a stable pneumoperitoneum with continuous smoke evacuation and CO 2 recirculation during laparoscopic surgery. Comparative evidence on the use of AirSeal® and standard CO 2 insufflator in laparoscopic general surgery procedures is scarce. The aim of this study was to compare surgical outcomes between AirSeal® and standard CO 2 insufflators in patients undergoing the most frequently performed laparoscopic procedures. METHODS One hundred and ninety-eight patients undergoing elective laparoscopic cholecystectomy, colorectal surgery and hernia repair were randomized to either AirSeal® (group A) or standard pressure CO 2 insufflator (group S). The primary endpoints were operative time and level of postoperative shoulder tip pain (Visual Analog Scale). Secondary outcomes included Clavien-Dindo grade complications, surgical side effect and length of hospital stay. RESULTS Patients were randomized to either group A (n = 101) or group S (n = 97) and were analyzed by intention-to-treat. There was no significant difference in mean operative time between the groups (median [IQR]; 71 min [56-94] in group A vs. 69 min [52-93] in group S; p = 0.434). Shoulder tip pain levels were significantly lower in group S (VAS 0 [0-3] in group S vs. 2 [0-4] in group A; p = 0.001). There was no significant difference in complications, surgical side effects (subcutaneous emphysema was not observed in any group) and length of hospital stay. CONCLUSION This randomized controlled trial showed that using the AirSeal® system did not reduce operative time and was associated with a higher postoperative shoulder tip pain compared to standard CO 2 insufflator for short elective surgeries. ClinicalTrials.gov (NCT01740011).",2020,"There was no significant difference in complications, surgical side effects (subcutaneous emphysema was not observed in any group) and length of hospital stay. ","['One hundred and ninety-eight patients undergoing elective laparoscopic cholecystectomy, colorectal surgery and hernia repair', 'patients undergoing the most frequently performed laparoscopic procedures']","['AirSeal® and standard CO', 'AirSeal®', 'standard CO 2 pressure pneumoperitoneum insufflator versus AirSeal®', 'standard pressure CO 2 insufflator']","['complications, surgical side effects (subcutaneous emphysema', 'surgical outcomes', 'Clavien-Dindo grade complications, surgical side effect and length of hospital stay', 'Shoulder tip pain levels', 'length of hospital stay', 'mean operative time', 'operative time', 'operative time and level of postoperative shoulder tip pain (Visual Analog Scale']","[{'cui': 'C4517622', 'cui_str': '190'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0162522', 'cui_str': 'Laparoscopic cholecystectomy'}, {'cui': 'C0009369', 'cui_str': 'Colorectal surgery'}, {'cui': 'C0019328', 'cui_str': 'Hernia repair'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0032320', 'cui_str': 'Pneumoperitoneum'}, {'cui': 'C0021639', 'cui_str': 'Insufflator'}]","[{'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0038536', 'cui_str': 'Subcutaneous emphysema'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0339897', 'cui_str': 'Transjugular intrahepatic portosystemic shunt'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",198.0,0.12362,"There was no significant difference in complications, surgical side effects (subcutaneous emphysema was not observed in any group) and length of hospital stay. ","[{'ForeName': 'Rosalia', 'Initials': 'R', 'LastName': 'Luketina', 'Affiliation': 'Department Hand, Plastic, Reconstructive and Burn Surgery, BG Trauma Center Tuebingen, Eberhard Karls University Tuebingen, Schnarrenbergstr. 95, 72076, Tuebingen, Germany. r_luketina@yahoo.de.'}, {'ForeName': 'Theodore L H', 'Initials': 'TLH', 'LastName': 'Luketina', 'Affiliation': 'Department of Anaesthesia & Intensive Care Medicine, Cantonal Hospital of Muensterlingen, Muensterlingen, Switzerland.'}, {'ForeName': 'Stavros A', 'Initials': 'SA', 'LastName': 'Antoniou', 'Affiliation': 'Department of Surgery, School of Medicine, European University Cyprus, Nicosia, Cyprus.'}, {'ForeName': 'Gernot', 'Initials': 'G', 'LastName': 'Köhler', 'Affiliation': 'Department of General and Visceral Surgery, Congregation Hospital (Sisters of Charity), Ordensklinikum Linz, Austria.'}, {'ForeName': 'Sören', 'Initials': 'S', 'LastName': 'Könneker', 'Affiliation': 'Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Hannover Medical School, Hanover, Germany.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Manzenreiter', 'Affiliation': 'Department of Surgery, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'Helwig', 'Initials': 'H', 'LastName': 'Wundsam', 'Affiliation': 'Department of General and Visceral Surgery, Congregation Hospital (Sisters of Charity), Ordensklinikum Linz, Austria.'}, {'ForeName': 'Oliver Owen', 'Initials': 'OO', 'LastName': 'Koch', 'Affiliation': 'Department of Surgery, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Knauer', 'Affiliation': 'Breast Center Ostschweiz, Schuppistrasse 10, 9016, St. Gallen, Switzerland.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Emmanuel', 'Affiliation': 'Department of Surgery, Paracelsus Medical University, Salzburg, Austria.'}]",Surgical endoscopy,['10.1007/s00464-020-07846-4'] 2661,32767160,A Single Session of Heart Rate Variability Biofeedback Produced Greater Increases in Heart Rate Variability Than Autogenic Training.,"Heart rate variability biofeedback (HRV-BF) has been confirmed to increase heart rate variability (HRV) and cardiac outflows by baroreflex in healthy populations and clinical patients. Autogenic training (AT) is common used in the psychological intervention. This study integrates a single-session of HRV-BF and AT into a high-technology mobile application (app), and examines the effects on HRV indices, breathing rates, and subjective relaxation scores. Healthy college students were recruited and assigned to the single-session HRV-BF group or AT group. Participants in the HRV-BF group received HRV-BF combined with paced breathing training, which gradually stepped down their breathing rates from 12, to 8, to 6 breaths/per min; and received feedback of HRV indices from the app. Participants in the AT group received autogenic training and feedback of heart rate from the app. A chest belt Zephyr BioHarness was connected through Bluetooth to a Zenfone5 mobile phone, it collected the signals of interbeat intervals and breathing rates at pre-training, mid-training, and post-training stages. The Kubios HRV software was used to analyze HRV indices. The results reveal higher HRV indices and lower breathing rates during mid-training and post-training in the HRV-BF group compared to the AT group. There were higher high-frequency of HRV at post-training than pre-training in the AT group. Participants of both groups increased their subjective relaxation scores after training. The HRV-BF protocol increased cardiac outflows by baroreflex and decreased breathing rates, and the AT protocol increased high-frequency of HRV. These high-technology wearable devices combined with psychological interventions will apply to various populations in the future.",2020,The results reveal higher HRV indices and lower breathing rates during mid-training and post-training in the HRV-BF group compared to the AT group.,"['healthy populations and clinical patients', 'Healthy college students']","['HRV-BF combined with paced breathing training', 'autogenic training', 'Autogenic training (AT', 'Heart rate variability biofeedback (HRV-BF']","['subjective relaxation scores', 'cardiac outflows by baroreflex and decreased breathing rates', 'Heart Rate Variability', 'HRV indices and lower breathing rates', 'heart rate variability (HRV) and cardiac outflows by baroreflex', 'high-frequency of HRV', 'HRV indices, breathing rates, and subjective relaxation scores']","[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005491', 'cui_str': 'Biofeedback procedure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0287990', 'cui_str': 'Furin'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0004361', 'cui_str': 'Autogenic therapy'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0206162', 'cui_str': 'Baroreceptor reflex'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}]",,0.0287486,The results reveal higher HRV indices and lower breathing rates during mid-training and post-training in the HRV-BF group compared to the AT group.,"[{'ForeName': 'I-Mei', 'Initials': 'IM', 'LastName': 'Lin', 'Affiliation': 'Department of Psychology, Kaohsiung Medical University, No 100, Shih-Chuan 1 st Rd, Kaohsiung, 80708, Taiwan. psyiml@kmu.edu.tw.'}, {'ForeName': 'San-Yu', 'Initials': 'SY', 'LastName': 'Wang', 'Affiliation': 'Department of Psychology, Kaohsiung Medical University, No 100, Shih-Chuan 1 st Rd, Kaohsiung, 80708, Taiwan.'}, {'ForeName': 'Sheng-Yu', 'Initials': 'SY', 'LastName': 'Fan', 'Affiliation': 'Institute of Gerontology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Peper', 'Affiliation': 'Institute for Holistic Health Studies, San Francisco State University, San Francisco, CA, USA.'}, {'ForeName': 'Sui-Pi', 'Initials': 'SP', 'LastName': 'Chen', 'Affiliation': 'Geographic Information Systems Research Center, Feng Chia University, Taichung, Taiwan.'}, {'ForeName': 'Ching-Yu', 'Initials': 'CY', 'LastName': 'Huang', 'Affiliation': 'Industrial Technology Research Institute, Hsinchu, Taiwan.'}]",Applied psychophysiology and biofeedback,['10.1007/s10484-020-09483-y'] 2662,32761500,"Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study.","BACKGROUND Botulinum toxin (BTX) is a potent neurotoxin with a long history of therapeutic application in neurological and dermatological conditions, with a strong efficacy and safety profile. OBJECTIVE Our aim was to assess whether intradermal injection with BTX-B is an effective treatment for hidradenitis suppurativa (HS). METHODS Twenty patients with HS stage I-III disease, according to Hurley's classification, were consecutively included for treatment with either a placebo or BTX-B. At the next intervention after 3 months, all participants received the active substance and another follow-up at 6 months. The primary outcome was quality of life, measured using the Dermatology Life Quality Index (DLQI), while secondary outcomes were the visual analogue scale (VAS) for pain in the worst boil and HS-related impairment of general health (VAS), as well as changes in physician-reported disease activity assessed as the number of total lesions, and reported adverse effects of treatment. RESULTS The DLQI improved from a median of 17 at baseline to 8 at 3 months in the BTX-B group, compared with a reduction from 13.5 to 11 in the placebo group (p <0.05). Improvement of the patients' own ratings of symptoms and a reduction in total lesions supplemented the primary outcome. Fifty-five percent of the study population reported some degree of hyperhidrosis. CONCLUSION BTX-B improves the quality of life in patients with HS. Furthermore, comorbidity between HS and hyperhidrosis is suggested. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT03103074.",2020,"The DLQI improved from a median of 17 at baseline to 8 at 3 months in the BTX-B group, compared with a reduction from 13.5 to 11 in the placebo group (p <0.05).","[""Twenty patients with HS stage I-III disease, according to Hurley's classification, were consecutively included for treatment with either a"", 'patients with HS', 'Hidradenitis Suppurativa']","['placebo or BTX-B', 'Placebo', 'Botulinum toxin (BTX', 'Botulinum Toxin Type B', 'BTX-B', 'intradermal injection with BTX-B', 'placebo']","['DLQI', 'quality of life', 'visual analogue scale (VAS) for pain in the worst boil and HS-related impairment of general health (VAS), as well as changes in physician-reported disease activity assessed as the number of total lesions, and reported adverse effects of treatment', 'quality of life, measured using the Dermatology Life Quality Index (DLQI']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162836', 'cui_str': 'Hidradenitis suppurativa'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006055', 'cui_str': 'botulinum toxin'}, {'cui': 'C0006051', 'cui_str': 'Botulinum Toxin Type B'}, {'cui': 'C0021489', 'cui_str': 'Intradermal injection'}]","[{'cui': 'C0451112', 'cui_str': 'Dermatology life quality index'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0242301', 'cui_str': 'Furuncle'}, {'cui': 'C0162836', 'cui_str': 'Hidradenitis suppurativa'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",20.0,0.500004,"The DLQI improved from a median of 17 at baseline to 8 at 3 months in the BTX-B group, compared with a reduction from 13.5 to 11 in the placebo group (p <0.05).","[{'ForeName': 'Øystein', 'Initials': 'Ø', 'LastName': 'Grimstad', 'Affiliation': 'Department of Dermatology, University Hospital of North Norway, Tromsö, Norway. oystein.grimstad@unn.no.'}, {'ForeName': 'Bjørn Øivind', 'Initials': 'BØ', 'LastName': 'Kvammen', 'Affiliation': 'Department of Dermatology, University Hospital of North Norway, Tromsö, Norway.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Swartling', 'Affiliation': 'Hidrosis Clinic, Stockholm, Sweden.'}]",American journal of clinical dermatology,['10.1007/s40257-020-00537-9'] 2663,32761731,A lifestyle intervention RCT in obese women with infertility improved body composition among those who experienced childhood adversity.,"Previous research indicates that tailoring lifestyle interventions to participant characteristics optimizes intervention effectiveness. Our objective was to assess whether the effects of a preconception lifestyle intervention in obese infertile women depended on women's exposure to adversity in childhood. A follow-up of a preconception lifestyle intervention randomized controlled trial (the LIFEstyle study) was conducted in the Netherlands among 577 infertile women (age 18-39 years) with a body mass index (BMI) ≥ 29 kg/m 2 at time of randomization. N=110 (19%) consented to the follow up assessment, six years later. A six-month preconception lifestyle intervention aimed weight loss through improving diet and increasing physical activity. The control group received care as usual. Outcome measures included weight, body mass index (BMI), waist and hip circumference, body fat percentage, blood pressure and metabolic syndrome. The potential moderator, childhood adversity, was assessed with the Life Events Checklist-5 questionnaire. Among the 110 women in our follow up study, n=65 (59%) reported no childhood adverse events, n=28 (25.5%) reported 1 type of childhood adverse events and n=17 (15.5%) reported ≥ 2 types of childhood adverse events. Regression models showed significant interactions between childhood adversity and effects of lifestyle intervention at the six-year follow up. Among women who experienced childhood adversity, the intervention significantly reduced weight (-10.0 (95% CI -18.5 to -1.5) kg, p = 0.02), BMI (-3.2 (-6.1 to -0.2) kg/m2, p = 0.04) and body fat percentage (-4.5 (95% CI -7.2 to -1.9) p < 0.01). Among women without childhood adversity, the intervention did not affect these outcomes (2.7 (-3.9 to 9.4) kg, p = 0.42), (0.9 (-1.4 to 3.3) kg/m2, p = 0.42) and (1.7 (95% CI -0.3 to 3.7) p = 0.10), respectively). Having a history of childhood adversity modified the effect of a preconception lifestyle intervention on women's body composition. If replicated, it may be important to consider childhood adversity as a determinant of lifestyle intervention effectiveness. This article is protected by copyright. All rights reserved.",2020,"Among women who experienced childhood adversity, the intervention significantly reduced weight (-10.0","[""women's body composition"", '577 infertile women (age 18-39 years) with a body mass index (BMI) ≥ 29 kg/m 2 at time of randomization', ""obese infertile women depended on women's exposure to adversity in childhood"", 'obese women with infertility']",['preconception lifestyle intervention'],"['weight, body mass index (BMI), waist and hip circumference, body fat percentage, blood pressure and metabolic syndrome', 'weight', 'body fat percentage', 'improved body composition', 'BMI', 'weight loss', '1 type of childhood adverse events', 'childhood adverse events']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0021359', 'cui_str': 'Sterility'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1097282', 'cui_str': '2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0230097', 'cui_str': 'Structure of waist (surface region)'}, {'cui': 'C0562350', 'cui_str': 'Hip circumference'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",577.0,0.0543525,"Among women who experienced childhood adversity, the intervention significantly reduced weight (-10.0","[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'van Dammen', 'Affiliation': 'Department of Human Development & Family Studies, Iowa State University, Ames, Iowa, USA.'}, {'ForeName': 'N R', 'Initials': 'NR', 'LastName': 'Bush', 'Affiliation': 'Departments of Psychiatry and Pediatrics, Center for Health and Community, Division of Developmental Medicine, University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'S R', 'Initials': 'SR', 'LastName': 'de Rooij', 'Affiliation': 'Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, location AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'B W J', 'Initials': 'BWJ', 'LastName': 'Mol', 'Affiliation': 'Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'M A Q', 'Initials': 'MAQ', 'LastName': 'Mutsaerts', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'van Oers', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Groen', 'Affiliation': 'Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Hoek', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'T J', 'Initials': 'TJ', 'LastName': 'Roseboom', 'Affiliation': 'Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, location AMC, Amsterdam, The Netherlands.'}]",Stress and health : journal of the International Society for the Investigation of Stress,['10.1002/smi.2976'] 2664,32761737,The effect of low glycemic index diet on reducing daylong glycemia in healthy young adults: a randomized crossover trial.,"AIMS We compared the effect of a low glycemic index (LGI) diet on reducing daylong glycemia with a macronutrient-match high glycemic index (HGI) diet, using customized meal delivery to ensure compliance. MATERIALS AND METHODS We conducted a single-blinded randomized crossover trial in 14 healthy adults (57% female) with a mean ± SD age of 21.6 ± 1.7 years. A flash glucose monitoring sensor was installed on the subjects in day 1 to capture interstitial glucose level every 15 minutes for 14 days. Subjects were randomized to receive an LGI (dietary GI = 40) or HGI (dietary GI = 60) diet (three meals and two snacks) from day 2 for 5 consecutive days, followed by a 2-day washout, and switched to the alternative diet for another 5 days. Paired t-test was used to test the differences in incremental area-under-curve (iAUC) of glucose, postprandial glucose concentration (PPG) and maximum postprandial glucose rise (MPGR) between the LGI and HGI periods. RESULTS Subjects had lower iAUC for average daylong glycemia during the LGI intervention period compared with the HGI period (mean ± SD, 865 ± 297 vs. 1024 ± 267 mmol * min/L; p = 0.047). PPG for breakfast and snack 2; and MPGR for breakfast, snack 2 and dinner were lower in the LGI period. CONCLUSIONS In young healthy adults, following an LGI diet resulted in lower average daylong glycemia compared with a macronutrient matched HGI diet. Our results support the use of LGI diets to reduce the risk of developing glucose intolerance. This article is protected by copyright. All rights reserved.",2020,"RESULTS Subjects had lower iAUC for average daylong glycemia during the LGI intervention period compared with the HGI period (mean ± SD, 865 ± 297 vs. 1024 ± 267 mmol * min/L; p = 0.047).","['14 healthy adults (57% female) with a mean ± SD age of 21.6 ±\u20091.7\u2009years', 'young healthy adults', 'healthy young adults']","['LGI diets', 'LGI diet', 'low glycemic index (LGI) diet', 'LGI (dietary GI\xa0=\xa040) or HGI (dietary GI\xa0', 'low glycemic index diet']","['incremental area-under-curve (iAUC) of glucose, postprandial glucose concentration (PPG) and maximum postprandial glucose rise (MPGR', 'average daylong glycemia', 'daylong glycemia', 'risk of developing glucose intolerance']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517512', 'cui_str': '1.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0205250', 'cui_str': 'High'}]","[{'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0427743', 'cui_str': 'Glucose concentration, test strip measurement'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}]",14.0,0.0429868,"RESULTS Subjects had lower iAUC for average daylong glycemia during the LGI intervention period compared with the HGI period (mean ± SD, 865 ± 297 vs. 1024 ± 267 mmol * min/L; p = 0.047).","[{'ForeName': 'Hannah Wing Han', 'Initials': 'HWH', 'LastName': 'Hon', 'Affiliation': 'School of Biological Sciences, Faculty of Science, The University of Hong Kong, Hong Kong SAR.'}, {'ForeName': 'Tommy Hon Ting', 'Initials': 'THT', 'LastName': 'Wong', 'Affiliation': 'School of Biological Sciences, Faculty of Science, The University of Hong Kong, Hong Kong SAR.'}, {'ForeName': 'Iris Mei Ying', 'Initials': 'IMY', 'LastName': 'Tse', 'Affiliation': 'School of Biological Sciences, Faculty of Science, The University of Hong Kong, Hong Kong SAR.'}, {'ForeName': 'Jimmy Chun Yu', 'Initials': 'JCY', 'LastName': 'Louie', 'Affiliation': 'School of Biological Sciences, Faculty of Science, The University of Hong Kong, Hong Kong SAR.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14167'] 2665,32761810,Laser-assisted regenerative surgical therapy for peri-implantitis: A randomized controlled clinical trial.,"BACKGROUND Different surgical approaches have been proposed to treat peri-implantitis defects with limited effectiveness and predictability. Laser has been proposed as an effective tool to assist in bacterial decontamination and modulating peri-implant tissue inflammation. The aim of this pilot clinical trial was to evaluate the adjunctive benefits of Er:YAG laser irradiation for regenerative surgical therapy of peri-implantitis-associated osseous defects. METHODS AND MATERIALS Twenty-four patients diagnosed with peri-implantitis with a radiographic infrabony defect were randomized into two groups. Both test and control groups received the following treatment: open flap mechanical debridement, supracrestal implantoplasty, bone grafting using a mixture of human allograft with demineralized bone matrix human allograft putty, and then covered with acellular dermal matrix membrane. The only difference in the test group was the adjunctive use of Er:YAG laser to modulate and remove inflammatory tissue as well as to decontaminate the implant surface. Clinical assessments, including pocket depth (PD), clinical attachment level (CAL), and gingival index (GI) were performed by calibrated masked examiners for up to 6 months following surgery. Standardized radiographs were also taken to evaluate linear bone gain and defect bone fill. Student t-tests were used to analyze those clinical parameters. RESULTS Both groups showed significant reductions in PD, GI, and CAL gain overtime. The test group demonstrated significantly higher PD reductions at the site level compared to the control group (2.65 ± 2.14 vs. 1.85 ± 1.71 mm; test vs. control, p = 0.014). There were no statistical differences found in CAL gain (1.90 ± 2.28 vs. 1.47 ± 1.76 mm; test vs. control), GI reduction (-1.14 ± 1.15 vs. -1.04 ± 0.89; test vs. control), radiographic linear bone gain (1.27 ± 1.14 vs. 1.08 ± 1.04 mm; test vs. control) or proportional defect size reduction (- 24.46 ± 19.00% vs. -15.19 ± 23.56%; test vs. control). There was a positive trend for test patients on PD reduction and CAL gain found in narrow infrabony defects. Major membrane exposure negatively impaired the overall treatment outcome of CAL gain (2.47±1.84 vs. 1.03±1.48 mm; no/minor vs. major exposure, p = 0.051) and PD reduction in the test group (-3.63±2.11 vs. -1.66±1.26 mm, p = 0.049). CONCLUSION This pilot study indicated using laser irradiation during peri-implantitis regenerative therapy may aid in better probing pocket depth reduction. Nonetheless, a larger sample size and longer follow-up is needed to confirm if Er:YAG laser irradiation provides additional clinical benefits for peri-implantitis regenerative therapy (Clinicaltrials.gov: NCT03127228) This article is protected by copyright. All rights reserved.",2020,"The test group demonstrated significantly higher PD reductions at the site level compared to the control group (2.65 ± 2.14 vs. 1.85 ± 1.71 mm; test vs. control, p = 0.014).","['Twenty-four patients diagnosed with peri-implantitis with a radiographic infrabony defect', 'peri-implantitis']","['laser irradiation', 'treatment: open flap mechanical debridement, supracrestal implantoplasty, bone grafting using a mixture of human allograft with demineralized bone matrix human allograft putty, and then covered with acellular dermal matrix membrane', 'Laser-assisted regenerative surgical therapy', 'Er:YAG laser irradiation']","['PD reduction', 'pocket depth (PD), clinical attachment level (CAL), and gingival index (GI', 'CAL gain', 'PD, GI, and CAL gain overtime', 'radiographic linear bone gain', 'PD reductions', 'linear bone gain and defect bone fill', 'PD reduction and CAL gain']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C2936258', 'cui_str': 'Dental peri-implantitis'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0243067', 'cui_str': 'defects'}]","[{'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0038925', 'cui_str': 'Flap'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0005976', 'cui_str': 'Bone graft'}, {'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0040739', 'cui_str': 'Allogeneic transplantation'}, {'cui': 'C0005962', 'cui_str': 'Bone matrix'}, {'cui': 'C0439844', 'cui_str': 'Covered'}, {'cui': 'C3494272', 'cui_str': 'Acellular Dermal Matrix'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0457903', 'cui_str': 'Erbium:YAG laser device'}]","[{'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C2961731', 'cui_str': 'Overtime'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0243067', 'cui_str': 'defects'}]",24.0,0.10956,"The test group demonstrated significantly higher PD reductions at the site level compared to the control group (2.65 ± 2.14 vs. 1.85 ± 1.71 mm; test vs. control, p = 0.014).","[{'ForeName': 'Jeff Chin-Wei', 'Initials': 'JC', 'LastName': 'Wang', 'Affiliation': 'Department of Periodontics & Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, USA.'}, {'ForeName': 'Sajjad', 'Initials': 'S', 'LastName': 'Ashnagar', 'Affiliation': 'Private practice, Dallas, Texas, USA.'}, {'ForeName': 'Riccardo Di', 'Initials': 'RD', 'LastName': 'Gianflippo', 'Affiliation': 'Department of Periodontics & Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Arnett', 'Affiliation': 'Division of Dental Hygiene, University of Minnesota School of Dentistry, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Kinney', 'Affiliation': 'Department of Periodontics & Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, USA.'}, {'ForeName': 'Hom-Lay', 'Initials': 'HL', 'LastName': 'Wang', 'Affiliation': 'Department of Periodontics & Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, USA.'}]",Journal of periodontology,['10.1002/JPER.20-0040'] 2666,32761844,Effects of resistance exercise on treatment outcome and laboratory parameters of Takayasu arteritis with magnetic resonance imaging diagnosis: A randomized parallel controlled clinical trial.,"BACKGROUND Elevated tumor necrosis factor-α (TNF-α) is correlated with refractory Takayasu arteritis (TA), and resistance exercise have been shown to inhibit TNF-α. HYPOTHESIS We aimed to explore the effect of resistance exercise in the clinical management of TA. METHODS This clinical trial enrolled a total of 342 acute TA patients, who were subsequently randomized to undergo either resistance exercise or relaxation control twice per week for 12 weeks. The disease activity was defined using the primary outcome of Birmingham Vascular Activity Score (BVAS). Secondary outcomes included levels of plasma TNF-α and C-reactive protein (CRP), and the erythrocyte sedimentation rate (ESR). RESULTS BVAS scores along with other laboratory parameters obtained from the patients in the resistance exercise group showed a gradual decline throughout the course of the trial. By contrast, outcomes appeared largely unaltered in the relaxation control group patients. Analyses also revealed that plasma TNF-α displayed strong linear correlations with ESR, BVAS scores, and plasma CRP levels. CONCLUSION Resistance exercise could substantially improve treatment outcomes as well as laboratory parameters in patients with acute TA, probably through decreasing TNF-α.",2020,"Secondary outcomes included levels of plasma TNF-α and C-reactive protein (CRP), and the erythrocyte sedimentation rate (ESR). ","['patients with acute TA, probably through decreasing TNF-α', '342 acute TA patients']","['resistance exercise or relaxation control', 'magnetic resonance imaging diagnosis', 'Resistance exercise', 'resistance exercise']","['ESR, BVAS scores, and plasma CRP levels', 'disease activity', 'levels of plasma TNF-α and C-reactive protein (CRP), and the erythrocyte sedimentation rate (ESR', 'Birmingham Vascular Activity Score (BVAS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0039263', 'cui_str': ""Takayasu's disease""}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C5191280', 'cui_str': '342'}]","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0428493', 'cui_str': 'Plasma C-reactive protein measurement'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}]",342.0,0.160481,"Secondary outcomes included levels of plasma TNF-α and C-reactive protein (CRP), and the erythrocyte sedimentation rate (ESR). ","[{'ForeName': 'Guoce', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'Department of MRI, Cangzhou Central Hospital, Cangzhou, China.'}, {'ForeName': 'Fenghai', 'Initials': 'F', 'LastName': 'Liu', 'Affiliation': 'Department of MRI, Cangzhou Central Hospital, Cangzhou, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, Cangzhou Central Hospital, Cangzhou, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Zhao', 'Affiliation': 'Department of MRI, Cangzhou Central Hospital, Cangzhou, China.'}, {'ForeName': 'Yancheng', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': 'Department of MRI, Cangzhou Central Hospital, Cangzhou, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of MRI, Cangzhou Central Hospital, Cangzhou, China.'}]",Clinical cardiology,['10.1002/clc.23439'] 2667,32762115,Assessment of suitable antihypertensive therapies: Combination with high-dose amlodipine/irbesartan vs triple combination with amlodipine/irbesartan/indapamide (ASAHI-AI study).,"Angiotensin receptor blockers (ARBs) plus calcium channel blockers (CCBs) are a widely used combination therapy for hypertensive patients. In order to determine which combination was better as the next-step therapy for standard-dose combination of ARBs and CCBs, a combination with high-dose CCBs or a triple combination with diuretics, the authors conducted a prospective, randomized, open-label trial to determine which of the following combination is better as the next-step treatment: a combination with high-dose CCBs or a triple combination with diuretics. Hypertensive outpatients who did not achieve their target blood pressure (BP) with usual dosages of ARBs and amlodipine 5 mg were randomly assigned to treatment with irbesartan 100 mg/amlodipine 10 mg (Group 1: n = 48) or indapamide 1 mg in addition to ARBs plus amlodipine 5 mg (Group 2: n = 46). The primary end point was changes in the systolic BP (SBP) and diastolic BP (DBP) after the 12-week treatment period, while secondary end points were changes in BP after the 24-week treatment period and laboratory values. At 12 weeks, the SBP/DBP significantly decreased from 152.1/83.4 mm Hg to 131.5/76.1 mm Hg in Group 1 and 153.9/82.1 mm Hg to 132.7/75.9 mm Hg in Group 2. Although both groups produced a similar efficacy in reducing the SBP/DBP (-19.2/-9.2 mm Hg in Group 1 and -21.6/-8.8 mm Hg in Group 2; SBP P = .378, DBP P = .825), high-dose CCBs combined with ARBs controlled hypertension without elevation of serum uric acid. These results will provide new evidence for selecting optimal combination therapies for uncontrolled hypertensive patients.",2020,Although both groups produced a similar efficacy in reducing the SBP/DBP (-19.2/-9.2 mm Hg in Group 1 and -21.6/-8.8 mm ,"['hypertensive patients', 'Hypertensive outpatients who did not achieve their target blood pressure (BP) with usual dosages of ARBs and amlodipine 5\xa0mg', 'uncontrolled hypertensive patients']","['Angiotensin receptor blockers (ARBs) plus calcium channel blockers (CCBs', 'amlodipine/irbesartan vs triple combination with amlodipine/irbesartan/indapamide', 'irbesartan 100\xa0mg/amlodipine 10\xa0mg (Group 1: n\xa0=\xa048) or indapamide 1\xa0mg in addition to ARBs plus amlodipine']","['serum uric acid', 'systolic BP (SBP) and diastolic BP (DBP', 'BP', 'SBP/DBP']","[{'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0034787', 'cui_str': 'Angiotensin receptor'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C1124796', 'cui_str': 'Amlodipine 5 MG'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}]","[{'cui': 'C0034787', 'cui_str': 'Angiotensin receptor'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0006684', 'cui_str': 'Calcium channel blocker'}, {'cui': 'C0051696', 'cui_str': 'Amlodipine'}, {'cui': 'C0288171', 'cui_str': 'irbesartan'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0021186', 'cui_str': 'Indapamide'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C1124794', 'cui_str': 'Amlodipine 10 MG'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}]","[{'cui': 'C0455272', 'cui_str': 'Serum urate measurement'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]",,0.0231858,Although both groups produced a similar efficacy in reducing the SBP/DBP (-19.2/-9.2 mm Hg in Group 1 and -21.6/-8.8 mm ,"[{'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Nakagawa', 'Affiliation': 'Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan.'}, {'ForeName': 'Nobuyuki', 'Initials': 'N', 'LastName': 'Sato', 'Affiliation': 'Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan.'}, {'ForeName': 'Yasuaki', 'Initials': 'Y', 'LastName': 'Saijo', 'Affiliation': 'Division of Community Medicine and Epidemiology, Department of Health Science, Asahikawa Medical University, Asahikawa, Japan.'}, {'ForeName': 'Hideo', 'Initials': 'H', 'LastName': 'Morimoto', 'Affiliation': 'Department of Internal Medicine, Fukagawa Municipal Hospital, Fukagawa, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Koyama', 'Affiliation': 'Department of Internal Medicine, Asahikawa Rehabilitation Hospital, Asahikawa, Japan.'}, {'ForeName': 'Yuji', 'Initials': 'Y', 'LastName': 'Ogawa', 'Affiliation': 'Department of Cardiology, Asahikawa Kosei General Hospital, Asahikawa, Japan.'}, {'ForeName': 'Kazumi', 'Initials': 'K', 'LastName': 'Uekita', 'Affiliation': 'Department of Cardiology, Hokkaido Kitami Hospital, Kitami, Japan.'}, {'ForeName': 'Junichi', 'Initials': 'J', 'LastName': 'Maruyama', 'Affiliation': 'Department of Internal Medicine, Asahikawa Rehabilitation Hospital, Asahikawa, Japan.'}, {'ForeName': 'Takafumi', 'Initials': 'T', 'LastName': 'Ohta', 'Affiliation': 'Department of Internal Medicine, Asahikawa Rehabilitation Hospital, Asahikawa, Japan.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Nakamura', 'Affiliation': 'Department of Cardiology, Municipal Ashibetsu Hospital, Ashibetsu, Japan.'}, {'ForeName': 'Toshiharu', 'Initials': 'T', 'LastName': 'Takeuchi', 'Affiliation': 'Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan.'}, {'ForeName': 'Naoyuki', 'Initials': 'N', 'LastName': 'Hasebe', 'Affiliation': 'Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Journal of clinical hypertension (Greenwich, Conn.)",['10.1111/jch.13977'] 2668,32762148,Effects of a Lifestyle Intervention Based on Type D Personality in Overweight and Obese Middle-Aged Women: A Feasibility Study.,"BACKGROUND Obesity is an important public health problem, particularly among middle-aged women. Type D personality, characterized by negative affectivity and social inhibition, is prevalent among obese and overweight middle-aged women and has been linked to maladaptive health-related behaviors and unhealthy lifestyle. Lifestyle interventions based on type D personality could be a first step in combatting obesity in middle-aged women. AIM To identify the effects of a lifestyle intervention based on type D personality on health-promoting lifestyle behaviors, psychological distress, type D personality, and body composition in overweight and obese middle-aged women. METHODS A total of 36 overweight and obese middle-aged women participated in a quasi-experimental design using a non-equivalent control group pretest-posttest. The experimental group received a total of eight sessions of a lifestyle intervention program based on type D personality over the course of four weeks. Outcomes were measured health-promoting lifestyle behaviors, psychological distress, type D personality, and body composition (body weight, body mass index, body fat, and abdominal fat). RESULTS Following the intervention, the experimental group scored significantly higher than the control group for health-promoting lifestyle behaviors, and significantly lower than the control group for psychological distress and type D personality. Body weight and body mass index decreased significantly in the experimental group compared to the control group. LINKING EVIDENCE TO ACTION Further research on various intervention programs for overweight and obese middle-aged women is warranted, including lifestyle interventions based on type D personality.",2020,"Following the intervention, the experimental group scored significantly higher than the control group for health-promoting lifestyle behaviors, and significantly lower than the control group for psychological distress and type D personality.","['overweight and obese middle-aged women', 'Type D Personality in Overweight and Obese Middle-Aged Women', 'middle-aged women', 'obese and overweight middle-aged women', '36 overweight and obese middle-aged women participated in a']","['lifestyle intervention', 'Lifestyle Intervention', 'Lifestyle interventions', 'quasi-experimental design using a non-equivalent control group pretest-posttest', 'lifestyle intervention program']","['health-promoting lifestyle behaviors', 'psychological distress and type D personality', 'health-promoting lifestyle behaviors, psychological distress, type D personality, and body composition (body weight, body mass index, body fat, and abdominal fat', 'Body weight and body mass index', 'health-promoting lifestyle behaviors, psychological distress, type D personality, and body composition']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3658239', 'cui_str': 'Personality Type D'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C3658239', 'cui_str': 'Personality Type D'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C1563742', 'cui_str': 'Fat, Abdominal'}]",36.0,0.0166452,"Following the intervention, the experimental group scored significantly higher than the control group for health-promoting lifestyle behaviors, and significantly lower than the control group for psychological distress and type D personality.","[{'ForeName': 'Sung Reul', 'Initials': 'SR', 'LastName': 'Kim', 'Affiliation': 'College of Nursing, Korea University, Seoul, South Korea.'}, {'ForeName': 'Ju-Hee', 'Initials': 'JH', 'LastName': 'Nho', 'Affiliation': 'College of Nursing, Jeonbuk Research Institute of Nursing Science, Jeonbuk National University, Jeonju, South Korea.'}, {'ForeName': 'Ji Young', 'Initials': 'JY', 'LastName': 'Kim', 'Affiliation': 'College of Nursing, Jeonbuk Research Institute of Nursing Science, Jeonbuk National University, Jeonju, South Korea.'}, {'ForeName': 'Joon', 'Initials': 'J', 'LastName': 'Hur', 'Affiliation': 'Department of Internal Medicine, Jiangun Medical Center, Jinangun, South Korea.'}]",Worldviews on evidence-based nursing,['10.1111/wvn.12457'] 2669,32762161,[Efficacy of letrozole in treatment of male adolescents with idiopathic short stature].,"Objective To evaluate the efficacy and safety of aromatase inhibitor letrozole in treatment of male adolescents with idiopathic short stature (ISS). Method Seventy five boys with height less than 2 standard deviation (SD) below the mean who had entered puberty were enrolled in our study from 2004 to 2017, in the Pediatric Department of the First Affiliated Hospital, Sun Yat-Sen University. Among 75 patients, 28 in letrozole group received letrozole and spironolactone, 30 in gonadotrophin releasing hormone analogue (GnRHa) group received GnRHa injection and 17 had no intervention. Height velocity (HV), increment of bone age/chronological age (ΔBA/ΔCA), the final adult height (FAH) were compared among groups and the safety of letrozole treatment was evaluated. Results HV maintained faster during letrozole treatment when compared with other groups. HV during GnRHa treatment showed slightly decline in the first 6 months, but decreased remarkably after 6 months, and was significantly lower than that in letrozole group ( P < 0.05). The maturation of BA slowed down in both letrozole and GnRHa groups. But the ΔBA/ΔCA in letrozole group during the first and the second year of treatment were significantly higher (0.67±0.09, 0.50±0.15, respectively) when compared with GnRHa group (0.59±0.16, 0.44±0.13, respectively) ( t =2.78 and 2.20, all P < 0.05). FAH in letrozole group and GnRHa group were (170±4) cm and (170±6)cm, there was no significant differences between the two groups ( P >0.05), and both were higher than that in no intervention group (162±4 cm, P < 0.01). After 6 months of letrozole treatment, testicular volumes and serum testerone levels increased; 39.2% (11/28) boys had clinical manifestations of hyperandrogenemia, and 82.1% (23/28) boys had decreased serum high-density lipoprotein (HDL) levels. Serum levels of HDL and testerone returned normal and the hyperandrogenemia disappeared after the cessation of letrozole treatment. No significant changes in serum triglyceride, serum low-density lipoprotein (LDL), fating serum levels of insulin and glucose, HOMA-IR were observed. No abnormal liver function, myalgia, scoliosis or aggravations of scoliosis was found. Conclusions Long term letrozole therapy during puberty in boys with ISS can delay bone maturation without significant decrease of linear growth, and thus can improve the final adult height. No severe adverse reactions were found.",2020,"No significant changes in serum triglyceride, serum low-density lipoprotein (LDL), fating serum levels of insulin and glucose, HOMA-IR were observed.","['75 patients, 28 in', 'male adolescents with idiopathic short stature (ISS', 'male adolescents with idiopathic short stature', 'Method Seventy five boys with height less than 2 standard deviation (SD) below the mean who had entered puberty were enrolled in our study from 2004 to 2017, in the Pediatric Department of the First Affiliated Hospital, Sun Yat-Sen University']","['letrozole', 'aromatase inhibitor letrozole', 'letrozole and spironolactone, 30 in gonadotrophin releasing hormone analogue (GnRHa) group received GnRHa injection and 17 had no intervention', 'letrozole therapy']","['severe adverse reactions', 'serum triglyceride, serum low-density lipoprotein (LDL), fating serum levels of insulin and glucose, HOMA-IR', 'testicular volumes and serum testerone levels', 'efficacy and safety', 'Height velocity (HV), increment of bone age/chronological age (ΔBA/ΔCA), the final adult height (FAH', 'serum high-density lipoprotein (HDL) levels', 'abnormal liver function, myalgia, scoliosis or aggravations of scoliosis', 'FAH', 'clinical manifestations of hyperandrogenemia', 'Serum levels of HDL and testerone returned normal and the hyperandrogenemia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001589', 'cui_str': 'Adolescents, Male'}, {'cui': 'C1740819', 'cui_str': 'Idiopathic short stature'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319621', 'cui_str': '75'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0034011', 'cui_str': 'Puberty'}, {'cui': 'C0587482', 'cui_str': 'Pediatric department'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0038817', 'cui_str': 'Sunlight'}, {'cui': 'C0036644', 'cui_str': 'Senegal'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C0593802', 'cui_str': 'Aromatase inhibitor'}, {'cui': 'C0037982', 'cui_str': 'Spironolactone'}, {'cui': 'C1518041', 'cui_str': 'Gonadotropin releasing hormone analogues'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0542495', 'cui_str': 'Measurement of serum triglyceride level'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0429619', 'cui_str': 'Testicular volume'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0429620', 'cui_str': 'Bone age'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0086565', 'cui_str': 'Abnormal liver function'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0036439', 'cui_str': 'Scoliosis deformity of spine'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205319', 'cui_str': 'Manifest'}, {'cui': 'C1299574', 'cui_str': 'Hyperandrogenemia'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0205307', 'cui_str': 'Normal'}]",75.0,0.0154012,"No significant changes in serum triglyceride, serum low-density lipoprotein (LDL), fating serum levels of insulin and glucose, HOMA-IR were observed.","[{'ForeName': 'Yanhong', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Pediatrics, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.'}, {'ForeName': 'Minlian', 'Initials': 'M', 'LastName': 'Du', 'Affiliation': 'Department of Pediatrics, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.'}, {'ForeName': 'Huamei', 'Initials': 'H', 'LastName': 'Ma', 'Affiliation': 'Department of Pediatrics, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.'}, {'ForeName': 'Qiuli', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'Department of Pediatrics, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.'}, {'ForeName': 'Hongshan', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Department of Pediatrics, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Pediatrics, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.'}]",Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,['10.3785/j.issn.1008-9292.2020.04.05'] 2670,32762170,[Aromatase inhibitors combined with growth hormone in treatment of adolescent boys with short stature].,"OBJECTIVE To assess the efficacy and safety of aromatase inhibitors (AIs) combined growth hormone in treatment of adolescent boys with short stature. METHODS One hundred and fifty-one short stature pubertal boys with age of 10-14 years and bone age of 13-15 years, who were admitted to the Department of Pediatrics, the First Affiliated Hospital, Zhejiang University School of Medicine, were included in this trial. According to their own or parents' intention, the children were divided into recombinant human growth hormone (rhGH)+AI group ( n =108) and rhGH group ( n =43). All children were injected subcutaneously with rhGH 0.15-0.2 IU·kg -1 ·d -1 , and those in rhGH+AI group were additionally given 2.5 mg/d letrozole or 1 mg/d anastrozole, orally for 12 months or longer. The children were followed-up every 3 months. During the follow-up visit, the predicted adult height (PAH), sex hormone level, glucose and lipid metabolism, and other indicators were measured, and adverse reactions were monitored. RESULTS After intervention, there were significant differences in ΔBA(bone age)/ΔCA(chronological age), ΔHtSDS BA (height standard deviation score based on bone age)and ΔPAH between rhGH+AI group and the rhGH group( P < 0.05 or P < 0.01). During follow-up, 63.9%of the children in the rhGH+AI group had elevated uric acid and 51.9%had decreased high-density lipoprotein (HDL); 25.9%showed severe acne, excitement, hyperactivity and irritability, 11.1%had knee pain; 4.6%had fracture; 2.8%had mild renal dysfunction; 1.9%had inactivity, drowsiness, memory loss and performance decline; 1.9%showed mild abnormal liver function; 0.9%showed impaired fasting glucose; 0.9%showed granulocytopenia. In the rhGH group, 11.6%of the children presented with knee pain and 2.3%with impaired fasting glucose. CONCLUSIONS AI combined with rhGH can delay the growth of BA and effectively improve the PAH of adolescent boys with larger bone age. However, the occurrence of adverse reactions of AI should be closely monitored during treatment.",2020,"During follow-up, 63.9%of the children in the rhGH+AI group had elevated uric acid and 51.9%had decreased high-density lipoprotein (HDL); 25.9%showed severe acne, excitement, hyperactivity and irritability, 11.1%had knee pain; 4.6%had fracture; 2.8%had mild renal dysfunction; 1.9%had inactivity, drowsiness, memory loss and performance decline;","['adolescent boys with short stature', 'adolescent boys with larger bone age', 'One hundred and fifty-one short stature pubertal boys with age of 10-14 years and bone age of 13-15 years, who were admitted to the Department of Pediatrics, the First Affiliated Hospital, Zhejiang University School of Medicine, were included in this trial']","['aromatase inhibitors (AIs) combined growth hormone', 'letrozole or 1 mg/d anastrozole', 'Aromatase inhibitors combined with growth hormone', 'recombinant human growth hormone (rhGH)+AI group ( n =108) and rhGH']","['knee pain and 2.3%with impaired fasting glucose', 'ΔBA(bone age)/ΔCA(chronological age), ΔHtSDS BA (height standard deviation score based on bone age)and ΔPAH', 'efficacy and safety', 'adult height (PAH), sex hormone level, glucose and lipid metabolism', 'elevated uric acid and 51.9%had decreased high-density lipoprotein (HDL); 25.9%showed severe acne, excitement, hyperactivity and irritability, 11.1%had knee pain; 4.6%had fracture; 2.8%had mild renal dysfunction; 1.9%had inactivity, drowsiness, memory loss and performance decline']","[{'cui': 'C0001589', 'cui_str': 'Adolescents, Male'}, {'cui': 'C0013336', 'cui_str': 'Constitutional short stature'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0429620', 'cui_str': 'Bone age'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C1627769', 'cui_str': 'Pubertal'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0593802', 'cui_str': 'Aromatase inhibitor'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0037663', 'cui_str': 'Somatotropin'}, {'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0290883', 'cui_str': 'anastrozole'}, {'cui': 'C0169964', 'cui_str': 'Somatropin'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517530', 'cui_str': '108'}]","[{'cui': 'C0231749', 'cui_str': 'Knee pain'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0036884', 'cui_str': 'Sex hormone'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0041981', 'cui_str': 'Increased uric acid level'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C0233571', 'cui_str': 'Excitement'}, {'cui': 'C0424295', 'cui_str': 'Hyperactive behavior'}, {'cui': 'C0022107', 'cui_str': 'Feeling irritable'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C1565489', 'cui_str': 'Renal impairment'}, {'cui': 'C3890554', 'cui_str': 'Physical Inactivity'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0002622', 'cui_str': 'Amnesia'}]",,0.0200373,"During follow-up, 63.9%of the children in the rhGH+AI group had elevated uric acid and 51.9%had decreased high-density lipoprotein (HDL); 25.9%showed severe acne, excitement, hyperactivity and irritability, 11.1%had knee pain; 4.6%had fracture; 2.8%had mild renal dysfunction; 1.9%had inactivity, drowsiness, memory loss and performance decline;","[{'ForeName': 'Yuanmei', 'Initials': 'Y', 'LastName': 'Kong', 'Affiliation': 'Department of Pediatrics, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Department of Pediatrics, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Liang', 'Affiliation': 'Department of Pediatrics, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.'}, {'ForeName': 'Maoni', 'Initials': 'M', 'LastName': 'Zheng', 'Affiliation': 'Department of Pediatrics, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.'}, {'ForeName': 'Yanlan', 'Initials': 'Y', 'LastName': 'Fang', 'Affiliation': 'Department of Pediatrics, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.'}, {'ForeName': 'Chunlin', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Pediatrics, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.'}]",Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,['10.3785/j.issn.1008-9292.2020.04.12'] 2671,32757634,Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH) versus atomoxetine on executive function improvement and clinical effectiveness in ADHD: A randomized controlled trial.,"OBJECTIVES The aim of this study to compare the clinic efficacy and effects of osmotic release oral system-methylphenidate and atomoxetine on executive function in children and adolescents with attention deficit hyperactivity disorder by a open-label, prospective, randomized controlled trial. METHODS The study was performed by 95 cases between ages 6 and 12 years who were diagnosed as attention-deficit/hyperactivity disorder (ADHD) and also 40 control individuals. In this study, Conners' Teacher Rating Scale (CTRS) was used in order to evaluate the efficacy of the treatment. Executive functions were assessed by the performance-based neuropsychological tests and ecological behavioral rating scales. Stroop test, cancellation test, and serial digit learning test were applied to performance based neuropsychological tests. Behavior Rating Inventory of Executive Function tests (BRIEFs) were used as behavioral assessment scales. RESULTS Among the ADHD groups, a reduction of over 40% in the CTRS subtest scores used to evaluate the efficacy of the treatment was considered to be an improvement, and no significant difference was found for both drugs. Both Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH) and atomoxetine (ATX) significantly improved scores in neuropsychological tests. CONCLUSION Atomoxetine and OROS-MPH treatments have shown similar efficacy in clinical recovery and improvement on executive functions. However, disturbances in executive functions observed in children with ADHD are persistent despite treatment, when compared with the control group.",2020,"Among the ADHD groups, a reduction of over 40% in the CTRS subtest scores used to evaluate the efficacy of the treatment was considered to be an improvement, and no significant difference was found for both drugs.","['children with ADHD', 'ADHD', 'children and adolescents with attention deficit hyperactivity disorder', '95 cases between ages 6 and 12 years who were diagnosed as attention-deficit/hyperactivity disorder (ADHD) and also 40 control individuals']","['Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH', 'Atomoxetine', 'Methylphenidate Hydrochloride (OROS-MPH) and atomoxetine (ATX', 'atomoxetine', 'osmotic release oral system-methylphenidate and atomoxetine']","['executive function improvement and clinical effectiveness', 'Stroop test, cancellation test, and serial digit learning test', 'Behavior Rating Inventory of Executive Function tests (BRIEFs', 'executive functions', 'performance-based neuropsychological tests and ecological behavioral rating scales', 'executive function', 'Executive functions', ""Conners' Teacher Rating Scale (CTRS""]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0029391', 'cui_str': 'Osmosis'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0700545', 'cui_str': 'Methylphenidate hydrochloride'}, {'cui': 'C0076823', 'cui_str': 'atomoxetine'}, {'cui': 'C0025810', 'cui_str': 'Methylphenidate'}]","[{'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C3850123', 'cui_str': 'Treatment Effectiveness'}, {'cui': 'C2718024', 'cui_str': 'Stroop Task'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0475483', 'cui_str': 'Behavior rating scale'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",95.0,0.0271921,"Among the ADHD groups, a reduction of over 40% in the CTRS subtest scores used to evaluate the efficacy of the treatment was considered to be an improvement, and no significant difference was found for both drugs.","[{'ForeName': 'Yasemin', 'Initials': 'Y', 'LastName': 'Taş Torun', 'Affiliation': 'Child and Adolescent Psychiatry Department, Gazi University Medical Faculty, Ankara, Turkey.'}, {'ForeName': 'Yasemen', 'Initials': 'Y', 'LastName': 'Işik Taner', 'Affiliation': 'Child and Adolescent Psychiatry Department, Gazi University Medical Faculty, Ankara, Turkey.'}, {'ForeName': 'Esra', 'Initials': 'E', 'LastName': 'Güney', 'Affiliation': 'Child and Adolescent Psychiatry Department, Gazi University Medical Faculty, Ankara, Turkey.'}, {'ForeName': 'Elvan', 'Initials': 'E', 'LastName': 'İseri', 'Affiliation': 'Child and Adolescent Psychiatry Department, Gazi University Medical Faculty, Ankara, Turkey.'}]",Applied neuropsychology. Child,['10.1080/21622965.2020.1796667'] 2672,32757652,Early mobilization reduces delirium after coronary artery bypass graft surgery.,"BACKGROUND Postoperative delirium is common in patients undergoing coronary artery bypass grafting, characterized by cognitive decline. This study aimed to evaluate the effect of early planned mobilization on delirium after coronary artery bypass grafting. METHODS This double-blind randomized clinical trial enrolled 92 consecutive patients who underwent coronary artery bypass grafting from September to December 2018. The patients were divided into two groups of 46: a mobilization protocol was applied in the intervention group in the first 2 days after surgery; the control group received routine nursing care only. Demographic data, medical records, and Neecham confusion scores were analyzed. RESULTS Patients in the control group used cigarettes (31.1% vs. 11.1%, p  = 0.020) and opium poppy for recreation (35.6% vs. 8.9%, p  = 0.002) more frequently, had longer intubation times (11.91 ± 3.87 vs. 10.23 ± 2.71 h, p  = 0.020), and fewer blood components infused (15.6% vs. 33.3%, p  = 0.05). More patients in the intervention group had normal function on the 2nd postoperative day compared to the control group (25 vs. 2, respectively, p  = 0.001). The intervention group had significantly higher Neecham scores on postoperative day 2 (22.49 ± 2.03 vs. 26.82 ± 2.10, p  = 0.001). Multivariable analysis showed significant associations between Neecham score and age ( p  = 0.022), ejection fraction ( p  = 0.015), myocardial infarction ( p  = 0.016), systolic pressure ( p  = 0.009), and diastolic pressure ( p  = 0.008). CONCLUSIONS Early planned mobilization was effective in reducing postoperative delirium in patients undergoing coronary artery bypass grafting.",2020,"RESULTS Patients in the control group used cigarettes (31.1% vs. 11.1%, p  = 0.020) and opium poppy for recreation (35.6% vs. 8.9%, p  = 0.002) more frequently, had longer intubation times (11.91 ± 3.87 vs. 10.23 ± 2.71 h, p  = 0.020), and fewer blood components infused (15.6% vs. 33.3%, p  = 0.05).","['92 consecutive patients who underwent coronary artery bypass grafting from September to December 2018', 'patients undergoing coronary artery bypass grafting', 'patients undergoing coronary artery bypass grafting, characterized by cognitive decline', 'after coronary artery bypass graft surgery']","['mobilization protocol', 'control group received routine nursing care only', 'early planned mobilization']","['longer intubation times', 'delirium', 'Neecham scores', 'blood components', 'systolic pressure', 'diastolic pressure', 'normal function', 'myocardial infarction', 'postoperative delirium', 'ejection fraction', 'Demographic data, medical records, and Neecham confusion scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C0234985', 'cui_str': 'Mental Deterioration'}]","[{'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0028678', 'cui_str': 'nursing'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0085430', 'cui_str': 'Transfusion of blood component'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C4721772', 'cui_str': 'Postoperative delirium'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0025102', 'cui_str': 'Medical record'}, {'cui': 'C0009676', 'cui_str': 'Confusional state'}]",92.0,0.153849,"RESULTS Patients in the control group used cigarettes (31.1% vs. 11.1%, p  = 0.020) and opium poppy for recreation (35.6% vs. 8.9%, p  = 0.002) more frequently, had longer intubation times (11.91 ± 3.87 vs. 10.23 ± 2.71 h, p  = 0.020), and fewer blood components infused (15.6% vs. 33.3%, p  = 0.05).","[{'ForeName': 'Fahimeh', 'Initials': 'F', 'LastName': 'Shirvani', 'Affiliation': 'Department of Nursing and Midwifery, Isfahan (Khorasgan) Branch, Islamic Azad University, Isfahan, Iran.'}, {'ForeName': 'Seyed Ali', 'Initials': 'SA', 'LastName': 'Naji', 'Affiliation': 'Department of Nursing and Midwifery, Isfahan (Khorasgan) Branch, Islamic Azad University, Isfahan, Iran.'}, {'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'Davari', 'Affiliation': 'Department of Nursing and Midwifery, Isfahan (Khorasgan) Branch, Islamic Azad University, Isfahan, Iran.'}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Sedighi', 'Affiliation': 'Department of Neuroscience, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.'}]",Asian cardiovascular & thoracic annals,['10.1177/0218492320947230'] 2673,32757658,"One-Year Echocardiographic, Functional, and Quality of Life Outcomes After Ultrasound-Facilitated Catheter-Based Fibrinolysis for Pulmonary Embolism.","BACKGROUND Accelerated tPA (tissue-type plasminogen activator) dosing regimens for ultrasound-facilitated, catheter-directed fibrinolysis improve short-term computed tomographic-measured right ventricular (RV)-to-left ventricular diameter ratio in massive and submassive pulmonary embolism. The impact on RV remodeling, functional status, and quality of life over the long-term remains unclear. METHODS To study 1-year changes in RV remodeling, functional status, and quality of life, we assessed patients with acute submassive pulmonary embolism randomly assigned to 1 of 4 tPA dosing regimens for ultrasound-facilitated, catheter-directed fibrinolysis in the OPTALYSE-PE trial (Optimum Duration and Dose of r-tPA With the Acoustic Pulse Thrombolysis Procedure for Intermediate-Risk Pulmonary Embolism; 8 mg/2 hours, 8 mg/4 hours, 12 mg/6 hours, and 24 mg/6 hours). Echocardiographic assessment included RV-to-left ventricular diameter ratio within 4 hours of treatment end, and at 48 hours, 30 days, 90 days, and 1 year. Functional status was assessed by 6-minute walk test at 30 days, 90 days, and 1 year and PROMIS-PF-6b scores at 30 days, 90 days, 180 days, 270 days, and 1 year. Quality of life was evaluated by PEmb-QOL scores at 30 days, 90 days, 180 days, 270 days, and 1 year. RESULTS Mean RV-to-left ventricular diameter ratio decreased from baseline to 4 hours and further at 48 hours and 30 days, with reductions maintained at 90 days and 1 year in all groups. Mean 6-minute walk distance, PROMIS-PF-6b, and PEmb-QOL scores improved over the course of 1 year in all groups. CONCLUSIONS Accelerated lower-dose tPA regimens for ultrasound-facilitated, catheter-directed fibrinolysis resulted in sustained recovery of RV-to-left ventricular diameter ratio and tricuspid annular plane systolic excursion and improvements in functional status and quality of life over 1 year. Registration: URL: https://www.ClinicalTrials.gov. Unique Identifier: NCT02396758.",2020,"Mean 6-minute walk distance, PROMIS-PF-6b, and PEmb-QOL scores improved over the course of 1 year in all groups. ",['patients with acute submassive pulmonary embolism'],['Facilitated Catheter-Based Fibrinolysis'],"['One-Year Echocardiographic, Functional, and Quality of Life Outcomes', 'RV remodeling, functional status, and quality of life', 'Echocardiographic assessment included RV-to-left ventricular diameter ratio', 'Mean RV-to-left ventricular diameter ratio', 'Quality of life', 'Mean 6-minute walk distance, PROMIS-PF-6b, and PEmb-QOL scores', 'Functional status', 'PEmb-QOL scores', 'functional status and quality of life', 'PF-6b scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}]","[{'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0016017', 'cui_str': 'Fibrinolysis'}]","[{'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0600519', 'cui_str': 'Ventricular remodelling'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.06081,"Mean 6-minute walk distance, PROMIS-PF-6b, and PEmb-QOL scores improved over the course of 1 year in all groups. ","[{'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Piazza', 'Affiliation': ""Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.P.).""}, {'ForeName': 'Keith M', 'Initials': 'KM', 'LastName': 'Sterling', 'Affiliation': 'Department of Cardiovascular and Interventional Radiology, INOVA Alexandria Hospital, VA (K.M.S.).'}, {'ForeName': 'Victor F', 'Initials': 'VF', 'LastName': 'Tapson', 'Affiliation': ''}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Ouriel', 'Affiliation': ''}, {'ForeName': 'Andrew S P', 'Initials': 'ASP', 'LastName': 'Sharp', 'Affiliation': ''}, {'ForeName': 'Ping-Yu', 'Initials': 'PY', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Samuel Z', 'Initials': 'SZ', 'LastName': 'Goldhaber', 'Affiliation': ''}]",Circulation. Cardiovascular interventions,['10.1161/CIRCINTERVENTIONS.120.009012'] 2674,32757687,Migration of the uncemented Echo Bi-Metric and Bi-Metric THA stems: a randomized controlled RSA study involving 62 patients with 24-month follow-up.,"Background and purpose - Despite the good results after total hip arthroplasty (THA), new implants are continuously being developed to improve durability. The Echo Bi-Metric (EBM) THA stem is the successor to the Bi-Metric (BM) THA stem. The EBM stem includes many of the features of the BM stem, but minor changes in the design might improve the clinical performance. We compared the migration behavior with radiostereometric analysis (RSA) of the EBM stem and the BM stem at 24 months and evaluated the clinical outcome.Patients and methods - We randomized 62 patients with osteoarthritis (mean age 64 years, female/male 28/34) scheduled for an uncemented THA to receive either an EBM or a BM THA stem. We performed RSA within 1 week after surgery and at 3, 6, 12, and 24 months. The clinical outcome was evaluated using Harris Hip Score (HHS) and Oxford Hip Score (OHS).Results - At 24 months, we found no statistically significant differences in migration between the two implants. During the first 3 months both the EBM and the BM stems showed visible subsidence (2.5 mm and 2.2 mm respectively), and retroversion (2.5° and 2.2° respectively), but after 3 months this stabilized. The expected increase in HHS and OHS was similar between the groups.Interpretation - The EBM stem showed a migration at 24 months not different from the BM stem, and both stems display satisfying clinical results.",2020,"The EBM stem showed a migration at 24 months not different from the BM stem, and both stems display satisfying clinical results.","['62 patients with osteoarthritis (mean age 64 years, female/male 28/34) scheduled for an', '62 patients with 24-month follow-up']","['uncemented THA to receive either an EBM or a BM THA stem', 'total hip arthroplasty (THA', 'uncemented Echo Bi-Metric and Bi-Metric THA stems']","['visible subsidence', 'Echo Bi-Metric (EBM', 'HHS and OHS', 'Harris Hip Score (HHS) and Oxford Hip Score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0039245', 'cui_str': 'Tacrine'}, {'cui': 'C0795974', 'cui_str': 'Epidermolysis Bullosa, Macular Type'}, {'cui': 'C0162731', 'cui_str': 'STEM'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0013520', 'cui_str': 'Doppler Echocardiography'}, {'cui': 'C0699680', 'cui_str': 'Metric'}]","[{'cui': 'C0205379', 'cui_str': 'Visible'}, {'cui': 'C0013520', 'cui_str': 'Doppler Echocardiography'}, {'cui': 'C0699680', 'cui_str': 'Metric'}, {'cui': 'C0795974', 'cui_str': 'Epidermolysis Bullosa, Macular Type'}, {'cui': 'C0041711', 'cui_str': 'United States. Dept. of Health and Human Services'}, {'cui': 'C0268353', 'cui_str': 'Cutis laxa, x-linked'}, {'cui': 'C2919875', 'cui_str': 'Harris hip score'}, {'cui': 'C1998079', 'cui_str': 'Oxford hip score'}]",62.0,0.0213282,"The EBM stem showed a migration at 24 months not different from the BM stem, and both stems display satisfying clinical results.","[{'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Dyreborg', 'Affiliation': 'Department of Orthopaedic Surgery, Rigshospitalet, University of Copenhagen, Denmark.'}, {'ForeName': 'Mikkel R', 'Initials': 'MR', 'LastName': 'Andersen', 'Affiliation': 'Department of Orthopaedic Surgery, Rigshospitalet, University of Copenhagen, Denmark.'}, {'ForeName': 'Nikolaj', 'Initials': 'N', 'LastName': 'Winther', 'Affiliation': 'Department of Orthopaedic Surgery, Rigshospitalet, University of Copenhagen, Denmark.'}, {'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Solgaard', 'Affiliation': 'Department of Hip and Knee Surgery, Herlev-Gentofte University Hospital, Hellerup, Denmark.'}, {'ForeName': 'Gunnar', 'Initials': 'G', 'LastName': 'Flivik', 'Affiliation': 'Department of Orthopedics, Lund University and Skåne University Hospital, Lund, Sweden.'}, {'ForeName': 'Michael M', 'Initials': 'MM', 'LastName': 'Petersen', 'Affiliation': 'Department of Orthopaedic Surgery, Rigshospitalet, University of Copenhagen, Denmark.'}]",Acta orthopaedica,['10.1080/17453674.2020.1802682'] 2675,32757879,"Prospective, Randomized, Comparative, Multicenter Study of the Hybrid Ultrasonic Advanced Bipolar Device and the Ultrasonic Coagulating Shears in Open Thyroidectomy.","Background. The hybrid ultrasonic advanced bipolar device (HUB) that integrates ultrasonic energy and advanced bipolar energy was recently developed and applied to thyroid surgery. The purpose of this study was to compare the efficacy and safety of HUB and ultrasonic coagulating shears for open thyroidectomy. Methods. A total of 200 patients were enrolled from April to September 2017 in this prospective, randomized, multicenter study. Patients were randomly assigned to an ultrasonic group (n = 101) or a hybrid group (n = 99). Results. Operation times were similar in the 2 study groups, that is, 54.2 ± 25.2 minutes in the ultrasonic group and 50.2 ± 21.6 minutes in the hybrid group. Postoperative surgical results and morbidities were no different in the 2 groups. However, the total amount of bleeding was significantly less in the hybrid group (13.0 ± 17.7 mg vs 8.6 ± 11.5 mg; P = .042). Conclusions. Our study showed that there was no significant difference between the 2 groups in postoperative surgical results and morbidity. The total bleeding amount was significantly less in the hybrid group. The study shows that HUB is comparable to the ultrasonic coagulating shears in terms of efficacy and safety during thyroid surgery.",2020,The study shows that HUB is comparable to the ultrasonic coagulating shears in terms of efficacy and safety during thyroid surgery.,['200 patients were enrolled from April to September 2017'],"['ultrasonic coagulating shears', 'HUB and ultrasonic coagulating shears', 'ultrasonic group', 'Hybrid Ultrasonic Advanced Bipolar Device and the Ultrasonic Coagulating Shears', 'hybrid ultrasonic advanced bipolar device (HUB']","['Postoperative surgical results and morbidities', 'efficacy and safety', 'postoperative surgical results and morbidity', 'total bleeding amount', 'Operation times', 'total amount of bleeding']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0175735', 'cui_str': 'Scissors'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0007597', 'cui_str': 'Cell hybridization'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0443156', 'cui_str': 'Bipolar'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]",200.0,0.0183842,The study shows that HUB is comparable to the ultrasonic coagulating shears in terms of efficacy and safety during thyroid surgery.,"[{'ForeName': 'Wan Wook', 'Initials': 'WW', 'LastName': 'Kim', 'Affiliation': 'Department of Surgery, School of Medicine, 65672Kyungpook National University, Daegu, Republic of Korea.'}, {'ForeName': 'Jihyoung', 'Initials': 'J', 'LastName': 'Cho', 'Affiliation': 'Department of Surgery, School of Medicine, 37976Keimyung University, Daegu, Republic of Korea.'}, {'ForeName': 'Young San', 'Initials': 'YS', 'LastName': 'Jeon', 'Affiliation': 'Department of Surgery, Goo Hospital, Daegu, Republic of Korea.'}, {'ForeName': 'Insoo', 'Initials': 'I', 'LastName': 'Kim', 'Affiliation': 'Department of Surgery, Daegu Fatima Hospital, Daegu, Republic of Korea.'}, {'ForeName': 'Young Ju', 'Initials': 'YJ', 'LastName': 'Jeong', 'Affiliation': 'Department of Surgery, School of Medicine, Catholic University of Daegu, Daegu, Republic of Korea.'}, {'ForeName': 'Jungeun', 'Initials': 'J', 'LastName': 'Choi', 'Affiliation': 'Department of Surgery, College of Medicine, Yeungnam University, Daegu, Republic of Korea.'}, {'ForeName': 'Moo Hyun', 'Initials': 'MH', 'LastName': 'Lee', 'Affiliation': 'Department of Surgery, School of Medicine, 37976Keimyung University, Daegu, Republic of Korea.'}, {'ForeName': 'Jehyung', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Department of Surgery, Goo Hospital, Daegu, Republic of Korea.'}, {'ForeName': 'Jin Gu', 'Initials': 'JG', 'LastName': 'Kang', 'Affiliation': 'Department of Surgery, College of Medicine, Yeungnam University, Daegu, Republic of Korea.'}, {'ForeName': 'Ralph P', 'Initials': 'RP', 'LastName': 'Tufano', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Su Hwan', 'Initials': 'SH', 'LastName': 'Kang', 'Affiliation': 'Department of Surgery, College of Medicine, Yeungnam University, Daegu, Republic of Korea.'}]",Surgical innovation,['10.1177/1553350620949000'] 2676,32757940,Feasibility and Acceptability of Heart Rate Variability Biofeedback in a Group of Veterans with Fibromyalgia.,"Objectives: To determine the feasibility and acceptability of a heart rate variability biofeedback (HRVB) protocol in a focus group of Veterans with fibromyalgia (FM). Design: A multimethod feasibility and acceptability study. Settings/location: A Veterans Health outpatient pain medicine clinic in the southern United States. Subjects: The researcher enrolled seven women and three men between the ages of 33 and 68 years with a diagnosis of FM. Interventions: Participants practiced HRVB on the emWave2 at home for 20 min twice daily for 7 weeks. Outcome measures: Feasibility to adhere to the HRVB protocol was measured using the practice frequency and time (minutes) data collected from the emWave2 . The author compared the individual reports from participants with the Credibility/Expectancy Questionnaire to measure the acceptability of the intervention. In addition, the principal investigator evaluated data from the Short-form McGill Pain Questionnaire (SFMQ) and the Revised Fibromyalgia Impact Questionnaire (FIQR) at the baseline and weekly study visits for a signal of efficacy for pain control, functional status, and quality of life (QOL). Results: The majority of participants (80%) expected 50% or more improvement in their pain, and (70%) felt HRVB would reduce their FM-related pain by 50%-80%. The mean daily practice frequency rate was 0.80. The mean practice duration was 19.36 min. Pain score differences from the SFMQ were insignificant preintervention and postintervention. The mean total FIQR scores postintervention improved by 18.1 points. Conclusions: Findings suggest twice-daily HRVB practice protocol is not feasible. However, 20-min HRVB sessions were feasible and acceptable. Improved FIQR scores post-treatment suggest HRVB may be an effective strategy to improve functional status and QOL for Veterans with FM. ClinicalTrials.gov ID: Pro00079144.",2020,Improved FIQR scores post-treatment suggest HRVB may be an effective strategy to improve functional status and QOL for Veterans with FM.,"['Veterans Health outpatient pain medicine clinic in the southern United States', 'researcher enrolled seven women and three men between the ages of 33 and 68 years with a diagnosis of FM', 'Subjects', 'Veterans with fibromyalgia (FM', 'Veterans with Fibromyalgia']","['heart rate variability biofeedback (HRVB) protocol', 'Heart Rate Variability Biofeedback']","['mean total FIQR scores postintervention', 'FIQR scores', 'mean daily practice frequency rate', 'McGill Pain Questionnaire (SFMQ) and the Revised Fibromyalgia Impact Questionnaire (FIQR', 'mean practice duration', 'Pain score differences', 'FM-related pain', 'functional status and QOL', 'Outcome measures: Feasibility to adhere to the HRVB protocol', 'practice frequency and time (minutes) data collected from the emWave2 ', 'pain control, functional status, and quality of life (QOL']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005491', 'cui_str': 'Biofeedback procedure'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0024985', 'cui_str': 'McGill pain chart questionnaire'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]",7.0,0.0664034,Improved FIQR scores post-treatment suggest HRVB may be an effective strategy to improve functional status and QOL for Veterans with FM.,"[{'ForeName': 'Marcelaine', 'Initials': 'M', 'LastName': 'Reneau', 'Affiliation': 'Integrative Pain Clinic, Ralph H. Johnson VA Medical Center, Charleston, SC, USA.'}]","Journal of alternative and complementary medicine (New York, N.Y.)",['10.1089/acm.2020.0071'] 2677,32757963,Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis: A Randomized Trial.,"Rationale Although early antimicrobial discontinuation guided by procalcitonin (PCT) has showed decreased antibiotic consumption in lower respiratory tract infections (LRTIs), the outcomes in long-term sepsis sequelae remain unclear. Objective To investigate if PCT-guidance may reduce the incidence of long-term infection-associated adverse events in sepsis. Methods In this multicenter trial, 266 sepsis (by Sepsis-3 definitions) patients with LRTIs, acute pyelonephritis, or primary bloodstream infection were randomized (1:1) to receive either PCT-guided discontinuation of antimicrobials or standard-of-care (SOC). The discontinuation criterion was ≥80% reduction in PCT levels or any PCT ≤0.5 μg/l at day 5 or later. The primary outcome was the rate of infection-associated adverse events at day 180, a composite of the incidence of any new infection by Clostridioides difficile or multidrug-resistant organisms (MDRO), or any death attributed to baseline C. difficile or MDRO infection. Secondary outcomes included 28-day mortality, length of antibiotic therapy (LOT), and cost of hospitalization. Measurements and Main Results The rate of infection-associated adverse events was 7.2% (95% CI, 3.8-13.1%; 9/125) versus 15.3% (95% CI, 10.1-22.4%; 20/131) (hazard ratio [HR], 0.45; 95% CI, 0.20-0.98; P=0.045); 28-day mortality 15.2% (95% CI,10-22.5%; 19/125) versus 28.2% (95% CI, 21.2-36.5%; 37/131) (HR, 0.51; 95% CI, 0.29-0.89; P =0.02); and median LOT 5 (range 5 to 7) versus 10 (range 7 to 15) days (P <0.001) in the PCT and SOC arms, respectively. The cost of hospitalization was also reduced in the PCT arm. Conclusions In sepsis, PCT-guidance was effective in reducing infection-associated adverse events, 28-day mortality, and cost of hospitalization. Clinical trial registration available at www.clinicaltrials.gov, ID: NCT03333304.",2020,"In sepsis, PCT-guidance was effective in reducing infection-associated adverse events, 28-day mortality, and cost of hospitalization.","['Sepsis', '266 sepsis (by Sepsis-3 definitions) patients with LRTIs, acute pyelonephritis, or primary bloodstream infection', 'sepsis']","['PCT-guidance', 'PCT-guided discontinuation of antimicrobials or standard-of-care (SOC', 'procalcitonin (PCT']","['composite of the incidence of any new infection by Clostridioides difficile or multidrug-resistant organisms (MDRO), or any death attributed to baseline C. difficile or MDRO infection', 'infection-associated adverse events, 28-day mortality, and cost of hospitalization', '28-day mortality', '28-day mortality, length of antibiotic therapy (LOT), and cost of hospitalization', 'rate of infection-associated adverse events', 'cost of hospitalization', 'PCT levels', 'median LOT']","[{'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0149725', 'cui_str': 'Lower respiratory tract infection'}, {'cui': 'C0520575', 'cui_str': 'Acute pyelonephritis'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C2316160', 'cui_str': 'Infection of bloodstream'}]","[{'cui': 'C0072027', 'cui_str': 'Procalcitonin'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439633', 'cui_str': 'New infection'}, {'cui': 'C0079134', 'cui_str': 'Clostridium difficile (bacteria)'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0029235', 'cui_str': 'Organism'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0449234', 'cui_str': 'Attribute'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C1535922', 'cui_str': 'Procalcitonin'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",266.0,0.348709,"In sepsis, PCT-guidance was effective in reducing infection-associated adverse events, 28-day mortality, and cost of hospitalization.","[{'ForeName': 'Evdoxia', 'Initials': 'E', 'LastName': 'Kyriazopoulou', 'Affiliation': 'National and Kapodistrian University of Athens School of Medicine, 68989, 4th Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Lydia', 'Initials': 'L', 'LastName': 'Liaskou-Antoniou', 'Affiliation': 'National and Kapodistrian University of Athens School of Medicine, 68989, 4th Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Adamis', 'Affiliation': 'G. Gennimatas General Hospital of Athens, 1st Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Antonia', 'Initials': 'A', 'LastName': 'Panagaki', 'Affiliation': 'National and Kapodistrian University of Athens School of Medicine, 68989, 4th Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Nikolaos', 'Initials': 'N', 'LastName': 'Melachroinopoulos', 'Affiliation': 'National and Kapodistrian University of Athens School of Medicine, 68989, 4th Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Elina', 'Initials': 'E', 'LastName': 'Drakou', 'Affiliation': 'G. Gennimatas General Hospital of Athens, 1st Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Marousis', 'Affiliation': 'G. Gennimatas General Hospital of Athens, 1st Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Georgios', 'Initials': 'G', 'LastName': 'Chrysos', 'Affiliation': 'Tzaneio General Hospital of Piraeus, 2nd Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Andronikos', 'Initials': 'A', 'LastName': 'Spyrou', 'Affiliation': 'G. Gennimatas General Hospital of Athens, 1st Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Nikolaos', 'Initials': 'N', 'LastName': 'Alexiou', 'Affiliation': 'Thriasio General Hospital of Eleusis, 1st Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Styliani', 'Initials': 'S', 'LastName': 'Symbardi', 'Affiliation': 'Thriasio General Hospital of Eleusis, 1st Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Zoi', 'Initials': 'Z', 'LastName': 'Alexiou', 'Affiliation': 'Thriasio General Hospital of Eleusis, 2nd Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Styliani', 'Initials': 'S', 'LastName': 'Lagou', 'Affiliation': 'National and Kapodistrian University of Athens School of Medicine, 68989, 3rd Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Kolonia', 'Affiliation': 'Sismanogleio General Hospital of Athens, 2nd Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Theologia', 'Initials': 'T', 'LastName': 'Gkavogianni', 'Affiliation': 'National and Kapodistrian University of Athens School of Medicine, 68989, 4th Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Miltiades', 'Initials': 'M', 'LastName': 'Kyprianou', 'Affiliation': 'National and Kapodistrian University of Athens School of Medicine, 68989, 4th Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Anagnostopoulos', 'Affiliation': 'National and Kapodistrian University of Athens School of Medicine, 68989, 3rd Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Garyfallia', 'Initials': 'G', 'LastName': 'Poulakou', 'Affiliation': 'National and Kapodistrian University of Athens School of Medicine, 68989, 3rd Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Malvina', 'Initials': 'M', 'LastName': 'Lada', 'Affiliation': 'Sismanogleio General Hospital of Athens, 2nd Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Makkina', 'Affiliation': 'Thriasio General Hospital of Eleusis, 1st Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Efrosyni', 'Initials': 'E', 'LastName': 'Roulia', 'Affiliation': 'Thriasio General Hospital of Eleusis, 2nd Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Koupetori', 'Affiliation': 'Thriasio General Hospital of Eleusis, 1st Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Vasileios', 'Initials': 'V', 'LastName': 'Apostolopoulos', 'Affiliation': 'Thriasio General Hospital of Eleusis, 1st Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Dimitra', 'Initials': 'D', 'LastName': 'Petrou', 'Affiliation': 'Thriasio General Hospital of Eleusis, 1st Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Nitsotolis', 'Affiliation': 'Tzaneio General Hospital of Piraeus, 2nd Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Anastasia', 'Initials': 'A', 'LastName': 'Antoniadou', 'Affiliation': 'National and Kapodistrian University of Athens School of Medicine, 68989, 4th Department of Internal Medicine, Athens, Greece.'}, {'ForeName': 'Evangelos J', 'Initials': 'EJ', 'LastName': 'Giamarellos-Bourboulis', 'Affiliation': 'National and Kapodistrian University of Athens School of Medicine, 68989, 4th Department of Internal Medicine, Athens, Greece; egiamarel@med.uoa.gr.'}]",American journal of respiratory and critical care medicine,['10.1164/rccm.202004-1201OC'] 2678,32757999,Prospective Single-Blinded Randomized Controlled Trial Comparing Pericapsular Injection Versus Lumbar Plexus Peripheral Nerve Block for Hip Arthroscopy.,"BACKGROUND Hip arthroscopy has become the standard for the operative treatment of symptomatic femoroacetabular impingement. Given the high levels of postoperative pain associated with hip arthroscopy, optimal analgesia is critical to ensure patient comfort and safety after discharge. PURPOSE/HYPOTHESIS Our purpose was to perform a single-blinded randomized controlled trial comparing the use of pericapsular injection versus lumbar plexus blockade for postoperative pain control after arthroscopic surgery on the hip. We hypothesized that pericapsular injection would provide equivalent pain relief to that of lumbar plexus blockade while minimizing adverse effects and alleviating the dependence on a qualified individual to administer. STUDY DESIGN Randomized controlled trial; Level of evidence, 1. METHODS A total of 64 consecutive patients undergoing hip arthroscopy were prospectively assessed over a 6-month period between 2017 and 2018. Patients were randomly allocated to 1 of 2 groups: 32 patients received a lumbar plexus blockade by a single anesthesiologist, while 32 patients received a pericapsular injection of 30 mL of ropivacaine and 12 mg of morphine. Postoperative pain in the postanesthesia care unit (PACU) as measured using the numeric rating scale, time to discharge, PACU morphine equivalents, and adverse effects were collected by PACU staff. Postoperative day 1 and 2 narcotic use was obtained through a telephone call with the patient on postoperative day 3. RESULTS We found no statistically significant difference in PACU pain scores at all time points, although there was a trend toward lower pain for patients receiving a pericapsular injection. PACU and short-term narcotic demand did not vary across the 2 arms. Time to discharge from the PACU did not differ. There were no major adverse events reported for either intervention. CONCLUSION Pericapsular injection provides equivalent analgesia when compared with lumbar plexus blockade. It is a safe intervention that allows for efficient postoperative analgesia for patients undergoing hip arthroscopy. REGISTRATION ClinicalTrials.gov ID: NCT03244631.",2020,"There were no major adverse events reported for either intervention. ","['patients undergoing hip arthroscopy', '64 consecutive patients undergoing hip arthroscopy were prospectively assessed over a 6-month period between 2017 and 2018', 'postoperative pain control after arthroscopic surgery on the hip', 'Hip Arthroscopy']","['pericapsular injection of 30 mL of ropivacaine and 12 mg of morphine', 'lumbar plexus blockade', 'pericapsular injection versus lumbar plexus blockade', 'Pericapsular Injection Versus Lumbar Plexus Peripheral Nerve Block', 'Pericapsular injection', 'pericapsular injection']","['numeric rating scale, time to discharge, PACU morphine equivalents, and adverse effects', 'Postoperative pain', 'lower pain', 'PACU pain scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0186190', 'cui_str': 'Diagnostic arthroscopy of hip joint'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0750934', 'cui_str': 'Arthroscopy with surgical procedure'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}]","[{'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0205826', 'cui_str': 'Lumbar plexus structure'}, {'cui': 'C0332206', 'cui_str': 'Blocking'}, {'cui': 'C0198807', 'cui_str': 'Peripheral block anesthesia'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0262723', 'cui_str': 'Postanesthesia care'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",64.0,0.258223,"There were no major adverse events reported for either intervention. ","[{'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Scanaliato', 'Affiliation': 'William Beaumont Army Medical Center, El Paso, Texas, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Christensen', 'Affiliation': 'Naval Medical Center Pensacola, Pensacola, Florida, USA.'}, {'ForeName': 'Michael M', 'Initials': 'MM', 'LastName': 'Polmear', 'Affiliation': 'William Beaumont Army Medical Center, El Paso, Texas, USA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Salfiti', 'Affiliation': 'Washington Orthopaedics and Sports Medicine, Washington, DC, USA.'}, {'ForeName': 'Patrick S', 'Initials': 'PS', 'LastName': 'Gaspar', 'Affiliation': 'Reston Anesthesia Associates, Reston, Virginia, USA.'}, {'ForeName': 'Andrew B', 'Initials': 'AB', 'LastName': 'Wolff', 'Affiliation': 'Washington Orthopaedics and Sports Medicine, Washington, DC, USA.'}]",The American journal of sports medicine,['10.1177/0363546520943580'] 2679,32762224,Influence of high-intensity intermittent training on glycolipid metabolism in obese male college students.,"BACKGROUND Obesity is a chronic metabolic disease that increases the risk of developing health problems including respiratory disease, hypertension, hyperlipidemia, diabetes, and coronary heart disease. In college students, as well as impacting physical health, obesity can also affect mental health and even students' future careers. Aerobic exercise is an effective way of achieving weight loss; however, for some students, it cannot be maintained over the long term. This study aimed to observe and analyze the influence of high-intensity intermittent training on glycolipid metabolism in obese male college students. METHODS A total of 300 obese male college students were enrolled in the study and were randomly divided into the study group and the control group (150 cases in each group). Over 12 weeks, the control group was given routine aerobic exercise intervention, while the study group was given high-intensity intermittent training. The blood sugar level, blood lipid level, and body measurements of the students were measured before and after intervention and compared between the two groups. RESULTS After 12 weeks of intervention, the body weight, waist circumference, waist-hip ratio, body mass index (BMI), body fat rate (BFR), serum level of insulin, low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and triglyceride (TG) of the college students were significantly lower than before intervention, and the differences were statistically significant (P<0.05). There were no significant differences in body weight, waist circumference, waist-hip ratio, BMI, or BFR between the two groups (P>0.05). The study group had significantly lower serum levels of TC, TG, and insulin than the control group, and the differences were statistically significant (P<0.05). CONCLUSIONS Aerobic exercise and high-intensity intermittent training both significantly improved the body shape of obese male college students. However, high-intensity intermittent training improved the glycolipid metabolism of obese male college students to a greater extent than aerobic exercise did.",2020,"There were no significant differences in body weight, waist circumference, waist-hip ratio, BMI, or BFR between the two groups (P>0.05).","['300 obese male college students', 'obese male college students', 'college students']","['Aerobic exercise', 'Aerobic exercise and high-intensity intermittent training', 'high-intensity intermittent training', 'routine aerobic exercise intervention']","['blood sugar level, blood lipid level, and body measurements of the students', 'body weight, waist circumference, waist-hip ratio, body mass index (BMI), body fat rate (BFR), serum level of insulin, low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and triglyceride (TG) of the college students', 'body weight, waist circumference, waist-hip ratio, BMI, or BFR', 'serum levels of TC, TG, and insulin', 'glycolipid metabolism', 'body shape']","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0428460', 'cui_str': 'Lipid level - finding'}, {'cui': 'C0203910', 'cui_str': 'Body measurement'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0205682', 'cui_str': 'Waist/hip ratio'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0017950', 'cui_str': 'Glycolipid'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0332479', 'cui_str': 'Shape finding'}]",300.0,0.0200114,"There were no significant differences in body weight, waist circumference, waist-hip ratio, BMI, or BFR between the two groups (P>0.05).","[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': 'Qufu Normal University, Qufu 273165, China.'}, {'ForeName': 'Wenjuan', 'Initials': 'W', 'LastName': 'Cheng', 'Affiliation': 'Qufu Normal University, Qufu 273165, China.'}, {'ForeName': 'Zhengzheng', 'Initials': 'Z', 'LastName': 'Fan', 'Affiliation': 'Qufu Normal University, Qufu 273165, China.'}, {'ForeName': 'Xuelin', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Qufu Normal University, Qufu 273165, China. xuezhezhang@yeah.net.'}]",Annals of palliative medicine,['10.21037/apm-20-1105'] 2680,32762229,A randomized clinical study of the treatment of white lesions of the vulva with a fractional ultrapulsed CO2 laser.,"BACKGROUND White lesions of the vulva are a common vulvar disease of unclear etiology. Although a variety of treatments have been used to treat the disease in clinical practice, there is currently a lack of effective radical therapies. This study aimed to compare the feasibility and effectiveness of fractional ultrapulsed CO2 laser with that of high-intensity focused ultrasound in the treatment of white lesions of the vulva. METHODS A total of 60 patients with pruritus vulvae who were treated at the Center for Diagnosis and Treatment of Cervical Diseases in our hospital between December, 2017, and December 2018 were enrolled in this study. The possibility of malignant lesions of the vulva was ruled out by histopathological diagnosis following colposcopic biopsy. The patients were randomly divided into two groups: a laser treatment group (group L, n=30) and a focused ultrasound treatment group (group U, n=30). The patients were monitored for changes in signs and symptoms during and after treatment, and the treatment outcomes of the two groups were compared. RESULTS The local symptoms of pruritus were alleviated by both the fractional ultrapulsed CO2 laser and high-intensity focused ultrasound. The patients in group L had no significant adverse reactions during the operation and needed no special postoperative treatment. The total effective rate in group L was 96.7%. In group U, five patients felt mild burning during the operation, painful blisters arose on the skin of the ablated area, and long-lasting local edema was observed. Seven patients had subcutaneous nodules. The total effective rate in group U was 90.0%. CONCLUSIONS Fractional ultrapulsed CO2 laser is a minimally invasive, effective, and safe treatment for white lesions of the vulva. It causes few complications and does not affect the daily and working life of patients. Therefore, it should be widely applied in clinical practice.",2020,"CONCLUSIONS Fractional ultrapulsed CO2 laser is a minimally invasive, effective, and safe treatment for white lesions of the vulva.","['Seven patients had subcutaneous nodules', '60 patients with pruritus vulvae who were treated at the Center for Diagnosis and Treatment of Cervical Diseases in our hospital between December, 2017, and December 2018 were enrolled in this study', 'white lesions of the vulva', 'white lesions of the vulva with a fractional ultrapulsed CO2 laser']","['fractional ultrapulsed CO2 laser', 'Fractional ultrapulsed CO2 laser', 'laser treatment group']","['total effective rate', 'adverse reactions', 'local symptoms of pruritus']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0151811', 'cui_str': 'Subcutaneous nodule'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0033778', 'cui_str': 'Pruritus of vulva'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0007867', 'cui_str': 'Disorder of uterine cervix'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0042993', 'cui_str': 'Vulval structure'}, {'cui': 'C0392251', 'cui_str': 'Carbon dioxide laser device'}]","[{'cui': 'C0392251', 'cui_str': 'Carbon dioxide laser device'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0033774', 'cui_str': 'Itching'}]",60.0,0.0199897,"CONCLUSIONS Fractional ultrapulsed CO2 laser is a minimally invasive, effective, and safe treatment for white lesions of the vulva.","[{'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Center for Diagnosis and Treatment of Cervical Diseases, Changzhou Maternal and Child Health Care Hospital, Nanjing Medical University, Changzhou, China.'}, {'ForeName': 'Yiqing', 'Initials': 'Y', 'LastName': 'Lai', 'Affiliation': 'Center for Diagnosis and Treatment of Cervical Diseases, Changzhou Maternal and Child Health Care Hospital, Nanjing Medical University, Changzhou, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Wan', 'Affiliation': 'Center for Diagnosis and Treatment of Cervical Diseases, Changzhou Maternal and Child Health Care Hospital, Nanjing Medical University, Changzhou, China.'}, {'ForeName': 'Beibei', 'Initials': 'B', 'LastName': 'Zhou', 'Affiliation': 'Center for Diagnosis and Treatment of Cervical Diseases, Changzhou Maternal and Child Health Care Hospital, Nanjing Medical University, Changzhou, China.'}, {'ForeName': 'Xian', 'Initials': 'X', 'LastName': 'Qiang', 'Affiliation': 'Department of Pathology, Changzhou Maternal and Child Care Health Hospital, Nanjing Medical University, Changzhou, China.'}, {'ForeName': 'Sumei', 'Initials': 'S', 'LastName': 'Ge', 'Affiliation': 'Department of Pathology, Changzhou Maternal and Child Care Health Hospital, Nanjing Medical University, Changzhou, China.'}, {'ForeName': 'Keliang', 'Initials': 'K', 'LastName': 'Zhang', 'Affiliation': 'Center for Diagnosis and Treatment of Cervical Diseases, Changzhou Maternal and Child Health Care Hospital, Nanjing Medical University, Changzhou, China. keliangzhang@njmu.edu.cn.'}, {'ForeName': 'Zhilei', 'Initials': 'Z', 'LastName': 'Mao', 'Affiliation': 'Center for Diagnosis and Treatment of Cervical Diseases, Changzhou Maternal and Child Health Care Hospital, Nanjing Medical University, Changzhou, China. mao598808386@126.com.'}]",Annals of palliative medicine,['10.21037/apm-20-1085'] 2681,32762271,Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.,"We report final analysis outcomes from the phase 3 HELIOS study (NCT01611090). Patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma without deletion 17p ( n  = 578) were randomized 1:1 to 420 mg daily ibrutinib or placebo plus ≤6 cycles of bendamustine plus rituximab (BR), followed by ibrutinib or placebo alone. Median follow-up was 63.7 months. Median investigator-assessed progression-free survival was longer with ibrutinib plus BR (65.1 months) than placebo plus BR (14.3 months; hazard ratio [HR] 0.229 [95% confidence interval (CI) 0.183-0.286]; p  < .0001). Despite crossover of 63.3% of patients from the placebo plus BR arm to ibrutinib treatment upon disease progression, ibrutinib plus BR versus placebo plus BR demonstrated an overall survival benefit (HR 0.611 [95% CI 0.455-0.822]; p  = .0010; median not reached in either arm). Long-term follow-up data confirm the survival benefit of ibrutinib plus BR over BR alone. Safety profiles were consistent with those known for ibrutinib and BR.",2020,Median investigator-assessed progression-free survival was longer with ibrutinib plus BR (65.1 months) than placebo plus BR (14.3 months; hazard ratio [HR] 0.229,"['patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma', 'Patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma without deletion 17p ( n \u2009=\u2009578']","['placebo plus ≤6 cycles of bendamustine plus rituximab (BR), followed by ibrutinib or placebo alone', 'bendamustine and rituximab', 'placebo']","['survival benefit', 'Median investigator-assessed progression-free survival', 'overall survival benefit']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0278791', 'cui_str': 'Chronic lymphocytic leukaemia refractory'}, {'cui': 'C0023434', 'cui_str': 'Chronic lymphocytic leukemia'}, {'cui': 'C0008628', 'cui_str': 'Chromosomal deletion'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0525079', 'cui_str': 'bendamustine'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C3501358', 'cui_str': 'Ibrutinib'}]","[{'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",578.0,0.538994,Median investigator-assessed progression-free survival was longer with ibrutinib plus BR (65.1 months) than placebo plus BR (14.3 months; hazard ratio [HR] 0.229,"[{'ForeName': 'Graeme A M', 'Initials': 'GAM', 'LastName': 'Fraser', 'Affiliation': 'Juravinski Cancer Centre, McMaster University, Hamilton, Canada.'}, {'ForeName': 'Asher', 'Initials': 'A', 'LastName': 'Chanan-Khan', 'Affiliation': 'Division of Hematology, Mayo Clinic Cancer Center, Jacksonville, FL, USA.'}, {'ForeName': 'Fatih', 'Initials': 'F', 'LastName': 'Demirkan', 'Affiliation': 'Division of Hematology, Dokuz Eylul University, Izmir, Turkey.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Santucci Silva', 'Affiliation': 'IEP São Lucas/Hemomed Oncologia e Hematologia, São Paulo, Brazil.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Grosicki', 'Affiliation': 'Department of Hematology and Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Janssens', 'Affiliation': 'Universitaire Ziekenhuizen Leuven, Leuven, Belgium.'}, {'ForeName': 'Jiri', 'Initials': 'J', 'LastName': 'Mayer', 'Affiliation': 'Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Jihlavska, Brno, Czech Republic.'}, {'ForeName': 'Nancy L', 'Initials': 'NL', 'LastName': 'Bartlett', 'Affiliation': 'Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.'}, {'ForeName': 'Marie-Sarah', 'Initials': 'MS', 'LastName': 'Dilhuydy', 'Affiliation': 'Hopital Haut Leveque, Bordeaux, France.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Loscertales', 'Affiliation': 'Hematology Department, Hospital Universitario La Princesa, IIS-IP, Madrid, Spain.'}, {'ForeName': 'Abraham', 'Initials': 'A', 'LastName': 'Avigdor', 'Affiliation': 'Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, University of Tel-Aviv, Tel-Aviv, Israel.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Rule', 'Affiliation': 'Department of Haematology, University of Plymouth Medical School, Plymouth, UK.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Samoilova', 'Affiliation': 'Nizhny Novogorod Regional Clinical Hospital, Nizhny Novogorod, Russia.'}, {'ForeName': 'Miguel A', 'Initials': 'MA', 'LastName': 'Pavlovsky', 'Affiliation': 'Department of Hematology, Fundaleu, Buenos Aires, Argentina.'}, {'ForeName': 'Andre', 'Initials': 'A', 'LastName': 'Goy', 'Affiliation': 'John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Mato', 'Affiliation': 'Memorial Sloan-Kettering Cancer Center, NY, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hallek', 'Affiliation': 'Department I of Internal Medicine and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.'}, {'ForeName': 'Mariya', 'Initials': 'M', 'LastName': 'Salman', 'Affiliation': 'Janssen Research & Development, Raritan, NJ, USA.'}, {'ForeName': 'Monelle', 'Initials': 'M', 'LastName': 'Tamegnon', 'Affiliation': 'Janssen Research & Development, Raritan, NJ, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Sun', 'Affiliation': 'Janssen Research & Development, Raritan, NJ, USA.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Connor', 'Affiliation': 'Janssen Research & Development, Spring House, PA, USA.'}, {'ForeName': 'Kerri', 'Initials': 'K', 'LastName': 'Nottage', 'Affiliation': 'Janssen Research & Development, Raritan, NJ, USA.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Schuier', 'Affiliation': 'Janssen-Cilag, Neuss, Germany.'}, {'ForeName': 'Sriram', 'Initials': 'S', 'LastName': 'Balasubramanian', 'Affiliation': 'Janssen Research & Development, Spring House, PA, USA.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Howes', 'Affiliation': 'Janssen Research & Development, High Wycombe, UK.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Cramer', 'Affiliation': 'Department I of Internal Medicine and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.'}]",Leukemia & lymphoma,['10.1080/10428194.2020.1795159'] 2682,32762272,The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study.,"BACKGROUND Cannabidiol (CBD) is being investigated as a potential treatment for several medical indications, many of which are characterised by altered memory processing. However, the mechanisms underlying these effects are unclear. AIMS Our primary aim was to investigate how CBD influences cerebral blood flow (CBF) in regions involved in memory processing. Our secondary aim was to determine if the effects of CBD on CBF were associated with differences in working and episodic memory task performance. METHODS We used a randomised, crossover, double-blind design in which 15 healthy participants were administered 600 mg oral CBD or placebo on separate days. We measured regional CBF at rest using arterial spin labelling 3 h after drug ingestion. We assessed working memory with the digit span (forward, backward) and n-back (0-back, 1-back, 2-back) tasks, and we used a prose recall task (immediate and delayed) to assess episodic memory. RESULTS CBD increased CBF in the hippocampus (mean (95% confidence intervals) = 15.00 (5.78-24.21) mL/100 g/min, t 14 = 3.489, Cohen's d = 0.75, p = 0.004). There were no differences in memory task performance, but there was a significant correlation whereby greater CBD-induced increases in orbitofrontal CBF were associated with reduced reaction time on the 2-back working memory task ( r = -0.73, p = 0.005). CONCLUSIONS These findings suggest that CBD increases CBF to key regions involved in memory processing, particularly the hippocampus. These results identify potential mechanisms of CBD for a range of conditions associated with altered memory processing, including Alzheimer's disease, schizophrenia, post-traumatic stress disorder and cannabis-use disorders.",2020,"RESULTS CBD increased CBF in the hippocampus (mean (95% confidence intervals) = 15.00 (5.78-24.21) mL/100 ",['15 healthy participants'],"['600\u2009mg oral CBD or placebo', 'CBD']","['working and episodic memory task performance', 'working memory with the digit span (forward, backward) and n-back (0-back, 1-back, 2-back) tasks', 'orbitofrontal CBF', 'memory task performance', 'regional CBF', 'reduced reaction time on the 2-back working memory task', 'cerebral blood flow and its relationship to memory', 'CBF', 'cerebral blood flow (CBF']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0006863', 'cui_str': 'Cannabidiol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0439780', 'cui_str': 'Forward'}, {'cui': 'C0439781', 'cui_str': 'Backward'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}]",15.0,0.313018,"RESULTS CBD increased CBF in the hippocampus (mean (95% confidence intervals) = 15.00 (5.78-24.21) mL/100 ","[{'ForeName': 'Michael A P', 'Initials': 'MAP', 'LastName': 'Bloomfield', 'Affiliation': 'Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, UK.'}, {'ForeName': 'Sebastian F', 'Initials': 'SF', 'LastName': 'Green', 'Affiliation': 'Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, UK.'}, {'ForeName': 'Chandni', 'Initials': 'C', 'LastName': 'Hindocha', 'Affiliation': 'Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, UK.'}, {'ForeName': 'Yumeya', 'Initials': 'Y', 'LastName': 'Yamamori', 'Affiliation': 'Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, UK.'}, {'ForeName': 'Jocelyn Lok Ling', 'Initials': 'JLL', 'LastName': 'Yim', 'Affiliation': 'Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, UK.'}, {'ForeName': 'Augustus P M', 'Initials': 'APM', 'LastName': 'Jones', 'Affiliation': 'Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, UK.'}, {'ForeName': 'Hannah R', 'Initials': 'HR', 'LastName': 'Walker', 'Affiliation': 'Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, UK.'}, {'ForeName': 'Pawel', 'Initials': 'P', 'LastName': 'Tokarczuk', 'Affiliation': 'Medical Research Council London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London, UK.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Statton', 'Affiliation': 'Medical Research Council London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London, UK.'}, {'ForeName': 'Oliver D', 'Initials': 'OD', 'LastName': 'Howes', 'Affiliation': 'Psychiatric Imaging Group, Medical Research Council London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London, UK.'}, {'ForeName': 'H Valerie', 'Initials': 'HV', 'LastName': 'Curran', 'Affiliation': 'Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.'}, {'ForeName': 'Tom P', 'Initials': 'TP', 'LastName': 'Freeman', 'Affiliation': 'Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, UK.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881120936419'] 2683,32762462,Faith Beliefs of African American Church Leaders Are Aligned With the Principles of Palliative and Hospice Care: A Community-Based Assessment and Intervention.,"BACKGROUND African American (AA) church leaders often advise AAs with serious and life-limiting illnesses (LLIs). OBJECTIVES 1) determine beliefs of AA church leaders about palliative care and hospice care (PCHC), 2) assess association of participants' attitude about encouraging a loved one to learn about PCHC with whether PC or HC is consistent with faith beliefs and can reduce suffering and bring comfort, and 3) evaluate an interactive, educational intervention. DESIGN prospective, one group, pre and post assessment of beliefs and attitudes Settings/Subjects: 100 church leaders from 3 AA Churches and one AA Church Consortium. RESULTS At baseline, participants held more receptive beliefs about HC than about PC. Those who reported knowing the meaning of PC believed PC is consistent with their faith (81% vs 28%, phi=.53) and can reduce suffering and bring comfort (86% vs 38%, phi =.50). Participants who believed PC was consistent with their faith were more likely to encourage a loved one with a LLI to learn about PCHC than did participants who did not (100% vs 77%, phi =.39, p < 0.001). Post intervention, more participants: 1) perceived that they knew the meaning of PC (48% vs 96%), 2) viewed PC as consistent with their faith (58% vs. 94%), and 3) viewed PC as a means to reduce suffering and bring comfort (67% vs 93%) with a p < 0.0001 for each item. The post intervention results for HC were variable. CONCLUSIONS Faith beliefs of AA Church leaders may be aligned with the principles of PCHC.",2020,"Post intervention, more participants: 1) perceived that they knew the meaning of PC (48% vs 96%), 2) viewed PC as consistent with their faith (58% vs. 94%), and 3) viewed PC as a means to reduce suffering and bring comfort (67% vs 93%) with a p < 0.0001 for each item.","['African American Church Leaders', 'beliefs and attitudes Settings/Subjects: 100 church leaders from 3 AA Churches and one AA Church Consortium', 'African American (AA) church leaders']",[],['suffering and bring comfort'],"[{'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0562324', 'cui_str': 'Church'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C1704407', 'cui_str': '100'}]",[],"[{'cui': 'C0332302', 'cui_str': 'Brought on by'}]",,0.0509667,"Post intervention, more participants: 1) perceived that they knew the meaning of PC (48% vs 96%), 2) viewed PC as consistent with their faith (58% vs. 94%), and 3) viewed PC as a means to reduce suffering and bring comfort (67% vs 93%) with a p < 0.0001 for each item.","[{'ForeName': 'Jerry', 'Initials': 'J', 'LastName': 'Johnson', 'Affiliation': 'Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'Hayden', 'Affiliation': 'Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Lynne Allen', 'Initials': 'LA', 'LastName': 'Taylor', 'Affiliation': 'Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Arthur Gilbert', 'Affiliation': 'Pastoral Counselor, Wissahickon Hospice, Philadelphia, PA, USA.'}]",The American journal of hospice & palliative care,['10.1177/1049909120948225'] 2684,32757702,The Effect of Metalinguistic Sentence Combining on Eighth-Grade Students' Understanding and Written Expression of Comparison and Contrast in Science.,"Purpose The purpose of this study was to examine whether sentence combining with an explicit metalinguistic approach in comparison to typical science instruction was effective in improving written expression and understanding of comparison/contrast in science for eighth-grade students who struggle with literacy. Method Eighty-four eighth-grade students who struggle with literacy participated in this study. The experimental group ( n = 36) received the writing intervention of metalinguistic sentence combining (MSC) during their science class for a total of 400 min (20 intervention sessions, 20 min each), while the comparison group ( n = 48) participated in their typical science instruction. Total science instruction time was held constant for both groups. All students completed pretests and posttests to determine an increase in (a) syntactic factors of academic science text such as longer sentence length and use of syntactic forms of connectives, targeted connectives, left embeddedness, and agentless passive voice when responding to a science compare and contrast writing prompt; and (b) listing similarities and differences between two science concepts on a graphic organizer. Results Treatment was effective in improving the experimental group's score in listing similarities and differences between two science concepts on a graphic organizer. There were no significant differences between the two groups in their use of syntactic factors typical of academic text when responding to a science compare and contrast writing prompt. Conclusions MSC was effective in improving the experimental student's ability to demonstrate understanding of comparison and contrast in science. Modifications to the MSC intervention may yield better results in the experimental group's posttreatment writing in future studies. Supplemental Material https://doi.org/10.23641/asha.12735950.",2020,There were no significant differences between the two groups in their use of syntactic factors typical of academic text when responding to a science compare and contrast writing prompt.,"['Method Eighty-four eighth-grade students who struggle with literacy participated in this study', 'for eighth-grade students who struggle with literacy']","['Metalinguistic Sentence', 'writing intervention of metalinguistic sentence combining (MSC', 'academic science text such as longer sentence length and use of syntactic forms of connectives, targeted connectives, left embeddedness, and agentless passive voice when responding to a science compare and contrast writing prompt', 'MSC intervention', 'typical science instruction']","['Total science instruction time', 'written expression and understanding of comparison/contrast in science']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319623', 'cui_str': '84'}, {'cui': 'C0205442', 'cui_str': 'Eighth'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0074299', 'cui_str': 'selenomethylselenocysteine'}, {'cui': 'C0036397', 'cui_str': 'Science'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0018582', 'cui_str': 'Handwriting'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0036397', 'cui_str': 'Science'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}]",84.0,0.0210589,There were no significant differences between the two groups in their use of syntactic factors typical of academic text when responding to a science compare and contrast writing prompt.,"[{'ForeName': 'Lynne', 'Initials': 'L', 'LastName': 'Telesca', 'Affiliation': 'Department of Communication Disorders, State University of New York at New Paltz.'}, {'ForeName': 'Barbara J', 'Initials': 'BJ', 'LastName': 'Ehren', 'Affiliation': 'Student Success Initiatives, Inc., Anna Maria, Student Success Initiatives, Inc., Anna Maria, FL.'}, {'ForeName': 'Debbie L', 'Initials': 'DL', 'LastName': 'Hahs-Vaughn', 'Affiliation': 'Department of Learning Sciences and Educational Research, University of Central Florida, Orlando.'}, {'ForeName': 'Vassiliki Vicky I', 'Initials': 'VVI', 'LastName': 'Zygouris-Coe', 'Affiliation': 'School of Teacher Education, University of Central Florida, Orlando.'}, {'ForeName': 'Anthony Pak-Hin', 'Initials': 'AP', 'LastName': 'Kong', 'Affiliation': 'School of Communication Sciences and Disorders, University of Central Florida, Orlando.'}]","Journal of speech, language, and hearing research : JSLHR",['10.1044/2020_JSLHR-19-00086'] 2685,32757725,Cognitive and Skill Performance of Individuals in Sitting versus Standing Workstations: A Quasi-experimental Study.,"Purpose: This study aimed to assess cognitive and skill performances in sitting and standing workstations among 40 students of Shiraz University of Medical Sciences. Materials and Methods: In this quasi-experimental study, a total of 40 students (20 females and 20 males) participated. The tests were performed among randomly selected participants over two consecutive days as follows: Day 1: Beck depression inventory (BDI) and Beck anxiety inventory (BAI) were used to assess the severity of depression and anxiety in the study participants, respectively. Raven's general intelligence test was used to measure intelligence quotient (IQ). Day 2: five performance assessment tests (cognitive performance assessment tests: 'n-back', 'Stroop', and 'advanced reaction time', and skill performance assessment tests: 'two arm coordination', and 'Purdue pegboard') were randomly selected and were presented to individuals in each workstation (sitting and standing workstations). At the end of each sitting and standing position, the comfort of the workstation was measured using a visual analogue scale (VAS). Results: The results showed no statistically significant difference between the sitting and standing positions in terms of 'n-back', 'Stroop', 'advanced reaction time', 'two arm coordination', and 'Purdue pegboard'. Participants were more comfortable in sitting positions and more easily distracted in standing positions. Conclusions: sitting and standing positions had no significant effects on the participants' cognitive and skill performances.",2020,"The results showed no statistically significant difference between the sitting and standing positions in terms of 'n-back', 'Stroop', 'advanced reaction time', 'two arm coordination', and 'Purdue pegboard'.","['40 students of Shiraz University of Medical Sciences', '40 students (20 females and 20 males) participated']",['Sitting versus Standing Workstations'],"['severity of depression and anxiety', 'visual analogue scale (VAS', 'Cognitive and Skill Performance', 'intelligence quotient (IQ', 'comfortable in sitting positions', ""participants' cognitive and skill performances"", ""sitting and standing positions in terms of 'n-back', 'Stroop', 'advanced reaction time', 'two arm coordination', and 'Purdue pegboard"", 'Beck depression inventory (BDI) and Beck anxiety inventory (BAI', ""performance assessment tests (cognitive performance assessment tests: 'n-back', 'Stroop', and 'advanced reaction time', and skill performance assessment tests: 'two arm coordination', and 'Purdue pegboard"", 'cognitive and skill performances']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C1736830', 'cui_str': 'Workstation'}]","[{'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0456149', 'cui_str': 'Intelligence quotient'}, {'cui': 'C0277814', 'cui_str': 'Sitting position'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",40.0,0.0234461,"The results showed no statistically significant difference between the sitting and standing positions in terms of 'n-back', 'Stroop', 'advanced reaction time', 'two arm coordination', and 'Purdue pegboard'.","[{'ForeName': 'Matin', 'Initials': 'M', 'LastName': 'Rostami', 'Affiliation': 'Department of Ergonomics, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Razeghi', 'Affiliation': 'Department of Physiotherapy, School of Rehabilitation Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Hadi', 'Initials': 'H', 'LastName': 'Daneshmandi', 'Affiliation': 'Research Center for Health Sciences, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Jafar', 'Initials': 'J', 'LastName': 'Hasanzadeh', 'Affiliation': 'Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Choobineh', 'Affiliation': 'Research Center for Health Sciences, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",International journal of occupational safety and ergonomics : JOSE,['10.1080/10803548.2020.1806565'] 2686,32757736,Cosmetic camouflage improves health-related quality of life in women with systemic lupus erythematosus and permanent skin damage: A controlled intervention study.,"OBJECTIVE To investigate the effect of cosmetic camouflage in health-related quality of life (HRQoL) in women with systemic lupus erythematosus (SLE) and permanent facial skin damage. METHODS This is a randomized controlled clinical trial (Universal Trial Number: U1111-1210-2554e) with SLE women from outpatients using ACR/1997 and/or SLICC/2012 criteria, aged over 18 years old, with modified SLEDAI 2k < 4 and permanent facial skin damage, recruited in two tertiary centers to use cosmetic camouflage (n = 36) or no intervention (n = 20). Endpoints were score variations in SLE Quality of Life (SLEQoL) (total and each domain), Dermatology Life Quality Index (DLQI), Rosenberg self-esteem scale and Hospital Anxiety and Depression Scale (HADS), after daily use of cosmetic camouflage for 12 +/-2 weeks (Phase I), ""as needed"" use of cosmetic camouflage for another 12 +/-2 weeks (Phase II), and during total follow up (24 +/-2 weeks). Univariate and multivariate linear regressions were conducted by protocol analysis. RESULTS Both groups were similar at baseline regarding age, disease duration, socio-demographic, clinical, laboratory and treatment characteristics. The comparison of score variations between intervention and control groups showed an independent HRQoL improvement in total SLEQoL score after using cosmetic camouflage in Phase I [β -27.56 (CI 95% -47.86 to -7.27) p = 0.009] and total follow up [β -28.04 (CI 95% -48.65 to -7.44) p = 0.09], specifically in mood, self-image and physical functioning domains. Also, there was an improvement in DLQI scores during Phase I [β -7.65 (CI 95% -12.31 to -3.00) p = 0.002] and total follow up [β -8.97(CI95% -12.99 to -4.94) p < 0.001). Scores for depression [β -1.92 (CI 95% -3.67 to -0.16) p = 0.033], anxiety [β -2.87 (CI 95% -5.67 to -0.07] p = 0.045] and self-esteem [β 2.79 (CI 95% 0.13 to 5.46) p = 0.041] improved considering the total follow up. No significant changes occurred in the control group scores. CONCLUSION The use of cosmetic camouflage improved the HRQoL in female SLE patients with permanent facial skin damage.",2020,"Scores for depression [β -1.92 (CI 95% -3.67 to -0.16) p = 0.033], anxiety [β -2.87 (CI 95% -5.67 to -0.07] p = 0.045] and self-esteem [β 2.79 (CI 95% 0.13 to 5.46) p = 0.041] improved considering the total follow up.","['women with systemic lupus erythematosus and permanent skin damage', 'women with systemic lupus erythematosus (SLE) and permanent facial skin damage', ' U1111-1210-2554e) with SLE women from outpatients using ACR/1997 and/or SLICC/2012 criteria, aged over 18\u2009years old, with modified SLEDAI 2k\u2009<\u20094 and permanent facial skin damage, recruited in two tertiary centers to use cosmetic camouflage (n\u2009=\u200936) or no intervention (n\u2009=\u200920', 'female SLE patients with permanent facial skin damage']","['Cosmetic camouflage', 'cosmetic camouflage']","['health-related quality of life (HRQoL', 'total and each domain), Dermatology Life Quality Index (DLQI), Rosenberg self-esteem scale and Hospital Anxiety and Depression Scale (HADS), after daily use of cosmetic camouflage for 12 +/-2 weeks (Phase I), ""as needed"" use of cosmetic camouflage', 'mood, self-image and physical functioning domains', 'anxiety', 'health-related quality of life', 'score variations in SLE Quality of Life (SLEQoL', 'DLQI scores', 'total SLEQoL score', 'self-esteem']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0024141', 'cui_str': 'Systemic lupus erythematosus'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0222084', 'cui_str': 'Skin structure of face'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451528', 'cui_str': 'Systemic lupus erythematosus disease activity index'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0010164', 'cui_str': 'Cosmetic'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0451112', 'cui_str': 'Dermatology life quality index'}, {'cui': 'C0582666', 'cui_str': 'Rosenberg self-esteem scale'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0242498', 'cui_str': 'Self-image'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0024141', 'cui_str': 'Systemic lupus erythematosus'}, {'cui': 'C4706308', 'cui_str': 'DLQI (Dermatology Life Quality Index) score'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}]",,0.109806,"Scores for depression [β -1.92 (CI 95% -3.67 to -0.16) p = 0.033], anxiety [β -2.87 (CI 95% -5.67 to -0.07] p = 0.045] and self-esteem [β 2.79 (CI 95% 0.13 to 5.46) p = 0.041] improved considering the total follow up.","[{'ForeName': 'Fernando Afrânio Palmeira de', 'Initials': 'FAP', 'LastName': 'Oliveira', 'Affiliation': 'School of Medicine, Universidade Federal of Minas Gerais, Universidade Federal of Minas Gerais-UFMG, Belo Horizonte, Brazil.'}, {'ForeName': 'Fabiana de Miranda Moura Dos', 'Initials': 'FMMD', 'LastName': 'Santos', 'Affiliation': 'Department of Locomotor Apparatus, School of Medicine, Universidade Federal of Minas Gerais-UFMG, Belo Horizonte, Brazil.'}, {'ForeName': 'Ana Flávia Madureira de Pádua', 'Initials': 'AFMP', 'LastName': 'Dias', 'Affiliation': 'Santa Casa Group of Belo Horizonte, Belo Horizonte, Brazil.'}, {'ForeName': 'Claudia Lopes Santoro', 'Initials': 'CLS', 'LastName': 'Neiva', 'Affiliation': 'Santa Casa Group of Belo Horizonte, Belo Horizonte, Brazil.'}, {'ForeName': 'Rosa Weiss', 'Initials': 'RW', 'LastName': 'Telles', 'Affiliation': 'Department of Internal Medicine, School of Medicine, Universidade Federal of Minas Gerais-UFMG, Belo Horizonte, Brazil.'}, {'ForeName': 'Cristina Costa Duarte', 'Initials': 'CCD', 'LastName': 'Lanna', 'Affiliation': 'Department of Locomotor Apparatus, School of Medicine, Universidade Federal of Minas Gerais-UFMG, Belo Horizonte, Brazil.'}]",Lupus,['10.1177/0961203320947802'] 2687,32757777,Long-term Outcome of Local Steroid Injections Versus Surgery in Carpal Tunnel Syndrome: Observational Extension of a Randomized Clinical Trial.,"Background: In a previous paper, we have demonstrated that: (1) local injection of corticosteroids for carpal tunnel syndrome (CTS) is as effective as decompressive surgery, at 1-year follow-up; and (2) surgery has an additional benefit in the 2-year follow-up. In this study, we assess the long-term outcomes of both therapies in an observational extension of the patients originally enrolled in our randomized clinical trial. Methods: Patients were included in an open, randomized clinical trial, comparing injections versus surgery in CTS. After the end of the clinical trial, patients received the treatment prescribed by their general practitioner or specialist. Therapeutic failure was defined as the need of any new therapeutic intervention on the involved wrist. Comparison between groups was made using Cox multiple regression analysis. Estimation of the accumulated incidence of new therapeutic failure was made considering the withdrawal as a competitive risk (Gooley's test). Results: Of 163 randomized wrists at the beginning of the study, only 148 were available at the final follow-up. The mean follow-up was 6.3 and the median was 5.9 years. In the long-term follow-up, the accumulated incidence of therapeutic failure in the surgery group was 11.6% versus 41.8% in the injection group. The Cox multiple regression analysis showed a risk of failure associated with injection group of 4.5 (95% confidence interval [CI], 2.1-9.8; P < .0001). Conclusions: In long-term follow-up, surgery seems more effective than local corticosteroid injections in primary CTS. Nonetheless, about 58% of the patients in the injection group will not need further therapeutic interventions during the follow-up.",2020,"The Cox multiple regression analysis showed a risk of failure associated with injection group of 4.5 (95% confidence interval [CI], 2.1-9.8; P < .0001). ","['Carpal Tunnel Syndrome', 'carpal tunnel syndrome (CTS']","['injections versus surgery in CTS', 'corticosteroids', 'Local Steroid Injections Versus Surgery']",['therapeutic failure'],"[{'cui': 'C0007286', 'cui_str': 'Carpal tunnel syndrome'}]","[{'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C1261311', 'cui_str': 'Injection of steroid'}]","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0231174', 'cui_str': 'Failure'}]",,0.071358,"The Cox multiple regression analysis showed a risk of failure associated with injection group of 4.5 (95% confidence interval [CI], 2.1-9.8; P < .0001). ","[{'ForeName': 'Domingo', 'Initials': 'D', 'LastName': 'Ly-Pen', 'Affiliation': 'Abbey House Medical Centre, Navan, Ireland.'}, {'ForeName': 'José Luis', 'Initials': 'JL', 'LastName': 'Andreu', 'Affiliation': 'Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Millán', 'Affiliation': 'Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.'}, {'ForeName': 'Gema', 'Initials': 'G', 'LastName': 'de Blas', 'Affiliation': 'Hospital Universitario Ramón y Cajal, Madrid, Spain.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Sánchez-Olaso', 'Affiliation': 'Hospital Universitario Ramón y Cajal, Madrid, Spain.'}]","Hand (New York, N.Y.)",['10.1177/1558944720944263'] 2688,32757822,Effect of Acupressure on Dynamic Balance in Elderly Women: A Randomized Controlled Trial.,"BACKGROUND Balance disorders are common in the elderly and are a major cause of falls. This study aimed to determine the effect of acupressure on dynamic balance in elderly women. METHODS This randomized controlled clinical trial was conducted on 72 elderly women in Qazvin, Iran. The intervention group received rotary massage using the thumb at the pressure points for 4 weeks, 3 times a week for 20 minutes each session. Dynamic balance in both groups was measured before, 2 and 4 weeks after the intervention using timed up and go test and the step test. Data were analyzed using two way repeated measures ANOVA. RESULTS The mean age of participants was 67.34 ± 6.30 with a range of 60 to 80 years old. The results showed statistically significant improvement in the dynamic balance quantified by timed up and go test (%Δ = 26.53) and step test for the right (%Δ = 35.22) and left (Δ% = 32.62) legs ( p < .001). However, in the control group, no significant change was observed in the dynamic balance after completion of the program. CONCLUSION The results support that acupressure therapy can be an effective, safe, and inexpensive method to improve the dynamic balance and maintain maximum autonomy of the elderly.",2020,The results showed statistically significant improvement in the dynamic balance quantified by timed up and go test (%Δ = 26.53) and step test for the right (%Δ = 35.22) and left (Δ% = 32.62) legs ( p < .001).,"['The mean age of participants was 67.34\xa0±\xa06.30 with a range of 60 to 80\xa0years old', 'Elderly Women', '72 elderly women in Qazvin, Iran', 'elderly women']","['Acupressure', 'rotary massage', 'acupressure', 'acupressure therapy']","['Dynamic balance', 'Dynamic Balance', 'dynamic balance']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0524338', 'cui_str': 'Elderly woman'}, {'cui': 'C0022065', 'cui_str': 'Iran'}]","[{'cui': 'C0282614', 'cui_str': 'Acupressure'}, {'cui': 'C0024875', 'cui_str': 'Massage'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]",72.0,0.0333272,The results showed statistically significant improvement in the dynamic balance quantified by timed up and go test (%Δ = 26.53) and step test for the right (%Δ = 35.22) and left (Δ% = 32.62) legs ( p < .001).,"[{'ForeName': 'Seyedeh Ameneh', 'Initials': 'SA', 'LastName': 'Motalebi', 'Affiliation': 'Social Determinants of Health Research Center (SDH), Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences , Qazvin, Iran.'}, {'ForeName': 'Zeinab', 'Initials': 'Z', 'LastName': 'Zajkani', 'Affiliation': 'Student Research Committee, School of Nursing and Midwifery, Qazvin University of Medical Sciences , Qazvin, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Mohammadi', 'Affiliation': 'Social Determinants of Health Research Center (SDH), Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences , Qazvin, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Habibi', 'Affiliation': 'Irannian Scientific Accupancture , Tehran, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Mafi', 'Affiliation': 'School of Nursing and Midwifery, Qazvin University of Medical Sciences , Qazvin, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Ranjkesh', 'Affiliation': 'Children Growth Research Center, Research Institute for Prevention of Non Communicable Diseases, Qazvin University of Medical Sciences , Qazvin, Iran.'}]",Experimental aging research,['10.1080/0361073X.2020.1802981'] 2689,32758033,Secondhand Smoke Risk Communication: Effects on Parent Smokers' Perceptions and Intentions.,"This study examined effective strategies to communicate with parent smokers about the risks of secondhand smoke (SHS) exposure to children. An online, between-subjects experimental survey was administered via TurkPrime Panels to recruit participants ( N =  623) comprising adult smokers living with children (aged 0-15). Participants were assigned to messages conditions that differed by message recommendation (cessation; cessation+exposure reduction) and format (video; text-only) or to a no-message control. Participants in a message condition viewed a message, and all participants responded to questions about their perceptions and intentions. Parent smokers who viewed either message recommendation reported greater harm perceptions ( p <.001), self-efficacy ( p <.001), and help-seeking intentions ( p <.05) than the no-message control group. Cessation+exposure reduction recommendations elicited greater quit intentions than the no-message control ( p <.05). Compared to text-only, videos elicited greater reduce-exposure intentions ( p <.05) and interpersonal communication intentions ( p <.05). Only videos elicited greater quit intentions ( p <.01) and help-seeking intentions ( p <.01) than the no-message control. Communication about this topic can be optimized by recommending both cessation and exposure-reduction behaviors (versus cessation only), and by using videos (versus traditional print/text-based materials).",2020,Only videos elicited greater quit intentions ( p <.01) and help-seeking intentions ( p <.01) than the no-message control.,"['parent smokers about the risks of secondhand smoke (SHS) exposure to children', ""Parent Smokers' Perceptions and Intentions"", 'adult smokers living with children (aged 0-15']","['messages conditions that differed by message recommendation (cessation; cessation+exposure reduction) and format (video; text-only) or to a no-message control', 'Cessation+exposure']","['reduce-exposure intentions', 'harm perceptions', 'help-seeking intentions', 'quit intentions', 'interpersonal communication intentions', 'self-efficacy']","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0037370', 'cui_str': 'Passive smoking'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0553288', 'cui_str': 'Lives with children'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1301627', 'cui_str': 'Format'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0086792', 'cui_str': 'Personal Communication'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",623.0,0.0101532,Only videos elicited greater quit intentions ( p <.01) and help-seeking intentions ( p <.01) than the no-message control.,"[{'ForeName': 'Jennah M', 'Initials': 'JM', 'LastName': 'Sontag', 'Affiliation': 'Center for Tobacco Studies, Rutgers University , New Brunswick, New Jersey, USA.'}, {'ForeName': 'Cristine D', 'Initials': 'CD', 'LastName': 'Delnevo', 'Affiliation': 'Center for Tobacco Studies, Rutgers University , New Brunswick, New Jersey, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Hegyi', 'Affiliation': 'The SIDS Center of New Jersey, Department of Pediatrics, Robert Wood Johnson Medical School, Rutgers University , New Brunswick, New Jersey, USA.'}, {'ForeName': 'Barbara M', 'Initials': 'BM', 'LastName': 'Ostfeld', 'Affiliation': 'The SIDS Center of New Jersey, Department of Pediatrics, Robert Wood Johnson Medical School, Rutgers University , New Brunswick, New Jersey, USA.'}, {'ForeName': 'Olivia A', 'Initials': 'OA', 'LastName': 'Wackowski', 'Affiliation': 'Center for Tobacco Studies, Rutgers University , New Brunswick, New Jersey, USA.'}]",Journal of health communication,['10.1080/10810730.2020.1797947'] 2690,32758038,Dietary nitrate reduces blood pressure and cerebral artery velocity fluctuations and improve cerebral autoregulation in transient ischemic attack patients.,"Accentuated blood pressure (BP) fluctuation and low cerebral blood flow (CBF) response to CO 2 increases the risk of transient ischemic attack (TIA) recurrence and stroke in TIA patients. Improving cardio- and cerebrovascular function may reduce stroke risk. We found dietary nitrate lowered dynamic blood pressure variability (BPV) in rats, and improved cerebrovascular CO 2 reactivity in healthy individuals. In thirty TIA patients, we examined the effects of a 7-day supplementation of dietary nitrate (0.1mmol/kg/day) on cerebrovascular function using a randomized, single-blinded, placebo-controlled study design. We hypothesized that 7-day dietary nitrate supplementation would decrease variabilities in BP and CBF and improve CBF-CO 2 slope and cerebral autoregulation (CA). We assessed beat-to-beat middle cerebral artery blood velocity (MCAv, index of CBF) and BP at rest and during CO 2 breathing. Transfer function analysis was performed on beat-to-beat MCAv and BP to determine CA parameters (gain, phase and coherence). Irrespective of treatment, high and low frequency BP-MCAv gain and MCAv-CO 2 slope increased 7 days following TIA onset, while low frequency BPV decreased (p<0.05 vs. baseline). At follow-up, dietary nitrate elevated plasma nitrate concentration by ˜547% (p<0.001) and moderately lowered BPV (d=0.6, p=0.011), MCAv variability (d = 0.7, p = 0.018) and BP-MCAv coherence (d=0.7, p=0.008) in the very-low frequency range (0.02-0.07 Hz), while MCAv-CO 2 slope and arterial stiffness were unaffected (p>0.05). Concurrent with standard treatment, dietary nitrate supplementation reduces BP and CBF fluctuation and improve cerebral autoregulation in TIA patients, without affecting cerebrovascular CO 2 reactivity.",2020,"At follow-up, dietary nitrate elevated plasma nitrate concentration by ˜547% (p<0.001) and moderately lowered BPV (d=0.6, p=0.011), MCAv variability (d = 0.7, p = 0.018) and BP-MCAv coherence (d=0.7, p=0.008) in the very-low frequency range (0.02-0.07 Hz), while MCAv-CO 2 slope and arterial stiffness were unaffected (p>0.05).","['transient ischemic attack patients', 'TIA patients', 'thirty TIA patients', 'healthy individuals']","['dietary nitrate supplementation', 'Dietary nitrate', '7-day supplementation of dietary nitrate', '7-day dietary nitrate supplementation', 'placebo']","['beat-to-beat middle cerebral artery blood velocity (MCAv, index of CBF) and BP at rest and during CO 2 breathing', 'cerebral autoregulation', 'Accentuated blood pressure (BP) fluctuation and low cerebral blood flow (CBF) response', 'low frequency BPV', 'MCAv variability', 'BP-MCAv coherence', 'blood pressure and cerebral artery velocity fluctuations', 'variabilities in BP and CBF and improve CBF-CO 2 slope and cerebral autoregulation (CA', 'dynamic blood pressure variability (BPV', 'BPV', 'cerebrovascular function', 'dietary nitrate elevated plasma nitrate concentration', 'transient ischemic attack (TIA) recurrence and stroke', 'MCAv-CO 2 slope and arterial stiffness', 'BP and CBF fluctuation and improve cerebral autoregulation', 'high and low frequency BP-MCAv gain and MCAv-CO 2 slope']","[{'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0149566', 'cui_str': 'Structure of middle cerebral artery'}, {'cui': 'C1531610', 'cui_str': 'Blood velocity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0443144', 'cui_str': 'At rest'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C1997416', 'cui_str': 'Accentuated'}, {'cui': 'C0231239', 'cui_str': 'Fluctuation'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205213', 'cui_str': 'Low frequency'}, {'cui': 'C0006072', 'cui_str': 'Bovine papillomavirus'}, {'cui': 'C0007770', 'cui_str': 'Structure of cerebral artery'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}]",30.0,0.0556527,"At follow-up, dietary nitrate elevated plasma nitrate concentration by ˜547% (p<0.001) and moderately lowered BPV (d=0.6, p=0.011), MCAv variability (d = 0.7, p = 0.018) and BP-MCAv coherence (d=0.7, p=0.008) in the very-low frequency range (0.02-0.07 Hz), while MCAv-CO 2 slope and arterial stiffness were unaffected (p>0.05).","[{'ForeName': 'Jui-Lin', 'Initials': 'JL', 'LastName': 'Fan', 'Affiliation': 'Department of Surgery & Anaesthesia, University of Otago, New Zealand.'}, {'ForeName': 'Terrence', 'Initials': 'T', 'LastName': ""O'Donnell"", 'Affiliation': 'Centre for Translational Physiology, University of Otago, New Zealand.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Lanford', 'Affiliation': 'Department of Neurology, Wellington Regional Hospital, New Zealand.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Croft', 'Affiliation': 'School of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Western Australia, Australia.'}, {'ForeName': 'Eloise', 'Initials': 'E', 'LastName': 'Watson', 'Affiliation': 'Department of Neurology, Wellington Regional Hospital, New Zealand.'}, {'ForeName': 'Duncan', 'Initials': 'D', 'LastName': 'Smyth', 'Affiliation': 'Department of Neurology, Wellington Regional Hospital, New Zealand.'}, {'ForeName': 'Henrietta', 'Initials': 'H', 'LastName': 'Koch', 'Affiliation': 'School of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Western Australia, Australia.'}, {'ForeName': 'Lai-Kin', 'Initials': 'LK', 'LastName': 'Wong', 'Affiliation': 'Department of Neurology, Wellington Regional Hospital, New Zealand.'}, {'ForeName': 'Yu-Chieh', 'Initials': 'YC', 'LastName': 'Tzeng', 'Affiliation': 'Department of Surgery & Anaesthesia, University of Otago, New Zealand.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00160.2020'] 2691,32758049,Polyacrylic Acid with Methylene Blue Dye as a Sensitizing Agent for Photodynamic Therapy to Reduce Streptococcus mutans in Dentinal Caries.,"Objective: To evaluate 11.5% polyacrylic acid (PA) containing 0.3% methylene blue (MB) dye as a photosensitizer for photodynamic therapy (PDT) of carious dentin. Methods: One hundred twenty molars were selected and the dentin was exposed for cariogenic challenge, where the molars were placed in brain heart infusion medium containing a standard strain of Streptococcus mutans (ATCC ). Samples were randomly divided into eight groups ( n  = 15): S: saline, PA, MB: MB 0.3%, PA+MB: PA containing 0.3% MB + LLL: irradiation with low-level laser, PDT (MB): MB 0.3% + laser, PDT (PA): PA + laser, and PDT (PA+MB): PA containing 0.3% MB + laser. Carious dentin was collected before and after exposure to S. mutans . All samples of carious dentin were homogenized, diluted, and seeded in mitis salivarius bacitracin medium, and the cultures were incubated at 37°C for 15 days in anaerobic jars. The Wilcoxon test was used for analysis. Results: The percent microbial reduction achieved with each treatment was as follows: PDT (MB), 53.62%; PDT (PA+MB), 50.47%; PDT (PA), 46.73%; PA, 38.51%; MB, 19.75%; PA+MB, 17.18%; LLL, 12.83%; S, 5.99%. The greatest reductions in S. mutans growth occurred with PDT (MB), PDT (PA+MB), and PDT (PA) when compared to the S group ( p  = 0.0002, 0.0023, and 0.0232, respectively). Conclusions: PA containing 0.3% MB can be used as a photosensitizer for PDT to reduce S. mutans burden in carious dentin.",2020,"The percent microbial reduction achieved with each treatment was as follows: PDT (MB), 53.62%; PDT (PA+MB), 50.47%; PDT (PA), 46.73%; PA, 38.51%; MB, 19.75%; PA+MB, 17.18%; LLL, 12.83%; S, 5.99%.","['Methods: One hundred twenty molars were selected and the dentin was exposed for cariogenic challenge, where the molars were']","['placed in brain heart infusion medium containing a standard strain of Streptococcus mutans (ATCC ', 'polyacrylic acid (PA) containing 0.3% methylene blue (MB) dye as a photosensitizer for photodynamic therapy (PDT', 'Polyacrylic Acid with Methylene Blue Dye', 'S: saline, PA, MB: MB 0.3%, PA+MB: PA containing 0.3% MB\u2009+ LLL: irradiation with low-level laser, PDT (MB): MB 0.3% + laser, PDT (PA): PA + laser, and PDT (PA+MB): PA containing 0.3% MB + laser']","['PDT (MB), PDT (PA+MB), and PDT (PA', 'Carious dentin', 'percent microbial reduction']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0011429', 'cui_str': 'Dentin structure'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}]","[{'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C0054720', 'cui_str': 'Carbomer-940'}, {'cui': 'C4068885', 'cui_str': '0.3'}, {'cui': 'C0025746', 'cui_str': 'Methylene blue'}, {'cui': 'C0013343', 'cui_str': 'Dye'}, {'cui': 'C0162713', 'cui_str': 'Photosensitizing agent'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C1261077', 'cui_str': 'Structure of lower lobe of left lung'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}]","[{'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C1707305', 'cui_str': 'Carious Dentin'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",120.0,0.0219433,"The percent microbial reduction achieved with each treatment was as follows: PDT (MB), 53.62%; PDT (PA+MB), 50.47%; PDT (PA), 46.73%; PA, 38.51%; MB, 19.75%; PA+MB, 17.18%; LLL, 12.83%; S, 5.99%.","[{'ForeName': 'Leticia Martins', 'Initials': 'LM', 'LastName': 'Pereira', 'Affiliation': 'Postgraduate Program in Health Sciences, Center for Life Sciences, Pontifical Catholic University of Campinas (PUC Campinas), Campinas, Brazil.'}, {'ForeName': 'Lorena Rodriguez', 'Initials': 'LR', 'LastName': 'Estevam', 'Affiliation': 'Postgraduate Program in Health Sciences, Center for Life Sciences, Pontifical Catholic University of Campinas (PUC Campinas), Campinas, Brazil.'}, {'ForeName': 'Mariana Franco', 'Initials': 'MF', 'LastName': 'da Silva', 'Affiliation': 'Postgraduate Program in Health Sciences, Center for Life Sciences, Pontifical Catholic University of Campinas (PUC Campinas), Campinas, Brazil.'}, {'ForeName': 'Sérgio Luiz', 'Initials': 'SL', 'LastName': 'Pinheiro', 'Affiliation': 'Postgraduate Program in Health Sciences, Center for Life Sciences, Pontifical Catholic University of Campinas (PUC Campinas), Campinas, Brazil.'}]","Photobiomodulation, photomedicine, and laser surgery",['10.1089/photob.2019.4736'] 2692,32758087,"Photobiomodulation Therapy Effects on Resistance Training Volume and Discomfort in Well-Trained Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.","Objective: To investigate the effects of photobiomodulation therapy (PBMT) on resistance training volume and discomfort of well-trained adults. Background: PBMT has been used to attenuate fatigue in several physical exercise topics. However, it is unclear if PBMT can increase volume and reduce discomfort in resistance training well-trained individuals. Methods: Fourteen participants (women = 7, 27.7 ± 6.0 years and men = 7, 28.3 ± 5.7 years) visited the laboratory three times, 7 days apart. In the first visit, 12-repetition maximum (12-RM) test was performed unilaterally on the standing calf raise machine. In the second and third visits, subjects were randomly submitted to a PBMT (60 J per site, 6 sites per limb, total dose = 360 J) or placebo treatment on the gastrocnemius and soleus muscles with a randomized crossover design. Five minutes after the treatment, subjects began the resistance training session, performed unilaterally with six sets of repetitions to concentric failure. In addition, the rate of perceived exertion for discomfort (RPE-D) was asked after each set. Results: After the training session, it was observed a similar force reduction of 10.0 ± 13.6% for placebo and 7.7 ± 7.3% for PBMT ( p  = 0.815). No differences between PBMT and placebo was observed for the repetitions fatigue index (53.4 ± 11.7% and 50.0 ± 11.6%; p  = 0.325) and total repetitions volume (55.4 ± 10.9 and 54.8 ± 13.0 reps; p  = 0.764), respectively. RPE-D presented large means for all sets representing a large discomfort during resistance training to concentric failure for both PBMT (7.3 ± 2.3) and placebo (7.5 ± 2.5). Conclusions: The PBMT was not effective for increasing volume and reducing discomfort during resistance training performed to concentric failure by well-trained men and women.",2020,The PBMT was not effective for increasing volume and reducing discomfort during resistance training performed to concentric failure by well-trained men and women.,"['Well-Trained Adults', 'Fourteen participants (women\u2009=\u20097, 27.7\u2009±\u20096.0 years and men\u2009=\u20097, 28.3\u2009±\u20095.7 years) visited the laboratory three times, 7 days apart']","['PBMT and placebo', 'Placebo', 'photobiomodulation therapy (PBMT', 'PBMT', 'placebo']","['rate of perceived exertion for discomfort (RPE-D', 'Resistance Training Volume and Discomfort', 'discomfort', 'total repetitions volume', 'repetitions fatigue index']","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C4517795', 'cui_str': '5.7'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4019433', 'cui_str': 'Photobiomodulation Therapy'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0035322', 'cui_str': 'Structure of retinal pigment epithelium'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.157086,The PBMT was not effective for increasing volume and reducing discomfort during resistance training performed to concentric failure by well-trained men and women.,"[{'ForeName': 'Lucas B R', 'Initials': 'LBR', 'LastName': 'Orssatto', 'Affiliation': 'School of Exercise and Nutrition Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia.'}, {'ForeName': 'Mateus', 'Initials': 'M', 'LastName': 'Rossato', 'Affiliation': 'Human Performance Laboratory, Faculty of Physical Education and Physiotherapy, Federal University of Amazonas, Manaus, Brazil.'}, {'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'Vargas', 'Affiliation': 'Department of Physical Education, Sports Center, Biomechanics Laboratory, Federal University of Santa Catarina, Florianópolis, Brazil.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Diefenthaeler', 'Affiliation': 'Department of Physical Education, Sports Center, Biomechanics Laboratory, Federal University of Santa Catarina, Florianópolis, Brazil.'}, {'ForeName': 'Cíntia', 'Initials': 'C', 'LastName': 'de la Rocha Freitas', 'Affiliation': 'Department of Physical Education, Sports Center, Biomechanics Laboratory, Federal University of Santa Catarina, Florianópolis, Brazil.'}]","Photobiomodulation, photomedicine, and laser surgery",['10.1089/photob.2019.4777'] 2693,32758233,A cluster randomized trial of delivery of intermittent preventive treatment of malaria in pregnancy at the community level in Burkina Faso.,"BACKGROUND Malaria in pregnancy is responsible for 8-14% of low birth weight and 20% of stillbirths in sub-Saharan Africa. To prevent these adverse consequences, the World Health Organization recommends intermittent preventive treatment of pregnant women (IPTp) with sulfadoxine-pyrimethamine be administered at each ANC visit starting as early as possible in the second trimester. Global IPTp coverage in targeted countries remains unacceptably low. Community delivery of IPTp was explored as a means to improve coverage. METHODS A cluster randomized, controlled trial was conducted in 12 health facilities in a 1:1 ratio to either an intervention group (IPTp delivered by CHWs) or a control group (standard practice, with IPTp delivered at HFs) in three districts of Burkina Faso to assess the effect of IPTp administration by community health workers (CHWs) on the coverage of IPTp and antenatal care (ANC). The districts and facilities were purposively selected taking into account malaria epidemiology, IPTp coverage, and the presence of active CHWs. Pre- and post-intervention surveys were carried out in March 2017 and July-August 2018, respectively. A difference in differences (DiD) analysis was conducted to assess the change in coverage of IPTp and ANC over time, accounting for clustering at the health facility level. RESULTS Altogether 374 and 360 women were included in the baseline and endline surveys, respectively. At baseline, women received a median of 2.1 doses; by endline, women received a median of 1.8 doses in the control group and 2.8 doses in the intervention group (p-value < 0.0001). There was a non-statistically significant increase in the proportion of women attending four ANC visits in the intervention compared to control group (DiD = 12.6%, p-value = 0.16). By the endline, administration of IPTp was higher in the intervention than control, with a DiD of 17.6% for IPTp3 (95% confidence interval (CI) - 16.3, 51.5; p-value 0.31) and 20.0% for IPTp4 (95% CI - 7.2, 47.3; p-value = 0.15). CONCLUSIONS Community delivery of IPTp could potentially lead to a greater number of IPTp doses delivered, with no apparent decrease in ANC coverage.",2020,"There was a non-statistically significant increase in the proportion of women attending four ANC visits in the intervention compared to control group (DiD = 12.6%, p-value = 0.16).","['pregnant women (IPTp) with', 'Altogether 374 and 360 women were included in the baseline and endline surveys, respectively', 'malaria in pregnancy at the community level in Burkina Faso', '12 health facilities in a 1:1 ratio to either an']","['sulfadoxine-pyrimethamine', 'intervention group (IPTp delivered by CHWs', 'control group (standard practice, with IPTp delivered at HFs', 'IPTp administration by community health workers (CHWs) on the coverage of IPTp and antenatal care (ANC']","['ANC coverage', 'proportion of women attending four ANC visits']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0747820', 'cui_str': 'Malaria, antepartum'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0006409', 'cui_str': 'Burkina Faso'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]","[{'cui': 'C0700599', 'cui_str': 'Pyrimethamine- and sulfadoxine-containing product'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2745948', 'cui_str': 'Juvenile hyaline fibromatosis'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}]","[{'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1456498', 'cui_str': 'Attended'}]",,0.0858406,"There was a non-statistically significant increase in the proportion of women attending four ANC visits in the intervention compared to control group (DiD = 12.6%, p-value = 0.16).","[{'ForeName': 'Julie R', 'Initials': 'JR', 'LastName': 'Gutman', 'Affiliation': 'Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, US Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop H24-3, Atlanta, GA, 30329, USA. fff2@cdc.gov.'}, {'ForeName': 'Daniel K', 'Initials': 'DK', 'LastName': 'Stephens', 'Affiliation': 'The Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Tiendrebeogo', 'Affiliation': 'Jhpiego, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Ousmane', 'Initials': 'O', 'LastName': 'Badolo', 'Affiliation': 'Jhpiego, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Mathurin', 'Initials': 'M', 'LastName': 'Dodo', 'Affiliation': 'Jhpiego, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Burke', 'Affiliation': 'Jhpiego, Baltimore, MD, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Williamson', 'Affiliation': 'Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, US Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop H24-3, Atlanta, GA, 30329, USA.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Vibbert', 'Affiliation': 'Jhpiego, Baltimore, MD, USA.'}, {'ForeName': 'Susan J', 'Initials': 'SJ', 'LastName': 'Youll', 'Affiliation': ""US President's Malaria Initiative, US Agency for International Development, Washington, D.C., USA.""}, {'ForeName': 'Yacouba', 'Initials': 'Y', 'LastName': 'Savadogo', 'Affiliation': 'National Malaria Control Programme, Ministry of Health, Ouagadougou, Burkina Faso.'}, {'ForeName': 'William R', 'Initials': 'WR', 'LastName': 'Brieger', 'Affiliation': 'Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, US Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop H24-3, Atlanta, GA, 30329, USA.'}]",Malaria journal,['10.1186/s12936-020-03356-9'] 2694,32758267,Carbon ion reirradiation compared to intensity-modulated re-radiotherapy for recurrent head and neck cancer (CARE): a randomized controlled trial.,"BACKGROUND Intensity-modulated re-radiotherapy (reIMRT) has been established as a standard local treatment option in patients with non-resectable, recurrent head and neck cancer (rHNC). However, the clinical outcome is unfavorable and severe toxicities (≥grade III) occurred in 30-40% of patients. The primary aim of the current trial is to investigate carbon ion reirradiation (reCIRT) compared to reIMRT in patients with rHNC regarding safety/toxicity as well as local control, overall survival (OS), and quality of life (QoL). METHODS The present trial will be performed as a single center, two-armed, prospective phase II study. A maximum of 72 patients will be treated with either reIMRT or reCIRT to evaluate severe (≥grade III) treatment-related toxicities (randomization ratio 1:1). The primary target value is to generate less than 35% acute/subacute severe toxicity (≥grade III), according to the Common Terminology Criteria for Adverse Events v5.0, within 6 months after study treatment. The total dose of reirradiation will range between 51 and 60 Gy or Gy (RBE), depending primarily on the radiotherapy interval and the cumulative dose to organs at risk. Individual dose prescription will be at the discretion of the treating radiation oncologist. The local and distant progression-free survival 12 months after reirradiation, the OS, and the QoL are the secondary endpoints of the trial. Explorative trial objectives are the longitudinal investigation of clinical patient-related parameters, tumor parameters on radiological imaging, and blood-based tumor analytics. DISCUSSION Recent retrospective studies suggested that reCIRT could represent a feasible and effective treatment modality for rHNC. This current randomized prospective trial is the first to investigate the toxicity and clinical outcome of reCIRT compared to reIMRT in patients with rHNC. TRIAL REGISTRATION ClinicalTrials.gov ; NCT04185974 ; December 4th 2019.",2020,"The local and distant progression-free survival 12 months after reirradiation, the OS, and the QoL are the secondary endpoints of the trial.","['patients with non-resectable, recurrent head and neck cancer (rHNC', 'patients with rHNC', '72 patients', 'patients with rHNC regarding', 'recurrent head and neck cancer (CARE']","['reCIRT', 'Carbon ion reirradiation compared to intensity-modulated re-radiotherapy', 'reIMRT', 'reIMRT or reCIRT', 'Intensity-modulated re-radiotherapy (reIMRT', 'carbon ion reirradiation (reCIRT']","['overall survival (OS), and quality of life (QoL', 'subacute severe toxicity', 'severe toxicities (≥grade III', 'safety/toxicity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}]","[{'cui': 'C0007009', 'cui_str': 'Carbon'}, {'cui': 'C0022023', 'cui_str': 'Ions'}, {'cui': 'C4042794', 'cui_str': 'Re Irradiation'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205365', 'cui_str': 'Subacute'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.119025,"The local and distant progression-free survival 12 months after reirradiation, the OS, and the QoL are the secondary endpoints of the trial.","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Held', 'Affiliation': 'Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Lang', 'Affiliation': 'Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Regnery', 'Affiliation': 'Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Weusthof', 'Affiliation': 'Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.'}, {'ForeName': 'Adriane', 'Initials': 'A', 'LastName': 'Hommertgen', 'Affiliation': 'Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.'}, {'ForeName': 'Cornelia', 'Initials': 'C', 'LastName': 'Jäkel', 'Affiliation': 'Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Tonndorf-Martini', 'Affiliation': 'Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Krisam', 'Affiliation': 'Institute of Medical Biometry and Informatics (IMBI), Heidelberg University Hospital, Heidelberg, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Plinkert', 'Affiliation': 'Department of Otorhinolaryngology, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Zaoui', 'Affiliation': 'Department of Otorhinolaryngology, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Freudlsperger', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Julius', 'Initials': 'J', 'LastName': 'Moratin', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Krauss', 'Affiliation': 'Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.'}, {'ForeName': 'Semi B', 'Initials': 'SB', 'LastName': 'Harrabi', 'Affiliation': 'Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Herfarth', 'Affiliation': 'Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Debus', 'Affiliation': 'Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Adeberg', 'Affiliation': 'Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. sebastian.adeberg@med.uni-heidelberg.de.'}]","Radiation oncology (London, England)",['10.1186/s13014-020-01625-0'] 2695,32758278,"Who knew? The misleading specificity of ""double-blind"" and what to do about it.","BACKGROUND In randomized trials, the term ""double-blind"" (and its derivatives, single- and triple-blind, fully blind, and partially blind or masked) has no standard or widely accepted definition. Agreement about which groups are blinded is poor, and authors using these terms often do not identify which groups were blinded, despite specific reporting guidelines to the contrary. Nevertheless, many readers assume-incorrectly-that they know which groups are blinded. Thus, the term is ambiguous at best, misleading at worst, and, in either case, interferes with the accurate reporting, interpretation, and evaluation of randomized trials. The problems with the terms have been thoroughly documented in the literature, and many authors have recommended that they be abandoned. PROPOSAL We and our co-signers suggest eliminating the use of adjectives that modify ""blinding"" in randomized trials; a trial would be described as either blinded or unblinded. We also propose that authors report in a standard table which groups or individuals were blinded, what they were blinded to, how blinding was implemented, and whether blinding was maintained. Individuals with dual responsibilities, such as caregiving and data collecting, would also be identified. If blinding was compromised, authors should describe the potential implications of the loss of blinding on interpreting the results. CONCLUSION ""Double blind"" and its derivatives are terms with little to recommend their continued use. Eliminating the use of adjectives that impart a false specificity to the term would reduce misinterpretations, and recommending that authors report who was blinded to what and how in a standard table would require them to be specific about which groups and individuals were blinded.",2020,"We and our co-signers suggest eliminating the use of adjectives that modify ""blinding"" in randomized trials; a trial would be described as either blinded or unblinded.",[],[],[],[],[],[],,0.497131,"We and our co-signers suggest eliminating the use of adjectives that modify ""blinding"" in randomized trials; a trial would be described as either blinded or unblinded.","[{'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Lang', 'Affiliation': 'West China Hospital/Sichuan Medical School Publishing Group, Kirkland, WA, USA. tomlangcom@aol.com.'}, {'ForeName': 'Donna F', 'Initials': 'DF', 'LastName': 'Stroup', 'Affiliation': 'Data for Solutions, Inc., Decatur, GA, USA.'}]",Trials,['10.1186/s13063-020-04607-5'] 2696,32758281,"Correction to: A nurse-led health coaching intervention for stroke survivors and their family caregivers in hospital to home transition care in Chongqing, China: a study protocol for a randomized controlled trial.",An amendment to this paper has been published and can be accessed via the original article.,2020,An amendment to this paper has been published and can be accessed via the original article.,"['stroke survivors and their family caregivers in hospital to home transition care in Chongqing, China']",['nurse-led health coaching intervention'],[],"[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C4019071', 'cui_str': 'Transition Care'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.0630952,An amendment to this paper has been published and can be accessed via the original article.,"[{'ForeName': 'Shuanglan', 'Initials': 'S', 'LastName': 'Lin', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, GPO Box 2100, Adelaide, SA, 5001, Australia.'}, {'ForeName': 'Lily Dongxia', 'Initials': 'LD', 'LastName': 'Xiao', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, GPO Box 2100, Adelaide, SA, 5001, Australia. lily.xiao@flinders.edu.au.'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Chamberlain', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, GPO Box 2100, Adelaide, SA, 5001, Australia.'}]",Trials,['10.1186/s13063-020-04609-3'] 2697,32758282,"Does propolis affect the quality of life and complications in subjects with irritable bowel syndrome (diagnosed with Rome IV criteria)? A study protocol of the randomized, double-blinded, placebo-controlled clinical trial.","BACKGROUND Irritable bowel syndrome (IBS) is one of the most frequent and recurrent gastrointestinal diseases. However, up to now, no pharmacological agent has been approved to treat IBS. Emerging evidence showed that inflammation has a vital role in enhancing nervous system sensitivity and perception of abdominal pain in subjects with IBS. Propolis is an herbal substance with a broad spectrum of antioxidants, anti-inflammatory, and prebiotic properties, which might exert beneficial effects to reduce the severity of IBS. The current clinical trial aims to evaluate the efficacy of propolis supplementation on IBS. METHODS This single-center, randomized, double-blind, placebo-controlled clinical trial will be performed to evaluate the effect of propolis supplementation in adult patients with IBS diagnosed with Rome IV criteria. Fifty-two eligible patients will randomly be allocated to receive a propolis tablet (450 mg, containing 100 mg polyphenol compounds) or identical placebo, twice daily for 6 weeks. The primary outcome of the trial is an improvement in IBS severity from baseline to the sixth week of intervention. The secondary outcomes include the change in weight, waist circumference, and IBS quality of life. We will use the paired sample t test or Mann-Whitney U test for the within-group comparison and independent sample t test or Wilcoxon rank-sum and chi-square test or Fisher's exact test for the between-group comparison. Besides, a multivariable-adjusted mean effect will be computed using the ANCOVA test. DISCUSSION We hypothesize that propolis supplementation would be useful for treating IBS through its antioxidants, anti-inflammatory, and prebiotic properties. This trial will show the results of propolis supplementation, whether positive or negative, on IBS. If the current trial confirms our hypothesis, propolis supplementation can be a new choice in adjunctive therapy of IBS. TRIAL REGISTRATION Iranian Registry of Clinical Trials IRCT20190708044154N1. Registered on 26 December 2019. Updated on 13 February 2020. https://en.irct.ir/trial/40983 SPONSOR: Tabriz University of Medical Sciences, Tabriz, Iran.",2020,Emerging evidence showed that inflammation has a vital role in enhancing nervous system sensitivity and perception of abdominal pain in subjects with IBS.,"['subjects with irritable bowel syndrome (diagnosed with Rome IV criteria', 'subjects with IBS', 'Fifty-two eligible patients', 'Tabriz University of Medical Sciences, Tabriz, Iran', 'adult patients with IBS diagnosed with Rome IV criteria']","['propolis tablet (450\u2009mg, containing 100\u2009mg polyphenol compounds) or identical placebo', 'https://en.irct.ir/trial/40983', 'propolis supplementation', 'placebo']","['quality of life and complications', 'IBS severity', 'change in weight, waist circumference, and IBS quality of life', 'IBS']","[{'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0035831', 'cui_str': 'Rome'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0033488', 'cui_str': 'Propolis'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C3844104', 'cui_str': '450'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0071649', 'cui_str': 'Polyphenol'}, {'cui': 'C0205198', 'cui_str': 'Compound'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}]",52.0,0.550332,Emerging evidence showed that inflammation has a vital role in enhancing nervous system sensitivity and perception of abdominal pain in subjects with IBS.,"[{'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Miryan', 'Affiliation': 'Nutrition Research Center, Student Research Committee, Department of Clinical Nutrition, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Pezhman', 'Initials': 'P', 'LastName': 'Alavinejad', 'Affiliation': 'Alimentary Tract Research Center, Ahvaz Imam Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Mohammadreza', 'Initials': 'M', 'LastName': 'Abbaspour', 'Affiliation': 'Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Davood', 'Initials': 'D', 'LastName': 'Soleimani', 'Affiliation': 'Nutritional Sciences Department, School of Nutrition Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Ostadrahimi', 'Affiliation': 'Nutrition Research Center, Department of Clinical Nutrition, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. Ostadrahimi@tbzmed.ac.ir.'}]",Trials,['10.1186/s13063-020-04615-5'] 2698,32758296,Effects of remaining dentin thickness on the bond strength of bleached dentin.,"BACKGROUND The bond strength of resin composites to dentin was reported to be related to either the remaining dentin thickness (RDT) or bleaching treatment. However, information is limited regarding the effects of RDT on the bond strength of bleached dentin. The present study aimed to investigate the effects of RDT on the microshear bond strength (μSBS) of resin cement to bleached dentin. METHODS A total of 120 dentin specimens were prepared and randomly divided into 2 groups: a bleaching group (group B) and a control group (group C). Hydrogen peroxide with a concentration of 35% (Ultradent, USA) was applied on the dentin surface for 2 × 1 d for group B, while no bleaching treatment was performed for group C. After the treatment, the specimens were finished and polished to obtain different RDTs (2, 1, and 0.5 mm) and divided into 3 groups of 20 specimens each. The bonding procedure was performed using Panavia V5 (Kuraray, Japan) with a bonding area of 0.785 mm 2 . For each group, half of the specimens were subjected to 5000 thermal cycles (subgroup T), while the other half did not receive thermocycling (subgroup N) (n = 10). The specimens were then subjected to the μSBS test using a universal testing machine. Data were analyzed by a three-way analysis of variance (α = 0.05). The fracture modes of the specimens were confirmed with a measuring microscope. Representative specimens with different fracture modes were observed with scanning electron microscopy (SEM). RESULTS The μSBS values were significantly affected by bleaching treatment (p < 0.001), whereas no significant effect was observed for thermocycling (p = 0.293). In terms of RDT, a significantly different μSBS value was found among the subgroups with different RDTs in group C (p = 0.003). However, the RDT did not significantly affect the μSBS values of bleached dentin in group B (p = 0.779). The μSBS values were significantly lower in group B than in group C (p < 0.001). A higher percentage of adhesive failure was observed in group B than in group C. CONCLUSION Based on the present findings, it can be concluded that the RDT did not affect the bond strength of resin cement to bleached dentin. CLINICAL SIGNIFICANCE Since RDT did not affect the bond strength of resin cement to bleached dentin, bonding procedures should not be performed immediately after intracoronal bleaching, even if the dentin is planned to be removed due to a tooth preparation process.",2020,The μSBS values were significantly lower in group B than in group C (p < 0.001).,['A total of 120 dentin specimens'],"['bleaching group', 'RDT', 'Hydrogen peroxide with a concentration of 35% (Ultradent, USA', 'scanning electron microscopy (SEM']","['bond strength of bleached dentin', 'microshear bond strength (μSBS', 'adhesive failure', 'μSBS values', 'μSBS value']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C1292488', 'cui_str': 'Dentin specimen'}]","[{'cui': 'C0303749', 'cui_str': 'Bleach'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0011429', 'cui_str': 'Dentin structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0020281', 'cui_str': 'Hydrogen Peroxide'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0026019', 'cui_str': 'Electron microscopic study'}]","[{'cui': 'C0028758', 'cui_str': 'Bonding (Psychology)'}, {'cui': 'C0303749', 'cui_str': 'Bleach'}, {'cui': 'C0011429', 'cui_str': 'Dentin structure'}, {'cui': 'C0001516', 'cui_str': 'Adhesive'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.0136598,The μSBS values were significantly lower in group B than in group C (p < 0.001).,"[{'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Jiang', 'Affiliation': 'Department of Prosthodontics, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Xiu-Jiao', 'Initials': 'XJ', 'LastName': 'Lin', 'Affiliation': 'Department of Prosthodontics, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Ying-Hui', 'Initials': 'YH', 'LastName': 'Chen', 'Affiliation': 'Department of Prosthodontics, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Yu', 'Affiliation': 'Department of Prosthodontics, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China. haoyu-cn@hotmail.com.'}]",BMC oral health,['10.1186/s12903-020-01206-3'] 2699,32758298,"A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial.","OBJECTIVES • Primary objective: to evaluate the effect of intravenous melatonin (IVM) on mortality in adult patients admitted to the intensive care unit (ICU) with COVID-19. • Secondary objectives: ◦ To evaluate the effect of IVM on ICU length of stay. ◦ To evaluate the effect of IVM on the length of mechanical ventilation (MV). ◦ To evaluate if the use of IVM is associated with an increase in the number of ventilator-free days. ◦ To evaluate if the use of IVM is associated with a reduced number of failing organs as determined by the sequential organ failure assessment (SOFA) scale. ◦ To evaluate if the use of IVM is associated with a reduction of the frequency and severity of COVID-19-associated thromboembolic phenomena. ◦ To evaluate if the use of IVM is associated with a decreased systemic inflammatory response assessed by plasma levels of ferritin, D-dimer, C-reactive protein, procalcitonin and interleukin-6. ◦ To evaluate if the use of IVM is associated with an improvement in hematologic parameters. ◦ To evaluate if the use of IVM is associated with an improvement in biochemical parameters. ◦ To evaluate if the use of IVM is associated with an improvement in blood gas analysis parameters. ◦ To evaluate adverse events during the 28 day study period. TRIAL DESIGN Phase II, single center, double-blind, placebo-controlled randomized trial with a two-arm parallel group design and 2:1 allocation ratio. PARTICIPANTS Only critically ill adult patients that fulfill all of the inclusion criteria and none of the exclusion criteria will be included. The study will be conducted in a mixed ICU of a publicly funded tertiary referral center in Madrid, Spain with a 30-bed capacity and 1100 admissions per year. • Inclusion criteria: ◦ Patient, family member or legal guardian has provided written Informed Consent. ◦ Age ε 18 years. ◦ Confirmed SARS-CoV-2 infection with compatible symptoms AND a positive RT-PCR. ◦ Admission to the ICU with acute hypoxemic respiratory failure attributed to SARS-CoV-2 infection. ◦ ICU length of stay of less than 7 days prior to randomization with or without MV and without signs of improvement in respiratory failure (MURRAY score at randomization greater or equal to the MURRAY score at ICU admission). • Exclusion criteria: ◦ Participant in a different COVID-19 study in which the study drug is under clinical development and hasn't been previously authorized for commercialization. ◦ Liver enzymes > 5 times the upper normal range. ◦ Chronic kidney disease with GFR < 30 mL/min/1.73 m 2 (stage 4 or greater) or need for hemodialysis. ◦ Pregnancy. A pregnancy test will be performed on every woman younger than 55 years of age prior to inclusion. ◦ Terminal surgical or medical illness. ◦ Autoimmune disease. ◦ Any patient condition that can prevent the study procedures to be carried out at the treating physician's judgement. INTERVENTION AND COMPARATOR All patients will receive standard-of-care treatment according to the current institutional protocols. In addition, patients will be randomized in a 2:1 ratio to receive: • Experimental group (12 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day. • Control group (6 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours. After 3 days of treatment, 3 intensive care physicians will evaluate the participant and decide whether or not to complete the treatment based on their clinical assessment: • If objective or subjective signs of improvement or no worsening of the general clinical condition, respiratory failure, inflammatory state or multi-organ failure are observed, the participant will continue the treatment until completion. • If an adverse effect or clinical impairment is observed that is objectively or subjectively attributable to the study drug the treatment will be stopped. MAIN OUTCOME Mortality in each study group represented in frequency and time-to-event at day 28 after randomization RANDOMIZATION: The randomization sequence was created using SAS version 9.4 statistical software (programmed and validated macros) with a 2:1 allocation. No randomization seed was pre-specified. The randomization seed was generated using the time on the computer where the program was executed. BLINDING (MASKING) Participants, caregivers and study groups will be blinded to arm allocation. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE) A total of 18 patients will be randomized in this trial: 12 to the experimental arm and 6 to the control arm. TRIAL STATUS Protocol version 2.0, June 5 th 2020. Trial status: recruitment not started. The first patient is expected to be recruited in October 2020. The last patient is anticipated to be recruited in August 2021. TRIAL REGISTRATION EU Clinical Trials Register. Date of trial registration: 10 July 2020. URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001808-42/ES FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.",2020,"◦ To evaluate if the use of IVM is associated with a decreased systemic inflammatory response assessed by plasma levels of ferritin, D-dimer, C-reactive protein, procalcitonin and interleukin-6.","['Protocol version 2.0, June 5 th 2020', 'mixed ICU of a publicly funded tertiary referral center in Madrid, Spain with a 30-bed capacity and 1100 admissions per year', '18 patients', 'adult patients admitted to the intensive care unit (ICU) with COVID-19', 'patients with COVID-19 admitted to the intensive care unit (MelCOVID study', '◦ Chronic kidney disease with GFR', 'every woman younger than 55 years of age prior to inclusion', 'Only critically ill adult patients that fulfill all of the inclusion criteria and none of the exclusion criteria will be included']","['intravenous melatonin (IVM', 'intravenous melatonin', 'IVM', 'intravenous identically-looking placebo', 'placebo']","['frequency and time-to-event', 'length of mechanical ventilation (MV', 'ICU length of stay', 'general clinical condition, respiratory failure, inflammatory state or multi-organ failure', 'respiratory failure (MURRAY score', 'efficacy and safety', 'plasma levels of ferritin, D-dimer, C-reactive protein, procalcitonin and interleukin-6', 'adverse events']","[{'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0016820', 'cui_str': 'Funds'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0004914', 'cui_str': 'Bedding'}, {'cui': 'C4517537', 'cui_str': '1100'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0439508', 'cui_str': '/year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C1318304', 'cui_str': 'With GFR'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0026766', 'cui_str': 'Multiple organ failure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015879', 'cui_str': 'Ferritin'}, {'cui': 'C0060323', 'cui_str': 'D-dimer'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0072027', 'cui_str': 'Procalcitonin'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",18.0,0.248881,"◦ To evaluate if the use of IVM is associated with a decreased systemic inflammatory response assessed by plasma levels of ferritin, D-dimer, C-reactive protein, procalcitonin and interleukin-6.","[{'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Rodríguez-Rubio', 'Affiliation': 'Pediatric Intensive Care Department, Hospital Universitario La Paz, Madrid, Spain.'}, {'ForeName': 'Juan Carlos', 'Initials': 'JC', 'LastName': 'Figueira', 'Affiliation': 'Intensive Care Medicine Department, Hospital Universitario La Paz, Madrid, Spain.'}, {'ForeName': 'Darío', 'Initials': 'D', 'LastName': 'Acuña-Castroviejo', 'Affiliation': 'Department of Physiology, Faculty of Medicine, Biomedical Research Center, Health Science Technology Park, University of Granada, Granada, Spain.'}, {'ForeName': 'Alberto M', 'Initials': 'AM', 'LastName': 'Borobia', 'Affiliation': 'Clinical Pharmacology Department, Clinical Trial Unit, Hospital Universitario La Paz - IdiPAZ, Madrid, Spain.'}, {'ForeName': 'Germaine', 'Initials': 'G', 'LastName': 'Escames', 'Affiliation': 'Department of Physiology, Faculty of Medicine, Biomedical Research Center, Health Science Technology Park, University of Granada, Granada, Spain. gescames@ugr.es.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'de la Oliva', 'Affiliation': 'Pediatric Intensive Care Department, Hospital Universitario La Paz, Madrid, Spain. pedro.oliva@salud.madrid.org.'}]",Trials,['10.1186/s13063-020-04632-4'] 2700,32758299,EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer.,"BACKGROUND Limited data are available regarding the use of nab-paclitaxel in older patients with breast cancer. A weekly schedule is recommended, but there is a paucity of evidence regarding the optimal dose. We evaluated the efficacy of two different doses of weekly nab-paclitaxel, with a specific focus on their corresponding impact on patient function, in order to address the lack of data specifically relating to the older population. METHODS EFFECT is an open-label, phase II trial wherein 160 women with advanced breast cancer aged ≥ 65 years were enrolled from 15 institutions within Italy. Patients were randomly assigned 1:1 to receive nab-paclitaxel 100 mg/m 2 (arm A) or 125 mg/m 2 (arm B) on days 1, 8, and 15 on a 28-day cycle, as first-line treatment for advanced disease. The primary endpoint was event-free survival (EFS), wherein an event was defined as disease progression (PD), functional decline (FD), or death. In each arm, the null hypothesis that the median EFS would be ≤ 7 months was tested against a one-sided alternative according to the Brookmeyer Crowley test. Secondary endpoints included objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS After a median follow-up of 32.6 months, 140 events were observed in 158 evaluable patients. Median EFS was 8.2 months (90% CI, 5.9-8.9; p = 0.188) in arm A vs 8.3 months (90% CI, 6.2-9.7, p = 0.078) in arm B. Progression-free survival, overall survival, and response rates were similar in both groups. A higher percentage of dose reductions and discontinuations due to adverse events (AEs) was noted in arm B. The most frequently reported non-haematological AEs were fatigue (grade [G] 2-3 toxicity occurrence in arm A vs B, 43% and 51%, respectively) and peripheral neuropathy (G2-3 arm A vs B, 19% and 38%, respectively). CONCLUSION Pre-specified outcomes were similar in both treatment arms. However, 100 mg/m 2 was significantly better tolerated with fewer neurotoxicity-related events, representing a more feasible dose to be recommended for older patients with advanced disease. TRIAL REGISTRATION EudraCT, 2012-002707-18 . Registered on June 4, 2012. NIH ClinicalTrials.gov, NCT02783222 . Retrospectively registered on May 26, 2016.",2020,A higher percentage of dose reductions and discontinuations due to adverse events (AEs) was noted in arm B.,"['older patients with breast cancer', 'older women with advanced breast cancer', '158 evaluable patients', '65\u2009years were enrolled from 15 institutions within Italy', 'older patients with advanced disease', '160 women with advanced breast cancer aged ≥']","['EFFECT', 'weekly nab-paclitaxel', 'nab-paclitaxel 100\u2009mg/m 2 (arm A) or 125', 'nab-paclitaxel']","['peripheral neuropathy', 'Median EFS', 'arm B. Progression-free survival, overall survival, and response rates', 'objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety', 'event-free survival (EFS), wherein an event was defined as disease progression (PD), functional decline (FD), or death', 'toxicity occurrence']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C4319551', 'cui_str': '125'}]","[{'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}]",160.0,0.185607,A higher percentage of dose reductions and discontinuations due to adverse events (AEs) was noted in arm B.,"[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Biganzoli', 'Affiliation': '""Sandro Pitigliani"" Department of Medical Oncology, Hospital of Prato, ASL Toscana Centro, Prato, Italy. laura.biganzoli@uslcentro.toscana.it.'}, {'ForeName': 'Saverio', 'Initials': 'S', 'LastName': 'Cinieri', 'Affiliation': 'Department of Medical Oncology, Perrino Hospital, ASL Brindisi, Brindisi, Italy.'}, {'ForeName': 'Rossana', 'Initials': 'R', 'LastName': 'Berardi', 'Affiliation': 'Department of Medical Oncology, Ospedali Riuniti di Ancona, Università Politecnica delle Marche, Ancona, Italy.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Pedersini', 'Affiliation': 'Breast Oncology Unit, Hospital Civili di Brescia, Brescia, Italy.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'McCartney', 'Affiliation': '""Sandro Pitigliani"" Department of Medical Oncology, Hospital of Prato, ASL Toscana Centro, Prato, Italy.'}, {'ForeName': 'Alessandro Marco', 'Initials': 'AM', 'LastName': 'Minisini', 'Affiliation': 'Department of Oncology, Azienda Ospedaliero Universitaria Integrata di Udine, Udine, Italy.'}, {'ForeName': 'Elena Rota', 'Initials': 'ER', 'LastName': 'Caremoli', 'Affiliation': 'Cancer Centre, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Spazzapan', 'Affiliation': 'Unit of Medical Oncology and Cancer Prevention, IRCCS CRO di Aviano, National Cancer Institute, Aviano, Italy.'}, {'ForeName': 'Emanuela', 'Initials': 'E', 'LastName': 'Magnolfi', 'Affiliation': 'Department of Medical Oncology, Hospital Civile SS Trinità di Sora, Frosinone, Italy.'}, {'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Brunello', 'Affiliation': 'Department of Medical Oncology, Veneto Institute of Oncology IOV Padova, Padua, Italy.'}, {'ForeName': 'Emanuela', 'Initials': 'E', 'LastName': 'Risi', 'Affiliation': '""Sandro Pitigliani"" Department of Medical Oncology, Hospital of Prato, ASL Toscana Centro, Prato, Italy.'}, {'ForeName': 'Raffaella', 'Initials': 'R', 'LastName': 'Palumbo', 'Affiliation': 'Department of Medical Oncology, IRCCS ICS Maugeri, Pavia, Italy.'}, {'ForeName': 'Silvana', 'Initials': 'S', 'LastName': 'Leo', 'Affiliation': 'Department of Medical Oncology, Vito Fazzi Hospital, Lecce, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Colleoni', 'Affiliation': 'Division of Medical Senology, IEO, European Institute of Oncology IRCCS, Milan, Italy.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Donati', 'Affiliation': 'Department of Oncology, Versilia Hospital (Camaiore-Lu), Viareggio, Italy.'}, {'ForeName': 'Sabino', 'Initials': 'S', 'LastName': 'De Placido', 'Affiliation': 'Department of Endocrinology and Molecular and Clinical Oncology, AOU Federico II, Naples, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Orlando', 'Affiliation': 'Department of Medical Oncology, Perrino Hospital, ASL Brindisi, Brindisi, Italy.'}, {'ForeName': 'Mirco', 'Initials': 'M', 'LastName': 'Pistelli', 'Affiliation': 'Department of Medical Oncology, Ospedali Riuniti di Ancona, Università Politecnica delle Marche, Ancona, Italy.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Parolin', 'Affiliation': 'Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Mislang', 'Affiliation': '""Sandro Pitigliani"" Department of Medical Oncology, Hospital of Prato, ASL Toscana Centro, Prato, Italy.'}, {'ForeName': 'Dimitri', 'Initials': 'D', 'LastName': 'Becheri', 'Affiliation': 'Geriatric Medicine Unit, AUSL Toscana Centro, Prato, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Puglisi', 'Affiliation': 'Department of Oncology, Azienda Ospedaliero Universitaria Integrata di Udine, Udine, Italy.'}, {'ForeName': 'Giuseppina', 'Initials': 'G', 'LastName': 'Sanna', 'Affiliation': '""Sandro Pitigliani"" Department of Medical Oncology, Hospital of Prato, ASL Toscana Centro, Prato, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Zafarana', 'Affiliation': '""Sandro Pitigliani"" Department of Medical Oncology, Hospital of Prato, ASL Toscana Centro, Prato, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Boni', 'Affiliation': 'Clinical Trials Centre, AOU University Hospital Careggi, Florence, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Mottino', 'Affiliation': 'Geriatric Medicine Unit, AUSL Toscana Centro, Prato, Italy.'}]",Breast cancer research : BCR,['10.1186/s13058-020-01319-1'] 2701,32758312,Long-term follow-up of a randomised controlled trial of prolonged exposure therapy and supportive counselling for post-traumatic stress disorder in adolescents: a task-shifted intervention.,"BACKGROUND Empirical evidence on the longer-term effectiveness of evidence-based treatments for adolescents with post-traumatic stress disorder (PTSD) in low-resource settings is needed. The aim of the study was to evaluate the maintenance of treatment gains achieved in a comparative study of effectiveness of prolonged exposure therapy for adolescents (PE-A) and supportive counselling (SC) in adolescents with PTSD up to 24-months post-treatment. METHOD Sixty-three adolescents (13-18 years) with PTSD were randomly assigned to receive either of the interventions comprising 7-14 sessions of treatment provided by trained and supervised non-specialist health workers (NSHWs). The primary outcome measure was PTSD symptom severity, as independently assessed on the Child PTSD Symptom Scale, at pretreatment, post-treatment, and at 3-, 6-, 12- and 24-months post-treatment follow-up (FU) evaluations. RESULTS Participants in both the prolonged exposure and SC treatment groups attained a significant reduction in PTSD symptoms and maintained this reduction in PTSD symptoms at 12- and 24-month assessment. Participants receiving prolonged exposure experienced greater improvement on the PTSD symptom severity scale than those receiving SC at 12-months FU [difference in PE-A v. SC mean scores = 9.24, 95% CI (3.66-14.83), p < 0.001; g = 0.88] and at 24-months FU [difference in PE-A v. SC mean scores = 9.35, 95% CI (3.53-15.17), p = 0.002; g = 0.68]. CONCLUSIONS Adolescents with PTSD continued to experience greater benefit from prolonged exposure treatment than SC provided by NSHWs in a community setting 12 and 24 months after completion of treatment.",2020,"Participants receiving prolonged exposure experienced greater improvement on the PTSD symptom severity scale than those receiving SC at 12-months FU [difference in PE-A v. SC mean scores = 9.24, 95% CI (3.66-14.83), p < 0.001; g = 0.88] and at 24-months FU [difference in PE-A v. SC mean scores = 9.35, 95% CI (3.53-15.17), p = 0.002; g = 0.68]. ","['adolescents with PTSD up to 24-months post-treatment', 'post-traumatic stress disorder in adolescents', 'adolescents (PE-A) and', 'Adolescents with PTSD', 'adolescents with post-traumatic stress disorder (PTSD', 'Sixty-three adolescents (13-18 years) with PTSD']","['prolonged exposure therapy and supportive counselling', 'prolonged exposure therapy', 'interventions comprising 7-14 sessions of treatment provided by trained and supervised non-specialist health workers (NSHWs', 'supportive counselling (SC']","['PTSD symptoms', 'Child PTSD Symptom Scale', 'PTSD symptom severity', 'PTSD symptom severity scale']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}, {'cui': 'C4319614', 'cui_str': '63'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}, {'cui': 'C3697360', 'cui_str': 'Supportive counseling'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1306056', 'cui_str': 'Worker'}]","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}]",,0.0280743,"Participants receiving prolonged exposure experienced greater improvement on the PTSD symptom severity scale than those receiving SC at 12-months FU [difference in PE-A v. SC mean scores = 9.24, 95% CI (3.66-14.83), p < 0.001; g = 0.88] and at 24-months FU [difference in PE-A v. SC mean scores = 9.35, 95% CI (3.53-15.17), p = 0.002; g = 0.68]. ","[{'ForeName': 'Jaco', 'Initials': 'J', 'LastName': 'Rossouw', 'Affiliation': 'Department of Psychiatry, Stellenbosch University, Stellenbosch, Western Cape, South Africa.'}, {'ForeName': 'Elna', 'Initials': 'E', 'LastName': 'Yadin', 'Affiliation': 'Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Alexander', 'Affiliation': 'Department of Psychiatry, Stellenbosch University, Stellenbosch, Western Cape, South Africa.'}, {'ForeName': 'Soraya', 'Initials': 'S', 'LastName': 'Seedat', 'Affiliation': 'Department of Psychiatry, Stellenbosch University, Stellenbosch, Western Cape, South Africa.'}]",Psychological medicine,['10.1017/S0033291720002731'] 2702,32762708,Immediate effects of cervicothoracic junction mobilization versus thoracic manipulation on the range of motion and pain in mechanical neck pain with cervicothoracic junction dysfunction: a pilot randomized controlled trial.,"BACKGROUND Cervicothoracic (CT) junction hypomobility has been proposed as a contributing factor for neck pain. However, there are limited studies that compared the effect of CT junction mobilization against an effective intervention in neck pain. Thoracic spine manipulation is a nonspecific intervention for neck pain where remote spinal segments are treated based on the concept of regional interdependence. The effectiveness of segment-specific spinal mobilization in the cervical spine has been researched in the last few years, and no definite conclusions could be made from the previous studies. The above reasons warrant the investigation of the effects of a specific CT junction mobilization against a nonspecific thoracic manipulation intervention in neck pain. The present study aims to compare the immediate effects of C7-T1 Maitland mobilization with thoracic manipulation in individuals with mechanical neck pain presenting with CT junction dysfunction specifically. METHODS A randomized clinical trial is conducted where participants with complaints of mechanical neck pain and CT junction dysfunction randomly assigned to either C7-T1 level Maitland mobilization group or mid-thoracic (T3-T6) manipulation group (active control group). In both the groups, the post graduate student (SJ) pursuing Master's in orthopedic physiotherapy delivered the intervention. The outcomes of cervical flexion, extension, side flexion & rotation range of motion (ROM) were measured before & after the intervention with a cervical range of motion (CROM) device. Self-reported pain intensity was measured with the numerical pain rating scale (NPRS). The post-intervention between-group comparison was performed using a one-way ANCOVA test. RESULTS Forty-two participants with mean age CT junction group: 35.14 ± 10.13 and Thoracic manipulation group: 38.47 ± 11.47 were recruited for the study. No significant differences in the post-intervention baseline adjusted outcomes of cervical ROM & self-reported pain intensity were identified between the groups after the treatment (p = 0.08, 0.95, 0.01, 0.39, 0.29, 0.27for flexion, extension, bilateral lateral flexion & rotations respectively) & neck pain intensity (p = 0.68). However, within-group, pre, and post comparison showed significant improvements in cervical ROM and pain in both groups. CONCLUSION This preliminary study identified that CT junction mobilization is not superior to thoracic manipulation on the outcomes of cervical ROM and neck pain when level-specific CT junction mobilization was compared with remote mid-thoracic manipulation in individuals with mechanical neck pain and CT junction dysfunction. TRIAL REGISTRATION CTRI: 2018/04/013088, Registered 6 April 2018, http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=24418.",2020,"No significant differences in the post-intervention baseline adjusted outcomes of cervical ROM & self-reported pain intensity were identified between the groups after the treatment (p = 0.08, 0.95, 0.01, 0.39, 0.29, 0.27for flexion, extension, bilateral lateral flexion & rotations respectively) & neck pain intensity (p = 0.68).","['participants with complaints of mechanical neck pain and CT junction dysfunction randomly assigned to either', 'individuals with mechanical neck pain presenting with CT junction dysfunction specifically', 'Forty-two participants with mean age CT junction group: 35.14\u2009±\u200910.13 and Thoracic manipulation group: 38.47\u2009±\u200911.47 were recruited for the study', 'mechanical neck pain with cervicothoracic junction dysfunction', 'individuals with mechanical neck pain and CT junction dysfunction', 'neck pain']","['cervicothoracic junction mobilization versus thoracic manipulation', 'CT junction mobilization', 'Thoracic spine manipulation', 'segment-specific spinal mobilization', 'C7-T1 level Maitland mobilization group or mid-thoracic (T3-T6) manipulation group (active control group', 'specific CT junction mobilization against a nonspecific thoracic manipulation intervention', 'C7-T1 Maitland mobilization with thoracic manipulation']","['cervical ROM & self-reported pain intensity', 'numerical pain rating scale (NPRS', 'range of motion and pain', 'cervical ROM and pain', 'neck pain intensity', 'Self-reported pain intensity', 'cervical flexion, extension, side flexion & rotation range of motion (ROM', 'cervical ROM and neck pain']","[{'cui': 'C0277786', 'cui_str': 'Complaint'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0450195', 'cui_str': 'Cervicothoracic'}, {'cui': 'C0205144', 'cui_str': 'Junctional'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0450195', 'cui_str': 'Cervicothoracic'}, {'cui': 'C0205144', 'cui_str': 'Junctional'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0581269', 'cui_str': 'Thoracic spine structure'}, {'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0446419', 'cui_str': 'Level of the first thoracic vertebra'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}]",42.0,0.166055,"No significant differences in the post-intervention baseline adjusted outcomes of cervical ROM & self-reported pain intensity were identified between the groups after the treatment (p = 0.08, 0.95, 0.01, 0.39, 0.29, 0.27for flexion, extension, bilateral lateral flexion & rotations respectively) & neck pain intensity (p = 0.68).","[{'ForeName': 'Shriya', 'Initials': 'S', 'LastName': 'Joshi', 'Affiliation': 'Department of Physiotherapy, Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal, Karnataka, India.'}, {'ForeName': 'Ganesh', 'Initials': 'G', 'LastName': 'Balthillaya', 'Affiliation': 'Department of Physiotherapy, Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal, Karnataka, India.'}, {'ForeName': 'Y V Raghava', 'Initials': 'YVR', 'LastName': 'Neelapala', 'Affiliation': 'Department of Physiotherapy, Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal, Karnataka, India. yuvaraghava999@gmail.com.'}]",Chiropractic & manual therapies,['10.1186/s12998-020-00327-4'] 2703,32762718,Fire needle plus cupping for acute herpes zoster: study protocol for a randomized controlled trial.,"BACKGROUND Acute herpes zoster (AHZ) is a common skin disease caused by invasion of the varicella zoster virus into the ganglia and skin, and the severe pain is the most complaint, which can seriously disturb the normal life of patients. Fire needle plus cupping is a special acupuncture treatment, which is widely used to treat AHZ for its better analgesic effect in China although it has not been fully verified by rigorous randomized controlled trial (RCT). METHODS/DESIGN To test the effect, a three-arm randomized parallel controlled trial protocol has been designed. A total of 105 AHZ patients suffering pain will be randomly divided into three groups in an equal proportion. The interventions are fire needle plus cupping (FC) in group A, famciclovir plus gabapentin (FG) in group B, and fire needle plus cupping plus famciclovir (FCF) in group C. The length for the trial is set for a week time frame. Precisely speaking, the A group (FC) is to carry out 1 treatment per day for the total of 7 treatment sessions within 1 week period. On the other hand, the B group (FG) will take drugs orally three times a day within the trial 1 week. Meanwhile, with its combination element, the C group (FCF) is due to undertake both treatments and drugs as prescribed for A and B groups within the trial week. As an intra-trial arrangement, analgesic medication will be carefully administered for temporary pain release if the sudden intolerable pain appeared. For the primary outcome, this study is due to apply visual analogue scale to identify pain intensity relief. As the secondary outcomes are concerned, this study is aiming to focus on the issues related to changes in substance P and beta-endorphin concentrations in peripheral plasma, as well as those issues of analgesic needs, side effects, symptoms, and physical signs including pain classification, local itching, burning sensation, fever, local lymphadenopathy, skin lesion area, blisters, herpes clusters, vesicular traits, ulcers, and pimples; all these are taken into account for evaluation. For the final stage, the participants are to be followed up for postherpetic neuralgia. DISCUSSION The results of this trial aim to provide sufficient evidence on FC treatment over both FG and FCF treatments. It will then give a credible alternative treatment to cut down acute pain and to cure AHZ infection. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiCTR1800015372 . Registered on 28 March 2018.",2020,"As the secondary outcomes are concerned, this study is aiming to focus on the issues related to changes in substance P and beta-endorphin concentrations in peripheral plasma, as well as those issues of analgesic needs, side effects, symptoms, and physical signs including pain classification, local itching, burning sensation, fever, local lymphadenopathy, skin lesion area, blisters, herpes clusters, vesicular traits, ulcers, and pimples; all these are taken into account for evaluation.","['acute herpes zoster', 'Acute herpes zoster (AHZ', '105 AHZ patients suffering pain']","['fire needle plus cupping plus famciclovir (FCF', 'famciclovir plus gabapentin (FG', 'fire needle plus cupping (FC', 'Fire needle plus cupping']","['visual analogue scale to identify pain intensity relief', 'analgesic needs, side effects, symptoms, and physical signs including pain classification, local itching, burning sensation, fever, local lymphadenopathy, skin lesion area, blisters, herpes clusters, vesicular traits, ulcers, and pimples']","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0019360', 'cui_str': 'Herpes zoster'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0014007', 'cui_str': 'Dismissed from job'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0220647', 'cui_str': 'Carcinoma of unknown primary'}, {'cui': 'C0209227', 'cui_str': 'famciclovir'}, {'cui': 'C0060926', 'cui_str': 'gabapentin'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0085624', 'cui_str': 'Burning sensation'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0497156', 'cui_str': 'Lymphadenopathy'}, {'cui': 'C0037284', 'cui_str': 'Skin lesion'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0005758', 'cui_str': 'Blister'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0205378', 'cui_str': 'Vesicular'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0241157', 'cui_str': 'Pustule'}]",105.0,0.0853366,"As the secondary outcomes are concerned, this study is aiming to focus on the issues related to changes in substance P and beta-endorphin concentrations in peripheral plasma, as well as those issues of analgesic needs, side effects, symptoms, and physical signs including pain classification, local itching, burning sensation, fever, local lymphadenopathy, skin lesion area, blisters, herpes clusters, vesicular traits, ulcers, and pimples; all these are taken into account for evaluation.","[{'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'The Six Affiliated Hospital of Kunming Medical University, Yuxi, 653100, China.'}, {'ForeName': 'Zuohui', 'Initials': 'Z', 'LastName': 'Liang', 'Affiliation': 'The Six Affiliated Hospital of Kunming Medical University, Yuxi, 653100, China.'}, {'ForeName': 'Shihua', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'The Six Affiliated Hospital of Kunming Medical University, Yuxi, 653100, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'The Six Affiliated Hospital of Kunming Medical University, Yuxi, 653100, China.'}, {'ForeName': 'Taipin', 'Initials': 'T', 'LastName': 'Guo', 'Affiliation': 'School of Acupuncture-Moxibustion and Tuina and Rehabilitation, Yunnan University of Chinese Medicine, Kunming, 650500, China. gtphncs@126.com.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': ""The Third People's Hospital of Yunnan Province, Kunming, 650011, China.""}, {'ForeName': 'Juanjuan', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'The Six Affiliated Hospital of Kunming Medical University, Yuxi, 653100, China.'}, {'ForeName': 'Qiannan', 'Initials': 'Q', 'LastName': 'Xu', 'Affiliation': 'The Six Affiliated Hospital of Kunming Medical University, Yuxi, 653100, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'The Six Affiliated Hospital of Kunming Medical University, Yuxi, 653100, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'The Six Affiliated Hospital of Kunming Medical University, Yuxi, 653100, China.'}, {'ForeName': 'Cailian', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'The Six Affiliated Hospital of Kunming Medical University, Yuxi, 653100, China.'}, {'ForeName': 'Xiuhong', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'The Six Affiliated Hospital of Kunming Medical University, Yuxi, 653100, China. 734182946@qq.com.'}]",Trials,['10.1186/s13063-020-04599-2'] 2704,32762736,Differential and shared effects of psychological skills training and mindfulness training on performance-relevant psychological factors in sport: a randomized controlled trial.,"BACKGROUND Mental training intends to support athletes in mastering challenges in sport. The aim of our study was to investigate the differential and shared effects of psychological skills training and mindfulness training on psychological variables relevant to athletic performance (e.g., handling emotions or attention control). We assumed that each approach has its own strengths (e.g., mindfulness has a differential effect on the acceptance of emotions), but for some goals (e.g., attention control), both training forms are expected to be equally successful (i.e., shared effects). METHODS A total of 95 athletes (M age  = 24.43, SD age  = 5.15; 49% female) were randomly assigned into three groups: psychological skills training intervention (PST), mindfulness training intervention (MT), and wait-list control group (WL). Participants completed a questionnaire battery before and after the training (pretest and posttest). We assessed mindfulness, use of mental strategies, handling of emotions, attention in training and competition, as well as the dealing with failure. The two intervention programs each consisted of four 90-min group workshops conducted over a period of 4 weeks. RESULTS Both interventions passed the manipulation check, that is, PST led to more mental strategies being used (probabilities > 95%), and MT led to an increase in two of three aspects of mindfulness (probabilities > 98%) when compared to WL. Compared to WL, both interventions equally improved in the ability to not let emotions interfere with performance (probabilities > 99%) and in controlling attention in training and competition (probabilities > 89%). To a lesser extend, both interventions showed shared improvements in dealing with failure indicated by more action orientation (probabilities > 82%). We found a differential effect of MT on decreased experiential avoidance: MT decreased compared to WL and PST (probabilities > 92%), whereas PST did not differ from WL. CONCLUSION We conclude that both forms of mental training lead to improvements in performance-relevant psychological factors, especially concerning the handling of emotions and attention control. The results of our study suggest that different paths may lead to the desired outcomes, and accordingly, both forms of mental training seem justified. TRIAL REGISTRATION NUMBER ISRCTN11147748 , date of registration: July 11, 2016.",2020,"Compared to WL, both interventions equally improved in the ability to not let emotions interfere with performance (probabilities > 99%) and in controlling attention in training and competition (probabilities > 89%).","['95 athletes (M age \u2009=\u200924.43, SD age \u2009=\u20095.15; 49% female', 'sport']","['MT', 'psychological skills training intervention (PST), mindfulness training intervention (MT), and wait-list control group (WL', 'psychological skills training and mindfulness training']","['experiential avoidance: MT', 'performance-relevant psychological factors']","[{'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038039', 'cui_str': 'Sport'}]","[{'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0033898', 'cui_str': 'Factors, Psychological'}]",95.0,0.0404468,"Compared to WL, both interventions equally improved in the ability to not let emotions interfere with performance (probabilities > 99%) and in controlling attention in training and competition (probabilities > 89%).","[{'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Röthlin', 'Affiliation': 'Swiss Federal Institute of Sport, Alpenstrasse 18, CH-2532, Magglingen, Switzerland. philipp.roethlin@baspo.admin.ch.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Horvath', 'Affiliation': 'Swiss Federal Institute of Sport, Alpenstrasse 18, CH-2532, Magglingen, Switzerland.'}, {'ForeName': 'Severin', 'Initials': 'S', 'LastName': 'Trösch', 'Affiliation': 'Swiss Federal Institute of Sport, Alpenstrasse 18, CH-2532, Magglingen, Switzerland.'}, {'ForeName': 'Martin Grosse', 'Initials': 'MG', 'LastName': 'Holtforth', 'Affiliation': 'Institute for Psychology, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Birrer', 'Affiliation': 'Swiss Federal Institute of Sport, Alpenstrasse 18, CH-2532, Magglingen, Switzerland.'}]",BMC psychology,['10.1186/s40359-020-00449-7'] 2705,32762763,Percutaneous vertebroplasty with high- versus low-viscosity bone cement for osteoporotic vertebral compression fractures.,"OBJECTIVE There is no consensus on the best choice between high- and low-viscosity bone cement for percutaneous vertebroplasty (PVP). This study aimed to compare the clinical and radiological outcomes and leakage between three cements with different viscosities in treating osteoporotic vertebral compression fractures. METHODS This is a prospective study comparing patients who were treated with PVP under local anesthesia: group A (n = 99, 107 vertebrae) with high-viscosity OSTEOPAL V cement, group B (n = 79, 100 vertebrae) with low-viscosity OSTEOPAL V cement, and group C (n = 88, 102 vertebrae) with low-viscosity Eurofix VTP cement. Postoperative pain severity was evaluated using the visual analog scale. Cement leakage was evaluated using radiography and computed tomography. RESULTS There was no significant difference in the incidence of cement leakage between the three groups (group A 20.6%, group B 24.2%, group C 20.6%, P = 0.767). All three groups showed significant reduction in postoperative pain scores but did not differ significantly in pain scores at postoperative 2 days (group A 2.01 ± 0.62, group B 2.15 ± 0.33, group C 1.92 ± 0.71, P = 0.646). During the 6 months after cement implantation, significantly less reduction in the fractured vertebral body height was noticed in group B and group C than in group A (group A 19.0%, group B 8.1%, group C 7.3%, P = 0.009). CONCLUSIONS Low-viscosity cement has comparable incidence of leakage compared to high-viscosity cement in PVP for osteoporotic vertebral compression fractures. It also can better prevent postoperative loss of fractured vertebral body's height.",2020,"All three groups showed significant reduction in postoperative pain scores but did not differ significantly in pain scores at postoperative 2 days (group A 2.01 ± 0.62, group B 2.15 ± 0.33, group C 1.92 ± 0.71, P = 0.646).","['osteoporotic vertebral compression fractures', 'patients who were treated with PVP under local anesthesia: group A (n = 99, 107 vertebrae) with']","['Percutaneous vertebroplasty with high- versus low-viscosity bone cement', 'low-viscosity Eurofix VTP cement', 'high-viscosity OSTEOPAL V cement']","['pain scores', 'postoperative pain scores', 'Cement leakage', 'Postoperative pain severity', 'fractured vertebral body height', 'incidence of cement leakage', 'visual analog scale']","[{'cui': 'C0262431', 'cui_str': 'Compression fracture of vertebral column'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0032856', 'cui_str': 'Povidone'}, {'cui': 'C1720162', 'cui_str': 'Under local anesthesia'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0549207', 'cui_str': 'Bone structure of spine'}]","[{'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C1303192', 'cui_str': 'Vertebroplasty'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0042784', 'cui_str': 'Viscosity'}, {'cui': 'C0005934', 'cui_str': 'Bone cements'}, {'cui': 'C0011343', 'cui_str': 'Cementum structure'}, {'cui': 'C1744326', 'cui_str': 'osteopal V'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011343', 'cui_str': 'Cementum structure'}, {'cui': 'C0015376', 'cui_str': 'Extravasation'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0080179', 'cui_str': 'Fracture of vertebral column'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",,0.0163968,"All three groups showed significant reduction in postoperative pain scores but did not differ significantly in pain scores at postoperative 2 days (group A 2.01 ± 0.62, group B 2.15 ± 0.33, group C 1.92 ± 0.71, P = 0.646).","[{'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Miao', 'Affiliation': 'Department of Spine Surgery, Renmin Hospital, Hubei University of Medicine, No.39 Middle Chaoyang Road, Shiyan, 442000, Hubei, China.'}, {'ForeName': 'Xiaojun', 'Initials': 'X', 'LastName': 'Zeng', 'Affiliation': 'Department of Spine Surgery, Renmin Hospital, Hubei University of Medicine, No.39 Middle Chaoyang Road, Shiyan, 442000, Hubei, China. znchick@163.com.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Spine Surgery, Renmin Hospital, Hubei University of Medicine, No.39 Middle Chaoyang Road, Shiyan, 442000, Hubei, China.'}, {'ForeName': 'Zhou', 'Initials': 'Z', 'LastName': 'Zhao', 'Affiliation': 'Department of Spine Surgery, Renmin Hospital, Hubei University of Medicine, No.39 Middle Chaoyang Road, Shiyan, 442000, Hubei, China.'}]",Journal of orthopaedic surgery and research,['10.1186/s13018-020-01835-y'] 2706,32762784,Flipped Classroom Approach Used in the Training of Mass Casualty Triage for Medical Undergraduate Students.,"OBJECTIVE The aim of this study was to explore the application of the flipped classroom approach in the training of Mass Casualty Triage (MCT) to medical undergraduate students. METHODS In this study, 103 fourth-year medical students were randomly divided into a Flipped Classroom (FC) group (n = 51) and a Traditional Lecture-based Classroom (TLC) group (n = 52). A post-class quiz, simulated field triage (SFT) and feedback questionnaires were performed to assess both groups of students for their learning of the course. RESULTS In the post-quiz, the median (IQR) scores achieved by students from the FC and TLC groups were 42(5) and 39(5.5), respectively. Significant differences were found between the two groups. In the SFT, overall triage accuracy was 67.06% for FC, and 64.23% for TLC students. Over-triage and under-triage errors occurred in 18.43% and 14.50% of the FC group, respectively. The TLC group had a similar pattern of 20.77% over-triage and 15.0% under-triage errors. No significant differences were found regarding overall triage accuracy or triage errors between the two groups. CONCLUSIONS The FC approach could enhance course grades reflected in the post-quiz and improve students' satisfaction with the class. However, there was no significant difference of competency between the two groups demonstrated in the SFT exercise.",2020,"No significant differences were found regarding overall triage accuracy or triage errors between the two groups. ","['Medical Undergraduate Students', '103 fourth-year medical students', 'medical undergraduate students']","['TLC', 'Flipped Classroom (FC', 'Traditional Lecture-based Classroom (TLC']","['median (IQR) scores', 'overall triage accuracy or triage errors', 'overall triage accuracy', 'SFT exercise']","[{'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0205438', 'cui_str': 'Fourth'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0376683', 'cui_str': 'Lectures'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0540654', 'cui_str': 'Casper Protein'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0040861', 'cui_str': 'Triage'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",103.0,0.0229306,"No significant differences were found regarding overall triage accuracy or triage errors between the two groups. ","[{'ForeName': 'Ziyu', 'Initials': 'Z', 'LastName': 'Zheng', 'Affiliation': 'Department of Emergency Medicine, the First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, China, 510080.'}, {'ForeName': 'Shiwen', 'Initials': 'S', 'LastName': 'Yuan', 'Affiliation': ""Department of Rheumatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China, No. 1, Panfu Road, Guangzhou, China, 510180.""}, {'ForeName': 'Mingcheng', 'Initials': 'M', 'LastName': 'Huang', 'Affiliation': 'Department of Nephrology, Kidney and Urology Center, the Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China, 518034.'}, {'ForeName': 'Jinli', 'Initials': 'J', 'LastName': 'Liao', 'Affiliation': 'Department of Emergency Medicine, the First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, China, 510080.'}, {'ForeName': 'Ruibin', 'Initials': 'R', 'LastName': 'Cai', 'Affiliation': 'Department of Emergency Medicine, the First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, China, 510080.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Zhan', 'Affiliation': 'Department of Emergency Medicine, the First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, China, 510080.'}, {'ForeName': 'Zhen', 'Initials': 'Z', 'LastName': 'Yang', 'Affiliation': 'Department of Emergency Medicine, the First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, China, 510080.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Xiong', 'Affiliation': 'Department of Emergency Medicine, the First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, China, 510080.'}]",Disaster medicine and public health preparedness,['10.1017/dmp.2020.162'] 2707,32763021,Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errors.,"Major depressive disorder negatively impacts the sensitivity and adaptability of the brain's predictive coding framework. The current electroencephalography study into the antidepressant properties of ketamine investigated the downstream effects of ketamine on predictive coding and short-term plasticity in thirty patients with depression using the auditory roving mismatch negativity (rMMN). The rMMN paradigm was run 3-4 h after a single 0.44 mg/kg intravenous dose of ketamine or active placebo (remifentanil infused to a target plasma concentration of 1.7 ng/mL) in order to measure the neural effects of ketamine in the period when an improvement in depressive symptoms emerges. Depression symptomatology was measured using the Montgomery-Asberg Depression Rating Scale (MADRS); 70% of patients demonstrated at least a 50% reduction their MADRS global score. Ketamine significantly increased the MMN and P3a event related potentials, directly contrasting literature demonstrating ketamine's acute attenuation of the MMN. This effect was only reliable when all repetitions of the post-deviant tone were used. Dynamic causal modelling showed greater modulation of forward connectivity in response to a deviant tone between right primary auditory cortex and right inferior temporal cortex, which significantly correlated with antidepressant response to ketamine at 24 h. This is consistent with the hypothesis that ketamine increases sensitivity to unexpected sensory input and restores deficits in sensitivity to prediction error that are hypothesised to underlie depression. However, the lack of repetition suppression evident in the MMN evoked data compared to studies of healthy adults suggests that, at least within the short term, ketamine does not improve deficits in adaptive internal model calibration.",2020,"Ketamine significantly increased the MMN and P3a event related potentials, directly contrasting literature demonstrating ketamine's acute attenuation of the MMN.",['thirty patients with depression using the auditory roving mismatch negativity (rMMN'],"['ketamine', 'Ketamine', 'ketamine or active placebo (remifentanil']","['Montgomery-Asberg Depression Rating Scale (MADRS', 'Depression symptomatology', 'MMN and P3a', 'MADRS global score']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}]","[{'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0393847', 'cui_str': 'Motor neuropathy with multiple conduction block'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",30.0,0.0416165,"Ketamine significantly increased the MMN and P3a event related potentials, directly contrasting literature demonstrating ketamine's acute attenuation of the MMN.","[{'ForeName': 'Rachael L', 'Initials': 'RL', 'LastName': 'Sumner', 'Affiliation': 'School of Pharmacy, University of Auckland, New Zealand. Electronic address: rsum009@aucklanduni.ac.nz.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'McMillan', 'Affiliation': 'School of Pharmacy, University of Auckland, New Zealand.'}, {'ForeName': 'Meg J', 'Initials': 'MJ', 'LastName': 'Spriggs', 'Affiliation': 'Centre for Psychedelic Research, Department of Medicine, Imperial College London, UK; Brain Research New Zealand; School of Psychology, University of Auckland, New Zealand.'}, {'ForeName': 'Doug', 'Initials': 'D', 'LastName': 'Campbell', 'Affiliation': 'Department of Anaesthesia and Perioperative Medicine, Auckland District Health Board, New Zealand.'}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Malpas', 'Affiliation': 'Department of Anaesthesia and Perioperative Medicine, Auckland District Health Board, New Zealand.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Maxwell', 'Affiliation': 'Department of Anaesthesia and Perioperative Medicine, Auckland District Health Board, New Zealand.'}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Deng', 'Affiliation': 'Department of Anaesthesia and Perioperative Medicine, Auckland District Health Board, New Zealand.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Hay', 'Affiliation': 'Department of Anaesthesia and Perioperative Medicine, Auckland District Health Board, New Zealand.'}, {'ForeName': 'Rhys', 'Initials': 'R', 'LastName': 'Ponton', 'Affiliation': 'School of Pharmacy, University of Auckland, New Zealand.'}, {'ForeName': 'Frederick', 'Initials': 'F', 'LastName': 'Sundram', 'Affiliation': 'Department of Psychological Medicine, University of Auckland, New Zealand.'}, {'ForeName': 'Suresh D', 'Initials': 'SD', 'LastName': 'Muthukumaraswamy', 'Affiliation': 'School of Pharmacy, University of Auckland, New Zealand.'}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2020.07.009'] 2708,32763026,"Asthma control affects school absence, achievement and quality of school life: a multicenter study.","INTRODUCTION AND OBJECTIVES Asthma may have a detrimental effect on school attendance and achievement. Friend relations, attendance to school activities, quality of life (QOL) of asthmatic children may be negatively affected. The aim of this study was to evaluate factors influencing school functioning for asthmatic school-age children. MATERIALS AND METHODS From January to May 2019, parents and school-age children who were followed by a diagnosis of asthma for more than one year, from seven pediatric allergy centers, were given a standard questionnaire including questions about child's disease, school performance, absenteeism, home-family-school conditions. A pediatric QOL questionnaire was filled out by children. For evaluating control in the previous year, children who had more than two exacerbations and/or had any exacerbations needing systemic corticosteroids in the previous year were defined as inadequate control. School absence over nine days was taken into account as this has been shown to bring a risk for successful school life. RESULTS 507 patients were included. Asthma control status was found to be effective on school absence (p < 0.001), on school success (especially math scores) (p < 0.001), on friend relations (p = 0.033), QOL (p < 0.001), attendance to school activities (p < 0.001). Regular follow-up (p < 0.001), regular use of asthma medication (p = 0.014), tobacco smoke exposure (p < 0.001), heating with stove at home (p = 0.01) affected asthma control. School conditions such as crowdedness (p = 0.044), humidity of the class (p = 0.025), knowledge of teacher about child's asthma (p = 0.012) were effective on asthma control independent of home conditions and asthma treatment parameters. CONCLUSION School interventions are important to improve asthma management.",2020,"Asthma control status was found to be effective on school absence (p < 0.001), on school success (especially math scores) (p < 0.001), on friend relations (p = 0.033), QOL (p < 0.001), attendance to school activities (p < 0.001).","['asthmatic school-age children', '507 patients were included', 'children who had more than two exacerbations and/or had any exacerbations needing systemic corticosteroids in the previous year', ""From January to May 2019, parents and school-age children who were followed by a diagnosis of asthma for more than one year, from seven pediatric allergy centers, were given a standard questionnaire including questions about child's disease, school performance, absenteeism, home-family-school conditions""]",[],"['attendance to school activities', 'school absence, achievement and quality of school life', 'QOL', 'school success', ""knowledge of teacher about child's asthma"", 'humidity of the class', 'regular use of asthma medication', 'tobacco smoke exposure', 'school absence', 'school functioning', 'Friend relations, attendance to school activities, quality of life (QOL']","[{'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0450381', 'cui_str': '507'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0002111', 'cui_str': 'Allergy - specialty'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0036373', 'cui_str': 'Academic Test Performance'}, {'cui': 'C0000849', 'cui_str': 'Absenteeism'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]",[],"[{'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0020167', 'cui_str': 'Humidity'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0439994', 'cui_str': 'Tobacco smoke'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0079382', 'cui_str': 'Friend'}, {'cui': 'C0080103', 'cui_str': 'Relative'}]",507.0,0.0250252,"Asthma control status was found to be effective on school absence (p < 0.001), on school success (especially math scores) (p < 0.001), on friend relations (p = 0.033), QOL (p < 0.001), attendance to school activities (p < 0.001).","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Toyran', 'Affiliation': 'Ankara City Hospital, Division of Pediatric Allergy and Immunology, Ankara, Turkey. Electronic address: mugetoyran@yahoo.com.'}, {'ForeName': 'I T', 'Initials': 'IT', 'LastName': 'Yagmur', 'Affiliation': 'Ankara City Hospital, Division of Pediatric Allergy and Immunology, Ankara, Turkey. Electronic address: iremtrgy@gmail.com.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Guvenir', 'Affiliation': 'Malatya Training and Research Hospital, Pediatric Allergy and Immunology Clinic, Malatya, Turkey. Electronic address: dr.hguvenir@gmail.com.'}, {'ForeName': 'I A', 'Initials': 'IA', 'LastName': 'Haci', 'Affiliation': 'Health Sciences University, Dr.Behçet Uz Children Training and Research Hospital, Division of Pediatric Allergy and Immunology, İzmir, Turkey. Electronic address: dridilakayhaci@gmail.com.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Bahceci', 'Affiliation': 'Cigli Training and Research Hospital, Division of Pediatric Allergy and Immunology, İzmir, Turkey. Electronic address: semihabahceci@hotmail.com.'}, {'ForeName': 'S B', 'Initials': 'SB', 'LastName': 'Batmaz', 'Affiliation': 'Tokat State Hospital, Pediatric Allergy and Clinical Immunology Clinic, Tokat, Turkey. Electronic address: drsehra@yahoo.com.'}, {'ForeName': 'O Y', 'Initials': 'OY', 'LastName': 'Topal', 'Affiliation': 'Ankara City Hospital, Division of Pediatric Allergy and Immunology, Ankara, Turkey. Electronic address: ozgeyilmaztopal@gmail.com.'}, {'ForeName': 'I K', 'Initials': 'IK', 'LastName': 'Celik', 'Affiliation': 'Ankara City Hospital, Division of Pediatric Allergy and Immunology, Ankara, Turkey. Electronic address: dr.ilknur-46@windowslive.com.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Karaatmaca', 'Affiliation': 'Ankara City Hospital, Division of Pediatric Allergy and Immunology, Ankara, Turkey. Electronic address: drbkatmaca@gmail.com.'}, {'ForeName': 'E D', 'Initials': 'ED', 'LastName': 'Misirlioglu', 'Affiliation': 'Ankara City Hospital, Division of Pediatric Allergy and Immunology, Ankara, Turkey. Electronic address: edibekm@yahoo.com.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Civelek', 'Affiliation': 'Ankara City Hospital, Division of Pediatric Allergy and Immunology, Ankara, Turkey. Electronic address: ersoycivelek@gmail.com.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Can', 'Affiliation': 'Balıkesir University School of Medicine, Department of Pediatrics, Balıkesir, Turkey. Electronic address: ddcan15@hotmail.com.'}, {'ForeName': 'C N', 'Initials': 'CN', 'LastName': 'Kocabas', 'Affiliation': 'Muğla Sitki Kocman University School of Medicine, Department of Pediatrics, Mugla, Turkey. Electronic address: cankocabas@yahoo.com.'}]",Allergologia et immunopathologia,['10.1016/j.aller.2020.05.005'] 2709,32763073,Impact of Repositioning on Outcomes Following Transcatheter Aortic Valve Replacement With a Self-Expandable Valve.,"OBJECTIVES This study sought to compare outcomes following transcatheter aortic valve replacement when valve repositioning was performed (repositioned group) versus procedures without repositioning (nonrepositioned group). BACKGROUND The Evolut R and Evolut PRO valves were designed to allow repositioning during deployment, yet the effect of repositioning on clinical outcomes remains unclear. METHODS Patients implanted with the Evolut R or PRO valve from the SURTAVI (Surgical Replacement and Transcatheter Aortic Valve Implantation) trial continued access study and the Evolut Low Risk Trial between June 2016 and November 2018 were combined. Baseline multidetector computed tomography data were analyzed for the Evolut Low Risk Trial patients. The primary outcomes were the rate of all-cause mortality and the rate of disabling stroke 30 days. Secondary outcomes were per Valve Academic Research Consortium-2. RESULTS The Evolut R or PRO valve was implanted in 946 patients, and repositioning was performed in 318 (33.6%). Compared with patients in the nonrepositioned group, patients in the repositioned group had lower Society of Thoracic Surgeons score (2.3 ± 1.3% vs. 2.6 ± 1.4%; p < 0.001) and fewer prior percutaneous coronary interventions (11.9% vs. 19.7%; p = 0.003). There were no differences in baseline multidetector computed tomography parameters between groups. There were no differences in the primary outcome of death (0.3% vs. 0.3%; p = 0.99) or disabling stroke (0.3% vs. 0.5%; p = 0.71) at 30 days or 1 year (1.9% vs. 2.9%; p = 0.44; and 0.8% vs. 0.9%%; p = 0.79, respectively). CONCLUSIONS The utilization of the repositioning feature of the Evolut valves was safe, and no differences in death or disabling stroke were observed at 30 days or 1 year between groups. (Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients; NCT02701283; Safety and Efficacy Study of the Medtronic CoreValve® System In the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement [SURTAVI]; NCT01586910).",2020,"The utilization of the repositioning feature of the Evolut valves was safe, and no differences in death or disabling stroke were observed at 30 days or 1 year between groups.","['Patients implanted with the Evolut R or PRO valve from the SURTAVI ', 'Intermediate Risk Subjects']","['transcatheter aortic valve replacement', 'Need Aortic Valve Replacement', 'Replacement With a Self-Expandable Valve', 'Transcatheter Aortic Valve', 'Medtronic CoreValve® System', 'Surgical Replacement and Transcatheter Aortic Valve Implantation', 'procedures without repositioning (nonrepositioned group']","['fewer prior percutaneous coronary interventions', 'death', 'rate of all-cause mortality and the rate of disabling stroke 30\xa0days', 'baseline multidetector computed tomography parameters', 'per Valve Academic Research Consortium-2', 'disabling stroke', 'death or disabling stroke', 'Evolut R or PRO valve', 'lower Society of Thoracic Surgeons score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]","[{'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0442343', 'cui_str': 'Transcatheter approach'}, {'cui': 'C0003501', 'cui_str': 'Aortic valve structure'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0556030', 'cui_str': 'Repositioning'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205388', 'cui_str': 'Few'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C3179130', 'cui_str': 'Multidetector-Row Computed Tomography'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0278626', 'cui_str': 'Thoracic surgeon'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",946.0,0.112353,"The utilization of the repositioning feature of the Evolut valves was safe, and no differences in death or disabling stroke were observed at 30 days or 1 year between groups.","[{'ForeName': 'Guilherme F', 'Initials': 'GF', 'LastName': 'Attizzani', 'Affiliation': 'Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio. Electronic address: guilherme.attizzani@uhhospitals.org.'}, {'ForeName': 'Luis Augusto P', 'Initials': 'LAP', 'LastName': 'Dallan', 'Affiliation': 'Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Markowitz', 'Affiliation': 'Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio.'}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Yakubov', 'Affiliation': 'Department of Interventional Cardiology, OhioHealth Riverside Methodist, Columbus, Ohio.'}, {'ForeName': 'G Michael', 'Initials': 'GM', 'LastName': 'Deeb', 'Affiliation': 'Departments of Cardiac Surgery, University of Michigan Hospitals, Ann Arbor, Michigan.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Reardon', 'Affiliation': 'Department of Cardiothoracic Surgery, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas.'}, {'ForeName': 'John K', 'Initials': 'JK', 'LastName': 'Forrest', 'Affiliation': 'Departments of Internal Medicine (Cardiology) and Cardiac Surgery, Yale University School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Abeel A', 'Initials': 'AA', 'LastName': 'Mangi', 'Affiliation': 'Departments of Internal Medicine (Cardiology) and Cardiac Surgery, Yale University School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Department of Biostatistics, Medtronic Statistical Services, Minneapolis, Minnesota.'}, {'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'Popma', 'Affiliation': 'Department of Interventional Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2020.04.028'] 2710,32763086,Randomised controlled trial of pharmacist-led patient counselling in controlling hypoglycaemic attacks in older adults with type 2 diabetes mellitus (ROSE-ADAM): A study protocol of the SUGAR intervention.,"INTRODUCTION Hypoglycaemia is one of the most serious adverse effects of diabetes treatment. Older adults are at the highest risk to develop hypoglycaemia. Several studies have established the important positive role of educational interventions on achieving glycaemic control and other clinical outcomes, however, there is still a lack in studies that evaluate the impact of such type of interventions on hypoglycaemia risk in elderly patients with type 2 diabetes. The purpose of this research is to evaluate the effectiveness of pharmacist-led patient counselling on reducing hypoglycaemic attacks in older adults with type 2 diabetes mellitus. METHODS and analysis: This study is an open-label, parallel controlled randomised trial, which will be conducted in the outpatient clinics at the largest referral hospital in the north of Jordan. Participants who are elderly (age ≥ 65 years), diagnosed with type 2 diabetes mellitus, and taking insulin, sulfonylurea, or any three anti-diabetic medications will be randomly assigned to intervention (SUGAR Handshake) and control (usual care) groups. The SUGAR Handshake participants will have an interactive, individualised, medications-focused counselling session reinforced with a pictogram and a phone call at week six of enrolment. The primary outcome measure is the frequency of total hypoglycaemic events within 12 weeks of follow up. Secondary outcomes include the frequency of asymptomatic, symptomatic, and severe hypoglycaemic events, hypoglycaemia incidence, and time to the first hypoglycaemic attack. We will also conduct a nested qualitative study for process evaluation. ETHICS AND DISSEMINATION The Human Research Ethics Committee of the University of Lincoln and the Institutional Review Board of King Abdullah University Hospital approved this protocol. The findings of this study will be presented in international conferences and published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER The study protocol has been registered with ClinicalTrials.gov, NCT04081766.",2020,"The purpose of this research is to evaluate the effectiveness of pharmacist-led patient counselling on reducing hypoglycaemic attacks in older adults with type 2 diabetes mellitus. ","['elderly patients with type 2 diabetes', 'older adults with type 2 diabetes mellitus', 'Older adults', 'outpatient clinics at the largest referral hospital in the north of Jordan', 'older adults with type 2 diabetes mellitus (ROSE-ADAM', 'Participants who are elderly (age\xa0≥\xa065 years), diagnosed with type 2 diabetes mellitus, and taking insulin, sulfonylurea, or any three anti-diabetic medications']","['SUGAR intervention', 'pharmacist-led patient counselling']","['frequency of total hypoglycaemic events', 'frequency of asymptomatic, symptomatic, and severe hypoglycaemic events, hypoglycaemia incidence, and time to the first hypoglycaemic attack', 'hypoglycaemic attacks', 'hypoglycaemia risk', 'Hypoglycaemia']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022418', 'cui_str': 'Jordan'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C1529905', 'cui_str': '(123I)ADAM'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0038766', 'cui_str': 'Sulfonylurea'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0600047', 'cui_str': 'Patient counseled'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic agent'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0745153', 'cui_str': 'Hypoglycaemic episode'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",,0.12039,"The purpose of this research is to evaluate the effectiveness of pharmacist-led patient counselling on reducing hypoglycaemic attacks in older adults with type 2 diabetes mellitus. ","[{'ForeName': 'Huda Y', 'Initials': 'HY', 'LastName': 'Almomani', 'Affiliation': 'School of Pharmacy, University of Lincoln, LN6 7DL, Lincoln, UK. Electronic address: huda.almomani@yahoo.com.'}, {'ForeName': 'Carlos Rodriguez', 'Initials': 'CR', 'LastName': 'Pascual', 'Affiliation': 'School of Pharmacy, University of Lincoln, LN6 7DL, Lincoln, UK.'}, {'ForeName': 'Sayer I', 'Initials': 'SI', 'LastName': 'Al-Azzam', 'Affiliation': 'Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan.'}, {'ForeName': 'Keivan', 'Initials': 'K', 'LastName': 'Ahmadi', 'Affiliation': 'Lincoln Medical School, Universities of Nottingham and Lincoln, University of Lincoln, LN6 7TS, Lincoln, UK.'}]",Research in social & administrative pharmacy : RSAP,['10.1016/j.sapharm.2020.07.012'] 2711,32763103,Improving the patient experience in the Emergency Department Short Stay Unit.,"BACKGROUND To explore whether giving patients admitted to the Short Stay Unit (SSU) in the Emergency Department (ED) their medical notes improved patient understanding of key information. METHODS A two armed non-blinded randomised controlled trial was performed, with patients enrolled on admission to the SSU from the ED. The intervention was provision of a copy of the patient's medical notes both on admission to SSU and on discharge, together with a plain English statement about their medical condition and a detailed care plan. Control patients were provided with standard care (verbal information). Patients were surveyed in SSU and followed up two weeks post discharge via telephone interview. Treating clinicians, in both the ED and SSU, were surveyed to establish acceptability of the intervention. RESULTS Two hundred patients were enrolled, with 176 completing the study. The intervention group found the information provided more helpful (p=0.048) and understood their condition and treatment plan better than the control group (p=0.034). All other data points, despite a positive trend towards the intervention, were statistically insignificant. CONCLUSIONS This study suggests that this simple intervention may positively contribute to the patient experience, with no discernible negative effect on the overall delivery of safe and efficient healthcare.",2020,The intervention group found the information provided more helpful (p=0.048) and understood their condition and treatment plan better than the control group (p=0.034).,"['patients enrolled on admission to the SSU from the ED', 'Two hundred patients were enrolled, with 176 completing the study', 'patients admitted to the Short Stay Unit (SSU) in the Emergency Department (ED']",['standard care (verbal information'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457453', 'cui_str': 'On admission'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}]",[],200.0,0.0360447,The intervention group found the information provided more helpful (p=0.048) and understood their condition and treatment plan better than the control group (p=0.034).,"[{'ForeName': 'Deb', 'Initials': 'D', 'LastName': 'Leach', 'Affiliation': 'Eastern Health, Australia; Monash University, Australia.'}, {'ForeName': 'Kellie', 'Initials': 'K', 'LastName': 'Vivekanantham', 'Affiliation': 'Eastern Health, Australia; Box Hill Hospital, Eastern Health, Australia. Electronic address: kellie.vive@gmail.com.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Kwong', 'Affiliation': 'Eastern Health, Australia.'}, {'ForeName': 'Emogene S', 'Initials': 'ES', 'LastName': 'Aldridge', 'Affiliation': 'Eastern Health, Australia.'}, {'ForeName': 'Paul G', 'Initials': 'PG', 'LastName': 'Buntine', 'Affiliation': 'Eastern Health, Australia; Box Hill Hospital, Eastern Health, Australia; Monash University, Australia.'}]",Australasian emergency care,['10.1016/j.auec.2020.07.004'] 2712,32758455,"Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.","BACKGROUND Debio 1143 is an orally available antagonist of inhibitor of apoptosis proteins with the potential to enhance the antitumour activity of cisplatin and radiotherapy. The radiosensitising effect of Debio 1143 is mediated through caspase activation and TNF, IFNγ, CD8 T cell-dependent pathways. We aimed to investigate the efficacy and safety of Debio 1143 in combination with standard chemoradiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck. METHODS This double-blind, multicentre, randomised, phase 2 study by the French Head and Neck Radiotherapy Oncology Group (GORTEC) was run at 19 hospitals in France and Switzerland. Eligible patients were aged 18-75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease), Eastern Cooperative Oncology Group performance status of 0 or 1, a history of heavy tobacco smoking (>10 pack-years) with no previous or current treatment for invasive head and neck cancer, and no previous treatment with inhibitor of apoptosis protein antagonists. Patients were randomly assigned (1:1) to receive oral Debio 1143 (200 mg per day on days 1-14 of 21-day cycles, for three cycles) or oral placebo (20 mg/mL, administered at the same dosing schedule) using a stochastic minimisation technique according to node involvement and primary tumour site, and HPV-16 status in patients with an oropharyngeal primary tumour site. All patients received standard high-dose cisplatin chemoradiotherapy. The primary endpoint was the proportion of patients with locoregional control 18 months after chemoradiotherapy, analysed in the intention-to-treat population (primary analysis), and repeated in the per-protocol population. Responses were assessed according to Response Evaluation Criteria in Solid Tumors (version 1.1). This trial is registered with ClinicalTrials.gov, NCT02022098, and is still active but not recruiting. FINDINGS Between Jan 25, 2016, and April 24, 2017, 48 patients were randomly assigned to the Debio 1143 group and 48 to the placebo group (one patient in the placebo group did not receive the study drug and was not included in the safety analysis). Median duration of follow-up was 25·0 months (IQR 19·6-29·4) in the Debio 1143 group and 24·2 months (6·6-26·8) in the placebo group. Locoregional control 18 months after chemoradiotherapy was achieved in 26 (54%; 95% CI 39-69) of 48 patients in the Debio 1143 group versus 16 (33%; 20-48) of 48 patients in the placebo group (odds ratio 2·69 [95% CI 1·13-6·42], p=0·026). Grade 3 or worse adverse events were reported in 41 (85%) of 48 patients in the Debio 1143 group and in 41 (87%) of 47 patients in the placebo group. The most common grade 3-4 adverse events were dysphagia (in 24 [50%] patients in the Debio 1143 group vs ten [21%] in the placebo group), mucositis (in 15 [31%] vs ten [21%]), and anaemia (in 17 [35%] vs 11 [23%]). Serious treatment-emergent adverse events were recorded in 30 (63%) of 48 patients in the Debio 1143 group and 28 (60%) of 47 in the placebo group. In the placebo group, two (4%) deaths were due to adverse events (one multiple organ failure and one asphyxia; neither was considered to be related to treatment). No deaths due to adverse events occurred in the Debio 1143 group. INTERPRETATION To our knowledge, this is the first treatment regimen to achieve superior efficacy in this disease setting against a high-dose cisplatin chemoradiotherapy comparator in a randomised trial. These findings suggest that inhibition of inhibitor of apoptosis proteins is a novel and promising approach in this poor prognostic population and warrant confirmation in a phase 3 study with the aim of expanding the therapeutic options for these patients. FUNDING Debiopharm.",2020,"18 months after chemoradiotherapy was achieved in 26 (54%; 95% CI 39-69) of 48 patients in the Debio 1143 group versus 16 (33%; 20-48) of 48 patients in the placebo group (odds ratio 2·69 [95% CI 1·13-6·42], p=0·026).","['patients with an oropharyngeal primary tumour site', 'French Head and Neck Radiotherapy Oncology Group (GORTEC) was run at 19 hospitals in France and Switzerland', 'patients with high-risk locally advanced squamous cell carcinoma of the head and neck', 'high-risk locoregionally advanced squamous cell carcinoma of the head and neck', '48 patients were randomly assigned to the Debio 1143 group and 48 to the', 'Between Jan 25, 2016, and April 24, 2017', 'Eligible patients were aged 18-75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease), Eastern Cooperative Oncology Group performance status of 0 or 1, a history of heavy tobacco smoking (>10 pack-years) with no previous or current treatment for invasive head and neck cancer, and no previous treatment with inhibitor of apoptosis protein antagonists']","['standard high-dose cisplatin chemoradiotherapy', 'Debio 1143 in combination with standard chemoradiotherapy', 'cisplatin chemoradiotherapy comparator', 'oral placebo', 'oral Debio', 'Debio 1143 and high-dose cisplatin chemoradiotherapy', 'cisplatin and radiotherapy', 'placebo']","['proportion of patients with locoregional control', 'Median duration', 'dysphagia', 'caspase activation and TNF, IFNγ, CD8 T cell-dependent pathways', 'mucositis', 'efficacy and safety', 'anaemia', 'Serious treatment-emergent adverse events', 'adverse events', 'Locoregional control', 'Grade 3 or worse adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521367', 'cui_str': 'Oropharyngeal structure'}, {'cui': 'C0475447', 'cui_str': 'Primary tumor site'}, {'cui': 'C0376246', 'cui_str': 'French language'}, {'cui': 'C0460004', 'cui_str': 'Structure of head and/or neck'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1168401', 'cui_str': 'Squamous cell carcinoma of head and neck'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C2983774', 'cui_str': 'AT 406'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0268575', 'cui_str': 'Isovaleryl-CoA dehydrogenase deficiency'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco smoking behavior - finding'}, {'cui': 'C1277691', 'cui_str': 'Pack years'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0893445', 'cui_str': 'Inhibitor-Of-Apoptosis Protein'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C2983774', 'cui_str': 'AT 406'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0333355', 'cui_str': 'Inflammatory disease of mucous membrane'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}]",48.0,0.373852,"18 months after chemoradiotherapy was achieved in 26 (54%; 95% CI 39-69) of 48 patients in the Debio 1143 group versus 16 (33%; 20-48) of 48 patients in the placebo group (odds ratio 2·69 [95% CI 1·13-6·42], p=0·026).","[{'ForeName': 'Xu-Shan', 'Initials': 'XS', 'LastName': 'Sun', 'Affiliation': 'Department of Radiation Oncology, Nord Franche-Comté de Montbéliard and CHRU de Besançon, Besançon, France.'}, {'ForeName': 'Yungan', 'Initials': 'Y', 'LastName': 'Tao', 'Affiliation': 'Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Le Tourneau', 'Affiliation': 'Department of Drug Development and Innovation, Institut Curie, Paris, France.'}, {'ForeName': 'Yoann', 'Initials': 'Y', 'LastName': 'Pointreau', 'Affiliation': 'Oncologie-Radiothérapie, Institut Inter-RégionaL de Cancérologie, Centre Jean Bernard, Le Mans, France.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Sire', 'Affiliation': 'Centre Hospitalier de Bretagne Sud, Hôpital du Scorff Radiothérapie, Lorient, France.'}, {'ForeName': 'Marie-Christine', 'Initials': 'MC', 'LastName': 'Kaminsky', 'Affiliation': ""L'Institut de Cancérologie de Lorraine Alexis Vautrin, Oncologie Médicale, Vandoeuvre-lès-Nancy, France.""}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Coutte', 'Affiliation': 'CHU Amiens Picardie, Oncologie-Radiothérapie, Amiens, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Alfonsi', 'Affiliation': 'Institut Sainte Catherine, Radiothérapie, Avignon, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Boisselier', 'Affiliation': ""Institut du Cancer de Montpellier, Val d'Aurelle, Oncologie-Radiothérapie, Montpellier, France.""}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Martin', 'Affiliation': 'Centre Guillaume le Conquérant, Radiothérapie, Le Havre, France.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Miroir', 'Affiliation': 'Centre Jean Perrin, Radiothérapie, Clermont-Ferrand, France.'}, {'ForeName': 'Jean-Francois', 'Initials': 'JF', 'LastName': 'Ramee', 'Affiliation': 'CHD Vendée, Radiothérapie, La Roche Sur Yon, France.'}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Delord', 'Affiliation': ""Institut Claudius Regaud, Oncopole, Unité de Recherche Clinique de l'Institut Claudius Regaud, Toulouse, France.""}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Clatot', 'Affiliation': ""Centre Henri Becquerel, Service Oncologie Médicale rue d'Amiens, Rouen, France.""}, {'ForeName': 'Frederic', 'Initials': 'F', 'LastName': 'Rolland', 'Affiliation': ""Institut de Cancérologie de l'Ouest René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.""}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Villa', 'Affiliation': 'CHU Grenoble, Radiothérapie, Pôle de Cancérologie, Grenoble, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Magne', 'Affiliation': 'Institut de Cancérologie Lucien Neuwirth, Radiothérapie, Saint-Priest en Jarez, France.'}, {'ForeName': 'Olgun', 'Initials': 'O', 'LastName': 'Elicin', 'Affiliation': 'Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Elisabeta', 'Initials': 'E', 'LastName': 'Gherga', 'Affiliation': 'Department of Radiation Oncology, Nord Franche-Comté de Montbéliard and CHRU de Besançon, Besançon, France.'}, {'ForeName': 'France', 'Initials': 'F', 'LastName': 'Nguyen', 'Affiliation': 'Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Cedrick', 'Initials': 'C', 'LastName': 'Lafond', 'Affiliation': 'Oncologie-Radiothérapie, Institut Inter-RégionaL de Cancérologie, Centre Jean Bernard, Le Mans, France.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Bera', 'Affiliation': 'Centre Hospitalier de Bretagne Sud, Hôpital du Scorff Radiothérapie, Lorient, France.'}, {'ForeName': 'Valentin', 'Initials': 'V', 'LastName': 'Calugaru', 'Affiliation': 'Department of Drug Development and Innovation, Institut Curie, Paris, France.'}, {'ForeName': 'Lionnel', 'Initials': 'L', 'LastName': 'Geoffrois', 'Affiliation': ""L'Institut de Cancérologie de Lorraine Alexis Vautrin, Oncologie Médicale, Vandoeuvre-lès-Nancy, France.""}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Chauffert', 'Affiliation': 'CHU Amiens Picardie, Oncologie-Radiothérapie, Amiens, France.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Zubel', 'Affiliation': 'Debiopharm International, Lausanne, Switzerland.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Zanna', 'Affiliation': 'Debiopharm International, Lausanne, Switzerland.'}, {'ForeName': 'Silvano', 'Initials': 'S', 'LastName': 'Brienza', 'Affiliation': 'Debiopharm International, Lausanne, Switzerland.'}, {'ForeName': 'Philippa', 'Initials': 'P', 'LastName': 'Crompton', 'Affiliation': 'Debiopharm International, Lausanne, Switzerland.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Rouits', 'Affiliation': 'Debiopharm International, Lausanne, Switzerland.'}, {'ForeName': 'Kathrin', 'Initials': 'K', 'LastName': 'Gollmer', 'Affiliation': 'Debiopharm International, Lausanne, Switzerland.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Szyldergemajn', 'Affiliation': 'Debiopharm International, Lausanne, Switzerland.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Bourhis', 'Affiliation': 'CHUV, Service de Radio-oncologie, Bâtiment Hospitalier, Lausanne, Switzerland. Electronic address: jean.bourhis@chuv.ch.'}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30327-2'] 2713,32758672,Beneficial Effects of Role Reversal in Comparison to role-playing on negative cognitions about Other's Judgments for Social Anxiety Disorder.,"BACKGROUND AND OBJECTIVES Negative beliefs about other's judgments play an important role in the development and maintenance of social anxiety disorder. The present experiment examined the effects of role-playing followed by role reversal compared to role-playing twice on altering these negative cognitions. METHODS Thirty-six adult social anxiety patients were randomized into two conditions: a role-playing condition in which 18 participants role-played an anxiety-provoking social situation twice, or a role reversal condition in which 18 participants role-played an anxiety-provoking social situation followed by enacting the same situation using role reversal. Before the start of the experiment, patients were asked to report their negative cognitions about the other's judgments. Next, they were asked to rate the believability of these negative cognitions, as well as the probability and cost estimates of negative judgments by the other person, at three time-points: before the first block of role-playing, after the first block of role-playing, and after the second block of the experiment. RESULTS Results demonstrated that role-playing followed by role reversal had a stronger effect on the most negative cognitions than role-playing twice. LIMITATIONS The most important limitation of the present study is that there was no control group to assess the effects of role-playing alone. Moreover, the second block of the experiment was repetitive in role-playing, however, it was a new task in role reversal. CONCLUSIONS The results support the hypothesis that role reversal is an effective technique that can be used to correct negative cognitions about other's judgments in SAD.",2020,"RESULTS Results demonstrated that role-playing followed by role reversal had a stronger effect on the most negative cognitions than role-playing twice. ","['Thirty-six adult social anxiety patients', ""negative cognitions about Other's Judgments for Social Anxiety Disorder""]","['role-playing condition in which 18 participants role-played an anxiety-provoking social situation twice, or a role reversal condition in which 18 participants role-played an anxiety-provoking social situation followed by enacting the same situation using role reversal']",[],"[{'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0022423', 'cui_str': 'Judgement'}, {'cui': 'C0031572', 'cui_str': 'Social phobia'}]","[{'cui': 'C0035822', 'cui_str': 'Role play technique'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C1444748', 'cui_str': 'Evoked'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0332282', 'cui_str': 'Following'}]",[],36.0,0.0134432,"RESULTS Results demonstrated that role-playing followed by role reversal had a stronger effect on the most negative cognitions than role-playing twice. ","[{'ForeName': 'Hanieh', 'Initials': 'H', 'LastName': 'Abeditehrani', 'Affiliation': 'University of Amsterdam, Department of Clinical Psychology, Amsterdam, the Netherlands. Electronic address: H.Abeditehrani@uva.nl.'}, {'ForeName': 'Corine', 'Initials': 'C', 'LastName': 'Dijk', 'Affiliation': 'University of Amsterdam, Department of Clinical Psychology, Amsterdam, the Netherlands.'}, {'ForeName': 'Mohsen Dehghani', 'Initials': 'MD', 'LastName': 'Neyshabouri', 'Affiliation': 'University of Social Welfare and Rehabilitation Sciences, Department of Clinical Psychology, Tehran, Iran.'}, {'ForeName': 'Arnoud', 'Initials': 'A', 'LastName': 'Arntz', 'Affiliation': 'University of Amsterdam, Department of Clinical Psychology, Amsterdam, the Netherlands.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2020.101599'] 2714,32758677,Inspiratory neural drive and dyspnea in interstitial lung disease: Effect of inhaled fentanyl.,"BACKGROUND Exertional dyspnea in interstitial lung disease (ILD) remains difficult to manage despite advances in disease-targeted therapies. Pulmonary opioid receptors present a potential therapeutic target for nebulized fentanyl to provide dyspnea relief. METHODS ILD patients were characterized with reference to healthy volunteers. A randomized, double-blind, placebo-controlled crossover comparison of 100 mcg nebulized fentanyl vs placebo on dyspnea intensity and inspiratory neural drive (IND) during constant work rate (CWR) cycle exercise was performed in 21 ILD patients. RESULTS Dyspnea intensity in ILD increased in association with an increase in IND (diaphragm activation) from a high resting value of 16.66 ± 6.52 %-60.04 ± 12.52 % of maximum (r = 0.798, p < 0.001). At isotime during CWR exercise, Borg dyspnea intensity ratings with fentanyl vs placebo were 4.1 ± 1.2 vs 3.8 ± 1.2, respectively (p = 0.174), and IND responses were also similar. CONCLUSION IND rose sharply during constant work rate exercise in association with dyspnea intensity in mild to moderate ILD but was not different after nebulized fentanyl compared with placebo.",2020,"At isotime during CWR exercise, Borg dyspnea intensity ratings with fentanyl vs placebo were 4.1 ± 1.2 vs 3.8 ± 1.2, respectively (p = 0.174), and IND responses were also similar. ","['ILD patients were characterized with reference to healthy volunteers', 'interstitial lung disease', '21 ILD patients']","['inhaled fentanyl', '100 mcg nebulized fentanyl vs placebo', 'nebulized fentanyl', 'fentanyl vs placebo', 'placebo']","['IND responses', 'IND (diaphragm activation', 'dyspnea intensity and inspiratory neural drive (IND) during constant work rate (CWR) cycle exercise', 'dyspnea intensity ratings', 'Inspiratory neural drive and dyspnea']","[{'cui': 'C0206062', 'cui_str': 'Interstitial lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439211', 'cui_str': 'mcg'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0011980', 'cui_str': 'Diaphragm structure'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",21.0,0.334941,"At isotime during CWR exercise, Borg dyspnea intensity ratings with fentanyl vs placebo were 4.1 ± 1.2 vs 3.8 ± 1.2, respectively (p = 0.174), and IND responses were also similar. ","[{'ForeName': 'Kathryn M', 'Initials': 'KM', 'LastName': 'Milne', 'Affiliation': ""Department of Medicine, Queen's University, Kingston Health Sciences Centre, Kingston, Ontario, Canada; Clinician Investigator Program, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.""}, {'ForeName': 'Megha', 'Initials': 'M', 'LastName': 'Ibrahim-Masthan', 'Affiliation': ""Department of Medicine, Queen's University, Kingston Health Sciences Centre, Kingston, Ontario, Canada.""}, {'ForeName': 'Robin E', 'Initials': 'RE', 'LastName': 'Scheeren', 'Affiliation': ""Department of Medicine, Queen's University, Kingston Health Sciences Centre, Kingston, Ontario, Canada.""}, {'ForeName': 'Matthew D', 'Initials': 'MD', 'LastName': 'James', 'Affiliation': ""Department of Medicine, Queen's University, Kingston Health Sciences Centre, Kingston, Ontario, Canada.""}, {'ForeName': 'Devin B', 'Initials': 'DB', 'LastName': 'Phillips', 'Affiliation': ""Department of Medicine, Queen's University, Kingston Health Sciences Centre, Kingston, Ontario, Canada.""}, {'ForeName': 'Onofre', 'Initials': 'O', 'LastName': 'Moran-Mendoza', 'Affiliation': ""Department of Medicine, Queen's University, Kingston Health Sciences Centre, Kingston, Ontario, Canada.""}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Alberto Neder', 'Affiliation': ""Department of Medicine, Queen's University, Kingston Health Sciences Centre, Kingston, Ontario, Canada.""}, {'ForeName': 'Denis E', 'Initials': 'DE', 'LastName': ""O'Donnell"", 'Affiliation': ""Department of Medicine, Queen's University, Kingston Health Sciences Centre, Kingston, Ontario, Canada. Electronic address: odonnell@queensu.ca.""}]",Respiratory physiology & neurobiology,['10.1016/j.resp.2020.103511'] 2715,32759117,Breathing Retraining for Individuals Who Fear Respiratory Sensations: Examination of Safety Behavior and Coping Aid Hypotheses.,"Cognitive behavioral theorists have suggested that breathing retraining may be used as a safety behavior. Safety behaviors are acts aimed at preventing or minimizing feared catastrophe and may maintain pathologic anxiety by hindering resolution of maladaptive cognitive processes. An opposing position is that breathing retraining is an effective coping aid. This study examined the safety behavior and coping aid hypotheses as they apply to breathing retraining. Individuals high in fear of respiratory sensations were randomly assigned to a psychoeducation control condition (EDU; n = 27) or a psychoeducation plus breathing retraining condition (EDU+BR; n = 30). As compared to psychoeducation alone, the addition of breathing retraining neither limited improvement of cognitive processes (e.g., anxiety sensitivity) nor added to the gains observed on measures of coping (e.g., perceived control). The findings are evaluated in light of the available literature regarding breathing retraining and the safety behavior and coping aid hypotheses.",2013,"As compared to psychoeducation alone, the addition of breathing retraining neither limited improvement of cognitive processes (e.g., anxiety sensitivity) nor added to the gains observed on measures of coping (e.g., perceived control).","['Individuals high in fear of respiratory sensations', 'Individuals Who Fear Respiratory Sensations']","['breathing retraining', 'psychoeducation control condition (EDU; n = 27) or a psychoeducation plus breathing retraining condition (EDU+BR; n = 30', 'Breathing Retraining']","['cognitive processes (e.g., anxiety sensitivity']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0059804', 'cui_str': 'ethylene diurea'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]",,0.0183105,"As compared to psychoeducation alone, the addition of breathing retraining neither limited improvement of cognitive processes (e.g., anxiety sensitivity) nor added to the gains observed on measures of coping (e.g., perceived control).","[{'ForeName': 'James J', 'Initials': 'JJ', 'LastName': 'Lickel', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital.'}, {'ForeName': 'Billy R', 'Initials': 'BR', 'LastName': 'Carruthers', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Dixon', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital.'}, {'ForeName': 'Brett J', 'Initials': 'BJ', 'LastName': 'Deacon', 'Affiliation': 'University of Wyoming.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.27.2.111'] 2716,32759141,A Comparison of Two Brief Interventions for Obsessional Thoughts: Exposure and Acceptance.,"Exposure and response prevention (ERP) is the most effective psychological treatment for unwanted, intrusive thoughts associated with obsessive-compulsive disorder (OCD). However, the procedures involved in ERP (i.e., exposure) are challenging, provoke high levels of anxiety, and may contribute to treatment refusal and dropout (Franklin & Foa, 1998). To address this problem, researchers have begun to evaluate alternative treatments for OCD, such as Acceptance and Commitment Therapy (ACT). Despite the value of both techniques, little is known about the differential impact of these strategies. This study examined the relative effects of a single session of ACT or exposure for obsessional thoughts. There were 56 undergraduate participants with obsessional thoughts randomly assigned to receive a brief intervention with the core components of exposure, ACT, or an expressive writing control condition. Obsessional symptoms and related process variables were assessed at baseline and at 1-week follow-up. There were no statistical differences in believability or acceptability of the 3 conditions. Significant reductions in obsessional severity, behavioral tests of distress and willingness to experience intrusive thoughts, and negative appraisals of intrusive thoughts occurred in all conditions, but no differences were found between these conditions. Furthermore, changes in dysfunctional beliefs, but not in willingness to experience intrusive thoughts, predicted changes in obsessional symptoms in both the ACT and exposure conditions.",2013,"Significant reductions in obsessional severity, behavioral tests of distress and willingness to experience intrusive thoughts, and negative appraisals of intrusive thoughts occurred in all conditions, but no differences were found between these conditions.",['56 undergraduate participants with obsessional thoughts randomly assigned to receive a'],"['ACT', 'brief intervention with the core components of exposure, ACT, or an expressive writing control condition', 'Exposure and response prevention (ERP']","['obsessional symptoms', 'Obsessional symptoms', 'believability or acceptability', 'obsessional severity, behavioral tests of distress and willingness to experience intrusive thoughts, and negative appraisals of intrusive thoughts', 'dysfunctional beliefs']","[{'cui': 'C0233697', 'cui_str': 'Obsessional thoughts'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]","[{'cui': 'C0029917', 'cui_str': 'Outpatient Commitment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0018582', 'cui_str': 'Handwriting'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0683444', 'cui_str': 'Behavioral Test'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0558066', 'cui_str': 'Intrusive thoughts'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}]",56.0,0.0244302,"Significant reductions in obsessional severity, behavioral tests of distress and willingness to experience intrusive thoughts, and negative appraisals of intrusive thoughts occurred in all conditions, but no differences were found between these conditions.","[{'ForeName': 'Laura E', 'Initials': 'LE', 'LastName': 'Fabricant', 'Affiliation': 'University of North Carolina at Chapel Hill.'}, {'ForeName': 'Jonathan S', 'Initials': 'JS', 'LastName': 'Abramowitz', 'Affiliation': 'University of North Carolina at Chapel Hill.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Dehlin', 'Affiliation': 'University of North Carolina at Chapel Hill.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Twohig', 'Affiliation': 'Utah State University.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.27.3.195'] 2717,32759142,A Comparison of Cognitive and Behavioral Approaches for Reducing Cost Bias in Social Anxiety.,"Cognitive-behavioral theories suggest that anxiety is maintained in part by estimates of the probability and cost of feared negative outcomes. Social phobia may be unique among the anxiety disorders in that it is characterized by overestimates of the cost of events that are objectively noncatastrophic (e.g., committing social mishaps). As such, treatment approaches that target cost bias may be particularly effective in reducing social phobia symptoms. This study examined the efficacy of 2 cost-specific techniques in a single-session intervention for social anxiety. Individuals ( n = 61) with elevated social interaction anxiety were randomly assigned to an expressive writing control condition, a cognitive restructuring condition, or a behavioral experiment condition. Results demonstrated that the cognitive restructuring condition produced significantly greater improvement in indices of social anxiety than the other conditions. Reduction in cost bias fully mediated the significantly greater improvement in social interaction anxiety in the cognitive restructuring condition relative to the behavioral experiment condition. The present findings highlight the value of techniques designed to reduce cost biases in social anxiety. Clinical implications are discussed.",2013,Reduction in cost bias fully mediated the significantly greater improvement in social interaction anxiety in the cognitive restructuring condition relative to the behavioral experiment condition.,"['social anxiety', 'Social Anxiety', 'Individuals ( n = 61) with elevated social interaction anxiety']","['Cognitive and Behavioral Approaches', 'expressive writing control condition, a cognitive restructuring condition, or a behavioral experiment condition']","['social anxiety', 'social phobia symptoms', 'social interaction anxiety']","[{'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0037420', 'cui_str': 'Interaction with others'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0018582', 'cui_str': 'Handwriting'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0150173', 'cui_str': 'Cognitive restructuring'}]","[{'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0031572', 'cui_str': 'Social phobia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0037420', 'cui_str': 'Interaction with others'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",61.0,0.00920448,Reduction in cost bias fully mediated the significantly greater improvement in social interaction anxiety in the cognitive restructuring condition relative to the behavioral experiment condition.,"[{'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Possis', 'Affiliation': 'Minneapolis Veterans Affairs Health Care System.'}, {'ForeName': 'Joshua J', 'Initials': 'JJ', 'LastName': 'Kemp', 'Affiliation': 'University of Wyoming, Department of Psychology.'}, {'ForeName': 'James J', 'Initials': 'JJ', 'LastName': 'Lickel', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital.'}, {'ForeName': 'Jennifer T', 'Initials': 'JT', 'LastName': 'Sy', 'Affiliation': 'Minneapolis Veterans Affairs Health Care System.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Dixon', 'Affiliation': 'Minneapolis Veterans Affairs Health Care System.'}, {'ForeName': 'Brett J', 'Initials': 'BJ', 'LastName': 'Deacon', 'Affiliation': 'University of Wyoming, Department of Psychology.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.27.3.210'] 2718,32759148,"Symptom Accommodation Related to Social Anxiety Symptoms in Adults: Phenomenology, Correlates, and Impairment.","BACKGROUND AND OBJECTIVES Socially anxious individuals often engage in various safety and avoidant behaviors to temporarily decrease distress. Similarly, friends or family members may engage in accommodating behaviors, commonly manifesting through the facilitation of avoidance, completion of tasks, or schedule modifications. Studies examining symptom accommodation in adult social anxiety are lacking, so this study seeks to better understand symptom accommodation and its consequent impairment in socially anxious adults. DESIGN AND METHODS There were 380 undergraduate students who completed a battery of self-report questionnaires through an online system. Constructs assessed include social anxiety, symptom accommodation, and impairment as well as related variables such as general anxiety, fear of negative evaluation, alcohol use, and anxiety sensitivity. RESULTS Symptom accommodation was positively correlated with social anxiety symptoms, functional impairment, general anxiety, anxiety sensitivity, fear of negative evaluation, and alcohol use. Individuals with considerable social anxiety reported significantly higher levels of symptom accommodation than individuals who reported lower levels of social anxiety. Anxiety sensitivity predicted symptom accommodation beyond the contribution of social anxiety. Symptom accommodation mediated the relationship between social anxiety and impairment. CONCLUSIONS These data help elucidate the presentation and impact of symptom accommodation related to social anxiety. Implications for assessment, treatment, and future directions are presented.",2015,Individuals with considerable social anxiety reported significantly higher levels of symptom accommodation than individuals who reported lower levels of social anxiety.,"['There were 380 undergraduate students who completed a battery of self-report questionnaires through an online system', 'Adults', 'socially anxious adults']",[],"['social anxiety, symptom accommodation, and impairment as well as related variables such as general anxiety, fear of negative evaluation, alcohol use, and anxiety sensitivity', 'social anxiety symptoms, functional impairment, general anxiety, anxiety sensitivity, fear of negative evaluation, and alcohol use', 'social anxiety and impairment', 'social anxiety', 'symptom accommodation']","[{'cui': 'C4319693', 'cui_str': '380'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0029038', 'cui_str': 'On-Line Systems'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",[],"[{'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]",380.0,0.0194043,Individuals with considerable social anxiety reported significantly higher levels of symptom accommodation than individuals who reported lower levels of social anxiety.,"[{'ForeName': 'Nayana', 'Initials': 'N', 'LastName': 'Joogoolsingh', 'Affiliation': 'University of South Florida estorch@health.usf.edu.'}, {'ForeName': 'Monica S', 'Initials': 'MS', 'LastName': 'Wu', 'Affiliation': 'University of South Florida.'}, {'ForeName': 'Adam B', 'Initials': 'AB', 'LastName': 'Lewin', 'Affiliation': 'University of South Florida.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Storch', 'Affiliation': 'University of South Florida.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.29.1.3'] 2719,32759162,The OCD Project: Educational or Sensational?,"Ninety-two young adults were randomly assigned to watch two episodes of The OCD Project , a reality television program depicting the treatment of obsessive-compulsive disorder using exposure therapy, or two episodes of another reality television program ( Big Brother ). Participants in The OCD Project condition ( n = 35) endorsed significantly fewer negative beliefs about exposure therapy than participants in the Big Brother condition ( n = 42). Participants' obsessive-compulsive disorder symptoms did not moderate the beneficial effects of watching The OCD Project These results provide preliminary evidence that reality television programs can have a modest psychoeducational benefit and might be used to change attitudes about mental health problems and their treatment.",2015,Participants' obsessive-compulsive disorder symptoms did not moderate the beneficial effects of watching ,['Ninety-two young adults'],"['watching', 'reality television program depicting the treatment of obsessive-compulsive disorder using exposure therapy, or two episodes of another reality television program ( Big Brother ']","['obsessive-compulsive disorder symptoms', 'negative beliefs']","[{'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0039461', 'cui_str': 'Television'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0028768', 'cui_str': 'Obsessive-compulsive disorder'}, {'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0337527', 'cui_str': 'Brother'}]","[{'cui': 'C0028768', 'cui_str': 'Obsessive-compulsive disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}]",92.0,0.0199464,Participants' obsessive-compulsive disorder symptoms did not moderate the beneficial effects of watching ,"[{'ForeName': 'Lindsay Mae', 'Initials': 'LM', 'LastName': 'Miller', 'Affiliation': 'Northern Illinois University dvalentiner@niu.edu.'}, {'ForeName': 'Brett J', 'Initials': 'BJ', 'LastName': 'Deacon', 'Affiliation': 'University of Wollongong.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Valentiner', 'Affiliation': 'Northern Illinois University.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.29.2.116'] 2720,32759251,"Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study.","INTRODUCTION There are no disease-modifying treatments for Parkinson's disease (PD). We undertook the first drug screen in PD patient tissue and idntified ursodeoxycholic acid (UDCA) as a promising mitochondrial rescue agent. The aims of this trial are to determine safety and tolerability of UDCA in PD at 30 mg/kg, confirm the target engagement of UDCA, apply a novel motion sensor-based approach to quantify disease progression objectively, and estimate the mean effect size and its variance on the change in motor severity. METHODS AND ANALYSIS This is a phase II, two-centre, double-blind, randomised, placebo-controlled trial of UDCA at a dose of 30 mg/kg in 30 participants with early PD. Treatment duration is 48 weeks, followed by an 8-week washout phase. Randomisation is 2:1, drug to placebo. Assessments are performed at baseline, week 12, 24, 36, 48 and 56. The primary outcome is safety and tolerability. Secondary outcomes will compare the change between baseline and week 48 using the following three approaches: the Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 in the practically defined 'OFF' medication state; confirmation of target engagement, applying 31 Phosphorus MR Spectroscopy to assess the levels of ATP and relevant metabolites in the brain; and objective quantification of motor impairment, using a validated, motion sensor-based approach. The primary outcome will be reported using descriptive statistics and comparisons between treatment groups. For each secondary outcome, the change from baseline will be summarised within treatment groups using summary statistics and appropriate statistical tests assessing for significant differences. All outcomes will use an intention-to-treat analysis population. ETHICS AND DISSEMINATION This trial has been approved by the East of England - Cambridgeshire and Hertfordshire Research Ethics committee. Results will be disseminated in peer-reviewed journals, presentations at scientific meetings and to patients in a lay-summary format. TRIAL REGISTRATION NUMBER NCT03840005.",2020,"This is a phase II, two-centre, double-blind, randomised, placebo-controlled trial of UDCA at a dose of 30 mg/kg in 30 participants with early PD.","[""Parkinson's disease"", '30 participants with early PD']","['Ursodeoxycholic acid', 'UDCA', 'ursodeoxycholic acid (UDCA', 'placebo']","[""Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 in the practically defined 'OFF' medication state; confirmation of target engagement, applying 31 Phosphorus MR Spectroscopy to assess the levels of ATP and relevant metabolites in the brain; and objective quantification of motor impairment, using a validated, motion sensor-based approach"", 'safety and tolerability']","[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C1279919', 'cui_str': 'Early'}]","[{'cui': 'C0042105', 'cui_str': 'ursodeoxycholic acid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0026650', 'cui_str': 'Movement disorder'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0521091', 'cui_str': 'Confirmation of'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0031705', 'cui_str': 'Phosphorus'}, {'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0001480', 'cui_str': 'Adenosine Triphosphate'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0183210', 'cui_str': 'Sensor device'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",30.0,0.546511,"This is a phase II, two-centre, double-blind, randomised, placebo-controlled trial of UDCA at a dose of 30 mg/kg in 30 participants with early PD.","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Payne', 'Affiliation': 'Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Matilde', 'Initials': 'M', 'LastName': 'Sassani', 'Affiliation': 'Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Buckley', 'Affiliation': 'NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Moll', 'Affiliation': 'NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Anton', 'Affiliation': 'NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Appleby', 'Affiliation': 'Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, UK.'}, {'ForeName': 'Seema', 'Initials': 'S', 'LastName': 'Maru', 'Affiliation': 'Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, UK.'}, {'ForeName': 'Rosie', 'Initials': 'R', 'LastName': 'Taylor', 'Affiliation': 'Statistical Services Unit, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Alisdair', 'Initials': 'A', 'LastName': 'McNeill', 'Affiliation': 'Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Hoggard', 'Affiliation': 'Academic Unit of Radiology, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Mazza', 'Affiliation': 'Institute for In Silico Medicine, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Iain D', 'Initials': 'ID', 'LastName': 'Wilkinson', 'Affiliation': 'Academic Unit of Radiology, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Jenkins', 'Affiliation': 'Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Foltynie', 'Affiliation': 'Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, UK.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Bandmann', 'Affiliation': 'Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK o.bandmann@sheffield.ac.uk.'}]",BMJ open,['10.1136/bmjopen-2020-038911'] 2721,32759258,Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.,"OBJECTIVES To characterise the safety and tolerability of nintedanib and the dose adjustments used to manage adverse events in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). METHODS In the SENSCIS trial, patients with SSc-ILD were randomised to receive nintedanib 150 mg two times per day or placebo. To manage adverse events, treatment could be interrupted or the dose reduced to 100 mg two times per day. We assessed adverse events and dose adjustments over 52 weeks. RESULTS A total of 576 patients received nintedanib (n=288) or placebo (n=288). The most common adverse event was diarrhoea, reported in 75.7% of patients in the nintedanib group and 31.6% in the placebo group; diarrhoea led to permanent treatment discontinuation in 6.9% and 0.3% of patients in the nintedanib and placebo groups, respectively. In the nintedanib and placebo groups, respectively, 48.3% and 12.2% of patients had ≥1 dose reduction and/or treatment interruption, and adverse events led to permanent discontinuation of the trial drug in 16.0% and 8.7% of patients. The adverse events associated with nintedanib were similar across subgroups defined by age, sex, race and weight. The rate of decline in forced vital capacity in patients treated with nintedanib was similar irrespective of dose adjustments. CONCLUSIONS The adverse event profile of nintedanib in patients with SSc-ILD is consistent with its established safety and tolerability profile in patients with idiopathic pulmonary fibrosis. Dose adjustment is important to minimise the impact of adverse events and help patients remain on therapy.",2020,"The most common adverse event was diarrhoea, reported in 75.7% of patients in the nintedanib group and 31.6% in the placebo group; diarrhoea led to permanent treatment discontinuation in 6.9% and 0.3% of patients in the nintedanib and placebo groups, respectively.","['576 patients received nintedanib (n=288) or', 'patients with systemic sclerosis-associated interstitial lung disease', 'patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD', 'patients with SSc-ILD', 'patients with idiopathic pulmonary fibrosis']","['nintedanib', 'nintedanib 150\u2009mg two times per day or placebo', 'placebo']","['Safety and tolerability', 'safety and tolerability', 'diarrhoea', 'diarrhoea led to permanent treatment discontinuation', 'rate of decline in forced vital capacity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2930789', 'cui_str': 'nintedanib'}, {'cui': 'C0036421', 'cui_str': 'Systemic sclerosis'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0206062', 'cui_str': 'Interstitial lung disease'}, {'cui': 'C0036429', 'cui_str': 'Sclerosis'}, {'cui': 'C1800706', 'cui_str': 'Idiopathic pulmonary fibrosis'}]","[{'cui': 'C2930789', 'cui_str': 'nintedanib'}, {'cui': 'C3859348', 'cui_str': 'nintedanib 150 MG'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}]",576.0,0.200888,"The most common adverse event was diarrhoea, reported in 75.7% of patients in the nintedanib group and 31.6% in the placebo group; diarrhoea led to permanent treatment discontinuation in 6.9% and 0.3% of patients in the nintedanib and placebo groups, respectively.","[{'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Seibold', 'Affiliation': 'Scleroderma Research Consultants, LLC, Aiken, South Carolina, USA jamesrseibold@gmail.com.'}, {'ForeName': 'Toby M', 'Initials': 'TM', 'LastName': 'Maher', 'Affiliation': 'National Heart and Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Kristin B', 'Initials': 'KB', 'LastName': 'Highland', 'Affiliation': 'Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.'}, {'ForeName': 'Shervin', 'Initials': 'S', 'LastName': 'Assassi', 'Affiliation': 'University of Texas Houston Medical School, Houston, Texas, USA.'}, {'ForeName': 'Arata', 'Initials': 'A', 'LastName': 'Azuma', 'Affiliation': 'Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Laura Kathleen', 'Initials': 'LK', 'LastName': 'Hummers', 'Affiliation': 'Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Costabel', 'Affiliation': 'Interstitial and Rare Lung Disease Unit, Department of Pneumology, Ruhrlandklinik, University Hospital Essen, Essen, Germany.'}, {'ForeName': 'Ute', 'Initials': 'U', 'LastName': 'von Wangenheim', 'Affiliation': 'Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.'}, {'ForeName': 'Veronika', 'Initials': 'V', 'LastName': 'Kohlbrenner', 'Affiliation': 'Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Gahlemann', 'Affiliation': 'Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland.'}, {'ForeName': 'Margarida', 'Initials': 'M', 'LastName': 'Alves', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Distler', 'Affiliation': 'Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Annals of the rheumatic diseases,['10.1136/annrheumdis-2020-217331'] 2722,32759285,Freeze-all versus fresh blastocyst transfer strategy during in vitro fertilisation in women with regular menstrual cycles: multicentre randomised controlled trial.,"OBJECTIVE To compare the ongoing pregnancy rate between a freeze-all strategy and a fresh transfer strategy in assisted reproductive technology treatment. DESIGN Multicentre, randomised controlled superiority trial. SETTING Outpatient fertility clinics at eight public hospitals in Denmark, Sweden, and Spain. PARTICIPANTS 460 women aged 18-39 years with regular menstrual cycles starting their first, second, or third treatment cycle of in vitro fertilisation or intracytoplasmic sperm injection. INTERVENTIONS Women were randomised at baseline on cycle day 2 or 3 to one of two treatment groups: the freeze-all group (elective freezing of all embryos) who received gonadotropin releasing hormone agonist triggering and single frozen-thawed blastocyst transfer in a subsequent modified natural cycle; or the fresh transfer group who received human chorionic gonadotropin triggering and single blastocyst transfer in the fresh cycle. Women in the fresh transfer group with more than 18 follicles larger than 11 mm on the day of triggering had elective freezing of all embryos and postponement of transfer as a safety measure. MAIN OUTCOME MEASURES The primary outcome was the ongoing pregnancy rate defined as a detectable fetal heart beat after eight weeks of gestation. Secondary outcomes were live birth rate, positive human chorionic gonadotropin rate, time to pregnancy, and pregnancy related, obstetric, and neonatal complications. The primary analysis was performed according to the intention-to-treat principle. RESULTS Ongoing pregnancy rate did not differ significantly between the freeze-all and fresh transfer groups (27.8% (62/223) v 29.6% (68/230); risk ratio 0.98, 95% confidence interval 0.87 to 1.10, P=0.76). Additionally, no significant difference was found in the live birth rate (27.4% (61/223) for the freeze-all group and 28.7% (66/230) for the fresh transfer group; risk ratio 0.98, 95% confidence interval 0.87 to 1.10, P=0.83). No significant differences between groups were observed for positive human chorionic gonadotropin rate or pregnancy loss, and none of the women had severe ovarian hyperstimulation syndrome; only one hospital admission related to this condition occurred in the fresh transfer group. The risks of pregnancy related, obstetric, and neonatal complications did not differ between the two groups except for a higher mean birth weight after frozen blastocyst transfer and an increased risk of prematurity after fresh blastocyst transfer. Time to pregnancy was longer in the freeze-all group. CONCLUSIONS In women with regular menstrual cycles, a freeze-all strategy with gonadotropin releasing hormone agonist triggering for final oocyte maturation did not result in higher ongoing pregnancy and live birth rates than a fresh transfer strategy. The findings warrant caution in the indiscriminate application of a freeze-all strategy when no apparent risk of ovarian hyperstimulation syndrome is present. TRIAL REGISTRATION Clinicaltrials.gov NCT02746562.",2020,"Ongoing pregnancy rate did not differ significantly between the freeze-all and fresh transfer groups (27.8% (62/223) v 29.6% (68/230); risk ratio 0.98, 95% confidence interval 0.87 to 1.10, P=0.76).","['460 women aged 18-39 years with regular menstrual cycles starting their first, second, or third treatment cycle of in vitro fertilisation or intracytoplasmic sperm injection', 'women with regular menstrual cycles', 'Outpatient fertility clinics at eight public hospitals in Denmark, Sweden, and Spain']","['gonadotropin releasing hormone agonist triggering', 'freeze-all group (elective freezing of all embryos) who received gonadotropin releasing hormone agonist triggering and single frozen-thawed blastocyst transfer in a subsequent modified natural cycle; or the fresh transfer group who received human chorionic gonadotropin triggering and single blastocyst transfer in the fresh cycle', 'Freeze-all versus fresh blastocyst transfer strategy']","['ongoing pregnancy and live birth rates', 'mean birth weight', 'Ongoing pregnancy rate', 'ongoing pregnancy rate defined as a detectable fetal heart beat', 'Time to pregnancy', 'live birth rate, positive human chorionic gonadotropin rate, time to pregnancy, and pregnancy related, obstetric, and neonatal complications', 'live birth rate', 'risk of prematurity', 'risks of pregnancy related, obstetric, and neonatal complications', 'severe ovarian hyperstimulation syndrome', 'positive human chorionic gonadotropin rate or pregnancy loss']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0025329', 'cui_str': 'Normal menstrual cycle'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C0455164', 'cui_str': 'IVF - In vitro fertilization with intracytoplasmic sperm injection (ICSI)'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C4760630', 'cui_str': 'Infertility Clinics'}, {'cui': 'C0020022', 'cui_str': 'Public Hospitals'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0037747', 'cui_str': 'Spain'}]","[{'cui': 'C1518041', 'cui_str': 'Gonadotropin releasing hormone analogues'}, {'cui': 'C0032930', 'cui_str': 'Precipitating Factors'}, {'cui': 'C0016701', 'cui_str': 'Freezing'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0013935', 'cui_str': 'Embryos'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0936221', 'cui_str': 'Blastocyst Transfer'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205296', 'cui_str': 'Natural'}, {'cui': 'C0443224', 'cui_str': 'Fresh'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0428402', 'cui_str': 'Human chorionic gonadotropin measurement'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rates'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0015935', 'cui_str': 'Fetal Heart'}, {'cui': 'C3494204', 'cui_str': 'Time-to-Pregnancy'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0428402', 'cui_str': 'Human chorionic gonadotropin measurement'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0404588', 'cui_str': 'Finding related to risk factor in pregnancy'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0085083', 'cui_str': 'Ovarian hyperstimulation syndrome'}, {'cui': 'C0156543', 'cui_str': 'Pregnancy with abortive outcome'}]",460.0,0.169415,"Ongoing pregnancy rate did not differ significantly between the freeze-all and fresh transfer groups (27.8% (62/223) v 29.6% (68/230); risk ratio 0.98, 95% confidence interval 0.87 to 1.10, P=0.76).","[{'ForeName': 'Sacha', 'Initials': 'S', 'LastName': 'Stormlund', 'Affiliation': 'Fertility Clinic, Department of Obstetrics and Gynaecology, Hvidovre University Hospital, Hvidovre, Kettegaard Allé 30, Copenhagen DK-2650, Denmark sacha.stormlund.01@regionh.dk.'}, {'ForeName': 'Negjyp', 'Initials': 'N', 'LastName': 'Sopa', 'Affiliation': 'Fertility Clinic, Department of Obstetrics and Gynaecology, Hvidovre University Hospital, Hvidovre, Kettegaard Allé 30, Copenhagen DK-2650, Denmark.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Zedeler', 'Affiliation': 'Fertility Clinic, Department of Obstetrics and Gynaecology, Hvidovre University Hospital, Hvidovre, Kettegaard Allé 30, Copenhagen DK-2650, Denmark.'}, {'ForeName': 'Jeanette', 'Initials': 'J', 'LastName': 'Bogstad', 'Affiliation': 'Fertility Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Lisbeth', 'Initials': 'L', 'LastName': 'Prætorius', 'Affiliation': 'Fertility Clinic, Department of Obstetrics and Gynaecology, Hvidovre University Hospital, Hvidovre, Kettegaard Allé 30, Copenhagen DK-2650, Denmark.'}, {'ForeName': 'Henriette Svarre', 'Initials': 'HS', 'LastName': 'Nielsen', 'Affiliation': 'Fertility Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Margaretha Laczna', 'Initials': 'ML', 'LastName': 'Kitlinski', 'Affiliation': 'Department of Reproductive Medicine, Skane University Hospital, Malmö, Sweden.'}, {'ForeName': 'Sven O', 'Initials': 'SO', 'LastName': 'Skouby', 'Affiliation': 'Fertility Clinic, Department of Obstetrics and Gynaecology, Herlev University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Anne Lis', 'Initials': 'AL', 'LastName': 'Mikkelsen', 'Affiliation': 'Fertility Clinic, Department of Obstetrics and Gynaecology, Holbæk University Hospital, Holbæk, Denmark.'}, {'ForeName': 'Anne Lærke', 'Initials': 'AL', 'LastName': 'Spangmose', 'Affiliation': 'Fertility Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Janni Vikkelsø', 'Initials': 'JV', 'LastName': 'Jeppesen', 'Affiliation': 'Fertility Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Khatibi', 'Affiliation': 'Department of Obstetrics and Gynaecology, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Reproductive Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'la Cour Freiesleben', 'Affiliation': 'Fertility Clinic, Department of Obstetrics and Gynaecology, Hvidovre University Hospital, Hvidovre, Kettegaard Allé 30, Copenhagen DK-2650, Denmark.'}, {'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Ziebe', 'Affiliation': 'Fertility Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Nikolaos P', 'Initials': 'NP', 'LastName': 'Polyzos', 'Affiliation': 'Department of Reproductive Medicine, Dexeus University Hospital, Barcelona, Spain.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Bergh', 'Affiliation': 'Department of Obstetrics and Gynaecology, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Reproductive Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Humaidan', 'Affiliation': 'Fertility Clinic, Skive Regional Hospital and Faculty of Health, Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Anders Nyboe', 'Initials': 'AN', 'LastName': 'Andersen', 'Affiliation': 'Fertility Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Løssl', 'Affiliation': 'Fertility Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Pinborg', 'Affiliation': 'Fertility Clinic, Department of Obstetrics and Gynaecology, Hvidovre University Hospital, Hvidovre, Kettegaard Allé 30, Copenhagen DK-2650, Denmark.'}]",BMJ (Clinical research ed.),['10.1136/bmj.m2519'] 2723,32759347,Reducing pain by using venous blood gas instead of arterial blood gas (VEINART): a multicentre randomised controlled trial.,"INTRODUCTION Venous sampling for blood gas analysis has been suggested as an alternative to arterial sampling in order to reduce pain. The main objective was to compare pain induced by venous and arterial sampling and to assess whether the type of sampling would affect clinical management or not. METHODS We performed an open-label randomised multicentre prospective study in four French EDs during a 4-week period. Non-hypoxaemic adults, whose medical management required blood gas analysis, were randomly allocated using a computer-generated randomisation list stratified by centres with an allocation ratio of 1:1 using random blocks to one of the two arms: venous or arterial sampling. The primary outcome was the maximal pain during sampling, using the visual analogue scale. Secondary outcomes pertained to ease of sampling as rated by the nurse drawing the blood, and physician satisfaction regarding usefulness of biochemical data. RESULTS 113 patients were included: 55 in the arterial and 58 in the venous sampling group. The mean maximal pain was 40.5 mm±24.9 mm and 22.6 mm±20.2 mm in the arterial group and the venous group, respectively, accounting for a mean difference of 17.9 mm (95% CI 9.6 to 26.3) (p<0.0001). Ease of blood sampling was greater in the venous group as compared with the arterial group (p=0.02). The usefulness of the results, evaluated by the prescriber, did not significantly differ (p=0.25). CONCLUSIONS Venous blood gas is less painful for patients than ABG in non-hypoxaemic patients. Venous blood gas should replace ABG in this setting. TRIAL REGISTRATION NUMBER NCT03784664.",2020,"The usefulness of the results, evaluated by the prescriber, did not significantly differ (p=0.25). ","['113 patients were included: 55 in the arterial and 58 in the venous sampling group', 'Non-hypoxaemic adults, whose medical management required blood gas analysis']",[],"['blood sampling', 'ease of sampling as rated by the nurse drawing the blood, and physician satisfaction regarding usefulness of biochemical data', 'maximal pain during sampling, using the visual analogue scale', 'Reducing pain', 'mean maximal pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0005800', 'cui_str': 'Blood gas analysis'}]",[],"[{'cui': 'C0005834', 'cui_str': 'Collection of blood specimen for laboratory'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0013113', 'cui_str': 'Drawings'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",113.0,0.128039,"The usefulness of the results, evaluated by the prescriber, did not significantly differ (p=0.25). ","[{'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Chauvin', 'Affiliation': 'Emergency Department, Hôpital Lariboisière, Assistance Publique-Hopitaux de Paris, Paris, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Javaud', 'Affiliation': 'Emergency department, Hôpital Louis Mourier, Assistance Publique-Hopitaux de Paris, Colombes, France.'}, {'ForeName': 'Aiham', 'Initials': 'A', 'LastName': 'Ghazali', 'Affiliation': 'Emergency Department, Hôpital Bichat, Assistance Publique-Hopitaux de Paris, Paris, Île-de-France, France.'}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Curac', 'Affiliation': 'Emergency Department, Hôpital Beaujon, Assistance Publique-Hopitaux de Paris, Clichy, Île-de-France, France.'}, {'ForeName': 'Adrien', 'Initials': 'A', 'LastName': 'Altar', 'Affiliation': 'Emergency department, Hôpital Louis Mourier, Assistance Publique-Hopitaux de Paris, Colombes, France.'}, {'ForeName': 'Talina', 'Initials': 'T', 'LastName': 'Ali', 'Affiliation': 'UFR de Médecine Paris Nord, Université de Paris, Paris, Île-de-France, France.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Beguin', 'Affiliation': 'UFR de Médecine Paris Nord, Université de Paris, Paris, Île-de-France, France.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Bellier', 'Affiliation': 'UFR de Médecine Paris Nord, Université de Paris, Paris, Île-de-France, France.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Coupier', 'Affiliation': 'UFR de Médecine Paris Nord, Université de Paris, Paris, Île-de-France, France.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Delsarte', 'Affiliation': 'UFR de Médecine Paris Nord, Université de Paris, Paris, Île-de-France, France.'}, {'ForeName': 'Dora', 'Initials': 'D', 'LastName': 'Dreyfuss', 'Affiliation': 'UFR de Médecine Paris Nord, Université de Paris, Paris, Île-de-France, France.'}, {'ForeName': 'Nour', 'Initials': 'N', 'LastName': 'Kheirbek', 'Affiliation': 'UFR de Médecine Paris Nord, Université de Paris, Paris, Île-de-France, France.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Oudar', 'Affiliation': 'UFR de Médecine Paris Nord, Université de Paris, Paris, Île-de-France, France.'}, {'ForeName': 'Yoann', 'Initials': 'Y', 'LastName': 'Stordeur', 'Affiliation': 'UFR de Médecine Paris Nord, Université de Paris, Paris, Île-de-France, France.'}, {'ForeName': 'Morgane', 'Initials': 'M', 'LastName': 'Weiss', 'Affiliation': 'UFR de Médecine Paris Nord, Université de Paris, Paris, Île-de-France, France.'}, {'ForeName': 'Stephane', 'Initials': 'S', 'LastName': 'Gaudry', 'Affiliation': 'Médecine Intensive Réanimation - Hôpital Avicenne, Assistance Publique-Hopitaux de Paris, Bobigny, France.'}, {'ForeName': 'Jerome', 'Initials': 'J', 'LastName': 'Lambert', 'Affiliation': 'UFR de Médecine Paris Nord, Université de Paris, Paris, Île-de-France, France.'}, {'ForeName': 'Damien', 'Initials': 'D', 'LastName': 'Roux', 'Affiliation': 'UFR de Médecine Paris Nord, Université de Paris, Paris, Île-de-France, France damien.roux@aphp.fr.'}]",Emergency medicine journal : EMJ,['10.1136/emermed-2019-209287'] 2724,32759621,Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial.,"INTRODUCTION It is unclear how baseline endoscopic characteristics in Crohn's disease (CD) affect the ability to achieve endoscopic remission (ER). We aimed to determine the endoscopic prognostic factors that influence achieving ER in CD. DESIGN This post hoc analysis of SONIC (NCT00094458; YODA #2019-3980) evaluated baseline and week 26 endoscopy indices in 172 patients using the CD Endoscopic Index of Severity (CDEIS) and the Simple Endoscopic Score for CD. The impact of baseline ulcer depth and size on achieving week 26 ER was assessed using multivariate logistic regression models adjusted for confounders. RESULTS The ER rate of ileal ulcers was significantly lower than ER rates throughout the colon (P < 0.0001). Ileal ulcers >2 cm were less likely to achieve ER compared with smaller ulcers {odds ratio (OR) 0.31 (95% confidence interval [CI] 0.11-0.89), P = 0.03}. Similarly, rectal ulcers >2 cm were associated with reduced odds of week 26 ER (OR 0.26 [95% CI 0.08-0.80], P = 0.02). Ulcer size in other colonic segments did not affect the achievement of week 26 ER. Deep ileal and rectal ulcers >2 cm compared with smaller or superficial ulcers were even less likely to achieve week 26 ER (ileum: OR 0.10, 95% CI 0.02-0.68, P = 0.02; rectum: OR 0.12, 0.02-0.82, P = 0.03). High baseline Simple Endoscopic Score for CD (≥16) or CDEIS scores (≥12) did not affect achieving week 26 ER. DISCUSSION Patients with larger and deep ulcers in the ileum or rectum may have difficulty achieving ER. Overall degree of endoscopic inflammation as measured numerically by endoscopic scores does not affect the likelihood of achieving week 26 ER.",2020,The ER rate of ileal ulcers was significantly lower than ER rates throughout the colon (P < 0.0001).,['172 patients using the CD Endoscopic Index of Severity (CDEIS) and the Simple Endoscopic Score for CD'],[],"['Deep ileal and rectal ulcers', 'Endoscopic Remission', 'High baseline Simple Endoscopic Score for CD (≥16) or CDEIS scores', 'Overall degree of endoscopic inflammation', 'Ileal and Rectal Ulcer', 'ER rate of ileal ulcers', 'Ulcer size']","[{'cui': 'C4517601', 'cui_str': '172'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",[],"[{'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0020885', 'cui_str': 'Ileal structure'}, {'cui': 'C0400839', 'cui_str': 'Ulcer of rectum'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0520564', 'cui_str': 'Ileal ulcer'}, {'cui': 'C0456389', 'cui_str': 'Size'}]",,0.0988739,The ER rate of ileal ulcers was significantly lower than ER rates throughout the colon (P < 0.0001).,"[{'ForeName': 'Neeraj', 'Initials': 'N', 'LastName': 'Narula', 'Affiliation': '1Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton Ontario, Canada; 2Division of Gastroenterology, University of California San Diego, La Jolla, California, USA; 3Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA; 4Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium; 5Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Emily C L', 'Initials': 'ECL', 'LastName': 'Wong', 'Affiliation': ''}, {'ForeName': 'Achuthan', 'Initials': 'A', 'LastName': 'Aruljothy', 'Affiliation': ''}, {'ForeName': 'Parambir S', 'Initials': 'PS', 'LastName': 'Dulai', 'Affiliation': ''}, {'ForeName': 'Jean-Frederic', 'Initials': 'JF', 'LastName': 'Colombel', 'Affiliation': ''}, {'ForeName': 'John K', 'Initials': 'JK', 'LastName': 'Marshall', 'Affiliation': ''}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Ferrante', 'Affiliation': ''}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Reinisch', 'Affiliation': ''}]",The American journal of gastroenterology,['10.14309/ajg.0000000000000617'] 2725,32759635,Effect of Flavonoid Supplementation on Alveolar Bone Healing-A Randomized Pilot Trial.,"We investigated the effects of two common dietary supplements on bone healing in dental extraction sockets in humans. In this randomized pilot trial, male subjects took Grape Seed Extract [GSE] or Grapefruit Extract [GFE] starting two weeks prior to dental extraction and maintained this regimen for sixty days after surgery. Extraction sockets were filled with a collagen plug. After 24 h, a socket sample was collected and processed for quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and an 84-gene wound healing assay. Sixty days after tooth extraction, a core of newly formed bone was obtained prior to dental implant placement and processed for histology. qRT-PCR revealed that GFE led to a significant decrease in platelet-derived growth factor and interleukin (IL)1-β compared to GSE, and a significant decrease in IL-6 and CXCL2 compared to control. GSE led to a significant increase in coagulation factor Von Willebrand and inflammatory marker IL1-β compared to GFE. WISP1 and CXCL5 were upregulated in both groups. Overall, GFE showed a downregulation of inflammation and GSE led to a decrease in collagen density and increased osteoclasts. This pilot trial highlights the need for further investigation on the mechanism of action of such supplements on bone healing and oral health.",2020,GSE led to a significant increase in coagulation factor Von Willebrand and inflammatory marker IL1-β compared to GFE.,"['dental extraction sockets in humans', 'male subjects took']","['Grape Seed Extract [GSE] or Grapefruit Extract [GFE', 'Flavonoid Supplementation', 'GFE', 'common dietary supplements', 'GSE']","['collagen density and increased osteoclasts', 'Alveolar Bone Healing', 'coagulation factor Von Willebrand and inflammatory marker IL1-β', 'bone healing', 'IL-6 and CXCL2', 'WISP1 and CXCL5', 'bone healing and oral health', 'platelet-derived growth factor and interleukin (IL)1-β']","[{'cui': 'C0040440', 'cui_str': 'Tooth extraction'}, {'cui': 'C0224517', 'cui_str': 'Gomphosis structure'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C1515187', 'cui_str': 'Take'}]","[{'cui': 'C0772454', 'cui_str': 'Grape Seed Extract'}, {'cui': 'C0440280', 'cui_str': 'GRAPEFRUIT EXTRACT'}, {'cui': 'C0596577', 'cui_str': 'Flavonoid'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}]","[{'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0029431', 'cui_str': 'Osteoclast'}, {'cui': 'C1321023', 'cui_str': 'Bone healing status'}, {'cui': 'C0005789', 'cui_str': 'Blood clotting factor'}, {'cui': 'C0042974', 'cui_str': 'von Willebrand disorder'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021755', 'cui_str': 'Interleukin-1'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0245297', 'cui_str': 'CXCL2 protein, human'}, {'cui': 'C1449212', 'cui_str': 'WISP1 protein, human'}, {'cui': 'C1435946', 'cui_str': 'CXCL5 protein, human'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0032200', 'cui_str': 'Platelet-derived growth factor'}]",,0.104126,GSE led to a significant increase in coagulation factor Von Willebrand and inflammatory marker IL1-β compared to GFE.,"[{'ForeName': 'Jose Moises', 'Initials': 'JM', 'LastName': 'Souza', 'Affiliation': 'Centro de Ciências da Saúde, Departamento de Odontologia, Campus Reitor David Ferreira Lima, Universidade Federal de Santa Catarina, Bairro Trindade, Florianópolis 88040-970, Brazil.'}, {'ForeName': 'Stephen A', 'Initials': 'SA', 'LastName': 'Tuin', 'Affiliation': 'Oral and Craniofacial Health Sciences, Adams School of Dentistry, Koury Oral Health Sciences Building, Rm 4608, CB# 7455, University of North Carolina at Chapel Hill, 385 South Columbia Street, Chapel Hill, NC 27599-7455, USA.'}, {'ForeName': 'Adam G', 'Initials': 'AG', 'LastName': 'Robinson', 'Affiliation': 'Oral and Craniofacial Health Sciences, Adams School of Dentistry, Koury Oral Health Sciences Building, Rm 4608, CB# 7455, University of North Carolina at Chapel Hill, 385 South Columbia Street, Chapel Hill, NC 27599-7455, USA.'}, {'ForeName': 'Joao Gustavo Oliveira de', 'Initials': 'JGO', 'LastName': 'Souza', 'Affiliation': 'Centro de Ciências da Saúde, Departamento de Odontologia, Campus Reitor David Ferreira Lima, Universidade Federal de Santa Catarina, Bairro Trindade, Florianópolis 88040-970, Brazil.'}, {'ForeName': 'Marco Aurelio', 'Initials': 'MA', 'LastName': 'Bianchini', 'Affiliation': 'Centro de Ciências da Saúde, Departamento de Odontologia, Campus Reitor David Ferreira Lima, Universidade Federal de Santa Catarina, Bairro Trindade, Florianópolis 88040-970, Brazil.'}, {'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Miguez', 'Affiliation': 'Division of Comprehensive Oral Health, Adams School of Dentistry, Koury Oral Health Sciences Building, Rm 4610, CB# 7455, University of North Carolina at Chapel Hill, Chapel Hill, NC 77599-7455, USA.'}]",Dentistry journal,['10.3390/dj8030086'] 2726,30915660,"Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.","BACKGROUND Tildrakizumab is an anti-interleukin-23p19 monoclonal antibody recently approved for the treatment of chronic plaque psoriasis. METHODS This analysis characterizes the population pharmacokinetics of subcutaneous tildrakizumab and identifies covariates influencing exposure in 2098 healthy volunteers and subjects with psoriasis. Tested covariates included body weight, formulation type, sex, age, race, serum albumin, creatinine clearance, Japanese origin, prior treatment with a biologic agent, subject status (subjects with psoriasis vs. healthy volunteers), and ethnicity. RESULTS The pharmacokinetics was described by a one-compartment model with first-order absorption and elimination kinetics, and inter-individual variability on clearance, volume of distribution, and absorption rate constant. The pharmacokinetics was characterized by low clearance and limited volume of distribution. In subjects with psoriasis, the geometric mean clearance (coefficient of variation) was 0.32 L/day (38%), volume of distribution was 10.8 L (24%), and absorption and elimination half-life were 1.5 days (18%) and 23.4 days (23%), respectively, with an absorption lag time of 1.2 h. For the 100-mg dose, steady-state area under the plasma concentration vs. time curve for one dosing interval and maximum plasma concentration were 305 µg*day/mL (41%) and 8.1 µg/mL (34%), respectively. Steady state was achieved by 16 weeks with the clinical regimen (dosing on week 0 and week 4 and every 12 weeks thereafter) with 1.1-fold accumulation in maximum plasma concentration. Healthy subjects had 31% higher bioavailability than subjects with psoriasis. Subjects with increased body weight had a lower area under the plasma concentration-time curve at steady state vs. those with lower body weight. The modeled exposures were contained within clinical comparability bounds for all covariates including body weight. CONCLUSIONS The pharmacokinetics of tildrakizumab behaves like a typical monoclonal antibody without requiring dosage adjustment. TRIAL REGISTRATION NCT01729754, NCT01225731, NCT01722331.",2019,Subjects with increased body weight had a lower area under the plasma concentration-time curve at steady state vs. those with lower body weight.,"['Healthy subjects', '2098 healthy volunteers and subjects with psoriasis', ' prior treatment with a biologic agent, subject status (subjects with psoriasis vs. healthy volunteers), and ethnicity', 'Healthy Volunteers and Subjects with Psoriasis']","['Tildrakizumab (MK-3222', 'Tildrakizumab', 'tildrakizumab', 'subcutaneous tildrakizumab']","['clearance, volume of distribution, and absorption rate constant', 'plasma concentration-time curve', 'geometric mean clearance', 'body weight, formulation type, sex, age, race, serum albumin, creatinine clearance, Japanese origin', 'bioavailability', 'maximum plasma concentration']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}]","[{'cui': 'C4043954', 'cui_str': 'tildrakizumab'}, {'cui': 'C4045758', 'cui_str': 'MK-3222'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}]","[{'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0036773', 'cui_str': 'Serum Albumin'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0806909', 'cui_str': 'Max'}]",2098.0,0.0168726,Subjects with increased body weight had a lower area under the plasma concentration-time curve at steady state vs. those with lower body weight.,"[{'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Jauslin', 'Affiliation': 'Certara USA, Inc., Princeton, NJ, USA.'}, {'ForeName': 'Pooja', 'Initials': 'P', 'LastName': 'Kulkarni', 'Affiliation': 'Certara USA, Inc., Princeton, NJ, USA.'}, {'ForeName': 'Hanbin', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Certara USA, Inc., Princeton, NJ, USA.'}, {'ForeName': 'Suresh', 'Initials': 'S', 'LastName': 'Vatakuti', 'Affiliation': 'Certara USA, Inc., Princeton, NJ, USA.'}, {'ForeName': 'Azher', 'Initials': 'A', 'LastName': 'Hussain', 'Affiliation': 'Merck & Co., Inc., Kenilworth, USA.'}, {'ForeName': 'Larissa', 'Initials': 'L', 'LastName': 'Wenning', 'Affiliation': 'Merck & Co., Inc., Kenilworth, USA. larissa_wenning@merck.com.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Kerbusch', 'Affiliation': 'Certara USA, Inc., Princeton, NJ, USA.'}]",Clinical pharmacokinetics,['10.1007/s40262-019-00743-7'] 2727,32763640,Implementing an intensive care unit (ICU) diary program at a large academic medical center: Results from a randomized control trial evaluating psychological morbidity associated with critical illness.,"BACKGROUND Psychological morbidity in both patients and family members related to the intensive care unit (ICU) experience is an often overlooked, and potentially persistent, healthcare problem recognized by the Society of Critical Care Medicine as Post-intensive Care Syndrome (PICS). ICU diaries are an intervention increasingly under study with potential to mitigate ICU-related psychological morbidity, including ICU-related post-traumatic stress disorder (PTSD), depression and anxiety. As we encounter a growing number of ICU survivors, in particular in the wake of the coronavirus pandemic, clinicians must be equipped to understand the severity and prevalence of significant psychiatric complications of critical illness. METHODS We compared the efficacy of the ICU diary, written by family and healthcare workers during the patient's intensive care course, versus education alone in reducing acute PTSD symptoms after discharge. Patients with an ICU stay >72 h, who were intubated and mechanically ventilated over 24 h, were recruited and randomized to either receive a diary at bedside with psychoeducation or psychoeducation alone. Intervention patients received their ICU diary within the first week of admission into the intensive care unit. Psychological symptom screening with IES-R, PHQ-8, HADS and GAD-7 was conducted at baseline within 1 week of ICU discharge and at weeks 4, 12, and 24 after ICU discharge. Change from baseline in these scores was assessed using Wilcoxon rank sum tests. RESULTS From September 26, 2017 to September 25, 2018, our team screened 265 patients from the surgical and medical ICUs at a single large academic urban hospital. 60 patients were enrolled and randomized, of which 35 patients completed post-discharge follow-up, (n = 18) in the diary intervention group and (n = 17) in the education-only control group. The control group had a significantly greater decrease in PTSD, hyperarousal, and depression symptoms at week 4 compared to the intervention group. There were no significant differences in other measures, or at other follow-up intervals. Both study groups exhibited clinically significant PTSD symptoms at all timepoints after ICU discharge. Follow-up phone interviews with patients revealed that while many were interested in getting follow-up for their symptoms, there were many barriers to accessing appropriate therapy and clinical attention. CONCLUSIONS Results from psychological screening tools demonstrate no benefit of ICU diaries versus bedside education-alone in reducing PTSD symptoms related to the intensive care stay. However, our study finds an important gap in clinical practice - patients at high risk for PICS are infrequently connected to appropriate follow-up care. Perhaps ICU diaries would prove beneficial if utilized to support the work within a program providing wrap-around services and close psychiatric follow up for PICS patients. This study demonstrates the high prevalence of ICU-related PTSD in our cohort of survivors, the high barrier to accessing care for appropriate treatment of PICS, and the consequence of that barrier-prolonged psychological morbidity. TRIAL REGISTRATION NCT04305353. GRANT IDENTIFICATION GH-17-022 (Arnold P. Gold Foundation).",2020,"CONCLUSIONS Results from psychological screening tools demonstrate no benefit of ICU diaries versus bedside education-alone in reducing PTSD symptoms related to the intensive care stay.","['From September 26, 2017 to September 25, 2018, our team screened 265 patients from the surgical and medical ICUs at a single large academic urban hospital', '60 patients', 'Patients with an ICU stay >72\u202fh, who were intubated and mechanically ventilated over 24\u202fh']","['intensive care unit (ICU) diary program', 'diary intervention group and (n\u202f=\u202f17) in the education-only control group', 'diary at bedside with psychoeducation or psychoeducation alone']","['acute PTSD symptoms', 'PTSD symptoms', 'PTSD, hyperarousal, and depression symptoms', 'Psychological symptom screening with IES-R, PHQ-8, HADS and GAD-7']","[{'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0020029', 'cui_str': 'Urban Hospitals'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0042491', 'cui_str': 'Ventilation'}]","[{'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}]","[{'cui': 'C0747767', 'cui_str': 'Acute Post-Traumatic Stress Disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C4552570', 'cui_str': 'Hyperarousal'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0233397', 'cui_str': 'Psychological symptom'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}, {'cui': 'C3641330', 'cui_str': 'GAD-7'}]",60.0,0.0503067,"CONCLUSIONS Results from psychological screening tools demonstrate no benefit of ICU diaries versus bedside education-alone in reducing PTSD symptoms related to the intensive care stay.","[{'ForeName': 'George E', 'Initials': 'GE', 'LastName': 'Sayde', 'Affiliation': 'Department of Internal Medicine and Psychiatry, Tulane University of School of Medicine, 1440 Canal Street, Suite 1000, New Orleans, LA 70112, USA. Electronic address: gsayde@tulane.edu.'}, {'ForeName': 'Andrei', 'Initials': 'A', 'LastName': 'Stefanescu', 'Affiliation': 'Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, 1440 Canal Street, New Orleans, LA 70122, USA. Electronic address: astefanescu@tulane.edu.'}, {'ForeName': 'Erich', 'Initials': 'E', 'LastName': 'Conrad', 'Affiliation': 'Department of Psychiatry, Louisiana State University, 2025 Gravier Street, New Orleans, LA 70112, USA. Electronic address: econra@lsuhsc.edu.'}, {'ForeName': 'Nathan', 'Initials': 'N', 'LastName': 'Nielsen', 'Affiliation': 'Department of Pulmonary, Critical Care and Sleep Medicine, University of New Mexico School of Medicine, 1 University of New Mexico, Albuquerque, NM 87131, USA.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Hammer', 'Affiliation': 'Department of Internal Medicine and Psychiatry, Tulane University of School of Medicine, 1440 Canal Street, Suite 1000, New Orleans, LA 70112, USA. Electronic address: rhammer@tulane.edu.'}]",General hospital psychiatry,['10.1016/j.genhosppsych.2020.06.017'] 2728,32763649,"Parenting, mental health and economic pathways to prevention of violence against children in South Africa.","BACKGROUND Parenting programs based on social learning theory have increasing empirical evidence for reducing violence against children. Trials are primarily from high-income countries and with young children. Globally, we know little about how parenting programs work to reduce violence, with no known studies in low or middle-income countries (LMICs). This study examines mechanisms of change of a non-commercialized parenting program, Parenting for Lifelong Health for Teens, designed with the World Health Organization and UNICEF. A cluster randomized trial showed main effects on parenting and other secondary outcomes. We conducted secondary analysis of trial data to investigate five potential mediators of reduced violence against children: improved parenting, adolescent behaviour, caregiver mental health, alcohol/drug avoidance, and family economic strengthening. METHODS The trial was implemented in rural South Africa with 40 sites, n = 552 family dyads (including adolescents aged 10-18 and primary caregivers). Intervention sites (n = 20) received the 14-session parenting program delivered by local community members, including modules on family budgeting and savings. Control sites (n = 20) received a brief informational workshop. Emotional and physical violence against children/adolescents and each potential mediator were reported by adolescents and caregivers at baseline and 9-13 months post-randomisation. Structural equation modelling was used to test simultaneous hypothesized pathways to violence reduction. RESULTS Improvements in four pathways mediated reduced violence against children: 1) improved parenting practices, 2) improved caregiver mental health (reduced depression), 3) increased caregiver alcohol/drug avoidance and 4) improved family economic welfare. Improved child behaviour was not a mediator, although it was associated with less violence. CONCLUSIONS Simultaneously bolstering a set of family processes can reduce violence. Supporting self-care and positive coping for caregivers may be essential in challenging contexts. In countries with minimal or no economic safety nets, linking social learning parenting programs with economic strengthening skills may bring us closer to ending violence against children.",2020,"RESULTS Improvements in four pathways mediated reduced violence against children: 1) improved parenting practices, 2) improved caregiver mental health (reduced depression), 3) increased caregiver alcohol/drug avoidance and 4) improved family economic welfare.","['rural South Africa with 40 sites, n\xa0=\xa0552 family dyads (including adolescents aged 10-18 and primary caregivers', 'reduced violence against children', 'Emotional and physical violence against children/adolescents', 'violence against children in South Africa', 'violence against children']","['brief informational workshop', '14-session parenting program delivered by local community members, including modules on family budgeting and savings']","['violence against children: 1) improved parenting practices, 2) improved caregiver mental health (reduced depression), 3) increased caregiver alcohol/drug avoidance and 4) improved family economic welfare', 'parenting, adolescent behaviour, caregiver mental health, alcohol/drug avoidance, and family economic strengthening', 'child behaviour']","[{'cui': 'C0037712', 'cui_str': 'South Africa'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1319883', 'cui_str': 'Primary caregiver'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0042693', 'cui_str': 'Violence'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0476480', 'cui_str': 'Physical violence'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0006347', 'cui_str': 'Budgets'}, {'cui': 'C0036245', 'cui_str': 'Savings'}]","[{'cui': 'C0042693', 'cui_str': 'Violence'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0013556', 'cui_str': 'Economics'}, {'cui': 'C0037440', 'cui_str': 'Social services'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",552.0,0.117351,"RESULTS Improvements in four pathways mediated reduced violence against children: 1) improved parenting practices, 2) improved caregiver mental health (reduced depression), 3) increased caregiver alcohol/drug avoidance and 4) improved family economic welfare.","[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Cluver', 'Affiliation': 'Centre for Evidence-Based Intervention, Department of Social Policy & Intervention, University of Oxford, United Kingdom; Department of Psychiatry and Mental Health, University of Cape Town, South Africa. Electronic address: lucie.cluver@spi.ox.ac.uk.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Shenderovich', 'Affiliation': 'Centre for Evidence-Based Intervention, Department of Social Policy & Intervention, University of Oxford, United Kingdom; Institute of Criminology, University of Cambridge, United Kingdom. Electronic address: yulia.shenderovich@spi.ox.ac.uk.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Meinck', 'Affiliation': 'School of Social and Political Science, University of Edinburgh, United Kingdom; Optentia, Faculty of Health Sciences, North-West University, South Africa. Electronic address: Franziska.Meinck@ed.ac.uk.'}, {'ForeName': 'M N', 'Initials': 'MN', 'LastName': 'Berezin', 'Affiliation': 'Centre for Evidence-Based Intervention, Department of Social Policy & Intervention, University of Oxford, United Kingdom; Department of Applied Psychology, New York University, New York, USA. Electronic address: mnb387@nyu.edu.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Doubt', 'Affiliation': 'Centre for Evidence-Based Intervention, Department of Social Policy & Intervention, University of Oxford, United Kingdom. Electronic address: jennydoubt@gmail.com.'}, {'ForeName': 'C L', 'Initials': 'CL', 'LastName': 'Ward', 'Affiliation': 'Department of Psychology, University of Cape Town, South Africa. Electronic address: Catherine.Ward@uct.ac.za.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Parra-Cardona', 'Affiliation': 'Steve Hicks School of Social Work, The University of Texas at Austin, Texas, USA. Electronic address: rparra@austin.utexas.edu.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Lombard', 'Affiliation': 'Biostatistics Unit, South African Medical Research Council, South Africa. Electronic address: carl.lombard@mrc.ac.za.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Lachman', 'Affiliation': 'Centre for Evidence-Based Intervention, Department of Social Policy & Intervention, University of Oxford, United Kingdom; MRC/CSO Social and Public Health Sciences Unit, University of Glasglow, United Kingdom. Electronic address: jamie.lachman@spi.ox.ac.uk.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Wittesaele', 'Affiliation': 'Centre for Evidence-Based Intervention, Department of Social Policy & Intervention, University of Oxford, United Kingdom. Electronic address: camille.wittesaele@spi.ox.ac.uk.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Wessels', 'Affiliation': 'Centre for Evidence-Based Intervention, Department of Social Policy & Intervention, University of Oxford, United Kingdom; Department of Psychology, University of Cape Town, South Africa. Electronic address: inge.wessels@spi.ox.ac.uk.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Gardner', 'Affiliation': 'Centre for Evidence-Based Intervention, Department of Social Policy & Intervention, University of Oxford, United Kingdom. Electronic address: frances.gardner@wolfson.ox.ac.uk.'}, {'ForeName': 'J I', 'Initials': 'JI', 'LastName': 'Steinert', 'Affiliation': 'Centre for Evidence-Based Intervention, Department of Social Policy & Intervention, University of Oxford, United Kingdom; TUM School of Governance, Technical University of Munich, Germany. Electronic address: janina.steinert@tum.de.'}]",Social science & medicine (1982),['10.1016/j.socscimed.2020.113194'] 2729,32763776,Effect of brief encouragement to use twitter on knowledge of the critical-care literature by ICU residents: The randomized controlled IMKREASE trial.,,2020,,['ICU residents'],[],[],"[{'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}]",[],[],,0.0232695,,"[{'ForeName': 'Jean Baptiste', 'Initials': 'JB', 'LastName': 'Lascarrou', 'Affiliation': 'Medecine Intensive Reanimation, University Hospital Center, Nantes, France. Electronic address: jeanbaptiste.lascarrou@chu-nantes.fr.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Ehrmann', 'Affiliation': 'Medecine Intensive Reanimation, University Hospital Center, Tours, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Potier', 'Affiliation': 'Department of internal medicine, University Hospital Center, Nantes, France. Electronic address: pierre.potier@chu-nantes.fr.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Reignier', 'Affiliation': 'Medecine Intensive Reanimation, University Hospital Center, Nantes, France. Electronic address: jean.reignier@chu-nantes.fr.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Canet', 'Affiliation': 'Medecine Intensive Reanimation, University Hospital Center, Nantes, France. Electronic address: emmanuel.canet@chu-nantes.fr.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of critical care,['10.1016/j.jcrc.2020.07.022'] 2730,32759848,"Assessing Adherence, Competence and Differentiation in a Stepped-Wedge Randomised Clinical Trial of a Complex Behaviour Change Intervention.","BACKGROUND A key challenge in behavioural medicine is developing interventions that can be delivered adequately (i.e., with fidelity) within real-world consultations. Accordingly, clinical trials should (but tend not to) report what is actually delivered (adherence), how well (competence) and the distinction between intervention and comparator conditions (differentiation). PURPOSE To address this important clinical and research priority, we apply best practice guidelines to evaluate fidelity within a real-world, stepped-wedge evaluation of ""EAT: Eating As Treatment"", a new dietitian delivered health behaviour change intervention designed to reduce malnutrition in head and neck cancer (HNC) patients undergoing radiotherapy. METHODS Dietitians ( n = 18) from five Australian hospitals delivered a period of routine care and following a randomly determined order each site received training and began delivering the EAT Intervention. A 20% random stratified sample of audio-recorded consultations (control n = 196; intervention n = 194) was coded by trained, independent, raters using a study specific checklist and the Behaviour Change Counselling Inventory. Intervention adherence and competence were examined relative to apriori benchmarks. Differentiation was examined by comparing control and intervention sessions (adherence, competence, non-specific factors, and dose), via multiple linear regression, logistic regression, or mixed-models. RESULTS Achievement of adherence benchmarks varied. The majority of sessions attained competence. Post-training consultations were clearly distinct from routine care regarding motivational and behavioural, but not generic, skills. CONCLUSIONS Although what level of fidelity is ""good enough"" remains an important research question, findings support the real-world feasibility of integrating EAT into dietetic consultations with HNC patients and provide a foundation for interpreting treatment effects.",2020,"Eating As Treatment"", a new dietitian delivered health behaviour change intervention designed to reduce malnutrition in head and neck cancer (HNC) patients undergoing radiotherapy. ","['head and neck cancer (HNC) patients undergoing radiotherapy', 'Dietitians ( n = 18) from five Australian hospitals delivered a period of routine care and following a randomly determined order each site received']","['EAT', 'training and began delivering the EAT Intervention', 'Complex Behaviour Change Intervention']","['Assessing Adherence, Competence and Differentiation']","[{'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0334932', 'cui_str': 'Dietitian (general)'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0205145', 'cui_str': 'Site'}]","[{'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0007589', 'cui_str': 'Differentiation, Cell'}]",,0.0381553,"Eating As Treatment"", a new dietitian delivered health behaviour change intervention designed to reduce malnutrition in head and neck cancer (HNC) patients undergoing radiotherapy. ","[{'ForeName': 'Alison Kate', 'Initials': 'AK', 'LastName': 'Beck', 'Affiliation': 'School of Medicine and Public Health, The University of Newcastle, Callaghan, NSW 2308, Australia.'}, {'ForeName': 'Amanda L', 'Initials': 'AL', 'LastName': 'Baker', 'Affiliation': 'School of Medicine and Public Health, The University of Newcastle, Callaghan, NSW 2308, Australia.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Carter', 'Affiliation': 'School of Medicine and Public Health, The University of Newcastle, Callaghan, NSW 2308, Australia.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Wratten', 'Affiliation': 'Department of Radiation Oncology, Calvary Mater Newcastle Hospital, Waratah, NSW 2298, Australia.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Bauer', 'Affiliation': 'Centre for Dietetics Research, The University of Queensland, St Lucia, QLD 4072, Australia.'}, {'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Wolfenden', 'Affiliation': 'School of Medicine and Public Health, The University of Newcastle, Callaghan, NSW 2308, Australia.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'McCarter', 'Affiliation': 'School of Medicine and Public Health, The University of Newcastle, Callaghan, NSW 2308, Australia.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Britton', 'Affiliation': 'Hunter New England Health, New Lambton 2305, Australia.'}]",Nutrients,['10.3390/nu12082332'] 2731,32759888,Elevated Lateral Position Improves the Success of Paramedian Approach Subarachnoid Puncture in Spinal Anesthesia before Hip Fracture Surgery in Elderly Patients: A Randomized Controlled Study.,"BACKGROUND The aim of this study was to determine whether an elevated lateral recumbent position, compared to regular lateral recumbent position, may reduce the number of needle passes and attempts required for success subarachnoid puncture in spinal aesthesia before surgery in elderly patients with hip fractures. MATERIAL AND METHODS This was a randomized controlled interventional study in Beijing Jishuitan Hospital. Patients older than 65 years of age with hip fracture orthopedics who were planned to receive subarachnoid block in the lateral recumbent position before surgery were enrolled. The eligible patients were randomly allocated into the experimental group, in which a lateral recumbent position with head and chest elevated 30° was taken during subarachnoid puncture. In the control group, subarachnoid puncture was performed in the lateral recumbent position. The main outcome was the numbers of needle passes required for a success puncture. Other outcomes included success rate in different numbers of attempts, patients reported discomfort score, and complications. RESULTS A total of 90 patients were enrolled, with 45 patients in each group. The number of needle passes (2.00 versus 3.00, P=0.001) and the number of attempts (1.00 versus 2.00, P<0.001) required for a successful subarachnoid puncture were significantly less in the experimental group than in the control group. Patients in the experimental group also had lower discomfort scores. The procedure process, including overall times needed for puncture, anesthesia, and surgery did not show differences between the 2 groups. Complications were few and similar between the 2 groups. CONCLUSIONS An elevated lateral recumbent position during the subarachnoid puncture in spinal anesthesia significantly reduced the needle pass numbers needed for success dural puncture, and reduced discomfort in elderly patients with hip fractures.",2020,"The procedure process, including overall times needed for puncture, anesthesia, and surgery did not show differences between the 2 groups.","['Beijing Jishuitan Hospital', 'Elderly Patients', 'elderly patients with hip fractures', '90 patients were enrolled, with 45 patients in each group', 'Patients older than 65 years of age with hip fracture orthopedics who were planned to receive subarachnoid block in the lateral recumbent position before surgery were enrolled']","['lateral recumbent position with head and chest elevated 30° was taken during subarachnoid puncture', 'Spinal Anesthesia before Hip Fracture Surgery']","['discomfort scores', 'number of attempts', 'numbers of needle passes required for a success puncture', 'number of needle passes', 'successful subarachnoid puncture', 'Complications', 'success rate', 'overall times needed for puncture, anesthesia, and surgery', 'discomfort score, and complications', 'subarachnoid puncture']","[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0444334', 'cui_str': 'Recumbent body position'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}]","[{'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0444334', 'cui_str': 'Recumbent body position'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0038527', 'cui_str': 'Subarachnoid space structure'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0038527', 'cui_str': 'Subarachnoid space structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]",90.0,0.11917,"The procedure process, including overall times needed for puncture, anesthesia, and surgery did not show differences between the 2 groups.","[{'ForeName': 'Wenchao', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Beijing Jishuitan Hospital, Beijing, China (mainland).'}, {'ForeName': 'Tianlong', 'Initials': 'T', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing, China (mainland).'}, {'ForeName': 'Geng', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Beijing Jishuitan Hospital, Beijing, China (mainland).'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Yuan', 'Affiliation': 'Department of Anesthesiology, Beijing Jishuitan Hospital, Beijing, China (mainland).'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesiology, Beijing Jishuitan Hospital, Beijing, China (mainland).'}, {'ForeName': 'Xiaoyu', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, Beijing Jishuitan Hospital, Beijing, China (mainland).'}, {'ForeName': 'Minghui', 'Initials': 'M', 'LastName': 'Yang', 'Affiliation': 'Department of Orthopaedics and Traumatology, Beijing Jishuitan Hospital, Beijing, China (mainland).'}, {'ForeName': 'Shaoqiang', 'Initials': 'S', 'LastName': 'Zheng', 'Affiliation': 'Department of Anesthesiology, Beijing Jishuitan Hospital, Beijing, China (mainland).'}]",Medical science monitor : international medical journal of experimental and clinical research,['10.12659/MSM.923813'] 2732,32759901,Application of 3D printed personalized prostate targeting puncture guidance in diagnosis of prostate cancer. Randomized controlled trial.,,2020,,['diagnosis of prostate cancer'],['3D printed personalized prostate targeting puncture guidance'],[],"[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}]","[{'cui': 'C0033161', 'cui_str': 'Printing'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}]",[],,0.130984,,"[{'ForeName': 'Qingquan', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Urology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': ""Department of Urology, Jinan City People's Hospital, Jinan, China.""}, {'ForeName': 'Ningning', 'Initials': 'N', 'LastName': 'You', 'Affiliation': 'Department of Urology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Shi', 'Affiliation': 'Department of Urology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'College of Pharmacy, Binzhou Medical University, Binzhou, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Urology, Zibo Maternal and Child Health Hospital, Zibo, China - wangwei3d@163.com.'}]",Panminerva medica,['10.23736/S0031-0808.20.04013-6'] 2733,32760093,Pain during pars plana vitrectomy following sub-Tenon versus peribulbar anesthesia: A randomized trial.,"PURPOSE To compare pain during pars plana vitrectomy (PPV) following topical lidocaine jelly and sub-Tenon anesthesia versus peribulbar anesthesia. METHODS Prospective, single-center, randomized study. Patients scheduled for PPV for macular hole (MH) or epiretinal membrane (ERM) at the Retina and Vitreous Section of the Department of Ophthalmology, Ribeirão Preto Medical School, University of São Paulo were randomly assigned to one of two groups in a 1:1 allocation ratio. Patients assigned to Group ST received topical anesthesia with 2% lidocaine jelly followed by sub-Tenon anesthesia with 2-4 ml of 1% ropivacaine. Patients assigned to PB received peribulbar anesthesia with 4-6 ml of 1% ropivacaine. After PPV, patients in both groups were asked to rate the level of pain they felt during the entire procedure (including anesthesia administration and PPV) by pointing at a 0-100 Visual Analogue Pain Scale (VAS). Data regarding demographics, patient characteristics and surgical features were also collected. RESULTS Fifty-four patients were enrolled in the study (26 in Group ST and 28 in Group PB). Baseline characteristics, including age, gender, and presence of comorbidities, were similar in both groups. The surgery performed was PPV alone in 10 and 14 patients in the ST and PB groups, respectively, and combined phacoemulsification and PPV in 16 and 14 patients in the ST and PB groups, respectively (p = 0.39, Pearson). Surgery duration (mean ± SD minutes) was similar in the two groups (62 ± 12 for ST and 70 ± 20 for PB, p = 0.09, t-Test). No patients needed supplemental topical or intravenous anesthesia during surgery. No sight- or life-threatening complication was observed in either group. VAS score was significantly lower in the ST compared to the PB group (median (interquartile range) was 1 (2.25-0) in the ST group compared to 11.5 (29.75-5) in the PB group, p< 0.0001, Wilcoxon). CONCLUSION In this study of patients who underwent PPV for MH or ERM, topical followed by sub-Tenon anesthesia was more effective in controlling pain during the whole vitrectomy procedure than peribulbar anesthesia. Compared to peribulbar anesthesia which is administered with a sharp needle, sub-Tenon anesthesia administered with a blunt cannula may be associated with a reduced risk of such adverse events as globe perforation, retrobulbar hemorrhage, and inadvertent injection of anesthesia into the optic nerve sheath.",2020,No sight- or life-threatening complication was observed in either group.,"['Fifty-four patients were enrolled in the study (26 in Group ST and 28 in Group PB', 'Patients scheduled for PPV for macular hole (MH) or epiretinal membrane (ERM) at the Retina and Vitreous Section of the Department of Ophthalmology, Ribeirão Preto Medical School, University of São Paulo', 'patients who underwent PPV for MH or']","['pars plana vitrectomy following sub-Tenon versus peribulbar anesthesia', 'peribulbar anesthesia', 'ERM, topical followed by sub-Tenon anesthesia', 'pars plana vitrectomy (PPV', 'topical anesthesia with 2% lidocaine jelly followed by sub-Tenon anesthesia with 2-4 ml of 1% ropivacaine', 'peribulbar anesthesia with 4-6 ml of 1% ropivacaine', 'topical lidocaine jelly and sub-Tenon anesthesia']","['VAS score', 'sight- or life-threatening complication', 'Pain', 'Surgery duration (mean ± SD minutes', 'Visual Analogue Pain Scale (VAS']","[{'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0563537', 'cui_str': 'Mechanical vitrectomy by pars plana approach'}, {'cui': 'C0024441', 'cui_str': 'Macular hole'}, {'cui': 'C0339543', 'cui_str': 'Epiretinal membrane'}, {'cui': 'C0035298', 'cui_str': 'Retinal structure'}, {'cui': 'C0029087', 'cui_str': 'Ophthalmology'}, {'cui': 'C0036378', 'cui_str': 'Medical School'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0563537', 'cui_str': 'Mechanical vitrectomy by pars plana approach'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0339543', 'cui_str': 'Epiretinal membrane'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0472473', 'cui_str': 'Topical local anesthetic'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0360097', 'cui_str': 'Lidocaine-containing product in cutaneous dose form'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C3537125', 'cui_str': 'Common terminology criteria for adverse events grade 4'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439232', 'cui_str': 'min'}]",54.0,0.0335394,No sight- or life-threatening complication was observed in either group.,"[{'ForeName': 'Jefferson A S', 'Initials': 'JAS', 'LastName': 'Ribeiro', 'Affiliation': 'Superior School of Health Sciences, Amazonas State University, Manaus, AM, Brazil.'}, {'ForeName': 'Daniel S', 'Initials': 'DS', 'LastName': 'Ribeiro', 'Affiliation': 'Department of Ophthalmology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Ingrid U', 'Initials': 'IU', 'LastName': 'Scott', 'Affiliation': 'Department of Ophthalmology, Penn State College of Medicine, Hershey, Pennsylvania, United States of America.'}, {'ForeName': 'João', 'Initials': 'J', 'LastName': 'Abrão', 'Affiliation': 'Department of Biomechanics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Jorge', 'Affiliation': 'Department of Ophthalmology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.'}]",PloS one,['10.1371/journal.pone.0236624'] 2734,32760097,Motor control integrated into muscle strengthening exercises has more effects on scapular muscle activities and joint range of motion before initiation of radiotherapy in oral cancer survivors with neck dissection: A randomized controlled trial.,"BACKGROUND Accessory nerve shoulder dysfunction is common after neck dissection in oral cancer survivors. This study aimed to investigate the short-term effects of scapular muscle strengthening exercises with motor-control techniques on neck dissection-related shoulder dysfunction in oral cancer survivors before the initiation of radiotherapy. METHODS Thirty-eight participants were randomly allocated into the motor-control and regular-exercise groups. Each group received conventional physical therapy and specific scapular muscle strengthening exercises for 1 month immediately after neck dissection. Motor control techniques were integrated with scapular strengthening exercises for the motor-control group. Shoulder pain, active range of motion (AROM) of shoulder abduction, and scapular muscle activities including upper trapezius (UT), middle trapezius (MT), lower trapezius (LT), and serratus anterior (SA) when performing maximal voluntary isometric contraction (MVIC) and scapular muscle exercises were evaluated at baseline and after 1 month of training. RESULTS Both groups reduced shoulder pain and increased muscle activity of maximum voluntary isometric contraction (MVIC) of each muscle after the intervention. Increased AROM of shoulder abduction was only observed in the motor-control group (95% CI 3.80 to 20.51, p = 0.004). Relative to baseline evaluation, muscle activities of UT decreased in the motor-control group when performing shoulder shrug with 1-kg weight (95% CI -33.06 to -1.29, p = 0.034). Moreover, the SA activity decreased in the motor-control group (95% CI -29.73 to -27.68, p<0.001) but increased in the regular-exercise group (95% CI 28.16 to 30.05, p<0.001) when performing shoulder horizontal adduction and flexion. CONCLUSION Early strengthening exercise with motor control techniques has greater benefits for improving AROM of shoulder abduction, muscle economy, and reducing compensatory scapular muscle activities in patients with neck dissection-related shoulder dysfunction before the initiation of radiotherapy.",2020,Both groups reduced shoulder pain and increased muscle activity of maximum voluntary isometric contraction (MVIC) of each muscle after the intervention.,"['oral cancer survivors with neck dissection', 'oral cancer survivors', 'Thirty-eight participants', 'patients with neck dissection-related shoulder dysfunction']","['scapular strengthening exercises', 'radiotherapy', 'Early strengthening exercise with motor control techniques', 'Motor control integrated into muscle strengthening exercises', 'conventional physical therapy and specific scapular muscle strengthening exercises', 'scapular muscle strengthening exercises with motor-control techniques', 'motor-control and regular-exercise groups']","['muscle activities of UT', 'Shoulder pain, active range of motion (AROM) of shoulder abduction, and scapular muscle activities including upper trapezius (UT), middle trapezius (MT), lower trapezius (LT), and serratus anterior (SA', 'shoulder pain and increased muscle activity of maximum voluntary isometric contraction (MVIC', 'SA activity', 'Increased AROM of shoulder abduction', 'maximal voluntary isometric contraction (MVIC) and scapular muscle exercises']","[{'cui': 'C0153381', 'cui_str': 'Malignant tumor of oral cavity'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0398395', 'cui_str': 'Block dissection of cervical lymph nodes'}, {'cui': 'C0450361', 'cui_str': '38'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}]","[{'cui': 'C0452260', 'cui_str': 'Muscular strength development exercise'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0582191', 'cui_str': 'Regular exercise'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0224361', 'cui_str': 'Structure of trapezius muscle'}, {'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0086505', 'cui_str': 'Kidnapping'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0224349', 'cui_str': 'Structure of serratus anterior muscle'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0022205', 'cui_str': 'Muscle isometric contraction'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",38.0,0.090319,Both groups reduced shoulder pain and increased muscle activity of maximum voluntary isometric contraction (MVIC) of each muscle after the intervention.,"[{'ForeName': 'Yueh-Hsia', 'Initials': 'YH', 'LastName': 'Chen', 'Affiliation': 'School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University, Taipei, Taiwan.'}, {'ForeName': 'Chi-Rung', 'Initials': 'CR', 'LastName': 'Lin', 'Affiliation': 'Rehabilitation Center, Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan.'}, {'ForeName': 'Wei-An', 'Initials': 'WA', 'LastName': 'Liang', 'Affiliation': 'Rehabilitation Center, Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan.'}, {'ForeName': 'Cheng-Ya', 'Initials': 'CY', 'LastName': 'Huang', 'Affiliation': 'School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University, Taipei, Taiwan.'}]",PloS one,['10.1371/journal.pone.0237133'] 2735,32760144,A gender-sensitised weight-loss and healthy living program for men with overweight and obesity in Australian Football League settings (Aussie-FIT): A pilot randomised controlled trial.,"BACKGROUND Recent evidence shows that sport settings can act as a powerful draw to engage men in weight loss. The primary objective of this pilot study was to test the feasibility of delivering and to evaluate preliminary efficacy of Aussie-FIT, a weight-loss program for men with overweight/obesity delivered in Australian Football League (AFL) settings, in preparation for a future definitive trial. METHODS AND FINDINGS This 6-month pilot trial took place in Perth, Australia. Participants were overweight/obese (Body Mass Index [BMI] ≥ 28 kg/m2), middle-aged (35-65 years old) men. Participants were recruited in May 2018, and the intervention took place between June and December 2018. The intervention involved 12 weekly 90-min face-to-face sessions, incorporating physical activity, nutrition, and behaviour change information and practical activities delivered by coaches at 2 clubs. Data were collected at baseline and immediately postintervention. For trial feasibility purposes, 6-month follow-ups were completed. Outcomes were differences in weight loss (primary outcome) and recruitment and retention rates, self-reported measures (for example, psychological well-being), device-measured physical activity, waist size, and blood pressure at 3 months. Within 3 days of advertising at each club, 426 men registered interest; 306 (72%) were eligible. Men were selected on a first-come first-served basis (n = 130; M age = 45.8, SD = 8; M BMI = 34.48 kg/m2, SD = 4.87) and randomised by a blinded researcher. Trial retention was 86% and 63% at 3- and 6-month follow-ups (respectively). No adverse events were reported. At 3 months, mean difference in weight between groups, adjusted for baseline weight and group, was 3.3 kg (95% CI 1.9, 4.8) in favour of the intervention group (p < 0.001). The intervention group's moderate-to-vigorous physical activity (MVPA) was higher than the control group by 8.54 min/day (95% CI 1.37, 15.71, p = 0.02). MVPA among men attracted to Aussie-FIT was high at baseline (intervention arm 35.61 min/day, control arm 38.38 min/day), which may have limited the scope for improvement. CONCLUSIONS Aussie-FIT was feasible to deliver; participants increased physical activity, decreased weight, and reported improvements in other outcomes. Issues with retention were a limitation of this trial. In a future, fully powered randomised controlled trial (RCT), retention could be improved by conducting assessments outside of holiday seasons. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry: ACTRN12617000515392.",2020,"MVPA among men attracted to Aussie-FIT was high at baseline (intervention arm 35.61 min/day, control arm 38.38 min/day), which may have limited the scope for improvement. ","['men with overweight/obesity delivered in Australian Football League (AFL) settings', '426 men registered interest; 306 (72%) were eligible', '28 kg/m2), middle-aged (35-65 years old) men', 'men with overweight and obesity in Australian Football League settings (Aussie-FIT', 'Men were selected on a first-come first-served basis (n = 130; M age = 45.8, SD = 8; M BMI = 34.48 kg/m2, SD = 4.87', 'Participants were overweight/obese', 'Participants were recruited in May 2018, and the intervention took place between June and December 2018']","['MVPA', 'Aussie-FIT, a weight-loss program']","['weight loss (primary outcome) and recruitment and retention rates, self-reported measures (for example, psychological well-being), device-measured physical activity, waist size, and blood pressure', 'moderate-to-vigorous physical activity (MVPA', 'physical activity, decreased weight', 'adverse events']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0016517', 'cui_str': 'American or Canadian football - sport'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0036572', 'cui_str': 'Seizure'}, {'cui': 'C0960273', 'cui_str': 'CAME'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0442504', 'cui_str': 'Place'}]","[{'cui': 'C0036572', 'cui_str': 'Seizure'}, {'cui': 'C3179079', 'cui_str': 'Weight Loss Programs'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0424578', 'cui_str': 'Well in self'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0230097', 'cui_str': 'Structure of waist (surface region)'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.212539,"MVPA among men attracted to Aussie-FIT was high at baseline (intervention arm 35.61 min/day, control arm 38.38 min/day), which may have limited the scope for improvement. ","[{'ForeName': 'Dominika', 'Initials': 'D', 'LastName': 'Kwasnicka', 'Affiliation': 'Physical Activity and Well-being Research Group, Curtin University, Perth, Australia.'}, {'ForeName': 'Nikos', 'Initials': 'N', 'LastName': 'Ntoumanis', 'Affiliation': 'Physical Activity and Well-being Research Group, Curtin University, Perth, Australia.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Hunt', 'Affiliation': 'Physical Activity and Well-being Research Group, Curtin University, Perth, Australia.'}, {'ForeName': 'Cindy M', 'Initials': 'CM', 'LastName': 'Gray', 'Affiliation': 'Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Robert U', 'Initials': 'RU', 'LastName': 'Newton', 'Affiliation': 'Exercise Medicine Research Institute, Edith Cowan University, Perth, Australia.'}, {'ForeName': 'Daniel F', 'Initials': 'DF', 'LastName': 'Gucciardi', 'Affiliation': 'Physical Activity and Well-being Research Group, Curtin University, Perth, Australia.'}, {'ForeName': 'Cecilie', 'Initials': 'C', 'LastName': 'Thøgersen-Ntoumani', 'Affiliation': 'Physical Activity and Well-being Research Group, Curtin University, Perth, Australia.'}, {'ForeName': 'Jenny L', 'Initials': 'JL', 'LastName': 'Olson', 'Affiliation': 'Physical Activity and Well-being Research Group, Curtin University, Perth, Australia.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'McVeigh', 'Affiliation': 'Physical Activity and Well-being Research Group, Curtin University, Perth, Australia.'}, {'ForeName': 'Deborah A', 'Initials': 'DA', 'LastName': 'Kerr', 'Affiliation': 'School of Public Health, Curtin University, Perth, Australia.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Wyke', 'Affiliation': 'Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'Morgan', 'Affiliation': 'Priority Research Centre in Physical Activity and Nutrition, School of Education, University of Newcastle, Newcastle, Australia.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Robinson', 'Affiliation': 'School of Public Health, Curtin University, Perth, Australia.'}, {'ForeName': 'Marshall', 'Initials': 'M', 'LastName': 'Makate', 'Affiliation': 'School of Public Health, Curtin University, Perth, Australia.'}, {'ForeName': 'Eleanor', 'Initials': 'E', 'LastName': 'Quested', 'Affiliation': 'Physical Activity and Well-being Research Group, Curtin University, Perth, Australia.'}]",PLoS medicine,['10.1371/journal.pmed.1003136'] 2736,32760148,Breastfeeding peer support by telephone in the RUBY randomised controlled trial: A qualitative exploration of volunteers' experiences.,"BACKGROUND There is growing evidence that peer support programs may be effective in supporting breastfeeding mothers. A randomised controlled trial (RCT) (the RUBY study) that tested peer support in the Australian context found that infants of first-time mothers who received proactive telephone peer support were more likely to be receiving breastmilk at six months of age. METHODS This qualitative sub-study of the RUBY RCT explores the experiences and views of peer volunteers who delivered the intervention. Focus groups were conducted with 17 peers from the RUBY RCT between November 2015 and March 2016. All had provided peer support to at least one mother. RESULTS We found that volunteers identified strongly with the mothers' need for support when establishing breastfeeding. Key components of the support were strengthening the mothers' self-belief through affirmation and sharing experiential knowledge. Volunteers found the role rewarding and personally therapeutic although some women reported challenges initiating and maintaining contact with some mothers. Data were analysed using a hybrid approach to thematic analysis combining inductive and deductive techniques. CONCLUSIONS Breastfeeding peer support programs are reliant on recruitment of motivated volunteers who can provide empathetic mother-to-mother support. This study provides important information regarding volunteers' experiences that may support the upscaling of breastfeeding peer support for new mothers. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry, ACTRN 12612001024831.",2020,"that tested peer support in the Australian context found that infants of first-time mothers who received proactive telephone peer support were more likely to be receiving breastmilk at six months of age. ","['Focus groups were conducted with 17 peers from the RUBY RCT between November 2015 and March 2016', ""volunteers' experiences""]","['RUBY RCT', 'proactive telephone']",[],"[{'cui': 'C0016400', 'cui_str': 'Focus Groups'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}]",[],,0.0535925,"that tested peer support in the Australian context found that infants of first-time mothers who received proactive telephone peer support were more likely to be receiving breastmilk at six months of age. ","[{'ForeName': 'Heather A', 'Initials': 'HA', 'LastName': 'Grimes', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Bundoora, Victoria, Australia.'}, {'ForeName': 'Della A', 'Initials': 'DA', 'LastName': 'Forster', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Bundoora, Victoria, Australia.'}, {'ForeName': 'Touran', 'Initials': 'T', 'LastName': 'Shafiei', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Bundoora, Victoria, Australia.'}, {'ForeName': 'Lisa H', 'Initials': 'LH', 'LastName': 'Amir', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Bundoora, Victoria, Australia.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'McLardie-Hore', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Bundoora, Victoria, Australia.'}, {'ForeName': 'Helen L', 'Initials': 'HL', 'LastName': 'McLachlan', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Bundoora, Victoria, Australia.'}]",PloS one,['10.1371/journal.pone.0237190'] 2737,32760241,"Examining the Dorsolateral and Ventromedial Prefrontal Cortex Involvement in the Self-Attention Network: A Randomized, Sham-Controlled, Parallel Group, Double-Blind, and Multichannel HD-tDCS Study.","Background Attention and perception are strongly biased toward information about oneself compared to information about others. The self-attention network, an integrative theoretical framework for understanding the self-prioritization effects (SPE), proposes that the ventromedial prefrontal cortex (VMPFC), and the posterior superior temporal sulcus (pSTS) are the two nodes responsible for the preferential processing of self-related stimuli, which interact with the attentional control network (associated with the dorsolateral prefrontal cortex, DLPFC), responsible for processing other-related stimuli. So far, neuroimaging studies have provided considerable correlational evidence supporting the self-attention network. Objective Here we went beyond correlational evidence by manipulating cortical activity using high-definition transcranial direct current stimulation (HD-tDCS), a non-invasive brain stimulation method. We assessed whether anodal and cathodal stimulation of the VMPFC or the DLPFC modulates the processing of self- and other-related stimuli. Methods We used an associative unbiased learning procedure, the so-called shape-label matching task, to assess the SPE in a sample of N = 90. We accomplished to overcome different methodological weaknesses of previous studies using different multichannel montages for excitatory and inhibitory effects over both the VMPFC and the DLPFC. Results We found no effect of shape association for non-matching pairs, whereas there was an effect of shape association in the matching condition. Performance (reaction times and accuracy) was better for the self association than for the other two associations, and performance for the friend association was better than for the stranger association. Thus, we replicated the SPE with behavioral data. At the neural level, none of the stimulation succeeded to modulate the magnitude of the SPE effect. Conclusion We discuss the implications of these findings, in particular why cognitive modeling theories about SPEs should favor an epiphenomenal rather than a causal link between VMPFC/DLPFC and the impact of personal significance stimuli on perception.",2020,"Performance (reaction times and accuracy) was better for the self association than for the other two associations, and performance for the friend association was better than for the stranger association.",[],['high-definition transcranial direct current stimulation (HD-tDCS'],['Performance (reaction times and accuracy'],[],"[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}]",,0.0501422,"Performance (reaction times and accuracy) was better for the self association than for the other two associations, and performance for the friend association was better than for the stranger association.","[{'ForeName': 'Víctor', 'Initials': 'V', 'LastName': 'Martínez-Pérez', 'Affiliation': 'Department of Basic Psychology and Methodology, University of Murcia, Murcia, Spain.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Campoy', 'Affiliation': 'Department of Basic Psychology and Methodology, University of Murcia, Murcia, Spain.'}, {'ForeName': 'Lucía B', 'Initials': 'LB', 'LastName': 'Palmero', 'Affiliation': 'Department of Basic Psychology and Methodology, University of Murcia, Murcia, Spain.'}, {'ForeName': 'Luis J', 'Initials': 'LJ', 'LastName': 'Fuentes', 'Affiliation': 'Department of Basic Psychology and Methodology, University of Murcia, Murcia, Spain.'}]",Frontiers in neuroscience,['10.3389/fnins.2020.00683'] 2738,32760304,Health-Related Quality of Life and Costs of Posttraumatic Stress Disorder in Adolescents and Young Adults in Germany.,"Background Posttraumatic stress disorder (PTSD) is one of the psychopathological consequences of sexual and/or physical abuse. The economic burden is assumed to be high, whereas health-related quality of life and education is negatively affected. This study aims to determine health care costs, health-related quality of life, and educational interruption in adolescents and young adults with PTSD after sexual and/or physical abuse in Germany. Methods This analysis used data of 87 participants aged 14-21 years of a randomized controlled trial. Health care utilization, health-related quality of life (EQ-5D-5L), sick leave days, productivity, and delay or failure to achieve educational aims were assessed. Health care costs from a payer perspective were calculated using unit costs for the year 2014. Results Mean health care costs for a six-month period were 5,243€ (SE 868€). In particular, costs of inpatient stays in psychiatric hospitals, general hospitals and rehabilitation as well as child welfare institutions were high. In addition, health-related quality of life was lower due to anxiety/depression, resulting in a mean EQ-5D index and EQ-VAS score of 0.70 and 61.0, respectively. Furthermore, participants reported on average 27 sick leave days, a productivity loss of 61%, and a delay in education attainment as well as having been unable to achieve educational aims. Conclusion PTSD in adolescents and young adults is associated with a high economic burden. Health-related quality of life was substantially reduced. Furthermore, delay and productivity losses in education were observed. Clinical Trial Registration German Clinical Trials Register identifier: DRKS00004787; date of registration: 18 th March 2013; https://www.drks.de.",2020,"Health care utilization, health-related quality of life (EQ-5D-5L), sick leave days, productivity, and delay or failure to achieve educational aims were assessed.","['\n\n\nPosttraumatic stress disorder (PTSD', 'Adolescents and Young Adults in Germany', 'adolescents and young adults', '87 participants aged 14-21 years', 'adolescents and young adults with PTSD after sexual and/or physical abuse in Germany']",[],"['Furthermore, delay and productivity losses', 'mean EQ-5D index and EQ-VAS score', 'health care costs, health-related quality of life, and educational interruption', 'Health care utilization, health-related quality of life (EQ-5D-5L), sick leave days, productivity, and delay or failure to achieve educational aims', 'Health-Related Quality of Life and Costs of Posttraumatic Stress Disorder', 'health-related quality of life', 'productivity loss', 'Health-related quality of life', 'Mean health care costs']","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C1621955', 'cui_str': 'Physical abuse'}]",[],"[{'cui': 'C0033269', 'cui_str': 'Productivity'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0085552', 'cui_str': 'Health Costs'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C0030672', 'cui_str': 'Health Care Utilization'}, {'cui': 'C0242807', 'cui_str': 'Sick Leave'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C2744535', 'cui_str': 'CD69 protein, human'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}]",87.0,0.161754,"Health care utilization, health-related quality of life (EQ-5D-5L), sick leave days, productivity, and delay or failure to achieve educational aims were assessed.","[{'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Dams', 'Affiliation': 'Hamburg Center for Health Economics (HCHE), Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Eline', 'Initials': 'E', 'LastName': 'Rimane', 'Affiliation': 'Department of Psychology, Catholic University Eichstätt-Ingolstadt, Eichstätt, Germany.'}, {'ForeName': 'Regina', 'Initials': 'R', 'LastName': 'Steil', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Institute of Psychology, Goethe University Frankfurt, Frankfurt, Germany.'}, {'ForeName': 'Babette', 'Initials': 'B', 'LastName': 'Renneberg', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Freie Universitaet Berlin, Berlin, Germany.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Rosner', 'Affiliation': 'Department of Psychology, Catholic University Eichstätt-Ingolstadt, Eichstätt, Germany.'}, {'ForeName': 'Hans-Helmut', 'Initials': 'HH', 'LastName': 'König', 'Affiliation': 'Hamburg Center for Health Economics (HCHE), Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}]",Frontiers in psychiatry,['10.3389/fpsyt.2020.00697'] 2739,32760306,Efficacy of a Computer-Based Learning Program in Children With Developmental Dyscalculia. What Influences Individual Responsiveness?,"This study presents the evaluation of a computer-based learning program for children with developmental dyscalculia and focuses on factors affecting individual responsiveness. The adaptive training program Calcularis 2.0 has been developed according to current neuro-cognitive theory of numerical cognition. It aims to automatize number representations, supports the formation and access to the mental number line and trains arithmetic operations as well as arithmetic fact knowledge in expanding number ranges. Sixty-seven children with developmental dyscalculia from second to fifth grade (mean age 8.96 years) were randomly assigned to one of two groups (Calcularis group, waiting control group). Training duration comprised a minimum of 42 training sessions à 20 min within a maximum period of 13 weeks. Compared to the waiting control group, children of the Calcularis group demonstrated a higher benefit in arithmetic operations and number line estimation. These improvements were shown to be stable after a 3-months post training interval. In addition, this study examines which predictors accounted for training improvements. Results indicate that this self-directed training was especially beneficial for children with low math anxiety scores and without an additional reading and/or spelling disorder. In conclusion, Calcularis 2.0 supports children with developmental dyscalculia to improve their arithmetical abilities and their mental number line representation. However, it is relevant to further adapt the setting to the individual circumstances.",2020,"Compared to the waiting control group, children of the Calcularis group demonstrated a higher benefit in arithmetic operations and number line estimation.","['Children With Developmental Dyscalculia', 'Sixty-seven children with developmental dyscalculia from second to fifth grade (mean age 8.96 years', 'children with developmental dyscalculia']","['computer-based learning program', 'Computer-Based Learning Program']",['arithmetic operations and number line estimation'],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1395913', 'cui_str': 'Primary Dyscalculia'}, {'cui': 'C4517852', 'cui_str': '67'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0205439', 'cui_str': 'Fifth'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086858', 'cui_str': 'Programmed Learning'}]","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}]",67.0,0.0119364,"Compared to the waiting control group, children of the Calcularis group demonstrated a higher benefit in arithmetic operations and number line estimation.","[{'ForeName': 'Juliane', 'Initials': 'J', 'LastName': 'Kohn', 'Affiliation': 'Department of Psychology, University of Potsdam, Potsdam, Germany.'}, {'ForeName': 'Larissa', 'Initials': 'L', 'LastName': 'Rauscher', 'Affiliation': 'Department of Child and Adolescent Psychiatry, German Red Cross Hospital, Berlin, Germany.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Kucian', 'Affiliation': ""Center for MR Research, University Children's Hospital Zürich, Zurich, Switzerland.""}, {'ForeName': 'Tanja', 'Initials': 'T', 'LastName': 'Käser', 'Affiliation': 'Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Wyschkon', 'Affiliation': 'Academy of Psychotherapy and Intervention Research, University of Potsdam, Potsdam, Germany.'}, {'ForeName': 'Günter', 'Initials': 'G', 'LastName': 'Esser', 'Affiliation': 'Department of Psychology, University of Potsdam, Potsdam, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'von Aster', 'Affiliation': 'Department of Psychology, University of Potsdam, Potsdam, Germany.'}]",Frontiers in psychology,['10.3389/fpsyg.2020.01115'] 2740,32760319,Dose-Response Effects of Acute Aerobic Exercise Duration on Cognitive Function in Patients With Breast Cancer: A Randomized Crossover Trial.,"Objective To examine the differential effects of acute exercise duration on domains of executive function and processing speed in patients with breast cancer. Methods Participants ( N = 48, M age = 56.02 ± 10.99) completed two sessions in counterbalanced order: moderate-intensity treadmill walking and sitting. Participants were also randomized to one of three duration conditions: 10 ( n = 15), 20 ( n = 16), or 30 ( n = 17) min, reflecting the length of time spent walking and sitting. Immediately before and after each session, women completed a battery of cognitive tasks (e.g., inhibition, cognitive flexibility, spatial working memory, and processing speed). Results Within- and between-subjects repeated-measures analyses of variance revealed time by condition interactions on both processing speed ( p = 0.02) and spatial working memory ( p s < 0.07), such that women demonstrated improved cognitive functioning regardless of the time spent walking. There were also several moderately sized three-way (e.g., time by condition by duration) interactions driven by declines in cognitive functioning after sitting on cognitive flexibility in the 10 ( d = -0.96) and 30-min ( d = -0.52) groups and inhibition in the 20-min group ( d = 0.75). On the processing speed task, women performed significantly faster after walking compared with after sitting in the 20-min group ( d = -0.24). Conclusions For select cognitive domains, walking anywhere from 10 to 30 min is associated with significant benefits. Our findings suggest the need for further research into the mechanisms and dose-response relationships between acute exercise and cognition as well as how such acute bouts may be accumulated for larger, lasting cognitive benefits after breast cancer. Clinical Trial Registration www.ClinicalTrials.gov, identifier NCT04255225.",2020,"On the processing speed task, women performed significantly faster after walking compared with after sitting in the 20-min group ( d = -0.24). ","['Methods\n\n\nParticipants ( N = 48, M age = 56.02 ± 10.99) completed two sessions in counterbalanced order', 'patients with breast cancer', 'Patients With Breast Cancer']","['acute exercise duration', 'Acute Aerobic Exercise Duration', 'moderate-intensity treadmill walking and sitting']","['cognitive functioning after sitting on cognitive flexibility', 'cognitive functioning', 'spatial working memory', 'Cognitive Function', 'cognitive tasks (e.g., inhibition, cognitive flexibility, spatial working memory, and processing speed']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}]","[{'cui': 'C4279937', 'cui_str': 'Acute Exercise'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0037216', 'cui_str': 'SITS'}]","[{'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0582591', 'cui_str': 'Processing speed'}]",,0.0857023,"On the processing speed task, women performed significantly faster after walking compared with after sitting in the 20-min group ( d = -0.24). ","[{'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Salerno', 'Affiliation': 'Cancer Prevention Fellowship Program, Division of Cancer Epidemiology & Genetics, Metabolic Epidemiology Branch, National Cancer Institute, Bethesda, MD, United States.'}, {'ForeName': 'Kendrith', 'Initials': 'K', 'LastName': 'Rowland', 'Affiliation': 'Carle Foundation Hospital, Urbana, IL, United States.'}, {'ForeName': 'Charles H', 'Initials': 'CH', 'LastName': 'Hillman', 'Affiliation': 'College of Science, Northeastern University, Boston, MA, United States.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Trinh', 'Affiliation': 'Department of Kinesiology & Physical Education, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Arthur F', 'Initials': 'AF', 'LastName': 'Kramer', 'Affiliation': 'College of Science, Northeastern University, Boston, MA, United States.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'McAuley', 'Affiliation': 'Department of Kinesiology & Community Health, University of Illinois at Urbana-Champaign, Champaign, IL, United States.'}]",Frontiers in psychology,['10.3389/fpsyg.2020.01500'] 2741,31909679,The effects of various irrigation protocols on root canal wall adaptation and apical microleakage in primary teeth.,"Objective: The objective of this study is to evaluate the wall adaptation and apical microleakage values following the application of various irrigation protocols in primary teeth. Material and methods: For the two parts of the study, extracted upper incisor primary teeth were randomly included to the 1% sodium hypochlorite (NaOCl), 10% ethylenediaminetetraacetic acid (EDTA)+1% NaOCl, 6% citric acid (CA)+1% NaOCl and 0.9% physiological saline (PS) groups. Canal wall adaptation and apical microleakage were assessed by scanning electron microscopy (SEM) and stereomicroscope, respectively. Results: 6% CA + 1% NaOCl group was found to be the most successful irrigation protocol in providing strong canal wall adaptation and less apical microleakage, followed by 10% EDTA +1% NaOCl. 6% CA +1% NaOCl was significantly superior regarding apical microleakage ( p  < .05). Conclusions: Due to the ability to provide appropriate changes in the root canal walls to make a well-adapted and leak-proof canal filling, 6% CA + 1% NaOCl can be recommended as an irrigation protocol in primary teeth.",2020,6% CA +1% NaOCl was significantly superior regarding apical microleakage ( p  < .05).,"['extracted upper incisor primary teeth', 'primary teeth']","['sodium hypochlorite (NaOCl), 10% ethylenediaminetetraacetic acid (EDTA)+1% NaOCl, 6% citric acid (CA)+1% NaOCl and 0.9% physiological saline (PS', 'various irrigation protocols', 'CA ']","['root canal wall adaptation and apical microleakage', 'wall adaptation and apical microleakage values', 'Canal wall adaptation and apical microleakage', 'strong canal wall adaptation and less apical microleakage', 'apical microleakage']","[{'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0021156', 'cui_str': 'Structure of incisor tooth'}, {'cui': 'C3266841', 'cui_str': 'All deciduous teeth'}]","[{'cui': 'C0037518', 'cui_str': 'sodium hypochlorite'}, {'cui': 'C0013618', 'cui_str': 'Edetic Acid'}, {'cui': 'C0055819', 'cui_str': 'Citric Acid'}, {'cui': 'C4068881', 'cui_str': '0.9'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0205380', 'cui_str': 'Walled'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0205111', 'cui_str': 'Apical'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0086881', 'cui_str': 'Pulp canal'}, {'cui': 'C0442821', 'cui_str': 'Strong'}]",,0.0185051,6% CA +1% NaOCl was significantly superior regarding apical microleakage ( p  < .05).,"[{'ForeName': 'Burcu Nihan', 'Initials': 'BN', 'LastName': 'Yüksel', 'Affiliation': 'Department of Pedodontics, Faculty of Dentistry, Ankara University, Ankara, Turkey.'}, {'ForeName': 'Akif', 'Initials': 'A', 'LastName': 'Demirel', 'Affiliation': 'Department of Pedodontics, Faculty of Dentistry, Ankara University, Ankara, Turkey.'}, {'ForeName': 'Meryem', 'Initials': 'M', 'LastName': 'Ziya', 'Affiliation': 'Department of Pedodontics, Faculty of Dentistry, Ankara University, Ankara, Turkey.'}, {'ForeName': 'Kevser', 'Initials': 'K', 'LastName': 'Kolçakoğlu', 'Affiliation': 'Department of Pedodontics, Faculty of Dentistry, Erciyes University, Kayseri, Turkey.'}, {'ForeName': 'Salih', 'Initials': 'S', 'LastName': 'Doğan', 'Affiliation': 'Department of Pedodontics, Faculty of Dentistry, Erciyes University, Kayseri, Turkey.'}, {'ForeName': 'Şaziye', 'Initials': 'Ş', 'LastName': 'Sarı', 'Affiliation': 'Department of Pedodontics, Faculty of Dentistry, Ankara University, Ankara, Turkey.'}]",Acta odontologica Scandinavica,['10.1080/00016357.2019.1709890'] 2742,32767349,Corticosteroid therapy for patients with severe novel Coronavirus disease 2019.,"OBJECTIVE To investigate the effect of corticosteroid on hospital mortality, hospital length of stay, and time of viral clearance in patients with severe and critical COVID-19. PATIENTS AND METHODS Patients with severe and critical COVID-19 who had been discharged or expired were enrolled in this study. Patients were divided into corticosteroid group and non-corticosteroid group according to the systemic corticosteroid use or not. Clinical data were collected, and hospital mortality, hospital length of stay, time of viral clearance, time of mechanical ventilation, and duration from illness onset to symptom resolution were compared between the two groups. RESULTS A total of 72 inpatients who were diagnosed with severe and critical COVID-19 were enrolled, in which 47 patients were divided into corticosteroid group and 25 were involved as the non-corticosteroid group. Baseline characteristics were generally similar between the two groups. Four (5.6%) patients died during hospitalization, and 68 (94.4%) were discharged. Among survivors, the mean duration time from admission to discharge was 19.5d (SD 7.05 d). The mean time of viral clearance among survivors was 17.5d (SD 7.67 d), with a maximum of 37 d, and a minimum of 5 d. Hospital mortality (4.3% vs. 8.0%), length of hospital stay (18.7d vs. 21.0d), and time of viral clearance (16.1d vs. 19.4d) had no significant difference between two groups (p>0.05). The duration of symptoms suffering was shorter in the corticosteroid group than non-corticosteroid group, with statistically significant difference (p<0.05). CONCLUSIONS Corticosteroid therapy in patients with severe COVID-19 cannot reduce the hospital mortality, and is not associated with delayed viral clearance, but it could relieve the inflammatory storm and improve clinical symptoms in brief. Patients with severe COVID-19 could benefit from low-dose corticosteroid treatment.",2020,"The duration of symptoms suffering was shorter in the corticosteroid group than non-corticosteroid group, with statistically significant difference (p<0.05). ","['Patients with severe and critical COVID-19 who had been discharged or expired were enrolled in this study', '72 inpatients who were diagnosed with severe and critical COVID-19 were enrolled, in which 47 patients were divided into corticosteroid group and 25 were involved as the non-corticosteroid group', 'patients with severe and critical COVID-19', 'patients with severe novel Coronavirus disease 2019']","['corticosteroid', 'Corticosteroid therapy', 'corticosteroid group and non-corticosteroid']","['Hospital mortality', 'duration of symptoms suffering', 'mean duration time from admission to discharge', 'hospital mortality, hospital length of stay, time of viral clearance, time of mechanical ventilation, and duration from illness onset to symptom resolution', 'hospital mortality, hospital length of stay, and time of viral clearance', 'mean time of viral clearance', 'length of hospital stay', 'hospital mortality', 'time of viral clearance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0149783', 'cui_str': 'Administration of steroid'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}, {'cui': 'C0436359', 'cui_str': 'Time symptom lasts'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",72.0,0.0940617,"The duration of symptoms suffering was shorter in the corticosteroid group than non-corticosteroid group, with statistically significant difference (p<0.05). ","[{'ForeName': 'Q', 'Initials': 'Q', 'LastName': 'Ma', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, The Second Affiliated hospital of Chongqing Medical Universty, Chongqing, China. 300293@hospital.cqmu.edu.cn.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Qi', 'Affiliation': ''}, {'ForeName': 'X-Y', 'Initials': 'XY', 'LastName': 'Deng', 'Affiliation': ''}, {'ForeName': 'G-D', 'Initials': 'GD', 'LastName': 'Yuan', 'Affiliation': ''}, {'ForeName': 'W-G', 'Initials': 'WG', 'LastName': 'Tian', 'Affiliation': ''}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Cui', 'Affiliation': ''}, {'ForeName': 'X-F', 'Initials': 'XF', 'LastName': 'Yan', 'Affiliation': ''}, {'ForeName': 'D-X', 'Initials': 'DX', 'LastName': 'Wang', 'Affiliation': ''}]",European review for medical and pharmacological sciences,['10.26355/eurrev_202008_22508'] 2743,32767414,Effect of Feru-guard 100M on amyloid-beta deposition in individuals with mild cognitive impairment.,"AIM Many researchers argue that Alzheimer's disease is at least partly caused by deposition of amyloid beta (Aβ) in the brain. Ferulic acid (FA) and Angelica archangelica (AA) are candidate agents for reducing Aβ and improving cognitive function. Feru-guard 100M is a supplement containing FA and AA extract. Using this supplement, we planned to assess the effect of FA and AA on Aβ deposition in the human brain. METHODS This was an open-label, interventional multi-institutional joint study of Kobe University and the Institute of Biomedical Research and Innovation (Kobe, Japan). Seventeen subjects diagnosed with mild cognitive impairment were divided into two groups: the intervention group (n = 10) and the control group (n = 7). The subjects in the intervention group used Feru-guard 100M every day for 48 weeks, whereas the subjects in the control group did not use the supplement. We assessed the differences between the two groups by examining Aβ deposition and brain atrophy at 48 weeks and cognitive function every 24 weeks. We used carbon-11-labelled Pittsburgh compound B (PiB) positron emission tomography to evaluate Aβ deposition. RESULTS There were no significant differences in Aβ deposition, brain atrophy, and cognitive function between the two groups. Specifically, differences in Aβ deposition change in seven regions of interest examined with PiB positron emission tomography, brain atrophy change in four indicators of voxel-based morphometry, and cognitive impairment measured by five psychological tests were not significantly between the two groups. CONCLUSION Treatment with Feru-guard 100M, a supplement containing FA and AA extract, for 48 weeks did not reduce cortical PiB retention, which reflects Aβ deposition. It also did not suppress the aggravation of brain atrophy or decline in cognitive function.",2020,"There were no significant differences in Aβ deposition, brain atrophy, and cognitive function between the two groups.","['Seventeen subjects diagnosed with mild cognitive impairment', 'individuals with mild cognitive impairment']","['carbon-11-labelled Pittsburgh compound B (PiB) positron emission tomography', 'Ferulic acid (FA) and Angelica archangelica (AA', 'Feru-guard 100M']","['amyloid-beta deposition', 'cortical PiB retention', 'Aβ deposition, brain atrophy, and cognitive function']","[{'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0302944', 'cui_str': 'Carbon-11'}, {'cui': 'C1568156', 'cui_str': 'Pittsburgh compound B'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C0060291', 'cui_str': 'ferulic acid'}, {'cui': 'C0877891', 'cui_str': 'Angelica archangelica'}, {'cui': 'C0278253', 'cui_str': 'Guarded prognosis'}, {'cui': 'C1704407', 'cui_str': '100'}]","[{'cui': 'C0002716', 'cui_str': 'Amyloid Substance'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0333562', 'cui_str': 'Deposition'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C1568156', 'cui_str': 'Pittsburgh compound B'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0235946', 'cui_str': 'Cerebral atrophy'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",17.0,0.0268915,"There were no significant differences in Aβ deposition, brain atrophy, and cognitive function between the two groups.","[{'ForeName': 'Kenichi', 'Initials': 'K', 'LastName': 'Matsuyama', 'Affiliation': 'Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.'}, {'ForeName': 'Yasuji', 'Initials': 'Y', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.'}, {'ForeName': 'Ichiro', 'Initials': 'I', 'LastName': 'Sora', 'Affiliation': 'Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.'}]",Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society,['10.1111/psyg.12581'] 2744,32767565,Supportive treatment following peri-implantitis surgery; an RCT using titanium curettes or chitosan brushes.,"AIMS The aim of this randomized controlled trial was to assess the effect of two maintenance programs when treatments were performed every third month from six to 18 months following surgical treatment of peri-implantitis. MATERIALS AND METHODS At the 6 months post-surgical evaluation, 44 subjects were randomized into groups receiving supportive peri-implant treatment either by the use of titanium curettes or chitosan brushes at implants registered with BoP and PPD >3 mm. Follow-up examinations and supportive therapy was performed 6-, 9-, 12-, 15- and 18-month post surgically. Clinical and radiographic assessments were made. RESULTS The percentage of implants registered with inflammation was high at the 6-month baseline examination (>80% bleeding on probing in both test and control group) and remained high throughout the observation period. Similar observations were made for all clinical parameters and no significant difference was found between test- and control groups. CONCLUSIONS In the present study, no statistical significant difference was found when supportive peri-implant treatment was performed with either titanium curettes or chitosan brushes. Within the limits of the study, the results might indicate the need of more effective submucosal cleaning procedures following peri-implant surgery.",2020,The percentage of implants registered with inflammation was high at the 6-month baseline examination (>80% bleeding on probing in both test and control group) and remained high throughout the observation period.,['44 subjects'],"['titanium curettes or chitosan brushes', 'supportive peri-implant treatment either by the use of titanium curettes or chitosan brushes at implants registered with BoP and PPD >3 mm']",['percentage of implants registered with inflammation'],[],"[{'cui': 'C0040302', 'cui_str': 'Titanium'}, {'cui': 'C0180236', 'cui_str': 'Curette'}, {'cui': 'C0162969', 'cui_str': 'Chitosan'}, {'cui': 'C0040461', 'cui_str': 'Brushing of teeth'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0796232', 'cui_str': 'Bohring Opitz syndrome'}, {'cui': 'C0034131', 'cui_str': 'Purified Protein Derivative of Tuberculin'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",44.0,0.0559019,The percentage of implants registered with inflammation was high at the 6-month baseline examination (>80% bleeding on probing in both test and control group) and remained high throughout the observation period.,"[{'ForeName': 'Odd Carsten', 'Initials': 'OC', 'LastName': 'Koldsland', 'Affiliation': 'Dept. of Periodontology, Institute of Clinical Dentistry, Faculty of Dentistry, University of Oslo, Norway.'}, {'ForeName': 'Anne Merete', 'Initials': 'AM', 'LastName': 'Aass', 'Affiliation': 'Dept. of Periodontology, Institute of Clinical Dentistry, Faculty of Dentistry, University of Oslo, Norway.'}]",Journal of clinical periodontology,['10.1111/jcpe.13357'] 2745,32767766,An Open-Label Study Evaluating the Pharmacokinetics and Safety of Diclofenac Potassium for Oral Solution for the Acute Treatment of MWA or MWoA in Pediatric Participants.,"OBJECTIVE To evaluate the pharmacokinetics, safety, and tolerability of a single 50-mg oral dose of diclofenac potassium for oral solution (OS) in a pediatric cohort with a diagnosis of episodic migraine; the 3-month safety trial following an outpatient dosing period was also evaluated. BACKGROUND Children and adolescents often experience migraine pain that is poorly controlled, which may affect their emotional and psychological well-being. Diclofenac potassium for OS is approved for the treatment of migraine with aura (MWA) or migraine without aura (MWoA) in adults 18 years of age or older. It is formulated in a soluble buffered powder that provides more rapid absorption than the tablet formulations of diclofenac potassium. In a randomized, double-blind, crossover trial, more adult patients were pain-free at 2 hours post-dose following treatment with diclofenac potassium for OS than those who received the diclofenac tablet formulation or placebo. METHODS This was a Phase 4 open-label study that took place at 2 US sites. Participants 12-17 years of age with a diagnosis of episodic MWA or MWoA for ≥3 months and ≤14 headaches per month were enrolled in the study. Participants received one 50-mg dose of diclofenac potassium for OS under fasted conditions on day 1. Blood samples were collected for PK analysis within 15 minutes pre-dose and at 5, 10, 15, 20, 30, 40, and 60 minutes post-dose, and at 2, 4, and 6 hours post-dose. Safety evaluations were performed after the initial dose and at the end of study on day 90; adverse events were monitored throughout the study. After completing the PK assessments, participants were given a 3-month supply (27 packets) of diclofenac potassium for OS (50-mg doses) for their migraine attacks. Participants were advised to take diclofenac potassium for OS at the onset of a migraine. They were told to take no more than 2 doses daily and not to use it more than 3 days/week. RESULTS Twenty-five participants completed the study; 84% were females and 96% were white or Caucasian, with a mean age of 15.5 years and a mean weight of 63.1 kg. Diclofenac was rapidly absorbed with a median time to maximum concentration of 15 minutes and a mean peak plasma concentration of 1412 (±846.2) ng/mL. Diclofenac had a half-life of 66.8 (±9.2) minutes. The mean area under the concentration-time curve from zero to the last measurable time point was 82,920.0 (±25,327.6) minutes × ng/mL, and the mean area under the concentration-time curve from time zero to infinity was 84,388.8 (±25,993.6) minutes × ng/mL. Participants took the study drug an average of 10 times over 79 days, with an overall total drug exposure of 506 mg. No deaths or discontinuations due to an AE were reported during the study. The most frequently reported treatment emergent adverse events were arthralgia and motion sickness, each of which occurred in 2 (8%) of the participants. CONCLUSIONS Diclofenac potassium for OS exhibited a favorable pharmacokinetic and safety profile in 12- to 17-year-old patients with a diagnosis of episodic MWA or MWoA.",2020,Diclofenac was rapidly absorbed with a median time to maximum concentration of 15 minutes and a mean peak plasma concentration of 1412 (±846.2),"['Twenty-five participants completed the study; 84% were females and 96% were white or Caucasian, with a mean age of 15.5\xa0years and a mean weight of 63.1\xa0kg', '12- to 17-year-old patients with a diagnosis of episodic MWA or MWoA', 'Pediatric Participants', 'migraine with aura (MWA) or migraine without aura (MWoA) in adults 18\xa0years of age or older', 'pediatric cohort with a diagnosis of episodic migraine', 'Participants 12-17\xa0years of age with a diagnosis of episodic MWA or MWoA for ≥3\xa0months and ≤14 headaches per month were enrolled in the study']","['diclofenac potassium', 'Diclofenac Potassium', 'diclofenac potassium for oral solution (OS', 'diclofenac potassium for OS', 'Diclofenac', 'diclofenac tablet formulation or placebo', 'Diclofenac potassium']","['pain-free', 'pharmacokinetic and safety profile', 'mean area under the concentration-time curve', 'adverse events', 'pharmacokinetics, safety, and tolerability']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C4760993', 'cui_str': 'Episodic migraine'}, {'cui': 'C0236018', 'cui_str': 'Aura'}, {'cui': 'C0338480', 'cui_str': 'Migraine without aura'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0154723', 'cui_str': 'Migraine with aura'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0018681', 'cui_str': 'Headache'}]","[{'cui': 'C0282131', 'cui_str': 'Diclofenac potassium'}, {'cui': 'C0991536', 'cui_str': 'Oral solution'}, {'cui': 'C0012091', 'cui_str': 'Diclofenac'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0908489', 'cui_str': 'Pain-Free'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",84.0,0.0704587,Diclofenac was rapidly absorbed with a median time to maximum concentration of 15 minutes and a mean peak plasma concentration of 1412 (±846.2),"[{'ForeName': 'Jennifer W', 'Initials': 'JW', 'LastName': 'McVige', 'Affiliation': 'Headache Clinic, Dent Neurologic Institute, Amherst, NY, USA.'}, {'ForeName': 'Rebecca M', 'Initials': 'RM', 'LastName': 'Hogan', 'Affiliation': 'Headache Clinic, Dent Neurologic Institute, Amherst, NY, USA.'}, {'ForeName': 'Clayton M', 'Initials': 'CM', 'LastName': 'Shanahan', 'Affiliation': 'Headache Clinic, Dent Neurologic Institute, Amherst, NY, USA.'}, {'ForeName': 'Diane L', 'Initials': 'DL', 'LastName': 'Amend', 'Affiliation': 'gRED Clinical Operations, Depomed, Inc, Newark, CA, USA.'}, {'ForeName': 'Shawn M', 'Initials': 'SM', 'LastName': 'Ferger', 'Affiliation': 'Department of Administration, Dent Neurologic Institute, Amherst, NY, USA.'}]",Headache,['10.1111/head.13922'] 2746,32767806,R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908study.,"The efficiency of upfront consolidation with high-dose chemotherapy/autologous stem-cell transplantation (HDCT/ASCT) for newly diagnosed high-risk diffuse large B-cell lymphoma (DLBCL) may be influenced by induction chemotherapy. To select better induction chemotherapy regimens for HDCT/ASCT, a randomized phase II study was conducted in high-risk DLBCL patients with age-adjusted International Prognostic Index (aaIPI) score 2 or 3. As induction chemotherapy, 6 cycles of R-CHOP-14 (arm A) or 3 cycles of R-CHOP-14 followed by 3 cycles of CHASER (arm B) were planned, and patients who responded proceeded to HDCT with LEED and ASCT. The primary endpoint was 2-year progression-free survival (PFS), and the main secondary endpoints included overall survival, overall response rate, and adverse events (AEs). A total of 71 patients were enrolled. With a median follow-up of 40.3 months, 2-year PFS in arms A and B were 68.6% (95% confidence interval [CI], 50.5-81.2%) and 66.7% (95% CI, 48.8-79.5%), respectively. Overall survival at 2 years in arms A and B were 74.3% (95% CI, 56.4-85.7%) and 83.3% (95% CI, 66.6-92.1%). Overall response rates were 82.9% in arm A and 69.4% in arm B. During induction chemotherapy, 45.7% and 75.0% of patients in arms A and B, respectively, had grade ≥3 non-hematologic toxicities. One patient in arm A and 6 in arm B discontinued induction chemotherapy due to AEs. In conclusion, R-CHOP-14 showed higher 2-year PFS and less toxicity compared with R-CHOP-14/CHASER in high-risk DLBCL, suggesting the former to be a more promising induction regimen for further investigations. (UMIN-CTR, UMIN000003823).",2020,"Overall survival at 2 years in arms A and B were 74.3% (95% CI, 56.4-85.7%) and 83.3% (95% CI, 66.6-92.1%).","['71 patients were enrolled', 'high-risk DLBCL patients with age-adjusted International Prognostic Index (aaIPI) score 2 or 3', 'newly diagnosed high-risk diffuse large B-cell lymphoma (DLBCL']","['upfront consolidation with high-dose chemotherapy/autologous stem-cell transplantation (HDCT/ASCT', 'HDCT with LEED and ASCT']","['grade ≥3 non-hematologic toxicities', '2-year PFS', 'Overall survival', '2-year progression-free survival (PFS', '2-year PFS and less toxicity', 'Overall response rates', 'overall survival, overall response rate, and adverse events (AEs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0079744', 'cui_str': 'Malignant lymphoma, large B-cell, diffuse'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C1512894', 'cui_str': 'International Prognostic Index'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0521530', 'cui_str': 'Lung consolidation'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1831743', 'cui_str': 'Transplantation of autologous hematopoietic stem cell'}]","[{'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0018943', 'cui_str': 'Hematology'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",71.0,0.277288,"Overall survival at 2 years in arms A and B were 74.3% (95% CI, 56.4-85.7%) and 83.3% (95% CI, 66.6-92.1%).","[{'ForeName': 'Yoshitoyo', 'Initials': 'Y', 'LastName': 'Kagami', 'Affiliation': 'Department of Hematology, Toyota Kosei Hospital, Toyota, Japan.'}, {'ForeName': 'Kazuhito', 'Initials': 'K', 'LastName': 'Yamamoto', 'Affiliation': 'Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.'}, {'ForeName': 'Taro', 'Initials': 'T', 'LastName': 'Shibata', 'Affiliation': 'JCOG Data Center/Operations Office, National Cancer Center, Tokyo, Japan.'}, {'ForeName': 'Kensei', 'Initials': 'K', 'LastName': 'Tobinai', 'Affiliation': 'Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Yoshitaka', 'Initials': 'Y', 'LastName': 'Imaizumi', 'Affiliation': 'Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.'}, {'ForeName': 'Toshiki', 'Initials': 'T', 'LastName': 'Uchida', 'Affiliation': 'Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.'}, {'ForeName': 'Kazuyuki', 'Initials': 'K', 'LastName': 'Shimada', 'Affiliation': 'Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.'}, {'ForeName': 'Koichiro', 'Initials': 'K', 'LastName': 'Minauchi', 'Affiliation': 'Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.'}, {'ForeName': 'Noriko', 'Initials': 'N', 'LastName': 'Fukuhara', 'Affiliation': 'Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan.'}, {'ForeName': 'Hirofumi', 'Initials': 'H', 'LastName': 'Kobayashi', 'Affiliation': 'Department of Hematology, Saitama Cancer Center, Ina-cho, Japan.'}, {'ForeName': 'Nobuhiko', 'Initials': 'N', 'LastName': 'Yamauchi', 'Affiliation': 'Department of Hematology, National Cancer Center East, Kashiwa, Japan.'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Tsujimura', 'Affiliation': 'Division of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Hangaishi', 'Affiliation': 'Division of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.'}, {'ForeName': 'Ryo', 'Initials': 'R', 'LastName': 'Tominaga', 'Affiliation': 'Division of Hematology, Hyogo Cancer Center, Akashi, Japan.'}, {'ForeName': 'Youko', 'Initials': 'Y', 'LastName': 'Suehiro', 'Affiliation': 'Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.'}, {'ForeName': 'Shinichiro', 'Initials': 'S', 'LastName': 'Yoshida', 'Affiliation': 'Department of Hematology, National Hospital Organization Nagasaki Medical Center, Ohmura, Japan.'}, {'ForeName': 'Yoshiko', 'Initials': 'Y', 'LastName': 'Inoue', 'Affiliation': 'Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.'}, {'ForeName': 'Sachiko', 'Initials': 'S', 'LastName': 'Suzuki', 'Affiliation': 'Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.'}, {'ForeName': 'Michihide', 'Initials': 'M', 'LastName': 'Tokuhira', 'Affiliation': 'Departments of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.'}, {'ForeName': 'Shigeru', 'Initials': 'S', 'LastName': 'Kusumoto', 'Affiliation': 'Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.'}, {'ForeName': 'Junya', 'Initials': 'J', 'LastName': 'Kuroda', 'Affiliation': 'Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Yakushijin', 'Affiliation': 'First Department of Internal Medicine, Ehime University Hospital, Toon, Japan.'}, {'ForeName': 'Yasushi', 'Initials': 'Y', 'LastName': 'Takamatsu', 'Affiliation': 'Division of Medical Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University Hospital, Fukuoka, Japan.'}, {'ForeName': 'Yasushi', 'Initials': 'Y', 'LastName': 'Kubota', 'Affiliation': 'Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.'}, {'ForeName': 'Kisato', 'Initials': 'K', 'LastName': 'Nosaka', 'Affiliation': 'Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.'}, {'ForeName': 'Satoko', 'Initials': 'S', 'LastName': 'Morishima', 'Affiliation': 'Second Department of Internal Medicine, University of the Ryukyus Hospital, Nishihara, Japan.'}, {'ForeName': 'Shigeo', 'Initials': 'S', 'LastName': 'Nakamura', 'Affiliation': 'Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.'}, {'ForeName': 'Michinori', 'Initials': 'M', 'LastName': 'Ogura', 'Affiliation': 'Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.'}, {'ForeName': 'Dai', 'Initials': 'D', 'LastName': 'Maruyama', 'Affiliation': 'Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Tomomitsu', 'Initials': 'T', 'LastName': 'Hotta', 'Affiliation': 'National Hospital Organization Nagoya Medical Center, Nagoya, Japan.'}, {'ForeName': 'Yasuo', 'Initials': 'Y', 'LastName': 'Morishima', 'Affiliation': 'Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.'}, {'ForeName': 'Kunihiro', 'Initials': 'K', 'LastName': 'Tsukasaki', 'Affiliation': 'Department of Hematology, International Medical Center, Saitama Medical University, Hidaka, Japan.'}, {'ForeName': 'Hirokazu', 'Initials': 'H', 'LastName': 'Nagai', 'Affiliation': 'Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.'}]",Cancer science,['10.1111/cas.14604'] 2747,32767824,"Transcutaneous vagus nerve stimulation prevents the development of, and reverses, established oesophageal pain hypersensitivity.","BACKGROUND The vagus nerve exerts an anti-nociceptive effect in the viscera. AIMS To investigate whether transcutaneous vagal nerve stimulation (t-VNS) prevents the development and/or reverses established visceral hypersensitivity in a validated model of acid-induced oesophageal pain. METHODS Before and after a 30-minute infusion of 0.15M hydrochloric acid into the distal oesophagus, pain thresholds to electrical stimulation were determined in the proximal non-acid exposed oesophagus. Validated sympathetic (cardiac sympathetic index) and parasympathetic (cardiac vagal tone [CVT]) nervous system measures were recorded. In study 1, 15 healthy participants were randomised in a blinded crossover design to receive either t-VNS or sham for 30 minutes during acid infusion. In study 2, 18 different healthy participants were randomised in a blinded crossover design to receive either t-VNS or sham, for 30 minutes after acid infusion. RESULTS Study 1: t-VNS increased CVT (31.6% ± 58.7 vs -9.6 ± 20.6, P = 0.02) in comparison to sham with no effect on cardiac sympathetic index. The development of acid-induced oesophageal hypersensitivity was prevented with t-VNS in comparison to sham (15.5 mA per unit time (95% CI 4.9 - 26.2), P = 0.004). Study 2: t-VNS increased CVT (26.3% ± 32.7 vs 3 ± 27.1, P = 0.03) in comparison to sham with no effect on cardiac sympathetic index. t-VNS reversed established acid-induced oesophageal hypersensitivity in comparison to sham (17.3mA/unit time (95% CI 9.8-24.7), P = 0.0001). CONCLUSIONS t-VNS prevents the development of, and reverses established, acid-induced oesophageal hypersensitivity. These results have therapeutic implications for the management of visceral pain hypersensitivity.",2020,"The development of acid-induced oesophageal hypersensitivity was prevented with t-VNS in comparison to sham (15.5 mA per unit time (95% CI 4.9 - 26.2), P = 0.004).","['15 healthy participants', '18 different healthy participants']","['transcutaneous vagal nerve stimulation (t-VNS', '0.15M hydrochloric acid into the distal oesophagus', 'Transcutaneous vagus nerve stimulation', 't-VNS or sham for 30\xa0minutes during acid infusion', 't-VNS']","['CVT', 'cardiac sympathetic index', 'oesophageal hypersensitivity', 'development of acid-induced oesophageal hypersensitivity', 'Validated sympathetic (cardiac sympathetic index) and parasympathetic (cardiac vagal tone [CVT]) nervous system measures', 'pain thresholds to electrical stimulation']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}, {'cui': 'C4068886', 'cui_str': '0.15'}, {'cui': 'C0020259', 'cui_str': 'Hydrochloric Acid'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0014876', 'cui_str': 'Esophageal structure'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}]","[{'cui': 'C0240912', 'cui_str': 'Congenital vertical talus'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0027763', 'cui_str': 'Structure of nervous system'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}]",15.0,0.214132,"The development of acid-induced oesophageal hypersensitivity was prevented with t-VNS in comparison to sham (15.5 mA per unit time (95% CI 4.9 - 26.2), P = 0.004).","[{'ForeName': 'Adam D', 'Initials': 'AD', 'LastName': 'Farmer', 'Affiliation': 'Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Wingate Institute of Neurogastroenterology, Barts and the London School of Medicine & Dentistry, Mary University of London, London, UK.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Albusoda', 'Affiliation': 'Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Wingate Institute of Neurogastroenterology, Barts and the London School of Medicine & Dentistry, Mary University of London, London, UK.'}, {'ForeName': 'Gehanjali', 'Initials': 'G', 'LastName': 'Amarasinghe', 'Affiliation': 'Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Wingate Institute of Neurogastroenterology, Barts and the London School of Medicine & Dentistry, Mary University of London, London, UK.'}, {'ForeName': 'James K', 'Initials': 'JK', 'LastName': 'Ruffle', 'Affiliation': 'Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Wingate Institute of Neurogastroenterology, Barts and the London School of Medicine & Dentistry, Mary University of London, London, UK.'}, {'ForeName': 'Heather E', 'Initials': 'HE', 'LastName': 'Fitzke', 'Affiliation': 'Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Wingate Institute of Neurogastroenterology, Barts and the London School of Medicine & Dentistry, Mary University of London, London, UK.'}, {'ForeName': 'Ruqaya', 'Initials': 'R', 'LastName': 'Idrees', 'Affiliation': 'Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Wingate Institute of Neurogastroenterology, Barts and the London School of Medicine & Dentistry, Mary University of London, London, UK.'}, {'ForeName': 'Ron', 'Initials': 'R', 'LastName': 'Fried', 'Affiliation': 'Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Wingate Institute of Neurogastroenterology, Barts and the London School of Medicine & Dentistry, Mary University of London, London, UK.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Brock', 'Affiliation': 'Mech-Sense, Department of Gastroenterology, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Qasim', 'Initials': 'Q', 'LastName': 'Aziz', 'Affiliation': 'Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Wingate Institute of Neurogastroenterology, Barts and the London School of Medicine & Dentistry, Mary University of London, London, UK.'}]",Alimentary pharmacology & therapeutics,['10.1111/apt.15869'] 2748,32767879,[Comparative study of anterior cruciate ligament reconstruction between the One Band and U-Two techniques].,"INTRODUCTION ACL injuries are found within the most common ligament injuries. This has led to the development of different surgical techniques to restore knee stability. MATERIAL Y METHODS Clinical study, randomized, blind comparing ACL reconstruction techniques with One Band and «U-Two» using clinical scales and arthrometria with KT-1000 and Pivot Shift Meter. RESULTS Of 36 patients, 52.94% was drawn for the One Band technique and 47.06% for «U-Two». 11.76% of patients had a displacement greater than 11mm in the affected knee with KT-1000. 8.82% showed an equal anterior displacement on both knees. One patient had a major previous displacement after reconstruction surgery with the one band technique, but with improvement on clinical scales. Pivot Shift measurements found a difference in displacement greater than 4,000 m/s on the X axis following the One Band technique compared to the healthy knee calculating integrals, while with U-Two the difference was less than 600 m/s. On the Y axis a difference of 3,500 m/s was found between the healthy and the injured leg, which decreases to less than 2,000 m/s after reconstruction using U-Two technique. CONCLUSIONS Differences have been found throughout the study in patient evolution, indicating that repair using the U-Dos technique has better results in recovering the anteroposterior and rotational stability of the affected limb.",2019,"On the Y axis a difference of 3,500 m/s was found between the healthy and the injured leg, which decreases to less than 2,000 m/s after reconstruction using U-Two technique. ",[],"['ACL reconstruction techniques with One Band and «', 'anterior cruciate ligament reconstruction']",['clinical scales'],[],"[{'cui': 'C0162596', 'cui_str': 'Cardiolipin antibody'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.0168216,"On the Y axis a difference of 3,500 m/s was found between the healthy and the injured leg, which decreases to less than 2,000 m/s after reconstruction using U-Two technique. ","[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Berumen-Nafarrate', 'Affiliation': 'Ortopedia y Traumatología, Hospital Christus Muguerza del Parque. Chihuahua, Chihuahua. México.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Carmona-González', 'Affiliation': 'Facultad de Medicina y Ciencias Biomédicas, Universidad Autónoma de Chihuahua. México.'}, {'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Tonche-Ramos', 'Affiliation': 'Facultad de Medicina y Ciencias Biomédicas, Universidad Autónoma de Chihuahua. México.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Carmona-Máynez', 'Affiliation': 'Ortopedia y Traumatología, Hospital Christus Muguerza del Parque. Chihuahua, Chihuahua. México.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Aguirre-Madrid', 'Affiliation': 'Ortopedia y Traumatología, Hospital Christus Muguerza del Parque. Chihuahua, Chihuahua. México.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Moreno-Brito', 'Affiliation': 'Facultad de Medicina y Ciencias Biomédicas, Universidad Autónoma de Chihuahua. México.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Leal-Berumen', 'Affiliation': 'Facultad de Medicina y Ciencias Biomédicas, Universidad Autónoma de Chihuahua. México.'}]",Acta ortopedica mexicana,[] 2749,32764769,A simple nomogram score for screening patients with type 2 diabetes to detect those with hypertension: A cross-sectional study based on a large community survey in China.,"OBJECTIVES Compared with unaffected individuals, patients with type 2 diabetes (T2DM) have higher risk of hypertension, and diabetes combined with hypertension can lead to server cardiovascular disease. Therefore, the purpose of this study was to establish a simple nomogram model to identify the determinants of hypertension in patients with T2DM and to quickly calculate the probability of hypertension in individuals with T2DM. MATERIALS AND METHODS A total of 643,439 subjects participating in the national physical examination has been recruited in this cross-sectional study. After excluding unqualified subjects, 30,507 adults with T2DM were included in the final analysis. 21,355 and 9,152 subjects were randomly assigned to the model developing group and validation group, respectively, with a ratio of 7:3. The potential risk factors used in this study to assess hypertension in patients with T2DM included questionnaire investigation and physical measurement variables. We used the least absolute shrinkage and selection operator models to optimize feature selection, and the multivariable logistic regression analysis was for predicting model. Discrimination and calibration were assessed using the receiver operating curve (ROC) and calibration curve. RESULTS The results showed that the major determinants of hypertension in patients with T2DM were age, gender, drinking, exercise, smoking, obesity and atherosclerotic vascular disease. The area under ROC curve of developing group and validation group are both 0.814, indicating that the prediction model owns high disease recognition ability. The p values of the two calibration curves are 0.625 and 0.445, suggesting that the nomogram gives good calibration. CONCLUSION The individualized nomogram model can facilitate improved screening and early identification of patients with hypertension in T2DM. This procedure will be useful in developing regions with high epidemiological risk and poor socioeconomic status just like Urumqi, in Northern China.",2020,"The results showed that the major determinants of hypertension in patients with T2DM were age, gender, drinking, exercise, smoking, obesity and atherosclerotic vascular disease.","['643,439 subjects participating in the national physical examination has been recruited in this cross-sectional study', 'large community survey in China', '30,507 adults with T2DM', '21,355 and 9,152 subjects', 'patients with T2DM and to quickly calculate the probability of hypertension in individuals with T2DM', 'patients with type 2 diabetes (T2DM) have higher risk of hypertension, and diabetes combined with hypertension can lead to server cardiovascular disease', 'screening patients with type 2 diabetes to detect those with hypertension', 'patients with T2DM included questionnaire investigation and physical measurement variables', 'patients with hypertension in T2DM']",[],['receiver operating curve (ROC) and calibration curve'],"[{'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0009483', 'cui_str': 'Community Surveys'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C1705194', 'cui_str': 'Computer network server'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1261322', 'cui_str': 'Evaluation procedure'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0439828', 'cui_str': 'Variable'}]",[],"[{'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0006751', 'cui_str': 'Calibration'}]",643439.0,0.0173558,"The results showed that the major determinants of hypertension in patients with T2DM were age, gender, drinking, exercise, smoking, obesity and atherosclerotic vascular disease.","[{'ForeName': 'Mingyue', 'Initials': 'M', 'LastName': 'Xue', 'Affiliation': 'College of Public Health, Xinjiang Medical University, Urumqi, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Hospital of Traditional Chinese Medicine Affiliated to the Fourth Clinical Medical College of Xinjiang Medical University, Urumqi, China.'}, {'ForeName': 'Shuxia', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Center of Health Management, The First Affiliated Hospital, Xinjiang Medical University, Urumqi, China.'}, {'ForeName': 'Yinxia', 'Initials': 'Y', 'LastName': 'Su', 'Affiliation': 'Center of Health Management, The First Affiliated Hospital, Xinjiang Medical University, Urumqi, China.'}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Lv', 'Affiliation': 'Hospital of Traditional Chinese Medicine Affiliated to the Fourth Clinical Medical College of Xinjiang Medical University, Urumqi, China.'}, {'ForeName': 'Mingchen', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Yao', 'Affiliation': 'Center of Health Management, The First Affiliated Hospital, Xinjiang Medical University, Urumqi, China.'}]",PloS one,['10.1371/journal.pone.0236957'] 2750,32764818,"Does type of active workstation matter? A randomized comparison of cognitive and typing performance between rest, cycling, and treadmill active workstations.","Active workstations are associated with improved health outcomes, but differences in cognitive and typing outcomes between the types of active workstations are unclear. We addressed two main questions: (1) Are there differences in cognitive and typing performance between seated and active workstations? (2) Are there differences in cognitive and typing performance between cycling and treadmill workstations, specifically? Participants included 137 healthy young adults (74 female, mean age = 20.8 years) who completed two sessions. At session one (baseline), all participants completed cognitive and typing tests including the Rey-Auditory Verbal Learning Test, Paced Auditory Serial Addition Test, a typing test, and a flanker task while sitting at rest. At session two, participants were randomized to an active workstation group (treadmill or cycling desk) during which they performed the tests listed above in a randomized fashion, using alternate versions when available. Participants showed significantly better attention and cognitive control scores during the active session as compared to the seated session, but worse verbal memory scores during the active session. Participants were faster and more accurate at typing during the active session relative to the seated session. There were no significant differences between cycling or treadmill workstations on any cognitive or typing outcomes. Improvements during active sessions may be influenced by practice effects, although alternate forms were used when possible. We conclude that active workstations do not seem to largely impact cognitive abilities, with the exception of a slight decrease in verbal memory performance. Findings suggest active workstations, whether walking or cycling, are useful to improve physical activity, particularly when completing tasks that do not require verbal memory recall.",2020,"Active workstations are associated with improved health outcomes, but differences in cognitive and typing outcomes between the types of active workstations are unclear.","['Participants included 137 healthy young adults (74 female, mean age = 20.8 years) who completed two sessions']",['active workstation group (treadmill or cycling desk'],"['verbal memory performance', 'verbal memory scores', 'better attention and cognitive control scores', 'health outcomes']","[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517569', 'cui_str': '137'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C1736830', 'cui_str': 'Workstation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}]","[{'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",137.0,0.0902228,"Active workstations are associated with improved health outcomes, but differences in cognitive and typing outcomes between the types of active workstations are unclear.","[{'ForeName': 'Kayla M', 'Initials': 'KM', 'LastName': 'Frodsham', 'Affiliation': 'Department of Psychology, Brigham Young University, Provo, UT, United States of America.'}, {'ForeName': 'Nicholas R', 'Initials': 'NR', 'LastName': 'Randall', 'Affiliation': 'Department of Psychology, Brigham Young University, Provo, UT, United States of America.'}, {'ForeName': 'Kaylie A', 'Initials': 'KA', 'LastName': 'Carbine', 'Affiliation': 'Department of Psychology, Brigham Young University, Provo, UT, United States of America.'}, {'ForeName': 'Rebekah E', 'Initials': 'RE', 'LastName': 'Rodeback', 'Affiliation': 'Department of Psychology, Brigham Young University, Provo, UT, United States of America.'}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'LeCheminant', 'Affiliation': 'Department of Nutrition, Dietetics, and Food Science, Brigham Young University, Provo, UT, United States of America.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Larson', 'Affiliation': 'Department of Psychology, Brigham Young University, Provo, UT, United States of America.'}]",PloS one,['10.1371/journal.pone.0237348'] 2751,32764830,Exploring collective emotion transmission in face-to-face interactions.,"Collective emotion is the synchronous convergence of an effective response across individuals toward a specific event or object. Previous studies have focused on the transmission of cyber collective emotion; however, little attention has been paid to the transmission of collective emotion in face-to-face interactions. Using an experimental design, we examined how emotions are transmitted from some members to the whole group in face-to-face situations. We used a news report of a social event as an emotion stimulus to induce anger and disgust in 158 middle school students aged 12 to 15, with an average age of 13.20 years (SD = 0.651) We randomly assigned one-third of the participants to be ""transmitters,"" while the others were ""receivers."" Transmitters shared their feelings with receivers; then, receivers communicated with other group members. The results indicated that negative collective emotions were transmitted from high- to low-intensity members, which converged through the effect of emotional contagion. It accumulated through the effect of an emotional circle, during which the feedback reinforced emotion intensity. The collective emotion transmission model comprised emotion diffusion, contagion, and accumulation. This model elucidates the intrinsic features of collective emotion transmission, enriches the research on collective emotion, and provides theoretical references for monitoring and managing future public events.",2020,"The results indicated that negative collective emotions were transmitted from high- to low-intensity members, which converged through the effect of emotional contagion.","['158 middle school students aged 12 to 15, with an average age of 13.20 years (SD = 0.651']","['transmitters,"" while the others were ""receivers']",['negative collective emotions'],"[{'cui': 'C0557797', 'cui_str': 'Middle school'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]",[],"[{'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}]",158.0,0.0145015,"The results indicated that negative collective emotions were transmitted from high- to low-intensity members, which converged through the effect of emotional contagion.","[{'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Zheng', 'Affiliation': 'Department of Psychology, Weiqing Building, Tsinghua University, Beijing, China.'}, {'ForeName': 'Ailin', 'Initials': 'A', 'LastName': 'Yu', 'Affiliation': 'Department of Psychology, Weiqing Building, Tsinghua University, Beijing, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Fang', 'Affiliation': 'School of Psychology, Capital Normal University, Beijing, China.'}, {'ForeName': 'Kaiping', 'Initials': 'K', 'LastName': 'Peng', 'Affiliation': 'Department of Psychology, Weiqing Building, Tsinghua University, Beijing, China.'}]",PloS one,['10.1371/journal.pone.0236953'] 2752,32764861,Comparing Combination Drop Therapy to a Standard Drop Regimen After Routine Cataract Surgery.,"Purpose To evaluate the efficacy of a combined steroid/antibiotic/non-steroidal anti-inflammatory drop relative to a regimen of multiple drops after cataract surgery. Setting Single clinical practice in the USA. Design Prospective randomized contralateral eye study. Methods Subjects presenting for bilateral cataract surgery were enrolled with contralateral eyes randomly assigned to one of the two groups. Test eyes received a combination therapy (prednisolone acetate 1%, gatifloxacin 0.5%, and bromfenac sodium 0.075%) while control eyes received the same medications in separate drops (bromfenac sodium was 0.07%). Subjects were examined 1, 15 and 30 days after surgery. Visual acuities were measured, along with the refraction, intraocular pressure, patient pain and satisfaction, macular thickness and corneal pachymetry. The primary measure of interest was the change in macular thickness from baseline to the 15- and 30-day visits. The frequency and severity of reported ocular adverse events were tabulated for each group and compared. Results Thirty-three subjects completed the study. Changes in central macular thickness were similar between groups, with only one control eye exhibiting significant macular edema. No differences in visual acuity, corneal edema, cells or flare were observed between groups. There were eight mild adverse events reported for all eyes of all subjects; the difference in the number of eyes experiencing adverse events was not statistically significantly different between groups (p ≥ 0.05 for all comparisons). While subjective symptoms were similar, all subjects indicated that they preferred the combination drop. Conclusion A combination drop showed similar efficacy to multiple drops and was overwhelmingly preferred by subjects.",2020,"No differences in visual acuity, corneal edema, cells or flare were observed between groups.","['Results\n\n\nThirty-three subjects completed the study', 'Methods\n\n\nSubjects presenting for bilateral cataract surgery']","['combination therapy (prednisolone acetate 1%, gatifloxacin 0.5%, and bromfenac sodium 0.075%) while control eyes', 'combined steroid/antibiotic/non-steroidal anti-inflammatory']","['refraction, intraocular pressure, patient pain and satisfaction, macular thickness and corneal pachymetry', 'number of eyes experiencing adverse events', 'mild adverse events', 'frequency and severity of reported ocular adverse events', 'visual acuity, corneal edema, cells or flare', 'central macular thickness', 'macular thickness', 'Visual acuities']","[{'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0521707', 'cui_str': 'Bilateral cataracts'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0009429', 'cui_str': 'Combination therapy'}, {'cui': 'C0071839', 'cui_str': 'Prednisolone acetate'}, {'cui': 'C0753645', 'cui_str': 'gatifloxacin'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0107211', 'cui_str': 'Bromfenac sodium'}, {'cui': 'C4517416', 'cui_str': '0.075'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0003209', 'cui_str': 'Antiinflammatory agent'}]","[{'cui': 'C0429585', 'cui_str': 'Refraction measurement - finding'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0412514', 'cui_str': 'Corneal pachymetry'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0010037', 'cui_str': 'Corneal edema'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0205099', 'cui_str': 'Central'}]",33.0,0.0395108,"No differences in visual acuity, corneal edema, cells or flare were observed between groups.","[{'ForeName': 'Kerry D', 'Initials': 'KD', 'LastName': 'Solomon', 'Affiliation': 'Carolina Eyecare Physicians, Mt Pleasant, SC, USA.'}, {'ForeName': 'Helga P', 'Initials': 'HP', 'LastName': 'Sandoval', 'Affiliation': 'Carolina Eyecare Physicians, Mt Pleasant, SC, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Potvin', 'Affiliation': 'Science in Vision, Bend, OR, USA.'}]","Clinical ophthalmology (Auckland, N.Z.)",['10.2147/OPTH.S260926'] 2753,32764898,A Randomized Controlled Trial of FNB versus FICB for Patients with Femoral Neck Fractures Before Spinal Anesthesia.,"Background and Objectives Patients with femoral neck fractures often suffer severe pain. This randomized controlled clinical study compared the effect of femoral nerve block (FNB) and fascia iliaca compartment block (FICB) in this population. Patients and Methods Forty-six patients were randomly assigned to one of the two groups: FNB group (femoral nerve block, n=23) or FICB group (fascia iliaca compartment block, n=23). Before positioning for spinal anesthesia, patients received FNB with 15 mL of 0.5% ropivacaine or FICB with 40 mL of 0.5% ropivacaine. Pain was evaluated using a visual analogue scale (VAS) at rest and during hip flexion after admission to the operation room; at 3, 5, 8, and 10 min after analgesia intervention; and during positioning for spinal anesthesia. Positioning was attempted after 10 min of analgesia intervention in each group. Time required to perform spinal anesthesia, quality of positioning, and patient satisfaction were documented. Results The VAS scores in the FNB group were significantly lower than those in FICB group at 3 and 5 min after analgesia intervention (P=0.000). However, there were no significant differences in VAS between groups at 8 or 10 min or during positioning. Conclusion FNB and FICB produce similar analgesic effects in patients with femoral neck fractures, but FNB has a more rapid onset of pain relief.",2020,The VAS scores in the FNB group were significantly lower than those in FICB group at 3 and 5 min after analgesia intervention (P=0.000).,"['Patients with Femoral Neck Fractures Before Spinal Anesthesia', 'Patients and Methods\n\n\nForty-six patients', 'patients with femoral neck fractures', 'Patients with femoral neck fractures often suffer severe pain']","['ropivacaine', 'femoral nerve block (FNB) and fascia iliaca compartment block (FICB', 'FICB', 'FNB group (femoral nerve block, n=23) or FICB group (fascia iliaca compartment block', 'FNB and FICB', 'FNB', 'FNB with 15 mL of 0.5% ropivacaine or FICB']","['analgesic effects', 'VAS', 'visual analogue scale (VAS', 'Pain', 'Time required to perform spinal anesthesia, quality of positioning, and patient satisfaction', 'VAS scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015806', 'cui_str': 'Fracture of neck of femur'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0278140', 'cui_str': 'Severe pain'}]","[{'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0394739', 'cui_str': 'Local anesthetic femoral nerve block'}, {'cui': 'C0225261', 'cui_str': 'Iliac fascia structure'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444500', 'cui_str': '0.5'}]","[{'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0150305', 'cui_str': 'Positioning - therapy'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",46.0,0.104019,The VAS scores in the FNB group were significantly lower than those in FICB group at 3 and 5 min after analgesia intervention (P=0.000).,"[{'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Liang', 'Affiliation': ""Department of Anesthesiology, The\u2009Affiliated\u2009Hospital\u2009of\u2009Guilin\u2009Medical\u2009University, Guilin, People's Republic of China.""}, {'ForeName': 'Lv', 'Initials': 'L', 'LastName': 'Lv', 'Affiliation': ""Emergency Department, The Affiliated\u2009Hospital\u2009of\u2009Guilin\u2009Medical\u2009University, Guilin, People's Republic of China.""}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'He', 'Affiliation': ""Department of Anesthesiology, The\u2009Affiliated\u2009Hospital\u2009of\u2009Guilin\u2009Medical\u2009University, Guilin, People's Republic of China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Deng', 'Affiliation': ""Department of Anesthesiology, The First Hospital of Jiaxing (Affiliated Hospital of Jiaxing University), Jiaxing, People's Republic of China.""}, {'ForeName': 'Cai', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': ""Department of Anesthesiology, The\u2009Affiliated\u2009Hospital\u2009of\u2009Guilin\u2009Medical\u2009University, Guilin, People's Republic of China.""}, {'ForeName': 'Jingjuan', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ""Department of Anesthesiology, The\u2009Affiliated\u2009Hospital\u2009of\u2009Guilin\u2009Medical\u2009University, Guilin, People's Republic of China.""}]",Clinical interventions in aging,['10.2147/CIA.S251025'] 2754,32764908,Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective.,"Purpose To evaluate the cost-effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) vs twice-daily budesonide/formoterol (BUD/FOR) in patients with symptomatic chronic obstructive pulmonary disease (COPD) at risk of exacerbations, from the Spanish National Healthcare System perspective. Patients and Methods The validated GALAXY-COPD model was used to simulate disease progression and predict healthcare costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) over a 3-year time horizon for a Spanish population. Patient characteristics from published literature were supplemented by data from FULFIL (NCT02345161), which compared FF/UMEC/VI vs BUD/FOR in patients with symptomatic COPD at risk of exacerbations. Treatment effects, extrapolated to 3 years, were based on Week 24 results in the FULFIL intent-to-treat population, including change in forced expiratory volume in 1 second, St. George's Respiratory Questionnaire score, and exacerbation rates. Treatment, exacerbations, and COPD management costs (2019€) were informed by Spanish public sources and published literature. A 3% discount rate for costs and benefits was applied. One-way sensitivity and scenario analyses, and probabilistic sensitivity analysis (PSA), were performed. Results FF/UMEC/VI treatment led to fewer moderate and severe exacerbations (2.126 and 0.306, respectively) vs BUD/FOR (2.608 and 0.515, respectively), with a mean incremental cost of €69 and gain of 0.107 QALYs, which resulted in an ICER of €642 per QALY gained. In sensitivity analyses, the ICER was most sensitive to treatment effect variations in exacerbations and healthcare resource utilization/event costs. Overall, 95% of 1000 PSA simulations resulted in an ICER less than €11,000 per QALY gained for FF/UMEC/VI vs BUD/FOR, confirming robustness of the results. The probability of FF/UMEC/VI being cost-effective vs BUD/FOR was 100% at a willingness-to-pay threshold of €30,000 per QALY gained. Conclusion At the accepted Spanish ICER threshold of €30,000, FF/UMEC/VI represents a cost-effective treatment option vs BUD/FOR in patients with symptomatic COPD at risk of exacerbations.",2020,"In sensitivity analyses, the ICER was most sensitive to treatment effect variations in exacerbations and healthcare resource utilization/event costs.","['patients with symptomatic chronic obstructive pulmonary disease (COPD) at risk of exacerbations, from the Spanish National Healthcare System perspective', 'Patients with Chronic Obstructive Pulmonary Disease (COPD', 'patients with symptomatic COPD at risk of exacerbations']","['Once-Daily Single-Inhaler Triple Therapy', 'fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) vs twice-daily budesonide/formoterol (BUD/FOR']","['healthcare costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs', 'moderate and severe exacerbations', 'Treatment, exacerbations, and COPD management costs', 'cost-effectiveness', ""forced expiratory volume in 1 second, St. George's Respiratory Questionnaire score, and exacerbation rates"", 'probability of FF/UMEC/VI being cost-effective vs BUD/FOR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0018696', 'cui_str': 'Healthcare Systems'}]","[{'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0021461', 'cui_str': 'Inhaler'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1948374', 'cui_str': 'fluticasone furoate'}, {'cui': 'C3709478', 'cui_str': 'umeclidinium / vilanterol'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C1276807', 'cui_str': 'formoterol and budesonide'}]","[{'cui': 'C0085552', 'cui_str': 'Health Costs'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C3472502', 'cui_str': ""Saint George's respiratory questionnaire score""}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C3709478', 'cui_str': 'umeclidinium / vilanterol'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1276807', 'cui_str': 'formoterol and budesonide'}]",,0.272579,"In sensitivity analyses, the ICER was most sensitive to treatment effect variations in exacerbations and healthcare resource utilization/event costs.","[{'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Schroeder', 'Affiliation': 'Value Evidence and Outcomes, GlaxoSmithKline plc., Brentford, UK.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Benjamin', 'Affiliation': 'Global Health Economics, ICON plc., Boston, MA, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Atienza', 'Affiliation': 'Market Access, GlaxoSmithKline SA, Madrid, Spain.'}, {'ForeName': 'Chandroday', 'Initials': 'C', 'LastName': 'Biswas', 'Affiliation': 'Global Health Economics, ICON plc., Bengaluru, Karnataka, India.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Martin', 'Affiliation': 'Value Evidence and Outcomes, GlaxoSmithKline plc., Uxbridge, UK.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Whalen', 'Affiliation': 'Global Health Economics, ICON plc., Abingdon, UK.'}, {'ForeName': 'José Luis', 'Initials': 'JL', 'LastName': 'Izquierdo Alonso', 'Affiliation': 'Pneumology, Hospital Universitario de Guadalajara, Guadalajara, Spain.'}, {'ForeName': 'Juan Antonio', 'Initials': 'JA', 'LastName': 'Riesco Miranda', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Servicio de Neumología, Hospital San Pedro de Alcántara, Cáceres, Spain.'}, {'ForeName': 'Juan José', 'Initials': 'JJ', 'LastName': 'Soler-Cataluña', 'Affiliation': 'Pneumology Department, Hospital Arnau de Vilanova-Lliria (Valencia), Valencia, Spain.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Huerta', 'Affiliation': 'Market Access, GlaxoSmithKline SA, Madrid, Spain.'}, {'ForeName': 'Afisi S', 'Initials': 'AS', 'LastName': 'Ismaila', 'Affiliation': 'Value Evidence and Outcomes, GlaxoSmithKline plc., Collegeville, PA, USA.'}]",International journal of chronic obstructive pulmonary disease,['10.2147/COPD.S240556'] 2755,32764918,The Summit Score Stratifies Mortality and Morbidity in Chronic Obstructive Pulmonary Disease.,"Introduction Tobacco use and other cardiovascular risk factors often accompany chronic obstructive pulmonary disease (COPD). This study derived and validated the Summit Score to predict mortality in people with COPD and cardiovascular risks. Methods SUMMIT trial subjects (N=16,485) ages 40-80 years with COPD were randomly assigned 50%/50% to derivation (N=8181) and internal validation (N=8304). Three external COPD validations from Intermountain Healthcare included outpatients with cardiovascular risks (N=9251), outpatients without cardiovascular risks (N=8551), and inpatients (N=26,170). Cox regression evaluated 40 predictors of all-cause mortality. SUMMIT treatments including combined fluticasone furoate (FF) 100μg/vilanterol 25μg (VI) were not included in the score. Results Mortality predictors were FEV 1 , heart rate, systolic blood pressure, body mass index, age, smoking pack-years, prior COPD hospitalizations, myocardial infarction, heart failure, diabetes, anti-thrombotics, anti-arrhythmics, and xanthines. Combined in the Summit Score (derivation: c=0.668), quartile 4 vs 1 had HR=4.43 in SUMMIT validation (p<0.001, 95% CI=3.27, 6.01, c=0.662) and HR=8.15 in Intermountain cardiovascular risk COPD outpatients (p<0.001, 95% CI=5.86, 11.34, c=0.736), and strongly predicted mortality in the other Intermountain COPD populations. Among all SUMMIT subjects with scores 14-19, FF 100μg/VI 25μg vs placebo had HR=0.76 (p=0.0158, 95% CI=0.61, 0.95), but FF 100μg/VI 25μg was not different from placebo for scores <14 or >19. Conclusion In this post hoc analysis of SUMMIT trial data, the Summit Score was derived and validated in multiple Intermountain COPD populations. The score was used to identify a subpopulation in which mortality risk was lower for FF 100μg/VI 25μg treatment. Trial Registration The SUMMIT trial is registered at ClinicalTrials.gov as number NCT01313676.",2020,"Combined in the Summit Score (derivation: c=0.668), quartile 4 vs 1 had HR=4.43 in SUMMIT validation (p<0.001, 95% CI=3.27, 6.01, c=0.662) and HR=8.15 in Intermountain cardiovascular risk COPD outpatients (p<0.001, 95% CI=5.86, 11.34, c=0.736), and strongly predicted mortality in the other Intermountain COPD populations.","['people with COPD and cardiovascular risks', 'outpatients with cardiovascular risks (N=9251), outpatients without cardiovascular risks (N=8551), and inpatients (N=26,170', 'accompany chronic obstructive pulmonary disease (COPD', 'Chronic Obstructive Pulmonary Disease', 'Methods\n\n\nSUMMIT trial subjects (N=16,485) ages 40-80 years with COPD']","['fluticasone furoate', 'placebo']","['Summit Score Stratifies Mortality and Morbidity', 'mortality risk', 'FEV 1 , heart rate, systolic blood pressure, body mass index, age, smoking pack-years, prior COPD hospitalizations, myocardial infarction, heart failure, diabetes, anti-thrombotics, anti-arrhythmics, and xanthines']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1948374', 'cui_str': 'fluticasone furoate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C1277691', 'cui_str': 'Pack years'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0003195', 'cui_str': 'Antiarrhythmic agent'}, {'cui': 'C0043314', 'cui_str': 'xanthine'}]",3.0,0.500894,"Combined in the Summit Score (derivation: c=0.668), quartile 4 vs 1 had HR=4.43 in SUMMIT validation (p<0.001, 95% CI=3.27, 6.01, c=0.662) and HR=8.15 in Intermountain cardiovascular risk COPD outpatients (p<0.001, 95% CI=5.86, 11.34, c=0.736), and strongly predicted mortality in the other Intermountain COPD populations.","[{'ForeName': 'Benjamin D', 'Initials': 'BD', 'LastName': 'Horne', 'Affiliation': 'Intermountain Medical Center Heart Institute, Salt Lake City, UT, USA.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Hegewald', 'Affiliation': 'Division of Pulmonary Medicine, Department of Internal Medicine, Intermountain Medical Center, Salt Lake City, UT, USA.'}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Crim', 'Affiliation': 'Research and Development, GlaxoSmithKline, Research Triangle Park, NC, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Rea', 'Affiliation': 'Care Transformation, Intermountain Healthcare, Salt Lake City, UT, USA.'}, {'ForeName': 'Tami L', 'Initials': 'TL', 'LastName': 'Bair', 'Affiliation': 'Intermountain Medical Center Heart Institute, Salt Lake City, UT, USA.'}, {'ForeName': 'Denitza P', 'Initials': 'DP', 'LastName': 'Blagev', 'Affiliation': 'Division of Pulmonary Medicine, Department of Internal Medicine, Intermountain Medical Center, Salt Lake City, UT, USA.'}]",International journal of chronic obstructive pulmonary disease,['10.2147/COPD.S254437'] 2756,32765023,Effect of Different Volumes of Interval Training and Continuous Exercise on Interleukin-22 in Adults with Metabolic Syndrome: A Randomized Trial.,"Introduction IL-22 may have a role in the alleviation of the metabolic syndrome (MetS) via protection of pancreatic beta and endothelial cells from oxidative and lipid-induced damage. We aimed to investigate the effects of moderate-intensity continuous training (MICT) and different volumes of high-intensity interval training (HIIT) on changes in circulating IL-22. Methods This was a sub-study of the ""Exercise in the prevention of Metabolic Syndrome"" (EX-MET) a multi-center, randomized trial. This study used data collected at the Brisbane site. Thirty-nine individuals with MetS were randomized to one of three 16-wk interventions: 1) MICT (n=10, 30min at 60-70% HR peak, 5x/wk); 2) 4HIIT (n=13, 4x4min at 85-95% HR peak, interspersed with 3min of active recovery at 50-70% HR peak, 3x/wk); or 3) 1HIIT (n=16, 1x4min at 85-95% HR peak, 3x/wk). Serum IL-22 concentration was measured following a 12-hr fast via an enzyme linked immunosorbent assay, before and after the intervention. MetS severity, insulin resistance (IR), visceral adipose tissue (VAT), and cardiorespiratory fitness (CRF) were also measured via MetS z-score, HOMA-IR, dual-energy X-ray absorptiometry, and indirect calorimetry (maximal exercise test), respectively. Results The median (IQR) IL-22% changes from pre- to post-intervention in the MICT, 4HIIT, and 1HIIT groups were -17% (-43.0% to 31.3%), +16.5% (-18.9% to 154.9%), and +15.9% (-28.7% to 46.1%), respectively. Although there were no significant between-group differences in IL-22 concentration change, there was a medium-to-large group × time interaction effect [F(2,35)=2.08, p=0.14, η 2 =0.14]. Conclusion Although there was no statistically significant between-group difference in IL-22 change, the study suggests that different exercise intensities may have opposing effects on IL-22 concentration in individuals with MetS.",2020,"Although there was no statistically significant between-group difference in IL-22 change, the study suggests that different exercise intensities may have opposing effects on IL-22 concentration in individuals with MetS.","['Adults with Metabolic Syndrome', 'individuals with MetS', 'Thirty-nine individuals with MetS']","['Interval Training and Continuous Exercise', 'Exercise', 'MICT', '4HIIT', 'moderate-intensity continuous training (MICT) and different volumes of high-intensity interval training (HIIT']","['median (IQR) IL-22', 'IL-22 concentration change', 'MetS severity, insulin resistance (IR), visceral adipose tissue (VAT), and cardiorespiratory fitness (CRF', 'IL-22 concentration', 'MetS z-score, HOMA-IR, dual-energy X-ray absorptiometry, and indirect calorimetry (maximal exercise test', 'Serum IL-22 concentration', 'IL-22 change']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3816447', 'cui_str': '39'}]","[{'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0961814', 'cui_str': 'interleukin-22'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C1563740', 'cui_str': 'Abdominal Visceral Fat'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0010132', 'cui_str': 'Corticotropin-Releasing Hormone'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}, {'cui': 'C0006781', 'cui_str': 'Indirect calorimetry'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",,0.0962552,"Although there was no statistically significant between-group difference in IL-22 change, the study suggests that different exercise intensities may have opposing effects on IL-22 concentration in individuals with MetS.","[{'ForeName': 'Joyce S', 'Initials': 'JS', 'LastName': 'Ramos', 'Affiliation': 'Centre for Research on Exercise, Physical Activity and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Lance C', 'Initials': 'LC', 'LastName': 'Dalleck', 'Affiliation': 'Caring Futures Institute and SHAPE Research Centre, Exercise Science and Clinical Exercise Physiology, College of Nursing and Health Sciences, Flinders University, Adelaide, South Australia, Australia.'}, {'ForeName': 'Rebecca C', 'Initials': 'RC', 'LastName': 'Stennett', 'Affiliation': 'Centre for Research on Exercise, Physical Activity and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Gregore I', 'Initials': 'GI', 'LastName': 'Mielke', 'Affiliation': 'Centre for Research on Exercise, Physical Activity and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Shelley E', 'Initials': 'SE', 'LastName': 'Keating', 'Affiliation': 'Centre for Research on Exercise, Physical Activity and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Lydia', 'Initials': 'L', 'LastName': 'Murray', 'Affiliation': 'Immunopathology Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Brisbane, Queensland, Australia.'}, {'ForeName': 'Sumaira Z', 'Initials': 'SZ', 'LastName': 'Hasnain', 'Affiliation': 'Immunopathology Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Brisbane, Queensland, Australia.'}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Fassett', 'Affiliation': 'Centre for Research on Exercise, Physical Activity and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'McGuckin', 'Affiliation': 'Immunopathology Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Brisbane, Queensland, Australia.'}, {'ForeName': 'Ilaria', 'Initials': 'I', 'LastName': 'Croci', 'Affiliation': 'Centre for Research on Exercise, Physical Activity and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Jeff S', 'Initials': 'JS', 'LastName': 'Coombes', 'Affiliation': 'Centre for Research on Exercise, Physical Activity and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}]","Diabetes, metabolic syndrome and obesity : targets and therapy",['10.2147/DMSO.S251567'] 2757,32767208,Long-lasting connectivity changes induced by intensive first-person shooter gaming.,"Action videogames have been shown to induce modifications in perceptual and cognitive systems, as well as in brain structure and function. Nevertheless, whether such changes are correlated with brain functional connectivity modifications outlasting the training period is not known. Functional magnetic resonance imaging (fMRI) was used in order to quantify acute and long-lasting connectivity changes following a sustained gaming experience on a first-person shooter (FPS) game. Thirty-five healthy participants were assigned to either a gaming or a control group prior to the acquisition of resting state fMRI data and a comprehensive cognitive assessment at baseline (T0), post-gaming (T1) and at a 3 months' follow-up (T2). Seed-based resting-state functional connectivity (rs-FC) analysis revealed a significant greater connectivity between left thalamus and left parahippocampal gyrus in the gamer group, both at T1 and at T2. Furthermore, a positive increase in the rs-FC between the cerebellum, Heschl's gyrus and the middle frontal gyrus paralleled improvements of in-gaming performance. In addition, baseline rs-FC of left supramarginal gyrus, left middle frontal gyrus and right cerebellum were associated with individual changes in videogame performance. Finally, enhancement of perceptual and attentional measures was observed at both T1 and T2, which correlated with a pattern of rs-FC changes in bilateral occipito-temporal regions belonging to the visual and attention fMRI networks. The present findings increase knowledge on functional connectivity changes induced by action videogames, pointing to a greater and long-lasting synchronization between brain regions associated with spatial orientation, visual discrimination and motor learning even after a relatively short multi-day gaming exposure.",2020,"Furthermore, a positive increase in the rs-FC between the cerebellum, Heschl's gyrus and the middle frontal gyrus paralleled improvements of in-gaming performance.",['Thirty-five healthy participants'],"['gaming or a control group prior to the acquisition of resting state fMRI data and a comprehensive cognitive assessment at baseline (T0), post-gaming (T1', 'Functional magnetic resonance imaging (fMRI']","['spatial orientation, visual discrimination and motor learning', 'gaming performance', 'enhancement of perceptual and attentional measures']","[{'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0687676', 'cui_str': 'After values'}]","[{'cui': 'C0037744', 'cui_str': 'Space Perception'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0012632', 'cui_str': 'Cognitive discrimination'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",35.0,0.0236318,"Furthermore, a positive increase in the rs-FC between the cerebellum, Heschl's gyrus and the middle frontal gyrus paralleled improvements of in-gaming performance.","[{'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Momi', 'Affiliation': 'Siena Brain Investigation & Neuromodulation Lab (Si-BIN Lab), Department of Medicine, Surgery and Neuroscience, Neurology and Clinical Neurophysiology Section, University of Siena, Siena, Italy.'}, {'ForeName': 'Carmelo L', 'Initials': 'CL', 'LastName': 'Smeralda', 'Affiliation': 'Siena Brain Investigation & Neuromodulation Lab (Si-BIN Lab), Department of Medicine, Surgery and Neuroscience, Neurology and Clinical Neurophysiology Section, University of Siena, Siena, Italy.'}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'Di Lorenzo', 'Affiliation': 'Laboratory of Psychophysiology and Cognitive Neuroscience, Chair of Psychiatry, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Neri', 'Affiliation': 'Siena Brain Investigation & Neuromodulation Lab (Si-BIN Lab), Department of Medicine, Surgery and Neuroscience, Neurology and Clinical Neurophysiology Section, University of Siena, Siena, Italy.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Rossi', 'Affiliation': 'Siena Brain Investigation & Neuromodulation Lab (Si-BIN Lab), Department of Medicine, Surgery and Neuroscience, Neurology and Clinical Neurophysiology Section, University of Siena, Siena, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Rossi', 'Affiliation': 'Siena Brain Investigation & Neuromodulation Lab (Si-BIN Lab), Department of Medicine, Surgery and Neuroscience, Neurology and Clinical Neurophysiology Section, University of Siena, Siena, Italy.'}, {'ForeName': 'Emiliano', 'Initials': 'E', 'LastName': 'Santarnecchi', 'Affiliation': 'Siena Brain Investigation & Neuromodulation Lab (Si-BIN Lab), Department of Medicine, Surgery and Neuroscience, Neurology and Clinical Neurophysiology Section, University of Siena, Siena, Italy. esantarn@bidmc.harvard.edu.'}]",Brain imaging and behavior,['10.1007/s11682-020-00350-2'] 2758,32767288,Comparison of endoscopic ultrasound-guided fine-needle biopsy versus fine-needle aspiration for genomic profiling and DNA yield in pancreatic cancer: a randomized crossover trial.,"BACKGROUND National guidelines recommend genomic profiling of tumor tissue to guide precision therapy. We compared the specimen adequacy for genomic profiling and yield of DNA between endoscopic ultrasound (EUS)-guided fine-needle biopsy (FNB) and EUS-guided fine-needle aspiration (FNA). METHODS In our tandem, randomized controlled trial, consecutive patients undergoing EUS for evaluation of pancreatic masses underwent both conventional EUS-FNA with a 25-gauge needle and paired EUS-FNB (19 or 22-gauge needle), with the order randomized (EUS-FNA first followed by EUS-FNB, or vice versa). A minimum of one pass with each needle was obtained for histology. Second and third passes were performed to collect DNA. Specimens were evaluated by a cytopathologist blinded to the needle type. Specimen adequacy for genomic profiling was calculated based on FoundationOne clinical diagnostic (CDx) adequacy requirements. We compared the adequacy for genomic profiling DNA (quantity) and histology yields with both needles. RESULTS Analysis included 50 patients (25 men; mean age 68 [standard deviation (SD) 13] years), with a mean lesion size of 38 (SD 17) mm; 37 lesions (74 %) were pancreatic ductal adenocarcinoma (PDAC). The mean DNA concentrations in PDAC by FNB and FNA needles were 5.930 (SD 0.881) µg/mL vs. 3.365 (SD 0.788) µg/mL, respectively ( P  = 0.01). The median standardized histology score per pass with EUS-FNB was 5 (sufficient for histology) and for EUS-FNA was 2 (enough for cytology). Specimen adequacy for genomic profiling and yield of DNA was significantly higher with FNB than with FNA needles. CONCLUSIONS In this study, adequacy for genomic profiling, DNA, and histology yield were considerably superior using an EUS-FNB needle compared with an EUS-FNA needle.",2020,"In this study, adequacy for genomic profiling, DNA, and histology yield were considerably superior using an EUS-FNB needle compared with an EUS-FNA needle.","['50 patients (25 men; mean age 68 [standard deviation (SD) 13] years), with a mean lesion size of 38 (SD 17) mm; 37 lesions (74\u200a%) were pancreatic ductal adenocarcinoma (PDAC', 'consecutive patients undergoing EUS for evaluation of pancreatic masses underwent both', 'pancreatic cancer']","['conventional EUS-FNA with a 25-gauge needle and paired EUS-FNB (19 or 22-gauge needle', 'endoscopic ultrasound-guided fine-needle biopsy versus fine-needle aspiration', 'endoscopic ultrasound (EUS)-guided fine-needle biopsy (FNB) and EUS-guided fine-needle aspiration (FNA']","['mean DNA concentrations', 'Specimen adequacy for genomic profiling and yield of DNA', 'median standardized histology score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0449453', 'cui_str': 'Lesion size'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C1335302', 'cui_str': 'Ductal adenocarcinoma of pancreas'}, {'cui': 'C0376443', 'cui_str': 'Endoscopic ultrasonography'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0877425', 'cui_str': 'Mass of pancreas'}, {'cui': 'C0235974', 'cui_str': 'Carcinoma of pancreas'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0376443', 'cui_str': 'Endoscopic ultrasonography'}, {'cui': 'C1510483', 'cui_str': 'Fine needle aspiration biopsy - action'}, {'cui': 'C0456638', 'cui_str': '25G'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0085846', 'cui_str': 'Fine needle biopsy'}, {'cui': 'C0450404', 'cui_str': '22G'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C1880510', 'cui_str': 'EUS-FNA'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0019638', 'cui_str': 'Histology'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0365319,"In this study, adequacy for genomic profiling, DNA, and histology yield were considerably superior using an EUS-FNB needle compared with an EUS-FNA needle.","[{'ForeName': 'Pujan', 'Initials': 'P', 'LastName': 'Kandel', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.'}, {'ForeName': 'Aziza', 'Initials': 'A', 'LastName': 'Nassar', 'Affiliation': 'Department of Laboratory Medicine & Pathology, Mayo Clinic, Jacksonville, Florida, USA.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Gomez', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Raimondo', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.'}, {'ForeName': 'Timothy A', 'Initials': 'TA', 'LastName': 'Woodward', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.'}, {'ForeName': 'Julia E', 'Initials': 'JE', 'LastName': 'Crook', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida, USA.'}, {'ForeName': 'Natalie S', 'Initials': 'NS', 'LastName': 'Fares', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.'}, {'ForeName': 'Michael B', 'Initials': 'MB', 'LastName': 'Wallace', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.'}]",Endoscopy,['10.1055/a-1223-2171'] 2759,32767636,A Randomised Controlled Trial Study of the Effects of a Digital Divorce Platform on Mental and Physical Health.,"BACKGROUND Two decades of divorce research has consistently documented adverse mental and physical health effects of divorce. Responding to calls for evidence-based online divorce interventions, this study tests effects of the ""Cooperation after Divorce"" (CAD) digital intervention platform on divorcees' mental and physical health. METHODS Randomised control trial 12-month longitudinal study using a sample of 1,856 newly divorced Danes. Mental and physical health were measured using the SF-36 at baseline and 3, 6, and 12 months from baseline. Intervention effects were investigated using linear mixed effect models and Cohen's (d) for effect sizes. RESULTS The study found significant treatment effects of the CAD intervention on mental and physical health. These effects were evident across all eight health domains constituting the mental and physical health components. The study also found that the intervention group had significantly better mental health than the control group at subsequent 6- and 12-month assessments from baseline while for physical health, the intervention group had significantly better physical health at the 6-month assessment from baseline only. CONCLUSION The results indicate that digital solutions allowing for individually tailored user experiences may hold great potential in reducing well-known adverse health effects of divorce. PRACTITIONER'S POINTS The study finds highly significant treatment effects of the ""CAD"" digital divorce intervention on mental and physical health indicating that online interventions may be successfully integrated into help offered to divorcees post-divorce.",2020,"The results indicate that digital solutions allowing for individually tailored user experiences may hold great potential in reducing well-known adverse health effects of divorce. ","['1,856 newly divorced Danes']","['CAD intervention', 'Cooperation after Divorce"" (CAD) digital intervention platform', 'CAD"" digital divorce intervention', 'Digital Divorce Platform']","['mental and physical health', 'Mental and Physical Health', 'mental health', 'physical health', 'Mental and physical health']","[{'cui': 'C0012828', 'cui_str': 'Divorce'}, {'cui': 'C0337800', 'cui_str': 'Danes'}]","[{'cui': 'C0012828', 'cui_str': 'Divorce'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]",1856.0,0.0429243,"The results indicate that digital solutions allowing for individually tailored user experiences may hold great potential in reducing well-known adverse health effects of divorce. ","[{'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Sander', 'Affiliation': 'University of Copenhagen, Denmark.'}, {'ForeName': 'Gert Martin', 'Initials': 'GM', 'LastName': 'Hald', 'Affiliation': 'University of Copenhagen, Denmark.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Cipric', 'Affiliation': 'University of Copenhagen, Denmark.'}, {'ForeName': 'Camilla S', 'Initials': 'CS', 'LastName': 'Øverup', 'Affiliation': 'University of Copenhagen, Denmark.'}, {'ForeName': 'Jenna Marie', 'Initials': 'JM', 'LastName': 'Strizzi', 'Affiliation': 'University of Copenhagen, Denmark.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Gad Kjeld', 'Affiliation': 'University of Copenhagen, Denmark.'}, {'ForeName': 'Theis', 'Initials': 'T', 'LastName': 'Lange', 'Affiliation': 'University of Copenhagen, Denmark.'}]",Applied psychology. Health and well-being,['10.1111/aphw.12213'] 2760,32767674,Questioning a randomized trial of a hospice video educational tool for patients with advanced cancer and their caregivers.,,2020,,['patients with advanced cancer and their caregivers'],['hospice video educational tool'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}]","[{'cui': 'C0019947', 'cui_str': 'Hospice'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0336791', 'cui_str': 'Tool'}]",[],,0.0464944,,"[{'ForeName': 'Kohei', 'Initials': 'K', 'LastName': 'Kajiwara', 'Affiliation': 'Japanese Red Cross Kyushu International College of Nursing, Munakata, Japan.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Kako', 'Affiliation': 'Division of Nursing Science, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'Masamitsu', 'Initials': 'M', 'LastName': 'Kobayashi', 'Affiliation': 'Faculty of Nursing, National Defense Medical College, Tokorozawa, Japan.'}, {'ForeName': 'Ayako', 'Initials': 'A', 'LastName': 'Ogata', 'Affiliation': 'Japanese Red Cross Kyushu International College of Nursing, Munakata, Japan.'}]",Cancer,['10.1002/cncr.33132'] 2761,32767679,"A phase I, randomized, double-blind study to assess the safety, tolerability, and efficacy of the topical RORC2 inverse agonist PF-06763809 in participants with mild-to-moderate plaque psoriasis.","BACKGROUND The transcription factor retinoic acid-related orphan receptor 2 (RORC2/RORγT) mediates interleukin (IL)-17A and IL-17F expression. IL-17A plays a central role in the pathogenesis of several inflammatory disorders, including psoriasis. The RORC2 inhibitor PF-06763809 has been hypothesized to inhibit IL-17A production in T-helper 17 (Th17) cells, thereby reducing psoriasis symptoms. AIM To assess the safety, tolerability, and effect on skin infiltrate thickness of PF-06763809 in participants with mild/moderate chronic plaque psoriasis. METHODS Randomized, double-blind, first-in-human study (NCT03469336). Participants received each of the following treatments once daily for 18 days: three topical doses (2.3%, 0.8%, 0.23%) of PF-06763809, vehicle, and two active comparators (betamethasone and calcipotriol). Primary endpoints included change from baseline in psoriatic skin infiltrate thickness (echo-poor band [EPB] by ultrasound) at Day 19 and safety. Change in psoriasis-associated gene expression (Day 19), evaluated by RT-PCR of skin biopsies, was an exploratory endpoint. RESULTS Seventeen participants completed the study. The change from baseline in the EPB on Day 19 for all three doses of PF-06763809 was not significantly different from that of vehicle (P > 0.05). A significant reduction in EPB from baseline was observed with betamethasone on Day 19 relative to all other treatments (P < 0.0001). Treatment-related adverse events were mild/moderate. There were no significant differences in gene expression on Day 19 between vehicle and PF-06763809-treated skin lesions. CONCLUSION Using a psoriasis plaque test design, PF-06763809 was well tolerated with an acceptable safety profile in participants with psoriasis, but without reduction in skin infiltrate thickness or disease biomarkers.",2020,"There were no significant differences in gene expression on Day 19 between vehicle and PF-06763809-treated skin lesions. ","['participants with mild-to-moderate plaque psoriasis', 'participants with mild/moderate chronic plaque psoriasis', 'participants with psoriasis', 'Seventeen participants completed the study']","['betamethasone', 'IL-17A', 'topical RORC2 inverse agonist PF-06763809', 'RORC2 inhibitor', 'PF-06763809, vehicle, and two active comparators (betamethasone and calcipotriol']","['psoriatic skin infiltrate thickness (echo-poor band [EPB] by ultrasound) at Day 19 and safety', 'skin infiltrate thickness or disease biomarkers', 'gene expression', 'EPB', 'safety, tolerability', 'safety, tolerability, and efficacy']","[{'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0406317', 'cui_str': 'Chronic small plaque psoriasis'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0005308', 'cui_str': 'Betamethasone'}, {'cui': 'C1701790', 'cui_str': 'IL17A protein, human'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0439850', 'cui_str': 'Inverse'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0065767', 'cui_str': 'calcipotriene'}]","[{'cui': 'C0241076', 'cui_str': 'Skin infiltration'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0013520', 'cui_str': 'Doppler Echocardiography'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",17.0,0.371838,"There were no significant differences in gene expression on Day 19 between vehicle and PF-06763809-treated skin lesions. ","[{'ForeName': 'G', 'Initials': 'G', 'LastName': 'Berstein', 'Affiliation': 'Inflammation and Immunology Research Unit, Pfizer Inc, Cambridge, MA, USA.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Inflammation and Immunology Research Unit, Pfizer Inc, Cambridge, MA, USA.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Berger', 'Affiliation': 'Inflammation and Immunology Research Unit, Pfizer Inc, Cambridge, MA, USA.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Kieras', 'Affiliation': 'Inflammation and Immunology Research Unit, Pfizer Inc, Cambridge, MA, USA.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'Early Clinical Development, Pfizer Inc, Collegeville, PA, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Samuel', 'Affiliation': 'Formulation and Process Design, Pfizer Inc, Groton, CT, USA.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Yeoh', 'Affiliation': 'Formulation and Process Design, Pfizer Inc, Groton, CT, USA.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Dowty', 'Affiliation': 'Inflammation and Immunology Research Unit, Pfizer Inc, Cambridge, MA, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Beaumont', 'Affiliation': 'Inflammation and Immunology Research Unit, Pfizer Inc, Cambridge, MA, USA.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Wigger-Alberti', 'Affiliation': 'Bioskin GmbH, Hamburg, Germany.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'von Mackensen', 'Affiliation': 'Bioskin GmbH, Hamburg, Germany.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Kroencke', 'Affiliation': 'Bioskin GmbH, Hamburg, Germany.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Hamscho', 'Affiliation': 'Rothhaar Studien GmbH, Berlin, Germany.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Garcet', 'Affiliation': 'Rockefeller University, New York, NY, USA.'}, {'ForeName': 'J G', 'Initials': 'JG', 'LastName': 'Krueger', 'Affiliation': 'Rockefeller University, New York, NY, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Banfield', 'Affiliation': 'Inflammation and Immunology Research Unit, Pfizer Inc, Cambridge, MA, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Oemar', 'Affiliation': 'Inflammation and Immunology Research Unit, Pfizer Inc, Cambridge, MA, USA.'}]",Clinical and experimental dermatology,['10.1111/ced.14412'] 2762,32767691,Reply to Questioning a randomized trial of a hospice video educational tool for patients with advanced cancer and their caregivers.,,2020,,['patients with advanced cancer and their caregivers'],['hospice video educational tool'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}]","[{'cui': 'C0019947', 'cui_str': 'Hospice'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0336791', 'cui_str': 'Tool'}]",[],,0.0374023,,"[{'ForeName': 'Areej', 'Initials': 'A', 'LastName': 'El-Jawahri', 'Affiliation': 'Department of Hematology Oncology, Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Temel', 'Affiliation': 'Department of Hematology Oncology, Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.'}]",Cancer,['10.1002/cncr.33131'] 2763,32767696,Predictors of Older Adult Adherence with Emergency Department Discharge Instructions.,"OBJECTIVE Older adults discharged from the emergency department (ED) are at high risk for adverse outcomes. Adherence to ED discharge instructions is necessary to reduce those risks. The objective of this study is to determine the individual-level factors associated with adherence with ED discharge instructions among older adult ED outpatients. METHODS We performed a secondary analysis of data from the control group of a randomized controlled trial testing a care transitions intervention among older adults (age≥60) discharged home from the ED in two states. Taking data from patient surveys and chart reviews, we used multivariable logistic regression to identify patient characteristics associated with adherence to printed discharge instructions. Outcomes were patient-reported medication adherence, provider follow-up visit adherence, and knowledge of ""red flags"" (signs of worsening health requiring further medical attention). RESULTS 824 patients were potentially eligible, and 699 had data in at least one pillar. 35% adhered to medication instructions and 76% adhered to follow-up instructions, 35% recalled at least one red flag. In the multivariate analysis, no factors were significantly associated with failure to adhere to medications. Participants with poor health status (adjusted odds ratio (AOR): 0.55, 95% CI=0.31-0.98) were less likely to adhere to follow-up instructions. Participants who were older (AORs trended downward as age category increased), depressed (AOR=0.39, 95% CI=0.17-0.85), or had one or more functional limitations (AOR=0.62, 95% CI=0.41-0.94) were less likely to recall red flags. CONCLUSION Older adults discharged home from the ED have mixed rates of adherence to discharge instructions. Although it is thought that some subgroups may be higher risk than others, given the opportunity to improve ED-to-home transitions, EDs and health systems should consider providing additional care transition supports to all older adults discharged home from the ED.",2020,"Outcomes were patient-reported medication adherence, provider follow-up visit adherence, and knowledge of ""red flags"" (signs of worsening health requiring further medical attention). ","['Older adults discharged from the emergency department (ED', '824 patients were potentially eligible, and 699 had data in at least one pillar', 'older adult ED outpatients', 'older adults (age≥60) discharged home from the ED in two states', 'Older Adult Adherence with Emergency Department Discharge Instructions']",['care transitions intervention'],"['medication adherence, provider follow-up visit adherence, and knowledge of ""red flags"" (signs of worsening health requiring further medical attention']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}]","[{'cui': 'C4019079', 'cui_str': 'Care Transition'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0589121', 'cui_str': 'Follow-up visit'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0332575', 'cui_str': 'Red color'}, {'cui': 'C5200790', 'cui_str': 'Flags'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",824.0,0.136991,"Outcomes were patient-reported medication adherence, provider follow-up visit adherence, and knowledge of ""red flags"" (signs of worsening health requiring further medical attention). ","[{'ForeName': 'Ivy', 'Initials': 'I', 'LastName': 'Benjenk', 'Affiliation': 'Department of Health Policy and Management, School of Public Health, University of Maryland, College Park, Maryland, USA.'}, {'ForeName': 'Eva H', 'Initials': 'EH', 'LastName': 'DuGoff', 'Affiliation': 'Department of Health Policy and Management, School of Public Health, University of Maryland, College Park, Maryland, USA.'}, {'ForeName': 'Gwen C', 'Initials': 'GC', 'LastName': 'Jacobsohn', 'Affiliation': 'Department of Emergency Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.'}, {'ForeName': 'Nia', 'Initials': 'N', 'LastName': 'Cayenne', 'Affiliation': 'Department of Emergency Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.'}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Mc Jones', 'Affiliation': 'Department of Public Health Sciences, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Thomas V', 'Initials': 'TV', 'LastName': 'Caprio', 'Affiliation': 'Division of Geriatrics, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Jeremy T', 'Initials': 'JT', 'LastName': 'Cushman', 'Affiliation': 'Department of Emergency Medicine, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Rebecca K', 'Initials': 'RK', 'LastName': 'Green', 'Affiliation': 'Department of Emergency Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Jh Kind', 'Affiliation': 'Division of Geriatrics and Gerontology, Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lohmeier', 'Affiliation': 'Department of Emergency Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.'}, {'ForeName': 'Ranran', 'Initials': 'R', 'LastName': 'Mi', 'Affiliation': 'Department of Emergency Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.'}, {'ForeName': 'Manish N', 'Initials': 'MN', 'LastName': 'Shah', 'Affiliation': 'Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.'}]",Academic emergency medicine : official journal of the Society for Academic Emergency Medicine,['10.1111/acem.14105'] 2764,32767710,The effect of concentrated pomegranate juice consumption on risk factors of cardiovascular diseases in women with polycystic ovary syndrome: A randomized controlled trial.,"Polycystic ovary syndrome (PCOS) is associated with insulin resistance and dyslipidemia. Pomegranate juice is a rich source of polyphenols that may improve blood pressure, lipid profile, and other risk factors of cardiovascular diseases (CVDs). No study has examined the effects of pomegranate juice consumption on the clinical outcomes of PCOS. This study aimed to examine the effects of concentrated pomegranate juice (CPJ) consumption on risk factors of CVDs in women with PCOS. In this randomized clinical trial, 44 PCOS women with an age range of 18-40 years and body mass index (BMI) of ≥25 kg/m 2 were recruited. They were randomly allocated to the CPJ (n = 22) and control (n = 22) groups, and followed for 8 weeks. Anthropometric measures, blood pressure, and biochemical parameters were measured at baseline and at the end of the trial. Compared with the control group, CPJ consumption significantly reduced systolic (-9.77 ± 1.46 vs. -1.18 ± 1.46 mmHg, p < .001) and diastolic (-3.87 ± 1.36 vs. 0.30 ± 1.36 mmHg, p = .05) blood pressure, serum triglyceride (TG) levels (-7.82 ± 6.32 vs. 16.63 ± 6.32 mg/dl, p = .01), TG/high-density lipoprotein-cholesterol (HDL-C) ratio (-0.39 ± 0.24 vs. 0.66 ± 0.24, p = .007), and increased serum concentrations of low-density lipoprotein-cholesterol (LDL-C) (6.03 ± 2.47 vs. -1.98 ± 2.47 mg/dl, p = .04) and HDL-C (1.93 ± 1.10 vs. -1.78 ± 1.10 mg/dl, p = .03). These findings were obtained after taking baseline measurements and potential confounders into account. No adverse event or complication was reported due to CPJ consumption throughout the study. We found that CPJ consumption has a beneficial effect on blood pressure, serum concentrations of TG and HDL-C, and TG/HDL-C ratio in women with PCOS. However, this juice could increase serum LDL-C levels in these patients. This trial was registered at www.irct.ir as IRCT20191109045383N1.",2020,"Compared with the control group, CPJ consumption significantly reduced systolic (-9.77 ± 1.46 vs. -1.18 ± 1.46 mmHg, p < .001) and diastolic (-3.87 ± 1.36 vs. 0.30 ± 1.36 mmHg, p = .05) blood pressure, serum triglyceride (TG) levels (-7.82 ± 6.32 vs. 16.63 ± 6.32 mg/dl, p = .01), TG/high-density lipoprotein-cholesterol (HDL-C) ratio (-0.39 ± 0.24 vs. 0.66 ± 0.24, p = .007), and increased serum concentrations of low-density lipoprotein-cholesterol (LDL-C) (6.03 ± 2.47 vs. -1.98 ± 2.47 mg/dl, p = .04) and HDL-C (1.93 ± 1.10 vs. -1.78 ± 1.10 mg/dl, p = .03).","['Polycystic ovary syndrome (PCOS', 'women with PCOS', '44 PCOS women with an age range of 18-40\u2009years and body mass index (BMI) of ≥25\u2009kg/m 2 were recruited', 'women with polycystic ovary syndrome']","['concentrated pomegranate juice (CPJ) consumption', 'concentrated pomegranate juice consumption', 'CPJ']","['Anthropometric measures, blood pressure, and biochemical parameters', 'TG/high-density lipoprotein-cholesterol (HDL-C) ratio', 'systolic', 'blood pressure, serum triglyceride (TG) levels', 'serum LDL-C levels', 'diastolic', 'blood pressure, serum concentrations of TG and HDL-C, and TG/HDL-C ratio', 'serum concentrations of low-density lipoprotein-cholesterol (LDL-C', 'risk factors of cardiovascular diseases', 'blood pressure, lipid profile', 'adverse event or complication']","[{'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C1327962', 'cui_str': 'POMEGRANATE JUICE'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0542495', 'cui_str': 'Measurement of serum triglyceride level'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",44.0,0.294645,"Compared with the control group, CPJ consumption significantly reduced systolic (-9.77 ± 1.46 vs. -1.18 ± 1.46 mmHg, p < .001) and diastolic (-3.87 ± 1.36 vs. 0.30 ± 1.36 mmHg, p = .05) blood pressure, serum triglyceride (TG) levels (-7.82 ± 6.32 vs. 16.63 ± 6.32 mg/dl, p = .01), TG/high-density lipoprotein-cholesterol (HDL-C) ratio (-0.39 ± 0.24 vs. 0.66 ± 0.24, p = .007), and increased serum concentrations of low-density lipoprotein-cholesterol (LDL-C) (6.03 ± 2.47 vs. -1.98 ± 2.47 mg/dl, p = .04) and HDL-C (1.93 ± 1.10 vs. -1.78 ± 1.10 mg/dl, p = .03).","[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Abedini', 'Affiliation': 'Department of Clinical Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Hatav', 'Initials': 'H', 'LastName': 'Ghasemi-Tehrani', 'Affiliation': 'Department of Reproductive, Shahid Beheshti Fertility and Infertility Clinic, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Mohammad J', 'Initials': 'MJ', 'LastName': 'Tarrahi', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Amani', 'Affiliation': 'Department of Clinical Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.6820'] 2765,32762289,Synchrony in Old Age: Playing the Mirror Game Improves Cognitive Performance.,"OBJECTIVE Studies have shown that synchronized motion between people positively affects a range of emotional and social functions. The mirror-game is a synchrony-based paradigm, common to theater, performance arts, and therapy, which includes dyadic synchronized motion, playfulness, and spontaneity. The goal of the current study is to examine the effects of the mirror-game on subjective and cognitive indices in late life. METHOD Thirty-four older adults (aged 71-98) participated in a within-group study design. Participants conducted two sessions of 9-minute movement activities: the mirror-game and the control condition - a physical exercise class. Several measures were taken before and after experimental sessions to assess socio-emotional and attentional functions. RESULTS The mirror-game enhanced performance on the attention sub-scale and led to faster detections of spoken words in noise. Further, it enhanced perceived partner responsiveness and led to an increase in positive reported experience. CONCLUSIONS Our preliminary findings suggest that the mirror-game, rather than the exercise class, may have an immediate impact on mood and some attentional functions. CLINICAL IMPLICATIONS The mirror-game is a novel intervention, with potential benefits of social-emotional and cognitive functioning, which can be easily implemented into the daily routine care of older adults. Future studies should explore the effect of the mirror-game on additional cognitive and socio-emotional aspects.",2020,Participants conducted two sessions of 9-minute movement activities: the mirror-game and the control condition - a physical exercise class.,"['Old Age', 'Thirty-four older adults (aged 71-98) participated in a within-group study design', 'older adults']",['9-minute movement activities: the mirror-game and the control condition - a physical exercise class'],"['socio-emotional and attentional functions', 'Cognitive Performance']","[{'cui': 'C0231337', 'cui_str': 'Senility'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0035171', 'cui_str': 'Research Design'}]","[{'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C2004436', 'cui_str': 'Activity therapy'}, {'cui': 'C0181868', 'cui_str': 'Mirror'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0456387', 'cui_str': 'Class'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",34.0,0.0252285,Participants conducted two sessions of 9-minute movement activities: the mirror-game and the control condition - a physical exercise class.,"[{'ForeName': 'Shoshi', 'Initials': 'S', 'LastName': 'Keisari', 'Affiliation': 'Department of Gerontology, University of Haifa , Haifa, Israel.'}, {'ForeName': 'Rinat', 'Initials': 'R', 'LastName': 'Feniger-Schaal', 'Affiliation': 'School of Creative Arts Therapies, The Center for the Study of Child Development, University of Haifa , Haifa, Israel.'}, {'ForeName': 'Yuval', 'Initials': 'Y', 'LastName': 'Palgi', 'Affiliation': 'Department of Gerontology, University of Haifa , Haifa, Israel.'}, {'ForeName': 'Yulia', 'Initials': 'Y', 'LastName': 'Golland', 'Affiliation': 'Sagol Center for Brain and Mind, Baruch Ivcher School of Psychology, Interdisciplinary Center (IDC) Herzliya , Herzliya, Israel.'}, {'ForeName': 'Anat', 'Initials': 'A', 'LastName': 'Gesser-Edelsburg', 'Affiliation': 'School of Public Health and the Health and Risk Communication Research Center, University of Haifa , Haifa, Israel.'}, {'ForeName': 'Boaz', 'Initials': 'B', 'LastName': 'Ben-David', 'Affiliation': 'Baruch Ivcher School of Psychology, The Interdisciplinary Center (IDC) Herzliya , Herzliya, Israel.'}]",Clinical gerontologist,['10.1080/07317115.2020.1799131'] 2766,32762340,"Immunotherapy to reduce frequency of urinary tract infections in people with neurogenic bladder dysfunction; a pilot randomised, placebo-controlled trial.","OBJECTIVE To establish the feasibility of a randomized, placebo-controlled trial to investigate the effect of a specific immunotherapy bacterial lysate OM-89 (Uro-Vaxom ® ) in reducing the frequency of urinary tract infections in people with neurogenic bladder dysfunction. DESIGN A parallel-group, double-blind, randomized, placebo-controlled trial. SETTING Patients at home, recruited through out-patient contact, social media and patient support groups. SUBJECTS People with a spinal cord injury, multiple sclerosis, transverse myelitis or cauda equina syndrome who had suffered three or more clinically diagnosed urinary tract infections treated with antibiotics over the preceding 12 months. INTERVENTIONS All participants took one capsule of oral OM-89 immunotherapy (6 mg) or matching Placebo (randomisation ratio 1:1), once daily in the morning for 3 months. MAIN MEASURES The primary outcome was occurrence of a symptomatic urinary tract infection treated with an antibiotic, assessed at 3 and 6 months. Feasibility measures included recruitment, retention and practical difficulties. RESULTS Of 115 patients screened, 49 were recruited, one withdrew before randomization, and 23 were allocated to the control group receiving matching placebo. Six participants, all in the control group, discontinued the intervention; all participants provided full data at both follow-up times. Over 6 months, 18/25 active group patients had 55 infections, and 18/23 control group patients had 47 infections. Most research and clinical procedures were practical, and acceptable to participants. CONCLUSION It is feasible to undertake a larger trial. We recommend broader inclusion criteria to increase eligibility and generalizability.",2020,"Six participants, all in the control group, discontinued the intervention; all participants provided full data at both follow-up times.","['115 patients screened', 'people with neurogenic bladder dysfunction', 'People with a spinal cord injury, multiple sclerosis, transverse myelitis or cauda equina syndrome who had suffered three or more clinically diagnosed urinary tract infections treated with antibiotics over the preceding 12\u2009months', 'Patients at home, recruited through out-patient contact, social media and patient support groups']","['Immunotherapy', 'oral OM-89 immunotherapy (6\u2009mg) or matching Placebo', 'control group receiving matching placebo', 'specific immunotherapy bacterial lysate OM-89 (Uro-Vaxom ® ', 'placebo']","['recruitment, retention and practical difficulties', 'occurrence of a symptomatic urinary tract infection treated with an antibiotic', '47 infections']","[{'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0005697', 'cui_str': 'Neurogenic bladder'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0026976', 'cui_str': 'Transverse myelopathy syndrome'}, {'cui': 'C0392548', 'cui_str': 'Cauda equina syndrome'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C3179065', 'cui_str': 'Social Medium'}, {'cui': 'C0036606', 'cui_str': 'Support Groups'}]","[{'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0069460', 'cui_str': 'OM 89'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C1569170', 'cui_str': 'polyvalent mechanical bacterial lysate'}]","[{'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]",49.0,0.519255,"Six participants, all in the control group, discontinued the intervention; all participants provided full data at both follow-up times.","[{'ForeName': 'Derick T', 'Initials': 'DT', 'LastName': 'Wade', 'Affiliation': 'Oxford Institute of Nursing, Midwifery and Allied Health Research (OxINMAHR), Faculty of Health & Life Sciences, Oxford Brookes University, Oxford, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Cooper', 'Affiliation': 'NSIC Research Programme Manager, National Spinal Injury Centre (NSIC), Stoke Mandeville Hospital, Buckinghamshire Healthcare NHS Trust, Aylesbury, Bucks, UK.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Peckham', 'Affiliation': 'Medical Statistician, Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, (NDORMS), University of Oxford, Botnar Research Centre, Headington, Oxford, UK.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Belci', 'Affiliation': 'Consultant in Spinal Cord Injuries, National Spinal Injury Centre (NSIC), Stoke Mandeville Hospital, Buckinghamshire Healthcare NHS Trust, Aylesbury, Bucks, UK.'}]",Clinical rehabilitation,['10.1177/0269215520946065'] 2767,32762424,The influence of culture and close others on the effectiveness of (self)-persuasion.,"Although self-persuasion was shown to be more effective than direct persuasion in changing attitudes and intentions, its effectiveness in different cultures remains unclear. Furthermore, research suggests that Eastern individuals tend to incorporate close others in the self to a larger extent than Western individuals. Combining both lines of research, the current studies examined whether thinking of a close other would influence the effectiveness of (self)-persuasion across cultures. Two parallel studies were conducted. U.S. participants ( n study 1 = 195; n study 2  = 292) and Chinese participants ( n study 1  = 187; n study 2  = 313) reported their initial attitudes and intentions toward five target behaviors prior to either think of a specific close other or not. Subsequently, they were randomly assigned to receive either a self-persuasion or a direct persuasion task. Specifically, the self-persuasion task led participants to generate own arguments or arguments that they think the close other would give; the direct persuasion task led participants to read given arguments or imagine that the arguments were from the close other. In the end, all participants reported their attitudes and intentions again after doing the persuasion tasks. The moderation effect of culture was only found in Study 1, such that direct persuasion worked more effectively in Chinese participants than self-persuasion, whereas the effectiveness of the two persuasive techniques did not differ in U.S. participants. In both studies, thinking of a close other was not found to influence the effectiveness of (self-)persuasion across cultures. Possible explanations and future research directions were discussed.",2020,"In both studies, thinking of a close other was not found to influence the effectiveness of (self-)persuasion across cultures.","['Eastern individuals', 'U.S. participants ( n study\u20091 = 195; n study\u20092 \u2009=\u2009292) and Chinese participants ( n study\u20091 \u2009=\u2009187']","['n study\u20092 \u2009=\u2009313) reported their initial attitudes and intentions toward five target behaviors prior to either think of a specific close other or not', 'self-persuasion or a direct persuasion task']",[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517624', 'cui_str': '195'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C4517618', 'cui_str': '187'}]","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517707', 'cui_str': '313'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0205394', 'cui_str': 'Other'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0031230', 'cui_str': 'Persuasion'}, {'cui': 'C0439851', 'cui_str': 'Direct'}]",[],,0.0174483,"In both studies, thinking of a close other was not found to influence the effectiveness of (self-)persuasion across cultures.","[{'ForeName': 'Shuang', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Institute of Governance, Shandong University, Qingdao, China.'}, {'ForeName': 'Rick B', 'Initials': 'RB', 'LastName': 'van Baaren', 'Affiliation': 'Behavioural Science Institute, Radboud University, Nijmegen, The Netherlands.'}, {'ForeName': 'Barbara C N', 'Initials': 'BCN', 'LastName': 'Müller', 'Affiliation': 'Behavioural Science Institute, Radboud University, Nijmegen, The Netherlands.'}]",The Journal of general psychology,['10.1080/00221309.2020.1803193'] 2768,32762427,"Medication use, renin-angiotensin system inhibitors, and acute care utilization after hospitalization in patients with chronic kidney disease.","OBJECTIVES The aims of this secondary analysis were to: (a) characterize medication use following hospital discharge for patients with chronic kidney disease (CKD), and (b) investigate relationships of medication use with the primary composite outcome of acute care utilization 90 days after hospitalization. METHODS The CKD-Medication Intervention Trial (CKD-MIT) enrolled acutely ill hospitalized patients with CKD stages 3-5 not dialyzed (CKD 3-5 ND). In this post hoc analysis, data for medication use were characterized, and the relationship of medication use with the primary outcome was evaluated using Cox proportional hazards models. RESULTS Participants were taking a mean of 12.6 (standard deviation=5.1) medications, including medications from a wide variety of medication classes. Nearly half of study participants were taking angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB). ACE inhibitor/ARB use was associated with decreased risk of the primary outcome (hazard ratio=0.51; 95% confidence interval 0.28-0.95; p =0.03) after adjustment for baseline estimated glomerular filtration rate, age, sex, race, blood pressure, albuminuria, and potential nephrotoxin use. CONCLUSIONS A large number, variety, and complexity of medications were used by hospitalized patients with CKD 3-5 ND. ACE inhibitor or ARB use at hospital discharge was associated with a decreased risk of 90-day acute care utilization.",2020,"ACE inhibitor/ARB use was associated with decreased risk of the primary outcome (hazard ratio=0.51; 95% confidence interval 0.28-0.95; p =0.03) after adjustment for baseline estimated glomerular filtration rate, age, sex, race, blood pressure, albuminuria, and potential nephrotoxin use. ","['acutely ill hospitalized patients with CKD stages 3-5 not dialyzed (CKD 3-5 ND', 'Participants were taking a mean of 12.6 (standard deviation=5.1) medications, including medications from a wide variety of medication classes', 'patients with chronic kidney disease', 'patients with chronic kidney disease (CKD), and (b) investigate relationships of medication use with the primary composite outcome of acute care utilization 90 days after hospitalization']","['ACE inhibitor or ARB', 'renin-angiotensin system inhibitors', 'ACE inhibitor/ARB', 'angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB']",[],"[{'cui': 'C0231218', 'cui_str': 'Malaise'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0442758', 'cui_str': '3/5'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4517545', 'cui_str': '12.6'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]","[{'cui': 'C0003015', 'cui_str': 'Angiotensin-converting enzyme inhibitor'}, {'cui': 'C0521942', 'cui_str': 'Angiotensin II receptor antagonist'}, {'cui': 'C0035094', 'cui_str': 'Renin'}, {'cui': 'C0003018', 'cui_str': 'Angiotensin'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0022709', 'cui_str': 'Dipeptidyl carboxypeptidase I'}]",[],,0.0473132,"ACE inhibitor/ARB use was associated with decreased risk of the primary outcome (hazard ratio=0.51; 95% confidence interval 0.28-0.95; p =0.03) after adjustment for baseline estimated glomerular filtration rate, age, sex, race, blood pressure, albuminuria, and potential nephrotoxin use. ","[{'ForeName': 'Joshua J', 'Initials': 'JJ', 'LastName': 'Neumiller', 'Affiliation': 'College of Pharmacy and Pharmaceutical Sciences, Washington State University, USA.'}, {'ForeName': 'Kenn B', 'Initials': 'KB', 'LastName': 'Daratha', 'Affiliation': 'School of Anesthesia, Providence Health Care, USA.'}, {'ForeName': 'Radica Z', 'Initials': 'RZ', 'LastName': 'Alicic', 'Affiliation': 'Providence Medical Research Center, Providence Health Care, USA.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Short', 'Affiliation': 'Providence Medical Research Center, Providence Health Care, USA.'}, {'ForeName': 'Haleigh M', 'Initials': 'HM', 'LastName': 'Miller', 'Affiliation': 'Sacred Heart Medical Center, Providence Health Care, USA.'}, {'ForeName': 'Liza', 'Initials': 'L', 'LastName': 'Gregg', 'Affiliation': 'Sacred Heart Medical Center, Providence Health Care, USA.'}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Gates', 'Affiliation': 'College of Pharmacy and Pharmaceutical Sciences, Washington State University, USA.'}, {'ForeName': 'Cynthia F', 'Initials': 'CF', 'LastName': 'Corbett', 'Affiliation': 'College of Nursing, University of South Carolina, USA.'}, {'ForeName': 'Sterling M', 'Initials': 'SM', 'LastName': 'McPherson', 'Affiliation': 'Providence Medical Research Center, Providence Health Care, USA.'}, {'ForeName': 'Katherine R', 'Initials': 'KR', 'LastName': 'Tuttle', 'Affiliation': 'Providence Medical Research Center, Providence Health Care, USA.'}]",Journal of the renin-angiotensin-aldosterone system : JRAAS,['10.1177/1470320320945137'] 2769,32762637,Colorectal Cancer Screening Patient Navigation for Patients with Mental Illness and/or Substance Use Disorder: Pilot Randomized Control Trial.,"OBJECTIVE Colorectal cancer (CRC) is the second leading cause of cancer death in the US. Screening has decreased CRC mortality. However, disadvantaged patients, particularly those with mental illness or substance use disorder (SUD), are less likely to be screened. The aim of this trial was to evaluate the impact of a patient navigation program on CRC screening in patients with mental illness and/or SUD. METHODS A pilot randomized nonblinded controlled trial was conducted from January to June 2017 in an urban community health center serving a low-income population. We randomized 251 patients aged 50-74 years with mental illness and/or SUD diagnosis overdue for CRC screening to intervention ( n  = 126) or usual care ( n  = 125) stratified by mental illness, SUD, or dual diagnosis. Intervention group patients received a letter followed by a phone call from patient navigators. Navigators helped patients overcome their individual barriers to CRC screening including: education, scheduling, explanation of bowel preparation, lack of transportation or accompaniment to appointments. If patient refused colonoscopy, navigators offered fecal occult blood testing. The main measure was proportion of patients completing CRC screening in intervention and usual care groups. RESULTS Navigators contacted 85 patients (67%) in the intervention group and 26 declined to participate. In intention-to treat analysis, more patients in the intervention group received CRC screening than in the usual care group, 19% versus 10.4% ( p = .04). Among 56 intervention patients who received navigation, 19 completed screening (33.9% versus 10.4% in the control group, p = .001). In the subgroup of patients with SUD, 20% in the intervention group were screened compared to none in the usual care group ( p = .05). CONCLUSIONS A patient navigation program improved CRC screening rates in patients with mental illness and/or SUD. Larger studies in diverse care settings are needed to demonstrate generalizability and explore which modality of CRC screening is most acceptable and which navigator activities are most effective for this vulnerable population. TRIALS REGISTRATION NUMBER 2016P001322.",2020,"In the subgroup of patients with SUD, 20% in the intervention group were screened compared to none in the usual care group ( p = .05). ","['Colorectal cancer (CRC', 'patients with mental illness and/or SUD', '251 patients aged 50-74 years with mental illness and/or SUD diagnosis overdue for CRC screening to intervention ( n \u2009=\u2009126) or usual care ( n \u2009=\u2009125) stratified by mental illness, SUD, or dual diagnosis', 'January to June 2017 in an urban community health center serving a low-income population', 'disadvantaged patients, particularly those with mental illness or substance use disorder (SUD', 'Patients with Mental Illness and/or Substance Use Disorder']","['patient navigation program', 'letter followed by a phone call from patient navigators', 'Colorectal Cancer Screening Patient Navigation']","['CRC mortality', 'CRC screening', 'CRC screening rates']","[{'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0038586', 'cui_str': 'Substance use disorder'}, {'cui': 'C0761050', 'cui_str': '(GVGVP)251'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0206308', 'cui_str': 'Dual Diagnosis'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0009469', 'cui_str': 'Satellite Centers'}, {'cui': 'C0024045', 'cui_str': 'Low Income Population'}, {'cui': 'C0012613', 'cui_str': 'Disadvantaged'}]","[{'cui': 'C3494323', 'cui_str': 'Patient Navigation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0282413', 'cui_str': 'Letters as Topic'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1709488', 'cui_str': 'Patient navigator'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]",251.0,0.119177,"In the subgroup of patients with SUD, 20% in the intervention group were screened compared to none in the usual care group ( p = .05). ","[{'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Abuelo', 'Affiliation': 'Massachusetts General Hospital, Division of General Internal Medicine, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Ashburner', 'Affiliation': 'Massachusetts General Hospital, Division of General Internal Medicine, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Atlas', 'Affiliation': 'Massachusetts General Hospital, Division of General Internal Medicine, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Knudsen', 'Affiliation': 'Massachusetts General Hospital Institute for Technology Assessment, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Morrill', 'Affiliation': 'Massachusetts General Hospital, Division of General Internal Medicine, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Corona', 'Affiliation': 'Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Derri', 'Initials': 'D', 'LastName': 'Shtasel', 'Affiliation': 'Massachusetts General Hospital, Division of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Sanja', 'Initials': 'S', 'LastName': 'Percac-Lima', 'Affiliation': 'Massachusetts General Hospital, Division of General Internal Medicine, Harvard Medical School, Boston, Massachusetts, USA.'}]",Journal of dual diagnosis,['10.1080/15504263.2020.1802542'] 2770,32762663,"A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial to assess the efficacy of adjunctive N-Acetylcysteine for treatment-resistant PTSD: a study protocol.","BACKGROUND Most patients with Posttraumatic Stress Disorder (PTSD) suffer residual symptoms following first-line treatment. Oxidative stress has been implicated in the pathophysiology of PTSD. N-acetylcysteine (NAC) is a precursor of the brain's primary antioxidant, glutathione, and may diminish oxidative cellular damage. An 8-week pilot study of NAC in veterans with PTSD found that symptoms were significantly reduced in the NAC group compared to placebo. This study aims to confirm these findings with a larger sample in a double-blind, placebo-controlled trial to further explore the efficacy of NAC as an adjunctive therapy in treatment-resistant PTSD. METHODS A multicentre, randomised, double-blind, placebo-controlled trial for adult patients who still meet criteria for PTSD following first-line treatment. The intervention comprises either NAC as a fixed dose regime of 2.7 g/day (900 mg three times daily) administered orally for 12 weeks, or placebo. Standard care for PTSD will continue in addition, including other pharmacotherapies. Detailed clinical data will be collected at randomisation and weeks 4, 8, 12, 16, and 64 post-randomisation, with self-report measures completed weekly from baseline to 16 weeks and at 64 weeks post-randomisation. Blood-based biomarkers will be collected at baseline and 12 weeks to assess the mechanism of effect. The primary outcome measure will be change in Clinician-Administered PTSD Scale for DSM-5 at 12 weeks compared with baseline. Secondary outcomes will be change in quality of life, depression, anxiety, substance use and craving, and somatic symptoms. With 126 completed participants (63 per arm), the study is powered at 80% to detect a true difference in the primary outcome measure using a two-tailed analysis with alpha = 0.05, beta = 0.2. DISCUSSION This is the first multicentre, double blind, randomised, placebo-controlled trial of adjunctive NAC for treatment-resistant PTSD. NAC has an established safety profile, is readily available and easy to administer, and has a favourable tolerability profile, therefore making it an attractive adjunctive therapy. Inclusion of blood analyses to assess potential target engagement biomarkers of oxidative stress and neuroinflammation may help gauge the biological mechanisms of effect of NAC. TRIAL REGISTRATION ACTRN12618001784202, retrospectively registered 31/10/2018, URL: http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=376004 .",2020,An 8-week pilot study of NAC in veterans with PTSD found that symptoms were significantly reduced in the NAC group compared to placebo.,"['veterans with PTSD', 'adult patients who still meet criteria for PTSD following first-line treatment', 'patients with Posttraumatic Stress Disorder (PTSD']","['N-acetylcysteine (NAC', 'adjunctive N-Acetylcysteine', 'NAC', 'adjunctive NAC', 'placebo']","['change in Clinician-Administered PTSD Scale for DSM-5', 'change in quality of life, depression, anxiety, substance use and craving, and somatic symptoms']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C1708063', 'cui_str': 'First line treatment'}]","[{'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C3839861', 'cui_str': 'Medically unexplained symptom'}]",126.0,0.718824,An 8-week pilot study of NAC in veterans with PTSD found that symptoms were significantly reduced in the NAC group compared to placebo.,"[{'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Maier', 'Affiliation': 'Department of Psychiatry, Austin Health, University of Melbourne, LTB10, 145 Studley Road, Heidelberg, VIC, 3084, Australia.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Dharan', 'Affiliation': 'Department of Psychiatry, Austin Health, University of Melbourne, LTB10, 145 Studley Road, Heidelberg, VIC, 3084, Australia.'}, {'ForeName': 'Gina', 'Initials': 'G', 'LastName': 'Oliver', 'Affiliation': 'Department of Psychiatry, The Melbourne Clinic, University of Melbourne, Richmond, VIC, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Berk', 'Affiliation': 'IMPACT - the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Barwon Health, Geelong, Australia.'}, {'ForeName': 'Suzy', 'Initials': 'S', 'LastName': 'Redston', 'Affiliation': 'Austin Health, Heidelberg, VIC, Australia.'}, {'ForeName': 'Sudie E', 'Initials': 'SE', 'LastName': 'Back', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina; Ralph H. Johnson VA Medical Center, Charleston, SC, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Kalivas', 'Affiliation': 'Department of Neuroscience, Medical University of South Carolina, Charleston, USA.'}, {'ForeName': 'Chee', 'Initials': 'C', 'LastName': 'Ng', 'Affiliation': 'Department of Psychiatry, The Melbourne Clinic, University of Melbourne, Richmond, VIC, Australia.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Kanaan', 'Affiliation': 'Department of Psychiatry, Austin Health, University of Melbourne, LTB10, 145 Studley Road, Heidelberg, VIC, 3084, Australia. richard.kanaan@unimelb.edu.au.'}]",BMC psychiatry,['10.1186/s12888-020-02793-9'] 2771,32762677,A randomized controlled trial comparing the clinical efficacy and cost-effectiveness of eye movement desensitization and reprocessing (EMDR) and integrated EMDR-Dialectical Behavioural Therapy (DBT) in the treatment of patients with post-traumatic stress disorder and comorbid (Sub)clinical borderline personality disorder: study design.,"BACKGROUND Comorbidity between Posttraumatic Stress Disorder (PTSD) and Borderline Personality Disorder (BPD) is high. There is growing motivation among clinicians to offer PTSD treatments - such as Eye Movement Desensitization and Reprocessing (EMDR) - to patients with PTSD and comorbid BPD. However, a large subgroup with comorbid BPD does not sufficiently respond to PTSD treatment and is more likely to be excluded or to dropout from treatment. Dialectical Behaviour Therapy (DBT) for BPD is well established and although there is some evidence that DBT combined with DBT Prolonged Exposure (DBT + DBT PE) is twice as effective in reducing PTSD symptoms than DBT alone, the comparative efficacy of integrated PTSD-DBT and PTSD-only treatment has not been investigated yet. The current study will therefore evaluate the comparative clinical efficacy and cost-effectiveness of EMDR-DBT and EMDR-only in patients with PTSD and comorbid (sub)clinical BPD. Moreover, it is not clear yet what treatment works best for which individual patient. The current study will therefore evaluate neurobiological predictors and mediators of the individual response to treatment. METHOD A randomized controlled trial comparing the clinical efficacy and cost-effectiveness of integrated EMDR-DBT (n = 63) and EMDR-only (n = 63) in treatment-seeking adult patients with PTSD and comorbid (sub)clinical BPD. In addition, neurobiological predictors and mediators of treatment outcome, such as hair cortisol, FKBP5 and BDNF protein levels and FKBP5 and BDNF methylation status, are measured through hair and blood samples. DISCUSSION This is the first study to compare the clinical efficacy and cost-effectiveness of integrated EMDR-DBT and EMDR-only in patients with PTSD and comorbid (sub)clinical BPD, while simultaneously identifying individual predictors and mediators of treatment response. Results will reveal which treatment works best for which individual patient, thereby guiding individual treatment choices and personalizing psychiatry. TRIAL REGISTRATION Clinical Trials, NCT03833453 . Retrospectively registered, 15 March 2019.",2020,There is growing motivation among clinicians to offer PTSD treatments - such as Eye Movement Desensitization and Reprocessing (EMDR) - to patients with PTSD and comorbid BPD.,"['patients with PTSD and comorbid (sub)clinical BPD', 'adult patients with PTSD and comorbid (sub)clinical BPD', 'patients with post-traumatic stress disorder and comorbid (Sub)clinical borderline personality disorder']","['integrated EMDR-DBT (n\u2009=\u200963) and EMDR-only (n\u2009=\u200963) in treatment-seeking', 'EMDR-DBT and EMDR', 'DBT Prolonged Exposure (DBT\u2009+\u2009DBT PE', 'Dialectical Behaviour Therapy (DBT', 'eye movement desensitization and reprocessing (EMDR) and integrated EMDR-Dialectical Behavioural Therapy (DBT', 'integrated EMDR-DBT and EMDR']","['PTSD symptoms', 'hair cortisol, FKBP5 and BDNF protein levels and FKBP5 and BDNF methylation status, are measured through hair and blood samples']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0006012', 'cui_str': 'Borderline personality disorder'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0870535', 'cui_str': 'EMDR'}, {'cui': 'C3472347', 'cui_str': 'Digital breast tomosynthesis'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C1321145', 'cui_str': 'Dialectical behavior therapy'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}]","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C1741214', 'cui_str': 'FKBP5 protein, human'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0428479', 'cui_str': 'Protein level - finding'}, {'cui': 'C0025723', 'cui_str': 'Methylation'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}]",,0.0204819,There is growing motivation among clinicians to offer PTSD treatments - such as Eye Movement Desensitization and Reprocessing (EMDR) - to patients with PTSD and comorbid BPD.,"[{'ForeName': 'Aishah', 'Initials': 'A', 'LastName': 'Snoek', 'Affiliation': 'Arkin Sinai Centrum, Amstelveen, The Netherlands. aishah.snoek@sinaicentrum.nl.'}, {'ForeName': 'Aartjan T F', 'Initials': 'ATF', 'LastName': 'Beekman', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam, the Netherlands.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Dekker', 'Affiliation': 'Amsterdam UMC, Vrije Universiteit Amsterdam, Anatomy and Neurosciences, Amsterdam Neuroscience, Amsterdam, the Netherlands.'}, {'ForeName': 'Inga', 'Initials': 'I', 'LastName': 'Aarts', 'Affiliation': 'Arkin Sinai Centrum, Amstelveen, The Netherlands.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'van Grootheest', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam, the Netherlands.'}, {'ForeName': 'Matthijs', 'Initials': 'M', 'LastName': 'Blankers', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam, the Netherlands.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Vriend', 'Affiliation': 'Vrije Universiteit Amsterdam, Faculty of Behavioural and Movement Sciences, Amsterdam, the Netherlands.'}, {'ForeName': 'Odile', 'Initials': 'O', 'LastName': 'van den Heuvel', 'Affiliation': 'Vrije Universiteit Amsterdam, Faculty of Behavioural and Movement Sciences, Amsterdam, the Netherlands.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Thomaes', 'Affiliation': 'Arkin Sinai Centrum, Amstelveen, The Netherlands.'}]",BMC psychiatry,['10.1186/s12888-020-02713-x'] 2772,32762701,"High-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease patients after extubation: a multicenter, randomized controlled trial.","BACKGROUND High-flow nasal cannula (HFNC) oxygen therapy is being increasingly used to prevent post-extubation hypoxemic respiratory failure and reintubation. However, evidence to support the use of HFNC in chronic obstructive pulmonary disease (COPD) patients with hypercapnic respiratory failure after extubation is limited. This study was conducted to test if HFNC is non-inferior to non-invasive ventilation (NIV) in preventing post-extubation treatment failure in COPD patients previously intubated for hypercapnic respiratory failure. METHODS COPD patients with hypercapnic respiratory failure who were already receiving invasive ventilation were randomized to HFNC or NIV at extubation at two large tertiary academic teaching hospitals. The primary endpoint was treatment failure, defined as either resumption of invasive ventilation or switching to the other study treatment modality (NIV for patients in the NFNC group or vice versa). RESULTS Ninety-six patients were randomly assigned to the HFNC group or NIV group. After secondary exclusion, 44 patients in the HFNC group and 42 patients in the NIV group were included in the analysis. The treatment failure rate in the HFNC group was 22.7% and 28.6% in the NIV group-risk difference of - 5.8% (95% CI, - 23.8-12.4%, p = 0.535), which was significantly lower than the non-inferior margin of 9%. Analysis of the causes of treatment failure showed that treatment intolerance in the HFNC group was significantly lower than that in the NIV group, with a risk difference of - 50.0% (95% CI, - 74.6 to - 12.9%, p = 0.015). One hour after extubation, the mean respiratory rates of both groups were faster than their baseline levels before extubation (p < 0.050). Twenty-four hours after extubation, the respiratory rate of the HFNC group had returned to baseline, but the NIV group was still higher than the baseline. Forty-eight hours after extubation, the respiratory rates of both groups were not significantly different from the baseline. The average number of daily airway care interventions in the NIV group was 7 (5-9.3), which was significantly higher than 6 (4-7) times in the HFNC group (p = 0.006). The comfort score and incidence of nasal and facial skin breakdown of the HFNC group was also significantly better than that of the NIV group [7 (6-8) vs 5 (4-7), P < 0.001] and [0 vs 9.6%, p = 0.027], respectively. CONCLUSION Among COPD patients with severe hypercapnic respiratory failure who received invasive ventilation, the use of HFNC after extubation did not result in increased rates of treatment failure compared with NIV. HFNC also had better tolerance and comfort than NIV. TRIAL REGISTRATION chictr.org ( ChiCTR1800018530 ). Registered on 22 September 2018, http://www.chictr.org.cn/usercenter.aspx.",2020,"The treatment failure rate in the HFNC group was 22.7% and 28.6% in the NIV group-risk difference of - 5.8% (95% CI, - 23.8-12.4%, p = 0.535), which was significantly lower than the non-inferior margin of 9%.","['COPD patients previously intubated for hypercapnic respiratory failure', 'COPD patients with severe hypercapnic respiratory failure who received', 'Ninety-six patients', '44 patients in the HFNC group and 42 patients in the NIV group were included in the analysis', 'chronic obstructive pulmonary disease (COPD) patients with hypercapnic respiratory failure after extubation', 'COPD patients with hypercapnic respiratory failure who were already receiving invasive ventilation were randomized to HFNC or NIV at extubation at two large tertiary academic teaching hospitals', 'chronic obstructive pulmonary disease patients after extubation']","['High-flow nasal cannula ', 'invasive ventilation', 'HFNC) oxygen therapy', 'HFNC', 'High-flow nasal cannula oxygen therapy versus non-invasive ventilation']","['rates of treatment failure', 'treatment failure rate', 'respiratory rates', 'treatment failure, defined as either resumption of invasive ventilation or switching to the other study treatment modality (NIV', 'mean respiratory rates', 'comfort score and incidence of nasal and facial skin breakdown', 'respiratory rate', 'average number of daily airway care interventions']","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0398353', 'cui_str': 'Hypercapnic respiratory failure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C4319625', 'cui_str': '96'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannulae'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannulae'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}, {'cui': 'C4761117', 'cui_str': 'High-flow nasal cannula oxygen therapy'}, {'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}]","[{'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0222084', 'cui_str': 'Skin structure of face'}, {'cui': 'C0699900', 'cui_str': 'Catabolism'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",96.0,0.196719,"The treatment failure rate in the HFNC group was 22.7% and 28.6% in the NIV group-risk difference of - 5.8% (95% CI, - 23.8-12.4%, p = 0.535), which was significantly lower than the non-inferior margin of 9%.","[{'ForeName': 'Dingyu', 'Initials': 'D', 'LastName': 'Tan', 'Affiliation': ""Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, 225001, China.""}, {'ForeName': 'Joseph Harold', 'Initials': 'JH', 'LastName': 'Walline', 'Affiliation': 'Accident and Emergency Medicine Academic Unit, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Bingyu', 'Initials': 'B', 'LastName': 'Ling', 'Affiliation': ""Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, 225001, China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': ""Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, 225001, China.""}, {'ForeName': 'Jiayan', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': ""Pharmacy Department, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, 225001, China. 32494845@qq.com.""}, {'ForeName': 'Bingxia', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': ""Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, 225001, China.""}, {'ForeName': 'Xueqin', 'Initials': 'X', 'LastName': 'Shan', 'Affiliation': ""Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, 225001, China.""}, {'ForeName': 'Yunyun', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ""Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, 225001, China.""}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Cao', 'Affiliation': ""Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, 225001, China.""}, {'ForeName': 'Qingcheng', 'Initials': 'Q', 'LastName': 'Zhu', 'Affiliation': ""Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, 225001, China.""}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Geng', 'Affiliation': ""Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, 225001, China.""}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Emergency Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China. xujunfree@126.com.'}]","Critical care (London, England)",['10.1186/s13054-020-03214-9'] 2773,32765189,The effect of a new perioperative practice model on length of hospital stay and on the surgical care process in patients undergoing hip and knee arthroplasty under spinal anesthesia: a randomized clinical trial.,"Background The shortened length of hospital stays (LOS) requires efficient and patient-participatory perioperative nursing approaches to enable early and safe discharge from hospitals for patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA). The primary aim of this study was to explore the effect comparative to standard perioperative care of a new perioperative practice model (NPPM) on the LOS and the time points of the surgical care process in patients undergoing THA and TKA under spinal anesthesia. The secondary aim was to find out if any subgroups with different response could be found. Methods Patients scheduled for elective, primary THA and TKA were assessed for eligibility. A two-group parallel randomized clinical trial was conducted with an intervention group ( n  = 230) and control group ( n  = 220), totaling 450 patients. The patients in the intervention group were each designated with one named anesthesia nurse, who took care of the patient during the entire perioperative process and visited the patient postoperatively. The patients in the control group received standard perioperative care from different nurses during their perioperative processes and without postoperative visits. The surgical care process time points for each study patient were gathered from the operating room management software and hospital information system until hospital discharge. Results We did not find any statistically significant differences between the intervention and control groups regarding to LOS. Only slight differences in the time points of the surgical care process could be detected. The subgroup examination revealed that higher age, type of arthroplasty and ASA score 3-4 all separately caused prolonged LOS. Conclusion We did not find the new perioperative practice model to shorten either length of hospital stays or the surgical care process in patients undergoing THA and TKA. Further studies at the subgroup level (gender, old age, and ASA score 3 and 4) are needed to recognize the patients who might benefit most from the NPPM. Trial registration This study was registered in NIH Clinical.Trials.gov under registration number NCT02906033, retrospectively registered September 19, 2016.",2020,We did not find the new perioperative practice model to shorten either length of hospital stays or the surgical care process in patients undergoing THA and TKA.,"['patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA', 'patients undergoing THA and TKA under spinal anesthesia', 'patients undergoing hip and knee arthroplasty under spinal anesthesia', 'patients undergoing THA and TKA']","['standard perioperative care', 'new perioperative practice model (NPPM']","['length of hospital stay', 'shortened length of hospital stays (LOS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0150706', 'cui_str': 'Perioperative care'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}]",,0.0887022,We did not find the new perioperative practice model to shorten either length of hospital stays or the surgical care process in patients undergoing THA and TKA.,"[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Pulkkinen', 'Affiliation': 'University of Helsinki, Helsinki University Hospital, Perioperative, Intensive Care and Pain Medicine, PO. Box. 900, Vantaa, FI00029 Helsinki, HUS Finland.'}, {'ForeName': 'Irma', 'Initials': 'I', 'LastName': 'Jousela', 'Affiliation': 'University of Helsinki, Helsinki University Hospital, Perioperative, Intensive Care and Pain Medicine, PO. Box. 900, Vantaa, FI00029 Helsinki, HUS Finland.'}, {'ForeName': 'Janne', 'Initials': 'J', 'LastName': 'Engblom', 'Affiliation': 'Department of Mathematics and Statistics, University of Turku, Turku, Finland.'}, {'ForeName': 'Sanna', 'Initials': 'S', 'LastName': 'Salanterä', 'Affiliation': 'Department of Nursing Science, University of Turku, Joukahaisenkatu 3-5, 20520 Turku, Finland.'}, {'ForeName': 'Kristiina', 'Initials': 'K', 'LastName': 'Junttila', 'Affiliation': 'Department of Nursing Science, University of Turku, Joukahaisenkatu 3-5, 20520 Turku, Finland.'}]",BMC nursing,['10.1186/s12912-020-00465-3'] 2774,32765274,"No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.","Background Currently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, causing an unprecedented pandemic. However, there is no specific antiviral therapy for coronavirus disease 2019 (COVID-19). We conducted a clinical trial to compare the effectiveness of three antiviral treatment regimens in patients with mild to moderate COVID-19. Methods This was a single-center, randomized, open-labeled, prospective clinical trial. Eligible patients with mild to moderate COVID-19 were randomized into three groups: ribavirin (RBV) plus interferon-α (IFN-α), lopinavir/ritonavir (LPV/r) plus IFN-α, and RBV plus LPV/r plus IFN-α at a 1:1:1 ratio. Each patient was invited to participate in a 28-d follow-up after initiation of an antiviral regimen. The outcomes include the difference in median interval to SARS-CoV-2 nucleic acid negativity, the proportion of patients with SARS-CoV-2 nucleic acid negativity at day 14, the mortality at day 28, the proportion of patients re-classified as severe cases, and adverse events during the study period. Results In total, we enrolled 101 patients in this study. Baseline clinical and laboratory characteristics of patients were comparable among the three groups. In the analysis of intention-to-treat data, the median interval from baseline to SARS-CoV-2 nucleic acid negativity was 12 d in the LPV/r+IFN-α-treated group, as compared with 13 and 15 d in the RBV+IFN-α-treated group and in the RBV+LPV/r+ IFN-α-treated group, respectively ( p =0.23). The proportion of patients with SARS-CoV-2 nucleic acid negativity in the LPV/r+IFN-α-treated group (61.1%) was higher than the RBV+ IFN-α-treated group (51.5%) and the RBV+LPV/r+IFN-α-treated group (46.9%) at day 14; however, the difference between these groups was calculated to be statistically insignificant. The RBV+LPV/r+IFN-α-treated group developed a significantly higher incidence of gastrointestinal adverse events than the LPV/r+ IFN-α-treated group and the RBV+ IFN-α-treated group. Conclusions Our results indicate that there are no significant differences among the three regimens in terms of antiviral effectiveness in patients with mild to moderate COVID-19. Furthermore, the combination of RBV and LPV/r is associated with a significant increase in gastrointestinal adverse events, suggesting that RBV and LPV/r should not be co-administered to COVID-19 patients simultaneously. Clinical Trial Registration www.ClinicalTrials.gov, ID: ChiCTR2000029387. Registered on January 28, 2019.",2020,"The RBV+LPV/r+IFN-α-treated group developed a significantly higher incidence of gastrointestinal adverse events than the LPV/r+ IFN-α-treated group and the RBV+ IFN-α-treated group. ","['101 patients in this study', 'Patients', 'patients with mild to moderate COVID-19', 'Eligible patients with mild to moderate COVID-19']","['RBV+LPV/r+IFN-α-treated', 'Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha', 'ribavirin (RBV) plus interferon-α (IFN-α), lopinavir/ritonavir (LPV/r) plus IFN-α, and RBV plus LPV/r plus IFN-α']","['antiviral effectiveness', 'proportion of patients with SARS-CoV-2 nucleic acid negativity', 'Antiviral Effectiveness', 'median interval to SARS-CoV-2 nucleic acid negativity, the proportion of patients with SARS-CoV-2 nucleic acid negativity', 'gastrointestinal adverse events', 'adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}]","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0035525', 'cui_str': 'Ribavirin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0002199', 'cui_str': 'interferon alfa natural'}, {'cui': 'C0939237', 'cui_str': 'lopinavir and ritonavir'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}]","[{'cui': 'C0003451', 'cui_str': 'Antiviral'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0028606', 'cui_str': 'Nucleic acid'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",101.0,0.0447419,"The RBV+LPV/r+IFN-α-treated group developed a significantly higher incidence of gastrointestinal adverse events than the LPV/r+ IFN-α-treated group and the RBV+ IFN-α-treated group. ","[{'ForeName': 'Yin-Qiu', 'Initials': 'YQ', 'LastName': 'Huang', 'Affiliation': 'National Key Laboratory for Infectious Diseases Prevention and Treatment with Traditional Chinese Medicine, Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Sheng-Quan', 'Initials': 'SQ', 'LastName': 'Tang', 'Affiliation': 'Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Xiao-Lei', 'Initials': 'XL', 'LastName': 'Xu', 'Affiliation': 'Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Yan-Ming', 'Initials': 'YM', 'LastName': 'Zeng', 'Affiliation': 'Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Xiao-Qing', 'Initials': 'XQ', 'LastName': 'He', 'Affiliation': 'Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Vijay', 'Initials': 'V', 'LastName': 'Harypursat', 'Affiliation': 'Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Yan-Qiu', 'Initials': 'YQ', 'LastName': 'Lu', 'Affiliation': 'Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Wan', 'Affiliation': 'Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Qiang-Zhong', 'Initials': 'QZ', 'LastName': 'Sun', 'Affiliation': 'Division of Tuberculosis, Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Nan-Nan', 'Initials': 'NN', 'LastName': 'Sun', 'Affiliation': 'Division of Tuberculosis, Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Gui-Xue', 'Initials': 'GX', 'LastName': 'Wang', 'Affiliation': 'School of Biological Engineering, Chongqing University, Chongqing, China.'}, {'ForeName': 'Zhong-Ping', 'Initials': 'ZP', 'LastName': 'Yang', 'Affiliation': 'National Key Laboratory for Infectious Diseases Prevention and Treatment with Traditional Chinese Medicine, Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Yao-Kai', 'Initials': 'YK', 'LastName': 'Chen', 'Affiliation': 'National Key Laboratory for Infectious Diseases Prevention and Treatment with Traditional Chinese Medicine, Chongqing Public Health Medical Center, Chongqing, China.'}]",Frontiers in pharmacology,['10.3389/fphar.2020.01071'] 2775,32765296,MNX (Medium Duration Nutrition and Resistance-Vibration Exercise) Bed-Rest: Effect of Resistance Vibration Exercise Alone or Combined With Whey Protein Supplementation on Cardiovascular System in 21-Day Head-Down Bed Rest.,"Current inflight countermeasures do not completely prevent bone and cardiovascular changes induced by microgravity. High load Resistance Exercise combined with whole body Vibration (RVE) demonstrated benefits on bone and cardiovascular system during previous Head-Down Bed Rest (HDBR) studies. We examined the effectiveness of RVE alone or combined with a nutritional supplementation of Whey protein (NeX) on cardiovascular deconditioning. Eight male subjects (age 34 ± 8 years) in a crossover design completed three 21-day HDBR campaigns (Control-CON, RVE, and NeX). Pre and post HDBR Orthostatic Tolerance (OT) was evaluated by a 15-min head-up tilt test followed by increasing levels of Lower Body Negative Pressure (LBNP). Heart rate (HR), blood pressure (BP), and Sympathetic Index (ΣI) through spectral analysis were measured during OT test. Plasma Volume (PV), and Maximal Oxygen Uptake (VO 2 max) were measured before and after each campaign. Left ventricular mass, left ventricular end diastolic (LVEDV), end systolic (LVESV), stroke (SV) volumes, and circumferential deformation at rest and during an orthostatic stress simulated by a 30 mmHg LBNP were measured by cardiac MRI. RVE failed to prevent any change in these variables and NeX did not have any additional effect over exercise alone. In the 3 groups, (1) OT time dropped similarly (bed rest p < 0.001), (2) HR and ΣI were increased at rest at the end of HDBR and HR increased markedly during LBNP-tilt test, with inability to increase further the ΣI, (3) PV dropped (bed rest p < 0.001), along with LVEDV, LVESV and SV ( p = 0.08, p < 0.001, and p = 0.045, respectively), (4) Left ventricle mass did not change significantly, (5) Deformation of the heart assessed by global circumferential strain was preserved and early diastolic circumferential strain rate was increased during orthostatic stress at the end of HDBR, illustrating preserved systolic and diastolic function respectively, without any difference between groups. Despite the drop in PV and LV volumes, RVE and NeX tended to alleviate the decrease in VO 2 max. In conclusion, RVE and NeX failed to prevent the cardiovascular deconditioning induced by a 21 day-HDBR.",2020,"In the 3 groups, (1) OT time dropped similarly (bed rest p < 0.001), (2) HR and ΣI were increased at rest at the end of HDBR and HR increased markedly during LBNP-tilt test, with inability to increase further the ΣI, (3) PV dropped (bed rest p < 0.001), along with LVEDV, LVESV and SV ( p = 0.08, p < 0.001, and p = 0.045, respectively), (4) Left ventricle mass did not change significantly, (5)",['Eight male subjects (age 34 ± 8 years'],"['21-day HDBR campaigns (Control-CON, RVE, and NeX', 'MNX (Medium Duration Nutrition and Resistance-Vibration Exercise', 'RVE', 'RVE alone or combined with a nutritional supplementation of Whey protein (NeX', 'High load Resistance Exercise combined with whole body Vibration (RVE', 'Resistance Vibration Exercise Alone or Combined With Whey Protein Supplementation']","['OT time', 'Left ventricular mass, left ventricular end diastolic (LVEDV), end systolic (LVESV), stroke (SV) volumes, and circumferential deformation at rest and during an orthostatic stress simulated by a 30 mmHg LBNP', 'Heart rate (HR), blood pressure (BP), and Sympathetic Index (ΣI) through spectral analysis', 'levels of Lower Body Negative Pressure (LBNP', 'Pre and post HDBR Orthostatic Tolerance (OT', 'Plasma Volume (PV), and Maximal Oxygen Uptake (VO 2 max', 'PV and LV volumes, RVE and NeX', 'cardiovascular deconditioning', 'diastolic circumferential strain rate', 'systolic and diastolic function', 'Cardiovascular System in 21-Day Head-Down Bed Rest']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0004910', 'cui_str': 'Bedrest'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0455825', 'cui_str': 'Left ventricular mass'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0038455', 'cui_str': 'Stroke volume'}, {'cui': 'C0205113', 'cui_str': 'Circumferential'}, {'cui': 'C0443144', 'cui_str': 'At rest'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0024047', 'cui_str': 'Negative lower body pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0004910', 'cui_str': 'Bedrest'}, {'cui': 'C0032127', 'cui_str': 'Blood plasma volume'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0242703', 'cui_str': 'Cardiovascular deconditioning'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",8.0,0.042841,"In the 3 groups, (1) OT time dropped similarly (bed rest p < 0.001), (2) HR and ΣI were increased at rest at the end of HDBR and HR increased markedly during LBNP-tilt test, with inability to increase further the ΣI, (3) PV dropped (bed rest p < 0.001), along with LVEDV, LVESV and SV ( p = 0.08, p < 0.001, and p = 0.045, respectively), (4) Left ventricle mass did not change significantly, (5)","[{'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Guinet', 'Affiliation': ""Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire de Rennes, Rennes, France.""}, {'ForeName': 'James Patrick', 'Initials': 'JP', 'LastName': 'MacNamara', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital, The University of Texas Southwestern Medical Center, Dallas, TX, United States.'}, {'ForeName': 'Matthieu', 'Initials': 'M', 'LastName': 'Berry', 'Affiliation': 'Ramsay Santé, Clinique des Cèdres, Toulouse, France.'}, {'ForeName': 'Françoise', 'Initials': 'F', 'LastName': 'Larcher', 'Affiliation': ""Laboratoire de Biochimie, Centre Hospitalier Universitaire d'Angers, Angers, France.""}, {'ForeName': 'Marie-Pierre', 'Initials': 'MP', 'LastName': 'Bareille', 'Affiliation': 'Institut de Médecine et de Physiologie Spatiales (MEDES), Toulouse, France.'}, {'ForeName': 'Marc-Antoine', 'Initials': 'MA', 'LastName': 'Custaud', 'Affiliation': ""Centre de Recherche Clinique, Centre Hospitalier Universitaire d'Angers, Angers, France.""}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Pavy-Le Traon', 'Affiliation': 'Department of Neurology, French Reference Center for MSA, University Hospital of Toulouse, Toulouse, France.'}, {'ForeName': 'Benjamin D', 'Initials': 'BD', 'LastName': 'Levine', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital, The University of Texas Southwestern Medical Center, Dallas, TX, United States.'}, {'ForeName': 'Nastassia', 'Initials': 'N', 'LastName': 'Navasiolava', 'Affiliation': ""Centre de Recherche Clinique, Centre Hospitalier Universitaire d'Angers, Angers, France.""}]",Frontiers in physiology,['10.3389/fphys.2020.00812'] 2776,32765315,Emotion Regulation as a Time-Invariant and Time-Varying Covariate Predicts Outcome in an Internet-Based Psychodynamic Treatment Targeting Adolescent Depression.,"Objective Although psychodynamic psychotherapy is efficacious in the treatment of depression, research on mechanisms of change is still scarce. The aim of this study was to investigate if and how emotion regulation affects outcome both as a time-invariant and a lagged time-varying predictor. Method The sample consisted of 67 adolescents diagnosed with major depressive disorder, attending affect-focused psychodynamic internet-based treatment (IPDT). Linear mixed models were used to analyze emotion regulation as a baseline predictor and to assess the effect of within-person changes in emotion regulation on depression. Results Analyses suggested that emotion regulation at baseline was a significant predictor of outcome, where participants with relatively larger emotion regulation deficits gained more from IPDT. Further, the results showed a significant effect of improved emotion regulation on subsequent depressive symptomatology. When not controlling for time, increased emotion regulation explained 41.23% of the variance in subsequent symptoms of depression. When detrending the results were still significant, but the amount of explained variance was reduced to 8.7%. Conclusion The findings suggest that patients with relatively larger deficits in emotion regulation gain more from IPDT. Decreased emotion regulation deficits seem to act as a mechanism of change in IPDT as it drives subsequent changes in depression. Clinical Trial Registration: International Standard Randomised Controlled Trial Number (ISRCTN) 16206254, https://doi.org/10.1186/ISRCTN16206254.",2020,"Results Analyses suggested that emotion regulation at baseline was a significant predictor of outcome, where participants with relatively larger emotion regulation deficits gained more from IPDT.","['67 adolescents diagnosed with major depressive disorder, attending affect-focused psychodynamic internet-based treatment (IPDT']","['psychodynamic psychotherapy', 'Internet-Based Psychodynamic Treatment']","['Decreased emotion regulation deficits', 'emotion regulation', 'emotion regulation gain', 'Emotion Regulation as a Time-Invariant and Time-Varying Covariate']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C1261382', 'cui_str': 'Psychodynamic psychotherapy'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",67.0,0.0707166,"Results Analyses suggested that emotion regulation at baseline was a significant predictor of outcome, where participants with relatively larger emotion regulation deficits gained more from IPDT.","[{'ForeName': 'Jakob', 'Initials': 'J', 'LastName': 'Mechler', 'Affiliation': 'Department of Psychology, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Lindqvist', 'Affiliation': 'Department of Psychology, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Fredrik', 'Initials': 'F', 'LastName': 'Falkenström', 'Affiliation': 'Department of Behavioural Sciences and Learning, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Carlbring', 'Affiliation': 'Department of Psychology, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Andersson', 'Affiliation': 'Department of Behavioural Sciences and Learning, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Björn', 'Initials': 'B', 'LastName': 'Philips', 'Affiliation': 'Department of Psychology, Stockholm University, Stockholm, Sweden.'}]",Frontiers in psychiatry,['10.3389/fpsyt.2020.00671'] 2777,32765653,Comparing post-operative analgesic effects of varying doses of dexmedetomidine as an adjuvant to ropivacaine for ultrasound-guided dual transversus abdominis plane block following laparotomy for gynecologic malignancies.,"The aim of the present study was to determine the analgesic effects of ropivacaine combined with different doses of dexmedetomidine for ultrasound-guided transversus abdominis plane (TAP) block immediately following laparotomy in patients with gynecologic malignancies. A further aim was to determine the appropriate clinical dose of dexmedetomidine as an adjuvant for ropivacaine. Patients with gynecologic malignancies scheduled for laparotomy were randomly assigned to group R (TAP block with 0.3% ropivacaine), group RD1 (TAP block with ropivacaine and 0.5 µg/kg dexmedetomidine), group RD2 (TAP block with ropivacaine and 1 µg/kg dexmedetomidine) and group RD3 (TAP block with ropivacaine and 2 µg/kg dexmedetomidine). TAP blocks were performed post-operatively. The four groups all received patient-controlled intravenous analgesia (PCIA) after the operation. The numerical rating scale (NRS) as well as the Ramsay sedation scale (RSS) scores, the first request time for PCIA bolus, oxycodone hydrochloride consumption, the plasma concentration of ropivacaine, the incidence of post-operative complications and adverse events, and patient satisfaction were recorded. Post-operative NRS scores at rest exhibited significant differences between the R group and all the RD groups at 24 h after surgery (P<0.05). Compared with the other groups, the NRS score in the RD3 group was decreased (P<0.05). The RSS scores were higher in all of the RD groups compared with those in the R group at 2 h (P<0.05) and were highest in the RD3 group compared with those in all other groups at 4 h (P<0.05). The first request time for PCIA was significantly longer in the RD3 group compared with that in the RD2, RD1 and R groups (510.47±102.67, 595.47±100.11, 682.43±104.46 and 776.42±143.91 min, respectively; P<0.05). Cumulative opioid consumption based on the number of PCIA bolus requested at 24 and 48 h post-operatively indicated that the total number of PCIA boluses was significantly lower in the RD groups compared with those in the R group at 24 and 48 h (P<0.05). The ropivacaine concentration did not differ among the four groups. There was no significant difference between groups with respect to post-operative nausea and vomiting, bradycardia and hypotension; however, all RD groups had a higher patient satisfaction than group R (P<0.05). Compared with that in the other groups, the duration of post-anesthesia care unit stay in group RD3 was relatively longer due to excessive sedation (P<0.05). In conclusion, TAP blockade using 0.5-2 µg/kg dexmedetomidine combined with 0.3% ropivacaine is a safe and effective treatment for analgesia in laparotomy procedures for gynecologic malignancies. The study was registered in the Chinese Clinical Trial Registry (CHICTR; www.chictr.org.cn) on January 15th, 2019 (registration no. ChiCTR1900020995).",2020,"There was no significant difference between groups with respect to post-operative nausea and vomiting, bradycardia and hypotension; however, all RD groups had a higher patient satisfaction than group R (P<0.05).","['laparotomy for gynecologic malignancies', 'patients with gynecologic malignancies', 'Patients with gynecologic malignancies scheduled for laparotomy']","['ropivacaine', 'ultrasound-guided transversus abdominis plane (TAP) block immediately following laparotomy', 'group R (TAP block with 0.3% ropivacaine), group RD1 (TAP block with ropivacaine and 0.5 µg/kg dexmedetomidine), group RD2 (TAP block with ropivacaine and 1 µg/kg dexmedetomidine) and group RD3 (TAP block with ropivacaine and 2 µg/kg dexmedetomidine', 'TAP blockade', 'dexmedetomidine', 'patient-controlled intravenous analgesia (PCIA']","['NRS score', 'analgesic effects', 'request time for PCIA', 'RSS scores', 'Cumulative opioid consumption', 'patient satisfaction', 'numerical rating scale (NRS', 'total number of PCIA boluses', 'Ramsay sedation scale (RSS) scores, the first request time for PCIA bolus, oxycodone hydrochloride consumption, the plasma concentration of ropivacaine, the incidence of post-operative complications and adverse events, and patient satisfaction', 'Post-operative NRS scores', 'ropivacaine concentration', 'post-operative nausea and vomiting, bradycardia and hypotension']","[{'cui': 'C0023038', 'cui_str': 'Laparotomy'}, {'cui': 'C0205480', 'cui_str': 'Gynecologic'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}]","[{'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0023038', 'cui_str': 'Laparotomy'}, {'cui': 'C0441852', 'cui_str': 'Group R'}, {'cui': 'C4068885', 'cui_str': '0.3'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0332206', 'cui_str': 'Blocking'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C1272683', 'cui_str': 'Requested'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0559295', 'cui_str': 'Ramsay sedation scale'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0282274', 'cui_str': 'Oxycodone hydrochloride'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}]",,0.0466807,"There was no significant difference between groups with respect to post-operative nausea and vomiting, bradycardia and hypotension; however, all RD groups had a higher patient satisfaction than group R (P<0.05).","[{'ForeName': 'Yuexiang', 'Initials': 'Y', 'LastName': 'Zeng', 'Affiliation': 'Department of Anesthesiology, Hunan Cancer Hospital, Changsha, Hunan 410013, P.R. China.'}, {'ForeName': 'Yiyun', 'Initials': 'Y', 'LastName': 'Wen', 'Affiliation': 'Department of Anesthesiology, Hunan Cancer Hospital, Changsha, Hunan 410013, P.R. China.'}, {'ForeName': 'Jinfeng', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, Hunan Cancer Hospital, Changsha, Hunan 410013, P.R. China.'}, {'ForeName': 'Huiping', 'Initials': 'H', 'LastName': 'Sun', 'Affiliation': 'Department of Anesthesiology, Hunan Cancer Hospital, Changsha, Hunan 410013, P.R. China.'}]",Experimental and therapeutic medicine,['10.3892/etm.2020.8787'] 2778,32765694,Expression of ADP and TNF-α in patients with gestational diabetes mellitus and its relationship with pregnancy outcomes.,"Expression of adiponectin (ADP) and tumor necrosis factor-α (TNF-α) in patients with gestational diabetes mellitus and its relationship with pregnancy outcomes was explored. A total of 78 patients with gestational diabetes mellitus admitted to Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University from June 2017 to December 2018 were enrolled as an experimental group, and further 70 healthy pregnant women in physical examination during the same period were enrolled as a control group. Concentrations of ADP and TNF-α were determined and compared between the two groups. The patients were divided into high ADP expression group (≥6.84), low ADP expression group (<6.84), high TNF-α expression group (≥6.17) and low TNF-α expression group (<6.17). Corresponding two groups were compared in terms of adverse pregnancy outcomes, respectively, and they were also compared with the control group. The clinical association between ADP and TNF-α was analyzed. TNF-α was highly expressed in the blood of patients with gestational diabetes mellitus, while ADP expression was low in the blood. The low expression of ADP was related to age, pregestational body mass index (BMI), gestational week, medical history and family history of diabetes mellitus (all P<0.05), and the high expression of TNF-α was related to age, pregestational BMI, gestational week, medical history, amniotic fluid volume, abortion history, and family history of diabetes mellitus (all P<0.05). The experimental group faced a higher risk of adverse pregnancy outcomes than the control group. Both ADP and TNF-α are abnormally expressed in the patients with gestational diabetes mellitus, and TNF-α is affected by more of the factors. The concentrations of ADP and TNF-α affect the pregnancy outcomes. It suggests that ADP and TNF-α can be used as indexes for predicating pregnancy outcomes, and for judging the disease conditions and treatment of patients.",2020,Expression of adiponectin (ADP) and tumor necrosis factor-α (TNF-α) in patients with gestational diabetes mellitus and its relationship with pregnancy outcomes was explored.,"['78 patients with gestational diabetes mellitus admitted to Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University from June 2017 to December 2018 were enrolled as an experimental group, and further 70 healthy pregnant women in physical examination during the same period were enrolled as a control group', 'patients with gestational diabetes mellitus']","['TNF-α', 'low TNF-α expression', 'ADP and TNF-α', 'TNF-α expression', 'low ADP expression']","['Expression of adiponectin (ADP) and tumor necrosis factor-α (TNF-α', 'adverse pregnancy outcomes', 'low expression of ADP', 'Concentrations of ADP and TNF-α', 'concentrations of ADP and TNF-α affect the pregnancy outcomes', 'ADP expression']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085207', 'cui_str': 'Gestational diabetes mellitus'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C1253959', 'cui_str': 'Branch of'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}]","[{'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0032972', 'cui_str': 'Outcomes, Pregnancy'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0001721', 'cui_str': 'Affect'}]",78.0,0.0117267,Expression of adiponectin (ADP) and tumor necrosis factor-α (TNF-α) in patients with gestational diabetes mellitus and its relationship with pregnancy outcomes was explored.,"[{'ForeName': 'Wengong', 'Initials': 'W', 'LastName': 'Wei', 'Affiliation': 'Department of Obstetrics and Gynecology, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai 201700, P.R. China.'}, {'ForeName': 'Xiaoping', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Obstetrics and Gynecology, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai 201700, P.R. China.'}]",Experimental and therapeutic medicine,['10.3892/etm.2020.8952'] 2779,32765709,Effects of vacuum sealing drainage to improve the therapeutic effect in patients with orthopedic trauma and to reduce post-operative infection and lower-limb deep venous thrombosis.,"The present study investigated the effects of vacuum sealing drainage (VSD) to improve the therapeutic efficacy in patients with orthopedic trauma (OT) and reduce post-operative infection and lower-limb deep venous thrombosis (DVT) through a retrospective analysis. A total of 76 patients with OT treated at our hospital were selected for observation. The patients were divided into the control group (CG; n=37) and the experimental group (EG; n=39) according to the treatment administered. For patients in the CG, routine dressing changes were applied. Patients in the EG underwent VSD treatment. The dressing change frequency, time between the first and second operation, hospital stay, treatment efficacy, wound healing time, interleukin-6 (IL-6) serum level, tumor necrosis factor-α (TNF-α) serum level, incidence of post-operative infection and incidence of lower-limb DVT were compared between the two groups. The dressing change frequency in the EG was less than that in the CG. The time between the first and second operation and hospital stay were shorter in the EG than in the CG (P<0.05). The total effective rate in the EG was 97.44%, which was higher than that in the CG (78.38%; P<0.05). The wound healing time in the EG was 1.72±0.73 weeks and shorter than that in the CG (2.23±0.85 weeks; P<0.05). With the progression of treatment, the serum IL-6 and TNF-α levels decreased in the two groups, but the levels in the EG were lower than those in the CG (P<0.05). The incidence of post-operative infection and lower-limb venous thrombosis in the EG were 7.69 and 0.00%, respectively, and lower than those in the CG (27.03 and 13.01%, respectively; P<0.05). In the treatment of OT, VSD may reduce the dressing change frequency, shorten the operation time and hospital stay, accelerate wound healing and reduce post-operative infection and lower-limb DVT. Thus, the VSD treatment method is worthy of promotion and implementation in clinic.",2020,The time between the first and second operation and hospital stay were shorter in the EG than in the CG (P<0.05).,"['76 patients with OT treated at our hospital were selected for observation', 'patients with orthopedic trauma (OT) and reduce post-operative infection and lower-limb deep venous thrombosis (DVT', 'patients with orthopedic trauma and to reduce post-operative infection and lower-limb deep venous thrombosis']","['vacuum sealing drainage', 'vacuum sealing drainage (VSD']","['total effective rate', 'wound healing time', 'therapeutic effect', 'dressing change frequency, time between the first and second operation, hospital stay, treatment efficacy, wound healing time, interleukin-6 (IL-6) serum level, tumor necrosis factor-α (TNF-α) serum level', 'incidence of post-operative infection and incidence of lower-limb DVT', 'serum IL-6 and TNF-α levels', 'time between the first and second operation and hospital stay', 'incidence of post-operative infection and lower-limb venous thrombosis', 'operation time and hospital stay, accelerate wound healing and reduce post-operative infection and lower-limb DVT', 'therapeutic efficacy']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1274117', 'cui_str': 'Trauma & orthopedics'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}]","[{'cui': 'C0042221', 'cui_str': 'Vacuum'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0085671', 'cui_str': 'Change of dressing'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0042487', 'cui_str': 'Venous thrombosis'}, {'cui': 'C0521110', 'cui_str': 'Accelerated'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",76.0,0.0119716,The time between the first and second operation and hospital stay were shorter in the EG than in the CG (P<0.05).,"[{'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Orthopaedics, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China.'}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Department of Orthopedics, Shandong Provincial ENT Hospital Affiliated to Shandong University, Jinan, Shandong 250000, P.R. China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'Department of Orthopaedics, Binzhou Central Hospital Affiliated to Binzhou Medical University, Binzhou, Shandong 251700, P.R. China.'}, {'ForeName': 'Pingping', 'Initials': 'P', 'LastName': 'He', 'Affiliation': 'Department of Clinical Pharmacy, Binzhou Central Hospital Affiliated to Binzhou Medical University, Binzhou, Shandong 251700, P.R. China.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'Department of Orthopaedics, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China.'}, {'ForeName': 'Zhanhui', 'Initials': 'Z', 'LastName': 'Lv', 'Affiliation': 'Department of Orthopaedics, Binzhou Central Hospital Affiliated to Binzhou Medical University, Binzhou, Shandong 251700, P.R. China.'}, {'ForeName': 'Yixin', 'Initials': 'Y', 'LastName': 'Shen', 'Affiliation': 'Department of Orthopaedics, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China.'}]",Experimental and therapeutic medicine,['10.3892/etm.2020.8941'] 2780,32765904,Blood Pressure Variability and Severity of Early Prognosis in Patients with Acute Pontine Infarction.,"Background Increased blood pressure (BP) variability may worsen the prognosis of stroke. This study aimed at investigating the association between BP variability and early functional prognosis in patients with pontine infarction. Methods According to types of pontine infarction, all the 137 patients were divided into two groups: 70 patients with paramedian pontine infarction (PPI) and 67 patients with deep pontine infarction (DPI). Common risk factors, 24-hour continuous blood pressure monitoring data, and the coefficient of variation were collected after admission in the hospital. Functional outcomes were evaluated with modified Rankin scale (mRS) at 3 months after discharge (favorable outcome: mRS scores ≤ 2; poor outcome: mRS scores > 2). Results The level of Glu, HbA1c, LDL, and NIHSS scores in the PPI group was significantly higher than that in the DPI group, and the concentration of blood uric acid was lower in the PPI group. Diastolic pressure in the PPI group is significantly higher than that in the DPI group, and coefficient of variation (CV) of systolic pressure in PPI is higher when compared with DPI ((88.77 ± 1.71) mmHg vs. (80.74 ± 1.31) mmHg; (11.54 ± 0.35) vs. (10.24 ± 0.25)). In multivariate analyses, the CV of systolic pressure, diastolic pressure, NIHSS scores, and the paramedian pontine infarction was independently associated with 3-month clinical outcome (OR = 1.94, 95% CI = 1.252-2.994, P =0.003; OR = 1.08, 95% CI = 1.002-1.166, P =0.04; OR = 1.58, 95% CI = 1.164-2.159, P =0.003; OR = 9.87, 95% CI = 1.045-32.193, P =0.04). Conclusion In conclusion, increased 24-hour (BP) variability, NIHSS scores, and paramedian pontine were associated with early poor prognosis in patients with acute pontine infarction.",2020,"The level of Glu, HbA1c, LDL, and NIHSS scores in the PPI group was significantly higher than that in the DPI group, and the concentration of blood uric acid was lower in the PPI group.","['137 patients were divided into two groups: 70 patients with paramedian pontine infarction (PPI) and 67 patients with deep pontine infarction (DPI', 'patients with acute pontine infarction', 'Patients with Acute Pontine Infarction', 'patients with pontine infarction']",['mRS'],"['Diastolic pressure', 'Blood Pressure Variability and Severity of Early Prognosis', 'level of Glu, HbA1c, LDL, and NIHSS scores', 'concentration of blood uric acid', 'coefficient of variation (CV) of systolic pressure in PPI', 'modified Rankin scale (mRS', 'CV of systolic pressure, diastolic pressure, NIHSS scores, and the paramedian pontine infarction', 'blood pressure (BP) variability', 'BP variability and early functional prognosis', '24-hour (BP) variability, NIHSS scores, and paramedian pontine']","[{'cui': 'C4517569', 'cui_str': '137'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441993', 'cui_str': 'Paramedian approach'}, {'cui': 'C0877587', 'cui_str': 'Pontine infarction'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}]","[{'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0033325', 'cui_str': 'Determination of prognosis'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0061055', 'cui_str': 'gamma-glutamyl-alpha-aminobutyrate'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C1697238', 'cui_str': 'NIH stroke scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0373739', 'cui_str': 'Blood uric acid'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0441993', 'cui_str': 'Paramedian approach'}, {'cui': 'C0877587', 'cui_str': 'Pontine infarction'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0032639', 'cui_str': 'Pontine structure'}]",137.0,0.0464049,"The level of Glu, HbA1c, LDL, and NIHSS scores in the PPI group was significantly higher than that in the DPI group, and the concentration of blood uric acid was lower in the PPI group.","[{'ForeName': 'Xinsheng', 'Initials': 'X', 'LastName': 'Han', 'Affiliation': 'The Fifth Ward of Neurology Department, Kaifeng Central Hospital, Kaifeng 475000, Henan Province, China.'}, {'ForeName': 'Gaocai', 'Initials': 'G', 'LastName': 'Zhang', 'Affiliation': 'The Fifth Ward of Neurology Department, Kaifeng Central Hospital, Kaifeng 475000, Henan Province, China.'}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Liu', 'Affiliation': 'The Fifth Ward of Neurology Department, Kaifeng Central Hospital, Kaifeng 475000, Henan Province, China.'}, {'ForeName': 'Hongyang', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'The Fifth Ward of Neurology Department, Kaifeng Central Hospital, Kaifeng 475000, Henan Province, China.'}, {'ForeName': 'Jianke', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'The Fifth Ward of Neurology Department, Kaifeng Central Hospital, Kaifeng 475000, Henan Province, China.'}, {'ForeName': 'Miao', 'Initials': 'M', 'LastName': 'Han', 'Affiliation': 'The Fifth Ward of Neurology Department, Kaifeng Central Hospital, Kaifeng 475000, Henan Province, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'The Fifth Ward of Neurology Department, Kaifeng Central Hospital, Kaifeng 475000, Henan Province, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'The Fifth Ward of Neurology Department, Kaifeng Central Hospital, Kaifeng 475000, Henan Province, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': ""The Child Neurology Department, Kaifeng Children's Hospital, Kaifeng 475000, Henan Province, China.""}]",International journal of hypertension,['10.1155/2020/1203546'] 2781,32762505,Effect of apple vinegar intake on metabolic parameters and constipation in patients with schizophrenia treated with clozapine: a pilot study.,"PURPOSE Clozapine is one of the drugs that cause the highest level of weight gain. Additionally, obese patients are at higher risk of developing various physical co-morbidities, such as type 2 diabetes and cardiovascular diseases. Forty-nine percent of patients on clozapine suffer from constipation. Apple vinegar (AV) had been assigned health benefits, such as weight loss, laxative properties, blood glucose lowering effects, and reducing the risk of heart disease. Our hypothesis was that AV would lower the mean glycated haemoglobin level and reduce the level of constipation. MATERIAL AND METHODS Pilot intervention study with a 12-week follow-up. All patients receiving clozapine treatment for schizophrenia at one outpatient clinic were eligible for inclusion. Intervention: Ten millilitres of AV diluted in 200 ml drinking water with breakfast and dinner. RESULTS Forty patients were suitable for inclusion and nine completed the intervention. Women had much higher-than-recommended body mass index. Scores for constipation were high. The reduction in constipation was of clinical interest (2.6 ( p  = 0.017)). However, there were no statistically significant differences in glycated haemoglobin, cholesterol, HDL, LDL or triglyceride levels. Patients with problems of constipation prior to the intervention experienced much better bowel habits and relief of their constipation. CONCLUSION AV lower the constipation problems faced by patients with schizophrenia treated with clozapine. Further research, repeating this pilot study with a meaningfully larger sample size and randomized with placebo, is needed.",2020,The reduction in constipation was of clinical interest (2.6 ( p  = 0.017)).,"['treatment for schizophrenia at one outpatient clinic were eligible for inclusion', 'patients with schizophrenia treated with', 'Forty patients were suitable for inclusion and nine completed the intervention']","['clozapine', 'apple vinegar intake', 'Clozapine', 'Apple vinegar (AV', 'Intervention', 'placebo']","['bowel habits and relief of their constipation', 'level of constipation', 'mean glycated haemoglobin level', 'reduction in constipation', 'glycated haemoglobin, cholesterol, HDL, LDL or triglyceride levels', 'metabolic parameters and constipation']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0009079', 'cui_str': 'Clozapine'}, {'cui': 'C0003625', 'cui_str': 'Malus'}, {'cui': 'C0148405', 'cui_str': 'Vinegar'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0202236', 'cui_str': 'Triglycerides measurement'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",40.0,0.0252899,The reduction in constipation was of clinical interest (2.6 ( p  = 0.017)).,"[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hjorth', 'Affiliation': 'Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Sebastian Markvard', 'Initials': 'SM', 'LastName': 'Petersen', 'Affiliation': 'Sociology, Psychiatric Hospital, Vejle, Denmark.'}, {'ForeName': 'Tine Louise', 'Initials': 'TL', 'LastName': 'Launholt', 'Affiliation': 'Human Nutrition, UCL, Vejle, Denmark.'}, {'ForeName': 'Connie Thurøe', 'Initials': 'CT', 'LastName': 'Nielsen', 'Affiliation': 'Psychiatric Hospital, Vejle, Denmark.'}]",Nordic journal of psychiatry,['10.1080/08039488.2020.1799432'] 2782,32762573,The accuracy of self-report logbooks of adherence to prescribed home-based exercise in Parkinson's disease.,"PURPOSE This study compared self-report logbooks of exercise performance to objective measures of performance to determine the accuracy of and patterns of misreporting in self-report logbooks in people with Parkinson's disease. MATERIALS AND METHODS Fifteen participants from the intervention arm of a randomized control trial were prescribed a minimally supervised, 12-week, home-based upper limb exergame program (ACTRN 12614001048673). The exergame system provided an objective electronic measure of adherence for comparison with self-report logbooks. RESULTS Logbooks showed excellent to good accuracy of overall reported adherence to prescribed sessions (Intraclass correlation (ICC) = 0.83) and games (ICC 0.71). Logbooks were also a good to fair representation of weekly adherence across participants for both sessions (ICC 0.66) and games (ICC 0.56). Individual participant ICCs ranged from minimal to perfect agreement between logbooks and electronic records (ICC sessions range: -0.02 to 1; games range: -0.24 to 0.99). The pattern of logbook reporting suggested some participants were biasing entries to match prescribed exercise. CONCLUSIONS Self-report logbooks may provide an accurate measure of overall adherence. However, the accuracy of individual logbooks was highly variable indicating caution is needed in using self-report measures to assess individual adherence in intervention studies and for clinical decision making. Clinical Trial Registration: Registered in Australia and New Zealand Clinical Trials Registry (https://www.anzctr.org.au/): Registration number: ACTRN12614001048673. Implications for rehabilitation Adherence to prescribed unsupervised exercise is usually self-reported. Self-reported logbooks gave a good to excellent indication of exercise adherence overall when compared to electronically captured records for a group of participants with mild to moderate Parkinson's disease. There were high levels of variability in the accuracy of individual logbooks with a tendency to record prescribed rather than actual exercise. Logbooks may be accurate to monitor group adherence, but caution is required when using them to assess an individual's adherence to an exercise prescription.",2020,Logbooks were also a good to fair representation of weekly adherence across participants for both sessions (ICC 0.66) and games (ICC 0.56).,"['Fifteen participants from the intervention arm of a randomized control trial were prescribed a', ""Parkinson's disease"", ""people with Parkinson's disease"", ""participants with mild to moderate Parkinson's disease""]","['minimally supervised, 12-week, home-based upper limb exergame program', 'https://www.anzctr.org.au']",[],"[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0282440', 'cui_str': 'Randomized Controlled Trials as Topic'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]",[],15.0,0.0467637,Logbooks were also a good to fair representation of weekly adherence across participants for both sessions (ICC 0.66) and games (ICC 0.56).,"[{'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Schmidt', 'Affiliation': 'School of Health Sciences, College of Health and Medicine, University of Tasmania, Hobart, Australia.'}, {'ForeName': 'Serene S', 'Initials': 'SS', 'LastName': 'Paul', 'Affiliation': 'Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.'}, {'ForeName': 'Colleen G', 'Initials': 'CG', 'LastName': 'Canning', 'Affiliation': 'Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.'}, {'ForeName': 'Jooeun', 'Initials': 'J', 'LastName': 'Song', 'Affiliation': 'Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Smith', 'Affiliation': 'School of Health and Human Sciences, Southern Cross University, Coffs Harbour, Australia.'}, {'ForeName': 'Rachelle', 'Initials': 'R', 'LastName': 'Love', 'Affiliation': 'Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.'}, {'ForeName': 'Natalie E', 'Initials': 'NE', 'LastName': 'Allen', 'Affiliation': 'Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.'}]",Disability and rehabilitation,['10.1080/09638288.2020.1800106'] 2783,32762590,Communicating value to patients-a high value care communication skills curriculum.,"INTRODUCTION With rising health care costs in the United States, trainees will be increasingly challenged in discussing testing stewardship with patients. OBJECTIVE We piloted a high value care (HVC) communication skills curriculum utilizing the Four Habits Model for communication. We hoped residents would 1) learn to apply the Four Habits communication model to HVC discussions with standardized patients (SP) and 2) improve value-based communication skills through training in a high intensity curriculum with feedback from trained faculty facilitators and peers. Methods: Thirty interns at the University of Minnesota were randomized to a standard HVC communication SP encounter (n=15) or a high intensity HVC communication skills curriculum (n=15). The high intensity curriculum included video and audio-recorded SP encounters followed by facilitated small group discussions/feedback. Experiences were reported in a post intervention survey; communication skills were assessed with the CARE empathy scale. RESULTS 70% (21/30) of interns (57% high intensity, 43% standard) responded to the survey. 88% of high intensity v. 44% of standard interns agreed/strongly agreed that the curriculum was valuable for their communication skills. High intensity interns were more likely to report that feedback was valuable with subsequent incorporation of feedback into future patient encounters. High intensity participants also reported higher levels of interest in future HVC curricula (55% vs 22%). Conclusion: There was no difference in overall performance on the CARE empathy scale. Our HVC high intensity skills curriculum was well received by interns and provided opportunities to practice structured conversations and debrief around testing stewardship.",2020,88% of high intensity v. 44% of standard interns agreed/strongly agreed that the curriculum was valuable for their communication skills.,['Thirty interns at the University of Minnesota'],['standard HVC communication SP encounter (n=15) or a high intensity HVC communication skills curriculum'],"['CARE empathy scale', 'overall performance on the CARE empathy scale']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0026183', 'cui_str': 'Minnesota'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0870313', 'cui_str': 'Communication skills'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}]","[{'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.0332911,88% of high intensity v. 44% of standard interns agreed/strongly agreed that the curriculum was valuable for their communication skills.,"[{'ForeName': 'Alisa', 'Initials': 'A', 'LastName': 'Duran', 'Affiliation': ""Section of Women's Health and General Internal Medicine, Minneapolis VA Health Care System, University of Minnesota.""}, {'ForeName': 'Crystal', 'Initials': 'C', 'LastName': 'Donelan', 'Affiliation': 'Dept of Emergency Medicine, George Washington University.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Bowman Peterson', 'Affiliation': 'University of Minnesota.'}, {'ForeName': 'Sophia P', 'Initials': 'SP', 'LastName': 'Gladding', 'Affiliation': 'University of Minnesota.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Weissmann', 'Affiliation': 'University of Minnesota.'}, {'ForeName': 'Craig S', 'Initials': 'CS', 'LastName': 'Roth', 'Affiliation': 'University of Minnesota.'}]",Postgraduate medicine,['10.1080/00325481.2020.1807728'] 2784,32762632,"The Hip Suction Seal, Part II: The Effect of Rim Trimming, Chondrolabral Junction Separation, and Labral Repair/Refixation on Hip Distractive Stability.","BACKGROUND The acetabular labrum contains free nerve endings, and an unstable labrum can result in increased femoral head movement during hip motion. This can be caused by chondrolabral junction (CLJ) separation, especially in association with pincer-type femoroacetabular impingement, and may contribute to hip pain. HYPOTHESIS Rim resection alone has no effect on suction seal biomechanics. Further, separation of the CLJ changes hip suction seal biomechanics when compared with those of the native state, whereas repair and refixation with suture anchors restore these biomechanical parameters. STUDY DESIGN Controlled laboratory study. METHODS A total of 12 fresh-frozen human cadaveric hips were used in this study. Hips were mounted in a saline bath on a dynamic tensile testing machine and were distracted at a rate of 0.5 mm/s from neutral position. A total of 3 parameters (force, displacement, and intra-articular pressure) were measured throughout testing. Before testing, hips were randomly allocated to 1 of 2 groups: 1 that included the CLJ separation (CLJ Cut group) and 1 that did not (CLJ Intact group). Hips were tested in the following states: (1) native, (2) rim trimming, (3) separated CLJ (CLJ Cut group only), and (4) labral repair/refixation. For each group a linear mixed-effects model was used to compare biomechanical parameters between states. RESULTS Rim trimming did not affect any suction seal parameters relative to those of the native state. In the CLJ Cut group, no significant difference in distance to break the suction seal was observed for any states compared with that of the native state. In the CLJ Intact group, the distance to break the suction seal was significantly shorter in the labral refixation state (1.8 mm) than the native state (5.6 mm; P = .002). The maximum distraction force (62.1 ± 54.1 N) and the peak negative pressure (-36.6 ± 24.2 kPa) of the labral repair/refixation state were significantly lower than those of the native state in both groups (93.4 ± 41.7 N, P = .01; -60.7 ± 20.4 kPa, P = .02). CONCLUSION Rim trimming did not change the biomechanical properties of the labral suction seal. Labral refixation resulted in a shorter distance to break the labral suction seal. This indicates that labral mobility is reduced by the labral refixation procedure, which could be beneficial in postoperative pain relief and labral healing. CLINICAL RELEVANCE The labral refixation reduced labral mobility, which could be beneficial for both pain relief and labral healing to the acetabulum after pincer-type femoroacetabular impingement resection.",2020,"In the CLJ Cut group, no significant difference in distance to break the suction seal was observed for any states compared with that of the native state.",['A total of 12 fresh-frozen human cadaveric hips'],"['CLJ (CLJ Cut group only), and (4) labral repair/refixation', 'CLJ separation (CLJ Cut group) and 1 that did not (CLJ Intact group', 'Rim Trimming, Chondrolabral Junction Separation, and Labral Repair/Refixation']","['maximum distraction force', 'labral repair/refixation state', 'distance to break the suction seal', 'suction seal parameters', 'pain relief and labral healing', 'peak negative pressure', 'labral refixation state', 'suction seal biomechanics']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0443224', 'cui_str': 'Fresh'}, {'cui': 'C0016701', 'cui_str': 'Freezing'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}]","[{'cui': 'C0205144', 'cui_str': 'Junctional'}, {'cui': 'C0000925', 'cui_str': 'Incised wound'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0185042', 'cui_str': 'Reattachment - action'}, {'cui': 'C0036679', 'cui_str': 'Separation'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0556630', 'cui_str': 'Anal penetration using tongue'}, {'cui': 'C0441645', 'cui_str': 'Trimming - action'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0150189', 'cui_str': 'Distraction training'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0185042', 'cui_str': 'Reattachment - action'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0038638', 'cui_str': 'Suction drainage'}, {'cui': 'C0036492', 'cui_str': 'Seal'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}]",12.0,0.0360113,"In the CLJ Cut group, no significant difference in distance to break the suction seal was observed for any states compared with that of the native state.","[{'ForeName': 'Hajime', 'Initials': 'H', 'LastName': 'Utsunomiya', 'Affiliation': 'Steadman Philippon Research Institute, Vail, Colorado, USA.'}, {'ForeName': 'Hunter W', 'Initials': 'HW', 'LastName': 'Storaci', 'Affiliation': 'Steadman Philippon Research Institute, Vail, Colorado, USA.'}, {'ForeName': 'Samuel I', 'Initials': 'SI', 'LastName': 'Rosenberg', 'Affiliation': 'Steadman Philippon Research Institute, Vail, Colorado, USA.'}, {'ForeName': 'Bryson R', 'Initials': 'BR', 'LastName': 'Kemler', 'Affiliation': 'Steadman Philippon Research Institute, Vail, Colorado, USA.'}, {'ForeName': 'Grant J', 'Initials': 'GJ', 'LastName': 'Dornan', 'Affiliation': 'Steadman Philippon Research Institute, Vail, Colorado, USA.'}, {'ForeName': 'Alex W', 'Initials': 'AW', 'LastName': 'Brady', 'Affiliation': 'Steadman Philippon Research Institute, Vail, Colorado, USA.'}, {'ForeName': 'Marc J', 'Initials': 'MJ', 'LastName': 'Philippon', 'Affiliation': 'Steadman Philippon Research Institute, Vail, Colorado, USA.'}]",The American journal of sports medicine,['10.1177/0363546520941859'] 2785,32762792,The Art of Remediating Age-Related Cognitive Decline: Art Therapy Enhances Cognition and Increases Cortical Thickness in Mild Cognitive Impairment.,"OBJECTIVE Previous research on art therapy (AT) in cognitive aging has been lacking. AT can potentially engender significant cognitive gains, due to its rigorous cognitive involvement, making it useful to tackle age-related cognitive decline. Along with these cognitive gains, associated neuroplastic changes are hypothesized to arise from AT as well. The current intervention examined the effects of an AT intervention on cognitive outcomes and cortical thickness (CT) among participants with mild cognitive impairment. METHOD Participants were assigned to AT (n = 22) and an active control group (n = 27). In both, weekly 45-min sessions were carried out across 3 months. Cognitive assessments and structural magnetic resonance imaging scans were carried out at baseline and 3-month follow-up. Whole brain analyses on CT were carried out. Cognitive outcomes were analyzed using hierarchical linear models. RESULTS Significant gains in immediate memory and working memory span were observed in the AT group, relative to the control group. Significantly increased CT in the AT group, relative to controls, was observed in a right middle frontal gyrus (MFG) cluster. Furthermore, CT changes in this cluster were significantly and positively correlated with changes in immediate memory. CONCLUSION These findings highlighted the role of MFG neuroplasticity in enhancing certain cognitive functions in AT. AT is a neuroplastic intervention capable of engendering significant cognitive gains and associated cortical changes in the context of age-related cognitive decline, even when executed as a low-intensity intervention across 3 months. Given the preliminary nature of these findings, future larger sampled studies are needed.",2020,"Significantly increased CT in the AT group, relative to controls, was observed in a right middle frontal gyrus (MFG) cluster.","['Mild Cognitive Impairment', 'Participants were assigned to AT (n = 22) and an active control group (n = 27', 'participants with mild cognitive impairment']",['AT intervention'],"['immediate memory and working memory span', 'cognitive outcomes and cortical thickness (CT', 'Cognitive outcomes', 'CT', 'immediate memory']","[{'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0003827', 'cui_str': 'Art therapy'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0003827', 'cui_str': 'Art therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}]",27.0,0.0134496,"Significantly increased CT in the AT group, relative to controls, was observed in a right middle frontal gyrus (MFG) cluster.","[{'ForeName': 'Junhong', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Department of Psychological Medicine, Mind Science Centre, Yong Loo Lin School of Medicine, National University of Singapore, 119077 Singapore, Singapore.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Rawtaer', 'Affiliation': 'Department of Psychiatry, Sengkang General Hospital, 544886 Singapore, Singapore.'}, {'ForeName': 'Lee Gan', 'Initials': 'LG', 'LastName': 'Goh', 'Affiliation': 'Department of Family Medicine, National University Health System, 119228 Singapore, Singapore.'}, {'ForeName': 'Alan Prem', 'Initials': 'AP', 'LastName': 'Kumar', 'Affiliation': 'Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 117600 Singapore, Singapore.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Feng', 'Affiliation': 'Department of Psychological Medicine, Mind Science Centre, Yong Loo Lin School of Medicine, National University of Singapore, 119077 Singapore, Singapore.'}, {'ForeName': 'Ee Heok', 'Initials': 'EH', 'LastName': 'Kua', 'Affiliation': 'Department of Psychological Medicine, Mind Science Centre, Yong Loo Lin School of Medicine, National University of Singapore, 119077 Singapore, Singapore.'}, {'ForeName': 'Rathi', 'Initials': 'R', 'LastName': 'Mahendran', 'Affiliation': 'Department of Psychological Medicine, Mind Science Centre, Yong Loo Lin School of Medicine, National University of Singapore, 119077 Singapore, Singapore.'}]",Journal of the International Neuropsychological Society : JINS,['10.1017/S1355617720000697'] 2786,32762882,A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study.,"BACKGROUND Recent studies report incongruent finds regarding the addition of pegylated interferon -alpha (Peg- IFNα) to nucleos(t)ide analogues. This study was designed to compare the efficacy of Peg- IFNα and tenofovir disoproxil fumarate (TDF) combination therapy with each of the treatments separately. METHODS In this open-label, randomized clinical trial, treatment-naive hepatitis B e antigen (HBeAg)-negative patients were randomly assigned to three treatment groups: Group A: Peg- IFNα (180 mcg/week) with TDF (300 mg/day); Group B: TDF (300 mg/day); and Group C: Peg- IFNα (180 mcg/week). The intervention spanned 48 weeks and patients were followed up every 12 weeks. The primary end-point was HBV DNA load <20 IU/mL. RESULTS Groups A, B and C each comprised of 22, 23 and 22 patients, respectively. The number of patients with HBV DNA suppression in group A was significantly higher compared to groups B and C (P = 0.034). No significant difference was observed in the normalization trends of serum ALT levels between the three groups (P = 0.082). At week 48, combination therapy was significantly more effective in suppressing HBV DNA concentration to below the level of detection than TDF monotherapy (OR = 2.1, 95%CI: 1.18-4.15; P = 0.034). Furthermore, a comparison between monotherapy arms revealed that both interventions had similar effects on the overall outcome (OR = 1.24, 95%CI: 1.02-5.8; P = 0.062). CONCLUSION A Peg- IFNα and TDF combination therapy resulted in improved virologic response and was safe in HBeAg negative patients. Monotherapy with Peg-IFNα or TDF procured limited benefits in comparison. TRIAL REGISTRATION This study was registered in the Iranian Registry of Clinical Trials (IRCT20181113041635N1).",2020,No significant difference was observed in the normalization trends of serum ALT levels between the three groups (P = 0.082).,"['hepatitis B e antigen-negative chronic hepatitis B', 'treatment-naive hepatitis B e antigen (HBeAg)-negative patients']","['pegylated interferon-alpha with tenofovir disoproxil fumarate', 'TDF', 'Monotherapy with Peg-IFNα or TDF', 'pegylated interferon -alpha', 'TDF combination therapy', 'Peg- IFNα and tenofovir disoproxil fumarate (TDF) combination therapy', 'Peg- IFNα']","['serum ALT levels', 'number of patients with HBV DNA suppression', 'virologic response', 'HBV DNA load <20 IU/mL', 'suppressing HBV DNA concentration']","[{'cui': 'C0948827', 'cui_str': 'Hepatitis B e antigen negative'}, {'cui': 'C0524909', 'cui_str': 'Chronic type B viral hepatitis'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0019167', 'cui_str': 'Hepatitis B e antigen'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0002199', 'cui_str': 'interferon alfa natural'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0032478', 'cui_str': 'Polyethylene Glycol 400'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}]","[{'cui': 'C0036828', 'cui_str': 'SGPT'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019163', 'cui_str': 'Type B viral hepatitis'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic acid'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C0439458', 'cui_str': 'IU/mL'}, {'cui': 'C1260953', 'cui_str': 'Suppressed'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",,0.094267,No significant difference was observed in the normalization trends of serum ALT levels between the three groups (P = 0.082).,"[{'ForeName': 'Mnasour', 'Initials': 'M', 'LastName': 'Bahardoust', 'Affiliation': 'Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran; Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Marjan', 'Initials': 'M', 'LastName': 'Mokhtare', 'Affiliation': 'Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mitra', 'Initials': 'M', 'LastName': 'Barati', 'Affiliation': 'Pediatric Infectious Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Bagheri-Hosseinabadi', 'Affiliation': 'Department of Clinical Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.'}, {'ForeName': 'Arman', 'Initials': 'A', 'LastName': 'Karimi Behnagh', 'Affiliation': 'Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Keyvani', 'Affiliation': 'Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Shahram', 'Initials': 'S', 'LastName': 'Agah', 'Affiliation': 'Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran. Electronic address: agah.sh@iums.ac.ir.'}]",Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,['10.1016/j.jiac.2020.07.005'] 2787,32762995,"Mapping From Visual Acuity to EQ-5D, EQ-5D With Vision Bolt-On, and VFQ-UI in Patients With Macular Edema in the LEAVO Trial.","OBJECTIVES Mappings to convert clinical measures to preference-based measures of health such as the EQ-5D-3L are sometimes required in cost-utility analyses. We developed mappings to convert best-corrected visual acuity (BCVA) to the EQ-5D-3L, the EQ-5D-3L with a vision bolt-on (EQ-5D V), and the Visual Functioning Questionnaire-Utility Index (VFQ-UI) in patients with macular edema caused by central retinal vein occlusion. METHODS We used data from Lucentis, Eylea, Avastin in vein occlusion (LEAVO), which is a phase-3 randomized controlled trial comparing ranibizumab, aflibercept, and bevacizumab in 463 patients with observations at 6 time points. We estimated adjusted limited dependent variable mixture models consisting of 1 to 4 distributions (components) using BCVA in each eye, age, and sex to predict utility within the components and BCVA as a determinant of component membership. We compared model fit using mean error, mean absolute error, root mean square error, Akaike information criteria, Bayesian information criteria, and visual inspection of mean predicted and observed utilities and cumulative distribution functions. RESULTS Mean utility scores were 0.82 for the EQ-5D-3L, 0.79 for the EQ-5D V, and 0.88 for the VFQ-UI. The best-fitting models for the EQ-5D and EQ-5D V had 2 components (with means of approximately 0.44 and 0.85), and the best-fitting model for VFQ-UI had 3 components (with means of approximately 0.95, 0.74, and 0.90). CONCLUSIONS Models with multiple components better predict utility than those with single components. This article provides a valuable addition to the literature, in which previous mappings in visual acuity have been limited to linear regressions, resulting in unfounded assumptions about the distribution of the dependent variable.",2020,"Mean utility scores were 0.82 for the EQ-5D-3L, 0.79 for the EQ-5D V, and 0.88 for the VFQ-UI.","['patients with macular edema caused by central retinal vein occlusion', '463 patients with observations at 6 time points', 'Patients With Macular Edema in the LEAVO Trial']","['ranibizumab, aflibercept, and bevacizumab', 'Lucentis, Eylea, Avastin in vein occlusion (LEAVO']","['mean error, mean absolute error, root mean square error, Akaike information criteria, Bayesian information criteria, and visual inspection of mean predicted and observed utilities and cumulative distribution functions', 'Mean utility scores', 'Visual Functioning Questionnaire-Utility Index (VFQ-UI']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0271051', 'cui_str': 'Macular retinal edema'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0154841', 'cui_str': 'Central retinal vein occlusion'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1721374', 'cui_str': 'Lucentis'}, {'cui': 'C3248025', 'cui_str': 'Eylea'}, {'cui': 'C1135130', 'cui_str': 'Avastin'}, {'cui': 'C0948441', 'cui_str': 'Venous occlusion'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C1134659', 'cui_str': 'aflibercept'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C3248025', 'cui_str': 'Eylea'}, {'cui': 'C1135130', 'cui_str': 'Avastin'}, {'cui': 'C0948441', 'cui_str': 'Venous occlusion'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0199219', 'cui_str': 'Inspection'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",463.0,0.141225,"Mean utility scores were 0.82 for the EQ-5D-3L, 0.79 for the EQ-5D V, and 0.88 for the VFQ-UI.","[{'ForeName': 'Becky M', 'Initials': 'BM', 'LastName': 'Pennington', 'Affiliation': 'School of Health and Related Research, University of Sheffield, Sheffield, England, UK. Electronic address: b.pennington@sheffield.ac.uk.'}, {'ForeName': 'Mónica', 'Initials': 'M', 'LastName': 'Hernández-Alava', 'Affiliation': 'School of Health and Related Research, University of Sheffield, Sheffield, England, UK.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Hykin', 'Affiliation': 'National Institute for Health Research Moorfields Biomedical Research Centre, London, England, UK.'}, {'ForeName': 'Sobha', 'Initials': 'S', 'LastName': 'Sivaprasad', 'Affiliation': 'National Institute for Health Research Moorfields Biomedical Research Centre, London, England, UK.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Flight', 'Affiliation': 'School of Health and Related Research, University of Sheffield, Sheffield, England, UK.'}, {'ForeName': 'Abualbishr', 'Initials': 'A', 'LastName': 'Alshreef', 'Affiliation': 'School of Health and Related Research, University of Sheffield, Sheffield, England, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Brazier', 'Affiliation': 'School of Health and Related Research, University of Sheffield, Sheffield, England, UK.'}]",Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research,['10.1016/j.jval.2020.03.008'] 2788,32762997,Mimicking Real-Life Decision Making in Health: Allowing Respondents Time to Think in a Discrete Choice Experiment.,"OBJECTIVE To empirically test the impact of allowing respondents time to think (TTT) about their choice options on the outcomes of a discrete choice experiments (DCE). METHODS In total, 613 participants of the Swedish CArdioPulmonary bioImage Study (SCAPIS) completed a DCE questionnaire that measured their preferences for receiving secondary findings of a genetic test. A Bayesian D-efficient design with 60 choice tasks divided over 4 questionnaires was used. Each choice task contained 2 scenarios with 4 attributes: type of disease, disease penetrance probability, preventive opportunities, and effectiveness of prevention. Respondents were randomly allocated to the TTT or no TTT (NTTT) sample. Latent class models (LCMs) were estimated to determine attribute-level values and their relative importance. In addition, choice certainty, attribute-level interpretation, choice consistency, and potential uptake rates were compared between samples. RESULTS In the TTT sample, 92% of the respondents (245 of 267) indicated they used the TTT period to (1) read the information they received (72%) and (2) discuss with their family (24%). In both samples, respondents were very certain about their choices. A 3-class LCM was fitted for both samples. Preference reversals were found for 3 of the 4 attributes in one class in the NTTT sample (34% class-membership probability). Relative importance scores of the attributes differed between the 2 samples, and significant scale effects indicating higher choice consistency in TTT sample were found. CONCLUSIONS Offering respondents TTT influences decision making and preferences. Developers of future DCEs regarding complex health-related decisions are advised to consider this approach to enhance the validity of the elicited preferences.",2020,"Relative importance scores of the attributes differed between the 2 samples, and significant scale effects indicating higher choice consistency in TTT sample were found. ","['613 participants of the Swedish CArdioPulmonary bioImage Study (SCAPIS) completed a', 'Health']","['TTT or no TTT', 'DCE questionnaire']",['potential uptake rates'],"[{'cui': 'C0038996', 'cui_str': 'Swedish language'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0039869', 'cui_str': 'Thinking'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",[],613.0,0.0487338,"Relative importance scores of the attributes differed between the 2 samples, and significant scale effects indicating higher choice consistency in TTT sample were found. ","[{'ForeName': 'Jorien', 'Initials': 'J', 'LastName': 'Veldwijk', 'Affiliation': 'Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Centre for Research Ethics and Bioethics, Uppsala University, Uppsala, Sweden; Erasmus Choice Modelling Centre, Erasmus University Rotterdam, Rotterdam, The Netherlands. Electronic address: veldwijk@eshpm.eur.nl.'}, {'ForeName': 'Jennifer Viberg', 'Initials': 'JV', 'LastName': 'Johansson', 'Affiliation': 'Centre for Research Ethics and Bioethics, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Bas', 'Initials': 'B', 'LastName': 'Donkers', 'Affiliation': 'Erasmus School of Economics, Erasmus University Rotterdam, Rotterdam, The Netherlands; Erasmus Choice Modelling Centre, Erasmus University Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'Esther W', 'Initials': 'EW', 'LastName': 'de Bekker-Grob', 'Affiliation': 'Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Erasmus Choice Modelling Centre, Erasmus University Rotterdam, Rotterdam, The Netherlands.'}]",Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research,['10.1016/j.jval.2020.02.014'] 2789,32763002,"Response to Letter to Editor ""Effects of handwriting exercise on functional outcome in parkinson disease: A randomized controlled trial"".",,2020,,['parkinson disease'],['handwriting exercise'],['functional outcome'],"[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}]","[{'cui': 'C0018582', 'cui_str': 'Handwriting'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0973615,,[],Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,['10.1016/j.jocn.2020.07.001'] 2790,32763006,Polyethylene Wear With Ceramic and Metal Femoral Heads at 5 Years: A Randomized Controlled Trial With Radiostereometric Analysis.,"BACKGROUND A common bearing combination in total hip arthroplasty today is a metal femoral head articulating with polyethylene in the cup. Ceramic heads are thought to be more resistant to third-body damage, and have better wettability and decreased surface roughness, which taken together have been suggested to result in less polyethylene wear. The purpose of this study is to compare the initial creep deformation and follow wear pattern, using radiostereometric analysis, of ceramic and metal femoral heads that articulate with a modern highly cross-linked polyethylene cup liner. METHODS Fifty patients with primary osteoarthritis and scheduled for an uncemented total hip arthroplasty were randomized 1:1 to either a ceramic (BIOLOX delta) or a metal (CoCr) femoral head. The patients were followed up for 5 years with repeated radiostereometric analysis examinations (postoperatively, then at 14 days, 3, 12, 24, and 60 months), as well as a hip-specific outcome questionnaire. RESULTS During the first 3 months both groups showed expected creep within the liner of 0.12 mm (standard deviation 0.03) for the ceramic and 0.08 mm (standard deviation 0.02) for the metal heads. Between 3 months and 5 years there was very little wear of the liner in either group, corresponding to 0.003 mm/y for ceramic and 0.007 mm/y for metal heads. There was no difference in cup migration or clinical outcome between the groups and no cups were revised. CONCLUSION With the introduction of modern highly cross-linked polyethylene, the ceramic head demonstrates no superiority when it comes to either early deformation or polyethylene wear compared with the metal head.",2020,"There was no difference in cup migration or clinical outcome between the groups and no cups were revised. ","['at 5 Years', 'Fifty patients with primary osteoarthritis and scheduled for an uncemented total hip arthroplasty']","['modern highly cross-linked polyethylene', 'Polyethylene Wear With Ceramic and Metal Femoral Heads', 'ceramic (BIOLOX delta) or a metal (CoCr) femoral head']",['cup migration or clinical outcome'],"[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0409952', 'cui_str': 'Idiopathic osteoarthritis'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0332220', 'cui_str': 'Cross-linking'}, {'cui': 'C0032487', 'cui_str': 'Polyethylenes'}, {'cui': 'C0007742', 'cui_str': 'Ceramic'}, {'cui': 'C0025552', 'cui_str': 'Metal'}, {'cui': 'C0015813', 'cui_str': 'Structure of head of femur'}, {'cui': 'C0439097', 'cui_str': 'Delta'}]","[{'cui': 'C0220647', 'cui_str': 'Carcinoma of unknown primary'}, {'cui': 'C0237731', 'cui_str': 'Human Migration'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",50.0,0.0929279,"There was no difference in cup migration or clinical outcome between the groups and no cups were revised. ","[{'ForeName': 'Halldor', 'Initials': 'H', 'LastName': 'Bergvinsson', 'Affiliation': 'Department of Orthopedics, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Sundberg', 'Affiliation': 'Department of Orthopedics, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.'}, {'ForeName': 'Gunnar', 'Initials': 'G', 'LastName': 'Flivik', 'Affiliation': 'Department of Orthopedics, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.'}]",The Journal of arthroplasty,['10.1016/j.arth.2020.06.057'] 2791,32763106,Comment on: Bariatric surgery in the elderly: a randomized prospective study comparing safety of sleeve gastrectomy and Roux-en-Y gastric bypass (BASE Trial).,,2020,,['elderly'],"['sleeve gastrectomy and Roux-en-Y gastric bypass', 'Bariatric surgery']",[],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}, {'cui': 'C0399839', 'cui_str': 'Bypass gastrojejunostomy'}, {'cui': 'C1456587', 'cui_str': 'Metabolic surgery'}]",[],,0.0107772,,"[{'ForeName': 'Emanuele', 'Initials': 'E', 'LastName': 'Lo Menzo', 'Affiliation': 'The Bariatric And Metabolic Institute, Cleveland Clinic Florida, Weston, Florida.'}]",Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery,['10.1016/j.soard.2020.06.048'] 2792,32763112,Examining the effect of a mindfulness based program for the improvement of cognitive function in an early stage of schizophrenia. A random controlled trial.,,2020,,['early stage of schizophrenia'],['mindfulness based program'],['cognitive function'],"[{'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",,0.0225595,,"[{'ForeName': 'Álvaro I', 'Initials': 'ÁI', 'LastName': 'Langer', 'Affiliation': 'Mind-Body Lab, Instituto de Estudios Psicológicos, Facultad de Medicina, Universidad Austral de Chile, Valdivia, Chile; Millennium Nucleus to Improve the Mental Health of Adolescents and Youths (Imhay), Santiago, Chile; Millennium Institute for Research in Depression and Personality (MIDAP), Santiago, Chile; Center for Interdisciplinary Studies on the Nervous System (CISNe), Universidad Austral de Chile, Valdivia, Chile. Electronic address: alvaro.langer@uach.cl.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Schmidt', 'Affiliation': 'Millennium Institute for Research in Depression and Personality (MIDAP), Santiago, Chile; Brain, Cognition and Behavior PhD Program, University of Barcelona, Spain.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Vergara', 'Affiliation': 'Departamento de Kinesiología, Facultad de Artes y Educación Física, Universidad Metropolitana de Ciencias de la Educación, Chile.'}, {'ForeName': 'Rocío', 'Initials': 'R', 'LastName': 'Mayol-Troncoso', 'Affiliation': 'Millennium Nucleus to Improve the Mental Health of Adolescents and Youths (Imhay), Santiago, Chile; Clínica Psiquiátrica Universitaria, Hospital Clínico y Facultad de Medicina, Universidad de Chile, Chile.'}, {'ForeName': 'Javiera', 'Initials': 'J', 'LastName': 'Lecaros', 'Affiliation': 'Escuela de Psicología, Universidad Adolfo Ibáñez, Chile.'}, {'ForeName': 'Edwin', 'Initials': 'E', 'LastName': 'Krogh', 'Affiliation': 'Mind-Body Lab, Instituto de Neurociencias Clínicas, Facultad de Medicina, Universidad Austral de Chile, Chile.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Vergara', 'Affiliation': 'Servicio de Psiquiatría y Salud Mental Hospital El Pino, San Bernardo, Santiago, Chile.'}, {'ForeName': 'Marcela', 'Initials': 'M', 'LastName': 'Díaz', 'Affiliation': 'Clínica Psiquiátrica Universitaria, Hospital Clínico y Facultad de Medicina, Universidad de Chile, Chile.'}, {'ForeName': 'Gerardo', 'Initials': 'G', 'LastName': 'Rivera', 'Affiliation': 'Mind-Body Lab, Instituto de Estudios Psicológicos, Facultad de Medicina, Universidad Austral de Chile, Valdivia, Chile; Mind-Body Lab, Instituto de Neurociencias Clínicas, Facultad de Medicina, Universidad Austral de Chile, Chile.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Aguirre-Baez', 'Affiliation': 'Mind-Body Lab, Instituto de Estudios Psicológicos, Facultad de Medicina, Universidad Austral de Chile, Valdivia, Chile.'}, {'ForeName': 'Pablo A', 'Initials': 'PA', 'LastName': 'Gaspar', 'Affiliation': 'Millennium Nucleus to Improve the Mental Health of Adolescents and Youths (Imhay), Santiago, Chile; Clínica Psiquiátrica Universitaria, Hospital Clínico y Facultad de Medicina, Universidad de Chile, Chile; Clínica Alemana de Santiago, RM, Chile; Instituto Milenio de Neurociencias, BNI, RM, Chile.'}]",Schizophrenia research,['10.1016/j.schres.2020.07.012'] 2793,32763217,"Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.","BACKGROUND Paediatric dolutegravir doses approved by stringent regulatory authorities (SRAs) for children weighing 20 kg to less than 40 kg until recently required 25 mg and 10 mg film-coated tablets. These tablets are not readily available in low-resource settings where the burden of HIV is highest. We did nested pharmacokinetic substudies in patients enrolled in the ODYSSEY-trial to evaluate simplified dosing in children with HIV. METHODS We did pharmacokinetic and safety substudies within the open-label, multicentre, randomised ODYSSEY trial (NCT02259127) of children with HIV starting treatment in four research centres in Uganda and Zimbabwe. Eligible children were randomised to dolutegravir in ODYSSEY and weighed 20 kg to less than 40 kg. In children weighing 20 kg to less than 25 kg, we assessed dolutegravir's pharmacokinetics in children given once daily 25 mg film-coated tablets (approved by the SRAs at the time of the study) in part one of the study, and 50 mg film-coated tablets (adult dose) or 30 mg dispersible tablets in part two of the study. In children weighing 25 kg to less than 40 kg, we also assessed dolutegravir pharmacokinetics within-subject on film-coated tablet doses of 25 mg or 35 mg once daily, which were approved by the SRAs for the children's weight band; then switched to 50 mg film-coated tablets once daily. Steady-state 24 h dolutegravir plasma concentration-time pharmacokinetic profiling was done in all enrolled children at baseline and 1, 2, 3, 4, 6, and 24 h after observed dolutegravir intake. Target dolutegravir trough concentrations (C trough ) were based on reference adult pharmacokinetic data and safety was evaluated in all children in the corresponding weight bands who consented to pharmacokinetic studies and received the studied doses. FINDINGS Between Sept 22, 2016, and May 31, 2018, we enrolled 62 black-African children aged from 6 years to younger than 18 years (84 pharmacokinetic-profiles). In children weighing 20 kg to less than 25 kg taking 25 mg film-coated tablets, the geometric mean (GM) C trough (coefficient of variation) was 0·32 mg/L (94%), which was 61% lower than the GM C trough of 0·83 mg/L (26%) in fasted adults on dolutegravir 50 mg once-daily; in children weighing 25 kg to less than 30 kg taking 25 mg film-coated tablets, the GM C trough was 0·39 mg/L (48%), which was 54% lower than the GM C trough in fasted adults; and in those 30 kg to less than 40 kg taking 35 mg film-coated tablets the GM C trough was 0·46 mg/L (63%), which was 45% lower than the GM C trough in fasted adults. On 50 mg film-coated tablets or 30 mg dispersible tablets, C trough was close to the adult reference (with similar estimates on the two formulations in children in the 20 to <25 kg weight band), with total exposure (area under the concentration-time curve from 0 h to 24 h) in between reference values in adults dosed once and twice daily, where safety data are reassuring, although maximum concentrations were higher in children weighing 20 kg to less than 25 kg than in the twice-daily adult reference. Over a 24-week follow-up period in 47 children on 30 mg dispersible tablets or 50 mg film-coated tablets, none of the three reported adverse events (cryptococcal meningitis, asymptomatic anaemia, and asymptomatic neutropenia) were considered related to dolutegravir. INTERPRETATION Adult dolutegravir 50 mg film-coated tablets given once daily provide appropriate pharmacokinetic profiles in children weighing 20 kg or more, with no safety signal, allowing simplified practical dosing and rapid access to dolutegravir. These results informed the WHO 2019 dolutegravir paediatric dosing guidelines and have led to US Food and Drug Administration approval of adult dosing down to 20 kg. FUNDING Paediatric European Network for Treatment of AIDS Foundation, ViiV Healthcare, UK Medical Research Council.",2020,"In children weighing 20 kg to less than 25 kg taking 25 mg film-coated tablets, the geometric mean (GM) C trough (coefficient of variation) was 0·32","['62 black-African children aged from 6 years to younger than 18 years (84 pharmacokinetic-profiles', 'children with HIV weighing 20 kg or more', '47 children', 'Between Sept 22, 2016, and May 31, 2018', 'patients enrolled in the ODYSSEY-trial to evaluate simplified dosing in children with HIV', 'Eligible children', 'children with HIV starting treatment in four research centres in Uganda and Zimbabwe']",[],"[""dolutegravir's pharmacokinetics"", 'dolutegravir pharmacokinetics', 'adverse events (cryptococcal meningitis, asymptomatic anaemia, and asymptomatic neutropenia']","[{'cui': 'C0337824', 'cui_str': 'Black African'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0041573', 'cui_str': 'Uganda'}, {'cui': 'C0043476', 'cui_str': 'Zimbabwe'}]",[],"[{'cui': 'C3253985', 'cui_str': 'dolutegravir'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0085436', 'cui_str': 'Cryptococcal meningitis'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}]",62.0,0.226703,"In children weighing 20 kg to less than 25 kg taking 25 mg film-coated tablets, the geometric mean (GM) C trough (coefficient of variation) was 0·32","[{'ForeName': 'Pauline D J', 'Initials': 'PDJ', 'LastName': 'Bollen', 'Affiliation': 'Department of Pharmacy, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.'}, {'ForeName': 'Cecilia L', 'Initials': 'CL', 'LastName': 'Moore', 'Affiliation': 'Medical Research Council Clinical Trials Unit, University College London, London, UK.'}, {'ForeName': 'Hilda A', 'Initials': 'HA', 'LastName': 'Mujuru', 'Affiliation': 'University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.'}, {'ForeName': 'Shafic', 'Initials': 'S', 'LastName': 'Makumbi', 'Affiliation': 'Joint Clinical Research Centre, Mbarara, Uganda.'}, {'ForeName': 'Adeodata R', 'Initials': 'AR', 'LastName': 'Kekitiinwa', 'Affiliation': ""Baylor College of Medicine Children's Foundation, Kampala, Uganda.""}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Kaudha', 'Affiliation': 'Joint Clinical Research Centre, Kampala, Uganda.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Parker', 'Affiliation': 'Medical Research Council Clinical Trials Unit, University College London, London, UK.'}, {'ForeName': 'Godfrey', 'Initials': 'G', 'LastName': 'Musoro', 'Affiliation': 'University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.'}, {'ForeName': 'Annet', 'Initials': 'A', 'LastName': 'Nanduudu', 'Affiliation': 'Joint Clinical Research Centre, Kampala, Uganda.'}, {'ForeName': 'Abbas', 'Initials': 'A', 'LastName': 'Lugemwa', 'Affiliation': 'Joint Clinical Research Centre, Mbarara, Uganda.'}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Amuge', 'Affiliation': ""Baylor College of Medicine Children's Foundation, Kampala, Uganda.""}, {'ForeName': 'James G', 'Initials': 'JG', 'LastName': 'Hakim', 'Affiliation': 'University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Rojo', 'Affiliation': 'Hospital 12 de Octubre, Madrid, Spain.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Giaquinto', 'Affiliation': 'University of Padova, Padova, Italy.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Colbers', 'Affiliation': 'Department of Pharmacy, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands. Electronic address: angela.colbers@radboudumc.nl.'}, {'ForeName': 'Diana M', 'Initials': 'DM', 'LastName': 'Gibb', 'Affiliation': 'Medical Research Council Clinical Trials Unit, University College London, London, UK.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Ford', 'Affiliation': 'Medical Research Council Clinical Trials Unit, University College London, London, UK.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Turkova', 'Affiliation': 'Medical Research Council Clinical Trials Unit, University College London, London, UK.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Burger', 'Affiliation': 'Department of Pharmacy, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The lancet. HIV,['10.1016/S2352-3018(20)30189-2'] 2794,32763218,Rapid antiretroviral therapy initiation in the Botswana Combination Prevention Project: a quasi-experimental before and after study.,"BACKGROUND Ensuring that individuals who are living with HIV rapidly initiate antiretroviral therapy (ART) is an essential step in meeting the 90-90-90 targets. We evaluated the feasibility and outcomes of rapid ART initiation in the Botswana Combination Prevention Project (BCPP). We aimed to establish whether simplified ART initiation with the offer of same-day treatment could increase uptake and reduce time from clinic linkage to treatment initiation, while maintaining rates of retention in care and viral suppression. METHODS We did a quasi-experimental before and after study with use of data from the BCPP. The BCPP was a community-randomised HIV-prevention trial done in 30 communities across Botswana from Oct 1, 2013, to June 30, 2018. Participants in the 15 intervention clusters, who were HIV-positive and not already taking ART were offered universal HIV-treatment and same-day ART with a dolutegravir-based regimen at first clinic visit. This rapid ART intervention was implemented mid-way through the trial on June 1, 2016, enabling us to determine the effect of rapid ART guidelines on time to ART initiation and rates of retention in care and viral suppression at 1 year in the BCPP intervention group. FINDINGS We assessed 1717 adults linked to study clinics before rapid ART introduction and 800 after rapid ART introduction. During the rapid ART period, 457 (57·1%, 95% CI 53·7-60·6) individuals initiated ART within 1 day of linkage, 589 (73·7%, 70·6-76·7) of 799 within 1 week, 678 (84·9%, 82·4-87·3) of 799 within 1 month, and 744 (93·5%, 91·6-95·1) of 796 within 1 year. Before the introduction of rapid ART, 163 (9·5%, 95% CI 8·2-11·0) individuals initiated ART within 1 day of linkage, 276 (16·1%, 14·4-17·9) within 1 week, 839 (48·9%, 46·5-51·3) within 1 month, and 1532 (89·2%, 87·7-90·6) within 1 year. 1 year after ART initiation, 1472 (90·5%, 87·4-92·8) of 1627 individuals who linked in the standard ART period were in care and had a viral load of less than 400 copies per mL, compared with 578 (91·6%, 88·1-94·1) of 631 in the rapid ART period (risk ratio 1·01, 95% CI 0·92-1·11). INTERPRETATION Our findings provide support for the WHO recommendations for rapid ART initiation, and add to the accumulating evidence showing the feasibility, acceptability, and safety of rapid ART initiation in low-income and middle-income country settings. FUNDING US President's Emergency Plan for AIDS Relief.",2020,"1 year after ART initiation, 1472 (90·5%, 87·4-92·8) of 1627 individuals who linked in the standard ART period were in care and had a viral load of less than 400 copies per mL, compared with 578 (91·6%, 88·1-94·1) of 631 in the rapid ART period (risk ratio 1·01, 95% CI 0·92-1·11). ","['30 communities across Botswana from Oct 1, 2013, to June 30, 2018', 'individuals who are living with HIV rapidly initiate antiretroviral therapy (ART', '1717 adults linked to study clinics before rapid ART introduction and 800 after rapid ART introduction', 'Participants in the 15 intervention clusters, who were HIV-positive and not already taking ART were offered universal HIV-treatment and same-day ART with a dolutegravir-based regimen at first clinic visit']",[],['time to ART initiation and rates of retention in care and viral suppression'],"[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0006041', 'cui_str': 'Botswana'}, {'cui': 'C1442824', 'cui_str': 'POU2F1 protein, human'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0019699', 'cui_str': 'HIV positive'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0175671', 'cui_str': 'Universal'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3253985', 'cui_str': 'dolutegravir'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0008952', 'cui_str': 'Clinic Visits'}]",[],"[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C4704685', 'cui_str': 'Care Retention'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}]",1717.0,0.242917,"1 year after ART initiation, 1472 (90·5%, 87·4-92·8) of 1627 individuals who linked in the standard ART period were in care and had a viral load of less than 400 copies per mL, compared with 578 (91·6%, 88·1-94·1) of 631 in the rapid ART period (risk ratio 1·01, 95% CI 0·92-1·11). ","[{'ForeName': 'Refeletswe', 'Initials': 'R', 'LastName': 'Lebelonyane', 'Affiliation': 'Botswana Ministry of Health and Wellness, Gaborone, Botswana.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Bachanas', 'Affiliation': 'Centers for Disease Control and Prevention, Division of Global HIV/AIDS and TB, Atlanta, GA, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Block', 'Affiliation': 'Northrop Grumman, Atlanta, GA, USA.'}, {'ForeName': 'Faith', 'Initials': 'F', 'LastName': 'Ussery', 'Affiliation': 'Centers for Disease Control and Prevention, Division of Global HIV/AIDS and TB, Atlanta, GA, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Abrams', 'Affiliation': 'Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Roland', 'Affiliation': 'Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'Joe', 'Initials': 'J', 'LastName': 'Theu', 'Affiliation': 'Botswana Ministry of Health and Wellness, Gaborone, Botswana.'}, {'ForeName': 'Max', 'Initials': 'M', 'LastName': 'Kapanda', 'Affiliation': 'Botswana Ministry of Health and Wellness, Gaborone, Botswana.'}, {'ForeName': 'Stembile', 'Initials': 'S', 'LastName': 'Matambo', 'Affiliation': 'Botswana Ministry of Health and Wellness, Gaborone, Botswana.'}, {'ForeName': 'Shahin', 'Initials': 'S', 'LastName': 'Lockman', 'Affiliation': ""Harvard T H Chan School of Public Health, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.""}, {'ForeName': 'Tendani', 'Initials': 'T', 'LastName': 'Gaolathe', 'Affiliation': 'Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; University of Botswana School of Medicine, Gaborone, Botswana.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Makhema', 'Affiliation': 'Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Moore', 'Affiliation': 'Centers for Disease Control and Prevention, Division of Global HIV/AIDS and TB, Atlanta, GA, USA.'}, {'ForeName': 'Joseph N', 'Initials': 'JN', 'LastName': 'Jarvis', 'Affiliation': 'Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Botswana-University of Pennsylvania Partnership, Gaborone, Botswana; Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK. Electronic address: joseph.jarvis@lshtm.ac.uk.'}]",The lancet. HIV,['10.1016/S2352-3018(20)30187-9'] 2795,32763234,Comparison of intermittent versus continuous-infusion vancomycin for treating severe patients in intensive care units.,"PURPOSE The aim of this study was to compare pharmacokinetic characteristics between intermittent infusion (II) and continuous infusion (CI) of vancomycin for critically ill patients admitted to intensive care units. METHODS Intermittent therapy was administered for 60minutes and prescribed as a loading dose of 30mg/kg and continued with 15mg/kg q12h. Continuous infusion was prescribed as a loading dose of 30mg/kg followed by 30mg/kg on constant infusion pump. Blood samples from vancomycin II group were collected 1h before third dose, 1h, 8h and 24h after third dose infusion. Blood samples from vancomycin CI group were collected 1h after loading dose, 12h, 24h, 36h, and 48h after continuous infusion initiation. RESULTS Median serum concentration of CI group at 24-hour was 23.59μg/mL [14.52-28.97], while of II group at 23-hour was 12.30μg/mL [7.27-18.12] and on 25-hour was 17.58μg/mL [12.5-22.5]. Medians AUC 24-48h were 357.2mg.h/L and 530.2mg.h/L for II and CI groups, respectively (p=0.559). CONCLUSION Vancomycin CI reached steady state earlier, which guaranteed therapeutic levels from the first day and made it possible to manage therapeutic drug monitoring faster.",2020,"AUC 24-48h were 357.2mg.h/L and 530.2mg.h/L for II and CI groups, respectively (p=0.559). ","['critically ill patients admitted to intensive care units', 'severe patients in intensive care units']","['vancomycin CI', 'vancomycin', 'intermittent versus continuous-infusion vancomycin', 'intermittent infusion (II) and continuous infusion (CI) of vancomycin', 'Vancomycin CI']","['pharmacokinetic characteristics', 'Median serum concentration']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0583239', 'cui_str': 'Admission to intensive care unit'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}]","[{'cui': 'C0042313', 'cui_str': 'Vancomycin'}, {'cui': 'C0444889', 'cui_str': 'Continuous infusion'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",,0.0813945,"AUC 24-48h were 357.2mg.h/L and 530.2mg.h/L for II and CI groups, respectively (p=0.559). ","[{'ForeName': 'Carolina Hikari', 'Initials': 'CH', 'LastName': 'Yamada', 'Affiliation': 'Pontifícia Universidade Católica do Paraná, Faculdade de Medicina, Curitiba, Paraná, PR, Brazil.'}, {'ForeName': 'João Paulo', 'Initials': 'JP', 'LastName': 'Telles', 'Affiliation': 'AC Camargo Cancer Center, São Paulo, SP, Brazil; Hospital Universitário Cajuru, Curitiba, Paraná, PR, Brazil; Pontifícia Universidade Católica do Paraná, Faculdade de Medicina, Laboratório de Doenças Infeccionas Emergentes, Curitiba, PR, Brazil.'}, {'ForeName': 'Dayana Dos Santos', 'Initials': 'DDS', 'LastName': 'Oliveira', 'Affiliation': 'Hospital Universitário Cajuru, Curitiba, Paraná, PR, Brazil.'}, {'ForeName': 'Juliette', 'Initials': 'J', 'LastName': 'Cieslinski', 'Affiliation': 'Pontifícia Universidade Católica do Paraná, Faculdade de Medicina, Curitiba, Paraná, PR, Brazil; Pontifícia Universidade Católica do Paraná, Faculdade de Medicina, Laboratório de Doenças Infeccionas Emergentes, Curitiba, PR, Brazil.'}, {'ForeName': 'Victoria Stadler Tasca', 'Initials': 'VST', 'LastName': 'Ribeiro', 'Affiliation': 'Pontifícia Universidade Católica do Paraná, Faculdade de Medicina, Curitiba, Paraná, PR, Brazil; Pontifícia Universidade Católica do Paraná, Faculdade de Medicina, Laboratório de Doenças Infeccionas Emergentes, Curitiba, PR, Brazil.'}, {'ForeName': 'Juliano', 'Initials': 'J', 'LastName': 'Gasparetto', 'Affiliation': 'Pontifícia Universidade Católica do Paraná, Faculdade de Medicina, Curitiba, Paraná, PR, Brazil; Hospital Universitário Cajuru, Curitiba, Paraná, PR, Brazil.'}, {'ForeName': 'Felipe Francisco', 'Initials': 'FF', 'LastName': 'Tuon', 'Affiliation': 'Pontifícia Universidade Católica do Paraná, Faculdade de Medicina, Curitiba, Paraná, PR, Brazil; Hospital Universitário Cajuru, Curitiba, Paraná, PR, Brazil; Pontifícia Universidade Católica do Paraná, Faculdade de Medicina, Laboratório de Doenças Infeccionas Emergentes, Curitiba, PR, Brazil. Electronic address: felipe.tuon@pucpr.br.'}]",The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases,['10.1016/j.bjid.2020.07.001'] 2796,32763240,"A Phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis.","BACKGROUND & AIMS Firmicutes bacteria produce metabolites that maintain the intestinal barrier and mucosal immunity. Firmicutes are reduced in the intestinal microbiota of patients with ulcerative colitis (UC). In a phase 1b trial of patients with UC, we evaluated the safety and efficacy of SER-287, an oral formulation of Firmicutes spores, and the effects of vancomycin preconditioning on expansion (engraftment) of SER-287 species in the colon. METHODS We conducted a double-blind trial of SER-287 in 58 adults with active mild-to-moderate UC (modified Mayo scores 4-10, endoscopic subscores ≥1). Participants received 6 days of preconditioning with oral vancomycin (125 mg, 4 times daily) or placebo followed by 8 weeks of oral SER-287 or placebo. Patients were randomly assigned (2:3:3:3) to groups that received placebo followed by either placebo or SER-287 once weekly, or vancomycin followed by SER-287 once weekly or SER-287 once daily. Clinical endpoints included safety and clinical remission (modified Mayo score ≤ 2; endoscopic subscores 0 or 1). Microbiome endpoints included SER-287 engraftment (dose species detected in stool after, but not before, SER-287 administration). Engraftment of SER-287 and changes in microbiome composition and associated metabolites were measured by analyses of stool specimens collected at baseline, after preconditioning, and during and 4 weeks after administration of SER-287 or placebo. RESULTS Proportions of patients with adverse events did not differ significantly among groups. A higher proportion of patients in the vancomycin/SER-287 daily group (40%) achieved clinical remission at week 8 than patients in the placebo/placebo group (0), placebo/SER-287 weekly group (13.3%), or vancomycin/SER-287 weekly group (17.7%) (P=.024 for vancomycin/SER-287 daily vs placebo/placebo). By day 7, higher numbers of SER-287 dose species were detected in stool samples from all SER-287 groups compared with the placebo group (P<.05), but this difference was not maintained beyond day 7 in the placebo/SER-287 weekly group. In the vancomycin groups, a greater number of dose species were detected in stool collected on day 10 and all subsequent time points, through 4 weeks post-dosing, compared with the placebo group (P<.05). A higher number of SER-287 dose species were detected in stool samples on days 7 and 10 from subjects who received daily vs weekly SER-287 doses (P<.05). Changes in fecal microbiome composition and metabolites were associated with both vancomycin/SER-287 groups. CONCLUSIONS In this small phase 1b trial of limited duration, the safety and tolerability of SER-287 were similar to placebo. SER-287 following vancomycin was significantly more effective than placebo for induction of remission in patients with active mild-to-moderate UC. Engraftment of dose species was facilitated by vancomycin preconditioning and daily dosing of SER-287.",2020,"By day 7, higher numbers of SER-287 dose species were detected in stool samples from all SER-287 groups compared with the placebo group (P<.05), but this difference was not maintained beyond day 7 in the placebo/SER-287 weekly group.","['patients with active mild-to-moderate UC', '58 adults with active mild-to-moderate UC (modified Mayo scores 4-10, endoscopic subscores ≥1', 'active mild to moderate ulcerative colitis', 'patients with ulcerative colitis (UC', 'patients with UC']","['placebo or SER-287', 'vancomycin', 'oral SER-287 or placebo', 'placebo/placebo', 'vancomycin/SER-287 daily vs placebo/placebo', 'preconditioning with oral vancomycin', 'vancomycin followed by SER-287 once weekly or SER-287 once daily', 'placebo/SER-287', 'vancomycin/SER-287', 'vancomycin preconditioning', 'vancomycin preconditioning and daily dosing of SER-287', 'SER-287', 'placebo']","['numbers of SER-287 dose species', 'safety and efficacy of SER-287', 'safety and clinical remission (modified Mayo score ≤ 2; endoscopic subscores 0 or 1', 'microbiome composition and associated metabolites', 'intestinal microbiota', 'SER-287 engraftment', 'number of dose species', 'safety and tolerability of SER-287', 'fecal microbiome composition and metabolites', 'adverse events', 'clinical remission']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0454788', 'cui_str': 'Mayo'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0036720', 'cui_str': 'Serine'}, {'cui': 'C4517682', 'cui_str': '287'}, {'cui': 'C0042313', 'cui_str': 'Vancomycin'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1709632', 'cui_str': 'Precondition'}, {'cui': 'C0360373', 'cui_str': 'Vancomycin-containing product in oral dose form'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0558293', 'cui_str': 'Once a week'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0036720', 'cui_str': 'Serine'}, {'cui': 'C4517682', 'cui_str': '287'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0454788', 'cui_str': 'Mayo'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C1956108', 'cui_str': 'Microbiome'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0301944', 'cui_str': 'Graft acceptance'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",58.0,0.414313,"By day 7, higher numbers of SER-287 dose species were detected in stool samples from all SER-287 groups compared with the placebo group (P<.05), but this difference was not maintained beyond day 7 in the placebo/SER-287 weekly group.","[{'ForeName': 'Matthew R', 'Initials': 'MR', 'LastName': 'Henn', 'Affiliation': ''}, {'ForeName': 'Edward J', 'Initials': 'EJ', 'LastName': ""O'Brien"", 'Affiliation': ''}, {'ForeName': 'Liyang', 'Initials': 'L', 'LastName': 'Diao', 'Affiliation': ''}, {'ForeName': 'Brian G', 'Initials': 'BG', 'LastName': 'Feagan', 'Affiliation': ''}, {'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Sandborn', 'Affiliation': ''}, {'ForeName': 'Curtis', 'Initials': 'C', 'LastName': 'Huttenhower', 'Affiliation': ''}, {'ForeName': 'Jennifer R', 'Initials': 'JR', 'LastName': 'Wortman', 'Affiliation': ''}, {'ForeName': 'Barbara H', 'Initials': 'BH', 'LastName': 'McGovern', 'Affiliation': ''}, {'ForeName': 'Sherry', 'Initials': 'S', 'LastName': 'Wang-Weigand', 'Affiliation': ''}, {'ForeName': 'David I', 'Initials': 'DI', 'LastName': 'Lichter', 'Affiliation': ''}, {'ForeName': 'Meghan', 'Initials': 'M', 'LastName': 'Chafee', 'Affiliation': ''}, {'ForeName': 'Chris B', 'Initials': 'CB', 'LastName': 'Ford', 'Affiliation': ''}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Bernardo', 'Affiliation': ''}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Zhao', 'Affiliation': ''}, {'ForeName': 'Sheri', 'Initials': 'S', 'LastName': 'Simmons', 'Affiliation': ''}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'Tomlinson', 'Affiliation': ''}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cook', 'Affiliation': ''}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Pomerantz', 'Affiliation': ''}, {'ForeName': 'Bharat K', 'Initials': 'BK', 'LastName': 'Misra', 'Affiliation': ''}, {'ForeName': 'John G', 'Initials': 'JG', 'LastName': 'Auninš', 'Affiliation': ''}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Trucksis', 'Affiliation': ''}]",Gastroenterology,['10.1053/j.gastro.2020.07.048'] 2797,32766062,Treatment of Post-mastectomy Lymphedema with Herbal Medicine: An Innovative Pilot Study.,"Background Lymphedema of the arms or legs is a difficult clinical problem yet devoid of effective treatment. Lymphedema is the result of obstructed lymphatic flow secondary to chronic infection, parasitic infestation, or postsurgical obstruction (eg, after axillary dissections). We arranged this clinical trial to investigate whether patients with limb lymphedema can benefit from a standard dose of Astragalus plus Paeoniae rubra to improve the symptomatology, functional capacity, and quality of life (QOL). Method The pilot study was designed as a self-control clinical trial. Patients with post-mastectomy lymphedema were recruited. A double-herb formulation ( Astragalus, Paeoniae rubra ) with standard dosage was administered orally in a powdered form, 6 times per week for 6 months. Outcome measurements included standard limb volume changes measured by water displacement method; handgrip strength; and QOL for limb lymphedema questionnaire (LYMQOL). Results There were no reported adverse effects or complications; there were no episodes of infection during the period of study. There was a tendency of limb volume reduction by 6 months, which, however, did not reach statistical significance. There was a significant improvement in appearance and symptom scores as was assessed with the LYMQOL questionnaire. Conclusions The oral herbal formula improved the symptomatology and QOL among the pilot group of patients with post-mastectomy lymphedema. Side effects were absent, and there was a trend of lymphedema reduction.",2020,There were no reported adverse effects or complications; there were no episodes of infection during the period of study.,"['patients with limb lymphedema', 'Patients with post-mastectomy lymphedema']",['Post-mastectomy Lymphedema with Herbal Medicine'],"['lymphedema reduction', 'symptomatology and QOL', 'limb volume reduction', 'LYMQOL questionnaire', 'appearance and symptom scores', 'Side effects', 'symptomatology, functional capacity, and quality of life (QOL', 'adverse effects or complications', 'standard limb volume changes measured by water displacement method; handgrip strength; and QOL for limb lymphedema questionnaire (LYMQOL']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0024236', 'cui_str': 'Lymphedema'}, {'cui': 'C0032775', 'cui_str': 'Post-mastectomy Lymphedema'}]","[{'cui': 'C0032775', 'cui_str': 'Post-mastectomy Lymphedema'}, {'cui': 'C0025125', 'cui_str': 'Herbs, Medicinal'}]","[{'cui': 'C0024236', 'cui_str': 'Lymphedema'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0025663', 'cui_str': 'Method'}]",,0.0374642,There were no reported adverse effects or complications; there were no episodes of infection during the period of study.,"[{'ForeName': 'Tor-Wo', 'Initials': 'TW', 'LastName': 'Chiu', 'Affiliation': 'Plastic, Reconstructive and Aesthetic Surgery, Burns Service, Prince of Wales Hospital, Shatin, Hong Kong.'}, {'ForeName': 'Shun-Ling', 'Initials': 'SL', 'LastName': 'Kong', 'Affiliation': 'Centre for Clinical Trials on Chinese Medicine, Institute of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong.'}, {'ForeName': 'King-Fai', 'Initials': 'KF', 'LastName': 'Cheng', 'Affiliation': 'Centre for Clinical Trials on Chinese Medicine, Institute of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong.'}, {'ForeName': 'Ping-Chung', 'Initials': 'PC', 'LastName': 'Leung', 'Affiliation': 'Centre for Clinical Trials on Chinese Medicine, Institute of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong.'}]",Plastic and reconstructive surgery. Global open,['10.1097/GOX.0000000000002915'] 2798,32766181,Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol.,"Background: Currently, the first line treatment of persistent ductus arteriosus (PDA) is either indomethacin or ibuprofen. However, the potentially life-threatening side effects associated to their use have prompted physicians to look for alternative options. The incorporation of paracetamol as an alternative to ibuprofen in the management of PDA is still based on insufficient clinical evidence. Hence, more clinical trials are needed to establish a therapeutic role for paracetamol in the management of PDA that take into consideration short- and long-term safety and efficacy outcomes. Study Design: This is a non-inferiority, randomized, multicenter, double-blinded study to evaluate the efficacy, and safety of intravenous (IV) paracetamol vs. IV ibuprofen (standard treatment) for PDA in preterm patients with a gestational age ≤ 30 weeks. At baseline, patients will be randomized (1:1) to treatment with paracetamol or ibuprofen. The primary endpoint is closure of the ductus after the first treatment course. Secondary endpoints are related to effectiveness (need for a second treatment course, rescue treatment, reopening rate, time to definitive closure, need for surgical ligation), safety (early and long-term complications), pharmacokinetics, and pharmacodynamics, pharmacogenetics, pharmacoeconomics, and genotoxicity. Long-term follow-up to 24 months of corrected postnatal age will be performed using Bayley III neurodevelopmental scale. Trial Registration: ClinicalTrials.gov Identifier: NCT04037514. EudraCT: 2015-003177-14.",2020,"Secondary endpoints are related to effectiveness (need for a second treatment course, rescue treatment, reopening rate, time to definitive closure, need for surgical ligation), safety (early and long-term complications), pharmacokinetics, and pharmacodynamics, pharmacogenetics, pharmacoeconomics, and genotoxicity.","['preterm patients with a gestational age ≤ 30 weeks', 'Arteriosus', 'persistent ductus arteriosus (PDA', 'Preterm Infants With Hemodynamically Significant Patent Ductus']","['indomethacin or ibuprofen', 'Paracetamol vs. Ibuprofen', 'intravenous (IV) paracetamol vs. IV ibuprofen', 'paracetamol', 'EudraCT', 'ibuprofen', 'paracetamol or ibuprofen']","['effectiveness (need for a second treatment course, rescue treatment, reopening rate, time to definitive closure, need for surgical ligation), safety (early and long-term complications), pharmacokinetics, and pharmacodynamics, pharmacogenetics, pharmacoeconomics, and genotoxicity', 'closure of the ductus']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0013274', 'cui_str': 'Patent ductus arteriosus'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0030650', 'cui_str': 'Patents'}]","[{'cui': 'C0021246', 'cui_str': 'Indomethacin'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0443196', 'cui_str': 'Definitive'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0023690', 'cui_str': 'Ligation'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0031325', 'cui_str': 'Pharmacogenetics'}, {'cui': 'C0206335', 'cui_str': 'Pharmaceutical Economics'}, {'cui': 'C0598309', 'cui_str': 'Genotoxicity'}]",,0.123765,"Secondary endpoints are related to effectiveness (need for a second treatment course, rescue treatment, reopening rate, time to definitive closure, need for surgical ligation), safety (early and long-term complications), pharmacokinetics, and pharmacodynamics, pharmacogenetics, pharmacoeconomics, and genotoxicity.","[{'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'García-Robles', 'Affiliation': 'Neonatal Research Group, Health Research Institute La Fe, University and Polytechnic Hospital La Fe, Valencia, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Gimeno Navarro', 'Affiliation': 'Neonatal Research Group, Health Research Institute La Fe, University and Polytechnic Hospital La Fe, Valencia, Spain.'}, {'ForeName': 'María Del Mar', 'Initials': 'MDM', 'LastName': 'Serrano Martín', 'Affiliation': 'Division of Neonatology, Regional University Hospital of Malaga, Málaga, Spain.'}, {'ForeName': 'María José', 'Initials': 'MJ', 'LastName': 'Párraga Quiles', 'Affiliation': 'Division of Neonatology, University Hospital Reina Sofía, Córdoba, Spain.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Parra Llorca', 'Affiliation': 'Neonatal Research Group, Health Research Institute La Fe, University and Polytechnic Hospital La Fe, Valencia, Spain.'}, {'ForeName': 'José Luis', 'Initials': 'JL', 'LastName': 'Poveda-Andrés', 'Affiliation': 'Division of Pharmacy, University and Polytechnic Hospital La Fe, Valencia, Spain.'}, {'ForeName': 'Máximo', 'Initials': 'M', 'LastName': 'Vento Torres', 'Affiliation': 'Neonatal Research Group, Health Research Institute La Fe, University and Polytechnic Hospital La Fe, Valencia, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Aguar Carrascosa', 'Affiliation': 'Neonatal Research Group, Health Research Institute La Fe, University and Polytechnic Hospital La Fe, Valencia, Spain.'}]",Frontiers in pediatrics,['10.3389/fped.2020.00372'] 2799,32766199,Effects of Female Community Health Volunteer Capacity Building and Text Messaging Intervention on Gestational Weight Gain and Hemoglobin Change Among Pregnant Women in Southern Nepal: A Cluster Randomized Controlled Trial.,"Introduction: Public health interventions such as text messaging are commonly evaluated in high-income countries and that the evaluation reports of the effectiveness of community health volunteers in low-income countries like Nepal is scarce. This study aimed to determine whether female community health volunteer (FCHV) capacity building and text messaging to expectant mother increases gestational weights and hemoglobin levels of pregnant women living in southern Nepal. Methods: A cluster randomized control trial was carried out in 52 clusters of 6 Village Development Committees in southern Nepal between July 2015 and March 2016. A total of 413 pregnant mothers of gestation age between 13 and 28 weeks (214 in the intervention group and 199 in the control group) were included in the analysis. Intervention consisted of FCHV capacity building followed by regular supervision and monitoring and mobile phone text messaging to expectant mothers. Regression analysis, controlled for confounders, was conducted to assess gestational weight gains and changes in hemoglobin levels. Results: At the end of the pregnancy, the mean weight gain difference between the intervention and control groups was 1.1 kg (95% CI: 1.0, 1.9). Rates of weight increases in the intervention and control groups were 0.504 kg/week (95% CI: 0.371, 0.528), and 0.399 kg/week (95% CI: 0.362, 0.465), respectively. Similarly, the mean inter group difference in hemoglobin levels was 0.11 gm/dl (95% CI: 0.09, 0.15), and rates of hemoglobin increases (gm/dl/week) in the intervention and control groups were 0.02 gm/dl (95% CI: 0.01, 0.09) and 0.004 gm/dl (95% CI: 0.02, 0.12), respectively. Conclusions: The study shows that FCHV capacity building and mobile text messaging have a positive effect on the gestational weights and hemoglobin levels of expectant mothers. Our findings suggest that mobile text messaging coupled with FCHV capacity building services should be supported and would usefully expand in resource poor settings. Trial registration: ISRCTN60684155.",2020,The study shows that FCHV capacity building and mobile text messaging have a positive effect on the gestational weights and hemoglobin levels of expectant mothers.,"['expectant mothers', '413 pregnant mothers of gestation age between 13 and 28 weeks (214 in the intervention group and 199 in the control group) were included in the analysis', 'female community health volunteer (FCHV', 'pregnant women living in southern Nepal', '52 clusters of 6 Village Development Committees in southern Nepal between July 2015 and March 2016', 'Pregnant Women in Southern Nepal']","['Female Community Health Volunteer Capacity Building and Text Messaging Intervention', 'FCHV capacity building followed by regular supervision and monitoring and mobile phone text messaging to expectant mothers']","['mean weight gain difference', 'gestational weights and hemoglobin levels', 'Gestational Weight Gain and Hemoglobin Change', 'gestational weight gains and changes in hemoglobin levels', 'rates of hemoglobin increases', 'hemoglobin levels', 'Rates of weight increases']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0027689', 'cui_str': 'Nepal'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C2718026', 'cui_str': 'Capacity Building'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0038842', 'cui_str': 'Supervision'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0439671', 'cui_str': 'Gestational'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C1398625', 'cui_str': 'Maternal Weight Gain'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0549448', 'cui_str': 'Increased hemoglobin'}]",413.0,0.240995,The study shows that FCHV capacity building and mobile text messaging have a positive effect on the gestational weights and hemoglobin levels of expectant mothers.,"[{'ForeName': 'Jitendra Kumar', 'Initials': 'JK', 'LastName': 'Singh', 'Affiliation': 'Department of Community Medicine, Janaki Medical College, Tribhuvan University, Janakpur, Nepal.'}, {'ForeName': 'Dilaram', 'Initials': 'D', 'LastName': 'Acharya', 'Affiliation': 'Department of Preventive Medicine, College of Medicine, Dongguk University, Gyeongju-si, South Korea.'}, {'ForeName': 'Rajan', 'Initials': 'R', 'LastName': 'Paudel', 'Affiliation': 'Central Department of Public Health, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal.'}, {'ForeName': 'Salila', 'Initials': 'S', 'LastName': 'Gautam', 'Affiliation': 'Department of Public Health, Sanjeevani College of Medical Sciences, Biratnagar, Nepal.'}, {'ForeName': 'Mandira', 'Initials': 'M', 'LastName': 'Adhikari', 'Affiliation': 'Nepal Development Society, Bharatpur, Nepal.'}, {'ForeName': 'Shambhu Prasad', 'Initials': 'SP', 'LastName': 'Kushwaha', 'Affiliation': 'District Health Office, Janakpur, Nepal.'}, {'ForeName': 'Ji-Hyuk', 'Initials': 'JH', 'LastName': 'Park', 'Affiliation': 'Department of Preventive Medicine, College of Medicine, Dongguk University, Gyeongju-si, South Korea.'}, {'ForeName': 'Seok-Ju', 'Initials': 'SJ', 'LastName': 'Yoo', 'Affiliation': 'Department of Preventive Medicine, College of Medicine, Dongguk University, Gyeongju-si, South Korea.'}, {'ForeName': 'Kwan', 'Initials': 'K', 'LastName': 'Lee', 'Affiliation': 'Department of Preventive Medicine, College of Medicine, Dongguk University, Gyeongju-si, South Korea.'}]",Frontiers in public health,['10.3389/fpubh.2020.00312'] 2800,32766259,The Role of Vitamin D in Combination Treatment for Patients With Rheumatoid Arthritis.,"Background: The aim of this study is to evaluate the clinical efficacy of vitamin D (VitD) supplementation in terms of response to treatment and improvement of disease activity in rheumatoid arthritis (RA). Methods: This study analyzed 1180 RA patients' records treated at Mianyang Central Hospital from February 2015 to July 2019. The patients were allocated into VitD group and control group based on their medical regimens. The outcome measures were primary efficacy, defined as treatment response-based EULAR response criteria in RA, and secondary efficacy, defined as improvement in disease activity indicators. Safety was evaluated according to the incidence of all-cause infections. Results: At month 6, the primary efficacy revealed that there were 22.8% good responders and 19.0% moderate responders in the VitD group, and 22.3% good responders and 22.3% moderate responders in the control group; there were no differences between the two groups ( p = 0.754). The similar primary efficacy outcomes were observed at months 3, 12, and >12. The secondary efficacy indicated that there were no differences in most indexes between the two groups at months 1, 3, 6, 12, and >12. The subgroups (based on baseline DAS28 (CRP), glucocorticoids use and disease duration) analysis results suggested that VitD group didn't have the advantage for treating RA. The incidence of infections was similar in the two groups. Conclusion: VitD supplementation did not provide additional benefit for anti-rheumatic treatment. These data supported the need for prospective, randomized, controlled trials to evaluate the role of VitD supplementation in treating RA.",2020,"The secondary efficacy indicated that there were no differences in most indexes between the two groups at months 1, 3, 6, 12, and >12.","[""1180 RA patients' records treated at Mianyang Central Hospital from February 2015 to July 2019"", 'rheumatoid arthritis (RA', 'Patients With Rheumatoid Arthritis']","['vitamin D (VitD) supplementation', 'Vitamin D']","['incidence of infections', 'treatment response-based EULAR response criteria in RA, and secondary efficacy, defined as improvement in disease activity indicators']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}]","[{'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}]",1180.0,0.0228291,"The secondary efficacy indicated that there were no differences in most indexes between the two groups at months 1, 3, 6, 12, and >12.","[{'ForeName': 'Jianhong', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Department of Rheumatology, Dazhou Central Hospital, Dazhou, China.'}, {'ForeName': 'Jianling', 'Initials': 'J', 'LastName': 'Dong', 'Affiliation': 'Department of Rheumatology, Mianyang Central Hospital, Mianyang, China.'}, {'ForeName': 'Shilin', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, China.'}, {'ForeName': 'Jiaang', 'Initials': 'J', 'LastName': 'Luo', 'Affiliation': 'Department of Rheumatology, Mianyang Central Hospital, Mianyang, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Rheumatology, Mianyang Central Hospital, Mianyang, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Department of Rheumatology, Mianyang Central Hospital, Mianyang, China.'}, {'ForeName': 'Yuanpiao', 'Initials': 'Y', 'LastName': 'Ni', 'Affiliation': 'Department of Rheumatology, Mianyang Central Hospital, Mianyang, China.'}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': 'Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, China.'}, {'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, China.'}, {'ForeName': 'Qianrong', 'Initials': 'Q', 'LastName': 'Xie', 'Affiliation': 'Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, China.'}, {'ForeName': 'Xuejun', 'Initials': 'X', 'LastName': 'Jiang', 'Affiliation': 'Department of Rheumatology, Dazhou Central Hospital, Dazhou, China.'}, {'ForeName': 'Tingting', 'Initials': 'T', 'LastName': 'Wang', 'Affiliation': 'Department of Rheumatology, Dazhou Central Hospital, Dazhou, China.'}, {'ForeName': 'Pingxi', 'Initials': 'P', 'LastName': 'Wang', 'Affiliation': 'Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, China.'}, {'ForeName': 'Fanwei', 'Initials': 'F', 'LastName': 'Zeng', 'Affiliation': 'Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, China.'}, {'ForeName': 'Yanpeng', 'Initials': 'Y', 'LastName': 'Chu', 'Affiliation': 'Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Department of Rheumatology, Mianyang Central Hospital, Mianyang, China.'}, {'ForeName': 'Fanxin', 'Initials': 'F', 'LastName': 'Zeng', 'Affiliation': 'Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, China.'}]",Frontiers in medicine,['10.3389/fmed.2020.00312'] 2801,32766334,"Effectiveness of emotional intelligence training program on marital satisfaction, sexual quality of life, and psychological well-being of women.","CONTEXT Emotional communications play an important role in having a satisfying relationship and a more successful marriage. If marriage does not provide suitable conditions to satisfy couple's needs, not only it does not help to mental health but also results in negative and irreversible effects. AIMS This research was performed with the aim of determining the impact of emotional intelligence training on marital satisfaction, sexual quality of life, and psychological well-being of women. SETTINGS AND DESIGN The present research is an experimental study conducted on 70 women referring to community health centers of Shahid Beheshti University of Medical Sciences in 2019. SUBJECTS AND METHODS The sampling was performed using multistage cluster sampling. Before implementing the training intervention, the research instruments (general questionnaire, Kansas Marital Satisfaction Scale, Iranian version of Sexual Quality of Life-Female questionnaire, and World Health Organization Five Well-Being Index) were provided to the participants in order to complete them. All participants recompleted the instruments immediately and 1 month after the training intervention. STATISTICAL ANALYSIS USED The significance level was considered as P < 0.05. RESULTS The mean scores of marital satisfaction in the control group had no significant difference before, immediately after, and 1 month after the intervention ( P = 0.895). However, in the intervention group, over time, the mean scores of marital satisfaction increased ( P = 0.001), and the difference between the two groups was significant ( P < 0.001). The mean scores of sexual quality of life and psychological well-being had no significant differences before, immediately after, and 1 month after the intervention in the control group. However, in the intervention group, over time, the mean scores of sexual quality of life and psychological well-being firstly increased and then decreased ( P < 0.001), and the difference between the two groups was significant ( P < 0.001). CONCLUSIONS Training the components of emotional intelligence can be effective on enhancing marital satisfaction, sexual quality of life, and psychological well-being of women.",2020,"The mean scores of marital satisfaction in the control group had no significant difference before, immediately after, and 1 month after the intervention ( P = 0.895).",['70 women referring to community health centers of Shahid Beheshti University of Medical Sciences in 2019'],"['emotional intelligence training program', 'emotional intelligence training']","['mean scores of marital satisfaction', 'enhancing marital satisfaction, sexual quality of life, and psychological well-being of women', 'marital satisfaction, sexual quality of life, and psychological well-being of women', 'mean scores of sexual quality of life and psychological well-being firstly', 'research instruments (general questionnaire, Kansas Marital Satisfaction Scale, Iranian version of Sexual Quality of Life-Female questionnaire, and World Health Organization Five Well-Being Index', 'mean scores of sexual quality of life and psychological']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0009469', 'cui_str': 'Satellite Centers'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}]","[{'cui': 'C1510539', 'cui_str': 'Emotional Intelligence'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0024841', 'cui_str': 'Marriage'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0424578', 'cui_str': 'Well in self'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1279901', 'cui_str': 'Firstly'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}]",70.0,0.0204812,"The mean scores of marital satisfaction in the control group had no significant difference before, immediately after, and 1 month after the intervention ( P = 0.895).","[{'ForeName': 'Arezoo Sheikh', 'Initials': 'AS', 'LastName': 'Milani', 'Affiliation': 'Department of Community Health Nursing, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Meimanat', 'Initials': 'M', 'LastName': 'Hosseini', 'Affiliation': 'Department of Community Health Nursing, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Matbouei', 'Affiliation': 'Department of Community Health Nursing, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Maliheh', 'Initials': 'M', 'LastName': 'Nasiri', 'Affiliation': 'Department of Biostatistics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}]",Journal of education and health promotion,['10.4103/jehp.jehp_124_20'] 2802,32766336,Comparing the effect of standardized patient-based education and feedback lecture on midwives' knowledge and practice in counseling screening for fetal malformations.,"INTRODUCTION Midwifery screening is one of the duties of midwives according to national guidelines. It is possible to increase midwives' knowledge and practice through effective education. The aim of this study was to compare the effect of standardized patient-based education and feedback lecture on midwives' knowledge and practice in screening counseling for fetal malformations. METHODS This quasi-experimental, two-group study (standardized patient-based training and feedback lecture) was performed on 67 midwives (licensed by the office) in Mashhad in 2018. Midwives' knowledge and practice before and 2 weeks after training (a 4-h training program) were assessed by the Objective Structured Clinical Examination and a questionnaire. The data were analyzed by the SPSS software version 16 using Mann-Whitney, Chi-square, Wilcoxon and independent t -test while P < 0.05 considered as a significant level. RESULTS Before intervention, the total score of knowledge and practice showed no statistically significant difference between the two groups ( P > 0.05). After intervention, knowledge score in feedback lecture group was statistically significantly higher than that of standard patient group ( P < 0.001). In addition, there was no statistically significant difference in performance scores between the two groups after intervention ( P = 0.761). CONCLUSION Both educational methods can increase midwives' knowledge and practice in fetal screening counseling. However, in raising midwives' awareness, feedback lecture group was more effective than standard patient group.",2020,"Before intervention, the total score of knowledge and practice showed no statistically significant difference between the two groups ( P > 0.05).","['67 midwives (licensed by the office) in Mashhad in 2018', ""midwives' knowledge and practice in counseling screening for fetal malformations""]",['standardized patient-based education and feedback lecture'],"['total score of knowledge and practice', 'knowledge score', 'performance scores']","[{'cui': 'C0026083', 'cui_str': 'Professional midwife'}, {'cui': 'C0023636', 'cui_str': 'Licenses'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0376683', 'cui_str': 'Lectures'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",,0.0194532,"Before intervention, the total score of knowledge and practice showed no statistically significant difference between the two groups ( P > 0.05).","[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Javidi-Sarafan', 'Affiliation': 'Department of Midwifery, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mahin', 'Initials': 'M', 'LastName': 'Tafazoli', 'Affiliation': 'Department of Midwifery, Evidence-Based Care Research Center, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Talat', 'Initials': 'T', 'LastName': 'Khadivzadeh', 'Affiliation': 'Department of Reproductive Health, Nursing and Midwifery Care Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Seyed Reza', 'Initials': 'SR', 'LastName': 'Mazloum', 'Affiliation': 'Nursing and Midwifery Care Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}]",Journal of education and health promotion,['10.4103/jehp.jehp_521_19'] 2803,32766340,Implementing of mental health training programs for promotion of health affected teenage girls to premenstrual syndrome: A community-based study.,"BACKGROUND Mental health is one of the major determinants of a person's health which has a significant impact on the quality of life. Implementing of mental health training programs for promotion of health affected teenage girls to premenstrual syndrome (PMS) in Shiraz, southern Iran: a community-based study. MATERIALS AND METHODS This study is randomized controlled trial done on 100 teenage girls affected to PMS in Shiraz-Iran (selected from400 girls). Multistage cluster sampling method was used f or sampling. In the intervention group, six training sessions were held twice a week for 2 h. For data collection, Standard Goldberg Mental Health Questionnaire-28 and Premenstrual Symptoms Screening Tool were used. For data analysis, independent t -test and Chi-square statistics were used at significant level of 0.05. RESULTS The average age was (16.56 ± 0.92) and (16.24 ± 1.45) in the intervention and control groups, respectively. The average intensity of physical complaints, level of anxiety and sleep disorder, level of social functions disorders and depression were significantly lower in the group of training classes than control group ( P < 0.001). CONCLUSION Appropriate training-care programs are effective in reducing stress and improving mental health, prevention and treatment of mental disorders, emotional growth, and development of communication skills among female students with premenstrual syndrome.",2020,"The average intensity of physical complaints, level of anxiety and sleep disorder, level of social functions disorders and depression were significantly lower in the group of training classes than control group ( P < 0.001). ","['health affected teenage girls to premenstrual syndrome (PMS) in Shiraz, southern Iran', 'health affected teenage girls to premenstrual syndrome', '100 teenage girls affected to PMS in Shiraz-Iran (selected from400 girls', 'female students with premenstrual syndrome']",['mental health training programs'],"['average intensity of physical complaints, level of anxiety and sleep disorder, level of social functions disorders and depression']","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0033046', 'cui_str': 'Premenstrual syndrome'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0277786', 'cui_str': 'Complaint'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0851578', 'cui_str': 'Sleep disorder'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",100.0,0.0319932,"The average intensity of physical complaints, level of anxiety and sleep disorder, level of social functions disorders and depression were significantly lower in the group of training classes than control group ( P < 0.001). ","[{'ForeName': 'Maliheh', 'Initials': 'M', 'LastName': 'Abootalebi', 'Affiliation': 'Department of Community Health Nursing, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Mansoureh', 'Initials': 'M', 'LastName': 'Dehghani', 'Affiliation': 'Department of Midwifery, School of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Marzieh', 'Initials': 'M', 'LastName': 'Akbarzadeh', 'Affiliation': 'Department of Midwifery, Maternal-Fetal Medicine Research Center, School of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",Journal of education and health promotion,['10.4103/jehp.jehp_118_20'] 2804,32763318,Does ureteral stent drainage prior to cystectomy increase the risk of subsequent upper tract urothelial carcinoma and ureteral complications?,"OBJECTIVES To guide management of preoperative hydronephrosis prior to radical cystectomy (RC), we compared post-RC risks of upper tract urothelial carcinoma (UTUC) and ureteroenteric anastomotic complications between ureteral stent and percutaneous nephrostomy tube drainage. METHODS Patients who underwent RC for urothelial carcinoma without a prior diagnosis of UTUC at our institution between 2000-2015 were included and divided into four patient groups: 1) no hydronephrosis (75%, N=787); 2) hydronephrosis without preoperative upper tract drainage (13%, N=132); 3) hydronephrosis treated with nephrostomy tube (3%, N=36); 4) hydronephrosis treated with ureteral stent (9%, N=94). The incidence of post-RC UTUC and ureteral complications was compared using Kaplan-Meier analyses and multivariable Cox proportional hazard modeling. RESULTS We identified a total of 1049 patients who underwent RC (median postoperative follow up 4.3 years). Five-year post-RC UTUC incidence was 6.6%, 10.2%, 17%, 18.7% for groups 1-4, respectively (p=0.13). On multivariable analysis, nephrostomy tube drainage (HR 4.10, P=0.02) and preoperative ureteral stenting (HR 2.35, P=0.04) were both associated with UTUC after RC, but ureteral stenting did not have a significantly higher association with UTUC than nephrostomy tube drainage. Severe hydronephrosis was also associated with development of UTUC (HR 4.03, P=0.02). The incidence of ureteroenteric anastomotic complications did not vary by drainage modality. CONCLUSIONS Pre-operative hydronephrosis was associated with UTUC after RC, but ureteral stent placement did not increase the risk of UTUC or ureteral complications relative to nephrostomy tube placement. The choice of hydronephrosis drainage pre-RC should not be guided by concern for UTUC risk.",2020,"On multivariable analysis, nephrostomy tube drainage (HR 4.10, P=0.02) and preoperative ureteral stenting (HR 2.35, P=0.04) were both associated with UTUC after RC, but ureteral stenting did not have a significantly higher association with UTUC than nephrostomy tube drainage.","['1049 patients who underwent RC (median postoperative follow up 4.3 years', 'Patients who underwent RC for urothelial carcinoma without a prior diagnosis of UTUC at our institution between 2000-2015 were included and divided into four patient groups: 1) no hydronephrosis (75%, N=787); 2']","['hydronephrosis treated with ureteral stent', 'hydronephrosis without preoperative upper tract drainage', 'hydronephrosis treated with nephrostomy tube', 'ureteral stent and percutaneous nephrostomy tube drainage', 'UTUC', 'ureteral stent drainage prior to cystectomy', 'preoperative hydronephrosis prior to radical cystectomy (RC']","['Severe hydronephrosis', 'risk of UTUC or ureteral complications', 'preoperative ureteral stenting', 'incidence of post-RC UTUC and ureteral complications', 'ureteroenteric anastomotic complications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0194401', 'cui_str': 'Complete cystectomy'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C4517759', 'cui_str': '4.3'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0007138', 'cui_str': 'Transitional cell carcinoma'}, {'cui': 'C0332132', 'cui_str': 'Prior diagnosis'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0020295', 'cui_str': 'Hydronephrosis'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0183518', 'cui_str': 'Ureteric stent'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0184149', 'cui_str': 'Nephrostomy tube'}, {'cui': 'C0027724', 'cui_str': 'Percutaneous insertion of nephrostomy tube'}, {'cui': 'C0184114', 'cui_str': 'Tube drain'}, {'cui': 'C0007138', 'cui_str': 'Transitional cell carcinoma'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0010651', 'cui_str': 'Bladder excision'}, {'cui': 'C0194401', 'cui_str': 'Complete cystectomy'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0020295', 'cui_str': 'Hydronephrosis'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0007138', 'cui_str': 'Transitional cell carcinoma'}, {'cui': 'C1522613', 'cui_str': 'Ureteral route'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0194401', 'cui_str': 'Complete cystectomy'}, {'cui': 'C1141928', 'cui_str': 'Anastomotic complication'}]",1049.0,0.0454897,"On multivariable analysis, nephrostomy tube drainage (HR 4.10, P=0.02) and preoperative ureteral stenting (HR 2.35, P=0.04) were both associated with UTUC after RC, but ureteral stenting did not have a significantly higher association with UTUC than nephrostomy tube drainage.","[{'ForeName': 'T S', 'Initials': 'TS', 'LastName': 'Miest', 'Affiliation': 'Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Sharma', 'Affiliation': 'Department of Urology, Mayo Clinic, Rochester, Minnesota, USA; Los Angeles VA - UCLA Department of Urology, Los Angeles, California, USA.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Boeri', 'Affiliation': 'Department of Urology, Mayo Clinic, Rochester, Minnesota, USA; Los Angeles VA - UCLA Department of Urology, Los Angeles, California, USA.'}, {'ForeName': 'M K', 'Initials': 'MK', 'LastName': 'Tollefson', 'Affiliation': 'Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'R H', 'Initials': 'RH', 'LastName': 'Thompson', 'Affiliation': 'Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'Boorjian', 'Affiliation': 'Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Frank', 'Affiliation': 'Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'R J', 'Initials': 'RJ', 'LastName': 'Karnes', 'Affiliation': 'Department of Urology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: karnes.r@mayo.edu.'}]",Urology,['10.1016/j.urology.2020.07.034'] 2805,32763435,Maxillary lateral incisor injection pain using the Dentapen electronic syringe.,"When patients express fear and anxiety about dentistry, one main source involves the administration of local anesthetic. The Dentapen is a Computer-Controlled Local Anesthetic Device (CCLAD) that regulates the rate of anesthetic deposition to reduce pain associated with dental injections. The purpose of this study was to evaluate differences in perceived pain during the administration of local anesthesia of the maxillary lateral incisors using the ramp-up and continuous injection modes of the Dentapen. METHODS This study utilized a randomized, controlled, double-blinded, crossover, experimental design. The investigators randomly assigned the order of the teeth (#7 or #10) and the 2 delivery modes (continuous or ramp-up). Participants completed a Corah's dental anxiety scale at each visit and were injected on 2 separate visits at least 2 weeks apart. After each injection, participants rated their perceived pain using a Heft-Parker visual analogue scale at needle insertion, needle placement, and solution deposition. Repeated-measures ANOVA was used to determine differences in perceived pain between the 2 modes. RESULTS The data from 116 participants were analyzed. The perceived pain at deposition with the ramp-up mode (M=51.98, sd=30.04) was less than the continuous mode (M=59.98, sd=36.28), although not statistically significant (F(1,230)=2.569, p>.05). Clinically, the perceived pain with the ramp-up mode was in the mild range (<54mm), whereas the mean perceived pain with the continuous mode was in the moderate/severe range (>54mm). CONCLUSION Further research should evaluate whether the ramp-up mode could be used to reduce the pain perceived with other dental injections.",2020,"The perceived pain at deposition with the ramp-up mode (M=51.98, sd=30.04) was less than the continuous mode (M=59.98, sd=36.28), although not statistically significant (F(1,230)=2.569, p>.05).",['116 participants were analyzed'],['Dentapen electronic syringe'],"[""Corah's dental anxiety scale"", 'perceived pain at deposition', 'Maxillary lateral incisor injection pain']","[{'cui': 'C4517541', 'cui_str': '116'}]","[{'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0039142', 'cui_str': 'Syringe'}]","[{'cui': 'C0085380', 'cui_str': 'Dental phobia'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0333562', 'cui_str': 'Deposition'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0021156', 'cui_str': 'Structure of incisor tooth'}, {'cui': 'C1096717', 'cui_str': 'Pain during injection'}]",116.0,0.101603,"The perceived pain at deposition with the ramp-up mode (M=51.98, sd=30.04) was less than the continuous mode (M=59.98, sd=36.28), although not statistically significant (F(1,230)=2.569, p>.05).","[{'ForeName': 'Brian B', 'Initials': 'BB', 'LastName': 'Partido', 'Affiliation': 'The Ohio State University College of Dentistry Division of Dental Hygiene. Electronic address: brian.partido@seattlecolleges.edu.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Nusstein', 'Affiliation': 'The Ohio State University College of Dentistry Division of Endodontics.'}, {'ForeName': 'Kyerston', 'Initials': 'K', 'LastName': 'Miller', 'Affiliation': 'The Ohio State University College of Dentistry Division of Dental Hygiene.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Lally', 'Affiliation': 'The Ohio State University College of Dentistry Division of Dental Hygiene.'}]",Journal of endodontics,['10.1016/j.joen.2020.07.029'] 2806,32763533,Effects of aerobic exercise on cardiorespiratory fitness and social functioning in veterans 40 to 65 years old with schizophrenia.,"The usual physical activity level of people with chronic histories of schizophrenia is very low. In this pilot study, we examined the effects of an easy to implement aerobic exercise (AE) program on cardiorespiratory fitness and social functioning in 54 Veterans aged 40-65 years old with schizophrenia. Participants were randomized 2:1 to AE (36 forty-minute sessions conducted 3 times per week over 12 weeks) versus a non-aerobic stretching exercise condition conducted under the same regimen and timeframe. Cardiorespiratory fitness improved significantly within the AE group (p<.0001), and differed significantly from the comparison group (p<.02; Cohen's d=.41). Trend-level improvements were seen in social functioning within the AE group (p<.09) and showed a similar trend level difference in the between-group comparison (p<.06; Cohen's d=.35). Improvements in social functioning were significantly related to gains in cardiorespiratory fitness (r=.42; p<.01). AE effects on other physical and mental health indices were also examined. Overall, the AE intervention was well-tolerated, safe, and showed low rates of attrition after the commencement of training. Our findings indicate it is feasible to improve cardiorespiratory fitness in this clinical population, and there is suggestive evidence that the interventions aimed to do so may also benefit social functioning.",2020,"Overall, the AE intervention was well-tolerated, safe, and showed low rates of attrition after the commencement of training.","['people with chronic histories of schizophrenia', 'veterans 40 to 65 years old with schizophrenia', '54 Veterans aged 40-65 years old with schizophrenia']","['easy to implement aerobic exercise (AE) program', 'non-aerobic stretching exercise condition', 'aerobic exercise']","['social functioning', 'tolerated, safe', 'Cardiorespiratory fitness', 'cardiorespiratory fitness and social functioning', 'physical and mental health indices', 'cardiorespiratory fitness']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0455502', 'cui_str': 'H/O: schizophrenia'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0332219', 'cui_str': 'Easy'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.0299191,"Overall, the AE intervention was well-tolerated, safe, and showed low rates of attrition after the commencement of training.","[{'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Kern', 'Affiliation': 'UCLA Semel Institute for Neuroscience & Human Behavior, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, California, United States of America; Department of Veterans Affairs Desert Pacific Mental Illness Research, Education, and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, California, United States of America. Electronic address: rkern@ucla.edu.'}, {'ForeName': 'L Felice', 'Initials': 'LF', 'LastName': 'Reddy', 'Affiliation': 'UCLA Semel Institute for Neuroscience & Human Behavior, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, California, United States of America.'}, {'ForeName': 'Amy N', 'Initials': 'AN', 'LastName': 'Cohen', 'Affiliation': 'UCLA Semel Institute for Neuroscience & Human Behavior, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, California, United States of America; Department of Veterans Affairs Desert Pacific Mental Illness Research, Education, and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, California, United States of America.'}, {'ForeName': 'Alexander S', 'Initials': 'AS', 'LastName': 'Young', 'Affiliation': 'UCLA Semel Institute for Neuroscience & Human Behavior, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, California, United States of America; Department of Veterans Affairs Desert Pacific Mental Illness Research, Education, and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, California, United States of America.'}, {'ForeName': 'Michael F', 'Initials': 'MF', 'LastName': 'Green', 'Affiliation': 'UCLA Semel Institute for Neuroscience & Human Behavior, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, California, United States of America; Department of Veterans Affairs Desert Pacific Mental Illness Research, Education, and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, California, United States of America.'}]",Psychiatry research,['10.1016/j.psychres.2020.113258'] 2807,32763541,"Residual symptoms of PTSD following Sertraline plus enhanced medication management, Sertraline plus PE, and PE plus placebo.","Although prolonged exposure (PE) and SSRI antidepressants are effective in treating posttraumatic stress disorder (PTSD), previous studies have shown that some symptoms tend to persist. The current study compared sertraline hydrochloride plus enhanced medication management (EMM), PE plus placebo, or PE plus sertraline hydrochloride in the likelihood of each individual PTSD symptom persisting in veterans with a PTSD diagnosis. We compared the likelihood of individual PTSD symptoms persisting in those with versus without a PTSD diagnosis at posttreatment. We found no significant differences across conditions in which symptoms were likely to persist posttreatment. Among those without a PTSD diagnosis at posttreatment, sleeping difficulties (63.0%), hypervigilance (47.3%), and nightmares (45.0%) were most likely to persist. Findings indicate no consistent differences in residual symptoms between PE and medications, and shared decision making with patients is encouraged in selecting treatments. Gold standard treatments (e.g., CBT-I) may be warranted for residual symptoms like insomnia.",2020,"Among those without a PTSD diagnosis at posttreatment, sleeping difficulties (63.0%), hypervigilance (47.3%), and nightmares (45.0%) were most likely to persist.",['veterans with a PTSD diagnosis'],"['Sertraline', 'prolonged exposure (PE) and SSRI antidepressants', 'Sertraline plus PE, and PE plus placebo', 'sertraline hydrochloride plus enhanced medication management (EMM), PE plus placebo, or PE plus sertraline hydrochloride']","['sleeping difficulties', 'hypervigilance']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0074393', 'cui_str': 'Sertraline'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0360105', 'cui_str': 'Selective serotonin re-uptake inhibitor'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0600526', 'cui_str': 'Sertraline hydrochloride'}, {'cui': 'C0150270', 'cui_str': 'Management of drug regimen'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}]","[{'cui': 'C0235162', 'cui_str': 'Difficulty sleeping'}, {'cui': 'C0235013', 'cui_str': 'Hypervigilance'}]",,0.0425289,"Among those without a PTSD diagnosis at posttreatment, sleeping difficulties (63.0%), hypervigilance (47.3%), and nightmares (45.0%) were most likely to persist.","[{'ForeName': 'Jessica C', 'Initials': 'JC', 'LastName': 'Tripp', 'Affiliation': 'VA San Diego Healthcare System, 3350 Villa La Jolla Drive, San Diego, CA 92161, USA; University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA 92037, USA.'}, {'ForeName': 'Sonya B', 'Initials': 'SB', 'LastName': 'Norman', 'Affiliation': 'VA San Diego Healthcare System, 3350 Villa La Jolla Drive, San Diego, CA 92161, USA; University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA 92037, USA; National Center for PTSD, 215 N. Main St., White River Junction, VT 05009, USA; VA Center of Excellence for Stress and Mental Health, 3350 La Jolla Village Dr., MC116B, San Diego, CA 92161, USA. Electronic address: snorman@health.ucsd.edu.'}, {'ForeName': 'H Myra', 'Initials': 'HM', 'LastName': 'Kim', 'Affiliation': 'Consulting for Statistics, Computing and Analytics Research, University of Michigan, 915 E. Washington Street, Ann Arbor, MI 48109, USA.'}, {'ForeName': 'Margaret R', 'Initials': 'MR', 'LastName': 'Venners', 'Affiliation': 'National Center for PTSD, Dissemination & Training Division, 795 Willow Road, Menlo Park, CA 94025, USA.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Martis', 'Affiliation': 'VA San Diego Healthcare System, 3350 Villa La Jolla Drive, San Diego, CA 92161, USA; University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA 92037, USA.'}, {'ForeName': 'Naomi M', 'Initials': 'NM', 'LastName': 'Simon', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, One Bowdoin Square, Boston, MA, USA; Department of Psychiatry, New York University Grossman School of Medicine, One Park Avenue 8(th) Floor, New York, NY 10016, USA.'}, {'ForeName': 'Murray B', 'Initials': 'MB', 'LastName': 'Stein', 'Affiliation': 'VA San Diego Healthcare System, 3350 Villa La Jolla Drive, San Diego, CA 92161, USA; University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA 92037, USA.'}, {'ForeName': 'Carolyn B', 'Initials': 'CB', 'LastName': 'Allard', 'Affiliation': 'VA San Diego Healthcare System, 3350 Villa La Jolla Drive, San Diego, CA 92161, USA; Alliant International University, 10455 Pomerado Road, San Diego, CA, USA.'}, {'ForeName': 'Sheila A M', 'Initials': 'SAM', 'LastName': 'Rauch', 'Affiliation': 'Mental Health Service Line, Veterans Affairs Atlanta Healthcare System, 1670 Clairmont Rd., GA 30030, USA; Emory University School of Medicine, 12 Executive Park, 3(rd) Floor, Atlanta, GA 30329, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Psychiatry research,['10.1016/j.psychres.2020.113279'] 2808,32763548,Effect of psychotropic drugs on cortical excitability of patients with major depressive disorders: A transcranial magnetic stimulation study.,"Transcranial magnetic stimulation (TMS) can be used to evaluate the effects of pharmacological interventions. The aim of this study was to assess the impact of the selective serotonin reuptake inhibitor, sertraline, and the atypical antipsychotic drugs quetiapine and olanzapine, on cortical excitability in unmedicated patients with major depressive disorder (MDD). The study included 45 medication-free MDD patients diagnosed according to DSM V. They were divided randomly into three groups who received a single oral dose of one of the three drugs sertraline (50 mg), quetiapine (100 mg) and olanzapine (10 mg). Psychological evaluation was conducted using the Mini-Mental State Examination (MMSE) and Beck Depression Inventory Scale (BDI). Resting and active motor thresholds (rMT and aMT) together with contralateral and ipsilateral cortical silent periods (cSP, and iSP) were measured for each participant before and at the time of maximum concentration of drug intake. There was significant increase in excitability of motor cortex after sertraline without changes in GABA B neurotransmission. Quetiapine and olanzapine potentiated inhibitory GABA B neurotransmission (prolongation of cSP); olanzapine additionally prolonged the iSP. Thus TMS can differentiate between the impact of different psychotropic drugs on excitatory and inhibitory transmission in motor cortex.",2020,Quetiapine and olanzapine potentiated inhibitory GABA B neurotransmission (prolongation of cSP); olanzapine additionally prolonged the iSP.,"['unmedicated patients with major depressive disorder (MDD', 'patients with major depressive disorders', '45 medication-free MDD patients diagnosed according to DSM V']","['olanzapine', 'sertraline', 'Quetiapine and olanzapine', 'Transcranial magnetic stimulation (TMS', 'psychotropic drugs', 'sertraline, and the atypical antipsychotic drugs quetiapine and olanzapine', 'quetiapine']","['cortical excitability', 'Mini-Mental State Examination (MMSE) and Beck Depression Inventory Scale (BDI', 'excitability of motor cortex', 'Resting and active motor thresholds (rMT and aMT) together with contralateral and ipsilateral cortical silent periods (cSP, and iSP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}]","[{'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C0074393', 'cui_str': 'Sertraline'}, {'cui': 'C0123091', 'cui_str': 'quetiapine'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}, {'cui': 'C0033978', 'cui_str': 'Psychotherapeutic agent'}, {'cui': 'C0205182', 'cui_str': 'Atypical'}, {'cui': 'C0040615', 'cui_str': 'Antipsychotic agent'}]","[{'cui': 'C4277734', 'cui_str': 'Cortical Excitability'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}, {'cui': 'C0026607', 'cui_str': 'Motor cortex'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0063517', 'cui_str': 'indopan'}, {'cui': 'C0441988', 'cui_str': 'Contralateral'}, {'cui': 'C0441989', 'cui_str': 'Ipsilateral'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0443304', 'cui_str': 'Silent'}, {'cui': 'C0010701', 'cui_str': 'Phyllodes tumour'}]",,0.0198595,Quetiapine and olanzapine potentiated inhibitory GABA B neurotransmission (prolongation of cSP); olanzapine additionally prolonged the iSP.,"[{'ForeName': 'Eman M', 'Initials': 'EM', 'LastName': 'Khedr', 'Affiliation': 'Neuropsychiatry Department, Faculty of Medicine, Assiut University, Assiut, Egypt. Electronic address: emankhedr99@yahoo.com.'}, {'ForeName': 'Yasser', 'Initials': 'Y', 'LastName': 'Elserogy', 'Affiliation': 'Neuropsychiatry Department, Faculty of Medicine, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Fawzy', 'Affiliation': 'Neuropsychiatry Department, Faculty of Medicine, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Ahmed A', 'Initials': 'AA', 'LastName': 'Abdelrahman', 'Affiliation': 'Neuropsychiatry Department, Faculty of Medicine, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Amr M', 'Initials': 'AM', 'LastName': 'Galal', 'Affiliation': 'Neuropsychiatry Department, Faculty of Medicine, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Mostafa M', 'Initials': 'MM', 'LastName': 'Noaman', 'Affiliation': 'Neuropsychiatry Department, Faculty of Medicine, Assiut University, Assiut, Egypt.'}]",Psychiatry research,['10.1016/j.psychres.2020.113287'] 2809,32763585,Plasma MCP-1 levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment.,"BACKGROUND Neuroinflammation plays a role in the pathophysiology of Bipolar Disorder Depression (BDD) and altered levels of inflammatory mediators, such as monocyte chemoattractant protein-1 (MCP-1, aka CCL2) have been reported. This study reports specifically on MCP-1 levels, as a potential marker of BDD and/or treatment response in patients receiving combination treatment with the cyclooxygenase-2 inhibitor, celecoxib (CBX). METHODS In this randomized, 10-week, double-blind, two-arm, placebo-controlled study, 47 patients with treatment resistant BDD received either escitalopram (ESC) + CBX, or ESC + placebo (PBO). Plasma MCP-1 levels were measured at 3 time points in the BDD subjects, and in a healthy control (HC) group. Depression severity was quantified using the Hamilton Depression Scale (HAMD-17). RESULTS The CBX group had significantly lower HAMD-17 scores vs. PBO at week 4 (P = 0.026) and week 8 (P = 0.002). MCP-1 levels were not significantly different in BDD vs. HC subjects at baseline (P = 0.588), nor in CBX vs. PBO groups at week 8 (P = 0.929). Week 8 HAMD-17 scores and MCP-1 levels were significantly negatively correlated in treatment non-responders to CBX or PBO (P = 0.050). Non-responders had significantly lower MCP-1 levels vs. responders at weeks 4 (P = 0.049) and 8 (P = 0.014). MCP-1 was positively correlated with pro-inflammatory analytes in the PBO group and with anti-inflammatory analytes in the CBX group. CONCLUSIONS Combination treatment reduced treatment resistance and augmented antidepressant response. Baseline plasma MCP-1 levels were not altered in BDD patients. Since non-responders had lower levels of MCP-1, elevated MCP-1 may indicate a better response to CBX + SSRI treatment.",2020,Non-responders had significantly lower MCP-1 levels vs. responders at weeks 4 (P = 0.049) and 8 (P = 0.014).,"['47 patients with treatment resistant BDD received either', 'patients receiving combination treatment with the']","['cyclooxygenase-2 inhibitor combination treatment', 'cyclooxygenase-2 inhibitor, celecoxib (CBX', 'CBX', 'escitalopram (ESC)\xa0+\xa0CBX, or ESC\xa0+\xa0placebo (PBO', 'placebo']","['Depression severity', 'Hamilton Depression Scale (HAMD-17', 'treatment resistance and augmented antidepressant response', 'MCP-1 levels', 'HAMD-17 scores and MCP-1 levels', 'MCP-1', 'Baseline plasma MCP-1 levels', 'Plasma MCP-1 levels', 'HAMD-17 scores vs. PBO']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0005587', 'cui_str': 'Bipolar affective disorder, current episode depression'}]","[{'cui': 'C1257954', 'cui_str': 'Cyclooxygenase-2 inhibitor'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0538927', 'cui_str': 'celecoxib'}, {'cui': 'C1099456', 'cui_str': 'Escitalopram'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C0128897', 'cui_str': 'Monocyte Chemoattractant Protein-1'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",47.0,0.0285352,Non-responders had significantly lower MCP-1 levels vs. responders at weeks 4 (P = 0.049) and 8 (P = 0.014).,"[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Edberg', 'Affiliation': 'Department of Psychiatry and Behavioral Neuroscience, Loyola University Stritch School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Hoppensteadt', 'Affiliation': 'Department of Pathology, Loyola University Stritch School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Walborn', 'Affiliation': 'Department of Pathology, Loyola University Stritch School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Jawed', 'Initials': 'J', 'LastName': 'Fareed', 'Affiliation': 'Department of Pathology, Loyola University Stritch School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Sinacore', 'Affiliation': 'Department of Public Health Sciences, Loyola University Stritch School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Angelos', 'Initials': 'A', 'LastName': 'Halaris', 'Affiliation': 'Department of Psychiatry and Behavioral Neuroscience, Loyola University Stritch School of Medicine, Chicago, IL, USA. Electronic address: ahalaris@lumc.edu.'}]",Journal of psychiatric research,['10.1016/j.jpsychires.2020.06.010'] 2810,32763623,Effect of exogenous progesterone administration on smoking topography.,"INTRODUCTION Progesterone has been implicated as protective against drug taking behaviors, including combustible cigarettes. While prior research indicates higher endogenous progesterone levels are associated with a reduction in smoking intensity (as measured by smoking topography), it is unknown if exogenous delivery of progesterone may have the same effect. METHODS This double-blind, counterbalanced, cross-over randomized trial enrolled women between the ages of 18 and 40 who smoked at least five cigarettes per day and were currently using oral contraceptives. After overnight abstinence participants attended two topography lab sessions. One lab session was conducted during progesterone (200 mg twice per day) treatment and the other was during placebo treatment. Analyses included linear mixed effect models to examine the effect of exogenous progesterone administration and endogenous progesterone values on topography outcomes. RESULTS Participants (n = 43) were 23.8 (standard deviation [SD] ± 4.5) years old, smoked 10.5 (SD ± 3.7) cigarettes per day. Compared to placebo administration, progesterone administration reduced cumulative puff volume by 300 mL (95% confidence interval [CI]: -536, -65; p-value = 0.01) with additional trends indicating possible reductions in the number of puffs, average puff volume, and average flow. There were no significant effects of endogenous progesterone on smoking topography outcomes. CONCLUSIONS Progesterone administration has the potential to reduce smoking intensity after overnight abstinence in women of reproductive age. Additional research is needed to explore how this may relate to smoking cessation outcomes in women of reproductive age.",2020,"Compared to placebo administration, progesterone administration reduced cumulative puff volume by 300 mL","['Participants (n\xa0=\xa043) were 23.8 (standard deviation [SD]\xa0±\xa04.5) years old, smoked 10.5 (SD\xa0±\xa03.7) cigarettes per day', 'trial enrolled women between the ages of 18 and 40 who smoked at least five cigarettes per day and were currently using oral contraceptives', 'women of reproductive age']","['progesterone', 'exogenous progesterone', 'Progesterone', 'placebo']","['cumulative puff volume', 'number of puffs, average puff volume, and average flow', 'smoking intensity', 'smoking topography']","[{'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C3844009', 'cui_str': '4.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C4517521', 'cui_str': '10.5'}, {'cui': 'C4517696', 'cui_str': '3.7'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C1527415', 'cui_str': 'Oral route'}, {'cui': 'C0009871', 'cui_str': 'Contraceptive agent'}, {'cui': 'C0035150', 'cui_str': 'Reproduction'}]","[{'cui': 'C0033308', 'cui_str': 'Progesterone'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1533107', 'cui_str': 'Puff - unit of product usage'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}]",43.0,0.178407,"Compared to placebo administration, progesterone administration reduced cumulative puff volume by 300 mL","[{'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Allen', 'Affiliation': 'Department of Family and Community Medicine, College of Medicine - Tucson, University of Arizona, United States. Electronic address: aliciaallen@arizona.edu.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Petersen', 'Affiliation': 'Division of Biostatistics, School of Public Health, University of Minnesota, United States.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Harrison', 'Affiliation': 'Department of Family Medicine and Community Health, Medical School, University of Minnesota, United States.'}, {'ForeName': 'Uma', 'Initials': 'U', 'LastName': 'Nair', 'Affiliation': 'Department of Family and Community Medicine, College of Medicine - Tucson, University of Arizona, United States.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Allen', 'Affiliation': 'Department of Family Medicine and Community Health, Medical School, University of Minnesota, United States.'}]",Addictive behaviors,['10.1016/j.addbeh.2020.106570'] 2811,32763625,Evaluation of impact-shock on gait after the implementation of two different training programs in older adults.,"BACKGROUND Gait is negatively affected with increasing age. It is widely accepted that training produces physical-functional improvements in older adults, which can be assessed with numerous physical-functional tests. However, very few studies have been carried out using accelerometry to analyse the training effect on kinetic and kinematic variables in older adults, and there is no one that investigate the effects of two different training programs. Therefore, the aim of this study is to analyse the effects of an interval-walking program and a multicomponent program on the acceleration impacts, shock attenuation, step-length, stride frequency, and gait speed in older adults. METHODS 23 participants were divided into multicomponent training group [n = 12, 7 female, 71.58 (4.56) years] and interval-walking group [n = 11, 6 female, 69.64 (3.56) years]. We evaluated the participants using three triaxial accelerometers, placing one on the distal end of each tibia and one on the forehead. FINDINGS After 14 weeks' of training, the maximum acceleration values both for the head accelerometer and for the non-dominant tibia, as well as the attenuation in the same leg, increased in the multicomponent training group. The maximum acceleration values for the head and the stride frequency also increased in the interval-walking group. Lower limb strength improved in both groups. INTERPRETATION Given the benefits we found for each of these programs, we encourage their consideration when planning older adults training programs and suggest that multicomponent programs should be introduced prior to the start of walking-based programs.",2020,"After 14 weeks' of training, the maximum acceleration values both for the head accelerometer and for the non-dominant tibia, as well as the attenuation in the same leg, increased in the multicomponent training group.","['participants using three triaxial accelerometers, placing one on the distal end of each tibia and one on the forehead', 'group [n\xa0=\xa012, 7 female, 71.58 (4.56) years] and interval-walking group [n\xa0=\xa011, 6 female, 69.64 (3.56) years', 'older adults', '23 participants']","['multicomponent training', 'interval-walking program and a multicomponent program']","['Lower limb strength', 'maximum acceleration values', 'stride frequency', 'acceleration impacts, shock attenuation, step-length, stride frequency, and gait speed']","[{'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0040184', 'cui_str': 'Bone structure of tibia'}, {'cui': 'C0016540', 'cui_str': 'Forehead structure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517763', 'cui_str': '4.56'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0000894', 'cui_str': 'Acceleration'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0036974', 'cui_str': 'Shock'}, {'cui': 'C0427126', 'cui_str': 'Step length'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}]",23.0,0.0172172,"After 14 weeks' of training, the maximum acceleration values both for the head accelerometer and for the non-dominant tibia, as well as the attenuation in the same leg, increased in the multicomponent training group.","[{'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Sanchis-Sanchis', 'Affiliation': 'Research Group in Sports Biomechanics (GIBD), Department of Physical Education and Sports, University of Valencia, Valencia, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Blasco-Lafarga', 'Affiliation': 'Sport Performance and Physical Fitness Research Group (UIRFIDE), Department of Physical Education and Sports, University of Valencia, Valencia, Spain.'}, {'ForeName': 'Andrés', 'Initials': 'A', 'LastName': 'Camacho-García', 'Affiliation': 'Departamento de Comunicaciones, Universitat Politècnica de València, Alcoy, Spain.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Encarnación-Martínez', 'Affiliation': 'Research Group in Sports Biomechanics (GIBD), Department of Physical Education and Sports, University of Valencia, Valencia, Spain.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Pérez-Soriano', 'Affiliation': 'Research Group in Sports Biomechanics (GIBD), Department of Physical Education and Sports, University of Valencia, Valencia, Spain. Electronic address: pedro.perez-soriano@uv.es.'}]","Clinical biomechanics (Bristol, Avon)",['10.1016/j.clinbiomech.2020.105131'] 2812,32763967,Value of FEops HEARTguide patient-specific computational simulations in the planning of left atrial appendage closure with the Amplatzer Amulet closure device: rationale and design of the PREDICT-LAA study.,"BACKGROUND Optimal preprocedural planning is essential to ensure successful device closure of the left atrial appendage (LAA). DESIGN The PREDICT-LAA study is a prospective, international, multicentre, randomised controlled trial (ClinicalTrials.gov NCT04180605). Two hundred patients eligible for LAA closure with an Amplatzer Amulet device (Abbott, USA) will be enrolled in the study. Patients will be allocated to a computational simulation arm (experimental) or standard treatment arm (control) using a 1:1 randomisation. For patients randomised to the computational simulation arm, preprocedural planning will be based on the analysis of cardiac computed tomography (CCT)-based patient-specific computational simulations (FEops HEARTguide, Ghent, Belgium) in order to predict optimal device size and position. For patients in the control arm, preprocedural planning will be based on local practice including CCT analysis. The LAA closure procedure and postprocedural antithrombotic therapy will follow local practice in both arms. The primary endpoint of the study is incomplete LAA closure and device-related thrombus as assessed at 3 months postprocedural CCT. Secondary endpoints encompass procedural efficiency (number of devices used, number of repositioning, procedural time, radiation exposure, contrast dye), procedure-related complications within 7 days postprocedure and a composite of all-cause death and thromboembolic events at 12 months. CONCLUSION The objective of the PREDICT-LAA study is to test the hypothesis that a preprocedural planning for LAA closure with the Amplatzer Amulet device based on patient-specific computational simulations can result in a more efficient procedure, optimised procedural outcomes and better clinical outcomes as compared with a standard preprocedural planning. TRIAL REGISTRATION NUMBER ClinicalTrials.gov Registry (NCT04180605).",2020,"Secondary endpoints encompass procedural efficiency (number of devices used, number of repositioning, procedural time, radiation exposure, contrast dye), procedure-related complications within 7 days postprocedure and a composite of all-cause death and thromboembolic events at 12 months. ","['Two hundred patients eligible for LAA closure with an Amplatzer Amulet device (Abbott, USA']",['computational simulation arm (experimental) or standard treatment arm (control'],"['incomplete LAA closure and device-related thrombus as assessed at 3 months postprocedural CCT', 'procedural efficiency (number of devices used, number of repositioning, procedural time, radiation exposure, contrast dye), procedure-related complications within 7 days postprocedure and a composite of all-cause death and thromboembolic events']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4523927', 'cui_str': 'Atrial appendage closure'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205257', 'cui_str': 'Incomplete'}, {'cui': 'C4523927', 'cui_str': 'Atrial appendage closure'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0087086', 'cui_str': 'Thrombus'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1298904', 'cui_str': 'Device used'}, {'cui': 'C0556030', 'cui_str': 'Repositioning'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0015333', 'cui_str': 'Exposure to radiation'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0013343', 'cui_str': 'Dye'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}]",200.0,0.183072,"Secondary endpoints encompass procedural efficiency (number of devices used, number of repositioning, procedural time, radiation exposure, contrast dye), procedure-related complications within 7 days postprocedure and a composite of all-cause death and thromboembolic events at 12 months. ","[{'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Garot', 'Affiliation': 'Department of Cardiology, Institut Cardiovasculaire Paris Sud, Massy, Île-de-France, France.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Iriart', 'Affiliation': 'Pediatric and Congenital Cardiology, University Hospital of Bordeaux, Pessac, MS, France.'}, {'ForeName': 'Adel', 'Initials': 'A', 'LastName': 'Aminian', 'Affiliation': 'Department of Cardiology, Centre Hospitalier Universitaire de Charleroi, Charleroi, Hainaut, Belgium.'}, {'ForeName': 'Joelle', 'Initials': 'J', 'LastName': 'Kefer', 'Affiliation': 'Division of Cardiology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Freixa', 'Affiliation': 'Cardiovascular Institute, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Cruz-Gonzalez', 'Affiliation': 'Department of Cardiology, Hospital Clínico Universitario de Salamanca, Salamanca, Spain.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Berti', 'Affiliation': 'Cardiology Unit, Fondazione CNR Regione Toscana, Massa, Italy.'}, {'ForeName': 'Liesbeth', 'Initials': 'L', 'LastName': 'Rosseel', 'Affiliation': 'Department of Cardiology, University Hospital Galway, Galway, Ireland.'}, {'ForeName': 'Reda', 'Initials': 'R', 'LastName': 'Ibrahim', 'Affiliation': 'Department of Cardiology, Montreal Heart Institute, Montreal, Quebec, Canada.'}, {'ForeName': 'Kasper', 'Initials': 'K', 'LastName': 'Korsholm', 'Affiliation': 'Department of Cardiology, Aarhus Universitetshospital Skejby, Aarhus, Denmark.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Odenstedt', 'Affiliation': 'Department of Cardiology, Sahlgrenska University Hospital, Goteborg, Sweden.'}, {'ForeName': 'Jens-Erik', 'Initials': 'JE', 'LastName': 'Nielsen-Kudsk', 'Affiliation': 'Department of Cardiology, Aarhus Universitetshospital Skejby, Aarhus, Denmark.'}, {'ForeName': 'Jaqueline', 'Initials': 'J', 'LastName': 'Saw', 'Affiliation': 'Department of Cardiology, Vancouver General Hospital, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Sondergaard', 'Affiliation': 'Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Ole', 'Initials': 'O', 'LastName': 'De Backer', 'Affiliation': 'Department of Cardiology, Rigshospitalet, Copenhagen, Denmark ole.debacker@gmail.com.'}]",Open heart,['10.1136/openhrt-2020-001326'] 2813,32764077,Theta-gamma cross-frequency transcranial alternating current stimulation over the trough impairs cognitive control.,"Cognitive control is a mental process, which underlies adaptive goal-directed decisions. Previous studies have linked cognitive control to electrophysiological fluctuations in the theta band and theta-gamma cross-frequency coupling (CFC) arising from the cingulate and frontal cortices. Yet, to date the behavioral consequences of different forms of theta-gamma CFC remain elusive. Here, we studied the behavioral effects of the theta-gamma CFC via transcranial alternating current stimulation (tACS) designed to stimulate the frontal and cingulate cortices in humans. Using a double-blind, randomized, repeated measures study design, 24 healthy participants were subjected to three active and one control CFC-tACS conditions. In the active conditions, 80 Hz gamma tACS was coupled to 4 Hz theta tACS. Specifically, in two of the active conditions, short gamma bursts were coupled to the delivered theta cycle to coincide with either its peaks or troughs. In the third active condition, the phase of a theta cycle modulated the amplitude of the gamma oscillation. In the fourth, control protocol, 80 Hz tACS was continuously superimposed over the 4 Hz tACS, therefore lacking any phase-specificity in the CFC. During the 20-minute of stimulation, the participants performed a Go/NoGo monetary reward- and punishment-based instrumental learning task. A Bayesian hierarchical logistic regression analysis revealed that relative to the control, the peak-coupled tACS had no effects on the behavioral performance, whereas the trough-coupled tACS and, to a lesser extent, amplitude-modulated tACS reduced performance in conflicting trials. Our results suggest that cognitive control depends on the phase-specificity of the theta-gamma CFC. Statement of significance This study investigated the behavioral effects of different forms of theta-gamma cross-frequency coupling in cognitive control. To this aim, we delivered cross-frequency transcranial alternating current stimulation over the cingulate and frontal cortices in humans. We found that when gamma tACS was coupled to the trough of theta tACS, the stimulation worsened the ability of healthy participants to employ cognitive control. Our findings highlight the role of theta-gamma cross frequency coupling in complex goal-directed behavior in humans.",2020,"A Bayesian hierarchical logistic regression analysis revealed that relative to the control, the peak-coupled tACS had no effects on the behavioral performance, whereas the trough-coupled tACS and, to a lesser extent, amplitude-modulated tACS reduced performance in conflicting trials.","['24 healthy participants were subjected to three active and one control CFC-tACS conditions', 'humans']","['theta-gamma CFC via transcranial alternating current stimulation (tACS', 'gamma tACS', 'Go/NoGo monetary reward- and punishment-based instrumental learning task']",['behavioral performance'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C3852966', 'cui_str': 'Transcranial Alternating Current Stimulation'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0017011', 'cui_str': 'Gamma radiation'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C3852966', 'cui_str': 'Transcranial Alternating Current Stimulation'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0006912', 'cui_str': 'Death Penalty'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009651', 'cui_str': 'Operant conditioning'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",24.0,0.0618721,"A Bayesian hierarchical logistic regression analysis revealed that relative to the control, the peak-coupled tACS had no effects on the behavioral performance, whereas the trough-coupled tACS and, to a lesser extent, amplitude-modulated tACS reduced performance in conflicting trials.","[{'ForeName': 'Zsolt', 'Initials': 'Z', 'LastName': 'Turi', 'Affiliation': 'Department of Clinical Neurophysiology, University Medical Center Göttingen, Göttingen 37073, Germany zsoltturi@gmail.com matthias.mittner@uit.no.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Mittner', 'Affiliation': 'Department of Psychology, UiT The Arctic University of Norway zsoltturi@gmail.com matthias.mittner@uit.no.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Lehr', 'Affiliation': 'Department of Clinical Neurophysiology, University Medical Center Göttingen, Göttingen 37073, Germany.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Bürger', 'Affiliation': 'Department of Clinical Neurophysiology, University Medical Center Göttingen, Göttingen 37073, Germany.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Antal', 'Affiliation': 'Department of Clinical Neurophysiology, University Medical Center Göttingen, Göttingen 37073, Germany.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Paulus', 'Affiliation': 'Department of Clinical Neurophysiology, University Medical Center Göttingen, Göttingen 37073, Germany.'}]",eNeuro,['10.1523/ENEURO.0126-20.2020'] 2814,32764081,"Acupuncture for acute non-specific low back pain: a randomised, controlled, multicentre intervention study in general practice-the Acuback study.","OBJECTIVES The aim of this study was to evaluate whether a single treatment session of acupuncture, when applied in addition to standard treatment for acute low back pain (ALBP), reduces the time to recovery compared with standard treatment alone. DESIGN A multicentre, randomised, controlled trial. SETTING Conducted at 11 Norwegian general practitioners' (GPs') offices. PARTICIPANTS 171 adults aged 20-55 years seeking their GP for ALBP (≤14 days) between March 2014 and March 2017. Patients with secondary back pain and previous sick leave and acupuncture treatment was excluded. INTERVENTIONS The participants were randomised to either the control group (CG) or the acupuncture group (AG) by online software. The CG received standard treatment according to the Norwegian guidelines, while the AG received one session of Western medical acupuncture treatment in addition to standard treatment. The statistician was blinded to group status. PRIMARY AND SECONDARY OUTCOME MEASURES The primary outcome was median days to recovery. Secondary outcomes were pain intensity, global improvement, back-specific functional status, sick leave, medication and adverse effects. RESULTS 185 participants were randomised, 95 in the CG and 90 in the AG. 14 participants did not receive the allocated intervention and 4 were excluded from the analysis. Thus, 167 participants were included in the analysis, 86 in the CG and 81 in the AG. The groups were similar according to baseline characteristics. The median time to recovery was 14 days for the CG and 9 days for the AG, HR 1.37 (95% CI 0.95 to 1.96), (p=0.089). No serious adverse effects were reported. CONCLUSIONS We did not find any statistically significant reduction in time-to-recovery after a single session of acupuncture for ALBP compared with standard care. TRIAL REGISTRATION NUMBER NCT01439412.",2020,"We did not find any statistically significant reduction in time-to-recovery after a single session of acupuncture for ALBP compared with standard care. ","['Patients with secondary back pain and previous sick leave and acupuncture treatment was excluded', '171 adults aged 20-55 years seeking their GP for ALBP (≤14 days) between March 2014 and March 2017', ""Conducted at 11 Norwegian general practitioners' (GPs') offices"", '14 participants did not receive the allocated intervention and 4 were excluded from the analysis', 'acute low back pain (ALBP', '167 participants were included in the analysis, 86 in the CG and 81 in the AG', 'acute non-specific low back pain', '185 participants were randomised, 95 in the CG and 90 in the AG']","['acupuncture', 'Acupuncture', 'control group (CG) or the acupuncture group (AG) by online software']","['median days to recovery', 'time-to-recovery', 'pain intensity, global improvement, back-specific functional status, sick leave, medication and adverse effects', 'median time to recovery', 'serious adverse effects']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0242807', 'cui_str': 'Sick Leave'}, {'cui': 'C0394664', 'cui_str': 'Acupuncture'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0457950', 'cui_str': 'Acute low back pain'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0028424', 'cui_str': 'Norwegian language'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0272302', 'cui_str': 'Gray platelet syndrome'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C4517595', 'cui_str': '167'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205370', 'cui_str': 'Non-specific'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C4517617', 'cui_str': '185'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0037585', 'cui_str': 'Software'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0242807', 'cui_str': 'Sick Leave'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",167.0,0.197259,"We did not find any statistically significant reduction in time-to-recovery after a single session of acupuncture for ALBP compared with standard care. ","[{'ForeName': 'Trygve', 'Initials': 'T', 'LastName': 'Skonnord', 'Affiliation': 'Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway trygve.skonnord@medisin.uio.no.'}, {'ForeName': 'Holgeir', 'Initials': 'H', 'LastName': 'Skjeie', 'Affiliation': 'Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Mette', 'Initials': 'M', 'LastName': 'Brekke', 'Affiliation': 'General Practice Research Unit (AFE), Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Atle', 'Initials': 'A', 'LastName': 'Klovning', 'Affiliation': 'Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Margreth', 'Initials': 'M', 'LastName': 'Grotle', 'Affiliation': 'Department of Physiotherapy, Oslo Metropolitan University, Oslo, Norway.'}, {'ForeName': 'Eline', 'Initials': 'E', 'LastName': 'Aas', 'Affiliation': 'Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Ibrahimu', 'Initials': 'I', 'LastName': 'Mdala', 'Affiliation': 'General Practice Research Unit (AFE), Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Arne', 'Initials': 'A', 'LastName': 'Fetveit', 'Affiliation': 'General Practice Research Unit (AFE), Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.'}]",BMJ open,['10.1136/bmjopen-2019-034157'] 2815,32764089,Study protocol for a cluster randomised controlled trial testing the effectiveness of the 'High schools High on life' intervention on reducing excessive drinking in Danish high schools.,"INTRODUCTION This paper describes the evaluation design of the 'High schools High on life' intervention; a school-based intervention to reduce excessive drinking among high school students in Denmark. The intervention includes a school environmental component to limit access to alcohol at school, a school-educational component to change social norms around alcohol among first year students and a parental component addressing parents' knowledge and attitudes towards alcohol. METHODS AND DESIGN The study will employ a cluster randomised controlled study design and will include a random sample of 16 high schools randomly allocated 1:1 to either intervention or control group. Target group: first year high school students. Timeline: baseline survey: January to March 2019, collected as part of the Danish National Youth Study 2019. Delivery of intervention: April 2019 to March 2020. Follow-up survey: April to May 2020. PRIMARY OUTCOME MEASURE 30% reduction in mean number of binge-drinking episodes (five or more alcoholic drinks on one occasion) within the last 30 days. SECONDARY OUTCOME MEASURES proportion of students who drink alcohol, mean weekly alcohol consumption, alcohol intake at last school party, alcohol intake at the school during last school party, proportion of students who agree to be able to have fun at a party without drinking and the proportion of students who think alcohol plays a too dominant part at the school. Implementation will be monitored through process evaluation. ETHICS AND DISSEMINATION The Scientific Ethics Committees for the Capital Region of Denmark has declared that the trial is not subject to notification (jnr. 19021957). The study is registered at the Research an Innovation Office at University of Southern Denmark (ref: 10.314) allowing collection of personal data. Results will be published in peer-reviewed journals. TRIAL REGISTRATION NUMBER NCT03906500.",2020,The Scientific Ethics Committees for the Capital Region of Denmark has declared that the trial is not subject to notification (jnr.,"['Danish high schools', 'Target group: first year high school students', 'Timeline: baseline survey: January to March 2019, collected as part of the Danish National Youth Study 2019', 'random sample of 16 high schools', 'high school students in Denmark']","[""school environmental component to limit access to alcohol at school, a school-educational component to change social norms around alcohol among first year students and a parental component addressing parents' knowledge and attitudes towards alcohol"", ""High schools High on life' intervention"", 'school-based intervention']","['proportion of students who drink alcohol, mean weekly alcohol consumption, alcohol intake at last school party, alcohol intake', 'mean number of binge-drinking episodes ']","[{'cui': 'C0010969', 'cui_str': 'Danish language'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0145943', 'cui_str': 'TimeLine'}, {'cui': 'C0282121', 'cui_str': 'Baseline Survey'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0556346', 'cui_str': 'Drinking binge'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}]",16.0,0.0307791,The Scientific Ethics Committees for the Capital Region of Denmark has declared that the trial is not subject to notification (jnr.,"[{'ForeName': 'Veronica Sofie Clara', 'Initials': 'VSC', 'LastName': 'Pisinger', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Syddanmark, Denmark vepi@sdu.dk.'}, {'ForeName': 'Sofie', 'Initials': 'S', 'LastName': 'Hoffmann', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Syddanmark, Denmark.'}, {'ForeName': 'Johanne Aviaja', 'Initials': 'JA', 'LastName': 'Rosing', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Syddanmark, Denmark.'}, {'ForeName': 'Morten', 'Initials': 'M', 'LastName': 'Grønbæk', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Syddanmark, Denmark.'}, {'ForeName': 'Janne Schurmann', 'Initials': 'JS', 'LastName': 'Tolstrup', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Syddanmark, Denmark.'}, {'ForeName': 'Lau', 'Initials': 'L', 'LastName': 'Thygesen', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Syddanmark, Denmark.'}, {'ForeName': 'Rikke', 'Initials': 'R', 'LastName': 'Krølner', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Syddanmark, Denmark.'}]",BMJ open,['10.1136/bmjopen-2020-038857'] 2816,32764219,"Comparisons of Within-Group Instead of Between-Group Affect the Conclusions. Comment on: ""Changes in Weight and Substrate Oxidation in Overweight Adults Following Isomaltulose Intake during a 12-Week Weight Loss Intervention: A Randomized, Double-Blind, Controlled Trial"". Nutrients 2019, 11 (10), 2367.",We read with interest the publication by Lightowler et al [...].,2020,We read with interest the publication by Lightowler et al [...].,['Overweight Adults Following Isomaltulose Intake during a 12-Week Weight Loss Intervention'],[],['Weight and Substrate Oxidation'],"[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0064002', 'cui_str': 'isomaltulose'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],"[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}]",,0.320393,We read with interest the publication by Lightowler et al [...].,"[{'ForeName': 'Colby J', 'Initials': 'CJ', 'LastName': 'Vorland', 'Affiliation': 'Department of Applied Health Science, Indiana University School of Public Health-Bloomington, Bloomington, IN 47405, USA.'}, {'ForeName': 'Theodore K', 'Initials': 'TK', 'LastName': 'Kyle', 'Affiliation': 'ConscienHealth, Pittsburgh, PA 15241, USA.'}, {'ForeName': 'Andrew W', 'Initials': 'AW', 'LastName': 'Brown', 'Affiliation': 'Department of Applied Health Science, Indiana University School of Public Health-Bloomington, Bloomington, IN 47405, USA.'}]",Nutrients,['10.3390/nu12082335'] 2817,32764258,"Reply to ""Comparisons of Within-Group Instead of Between-Group Affect the Conclusions. Comment on: Changes in Weight and Substrate Oxidation in Overweight Adults Following Isomaltulose Intake during a 12-Week Weight Loss Intervention: A Randomized, Double-Blind, Controlled Trial. Nutrients 2019, 11 (10), 2367"".","We thank the authors Vorland, Kyle and Brown for their interest in our paper and their comments [...].",2020,"We thank the authors Vorland, Kyle and Brown for their interest in our paper and their comments [...].",['Overweight Adults Following Isomaltulose Intake during a 12-Week Weight Loss Intervention'],[],['Weight and Substrate Oxidation'],"[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0064002', 'cui_str': 'isomaltulose'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],"[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}]",,0.215808,"We thank the authors Vorland, Kyle and Brown for their interest in our paper and their comments [...].","[{'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Lightowler', 'Affiliation': 'Oxford Brookes Centre for Nutrition and Health, Department of Sport, Health Sciences and Social Work, Faculty of Health and Life Sciences, Oxford Brookes University, Headington Campus, Gipsy Lane, Oxford OX3 0BP, UK.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Schweitzer', 'Affiliation': 'BENEO-Institute, BENEO GmbH, Wormser Straße 11, 67283 Obrigheim/Pfalz, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Theis', 'Affiliation': 'BENEO-Institute, BENEO GmbH, Wormser Straße 11, 67283 Obrigheim/Pfalz, Germany.'}, {'ForeName': 'Christiani Jeyakumar', 'Initials': 'CJ', 'LastName': 'Henry', 'Affiliation': 'Clinical Nutrition Research Centre (CNRC), Singapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research (A*STAR) and National University Health System, Centre for Translational Medicine, 14 Medical Drive #07-02, MD 6 Building, Yong Loo Lin School of Medicine, Singapore 117599, Singapore.'}]",Nutrients,['10.3390/nu12082339'] 2818,32764261,The Impact of the Timing of Health-Related Quality of Life Assessments on the Actual Results in Glioma Patients: A Randomized Prospective Study.,"BACKGROUND The aim of this study was to explore the impact of the timing of Health-Related Quality of Life (HRQoL) measurements in clinical care on the obtained HRQoL scores in glioma patients, and the association with feelings of anxiety or depression. METHODS Patients completed the European Organisation for Research and Treatment of Cancer (EORTC)'s Quality of Life Questionnaires (QLQ-C30 and QLQ-BN20), and the Hospital Anxiety and Depression Scale (HADS) twice. All patients completed the first measurement on the day of the Magnetic Resonance Imaging (MRI) scan ( t = 0), but the second measurement ( t = 1) depended on randomization; Group 1 ( n = 49) completed the questionnaires before and Group 2 ( n = 51) after the consultation with the physician. RESULTS median HRQoL scale scores on t0/t1 and change scores were comparable between the two groups. Between 8-58% of patients changed to a clinically relevant extent (i.e., ≥10 points) on the evaluated HRQoL scales in about one-week time, in both directions, with only 3% of patients remaining stable in all scales. Patients with a stable role functioning had a lower HADS anxiety change score. The HADS depression score was not associated with a change in HRQoL. CONCLUSIONS Measuring HRQoL before or after the consultation did not impact HRQoL scores on a group level. However, most patients reported a clinically relevant difference in at least one HRQoL scale between the two time points. These findings highlight the importance of standardized moments of HRQoL assessments, or patient-reported outcomes in general, during treatment and follow-up in clinical trials.",2020,"The HADS depression score was not associated with a change in HRQoL. CONCLUSIONS Measuring HRQoL before or after the consultation did not impact HRQoL scores on a group level.","['Patients completed the European Organisation for Research and Treatment of', 'Glioma Patients', 'glioma patients']",['Magnetic Resonance Imaging (MRI) scan'],"['evaluated HRQoL scales', 'HRQoL scale', 'HADS anxiety change score', 'HADS depression score', 'median HRQoL scale scores', ""Cancer (EORTC)'s Quality of Life Questionnaires (QLQ-C30 and QLQ-BN20), and the Hospital Anxiety and Depression Scale (HADS) twice""]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0017638', 'cui_str': 'Glioma'}]","[{'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1720725', 'cui_str': 'Twice'}]",,0.0694939,"The HADS depression score was not associated with a change in HRQoL. CONCLUSIONS Measuring HRQoL before or after the consultation did not impact HRQoL scores on a group level.","[{'ForeName': 'Marthe C M', 'Initials': 'MCM', 'LastName': 'Peeters', 'Affiliation': 'Department of Neurology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.'}, {'ForeName': 'Hanneke', 'Initials': 'H', 'LastName': 'Zwinkels', 'Affiliation': 'Department of Neurology, Haaglanden Medical Center, 2262 BA The Hague, The Netherlands.'}, {'ForeName': 'Johan A F', 'Initials': 'JAF', 'LastName': 'Koekkoek', 'Affiliation': 'Department of Neurology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.'}, {'ForeName': 'Maaike J', 'Initials': 'MJ', 'LastName': 'Vos', 'Affiliation': 'Department of Neurology, Haaglanden Medical Center, 2262 BA The Hague, The Netherlands.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Dirven', 'Affiliation': 'Department of Neurology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.'}, {'ForeName': 'Martin J B', 'Initials': 'MJB', 'LastName': 'Taphoorn', 'Affiliation': 'Department of Neurology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.'}]",Cancers,['10.3390/cancers12082172'] 2819,32764397,Effects of High Intensity Dynamic Resistance Exercise and Whey Protein Supplements on Osteosarcopenia in Older Men with Low Bone and Muscle Mass. Final Results of the Randomized Controlled FrOST Study.,"The present study aimed to evaluate the effect of high intensity dynamic resistance exercise (HIT-DRT) and whey protein supplementation (WPS) on bone mineral density (BMD) and sarcopenia parameters in osteosarcopenic men. Men ≥ 72 years with osteosarcopenia ( n = 43) were randomly assigned to a HIT-RT (HIT-RT: n = 21) or a non-training control group ( n = 22). Supervised HIT-RT twice/week was applied for 18 months, while the control group maintained their habitual lifestyle. Supplying WPS, total protein intake amounted to 1.5-1.6 (HIT-RT) and 1.2 g/kg/body mass/d (control). Both groups were supplied with calcium and vitamin D. Primary study outcomes were BMD and the sarcopenia Z-score. After adjusting for multiplicity, we observed significant positive effects for sarcopenia Z-score (standardized mean difference (SMD): 1.40), BMD at lumbar spine (SMD: 0.72) and total hip (SMD: 0.72). In detail, effect sizes for skeletal muscle mass changes were very pronounced (1.97, p < 0.001), while effects for functional sarcopenia parameters were moderate (0.87, p = 0.008; handgrip strength) or low (0.39, p = 0.209; gait velocity). Apart from one man who reported short periods of temporary worsening of existing joint pain, no HIT-RT/WPS-related adverse effects or injuries were reported. We consider HIT-RT supported by whey protein supplementation as a feasible, attractive, safe and highly effective option to fight osteosarcopenia in older men.",2020,"In detail, effect sizes for skeletal muscle mass changes were very pronounced (1.97, p < 0.001), while effects for functional sarcopenia parameters were moderate (0.87, p = 0.008; handgrip strength) or low (0.39, p = 0.209; gait velocity).","['Men ≥ 72 years with osteosarcopenia ( n = 43', 'older men', 'Older Men with Low Bone and Muscle Mass', 'osteosarcopenic men']","['HIT-RT (HIT-RT: n = 21) or a non-training control group', 'high intensity dynamic resistance exercise (HIT-DRT) and whey protein supplementation (WPS', 'High Intensity Dynamic Resistance Exercise and Whey Protein Supplements']","['Supplying WPS, total protein intake', 'BMD and the sarcopenia Z-score', 'sarcopenia Z-score', 'BMD at lumbar spine', 'bone mineral density (BMD) and sarcopenia parameters']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle'}]","[{'cui': 'C0272285', 'cui_str': 'Heparin-induced thrombocytopenia'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}]","[{'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0555903', 'cui_str': 'Total protein measurement'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0872084', 'cui_str': 'Sarcopenia'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0024091', 'cui_str': 'Bone structure of lumbar vertebra'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",43.0,0.045492,"In detail, effect sizes for skeletal muscle mass changes were very pronounced (1.97, p < 0.001), while effects for functional sarcopenia parameters were moderate (0.87, p = 0.008; handgrip strength) or low (0.39, p = 0.209; gait velocity).","[{'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Kemmler', 'Affiliation': 'Institute of Medical Physics, Friedrich-Alexander University of Erlangen-Nürnberg, Henkestrasse 91, 91053 Erlangen, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Kohl', 'Affiliation': 'Faculty Medical and Life Sciences, University of Furtwangen, Neckarstrasse 1, 78054 Villingen-Schwenningen, Germany.'}, {'ForeName': 'Franz', 'Initials': 'F', 'LastName': 'Jakob', 'Affiliation': 'Bernhard-Heine-Center for Locomotion Research, University of Würzburg, Brettreichstrasse 11, 97074 Würzburg, Germany.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Engelke', 'Affiliation': 'Institute of Medical Physics, Friedrich-Alexander University of Erlangen-Nürnberg, Henkestrasse 91, 91053 Erlangen, Germany.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'von Stengel', 'Affiliation': 'Institute of Medical Physics, Friedrich-Alexander University of Erlangen-Nürnberg, Henkestrasse 91, 91053 Erlangen, Germany.'}]",Nutrients,['10.3390/nu12082341'] 2820,32766521,Canal Transportation and Centring Ability of Reciproc and Reciproc Blue With or Without Use of Glide Path Instruments: A CBCT Study.,"Objective The objective of this ex vivo study was to evaluate canal transportation and centring ability of Reciproc and Reciproc blue systems in curved root canals with or without prior use of PathFile rotary system (PF) using Cone Beam Computed Tomography (CBCT). Methods One hundred and twenty curved root canals from maxillary and mandibular premolars were selected. Canals were divided randomly into 4 groups (n=30): Reciproc 25 (R25), (PF+R25), Reciproc Blue 25 (RB25), (PF+RB 25). Specimens were scanned before and after root canal preparation. Using CBCT, root canal transportation and centring ability was assessed by measuring the shortest distance from the edge of uninstrumented canal to the periphery of the root (mesial and distal) before and after preparation. Data were analysed using a one-way analysis of variance and Tukey test. The p value was set at 0.05. Results Less transportation and better centring ability occurred when PF was used before R25 or RB25 (P<0.0001). There was no significant difference between R25 and RB25 groups. Conclusion Using PF before R25 and RB25 resulted in less root canal transportation and better centring ability. The specific thermo-mechanical treatment of RB25 did not provide better results when compared to R25.",2020,Less transportation and better centring ability occurred when PF was used before R25 or RB25 (P<0.0001).,['Methods\n\n\nOne hundred and twenty curved root canals from maxillary and mandibular premolars were selected'],"['PathFile rotary system (PF) using Cone Beam Computed Tomography (CBCT', 'Reciproc and Reciproc Blue']","['CBCT, root canal transportation and centring ability', 'root canal transportation and better centring ability', 'Less transportation and better centring ability', 'Reciproc 25 (R25), (PF+R25), Reciproc Blue 25 (RB25), (PF+RB 25']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0205133', 'cui_str': 'Bent'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C1704302', 'cui_str': 'Structure of premolar tooth'}]","[{'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C1956110', 'cui_str': 'Cone beam CT'}, {'cui': 'C1260957', 'cui_str': 'Blue color'}]","[{'cui': 'C1956110', 'cui_str': 'Cone beam CT'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0040756', 'cui_str': 'Transportation'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1260957', 'cui_str': 'Blue color'}]",,0.0238687,Less transportation and better centring ability occurred when PF was used before R25 or RB25 (P<0.0001).,"[{'ForeName': 'Wajih', 'Initials': 'W', 'LastName': 'Hage', 'Affiliation': 'Department of Endodontics, School of Dentistry, Saint Joseph University, Beirut, Lebanon.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Zogheib', 'Affiliation': 'Department of Endodontics, School of Dentistry, Saint Joseph University, Beirut, Lebanon.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Bukiet', 'Affiliation': 'Department of Odontology, Aix Marseille Univ, CNRS, ISM, Inst Movement Sci, Marseille, France; APHM, Timone Hospital, Marseille, France.'}, {'ForeName': 'Germain', 'Initials': 'G', 'LastName': 'Sfeir', 'Affiliation': 'Department of Endodontics, School of Dentistry, Saint Joseph University, Beirut, Lebanon.'}, {'ForeName': 'Issam', 'Initials': 'I', 'LastName': 'Khalil', 'Affiliation': 'Department of Endodontics, School of Dentistry, Saint Joseph University, Beirut, Lebanon.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Gergi', 'Affiliation': 'Department of Endodontics, School of Dentistry, Saint Joseph University, Beirut, Lebanon.'}, {'ForeName': 'Alfred', 'Initials': 'A', 'LastName': 'Naaman', 'Affiliation': 'Department of Endodontics, School of Dentistry, Saint Joseph University, Beirut, Lebanon.'}]",European endodontic journal,['10.14744/eej.2019.86570'] 2821,32766527,Effect of Gravity on Periapical Extrusion of Irrigating Solution With Different Irrigation Protocols in Immature Anterior Teeth.,"Objective Periapical extrusion is frequently observed during endodontic therapy. It can lead to acute injury of periapical tissues, resulting in interappointment pain or swelling. The effect is pronounced in teeth with immature teeth which are more susceptible to the extrusion of irrigant. The aim of this study was to evaluate the effect of gravity on apical extrusion of irrigating solution with different irrigation protocols in immature anterior teeth. Methods An extracted maxillary central incisor was modified to simulate an open apex with an apical diameter of 1.3 mm and parallel canal walls. The tooth was subjected to a cone-beam computed tomographic scan, and the image data set was utilized to prepare 30 resin tooth models with a 3D printer. These resin teeth were used to form an open-ended Myers and Montgomery extrusion models. These were then randomly divided into two groups to simulate their orientation in the jaw during endodontic therapy, i.e., group I (maxillary arch, n=15) models fixed at 45° inclined plane and group II (mandibular arch, n=15) models placed at a plane parallel to the floor. Five models from each group (n=5) were tested by three different irrigation protocols: positive pressure (PP) Irrigation, passive ultrasonic irrigation (PUI), and negative pressure (NP) irrigation. The extruded irrigating solution was collected in glass vials, and the volume was measured. Results The volume of extruded irrigating solution in groups I and II was compared using Mann-Whitney U-test. The median values for PP, PUI, and NP irrigation protocols were 0.6, 1, and 0 ml and 10, 10, and 0.5 ml for groups I and II, respectively. PP and PUI protocols were associated with significantly less extrusion in group I when compared to group II (P=0.004). There was no statistically significant difference in the volume of irrigating solution extruded in groups I and II (P=0.007) for NP irrigation protocol. Conclusion Gravitation force has an influence on periapical extrusion of irrigant in immature permanent teeth irrespective of the irrigant system used. NP performed better when compared to PP or PUI irrigation protocol irrespective of the tooth orientation.",2020,PP and PUI protocols were associated with significantly less extrusion in group,"['immature anterior teeth', 'Immature Anterior Teeth']","['irrigation protocols: positive pressure (PP) Irrigation, passive ultrasonic irrigation (PUI), and negative pressure (NP) irrigation', 'models fixed at 45° inclined plane and group II (mandibular arch, n=15) models placed at a plane parallel to the floor']","['median values for PP, PUI, and NP irrigation protocols', 'volume of irrigating solution']","[{'cui': 'C0205252', 'cui_str': 'Immature'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}]","[{'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0231063', 'cui_str': 'First branchial arch structure'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0016249', 'cui_str': 'Walking surface of room'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0593225', 'cui_str': 'Solution for irrigation'}]",,0.0289705,PP and PUI protocols were associated with significantly less extrusion in group,"[{'ForeName': 'Radha', 'Initials': 'R', 'LastName': 'Sharma', 'Affiliation': 'Division of Conservative Dentistry and Endodontics Centre, Dental Education and Research All India Institute of Medical Sciences New Delhi, India.'}, {'ForeName': 'Vijay', 'Initials': 'V', 'LastName': 'Kumar', 'Affiliation': 'Division of Conservative Dentistry and Endodontics Centre, Dental Education and Research All India Institute of Medical Sciences New Delhi, India.'}, {'ForeName': 'Ajay', 'Initials': 'A', 'LastName': 'Logani', 'Affiliation': 'Division of Conservative Dentistry and Endodontics Centre, Dental Education and Research All India Institute of Medical Sciences New Delhi, India.'}, {'ForeName': 'Amrita', 'Initials': 'A', 'LastName': 'Chawla', 'Affiliation': 'Division of Conservative Dentistry and Endodontics Centre, Dental Education and Research All India Institute of Medical Sciences New Delhi, India.'}, {'ForeName': 'Sidhartha', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'Division of Conservative Dentistry and Endodontics Centre, Dental Education and Research All India Institute of Medical Sciences New Delhi, India.'}, {'ForeName': 'Bhawna', 'Initials': 'B', 'LastName': 'Koli', 'Affiliation': 'Division of Conservative Dentistry and Endodontics Centre, Dental Education and Research All India Institute of Medical Sciences New Delhi, India.'}]",European endodontic journal,['10.14744/eej.2020.20592'] 2822,32766563,Leveraging Tele-Critical Care Capabilities for Clinical Trial Consent.,"A severe coronavirus disease 2019 patient admitted to our institution for medical management was enrolled in a randomized placebo-controlled trial of an investigational therapeutic for coronavirus disease 2019. We leveraged existing video-telecommunication equipment to obtain informed consent. We found video-telecommunication use closely mirrored person-to-person contact for research consent by maintaining engagement and ensuring understanding. Video-telecommunication use facilitated clinical research while minimizing unnecessary exposure to coronavirus disease 2019 and conserving personal protective equipment. Prior to the coronavirus disease 2019 pandemic, research regulatory agencies were essentially silent on the matter of video-telecommunication consent. Regulatory guidance became available during the pandemic in response to increased isolation and social distancing practices. Virtual health and telemedicine use expanded greatly during the pandemic, and this increase will likely persist after the pandemic ends. We anticipate video-telecommunication adoption and implementation for research consent will also continue to grow after the coronavirus disease 2019 pandemic is over.",2020,"Prior to the coronavirus disease 2019 pandemic, research regulatory agencies were essentially silent on the matter of video-telecommunication consent.",['A severe coronavirus disease 2019 patient admitted to our institution for medical management'],['placebo'],[],"[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.031852,"Prior to the coronavirus disease 2019 pandemic, research regulatory agencies were essentially silent on the matter of video-telecommunication consent.","[{'ForeName': 'Kristina M', 'Initials': 'KM', 'LastName': 'Ieronimakis', 'Affiliation': 'Madigan Army Medical Center, Tacoma, WA.'}, {'ForeName': 'Janell A', 'Initials': 'JA', 'LastName': 'Cain', 'Affiliation': 'Madigan Army Medical Center, Tacoma, WA.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Switzer', 'Affiliation': 'Madigan Army Medical Center, Tacoma, WA.'}, {'ForeName': 'David D', 'Initials': 'DD', 'LastName': 'Odineal', 'Affiliation': 'Madigan Army Medical Center, Tacoma, WA.'}, {'ForeName': 'Thomas K', 'Initials': 'TK', 'LastName': 'Deacy', 'Affiliation': 'Madigan Army Medical Center, Tacoma, WA.'}, {'ForeName': 'Michael T O', 'Initials': 'MTO', 'LastName': 'Stein', 'Affiliation': 'Madigan Army Medical Center, Tacoma, WA.'}, {'ForeName': 'Rhonda E', 'Initials': 'RE', 'LastName': 'Colombo', 'Affiliation': 'Madigan Army Medical Center, Tacoma, WA.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Colombo', 'Affiliation': 'Madigan Army Medical Center, Tacoma, WA.'}]",Critical care explorations,['10.1097/CCE.0000000000000167'] 2823,32766676,Cuing Prospective Memory With Smartphone-Based Calendars in Alzheimer's Disease.,"OBJECTIVES We investigated the effect of using smartphone-based calendars (Google and Outlook Calendar) on prospective memory in Alzheimer's disease (AD). METHODS we recruited two groups of participants with mild AD. In one group, prospective memory was cued by a paper-and-pencil calendar, whereas in the second group prospective memory was cued by a smartphone calendar application. After 2 weeks of training to familiarize the participants with calendar use, we invited participants to perform three prospective events per week (e.g., remembering to go to the grocery store) during a 3-week period. Events were cued either by the paper- or smartphone-based calendar. RESULTS we observed fewer omissions of prospective events in the smartphone-based calendar group than in the paper-based calendar group. CONCLUSIONS our study suggests positive effects of smartphone calendar applications on prospective memory in AD.",2020,"we observed fewer omissions of prospective events in the smartphone-based calendar group than in the paper-based calendar group. ","[""Alzheimer's disease (AD"", 'participants with mild AD', ""Alzheimer's Disease""]",['smartphone-based calendars (Google and Outlook Calendar'],[],"[{'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1516147', 'cui_str': 'Calendars'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}]",[],,0.015154,"we observed fewer omissions of prospective events in the smartphone-based calendar group than in the paper-based calendar group. ","[{'ForeName': 'Mohamad', 'Initials': 'M', 'LastName': 'El Haj', 'Affiliation': 'Nantes Université, Univ Angers, Laboratoire de Psychologie des Pays de la Loire (LPPL - EA 4638), Nantes, France.'}, {'ForeName': 'Ahmed A', 'Initials': 'AA', 'LastName': 'Moustafa', 'Affiliation': 'School of Social Sciences and Psychology & Marcs Institute for Brain and Behaviour, Western Sydney University, Sydney, Australia.'}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Gallouj', 'Affiliation': 'Unité de Gériatrie, Centre Hospitalier de Tourcoing, Tourcoing, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Allain', 'Affiliation': 'Laboratoire de Psychologie des Pays de la Loire, LPPL EA 4638, SFR Confluences, UNIV Angers, Nantes Université, Maison de la recherche Germaine Tillion, 5 bis Boulevard Lavoisier Angers, France.'}]",Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists,['10.1093/arclin/acaa060'] 2824,32766705,Effectiveness of clinical decision support systems and telemedicine on outcomes of depression: a cluster randomized trial in general practice.,"BACKGROUND Computerized Clinical Decision Support Systems (CCDSS) are information technology tools, designed to improve clinical decision-making. Telemedicine is a health care service delivery using videoconferencing, telephone or messaging technologies. OBJECTIVES Our project aimed at testing the effectiveness of a composite CCDSS and telemedicine approach designed to treat depression in primary care. METHODS This cluster randomized trial involved four GP clinics located in Northern Italy. Two clinics were assigned to the experimental protocol, and two served as controls. The study compared the telemedicine group (TG), in which GPs had access to a CCDSS platform, with the control group (CG) in which GPs provided treatment as usual (TAU). Patients scoring ≥11 on Patient Heath Questionnaire and ≥26 on the Inventory of Depressive Symptomatology-Self-Report were eligible for participation. Patients were also administered the World Health Organization Quality of Life-BREF to assess quality of life and Medical Interview Satisfaction Scale 21 to assess satisfaction with the medical interview. RESULTS Overall, 2810 patients were screened and 66 in the experimental group and 32 in the CG passed the screening stages and met inclusion criteria. The percentage of remitters at 6 months was significantly higher in the TG than in the CG group (24.1% versus 3.1%, χ 2 = 6.6, P = 0.01). This difference remained significant after adjusting for baseline confounders. Physical and psychological quality of life improved significantly from baseline in both groups. Patients reported, on average, good satisfaction with the medical interview. CONCLUSIONS Our study showed that a combined CCDSS and telemedicine approach may be more effective than the TAU offered by GPs to patients with depression. TRIAL REGISTRATION The trial was registered on https://clinicaltrials.gov/ on 5 October 2012 with identifier: NCT01701791. The first participant was enrolled on 5 May 2014 and the study was completed on May 2016.",2020,"The percentage of remitters at 6 months was significantly higher in the TG than in the CG group (24.1% versus 3.1%, χ 2 = 6.6, P = 0.01).","['four GP clinics located in Northern Italy', 'patients with depression', 'Patients scoring ≥11 on Patient Heath Questionnaire and ≥26 on the Inventory of Depressive Symptomatology-Self-Report were eligible for participation', 'The first participant was enrolled on 5 May 2014 and the study was completed on May 2016', '2810 patients were screened and 66 in the experimental group and 32 in the CG passed the screening stages and met inclusion criteria']","['telemedicine group (TG', 'composite CCDSS and telemedicine approach', 'clinical decision support systems and telemedicine', 'Telemedicine']","['outcomes of depression', 'World Health Organization Quality of Life-BREF to assess quality of life and Medical Interview Satisfaction Scale', 'percentage of remitters', 'Physical and psychological quality of life']","[{'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0525070', 'cui_str': 'Clinical Decision Support Systems'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}]","[{'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0582644', 'cui_str': 'Medical interview satisfaction scale'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}]",4.0,0.0825773,"The percentage of remitters at 6 months was significantly higher in the TG than in the CG group (24.1% versus 3.1%, χ 2 = 6.6, P = 0.01).","[{'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Balestrieri', 'Affiliation': 'Unit of Psychiatry, DAME, University of Udine, Udine, Italy.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Sisti', 'Affiliation': ""Department of Biomolecular Sciences-Unit of Medical Statistic and Biometry, University of Urbino 'Carlo Bo', Urbino, Italy.""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Rocchi', 'Affiliation': ""Department of Biomolecular Sciences-Unit of Medical Statistic and Biometry, University of Urbino 'Carlo Bo', Urbino, Italy.""}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Rucci', 'Affiliation': 'Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Simon', 'Affiliation': 'Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Araya', 'Affiliation': ""Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London.""}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'de Girolamo', 'Affiliation': 'Unit of Psychiatric Epidemiology and Evaluation, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.'}]",Family practice,['10.1093/fampra/cmaa077'] 2825,32767064,"Sexual activity and function in women with advanced stages of pelvic organ prolapse, before and after laparoscopic or vaginal mesh surgery.","INTRODUCTION AND HYPOTHESIS The differential impact of specific pelvic organ prolapse (POP) surgery on sexual activity and function is unknown. Our primary aim was to analyse sexual inactivity and function in women with symptomatic advanced stages of POP and the changes incurred after laparoscopic or vaginal mesh surgery. METHODS We performed a secondary analysis of sexual outcomes of a previously published randomised controlled trial comparing laparoscopic sacrocolpopexy/cervicopexy (LSC-Cx) and anterior vaginal mesh (AVM) in 120 women (60/group) with symptomatic anterior POP stage ≥ 3 and apical ≥ 2. Sexual activity and function were assessed preoperatively and 1 and 2 years postoperatively using the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire-IUGA-Revised (PISQ-IR). RESULTS Sexual activity was recovered in 42.9% of non-sexually active (NSA) women 1 year postoperatively, mainly in women with higher preoperative POP-related subscale scores of the PISQ-IR, which indicated a negative preoperative sexuality by POP. Recovery of sexual activity was greater after LSC-Cx, albeit not significantly (2 years: 35.5% AVM vs. 45% LSC-Cx). Among sexually active (SA) women preoperatively remaining SA postoperatively, the difference in the mean PISQ-IR summary score significantly improved [mean baseline difference - 2 years; all: 0.3 (95% CI 0.1 to 0.5) p = 0.001; AVM 0.19 (95% CI -0.1 to -0.5) p > 0.05; LSC-Cx 0.37 (95% CI 0.1 to 0.7) p = 0.003]. Preoperative dyspareunia was significantly reduced after LSC-Cx (baseline: 24.6%, 2 years: 9.8%, p = 0.0448), but not after AVM (baseline: 20.7%, 2 years: 18.2%, p = 0.7385). CONCLUSIONS Most women reported improved sexual activity and function 2 years after LSC-Cx or AVM, mainly because of enhanced POP-related subscales in both NSA and SA women. Recovery of sexual activity and improved sexual function were greater after LSC-Cx compared to AVM, likely related to less postoperative dyspareunia.",2020,"Sexual activity and function were assessed preoperatively and 1 and 2 years postoperatively using the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire-IUGA-Revised (PISQ-IR). ","['women with advanced stages of pelvic organ prolapse, before and after laparoscopic or vaginal mesh surgery', 'women with symptomatic advanced stages of POP and the changes incurred after laparoscopic or vaginal mesh surgery', '120 women (60/group) with symptomatic anterior POP stage ≥ 3 and apical ≥ 2']","['laparoscopic sacrocolpopexy/cervicopexy (LSC-Cx) and anterior vaginal mesh (AVM', 'specific pelvic organ prolapse (POP) surgery']","['sexual inactivity and function', 'Sexual activity and function', 'sexual activity', 'postoperative dyspareunia', 'Pelvic Organ Prolapse/Incontinence Sexual Questionnaire-IUGA-Revised (PISQ-IR', 'Sexual activity', 'Recovery of sexual activity', 'Recovery of sexual activity and improved sexual function', 'Preoperative dyspareunia', 'mean PISQ-IR summary score']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0877015', 'cui_str': 'Urogenital prolapse'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0181805', 'cui_str': 'Mesh'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0033377', 'cui_str': 'Prolapse'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0205111', 'cui_str': 'Apical'}]","[{'cui': 'C3472566', 'cui_str': 'Laparoscopic sacrocolpopexy'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0181805', 'cui_str': 'Mesh'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0877015', 'cui_str': 'Urogenital prolapse'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C3890554', 'cui_str': 'Physical Inactivity'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0013394', 'cui_str': 'Pain in female genitalia on intercourse'}, {'cui': 'C0877015', 'cui_str': 'Urogenital prolapse'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0033377', 'cui_str': 'Prolapse'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0278092', 'cui_str': 'Sexual function'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",120.0,0.142923,"Sexual activity and function were assessed preoperatively and 1 and 2 years postoperatively using the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire-IUGA-Revised (PISQ-IR). ","[{'ForeName': 'Sònia', 'Initials': 'S', 'LastName': 'Anglès-Acedo', 'Affiliation': 'Pelvic Floor Unit, ICGON, Hospital Clínic de Barcelona, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Ros-Cerro', 'Affiliation': 'Pelvic Floor Unit, ICGON, Hospital Clínic de Barcelona, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain. cros@clinic.cat.'}, {'ForeName': 'Sílvia', 'Initials': 'S', 'LastName': 'Escura-Sancho', 'Affiliation': 'Pelvic Floor Unit, ICGON, Hospital Clínic de Barcelona, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.'}, {'ForeName': 'M José', 'Initials': 'MJ', 'LastName': 'Palau-Pascual', 'Affiliation': 'Pelvic Floor Unit, ICGON, Hospital Clínic de Barcelona, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Bataller-Sánchez', 'Affiliation': 'Pelvic Floor Unit, ICGON, Hospital Clínic de Barcelona, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.'}, {'ForeName': 'Montserrat', 'Initials': 'M', 'LastName': 'Espuña-Pons', 'Affiliation': 'Pelvic Floor Unit, ICGON, Hospital Clínic de Barcelona, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Carmona-Herrera', 'Affiliation': 'Pelvic Floor Unit, ICGON, Hospital Clínic de Barcelona, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.'}]",International urogynecology journal,['10.1007/s00192-020-04406-1'] 2826,30975584,Acute effects of ∆9-tetrahydrocannabinol (THC) on resting state brain function and their modulation by COMT genotype.,"Cannabis produces a broad range of acute, dose-dependent psychotropic effects. Only a limited number of neuroimaging studies have mapped these effects by examining the impact of cannabis on resting state brain neurophysiology. Moreover, how genetic variation influences the acute effects of cannabis on resting state brain function is unknown. Here we investigated the acute effects of ∆9-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, on resting state brain neurophysiology, and their modulation by catechol-methyl-transferase (COMT) Val158Met genotype. Thirty-nine healthy volunteers participated in a pharmacological MRI study, where we applied Arterial Spin Labelling (ASL) to measure perfusion and functional MRI to assess resting state connectivity. THC increased perfusion in bilateral insula, medial superior frontal cortex, and left middle orbital frontal gyrus. This latter brain area showed significantly decreased connectivity with the precuneus after THC administration. THC effects on perfusion in the left insula were significantly related to subjective changes in perception and relaxation. These findings indicate that THC enhances metabolism and thus neural activity in the salience network. Furthermore, results suggest that recruitment of brain areas within this network is involved in the acute effects of THC. Resting state perfusion was modulated by COMT genotype, indicated by a significant interaction effect between drug and genotype on perfusion in the executive network, with increased perfusion after THC in Val/Met heterozygotes only. This finding suggests that prefrontal dopamine levels are involved in the susceptibility to acute effects of cannabis.",2019,"THC increased perfusion in bilateral insula, medial superior frontal cortex, and left middle orbital frontal gyrus.",['Thirty-nine healthy volunteers'],"['∆9-tetrahydrocannabinol (THC', 'Arterial Spin Labelling (ASL', 'THC']","['THC increased perfusion in bilateral insula, medial superior frontal cortex, and left middle orbital frontal gyrus']","[{'cui': 'C3816447', 'cui_str': '39'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}]","[{'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0021640', 'cui_str': 'Insular structure'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0016733', 'cui_str': 'Frontal lobe structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0699036', 'cui_str': 'Orbital'}, {'cui': 'C0228195', 'cui_str': 'Structure of frontal lobe gyrus'}]",39.0,0.0466401,"THC increased perfusion in bilateral insula, medial superior frontal cortex, and left middle orbital frontal gyrus.","[{'ForeName': 'Matthijs G', 'Initials': 'MG', 'LastName': 'Bossong', 'Affiliation': ""Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, United Kingdom. Electronic address: m.bossong@umcutrecht.nl.""}, {'ForeName': 'Hendrika H', 'Initials': 'HH', 'LastName': 'van Hell', 'Affiliation': 'Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.'}, {'ForeName': 'Chris D', 'Initials': 'CD', 'LastName': 'Schubart', 'Affiliation': 'Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; Department of Psychiatry, Tergooi Hospital, Van Riebeeckweg 212, 1213 XZ Hilversum, The Netherlands.'}, {'ForeName': 'Wesley', 'Initials': 'W', 'LastName': 'van Saane', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, United Kingdom.""}, {'ForeName': 'Tabitha A', 'Initials': 'TA', 'LastName': 'Iseger', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, United Kingdom; Department of Experimental Psychology, Utrecht University, Heidelberglaan 1, 3584 CS Utrecht, The Netherlands; Research Institute Brainclinics, Bijleveldsingel 32, 6524 AD Nijmegen, The Netherlands.""}, {'ForeName': 'Gerry', 'Initials': 'G', 'LastName': 'Jager', 'Affiliation': 'Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; Division of Human Nutrition, Wageningen University, Bomenweg 2, 6703 HD, Wageningen, The Netherlands.'}, {'ForeName': 'Matthias J P', 'Initials': 'MJP', 'LastName': 'van Osch', 'Affiliation': 'Department of Radiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.'}, {'ForeName': 'J Martijn', 'Initials': 'JM', 'LastName': 'Jansma', 'Affiliation': 'Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; Department of Neurosurgery, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.'}, {'ForeName': 'René S', 'Initials': 'RS', 'LastName': 'Kahn', 'Affiliation': 'Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1230, New York, NY 10029-6574, United States.'}, {'ForeName': 'Marco P', 'Initials': 'MP', 'LastName': 'Boks', 'Affiliation': 'Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.'}, {'ForeName': 'Nick F', 'Initials': 'NF', 'LastName': 'Ramsey', 'Affiliation': 'Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.'}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2019.03.010'] 2827,32757521,Subcutaneous or Transvenous Defibrillator Therapy.,"BACKGROUND The subcutaneous implantable cardioverter-defibrillator (ICD) was designed to avoid complications related to the transvenous ICD lead by using an entirely extrathoracic placement. Evidence comparing these systems has been based primarily on observational studies. METHODS We conducted a noninferiority trial in which patients with an indication for an ICD but no indication for pacing were assigned to receive a subcutaneous ICD or transvenous ICD. The primary end point was the composite of device-related complications and inappropriate shocks; the noninferiority margin for the upper boundary of the 95% confidence interval for the hazard ratio (subcutaneous ICD vs. transvenous ICD) was 1.45. A superiority analysis was prespecified if noninferiority was established. Secondary end points included death and appropriate shocks. RESULTS A total of 849 patients (426 in the subcutaneous ICD group and 423 in the transvenous ICD group) were included in the analyses. At a median follow-up of 49.1 months, a primary end-point event occurred in 68 patients in the subcutaneous ICD group and in 68 patients in the transvenous ICD group (48-month Kaplan-Meier estimated cumulative incidence, 15.1% and 15.7%, respectively; hazard ratio, 0.99; 95% confidence interval [CI], 0.71 to 1.39; P = 0.01 for noninferiority; P = 0.95 for superiority). Device-related complications occurred in 31 patients in the subcutaneous ICD group and in 44 in the transvenous ICD group (hazard ratio, 0.69; 95% CI, 0.44 to 1.09); inappropriate shocks occurred in 41 and 29 patients, respectively (hazard ratio, 1.43; 95% CI, 0.89 to 2.30). Death occurred in 83 patients in the subcutaneous ICD group and in 68 in the transvenous ICD group (hazard ratio, 1.23; 95% CI, 0.89 to 1.70); appropriate shocks occurred in 83 and 57 patients, respectively (hazard ratio, 1.52; 95% CI, 1.08 to 2.12). CONCLUSIONS In patients with an indication for an ICD but no indication for pacing, the subcutaneous ICD was noninferior to the transvenous ICD with respect to device-related complications and inappropriate shocks. (Funded by Boston Scientific; PRAETORIAN ClinicalTrials.gov number, NCT01296022.).",2020,"Device-related complications occurred in 31 patients in the subcutaneous ICD group and in 44 in the transvenous ICD group (hazard ratio, 0.69; 95% CI, 0.44 to 1.09); inappropriate shocks occurred in 41 and 29 patients, respectively (hazard ratio, 1.43; 95% CI, 0.89 to 2.30).","['patients with an indication for an ICD but no indication for pacing', '849 patients (426 in the subcutaneous ICD group and 423 in the transvenous ICD group) were included in the analyses']","['Subcutaneous or Transvenous Defibrillator Therapy', 'subcutaneous implantable cardioverter-defibrillator (ICD', 'subcutaneous ICD or transvenous ICD', 'subcutaneous ICD', 'transvenous ICD']","['death and appropriate shocks', 'inappropriate shocks', 'composite of device-related complications and inappropriate shocks; the noninferiority margin for the upper boundary of the 95% confidence interval for the hazard ratio (subcutaneous ICD vs. transvenous ICD', 'Device-related complications', 'appropriate shocks', 'Death']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0162589', 'cui_str': 'Implantable defibrillator'}, {'cui': 'C0521090', 'cui_str': 'No indication of'}, {'cui': 'C0562458', 'cui_str': 'Pacing up and down'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0522521', 'cui_str': 'Transvenous approach'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0522521', 'cui_str': 'Transvenous approach'}, {'cui': 'C0180307', 'cui_str': 'Defibrillator'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0162589', 'cui_str': 'Implantable defibrillator'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0036974', 'cui_str': 'Shock'}, {'cui': 'C3542467', 'cui_str': 'Inappropriate'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0009667', 'cui_str': 'Confidence Intervals'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0162589', 'cui_str': 'Implantable defibrillator'}, {'cui': 'C0522521', 'cui_str': 'Transvenous approach'}]",849.0,0.240788,"Device-related complications occurred in 31 patients in the subcutaneous ICD group and in 44 in the transvenous ICD group (hazard ratio, 0.69; 95% CI, 0.44 to 1.09); inappropriate shocks occurred in 41 and 29 patients, respectively (hazard ratio, 1.43; 95% CI, 0.89 to 2.30).","[{'ForeName': 'Reinoud E', 'Initials': 'RE', 'LastName': 'Knops', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Louise R A', 'Initials': 'LRA', 'LastName': 'Olde Nordkamp', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Peter-Paul H M', 'Initials': 'PHM', 'LastName': 'Delnoy', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Lucas V A', 'Initials': 'LVA', 'LastName': 'Boersma', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Kuschyk', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Mikhael F', 'Initials': 'MF', 'LastName': 'El-Chami', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Hendrik', 'Initials': 'H', 'LastName': 'Bonnemeier', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Elijah R', 'Initials': 'ER', 'LastName': 'Behr', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Tom F', 'Initials': 'TF', 'LastName': 'Brouwer', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Kääb', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Suneet', 'Initials': 'S', 'LastName': 'Mittal', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Anne-Floor B E', 'Initials': 'ABE', 'LastName': 'Quast', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Lonneke', 'Initials': 'L', 'LastName': 'Smeding', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Willeke', 'Initials': 'W', 'LastName': 'van der Stuijt', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Anouk', 'Initials': 'A', 'LastName': 'de Weger', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Koen C', 'Initials': 'KC', 'LastName': 'de Wilde', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Nick R', 'Initials': 'NR', 'LastName': 'Bijsterveld', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Richter', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Marc A', 'Initials': 'MA', 'LastName': 'Brouwer', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Joris R', 'Initials': 'JR', 'LastName': 'de Groot', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Kirsten M', 'Initials': 'KM', 'LastName': 'Kooiman', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Pier D', 'Initials': 'PD', 'LastName': 'Lambiase', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Petr', 'Initials': 'P', 'LastName': 'Neuzil', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Vernooy', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Alings', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Tim R', 'Initials': 'TR', 'LastName': 'Betts', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Frank A L E', 'Initials': 'FALE', 'LastName': 'Bracke', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Martin C', 'Initials': 'MC', 'LastName': 'Burke', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Jonas S S G', 'Initials': 'JSSG', 'LastName': 'de Jong', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Wright', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Jan G P', 'Initials': 'JGP', 'LastName': 'Tijssen', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': 'Arthur A M', 'Initials': 'AAM', 'LastName': 'Wilde', 'Affiliation': ""From the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam (R.E.K., L.R.A.O.N., L.V.A.B., T.F.B., A.-F.B.E.Q., L.S., W.S., A.W., K.C.W., J.R.G., K.M.K., M.C.B., J.G.P.T., A.A.M.W.), ERN GUARD-Heart (E.R.B., P.D.L., A.A.M.W.), and the Department of Cardiology, OLVG (J.S.S.G.J.), Amsterdam, the Department of Cardiology, Isala Heart Centre, Zwolle (P.-P.H.M.D.), the Department of Cardiology, St. Antonius Hospital, Nieuwegein (L.V.A.B.), the Department of Cardiology, Flevoziekenhuis, Almere (N.R.B.), the Department of Cardiology, Radboud University Medical Center, Nijmegen (M.A.B.), the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht (K.V.), the Department of Cardiology, Amphia Hospital, Breda (M.A.), Werkgroep Cardiologische Centra Nederland, Utrecht (M.A.), and the Department of Electrophysiology, Catharina Hospital, Eindhoven (F.A.L.E.B.) - all in the Netherlands; the First Department of Medicine-Cardiology, University Medical Center Mannheim, and the German Center for Cardiovascular Research Partner Site Heidelberg-Mannheim, Mannheim (J.K.), Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel (H.B.), the Department of Medicine I, Ludwig-Maximilians University Hospital, and the German Center for Cardiovascular Research, Munich Heart Alliance, Munich (S.K.), and the Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig (S.R.) - all in Germany; the Division of Cardiology Section of Electrophysiology, Emory University, Atlanta (M.F.E.-C.); the Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust London (E.R.B.), and Office of the Director of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and Barts Heart Centre (P.D.L.), London, the Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford (T.R.B.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - all in the United Kingdom; Valley Health System, Ridgewood, NJ (S.M.); the Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N.); and CorVita Science Foundation, Chicago (M.C.B.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1915932'] 2828,32757523,Ofatumumab versus Teriflunomide in Multiple Sclerosis.,"BACKGROUND Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known. METHODS In two double-blind, double-dummy, phase 3 trials, we randomly assigned patients with relapsing multiple sclerosis to receive subcutaneous ofatumumab (20 mg every 4 weeks after 20-mg loading doses at days 1, 7, and 14) or oral teriflunomide (14 mg daily) for up to 30 months. The primary end point was the annualized relapse rate. Secondary end points included disability worsening confirmed at 3 months or 6 months, disability improvement confirmed at 6 months, the number of gadolinium-enhancing lesions per T1-weighted magnetic resonance imaging (MRI) scan, the annualized rate of new or enlarging lesions on T2-weighted MRI, serum neurofilament light chain levels at month 3, and change in brain volume. RESULTS Overall, 946 patients were assigned to receive ofatumumab and 936 to receive teriflunomide; the median follow-up was 1.6 years. The annualized relapse rates in the ofatumumab and teriflunomide groups were 0.11 and 0.22, respectively, in trial 1 (difference, -0.11; 95% confidence interval [CI], -0.16 to -0.06; P<0.001) and 0.10 and 0.25 in trial 2 (difference, -0.15; 95% CI, -0.20 to -0.09; P<0.001). In the pooled trials, the percentage of patients with disability worsening confirmed at 3 months was 10.9% with ofatumumab and 15.0% with teriflunomide (hazard ratio, 0.66; P = 0.002); the percentage with disability worsening confirmed at 6 months was 8.1% and 12.0%, respectively (hazard ratio, 0.68; P = 0.01); and the percentage with disability improvement confirmed at 6 months was 11.0% and 8.1% (hazard ratio, 1.35; P = 0.09). The number of gadolinium-enhancing lesions per T1-weighted MRI scan, the annualized rate of lesions on T2-weighted MRI, and serum neurofilament light chain levels, but not the change in brain volume, were in the same direction as the primary end point. Injection-related reactions occurred in 20.2% in the ofatumumab group and in 15.0% in the teriflunomide group (placebo injections). Serious infections occurred in 2.5% and 1.8% of the patients in the respective groups. CONCLUSIONS Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide. (Funded by Novartis; ASCLEPIOS I and II ClinicalTrials.gov numbers, NCT02792218 and NCT02792231.).",2020,"Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide.","['patients with multiple sclerosis', '946 patients were assigned to receive ofatumumab and 936 to receive']","['Ofatumumab versus Teriflunomide', 'teriflunomide', 'Teriflunomide', 'subcutaneous ofatumumab', 'oral teriflunomide']","['disability worsening confirmed at 3 months or 6 months, disability improvement', 'annualized relapse rate', 'number of gadolinium-enhancing lesions per T1-weighted MRI scan, the annualized rate of lesions on T2-weighted MRI, and serum neurofilament light chain levels', 'Serious infections', 'percentage with disability worsening', 'percentage with disability improvement', 'disability worsening', 'Injection-related reactions', 'T-cell and B-cell activation', 'annualized relapse rates', 'number of gadolinium-enhancing lesions per T1-weighted magnetic resonance imaging (MRI) scan, the annualized rate of new or enlarging lesions on T2-weighted MRI, serum neurofilament light chain levels at month 3, and change in brain volume']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C1832027', 'cui_str': 'ofatumumab'}]","[{'cui': 'C1832027', 'cui_str': 'ofatumumab'}, {'cui': 'C1718383', 'cui_str': 'teriflunomide'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0016911', 'cui_str': 'Gadolinium'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0027834', 'cui_str': 'Neurofilaments'}, {'cui': 'C1562562', 'cui_str': 'Light chain level'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C3160907', 'cui_str': 'Injection related reaction'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0004561', 'cui_str': 'B lymphocyte'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0442800', 'cui_str': 'Enlarged'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",946.0,0.212435,"Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide.","[{'ForeName': 'Stephen L', 'Initials': 'SL', 'LastName': 'Hauser', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Bar-Or', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Cohen', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'Comi', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Correale', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Patricia K', 'Initials': 'PK', 'LastName': 'Coyle', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Anne H', 'Initials': 'AH', 'LastName': 'Cross', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Jerome', 'Initials': 'J', 'LastName': 'de Seze', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Leppert', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Montalban', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Krzysztof', 'Initials': 'K', 'LastName': 'Selmaj', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Heinz', 'Initials': 'H', 'LastName': 'Wiendl', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Cecile', 'Initials': 'C', 'LastName': 'Kerloeguen', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Willi', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Bingbing', 'Initials': 'B', 'LastName': 'Li', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Algirdas', 'Initials': 'A', 'LastName': 'Kakarieka', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Davorka', 'Initials': 'D', 'LastName': 'Tomic', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Goodyear', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Ratnakar', 'Initials': 'R', 'LastName': 'Pingili', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Dieter A', 'Initials': 'DA', 'LastName': 'Häring', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Krishnan', 'Initials': 'K', 'LastName': 'Ramanathan', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Merschhemke', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': 'Ludwig', 'Initials': 'L', 'LastName': 'Kappos', 'Affiliation': ""From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1917246'] 2829,32763878,Notifications to Improve Engagement With an Alcohol Reduction App: Protocol for a Micro-Randomized Trial.,"BACKGROUND Drink Less is a behavior change app that aims to help users in the general adult population reduce hazardous and harmful alcohol consumption. The app includes a daily push notification, delivered at 11 am, asking users to ""Please complete your mood and drinking diaries."" Previous analysis of Drink Less engagement data suggests the current notification strongly influences how users engage with the app in the subsequent hour. To exploit a potential increase of vulnerability of excess drinking and opportunity to engage with the app in the evenings, we changed the delivery time from 11 am to 8 pm. We now aim to further optimise the content and sequence of notifications, testing 30 new evidence-informed notifications targeting the user's perceived usefulness of the app. OBJECTIVE The primary objective is to assess whether sending a notification at 8 pm increases behavioral engagement (opening the app) in the subsequent hour. Secondary objectives include comparing the effect of the new bank of messages with the standard message and effect moderation over time. We also aim to more generally understand the role notifications have on the overall duration, depth, and frequency of engagement with Drink Less over the first 30 days after download. METHODS This is a protocol for a micro-randomized trial with two additional parallel arms. Inclusion criteria are Drink Less users who (1) consent to participate in the trial; (2) self-report a baseline Alcohol Use Disorders Identification Test score of 8 or above; (3) reside in the United Kingdom; (4) age ≥18 years and; (5) report interest in drinking less alcohol. In the micro-randomized trial, participants will be randomized daily at 8 pm to receive no notification, a notification with text from the new message bank, or the standard message. The primary outcome is the time-varying, binary outcome of ""Did the user open the app in the hour from 8 pm to 9 pm?"". The primary analysis will estimate the marginal relative risk for the notifications using an estimator developed for micro-randomized trials with binary outcomes. Participants randomized to the parallel arms will receive no notifications (Secondary Arm A), or the standard notification delivered daily at 11 am (Secondary Arm B) over 30 days, allowing the comparison of overall engagement between different notification delivery strategies. RESULTS Approval was granted by the University College of London's Departmental Research Ethics Committee (CEHP/2016/556) on October 11, 2019, and The London School of Hygiene and Tropical Medicine Interventions Research Ethics Committee (17929) on November 27, 2019. Recruitment began on January 2, 2020, and is ongoing. CONCLUSIONS Understanding how push notifications may impact engagement with a behavior change app can lead to further improvements in engagement, and ultimately help users reduce their alcohol consumption. This understanding may also be generalizable to other apps that target a variety of behavior changes. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/18690.",2020,"We now aim to further optimise the content and sequence of notifications, testing 30 new evidence-informed notifications targeting the user's perceived usefulness of the app. ",['Inclusion criteria are Drink Less users who (1) consent to participate in the trial; (2) self-report a baseline Alcohol Use Disorders Identification Test score of 8 or above; (3) reside in the United Kingdom; (4) age ≥18 years and; (5) report interest in drinking less alcohol'],"['asking users to ""Please complete your mood and drinking diaries']","['overall duration, depth, and frequency of engagement with Drink Less', 'new bank of messages with the standard message and effect moderation over time', 'time-varying, binary outcome of ""Did the user open the app in the hour from 8 pm to 9 pm']","[{'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C2732658', 'cui_str': 'Alcohol use disorders identification test score'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom of Great Britain and Northern Ireland'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}]","[{'cui': 'C1172410', 'cui_str': 'ASK protein, human'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0442598', 'cui_str': 'Bank'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0439227', 'cui_str': 'hour'}]",,0.161916,"We now aim to further optimise the content and sequence of notifications, testing 30 new evidence-informed notifications targeting the user's perceived usefulness of the app. ","[{'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Bell', 'Affiliation': 'Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Garnett', 'Affiliation': 'Research Department of Behavioural Science and Health, University College London, London, United Kingdom.'}, {'ForeName': 'Tianchen', 'Initials': 'T', 'LastName': 'Qian', 'Affiliation': 'Department of Statistics, Harvard University, Cambridge, MA, United States.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Perski', 'Affiliation': 'Research Department of Behavioural Science and Health, University College London, London, United Kingdom.'}, {'ForeName': 'Henry W W', 'Initials': 'HWW', 'LastName': 'Potts', 'Affiliation': 'Institute of Health Informatics, University College London, London, United Kingdom.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Williamson', 'Affiliation': 'Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}]",JMIR research protocols,['10.2196/18690'] 2830,32763882,A Novel HIV-1 RNA Testing Intervention to Detect Acute and Prevalent HIV Infection in Young Adults and Reduce HIV Transmission in Kenya: Protocol for a Randomized Controlled Trial.,"BACKGROUND Detection and management of acute HIV infection (AHI) is a clinical and public health priority, and HIV infections diagnosed among young adults aged 18 to 39 years are usually recent. Young adults with recent HIV acquisition frequently seek care for symptoms and could potentially be diagnosed through the health care system. Early recognition of HIV infection provides considerable individual and public health benefits, including linkage to treatment as prevention, access to risk reduction counseling and treatment, and notification of partners in need of HIV testing. OBJECTIVE The Tambua Mapema Plus study aims to (1) test 1500 young adults (aged 18-39 years) identified by an AHI screening algorithm for acute and prevalent (ie, seropositive) HIV, linking all newly diagnosed HIV-infected patients to care and offering immediate treatment; (2) offer assisted HIV partner notification services to all patients with HIV, testing partners for acute and prevalent HIV infection and identifying local sexual networks; and (3) model the potential impact of these two interventions on the Kenyan HIV epidemic, estimating incremental costs per HIV infection averted, death averted, and disability-adjusted life year averted using data on study outcomes. METHODS A modified stepped-wedge design is evaluating the yield of this HIV testing intervention at 4 public and 2 private health facilities in coastal Kenya before and after intervention delivery. The intervention uses point-of-care HIV-1 RNA testing combined with standard rapid antibody tests to diagnose AHI and prevalent HIV among young adults presenting for care, employs HIV partner notification services to identify linked acute and prevalent infections, and follows all newly diagnosed patients and their partners for 12 months to ascertain clinical outcomes, including linkage to care, antiretroviral therapy (ART) initiation and virologic suppression in HIV-infected patients, and pre-exposure prophylaxis uptake in uninfected individuals in discordant partnerships. RESULTS Enrollment started in December 2017. As of April 2020, 1374 participants have been enrolled in the observation period and 1500 participants have been enrolled in the intervention period, with 13 new diagnoses (0.95%) in the observation period and 37 new diagnoses (2.47%), including 2 AHI diagnoses, in the intervention period. Analysis is ongoing and will include adjusted comparisons of the odds of the following outcomes in the observation and intervention periods: being tested for HIV infection, newly diagnosed with prevalent or acute HIV infection, linked to care, and starting ART by week 6 following HIV diagnosis. Participants newly diagnosed with acute or prevalent HIV infection in the intervention period are being followed for outcomes, including viral suppression by month 6 and month 12 following ART initiation and partner testing outcomes. CONCLUSIONS The Tambua Mapema Plus study will provide foundational data on the potential of this novel combination HIV prevention intervention to reduce ongoing HIV transmission in Kenya and other high-prevalence African settings. TRIAL REGISTRATION ClinicalTrials.gov NCT03508908; https://clinicaltrials.gov/ct2/show/NCT03508908. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/16198.",2020,"The Tambua Mapema Plus study will provide foundational data on the potential of this novel combination HIV prevention intervention to reduce ongoing HIV transmission in Kenya and other high-prevalence African settings. ","['4 public and 2 private health facilities in coastal Kenya before and after intervention delivery', '1374 participants have been enrolled in the observation period and 1500 participants have been enrolled in the intervention period, with 13 new diagnoses (0.95%) in the observation period and 37 new diagnoses (2.47%), including 2 AHI diagnoses, in the intervention period', 'Participants newly diagnosed with acute or prevalent HIV infection in the intervention period are being followed for outcomes, including viral suppression by month 6 and month 12 following ART initiation and partner testing outcomes', 'young adults aged 18 to 39 years', '1500 young adults (aged 18-39 years) identified by an AHI screening algorithm for acute and prevalent (ie, seropositive) HIV, linking all newly diagnosed HIV-infected patients to care and offering immediate treatment', 'young adults presenting for care, employs HIV partner notification services', 'Young Adults and Reduce HIV Transmission in Kenya', 'Young adults']",['HIV-1 RNA Testing Intervention'],[],"[{'cui': 'C0033175', 'cui_str': 'Private Room'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C4517582', 'cui_str': '1500'}, {'cui': 'C2585997', 'cui_str': 'New diagnosis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0343752', 'cui_str': 'Acute HIV infection'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0019693', 'cui_str': 'Human immunodeficiency virus infection'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0521143', 'cui_str': 'Seropositive'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C0079990', 'cui_str': 'Partner Notification'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0040722', 'cui_str': 'transmission'}]","[{'cui': 'C0369499', 'cui_str': 'Human immunodeficiency virus 1 RNA'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],1500.0,0.117879,"The Tambua Mapema Plus study will provide foundational data on the potential of this novel combination HIV prevention intervention to reduce ongoing HIV transmission in Kenya and other high-prevalence African settings. ","[{'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Graham', 'Affiliation': 'Department of Global Health, University of Washington, Seattle, WA, United States.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Agutu', 'Affiliation': 'Kenya Medical Research Institute - Wellcome Trust Research Programme, Kilifi, Kenya.'}, {'ForeName': 'Elise', 'Initials': 'E', 'LastName': 'van der Elst', 'Affiliation': 'Kenya Medical Research Institute - Wellcome Trust Research Programme, Kilifi, Kenya.'}, {'ForeName': 'Amin S', 'Initials': 'AS', 'LastName': 'Hassan', 'Affiliation': 'Kenya Medical Research Institute - Wellcome Trust Research Programme, Kilifi, Kenya.'}, {'ForeName': 'Evanson', 'Initials': 'E', 'LastName': 'Gichuru', 'Affiliation': 'Kenya Medical Research Institute - Wellcome Trust Research Programme, Kilifi, Kenya.'}, {'ForeName': 'Peter M', 'Initials': 'PM', 'LastName': 'Mugo', 'Affiliation': 'Kenya Medical Research Institute - Wellcome Trust Research Programme, Kilifi, Kenya.'}, {'ForeName': 'Carey', 'Initials': 'C', 'LastName': 'Farquhar', 'Affiliation': 'Department of Global Health, University of Washington, Seattle, WA, United States.'}, {'ForeName': 'Joseph B', 'Initials': 'JB', 'LastName': 'Babigumira', 'Affiliation': 'Department of Global Health, University of Washington, Seattle, WA, United States.'}, {'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'Goodreau', 'Affiliation': 'Department of Epidemiology, University of Washington, Seattle, WA, United States.'}, {'ForeName': 'Deven T', 'Initials': 'DT', 'LastName': 'Hamilton', 'Affiliation': 'Center for Studies in Demography and Ecology, University of Washington, Seattle, WA, United States.'}, {'ForeName': 'Thumbi', 'Initials': 'T', 'LastName': ""Ndung'u"", 'Affiliation': 'Africa Health Research Institute, Durban, South Africa.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Sirengo', 'Affiliation': 'Department of Health Infrastructure Management, Ministry of Health, Nairobi, Kenya.'}, {'ForeName': 'Wairimu', 'Initials': 'W', 'LastName': 'Chege', 'Affiliation': 'Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States.'}, {'ForeName': 'Eduard J', 'Initials': 'EJ', 'LastName': 'Sanders', 'Affiliation': 'Kenya Medical Research Institute - Wellcome Trust Research Programme, Kilifi, Kenya.'}]",JMIR research protocols,['10.2196/16198'] 2831,32763885,Evaluating the Effectiveness of an Intervention Integrating Technology and In-Person Sexual Health Education for Adolescents (In the Know): Protocol for a Cluster Randomized Controlled Trial.,"BACKGROUND Access to a smartphone is nearly universal among American adolescents, and most of them have used the internet to seek health information. Integrating digital technologies into health program delivery may expand opportunities for youth to receive important health information, yet there are few rigorous studies assessing the effectiveness of this type of intervention. OBJECTIVE The purpose of this study is to assess the effectiveness of In the Know (ITK), a program integrating in-person and technology-based sexual health education for underserved adolescents. METHODS Youth were engaged in the development of the intervention, including the design of the digital technology and the curriculum content. The intervention focuses on 3 main areas: sexual health and contraceptive use, healthy relationships, and educational and career success. It includes an in-person, classroom component, along with a web-based component to complement and reinforce key content. A cluster randomized controlled trial is in progress among adolescents aged 13-19 years living in Fresno County, California. It is designed to examine the differences in self-reported health and behavioral outcomes among youth in the intervention and control groups at 3 and 9 months. Primary outcomes are condom and contraceptive use or no sex in the past 3 months and use of any clinical health services in the past 3 months. Secondary outcomes include the number of sexual partners in the past 3 months and knowledge of local clinical sexual health services. We will use mixed-effects linear and logistic regression models to assess differences between the intervention and control groups. RESULTS Trial enrollment began in October 2017 and ended in March 2020 with a total of 1260 participants. The mean age of the participants is 15.73 (SD 1.83) years, and 69.98% (867/1239) of the participants report being Hispanic or Latino. Study results will be available in 2021. CONCLUSIONS ITK has the potential to improve contraceptive and clinic use among underserved youth. This trial will inform future youth-focused health interventions that are considering incorporating technology. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/18060.",2020,It is designed to examine the differences in self-reported health and behavioral outcomes among youth in the intervention and control groups at 3 and 9 months.,"['underserved youth', 'underserved adolescents', 'Youth', 'American adolescents', 'adolescents aged 13-19 years living in Fresno County, California', 'Trial enrollment began in October 2017 and ended in March 2020 with a total of 1260 participants']",['Intervention Integrating Technology and In-Person Sexual Health Education'],"['number of sexual partners in the past 3 months and knowledge of local clinical sexual health services', 'condom and contraceptive use or no sex in the past 3 months and use of any clinical health services']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0036879', 'cui_str': 'Sexuality education'}]","[{'cui': 'C0556463', 'cui_str': 'Number of sexual partners'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C2362326', 'cui_str': 'Sexual Health'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0009871', 'cui_str': 'Contraceptive agent'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0018747', 'cui_str': 'Services, Health'}]",1260.0,0.0898288,It is designed to examine the differences in self-reported health and behavioral outcomes among youth in the intervention and control groups at 3 and 9 months.,"[{'ForeName': 'Martha J', 'Initials': 'MJ', 'LastName': 'Decker', 'Affiliation': 'Department of Epidemiology and Biostatistics, Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA, United States.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Gutmann-Gonzalez', 'Affiliation': 'Philip R Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA, United States.'}, {'ForeName': 'Melisa', 'Initials': 'M', 'LastName': 'Price', 'Affiliation': 'Philip R Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA, United States.'}, {'ForeName': 'Julio', 'Initials': 'J', 'LastName': 'Romero', 'Affiliation': 'Fresno Economic Opportunities Commission, Fresno, CA, United States.'}, {'ForeName': 'Bhupendra', 'Initials': 'B', 'LastName': 'Sheoran', 'Affiliation': 'Youth Tech Health, ETR, Oakland, CA, United States.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Yarger', 'Affiliation': 'Philip R Lee Institute for Health Policy Studies, Bixby Center for Global Reproductive Health, University of California, San Francisco, San Francisco, CA, United States.'}]",JMIR research protocols,['10.2196/18060'] 2832,32763887,A Web-Delivered Acceptance and Commitment Therapy Intervention With Email Reminders to Enhance Subjective Well-Being and Encourage Engagement With Lifestyle Behavior Change in Health Care Staff: Randomized Cluster Feasibility Stud.,"BACKGROUND Poor mental health and emotional well-being can negatively impact ability to engage in healthy lifestyle behavior change. Health care staff have higher rates of sickness and absence than other public sector staff, which has implications at both individual and societal levels. Individual efforts to self-manage health and well-being which add to the UK mental health prevention agenda need to be supported. OBJECTIVE The objective of this study was to establish the feasibility and acceptability of the inclusion of a self-guided, automated, web-based acceptance and commitment therapy intervention in an existing health promotion program, to improve subjective well-being and encourage engagement with lifestyle behavior change. METHODS For this 12-week, 4-armed, randomized controlled cluster feasibility study, we recruited participants offline and randomly allocated them to 1 of 3 intervention arms or control (no well-being intervention) using an automated web-based allocation procedure. Eligibility criteria were current health care staff in 1 Welsh health board, age≥18 years, ability to read English, and ability to provide consent. The primary researcher was blinded to cluster allocation. Feasibility outcomes were randomization procedure, acceptance of intervention, and adherence to and engagement with the wider program. We evaluated health and well-being data via self-assessment at 2 time points, registration and postintervention, using the 14-item Warwick-Edinburgh Mental Well-Being Scale, the 4-item Patient Health Questionnaire, and the 7-item Acceptance and Action Questionnaire-Revised. RESULTS Of 124 participants who provided consent and were randomly allocated, 103 completed full registration and engaged with the program. Most participants (76/103) enrolled in at least one health behavior change module, and 43% (41/96) of those randomly allocated to an intervention arm enrolled in the well-being module. Adherence and engagement was low (7/103, 6.8%), but qualitative feedback was positive. CONCLUSIONS The procedure and randomization process proved feasible, and the addition of the well-being module proved acceptable to health care staff. However, participant engagement was limited, and no one completed the full 12-week program. User feedback should be used to develop the intervention to address poor engagement. Effectiveness should then be evaluated in a full-scale randomized controlled trial, which would be feasible with additional recruitment. TRIAL REGISTRATION International Standard Randomised Controlled Trial Number (ISRCTN) 50074817; http://www.isrctn.com/ISRCTN50074817.",2020,"The procedure and randomization process proved feasible, and the addition of the well-being module proved acceptable to health care staff.","['Most participants (76/103) enrolled in at least one health behavior change module, and 43% (41/96) of those randomly allocated to an intervention arm enrolled in the well-being module', 'Health Care Staff', '124 participants who provided consent and were randomly allocated, 103 completed full registration and engaged with the program']","['control (no well-being intervention) using an automated web-based allocation procedure', 'Email Reminders']","['14-item Warwick-Edinburgh Mental Well-Being Scale, the 4-item Patient Health Questionnaire, and the 7-item Acceptance and Action Questionnaire-Revised', 'acceptance of intervention, and adherence to and engagement with the wider program', 'Adherence and engagement']","[{'cui': 'C4505266', 'cui_str': 'One Health Concept'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0013849', 'cui_str': 'Email'}]","[{'cui': 'C4273514', 'cui_str': 'Warwick Edinburgh Mental Well Being Scale'}, {'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]",,0.109443,"The procedure and randomization process proved feasible, and the addition of the well-being module proved acceptable to health care staff.","[{'ForeName': 'Menna', 'Initials': 'M', 'LastName': 'Brown', 'Affiliation': 'Swansea University Medical School, Swansea University, Swansea, United Kingdom.'}, {'ForeName': 'Nic', 'Initials': 'N', 'LastName': 'Hooper', 'Affiliation': 'Department of Health and Social Sciences, University of the West of England, Bristol, United Kingdom.'}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'James', 'Affiliation': 'Department of Computer Science, Swansea University, Swansea, United Kingdom.'}, {'ForeName': 'Darren', 'Initials': 'D', 'LastName': 'Scott', 'Affiliation': 'Department of Computer Science, Swansea University, Swansea, United Kingdom.'}, {'ForeName': 'Owen', 'Initials': 'O', 'LastName': 'Bodger', 'Affiliation': 'Swansea University Medical School, Swansea University, Swansea, United Kingdom.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'John', 'Affiliation': 'Swansea University Medical School, Swansea University, Swansea, United Kingdom.'}]",JMIR formative research,['10.2196/18586'] 2833,31823135,Long-term analyses of spastic muscle behavior in chronic poststroke patients after near-infrared low-level laser therapy (808 nm): a double-blinded placebo-controlled clinical trial.,"Stroke results in impairment of basic motor functions, such as muscle weakness in limbs affected by spasticity, leading to peripheral fatigue and impaired functionality. The clinical use of photobiomodulation therapy (PBMT) has provided major advances in the treatment of muscular disorders and prevention of muscle fatigue. The aim of this study was to analyze the effects of two distinct therapies in biceps spasticity of chronic hemiparetic patients. We analyzed range of elbow motion, torque, electromyography, and mean spectral frequency after 10 sessions of PBMT (Laser 100 mW, 808 nm, 159.24 J/cm 2 /point, 5 J/point); PBMT active or placebo was associated with exoskeleton-assisted functional treatment. A double-blind placebo-controlled sequential clinical trial was conducted with 12 healthy volunteers and 15 poststroke patients who presented upper-limb spasticity. The healthy volunteers performed only the evaluation protocol, and the poststroke volunteers participated in three consecutive phases (PBMT, PBMT + exoskeleton, placebo + PBMT) with a washout period of 4 weeks between each phase. We could observe significant increases in range of elbow motion after PBMT from 57.7 ± 14 to 84.3 ± 27.6 degrees (p < 0.001). The root mean square (RMS) values also increased after PBMT + exoskeleton from 23.2 ± 15 to 34.9 ± 21 μV (p = 0.0178). Our results suggest that the application of PBMT may contribute to an increased range of elbow motion and muscle fiber recruitment, increases in muscle strength, and, hence, to increase signal conduction on spastic muscle fibers in spastic patients.",2020,The clinical use of photobiomodulation therapy (PBMT) has provided major advances in the treatment of muscular disorders and prevention of muscle fatigue.,"['spastic patients', 'chronic hemiparetic patients', 'healthy volunteers performed only the evaluation protocol, and the poststroke volunteers participated in three', 'chronic poststroke patients after', '12 healthy volunteers and 15 poststroke patients who presented upper-limb spasticity']","['placebo', 'photobiomodulation therapy (PBMT', 'PBMT ', 'near-infrared low-level laser therapy', 'consecutive phases (PBMT, PBMT + exoskeleton, placebo + PBMT', 'PBMT active or placebo']","['range of elbow motion', 'root mean square (RMS) values', 'elbow motion, torque, electromyography, and mean spectral frequency']","[{'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C1273957', 'cui_str': 'Upper limb spasticity'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4019433', 'cui_str': 'Photobiomodulation Therapy'}, {'cui': 'C0475806', 'cui_str': '1/3 meter'}, {'cui': 'C1532326', 'cui_str': 'Infra-red'}, {'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0205177', 'cui_str': 'Active'}]","[{'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}]",12.0,0.12055,The clinical use of photobiomodulation therapy (PBMT) has provided major advances in the treatment of muscular disorders and prevention of muscle fatigue.,"[{'ForeName': 'Marcele Florêncio', 'Initials': 'MF', 'LastName': 'das Neves', 'Affiliation': 'Laboratório de Engenharia de Reabilitação Sensório Motora, Faculdade de Ciências da Saúde, Universidade do Vale do Paraíba, São José dos Campos, SP, Brasil.'}, {'ForeName': 'Diane Cristina', 'Initials': 'DC', 'LastName': 'Aleixo', 'Affiliation': 'Laboratório de Engenharia de Reabilitação Sensório Motora, Faculdade de Ciências da Saúde, Universidade do Vale do Paraíba, São José dos Campos, SP, Brasil.'}, {'ForeName': 'Izabela Santos', 'Initials': 'IS', 'LastName': 'Mendes', 'Affiliation': 'Laboratório de Engenharia de Reabilitação Sensório Motora, Faculdade de Ciências da Saúde, Universidade do Vale do Paraíba, São José dos Campos, SP, Brasil.'}, {'ForeName': 'Fernanda Púpio Silva', 'Initials': 'FPS', 'LastName': 'Lima', 'Affiliation': 'Laboratório de Engenharia de Reabilitação Sensório Motora, Faculdade de Ciências da Saúde, Universidade do Vale do Paraíba, São José dos Campos, SP, Brasil.'}, {'ForeName': 'Renata Amadei', 'Initials': 'RA', 'LastName': 'Nicolau', 'Affiliation': 'Laboratório de Terapia Fotodinâmica - Instituto de Pesquisa & Desenvolvimento, Universidade do Vale do Paraíba, São José dos Campos, SP, Brasil.'}, {'ForeName': 'Emilia Angela Loschiavo', 'Initials': 'EAL', 'LastName': 'Arisawa', 'Affiliation': 'Laboratório de Imunologia - Instituto de Pesquisa e Desenvolvimento, Universidade do Vale do Paraíba, São José dos Campos, SP, Brasil.'}, {'ForeName': 'Rodrigo Alvaro Brandão', 'Initials': 'RAB', 'LastName': 'Lopes-Martins', 'Affiliation': 'Laboratório de Biofotônica e Terapêutica Experimental - Instituto de Pesquisa & Desenvolvimento, Universidade do Vale do Paraíba, São José dos Campos, SP, Brasil. ralopesmartins@gmail.com.'}, {'ForeName': 'Mário Oliveira', 'Initials': 'MO', 'LastName': 'Lima', 'Affiliation': 'Laboratório de Engenharia de Reabilitação Sensório Motora, Faculdade de Ciências da Saúde, Universidade do Vale do Paraíba, São José dos Campos, SP, Brasil.'}]",Lasers in medical science,['10.1007/s10103-019-02920-3'] 2834,31829943,Outcomes of stent optimisation in intravascular ultrasound-guided interventions for long lesions or chronic total occlusions.,"AIMS We sought to investigate the incidence, predictors, and clinical outcomes of stent optimisation with intravascular ultrasound (IVUS) in long coronary lesions treated with new-generation drug-eluting stents (DESs). METHODS AND RESULTS From four randomised trials comparing IVUS and angiography guidance in long (≥26 mm) or chronic total occlusion coronary lesions, a total of 1,396 patients who underwent IVUS-guided intervention were classified into two groups (stent optimisation and non-optimisation) according to optimisation criteria (minimal stent area [MSA] ≥5.5 mm2 or 80% of mean reference lumen area [MLA]). Major adverse cardiac event (MACE) occurrence, defined as a composite of cardiac death, myocardial infarction, stent thrombosis, or target vessel revascularisation, was compared. Stent optimisation was not met in 578 (41%) patients. Predictors of non-optimisation were older age, longer lesion length, and smaller stent diameter. The MACE rate was significantly higher in the non-optimisation versus the stent optimisation group (4.8% vs 1.9%, log-rank p=0.002; adjusted hazard ratio 2.95, 95% CI: 1.43-6.06). Among possible combinations of absolute and relative expansion criteria, the one best predicting MACE was at least one of MSA ≥5.4 mm2 and/or ≥80% of MLA (Youden index=0.264). CONCLUSIONS Achieving stent optimisation using IVUS evaluation was associated with favourable outcomes in IVUS-guided, new-generation DES implantation for long coronary lesions including CTOs.",2020,"Achieving stent optimisation using IVUS evaluation was associated with favourable outcomes in IVUS-guided, new-generation DES implantation for long coronary lesions including CTOs.","['long lesions or chronic total occlusions', 'in long (≥26 mm) or chronic total occlusion coronary lesions, a total of 1,396 patients who underwent IVUS-guided intervention']","['new-generation drug-eluting stents (DESs', 'intravascular ultrasound-guided interventions', 'stent optimisation with intravascular ultrasound (IVUS', 'IVUS and angiography guidance']","['MACE rate', 'Major adverse cardiac event (MACE) occurrence, defined as a composite of cardiac death, myocardial infarction, stent thrombosis, or target vessel revascularisation']","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C0151814', 'cui_str': 'Coronary occlusion'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442123', 'cui_str': 'Intravascular'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C1322815', 'cui_str': 'Drug eluting stent'}, {'cui': 'C0442123', 'cui_str': 'Intravascular'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0376297', 'cui_str': 'Cardiac death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0449618', 'cui_str': 'Target vessel'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}]",1396.0,0.0527222,"Achieving stent optimisation using IVUS evaluation was associated with favourable outcomes in IVUS-guided, new-generation DES implantation for long coronary lesions including CTOs.","[{'ForeName': 'Daehoon', 'Initials': 'D', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Sung-Jin', 'Initials': 'SJ', 'LastName': 'Hong', 'Affiliation': ''}, {'ForeName': 'Byeong-Keuk', 'Initials': 'BK', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Dong-Ho', 'Initials': 'DH', 'LastName': 'Shin', 'Affiliation': ''}, {'ForeName': 'Chul-Min', 'Initials': 'CM', 'LastName': 'Ahn', 'Affiliation': ''}, {'ForeName': 'Jung-Sun', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Young-Guk', 'Initials': 'YG', 'LastName': 'Ko', 'Affiliation': ''}, {'ForeName': 'Donghoon', 'Initials': 'D', 'LastName': 'Choi', 'Affiliation': ''}, {'ForeName': 'Myeong-Ki', 'Initials': 'MK', 'LastName': 'Hong', 'Affiliation': ''}, {'ForeName': 'Yangsoo', 'Initials': 'Y', 'LastName': 'Jang', 'Affiliation': ''}]",EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,['10.4244/EIJ-D-19-00762'] 2835,32768394,Impact of aerobic training with and without whole-body vibration training on metabolic features and quality of life in non-alcoholic fatty liver disease patients.,"The present study examined the effectiveness of including exercises with whole-body vibration (WBV) to aerobic training in terms of metabolic features and quality of life. Patients with non-alcoholic fatty liver disease confirmed on imaging underwent an 8-week individualized exercise program randomized between aerobic training with and without WBV. Training was performed at 60-80% heart-rate workload for 155 min/week. The WBV amplitude was 2-4 mm and the training frequency was 30 Hz, for 15 min. Assessments were carried out on surrogate scores of steatosis and fibrosis including transient elastography (FibroScan), metabolic features (biochemical analysis) and quality of life (SF-36). Insulin resistance was markedly reduced (-2.36; 95%CI: -4.96 to -0.24; P: 0.049) in aerobic training with WBV. The decrease in serum aspartate transaminase was significantly greater in aerobic training without WBV (-14.81; 95%CI: -23.36 to -6.25; P: 0.029). There were no significant differences between groups for the other metabolic features (P˂0.05). All quality-of-life well-being domains improved in both groups (P˂0.05). Given this reduction in insulin resistance, WBV can usefully be added to aerobic training. However, WBV did not provide further benefits in improving metabolic properties or quality of life.",2020,The decrease in serum aspartate transaminase was significantly greater in aerobic training without WBV (-14.81; 95%CI: -23.36 to -6.25; P: 0.029).,"['non-alcoholic fatty liver disease patients', 'Patients with non-alcoholic fatty liver disease confirmed on imaging underwent an 8-week']","['exercises with whole-body vibration (WBV) to aerobic training', 'individualized exercise program randomized between aerobic training with and without WBV', 'aerobic training with and without whole-body vibration training']","['surrogate scores of steatosis and fibrosis including transient elastography (FibroScan), metabolic features (biochemical analysis) and quality of life (SF-36', 'metabolic features and quality of life', 'serum aspartate transaminase', 'WBV amplitude', 'Insulin resistance', 'metabolic properties or quality of life']","[{'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0152254', 'cui_str': 'Fatty degeneration'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C2748260', 'cui_str': 'Transient elastography'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0871161', 'cui_str': 'Property'}]",,0.0409261,The decrease in serum aspartate transaminase was significantly greater in aerobic training without WBV (-14.81; 95%CI: -23.36 to -6.25; P: 0.029).,"[{'ForeName': 'Tülay Çevik', 'Initials': 'TÇ', 'LastName': 'Saldıran', 'Affiliation': 'TÇS [PT. Assistant Professor] Department of Physiotherapy and Rehabilitation, Bitlis Eren University, Bitlis, Turkey. Electronic address: tlyfztcvk@gmail.com.'}, {'ForeName': 'Fatma Karantay', 'Initials': 'FK', 'LastName': 'Mutluay', 'Affiliation': 'FKM, [PT. Professor] Department of Physiotherapy and Rehabilitation, Istanbul Medipol University, Istanbul, Turkey.'}, {'ForeName': 'İlker', 'Initials': 'İ', 'LastName': 'Yağcı', 'Affiliation': 'IY, [MD. Professor] Department of Physical Therapy and Rehabilitation Medicine, Marmara University İstanbul, Turkey.'}, {'ForeName': 'Yusuf', 'Initials': 'Y', 'LastName': 'Yılmaz', 'Affiliation': 'YY, [MD. Professor] Department of Gastroenterology Medicine, Marmara University İstanbul, Turkey.'}]",Annales d'endocrinologie,['10.1016/j.ando.2020.05.003'] 2836,32768403,"Effects of Dexamethasone and Low-Level Laser Therapy on Pain, Swelling, and Quality of Life After Buccal Fat Pad Removal: A Clinical Trial.","PURPOSE In this study we aimed to compare the effects of low-level laser therapy (LLLT) and dexamethasone (DXM) on pain, swelling, and the quality of life (QOL) of patients submitted to buccal fat pad removal. PATIENTS AND METHODS A total of 20 patients with pseudoherniation of buccal fat pad were included in the present study. The patients were divided randomly into 2 groups: the LLLT group (660 nm, 100 mW, 6 seconds, 2 J/cm 2 ) and the DXM group (4 mg every 8 hours for 3 days after the procedure). Pain levels were evaluated using a visual analog scale at days 2 and 4 after surgery, whereas the edema was evaluated by measuring the distance between 6 reference points: tragus, pogonion of the soft tissue, lateral corner of the eye, the angle of the mandible, nose wing, and mouth commissure at days 2, 4, 7, 15, 30, 60, and 90. The QOL was evaluated using the Oral Health Impact Profile 14 questionnaire at days 2 and 4 after surgery. CONCLUSIONS There were no differences between the LLLT and DXM groups in pain or edema. In terms of the QOL, the LLLT group was significantly more comfortable when chewing than the DXM group (P < .05).The use of LLLT at a power of 100 mW and 2 J/cm 2 per point had similar effects to oral DXM for the control of pain and edema, as well as in the QOL, except for masticatory function, which was significantly better in the LLLT group.",2020,There were no differences between the LLLT and DXM groups in pain or edema.,"['patients submitted to buccal fat pad removal', '20 patients with pseudoherniation of buccal fat pad were included in the present study']","['Dexamethasone and Low-Level Laser Therapy', 'LLLT', 'DXM group', 'DXM', 'LLLT and DXM', 'low-level laser therapy (LLLT) and dexamethasone (DXM', 'oral DXM', 'Buccal Fat Pad Removal']","['Pain, Swelling, and Quality of Life', 'pain, swelling, and the quality of life (QOL', 'Pain levels', 'pain and edema', 'pain or edema']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0226900', 'cui_str': 'Buccal fat pad'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0360528', 'cui_str': 'Dexamethasone-containing product in oral dose form'}, {'cui': 'C0226900', 'cui_str': 'Buccal fat pad'}, {'cui': 'C0015252', 'cui_str': 'Removal'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0013604', 'cui_str': 'Edema'}]",20.0,0.0567639,There were no differences between the LLLT and DXM groups in pain or edema.,"[{'ForeName': 'Diego Assunção', 'Initials': 'DA', 'LastName': 'Calixto Da Silva', 'Affiliation': 'Resident, Dental School, University Center of Pará, Belém, Pará, Brazil.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'De Lucas Da Silva Almeida', 'Affiliation': 'Resident, Dental School, University Center of Pará, Belém, Pará, Brazil.'}, {'ForeName': 'Tamara Melo', 'Initials': 'TM', 'LastName': 'Nunes Ota', 'Affiliation': 'Resident, Dental School, University Center of Pará, Belém, Pará, Brazil.'}, {'ForeName': 'Douglas Magno', 'Initials': 'DM', 'LastName': 'Guimaraes', 'Affiliation': 'Professor, Dental School, University Center of Pará, Belém, Pará, Brazil; EBSERH, Belém, Pará, Brazil; and Postgraduate Program in Biophotonics Applied to Health Sciences, Nove de Julho University - UNINOVE, São Paulo, São Paulo, Brazil. Electronic address: Douglas_guima@hotmail.com.'}, {'ForeName': 'Kristianne Porta', 'Initials': 'KP', 'LastName': 'Santos Fernandes', 'Affiliation': 'Department Head, Postgraduate Program in Biophotonics Applied to Health Sciences, Nove de Julho University - UNINOVE, São Paulo, São Paulo, Brazil.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2020.07.006'] 2837,32768465,Safety of Enalapril in Infants: Data from the Pediatric Heart Network Infant with Single Ventricle Trial.,"OBJECTIVE To assess the safety profile of angiotensin converting enzyme (ACE) inhibitor therapy in infants with single ventricle (ISV). STUDY DESIGN The Pediatric Heart Network (PHN) conducted a double-blind trial involving infants with single ventricle physiology randomized to receive enalapril or placebo and followed to 14 months of age. Data including demographics, drug administration, hemodynamic monitoring, laboratory measurements, adverse events, and survival were extracted from the public use data set and compared between the placebo and enalapril-treated groups. RESULTS The ISV trial randomized 230 patients, with 115 patients in each group. Initial enalapril dose was 0.10 mg/kg/day and median maximal dose was 0.38 mg/kg/day. There was no significant difference in change in blood pressure at study drug initiation or when resuming study drug after Glenn surgery. The incidence of hyperkalemia and neutropenia did not differ between groups. Renal dysfunction occurred in 3% of the enalapril group and none of the placebo patients, which was not statistically significant. There was a high frequency of serious adverse events in both groups. There was no difference in the frequency of heart transplant or death between groups. CONCLUSION Enalapril did not have sustained hemodynamic effects at initiation or up-titration of drug. Creatinine and potassium were not different between groups, although renal dysfunction occurred more often in the enalapril patients. Although efficacy of enalapril in neonates and single ventricles has not been demonstrated, the safety profile of ACE inhibitors appears to be low risk in infants and children with significant heart disease.",2020,There was no significant difference in change in blood pressure at study drug initiation or when resuming study drug after Glenn surgery.,"['Infants', 'infants with single ventricle (ISV', '230 patients, with 115 patients in each group', 'infants and children with significant heart disease', 'neonates and single ventricles', 'The Pediatric Heart Network (PHN) conducted a double-blind trial involving infants with single ventricle physiology randomized to receive']","['enalapril or placebo', 'enalapril', 'Initial enalapril', 'Enalapril', 'angiotensin converting enzyme (ACE) inhibitor therapy', 'placebo']","['blood pressure', 'frequency of heart transplant or death', 'Renal dysfunction', 'sustained hemodynamic effects', 'serious adverse events', 'Creatinine and potassium', 'demographics, drug administration, hemodynamic monitoring, laboratory measurements, adverse events, and survival', 'renal dysfunction', 'hyperkalemia and neutropenia']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0152424', 'cui_str': 'Common ventricle'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0018799', 'cui_str': 'Heart disease'}, {'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0031842', 'cui_str': 'Physiology'}]","[{'cui': 'C0014025', 'cui_str': 'Enalapril'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0022709', 'cui_str': 'Dipeptidyl carboxypeptidase I'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0018823', 'cui_str': 'Transplantation of heart'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1565489', 'cui_str': 'Renal impairment'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0032821', 'cui_str': 'Potassium'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0150270', 'cui_str': 'Management of drug regimen'}, {'cui': 'C4082936', 'cui_str': 'Hemodynamic monitoring'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0020461', 'cui_str': 'Hyperkalemia'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}]",230.0,0.535615,There was no significant difference in change in blood pressure at study drug initiation or when resuming study drug after Glenn surgery.,"[{'ForeName': 'Kanika', 'Initials': 'K', 'LastName': 'Mathur', 'Affiliation': ""Division of Pediatric Cardiology, Children's Hospital at Montefiore/Albert Einstein College of Medicine. Electronic address: kanikamathur@gmail.com.""}, {'ForeName': 'Daphne T', 'Initials': 'DT', 'LastName': 'Hsu', 'Affiliation': ""Division of Pediatric Cardiology, Children's Hospital at Montefiore/Albert Einstein College of Medicine.""}, {'ForeName': 'Jacqueline M', 'Initials': 'JM', 'LastName': 'Lamour', 'Affiliation': ""Division of Pediatric Cardiology, Children's Hospital at Montefiore/Albert Einstein College of Medicine.""}, {'ForeName': 'Scott I', 'Initials': 'SI', 'LastName': 'Aydin', 'Affiliation': ""Division of Pediatric Cardiology, Children's Hospital at Montefiore/Albert Einstein College of Medicine; Division of Pediatric Critical Care, Children's Hospital at Montefiore/Albert Einstein College of Medicine.""}]",The Journal of pediatrics,['10.1016/j.jpeds.2020.07.058'] 2838,32763872,Translatability of a Wearable Technology Intervention to Increase Adolescent Physical Activity: Mixed Methods Implementation Evaluation.,"BACKGROUND Wearable technology interventions combined with digital behavior change resources provide opportunities to increase physical activity in adolescents. The implementation of such interventions in real-world settings is unknown. The Raising Awareness of Physical Activity (RAW-PA) study was a 12-week cluster randomized controlled trial targeting inactive adolescents attending schools in socioeconomically disadvantaged areas of Melbourne, Australia. The aim was to increase moderate- to vigorous-intensity physical activity using (1) a wrist-worn Fitbit Flex and app, (2) weekly challenges, (3) digital behavior change resources, and (4) email or text message alerts. OBJECTIVE This paper presents adolescents' and teachers' perceptions of RAW-PA in relation to program acceptability, feasibility and perceived impact, adolescent engagement and adherence, and the potential for future scale-up. METHODS A mixed methods evaluation of the RAW-PA study assessed acceptability, engagement, feasibility, adherence, and perceived impact. A total of 9 intervention schools and 144 intervention adolescents were recruited. Only adolescents and teachers (n=17) in the intervention group were included in the analysis. Adolescents completed web-based surveys at baseline and surveys and focus groups postintervention. Teachers participated in interviews postintervention. Facebook data tracked engagement with web-based resources. Descriptive statistics were reported by sex. Qualitative data were analyzed thematically. RESULTS Survey data were collected from 142 adolescents at baseline (mean age 13.7 years, SD 0.4 years; 51% males) and 132 adolescents postintervention. A total of 15 focus groups (n=124) and 9 interviews (n=17) were conducted. RAW-PA had good acceptability among adolescents and teachers. Adolescents perceived the intervention content as easy to understand (100/120, 83.3%) and the Fitbit easy to use (112/120; 93.3%). Half of the adolescents perceived the text messages to be useful (61/120; 50.8%), whereas 47.5% (57/120) liked the weekly challenges and 38.3% (46/120) liked the Facebook videos. Facebook engagement declined over time; only 18.6% (22/118) of adolescents self-reported wearing the Fitbit Flex daily postintervention. Adolescents perceived the Fitbit Flex to increase their physical activity motivation (85/120, 70.8%) and awareness (93/119, 78.2%). The web-based delivery facilitated implementation of the intervention, although school-level policies restricting phone use were perceived as potential inhibitors to program roll-out. CONCLUSIONS RAW-PA showed good acceptability among adolescents attending schools in socioeconomically disadvantaged areas and their teachers. Low levels of teacher burden enhanced their perceptions concerning the feasibility of intervention delivery. Although adolescents perceived that RAW-PA had short-term positive effects on their motivation to be physically active, adolescent adherence and engagement were low. Future research exploring the feasibility of different strategies to engage adolescents with wearable technology interventions and ways of maximizing system-level embeddedness of interventions in practice would greatly advance the field.",2020,Facebook engagement declined over time; only 18.6% (22/118) of adolescents self-reported wearing the Fitbit Flex daily postintervention.,"['A total of 15 focus groups (n=124) and 9 interviews (n=17) were conducted', 'adolescents attending schools in socioeconomically disadvantaged areas and their teachers', 'Only adolescents and teachers (n=17) in the intervention group were included in the analysis', 'inactive adolescents attending schools in socioeconomically disadvantaged areas of Melbourne, Australia', 'A total of 9 intervention schools and 144 intervention adolescents', '142 adolescents at baseline (mean age 13.7 years, SD 0.4 years; 51% males) and 132 adolescents postintervention', 'adolescents']","['moderate- to vigorous-intensity physical activity using (1) a wrist-worn Fitbit Flex and app, (2) weekly challenges, (3) digital behavior change resources, and (4) email or text message alerts', 'Wearable Technology Intervention', 'RAW-PA']","['acceptability, engagement, feasibility, adherence, and perceived impact', 'good acceptability', 'Facebook engagement', 'physical activity motivation']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0016400', 'cui_str': 'Focus Groups'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0557295', 'cui_str': 'School attendance - finding'}, {'cui': 'C0012613', 'cui_str': 'Disadvantaged'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517457', 'cui_str': '0.4'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C4505348', 'cui_str': 'Wearable Technology'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0442818', 'cui_str': 'Raised'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}]",17.0,0.0406149,Facebook engagement declined over time; only 18.6% (22/118) of adolescents self-reported wearing the Fitbit Flex daily postintervention.,"[{'ForeName': 'Harriet', 'Initials': 'H', 'LastName': 'Koorts', 'Affiliation': 'School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Burwood, Australia.'}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Salmon', 'Affiliation': 'School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Burwood, Australia.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Timperio', 'Affiliation': 'School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Burwood, Australia.'}, {'ForeName': 'Kylie', 'Initials': 'K', 'LastName': 'Ball', 'Affiliation': 'School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Burwood, Australia.'}, {'ForeName': 'Susie', 'Initials': 'S', 'LastName': 'Macfarlane', 'Affiliation': 'Learning Futures, Deakin University, Geelong, Australia.'}, {'ForeName': 'Samuel K', 'Initials': 'SK', 'LastName': 'Lai', 'Affiliation': 'School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Burwood, Australia.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Brown', 'Affiliation': 'School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Burwood, Australia.'}, {'ForeName': 'Stephanie E', 'Initials': 'SE', 'LastName': 'Chappel', 'Affiliation': 'School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Burwood, Australia.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Lewis', 'Affiliation': 'School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia.'}, {'ForeName': 'Nicola D', 'Initials': 'ND', 'LastName': 'Ridgers', 'Affiliation': 'School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Burwood, Australia.'}]",Journal of medical Internet research,['10.2196/13573'] 2839,32763873,Comparing a mobile phone automated system with a paper and email data collection system: a sub-study within a randomised controlled trial.,"BACKGROUND Traditional data collection methods using paper and email are increasingly being replaced by data collection using mobile phones, with limited evidence evaluating the impact of mobile phone technology as part of an automated research management system on data collection and health outcomes. OBJECTIVE The aim of this study was to compare a web-based mobile phone automated system (MPAS) with a more traditional delivery and data collection system combining paper and email data collection (PEDC) in a cohort of breastfeeding women. METHODS We conducted a sub-study of a randomised controlled trial in Sydney, Australia which included women with uncomplicated term births who intended to breastfeed. Women were recruited within 72 hours of birth. A quasi-randomised number of women were recruited using the PEDC, and the remainder using the MPAS. Outcomes assessed included effectiveness of data collection, impact on study outcomes, response rate, acceptability and cost analysis between the MPAS and PEDC methods. RESULTS Women were recruited between April 2015 and December 2016. Analysis included 555 women: 471 using the MPAS and 84 the PEDC. There were no differences in clinical outcomes between the two groups. At the end of the 8-week treatment phase, the MPAS participants showed an increased response rate compared to the PEDC group (56% vs 37%; P <0.001), which was also seen at the 2, 6, and 12-month follow-ups. At the 2-month follow-up, the MPAS participants also showed an increased rate of self-reported treatment compliance (70% vs 56%; P<0.001) and a higher recommendation rate for future use (95% vs 64%; p<0.001) as compared to the PEDC group. Cost analysis between the two groups were comparable. CONCLUSIONS A mobile phone automated system is an effective and acceptable method for improving the overall management, treatment compliance and methodological quality of clinical research to ensure validity and reliability of findings. CLINICALTRIAL Australian New Zealand Clinical Trials Registry: ACTRN12615000923561.",2020,"A mobile phone automated system is an effective and acceptable method for improving the overall management, treatment compliance and methodological quality of clinical research to ensure validity and reliability of findings. ","['555 women: 471 using the MPAS and 84 the PEDC', 'Women were recruited between April 2015 and December 2016', 'a cohort of breastfeeding women', 'Sydney, Australia which included women with uncomplicated term births who intended to breastfeed', 'Women were recruited within 72 hours of birth']","['PEDC', 'web-based mobile phone automated system (MPAS) with a more traditional delivery and data collection system combining paper and email data collection (PEDC', 'mobile phone automated system with a paper and email data collection system']","['effectiveness of data collection, impact on study outcomes, response rate, acceptability and cost analysis between the MPAS and PEDC methods', 'response rate', 'rate of self-reported treatment compliance', 'clinical outcomes']","[{'cui': 'C4517810', 'cui_str': '555'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0030351', 'cui_str': 'Paper'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0010995', 'cui_str': 'Data Collection'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0443334', 'cui_str': 'Uncomplicated'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C0005615', 'cui_str': 'Birth'}]","[{'cui': 'C0030351', 'cui_str': 'Paper'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0010995', 'cui_str': 'Data Collection'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010995', 'cui_str': 'Data Collection'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0543472', 'cui_str': 'Outcome Studies'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0010171', 'cui_str': 'Analysis, Cost'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0030351', 'cui_str': 'Paper'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C3887707', 'cui_str': 'Data Collection Methods'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C1321605', 'cui_str': 'Compliance behavior'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",555.0,0.169899,"A mobile phone automated system is an effective and acceptable method for improving the overall management, treatment compliance and methodological quality of clinical research to ensure validity and reliability of findings. ","[{'ForeName': 'Diana M', 'Initials': 'DM', 'LastName': 'Bond', 'Affiliation': 'Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Level 2Charles Perkins Centre D17, Sydney, AU.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Hammond', 'Affiliation': 'Strategic Ventures, University of Sydney, Sydney, AU.'}, {'ForeName': 'Antonia W', 'Initials': 'AW', 'LastName': 'Shand', 'Affiliation': ""Children's Hospital at Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, AU.""}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Nassar', 'Affiliation': 'Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Level 2Charles Perkins Centre D17, Sydney, AU.'}]",JMIR mHealth and uHealth,['10.2196/15284'] 2840,32764462,"Dietary Intake of Carotenoid-Rich Vegetables Reduces Visceral Adiposity in Obese Japanese men-A Randomized, Double-Blind Trial.","Metabolic syndrome, whose main diagnostic component is obesity, is a risk factor for lifestyle-related diseases, type 2 diabetes, and cardiovascular disease. Diet is known to affect the prevalence of metabolic syndrome. However, the effect of diet on metabolic syndrome in Japanese subjects has not been thoroughly explored. In the present study, we investigated the effect of carotenoid-rich vegetables, particularly lycopene- and lutein-rich vegetables, on the metabolic syndrome in obese Japanese men. We conducted an 8-week long randomized, double-blinded, controlled clinical trial in which, 28 middle-aged (40 ≤ age < 65) Japanese men with high body mass index (BMI ≥ 25) were randomized into four dietary groups: high lycopene + high lutein (HLyHLu), high lycopene + low lutein (HLyLLu), low lycopene + high lutein (LLyHLu), and low lycopene + low lutein (LLyLLu). Our results showed that daily beverage-intake increased the plasma levels of carotenoids without adverse effects, and the visceral fat level was significantly decreased in all the groups. The waist circumference was significantly decreased only in the HLyLLu group, whereas the CoQ10 oxidation rate was decreased in all the groups. The gene expression profiles of whole blood samples before and after ingestion differed only in the LLyLLu group, indicating the effect of carotenoids on gene expression profile. In conclusion, our results suggest that dietary uptake of carotenoid-rich vegetables increases their concentration in blood and reduces the intra-abdominal visceral fat.",2020,"The waist circumference was significantly decreased only in the HLyLLu group, whereas the CoQ10 oxidation rate was decreased in all the groups.","['Japanese subjects', '28 middle-aged (40 ≤ age < 65) Japanese men with high body mass index (BMI ≥ 25', 'Obese Japanese men', 'obese Japanese men']","['lycopene + high lutein (HLyHLu), high lycopene + low lutein (HLyLLu), low lycopene + high lutein (LLyHLu), and low lycopene + low lutein (LLyLLu', 'carotenoid-rich vegetables, particularly lycopene- and lutein-rich vegetables', 'Carotenoid-Rich Vegetables']","['waist circumference', 'intra-abdominal visceral fat', 'Visceral Adiposity', 'plasma levels of carotenoids without adverse effects', 'metabolic syndrome', 'CoQ10 oxidation rate', 'visceral fat level']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0026062', 'cui_str': 'Middle-age'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0065331', 'cui_str': 'lycopene'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0043328', 'cui_str': 'Lutein'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0007271', 'cui_str': 'Carotinoid'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}]","[{'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C1512911', 'cui_str': 'Intraabdominal route'}, {'cui': 'C1563740', 'cui_str': 'Abdominal Visceral Fat'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0007271', 'cui_str': 'Carotinoid'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0056077', 'cui_str': 'Ubiquinone'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}]",,0.081307,"The waist circumference was significantly decreased only in the HLyLLu group, whereas the CoQ10 oxidation rate was decreased in all the groups.","[{'ForeName': 'Tomohisa', 'Initials': 'T', 'LastName': 'Takagi', 'Affiliation': 'Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.'}, {'ForeName': 'Ryotaro', 'Initials': 'R', 'LastName': 'Hayashi', 'Affiliation': 'Nippon Flour Mills Co., Ltd., Innovation Center, Kanagawa 243-0041, Japan.'}, {'ForeName': 'Yuji', 'Initials': 'Y', 'LastName': 'Nakai', 'Affiliation': 'Section of Food Sciences, Institute of Regional Innovation, Hirosaki University, Aomori 038-0012, Japan.'}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Okada', 'Affiliation': 'Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8654, Japan.'}, {'ForeName': 'Rumiko', 'Initials': 'R', 'LastName': 'Miyashita', 'Affiliation': 'Nippon Flour Mills Co., Ltd., Innovation Center, Kanagawa 243-0041, Japan.'}, {'ForeName': 'Mayumi', 'Initials': 'M', 'LastName': 'Yamada', 'Affiliation': 'Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.'}, {'ForeName': 'Yoichi', 'Initials': 'Y', 'LastName': 'Mihara', 'Affiliation': 'NK Medico co., LTD., Tokyo 105-0012, Japan.'}, {'ForeName': 'Katsura', 'Initials': 'K', 'LastName': 'Mizushima', 'Affiliation': 'Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.'}, {'ForeName': 'Mayuko', 'Initials': 'M', 'LastName': 'Morita', 'Affiliation': 'Health Care Nutrition, Showa Gakuin Junior College, Chiba 272-0823, Japan.'}, {'ForeName': 'Kazuhiko', 'Initials': 'K', 'LastName': 'Uchiyama', 'Affiliation': 'Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.'}, {'ForeName': 'Yuji', 'Initials': 'Y', 'LastName': 'Naito', 'Affiliation': 'Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.'}, {'ForeName': 'Yoshito', 'Initials': 'Y', 'LastName': 'Itoh', 'Affiliation': 'Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.'}]",Nutrients,['10.3390/nu12082342'] 2841,32764474,Effect of Experiential Vegetable Education Program on Mediating Factors of Vegetable Consumption in Australian Primary School Students: A Cluster-Randomized Controlled Trial.,"Schools provide a relevant and equitable environment to influence students towards increased vegetable consumption. This study aimed to evaluate the effectiveness of a Vegetable Education Resource To Increase Children's Acceptance and Liking (VERTICAL) for Australian primary schools (curriculum aligned and based on a framework of food preference development and sensory experiential learning) on positively influencing factors predisposing children towards increased vegetable consumption. The secondary aim was to evaluate two levels of teacher training intensity on intervention effectiveness. A cluster-RCT amongst schools with three conditions was conducted: 1 = teaching VERTICAL preceded by online teacher training; 2 = as per 1 with additional face-to-face teacher training; 3 = Control. Pre-test, post-test and 3-month follow-up measures (knowledge, verbalization ability, vegetable acceptance, behavioural intentions, willing to taste, new vegetables consumed) were collected from students ( n = 1639 from 25 schools in Sydney/Adelaide, Australia). Data were analyzed using mixed model analysis. No difference in intervention effectiveness was found between the two training methods. Compared to the Control, VERTICAL positively affected all outcome measures after intervention ( p < 0.01) with knowledge sustained at 3-month follow-up ( p < 0.001). In conclusion, VERTICAL was effective in achieving change amongst students in mediating factors known to be positively associated with vegetable consumption.",2020,"Compared to the Control, VERTICAL positively affected all outcome measures after intervention ( p < 0.01) with knowledge sustained at 3-month follow-up ( p < 0.001).",['Australian Primary School Students'],"['Vegetable Education Resource', 'online teacher training', 'Experiential Vegetable Education Program']","['Mediating Factors of Vegetable Consumption', 'intervention effectiveness']","[{'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C4082803', 'cui_str': 'Teacher Training'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}]","[{'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.0717293,"Compared to the Control, VERTICAL positively affected all outcome measures after intervention ( p < 0.01) with knowledge sustained at 3-month follow-up ( p < 0.001).","[{'ForeName': 'Astrid A M', 'Initials': 'AAM', 'LastName': 'Poelman', 'Affiliation': 'Sensory and Consumer Science, CSIRO Agriculture and Food, North Ryde, NSW 2113, Australia.'}, {'ForeName': 'Maeva', 'Initials': 'M', 'LastName': 'Cochet-Broch', 'Affiliation': 'Sensory and Consumer Science, CSIRO Agriculture and Food, North Ryde, NSW 2113, Australia.'}, {'ForeName': 'Bonnie', 'Initials': 'B', 'LastName': 'Wiggins', 'Affiliation': 'Public Health Nutrition, CSIRO Health and Biosecurity, Adelaide, SA 5000, Australia.'}, {'ForeName': 'Rod', 'Initials': 'R', 'LastName': 'McCrea', 'Affiliation': 'Adaptive Communities and Industries Group, CSIRO Land and Water, Dutton Park, QLD 4102, Australia.'}, {'ForeName': 'Jessica E', 'Initials': 'JE', 'LastName': 'Heffernan', 'Affiliation': 'Sensory and Consumer Science, CSIRO Agriculture and Food, North Ryde, NSW 2113, Australia.'}, {'ForeName': 'Janne', 'Initials': 'J', 'LastName': 'Beelen', 'Affiliation': 'Sensory and Consumer Science, CSIRO Agriculture and Food, North Ryde, NSW 2113, Australia.'}, {'ForeName': 'David N', 'Initials': 'DN', 'LastName': 'Cox', 'Affiliation': 'Public Health Nutrition, CSIRO Health and Biosecurity, Adelaide, SA 5000, Australia.'}]",Nutrients,['10.3390/nu12082343'] 2842,32764524,Associations of Lifestyle Intervention Effect with Blood Pressure and Physical Activity among Community-Dwelling Older Americans with Hypertension in Southern California.,"A healthy lifestyle and regular physical activity are highly recommended for older adults. However, there has been limited research into testing lifestyle intervention effects on physical activity in older adults with hypertension. The purpose of this study was to assess the association of lifestyle intervention effects with physical activity and blood pressure in older adults with hypertension, accounting for social support and perceived stress as control variables. This study performed a secondary analysis of a two-arm randomized controlled trial. A total of 196 participants were randomly assigned to a six-month lifestyle intervention group or a control group. Hierarchical multiple regression analyses demonstrated that lifestyle intervention effects were not significantly associated with improvements in physical activity and blood pressure, but the final regression models were statistically significant (all p < 0.001). The result revealed that only physical activity frequency at baseline was significantly related to improvement in physical activity. Systolic blood pressure (SBP) at baseline and monthly income were significantly associated with change in SBP, while age and diastolic blood pressure (DBP) at baseline were significantly related to change in DBP. The findings provide empirical evidence for developing and optimizing lifestyle interventions for future research and clinical practice in this population.",2020,"Hierarchical multiple regression analyses demonstrated that lifestyle intervention effects were not significantly associated with improvements in physical activity and blood pressure, but the final regression models were statistically significant (all p < 0.001).","['older adults with hypertension', 'Community-Dwelling Older Americans with Hypertension in Southern California', 'A total of 196 participants', 'older adults']","['lifestyle intervention group or a control group', 'physical activity and blood pressure', 'Blood Pressure and Physical Activity']","['physical activity frequency', 'physical activity', 'physical activity and blood pressure', 'Systolic blood pressure (SBP', 'diastolic blood pressure (DBP']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517625', 'cui_str': '196'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}]",196.0,0.0192055,"Hierarchical multiple regression analyses demonstrated that lifestyle intervention effects were not significantly associated with improvements in physical activity and blood pressure, but the final regression models were statistically significant (all p < 0.001).","[{'ForeName': 'Mei-Lan', 'Initials': 'ML', 'LastName': 'Chen', 'Affiliation': 'Byrdine F. Lewis College of Nursing and Health Professions, Georgia State University, Atlanta, GA 30303, USA.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': 'College of Nursing, The Ohio State University, Columbus, OH 43210, USA.'}, {'ForeName': 'Thomas P', 'Initials': 'TP', 'LastName': 'McCoy', 'Affiliation': 'School of Nursing, University of North Carolina at Greensboro, Greensboro, NC 27402, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Letvak', 'Affiliation': 'School of Nursing, University of North Carolina at Greensboro, Greensboro, NC 27402, USA.'}, {'ForeName': 'Luba', 'Initials': 'L', 'LastName': 'Ivanov', 'Affiliation': 'College of Nursing, Chamberlain University, Downers Grove, IL 60515, USA.'}]",International journal of environmental research and public health,['10.3390/ijerph17165673'] 2843,32764634,"Randomised, double-blind, placebo-controlled trial of oral probiotic Streptococcus salivarius M18 on head and neck cancer patients post-radiotherapy: a pilot study.","Xerostomia detrimentally affects the oral health of many head and neck cancer patients who undergo radiotherapy. Its sequelae become an ongoing burden for patients that often manifest as periodontal disease and dental decay. Bacteria play a major role in the pathogenesis of these conditions and here we explore the use of an oral probiotic to beneficially modulate the oral bacterial community post-radiotherapy. In this pilot study, a four-week intervention with oral probiotic lozenges containing Streptococcus salivarius M18 was trialled in seven patients. Post-intervention changes in oral health and in the composition of the plaque and saliva bacterial communities were compared with six patients in a placebo group. An improvement in periodontal screening and plaque index scores was observed in both groups after the intervention period. The oral probiotic lozenges did not significantly impact bacterial community composition or diversity, nor did the probiotic lozenges increase the relative sequence abundance of ZOTU_1 (the probiotic-associated sequence assigned to S. salivarius) detected in the samples. Network analyses suggest negative interactions occurred between ZOTU_1 and species from the periopathogenic genera Campylobacter, Fretibacterium, Selenomonas and Treponema but further investigation is required to more fully understand the beneficial properties of this oral probiotic.",2020,"The oral probiotic lozenges did not significantly impact bacterial community composition or diversity, nor did the probiotic lozenges increase the relative sequence abundance of ZOTU_1 (the probiotic-associated sequence assigned to S. salivarius) detected in the samples.","['head and neck cancer patients post', 'seven patients', 'many head and neck cancer patients who undergo radiotherapy']","['oral probiotic lozenges', 'oral probiotic Streptococcus salivarius M18', 'radiotherapy', 'placebo']","['periodontal screening and plaque index scores', 'relative sequence abundance of ZOTU_1']","[{'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0991564', 'cui_str': 'Lozenge'}, {'cui': 'C0318179', 'cui_str': 'Streptococcus salivarius'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0004793', 'cui_str': 'Base sequence'}]",7.0,0.0738193,"The oral probiotic lozenges did not significantly impact bacterial community composition or diversity, nor did the probiotic lozenges increase the relative sequence abundance of ZOTU_1 (the probiotic-associated sequence assigned to S. salivarius) detected in the samples.","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Vesty', 'Affiliation': 'Department of Surgery, The University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Gear', 'Affiliation': 'Department of Otorhinolaryngology, Auckland District Health Board, Auckland, New Zealand.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Boutell', 'Affiliation': 'Oral Health, Auckland University of Technology, Auckland, New Zealand.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Taylor', 'Affiliation': 'School of Biological Sciences, The University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Richard G', 'Initials': 'RG', 'LastName': 'Douglas', 'Affiliation': 'Department of Surgery, The University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Kristi', 'Initials': 'K', 'LastName': 'Biswas', 'Affiliation': 'Department of Surgery, The University of Auckland, Auckland, New Zealand. k.biswas@auckland.ac.nz.'}]",Scientific reports,['10.1038/s41598-020-70024-y'] 2844,32764866,Binocular Visual Function in a Pre-Presbyopic Patient with Uniocular Cataract Undergoing Cataract Surgery with a Multifocal Intraocular Lens.,"Background/Aim An increasing number of pre-presbyopic patients are undergoing uniocular cataract extraction. We aim to compare the binocular status of subjects with uniocular cataracts, implanted either with a multifocal or a monofocal intraocular lens (IOL). Materials and Methods Subjects were recruited from outpatient ophthalmology clinics and randomized to an IOL type. Corrected and uncorrected LogMAR distance visual acuity (VA) and near and intermediate VA using the Radner reading test were completed. The binocular tests included the Worth Four Dot Test, fixation disparity, TNO stereoacuity and foveal suppression assessment. In addition to the near activity vision questionnaire. The trial was closed early because the chosen multifocal lens had been superseded by newer models. We report two subjects, one receiving the multifocal IOL and a monofocal IOL control with the most comparable baseline characteristics. Results Both subjects experienced uncomplicated cataract surgery, showing clinically significant improved corrected distance VA, 0.06 LogMAR and -0.16 LogMAR in the monofocal and multifocal IOL, respectively. The multifocal subject had 30 seconds of arc stereoacuity indicating normal binocular vision. Only gross binocular single vision with no stereopsis was found in the monofocal IOL subject. The latter subject also had reduced near vision quality-of-life questionnaire results. Conclusion This two-patient case series demonstrates greater binocular near ability, with the multifocal IOL, in the pre-presbyopic patient undergoing uniocular cataract surgery. The case series highlights the need, and methodology for investigating further the functional and quality-of-life benefits of implanting multifocal IOLs in pre-presbyopic patients, those in their twenties and thirties, undergoing uniocular cataract surgery.",2020,"Both subjects experienced uncomplicated cataract surgery, showing clinically significant improved corrected distance VA, 0.06 LogMAR and -0.16 LogMAR in the monofocal and multifocal IOL, respectively.","['subjects with uniocular cataracts, implanted either with a multifocal or a monofocal intraocular lens (IOL', 'a Pre-Presbyopic Patient with Uniocular Cataract Undergoing Cataract Surgery with a Multifocal Intraocular Lens', 'pre-presbyopic patients are undergoing uniocular cataract extraction']",[],"['uncorrected LogMAR distance visual acuity (VA) and near and intermediate VA', 'Binocular Visual Function', 'Worth Four Dot Test, fixation disparity, TNO stereoacuity and foveal suppression assessment', 'corrected distance VA', 'near activity vision questionnaire']","[{'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0205292', 'cui_str': 'Multifocal'}, {'cui': 'C0023311', 'cui_str': 'Insertion of intraocular lens'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C0493722', 'cui_str': 'Multifocal Intraocular Lens'}]",[],"[{'cui': 'C0429537', 'cui_str': 'Distance visual acuity'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0475806', 'cui_str': '1/3 meter'}, {'cui': 'C1690987', 'cui_str': 'Intermediate visual acuity'}, {'cui': 'C2594855', 'cui_str': 'Binoculars'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0430908', 'cui_str': 'Worth four-dot test'}, {'cui': 'C0042791', 'cui_str': 'Binocular Disparity'}, {'cui': 'C1275505', 'cui_str': 'Stereoscopic acuity'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.0295786,"Both subjects experienced uncomplicated cataract surgery, showing clinically significant improved corrected distance VA, 0.06 LogMAR and -0.16 LogMAR in the monofocal and multifocal IOL, respectively.","[{'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Wood', 'Affiliation': 'Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Jasleen K', 'Initials': 'JK', 'LastName': 'Jolly', 'Affiliation': 'Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Groppe', 'Affiliation': 'Stoke Mandeville Hospital, Buckingham Healthcare NHS Trust, Walton, UK.'}, {'ForeName': 'Larry', 'Initials': 'L', 'LastName': 'Benjamin', 'Affiliation': 'Stoke Mandeville Hospital, Buckingham Healthcare NHS Trust, Walton, UK.'}, {'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Kirwan', 'Affiliation': 'Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Portsmouth, UK.'}, {'ForeName': 'Nishal', 'Initials': 'N', 'LastName': 'Patel', 'Affiliation': 'Kent and Canterbury Hospital, East Kent Hospitals University NHS Foundation Trust, Canterbury, UK.'}, {'ForeName': 'Mostafa A', 'Initials': 'MA', 'LastName': 'Elgohary', 'Affiliation': 'Kingston Hospital, Kingston Hospital NHS Foundation Trust, Kingston Upon Thames, UK.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'MacLaren', 'Affiliation': 'Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.'}]","Clinical ophthalmology (Auckland, N.Z.)",['10.2147/OPTH.S254532'] 2845,32764872,"Clostridium histolyticum (AA4500) for the Treatment of Adhesive Capsulitis of the Shoulder: A Randomised Double-Blind, Placebo-Controlled Study for the Safety and Efficacy of Collagenase - Single Site Report.","Background/Hypothesis Adhesive capsulitis of the shoulder results in pain and restricted movement of the glenohumeral joint. Hypothesis: There would be a difference in active range of movement in the affected shoulder of patients with adhesive capsulitis after receiving a series of injections of collagenase Clostridium histolyticum (CCH) compared to placebo. Methods This study reports the results from a single site that was part of a 321-participant, multicenter, double-blind, prospective parallel-group, randomized controlled clinical trial. Inclusion criteria: over 18 years of age, unilateral idiopathic adhesive capsulitis for >3 months, but <12 months. Exclusion criteria: recent physical therapy, injections, subacromial impingement, calcific tendonitis or glenohumeral joint arthritis in the affected shoulder. Subjects were randomized 3:1 to receive CCH 0.58 mg or placebo under ultrasound guidance. Injections were on days 1, 22, and 43. The primary outcome measure was a functional assessment of active range of movement. Results Overall, 37 patients were screened, 26 subjects were excluded, and 11 subjects were randomly assigned to the treatment group (n=9) or the control group (n=2). Both control and treatment groups showed improvement in ROM between baseline and day 95. In the treatment group, AROM improved from the baseline of 272.89° (SD 86.25) to 462.11° (SD 96.89) and the control group from 246.00° (SD 5.66) to 451.50° (SD 50.20) at day 95 with no statistical difference between groups p=0.78. Site data were in line with the whole study findings. Treatment-related adverse events at the injection site, including haematoma (bruising) and localised pain and swelling, were common. Conclusion Although the participants showed improvement in function, statistical significance was neither reached in the site nor the overall study cohort. Given the adverse events and the potential risks of the procedure, we would not recommend this drug for the treatment of adhesive capsulitis of the shoulder. Level of Evidence 2, cohort from one site of RCT.",2020,"Treatment-related adverse events at the injection site, including haematoma (bruising) and localised pain and swelling, were common. ","['Inclusion criteria: over 18 years of age, unilateral idiopathic adhesive capsulitis for >3 months, but <12 months', 'Adhesive Capsulitis of the Shoulder', '37 patients were screened, 26 subjects were excluded, and 11 subjects']","['CCH 0.58 mg or placebo', 'Placebo', 'Clostridium histolyticum (AA4500', 'placebo']","['functional assessment of active range of movement', 'haematoma (bruising) and localised pain and swelling', 'AROM', 'ROM']","[{'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0158300', 'cui_str': 'Capsulitis, Adhesive'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0311223', 'cui_str': 'Adhesive capsulitis of shoulder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}]","[{'cui': 'C4517463', 'cui_str': '0.58'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0315088', 'cui_str': 'Clostridium histolyticum'}]","[{'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0003805', 'cui_str': 'Androstenedione Aromatase'}, {'cui': 'C0948106', 'cui_str': 'Amniorrhexis'}]",26.0,0.446359,"Treatment-related adverse events at the injection site, including haematoma (bruising) and localised pain and swelling, were common. ","[{'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Fitzpatrick', 'Affiliation': 'Centre for Health and Exercise Sports Medicine, School of Health Sciences, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia.'}, {'ForeName': 'Christen', 'Initials': 'C', 'LastName': 'Richardson', 'Affiliation': 'Medical School, College of Health and Medicine, Australian National University, Acton, ACT, Australia.'}, {'ForeName': 'Ianiv', 'Initials': 'I', 'LastName': 'Klaber', 'Affiliation': 'Orthopaedic Surgery Department, School of Medicine, Pontifical Catholic University of Chile, Santiago, Chile.'}, {'ForeName': 'Martin D', 'Initials': 'MD', 'LastName': 'Richardson', 'Affiliation': 'Centre for Health and Exercise Sports Medicine, School of Health Sciences, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia.'}]","Drug design, development and therapy",['10.2147/DDDT.S259228'] 2846,32764878,Does an Earlier or Late Intravenous Injection of Ondansetron Affect the Dose of Phenylephrine Needed to Prevent Spinal-Anesthesia Induced Hypotension in Cesarean Sections?,"Background There was controversy about ondansetron can reduce the incidence of spinal-induced hypotension and decrease the consumption of vasopressor in cesarean delivery with spinal anesthesia. We hypothesized that different timing of ondansetron administration may contribute to the controversy. Therefore, we aimed to determine the effect of different timing of ondansetron administration on the dose requirement of preventing phenylephrine via comparing the ED 50 of prophylactic phenylephrine. Methods Seventy-five parturients were finally enrolled in this prospective, randomized, double-blinded dose finding study. Ondansetron or placebo was administered 5 min or 15 min before intrathecal injection. Up-down allocation method was used to determine the dose of prophylactic phenylephrine for each parturient in the three groups. The initial infusion rate of first patient was 0.5 µg/kg/min. Then, the rate for next patient was varied with increasing or decreasing of 0.05 μg/kg/min according to the response of the previous patient. An effective dose was defined as no hypotension occurred during the study period. An ineffective dose was defined as hypotension occurred during the study period. Study period in this study is from intrathecal injection to neonatal delivery. ED 50 of phenylephrine infusion was calculated by probit regression. Results The ED 50 of intravenous phenylephrine calculated by probit analysis was 0.33 (95% CI 0.20 to 0.38) µg/kg/min and 0.36 (95% CI 0.32 to 0.38) µg/kg/min in group A and B, and 0.41 (95% CI 0.37 to 0.44) µg/kg/min in group C for patients undergoing cesarean delivery with combined spinal-epidural anesthesia. Conclusion An earlier administration of 4 mg prophylactic ondansetron contributed no benefits for lowing the dose of prophylactic phenylephrine compared to a late administration, but can decrease the dose of preventing phenylephrine in patients undergoing cesarean delivery with combined spinal-epidural anesthesia. This finding may be useful for clinical practice and further studies.",2020,There was controversy about ondansetron can reduce the incidence of spinal-induced hypotension and decrease the consumption of vasopressor in cesarean delivery with spinal anesthesia.,"['Methods\n\n\nSeventy-five parturients', 'patients undergoing cesarean delivery with combined spinal-epidural anesthesia']","['phenylephrine', 'Ondansetron or placebo', 'prophylactic phenylephrine', 'Phenylephrine', 'ondansetron', 'Ondansetron', 'prophylactic ondansetron']","['hypotension', 'initial infusion rate']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319621', 'cui_str': '75'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002913', 'cui_str': 'Epidural anesthesia'}]","[{'cui': 'C0031469', 'cui_str': 'Phenylephrine'}, {'cui': 'C0061851', 'cui_str': 'Ondansetron'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009653', 'cui_str': 'Condom'}]","[{'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}]",75.0,0.439756,There was controversy about ondansetron can reduce the incidence of spinal-induced hypotension and decrease the consumption of vasopressor in cesarean delivery with spinal anesthesia.,"[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Qian', 'Affiliation': ""Department of Anesthesia, Jiaxing University Affiliated Women and Children Hospital, Jiaxing, People's Republic of China.""}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': ""Department of Anesthesia, Jiaxing University Affiliated Women and Children Hospital, Jiaxing, People's Republic of China.""}, {'ForeName': 'Xiufeng', 'Initials': 'X', 'LastName': 'Zheng', 'Affiliation': ""Department of Obstetrics, Jiaxing University Affiliated Women and Children Hospital, Jiaxing, People's Republic of China.""}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Xiao', 'Affiliation': ""Department of Anesthesia, Jiaxing University Affiliated Women and Children Hospital, Jiaxing, People's Republic of China.""}]","Drug design, development and therapy",['10.2147/DDDT.S257880'] 2847,32764887,"The Safety and Efficacy of Ultrasound-Guided Bilateral Dual Transversus Abdominis Plane (BD-TAP) Block in ERAS Program of Laparoscopic Hepatectomy: A Prospective, Randomized, Controlled, Blinded, Clinical Study.","Purpose Postoperative pain management for patients undergoing hepatic resection is still a challenge due to the risk of perioperative liver dysfunction. The transversus abdominis plane (TAP) block is a promising regional analgesic technique. However, the correct guidelines regarding the dose and regimen of local anesthetics in patients undergoing hepatic resection have yet to be established completely. This study aimed to evaluate the safety and efficacy of ultrasound-guided BD-TAP block with a large dose of ropivacaine in laparoscopic hepatectomy. Patients and Methods This prospective, blinded, randomized, controlled study was conducted with 50 patients who were scheduled for selective laparoscopic hepatectomy. Patients who received a BD-TAP block (3 mg/kg of ropivacaine diluted to 60 mL) with general anesthesia were categorized into the BD-TAP block group (n = 25), and those who received general anesthesia were categorized into the control group (n = 25). The primary outcomes were consumption of sufentanil within 48 hours post-operation and plasma ropivacaine concentration. The secondary outcomes were the severity of pain (at rest and upon coughing), nausea and/or vomiting, and quality of recovery. Results Compared with the control group, the patients in BD-TAP block group had a significant reduction of postoperative sufentanil consumption at 2 hours ( P = 0.019), 24 hours ( P = 0.001), and 48 hours ( P = 0.001), and the visual analog scale (VAS) scores on coughing were significantly lower at postoperative 2 hours ( P = 0.004). There were no statistically significant differences in postoperative nausea and/or vomiting, flatus, catheter removal, off-bed activity, liver function, or postoperative hospital stay. The mean peak total ropivacaine concentration was 1,067.85 ng/mL, which occurred 1 hour after administering the block, and mean free ropivacaine concentration was 52.32 ng/mL. The highest individual peak plasma concentration was 2,360.90 ng/mL at 45 min postinjection, and the free ropivacaine concentration was 139.29 ng/mL. Conclusion Ultrasound-guided BD-TAP block provides effective postoperative analgesia after laparoscopic hepatectomy. This study also confirms that ultrasound-guided BD-TAP blocks with 3 mg/kg ropivacaine during laparoscopic hepatectomy almost never results in the plasma ropivacaine concentrations associated with neurotoxicity.",2020,"There were no statistically significant differences in postoperative nausea and/or vomiting, flatus, catheter removal, off-bed activity, liver function, or postoperative hospital stay.","['50 patients who were scheduled for', 'patients undergoing hepatic resection']","['selective laparoscopic hepatectomy', 'BD-TAP block', 'Ultrasound-Guided Bilateral Dual Transversus Abdominis Plane (BD-TAP', 'ropivacaine diluted to 60 mL) with general anesthesia were categorized into the BD-TAP block', 'ropivacaine', 'Laparoscopic Hepatectomy', 'ultrasound-guided BD-TAP block', 'transversus abdominis plane (TAP) block']","['visual analog scale (VAS) scores on coughing', 'postoperative sufentanil consumption', 'postoperative nausea and/or vomiting, flatus, catheter removal, off-bed activity, liver function, or postoperative hospital stay', 'consumption of sufentanil within 48 hours post-operation and plasma ropivacaine concentration', 'mean free ropivacaine concentration', 'safety and efficacy', 'severity of pain (at rest and upon coughing), nausea and/or vomiting, and quality of recovery', 'mean peak total ropivacaine concentration']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0015252', 'cui_str': 'Removal'}]","[{'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0019144', 'cui_str': 'Liver excision'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0224378', 'cui_str': 'Structure of transversus abdominis muscle'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C1720119', 'cui_str': 'Dilute'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}]","[{'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0520904', 'cui_str': 'Postoperative nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0394884', 'cui_str': 'Removal of catheter'}, {'cui': 'C0004914', 'cui_str': 'Bedding'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0232741', 'cui_str': 'Liver function'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0439586', 'cui_str': '48 hours'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0443144', 'cui_str': 'At rest'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",,0.0826301,"There were no statistically significant differences in postoperative nausea and/or vomiting, flatus, catheter removal, off-bed activity, liver function, or postoperative hospital stay.","[{'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.""}, {'ForeName': 'Tieshuai', 'Initials': 'T', 'LastName': 'Liu', 'Affiliation': ""Department of Anesthesiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.""}, {'ForeName': 'Haiyan', 'Initials': 'H', 'LastName': 'Zhou', 'Affiliation': ""Department of Anesthesiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.""}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Fei', 'Affiliation': ""Department of Anesthesiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.""}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': ""Department of Anesthesiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.""}]","Drug design, development and therapy",['10.2147/DDDT.S255385'] 2848,32765052,Modified Pectoral Nerve Block versus Serratus Block for Analgesia Following Modified Radical Mastectomy: A Randomized Controlled Trial.,"Background Modified pectoral nerves (PECSII) and serratus blocks have been recently used for analgesia in breast surgery, but evidence comparing their analgesic benefits is limited. This prospective randomized, controlled study aims to examine the analgesic efficacy and safety profile of ultrasound-guided PECSII versus serratus blocks in patients undergoing modified radical mastectomy (MRM) for breast cancer. Patients and Methods One-hundred and eighty adult females scheduled for MRM were randomly allocated to three groups. PECS group patients received a PECSII block with 30mL of bupivacaine 0.25%, whereas SAPB group received a serratus anterior plane block (SAPB) using the same volume of bupivacaine 0.25% before induction of anesthesia. The control group received general anesthesia alone. Outcomes included 24 hours morphine consumption, intraoperative fentanyl requirements, visual analogue scale (VAS) scores for pain at rest and during movement, time to first rescue analgesia, postoperative nausea and vomiting (PONV), and sedation scores. Results Both PECSII and serratus blocks were associated with reduced postoperative morphine consumption compared to the control group (p<0.001). Both blocks were associated with reduced intraoperative fentanyl requirements, VAS scores, and PONV as compared with the control group. Also, they were associated with prolonged time to first rescue analgesia and better sedation scores in comparison with the control group. However, there were no differences between both blocks for all outcomes. Conclusion PECSII and serratus blocks provide similarly adequate analgesia following modified radical mastectomy. Clinical Trial Registration NCT02946294.",2020,"Both blocks were associated with reduced intraoperative fentanyl requirements, VAS scores, and PONV as compared with the control group.","['patients undergoing modified radical mastectomy (MRM) for breast cancer', 'Patients and Methods\n\n\nOne-hundred and eighty adult females scheduled for MRM']","['general anesthesia alone', 'bupivacaine', 'PECSII block with 30mL of bupivacaine', 'ultrasound-guided PECSII versus serratus blocks', '\n\n\nModified pectoral nerves (PECSII) and serratus blocks', 'PECS', 'Modified Pectoral Nerve Block versus Serratus Block for Analgesia Following Modified Radical Mastectomy', 'serratus anterior plane block (SAPB', 'SAPB']","['analgesic efficacy and safety profile', 'prolonged time to first rescue analgesia and better sedation scores', '24 hours morphine consumption, intraoperative fentanyl requirements, visual analogue scale (VAS) scores for pain at rest and during movement, time to first rescue analgesia, postoperative nausea and vomiting (PONV), and sedation scores', 'postoperative morphine consumption', 'intraoperative fentanyl requirements, VAS scores, and PONV']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024883', 'cui_str': 'Modified radical mastectomy'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}]","[{'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205967', 'cui_str': 'Pectoral Nerves'}, {'cui': 'C0055065', 'cui_str': 'CEP combination'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0024883', 'cui_str': 'Modified radical mastectomy'}, {'cui': 'C0224349', 'cui_str': 'Structure of serratus anterior muscle'}, {'cui': 'C0444660', 'cui_str': 'Plane'}]","[{'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0234253', 'cui_str': 'Rest pain'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",180.0,0.157085,"Both blocks were associated with reduced intraoperative fentanyl requirements, VAS scores, and PONV as compared with the control group.","[{'ForeName': 'Ahmed H', 'Initials': 'AH', 'LastName': 'Bakeer', 'Affiliation': 'Department of Anesthesia and Pain Management, National Cancer Institute, Cairo, Egypt.'}, {'ForeName': 'Khaled M', 'Initials': 'KM', 'LastName': 'Kamel', 'Affiliation': 'Department of Anesthesia and Pain Management, National Cancer Institute, Cairo, Egypt.'}, {'ForeName': 'Ahmed S', 'Initials': 'AS', 'LastName': 'Abdelgalil', 'Affiliation': 'Department of Anesthesia and Pain Management, National Cancer Institute, Cairo, Egypt.'}, {'ForeName': 'Ayman A', 'Initials': 'AA', 'LastName': 'Ghoneim', 'Affiliation': 'Department of Anesthesia and Pain Management, National Cancer Institute, Cairo, Egypt.'}, {'ForeName': 'Ahmed H', 'Initials': 'AH', 'LastName': 'Abouel Soud', 'Affiliation': 'Department of Anesthesia and Pain Management, National Cancer Institute, Cairo, Egypt.'}, {'ForeName': 'Mohamed E', 'Initials': 'ME', 'LastName': 'Hassan', 'Affiliation': 'Department of Anesthesia and Pain Management, National Cancer Institute, Cairo, Egypt.'}]",Journal of pain research,['10.2147/JPR.S252539'] 2849,32765053,"Efficacy, Practicality, and Safety of Inhaled Methoxyflurane in Elderly Patients with Acute Trauma Pain: Subgroup Analysis of a Randomized, Controlled, Multicenter, Open-Label Trial (MEDITA).","Purpose Acute trauma pain management in the elderly population is a challenge. Inhaled methoxyflurane represents a promising treatment option; however, data in the elderly population are limited. Patients and Methods Subgroup, post hoc analysis including 69 patients aged ≥65 years from a randomized, active-controlled, open-label study in the emergency setting. Key inclusion criterion was moderate-to-severe pain (Numerical Rating Scale [NRS] score ≥ 4]) secondary to trauma in a single limb. Patients received inhaled methoxyflurane (3 mL) or standard analgesic treatment (SAT; IV paracetamol 1 g or ketoprofen 100 mg for moderate pain [NRS 4-6] and IV morphine 0.1mg/kg for severe pain [NRS ≥7]). The primary endpoint was the overall change in visual analog scale (VAS) pain intensity from randomization to the next 3, 5, and 10 min. Secondary endpoints included time to onset of pain relief (TOPR), efficacy up to 30 min, judgment of operators and patients, and safety. Results Pain reduction over time was similar in both groups. Median TOPR was shorter for methoxyflurane (9 min; 95% CI: 7.8, 10.2 min) than SAT (15 min; 95% CI: 10.2, 19.8 min). In terms of treatment satisfaction, patients and operators rated treatment efficacy and practicality, respectively, as ""Excellent"" or ""Very good"" 5.7 times and 3.4 times more frequently than SAT. A similar rate of adverse events (methoxyflurane: 6 events; SAT: 7 events) was recorded, all non-serious. No clinically significant changes in vital signs parameters were observed, and methoxyflurane did not result in cases of bradycardia or hypotension. Conclusion In elderly patients with trauma pain, inhaled methoxyflurane shows similar pain relief and safety compared to SAT, offering advantages in terms of onset of effect and user's satisfaction. Although this analysis presents some methodological limitations, it provides the first specific evidence of the use of inhaled methoxyflurane in the elderly population. Trial Registration EudraCT number: 2017-001565-25; Clinicaltrials.gov identifier NCT03585374.",2020,"Median TOPR was shorter for methoxyflurane (9 min; 95% CI: 7.8, 10.2 min) than SAT (15 min; 95% CI: 10.2, 19.8 min).","['69 patients aged ≥65 years from a randomized, active-controlled, open-label study in the emergency setting', 'elderly patients with trauma pain', 'Elderly Patients with Acute Trauma Pain', 'EudraCT number']","['Inhaled methoxyflurane', 'inhaled methoxyflurane', 'Inhaled Methoxyflurane', 'methoxyflurane', 'inhaled methoxyflurane (3 mL) or standard analgesic treatment (SAT; IV paracetamol 1 g or ketoprofen', 'morphine']","['Efficacy, Practicality, and Safety', 'time to onset of pain relief (TOPR), efficacy up to 30 min, judgment of operators and patients, and safety', 'Median TOPR', 'overall change in visual analog scale (VAS) pain intensity', 'vital signs parameters', 'pain relief and safety', 'bradycardia or hypotension', 'Pain reduction', 'moderate-to-severe pain (Numerical Rating Scale [NRS] score ≥ 4]) secondary to trauma in a single limb']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0237753', 'cui_str': 'Number'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0025688', 'cui_str': 'Methoxyflurane'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0022635', 'cui_str': 'Ketoprofen'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332162', 'cui_str': 'Onset of'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0022423', 'cui_str': 'Judgement'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0175668', 'cui_str': 'Secondary'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}]",69.0,0.213658,"Median TOPR was shorter for methoxyflurane (9 min; 95% CI: 7.8, 10.2 min) than SAT (15 min; 95% CI: 10.2, 19.8 min).","[{'ForeName': 'Sossio', 'Initials': 'S', 'LastName': 'Serra', 'Affiliation': 'Emergency Department, Maurizio Bufalini Hospital, Cesena, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Voza', 'Affiliation': 'Emergency Department, IRCCS Humanitas Research Teaching Hospital, Rozzano, Milan, Italy.'}, {'ForeName': 'Germana', 'Initials': 'G', 'LastName': 'Ruggiano', 'Affiliation': 'Emergency Medicine Department, Santa Maria Annunziata Hospital, Florence, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Fabbri', 'Affiliation': 'Department of Emergency Medicine, Morgagni-Pierantoni Hospital, Forlì, Italy.'}, {'ForeName': 'Elisabetta', 'Initials': 'E', 'LastName': 'Bonafede', 'Affiliation': 'YGHEA, CRO Division of Ecol Studio Bioikos S.r.l., Bologna, Italy.'}, {'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Sblendido', 'Affiliation': 'Medical Affairs Department, Mundipharma Pharmaceuticals Srl, Milan, Italy.'}, {'ForeName': 'Amedeo', 'Initials': 'A', 'LastName': 'Soldi', 'Affiliation': 'Medical Affairs Department, Mundipharma Pharmaceuticals Srl, Milan, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Farina', 'Affiliation': 'Medical Affairs Department, Mundipharma Pharmaceuticals Srl, Milan, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of pain research,['10.2147/JPR.S255532'] 2850,32765057,"Digital Treatment of Back Pain versus Standard of Care: The Cluster-Randomized Controlled Trial, Rise-uP.","Purpose Non-specific low back pain (NLBP) causes an enormous burden to patients and tremendous costs for health care systems worldwide. Frequently, treatments are not oriented to existing guidelines. In the future, digital elements may be promising tools to support guideline-oriented treatment in a broader range of patients. The cluster-randomized controlled ""Rise-uP"" trial aims to support a General Practitioner (GP)-centered back pain treatment (Registration No: DRKS00015048) and includes the following digital elements: 1) electronic case report form (eCRF), 2) a treatment algorithm for guideline-based clinical decision making of GPs, 3) teleconsultation between GPs and pain specialists for patients at risk for development of chronic back pain, and 4) a multidisciplinary mobile back pain app for all patients (Kaia App). Methods In the Rise-uP trial, 111 GPs throughout Bavaria (southern Germany) were randomized either to the Rise-uP intervention group (IG) or the control group (CG). Rise-uP patients were treated according to the guideline-oriented Rise-uP treatment algorithm. Standard of care was applied to the CG patients with consideration given to the ""National guideline for the treatment of non-specific back pain"". Pain rating on the numeric rating scale was the primary outcome measure. Psychological measures (anxiety, depression, stress), functional ability, as well as physical and mental wellbeing, served as secondary outcomes. All values were assessed at the beginning of the treatment and at 3-month follow-ups. Results In total, 1245 patients (IG: 933; CG: 312) with NLBP were included in the study. The Rise-uP group showed a significantly stronger pain reduction compared to the control group after 3 months (IG: M=-33.3% vs CG: M=-14.3%). The Rise-uP group was also superior in secondary outcomes. Furthermore, high-risk patients who received a teleconsultation showed a larger decrease in pain intensity (-43.5%) than CG patients (-14.3%). ANCOVA analysis showed that the impact of teleconsultation was mediated by an increased training activity in the Kaia App. Conclusion Our results show the superiority of the innovative digital treatment algorithm realized in Rise-uP, even though the CG also received relevant active treatment by their GPs. This provides clear evidence that digital treatment may be a promising tool to improve the quality of treatment of non-specific back pain. In 2021, analyses of routine data from statutory health insurances will enable us to investigate the cost-effectiveness of digital treatment.",2020,The Rise-uP group showed a significantly stronger pain reduction compared to the control group after 3 months (IG: M=-33.3% vs CG:,"['patients at risk for development of chronic back pain, and 4) a multidisciplinary mobile back pain app for all patients (Kaia App', '1245 patients (IG: 933; CG: 312) with NLBP were included in the study', '111 GPs throughout Bavaria (southern Germany']","['electronic case report form (eCRF), 2) a treatment algorithm for guideline-based clinical decision making of GPs, 3) teleconsultation between GPs and pain specialists', 'Digital Treatment of Back Pain versus Standard of Care', 'CG']","['Pain rating', 'pain reduction', 'pain intensity', 'numeric rating scale', 'Psychological measures (anxiety, depression, stress), functional ability, as well as physical and mental wellbeing, served as secondary outcomes', 'training activity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0740418', 'cui_str': 'Chronic back pain'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C5191368', 'cui_str': '933'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517706', 'cui_str': '312'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0272302', 'cui_str': 'Gray platelet syndrome'}, {'cui': 'C0017480', 'cui_str': 'Germany'}]","[{'cui': 'C4551412', 'cui_str': 'Electronic case report form'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4042877', 'cui_str': 'Medical Decision-Making'}, {'cui': 'C0272302', 'cui_str': 'Gray platelet syndrome'}, {'cui': 'C0282675', 'cui_str': 'Teleconsultation'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0040606', 'cui_str': 'Training Activities'}]",1245.0,0.0600738,The Rise-uP group showed a significantly stronger pain reduction compared to the control group after 3 months (IG: M=-33.3% vs CG:,"[{'ForeName': 'Janosch A', 'Initials': 'JA', 'LastName': 'Priebe', 'Affiliation': 'Center of Interdisciplinary Pain Medicine, Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Katharina K', 'Initials': 'KK', 'LastName': 'Haas', 'Affiliation': 'Center of Interdisciplinary Pain Medicine, Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Leida F', 'Initials': 'LF', 'LastName': 'Moreno Sanchez', 'Affiliation': 'Center of Interdisciplinary Pain Medicine, Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Schoefmann', 'Affiliation': 'Center of Interdisciplinary Pain Medicine, Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Utpadel-Fischler', 'Affiliation': 'Center of Interdisciplinary Pain Medicine, Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Stockert', 'Affiliation': 'Center of Interdisciplinary Pain Medicine, Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Thoma', 'Affiliation': 'Pain Clinic, Algesiologikum Pain Center, Munich, Germany.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Schiessl', 'Affiliation': 'Pain Clinic, Algesiologikum Pain Center, Munich, Germany.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Kerkemeyer', 'Affiliation': 'Institute for Applied Health Services Research, inav GmbH, Berlin, Germany.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Amelung', 'Affiliation': 'Institute for Applied Health Services Research, inav GmbH, Berlin, Germany.'}, {'ForeName': 'Siegfried', 'Initials': 'S', 'LastName': 'Jedamzik', 'Affiliation': 'Bayerische TelemedAllianz (BTA), Ingolstadt, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Reichmann', 'Affiliation': 'StatConsult GmbH Magdeburg, Magdeburg, Germany.'}, {'ForeName': 'Ursula', 'Initials': 'U', 'LastName': 'Marschall', 'Affiliation': 'Barmer Hauptverwaltung, Wuppertal, Germany.'}, {'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'Toelle', 'Affiliation': 'Center of Interdisciplinary Pain Medicine, Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.'}]",Journal of pain research,['10.2147/JPR.S260761'] 2851,32765070,Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer.,"Men treated with androgen deprivation therapy for rising PSA after failed local therapy will often develop castrate resistance, and the appearance of metastases predicts a poor prognosis. Thus, researchers have long sought to prolong the onset of metastasis in patients with nonmetastatic castration-resistant prostate cancer (CRPC). Until 2018, patients in this group had no FDA-approved treatment options. They were typically managed with androgen-deprivation therapy (ADT) to maintain castrate systemic testosterone levels and given approved therapies for metastatic CRPC once metastases appeared. However, third-generation androgen receptor inhibitors (ARIs) have dramatically changed the treatment paradigm, having shown the ability to extend metastasis-free survival (MFS) significantly over ADT alone in Phase 3 trials. The newest of these, darolutamide, prolonged MFS 22 months over placebo while also improving a host of secondary and exploratory endpoints such as overall survival (OS), prostate-specific antigen (PSA) progression and time to pain progression, chemotherapy initiation, and symptomatic skeletal events. Among third-generation ARIs, darolutamide is unique in that it incorporates two pharmacologically active diastereomers and has demonstrated resistance to all known androgen receptor (AR) mutations. Additionally, patients taking darolutamide appear to experience comparatively few central nervous system-related adverse events (AEs) such as fatigue and falls, and no increases in seizures have been reported in the drug's clinical or preclinical development. Various authors attribute the low incidence of CNS-related AEs to darolutamide's minimal penetration of the blood-brain barrier (BBB). Other side effects ranging from hot flashes to hypothyroidism also occurred at rates similar to those of the placebo arm in Phase 3. As ADT in itself raises cardiovascular risk, the cardiovascular safety of third-generation antiandrogens as a category warrants continued scrutiny. In total, however, published data suggest that darolutamide provides a reasonable option for patients with nonmetastatic CRPC. Ongoing research will determine darolutamide's potential role in additional disease states such as localized and castration-sensitive PCa.",2020,Other side effects ranging from hot flashes to hypothyroidism also occurred at rates similar to those of the placebo arm in Phase 3.,"['patients with nonmetastatic castration-resistant prostate cancer (CRPC', 'Prostate Cancer', 'patients with nonmetastatic CRPC']","['androgen deprivation therapy', 'Darolutamide', 'darolutamide', 'androgen-deprivation therapy (ADT', 'placebo']","['overall survival (OS), prostate-specific antigen (PSA) progression and time to pain progression, chemotherapy initiation, and symptomatic skeletal events', 'blood-brain barrier (BBB']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1328504', 'cui_str': 'Hormone refractory prostate cancer'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}]","[{'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C4547776', 'cui_str': 'darolutamide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0005854', 'cui_str': 'Brain-Blood Barrier'}]",,0.0766034,Other side effects ranging from hot flashes to hypothyroidism also occurred at rates similar to those of the placebo arm in Phase 3.,"[{'ForeName': 'E David', 'Initials': 'ED', 'LastName': 'Crawford', 'Affiliation': 'Department of Urology, University of California at San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Whitney', 'Initials': 'W', 'LastName': 'Stanton', 'Affiliation': 'Department of Pathology, University of Colorado School of Medicine, Aurora, CO, USA.'}, {'ForeName': 'Divneet', 'Initials': 'D', 'LastName': 'Mandair', 'Affiliation': 'Department of Pathology, University of Colorado School of Medicine, Aurora, CO, USA.'}]",Cancer management and research,['10.2147/CMAR.S227583'] 2852,32769519,"A Randomized, Double-Blinded Study Evaluating the Safety and Efficacy of AbobotulinumtoxinA Injections for Oily Skin of the Forehead: A Dose-Response Analysis.","BACKGROUND AbobotulinumtoxinA has been investigated for applications beyond facial rhytides, including the treatment of oily skin. OBJECTIVE The authors sought to investigate the optimal number of units and the duration of abobotulinumtoxinA for the treatment of oily skin. MATERIALS AND METHODS This randomized, double-blinded, placebo-controlled study included 50 male and female subjects that got either 0, 15, 30, or 45 units of abobotulinumtoxinA injected into their forehead. For the 6 months after treatment, subjects were evaluated for the effectiveness of the treatment in decreasing the oiliness of their skin and the duration of this effect. RESULTS Subjects in the treatment groups that received either 30 or 45 units of neurotoxin experienced a significant reduction in oily skin. This effect was present for the 6-month duration of the study. No treatment-related adverse events were reported during this study, and both subjects and investigators reported a high level of satisfaction with the treatment. CONCLUSION Thirty or 45 units of abobotulinumtoxinA are safe and effective doses in treating oily skin for improved cosmetic appearance.",2020,"No treatment-related adverse events were reported during this study, and both subjects and investigators reported a high level of satisfaction with the treatment. ","['50 male and female subjects that got either 0, 15, 30, or 45 units of abobotulinumtoxinA injected into their forehead', 'Oily Skin of the Forehead']","['placebo', 'AbobotulinumtoxinA Injections', 'neurotoxin', 'abobotulinumtoxinA']","['oily skin', 'cosmetic appearance', 'adverse events', 'Safety and Efficacy']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C2719424', 'cui_str': 'AbobotulinumtoxinA'}, {'cui': 'C1720154', 'cui_str': 'Inject'}, {'cui': 'C0016540', 'cui_str': 'Forehead structure'}, {'cui': 'C0234925', 'cui_str': 'Greasy skin'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2719424', 'cui_str': 'AbobotulinumtoxinA'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0027934', 'cui_str': 'Neurotoxin'}]","[{'cui': 'C0234925', 'cui_str': 'Greasy skin'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",50.0,0.121903,"No treatment-related adverse events were reported during this study, and both subjects and investigators reported a high level of satisfaction with the treatment. ","[{'ForeName': 'Katarina', 'Initials': 'K', 'LastName': 'Kesty', 'Affiliation': 'Skin Laser and Surgery Specialists of NY and NJ, Hackensack, NJ.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Goldberg', 'Affiliation': 'Skin Laser and Surgery Specialists of NY and NJ, Hackensack, NJ.'}]",Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],['10.1097/DSS.0000000000002494'] 2853,32769524,Clinical Efficacy of Topical Tranexamic Acid With Microneedling in Melasma.,"BACKGROUND Melasma is a common, recurrent, and refractory cause of facial pigmentation resulting in cosmetic disfigurement. Tranexamic acid (TA) has been used systemically and locally for clearance of pigmentation. OBJECTIVE To assess the clinical efficacy of topical TA (10%) with microneedling in melasma. METHODS A split face, prospective, randomized, open-label study with a sample size of 40. Left or right side of the face was chosen randomly and microneedling was done on both the sides, followed by 10% TA solution application on one side of the face (test side) and distilled water on the other side of face (control). The procedure was done at 2 weekly intervals (0, 2, 4, and 6 weeks). Clinical images were taken at each visit including modified Melasma Area and Severity Index (mMASI) scoring of each half of the face to assess the clinical response along with patient satisfaction scores and side effects. RESULTS On the test side, there was 65.92% improvement in the mean mMASI score compared with 20.75% on the control side of the face at the end of 8 weeks. CONCLUSION Tranexamic acid may be a promising therapeutic agent in melasma and the topical solution along with microneedling seems to be efficacious.",2020,"On the test side, there was 65.92% improvement in the mean mMASI score compared with 20.75% on the control side of the face at the end of 8 weeks. ",['Melasma'],"['Tranexamic acid (TA', 'topical TA', 'Tranexamic acid', 'Topical Tranexamic Acid']",['mean mMASI score'],"[{'cui': 'C0025218', 'cui_str': 'Chloasma'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0332237', 'cui_str': 'Topical'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0025218', 'cui_str': 'Chloasma'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0485299,"On the test side, there was 65.92% improvement in the mean mMASI score compared with 20.75% on the control side of the face at the end of 8 weeks. ","[{'ForeName': 'Amrit', 'Initials': 'A', 'LastName': 'Kaur', 'Affiliation': ''}, {'ForeName': 'Mala', 'Initials': 'M', 'LastName': 'Bhalla', 'Affiliation': ''}, {'ForeName': 'Gurvinder', 'Initials': 'G', 'LastName': 'Pal Thami', 'Affiliation': ''}, {'ForeName': 'Jasleen', 'Initials': 'J', 'LastName': 'Sandhu', 'Affiliation': 'Dermatology and Venereology, Government Medical College and Hospital, Chandigarh, India.'}]",Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],['10.1097/DSS.0000000000002520'] 2854,32769526,The Effect of Conditioned Media From Human Adipocyte-Derived Mesenchymal Stem Cells on Androgenetic Alopecia After Nonablative Fractional Laser Treatment.,"BACKGROUND The conditioned media from adipocyte-derived mesenchymal stem cells-conditioned media (ADSC-CM) contains cytokines and growth factors that stimulate hair regeneration. OBJECTIVE We evaluated the efficacy and safety of human ADSC-CM treatment on patients who underwent nonablative fractional laser for the treatment of androgenetic alopecia (AGA). MATERIALS AND METHODS Thirty patients who underwent nonablative fractional laser treatment were topically administered either ADSC-CM or placebo solution. As a primary outcome, phototrichograms were taken to measure changes in hair density at each visit. In addition, global improvement scores (GISs) were compared by clinical digital photographs, which were taken at the initial and final visits, and assessed by 2 independent dermatologists. Finally, the investigator's improvement score was measured by questionnaire response during the final visit. RESULTS Hair density comparisons during the treatment period revealed that the ADSC-CM group had significantly higher final densities compared with the placebo group. The GIS of the ADSC-CM group was also significantly higher than the placebo group. Finally, no adverse effects associated with the application of ADSC-CM were noted during the study. CONCLUSION The application of ADSC-CM after nonablative fractional laser treatment accelerated increases in hair density and volume in AGA patients.",2020,The application of ADSC-CM after nonablative fractional laser treatment accelerated increases in hair density and volume in AGA patients.,"['AGA patients', 'Thirty patients who underwent', 'patients who underwent nonablative fractional laser for the treatment of androgenetic alopecia (AGA']","['ADSC-CM or placebo solution', 'Conditioned Media From Human Adipocyte-Derived Mesenchymal Stem Cells', 'human ADSC-CM treatment', 'nonablative fractional laser treatment', 'Nonablative Fractional Laser Treatment', 'placebo']","['Androgenetic Alopecia', 'hair density and volume', 'efficacy and safety', 'Hair density comparisons', 'questionnaire response', 'hair density', 'global improvement scores (GISs']","[{'cui': 'C0162311', 'cui_str': 'Alopecia hereditaria'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0206131', 'cui_str': 'Adipocyte'}, {'cui': 'C1257975', 'cui_str': 'Mesenchymal stem cell'}, {'cui': 'C0162518', 'cui_str': 'Conditioned Culture Medium'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}]","[{'cui': 'C0162311', 'cui_str': 'Alopecia hereditaria'}, {'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",30.0,0.0523452,The application of ADSC-CM after nonablative fractional laser treatment accelerated increases in hair density and volume in AGA patients.,"[{'ForeName': 'Young In', 'Initials': 'YI', 'LastName': 'Lee', 'Affiliation': 'Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Jihee', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Jemin', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Sujin', 'Initials': 'S', 'LastName': 'Park', 'Affiliation': 'Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Ju Hee', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.'}]",Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],['10.1097/DSS.0000000000002518'] 2855,32765075,A New Surgical Technique of Combination Retroperitoneal with Transperitoneal Laparoscopic Nephroureterectomy in a Single Position and Comparative Outcomes.,"Background The traditional surgical treatment for upper urinary tract urothelial carcinoma (UTUC) is time-consuming owing to changing the surgical position and larger surgical trauma because of open surgery in handling the distal ureter. Therefore, we created a new surgical technique of combination retroperitoneal with transperitoneal (CRT) laparoscopic nephroureterectomy (LNU) in a single position and here report our early outcomes. Methods From January 2017 to December 2019, a total of 106 patients underwent LNU by a single surgeon at our department, of whom 50 patients underwent standard technique and 56 patients underwent CRT technique. Relevant clinical data were collected including each patient's characteristics, surgical outcomes, and follow-up results. A comparative analysis between standard LNU cases and CRT LNU cases was performed. Results LNU was performed successfully on all 106 patients. There was no significant difference in patients' characteristics. Compared to the standard group, patients in the CRT group had shorter operative time ( P =0.001), less estimated blood loss (EBL) ( P <0.001), lower visual analogue scale (VAS) pain score ( P =0.020) and less scarring ( P =0.013). The median time of surgical drain stay decreased from 5 to 2 days ( P =0.004) and median hospital stay after surgery decreased from 5 to 3 days ( P =0.001). The complication rates did not show statistical differences between the two groups within the first 30 days postoperatively ( P =0.263). For the long-term complications, the incidence of abdomen bulge or incisional hernia in the CRT group was less than that in the standard group ( P <0.001). Conclusion The CRT technique, which combines both the advantages of retroperitoneal and transperitoneal approaches, is a more minimally invasive, simplified and effective way to perform the LNU.",2020,"Compared to the standard group, patients in the CRT group had shorter operative time ( P =0.001), less estimated blood loss (EBL) ( P <0.001), lower visual analogue scale (VAS) pain score ( P =0.020) and less scarring ( P =0.013).","['From January 2017 to December 2019, a total of 106 patients underwent LNU by a single surgeon at our department, of whom 50 patients underwent standard technique and 56 patients underwent', 'upper urinary tract urothelial carcinoma (UTUC']","['combination retroperitoneal with transperitoneal (CRT) laparoscopic nephroureterectomy (LNU', 'Transperitoneal Laparoscopic Nephroureterectomy', 'CRT technique']","['complication rates', 'median time of surgical drain stay', 'incidence of abdomen bulge or incisional hernia', 'scarring', 'lower visual analogue scale (VAS) pain score', 'estimated blood loss (EBL', 'median hospital stay', 'shorter operative time']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2111394', 'cui_str': 'Laparoscopic nephroureterectomy'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C1508753', 'cui_str': 'Urinary system structure'}, {'cui': 'C0007138', 'cui_str': 'Transitional cell carcinoma'}]","[{'cui': 'C0035359', 'cui_str': 'Retroperitoneal'}, {'cui': 'C0205501', 'cui_str': 'Transperitoneal approach'}, {'cui': 'C2111394', 'cui_str': 'Laparoscopic nephroureterectomy'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C2607832', 'cui_str': 'Surgical drain'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0267716', 'cui_str': 'Incisional hernia'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C1443559', 'cui_str': 'Estimated blood loss'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}]",106.0,0.0287389,"Compared to the standard group, patients in the CRT group had shorter operative time ( P =0.001), less estimated blood loss (EBL) ( P <0.001), lower visual analogue scale (VAS) pain score ( P =0.020) and less scarring ( P =0.013).","[{'ForeName': 'Liming', 'Initials': 'L', 'LastName': 'Song', 'Affiliation': ""Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China.""}, {'ForeName': 'Wenkuan', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': ""Department of Urology, Beijing Haidian Hospital/Haidian Hospital of Beijing University Third Hospital, Beijing, People's Republic of China.""}, {'ForeName': 'Qinxin', 'Initials': 'Q', 'LastName': 'Zhao', 'Affiliation': ""Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.""}, {'ForeName': 'Yuhong', 'Initials': 'Y', 'LastName': 'Wen', 'Affiliation': ""Department of Urology, Huhehaote First Hospital, Inner Mongolia, People's Republic of China.""}, {'ForeName': 'Xiaoguang', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': ""Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China.""}, {'ForeName': 'Hu', 'Initials': 'H', 'LastName': 'Han', 'Affiliation': ""Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China.""}, {'ForeName': 'Xiaodong', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ""Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China.""}]",Cancer management and research,['10.2147/CMAR.S259964'] 2856,32765139,"Enhancing Slow Oscillations and Increasing N3 Sleep Proportion with Supervised, Non-Phase-Locked Pink Noise and Other Non-Standard Auditory Stimulation During NREM Sleep.","Purpose In non-rapid eye movement (NREM) stage 3 sleep (N3), phase-locked pink noise auditory stimulation can amplify slow oscillatory activity (0.5-1 Hz). Open-loop pink noise auditory stimulation can amplify slow oscillatory and delta frequency activity (0.5-4 Hz). We assessed the ability of pink noise and other sounds to elicit delta power, slow oscillatory power, and N3 sleep. Participants and Methods Participants ( n = 8) underwent four consecutive inpatient nights in a within-participants design, starting with a habituation night. A registered polysomnographic technologist live-scored sleep stage and administered stimuli on randomized counterbalanced Enhancing and Disruptive nights, with a preceding Habituation night (night 1) and an intervening Sham night (night 3). A variety of non-phase-locked pink noise stimuli were used on Enhancing night during NREM; on Disruptive night, environmental sounds were used throughout sleep to induce frequent auditory-evoked arousals. Results Total sleep time did not differ between conditions. Percentage of N3 was higher in the Enhancing condition, and lower in the Disruptive condition, versus Sham. Standard 0.8 Hz pink noise elicited low-frequency power more effectively than other pink noise, but was not the most effective stimulus. Both pink noise on the ""Enhancing"" night and sounds intended to Disrupt sleep administered on the ""Disruptive"" night increased momentary delta and slow-wave activity (ie, during stimulation versus the immediate pre-stimulation period). Disruptive auditory stimulation degraded sleep with frequent arousals and increased next-day vigilance lapses versus Sham despite preserved sleep duration and momentary increases in delta and slow-wave activity. Conclusion These findings emphasize sound features of interest in ecologically valid, translational auditory intervention to increase restorative sleep. Preserving sleep continuity should be a primary consideration if auditory stimulation is used to enhance slow-wave activity.",2020,"Disruptive auditory stimulation degraded sleep with frequent arousals and increased next-day vigilance lapses versus Sham despite preserved sleep duration and momentary increases in delta and slow-wave activity. ",[],"['Open-loop pink noise auditory stimulation', 'polysomnographic technologist live-scored sleep stage and administered stimuli on randomized counterbalanced Enhancing and Disruptive nights, with a preceding Habituation night (night 1) and an intervening Sham night (night 3']","['ability of pink noise and other sounds to elicit delta power, slow oscillatory power, and N3 sleep', 'sleep duration and momentary increases in delta and slow-wave activity', 'momentary delta and slow-wave activity', 'Total sleep time', 'restorative sleep']",[],"[{'cui': 'C0559530', 'cui_str': 'Open loop'}, {'cui': 'C0332585', 'cui_str': 'Pink color'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0001164', 'cui_str': 'Stimulation, Acoustic'}, {'cui': 'C0260280', 'cui_str': 'Technologist'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0037319', 'cui_str': 'Sleep Stages'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0013170', 'cui_str': 'Drug habituation'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0332585', 'cui_str': 'Pink color'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}, {'cui': 'C0449265', 'cui_str': 'Elicited by'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0234451', 'cui_str': 'Non-rapid eye movement sleep'}, {'cui': 'C0424574', 'cui_str': 'Duration of sleep'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0858603', 'cui_str': 'Wave slowing'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",,0.0240526,"Disruptive auditory stimulation degraded sleep with frequent arousals and increased next-day vigilance lapses versus Sham despite preserved sleep duration and momentary increases in delta and slow-wave activity. ","[{'ForeName': 'Margeaux M', 'Initials': 'MM', 'LastName': 'Schade', 'Affiliation': 'Biobehavioral Health, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Gina Marie', 'Initials': 'GM', 'LastName': 'Mathew', 'Affiliation': 'Biobehavioral Health, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Roberts', 'Affiliation': 'Proactive Life, Inc., New York, NY, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Gartenberg', 'Affiliation': 'Proactive Life, Inc., New York, NY, USA.'}, {'ForeName': 'Orfeu M', 'Initials': 'OM', 'LastName': 'Buxton', 'Affiliation': 'Biobehavioral Health, Pennsylvania State University, University Park, PA, USA.'}]",Nature and science of sleep,['10.2147/NSS.S243204'] 2857,32765143,"Comparison of Morning and Evening Operation Under General Anesthesia on Intraoperative Anesthetic Requirement, Postoperative Sleep Quality, and Pain: A Randomized Controlled Trial.","Objective Postoperative sleep disorders can cause serious adverse effects on postoperative outcomes. The purpose of our study was to compare the effects of the timing of surgery under general anesthesia on intraoperative anesthetic drug requirements, postoperative sleep quality and pain in patients. Materials and Methods Eighty-four patients who underwent selective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to the Day Group (8:00-12:00) or the Night Group (18:00-22:00). The portable sleep monitor (PSM) was used to determine sleep quality on the night before surgery (Sleep-preop), the first night after surgery (Sleep POD 1), and the third night after surgery (Sleep POD 3). The visual analog scale (VAS) was used to evaluate postoperative pain scores and the Athens Insomnia Scale (AIS) was used for assessing insomnia symptoms. The total dose of general anesthetics required and adverse effects after surgery were also assessed. Results Compared to Sleep-preop, patients presented with a lower sleep efficiency and a higher AIS score during Sleep POD 1 and Sleep POD 3. Furthermore, the Night Group had a significantly lower proportion of rapid eye movement sleep, stable sleep, and unstable sleep than did the Day Group at Sleep POD 1 and Sleep POD 3. The dosage of propofol and remifentanil required in the Day Group was significantly higher than that in the Night Group. Furthermore, patients in the Day Group had better pain relief, with a lower VAS score at 1, 6, 12, and 24 hours after surgery. The incidences of postoperative nausea and vomiting and dizziness were significantly higher in the Night Group than those in the Day Group. Conclusion Morning operations required a higher dose of anesthetic drugs than did evening operations, which may be related to the circadian rhythm. The degree of postoperative sleep disorders was greater when the operation was performed in the evening than in the morning, which was also associated with increased pain perception and increased incidence of postoperative adverse effects. Thus, our results suggest that patients with hyperalgesia and sleep disorders may benefit from operations performed in the morning.",2020,The dosage of propofol and remifentanil required in the Day Group was significantly higher than that in the Night Group.,"['patients', 'patients with hyperalgesia and sleep disorders', 'Materials and Methods\n\n\nEighty-four patients who underwent selective laparoscopic abdominal surgeries under general anesthesia']","['surgery under general anesthesia', 'portable sleep monitor (PSM', 'propofol and remifentanil', 'Morning and Evening Operation Under General Anesthesia']","['postoperative sleep quality and pain', 'postoperative pain scores and the Athens Insomnia Scale (AIS', 'pain relief', 'visual analog scale (VAS', 'VAS score', 'postoperative nausea and vomiting and dizziness', 'degree of postoperative sleep disorders', 'postoperative adverse effects', 'Intraoperative Anesthetic Requirement, Postoperative Sleep Quality, and Pain', 'pain perception', 'rapid eye movement sleep, stable sleep, and unstable sleep']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020429', 'cui_str': 'Hyperalgesia'}, {'cui': 'C0851578', 'cui_str': 'Sleep disorder'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319623', 'cui_str': '84'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}]","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0587117', 'cui_str': 'Evening'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0851578', 'cui_str': 'Sleep disorder'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C0037322', 'cui_str': 'Rapid eye movement sleep'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0443343', 'cui_str': 'Unstable status'}]",84.0,0.0391005,The dosage of propofol and remifentanil required in the Day Group was significantly higher than that in the Night Group.,"[{'ForeName': 'Bijia', 'Initials': 'B', 'LastName': 'Song', 'Affiliation': ""Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.""}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ""Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.""}, {'ForeName': 'Xiufei', 'Initials': 'X', 'LastName': 'Teng', 'Affiliation': ""Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.""}, {'ForeName': 'Xiuyan', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': ""Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.""}, {'ForeName': 'Yanchao', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': ""Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.""}, {'ForeName': 'Junchao', 'Initials': 'J', 'LastName': 'Zhu', 'Affiliation': ""Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.""}]",Nature and science of sleep,['10.2147/NSS.S257896'] 2858,32765146,Efficacy of Electroacupuncture on Treating Depression-Related Insomnia: A Randomized Controlled Trial.,"Objective To evaluate the efficacy of electroacupuncture (EA) on treating insomnia in patients with depression. Patients and Methods In a patient-assessor-blind, randomized and sham controlled trial, 90 depression patients with insomnia were assigned into three different groups, receiving EA in the treatment group, superficial acupuncture at sham points in the control group A, or Streitberger non-insertion sham acupuncture in the control group B. Treatment was applied 3 times weekly for 8 consecutive weeks. The primary outcome was measured using the Pittsburgh Sleep Quality Index (PSQI). Secondary outcomes were sleep parameters including sleep efficiency (SE), total sleep time (TST) and numbers of sleep awakenings (SA) recorded in the actigraphy, as well as applying the Hamilton Rating Scale for Depression (HAMD-17), Self-Rating Depression Scale (SDS) and Hamilton Rating Scale for Anxiety (HAMA). Assessments were performed at the baseline (week 0), week 4, week 8, and week 12. Linear mixed-effects models were used for analyses and all statistical tests were two-sided. Results Patients in the EA group had more significant improvement in PSQI scores than those in the control groups over time (respectively p <0.001 and p =0.04 for treatment and time interaction). At 8-week posttreatment, the EA group reported a reduction of -6.64 points in PSQI scores compared with -2.23 points in the control group A (95% CI= -5.74 to -2.39) and -2.94 points in the control group B (95% CI= -5.73 to -2.47). Compared with the two control groups, significant between-group differences were seen in SE (both p <0.01) and TST (both p <0.01) at week 8; similar results can be found in HAMD-17, SDS, and HAMA scores as well. However, there were no between-group differences in SA (respectively p =0.24 and p =0.08) after 8-weeks of treatment. Conclusion Electroacupuncture may improve the sleep quality of patients with depression. Trial Registration Chinese Clinical Trial Registry (ChiCTR); URL: http://www.chictr.org.cn/showproj.aspx?proj=12327; Trial ID: ChiCTR-IIR-16008058.",2020,"Compared with the two control groups, significant between-group differences were seen in SE (both p <0.01) and TST (both p <0.01) at week 8; similar results can be found in HAMD-17, SDS, and HAMA scores as well.","['patients with depression', '90 depression patients with insomnia', 'Treating Depression-Related Insomnia']","['electroacupuncture (EA', 'Electroacupuncture', 'superficial acupuncture at sham points in the control group A, or Streitberger non-insertion sham acupuncture']","['SE', 'sleep parameters including sleep efficiency (SE), total sleep time (TST) and numbers of sleep awakenings (SA) recorded in the actigraphy, as well as applying the Hamilton Rating Scale for Depression (HAMD-17), Self-Rating Depression Scale (SDS) and Hamilton Rating Scale for Anxiety (HAMA', 'HAMD-17, SDS, and HAMA scores', 'Pittsburgh Sleep Quality Index (PSQI', 'PSQI scores', 'TST', 'SA', 'sleep quality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]","[{'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1720052', 'cui_str': 'Awakening'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C4545801', 'cui_str': 'Pittsburgh Sleep Quality Index score'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}]",90.0,0.0801643,"Compared with the two control groups, significant between-group differences were seen in SE (both p <0.01) and TST (both p <0.01) at week 8; similar results can be found in HAMD-17, SDS, and HAMA scores as well.","[{'ForeName': 'Xuan', 'Initials': 'X', 'LastName': 'Yin', 'Affiliation': ""Department of Acupuncture and Moxibustion, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, People's Republic of China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': ""Department of Acupuncture and Moxibustion, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, People's Republic of China.""}, {'ForeName': 'Huangan', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': ""Shanghai Research Institute of Acupuncture and Meridian, Shanghai University of Traditional Chinese Medicine, Shanghai, 200003, People's Republic of China.""}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Dong', 'Affiliation': ""Department of Acupuncture and Moxibustion, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, People's Republic of China.""}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': ""Department of Acupuncture and Moxibustion, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, People's Republic of China.""}, {'ForeName': 'Shanshan', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': ""Department of Acupuncture and Moxibustion, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, People's Republic of China.""}, {'ForeName': 'Lixing', 'Initials': 'L', 'LastName': 'Lao', 'Affiliation': 'School of Chinese Medicine, The University of Hong Kong, Hong Kong.'}, {'ForeName': 'Shifen', 'Initials': 'S', 'LastName': 'Xu', 'Affiliation': ""Department of Acupuncture and Moxibustion, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, People's Republic of China.""}]",Nature and science of sleep,['10.2147/NSS.S253320'] 2859,32765322,Short-Term and Highly Intensive Early Intervention FIAS: Two-Year Outcome Results and Factors of Influence.,"Background Comprehensive behaviorally or developmentally based early intervention programs have been shown to be effective in improving cognitive, social communicative, and adaptive skills of children with autism spectrum disorder (ASD). Besides the definition of relevant outcome predictors, the question of whether early intensive intervention positively changes core autism symptoms in children, as well as their long-term outcome, is an important issue for current research. The primary objective of the current study was to examine whether symptomatic and behavioral changes in children up to 4.5 years with ASD were sustained one and two years after an initial 18 days of intensive FIAS (Frühintervention bei autistischen Störungen) intervention. Methods We analyzed the data of 32 young children with moderately severe to severe ASD who had been treated at the FIAS center between January 2011 and July 2017 and who had completed their 2-year follow-up in summer 2019. Results ADOS total scores decreased significantly from baseline to the 1-year follow-up and from baseline to the 2-year follow-up (p < 0.01), with the most prominent change being from baseline to 2-year follow-up. The DD-C-GAS, a global scale used to assess four areas of everyday functioning, showed highly significant improvements on all subdomains. We found mostly significant correlations between results on both rating instruments at all time points, yet mostly no meaningful correlation between their changes over time. There was a close and statistically significant relationship between parents' treatment adherence and ADOS scores, indicating that the better parents' treatment adherence, the lower the children scored on the ADOS at 1- and 2-year follow-up. Overall, improvement on both scales was virtually independent of age and autism symptom severity at baseline, suggesting that older (>43 months) and more severely affected children (ADOS total score >20) may benefit from the FIAS intervention to the same extent as younger children do. Conclusions The results of the study indicate that the FIAS approach of providing an initial highly intensive 18-day intervention period, followed by 2 years of less intensive follow-up care had an impact on the core autism symptoms as well as the adaptive functioning of children with ASD.",2020,"The DD-C-GAS, a global scale used to assess four areas of everyday functioning, showed highly significant improvements on all subdomains.","['children with ASD', 'children up to 4.5 years with ASD', 'children with autism spectrum disorder (ASD', '32 young children with moderately severe to severe ASD who had been treated at the FIAS center between January 2011 and July 2017 and who had completed their 2-year follow-up in summer 2019']","['Short-Term and Highly Intensive Early Intervention', 'intensive FIAS (Frühintervention bei autistischen Störungen) intervention', 'FIAS']","[""parents' treatment adherence and ADOS scores"", 'ADOS total scores']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C3844009', 'cui_str': '4.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0180917', 'cui_str': 'Fluorescence immunoassay analyzer'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0242687', 'cui_str': 'Provision of early intervention service for child'}, {'cui': 'C0180917', 'cui_str': 'Fluorescence immunoassay analyzer'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C4505265', 'cui_str': 'Therapeutic Adherence'}, {'cui': 'C0001443', 'cui_str': 'Adenosine'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",32.0,0.0278198,"The DD-C-GAS, a global scale used to assess four areas of everyday functioning, showed highly significant improvements on all subdomains.","[{'ForeName': 'Evelyn', 'Initials': 'E', 'LastName': 'Herbrecht', 'Affiliation': 'Child and Adolescent Psychiatry, Psychiatric University Hospitals, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Lazari', 'Affiliation': 'Child and Adolescent Psychiatry, Psychiatric University Hospitals, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Notter', 'Affiliation': 'Child and Adolescent Psychiatry, Psychiatric University Hospitals, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Kievit', 'Affiliation': 'Child and Adolescent Psychiatry, Psychiatric University Hospitals, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Schmeck', 'Affiliation': 'Child and Adolescent Psychiatry, Psychiatric University Hospitals, University of Basel, Basel, Switzerland.'}, {'ForeName': 'René', 'Initials': 'R', 'LastName': 'Spiegel', 'Affiliation': 'Child and Adolescent Psychiatry, Psychiatric University Hospitals, University of Basel, Basel, Switzerland.'}]",Frontiers in psychiatry,['10.3389/fpsyt.2020.00687'] 2860,32765344,Contracting Students for the Reduction of Foreign Language Classroom Anxiety: An Approach Nurturing Positive Mindsets and Behaviors.,"The quasi-experimental study reported in this paper investigated whether contracting students' speaking in the foreign language (FL) classroom could effectively mitigate their FL classroom anxiety. It also explored the working mechanisms of this approach to the reduction of classroom anxiety and examined the attitudes FL students had toward it. To these ends, 42 Chinese-as-the-first-language university students learning English as a foreign language (EFL) were recruited and placed into the experimental ( n = 20) and comparison groups ( n = 22). Both groups were tested for anxiety before and after completing a 1-week contract and a non-contracting treatment, respectively. The experimental group participants' diaries were also collected, and their attitudes toward the intervention were elicited. Results showed that the experimental group's level of anxiety decreased significantly more as compared with that of the comparison group, suggesting the better efficacy of contracting speaking in FL anxiety reduction. Diary analyses also suggested that contracting speaking could increase learners' FL learning engagement; enhance their self-efficacy; facilitate their self-reflection of weaknesses and strengths as an FL learner; cultivate their character strengths and positive emotions; and diminish their fear, nervousness, and worries in class. Furthermore, the experimental group participants generally did not feel uncomfortable with the intervention. These findings were discussed in relation to classroom pedagogy for more effective delivery of FL education.",2020,"Results showed that the experimental group's level of anxiety decreased significantly more as compared with that of the comparison group, suggesting the better efficacy of contracting speaking in FL anxiety reduction.","['42 Chinese-as-the-first-language university students learning English as a foreign language (EFL', 'Contracting Students for the Reduction of Foreign Language Classroom Anxiety']",[],"['level of anxiety', 'fear, nervousness, and worries in class']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0557073', 'cui_str': 'First language'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0376327', 'cui_str': 'Multinational Aspects'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0332522', 'cui_str': 'Contracts'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",[],"[{'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0027769', 'cui_str': 'Nervousness'}, {'cui': 'C0233481', 'cui_str': 'Worried'}, {'cui': 'C0456387', 'cui_str': 'Class'}]",,0.01231,"Results showed that the experimental group's level of anxiety decreased significantly more as compared with that of the comparison group, suggesting the better efficacy of contracting speaking in FL anxiety reduction.","[{'ForeName': 'Yinxing', 'Initials': 'Y', 'LastName': 'Jin', 'Affiliation': 'School of Foreign Languages, Hainan Normal University, Haikou, China.'}, {'ForeName': 'Lawrence Jun', 'Initials': 'LJ', 'LastName': 'Zhang', 'Affiliation': 'Faculty of Education and Social Work, The University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Peter D', 'Initials': 'PD', 'LastName': 'MacIntyre', 'Affiliation': 'Department of Psychology, Cape Breton University, Sydney, NS, Canada.'}]",Frontiers in psychology,['10.3389/fpsyg.2020.01471'] 2861,32765384,The Use of Virtual Reality Alone Does Not Promote Training Performance (but Sense of Presence Does).,"Virtual reality (VR) offers novel ways to develop skills and learning. This technology can be used to enhance the way we educate and train professionals by possibly being more effective, cost-efficient, and reducing training-related risks. However, the potential benefits from virtual training assume that the trained skills can be transferred to the real world. Nevertheless, in the current published scientific literature, there is limited empirical evidence that links VR use to better learning. The present investigation aimed to explore the use of VR as a tool for training procedural skills and compare this modality with traditional instruction methods. To investigate skill development using the two forms of training, participants were randomly divided into two groups. The first group received training through an instructional video, while the second group trained in VR. After the training session, the participants performed the trained task in a real setting, and task performance was measured. Subsequently, the user's experienced sense of presence and simulator sickness (SS) was measured with self-report questionnaires. There were no significant differences between groups for any of the performance measures. There was no gender effect on performance. Importantly, the results of the present study indicate that a high sense of presence during the VR simulation might contribute to increased skill learning. These findings can be used as a starting point that could be of value when further exploring VR as a tool for skill development.",2020,"This technology can be used to enhance the way we educate and train professionals by possibly being more effective, cost-efficient, and reducing training-related risks.",[],"['Virtual Reality Alone', 'training through an instructional video, while the second group trained in VR', 'Virtual reality (VR']","['performance', 'skill learning', 'sense of presence and simulator sickness (SS']",[],"[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C0221423', 'cui_str': 'Illness'}]",,0.0126431,"This technology can be used to enhance the way we educate and train professionals by possibly being more effective, cost-efficient, and reducing training-related risks.","[{'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Grassini', 'Affiliation': 'Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Laumann', 'Affiliation': 'Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Rasmussen Skogstad', 'Affiliation': 'Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway.'}]",Frontiers in psychology,['10.3389/fpsyg.2020.01743'] 2862,32765401,The Role of Cerebral Hypoperfusion in Multiple Sclerosis (ROCHIMS) Trial in Multiple Sclerosis: Insights From Negative Results.,"Background: Accumulating evidence indicates that mitochondrial energy failure is involved in the progressive axonal degeneration in multiple sclerosis (MS). In patients with MS, it has been shown that both levels of N-acetylaspartate (NAA), which is a marker of axonal mitochondrial energy, and cerebral blood flow (CBF) are reduced in cerebral normal appearing white matter (NAWM). The latter is likely due to the vasoconstrictive action of endothelin-1 (ET-1) produced by reactive astrocytes, which is triggered by local proinflammatory cytokines. A preliminary study in patients with MS showed that CBF could be restored to normal values after a single dose of 62.5 mg of the ET-1 antagonist bosentan. Objective: To investigate whether restoring CBF in patients with relapsing remitting MS (RRMS) increases levels of NAA in cerebral NAWM and improves clinical symptoms. Methods: 27 RRMS patients were included in a 4 weeks proof-of-concept, randomized, double-blind placebo-controlled trial (ROCHIMS) to investigate whether bosentan 62.5 mg twice daily could increase the NAA/creatine (NAA/Cr) ratio in NAWM of the centrum semiovale. Magnetic resonance imaging (MRI) assessing CBF and NAA/Cr, and clinical evaluations were performed at baseline and at end of study. Separately from the clinical trial, 10 healthy controls underwent the same baseline multimodal brain MRI protocol as the MS patients. Results: Eleven patients in the bosentan arm and thirteen patients in the placebo arm completed the study. Bosentan did not increase CBF. However, we found that CBF in the patients was not different from that of the healthy controls. There were no effects on NAA levels and clinical symptoms. Conclusions: Our study showed that CBF in RRMS patients is not always decreased and that bosentan has no effect when CBF values are within the normal range. We hypothesize that in our patients there was no significant astrocytic production of ET-1 because they had a mild disease course, with minimal local inflammatory activity. Future studies with bosentan in MS should focus on patients with elevated ET-1 levels in cerebrospinal fluid or blood.",2020,There were no effects on NAA levels and clinical symptoms. ,"['10 healthy controls underwent the same baseline multimodal brain MRI protocol as the MS patients', '27 RRMS patients', 'Eleven patients in the bosentan arm and thirteen patients in the', 'patients with MS', 'patients with relapsing remitting MS (RRMS']","['Magnetic resonance imaging (MRI', 'CBF', 'placebo']","['CBF', 'NAA/creatine (NAA/Cr) ratio in NAWM of the centrum semiovale', 'NAA levels and clinical symptoms']","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C4028269', 'cui_str': 'Nuclear magnetic resonance imaging brain'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1522002', 'cui_str': 'RRM Motif'}, {'cui': 'C0252643', 'cui_str': 'bosentan'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}]","[{'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0067684', 'cui_str': 'N-acetyl-L-aspartate'}, {'cui': 'C0010286', 'cui_str': 'Creatine'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0228181', 'cui_str': 'Structure of centrum semiovale'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",27.0,0.156998,There were no effects on NAA levels and clinical symptoms. ,"[{'ForeName': 'Stéphanie', 'Initials': 'S', 'LastName': 'Hostenbach', 'Affiliation': 'Department of Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium.'}, {'ForeName': 'Hubert', 'Initials': 'H', 'LastName': 'Raeymaekers', 'Affiliation': 'Department of Radiology and Medical Physics, Universitair Ziekenhuis Brussel, Brussels, Belgium.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Van Schuerbeek', 'Affiliation': 'Department of Radiology and Medical Physics, Universitair Ziekenhuis Brussel, Brussels, Belgium.'}, {'ForeName': 'Anne-Marie', 'Initials': 'AM', 'LastName': 'Vanbinst', 'Affiliation': 'Department of Radiology and Medical Physics, Universitair Ziekenhuis Brussel, Brussels, Belgium.'}, {'ForeName': 'Wilfried', 'Initials': 'W', 'LastName': 'Cools', 'Affiliation': 'Interfaculty Center Data Processing and Statistics, Vrije Universiteit Brussel, Brussels, Belgium.'}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'De Keyser', 'Affiliation': 'Department of Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': ""D'Haeseleer"", 'Affiliation': 'Department of Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium.'}]",Frontiers in neurology,['10.3389/fneur.2020.00674'] 2863,32765402,"Excitability, Inhibition, and Neurotransmitter Levels in the Motor Cortex of Symptomatic and Asymptomatic Individuals Following Mild Traumatic Brain Injury.","Purpose: The purpose of this study was to determine the level of excitability and inhibition, as well as the concentrations of excitatory and inhibitory neurotransmitters, in the motor cortex of individuals with acute and chronic symptoms from mTBI. Methods: Fifty-three individuals were assigned to one of four groups: (i) without history of mTBI (Control), (ii) within 72-h of diagnosis of mTBI (Acute), (iii) with history of mTBI and no remaining symptoms (Chronic Asymptomatic), and (iv) with chronic symptoms from mTBI, lasting at least 3 months post-injury (Chronic Symptomatic). Measures of corticospinal excitability and inhibition were obtained using transcranial magnetic stimulation (TMS). On the same day, measures of glutamate and GABA concentrations were obtained from the primary motor cortex (M1) using proton magnetic resonance spectroscopy. Results: MEP amplitude and area were both significantly lower in the Chronic Symptomatic group compared to the Control and Chronic Asymptomatic groups ( p ≤ 0.05). Intracortical inhibition was not significantly different among groups ( p = 0.14). The concentration of glutamate in M1 was similar between groups ( p = 0.93) while there was a trend for a lower concentration of GABA in the Chronic Symptomatic group compared to the Acute group ( p = 0.06). Conclusions: Individuals with chronic mTBI symptoms appear to have lower corticospinal excitability compared with acutely-injured individuals and asymptomatic controls, but the absence of differences in intracortical inhibition, and concentrations of excitatory and inhibitory neurotransmitters in M1 suggests that neurotransmitter changes in the human brain post-mTBI do not follow the pattern typically seen in the animal literature.",2020,MEP amplitude and area were both significantly lower in the Chronic Symptomatic group compared to the Control and Chronic Asymptomatic groups ( p ≤ 0.05).,"['individuals with acute and chronic symptoms from mTBI', 'Methods: Fifty-three individuals', 'Individuals with chronic mTBI symptoms']","['transcranial magnetic stimulation (TMS', 'without history of mTBI (Control), (ii) within 72-h of diagnosis of mTBI (Acute), (iii) with history of mTBI and no remaining symptoms (Chronic Asymptomatic']","['Intracortical inhibition', 'corticospinal excitability and inhibition', 'concentration of GABA', 'glutamate and GABA concentrations', 'concentration of glutamate in M1', 'Excitability, Inhibition, and Neurotransmitter Levels', 'MEP amplitude and area', 'corticospinal excitability']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}]","[{'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0016904', 'cui_str': 'Gamma-aminobutyric acid'}, {'cui': 'C0017789', 'cui_str': 'Glutamates'}, {'cui': 'C0027908', 'cui_str': 'Neurotransmitter'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0054871', 'cui_str': 'Cathepsin L'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]",53.0,0.0900657,MEP amplitude and area were both significantly lower in the Chronic Symptomatic group compared to the Control and Chronic Asymptomatic groups ( p ≤ 0.05).,"[{'ForeName': 'Alia L', 'Initials': 'AL', 'LastName': 'Yasen', 'Affiliation': 'Department of Human Physiology, University of Oregon, Eugene, OR, United States.'}, {'ForeName': 'Miranda M', 'Initials': 'MM', 'LastName': 'Lim', 'Affiliation': 'Sleep Disorders Clinic, VA Portland Health Care System, Portland, OR, United States.'}, {'ForeName': 'Kristianna B', 'Initials': 'KB', 'LastName': 'Weymann', 'Affiliation': 'Sleep Disorders Clinic, VA Portland Health Care System, Portland, OR, United States.'}, {'ForeName': 'Anita D', 'Initials': 'AD', 'LastName': 'Christie', 'Affiliation': 'Department of Human Physiology, University of Oregon, Eugene, OR, United States.'}]",Frontiers in neurology,['10.3389/fneur.2020.00683'] 2864,32765619,Early administration of amino acids with different doses in low birth weight premature infants.,"Background The reasonable use of amino acids (AAs) in parenteral nutrition (PN) is very critical to the growth and development of premature infants. However, the appropriate dose of AAs has not been determined. Our study was designed to investigate the clinical effect of two different doses of AAs in PN for low birth weight premature infants. Materials and Methods This randomized controlled study included 191 preterm infants who admitted to the neonatal intensive care unit of the First Affiliated Hospital of Nanjing Medical University from June 2015 to December 2016 and they were randomly divided into Group 1 ( n = 81) and Group 2 ( n = 110). In Group 1, the starting dose of AAs dose was 1.0-1.5 g/kg/day, which was increased by 0.5 g/kg with the maximum dose at 3.5 g/kg/day. In Group 2, the starting dose of AAs was 1.8-2.5 g/kg/day and was increased by 1.0 g/kg with the maximum dose at 4.0-4.5 g/kg/day. We analyzed the clinical characteristics, body weight, body length, total calorie intake, nonprotein calorie intake, total protein intake, liver and kidney function, and complications of the two groups of preterm infants. Results The start of enteral feeding and the recovery of birth weight in Group 2 were earlier than those in Group 1 (3.83 ± 3.15 day vs. 5.53 ± 5.63 day, P = 0.016 and 6.36 ± 4.88 day vs. 8.48 ± 9.27 day, P = 0.043, respectively). The duration of PN and the time before total enteral nutrition were shorter in Group 2 than in Group 1 (16.46 ± 10.33 day vs. 21.41 ± 18.00 day, P = 0.029 and 15.47 ± 10.54 day vs. 19.47 ± 14.57 day, P = 0.038; respectively). The duration of mechanical ventilation (1.12 ± 2.62 day vs. 3.31 ± 8.13 day, P = 0.028) in Group 2 was shorter than that in Group 1. Conclusion High doses of AAs in the early PN for preterm infants facilitate the promotion of early growth and development, advance recovery of birth weight, reduce the duration of PN, and reduce respiratory support without increasing the incidence of complications.",2020,"The duration of mechanical ventilation (1.12 ± 2.62 day vs. 3.31 ± 8.13 day, P = 0.028) in Group 2 was shorter than that in Group 1. ","['low birth weight premature infants', '191 preterm infants who admitted to the neonatal intensive care unit of the First Affiliated Hospital of Nanjing Medical University from June 2015 to December 2016 and they', 'premature infants']","['amino acids (AAs) in parenteral nutrition (PN', 'amino acids']","['duration of mechanical ventilation', 'clinical characteristics, body weight, body length, total calorie intake, nonprotein calorie intake, total protein intake, liver and kidney function, and complications of the two groups of preterm infants', 'duration of PN and the time before total enteral nutrition', 'recovery of birth weight']","[{'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0002520', 'cui_str': 'amino acids'}, {'cui': 'C0030547', 'cui_str': 'Parenteral nutrition'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0221097', 'cui_str': 'Length of body'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0555903', 'cui_str': 'Total protein measurement'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0232804', 'cui_str': 'Renal function'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0030547', 'cui_str': 'Parenteral nutrition'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}]",191.0,0.0466901,"The duration of mechanical ventilation (1.12 ± 2.62 day vs. 3.31 ± 8.13 day, P = 0.028) in Group 2 was shorter than that in Group 1. ","[{'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Pediatrics, First Affiliation Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.'}, {'ForeName': 'Zhongyi', 'Initials': 'Z', 'LastName': 'Sun', 'Affiliation': 'Department of Pediatrics, First Affiliation Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.'}, {'ForeName': 'Yuhua', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Department of Pediatrics, First Affiliation Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.'}, {'ForeName': 'Bingjie', 'Initials': 'B', 'LastName': 'Li', 'Affiliation': 'Department of Pediatrics, First Affiliation Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.'}, {'ForeName': 'Xinxin', 'Initials': 'X', 'LastName': 'Bu', 'Affiliation': 'Department of Pediatrics, First Affiliation Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.'}, {'ForeName': 'Yanyan', 'Initials': 'Y', 'LastName': 'Luo', 'Affiliation': 'Department of Pediatrics, First Affiliation Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.'}, {'ForeName': 'Shujun', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Department of Pediatrics, First Affiliation Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.'}, {'ForeName': 'Xiaoqing', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Pediatrics, First Affiliation Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.'}]",Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences,['10.4103/jrms.JRMS_213_19'] 2865,32765622,"Comparison of ""cough peak expiratory flow measurement"" and ""cough strength measurement using the white card test"" in extubation success: A randomized controlled trial.","Background Failed extubation and subsequent re-intubation in ventilated patients can lead to many adverse consequences, including organizational and personal expenditures. Extubation decisions based on subjective methods are a major contributor to extubation failure. This study compared the effect of cough peak expiratory flow (PEF) measurement and cough strength measurement using the white card test (WCT) on extubation success. Materials and Methods This randomized clinical trial was conducted in two groups in 2018 on 88 ventilated patients in intensive care units of Imam Reza Hospital in Mashhad, Iran. Ninety patients were divided into two groups of 45, but two were excluded from the white card group. The criteria established for extubation included PEF ≥60 L/min during coughing in the cough PEF group and noticing card humidity in the WCT group. In both groups, extubation success was determined as the sole outcome and was compared with the standard PEF and cough strength. The researcher who assessed the outcome and statistician were blinded about group allocation. Results Extubation success was measured as 97.8% in the cough PEF group and 76.7% in the WCT group ( P = 0.003) during the first 24 h. In the second 24 h, however, successful extubation was reported as 90.9% in the cough PEF group and 60.6% in the WCT group ( P = 0.002). Conclusion Using the cough PEF rate increases the likelihood of extubation success and reduces adverse effects, and is recommended to be used for extubation decision-making.",2020,"Results Extubation success was measured as 97.8% in the cough PEF group and 76.7% in the WCT group ( P = 0.003) during the first 24 h.","['ventilated patients', 'two groups in 2018 on 88 ventilated patients in intensive care units of Imam Reza Hospital in Mashhad, Iran', 'Ninety patients were divided into two groups of 45, but two were excluded from the white card group']","['cough peak expiratory flow measurement"" and ""cough strength measurement', 'cough peak expiratory flow (PEF) measurement and cough strength measurement using the white card test (WCT', 'WCT']","['extubation success', 'successful extubation', 'cough', 'standard PEF and cough strength', 'Extubation success', 'adverse effects']","[{'cui': 'C1299448', 'cui_str': 'Patient ventilated'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0521321', 'cui_str': 'Imam'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}]","[{'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0521299', 'cui_str': 'Peak expiratory flow measurement'}, {'cui': 'C4708767', 'cui_str': 'Cough strength'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C4708767', 'cui_str': 'Cough strength'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",90.0,0.0438229,"Results Extubation success was measured as 97.8% in the cough PEF group and 76.7% in the WCT group ( P = 0.003) during the first 24 h.","[{'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Abedini', 'Affiliation': 'Department of Medical Surgical Nursing, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Razieh', 'Initials': 'R', 'LastName': 'Froutan', 'Affiliation': 'Department of Medical Surgical Nursing, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Bagheri Moghaddam', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Seyed Reza', 'Initials': 'SR', 'LastName': 'Mazloum', 'Affiliation': 'Department of Medical Surgical Nursing, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.'}]",Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences,['10.4103/jrms.JRMS_939_19'] 2866,32765624,Unilateral medial rectus muscle recession combined lateral rectus muscle marginal myotomy for the treatment of Duane's retraction syndrome: A promising surgical procedure.,"Background Duane's retraction syndrome is a congenital eye movement anomaly with narrowing of the palpebral fissure and globe retraction on attempted adduction. There are several surgical approaches to treat the narrowing of the palpebral fissure. The purpose of the present study was to evaluate the efficacy of unilateral medial rectus recession (MRR) muscle combined lateral rectus (LR) muscle marginal myotomy (MM) with unilateral MRR alone in the management of narrowing of the palpebral fissure of patients with Type 1 Duane's retraction syndrome (DRS). Materials and Methods Twenty-eight patients with unilateral DRS Type 1 were randomly divided into two groups (14 eyes of 14 patients in each group). Age ≥5 years with DRS Type 1 with <20 prism diopters in primary position who were candidates for surgery were consecutively enrolled in this randomized controlled trial. Patients were divided into treatment groups to receive unilateral MR recession with simultaneous MM group or with unilateral MR recession alone. The amount of deviation in primary position, abnormal head position, palpebral fissure width (PFW), and up/down shoot was evaluated before and 3 months after the surgery. This study was registered at the Iranian Registry of Clinical Trials under the registration code IRCT20131229015975N3. Results PFW increased within MRR/MM group at the end of the study (8.86 ± 1.51) compared with the baseline (7.79 ± 1.48) ( P < 0.001). In contrast, in the MRR/MM group, PFW did not increase statistically significantly within the MRR group at the end of the study (8.14 ± 1.35) compared with the baseline (8.07 ± 1.38) ( P = 0.67). Mean ± standard deviation of PFW (mm) in MRR/MM group after surgery (8.86 ± 1.51) was statistically significantly higher than that in the MRR group (8.14 ± 1.35), ( P = 0.002). Conclusion The results of our study demonstrate PFW significantly increased after unilateral MRR muscle combined LR muscle MM.",2020,"In contrast, in the MRR/MM group, PFW did not increase statistically significantly within the MRR group at the end of the study (8.14 ± 1.35) compared with the baseline (8.07 ± 1.38) ( P = 0.67).","[""patients with Type 1 Duane's retraction syndrome (DRS"", 'Age ≥5 years with DRS Type 1 with <20 prism diopters in primary position who were candidates for surgery', 'Materials and Methods\n\n\nTwenty-eight patients with unilateral DRS Type 1', ""Duane's retraction syndrome""]","['unilateral MR recession with simultaneous MM group or with unilateral MR recession alone', 'unilateral medial rectus recession (MRR) muscle combined lateral rectus (LR) muscle marginal myotomy (MM) with unilateral MRR alone', 'Unilateral medial rectus muscle recession combined lateral rectus muscle marginal myotomy']","['abnormal head position, palpebral fissure width (PFW), and up/down shoot', 'PFW', 'Mean ± standard deviation of PFW (mm']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0013261', 'cui_str': ""Duane's syndrome""}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0439487', 'cui_str': 'prism diopters'}, {'cui': 'C0444508', 'cui_str': 'Primary position'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}]","[{'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0333047', 'cui_str': 'Recession'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0185181', 'cui_str': 'Incision of muscle'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0395295', 'cui_str': 'Medial rectus recession'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0582821', 'cui_str': 'Lateral rectus muscle structure'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0582820', 'cui_str': 'Medial rectus muscle structure'}]","[{'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C0582540', 'cui_str': 'Head position finding'}, {'cui': 'C0229244', 'cui_str': 'Structure of palpebral fissure'}, {'cui': 'C0487742', 'cui_str': 'Width'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}]",28.0,0.0361124,"In contrast, in the MRR/MM group, PFW did not increase statistically significantly within the MRR group at the end of the study (8.14 ± 1.35) compared with the baseline (8.07 ± 1.38) ( P = 0.67).","[{'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Zandi', 'Affiliation': 'Department of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Arman', 'Initials': 'A', 'LastName': 'Amirkhani', 'Affiliation': 'Department of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Pourazizi', 'Affiliation': 'Department of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}]",Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences,['10.4103/jrms.JRMS_836_19'] 2867,32765786,Effect of multi-level stroke education on treatment and prognosis of acute ischemic stroke.,"This observational study aimed at the significance of multi-level education in the treatment and prognosis of acute ischemic stroke. Multi-level stroke education was carried out among residents and medical staff for one year in Guancheng district. After 1 year, 519 patients with acute ischemic stroke admitted to The First People's Hospital of Zhengzhou were invited to the study, 272 patients from the Guancheng district were divided into the experimental group, and 247 patients who were not from the Guancheng district but in the neighborhood of The First People's Hospital of Zhengzhou were divided into the control group. Statistical methods were applied to analyze the degree of awareness of stroke, the time from onset to hospital, the route to hospital, the number of patients coming to the hospital within 4.5 h, the number of intravenous thrombolysis, door-to-needle time (DNT), modified Rankin scale (MRS) score, and the number of hemorrhagic transformation cases. After one year of multi-level systematic stroke education, there were significant differences in stroke awareness between the experimental group and the control group in terms of limb weakness (87.87 vs. 62.75%), speech inarticulation (78.3 vs. 55.06%), facial paralysis (69.12 vs. 38.06%), limb numbness (57.35 vs. 29.15%), consciousness disorder (62.50 vs. 42.11%), walking instability with severe dizziness (39.97 vs. 15.79%) (P<0.05). There was no statistical significant difference in unclear vision or blind eyes or severe headache (P>0.05). There were statistical differences between the two groups in the time from the onset to the hospital (14.82±17.67 vs. 25.92±25.23), emergency medical services (EMS) (36.02 vs. 16.19%), number of patients coming to the hospital within 4.5 h (67 vs. 32), venous thrombolysis cases (55 vs. 17), DNT time (42.43±17.30 vs. 63.35±26.53), hemorrhagic transformation cases (11 vs. 21), and MRS score grade ≥2 (230 vs. 169) (P<0.05). Multi-level education can effectively improve the patient's awareness of stroke, encourage more patients to use EMS system to the hospital. More patients were aware that they should reach the hospital within 4.5 h. It helps shorten DNT time and give more patients the opportunity to receive intravenous thrombolysis or intravascular thrombectomy, which may improve the prognosis and reduce hemorrhagic transformation without reducing mortality.",2020,There was no statistical significant difference in unclear vision or blind eyes or severe headache (P>0.05).,"[""519 patients with acute ischemic stroke admitted to The First People's Hospital of Zhengzhou were invited to the study, 272 patients from the Guancheng district were divided into the experimental group, and 247 patients who were not from the Guancheng district but in the neighborhood of The First People's Hospital of Zhengzhou were divided into the control group"", 'residents and medical staff for one year in Guancheng district']",['multi-level stroke education'],"['venous thrombolysis cases', 'hemorrhagic transformation cases', 'stroke awareness', 'speech inarticulation', 'limb numbness', 'number of patients coming to the hospital', 'facial paralysis', 'walking instability with severe dizziness', 'emergency medical services (EMS', 'number of intravenous thrombolysis, door-to-needle time (DNT), modified Rankin scale (MRS) score', 'consciousness disorder', 'limb weakness', 'acute ischemic stroke', 'DNT time', 'unclear vision or blind eyes or severe headache']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0027569', 'cui_str': 'Neighborhood'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0025106', 'cui_str': 'Medical Staffs'}, {'cui': 'C4082117', 'cui_str': 'One year'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4303794', 'cui_str': 'Education about stroke'}]","[{'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0333275', 'cui_str': 'Hemorrhagic'}, {'cui': 'C3714584', 'cui_str': 'Transformation'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0239375', 'cui_str': 'Numbness of limbs'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205115', 'cui_str': 'Afferent'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0015469', 'cui_str': 'Facial palsy'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0085633', 'cui_str': 'Mood swings'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0013961', 'cui_str': 'Emergency medical services'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C1278452', 'cui_str': 'Time from arrival at facility to administration of parenteral treatment'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0009792', 'cui_str': 'Consciousness Disorders'}, {'cui': 'C0587246', 'cui_str': 'Muscle weakness of limb'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0271240', 'cui_str': 'Blindness of one eye'}, {'cui': 'C0018681', 'cui_str': 'Headache'}]",519.0,0.0228901,There was no statistical significant difference in unclear vision or blind eyes or severe headache (P>0.05).,"[{'ForeName': 'Xiaoman', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ""Department of Neurology, The First People's Hospital of Zhengzhou, Zhengzhou, Henan 450004, P.R. China.""}, {'ForeName': 'Yinfang', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': ""Department of Neurology, The First People's Hospital of Zhengzhou, Zhengzhou, Henan 450004, P.R. China.""}, {'ForeName': 'Xinhui', 'Initials': 'X', 'LastName': 'Cao', 'Affiliation': ""Department of Neurology, The First People's Hospital of Zhengzhou, Zhengzhou, Henan 450004, P.R. China.""}, {'ForeName': 'Xiaoyu', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': ""Department of Neurology, The First People's Hospital of Zhengzhou, Zhengzhou, Henan 450004, P.R. China.""}, {'ForeName': 'Yatao', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': ""Department of Neurology, The First People's Hospital of Zhengzhou, Zhengzhou, Henan 450004, P.R. China.""}, {'ForeName': 'Chaogang', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': ""Department of Neurology, The First People's Hospital of Zhengzhou, Zhengzhou, Henan 450004, P.R. China.""}]",Experimental and therapeutic medicine,['10.3892/etm.2020.9028'] 2868,32765813,"The fruit of Acanthopanax senticosus Harms improves arterial stiffness and blood pressure: a randomized, placebo-controlled trial.","BACKGROUND/OBJECTIVES Arterial stiffness and endothelial dysfunction are 2 of the independent predictors for cardiovascular disease, while Acanthopanax senticosus Harms (ASH) is a traditional medicinal plant that can improve cardiovascular health. This study aimed to investigate the efficacy of the fruit of ASH on vascular function in apparently healthy subjects. SUBJECTS/METHODS A 12-week, randomized, double-blind, placebo-controlled design, consisting of healthy adults with at least 2 of the following 3 conditions: borderline high blood pressure (BP; 120 mmHg ≤ systolic BP ≤ 160 mmHg or 80 mmHg ≤ diastolic BP ≤ 100 mmHg), smoking (≥10 cigarettes/day), and borderline blood lipid levels (220 ≤ total cholesterol ≤ 240, 130 ≤ low density lipoprotein cholesterol ≤ 165, or 150 ≤ triglyceride ≤ 220 mg/dL). Randomly assigned 76 subjects who received a placebo or 2 doses of ASH fruit (low, 500 mg/day; high, 1,000 mg/day) completed the intervention. Brachial-ankle pulse wave velocity (baPWV), flow-mediated dilation, carotid intima-media thickness, and BP were measured both at baseline and following the 12-week intervention. Endothelial nitric oxide synthase (eNOS) phosphorylation was assessed by western blotting. RESULTS Compared with the placebo group, the low-dose group showed more significant changes after the 12-week intervention period in terms of systolic BP (0.1 vs. -7.7 mmHg; P = 0.044), baPWV (31.3 vs. -98.7 cm/s; P = 0.007), and the ratio of phospho-eNOS/eNOS (0.8 vs. 1.22; P = 0.037). CONCLUSIONS These results suggest that ASH fruit extract at 500 mg/day has the potential to improve BP and arterial stiffness via endothelial eNOS activation in healthy adults with smoking and the tendency of having elevated BP or blood lipid parameters. Trial Registration Clinical Research Information Service Identifier: KCT0001072.",2020,"Compared with the placebo group, the low-dose group showed more significant changes after the 12-week intervention period in terms of systolic BP (0.1 vs. -7.7 mmHg; P = 0.044), baPWV (31.3 vs. -98.7 cm/s; P = 0.007), and the ratio of phospho-eNOS/eNOS (0.8 vs. 1.22; P = 0.037). ","['borderline high blood pressure (BP; 120 mmHg ≤ systolic BP ≤ 160 mmHg or 80 mmHg ≤ diastolic BP ≤ 100 mmHg), smoking (≥10 cigarettes/day), and borderline blood lipid levels (220 ≤ total cholesterol ≤ 240, 130 ≤ low density lipoprotein cholesterol ≤ 165, or 150 ≤ triglyceride ≤ 220 mg/dL', 'healthy adults with smoking', 'apparently healthy subjects', 'healthy adults with at least 2 of the following 3 conditions']","['fruit of ASH', 'placebo or 2 doses of ASH fruit', 'ASH fruit extract', 'placebo']","['baPWV', 'ratio of phospho-eNOS/eNOS', 'systolic BP', 'Endothelial nitric oxide synthase (eNOS) phosphorylation', 'BP and arterial stiffness via endothelial eNOS activation', 'Brachial-ankle pulse wave velocity (baPWV), flow-mediated dilation, carotid intima-media thickness, and BP', 'arterial stiffness and blood pressure', 'vascular function']","[{'cui': 'C2711208', 'cui_str': 'Borderline high'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0428460', 'cui_str': 'Lipid level - finding'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0994524', 'cui_str': 'Ash'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}]","[{'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0232154', 'cui_str': 'Ankle pulse'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0669365', 'cui_str': 'NOS3 protein, human'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0031715', 'cui_str': 'Phosphorylation'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0162864', 'cui_str': 'Tunica intima'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}]",76.0,0.364672,"Compared with the placebo group, the low-dose group showed more significant changes after the 12-week intervention period in terms of systolic BP (0.1 vs. -7.7 mmHg; P = 0.044), baPWV (31.3 vs. -98.7 cm/s; P = 0.007), and the ratio of phospho-eNOS/eNOS (0.8 vs. 1.22; P = 0.037). ","[{'ForeName': 'Eunkyoung', 'Initials': 'E', 'LastName': 'Oh', 'Affiliation': 'Department of Nutritional Science and Food Management, Ewha Womans University, Seoul 03760, Korea.'}, {'ForeName': 'Youjin', 'Initials': 'Y', 'LastName': 'Kim', 'Affiliation': 'Department of Nutritional Science and Food Management, Ewha Womans University, Seoul 03760, Korea.'}, {'ForeName': 'Soo-Yeon', 'Initials': 'SY', 'LastName': 'Park', 'Affiliation': 'Department of Nutritional Science and Food Management, Ewha Womans University, Seoul 03760, Korea.'}, {'ForeName': 'Yeni', 'Initials': 'Y', 'LastName': 'Lim', 'Affiliation': 'Department of Nutritional Science and Food Management, Ewha Womans University, Seoul 03760, Korea.'}, {'ForeName': 'Ji-Yoon', 'Initials': 'JY', 'LastName': 'Shin', 'Affiliation': 'Ewha Graduate School of Converging Clinical & Public Health, Seoul 03760, Korea.'}, {'ForeName': 'Ji Yeon', 'Initials': 'JY', 'LastName': 'Kim', 'Affiliation': 'Department of Food Science and Technology, Seoul National University of Science and Technology, Seoul 01811, Korea.'}, {'ForeName': 'Ji-Hyun', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Cardiovascular Center, Dongguk University Ilsan Hospital, Goyang 10326, Korea.'}, {'ForeName': 'Moo-Yong', 'Initials': 'MY', 'LastName': 'Rhee', 'Affiliation': 'Cardiovascular Center, Dongguk University Ilsan Hospital, Goyang 10326, Korea.'}, {'ForeName': 'Oran', 'Initials': 'O', 'LastName': 'Kwon', 'Affiliation': 'Department of Nutritional Science and Food Management, Ewha Womans University, Seoul 03760, Korea.'}]",Nutrition research and practice,['10.4162/nrp.2020.14.4.322'] 2869,32765876,Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial.,"Molecular targeted therapies are commonly used in patients with metastatic renal cell carcinoma (RCC). However, the efficacy and safety of these therapeutic interventions require enhancement to improve prognosis in these patients. Royal jelly (RJ) has anti-cancer effects and adverse events across a variety of types of malignancy. The present study investigated the detailed mechanism underlying the effects of oral administration of RJ in patients with advanced RCC that were treated with molecular targeted agents in a randomized clinical trial. The study cohort comprised 16 patients treated with RJ and 17 patients treated with a placebo. Serum levels of tumor necrosis factor (TNF)-α and transforming growth factor (TGF)-β were measured using enzyme-linked immunosorbent assays. The results of the present study demonstrated a larger decrease in tumor size upon supplementing patients with RJ following molecular targeted therapy compared with that in patients administered with the placebo. Patients exhibited reduced anorexia and fatigue in the RJ group compared with the placebo group. The relative dose intensity for patients in the RJ group was higher than that in patients in the placebo group. Post- and pre-treatment ratios of the serum levels of TNF-α and TGF-β in patients in the RJ group were lower than those in patients in the placebo group, and these ratios correlated with decreasing tumor size and frequency of anorexia or fatigue in patients. In conclusion, the results of the present study indicated that oral intake of RJ improved the efficacy and safety of molecular targeted therapy in patients with RCC and changed the levels of TNF-α and TGF-β in the serum of patients, which is speculated to serve an important role in RJ-induced biological activities.",2020,"Post- and pre-treatment ratios of the serum levels of TNF-α and TGF-β in patients in the RJ group were lower than those in patients in the placebo group, and these ratios correlated with decreasing tumor size and frequency of anorexia or fatigue in patients.","['patients with RCC', 'patients with advanced RCC', 'renal cell carcinoma', 'patients with metastatic renal cell carcinoma (RCC', '16 patients treated with RJ and 17 patients treated with a']","['TNF-α and TGF-β', 'Royal jelly (RJ', 'RJ', 'royal jelly', 'placebo']","['efficacy and safety', 'serum levels of TNF-α and TGF-β', 'anorexia and fatigue', 'anti-cancer effects', 'Serum levels of tumor necrosis factor (TNF)-α and transforming growth factor ', 'tumor size and frequency of anorexia or fatigue']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007134', 'cui_str': 'Renal cell carcinoma'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C4721698', 'cui_str': 'Metastatic renal cell carcinoma'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0073603', 'cui_str': 'royal jelly'}]","[{'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0040691', 'cui_str': 'Transforming Growth Factor'}, {'cui': 'C0073603', 'cui_str': 'royal jelly'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0040691', 'cui_str': 'Transforming Growth Factor'}, {'cui': 'C0003123', 'cui_str': 'Anorexia'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0475440', 'cui_str': 'Tumor size'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}]",,0.135046,"Post- and pre-treatment ratios of the serum levels of TNF-α and TGF-β in patients in the RJ group were lower than those in patients in the placebo group, and these ratios correlated with decreasing tumor size and frequency of anorexia or fatigue in patients.","[{'ForeName': 'Yasuyoshi', 'Initials': 'Y', 'LastName': 'Miyata', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.'}, {'ForeName': 'Kyohei', 'Initials': 'K', 'LastName': 'Araki', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.'}, {'ForeName': 'Kojiro', 'Initials': 'K', 'LastName': 'Ohba', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.'}, {'ForeName': 'Tomhiro', 'Initials': 'T', 'LastName': 'Mastuo', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.'}, {'ForeName': 'Yuichiro', 'Initials': 'Y', 'LastName': 'Nakamura', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.'}, {'ForeName': 'Tsutomu', 'Initials': 'T', 'LastName': 'Yuno', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.'}, {'ForeName': 'Yuta', 'Initials': 'Y', 'LastName': 'Mukai', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.'}, {'ForeName': 'Asato', 'Initials': 'A', 'LastName': 'Otsubo', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.'}, {'ForeName': 'Kensuke', 'Initials': 'K', 'LastName': 'Mitsunari', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.'}, {'ForeName': 'Yasushi', 'Initials': 'Y', 'LastName': 'Mochizuki', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Sakai', 'Affiliation': 'Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.'}]",Molecular and clinical oncology,['10.3892/mco.2020.2099'] 2870,32765902,Comparing the Effect of Monofocal and Multifocal Intraocular Lenses on Macular Surgery.,"Aim To compare the effects of previously implanted monofocal and multifocal intraocular lenses (IOL) on macular surgery. Methods Seventy eyes of 70 patients with epiretinal membrane (ERM) and symptomatic vitromacular traction syndrome that previously had IOL implantation for cataract surgery were included in this prospective randomized clinical trial. Cases were divided into two groups. Group 1 and Group 2 were composed of eyes with monofocal and multifocal IOLs, respectively. The effects of refraction error and IOL decentration at the time of macular surgery performed for ERM and ILM peeling, according to the lens type, were investigated. Pars plana vitrectomy (PPV) was performed to peel ERM and ILM in all cases. Complete ophthalmological examination, fundus fluorescein angiography, and optical coherence tomography imaging were made to all cases, preoperatively and postoperatively. Results The mean BCVA in Group 1 and Group 2 improved from 0.69 ± 0.15 and 0.38 ± 0.14 logMAR to 0.40 ± 0.14 and 0.10 ± 0.04 logMAR, respectively, at the 6 th month. There was no statistically significant difference between the groups in terms of the mean spherical refraction error ( P > 0.05) and IOL decentration level ( P > 0.05). The mean time required for macular surgery in Group 2 was statistically significantly longer than that for Group 1 ( P < 0.05). There was no statistically significant relationship between IOL decentration and macular surgery time in Group 1 ( P > 0.05), but there it was found in Group 2 ( P < 0.05). In Group 2, there was a positive correlation between IOL decentration and macular surgery time. Conclusion In cases with multifocal IOL implants, especially with lens decentration, the time of macular surgery for ERM and ILM peeling during PPV is longer than that of eyes with monofocal IOL due to fluctuations in the clarity of the surgeon's view.",2020,There was no statistically significant difference between the groups in terms of the mean spherical refraction error ( P > 0.05) and IOL decentration level ( P > 0.05).,"['Macular Surgery', 'Methods\n\n\nSeventy eyes of 70 patients with epiretinal membrane (ERM) and symptomatic vitromacular traction syndrome that previously had IOL implantation for cataract surgery']","['Pars plana vitrectomy (PPV', 'implanted monofocal and multifocal intraocular lenses (IOL', 'Monofocal and Multifocal Intraocular Lenses']","['mean time required for macular surgery', 'mean BCVA', 'mean spherical refraction error', 'IOL decentration level', 'IOL decentration and macular surgery time', 'Complete ophthalmological examination, fundus fluorescein angiography, and optical coherence tomography imaging']","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0339543', 'cui_str': 'Epiretinal membrane'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0040597', 'cui_str': 'Traction'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0023311', 'cui_str': 'Insertion of intraocular lens'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}]","[{'cui': 'C0563537', 'cui_str': 'Mechanical vitrectomy by pars plana approach'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0493722', 'cui_str': 'Multifocal Intraocular Lens'}, {'cui': 'C0023311', 'cui_str': 'Insertion of intraocular lens'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332501', 'cui_str': 'Spherical shape'}, {'cui': 'C0034951', 'cui_str': 'Disorder of refraction'}, {'cui': 'C2609312', 'cui_str': 'Intraocular lens decentration'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0200149', 'cui_str': 'Ophthalmic examination and evaluation'}, {'cui': 'C0430878', 'cui_str': 'Posterior segment fluorescein angiography'}, {'cui': 'C0920367', 'cui_str': 'Optical coherence tomography'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}]",70.0,0.026787,There was no statistically significant difference between the groups in terms of the mean spherical refraction error ( P > 0.05) and IOL decentration level ( P > 0.05).,"[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Altun', 'Affiliation': 'Bahcesehir University, Faculty of Medicine, Department of Ophthalmology, Istanbul, Turkey.'}]",Journal of ophthalmology,['10.1155/2020/1375298'] 2871,32769643,Botulinum Toxin A as a Treatment for Provoked Vestibulodynia: A Randomized Controlled Trial.,"OBJECTIVE To evaluate pain reduction after two injections of 50 units botulinum toxin A compared with placebo for provoked vestibulodynia. METHODS We conducted a double-blinded, placebo-controlled randomized trial of 50 units botulinum toxin A or placebo injected in the bulbocavernosus muscles twice, 3 months apart, in women with provoked vestibulodynia. Primary outcome was self-reported dyspareunia or pain at tampon use on a visual analog scale (VAS, 0-100). Secondary outcomes were pain at weekly tampon insertion (VAS score), reduction of pelvic floor hypertonicity (measured with a vaginal manometer), adverse events, and sexual function and distress. A sample size of 38 participants for each group was calculated to achieve a statistical power of 80% based on an effect size of 20 VAS units (0-100) (mean score range 56-76±31 SD). RESULTS Between May 2016 and June 2018, 124 women with provoked vestibulodynia were assessed, and 88 were randomized to botulinum toxin A (BTA group, n=44) or placebo (placebo group, n=44). Primary outcome showed a lower but statistically nonsignificant pain rating by 7 VAS units (95% CI -15.0 to 0.4) in the BTA group compared with the placebo group. Secondary results showed a significant decrease in pain at weekly tampon insertion by 11 VAS units (95% CI -16.6 to 6.0) with botulinum toxin A injection. The vaginal manometer measured lower maximum contraction strength by 7 mm Hg (95% CI -12.7 to -2.4) and lower 10-second endurance strength by 4 mm Hg (95% CI -7.72 to -1.16) in the BTA group compared with the placebo group. No changes were observed for sexual function and distress, but there was a significant increase in women attempting vaginal intercourse in the BTA group (0.27, 95% CI 0.06-0.48). No severe adverse events were reported. CONCLUSION Twice-repeated injections of 50 units of botulinum toxin A in women with provoked vestibulodynia did not reduce dyspareunia or pain at tampon use, but secondary outcomes suggested positive effects of the treatment. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT02773641.",2020,The vaginal manometer measured lower maximum contraction strength by 7 mm Hg (95% CI -12.7 to -2.4) and lower 10-second endurance strength by 4 mm,"['38 participants for each group was calculated to achieve a statistical power of 80% based on an effect size of 20 VAS units (0-100) (mean score range 56-76±31 SD', 'group, n=44', 'women with provoked vestibulodynia', 'Provoked Vestibulodynia', 'Between May 2016 and June 2018, 124 women with provoked vestibulodynia']","['Botulinum Toxin A', 'botulinum toxin A (BTA', '50 units botulinum toxin A or placebo', 'placebo (placebo', 'placebo']","['women attempting vaginal intercourse', 'sexual function and distress', 'severe adverse events', 'pain reduction', 'pain at weekly tampon insertion by 11 VAS units', 'self-reported dyspareunia or pain at tampon use on a visual analog scale (VAS, 0-100', 'pain at weekly tampon insertion (VAS score), reduction of pelvic floor hypertonicity (measured with a vaginal manometer), adverse events, and sexual function and distress', '10-second endurance strength', 'pain rating', 'maximum contraction strength', 'dyspareunia or pain']","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1444748', 'cui_str': 'Evoked'}, {'cui': 'C0269084', 'cui_str': 'Vulvar vestibulitis'}, {'cui': 'C4517553', 'cui_str': '124'}]","[{'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0278092', 'cui_str': 'Sexual function'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0039288', 'cui_str': 'Tampon'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0013394', 'cui_str': 'Pain in female genitalia on intercourse'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026826', 'cui_str': 'Increased muscle tone'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C2720530', 'cui_str': 'Manometer'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}]",124.0,0.796461,The vaginal manometer measured lower maximum contraction strength by 7 mm Hg (95% CI -12.7 to -2.4) and lower 10-second endurance strength by 4 mm,"[{'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Haraldson', 'Affiliation': 'Department of Clinical Sciences, Division of Obstetrics and Gynecology, Karolinska Institutet Danderyd Hospital, Stockholm, and the Center for Clinical Research, Uppsala University, County Council of Västmanland Central Hospital, and the School of Health, Care and Social Welfare, Mälardalen University, Västerås, Sweden.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Mühlrad', 'Affiliation': ''}, {'ForeName': 'Ulrika', 'Initials': 'U', 'LastName': 'Heddini', 'Affiliation': ''}, {'ForeName': 'Kent', 'Initials': 'K', 'LastName': 'Nilsson', 'Affiliation': ''}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Bohm-Starke', 'Affiliation': ''}]",Obstetrics and gynecology,['10.1097/AOG.0000000000004008'] 2872,32769647,Characteristics Associated With Treatment Failure 1 Year After Midurethral Sling in Women With Mixed Urinary Incontinence.,"OBJECTIVE To evaluate characteristics associated with treatment failure 1 year after midurethral sling in women with mixed urinary incontinence. METHODS Four hundred three women who participated in a randomized trial that compared midurethral sling and behavioral and pelvic floor muscle therapy (combined group) against midurethral sling alone for mixed incontinence with 1 year of follow-up data were eligible for this planned secondary analysis. Overall treatment failure was defined as meeting criteria for subjective failure, objective failure, or both. Subjective failure was defined as not meeting the minimal clinically important difference for improvement on the UDI (Urogenital Distress Inventory)-total score (26.1 points). Objective failure was not achieving 70% improvement on mean incontinence episodes of any type per day or having undergone any additional treatment for urinary symptoms at 12 months postoperative. Logistic regression models for treatment failure were constructed. Independent variables included site and treatment group, and clinical and demographic variables based on bivariate comparisons (P<.2). Treatment group interaction effects were evaluated. RESULTS Previous overactive bladder medication use (unadjusted odds ratio [OR] 2.19, adjusted odds ratio [aOR] 1.89, 95% CI 1.10-3.25), detrusor overactivity on cystometrogram (OR 2.25, aOR 2.72, 95% CI 1.53-4.84), body mass index (OR 1.29, aOR 1.27, 95% CI 1.03-1.57), and Valsalva leak point pressure less than 60 cm H2O (OR 1.96, aOR 3.13, 95% CI 1.65-5.94) were associated with overall failure. Worse UDI urgency scores were associated with failure in the midurethral sling-alone group. Sling type (retropubic vs transobturator) was not associated with failure. CONCLUSION Certain clinical and urodynamic variables are associated with treatment failure after midurethral sling among women with mixed urinary incontinence. Women with more severe urgency symptoms at baseline may benefit from perioperative behavioral and pelvic floor muscle therapy combined with midurethral sling. This information is helpful for counseling women with mixed incontinence who are considering surgery. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT01959347.",2020,Certain clinical and urodynamic variables are associated with treatment failure after midurethral sling among women with mixed urinary incontinence.,"['Four hundred three women who participated in a randomized trial that compared', 'counseling women with mixed incontinence who are considering surgery', 'women with mixed urinary incontinence', 'Women With Mixed Urinary Incontinence']","['Midurethral Sling', 'Sling type (retropubic vs transobturator', 'perioperative behavioral and pelvic floor muscle therapy combined with midurethral sling', 'midurethral sling', 'midurethral sling and behavioral and pelvic floor muscle therapy (combined group) against midurethral sling alone']","['Worse UDI urgency scores', 'UDI (Urogenital Distress Inventory)-total score', 'Subjective failure', 'body mass index', 'Valsalva leak point pressure', 'mean incontinence episodes', 'Overall treatment failure', 'detrusor overactivity on cystometrogram (OR 2.25, aOR', 'overall failure', 'Objective failure']","[{'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0341618', 'cui_str': 'Counsel'}, {'cui': 'C0869256', 'cui_str': 'Mixed urinary incontinence'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C3179501', 'cui_str': 'Mid-Urethral Slings'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205499', 'cui_str': 'Retropubic approach'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042066', 'cui_str': 'Structure of genitourinary system'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0332234', 'cui_str': 'Leaking'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0268849', 'cui_str': 'Detrusor overactivity'}, {'cui': 'C0200000', 'cui_str': 'Cystometrogram'}, {'cui': 'C4068875', 'cui_str': '2.25'}, {'cui': 'C0018017', 'cui_str': 'Goal'}]",403.0,0.319142,Certain clinical and urodynamic variables are associated with treatment failure after midurethral sling among women with mixed urinary incontinence.,"[{'ForeName': 'Vivian W', 'Initials': 'VW', 'LastName': 'Sung', 'Affiliation': ""Division of Urogynecology and Reconstructive Pelvic Surgery, Department of Obstetrics and Gynecology, Alpert Medical School of Brown University, Providence, Rhode Island; the Division of Urogynecology and Pelvic Reconstructive Surgery, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama; the Division of Urogynecology and Reconstructive Pelvic Surgery, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; the Division of Urogynecology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina; the Division of Female Pelvic Medicine & Reconstructive Surgery, Department of Obstetrics & Gynecology, Kaiser Permanente, Downey, California; the Division of Urology, Department of Surgery, Perelman School of Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania; the Division of Urogynecology, Department of Obstetrics and Gynecology, University of New Mexico, Albuquerque, New Mexico; the Center for Urogynecology and Reconstructive Pelvic Surgery, Obstetrics, Gynecology and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio; the Department of Physical Therapy, Rangos School of Health Sciences, Duquesne University, Pittsburgh, Pennsylvania; the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland; and Social, Statistical, & Environmental Sciences, RTI International, Research Triangle Park, North Carolina.""}, {'ForeName': 'Holly E', 'Initials': 'HE', 'LastName': 'Richter', 'Affiliation': ''}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Moalli', 'Affiliation': ''}, {'ForeName': 'Alison C', 'Initials': 'AC', 'LastName': 'Weidner', 'Affiliation': ''}, {'ForeName': 'John N', 'Initials': 'JN', 'LastName': 'Nguyen', 'Affiliation': ''}, {'ForeName': 'Ariana L', 'Initials': 'AL', 'LastName': 'Smith', 'Affiliation': ''}, {'ForeName': 'Gena', 'Initials': 'G', 'LastName': 'Dunivan', 'Affiliation': ''}, {'ForeName': 'Beri', 'Initials': 'B', 'LastName': 'Ridgeway', 'Affiliation': ''}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Borello-France', 'Affiliation': ''}, {'ForeName': 'Diane K', 'Initials': 'DK', 'LastName': 'Newman', 'Affiliation': ''}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Mazloomdoost', 'Affiliation': ''}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Carper', 'Affiliation': ''}, {'ForeName': 'Marie G', 'Initials': 'MG', 'LastName': 'Gantz', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Obstetrics and gynecology,['10.1097/AOG.0000000000003989'] 2873,32769657,Two Intraoperative Techniques for Midurethral Sling Tensioning: A Randomized Controlled Trial.,"OBJECTIVE To evaluate whether the use of a Mayo Scissor as a suburethral spacer compared with a Babcock clamp holding a loop of tape under the urethra results in different rates of abnormal bladder outcomes 12 months after retropubic midurethral sling surgery. METHODS The MUST (Mid-Urethral Sling Tensioning) trial was a block-randomized, double-blind, multicenter clinical trial that allocated women to have their retropubic midurethral slings tensioned by Scissor or Babcock technique. The primary outcome (abnormal bladder) was a composite of persistent stress urinary incontinence (SUI), overactive bladder, and urinary retention. Secondary outcomes included outcomes of the composite, postoperative catheterization, incontinence-related questionnaires, repeat incontinence treatment, and uroflowmetry. Sample size of 159 in each arm (N=318) was planned for a superiority trial, hypothesizing a 10% difference in primary outcome. RESULTS From September 2015 to December 2017, 506 women were screened and 318 were randomized. Baseline characteristics were similar in each arm. At 12 months, 253 (79.6%) women provided information on primary outcome: 40 of 128 (31.3%) patients with midurethral slings tensioned by Scissor experienced abnormal bladder, compared with 23 of 125 (18.4%) of those with midurethral slings tensioned by Babcock (P=.018, relative difference 12.9%). Secondary analyses favored Babcock for median duration of catheterization and the proportions of women experiencing urinary retention requiring sling lysis. Uroflowmetry parameters suggest the Scissor technique is more restrictive. Rates of mesh erosion were lower for the Scissor arm. No differences occurred in proportions of women experiencing patient reported persistent SUI after surgery. CONCLUSION Abnormal bladder outcomes were 12.9% less frequent for women with midurethral slings tensioned by Babcock. Both techniques provided a comparable patient reported cure for SUI at 12 months. Women with midurethral slings tensioned by Scissors experienced more intervention for obstruction, whereas those with midurethral slings tensioned by Babcock experienced higher rates of mesh erosion. This information about how the postoperative courses differ allows surgeons to better counsel patients preoperatively or tailor their choice of technique. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT02480231. FUNDING SOURCE Boston Scientific.",2020,Abnormal bladder outcomes were 12.9% less frequent for women with midurethral slings tensioned by Babcock.,"['From September 2015 to December 2017, 506 women were screened and 318 were randomized', 'allocated women to have their retropubic midurethral slings tensioned by Scissor or Babcock technique']","['retropubic midurethral sling surgery', 'Babcock clamp holding a loop of tape', 'Midurethral Sling Tensioning', 'Mayo Scissor']","['Rates of mesh erosion', 'primary outcome (abnormal bladder) was a composite of persistent stress urinary incontinence (SUI), overactive bladder, and urinary retention', 'median duration of catheterization and the proportions of women experiencing urinary retention requiring sling lysis', 'Abnormal bladder outcomes', 'abnormal bladder', 'rates of mesh erosion', 'outcomes of the composite, postoperative catheterization, incontinence-related questionnaires, repeat incontinence treatment, and uroflowmetry']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C3179501', 'cui_str': 'Mid-Urethral Slings'}, {'cui': 'C0233494', 'cui_str': 'Tension'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0205499', 'cui_str': 'Retropubic approach'}, {'cui': 'C3179501', 'cui_str': 'Mid-Urethral Slings'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0175721', 'cui_str': 'Clamp'}, {'cui': 'C0675390', 'cui_str': 'ARID1A protein, human'}, {'cui': 'C4505203', 'cui_str': 'A-Loop'}, {'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C1272733', 'cui_str': 'Mayo scissors'}]","[{'cui': 'C0181805', 'cui_str': 'Mesh'}, {'cui': 'C0333307', 'cui_str': 'Superficial ulcer'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C0005682', 'cui_str': 'Urinary bladder structure'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C0878773', 'cui_str': 'Overactive bladder'}, {'cui': 'C0080274', 'cui_str': 'Bladder retention of urine'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0183346', 'cui_str': 'Sling'}, {'cui': 'C0024348', 'cui_str': 'Lysis'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0200008', 'cui_str': 'Uroflowmetry'}]",506.0,0.669678,Abnormal bladder outcomes were 12.9% less frequent for women with midurethral slings tensioned by Babcock.,"[{'ForeName': 'Erin A', 'Initials': 'EA', 'LastName': 'Brennand', 'Affiliation': 'Department of Obstetrics & Gynecology, the Department of Community Health Sciences, the Division of Urology, Department of Surgery, Cumming School of Medicine, University of Calgary, Calgary, Alberta, the Department of Obstetrics & Gynecology, University of British Columbia, Vancouver, British Columbia, the Department of Obstetrics & Gynecology, University of Manitoba, Winnipeg, Manitoba, the Department of Obstetrics & Gynecology, University of Toronto, Toronto, Ontario, the Department of Obstetrics & Gynecology, University of Alberta, Edmonton, Alberta, Canada; and the Department of Obstetrics & Gynecology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.'}, {'ForeName': 'Guosong', 'Initials': 'G', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Houlihan', 'Affiliation': ''}, {'ForeName': 'Dobrochna', 'Initials': 'D', 'LastName': 'Globerman', 'Affiliation': ''}, {'ForeName': 'Louise-Helene', 'Initials': 'LH', 'LastName': 'Gagnon', 'Affiliation': ''}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Birch', 'Affiliation': ''}, {'ForeName': 'Momoe', 'Initials': 'M', 'LastName': 'Hyakutake', 'Affiliation': ''}, {'ForeName': 'Kevin V', 'Initials': 'KV', 'LastName': 'Carlson', 'Affiliation': ''}, {'ForeName': 'Hanan', 'Initials': 'H', 'LastName': 'Al-Shankiti', 'Affiliation': ''}, {'ForeName': 'Magali', 'Initials': 'M', 'LastName': 'Robert', 'Affiliation': ''}, {'ForeName': 'Darren', 'Initials': 'D', 'LastName': 'Lazare', 'Affiliation': ''}, {'ForeName': 'Shunaha', 'Initials': 'S', 'LastName': 'Kim-Fine', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Obstetrics and gynecology,['10.1097/AOG.0000000000004027'] 2874,32769658,Outpatient Foley Catheter for Induction of Labor in Nulliparous Women: A Randomized Controlled Trial.,"OBJECTIVE To assess whether outpatient cervical ripening with a transcervical Foley catheter in nulliparous women undergoing elective labor induction shortens the time from admission to delivery. METHODS We performed a randomized controlled trial of patients with singleton pregnancies undergoing elective labor induction at 39 weeks of gestation or more with a modified Bishop score less than 5. Women were randomized 1:1 to outpatient or inpatient transcervical Foley. In the outpatient group, the Foley was inserted the day before admission for scheduled induction; insertion was performed at scheduled admission in the inpatient group. The primary outcome was duration of time from admission to the labor and delivery unit to delivery. With 80% power and a two-sided α of 0.05, a sample size of 126 was estimated to detect at least a 5-hour mean difference in time from admission to delivery between groups from a baseline duration of 19±10 hours. RESULTS From May 2018 to October 2019, 126 women were randomized, 63 in each group. Baseline characteristics were balanced between groups, except that body mass index (31±5.4 vs 34±7.5, P=.01) and group B streptococcus colonization (31% vs 54%, P=.01) were lower in the outpatient group. The time from admission to delivery was shorter in the outpatient group (17.4±7.4 vs 21.7±9.1 hours, P<.01, mean difference 4.3 hours, 95% CI 1.3-7.2). Admissions before scheduled induction were higher in the outpatient group (22% vs 5%, relative risk [RR] 4.7, 95% CI 1.4-15.4, P<.01), as was median modified Bishop score on admission (3 vs 1, P<.01). Cesarean delivery (24% vs 32%, RR 0.8, 95% CI 0.4-1.3, P=.32) and chorioamnionitis (22% vs 13%, RR 1.8, 95% CI 0.8-3.9, P=.16) were not significantly different between groups. CONCLUSION In nulliparous patients undergoing elective labor induction at term, outpatient cervical ripening with a transcervical Foley catheter reduced the time from admission to delivery. CLINCAL TRIAL REGISTRATION ClinicalTrials.gov, NCT03472937.",2020,"Admissions before scheduled induction were higher in the outpatient group (22% vs 5%, relative risk [RR]","['nulliparous patients undergoing elective labor induction at term, outpatient cervical ripening with a', 'patients with singleton pregnancies undergoing elective labor induction at 39 weeks of gestation or more with a modified Bishop score less than 5', 'Nulliparous Women', 'nulliparous women undergoing elective labor induction shortens the time from admission to delivery', 'From May 2018 to October 2019, 126 women were randomized, 63 in each group']","['outpatient cervical ripening with a transcervical Foley catheter', 'transcervical Foley catheter', 'Outpatient Foley Catheter', 'inpatient transcervical Foley']","['duration of time from admission to the labor and delivery unit to delivery', 'Cesarean delivery', 'relative risk [RR', 'time from admission to delivery', 'streptococcus colonization', 'chorioamnionitis']","[{'cui': 'C0425979', 'cui_str': 'Nulliparous'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0259787', 'cui_str': 'Induction of labor'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2225498', 'cui_str': 'Bishop score'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0442344', 'cui_str': 'Transcervical approach - uterine'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C1321138', 'cui_str': 'Labor and delivery unit'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C0008495', 'cui_str': 'Chorioamnionitis'}]",126.0,0.316198,"Admissions before scheduled induction were higher in the outpatient group (22% vs 5%, relative risk [RR]","[{'ForeName': 'Elizabeth B', 'Initials': 'EB', 'LastName': 'Ausbeck', 'Affiliation': ""Center for Women's Reproductive Health, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama; and Tri-State Perinatology, Deaconess-The Women's Hospital, Newburgh, Indiana.""}, {'ForeName': 'Victoria C', 'Initials': 'VC', 'LastName': 'Jauk', 'Affiliation': ''}, {'ForeName': 'Yumo', 'Initials': 'Y', 'LastName': 'Xue', 'Affiliation': ''}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Files', 'Affiliation': ''}, {'ForeName': 'Spencer G', 'Initials': 'SG', 'LastName': 'Kuper', 'Affiliation': ''}, {'ForeName': 'Akila', 'Initials': 'A', 'LastName': 'Subramaniam', 'Affiliation': ''}, {'ForeName': 'Brian M', 'Initials': 'BM', 'LastName': 'Casey', 'Affiliation': ''}, {'ForeName': 'Jeff M', 'Initials': 'JM', 'LastName': 'Szychowski', 'Affiliation': ''}, {'ForeName': 'Lorie M', 'Initials': 'LM', 'LastName': 'Harper', 'Affiliation': ''}, {'ForeName': 'Alan T', 'Initials': 'AT', 'LastName': 'Tita', 'Affiliation': ''}]",Obstetrics and gynecology,['10.1097/AOG.0000000000004041'] 2875,32769818,A Non-Invasive Stroke Volume Monitoring for Early Detection of Minimal Blood Loss: A Pilot Study.,"INTRODUCTION Alternation in traditional vital signs can only be observed during advanced stages of hypovolemia and shortly before the hemodynamic collapse. However, even minimal blood loss induces a decrease in the cardiac preload which translates to a decrease in stroke volume, but these indices are not readily monitored. We aimed to determine whether minor hemodynamic alternations induced by controlled and standardized hypovolemia can be detected by a whole-body bio-impedance technology. METHODS This was a non-randomized controlled trial that enrolled healthy blood donors. Vital signs, as well as shock index and stroke volume (SV), were recorded using NiCAS, a non-invasive whole-body impedance-based hemodynamic analysis system, during phlebotomy. RESULTS Sixty subjects were included in the study group and 20 in the control group. Blood loss of 450 ml resulted in a significant decrease in systolic blood pressure (5 mmHg; 95% CI 3, 6) and SV (5.07 ml; 95% CI 3.21, 6.92), and increase in shock index (0.03 bpm/mmHg; 95% CI 0.01, 0.05). Clinically detectable changes (≥10%) in blood pressure and shock index were detectable in 15% and 5%, respectively. SV decreased by more than 10% in 40% of blood donors. No significant changes occurred in the control group. CONCLUSION Continuous non-invasive monitoring of SV may be superior to conventional indices (e.g. heart rate, blood pressure or shock index) for early identification of acute blood loss. As an operator-independent and point of care technology, the SV whole body bio-impedance measurement may assist in accurate monitoring of potentially bleeding patients and early identification of hemorrhage.",2020,"Blood loss of 450 ml resulted in a significant decrease in systolic blood pressure (5 mmHg; 95% CI 3, 6) and SV (5.07 ml; 95% CI 3.21, 6.92), and increase in shock index (0.03 bpm/mmHg; 95% CI 0.01, 0.05).","['enrolled healthy blood donors', 'Early Detection of Minimal Blood Loss', 'Sixty subjects were included in the study group and 20 in the control group']",[],"['stroke volume', 'shock index and stroke volume (SV', 'shock index', 'heart rate, blood pressure or shock index', 'SV', 'systolic blood pressure', 'blood pressure and shock index', 'Blood loss']","[{'cui': 'C0005795', 'cui_str': 'Blood donor'}, {'cui': 'C0596473', 'cui_str': 'Early Diagnosis'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],"[{'cui': 'C0038455', 'cui_str': 'Stroke volume'}, {'cui': 'C0036974', 'cui_str': 'Shock'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]",60.0,0.127406,"Blood loss of 450 ml resulted in a significant decrease in systolic blood pressure (5 mmHg; 95% CI 3, 6) and SV (5.07 ml; 95% CI 3.21, 6.92), and increase in shock index (0.03 bpm/mmHg; 95% CI 0.01, 0.05).","[{'ForeName': 'Danny', 'Initials': 'D', 'LastName': 'Epstein', 'Affiliation': 'Department of Internal Medicine ""B"", Rambam Health Care Campus, Haifa, Israel.'}, {'ForeName': 'Ariel', 'Initials': 'A', 'LastName': 'Guinzburg', 'Affiliation': 'Medical Corps, Israeli Defense Forces, Tel-Hashomer, Israel.'}, {'ForeName': 'Saar', 'Initials': 'S', 'LastName': 'Sharon', 'Affiliation': 'Medical Corps, Israeli Defense Forces, Tel-Hashomer, Israel.'}, {'ForeName': 'Shai', 'Initials': 'S', 'LastName': 'Kiso', 'Affiliation': 'Medical Corps, Israeli Defense Forces, Tel-Hashomer, Israel.'}, {'ForeName': 'Yuval', 'Initials': 'Y', 'LastName': 'Glick', 'Affiliation': 'Medical Corps, Israeli Defense Forces, Tel-Hashomer, Israel.'}, {'ForeName': 'Erez', 'Initials': 'E', 'LastName': 'Marcusohn', 'Affiliation': 'Department of Cardiology, Rambam Health Care Campus, Haifa, Israel.'}, {'ForeName': 'Yehuda Daniel', 'Initials': 'YD', 'LastName': 'Glass', 'Affiliation': 'Medical Intensive Care Unit, Rambam Health Care Campus, Haifa, Israel.'}, {'ForeName': 'Asaf', 'Initials': 'A', 'LastName': 'Miller', 'Affiliation': 'Medical Intensive Care Unit, Rambam Health Care Campus, Haifa, Israel.'}, {'ForeName': ""Sa'ar"", 'Initials': 'S', 'LastName': 'Minha', 'Affiliation': 'Department of Cardiology, Shamir Medical Center, Zerifin, Israel.'}, {'ForeName': 'Ariel', 'Initials': 'A', 'LastName': 'Furer', 'Affiliation': 'Medical Corps, Israeli Defense Forces, Tel-Hashomer, Israel.'}]","Shock (Augusta, Ga.)",['10.1097/SHK.0000000000001621'] 2876,32769826,Predictors of Intervention Adherence in Compensatory Cognitive Training for Veterans With a History of Mild Traumatic Brain Injury.,"OBJECTIVE The purpose of this study was to determine modifiable predictors of intervention adherence in a study of group-based Compensatory Cognitive Training (CCT) for Iraq/Afghanistan War veterans with a history of mild traumatic brain injury (mTBI). METHODS One hundred twenty-three veterans enrolled in a randomized controlled trial of a 10-week CCT intervention (54 assigned to CCT) and were evaluated at baseline, 5 weeks, 10 weeks, and 15 weeks. CCT adherence was determined by the number of CCT sessions attended, with more sessions indicative of greater adherence. Baseline demographic and clinical characteristics, and subjective and objective neuropsychological performance, were examined in relation to CCT session attendance. RESULTS Older age and worse attention performance at baseline were associated with higher CCT attendance rates. CONCLUSIONS This study generates preliminary evidence for potential modifiable neuropsychological factors that may improve engagement in CCT interventions.",2020,"RESULTS Older age and worse attention performance at baseline were associated with higher CCT attendance rates. ","['Iraq/Afghanistan War veterans with a history of mild traumatic brain injury (mTBI', 'One hundred twenty-three veterans enrolled', 'Veterans With a History of Mild Traumatic Brain Injury']","['CCT intervention (54 assigned to CCT', 'Compensatory Cognitive Training', 'group-based Compensatory Cognitive Training (CCT']","['attention performance', 'CCT attendance rates', 'Baseline demographic and clinical characteristics, and subjective and objective neuropsychological performance', 'CCT adherence']","[{'cui': 'C0022066', 'cui_str': 'Iraq'}, {'cui': 'C0001732', 'cui_str': 'Afghanistan'}, {'cui': 'C0043027', 'cui_str': 'War'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0450348', 'cui_str': '23'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",123.0,0.10293,"RESULTS Older age and worse attention performance at baseline were associated with higher CCT attendance rates. ","[{'ForeName': 'Zanjbeel', 'Initials': 'Z', 'LastName': 'Mahmood', 'Affiliation': ""SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, California (Ms Mahmood); Research Service (Ms Mahmood and Dr Twamley), Center of Excellence for Stress and Mental Health (Drs Clark, Jak and Twamley), and Psychology Service (Dr Jak), VA San Diego Healthcare System, San Diego, California; Department of Psychiatry, University of California San Diego (Drs Clark, Jak and Twamley); VA Portland Health Care System, Portland, Oregon (Drs Huckans, O'Neil, Roost, and Storzbach); Departments of Psychiatry (Drs Huckans, O'Neil, and Storzbach), Medical Informatics and Clinical Epidemiology (Dr O'Neil), and Neurology (Dr Storzbach), Oregon Health & Science University, Portland; VA Puget Sound Health Care System, Seattle, Washington (Drs Williams, Pagulayan and Turner); and Departments of Rehabilitation Medicine (Drs Williams and Turner) and Psychiatry and Behavioral Sciences (Dr Pagulayan), University of Washington School of Medicine, Seattle.""}, {'ForeName': 'Jillian M R', 'Initials': 'JMR', 'LastName': 'Clark', 'Affiliation': ''}, {'ForeName': 'Amy J', 'Initials': 'AJ', 'LastName': 'Jak', 'Affiliation': ''}, {'ForeName': 'Marilyn', 'Initials': 'M', 'LastName': 'Huckans', 'Affiliation': ''}, {'ForeName': 'Maya E', 'Initials': 'ME', 'LastName': 'OʼNeil', 'Affiliation': ''}, {'ForeName': 'Mai S', 'Initials': 'MS', 'LastName': 'Roost', 'Affiliation': ''}, {'ForeName': 'Rhonda M', 'Initials': 'RM', 'LastName': 'Williams', 'Affiliation': ''}, {'ForeName': 'Kathleen F', 'Initials': 'KF', 'LastName': 'Pagulayan', 'Affiliation': ''}, {'ForeName': 'Aaron P', 'Initials': 'AP', 'LastName': 'Turner', 'Affiliation': ''}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Storzbach', 'Affiliation': ''}, {'ForeName': 'Elizabeth W', 'Initials': 'EW', 'LastName': 'Twamley', 'Affiliation': ''}]",The Journal of head trauma rehabilitation,['10.1097/HTR.0000000000000596'] 2877,32769833,Concussion Symptom Treatment and Education Program: A Feasibility Study.,"OBJECTIVE To evaluate the feasibility and potential benefits of a manualized, brief cognitive-behavioral therapy-based intervention program for children and adolescents with persistent postconcussive symptoms. SETTING Two outpatient pediatric concussion programs in the United States. PARTICIPANTS Patients aged 8 to 17 years who sustained concussions between 2 and 12 months prior to enrollment. DESIGN Pre-/postretrospective study. MAIN MEASURES SCAT-3; HBI; PedsQL 4.0 Generic Core Scales; and RCADS. RESULTS Thirty children and adolescents completed the treatment program. Self- and parent-reported postconcussive symptoms, quality of life, and internalizing symptoms significantly improved with treatment. Mixed-effects models revealed a significant decline in self-reported postconcussive symptoms across treatment sessions, a = -2.07, SE = 0.25, P < .001. The largest change occurred between sessions 2 and 3, following the session focusing on concussion psychoeducation and sleep hygiene (estimated mean change between sessions 2 and 3 = -4.72, P < .0001). CONCLUSIONS Our findings indicate that a 6-session manualized cognitive behavioral intervention is feasible to initiate in an outpatient clinic 1 to 12 months following a pediatric mild traumatic brain injury. With a manualized format, clinicians at most levels of training should be able to implement this treatment manual and flexibly adapt as needed when working with children and adolescents who are experiencing delayed symptom recovery following concussion.",2020,"Self- and parent-reported postconcussive symptoms, quality of life, and internalizing symptoms significantly improved with treatment.","['Two outpatient pediatric concussion programs in the United States', 'children and adolescents with persistent postconcussive symptoms', 'Thirty children and adolescents completed the treatment program', 'Patients aged 8 to 17 years who sustained concussions between 2 and 12 months prior to enrollment']","['Concussion Symptom Treatment and Education Program', '6-session manualized cognitive behavioral intervention', 'manualized, brief cognitive-behavioral therapy-based intervention program']","['concussion psychoeducation and sleep hygiene', 'Self- and parent-reported postconcussive symptoms, quality of life, and internalizing symptoms']","[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}]","[{'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C4277672', 'cui_str': 'Good Sleep Habits'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",30.0,0.0277906,"Self- and parent-reported postconcussive symptoms, quality of life, and internalizing symptoms significantly improved with treatment.","[{'ForeName': 'Tess S', 'Initials': 'TS', 'LastName': 'Simpson', 'Affiliation': ""Department of Physical Medicine & Rehabilitation, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora (Drs Simpson, Peterson, and Forster); Department of Neurology, University of Washington School of Medicine and Seattle Children's Hospital, Seattle (Dr Patrick); Rocky Mountain Mental Illness Research, Education, and Clinical Center for Veteran Suicide Prevention, Rocky Mountain Regional Veterans Affairs (VA) Medical Facility, Aurora, Colorado (Dr Forster); and Department of Pediatrics, The Ohio State University and Nationwide Children's Hospital, Columbus (Dr McNally).""}, {'ForeName': 'Robin L', 'Initials': 'RL', 'LastName': 'Peterson', 'Affiliation': ''}, {'ForeName': 'Kristina E', 'Initials': 'KE', 'LastName': 'Patrick', 'Affiliation': ''}, {'ForeName': 'Jeri E', 'Initials': 'JE', 'LastName': 'Forster', 'Affiliation': ''}, {'ForeName': 'Kelly A', 'Initials': 'KA', 'LastName': 'McNally', 'Affiliation': ''}]",The Journal of head trauma rehabilitation,['10.1097/HTR.0000000000000592'] 2878,32769914,Effect of butylphthalide on new cerebral microbleeds in patients with acute ischemic stroke.,"BACKGROUND To evaluate the effect of dl-3-N-butylphthalide (NBP) on new cerebral microbleeds (CMBs) in patients with acute ischemic stroke (AIS). METHODS We will prospectively enroll patients with AIS admitted to the stroke center of Jingjiang People's Hospital. Qualified participants will be randomly assigned to either the NBP group (NBP injection) or the control group (NBP injection placebo) in a ratio of 1:1. Patients will complete the brain magnetic resonance imaging within 48 hours and 14 days after stroke onset to observe the CMBs through susceptibility weighted imaging, and evaluate whether the use of NBP will affect the new CMBs in AIS patients. SPSS 20.0 will be used for statistical analyses. RESULT We will provide practical and targeted results assessing the safety of NBP for AIS patients, to provide reference for clinical use of NBP. CONCLUSION The stronger evidence about the effect of NBP on new CMBs in AIS patients will be provided for clinicians.",2020,Qualified participants will be randomly assigned to either the NBP group (NBP injection) or the control group (NBP injection placebo) in a ratio of 1:1.,"[""enroll patients with AIS admitted to the stroke center of Jingjiang People's Hospital"", 'patients with acute ischemic stroke (AIS', 'patients with acute ischemic stroke']","['butylphthalide', 'dl-3-N-butylphthalide (NBP', 'NBP group (NBP injection) or the control group (NBP injection placebo', 'NBP']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0047625', 'cui_str': '3-n-butylphthalide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.122005,Qualified participants will be randomly assigned to either the NBP group (NBP injection) or the control group (NBP injection placebo) in a ratio of 1:1.,"[{'ForeName': 'Yunlong', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': ""Department of Neurology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jiangsu, China.""}, {'ForeName': 'Zhiqun', 'Initials': 'Z', 'LastName': 'Gu', 'Affiliation': ""Department of Neurology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jiangsu, China.""}, {'ForeName': 'Tingting', 'Initials': 'T', 'LastName': 'Zhai', 'Affiliation': ""Department of Neurology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jiangsu, China.""}, {'ForeName': 'Wenjuan', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': ""Department of Neurology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jiangsu, China.""}, {'ForeName': 'Yanrong', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ""Department of Neurology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jiangsu, China.""}, {'ForeName': 'Can', 'Initials': 'C', 'LastName': 'Wei', 'Affiliation': ""Department of Neurology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jiangsu, China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': ""Department of Neurology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jiangsu, China.""}, {'ForeName': 'Jiali', 'Initials': 'J', 'LastName': 'Niu', 'Affiliation': ""Department of Clinical Pharmacy, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jiangsu, China.""}]",Medicine,['10.1097/MD.0000000000021594'] 2879,32769919,"Light-emitting diode photobiomodulation therapy for non-specific low back pain in working nurses: A single-center, double-blind, prospective, randomized controlled trial.","BACKGROUND Low back pain (LBP) affects approximately 51% to 57% of hospital nurses and nurses' aides in Europe. New high-risk groups include home- and long-term-care nurses and physiotherapists. A number of European countries are experiencing a shortage of healthcare workers. Light therapy has been shown to be an effective treatment for various musculoskeletal disorders, including lateral epicondylitis, temporomandibular joint pain, carpal tunnel syndrome, and delayed-onset muscle soreness. A systematic review and meta-analysis demonstrated that low-level laser therapy is an effective method for relieving non-specific chronic low back pain (NSCLBP). However, the efficacy of light-emitting diode (LED) therapy for NSCLBP is disputed. This study aims to evaluate the effect of LED therapy on NSCLBP. METHODS AND ANALYSIS We conducted a prospective, double-blind, randomized placebo-controlled trial of 148 patients with NSCLBP. The patients were randomly assigned to 2 groups: intervention group, where patients received LED photobiomodulation therapy 3 times a week for 2 weeks, and the sham group, where patients had sham therapy 3 times a week for 2 weeks. Primary outcome measures included the visual analog scale for pain, lumbar active range of motion assessments, and chair-rising times. Secondary outcome measures included a multidimensional fatigue inventory, fear-avoidance beliefs questionnaire, and the Oswestry disability index. The outcome measures were assessed before therapy and 2weeks, 4 weeks, 8 weeks, 12 weeks, and 6 months after the first interventions were completed. DISCUSSION This study is a prospective, single-center, double-blind, randomized, controlled study. This study aims to research the efficacy of a 2-week LED program for NSCLBP working nurse. Our results will be useful for patients, working nurses, nurses' aides, and other healthcare workers with chronic low back pain. TRIAL REGISTRATION NUMBER NCT04424823.",2020,"Secondary outcome measures included a multidimensional fatigue inventory, fear-avoidance beliefs questionnaire, and the Oswestry disability index.","['non-specific low back pain in working nurses', ""hospital nurses and nurses' aides in Europe"", ""patients, working nurses, nurses' aides, and other healthcare workers with chronic low back pain"", '148 patients with NSCLBP']","['Light-emitting diode photobiomodulation therapy', 'LED therapy', 'light-emitting diode (LED) therapy', 'low-level laser therapy', 'LED photobiomodulation therapy', 'Light therapy', 'placebo']","['visual analog scale for pain, lumbar active range of motion assessments, and chair-rising times', 'multidimensional fatigue inventory, fear-avoidance beliefs questionnaire, and the Oswestry disability index']","[{'cui': 'C0205370', 'cui_str': 'Non-specific'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0557351', 'cui_str': 'Employed'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C1271036', 'cui_str': 'Hospital nurse'}, {'cui': 'C0028663', 'cui_str': 'Nursing aid'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}]","[{'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0162676', 'cui_str': 'Enzyme-multiplied immunoassay technique'}, {'cui': 'C4019433', 'cui_str': 'Photobiomodulation Therapy'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C0031765', 'cui_str': 'Light therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C1444228', 'cui_str': 'Range of motion assessment'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}]",148.0,0.57227,"Secondary outcome measures included a multidimensional fatigue inventory, fear-avoidance beliefs questionnaire, and the Oswestry disability index.","[{'ForeName': 'Yen-Po', 'Initials': 'YP', 'LastName': 'Lin', 'Affiliation': 'National Taiwan University Hospital Hsin-Chu Branch, Hsinchu City.'}, {'ForeName': 'Ying-Hao', 'Initials': 'YH', 'LastName': 'Su', 'Affiliation': 'National Taiwan University Hospital Hsin-Chu Branch, Hsinchu City.'}, {'ForeName': 'Shih-Fang', 'Initials': 'SF', 'LastName': 'Chin', 'Affiliation': 'National Taiwan University Hospital Hsin-Chu Branch, Hsinchu City.'}, {'ForeName': 'Yu-Ching', 'Initials': 'YC', 'LastName': 'Chou', 'Affiliation': 'School of Public Health, National Defense Medical Center, Taipei, Taiwan (R.O.C.).'}, {'ForeName': 'Wei-Tso', 'Initials': 'WT', 'LastName': 'Chia', 'Affiliation': 'National Taiwan University Hospital Hsin-Chu Branch, Hsinchu City.'}]",Medicine,['10.1097/MD.0000000000021611'] 2880,32769965,Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.,"Adults with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) have a poor prognosis, especially if disease burden is high. This post hoc analysis of the phase 3 INO-VATE trial examined the efficacy and safety of inotuzumab ozogamicin (InO) vs. standard of care chemotherapy (SC) among R/R ALL patients with low, moderate, or high disease burden, respectively, defined as bone marrow blasts (BMB) < 50% (n = 53 vs. 48), 50-90% (n = 79 vs. 83), and >90% (n = 30 vs. 30). Patients in the InO vs. SC arm with low, moderate, and high BMB%, respectively, had improved rates of complete remission/complete remission with incomplete hematologic recovery (74% vs. 46% [p = 0.0022], 75 vs. 27% [p < 0.0001], and 70 vs. 17% [p < 0.0001]), and improved overall survival (hazard ratio: 0.64 [p = 0.0260], 0.81 [p = 0.1109], and 0.60 [p = 0.0335]). Irrespective of BMB%, cytopenias were the most common treatment-emergent adverse events, and post-transplant veno-occlusive disease was more common with InO vs. SC. Patients with extramedullary disease or lymphoblastic lymphoma showed similar efficacy and safety outcomes. This favorable benefit-to-risk ratio of InO treatment irrespective of disease burden supports its use in challenging and high disease burden subpopulations. INO-VATE is registered at www.clinicaltrials.gov : #NCT01564784.",2020,"Irrespective of BMB%, cytopenias were the most common treatment-emergent adverse events, and post-transplant veno-occlusive disease was more common with InO vs. SC.","['relapsed/refractory acute lymphoblastic leukemia', 'Patients with extramedullary disease or lymphoblastic lymphoma', 'R/R ALL patients with low, moderate, or high disease burden, respectively, defined as bone marrow blasts (BMB)\u2009<\u200950% (n\u2009=\u200953 vs. 48), 50-90% (n\u2009=\u200979 vs. 83), and >90% (n\u2009=\u200930 vs. 30', 'Adults with relapsed/refractory acute lymphoblastic leukemia (R/R ALL']","['Inotuzumab ozogamicin', 'inotuzumab ozogamicin (InO) vs. standard of care chemotherapy (SC']","['rates of complete remission/complete remission with incomplete hematologic recovery', 'overall survival']","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0023449', 'cui_str': 'Acute lymphoid leukemia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0079748', 'cui_str': 'Precursor cell lymphoblastic lymphoma'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0005953', 'cui_str': 'Bone marrow structure'}, {'cui': 'C0337026', 'cui_str': 'Blast'}, {'cui': 'C0439083', 'cui_str': '>90'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C1567130', 'cui_str': 'inotuzumab ozogamicin'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0205257', 'cui_str': 'Incomplete'}, {'cui': 'C0018943', 'cui_str': 'Hematology'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.0996714,"Irrespective of BMB%, cytopenias were the most common treatment-emergent adverse events, and post-transplant veno-occlusive disease was more common with InO vs. SC.","[{'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'DeAngelo', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA, 02215, USA. Daniel_Deangelo@dfci.harvard.edu.'}, {'ForeName': 'Anjali S', 'Initials': 'AS', 'LastName': 'Advani', 'Affiliation': 'Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, 44106, USA.'}, {'ForeName': 'David I', 'Initials': 'DI', 'LastName': 'Marks', 'Affiliation': 'University Hospitals Bristol, Bristol, BS1 3NU, UK.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Stelljes', 'Affiliation': 'Universitätsklinikum Münster, 48149, Münster, Germany.'}, {'ForeName': 'Michaela', 'Initials': 'M', 'LastName': 'Liedtke', 'Affiliation': 'Stanford Cancer Institute, Stanford, CA, 94304, USA.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Stock', 'Affiliation': 'University of Chicago, Chicago, IL, 60637, USA.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Gökbuget', 'Affiliation': 'Goethe University Hospital, 60596, Frankfurt, Germany.'}, {'ForeName': 'Elias', 'Initials': 'E', 'LastName': 'Jabbour', 'Affiliation': 'University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.'}, {'ForeName': 'Akil', 'Initials': 'A', 'LastName': 'Merchant', 'Affiliation': 'Cedars Sinai Medical Center, Los Angeles, CA, 90048, USA.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Wang', 'Affiliation': 'Pfizer Inc, Cambridge, MA, 02139, USA.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Vandendries', 'Affiliation': 'Pfizer Inc, Cambridge, MA, 02139, USA.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Neuhof', 'Affiliation': 'Pfizer Pharma GmbH, 10785, Berlin, Germany.'}, {'ForeName': 'Hagop', 'Initials': 'H', 'LastName': 'Kantarjian', 'Affiliation': 'University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': ""O'Brien"", 'Affiliation': 'Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA, 92697, USA.'}]",Blood cancer journal,['10.1038/s41408-020-00345-8'] 2881,32770131,"A randomized, double-blind water taste test to evaluate the equivalence of taste between tap water and filtered water in the Taipei metropolis.","High water quality and sufficient water availability are the main concerns of water users. Promoting the efficient use of tap water can contribute to sustainable drinking water management and progress towards Sustainable Development Goals. In many metropolises, water suppliers treat municipal water with appropriate treatment processes and well-maintained distribution infrastructure. Under this circumstance, it is acceptable that municipal water can be a source of drinking water. The presence of residual chlorine in tap water, connected to municipal water supply, inactivates pathogenic microorganisms and prevents recontamination. However, adding chlorine to tap water may affect the organoleptic properties of drinking water. On the other hand, the use of point-of-use (POU) water dispensers, which provides an additional treatment step on tap water, is not energy-efficient. A randomized, double-blind water taste test was conducted in the Taipei metropolis to assess whether tap water from public drinking fountains and filtered water from POU water dispensers have similar organoleptic properties. An odds ratio (OR) and the area under the receiver operating characteristic curve (AUC) were used to measure the participants' ability to distinguish between the two water varieties. A five-region hypothesis test was conducted to test the OR, and a 95% bootstrap confidence interval of the AUC was calculated. The results of the study showed that the 95% five-region confidence interval of OR equal to (0.5, 1.49), and the 95% bootstrap confidence interval of AUC equal to (0.42, 0.56). These results implied that people in the Taipei metropolis could not distinguish between tap water and filtered water. It is recommended that more drinking fountains be installed and maintained fully functional and clean to achieve excellence in tap water access.",2020,"The presence of residual chlorine in tap water, connected to municipal water supply, inactivates pathogenic microorganisms and prevents recontamination.",[],[],"['odds ratio (OR) and the area under the receiver operating characteristic curve (AUC', 'organoleptic properties of drinking water']",[],[],"[{'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0034772', 'cui_str': 'Receiver Operating Characteristic'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C0599638', 'cui_str': 'Drinking Water'}]",,0.0565847,"The presence of residual chlorine in tap water, connected to municipal water supply, inactivates pathogenic microorganisms and prevents recontamination.","[{'ForeName': 'Jing-Rong', 'Initials': 'JR', 'LastName': 'Jhuang', 'Affiliation': 'Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Rm. 536, No. 17, Xuzhou Rd., Taipei, 100, Taiwan.'}, {'ForeName': 'Wen-Chung', 'Initials': 'WC', 'LastName': 'Lee', 'Affiliation': 'Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Rm. 536, No. 17, Xuzhou Rd., Taipei, 100, Taiwan. wenchung@ntu.edu.tw.'}, {'ForeName': 'Chang-Chuan', 'Initials': 'CC', 'LastName': 'Chan', 'Affiliation': 'Innovation and Policy Center for Population Health and Sustainable Environment, College of Public Health, National Taiwan University, Taipei, Taiwan. ccchan@ntu.edu.tw.'}]",Scientific reports,['10.1038/s41598-020-70272-y'] 2882,32770186,"How to Teach Medical Students About Pain and Dementia: E-Learning, Experiential Learning, or Both?","OBJECTIVE Pain management in persons with mild to moderate dementia poses unique challenges because of altered pain modulation and the tendency of some individuals to perseverate. We aimed to test the impact of an e-learning module about pain in communicative people with dementia on third-year medical students who had or had not completed an experiential geriatrics course. DESIGN Analysis of pre- to postlearning changes and comparison of the same across the student group. SETTING University of Pittsburgh School of Medicine and Saint Louis University School of Medicine. SUBJECTS One hundred four University of Pittsburgh and 57 Saint Louis University medical students. METHODS University of Pittsburgh students were randomized to view either the pain and dementia module or a control module on pain during a five-day geriatrics course. Saint Louis University students were asked to complete either of the two modules without the context of a geriatrics course. A 10-item multiple choice knowledge test and three-item attitudes and confidence questionnaires were administered before viewing the module and up to seven days later. RESULTS Knowledge increase was significantly greater among students who viewed the dementia module while participating in the geriatrics course than among students who viewed the module without engaging in the course (P < 0.001). The modules did not improve attitudes in any group, while student confidence improved in all groups. CONCLUSIONS Medical students exposed to e-learning or experiential learning demonstrated improved confidence in evaluating and managing pain in patients with dementia. Those exposed to both educational methods also significantly improved their knowledge.",2020,"The modules did not improve attitudes in any group, while student confidence improved in all groups. ","['University of Pittsburgh students', 'Saint Louis University students', 'patients with dementia', 'communicative people with dementia on third-year medical students who had or had not completed an experiential geriatrics course', 'One hundred four University of Pittsburgh and 57 Saint Louis University medical students', 'Teach Medical Students About Pain and Dementia', 'University of Pittsburgh School of Medicine and Saint Louis University School of Medicine', 'persons with mild to moderate dementia']","['e-learning module about pain', 'pain and dementia module or a control module']","['student confidence', 'confidence in evaluating and managing pain']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0014048', 'cui_str': 'St. Louis encephalitis virus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C1444661', 'cui_str': 'Stopped before completion'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}]","[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]",,0.0317668,"The modules did not improve attitudes in any group, while student confidence improved in all groups. ","[{'ForeName': 'Keelin', 'Initials': 'K', 'LastName': 'Moehl', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Rollin M', 'Initials': 'RM', 'LastName': 'Wright', 'Affiliation': 'Department of Medicine (Geriatric Medicine), University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Shega', 'Affiliation': 'VITAS Healthcare and University of Central Florida, Orlando, Florida.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Malec', 'Affiliation': 'Department of Medicine (Geriatric and Palliative Medicine), University of Chicago, Chicago, Illinois.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Kelley Fitzgerald', 'Affiliation': 'Department of Physical Therapy, University of Pittsburgh School of Health and Rehabilitation Science, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Gregg', 'Initials': 'G', 'LastName': 'Robbins-Welty', 'Affiliation': 'Duke University Hospital, Durham, North Carolina.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Zoberi', 'Affiliation': 'Saint Louis University School of Medicine, St. Louis, Missouri.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Tait', 'Affiliation': 'Saint Louis University School of Medicine, St. Louis, Missouri.'}, {'ForeName': 'Subashan', 'Initials': 'S', 'LastName': 'Perera', 'Affiliation': 'VITAS Healthcare and University of Central Florida, Orlando, Florida.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Deverts', 'Affiliation': 'Office of Research, University of Pittsburgh School of Dental Medicine, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Zsuzsa', 'Initials': 'Z', 'LastName': 'Horvath', 'Affiliation': 'Department of Dental Public Health, University of Pittsburgh School of Dental Medicine, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Debra K', 'Initials': 'DK', 'LastName': 'Weiner', 'Affiliation': 'Department of Medicine (Geriatric Medicine), University of Pittsburgh, Pittsburgh, Pennsylvania.'}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pnaa187'] 2883,32765963,Impact of a Maternal Prevention of Mother-to-child Transmission of HIV (PMTCT) Intervention on HIV-exposed Infants in Uganda.,"Background Uganda has successfully reduced pediatric HIV infections through prevention of mother-to-child transmission of HIV (PMTCT) programs, yet little is known about adherence to infant-specific components of interventions. We hypothesized that infants born to mothers receiving the WiseMama (WM) electronic drug monitoring (EDM)-based adherence intervention would have increased uptake of six-week post-natal nevirapine (NVP) infant prophylaxis and better adherence to six-week early infant diagnosis (EID) HIV testing. Methods At two sites in Uganda, the Wise Infant Study (WIN) prospectively followed an infant cohort. Infants were born to women enrolled in an RCT testing the effect of real-time reminders delivered via EDM on maternal adherence to antiretroviral therapy. We assessed intrapartum and discharge receipt of NVP prophylaxis using pharmacy and infant HIV DNA testing laboratory data. Results Of 121 women eligible for WIN, 97 (80%) consented and enrolled; 46 had been randomized to control and 51 to intervention. There were no differences in receipt of a six-week NVP supply (control 87%, intervention 82%, p = 0.53). Receipt of any NVP prophylaxis did not vary by delivery location (p = 0.35), and although 12% of infants were delivered at non-study health facilities, they were not less likely to receive NVP at discharge (p = 0.37). Among infants with a completed HIV test, there was no difference in mean time to first test (control 52 days (SD 18), intervention 51 days (SD 15), p = 0.86). Only one infant, in the control group, tested positive for HIV. Conclusion and Global Health Implications We found no significant differences in adherence to infant PMTCT practices between intervention and control infants with relatively high rates of NVP receipt albeit with suboptimal adherence to six-week EID testing. Further work is needed to ensure improved access, uptake, and follow-up of HIV-exposed infants in the Option B+ era.",2020,"There were no differences in receipt of a six-week NVP supply (control 87%, intervention 82%, p = 0.53).","['infants born to mothers receiving the', '121 women eligible for WIN, 97 (80%) consented and enrolled; 46', 'HIV-exposed Infants in Uganda']","['WiseMama (WM) electronic drug monitoring (EDM)-based adherence intervention', 'Maternal Prevention of Mother-to-child Transmission of HIV (PMTCT']","['mean time to first test', 'receipt of a six-week NVP supply']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0041573', 'cui_str': 'Uganda'}]","[{'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0085421', 'cui_str': 'Medication monitoring'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0282474', 'cui_str': 'Infection Transmission, Maternal-Fetal'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0132326', 'cui_str': 'Nevirapine'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}]",121.0,0.121712,"There were no differences in receipt of a six-week NVP supply (control 87%, intervention 82%, p = 0.53).","[{'ForeName': 'Anays', 'Initials': 'A', 'LastName': 'Murillo', 'Affiliation': 'Department of Global Health, Boston University School of Public Health, Boston University, 801 Massachusetts Avenue Crosstown Center, 3 Floor, Boston, MA, 02118 USA.'}, {'ForeName': 'Mary Bachman', 'Initials': 'MB', 'LastName': 'DeSilva', 'Affiliation': 'University of New England, 716 Stevens Ave, Portland, ME, 04103 USA.'}, {'ForeName': 'Lora L', 'Initials': 'LL', 'LastName': 'Sabin', 'Affiliation': 'Department of Global Health, Boston University School of Public Health, Boston University, 801 Massachusetts Avenue Crosstown Center, 3 Floor, Boston, MA, 02118 USA.'}, {'ForeName': 'Nafisa', 'Initials': 'N', 'LastName': 'Halim', 'Affiliation': 'Department of Global Health, Boston University School of Public Health, Boston University, 801 Massachusetts Avenue Crosstown Center, 3 Floor, Boston, MA, 02118 USA.'}, {'ForeName': 'Harriet', 'Initials': 'H', 'LastName': 'Chemusto', 'Affiliation': 'Mildmay Uganda, Lweza Kampala-Entebbe Road, Kampala, Uganda.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Aroda', 'Affiliation': 'Mildmay Uganda, Lweza Kampala-Entebbe Road, Kampala, Uganda.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Gasuza', 'Affiliation': 'Mildmay Uganda, Lweza Kampala-Entebbe Road, Kampala, Uganda.'}, {'ForeName': 'Davidson H', 'Initials': 'DH', 'LastName': 'Hamer', 'Affiliation': 'Department of Global Health, Boston University School of Public Health, Boston University, 801 Massachusetts Avenue Crosstown Center, 3 Floor, Boston, MA, 02118 USA.'}, {'ForeName': 'Anna Larson', 'Initials': 'AL', 'LastName': 'Williams', 'Affiliation': 'Department of Global Health, Boston University School of Public Health, Boston University, 801 Massachusetts Avenue Crosstown Center, 3 Floor, Boston, MA, 02118 USA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Mukasa', 'Affiliation': 'Mildmay Uganda, Lweza Kampala-Entebbe Road, Kampala, Uganda.'}, {'ForeName': 'Lisa J', 'Initials': 'LJ', 'LastName': 'Messersmith', 'Affiliation': 'Department of Global Health, Boston University School of Public Health, Boston University, 801 Massachusetts Avenue Crosstown Center, 3 Floor, Boston, MA, 02118 USA.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Bonawitz', 'Affiliation': 'Department of Global Health, Boston University School of Public Health, Boston University, 801 Massachusetts Avenue Crosstown Center, 3 Floor, Boston, MA, 02118 USA.'}]",International journal of MCH and AIDS,['10.21106/ijma.380'] 2884,32766034,Does the Approach of the Lateral Platysmal Bands Widen the Gap between the Medial Bands?,"Background The first visible change in an aging face and neck is the loss of neck contour, which can be corrected by treating the platysmal bands; however, it remains unclear as to which is the best strategy to approach these bands. The aim of the present study is to verify whether the lateral platysmal bands approaches, before the medial ones, cause widening of the gap between them. Methods This is a prospective, randomized, comparative study involving 30 individuals presenting various stages of neck and facial flaccidity and sagging. The patients were split into 2 groups according to the lateral platysmal approach (group A: lateral platysmal traction/plication; group B: lateral platysmal undermined/traction). A protocol was established to measure the gap between the medial bands, 3 and 5 cm away from the chin, before and after superficial musculoaponeurotic system/platysma lateral suspension. Measurements were taken using a compass and a ruler. The endpoint was to determine whether the gap between the medial platysmal bands widens after the lateral procedure. Results Group A, first measure (1-M): the gap ranged between 1.0 and 1.6 cm in point M3 (3 cm away from chin) and between 1.8 and 3.0 cm in point M5 (5 cm away from chin) (mean in M3 = 1.2; SD, 0.22 and mean in M5 =2.3; SD, 0.52). Group A, second measure (2-M): the measure ranged between 1.0 and 1.7 cm in point M3 and between 1.8 and 3.2 cm in point M5 (mean = 1.28; SD, 0.25 and mean = 2.42; SD, 0.63, respectively). Group B, first measure (1-M): the gap ranged between 1.1 and 1.7 cm in M3 (mean = 1.32; SD, 0.21) and between 1.8 and 3.2 cm in M5 (mean = 2.38; SD, 0.57). Group B, second measure (2-M): the measure ranged between 1.2 and 1.7 cm in M3 (mean = 1.4; SD, 0.18) and between 2.0 and 3.2 cm in M5 (mean = 2.5; SD, 0.55). Group A: P = 0.07 (M3) and 0.10 (M5); Group B: P = 0.09 (M3) and 0.07 (M5). Conclusion The lateral platysmal approach, plication or undermined, does not lead to a widening of the gap between the medial platysmal bands.",2020,"Group A: P = 0.07 (M3) and 0.10 (M5); Group B: P = 0.09 (M3) and 0.07 (M5). ",['30 individuals presenting various stages of neck and facial flaccidity and sagging'],['lateral platysmal approach (group A: lateral platysmal traction/plication; group B: lateral platysmal undermined/traction'],[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0026825', 'cui_str': 'Flaccidity - muscle'}, {'cui': 'C0574427', 'cui_str': 'Sango language'}]","[{'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0040597', 'cui_str': 'Traction'}, {'cui': 'C0185026', 'cui_str': 'Plication'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}]",[],30.0,0.0192337,"Group A: P = 0.07 (M3) and 0.10 (M5); Group B: P = 0.09 (M3) and 0.07 (M5). ","[{'ForeName': 'Luiz', 'Initials': 'L', 'LastName': 'Charles-de-Sá', 'Affiliation': 'Department of Plastic Reconstructive and Aesthetic Surgery, University of the Estate of Rio de Janeiro (UERJ), Rio de Janeiro, Brazil.'}, {'ForeName': 'Natale F', 'Initials': 'NF', 'LastName': 'Gontijo-de-Amorim', 'Affiliation': 'Pitanguy School and Perform Clinic, Rio de Janeiro, Brazil.'}, {'ForeName': 'Valéria', 'Initials': 'V', 'LastName': 'Loureiro Claro', 'Affiliation': 'Department of Plastic Reconstructive and Aesthetic Surgery, University of the Estate of Rio de Janeiro (UERJ), Rio de Janeiro, Brazil.'}, {'ForeName': 'Diogo Maciel Lobão', 'Initials': 'DML', 'LastName': 'Vieira', 'Affiliation': 'Department of Plastic Reconstructive and Aesthetic Surgery, University of the Estate of Rio de Janeiro (UERJ), Rio de Janeiro, Brazil.'}, {'ForeName': 'Gustavo Maltez', 'Initials': 'GM', 'LastName': 'de Andrade', 'Affiliation': 'Department of Plastic Reconstructive and Aesthetic Surgery, University of the Estate of Rio de Janeiro (UERJ), Rio de Janeiro, Brazil.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Dantas-Rocha', 'Affiliation': 'Department of Plastic Reconstructive and Aesthetic Surgery, University of the Estate of Rio de Janeiro (UERJ), Rio de Janeiro, Brazil.'}, {'ForeName': 'Cláudio Gonçalves Ramos', 'Initials': 'CGR', 'LastName': 'da Silva', 'Affiliation': 'Department of Plastic Reconstructive and Aesthetic Surgery, University of the Estate of Rio de Janeiro (UERJ), Rio de Janeiro, Brazil.'}, {'ForeName': 'José Horácio', 'Initials': 'JH', 'LastName': 'Abboudib', 'Affiliation': 'Department of Plastic Reconstructive and Aesthetic Surgery, University of the Estate of Rio de Janeiro (UERJ), Rio de Janeiro, Brazil.'}, {'ForeName': 'Cláudio Cardoso', 'Initials': 'CC', 'LastName': 'de Castro', 'Affiliation': 'Department of Plastic Reconstructive and Aesthetic Surgery, University of the Estate of Rio de Janeiro (UERJ), Rio de Janeiro, Brazil.'}]",Plastic and reconstructive surgery. Global open,['10.1097/GOX.0000000000002853'] 2885,32766042,Effect of Platelet Rich Plasma versus Saline Solution as a Preservation Solution for Hair Transplantation.,"Background Hair transplantation is the only method available to regrow new hairs; hence, enhancing the results of this procedure using state-of-the-art methods has become mandatory in clinical practice. Recent studies have suggested that significant improvements in hair density and stimulation of hair growth occur when follicular units are pretreated with platelet plasma growth factors before implantation. This study aimed to investigate and compare the outcomes of this procedure using platelet-rich plasma (PRP)-preserved hair grafts and saline-preserved hair grafts. Methods This is a randomized controlled study. The study included 27 men and 3 women aged 22-51 years. Clinical examination (general and local) and preoperative marking were performed in these patients. The surgical technique involved graft extraction, PRP preparation, and hair implantation. Postsurgical patient satisfaction and clinical improvement were evaluated. Results There were significant differences between the groups in hair uptake and hair thickness after 1 year follow-up, with P value <0.05. Using PRP therapy with follicular unit extraction increases the success of follicular unit extraction hair transplantation. All participants in the PRP group had >75% hair regrowth after 6 months. They had more rapid improvements in hair density and skin recovery than those in the non-PRP group. Conclusion Preserving hair grafts in PRP before implantation increases the hair density, the graft uptake, and the hair thickness compared with pretreatment preservation of hair grafts in saline.",2020,"There were significant differences between the groups in hair uptake and hair thickness after 1 year follow-up, with P value <0.05.","['Hair Transplantation', '27 men and 3 women aged 22-51 years']","['PRP therapy with follicular unit extraction', 'Platelet Rich Plasma versus Saline Solution', 'platelet-rich plasma (PRP)-preserved hair grafts and saline-preserved hair grafts']","['hair density, the graft uptake, and the hair thickness', 'hair density and stimulation of hair growth', 'hair density and skin recovery', 'Postsurgical patient satisfaction and clinical improvement', 'hair regrowth', 'hair uptake and hair thickness']","[{'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C4727879', 'cui_str': 'Platelet rich plasma therapy'}, {'cui': 'C0439682', 'cui_str': 'Follicular'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}]","[{'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0232407', 'cui_str': 'Hair growth'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",27.0,0.090237,"There were significant differences between the groups in hair uptake and hair thickness after 1 year follow-up, with P value <0.05.","[{'ForeName': 'Rasha', 'Initials': 'R', 'LastName': 'Abdelkader', 'Affiliation': 'Department of Plastic Surgery, Alkasr Allni Hospital, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Sahar', 'Initials': 'S', 'LastName': 'Abdalbary', 'Affiliation': 'Orthopaedic Physical Therapy Department, Alkasr Alainy Hospital, Cairo University, Cairo, Egpyt.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Naguib', 'Affiliation': 'Department of Plastic Surgery, Alkasr Allni Hospital, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Kyrillos', 'Initials': 'K', 'LastName': 'Makarem', 'Affiliation': 'Department of Plastic Surgery, Alkasr Allni Hospital, Cairo University, Cairo, Egypt.'}]",Plastic and reconstructive surgery. Global open,['10.1097/GOX.0000000000002875'] 2886,32766263,"Peripheral Enthesitis Detected by Ultrasonography in Patients With Axial Spondyloarthritis-Anatomical Distribution, Morphology, and Response to Tumor Necrosis Factor-Inhibitor Therapy.","Objectives: To investigate the anatomical distribution, morphological abnormalities and response to adalimumab therapy of ultrasound(US)-detected peripheral enthesitis in patients with axial spondyloarthritis (SpA). Methods: In a randomized, placebo-controlled, double-blinded, investigator-initiated trial (NCT01029847), patients with axial SpA according to the Assessment of Spondyloarthritis International Society criteria were randomized to subcutaneous adalimumab 40 mg every other week or placebo from baseline to week 6. From week 6 to 24, all patients received adalimumab 40 mg every other week. Of 49 patients enrolled, 21 patients participated in our observational US sub-study. US assessment applying the OMERACT US definitions for enthesitis of 10 peripheral entheseal regions of the upper and lower extremities and clinical examination were performed at baseline, weeks 6 and 24. US was performed by one experienced investigator. Hypo-echogenicity, increased thickness and Doppler activity of the enthesis were considered signs of active inflammation, whereas insertional bone erosions, intratendinous calcifications, and enthesophytes were regarded as signs of structural lesions. Results: Enthesitis on US was mostly present in the lower limbs, especially in the Achilles tendon (81%), the quadriceps tendon (62%), and the greater femoral trochanter (52%). Structural lesions were predominant (38 vs. 12% of examined entheses with inflammatory changes), particularly in the entheses of the lower limbs, and exhibited no change during treatment. Conclusion: US-detected structural lesions were common while inflammatory lesions were relatively rare in patients initiating adalimumab due to axial SpA. Structural lesions did not appear to change during 24 weeks follow-up, suggesting that these lesions may not be helpful outcome measures in short-term clinical trials.",2020,"Structural lesions were predominant (38 vs. 12% of examined entheses with inflammatory changes), particularly in the entheses of the lower limbs, and exhibited no change during treatment. ","['patients with axial SpA according to the Assessment of Spondyloarthritis International Society criteria', 'patients with axial spondyloarthritis (SpA', '49 patients enrolled, 21 patients participated in our observational US sub-study']","['placebo', 'subcutaneous adalimumab 40 mg every other week or placebo', 'adalimumab', 'adalimumab therapy of ultrasound(US)-detected peripheral enthesitis']","['Hypo-echogenicity, increased thickness and Doppler activity', 'quadriceps tendon', 'greater femoral trochanter']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205131', 'cui_str': 'Axial'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0949690', 'cui_str': 'Arthritis of spine'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C3203547', 'cui_str': 'Axial spondyloarthritis'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C1122087', 'cui_str': 'adalimumab'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4302634', 'cui_str': 'Adalimumab therapy'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}]","[{'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0554756', 'cui_str': 'Doppler studies'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0224941', 'cui_str': 'Structure of quadriceps tendon'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0162370', 'cui_str': 'Trochanter'}]",49.0,0.115992,"Structural lesions were predominant (38 vs. 12% of examined entheses with inflammatory changes), particularly in the entheses of the lower limbs, and exhibited no change during treatment. ","[{'ForeName': 'Sengul', 'Initials': 'S', 'LastName': 'Seven', 'Affiliation': 'Copenhagen Center for Arthritis Research and Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.'}, {'ForeName': 'Susanne Juhl', 'Initials': 'SJ', 'LastName': 'Pedersen', 'Affiliation': 'Copenhagen Center for Arthritis Research and Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.'}, {'ForeName': 'Mikkel', 'Initials': 'M', 'LastName': 'Østergaard', 'Affiliation': 'Copenhagen Center for Arthritis Research and Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.'}, {'ForeName': 'Sara Kamp', 'Initials': 'SK', 'LastName': 'Felbo', 'Affiliation': 'Copenhagen Center for Arthritis Research and Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.'}, {'ForeName': 'Inge Juul', 'Initials': 'IJ', 'LastName': 'Sørensen', 'Affiliation': 'Copenhagen Center for Arthritis Research and Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.'}, {'ForeName': 'Uffe Møller', 'Initials': 'UM', 'LastName': 'Døhn', 'Affiliation': 'Copenhagen Center for Arthritis Research and Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.'}, {'ForeName': 'Lene', 'Initials': 'L', 'LastName': 'Terslev', 'Affiliation': 'Copenhagen Center for Arthritis Research and Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.'}]",Frontiers in medicine,['10.3389/fmed.2020.00341'] 2887,32766301,"Borassus aethiopum -Fortified Bread Reduces Metabolic Risk Factors among Cardiovascular Disease Outpatients at 37 Military Hospital, Accra: A Pilot Study.","Background Dyslipidemia and hypertension are the leading causes of morbidity and mortality in patients with cardiovascular diseases (CVDs). Objective The study sought to evaluate the effects of Borassus aethiopum -fortified bread on metabolic risk factors among CVD outpatients. Method From August 2016 to April 2017, a pilot study using a single-blinded randomized placebo-controlled trial was conducted by administering Borassus -fortified bread (150 g) and indistinguishable placebo (150 g white flour bread) daily to 122 CVD outpatients at 37 Military Hospital, Accra, Ghana, for 90 days. Body composition, blood pressure, and biochemical parameters were evaluated before and after the intervention. Results Following the intervention, the mean waist circumference (before: 98.3 ± 14.6 cm, after: 95.9 ± 15.8 cm, P = 0.030), BMI (before: 31.4 ± 6.9 kg/m 2 , after: 28.0 ± 5.8 kg/m 2 , P = 0.027), and visceral fat (before: 10.4 ± 3.2, after: 9.9 ± 3.0, P = 0.013), as well as systolic (from 161.2 ± 25.5 to 137.6 ± 22.9and diastolic (from 99.2 ± 13.6 to 85.1 ± 10.8) blood pressure, were significantly reduced among the experimental group. Likewise, serum total cholesterol (TC), LDL, and HDL were significantly reduced within the experimental group before (TC: 5.9 ± 1.1, LDL: 3.4 ± 1.1, and HDL: 2.2 ± 0.5) and after the intervention (TC: 4.9 ± 1.1, LDL: 2.8 ± 0.9, and HDL: 1.5 ± 0.4) (TC: P = 0.001, LDL: P = 0.016, and HDL: P < 0.001, in mmol/L). These reductions were not observed in the controls. Conclusion The Borassus -fortified bread significantly reduced blood pressure and improved lipid profile and other metabolic risk factors among the CVD outpatients studied. Therefore, its potential in the management of CVDs and other metabolic-related diseases should be looked at.",2020,The Borassus -fortified bread significantly reduced blood pressure and improved lipid profile and other metabolic risk factors among the CVD outpatients studied.,"['Cardiovascular Disease Outpatients at 37 Military Hospital, Accra', '122 CVD outpatients at 37 Military Hospital, Accra, Ghana, for 90 days', 'Method\n\n\nFrom August 2016 to April 2017', 'CVD outpatients', 'patients with cardiovascular diseases (CVDs']","['Borassus -fortified bread (150\u2009g) and indistinguishable placebo', 'Borassus aethiopum -fortified bread', 'placebo']","['blood pressure', 'Likewise, serum total cholesterol (TC), LDL, and HDL', 'mean waist circumference', 'BMI', 'Body composition, blood pressure, and biochemical parameters', 'metabolic risk factors', 'blood pressure and improved lipid profile and other metabolic risk factors', 'visceral fat', 'Metabolic Risk Factors']","[{'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0020012', 'cui_str': 'Military Hospitals'}, {'cui': 'C0017516', 'cui_str': 'Ghana'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0006138', 'cui_str': 'Bread'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C1563740', 'cui_str': 'Abdominal Visceral Fat'}]",,0.0336266,The Borassus -fortified bread significantly reduced blood pressure and improved lipid profile and other metabolic risk factors among the CVD outpatients studied.,"[{'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Apprey', 'Affiliation': 'Department of Biochemistry and Biotechnology, Faculty of Biosciences, College of Science, Kwame Nkrumah University of Science and Technology, PMB KNUST, Kumasi, Ghana.'}, {'ForeName': 'Marian', 'Initials': 'M', 'LastName': 'Peprah', 'Affiliation': 'Department of Biochemistry and Biotechnology, Faculty of Biosciences, College of Science, Kwame Nkrumah University of Science and Technology, PMB KNUST, Kumasi, Ghana.'}, {'ForeName': 'Reginald Adjetey', 'Initials': 'RA', 'LastName': 'Annan', 'Affiliation': 'Department of Biochemistry and Biotechnology, Faculty of Biosciences, College of Science, Kwame Nkrumah University of Science and Technology, PMB KNUST, Kumasi, Ghana.'}, {'ForeName': 'Marina A', 'Initials': 'MA', 'LastName': 'Tandoh', 'Affiliation': 'Department of Biochemistry and Biotechnology, Faculty of Biosciences, College of Science, Kwame Nkrumah University of Science and Technology, PMB KNUST, Kumasi, Ghana.'}, {'ForeName': 'Odeafo', 'Initials': 'O', 'LastName': 'Asamoah-Boakye', 'Affiliation': 'Department of Biochemistry and Biotechnology, Faculty of Biosciences, College of Science, Kwame Nkrumah University of Science and Technology, PMB KNUST, Kumasi, Ghana.'}]",International journal of food science,['10.1155/2020/2379061'] 2888,32766306,Impact of Acute Eccentric versus Concentric Running on Exercise-Induced Fat Oxidation and Postexercise Physical Activity in Untrained Men.,"Introduction This study aimed at comparing the rate of exercise-induced fat oxidation and postexercise free-living physical activity after constant-load flat running (FR) and downhill running (DHR) bouts at an intensity that elicited maximal fat oxidation. Methods Participants were 11 healthy untrained men (mean age 25.6 ± 3.3 years; VO 2max 39.11 ± 8.05 ml/kg/min). The study included four visits. The first two visits determined the intensity of maximal fat oxidation during incremental FR and DHR tests. The second two visits involved constant-load FR or DHR at the intensity that elicited maximal fat oxidation in a counterbalanced order separated by two weeks. Gas exchange analysis was used to measure substrate oxidation during all exercise sessions. Sedentary time and physical activity were measured using ActiGraph triaxial accelerometers for three days including the day of exercise tests (the second day). Results During the incremental exercise tests, fat oxidation was significantly greater during the first stage of FR ( P < 0.05) but started to increase during the fourth stage of DHR, although this did not reach significance. Of the 11 participants, 7 had greater fat oxidation during DHR. During continuous constant-load running, fat oxidation was higher during DHR than FR but at only two stages was either significant or borderline significant, and the time/group interaction was not significant. There was no significant effect on sedentary time of time/group interaction ( P = 0.769), but there was a significant effect of time ( P = 0.005), and there was no significant effect on total physical activity of time/group interaction ( P = 0.283) or time ( P = 0.602). Conclusion Acute aerobic eccentric exercise at an intensity eliciting maximal fat oxidation enhanced exercise-induced fat oxidation without worsening postexercise free-living physical activity, indicating it could be a useful training modality in weight management programs.",2020,"During the incremental exercise tests, fat oxidation was significantly greater during the first stage of FR ( P < 0.05) but started to increase during the fourth stage of DHR, although this did not reach significance.","['11 healthy untrained men (mean age 25.6 ± 3.3 years; VO 2max 39.11 ± 8.05\u2009ml/kg/min', 'Untrained Men']","['exercise-induced fat oxidation and postexercise free-living physical activity after constant-load flat running (FR) and downhill running (DHR', 'Acute aerobic eccentric exercise', 'Acute Eccentric versus Concentric Running on Exercise-Induced Fat Oxidation and Postexercise Physical Activity']","['total physical activity of time/group interaction', 'sedentary time of time/group interaction', 'intensity of maximal fat oxidation', 'Sedentary time and physical activity', 'substrate oxidation', 'fat oxidation', 'fat oxidation during DHR']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517688', 'cui_str': '3.3'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439402', 'cui_str': 'mL/min/kg'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0205324', 'cui_str': 'Flat'}, {'cui': 'C0035953', 'cui_str': 'Running'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0439744', 'cui_str': 'Concentric'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0035953', 'cui_str': 'Running'}]",11.0,0.0290585,"During the incremental exercise tests, fat oxidation was significantly greater during the first stage of FR ( P < 0.05) but started to increase during the fourth stage of DHR, although this did not reach significance.","[{'ForeName': 'Shaea', 'Initials': 'S', 'LastName': 'Alkahtani', 'Affiliation': 'Department of Exercise Physiology, College of Sport Sciences and Physical Activity, King Saud University, Riyadh, Saudi Arabia.'}, {'ForeName': 'Osama', 'Initials': 'O', 'LastName': 'Aljuhani', 'Affiliation': 'Department of Physical Education, College of Sport Sciences and Physical Activity, King Saud University, Riyadh, Saudi Arabia.'}, {'ForeName': 'Nasser', 'Initials': 'N', 'LastName': 'Alkhalidi', 'Affiliation': 'Department of Exercise Physiology, College of Sport Sciences and Physical Activity, King Saud University, Riyadh, Saudi Arabia.'}, {'ForeName': 'Naif', 'Initials': 'N', 'LastName': 'Almasuod', 'Affiliation': 'Department of Exercise Physiology, College of Sport Sciences and Physical Activity, King Saud University, Riyadh, Saudi Arabia.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Hezam', 'Affiliation': 'Department of Exercise Physiology, College of Sport Sciences and Physical Activity, King Saud University, Riyadh, Saudi Arabia.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Aljaloud', 'Affiliation': 'Department of Exercise Physiology, College of Sport Sciences and Physical Activity, King Saud University, Riyadh, Saudi Arabia.'}, {'ForeName': 'Haitham Abdel Hamid', 'Initials': 'HAH', 'LastName': 'Dawoud', 'Affiliation': 'Department of Sport Health Sciences, Faculty of Physical Education, Helwan University, Cairo, Egypt.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Abdusalam', 'Affiliation': 'Department of Biomechanics and Motor Behavior, College of Sport Sciences and Physical Activity, King Saud University, Riyadh, Saudi Arabia.'}]",BioMed research international,['10.1155/2020/2608730'] 2889,32766321,"A new method of ""student-centered formative assessment"" and improving students' performance: An effort in the health promotion of community.","BACKGROUND Improving the learning process in education will empower medical students, and also formative assessment helps improve the teaching-learning process by providing ongoing reflective information about learning gaps. OBJECTIVE The aim of this study was to explore the effect of student-centered formative assessment by weekly reflective self-correction quizzes on medical laboratory students' performance on the final examination of hematology course in 2018. MATERIALS AND METHODS A semi-experimental study was conducted on fifty students divided randomly into intervention ( n = 25) and control groups ( n = 25) using convenience sampling in 2018 from Torbat Heydariyeh University of Medical Sciences, Iran. Data analysis was performed using SPSS software version 16, two-sample t -test, Chi-square test, and analysis of covariance. RESULTS The intervention had positive effects on students' mean test scores in hematology II so that the intervention and control groups managed to obtain 18.45 ± 1.46 and 14.57 ± 2.64, respectively ( P < 0.01). CONCLUSIONS The results suggested that weekly formative assessments along with reflective self-correction activity and active participation of students in the learning process by designing questions could improve student learning.",2020,"The intervention had positive effects on students' mean test scores in hematology II so that the intervention and control groups managed to obtain 18.45 ± 1.46 and 14.57 ± 2.64, respectively ( P < 0.01). ","[""students' performance"", ""medical laboratory students' performance on the final examination of hematology course in 2018"", 'A semi-experimental study was conducted on fifty students divided randomly into intervention ( n = 25) and control groups ( n = 25) using convenience sampling in 2018 from Torbat Heydariyeh University of Medical Sciences, Iran']","['student-centered formative assessment', 'student-centered formative assessment by weekly reflective self-correction quizzes']",['student learning'],"[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0022065', 'cui_str': 'Iran'}]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0036588', 'cui_str': 'Self'}]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0013621', 'cui_str': 'Education'}]",50.0,0.0247571,"The intervention had positive effects on students' mean test scores in hematology II so that the intervention and control groups managed to obtain 18.45 ± 1.46 and 14.57 ± 2.64, respectively ( P < 0.01). ","[{'ForeName': 'Fateme', 'Initials': 'F', 'LastName': 'Shahedi', 'Affiliation': 'Department of Radiology, School of Paramedical Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.'}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Ahmadi', 'Affiliation': 'Health Sciences Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.'}, {'ForeName': 'Tahereh', 'Initials': 'T', 'LastName': 'Sharifi', 'Affiliation': 'Department of Health Care Management, School of Health, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Seyedeh Nahid', 'Initials': 'SN', 'LastName': 'Seyedhasani', 'Affiliation': 'Health Sciences Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.'}, {'ForeName': 'Mahbubeh', 'Initials': 'M', 'LastName': 'Abdollahi', 'Affiliation': 'Health Sciences Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.'}, {'ForeName': 'Negar', 'Initials': 'N', 'LastName': 'Shaabani', 'Affiliation': 'Student Research Committee, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Sarmadi', 'Affiliation': 'Health Sciences Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.'}]",Journal of education and health promotion,['10.4103/jehp.jehp_753_19'] 2890,32766322,Enhancing academic engagement of underachieving gifted students: The effects of Martin's educational program.,"INTRODUCTION Gifted students are superior to their peers in terms of cognitive, educational, scientific, creativity, and artistic abilities. There are also gifted students who struggle with cognitive, educational, social, emotional, and behavioral development, especially academic performance. They are called underachieving students. One of the main problems of these students is the low level of academic engagement in educational settings. Thus, this study investigated the effectiveness of Martin's educational program on academic engagement (behavioral, emotional, cognitive, and agency) of underachieving gifted students. MATERIALS AND METHODS Thirty underachieving gifted students were selected by purposeful sampling from a high school in Isfahan, Iran, and were divided randomly into the experimental ( n = 15) and the control ( n = 15) groups. All participants completed the students' academic engagement questionnaire (behavioral engagement, emotional engagement, cognitive engagement, and agency engagement) at pre/post-test. RESULTS The findings showed that Martin's cognitive-behavioral program had a significant effect on academic engagement and its subscales, including behavioral engagement, emotional engagement, cognitive engagement, and agency engagement. CONCLUSION School counselors could benefit Martin's cognitive-behavioral program to promote the academic engagement of underachieving gifted students.",2020,"All participants completed the students' academic engagement questionnaire (behavioral engagement, emotional engagement, cognitive engagement, and agency engagement) at pre/post-test. ","['underachieving gifted students', 'Thirty underachieving gifted students were selected by purposeful sampling from a high school in Isfahan, Iran']","[""Martin's educational program""]","[""students' academic engagement questionnaire (behavioral engagement, emotional engagement, cognitive engagement, and agency engagement"", 'academic engagement (behavioral, emotional, cognitive, and agency', 'academic engagement and its subscales, including behavioral engagement, emotional engagement, cognitive engagement, and agency engagement']","[{'cui': 'C0423899', 'cui_str': 'Above average intellect'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0022065', 'cui_str': 'Iran'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]",,0.0153828,"All participants completed the students' academic engagement questionnaire (behavioral engagement, emotional engagement, cognitive engagement, and agency engagement) at pre/post-test. ","[{'ForeName': 'Meadeh', 'Initials': 'M', 'LastName': 'Hesam', 'Affiliation': 'Master of Counseling in Yazd Science and Research Branch of The Islamic Azad University, Yazd, Iran.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Abedi', 'Affiliation': 'Department of Children with Special Needs, University of Isfahan, Isfahan, Iran.'}]",Journal of education and health promotion,['10.4103/jehp.jehp_715_19'] 2891,32766327,Effectiveness of school-based mental health programs on mental health among adolescents.,"AIM This study aimed to investigate the effect of school-based interventions on mental health among adolescents in the southeast of Iran. METHODS This interventional quasi-experimental study included a total of 420 adolescent girls studying 10 th grade in the public schools of Zahedan, Iran. Data were collected using general health questionnaire-28 questionnaire. After pretest, multidimensional interventions (individual education, group education, individual consultations, modern education, and parents' educational packages) were given to the intervention group from October 2015 to June 2016. After a 3-month interval, the posttest was conducted in October 2016. Data were analyzed by covariance analysis. RESULTS There was a significant statistical difference between the changes in the mental health scores after the intervention among the two study groups ( P < 0.05). Furthermore, after the intervention, moderate-to-severe mental health problems decreased considerably among the students in the intervention group compared to controls. The greatest impact was on individual psychological counseling. CONCLUSIONS The results of the study showed that by applying group training and individual counseling in the schools improves mental health. Therefore, identifying student problems and parent-teacher cooperation as well as consulting with specialist counselors can be effective in providing practical and effective solutions in this regard. Therefore, findings suggest that prioritizing mental health and taking action on the field are of utmost importance.",2020,"Furthermore, after the intervention, moderate-to-severe mental health problems decreased considerably among the students in the intervention group compared to controls.","['mental health among adolescents', '420 adolescent girls studying 10 th grade in the public schools of Zahedan, Iran', 'mental health among adolescents in the southeast of Iran']","['school-based interventions', ""multidimensional interventions (individual education, group education, individual consultations, modern education, and parents' educational packages"", 'school-based mental health programs']","['mental health', 'mental health scores', 'moderate-to-severe mental health problems']","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C4517774', 'cui_str': '420'}, {'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0557800', 'cui_str': 'Public school'}, {'cui': 'C0022065', 'cui_str': 'Iran'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0150375', 'cui_str': 'Group education'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C1446377', 'cui_str': 'Mental health problem'}]",420.0,0.0214979,"Furthermore, after the intervention, moderate-to-severe mental health problems decreased considerably among the students in the intervention group compared to controls.","[{'ForeName': 'Fariba', 'Initials': 'F', 'LastName': 'Shahraki-Sanavi', 'Affiliation': 'Department of Public Health and Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Ansari-Moghaddam', 'Affiliation': 'Department of Epidemiology and Biostatistics, Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.'}, {'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Mohammadi', 'Affiliation': 'Department of Epidemiology and Biostatistics, Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.'}, {'ForeName': 'Nour-Mohammad', 'Initials': 'NM', 'LastName': 'Bakhshani', 'Affiliation': 'Department of Psychiatric and Clinical Psychology, Children and Adolescents Health Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.'}, {'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Salehiniya', 'Affiliation': 'Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran.'}]",Journal of education and health promotion,['10.4103/jehp.jehp_421_19'] 2892,32766331,The effect of empowerment program based on the social cognitive theory on the activity of daily living in patients with chronic obstructive pulmonary disease.,"OBJECTIVE AND AIM Chronic obstructive pulmonary disease (COPD) is one of the most common chronic diseases. The patient's fear and anxiety of shortness of breath and coughing during exercise may lead to a decrease in patients' daily activities. Therefore, the present study aimed to determine the effect of empowerment program based on the social cognitive theory (SCT) on the daily activity of patients with COPD. METHODS This quasi-experimental study was performed on 70 patients with COPD referred to Kashani and Hajar centers in 2019. Samples were randomly divided into two groups of experimental and control. Data collection tools included demographic information questionnaire and activity of daily living questionnaire, specific for COPD, and a researcher-made questionnaire for measuring SCT constructs. For the experimental group, the training program consisted of four theoretical and practical sessions of 40 min/week. The data were collected at three time points, before, immediately and 3 months after the training are 3 time. The data were analyzed by SPSS software using descriptive and inferential statistics. RESULTS The difference between the mean scores of behavioral ability, self-efficacy, and empowerment in the three stages was significant only in the experimental group ( P < 0.001). The mean daily activity score of patients before, immediately, and 3 months after intervention showed a statistically significant difference between the two groups (52.46 ± 21.98, 63.36 ± 21.95, and 71.34 ± 19.02), respectively, in the intervention group, and (51.79 ± 19.29, 53.70 ± 19.28, and 53.82 ± 19.26), respectively, in the control group ( P < 0.001). CONCLUSION The results of this study showed that empowerment of patients through interventions based on SCT can increase the daily activity of patients with COPD. Because nurses play an important role in patient education and improvement, it is hoped that the findings of this study will be used as a strategy to increase the daily activity and ultimately improve the quality of life in these patients.",2020,"The difference between the mean scores of behavioral ability, self-efficacy, and empowerment in the three stages was significant only in the experimental group ( P < 0.001).","['Chronic obstructive pulmonary disease (COPD', '70 patients with COPD referred to Kashani and Hajar centers in 2019', 'patients with chronic obstructive pulmonary disease', 'patients with COPD', 'patients with COPD.\nMETHODS']","['SCT', 'empowerment program', 'social cognitive theory (SCT']","['quality of life', 'demographic information questionnaire and activity of daily living questionnaire, specific for COPD', ""patient's fear and anxiety of shortness of breath and coughing"", 'daily activity', 'mean scores of behavioral ability, self-efficacy, and empowerment', 'mean daily activity score']","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0679959', 'cui_str': 'Empowerment'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0679959', 'cui_str': 'Empowerment'}]",70.0,0.0366156,"The difference between the mean scores of behavioral ability, self-efficacy, and empowerment in the three stages was significant only in the experimental group ( P < 0.001).","[{'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Aliakbari', 'Affiliation': 'Community Oriented Nursing Midwifery Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.'}, {'ForeName': 'Forouzan Mohammad', 'Initials': 'FM', 'LastName': 'Alipour', 'Affiliation': 'Community Oriented Nursing Midwifery Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.'}, {'ForeName': 'Elahe', 'Initials': 'E', 'LastName': 'Tavassoli', 'Affiliation': 'Health School, Shahrekord University of Medical Science, Shahrekord, Iran.'}, {'ForeName': 'Morteza', 'Initials': 'M', 'LastName': 'Sedehi', 'Affiliation': 'Health School, Shahrekord University of Medical Science, Shahrekord, Iran.'}]",Journal of education and health promotion,['10.4103/jehp.jehp_752_19'] 2893,32766383,Five-Day vs 10-Day Postexposure Chemoprophylaxis With Oseltamivir to Prevent Hospital Transmission of Influenza: A Noninferiority Randomized Open-Label Study.,"Background The efficacy and optimal duration of postexposure influenza prophylaxis with oseltamivir are undetermined in hospital settings, where immediate separation from index cases is not feasible. Methods In an open-label noninferiority randomized clinical trial in a single-center university hospital, the efficacy of 5-day vs 10-day postexposure prophylaxis with oseltamivir was compared in adult patients exposed to influenza who could not be immediately separated from index influenza cases. Influenza incidence was assessed for 10 days after discontinuing prophylaxis. Results Among 222 exposed patients (median age, 75 years; male 119; median Charlson Comorbidity Index, 5), 110 patients were assigned to 5 days of postexposure prophylaxis with oseltamivir, and 112 patients were assigned to the 10-day group. The median duration of exposure to influenza (interquartile range) was 2 (1-3) days. In the intention-to-treat analysis, the incidence of influenza was 2/110 (1.8%) in the 5-day group and 0/112 (0%) in the 10-day group (difference, 1.8 percentage points; 1-sided 95% CI, -1 to 4.9 percentage points; P  = .77). Conclusions For patients exposed to influenza in a hospital setting and who were not immediately separated from index cases, postexposure prophylaxis with oseltamivir resulted in low incidence of nosocomial influenza transmission. Five-day postexposure prophylaxis was noninferior to 10-day regimen. ClinicalTrialsgov Registration NCT03899571.",2020,"In the intention-to-treat analysis, the incidence of influenza was 2/110 (1.8%) in the 5-day group and 0/112 (0%) in the 10-day group (difference, 1.8 percentage points; 1-sided 95% CI, -1 to 4.9 percentage points; P  = .77). ","['adult patients exposed to influenza who could not be immediately separated from index influenza cases', 'male 119; median Charlson Comorbidity Index, 5', '222 exposed patients (median age, 75 years', '110 patients']","['5-day vs 10-day postexposure prophylaxis with oseltamivir', 'Five-Day vs 10-Day Postexposure Chemoprophylaxis', 'postexposure prophylaxis with oseltamivir', 'Oseltamivir']","['Influenza incidence', 'Hospital Transmission of Influenza', 'median duration of exposure to influenza', 'incidence of influenza']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C4546361', 'cui_str': 'Charlson Comorbidity Index'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517536', 'cui_str': '110'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0874161', 'cui_str': 'Oseltamivir'}]","[{'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0040722', 'cui_str': 'transmission'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}]",222.0,0.0744068,"In the intention-to-treat analysis, the incidence of influenza was 2/110 (1.8%) in the 5-day group and 0/112 (0%) in the 10-day group (difference, 1.8 percentage points; 1-sided 95% CI, -1 to 4.9 percentage points; P  = .77). ","[{'ForeName': 'Lidija', 'Initials': 'L', 'LastName': 'Lepen', 'Affiliation': 'Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Rok', 'Initials': 'R', 'LastName': 'Blagus', 'Affiliation': 'Institute for Biostatistics and Medical Informatics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Maša', 'Initials': 'M', 'LastName': 'Velušček', 'Affiliation': 'Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Rajko', 'Initials': 'R', 'LastName': 'Saletinger', 'Affiliation': 'Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Miroslav', 'Initials': 'M', 'LastName': 'Petrovec', 'Affiliation': 'Institute for Microbiology and Immunology Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Fajko F', 'Initials': 'FF', 'LastName': 'Bajrović', 'Affiliation': 'Department of Neurology, University Medical Center Ljubljana, Ljubljana, Slovenia and Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Daša', 'Initials': 'D', 'LastName': 'Stupica', 'Affiliation': 'Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia.'}]",Open forum infectious diseases,['10.1093/ofid/ofaa240'] 2894,32766392,Intra-articular versus Intravenous Tranexamic Acid in Total Knee Arthroplasty: A Randomized Clinical Trial.,"Background Total knee arthroplasty (TKA) can cause excessive blood loss requiring allogenic transfusions. Tranexamic acid (TXA) has been increasingly used for lowering blood loss. The present study aimed to compare the efficacy of intravenous (IV) and intra-articular (IA) administrations of TXA in TKA patients who receive aspirin as chemoprophylaxis and uses no drain post-operative. Methods In this prospective randomized clinical trial, 49 TKA patients were intravenously given 15 mg/kg dose of TXA, and 49 patients intraarticularly received 15 mg/kg of TXA. Demographic information, pre-operative and post-operative hemoglobin values of the patients were used for assessing total perioperative blood loss by GOOD & NADLER formulae. Results There was not any significant difference between the IV TXA and IA TXA groups concerning blood loss ( P=0.102 ). However, the decrease in hemoglobin level at 48 hours post-operation compared to the preoperative level in the IV TXA group was significantly higher than that in the IA TXA group (-2.3 ±0.8 vs. -1.9 ±1.0 g/dL; P=0.038 ). No blood transfusion was needed, and the deep venous thrombosis and pulmonary embolization were not observed in either of the groups ( P>0.05 ). Conclusion Our study showed that during TKA, the IA TXA is equally safe and effective as its IV infusion concerning decreased blood loss and adverse effects. The use of TXA during TKA is safe for patients who receive less potent chemoprophylaxis agents such as aspirin.",2020,There was not any significant difference between the IV TXA and IA TXA groups concerning blood loss ( P=0.102 ).,"['Total Knee Arthroplasty', 'TKA patients who receive aspirin as chemoprophylaxis and uses no drain post-operative', '49 TKA patients', 'patients who receive less potent chemoprophylaxis agents such as aspirin']","['TXA', 'IA TXA', '\n\n\nTotal knee arthroplasty (TKA', 'Tranexamic acid (TXA', 'intravenous (IV) and intra-articular (IA) administrations of TXA', 'Intra-articular versus Intravenous Tranexamic Acid']","['Demographic information, pre-operative and post-operative hemoglobin values', 'deep venous thrombosis and pulmonary embolization', 'hemoglobin level', 'blood loss and adverse effects', 'blood transfusion', 'blood loss']","[{'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0013103', 'cui_str': 'Drainage procedure'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0450442', 'cui_str': 'Agent'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0442108', 'cui_str': 'Intra-articular'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0013931', 'cui_str': 'Embolization - action'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}]",49.0,0.040391,There was not any significant difference between the IV TXA and IA TXA groups concerning blood loss ( P=0.102 ).,"[{'ForeName': 'Sm Javad', 'Initials': 'SJ', 'LastName': 'Mortazavi', 'Affiliation': 'Joint Reconstruction Research Center, Tehran University of Medical Science, Tehran, Iran.'}, {'ForeName': 'Babak', 'Initials': 'B', 'LastName': 'Sattartabar', 'Affiliation': 'Joint Reconstruction Research Center, Tehran University of Medical Science, Tehran, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Moharrami', 'Affiliation': 'Joint Reconstruction Research Center, Tehran University of Medical Science, Tehran, Iran.'}, {'ForeName': 'Seyed Hadi', 'Initials': 'SH', 'LastName': 'Kalantar', 'Affiliation': 'Joint Reconstruction Research Center, Tehran University of Medical Science, Tehran, Iran.'}]",The archives of bone and joint surgery,['10.22038/abjs.2019.39080.2039'] 2895,32766393,The Efficacy of Intravenous Versus Topical Use of Tranexamic Acid in Reducing Blood Loss after Primary Total Knee Arthroplasty: A Randomized Clinical Trial.,"Background Blood loss during and immediately after total knee arthroplasty (TKA) is among the most challenging concerns. It has been demonstrated that Tranexamic acid (TXA) can help to reduce perioperative blood loss. TXA can be used as an oral, topical or intravenous injection. Many studies evaluated the effectiveness of each route of administration but few works on a comparison between them. The current study aimed to compare the effectiveness of intravenous injection versus topical use of TXA in reducing perioperative blood loss after primary total knee arthroplasty. Methods Eighty-five patients who were a candidate for total knee arthroplasty were randomized into two groups: one group received Intravenous injection of 15 mg/kg TXA, 10 min before tourniquet inflation while the other group received 1 g diluted TXA during wound closure. The postoperative blood loss was estimated by measuring the whole drain output and also hemoglobin (HB) drops. Both groups compared based on the need for allogenic blood transfusion and also thromboembolic events. Results Patients who received topical TXA had a higher total drain output ( p <0.0001 ) compared to intravenous injection. The hemoglobin drop also was more in the topical group although it was marginally significant ( p =0.05 ). Conclusion Intravenous injection of TXA is more effective in reducing postoperative blood loss after primary TKA compared to topical administration.",2020,"Results Patients who received topical TXA had a higher total drain output ( p <0.0001 ) compared to intravenous injection.","['after Primary Total Knee Arthroplasty', 'primary total knee arthroplasty', 'Methods\n\n\nEighty-five patients who were a candidate for total knee arthroplasty']","['TXA', 'Intravenous injection of 15 mg/kg TXA, 10 min before tourniquet inflation while the other group received 1 g diluted TXA', 'topical TXA', 'Tranexamic Acid', 'Tranexamic acid (TXA']","['postoperative blood loss', 'perioperative blood loss', 'Blood Loss', 'total drain output']","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4517892', 'cui_str': '85'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0021494', 'cui_str': 'Intravenous injection'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0040519', 'cui_str': 'Tourniquet'}, {'cui': 'C0021398', 'cui_str': 'Economic Inflation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1720119', 'cui_str': 'Dilute'}, {'cui': 'C0332237', 'cui_str': 'Topical'}]","[{'cui': 'C0032788', 'cui_str': 'Postoperative hemorrhage'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0013103', 'cui_str': 'Drainage procedure'}, {'cui': 'C3251815', 'cui_str': 'Measurement of fluid output'}]",85.0,0.044701,"Results Patients who received topical TXA had a higher total drain output ( p <0.0001 ) compared to intravenous injection.","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Torkaman', 'Affiliation': 'epartment of Knee Surgery, Firouzgar Hospital, Iran University of Medical Sciences,Tehran , Iran.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Rostami', 'Affiliation': 'Bone and Joint Reconstruction Research Center, Firouzgar Hospital, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Sarshar', 'Affiliation': 'Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Akbari Aghdam', 'Affiliation': 'Department of Orthopedic Surgery, School of Medicine, Isfahan University of Medical Sciences , Isfahan, Iran.'}, {'ForeName': 'Paniz', 'Initials': 'P', 'LastName': 'Motaghi', 'Affiliation': 'Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hamidreza', 'Initials': 'H', 'LastName': 'Yazdi', 'Affiliation': 'Bone and Joint Reconstruction Research Center, Firouzgar Hospital, Iran University of edical ciences, Tehran, Iran.'}]",The archives of bone and joint surgery,['10.22038/abjs.2020.40528.2099'] 2896,32766402,Modified Camitz versus BRAND Procedures for the Treatment of Severe Carpal Tunnel Syndrome: A Comparative Trial Study.,"Background Carpal tunnel syndrome (CTS) is characterized by complications such as pain, paresthesia, and numbness in the fingers. There are some surgical therapies for the management of severe carpal tunnel, but differences exist between the treatments available for creating the opposition. The current study was conducted to compare the effect of modified Camitz and BRAND techniques on thumb opposition in patients with severe CTS. Methods A total of 40 patients with severe CTS who were candidates for opponensplasty were enrolled in this clinical trial study at Alzahra and Kashani hospitals, Isfahan, Iran, from 2014 to 2018. The patients were divided into two groups of modified Camitz and BRAND. Quick DASH-9 and Kapandji scores as well as pulp and side pinch and pronation angle were assessed before and after the surgeries. Results Quick DASH-9 score, Kapandji score, pulp and side pinch and pronation angle significantly improved post-operatively ( P=0.0XXX , P=0.0XXX , P=0.0XXX , P=0.0XXX , and P=0.0XXX , respectively). But, no significant differences were seen in the mentioned variables between both groups pre and post-operative ( P>0.05 , for all the studied variables). No postsurgical complications were seen in any of the groups. Conclusion The findings of the present study demonstrated that, both Modified Camitz and BRAND techniques are effective and safe techniques, yielding high improvements, but no serious complications. Both techniques can be considered for treatment of patients with severe CTS.",2020,"Results Quick DASH-9 score, Kapandji score, pulp and side pinch and pronation angle significantly improved post-operatively ( P=0.0XXX , P=0.0XXX , P=0.0XXX , P=0.0XXX , and P=0.0XXX , respectively).","['40 patients with severe CTS who were candidates for opponensplasty were enrolled in this clinical trial study at Alzahra and Kashani hospitals, Isfahan, Iran, from 2014 to 2018', 'patients with severe CTS', 'Severe Carpal Tunnel Syndrome']","['modified Camitz and BRAND techniques', 'Modified Camitz versus BRAND Procedures', 'modified Camitz and BRAND']","['postsurgical complications', 'Quick DASH-9 and Kapandji scores', 'Quick DASH-9 score, Kapandji score, pulp and side pinch and pronation angle']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0007286', 'cui_str': 'Carpal tunnel syndrome'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022065', 'cui_str': 'Iran'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011399', 'cui_str': 'Structure of pulp of tooth'}, {'cui': 'C0418416', 'cui_str': 'Pinched'}, {'cui': 'C0033421', 'cui_str': 'Pronation'}, {'cui': 'C0205143', 'cui_str': 'Angular'}]",40.0,0.0195449,"Results Quick DASH-9 score, Kapandji score, pulp and side pinch and pronation angle significantly improved post-operatively ( P=0.0XXX , P=0.0XXX , P=0.0XXX , P=0.0XXX , and P=0.0XXX , respectively).","[{'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Dehghani', 'Affiliation': 'Department of Orthopedic, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Behrooz', 'Initials': 'B', 'LastName': 'Fadaei', 'Affiliation': 'Department of Orthopedic, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Shirvan', 'Initials': 'S', 'LastName': 'Rastegar', 'Affiliation': 'Department of Orthopedic, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Abolghasem', 'Initials': 'A', 'LastName': 'Zarezadeh', 'Affiliation': 'Department of Orthopedic, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Keyvan', 'Initials': 'K', 'LastName': 'Ghadimi', 'Affiliation': 'School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Roham', 'Initials': 'R', 'LastName': 'Nikkhah', 'Affiliation': 'School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Sepehr', 'Initials': 'S', 'LastName': 'Eslami', 'Affiliation': 'Department of Orthopedic, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}]",The archives of bone and joint surgery,['10.22038/abjs.2019.14127'] 2897,32766747,Short-Term Changes in the Photopic Negative Response Following Intraocular Pressure Lowering in Glaucoma.,"Purpose To evaluate the short-term changes in inner retinal function using the photopic negative response (PhNR) after intraocular pressure (IOP) reduction in glaucoma. Methods Forty-seven participants with glaucoma who were commencing a new or additional IOP-lowering therapy (treatment group) and 39 participants with stable glaucoma (control group) were recruited. IOP, visual field, retinal nerve fiber layer thickness, and electroretinograms (ERGs) were recorded at baseline and at a follow-up visit (3 ± 2 months). An optimized protocol developed for a portable ERG device was used to record the PhNR. The PhNR saturated amplitude (Vmax), Vmax ratio, semi-saturation constant (K), and slope of the Naka-Rushton function were analyzed. Results A significant percentage reduction in IOP was observed in the treatment group (28 ± 3%) compared to the control group (2 ± 3%; P < 0.0001). For PhNR Vmax, there was no significant interaction (F1,83 = 2.099, P = 0.15), but there was a significant difference between the two time points (F1,83 = 5.689, P = 0.019). Post hoc analysis showed a significant difference between baseline and 3 months in the treatment group (mean difference, 1.23 µV; 95% confidence interval [CI], 0.24-2.22) but not in the control group (0.30 µV; 95% CI, 0.78-1.38). K and slope were not significantly different in either group. Improvement beyond test-retest variability was seen in 17% of participants in the treatment group compared to 3% in the control group (P = 0.007, χ2 test). Conclusions The optimized protocol for measuring the PhNR detected short-term improvements in a proportion of participants following IOP reduction, although the majority showed no change.",2020,A significant percentage reduction in IOP was observed in the treatment group (28 ± 3%) compared to the control group (2 ± 3%; P < 0.0001).,"['Glaucoma', 'Methods\n\n\nForty-seven participants with glaucoma who were commencing a new or additional IOP-lowering therapy (treatment group) and 39 participants with stable glaucoma (control group) were recruited', 'glaucoma']",['photopic negative response (PhNR) after intraocular pressure (IOP'],"['Improvement beyond test-retest variability', 'K and slope', 'Photopic Negative Response', 'IOP, visual field, retinal nerve fiber layer thickness, and electroretinograms (ERGs', 'IOP', 'PhNR saturated amplitude (Vmax), Vmax ratio, semi-saturation constant (K), and slope of the Naka-Rushton function']","[{'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}]","[{'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0042826', 'cui_str': 'Visual field'}, {'cui': 'C0035298', 'cui_str': 'Retinal structure'}, {'cui': 'C1720466', 'cui_str': 'Nerve fiber layer'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0013867', 'cui_str': 'Electroretinography'}, {'cui': 'C0522534', 'cui_str': 'Saturated'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",47.0,0.0895277,A significant percentage reduction in IOP was observed in the treatment group (28 ± 3%) compared to the control group (2 ± 3%; P < 0.0001).,"[{'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': 'Glaucoma Research Unit, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Flora', 'Initials': 'F', 'LastName': 'Hui', 'Affiliation': 'Glaucoma Research Unit, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Hadoux', 'Affiliation': 'Glaucoma Research Unit, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Bernardo', 'Initials': 'B', 'LastName': 'Soares', 'Affiliation': 'Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Jamieson', 'Affiliation': 'Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'van Wijngaarden', 'Affiliation': 'Glaucoma Research Unit, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Coote', 'Affiliation': 'Glaucoma Research Unit, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Jonathan G', 'Initials': 'JG', 'LastName': 'Crowston', 'Affiliation': 'Glaucoma Research Unit, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}]",Investigative ophthalmology & visual science,['10.1167/iovs.61.10.16'] 2898,32766757,Long-term glycaemic variability and vascular complications in Type 2 diabetes: Post-hoc analysis of the FIELD Study.,"AIMS To investigate whether long-term glycaemic variability (GV) is associated with vascular complication development in Type 2 diabetes. METHODS In a post-hoc FIELD trial analysis, GV was calculated as the standard deviation and coefficient of variation (CV) of HbA1c and fasting plasma glucose. Baseline variables were compared across quartiles of on-study variability by Chi square and ANOVA. Prospective associations between baseline to two-year GV and subsequent vascular and mortality outcomes were analysed using landmark logistic and Cox proportional hazards regression. RESULTS Baseline factors associated with higher on-study GV included younger age, male gender, longer diabetes duration and higher pharmacological therapies usage. Both HbA1c and fasting glucose CV were associated with increased risk of microvascular complications (HR 1.02 (95% CI 1.01-1.03) p<0.01; HR 1.01 (95% CI 1.00-1.01) p<0.001, respectively). HbA1c and fasting glucose CV were associated with increased cardiovascular disease (HR 1.02 (95% CI 1.00-1.04); HR 1.01 (95% CI 1.00-1.02), both p<0.05). HbA1c CV associated with increased stroke (HR 1.03 (95% CI 1.01-1.06) p<0.01). Glucose CV associated with increased coronary events (HR 1.01 (95% CI 1.00-1.02) p<0.05). Both HbA1c and glucose CV associated with increased total mortality (HR 1.04 (95% CI 1.02-1.06); HR 1.01 (95% CI 1.01-1.02), both p<0.001) and non-cardiovascular mortality (HR 1.05 (95% CI (1.03-1.07); HR 1.02 (95% CI 1.01-1.03), both p<0.001). HbA1c CV associated with coronary mortality (HR 1.04 (95% CI 1.01-1.07) p<0.05). CONCLUSIONS Long-term GV was associated with increased risk of vascular outcomes in Type 2 diabetes.",2020,"HbA1c and fasting glucose CV were associated with increased cardiovascular disease (HR 1.02 (95% CI 1.00-1.04); HR 1.01 (95% CI 1.00-1.02), both p<0.05).",['Type 2 diabetes'],['long-term glycaemic variability (GV'],"['Glucose CV associated with increased coronary events', 'cardiovascular disease', 'risk of vascular outcomes', 'stroke', 'total mortality', 'HbA1c and fasting glucose CV', 'non-cardiovascular mortality', 'standard deviation and coefficient of variation (CV) of HbA1c and fasting plasma glucose', 'coronary mortality', 'risk of microvascular complications']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",,0.264684,"HbA1c and fasting glucose CV were associated with increased cardiovascular disease (HR 1.02 (95% CI 1.00-1.04); HR 1.01 (95% CI 1.00-1.02), both p<0.05).","[{'ForeName': 'Emma S', 'Initials': 'ES', 'LastName': 'Scott', 'Affiliation': 'National Health and Medical Research Council (NHMRC) Clinical Trial Centre, University of Sydney, Australia.'}, {'ForeName': 'Andrzej S', 'Initials': 'AS', 'LastName': 'Januszewski', 'Affiliation': 'National Health and Medical Research Council (NHMRC) Clinical Trial Centre, University of Sydney, Australia.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': ""O'Connell"", 'Affiliation': 'National Health and Medical Research Council (NHMRC) Clinical Trial Centre, University of Sydney, Australia.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Fulcher', 'Affiliation': 'Department of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia.'}, {'ForeName': 'Russell', 'Initials': 'R', 'LastName': 'Scott', 'Affiliation': 'Canterbury District Health Board, Christchurch, New Zealand.'}, {'ForeName': 'Antero', 'Initials': 'A', 'LastName': 'Kesaniemi', 'Affiliation': 'Oulu Medical Research Centre, University of Oulu and Oulu University Hospital, Oulu, Finland.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Wu', 'Affiliation': 'National Health and Medical Research Council (NHMRC) Clinical Trial Centre, University of Sydney, Australia.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Colagiuri', 'Affiliation': 'The Boden Institute, University of Sydney, Australia.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Keech', 'Affiliation': 'National Health and Medical Research Council (NHMRC) Clinical Trial Centre, University of Sydney, Australia.'}, {'ForeName': 'Alicia J', 'Initials': 'AJ', 'LastName': 'Jenkins', 'Affiliation': 'National Health and Medical Research Council (NHMRC) Clinical Trial Centre, University of Sydney, Australia.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgaa361'] 2899,32766779,Manual Therapy Versus Surgery for Carpal Tunnel Syndrome: 4-Year Follow-up From a Randomized Controlled Trial.,"OBJECTIVE No study has investigated the effects longer than 1-year of manual therapy in carpal tunnel syndrome (CTS). The purpose of this study was to investigate the effects of manual therapy versus surgery at 4-year follow-up and to compare the post-study surgery rate in carpal tunnel syndrome CTS. METHODS This randomized controlled trial was conducted in a tertiary public hospital and included 120 women with CTS who were randomly allocated to manual therapy or surgery. The participants received 3 sessions of physical therapy including desensitization maneuvers of the central nervous system or carpal tunnel release combined with a tendon/nerve gliding exercise program at home. Primary outcome was pain intensity (mean and the worst pain). Secondary outcomes included functional status, symptom severity, and self-perceived improvement measured using a global rating of change scale. Outcomes for this analysis were assessed at baseline, 1 year, and 4 years. The rate of surgical intervention received by each group was assessed throughout the study. RESULTS At 4 years, 97 (81%) women completed the study. Between-group changes for all outcomes were not significantly different at 1 year (mean pain: mean difference [MD] = -0.3, 95% CI = -0.9 to 0.3; worst pain: MD = -1.2, 95% CI = -3.6 to 1.2; function: MD = -0.1, 95% CI = -0.4 to 0.2; symptom severity: MD = -0.1, 95% CI = -0.3 to 0.1), and 4 years (mean pain: MD = 0.1, 95% CI = -0.2 to 0.4; worst pain: MD = 0.2, 95% CI = -0.8 to 1.2; function: MD = 0.1, 95% CI = -0.1 to 0.3; symptom severity: MD = 0.2, 95% CI = -0.2 to 0.6). Self-perceived improvement was also similar in both groups. No between-group differences (15% physical therapy versus 13% surgery) in surgery rate were observed during the 4-years. CONCLUSIONS In the long term, manual therapy including desensitization maneuvers of the central nervous system resulted in similar outcomes and similar surgery rates compared to surgery in women with CTS. Both interventions were combined with a tendon/nerve gliding exercise program at home. IMPACT This is the first study to report clinical outcomes and surgical rates during a 4-year follow-up and will inform decisions regarding surgical versus conservative management of CTS.",2020,"Between-group changes for all outcomes were not significantly different at 1 year (mean pain: mean difference [MD] = -0.3, 95% CI = -0.9 to 0.3; worst pain: MD = -1.2, 95% CI = -3.6 to 1.2; function: MD = -0.1, 95% CI = -0.4 to 0.2; symptom severity: MD = -0.1, 95% CI = -0.3 to 0.1), and 4 years (mean pain: MD = 0.1, 95% CI = ","['carpal tunnel syndrome CTS', 'carpal tunnel syndrome (CTS', 'At 4\xa0years, 97 (81%) women completed the study', 'Carpal Tunnel Syndrome', 'tertiary public hospital and included 120 women with CTS']","['tendon/nerve gliding exercise program at home', 'manual therapy', 'physical therapy including desensitization maneuvers of the central nervous system or carpal tunnel release combined with a tendon/nerve gliding exercise program at home', 'manual therapy or surgery', 'Manual Therapy Versus Surgery']","['surgery rate', 'pain intensity (mean and the worst pain', 'rate of surgical intervention', 'functional status, symptom severity, and self-perceived improvement measured using a global rating of change scale', 'surgery rates']","[{'cui': 'C0007286', 'cui_str': 'Carpal tunnel syndrome'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0020022', 'cui_str': 'Public Hospitals'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4319550', 'cui_str': '120'}]","[{'cui': 'C0039508', 'cui_str': 'Tendon structure'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C0336966', 'cui_str': 'Gliding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0454525', 'cui_str': 'Manual therapy'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0178702', 'cui_str': 'Desensitization therapy'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C0196576', 'cui_str': 'Decompression of median nerve'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",120.0,0.131334,"Between-group changes for all outcomes were not significantly different at 1 year (mean pain: mean difference [MD] = -0.3, 95% CI = -0.9 to 0.3; worst pain: MD = -1.2, 95% CI = -3.6 to 1.2; function: MD = -0.1, 95% CI = -0.4 to 0.2; symptom severity: MD = -0.1, 95% CI = -0.3 to 0.1), and 4 years (mean pain: MD = 0.1, 95% CI = ","[{'ForeName': 'César', 'Initials': 'C', 'LastName': 'Fernández-de-Las-Peñas', 'Affiliation': 'Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, Avenida de Atenas s/n, Alcorcón, Madrid, Spain 28922, and Cátedra Institucional en Docencia, Clínica e Investigación en Fisioterapia Terapia Manual, Punción Seca y Ejercicio Terapéutico, Universidad Rey Juan Carlos.'}, {'ForeName': 'José L', 'Initials': 'JL', 'LastName': 'Arias-Buría', 'Affiliation': 'Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, Avenida de Atenas s/n, Alcorcón, Madrid, Spain 28922, and Cátedra Institucional en Docencia, Clínica e Investigación en Fisioterapia Terapia Manual, Punción Seca y Ejercicio Terapéutico, Universidad Rey Juan Carlos.'}, {'ForeName': 'Joshua A', 'Initials': 'JA', 'LastName': 'Cleland', 'Affiliation': 'Doctor of Physical Therapy Program, Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts; Rehabilitation Services, Concord Hospital, Concord, New Hampshire; and Manual Therapy Fellowship Program, Regis University, Denver, Colorado.'}, {'ForeName': 'Juan A', 'Initials': 'JA', 'LastName': 'Pareja', 'Affiliation': 'Department of Neurology and Neurophysiology, Hospital Universitario Fundación, Alcorcón, Madrid, Spain.'}, {'ForeName': 'Gustavo', 'Initials': 'G', 'LastName': 'Plaza-Manzano', 'Affiliation': 'Department of Radiology, Rehabilitation and Physiotherapy, Universidad Complutense de Madrid, Madrid, Spain, and Instituto de Investigación Sanitaria del Hospital Clinico San Carlos, Madrid, Spain.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Ortega-Santiago', 'Affiliation': 'Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, Avenida de Atenas s/n, Alcorcón, Madrid, Spain 28922, and Cátedra Institucional en Docencia, Clínica e Investigación en Fisioterapia Terapia Manual, Punción Seca y Ejercicio Terapéutico, Universidad Rey Juan Carlos.'}]",Physical therapy,['10.1093/ptj/pzaa150'] 2900,32766808,Effectiveness of Osteopathic Manipulative Medicine vs Concussion Education in Treating Student Athletes With Acute Concussion Symptoms.,"Context Concussion, a type of mild traumatic brain injury, is a disruption in normal brain function due to head injury. New-onset symptoms from concussion vary, likely depending on the areas of the head and neck affected; they can be severe and debilitating. Current treatment options are limited and difficult to individualize. Osteopathic manipulative medicine (OMM) can aid musculoskeletal restrictions that can potentially improve concussion symptoms. Objective To assess concussion symptom number and severity in participants with concussion who received either OMM or an educational intervention. Methods A randomized controlled trial was conducted at the New York Institute of Technology Academic Health Care Center. Patients presenting to the center with concussion-like symptoms due to recent head injury within the previous 7 days provided consent and were randomized into 2 intervention groups, receiving either 1 OMM treatment (n=16) or 1 concussion education intervention (n=15). Participants were assessed before and after the intervention with the validated Symptom Concussion Assessment Tool fifth edition (SCAT-5) for quantification of number of symptoms and their severity. Collected data were analyzed using the Mann-Whitney U test and the repeated-measures analysis of variance. Results Thirty-one participants were enrolled in the study; after 1 control participant was excluded due to incomplete data, 30 patient records were analyzed. The OMM intervention group had a significant decrease in symptom number (P=.002) and symptom severity (P=.001) compared with the concussion education group. Conclusion When used in the acute setting, OMM significantly decreased concussion symptom number and severity compared with concussion education. This study demonstrates that integration of OMM using a physical examination-guided, individualized approach is safe and effective in the management of new-onset symptoms of uncomplicated concussions. (Clinicaltrials.gov No. NCT02750566).",2020,"The OMM intervention group had a significant decrease in symptom number (P=.002) and symptom severity (P=.001) compared with the concussion education group. ","['Student Athletes With Acute Concussion Symptoms', 'Thirty-one participants were enrolled in the study; after 1 control participant was excluded due to incomplete data, 30 patient records were analyzed', 'participants with concussion who received either OMM or an educational intervention', 'Patients presenting to the center with concussion-like symptoms due to recent head injury within the previous 7 days provided consent', 'New York Institute of Technology Academic Health Care Center']","['Osteopathic manipulative medicine (OMM', 'Osteopathic Manipulative Medicine vs Concussion Education', 'OMM', 'OMM treatment (n=16) or 1 concussion education intervention', 'OMM intervention']","['symptom severity', 'symptom number']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0205257', 'cui_str': 'Incomplete'}, {'cui': 'C0025102', 'cui_str': 'Medical record'}, {'cui': 'C1562764', 'cui_str': 'Osteopathic manipulative medicine'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0018674', 'cui_str': 'Injury of head'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}]","[{'cui': 'C1562764', 'cui_str': 'Osteopathic manipulative medicine'}, {'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",31.0,0.0601609,"The OMM intervention group had a significant decrease in symptom number (P=.002) and symptom severity (P=.001) compared with the concussion education group. ","[{'ForeName': 'Sheldon C', 'Initials': 'SC', 'LastName': 'Yao', 'Affiliation': ''}, {'ForeName': 'Hallie', 'Initials': 'H', 'LastName': 'Zwibel', 'Affiliation': ''}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Angelo', 'Affiliation': ''}, {'ForeName': 'Adena', 'Initials': 'A', 'LastName': 'Leder', 'Affiliation': ''}, {'ForeName': 'Jayme', 'Initials': 'J', 'LastName': 'Mancini', 'Affiliation': ''}]",The Journal of the American Osteopathic Association,['10.7556/jaoa.2020.099'] 2901,32770665,Pharmacokinetics and Bioequivalence of 2 Immediate-Release Tofacitinib Tablet Formulations in Chinese Healthy Volunteers Under Fasting and Fed Conditions.,"The purpose of this study was to evaluate the bioequivalence of a generic immediate-release tofacitinib tablet versus a brand-named immediate-release tofacitinib tablet under fasting and fed conditions, and the food effect on pharmacokinetic profiles of the both formulations. This randomized, open-label, 2-period, crossover, bioequivalence study included 52 healthy Chinese subjects (fasting cohort: n = 26; fed cohort: n = 26). The subjects were assigned to receive a single 5-mg dose of generic or brand-named tofacitinib. Blood samples were collected at predosing and up to 14 hours after dosing. Tofacitinib concentrations in plasma were analyzed by high-performance liquid chromatography-tandem mass spectrometry. Safety was monitored. There were no significant differences in maximum plasma concentration, area under the plasma concentration-time curve from time zero to time t (AUC 0-t ), AUC from time zero to infinity (AUC 0-∞ ) , and terminal elimination half-life between the test and reference formulations (all P > .05); high-fat food had no significant effect on AUC 0-t , AUC 0-∞, or terminal elimination half-life of immediate-release tofacitinib tablets (all P > .05). The 90% confidence intervals of the test/reference ratios of log-transformed maximum plasma concentration, AUC 0-t , and AUC 0-∞ were within the range of 80% to 125% under both fasting and fed conditions. No serious adverse events were reported. The 2 formulations of immediate-release tofacitinib tablets are bioequivalent and well tolerated under both fasting and fed conditions in healthy Chinese volunteers. Food had no clinically relevant effects on drug exposure of tofacitinib.",2020,"There were no significant differences in maximum plasma concentration, area under the plasma concentration-time curve from time zero to time t (AUC 0-t ), AUC from time zero to infinity (AUC 0-∞ ) , and terminal elimination half-life between the test and reference formulations (all P > .05); high-fat food had no significant effect on AUC 0-t , AUC 0-∞, or terminal elimination half-life of immediate-release tofacitinib tablets (all P > .05).","['52 healthy Chinese subjects (fasting cohort: n = 26; fed cohort: n = 26', 'Chinese Healthy Volunteers', 'healthy Chinese volunteers']","['generic or brand-named tofacitinib', '2 Immediate-Release Tofacitinib Tablet Formulations']","['maximum plasma concentration, area under the plasma concentration-time curve from time zero to time t (AUC 0-t ), AUC from time zero to infinity (AUC 0-∞ ) , and terminal elimination half-life', 'Blood samples', 'serious adverse events', 'reference ratios of log-transformed maximum plasma concentration, AUC 0-t , and AUC 0-∞', 'AUC 0-t , AUC 0-∞, or terminal elimination half-life of immediate-release tofacitinib tablets']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0027365', 'cui_str': 'Name'}, {'cui': 'C2930696', 'cui_str': 'tofacitinib'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C3505043', 'cui_str': 'tofacitinib Oral Tablet'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0919414', 'cui_str': '0'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C3505043', 'cui_str': 'tofacitinib Oral Tablet'}]",52.0,0.142507,"There were no significant differences in maximum plasma concentration, area under the plasma concentration-time curve from time zero to time t (AUC 0-t ), AUC from time zero to infinity (AUC 0-∞ ) , and terminal elimination half-life between the test and reference formulations (all P > .05); high-fat food had no significant effect on AUC 0-t , AUC 0-∞, or terminal elimination half-life of immediate-release tofacitinib tablets (all P > .05).","[{'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.'}, {'ForeName': 'Lihua', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Deng', 'Affiliation': 'Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.'}, {'ForeName': 'Yangyang', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Xu', 'Affiliation': 'Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Feng', 'Affiliation': 'Jangsu Sinomune Pharmaceutical Company Limited, Jiangsu, China.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Jangsu Sinomune Pharmaceutical Company Limited, Jiangsu, China.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.864'] 2902,32770667,Pharmacokinetics and Bioequivalence Estimation of Two Formulations of Alfuzosin Extended-Release Tablets.,"Alfuzosin is a medication approved by the US Food and Drug Administration to treat benign prostatic hyperplasia symptoms. Bioequivalence studies are demanded by regulatory authorities to evaluate the expected in vivo biological similarity of 2 formulations of a medication. The aim of this study is to assess the bioavailability of the generic (test) and branded (reference) formulations of 10-mg alfuzosin extended-release tablets after oral administration to healthy adults under fed conditions. The study used a comparative randomized, single-dose, 2-way crossover open-label study design. Thirty-three participants were recruited and completed the clinical assessment. The pharmacokinetic parameters maximum plasma concentration (C max ), area under the plasma concentration-time curve (AUC 0-t ), AUC extrapolated to infinity (AUC 0-∞ ), time to maximum concentration, and elimination half-life were estimated to prove bioequivalence. The confidence intervals for the log-transformed test/reference ratios for alfuzosin 110.7% (98.0-124.9) and 112.0% (101.9-123.1) for C max and AUC 0-t respectively, which are within the allowed limits specified by the regulatory authorities (80-125% for C max and AUC 0-t ). The test formulation can therefore be prescribed as an alternative to the reference for symptomatic treatment of benign prostatic hyperplasia.",2020,Bioequivalence studies are demanded by regulatory authorities to evaluate the expected in vivo biological similarity of 2 formulations of a medication.,"['Thirty-three participants were recruited and completed the clinical assessment', 'healthy adults under fed conditions']","['Alfuzosin Extended-Release Tablets', '10-mg alfuzosin', 'Alfuzosin', 'alfuzosin']","['pharmacokinetic parameters maximum plasma concentration (C max ), area under the plasma concentration-time curve (AUC 0-t ), AUC extrapolated to infinity (AUC 0-∞ ), time to maximum concentration, and elimination half-life']","[{'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0051150', 'cui_str': 'alfuzosin'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}]",33.0,0.0447721,Bioequivalence studies are demanded by regulatory authorities to evaluate the expected in vivo biological similarity of 2 formulations of a medication.,"[{'ForeName': 'Abdel Qader', 'Initials': 'AQ', 'LastName': 'Al Bawab', 'Affiliation': 'Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.'}, {'ForeName': 'Bashar A', 'Initials': 'BA', 'LastName': 'Alkhalidi', 'Affiliation': 'School of Pharmacy, The University of Jordan, Amman, Jordan.'}, {'ForeName': ""Esra'a"", 'Initials': 'E', 'LastName': 'Albarahmieh', 'Affiliation': 'School of Applied Medical Sciences, German Jordanian University, Amman, Jordan.'}, {'ForeName': 'Sami M A', 'Initials': 'SMA', 'LastName': 'Qassim', 'Affiliation': 'Tabuk Pharmaceuticals, Tabuk, Kingdom of Saudi Arabia.'}, {'ForeName': 'Mohammad A D', 'Initials': 'MAD', 'LastName': 'Al-Saifi', 'Affiliation': 'Tabuk Pharmaceuticals, Tabuk, Kingdom of Saudi Arabia.'}, {'ForeName': 'Bashar', 'Initials': 'B', 'LastName': 'Al-Saifi', 'Affiliation': 'Tabuk Pharmaceuticals, Tabuk, Kingdom of Saudi Arabia.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Ling', 'Affiliation': 'University of Sunderland, Sunderland, UK.'}, {'ForeName': 'Walid', 'Initials': 'W', 'LastName': 'Al-Qerem', 'Affiliation': 'Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.860'] 2903,32770685,Ablative Fractional Carbon Dioxide Laser and Autologous Platelet-Rich Plasma in the Treatment of Atrophic Acne Scars: A Comparative Clinico-Immuno-Histopathological Study.,"BACKGROUND AND OBJECTIVES To compare the efficacy of autologous platelet-rich plasma (PRP), ablative fractional carbon dioxide (FCO 2 ) laser, and their combination in the treatment of atrophic acne scars, both clinically and immuno-histopathologically. STUDY DESIGN/MATERIALS AND METHODS Sixty patients were randomly divided into three equal groups. Group 1 received intradermal PRP injection sessions. Group 2 received FCO 2 laser sessions. Group 3 received FCO 2 laser followed by intradermal PRP injection sessions. Each group received three sessions at monthly intervals. The final assessment took place 3 months after the last session. Skin biopsies were obtained before and 1 month after treatment sessions with pathological evaluation. RESULTS Combined PRP and FCO 2 laser-treated patients had a better clinical response, fewer side effects, and shorter downtime than FCO 2 laser alone. PRP-treated patients had some improvement but significantly lower than the other two groups. CONCLUSION The current study concluded that a combination of PRP and FCO 2 laser is an effective and safe modality in the treatment of atrophic acne scars with better results than PRP or FCO 2 laser alone. Lasers Surg. Med. © 2020 Wiley Periodicals LLC.",2020,"RESULTS Combined PRP and FCO 2 laser-treated patients had a better clinical response, fewer side effects, and shorter downtime than FCO 2 laser alone.","['Atrophic Acne Scars', 'Sixty patients']","['Ablative Fractional Carbon Dioxide Laser and Autologous Platelet-Rich Plasma', 'PRP and FCO 2 laser', 'FCO 2 laser followed by intradermal PRP injection sessions', 'intradermal PRP injection sessions', 'autologous platelet-rich plasma (PRP), ablative fractional carbon dioxide (FCO 2 ) laser, and their combination', 'FCO 2 laser sessions']","['Skin biopsies', 'atrophic acne scars', 'side effects, and shorter downtime']","[{'cui': 'C1274728', 'cui_str': 'Atrophic acne scar'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0392251', 'cui_str': 'Carbon dioxide laser device'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C1522475', 'cui_str': 'Intradermal route'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}]","[{'cui': 'C0150866', 'cui_str': 'Biopsy of skin'}, {'cui': 'C1274728', 'cui_str': 'Atrophic acne scar'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}]",60.0,0.0115931,"RESULTS Combined PRP and FCO 2 laser-treated patients had a better clinical response, fewer side effects, and shorter downtime than FCO 2 laser alone.","[{'ForeName': 'Esraa E', 'Initials': 'EE', 'LastName': 'El-Hawary', 'Affiliation': 'Department of Dermatology, Venereology, and Andrology, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Samia', 'Initials': 'S', 'LastName': 'Nassar', 'Affiliation': 'Department of Dermatology, Venereology, and Andrology, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Abeer A', 'Initials': 'AA', 'LastName': 'Hodeib', 'Affiliation': 'Department of Dermatology, Venereology, and Andrology, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Mohamed M', 'Initials': 'MM', 'LastName': 'Shareef', 'Affiliation': 'Department of Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Mohamed M', 'Initials': 'MM', 'LastName': 'Fawzy', 'Affiliation': 'Department of Dermatology, Venereology, and Andrology, Faculty of Medicine, Tanta University, Tanta, Egypt.'}]",Lasers in surgery and medicine,['10.1002/lsm.23306'] 2904,32770686,A Randomized Controlled Trial of Novel Loop Drainage Technique versus Standard Incision and Drainage in the Treatment of Skin Abscesses.,"OBJECTIVES To compare the failure rate of incision and drainage (I&D) with LOOP technique versus I&D with standard packing technique in adults and children presenting to the ED with subcutaneous abscess. METHODS This prospective, randomized controlled trial (NCT03398746) enrolled a convenience sample of patients presenting to two Level 1 trauma centers over 12-months with skin abscesses. Of 256 patients screened, 217 patients were enrolled, 109 randomized to I&D with packing (50%) and 108 (50%) to I&D with LOOP. The primary outcome was treatment failure defined by admission, IV antibiotics, or repeat drainage within 10-day follow-up. The secondary outcomes included ease of procedure, ease of care, pain and satisfaction using a 10-point numeric rating scale. RESULTS There were no differences in patient characteristics between groups. Follow-up data were available in 196 (90%). Treatment failure occurred in 20% (12-28) of packing patients and 13% (6- 20) of LOOP patients(p=0.25). There were no significant differences in failure rates in adults (p=0.82), but there was a significant difference in children (age≤18) at 21% (8-34) in the packing group and 0 (0%) in the LOOP group (P=0.002). Operators reported no significant differences in ease of procedure between techniques (p=0.221). There was significantly less pain at follow-up in the LOOP group versus packing (p=0.004). The wound was much easier to care for over the first 36 hours in the LOOP group (p=0.002). Patient satisfaction at 10 days post-procedure was significantly higher in the LOOP group (p=0.005). CONCLUSIONS The LOOP and packing techniques had similar failure rates for treatment of subcutaneous abscesses in adults, but the LOOP technique had significantly fewer failures in children. Overall, pain and patient satisfaction were significantly better in patients treated using the LOOP technique.",2020,There was significantly less pain at follow-up in the LOOP group versus packing (p=0.004).,"['adults and children presenting to the ED with subcutaneous abscess', 'Skin Abscesses', '256 patients screened, 217 patients were enrolled, 109 randomized to I&D with packing (50%) and 108 (50%) to I&D with', 'patients presenting to two Level 1 trauma centers over 12-months with skin abscesses']","['LOOP', 'Novel Loop Drainage Technique versus Standard Incision and Drainage', 'incision and drainage (I&D) with LOOP technique versus I&D with standard packing technique']","['Patient satisfaction', 'Overall, pain and patient satisfaction', 'Treatment failure', 'treatment failure defined by admission, IV antibiotics, or repeat drainage within 10-day follow-up', 'ease of procedure, ease of care, pain and satisfaction using a 10-point numeric rating scale', 'pain', 'failure rates']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0149777', 'cui_str': 'Abscess of skin and/or subcutaneous tissue'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4517646', 'cui_str': '217'}, {'cui': 'C0152277', 'cui_str': 'Incision AND drainage'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0456947', 'cui_str': 'Level 1'}, {'cui': 'C0040786', 'cui_str': 'Trauma center'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0445022', 'cui_str': 'Loop'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0152277', 'cui_str': 'Incision AND drainage'}]","[{'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0231174', 'cui_str': 'Failure'}]",217.0,0.152555,There was significantly less pain at follow-up in the LOOP group versus packing (p=0.004).,"[{'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Ladde', 'Affiliation': 'Department of Emergency Medicine, Orlando Regional Medical Center, Orlando, Florida, United States.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Baker', 'Affiliation': 'Department of Emergency Medicine, Orlando Regional Medical Center, Orlando, Florida, United States.'}, {'ForeName': 'Natali', 'Initials': 'N', 'LastName': 'Lilburn', 'Affiliation': 'Pasco County Emergency Physicians, Morton Plant North Bay Hospital, New Port Richey, United States.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Wan', 'Affiliation': 'Department of Emergency Medicine, Dekalb Medical Center, Atlanta, Georgia, United States.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Papa', 'Affiliation': 'Department of Emergency Medicine, Orlando Regional Medical Center, Orlando, Florida, United States.'}]",Academic emergency medicine : official journal of the Society for Academic Emergency Medicine,['10.1111/acem.14106'] 2905,32766341,Promoting health and quality of life of patients with osteoarthritis of knee joint through non-pharmacological treatment strategies: A randomized controlled trial.,"BACKGROUND AND OBJECTIVE Osteoarthritis (OA) is a chronic degenerative disorder which primarily affects the articular cartilage of synovial joints followed by bony remodeling and overgrowth at the margins of these joints. The consequences of OA are pain, joint stiffness, decreased muscle performance, and decreased aerobic capacity, which eventually affect the quality of life (QOL) and increased risk for disability. The objective of the present study was to investigate the effectiveness of two nonpharmacological treatment regimens, that is, yoga and conventional physiotherapy, on QOL in patients suffering from OA of knee joint. MATERIALS AND METHODS A total of 83 patients with bilateral OA of knee joint, between the age group of 40 and 80 years, both males and females, were assigned into two groups using computer-generated scheme: 43 in the experimental group (yoga with conventional physiotherapy program) and 40 in control group (conventional physiotherapy program). Western Ontario and McMaster Universities OA index (WOMAC) and Short-Form 36 (SF-36) health survey were measured before, after 15 days, and after 30 days of treatment sessions, and the data were analyzed using paired and unpaired t -test. RESULTS The results of the study show significant improvement in both groups with regard to WOMAC and SF-36 at the end of 15 and 30 days of treatment regimen; however, when compared to the control group, experimental group had more significant improvement ( P < 0.05) in WOMAC and SF-36 at the end of 15 and 30 days of treatment. CONCLUSION Yoga is more beneficial when added to conventional physiotherapy treatment regimen in promoting health and improving QOL in patients with OA of knee joint.",2020,"The results of the study show significant improvement in both groups with regard to WOMAC and SF-36 at the end of 15 and 30 days of treatment regimen; however, when compared to the control group, experimental group had more significant improvement ( P < 0.05) in WOMAC and SF-36 at the end of 15 and 30 days of treatment. ","['patients suffering from OA of knee joint', 'patients with osteoarthritis of knee joint through non-pharmacological treatment strategies', '83 patients with bilateral OA of knee joint, between the age group of 40 and 80 years, both males and females', 'patients with OA of knee joint']","['computer-generated scheme: 43 in the experimental group (yoga with conventional physiotherapy program) and 40 in control group (conventional physiotherapy program', 'yoga and conventional physiotherapy']","['Promoting health and quality of life', 'OA are pain, joint stiffness, decreased muscle performance, and decreased aerobic capacity', 'quality of life (QOL) and increased risk for disability', 'WOMAC and SF-36', 'Western Ontario and McMaster Universities OA index (WOMAC) and Short-Form 36 (SF-36) health survey']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C4757989', 'cui_str': 'Bilateral osteoarthritis of knees'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0162298', 'cui_str': 'Joint stiffness'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C3472647', 'cui_str': 'Western Ontario and McMaster Universities osteoarthritis index'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}]",83.0,0.0345913,"The results of the study show significant improvement in both groups with regard to WOMAC and SF-36 at the end of 15 and 30 days of treatment regimen; however, when compared to the control group, experimental group had more significant improvement ( P < 0.05) in WOMAC and SF-36 at the end of 15 and 30 days of treatment. ","[{'ForeName': 'Nirav', 'Initials': 'N', 'LastName': 'Vaghela', 'Affiliation': 'Department of Physiotherapy, K M Patel Institute of Physiotherapy, H M Patel Centre for Medical Care and Education, Shree Krishna Hospital, Karamsad, Anand, India.'}, {'ForeName': 'Daxa', 'Initials': 'D', 'LastName': 'Mishra', 'Affiliation': 'Department of Physiotherapy, K M Patel Institute of Physiotherapy, H M Patel Centre for Medical Care and Education, Shree Krishna Hospital, Karamsad, Anand, India.'}, {'ForeName': 'Jayshree', 'Initials': 'J', 'LastName': 'Patel', 'Affiliation': 'Physiotherapist, Himatnagar, Gujarat, India.'}, {'ForeName': 'Vyoma', 'Initials': 'V', 'LastName': 'Dani', 'Affiliation': 'Department of Physiotherapy, K M Patel Institute of Physiotherapy, H M Patel Centre for Medical Care and Education, Shree Krishna Hospital, Karamsad, Anand, India.'}]",Journal of education and health promotion,['10.4103/jehp.jehp_39_20'] 2906,32766406,The Effect of Suspension and Conventional Core Stability Exercises on Characteristics of Intervertebral Disc and Chronic Pain in Office Staff Due to Lumbar Herniated Disc.,"Background The purpose of this study was to identify the effects of eight weeks of conventional and suspension core stability exercises by use of the designed device on characteristic of intervertebral discs in low back pain. Methods A total of 27 men with chronic low back (CLB) pain due to lumbar disc herniation in L4-L5 and L5-S1 regions were enrolled in this quasi-experimental study. After assessing the pain intensity using a visual analog scale (VAS) and determining the disc herniation index using MRI, each group of patients were asked to perform either conventional or suspension exercises for eight weeks, each week consisting of three training sessions. The pain intensity was assessed at the end of the first, second, third, fourth and eighth weeks and the disc hernia index was determined again at the end of the eight weeks of exercises. Results The results indicated significant changes in the intensity of pain in both groups through the period of eight weeks of exercise with a remarkable pain relief. In relation to the structural characteristics of the intervertebral disc, data analysis did not reveal any significant change between the pre- and post-test. Conclusion Considering the beneficial effects of the stability exercises and specially suspension stability exercises with respect to pain alleviation and reduced use of sedatives and anti-inflammatory drugs, this method can be helpful at early stages of treatment for chronic pains.",2020,"In relation to the structural characteristics of the intervertebral disc, data analysis did not reveal any significant change between the pre- and post-test. ","['Office Staff Due to Lumbar Herniated Disc', '27 men with chronic low back (CLB) pain due to lumbar disc herniation in L4-L5 and L5-S1 regions']","['conventional or suspension exercises', 'stability exercises and specially suspension stability exercises', 'conventional and suspension core stability exercises', 'Suspension and Conventional Core Stability Exercises']","['Characteristics of Intervertebral Disc and Chronic Pain', 'pain relief', 'pain intensity using a visual analog scale (VAS', 'pain intensity', 'disc hernia index', 'intensity of pain']","[{'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0281899', 'cui_str': 'Prolapsed lumbar intervertebral disc'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0007985', 'cui_str': 'Chemical suspension'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0444669', 'cui_str': 'Core'}]","[{'cui': 'C0021815', 'cui_str': 'Structure of intervertebral disc'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",27.0,0.0281409,"In relation to the structural characteristics of the intervertebral disc, data analysis did not reveal any significant change between the pre- and post-test. ","[{'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Khanzadeh', 'Affiliation': 'Department of Physical Education Faculty of Sports Sciences, Isfahan, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Mahdavinejad', 'Affiliation': 'Department of Physical Education Faculty of Sports Sciences, Isfahan, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Borhani', 'Affiliation': 'Department of Radiology, Tehran, Iran.'}]",The archives of bone and joint surgery,['10.22038/abjs.2019.40758.2102'] 2907,32766430,Educational Animations to Inform Transplant Candidates About Deceased Donor Kidney Options: An Efficacy Randomized Trial.,"Background Transplant candidates struggle making decisions about accepting kidneys with variable kidney donor profile index (KDPI) and increased risk donor (IRD) status. Methods This single site, pilot randomized controlled trial evaluated the efficacy of 2 animations to improve KDPI/IRD knowledge, decisional self-efficacy, and willingness. Kidney candidates were randomly assigned to animation viewing plus standard nurse discussion (intervention) or standard nurse discussion alone (control). Linear regression was used to test the significance of animation exposure after controlling for covariates (α < 0.1). Results Mean age was 60 years, and 27% were African American. Both intervention (n = 42) and control (n = 38) groups received similar education at similar duration (12.8 versus 11.8 min, respectively), usually by the same dedicated nurse educator (85% versus 75%, respectively). On multivariate analysis, the intervention group (versus control) exhibited significantly increased knowledge (β = 0.23; 95% confidence interval, 0.66-1.77) and IRD willingness (β = 0.22; 95% confidence interval, 0.05-0.86). There were no between-group differences in KDPI >85% willingness or distribution of KDPI/IRD decisional self-efficacy. Over 90% of participants provided positive ratings on each of 11 acceptability items. Conclusions Supporting conventional IRD and KDPI education with educational animations can improve knowledge and IRD willingness compared with standard methods.",2020,There were no between-group differences in KDPI >85% willingness or distribution of KDPI/IRD decisional self-efficacy.,"['Kidney candidates', 'Mean age was 60 years, and 27% were African American']",['animation viewing plus standard nurse discussion (intervention) or standard nurse discussion alone (control'],"['KDPI >85% willingness or distribution of KDPI/IRD decisional self-efficacy', 'knowledge and IRD willingness', 'IRD willingness', 'KDPI/IRD knowledge, decisional self-efficacy, and willingness']","[{'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0085756', 'cui_str': 'African American'}]","[{'cui': 'C0376650', 'cui_str': 'Animation'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0260788', 'cui_str': 'Donor of kidney for transplant'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",,0.112547,There were no between-group differences in KDPI >85% willingness or distribution of KDPI/IRD decisional self-efficacy.,"[{'ForeName': 'Liise K', 'Initials': 'LK', 'LastName': 'Kayler', 'Affiliation': 'Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY.'}, {'ForeName': 'Beth A', 'Initials': 'BA', 'LastName': 'Dolph', 'Affiliation': 'Department of Surgery, University at Buffalo, Buffalo, NY.'}, {'ForeName': 'Chelsea N', 'Initials': 'CN', 'LastName': 'Cleveland', 'Affiliation': 'Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY.'}, {'ForeName': 'Maria M', 'Initials': 'MM', 'LastName': 'Keller', 'Affiliation': 'Department of Community Health and Health Behavior, University at Buffalo, State University of New York, Buffalo, NY.'}, {'ForeName': 'Thomas H', 'Initials': 'TH', 'LastName': 'Feeley', 'Affiliation': 'Department of Communication, University at Buffalo, State University of New York, Buffalo, NY.'}]",Transplantation direct,['10.1097/TXD.0000000000001026'] 2908,32766465,Conditioning open-label placebo: a pilot pharmacobehavioral approach for opioid dose reduction and pain control.,"Opioid consumption for those in comprehensive inpatient rehabilitation units is high because of the complexity of their injuries. Notably, pain in rehabilitation leads to worsened clinical outcomes because of maladaptive behaviors and poor engagement during therapies. It is critical to developing evidence-based pharmacobehavioral interventions. Based on principles of classical conditioning, conditioning open-label placebo (COLP) is a promising approach for reducing opioid use in comprehensive inpatient rehabilitation, and this technique takes advantage of the possibility of association learning and opioid pharmacology to promote evoked placebo-driven analgesia. Objectives In this brief report, we evaluate the feasibility of COLP as a pharmacobehavioral intervention to decrease total opioid consumption in patients with pain hospitalized at Spaulding Rehabilitation Hospital. Methods Inpatients with spinal cord injury and polytrauma (n = 20) with moderate to severe pain were randomized to receive COLP (n = 10) or treatment-as-usual for 6 consecutive days. Opioid utilization was measured by morphine equivalents using the morphine equivalent dose conversion; pain severity was assessed using the numerical visual analog scale. Results Conditioning open-label placebo significantly reduced total opioid consumption by the end of the intervention period ( P ≤ 0.001). Pain reduction was also significant for the COLP group ( P = 0.005), whereas the treatment-as-usual group demonstrated a trend towards pain reduction ( P = 0.05). Conclusions This study presents the first data in the use of a pharmacobehavioral intervention that capitalize on the benefits of open-label placebo and classical drug conditioning for opioid dose reduction in a population with moderate to severe pain exposed to intensive inpatient rehabilitation.",2020,"Pain reduction was also significant for the COLP group ( P = 0.005), whereas the treatment-as-usual group demonstrated a trend towards pain reduction ( P = 0.05). ","['population with moderate to severe pain exposed to intensive inpatient rehabilitation', 'Methods\n\n\nInpatients with spinal cord injury and polytrauma (n = 20) with moderate to severe pain', 'patients with pain hospitalized at Spaulding Rehabilitation Hospital']","['Conditioning open-label placebo', 'COLP', 'classical conditioning, conditioning open-label placebo (COLP', 'pharmacobehavioral intervention']","['pain reduction', 'pain control', 'Opioid utilization', 'total opioid consumption', 'Pain reduction']","[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0026771', 'cui_str': 'Multiple injuries'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0337962', 'cui_str': 'Rehabilitation hospital'}]","[{'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009649', 'cui_str': 'Conditioning, Classical'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]",20.0,0.0633245,"Pain reduction was also significant for the COLP group ( P = 0.005), whereas the treatment-as-usual group demonstrated a trend towards pain reduction ( P = 0.05). ","[{'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Morales-Quezada', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Ines', 'Initials': 'I', 'LastName': 'Mesia-Toledo', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Anayali', 'Initials': 'A', 'LastName': 'Estudillo-Guerra', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': ""O'Connor"", 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Jeffrey C', 'Initials': 'JC', 'LastName': 'Schneider', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Douglas J', 'Initials': 'DJ', 'LastName': 'Sohn', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Crandell', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Ted', 'Initials': 'T', 'LastName': 'Kaptchuk', 'Affiliation': 'Program in Placebo Studies and Therapeutic Encounter, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Ross', 'Initials': 'R', 'LastName': 'Zafonte', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA.'}]",Pain reports,['10.1097/PR9.0000000000000828'] 2909,32766514,Determination of Anesthetic Efficacy of Lidocaine Versus Bupivacaine in Single Visit Root Canal Treatment.,"Objective To compare the anesthetic efficacy of 2% Lidocaine with 1:80,000 epinephrine and 0.5% Bupivacaine with 1:200,000 epinephrine in one-visit root canal treatment in patients with symptomatic irreversible pulpitis. Methods A total of 60 patients presenting with symptomatic irreversible pulpitis with normal periapical tissues on periapical radiography of mandibular 1 st and 2 nd molars, reporting moderate to severe pain as assessed by visual analogue scale (VAS) for at least 24 hours were included in this study. All patients received local anesthesia via the inferior alveolar nerve block technique by the investigator. These patients were randomly allocated into two groups in which first group received 2% lidocaine with 1:80,000 epinephrine and the second group received 0.5% bupivacaine with 1:200,000 epinephrine. Patients were instructed to rate the intensity of pain during root canal treatment which was then noted on visual analogue scale (VAS). Results The average age of the patients was 34.15±9.49 years, in which 32 (53.3%) were male and 28 (46.7%) were female. The anesthetic efficacy was significantly high in bupivacaine as compared to lidocaine local anesthesia group (76.7% versus 40%; P=0.004). Conclusion The administration of bupivacaine anesthetic agent for inferior alveolar nerve block (IANB) injections can be a better and appropriate pain management aid as compared to lidocaine during root canal treatment of patient with symptomatic irreversible pulpitis.",2020,"The anesthetic efficacy was significantly high in bupivacaine as compared to lidocaine local anesthesia group (76.7% versus 40%; P=0.004). ","['patient with symptomatic irreversible pulpitis', 'Single Visit Root Canal Treatment', 'patients with symptomatic irreversible pulpitis', 'The average age of the patients was 34.15±9.49 years, in which 32 (53.3%) were male and 28 (46.7%) were female', '60 patients presenting with symptomatic irreversible pulpitis with normal periapical tissues on periapical radiography of mandibular 1 st and 2 nd molars, reporting moderate to severe pain as assessed by visual analogue scale (VAS) for at least 24 hours were included in this study']","['bupivacaine anesthetic agent', 'bupivacaine with 1:200,000 epinephrine', 'bupivacaine', 'Lidocaine', 'Lidocaine Versus Bupivacaine', 'lidocaine', 'lidocaine local anesthesia', 'epinephrine and 0.5% Bupivacaine with 1:200,000 epinephrine', 'lidocaine with 1:80,000 epinephrine', 'local anesthesia via the inferior alveolar nerve block technique by the investigator']","['visual analogue scale (VAS', 'anesthetic efficacy']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C4041064', 'cui_str': 'Normal periapical tissue'}, {'cui': 'C0729269', 'cui_str': 'Periapical'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0002932', 'cui_str': 'Anesthetic'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0394801', 'cui_str': 'Local anesthetic inferior alveolar nerve block'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",60.0,0.0548869,"The anesthetic efficacy was significantly high in bupivacaine as compared to lidocaine local anesthesia group (76.7% versus 40%; P=0.004). ","[{'ForeName': 'Rizwan', 'Initials': 'R', 'LastName': 'Jouhar', 'Affiliation': 'Department of Restorative Dentistry and Endodontics, College of Dentistry, King Faisal Univeristy, Al Ahsa, Saudi Arabia.'}, {'ForeName': 'Muhammad Adeel', 'Initials': 'MA', 'LastName': 'Ahmed', 'Affiliation': 'Department of Restorative Dentistry and Endodontics, College of Dentistry, King Faisal Univeristy, Al Ahsa, Saudi Arabia.'}, {'ForeName': 'Bushra', 'Initials': 'B', 'LastName': 'Ghani', 'Affiliation': 'Department of Operative Dentistry and Endodontics, Altamash Institute of Dental Medicine, Sindh, Pakistan.'}]",European endodontic journal,['10.14744/eej.2020.88597'] 2910,32766852,"In childhood mature B-NHL with CNS disease, patients with blasts in cerebrospinal fluid are at higher risk of failure.","To identify the factors influencing outcome in childhood mature B-cell non-Hodgkin lymphoma and acute leukemia (B-NHL/AL) with central nervous system (CNS) disease (CNS+), we analyzed patients <18 years with newly diagnosed B-NHL/AL registered in 3 Lymphomes Malins B studies in France between 1989 to 2011. CNS+ was diagnosed on fulfillment of ≥1 of the following criteria: any L3 cerebrospinal fluid (CSF) blasts (CSF+), cranial nerve palsy, isolated intracerebral mass but also clinical spinal cord compression, and cranial or spinal parameningeal extension. Two hundred seventeen out of 1690 patients (12.8%) were CNS+. CNS+ was significantly associated with male gender, head/neck locations, Burkitt histology, high initial lactate dehydrogenase (LDH) level, and bone marrow involvement. CSF+ was the most frequent pattern of CNS+ (45%). For the 217 CNS+ patients, the 5-year event-free survival (EFS) and overall survival rates (95% confidence interval) were 81.5% (75.8% to 86.1%) and 83.9% (78.4% to 88.2%), respectively. In multivariate analysis, among CNS+ patients, low EFS was associated with CSF+, high initial LDH level, and poor response to cyclophosphamide, oncovin (vincristine), prednisone prephase. These findings have been considered for patient's stratification in the international randomized phase 3 trial Inter-B-NHL-ritux 2010 for children and adolescents with high-risk B-NHL/AL with CNS+ CSF+ patients only receiving intensified chemotherapy.",2020,"For the 217 CNS+ patients, the 5-year event-free survival (EFS) and overall survival rates (95% confidence interval) were 81.5% (75.8% to 86.1%) and 83.9% (78.4% to 88.2%), respectively.","['Two hundred seventeen out of 1690 patients (12.8%) were CNS', 'childhood mature B-cell non-Hodgkin lymphoma and acute leukemia (B-NHL/AL) with central nervous system (CNS) disease (CNS+), we analyzed patients <18 years with newly diagnosed B-NHL/AL registered in 3 Lymphomes Malins B studies in France between 1989 to 2011', 'children and adolescents with high-risk B-NHL/AL with CNS+ CSF+ patients only receiving intensified chemotherapy']","['CSF', 'CNS', 'cyclophosphamide, oncovin (vincristine), prednisone']","['male gender, head/neck locations, Burkitt histology, high initial lactate dehydrogenase (LDH) level, and bone marrow involvement', '5-year event-free survival (EFS) and overall survival rates']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517547', 'cui_str': '12.8'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0205286', 'cui_str': 'Mature'}, {'cui': 'C0079731', 'cui_str': 'B-cell lymphoma (clinical)'}, {'cui': 'C0085669', 'cui_str': 'Acute leukemia'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0027769', 'cui_str': 'Nervousness'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0591904', 'cui_str': 'Oncovine'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0019638', 'cui_str': 'Histology'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0022917', 'cui_str': 'Lactate dehydrogenase'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005953', 'cui_str': 'Bone marrow structure'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",1690.0,0.0824711,"For the 217 CNS+ patients, the 5-year event-free survival (EFS) and overall survival rates (95% confidence interval) were 81.5% (75.8% to 86.1%) and 83.9% (78.4% to 88.2%), respectively.","[{'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Simonin', 'Affiliation': 'Department of Pediatric Oncology and Hematology, Armand Trousseau Hospital, Assistance Publique-Hôpitaux de Paris and Sorbonne University, Paris, France.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Auperin', 'Affiliation': 'Unit of Biostatistics and Epidemiology, Gustave Roussy, Paris-Saclay University, INSERM 1018, Villejuif, France.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Bertrand', 'Affiliation': 'Department of Pediatric Hematology, Institute of Pediatric Hematology and Oncology, Claude Bernard University Lyon, Paris, France.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Aladjidi', 'Affiliation': 'Department of Pediatric Oncology and Haematology, University Hospital of Bordeaux, Bordeaux, France.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Baruchel', 'Affiliation': 'Department of Pediatric Hematology and Immunology, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris and University Paris Diderot, Paris, France.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Contet', 'Affiliation': 'Department of Pediatric Onco-Hematology, University Hospital of Nancy, Nancy, France.'}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Coze', 'Affiliation': 'Department of Pediatric Hematology and Oncology, Timone Enfants Hospital, Assistance Publique-Hôpitaux de Marseille and Aix-Marseille University, Marseille, France.'}, {'ForeName': 'Virginie', 'Initials': 'V', 'LastName': 'Gandemer', 'Affiliation': 'Department of Pediatric Onco-Hematology, University Hospital of Rennes, University of Rennes 1, Rennes, France.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Haouy', 'Affiliation': 'Department of Pediatric Onco-Hematology, University Hospital of Montpellier, Montpellier, France.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Leblanc', 'Affiliation': 'Department of Pediatric Hematology and Immunology, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris and University Paris Diderot, Paris, France.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Leverger', 'Affiliation': 'Department of Pediatric Oncology and Hematology, Armand Trousseau Hospital, Assistance Publique-Hôpitaux de Paris and Sorbonne University, Paris, France.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Michon', 'Affiliation': 'Pediatric Oncology Unit, SIREDO, Institut Curie, Paris, France.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Patte', 'Affiliation': 'Department of Pediatric and Adolescent Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France; and.'}, {'ForeName': 'Veronique', 'Initials': 'V', 'LastName': 'Minard-Colin', 'Affiliation': 'Department of Pediatric and Adolescent Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France; and.'}]",Blood advances,['10.1182/bloodadvances.2019001398'] 2911,32766863,Community delivery of brief therapy for depressed older adults impacted by Hurricane Sandy.,"Older adults frequently under-report depressive symptoms and often fail to access services after a disaster. To address unmet mental health needs, we developed a service delivery program (SMART-MH) that combines outreach, assessment, and therapy and implemented it in New York City after Hurricane Sandy. This study aimed to examine the feasibility, effectiveness, and patients' engagement of our brief psychotherapy (""Engage""). We predicted that Engage would result in reductions of depression, and that the benefits would be comparable to those of a historical comparison group who received Engage in a controlled experimental setting. A total of 2,831 adults (age ≥ 60) impacted by Hurricane Sandy were screened for depression. Assessments and therapy were conducted in English, Spanish, Cantonese, and Russian. Depressed individuals (PHQ-9 ≥ 10) who were not in treatment were offered Engage therapy in their native language at local senior center/nutrition sites. Twelve percent of the participants reported depression (N = 333). Of these 333 participants, 201 (60%) were not receiving treatment and 143 agreed to receive Engage therapy. Linear mixed-effects model showed that depression severity decreased significantly over time. More than two thirds had a five-point reduction in PHQ-9 scores and post-treatment scores ≤9. Post-hoc comparison of standardized slopes of change found patterns of depression reductions equivalent to Engage provided in a controlled setting. Partnerships to integrate mental health care into community settings can increase detection of mental-health needs and access to services in patients' native language. Brief reward exposure-based psychotherapy delivered in the community can provide comparable benefits to those achieved in research settings.",2020,More than two thirds had a five-point reduction in PHQ-9 scores and post-treatment scores ≤9.,"['depressed older adults impacted by Hurricane Sandy', '333 participants, 201 (60%) were not receiving treatment and 143 agreed to receive Engage therapy', 'Depressed individuals (PHQ-9 ≥ 10) who were not in treatment were offered Engage therapy in their native language at local senior center/nutrition sites', ""patients' native language"", 'Older adults', '2,831 adults (age ≥ 60) impacted by Hurricane Sandy were screened for depression']",['Brief reward exposure-based psychotherapy'],"['depression severity', 'PHQ-9 scores']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0020183', 'cui_str': 'Hurricane'}, {'cui': 'C4517724', 'cui_str': '333'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4517573', 'cui_str': '143'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C3658240', 'cui_str': 'Centers for the Aged'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0079891', 'cui_str': 'Indigenous Population'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0033968', 'cui_str': 'Psychotherapy'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",2831.0,0.0336343,More than two thirds had a five-point reduction in PHQ-9 scores and post-treatment scores ≤9.,"[{'ForeName': 'Jo Anne', 'Initials': 'JA', 'LastName': 'Sirey', 'Affiliation': 'Department of Psychiatry, Weill Cornell Medical College, White Plains, NY, USA.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Raue', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.'}, {'ForeName': 'Nili', 'Initials': 'N', 'LastName': 'Solomonov', 'Affiliation': 'Department of Psychiatry, Weill Cornell Medical College, White Plains, NY, USA.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Scher', 'Affiliation': 'Department of Psychiatry, Weill Cornell Medical College, White Plains, NY, USA.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Chalfin', 'Affiliation': 'Department of Psychiatry, Weill Cornell Medical College, White Plains, NY, USA.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Zanotti', 'Affiliation': 'Department of Psychiatry, Weill Cornell Medical College, White Plains, NY, USA.'}, {'ForeName': 'Jacquelin', 'Initials': 'J', 'LastName': 'Berman', 'Affiliation': 'New York City Department for the Aging, New York, NY, USA.'}, {'ForeName': 'George S', 'Initials': 'GS', 'LastName': 'Alexopoulos', 'Affiliation': 'Department of Psychiatry, Weill Cornell Medical College, White Plains, NY, USA.'}]",Translational behavioral medicine,['10.1093/tbm/ibz145'] 2912,32766885,Tolerance to graded dosages of histidine supplementation in healthy human adults.,"BACKGROUND Histidine is an essential amino acid with health benefits that may warrant histidine supplementation; however, the clinical safety of histidine intake above the average dietary intake (1.52-5.20 g/d) needs to be vetted. OBJECTIVES We aimed to determine the tolerance to graded dosages of histidine in a healthy adult population. METHODS Healthy adults aged 21-50 y completed graded dosages of histidine supplement (4, 8, and 12 g/d, Study 1) (n = 20 men and n = 20 women) and/or a 16-g/d dosage of histidine (Study 2, n = 21 men and n = 19 women); 27 participants (n = 12 men and n = 15 women) completed both studies. After study enrollment and baseline measures, participants consumed encapsulated histidine for 4 wk followed by a 3-wk recovery period. Primary outcomes included vitals, select biochemical analytes, anthropometry, serum zinc, and body composition (via DXA). RESULTS No changes in vitals or body composition occurred with histidine supplementation in either study. Plasma histidine (measured in subjects who completed all dosages for Studies 1 and 2) was elevated at the 12- and 16-g/d dosages (compared with 0-8 g/d, P < 0.05) and blood urea nitrogen increased with dosage (P = 0.013) and time (P < 0.001) in Study 1 and with time in Study 2 (P < 0.001). In Study 1, mean ferritin concentrations were lower in 12 g/d (46.0 ng/mL; 95% CI: 34.8, 60.9 ng/mL) than in 4 g/d (51.6 ng/mL; 95% CI: 39.0, 68.4 ng/mL; P = 0.038). In Study 2, 16 g/d increased mean aspartate aminotransferase from baseline (19 U/L; 95% CI: 17, 22 U/L) to week 4 (24 U/L; 95% CI: 21, 27 U/L; P < 0.001) and mean serum zinc decreased from baseline (0.75 μg/dL; 95% CI: 0.71, 0.80 μg/dL) to week 4 (0.70 μg/dL; 95% CI: 0.66, 0.74 μg/dL; P = 0.011). CONCLUSIONS Although values remained within the normal reference ranges for all analytes measured, in all dosages tested, the human no-observed adverse effect level was determined to be 8 g/d owing to changes in blood parameters at the 12-g/d dosage.This trial was registered at clinicaltrials.gov as NCT04142294.",2020,No changes in vitals or body composition occurred with histidine supplementation in either study.,"['4, 8, and 12 g/d, Study 1', 'n\xa0=\xa020 men and n\xa0=\xa020 women', 'healthy adult population', 'Study 2, n\xa0=\xa021 men and n\xa0=\xa019 women); 27 participants (n\xa0=\xa012 men and n\xa0=\xa015 women) completed both studies', 'Healthy adults aged 21-50 y completed graded dosages of', 'healthy human adults']","['histidine', 'histidine supplement', 'histidine supplementation']","['Plasma histidine', 'vitals, select biochemical analytes, anthropometry, serum zinc, and body composition (via DXA', 'mean aspartate aminotransferase', 'blood parameters', 'adverse effect level', 'blood urea nitrogen', 'mean serum zinc', 'vitals or body composition', 'mean ferritin concentrations']","[{'cui': 'C1318183', 'cui_str': '12G'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0019602', 'cui_str': 'Histidine'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0019602', 'cui_str': 'Histidine'}, {'cui': 'C0442732', 'cui_str': 'Vital'}, {'cui': 'C0443355', 'cui_str': 'Biochemical analyte'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0856205', 'cui_str': 'Serum zinc'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005845', 'cui_str': 'Blood urea nitrogen measurement'}, {'cui': 'C0015879', 'cui_str': 'Ferritin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",20.0,0.539875,No changes in vitals or body composition occurred with histidine supplementation in either study.,"[{'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Gheller', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA.'}, {'ForeName': 'Francoise', 'Initials': 'F', 'LastName': 'Vermeylen', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA.'}, {'ForeName': 'Michal K', 'Initials': 'MK', 'LastName': 'Handzlik', 'Affiliation': 'Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Brandon J', 'Initials': 'BJ', 'LastName': 'Gheller', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Bender', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Metallo', 'Affiliation': 'Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Tolunay B', 'Initials': 'TB', 'LastName': 'Aydemir', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA.'}, {'ForeName': 'Miro', 'Initials': 'M', 'LastName': 'Smriga', 'Affiliation': 'International Council on Amino Acid Science, Brussels, Belgium.'}, {'ForeName': 'Anna E', 'Initials': 'AE', 'LastName': 'Thalacker-Mercer', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqaa210'] 2913,32767049,Radiomics derived from dynamic contrast-enhanced MRI pharmacokinetic protocol features: the value of precision diagnosis ovarian neoplasms.,"OBJECTIVES To evaluate the efficiency of 2- and 3-class classification predictive tasks constructed from radiomics features extracted from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) pharmacokinetic (PK) protocol in discriminating among benign, borderline, and malignant ovarian tumors. METHODS One hundred and four ovarian lesions were evaluated using preoperative DCE-MRI. Radiomics features were extracted from 7 types of DCE-MR images. To explore the differential ability of radiomics between three types of ovarian tumors, two- and three-class classification tasks were established. The 2-class classification task was divided into three subtasks: benign vs. borderline (task A), benign vs. malignant (task B), and borderline vs. malignant (task C). For the 3-class classification task, 104 lesions were randomly divided into training (72 lesions) and validation (32 lesions) cohorts. The discrimination abilities of the radiomics signatures were established with the training cohort and tested with the independent validation cohort. The predictive performance of the task was evaluated by receiver operating characteristic (ROC) curve, calibration curve analysis, and decision curve analysis (DCA). RESULTS For the 2-class classification task, the combination of PK radiomics signatures model (PK model) showed a good diagnostic ability with the highest area under the ROC curves (AUCs) of 0.899, 0.865, and 0.893 for tasks A, B, and C, respectively. Additionally, the 3-class classification task demonstrated a good discrimination performance with AUCs of 0.893, 0.944, and 0.891 for the benign, borderline, and malignant groups, respectively. CONCLUSIONS Radiomics analysis based on the DCE-MRI PK protocol showed promise for discriminating among benign, borderline, and malignant ovarian tumors. KEY POINTS • Two-class classification predictive task of DCE-MRI PK protocol enabled the classification of 3 categories of ovarian tumors through the pairwise comparison strategy with a perfect diagnostic ability. • Three-class classification predictive task maintained good performance to effectively judge each category of ovarian tumors directly.",2020,"Additionally, the 3-class classification task demonstrated a good discrimination performance with AUCs of 0.893, 0.944, and 0.891 for the benign, borderline, and malignant groups, respectively. ","['104 lesions', 'One hundred and four ovarian lesions']","['DCE-MRI PK protocol', 'dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) pharmacokinetic (PK) protocol']","['receiver operating characteristic (ROC) curve, calibration curve analysis, and decision curve analysis (DCA']","[{'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]","[{'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}]","[{'cui': 'C0034772', 'cui_str': 'Receiver Operating Characteristic'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0006751', 'cui_str': 'Calibration'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0037501', 'cui_str': 'Sodium Dichloroacetate'}]",104.0,0.0222798,"Additionally, the 3-class classification task demonstrated a good discrimination performance with AUCs of 0.893, 0.944, and 0.891 for the benign, borderline, and malignant groups, respectively. ","[{'ForeName': 'Xiao-Li', 'Initials': 'XL', 'LastName': 'Song', 'Affiliation': 'Radiology Department, Shanxi Medical University Second Affiliated Hospital, Taiyuan, 030001, Shanxi, China.'}, {'ForeName': 'Jia-Liang', 'Initials': 'JL', 'LastName': 'Ren', 'Affiliation': 'GE Healthcare, Beijing, China.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Zhao', 'Affiliation': 'Radiology Department, Shanxi Medical University Second Affiliated Hospital, Taiyuan, 030001, Shanxi, China.'}, {'ForeName': 'Lifang', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': ""Radiology Department, Xi'an International Medical Center, Xi'an, Shanxi, China.""}, {'ForeName': 'Honghong', 'Initials': 'H', 'LastName': 'Ren', 'Affiliation': 'Radiology Department, Shanxi Medical University Second Affiliated Hospital, Taiyuan, 030001, Shanxi, China.'}, {'ForeName': 'Jinliang', 'Initials': 'J', 'LastName': 'Niu', 'Affiliation': 'Radiology Department, Shanxi Medical University Second Affiliated Hospital, Taiyuan, 030001, Shanxi, China. sxlscjy@163.com.'}]",European radiology,['10.1007/s00330-020-07112-0'] 2914,31285161,"Estimating obstructive sleep apnea in Cyprus: a randomised, stratified epidemiological study using STOP-Bang sleep apnea questionnaire.","INTRODUCTION Several epidemiological studies have demonstrated that Obstructive Sleep Apnea (OSA) is a highly prevalent disorder in the general population and increases over time all over the world. The high prevalence is in part due to increasing rates of obesity. However, estimates of OSA prevalence in Southern Europe are generally lacking. AIM The aim of our study was to predict the risk of OSA in the general population of Cyprus, the southeast part of Europe, by using a dedicated questionnaire like STOP-Bang. SUBJECTS AND METHOD We screened 5736 sample housing units for eligible adults and a total population of 4118 eligible responders completed the STOP-Bang questionnaire. Participants were all adults, age 18 + residing in Cyprus. The sample was stratified according to the last demographic report (2016) by district, rural or urban area, gender and age and the estimated sample size needed was 2000. Our survey was conducted by Computer Aided Telephone Interviewing (CATI) method. The question about Neck Circumference was removed from the final evaluation due to the uncertainty of most of the participants and the risk of bias. RESULTS From a total of 4118 participants (2252 males - 54.7%, 1862 females - 45.3%), with 46.6% over 50 years old, 2641 (64.1%) were at low risk for OSA (0-2 positive answers), 1200 (29.1%) at intermediate risk (3-4 positive answers) and 277 (6.7%) at high risk (≥5 positive answers). In sum, 29.9% responded positively for snoring, 39.3% for feeling tired or sleepy during the day, 12.3% for observed apnea during sleep, and 24.6% for having or being treated for hypertension. Class II and III obesity with Body Mass Index (BMI) > 35 kgr/m 2 was observed in 192 subjects (4.7%). In the subpopulation of obese participants (BMI>30 kg/m 2 ), intermediate to high risk of OSA was present in 45%, whereas in obesity class II and III the percentage reached almost 90%. CONCLUSIONS Our survey yielded that the prevalence of intermediate to high risk for OSA was 50% in males and 18% in females, in the general population of Cyprus. These findings were similar to previously reported high OSA prevalence worldwide, considering the fact that a single questionnaire is only a screening tool and cannot alone diagnose sleep apnea.",2019,"In sum, 29.9% responded positively for snoring, 39.3% for feeling tired or sleepy during the day, 12.3% for observed apnea during sleep, and 24.6% for having or being treated for hypertension.","['From a total of 4118 participants (2252 males - 54.7%, 1862 females - 45.3%), with 46.6% over 50 years old, 2641 (64.1%) were at low risk for OSA (0-2 positive answers), 1200 (29.1%) at intermediate risk (3-4 positive answers) and 277 (6.7%) at high risk (≥5 positive answers', '5736 sample housing units for eligible adults and a total population of 4118 eligible responders completed the STOP-Bang questionnaire', 'The sample was stratified according to the last demographic report (2016) by district, rural or urban area, gender and age and the estimated sample size needed was 2000', 'Participants were all adults, age 18', 'Estimating obstructive sleep apnea in Cyprus']",[],"['feeling tired or sleepy', 'OSA prevalence', 'Class II and III obesity with Body Mass Index']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C4517548', 'cui_str': '1200'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0442757', 'cui_str': '3/4'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0020056', 'cui_str': 'Housed'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0450446', 'cui_str': 'Stops'}, {'cui': 'C0302363', 'cui_str': 'Infection due to Brucella abortus'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0010622', 'cui_str': 'Cyprus'}]",[],"[{'cui': 'C0849970', 'cui_str': 'Tired'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0441886', 'cui_str': 'Class 2'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",4118.0,0.020409,"In sum, 29.9% responded positively for snoring, 39.3% for feeling tired or sleepy during the day, 12.3% for observed apnea during sleep, and 24.6% for having or being treated for hypertension.","[{'ForeName': 'Frangiskos', 'Initials': 'F', 'LastName': 'Frangopoulos', 'Affiliation': 'Respiratory Department, Nicosia General Hospital, 215 Nicosia - Limassol Old Road, 2029, Strovolos, Nicosia, Cyprus.'}, {'ForeName': 'Ivi', 'Initials': 'I', 'LastName': 'Nicolaou', 'Affiliation': 'Respiratory Department, Nicosia General Hospital, 215 Nicosia - Limassol Old Road, 2029, Strovolos, Nicosia, Cyprus.'}, {'ForeName': 'Savvas', 'Initials': 'S', 'LastName': 'Zannetos', 'Affiliation': 'Respiratory Department, Nicosia General Hospital, 215 Nicosia - Limassol Old Road, 2029, Strovolos, Nicosia, Cyprus.'}, {'ForeName': 'Nicholas-Tiberio', 'Initials': 'NT', 'LastName': 'Economou', 'Affiliation': 'Division of Pulmonology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra Hospital, Athens, Greece.'}, {'ForeName': 'Tonia', 'Initials': 'T', 'LastName': 'Adamide', 'Affiliation': 'Respiratory Department, Nicosia General Hospital, 215 Nicosia - Limassol Old Road, 2029, Strovolos, Nicosia, Cyprus.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Georgiou', 'Affiliation': 'Respiratory Department, Nicosia General Hospital, 215 Nicosia - Limassol Old Road, 2029, Strovolos, Nicosia, Cyprus.'}, {'ForeName': 'Georgia', 'Initials': 'G', 'LastName': 'Trakada', 'Affiliation': 'Division of Pulmonology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra Hospital, Athens, Greece. Electronic address: gtrakada@hotmail.com.'}]",Sleep medicine,['10.1016/j.sleep.2019.04.013'] 2915,32216764,Dating SOS: a systematic and theory-based development of a web-based tailored intervention to prevent dating violence among Brazilian youth.,"BACKGROUND Dating violence has an alarming prevalence among Brazilian adolescents. School-based preventive programs have been implemented, but remain isolated initiatives with low reach. Health communication strategies based on innovative technologies with a high potential of diffusion are urgent. This study aimed to develop a computer-tailored intervention to prevent victimization and perpetration of dating violence among Brazilian youth. METHODS The intervention, called Dating SOS (SOS Namoro), is based on the I-Change Model and attachment theory and is a comprehensive preventive program targeted to young people with a current partner. The intervention design included the stages of needs assessment; definition of objectives of change; development of the library of messages; elaboration of a questionnaire for tailoring feedbacks according to the relevant variables; integration of the content in the software Tailor Builder; pre-testing; and usability and efficacy evaluation planning. Dating SOS is composed of four online sessions. The first session gives a tailored orientation on attachment style and risk perception of violence. The second session addresses knowledge on conflict management, positive and negative social models of intimate relationships and an action plan to improve everyday interactions. The third session covers social norms, self-efficacy and an action plan to cope with conflicts. The fourth session discusses attitudes, social support and an action plan to protect from violence. Improvements on the interface and tailoring refinement was done after pre-testing to improve attractiveness and decrease risk of iatrogenic effects. DISCUSSION The principal merit of the present study resides in the development of an innovative strategy based on the qualified use of the internet for education surrounding romantic relationships and the prevention of dating violence among adolescent and young Brazilians, a hitherto unaddressed need in the field. The intervention usability and efficacy should be investigated in further studies. TRIAL REGISTRATION Brazilian Registry of Clinical Trials. RBR-9frj8q. Prospectively registered on July 25, 2019. http://www.ensaiosclinicos.gov.br/rg/RBR-9frj8q/.",2020,"The intervention, called Dating SOS (SOS Namoro), is based on the I-Change Model and attachment theory and is a comprehensive preventive program targeted to young people with a current partner.","['Brazilian adolescents', 'Brazilian youth']","['http://www.ensaiosclinicos.gov.br/rg/RBR-9frj8q', 'computer-tailored intervention']",['attachment style and risk perception of violence'],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}]","[{'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0042693', 'cui_str': 'Violence'}]",,0.0185807,"The intervention, called Dating SOS (SOS Namoro), is based on the I-Change Model and attachment theory and is a comprehensive preventive program targeted to young people with a current partner.","[{'ForeName': 'Sheila Giardini', 'Initials': 'SG', 'LastName': 'Murta', 'Affiliation': 'Department of Clinical Psychology, Institute of Psychology, University of Brasília, Campus Darcy Ribeiro, Brasília, DF, CEP 70910-900, Brazil. giardini@unb.br.'}, {'ForeName': 'Priscila de Oliveira', 'Initials': 'PO', 'LastName': 'Parada', 'Affiliation': 'Department of Clinical Psychology, Institute of Psychology, University of Brasília, Campus Darcy Ribeiro, Brasília, DF, CEP 70910-900, Brazil.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'da Silva Meneses', 'Affiliation': 'Department of Clinical Psychology, Institute of Psychology, University of Brasília, Campus Darcy Ribeiro, Brasília, DF, CEP 70910-900, Brazil.'}, {'ForeName': 'João Victor Venâncio', 'Initials': 'JVV', 'LastName': 'Medeiros', 'Affiliation': 'Department of Clinical Psychology, Institute of Psychology, University of Brasília, Campus Darcy Ribeiro, Brasília, DF, CEP 70910-900, Brazil.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Balbino', 'Affiliation': 'Department of Clinical Psychology, Institute of Psychology, University of Brasília, Campus Darcy Ribeiro, Brasília, DF, CEP 70910-900, Brazil.'}, {'ForeName': 'Marina Caricatti', 'Initials': 'MC', 'LastName': 'Rodrigues', 'Affiliation': 'Department of Clinical Psychology, Institute of Psychology, University of Brasília, Campus Darcy Ribeiro, Brasília, DF, CEP 70910-900, Brazil.'}, {'ForeName': 'Marco Akira', 'Initials': 'MA', 'LastName': 'Miura', 'Affiliation': 'Department of Design, Institute of Arts, University of Brasília, Brasília, Brazil.'}, {'ForeName': 'Thiago André Araújo', 'Initials': 'TAA', 'LastName': 'Dos Santos', 'Affiliation': 'Department of Computer Sciences, Institute of Exact Sciences, University of Brasília, Brasília, Brazil.'}, {'ForeName': 'Hein', 'Initials': 'H', 'LastName': 'de Vries', 'Affiliation': 'Department of Health Promotion, CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, the Netherlands.'}]",BMC public health,['10.1186/s12889-020-08487-x'] 2916,32472590,Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population.,"OBJECTIVE Transarterial chemoembolization (TACE) is the treatment modality for intermediate, or Barcelona Clinic Liver Cancer stage B, hepatocellular carcinoma (HCC), but its beneficial effect on outcomes is still unsatisfactory. This study aimed to assess the outcomes of combined TACE and sorafenib for patients with intermediate HCC. METHODS Patients with intermediate HCC who were receiving TACE alone (the monotherapy group), or combined TACE and sorafenib (the combined therapy group) from January 2013 to June 2018 were enrolled. RESULTS Altogether 64 patients were enrolled, of whom 34 were assigned to the monotherapy group and 30 to the combined therapy group. A prolonged time-to-progression (TTP) (mean 14.46 mo vs 6.39 mo, P = 0.001) was noted in the combined therapy group compared with the monotherapy group. Overall survival (OS) (mean 18.96 mo vs15.44 mo, P = 1.000) between the two groups did not differ significantly. After adjustment, there were no significant differences in the 12-18 month mortality rate between the two groups. CONCLUSION Patients with intermediate HCC receiving combined TACE and sorafenib had a better TTP, but not OS, than those receiving TACE alone.",2020,"Overall survival (OS) (mean 18.96 mo vs15.44 mo, P = 1.000) between the two groups did not differ significantly.","['Altogether 64 patients were enrolled, of whom 34 were assigned to the monotherapy group and 30 to the combined therapy group', 'the combined therapy group) from January 2013 to June 2018 were enrolled', 'Patients with intermediate HCC who were receiving TACE alone (the monotherapy group), or', 'patients with intermediate HCC', 'intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population']","['TACE', 'combined TACE and sorafenib', 'Transarterial chemoembolization (TACE', 'TACE and sorafenib', 'combined sorafenib']","['prolonged time-to-progression (TTP', 'Overall survival (OS', 'mortality rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1527374', 'cui_str': 'Group Therapy'}, {'cui': 'C0033972', 'cui_str': 'Combined therapy'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}, {'cui': 'C0522522', 'cui_str': 'Transarterial approach'}, {'cui': 'C0796679', 'cui_str': 'Chemoembolization'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0522522', 'cui_str': 'Transarterial approach'}, {'cui': 'C0796679', 'cui_str': 'Chemoembolization'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",64.0,0.026161,"Overall survival (OS) (mean 18.96 mo vs15.44 mo, P = 1.000) between the two groups did not differ significantly.","[{'ForeName': 'Shou Wu', 'Initials': 'SW', 'LastName': 'Lee', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan Province, China.'}, {'ForeName': 'Chun Fang', 'Initials': 'CF', 'LastName': 'Tung', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan Province, China.'}, {'ForeName': 'Yen Chun', 'Initials': 'YC', 'LastName': 'Peng', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan Province, China.'}, {'ForeName': 'Han Chung', 'Initials': 'HC', 'LastName': 'Lien', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan Province, China.'}, {'ForeName': 'Chi Sen', 'Initials': 'CS', 'LastName': 'Chang', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan Province, China.'}]",Journal of digestive diseases,['10.1111/1751-2980.12911'] 2917,31761771,Foreign language learning as potential treatment for mild cognitive impairment.,,2019,,['mild cognitive impairment'],['Foreign language learning'],[],"[{'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}]","[{'cui': 'C0376327', 'cui_str': 'Multinational Aspects'}, {'cui': 'C0023013', 'cui_str': 'Language Development'}]",[],,0.0204668,,"[{'ForeName': 'P C M', 'Initials': 'PCM', 'LastName': 'Wong', 'Affiliation': 'Department of Linguistics and Modern Languages, The Chinese University of Hong Kong, China.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Ou', 'Affiliation': 'Department of Linguistics and Modern Languages, The Chinese University of Hong Kong, China.'}, {'ForeName': 'C W Y', 'Initials': 'CWY', 'LastName': 'Pang', 'Affiliation': 'Department of Linguistics and Modern Languages, The Chinese University of Hong Kong, China.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Chinese Language Studies, The Education University of Hong Kong, China.'}, {'ForeName': 'C S', 'Initials': 'CS', 'LastName': 'Tse', 'Affiliation': 'Department of Educational Psychology, The Chinese University of Hong Kong, China.'}, {'ForeName': 'L C W', 'Initials': 'LCW', 'LastName': 'Lam', 'Affiliation': 'Department of Psychiatry, The Chinese University of Hong Kong, China.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Antoniou', 'Affiliation': 'The MARCS Institute for Brain, Behaviour and Development, Western Sydney University, Australia.'}]",Hong Kong medical journal = Xianggang yi xue za zhi,[] 2918,32768154,Ca2+ channel dynamics explain the nonlinear neuroplasticity induction by cathodal transcranial direct current stimulation over the primary motor cortex.,"Transcranial direct current stimulation (tDCS) induces polarity-dependent neuroplasticity: with conventional protocols, anodal tDCS results in excitability enhancement while cathodal stimulation reduces excitability. However, partially non-linear responses are observed with increased stimulation intensity and/or duration. Cathodal tDCS with 2 mA for 20 min reverses the excitability-diminishing plasticity induced by stimulation with 1 mA into excitation, while cathodal tDCS with 3 mA again results in excitability diminution. Since tDCS generates NMDA receptor-dependent neuroplasticity, such non-linearity could be explained by different levels of calcium concentration changes, which have been demonstrated in animal models to control for the directionality of plasticity. In this study, we tested the calcium dependency of non-linear cortical plasticity induced by cathodal tDCS in human subjects in a placebo controlled, double-blind and randomized design. The calcium channel blocker flunarizine was applied in low (2.5 mg), medium (5 mg) or high (10 mg) dosages before 20 min cathodal motor cortex tDCS with 3 mA in 12 young healthy subjects. After-effects of stimulation were monitored with TMS-induced motor evoked potentials (MEPs) until 2 h after stimulation. The results show that motor cortical excitability-diminishing after-effects of stimulation were unchanged, diminished, or converted to excitability enhancement with low, medium and high dosages of flunarizine. These results suggest a calcium-dependency of the directionality of tDCS-induced neuroplasticity, which may have relevant implications for future basic and clinical research.",2020,"Cathodal tDCS with 2 mA for 20 min reverses the excitability-diminishing plasticity induced by stimulation with 1 mA into excitation, while cathodal tDCS with 3 mA again results in excitability diminution.","['human subjects in a', '12 young healthy subjects']","['Transcranial direct current stimulation (tDCS', 'calcium channel blocker flunarizine', 'medium (5\xa0mg) or high (10\xa0mg) dosages before 20\xa0min cathodal motor cortex tDCS', 'cathodal tDCS', 'flunarizine', 'placebo']","['TMS-induced motor evoked potentials (MEPs', 'motor cortical excitability-diminishing after-effects of stimulation', 'excitability diminution', 'excitability-diminishing plasticity']","[{'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0006684', 'cui_str': 'Calcium channel blocker'}, {'cui': 'C0016295', 'cui_str': 'Flunarizine'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0026607', 'cui_str': 'Motor cortex'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0282617', 'cui_str': 'Motor Evoked Potentials'}, {'cui': 'C4277734', 'cui_str': 'Cortical Excitability'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}, {'cui': 'C0332511', 'cui_str': 'Decreased size'}, {'cui': 'C0678558', 'cui_str': 'Plasticity'}]",12.0,0.0831006,"Cathodal tDCS with 2 mA for 20 min reverses the excitability-diminishing plasticity induced by stimulation with 1 mA into excitation, while cathodal tDCS with 3 mA again results in excitability diminution.","[{'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Mosayebi-Samani', 'Affiliation': 'Department Psychology and Neurosciences, Leibniz Research Centre for Working Environment and Human Factors, Ardeystr. 67, 44139 Dortmund, Germany; Institute of Biomedical Engineering and Informatics, Ilmenau University of Technology, Ilmenau, Germany.'}, {'ForeName': 'Lorena', 'Initials': 'L', 'LastName': 'Melo', 'Affiliation': 'Department Psychology and Neurosciences, Leibniz Research Centre for Working Environment and Human Factors, Ardeystr. 67, 44139 Dortmund, Germany; International Graduate School of Neuroscience, IGSN, Ruhr University Bochum, Bochum, Germany.'}, {'ForeName': 'Desmond', 'Initials': 'D', 'LastName': 'Agboada', 'Affiliation': 'Department Psychology and Neurosciences, Leibniz Research Centre for Working Environment and Human Factors, Ardeystr. 67, 44139 Dortmund, Germany; International Graduate School of Neuroscience, IGSN, Ruhr University Bochum, Bochum, Germany.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Nitsche', 'Affiliation': 'Department Psychology and Neurosciences, Leibniz Research Centre for Working Environment and Human Factors, Ardeystr. 67, 44139 Dortmund, Germany; Department of Neurology, University Hospital Bergmannsheil, Bochum, Germany.'}, {'ForeName': 'Min-Fang', 'Initials': 'MF', 'LastName': 'Kuo', 'Affiliation': 'Department Psychology and Neurosciences, Leibniz Research Centre for Working Environment and Human Factors, Ardeystr. 67, 44139 Dortmund, Germany. Electronic address: kuo@ifado.de.'}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2020.07.011'] 2919,32768182,Clinical and radiographic evaluation of implants placed with fully guided versus partially guided tissue-supported surgical guides: A split-mouth clinical study.,"STATEMENT OF PROBLEM The effect of placing implants by using a fully guided protocol versus a partially guided protocol on the peri-implant soft and hard tissues is unclear. C-shaped guide holes are often used; however, their effect on drilling and peri-implant tissues has not been thoroughly investigated. PURPOSE The purpose of this split-mouth clinical study was to clinically and radiographically evaluate peri-implant soft and hard tissues after implant placement by using fully guided versus partially guided surgical guides with cylindrical versus C-shaped guide holes. MATERIAL AND METHODS Adopting an 80% power of the study in calculating sample size, a total of 48 implants were placed in the mandibular interforaminal area of 12 edentulous participants. Implants were randomly divided into 2 groups: a fully guided group comprising 24 implants placed on 1 side by using a fully guided protocol and a partially guided group comprising 24 implants placed on the other side of the same participant by using a partially guided protocol. Each group was further subdivided into 2 subgroups: cylindrical, including 12 implants placed through cylindrical guide holes, and C-shaped (12 implants) placed through C-shaped guide holes. All participants were clinically evaluated in terms of a modified plaque index, modified gingival index, peri-implant probing depth, and probing attachment level at 2, 4, and 6 months. Implant stability, marginal bone level, and bone density were then evaluated immediately after implant placement at 2, 4, and 6 months. RESULTS No statistically significant differences were found in the plaque index (P=.927), modified gingival index (P=.916), probing depth (P=.832), probing attachment level (P=.096), implant stability (P=.338), bone level (P=.063), or bone density (P=.390) between the fully guided protocol and partially guided protocol. CONCLUSIONS The soft and hard tissues surrounding the implants placed by using fully guided surgical guides were clinically comparable with those placed by using partially guided surgical guides whether the guiding holes were cylindrical or C-shaped.",2020,"No statistically significant differences were found in the plaque index (P=.927), modified gingival index (P=.916), probing depth (P=.832), probing attachment level (P=.096), implant stability (P=.338), bone level (P=.063), or bone density (P=.390) between the fully guided protocol and partially guided protocol. ",['48 implants were placed in the mandibular interforaminal area of 12 edentulous participants'],"['fully guided group comprising 24 implants placed on 1 side by using a fully guided protocol and a partially guided group comprising 24 implants placed on the other side of the same participant by using a partially guided protocol', 'implant placement by using fully guided versus partially guided surgical guides with cylindrical versus C-shaped guide holes', 'implants placed with fully guided versus partially guided tissue-supported surgical guides', '12 implants placed through cylindrical guide holes, and C-shaped (12 implants) placed through C-shaped guide holes']","['bone density', 'modified gingival index (P=.916), probing depth (P=.832), probing attachment level', 'modified plaque index, modified gingival index, peri-implant probing depth, and probing attachment level', 'implant stability', 'bone level', 'Implant stability, marginal bone level, and bone density', 'plaque index']","[{'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0026644', 'cui_str': 'Edentulous'}]","[{'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0205114', 'cui_str': 'Cylindrical'}, {'cui': 'C0332479', 'cui_str': 'Shape finding'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0183683', 'cui_str': 'Support'}]","[{'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}]",48.0,0.0345364,"No statistically significant differences were found in the plaque index (P=.927), modified gingival index (P=.916), probing depth (P=.832), probing attachment level (P=.096), implant stability (P=.338), bone level (P=.063), or bone density (P=.390) between the fully guided protocol and partially guided protocol. ","[{'ForeName': 'Mostafa M', 'Initials': 'MM', 'LastName': 'Elkomy', 'Affiliation': 'Postgraduate student, Prosthodontic Department, Faculty of Dentistry, Alexandria University, Alexandria, Egypt.'}, {'ForeName': 'Mohamed M', 'Initials': 'MM', 'LastName': 'Khamis', 'Affiliation': 'Professor and Chairman, Prosthodontic Department, Faculty of Dentistry, Alexandria University, Alexandria, Egypt. Electronic address: moataz_khamis@yahoo.com.'}, {'ForeName': 'Ahlam M', 'Initials': 'AM', 'LastName': 'El-Sharkawy', 'Affiliation': 'Professor of Prosthodontics, Faculty of Dentistry, Alexandria University, Alexandria, Egypt.'}]",The Journal of prosthetic dentistry,['10.1016/j.prosdent.2020.05.009'] 2920,32768259,No Differences in Midterm Sports Participation or Functional Scores After Total Hip Arthroplasty by Posterolateral Vs Anterolateral Approach.,"BACKGROUND Patients undergoing total hip arthroplasty (THA) frequently question surgeons on return to sports. We compared midterm sports participation and functional scores after THA by posterolateral approach (PLA) vs anterolateral approach (ALA). METHODS Of 1381 patients who underwent uncemented ceramic-on-ceramic THA for primary osteoarthritis, 503 were excluded because of preoperative or postoperative lower limb surgery, leaving 594 operated by PLA and 284 by ALA. Forgotten Joint Score (FJS), Oxford Hip Score (OHS), satisfaction, as well as motivation, participation, and discomfort regarding 22 sports were collected. A 1:1 matching was performed to obtain 2 groups of PLA and ALA patients with similar age, gender, body mass index, and sports motivation. RESULTS Matching yielded 2 equal groups of 259 patients. There were no significant differences in FJS (P = .057), OHS (P = .685), satisfaction (P = .369), or rates of participation in light (P = .999), moderate (P = .632), or strenuous sports (P = .284). Participation in strenuous sports was reported by 50 PLA (19%) and 61 ALA (24%) patients, with differences for downhill skiing (22 vs 39), running (10 vs 19), and cross-country skiing (18 vs 10). More than 50% of motivated patients practiced most of their sports. Severe discomfort was reported similarly in PLA and ALA patients, mainly during running (13 vs 11), team ball games (9 vs 7), and downhill skiing (7 vs 8). CONCLUSION There were no significant differences between PLA and ALA patients in terms of OHS, FJS, satisfaction, or sports participation rates. There is little or no evidence to promote an approach based on sports participation or functional improvement. LEVEL OF EVIDENCE Level III, comparative study.",2020,"There were no significant differences between PLA and ALA patients in terms of OHS, FJS, satisfaction, or sports participation rates.","['1381 patients who underwent uncemented ceramic-on-ceramic THA for primary osteoarthritis, 503 were excluded because of preoperative or postoperative lower limb surgery, leaving 594 operated by PLA and 284 by ALA', 'Patients undergoing total hip arthroplasty (THA) frequently question surgeons on return to sports']",['THA by posterolateral approach (PLA) vs anterolateral approach (ALA'],"['Severe discomfort', 'rates of participation in light', 'Midterm Sports Participation or Functional Scores', 'Forgotten Joint Score (FJS), Oxford Hip Score (OHS), satisfaction, as well as motivation, participation, and discomfort regarding 22 sports', 'satisfaction', 'OHS, FJS, satisfaction, or sports participation rates', 'OHS', 'FJS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007742', 'cui_str': 'Ceramic'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0409952', 'cui_str': 'Idiopathic osteoarthritis'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0587271', 'cui_str': 'Posterolateral approach'}, {'cui': 'C0332194', 'cui_str': 'Anterolateral'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C4042817', 'cui_str': 'Return to Play'}]","[{'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0587271', 'cui_str': 'Posterolateral approach'}, {'cui': 'C0332194', 'cui_str': 'Anterolateral'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4759288', 'cui_str': 'Forgotten Joint Score'}, {'cui': 'C1998079', 'cui_str': 'Oxford hip score'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}]",22.0,0.0427256,"There were no significant differences between PLA and ALA patients in terms of OHS, FJS, satisfaction, or sports participation rates.","[{'ForeName': 'Michel P', 'Initials': 'MP', 'LastName': 'Bonnin', 'Affiliation': 'Hôpital Privé Jean Mermoz, Centre Orthopédique Santy, Ramsay Santé, Lyon, France; Artro Institute, Lyon, France.'}, {'ForeName': 'Michel-Henri', 'Initials': 'MH', 'LastName': 'Fessy', 'Affiliation': 'Artro Institute, Lyon, France; Department of Orthopaedic Surgery and Sports Medicine, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.'}, {'ForeName': 'Floris', 'Initials': 'F', 'LastName': 'Van Rooij', 'Affiliation': 'ReSurg SA, Nyon, Switzerland.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Nover', 'Affiliation': 'ReSurg SA, Nyon, Switzerland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Tarik', 'Initials': 'T', 'LastName': 'Ait-Si-Selmi', 'Affiliation': 'Hôpital Privé Jean Mermoz, Centre Orthopédique Santy, Ramsay Santé, Lyon, France; Artro Institute, Lyon, France.'}]",The Journal of arthroplasty,['10.1016/j.arth.2020.07.009'] 2921,32768272,Effect of Kangaroo Care and Oral Sucrose on Pain in Premature Infants: A Randomized Controlled Trial.,"BACKGROUND Premature infants hospitalized in the neonatal intensive care unit are routinely exposed to many painful procedures. Pain experienced during the neonatal period may lead to negative outcomes, especially in preterm neonates, hence pain in infants should be reduced. Kangaroo care and oral sucrose are some of the methods that can help reduce pain. AIM This study aimed to compare the effects of kangaroo care and oral sucrose on pain relief in preterm infants during heel lancing. METHODS Our study involved 64 infants. The infants were randomly divided into two groups using a randomized block design of drawing out slips from a thick, non-transparent envelope. There were 64 slips in this envelope (32 for kangaroo care and 32 for oral sucrose). Kangaroo care was given to the preterm infants in the first group and oral sucrose to those in the second group. In both groups, heart rate and oxygen saturation were measured and pain score was evaluated by two observers using the Premature Infant Pain Profile (PIPP) before, during, and 2 minutes after blood sampling by heel lancing. RESULTS There was a statistically significant difference between the groups in favor of the kangaroo group in terms of change in the PIPP values after heel lancing. Kangaroo care is more effective than oral sucrose in pain relief during heel lancing in preterm infants. CONCLUSIONS In addition to many benefits it offers to infants, kangaroo care can be used to reduce pain during painful procedures in premature infants.",2020,There was a statistically significant difference between the groups in favor of the kangaroo group in terms of change in the PIPP values after heel lancing.,"['64 infants', 'preterm infants during heel lancing', 'preterm infants', 'Premature infants hospitalized in the neonatal intensive care unit', 'premature infants', 'Premature Infants']","['Kangaroo care', 'kangaroo care and oral sucrose', 'Kangaroo Care and Oral Sucrose', 'Kangaroo care and oral sucrose', 'oral sucrose']","['heart rate and oxygen saturation', 'pain relief', 'Pain', 'pain', 'PIPP values', 'pain score']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0018870', 'cui_str': 'Heel structure'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}]","[{'cui': 'C0262705', 'cui_str': 'Kangaroo care'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0038636', 'cui_str': 'Sucrose'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",64.0,0.0656902,There was a statistically significant difference between the groups in favor of the kangaroo group in terms of change in the PIPP values after heel lancing.,"[{'ForeName': 'Elif', 'Initials': 'E', 'LastName': 'Sen', 'Affiliation': 'Health Sciences Institute, University of Uskudar, Istanbul, Turkey. Electronic address: nurelifsenn@gmail.com.'}, {'ForeName': 'Gulay', 'Initials': 'G', 'LastName': 'Manav', 'Affiliation': 'Faculty of Health Sciences Department of Nursing, University of Uskudar, Istanbul, Turkey.'}]",Pain management nursing : official journal of the American Society of Pain Management Nurses,['10.1016/j.pmn.2020.05.003'] 2922,32770859,Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk.,"BACKGROUND Aspirin is associated with decreased risk of colorectal cancer (CRC), potentially by modulating the gut microbiome. AIMS To evaluate the effect of aspirin on the gut microbiome in a double-blinded, randomised placebo-controlled pilot trial. METHODS Healthy volunteers aged 50-75 received a standard dose of aspirin (325 mg, N = 30) or placebo (N = 20) once daily for 6 weeks and provided stool samples every 3 weeks for 12 weeks. Serial measurements of gut microbial community composition and bacterial abundance were derived from 16S rRNA sequences. Linear discriminant analysis of effect size (LEfSe) was tested for between-arm differences in bacterial abundance. Mixed-effect regression with binomial distribution estimated the effect of aspirin use on changes in the relative abundance of individual bacterial taxa via an interaction term (treatment × time). RESULTS Over the study period, there were differences in microbial composition in the aspirin vs placebo arm. After treatment, four taxa were differentially abundant across arms: Prevotella, Veillonella, Clostridium XlVa and Clostridium XVIII clusters. Of pre-specified bacteria associated with CRC (n = 8) or aspirin intake (n = 4) in published studies, interactions were significant for four taxa, suggesting relative increases in Akkermansia, Prevotella and Ruminococcaceae and relative decreases in Parabacteroides, Bacteroides and Dorea in the aspirin vs placebo arm. CONCLUSION Compared to placebo, aspirin intake influenced several microbial taxa (Ruminococcaceae, Clostridium XlVa, Parabacteroides and Dorea) in a direction consistent with a priori hypothesis based on their association with CRC. This suggests that aspirin may influence CRC development through an effect on the gut microbiome. The findings need replication in a larger trial. The study was registered using Clinical Trials Registration NCT02761486.",2020,"Compared to placebo, aspirin intake influenced several microbial taxa (Ruminococcaceae, Clostridium XlVa, Parabacteroides and Dorea) in a direction consistent with a priori hypothesis based on their association with CRC.",['Healthy volunteers aged 50-75 received a'],"['placebo, aspirin', 'aspirin intake ', 'aspirin 325\xa0mg daily vs placebo', 'Aspirin', 'aspirin', 'standard dose of aspirin', 'placebo']","['Akkermansia, Prevotella and Ruminococcaceae and relative decreases in Parabacteroides, Bacteroides and Dorea', 'microbial composition and bacterial taxa associated with colorectal cancer risk', 'several microbial taxa (Ruminococcaceae, Clostridium XlVa, Parabacteroides and Dorea', 'microbial composition']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0992015', 'cui_str': 'Aspirin 325 MG'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]","[{'cui': 'C1490589', 'cui_str': 'Akkermansia'}, {'cui': 'C0242946', 'cui_str': 'Prevotella'}, {'cui': 'C2584567', 'cui_str': 'Ruminococcaceae'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C1927848', 'cui_str': 'Parabacteroides'}, {'cui': 'C1212549', 'cui_str': 'Dorea'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0009054', 'cui_str': 'Clostridium'}]",,0.618793,"Compared to placebo, aspirin intake influenced several microbial taxa (Ruminococcaceae, Clostridium XlVa, Parabacteroides and Dorea) in a direction consistent with a priori hypothesis based on their association with CRC.","[{'ForeName': 'Anna E', 'Initials': 'AE', 'LastName': 'Prizment', 'Affiliation': 'Minneapolis, MN, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Staley', 'Affiliation': 'Minneapolis, MN, USA.'}, {'ForeName': 'Guillaume C', 'Initials': 'GC', 'LastName': 'Onyeaghala', 'Affiliation': 'Minneapolis, MN, USA.'}, {'ForeName': 'Sithara', 'Initials': 'S', 'LastName': 'Vivek', 'Affiliation': 'Minneapolis, MN, USA.'}, {'ForeName': 'Bharat', 'Initials': 'B', 'LastName': 'Thyagarajan', 'Affiliation': 'Minneapolis, MN, USA.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Straka', 'Affiliation': 'Minneapolis, MN, USA.'}, {'ForeName': 'Ryan T', 'Initials': 'RT', 'LastName': 'Demmer', 'Affiliation': 'Minneapolis, MN, USA.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Knights', 'Affiliation': 'Minneapolis, MN, USA.'}, {'ForeName': 'Katie A', 'Initials': 'KA', 'LastName': 'Meyer', 'Affiliation': 'Chapel Hill, NC, USA.'}, {'ForeName': 'Aasma', 'Initials': 'A', 'LastName': 'Shaukat', 'Affiliation': 'Minneapolis, MN, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Sadowsky', 'Affiliation': 'Minneapolis, MN, USA.'}, {'ForeName': 'Timothy R', 'Initials': 'TR', 'LastName': 'Church', 'Affiliation': 'Minneapolis, MN, USA.'}]",Alimentary pharmacology & therapeutics,['10.1111/apt.16013'] 2923,32768682,Weight management for adults with mobility related disabilities: Rationale and design for an 18-month randomized trial.,"Adults with mobility related disabilities (MRDs) represent an underserved group with a high prevalence of overweight/obesity and limited options for weight management. We previously demonstrated clinically meaningful 12-month weight loss in adults with MRDs (-6.2%, 36% ≥5% of baseline weight) using an enhanced Stop Light Diet (eSLD) delivered using at home face-to-face behavioral sessions and optional physical activity. However, the costs/logistics associated with intervention delivery by individual home visits limits the potential for scaling and implementation of this approach. Thus, we will conduct a two-arm randomized trial in 128 overweight/obese adults with MRDs to compare weight loss (6 mos.) and maintenance (12 mos.) between interventions utilizing the eSLD, behavioral counseling, and increased physical activity delivered to individual participants in their homes or delivered to groups of participants in their homes remotely via video conferencing. The primary aim will compare weight loss between interventions arms across 6 months. Secondarily, we will compare weight loss (0-18 mos.), the proportion of participants who achieve clinically meaningful weight loss (≥5%) from 0 to 6 and 0 to18 months, and changes in quality of life from 0 to 6 and 0 to 18 months between interventions arms. We will also conduct cost, cost-effectiveness and contingent valuation comparisons and explore the influence of behavioral session attendance, compliance with the recommendations for diet and physical activity, self-monitoring of diet and physical activity, barriers to physical activity, sleep quality, and medications on weight change across 6 and 18 months. NCT REGISTRATION: NCT04046471.",2020,"We previously demonstrated clinically meaningful 12-month weight loss in adults with MRDs (-6.2%, 36% ≥5% of baseline weight) using an enhanced Stop Light Diet (eSLD) delivered using at home face-to-face behavioral sessions and optional physical activity.","['adults with mobility related disabilities', 'adults with MRDs (-6.2%, 36% ≥5% of baseline weight) using an', '128 overweight/obese adults with MRDs to compare weight loss (6 mos.) and maintenance (12 mos.) between', 'Adults with mobility related disabilities (MRDs']","['Weight management', 'enhanced Stop Light Diet (eSLD', 'interventions utilizing the eSLD, behavioral counseling, and increased physical activity delivered to individual participants in their homes or delivered to groups of participants in their homes remotely via video conferencing']","['quality of life', 'weight loss', 'physical activity, sleep quality, and medications on weight change', 'meaningful weight loss']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C4517820', 'cui_str': '6.2'}, {'cui': 'C1303013', 'cui_str': 'Baseline weight'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}]","[{'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen'}, {'cui': 'C0450446', 'cui_str': 'Stops'}, {'cui': 'C0419181', 'cui_str': 'Light diet'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4546207', 'cui_str': 'Behavioral counseling'}, {'cui': 'C4039165', 'cui_str': 'Increased physical activity'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0042655', 'cui_str': 'Video'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}]",128.0,0.0374796,"We previously demonstrated clinically meaningful 12-month weight loss in adults with MRDs (-6.2%, 36% ≥5% of baseline weight) using an enhanced Stop Light Diet (eSLD) delivered using at home face-to-face behavioral sessions and optional physical activity.","[{'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Washburn', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA. Electronic address: rwashburn@ku.edu.'}, {'ForeName': 'Lauren T', 'Initials': 'LT', 'LastName': 'Ptomey', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA. Electronic address: lptomey@kumc.edu.'}, {'ForeName': 'Anna M', 'Initials': 'AM', 'LastName': 'Gorczyca', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA. Electronic address: agorczyca@kumc.edu.'}, {'ForeName': 'Patricia R', 'Initials': 'PR', 'LastName': 'Smith', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA. Electronic address: psmith18@kumc.edu.'}, {'ForeName': 'Matthew S', 'Initials': 'MS', 'LastName': 'Mayo', 'Affiliation': 'Department of Biostatistics and Data Science, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA. Electronic address: mmayo@kumc.edu.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Lee', 'Affiliation': 'Department of Population Health, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA. Electronic address: rlee2@kumc.edu.'}, {'ForeName': 'Joseph E', 'Initials': 'JE', 'LastName': 'Donnelly', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA. Electronic address: jdonnelly@ku.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106098'] 2924,32768694,"Re: Arshad S, Kilgore P, Chaudhry ZS et al. Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19. Int J Infect Dis: 2020. Epub 2020 Jul 1 http://doi.org/10.1016/j.ijid.2020.06.099.",,2020,,"['Patients Hospitalized with COVID-19', 'Epub 2020']","['Hydroxychloroquine, Azithromycin, and Combination']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}]","[{'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}]",[],,0.0210752,,"[{'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Wiseman', 'Affiliation': 'Synechion, Inc., 18208 Preston Road, Suite D9-405, Dallas, TX 75252. Electronic address: synechion@aol.com.'}]",International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,['10.1016/j.ijid.2020.07.064'] 2925,32768792,The emotion regulatory function of online social networking: Preliminary experimental evidence.,"Correlational research suggests that emotion regulation deficits, which are known risk factors for substance addictions, may also play a role in the development of problem behaviors such as excessive or maladaptive use of social networking sites (SNS). This study sought to experimentally assess the hypothesized emotion regulatory function of SNS use. 139 undergraduates (53.2% female) were randomized to view brief movie clips known to reliably induce positive (37.4%), negative (29.5%), or neutral mood (33.1%) and then to browse a SNS (46.8%) or control website (53.2%). Mood and subjective urge to access SNS and the Internet were assessed before and after viewing the movie clips and browsing the websites. Participants meeting criteria for ""moderate"" levels of disordered SNS use self-reported significantly greater deficits in emotion regulation (p = .02, η p 2  = 0.14). Increases in positive and negative affect following the mood induction were associated with a decrease in subjective urge to access SNS (r = -0.22, p = .02, r = -0.28, p = .002, respectively). Time spent browsing SNS resulted in significantly greater increases in self-reported positive affect, compared to the control website (p = .001, η p 2  = 0.09). We replicate previous findings of greater emotion regulation deficits in individuals endorsing problematic SNS use. Increased positive and negative affect resulted in decreased urge to access SNS, suggesting that social networking may primarily serve to counter low-arousal emotions like boredom. Data provide initial experimental evidence to support the hypothesized emotion regulatory function of SNS, with SNS exposure resulting in increased positive affect. Findings suggest that interventions targeting problematic SNS use should incorporate strategies for improved emotion regulation.",2020,"Time spent browsing SNS resulted in significantly greater increases in self-reported positive affect, compared to the control website (p = .001, η p 2  = 0.09).","['individuals endorsing problematic SNS use', '139 undergraduates (53.2% female']",[],"['subjective urge to access SNS', 'deficits in emotion regulation']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3179002', 'cui_str': 'Social Networking'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C5191072', 'cui_str': '139'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",[],"[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C3179002', 'cui_str': 'Social Networking'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}]",,0.0379552,"Time spent browsing SNS resulted in significantly greater increases in self-reported positive affect, compared to the control website (p = .001, η p 2  = 0.09).","[{'ForeName': 'Rae D', 'Initials': 'RD', 'LastName': 'Drach', 'Affiliation': 'Department of Psychology, University at Albany, State University of New York, United States.'}, {'ForeName': 'Natalia C', 'Initials': 'NC', 'LastName': 'Orloff', 'Affiliation': ""Department of Psychology, University at Albany, State University of New York, United States; Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, United States.""}, {'ForeName': 'Julia M', 'Initials': 'JM', 'LastName': 'Hormes', 'Affiliation': 'Department of Psychology, University at Albany, State University of New York, United States. Electronic address: jhormes@albany.edu.'}]",Addictive behaviors,['10.1016/j.addbeh.2020.106559'] 2926,32768993,The relationship between insomnia and the intensity of drinking in treatment-seeking individuals with alcohol dependence.,"BACKGROUND Although insomnia is highly prevalent in alcohol use disorders(AUD), its associations with the severity of alcohol use, pre-existing psychiatric comorbidities and psychosocial problems are understudied. The present study evaluates the interplay between these factors using a structural equation model (SEM). METHODS We assessed baseline cross-sectional data on patients with AUD (N = 123) recruited to a placebo-controlled medication trial. Severity of alcohol use was measured by the Brief Michigan Alcoholism Screening Test (B-MAST). Insomnia Severity Index was used to assess insomnia symptoms. The Hamilton scales for Depression and Anxiety, Short Index of Problems and Timeline Follow Back evaluated psychiatric symptoms, psychosocial consequences of drinking and level of alcohol consumption respectively. We used logistic regression to evaluate the association between insomnia and severity of alcohol use while controlling for covariates. We constructed a SEM with observed variables to delineate the effect of psychiatric symptoms, psychosocial factors and current alcohol use on the pathway between alcohol use severity and insomnia. RESULTS The sample was predominately male(83.9 %), Black(54.6 %) and employed(60.0 %). About 45 % of the participants reported moderate-severe insomnia.The association between insomnia and B-MAST attenuated after adjustment for demographics, psychiatric symptoms and psychosocial problems(OR[95 % CI] = 1.17(0.99-1.47). SEM findings demonstrated that B-MAST and insomnia were linked to psychiatric symptoms (95 % Asymptotic-Confidence Interval (ACI): 0.015-0.159, p < 0.05) but not to psychosocial problems or current alcohol use. CONCLUSION Among treatment-seeking patients with AUD, psychiatric burden mediated the relationship between severity of alcohol use and insomnia. Clinicians should screen for underlying psychiatric disorders among treatment-seeking patients with AUD complaining of insomnia.",2020,"The association between insomnia and B-MAST attenuated after adjustment for demographics, psychiatric symptoms and psychosocial problems(OR[95 % CI] =","['patients with AUD (N = 123) recruited to a placebo-controlled medication trial', 'treatment-seeking patients with AUD', 'treatment-seeking patients with AUD complaining of insomnia', 'treatment-seeking individuals with alcohol dependence']",[],"['Hamilton scales for Depression and Anxiety, Short Index of Problems and Timeline Follow Back evaluated psychiatric symptoms, psychosocial consequences of drinking and level of alcohol consumption respectively', 'Insomnia Severity Index', 'insomnia symptoms', 'psychiatric symptoms', 'moderate-severe insomnia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439022', 'cui_str': 'Complaining of insomnia'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001973', 'cui_str': 'Alcohol dependence'}]",[],"[{'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0145943', 'cui_str': 'TimeLine'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0233401', 'cui_str': 'Psychiatric symptom'}, {'cui': 'C0686907', 'cui_str': 'Consequence of'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4520529', 'cui_str': 'Insomnia severity index'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",123.0,0.022062,"The association between insomnia and B-MAST attenuated after adjustment for demographics, psychiatric symptoms and psychosocial problems(OR[95 % CI] =","[{'ForeName': 'Ninad S', 'Initials': 'NS', 'LastName': 'Chaudhary', 'Affiliation': 'University of Alabama at Birmingham School of Public Health, 1665 University Blvd, Birmingham, AL, 35211, USA. Electronic address: ninadsc@uab.edu.'}, {'ForeName': 'Maria M', 'Initials': 'MM', 'LastName': 'Wong', 'Affiliation': 'Idaho State University, 921 S 8th Ave, Stop 8112, Pocatello, ID, 83209, USA.'}, {'ForeName': 'Bhanu Prakash', 'Initials': 'BP', 'LastName': 'Kolla', 'Affiliation': 'Department of Psychiatry and Psychology, Mayo Clinic, 2nd ST SW, Rochester, MN, 55905, USA.'}, {'ForeName': 'Kyle M', 'Initials': 'KM', 'LastName': 'Kampman', 'Affiliation': 'Department of Psychiatry, Perelman School of Medicine, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA; Cpl. Michael J. Crescenz VA Medical Center, 3900 Woodland Ave, Philadelphia, PA, 19104, USA.'}, {'ForeName': 'Subhajit', 'Initials': 'S', 'LastName': 'Chakravorty', 'Affiliation': 'Department of Psychiatry, Perelman School of Medicine, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA; Cpl. Michael J. Crescenz VA Medical Center, 3900 Woodland Ave, Philadelphia, PA, 19104, USA. Electronic address: Subhajit.Chakravorty@uphs.upenn.edu.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108189'] 2927,32769027,Does CPAP treat depressive symptoms in individuals with OSA? An analysis of two 12-week randomized sham CPAP-controlled trials.,"BACKGROUND Depression is common in patients with obstructive sleep apnea (OSA). Whether treating OSA with continuous positive airway pressure (CPAP) improves depressive symptoms remains inconclusive. We examined the impact of CPAP on depressive symptoms in OSA patients compared to sham CPAP. METHODS A sub-analysis of two previous randomized sham-controlled trials was conducted. 126 male OSA patients (age = 51 ± 11 years; BMI = 32.0 ± 5.1 kg/m 2 ; apnea hypopnea index = 42.4 ± 22.6 events/hour) were randomised either to therapeutic CPAP (n = 65) or sham CPAP (n = 61). Depressive symptoms were measured using the Depression, Anxiety and Stress Scale (DASS). The main outcome was the change in the DASS depression score (DASSD) after three months between the therapeutic and sham CPAP arms. RESULTS The change in DASSD at three months did not differ between therapeutic and sham CPAP (mean difference: 0.5, 95% CI -3.6 to 4.6, p = 0.80). There was no significant between-group differences within the sub-groups of adherent users (device usage≥4hrs/day), or those with baseline depression (DASSD>9). In a secondary analysis of patients with baseline depression, adherent therapeutic CPAP use was associated with a greater reduction in DASSD scores compared to non-adherers (-10.0, 95% CI -18.3 to -1.8, p = 0.019). CONCLUSIONS Overall, three months of CPAP did not significantly improve depression scores in OSA patients. Adherent use of therapeutic CPAP in patients with baseline depressive symptoms was associated with a reduction in symptom score. Future trials involving OSA patients with higher depressive symptoms will enable us to understand the complex interaction between OSA and depression.",2020,"There was no significant between-group differences within the sub-groups of adherent users (device usage≥4hrs/day), or those with baseline depression (DASSD>9).","['OSA patients with higher depressive symptoms', '126 male OSA patients (age\xa0=\xa051\xa0±\xa011 years; BMI\xa0=\xa032.0\xa0±\xa05.1\xa0kg/m 2 ; apnea hypopnea index\xa0=\xa042.4\xa0±\xa022.6 events/hour', 'patients with baseline depressive symptoms', 'individuals with OSA', 'OSA patients', 'patients with obstructive sleep apnea (OSA']","['OSA with continuous positive airway pressure (CPAP', 'sham CPAP', 'CPAP', 'therapeutic CPAP']","['depression scores', 'Depression, Anxiety and Stress Scale (DASS', 'change in DASSD', 'Depressive symptoms', 'DASSD scores', 'DASS depression score (DASSD', 'depressive symptoms']","[{'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C2111846', 'cui_str': 'Apnea Hypopnea Index'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1832594', 'cui_str': 'Verloes Bourguignon syndrome'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",126.0,0.313538,"There was no significant between-group differences within the sub-groups of adherent users (device usage≥4hrs/day), or those with baseline depression (DASSD>9).","[{'ForeName': 'Yingjuan', 'Initials': 'Y', 'LastName': 'Mok', 'Affiliation': 'Centre for Sleep and Chronobiology,(CIRUS), Woolcock Institute of Medical Research, University of Sydney, Glebe, Australia; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Department of Sleep Medicine, Surgery and Science, Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore.'}, {'ForeName': 'Kerri L', 'Initials': 'KL', 'LastName': 'Melehan', 'Affiliation': 'Centre for Sleep and Chronobiology,(CIRUS), Woolcock Institute of Medical Research, University of Sydney, Glebe, Australia; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.'}, {'ForeName': 'Craig L', 'Initials': 'CL', 'LastName': 'Phillips', 'Affiliation': 'Centre for Sleep and Chronobiology,(CIRUS), Woolcock Institute of Medical Research, University of Sydney, Glebe, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Brendon J', 'Initials': 'BJ', 'LastName': 'Yee', 'Affiliation': 'Centre for Sleep and Chronobiology,(CIRUS), Woolcock Institute of Medical Research, University of Sydney, Glebe, Australia; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Miller', 'Affiliation': 'Centre for Sleep and Chronobiology,(CIRUS), Woolcock Institute of Medical Research, University of Sydney, Glebe, Australia; Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Ronald R', 'Initials': 'RR', 'LastName': 'Grunstein', 'Affiliation': 'Centre for Sleep and Chronobiology,(CIRUS), Woolcock Institute of Medical Research, University of Sydney, Glebe, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Delwyn', 'Initials': 'D', 'LastName': 'Bartlett', 'Affiliation': 'Centre for Sleep and Chronobiology,(CIRUS), Woolcock Institute of Medical Research, University of Sydney, Glebe, Australia.'}, {'ForeName': 'Peter Y', 'Initials': 'PY', 'LastName': 'Liu', 'Affiliation': 'The Lundquist Institute of Biomedical Innovation at Harbor-UCLA Medical Center Torrance, California, USA.'}, {'ForeName': 'Keith K', 'Initials': 'KK', 'LastName': 'Wong', 'Affiliation': 'Centre for Sleep and Chronobiology,(CIRUS), Woolcock Institute of Medical Research, University of Sydney, Glebe, Australia; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.'}, {'ForeName': 'Camilla M', 'Initials': 'CM', 'LastName': 'Hoyos', 'Affiliation': 'Centre for Sleep and Chronobiology,(CIRUS), Woolcock Institute of Medical Research, University of Sydney, Glebe, Australia; School of Psychology, Brain and Mind Centre and Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia. Electronic address: camilla.hoyos@sydney.edu.au.'}]",Sleep medicine,['10.1016/j.sleep.2020.04.021'] 2928,30977581,Implementation of person-centred practice principles and behaviour change techniques after a 2-day training workshop: A nested case study involving physiotherapists.,"OBJECTIVES The aims of the present study were to determine how well physiotherapists implemented person-centred practice principles and behaviour change techniques after a workshop, and to evaluate whether self-audit of performance differed from audits of an experienced training facilitator. METHODS Eight physiotherapists each completed a 2-day workshop followed by two telephone consultations with four patients with knee osteoarthritis. The training facilitator audited audio-recordings of all consultations, and therapists self-audited 50% of consultations using a tool comprising: (a) 10 person-centred practice principles rated on a numerical rating scale of 0 (need to work on this) to 10 (doing really well); and (b) seven behaviour change techniques rated with an ordinal scale (using this technique effectively; need to improve skill level; or need to learn how to apply this technique). RESULTS Physiotherapists showed ""moderate"" fidelity to person-centred principles, with mean scores between 5 and 7 out of 10. For behaviour change techniques, the training facilitator believed that physiotherapists were using three of seven techniques ""effectively"" during most consultations and ""needed to improve skill levels"" with most other techniques. Physiotherapists scored themselves significantly lower than the training facilitator for two of 10 person-centred principles, and tended to rate their skills using behaviour change techniques less favourably. CONCLUSIONS Physiotherapists performed moderately well when implementing person-centred practice principles and behaviour change techniques immediately after training, but had room for improvement, particularly for skills relating to providing management options and changing thinking habits. Physiotherapists' self-ratings of performance generally did not differ from expert ratings; however, they underestimated their ability to implement some principles and techniques.",2019,"CONCLUSIONS Physiotherapists performed moderately well when implementing person-centred practice principles and behaviour change techniques immediately after training, but had room for improvement, particularly for skills relating to providing management options and changing thinking habits.",['Eight physiotherapists each completed a 2-day workshop followed by two telephone consultations with four patients with knee osteoarthritis'],"['training facilitator audited audio-recordings of all consultations, and therapists self-audited 50% of consultations using a tool comprising: (a) 10 person-centred practice principles rated on a numerical rating scale of 0 (need to work on this) to 10 (doing really well); and (b) seven behaviour change techniques rated with an ordinal scale (using this technique effectively; need to improve skill level; or need to learn how to apply this technique', '2-day training workshop']","['moderate"" fidelity']","[{'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0175745', 'cui_str': 'Telephone consultation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0450985', 'cui_str': 'Alcohol use disorders identification test'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439080', 'cui_str': 'Ordinal number'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate'}]",4.0,0.0237845,"CONCLUSIONS Physiotherapists performed moderately well when implementing person-centred practice principles and behaviour change techniques immediately after training, but had room for improvement, particularly for skills relating to providing management options and changing thinking habits.","[{'ForeName': 'Belinda J', 'Initials': 'BJ', 'LastName': 'Lawford', 'Affiliation': 'Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, School of Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.'}, {'ForeName': 'Kim L', 'Initials': 'KL', 'LastName': 'Bennell', 'Affiliation': 'Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, School of Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Kasza', 'Affiliation': 'Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Penny K', 'Initials': 'PK', 'LastName': 'Campbell', 'Affiliation': 'Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, School of Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.'}, {'ForeName': 'Janette', 'Initials': 'J', 'LastName': 'Gale', 'Affiliation': 'HealthChange Australia, Sydney, NSW, Australia.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Bills', 'Affiliation': 'HealthChange Australia, Sydney, NSW, Australia.'}, {'ForeName': 'Rana S', 'Initials': 'RS', 'LastName': 'Hinman', 'Affiliation': 'Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, School of Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.'}]",Musculoskeletal care,['10.1002/msc.1395'] 2929,30993773,Peripheral artery endothelial function responses to altered shear stress patterns in humans.,"NEW FINDINGS What is the central question of this study? What is the effect of altered shear stress pattern, with or without concurrent neurohumoral and metabolic activation, on the acute endothelial function response assessed via brachial artery flow-mediated dilatation? What is the main finding and its importance? Despite generating distinctive shear stress patterns (i.e. increases in anterograde only, anterograde only with neurohumoral and metabolic activation, and both anterograde and retrograde), similar acute improvements were observed in the brachial artery flow-mediated dilatation response in all conditions, indicating that anterograde and/or turbulent shear stress might be the essential element to induce acute increases in endothelial function. ABSTRACT Endothelial function is influenced by both the direction and the magnitude of shear stress. Acute improvements in endothelial function have mostly been attributed to increased anterograde shear, whereas results from many interventional models in humans suggest that enhancing shear stress in an oscillatory manner (anterograde and retrograde) might be optimal. Here, we determined the acute brachial artery shear stress (SS) and flow-mediated dilatation (FMD) responses to three shear-altering interventions [passive heat stress (HEAT), mechanical forearm compression (CUFF) and handgrip exercise (HGEX)] and examined the relationship between changes in oscillatory shear index (OSI) and changes in FMD. During separate visits, 10 young healthy men (22 ± 3 years old) underwent 10 min of HEAT, CUFF or HGEX in their left forearm. Anterograde and retrograde SS, Reynolds number, OSI and FMD were assessed at rest and during/after each intervention. Anterograde SS increased during all interventions in a stepwise manner (P < 0.05 between interventions), with the change in HGEX (∆37.7 ± 12.2 dyn cm -2 , P < 0.05) > CUFF (∆25.1 ± 11.9 dyn cm -2 , P < 0.05) > HEAT (∆14.5 ± 7.9 dyn cm -2 , P < 0.05). Retrograde SS increased during CUFF (∆-19.6 ± 4.3 dyn cm -2 , P < 0.05). Anterograde blood flow was turbulent (i.e. Reynolds number ≥ |2000|) during all interventions (P < 0.05). The relative FMD improved after all interventions (P = 0.01), and there was no relationship between ∆OSI and ∆FMD. We elicited changes in SS profiles including increased anterograde SS (HEAT and HGEX) and both increased anterograde and retrograde SS (CUFF); regardless of the SS pattern, FMD improved to the same extent. These findings suggest that the presence of anterograde and/or turbulent SS might be the key to optimizing endothelial function in acute assessment protocols.",2019,"Retrograde SS increased during CUFF (∆-19.6 ± 4.3 dyn cm -2 , P < 0.05).","['10 young healthy men (22\xa0±\xa03\xa0years old) underwent', 'humans']","['10\xa0min of HEAT, CUFF or HGEX', 'shear-altering interventions [passive heat stress (HEAT), mechanical forearm compression (CUFF) and handgrip exercise (HGEX']","['Retrograde SS increased during CUFF', 'Anterograde SS', 'relative FMD', 'SS profiles including increased anterograde SS (HEAT and HGEX', 'Anterograde and retrograde SS, Reynolds number, OSI and FMD', 'Peripheral artery endothelial function responses', 'brachial artery flow-mediated dilatation response', 'Anterograde blood flow', 'oscillatory shear index (OSI) and changes in FMD', 'acute brachial artery shear stress (SS) and flow-mediated dilatation (FMD) responses', 'anterograde and retrograde SS (CUFF']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0282507', 'cui_str': 'Stress Disorders, Heat'}, {'cui': 'C0441107', 'cui_str': 'Device cuff'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0175735', 'cui_str': 'Scissors'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0016536', 'cui_str': 'Forearm structure'}, {'cui': 'C0332459', 'cui_str': 'Compression'}]","[{'cui': 'C0439784', 'cui_str': 'Retrograde direction'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0441107', 'cui_str': 'Device cuff'}, {'cui': 'C0589502', 'cui_str': 'Antegrade direction'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0002940', 'cui_str': 'Aneurysm'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0282507', 'cui_str': 'Stress Disorders, Heat'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175735', 'cui_str': 'Scissors'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0006087', 'cui_str': 'Structure of brachial artery'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}]",,0.0191569,"Retrograde SS increased during CUFF (∆-19.6 ± 4.3 dyn cm -2 , P < 0.05).","[{'ForeName': 'Jem L', 'Initials': 'JL', 'LastName': 'Cheng', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Jason S', 'Initials': 'JS', 'LastName': 'Au', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Maureen J', 'Initials': 'MJ', 'LastName': 'MacDonald', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, Canada.'}]",Experimental physiology,['10.1113/EP087597'] 2930,31087588,The Aesthetic Preference for Nature Sounds Depends on Sound Object Recognition.,"People across the world seek out beautiful sounds in nature, such as a babbling brook or a nightingale song, for positive human experiences. However, it is unclear whether this positive aesthetic response is driven by a preference for the perceptual features typical of nature sounds versus a higher-order association of nature with beauty. To test these hypotheses, participants provided aesthetic judgments for nature and urban soundscapes that varied on ease of recognition. Results demonstrated that the aesthetic preference for nature soundscapes was eliminated for the sounds hardest to recognize, and moreover the relationship between aesthetic ratings and several measured acoustic features significantly changed as a function of recognition. In a follow-up experiment, requiring participants to classify these difficult-to-identify sounds into nature or urban categories resulted in a robust preference for nature sounds and a relationship between aesthetic ratings and our measured acoustic features that was more typical of easy-to-identify sounds. This pattern of results was replicated with computer-generated artificial noises, which acoustically shared properties with the nature and urban soundscapes but by definition did not come from these environments. Taken together, these results support the conclusion that the recognition of a sound as either natural or urban dynamically organizes the relationship between aesthetic preference and perceptual features and that these preferences are not inherent to the acoustic features. Implications for nature's role in cognitive and affective restoration are discussed.",2019,"Results demonstrated that the aesthetic preference for nature soundscapes was eliminated for the sounds hardest to recognize, and moreover the relationship between aesthetic ratings and several measured acoustic features significantly changed as a function of recognition.",[],[],['aesthetic preference for nature soundscapes'],[],[],"[{'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0349590', 'cui_str': 'Nature'}]",,0.017068,"Results demonstrated that the aesthetic preference for nature soundscapes was eliminated for the sounds hardest to recognize, and moreover the relationship between aesthetic ratings and several measured acoustic features significantly changed as a function of recognition.","[{'ForeName': 'Stephen C', 'Initials': 'SC', 'LastName': 'Van Hedger', 'Affiliation': 'Department of Psychology, The University of Chicago.'}, {'ForeName': 'Howard C', 'Initials': 'HC', 'LastName': 'Nusbaum', 'Affiliation': 'Department of Psychology, The University of Chicago.'}, {'ForeName': 'Shannon L M', 'Initials': 'SLM', 'LastName': 'Heald', 'Affiliation': 'Department of Psychology, The University of Chicago.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Huang', 'Affiliation': 'Department of Psychology, The University of Chicago.'}, {'ForeName': 'Hiroki P', 'Initials': 'HP', 'LastName': 'Kotabe', 'Affiliation': 'SKK Graduate School of Business, Sungkyunkwan University.'}, {'ForeName': 'Marc G', 'Initials': 'MG', 'LastName': 'Berman', 'Affiliation': 'Department of Psychology, The University of Chicago.'}]",Cognitive science,['10.1111/cogs.12734'] 2931,32767902,Progress testing anytime and anywhere - Does a mobile-learning approach enhance the utility of a large-scale formative assessment tool?,"BACKGROUND The widespread use of mobile devices among students favors the use of mobile learning scenarios at universities. In this study, we explore whether a time- and location-independent variant of a formative progress test has an impact on the students' acceptance, its validity and reliability and if there is a difference in response processes between the two exam conditions. METHODS Students were randomly assigned to two groups of which one took the test free of local or temporal fixations, while the other group took the test at the local testing center under usual examination conditions. Beside the generated test data, such as test score, time-on-test, and semester status, students also evaluated the settings. RESULTS While there was no significant effect on the test score between the two groups, students in the mobile group spent more time on the test and were more likely to use the help of books or online resources. The results of the evaluation show that the acceptability among students is increased by a mobile version of the formative progress test. CONCLUSIONS The results suggest that the acceptance and motivation to participate in formative tests is enhanced by lifting local and temporal restrictions. The mobile version nonetheless does not have an impact on the students' performance.",2020,"The results of the evaluation show that the acceptability among students is increased by a mobile version of the formative progress test. ",['Students'],[],[],"[{'cui': 'C0038492', 'cui_str': 'Student'}]",[],[],,0.0359183,"The results of the evaluation show that the acceptability among students is increased by a mobile version of the formative progress test. ","[{'ForeName': 'Yassin', 'Initials': 'Y', 'LastName': 'Karay', 'Affiliation': ""Dean's Office for Student Affairs, Faculty of Medicine, University of Cologne, Cologne, Germany.""}, {'ForeName': 'Birger', 'Initials': 'B', 'LastName': 'Reiss', 'Affiliation': ""Dean's Office for Student Affairs, Faculty of Medicine, University of Cologne, Cologne, Germany.""}, {'ForeName': 'Stefan K', 'Initials': 'SK', 'LastName': 'Schauber', 'Affiliation': 'Centre for Health Sciences Education, Faculty of Medicine, University of Oslo, Oslo, Norway.'}]",Medical teacher,['10.1080/0142159X.2020.1798910'] 2932,32767971,Intraoperative cell salvage for obstetrics: a prospective randomized controlled clinical trial.,"BACKGROUND The latest basic studies and clinical evidence have confirmed the safety and efficacy of intraoperative autologous blood cell transfusion in cardiac surgery and orthopaedics. However, in caesarean section, there are still concerns about the contamination of amniotic fluid and foetal components, and consequently the application of intraoperative autologous blood cell transfusion is not universal. Therefore, this study aimed to evaluate the clinical value of intraoperative autologous blood cell transfusion in obstetric surgery. METHODS A prospective, randomized, controlled, feasibility study was performed in women undergoing caesarean section. One hundred sixteen participants were randomly assigned at a 1:1 ratio into either the intraoperative cell salvage group or the control group. Allogeneic blood cells were transfused into patients with haemoglobin concentrations < 80 g/dL in both the intraoperative cell salvage group and the control group. RESULTS No significant differences were found between the two groups in age, weight, maternal parity, history of previous caesarean section, gestational weeks of delivery, etc. However, compared with the control group, patients in the intraoperative cell salvage group had a significantly lower amount of allogeneic blood cell transfusion, lower incidence of postoperative incision infection, delayed wound healing, perioperative allergy, adverse cardiovascular events, hypoproteinaemia and shorter hospital stay. CONCLUSION The results of this study suggest that the use of autologous blood cell transfusion is safe and effective for patients with obstetric haemorrhage. TRIAL REGISTRATION All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional and/or National Research Committee of Beijing Obstetrics and Gynecology Hospital, Capital Medical University (2016-XJS-003-01) as well as the 1964 Helsinki Declaration and its later amendments or other comparable ethical standards. The clinical trials were registered (ChiCTR-ICC-15,007,096) on September 28, 2015.",2020,"No significant differences were found between the two groups in age, weight, maternal parity, history of previous caesarean section, gestational weeks of delivery, etc.","['women undergoing caesarean section', 'patients with obstetric haemorrhage', 'obstetrics', 'One hundred sixteen participants']","['Intraoperative cell salvage', 'intraoperative cell salvage group or the control group', 'autologous blood cell transfusion', 'intraoperative autologous blood cell transfusion']","['Allogeneic blood cells', 'age, weight, maternal parity, history of previous caesarean section, gestational weeks of delivery, etc', 'allogeneic blood cell transfusion, lower incidence of postoperative incision infection, delayed wound healing, perioperative allergy, adverse cardiovascular events, hypoproteinaemia and shorter hospital stay']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C3715157', 'cui_str': '16'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0085405', 'cui_str': 'Salvage therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0005773', 'cui_str': 'Blood cell'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}]","[{'cui': 'C0005773', 'cui_str': 'Blood cell'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0030563', 'cui_str': 'Parity'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0269733', 'cui_str': 'Previous caesarean section'}, {'cui': 'C0439671', 'cui_str': 'Gestational'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0151692', 'cui_str': 'Impaired wound healing'}, {'cui': 'C0002111', 'cui_str': 'Allergy - specialty'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0020639', 'cui_str': 'Hypoproteinemia'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",116.0,0.0395346,"No significant differences were found between the two groups in age, weight, maternal parity, history of previous caesarean section, gestational weeks of delivery, etc.","[{'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Anaesthesiology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, 100026, Beijing, China.'}, {'ForeName': 'Xiaoguang', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Anaesthesiology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, 100026, Beijing, China.'}, {'ForeName': 'Xiangming', 'Initials': 'X', 'LastName': 'Che', 'Affiliation': 'Department of Anaesthesiology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, 100026, Beijing, China.'}, {'ForeName': 'Guosheng', 'Initials': 'G', 'LastName': 'Zhao', 'Affiliation': 'Department of Anaesthesiology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, 100026, Beijing, China.'}, {'ForeName': 'Mingjun', 'Initials': 'M', 'LastName': 'Xu', 'Affiliation': 'Department of Anaesthesiology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, 100026, Beijing, China. snake650222@126.com.'}]",BMC pregnancy and childbirth,['10.1186/s12884-020-03138-w'] 2933,32767988,"A single-center, randomized, non-inferiority study evaluating seroma formation after mastectomy combined with flap fixation with or without suction drainage: protocol for the Seroma reduction and drAin fRee mAstectomy (SARA) trial.","BACKGROUND Seroma formation is a common complication after breast cancer surgery and can lead to delayed wound healing, infection, patient discomfort and repeated visits to the outpatient clinic. Mastectomy combined with flap fixation is becoming standard practice and is currently combined with closed-suction drainage. There is evidence showing that closed-suction drainage may be insufficient in preventing seroma formation. There is reasonable doubt whether there is still place for closed-suction drainage after mastectomy when flap fixation is performed. We hypothesize that mastectomy combined with flap fixation and closed suction drainage does not cause a significant lower incidence of seroma aspirations, when compared to mastectomy and flap fixation alone. Furthermore, we expect that patients without drainage will experience significantly less discomfort and comparable rates of surgical site infections. METHODS This is a randomized controlled trial in female breast cancer patients undergoing mastectomy and flap fixation using sutures with or without sentinel lymph node biopsy (SLNB). Patients will be eligible for inclusion if they are older than 18 years, have an indication for mastectomy with or without sentinel procedure. Exclusion criteria are modified radical mastectomy, direct breast reconstruction, previous history of radiation therapy of the unilateral breast, breast conserving therapy and inability to give informed consent. A total of 250 patients will be randomly allocated to one of two groups: mastectomy combined with flap fixation and closed-suction drainage or mastectomy combined with flap fixation without drainage. Follow-up will be conducted up to six months postoperatively. The primary outcome is the proportion of patients undergoing one or more seroma aspirations. Secondary outcome measures consist of the number of invasive interventions, surgical site infection, quality of life measured using the SF-12 Health Survey, cosmesis, pain and number of additional outpatient department visits. DISCUSSION To our knowledge, no randomized controlled trial has been conducted comparing flap fixation with and without closed-suction drainage with seroma aspiration as the primary outcome. This study could result in finding evidence that supports performing mastectomy without closed-suction drainage. TRIAL REGISTRATION This trial was approved by the medical ethical committee of Zuyderland Medical Center METC-Z on 20 March 2019 (METCZ20190023). The SARA Trial was registered at ClinicalTrials.gov as per July 2019, Identifier: NCT04035590 .",2020,"We hypothesize that mastectomy combined with flap fixation and closed suction drainage does not cause a significant lower incidence of seroma aspirations, when compared to mastectomy and flap fixation alone.","['Patients will be eligible for inclusion if they are older than 18\u2009years, have an indication for mastectomy with or without sentinel procedure', '250 patients', 'female breast cancer patients undergoing']","['Mastectomy combined with flap fixation', 'mastectomy combined with flap fixation with or without suction drainage: protocol', 'flap fixation with and without closed-suction drainage with seroma aspiration', 'mastectomy combined with flap fixation and closed suction drainage', 'mastectomy combined with flap fixation and closed-suction drainage or mastectomy combined with flap fixation without drainage', 'mastectomy and flap fixation using sutures with or without sentinel lymph node biopsy (SLNB']","['seroma formation', 'number of invasive interventions, surgical site infection, quality of life measured using the SF-12 Health Survey, cosmesis, pain and number of additional outpatient department visits', 'proportion of patients undergoing one or more seroma aspirations', 'discomfort']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0235653', 'cui_str': 'Malignant neoplasm of female breast'}]","[{'cui': 'C0024881', 'cui_str': 'Mastectomy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0038925', 'cui_str': 'Flap'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0038638', 'cui_str': 'Suction drainage'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0262627', 'cui_str': 'Seroma'}, {'cui': 'C0004056', 'cui_str': 'Aspiration, Psychology'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0796693', 'cui_str': 'Sentinel lymph node biopsy'}]","[{'cui': 'C0262627', 'cui_str': 'Seroma'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004056', 'cui_str': 'Aspiration, Psychology'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}]",250.0,0.150699,"We hypothesize that mastectomy combined with flap fixation and closed suction drainage does not cause a significant lower incidence of seroma aspirations, when compared to mastectomy and flap fixation alone.","[{'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'de Rooij', 'Affiliation': 'Department of Surgery, Zuyderland Medical Center, Postbus 5500, 6130, MB, Sittard, the Netherlands. l.derooij@zuyderland.nl.'}, {'ForeName': 'Sander M J', 'Initials': 'SMJ', 'LastName': 'van Kuijk', 'Affiliation': 'Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, the Netherlands.'}, {'ForeName': 'Els R M', 'Initials': 'ERM', 'LastName': 'van Haaren', 'Affiliation': 'Department of Surgery, Zuyderland Medical Center, Postbus 5500, 6130, MB, Sittard, the Netherlands.'}, {'ForeName': 'Alfred', 'Initials': 'A', 'LastName': 'Janssen', 'Affiliation': 'Department of Surgery, Zuyderland Medical Center, Postbus 5500, 6130, MB, Sittard, the Netherlands.'}, {'ForeName': 'Yvonne L J', 'Initials': 'YLJ', 'LastName': 'Vissers', 'Affiliation': 'Department of Surgery, Zuyderland Medical Center, Postbus 5500, 6130, MB, Sittard, the Netherlands.'}, {'ForeName': 'Geerard L', 'Initials': 'GL', 'LastName': 'Beets', 'Affiliation': 'Department of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'van Bastelaar', 'Affiliation': 'Department of Surgery, Zuyderland Medical Center, Postbus 5500, 6130, MB, Sittard, the Netherlands.'}]",BMC cancer,['10.1186/s12885-020-07242-0'] 2934,32767989,Technology versus tradition: a non-inferiority trial comparing video to face-to-face consultations with a physiotherapist for people with knee osteoarthritis. Protocol for the PEAK randomised controlled trial.,"BACKGROUND Knee osteoarthritis (OA) is a global problem that causes significant pain and physical dysfunction, substantially impacting on quality of life and imposing enormous cost to the healthcare system. Exercise is pivotal to OA management, yet uptake by people with knee OA is inadequate. Limited access to appropriately skilled health professionals, such as physiotherapists, for prescription of an exercise program and support with exercise is a major barrier to optimal care. Internet-enabled video consultations permit widespread reach. However, services offering video consultations with physiotherapists for musculoskeletal conditions are scant in Australia where there is typically no Government or private health insurer funding for such services. The paucity of robust evidence demonstrating video consultations with physiotherapists are clinically effective, safe and cost-effective for knee OA is hampering implementation of, and willingness of healthcare policymakers to pay for, these services. METHODS This is an assessor- and participant-blinded, two-arm, pragmatic, comparative effectiveness non-inferiority randomised controlled trial (RCT) conducted in Australia. We are recruiting 394 people from the community with chronic knee pain consistent with a clinical diagnosis of knee OA. Participants are randomly allocated to receive physiotherapy care via i) video-conferencing or; ii) face-to-face consultations. Participants are provided five consultations (30-45 min each) with a physiotherapist over 3 months for prescription of a home-based strengthening exercise program (to be conducted independently at home) and physical activity plan, as well as OA education. Participants in both groups are provided with educational booklets and simple exercise equipment via post. The co-primary outcomes are change in self-reported i) knee pain on walking; and ii) physical function, with a primary end-point of 3 months and a secondary end-point of 9 months. Secondary outcomes include changes in other clinical outcomes (health-related quality of life; therapeutic relationship; global ratings of change; satisfaction with care; self-efficacy; physical activity levels), time and financial costs of attending consultations, healthcare usage and convenience. Non-inferiority will be assessed using the per-protocol dataset. DISCUSSION Findings will determine if video consultations with physiotherapists are non-inferior to traditional face-to-face consultations for management of people with knee OA. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry, ACTRN12619001240134. http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377672&isReview=true.",2020,"DISCUSSION Findings will determine if video consultations with physiotherapists are non-inferior to traditional face-to-face consultations for management of people with knee OA. ","['394 people from the community with chronic knee pain consistent with a clinical diagnosis of knee OA', 'Knee osteoarthritis (OA', 'people with knee osteoarthritis']","['http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377672&isReview=true', 'Technology versus tradition', 'educational booklets and simple exercise equipment via post', 'physiotherapy care via i) video-conferencing or; ii) face-to-face consultations', 'physiotherapist over 3\u2009months for prescription of a home-based strengthening exercise program (to be conducted independently at home) and physical activity plan, as well as OA education']","['change in self-reported i) knee pain on walking; and ii) physical function, with a primary end-point of 3\u2009months and a secondary end-point of 9\u2009months', 'changes in other clinical outcomes (health-related quality of life; therapeutic relationship; global ratings of change; satisfaction with care; self-efficacy; physical activity levels), time and financial costs of attending consultations, healthcare usage and convenience']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0231749', 'cui_str': 'Knee pain'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C0332140', 'cui_str': 'Clinical diagnosis'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0452260', 'cui_str': 'Muscular strength development exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0231749', 'cui_str': 'Knee pain'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0457083', 'cui_str': 'Usage'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}]",394.0,0.114132,"DISCUSSION Findings will determine if video consultations with physiotherapists are non-inferior to traditional face-to-face consultations for management of people with knee OA. ","[{'ForeName': 'Rana S', 'Initials': 'RS', 'LastName': 'Hinman', 'Affiliation': 'Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, School of Health Sciences, Faculty of Medicine Dentistry & Health Sciences, The University of Melbourne, Melbourne, Australia. ranash@unimelb.edu.au.'}, {'ForeName': 'Alexander J', 'Initials': 'AJ', 'LastName': 'Kimp', 'Affiliation': 'Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, School of Health Sciences, Faculty of Medicine Dentistry & Health Sciences, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Penny K', 'Initials': 'PK', 'LastName': 'Campbell', 'Affiliation': 'Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, School of Health Sciences, Faculty of Medicine Dentistry & Health Sciences, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Trevor', 'Initials': 'T', 'LastName': 'Russell', 'Affiliation': 'RECOVER Injury Research Centre, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Nadine E', 'Initials': 'NE', 'LastName': 'Foster', 'Affiliation': 'Primary Care Centre Versus Arthritis, School of Primary, Community and Social Care, Keele University, Staffordshire, UK.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Kasza', 'Affiliation': 'School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Harris', 'Affiliation': 'Centre for Health Economics, Monash Business School, Monash University, Melbourne, Australia.'}, {'ForeName': 'Kim L', 'Initials': 'KL', 'LastName': 'Bennell', 'Affiliation': 'Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, School of Health Sciences, Faculty of Medicine Dentistry & Health Sciences, The University of Melbourne, Melbourne, Australia.'}]",BMC musculoskeletal disorders,['10.1186/s12891-020-03523-8'] 2935,32768050,Spatially localized sparse representations for breast lesion characterization.,"RATIONALE The topic of sparse representation of samples in high dimensional spaces has attracted growing interest during the past decade. In this work, we develop sparse representation-based methods for classification of radiological imaging patterns of breast lesions into benign and malignant states. METHODS We propose a spatial block decomposition method to address irregularities of the approximation problem and to build an ensemble of classifiers (CL) that we expect to yield more accurate numerical solutions than conventional whole-region of interest (ROI) sparse analyses. We introduce two classification decision strategies based on maximum a posteriori probability (BBMAP-S), or a log likelihood function (BBLL-S). RESULTS To evaluate the performance of the proposed approach we used cross-validation techniques on imaging datasets with disease class labels. We utilized the proposed approach for separation of breast lesions into benign and malignant categories in mammograms. The level of difficulty is high in this application and the accuracy may depend on the lesion size. Our results indicate that the proposed integrative sparse analysis addresses the ill-posedness of the approximation problem, producing AUC (area under the receiver operating curve) value of 89.1% for randomized 30-fold cross-validation. CONCLUSIONS Furthermore, our comparative experiments showed that the BBLL-S decision function may yield more accurate classification than BBMAP-S because BBLL-S accounts for possible estimation bias.",2020,"We introduce two classification decision strategies based on maximum a posteriori probability (BBMAP-S), or a log likelihood function (BBLL-S). ",[],[],[],[],[],[],,0.0375101,"We introduce two classification decision strategies based on maximum a posteriori probability (BBMAP-S), or a log likelihood function (BBLL-S). ","[{'ForeName': 'Keni', 'Initials': 'K', 'LastName': 'Zheng', 'Affiliation': 'Division of Physics, Engineering, Mathematics and Computer Science, Delaware State University, 1200 N. DuPont Hwy, Dover, DE, 19901-2277, USA.'}, {'ForeName': 'Chelsea', 'Initials': 'C', 'LastName': 'Harris', 'Affiliation': 'Division of Physics, Engineering, Mathematics and Computer Science, Delaware State University, 1200 N. DuPont Hwy, Dover, DE, 19901-2277, USA.'}, {'ForeName': 'Predrag', 'Initials': 'P', 'LastName': 'Bakic', 'Affiliation': 'Department of Radiology, Univ. of Pennsylvania, Philadelphia, PA, 19152, USA.'}, {'ForeName': 'Sokratis', 'Initials': 'S', 'LastName': 'Makrogiannis', 'Affiliation': 'Division of Physics, Engineering, Mathematics and Computer Science, Delaware State University, 1200 N. DuPont Hwy, Dover, DE, 19901-2277, USA. Electronic address: smakrogiannis@desu.edu.'}]",Computers in biology and medicine,['10.1016/j.compbiomed.2020.103914'] 2936,32768315,"Effects of high versus standard essential amino acid intakes on whole-body protein turnover and mixed muscle protein synthesis during energy deficit: A randomized, crossover study.","BACKGROUND & AIMS Consuming 0.10-0.14 g essential amino acids (EAA)/kg/dose (0.25-0.30 g protein/kg/dose) maximally stimulates muscle protein synthesis (MPS) during energy balance. Whether consuming EAA beyond that amount enhances MPS and whole-body anabolism following energy deficit is unknown. The aims of this study were to determine the effects of standard and high EAA ingestion on mixed MPS and whole-body protein turnover following energy deficit. DESIGN Nineteen males (mean ± SD; 23 ± 5 y; 25.4 ± 2.7 kg/m 2 ) completed a randomized, double-blind crossover study consisting of two, 5-d energy deficits (-30 ± 4% of total energy requirements), separated by 14-d. Following each energy deficit, mixed MPS and whole-body protein synthesis (PS), breakdown (PB), and net balance (NET) were determined at rest and post-resistance exercise (RE) using primed, constant L-[ 2 H 5 ]-phenylalanine and L-[ 2 H 2 ]-tyrosine infusions. Beverages providing standard (0.1 g/kg, 7.87 ± 0.87 g) or high (0.3 g/kg, 23.5 ± 2.54 g) EAA were consumed post-RE. Circulating EAA were measured. RESULTS Postabsorptive mixed MPS (%/h) at rest was not different (P = 0.67) between treatments. Independent of EAA, postprandial mixed MPS at rest (standard EAA, 0.055 ± 0.01; high EAA, 0.061 ± 0.02) and post-RE (standard EAA, 0.055 ± 0.01; high EAA, 0.065 ± 0.02) were greater than postabsorptive mixed MPS at rest (P = 0.02 and P = 0.01, respectively). Change in (Δ postabsorptive) whole-body (g/180 min) PS and PB was greater for high than standard EAA [mean treatment difference (95% CI), 3.4 (2.3, 4.4); P = 0.001 and -15.6 (-17.8, -13.5); P = 0.001, respectively]. NET was more positive for high than standard EAA [19.0 (17.3, 20.7); P = 0.001]. EAA concentrations were greater in high than standard EAA (P = 0.001). CONCLUSIONS These data demonstrate that high compared to standard EAA ingestion enhances whole-body protein status during underfeeding. However, the effects of consuming high and standard EAA on mixed MPS are the same during energy deficit. CLINICAL TRIAL REGISTRY NCT03372928, https://clinicaltrials.gov.",2020,"RESULTS Postabsorptive mixed MPS (%/h) at rest was not different (P = 0.67) between treatments.","['Nineteen males (mean\xa0±\xa0SD; 23\xa0±', 'energy deficit', 'y; 25.4\xa0±\xa02.7\xa0kg/m 2 ']","['high versus standard essential amino acid intakes', 'resistance exercise (RE) using primed, constant L-[ 2 H 5 ]-phenylalanine and L', 'standard and high EAA ingestion']","['Circulating EAA', 'EAA concentrations', 'PS and PB', 'mixed MPS and whole-body protein synthesis (PS), breakdown (PB), and net balance (NET']","[{'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4517635', 'cui_str': '2.7'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0556115', 'cui_str': 'Essential amino acid intake'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0331021', 'cui_str': 'Ligustrum vulgare'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}, {'cui': 'C0031453', 'cui_str': 'Phenylalanine'}, {'cui': 'C0002525', 'cui_str': 'Essential amino acid'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0002525', 'cui_str': 'Essential amino acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0597295', 'cui_str': 'Genetic translation'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0026832', 'cui_str': 'Muscle Protein'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0699900', 'cui_str': 'Catabolism'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]",,0.113231,"RESULTS Postabsorptive mixed MPS (%/h) at rest was not different (P = 0.67) between treatments.","[{'ForeName': 'Jess A', 'Initials': 'JA', 'LastName': 'Gwin', 'Affiliation': 'Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA, USA; Oak Ridge Institute for Science and Education, Belcamp, MD, USA.'}, {'ForeName': 'David D', 'Initials': 'DD', 'LastName': 'Church', 'Affiliation': 'Department of Geriatrics, Donald W. Reynolds Institute on Aging, Center for Translational Research in Aging & Longevity, University of Arkansas for Medical Sciences, Little Rock, AR, USA.'}, {'ForeName': 'Adrienne', 'Initials': 'A', 'LastName': 'Hatch-McChesney', 'Affiliation': 'Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA, USA.'}, {'ForeName': 'Emily E', 'Initials': 'EE', 'LastName': 'Howard', 'Affiliation': 'Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA, USA; Oak Ridge Institute for Science and Education, Belcamp, MD, USA.'}, {'ForeName': 'Christopher T', 'Initials': 'CT', 'LastName': 'Carrigan', 'Affiliation': 'Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA, USA.'}, {'ForeName': 'Nancy E', 'Initials': 'NE', 'LastName': 'Murphy', 'Affiliation': 'Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA, USA.'}, {'ForeName': 'Marques A', 'Initials': 'MA', 'LastName': 'Wilson', 'Affiliation': 'Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA, USA.'}, {'ForeName': 'Lee M', 'Initials': 'LM', 'LastName': 'Margolis', 'Affiliation': 'Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA, USA.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Carbone', 'Affiliation': 'School of Health Sciences, Eastern Michigan University, Ypsilanti, MI, USA.'}, {'ForeName': 'Robert R', 'Initials': 'RR', 'LastName': 'Wolfe', 'Affiliation': 'Department of Geriatrics, Donald W. Reynolds Institute on Aging, Center for Translational Research in Aging & Longevity, University of Arkansas for Medical Sciences, Little Rock, AR, USA.'}, {'ForeName': 'Arny A', 'Initials': 'AA', 'LastName': 'Ferrando', 'Affiliation': 'Department of Geriatrics, Donald W. Reynolds Institute on Aging, Center for Translational Research in Aging & Longevity, University of Arkansas for Medical Sciences, Little Rock, AR, USA.'}, {'ForeName': 'Stefan M', 'Initials': 'SM', 'LastName': 'Pasiakos', 'Affiliation': 'Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA, USA. Electronic address: stefan.m.pasiakos.civ@mail.mil.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.07.019'] 2937,32768353,Impact of Simulation Training on Radiology Resident Performance in Neonatal Head Ultrasound.,"RATIONALE AND OBJECTIVES The aim of this study was to determine whether resident performance in head ultrasound on neonates improves following brain phantom simulation training. MATERIALS AND METHODS Ten junior radiology residents with at least one year of radiology training were divided into two equal groups. Both groups received a detailed head ultrasound protocol sheet and observed a technologist perform a head ultrasound on a neonatal patient at the beginning of their first pediatric radiology rotation. Both groups of residents also received teaching with a brain phantom model. Group A residents independently performed one head ultrasound exam, subsequently received phantom simulation training, and then performed a post-training head ultrasound exam. Group B residents received phantom simulation training prior to their first head ultrasound exam. Three pediatric radiologists independently and blindly reviewed the ultrasound images of each head ultrasound exam for proficiency of image acquisition using a validated scoring system. Scores of Group A residents prior to phantom training were compared to their scores after phantom training as well as to scores of Group B residents using simple linear regression. RESULTS There was a statistically significant improvement in the performance of head ultrasound on neonates when comparing the same residents pre- and postphantom training (p = 0.003). Residents who initially trained with the phantom performed significantly better on their first head ultrasound examination on a neonate than those residents who did not (p = 0.005). CONCLUSION Our novel head ultrasound phantom training model significantly improves radiology resident performance of head ultrasound on neonates and may, therefore, be beneficial for residency education.",2020,There was a statistically significant improvement in the performance of head ultrasound on neonates when comparing the same residents pre- and postphantom training (p = 0.003).,"['Ten junior radiology residents with at least one year of radiology training', 'Neonatal Head Ultrasound']","['phantom simulation training', 'Simulation Training', 'detailed head ultrasound protocol sheet and observed a technologist perform a head ultrasound', 'teaching with a brain phantom model']",['performance of head ultrasound'],"[{'cui': 'C0034599', 'cui_str': 'Radiology - specialty'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}]","[{'cui': 'C0282611', 'cui_str': 'Phantom'}, {'cui': 'C4042947', 'cui_str': 'Simulation Training'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0439643', 'cui_str': 'Sheets'}, {'cui': 'C0260280', 'cui_str': 'Technologist'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}]",10.0,0.0150092,There was a statistically significant improvement in the performance of head ultrasound on neonates when comparing the same residents pre- and postphantom training (p = 0.003).,"[{'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Gorelik', 'Affiliation': 'Department of Diagnostic Radiology, McGill University Health Center, 1001 Decarie Blvd, Montreal, QC, Canada H4A 3J1. Electronic address: natalia.gorelik@mail.mcgill.ca.'}, {'ForeName': 'Kedar', 'Initials': 'K', 'LastName': 'Patil', 'Affiliation': 'Department of Diagnostic Imaging, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Sean Jy-Shyang', 'Initials': 'SJ', 'LastName': 'Chen', 'Affiliation': 'McConnell Brain Imaging, Montreal Neurological Institute, Montreal, Quebec, Canada.'}, {'ForeName': 'Sahir', 'Initials': 'S', 'LastName': 'Bhatnagar', 'Affiliation': 'Departments of Epidemiology, Biostatistics and Occupational Health, Diagnostic Radiology, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Faingold', 'Affiliation': 'Department of Diagnostic Imaging, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.'}]",Academic radiology,['10.1016/j.acra.2020.06.040'] 2938,32768361,"One Year of Netarsudil and Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Phase 3, Randomized MERCURY-1 Study.","PURPOSE A phase 3 trial (MERCURY-1) investigated efficacy and safety of a once-daily, fixed-dose combination (FDC) of netarsudil and latanoprost, compared with each active component, in reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). A planned 3-month analysis demonstrated the superiority of netarsudil/latanoprost FDC over its individual active components at every assessment. Herein, the 12-month efficacy and safety of netarsudil/latanoprost FDC are reported. DESIGN Double-masked, randomized, active-controlled, parallel-group trial. PARTICIPANTS Patients had unmedicated IOP >20 to <36 mmHg in both eyes at 8:00 am and met other standard criteria for OAG or OHT. METHODS Randomization to once-daily netarsudil 0.02%/latanoprost 0.005% FDC (n = 238), netarsudil 0.02% only (n = 243), or latanoprost 0.005% only (n = 237). Patients instilled study drug into each eye between 8:00 pm and 10:00 pm. MAIN OUTCOME MEASURES IOP was obtained at 8:00 am, 10:00 am, and 4:00 pm on day 1 (baseline); at weeks 2 and 6; and at months 3, 6, 9, and 12. Ocular and systemic safety were evaluated up to month 12. RESULTS Netarsudil/latanoprost FDC maintained statistically superior IOP lowering compared to its components at every assessment for 12 months. Least squares mean diurnal IOP (± standard error) at month 12 was 16.2 ± 0.23 mmHg for netarsudil/latanoprost FDC, 17.9 ± 0.20 mmHg for netarsudil, and 17.6 ± 0.18 mmHg for latanoprost (P < 0.05 for netarsudil/latanoprost FDC versus each comparator). The safety profile of netarsudil/latanoprost FDC was consistent with its individual components. The proportion of patients who experienced at least 1 adverse event (AE) was 82.8% (197/238) in the netarsudil/latanoprost FDC group, 78.2% (190/243) in the netarsudil group, and 54.0% (128/237) in the latanoprost group. The most common AE was conjunctival hyperemia, mostly of mild severity, with an incidence of 63.0% in the netarsudil/ latanoprost FDC treatment group compared with 51.4% in the netarsudil group and 21.9% in the latanoprost group. CONCLUSIONS Results at 12 months revealed superior efficacy for netarsudil/latanoprost FDC compared with the individual components, netarsudil and latanoprost, at every time point assessed and an ocular tolerability profile similar to that of netarsudil alone.",2020,"The most common AE was conjunctival hyperemia, mostly of mild severity, with an incidence of 63.0% in the netarsudil/ latanoprost FDC treatment group compared with 51.4% in the netarsudil group and 21.9% in the latanoprost group. ","['Patients had unmedicated IOP >20 to <36 mmHg in both eyes at 8:00 am and met other standard criteria for OAG or OHT', 'patients with open-angle glaucoma (OAG) or ocular hypertension (OHT']","['Netarsudil and Latanoprost Fixed-Dose Combination', 'netarsudil/latanoprost FDC', 'latanoprost', 'latanoprost FDC', 'fixed-dose combination (FDC) of netarsudil and latanoprost']","['elevated intraocular pressure (IOP', 'ocular tolerability profile', 'Ocular and systemic safety', 'efficacy and safety', 'conjunctival hyperemia']","[{'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0229118', 'cui_str': 'Structure of both eyes'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0017612', 'cui_str': 'Open-angle glaucoma'}, {'cui': 'C0028840', 'cui_str': 'Ocular hypertension'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4535718', 'cui_str': 'netarsudil'}, {'cui': 'C0090306', 'cui_str': 'latanoprost'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]","[{'cui': 'C0234708', 'cui_str': 'Raised intraocular pressure'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1761613', 'cui_str': 'Conjunctival hyperemia'}]",,0.143493,"The most common AE was conjunctival hyperemia, mostly of mild severity, with an incidence of 63.0% in the netarsudil/ latanoprost FDC treatment group compared with 51.4% in the netarsudil group and 21.9% in the latanoprost group. ","[{'ForeName': 'Jacob W', 'Initials': 'JW', 'LastName': 'Brubaker', 'Affiliation': 'Sacramento Eye Consultants, Sacramento, California. Electronic address: jbrubaker@SacEye.com.'}, {'ForeName': 'Savak', 'Initials': 'S', 'LastName': 'Teymoorian', 'Affiliation': 'Harvard Eye Associates, Laguna Hills, California.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Lewis', 'Affiliation': 'Sacramento Eye Consultants, Sacramento, California; Aerie Pharmaceuticals, Inc., Durham, North Carolina.'}, {'ForeName': 'Dale', 'Initials': 'D', 'LastName': 'Usner', 'Affiliation': 'Statistics & Data Corporation, Tempe, Arizona.'}, {'ForeName': 'Hayley J', 'Initials': 'HJ', 'LastName': 'McKee', 'Affiliation': 'Aerie Pharmaceuticals, Inc., Durham, North Carolina.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Ramirez', 'Affiliation': 'Aerie Pharmaceuticals, Inc., Durham, North Carolina.'}, {'ForeName': 'Casey C', 'Initials': 'CC', 'LastName': 'Kopczynski', 'Affiliation': 'Aerie Pharmaceuticals, Inc., Durham, North Carolina.'}, {'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Heah', 'Affiliation': 'Aerie Pharmaceuticals, Inc., Durham, North Carolina.'}]",Ophthalmology. Glaucoma,['10.1016/j.ogla.2020.05.008'] 2939,32768376,Effect of Various Exercises on Intrinsic Capacity in Older Adults With Subjective Cognitive Concerns.,"OBJECTIVES Physical activity is associated with improvement in overall health and well-being, but robust evidence with comprehensive assessment of general health is lacking. This study aimed to clarify the effects of physical activity on intrinsic capacity among community-dwelling older adults with subjective memory concerns. DESIGN A single-blind randomized controlled trial compared aerobic training (AT), resistance training (RT), and combined training (AT+RT) programs for improving general health evaluated by intrinsic capacity. SETTING Toyota, Japan. PARTICIPANTS Residents (65-85 years old) who screened positive for subjective memory concerns using the Kihon checklist were invited for eligibility assessment. In total, 415 community-dwelling older adults were enrolled and randomized into the AT, RT, AT+RT, and control groups. METHODS Participants in the intervention groups underwent a group training program and self-paced home training for 26 weeks. The control group received lectures about health promotion. Intrinsic capacity (IC), constructed based on locomotion, cognition, psychological function, and vitality domains, was used to assess general health at baseline, week 26, and week 52. Between-group differences were exhibited with Z-score change in individual domain and combination of all domains. RESULTS At baseline, mean age of all participants (47% women) was 72.3 ± 4.6 years, with a mean composited IC Z-score of -0.2 ± 0.5. Overall, AT and RT improved composite IC Z-scores by 0.17 (95% confidence interval [CI] 0.03-0.30) and 0.17 (95% CI 0.05-0.28) at week 26, respectively, but the beneficial effects waned at week 52. No significant differences in composite IC Z-scores were found in the AT+RT group at weeks 26 and 52. CONCLUSIONS AND IMPLICATIONS Twenty-six-week AT with self-paced home training and RT with self-paced home training improve IC among community-dwelling older adults with subjective memory concerns, but the benefits waned subsequently. It will be required to develop optimal interventions that have a continuous beneficial effect on IC among community-dwelling older adults.",2020,"Overall, AT and RT improved composite IC Z-scores by 0.17 (95% confidence interval [CI] 0.03-0.30) and 0.17 (95% CI 0.05-0.28) at week 26, respectively, but the beneficial effects waned at week 52.","['Older Adults With Subjective Cognitive Concerns', 'Toyota, Japan', 'community-dwelling older adults with subjective memory concerns', 'community-dwelling older adults', 'Participants in the intervention groups underwent a', '415 community-dwelling older adults', 'Residents (65-85\xa0years old) who screened positive for subjective memory concerns using the Kihon checklist were invited for eligibility assessment']","['lectures about health promotion', 'AT+RT', 'Various Exercises', 'physical activity', 'RT with self-paced home training improve IC', 'aerobic training (AT), resistance training (RT), and combined training (AT+RT) programs', 'group training program and self-paced home training']","['Overall, AT and RT improved composite IC Z-scores', 'Intrinsic capacity (IC), constructed based on locomotion, cognition, psychological function, and vitality domains', 'Intrinsic Capacity', 'composite IC Z-scores', 'intrinsic capacity']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517772', 'cui_str': '415'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0376683', 'cui_str': 'Lectures'}, {'cui': 'C0018738', 'cui_str': 'Health promotion'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0287990', 'cui_str': 'Furin'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0012931', 'cui_str': 'Recombinant DNA'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0023946', 'cui_str': 'Locomotor Activity'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0233398', 'cui_str': 'Psychological function'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]",415.0,0.0343818,"Overall, AT and RT improved composite IC Z-scores by 0.17 (95% confidence interval [CI] 0.03-0.30) and 0.17 (95% CI 0.05-0.28) at week 26, respectively, but the beneficial effects waned at week 52.","[{'ForeName': 'Chi Hsien', 'Initials': 'CH', 'LastName': 'Huang', 'Affiliation': 'Department of Community Healthcare and Geriatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi Prefecture, Japan; Department of Family Medicine, E-Da Hospital, Kaohsiung City, Taiwan, R.O.C.; School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung City, Taiwan, R.O.C.; Institutes of Innovation for Future Society, Nagoya University, Nagoya, Aichi Prefecture, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Umegaki', 'Affiliation': 'Department of Community Healthcare and Geriatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi Prefecture, Japan.'}, {'ForeName': 'Taeko', 'Initials': 'T', 'LastName': 'Makino', 'Affiliation': 'Department of Community Healthcare and Geriatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi Prefecture, Japan.'}, {'ForeName': 'Kazuki', 'Initials': 'K', 'LastName': 'Uemura', 'Affiliation': 'Department of Community Healthcare and Geriatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi Prefecture, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Hayashi', 'Affiliation': 'Department of Community Healthcare and Geriatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi Prefecture, Japan.'}, {'ForeName': 'Tomoharu', 'Initials': 'T', 'LastName': 'Kitada', 'Affiliation': 'Institutes of Innovation for Future Society, Nagoya University, Nagoya, Aichi Prefecture, Japan.'}, {'ForeName': 'Aiko', 'Initials': 'A', 'LastName': 'Inoue', 'Affiliation': 'Institutes of Innovation for Future Society, Nagoya University, Nagoya, Aichi Prefecture, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Shimada', 'Affiliation': 'Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Obu City, Aichi Prefecture, Japan.'}, {'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Kuzuya', 'Affiliation': 'Department of Community Healthcare and Geriatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi Prefecture, Japan; Institutes of Innovation for Future Society, Nagoya University, Nagoya, Aichi Prefecture, Japan. Electronic address: kuzuya@med.nagoya-u.ac.jp.'}]",Journal of the American Medical Directors Association,['10.1016/j.jamda.2020.06.048'] 2940,32768551,Electro-acupuncture for post-stroke spasticity: results of a pilot pragmatic randomized controlled trial.,"CONTEXT People with spasticity which occurred between 30 days and one year after stroke onset with a baseline Modified Ashworth Scale (MAS) ≥ 1. OBJECTIVE To determine the practicality of a pragmatic parallel-group open-labeled randomized controlled trial, and to collect preliminary data of effectiveness and safety of electro-acupuncture for post-stroke spasticity (PSS) METHODS: Eligible participants were randomly allocated to the intervention group (electro-acupuncture plus usual care) or the control group (usual care alone) at a 1:1 ratio with block sizes of six. Participants received electro-acupuncture three times a week for four weeks then were followed up for another four weeks. Participants' retention and adherence in the trial were assessed to determine the practicality of trial design. Clinical outcome measures were the change scores of MAS, Fugl-Meyer Assessment (FMA) of motor performance and Barthel Index (BI), and adverse events. RESULTS Seventy-two people were screened for eligibility, and 30 of them were recruited and randomized. At the end, 25 participants followed the trial protocol and were included in our final data analyses using an intention-to-treat approach. No significant between-group difference was detected for the change scores of MAS, FMA or BI at the end of treatment or end of follow-up. Eighteen participants reported 37 adverse events, but none was deemed related to electro-acupuncture. CONCLUSION It is feasible to conduct a full-scale trial to precisely evaluate the effectiveness and safety of electro-acupuncture for treating PSS, however, longer treatment and follow-up phases should be considered in the full-scale trial.",2020,"No significant between-group difference was detected for the change scores of MAS, FMA or BI at the end of treatment or end of follow-up.","[' Eligible participants', 'post-stroke spasticity', 'Seventy-two people were screened for eligibility, and 30 of them were recruited and randomized']","['electro-acupuncture', 'intervention group (electro-acupuncture plus usual care) or the control group (usual care alone', 'Electro-acupuncture']","['change scores of MAS, FMA or BI', '37 adverse events', 'change scores of MAS, Fugl-Meyer Assessment (FMA) of motor performance and Barthel Index (BI), and adverse events']","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C4319632', 'cui_str': '72'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4707572', 'cui_str': 'Modified Ashworth Scale'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",72.0,0.242333,"No significant between-group difference was detected for the change scores of MAS, FMA or BI at the end of treatment or end of follow-up.","[{'ForeName': 'Yiyi', 'Initials': 'Y', 'LastName': 'Cai', 'Affiliation': 'Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy of Chinese Medical Sciences, and The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, 510120, China; China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Melbourne, 3083, Australia.'}, {'ForeName': 'Claire Shuiqing', 'Initials': 'CS', 'LastName': 'Zhang', 'Affiliation': 'China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Melbourne, 3083, Australia.'}, {'ForeName': 'Anthony Lin', 'Initials': 'AL', 'LastName': 'Zhang', 'Affiliation': 'China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Melbourne, 3083, Australia.'}, {'ForeName': 'Cliff', 'Initials': 'C', 'LastName': 'Da Costa', 'Affiliation': 'School of Science Cluster, RMIT University, Melbourne, 3083, Australia.'}, {'ForeName': 'Charlie', 'Initials': 'C', 'LastName': 'Changli Xue', 'Affiliation': 'Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy of Chinese Medical Sciences, and The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, 510120, China; China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Melbourne, 3083, Australia.'}, {'ForeName': 'Zehuai', 'Initials': 'Z', 'LastName': 'Wen', 'Affiliation': 'Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy of Chinese Medical Sciences, and The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, 510120, China. Electronic address: wenzh@gzucm.edu.cn.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2020.07.034'] 2941,32768555,Association between pre-treatment sleep disturbance and radiation therapy-induced pain in 573 women with breast cancer.,"CONTEXT Pain can be a debilitating side effect of radiation therapy (RT). Data from the general population has shown that sleep disturbance can influence pain incidence and severity; however, less is known about this relationship in breast cancer patients receiving RT. OBJECTIVES This secondary analysis examined the association of pre-treatment moderate/severe levels of sleep disturbance with subsequent RT-induced pain after adjusting for pre-RT pain. METHODS We report on 573 female breast cancer patients undergoing RT from a previously completed phase II clinical trial for radiation dermatitis. Sleep disturbance, total pain, and pain subdomains - sensory pain, affective pain, and perceived pain intensity were assessed at pre- and post-RT. At pre-RT, patients were dichotomized into 2 groups: those with moderate/severe sleep disturbance (N=85) vs. those with no/mild sleep disturbance (control; N=488). RESULTS At pre-RT, women with moderate/severe sleep disturbance were younger, less likely to be married, more likely to have had mastectomy and chemotherapy, and more likely to have depression/anxiety disorder and fatigue than the control group (all p's<0.05). Generalized estimating equations model, after controlling for pre-RT pain and other covariates (e.g., trial treatment condition and covariates that were significantly correlated with post-RT pain), showed that women with moderate/severe sleep disturbance at pre-RT vs. control group had significantly higher mean post-RT total pain as well as sensory, affective, and perceived pain (effect size=0.62, 0.60, 0.69, and 0.52 respectively; all p's<0.05). CONCLUSION These findings suggest that moderate/severe disturbed sleep prior to RT is associated with increased pain from pre-to-post-RT in breast cancer patients.",2020,"This secondary analysis examined the association of pre-treatment moderate/severe levels of sleep disturbance with subsequent RT-induced pain after adjusting for pre-RT pain. ","['breast cancer patients receiving RT', 'breast cancer patients', '573 female breast cancer patients undergoing RT from a previously completed phase II clinical trial for radiation dermatitis', '573 women with breast cancer', 'N=85) vs. those with no/mild sleep disturbance (control; N=488']",['radiation therapy-induced pain'],"['severe sleep disturbance', 'sensory, affective, and perceived pain (effect', 'mean post-RT total pain', 'depression/anxiety disorder and fatigue', 'Sleep disturbance, total pain, and pain subdomains - sensory pain, affective pain, and perceived pain intensity', 'pain']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C4708164', 'cui_str': '573'}, {'cui': 'C0235653', 'cui_str': 'Malignant neoplasm of female breast'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0282460', 'cui_str': 'Clinical Trials, Phase II as Topic'}, {'cui': 'C0034561', 'cui_str': 'Radiation dermatitis'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0445177', 'cui_str': 'Post-radiation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",573.0,0.0252795,"This secondary analysis examined the association of pre-treatment moderate/severe levels of sleep disturbance with subsequent RT-induced pain after adjusting for pre-RT pain. ","[{'ForeName': 'Anita R', 'Initials': 'AR', 'LastName': 'Peoples', 'Affiliation': 'Clinical and Translational Science Institute, University of Rochester Medical Center, Rochester, NY, USA;. Electronic address: anita.peoples@hci.utah.edu.'}, {'ForeName': 'Wilfred R', 'Initials': 'WR', 'LastName': 'Pigeon', 'Affiliation': 'Department of Psychiatry, University of Rochester Medical Center, Rochester, NY, USA;; Department of Public Health Sciences, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Dongmei', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Clinical and Translational Science Institute, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Sheila N', 'Initials': 'SN', 'LastName': 'Garland', 'Affiliation': ""Departments of Psychology and Oncology, Memorial University of Newfoundland, St. John's, NL, Canada.""}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Perlis', 'Affiliation': 'Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Julia E', 'Initials': 'JE', 'LastName': 'Inglis', 'Affiliation': 'Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Vinciguerra', 'Affiliation': 'Northwell Health NCORP, Lake Success, NY, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Anderson', 'Affiliation': 'Columbus NCORP, Columbus, OH, USA.'}, {'ForeName': 'Lisa S', 'Initials': 'LS', 'LastName': 'Evans', 'Affiliation': 'Southeast Clinical Oncology Research Consortium NCORP, Winston-Salem, NC, USA.'}, {'ForeName': 'James L', 'Initials': 'JL', 'LastName': 'Wade', 'Affiliation': 'Heartland Cancer Research NCORP, Decatur, IL, USA.'}, {'ForeName': 'Deborah J', 'Initials': 'DJ', 'LastName': 'Ossip', 'Affiliation': 'Clinical and Translational Science Institute, University of Rochester Medical Center, Rochester, NY, USA;; Department of Public Health Sciences, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Gary R', 'Initials': 'GR', 'LastName': 'Morrow', 'Affiliation': 'Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Julie Ryan', 'Initials': 'JR', 'LastName': 'Wolf', 'Affiliation': 'Departments of Dermatology and Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2020.07.041'] 2942,32768569,The effect of conservative oxygen therapy on systemic biomarkers of oxidative stress in critically ill patients.,"BACKGROUND Supplemental oxygen is delivered to critically ill patients who require mechanical ventilation. Oxidative stress is a potential complication of oxygen therapy, resulting in damage to essential biomolecules such as nucleic acids, lipids and proteins. Whether plasma levels of oxidative stress biomarkers vary based on how liberally oxygen therapy is applied during mechanical ventilation is unknown. METHODS We carried out an oxidative stress substudy nested within a large multi-centre randomized controlled trial in which critically ill adults were randomized to receive either conservative oxygen therapy or standard oxygen therapy. Blood samples were collected at enrolment, and daily thereafter for up to three days. The antioxidant ascorbate (vitamin C) was assessed using HPLC with electrochemical detection and protein oxidation using a sensitive protein carbonyl ELISA. We also assessed whether critically ill patients with different disease states exhibited varying levels of oxidative stress biomarkers. RESULTS A total of 125 patients were included. Mean ascorbate concentrations decreased over time (from 25 ± 9 μmol/L to 14 ± 2 μmol/L, p < 0.001), however, there was no significant difference between the conservative oxygen group and standard care (p = 0.2), despite a significantly lower partial pressure of oxygen (PaO 2 ) in the conservative oxygen group (p = 0.03). Protein carbonyl concentrations increased over time (from 208 ± 30 μmol/L to 249 ± 29 μmol/L; p = 0.016), however, there was no significant difference between the conservative and standard oxygen groups (p = 0.3). Patients with sepsis had significantly higher protein carbonyl concentrations than the other critically ill patients (293 ± 92 μmol/L vs 184 ± 24 μmol/L, p = 0.03). Within the septic subgroup, there were no significant differences in protein carbonyl concentrations between the two interventions (p = 0.4). CONCLUSIONS Conservative oxygen therapy does not alter systemic markers of oxidative stress in critically ill ventilated patients compared with standard oxygen therapy. Patients with sepsis exhibited elevated protein carbonyls compared with the other critically ill patients implying increased oxidative stress in this patient subgroup.",2020,"CONCLUSIONS Conservative oxygen therapy does not alter systemic markers of oxidative stress in critically ill ventilated patients compared with standard oxygen therapy.","['critically ill adults', 'critically ill patients', 'critically ill ventilated patients', 'critically ill patients with different disease states exhibited varying levels of oxidative stress biomarkers', 'A total of 125 patients were included', 'critically ill patients who require mechanical ventilation']","['conservative oxygen therapy', 'antioxidant ascorbate (vitamin C', 'Conservative oxygen therapy', 'standard oxygen therapy', 'conservative oxygen therapy or standard oxygen therapy']","['Mean ascorbate concentrations', 'systemic biomarkers of oxidative stress', 'oxidative stress', 'Blood samples', 'protein carbonyl concentrations', 'Protein carbonyl concentrations', 'systemic markers of oxidative stress', 'partial pressure of oxygen (PaO 2 ']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299448', 'cui_str': 'Patient ventilated'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0015272', 'cui_str': 'Exhibits as Topic'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}]","[{'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0178487', 'cui_str': 'Ascorbate'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0178487', 'cui_str': 'Ascorbate'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0202155', 'cui_str': 'Oxygen measurement, partial pressure, arterial'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output'}]",125.0,0.329893,"CONCLUSIONS Conservative oxygen therapy does not alter systemic markers of oxidative stress in critically ill ventilated patients compared with standard oxygen therapy.","[{'ForeName': 'Anitra C', 'Initials': 'AC', 'LastName': 'Carr', 'Affiliation': 'Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand. Electronic address: anitra.carr@otago.ac.nz.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Spencer', 'Affiliation': 'Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Mackle', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Hunt', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand; Wellington Hospital Intensive Care Unit, Wellington, New Zealand.'}, {'ForeName': 'Harriet', 'Initials': 'H', 'LastName': 'Judd', 'Affiliation': 'Wellington Hospital Intensive Care Unit, Wellington, New Zealand.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Mehrtens', 'Affiliation': 'Christchurch Hospital Intensive Care Unit, Christchurch, New Zealand.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Parker', 'Affiliation': 'Christchurch Hospital Intensive Care Unit, Christchurch, New Zealand.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Stockwell', 'Affiliation': 'Centre for Postgraduate Nursing Studies, University of Otago, Christchurch, New Zealand.'}, {'ForeName': 'Caitlin', 'Initials': 'C', 'LastName': 'Gale', 'Affiliation': 'Centre for Postgraduate Nursing Studies, University of Otago, Christchurch, New Zealand.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Beaumont', 'Affiliation': 'Centre for Postgraduate Nursing Studies, University of Otago, Christchurch, New Zealand.'}, {'ForeName': 'Simran', 'Initials': 'S', 'LastName': 'Kaur', 'Affiliation': 'Centre for Postgraduate Nursing Studies, University of Otago, Christchurch, New Zealand.'}, {'ForeName': 'Shailesh', 'Initials': 'S', 'LastName': 'Bihari', 'Affiliation': 'Intensive and Critical Care Unit, Flinders Medical Centre, Adelaide, Australia; College of Medicine and Public Health, Flinders University, Adelaide, Australia.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Young', 'Affiliation': 'Medical Research Institute of New Zealand, Wellington, New Zealand; Wellington Hospital Intensive Care Unit, Wellington, New Zealand.'}]",Free radical biology & medicine,['10.1016/j.freeradbiomed.2020.06.018'] 2943,32768588,Evaluation of combined efficacy of photodynamic therapy using indocyanine green photosensitizer and non-surgical periodontal therapy on clinical and microbial parameters in the management of chronic periodontitis subjects: A randomized split-mouth design.,"BACKGROUND Diode laser is a versatile clinical tool with wide range of applications in periodontal therapy. The clinical efficacy of multiple applications of Photodynamic therapy (PDT) needs to be investigated in management of chronic periodontitis subjects. AIM The aim of this study was to evaluate the clinical and antimicrobial efficacy of multiple application of PDT as an adjunct to scaling and root planning in management of moderate periodontal pockets. MATERIALS AND METHODS 33 patients with bilateral periodontal destruction in mandibular posterior sextants were randomly treated with either test (SRP + multiplePDT) or control (SRP) intervention. PDT was employed with diode laser(810 nm) and Indocyanine green(ICG) dye at baseline, 1 st, 2nd and 4th week post SRP. Probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), gingival bleeding index (GBI) were recorded at baseline, 3 and 6 months. Subgingival plaque samples were analysed for Porphyromonas gingivalis (P.g), Aggregatibacter actinomycetemcomitans (A.a), Tannerella forsythia (T.f), Fusobacterium nucleatum (F.n), Treponema denticola (T.d). RESULTS Statistically significant improvement was noted in all clinical parameters in both the groups from baseline to 3 and 6 months. The mean PPD and CAL decreased in control sites from 5.83 ± 0.64 and 5.60 ± 0.72 at baseline to 3.80 ± 0.40 and 3.70 ± 0.91 at 6 months and in test sites from 5.93 ± 0.82 and 5.73 ± 0.69 to 3.40 ± 0.56 and 3.00 ± 0.91 at 6 months (P ≤ 0.05). Test sites showed significantly greater reduction in P.g, A.a, T.f, F.n and T.d compared to control sites at 3 and 6 months (P ≤ 0.05). CONCLUSION The outcomes suggested that adjunctive multiple applications of PDT to SRP had showed significant reduction in periodontal pathogens over SRP alone.",2020,"Probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), gingival bleeding index (GBI) were recorded at baseline, 3 and 6 months.","['chronic periodontitis subjects', '33 patients with bilateral periodontal destruction in mandibular posterior sextants']","['Photodynamic therapy (PDT', 'photodynamic therapy', 'PDT', 'Diode laser', 'test (SRP\u2009+\u2009multiplePDT) or control (SRP) intervention', 'indocyanine green photosensitizer and non-surgical periodontal therapy']","['mean PPD and CAL', 'Probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), gingival bleeding index (GBI', 'Porphyromonas gingivalis (P.g), Aggregatibacter actinomycetemcomitans (A.a), Tannerella forsythia (T.f), Fusobacterium nucleatum (F.n), Treponema denticola (T.d', 'periodontal pathogens']","[{'cui': 'C0266929', 'cui_str': 'Chronic periodontitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0236023', 'cui_str': 'Periodontal destruction'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}]","[{'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0392254', 'cui_str': 'Semiconductor laser device'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0074512', 'cui_str': 'SRP (Signal Recognition Particle)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0021234', 'cui_str': 'Indocyanine Green'}, {'cui': 'C0162713', 'cui_str': 'Photosensitizing agent'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C0580084', 'cui_str': 'Gingival bleeding index'}, {'cui': 'C0085478', 'cui_str': 'Porphyromonas gingivalis'}, {'cui': 'C0085488', 'cui_str': 'Aggregatibacter actinomycetemcomitans'}, {'cui': 'C0314961', 'cui_str': 'Tannerella forsythia'}, {'cui': 'C0085479', 'cui_str': 'Fusobacterium nucleatum'}, {'cui': 'C0318222', 'cui_str': 'Treponema denticola'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0450254', 'cui_str': 'Pathogenic organism'}]",33.0,0.0339033,"Probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), gingival bleeding index (GBI) were recorded at baseline, 3 and 6 months.","[{'ForeName': 'Kanchana', 'Initials': 'K', 'LastName': 'Sukumar', 'Affiliation': 'Department of Periodontics SRM Dental College, Ramapuram, Chennai, 600089, Tamilnadu, India. Electronic address: kancha1308@gmail.com.'}, {'ForeName': 'Anupama', 'Initials': 'A', 'LastName': 'Tadepalli', 'Affiliation': 'Department of Periodontics SRM Dental College, Ramapuram, Chennai, 600089, Tamilnadu, India. Electronic address: anupamamds@gmail.com.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Harinath', 'Affiliation': 'Department of Periodontics SRM Dental College, Ramapuram, Chennai, 600089, Tamilnadu, India. Electronic address: hari_feb14@hotmail.com.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Deepa', 'Affiliation': 'Department of Periodontics SRM Dental College, Ramapuram, Chennai, 600089, Tamilnadu, India. Electronic address: deepa_ponnaiyan@yahoo.co.in.'}]",Photodiagnosis and photodynamic therapy,['10.1016/j.pdpdt.2020.101949'] 2944,32768512,Abuse Liability of Cigarettes with Very Low Nicotine Content in Pregnant Cigarette Smokers.,"The U.S. Food and Drug Administration has proposed reducing the nicotine content of cigarettes to a minimally-addictive level. To our knowledge, this study is the first to examine how pregnant smokers respond to very low nicotine content (VLNC) cigarettes. In Phase 1, participants blindly sampled two VLNC cigarettes (0.4 and 2.4 mg/g of tobacco) and their usual brand (UB) cigarette in separate sessions, then completed a behavioral economic simulation task and measures of subjective effects, craving/withdrawal, and smoking topography. Phase 2 directly compared the relative reinforcing effects of the cigarettes using concurrent choice testing. All possible dose-pair combinations were tested in separate sessions where puffs were earned ad libitum by clicking the code associated with their preferred cigarette 10 times. Phase 3 tested the 0.4mg/g-UB dose-pair where UB puffs could be earned with a progressively incremented number of clicks (maximum 8,400). Ten pregnant smokers in Burlington, VT and Baltimore, MD participated in 2017-2018. Regarding abuse liability, participants chose the 0.4-mg/g dose less than UB (22% vs. 78%) during concurrent choice testing and the 0.4-mg/g dose sustained less demand than the 2.4-mg/g and UB doses on the simulation task. Positive subjective effects were also lower for both VLNC cigarettes vs. UB. Each cigarette reduced nicotine craving/withdrawal and no significant changes indicative of compensatory smoking were noted. Reducing the nicotine content of cigarettes may decrease their abuse liability in pregnant smokers without causing untoward craving/withdrawal or compensatory smoking. Studies of extended exposure to VLNCs in pregnant women are warranted.",2020,Reducing the nicotine content of cigarettes may decrease their abuse liability in pregnant smokers without causing untoward craving/withdrawal or compensatory smoking.,"['Pregnant Cigarette Smokers', 'Ten pregnant smokers in Burlington, VT and Baltimore, MD participated in 2017-2018', 'pregnant smokers respond to very low nicotine content (VLNC) cigarettes', 'pregnant smokers', 'pregnant women']",[],"['compensatory smoking', 'abuse liability', 'Positive subjective effects']","[{'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0337667', 'cui_str': 'Cigarette smoker'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0004716', 'cui_str': 'Baltimore'}, {'cui': 'C0442811', 'cui_str': 'Very low'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}]",[],"[{'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0562381', 'cui_str': 'Victim of abuse'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",10.0,0.0143412,Reducing the nicotine content of cigarettes may decrease their abuse liability in pregnant smokers without causing untoward craving/withdrawal or compensatory smoking.,"[{'ForeName': 'Sarah H', 'Initials': 'SH', 'LastName': 'Heil', 'Affiliation': 'Vermont Center on Behavior and Health, University of Vermont, UHC MS #482, 1, South, Prospect St., Burlington, Vermont 05401. Electronic address: sarah.heil@uvm.edu.'}, {'ForeName': 'Cecilia L', 'Initials': 'CL', 'LastName': 'Bergeria', 'Affiliation': 'Vermont Center on Behavior and Health, University of Vermont, UHC MS #482, 1, South, Prospect St., Burlington, Vermont 05401. Electronic address: cecilia.bergeria@uvm.edu.'}, {'ForeName': 'Dustin C', 'Initials': 'DC', 'LastName': 'Lee', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, Maryland 21224-6823. Electronic address: dlee214@jhmi.edu.'}, {'ForeName': 'Janice Y', 'Initials': 'JY', 'LastName': 'Bunn', 'Affiliation': 'Vermont Center on Behavior and Health, University of Vermont, UHC MS #482, 1, South, Prospect St., Burlington, Vermont 05401. Electronic address: janice.bunn@uvm.edu.'}, {'ForeName': 'Roxanne F', 'Initials': 'RF', 'LastName': 'Harfmann', 'Affiliation': 'Vermont Center on Behavior and Health, University of Vermont, UHC MS #482, 1, South, Prospect St., Burlington, Vermont 05401. Electronic address: roxanne.harfmann@uvm.edu.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Hughes', 'Affiliation': 'Vermont Center on Behavior and Health, University of Vermont, UHC MS #482, 1, South, Prospect St., Burlington, Vermont 05401. Electronic address: john.hughes@med.uvm.edu.'}, {'ForeName': 'Haley J', 'Initials': 'HJ', 'LastName': 'Tetreault', 'Affiliation': 'Vermont Center on Behavior and Health, University of Vermont, UHC MS #482, 1, South, Prospect St., Burlington, Vermont 05401. Electronic address: haley.tetreault@uvm.edu.'}, {'ForeName': 'Stephen T', 'Initials': 'ST', 'LastName': 'Higgins', 'Affiliation': 'Vermont Center on Behavior and Health, University of Vermont, UHC MS #482, 1, South, Prospect St., Burlington, Vermont 05401. Electronic address: stephen.higgins@uvm.edu.'}]",Preventive medicine,['10.1016/j.ypmed.2020.106227'] 2945,32768592,Efficacy and Safety of Basiliximab as Initial Immunosuppression in Liver Transplantation: A Single Center Study.,"INTRODUCTION AND AIM The interleukin-2 receptor antagonist; basiliximab is used to allow delayed introduction of Calcineurin inhibitors (CNI) after liver transplantation and thus delay their renal insult. However, there is only little evidence for the safety and the efficacy of this regimen. This study aimed to evaluate the effectiveness and safety of basiliximab induction in liver transplantation. MATERIALS AND METHODS This study included 89 patients who were classified into two groups: standard triple immunosuppression (IS) regimen of steroid, tacrolimus (TAC) and mycophenolate mofetil (MMF) (n = 47) and induction IS regimen of basiliximab, low dose steroids and MMF with delayed introduction of CNI (n = 42). All patients were followed after liver transplantation for at least six months or until death. RESULTS There were no significant differences in patient survival, graft dysfunction, infection rate or type, or wound healing between both groups. The acute rejection rate was equivalent in both groups. Renal dysfunction in the first six months post-transplant was less in the basiliximab group in comparison to the other group (7.1% and 19.1% respectively). CONCLUSION Basiliximab-induced IS protocol is a safe regimen that reduces medium-term renal dysfunction and achieves similar survival without increasing the acute rejection or infection rate in liver transplantation recipients.",2020,"There were no significant differences in patient survival, graft dysfunction, infection rate or type, or wound healing between both groups.","['liver transplantation recipients', '89 patients who were classified into two groups', 'Liver Transplantation']","['interleukin-2 receptor antagonist', 'Basiliximab', 'standard triple immunosuppression (IS) regimen of steroid, tacrolimus (TAC) and mycophenolate mofetil (MMF) (n\u2009=\u200947) and induction IS regimen of basiliximab, low dose steroids and MMF with delayed introduction of CNI', 'Basiliximab-induced IS protocol']","['Efficacy and Safety', 'Renal dysfunction', 'acute rejection rate', 'patient survival, graft dysfunction, infection rate or type, or wound healing']","[{'cui': 'C0023911', 'cui_str': 'Transplantation of liver'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0034819', 'cui_str': 'Interleukin-2 receptor'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0676831', 'cui_str': 'basiliximab'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0021079', 'cui_str': 'Immunosuppressive therapy'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0209368', 'cui_str': 'mycophenolate mofetil'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C1453118', 'cui_str': 'CABIN1 protein, human'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1565489', 'cui_str': 'Renal impairment'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0035015', 'cui_str': 'Rejection (Psychology)'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1167870', 'cui_str': 'Transplant dysfunction'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}]",89.0,0.0258293,"There were no significant differences in patient survival, graft dysfunction, infection rate or type, or wound healing between both groups.","[{'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Hashim', 'Affiliation': 'Department of Hepatology, National Liver Institute, Menoufiya University, Shebin Elkom, Egypt. Electronic address: msaadhh@hotmail.com.'}, {'ForeName': 'Ayman', 'Initials': 'A', 'LastName': 'Alsebaey', 'Affiliation': 'Department of Hepatology, National Liver Institute, Menoufiya University, Shebin Elkom, Egypt.'}, {'ForeName': 'Amr', 'Initials': 'A', 'LastName': 'Ragab', 'Affiliation': 'Department of Hepatology, National Liver Institute, Menoufiya University, Shebin Elkom, Egypt.'}, {'ForeName': 'Hossam Eldeen', 'Initials': 'HE', 'LastName': 'Soliman', 'Affiliation': 'Department of Hepatobiliary and pancreatic surgery, National Liver Institute, Menoufiya University, Shebin Elkom, Egypt.'}, {'ForeName': 'Imam', 'Initials': 'I', 'LastName': 'Waked', 'Affiliation': 'Department of Hepatology, National Liver Institute, Menoufiya University, Shebin Elkom, Egypt.'}]",Annals of hepatology,['10.5604/01.3001.0012.2246'] 2946,32768597,Reply to letter to the editor: 'Effect of the dr. Bart application on healthcare use and clinical outcomes in people with osteoarthritis of the knee and/or hip in the Netherlands; a randomized controlled trial'.,,2020,,['people with osteoarthritis of the knee and/or hip in the Netherlands'],[],[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}]",[],[],,0.0830795,,"[{'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Pelle', 'Affiliation': ''}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Bevers', 'Affiliation': ''}, {'ForeName': 'Job', 'Initials': 'J', 'LastName': 'van der Palen', 'Affiliation': ''}, {'ForeName': 'Frank H J', 'Initials': 'FHJ', 'LastName': 'van den Hoogen', 'Affiliation': ''}, {'ForeName': 'Cornelia H M', 'Initials': 'CHM', 'LastName': 'van den Ende', 'Affiliation': ''}]",Osteoarthritis and cartilage,['10.1016/j.joca.2020.07.007'] 2947,32768599,Commentary on: Effect of the dr. Bart application on healthcare use and clinical outcomes in people with osteoarthritis of the knee and/or hip in the Netherlands; a randomized controlled trial.,,2020,,['people with osteoarthritis of the knee and/or hip in the Netherlands'],[],[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}]",[],[],,0.10498,,"[{'ForeName': 'S F J', 'Initials': 'SFJ', 'LastName': 'Chudy', 'Affiliation': 'Erasmus MC.'}, {'ForeName': 'M M M', 'Initials': 'MMM', 'LastName': 'Volwater', 'Affiliation': 'Leiden University.'}, {'ForeName': 'Ö F', 'Initials': 'ÖF', 'LastName': 'Ozbulut', 'Affiliation': 'Department of General Practice, Erasmus MC.'}, {'ForeName': 'B W', 'Initials': 'BW', 'LastName': 'Koes', 'Affiliation': 'Department of General Practice, Erasmus MC.'}]",Osteoarthritis and cartilage,['10.1016/j.joca.2020.06.011'] 2948,32768608,Performance characteristics and optimal cut-off value of triple adenylate nucleotides test versus adenosine triphosphate test as point of care testing for predicting inadequacy of duodenoscope reprocessing.,"BACKGROUND Adenosine triphosphate (ATP) test based on one nucleotide has been applied as a point of care testing (POCT) for bacterial contamination in medical and food industries. Hypothetically, testing three adenylate nucleotides (A3) may provide better detection of duodenoscope bacterial contamination than ATP test. We aimed to evaluate performance characteristics and optimal cut-off value of A3 and ATP tests in predicting bacterial contamination of duodenoscopes. METHODS 400 duodenoscopes samples obtained after 100 ERCPs were randomized into group A (A3 test) or B (ATP test). Samples were collected from the elevator at the 4-step cleaning process of duodenoscope. We defined the new cut-off value of the test that reach 100% NPV from our receiver operating characteristic (ROC). FINDINGS Using the cultures from the 4-step cleaning process as the reference, the area under ROC (AUROC) were 0.83 and 0.84 for group A (n=200) and B (n=200), respectively. Using the cultures from post-high-level disinfection (HLD) as the reference, the AUROC were 0.35 and 0.74 for group A (n=50) and B (n=50). We investigated ATP as a POCT after HLD with a new cut-off value of 40 RLU. However, this threshold did not allow detection of low levels of bacteria. CONCLUSIONS A3 and ATP tests provide good performances in predicting bacterial contamination of duodenoscopes for the 4-step cleaning process. Although the ATP < 40 RLU is helpful as a POCT after HLD it cannot achieve 100% NPV, the limitation of this cut-off value being its inability to detect low levels of bacteria.",2020,"CONCLUSIONS A3 and ATP tests provide good performances in predicting bacterial contamination of duodenoscopes for the 4-step cleaning process.",['400 duodenoscopes samples obtained after 100 ERCPs'],"['adenosine triphosphate test', 'Adenosine triphosphate (ATP']",[],"[{'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0180565', 'cui_str': 'Duodenoscope'}, {'cui': 'C1277697', 'cui_str': 'Sample obtained'}, {'cui': 'C1704407', 'cui_str': '100'}]","[{'cui': 'C0001480', 'cui_str': 'Adenosine Triphosphate'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",[],,0.0232887,"CONCLUSIONS A3 and ATP tests provide good performances in predicting bacterial contamination of duodenoscopes for the 4-step cleaning process.","[{'ForeName': 'Wiriyaporn', 'Initials': 'W', 'LastName': 'Ridtitid', 'Affiliation': 'Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society; Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Piyapoom', 'Initials': 'P', 'LastName': 'Pakvisal', 'Affiliation': 'Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society.'}, {'ForeName': 'Tanittha', 'Initials': 'T', 'LastName': 'Chatsuwan', 'Affiliation': 'Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Kerr', 'Affiliation': 'Biostatistics Excellence Centre, Faculty of Medicine, Chulalongkorn University.'}, {'ForeName': 'Panida', 'Initials': 'P', 'LastName': 'Piyachaturawat', 'Affiliation': 'Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society.'}, {'ForeName': 'Thanawat', 'Initials': 'T', 'LastName': 'Luangsukrerk', 'Affiliation': 'Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society.'}, {'ForeName': 'Pradermchai', 'Initials': 'P', 'LastName': 'Kongkam', 'Affiliation': 'Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society; Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Rungsun', 'Initials': 'R', 'LastName': 'Rerknimitr', 'Affiliation': 'Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society; Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Electronic address: ercp@live.com.'}]",The Journal of hospital infection,['10.1016/j.jhin.2020.07.038'] 2949,32768635,Bidirectional effects between expressive regulatory abilities and peer acceptance among Chinese adolescents.,"The current study examined potential bidirectional effects between adolescents' expressive regulation (the ability to enhance and suppress overt emotional behavior in line with situational demands) and peer interactions via two experiments. Experiment 1 tested the hypothesis that adolescents' expressive regulation affects their social acceptance from peers. Participants (N = 147) were randomly divided into three conditions and watched video clips in which a same-sex partner differed in his or her levels of expressive enhancement and suppression abilities. Results showed that participants reported greater liking of the partner when he or she was able to flexibly enhance and suppress emotional expressions in line with situational demands compared with when either one of these abilities was impaired. Experiment 2 then examined whether peer rejection reduced participants' enhancement and suppression abilities. We manipulated participants' feelings of rejection through a virtual Cyberball game. Following this manipulation (N = 100; Inclusion vs. Exclusion), we tested participants' expressive enhancement and suppression abilities, as well as their natural expressivity, via an observational task. Peer exclusion resulted in lower levels of enhancement ability and natural expressive behaviors but did not impair suppression ability. The results of these experiments suggest that both expressive enhancement and expressive suppression are important for adolescents to obtain higher peer acceptance. In addition, peer exclusion also caused impairments in expressive regulation, specifically reduced enhancement abilities. In summary, these results evidenced the bidirectional effects between expressive regulation and peer acceptance.",2020,Peer exclusion resulted in lower levels of enhancement ability and natural expressive behaviors but did not impair suppression ability.,"['Chinese adolescents', 'Participants (N\xa0=\xa0147']",['watched video clips'],"['enhancement ability and natural expressive behaviors', 'enhancement abilities', 'emotional expressions']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0175722', 'cui_str': 'Clip'}]","[{'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0205296', 'cui_str': 'Natural'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}]",147.0,0.0275084,Peer exclusion resulted in lower levels of enhancement ability and natural expressive behaviors but did not impair suppression ability.,"[{'ForeName': 'Yingqian', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Psychology, School of Sociology and Psychology, Central University of Finance and Economics, Beijing 100081, China; Department of Educational Psychology, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China. Electronic address: wangyingqian@link.cuhk.edu.hk.'}, {'ForeName': 'Skyler T', 'Initials': 'ST', 'LastName': 'Hawk', 'Affiliation': 'Department of Educational Psychology, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China.'}, {'ForeName': 'Wenqing', 'Initials': 'W', 'LastName': 'Zong', 'Affiliation': 'Department of Educational Psychology, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China.'}]",Journal of experimental child psychology,['10.1016/j.jecp.2020.104891'] 2950,32769506,Oral fluid intake during the first stage of labour: A randomised trial.,"BACKGROUND Obstetric anaesthesia has been associated with concern for the inhalation of gastric contents for many years, justifying fasting during labour. However, many anaesthesiologists and obstetricians now allow fluid intake during labour. OBJECTIVE(S) We hypothesised that allowing oral fluid intake during labour is not associated with increased gastric contents. We used ultrasound assessment of gastric contents to evaluate this hypothesis. DESIGN A randomised, single-blind and intention-to-treat noninferiority trial comparing antral area measured by ultrasound in fasting parturients and in those who were allowed to drink fluid for 90 min after randomisation. SETTING Tenon University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France. PATIENTS Pregnant women, aged from 18 to 40 years and from week 36 of an uncomplicated singleton gestation, were randomised into a fasting group and a fluid intake group after admission to the delivery room. Of the 184 patients screened, data from 125 were analysed: fasting group (62), fluid intake group (63). INTERVENTION Women in the fluid intake group were allowed to drink up to 400 ml of apple juice for 90 min after randomisation. MAIN OUTCOME MEASURE We compared the percentage of women with an 'empty stomach' between the two groups: empty stomach was defined as an antral cross-sectional area (CSA) less than 300 mm assessed in a semirecumbent position with a 45-degree head-up tilt. RESULTS At full cervical dilatation an antral CSA less than 300 mm was measured in 76 and 79% of the parturients in the fasting group and the fluid intake groups respectively (P = 0.633). CONCLUSION The current study reveals that the percentage of pregnant women with an 'empty stomach', defined by an antral CSA less than 300 mm in a semirecumbent position with a 45-degree head-up tilt, was comparable at full cervical dilation among those who remained nil by mouth and those allowed to drink up to 400 ml for 90 min after their randomisation. TRIAL REGISTRATION Clinicaltrials.gov identifier: NCT02362815.",2020,"At full cervical dilatation an antral CSA less than 300 mm was measured in 76 and 79% of the parturients in the fasting group and the fluid intake groups respectively (P = 0.633). ","['184 patients screened, data from 125 were analysed: fasting group (62), fluid intake group (63', 'Tenon University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France', ""pregnant women with an 'empty stomach"", 'Pregnant women, aged from 18 to 40 years and from week 36 of an uncomplicated singleton gestation', ""women with an 'empty stomach' between the two groups: empty stomach was defined as an antral cross-sectional area (CSA) less than 300\u200amm assessed in a semirecumbent position with a 45-degree head-up tilt"", 'first stage of labour', 'fasting parturients and in those who were allowed to drink fluid for 90\u200amin after randomisation']","['fasting group and a fluid intake group after admission to the delivery room', 'drink up to 400\u200aml of apple juice']",['Oral fluid intake'],"[{'cui': 'C4517616', 'cui_str': '184'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0429791', 'cui_str': 'Fluid intake'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0030561', 'cui_str': 'Paris'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0443334', 'cui_str': 'Uncomplicated'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0293352', 'cui_str': 'Antral'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1293898', 'cui_str': 'Head up'}, {'cui': 'C0022871', 'cui_str': 'First stage of labor'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0439232', 'cui_str': 'min'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0429791', 'cui_str': 'Fluid intake'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0011212', 'cui_str': 'Delivery suite'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0452454', 'cui_str': 'Apple juice'}]","[{'cui': 'C0429648', 'cui_str': 'Quantity of drinking'}]",,0.217113,"At full cervical dilatation an antral CSA less than 300 mm was measured in 76 and 79% of the parturients in the fasting group and the fluid intake groups respectively (P = 0.633). ","[{'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Rousset', 'Affiliation': 'From the Department of Anaesthesiology and Perioperative Medicine, Hôpital Tenon (JR, SC, FT, JB, EMH, CQ, FB), Biostatistics Department, Hôpital Saint Louis-Lariboisière, Assistance Publique Hôpitaux de Paris (EF), Faculty of Medicine Paris VI, Sorbonne University (CQ, FB) and Department of Anaesthesiology, Hôpital Foch, Paris, France (MF).'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Clariot', 'Affiliation': ''}, {'ForeName': 'Félix', 'Initials': 'F', 'LastName': 'Tounou', 'Affiliation': ''}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Burey', 'Affiliation': ''}, {'ForeName': 'El M', 'Initials': 'EM', 'LastName': 'Hafiani', 'Affiliation': ''}, {'ForeName': 'Elodie', 'Initials': 'E', 'LastName': 'Féliot', 'Affiliation': ''}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Quesnel', 'Affiliation': ''}, {'ForeName': 'Francis', 'Initials': 'F', 'LastName': 'Bonnet', 'Affiliation': ''}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Fischler', 'Affiliation': ''}]",European journal of anaesthesiology,['10.1097/EJA.0000000000001278'] 2951,32769511,"Clinical effectiveness of ultrasound-guided dual transversus abdominis plane block for postoperative analgesia in open abdominal aortic surgery patients: The randomised, double-blind ETAP trial.",,2020,,['open abdominal aortic surgery patients'],['ultrasound-guided dual transversus abdominis plane block'],[],"[{'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0877130', 'cui_str': 'Aortic surgery'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}]",[],,0.615371,,"[{'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Chenet', 'Affiliation': 'From the Department of Anaesthesiology and Intensive Care Medicine, University Hospital of Besancon (JC, ED, TL, VS, SP-F, ES, GB), EA 3920, Bourgogne Franche-Comte University (LSdM, SP-F, ES, GB), Department of Vascular Surgery (LSdM) and Clinical Methodology Center, University Hospital of Besancon, Besancon, France (MP).'}, {'ForeName': 'Elodie', 'Initials': 'E', 'LastName': 'Dupont', 'Affiliation': ''}, {'ForeName': 'Lucie', 'Initials': 'L', 'LastName': 'Salomon du Mont', 'Affiliation': ''}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Levy', 'Affiliation': ''}, {'ForeName': 'Vivien', 'Initials': 'V', 'LastName': 'Salignon', 'Affiliation': ''}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Puyraveau', 'Affiliation': ''}, {'ForeName': 'Sebastien', 'Initials': 'S', 'LastName': 'Pili-Floury', 'Affiliation': ''}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Samain', 'Affiliation': ''}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Besch', 'Affiliation': ''}]",European journal of anaesthesiology,['10.1097/EJA.0000000000001240'] 2952,32769515,Efficacy of incisional infiltration and intraperitoneal instillation of ropivacaine for the management of pain after laparoscopic sleeve gastrectomy: A randomised clinical trial.,,2020,,['pain after laparoscopic sleeve gastrectomy'],['incisional infiltration and intraperitoneal instillation of ropivacaine'],[],"[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}]","[{'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0442120', 'cui_str': 'Intraperitoneal'}, {'cui': 'C0184959', 'cui_str': 'Instillation'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}]",[],,0.0516737,,"[{'ForeName': 'Leonidas', 'Initials': 'L', 'LastName': 'Alevizos', 'Affiliation': 'From the 1st Department of Propaedeutic Surgery, Hippokration General Hospital, Athens Medical School, Athens, Greece (LA, VK, KA, EM, GZ, EL) and Department of Anaesthesiology and Pain Management, American Medical Centre, Nicosia, Cyprus (PZ).'}, {'ForeName': 'Periklis', 'Initials': 'P', 'LastName': 'Zavridis', 'Affiliation': ''}, {'ForeName': 'Vasileios', 'Initials': 'V', 'LastName': 'Kalles', 'Affiliation': ''}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Albanopoulos', 'Affiliation': ''}, {'ForeName': 'Evangelos', 'Initials': 'E', 'LastName': 'Menenakos', 'Affiliation': ''}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Zografos', 'Affiliation': ''}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Leandros', 'Affiliation': ''}]",European journal of anaesthesiology,['10.1097/EJA.0000000000001206'] 2953,32769608,"Shockwave: Does It Work Like Magic for Greater Trochanteric Pain Syndrome?: Commentary on an article by Silvia Ramon MD, PhD, et al.: ""Focused Shockwave Treatment for Greater Trochanteric Pain Syndrome. A Multicenter, Randomized, Controlled Clinical Trial"".",,2020,,['Greater Trochanteric Pain Syndrome'],"['Focused Shockwave Treatment', 'Shockwave']",[],"[{'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0391976', 'cui_str': 'Pain Disorder'}]","[{'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",[],,0.0335625,,"[{'ForeName': 'Mengnai', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Department of Orthopaedic Surgery, Ohio State University Wexner Medical Center, Columbus, Ohio.'}]",The Journal of bone and joint surgery. American volume,['10.2106/JBJS.20.01067'] 2954,32769625,"Online Cognitive Training: An Adaptation of the Memory, Attention, and Problem Solving Skills for Persons With Diabetes Intervention.","Research shows the risk for cognitive impairment and the rate of cognitive decline double after type 2 diabetes mellitus is diagnosed and can make self-management more difficult. Cognitive training has been found to be one way to improve self-management and cognitive function, and this article reports the adaptation of one such intervention to an online format. Ten adults with diabetes participated in an 8-week intervention that combined webinar classes with online computer game training. Perceived memory ability, executive function, self-management, and self-efficacy were measured. Evaluation of recruitment, data collection, and implementation demonstrated good feasibility and reduced barriers to engagement. Although the intervention did not result in significant changes in cognitive function, scores on all surveys improved. Adherence to diet, exercise, and foot care recommendations also improved. Most participants stated they preferred the intervention's online format to ""traditional"" in-person formats. Online technology in this 8-week intervention helped improve recruitment, retention, participant engagement, and use of cognitive strategies in people with type 2 diabetes mellitus. Overall, participants found the intervention helpful and said it reduced the time and travel burden associated with educational interventions. A larger randomized controlled trial is needed to further explore the intervention's potential impact over a longer period.",2020,"Online technology in this 8-week intervention helped improve recruitment, retention, participant engagement, and use of cognitive strategies in people with type 2 diabetes mellitus.","['Persons With Diabetes Intervention', 'Ten adults with diabetes participated in an', 'people with type 2 diabetes mellitus']","['8-week intervention that combined webinar classes with online computer game training', 'Online Cognitive Training', 'Cognitive training']","['time and travel burden', 'Perceived memory ability, executive function, self-management, and self-efficacy', 'cognitive function, scores']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0029038', 'cui_str': 'On-Line Systems'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0040802', 'cui_str': 'Travel'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",10.0,0.0343471,"Online technology in this 8-week intervention helped improve recruitment, retention, participant engagement, and use of cognitive strategies in people with type 2 diabetes mellitus.","[{'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Cuevas', 'Affiliation': 'Author Affiliations: School of Nursing, The University of Texas at Austin, Texas.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Carter', 'Affiliation': ''}]","Computers, informatics, nursing : CIN",['10.1097/CIN.0000000000000663'] 2955,32769629,Uromodulin to Osteopontin Ratio in Deceased Donor Urine is Associated with Kidney Graft Outcomes.,"BACKGROUND Deceased-donor kidneys experience extensive injury, activating adaptive and maladaptive pathways therefore impacting graft function. We evaluated urinary donor uromodulin (UMOD) and osteopontin (OPN) in recipient graft outcomes. METHODS Primary outcomes: all-cause graft failure (GF) and death-censored graft failure (dcGF). SECONDARY OUTCOMES delayed graft function (DGF) and 6-month eGFR. We randomly divided our cohort of deceased donors and recipients into training and test datasets. We internally validated associations between donor urine UMOD and OPN at time of procurement, with our primary outcomes. The direction of association between biomarkers and graft failure contrasted. Subsequently, we evaluated UMOD:OPN ratio with all outcomes. To understand these mechanisms, we examined the effect of UMOD on expression of major histocompatibility complex II (MHCII) in mouse macrophages. RESULTS Doubling of UMOD increased dcGF risk (adjusted hazard ratio (aHR) of 1.1 (95% CI: 1.02-1.2)), whereas OPN decreased dcGF risk [aHR 0.94 (95% CI: 0.88-1)]. UMOD:OPN ratio ≤ 3 strengthened the association, with reduced dcGF risk [aHR 0.57 (0.41-0.80)] with similar associations for GF, and in the test dataset. A ratio ≤ 3 was also associated with lower DGF [aOR 0.73 (95% CI: 0.60-0.89)] and higher 6-month eGFR [adjusted B-coefficient 3.19 (95% CI: 1.28-5.11)]. UMOD increased MHCII expression elucidating a possible mechanism behind UMOD's association with GF. CONCLUSIONS UMOD:OPN ratio ≤3 was protective, with lower risk of DGF, higher 6-month eGFR and improved graft survival. This ratio may supplement existing strategies for evaluating kidney quality and allocation decisions regarding deceased-donor kidney transplantation. TRIAL REGISTRATION NUMBER NCT01848249.",2020,A ratio ≤ 3 was also associated with lower DGF [aOR 0.73 (95% CI: 0.60-0.89)] and higher 6-month eGFR [adjusted B-coefficient 3.19 (95% CI: 1.28-5.11)].,[],['UMOD'],"['cause graft failure (GF) and death-censored graft failure (dcGF', 'OPN ratio', 'graft survival', 'OPN decreased dcGF risk', 'dcGF risk', 'urinary donor uromodulin (UMOD) and osteopontin (OPN', 'delayed graft function (DGF) and 6-month eGFR']",[],"[{'cui': 'C0077918', 'cui_str': 'Uromucoid protein'}]","[{'cui': 'C1262018', 'cui_str': 'Transplant failure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0069676', 'cui_str': 'Osteopontin'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0018131', 'cui_str': 'Graft Survival'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0077918', 'cui_str': 'Uromucoid protein'}, {'cui': 'C1566590', 'cui_str': 'Delayed graft function'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}]",,0.174413,A ratio ≤ 3 was also associated with lower DGF [aOR 0.73 (95% CI: 0.60-0.89)] and higher 6-month eGFR [adjusted B-coefficient 3.19 (95% CI: 1.28-5.11)].,"[{'ForeName': 'Sherry G', 'Initials': 'SG', 'LastName': 'Mansour', 'Affiliation': ''}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Yaqi', 'Initials': 'Y', 'LastName': 'Jia', 'Affiliation': ''}, {'ForeName': 'Peter P', 'Initials': 'PP', 'LastName': 'Reese', 'Affiliation': ''}, {'ForeName': 'Isaac E', 'Initials': 'IE', 'LastName': 'Hall', 'Affiliation': ''}, {'ForeName': 'Tarek M', 'Initials': 'TM', 'LastName': 'El-Achkar', 'Affiliation': ''}, {'ForeName': 'Kaice A', 'Initials': 'KA', 'LastName': 'LaFavers', 'Affiliation': ''}, {'ForeName': 'Wassim', 'Initials': 'W', 'LastName': 'Obeid', 'Affiliation': ''}, {'ForeName': 'Avi Z', 'Initials': 'AZ', 'LastName': 'Rosenberg', 'Affiliation': ''}, {'ForeName': 'Parnaz', 'Initials': 'P', 'LastName': 'Daneshpajouhnejad', 'Affiliation': ''}, {'ForeName': 'Mona D', 'Initials': 'MD', 'LastName': 'Doshi', 'Affiliation': ''}, {'ForeName': 'Enver', 'Initials': 'E', 'LastName': 'Akalin', 'Affiliation': ''}, {'ForeName': 'Jonathan S', 'Initials': 'JS', 'LastName': 'Bromberg', 'Affiliation': ''}, {'ForeName': 'Meera N', 'Initials': 'MN', 'LastName': 'Harhay', 'Affiliation': ''}, {'ForeName': 'Sumit', 'Initials': 'S', 'LastName': 'Mohan', 'Affiliation': ''}, {'ForeName': 'Thangamani', 'Initials': 'T', 'LastName': 'Muthukumar', 'Affiliation': ''}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Schröppel', 'Affiliation': ''}, {'ForeName': 'Pooja', 'Initials': 'P', 'LastName': 'Singh', 'Affiliation': ''}, {'ForeName': 'Joe M', 'Initials': 'JM', 'LastName': 'El-Khoury', 'Affiliation': ''}, {'ForeName': 'Francis L', 'Initials': 'FL', 'LastName': 'Weng', 'Affiliation': ''}, {'ForeName': 'Heather R', 'Initials': 'HR', 'LastName': 'Thiessen-Philbrook', 'Affiliation': ''}, {'ForeName': 'Chirag R', 'Initials': 'CR', 'LastName': 'Parikh', 'Affiliation': ''}]",Transplantation,['10.1097/TP.0000000000003299'] 2956,32769633,Health-Related Quality of Life Improvements in Patients With Endometriosis Treated With Elagolix.,"OBJECTIVE To evaluate the effects of elagolix on clinically meaningful improvements in health-related quality of life (HRQOL) measured by the EHP-30 (Endometriosis Health Profile-30). METHODS Data from two phase III trials of elagolix for moderate to severe pain associated with endometriosis were pooled and analyzed as three groups: placebo, elagolix 150 mg once daily, or elagolix 200 mg twice daily. Patients were administered the EHP-30 questionnaire at baseline, and at months 1, 3, and 6 of treatment. Previously established responder definitions were applied to determine percentages of patients with clinically meaningful EHP-30 improvements. The probability of meeting EHP-30 responder definitions with elagolix compared with placebo at months 3 and 6 was determined by Poisson regression analysis, controlling for baseline scores. RESULTS At month 6, the probabilities of meeting EHP-30 subscale responder definitions for pain, control and powerlessness, self-image, social support, emotional well-being, and sexual intercourse were 169% (adjusted relative risk [aRR]: 2.69, 95% CI 2.26-3.21), 129% (aRR 2.29, 95% CI 1.96-2.67), 80% (aRR 1.80, 95% CI 1.54-2.11), 70% (aRR 1.70, 95% CI 1.47-1.97), 67% (aRR 1.67, 95% CI 1.45-1.92), and 62% (aRR 1.62, 95% CI 1.36-1.92) greater, respectively (all P<.001), in the 200-mg group than in the placebo group. Although lower in magnitude than the 200-mg group, the 150-mg group also had greater probabilities of meeting responder definitions than the placebo group for all subscales except sexual intercourse. The probabilities of meeting responder definitions for pain, control and powerlessness, self-image, social support, and emotional well-being were 75% (aRR 1.75, 95% CI 1.44-2.14), 50% (aRR 1.50, 95% CI 1.25-1.80), 22% (aRR 1.22, 95% CI 1.01-1.47), 30% (aRR 1.30, 95% CI 1.09-1.53), and 35% (aRR 1.35, 95% CI 1.16-1.57) greater, respectively (all P<.05), in the 150-mg group than in the placebo group. CONCLUSION Patients with moderate to severe pain associated with endometriosis and were treated with elagolix experienced clinically meaningful HRQOL improvements. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT01620528 and NCT01931670. FUNDING SOURCE AbbVie Inc.",2020,"At month 6, the probabilities of meeting EHP-30 subscale responder definitions for pain, control and powerlessness, self-image, social support, emotional well-being, and sexual intercourse were 169% (adjusted relative risk [aRR]: 2.69, 95% CI 2.26-3.21), 129% (aRR 2.29, 95% CI 1.96-2.67), 80% (aRR 1.80, 95% CI 1.54-2.11), 70% (aRR 1.70, 95% CI 1.47-1.97), 67% (aRR 1.67, 95% CI 1.45-1.92), and 62% (aRR 1.62, 95% CI 1.36-1.92) greater, respectively (all P<.001), in the 200-mg group than in the placebo group.","['Patients', 'Data from two phase III trials of elagolix for moderate to severe pain associated with endometriosis']","['elagolix', 'Elagolix', 'placebo, elagolix 150 mg once daily, or elagolix 200 mg twice daily', 'placebo']","['health-related quality of life (HRQOL', 'Health-Related Quality of Life Improvements', 'probabilities of meeting responder definitions for pain, control and powerlessness, self-image, social support, and emotional well-being', 'probabilities of meeting EHP-30 subscale responder definitions for pain, control and powerlessness, self-image, social support, emotional well-being, and sexual intercourse', 'probabilities of meeting responder definitions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C2714632', 'cui_str': 'elagolix'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0014175', 'cui_str': 'Endometriosis'}]","[{'cui': 'C2714632', 'cui_str': 'elagolix'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4704593', 'cui_str': 'elagolix 150 MG'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C4704604', 'cui_str': 'elagolix 200 MG'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0150063', 'cui_str': 'Feeling powerless'}, {'cui': 'C0242498', 'cui_str': 'Self-image'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}]",,0.419231,"At month 6, the probabilities of meeting EHP-30 subscale responder definitions for pain, control and powerlessness, self-image, social support, emotional well-being, and sexual intercourse were 169% (adjusted relative risk [aRR]: 2.69, 95% CI 2.26-3.21), 129% (aRR 2.29, 95% CI 1.96-2.67), 80% (aRR 1.80, 95% CI 1.54-2.11), 70% (aRR 1.70, 95% CI 1.47-1.97), 67% (aRR 1.67, 95% CI 1.45-1.92), and 62% (aRR 1.62, 95% CI 1.36-1.92) greater, respectively (all P<.001), in the 200-mg group than in the placebo group.","[{'ForeName': 'Hugh S', 'Initials': 'HS', 'LastName': 'Taylor', 'Affiliation': 'Yale School of Medicine, New Haven, Connecticut; AbbVie Inc., North Chicago, Illinois; and Evidera, Bethesda, Maryland.'}, {'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'Soliman', 'Affiliation': ''}, {'ForeName': 'Beverly', 'Initials': 'B', 'LastName': 'Johns', 'Affiliation': ''}, {'ForeName': 'Robin M', 'Initials': 'RM', 'LastName': 'Pokrzywinski', 'Affiliation': ''}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Snabes', 'Affiliation': ''}, {'ForeName': 'Karin S', 'Initials': 'KS', 'LastName': 'Coyne', 'Affiliation': ''}]",Obstetrics and gynecology,['10.1097/AOG.0000000000003917'] 2957,32769639,Reducing the Risk for Postpartum Depression in Adolescent Mothers: A Randomized Controlled Trial.,"OBJECTIVE To estimate the effect of an interpersonal therapy-based intervention on reducing the risk of postpartum depression in adolescents. METHODS A randomized controlled trial enrolled 250 pregnant adolescents who were aged 18 years or younger at conception. The initial sample size calculation estimated 276 participants (324 with attrition) were needed to detect a 50% reduction in risk of the primary outcome, postpartum major depressive episode, with an alpha of 0.05% and 80% power. An interim analysis by the Data Safety and Monitoring Committee informed a revision in the sample size target to 250. Participants were randomized to the intervention (n=129) or a time-matched control group (n=121) who attended sessions about pregnancy topics. Each group received five prenatal sessions and a postpartum booster session. A structured diagnostic interview was administered at baseline and specific time points through 12-months postpartum to assess for major depressive episode onset. RESULTS Participants were recruited from December 2011 to May 2016 through urban prenatal care sites in the state of Rhode Island. Of the 250 participants, 58% identified as Hispanic and 20% as black or African American. The rate of major depressive episode by 12 months postpartum was 7.0% (95% CI 2.3-11.7%) in the control group and 7.6% (95% CI 2.5-12.7%) in the intervention group, with no significant difference between groups at any time point (P=.88 by log-rank test). CONCLUSION No benefit was shown between the intervention and control groups in the rates of major depressive episode, which is likely related to a lower than predicted rate of this outcome in the control group (7.6% actual vs 25% predicted). Enhanced local community resources available to pregnant and parenting adolescents during the study period may be an explanation for this result. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT01482832.",2020,"No benefit was shown between the intervention and control groups in the rates of major depressive episode, which is likely related to a lower than predicted rate of this outcome in the control group (7.6% actual vs 25% predicted).","['250 pregnant adolescents who were aged 18 years or younger at conception', 'Participants were recruited from December 2011 to May 2016 through urban prenatal care sites in the state of Rhode Island', '276 participants (324 with attrition', 'pregnant and parenting adolescents', 'Adolescent Mothers', 'adolescents', '250 participants, 58% identified as Hispanic and 20% as black or African American']","['time-matched control group (n=121) who attended sessions about pregnancy topics', 'interpersonal therapy-based intervention', 'five prenatal sessions and a postpartum booster session']","['rate of major depressive episode', 'rates of major depressive episode']","[{'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0009637', 'cui_str': 'Conception'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0035487', 'cui_str': 'Rhode Island'}, {'cui': 'C4517713', 'cui_str': '324'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0085756', 'cui_str': 'African American'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C1522168', 'cui_str': 'Topical route'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0020975', 'cui_str': 'Booster vaccination'}]","[{'cui': 'C0024517', 'cui_str': 'Major depression, single episode'}]",250.0,0.208404,"No benefit was shown between the intervention and control groups in the rates of major depressive episode, which is likely related to a lower than predicted rate of this outcome in the control group (7.6% actual vs 25% predicted).","[{'ForeName': 'Maureen G', 'Initials': 'MG', 'LastName': 'Phipps', 'Affiliation': 'Departments of Obstetrics and Gynecology and Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, the Department of Epidemiology, Brown University School of Public Health, the Department of Obstetrics and Gynecology, Women & Infants Hospital of Rhode Island, and the Women & Infants Hospital of Rhode Island, Providence, Rhode Island; the University of Cape Town, Cape Town, South Africa, and the Pacific Institute for Research and Evaluation, Beltsville, Maryland.'}, {'ForeName': 'Crystal F', 'Initials': 'CF', 'LastName': 'Ware', 'Affiliation': ''}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Stout', 'Affiliation': ''}, {'ForeName': 'Christina A', 'Initials': 'CA', 'LastName': 'Raker', 'Affiliation': ''}, {'ForeName': 'Caron', 'Initials': 'C', 'LastName': 'Zlotnick', 'Affiliation': ''}]",Obstetrics and gynecology,['10.1097/AOG.0000000000004003'] 2958,32769842,Lipid Analysis on Block Copolymer-containing Packaging Solution and Lens Care Regimens: A Randomized Clinical Trial.,"SIGNIFICANCE Lotrafilcon B lenses packaged in and cared for with block copolymer-containing (polyoxyethylene-polyoxybutylene; EOBO) lens care solutions resulted in lower cholesterol extraction than each of the habitual silicone hydrogel lens/multipurpose solution (MPS) regimens tested. PURPOSE This study aimed to compare the extracted cholesterol of lotrafilcon B lenses packaged in and cared for with EOBO-containing lens care solutions with the extracted cholesterol of habitual silicone hydrogel lenses cared for with MPS not containing EOBO. METHODS In this prospective, randomized, observer-masked parallel study, habitual wearers of senofilcon C, senofilcon A, comfilcon A, and samfilcon A contact lenses using a non-EOBO MPS were randomized 1:1 to lotrafilcon B lenses packaged in and cared for with EOBO-containing solutions or to their habitual lenses and MPS. Subjects randomized to lotrafilcon B were further randomized to one of two EOBO-containing lens care solutions, OPTI-FREE PUREMOIST or CLEAR CARE PLUS with HydraGlyde (Alcon Laboratories, Inc., Fort Worth, TX). A subset of right eye lenses was collected after wear, and total cholesterol was extracted and measured using a fluorometric enzymatic assay. RESULTS Of 143 lenses analyzed, 95 were from subjects randomized to their habitual lenses/MPS and 48 to lotrafilcon B + EOBO lenses plus CLEAR CARE PLUS with HydraGlyde or OPTI-FREE PUREMOIST. The mean amounts of cholesterol extracted from lotrafilcon B + EOBO lenses cared for with CLEAR CARE PLUS with HydraGlyde (0.28 ± 0.18 μg/lens) and OPTI-FREE PUREMOIST (0.28 ± 0.48 μg/lens) were significantly lower than those extracted from senofilcon C (4.18 ± 3.25 μg/lens), senofilcon A (2.19 ± 2.69 μg/lens), comfilcon A (2.17 ± 1.47 μg/lens), and samfilcon A (2.07 ± 1.48 μg/lens) lenses used with MPS (P < .0001 each). CONCLUSIONS Cholesterol sorption was significantly lower in wearers of lotrafilcon B lenses cared for with polyoxyethylene-polyoxybutylene-containing lens care solutions than in users of habitual silicone hydrogel lenses cared for with non-polyoxyethylene-polyoxybutylene MPS.",2020,"CONCLUSIONS Cholesterol sorption was significantly lower in wearers of lotrafilcon B lenses cared for with polyoxyethylene-polyoxybutylene-containing lens care solutions than in users of habitual silicone hydrogel lenses cared for with non-polyoxyethylene-polyoxybutylene MPS.","['habitual silicone hydrogel lenses cared for with MPS not containing EOBO', 'Of 143 lenses analyzed', 'habitual wearers of senofilcon C, senofilcon A, comfilcon A, and samfilcon A contact lenses using a non-EOBO MPS']","['polyoxyethylene-polyoxybutylene-containing lens care solutions', 'lotrafilcon B lenses packaged in and cared for with EOBO-containing solutions or to their habitual lenses and MPS', 'EOBO-containing lens care solutions, OPTI-FREE PUREMOIST or CLEAR CARE PLUS with HydraGlyde', 'habitual lenses/MPS and 48 to lotrafilcon B + EOBO lenses plus CLEAR CARE PLUS with HydraGlyde or OPTI-FREE']",[],"[{'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0037114', 'cui_str': 'Silicones'}, {'cui': 'C0063083', 'cui_str': 'Hydrogel'}, {'cui': 'C0023317', 'cui_str': 'Lens clear'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C4517573', 'cui_str': '143'}, {'cui': 'C2002497', 'cui_str': 'senofilcon A'}, {'cui': 'C2715682', 'cui_str': 'comfilcon A'}, {'cui': 'C0009836', 'cui_str': 'Contact lenses'}]","[{'cui': 'C0032483', 'cui_str': 'Polyethylene Glycols'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0023317', 'cui_str': 'Lens clear'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C2001571', 'cui_str': 'lotrafilcon B'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}]",[],,0.0694105,"CONCLUSIONS Cholesterol sorption was significantly lower in wearers of lotrafilcon B lenses cared for with polyoxyethylene-polyoxybutylene-containing lens care solutions than in users of habitual silicone hydrogel lenses cared for with non-polyoxyethylene-polyoxybutylene MPS.","[{'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Shows', 'Affiliation': 'Alcon Research, LLC, Fort Worth, Texas.'}, {'ForeName': 'Rachel L', 'Initials': 'RL', 'LastName': 'Redfern', 'Affiliation': 'College of Optometry, University of Houston, Houston, Texas.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Sickenberger', 'Affiliation': 'Jenvis Research, Ernst-Abbe University of Applied Sciences, Jena, Germany.'}, {'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Fogt', 'Affiliation': 'The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Schulze', 'Affiliation': 'University of Waterloo, Waterloo, Ontario, Canada.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Lievens', 'Affiliation': 'Southern College of Optometry, Memphis, Tennessee.'}, {'ForeName': 'Loretta', 'Initials': 'L', 'LastName': 'Szczotka-Flynn', 'Affiliation': 'University Hospitals of Cleveland Eye Institute, Cleveland, Ohio.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Schwarz', 'Affiliation': 'Private Practice, Hildesheim, Germany.'}, {'ForeName': 'Anna A', 'Initials': 'AA', 'LastName': 'Tichenor', 'Affiliation': 'Indiana University, Bloomington, Indiana.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Marx', 'Affiliation': 'Jenvis Research, Ernst-Abbe University of Applied Sciences, Jena, Germany.'}, {'ForeName': 'Jessie M', 'Initials': 'JM', 'LastName': 'Lemp-Hull', 'Affiliation': 'Alcon Research, LLC, Fort Worth, Texas.'}]",Optometry and vision science : official publication of the American Academy of Optometry,['10.1097/OPX.0000000000001553'] 2959,32769849,"SUPPORT-1 (Subjects Undergoing PCI and Perioperative Reperfusion Treatment): A Prospective, Randomized Trial of CMX-2043 in Patients Undergoing Elective Percutaneous Coronary Intervention.","OBJECTIVE The natural molecule α-lipoic acid has been shown to be partially cytoprotective through antioxidant and antiapoptotic mechanisms. To obtain an initial assessment of the safety and potential efficacy of a synthetic derivative, CMX-2043, in preventing ischemic complications of percutaneous coronary intervention (PCI) we conducted the Subjects Undergoing PCI and Perioperative Reperfusion Treatment (SUPPORT-1) trial, the first patient experience with this agent. METHODS AND RESULTS SUPPORT-1 was a phase 2a, 6-center, international, placebo-controlled, randomized, double-blind trial. A total of 142 patients were randomized to receive a single intravenous bolus dose of drug or placebo administered 15-60 minutes before PCI. Cardiac biomarker assessments included serial measurements of creatine kinase myocardial band (CK-MB) at 6, 12, 18, and 24 hours after PCI and a single measurement of troponin T (TnT) at 24 hours. Peak concentrations of CK-MB and TnT were significantly reduced in the 2.4 mg/kg group compared with placebo (P = 0.05 and 0.03, respectively). No subject administered 2.4 mg/kg of CMX-2043 had an increase of CK-MB to ≥3X upper limit of normal versus 16% for placebo (P = 0.02); 16% of the 2.4-mg/kg dose group developed an elevation of TnT to ≥3X upper limit of normal versus 39% in the placebo group (P = 0.05). No drug-related serious adverse events were observed in any group. CONCLUSION These data suggest that CMX-2043 may reduce PCI periprocedural myonecrosis and support further clinical evaluation of this novel agent for its potential cytoprotective effects.",2020,"Peak concentrations of CK-MB and TnT were significantly reduced in the 2.4 mg/kg group compared with placebo (P = 0.05 and 0.03, respectively).","['SUPPORT-1 (Subjects Undergoing PCI and Perioperative Reperfusion Treatment', 'Patients Undergoing Elective Percutaneous Coronary Intervention', 'Subjects Undergoing PCI and Perioperative Reperfusion Treatment (SUPPORT-1) trial, the first patient experience with this agent', '142 patients']","['percutaneous coronary intervention (PCI', 'synthetic derivative, CMX-2043', 'CMX-2043', 'placebo']","['Peak concentrations of CK-MB and TnT', 'CK-MB', 'elevation of TnT to ≥3X upper limit of normal', 'serious adverse events']","[{'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0035124', 'cui_str': 'Reperfusion'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0450442', 'cui_str': 'Agent'}]","[{'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0243072', 'cui_str': 'derivatives'}, {'cui': 'C4079957', 'cui_str': 'CMX-2043'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C0077404', 'cui_str': 'Troponin T'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",142.0,0.53467,"Peak concentrations of CK-MB and TnT were significantly reduced in the 2.4 mg/kg group compared with placebo (P = 0.05 and 0.03, respectively).","[{'ForeName': 'James E', 'Initials': 'JE', 'LastName': 'Tcheng', 'Affiliation': 'Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Gibson', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Mitchell W', 'Initials': 'MW', 'LastName': 'Krucoff', 'Affiliation': 'Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC.'}, {'ForeName': 'Manesh R', 'Initials': 'MR', 'LastName': 'Patel', 'Affiliation': 'Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC.'}, {'ForeName': 'Mullasari', 'Initials': 'M', 'LastName': 'Ajit', 'Affiliation': 'Madras Medical Mission, Chennai, India.'}, {'ForeName': 'Jagdish', 'Initials': 'J', 'LastName': 'Hiremath', 'Affiliation': 'Poona Hospital and Research Centre, Pune, India.'}, {'ForeName': 'Chandrashekhar', 'Initials': 'C', 'LastName': 'Ponde', 'Affiliation': 'P. D. Hinduja National Hospital & Medical Research Centre, Mumbai, India.'}, {'ForeName': 'Eddison', 'Initials': 'E', 'LastName': 'Ramsaran', 'Affiliation': 'Department of Interventional Cardiology, Reliant Medical Group, Worcester, MA.'}, {'ForeName': 'Geoffrey', 'Initials': 'G', 'LastName': 'Clark', 'Affiliation': 'Ischemix, Inc, Maynard, MA.'}, {'ForeName': 'Alan S', 'Initials': 'AS', 'LastName': 'Lader', 'Affiliation': 'Ischemix, Inc, Maynard, MA.'}, {'ForeName': 'Reinier', 'Initials': 'R', 'LastName': 'Beeuwkes', 'Affiliation': 'Ischemix, Inc, Maynard, MA.'}]",Journal of cardiovascular pharmacology,['10.1097/FJC.0000000000000830'] 2960,32769863,Long-term beneficial effects of an online mind-body training program on stress and psychological outcomes in female healthcare providers: A non-randomized controlled study.,"Mind-body training (MBT) programs are effective interventions for relieving stress and improving psychological capabilities. To expand our previous study which demonstrated the short-term effects of an 8-week online MBT program, the present study investigated whether those short-term effects persist up to a month after the end of the intervention.Among previous participants, 56 (64%) participated in this follow-up study, 25 in the MBT group and 31 in the control group. Outcome measures included the stress response, emotional intelligence, resilience, coping strategies, positive and negative affect, and anger expression of both groups at baseline, at 8 weeks (right after the training or waiting period), and at 12 weeks (a month after the training or waiting period).The MBT group showed a greater decrease in stress response at 8 weeks, and this reduction remained a month after the end of the intervention. The effect of MBT on resilience and effective coping strategies was also significant at 8 weeks and remained constant a month later. However, the improvement to emotional intelligence and negative affect did not persist a month after training.These findings suggest that the beneficial short-term effects of MBT may last beyond the training period even without continuous practice, but the retention of these benefits seems to depend on the outcome variables. Through a convenient, affordable, and easily accessible online format, MBT may provide cost-effective solutions for employees at worksites.",2020,The effect of MBT on resilience and effective coping strategies was also significant at 8 weeks and remained constant a month later.,['female healthcare providers'],"['MBT', 'online mind-body training program', 'Mind-body training']","['emotional intelligence', 'stress and psychological outcomes', 'stress response, emotional intelligence, resilience, coping strategies, positive and negative affect, and anger expression', 'resilience and effective coping strategies', 'stress response']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C1510539', 'cui_str': 'Emotional Intelligence'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0002957', 'cui_str': 'Feeling angry'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C2364069', 'cui_str': 'Able to cope'}]",,0.0207628,The effect of MBT on resilience and effective coping strategies was also significant at 8 weeks and remained constant a month later.,"[{'ForeName': 'Dasom', 'Initials': 'D', 'LastName': 'Lee', 'Affiliation': 'Emotional Information and Communication Technology Association.'}, {'ForeName': 'Won Joon', 'Initials': 'WJ', 'LastName': 'Lee', 'Affiliation': 'Department of Psychiatry, Kangdong Sacred Heart Hospital.'}, {'ForeName': 'Soo-Hee', 'Initials': 'SH', 'LastName': 'Choi', 'Affiliation': 'Department of Psychiatry, Seoul National University Hospital.'}, {'ForeName': 'Joon-Hwan', 'Initials': 'JH', 'LastName': 'Jang', 'Affiliation': 'Department of Psychiatry, Seoul National University Hospital.'}, {'ForeName': 'Do-Hyung', 'Initials': 'DH', 'LastName': 'Kang', 'Affiliation': 'Emotional Information and Communication Technology Association.'}]",Medicine,['10.1097/MD.0000000000021027'] 2961,32769873,A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial).,"INTRODUCTION Human epidermal growth factor receptor 2 (HER2) gene amplification and mutations have emerged as oncogenic drivers and therapeutic targets not limited to breast and gastric cancers, but also in a variety of cancers. However, even if an actionable gene alteration is found, the incidence of HER2 amplification in these cancers is less than 5%. It is too difficult to conduct a conventional randomized, controlled trial in a rare fraction. Therefore, we have designed a organ-agnostic basket study, which covers a variety of solid cancers harboring HER2 amplification, in 1 study protocol. METHODS/DESIGN This trial is a multicenter, single-arm, basket phase 2 study in Japan. Patients with solid cancers harboring HER2 amplification that have progressed with standard treatment, or rare cancers for which there is no standard treatment, will be eligible. Target cancers include bile duct, urothelial, uterine, ovarian, and other solid cancers where HER2 amplification is detected by comprehensive genomic profiling using next-generation sequencing technology. A total of 38 patients will be treated with combination therapy with trastuzumab and pertuzumab every 3 weeks until disease progression, unmanageable toxicity, death, or patient refusal. The primary endpoint is the objective response rate, and secondary endpoints are progression-free survival, overall survival, and duration of response. DISCUSSION The aim of this trial is to evaluate the safety and efficacy of combination therapy with trastuzumab and pertuzumab in patients with locally advanced or metastatic, solid cancers harboring HER2 amplification. Instead of focusing on 1 organ type, our trial design uses a basket study focusing on HER2 amplification, regardless of the site or origin of the cancer. The results of our study will advance clinical and scientific knowledge concerning the treatment of locally advanced, rare solid cancers harboring HER2 amplification, using the combination of trastuzumab and pertuzumab. TRIAL REGISTRATION This trial was registered in Japan Registry of Clinical Trials (jCRT) on February 25, 2019, as jRCT2031180150.",2020,"The primary endpoint is the objective response rate, and secondary endpoints are progression-free survival, overall survival, and duration of response. ","['Japan', 'Patients with solid cancers harboring HER2 amplification that have progressed with standard treatment, or rare cancers', 'patients with locally advanced or metastatic, solid cancers harboring HER2 amplification', '38 patients will be treated with combination therapy with', 'patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial']",['trastuzumab and pertuzumab'],"['safety and efficacy', 'objective response rate, and secondary endpoints are progression-free survival, overall survival, and duration of response']","[{'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205208', 'cui_str': 'Solid'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0475311', 'cui_str': 'Harbor'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0521114', 'cui_str': 'Infrequent'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}, {'cui': 'C0242754', 'cui_str': 'Jupiter'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C1328025', 'cui_str': 'pertuzumab'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]",38.0,0.115023,"The primary endpoint is the objective response rate, and secondary endpoints are progression-free survival, overall survival, and duration of response. ","[{'ForeName': 'Kenta', 'Initials': 'K', 'LastName': 'Takahashi', 'Affiliation': 'Center for Innovative Cancer Treatment.'}, {'ForeName': 'Eri', 'Initials': 'E', 'LastName': 'Ishibashi', 'Affiliation': 'Medical Innovation Promotion Center, Tokyo Medical and Dental University, Tokyo.'}, {'ForeName': 'Toshio', 'Initials': 'T', 'LastName': 'Kubo', 'Affiliation': 'Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama.'}, {'ForeName': 'Yohei', 'Initials': 'Y', 'LastName': 'Harada', 'Affiliation': 'Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga.'}, {'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Hayashi', 'Affiliation': 'Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo.'}, {'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Kano', 'Affiliation': 'Department of Frontier Surgery, Chiba University, Chiba.'}, {'ForeName': 'Yasushi', 'Initials': 'Y', 'LastName': 'Shimizu', 'Affiliation': 'Department of Medical Oncology, Faculty of Medicine & Graduate School of Medicine, Hokkaido University, Hokkaido.'}, {'ForeName': 'Hidekazu', 'Initials': 'H', 'LastName': 'Shirota', 'Affiliation': 'Department of Clinical Oncology, Tohoku University Hospital, Sendai.'}, {'ForeName': 'Yukiko', 'Initials': 'Y', 'LastName': 'Mori', 'Affiliation': 'Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto.'}, {'ForeName': 'Manabu', 'Initials': 'M', 'LastName': 'Muto', 'Affiliation': 'Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto.'}, {'ForeName': 'Chikashi', 'Initials': 'C', 'LastName': 'Ishioka', 'Affiliation': 'Department of Clinical Oncology, Tohoku University Hospital, Sendai.'}, {'ForeName': 'Hirotoshi', 'Initials': 'H', 'LastName': 'Dosaka-Akita', 'Affiliation': 'Department of Medical Oncology, Faculty of Medicine & Graduate School of Medicine, Hokkaido University, Hokkaido.'}, {'ForeName': 'Hisahiro', 'Initials': 'H', 'LastName': 'Matsubara', 'Affiliation': 'Department of Frontier Surgery, Chiba University, Chiba.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Nishihara', 'Affiliation': 'Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo.'}, {'ForeName': 'Naoko', 'Initials': 'N', 'LastName': 'Sueoka-Aragane', 'Affiliation': 'Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga.'}, {'ForeName': 'Shinichi', 'Initials': 'S', 'LastName': 'Toyooka', 'Affiliation': 'Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama.'}, {'ForeName': 'Akihiro', 'Initials': 'A', 'LastName': 'Hirakawa', 'Affiliation': 'Clinical Research Center.'}, {'ForeName': 'Ukihide', 'Initials': 'U', 'LastName': 'Tateishi', 'Affiliation': 'Department of Diagnostic Radiology, Tokyo Medical and Dental University, Tokyo, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Miyake', 'Affiliation': 'Center for Innovative Cancer Treatment.'}, {'ForeName': 'Sadakatsu', 'Initials': 'S', 'LastName': 'Ikeda', 'Affiliation': 'Center for Innovative Cancer Treatment.'}]",Medicine,['10.1097/MD.0000000000021457'] 2962,32769533,Does Virtual Reality Improve Procedural Completion and Accuracy in an Intramedullary Tibial Nail Procedure? A Randomized Control Trial.,"BACKGROUND Artificial reality technologies are currently being explored as potential options to improve surgical education. Previous studies have primarily examined the efficacy of artificial reality in laparoscopic procedures, but to our knowledge, none have been performed in orthopaedically relevant procedures such as intramedullary tibial nailing, which calls for more versatile large-scale movements. QUESTIONS/PURPOSES Does a virtual reality simulator with or without a standard technique guide result in (1) a higher proportion of participants who completed the insertion of an intramedullary tibial nail in a synthetic bones model and (2) greater procedural accuracy than does training with a technique guide alone? METHODS Twenty-five first- and second-year medical students without prior exposure to intramedullary tibial nail insertion were recruited. Participants were randomly assigned to the technique guide control group (n = 8), the virtual reality group (n = 8), or the virtual reality and technique guide group (n = 9). The technique guide was adapted from a commercially available technique guide, which participants in the assigned groups could use to prepare as much as desired. The virtual reality simulation was based on the same procedure, and we used a commercially available virtual reality simulator that we purchased for this task. Participants in the virtual reality experimental groups completed the simulation on three separate sessions, at a set interval of 3 to 4 days apart. After 10 to 14 days of preparation, all participants attempted to insert an intramedullary nail into an intact, compact bone-model tibia that lacked surrounding soft tissue. Participants were given written hints if requested, but no other assistance was given. A procedure was considered complete if the nail and screw were properly placed. Procedural accuracy was defined as the number of incorrect steps normalized out of the 16 possible performed. After the procedure, one orthopaedic surgeon assessed a blinded video of the participant performing it so the assessor could not recognize the individual or that individual's gender. Additionally, the assessor was unaware of which group each participant had been randomized to during the evaluation. RESULTS A higher proportion of participants in the virtual reality group (6 of 8) and the virtual reality and technique guide group (7 of 9) completed the intramedullary nail than did participants in the technique guide group (2 of 8; p = 0.01). There was no difference in completion between the virtual reality groups (p = 0.89). Participants in the virtual reality and virtual reality and technique guide had fewer normalized incorrect steps than did participants in the technique guide group (3.2 ± 0.1 of 16 and 3.1 ± 0.1 of 16 versus 5.7 ± 0.2 of 16, respectively; p = 0.02 for comparisons of virtual reality groups to technique guide, p = 0.63 between the virtual reality group). CONCLUSIONS Virtual reality increased both procedural accuracy and the completion proportion compared with a technique guide in medical students. Based on our findings, virtual reality may help residents learn the procedural workflow and movements required to perform surgical procedures. Future studies should examine how and when exactly the technology can be applied to residencies and its impact on residents. LEVEL OF EVIDENCE Level I, therapeutic study.",2020,"Participants in the virtual reality and virtual reality and technique guide had fewer normalized incorrect steps than did participants in the technique guide group (3.2 ± 0.1 of 16 and 3.1 ± 0.1 of 16 versus 5.7 ± 0.2 of 16, respectively; p = 0.02 for comparisons of virtual reality groups to technique guide, p = 0.63 between the virtual reality group). ","['Twenty-five', 'first- and second-year medical students without prior exposure to intramedullary tibial nail insertion were recruited']","['virtual reality group (n = 8), or the virtual reality and technique guide group']","['intramedullary nail', 'Procedural accuracy', 'normalized incorrect steps']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C1512957', 'cui_str': 'Intramedullary route'}, {'cui': 'C0040184', 'cui_str': 'Bone structure of tibia'}, {'cui': 'C0027342', 'cui_str': 'Nail plate structure'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0181090', 'cui_str': 'Guide'}]","[{'cui': 'C0021885', 'cui_str': 'Bone nailing'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}]",,0.0343419,"Participants in the virtual reality and virtual reality and technique guide had fewer normalized incorrect steps than did participants in the technique guide group (3.2 ± 0.1 of 16 and 3.1 ± 0.1 of 16 versus 5.7 ± 0.2 of 16, respectively; p = 0.02 for comparisons of virtual reality groups to technique guide, p = 0.63 between the virtual reality group). ","[{'ForeName': 'Mark D', 'Initials': 'MD', 'LastName': 'Orland', 'Affiliation': 'M. D. Orland, M. J. Patetta, E. Kayupoy, M. H. Gonzalez, Department of Orthopaedic Surgery, University of Illinois, Chicago, IL, USA M. Wieser, Institute for Orthopaedic Surgery, Lima, OH, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Patetta', 'Affiliation': ''}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Wieser', 'Affiliation': ''}, {'ForeName': 'Erdan', 'Initials': 'E', 'LastName': 'Kayupov', 'Affiliation': ''}, {'ForeName': 'Mark H', 'Initials': 'MH', 'LastName': 'Gonzalez', 'Affiliation': ''}]",Clinical orthopaedics and related research,['10.1097/CORR.0000000000001362'] 2963,32769596,"Focused Shockwave Treatment for Greater Trochanteric Pain Syndrome: A Multicenter, Randomized, Controlled Clinical Trial.","BACKGROUND Greater trochanteric pain syndrome (GTPS) is a condition of lateral hip pain. Its physiopathology remains unknown, and there is no consensus on optimal management. The aim of this study was to assess the effectiveness of electromagnetic-focused extracorporeal shockwave treatment (F-ESWT) in patients with GTPS. METHODS This multicenter clinical trial included 103 patients with chronic GTPS randomly assigned to the treatment group, consisting of electromagnetic F-ESWT and a specific exercise protocol, or the control group, receiving sham F-ESWT and the same exercise protocol. Both groups were treated with 3 weekly sessions; the F-ESWT group received an energy flux density of 0.20 mJ/mm, whereas the control group received 0.01 mJ/mm. Patients were assessed at baseline and 1, 2, 3, and 6 months after treatment. A visual analogue scale (VAS) score for pain at 2 months was the primary outcome. The Harris hip score (HHS), Lower Extremity Functional Scale (LEFS), EuroQoL-5 Dimensions Questionnaire (EQ-5D), and Roles and Maudsley score were used as secondary outcomes. Complications were recorded. RESULTS The mean VAS score decreased from 6.3 at baseline in both groups to 2.0 in the F-ESWT group versus 4.7 in the control group at 2 months; the 2-month score differed significantly between groups (p < 0.001). All secondary outcomes at all follow-up intervals were significantly better in the F-ESWT group, except for the LEFS score at 1 month after treatment (p = 0.25). No complications were observed. CONCLUSIONS F-ESWT in association with a specific exercise program is safe and effective for GTPS, with a success rate of 86.8% at 2 months after treatment, which was maintained until the end of follow-up. LEVEL OF EVIDENCE Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.",2020,The mean VAS score decreased from 6.3 at baseline in both groups to 2.0 in the F-ESWT group versus 4.7 in the control group at 2 months; the 2-month score differed significantly between groups (p < 0.001).,"['patients with GTPS', '103 patients with chronic GTPS', 'Greater Trochanteric Pain Syndrome']","['Shockwave Treatment', 'electromagnetic F-ESWT and a specific exercise protocol, or the control group, receiving sham F-ESWT and the same exercise protocol', 'electromagnetic-focused extracorporeal shockwave treatment (F-ESWT']","['mean VAS score', 'visual analogue scale (VAS) score for pain', 'LEFS score', 'Harris hip score (HHS), Lower Extremity Functional Scale (LEFS), EuroQoL-5 Dimensions Questionnaire (EQ-5D), and Roles and Maudsley score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0391976', 'cui_str': 'Pain Disorder'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0013838', 'cui_str': 'Electromagnetics'}, {'cui': 'C0442087', 'cui_str': 'Extracorporeal'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4305124', 'cui_str': 'Lower Extremity Functional Scale score'}, {'cui': 'C2919875', 'cui_str': 'Harris hip score'}, {'cui': 'C4305121', 'cui_str': 'Lower Extremity Functional Scale'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0035820', 'cui_str': 'Role'}]",103.0,0.126826,The mean VAS score decreased from 6.3 at baseline in both groups to 2.0 in the F-ESWT group versus 4.7 in the control group at 2 months; the 2-month score differed significantly between groups (p < 0.001).,"[{'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Ramon', 'Affiliation': 'Department of Physical Medicine and Rehabilitation (PMR) (S. Ramon and R.d.U.) and Department of Orthopedic Surgery, Instituto Cugat (R.C. and R.S.), Quirónsalud Hospital, Barcelona, Spain.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Russo', 'Affiliation': 'Department of Public Health, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Flavia', 'Initials': 'F', 'LastName': 'Santoboni', 'Affiliation': 'Physical Medicine and Rehabilitation (F.S., M.V., R.B., G.S., S.-M.N., and M.-C.V.), and Department of Statistics (R.B.), Sapienza University School of Medicine, Rome, Italy.'}, {'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Lucenteforte', 'Affiliation': 'Policlinico Vittorio Emanuele, Università degli Studi di Catania, Catania. Italy.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Di Luise', 'Affiliation': 'Department of Public Health, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Rocio', 'Initials': 'R', 'LastName': 'de Unzurrunzaga', 'Affiliation': 'Department of Physical Medicine and Rehabilitation (PMR) (S. Ramon and R.d.U.) and Department of Orthopedic Surgery, Instituto Cugat (R.C. and R.S.), Quirónsalud Hospital, Barcelona, Spain.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Vetrano', 'Affiliation': 'Physical Medicine and Rehabilitation (F.S., M.V., R.B., G.S., S.-M.N., and M.-C.V.), and Department of Statistics (R.B.), Sapienza University School of Medicine, Rome, Italy.'}, {'ForeName': 'Mariantonia', 'Initials': 'M', 'LastName': 'Albano', 'Affiliation': 'Department of Public Health, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Rosella', 'Initials': 'R', 'LastName': 'Baldini', 'Affiliation': 'Physical Medicine and Rehabilitation (F.S., M.V., R.B., G.S., S.-M.N., and M.-C.V.), and Department of Statistics (R.B.), Sapienza University School of Medicine, Rome, Italy.'}, {'ForeName': 'Ramon', 'Initials': 'R', 'LastName': 'Cugat', 'Affiliation': 'Department of Physical Medicine and Rehabilitation (PMR) (S. Ramon and R.d.U.) and Department of Orthopedic Surgery, Instituto Cugat (R.C. and R.S.), Quirónsalud Hospital, Barcelona, Spain.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Stella', 'Affiliation': 'Physical Medicine and Rehabilitation (F.S., M.V., R.B., G.S., S.-M.N., and M.-C.V.), and Department of Statistics (R.B.), Sapienza University School of Medicine, Rome, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Balato', 'Affiliation': 'Department of Public Health, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Seijas', 'Affiliation': 'Department of Physical Medicine and Rehabilitation (PMR) (S. Ramon and R.d.U.) and Department of Orthopedic Surgery, Instituto Cugat (R.C. and R.S.), Quirónsalud Hospital, Barcelona, Spain.'}, {'ForeName': 'Sveva-Maria', 'Initials': 'SM', 'LastName': 'Nusca', 'Affiliation': 'Physical Medicine and Rehabilitation (F.S., M.V., R.B., G.S., S.-M.N., and M.-C.V.), and Department of Statistics (R.B.), Sapienza University School of Medicine, Rome, Italy.'}, {'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Servodidio', 'Affiliation': 'Department of Public Health, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Maria-Chiara', 'Initials': 'MC', 'LastName': 'Vulpiani', 'Affiliation': 'Physical Medicine and Rehabilitation (F.S., M.V., R.B., G.S., S.-M.N., and M.-C.V.), and Department of Statistics (R.B.), Sapienza University School of Medicine, Rome, Italy.'}]",The Journal of bone and joint surgery. American volume,['10.2106/JBJS.20.00093'] 2964,32769744,Functional and Short-term Outcomes in Elective Laparoscopic Colectomy for Symptomatic Diverticular Disease With Either Low Ligation or Inferior Mesenteric Artery Preservation: A Randomized Trial.,"BACKGROUND The current treatment of symptomatic diverticular disease is left colectomy/sigmoidectomy with low ligation of the inferior mesenteric artery versus the inferior mesenteric artery preservation. Up to now, there is no strong evidence in favor of one of the 2 strategies. The aim of this study is to compare the bowel-specific quality of life and functional outcomes between these 2. METHODS Between June 2015 and February 2019, patients were randomly assigned to inferior mesenteric artery low ligation or inferior mesenteric artery preservation during elective laparoscopic sigmoidectomy for diverticular disease. Gastrointestinal, genitourinary functions and surgical outcomes were compared postoperatively between groups. RESULTS One-hundred sixty-eight patients were randomized providing 2 homogenous groups. Gastrointestinal and genitourinary functions were not significantly different between groups after 1 and 6 months postoperative. In both groups, the function was restored to the preoperative level 6 months after surgery. There was no statistically significant difference in terms of conversion rate, blood loss, length of surgery, between groups. There was no difference in the overall complication rate and the anastomotic leak rate among groups. CONCLUSIONS Inferior mesenteric artery low ligation or inferior mesenteric artery preservation during elective laparoscopic sigmoidectomy for a diverticular disease can be considered equivalent in affecting the postoperative bowel-related quality of life, genitourinary function, and surgical outcomes.",2020,"There was no statistically significant difference in terms of conversion rate, blood loss, length of surgery, between groups.","['Between June 2015 and February 2019', 'One-hundred sixty-eight patients', 'Symptomatic Diverticular Disease With Either Low Ligation or Inferior Mesenteric Artery Preservation']","['Elective Laparoscopic Colectomy', 'elective laparoscopic sigmoidectomy', 'inferior mesenteric artery low ligation or inferior mesenteric artery preservation during elective laparoscopic sigmoidectomy']","['overall complication rate', 'bowel-specific quality of life and functional outcomes', 'anastomotic leak rate', 'Gastrointestinal, genitourinary functions and surgical outcomes', 'conversion rate, blood loss, length of surgery', 'Gastrointestinal and genitourinary functions']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0450387', 'cui_str': '68'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C1510475', 'cui_str': 'Diverticula of intestine'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0023690', 'cui_str': 'Ligation'}, {'cui': 'C0162860', 'cui_str': 'Structure of inferior mesenteric artery'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}]","[{'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C1517722', 'cui_str': 'Laparoscopic colectomy'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0192866', 'cui_str': 'Sigmoid colectomy'}, {'cui': 'C0162860', 'cui_str': 'Structure of inferior mesenteric artery'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0023690', 'cui_str': 'Ligation'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0919691', 'cui_str': 'Anastomotic leak'}, {'cui': 'C0042066', 'cui_str': 'Structure of genitourinary system'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]",168.0,0.0686412,"There was no statistically significant difference in terms of conversion rate, blood loss, length of surgery, between groups.","[{'ForeName': 'Giulio', 'Initials': 'G', 'LastName': 'Mari', 'Affiliation': 'Colorectal Department, ASST Monza, Desio Hospital, Desio.'}, {'ForeName': 'Isacco', 'Initials': 'I', 'LastName': 'Montroni', 'Affiliation': 'Colorectal Department, Infermi Hospital, Faenza.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Origi', 'Affiliation': 'Colorectal Department, ASST Niguarda, Milano, Italy.'}, {'ForeName': 'Jacopo', 'Initials': 'J', 'LastName': 'Crippa', 'Affiliation': 'Colorectal Department, ASST Niguarda, Milano, Italy.'}, {'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Achilli', 'Affiliation': 'Colorectal Department, ASST Niguarda, Milano, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Costanzi', 'Affiliation': 'Colorectal Department, ASST Monza, Desio Hospital, Desio.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Ferrari', 'Affiliation': 'Colorectal Department, ASST Niguarda, Milano, Italy.'}, {'ForeName': 'Giampaolo', 'Initials': 'G', 'LastName': 'Ugolini', 'Affiliation': 'Colorectal Department, Infermi Hospital, Faenza.'}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Maggioni', 'Affiliation': 'Colorectal Department, ASST Monza, Desio Hospital, Desio.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Surgical laparoscopy, endoscopy & percutaneous techniques",['10.1097/SLE.0000000000000850'] 2965,32769754,Remote corneal suturing wet lab: Microsurgical education during the COVID-19 pandemic.,"PURPOSE To study the feasibility and efficacy of a novel remote wet lab for microsurgical education using a corneal suturing task. SETTING Department of Ophthalmology, University of California San Francisco, San Francisco, California, USA. DESIGN Prospective randomized controlled study. METHODS Ten ophthalmology residents were stratified by postgraduate year and randomized to perform a corneal suturing task consisting of placing the 4 cardinal sutures for a penetrating keratoplasty in porcine eyes with or without remote ophthalmology attending feedback. Subsequently, both groups repeated the same task without remote feedback to test whether initial remote feedback affected subsequent performance. Finally, the group without feedback was crossed over to repeat the same corneal suturing task with remote feedback. The effectiveness of the remote wet lab was assessed subjectively by survey and objectively by grading each suture pass. RESULTS Resident-reported comfort with corneal suturing improved significantly after the remote wet lab for all residents. Residents and attendings rated the remote wet lab as equally or more effective compared to prior in-person wet labs and overall effective in corneal suturing. Attendings rated the remote wet lab as effective in multiple domains of microsurgical education using a modified microsurgical global rating scale. Objective corneal suturing performance was similar for both groups. CONCLUSION The remote wet lab was feasible and effective for training ophthalmology residents in corneal suturing. This represents a novel social distancing compliant platform for microsurgical education during the COVID-19 pandemic.",2020,Attendings rated the remote wet lab as effective in multiple domains of microsurgical education using a modified microsurgical global rating scale.,"['Ten ophthalmology residents', 'Department of Ophthalmology, University of California San Francisco, San Francisco, California, USA']","['Remote corneal suturing wet lab', 'corneal suturing task consisting of placing the 4 cardinal sutures for a penetrating keratoplasty in porcine eyes with or without remote ophthalmology attending feedback', 'novel remote wet lab for microsurgical education']","['comfort with corneal suturing', 'Objective corneal suturing performance']","[{'cui': 'C0029087', 'cui_str': 'Ophthalmology'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0036152', 'cui_str': 'San Francisco'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0205381', 'cui_str': 'Wet'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0326926', 'cui_str': 'Cardinalis cardinalis'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0022592', 'cui_str': 'Penetrating keratoplasty'}, {'cui': 'C0039005', 'cui_str': 'Suidae'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0029087', 'cui_str': 'Ophthalmology'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}]",,0.0200271,Attendings rated the remote wet lab as effective in multiple domains of microsurgical education using a modified microsurgical global rating scale.,"[{'ForeName': 'Neel D', 'Initials': 'ND', 'LastName': 'Pasricha', 'Affiliation': 'From the Department of Ophthalmology (Pasricha, Haq, Chan, Redd, Seitzman, Parikh, Kim, Schallhorn, Ramanathan), School of Medicine (Ahmad), and Francis I. Proctor Foundation (Redd, Seitzman, Schallhorn), University of California San Francisco, San Francisco, California, USA. Supported in part by a Research to Prevent Blindness unrestricted grant to the University of California San Francisco, Department of Ophthalmology.'}, {'ForeName': 'Zeeshan', 'Initials': 'Z', 'LastName': 'Haq', 'Affiliation': ''}, {'ForeName': 'Tessnim R', 'Initials': 'TR', 'LastName': 'Ahmad', 'Affiliation': ''}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Chan', 'Affiliation': ''}, {'ForeName': 'Travis K', 'Initials': 'TK', 'LastName': 'Redd', 'Affiliation': ''}, {'ForeName': 'Gerami D', 'Initials': 'GD', 'LastName': 'Seitzman', 'Affiliation': ''}, {'ForeName': 'Neeti', 'Initials': 'N', 'LastName': 'Parikh', 'Affiliation': ''}, {'ForeName': 'Tyson N', 'Initials': 'TN', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Julie M', 'Initials': 'JM', 'LastName': 'Schallhorn', 'Affiliation': ''}, {'ForeName': 'Saras', 'Initials': 'S', 'LastName': 'Ramanathan', 'Affiliation': ''}]",Journal of cataract and refractive surgery,['10.1097/j.jcrs.0000000000000374'] 2966,32769757,"Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).","OBJECTIVE In the primary analysis of the phase 2b VESTA study, oral fezolinetant reduced frequency and severity of menopausal vasomotor symptoms (VMS) compared with placebo. This secondary analysis evaluates effects of fezolinetant on responder rates and patient-reported outcomes (PROs). METHODS In this 12-week, double-blind study, postmenopausal women with moderate/severe VMS were randomized to fezolinetant 15, 30, 60, or 90 mg BID or 30, 60, or 120 mg QD or placebo. Proportion of responders was based on reductions in VMS from daily diary records. P values for comparisons between active treatment and placebo were calculated using logistic regression. Changes from baseline in PROs (Menopause-Specific Quality of Life questionnaire, Hot Flash-Related Daily Interference Scale, Greene Climacteric Scale) were conducted using a mixed model for repeated measurements and compared post hoc with published minimally important differences (MIDs). RESULTS Of 356 women randomized, 352 were treated and analyzed. A greater proportion of women receiving fezolinetant versus placebo met definitions of response at week 12. For all doses, mean changes from baseline in Menopause-Specific Quality of Life questionnaire VMS scores exceeded the MID (1.2) at weeks 4 (placebo: -1.8; fezolinetant: range, -1.9 to -3.6) and 12 (placebo: -2.3; fezolinetant: range, -2.9 to -4.4). Mean changes in Hot Flash-Related Daily Interference Scale at weeks 4 (placebo: -2.2; fezolinetant: range, -2.5 to -3.8) and 12 (placebo: -2.9; fezolinetant: range, -3.3 to -4.3) exceeded the MID (1.76). Greene Climacteric Scale-VMS domain scores improved for most fezolinetant doses versus placebo (week 4, placebo: -1.7; fezolinetant: range, -2.1 to -3.3; week 12, placebo: -2.1; fezolinetant: range, -2.7 to -3.6). CONCLUSIONS Oral fezolinetant was associated with higher responder rates than placebo and larger improvements in QoL and other PRO measures, including a reduction in VMS-related interference with daily life.",2020,"Greene Climacteric Scale-VMS domain scores improved for most fezolinetant doses versus placebo (week 4, placebo: -1.7; fezolinetant: range, -2.1 to -3.3; week 12, placebo: -2.1; fezolinetant: range, -2.7 to -3.6). ","['postmenopausal women with moderate/severe VMS', '356 women randomized, 352 were treated and analyzed', 'postmenopausal women with vasomotor symptoms']","['fezolinetant', 'neurokinin 3 receptor antagonist fezolinetant', 'placebo']","['responder rates and patient-reported outcomes (PROs', 'Menopause-Specific Quality of Life questionnaire VMS scores', 'responder rates', 'Mean changes in Hot Flash-Related Daily Interference Scale', 'frequency and severity of menopausal vasomotor symptoms (VMS', 'Greene Climacteric Scale-VMS domain scores', 'PROs (Menopause-Specific Quality of Life questionnaire, Hot Flash-Related Daily Interference Scale, Greene Climacteric Scale']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C4547455', 'cui_str': 'fezolinetant'}, {'cui': 'C0068603', 'cui_str': 'Neuromedin K Receptor'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0600142', 'cui_str': 'Menopausal flushing'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0008943', 'cui_str': 'Change of Life'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]",356.0,0.517058,"Greene Climacteric Scale-VMS domain scores improved for most fezolinetant doses versus placebo (week 4, placebo: -1.7; fezolinetant: range, -2.1 to -3.3; week 12, placebo: -2.1; fezolinetant: range, -2.7 to -3.6). ","[{'ForeName': 'Nanette', 'Initials': 'N', 'LastName': 'Santoro', 'Affiliation': 'University of Colorado School of Medicine, Aurora, CO.'}, {'ForeName': 'Arthur', 'Initials': 'A', 'LastName': 'Waldbaum', 'Affiliation': ""Downtown Women's Healthcare, Denver, CO.""}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Lederman', 'Affiliation': 'Altus Research, Lake Worth, FL.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Kroll', 'Affiliation': ""Seattle Women's: Health, Research, Gynecology, Seattle, WA.""}, {'ForeName': 'Graeme L', 'Initials': 'GL', 'LastName': 'Fraser', 'Affiliation': 'OGEDA SA, subsidiary of Astellas Pharma, Inc., Gosselies, Belgium.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Lademacher', 'Affiliation': 'Astellas Pharma US, Inc., Northbrook, IL.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Skillern', 'Affiliation': 'Astellas Pharma Europe Ltd, Chertsey, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Young', 'Affiliation': 'Astellas Pharma US, Inc., Northbrook, IL.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Ramael', 'Affiliation': 'OGEDA SA, subsidiary of Astellas Pharma, Inc., Gosselies, Belgium.'}]","Menopause (New York, N.Y.)",['10.1097/GME.0000000000001621'] 2967,32769877,Protective effect of probiotics in patients with non-alcoholic fatty liver disease.,"To investigate the effects of probiotics on liver function, glucose and lipids metabolism, and hepatic fatty deposition in patients with non-alcoholic fatty liver disease (NAFLD).Totally 140 NAFLD cases diagnosed in our hospital from March 2017 to March 2019 were randomly divided into the observation group and control group, 70 cases in each. The control group received the diet and exercise therapy, while the observation group received oral probiotics based on the control group, and the intervention in 2 groups lasted for 3 months. The indexes of liver function, glucose and lipids metabolism, NAFLD activity score (NAS), and conditions of fecal flora in 2 groups were compared before and after the treatment.Before the treatment, there were no significant differences on alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamine transferase (GGT), total bilirubin (TBIL), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), insulin resistance index (HOMA-IR), NAFLD activity score (NAS), and conditions of fecal flora in 2 groups (P > .05). After the treatment, ALT, AST, GGT, TC, TG, HOMA-IR, NAS, and conditions of fecal flora in the observation group were better than those in the control group, and the observation group was better after treatment than before. All these above differences were statistically significant (P < .05).Probiotics can improve some liver functions, glucose and lipids metabolism, hepatic fatty deposition in patients with NAFLD, which will enhance the therapeutic effects of NAFLD.",2020,"All these above differences were statistically significant (P < .05).Probiotics can improve some liver functions, glucose and lipids metabolism, hepatic fatty deposition in patients with NAFLD, which will enhance the therapeutic effects of NAFLD.","['patients with NAFLD', 'patients with non-alcoholic fatty liver disease (NAFLD).Totally 140 NAFLD cases diagnosed in our hospital from March 2017 to March 2019', 'patients with non-alcoholic fatty liver disease']","['diet and exercise therapy, while the observation group received oral probiotics', 'probiotics']","['ALT, AST, GGT, TC, TG, HOMA-IR, NAS, and conditions of fecal flora', 'liver functions, glucose and lipids metabolism, hepatic fatty deposition', 'liver function, glucose and lipids metabolism, and hepatic fatty deposition', 'indexes of liver function, glucose and lipids metabolism, NAFLD activity score (NAS), and conditions of fecal flora', 'alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamine transferase (GGT), total bilirubin (TBIL), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), insulin resistance index (HOMA-IR), NAFLD activity score (NAS), and conditions of fecal flora']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}]","[{'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0017040', 'cui_str': 'Gamma-glutamyltransferase'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0232741', 'cui_str': 'Liver function'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0333574', 'cui_str': 'Fatty deposition'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0061485', 'cui_str': 'Glutamine phenylacetyltransferase'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}]",,0.0164329,"All these above differences were statistically significant (P < .05).Probiotics can improve some liver functions, glucose and lipids metabolism, hepatic fatty deposition in patients with NAFLD, which will enhance the therapeutic effects of NAFLD.","[{'ForeName': 'Gen-Shen', 'Initials': 'GS', 'LastName': 'Cai', 'Affiliation': 'Department of General Medicine.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Su', 'Affiliation': 'Department of Gastroenterology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of General Medicine.'}]",Medicine,['10.1097/MD.0000000000021464'] 2968,32769878,A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension.,"BACKGROUND Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has a well-characterized efficacy and safety profile in patients with hypertension. AZL-M is approved for use in over 40 countries globally; however, it is not yet approved in China. Therefore, a phase 3 registration study to assess the efficacy (antihypertensive effect), safety, and tolerability of AZL-M compared with valsartan in Chinese patients with essential hypertension was undertaken. METHODS This multicenter, double-blind, randomized, 8-week phase 3 study compared AZL-M with valsartan in Chinese patients aged ≥18 years with essential hypertension. Endpoints included change from baseline to week 8 in trough sitting clinic systolic blood pressure (scSBP) and ambulatory blood pressure monitoring parameters. RESULTS Overall, 612 patients (mean age, 57.1 years; 57.5% male) were randomized to AZL-M 80 mg (n = 209), AZL-M 40 mg (n = 199), or valsartan 160 mg (n = 204). Baseline mean scSBP was similar in all groups (157.9-158.5 mm Hg). The mean reduction in trough scSBP from baseline to week 8 was significantly greater with AZL-M 80 mg than with valsartan (-24.2 vs -20.6 mm Hg; P = .010), and noninferior with AZL-M 40 mg versus valsartan (-22.5 vs -20.6 mm Hg; P = .184). Mean reduction in 24-hour mean systolic blood pressure (n = 257) was significantly greater with both AZL-M 80 mg (-17.0 mm Hg; P < .001) and AZL-M 40 mg (-14.7 mm Hg; P = .014) than with valsartan (-9.4 mm Hg). Treatment-emergent adverse events had similar incidence (52.8%-56.5%) across the treatment groups and were generally mild or moderate. Dizziness was the most frequent treatment-related treatment-emergent adverse events (AZL-M 80 mg, 1.9%; AZL-M 40 mg, 1.5%; valsartan, 1.0%). The safety and tolerability of AZL-M were comparable with valsartan. CONCLUSIONS AZL-M was noninferior to valsartan at the 40-mg dose and superior to valsartan at the 80-mg dose in reducing trough scSBP, and showed acceptable safety-consistent with the AZL-M safety profile in other populations-in Chinese adults with hypertension. TRIAL REGISTRATION NUMBER NCT02480764.",2020,Treatment-emergent adverse events had similar incidence (52.8%-56.5%) across the treatment groups and were generally mild or moderate.,"['612 patients (mean age, 57.1 years; 57.5% male', 'Chinese patients with essential hypertension was undertaken', 'Chinese patients with essential hypertension', 'patients with hypertension', 'Chinese patients aged ≥18 years with essential hypertension', 'Chinese adults with hypertension']","['AZL-M', 'valsartan', 'AZL-M with valsartan', 'AZL-M 40\u200amg (n\u200a=\u200a199), or valsartan', 'azilsartan medoxomil', 'Azilsartan medoxomil (AZL-M']","['Baseline mean scSBP', 'mean reduction in trough scSBP', 'efficacy (antihypertensive effect), safety, and tolerability', 'safety and tolerability of AZL-M', 'Mean reduction in 24-hour mean systolic blood pressure', 'Dizziness', 'trough sitting clinic systolic blood pressure (scSBP) and ambulatory blood pressure monitoring parameters']","[{'cui': 'C4517834', 'cui_str': '612'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0085580', 'cui_str': 'Essential hypertension'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C2698291', 'cui_str': 'azilsartan medoxomil'}, {'cui': 'C0216784', 'cui_str': 'valsartan'}, {'cui': 'C2979834', 'cui_str': 'azilsartan medoxomil 40 MG'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0444506', 'cui_str': 'Trough'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2698291', 'cui_str': 'azilsartan medoxomil'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0242876', 'cui_str': 'Ambulatory Blood Pressure Monitoring'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",612.0,0.157334,Treatment-emergent adverse events had similar incidence (52.8%-56.5%) across the treatment groups and were generally mild or moderate.,"[{'ForeName': 'Jiahui', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Department of Cardiology, Beijing Anzhen Hospital, Beijing.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Du', 'Affiliation': 'Department of Cardiology, Beijing Anzhen Hospital, Beijing.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Lv', 'Affiliation': 'Department of Cardiology, Beijing Anzhen Hospital, Beijing.'}, {'ForeName': 'Zhanquan', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': ""Department of Cardiology, People's Hospital of Liaoning Province, Liaoning.""}, {'ForeName': 'Zeqi', 'Initials': 'Z', 'LastName': 'Zheng', 'Affiliation': 'Department of Cardiology, the First Affiliated Hospital of NanChang University, Jiangxi.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Xia', 'Affiliation': 'Department of Cardiology, the Affiliated Hospital of Xuzhou Medical College.'}, {'ForeName': 'Chengchun', 'Initials': 'C', 'LastName': 'Tang', 'Affiliation': 'Department of Cardiology, Southeast University, Zhongda Hospital, Jiangsu.'}, {'ForeName': 'Zhuhua', 'Initials': 'Z', 'LastName': 'Yao', 'Affiliation': ""Department of Cardiology, Tianjin People's Hospital, Tianjin.""}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiology, Hebei Cangzhou Central Hospital, Hebei.'}, {'ForeName': 'Mingzhi', 'Initials': 'M', 'LastName': 'Long', 'Affiliation': 'Department of Cardiology, Nanjing Medical University Affiliated 2nd Hospital, Jiangsu, China.'}, {'ForeName': 'Michie', 'Initials': 'M', 'LastName': 'Hisada', 'Affiliation': 'Global Patient Safety Evaluation, Takeda Development Center Americas, Inc., Deerfield, IL.'}, {'ForeName': 'Jingtao', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Statistics and Quantitative Sciences, Takeda Development Center Americas, Inc., Cambridge, MA, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Zhou', 'Affiliation': 'Clinical Science, Takeda Development Center Asia, Pte. Ltd., Shanghai, China.'}, {'ForeName': 'Changsheng', 'Initials': 'C', 'LastName': 'Ma', 'Affiliation': 'Department of Cardiology, Beijing Anzhen Hospital, Beijing.'}]",Medicine,['10.1097/MD.0000000000021465'] 2969,32769884,The therapeutic effect of repetitive transcranial magnetic stimulation in elderly depression patients.,"BACKGROUND Depression, a common psychiatric disorder in elderly, serves as a remarkable precipitating factor for suicide among the elderly people. Here, a randomized double-blinded study was performed to investigate the efficacy of repetitive transcranial magnetic stimulation (rTMS) on improving the clinical symptoms and reducing suicidal ideation in elderly patients with depression. METHODS In this study, 103 elderly patients with depression and suicidal ideation were randomly divided into 2 groups, 48 cases in the rTMS group and 55 cases in the control group (sham rTMS). Both groups received routine drug therapy with rTMS or sham rTMS. The patients received evaluation by Hamilton depression scale and self-rating idea of suicide scale before treatment and after 2 and 4 weeks of treatment, respectively. RESULTS The measurement from the present study demonstrated that Hamilton depression scale and self-rating idea of suicide scale scores decreased to varying degrees in the 2 groups after treatment, and the decrease was more significant in rTMS group. The rate of marked effectiveness was much higher in rTMS group after 2 weeks of treatment compared with the control group. Furthermore, the rate of moderate effectiveness at 4 weeks after treatment was significantly higher in rTMS group compared with the control group. CONCLUSION Together, the present study shows that rTMS with routine drug therapy exhibited effect with quick onset to improve the clinical symptoms and reduce suicidal ideation in elderly patients with depression.",2020,"Furthermore, the rate of moderate effectiveness at 4 weeks after treatment was significantly higher in rTMS group compared with the control group. ","['elderly depression patients', 'elderly patients with depression', '103 elderly patients with depression and suicidal ideation']","['repetitive transcranial magnetic stimulation', 'rTMS', 'control group (sham rTMS', 'routine drug therapy with rTMS or sham rTMS', 'repetitive transcranial magnetic stimulation (rTMS']","['Hamilton depression scale and self-rating idea of suicide scale', 'rate of marked effectiveness', 'suicidal ideation', 'Hamilton depression scale and self-rating idea of suicide scale scores', 'rate of moderate effectiveness']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0459920', 'cui_str': 'Ability to think abstractly'}, {'cui': 'C0038661', 'cui_str': 'Suicide'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}]",103.0,0.0269797,"Furthermore, the rate of moderate effectiveness at 4 weeks after treatment was significantly higher in rTMS group compared with the control group. ","[{'ForeName': 'Lilei', 'Initials': 'L', 'LastName': 'Dai', 'Affiliation': ""Department of Clinical Psychology, Jingmen NO.2 People's Hospital, Jingmen, Hubei.""}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Wang', 'Affiliation': ""Department of Psychiatry, The Affiliated Xi'an Central Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi.""}, {'ForeName': 'Panpan', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'Department of Clinical Psychology, Jingmen Oral Hospital, Jingmen, Hubei, China.'}, {'ForeName': 'Qingshan', 'Initials': 'Q', 'LastName': 'Guo', 'Affiliation': ""Department of Clinical Psychology, Jingmen NO.2 People's Hospital, Jingmen, Hubei.""}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Du', 'Affiliation': ""Department of Clinical Psychology, Jingmen NO.2 People's Hospital, Jingmen, Hubei.""}, {'ForeName': 'Fen', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': ""Department of Clinical Psychology, Jingmen NO.2 People's Hospital, Jingmen, Hubei.""}, {'ForeName': 'Xinfu', 'Initials': 'X', 'LastName': 'He', 'Affiliation': ""Department of Clinical Psychology, Jingmen NO.2 People's Hospital, Jingmen, Hubei.""}, {'ForeName': 'Rongrong', 'Initials': 'R', 'LastName': 'Luan', 'Affiliation': ""Department of Psychiatry, The Affiliated Xi'an Central Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi.""}]",Medicine,['10.1097/MD.0000000000021493'] 2970,32769888,Computer-navigated versus conventional total knee arthroplasty: A randomized controlled trial protocol in China.,"BACKGROUND The literature lacks studies that confirm whether the improved radiographic alignment that can be achieved with computer-navigated total knee arthroplasty (TKA) improves patients' activities of daily living or the durability of total knee prostheses. Thus, in this protocol, we designed a randomized controlled trial to compare implant alignment, functional scores, and survival of the implant using computer-assisted surgery versus a conventional surgical technique. METHODS This prospective, blinded randomized controlled trial was conducted at our single hospital. This study was approved by the ethics committee of Jiaxing Second Hospital. The patient inclusion criteria were age 20 to 80 years' old, a body mass index of ≤35 kg/m, and consented for primary knee arthroplasty performed through a medial parapatellar approach by the senior author. We randomized consented study participants on a 1:1 ratio to 1 of 2 study groups using a computer-generated list of random numbers in varying block sizes. The primary outcome in this study was the Knee Injury and Osteoarthritis Outcome Score. Secondary outcomes were the Knee Society Score, Western Ontario and McMaster Universities Osteoarthritis Index, complications, and range of motion together with alignment and rotational positioning of the implant. Statistical significance was defined as a P value of ≤0.05. CONCLUSIONS Authors hypothesized that computer-assisted surgery in primary TKA improves implant alignment, functional scores, and survival of the implant compared to the conventional technique.",2020,"Secondary outcomes were the Knee Society Score, Western Ontario and McMaster Universities Osteoarthritis Index, complications, and range of motion together with alignment and rotational positioning of the implant.","[""patient inclusion criteria were age 20 to 80 years' old, a body mass index of ≤35\u200akg/m, and consented for primary knee arthroplasty performed through a medial parapatellar approach by the senior author""]","['computer-navigated total knee arthroplasty (TKA', 'implant using computer-assisted surgery versus a conventional surgical technique', 'Computer-navigated versus conventional total knee arthroplasty']","['implant alignment, functional scores, and survival of the implant', 'Knee Society Score, Western Ontario and McMaster Universities Osteoarthritis Index, complications, and range of motion together with alignment and rotational positioning of the implant', 'Knee Injury and Osteoarthritis Outcome Score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0442141', 'cui_str': 'Medial parapatellar approach'}, {'cui': 'C3812881', 'cui_str': 'Author'}]","[{'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0949696', 'cui_str': 'Computer-Assisted Surgery'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C3472647', 'cui_str': 'Western Ontario and McMaster Universities osteoarthritis index'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0445237', 'cui_str': 'Rotational'}, {'cui': 'C0150305', 'cui_str': 'Positioning - therapy'}, {'cui': 'C3476088', 'cui_str': 'Knee Injury and Osteoarthritis Outcome Score'}]",,0.166324,"Secondary outcomes were the Knee Society Score, Western Ontario and McMaster Universities Osteoarthritis Index, complications, and range of motion together with alignment and rotational positioning of the implant.","[{'ForeName': 'Yefeng', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': 'Department of orthopedics, Jiaxing Second Hospital, Zhejiang Province, China.'}, {'ForeName': 'Jianming', 'Initials': 'J', 'LastName': 'Sheng', 'Affiliation': ''}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021508'] 2971,32770353,Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.,"PURPOSE The CD79b-targeted antibody-drug conjugate polatuzumab vedotin (pola), alone and with chemoimmunotherapy, has clinical efficacy and a tolerable safety profile in B-cell non-Hodgkin lymphoma (B-NHL). We assessed (a) whether exposure from global studies of pola is comparable to Asian patients, and (b) if the recommended pola dose is appropriate in Asian patients based on exposure. METHODS The pharmacokinetics (PK) of pola in Asian and global populations was characterized for three analytes (antibody-conjugated monomethyl auristatin E (MMAE) [acMMAE], total antibody, and unconjugated MMAE) in five phase 1b/2 single-agent and combination studies in B-NHL patients (JO29138 [JAPICCTI-142580], DCS4968g [NCT01290549], GO27834 [NCT01691898], GO29044 [NCT01992653], and GO29365 [NCT02257567]). PK data were compared between Japanese phase 1 JO29138 (JAPICCTI-142580) and global phase 1 DCS4968g (NCT01290549) studies and between Asian and non-Asian patients in the randomized relapsed/refractory B-NHL cohorts of the phase 1b/2 study GO29365 (NCT02257567). A population PK (popPK) model was used to assess the effects of Asian race and region on acMMAE and unconjugated MMAE exposure. RESULTS PK non-compartmental analysis (NCA) parameters for the key analyte acMMAE in the Japanese JO29138 (JAPICCTI-142580) and global phase 1 DCS4968g (NCT01290549) studies were similar. In GO29365 (NCT02257567), the phase 1b/2 combination study, mean exposure to the analytes was generally lower in Asian patients (by ~ 9.9 to 17.5%), but not to a clinically meaningful extent. Overall, the popPK model further suggested comparable PK in Asian patients with B-NHL (race or region) versus non-Asian patients. CONCLUSION Race has no clinically meaningful effect on pola PK. These results (and observations from efficacy/safety exposure-response analyses) support no pola dose adjustments are warranted for Asian patients with DLBCL.",2020,"Overall, the popPK model further suggested comparable PK in Asian patients with B-NHL (race or region) versus non-Asian patients. ","['Asian patients with DLBCL', 'patients with relapsed/refractory B-cell non-Hodgkin lymphoma', 'Asian patients with B-NHL (race or region) versus non-Asian patients']","['CD79b-targeted antibody-drug conjugate polatuzumab vedotin (pola), alone and with chemoimmunotherapy']","['total antibody, and unconjugated MMAE']","[{'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0079744', 'cui_str': 'Malignant lymphoma, large B-cell, diffuse'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0855090', 'cui_str': 'B-cell lymphoma refractory'}, {'cui': 'C0079731', 'cui_str': 'B-cell lymphoma (clinical)'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]","[{'cui': 'C0104979', 'cui_str': 'Lymphocyte antigen CD79B'}, {'cui': 'C4704928', 'cui_str': 'Antibody-Drug Conjugates'}, {'cui': 'C4078806', 'cui_str': 'polatuzumab vedotin'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0522530', 'cui_str': 'Unconjugated'}, {'cui': 'C1565020', 'cui_str': 'monomethyl auristatin E'}]",,0.0175106,"Overall, the popPK model further suggested comparable PK in Asian patients with B-NHL (race or region) versus non-Asian patients. ","[{'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Shi', 'Affiliation': 'Genentech Inc., South San Francisco, CA, USA. rongshi@gmail.com.'}, {'ForeName': 'Tong', 'Initials': 'T', 'LastName': 'Lu', 'Affiliation': 'Genentech Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Ku', 'Affiliation': 'Genentech Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Ding', 'Affiliation': 'Genentech Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Tomohisa', 'Initials': 'T', 'LastName': 'Saito', 'Affiliation': 'Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Leonid', 'Initials': 'L', 'LastName': 'Gibiansky', 'Affiliation': 'QuantPharm LLC, North Potomac, MD, USA.'}, {'ForeName': 'Priya', 'Initials': 'P', 'LastName': 'Agarwal', 'Affiliation': 'Genentech Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Xiaobin', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Genentech Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Jin Yan', 'Initials': 'JY', 'LastName': 'Jin', 'Affiliation': 'Genentech Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Sandhya', 'Initials': 'S', 'LastName': 'Girish', 'Affiliation': 'Genentech Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Dale', 'Initials': 'D', 'LastName': 'Miles', 'Affiliation': 'Genentech Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Chunze', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Genentech Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Lu', 'Affiliation': 'Genentech Inc., South San Francisco, CA, USA. Lu.Dan@gene.com.'}]",Cancer chemotherapy and pharmacology,['10.1007/s00280-020-04119-8'] 2972,32770381,A Randomized Controlled Trial Comparing Physical and Mental Lingual Exercise for Healthy Older Adults.,"Mental practice using motor imagery (MP-MI) has been shown to improve motor outcomes of upper and lower extremities especially when combined with physical exercise. Here, we studied community-dwelling, healthy older adults to determine the effects of including an MP-MI component with lingual strengthening exercise. In this pilot study, twenty-nine typically aging participants were assigned to an intervention group: physical lingual exercise (n = 7), physical and MP-MI lingual exercise (n = 8), MPMI lingual exercise (n = 7), or a control group (placebo exercise) (n = 7). All participants completed the assigned exercise regimen with three sessions per day, three days a week, for 6 consecutive weeks. Maximum isometric pressure (MIP) and regular effort saliva swallowing (RESS) pressure were collected at baseline and weeks 2, 4, and 6. A post hoc Bonferroni corrected treatment effect from baseline to week 6 was shown for only participants in the MP-MI/Physical exercise group for MIP (p = 0.003 MPMI/ Physical group; p = 0.11 Control group; p = 0.32 Physical only group; p = 0.14 MP-MI only group) and RESS (p = 0.009 MP-MI/Physical group; p = 0.14 Control group; p = 0.10 Physical only group; p = 0.04 MP-MI only group). Findings also indicate spontaneous carryover of significantly increased swallowing pressure when mental and physical exercise are combined. In conclusion, the potential effect of including an MPMI lingual exercise component in preventative and rehabilitative frameworks with older persons to possibly enhance functional swallowing improvement is promising and should be investigated.",2020,Mental practice using motor imagery (MP-MI) has been shown to improve motor outcomes of upper and lower extremities especially when combined with physical exercise.,"['community-dwelling, healthy older adults', 'twenty-nine typically aging participants', 'Healthy Older Adults', 'older persons']","['physical lingual exercise (n\u2009=\u20097), physical and MP-MI lingual exercise (n\u2009=\u20098), MPMI lingual exercise (n\u2009=\u20097), or a control group (placebo exercise', 'Mental practice using motor imagery (MP-MI', 'MP-MI component with lingual strengthening exercise', 'Physical and Mental Lingual Exercise', 'MPMI lingual exercise component']","['swallowing pressure', 'Maximum isometric pressure (MIP) and regular effort saliva swallowing (RESS) pressure']","[{'cui': 'C4045975', 'cui_str': 'Community Dwelling'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0450351', 'cui_str': '29'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0040408', 'cui_str': 'Tongue structure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0449432', 'cui_str': 'Component'}]","[{'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}]",29.0,0.0466588,Mental practice using motor imagery (MP-MI) has been shown to improve motor outcomes of upper and lower extremities especially when combined with physical exercise.,"[{'ForeName': 'Sarah H', 'Initials': 'SH', 'LastName': 'Szynkiewicz', 'Affiliation': 'College of Science and Mathematics, Communication Sciences and Disorders, University of South Florida, Sarasota-Manate, 8350 N. Tamiami Trail, Sarasota, FL, 34243, USA. sszynkie@samford.edu.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Kamarunas', 'Affiliation': 'College of Health and Behavioral Studies, Communication Sciences and Disorders, James Madison University, MSC 4304, 235 Martin Luther King Jr. Way, Harrisonburg, VA, 22807, USA.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Drulia', 'Affiliation': 'Harris College of Nursing and Health Sciences, Davies School of Communication Sciences and Disorders, Texas Christian University, TCU Box 297450, Fort Worth, TX, 76109, USA.'}, {'ForeName': 'Christina V', 'Initials': 'CV', 'LastName': 'Nobriga', 'Affiliation': 'School of Allied Health Professions, Communication Sciences and Disorders, Loma Linda University, Loma Linda, CA, 92350, USA.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Griffin', 'Affiliation': 'College of Health and Behavioral Studies, Communication Sciences and Disorders, James Madison University, MSC 4304, 235 Martin Luther King Jr. Way, Harrisonburg, VA, 22807, USA.'}, {'ForeName': 'Cynthia R', 'Initials': 'CR', 'LastName': ""O'Donoghue"", 'Affiliation': 'College of Health and Behavioral Studies, Communication Sciences and Disorders, James Madison University, MSC 4304, 235 Martin Luther King Jr. Way, Harrisonburg, VA, 22807, USA.'}]",Dysphagia,['10.1007/s00455-020-10164-5'] 2973,32770384,Decline in endothelial function across the menopause transition in healthy women is related to decreased estradiol and increased oxidative stress.,"Endothelial function declines progressively across stages of the menopause transition; however, the mechanisms contributing to this decline are unknown. We hypothesized that differences in endothelial function among pre-, peri, and postmenopausal women are related to differences in estradiol and oxidative stress. Brachial artery flow-mediated dilation (FMD) was measured in 87 healthy women categorized by menopause stage (24 premenopausal, 17 early and 21 late perimenopausal, and 25 postmenopausal) before and after 3 days of ovarian hormone suppression (gonadotropin releasing hormone antagonist [GnRH ant ]) alone, and an additional 3 days of GnRH ant with concurrent transdermal estradiol or placebo add-back treatment. In 82 women, FMD during acute vitamin C (antioxidant) infusion was measured before and after GnRH ant + add-back. Before GnRH ant , FMD was different among groups (p < 0.005; reduced across stages of menopause). Vitamin C increased FMD in late peri- and post- (p < 0.005) but not pre- or early perimenopausal women (p > 0.54). After GnRH ant alone, FMD decreased in pre- and peri- (p < 0.01), but not postmenopausal women, and was restored to premenopausal levels by estradiol add-back in the pre- and perimenopausal groups. Vitamin C improved FMD in pre-, peri-, and postmenopausal women on GnRH ant + placebo. There was no effect of vitamin C on FMD in women on GnRH ant + estradiol. These observations support the concept that the decline in endothelial function across the menopause transition is related to the loss of ovarian estradiol. The decline in estradiol may alter redox balance, thereby increasing oxidative stress and impairing endothelial function.",2020,"Before GnRH ant , FMD was different among groups (p < 0.005; reduced across stages of menopause).","['87 healthy women categorized by menopause stage (24 premenopausal, 17 early and 21 late perimenopausal, and 25 postmenopausal) before and after 3 days of ovarian hormone suppression (gonadotropin releasing hormone antagonist [GnRH ant ]) alone, and an additional 3 days of GnRH ant with concurrent', 'healthy women']","['transdermal estradiol or placebo add-back treatment', 'vitamin C', 'Vitamin C', 'Brachial artery flow-mediated dilation (FMD']","['endothelial function', 'FMD decreased in pre', 'FMD']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C3839366', 'cui_str': 'Perimenopausal state'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0729511', 'cui_str': 'Ovarian hormone'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C1268855', 'cui_str': 'Gonadotropin releasing hormone receptor antagonist-containing product'}, {'cui': 'C0023610', 'cui_str': 'Gonadorelin'}, {'cui': 'C0003455', 'cui_str': 'Family Formicidae'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}]","[{'cui': 'C0040652', 'cui_str': 'Transdermal route'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0006087', 'cui_str': 'Structure of brachial artery'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}]","[{'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]",87.0,0.130331,"Before GnRH ant , FMD was different among groups (p < 0.005; reduced across stages of menopause).","[{'ForeName': 'Kerrie L', 'Initials': 'KL', 'LastName': 'Moreau', 'Affiliation': 'Division of Geriatric Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Bldg. L15 Rm 8111, 12631 East 17th Ave., Mail Stop B179, Aurora, CO, 80045, USA. Kerrie.moreau@cuanschutz.edu.'}, {'ForeName': 'Kerry L', 'Initials': 'KL', 'LastName': 'Hildreth', 'Affiliation': 'Division of Geriatric Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Bldg. L15 Rm 8111, 12631 East 17th Ave., Mail Stop B179, Aurora, CO, 80045, USA.'}, {'ForeName': 'Jelena', 'Initials': 'J', 'LastName': 'Klawitter', 'Affiliation': 'Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Blatchford', 'Affiliation': 'Veterans Affairs Eastern Colorado Geriatric Research, Education and Clinical Center, Denver, CO, USA.'}, {'ForeName': 'Wendy M', 'Initials': 'WM', 'LastName': 'Kohrt', 'Affiliation': 'Division of Geriatric Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Bldg. L15 Rm 8111, 12631 East 17th Ave., Mail Stop B179, Aurora, CO, 80045, USA.'}]",GeroScience,['10.1007/s11357-020-00236-7'] 2974,32770394,No effect of mindfulness-based cancer recovery on cardiovascular or cortisol reactivity in female cancer survivors.,"Psychosocial stress in cancer survivors may contribute to compromised quality of life and negative cancer outcomes, which can be exacerbated by poor coping skills and emotional reactivity. Mindfulness based interventions (MBIs) have shown effectiveness in reducing stress, improving quality of life and coping skills in cancer survivors. We tested whether an MBI would also improve reactivity to an acute laboratory stress task. A total of 77 women with a cancer diagnosis were recruited for a waitlist-controlled trial of Mindfulness-Based Cancer Recovery (MBCR). Participants completed a laboratory-based psychosocial stress paradigm (the Trier Social Stress Test-TSST) pre- and post-intervention, throughout which cortisol and cardiovascular profiles were measured. Neither cortisol nor cardiovascular reactivity to the TSST was changed pre-to post intervention, either between or within groups. Blunted cortisol, but not cardiovascular, reactivity was observed across both groups, which may have contributed to the lack of intervention effect. Previous research suggests that diurnal cortisol is blunted following cancer treatment; the current findings suggest this blunting may also occur during exposure to acute stress.",2020,"Mindfulness based interventions (MBIs) have shown effectiveness in reducing stress, improving quality of life and coping skills in cancer survivors.","['77 women with a cancer diagnosis', 'cancer survivors', 'female cancer survivors']","['TSST', 'laboratory-based psychosocial stress paradigm (the Trier Social Stress Test-TSST', 'Mindfulness based interventions (MBIs', 'Mindfulness-Based Cancer Recovery (MBCR', 'mindfulness-based cancer recovery', 'MBI']","['cardiovascular or cortisol reactivity', 'cortisol nor cardiovascular reactivity', 'quality of life and coping skills']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}]","[{'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0065404', 'cui_str': 'lysyl-5-fluorotryptophyl-lysine'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C2985547', 'cui_str': 'Scintimammography'}]","[{'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0086059', 'cui_str': 'Coping Skills'}]",77.0,0.0251975,"Mindfulness based interventions (MBIs) have shown effectiveness in reducing stress, improving quality of life and coping skills in cancer survivors.","[{'ForeName': 'Lauren L', 'Initials': 'LL', 'LastName': 'Drogos', 'Affiliation': 'Department of Psychology, University of Calgary, Calgary, Canada.'}, {'ForeName': 'Kirsti I', 'Initials': 'KI', 'LastName': 'Toivonen', 'Affiliation': 'Department of Psychology, University of Calgary, Calgary, Canada.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Labelle', 'Affiliation': 'Department of Psychosocial Resources, Tom Baker Cancer Centre Holy Cross Site, 2202 2nd St SW, Calgary, T2S 3C1, Canada.'}, {'ForeName': 'Tavis S', 'Initials': 'TS', 'LastName': 'Campbell', 'Affiliation': 'Department of Psychology, University of Calgary, Calgary, Canada.'}, {'ForeName': 'Linda E', 'Initials': 'LE', 'LastName': 'Carlson', 'Affiliation': 'Department of Psychosocial Resources, Tom Baker Cancer Centre Holy Cross Site, 2202 2nd St SW, Calgary, T2S 3C1, Canada. lcarlso@ucalgary.ca.'}]",Journal of behavioral medicine,['10.1007/s10865-020-00167-w'] 2975,32770612,Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation.,"BACKGROUND Radiation for patients with head and neck cancer (HNC) is associated with painful mucositis that impacts the delivery of treatment and contributes to high symptom burden. METHODS This was a prospective, randomized pilot trial. Eligible patients received primary or adjuvant chemoradiation. Patients were randomized to usual care vs usual care plus gabapentin titrated to drug tolerance during radiation. Patients completed a symptom survey at baseline and weekly during therapy. RESULTS Seventy-nine patients were enrolled in the study (38 control, 41 treatment). At interim analysis, gabapentin use resulted in a decrease in pain (P = .004), with the biggest decreases being in the latter weeks of therapy. By week 7, the median pain score in the treatment group was below the 0.25 quantile of the control group. CONCLUSION Prophylactic use of gabapentin during chemoradiation for HNC patients resulted in a decrease in pain, neurosensory symptoms, and general systemic symptoms.",2020,"By week 7, the median pain score in the treatment group was below the 0.25 quantile of the control group. ","['patients with head and neck cancer undergoing chemoradiation', 'Seventy-nine patients were enrolled in the study (38 control, 41 treatment', 'patients with head and neck cancer (HNC']","['usual care vs usual care plus gabapentin', 'gabapentin', 'primary or adjuvant chemoradiation']","['pain, neurosensory symptoms, and general systemic symptoms', 'pain and systemic symptoms', 'median pain score', 'pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0060926', 'cui_str': 'gabapentin'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",79.0,0.0409428,"By week 7, the median pain score in the treatment group was below the 0.25 quantile of the control group. ","[{'ForeName': 'Derek K', 'Initials': 'DK', 'LastName': 'Smith', 'Affiliation': 'Department of Biostatistics and Oral & Maxillofacial Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Cmelak', 'Affiliation': 'Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Niermann', 'Affiliation': 'Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Ghiam', 'Affiliation': 'Department of Otolaryngology, University of Miami, Miami, Florida, USA.'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Lou', 'Affiliation': 'Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Gilbert', 'Affiliation': 'Department of Medicine, Oncology Division, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Gibson', 'Affiliation': 'Department of Medicine, Oncology Division, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Hawkins', 'Affiliation': 'Department of Medicine, Oncology Division, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Murphy', 'Affiliation': 'Department of Medicine, Oncology Division, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}]",Head & neck,['10.1002/hed.26407'] 2976,32770616,Cesarean section in the second delivery to prevent anal incontinence after asymptomatic obstetrical anal sphincter injury: the EPIC multicenter randomized trial.,"OBJECTIVE To determine whether planned cesarean section (CS) for a second delivery protects against anal continence in women with obstetrical anal sphincter lesions. DESIGN Randomized trial SETTING: 6 maternity units in the Paris area. SAMPLE Women at high risk of sphincter lesions (first delivery with 3d degree laceration and/or forceps) but no symptomatic anal incontinence. METHODS Endoanal ultrasound was performed in the third trimester of the second pregnancy. Women with sphincter lesions were randomized to planned CS or vaginal delivery (VD). MAIN OUTCOME MEASURES Anal continence at 6 months post-partum. Secondary outcomes were urinary continence, sexual morbidity, maternal and neonatal morbidities and worsening of external sphincter lesions. RESULTS Anal sphincter lesions were detected by ultrasound in 264/434 women enrolled (60.8%) ; 112 were randomized to planned VD and 110 to planned CS. At 6-8 weeks after delivery, there was no significant difference in anal continence between the 2 groups. At 6 months after delivery, median Vaizey scores of anal continence were 1 [IQR 0-4] in the CS group and 1 [IQR 0-3] in the VD group (p = 0.34). There were no significant differences for urinary continence, sexual functions or for other maternal and neonatal morbidities. CONCLUSIONS In women with asymptomatic obstetrical anal sphincter lesions diagnosed by ultrasound, planning a CS had no significant impact on anal continence 6 months after the second delivery. These results do not support advising systematic CS for this indication.",2020,"In women with asymptomatic obstetrical anal sphincter lesions diagnosed by ultrasound, planning a CS had no significant impact on anal continence 6 months after the second delivery.","['SAMPLE\n\n\nWomen at high risk of sphincter lesions (first delivery with 3d degree laceration and/or forceps', 'women with asymptomatic obstetrical anal sphincter lesions', ' 6 maternity units in the Paris area', 'Anal sphincter lesions were detected by ultrasound in 264/434 women enrolled (60.8%) ; 112', 'asymptomatic obstetrical anal sphincter injury', 'Women with sphincter lesions', 'women with obstetrical anal sphincter lesions']","['planned cesarean section (CS', 'planned CS or vaginal delivery (VD', 'Endoanal ultrasound', 'Cesarean section']","['urinary continence, sexual functions or for other maternal and neonatal morbidities', 'median Vaizey scores of anal continence', 'Anal continence', 'anal incontinence', 'urinary continence, sexual morbidity, maternal and neonatal morbidities and worsening of external sphincter lesions', 'anal continence']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0043246', 'cui_str': 'Laceration'}, {'cui': 'C0016533', 'cui_str': 'Forceps'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0002760', 'cui_str': 'Structure of sphincter ani muscle'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0030561', 'cui_str': 'Paris'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C1142258', 'cui_str': 'Anal sphincter injury'}]","[{'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}]","[{'cui': 'C0542565', 'cui_str': 'Bladder control'}, {'cui': 'C0278092', 'cui_str': 'Sexual function'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1290944', 'cui_str': 'Anorectal continence'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]",112.0,0.119998,"In women with asymptomatic obstetrical anal sphincter lesions diagnosed by ultrasound, planning a CS had no significant impact on anal continence 6 months after the second delivery.","[{'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Abramowitz', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris, Hôpital Bichat. Proctology Unit, Department of Gastro-enterology, Paris, France.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Mandelbrot', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris, Hôpital Louis Mourier, Department of Obstetrics and Gynecology, Colombes, France.'}, {'ForeName': 'Agnès', 'Initials': 'A', 'LastName': 'Bourgeois Moine', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris, Hôpital Bichat. Department of Obstetrics and Gynecology, Paris, France.'}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Le Tohic', 'Affiliation': 'Centre Hospitalier de Versailles, Department of Obstetrics and Gynecology, Le Chesnay, France.'}, {'ForeName': 'Céline', 'Initials': 'C', 'LastName': 'de Carne Carnavalet', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris, Hôpital Armand Trousseau, Department of Obstetrics and Gynecology, Paris, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Poujade', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris, Hôpital Beaujon, Department of Obstetrics and Gynecology, 92110, Clichy, France.'}, {'ForeName': 'Carine', 'Initials': 'C', 'LastName': 'Roy', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Unité de Recherche Clinique, Paris, France.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Tubach', 'Affiliation': ""Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, CIC-1422, Paris, France.""}]",BJOG : an international journal of obstetrics and gynaecology,['10.1111/1471-0528.16452'] 2977,32770640,Secukinumab improves signs and symptoms of non-radiographic axial spondyloarthritis: primary results of a randomized controlled phase III study.,"OBJECTIVE To report the primary (1-year) results from PREVENT, the first phase III study evaluating secukinumab in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). METHODS A total of 555 patients were randomized (1:1:1) to subcutaneous secukinumab 150 mg with loading (LD), without loading (NL), or placebo weekly and then every 4 weeks starting at Week 4. NL group received placebo at Weeks 1, 2, and 3 to maintain blinding. Switch to open-label secukinumab (OL) or standard of care (SoC) was permitted after Week 20. The study had 2 independent analysis plans per EU and non-US (Plan A: Week 16) and US (Plan B: Week 52) regulatory requirements. Primary endpoint was ASAS40 at Week 16 (LD) and at Week 52 (NL) in tumor necrosis factor inhibitor (TNFi)-naïve patients. Safety analyses included all patients who received ≥1 dose of study treatment. RESULTS Overall, 481 patients completed 52 weeks treatment: 84.3% (156/185) LD, 89.7% (165/184) NL, and 86.0% (160/186) placebo. Proportion of patients who switched to OL or SoC between Weeks 20 and 48 was 50.8% LD, 47.3% NL, and 64.0% placebo. Both primary and all secondary endpoints were met at Week 16. ASAS40 in TNFi-naïve patients was significantly higher for LD (41.5%) at Week 16 and NL (39.8%) at Week 52 versus placebo (29.2% at Week 16 and 19.9% at Week 52; both P <0.05). No new safety findings were reported. CONCLUSIONS Secukinumab 150 mg provided significant and sustained improvement in signs and symptoms of patients with nr-axSpA through 52 weeks. Safety was consistent with previous reports.",2020,"CONCLUSIONS Secukinumab 150 mg provided significant and sustained improvement in signs and symptoms of patients with nr-axSpA through 52 weeks.","['patients who received ≥1 dose of study treatment', 'A total of 555 patients', 'patients with active non-radiographic axial spondyloarthritis (nr-axSpA']","['subcutaneous secukinumab 150 mg with loading (LD), without loading (NL), or placebo', 'open-label secukinumab (OL) or standard of care (SoC', 'Secukinumab', 'ASAS40', 'placebo']",['signs and symptoms of non-radiographic axial spondyloarthritis'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517810', 'cui_str': '555'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C3889038', 'cui_str': 'Non-radiographic axial spondyloarthritis'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C3179547', 'cui_str': 'secukinumab'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C3889038', 'cui_str': 'Non-radiographic axial spondyloarthritis'}]",555.0,0.186013,"CONCLUSIONS Secukinumab 150 mg provided significant and sustained improvement in signs and symptoms of patients with nr-axSpA through 52 weeks.","[{'ForeName': 'Atul', 'Initials': 'A', 'LastName': 'Deodhar', 'Affiliation': 'Oregon Health & Science University, Portland, USA.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Blanco', 'Affiliation': 'Hospital University Marqués de Valdecilla, IDIVAL, Santander, Spain.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Dokoupilová', 'Affiliation': 'MEDICAL PLUS s.r.o., Uherske Hradiste, University of Veterinary and Pharmaceutical sciences, Brno, Czech Republic.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Hall', 'Affiliation': 'Monash University, Melbourne, Australia.'}, {'ForeName': 'Hideto', 'Initials': 'H', 'LastName': 'Kameda', 'Affiliation': 'Toho University, Tokyo, Japan.'}, {'ForeName': 'Alan J', 'Initials': 'AJ', 'LastName': 'Kivitz', 'Affiliation': 'Altoona Center for Clinical Research, Duncansville, USA.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Poddubnyy', 'Affiliation': 'Charité Universitätsmedizin, Berlin, Germany.'}, {'ForeName': 'Marleen', 'Initials': 'M', 'LastName': 'van de Sande', 'Affiliation': 'Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Anna S', 'Initials': 'AS', 'LastName': 'Wiksten', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Brian O', 'Initials': 'BO', 'LastName': 'Porter', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, USA.'}, {'ForeName': 'Hanno B', 'Initials': 'HB', 'LastName': 'Richards', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Sibylle', 'Initials': 'S', 'LastName': 'Haemmerle', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Braun', 'Affiliation': 'Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany.'}]","Arthritis & rheumatology (Hoboken, N.J.)",['10.1002/art.41477'] 2978,32770664,"The Un Oeuf study: Design, methods and baseline data from a cluster randomised controlled trial to increase child egg consumption in Burkina Faso.","In many low-income countries, such as Burkina Faso, rates of malnutrition are high among children. Research indicates that animal source foods may provide important elements to improve growth and development of young children, especially during periods of rapid development, such as the first 1,000 days of life. The Un Oeuf study is designed to test an innovative behaviour change communication strategy to increase egg consumption in children 6-24 months in Burkina Faso, thereby improving dietary diversity and nutritional outcomes. This 1-year cluster randomised controlled trial tests whether the gifting of chickens by a community champion directly to a child, combined with a behaviour change package of integrated poultry management and human nutrition trainings, can significantly increase egg consumption among children under 2 years in rural communities where egg consumption is very low. The nutrition-sensitive behaviour change package is designed to increase egg consumption through improving livestock production, women's empowerment and food security at the household level. This paper presents a detailed account of the study design and protocol for the Un Oeuf study, alongside a description of the study population. Baseline data show a study population with high rates of malnutrition (stunting 21.6%, wasting 10.8% and underweight 20.4%) and a very low rate of egg consumption-less than 10% among children. Although poultry production is quite common, egg consumption is low reportedly because of cultural norms, including widespread practice of allowing eggs to hatch and a lack of knowledge about the nutritional benefits of egg consumption.",2020,"The nutrition-sensitive behaviour change package is designed to increase egg consumption through improving livestock production, women's empowerment and food security at the household level.","['children under 2 years in rural communities', 'child egg consumption in Burkina Faso', 'children 6-24 months in Burkina Faso']",['behaviour change package of integrated poultry management and human nutrition trainings'],['egg consumption'],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086944', 'cui_str': 'Rural Communities'}, {'cui': 'C0013710', 'cui_str': 'Eggs (edible)'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0006409', 'cui_str': 'Burkina Faso'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C0032850', 'cui_str': 'Fowls, Domestic'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0013710', 'cui_str': 'Eggs (edible)'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]",,0.0707621,"The nutrition-sensitive behaviour change package is designed to increase egg consumption through improving livestock production, women's empowerment and food security at the household level.","[{'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Stark', 'Affiliation': 'Department of Environment and Global Health, College of Public Health and Health Practices, University of Florida, Gainesville, Florida, USA.'}, {'ForeName': 'Anteneh', 'Initials': 'A', 'LastName': 'Omer', 'Affiliation': 'School of Nutrition, Food Science and Technology, Hawassa University, Hawassa, Ethiopia.'}, {'ForeName': 'Aïssata', 'Initials': 'A', 'LastName': ""Wereme N'Diaye"", 'Affiliation': ""Institut de l'Environnement et de Recherches Agricoles, Kamboinsé Agricultural Environnemental Research and Training Center, Ouagadougou, PO box 476, Burkina Faso.""}, {'ForeName': 'Amanda C', 'Initials': 'AC', 'LastName': 'Sapp', 'Affiliation': 'Department of Environment and Global Health, College of Public Health and Health Practices, University of Florida, Gainesville, Florida, USA.'}, {'ForeName': 'Emily V', 'Initials': 'EV', 'LastName': 'Moore', 'Affiliation': 'Department of Environment and Global Health, College of Public Health and Health Practices, University of Florida, Gainesville, Florida, USA.'}, {'ForeName': 'Sarah L', 'Initials': 'SL', 'LastName': 'McKune', 'Affiliation': 'Department of Environment and Global Health, College of Public Health and Health Practices, University of Florida, Gainesville, Florida, USA.'}]",Maternal & child nutrition,['10.1111/mcn.13069'] 2979,32770211,Sleep-wake regulation in pre-term and term infants.,"STUDY OBJECTIVES In adults, wakefulness can be markedly prolonged at the expense of sleep, e.g. to stay vigilant in the presence of a stressor. These extra-long wake bouts result in a heavy-tailed distribution (highly right-skewed) of wake but not sleep durations. In infants, the relative importance of wakefulness and sleep are reversed, as sleep is necessary for brain maturation. Here we tested whether these developmental pressures are associated with unique regulation of sleep-wake states. METHODS In 175 infants 28-40 weeks postmenstrual age (PMA), we monitored sleep-wake states using electroencephalography and behaviour. We constructed survival models of sleep-wake bout durations and the effect of PMA and other factors including stress (salivary cortisol), and examined whether sleep is resilient to nociceptive perturbations (a clinically necessary heel lance). RESULTS Wake durations followed a heavy-tailed distribution as in adults, and lengthened with PMA and stress. However, differently from adults, active sleep durations also had a heavy-tailed distribution, and with PMA these shortened and became vulnerable to nociception-associated awakenings. CONCLUSIONS Sleep bouts are differently regulated in infants, with especially long active sleep durations which could consolidate this state's maturational functions. Curtailment of sleep by stress and nociception may be disadvantageous, especially for pre-term infants given the limited value of wakefulness at this age. This could be addressed by environmental interventions in future.",2020,"However, differently from adults, active sleep durations also had a heavy-tailed distribution, and with PMA these shortened and became vulnerable to nociception-associated awakenings. ","['175 infants 28-40 weeks postmenstrual age (PMA), we monitored sleep-wake states using electroencephalography and behaviour']",['PMA'],"['Sleep-wake regulation', 'active sleep durations']","[{'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0162701', 'cui_str': 'Polysomnography'}, {'cui': 'C0442696', 'cui_str': 'Waking'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]","[{'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0442696', 'cui_str': 'Waking'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0037322', 'cui_str': 'Rapid eye movement sleep'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]",,0.0382623,"However, differently from adults, active sleep durations also had a heavy-tailed distribution, and with PMA these shortened and became vulnerable to nociception-associated awakenings. ","[{'ForeName': 'Anastasis', 'Initials': 'A', 'LastName': 'Georgoulas', 'Affiliation': 'Research IT Services, University College London, London, United Kingdom.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Jones', 'Affiliation': 'Department of Neuroscience, Physiology and Pharmacology, University College London, London, United Kingdom.'}, {'ForeName': 'Maria Pureza', 'Initials': 'MP', 'LastName': 'Laudiano-Dray', 'Affiliation': 'Department of Neuroscience, Physiology and Pharmacology, University College London, London, United Kingdom.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Meek', 'Affiliation': 'Elizabeth Garrett Anderson Wing, University College London Hospitals, London, United Kingdom.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Fabrizi', 'Affiliation': 'Department of Neuroscience, Physiology and Pharmacology, University College London, London, United Kingdom.'}, {'ForeName': 'Kimberley', 'Initials': 'K', 'LastName': 'Whitehead', 'Affiliation': 'Department of Neuroscience, Physiology and Pharmacology, University College London, London, United Kingdom.'}]",Sleep,['10.1093/sleep/zsaa148'] 2980,32770222,Should Graphic Warning Labels Proposed For Cigarette Packages Sold in the United States Mention the Food and Drug Administration?,"INTRODUCTION Under the US Family Smoking Prevention and Tobacco Control Act, the US Food and Drug Administration (FDA) has the authority to implement graphic warning labels (GWLs) on cigarette packages. Neither the original labels proposed by the FDA nor the revised labels include a source to indicate sponsorship of the warnings. This study tests the potential impact of adding a sponsor to the content of GWLs. METHODS We recruited adult smokers (N=245) and middle-school youth (N=242) from low-income areas in the Northeastern US. We randomly assigned participants to view one of three versions of the original FDA-proposed warning labels in a between-subjects experiment: no sponsor, ""US Food and Drug Administration,"" or ""American Cancer Society"" sponsor. We tested the effect of varying sponsorship on source attribution and source credibility. RESULTS Compared to unsponsored labels, FDA sponsorship increased source attributions that the FDA sponsored the labels among both middle-school, largely non-smoking youth and adult smokers. However, sponsorship had no effect on source credibility among either population. CONCLUSIONS We found no evidence that adding FDA as the source is likely to boost source credibility judgments, at least in the short term; though doing so would not appear to have adverse effects on credibility judgments. As such, our data are largely consistent with the Tobacco Control Act's provisions that allow, but do not require, FDA sponsorship on the labels. IMPLICATIONS This study addresses FDA's regulatory efforts by informing the possible design and content of future cigarette warning labels. Our results do not offer compelling evidence that adding the FDA name on GWLs will directly increase source credibility. Future work may test more explicit FDA source labeling and continue to examine the credibility of tobacco message content among high-priority populations.",2020,"Compared to unsponsored labels, FDA sponsorship increased source attributions that the FDA sponsored the labels among both middle-school, largely non-smoking youth and adult smokers.",['adult smokers (N=245) and middle-school youth (N=242) from low-income areas in the Northeastern US'],"['original FDA-proposed warning labels in a between-subjects experiment: no sponsor, ""US Food and Drug Administration,"" or ""American Cancer Society"" sponsor']",['source credibility'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0557797', 'cui_str': 'Middle school'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]","[{'cui': 'C0205313', 'cui_str': 'Original'}, {'cui': 'C0041714', 'cui_str': 'United States Food, Drug Administration'}, {'cui': 'C0002455', 'cui_str': 'American Cancer Society'}]","[{'cui': 'C0449416', 'cui_str': 'Source'}]",,0.0210051,"Compared to unsponsored labels, FDA sponsorship increased source attributions that the FDA sponsored the labels among both middle-school, largely non-smoking youth and adult smokers.","[{'ForeName': 'Mia', 'Initials': 'M', 'LastName': 'Jovanova', 'Affiliation': 'Annenberg School for Communication, University of Pennsylvania, PA.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Skurka', 'Affiliation': 'Department of Film/Video and Media Studies, Donald P. Bellisario College of Communications, Penn State University, University Park, PA.'}, {'ForeName': 'Sahara', 'Initials': 'S', 'LastName': 'Byrne', 'Affiliation': 'Department of Communication, Cornell University, Ithaca, NY.'}, {'ForeName': 'Motasem', 'Initials': 'M', 'LastName': 'Kalaji', 'Affiliation': 'Department of Communication, Cornell University, Ithaca, NY.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'Greiner Safi', 'Affiliation': 'Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY.'}, {'ForeName': 'Norman', 'Initials': 'N', 'LastName': 'Porticella', 'Affiliation': 'Department of Communication, Cornell University, Ithaca, NY.'}, {'ForeName': 'Alan D', 'Initials': 'AD', 'LastName': 'Mathios', 'Affiliation': 'Department of Policy Analysis and Management, Cornell University, Ithaca, NY.'}, {'ForeName': 'Rosemary J', 'Initials': 'RJ', 'LastName': 'Avery', 'Affiliation': 'Department of Policy Analysis and Management, Cornell University, Ithaca, NY.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Dorf', 'Affiliation': 'Cornell Law School, Ithaca, NY.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Niederdeppe', 'Affiliation': 'Department of Communication, Cornell University, Ithaca, NY.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntaa142'] 2981,32770240,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.,"In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.",2020,"In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.",['Patients with Moderate COVID-19'],[],"['safe and well-tolerated', 'SARS-CoV-2 viral clearance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}]",[],"[{'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}]",,0.0173668,"In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.","[{'ForeName': 'Andrey A', 'Initials': 'AA', 'LastName': 'Ivashchenko', 'Affiliation': 'ChemRar High-Tech Center, Khimki, Moscow region, Russian Federation.'}, {'ForeName': 'Kirill A', 'Initials': 'KA', 'LastName': 'Dmitriev', 'Affiliation': 'Russian Direct Investment Fund, Moscow, Russian Federation.'}, {'ForeName': 'Natalia V', 'Initials': 'NV', 'LastName': 'Vostokova', 'Affiliation': 'IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.'}, {'ForeName': 'Valeria N', 'Initials': 'VN', 'LastName': 'Azarova', 'Affiliation': 'IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.'}, {'ForeName': 'Andrew A', 'Initials': 'AA', 'LastName': 'Blinow', 'Affiliation': 'Chromis LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.'}, {'ForeName': 'Alina N', 'Initials': 'AN', 'LastName': 'Egorova', 'Affiliation': 'IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.'}, {'ForeName': 'Ivan G', 'Initials': 'IG', 'LastName': 'Gordeev', 'Affiliation': 'City Clinical Hospital n.a. O.M. Filatov, Moscow, Russian Federation.'}, {'ForeName': 'Alexey P', 'Initials': 'AP', 'LastName': 'Ilin', 'Affiliation': 'Department of Chemistry and Technology, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.'}, {'ForeName': 'Ruben N', 'Initials': 'RN', 'LastName': 'Karapetian', 'Affiliation': 'Department of Biology, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.'}, {'ForeName': 'Dmitry V', 'Initials': 'DV', 'LastName': 'Kravchenko', 'Affiliation': 'Department of Chemistry and Technology, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.'}, {'ForeName': 'Nikita V', 'Initials': 'NV', 'LastName': 'Lomakin', 'Affiliation': 'Central Clinical Hospital with Polyclinic, Moscow, Russian Federation.'}, {'ForeName': 'Elena A', 'Initials': 'EA', 'LastName': 'Merkulova', 'Affiliation': 'IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.'}, {'ForeName': 'Natalia A', 'Initials': 'NA', 'LastName': 'Papazova', 'Affiliation': 'Department of finished dosage forms, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.'}, {'ForeName': 'Elena P', 'Initials': 'EP', 'LastName': 'Pavlikova', 'Affiliation': 'Moscow State University n.a. M. V. Lomonosov, Moscow, Russian Federation.'}, {'ForeName': 'Nikolay P', 'Initials': 'NP', 'LastName': 'Savchuk', 'Affiliation': 'Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.'}, {'ForeName': 'Elena N', 'Initials': 'EN', 'LastName': 'Simakina', 'Affiliation': 'Clinical Hospital No.1, Smolensk, Russian Federation.'}, {'ForeName': 'Tagir A', 'Initials': 'TA', 'LastName': 'Sitdekov', 'Affiliation': 'Russian Direct Investment Fund, Moscow, Russian Federation.'}, {'ForeName': 'Elena A', 'Initials': 'EA', 'LastName': 'Smolyarchuk', 'Affiliation': 'First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Russian Federation.'}, {'ForeName': 'Elena G', 'Initials': 'EG', 'LastName': 'Tikhomolova', 'Affiliation': 'Infectious clinical hospital No. 2, Nizhny Novgorod, Russian Federation.'}, {'ForeName': 'Elena V', 'Initials': 'EV', 'LastName': 'Yakubova', 'Affiliation': 'Chromis LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.'}, {'ForeName': 'Alexandre V', 'Initials': 'AV', 'LastName': 'Ivachtchenko', 'Affiliation': 'Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciaa1176'] 2982,32770246,QuitNic: A pilot randomised controlled trial comparing nicotine vaping products with nicotine replacement therapy for smoking cessation following residential detoxification.,"INTRODUCTION The QuitNic pilot trial aimed to test the feasibility of providing a nicotine vaping product (NVP) compared with combination nicotine replacement therapy (NRT) to smokers upon discharge from a smoke-free residential substance use disorder (SUD) treatment service. METHODS QuitNic was a pragmatic two-arm randomised controlled trial. At discharge from residential withdrawal, 100 clients received telephone Quitline behavioural support and either 12-weeks supply of NRT, or an NVP. Treatment adherence and acceptability, self-reported abstinence, cigarettes smoked per day (CPD), frequency of cravings, and severity of withdrawal symptoms, were assessed at 6-weeks and 12-weeks. Results are reported for complete cases and for abstinence outcomes, Penalized Imputation results are reported where missing is assumed smoking. RESULTS Retention was 63% at 6-weeks and 50% at 12-weeks. At 12-weeks, 68% of the NRT group reported using combination NRT while 96% of the NVP group used the device. Acceptability ratings for the products were high in both groups. At 12-weeks, 14% of the NVP group and 18% of the NRT group reported not smoking at all in the last 7 days. Mean CPD among continued smokers decreased significantly between baseline to 12-weeks in both groups; from 19.91 to 4.72 for the NVP group (p<0.001) and from 20.88 to 5.52 in the NRT group (p<0.001). Cravings and withdrawal symptoms significantly decreased for both groups. CONCLUSION Clients completing residential withdrawal readily engaged with smoking cessation post-treatment when given the opportunity. Further research is required to identify the most effective treatments post-withdrawal for this population at elevated risk of tobacco-related harm. IMPLICATIONS This pilot study showed that smoking cessation support involving options for nicotine replacement and Quitline-delivered cognitive behavioural counselling is attractive to people after they have been discharged from SUD treatment. Both nicotine vaping products and nicotine replacement therapies were highly acceptable and used by participants who reported reductions in cravings for cigarettes and perceptions of withdrawal symptoms and reductions in number of cigarettes smoked. Some participants self-reported abstinence from cigarettes - around one in five reported having quit smoking cigarettes at 12-weeks post-discharge. The results have significant public health implications for providing quit support following discharge from SUD treatment.",2020,Both nicotine vaping products and nicotine replacement therapies were highly acceptable and used by participants who reported reductions in cravings for cigarettes and perceptions of withdrawal symptoms and reductions in number of cigarettes smoked.,"['smokers upon discharge from a smoke-free residential substance use disorder (SUD) treatment service', 'smoking cessation following residential detoxification']","['NVP', 'combination nicotine replacement therapy (NRT', 'nicotine vaping product (NVP', 'telephone Quitline behavioural support and either 12-weeks supply of NRT, or an NVP', 'nicotine replacement and Quitline-delivered cognitive behavioural counselling', 'QuitNic', 'NRT', 'nicotine replacement therapy', 'nicotine']","['cigarettes smoked per day (CPD), frequency of cravings, and severity of withdrawal symptoms', 'Mean CPD', 'Treatment adherence and acceptability, self-reported abstinence', 'quit smoking cigarettes', 'Acceptability ratings', 'Cravings and withdrawal symptoms']","[{'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038586', 'cui_str': 'Substance use disorder'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0025516', 'cui_str': 'Detoxication, Drug, Metabolic'}]","[{'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0052148', 'cui_str': 'APEL protocol'}, {'cui': 'C1278444', 'cui_str': 'Nicotine replacement therapy'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C4546207', 'cui_str': 'Behavioral counseling'}]","[{'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0087169', 'cui_str': 'Withdrawal symptom'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4505265', 'cui_str': 'Therapeutic Adherence'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}]",,0.148324,Both nicotine vaping products and nicotine replacement therapies were highly acceptable and used by participants who reported reductions in cravings for cigarettes and perceptions of withdrawal symptoms and reductions in number of cigarettes smoked.,"[{'ForeName': 'Billie', 'Initials': 'B', 'LastName': 'Bonevski', 'Affiliation': 'School of Medicine & Public Health, University of Newcastle, Callaghan, Australia.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Manning', 'Affiliation': 'Monash Addiction Research Centre and Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia.'}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Wynne', 'Affiliation': 'School of Medicine & Public Health, University of Newcastle, Callaghan, Australia.'}, {'ForeName': 'Coral', 'Initials': 'C', 'LastName': 'Gartner', 'Affiliation': 'Faculty of Medicine, School of Public Health, The University of Queensland, Herston, QLD, Australia.'}, {'ForeName': 'Ron', 'Initials': 'R', 'LastName': 'Borland', 'Affiliation': 'The Cancer Council Victoria, Melbourne, Victoria, Australia.'}, {'ForeName': 'Amanda L', 'Initials': 'AL', 'LastName': 'Baker', 'Affiliation': 'School of Medicine & Public Health, University of Newcastle, Callaghan, Australia.'}, {'ForeName': 'Catherine J', 'Initials': 'CJ', 'LastName': 'Segan', 'Affiliation': 'The Cancer Council Victoria, Melbourne, Victoria, Australia.'}, {'ForeName': 'Eliza', 'Initials': 'E', 'LastName': 'Skelton', 'Affiliation': 'School of Medicine & Public Health, University of Newcastle, Callaghan, Australia.'}, {'ForeName': 'Lyndell', 'Initials': 'L', 'LastName': 'Moore', 'Affiliation': 'School of Medicine & Public Health, University of Newcastle, Callaghan, Australia.'}, {'ForeName': 'Ramez', 'Initials': 'R', 'LastName': 'Bathish', 'Affiliation': 'Monash Addiction Research Centre and Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Chiu', 'Affiliation': 'Hunter Medical Research Institute (HMRI), Lambton, NSW, Australia.'}, {'ForeName': 'Ashleigh', 'Initials': 'A', 'LastName': 'Guillaumier', 'Affiliation': 'School of Medicine & Public Health, University of Newcastle, Callaghan, Australia.'}, {'ForeName': 'Dan I', 'Initials': 'DI', 'LastName': 'Lubman', 'Affiliation': 'Monash Addiction Research Centre and Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntaa143'] 2983,32770280,Effect of benzalkonium chloride addition to EDTA on attachment and proliferation of dental pulp stem cells on dentin and on transforming growth factor-β1 release.,"To investigate the effect of benzalkonium chloride (BAC) addition to ethylenediaminetetraacetic acid (EDTA) on transforming growth factor-β1 (TGF-β1) release, as well as attachment and proliferation of dental pulp stem cells (DPSCs) on dentin. A total of standard 268 human dentin disks were prepared and immersed in 1.5% sodium hypochlorite (NaOCl) for 5 min. The disks were rinsed with distilled water and randomly divided into seven groups. In control group, the disks received no further treatment. The remaining disks were immersed in following solutions: 17% EDTA or 17% EDTA + 0.008% BAC for 1, 5 or 10 min and rinsed with distilled water. DPSCs were seeded in part of the disks since the TGF-β1 release assay was performed with disks with and without cells. The attachment and proliferation of DPSCs on dentin disks were analyzed using lactate dehydrogenase activity and WST-1 assays, respectively. The cell morphology was observed by scanning electron microscopy. The release of TGF-β1 was quantified using ELISA. Data were analyzed using three- and two-way analysis of variance with Bonferroni corrections. Both EDTA solutions increased the attachment and proliferation of DPSCs (p < .05) while there was no significant difference between them (p > .05). The exposure time of both EDTA solutions had no influence on cell attachment, proliferation and TGF-β1 release (p > .05). There was no significant difference in TGF-β1 release between the control and experimental groups (p > .05). The amount of released TGF-β1 from dentin disks was similar whether or not they were seeded with cells (p > .05). Dentin treatment with either of the EDTA solutions had no effect on the amount of TGF-β1 release while both EDTA solutions improved cell attachment and proliferation on dentin surface regardless of exposure time.",2020,Both EDTA solutions increased the attachment and proliferation of DPSCs (p < .05) while there was no significant difference between them (p > .05).,['A total of standard 268 human dentin disks'],"['benzalkonium chloride addition to EDTA', 'benzalkonium chloride (BAC', 'sodium hypochlorite (NaOCl', 'ethylenediaminetetraacetic acid (EDTA']","['transforming growth factor-β1', 'attachment and proliferation of DPSCs', 'cell attachment, proliferation and TGF-β1 release', 'cell attachment and proliferation on dentin surface regardless of exposure time', 'attachment and proliferation of dental pulp stem cells (DPSCs) on dentin', 'attachment and proliferation of DPSCs on dentin disks', 'release of TGF-β1', 'TGF-β1 release']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C4517673', 'cui_str': '268'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0011429', 'cui_str': 'Dentin structure'}, {'cui': 'C1705370', 'cui_str': 'Disc - unit of product usage'}]","[{'cui': 'C0005026', 'cui_str': 'Benzalkonium chloride'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013618', 'cui_str': 'Edetic Acid'}, {'cui': 'C0037518', 'cui_str': 'sodium hypochlorite'}]","[{'cui': 'C0040691', 'cui_str': 'Transforming Growth Factor'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0334094', 'cui_str': 'Proliferation'}, {'cui': 'C0011399', 'cui_str': 'Structure of pulp of tooth'}, {'cui': 'C0038250', 'cui_str': 'Stem cell'}, {'cui': 'C0887869', 'cui_str': 'Cell-Matrix Adhesions'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0011429', 'cui_str': 'Dentin structure'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1705370', 'cui_str': 'Disc - unit of product usage'}]",,0.0171646,Both EDTA solutions increased the attachment and proliferation of DPSCs (p < .05) while there was no significant difference between them (p > .05).,"[{'ForeName': 'Selen', 'Initials': 'S', 'LastName': 'Kucukkaya Eren', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Hacettepe University, 06100, Ankara, Turkey. selenkkkaya@yahoo.com.'}, {'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'Bahador Zırh', 'Affiliation': 'Department of Histology and Embryology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.'}, {'ForeName': 'Naciye Dilara', 'Initials': 'ND', 'LastName': 'Zeybek', 'Affiliation': 'Department of Histology and Embryology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.'}, {'ForeName': 'Sevinc', 'Initials': 'S', 'LastName': 'Askerbeyli Örs', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Hacettepe University, 06100, Ankara, Turkey.'}, {'ForeName': 'Hacer', 'Initials': 'H', 'LastName': 'Aksel', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Hacettepe University, 06100, Ankara, Turkey.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Parashos', 'Affiliation': 'Melbourne Dental School, University of Melbourne, Melbourne, VIC, Australia.'}]",Odontology,['10.1007/s10266-020-00545-5'] 2984,32770409,"Bounce Back: randomised trial of a brief, school-based group intervention for children with emergent mental health difficulties.","We report the findings of the first randomised trial of Bounce Back, a brief, school-based group intervention for children with emergent mental health difficulties, whose aim is to improve their understanding of resilience and well-being, support them to build their confidence and friendships, and provide practical skills to make positive behaviour changes. 24 primary schools (N = 326 children) were randomly allocated to deliver the intervention or continue practice as usual in a waitlist design. Children in the intervention arm of the trial worked in groups of up to 15, supported by a trained youth practitioner, over ten weekly sessions that were delivered during the school day for up to an hour. Measures of emotional symptoms, behavioural difficulties, problem-solving, and self-esteem were recorded at baseline and post-intervention follow-up. Routinely collected session attendance data were used as a proxy for intervention compliance. Intent to treat analyses revealed that Bounce Back produced significant reductions in emotional symptoms (d = - 0.21). Furthermore, complier average causal effect analyses established that intervention compliance modified this treatment effect, such that children who attended more sessions accrued greater reductions in symptoms (moderate compliance d = - 0.54; high compliance d = - 0.61). There were no intervention effects for any of the other outcomes. Collectively, these findings provide robust preliminary evidence of the efficacy of Bounce Back.Trial registration: ISRCTN11162672.",2020,Intent to treat analyses revealed that Bounce Back produced significant reductions in emotional symptoms (d = - 0.21).,"['children with emergent mental health difficulties', '24 primary schools (N\u2009=\u2009326 children']","['intervention or continue practice as usual in a waitlist design', 'school-based group intervention']","['emotional symptoms, behavioural difficulties, problem-solving, and self-esteem', 'emotional symptoms']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C5191353', 'cui_str': '326'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0033211', 'cui_str': 'Problem solving'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}]",326.0,0.102441,Intent to treat analyses revealed that Bounce Back produced significant reductions in emotional symptoms (d = - 0.21).,"[{'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Humphrey', 'Affiliation': 'Manchester Institute of Education, University of Manchester, Manchester, UK. Neil.humphrey@manchester.ac.uk.'}, {'ForeName': 'Margarita', 'Initials': 'M', 'LastName': 'Panayiotou', 'Affiliation': 'Manchester Institute of Education, University of Manchester, Manchester, UK.'}]",European child & adolescent psychiatry,['10.1007/s00787-020-01612-6'] 2985,32770431,ACURATE neo: How Is This TAVR Valve Doing to Fit into an Increasingly Crowded Field?,"PURPOSE OF REVIEW Critical appraisal of the available evidence on the self-expanding ACURATE neo transcatheter heart valve (THV) for the treatment of aortic valve disease. RECENT FINDINGS In an investigator-initiated, multicenter, randomized non-inferiority trial with broad inclusion criteria, ACURATE neo failed to meet non-inferiority compared with SAPIEN 3 with regard to a primary composite safety and efficacy endpoint at 30 days. The difference was driven by higher rates of moderate or severe paravalvular regurgitation and higher rates of acute kidney injury. In turn, registry data suggest that the safety and efficacy profile of the ACURATE neo is comparable to that of other commercially available devices. Randomized evidence indicated favorable hemodynamic results with large effective orifice areas and low residual gradients. The self-expanding ACURATE neo THV is associated with higher rates of residual aortic regurgitation compared to the balloon-expandable SAPIEN 3 THV. The supra-annular design with low residual gradients may be advantageous in patients with small anatomy and mild degree of calcification.",2020,The self-expanding ACURATE neo THV is associated with higher rates of residual aortic regurgitation compared to the balloon-expandable SAPIEN 3 THV.,['patients with small anatomy and mild degree of calcification'],[],['residual aortic regurgitation'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0002808', 'cui_str': 'Anatomy'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}]",[],"[{'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0003504', 'cui_str': 'Aortic valve regurgitation'}]",,0.0784333,The self-expanding ACURATE neo THV is associated with higher rates of residual aortic regurgitation compared to the balloon-expandable SAPIEN 3 THV.,"[{'ForeName': 'Taishi', 'Initials': 'T', 'LastName': 'Okuno', 'Affiliation': 'Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, CH-3010, Bern, Switzerland.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Lanz', 'Affiliation': 'Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, CH-3010, Bern, Switzerland.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Pilgrim', 'Affiliation': 'Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, CH-3010, Bern, Switzerland. thomas.pilgrim@insel.ch.'}]",Current cardiology reports,['10.1007/s11886-020-01364-4'] 2986,32770443,Intervention Delivery Matters: What Mothers at High Risk for Type 2 Diabetes Want in a Diabetes Prevention Program-Results from a Comparative Effectiveness Trial.,"Participants in the ENCOURAGE Healthy Families Study, a family-focused, modified Diabetes Prevention Program, reported challenges to and preferences for engaging in a diabetes prevention program. Challenges with flexible intervention delivery, accessibility, the traditional group-based format, and Coronavirus Disease 2019 (COVID-19) exposure risk can be mitigated by participant preferences for one-on-one, virtual/online intervention delivery.Trial Registration: ClinicalTrials.gov identifier, NCT01823367.",2020,"Participants in the ENCOURAGE Healthy Families Study, a family-focused, modified Diabetes Prevention Program, reported challenges to and preferences for engaging in a diabetes prevention program.",['Intervention Delivery Matters'],[],[],"[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}]",[],[],,0.0293589,"Participants in the ENCOURAGE Healthy Families Study, a family-focused, modified Diabetes Prevention Program, reported challenges to and preferences for engaging in a diabetes prevention program.","[{'ForeName': 'Kelly N B', 'Initials': 'KNB', 'LastName': 'Palmer', 'Affiliation': 'Department of Medicine, Indiana University School of Medicine, Indianapolis, USA. kpalmer1@arizona.edu.'}, {'ForeName': 'Valene E', 'Initials': 'VE', 'LastName': 'Garr Barry', 'Affiliation': 'Department of Nutrition Sciences, University of Alabama, Birmingham, AL, USA.'}, {'ForeName': 'David G', 'Initials': 'DG', 'LastName': 'Marrero', 'Affiliation': 'Department of Medicine, Indiana University School of Medicine, Indianapolis, USA.'}, {'ForeName': 'Brett M', 'Initials': 'BM', 'LastName': 'McKinney', 'Affiliation': 'Department of Medicine, Indiana University School of Medicine, Indianapolis, USA.'}, {'ForeName': 'Anne N', 'Initials': 'AN', 'LastName': 'Graves', 'Affiliation': 'YMCA of Greater Indianapolis, Indianapolis, USA.'}, {'ForeName': 'Chelsy K', 'Initials': 'CK', 'LastName': 'Winters', 'Affiliation': 'YMCA of Greater Indianapolis, Indianapolis, USA.'}, {'ForeName': 'Tamara S', 'Initials': 'TS', 'LastName': 'Hannon', 'Affiliation': 'Department of Pediatrics, Indiana University School of Medicine, Indianapolis, USA.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00891-1'] 2987,32770491,Clinical outcomes after aphakic versus aphakic/pseudophakic intraoperative aberrometry in cataract surgery with toric IOL implantation.,"PURPOSE To determine if there was a clinically significant difference in clinical outcomes after toric IOL implantation based on intraoperative aberrometry (IA), where eyes were measured either in the aphakic state only or both the aphakic and pseudophakic states. METHODS A prospective, randomized, contralateral eye study was performed at one site in Poughkeepsie, NY, USA. Subjects included patients presenting for uncomplicated bilateral cataract surgery eligible for toric lens implantation with regular corneal astigmatism in both eyes whose toric IOL implantation was based on IA. One eye was measured when aphakic and the other when both aphakic and pseudophakic. The primary outcome measure was the magnitude of residual refractive astigmatism. Secondary measures included the percentage of eyes with 0.50D or less of residual refractive astigmatism, the spherical equivalent refraction and the time for IA measurement. RESULTS Mean residual refractive astigmatism was not statistically significantly different between groups (0.32D ± 0.46D IA_1 vs. 0.23D ± 0.35D IA_2, p = 0.25), nor was the percentage of eyes with a residual refractive cylinder of 0.50D or less (94% in both groups, p = 1.0). The average time to measure the pseudophakic eye was 3 min, 46 s. Aphakic IA measurements appeared to produce better spherical equivalent refractive results relative to preoperative calculations. CONCLUSION Pseudophakic IA measurements took nearly 4 min per case. Residual refractive astigmatism was not appreciably lower when pseudophakic IA measurements were made after aphakic IA measurements, which suggests aphakic IA measurements alone provide good clinical results with toric IOLs.",2020,"Residual refractive astigmatism was not appreciably lower when pseudophakic IA measurements were made after aphakic IA measurements, which suggests aphakic IA measurements alone provide good clinical results with toric IOLs.","['cataract surgery with toric IOL implantation', 'Subjects included patients presenting for uncomplicated bilateral cataract surgery eligible for']","['toric IOL implantation', 'aphakic versus aphakic/pseudophakic intraoperative aberrometry', 'toric lens implantation with regular corneal astigmatism']","['Mean residual refractive astigmatism', 'average time to measure the pseudophakic eye', 'percentage of eyes with 0.50D or less of residual refractive astigmatism, the spherical equivalent refraction and the time for IA measurement', 'magnitude of residual refractive astigmatism']","[{'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C0281658', 'cui_str': 'Intraocular Lymphoma'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0443334', 'cui_str': 'Uncomplicated'}, {'cui': 'C0521707', 'cui_str': 'Bilateral cataracts'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0281658', 'cui_str': 'Intraocular Lymphoma'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C2717991', 'cui_str': 'Aberrometry'}, {'cui': 'C0023311', 'cui_str': 'Insertion of intraocular lens'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0339682', 'cui_str': 'Regular astigmatism - corneal'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0004106', 'cui_str': 'Astigmatism'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0332501', 'cui_str': 'Spherical shape'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0429585', 'cui_str': 'Refraction measurement - finding'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C2717991', 'cui_str': 'Aberrometry'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0449286', 'cui_str': 'Degree'}]",,0.0833763,"Residual refractive astigmatism was not appreciably lower when pseudophakic IA measurements were made after aphakic IA measurements, which suggests aphakic IA measurements alone provide good clinical results with toric IOLs.","[{'ForeName': 'Satish S', 'Initials': 'SS', 'LastName': 'Modi', 'Affiliation': 'Seeta Eye Centers, Poughkeepsie, NY, USA. SModieyes@aol.com.'}]",International ophthalmology,['10.1007/s10792-020-01509-y'] 2988,32770520,"Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study.","PURPOSE The glucose-lowering drug metformin has recently been shown to reduce myocardial oxygen consumption and increase myocardial efficiency in chronic heart failure (HF) patients without diabetes. However, it remains to be established whether these beneficial myocardial effects are associated with metformin-induced alterations in whole-body insulin sensitivity and substrate metabolism. METHODS Eighteen HF patients with reduced ejection fraction and without diabetes (median age, 65 (interquartile range 55-68); ejection fraction 39 ± 6%; HbA1c 5.5 to 6.4%) were randomized to receive metformin (n = 10) or placebo (n = 8) for 3 months. We studied the effects of metformin on whole-body insulin sensitivity using a two-step hyperinsulinemic euglycemic clamp incorporating isotope-labeled tracers of glucose, palmitate, and urea. Substrate metabolism and skeletal muscle mitochondrial respiratory capacity were determined by indirect calorimetry and high-resolution respirometry, and body composition was assessed by bioelectrical impedance analysis. The primary outcome measure was change in insulin sensitivity. RESULTS Compared with placebo, metformin treatment lowered mean glycated hemoglobin levels (absolute mean difference, - 0.2%; 95% CI - 0.3 to 0.0; p = 0.03), reduced body weight (- 2.8 kg; 95% CI - 5.0 to - 0.6; p = 0.02), and increased fasting glucagon levels (3.2 pmol L -1 ; 95% CI 0.4 to 6.0; p = 0.03). No changes were observed in whole-body insulin sensitivity, endogenous glucose production, and peripheral glucose disposal or oxidation with metformin. Equally, resting energy expenditure, lipid and urea turnover, and skeletal muscle mitochondrial respiratory capacity remained unaltered. CONCLUSION Increased myocardial efficiency during metformin treatment is not mediated through improvements in insulin action in HF patients without diabetes. CLINICAL TRIAL REGISTRATION URL: https://clinicaltrials.gov . Unique identifier: NCT02810132. Date of registration: June 22, 2016.",2020,"No changes were observed in whole-body insulin sensitivity, endogenous glucose production, and peripheral glucose disposal or oxidation with metformin.","['HF patients without diabetes', 'chronic heart failure (HF) patients without diabetes', 'Chronic Heart Failure Patients without Diabetes', 'Eighteen HF patients with reduced ejection fraction and without diabetes (median age, 65 (interquartile range 55-68); ejection fraction 39\u2009±\u20096%; HbA1c 5.5 to 6.4']","['placebo, metformin', 'Metformin', 'Placebo', 'metformin', 'placebo']","['insulin action', 'fasting glucagon levels', 'resting energy expenditure, lipid and urea turnover, and skeletal muscle mitochondrial respiratory capacity', 'myocardial oxygen consumption', 'mean glycated hemoglobin levels', 'whole-body insulin sensitivity, endogenous glucose production, and peripheral glucose disposal or oxidation with metformin', 'change in insulin sensitivity', 'Body Weight', 'reduced body weight', 'Substrate metabolism and skeletal muscle mitochondrial respiratory capacity', 'myocardial efficiency']","[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C3844008', 'cui_str': '5.5'}, {'cui': 'C4517822', 'cui_str': '6.4'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0337437', 'cui_str': 'Glucagon measurement'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0041942', 'cui_str': 'Urea'}, {'cui': 'C0031227', 'cui_str': 'Employee Turnover'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0428863', 'cui_str': 'Myocardial oxygen consumption'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0205227', 'cui_str': 'Endogenous'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0333779', 'cui_str': 'Reducing bodies'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}]",18.0,0.456597,"No changes were observed in whole-body insulin sensitivity, endogenous glucose production, and peripheral glucose disposal or oxidation with metformin.","[{'ForeName': 'Anders Hostrup', 'Initials': 'AH', 'LastName': 'Larsen', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Wiggers', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Ole Lindgård', 'Initials': 'OL', 'LastName': 'Dollerup', 'Affiliation': 'Department of Clinical Medicine, Medical Research Laboratory, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Nichlas Riise', 'Initials': 'NR', 'LastName': 'Jespersen', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Nils Henrik', 'Initials': 'NH', 'LastName': 'Hansson', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Jørgen', 'Initials': 'J', 'LastName': 'Frøkiær', 'Affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Brøsen', 'Affiliation': 'Department of Clinical Pharmacology, University of Southern Denmark, Odense C, Denmark.'}, {'ForeName': 'Helene', 'Initials': 'H', 'LastName': 'Nørrelund', 'Affiliation': 'Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Hans Erik', 'Initials': 'HE', 'LastName': 'Bøtker', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Møller', 'Affiliation': 'Department of Clinical Medicine, Medical Research Laboratory, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Jessen', 'Affiliation': 'Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark. niels.jessen@biomed.au.dk.'}]",Cardiovascular drugs and therapy,['10.1007/s10557-020-07050-5'] 2989,32770558,Update to the ASFA guidelines on the use of therapeutic apheresis in ANCA-associated vasculitis.,"Since 1986, the American Society for Apheresis (ASFA) has published practice guidelines on the use of therapeutic apheresis in the Journal of Clinical Apheresis (JCA) Special Issue. Since 2007, updated guidelines have been published every 3 years to reflect current evidence based apheresis practice with the most recent edition (8th) published in 2019. With each edition, the guidelines are reviewed and updated based on any newly published literature since the last review. The PEXIVAS study, an international, randomized controlled trial comparing therapeutic plasma exchange (TPE) vs no TPE and standard vs reduced dose steroid regimen on the primary composite outcome of end stage renal disease or death in patients with ANCA-associated vasculitis (AAV), was published in February 2020. This study represents the largest study on the role of therapeutic apheresis in AAV published to date and prompted the JCA Special Issue Writing Committee to reassess the current AAV fact sheet for updates based on this newly available evidence. This interim fact sheet summarizes current ASFA recommendations for the evidence-based use of therapeutic apheresis in AAV and supersedes the recommendations published in the 2019 guidelines.",2020,"Since 1986, the American Society for Apheresis (ASFA) has published practice guidelines on the use of therapeutic apheresis in the Journal of Clinical Apheresis (JCA) Special Issue.","['patients with ANCA-associated vasculitis (AAV), was published in February 2020']",['therapeutic plasma exchange (TPE) vs no TPE and standard vs reduced dose steroid regimen'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2717865', 'cui_str': 'Pauci-Immune Vasculitis'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0042384', 'cui_str': 'Vasculitis'}, {'cui': 'C0034037', 'cui_str': 'Publishing'}]","[{'cui': 'C0032113', 'cui_str': 'Plasma exchange'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]",[],,0.0304744,"Since 1986, the American Society for Apheresis (ASFA) has published practice guidelines on the use of therapeutic apheresis in the Journal of Clinical Apheresis (JCA) Special Issue.","[{'ForeName': 'Rasheed A', 'Initials': 'RA', 'LastName': 'Balogun', 'Affiliation': 'Division of Nephrology, University of Virginia, Charlottesville, Virginia, USA.'}, {'ForeName': 'Amber P', 'Initials': 'AP', 'LastName': 'Sanchez', 'Affiliation': 'Department of Medicine, Division of Nephrology, University of California, and Therapeutic Apheresis Program, UCSD Medical Center, San Diego, California, USA.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Klingel', 'Affiliation': 'Apheresis Research Institute, Cologne, Germany.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Witt', 'Affiliation': 'Department for Pediatrics, St. Anna Kinderspital, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Aqui', 'Affiliation': 'Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Meyer', 'Affiliation': 'American Red Cross, Columbus, Ohio, USA.'}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Padmanabhan', 'Affiliation': 'Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'Huy P', 'Initials': 'HP', 'LastName': 'Pham', 'Affiliation': 'Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Schneiderman', 'Affiliation': ""Department of Pediatric Hematology/Oncology/Neuro-oncology/Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.""}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Schwartz', 'Affiliation': 'Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, USA.'}, {'ForeName': 'Yanyun', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Department of Pathology and Laboratory Medicine, University of Miami, Miami, Florida, USA.'}, {'ForeName': 'Nicole D', 'Initials': 'ND', 'LastName': 'Zantek', 'Affiliation': 'Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Connelly-Smith', 'Affiliation': 'Department of Medicine, Seattle Cancer Care Alliance & University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Nancy M', 'Initials': 'NM', 'LastName': 'Dunbar', 'Affiliation': 'Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.'}]",Journal of clinical apheresis,['10.1002/jca.21820'] 2990,32770693,"Single-Plane Versus Dual-Plane Microfocused Ultrasound With Visualization in the Treatment of Upper Arm Skin Laxity: A Randomized, Single-Blinded, Controlled Trial.","BACKGROUND AND OBJECTIVES Non-invasive skin tightening devices have become a safe and non-invasive treatment for patients with skin laxity of the upper arm. The efficacy of microfocused ultrasound with visualization (MFU-V) in skin tightening had been demonstrated in several studies. This study aimed to evaluate the efficacy and safety of MFU-V in treating skin laxity of the upper arm using different treatment protocols. STUDY DESIGN/MATERIALS AND METHODS Thirty patients with upper arm laxity were enrolled. Patients were randomly assigned to receive single-plane MFU-V treatment (4 MHz/4.5 mm transducer) on one arm and dual-plane treatment (4 MHz/4.5 mm and 7 MHz/3.0 mm transducer) on the contralateral arm, totaling 200 lines in each arm. Investigator Assessment Skin Laxity Scoring System (IASLSS) and improvement scores were evaluated at 1, 3, and 6 months after the treatment. Adverse events were recorded. RESULTS A modest reduction of mean arm circumference was observed on both sides. Mean physician-rated improvement scores,  single-plane treatment received 2.22 (±1.05), 2.70 (±1.32), and 1.61 (±0.79), respectively. Dual-plane treatment received 2.00 (±1.00), 2.56 (±1.05), and 1.39 (±0.54), respectively. Single-plane treatment was superior from physician's ratings (P < 0.05). IASLSS followed the same trend as the improvement scores. Mean patient-rated improvement scores in single-plane treatment were 3.63 (±2.63), 3.69 (±2.83), 1.90(±2.51) for 1, 3, and 6 months, respectively. Dual-plane treatment received 3.5 (±2.57), 3.22 (±2.59), 1.78 (±2.48), respectively. The median pain scores were 2.6 (0-8) for single-plane treatment and 1.9 (0-8) for dual-plane treatment (P = 0.136). No other significant side effects were observed. CONCLUSION Both single-plane and dual-plane treatment provide a modest skin tightening effect in the upper arm for at least 3 months. Physicians should assess skin thickness in every patient using the visualization screen to select the appropriate transducer for each individual patient. Lasers Surg. Med. © 2020 Wiley Periodicals LLC.",2020,Single-plane treatment was superior from physician's ratings (P < 0.05).,"['Upper Arm Skin Laxity', 'Thirty patients with upper arm laxity were enrolled', 'patients with skin laxity of the upper arm']","['Single-Plane Versus Dual-Plane Microfocused Ultrasound With Visualization', 'single-plane MFU-V treatment (4\u2009MHz/4.5\u2009mm transducer) on one arm and dual-plane treatment', 'microfocused ultrasound with visualization (MFU-V', 'MFU-V']","['Mean physician-rated improvement scores', 'skin thickness', 'Mean patient-rated improvement scores', 'median pain scores', 'Adverse events', 'Investigator Assessment Skin Laxity Scoring System (IASLSS) and improvement scores', 'skin tightening effect', 'mean arm circumference', 'side effects']","[{'cui': 'C0230348', 'cui_str': 'Both upper arms'}, {'cui': 'C0010495', 'cui_str': 'Cutis laxa'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332536', 'cui_str': 'Laxity'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0040661', 'cui_str': 'Transducer'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0423756', 'cui_str': 'Thickness of skin'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0558035', 'cui_str': 'Skin assessment'}, {'cui': 'C0332536', 'cui_str': 'Laxity'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",30.0,0.0247437,Single-plane treatment was superior from physician's ratings (P < 0.05).,"[{'ForeName': 'Vasanop', 'Initials': 'V', 'LastName': 'Vachiramon', 'Affiliation': 'Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand.'}, {'ForeName': 'Korn', 'Initials': 'K', 'LastName': 'Triyangkulsri', 'Affiliation': 'Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand.'}, {'ForeName': 'Wimolsiri', 'Initials': 'W', 'LastName': 'Iamsumang', 'Affiliation': 'Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Chayavichitsilp', 'Affiliation': 'Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand.'}]",Lasers in surgery and medicine,['10.1002/lsm.23307'] 2991,32770730,"Early clinical experience with AZD4831, a novel myeloperoxidase inhibitor, developed for patients with heart failure with preserved ejection fraction.","We evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4831, a novel oral myeloperoxidase (MPO) inhibitor, in a randomized, single blind, placebo-controlled study, following once daily multiple ascending dosing to steady state in healthy subjects. Target engagement was measured as specific MPO activity in plasma following ex vivo zymosan stimulation of whole blood. Except for generalized maculopapular rash in 4 out of 13 subjects receiving the two highest doses, 15 mg and 45 mg AZD4831, no clinically relevant safety and tolerability findings were observed. AZD4831 was rapidly absorbed and plasma concentrations declined slowly with an elimination half-life of approximately 60 hours. A dose/concentration-effect relationship between MPO inhibition vs. AZD4831 exposure was established with >50 % MPO inhibition in plasma at concentrations in the low nanomolar range. Steady state levels were achieved within 10 days. Taken together the pharmacokinetic profile, the sustained dose/concentration dependent MPO inhibition, and available clinical data support further clinical development of AZD4831 in patients with heart failure with preserved ejection fraction (HFpEF).",2020,A dose/concentration-effect relationship between MPO inhibition vs. AZD4831 exposure was established with >50 % MPO inhibition in plasma at concentrations in the low nanomolar range.,"['healthy subjects', 'patients with heart failure with preserved ejection fraction (HFpEF', 'patients with heart failure with preserved ejection fraction']","['AZD4831, a novel oral myeloperoxidase (MPO) inhibitor', 'placebo']","['specific MPO activity', 'Steady state levels', 'safety, tolerability, pharmacokinetics and pharmacodynamics']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2960127', 'cui_str': 'Heart failure with normal ejection fraction'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0027021', 'cui_str': 'Peroxidase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0027021', 'cui_str': 'Peroxidase'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205361', 'cui_str': 'Steady'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}]",13.0,0.0253714,A dose/concentration-effect relationship between MPO inhibition vs. AZD4831 exposure was established with >50 % MPO inhibition in plasma at concentrations in the low nanomolar range.,"[{'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Nelander', 'Affiliation': 'Early Biometrics and Statistical Innovation, Data Science and AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Lagerstrom-Fermer', 'Affiliation': 'Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Amilon', 'Affiliation': 'Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Michaëlsson', 'Affiliation': 'Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Heijer', 'Affiliation': 'Clinical Pharmacology Biologics and Bioanalysis, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Kjaer', 'Affiliation': 'Early Biometrics and Statistical Innovation, Data Science and AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Muir', 'Initials': 'M', 'LastName': 'Russell', 'Affiliation': 'Study Delivery, Early Oncology Clinical, Oncology R&D, AstraZeneca, Cambridge, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Han', 'Affiliation': 'PAREXEL Early Phase Clinical Unit, Los Angeles, USA.'}, {'ForeName': 'Eva-Lotte', 'Initials': 'EL', 'LastName': 'Lindstedt', 'Affiliation': 'Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Whatling', 'Affiliation': 'Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Li-Ming', 'Initials': 'LM', 'LastName': 'Gan', 'Affiliation': 'Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Ericsson', 'Affiliation': 'Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}]",Clinical and translational science,['10.1111/cts.12859'] 2992,32770757,Opioid overdose experiences in a sample of US adolescents and young adults: a thematic analysis.,"BACKGROUND AND AIMS Opioid overdose deaths among adolescents and young adults have risen sharply in the US over recent decades. This study aimed to explore the nature of adolescent and young adult perspectives on overdose experiences. DESIGN This study involved thematic analysis of interviews undertaken as part of a mixed methods, randomised trial of extended release naltrexone (XR-NTX) versus treatment-as-usual (TAU) for adolescents and young adults (15-21 years) with opioid use disorder (OUD). SETTING Participants were recruited during a residential treatment episode at Mountain Manor Treatment Center, in Baltimore, Maryland, USA. PARTICIPANTS/CASES As part of the qualitative component of this study, 35 adolescents/young adults completed up to three interviews: at baseline, 3 months, and 6 months after release from residential opioid use disorder treatment. MEASUREMENTS Semi-structured interviews solicited participant experiences with opioid use disorder treatment; their satisfaction with the medications used to treat opioid use disorder; counseling received; current substance use; issues related to treatment retention; their treatment goals; and their future outlook. FINDINGS Four broad themes emerged: 1) adolescents/young adults had difficulty identifying overdoses due to interpreting subjective symptoms and a lack of memory of the event, 2) this sample had difficulty perceiving risk that is misaligned with traditional understandings of overdose intentionality, 3) adolescents/young adults did not interpret personal overdose events as a catalyst for behavior change, and 4) this sample experienced a greater impact to behavior change through witnessing an overdose of someone in their social network. CONCLUSIONS The sample of US adolescents and young adults in treatment for opioid use disorder expressed difficulty identifying whether or not they had experienced an overdose, expressed fluctuating intentionality for those events, and did not have clear intentions to change their behaviour. Witnessing an overdose appeared to be as salient an experience as going through an overdose oneself.",2020,"FINDINGS Four broad themes emerged: 1) adolescents/young adults had difficulty identifying overdoses due to interpreting subjective symptoms and a lack of memory of the event, 2) this sample had difficulty perceiving risk that is misaligned with traditional understandings of overdose intentionality, 3) adolescents/young adults did not interpret personal overdose events as a catalyst for behavior change, and 4) this sample experienced a greater impact to behavior change through witnessing an overdose of someone in their social network. ","['adolescents and young adults', '35 adolescents/young adults completed up to three interviews: at baseline, 3 months, and 6 months after release from residential opioid use disorder treatment', 'Participants were recruited during a residential treatment episode at Mountain Manor Treatment Center, in Baltimore, Maryland, USA', 'US adolescents and young adults', 'adolescents and young adults (15-21 years) with opioid use disorder (OUD']",['naltrexone (XR-NTX) versus treatment-as-usual (TAU'],[],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0035189', 'cui_str': 'Residential Treatment'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0442533', 'cui_str': 'Mountain'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0004716', 'cui_str': 'Baltimore'}, {'cui': 'C0024858', 'cui_str': 'Maryland'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",[],35.0,0.0746849,"FINDINGS Four broad themes emerged: 1) adolescents/young adults had difficulty identifying overdoses due to interpreting subjective symptoms and a lack of memory of the event, 2) this sample had difficulty perceiving risk that is misaligned with traditional understandings of overdose intentionality, 3) adolescents/young adults did not interpret personal overdose events as a catalyst for behavior change, and 4) this sample experienced a greater impact to behavior change through witnessing an overdose of someone in their social network. ","[{'ForeName': 'Laura B', 'Initials': 'LB', 'LastName': 'Monico', 'Affiliation': 'Friends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, Maryland, 21201.'}, {'ForeName': 'Ariel', 'Initials': 'A', 'LastName': 'Ludwig', 'Affiliation': 'Friends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, Maryland, 21201.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Lertch', 'Affiliation': 'Friends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, Maryland, 21201.'}, {'ForeName': 'Ross', 'Initials': 'R', 'LastName': 'Dionne', 'Affiliation': 'Pacifica Graduate Institute, 249 Lambert Rd., Carpinteria, CA, 93013.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Fishman', 'Affiliation': 'Mountain Manor Treatment Center, 3800 Frederick Ave, Baltimore, MD, 21229.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Schwartz', 'Affiliation': 'Friends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, Maryland, 21201.'}, {'ForeName': 'Shannon Gwin', 'Initials': 'SG', 'LastName': 'Mitchell', 'Affiliation': 'Friends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, Maryland, 21201.'}]","Addiction (Abingdon, England)",['10.1111/add.15216'] 2993,32770782,The effect of Hyperbaric Oxygen Therapy combined with Hair transplantation surgery for the treatment of alopecia.,"BACKGROUND Transplanted hair follicles suffer from various injury, which are difficult to prevent. Hyperbaric Oxygen Therapy (HBOT) was reported to be an excellent procedure to promote capillary regeneration and reduce ischemia-reperfusion injury. AIM To evaluate the clinical efficacy of HBOT as an adjuvant therapy for hair transplantation surgery. METHODS 34 patients with II-IV alopecia were divided into the control group and HBOT group randomly. The control group were treated with routine FUE procedure, while HBOT group combined with HBOT. Patients were treated with 100% oxygen under 2.0 atmospheres absolute pressure for 60 minutes through a facemask during HBOT and take the therapy daily for 7 days continuously after operation. Satisfaction and clinical improvement were evaluated at the fourth week and the sixth month postoperatively. RESULT Itching and folliculitis was significantly decreased in HBOT group (11.8% versus 35.3%). In addition, HBOT resulted in a lower postoperative shedding rate (27.6±2.6% versus 69.1±2.4%), nevertheless, the survival rate at 9 months showed no significant difference between HBOT (96.9±0.5%) and control (93.8±0.6%). The early postoperative satisfaction in control group was much lower than HBOT group (52.9% versus 88.2%), whereas all patients showed satisfaction with the final result. CONCLUSION HBOT is able to minimize the postsurgical follicle shedding and lead to less folliculitis and itching, which provides evidence for HBOT to act as an adjuvant therapy for hair transplantation surgery.",2020,"RESULT Itching and folliculitis was significantly decreased in HBOT group (11.8% versus 35.3%).","['34 patients with II-IV alopecia', 'hair transplantation surgery', 'alopecia']","['Hyperbaric Oxygen Therapy (HBOT', 'Hyperbaric Oxygen Therapy combined\xa0with\xa0Hair transplantation\xa0surgery', 'routine FUE procedure, while HBOT group combined with HBOT', 'HBOT']","['early postoperative satisfaction', 'Itching and folliculitis', 'survival rate', 'Satisfaction and clinical improvement', 'postoperative shedding rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002170', 'cui_str': 'Alopecia'}, {'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}]","[{'cui': 'C0020431', 'cui_str': 'Hyperbaric oxygen therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0016436', 'cui_str': 'Folliculitis'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",34.0,0.0278915,"RESULT Itching and folliculitis was significantly decreased in HBOT group (11.8% versus 35.3%).","[{'ForeName': 'Zhe-Xiang', 'Initials': 'ZX', 'LastName': 'Fan', 'Affiliation': 'Department of Plastic and Aesthetic Surgery, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong Province, 510515, China.'}, {'ForeName': 'Yuyang', 'Initials': 'Y', 'LastName': 'Gan', 'Affiliation': 'Department of Plastic and Aesthetic Surgery, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong Province, 510515, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Qu', 'Affiliation': 'Department of Plastic and Aesthetic Surgery, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong Province, 510515, China.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Plastic and Aesthetic Surgery, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong Province, 510515, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Lunan', 'Affiliation': 'Department of Plastic and Aesthetic Surgery, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong Province, 510515, China.'}, {'ForeName': 'Bingcheng', 'Initials': 'B', 'LastName': 'Liu', 'Affiliation': 'Department of Plastic and Aesthetic Surgery, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong Province, 510515, China.'}, {'ForeName': 'Ruosi', 'Initials': 'R', 'LastName': 'Chen', 'Affiliation': 'Department of Plastic and Aesthetic Surgery, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong Province, 510515, China.'}, {'ForeName': 'Zhi-Qi', 'Initials': 'ZQ', 'LastName': 'Hu', 'Affiliation': 'Department of Plastic and Aesthetic Surgery, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong Province, 510515, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Miao', 'Affiliation': 'Department of Plastic and Aesthetic Surgery, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong Province, 510515, China.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13665'] 2994,32770781,An economic evaluation of tranexamic acid to prevent postpartum hemorrhage in women with vaginal delivery : the randomized controlled TRAAP trial.,"OBJECTIVE To estimate the cost effectiveness of tranexamic acid (TXA) use to prevent postpartum hemorrhage. DESIGN A trial-based economic evaluation. SETTING 15 French university maternity hospitals. POPULATION women enrolled in the TRAAP randomized controlled trial comparing TXA versus placebo in women with vaginal delivery. TRAAP failed to show a reduction in postpartum hemorrhage of at least 500 ml in the intervention arm but evidenced significant lower rates of secondary outcomes related to blood loss METHODS & MAIN OUTCOME MEASURES: We estimated direct medical costs from within-trial hospital resources collected prospectively from the study report form. All resources were costed at their value to the hospital. We estimated incremental cost per incremental hemorrhage averted. RESULTS Among the 4,079 women in the TRAAP trial, data necessary to calculate costs were available for 3,836 (94.0%). The average total costs in the TXA and control groups were €2,278 ±388 and €2,288 ±409 per woman respectively (p= 0.79). In women with postpartum hemorrhage of at least 500 ml (trial primary endpoint), costs were €2,359±354 and €2,409±525 (p=0.14); for provider-assessed clinically significant postpartum hemorrhage and postpartum hemorrhage of at least 1000 ml, costs were respectively €2,316±347 versus €2,381±521 (p=0.22) and €2,321±318versus €2,411±590 (p=0.35) in the tranexamic and placebo groups, respectively. The probabilistic sensitivity analysis showed that the use of TXA had a 65-73% % probability of being cost saving and outcome improving. CONCLUSIONS Our findings support the use of TXA as both bleeding events and cost may be reduced 3 out of 4 times.",2020,"The probabilistic sensitivity analysis showed that the use of TXA had a 65-73% % probability of being cost saving and outcome improving. ","['15 French university maternity hospitals', 'women enrolled in the', 'women with vaginal delivery ', 'women with vaginal delivery', '4,079 women in the TRAAP trial']","['tranexamic acid (TXA', 'TXA', 'tranexamic and placebo', 'TRAAP', 'tranexamic acid', 'placebo']","['postpartum hemorrhage', 'average total costs', 'postpartum hemorrhage and postpartum hemorrhage']","[{'cui': 'C0376246', 'cui_str': 'French language'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0020010', 'cui_str': 'Maternity Hospitals'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0032797', 'cui_str': 'Postpartum hemorrhage'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",4079.0,0.329071,"The probabilistic sensitivity analysis showed that the use of TXA had a 65-73% % probability of being cost saving and outcome improving. ","[{'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Durand-Zaleski', 'Affiliation': 'AP-HP Health economics research unit, Hotel Dieu hospital, Paris, France.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Deneux-Tharaux', 'Affiliation': 'INSERM, UMR 1153 CRESS, Clinical epidemiology(Methods) & Obstetrical, Perinatal and Pediatric Epidemiology (Epopé) Research Team, Paris Descartes University, Paris, France.'}, {'ForeName': 'Aurelien', 'Initials': 'A', 'LastName': 'Seco', 'Affiliation': 'INSERM, UMR 1153 CRESS, Clinical epidemiology(Methods) & Obstetrical, Perinatal and Pediatric Epidemiology (Epopé) Research Team, Paris Descartes University, Paris, France.'}, {'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Malki', 'Affiliation': 'AP-HP Health economics research unit, Hotel Dieu hospital, Paris, France.'}, {'ForeName': 'Jerome', 'Initials': 'J', 'LastName': 'Frenkiel', 'Affiliation': 'AP-HP Health economics research unit, Hotel Dieu hospital, Paris, France.'}, {'ForeName': 'Loic', 'Initials': 'L', 'LastName': 'Sentilhes', 'Affiliation': 'Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BJOG : an international journal of obstetrics and gynaecology,['10.1111/1471-0528.16456'] 2995,32770791,Sleep Well Be Well: Pilot of a digital intervention to improve child behavioural sleep problems.,"AIM To investigate whether a digital sleep intervention improves child and care giver sleep and psychosocial outcomes. METHODS A total of 120 families with children aged 2-13 years, reporting moderate to severe child behavioural sleep problems, were recruited from a hospital sleep clinic waitlist or the community. Children from non-English speaking families, with known intellectual disability (IQ < 70) or severe medical problems excluded. Tailored behavioural sleep strategies were delivered to primary care givers via a smart phone app and complementary website. Eligible families completed a baseline questionnaire and child 'sleep check' then received the digital sleep intervention for 5 weeks, and then completed a post questionnaire. OUTCOMES care giver report of child sleep as no/mild versus moderate/severe problem over past month (primary outcome); problem child sleep patterns (Brief Infant Sleep Questionnaire or Child Sleep Habits Questionnaire), child temperament, care giver mental health (Kessler 6), care giver sleep, health service use for their child's sleep and time off work/activities to access services. RESULTS At follow up, care givers reported fewer moderate/severe child sleep problems (84.6-40.7%), improved problem child sleep patterns, better temperament and improved care giver mental health. Care giver sleep quality and quantity remained unchanged. Health service use (averaged over a 6-month period pre- and post-intervention) fell from 18.9% pre- to 14.1% post-intervention. CONCLUSION A digital sleep intervention appears promising in improving sleep in children with moderate/severe behavioural sleep problems, and care giver mental health. It may be a useful alternative to face-to-face management of behavioural sleep problems.",2020,"At follow up, care givers reported fewer moderate/severe child sleep problems (84.6-40.7%), improved problem child sleep patterns, better temperament and improved care giver mental health.","['Children from non-English speaking families, with known intellectual disability (IQ\u2009<\u200970) or severe medical problems excluded', '120 families with children aged 2-13\u2009years, reporting moderate to severe child behavioural sleep problems, were recruited from a hospital sleep clinic waitlist or the community', 'children with moderate/severe behavioural sleep problems, and care giver mental health']","['digital sleep intervention', 'digital intervention']","['Care giver sleep quality and quantity', 'moderate/severe child sleep problems', 'problem child sleep patterns, better temperament and improved care giver mental health', 'child behavioural sleep problems', ""child sleep as no/mild versus moderate/severe problem over past month (primary outcome); problem child sleep patterns (Brief Infant Sleep Questionnaire or Child Sleep Habits Questionnaire), child temperament, care giver mental health (Kessler 6), care giver sleep, health service use for their child's sleep and time off work/activities to access services"", 'Sleep']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0234856', 'cui_str': 'Speaking'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C3714756', 'cui_str': 'Intellectual disability'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnia'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnia'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0474396', 'cui_str': 'Sleep behavior finding'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0039474', 'cui_str': 'Temperament'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C2133558', 'cui_str': 'Sleep Habits'}, {'cui': 'C0018747', 'cui_str': 'Services, Health'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0585074', 'cui_str': 'Amount of time off work'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0557854', 'cui_str': 'Services'}]",120.0,0.0424414,"At follow up, care givers reported fewer moderate/severe child sleep problems (84.6-40.7%), improved problem child sleep patterns, better temperament and improved care giver mental health.","[{'ForeName': 'Harriet', 'Initials': 'H', 'LastName': 'Hiscock', 'Affiliation': ""Health Services Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.""}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Ng', 'Affiliation': ""Health Services Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.""}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Crossley', 'Affiliation': ""Health Services Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.""}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Chow', 'Affiliation': ""Health Services Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.""}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Rausa', 'Affiliation': ""Health Services Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.""}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Hearps', 'Affiliation': ""Health Services Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.""}]",Journal of paediatrics and child health,['10.1111/jpc.15106'] 2996,32770831,"Cannabidivarin for HIV-associated neuropathic pain - a randomized, blinded, controlled clinical trial.","The human immunodeficiency virus (HIV) remains a major burden to the health care system and neuropathic pain is the most common neurological complication of HIV infection. Since current treatment strategies often lack satisfying pain relief, cannabinoids are discussed as a new option. We investigated cannabidivarin as treatment for HIV-associated neuropathic pain. We conducted a randomized, double-blind, placebo-controlled cross-over study. Patients underwent two successive treatment phases (4 weeks each) and were treated with cannabidivarin (400mg/d) or placebo in a randomized order. A 3-week wash-out phase was designed to eliminate potential carry-over effects. Patients were followed up for 3 weeks after the end of the second treatment phase. The primary endpoint was pain intensity on an 11-point numeric rating scale, recorded in a diary. Secondary endpoints were additional pain medication, pain characteristics and quality of life. We included 32 patients. The mean pain intensity under cannabidivarin was 0.62 points higher compared to placebo (p=0.16; 95% CI -0.27 to 1.51). Cannabidivarin did not influence the amount of additional pain medication, pain characteristics or quality of life. The incidence of adverse events was similar during both treatments. No suspected unexpected adverse reactions occurred during either treatment. Cannabidivarin was safe but failed to reduce neuropathic pain in HIV-patients. This may be explained by a lack of cannabinoid receptor activation, as indicated by preclinical experiments. Although a larger patient number might be desirable, we would not expect a change in the conclusions since the present differences are far from statistical significance. Therefore, we would currently not consider CBDV as a clinically meaningful treatment option for neuropathic pain.",2020,The mean pain intensity under cannabidivarin was 0.62 points higher compared to placebo (p=0.16; 95% CI -0.27 to 1.51).,"['HIV-associated neuropathic pain', '32 patients']","['cannabidivarin (400mg/d) or placebo', 'Cannabidivarin', 'placebo']","['mean pain intensity under cannabidivarin', 'pain intensity on an 11-point numeric rating scale', 'adverse events', 'adverse reactions', 'additional pain medication, pain characteristics or quality of life', 'neuropathic pain', 'additional pain medication, pain characteristics and quality of life']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0027796', 'cui_str': 'Neuralgia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C3657549', 'cui_str': 'cannabidivarin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C3657549', 'cui_str': 'cannabidivarin'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1286315', 'cui_str': 'Characteristic of pain'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0027796', 'cui_str': 'Neuralgia'}]",32.0,0.414352,The mean pain intensity under cannabidivarin was 0.62 points higher compared to placebo (p=0.16; 95% CI -0.27 to 1.51).,"[{'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Eibach', 'Affiliation': 'Department of Anesthesiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Scheffel', 'Affiliation': 'Department of Anesthesiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Madeleine', 'Initials': 'M', 'LastName': 'Cardebring', 'Affiliation': 'Department of Anesthesiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Lettau', 'Affiliation': 'Department of Anesthesiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'M Özgür', 'Initials': 'MÖ', 'LastName': 'Celik', 'Affiliation': 'Department of Anesthesiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Morguet', 'Affiliation': 'Department of Cardiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Roehle', 'Affiliation': 'Institute of Biometry and Clinical Epidemiology, Coordinating Center for Clinical Studies, Berlin Institute of Health, Charité Universitätsmedizin Berlin, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Stein', 'Affiliation': 'Department of Anesthesiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany.'}]",Clinical pharmacology and therapeutics,['10.1002/cpt.2016'] 2997,32770840,Intraoperative MgSO 4 infusion protects oxygenation and lung mechanics in COPD patients during general anesthesia. A randomized clinical trial.,"BACKGROUND The purpose of this study was to examine the effects of an intraoperative MgSO 4 infusion on arterial oxygenation and lung mechanics in patients with moderate COPD undergoing cancer larynx surgery under general anesthesia (GA). Our primary outcome was arterial oxygenation determined by the PaO 2 and PaO 2 /FiO 2 . The secondary outcomes were lung mechanics (peak airway pressure, airway plateau pressure, dead space, lung compliance, airway resistance) and postoperative complications. METHODS In this randomized controlled double blinded trial, 40 patients with an ASA classifications II and/or III who were diagnosed with moderate COPD and who were scheduled for cancer larynx surgery under GA were randomly allocated into two equal groups, the target (Mg-group) and control group (C-group). In the Mg-group, 30 mg/kg of 10% MgSO 4 solution was administered intravenously for over 20 min as the loading dose, followed by the continuous infusion of 10 mg/kg/hr. In the C-group, the same loading and maintenance infusion rates were administered using 0.9% saline. RESULTS Unlike the C-group (baseline ""T0"" to post-infusion ""T1"" interval 294±97 vs 238±71 mmHg respectively, p=0.04 ±SD), the Mg-group exhibited preserved intraoperative PaO 2 (T0 to T1 interval 271±89 vs 257±53 mmHg respectively, p=0.54 ±SD) and PaO 2 /FiO 2 (C-group T0 to T1 interval 404±81 vs 349±84, p=0.04 and Mg- group 394±91 vs 379±95, p=0.61, respectively), and these effects were modest. Further, compared to the C-group, the Mg-group exhibited lower airway resistance, dead space, airway plateau pressure, and peak airway pressure, and higher dynamic compliance. The postoperative PaO 2 and PaO 2 /FiO 2 were higher in the Mg-group compared to the C-group. CONCLUSIONS Intraoperative infusion of MgSO 4 in patients with moderate COPD undergoing laryngectomy surgery under GA produces mild perioperative protective effects on both arterial oxygenation and lung mechanics.",2020,"The postoperative PaO 2 and PaO 2 /FiO 2 were higher in the Mg-group compared to the C-group. ","['COPD patients during general anesthesia', 'patients with moderate COPD undergoing laryngectomy surgery under', '40 patients with an ASA classifications II and/or III who were diagnosed with moderate COPD and who were scheduled for cancer larynx surgery under GA', 'patients with moderate COPD undergoing cancer larynx surgery under general anesthesia (GA']","['GA', 'intraoperative MgSO 4 infusion']","['lung mechanics (peak airway pressure, airway plateau pressure, dead space, lung compliance, airway resistance) and postoperative complications', 'arterial oxygenation', 'postoperative PaO 2 and PaO 2 /FiO 2', 'airway resistance, dead space, airway plateau pressure, and peak airway pressure, and higher dynamic compliance', 'intraoperative PaO 2', 'arterial oxygenation and lung mechanics']","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0023065', 'cui_str': 'Laryngectomy'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0007107', 'cui_str': 'Malignant tumor of larynx'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}]","[{'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0376706', 'cui_str': 'Mechanics'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}, {'cui': 'C3697386', 'cui_str': 'Airway plateau pressure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0024112', 'cui_str': 'Lung compliance'}, {'cui': 'C0001884', 'cui_str': 'Airway Resistance'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0429680', 'cui_str': 'Dynamic compliance'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}]",40.0,0.289299,"The postoperative PaO 2 and PaO 2 /FiO 2 were higher in the Mg-group compared to the C-group. ","[{'ForeName': 'Abeer', 'Initials': 'A', 'LastName': 'Ahmed', 'Affiliation': 'Department of Anesthesiology, Surgical ICU and Pain Management, Kasr Alainy Faculty of Medicine, Cairo University, Egypt.'}, {'ForeName': 'Ahmed H', 'Initials': 'AH', 'LastName': 'Sayed', 'Affiliation': 'Department of Anesthesiology, Surgical ICU and Pain Management, Kasr Alainy Faculty of Medicine, Cairo University, Egypt.'}, {'ForeName': 'Jehan', 'Initials': 'J', 'LastName': 'Elkholy', 'Affiliation': 'Department of Anesthesiology, Surgical ICU and Pain Management, Kasr Alainy Faculty of Medicine, Cairo University, Egypt.'}, {'ForeName': 'Sahar', 'Initials': 'S', 'LastName': 'Elshal', 'Affiliation': 'Department of Anesthesiology, Surgical ICU and Pain Management, Kasr Alainy Faculty of Medicine, Cairo University, Egypt.'}, {'ForeName': 'Abdelrahman', 'Initials': 'A', 'LastName': 'Badwy', 'Affiliation': 'Department of Otorhinolaryngology, Kasr Alainy Faculty of Medicine, Cairo University, Egypt.'}, {'ForeName': 'Bassant', 'Initials': 'B', 'LastName': 'Abdelhamid', 'Affiliation': 'Department of Anesthesiology, Surgical ICU and Pain Management, Kasr Alainy Faculty of Medicine, Cairo University, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Ollaek', 'Affiliation': 'Department of Anesthesiology, Surgical ICU and Pain Management, Kasr Alainy Faculty of Medicine, Cairo University, Egypt.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13684'] 2998,32768874,Intermittent Motivational Interviewing and Transdiagnostic CBT for Anxiety: A Randomized Controlled Trial.,"Recent meta-analytic findings suggest that Motivational Interviewing (MI) used as an adjunct to Cognitive Behavior Therapy (CBT) for anxiety disorders improves overall treatment outcomes (Marker & Norton, 2018). However, when used as a prelude to CBT, MI significantly increases the length of treatment and numerous studies note that the effectiveness of pre-treatment MI subsides over time. The current study adapted an already established 12-session transdiagnostic CBT protocol (tCBT, Norton, 2012) to include one hour of MI spread across four sessions of tCBT (sessions 1, 3, 8, and 10) at 15 minutes each, with the option of including additional MI if resistance arose in therapy. Thirty-six treatment seeking adults with principal anxiety disorder diagnosis were randomly assigned to receive intermittent MI and tCBT (iMI + tCBT) or tCBT and psychoeducation. Results indicated that the iMI + tCBT condition significantly outperformed the tCBT condition on several primary outcome variables. While no significant difference was found between the two groups on clinician rated scores of participant principal anxiety disorder, differences were found on a composite index of participants' self-report measures of symptom improvement, and on clinician rated scores of global psychiatric functioning. These effects were not moderated by baseline motivation or baseline ambivalence. The study also found that the iMI + tCBT condition showed significantly greater improvement to comorbid conditions and greater reduction in self-report depressive symptoms. The inclusion of MI did not impact participant drop out. This study provides further support for integrating MI and tCBT and highlights that even small doses of MI can improve treatment outcomes, without increasing length of usual therapy. Limitations and future research options are also discussed.",2020,"While no significant difference was found between the two groups on clinician rated scores of participant principal anxiety disorder, differences were found on a composite index of participants' self-report measures of symptom improvement, and on clinician rated scores of global psychiatric functioning.","['for Anxiety', 'Thirty-six treatment seeking adults with principal anxiety disorder diagnosis']","['Intermittent Motivational Interviewing and Transdiagnostic CBT', 'Cognitive Behavior Therapy (CBT', 'Motivational Interviewing (MI', 'intermittent MI and tCBT (iMI\u202f+\u202ftCBT) or tCBT and psychoeducation']","['self-report depressive symptoms', ""composite index of participants' self-report measures of symptom improvement, and on clinician rated scores of global psychiatric functioning""]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0340305', 'cui_str': 'Myocardial Infarction, Inferior Wall'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}]",36.0,0.0207886,"While no significant difference was found between the two groups on clinician rated scores of participant principal anxiety disorder, differences were found on a composite index of participants' self-report measures of symptom improvement, and on clinician rated scores of global psychiatric functioning.","[{'ForeName': 'Isabella', 'Initials': 'I', 'LastName': 'Marker', 'Affiliation': 'Monash University, Australia.'}, {'ForeName': 'Bronte E', 'Initials': 'BE', 'LastName': 'Corbett', 'Affiliation': 'Monash University, Australia.'}, {'ForeName': 'Sean P A', 'Initials': 'SPA', 'LastName': 'Drummond', 'Affiliation': 'Monash University, Australia.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Norton', 'Affiliation': 'Monash University, Australia. Electronic address: Peter.Norton@monash.edu.'}]",Journal of anxiety disorders,['10.1016/j.janxdis.2020.102276'] 2999,32768938,Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a.,"The present study investigates the differences in inflammatory agents alterations, immune function, and leukocyte differential count evaluation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome after the recommended Chinese medicine prescription of Yidu-toxicity blocking lung decoction. A total of 40 patients with yidu-toxicity blocking lung syndrome, diagnosed as severe pneumonia of SARS-COV-2 following the latest Chinese national recommendations for the diagnosis and treatment of pneumonia caused by SARS-COV-2 (the 5th edition), were recruited. They were randomly divided into the pure western medicine therapy group (PWM) and integrated into Chinese and Western medicine therapy group (ICW). The general strategies were given to both groups according to the national recommendations, and the ICW group was given Yidu-toxicity blocking lung decoction extraorally. A radioimmunoassay method was adopted to detect the content of IL-6, IL-8,IL-2R,TNF-α, procalcitonin (PCT) and high-sensitivity C-reactive protein (hs-CRP) in sera. Flow cytometry was used to determine the peripheral blood lymphocyte subsets (the levels of CD3+, CD4+, CD8+, and the ratios of CD4+/CD8+). The white blood cell counts (WBC#), neutrophils count(N#), and lymphocyte counts (L#) were measured using a fully automatic blood rheological instrument. The t-test or Rank Sum Test and Spearman analysis were conducted to evaluate the differences. The results showed that IL-6 (P = 0.013) and TNF-α (P = 0.035) levels in the PWM group were significantly higher than those in the ICW group after treatment. Infection related indicators such as WBC#, N#, L#, hs-CRP showed no differences. The analysis showed that there was no statistical difference in the values of CD4 and CD8 between the two groups. By the end of Day 29, all patients were discharged and the final cure rate for both group were 100 %. Taken together, we conclude that Yidu-toxicity blocking lung decoction could relieve inflammation of SARS-COV-2 patients with yidu-toxicity blocking lung syndrome by eliminating inflammatory agents. CM can serve as a complementary medication to western medicine, which should be highlighted in clinical settings.",2020,The results showed that IL-6 (P = 0.013) and TNF-α (P = 0.035) levels in the PWM group were significantly higher than those in the ICW group after treatment.,"['severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome', '40 patients with yidu-toxicity blocking lung syndrome, diagnosed as severe pneumonia of SARS-COV-2 following the latest Chinese national recommendations for the diagnosis and treatment of pneumonia caused by SARS-COV-2 (the 5th edition), were recruited', 'severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome after the recommended Chinese medicine prescription of Yidu-toxicity blocking lung decoction']","['ICW', 'pure western medicine therapy group (PWM) and integrated into Chinese and Western medicine therapy group (ICW', 'ICW group was given Yidu-toxicity blocking lung decoction extraorally', 'Yidu-toxicity blocking lung decoction']","['TNF-α', 'final cure rate', 'content of IL-6, IL-8,IL-2R,TNF-α, procalcitonin (PCT) and high-sensitivity C-reactive protein (hs-CRP', 'values of CD4 and CD8', 'white blood cell counts (WBC#), neutrophils count(N#), and lymphocyte counts (L', 'IL-6', 'peripheral blood lymphocyte subsets (the levels of CD3+, CD4+, CD8+, and the ratios of CD4+/CD8']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0205439', 'cui_str': 'Fifth'}, {'cui': 'C0441792', 'cui_str': 'Editions'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1527374', 'cui_str': 'Group Therapy'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}]","[{'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0072027', 'cui_str': 'Procalcitonin'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0200635', 'cui_str': 'Lymphocyte count'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0079720', 'cui_str': 'Lymphocyte Subpopulations'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0108779', 'cui_str': 'Lymphocyte antigen CD3'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",40.0,0.0200254,The results showed that IL-6 (P = 0.013) and TNF-α (P = 0.035) levels in the PWM group were significantly higher than those in the ICW group after treatment.,"[{'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'Department of Chinese Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. Electronic address: zhaojie0506888@126.com.'}, {'ForeName': 'Xiaodong', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.'}, {'ForeName': 'Chenghua', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Chinese Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.'}, {'ForeName': 'Shuai', 'Initials': 'S', 'LastName': 'Song', 'Affiliation': 'Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.'}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Cao', 'Affiliation': 'Department of Orthopaedic, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.'}, {'ForeName': 'Taohua', 'Initials': 'T', 'LastName': 'Wei', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230022, China.'}, {'ForeName': 'Qiaoxue', 'Initials': 'Q', 'LastName': 'Ji', 'Affiliation': 'Department of Chinese Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.'}, {'ForeName': 'Wanqun', 'Initials': 'W', 'LastName': 'Zheng', 'Affiliation': 'Department of Chinese Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.'}, {'ForeName': 'Jiali', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Chinese Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.'}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'Department of Chinese Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Institute for Medical Virology, Goethe University Frankfurt am Main, Frankfurt 60596, Germany.'}]",Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,['10.1016/j.biopha.2020.110436'] 3000,32768967,Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson's disease.,"Sleep disorders are a widespread condition in patients with Parkinson's disease (PD), which has been linked to a deregulation of the circadian cycle and therefore of the clock genes. The aim of this study was to evaluate the effect of melatonin (MEL) on the PER1 and BMAL1 clock genes in patients with PD. A double-blind, cross-over, placebo-controlled randomized clinical trial pilot study was conducted in 26 patients with stage 1-3 PD according to the Hoehn & Yahr scale, who received either 25 mg of MEL or a placebo at noon and 30 min before bedtime for three months. The relative expression of the PER1 and BMAL1 genes was measured, as well as the presence of daytime, nocturnal, and global sleepiness, and the progression of PD. The levels of the PER1 and BMAL1 genes at baseline were 0.9 (0.1-3) vs. 0.56 (0.1-2.5), respectively; while after the intervention with MEL or placebo the BMAL1 levels increased to 2.5 (0-3.70) vs. 2.2 (0.10-3.30), respectively (d = 0.387). Fifty percent (50 %) of patients had daytime sleepiness and sixty-five percent (65 %) had abnormal nighttime sleepiness, yet neither group showed changes after the intervention. Patients with PD exhibited an alteration in the levels of the clock genes: MEL increased the levels of BMAL1, but the PER1 levels remained unchanged.",2020,"Patients with PD exhibited an alteration in the levels of the clock genes: MEL increased the levels of BMAL1, but the PER1 levels remained unchanged.","[""patients with Parkinson's disease"", ""patients with Parkinson's disease (PD"", '26 patients with stage 1-3 PD according to the Hoehn & Yahr scale, who received either 25 mg of', 'patients with PD']","['melatonin (MEL', 'melatonin', 'MEL or a placebo', 'placebo']","['presence of daytime, nocturnal, and global sleepiness, and the progression of PD', 'daytime sleepiness', 'PER1 and BMAL1 clock genes', 'PER1 levels', 'abnormal nighttime sleepiness', 'levels of BMAL1', 'BMAL1 levels', 'levels of the PER1 and BMAL1 genes', 'relative expression of the PER1 and BMAL1 genes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]","[{'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0541854', 'cui_str': 'Daytime sleepiness'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}]",26.0,0.258246,"Patients with PD exhibited an alteration in the levels of the clock genes: MEL increased the levels of BMAL1, but the PER1 levels remained unchanged.","[{'ForeName': 'D L', 'Initials': 'DL', 'LastName': 'Delgado-Lara', 'Affiliation': 'Department of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, Mexico.'}, {'ForeName': 'G V', 'Initials': 'GV', 'LastName': 'González-Enríquez', 'Affiliation': 'Department of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, Mexico.'}, {'ForeName': 'B M', 'Initials': 'BM', 'LastName': 'Torres-Mendoza', 'Affiliation': 'Department of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, Mexico; Division of Neurosciences, Western Biomedical Research Center, Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'González-Usigli', 'Affiliation': 'Department of Neurology, Sub-Specialty Medical Unit, Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Cárdenas-Bedoya', 'Affiliation': 'Department of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, Mexico.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Macías-Islas', 'Affiliation': 'Department of Neurosciences, University Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, Mexico.'}, {'ForeName': 'A Celis', 'Initials': 'AC', 'LastName': 'de la Rosa', 'Affiliation': 'Department of Public Health, University Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, Mexico.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Jiménez-Delgado', 'Affiliation': 'Department of Chemistry, University Center of Exact Sciences and Engineering, University of Guadalajara, Guadalajara, Jalisco, Mexico.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Pacheco-Moisés', 'Affiliation': 'Department of Chemistry, University Center of Exact Sciences and Engineering, University of Guadalajara, Guadalajara, Jalisco, Mexico.'}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Cruz-Serrano', 'Affiliation': 'Kurago Biotek, Guadalajara, Jalisco, Mexico.'}, {'ForeName': 'G G', 'Initials': 'GG', 'LastName': 'Ortiz', 'Affiliation': 'Department of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, Mexico; Department of Neurology, Sub-Specialty Medical Unit, Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico. Electronic address: genarogabriel@yahoo.com.'}]",Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,['10.1016/j.biopha.2020.110485'] 3001,32768992,Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial.,"INTRODUCTION AND AIMS Previous studies suggest cannabinoid agonist treatment is effective in reducing cannabis use in dependent treatment seekers, however few studies have reported on post-treatment outcomes. We examine cannabis use outcomes 12 weeks after cessation of treatment from a randomised placebo-controlled trial of nabiximols for the treatment of cannabis dependence. METHOD 128 participants received either nabiximols (n = 61) or placebo (n = 67) for 12 weeks, in combination with psychosocial interventions. Self-reported number of days of cannabis use in the previous 28 days was measured at baseline, 4, 8, and 12 weeks (end of treatment) and again at 24 weeks (3 months after treatment ceased). Urinalysis was used to confirm self-report data at Week 24 interview. RESULTS A factorial mixed-effects model for repeated measures regression revealed that the nabiximols group used cannabis on 6.8 fewer days in the previous 28 days at week 12 (end of treatment) than the placebo group (p = 0.002, CI: 2.1,11.4), and 6.7 fewer days in the previous 28 days at the week-24 follow-up than the placebo group (p = 0.006, CI: 1.4,12.1). A significantly higher proportion of the nabiximols group (14/61; 23 %) than the placebo group (6/67; 9%) reported abstinence from cannabis in the previous 28 days at the week-24 research interview OR=3.0, CI: 1.1, 9.1; p=0.035, NNT=8, CI: 4, 71). DISCUSSIONS AND CONCLUSIONS The benefits of treatment incorporating nabiximols with psychosocial interventions in reducing cannabis use appears to persist for up to 3 months after the cessation of treatment. A stepped care model of treatment is proposed. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry (ACTRN12616000103460) https://www.anzctr.org.au.",2020,"A significantly higher proportion of the nabiximols group (14/61; 23 %) than the placebo group (6/67; 9%) reported abstinence from cannabis in the previous 28 days at the week-24 research interview OR=3.0, CI: 1.1, 9.1; p=0.035, NNT=8, CI: 4, 71). ","['patients 3 months after ceasing nabiximols for the treatment of cannabis dependence', '128 participants received either nabiximols (n = 61) or']","['nabiximols with psychosocial interventions', 'placebo']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C2347556', 'cui_str': 'nabiximols'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006870', 'cui_str': 'Cannabis dependence'}]","[{'cui': 'C2347556', 'cui_str': 'nabiximols'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],128.0,0.260502,"A significantly higher proportion of the nabiximols group (14/61; 23 %) than the placebo group (6/67; 9%) reported abstinence from cannabis in the previous 28 days at the week-24 research interview OR=3.0, CI: 1.1, 9.1; p=0.035, NNT=8, CI: 4, 71). ","[{'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Lintzeris', 'Affiliation': 'Drug and Alcohol Services, South East Sydney Local Health District, NSW, Australia; Division Addiction Medicine, Faculty Medicine and Health, University of Sydney, NSW, Australia; NSW Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Australia. Electronic address: Nicholas.lintzeris@health.nsw.gov.au.'}, {'ForeName': 'Llewellyn', 'Initials': 'L', 'LastName': 'Mills', 'Affiliation': 'Drug and Alcohol Services, South East Sydney Local Health District, NSW, Australia; Division Addiction Medicine, Faculty Medicine and Health, University of Sydney, NSW, Australia; NSW Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Australia.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Dunlop', 'Affiliation': 'NSW Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Australia; Drug and Alcohol Services, Hunter New England Local Health District, NSW, Australia; Priority Research Centre for Brain and Mental Health, School of Medicine and Public Health, University of Newcastle, NSW, Australia.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Copeland', 'Affiliation': 'University of New South Wales, NSW, Australia.'}, {'ForeName': 'Iain', 'Initials': 'I', 'LastName': 'Mcgregor', 'Affiliation': 'Lambert Initiative Cannabinoid Therapeutics, University of Sydney, NSW, Australia.'}, {'ForeName': 'Raimondo', 'Initials': 'R', 'LastName': 'Bruno', 'Affiliation': 'University of Tasmania, TAS, Australia.'}, {'ForeName': 'Adrienne', 'Initials': 'A', 'LastName': 'Kirby', 'Affiliation': 'National Health and Medical Research Council, Clinical Trials Centre, Faculty Medicine and Public Health, University of Sydney, NSW, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Montebello', 'Affiliation': 'Drug and Alcohol Services, South East Sydney Local Health District, NSW, Australia; Division Addiction Medicine, Faculty Medicine and Health, University of Sydney, NSW, Australia; NSW Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Australia; University of New South Wales, NSW, Australia.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Hall', 'Affiliation': 'NSW Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Australia; Drug and Alcohol Services, Hunter New England Local Health District, NSW, Australia.'}, {'ForeName': 'Meryem', 'Initials': 'M', 'LastName': 'Jefferies', 'Affiliation': 'NSW Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Australia; Drug Health, Western Sydney Local Health District, NSW, Australia.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Kevin', 'Affiliation': 'Lambert Initiative Cannabinoid Therapeutics, University of Sydney, NSW, Australia.'}, {'ForeName': 'Anjali', 'Initials': 'A', 'LastName': 'Bhardwaj', 'Affiliation': 'Drug and Alcohol Services, South East Sydney Local Health District, NSW, Australia; Division Addiction Medicine, Faculty Medicine and Health, University of Sydney, NSW, Australia; National Health and Medical Research Council, Clinical Trials Centre, Faculty Medicine and Public Health, University of Sydney, NSW, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108220'] 3002,32769457,Expanding the Traditional History and Physical Examination to Address Chronic Diseases and Social Needs: A Multi-Site Randomized Control Trial of Four Medical Schools.,"PURPOSE This study gathers validity evidence of an expanded History and Physical (H&P 360) examination to address chronic diseases through incorporation of biopsychosocial elements that are lacking in traditional H&P assessments via a multi-site randomized controlled trial among medical students. METHOD Third- and fourth-year medical students (n = 159) at 4 schools participated in an Objective Structured Clinical Examination designed with two cases for chronic disease. Students were randomized into the treatment group, which involved brief written instructions on how to use the H&P 360 followed by a standardized patient (SP) interaction, or the control group, which utilized the traditional H&P in an SP interaction without additional instructions. Validity evidence was gathered for content (alignment with an empirically-derived expanded history list), response process (feedback from raters and learners on the process), internal structure (reliability and item-level psychometrics), relations to other variables (comparison between treatment and control groups), and consequences (survey results from learners on experience). RESULTS H&P 360 items were blueprinted by faculty experts. SP observation checklist grading was consistent, and post-assessment debrief confirmed favorable educational experience among learners. The reliability of the H&P 360 was .76. Overall mean scores on the H&P 360 content (mean = 15.96, standard deviation [SD] = 3.66) were significantly higher compared to the traditional H&P (mean = 10.99, SD = 2.69), Cohen's d = 1.17, P < .001. CONCLUSIONS Medical students using the H&P 360 collected significantly more biopsychosocial information compared to students using the traditional H&P, providing empirical support for teaching and assessing biopsychosocial information. The assessment demonstrated strong validity evidence supporting the use of the H&P 360 assessment in medical schools.",2020,"CONCLUSIONS Medical students using the H&P 360 collected significantly more biopsychosocial information compared to students using the traditional H&P, providing empirical support for teaching and assessing biopsychosocial information.","['medical students', 'Third- and fourth-year medical students (n = 159) at 4 schools participated in an Objective Structured Clinical Examination designed with two cases for chronic disease']","['expanded History and Physical (H&P 360) examination', 'H&P 360 followed by a standardized patient (SP) interaction, or the control group, which utilized the traditional H&P in an SP interaction without additional instructions']",['biopsychosocial information'],"[{'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0205438', 'cui_str': 'Fourth'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}]","[{'cui': 'C0205229', 'cui_str': 'Expanding'}, {'cui': 'C0150618', 'cui_str': 'History AND physical examination'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}]",[],360.0,0.0288305,"CONCLUSIONS Medical students using the H&P 360 collected significantly more biopsychosocial information compared to students using the traditional H&P, providing empirical support for teaching and assessing biopsychosocial information.","[{'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Kirley', 'Affiliation': 'K. Kirley is director of chronic disease prevention, Improving Health Outcomes, American Medical Association, Chicago, Illinois. R. Hayer is senior program manager, Improving Health Outcomes, American Medical Association, Chicago, Illinois. T. Khan is senior economist, Improving Health Outcomes, American Medical Association, Chicago, Illinois. E. Johnson is associate professor, Family & Community Medicine, and director, interprofessional education, Education Resources, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota. E.S. Sanchez is associate program director, Internal Medicine Residency, and associate professor of internal medicine, University of California Davis, Sacramento, California. L. Kosowicz is associate professor and director, Clinical Skills Assessment Program, Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut. V. Terry is clinical assistant professor, Department of Psychiatry, University of Texas Rio Grande Valley School of Medicine, Harlingen, Texas. D. Henderson is associate professor and chair, Department of Family Medicine, and associate dean for multicultural and community affairs, University of Connecticut School of Medicine, Farmington, Connecticut. C. Krebsbach is assistant director, standardized patient program, Department of Healthcare Simulation, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois. Y.S. Park is associate professor and associate head, Department of Medical Education, and director of research, educational affairs, University of Illinois College of Medicine at Chicago, Chicago, Illinois. M. Dekhtyar is research associate, Department of Medical Education, University of Illinois College of Medicine at Chicago, Chicago, Illinois. B.C. Williams is director, Global Health and Disparities Path of Excellence, and professor of internal medicine, University of Michigan Medical School, Ann Arbor, Michigan.'}, {'ForeName': 'Rupinder', 'Initials': 'R', 'LastName': 'Hayer', 'Affiliation': ''}, {'ForeName': 'Tamkeen', 'Initials': 'T', 'LastName': 'Khan', 'Affiliation': ''}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Johnson', 'Affiliation': ''}, {'ForeName': 'Erin Stephany', 'Initials': 'ES', 'LastName': 'Sanchez', 'Affiliation': ''}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Kosowicz', 'Affiliation': ''}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Terry', 'Affiliation': ''}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Henderson', 'Affiliation': ''}, {'ForeName': 'Cory', 'Initials': 'C', 'LastName': 'Krebsbach', 'Affiliation': ''}, {'ForeName': 'Yoon Soo', 'Initials': 'YS', 'LastName': 'Park', 'Affiliation': ''}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Dekhtyar', 'Affiliation': ''}, {'ForeName': 'Brent C', 'Initials': 'BC', 'LastName': 'Williams', 'Affiliation': ''}]",Academic medicine : journal of the Association of American Medical Colleges,['10.1097/ACM.0000000000003640'] 3003,32769505,"Effects of adding a combined femoral and sciatic nerve block with levobupivacaine and clonidine to general anaesthesia in femoropopliteal bypass surgery: A randomised, double-blind, controlled trial.","BACKGROUND Adding a regional block to general anaesthesia can prevent postoperative pain and improve peripheral circulation. OBJECTIVE To seek improved postoperative analgesia and care due to a long-acting combined femoral and sciatic nerve block in patients undergoing femoropopliteal bypass surgery. DESIGN A randomised, double-blind, controlled trial. SETTING Vascular surgery unit of a French university hospital. PATIENTS Forty-four adults scheduled for bypass surgery under general anaesthesia. INTERVENTION Patients were allocated to receive either an active nerve block with 20 ml of 0.375% levobupivacaine and clonidine 0.5 μg kg, or a simulated (sham) block only, but with local anaesthesia of the skin, before general anaesthesia. General anaesthesia was standardised with propofol, then sevoflurane and sufentanil adjusted according to clinical need. Postoperative analgesia was standardised with paracetamol 1 g every 6 h, and intravenous morphine, initially titrated in the postanaesthesia care unit and then patient-controlled. Oral analgesics were repeated up to day 3. MAIN OUTCOME MEASURES The primary outcome was morphine consumption during the first 24 postoperative hours. In a subgroup of postoperative patients distal tissue oxygen saturation was recorded at the lateral side of the blocked calf. RESULTS Patients in the active group received less intra-operative sufentanil (median dose 25 vs. 41 μg), needed less morphine during the first 24 h (15 vs. 27 mg) and 72 (20 vs. 35 mg) postoperative hours, than in the control group. They also had less pain on movement, but pain at rest, the tissue oxygen saturation and other rehabilitation outcomes were unaffected by the treatment. Tolerance outcomes were also similar between groups. CONCLUSION Combining the two regional blocks improves the quality of postoperative care in this frail population, probably by reducing the amount of peri-operative opioid. TRIAL REGISTRATION ClinicalTrials.gov (ref. NCT01785693).",2020,"They also had less pain on movement, but pain at rest, the tissue oxygen saturation and other rehabilitation outcomes were unaffected by the treatment.","['patients undergoing femoropopliteal bypass surgery', 'Forty-four adults scheduled for bypass surgery under general anaesthesia', 'femoropopliteal bypass surgery', 'Vascular surgery unit of a French university hospital']","['sevoflurane and sufentanil', 'active nerve block with 20\u200aml of 0.375% levobupivacaine and clonidine 0.5\u200aμg\u200akg, or a simulated (sham) block only, but with local anaesthesia of the skin, before general anaesthesia', 'paracetamol', 'long-acting combined femoral and sciatic nerve block', 'levobupivacaine and clonidine', 'propofol', 'morphine']","['Postoperative analgesia', 'pain on movement, but pain at rest, the tissue oxygen saturation and other rehabilitation outcomes', 'postoperative patients distal tissue oxygen saturation', 'quality of postoperative care', 'morphine consumption', 'intra-operative sufentanil', 'Tolerance outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0190932', 'cui_str': 'Femoral-popliteal artery bypass graft'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C1536078', 'cui_str': 'Bypass surgery'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0042381', 'cui_str': 'Vascular surgery procedure'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0376246', 'cui_str': 'French language'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}]","[{'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0027741', 'cui_str': 'Nerve block'}, {'cui': 'C4517455', 'cui_str': '0.375'}, {'cui': 'C0873118', 'cui_str': 'Levobupivacaine'}, {'cui': 'C0009014', 'cui_str': 'Clonidine'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0394735', 'cui_str': 'Injection of anesthetic agent into sciatic nerve'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]","[{'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0234253', 'cui_str': 'Rest pain'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0600378', 'cui_str': 'Rehabilitation Outcome'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0032786', 'cui_str': 'Postoperative care'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",44.0,0.534089,"They also had less pain on movement, but pain at rest, the tissue oxygen saturation and other rehabilitation outcomes were unaffected by the treatment.","[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Charvin', 'Affiliation': 'From the CHU Clermont-Ferrand, Médecine Péri-Opératoire (MC, FL, PJ, A-LC, EF); Université Clermont-Auvergne (EF); CHU Clermont-Ferrand, Unité de Biostatistiques, Direction de la Recherche Clinique et des Innovations (BP); CHU Clermont-Ferrand, Centre de Pharmacologie Clinique (CD); and INSERM, CIC1405 & UMR1107, Clermont-Ferrand, France (CD).'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Longeras', 'Affiliation': ''}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Jouve', 'Affiliation': ''}, {'ForeName': 'Anne-Laure', 'Initials': 'AL', 'LastName': 'Cherprenet', 'Affiliation': ''}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Futier', 'Affiliation': ''}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Pereira', 'Affiliation': ''}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Dualé', 'Affiliation': ''}]",European journal of anaesthesiology,['10.1097/EJA.0000000000001263'] 3004,32590402,Prehospital Administration of Unfractionated Heparin in ST-Segment Elevation Myocardial Infarction Is Associated With Improved Long-Term Survival.,"OBJECTIVE Administration of unfractionated heparin to STEMI patients by the ambulance service is an established practice in Scotland, but the efficacy is unknown. We studied the effects of unfractionated heparin in STEMI patients treated by primary percutaneous coronary intervention, on infarct artery patency and mortality. METHODS AND RESULTS Consecutive patients (n = 1000) admitted to Ninewells Hospital, Dundee, from 2010 to 2014 for primary percutaneous coronary intervention were allocated to 2 groups: 437 (44%) prehospital heparin (PHH) administered by paramedics, and 563 (56%) in-hospital heparin. A trained medical student assessed coronary flow at presentation and collected the data. Mortality status was ascertained at 30 days and 5 years. Cox proportional hazards regression models were generated. The patient groups were similar, although PHH had shorter symptom onset-treatment time (187 vs. 251 minutes, P < 0.001) and less cardiogenic shock (3.9% vs. 8.0%, P = 0.008). Initial coronary flow was not different between the groups. Thirty day mortality in PHH was 2.5% versus 8.3%, P < 0.001. Independent predictors of 30-day mortality were age (odds ratio 1.07, 95% CI 1.04-1.09), cardiogenic shock (5.97, 3.33-10.69), radial access (0.53, 0.28-0.98), and PHH (0.33, 0.17-0.66). Five-year mortality in PHH was 13.0% versus 21.6%, P < 0.001. Significant predictors of long-term mortality were age (1.07, 1.06-1.09), cardiogenic shock (3.40, 2.23-5.17), and PHH (0.68, 0.49-0.96). CONCLUSIONS PHH was associated with reduced short- and long-term mortality after adjusting for important potential confounders.",2020,"Thirty day mortality in PHH was 2.5% versus 8.3%, P < 0.001.","['Consecutive patients (n = 1000) admitted to Ninewells Hospital, Dundee, from 2010 to 2014 for primary percutaneous coronary intervention were allocated to 2 groups: 437 (44', 'STEMI patients treated by primary percutaneous coronary intervention, on infarct artery patency and mortality']","['prehospital heparin (PHH', 'unfractionated heparin', 'Unfractionated Heparin']","['Mortality status', 'Thirty day mortality in PHH', 'long-term mortality', 'shorter symptom onset-treatment time', 'Initial coronary flow', 'short- and long-term mortality', 'radial access', '30-day mortality', 'cardiogenic shock']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1536220', 'cui_str': 'ST Segment Elevation Myocardial Infarction'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0021308', 'cui_str': 'Infarct'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]","[{'cui': 'C0019134', 'cui_str': 'heparin'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0036980', 'cui_str': 'Cardiogenic shock'}]",1000.0,0.058961,"Thirty day mortality in PHH was 2.5% versus 8.3%, P < 0.001.","[{'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'McGinley', 'Affiliation': 'University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom.'}, {'ForeName': 'Ify R', 'Initials': 'IR', 'LastName': 'Mordi', 'Affiliation': 'University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Kell', 'Affiliation': 'Scottish Ambulance Service, Edinburgh, United Kingdom.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Currie', 'Affiliation': 'Department of Cardiology, Ninewells Hospital and Medical School, Dundee, United Kingdom.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Hutcheon', 'Affiliation': 'Department of Cardiology, Ninewells Hospital and Medical School, Dundee, United Kingdom.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Koch', 'Affiliation': 'Department of Cardiology, Ninewells Hospital and Medical School, Dundee, United Kingdom.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Martin', 'Affiliation': 'Department of Cardiology, Ninewells Hospital and Medical School, Dundee, United Kingdom.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Irving', 'Affiliation': 'Department of Cardiology, Ninewells Hospital and Medical School, Dundee, United Kingdom.'}]",Journal of cardiovascular pharmacology,['10.1097/FJC.0000000000000865'] 3005,32769065,The effects of foot reflexology on agitation and extubation time in male patients following coronary artery bypass surgery: A randomized controlled clinical trial.,"BACKGROUND AND PURPOSE This study examined the effects of foot reflexology on agitation and extubation time of male patients following coronary artery bypass graft surgery. MATERIALS AND METHODS In this randomized three-arm controlled clinical trial, participants (n = 120) were randomly assigned to the intervention, placebo, or control groups. The intervention group received foot reflexology massage for 15 min. Agitation was assessed using the Richmond Agitation- Sedation Scale before the intervention (Time 1) and immediately (Time 2) and 10 min after the intervention (Time 3). Extubation time was measured as the time from gaining full consciousness to endotracheal extubation. RESULTS Agitation reduced in all groups from Time 1 to Time 3 (p < 0.05); however, the intervention group showed a significantly higher reduction at Time 2 (p < 0.001) and Time 3 (p < 0.001). Also, extubation time was significantly shorter in the intervention group (p < 0.01). CONCLUSION Foot reflexology may be introduced as a nursing intervention to facilitate the weaning process in the cardiac ICUs.",2020,"RESULTS Agitation reduced in all groups from Time 1 to Time 3 (p < 0.05); however, the intervention group showed a significantly higher reduction at Time 2 (p < 0.001) and Time 3 (p < 0.001).","['male patients following coronary artery bypass surgery', 'male patients following coronary artery bypass graft surgery', 'participants (n\xa0=\xa0120']","['foot reflexology', 'foot reflexology massage', 'placebo']","['agitation and extubation time', 'Extubation time', 'extubation time', 'Richmond Agitation- Sedation Scale', 'Agitation']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C4319550', 'cui_str': '120'}]","[{'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0034945', 'cui_str': 'Reflexology'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C4720839', 'cui_str': 'Richmond agitation-sedation scale'}]",120.0,0.0559303,"RESULTS Agitation reduced in all groups from Time 1 to Time 3 (p < 0.05); however, the intervention group showed a significantly higher reduction at Time 2 (p < 0.001) and Time 3 (p < 0.001).","[{'ForeName': 'Atefeh', 'Initials': 'A', 'LastName': 'Allahbakhhsian', 'Affiliation': 'Faculty of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Gholizadeh', 'Affiliation': 'IMPACCT, Faculty of Health, University of Technology Sydney, Sydney, Australia. Electronic address: Leila.gholizadeh@uts.edu.au.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Allahbakhshian', 'Affiliation': 'Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences. Tehran, Iran.'}, {'ForeName': 'Parvin', 'Initials': 'P', 'LastName': 'Sarbakhsh', 'Affiliation': 'Faculty of Public Health, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Yasser', 'Initials': 'Y', 'LastName': 'Abbaszadeh', 'Affiliation': 'Faculty of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: abbaszadeh_yaser@yahoo.com.'}]",Complementary therapies in clinical practice,['10.1016/j.ctcp.2020.101201'] 3006,32769165,Correction: Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study .,,2020,,['advanced cervical cancer'],"['anti-angiogenesis therapy', 'chemotherapy with bevacizumab']",[],"[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}]",[],,0.0253617,,[],International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,['10.1136/ijgc-2019-000869corr1'] 3007,32769437,Acclimatization to Hearing Aids by Older Adults.,"OBJECTIVES Audiologists and hearing aid users (HAUs) generally agree that an adaptation period is needed following the first hearing aid (HA) experience. The main purpose of this study is to investigate the acclimatization of older adult listeners with hearing loss to HAs using listening effort and behavioral measures. DESIGN Participants (N=47) were older adults with mild to moderately severe sensorineural hearing loss. Thirty-two participants were new HAUs and 15 participants were experienced HAUs. New HAUs were randomly assigned to one of two groups: noise reduction algorithms and directional microphones activated or noise reduction algorithms and directional microphones deactivated. Speech recognition in noise and listening effort were assessed on 8 different occasions during a 10-month period. A dual-task paradigm was used to measure the listening effort deployed to recognize speech in noise. The primary task consisted of the Hearing in Noise Test which also served as the behavioral speech in noise measure. The secondary task was a tactile pattern-recognition task in which participants had to identify a sequence of three tactile stimuli that varied in duration. The two listening effort outcomes were the proportional dual-task cost and the response time on the secondary task. Cognitive abilities, including working memory and speed of processing, were evaluated using the Reading Span Test and the Digit Symbol Substitution Test, respectively. RESULTS Results show a significant time*group interaction. Both groups of new HAUs showed improvement over time in speech in noise performances (change of ~2 dB signal to noise ratio) and the experienced HAUs did not improve over time. The acclimatization effect was observed over a period of 4 weeks. There was no significant change over time on both measures of listening effort. There was no association between amplitude of acclimatization and the cognitive abilities measured. CONCLUSION An acclimatization effect following HA experience was observed. Specifically, the new HAUs displayed a clinically significant change of 2 dB in signal to noise ratio on the Hearing in Noise Test 4 weeks following their initial fitting. The acclimatization effect is not correlated to cognitive abilities.",2020,Both groups of new HAUs showed improvement over time in speech in noise performances (change of ~2 dB signal to noise ratio) and the experienced HAUs did not improve over time.,"['Participants (N=47) were older adults with mild to moderately severe sensorineural hearing loss', 'Thirty-two participants were new HAUs and 15 participants were experienced HAUs', 'Older Adults', 'older adult listeners with hearing loss']","['noise reduction algorithms and directional microphones activated or noise reduction algorithms and directional microphones deactivated', 'Hearing in Noise Test which also served as the behavioral speech in noise measure']","['proportional dual-task cost and the response time on the secondary task', 'time in speech in noise performances', 'acclimatization effect', 'tactile pattern-recognition task', 'Cognitive abilities, including working memory and speed of processing', 'amplitude of acclimatization and the cognitive abilities measured', 'listening effort']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018784', 'cui_str': 'Sensorineural hearing loss'}, {'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0919808', 'cui_str': 'Hearing aid user'}]","[{'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1709026', 'cui_str': 'Microphone'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]","[{'cui': 'C0205351', 'cui_str': 'Proportional'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C1449635', 'cui_str': 'Pattern Recognition, Tactile'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0004309', 'cui_str': 'Auditory Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}]",32.0,0.0165192,Both groups of new HAUs showed improvement over time in speech in noise performances (change of ~2 dB signal to noise ratio) and the experienced HAUs did not improve over time.,"[{'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Wright', 'Affiliation': ""Centre de recherche de l'Institut universitaire de gériatrie de Montréal, Quebec, Canada.""}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Gagné', 'Affiliation': ""Centre de recherche de l'Institut universitaire de gériatrie de Montréal, Quebec, Canada.""}]",Ear and hearing,['10.1097/AUD.0000000000000913'] 3008,31415206,Causal Language in Health Warning Labels and US Adults' Perception: A Randomized Experiment.,"Objectives. To examine US adults' reactions to health warnings with strong versus weak causal language. Methods. In 2018, we randomly assigned 1360 US adults to answer an online survey about health warnings for cigarettes, sugar-sweetened beverages, or alcohol. Participants rated 4 warning statements using different causal language variants (""causes,"" ""contributes to,"" ""can contribute to,"" and ""may contribute to"") displayed in random arrangement. Results. Most participants (76.3%) selected the warning that used ""causes"" as the 1 that most discouraged them from wanting to use the product. ""Causes"" was also selected most often (39.0% of participants) as the warning that participants most supported implementing. By contrast, most (66.1%) chose ""may contribute to"" as the warning that least discouraged them from wanting to use the product. We found few demographic differences in these patterns. Conclusions. Warnings with stronger causal language are perceived to be effective and are supported by the public.",2019,"Most participants (76.3%) selected the warning that used ""causes"" as the 1 that most discouraged them from wanting to use the product.","[""Health Warning Labels and US Adults' Perception""]","['online survey about health warnings for cigarettes, sugar-sweetened beverages, or alcohol']",[],"[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]","[{'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0242209', 'cui_str': 'Sugars'}, {'cui': 'C0005329', 'cui_str': 'Beverages'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}]",[],1360.0,0.0260938,"Most participants (76.3%) selected the warning that used ""causes"" as the 1 that most discouraged them from wanting to use the product.","[{'ForeName': 'Marissa G', 'Initials': 'MG', 'LastName': 'Hall', 'Affiliation': 'Marissa G. Hall, Anna H. Grummon, and Madeline R. Kameny are with the Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill. Olivia M. Maynard is with the Medical Research Council Integrative Epidemiology Unit, School of Psychological Science, University of Bristol, Bristol, UK. Desmond Jenson is with the Public Health Law Center, Mitchell Hamline School of Law, St. Paul, MN. Barry M. Popkin is with the Department of Nutrition, Gillings School of Global Public Health, University of North Carolina, Chapel Hill.'}, {'ForeName': 'Anna H', 'Initials': 'AH', 'LastName': 'Grummon', 'Affiliation': 'Marissa G. Hall, Anna H. Grummon, and Madeline R. Kameny are with the Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill. Olivia M. Maynard is with the Medical Research Council Integrative Epidemiology Unit, School of Psychological Science, University of Bristol, Bristol, UK. Desmond Jenson is with the Public Health Law Center, Mitchell Hamline School of Law, St. Paul, MN. Barry M. Popkin is with the Department of Nutrition, Gillings School of Global Public Health, University of North Carolina, Chapel Hill.'}, {'ForeName': 'Olivia M', 'Initials': 'OM', 'LastName': 'Maynard', 'Affiliation': 'Marissa G. Hall, Anna H. Grummon, and Madeline R. Kameny are with the Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill. Olivia M. Maynard is with the Medical Research Council Integrative Epidemiology Unit, School of Psychological Science, University of Bristol, Bristol, UK. Desmond Jenson is with the Public Health Law Center, Mitchell Hamline School of Law, St. Paul, MN. Barry M. Popkin is with the Department of Nutrition, Gillings School of Global Public Health, University of North Carolina, Chapel Hill.'}, {'ForeName': 'Madeline R', 'Initials': 'MR', 'LastName': 'Kameny', 'Affiliation': 'Marissa G. Hall, Anna H. Grummon, and Madeline R. Kameny are with the Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill. Olivia M. Maynard is with the Medical Research Council Integrative Epidemiology Unit, School of Psychological Science, University of Bristol, Bristol, UK. Desmond Jenson is with the Public Health Law Center, Mitchell Hamline School of Law, St. Paul, MN. Barry M. Popkin is with the Department of Nutrition, Gillings School of Global Public Health, University of North Carolina, Chapel Hill.'}, {'ForeName': 'Desmond', 'Initials': 'D', 'LastName': 'Jenson', 'Affiliation': 'Marissa G. Hall, Anna H. Grummon, and Madeline R. Kameny are with the Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill. Olivia M. Maynard is with the Medical Research Council Integrative Epidemiology Unit, School of Psychological Science, University of Bristol, Bristol, UK. Desmond Jenson is with the Public Health Law Center, Mitchell Hamline School of Law, St. Paul, MN. Barry M. Popkin is with the Department of Nutrition, Gillings School of Global Public Health, University of North Carolina, Chapel Hill.'}, {'ForeName': 'Barry M', 'Initials': 'BM', 'LastName': 'Popkin', 'Affiliation': 'Marissa G. Hall, Anna H. Grummon, and Madeline R. Kameny are with the Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill. Olivia M. Maynard is with the Medical Research Council Integrative Epidemiology Unit, School of Psychological Science, University of Bristol, Bristol, UK. Desmond Jenson is with the Public Health Law Center, Mitchell Hamline School of Law, St. Paul, MN. Barry M. Popkin is with the Department of Nutrition, Gillings School of Global Public Health, University of North Carolina, Chapel Hill.'}]",American journal of public health,['10.2105/AJPH.2019.305222'] 3009,30942383,Corrigendum: Analysis of cluster-randomized test-negative designs: cluster-level methods.,,2019,,[],[],[],[],[],[],,0.119639,,"[{'ForeName': 'Nicholas P', 'Initials': 'NP', 'LastName': 'Jewell', 'Affiliation': 'London School of Hygiene & Tropical Medicine, Keppel Street, Bloomsbury, London, WC1E 7HT, UK.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Dufault', 'Affiliation': 'Division of Biostatistics, School of Public Health, University of California, Berkeley, CA 94720, USA.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Cutcher', 'Affiliation': 'World Mosquito Program, Institute of Vector Borne Disease, Monash University, Level 1, 12 Innovation Walk, Clayton, Victoria 3800, Australia.'}, {'ForeName': 'Cameron P', 'Initials': 'CP', 'LastName': 'Simmons', 'Affiliation': 'World Mosquito Program, Institute of Vector Borne Disease, Monash University, Level 1, 12 Innovation Walk, Clayton, Victoria 3800, Australia.'}, {'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': 'Anders', 'Affiliation': 'World Mosquito Program, Institute of Vector Borne Disease, Monash University, Level 1, 12 Innovation Walk, Clayton, Victoria 3800, Australia.'}]","Biostatistics (Oxford, England)",['10.1093/biostatistics/kxz008'] 3010,31445180,Feasibility and efficacy trial comparing liposomal bupivacaine and bupivacaine mixture with bupivacaine only in pre-operative four compartments periarticular infiltration block for patients undergoing total knee arthroplasty; An assessor-blinded single-center randomized trial.,,2020,,['patients undergoing total knee arthroplasty'],"['liposomal bupivacaine', 'bupivacaine mixture with bupivacaine']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}]","[{'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0439962', 'cui_str': 'Mixture (qualifier value)'}]",[],,0.199137,,"[{'ForeName': 'Anis', 'Initials': 'A', 'LastName': 'Dizdarevic', 'Affiliation': 'Montefiore Hospital and Medical Center, Department of Anesthesiology, Bronx, NY, USA. Electronic address: adizdare@montefiore.org.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Aviles', 'Affiliation': 'Montefiore Hospital and Medical Center, Department of Anesthesiology, Bronx, NY, USA.'}, {'ForeName': 'Boleslav', 'Initials': 'B', 'LastName': 'Kosharskyy', 'Affiliation': 'Montefiore Hospital and Medical Center, Department of Anesthesiology, Bronx, NY, USA.'}, {'ForeName': 'Sun Jin', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'Montefiore Hospital and Medical Center, Department of Anesthesiology, Bronx, NY, USA.'}, {'ForeName': 'Lyle', 'Initials': 'L', 'LastName': 'Nolasco', 'Affiliation': 'Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Radha', 'Initials': 'R', 'LastName': 'Kumar', 'Affiliation': 'Montefiore Medical Center, Department of Physical Medicine and Rehabilitation, Bronx, NY, USA.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Corvini', 'Affiliation': 'Montefiore Hospital and Medical Center, Department of Anesthesiology, Bronx, NY, USA.'}, {'ForeName': 'Emmylou', 'Initials': 'E', 'LastName': 'Cuevas', 'Affiliation': 'Montefiore Hospital and Medical Center, Department of Anesthesiology, Bronx, NY, USA.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Lockwood', 'Affiliation': 'Montefiore Medical Center, Department of Physical Medicine and Rehabilitation, Bronx, NY, USA.'}, {'ForeName': 'Singh', 'Initials': 'S', 'LastName': 'Nair', 'Affiliation': 'Montefiore Hospital and Medical Center, Department of Anesthesiology, Bronx, NY, USA.'}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2019.08.020'] 3011,29182037,DRD4 exon 3 genotype and ADHD: Randomised pharmacodynamic investigation of treatment response to methylphenidate.,"Objectives: Dopamine plays an important role in modulating attention and motor behaviours, dimensions altered in attention deficit/hyperactivity disorder (ADHD). Numerous association studies have linked dopamine receptor 4 ( DRD4 ) to increased risk of ADHD. This study investigated the effect of DRD4 exon 3 polymorphism on child behaviours in response to treatment with methylphenidate. Methods: A total of 374 children diagnosed with ADHD (ages 6-12 years) were evaluated under three experimental conditions: baseline, placebo and MPH (0.5 mg/kg/day). This was a 2-week prospective within-subject, placebo-controlled, crossover trial. The Conners' Global Index for parents and for teachers was used to evaluate the behaviours of the children. One-way repeated measures analysis of variance was used to test the effect of the interaction between DRD4 genotype and experimental conditions. Results: A significant interaction between DRD4 genotype and treatment was detected when the child's behaviour was evaluated by the parents ( P  = 0.035, effect size of 0.014), driven by a better treatment response in children homozygous for long 7-repeat allele. Conclusions: According to the parent assessment, children homozygous for the long 7-repeat allele were more responsive to experimental condition. This is the largest pharmacogenetic investigation of the effect of DRD4 exon 3 polymorphism in childhood ADHD. Trial Registration: clinicaltrials.gov, identifier NCT00483106.",2019,"A significant interaction between DRD4 genotype and treatment was detected when the child's behaviour was evaluated by the parents (P = 0.035, effect size of 0.014), driven by a better treatment response in children homozygous for long 7-repeat allele. ",['374 children diagnosed with ADHD (ages 6-12 years'],"['placebo and MPH', 'methylphenidate', 'placebo']","[""child's behaviour"", 'child behaviours', 'DRD4 exon 3 genotype and ADHD']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1263846', 'cui_str': 'ADDH'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0048853', 'cui_str': 'MPH'}, {'cui': 'C0025810', 'cui_str': 'Methylphenidate'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0015295', 'cui_str': 'Exons'}, {'cui': 'C1285573', 'cui_str': 'Genotype determination'}, {'cui': 'C1263846', 'cui_str': 'ADDH'}]",374.0,0.19056,"A significant interaction between DRD4 genotype and treatment was detected when the child's behaviour was evaluated by the parents (P = 0.035, effect size of 0.014), driven by a better treatment response in children homozygous for long 7-repeat allele. ","[{'ForeName': 'Darya', 'Initials': 'D', 'LastName': 'Naumova', 'Affiliation': 'Department of Human Genetics, McGill University , Montreal , QC , Canada.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Grizenko', 'Affiliation': 'Douglas Mental Health University Institute , Verdun , QC , Canada.'}, {'ForeName': 'Sarojini M', 'Initials': 'SM', 'LastName': 'Sengupta', 'Affiliation': 'Douglas Mental Health University Institute , Verdun , QC , Canada.'}, {'ForeName': 'Ridha', 'Initials': 'R', 'LastName': 'Joober', 'Affiliation': 'Department of Human Genetics, McGill University , Montreal , QC , Canada.'}]",The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry,['10.1080/15622975.2017.1410221'] 3012,29369813,Yoga versus physical exercise for cardio-respiratory fitness in adolescent school children: a randomized controlled trial.,"Background Yoga is very effective in improving health especially cardio-respiratory fitness and also overall performance in adolescents. There are no large numbers of randomized controlled studies conducted on comparing yoga with physical activity for cardio-respiratory fitness in adolescent school children with large sample size. Objective Aerobic training is known to improve physical and cardio-respiratory fitness in children. Cardio-respiratory fitness is an important indicator of health in children. In this study we evaluate the effects of yoga versus physical exercise training on cardio-respiratory fitness in adolescent school children. Subjects Eight hundred two school students from 10 schools across four districts were recruited for this study. Methods In this prospective two arm RCT around 802 students were randomized to receive daily one hour yoga training (n = 411) or physical exercise (n = 391) over a period of two months. VO2 max was estimated using 20 m shuttle run test. However, yoga (n = 377) and physical exercise (n = 371) students contributed data to the analyses. Data was analysed using students t test. Results There was a significant improvement in VO2 max using 20 m Shuttle run test in both yoga (p < 0.001) and exercise (p < 0.001) group following intervention. There was no significant change in VO2 max between yoga and physical exercise group following intervention. However, in the subgroup with an above median cut-off of VO2 max; there was a significant improvement in yoga group compared to control group following intervention (p = 0.03). Conclusion The results suggest yoga can improve cardio-respiratory fitness and aerobic capacity as physical exercise intervention in adolescent school children.",2018,There was a significant improvement in VO2 max using 20 m Shuttle run test in both yoga (p < 0.001) and exercise (p < 0.001) group following intervention.,"['children', 'adolescents', 'adolescent school children with large sample size', 'Subjects Eight hundred two school students from 10 schools across four districts were recruited for this study', 'adolescent school children', '802 students']","['physical exercise intervention', 'Yoga versus physical exercise', 'physical exercise', 'yoga with physical activity', ' Yoga', 'Objective Aerobic training', 'daily one hour yoga training (n\u2009=\u2009411) or physical exercise', 'yoga versus physical exercise training']","['cardio-respiratory fitness', 'VO2 max', 'cardio-respiratory fitness and aerobic capacity']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0260267', 'cui_str': 'School child (occupation)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}, {'cui': 'C3844106', 'cui_str': 'Eight hundred'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}]","[{'cui': 'C1701256', 'cui_str': 'bis(acetylacetonato)oxovanadium(IV)'}, {'cui': 'C0806909', 'cui_str': 'Max'}]",802.0,0.0221972,There was a significant improvement in VO2 max using 20 m Shuttle run test in both yoga (p < 0.001) and exercise (p < 0.001) group following intervention.,"[{'ForeName': 'Vhavle', 'Initials': 'V', 'LastName': 'Satish', 'Affiliation': 'Swami Vivekananda Yoga Anusandhana Samsthana, Department of Life Sciences, Bengaluru, India.'}, {'ForeName': 'Raghavendra Mohan', 'Initials': 'RM', 'LastName': 'Rao', 'Affiliation': 'Centre for Academic Research, HCG Foundation, Healthcare Global Enterprises Ltd., #8, P Kalinga Rao Rd, Sampangiramanagara, Bengaluru-560027, India.'}, {'ForeName': 'Nandi Krishnamurthy', 'Initials': 'NK', 'LastName': 'Manjunath', 'Affiliation': 'Swami Vivekananda Yoga Anusandhana Samsthana, Department of Life Sciences, Bengaluru, India.'}, {'ForeName': 'Ram', 'Initials': 'R', 'LastName': 'Amritanshu', 'Affiliation': 'Healthcare Global Enterprises ltd., Department of CAM, Sampangiramanagara, Bengaluru, India.'}, {'ForeName': 'Udupa', 'Initials': 'U', 'LastName': 'Vivek', 'Affiliation': 'Divine Park, Department of Research and Development, Saligrama, Udupi, India.'}, {'ForeName': 'Hassan Ratnakar', 'Initials': 'HR', 'LastName': 'Shreeganesh', 'Affiliation': 'Divine Park, Department of Research and Development, Saligrama, Udupi, India.'}, {'ForeName': 'Shashidhara', 'Initials': 'S', 'LastName': 'Deepashree', 'Affiliation': 'Healthcare Global Enterprises ltd., Department of CAM, Sampangiramanagara, Bengaluru, India.'}]",International journal of adolescent medicine and health,['10.1515/ijamh-2017-0154'] 3013,31098985,Elucidating individuals' beliefs about the severity of eating disorders and obesity: implications for public health programs.,"PURPOSE To examine perceptions of the severity of eating disorders and obesity and the effects on these of an information manipulation while also considering the influence of potential covariates such as age, gender, physical and mental health and beliefs about the prevalence and causes of the respective conditions. METHODS Australian women and men (n = 488) aged 18-73 years were randomly assigned to one of four conditions: no information, neutral information, eating disorders emphasis and obesity emphasis. Mixed-model analysis of variance (ANOVA) was used to compare the perceived severity of eating disorders and obesity (within-subjects factor), while also testing the effect of manipulating information, i.e., selectively emphasising the occurrence and adverse effects of one condition or the other (between-subjects factor), on perceptions of severity. Correlational analysis was used to examine associations between perceptions of severity and potential covariates, those covariates for which significant associations were observed being included as covariates in the ANOVA. RESULTS Eating disorders were perceived to be a more severe condition than obesity and the information manipulation was largely ineffective. Perceptions of the severity of both eating disorders and obesity were found to be associated with several covariates, including gender, body dissatisfaction, familiarity with and beliefs about the prevalence of eating disorders and beliefs about the causes of both eating disorders and obesity. CONCLUSIONS The findings support the need for-and provide a platform for-greater collaboration between obesity and eating disorder researchers in the development of integrated prevention and health promotion programs. LEVEL OF EVIDENCE Level III.",2020,"RESULTS Eating disorders were perceived to be a more severe condition than obesity and the information manipulation was largely ineffective.",['Australian women and men (n\u2009=\u2009488) aged 18-73\xa0years'],[],[],"[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",[],[],488.0,0.0233231,"RESULTS Eating disorders were perceived to be a more severe condition than obesity and the information manipulation was largely ineffective.","[{'ForeName': 'Bianca', 'Initials': 'B', 'LastName': 'Bullivant', 'Affiliation': 'Boden Institute of Obesity, Nutrition, Exercise and Eating Disorders, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Mitchison', 'Affiliation': 'Centre for Emotional Health, Macquarie University, Sydney, Australia.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Skromanis', 'Affiliation': 'Centre for Rural Health, College of Health and Medicine, University of Tasmania, E, Rm 003, Locked Bag 1322, Launceston, TAS, 7250, Australia.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Mond', 'Affiliation': 'School of Medicine, Western Sydney University, Sydney, Australia. Jon.Mond@utas.edu.au.'}]",Eating and weight disorders : EWD,['10.1007/s40519-019-00708-6'] 3014,32180260,The Bright and Dark Sides of Performance-Dependent Monetary Rewards: Evidence From Visual Perception Tasks.,"Studies have shown that performance-dependent monetary rewards facilitate visual perception. However, no study has examined whether such a positive effect is limited to the rewarded task or may be generalized to other tasks. In the current study, two groups of people were asked to perform two visual perception tasks, one being a reward-relevant task and the other being a reward-irrelevant task. For the reward-relevant task, the experimental group received performance-dependent monetary rewards, whereas the control group did not. For the reward-irrelevant task, both groups were not rewarded. The two tasks were randomly intermixed trial by trial (Experiment 1) or presented block by block (Experiment 2) or session by session (Experiments 3a, 3b, and 3c). Results showed that performance-dependent monetary rewards improved participants' performance on the relevant task in all experiments and impaired their performance on the irrelevant task in Experiments 2, 3a, 3b, and 3c. These results suggested that monetary rewards might incur a cost on reward-irrelevant tasks. Finally, the benefit of monetary rewards disappeared when they were no longer provided during the final session. This is the first study that reveals both the bright and dark sides of the performance-dependent monetary rewards in visual perception.",2020,"Results showed that performance-dependent monetary rewards improved participants' performance on the relevant task in all experiments and impaired their performance on the irrelevant task in Experiments 2, 3a, 3b, and 3c.",[],"['visual perception tasks, one being a reward-relevant task and the other being a reward-irrelevant task']",[],[],"[{'cui': 'C0042830', 'cui_str': 'Visual Perception'}, {'cui': 'C1292718', 'cui_str': 'Is a'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}]",[],2.0,0.0346383,"Results showed that performance-dependent monetary rewards improved participants' performance on the relevant task in all experiments and impaired their performance on the irrelevant task in Experiments 2, 3a, 3b, and 3c.","[{'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Qin', 'Affiliation': 'CAS Key Laboratory of Behavioral Science, Institute of Psychology.'}, {'ForeName': 'Jingming', 'Initials': 'J', 'LastName': 'Xue', 'Affiliation': 'Faculty of Psychology, Beijing Normal University.'}, {'ForeName': 'Chuansheng', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Department of Psychological Science, University of California.'}, {'ForeName': 'Mingxia', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'CAS Key Laboratory of Behavioral Science, Institute of Psychology.'}]",Cognitive science,['10.1111/cogs.12825'] 3015,29929387,Malingering and Defensiveness on the Spanish Personality Assessment Inventory: An Initial Investigation with Mostly Spanish-Speaking Outpatients.,"Psychological assessments can be essentially invalidated by examinees' intentional response styles, such as feigning (i.e., fabrication or marked overreporting of symptoms/impairment) and defensiveness (i.e., denial or minimization of symptoms/impairment). As a psychometric strength, the Personality Assessment Inventory (PAI) has established validity indicators for identifying both response styles. With the United States' increasing ethnic and cultural diversity, predominantly Spanish-speaking individuals are now estimated in the range of 15 million persons. Unfortunately, very little research has been conducted on the Spanish-translated PAI regarding its effectiveness in clinical populations. Using a between-subjects design, a sample of mostly Spanish-speaking outpatients was randomly assigned to genuine, feigning, or defensive conditions. For feigning, PAI malingering indicators using rare symptoms strategies (i.e., Negative Impression [NIM] and Negative Distortion [NDS] scales) demonstrated moderate to large effect sizes. For defensiveness, the Defensive (DEF) index proved the most effective with a very large effect size ( M = 1.68). Different cut scores were examined to increase the clinical utility of the Spanish PAI for determining response styles.",2020,"For defensiveness, the Defensive (DEF) index proved the most effective with a very large effect size ( M = 1.68).",[],[],"['Malingering and Defensiveness on the Spanish Personality Assessment Inventory', 'For defensiveness, the Defensive (DEF) index']",[],[],"[{'cui': 'C0024630', 'cui_str': 'Malingering'}, {'cui': 'C3161473', 'cui_str': 'Spaniards (ethnic group)'}, {'cui': 'C0031209', 'cui_str': 'Personality Assessment'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.0158233,"For defensiveness, the Defensive (DEF) index proved the most effective with a very large effect size ( M = 1.68).","[{'ForeName': 'Amor A', 'Initials': 'AA', 'LastName': 'Correa', 'Affiliation': 'Federal Medical Center Carswell, Fort Worth, TX, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Rogers', 'Affiliation': 'University of North Texas, Denton, TX, USA.'}, {'ForeName': 'Margot M', 'Initials': 'MM', 'LastName': 'Williams', 'Affiliation': 'University of North Texas, Denton, TX, USA.'}]",Assessment,['10.1177/1073191118778895'] 3016,32191129,The cluster randomized crossover trial: The effects of attrition in the AB/BA design and how to account for it in sample size calculations.,"BACKGROUND/AIMS This article studies the effect of attrition in the cluster randomized crossover trial. The focus is on the two-treatment two-period AB/BA design where attrition occurs during the washout period. Attrition may occur at either the subject level or the cluster level. In the latter case, clusters drop out entirely and provide no measurements in the second period. Subject attrition can only occur in the cohort design, where each subject receives both treatments. Cluster attrition can also occur in the cross-sectional design, where different subjects are measured in the two time periods. Furthermore, this article explores two different strategies to account for potential levels of attrition: increasing sample size and replacing those subjects who drop out by others. METHODS The statistical model that takes into account the nesting of subjects within clusters, and the nesting of repeated measurements within subjects is presented. The effect of attrition is evaluated on the basis of the efficiency of the treatment effect estimator. Matrix algebra is used to derive the relation between efficiency, the degree of attrition, cluster size and the intraclass correlations: the within-cluster within-period correlation, the within-cluster between-period correlation and (in the case of a cohort design) the within-subject correlation. The methodology is implemented in two Shiny Apps. RESULTS Attrition in a cluster randomized crossover trial implies a loss of efficiency. Efficiency decreases with an increase of the attrition rate. The loss of efficiency due to attrition of subjects in a cohort design is largest for small number of subjects per cluster-period, but it may be repaired to a large degree by increasing the number of subjects per cluster-period or by replacing those subjects who drop out by others. Attrition of clusters results in a larger loss of efficiency, but this loss does not depend on the number of subjects per cluster-period. Repairing for this loss requires a large increase in the number of subjects per cluster-period. The methodology of this article is illustrated by an example on the effect of lavender scent on dental patients' anxiety. CONCLUSION This article provides the methodology of exploring the effect of attrition in cluster randomized crossover trials, and to repair for attrition. As such, it helps researchers plan their trial in an appropriate way and avoid underpowered trials. To use the methodology, prior estimates of the degree of attrition and intraclass correlation coefficients are needed. It is advocated that researchers clearly report the estimates of these quantities to help facilitate planning future trials.",2020,"Matrix algebra is used to derive the relation between efficiency, the degree of attrition, cluster size and the intraclass correlations: the within-cluster within-period correlation, the within-cluster between-period correlation and (in the case of a cohort design) the within-subject correlation.","[""dental patients' anxiety""]",['lavender scent'],['attrition rate'],"[{'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]","[{'cui': 'C0524903', 'cui_str': 'Lavender'}, {'cui': 'C2987717', 'cui_str': 'Aroma'}]",[],,0.028077,"Matrix algebra is used to derive the relation between efficiency, the degree of attrition, cluster size and the intraclass correlations: the within-cluster within-period correlation, the within-cluster between-period correlation and (in the case of a cohort design) the within-subject correlation.","[{'ForeName': 'Mirjam', 'Initials': 'M', 'LastName': 'Moerbeek', 'Affiliation': 'Department of Methodology and Statistics, Utrecht University, Utrecht, The Netherlands.'}]","Clinical trials (London, England)",['10.1177/1740774520913042'] 3017,31980993,The Power of the Shared Experience: MTN-020/ASPIRE Trial Participants' Descriptions of Peer Influence on Acceptability of and Adherence to the Dapivirine Vaginal Ring for HIV Prevention.,"Women are disproportionately at risk of acquiring HIV in East and Southern Africa, despite global declines in incidence. Female-initiated HIV prevention methods, like the dapivirine vaginal ring, are needed to end the HIV epidemic. In-depth interviews and focus groups retrospectively explored peer influence on acceptability of and adherence to the ring during the ASPIRE trial, a phase III placebo-controlled trial. Results were analyzed using an inductive analytic approach. Study participants (peers) of all ages and adherence groups developed important interpersonal connections and reported being more open and honest with each other than with external peers or study staff. Study peers who knew each other prior to joining appeared to have a stronger influence on each other's adherence than peers who met in the study. External peers provided primarily negative input about the ring and study, which sometimes led to ring removals. Peers' influence on each other's behavior in both prosocial and detrimental manners could have repercussions on adherence to a biomedical intervention, and consequently, individual disease risk and clinical trial outcomes. Future ring demonstration and implementation studies could use peer networks to intentionally influence uptake and adherence to the ring.",2020,Study peers who knew each other prior to joining appeared to have a stronger influence on each other's adherence than peers who met in the study.,['Study participants (peers) of all ages and adherence groups developed important interpersonal connections and reported being more open and honest with each other than with external peers or study staff'],[],[],"[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0449379', 'cui_str': 'Connection (attribute)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}]",[],[],,0.0378847,Study peers who knew each other prior to joining appeared to have a stronger influence on each other's adherence than peers who met in the study.,"[{'ForeName': 'Ariana W K', 'Initials': 'AWK', 'LastName': 'Katz', 'Affiliation': ""Women's Global Health Imperative, RTI International, 351 California St, Suite 500, San Francisco, CA, 94104, USA. awkatz@rti.org.""}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Naidoo', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Reddy', 'Affiliation': 'Wits Reproductive Health and HIV Institute (Wits RHI), Johannesburg, South Africa.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Chitukuta', 'Affiliation': 'University of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Harare, Zimbabwe.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Nabukeera', 'Affiliation': 'Makerere University-Johns Hopkins University Research Unit, Kampala, Uganda.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Siva', 'Affiliation': 'HIV Prevention Research Unit, South African Medical Research Council, Durban, South Africa.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Zimba', 'Affiliation': 'University of North Carolina (UNC) Project-Lilongwe, Tidziwe Center, P/Bag A104, Lilongwe, Malawi.'}, {'ForeName': 'E T', 'Initials': 'ET', 'LastName': 'Montgomery', 'Affiliation': ""Women's Global Health Imperative, RTI International, 351 California St, Suite 500, San Francisco, CA, 94104, USA.""}]",AIDS and behavior,['10.1007/s10461-020-02799-0'] 3018,30374191,Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.,"The endogenous opioid system is thought to play an important role in the regulation of mood. Buprenorphine/samidorphan (BUP/SAM) combination is an investigational opioid system modulator for adjunctive treatment of major depressive disorder (MDD). To confirm results from early studies, we report the efficacy and safety of BUP/SAM as adjunctive treatment in patients with MDD and an inadequate response to antidepressant therapy (ADT) in FORWARD-4 and FORWARD-5: two phase 3, randomized, double-blind, placebo-controlled studies that utilized the same sequential parallel-comparison design. Efficacy was measured using the Montgomery-Åsberg Depression Rating Scale (MADRS). FORWARD-5 achieved the primary endpoint and demonstrated that adjunctive BUP/SAM 2 mg/2 mg was superior to placebo (average difference change from baseline to week 3 through end of treatment [EOT] in MADRS-6 and -10 versus placebo: -1.5, P = 0.018; -1.9, P = 0.026, respectively). FORWARD-4 did not achieve the primary endpoint (change from baseline in MADRS-10 at week 5 versus placebo: -1.8, P = 0.109), although separate analyses showed significant treatment differences at other timepoints using traditional, regulatory-accepted endpoints such as reduction in MADRS-10 at EOT. The pooled analysis of the two studies demonstrated consistently greater reduction in MADRS-10 scores from baseline for BUP/SAM 2 mg/2 mg versus placebo at multiple timepoints including EOT and average change from baseline to week 3 through EOT (-1.8, P = 0.010; -1.8, P = 0.004, respectively). The overall effect size (Hedges' g) in the pooled analyses for MADRS-10 change from baseline to EOT was 0.22. Overall, BUP/SAM was generally well tolerated, with most adverse events (AEs) being mild or moderate in severity. The most common AEs, occurring in ≥5% of patients in the BUP/SAM 2 mg/2 mg treatment group, which was more frequently than the placebo group, included nausea, constipation, dizziness, vomiting, somnolence, fatigue, and sedation. There was minimal evidence of abuse, and no evidence of dependence or opioid withdrawal by AEs or objective measures. This report describes adjunctive BUP/SAM 2 mg/2 mg combination, a therapy with a novel opioidergic mechanism of action, as a potential new treatment option for patients with MDD who have an inadequate response to currently available ADT.",2020,,['major depressive disorder'],['buprenorphine/samidorphan combination'],[],"[{'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}]","[{'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C4277369', 'cui_str': '3-carboxamido-4-hydroxynaltrexone'}]",[],,0.231079,,"[{'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Fava', 'Affiliation': 'Massachusetts General Hospital Clinical Trials Network and Institute (CTNI), Harvard Medical School, Boston, MA, USA. MFAVA@mgh.harvard.edu.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Thase', 'Affiliation': 'University of Pennsylvania Perelman School of Medicine and the Corporal Michael Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.'}, {'ForeName': 'Madhukar H', 'Initials': 'MH', 'LastName': 'Trivedi', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Elliot', 'Initials': 'E', 'LastName': 'Ehrich', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'William F', 'Initials': 'WF', 'LastName': 'Martin', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Asli', 'Initials': 'A', 'LastName': 'Memisoglu', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Narinder', 'Initials': 'N', 'LastName': 'Nangia', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Arielle D', 'Initials': 'AD', 'LastName': 'Stanford', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Miao', 'Initials': 'M', 'LastName': 'Yu', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Sanjeev', 'Initials': 'S', 'LastName': 'Pathak', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}]",Molecular psychiatry,['10.1038/s41380-018-0284-1'] 3019,31506029,The effect of counseling based on Bandura's self-efficacy theory on sexual self-efficacy and quality of sexual life.,"This study aimed to determine the effect of counseling, based on Bandura's self-efficacy theory, on sexual self-efficacy and quality of sexual life. This randomized controlled trial was conducted on 96 newlywed women in Zanjan, Iran during 2015-2016. The participants were assigned to the control and intervention groups through block randomization. Six 90-minute counseling sessions were held weekly for participants in the intervention group. Questionnaires of sexual self-efficacy and quality of sexual life were completed before and 8 weeks after the end of intervention. No significant difference was observed between groups in sexual self-efficacy and quality of sexual life at baseline ( p > .05). Using ANCOVA, the mean score for sexual self-efficacy in the intervention group was significantly higher than the control group 8 weeks after the intervention ended (mean difference in scores = 9.4; 95% confidence interval [CI] 2.6 to 16.2; p = .007). However, no significant difference was observed in the quality of sexual life between the two groups (mean difference in mean score = 2.1; 95% CI -2.5 to 6.7; p = .365). Thus, counseling had a positive impact on sexual self-efficacy. However, the intervention had no significant impact on the quality of sexual life, which may be attributed to the short duration of follow-up.",2020,"Using ANCOVA, the mean score for sexual self-efficacy in the intervention group was significantly higher than the control group 8 weeks after the intervention ended (mean difference in scores = 9.4; 95% confidence interval [CI] 2.6 to 16.2; ","['96 newlywed women in Zanjan, Iran during 2015-2016']",[],"['Questionnaires of sexual self-efficacy and quality of sexual life', 'sexual self-efficacy', 'sexual self-efficacy and quality of sexual life', 'quality of sexual life', 'mean score for sexual self-efficacy']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}]",[],"[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0401251,"Using ANCOVA, the mean score for sexual self-efficacy in the intervention group was significantly higher than the control group 8 weeks after the intervention ended (mean difference in scores = 9.4; 95% confidence interval [CI] 2.6 to 16.2; ","[{'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Alimohammadi', 'Affiliation': 'Department of Midwifery, Students Research Committee, Faculty of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Zarei', 'Affiliation': 'Department of Health Education, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.'}, {'ForeName': 'Mojgan', 'Initials': 'M', 'LastName': 'Mirghafourvand', 'Affiliation': 'Department of Midwifery, Social determinants of Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.'}]",Women & health,['10.1080/03630242.2019.1662871'] 3020,31603024,Rushing to Appear Virtuous: Time Pressure Increases Socially Desirable Responding.,"Prosociality increases when decisions are made under time pressure. Here, we investigated whether time pressure increases socially desirable responding outside social interactions (Study 1). Finding that it did, we then examined whether this is because people align their responses with the concept of their ""true"" self or because of an intuitive tendency to comply with norms (Study 2). In Study 1, we randomly assigned each of 1,500 Americans to answer a measure of social-desirability bias either quickly or slowly and found that quick responding increased social desirability. In Study 2, we recruited a similar sample and tested whether fast-responding effects were moderated by the extent to which people display a good-true-self bias. A greater tendency to ascribe good behaviors to the true self predicted social desirability, but this relationship disappeared under time pressure. These results of socially desirable behavior under time pressure do not reflect people's deep-down good selves but, rather, their desire to present themselves favorably to other people.",2019,"A greater tendency to ascribe good behaviors to the true self predicted social desirability, but this relationship disappeared under time pressure.","['1,500 Americans']",[],['social desirability'],[],[],"[{'cui': 'C0037408', 'cui_str': 'Social Desirability'}]",1500.0,0.0182354,"A greater tendency to ascribe good behaviors to the true self predicted social desirability, but this relationship disappeared under time pressure.","[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'Protzko', 'Affiliation': 'Department of Psychological & Brain Sciences, University of California, Santa Barbara.'}, {'ForeName': 'Claire M', 'Initials': 'CM', 'LastName': 'Zedelius', 'Affiliation': 'Department of Psychological & Brain Sciences, University of California, Santa Barbara.'}, {'ForeName': 'Jonathan W', 'Initials': 'JW', 'LastName': 'Schooler', 'Affiliation': 'Department of Psychological & Brain Sciences, University of California, Santa Barbara.'}]",Psychological science,['10.1177/0956797619867939'] 3021,32197915,Post-antibiotic Ocular Surface Microbiome in Children: A Cluster-Randomized Trial.,,2020,,['Children'],[],[],"[{'cui': 'C0008059', 'cui_str': 'Child'}]",[],[],,0.0653268,,"[{'ForeName': 'Thuy', 'Initials': 'T', 'LastName': 'Doan', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California. Electronic address: Thuy.Doan@ucsf.edu.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Hinterwirth', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'Worden', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'Arzika', 'Affiliation': 'The Carter Center, Niamey, Niger.'}, {'ForeName': 'Ramatou', 'Initials': 'R', 'LastName': 'Maliki', 'Affiliation': 'The Carter Center, Niamey, Niger.'}, {'ForeName': 'Cindi', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Zhong', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Zhaoxia', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Nisha R', 'Initials': 'NR', 'LastName': 'Acharya', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Travis C', 'Initials': 'TC', 'LastName': 'Porco', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California; Institute for Global Health Sciences, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Jeremy D', 'Initials': 'JD', 'LastName': 'Keenan', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Lietman', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California; Institute for Global Health Sciences, University of California San Francisco, San Francisco, California.'}]",Ophthalmology,['10.1016/j.ophtha.2020.02.014'] 3022,31970581,"Stigma Related to HIV and Drug Use: Layers, Types, and Relations to Mental Health.","Stigma poses considerable challenges to the mental health of people living with HIV who use drugs (PLHWUD). In this study, we explored factors related to different types of stigma (perceived and internalized) attached to layered stigmatizing characters (HIV and drug use) and their mental health influences on PLHWUD. The study used baseline data of an ongoing randomized controlled trial among 241 PLHWUD recruited between March and December 2018 in Vietnam. A structural equation model was used to assess the relationships among different types and layers of stigma and mental health status. Both perceived and internalized drug-related stigma measures were significantly higher than their corresponding HIV-related stigma. HIV-related stigma was negatively associated with mental health status; however, we did not find a significant relationship between drug-related stigma and mental health. Tailored intervention strategies in consideration of types and layers of stigma are needed to address stigma-related challenges faced by PLHWUD.",2020,Both perceived and internalized drug-related stigma measures were significantly higher than their corresponding HIV-related stigma.,['241 PLHWUD recruited between March and December 2018 in Vietnam'],[],[],"[{'cui': 'C0042658', 'cui_str': 'Viet Nam'}]",[],[],241.0,0.0331404,Both perceived and internalized drug-related stigma measures were significantly higher than their corresponding HIV-related stigma.,"[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior - Center for Community Health, University of California, Los Angeles, CA, USA. lililili@ucla.edu.'}, {'ForeName': 'Chunqing', 'Initials': 'C', 'LastName': 'Lin', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior - Center for Community Health, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Feng', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior - Center for Community Health, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Diep Bich', 'Initials': 'DB', 'LastName': 'Nguyen', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior - Center for Community Health, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Cao', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior - Center for Community Health, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Anh Tuan', 'Initials': 'AT', 'LastName': 'Le', 'Affiliation': 'National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.'}, {'ForeName': 'Anh Tuan', 'Initials': 'AT', 'LastName': 'Nguyen', 'Affiliation': 'National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.'}]",AIDS and behavior,['10.1007/s10461-020-02794-5'] 3023,32242252,Re: 18 F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial.,,2020,,['ulcerative colitis'],['18 F-FDG PET-MR enterography'],[],"[{'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}]","[{'cui': 'C0046056', 'cui_str': 'Fluorodeoxyglucose F18'}, {'cui': 'C0031268', 'cui_str': 'Companion Animals'}]",[],,0.255521,,"[{'ForeName': 'Shintaro', 'Initials': 'S', 'LastName': 'Akiyama', 'Affiliation': 'Inflammatory Bowel Disease Center, University of Chicago Medicine, 5841 S. Maryland Avenue MC 4076, Chicago, IL, 60637, USA.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Traboulsi', 'Affiliation': 'Inflammatory Bowel Disease Center, University of Chicago Medicine, 5841 S. Maryland Avenue MC 4076, Chicago, IL, 60637, USA.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Rai', 'Affiliation': 'Inflammatory Bowel Disease Center, University of Chicago Medicine, 5841 S. Maryland Avenue MC 4076, Chicago, IL, 60637, USA.'}, {'ForeName': 'David T', 'Initials': 'DT', 'LastName': 'Rubin', 'Affiliation': 'Inflammatory Bowel Disease Center, University of Chicago Medicine, 5841 S. Maryland Avenue MC 4076, Chicago, IL, 60637, USA. drubin@medicine.bsd.uchicago.edu.'}]",European journal of nuclear medicine and molecular imaging,['10.1007/s00259-020-04774-2'] 3024,32108161,Urethral Instillation of Povidone-Iodine Reduces Post-Cystoscopy Urinary Tract Infection in Males: A Randomized Controlled Trial.,"Office cystoscopy may be associated with urinary tract infection (UTI) in up to 10-20% of patients. Current practice of surgical part preparation in males with povidone-iodine excludes distal urethra in males, leaving a possibility for resident intra-urethral flora to cause post-procedural UTI. We designed this randomized study to assess whether additional cleaning of distal urethra with povidone-iodine solution can help reduce post-procedural incidence of UTIs in this setting. Additionally, urethral swab culture was done in the entire cohort to identify the prevalent microflora in the distal male urethra and to evaluate its role in causation of post-procedural UTI. Using a specialized urethral swab culture methodology, 85% males demonstrated some bacteria and 16% showed common uro-pathogens. 28 (14.5%) cases had post-procedure culture positive UTI. The incidence of UTI in control group (22%) was significantly more than the intervention group (7%) (p value <0.007). This result strongly supports inclusion of distal urethral irrigation with povidone-iodine in males before office cystoscopy, even when pre-procedure mid-stream urine culture is sterile.",2020,The incidence of UTI in control group (22%) was significantly more than the intervention group (7%) (p value <0.007).,"['Males', 'males with povidone-iodine excludes distal urethra in males']","['Povidone-Iodine', 'povidone-iodine', 'povidone-iodine solution']","['incidence of UTI', 'urinary tract infection (UTI']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0032857', 'cui_str': 'Povidone-Iodine'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0205108', 'cui_str': 'Distal (qualifier value)'}, {'cui': 'C0041967', 'cui_str': 'Urethra'}]","[{'cui': 'C0032857', 'cui_str': 'Povidone-Iodine'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}]",85.0,0.0843778,The incidence of UTI in control group (22%) was significantly more than the intervention group (7%) (p value <0.007).,"[{'ForeName': 'Rishi', 'Initials': 'R', 'LastName': 'Nayyar', 'Affiliation': 'Department of Urology, AIIMS, New Delhi, 110029, New Delhi, India. nayyarrishi@gmail.com.'}, {'ForeName': 'Rohit', 'Initials': 'R', 'LastName': 'Dadhwal', 'Affiliation': 'Department of Urology, AIIMS, New Delhi, 110029, New Delhi, India.'}, {'ForeName': 'Arti', 'Initials': 'A', 'LastName': 'Kapil', 'Affiliation': 'Department of Microbiology, AIIMS, New Delhi, 110029, New Delhi, India.'}, {'ForeName': 'Ravindra Mohan', 'Initials': 'RM', 'LastName': 'Pandey', 'Affiliation': 'Department of Biostatistics, AIIMS, New Delhi, 110029, New Delhi, India.'}, {'ForeName': 'PremNath', 'Initials': 'P', 'LastName': 'Dogra', 'Affiliation': 'Department of Urology, AIIMS, New Delhi, 110029, New Delhi, India.'}]",Scientific reports,['10.1038/s41598-020-60522-4'] 3025,31405866,A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women.,"Emerging malaria parasite sulfadoxine-pyrimethamine (SP) resistance has prompted assessment of alternatives for intermittent preventive treatment in pregnancy (IPTp). The objective was to evaluate the tolerability and prophylactic efficacy of azithromycin (AZ) plus piperaquine (PQ) in pregnant women in Papua New Guinea. The study was an open-label, randomized, parallel-group trial. A total of 122 women (median gestation, 26 weeks [range, 14 to 32 weeks]) were randomized 1:1 to three daily doses of 1 g AZ plus 960 mg PQ tetraphosphate or single-dose SP (4,500 mg sulfadoxine plus 225 mg pyrimethamine), based on computer-generated block randomization. Tolerability was assessed to day 7, and efficacy was assessed to day 42 (when participants were returned to usual care) and at delivery. Data for 119 participants (AZ-PQ, n  = 61; SP, n  = 58) were analyzed. Both regimens were well tolerated, but AZ-PQ was associated with more gastrointestinal side effects (31%) and dizziness (21%). Eight women (6.7%) were parasitemic at recruitment but all were aparasitemic by 72 h. There were no differences in blood smear positivity rates between AZ-PQ and SP up to day 42 (0% versus 5.2%; relative risk [RR], 0.14 [95% confidence interval [CI], 0.01 to 2.58] [ P =  0.18]; absolute risk reduction [ARR], 5.2% [95% CI, -1.3 to 11.6%]) and at the time of delivery (0% versus 8.7%; RR, 0.11 [95% CI, 0.01 to 2.01] [ P =  0.14]; ARR, 8.7% [95% CI, -0.2 to 17.6%]). Of 92 women who were monitored to parturition, 89 (97%) delivered healthy babies; there were 3 stillbirths (SP, n  = 1; AZ-PQ, n  = 2 [twins]). There was a higher live birth weight (mean ± standard deviation) in the AZ-PQ group (3.13 ± 0.42 versus 2.88 ± 0.55 kg [ P =  0.016]; mean difference, 0.25 kg [95% CI, 0.02 to 0.48 kg]). AZ-PQ is a promising candidate for IPTp.",2019,"There was no difference in blood smear positivity between AZ-PQ and SP up to Day 42 (0% versus 5.2%; relative risk (RR) (95% CI) 0.14 (0.01,2.58), P =0.18; absolute risk reduction (ARR) (95% CI) 5.2","['92 women followed to parturition, 89 (97%) delivered healthy babies and there were three stillbirths (SP n=1, AZ-PQ n=2 (twins', 'pregnant Papua New Guinean women', '119 participants (AZ-PQ n=61, SP n=58', '122 women (median gestation 26']","['AZ plus 960 mg PQ tetraphosphate or single-dose SP (4,500 mg sulfadoxine, 225 mg pyrimethamine', 'azithromycin-piperaquine versus sulfadoxine-pyrimethamine', 'azithromycin (AZ) plus piperaquine (PQ', 'sulfadoxine-pyrimethamine']","['gastrointestinal side-effects', 'time of delivery', 'tolerability and prophylactic efficacy', 'absolute risk reduction (ARR', 'dizziness', 'Tolerability', 'blood smear positivity', 'mean±SD live birthweight']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C1148523', 'cui_str': 'Childbirth'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0549206', 'cui_str': 'Pregnancy not delivered'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}]","[{'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C4517908', 'cui_str': '960 (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0038679', 'cui_str': 'Sulfadoxine'}, {'cui': 'C4517652', 'cui_str': '225 (qualifier value)'}, {'cui': 'C0034283', 'cui_str': 'Pyrimethamine'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0071105', 'cui_str': ""Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-)""}, {'cui': 'C0700599', 'cui_str': 'Pyrimethamine / Sulfadoxine'}]","[{'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C1301668', 'cui_str': 'Time of delivery'}, {'cui': 'C0445202', 'cui_str': 'Prophylactic (qualifier value)'}, {'cui': 'C3179139', 'cui_str': 'Absolute Risk Reduction'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0005768'}, {'cui': 'C0444186', 'cui_str': 'Smear test'}]",122.0,0.153709,"There was no difference in blood smear positivity between AZ-PQ and SP up to Day 42 (0% versus 5.2%; relative risk (RR) (95% CI) 0.14 (0.01,2.58), P =0.18; absolute risk reduction (ARR) (95% CI) 5.2","[{'ForeName': 'Brioni R', 'Initials': 'BR', 'LastName': 'Moore', 'Affiliation': 'School of Pharmacy and Biomedical Sciences, Curtin University, Bentley, Australia.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Benjamin', 'Affiliation': 'Vector Borne Disease Unit, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.'}, {'ForeName': 'Roselyn', 'Initials': 'R', 'LastName': 'Tobe', 'Affiliation': 'Vector Borne Disease Unit, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Ome-Kaius', 'Affiliation': 'Vector Borne Disease Unit, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.'}, {'ForeName': 'Gumul', 'Initials': 'G', 'LastName': 'Yadi', 'Affiliation': 'Vector Borne Disease Unit, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.'}, {'ForeName': 'Bernadine', 'Initials': 'B', 'LastName': 'Kasian', 'Affiliation': 'Vector Borne Disease Unit, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Kong', 'Affiliation': 'Vector Borne Disease Unit, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.'}, {'ForeName': 'Leanne J', 'Initials': 'LJ', 'LastName': 'Robinson', 'Affiliation': 'Vector Borne Disease Unit, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.'}, {'ForeName': 'Moses', 'Initials': 'M', 'LastName': 'Laman', 'Affiliation': 'Medical School, The University of Western Australia, Crawley, Australia.'}, {'ForeName': 'Ivo', 'Initials': 'I', 'LastName': 'Mueller', 'Affiliation': 'Population Health and Immunity Division, Walter and Eliza Hall Institute, Parkville, Australia.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Rogerson', 'Affiliation': 'Department of Medicine, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Australia.'}, {'ForeName': 'Timothy M E', 'Initials': 'TME', 'LastName': 'Davis', 'Affiliation': 'Medical School, The University of Western Australia, Crawley, Australia tim.davis@uwa.edu.au.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.00302-19'] 3026,31871223,Community-Based Upper Gastrointestinal Cancer Screening in a Randomized Controlled Trial: Baseline Results in a Non-high-incidence Area.,"A cluster-randomized controlled trial (RCT) was conducted to evaluate to the effectiveness of reducing mortality of upper gastrointestinal cancer (UGC) and feasibility of screening through a questionnaire combined with endoscopy in non-high-incidence urban areas in China. The trial design, recruitment performance, and preliminary results from baseline endoscopy are reported. Seventy-five communities in two urban cities with a non-high-incidence of UGC were randomized to a screening endoscopy arm ( n = 38) or a control arm ( n = 37). In the screening arm, individuals at high risk of UGC underwent endoscopic screening. The primary outcome was the UGC mortality, and secondary outcomes included the UGC detection rate, incidence rate, survival rate, and clinical stage at the time of diagnosis. A total of 10,416 and 9,565 individuals were recruited into the screening and control arms, respectively. The participation rate was 74.3%. In the screening arm, 5,242 individuals (50.3%) were estimated to be high-risk. Among them, 2,388 (45.6%) underwent endoscopic screening. Age and household income were associated with undergoing endoscopy. Three early esophageal cancer (0.13%), one gastric cancer (0.04%), 29 precancerous esophageal lesions (1.21%), and 53 precancerous gastric lesions (2.22%) were detected. Age, sex, a family history of cancer, intake of meat-egg-milk frequently, superficial gastritis, and clinical symptoms of gastric cancer were associated with the presence of precancerous lesions. The detection rate was low using endoscopic screening in non-high-incidence area given the relatively low compliance rate. These findings provide a reference for designing effective community-based UGC screening strategies in non-high-incidence urban areas.",2020,"The primary outcome was the UGC mortality, and secondary outcomes included the UGC detection rate, incidence rate, survival rate, and clinical stage at the time of diagnosis.","['Seventy-five communities in two urban cities with a non-high-incidence of UGC', 'A total of 10,416 and 9,565 individuals', '5,242 individuals (50.33%) were estimated to be high-risk', 'non-high-incidence urban areas in China']","['screening endoscopy', 'Community-based upper gastrointestinal cancer screening', 'endoscopic screening', 'questionnaire combined with endoscopy']","['53 precancerous gastric lesions', 'UGC mortality', 'UGC detection rate, incidence rate, survival rate, and clinical stage at the time of diagnosis', 'early esophageal cancer', 'participation rate', '29 precancerous esophageal lesions', 'detection rate', 'gastric cancer']","[{'cui': 'C4319621', 'cui_str': 'Seventy-five'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}]","[{'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0685938', 'cui_str': 'Gastrointestinal Cancer'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0205563', 'cui_str': 'Clinical staging (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0546837', 'cui_str': 'Cancer of Esophagus'}, {'cui': 'C0024623', 'cui_str': 'Cancer of Stomach'}]",,0.160427,"The primary outcome was the UGC mortality, and secondary outcomes included the UGC detection rate, incidence rate, survival rate, and clinical stage at the time of diagnosis.","[{'ForeName': 'Hai-Fan', 'Initials': 'HF', 'LastName': 'Xiao', 'Affiliation': 'The Department of Cancer Prevention and Control, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.'}, {'ForeName': 'Shi-Peng', 'Initials': 'SP', 'LastName': 'Yan', 'Affiliation': 'The Department of Cancer Prevention and Control, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.'}, {'ForeName': 'Yan-Fang', 'Initials': 'YF', 'LastName': 'Chen', 'Affiliation': 'Yueyanglou District Center for Disease Control and Prevention, Yueyang City, Hunan Province, China.'}, {'ForeName': 'Zhaohui', 'Initials': 'Z', 'LastName': 'Shi', 'Affiliation': 'The Department of Cancer Prevention and Control, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.'}, {'ForeName': 'Yan-Hua', 'Initials': 'YH', 'LastName': 'Zou', 'Affiliation': 'The Department of Cancer Prevention and Control, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.'}, {'ForeName': 'Song-Lin', 'Initials': 'SL', 'LastName': 'Zhu', 'Affiliation': 'The Department of Cancer Prevention and Control, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.'}, {'ForeName': 'Ke-Kui', 'Initials': 'KK', 'LastName': 'Xu', 'Affiliation': 'The Department of Cancer Prevention and Control, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Song', 'Affiliation': 'Yueyanglou District Center for Disease Control and Prevention, Yueyang City, Hunan Province, China.'}, {'ForeName': 'Xian-Zhen', 'Initials': 'XZ', 'LastName': 'Liao', 'Affiliation': 'The Department of Cancer Prevention and Control, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. 125844068@qq.com.'}]","Cancer prevention research (Philadelphia, Pa.)",['10.1158/1940-6207.CAPR-19-0422'] 3027,31541431,"Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus.","BACKGROUND Venetoclax is a selective inhibitor of B-cell lymphoma-2, which plays a role in the development of various autoimmune diseases including systemic lupus erythematosus. The aim of these analyses was to quantify the exposure-response relationship for venetoclax effects on B-lymphocyte and total lymphocyte counts as pharmacodynamic markers of efficacy and safety, respectively, in women with systemic lupus erythematosus. The developed modeling framework was also used to evaluate venetoclax effects following cyclic, continuous, or induction/maintenance dosing paradigms as potential dosing alternatives in systemic lupus erythematosus. METHODS Serial pharmacokinetic and lymphocyte count data from 73 women enrolled in a phase I study of venetoclax (single doses of 10-500 mg or two cycles of 30-600 mg or placebo once daily for 7 days followed by a 21-day washout) were analyzed using a sequential population pharmacokinetic/pharmacodynamic modeling approach. Simulations to evaluate changes in B-lymphocyte and total lymphocyte counts following different venetoclax dosing scenarios were conducted. RESULTS Effect of venetoclax plasma exposures on B lymphocytes was described using an indirect linear response model and on total lymphocytes using a maximal response (E max ) with an effect site compartment. Baseline lymphocyte counts were significant covariates on the slope and half maximal inhibitory concentration parameter estimates for the respective models; with higher baseline counts associated with a greater reduction upon treatment with venetoclax. Model simulations showed that continuous dosing with lower doses of venetoclax (e.g., 150 mg daily) are predicted to achieve similar maximal effects on B-lymphocyte counts compared to cyclic dosing with higher doses (e.g., 400 mg 1 week on/3 weeks off); with better recovery of total lymphocyte counts during off-treatment weeks for the cyclic regimens. CONCLUSIONS Venetoclax treatment in women with systemic lupus erythematosus was associated with exposure-dependent reductions in B lymphocytes, and to a lesser extent, total lymphocyte counts. Results from this study support evaluation of B-cell lymphoma-2 inhibitors as potential therapies for the treatment of systemic lupus erythematosus. CLINICALTRIALS.GOV: NCT01686555.",2020,"CONCLUSIONS Venetoclax treatment in women with systemic lupus erythematosus was associated with exposure-dependent reductions in B lymphocytes, and to a lesser extent, total lymphocyte counts.","['Women with Systemic Lupus Erythematosus', 'women with systemic lupus erythematosus', '73 women enrolled in a phase I study of']","['venetoclax (single doses of 10-500\xa0mg or two cycles of 30-600\xa0mg or placebo', 'Venetoclax treatment', 'Venetoclax, a Selective BCL-2 Inhibitor', 'venetoclax']","['B-lymphocyte and total lymphocyte counts', 'total lymphocyte counts', 'Baseline lymphocyte counts']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0024141', 'cui_str': 'Lupus Erythematosus Disseminatus'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C4079830', 'cui_str': 'venetoclax'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4319834', 'cui_str': 'Bcl-2 inhibitor'}]","[{'cui': 'C0004561', 'cui_str': 'B-Cells'}, {'cui': 'C0200635', 'cui_str': 'Lymphocyte Number'}]",73.0,0.166105,"CONCLUSIONS Venetoclax treatment in women with systemic lupus erythematosus was associated with exposure-dependent reductions in B lymphocytes, and to a lesser extent, total lymphocyte counts.","[{'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Nader', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA.'}, {'ForeName': 'Mukul', 'Initials': 'M', 'LastName': 'Minocha', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA.'}, {'ForeName': 'Ahmed A', 'Initials': 'AA', 'LastName': 'Othman', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA. ahmed.othman@abbvie.com.'}]",Clinical pharmacokinetics,['10.1007/s40262-019-00818-5'] 3028,32128561,Effect of a Home Pregnancy Test Intervention on Cohort Retention and Pregnancy Detection: A Randomized Trial.,"We conducted a parallel, nonblinded randomized trial to assess whether offering home pregnancy tests (HPTs) to preconception cohort study participants influenced cohort retention or pregnancy detection. Pregnancy Study Online participants were female, aged 21-45 years, attempting pregnancy, and not using fertility treatment. At enrollment (2017-2018), 1,493 participants with 6 or fewer cycles of attempt time were randomly assigned with 50% probability to receive 12 Clearblue visual HPTs plus the standard protocol (n = 720) or the standard protocol alone (n = 773). Women completed bimonthly questionnaires for 12 months or until conception, whichever came first. In intent-to-treat analyses, retention (≥1 follow-up) was higher in the HPT arm (n = 598; 83%) than the standard protocol arm (n = 535 (69%); mean difference = 15%, 95% CI: 10, 19). Mean time at first pregnancy testing was identical in both arms (2 days before expected menses), as was mean gestational weeks at first positive pregnancy test (4 weeks). Conception was reported by 78% of women in the HPT arm and 75% in the standard protocol arm. Spontaneous abortion was reported by 21% in the HPT arm (mean gestational weeks = 7) and 21% in the standard protocol arm (mean gestational weeks = 6). Randomization of HPTs was associated with greater cohort retention but had little impact on incidence or timing of pregnancy detection.",2020,"In intent-to-treat analyses, retention (≥1 follow-ups) was higher in the HPT arm (","['Pregnancy Study Online (PRESTO) participants were female, aged 21-45 years, attempting pregnancy, and not using fertility treatment', '1,493 participants with ≤6 cycles of attempt time']","['home pregnancy tests (HPT', 'Home Pregnancy Test Intervention', 'Clearblue visual HPTs plus the standard protocol (N=720) or the standard protocol']","['Mean time at first pregnancy testing', 'Conception', 'cohort retention or pregnancy detection', 'Cohort Retention and Pregnancy Detection', 'Spontaneous abortion']","[{'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0445107', 'cui_str': 'Not used (qualifier value)'}, {'cui': 'C0015895', 'cui_str': 'Fecundity'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1632851', 'cui_str': 'Times'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0032976', 'cui_str': 'Pregnancy Tests'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0860096', 'cui_str': 'Primigravida (finding)'}, {'cui': 'C0009637', 'cui_str': 'Conception'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0000786', 'cui_str': 'Vaginal expulsion of product of conception'}]",1493.0,0.233746,"In intent-to-treat analyses, retention (≥1 follow-ups) was higher in the HPT arm (","[{'ForeName': 'Lauren A', 'Initials': 'LA', 'LastName': 'Wise', 'Affiliation': 'Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Tanran R', 'Initials': 'TR', 'LastName': 'Wang', 'Affiliation': 'Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Sydney K', 'Initials': 'SK', 'LastName': 'Willis', 'Affiliation': 'Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Amelia K', 'Initials': 'AK', 'LastName': 'Wesselink', 'Affiliation': 'Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Kenneth J', 'Initials': 'KJ', 'LastName': 'Rothman', 'Affiliation': 'Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Elizabeth E', 'Initials': 'EE', 'LastName': 'Hatch', 'Affiliation': 'Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.'}]",American journal of epidemiology,['10.1093/aje/kwaa027'] 3029,32122797,The Effect of Using PARO for People Living With Dementia and Chronic Pain: A Pilot Randomized Controlled Trial.,"OBJECTIVES To evaluate the effect of interaction with a robotic seal (PARO) on pain and behavioral and psychological symptoms of people with dementia and chronic pain. DESIGN A parallel pilot randomized controlled trial conducted between January 2018 and January 2019. SETTING Three long-term care facilities in Australia. PARTICIPANTS Forty-three participants aged ≥65 years living with dementia and chronic pain. INTERVENTION Participants were randomized to the PARO group (individual, nonfacilitated, 30-minute sessions, 5 days per week for 6 weeks) or a usual care group using a computer-generated random number. MEASUREMENTS The primary outcome was researcher-rated observational pain behaviors before and after each session. Secondary outcomes were staff-rated pain level, agitation, depression, and anxiety measured at baseline and the end of week 6. Medications regularly prescribed and as needed were recorded weekly. Analyses followed intention-to-treat, using the generalized estimating equation model. Australian New Zealand Clinical Trials Registry (ACTRN12618000082202). RESULTS Participants in the PARO group had a significantly lowered level of observed pain [-0.514, 95% confidence interval (CI) -0.774 to -0.254, P < .001] and used fewer pro re nata medications (-1.175, 95% CI -2.205 to -0.145, P = .025) than those in usual care after controlling for age, sex, cognitive function and medications. There were no significant differences in staff-rated pain, agitation, anxiety, and depression, nor regularly scheduled medications between intervention and control group. CONCLUSIONS AND IMPLICATIONS PARO shows promise in reducing pain and medications for individuals with dementia and chronic pain in long-term care facilities. This intervention might be incorporated into daily practice as an alternative to manage pain in people with dementia. Larger randomized controlled trials with longer time frames are needed to identify further and test the use of PARO in long-term care settings.",2020,"Participants in the PARO group had a significantly lowered level of observed pain [-0.514, 95% confidence interval (CI) -0.774 to -0.254, P < .001] and used fewer pro re nata medications (-1.175","['January 2018 and January\xa02019', 'Forty-three participants aged ≥65\xa0years living with dementia and chronic pain', 'Three long-term care facilities in Australia', 'individuals with dementia and chronic pain in long-term care facilities', 'people with dementia and chronic pain', 'people with dementia', 'People Living With Dementia and Chronic Pain']","['robotic seal (PARO', 'usual care group using a computer-generated random number', 'PARO']","['researcher-rated observational pain behaviors', 'staff-rated pain level, agitation, depression, and anxiety', 'pain and medications', 'level of observed pain', 'pain and behavioral and psychological symptoms', 'staff-rated pain, agitation, anxiety, and depression, nor regularly scheduled medications']","[{'cui': 'C0450368', 'cui_str': '43 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}, {'cui': 'C0028688', 'cui_str': 'Nursing Homes'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0036492', 'cui_str': 'Seal (organism)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}]","[{'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated (finding)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0233397', 'cui_str': 'Psychological symptom'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}]",43.0,0.236466,"Participants in the PARO group had a significantly lowered level of observed pain [-0.514, 95% confidence interval (CI) -0.774 to -0.254, P < .001] and used fewer pro re nata medications (-1.175","[{'ForeName': 'Lihui', 'Initials': 'L', 'LastName': 'Pu', 'Affiliation': 'School of Nursing and Midwifery, Nathan Campus, Griffith University, Brisbane, Queensland, Australia; Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia. Electronic address: lihui.pu@griffithuni.edu.au.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Moyle', 'Affiliation': 'School of Nursing and Midwifery, Nathan Campus, Griffith University, Brisbane, Queensland, Australia; Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Jones', 'Affiliation': 'Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia; Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Todorovic', 'Affiliation': 'School of Nursing and Midwifery, Nathan Campus, Griffith University, Brisbane, Queensland, Australia; Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia.'}]",Journal of the American Medical Directors Association,['10.1016/j.jamda.2020.01.014'] 3030,32093617,Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache.,"BACKGROUND Pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) induces headache in healthy volunteers but the precise mechanisms by which PACAP38 leads to headache are unclear. We investigated the headache preventive effect of sumatriptan and ketorolac on PACAP38-induced headache in healthy volunteers. In addition, we explored contribution of vascular mechanisms to PACAP38-induced headache using high resolution magnetic resonance angiography. METHODS Thirty-four healthy volunteers were divided in two groups (A and B) and received infusion of PACAP38 (10 picomol/kg/min) over 20 min. Group A was pretreated with intravenous sumatriptan (4 mg) or ketorolac (30 mg) 20 min before infusion of PACAP38. Group B received infusion of sumatriptan or ketorolac as post-treatment 90 min after infusion of PACAP38. In both experiments, we used a randomized, double-blind, cross-over design. We recorded headache characteristics and circumference of extra-intracerebral arteries. RESULTS We found no difference in AUC (0-6 h) of PACAP38-induced headache in group A, pretreated with sumatriptan or ketorolac (p = 0.297). There was no difference between sumatriptan and ketorolac in PACAP38-induced circumference change (AUC Baseline-110 min ) of MMA (p = 0.227), STA (p = 0.795) and MCA (p = 0.356). In group B, post-treatment with ketorolac reduced PACAP38-headache compared to sumatriptan (p < 0.001). Post-treatment with sumatriptan significantly reduced the circumference of STA (p = 0.039) and MMA (p = 0.015) but not of MCA (p = 0.981) compared to ketorolac. In an explorative analysis, we found that pre-treatment with sumatriptan reduced PACAP38-induced headache compared to no treatment (AUC 0-90min ). CONCLUSIONS Post-treatment with ketorolac was more effective in attenuating PACAP38-induced headache compared to sumatriptan. Ketorolac exerted its effect without affecting PACAP38-induced arterial dilation, whereas sumatriptan post-treatment attenuated PACAP38-induced dilation of MMA and STA. Pre-treatment with sumatriptan attenuated PACAP38-induced headache without affecting PACAP38-induced arterial dilation. Our findings suggest that ketorolac and sumatriptan attenuated PACAP38-induced headache in healthy volunteers without vascular effects. TRIAL REGISTRATION Clinicaltrials.gov (NCT03585894). Registered 13 July 2018.",2020,"In group B, post-treatment with ketorolac reduced PACAP38-headache compared to sumatriptan (p < 0.001).","['Thirty-four healthy volunteers', 'healthy volunteers']","['sumatriptan', 'intravenous sumatriptan', 'sumatriptan and ketorolac trometamol', 'sumatriptan and ketorolac', 'Pituitary adenylate cyclase-activating polypeptide-38 (PACAP38', 'sumatriptan or ketorolac', 'Ketorolac', 'infusion of PACAP38', 'ketorolac', 'PACAP38']","['PACAP38-induced arterial dilation', 'PACAP38-induced headache', 'PACAP38-induced circumference change (AUC Baseline-110 min ) of MMA', 'circumference of STA', 'MMA', 'headache characteristics and circumference of extra-intracerebral arteries']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0075632', 'cui_str': 'Sumatriptan'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0064326', 'cui_str': 'Ketorolac Tromethamine'}, {'cui': 'C0073631', 'cui_str': 'Ketorolac'}, {'cui': 'C0001492', 'cui_str': 'Adenylate Cyclase'}, {'cui': 'C1305923', 'cui_str': 'Polypeptides'}, {'cui': 'C1314954', 'cui_str': 'Pituitary Adenylate Cyclase Activating Polypeptide 38'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}]","[{'cui': 'C1314954', 'cui_str': 'Pituitary Adenylate Cyclase Activating Polypeptide 38'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0916871', 'cui_str': 'MMA(III)'}, {'cui': 'C1529286', 'cui_str': 'stas'}, {'cui': 'C0442111', 'cui_str': 'Intracerebral (qualifier value)'}, {'cui': 'C0003842', 'cui_str': 'Arteries'}]",34.0,0.0468834,"In group B, post-treatment with ketorolac reduced PACAP38-headache compared to sumatriptan (p < 0.001).","[{'ForeName': 'Hashmat', 'Initials': 'H', 'LastName': 'Ghanizada', 'Affiliation': 'Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Valdemar Hansens Vej 5, DK-2600, Glostrup, Denmark.'}, {'ForeName': 'Mohammad Al-Mahdi', 'Initials': 'MA', 'LastName': 'Al-Karagholi', 'Affiliation': 'Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Valdemar Hansens Vej 5, DK-2600, Glostrup, Denmark.'}, {'ForeName': 'Nanna', 'Initials': 'N', 'LastName': 'Arngrim', 'Affiliation': 'Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Valdemar Hansens Vej 5, DK-2600, Glostrup, Denmark.'}, {'ForeName': 'Mette', 'Initials': 'M', 'LastName': 'Mørch-Rasmussen', 'Affiliation': 'Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Valdemar Hansens Vej 5, DK-2600, Glostrup, Denmark.'}, {'ForeName': 'Matias', 'Initials': 'M', 'LastName': 'Metcalf-Clausen', 'Affiliation': 'Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Valdemar Hansens Vej 5, DK-2600, Glostrup, Denmark.'}, {'ForeName': 'Henrik Bo Wiberg', 'Initials': 'HBW', 'LastName': 'Larsson', 'Affiliation': 'Functional Imaging Unit, Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Faisal Mohammad', 'Initials': 'FM', 'LastName': 'Amin', 'Affiliation': 'Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Valdemar Hansens Vej 5, DK-2600, Glostrup, Denmark.'}, {'ForeName': 'Messoud', 'Initials': 'M', 'LastName': 'Ashina', 'Affiliation': 'Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Valdemar Hansens Vej 5, DK-2600, Glostrup, Denmark. ashina@dadlnet.dk.'}]",The journal of headache and pain,['10.1186/s10194-020-01089-3'] 3031,32019343,Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention: Insights From DIVA Trial.,"BACKGROUND Direct stenting without pre-dilation or post-dilation has been advocated for saphenous vein graft percutaneous coronary intervention to decrease the incidence of distal embolization, periprocedural myocardial infarction, and target lesion revascularization. METHODS We performed a post hoc analysis of patients enrolled in the DIVA (Drug-Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Angioplasty; NCT01121224) prospective, double-blind, randomized controlled trial. Patients were stratified into stent-only and balloon-stent groups. Primary end point was 12-month incidence of target vessel failure (defined as the composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization). Secondary end points included all-cause death, stent thrombosis, myocardial infarction, and target lesion revascularization during follow-up. RESULTS Of the 575 patients included in this substudy, 185 (32%) patients underwent stent-only percutaneous coronary intervention. Patients in the stent-only versus balloon-stent group had similar baseline characteristics and similar incidence of target vessel failure at 12-months (15% versus 19%; hazard ratio, 1.34 [95% CI, 0.86-2.08]; P =0.19). During long-term follow-up (median of 2.7 years), the incidence of definite stent thrombosis (1% versus 5%; hazard ratio, 9.20 [95% CI, 1.23-68.92]; P =0.0085), the composite of definite or probable stent thrombosis (5% versus 11%; hazard ratio, 2.52 [95% CI, 1.23-5.18]; P =0.009), and target vessel myocardial infarction (8% versus 14%; hazard ratio, 1.92 [95% CI, 1.08-3.40]; P =0.023) was lower in the stent-only group. Multivariable analysis showed that a higher number of years since coronary artery bypass grafting and >1 target saphenous vein graft lesions were associated with increased target vessel failure during entire follow-up, while preintervention Thrombolysis in Myocardial Infarction-3 flow was protective. CONCLUSIONS In patients undergoing percutaneous coronary intervention of de novo saphenous vein graft lesions, there was no difference in target vessel failure at 12 months and long-term follow-up in the stent-only versus the balloon-stent group; however, the incidence of stent thrombosis was lower in the stent-only group, as was target vessel myocardial infarction. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01121224.",2020,"Patients in the stent-only versus balloon-stent group had similar baseline characteristics and similar incidence of target vessel failure at 12-months (15% versus 19%; hazard ratio, 1.34 [95% CI, 0.86-2.08]; P =0.19).","['patients undergoing percutaneous coronary intervention of de novo saphenous vein graft lesions', 'Saphenous Vein Graft Percutaneous Coronary Intervention', 'patients enrolled in the', '575 patients included in this substudy']","['Direct stenting without pre-dilation or post-dilation', 'DIVA (Drug-Eluting Stents Versus Bare Metal Stents', 'stent-only percutaneous coronary intervention', 'Stent-Only Versus Adjunctive Balloon Angioplasty Approach']","['number of years since coronary artery bypass grafting and >1 target saphenous vein graft lesions', 'composite of definite or probable stent thrombosis', 'target vessel failure', 'vessel myocardial infarction', 'incidence of target vessel failure', '12-month incidence of target vessel failure (defined as the composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization', 'cause death, stent thrombosis, myocardial infarction, and target lesion revascularization during follow-up', 'incidence of stent thrombosis', 'incidence of definite stent thrombosis', 'target vessel myocardial infarction']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C0729538', 'cui_str': 'Saphenous vein graft (substance)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C3844102', 'cui_str': '575'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C2825200', 'cui_str': 'Bare metal stent (physical object)'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C0002996', 'cui_str': 'Dilation, Transluminal Arterial'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0010055', 'cui_str': 'Coronary Artery Bypass Grafting'}, {'cui': 'C4280965', 'cui_str': '>1'}, {'cui': 'C0729538', 'cui_str': 'Saphenous vein graft (substance)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0439544', 'cui_str': 'Definite (qualifier value)'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis (contextual qualifier) (qualifier value)'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0449618', 'cui_str': 'Target vessel (attribute)'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0148346', 'cui_str': 'Vessel'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0376297', 'cui_str': 'Cardiac Death'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0014742', 'cui_str': 'Erythema Multiforme'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]",575.0,0.419308,"Patients in the stent-only versus balloon-stent group had similar baseline characteristics and similar incidence of target vessel failure at 12-months (15% versus 19%; hazard ratio, 1.34 [95% CI, 0.86-2.08]; P =0.19).","[{'ForeName': 'Faisal', 'Initials': 'F', 'LastName': 'Latif', 'Affiliation': 'VA Medical Center, Oklahoma City (F.L.).'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Uyeda', 'Affiliation': 'VA Cooperative Studies Program Coordinating Center, Mountain View, CA (L.U., R.E., M.-C.S.).'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Edson', 'Affiliation': 'VA Cooperative Studies Program Coordinating Center, Mountain View, CA (L.U., R.E., M.-C.S.).'}, {'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': 'VA Boston Healthcare System, MA (D.L., S.K., R.S.V).'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Goldman', 'Affiliation': 'University of Arizona Sarver Heart Center, Tucson (S.G.).'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Holmes', 'Affiliation': 'Mayo Clinic, Rochester, MN (D.R.H.).'}, {'ForeName': 'Sunil V', 'Initials': 'SV', 'LastName': 'Rao', 'Affiliation': 'Durham VA Medical Center, NC (S.V.R.).'}, {'ForeName': 'Kendrick', 'Initials': 'K', 'LastName': 'Shunk', 'Affiliation': 'San Francisco VA Medical Center, CA (K.S.).'}, {'ForeName': 'Kul', 'Initials': 'K', 'LastName': 'Aggarwal', 'Affiliation': 'Harry S Truman VA Hospital, Columbia, MO (K.A.).'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Uretsky', 'Affiliation': 'Central Arkansas Veterans Health System, Little Rock (B.U.).'}, {'ForeName': 'Islam', 'Initials': 'I', 'LastName': 'Bolad', 'Affiliation': 'Indiana University School of Medicine, Indianapolis (I.B.).'}, {'ForeName': 'Khaled', 'Initials': 'K', 'LastName': 'Ziada', 'Affiliation': 'University of Kentucky, Lexington (K.Z.).'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'McFalls', 'Affiliation': 'VA Medical Center, Minneapolis, MN (E.M.).'}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Irimpen', 'Affiliation': 'Southeast Louisiana Veterans Health Care System, New Orleans (A.I.).'}, {'ForeName': 'Huu Tam', 'Initials': 'HT', 'LastName': 'Truong', 'Affiliation': 'VA Loma Linda Medical Center, CA (H.T.T.).'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Kinlay', 'Affiliation': 'VA Cooperative Studies Program Coordinating Center, Mountain View, CA (L.U., R.E., M.-C.S.).'}, {'ForeName': 'Vasilios', 'Initials': 'V', 'LastName': 'Papademetriou', 'Affiliation': 'VA Medical center Washington DC (V.P.).'}, {'ForeName': 'Raghava S', 'Initials': 'RS', 'LastName': 'Velagaleti', 'Affiliation': 'VA Boston Healthcare System, MA (D.L., S.K., R.S.V).'}, {'ForeName': 'Bavana V', 'Initials': 'BV', 'LastName': 'Rangan', 'Affiliation': 'Minneapolis Heart Institute Foundation, MN (B.V.R., E.S.B.).'}, {'ForeName': 'Kreton', 'Initials': 'K', 'LastName': 'Mavromatis', 'Affiliation': 'Atlanta VA Healthcare System, GA (K.M.).'}, {'ForeName': 'Mei-Chiung', 'Initials': 'MC', 'LastName': 'Shih', 'Affiliation': 'VA Cooperative Studies Program Coordinating Center, Mountain View, CA (L.U., R.E., M.-C.S.).'}, {'ForeName': 'Subhash', 'Initials': 'S', 'LastName': 'Banerjee', 'Affiliation': 'Dallas VA Medical Center, TX (S.B.).'}, {'ForeName': 'Emmanouil S', 'Initials': 'ES', 'LastName': 'Brilakis', 'Affiliation': 'Minneapolis Heart Institute Foundation, MN (B.V.R., E.S.B.).'}]",Circulation. Cardiovascular interventions,['10.1161/CIRCINTERVENTIONS.119.008494'] 3032,32087694,Dual-task training with progression from variable- to fixed-priority instructions versus dual-task training with variable-priority on gait speed in community-dwelling older adults: A protocol for a randomized controlled trial : Variable- and fixed-priority dual-task for older adults.,"BACKGROUND Functional independence and safe mobility, especially in older people, mostly rely on the ability to perform dual tasks, particularly during activities with variable- and fixed-priority attention. The aim of this study is to compare the dual-task training with progression from variable- to fixed-priority instructions versus dual-task training with variable-priority on gait speed in community-dwelling older adults. METHODS This is an assessor- and participant-blinded, two-arm, randomized controlled trial with 60 community-dwelling male and female older adults between the ages of 60 and 80 years old. Participants will be randomly allocated into either the intervention group or the control group using a computer-generated permuted block randomization schedule. The intervention group will undertake a progressive dual-task training in which the participants will be progressively submitted to dual-task walking and postural balance exercises with variable- to fixed-priority instructions. The control group will be submitted to dual-task training with variable-priority attention exercises. Both groups will receive 48 sessions lasting for 60 min each over 24 weeks. The primary outcome will be the gait speed under single- and dual-task conditions. Secondary outcomes will include spatiotemporal gait parameters, functional balance, executive function, falls, quality of life, and depression symptoms. All the analyses will be based on the intention-to-treat principle. DISCUSSION This is the first assessor- and participant-blinded, two-arm, randomized controlled trial with 6 months of intervention and an additional 6-month post-training follow up aiming to evaluate the effectiveness of training with progression from variable- to fixed-priority instructions on gait biomechanics, postural balance, falls episodes, executive functioning, and quality of life in community-dwelling older adults. If our hypotheses are confirmed, this training protocol can be implemented widely to improve gait speed and other functional activities and quality of life in community-dwelling older adults. This study protocol can be used to improve these functional aspects of community-dwelling older adults. This study may also contribute to future guidelines for the improvement of these clinical and biomechanical aspects in older people. TRIAL REGISTRATION ClinicalTrials.gov Identifier - NCT03886805, Registered 22 March 2019.",2020,Participants will be randomly allocated into either the intervention group or the control group using a computer-generated permuted block randomization schedule.,"['community-dwelling older adults', 'older adults', '60 community-dwelling male and female older adults between the ages of 60 and 80\u2009years old', 'older people']","['progressive dual-task training in which the participants will be progressively submitted to dual-task walking and postural balance exercises with variable- to fixed-priority instructions', 'dual-task training with progression from variable- to fixed-priority instructions versus dual-task training with variable-priority', 'Dual-task training with progression from variable- to fixed-priority instructions versus dual-task training with variable-priority', 'control group using a computer-generated permuted block randomization schedule', 'dual-task training with variable-priority attention exercises']","['gait biomechanics, postural balance, falls episodes, executive functioning, and quality of life', 'gait speed and other functional activities and quality of life', 'spatiotemporal gait parameters, functional balance, executive function, falls, quality of life, and depression symptoms', 'gait speed under single- and dual-task conditions']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1256755', 'cui_str': 'Postural Equilibrium'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0549179', 'cui_str': 'Priority (attribute)'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C1256755', 'cui_str': 'Postural Equilibrium'}, {'cui': 'C0034380'}, {'cui': 'C2009910', 'cui_str': 'Gait Speed'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]",60.0,0.0467328,Participants will be randomly allocated into either the intervention group or the control group using a computer-generated permuted block randomization schedule.,"[{'ForeName': 'Francis', 'Initials': 'F', 'LastName': 'Trombini-Souza', 'Affiliation': 'Department of Physical Therapy, University of Pernambuco (UPE) Campus Petrolina, Petrolina, PE, Brazil. francis.trombini@upe.br.'}, {'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'de Maio Nascimento', 'Affiliation': 'Department of Physical Education, Federal University of Sao Francisco Valley (UNIVASF) Campus Petrolina, Petrolina, PE, Brazil.'}, {'ForeName': 'Tarcísio Fulgêncio Alves', 'Initials': 'TFA', 'LastName': 'da Silva', 'Affiliation': 'Department of Physical Therapy, University of Pernambuco (UPE) Campus Petrolina, Petrolina, PE, Brazil.'}, {'ForeName': 'Rodrigo Cappato', 'Initials': 'RC', 'LastName': 'de Araújo', 'Affiliation': 'Department of Physical Therapy, University of Pernambuco (UPE) Campus Petrolina, Petrolina, PE, Brazil.'}, {'ForeName': 'Mônica Rodrigues', 'Initials': 'MR', 'LastName': 'Perracini', 'Affiliation': ""Master's and Doctoral Programs in Physical Therapy, Universidade Cidade de São Paulo, São Paulo, SP, Brazil.""}, {'ForeName': 'Isabel C N', 'Initials': 'ICN', 'LastName': 'Sacco', 'Affiliation': 'Physical Therapy, Speech and Occupational Therapy Department, Universidade de Sao Paulo (USP), School of Medicine, São Paulo, SP, Brazil.'}]",BMC geriatrics,['10.1186/s12877-020-1479-2'] 3033,31370779,"A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.","BACKGROUND Fragile X syndrome (FXS) is characterized by a range of developmental, neuropsychiatric, and behavioral symptoms that cause significant impairment in those with the disorder. Cannabidiol (CBD) holds promise as a potential treatment for FXS symptoms due to its safety profile and positive effects on a number of emotional and behavioral symptoms associated with FXS. The aim of the current study was to evaluate the safety, tolerability, and initial efficacy of ZYN002, a transdermal CBD gel, in a pediatric population with FXS. METHODS Twenty children and adolescents (aged 6-17 years) with a diagnosis of FXS (confirmed through molecular documentation of FMR1 full mutation) were enrolled in an open-label, multi-site, trial of ZYN002. Transdermal CBD gel was administered twice daily for 12 weeks, titrated from 50 mg to a maximum daily dose of 250 mg. The primary efficacy endpoint was change from screening to week 12 on the Anxiety, Depression, and Mood Scale (ADAMS). Secondary endpoint measures included the Aberrant Behavior Checklist-Community for FXS (ABC-C FXS ), Pediatric Anxiety Rating Scale (PARS-R), Pediatric Quality of Life Inventory (PedsQL™), three Visual Analogue Scales (VAS), and the Clinical Global Impression Scale-Severity (CGI-S) and Improvement (CGI-I). RESULTS The majority of treatment-emergent AEs (reported by 85% of participants) were mild in severity (70%), and no serious adverse events were reported. There was a statistically significant reduction in ADAMS total score from screening to week 12 and significant reductions on nearly all other secondary endpoints, including all ADAMS subscales (except depressed mood), all ABC-C FXS subscale scores (e.g., social avoidance, irritability), PARS-R total severity score, and PedsQL total score. CONCLUSIONS ZYN002 was well tolerated and produced clinically meaningful reductions in anxiety and behavioral symptoms in children and adolescents with FXS. These findings support further study of ZYN002 in a randomized, well-controlled trial for the treatment of behavioral symptoms of FXS. TRIAL REGISTRATION ANZCTR, ACTRN12617000150347 Registered 27 January 2017.",2019,"There was a statistically significant reduction in ADAMS total score from screening to week 12 and significant reductions on nearly all other secondary endpoints, including all ADAMS subscales (except depressed mood), all ABC-C FXS subscale scores (e.g., social avoidance, irritability), PARS-R total severity score, and PedsQL total score. ","['pediatric population with FXS', 'children and adolescents with FXS', 'pediatric fragile X syndrome', 'Twenty children and adolescents (aged 6-17\u2009years) with a diagnosis of FXS (confirmed through molecular documentation of FMR1 full mutation']","['Cannabidiol (CBD', 'ZYN002, a transdermal CBD gel', 'Transdermal CBD gel', 'transdermal cannabidiol (ZYN002']","['ADAMS total score', 'ABC-C FXS subscale scores (e.g., social avoidance, irritability), PARS-R total severity score, and PedsQL total score', 'anxiety and behavioral symptoms', 'serious adverse events', 'ABC-C FXS ), Pediatric Anxiety Rating Scale (PARS-R), Pediatric Quality of Life Inventory (PedsQL™), three Visual Analogue Scales (VAS), and the Clinical Global Impression Scale-Severity (CGI-S) and Improvement (CGI-I', 'change from screening to week 12 on the Anxiety, Depression, and Mood Scale (ADAMS', 'all ADAMS subscales', 'safety, tolerability, and initial efficacy', 'Aberrant Behavior Checklist-Community for FXS', 'safety, tolerability, and efficacy']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0016667', 'cui_str': 'X-Linked Mental Retardation and Macroorchidism'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0920316', 'cui_str': 'Documentation'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}]","[{'cui': 'C0006863', 'cui_str': '1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-'}, {'cui': 'C4521342', 'cui_str': 'Transdermal (intended site)'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0459443', 'cui_str': 'Subscale score (qualifier value)'}, {'cui': 'C0022107', 'cui_str': 'Irritable Mood'}, {'cui': 'C0457451', 'cui_str': 'Severity score (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0004941', 'cui_str': 'Behavioral Symptoms'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0222045'}, {'cui': 'C0034380'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C3639708', 'cui_str': 'Clinical global impression scale'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0443127', 'cui_str': 'Aberrant (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0009462', 'cui_str': 'Community'}]",20.0,0.0439354,"There was a statistically significant reduction in ADAMS total score from screening to week 12 and significant reductions on nearly all other secondary endpoints, including all ADAMS subscales (except depressed mood), all ABC-C FXS subscale scores (e.g., social avoidance, irritability), PARS-R total severity score, and PedsQL total score. ","[{'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Heussler', 'Affiliation': ""Centre for Clinical Trials in Rare Neurodevelopmental Disorders, Children's Health Queensland, Brisbane, Australia.""}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Cohen', 'Affiliation': 'Fragile X Alliance Inc. and Genetic Clinics Australia, Melbourne, Australia.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Silove', 'Affiliation': ""The Children's Hospital at Westmead, Sydney, Australia.""}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Tich', 'Affiliation': 'Zynerba Pharmaceuticals, Devon, PA, 19333, USA. TichN@Zynerba.com.'}, {'ForeName': 'Marcel O', 'Initials': 'MO', 'LastName': 'Bonn-Miller', 'Affiliation': 'Canopy Growth Corporation, Smith Falls, Ontario, V7A 0A8, Canada.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Du', 'Affiliation': 'Clinical Statistics Consulting, Blue Bell, PA, 19422, USA.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': ""O'Neill"", 'Affiliation': 'Zynerba Pharmaceuticals, Devon, PA, 19333, USA.'}, {'ForeName': 'Terri', 'Initials': 'T', 'LastName': 'Sebree', 'Affiliation': 'Zynerba Pharmaceuticals, Devon, PA, 19333, USA.'}]",Journal of neurodevelopmental disorders,['10.1186/s11689-019-9277-x'] 3034,32093667,Topical povidone iodine inhibits bacterial growth in the oral cavity of patients on mechanical ventilation: a randomized controlled study.,"BACKGROUND Topical 0.12% chlorhexidine has been used widely to prevent ventilator-associated pneumonia in patients undergoing mechanical ventilation. However, it is not approved for mucosal application in Japan. The aims of this study were to investigate if topical povidone iodine (i) inhibits bacterial growth and (ii) disrupts the balance of the oral microbiota. METHODS This randomized controlled clinical trial included 23 patients who underwent mechanical ventilation in the intensive care unit. The patients were divided randomly into two groups: the intervention group (n = 16) and the control group (n = 7). All patients received oral cleaning with 3% hydrogen peroxide, followed by irrigation with tap water. The patients in the intervention group received 10% povidone iodine applied topically to the oral cavity. The concentration of total bacteria in the oropharyngeal fluid were determined before, immediately after, 1 h, 2 h, and 3 h after oral care using the Rapid Oral Bacteria Quantification System, which is based on dielectrophoresis and impedance measurements. The number of streptococci, methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas aeruginosa, Porphyromonas gingivalis, and Candida albicans before, immediately after, 1 h, and 3 h after oral care were estimated based on real-time polymerase chain reaction data. RESULTS After irrigation of the oral cavity, the number of bacteria decreased, but increased again at 1 h after oral care in the control group; however, in the intervention group, the concentration of bacteria was significantly lower than that in the control group at 1 hour (p = 0.009), 2 h (p = 0.001), and 3 h (p = 0.001) after oral care. The growth of all bacterial species tested was inhibited in the intervention group at 3 h after oral care, suggesting that povidone iodine did not disturb the balance of the oral microbiota. CONCLUSIONS Topical application of povidone iodine after cleaning and irrigation of the oral cavity inhibited bacterial growth in the oropharyngeal fluid of patients on mechanical ventilation while not disrupting the balance of the oral microbiota. TRIAL REGISTRATION University Hospitals Medical Information Network Clinical Trials Registry (UMIN-CTR), UMIN000028307. Registered 1 September 2017.",2020,"After irrigation of the oral cavity, the number of bacteria decreased, but increased again at 1 h after oral care in the control group; however, in the intervention group, the concentration of bacteria was significantly lower than that in the control group at 1 hour (p = 0.009), 2 h (p = 0.001), and 3 h (p = 0.001) after oral care.","['patients undergoing mechanical ventilation', '23 patients who underwent mechanical ventilation in the intensive care unit', 'patients on mechanical ventilation']","['chlorhexidine', 'oral cleaning with 3% hydrogen peroxide, followed by irrigation with tap water', 'Topical povidone iodine', 'topical povidone iodine (i', 'povidone iodine']","['concentration of total bacteria', 'concentration of bacteria', 'number of bacteria', 'number of streptococci, methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas aeruginosa, Porphyromonas gingivalis, and Candida albicans']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}]","[{'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C0020281', 'cui_str': 'Hydrogen Peroxide'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0022100', 'cui_str': 'Lavage'}, {'cui': 'C2919405', 'cui_str': 'Tap water (substance)'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0032857', 'cui_str': 'Povidone-Iodine'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1510439', 'cui_str': 'bacteria'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1265292', 'cui_str': 'MRSA'}, {'cui': 'C0038410', 'cui_str': 'Streptococcus pneumoniae'}, {'cui': 'C0033808', 'cui_str': 'Flavimonas'}, {'cui': 'C0206347', 'cui_str': 'Porphyromonas'}, {'cui': 'C0006837', 'cui_str': 'Candida albicans'}]",23.0,0.0420973,"After irrigation of the oral cavity, the number of bacteria decreased, but increased again at 1 h after oral care in the control group; however, in the intervention group, the concentration of bacteria was significantly lower than that in the control group at 1 hour (p = 0.009), 2 h (p = 0.001), and 3 h (p = 0.001) after oral care.","[{'ForeName': 'Shoma', 'Initials': 'S', 'LastName': 'Tsuda', 'Affiliation': 'Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8588, Japan.'}, {'ForeName': 'Sakiko', 'Initials': 'S', 'LastName': 'Soutome', 'Affiliation': 'Oral Care Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8588, Japan. Sakiko@nagasaki-u.ac.jp.'}, {'ForeName': 'Saki', 'Initials': 'S', 'LastName': 'Hayashida', 'Affiliation': 'Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8588, Japan.'}, {'ForeName': 'Madoka', 'Initials': 'M', 'LastName': 'Funahara', 'Affiliation': 'Kyushu Dental University School of Oral Health Sciences, 2-6-1 Manazuru, Kokurakitaku, Kitakyushu, 803-8580, Japan.'}, {'ForeName': 'Souichi', 'Initials': 'S', 'LastName': 'Yanamoto', 'Affiliation': 'Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8588, Japan.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Umeda', 'Affiliation': 'Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8588, Japan.'}]",BMC oral health,['10.1186/s12903-020-1043-7'] 3035,32122618,Electronic cigarettes containing nicotine increase endothelial and platelet derived extracellular vesicles in healthy volunteers.,"BACKGROUND AND AIMS E-cigarette use is increasingly common. Whether e-cigarettes are harmful to human health is an intensely debated subject. In order to investigate whether e-cigarettes with and without nicotine cause different vascular responses, we obtained blood samples from healthy young volunteers who performed brief active e-cigarette inhalations. Extracellular vesicles (EVs) of endothelial and platelet origin were measured to determine vascular changes. METHODS Using a randomized, double-blind, crossover design, 17 healthy occasional smokers inhaled 30 puffs of e-cigarette vapor during 30 min. Blood samples were collected at baseline, as well as at 0, 2, 4 and 6 h post-exposure. EVs from platelets and endothelial cells were measured by flow cytometry. RESULTS Platelet and endothelial derived EVs were significantly increased with peak levels seen at 4 h following exposure to active inhalation of e-cigarette vapor with nicotine. Moreover, platelet derived EVs, expressing platelet activation marker P-selectin and the inflammation marker, CD40 ligand, were also significantly increased following inhalation of e-cigarette vapor with nicotine. In addition, platelet derived EVs expressing CD40 ligand was increased after inhalation of e-cigarette vapor without nicotine. CONCLUSION As few as 30 puffs of nicotine-containing e-cigarette vapor caused an increase in levels of circulating EVs of endothelial and platelet origin, which may signify underlying vascular changes. Although e-cigarette vapor without nicotine caused an increase in platelet EVs expressing CD40 ligand, nicotine, as a component in the vapor, seems to have a more compelling effect on extracellular vesicle formation and protein composition.",2020,"Although e-cigarette vapor without nicotine caused an increase in platelet EVs expressing CD40 ligand, nicotine, as a component in the vapor, seems to have a more compelling effect on extracellular vesicle formation and protein composition.","['17 healthy occasional smokers inhaled 30 puffs of e-cigarette vapor during 30\xa0min', 'healthy volunteers', 'healthy young volunteers who performed brief active e-cigarette inhalations']","['e-cigarettes with and without nicotine', 'Electronic cigarettes containing nicotine']","['levels of circulating EVs of endothelial and platelet origin', 'Extracellular vesicles (EVs) of endothelial and platelet origin', 'platelets and endothelial cells', 'Blood samples']","[{'cui': 'C0425294', 'cui_str': 'Trivial cigarette smoker (less than one cigarette/day) (finding)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C1533107', 'cui_str': 'Puffs'}, {'cui': 'C3849993', 'cui_str': 'Electronic Cigarettes'}, {'cui': 'C0597635', 'cui_str': 'Vapor (substance)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C1705211', 'cui_str': 'Inhalation - unit of product usage'}]","[{'cui': 'C3849993', 'cui_str': 'Electronic Cigarettes'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0439659', 'cui_str': 'Origins (qualifier value)'}, {'cui': 'C3894683', 'cui_str': 'Extracellular Vesicles'}, {'cui': 'C0225336', 'cui_str': 'Endothelial Cells'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}]",17.0,0.0537835,"Although e-cigarette vapor without nicotine caused an increase in platelet EVs expressing CD40 ligand, nicotine, as a component in the vapor, seems to have a more compelling effect on extracellular vesicle formation and protein composition.","[{'ForeName': 'Fariborz', 'Initials': 'F', 'LastName': 'Mobarrez', 'Affiliation': 'Department of Medical Sciences, Uppsala University, 75185, Uppsala, Sweden.'}, {'ForeName': 'Lukasz', 'Initials': 'L', 'LastName': 'Antoniewicz', 'Affiliation': 'Karolinska Institutet, Department of Clinical Sciences, Division of Internal Medicine, Danderyd University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Linnea', 'Initials': 'L', 'LastName': 'Hedman', 'Affiliation': 'Umeå University, Department of Public Health and Clinical Medicine, Section of Sustainable Health, The OLIN Unit, Umeå, Sweden.'}, {'ForeName': 'Jenny A', 'Initials': 'JA', 'LastName': 'Bosson', 'Affiliation': 'Umeå University, Department of Public Health and Clinical Medicine, Division of Medicine/Respiratory Medicine, Umeå, Sweden.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Lundbäck', 'Affiliation': 'Karolinska Institutet, Department of Clinical Sciences, Division of Cardiovascular Medicine, Danderyd University Hospital, Stockholm, Sweden. Electronic address: magnus.lundback@sll.se.'}]",Atherosclerosis,['10.1016/j.atherosclerosis.2020.02.010'] 3036,31567051,"Effect of childbirth education on the perceptions of childbirth and breastfeeding self-efficacy and the obstetric outcomes of nulliparous women *,**,** .","In this quasi-experimental and prospective study, we aimed to determine the effect of education about childbirth on the perceptions of nulliparous women regarding the experience of childbirth, obstetric outcomes (e.g., type of delivery, use of induction, and instrument-assisted delivery), and breastfeeding self-efficacy. The study population comprised 121 women, of whom 64 and 57 were classified into the education and control groups, respectively. Study data were collected using a participant identification form, the Perception of Birth Scale, Visual Analog Scale, and Breastfeeding Self-Efficacy Scale-Short Form. Compared to the control group, participants in the education group held significantly more positive birth-related perceptions ( p  = 0.000) and experienced a lower level of pain during delivery ( p  = 0.016). However, education did not affect the obstetric outcomes. During the first month postpartum, a higher level of breastfeeding self-efficacy was reported by mothers in the education group than by those in the control group. In conclusion, systematic childbirth education positively affected the mothers' perceptions of the childbirth experience and their breastfeeding self-efficacy, but had no effect on the type of delivery or other birth-related obstetric interventions.",2020,"During the first month postpartum, a higher level of breastfeeding self-efficacy was reported by mothers in the education group than by those in the control group.","['nulliparous women ', 'nulliparous women', '121 women, of whom 64 and 57 were classified into the education and control groups, respectively']","['education about childbirth', 'childbirth education']","['perceptions of childbirth and breastfeeding self-efficacy', 'level of pain during delivery', 'Perception of Birth Scale, Visual Analog Scale, and Breastfeeding Self-Efficacy Scale-Short Form', 'level of breastfeeding self-efficacy', 'positive birth-related perceptions']","[{'cui': 'C0425979', 'cui_str': 'Nulliparous (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0008902', 'cui_str': 'Systematics'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C1148523', 'cui_str': 'Childbirth'}, {'cui': 'C3658257', 'cui_str': 'Childbirth Classes'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1148523', 'cui_str': 'Childbirth'}, {'cui': 'C1623040', 'cui_str': 'Breastfeeding (mother)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0222045'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}]",121.0,0.0295208,"During the first month postpartum, a higher level of breastfeeding self-efficacy was reported by mothers in the education group than by those in the control group.","[{'ForeName': 'Nevin', 'Initials': 'N', 'LastName': 'Citak Bilgin', 'Affiliation': 'Department of Obstetrics and Gynecology Nursing, Faculty of Health Sciences, Bolu Abant Izzet Baysal University, Bolu, Turkey.'}, {'ForeName': 'Bedriye', 'Initials': 'B', 'LastName': 'Ak', 'Affiliation': 'Department of Pediatric Nursing, Faculty of Health Sciences, Bolu Abant Izzet Baysal University, Bolu, Turkey.'}, {'ForeName': 'Fatma', 'Initials': 'F', 'LastName': 'Ayhan', 'Affiliation': 'Department of Obstetrics and Gynecology Nursing, Faculty of Health Sciences, Bolu Abant Izzet Baysal University, Bolu, Turkey.'}, {'ForeName': 'Fatma', 'Initials': 'F', 'LastName': 'Kocyigit', 'Affiliation': 'Bolu Izzet Baysal State Hospital, Bolu, Turkey.'}, {'ForeName': 'Songul', 'Initials': 'S', 'LastName': 'Yorgun', 'Affiliation': 'Bolu Izzet Baysal State Hospital, Bolu, Turkey.'}, {'ForeName': 'Mehmet Ata', 'Initials': 'MA', 'LastName': 'Topcuoglu', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Bolu Abant Izzet Baysal University, Bolu, Turkey.'}]",Health care for women international,['10.1080/07399332.2019.1672171'] 3037,32065861,Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial.,"INTRODUCTION To compare 3-year efficacy and safety after prostate resection with Aquablation therapy or transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostate hyperplasia (BPH). MATERIALS AND METHODS One hundred and eighty-one patients assigned to either Aquablation therapy or TURP were followed for 3 years postoperatively. Patients and follow up assessors were blinded to treatment. Assessments included International Prostate Symptom Score (IPSS), Male Sexual Health Questionnaire (MSHQ-EjD), International Index of Erectile Function (IIEF) and uroflow. RESULTS Over 3 years of treatment, improvements in IPSS scores were statistically similar across groups. Mean 3-year improvements were 14.4 and 13.9 points in the Aquablation and TURP groups, respectively (difference of 0.6 points, 95% CI -3.3-2.2, p = .6848). Similarly, 3-year improvements in Qmax were 11.6 and 8.2 cc/sec (difference of 3.3 [95% CI -0.5-7.1] cc/sec, p = .0848). At 3 years, PSA was reduced significantly in both groups by 0.9 and 1.1 ng/mL, respectively; the reduction was similar across groups (p = .5983). There were no surgical retreatments for BPH beyond 20 months for either Aquablation or TURP. CONCLUSIONS Three-year BPH symptom reduction and urinary flow rate improvement were similar after TURP and Aquablation therapy. No subjects required surgical retreatment beyond 20 months postoperatively. (ClinicalTrials.gov number, NCT02505919).",2020,"CONCLUSIONS Three-year BPH symptom reduction and urinary flow rate improvement were similar after TURP and Aquablation therapy.","['One hundred and eighty-one patients assigned to either', 'lower urinary tract symptoms related to benign prostate hyperplasia (BPH']","['prostate resection with Aquablation therapy or transurethral resection of the prostate (TURP', 'Aquablation therapy or TURP', 'TURP']","['IPSS scores', 'Mean 3-year improvements', '3-year improvements in Qmax', 'BPH symptom reduction and urinary flow rate improvement', 'PSA', 'International Prostate Symptom Score (IPSS), Male Sexual Health Questionnaire (MSHQ-EjD), International Index of Erectile Function (IIEF) and uroflow', '3-year efficacy and safety']","[{'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0574785', 'cui_str': 'Lower Urinary Tract Symptoms'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0205183', 'cui_str': 'Benign (qualifier value)'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0020507', 'cui_str': 'Hyperplasia'}, {'cui': 'C0005001', 'cui_str': 'Benign enlargement of prostate'}]","[{'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205497', 'cui_str': 'Transurethral approach (qualifier value)'}, {'cui': 'C0040771', 'cui_str': 'Prostatectomy, Transurethral'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005001', 'cui_str': 'Benign enlargement of prostate'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0429783', 'cui_str': 'Urinary flow rate (observable entity)'}, {'cui': 'C0201544', 'cui_str': 'Prostate specific antigen measurement (procedure)'}, {'cui': 'C1998280', 'cui_str': 'International prostate symptom score (assessment scale)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C2362326', 'cui_str': 'Sexual Health'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C2960541', 'cui_str': 'International index of erectile function'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",181.0,0.155074,"CONCLUSIONS Three-year BPH symptom reduction and urinary flow rate improvement were similar after TURP and Aquablation therapy.","[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Gilling', 'Affiliation': 'Tauranga Urology Research, Tauranga, New Zealand.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Barber', 'Affiliation': ''}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Bidair', 'Affiliation': ''}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Anderson', 'Affiliation': ''}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Sutton', 'Affiliation': ''}, {'ForeName': 'Tev', 'Initials': 'T', 'LastName': 'Aho', 'Affiliation': ''}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Kramolowsky', 'Affiliation': ''}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Thomas', 'Affiliation': ''}, {'ForeName': 'Barrett', 'Initials': 'B', 'LastName': 'Cowan', 'Affiliation': ''}, {'ForeName': 'Ronald P', 'Initials': 'RP', 'LastName': 'Kaufman', 'Affiliation': ''}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Trainer', 'Affiliation': ''}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Arther', 'Affiliation': ''}, {'ForeName': 'Gopal', 'Initials': 'G', 'LastName': 'Badlani', 'Affiliation': ''}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Plante', 'Affiliation': ''}, {'ForeName': 'Mihir', 'Initials': 'M', 'LastName': 'Desai', 'Affiliation': ''}, {'ForeName': 'Leo', 'Initials': 'L', 'LastName': 'Doumanian', 'Affiliation': ''}, {'ForeName': 'Alexis E', 'Initials': 'AE', 'LastName': 'Te', 'Affiliation': ''}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'DeGuenther', 'Affiliation': ''}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Roehrborn', 'Affiliation': ''}]",The Canadian journal of urology,[] 3038,32118604,CORR Insights®: Does Preoperative Decolonization Reduce Surgical Site Infections in Elective Orthopaedic Surgery? A Prospective Randomized Controlled Trial.,,2020,,[],['CORR Insights®'],[],[],[],[],,0.0565187,,"[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Schlatterer', 'Affiliation': 'D. Schlatterer, Vice Chair, Department of Orthopedic Surgery, Atlanta Medical Center, Atlanta, GA, USA.'}]",Clinical orthopaedics and related research,['10.1097/CORR.0000000000001199'] 3039,32123969,"Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177 Lu-Dotatate: an analysis of the NETTER-1 study.","PURPOSE To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with 177 Lu-Dotatate. METHODS In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression. RESULTS Significantly prolonged median PFS occurred with 177 Lu-Dotatate versus octreotide LAR 60 mg in patients with low (< 25%), moderate (25-50%), and high (> 50%) liver tumour burden (HR 0.187, 0.216, 0.145), and normal or elevated ALP (HR 0.153, 0.177), and in the presence or absence of a large target lesion (diameter > 30 mm; HR, 0.213, 0.063). Within the 177 Lu-Dotatate arm, no significant difference in PFS was observed amongst patients with low/moderate/high liver tumour burden (P = 0.7225) or with normal/elevated baseline ALP (P = 0.3532), but absence of a large target lesion was associated with improved PFS (P = 0.0222). Grade 3 and 4 liver function abnormalities were rare and did not appear to be associated with high baseline liver tumour burden. CONCLUSIONS 177 Lu-Dotatate demonstrated significant prolongation in PFS versus high-dose octreotide LAR in patients with advanced, progressive midgut NET, regardless of baseline liver tumour burden, elevated ALP, or the presence of a large target lesion. Clinicaltrials.gov : NCT01578239, EudraCT: 2011-005049-11.",2020,"Grade 3 and 4 liver function abnormalities were rare and did not appear to be associated with high baseline liver tumour burden. ","['patients with advanced, progressive midgut neuroendocrine tumours (NET']","['octreotide LAR', 'octreotide long-acting release (LAR) or to octreotide LAR 60 mg']","['median PFS', 'PFS', 'progression-free survival (PFS', 'baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size', 'liver tumour burden, ALP elevation, and target lesion size', 'liver tumour burden']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0231052', 'cui_str': 'Primitive midgut structure'}, {'cui': 'C0206754', 'cui_str': 'Neuroendocrine Tumors'}]","[{'cui': 'C0028833', 'cui_str': 'Octreotide'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0023903', 'cui_str': 'Neoplasms, Hepatic'}, {'cui': 'C0002059', 'cui_str': 'Orthophosphoric-monoester phosphohydrolase (alkaline optimum)'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0014742', 'cui_str': 'Erythema Multiforme'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}]",,0.355159,"Grade 3 and 4 liver function abnormalities were rare and did not appear to be associated with high baseline liver tumour burden. ","[{'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Strosberg', 'Affiliation': 'Gastrointestinal Department/Neuroendocrine Tumor Division, Moffitt Cancer Center, Tampa, FL, USA. jonathan.strosberg@moffitt.org.'}, {'ForeName': 'Pamela L', 'Initials': 'PL', 'LastName': 'Kunz', 'Affiliation': 'Department of Medicine - Med/Oncology, Stanford University Medical Center, Stanford, CA, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Hendifar', 'Affiliation': 'Department of Internal Medicine/Hematology/Oncology, Cedars Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Yao', 'Affiliation': 'Department of Gastrointestinal Medicinal Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Bushnell', 'Affiliation': 'Department of Radiology, The University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Matthew H', 'Initials': 'MH', 'LastName': 'Kulke', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.'}, {'ForeName': 'Richard P', 'Initials': 'RP', 'LastName': 'Baum', 'Affiliation': 'Department of Nuclear Medicine, Zentralklinik Bad Berka, Bad Berka, Germany.'}, {'ForeName': 'Martyn', 'Initials': 'M', 'LastName': 'Caplin', 'Affiliation': 'Department of Gastroenterology and Tumour Neuroendocrinology, Royal Free Hospital, London, UK.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Ruszniewski', 'Affiliation': 'Division of Gastroenterology and Pancreatology, Hôpital Beaujon, Clichy, France.'}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Delpassand', 'Affiliation': 'Department of Clinical Nuclear Medicine, Excel Diagnostics Imaging Clinic, Houston, TX, USA.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Hobday', 'Affiliation': 'Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Verslype', 'Affiliation': 'Department of Hepatology, University Hospitals and KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Al', 'Initials': 'A', 'LastName': 'Benson', 'Affiliation': 'Hematology Oncology Division, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.'}, {'ForeName': 'Rajaventhan', 'Initials': 'R', 'LastName': 'Srirajaskanthan', 'Affiliation': ""Department of Gastroenterology and General Internal Medicine, King's College Hospital - NHS Foundation Trust, London, UK.""}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Pavel', 'Affiliation': 'Division of Hepatology and Gastroenterology, Charite-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Jaume', 'Initials': 'J', 'LastName': 'Mora', 'Affiliation': 'Department of Nuclear Medicine, Hospital Universitari de Bellvitge, Barcelona, Spain.'}, {'ForeName': 'Jordan', 'Initials': 'J', 'LastName': 'Berlin', 'Affiliation': 'Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'Grande', 'Affiliation': 'Department of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Reed', 'Affiliation': 'Department of Medical Oncology, Beatson Oncology Centre, Glasgow, UK.'}, {'ForeName': 'Ettore', 'Initials': 'E', 'LastName': 'Seregni', 'Affiliation': 'Department of Nuclear Medicine Therapy and Endocrinology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Paganelli', 'Affiliation': 'Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Severi', 'Affiliation': 'Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Morse', 'Affiliation': 'Department of Surgery, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Metz', 'Affiliation': 'GI Division, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Ansquer', 'Affiliation': 'Nuclear Medicine Department, Hôtel Dieu, University Hospital, Nantes, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Courbon', 'Affiliation': 'Medical Imaging, Oncology University Institut Claudius Regaud, Toulouse, France.'}, {'ForeName': 'Adil', 'Initials': 'A', 'LastName': 'Al-Nahhas', 'Affiliation': 'Division of Imaging and Interventional Radiology, Imperial College London, London, UK.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Baudin', 'Affiliation': 'Department of Endocrine Oncology and Nuclear Medicine, Institut Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Giammarile', 'Affiliation': 'Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Taïeb', 'Affiliation': 'Department of Nuclear Medicine, Hôpital de la Timone, Marseille, France.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Mittra', 'Affiliation': 'Department of Nuclear Medicine, Oregon Health & Science University, Portland, OR, USA.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Wolin', 'Affiliation': 'Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': ""O'Dorisio"", 'Affiliation': 'Department of Internal Medicine, The University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Rachida', 'Initials': 'R', 'LastName': 'Lebtahi', 'Affiliation': 'Department of Nuclear Medicine, Royal Free Hospital, London, UK.'}, {'ForeName': 'Christophe M', 'Initials': 'CM', 'LastName': 'Deroose', 'Affiliation': 'Nuclear Medicine Department, University Hospitals and KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Chiara M', 'Initials': 'CM', 'LastName': 'Grana', 'Affiliation': 'Division of Nuclear Medicine, Istituto Europeo di Oncologia, Milan, Italy.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Bodei', 'Affiliation': 'Department of Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Kjell', 'Initials': 'K', 'LastName': 'Öberg', 'Affiliation': 'Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden.'}, {'ForeName': 'Berna Degirmenci', 'Initials': 'BD', 'LastName': 'Polack', 'Affiliation': 'Department of Medical Information, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.'}, {'ForeName': 'Beilei', 'Initials': 'B', 'LastName': 'He', 'Affiliation': 'Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.'}, {'ForeName': 'Maurizio F', 'Initials': 'MF', 'LastName': 'Mariani', 'Affiliation': 'Research and Development, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.'}, {'ForeName': 'Germo', 'Initials': 'G', 'LastName': 'Gericke', 'Affiliation': 'Research and Development, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Santoro', 'Affiliation': 'Department of Clinical Development, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.'}, {'ForeName': 'Jack L', 'Initials': 'JL', 'LastName': 'Erion', 'Affiliation': 'Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Ravasi', 'Affiliation': 'Research and Development, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Krenning', 'Affiliation': 'Department of Nuclear Medicine, Cyclotron Rotterdam BV, Erasmus University Medical Center, Rotterdam, Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of nuclear medicine and molecular imaging,['10.1007/s00259-020-04709-x'] 3040,32116309,A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills.,"Today, many functional skills are technology-based, so development of a technology-based training program has broad importance. Here we present a computerized functional skills training program that was paired in half of the participants with a commercially available cognitive training (CCT) program. Non-impaired older individuals (NC) aged 60+ (n=45) and similarly aged individuals with mild cognitive impairment (MCI; n=50) were randomized to receive 12 weeks of twice-weekly computerized functional skills training (CFST) or 12 weeks of twice-weekly sessions split between CCT and CFST. Skills trained were use of an ATM; internet banking; ticket kiosk; telephone and internet prescription refill; medication management; and internet shopping. As with previous functional capacity assessments, we focus on completion time for each simulation. 51 participants completed the training program, either by mastering all 6 tasks (34) or completing 12 weeks of training. 44 more participants completed 4 or more training sessions so they were also analyzed for improvement up to their last training session. Completion time for all 6 tests significantly improved from the baseline assessment to the final training session in both groups of participants (all p<0.001 with an average improvement in task completion time of 45%). Further, there was no differential improvement in MCI and NC in the 6 tests from baseline to end of training (all t<1.66, all p>0.12). Finally, combined CCT plus CFST did not differ from CSFT alone on any of the percent-change score measures (all t<1.64, all p>0.11). Both NC and MCI groups evidenced substantial improvements in performance. CCT supplementation led to similar functional gains with half as many training sessions. The NC participants proceeded through the training fairly rapidly even without CCT supplementation; MCI participants required more training but learned equivalently. These findings suggest that even in cases with memory impairments, functional skills can be efficiently learned with training.",2020,Completion time for all 6 tests significantly improved from the baseline assessment to the final training session in both groups of participants (all p<0.001 with an average improvement in task completion time of 45%).,"['Non-impaired older individuals (NC) aged 60+ (n=45) and similarly aged individuals with mild cognitive impairment (MCI; n=50', '51 participants completed the']","['computerized functional skills training program', 'CSFT', 'twice-weekly computerized functional skills training (CFST', 'Computerized Functional Skills Assessment and Training Program Targeting Technology', 'training program, either by mastering all 6 tasks (34) or completing 12 weeks of training', 'commercially available cognitive training (CCT) program', 'CCT supplementation']","['MCI and NC', 'Completion time']","[{'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C0560005', 'cui_str': 'millicurie'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0589106', 'cui_str': 'Functional skills training (procedure)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0556985', 'cui_str': 'Two times a week'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0444649', 'cui_str': 'Master (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]","[{'cui': 'C0560005', 'cui_str': 'millicurie'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",51.0,0.0209479,Completion time for all 6 tests significantly improved from the baseline assessment to the final training session in both groups of participants (all p<0.001 with an average improvement in task completion time of 45%).,"[{'ForeName': 'Philip D', 'Initials': 'PD', 'LastName': 'Harvey', 'Affiliation': 'University of Miami Miller School of Medicine; i-Function; pharvey@miami.edu.'}, {'ForeName': 'Lize', 'Initials': 'L', 'LastName': 'Tibiriçá', 'Affiliation': 'i-Function; Albizu University.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Kallestrup', 'Affiliation': 'i-Function.'}, {'ForeName': 'Sara J', 'Initials': 'SJ', 'LastName': 'Czaja', 'Affiliation': 'University of Miami Miller School of Medicine; i-Function; Weill-Cornell Medical Center.'}]",Journal of visualized experiments : JoVE,['10.3791/60330'] 3041,30877622,"DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment.","BACKGROUND The commercial formulation of sumatriptan nasal spray is an effective option for migraine patients requiring or preferring a non-oral route of drug administration, but its utility is limited by poor absorption and tolerability issues. DFN-02, a new formulation of sumatriptan 10 mg nasal spray, is co-formulated with a permeation enhancer that gives it pharmacokinetics comparable to subcutaneous sumatriptan. As reported previously, DFN-02 was significantly better than placebo on multiple efficacy endpoints at 2 h postdose, including pain freedom, absence of the most bothersome symptom, and pain relief, and its safety and tolerability profiles were excellent. OBJECTIVE The objective of this study was to assess the efficacy of acute treatment of migraine with DFN-02, including its effect on migraine-related functional disability and patient satisfaction with treatment. METHODS This was a multicenter, randomized, double-blind, placebo-controlled efficacy and safety study of DFN-02 in adults with episodic migraine. Functional disability and subject satisfaction with treatment were prespecified endpoints, assessed in real-time by subjects, using an electronic diary. RESULTS In total, 107 subjects were randomized. DFN-02 was significantly superior to placebo for the reduction in functional disability score from predose level at 2 h after treatment (- 1.2 vs. - 0.6, p < 0.001). Subjects treated with DFN-02 were also more likely to be satisfied or very satisfied than subjects treated with placebo at 2 h postdose (70.0% vs. 44.2%, p = 0.027). Using the Patient Perception of Migraine Questionnaire-Revised at 24 h postdose, DFN-02 mean scores were significantly superior to placebo for the subscales of efficacy (65.2 vs. 42.5, p = 0.016) and function (68.9 vs. 42.1, p = 0.001), and for total score (71.0 vs. 56.6, p = 0.016); global medication effectiveness (p = 0.027); and overall satisfaction (p = 0.019). Placebo was significantly better than DFN-02 on the tolerability subscale (94.8 vs. 88.5, p = 0.026). At 24 h postdose, subjects reported significantly higher satisfaction with DFN-02 compared with satisfaction reported pre-randomization regarding their usual migraine medication (p = 0.012). CONCLUSION DFN-02 was superior to placebo for the relief of migraine-related functional disability, and provided greater satisfaction than placebo or subjects' usual acute treatment. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02856802.",2019,"DFN-02 was significantly superior to placebo for the reduction in functional disability score from predose level at 2 h after treatment (- 1.2 vs. - 0.6, p < 0.001).","['Migraine', 'migraine patients requiring or preferring a non-oral route of drug administration', 'adults with episodic migraine', '107 subjects were randomized']","['placebo', 'Placebo', 'sumatriptan nasal spray', 'DFN-02, Sumatriptan 10\xa0mg Nasal Spray with Permeation Enhancer', 'DFN-02', 'sumatriptan']","['overall satisfaction', 'functional disability score from predose level', 'global medication effectiveness', 'Functional disability and subject satisfaction', 'tolerability subscale', 'pain freedom, absence of the most bothersome symptom, and pain relief, and its safety and tolerability profiles', 'Patient Perception of Migraine Questionnaire-Revised at 24\xa0h postdose, DFN-02 mean scores', 'total score']","[{'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3543840', 'cui_str': 'Preferred'}, {'cui': 'C1527415', 'cui_str': 'Per oral route'}, {'cui': 'C0150270', 'cui_str': 'Medication administration case management'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1455761', 'cui_str': 'Episodic (qualifier value)'}, {'cui': 'C4517529', 'cui_str': 'One hundred and seven'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1615718', 'cui_str': 'Sumatriptan Nasal Spray [Imitrex]'}, {'cui': 'C4508544', 'cui_str': 'DFN-02'}, {'cui': 'C1319680', 'cui_str': 'sumatriptan 10 MG/Spray Nasal Spray'}, {'cui': 'C0075632', 'cui_str': 'Sumatriptan'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0332197', 'cui_str': 'Absent (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C4508544', 'cui_str': 'DFN-02'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",107.0,0.462015,"DFN-02 was significantly superior to placebo for the reduction in functional disability score from predose level at 2 h after treatment (- 1.2 vs. - 0.6, p < 0.001).","[{'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Lipton', 'Affiliation': 'Albert Einstein College of Medicine, Bronx, NY, USA. Richard.Lipton@einstein.yu.edu.'}, {'ForeName': 'Sagar', 'Initials': 'S', 'LastName': 'Munjal', 'Affiliation': ""Promius Pharma, A Subsidiary of Dr. Reddy's Laboratories, Princeton, NJ, USA.""}, {'ForeName': 'Elimor', 'Initials': 'E', 'LastName': 'Brand-Schieber', 'Affiliation': ""Promius Pharma, A Subsidiary of Dr. Reddy's Laboratories, Princeton, NJ, USA.""}, {'ForeName': 'Alan M', 'Initials': 'AM', 'LastName': 'Rapoport', 'Affiliation': 'The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}]",CNS drugs,['10.1007/s40263-019-00614-6'] 3042,31051151,Prognostic Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure: Insights From TIME-CHF Trial.,"BACKGROUND The relationship between longitudinal clinical congestion pattern and heart failure outcome is uncertain. This study was designed to assess the prevalence of congestion over time and to investigate its impact on outcome in chronic heart failure. METHODS A total of 588 patients with chronic heart failure older than 60 years of age with New York Heart Association (NYHA) functional class ≥II from the TIME-CHF study were included. The endpoints for this study were survival and hospitalization-free heart failure survival. Orthopnea, NYHA ≥III, paroxysmal nocturnal dyspnea, hepatomegaly, peripheral pitting edema, jugular venous distension, and rales were repeatedly investigated and related to outcomes. These congestion-related signs and symptoms were used to design a 7-item Clinical Congestion Index. RESULTS Sixty-one percent of patients had a Clinical Congestion Index ≥3 at baseline, which decreased to 18% at month 18. During the median [interquartile range] follow-up of 27.2 [14.3-39.8] months, 17%, 27%, and 47% of patients with baseline Clinical Congestion Index of 0, 1-2, and ≥3 at inclusion, respectively, died (P <.001). Clinical Congestion Index was identified as an independent predictor of mortality at all visits (P <.05) except month 6 and reduced hospitalization-free heart failure survival (P <.05). Successful decongestion was related to better outcome as compared to persistent congestion or partial decongestion (log-rank P <0.001). CONCLUSIONS The extent of congestion as assessed by means of clinical signs and symptoms decreased over time with intensified treatment, but it remained present or relapsed in a substantial number of patients with heart failure and was associated with poor outcome. This highlights the importance of appropriate decongestion in chronic heart failure.",2019,Clinical Congestion Index was identified as an independent predictor of mortality at all visits (P <.05) except month 6 and reduced hospitalization-free heart failure survival (P <.05).,"['Chronic Heart Failure', '588 patients with chronic heart failure older than 60 years of age with New York Heart Association (NYHA) functional class ≥II from the TIME-CHF study were included', 'chronic heart failure']",[],"['Orthopnea, NYHA ≥III, paroxysmal nocturnal dyspnea, hepatomegaly, peripheral pitting edema, jugular venous distension, and rales', 'survival and hospitalization-free heart failure survival', 'Clinical Congestion Index', 'hospitalization-free heart failure survival']","[{'cui': 'C0264716', 'cui_str': 'Chronic heart failure (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]",[],"[{'cui': 'C0085619', 'cui_str': 'Orthopnea (finding)'}, {'cui': 'C1956415', 'cui_str': 'Paroxysmal nocturnal dyspnea (finding)'}, {'cui': 'C0019209', 'cui_str': 'Enlarged Liver'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0333243', 'cui_str': 'Pitting edema (morphologic abnormality)'}, {'cui': 'C0425687', 'cui_str': 'Jugular venous engorgement (finding)'}, {'cui': 'C0034642', 'cui_str': 'Rales'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0700148', 'cui_str': 'Congestion (morphologic abnormality)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",588.0,0.039086,Clinical Congestion Index was identified as an independent predictor of mortality at all visits (P <.05) except month 6 and reduced hospitalization-free heart failure survival (P <.05).,"[{'ForeName': 'Justas', 'Initials': 'J', 'LastName': 'Simonavičius', 'Affiliation': 'Centre of Cardiology and Angiology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands. Electronic address: j.simonavicius@gmail.com.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Sanders van-Wijk', 'Affiliation': 'Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Rickenbacher', 'Affiliation': 'Department of Cardiology, University Hospital Bruderholz, Bruderholz, Switzerland.'}, {'ForeName': 'Micha T', 'Initials': 'MT', 'LastName': 'Maeder', 'Affiliation': 'Department of Cardiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.'}, {'ForeName': 'Otmar', 'Initials': 'O', 'LastName': 'Pfister', 'Affiliation': 'Department of Cardiology, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Beat A', 'Initials': 'BA', 'LastName': 'Kaufmann', 'Affiliation': 'Department of Cardiology, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Pfisterer', 'Affiliation': 'Department of Cardiology, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Jelena', 'Initials': 'J', 'LastName': 'Čelutkienė', 'Affiliation': 'Institute of Clinical Medicine, Medical Faculty of Vilnius University, Vilnius, Lithuania.'}, {'ForeName': 'Roma', 'Initials': 'R', 'LastName': 'Puronaitė', 'Affiliation': 'Department of Information Systems, Centre of Informatics and Development, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; Clinic of Cardiac and Vascular diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; Institute of Data Science and Digital Technologies, Faculty of Mathematics and Informatics, Vilnius University, Vilnius, Lithuania.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Knackstedt', 'Affiliation': 'Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'van Empel', 'Affiliation': 'Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands.'}, {'ForeName': 'Hans-Peter', 'Initials': 'HP', 'LastName': 'Brunner-La Rocca', 'Affiliation': 'Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Cardiology, University Hospital Basel, Basel, Switzerland.'}]",The American journal of medicine,['10.1016/j.amjmed.2019.04.010'] 3043,32118826,Combat medic testing of a novel monitoring capability for early detection of hemorrhage.,"BACKGROUND Current out-of-hospital protocols to determine hemorrhagic shock in civilian trauma systems rely on standard vital signs with military guidelines relying on heart rate and strength of the radial pulse on palpation, all of which have proven to provide little forewarning for the need to implement early intervention prior to decompensation. We tested the hypothesis that addition of a real-time decision-assist machine-learning algorithm, the compensatory reserve measurement (CRM), used by combat medics could shorten the time required to identify the need for intervention in an unstable patient during a hemorrhage profile as compared with vital signs alone. METHODS We randomized combat medics from the Army Medical Department Center and School Health Readiness Center of Excellence into three groups: group 1 viewed a display of no simulated hemorrhage and unchanging vital signs as a control (n = 24), group 2 viewed a display of simulated hemorrhage and changing vital signs alone (hemorrhage; n = 31), and group 3 viewed a display of changing vital signs with the addition of the CRM (hemorrhage + CRM; n = 22). Participants were asked to push a computer key when they believed the patient was becoming unstable and needed medical intervention. RESULTS The average time of 11.0 minutes (95% confidence interval, 8.7-13.3 minutes) required by the hemorrhage + CRM group to identify an unstable patient (i.e., stop the video sequence) was less by more than 40% (p < 0.01) compared with 18.9 minutes (95% confidence interval, 17.2-20.5 minutes) in the hemorrhage group. CONCLUSION The use of a machine-learning monitoring technology designed to measure the capacity to compensate for central blood volume loss resulted in reduced time required by combat medics to identify impending hemodynamic instability. LEVEL OF EVIDENCE Diagnostic, level IV.",2020,"The average time of 11.0 minutes (95% CI = 8.7 - 13.3 minutes) required by the hemorrhage + CRM group to identify an unstable patient (i.e., stop the video sequence) was reduced by > 40% (p < 0.01) compared to 18.9 minutes (95% CI = 17.2 - 20.5 minutes) in the hemorrhage group. ",['Army Medical Department (AMEDD) Center & School Health Readiness Center of Excellence (HCRoE) into three groups'],"['real-time decision-assist machine-learning algorithm, the compensatory reserve measurement (CRM', 'Group 1 viewed a display of no simulated hemorrhage and unchanging vital signs as a control (n = 24); Group 2 viewed a display of simulated hemorrhage and changing vital signs alone']",['average time'],"[{'cui': 'C0587450', 'cui_str': 'Medical department (environment)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0376284', 'cui_str': 'Machine Learning'}, {'cui': 'C0002045'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C0449911', 'cui_str': 'View (attribute)'}, {'cui': 'C1869041', 'cui_str': 'Haemorrhages (SMQ)'}, {'cui': 'C0518766'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}]",,0.0356472,"The average time of 11.0 minutes (95% CI = 8.7 - 13.3 minutes) required by the hemorrhage + CRM group to identify an unstable patient (i.e., stop the video sequence) was reduced by > 40% (p < 0.01) compared to 18.9 minutes (95% CI = 17.2 - 20.5 minutes) in the hemorrhage group. ","[{'ForeName': 'Natalie J', 'Initials': 'NJ', 'LastName': 'Koons', 'Affiliation': 'From the Battlefield Health and Trauma Center for Human Integrative Physiology (N.J.K., S.G.S., J.L.B., V.A.C.), US Army Institute of Surgical Research; and Defense Health Agency Medical Education and Training Campus (G.A.O., D.L.P.), JBSA Fort Sam Houston, Texas.'}, {'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Owens', 'Affiliation': ''}, {'ForeName': 'Donald L', 'Initials': 'DL', 'LastName': 'Parsons', 'Affiliation': ''}, {'ForeName': 'Steven G', 'Initials': 'SG', 'LastName': 'Schauer', 'Affiliation': ''}, {'ForeName': 'Jerome L', 'Initials': 'JL', 'LastName': 'Buller', 'Affiliation': ''}, {'ForeName': 'Victor A', 'Initials': 'VA', 'LastName': 'Convertino', 'Affiliation': ''}]",The journal of trauma and acute care surgery,['10.1097/TA.0000000000002649'] 3044,31313237,Impact of Exercise on Body Composition and Cardiometabolic Risk Factors in Patients Awaiting Bariatric Surgery.,"BACKGROUND The role of exercise to achieve weight reductions in patients awaiting bariatric surgery has been little studied. The aim of this study was to describe the effects of an exercise program on body composition and cardiometabolic risk factors in patients awaiting bariatric surgery. METHODS Twenty-three patients awaiting bariatric surgery were divided into two groups: (a) an exercise group (EG, n = 12) and (b) a control group (CG, n = 11). Both groups received the usual care prior to surgery, but the EG also performed a 12-week exercise program which combined endurance and resistance training. Body composition, cardiometabolic risk factors, physical fitness, basal metabolic rate, and quality of life were assessed at baseline and at the end of the study. RESULTS After the exercise program, the EG achieved significant reductions in total weight (- 7.3 ± 4.1 kg, P < 0.01), fat mass (- 7.1 ± 4.7 kg, P < 0.01), and waist circumference (- 5.3 ± 2.1 cm, P < 0.01), while they maintained their fat-free mass and basal metabolic rate levels. Only the EG showed reductions in HbA1c (- 0.4 ± 0.45%, P < 0.05), systolic (- 10.5 ± 12.7 mmHg), and diastolic blood pressure (- 3.9 ± 5.2 mmHg, P < 0.05), as well as a decrease in waist-to-height ratio (- 0.032 ± 0.12, P < 0.01) and an improvement in quality of life. CONCLUSIONS The implementation of an exercise program prior to bariatric surgery reduces fat mass and central obesity and improves cardiometabolic risk factors and quality of life, especially in the physical scales. TRIAL REGISTRATION The study was registered at ClinicalTrials.gov (NCT03613766).",2019,"Only the EG showed reductions in HbA1c (- 0.4 ± 0.45%, P < 0.05), systolic (- 10.5 ± 12.7 mmHg), and diastolic blood pressure (- 3.9 ± 5.2 mmHg, P < 0.05), as well as a decrease in waist-to-height ratio (- 0.032 ± 0.12, P < 0.01) and an improvement in quality of life. ","['Twenty-three patients awaiting bariatric surgery', 'Patients Awaiting Bariatric Surgery', 'patients awaiting bariatric surgery']","['exercise program', 'Exercise', 'exercise program prior to bariatric surgery', 'usual care prior to surgery, but the EG also performed a 12-week exercise program which combined endurance and resistance training']","['waist-to-height ratio', 'Body composition, cardiometabolic risk factors, physical fitness, basal metabolic rate, and quality of life', 'fat mass and central obesity and improves cardiometabolic risk factors and quality of life', 'diastolic blood pressure', 'total weight', 'Body Composition and Cardiometabolic Risk Factors', 'quality of life', 'weight reductions', 'fat mass', 'systolic', 'waist circumference', 'body composition and cardiometabolic risk factors']","[{'cui': 'C0450348', 'cui_str': '23 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1456587', 'cui_str': 'Bariatric Surgery'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C1456587', 'cui_str': 'Bariatric Surgery'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0518031', 'cui_str': 'Endurance capacity'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C1821269', 'cui_str': 'Height-Weight Ratio'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0678121', 'cui_str': 'Basal metabolic rate (observable entity)'}, {'cui': 'C0034380'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C4551560', 'cui_str': 'Central obesity (disorder)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}]",23.0,0.0221704,"Only the EG showed reductions in HbA1c (- 0.4 ± 0.45%, P < 0.05), systolic (- 10.5 ± 12.7 mmHg), and diastolic blood pressure (- 3.9 ± 5.2 mmHg, P < 0.05), as well as a decrease in waist-to-height ratio (- 0.032 ± 0.12, P < 0.01) and an improvement in quality of life. ","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Marc-Hernández', 'Affiliation': 'Laboratory of Training Analysis and Optimization, Sport Research Center, Miguel Hernandez University, Elche, Spain.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Ruiz-Tovar', 'Affiliation': 'Center of Excellence for the Diagnosis and Treatment of Obesity and Diabetes, Valladolid, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Aracil', 'Affiliation': 'Department of Sport Sciences, Sport Research Center, Miguel Hernandez University, Elche, Spain.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Guillén', 'Affiliation': 'Laboratory of Training Analysis and Optimization, Sport Research Center, Miguel Hernandez University, Elche, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Moya-Ramón', 'Affiliation': 'Laboratory of Training Analysis and Optimization, Sport Research Center, Miguel Hernandez University, Elche, Spain. mmoya@umh.es.'}]",Obesity surgery,['10.1007/s11695-019-04088-9'] 3045,32114063,Comparing Ultrasound-Guided Needling Combined With a Subacromial Corticosteroid Injection Versus High-Energy Extracorporeal Shockwave Therapy for Calcific Tendinitis of the Rotator Cuff: A Randomized Controlled Trial.,"PURPOSE To compare clinical and radiographic outcomes after treatment with standardized high-energy extracorporeal shock wave therapy (ESWT) and ultrasound-guided needling (UGN) in patients with symptomatic calcific tendinitis of the rotator cuff who were nonresponsive to conservative treatment. METHODS The study was designed as a randomized controlled trial. The ESWT group received ESWT (2000 pulses, energy flux density 0.35 mJ/mm 2 ) in 4 sessions with 1-week intervals. UGN was combined with a corticosteroid ultrasound-guided subacromial bursa injection. Shoulder function was assessed at standardized follow-up intervals (6 weeks and 3, 6, and 12 months) using the Constant Murley Score (CMS), the Disabilities of the Arm, Shoulder, and Hand questionnaire, and visual analog scale for pain and satisfaction. The size, location, and morphology of the deposits were evaluated on radiographs. The a priori sample size calculation computed that 44 participants randomized in each treatment group was required to achieve a power of 80%. RESULTS Eighty-two patients were treated (56 female, 65%; mean age 52.1 ± 9 years) with a mean baseline CMS of 66.8 ± 12 and mean calcification size of 15.1 ± 4.7 mm. One patient was lost to follow-up. At 1-year follow-up, the UGN group showed similar results as the ESWT group with regard to the change from baseline CMS (20.9 vs 15.7; P = .23), Disabilities of the Arm, Shoulder, and Hand questionnaire (-20.1 vs -20.7; P = .78), and visual analog scale for pain (-3.9 and -2.6; P = .12). The mean calcification size decreased by 13 ± 3.9 mm in the UGN group and 6.7 ± 8.2 mm in the ESWT group (.05). CONCLUSION Perioperative duloxetine did not reduce pain, need for narcotic analgesia, or hospital length of stay following laparoscopic hysterectomy.",2020,"The groups did not differ in terms of postoperative narcotic analgesic use and hospital length of stay (p > .05). ","['Of 100 patients enrolled, 80', 'A university hospital', 'patients recovering from laparoscopic hysterectomy']","['laparoscopic hysterectomy', 'perioperative duloxetine', 'duloxetine', 'placebo', 'Laparoscopic Hysterectomy', 'duloxetine or placebo', 'Perioperative Duloxetine', 'Placebo']","['pain, need for narcotic analgesia, or reduce hospital length of stay', 'median total QoR-40 scores', 'Quality of Recovery (QoR)-40 questionnaire', 'pain management', 'Pain Management', 'postoperative narcotic analgesic use and hospital length of stay', 'questionnaire scores, opioid analgesic use, and hospital length of stay']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0521108', 'cui_str': 'Recovering from (contextual qualifier) (qualifier value)'}, {'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy (procedure)'}]","[{'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy (procedure)'}, {'cui': 'C0245561', 'cui_str': 'duloxetine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C0027415', 'cui_str': 'Narcotics'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0002766', 'cui_str': 'Pain management (procedure)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0027409', 'cui_str': 'Narcotic Analgesics'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0002772', 'cui_str': 'Analgesics, Opioid'}]",80.0,0.494381,"The groups did not differ in terms of postoperative narcotic analgesic use and hospital length of stay (p > .05). ","[{'ForeName': 'Ozguc', 'Initials': 'O', 'LastName': 'Takmaz', 'Affiliation': 'Department of Obstetrics and Gynecology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey (Drs. Takmaz, Bastu, Ozbasli, Gundogan, Karabuk, Dede, Naki, Kose, and Gungor).'}, {'ForeName': 'Ercan', 'Initials': 'E', 'LastName': 'Bastu', 'Affiliation': 'Department of Obstetrics and Gynecology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey (Drs. Takmaz, Bastu, Ozbasli, Gundogan, Karabuk, Dede, Naki, Kose, and Gungor). Electronic address: ercanbastu@gmail.com.'}, {'ForeName': 'Esra', 'Initials': 'E', 'LastName': 'Ozbasli', 'Affiliation': 'Department of Obstetrics and Gynecology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey (Drs. Takmaz, Bastu, Ozbasli, Gundogan, Karabuk, Dede, Naki, Kose, and Gungor).'}, {'ForeName': 'Savas', 'Initials': 'S', 'LastName': 'Gundogan', 'Affiliation': 'Department of Obstetrics and Gynecology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey (Drs. Takmaz, Bastu, Ozbasli, Gundogan, Karabuk, Dede, Naki, Kose, and Gungor).'}, {'ForeName': 'Emine', 'Initials': 'E', 'LastName': 'Karabuk', 'Affiliation': 'Department of Obstetrics and Gynecology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey (Drs. Takmaz, Bastu, Ozbasli, Gundogan, Karabuk, Dede, Naki, Kose, and Gungor).'}, {'ForeName': 'Muharrem', 'Initials': 'M', 'LastName': 'Kocyigit', 'Affiliation': 'Department of Anesthesiology, Acibadem Mehmet Ali Aydinlar University, Maslak Hospital, Istanbul, Turkey (Dr. Kocyigit).'}, {'ForeName': 'Suat', 'Initials': 'S', 'LastName': 'Dede', 'Affiliation': 'Department of Obstetrics and Gynecology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey (Drs. Takmaz, Bastu, Ozbasli, Gundogan, Karabuk, Dede, Naki, Kose, and Gungor).'}, {'ForeName': 'Murat', 'Initials': 'M', 'LastName': 'Naki', 'Affiliation': 'Department of Obstetrics and Gynecology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey (Drs. Takmaz, Bastu, Ozbasli, Gundogan, Karabuk, Dede, Naki, Kose, and Gungor).'}, {'ForeName': 'Faruk', 'Initials': 'F', 'LastName': 'Kose', 'Affiliation': 'Department of Obstetrics and Gynecology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey (Drs. Takmaz, Bastu, Ozbasli, Gundogan, Karabuk, Dede, Naki, Kose, and Gungor).'}, {'ForeName': 'Mete', 'Initials': 'M', 'LastName': 'Gungor', 'Affiliation': 'Department of Obstetrics and Gynecology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey (Drs. Takmaz, Bastu, Ozbasli, Gundogan, Karabuk, Dede, Naki, Kose, and Gungor).'}]",Journal of minimally invasive gynecology,['10.1016/j.jmig.2019.04.028'] 3048,31587622,"The effects of head rotation exercise on postural balance, muscle strength, and gait in older women.","This study aimed to evaluate the effects of resistive exercise (RE) with head rotation exercise (RE+HRE) on postural balance, lower limb muscle strength, and gait in older women. This study was conducted from December 7, 2015 to January 29, 2016 in Seoul, South Korea. Forty older women were recruited at welfare center and randomly allocated to RE+HRE (n = 20) or RE (n = 20) groups. The RE+HRE group performed RE+HRE for 60 min twice per week for 6 weeks, using an elastic band with variable resistance along the length. The HRE included horizontal or vertical head movement during the exercise. The RE group performed RE in a similar manner, but without head movements. The outcome measures were static postural balance (one-leg stance test, functional reach test, and postural sway), dynamic postural balance (timed up and go test, four square step test, and Mini-balance evaluation systems test), lower limb muscle strength (sit-to-stand test), and temporal gait parameters. In the RE+HRE group, all variables were significantly improved compared to baseline ( p < .05), and postural balance and gait were significantly improved compared to those in the RE group ( p < .05). These findings suggest that RE+HRE can improve dynamic postural balance, gait speed, and cadence in older women.",2020,"In the RE+HRE group, all variables were significantly improved compared to baseline ( p < .05), and postural balance and gait were significantly improved compared to those in the RE group ( p < .05).","['Forty older women were recruited at welfare center', 'December 7, 2015 to January 29, 2016 in Seoul, South Korea', 'older women']","['RE', 'RE+HRE', 'head rotation exercise', 'resistive exercise (RE) with head rotation exercise (RE+HRE']","['dynamic postural balance, gait speed, and cadence', 'static postural balance (one-leg stance test, functional reach test, and postural sway), dynamic postural balance (timed up and go test, four square step test, and Mini-balance evaluation systems test), lower limb muscle strength (sit-to-stand test), and temporal gait parameters', 'postural balance, muscle strength, and gait', 'postural balance and gait', 'postural balance, lower limb muscle strength, and gait']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C3850150', 'cui_str': 'Seoul'}, {'cui': 'C0022773', 'cui_str': 'South Korea'}]","[{'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0203991', 'cui_str': 'Resistive exercise (regime/therapy)'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C1256755', 'cui_str': 'Postural Equilibrium'}, {'cui': 'C2009910', 'cui_str': 'Gait Speed'}, {'cui': 'C0441463', 'cui_str': 'Static (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C1998271', 'cui_str': 'Functional reach test (procedure)'}, {'cui': 'C0205278', 'cui_str': 'Postural (qualifier value)'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go'}, {'cui': 'C0205120', 'cui_str': 'Square (qualifier value)'}, {'cui': 'C0087028', 'cui_str': 'Step Test'}, {'cui': 'C0445542', 'cui_str': 'Mini (qualifier value)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C3888057', 'cui_str': 'Stand'}, {'cui': 'C0442043', 'cui_str': 'Temporal (qualifier value)'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",40.0,0.0251367,"In the RE+HRE group, all variables were significantly improved compared to baseline ( p < .05), and postural balance and gait were significantly improved compared to those in the RE group ( p < .05).","[{'ForeName': 'Wonjae', 'Initials': 'W', 'LastName': 'Choi', 'Affiliation': 'Physical Therapy, Institute of SMART Rehabilitation, Sahmyook University, Seoul, Korea (the Republic of).'}, {'ForeName': 'Changmin', 'Initials': 'C', 'LastName': 'Han', 'Affiliation': 'Physical Therapy, Moon Rehab, New York, USA.'}, {'ForeName': 'Seungwon', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'Physical Therapy, Institute of SMART Rehabilitation, Sahmyook University, Seoul, Korea (the Republic of).'}]",Women & health,['10.1080/03630242.2019.1662870'] 3049,31248744,Family Physical Activity Planning and Child Physical Activity Outcomes: A Randomized Trial.,"INTRODUCTION Regular moderate-to-vigorous physical activity and high physical fitness are extremely important to the health of children and track to positive health profiles in adulthood. Family-based interventions to improve moderate-to-vigorous physical activity are essential given that children live within a structure of parental influence. The purpose of this study was to examine the effect of a parent planning skills intervention to support child physical activity on the subsequent moderate-to-vigorous physical activity (primary outcome) and fitness of their children across 26 weeks (primary endpoint). STUDY DESIGN Two-arm randomized trial with physical activity assessment at baseline 6 weeks, 13 weeks, and 26 weeks and fitness and BMI tests at baseline and 26 weeks from 2012 and 2017. SETTING/PARTICIPANTS One hundred and two children (aged 6-12 years) who were below international physical activity recommendations at baseline were recruited through advertisements. INTERVENTION Participants received a planning plus education intervention (n=52) or an education-only intervention (n=50). MAIN OUTCOME MEASURES Moderate-to-vigorous physical activity was assessed via accelerometry and fitness tests included aerobic fitness, muscular strength, flexibility. BMI was calculated by objectively assessed height and weight. RESULTS Generalized linear mixed modeling conducted in 2019 showed that the patterns varied by condition over time (β=-0.05, p<0.05), where children in the planning intervention significantly increased moderate-to-vigorous physical activity compared with the education condition at 6 weeks and 13 weeks but not at 26 weeks. Aerobic fitness (p=0.04, d=0.26) was the only significant health-related physical fitness change between the two groups and favored the planning group over the education group. CONCLUSIONS There was initial efficacy of the planning intervention, but effectiveness waned by 26 weeks. These changes appeared to be sufficient for modest changes in aerobic fitness. Future research should aim to improve the maintenance of these early positive changes and assist parents in planning for activities that also include opportunities to improve child musculoskeletal fitness. TRIAL REGISTRATION This study is registered at www.clinicaltrials.gov NCT01882192.",2019,"Aerobic fitness (p=0.04, d=0.26) was the only significant health-related physical fitness change between the two groups and favored the planning group over the education group. ",['One hundred and two children (aged 6-12 years) who were below international physical activity recommendations at baseline were recruited through advertisements'],"['planning plus education intervention (n=52) or an education-only intervention', 'parent planning skills intervention']","['Family Physical Activity Planning and Child Physical Activity', 'BMI', 'moderate-to-vigorous physical activity', 'Aerobic fitness', 'aerobic fitness, muscular strength, flexibility']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0949214', 'cui_str': 'Advertisements'}]","[{'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning (observable entity)'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning (observable entity)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0442025', 'cui_str': 'Muscular (qualifier value)'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}]",102.0,0.0529452,"Aerobic fitness (p=0.04, d=0.26) was the only significant health-related physical fitness change between the two groups and favored the planning group over the education group. ","[{'ForeName': 'Ryan E', 'Initials': 'RE', 'LastName': 'Rhodes', 'Affiliation': 'School of Exercise Science, Physical and Health Education, University of Victoria, Victoria, British Columbia, Canada. Electronic address: rhodes@uvic.ca.'}, {'ForeName': 'Chris M', 'Initials': 'CM', 'LastName': 'Blanchard', 'Affiliation': 'Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Quinlan', 'Affiliation': 'School of Exercise Science, Physical and Health Education, University of Victoria, Victoria, British Columbia, Canada.'}, {'ForeName': 'Patti-Jean', 'Initials': 'PJ', 'LastName': 'Naylor', 'Affiliation': 'School of Exercise Science, Physical and Health Education, University of Victoria, Victoria, British Columbia, Canada.'}, {'ForeName': 'Darren E R', 'Initials': 'DER', 'LastName': 'Warburton', 'Affiliation': 'School of Kinesiology, University of British Columbia, Vancouver, British Columbia, Canada.'}]",American journal of preventive medicine,['10.1016/j.amepre.2019.03.007'] 3050,31248745,"Frequent Nutritional Feedback, Personalized Advice, and Behavioral Changes: Findings from the European Food4Me Internet-Based RCT.","INTRODUCTION This study tested the hypothesis that providing personalized nutritional advice and feedback more frequently would promote larger, more appropriate, and sustained changes in dietary behavior as well as greater reduction in adiposity. STUDY DESIGN A 6-month RCT (Food4Me) was conducted in seven European countries between 2012 and 2013. SETTING/PARTICIPANTS A total of 1,125 participants were randomized to Lower- (n=562) or Higher- (n=563) Frequency Feedback groups. INTERVENTION Participants in the Lower-Frequency group received personalized nutritional advice at baseline and at Months 3 and 6 of the intervention, whereas the Higher-Frequency group received personalized nutritional advice at baseline and at Months 1, 2, 3 and 6. MAIN OUTCOME MEASURES The primary outcomes were change in dietary intake (at food and nutrient levels) and obesity-related traits (body weight, BMI, and waist circumference). Participants completed an online Food Frequency Questionnaire to estimate usual dietary intake at baseline and at Months 3 and 6 of the intervention. Overall diet quality was evaluated using the 2010 Healthy Eating Index. Obesity-related traits were self-measured and reported by participants via the Internet. Statistical analyses were performed during the first quarter of 2018. RESULTS At 3 months, participants in the Lower- and Higher-Frequency Feedback groups showed improvements in Healthy Eating Index score; this improvement was larger in the Higher-Frequency group than the Lower-Frequency group (Δ=1.84 points, 95% CI=0.79, 2.89, p=0.0001). Similarly, there were greater improvements for the Higher- versus Lower-Frequency group for body weight (Δ= -0.73 kg, 95% CI= -1.07, -0.38, p<0.0001), BMI (Δ= -0.24 kg/m 2 , 95% CI= -0.36, -0.13, p<0.0001), and waist circumference (Δ= -1.20 cm, 95% CI= -2.36, -0.04, p=0.039). However, only body weight and BMI remained significant at 6 months. CONCLUSIONS At 3 months, higher-frequency feedback produced larger improvements in overall diet quality as well as in body weight and waist circumference than lower-frequency feedback. However, only body weight and BMI remained significant at 6 months. TRIAL REGISTRATION This study is registered at www.clinicaltrials.gov NCT01530139.",2019,"At 3 months, higher-frequency feedback produced larger improvements in overall diet quality as well as in body weight and waist circumference than lower-frequency feedback.","['n=563', '1,125 participants were randomized to Lower', '2010 Healthy Eating Index', 'A 6-month RCT (Food4Me) was conducted in seven European countries between 2012 and 2013', 'n=562) or Higher']","['personalized nutritional advice at baseline and at Months 3 and 6 of the intervention, whereas the Higher-Frequency group received personalized nutritional advice']","['Healthy Eating Index score', 'BMI', 'waist circumference', 'change in dietary intake (at food and nutrient levels) and obesity-related traits (body weight, BMI, and waist circumference', 'body weight and BMI', 'overall diet quality', 'body weight and waist circumference', 'Overall diet quality', 'body weight']","[{'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C4280021', 'cui_str': 'Healthy Eating Index'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0454713', 'cui_str': 'European country (geographic location)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]","[{'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205212', 'cui_str': 'High frequency (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C4280021', 'cui_str': 'Healthy Eating Index'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}]",1125.0,0.0796778,"At 3 months, higher-frequency feedback produced larger improvements in overall diet quality as well as in body weight and waist circumference than lower-frequency feedback.","[{'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Celis-Morales', 'Affiliation': 'Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Exercise Physiology Research Centre (CIFE), Universidad Mayor, Santiago, Chile; BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Katherine M', 'Initials': 'KM', 'LastName': 'Livingstone', 'Affiliation': 'Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Victoria, Australia.'}, {'ForeName': 'Fanny', 'Initials': 'F', 'LastName': 'Petermann-Rocha', 'Affiliation': 'BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Santiago', 'Initials': 'S', 'LastName': 'Navas-Carretero', 'Affiliation': 'Department of Nutrition, Food Science and Physiology, University of Navarra, Pamplona, Spain; CIBERobn, Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'San-Cristobal', 'Affiliation': 'Department of Nutrition, Food Science and Physiology, University of Navarra, Pamplona, Spain; Precision Nutrition and Cardiometabolic Health, IMDEA-Food Institute, Madrid Institute for Advanced Studies, CEI UAM\u202f+\u202fCSIC, Madrid, Spain.'}, {'ForeName': 'Clare B', 'Initials': 'CB', 'LastName': ""O'Donovan"", 'Affiliation': 'UCD Institute of Food and Health, University College Dublin, Belfield, Dublin, Republic of Ireland.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Moschonis', 'Affiliation': 'Department of Dietetics, Nutrition and Sport, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Yannis', 'Initials': 'Y', 'LastName': 'Manios', 'Affiliation': 'Department of Nutrition and Dietetics, Harokopio University, Athens, Greece.'}, {'ForeName': 'Iwona', 'Initials': 'I', 'LastName': 'Traczyk', 'Affiliation': 'Department of Human Nutrition, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland.'}, {'ForeName': 'Christian A', 'Initials': 'CA', 'LastName': 'Drevon', 'Affiliation': 'Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Hannelore', 'Initials': 'H', 'LastName': 'Daniel', 'Affiliation': 'Molecular Nutrition Unit, Department Food and Nutrition, Technische Universität München, Munich, Germany.'}, {'ForeName': 'Cyril F M', 'Initials': 'CFM', 'LastName': 'Marsaux', 'Affiliation': 'Department of Human Biology, NUTRIM, School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, The Netherlands.'}, {'ForeName': 'Wim H M', 'Initials': 'WHM', 'LastName': 'Saris', 'Affiliation': 'Department of Human Biology, NUTRIM, School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, The Netherlands.'}, {'ForeName': 'Rosalind', 'Initials': 'R', 'LastName': 'Fallaize', 'Affiliation': 'School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom; Hugh Sinclair Unit of Human Nutrition and Institute for Cardiovascular and Metabolic Research, University of Reading, Reading, United Kingdom.'}, {'ForeName': 'Anna L', 'Initials': 'AL', 'LastName': 'Macready', 'Affiliation': 'Hugh Sinclair Unit of Human Nutrition and Institute for Cardiovascular and Metabolic Research, University of Reading, Reading, United Kingdom.'}, {'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Lovegrove', 'Affiliation': 'Hugh Sinclair Unit of Human Nutrition and Institute for Cardiovascular and Metabolic Research, University of Reading, Reading, United Kingdom.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Gibney', 'Affiliation': 'UCD Institute of Food and Health, University College Dublin, Belfield, Dublin, Republic of Ireland.'}, {'ForeName': 'Eileen R', 'Initials': 'ER', 'LastName': 'Gibney', 'Affiliation': 'UCD Institute of Food and Health, University College Dublin, Belfield, Dublin, Republic of Ireland.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Walsh', 'Affiliation': 'UCD Institute of Food and Health, University College Dublin, Belfield, Dublin, Republic of Ireland.'}, {'ForeName': 'Lorraine', 'Initials': 'L', 'LastName': 'Brennan', 'Affiliation': 'UCD Institute of Food and Health, University College Dublin, Belfield, Dublin, Republic of Ireland.'}, {'ForeName': 'J Alfredo', 'Initials': 'JA', 'LastName': 'Martinez', 'Affiliation': 'Department of Nutrition, Food Science and Physiology, University of Navarra, Pamplona, Spain; CIBERobn, Instituto de Salud Carlos III, Madrid, Spain; Precision Nutrition and Cardiometabolic Health, IMDEA-Food Institute, Madrid Institute for Advanced Studies, CEI UAM\u202f+\u202fCSIC, Madrid, Spain.'}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Mathers', 'Affiliation': 'Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom. Electronic address: john.mathers@newcastle.ac.uk.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of preventive medicine,['10.1016/j.amepre.2019.03.024'] 3051,31402234,Randomized controlled trial to improve primary care follow-up among emergency department patients.,"STUDY OBJECTIVE Primary care (PC) follow-up for discharged emergency department (ED) patients provides patients with further medical attention. We conducted a pilot randomized controlled trial to determine whether using a freely-available physician appointment-booking website results in higher self-reported PC follow-up. METHODS We randomized discharged patients whom treating physicians determined PC follow-up was important and who possessed health insurance but had no PC provider to one of three groups: (1) a PC appointment booked through the booking website prior to ED discharge; (2) written information on how to use the booking website; or (3) usual care (i.e. standard follow-up instructions). We phoned subjects two weeks after the ED visit to determine whether they had completed a PC follow-up visit. We also asked subjects about their satisfaction with obtaining a PC appointment, satisfaction with the ED visit, symptom resolution and subsequent ED visits. The self-reported PCP follow-up rate was compared among the study groups by estimating the risk difference (RD) and 95% CI between usual care and each intervention group. RESULTS 272 subjects were enrolled and randomized and 68% completed the two-week telephone follow-up interview. The self-reported PCP follow-up rate was higher (52%) among subjects whose appointment was booked on the website before ED discharge (RD = 16%; 95% CI -1%, 34%) and lower (25%) for subjects who received booking website information (RD = 13%; 95% CI -32%, 7%) compared to subjects (36%) in the usual care group. A higher percentage of subjects in the booking group were more likely to report being extremely or very satisfied with obtaining a PC appointment (78%) compared to those who received booking website information (54%) or usual care (40%). CONCLUSION Among ED patients that providers judged PC follow-up is important, using a booking website to schedule an appointment before ED discharge resulted in a higher but not statistically significant self-reported PC follow-up rate. This intervention warrants further investigation in a study with a larger sample size and objective follow-up visit data.",2020,"The self-reported PCP follow-up rate was higher (52%) among subjects whose appointment was booked on the website before ED discharge (RD = 16%; 95% CI -1%, 34%) and lower (25%) for subjects who received booking website information (RD = 13%; 95% CI -32%, 7%) compared to subjects (36%) in the usual care group.","['Primary care (PC) follow-up for discharged emergency department (ED) patients provides patients with further medical attention', '272 subjects', 'patients whom treating physicians determined PC follow-up was important and who possessed health insurance but had no PC provider to one of three groups', 'emergency department patients']",[],['PCP follow-up rate'],"[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0021682', 'cui_str': 'Health Insurance'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]",[],"[{'cui': 'C0031381', 'cui_str': '1-(1-Phenylcyclohexyl)piperidine'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]",272.0,0.047437,"The self-reported PCP follow-up rate was higher (52%) among subjects whose appointment was booked on the website before ED discharge (RD = 16%; 95% CI -1%, 34%) and lower (25%) for subjects who received booking website information (RD = 13%; 95% CI -32%, 7%) compared to subjects (36%) in the usual care group.","[{'ForeName': 'Rory J', 'Initials': 'RJ', 'LastName': 'Merritt', 'Affiliation': 'Department of Emergency Medicine, Brown University, 55 Claverick Street, Providence, RI 02903, United States of America. Electronic address: Rory_Merritt@Brown.edu.'}, {'ForeName': 'Paige', 'Initials': 'P', 'LastName': 'Kulie', 'Affiliation': 'Department of Emergency Medicine, George Washington University, Washington, DC, United States of America.'}, {'ForeName': 'Andrew W', 'Initials': 'AW', 'LastName': 'Long', 'Affiliation': 'Department of Emergency Medicine, George Washington University, Washington, DC, United States of America.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Choudhri', 'Affiliation': 'University of Michigan, Ann Arbor, MI, United States of America.'}, {'ForeName': 'Melissa L', 'Initials': 'ML', 'LastName': 'McCarthy', 'Affiliation': 'Department of Health Policy and Management, Department of Emergency Medicine, George Washington University, Washington, DC, United States of America.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2019.158384'] 3052,32081514,Are patient educational resources effective at deterring stroke survivors from considering experimental stem cell treatments? A randomized controlled trial.,"OBJECTIVE To evaluate whether online resources developed to educate people about the risks associated with experimental stem cell (SC) treatments influence stroke survivors' attitudes about the safety and effectiveness of these treatments. METHODS Adult stroke survivors who had not previously received SC treatments (N = 112) were recruited from international stroke advocacy/support groups for a prospective, parallel-group randomized controlled trial. Participants indicated whether they were considering SC treatments (yes/no) prior to, immediately following, and 30-days after reading/viewing the International Society for Stem Cell Research booklet or Stem Cell Network video. Participant attitudes regarding the safety, effectiveness, accessibility and affordability of SC treatments were examined on each occasion, and compared to those of a waitlist control group. RESULTS Significantly fewer participants were considering SC treatments immediately after reading the SC research booklet (p =.031), although neither intervention had any impact after 30-days (p >.05). Waitlist and intervention groups reported positive attitudes toward SC treatments at each assessment. CONCLUSIONS Stroke survivor attitudes toward SC treatments were initially influenced by the patient booklet, however these changes were not maintained. PRACTICAL IMPLICATIONS Clinicians are encouraged to initiate discussions about experimental SC treatments during inpatient rehabilitation and to reinforce the risks throughout subsequent care.",2020,"Significantly fewer participants were considering SC treatments immediately after reading the SC research booklet (p =.031), although neither intervention had any impact after 30-days (p >.05).",['Adult stroke survivors who had not previously received SC treatments (N = 112'],[],"['safety, effectiveness, accessibility and affordability of SC treatments']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4319548', 'cui_str': '112'}]",[],"[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0814630', 'cui_str': 'Affordabilities'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",112.0,0.0626666,"Significantly fewer participants were considering SC treatments immediately after reading the SC research booklet (p =.031), although neither intervention had any impact after 30-days (p >.05).","[{'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Unsworth', 'Affiliation': 'Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Mathias', 'Affiliation': 'Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia. Electronic address: a1064843@adelaide.edu.au.'}, {'ForeName': 'D S', 'Initials': 'DS', 'LastName': 'Dorstyn', 'Affiliation': 'Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'Koblar', 'Affiliation': 'Stroke Research Programme, University of Adelaide School of Medicine, South Australian Health and Medical Research (SAHMRI), Adelaide, South Australia, Australia; Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}]",Patient education and counseling,['10.1016/j.pec.2020.02.012'] 3053,32032786,Microsurgery for Unruptured Cerebral Arteriovenous Malformations in the National Inpatient Sample is More Common Post-ARUBA.,"BACKGROUND The ARUBA trial (A Randomized Trial of Unruptured Brain Arteriovenous Malformations) was the first randomized control trial to investigate unruptured cerebral arteriovenous malformation (cAVM) treatments and concluded that medical management was superior to interventional therapy for the treatment of unruptured cAVMs. This conclusion generated considerable controversy and was followed by rebuttals and meta-analyses of the ARUBA methodology and results. We sought to determine whether the ARUBA results altered treatment trends of cAVMs within the United States. METHODS Using the National Inpatient Sample, the largest all-payer inpatient care database within the United States, we isolated patients who were admitted on an elective basis for cAVM treatment and determined the treatment modality undergone by these patients. The cohort was dichotomized separately at 2 ARUBA time points: the European Stroke Conference presentation in May 2013, and The Lancet publication in February 2014. RESULTS We found that the overall treatment rate of unruptured cAVMs decreased after both time points. However, the rate of surgical excision alone, relative to other modalities, was significantly increased, and endovascular intervention demonstrated a nonsignificant decrease. CONCLUSIONS Our findings suggest that the ARUBA trial has influenced unruptured cAVM treatment patterns within the United States. Although the overall treatment rate has decreased, unruptured cAVMs, when treated post-ARUBA, are most commonly approached with surgical excision alone.",2020,"However, the rate of surgical excision alone, relative to other modalities, was significantly increased, and endovascular intervention demonstrated a nonsignificant decrease. ","['Unruptured Brain Arteriovenous Malformations', 'National Inpatient Sample, the largest all-payer inpatient care database within the United States, we isolated patients who were admitted on an elective basis for cAVM treatment and determined the treatment modality undergone by these patients']",[],"['unruptured cAVMs', 'rate of surgical excision alone']","[{'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0003857', 'cui_str': 'Arteriovenous Malformations'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0043237', 'cui_str': 'WHO'}, {'cui': 'C1626935', 'cui_str': 'Base'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}]",[],"[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}]",,0.0468672,"However, the rate of surgical excision alone, relative to other modalities, was significantly increased, and endovascular intervention demonstrated a nonsignificant decrease. ","[{'ForeName': 'Lee A', 'Initials': 'LA', 'LastName': 'Birnbaum', 'Affiliation': 'Department of Neurosurgery, University of Texas Health San Antonio, San Antonio, Texas, USA. Electronic address: birnbaum@uthscsa.edu.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Straight', 'Affiliation': 'Department of Neurosurgery, University of Texas Health San Antonio, San Antonio, Texas, USA.'}, {'ForeName': 'Sheetal', 'Initials': 'S', 'LastName': 'Hegde', 'Affiliation': 'Department of Neurosurgery, University of Texas Health San Antonio, San Antonio, Texas, USA.'}, {'ForeName': 'John V', 'Initials': 'JV', 'LastName': 'Lacci', 'Affiliation': 'Department of Neurosurgery, University of Texas Health San Antonio, San Antonio, Texas, USA.'}, {'ForeName': 'Mateja', 'Initials': 'M', 'LastName': 'de Leonni Stanonik', 'Affiliation': 'Department of Neurosurgery, University of Texas Health San Antonio, San Antonio, Texas, USA.'}, {'ForeName': 'Justin R', 'Initials': 'JR', 'LastName': 'Mascitelli', 'Affiliation': 'Department of Neurosurgery, University of Texas Health San Antonio, San Antonio, Texas, USA.'}, {'ForeName': 'Cameron M', 'Initials': 'CM', 'LastName': 'McDougall', 'Affiliation': 'Department of Neurosurgery, University of Texas Health San Antonio, San Antonio, Texas, USA.'}, {'ForeName': 'Jean-Louis R', 'Initials': 'JR', 'LastName': 'Caron', 'Affiliation': 'Department of Neurosurgery, University of Texas Health San Antonio, San Antonio, Texas, USA.'}]",World neurosurgery,['10.1016/j.wneu.2020.01.211'] 3054,31744331,"Research Needs and Priorities for Catheter Ablation of Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop.","Catheter ablation has brought major advances in the management of patients with atrial fibrillation (AF). As evidenced by multiple randomized trials, AF catheter ablation can reduce the risk of recurrent AF and improve quality of life. In some studies, AF ablation significantly reduced cardiovascular hospitalizations. Despite the existing data on AF catheter ablation, numerous knowledge gaps remain concerning this intervention. This report is based on a recent virtual workshop convened by the National Heart, Lung, and Blood Institute to identify key research opportunities in AF ablation. We outline knowledge gaps related to emerging technologies, the relationship between cardiac structure and function and the success of AF ablation in patient subgroups in whom clinical benefit from ablation varies, and potential platforms to advance clinical research in this area. This report also considers the potential value and challenges of a sham ablation randomized trial. Prioritized research opportunities are identified and highlighted to empower relevant stakeholders to collaborate in designing and conducting effective, cost-efficient, and transformative research to optimize the use and outcomes of AF ablation.",2020,"In some studies, AF ablation significantly reduced cardiovascular hospitalizations.","['patients with atrial fibrillation (AF', 'Atrial Fibrillation']","['AF ablation', 'Catheter ablation', 'AF catheter ablation']","['cardiovascular hospitalizations', 'quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}]","[{'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0162563', 'cui_str': 'Catheter Ablation'}]","[{'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0034380'}]",,0.0172834,"In some studies, AF ablation significantly reduced cardiovascular hospitalizations.","[{'ForeName': 'Sana M', 'Initials': 'SM', 'LastName': 'Al-Khatib', 'Affiliation': 'Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (S.M.A., J.P.P.).'}, {'ForeName': 'Emelia J', 'Initials': 'EJ', 'LastName': 'Benjamin', 'Affiliation': 'Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, and Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.).'}, {'ForeName': 'Alfred E', 'Initials': 'AE', 'LastName': 'Buxton', 'Affiliation': 'Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (A.E.B.).'}, {'ForeName': 'Hugh', 'Initials': 'H', 'LastName': 'Calkins', 'Affiliation': 'Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD (H.C.).'}, {'ForeName': 'Mina K', 'Initials': 'MK', 'LastName': 'Chung', 'Affiliation': 'Department of Cardiovascular Medicine, Cleveland Clinic, OH (M.K.C.).'}, {'ForeName': 'Anne B', 'Initials': 'AB', 'LastName': 'Curtis', 'Affiliation': 'Department of Medicine, University at Buffalo School of Medicine and Biomedical Sciences, NY (A.B.C.).'}, {'ForeName': 'Patrice', 'Initials': 'P', 'LastName': 'Desvigne-Nickens', 'Affiliation': 'Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (P.D.N., Y.R., L.S.C.).'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Jais', 'Affiliation': 'Cardiology Hospital, University of Bordeaux, France (P.J.).'}, {'ForeName': 'Douglas L', 'Initials': 'DL', 'LastName': 'Packer', 'Affiliation': 'Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (D.L.P.).'}, {'ForeName': 'Jonathan P', 'Initials': 'JP', 'LastName': 'Piccini', 'Affiliation': 'Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (S.M.A., J.P.P.).'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Rosenberg', 'Affiliation': 'Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (P.D.N., Y.R., L.S.C.).'}, {'ForeName': 'Andrea M', 'Initials': 'AM', 'LastName': 'Russo', 'Affiliation': 'Division of Cardiology, Cooper University, Camden, NJ (A.M.R.).'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Wang', 'Affiliation': 'Departments of Medicine and Health Research and Policy, Stanford University, CA (P.J.W.).'}, {'ForeName': 'Lawton S', 'Initials': 'LS', 'LastName': 'Cooper', 'Affiliation': 'Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (P.D.N., Y.R., L.S.C.).'}, {'ForeName': 'Alan S', 'Initials': 'AS', 'LastName': 'Go', 'Affiliation': 'Division of Research, Kaiser Permanente Northern California, Oakland (A.S.G.).'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Circulation,['10.1161/CIRCULATIONAHA.119.042706'] 3055,31044227,Blood Pressure Variability Is Associated With White Matter Lesion Growth in Intracranial Atherosclerosis.,"BACKGROUND High blood pressure variability (BPV) is associated with recurrent stroke. We investigated the association between BPV, new ischemic lesions (NILs), and white matter lesion (WML) growth in patients with ischemic stroke due to intracranial atherosclerosis (ICAS). METHODS This study was performed as a post-hoc analysis of the STABLE-ICAS trial, which enrolled subacute ischemic stroke patients with symptomatic ICAS (>50% stenosis) and hypertension. BPV was measured at the office (visit by visit) and at home (day by day). Patients were divided into 3 groups (tertiles) according to their home BPV. WML growth and the occurrence of NILs were compared among the 3 groups. Multivariable analyses were performed to identify the independent risk factors of WML growth and NILs. RESULTS Of the 111 enrolled patients, 69 patients (67.6%) demonstrated WML growth and 15 patients (13.7%) had NILs. Patients with higher BPV demonstrated a more WML growth (50% vs. 61.8% vs. 83.8; P = 0.02, by tertiles) and more NILs (5.4% vs. 5.4% vs. 29.7%; P = 0.002, by tertiles). In multivariable analyses, old age [odds ratio (OR) = 1.052 (95% confidence interval (CI) = 1.005-1.101); P = 0.03] and home BPV [OR = 1.149 (95% CI = 1.013-1.304); P = 0.02] were independently associated with WML growth. Low mean diastolic blood pressure [OR = 0.913 (95% CI = 0.874-0.984); P = 0.02] and high home BPV [OR = 1.287 (95% CI = 1.086-1.526); P = 0.004] were independently associated with NILs at follow-up. CONCLUSIONS High BPV is associated with WML growth and NIL in ischemic stroke patients with symptomatic ICAS. BPV monitoring at home may be helpful.",2019,"Patients with higher BPV demonstrated a more WML growth (50% vs. 61.8% vs. 83.8; p=0.02, by tertiles) and more NILs (5.4% vs. 5.4% vs. 29.7%; p=0.002, b6y tertiles).","['enrolled subacute ischemic stroke patients with symptomatic ICAS (> 50% stenosis) and hypertension', 'ischemic stroke patients due to intracranial atherosclerosis (ICAS', 'ischemic stroke patients with symptomatic ICAS']",[],"['BPV', 'WML growth', 'BPV, new ischemic lesions (NILs), and white matter lesion (WML) growth', 'home-BPV', 'WML growth and the occurrence of NILs', 'Blood Pressure Variability', 'Low mean diastolic BP']","[{'cui': 'C0205365', 'cui_str': 'Subacute course'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C1261287', 'cui_str': 'Stenosis'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0751007', 'cui_str': 'Intracranial Atherosclerosis'}]",[],"[{'cui': 'C0531207', 'cui_str': 'bpV(phen)'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C2752009', 'cui_str': 'White matter lesion'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0442734', 'cui_str': 'Nil (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",111.0,0.0235591,"Patients with higher BPV demonstrated a more WML growth (50% vs. 61.8% vs. 83.8; p=0.02, by tertiles) and more NILs (5.4% vs. 5.4% vs. 29.7%; p=0.002, b6y tertiles).","[{'ForeName': 'Bum Joon', 'Initials': 'BJ', 'LastName': 'Kim', 'Affiliation': 'Department of Neurology, Kyung Hee University Hospital, Kyung Hee University, Seoul, South Korea.'}, {'ForeName': 'Sun U', 'Initials': 'SU', 'LastName': 'Kwon', 'Affiliation': 'Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, South Korea.'}, {'ForeName': 'Jong-Moo', 'Initials': 'JM', 'LastName': 'Park', 'Affiliation': 'Department of Neurology, Eulji General Hospital, Eulji University, Seoul, South Korea.'}, {'ForeName': 'Yang-Ha', 'Initials': 'YH', 'LastName': 'Hwang', 'Affiliation': 'Department of Neurology, Kyungpook National University Hospital, Kyungpook National University, Daegu, South Korea.'}, {'ForeName': 'Sung Hyuk', 'Initials': 'SH', 'LastName': 'Heo', 'Affiliation': 'Department of Neurology, Kyung Hee University Hospital, Kyung Hee University, Seoul, South Korea.'}, {'ForeName': 'Joung-Ho', 'Initials': 'JH', 'LastName': 'Rha', 'Affiliation': 'Department of Neurology, Inha University Hospital, Inha University, Incheon, South Korea.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Department of Neurology, Yeungnam University Hospital, Yeungnam University, Daegu, South Korea.'}, {'ForeName': 'Man-Seok', 'Initials': 'MS', 'LastName': 'Park', 'Affiliation': 'Department of Neurology, Chonnam National University Hospital, Gwangju, South Korea.'}, {'ForeName': 'Joon-Tae', 'Initials': 'JT', 'LastName': 'Kim', 'Affiliation': 'Department of Neurology, Chonnam National University Hospital, Gwangju, South Korea.'}, {'ForeName': 'Hee-Jung', 'Initials': 'HJ', 'LastName': 'Song', 'Affiliation': 'Department of Neurology, Chungnam National University Hospital, Daejeon, South Korea.'}, {'ForeName': 'Jong-Ho', 'Initials': 'JH', 'LastName': 'Park', 'Affiliation': 'Department of Neurology, Hanyang University, Seoul, South Korea.'}, {'ForeName': 'Sungwook', 'Initials': 'S', 'LastName': 'Yu', 'Affiliation': 'Department of Neurology, Anam Hospital, Korea University, Seoul, South Korea.'}, {'ForeName': 'Soo Joo', 'Initials': 'SJ', 'LastName': 'Lee', 'Affiliation': 'Department of Neurology, Eulji University Hospital, Eulji University, Daejeon, South Korea.'}, {'ForeName': 'Tai Hwan', 'Initials': 'TH', 'LastName': 'Park', 'Affiliation': 'Department of Neurology, Seoul Medical Center, Seoul, South Korea.'}, {'ForeName': 'Jae-Kwan', 'Initials': 'JK', 'LastName': 'Cha', 'Affiliation': 'Department of Neurology, Dong-A University Hospital, Busan, South Korea.'}, {'ForeName': 'Hyung-Min', 'Initials': 'HM', 'LastName': 'Kwon', 'Affiliation': 'Department of Neurology, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Eung-Gyu', 'Initials': 'EG', 'LastName': 'Kim', 'Affiliation': 'Department of Neurology, Busan Paik Hospital, Inje University, Busan, South Korea.'}, {'ForeName': 'Seung-Hoon', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Department of Neurology, Seoul National University Hospital, Seoul, South Korea.'}, {'ForeName': 'Ji Sung', 'Initials': 'JS', 'LastName': 'Lee', 'Affiliation': 'Clinical Research Center, Asan Medical Center, Seoul, South Korea.'}, {'ForeName': 'Juneyoung', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Department of Biostatistics, Korea University, Seoul, South Korea.'}, {'ForeName': 'Dong-Wha', 'Initials': 'DW', 'LastName': 'Kang', 'Affiliation': 'Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, South Korea.'}]",American journal of hypertension,['10.1093/ajh/hpz068'] 3056,31786338,"An exploratory randomized sub-study of light-to-moderate intensity exercise on cognitive function, depression symptoms and inflammation in older adults with heart failure.","OBJECTIVE Almost half of patients with heart failure (HF) have cognitive impairment. While exercise relates to better cognitive health, a hallmark of HF is exercise intolerance. The study objective was to explore whether light-to-moderate exercise improves cognitive function in patients with HF. METHODS This was an exploratory parallel design study of 69 patients with symptomatic HF (mean age = 65, SD = 10), recruited from VA and University of California, San Diego Healthcare Systems. Participants were randomized to Tai Chi (TC) (n = 24), resistance band (RB) exercise (n = 22) or treatment as usual (TAU) (n = 23). The primary outcome was change in Montreal Cognitive Assessment (MoCA) scores. We further explored if changes in Beck Depression Inventory - IA (BDI-IA) scores or inflammation biomarkers, CRP, TNFα and IL-6 related to altered cognitive function. RESULTS There was a fixed effect of group for MoCA scores changes (F = 8.07, p = .001). TC and RB groups had greater MoCA score increases versus TAU, but no differences were found between TC and RB. Depression symptom changes predicted altered MoCA scores (ΔR 2  = 0.15, Β = -0.413, p = .001). However, group did not interact with depression symptom levels for MoCA alterations (p = .392). Changes in CRP levels predicted MoCA scores (ΔR 2  = 0.078, Β = -0.283, p = .01), but group did not interact with CRP levels for MoCA alterations (p = .689). CONCLUSIONS Light-to-moderate exercises, TC and RB may improve cognitive function. However, the mechanisms remain unclear. ClinicalTrials.gov: NCT01625819.",2020,"There was a fixed effect of group for MoCA scores changes (F = 8.07, p = .001).","['patients with heart failure (HF', 'older adults with heart failure', 'patients with HF', '69 patients with symptomatic HF']","['TC and RB', 'resistance band (RB) exercise (n\xa0=\xa022) or treatment as usual (TAU) ', 'light-to-moderate exercise', 'light-to-moderate intensity exercise', 'Tai Chi (TC']","['MoCA score', 'MoCA scores changes', 'Changes in CRP levels predicted MoCA scores', 'cognitive function', 'MoCA scores', 'cognitive function, depression symptoms and inflammation', 'Beck Depression Inventory - IA (BDI-IA) scores or inflammation biomarkers, CRP, TNFα and IL-6', 'Montreal Cognitive Assessment (MoCA) scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}]","[{'cui': 'C0185014', 'cui_str': 'Banding'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0376403', 'cui_str': 'Taiji'}]","[{'cui': 'C4721272', 'cui_str': 'Montreal cognitive assessment score'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory (assessment scale)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}]",69.0,0.064532,"There was a fixed effect of group for MoCA scores changes (F = 8.07, p = .001).","[{'ForeName': 'Laura S', 'Initials': 'LS', 'LastName': 'Redwine', 'Affiliation': 'Department of Psychiatry, University of California, San Diego, CA, USA; College of Nursing, University of South Florida, Tampa, FL, USA. Electronic address: lredwine@usf.edu.'}, {'ForeName': 'Meredith A', 'Initials': 'MA', 'LastName': 'Pung', 'Affiliation': 'Department of Family Medicine and Public Health, University of California, San Diego, CA, USA; College of Nursing, University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Wilson', 'Affiliation': 'Department of Family Medicine and Public Health, University of California, San Diego, CA, USA.'}, {'ForeName': 'Katherine J', 'Initials': 'KJ', 'LastName': 'Bangen', 'Affiliation': 'Department of Psychiatry, University of California, San Diego, CA, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Delano-Wood', 'Affiliation': 'Department of Psychiatry, University of California, San Diego, CA, USA.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Hurwitz', 'Affiliation': 'Psychology Department, University of Miami, USA.'}]",Journal of psychosomatic research,['10.1016/j.jpsychores.2019.109883'] 3057,30145267,A SMART design to determine the optimal treatment of chronic pain among military personnel.,"Chronic pain is a leading cause of disability among active duty service members in the U.S. armed forces. Standard rehabilitative care and complementary and integrative health therapies are used for chronic pain rehabilitation. However, the optimal sequence and duration of these therapies has yet to be determined. This article describes a sequential multiple assignment randomized trial (SMART) protocol being used to identify the optimal components and sequence of standard rehabilitative care and complementary and integrative health therapies for reducing pain impact and improving other patient outcomes. Active duty service members referred to Madigan Army Medical Center for treatment of chronic pain are being recruited to the Determinants of the Optimal Dose and Sequence of Functional Restoration and Integrative Therapies study. Study participants are randomized to either standard rehabilitative care (physical and occupational therapy and psychoeducation) or complementary and integrative health therapies (chiropractic, acupuncture, yoga and psychoeducation). Those participants who do not respond to the first 3 weeks of treatment are randomized to receive an additional 3 weeks of either (1) the alternative treatment or (2) the first-stage treatment plus the alternative treatment. This study will also determine factors associated with treatment response that can support clinical decision making, such as baseline fitness, pain catastrophizing, kinesiophobia, post-traumatic stress, pain self-efficacy, and biological indicators. The information gained from this research will be applicable to all integrative chronic pain rehabilitation programs throughout the U.S. Department of Defense and the U.S. Department of Veterans Affairs, and the broader rehabilitation community.",2018,Active duty service members referred to Madigan Army Medical Center for treatment of chronic pain are being recruited to the Determinants of the Optimal Dose and Sequence of Functional Restoration and Integrative Therapies study.,['chronic pain among military personnel'],"['standard rehabilitative care (physical and occupational therapy and psychoeducation) or complementary and integrative health therapies (chiropractic, acupuncture, yoga and psychoeducation', 'standard rehabilitative care and complementary and integrative health therapies', 'Standard rehabilitative care and complementary and integrative health therapies']",['Chronic pain'],"[{'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}, {'cui': 'C0026126', 'cui_str': 'Armed Forces Personnel'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C1318464', 'cui_str': 'Occupational Therapy'}, {'cui': 'C0871175', 'cui_str': 'Psycho-education'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0008138', 'cui_str': 'Chiropractic'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}]","[{'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}]",,0.0344217,Active duty service members referred to Madigan Army Medical Center for treatment of chronic pain are being recruited to the Determinants of the Optimal Dose and Sequence of Functional Restoration and Integrative Therapies study.,"[{'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Flynn', 'Affiliation': 'Madigan Army Medical Center, 9040 Jackson Ave, Tacoma, WA 98431, USA. Electronic address: diane.m.flynn4.civ@mail.mil.'}, {'ForeName': 'Linda H', 'Initials': 'LH', 'LastName': 'Eaton', 'Affiliation': 'School of Nursing & Health Studies, University of Washington Bothell, Box 358531, Bothell, WA 98011, USA. Electronic address: lineaton@uw.edu.'}, {'ForeName': 'Dale J', 'Initials': 'DJ', 'LastName': 'Langford', 'Affiliation': 'School of Medicine, University of Washington Seattle, Box 356340, Seattle, WA 98195, USA. Electronic address: dalejwl@uw.edu.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Ieronimakis', 'Affiliation': 'Madigan Army Medical Center, Department of Clinical Investigations, 9040 Jackson Ave, Tacoma, WA 98431, USA. Electronic address: nicholas.m.ieronimakis.civ@mail.mil.'}, {'ForeName': 'Honor', 'Initials': 'H', 'LastName': 'McQuinn', 'Affiliation': 'Madigan Army Medical Center, 9040 Jackson Ave, Tacoma, WA 98431, USA. Electronic address: honor.m.mcquinn.civ@mail.mil.'}, {'ForeName': 'Richard O', 'Initials': 'RO', 'LastName': 'Burney', 'Affiliation': 'Madigan Army Medical Center, Department of Clinical Investigations, 9040 Jackson Ave, Tacoma, WA 98431, USA. Electronic address: richard.o.burney.mil@mail.mil.'}, {'ForeName': 'Samuel L', 'Initials': 'SL', 'LastName': 'Holmes', 'Affiliation': 'Madigan Army Medical Center, Department of Pain Management, 9040 Jackson Ave, Tacoma, WA 98431, USA. Electronic address: samuel.l.holmes12.mil@mail.mil.'}, {'ForeName': 'Ardith Z', 'Initials': 'AZ', 'LastName': 'Doorenbos', 'Affiliation': 'College of Nursing, University of Illinois at Chicago, 845 S. Damen Ave, Chicago, IL 60612, USA. Electronic address: ardith@uic.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2018.08.008'] 3058,32075583,"Effects of aquatic physical intervention on fall risk, working memory and hazard-perception as pedestrians in older people: a pilot trial.","BACKGROUND Normal aging is associated with balance, mobility and working memory decline that increase fall risk and influence activity of daily living functions. Mounting evidence suggests that physical activity is beneficial for decreasing aging effects. Previous studies have focused on land-based physical activity. Research concerning the aquatic environment is scarce. The primary objectives of this three arm intervention pilot study were to examine the effects of an aquatic physical intervention program on balance, gait, fall risk and working memory among community-dwelling older individuals. The secondary objective was to examine the effects of an aquatic physical intervention program on safety of street-crossing among community-dwelling older individuals. METHODS Forty-two healthy participants aged 65 or older were enrolled into one of three intervention groups: aquatic physical intervention (API) (N = 13), on-land physical intervention (OLPI) (N = 14) or non-physical intervention (NPI) (N = 15). The intervention took place from 2018 until 2019 at Tel-Aviv University, Sheba medical center and Reich Center. The protocol included 30-min sessions twice a week for 12 weeks. Balance, gait and fall risk were assessed by the Tinneti test, working memory abilities were assessed by digit span and Corsi blocks tests and simulated safe streets-crossing was assessed by the hazard perception test for pedestrians. Testing and data collection was conducted at baseline, after six weeks and 12 weeks of intervention. All members of the professional team involved in evaluating participants were blind to the intervention group to which participants were allocated. RESULTS The differences in Tinetti balance (F (2, 39)=10.03, p < 0.01), fall risk (F (2, 39)=5.62, p0 > .05), digit span forward (F (2, 39)=8.85, p < 0.01) and Corsi blocks forward (F (2, 39)=3.54, p < 0.05) and backward (F (2, 39)=6.50, p < 0.05) scores after 12 weeks between the groups were significant. The API group showed improved scores. The differences in hazard perception test for pedestrians scores after 12 weeks of intervention between the groups were marginally significant (F (2, 39)=3.13, p = 0.055). The API group showed improved scores. CONCLUSIONS These findings may affect experts working with the elderly population when making decisions concerning therapeutic prevention interventions for the deficiencies of elderly patients. Older adults practicing aquatic physical activity could contribute to their increased safety. TRIAL REGISTRATION Trial registration number: ClinicalTrials.gov Registry NCT03510377. Date of registration: 10/31/2017.",2020,"The differences in Tinetti balance (F (2, 39)=10.03, p < 0.01), fall risk (F (2, 39)=5.62, p0 > .05), digit span forward (F (2, 39)=8.85, p < 0.01) and Corsi blocks forward (F (2, 39)=3.54, p < 0.05) and backward (F (2, 39)=6.50, p < 0.05) scores after 12 weeks between the groups were significant.","['older people', 'community-dwelling older individuals', 'elderly patients', 'Older adults practicing aquatic physical activity', 'Forty-two healthy participants aged 65 or older were enrolled into one of three intervention groups']","['aquatic physical intervention (API) (N\u2009=\u200913), on-land physical intervention (OLPI) (N\u2009=\u200914) or non-physical intervention (NPI', 'aquatic physical intervention', 'aquatic physical intervention program']","['Corsi blocks', 'balance, gait, fall risk and working memory', 'hazard perception test for pedestrians scores', 'fall risk, working memory and hazard-perception', 'digit span and Corsi blocks tests and simulated safe streets-crossing', 'digit span', 'Tinneti test, working memory abilities', 'Tinetti balance', 'Balance, gait and fall risk', 'fall risk']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C4319566', 'cui_str': 'Forty-two'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C1268740', 'cui_str': 'Fall risk'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0450063', 'cui_str': 'Pedestrians'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0582802', 'cui_str': 'Digit'}, {'cui': 'C0442658', 'cui_str': 'Street (environment)'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0085732', 'cui_str': 'Ability'}]",42.0,0.021022,"The differences in Tinetti balance (F (2, 39)=10.03, p < 0.01), fall risk (F (2, 39)=5.62, p0 > .05), digit span forward (F (2, 39)=8.85, p < 0.01) and Corsi blocks forward (F (2, 39)=3.54, p < 0.05) and backward (F (2, 39)=6.50, p < 0.05) scores after 12 weeks between the groups were significant.","[{'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Nissim', 'Affiliation': 'Sackler Faculty of Medicine, School of Health Professions, Department of Occupational Therapy, Tel Aviv University, Tel Aviv, Israel. Michal.beren@gmail.com.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Livny', 'Affiliation': 'The Division of Diagnostic Imaging at the Sheba Medical Center, Tel-Hashomer, Israel.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Barmatz', 'Affiliation': 'Sheba Medical Center, Tel-Hashomer, Israel.'}, {'ForeName': 'Galia', 'Initials': 'G', 'LastName': 'Tsarfaty', 'Affiliation': 'The Division of Diagnostic Imaging at the Sheba Medical Center, Tel-Hashomer, Israel.'}, {'ForeName': 'Yitshal', 'Initials': 'Y', 'LastName': 'Berner', 'Affiliation': 'The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Yaron', 'Initials': 'Y', 'LastName': 'Sacher', 'Affiliation': 'The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Giron', 'Affiliation': 'IDC Herzliya, Herzliya, Israel.'}, {'ForeName': 'Navah Z', 'Initials': 'NZ', 'LastName': 'Ratzon', 'Affiliation': 'Sackler Faculty of Medicine, School of Health Professions, Department of Occupational Therapy, Tel Aviv University, Tel Aviv, Israel.'}]",BMC geriatrics,['10.1186/s12877-020-1477-4'] 3059,30676094,Ovarian tissue cryopreservation for patients with premature ovary insufficiency caused by cancer treatment: optimal protocol.,"Objective: Premature ovary insufficiency is frequent after chemotherapy/radiotherapy in cancer patients. Ovarian tissue (OT) cryopreservation and later retransplantation, the routine method in Europe, has recently been implemented at the first center in China. We investigated the protective effect of the antioxidant N -acetyl-l-cysteine (NAC) during the decisive freezing-thawing steps. Methods: Fifteen OT samples were obtained from each of 13 cancer patients prospectively and randomly assigned to a control group and four groups with different NAC concentrations (Group 1, 0 mM NAC; Group 2, 0.5 mM NAC; Group 3, 1 mM NAC; Group 4, 5 mM NAC; Group 5, 25 mM NAC). After thawing, the follicle viability, DNA fragmentation, levels of reactive oxygen species (ROS), and total antioxidant capacity (TAC) were evaluated. Results: OT cryopreserved and thawed with 25 mM NAC (Group 5) has the lowest proportion of apoptotic stroma cells, but the worst follicle viability. The other four groups show similar anti-apoptosis and good follicle viability. Group 4 presented the lowest ROS and highest TAC levels. Conclusions: OT cryopreserved and thawed in medium supplemented with 5 mM NAC shows the highest antioxidant and lowest ROS capability, good apoptotic parameters, and follicle viability. Our results need to be confirmed in larger patient cohorts prior to being accepted as a standard protocol.",2019,"After thawing, the follicle viability, DNA fragmentation, levels of reactive oxygen species (ROS), and total antioxidant capacity (TAC) were evaluated. ","['patients with premature ovary insufficiency', 'cancer patients', 'Methods: Fifteen OT samples were obtained from each of 13 cancer patients']","['chemotherapy/radiotherapy', 'Ovarian tissue (OT) cryopreservation and later retransplantation', 'antioxidant N -acetyl-l-cysteine (NAC', 'control group and four groups with different NAC concentrations (Group 1, 0\u2009mM NAC; Group 2, 0.5\u2009mM NAC; Group 3, 1\u2009mM NAC; Group 4, 5\u2009mM NAC', 'Ovarian tissue cryopreservation']","['anti-apoptosis and good follicle viability', 'lowest ROS and highest TAC levels', 'apoptotic stroma cells', 'follicle viability, DNA fragmentation, levels of reactive oxygen species (ROS), and total antioxidant capacity (TAC', 'highest antioxidant and lowest ROS capability, good apoptotic parameters, and follicle viability']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205252', 'cui_str': 'Immature (qualifier value)'}, {'cui': 'C0029939', 'cui_str': 'Ovary'}, {'cui': 'C0231179', 'cui_str': 'Insufficiency (finding)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}]","[{'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0010405', 'cui_str': 'Cryofixation'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0441869', 'cui_str': 'Group 3 (qualifier value)'}, {'cui': 'C0441876', 'cui_str': 'Group 4 (qualifier value)'}]","[{'cui': 'C0162638', 'cui_str': 'Programmed Cell Death, Type I'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C3489891', 'cui_str': 'TAC(a)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0376669', 'cui_str': 'DNA Fragmentation'}, {'cui': 'C0162772', 'cui_str': 'Active Oxygen'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",,0.0326269,"After thawing, the follicle viability, DNA fragmentation, levels of reactive oxygen species (ROS), and total antioxidant capacity (TAC) were evaluated. ","[{'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'a Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital , Capital Medical University , Beijing , China.'}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Ruan', 'Affiliation': 'a Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital , Capital Medical University , Beijing , China.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Liebenthron', 'Affiliation': ""c University Cryobank for Assisted Reproductive Medicine and Fertility Protection Duesseldorf, UniCareD, University Women's Hospital Duesseldorf , Duesseldorf , Germany.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Montag', 'Affiliation': 'd ilabcomm GmbH , Sankt Augustin , Germany.'}, {'ForeName': 'Q', 'Initials': 'Q', 'LastName': 'Zhou', 'Affiliation': 'e Department of Gynecology, Beijing Obstetrics and Gynecology Hospital , Capital Medical University , Beijing , China.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Kong', 'Affiliation': 'f Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital , Capital Medical University , Beijing , China.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Du', 'Affiliation': 'a Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital , Capital Medical University , Beijing , China.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Jin', 'Affiliation': 'a Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital , Capital Medical University , Beijing , China.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'e Department of Gynecology, Beijing Obstetrics and Gynecology Hospital , Capital Medical University , Beijing , China.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Cheng', 'Affiliation': 'a Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital , Capital Medical University , Beijing , China.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'a Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital , Capital Medical University , Beijing , China.'}, {'ForeName': 'A O', 'Initials': 'AO', 'LastName': 'Mueck', 'Affiliation': 'a Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital , Capital Medical University , Beijing , China.'}]",Climacteric : the journal of the International Menopause Society,['10.1080/13697137.2018.1554644'] 3060,32098534,2-year results of an RCT of 2 uncemented isoelastic monoblock acetabular components: lower wear rate with vitamin E blended highly cross-linked polyethylene compared to ultra-high molecular weight polyethylene.,"Background and purpose - The long-term survival of arthroplasty components may be limited by polyethylene wear-related problems such as periprosthetic osteolysis and aseptic loosening. Highly cross-linked polyethylene (HXLPE) blended with vitamin E was introduced to improve oxidative stability and to avoid long-term embrittlement. This study clinically compares the tribological behavior and clinical outcome of vitamin E blended HXLPE with ultra-high molecular weight polyethylene (UHMWPE) in an isoelastic monoblock cup for uncemented total hip arthroplasty. Patients and methods - In this randomized controlled trial (RCT), 199 patients were included: 102 patients received the vitamin E blended HXLPE cup, 97 patients the UHMWPE cup. Clinical and radiographic parameters were obtained preoperatively, directly postoperative and at 3, 12, and 24 months. Wear rates were compared using the mean linear femoral head penetration (FHP) rate. Results - 188 patients (94%) completed the 2-year follow-up. Mean patient satisfaction was higher in the vitamin E blended HXLPE group (8.9 [1]) than in in the control group (8.5 [2], p = 0.03). The Harris Hip Score (HHS) was higher in the vitamin E blended HXLPE group (95 [8]) than in the control group (92 [11], p = 0.3). The FHP rate was lower in the vitamin E blended HXLPE group: 0.046 mm/year compared with 0.056 mm/year in the control group (p = 0.05). No adverse reactions associated with the clinical application of vitamin E blended HXLPE were observed during follow-up, with an excellent 2-year survival to revision rate of 98% for both cups. Interpretation - This study shows the superior performance of the HXLPE blended with vitamin E acetabular cup with lower linear femoral head penetration rates and better clinical results compared with the UHMWPE acetabular cup after 2 years.",2020,The FHP rate was lower in the vitamin E blended HXLPE group: 0.046 mm/year compared with 0.056 mm/year in the control group (p = 0.05).,"['199 patients were included: 102 patients received the', 'uncemented total hip arthroplasty']","['HXLPE blended with vitamin E acetabular cup', 'vitamin E blended HXLPE', 'Highly cross-linked polyethylene (HXLPE) blended with vitamin E', 'RCT', 'vitamin E blended HXLPE cup', 'vitamin E blended HXLPE with ultra-high molecular weight polyethylene (UHMWPE', 'vitamin E', 'UHMWPE acetabular cup']","['Mean patient satisfaction', '2-year survival to revision rate', 'FHP rate', 'oxidative stability', 'Harris Hip Score (HHS', 'Wear rates']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0186193', 'cui_str': 'Arthroplasty of coxofemoral joint'}]","[{'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C2949743', 'cui_str': 'Cup - unit of product usage'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0137914', 'cui_str': 'Polythene'}, {'cui': 'C0673477', 'cui_str': 'UHMWPE'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0439617', 'cui_str': 'Revision - value'}, {'cui': 'C2919875', 'cui_str': 'Harris hip score (observable entity)'}]",199.0,0.144797,The FHP rate was lower in the vitamin E blended HXLPE group: 0.046 mm/year compared with 0.056 mm/year in the control group (p = 0.05).,"[{'ForeName': 'Joost H J', 'Initials': 'JHJ', 'LastName': 'van Erp', 'Affiliation': 'Clinical Orthopedic Research Center-mN, Zeist, the Netherlands.'}, {'ForeName': 'Julie R A', 'Initials': 'JRA', 'LastName': 'Massier', 'Affiliation': 'Clinical Orthopedic Research Center-mN, Zeist, the Netherlands.'}, {'ForeName': 'Jelle J', 'Initials': 'JJ', 'LastName': 'Halma', 'Affiliation': 'Clinical Orthopedic Research Center-mN, Zeist, the Netherlands.'}, {'ForeName': 'Thom E', 'Initials': 'TE', 'LastName': 'Snijders', 'Affiliation': 'Clinical Orthopedic Research Center-mN, Zeist, the Netherlands.'}, {'ForeName': 'Arthur', 'Initials': 'A', 'LastName': 'de Gast', 'Affiliation': 'Clinical Orthopedic Research Center-mN, Zeist, the Netherlands.'}]",Acta orthopaedica,['10.1080/17453674.2020.1730073'] 3061,31173939,"Minilaparoscopic Total Hysterectomy in Current Practice Feasibility and Benefits: A Unicentric, Randomized Controlled Trial.","STUDY OBJECTIVE To investigate whether mini-instrumentation may be used for hysterectomy (HT) by all surgeons (assistants and seniors) without increasing the operative time or altering surgeon working conditions. DESIGN A unicenter, randomized controlled, single blind, parallel, noninferiority trial comparing 2 surgical techniques. SETTING A tertiary referral center. PATIENTS Thirty-two patients undergoing HT for a benign gynecologic disease were enrolled in this study in our center between April 2, 2015, and June 1, 2018. Sixteen patients were randomized in group A and 16 patients in group B. INTERVENTIONS HT with bilateral annexectomy or ovarian conservation using 3-mm instruments (group A) or conventional 5-mm instruments (group B). MEASUREMENTS AND MAIN RESULTS Concerning the primary outcome, the operative time for the HT 3-mm group was 128 minutes (range, 122-150 minutes) versus 111 minutes (range, 92-143 minutes) for the HT 5-mm group (i.e., δ = 17 [90% confidence interval, -6 to 39]), with rejection of the noninferiority threshold at 35 minutes. Thirty-one percent of HTs initially performed using 3-mm instruments were completed with conventional instruments. HTs performed with mini-instruments required more concentration (p = .02) with surgeons reporting higher levels of frustration (p = .009) and sense of failure (p = .006). Patients tend to experience greater satisfaction regarding scars with a significant difference noted during the postoperative visit both for scar pain (1 vs 4 patients with moderate pain [30-50 mm on the Patient Scar Assessment Scale) in the HT 3-mm group and the HT 5-mm group, respectively) and scar firmness (p = .021; 3 vs 7 patients with moderate firmness [30-50 mm on the Patient Scar Assessment Scale] in the HT 3-mm group and the HT 5-mm group, respectively). CONCLUSION Total minilaparoscopic HT appears inferior to standard laparoscopy in terms of operative time and surgeon working conditions; only the short-term cosmetic appearance was in favor of the 3-mm approach.",2020,Hysterectomy carried out with mini instruments required more concentration (p=0.02) with surgeons reporting higher levels of frustration (p=0.009) and sense of failure (p=0.006).,"['16 patients', 'hysterectomy by all surgeons (assistants and seniors', '32 patients undergoing a hysterectomy for a benign gynecological disease were enrolled in this study in our center between April 2nd 2015 and June 1st 2018']","['surgical techniques', 'Total mini-laparoscopic hysterectomy', 'Mini-laparoscopic total hysterectomy', 'mini-instrumentation', 'Hysterectomy (HT) with bilateral annexectomy or ovarian conservation using 3-mm instruments (group A) or conventional 5-mm instruments']","['postoperative visit both for scar pain', 'operative time', 'scar firmness']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C0582175', 'cui_str': 'Surgeon (occupation)'}, {'cui': 'C0205183', 'cui_str': 'Benign (qualifier value)'}, {'cui': 'C0017411', 'cui_str': 'Gynecologic Diseases'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0205436', 'cui_str': 'Second - ordinal'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0205435', 'cui_str': 'First (qualifier value)'}]","[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0445542', 'cui_str': 'Mini (qualifier value)'}, {'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy (procedure)'}, {'cui': 'C0404090', 'cui_str': 'Laparoscopic total hysterectomy (procedure)'}, {'cui': 'C0021632', 'cui_str': 'instrumentation'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C4551823', 'cui_str': 'instruments'}, {'cui': 'C0441835', 'cui_str': 'Group A (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]","[{'cui': 'C0580703', 'cui_str': 'Postoperative visit (finding)'}, {'cui': 'C0877113', 'cui_str': 'Painful scar'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0008767', 'cui_str': 'Cicatrization'}]",16.0,0.104929,Hysterectomy carried out with mini instruments required more concentration (p=0.02) with surgeons reporting higher levels of frustration (p=0.009) and sense of failure (p=0.006).,"[{'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Béguinot', 'Affiliation': 'Department of Gynecologic Surgery (Drs. Béguinot, Botchorishvili, Comptour, Curinier, Campagne-Loiseau, Chauvet, Pouly, Rabischong, Canis, and Bourdel); Centre Hospitalier Universitaire Clermont-Ferrand, Clermont-Ferrand, France, and Department of Surgery, Jean Perrin Comprehensive Center, Clermont-Ferrand, France (Dr. Béguinot).'}, {'ForeName': 'Revaz', 'Initials': 'R', 'LastName': 'Botchorishvili', 'Affiliation': 'Department of Gynecologic Surgery (Drs. Béguinot, Botchorishvili, Comptour, Curinier, Campagne-Loiseau, Chauvet, Pouly, Rabischong, Canis, and Bourdel).'}, {'ForeName': 'Aurélie', 'Initials': 'A', 'LastName': 'Comptour', 'Affiliation': 'Department of Gynecologic Surgery (Drs. Béguinot, Botchorishvili, Comptour, Curinier, Campagne-Loiseau, Chauvet, Pouly, Rabischong, Canis, and Bourdel).'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Curinier', 'Affiliation': 'Department of Gynecologic Surgery (Drs. Béguinot, Botchorishvili, Comptour, Curinier, Campagne-Loiseau, Chauvet, Pouly, Rabischong, Canis, and Bourdel).'}, {'ForeName': 'Sandrine', 'Initials': 'S', 'LastName': 'Campagne-Loiseau', 'Affiliation': 'Department of Gynecologic Surgery (Drs. Béguinot, Botchorishvili, Comptour, Curinier, Campagne-Loiseau, Chauvet, Pouly, Rabischong, Canis, and Bourdel).'}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Chauvet', 'Affiliation': 'Department of Gynecologic Surgery (Drs. Béguinot, Botchorishvili, Comptour, Curinier, Campagne-Loiseau, Chauvet, Pouly, Rabischong, Canis, and Bourdel).'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Pereira', 'Affiliation': ""Biostatistics Division (Direction de la Recherche Clinique et de l'Innovation) (Dr. Pereira).""}, {'ForeName': 'Jean-Luc', 'Initials': 'JL', 'LastName': 'Pouly', 'Affiliation': 'Department of Gynecologic Surgery (Drs. Béguinot, Botchorishvili, Comptour, Curinier, Campagne-Loiseau, Chauvet, Pouly, Rabischong, Canis, and Bourdel).'}, {'ForeName': 'Benoit', 'Initials': 'B', 'LastName': 'Rabischong', 'Affiliation': 'Department of Gynecologic Surgery (Drs. Béguinot, Botchorishvili, Comptour, Curinier, Campagne-Loiseau, Chauvet, Pouly, Rabischong, Canis, and Bourdel).'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Canis', 'Affiliation': 'Department of Gynecologic Surgery (Drs. Béguinot, Botchorishvili, Comptour, Curinier, Campagne-Loiseau, Chauvet, Pouly, Rabischong, Canis, and Bourdel).'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Bourdel', 'Affiliation': 'Department of Gynecologic Surgery (Drs. Béguinot, Botchorishvili, Comptour, Curinier, Campagne-Loiseau, Chauvet, Pouly, Rabischong, Canis, and Bourdel). Electronic address: nicolas.bourdel@gmail.com.'}]",Journal of minimally invasive gynecology,['10.1016/j.jmig.2019.05.016'] 3062,32100212,Re-recurrence and pain 12 years after laparoscopic transabdominal preperitoneal (TAPP) or Lichtenstein's repair for a recurrent inguinal hernia: a multi-centre single-blinded randomised clinical trial.,"BACKGROUND Long-term clinical outcome after a recurrent inguinal hernia repair may be associated with the type of repair, that is, laparoscopic or open. The results from previous randomised controlled trials are inconclusive regarding the long-term risk of re-recurrence chronic pain. Accordingly, this trial compared laparoscopic transabdominal preperitoneal repair (TAPP) with Lichtenstein's repair. The primary outcome was repair for a re-recurrence. The secondary outcome was chronic pain. METHODS Multi-centre single-blinded, randomised trial on TAPP vs Lichtenstein's repair in male patients operated for a recurrent inguinal hernia after a primary open inguinal hernia repair. Follow-up for repair for a re-recurrence was registered in the Danish Hernia Database. Prospective follow-up data were achieved by a structured questionnaire on pain-related functional impairment using the Activities Assessment Scale (AAS-pain). RESULT A total of 360 patients were randomised, 297 were mailed the follow-up questionnaire (63 excluded) after median 12 years (range 9-15). A total of 265 patients responded to the questionnaire (response rate 89%). The cumulative rate of repair for re-recurrence after 12 years was 10% (95% confidence interval (CI) 5.3-15.1%) vs 10% (5.6-14.7%) after TAPP or Lichtenstein, respectively (p = 0.764). Moderate/severe AAS-pain was reported by 4% (95% CI 1-8%) vs 7% (95% CI 3-11%) patients after TAPP or Lichtenstein, respectively (p = 0.698) CONCLUSION: Long-term re-recurrence rate and incidence of chronic pain was surprisingly high respectless of surgical approach and neither TAPP nor Lichtenstein's procedure was superior to improve surgical results.",2020,Long-term re-recurrence rate and incidence of chronic pain was surprisingly high respectless of surgical approach and neither TAPP nor Lichtenstein's procedure was superior to improve surgical results.,"['265 patients responded to the questionnaire (response rate 89', 'A total of 360 patients were randomised, 297 were mailed the follow-up questionnaire (63 excluded) after median 12\xa0years (range 9-15', 'male patients operated for a recurrent inguinal hernia after a primary open inguinal hernia repair']","[""laparoscopic transabdominal preperitoneal repair (TAPP) with Lichtenstein's repair"", ""TAPP vs Lichtenstein's repair"", 'laparoscopic transabdominal preperitoneal (TAPP', ""Lichtenstein's repair""]","['pain-related functional impairment using the Activities Assessment Scale (AAS-pain', 'chronic pain', 'recurrent inguinal hernia', 'Moderate/severe AAS-pain', 'repair for a re-recurrence', 'cumulative rate of repair for re-recurrence']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4319607', 'cui_str': '360 (qualifier value)'}, {'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0281962', 'cui_str': 'Recurrent inguinal hernia'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0021446', 'cui_str': 'Repair of inguinal hernia (procedure)'}]","[{'cui': 'C0205496', 'cui_str': 'Abdominal approach (qualifier value)'}, {'cui': 'C0442170', 'cui_str': 'Preperitoneal approach (qualifier value)'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C0163807', 'cui_str': 'tetra-4-amidinophenoxypropane'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales (assessment scale)'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}, {'cui': 'C0281962', 'cui_str': 'Recurrent inguinal hernia'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}]",360.0,0.710213,Long-term re-recurrence rate and incidence of chronic pain was surprisingly high respectless of surgical approach and neither TAPP nor Lichtenstein's procedure was superior to improve surgical results.,"[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Lydeking', 'Affiliation': 'GastroUnit, Surgical Division, Hvidovre Hospital, University of Copenhagen,, Hvidovre, Denmark.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Johansen', 'Affiliation': 'Surgical Department, University of Southern Denmark, Kolding Hospital, Kolding, Denmark.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Oehlenschläger', 'Affiliation': 'Surgical Department, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Bay-Nielsen', 'Affiliation': 'Surgical Department of Digestive Disease, Bispebjerg Hospital, University of Copenhagen,, Copenhagen, Denmark.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Bisgaard', 'Affiliation': 'GastroUnit, Surgical Division, Hvidovre Hospital, University of Copenhagen,, Hvidovre, Denmark. thue.bisgaard@gmail.com.'}]",Hernia : the journal of hernias and abdominal wall surgery,['10.1007/s10029-020-02139-0'] 3063,32094516,Effects of hybrid-functional electrical stimulation (FES) rowing whole-body exercise on neurologic improvement in subacute spinal cord injury: secondary outcomes analysis of a randomized controlled trial.,"STUDY DESIGN Secondary outcome measures analysis of a randomized, controlled study. OBJECTIVE To assess the effects of hybrid-functional electrical stimulation (FES) rowing on motor and sensory recovery in individuals with spinal cord injury (SCI) 6-18 months post injury. SETTING Outpatient rehabilitation network. METHODS 25 participants 6-12 months after SCI were randomly assigned to hybrid-FES rowing (n = 10) or standard of care (n = 15) groups. The hybrid-FES rowing group completed 6 months of rowing scheduled 3 times per week for 26 weeks at an exercise intensity of 70-85% of maximal heart rate. The standard of care group either participated in an arm ergometer exercise program (n = 6) or a waitlist without an explicit exercise program (n = 9). Changes in motor score and combined sensory score of the International Standards for Neurological Classification of SCI (ISNCSCI) were analyzed. RESULTS Both groups demonstrated increases in motor and combined sensory scores, but no significant differences were noted between intervention groups (motor difference mean ↑1.3 (95% CI, -1.9 to 4.4), combined sensory difference mean ↓10 (-30 to 18)). There was an average of 63% adherence to the hybrid-FES rowing protocol, with no significant correlation in changes in motor or combined sensory score in the hybrid-FES rowing group with total distance or time rowed. CONCLUSIONS No significant effects to neurologic improvement were found with hybrid-FES rowing when compared with standard of care interventions in individuals with SCI 6-18 months post injury.",2020,No significant effects to neurologic improvement were found with hybrid-FES rowing when compared with standard of care interventions in individuals with SCI 6-18 months post injury.,"['individuals with spinal cord injury (SCI) 6-18 months post injury', '25 participants 6-12 months after SCI', 'Outpatient rehabilitation network', 'subacute spinal cord injury']","['hybrid-FES rowing', 'hybrid-functional electrical stimulation (FES) rowing', 'hybrid-FES rowing (n\u2009=\u200910) or standard of care', 'hybrid-functional electrical stimulation (FES) rowing whole-body exercise', 'care group either participated in an arm ergometer exercise program (n\u2009=\u20096) or a waitlist without an explicit exercise program']","['motor score and combined sensory score', 'motor and combined sensory scores', 'motor or combined sensory score', 'neurologic improvement']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0205365', 'cui_str': 'Subacute course'}]","[{'cui': 'C0020205', 'cui_str': 'Hybrids'}, {'cui': 'C0674267', 'cui_str': 'greigite'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0013786', 'cui_str': 'Electrical Stimulation'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}, {'cui': 'C4505111', 'cui_str': 'Rowing'}, {'cui': 'C0444584', 'cui_str': 'Whole body (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0445254', 'cui_str': 'Sensory (qualifier value)'}, {'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}]",25.0,0.116675,No significant effects to neurologic improvement were found with hybrid-FES rowing when compared with standard of care interventions in individuals with SCI 6-18 months post injury.,"[{'ForeName': 'Raymond C', 'Initials': 'RC', 'LastName': 'Chou', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA, USA. rchou1@partners.org.'}, {'ForeName': 'J Andrew', 'Initials': 'JA', 'LastName': 'Taylor', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Solinsky', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA, USA.'}]",Spinal cord,['10.1038/s41393-020-0445-3'] 3064,32065946,Assessing BDNF as a mediator of the effects of exercise on depression.,"Brain-derived neurotrophic factor (BDNF) is associated with neuronal growth and reduced BDNF has been implicated in depression. A recent meta-analysis documented reliable effects of exercise on BDNF levels (Szuhany et al., 2015); although, few studies included participants with mental health conditions. In this study, we examine whether increased exercise was associated with enhanced BDNF response in depressed patients, and whether this change mediated clinical benefits. A total of 29 depressed, sedentary participants were randomized to receive either behavioral activation (BA) plus an exercise or stretching prescription. Blood was collected prior to (resting BDNF levels) and following an exercise test (pre-to post-exercise BDNF change) at four points throughout the study. Participants also completed depression and exercise assessments. BDNF increased significantly across all assessment points (p < 0.001, d = 0.83). Changes in BDNF from pre-to post-exercise were at a moderate effect for the interaction of exercise and time which did not reach significance (p = 0.13, d = 0.53), with a similar moderate, non-significant effect for resting BDNF levels (p = 0.20, d = 0.49). Contrary to hypotheses, change in resting BDNF or endpoint change in BDNF was not associated with changes in depression. In an intervention that included active treatment (BA), we could not verify an independent predictive effect for changes in BDNF across the trial. Overall, this study adds to the literature showing reliable effects of acute exercise on increasing BDNF and extends this research to the infrequently studied depressed population, but does not clarify the mechanism behind exercise benefits for depression. CLINICAL TRIALS REGISTRY (CLINICALTRIALS.GOV): NCT02176408, ""Efficacy of Adjunctive Exercise for the Behavioral Treatment of Major Depression"".",2020,BDNF increased significantly across all assessment points (,"['Major Depression', 'A total of 29 depressed, sedentary participants', 'depressed patients', 'participants with mental health conditions']","['behavioral activation (BA) plus an exercise or stretching prescription', 'Brain-derived neurotrophic factor (BDNF', 'Adjunctive Exercise']","['BDNF', 'resting BDNF levels', 'enhanced BDNF response']","[{'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0600080', 'cui_str': 'Stretching procedure (procedure)'}, {'cui': 'C0033080', 'cui_str': 'Prescriptions'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}]","[{'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",29.0,0.124543,BDNF increased significantly across all assessment points (,"[{'ForeName': 'Kristin L', 'Initials': 'KL', 'LastName': 'Szuhany', 'Affiliation': 'Department of Psychological and Brain Sciences, Boston University, 900 Commonwealth Avenue, Boston, MA, 02215, USA; Department of Psychiatry, NYU Langone Health, 1 Park Avenue, 8th Floor, New York, NY, 10016, USA. Electronic address: Kristin.szuhany@nyulangone.org.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Otto', 'Affiliation': 'Department of Psychological and Brain Sciences, Boston University, 900 Commonwealth Avenue, Boston, MA, 02215, USA.'}]",Journal of psychiatric research,['10.1016/j.jpsychires.2020.02.003'] 3065,31389909,Effects of Exercise Training and Statin Use in People Living with HIV with Dyslipidemia.,"PURPOSE To evaluate the effects of the combination of ET and statins in people living with HIV. METHODS This was a randomized, double-blind, placebo-controlled clinical trial. Eighty-three people living with HIV were assigned to either placebo (PL), statins (STA), placebo + ET (PLET) or statins + ET (STAET) groups. Volunteers assigned to STA and STAET groups were administered 10 mg of rosuvastatin, whereas the PL and PLET groups were administered a placebo. PLET and STAET groups performed ET three times a week. Before and after the 12-week follow-up, the volunteers underwent to anthropometric assessment and blood collection to evaluate lipid profile, cardiovascular markers, inflammatory profile; a Doppler ultrasound examination, muscle strength (MS) and cardiorespiratory fitness (CF) tests were performed. RESULTS There was a decrease in total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-c), C-reactive protein, fibrinogen, interleukin (IL)-1β and right carotid intima-media thickness (cIMT) in the STA, PLET, and STAET groups compared to PL group (p<0.001). Furthermore, there was a decrease in TC, TG, LDL, IL-1β, IL-6, and IL-8 levels and in left and right cIMT and an increase in HDL-c levels in the STAET groups compared to the STA (p<0.001) and PLET groups (p<0.001). There was an increase in IL-10 levels, peak-systolic velocity, end-diastolic velocity, wall shear rate in the PLET and STAET groups compared to the PL (p<0.001) and STA groups (p<0.001). The PLET and STAET groups reduced body fat mass, body fat percentage and increased lean body mass, MS and CF compared to PL (p<0.001) and STA (p<0.001) groups. CONCLUSION The combination of ET and statins is useful to enhance lipid and inflammatory profiles, reduce CVD markers, and improve Doppler ultrasound findings, MS and CF in people living with HIV.",2019,"There was an increase in IL-10 levels, peak-systolic velocity, end-diastolic velocity, wall shear rate in the PLET and STAET groups compared to the PL (p<0.001) and STA groups (p<0.001).","['people living with HIV', 'People Living with HIV with Dyslipidemia', 'Eighty-three people living with HIV']","['STA', 'placebo (PL), statins (STA), placebo + ET (PLET) or statins + ET (STAET', 'rosuvastatin', 'Exercise Training and Statin Use', 'placebo', 'PLET', 'ET and statins']","['TC, TG, LDL, IL-1β, IL-6, and IL-8 levels and in left and right cIMT and an increase in HDL-c levels', 'lipid profile, cardiovascular markers, inflammatory profile; a Doppler ultrasound examination, muscle strength (MS) and cardiorespiratory fitness (CF) tests', 'IL-10 levels, peak-systolic velocity, end-diastolic velocity, wall shear rate', 'body fat mass, body fat percentage and increased lean body mass, MS and CF', 'total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-c), C-reactive protein, fibrinogen, interleukin (IL)-1β and right carotid intima-media thickness (cIMT']","[{'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemias'}, {'cui': 'C4517888', 'cui_str': '83'}]","[{'cui': 'C1529286', 'cui_str': 'stas'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C1947944', 'cui_str': 'Use'}]","[{'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0162481', 'cui_str': 'Doppler Ultrasound'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0442710', 'cui_str': 'Peak systolic, function (observable entity)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0205380', 'cui_str': 'Walled (qualifier value)'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass (observable entity)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0982156', 'cui_str': 'fibrinogen (125I)'}, {'cui': 'C0021764', 'cui_str': 'Interleukins'}, {'cui': 'C0162864', 'cui_str': 'Vascular Intima'}]",83.0,0.0940275,"There was an increase in IL-10 levels, peak-systolic velocity, end-diastolic velocity, wall shear rate in the PLET and STAET groups compared to the PL (p<0.001) and STA groups (p<0.001).","[{'ForeName': 'Hugo Ribeiro', 'Initials': 'HR', 'LastName': 'Zanetti', 'Affiliation': 'Postgraduate Program in Health Science, Faculty of Medicine, Federal University of Uberlândia, Uberlândia/MG, Brazil.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Gonçalves', 'Affiliation': 'Master Institute of Education President Antônio Carlos, Araguari/MG, Brazil.'}, {'ForeName': 'Leandro Teixeira', 'Initials': 'LT', 'LastName': 'Paranhos Lopes', 'Affiliation': 'Brazil University, Fernandópolis/SP, Brazil.'}, {'ForeName': 'Edmar Lacerda', 'Initials': 'EL', 'LastName': 'Mendes', 'Affiliation': 'Institute of Health Sciences, Department of Sport Sciences, Federal University of Triângulo Mineiro, Uberaba/MG, Brazil.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Roever', 'Affiliation': 'Postgraduate Program in Health Science, Faculty of Medicine, Federal University of Uberlândia, Uberlândia/MG, Brazil.'}, {'ForeName': 'Mário Leon', 'Initials': 'ML', 'LastName': 'Silva-Vergara', 'Affiliation': 'Institute of Health Sciences, Department of Medical Clinics, Clinics Hospital, Federal University of Triângulo Mineiro, Uberaba/MG, Brazil.'}, {'ForeName': 'Fernando Freitas', 'Initials': 'FF', 'LastName': 'Neves', 'Affiliation': 'Institute of Health Sciences, Department of Medical Clinics, Clinics Hospital, Federal University of Triângulo Mineiro, Uberaba/MG, Brazil.'}, {'ForeName': 'Elmiro Santos', 'Initials': 'ES', 'LastName': 'Resende', 'Affiliation': 'Postgraduate Program in Health Science, Faculty of Medicine, Federal University of Uberlândia, Uberlândia/MG, Brazil.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002120'] 3066,31651251,Building the skills and confidence of early childhood educators to work with parents: study protocol for the Partnering with Parents cluster randomised controlled trial.,"BACKGROUND In the early years of life, the benefits of parental engagement in children's learning are well documented. Early childhood educators are a potentially effective source of support, having opportunity to engage with parents on key issues related to children's learning and development. Educators report a need for more practical strategies for building positive partnerships with the parents of children in their care. To address this need, we have developed a practice support system, Partnering with Parents, to guide educators in Early Childhood Education and Care (ECEC) through practical strategies for working with parents. Partnering with Parents is designed to be embedded in everyday service delivery. METHODS Using a cluster randomised controlled trial (cRCT) with intervention and wait-list control groups, we aim to evaluate the effectiveness of the Partnering with Parents practice support system under normal service conditions. The intervention is being trialled in ECEC services across Victoria, Australia. Services in the intervention group implemented the 10-week intervention before the control group commenced the intervention. Educators and parents of children attending the participating services are taking part in evaluating the intervention by completing questionnaires online at three time points (before, immediately after, and 3 months after the intervention group received the intervention). RESULTS One hundred eighteen educators and 302 parents recruited from 19 participating ECEC services have consented to take part in the trial. CONCLUSIONS There is considerable potential for ECEC services to improve everyday interactions with parents and potentially child outcomes, by implementing this practice support model. Future research in this field can examine long-term effects of improving the parent-educator relationship. The intervention has potential to be widely embedded in educator training or professional development. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12619000488101 . Prospectively registered 25 March 2019.",2019,"There is considerable potential for ECEC services to improve everyday interactions with parents and potentially child outcomes, by implementing this practice support model.","['One hundred eighteen educators and 302 parents recruited from 19 participating ECEC services have consented to take part in the trial', 'Partnering with Parents practice support system under normal service conditions']",['ANZCTR'],[],"[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]",[],[],302.0,0.0904343,"There is considerable potential for ECEC services to improve everyday interactions with parents and potentially child outcomes, by implementing this practice support model.","[{'ForeName': 'Zvezdana', 'Initials': 'Z', 'LastName': 'Petrovic', 'Affiliation': 'Parenting Research Centre, 5/232 Victoria Parade, East Melbourne, Victoria, 3002, Australia.'}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Clayton', 'Affiliation': 'Parenting Research Centre, 5/232 Victoria Parade, East Melbourne, Victoria, 3002, Australia. oclayton@parentingrc.org.au.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Matthews', 'Affiliation': 'Parenting Research Centre, 5/232 Victoria Parade, East Melbourne, Victoria, 3002, Australia.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Wade', 'Affiliation': 'Parenting Research Centre, 5/232 Victoria Parade, East Melbourne, Victoria, 3002, Australia.'}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Tan', 'Affiliation': 'Parenting Research Centre, 5/232 Victoria Parade, East Melbourne, Victoria, 3002, Australia.'}, {'ForeName': 'Denny', 'Initials': 'D', 'LastName': 'Meyer', 'Affiliation': 'Department of Statistics, Data Science and Epidemiology, Swinburne University of Technology, John Street, Hawthorn, Victoria, 3122, Australia.'}, {'ForeName': 'Antony', 'Initials': 'A', 'LastName': 'Gates', 'Affiliation': 'Parenting Research Centre, 5/232 Victoria Parade, East Melbourne, Victoria, 3002, Australia.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Almendingen', 'Affiliation': 'Parenting Research Centre, 5/232 Victoria Parade, East Melbourne, Victoria, 3002, Australia.'}, {'ForeName': 'Warren', 'Initials': 'W', 'LastName': 'Cann', 'Affiliation': 'Parenting Research Centre, 5/232 Victoria Parade, East Melbourne, Victoria, 3002, Australia.'}]",BMC medical research methodology,['10.1186/s12874-019-0846-1'] 3067,31383945,Umbilical venous catheter insertion depth estimation using birth weight versus surface measurement formula: a randomized controlled trial.,"OBJECTIVE To determine if umbilical venous catheter (UVC) insertion depth estimated by surface measurement (SM) results in optimal catheter tip position on ultrasound as compared with formula using birth weight (BW). METHODS In this randomized controlled trial, eligible infants were randomized to UVC insertion depth estimated by SM or BW method. We compared proportion of optimum UVC position on ultrasound read by neonatologist masked with group assignment. RESULTS UVC was inserted to estimated depth in 164 of 200 enroled infants. There was no difference in the proportion of correctly positioned UVCs between the groups (SM 33/82 (40.2%) vs BW 27/82 (32.9%), p = 0.33). Among BW < 1000 g, SM method had higher correctly positioned UVC (43.7% vs 22.5%, p = 0.07). CONCLUSION There was no difference in the rate of optimally positioned UVC tip between the two methods for estimating UVC insertion depth. However, SM method results in more optimal positioning of UVC tip among BW < 1000 g infants.",2020,There was no difference in the rate of optimally positioned UVC tip between the two methods for estimating UVC insertion depth.,"['164 of 200 enroled infants', 'eligible infants']","['Umbilical venous catheter insertion depth estimation using birth weight versus surface measurement formula', 'umbilical venous catheter (UVC) insertion depth estimated by surface measurement (SM']","['rate of optimally positioned UVC tip', 'proportion of correctly positioned UVCs', 'correctly positioned UVC']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0745442', 'cui_str': 'Venous catheter (physical object)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}, {'cui': 'C0205148', 'cui_str': 'Surface (attribute)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}]","[{'cui': 'C1561964', 'cui_str': 'Patient Positioning'}]",,0.218732,There was no difference in the rate of optimally positioned UVC tip between the two methods for estimating UVC insertion depth.,"[{'ForeName': 'Ayman', 'Initials': 'A', 'LastName': 'Sheta', 'Affiliation': 'Department of Pediatrics, Section of Neonatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Majeeda', 'Initials': 'M', 'LastName': 'Kamaluddeen', 'Affiliation': 'Department of Pediatrics, Section of Neonatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Amuchou Singh', 'Initials': 'AS', 'LastName': 'Soraisham', 'Affiliation': 'Department of Pediatrics, Section of Neonatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. asoraish@ucalgary.ca.'}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/s41372-019-0456-0'] 3068,32087113,Contact isolation versus standard precautions to decrease acquisition of extended-spectrum β-lactamase-producing Enterobacterales in non-critical care wards: a cluster-randomised crossover trial.,"BACKGROUND The effectiveness of contact isolation for decreasing the spread of extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) has been questioned. The aim of this study was to establish the benefits of contact isolation over standard precautions for reducing the incidence density of ESBL-E colonisation and infection in adult medical and surgical wards with an active surveillance culture programme. METHODS We did a cluster-randomised crossover trial in adult wards in four European university hospitals. Medical, surgical, or combined medical-surgical wards without critical care were randomised to continue standard precautions alone or implement contact isolation alongside standard precautions for 12 months, followed by a 1 month washout period and 12 months of the alternate strategy. Randomisation was done via a computer-generated sequence, with a block size of two consecutive wards. Only laboratory technicians and data analysts were masked to allocation. Patients were screened for ESBL-E carriage within 3 days of admission, once a week thereafter, and on discharge. The primary outcome was the incidence density of ESBL-E, defined as the acquisition rate per 1000 patient-days at risk at the ward level and assessed in the per-protocol population, which included all patients screened at least twice with a length of stay of more than 1 week for each intervention period. No specific safety measures were assessed given the minimal risk of adverse events. The trial is registered, ISRCTN57648070. FINDINGS We enrolled 20 wards from four hospitals in Germany (eight wards), the Netherlands (four wards), Spain (four wards), and Switzerland (four wards). Between Jan 6, 2014, and Aug 31, 2016, 38 357 patients were admitted to these wards. Among 15 184 patients with a length of stay of more than 1 week, 11 368 patients (75%) were screened at least twice. The incidence density of ward-acquired ESBL-E was 6·0 events per 1000 patient-days at risk (95% CI 5·4-6·7) during periods of contact isolation and 6·1 (5·5-6·7) during periods of standard precautions (p=0·9710). Multivariable analysis adjusted for length of stay, percentage of patients screened, and prevalence in first screening cultures yielded an incidence rate ratio of 0·99 (95% CI 0·80-1·22; p=0·9177) for care under contact isolation compared with standard precautions. INTERPRETATION Contact isolation showed no benefit when added to standard precautions for controlling the spread of ESBL-E on non-critical care wards with extensive surveillance screening. FUNDING European Commission.",2020,"INTERPRETATION Contact isolation showed no benefit when added to standard precautions for controlling the spread of ESBL-E on non-critical care wards with extensive surveillance screening. ","['adult wards in four European university hospitals', 'adult medical and surgical wards with an active surveillance culture programme', 'Between Jan 6, 2014, and Aug 31, 2016, 38 357 patients were admitted to these wards', 'Medical, surgical, or combined medical-surgical wards without critical care', 'enrolled 20 wards from four hospitals in Germany (eight wards), the Netherlands (four wards), Spain (four wards), and Switzerland (four wards', 'Among 15\u2008184 patients with a length of stay of more than 1 week, 11\u2008368 patients (75%) were screened at least twice']",['Contact isolation versus standard precautions'],"['incidence density of ESBL-E, defined as the acquisition rate per 1000 patient-days at risk at the ward level', 'minimal risk of adverse events', 'incidence density of ward-acquired ESBL-E', 'ESBL-E carriage']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}, {'cui': 'C0239307', 'cui_str': 'European (ethnic group)'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C1827061', 'cui_str': 'Active surveillance'}, {'cui': 'C0220814', 'cui_str': 'culture'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0010337', 'cui_str': 'Critical Care'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}, {'cui': 'C4517616', 'cui_str': 'One hundred and eighty-four'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C1720725', 'cui_str': 'Twice'}]","[{'cui': 'C0034386', 'cui_str': 'Quarantine'}, {'cui': 'C1443867', 'cui_str': 'Standard precautions'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C1444096', 'cui_str': 'Extended spectrum beta-lactamase producing bacteria'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0547040', 'cui_str': 'Minimal (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439661', 'cui_str': 'Acquired (qualifier value)'}]",38357.0,0.141702,"INTERPRETATION Contact isolation showed no benefit when added to standard precautions for controlling the spread of ESBL-E on non-critical care wards with extensive surveillance screening. ","[{'ForeName': 'Friederike', 'Initials': 'F', 'LastName': 'Maechler', 'Affiliation': 'Institute of Hygiene and Environmental Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany. Electronic address: friederike.maechler@charite.de.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Schwab', 'Affiliation': 'Institute of Hygiene and Environmental Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Hansen', 'Affiliation': 'Institute of Hygiene and Environmental Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Fankhauser', 'Affiliation': 'Infection Control Program, Geneva University Hospitals and Medical School, Geneva, Switzerland.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Harbarth', 'Affiliation': 'Infection Control Program, Geneva University Hospitals and Medical School, Geneva, Switzerland.'}, {'ForeName': 'Benedikt D', 'Initials': 'BD', 'LastName': 'Huttner', 'Affiliation': 'Infection Control Program, Geneva University Hospitals and Medical School, Geneva, Switzerland.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Diaz-Agero', 'Affiliation': 'Servicio de Medicina Preventiva y Salud Pública, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.'}, {'ForeName': 'Nieves', 'Initials': 'N', 'LastName': 'Lopez', 'Affiliation': 'Servicio de Medicina Preventiva y Salud Pública, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Canton', 'Affiliation': 'Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Ruiz-Garbajosa', 'Affiliation': 'Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.'}, {'ForeName': 'Hetty', 'Initials': 'H', 'LastName': 'Blok', 'Affiliation': 'Department of Medical Microbiology and Infection Control, Julius Center, University Medical Center Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Marc J', 'Initials': 'MJ', 'LastName': 'Bonten', 'Affiliation': 'Department of Medical Microbiology and Infection Control, Julius Center, University Medical Center Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Fieke', 'Initials': 'F', 'LastName': 'Kloosterman', 'Affiliation': 'Department of Medical Microbiology and Infection Control, Julius Center, University Medical Center Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Joost', 'Initials': 'J', 'LastName': 'Schotsman', 'Affiliation': 'Department of Biostatistics and Research Support, Julius Center, University Medical Center Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Ben S', 'Initials': 'BS', 'LastName': 'Cooper', 'Affiliation': 'Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Behnke', 'Affiliation': 'Institute of Hygiene and Environmental Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Golembus', 'Affiliation': 'Institute of Hygiene and Environmental Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Kola', 'Affiliation': 'Institute of Hygiene and Environmental Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Gastmeier', 'Affiliation': 'Institute of Hygiene and Environmental Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(19)30626-7'] 3069,31060836,"Fish oil decreases the severity of treatment-related adverse events in gastrointestinal cancer patients undergoing chemotherapy: A randomized, placebo-controlled, triple-blind clinical trial.","BACKGROUND AND AIMS Due to its high peroxidizable characteristics, n-3 fatty acids, present in fish oil, could increase tumor cells sensitivity to conventional cancer treatment while non-neoplastic cells remain unaffected, this may lead to an increase in cancer treatment response with no increase on adverse effects. The aim of this study was to evaluate anti-cancer treatment response, performance status and adverse events in gastrointestinal cancer patients supplemented with fish oil. Oxidative stress parameters were investigated in blood non-neoplastic cells as an indicator of cytotoxicity. METHODS This is a randomized, triple-blind, placebo-controlled clinical trial. Fish oil group (FOG) received two capsules of fish oil containing 1.55 g of EPA + DHA a day for nine weeks, placebo group (PG) received two capsules containing olive oil. Baseline was set right before the administration of the first chemotherapy, oxidative stress parameters, adverse events presence and grading and performance status were assessed at baseline and after nine weeks of supplementation. Tumor markers, response to treatment and survival were evaluated at baseline and after one year of study inclusion. RESULTS 76 patients were considered eligible, 56 were randomized, and 51 remained for analysis. After nine weeks, although there were no differences between groups for treatment response and presence of adverse events, PG patients were graded with more severe diarrhea than FOG patients (p = 0.03) and with higher (worse) performance status score (p = 0.02). No differences in lipid peroxidation and activity of antioxidant enzymes were observed between groups. CONCLUSIONS Fish oil may lead to a better performance status for gastrointestinal cancer patients undergoing chemotherapy while does not seem to increase treatment-related toxicity. Registered under ClinicalTrials.gov Identifier no. NCT02699047, www.clinicaltrials.gov.",2019,"No differences in lipid peroxidation and activity of antioxidant enzymes were observed between groups. ","['gastrointestinal cancer patients undergoing chemotherapy', 'gastrointestinal cancer patients undergoing', 'gastrointestinal cancer patients supplemented with', '76 patients were considered eligible, 56 were randomized, and 51 remained for analysis']","['fish oil', 'placebo', 'chemotherapy', 'capsules containing olive oil', 'Fish oil', 'Fish oil group (FOG) received two capsules of fish oil containing 1.55\xa0g of EPA\xa0']","['Tumor markers, response to treatment and survival', 'Oxidative stress parameters', 'treatment response and presence of adverse events', 'oxidative stress parameters, adverse events presence and grading and performance status', 'adverse effects', 'lipid peroxidation and activity of antioxidant enzymes', 'performance status score', 'severe diarrhea', 'severity of treatment-related adverse events', 'anti-cancer treatment response, performance status and adverse events']","[{'cui': 'C0685938', 'cui_str': 'Gastrointestinal Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1524024', 'cui_str': 'analysis'}]","[{'cui': 'C0016157', 'cui_str': 'Fish Oils'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0059057', 'cui_str': 'EPA (prealbumin)'}]","[{'cui': 'C0041365', 'cui_str': 'Biomarkers, Cancer'}, {'cui': 'C0521982', 'cui_str': 'Therapeutic response, function (observable entity)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C3854307', 'cui_str': 'Presence'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0023775', 'cui_str': 'Lipid Peroxidation'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C3541394', 'cui_str': 'Enzymes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1443924', 'cui_str': 'Severe diarrhea'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}]",76.0,0.70844,"No differences in lipid peroxidation and activity of antioxidant enzymes were observed between groups. ","[{'ForeName': 'Carolina de Quadros', 'Initials': 'CQ', 'LastName': 'Camargo', 'Affiliation': 'Laboratory of Investigation in Chronic Diseases, Department of Physiological Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil; Nutrition Graduation Program, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil.'}, {'ForeName': 'Michel Carlos', 'Initials': 'MC', 'LastName': 'Mocellin', 'Affiliation': 'Nutrition Graduation Program, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil.'}, {'ForeName': 'Henver Simionato', 'Initials': 'HS', 'LastName': 'Brunetta', 'Affiliation': 'Laboratory of Investigation in Chronic Diseases, Department of Physiological Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil; Multicenter Graduation Program in Physiological Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil.'}, {'ForeName': 'Thayz Rodrigues', 'Initials': 'TR', 'LastName': 'Chagas', 'Affiliation': 'Laboratory of Investigation in Chronic Diseases, Department of Physiological Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil; Nutrition Graduation Program, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil.'}, {'ForeName': 'Maria Emília de Souza', 'Initials': 'MES', 'LastName': 'Fabre', 'Affiliation': 'Oncology Research Center, Florianópolis, Santa Catarina, Brazil.'}, {'ForeName': 'Erasmo Benício Santos de Moraes', 'Initials': 'EBSM', 'LastName': 'Trindade', 'Affiliation': 'Nutrition Graduation Program, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil.'}, {'ForeName': 'Edson Luiz da', 'Initials': 'ELD', 'LastName': 'Silva', 'Affiliation': 'Nutrition Graduation Program, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil.'}, {'ForeName': 'Everson Araújo', 'Initials': 'EA', 'LastName': 'Nunes', 'Affiliation': 'Laboratory of Investigation in Chronic Diseases, Department of Physiological Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil; Nutrition Graduation Program, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil; Multicenter Graduation Program in Physiological Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil. Electronic address: everson.nunes@ufsc.br.'}]",Clinical nutrition ESPEN,['10.1016/j.clnesp.2019.02.015'] 3070,31379271,The impact of international videoconferencing among older adults and secondary students.,"This study explores young adults' emotional affect and attitudes towards ageing, as well as older adults' emotional affect and self-esteem following participation in the intergenerational videoconferencing programme Smile Connect (SC). The sample consisted of 94 participants (46 older Spanish adults living in a care home in Spain and 48 young Italian adults -secondary students- learning Spanish at school in Italy). Each age group was divided into an intervention and control group. SC consists of twelve 30-minute chat sessions conducted via Skype between the target groups over six weeks. Pre and post evaluations were made to assess the affect level in both groups, self-esteem among older people, and the level of negative stereotypes about ageing among young adults. At the end of the SC, the intervention group of older adults recorded significantly improved scores in self-esteem compared to the control group. Young adults recorded a reduction in their negative stereotypes about old age after taking part in the SC programme compared to those who did not. These findings suggest that involvement in the SC programme helps to improve the emotional affect of older adults living in care homes, as well as change the negative stereotypes about ageing among young adults.",2020,"At the end of the SC, the intervention group of older adults recorded significantly improved scores in self-esteem compared to the control group.","['Young adults', '94 participants (46 older Spanish adults living in a care home in Spain and 48 young Italian adults -secondary students- learning Spanish at school in Italy', 'older adults and secondary students', 'older adults living in care homes']",['international videoconferencing'],['scores in self-esteem'],"[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C3161473', 'cui_str': 'Spaniards (ethnic group)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0337810', 'cui_str': 'Italians (ethnic group)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0856538', 'cui_str': 'Living in care'}]","[{'cui': 'C1450048', 'cui_str': 'Videoconferencing'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0036597', 'cui_str': 'Self Esteem'}]",94.0,0.0341441,"At the end of the SC, the intervention group of older adults recorded significantly improved scores in self-esteem compared to the control group.","[{'ForeName': 'N', 'Initials': 'N', 'LastName': 'Carcavilla', 'Affiliation': 'Institute of Neurosciences of Castile and Leon, University of Salamanca, University of Salamanca , Salamanca, Spain.'}, {'ForeName': 'J J G', 'Initials': 'JJG', 'LastName': 'Meilán', 'Affiliation': 'Faculty of Psychology, University of Salamanca , Salamanca, Spain.'}, {'ForeName': 'T E', 'Initials': 'TE', 'LastName': 'Llorente', 'Affiliation': 'Institute of Neurosciences of Castile and Leon, University of Salamanca, University of Salamanca , Salamanca, Spain.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Martínez-Nicolás', 'Affiliation': 'Institute of Neurosciences of Castile and Leon, University of Salamanca, University of Salamanca , Salamanca, Spain.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Tamayo-Mortera', 'Affiliation': 'The New Zealand Society of Diversional and Recreational Therapists Inc , Auckland, New Zealand.'}]",Gerontology & geriatrics education,['10.1080/02701960.2019.1651724'] 3071,32086442,"The effects of 10,000 voluntary contractions over 8 weeks on the strength of very weak muscles in people with spinal cord injury: a randomised controlled trial.","STUDY DESIGN A multi-centred, single-blinded randomised controlled trial. OBJECTIVES To determine the effect of 10,000 voluntary contractions over 8 weeks on the strength of very weak muscles in people with spinal cord injury (SCI). SETTINGS Seven hospitals in Australia and Asia. METHODS One hundred and twenty people with recent SCI undergoing inpatient rehabilitation were randomised to either a Treatment or Control Group. One major muscle group from an upper or lower limb was selected if the muscle had grade 1 or grade 2 strength on a standard six-point manual muscle test. Participants allocated to the Treatment Group performed 10,000 isolated contractions of the selected muscle group, as well as usual care in 48 sessions over 8 weeks. Participants allocated to the Control Group received usual care alone. Participants were assessed at baseline and 8 weeks by a blinded assessor. The primary outcome was voluntary muscle strength on a 13-point manual muscle test. There were three secondary outcomes capturing therapists' and participants' perceptions of strength and function. RESULTS The mean between-group difference of voluntary strength at 8 weeks was 0.4/13 points (95% confidence interval -0.5 to 1.4) in favour of the Treatment Group. There were no notable between-group differences on any secondary outcome. CONCLUSION Ten thousand isolated contractions of very weak muscles in people with SCI over 8 weeks has either no or a very small effect on voluntary strength.",2020,The mean between-group difference of voluntary strength at 8 weeks was 0.4/13 points (95% confidence interval -0.5 to 1.4) in favour of the Treatment Group.,"['One hundred and twenty people with recent SCI undergoing inpatient rehabilitation', 'people with spinal cord injury (SCI', 'Seven hospitals in Australia and Asia', 'people with spinal cord injury']",['Control Group received usual care alone'],"['voluntary strength', 'perceptions of strength and function', 'voluntary muscle strength on a 13-point manual muscle test']","[{'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0003980', 'cui_str': 'Asia'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439656', 'cui_str': 'Voluntary (qualifier value)'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0242692', 'cui_str': 'Muscle, Voluntary'}, {'cui': 'C0451362', 'cui_str': 'Oxford grading scale for muscle strength (assessment scale)'}]",10000.0,0.21565,The mean between-group difference of voluntary strength at 8 weeks was 0.4/13 points (95% confidence interval -0.5 to 1.4) in favour of the Treatment Group.,"[{'ForeName': 'Lydia W', 'Initials': 'LW', 'LastName': 'Chen', 'Affiliation': 'John Walsh Centre for Rehabilitation Research, Faculty of Medicine and Health Sciences, University of Sydney, St Leonards, NSW, Australia.'}, {'ForeName': 'Joanne V', 'Initials': 'JV', 'LastName': 'Glinsky', 'Affiliation': 'John Walsh Centre for Rehabilitation Research, Faculty of Medicine and Health Sciences, University of Sydney, St Leonards, NSW, Australia.'}, {'ForeName': 'Md Shofiqul', 'Initials': 'MS', 'LastName': 'Islam', 'Affiliation': 'Centre for the Rehabilitation of the Paralysed, Savar, Dhaka, Bangladesh.'}, {'ForeName': 'Muzaffor', 'Initials': 'M', 'LastName': 'Hossain', 'Affiliation': 'Centre for the Rehabilitation of the Paralysed, Savar, Dhaka, Bangladesh.'}, {'ForeName': 'Claire L', 'Initials': 'CL', 'LastName': 'Boswell-Ruys', 'Affiliation': 'Spinal Injuries Unit, Prince of Wales Hospital, Randwick, NSW, Australia.'}, {'ForeName': 'Chitra', 'Initials': 'C', 'LastName': 'Kataria', 'Affiliation': 'Indian Spinal Injuries Centre, Sector-C, Vasant Kunj, Delhi, India.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Redhead', 'Affiliation': 'Spinal Injuries Unit, Royal Rehab, Ryde, NSW, Australia.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Xiong', 'Affiliation': 'Guangdong Work Injury Rehabilitation Hospital, Guangdong, China.'}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Gollan', 'Affiliation': 'Queensland Spinal Cord Injuries Service, Metro South Health, Brisbane, QLD, Australia.'}, {'ForeName': 'Punam D', 'Initials': 'PD', 'LastName': 'Costa', 'Affiliation': 'Centre for the Rehabilitation of the Paralysed, Savar, Dhaka, Bangladesh.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Denis', 'Affiliation': 'Spinal Injuries Unit, Prince of Wales Hospital, Randwick, NSW, Australia.'}, {'ForeName': 'Marsha', 'Initials': 'M', 'LastName': 'Ben', 'Affiliation': 'NSW Spinal Outreach Service, Ryde, NSW, Australia.'}, {'ForeName': 'Lovely', 'Initials': 'L', 'LastName': 'Chaudhary', 'Affiliation': 'Indian Spinal Injuries Centre, Sector-C, Vasant Kunj, Delhi, India.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Guangdong Work Injury Rehabilitation Hospital, Guangdong, China.'}, {'ForeName': 'Md Abu Khayer', 'Initials': 'MAK', 'LastName': 'Hasnat', 'Affiliation': 'Centre for the Rehabilitation of the Paralysed, Savar, Dhaka, Bangladesh.'}, {'ForeName': 'Jayne', 'Initials': 'J', 'LastName': 'Yeomans', 'Affiliation': 'Spinal Injuries Unit, Royal North Shore Hospital, St Leonards, NSW, Australia.'}, {'ForeName': 'Simon C', 'Initials': 'SC', 'LastName': 'Gandevia', 'Affiliation': 'Neuroscience Research Australia (NeuRA), University of New South Wales, Randwick, NSW, Australia.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Harvey', 'Affiliation': 'John Walsh Centre for Rehabilitation Research, Faculty of Medicine and Health Sciences, University of Sydney, St Leonards, NSW, Australia. lisa.harvey@sydney.edu.au.'}]",Spinal cord,['10.1038/s41393-020-0439-1'] 3072,32085844,Effect of early parenteral nutrition during paediatric critical illness on DNA methylation as a potential mediator of impaired neurocognitive development: a pre-planned secondary analysis of the PEPaNIC international randomised controlled trial.,"BACKGROUND Early use of parenteral nutrition in the paediatric intensive care unit (PICU) negatively affects development of executive functions, externalising behaviour, and visual-motor integration 2 years later, compared with omitting parenteral nutrition until PICU day 8 (late parenteral nutrition). The molecular basis of this finding is uncertain. We aimed to test the hypothesis that DNA methylation changes occur during critical illness and that early parenteral nutrition (or a specific macronutrient component hereof) contributes to these changes, which could explain its negative effects on neurocognitive development. METHODS This pre-planned secondary analysis of the multicentre PEPaNIC trial (2012-18) included all patients with a last PICU day blood sample (n=825, aged 0-17 years at PICU admission) who were randomly allocated (1:1) to early parenteral nutrition or late parenteral nutrition, as compared with 352 demographically matched healthy children. Investigators were masked to treatment allocation. We used the Infinium Human MethylationEPIC BeadChip to determine the genome-wide peripheral blood leukocyte DNA methylation of 865 859 CpG sites, yielding high-quality results for 403 patients allocated to early parenteral nutrition and for 411 patients allocated to late parenteral nutrition. Applying a false discovery rate of less than 0·05, DNA methylation of patients on the last PICU day was compared with that of healthy children, after excluding all CpG sites differentially methylated upon PICU admission, because these reflected pre-admission conditions and altered leukocyte composition. We used bootstrapped multivariable linear and non-linear regression analyses to assess the effect of early parenteral nutrition versus late parenteral nutrition on illness-induced alterations in DNA methylation and to what extent differentially methylated CpG sites explained impaired neurocognitive development 2 years later. FINDINGS During PICU stay, 159 CpG sites were methylated differently in patients admitted to the PICU than in healthy children, with mean effect sizes of 2·6% (SD 2·5) up to 21·6% (p<0·02). These differentially methylated CpG sites occurred in genes involved in brain development, plasticity, and signalling; neuronal differentiation, migration, and growth; metabolism; transcriptional regulation; physical development and locomotion; and several neurodegenerative and neuropsychiatric diseases. Early parenteral nutrition and, in particular, the dose of amino acids, independently contributed to the differential methylation of 37 (23%) of these 159 CpG sites (p=0·0001 to 0·050), which could explain the adverse effect of early parenteral nutrition on neurocognitive development at 2-year follow-up (R 2 0·61 [SD 0·01]). INTERPRETATION Early parenteral nutrition during paediatric critical illness altered DNA methylation, which suggests a plausible molecular basis for its negative effect on long-term neurocognitive development. Early administration of amino acids, rather than of glucose or lipids, mostly explained the aberrant DNA methylation-a finding that requires further investigation. FUNDING European Research Council, Methusalem, Flanders Institute for Science and Technology, Research Foundation Flanders, Sophia Foundation, Stichting Agis Zorginnovatie, Erasmus Trustfonds, and European Society for Clinical Nutrition and Metabolism.",2020,"During PICU stay, 159 CpG sites were methylated differently in patients admitted to the PICU than in healthy children, with mean effect sizes of 2·6% (SD 2·5) up to 21·6% (p<0·02).","['403 patients allocated to early parenteral nutrition and for 411 patients allocated to', '352 demographically matched healthy children', '2012-18) included all patients with a last PICU day blood sample (n=825, aged 0-17 years at PICU admission']","['early parenteral nutrition or late parenteral nutrition', 'early parenteral nutrition', 'late parenteral nutrition', 'parenteral nutrition', 'amino acids']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0030547', 'cui_str': 'Parenteral Nutrition'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0686744', 'cui_str': 'Well child (finding)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0030547', 'cui_str': 'Parenteral Nutrition'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C3539946', 'cui_str': 'Amino acids'}]",[],,0.0823443,"During PICU stay, 159 CpG sites were methylated differently in patients admitted to the PICU than in healthy children, with mean effect sizes of 2·6% (SD 2·5) up to 21·6% (p<0·02).","[{'ForeName': 'Fabian', 'Initials': 'F', 'LastName': 'Güiza', 'Affiliation': 'Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Ilse', 'Initials': 'I', 'LastName': 'Vanhorebeek', 'Affiliation': 'Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Sören', 'Initials': 'S', 'LastName': 'Verstraete', 'Affiliation': 'Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Ines', 'Initials': 'I', 'LastName': 'Verlinden', 'Affiliation': 'Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Inge', 'Initials': 'I', 'LastName': 'Derese', 'Affiliation': 'Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Ingels', 'Affiliation': 'Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Karolijn', 'Initials': 'K', 'LastName': 'Dulfer', 'Affiliation': ""Intensive Care Unit, Department of Paediatrics and Paediatric Surgery, Erasmus Medical Centre, Sophia Children's Hospital, Rotterdam, Netherlands.""}, {'ForeName': 'Sascha C', 'Initials': 'SC', 'LastName': 'Verbruggen', 'Affiliation': ""Intensive Care Unit, Department of Paediatrics and Paediatric Surgery, Erasmus Medical Centre, Sophia Children's Hospital, Rotterdam, Netherlands.""}, {'ForeName': 'Gonzalo', 'Initials': 'G', 'LastName': 'Garcia Guerra', 'Affiliation': ""Department of Paediatrics, Intensive Care Unit, University of Alberta, Stollery Children's Hospital, Edmonton, AB, Canada.""}, {'ForeName': 'Koen F', 'Initials': 'KF', 'LastName': 'Joosten', 'Affiliation': ""Intensive Care Unit, Department of Paediatrics and Paediatric Surgery, Erasmus Medical Centre, Sophia Children's Hospital, Rotterdam, Netherlands.""}, {'ForeName': 'Pieter J', 'Initials': 'PJ', 'LastName': 'Wouters', 'Affiliation': 'Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Greet', 'Initials': 'G', 'LastName': 'Van den Berghe', 'Affiliation': 'Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium. Electronic address: greet.vandenberghe@kuleuven.be.'}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(20)30046-1'] 3073,32080009,"A Long-Term Follow-up, Multicenter, Comparative Study of the Radiologic, and Clinical Results Between a CaO-SiO2-P2O5-B2O3 Bioactive Glass Ceramics (BGS-7) Intervertebral Spacer and Titanium Cage in 1-Level Posterior Lumbar Interbody Fusion.","STUDY DESIGN This is a prospective, stratified randomized, multicenter, 4-year follow-up study. OBJECTIVE The authors aimed to evaluate the long-term clinical efficacy and safety of CaO-SiO2-P2O5-B2O3 glass ceramics (BGS-7) spacers in 1-level posterior lumbar interbody fusion (PLIF) at a 4-year follow-up. SUMMARY OF BACKGROUND DATA According to 1-year follow-up results, BGS-7 spacer showed similar fusion rates and clinical outcomes compared with titanium cage. A long-term follow-up study beyond 2 years is necessary to investigate the status of intervertebral bone graft volumes. Moreover, longer follow-up is mandatory to also evaluate the safety and efficacy of BGS-7 spacers, because they remain in the intervertebral space for a long time. MATERIALS AND METHODS In this prospective, randomized, multicenter, 4-year follow-up study, we evaluated 62 of the 74 patients who underwent 1-level PLIF. During 1-level PLIF, titanium cages filled with autologous local bone were inserted into the control group patients and BGS-7 spacers were inserted to the experimental group patients. Bone fusion was evaluated by plain radiography and thin-section computed tomography. Visual Analog Scale (VAS), the Oswestry Disability Index (ODI), Short Form-36 Health Survey (SF-36), and evaluation of safety were conducted after 48 months. RESULTS Computed tomography scan showed a bone fusion rate of 90.6% in the BGS-7 spacer group and 93.3% in the control group, with no significant differences between groups. The BGS-7 spacer group showed a significantly larger area directly fused to the endplate than the control group (P<0.001). The BGS-7 spacer group showed a significant increase in the fused area compared with the titanium group at 1- and 4-year follow-up. The ODI, SF-36, back pain, and lower limb pain in both groups showed significant improvement after surgery, and no significant differences were observed between the groups. Both groups showed no additional adverse events. CONCLUSIONS The 4-year follow-up study showed similar fusion rates and clinical outcomes in both the BGS-7 spacer and autologous bone with a titanium cage in 1-level PLIF. However, the BGS-7 spacer implants showed a larger area of fusion with the endplates than that of autologous bone with a titanium cage. Therefore, the results demonstrated that the BGS-7 spacer can be considered as a novel intervertebral spacer to achieve successful spinal fusion without safety concerns for long-term use.",2020,"The ODI, SF-36, back pain, and lower limb pain in both groups showed significant improvement after surgery, and no significant differences were observed between the groups.",['62 of the 74 patients who underwent 1-level PLIF'],"['CaO-SiO2-P2O5-B2O3 glass ceramics (BGS-7) spacers', 'plain radiography and thin-section computed tomography', 'CaO-SiO2-P2O5-B2O3 Bioactive Glass Ceramics (BGS-7) Intervertebral Spacer and Titanium Cage']","['ODI, SF-36, back pain, and lower limb pain', 'Bone fusion', 'Visual Analog Scale (VAS), the Oswestry Disability Index (ODI), Short Form-36 Health Survey (SF-36), and evaluation of safety', 'bone fusion rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]","[{'cui': 'C3712088', 'cui_str': 'CaO-SiO2-P2O5-B2O3 glass'}, {'cui': 'C0221874', 'cui_str': 'Spacer (physical object)'}, {'cui': 'C1306645', 'cui_str': 'Plain x-ray'}, {'cui': 'C0332528', 'cui_str': 'Decreased thickness (finding)'}, {'cui': 'C0040395', 'cui_str': 'Tomographic imaging'}, {'cui': 'C0541042', 'cui_str': '(PMMA)-SiO2'}, {'cui': 'C0136917', 'cui_str': 'phosphoric anhydride'}, {'cui': 'C0164142', 'cui_str': 'boron oxide'}, {'cui': 'C1618088', 'cui_str': 'Glass ceramics'}, {'cui': 'C0442106', 'cui_str': 'Intervertebral (qualifier value)'}, {'cui': 'C0441240', 'cui_str': 'Titanium cage (physical object)'}]","[{'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0185364', 'cui_str': 'Repair or plastic operation on bone'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index (assessment scale)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",74.0,0.0227135,"The ODI, SF-36, back pain, and lower limb pain in both groups showed significant improvement after surgery, and no significant differences were observed between the groups.","[{'ForeName': 'Jae Hyup', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Department of Orthopedic Surgery, College of Medicine Seoul National University.'}, {'ForeName': 'Sun Ki', 'Initials': 'SK', 'LastName': 'Kim', 'Affiliation': 'Department of Orthopedic Surgery, SMG-SNU Boramae Medical Center.'}, {'ForeName': 'Sung Shik', 'Initials': 'SS', 'LastName': 'Kang', 'Affiliation': 'Department of Orthopedic Surgery, Seoul National University Bundang Hospital.'}, {'ForeName': 'Seung Jung', 'Initials': 'SJ', 'LastName': 'Han', 'Affiliation': 'Department of Medical and Scientific Affairs, CGBio.'}, {'ForeName': 'Choon-Ki', 'Initials': 'CK', 'LastName': 'Lee', 'Affiliation': 'Department of Orthopedic Surgery, College of Medicine Seoul National University.'}, {'ForeName': 'Bong-Soon', 'Initials': 'BS', 'LastName': 'Chang', 'Affiliation': 'Department of Orthopedic Surgery, College of Medicine Seoul National University.'}]",Clinical spine surgery,['10.1097/BSD.0000000000000950'] 3074,32078427,"Letter by Weingärtner et al Regarding Article, ""Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial"".",,2020,,['75 or Older (EWTOPIA 75'],[],[],"[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]",[],[],,0.134867,,"[{'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Weingärtner', 'Affiliation': 'Klinik für Innere Medizin I, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747 Jena, Germany (O.W.).'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Sijbrands', 'Affiliation': 'Department of Internal Medicine, Erasmus MC-University Medical Center Rotterdam, The Netherlands (E.S.).'}, {'ForeName': 'Dieter', 'Initials': 'D', 'LastName': 'Lütjohann', 'Affiliation': 'Institut für Klinische Chemie und Klinische Pharmakologie, Universitätsklinikum Bonn, Bonn, Germany (D.L.).'}]",Circulation,['10.1161/CIRCULATIONAHA.119.043726'] 3075,32078428,"Response by Kuwabara et al to Letter Regarding Article, ""Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized Controlled Trial"".",,2020,,['75 or Older (EWTOPIA 75'],[],[],"[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]",[],[],,0.103496,,"[{'ForeName': 'Masanari', 'Initials': 'M', 'LastName': 'Kuwabara', 'Affiliation': 'Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan (M.K., Y.O.).'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Sasaki', 'Affiliation': 'International University of Health and Welfare, Fukuoka, Japan (J.S.).'}, {'ForeName': 'Tetsunori', 'Initials': 'T', 'LastName': 'Saikawa', 'Affiliation': 'Okubo Hospital, Oita, Japan (T.S.).'}, {'ForeName': 'Yasuyoshi', 'Initials': 'Y', 'LastName': 'Ouchi', 'Affiliation': 'Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan (M.K., Y.O.).'}]",Circulation,['10.1161/CIRCULATIONAHA.120.045318'] 3076,32051080,[Effect of low-dose dopamine adjuvant therapy on inflammatory factors and prognosis in preterm infants with necrotizing enterocolitis].,"OBJECTIVE To study the effect of low-dose dopamine adjuvant therapy on inflammatory factors and prognosis in preterm infants with necrotizing enterocolitis (NEC). METHODS A total of 100 preterm infants with NEC from June 2017 to June 2019 were enrolled and divided into a dopamine treatment group and a conventional treatment group using a random number table, with 50 infants in each group. The infants in the conventional treatment group were given symptomatic treatment, and those in the dopamine treatment group were given low-dose dopamine adjuvant therapy in addition to the conventional treatment. ELISA was used to measure the levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukin-8 (IL-8). The two groups were compared in terms of time to relief of clinical symptoms, fasting time, treatment outcome, prognosis, and adverse reactions. RESULTS Both groups had significant reductions in the levels of CRP, TNF-α, and IL-8 after treatment, and the dopamine treatment group had significantly lower levels of these markers than the conventional treatment group after treatment (P<0.05). Compared with the conventional treatment group, the dopamine treatment group had significantly shorter time to defecation improvement, time to relief of abdominal distension and diarrhea, and fasting time (P<0.05), a significantly higher response rate (P<0.05), and a significantly lower surgery rate (P<0.05). There were no significant differences in the mortality rate and incidence of adverse events between the two groups (P>0.05). CONCLUSIONS Low-dose dopamine adjuvant therapy can effectively improve the levels of inflammatory factors and clinical symptoms in preterm infants with NEC and has good safety, and therefore, it holds promise for clinical application.",2020,"Both groups had significant reductions in the levels of CRP, TNF-α, and IL-8 after treatment, and the dopamine treatment group had significantly lower levels of these markers than the conventional treatment group after treatment (P<0.05).","['preterm infants with necrotizing enterocolitis (NEC', 'preterm infants with necrotizing enterocolitis', 'preterm infants with NEC', '100 preterm infants with NEC from June 2017 to June 2019 were enrolled and divided into a']","['ELISA', 'dopamine treatment group were given low-dose dopamine adjuvant therapy', 'dopamine treatment group and a conventional treatment', 'low-dose dopamine adjuvant therapy']","['response rate', 'levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukin-8 (IL-8', 'shorter time to defecation improvement, time to relief of abdominal distension and diarrhea, and fasting time', 'surgery rate', 'levels of CRP, TNF-α, and IL-8', 'time to relief of clinical symptoms, fasting time, treatment outcome, prognosis, and adverse reactions', 'mortality rate and incidence of adverse events']","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0520459', 'cui_str': 'Necrotizing Enterocolitis'}, {'cui': 'C0912341', 'cui_str': ""N'(OB)EC""}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0332849', 'cui_str': 'Divide'}]","[{'cui': 'C0014441', 'cui_str': 'ELISA'}, {'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0041368', 'cui_str': 'Tumor Necrosis Factors'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C1301676', 'cui_str': 'Relieves (qualifier value)'}, {'cui': 'C0000731', 'cui_str': 'Swollen abdomen (finding)'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0085415'}, {'cui': 'C0033325', 'cui_str': 'Prognosis'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",100.0,0.0322797,"Both groups had significant reductions in the levels of CRP, TNF-α, and IL-8 after treatment, and the dopamine treatment group had significantly lower levels of these markers than the conventional treatment group after treatment (P<0.05).","[{'ForeName': 'Ya-Juan', 'Initials': 'YJ', 'LastName': 'Tan', 'Affiliation': 'Department of Pediatrics, Enshi National Hospital of Tujia and Miao Autonomous Prefecture, Enshi, Hubei 445000, China. 1223836194@qq.com.'}, {'ForeName': 'Cong-Rong', 'Initials': 'CR', 'LastName': 'Tan', 'Affiliation': ''}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Tang', 'Affiliation': ''}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Yong-Jiang', 'Initials': 'YJ', 'LastName': 'Yu', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 3077,31806127,Risk Factors for Infections Involving Cardiac Implanted Electronic Devices.,"BACKGROUND Cardiac implantable electronic device infection is a major complication that usually requires device removal. PADIT (Prevention of Arrhythmia Device Infection Trial) was a large cluster crossover trial of conventional versus incremental antibiotics. OBJECTIVES This study sought to investigate independent predictors of device infection in PADIT and develop a novel infection risk score. METHODS In brief, over 4 6-month periods, 28 centers used either conventional or incremental prophylactic antibiotic treatment in all patients. The primary outcome was hospitalization for device infection within 1 year (blinded endpoint adjudication). Multivariable logistic prediction modeling was used to identify the independent predictors and develop a risk score for device infection. The prediction models were internally validated with bootstrap methods. RESULTS Device procedures were performed in 19,603 patients, and hospitalization for infection occurred in 177 (0.90%) within 1 year of follow-up. The final prediction model identified 5 independent predictors of device infection (prior procedures [P], age [A], depressed renal function [D], immunocompromised [I], and procedure type [T]) with an optimism-corrected C-statistic of 0.704 (95% confidence interval: 0.660 to 0.744). A PADIT risk score ranging from 0 to 15 points classified patients into low (0 to 4), intermediate (5 to 6) and high (≥7) risk groups with rates of hospitalization for infection of 0.51%, 1.42%, and 3.41%, respectively. CONCLUSIONS This study identified 5 independent predictors of device infection and developed a novel infection risk score in the largest cardiac implantable electronic device trial to date, warranting validation in an independent cohort. The 5 independent predictors in the PADIT score are readily adopted into clinical practice. (Prevention of Arrhythmia Device Infection Trial [PADIT Pilot]; NCT01002911).",2019,"RESULTS Device procedures were performed in 19,603 patients, and hospitalization for infection occurred in 177 (0.90%) within 1 year of follow-up.",[],"['conventional or incremental prophylactic antibiotic treatment', 'conventional versus incremental antibiotics']","['novel infection risk score', 'depressed renal function [D], immunocompromised [I], and procedure type [T]) with an optimism-corrected C-statistic of 0.704', 'hospitalization for infection', 'hospitalization for device infection']",[],"[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0445202', 'cui_str': 'Prophylactic (qualifier value)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0085393', 'cui_str': 'Immunosuppressed Host'}, {'cui': 'C0455713', 'cui_str': 'Procedure type (qualifier value)'}, {'cui': 'C0237428', 'cui_str': 'Optimism'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0600673', 'cui_str': 'Statistics'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0220819', 'cui_str': 'devices'}]",19603.0,0.110691,"RESULTS Device procedures were performed in 19,603 patients, and hospitalization for infection occurred in 177 (0.90%) within 1 year of follow-up.","[{'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Birnie', 'Affiliation': 'University of Ottawa Heart Institute, Ottawa, Ontario, Canada.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Alings', 'Affiliation': 'Amphia Ziekenhuis and Working Group on Cardiovascular Research the Netherlands, Breda, the Netherlands.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Philippon', 'Affiliation': 'Institut universitaire de cardiologie et de pneumologie de Québec, Laval University, Quebec City, Quebec, Canada.'}, {'ForeName': 'Ratika', 'Initials': 'R', 'LastName': 'Parkash', 'Affiliation': 'Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada.'}, {'ForeName': 'Jaimie', 'Initials': 'J', 'LastName': 'Manlucu', 'Affiliation': 'Lawson Health Research Institute, London Health Sciences, Western University, London, Ontario, Canada.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Angaran', 'Affiliation': 'Department of Medicine, University of Toronto, Division of Cardiology, St. Michael Hospital, Toronto, Ontario, Canada.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Rinne', 'Affiliation': ""St. Mary's General Hospital, Kitchener, Ontario, Canada.""}, {'ForeName': 'Benoit', 'Initials': 'B', 'LastName': 'Coutu', 'Affiliation': ""Centre hospitalier de l'Université de Montréal, University of Montreal, Montreal, Quebec, Canada.""}, {'ForeName': 'R Aaron', 'Initials': 'RA', 'LastName': 'Low', 'Affiliation': 'Chinook Regional Hospital, Lethbridge, Alberta, Canada.'}, {'ForeName': 'Vidal', 'Initials': 'V', 'LastName': 'Essebag', 'Affiliation': 'McGill University Health Center, Montreal, Quebec, Canada.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Morillo', 'Affiliation': 'Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Damian', 'Initials': 'D', 'LastName': 'Redfearn', 'Affiliation': ""Kingston General Hospital, Queen's University, Kingston, Ontario, Canada.""}, {'ForeName': 'Satish', 'Initials': 'S', 'LastName': 'Toal', 'Affiliation': 'Horizon Health Network, Saint John, New Brunswick, Canada.'}, {'ForeName': 'Giuliano', 'Initials': 'G', 'LastName': 'Becker', 'Affiliation': 'Hôpital du Sacré-Coeur de Montréal, University of Montreal, Montreal, Quebec, Canada.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Degrâce', 'Affiliation': 'Hôtel-Dieu de Lévis, Lévis, Quebec, Canada.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Thibault', 'Affiliation': 'Montreal Heart Institute, Montreal, Quebec, Canada.'}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Crystal', 'Affiliation': 'Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Stanley', 'Initials': 'S', 'LastName': 'Tung', 'Affiliation': ""St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'LeMaitre', 'Affiliation': 'Royal Columbian Hospital, New Westminster, British Columbia, Canada.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Sultan', 'Affiliation': 'Regina General Hospital, Saskatchewan Health Authority, Regina, Saskatchewan, Canada.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Bennett', 'Affiliation': 'Regina General Hospital, Saskatchewan Health Authority, Regina, Saskatchewan, Canada; Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Jamil', 'Initials': 'J', 'LastName': 'Bashir', 'Affiliation': 'University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Ayala-Paredes', 'Affiliation': 'Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Gervais', 'Affiliation': 'Institut universitaire de cardiologie et de pneumologie de Québec, Laval University, Quebec City, Quebec, Canada.'}, {'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Rioux', 'Affiliation': 'Centre de santé et de services sociaux de Rimouski-Neigette, Rimouski, Quebec, Canada.'}, {'ForeName': 'Martin E W', 'Initials': 'MEW', 'LastName': 'Hemels', 'Affiliation': 'Rijnstate Hospital, Arnhem, the Netherlands; Radboud University Medical Centre, Nijmegen, the Netherlands.'}, {'ForeName': 'Leon H R', 'Initials': 'LHR', 'LastName': 'Bouwels', 'Affiliation': 'Canisius Wilhelmina Ziekenhuis, Nijmegen, the Netherlands.'}, {'ForeName': 'Derek V', 'Initials': 'DV', 'LastName': 'Exner', 'Affiliation': 'Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Dorian', 'Affiliation': 'Department of Medicine, University of Toronto, Division of Cardiology, St. Michael Hospital, Toronto, Ontario, Canada.'}, {'ForeName': 'Stuart J', 'Initials': 'SJ', 'LastName': 'Connolly', 'Affiliation': 'Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Longtin', 'Affiliation': 'Jewish General Hospital Sir Mortimer B. Davis, McGill University, Montreal, Quebec, Canada.'}, {'ForeName': 'Andrew D', 'Initials': 'AD', 'LastName': 'Krahn', 'Affiliation': 'University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: akrahn@mail.ubc.ca.'}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2019.09.060'] 3078,32001397,Early Intensive Rehabilitation for Patients with Traumatic Brain Injury: A Prospective Pilot Trial.,"OBJECTIVE To investigate the effects of early intensive rehabilitation management on the recovery of motor function and activities of daily living in patients with moderate traumatic brain injury. METHODS Eighty-seven patients (age range, 18-65 years) with traumatic brain injury that met the enrollment criteria were randomly divided into 2 groups. Group 1 received early and high-intensity rehabilitation management (from 7 days after injury, 7 d/wk, 4 times/d, 1 h/session) for 4 weeks; group 2 received ordinary rehabilitation (from 14 days after injury, 5 d/wk, 2 times/d, 1 h/session) for 4 weeks. The Fugl-Meyer Assessment (FMA, motor function) and Barthel Index (BI) were used to assess the daily living functional state before treatment, 3 months after injury, and 6 months after injury. The Glasgow Coma Scale (GCS) was used to assess outcomes 6 months after injury. RESULTS Three months after rehabilitation, the FMA (motor function) score was significantly higher in the early intensive intervention group versus the control group (59.83 ± 11.87 vs. 44.56 ± 8.32, respectively; P < 0.05); no significant between-group differences were found in the GCS score or BI score (P > 0.05). Six months after rehabilitation, the FMA score and BI score were significantly higher in the early intensive intervention group versus the control group (FMA: 73.18 ± 16.55 vs. 57.86 ± 10.67, P < 0.01; BI: 87.17 ± 13.85 vs. 60.68 ± 11.98, P < 0.01, respectively). The GCS score was higher in the early intensive intervention group versus the control group (4.24 ± 0.91 vs. 3.43 ± 0.88, P < 0.05, respectively) 6 months after injury. CONCLUSIONS Early intensive rehabilitation management might be more beneficial for neurologic function and activities of daily living in patients with moderate traumatic brain injury.",2020,"Six months after rehabilitation, the FMA score and BI score were significantly higher in Early Intensive Intervention group vs. Control group (FMA: 73.18±16.55 vs. 57.86±10.67, P<0.01; BI: 87.17±13.85 vs. 60.68±11.98, P<0.01).","['patients with traumatic brain injury', 'Eighty-seven patients (age range 18-65 years) with traumatic brain injury that met the enrolment criteria', 'patients with moderate traumatic brain injury']","['early intensive rehabilitation management', 'ordinary rehabilitation', 'early and high-intensity rehabilitation management']","['GOS score or BI', 'FMA score and BI score', 'Glasgow Coma Scale (GOS', 'daily living functional state', 'GOS score', 'FMA (motor function) score', 'Fugl-Meyer Assessment (FMA, motor function) and Barthel Index (BI', 'recovery of motor and activities of daily living']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0876926', 'cui_str': 'TBI (Traumatic Brain Injury)'}, {'cui': 'C4517895', 'cui_str': 'Eighty-seven'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}]","[{'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0017594', 'cui_str': 'Glasgow coma scale (assessment scale)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0234130', 'cui_str': 'Motor function (observable entity)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0451019', 'cui_str': 'Barthel index (assessment scale)'}, {'cui': 'C0001288', 'cui_str': 'ADL'}]",87.0,0.0557411,"Six months after rehabilitation, the FMA score and BI score were significantly higher in Early Intensive Intervention group vs. Control group (FMA: 73.18±16.55 vs. 57.86±10.67, P<0.01; BI: 87.17±13.85 vs. 60.68±11.98, P<0.01).","[{'ForeName': 'Ming-Chao', 'Initials': 'MC', 'LastName': 'Fan', 'Affiliation': 'Department of Neurosurgery The Affiliated Hospital of Qingdao University, Qingdao, China; Neurosurgical Intensive Care Unit The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Shi-Fang', 'Initials': 'SF', 'LastName': 'Li', 'Affiliation': 'Department of Neurosurgery The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Sun', 'Affiliation': 'Department of Neurosurgery The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Guang-Tao', 'Initials': 'GT', 'LastName': 'Bai', 'Affiliation': 'Department of Rehabilitation Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Nian', 'Initials': 'N', 'LastName': 'Wang', 'Affiliation': 'Neurosurgical Intensive Care Unit The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Han', 'Affiliation': 'Department of Rehabilitation Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': 'Neurosurgical Intensive Care Unit The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Neurosurgical Intensive Care Unit The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Huan-Ting', 'Initials': 'HT', 'LastName': 'Li', 'Affiliation': 'Department of Neurosurgery The Affiliated Hospital of Qingdao University, Qingdao, China. Electronic address: fanmcqd@163.com.'}]",World neurosurgery,['10.1016/j.wneu.2020.01.113'] 3079,32051393,Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.,"The poor prognosis of clear-cell renal cell carcinoma (ccRCC) patients is due to progression and targeted drug resistance, but the underlying molecular mechanisms need further elucidation. This study examined the biological function and related mechanisms of gankyrin in ccRCC based on the results of our previous study. To this end, in vitro functional experiments; in vivo models of subcutaneous tumor formation, lung metastasis, and orthotopic ccRCC; and antibody chip detection, co-IP, ChIP assays were performed to examine the biological role and molecular mechanisms of gankyrin in ccRCC. Two hundred fifty-six ccRCC patients were randomly divided into training and validation cohorts to examine the prognostic value of gankyrin and other markers through IHC and statistical analyses. We observed that the gankyrin-overexpressing ccRCC cell lines 786-O and 769-P exhibited increased proliferation, invasion, migration, tumorigenicity, and pazopanib resistance and decreased apoptosis, while gankyrin knockdown achieved the opposite results. Mechanistically, gankyrin recruited STAT3 via direct binding, and STAT3 binding to the CCL24 promoter promoted its expression. Reciprocally, an increase in autocrine CCL24 enhanced the expression of gankyrin and STAT3 activation via CCR3 in ccRCC, forming a positive autocrine-regulatory loop. Furthermore, in vivo experimental results revealed that blocking the positive loop through gankyrin knockdown or treatment with the CCR3 inhibitor SB328437 reversed the resistance to pazopanib and inhibited lung metastasis in ccRCC. Moreover, a positive correlation between gankyrin and STAT3 or CCL24 expression in ccRCC specimens was observed, and improved accuracy for ccRCC patient prognosis was achieved by combining gankyrin and STAT3 or CCL24 expression with existing clinical prognostic indicators, including the TNM stage and SSIGN score. In summary, targeting the gankyrin/STAT3/CCL24/CCR3 autocrine-regulatory loop may serve as a remedy for patients with advanced ccRCC, and combining gankyrin and STAT3 or CCL24 expression with the current clinical indicators better predicts ccRCC patient prognosis.",2020,"Moreover, a positive correlation between gankyrin and STAT3 or CCL24 expression in ccRCC specimens was observed, and improved accuracy for ccRCC patient prognosis was achieved by combining gankyrin and STAT3 or CCL24 expression with existing clinical prognostic indicators, including the TNM stage and SSIGN score.","['clear cell renal cell carcinoma', 'patients with advanced ccRCC', 'Two hundred fifty-six ccRCC patients']",['Gankyrin/STAT3/CCL24/CCR3'],"['proliferation, invasion, migration, tumorigenicity, and pazopanib resistance and decreased apoptosis, while gankyrin knockdown']","[{'cui': 'C0279702', 'cui_str': 'Clear Cell Renal Carcinoma'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C4319558', 'cui_str': '200'}]",[],"[{'cui': 'C0334094', 'cui_str': 'Proliferation (morphologic abnormality)'}, {'cui': 'C1533574', 'cui_str': 'Migration, function (observable entity)'}, {'cui': 'C1519697', 'cui_str': 'Tumorigenicity'}, {'cui': 'C1831796', 'cui_str': 'pazopanib'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0162638', 'cui_str': 'Programmed Cell Death, Type I'}]",256.0,0.022439,"Moreover, a positive correlation between gankyrin and STAT3 or CCL24 expression in ccRCC specimens was observed, and improved accuracy for ccRCC patient prognosis was achieved by combining gankyrin and STAT3 or CCL24 expression with existing clinical prognostic indicators, including the TNM stage and SSIGN score.","[{'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Urinary Surgery, Gongli Hospital, Second Military Medical University (Naval Medical University), 219 Miaopu Road, Shanghai, 200135, China.'}, {'ForeName': 'Yuning', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Urinary Surgery, Gongli Hospital, Second Military Medical University (Naval Medical University), 219 Miaopu Road, Shanghai, 200135, China.'}, {'ForeName': 'Tianyu', 'Initials': 'T', 'LastName': 'Hong', 'Affiliation': 'Department of Urinary Surgery, Gongli Hospital, Second Military Medical University (Naval Medical University), 219 Miaopu Road, Shanghai, 200135, China.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Cheng', 'Affiliation': 'Department of Urology, Affiliated Hospital of Nantong University, 20 Xisi Road, Changzhou, Jiangsu, China.'}, {'ForeName': 'Sishun', 'Initials': 'S', 'LastName': 'Gan', 'Affiliation': 'Department of Urinary Surgery, The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), 700 North Moyu Road, Shanghai, 201805, China.'}, {'ForeName': 'Linbao', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Urinary Surgery, Gongli Hospital, Second Military Medical University (Naval Medical University), 219 Miaopu Road, Shanghai, 200135, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Urinary Surgery, Gongli Hospital, Second Military Medical University (Naval Medical University), 219 Miaopu Road, Shanghai, 200135, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zuo', 'Affiliation': ""Department of Urology, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, 29 Xinglong Road, Changzhou, Jiangsu, 213000, China. zuoli@njmu.edu.cn.""}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Urinary Surgery, Gongli Hospital, Second Military Medical University (Naval Medical University), 219 Miaopu Road, Shanghai, 200135, China. lijian_771103@126.com.'}, {'ForeName': 'Xingang', 'Initials': 'X', 'LastName': 'Cui', 'Affiliation': 'Department of Urinary Surgery, Gongli Hospital, Second Military Medical University (Naval Medical University), 219 Miaopu Road, Shanghai, 200135, China. cuixingang@smmu.edu.cn.'}]",Cell death & disease,['10.1038/s41419-020-2306-6'] 3080,31381021,Association of Renal Scarring With Number of Febrile Urinary Tract Infections in Children.,"Importance Although prior studies have suggested that the risk of renal scarring gradually increases with each febrile urinary tract infection (UTI), recent and detailed data are lacking. Objective To evaluate how the risk of renal scarring is associated with the number of febrile UTIs. Design, Setting, and Participants A post hoc analysis was performed from June 2018 to April 2019 of data collected in the context of 2 multicenter prospective studies (RIVUR [Randomized Intervention for Children With Vesicoureteral Reflux], conducted from June 2007 to June 2013, and CUTIE [Careful Urinary Tract Infection Evaluation], conducted from May 2008 to October 2013), of children with a first UTI without baseline renal abnormalities who were followed up for 2 years for febrile recurrences. Exposure Number of known febrile UTIs. Main Outcomes and Measures Renal scarring was defined as decreased uptake of tracer associated with the loss of contours or cortical thinning on a technetium 99m dimercaptosuccinic acid renal scan obtained at study exit or approximately 4 months after the last febrile UTI. Results A total of 345 children were included (307 girls and 38 boys; mean [SD] age, 19.4 [18.2] months; 221 with vesicoureteral reflux and 124 without vesicoureteral reflux). The incidence of renal scarring was 2.8% (95% CI, 1.2%-5.8%) after 1 febrile UTI, 25.7% (95% CI, 12.5%-43.3%) after 2 febrile UTIs, and 28.6% (95% CI, 8.4%-58.1%) after 3 or more febrile UTIs. The odds of renal scarring after a second febrile infection were 11.8 (95% CI, 4.1-34.4) times greater than after a single febrile infection, and the odds of renal scarring after 3 or more febrile infections were 13.7 (95% CI, 3.4-54.4) times greater than after a single febrile infection. Conclusions and Relevance Although relatively few children have 2 febrile UTIs, those who do have a substantially higher risk of renal scarring compared with children with a single febrile UTI. This finding suggests that research should focus on the identification of biomarkers that could noninvasively identify children at risk for subsequent febrile infections. More research is also needed to understand the molecular basis of the increased risk of renal scarring among children with recurrent febrile UTIs.",2019,"The incidence of renal scarring was 2.8% (95% CI, 1.2%-5.8%) after 1 febrile UTI, 25.7% (95% CI, 12.5%-43.3%) after 2 febrile UTIs, and 28.6% (95% CI, 8.4%-58.1%) after 3 or more febrile UTIs.","['345 children were included (307 girls and 38 boys; mean [SD] age, 19.4 [18.2] months; 221 with vesicoureteral reflux and 124 without vesicoureteral reflux', 'June 2018 to April 2019 of data collected in the context of 2 multicenter prospective studies (RIVUR [Randomized Intervention for Children With Vesicoureteral Reflux], conducted from June 2007 to June 2013, and CUTIE [Careful Urinary Tract Infection Evaluation], conducted from May 2008 to October 2013), of children with a first UTI without baseline renal abnormalities who were followed up for 2 years for febrile recurrences', 'children with recurrent febrile UTIs', 'Children']",[],"['renal scarring', 'uptake of tracer associated with the loss of contours or cortical thinning on a technetium 99m dimercaptosuccinic acid renal scan', 'febrile infections', 'Measures\n\n\nRenal scarring', 'renal scarring after a second febrile infection', 'incidence of renal scarring', 'Renal Scarring']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4709305', 'cui_str': '19.4 (qualifier value)'}, {'cui': 'C4517610', 'cui_str': '18.2'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0042580', 'cui_str': 'Vesicoureteral Reflux'}, {'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C0449255', 'cui_str': 'Context (attribute)'}, {'cui': 'C0033522', 'cui_str': 'Prospective Studies'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0000769', 'cui_str': 'anomalies'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}]",[],"[{'cui': 'C1700247', 'cui_str': 'Renal scarring'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0075928', 'cui_str': 'Technetium-99m-DMSA'}, {'cui': 'C0412412', 'cui_str': 'Renal isotope studies (procedure)'}, {'cui': 'C0948233', 'cui_str': 'Febrile infection'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}]",307.0,0.0648792,"The incidence of renal scarring was 2.8% (95% CI, 1.2%-5.8%) after 1 febrile UTI, 25.7% (95% CI, 12.5%-43.3%) after 2 febrile UTIs, and 28.6% (95% CI, 8.4%-58.1%) after 3 or more febrile UTIs.","[{'ForeName': 'Nader', 'Initials': 'N', 'LastName': 'Shaikh', 'Affiliation': ""Division of General Academic Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.""}, {'ForeName': 'Mary Ann', 'Initials': 'MA', 'LastName': 'Haralam', 'Affiliation': ""Division of General Academic Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.""}, {'ForeName': 'Marcia', 'Initials': 'M', 'LastName': 'Kurs-Lasky', 'Affiliation': ""Division of General Academic Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.""}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Hoberman', 'Affiliation': ""Division of General Academic Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.""}]",JAMA pediatrics,['10.1001/jamapediatrics.2019.2504'] 3081,31889691,"Standardized Patients Versus Peer Role Play-Exploring the Experience, Efficacy, and Cost-Effectiveness in Residency Training Module for Breaking Bad News.","BACKGROUND Delivering bad news is a difficult task for the clinician and one that is important to address and nurture in residency training. METHODS Residents were assigned to receive communication training with either standardized patients (SP) or peer role play (RP). Anonymized pre- and post-questionnaires were filled by residents detailing their experience. Independent assessors blinded to the study hypothesis rated the residents' performance using a standardized plus-delta assessment form as a measure of effectiveness of either methods. In our study additionally, corresponding costs were assessed as man-hours resulting from the hours of work of SP, RP, and tutors in order to generate the incremental cost-effectiveness ratio for the use of SP against the use of RP. SETTING The study took place in a tertiary academic hospital, National University Hospital, Singapore. PARTICIPANTS A total of 15 junior residents in anesthetic training entered and completed the study and were evaluated during the 2017-2018 academic year. RESULTS The mean performance scores were 63.3% (RP group) and 74.3% (SP group) attributing advantage to the SP group. Costs however were slighter greater in the SP group (14 man-hours) versus (10 man-hours) in the RP group. The resulting incremental cost-effectiveness ratio was 0.36 man-hours per 1-point increase in the performance score when comparing SP to peer RP. CONCLUSIONS SPs proved to be the more cost-effective modality when employing communication training for delivering bad news. The successful experience and use of SPs should be balanced against the marginally lesser costs involved in peer RP in planning residency teaching sessions.",2020,Costs however were slighter greater in the SP group (14 man-hours) versus (10 man-hours) in the RP group.,"['tertiary academic hospital, National University Hospital, Singapore', 'A total of 15 junior residents in anesthetic training entered and completed the study and were evaluated during the 2017-2018 academic year', 'Residents']",['communication training with either standardized patients (SP) or peer role play (RP'],"['Costs', 'mean performance scores', 'incremental cost-effectiveness ratio']","[{'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0037173', 'cui_str': 'Singapore'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0002930', 'cui_str': 'Anesthesiology'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0699820', 'cui_str': 'Role playing (finding)'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",,0.0249748,Costs however were slighter greater in the SP group (14 man-hours) versus (10 man-hours) in the RP group.,"[{'ForeName': 'Ambika', 'Initials': 'A', 'LastName': 'Paramasivan', 'Affiliation': 'National University Hospital, Singapore. Electronic address: ambika_paramasivan@nuhs.edu.sg.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Khoo', 'Affiliation': 'National University Hospital, Singapore.'}]",Journal of surgical education,['10.1016/j.jsurg.2019.10.009'] 3082,32086985,Effectiveness of an encecalin standardized extract of Ageratina pichinchensis on the treatment of onychomycosis in patients with diabetes mellitus.,"Ageratina pichinchensis is utilized in traditional medicine for the treatment of dermatomycosis and inflammation. The aim of this study was to evaluate the clinical and mycological effectiveness of the topical administration of an enecalin standardized extract of A. pichinchensis for treating onychomycosis in patients with type 2 diabetes mellitus (DM2). A double blind, randomized, and controlled clinical trial was carried out that included patients with DM2 and who had mild or moderate onychomycosis. Participants were administered topically, for 6 months, a lacquer containing the encecalin standardized extract of A. pichinchensis (experimental group) or 8% ciclopirox (control group). In a large percentage of both, the control group (77.2%) and the experimental group (78.5%), clinical efficacy was detected as a decrease in the number of affected nails and a reduction in the severity of nail involvement. Without exhibiting statistically significant differences between groups, the encecalin standardized extract of A. pichinchensis was clinically and mycologically effective in the treatment of mild and moderate onychomycosis in patients with DM2. The treatment of onychomycosis in patients with DM2 implies a greater challenge, while control of blood glucose levels in these patients, played a very important role in the response of patients to treatment.",2020,"Without exhibiting statistically significant differences between groups, the encecalin standardized extract of A. pichinchensis was clinically and mycologically effective in the treatment of mild and moderate onychomycosis in patients with DM2.","['included patients with DM2 and who had mild or moderate onychomycosis', 'patients with DM2', 'patients with diabetes mellitus', 'patients with type 2 diabetes mellitus (DM2']","['lacquer containing the encecalin standardized extract of A. pichinchensis (experimental group) or 8% ciclopirox (control group', 'enecalin standardized extract of A. pichinchensis', 'encecalin standardized extract of Ageratina pichinchensis']","['number of affected nails', 'severity of nail involvement', 'blood glucose levels', 'clinical efficacy']","[{'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1300562', 'cui_str': 'dm2'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0040261', 'cui_str': 'Tinea Unguium'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0022902', 'cui_str': 'Lacquer'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0055711', 'cui_str': 'ciclopirox'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1047415', 'cui_str': 'Ageratina'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0027342', 'cui_str': 'Nails'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0205428', 'cui_str': 'Involvements (qualifier value)'}, {'cui': 'C0428554', 'cui_str': 'Blood glucose result - finding'}, {'cui': 'C0087113', 'cui_str': 'Treatment Efficacy'}]",,0.0365675,"Without exhibiting statistically significant differences between groups, the encecalin standardized extract of A. pichinchensis was clinically and mycologically effective in the treatment of mild and moderate onychomycosis in patients with DM2.","[{'ForeName': 'Ofelia', 'Initials': 'O', 'LastName': 'Romero-Cerecero', 'Affiliation': 'Centro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social (CIBIS-IMSS), Xochitepec, Mexico.'}, {'ForeName': 'Ana Laura', 'Initials': 'AL', 'LastName': 'Islas-Garduño', 'Affiliation': 'Centro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social (CIBIS-IMSS), Xochitepec, Mexico.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Zamilpa', 'Affiliation': 'Centro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social (CIBIS-IMSS), Xochitepec, Mexico.'}, {'ForeName': 'Jaime', 'Initials': 'J', 'LastName': 'Tortoriello', 'Affiliation': 'Centro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social (CIBIS-IMSS), Xochitepec, Mexico.'}]",Phytotherapy research : PTR,['10.1002/ptr.6644'] 3083,32054535,"A cluster-randomized field trial to reduce cesarean section rates with a multifaceted intervention in Shanghai, China.","BACKGROUND Cesarean section (CS) rate has risen dramatically and stayed at a very high level in China over the past two to three decades. Given the short- and long-term adverse effects of CS, effective strategies are needed to reduce unnecessary CS. We aimed to evaluate whether a multifaceted intervention would decrease the CS rate in China. METHODS We carried out a cluster-randomized field trial with a multifaceted intervention in Shanghai, China, from 2015 to 2017. A total of 20 hospitals were randomly allocated into an intervention or a control group. The intervention consisted of more targeted health education to pregnant women, improved hospital CS policy, and training of midwives/doulas for 8 months. The study included a baseline survey, the intervention, and an evaluation survey. The primary outcome was the changes of overall CS rate from the pre-intervention to the post-intervention period. A subgroup analysis stratified by the Robson classification was also conducted to examine the CS change among women with various obstetric characteristics. RESULTS A total of 10,752 deliveries were randomly selected from the pre-intervention period and 10,521 from the post-intervention period. The baseline CS rates were 42.5% and 41.5% in the intervention and control groups, respectively, while the post-intervention CS rates were 43.4% and 42.4%, respectively. Compared with the control group, the intervention did not significantly reduce the CS rate (adjusted OR = 0.92; 95% CI 0.73, 1.15). Similar results were obtained in subgroup analyses stratified by the risk level of pregnancy, maternal age, number of previous CS, or parity. Scarred uterus and maternal request remained the primary reasons for CS after the interventions in both groups. The intervention did not alter the perinatal outcomes (adjusted change of risk score = - 0.06; 95%CI - 0.43, 0.31). CONCLUSIONS A multifaceted intervention including more targeted prenatal health education, improved hospital CS policy, and training of midwives/doulas, did not significantly reduce the CS rate in Shanghai, China. However, our experience in implementing a multifaceted intervention may provide useful information to other similar areas with high CS use. TRIAL REGISTRATION This trial was registered at the Chinese Clinical Trial Registry (www.chictr.org.cn) (ChiCTR-IOR-16009041) on 17 August 2016.",2020,"The intervention did not alter the perinatal outcomes (adjusted change of risk score = - 0.06; 95%CI - 0.43, 0.31). ","['A total of 20 hospitals', '17 August 2016', 'A total of 10,752 deliveries', 'in Shanghai, China, from 2015 to 2017', 'Shanghai, China', 'women with various obstetric characteristics']","['multifaceted intervention', 'intervention consisted of more targeted health education to pregnant women, improved hospital CS policy, and training of midwives/doulas for 8\xa0months']","['cesarean section rates', 'baseline CS rates', 'perinatal outcomes', 'changes of overall CS rate', 'CS rate']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}]","[{'cui': 'C0205291', 'cui_str': 'Multifaceted (qualifier value)'}, {'cui': 'C0018701'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0242456', 'cui_str': 'Policy'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0026083', 'cui_str': 'Midwife'}, {'cui': 'C2936640', 'cui_str': 'Doulas'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0007876', 'cui_str': 'C-Section (OB)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",10752.0,0.176262,"The intervention did not alter the perinatal outcomes (adjusted change of risk score = - 0.06; 95%CI - 0.43, 0.31). ","[{'ForeName': 'Lulu', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': ""Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Obstetrics and Gynecology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': ""Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Xi', 'Affiliation': 'Department of Obstetrics, Jiading District Maternal and Child Health Hospital, Shanghai, China.'}, {'ForeName': 'Xiaohua', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Maternal Health Care, Minhang District Maternal and Child Health Hospital, Shanghai, China.'}, {'ForeName': 'Zhenni', 'Initials': 'Z', 'LastName': 'Meng', 'Affiliation': 'Department of Obstetrics, First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Obstetrics, Songjiang District Maternal and Child Health Hospital, Shanghai, China.'}, {'ForeName': 'Huaping', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': ""Department of Obstetrics and Gynecology, Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Xiaohua', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Obstetrics, First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China.'}, {'ForeName': 'Feihua', 'Initials': 'F', 'LastName': 'Ju', 'Affiliation': 'Department of Obstetrics and Gynecology, Pudong New District Maternal and Child Health Hospital, Shanghai, China.'}, {'ForeName': 'Yuping', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': ""Department of Obstetrics and Gynecology, Pudong New Area People's Hospital, Shanghai, China.""}, {'ForeName': 'Huijun', 'Initials': 'H', 'LastName': 'Tang', 'Affiliation': 'Department of Obstetrics, Putuo District Maternal and Child Health Hospital, Shanghai, China.'}, {'ForeName': 'Xianju', 'Initials': 'X', 'LastName': 'Qin', 'Affiliation': ""Department of General Surgery, Eighth People's Hospital, Shanghai, China.""}, {'ForeName': 'Yanhong', 'Initials': 'Y', 'LastName': 'Ming', 'Affiliation': ""Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Huang', 'Affiliation': ""Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Guohong', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'Shanghai Jiao Tong University School of Public Health, Shanghai, China.'}, {'ForeName': 'Hongying', 'Initials': 'H', 'LastName': 'Dai', 'Affiliation': 'Nursing College, Shanghai University of Medicine & Health Sciences, Shanghai, China.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Zhang', 'Affiliation': 'Shanghai Maternal and Child Health Center, Shanghai, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Qin', 'Affiliation': 'Shanghai Maternal and Child Health Center, Shanghai, China. qinmin0902@163.com.'}, {'ForeName': 'Liping', 'Initials': 'L', 'LastName': 'Zhu', 'Affiliation': 'Shanghai Maternal and Child Health Center, Shanghai, China. shzhuliping@163.com.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhangjun@xinhuamed.com.cn.""}]",BMC medicine,['10.1186/s12916-020-1491-6'] 3084,28682190,Advance Care Planning Program and the Knowledge and Attitude Concerning Palliative Care.,"OBJECTIVES The study aimed to evaluate the effects of an advance care planning (ACP) program on knowledge and attitudes concerning palliative care, and decisions regarding DNR orders in the older residents in a long-term care institution. METHODS A quasi-experimental design was used. Participants were cognitively unimpaired older residents in a long-term care institution in Taiwan. The experimental group (n = 29) received the intervention including an individual interview using an ACP handbook and a group patient education; whereas the control group (n = 28) received the group patient education only. RESULTS There were significant positive effects of the ACP program on understanding of DNR and palliative care, willingness to sign a DNR order, and knowledge of and attitude towards palliative care; however, there was no significant effect on willingness to receive palliative care. Six participants signed the DNR order after the intervention compared to none in the control group. CONCLUSIONS The ACP program can improve knowledge and attitudes towards palliative care in older residents in long-term care institutions. CLINICAL IMPLICATIONS The ACP program could incorporate multiple components, including individual interview using ACP handbook and group patient education, and address knowledge and attitudes towards palliative care.",2019,"There were significant positive effects of the ACP program on understanding of DNR and palliative care, willingness to sign a DNR order, and knowledge of and attitude towards palliative care; however, there was no significant effect on willingness to receive palliative care.","['Participants were cognitively unimpaired older residents in a long-term care institution in Taiwan', 'older residents in a long-term care institution']","['ACP program', 'intervention including an individual interview using an ACP handbook and a group patient education; whereas the control group (n\xa0=\xa028) received the group patient education only', 'advance care planning (ACP) program']",['knowledge and attitudes towards palliative care'],"[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0023977'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0039260', 'cui_str': 'Formosa'}]","[{'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0596654', 'cui_str': 'Handbooks'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0030688', 'cui_str': 'Education of Patients'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0600371', 'cui_str': 'Advance Health Care Planning'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0700049', 'cui_str': 'Palliative care'}]",6.0,0.0162053,"There were significant positive effects of the ACP program on understanding of DNR and palliative care, willingness to sign a DNR order, and knowledge of and attitude towards palliative care; however, there was no significant effect on willingness to receive palliative care.","[{'ForeName': 'Huei-Chuan', 'Initials': 'HC', 'LastName': 'Sung', 'Affiliation': 'a Graduate Institute of Long-Term Care & Department of Nursing, Tzu Chi University of Science and Technology , Hualien City , Taiwan.'}, {'ForeName': 'Shu-Chen', 'Initials': 'SC', 'LastName': 'Wang', 'Affiliation': 'c Department of Nursing, Buddhist Tzu Chi General Hospital , Hualien City , Taiwan.'}, {'ForeName': 'Sheng-Yu', 'Initials': 'SY', 'LastName': 'Fan', 'Affiliation': 'f Institute of Gerontology, College of Medicine , National Cheng Kung University , Tainan City , Taiwan.'}, {'ForeName': 'Chia-Ying', 'Initials': 'CY', 'LastName': 'Lin', 'Affiliation': 'a Graduate Institute of Long-Term Care & Department of Nursing, Tzu Chi University of Science and Technology , Hualien City , Taiwan.'}]",Clinical gerontologist,['10.1080/07317115.2017.1336142'] 3085,32051083,[Association of microRNA expression before and after drug therapy with clinical symptoms in children with attention deficit hyperactivity disorder].,"OBJECTIVE To study the association of microRNA expression before and after drug therapy with clinical symptoms in children with attention deficit hyperactivity disorder (ADHD). METHODS A total of 80 previously untreated children with ADHD who were diagnosed from May 2017 to October 2018 were enrolled. The children who were willing to receive drug therapy were randomly divided into concerta-treated group with 31 children and strattera-treated group with 33 children. The children who were unwilling to receive treatment were enrolled as the untreated group with 16 children. A total of 60 children who underwent physical examination during the same period of time were enrolled as the healthy control group. SNAP-V score was determined at initial diagnosis and 3 and 6 months of follow-up. Serum samples were collected from the children with ADHD and the healthy control group. Quantitative real-time PCR was used to measure the relative expression of miR-4566-3p and miR-7641. RESULTS The repeated measures analysis of variance showed that the SNAP-V score of attention deficit symptoms were different among the two treatment groups and the untreated group at the first visit and 3 months and 6 months after treatment (P<0.05). There were significant differences in the relative expression of the two miRNAs among the two treatment groups and the healthy control group at the first visit and 3 months and 6 months after treatment (P<0.05). The SNAP-V score of attention deficit symptoms and the relative expression of the two miRNAs were different in different time points in the subjects (P<0.05). There were interactions between grouping and time factors in the SNAP-V score of attention deficit symptoms and the relative expression of the two miRNAs (P<0.05). The SNAP-V score of hyperactive impulsive symptoms was different in different time points in the two treatment groups and the untreated group (P<0.05), but the significant difference in the score was not observed between two treatment groups and the untreated group (P>0.05), and there was no interaction between the time factor and the grouping factor (P>0.05). The SNAP-V score of attention deficit symptoms was negatively correlated with the relative expression of miRNA-4655-3p and miRNA-7641 (r=-0.314, -0.495 respectively; P<0.05) in ADHD children after drug treatment. CONCLUSIONS Drug therapy can significantly improve the clinical symptoms of children with ADHD. The expression of miR-4655-3p and miR-7641 in serum can be used as biomarkers for the diagnosis and outcome evaluation of ADHD.",2020,The repeated measures analysis of variance showed that the SNAP-V score of attention deficit symptoms were different among the two treatment groups and the untreated group at the first visit and 3 months and 6 months after treatment (P<0.05).,"['60 children who underwent physical examination during the same period of time were enrolled as the healthy control group', 'children who were unwilling to receive treatment were enrolled as the untreated group with 16 children', 'children with attention deficit hyperactivity disorder', 'children with attention deficit hyperactivity disorder (ADHD', 'children with ADHD and the healthy control group', '80 previously untreated children with ADHD who were diagnosed from May 2017 to October 2018 were enrolled', 'children with ADHD', 'children who were willing to receive drug therapy were randomly divided into concerta-treated group with 31 children and strattera-treated group with 33 children']",[],"['SNAP-V score of hyperactive impulsive symptoms', 'SNAP-V score of attention deficit symptoms', 'SNAP-V score', 'relative expression']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0031809', 'cui_str': 'Physical Examination'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0558080', 'cui_str': 'Unwilling (finding)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1263846', 'cui_str': 'ADDH'}, {'cui': 'C0600109', 'cui_str': 'Willing (finding)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0939301', 'cui_str': 'Concerta'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C1176420', 'cui_str': 'Strattera'}]",[],"[{'cui': 'C0074709', 'cui_str': 'Snap (resin)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0424295', 'cui_str': 'Increased purposeful goal-directed activity'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C3854321', 'cui_str': 'Expression'}]",60.0,0.0328053,The repeated measures analysis of variance showed that the SNAP-V score of attention deficit symptoms were different among the two treatment groups and the untreated group at the first visit and 3 months and 6 months after treatment (P<0.05).,"[{'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Zhang', 'Affiliation': 'Graduate School of Bengbu Medical College, Bengbu, Anhui 233000, China. lhwu@wzmc.ne.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Zhu', 'Affiliation': ''}, {'ForeName': 'Li-Hui', 'Initials': 'LH', 'LastName': 'Wu', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 3086,32073417,Safety and efficacy of intracoronary prourokinase administration in patients with high thrombus burden.,"OBJECTIVES The study was designed to evaluate the effect of low-dose intracoronary prourokinase administration immediately after thrombus aspiration in patients with ST-segment elevation myocardial infarction (STEMI) presenting with a serious thrombus burden. METHODS Consecutive STEMI patients with high thrombus burden received thrombus aspiration during primary percutaneous coronary intervention (PCI) were randomly assigned to study group (intracoronary prourokinase administration) or control group (intracoronary 0.9% sodium chloride administration). The primary endpoint was complete ST-segment resolution (STR) at 90 min after primary PCI, and the secondary endpoints included angiographic myocardial perfusion indexes. RESULTS Patients in study group had a higher incidence of complete STR and myocardial blush grade 3 compared with those in control group (56.52% vs. 38.89%, P = 0.017 and 57.61% vs. 38.89%, P = 0.041). The peak cardiac troponin I value and corrected thrombolysis in myocardial infarction frame count were significantly lower in study group (52.16 ± 24.67 ng/mL vs. 60.91 ± 28.81 ng/mL, P = 0.029; and 19.57 ± 9.05 vs. 22.91 ± 10.22, P = 0.020). A significant improvement in left ventricular ejection fraction and major adverse cardiac events (MACEs)-free survival was observed in study group (55.22 ± 10.50% vs. 52.18 ± 9.39%, P = 0.041; 10.87% vs. 22.22%, P = 0.039) at the 6-month follow-up. The bleeding complication was similar in both groups (17.39% vs. 12.22%, P = 0.327). CONCLUSIONS In STEMI patients with high thrombus burden, low-dose prourokinase intracoronary administered immediately after thrombus aspiration improves myocardial perfusion, cardiac function, and MACEs-free survival with no significant increase in major bleeding.",2020,"A significant improvement in left ventricular ejection fraction and major adverse cardiac events (MACEs)-free survival was observed in study group (55.22 ± 10.50% vs. 52.18 ± 9.39%, P = 0.041; 10.87% vs. 22.22%, P = 0.039) at the 6-month follow-up.","['patients with high thrombus burden', 'Consecutive STEMI patients with high thrombus burden received thrombus aspiration during primary percutaneous coronary intervention (PCI', 'patients with ST-segment elevation myocardial infarction (STEMI) presenting with a serious thrombus burden']","['intracoronary prourokinase', 'intracoronary prourokinase administration) or control group (intracoronary 0.9% sodium chloride administration', 'low-dose intracoronary prourokinase']","['peak cardiac troponin I value and corrected thrombolysis in myocardial infarction frame count', 'complete STR and myocardial blush grade', 'angiographic myocardial perfusion indexes', 'complete ST-segment resolution (STR', 'left ventricular ejection fraction and major adverse cardiac events (MACEs)-free survival', 'myocardial perfusion, cardiac function, and MACEs-free survival', 'major bleeding', 'Safety and efficacy', 'bleeding complication']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0302148', 'cui_str': 'Blood coagulum'}, {'cui': 'C1536220', 'cui_str': 'ST Elevated Myocardial Infarction'}, {'cui': 'C0349707', 'cui_str': 'Aspiration - action (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}]","[{'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4068881', 'cui_str': 'Zero point nine'}, {'cui': 'C0037494', 'cui_str': 'Sodium Chloride'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0883409', 'cui_str': 'Cardiac troponin I'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis, function (observable entity)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0180979', 'cui_str': 'Frame (physical object)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0005874', 'cui_str': 'Blushings'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0428857', 'cui_str': 'Myocardial perfusion (observable entity)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0429029', 'cui_str': 'ST segment (observable entity)'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function (observable entity)'}, {'cui': 'C0349381', 'cui_str': 'Mace (substance)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}]",,0.0571239,"A significant improvement in left ventricular ejection fraction and major adverse cardiac events (MACEs)-free survival was observed in study group (55.22 ± 10.50% vs. 52.18 ± 9.39%, P = 0.041; 10.87% vs. 22.22%, P = 0.039) at the 6-month follow-up.","[{'ForeName': 'Xuechao', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiology, Hebei General Hospital, Shijiazhuang, Hebei, P.R. China.'}, {'ForeName': 'Huiliang', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Haibo', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Yuyang', 'Initials': 'Y', 'LastName': 'Xiao', 'Affiliation': ''}, {'ForeName': 'Shiru', 'Initials': 'S', 'LastName': 'Bai', 'Affiliation': ''}, {'ForeName': 'Xinning', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Xiangming', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Tianlei', 'Initials': 'T', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Hongxiao', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Rongpin', 'Initials': 'R', 'LastName': 'Du', 'Affiliation': ''}]",Coronary artery disease,['10.1097/MCA.0000000000000853'] 3087,30299351,Successful Treatment of an Adolescent Male With Severe Refractory Evans Syndrome Using Bortezomib-based Therapy.,"Evans syndrome is defined by bilineal autoimmune cytopenia, typically coombs positive hemolytic anemia and thrombocytopenia. Corticosteroids are the mainstay of treatment, with rituximab and/or mycophenolate mofetil often used in steroid-refractory cases. However, no treatment methodology has ever evaluated by a randomized clinical trial. We present a 15-year-old boy with Evans syndrome and common variable immunodeficiency who experienced a severe, refractory flare 16 months postsplenectomy. After failing to respond to multiple other agents, he achieved a durable response to a bortezomib-based regimen. Bortezomib may be a reasonable second or third line option, especially before high-morbidity therapies such as splenectomy or stem cell transplantation.",2020,"Evans syndrome is defined by bilineal autoimmune cytopenia, typically coombs positive hemolytic anemia and thrombocytopenia.","['15-year-old boy with Evans syndrome and common variable immunodeficiency who experienced a severe, refractory flare 16 months postsplenectomy', 'Adolescent Male With Severe Refractory Evans Syndrome Using']","['Bortezomib', 'Corticosteroids', 'Bortezomib-based Therapy', 'rituximab and/or mycophenolate mofetil']",[],"[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0009447', 'cui_str': 'Common Variable Hypogammaglobulinemia'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0209368', 'cui_str': 'mycophenolate mofetil'}]",[],,0.0507357,"Evans syndrome is defined by bilineal autoimmune cytopenia, typically coombs positive hemolytic anemia and thrombocytopenia.","[{'ForeName': 'Tristan', 'Initials': 'T', 'LastName': 'Knight', 'Affiliation': ""Department of Pediatrics, Division of Pediatric Hematology and Oncology, Children's Hospital of Michigan.""}, {'ForeName': 'Yaddanapudi', 'Initials': 'Y', 'LastName': 'Ravindranath', 'Affiliation': ""Department of Pediatrics, Division of Pediatric Hematology and Oncology, Children's Hospital of Michigan.""}, {'ForeName': 'Michael U', 'Initials': 'MU', 'LastName': 'Callaghan', 'Affiliation': ""Department of Pediatrics, Division of Pediatric Hematology and Oncology, Children's Hospital of Michigan.""}]",Journal of pediatric hematology/oncology,['10.1097/MPH.0000000000001325'] 3088,32068423,A multimethod investigation of the impact of attentional control on a brief intervention for anxiety and depression.,"OBJECTIVE Anxiety sensitivity (AS; fear of anxiety) is a malleable risk factor for anxiety and depression. Brief computerized interventions, including elements of psychoeducation, interoceptive exposure, and cognitive bias modification (CBM) can reduce anxiety and depression through AS reductions. These interventions are not equally efficacious for all who receive them, suggesting the need to explore moderators. Attentional control (AC), the ability to regulate attentional processes by focusing and shifting attention as needed, has been linked to AS, anxiety, and depression suggesting that it may moderate treatment efficacy. The moderating effects of self-report and neurophysiological (i.e., theta/beta ratio, occipital alpha power) indices associated with AC processes on a brief AS-focused intervention were examined. METHOD Participants ( M age = 36.43, SD = 16.47; 57.5% female) were randomized to cognitive AS treatment ( n = 67) or a repeated contact control ( n = 60). RESULTS Occipital alpha power moderated the rate of change in AS across three weekly treatment sessions as well as the effects of the intervention on anxiety and depression symptoms at the 1-month follow-up. Lower alpha power was associated with a swifter reduction in AS symptoms and marginally lower levels of anxiety and depression at follow-up. AC indices were not correlated with each other. CONCLUSIONS These findings present a novel hypothesis that lower AC as indexed by occipital alpha power might increase treatment gains in the context of a brief transdiagnostic treatment for anxiety and depression. These findings also highlight the need for external validity studies of AC indices. (PsycINFO Database Record (c) 2020 APA, all rights reserved).",2020,Lower alpha power was associated with a swifter reduction in AS symptoms and marginally lower levels of anxiety and depression at follow-up.,"['Participants ( M age = 36.43, SD = 16.47; 57.5% female']","['cognitive AS treatment ( n = 67) or a repeated contact control', 'Attentional control (AC', 'Brief computerized interventions, including elements of psychoeducation, interoceptive exposure, and cognitive bias modification (CBM', 'attentional control']","['anxiety and depression symptoms', 'anxiety and depression', 'AC indices']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0013879', 'cui_str': 'Elements'}, {'cui': 'C0871175', 'cui_str': 'Psycho-education'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0005346', 'cui_str': 'Bias'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.0116405,Lower alpha power was associated with a swifter reduction in AS symptoms and marginally lower levels of anxiety and depression at follow-up.,"[{'ForeName': 'Nicholas P', 'Initials': 'NP', 'LastName': 'Allan', 'Affiliation': 'Department of Psychology, Ohio University.'}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Albanese', 'Affiliation': 'Department of Psychology, Florida State University.'}, {'ForeName': 'Matt R', 'Initials': 'MR', 'LastName': 'Judah', 'Affiliation': 'Department of Psychology, Old Dominion University.'}, {'ForeName': 'Caroline V', 'Initials': 'CV', 'LastName': 'Gooch', 'Affiliation': 'Department of Psychology, Ohio University.'}, {'ForeName': 'Norman B', 'Initials': 'NB', 'LastName': 'Schmidt', 'Affiliation': 'Department of Psychology, Florida State University.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000484'] 3089,32067836,Effect of blood pressure control on sudden death risk score in the SPRINT trial.,"BACKGROUND Recent data suggest that population screening for risk of sudden cardiac death (SCD) may be feasible with risk scores that can be implemented in the electronic health record. But, there are no established therapeutic strategies to target lowering risk for SCD in the general population. Our aim was to evaluate the effect of the Systolic Blood Pressure Intervention Trial (SPRINT) intensive blood pressure intervention on SCD risk and cardiovascular (CV) outcomes. METHODS We conducted a prospective cohort study within the SPRINT trial including all participants who had information required to calculate a SCD score. We classified SPRINT participants at baseline by randomized arm into high, intermediate and low SCD risk and followed them for a period of 12 months. We determined changes in SCD risk by comparing the baseline SCD risk score with the 12-month recalculated SCD risk score and determined the incidence of the primary SPRINT outcome and all-cause mortality. We used both linear regression and Cox proportional models to evaluate outcomes adjusted for CV risk, prevalent CV diseases, and randomization site. RESULTS We included 8052 SPRINT participants who met our inclusion criteria. The median baseline SCD score was 2.7% SCD per 10 years; 95% CI 1.6 to 4.7 for both randomized arms. At 12-month follow-up, the median SCD score for the intensive group was 5.5 (2.0-20) while the standard group was 6.8 (2.4-26) p<0.01. Over a follow-up period of 3.8 years, in the intensive arm, the HR for those who had a reduction in SCD risk score was 0.80; 95% CI 0.62-0.98 for the primary event while the HR for the standard arm was 1.01; 95% CI 0.81-1.26. The changes in SCD risk were mediated by decreases in blood pressure and an increase in diabetes incidence as well as age. CONCLUSIONS SCD risk changed in SPRINT because of intensive blood pressure control and those who changed their score had fewer cardiovascular events. Future studies should target comprehensive interventions targeting all modifiable risk factors.",2020,The median baseline SCD score was 2.7% SCD per 10 years; 95% CI 1.6 to 4.7 for both randomized arms.,"['participants who had information required to calculate a SCD score', '8052 SPRINT participants who met our inclusion criteria']","['blood pressure control', 'Systolic Blood Pressure Intervention Trial (SPRINT) intensive blood pressure intervention']","['SCD risk and cardiovascular (CV) outcomes', 'SCD risk', 'median baseline SCD score', 'blood pressure', 'sudden death risk score', 'SCD risk score', 'diabetes incidence', 'median SCD score', 'cardiovascular events']","[{'cui': 'C0444686', 'cui_str': 'Calculated (qualifier value)'}, {'cui': 'C0964695', 'cui_str': 's(7)(beta)CD'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}]","[{'cui': 'C0964695', 'cui_str': 's(7)(beta)CD'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0011071', 'cui_str': 'Sudden death (event)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",8052.0,0.162061,The median baseline SCD score was 2.7% SCD per 10 years; 95% CI 1.6 to 4.7 for both randomized arms.,"[{'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Tamariz', 'Affiliation': 'Department of Medicine Miller School of Medicine at the University of Miami, Miami, FL, United States of America; Department of Medicine Veterans Affairs Medical Center, Miami, FL, United States of America. Electronic address: ltamariz@med.miami.edu.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Palacio', 'Affiliation': 'Department of Medicine Miller School of Medicine at the University of Miami, Miami, FL, United States of America; Department of Medicine Veterans Affairs Medical Center, Miami, FL, United States of America.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Contreras', 'Affiliation': 'Department of Medicine Miller School of Medicine at the University of Miami, Miami, FL, United States of America.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Myerburg', 'Affiliation': 'Department of Medicine Miller School of Medicine at the University of Miami, Miami, FL, United States of America.'}, {'ForeName': 'Juhani', 'Initials': 'J', 'LastName': 'Junttila', 'Affiliation': 'Department of Medicine Oulu University Hospital and University of Oulu, Oulu, Finland.'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Olarte', 'Affiliation': 'Department of Medicine Miller School of Medicine at the University of Miami, Miami, FL, United States of America.'}, {'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'Goldberger', 'Affiliation': 'Department of Medicine Division of Cardiology, United States of America.'}]",International journal of cardiology,['10.1016/j.ijcard.2020.01.060'] 3090,32072340,Does the use of monopolar energy as the preferred mode of dissection effectively reduce seroma formation in laparoscopic total extra peritoneal hernioplasty? A prospective double-blinded randomized control trial.,"INTRODUCTION Seroma is a commonly encountered sequela after hernia repair. Tremendous effort has been spent to investigate the effective way to prevent this ""complication"" including the modification of surgical technique, use of per-peritoneal drainage, etc. There were debates about the use of monopolar diathermy versus blunt dissection in laparoscopic TEP in the prevention of seroma formation. This randomized study aims to compare the effects of using 2 techniques in laparoscopic TEP on pre-peritoneal drain output and seroma formation. METHOD From 1.9.2018 to 30.9.2019, all male and female patients presented with the first occurrence, unilateral inguinal hernia anticipated for laparoscopic TEP were enrolled into the study after informed consent. Patients were randomized into ""monopolar dissection preferred"" (MDP) group and ""blunt dissection-preferred"" (BDP) group just before commencing of operation after general anesthesia. Surgeons were instructed to use monopolar energy as main dissection method for the whole operation if possible (MDP), whereas blunt dissection is the preferred choice in BDP group, but the use of monopolar energy was allowed if needed. Total energy time was measured by a specially designed homemade device attaching to the monopolar pedals as accurate as to millisecond (ms). Pre-peritoneal drains were inserted for drainage and removed 23 h after operation. Drainage output, total operating time, energy time, clinical and ultrasonic seroma sizes at day 1, day 6, 1-month post operations, recurrence are compared between 2 groups. RESULTS A total of 103 patients where included. There was no significant difference in age, gender, co-morbidities, side of hernia, mean defect size, operating time, fixation adjuncts, or postoperative stay. The drain volume in BDP group is 71.13 ± 31.42 mL while it in MDP group is 56.36 ± 21.46 mL. The MDP group had significantly fewer drain output at 23 h post operation (p = 0.007) and lower seroma incidence on days 6 (p = 0.036). Overall incidence of seroma formation was 12% on postoperative day 1, 11% on postoperative day 7. No statistically differences in postoperative pain score or complications were observed at the first week, 1- and 3-months' post operation. There was no correlation with energy time to the drain output. No recurrence was found in subsequent follow-up. CONCLUSION Pre-peritoneal drainage is clinically safe in laparoscopic totally extra-peritoneal hernioplasty and can effectively reduce the size and incidence of seroma. The seroma formation can be further reduced by appropriate use of monopolar energy as preferred dissection approach in lap TEP. Due to limitation in measuring the actual energy time, the result should be further validated by randomized multi-centers trial on its potential benefit in hernia repair by a more accurate measuring device on energy used.",2020,"No statistically differences in postoperative pain score or complications were observed at the first week,","['all male and female patients presented with the first occurrence, unilateral inguinal hernia anticipated for laparoscopic TEP were enrolled into the study after informed consent', '103 patients where included']","['Pre-peritoneal drainage', 'monopolar dissection preferred"" (MDP) group and ""blunt dissection-preferred"" (BDP', 'laparoscopic TEP', 'monopolar diathermy versus blunt dissection in laparoscopic TEP']","['energy time to the drain output', 'seroma formation', 'drain volume', 'Overall incidence of seroma formation', 'postoperative pain score or complications', 'Drainage output, total operating time, energy time, clinical and ultrasonic seroma sizes', 'size and incidence of seroma', 'age, gender, co-morbidities, side of hernia, mean defect size, operating time, fixation adjuncts, or postoperative stay', 'drain output', 'Total energy time', 'seroma incidence']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0019294', 'cui_str': 'Hernia, Inguinal'}, {'cui': 'C0145334', 'cui_str': 'Pyrazine, tetraethyl-'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C4517526', 'cui_str': 'One hundred and three'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0442034', 'cui_str': 'Peritoneal (qualifier value)'}, {'cui': 'C0013103', 'cui_str': 'Drainage'}, {'cui': 'C0012737', 'cui_str': 'Dissection'}, {'cui': 'C3543840', 'cui_str': 'Preferred'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1997138', 'cui_str': 'Blunted'}, {'cui': 'C0145334', 'cui_str': 'Pyrazine, tetraethyl-'}, {'cui': 'C0012002', 'cui_str': 'Diathermy'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0180499', 'cui_str': 'Drain, device (physical object)'}, {'cui': 'C0262627', 'cui_str': 'Seroma'}, {'cui': 'C0439634', 'cui_str': 'Formations (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0013103', 'cui_str': 'Drainage'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1456803', 'cui_str': 'Ultrasonics'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}]",103.0,0.0614289,"No statistically differences in postoperative pain score or complications were observed at the first week,","[{'ForeName': 'J W', 'Initials': 'JW', 'LastName': 'Liu', 'Affiliation': 'Department of Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.'}, {'ForeName': 'K J', 'Initials': 'KJ', 'LastName': 'Chen', 'Affiliation': 'Department of Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.'}, {'ForeName': 'X H', 'Initials': 'XH', 'LastName': 'Xu', 'Affiliation': 'Department of Radiology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Deng', 'Affiliation': 'Department of Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.'}, {'ForeName': 'F S Y', 'Initials': 'FSY', 'LastName': 'Chan', 'Affiliation': 'Department of Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.'}, {'ForeName': 'H J', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': ""Department of Surgery, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.""}, {'ForeName': 'J K M', 'Initials': 'JKM', 'LastName': 'Fan', 'Affiliation': 'Department of Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China. drfanj@gmail.com.'}]",Hernia : the journal of hernias and abdominal wall surgery,['10.1007/s10029-020-02136-3'] 3091,32068531,Plaster cast versus functional bracing for Achilles tendon rupture: the UKSTAR RCT.,"BACKGROUND Achilles tendon rupture affects > 11,000 people each year in the UK, leading to prolonged periods away from work, sports and social activities. Traditionally, the ruptured tendon is held still in a plaster cast for ≥ 8 weeks. Functional bracing is an alternative treatment that allows patients to mobilise earlier, but there is little evidence about how bracing affects patients' recovery. OBJECTIVES To measure the Achilles Tendon Rupture Score, quality of life, complications and resource use of patients receiving non-operative treatment for an Achilles tendon rupture treated with plaster cast compared with those treated with functional bracing. DESIGN This was a multicentre, randomised, pragmatic, two-group superiority trial. SETTING The setting was 39 NHS hospitals. PARTICIPANTS A total of 540 adult patients treated non-operatively for Achilles tendon rupture were randomised from July 2016 to May 2018. Exclusion criteria included presenting after 14 days, having had previous rupture and being unable to complete questionnaires. INTERVENTIONS A total of 266 participants had a plaster cast applied, with their toes initially pointing to the floor. The cast was changed over 8 weeks to bring the foot into a walking position. A total of 274 patients had a functional brace that facilitated immediate weight-bearing. The foot position was adjusted within the brace over the same 8-week period. MAIN OUTCOME MEASURES Achilles Tendon Rupture Score is patient reported and assesses symptoms and physical activity related to the Achilles tendon (score 0-100, with 100 being the best possible outcome). The secondary outcomes were quality of life, complications and resource use at 8 weeks and at 3, 6 and 9 months. RESULTS Participants had a mean age of 48.7 years, were predominantly male (79%) and had ruptured their tendon during sports (70%). Over 93% of participants completed follow-up. There was no statistically significant difference in Achilles Tendon Rupture Score at 9 months post injury (-1.38, 95% confidence interval -4.9 to 2.1). There was a statistically significant difference in Achilles Tendon Rupture Score at 8 weeks post injury in favour of the functional brace group (5.53, 95% confidence interval 2.0 to 9.1), but not at 3 or 6 months post injury. Quality of life showed the same pattern, with a statistically significant difference at 8 weeks post injury but not at later time points. Complication profiles were similar in both groups. Re-rupture of the tendon occurred 17 times in the plaster cast group and 13 times in the functional brace group. There was no difference in resource use. CONCLUSIONS This trial provides strong evidence that early weight-bearing in a functional brace provides similar outcomes to traditional plaster casting and is safe for patients receiving non-operative treatment of Achilles tendon rupture. The probability that functional bracing is cost-effective exceeds 95% for the base-case imputed analysis, assuming a cost-effectiveness threshold of £20,000 per quality-adjusted life-year. On average, functional brace is associated with lower costs (-£103, 95% confidence interval -£290 to £84) and more quality-adjusted life-years (0.015, 95% confidence interval -0.0013 to 0.030) than plaster cast. LIMITATIONS Some patients declined to participate in the trial, but only a small proportion of these declined because they had a preference for one treatment or another. Overall, 58% of eligible patients agreed to participate, so the participants are broadly representative of the population under investigation. FUTURE WORK Although the UK Study of Tendo Achilles Rehabilitation provides guidance with regard to early management, rehabilitation following Achilles tendon rupture is prolonged and further research is required to define the optimal mode of rehabilitation after the initial cast/brace has been removed. TRIAL REGISTRATION Current Controlled Trials ISRCTN62639639. FUNDING This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 24, No. 8. See the NIHR Journals Library website for further project information.",2020,"There was a statistically significant difference in Achilles Tendon Rupture Score at 8 weeks post injury in favour of the functional brace group (5.53, 95% confidence interval 2.0 to 9.1), but not at 3 or 6 months post injury.","['274 patients had a functional brace that facilitated immediate weight-bearing', 'Exclusion criteria included presenting after 14 days, having had previous rupture and being unable to complete questionnaires', 'A total of 540 adult patients treated non-operatively for Achilles tendon rupture were randomised from July 2016 to May 2018', 'Achilles tendon rupture', '266 participants had a plaster cast applied, with their toes initially pointing to the floor', 'Participants had a mean age of 48.7 years, were predominantly male (79%) and had ruptured their tendon during sports (70', 'patients receiving non-operative treatment of Achilles tendon rupture']","['Plaster cast versus functional bracing', 'plaster cast']","['Achilles Tendon Rupture Score is patient reported and assesses symptoms and physical activity related to the Achilles tendon', 'Achilles Tendon Rupture Score, quality of life, complications and resource use of patients receiving non-operative treatment', 'Quality of life', 'Complication profiles', 'quality-adjusted life-years', 'Achilles Tendon Rupture Score', 'quality of life, complications and resource use']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0438847', 'cui_str': 'Functional brace (physical object)'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0085086', 'cui_str': 'Finding of weight-bearing'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0443294', 'cui_str': 'Ruptured (qualifier value)'}, {'cui': 'C1299582', 'cui_str': 'Unable'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0263970', 'cui_str': 'Rupture of Achilles tendon'}, {'cui': 'C0151937', 'cui_str': 'Traumatic rupture of tendon'}, {'cui': 'C0032159', 'cui_str': 'Plaster Casts'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0016249', 'cui_str': 'Floors'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0347984', 'cui_str': 'During (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0032159', 'cui_str': 'Plaster Casts'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}]","[{'cui': 'C0151937', 'cui_str': 'Traumatic rupture of tendon'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0001074', 'cui_str': 'Calcaneal Tendon'}, {'cui': 'C0034380'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0080071', 'cui_str': 'QALY'}, {'cui': 'C1947944', 'cui_str': 'Use'}]",540.0,0.194175,"There was a statistically significant difference in Achilles Tendon Rupture Score at 8 weeks post injury in favour of the functional brace group (5.53, 95% confidence interval 2.0 to 9.1), but not at 3 or 6 months post injury.","[{'ForeName': 'Matthew L', 'Initials': 'ML', 'LastName': 'Costa', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Juul', 'Initials': 'J', 'LastName': 'Achten', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Wagland', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Ioana R', 'Initials': 'IR', 'LastName': 'Marian', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Mandy', 'Initials': 'M', 'LastName': 'Maredza', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Michael Maia', 'Initials': 'MM', 'LastName': 'Schlüssel', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Anna S', 'Initials': 'AS', 'LastName': 'Liew', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Nick R', 'Initials': 'NR', 'LastName': 'Parsons', 'Affiliation': 'Statistics and Epidemiology Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Susan J', 'Initials': 'SJ', 'LastName': 'Dutton', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Rebecca S', 'Initials': 'RS', 'LastName': 'Kearney', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Lamb', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Ollivere', 'Affiliation': ""Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, Queen's Medical Centre Nottingham, University of Nottingham, Nottingham, UK.""}, {'ForeName': 'Stavros', 'Initials': 'S', 'LastName': 'Petrou', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}]","Health technology assessment (Winchester, England)",['10.3310/hta24080'] 3092,32012434,Brief O 2 uploading during continuous hypothermic machine perfusion is simple yet effective oxygenation method to improve initial kidney function in a porcine autotransplant model.,"With oxygenation proposed as a resuscitative measure during hypothermic models of preservation, the aim of this study was to evaluate the optimal start time of oxygenation during continuous hypothermic machine perfusion (HMP). In this porcine ischemia-reperfusion autotransplant model, the left kidney of a ±40 kg pig was exposed to 30 minutes of warm ischemia prior to 22 hours of HMP and autotransplantation. Kidneys were randomized to receive 2 hours of oxygenation during HMP either at the start (n = 6), or end of the perfusion (n = 5) and outcomes were compared to standard, nonoxygenated HMP (n = 6) and continuous oxygenated HMP (n = 8). The brief initial and continuous oxygenated HMP groups were associated with superior graft recovery compared to either standard, nonoxygenated HMP or kidneys oxygenated at the end of HMP. This correlated with significant metabolic differences in perfusate (eg, lactate, succinate, flavin mononucleotide) and tissues (eg, succinate, adenosine triphosphate, hypoxia-inducible factor-1α, nuclear factor erythroid 2-related factor 2) suggesting superior mitochondrial preservation with initial oxygenation. Brief initial O 2 uploading during HMP at procurement site might be an easy and effective preservation strategy to maintain aerobic metabolism, protect mitochondria, and achieve an improved early renal graft function compared with standard HMP or oxygen supply shortly at the end of HMP preservation.",2020,"The brief initial and continuous oxygenated HMP groups were associated with superior graft recovery compared to either standard, non-oxygenated HMP or kidneys oxygenated at the end of HMP.",[],"['standard, non-oxygenated HMP (n=6) and continuous oxygenated HMP']","['metabolic differences in perfusate (e.g. lactate, succinate, flavin mononucleotide) and tissues (e.g. succinate, ATP, HIF-1α, Nrf2', 'initial kidney function', 'superior graft recovery']",[],"[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}]","[{'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C0038617', 'cui_str': 'Succinates'}, {'cui': 'C0016388', 'cui_str': 'riboflavin mononucleotide'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0001480', 'cui_str': 'ATP'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C1527362', 'cui_str': 'grafts'}]",,0.0203622,"The brief initial and continuous oxygenated HMP groups were associated with superior graft recovery compared to either standard, non-oxygenated HMP or kidneys oxygenated at the end of HMP.","[{'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Darius', 'Affiliation': 'Surgery and Abdominal Transplant Unit, University Clinics Saint Luc, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Martial', 'Initials': 'M', 'LastName': 'Vergauwen', 'Affiliation': 'Pole de Chirurgie Expérimentale et Transplantation, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Smith', 'Affiliation': 'The Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Gerin', 'Affiliation': 'Walloon Excellence in Lifesciences and Biotechnology (WELBIO), Laboratory of Physiological Chemistry, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Virginie', 'Initials': 'V', 'LastName': 'Joris', 'Affiliation': 'Pole of Pharmacology and Therapeutics, Experimental and Clinical Research Institute, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Mueller', 'Affiliation': 'Department of Surgery and Transplantation, Swiss HPB Center, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Selda', 'Initials': 'S', 'LastName': 'Aydin', 'Affiliation': 'Department of Pathology, University Clinics Saint Luc, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Muller', 'Affiliation': 'Department of Surgery and Transplantation, Swiss HPB Center, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Schlegel', 'Affiliation': 'Liver Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham, Birmingham, UK.'}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Nath', 'Affiliation': 'Department of Renal Transplantation, Southmead Hospital Bristol, Bristol, UK.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Ludwig', 'Affiliation': 'The Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Chantal', 'Initials': 'C', 'LastName': 'Dessy', 'Affiliation': 'Pole of Pharmacology and Therapeutics, Experimental and Clinical Research Institute, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Marie-Christine', 'Initials': 'MC', 'LastName': 'Many', 'Affiliation': 'Department of Morphology, Experimental and Clinical Research Institute, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Guido', 'Initials': 'G', 'LastName': 'Bommer', 'Affiliation': 'Walloon Excellence in Lifesciences and Biotechnology (WELBIO), Laboratory of Physiological Chemistry, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Dutkowski', 'Affiliation': 'Department of Surgery and Transplantation, Swiss HPB Center, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Gianello', 'Affiliation': 'Pole de Chirurgie Expérimentale et Transplantation, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Mourad', 'Affiliation': 'Surgery and Abdominal Transplant Unit, University Clinics Saint Luc, Université Catholique de Louvain, Brussels, Belgium.'}]",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,['10.1111/ajt.15800'] 3093,32071367,Optimizing individual nutrition in preterm very low birth weight infants: double-blinded randomized controlled trial.,"OBJECTIVE In preterm neonates fed human milk, fortification may be adjusted by (1) optimization, based on growth rate and serum nutrient analyses, or (2) individualization, based on serial milk nutrient analyses. The primary aim was to determine whether individualized plus optimized nutrition (experimental) improves velocity of weight gain and linear growth from birth to endpoint (36 weeks postmenstrual age or discharge) when compared with optimized nutrition alone (controls). STUDY DESIGN Double-blinded parallel group randomized trial in 120 neonates <29 weeks gestational age (GA) or <35 weeks and small for GA (birth weight < 10th centile). RESULT Weight-gain velocity (13.1 ± 2.1, n = 57 controls, vs. 13.0 ± 2.6 g kg -1  day -1 , n = 59 experimental, P = 0.87), linear growth (0.9 ± 0.2, n = 55, vs. 0.9 ± 0.2 cm week -1 , n = 52, P = 0.90) and frequency of weight/length disproportion (2% vs. 2%, P = 0.98) were similar in both groups. CONCLUSIONS Individualized plus optimized nutrition does not improve weight gain, linear growth, or weight/length disproportion at endpoint versus optimized nutrition alone.",2020,"Individualized plus optimized nutrition does not improve weight gain, linear growth, or weight/length disproportion at endpoint versus optimized nutrition alone.","['preterm very low birth weight infants', '120 neonates <29 weeks gestational age (GA) or <35 weeks and small for GA (birth weight\u2009<\u200910th centile']","['optimized nutrition alone (controls', 'individualized plus optimized nutrition (experimental']","['weight gain, linear growth, or weight/length disproportion', 'velocity of weight gain and linear growth', 'frequency of weight/length disproportion', 'Weight-gain velocity']","[{'cui': 'C0282667', 'cui_str': 'Infant, Very Low Birth Weight'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}]","[{'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]",120.0,0.444572,"Individualized plus optimized nutrition does not improve weight gain, linear growth, or weight/length disproportion at endpoint versus optimized nutrition alone.","[{'ForeName': 'Luc P', 'Initials': 'LP', 'LastName': 'Brion', 'Affiliation': 'Division of Neonatal-Perinatal Medicine, Department of Pediatrics, University of Texas, Southwestern Medical Center, Dallas, TX, USA. luc.brion@utsouthwestern.edu.'}, {'ForeName': 'Charles R', 'Initials': 'CR', 'LastName': 'Rosenfeld', 'Affiliation': 'Division of Neonatal-Perinatal Medicine, Department of Pediatrics, University of Texas, Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Roy', 'Initials': 'R', 'LastName': 'Heyne', 'Affiliation': 'Division of Neonatal-Perinatal Medicine, Department of Pediatrics, University of Texas, Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'L Steven', 'Initials': 'LS', 'LastName': 'Brown', 'Affiliation': 'Parkland Health & Hospital System, Dallas, TX, USA.'}, {'ForeName': 'Cheryl S', 'Initials': 'CS', 'LastName': 'Lair', 'Affiliation': 'Parkland Health & Hospital System, Dallas, TX, USA.'}, {'ForeName': 'Elen', 'Initials': 'E', 'LastName': 'Petrosyan', 'Affiliation': 'Parkland Health & Hospital System, Dallas, TX, USA.'}, {'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Jacob', 'Affiliation': 'Parkland Health & Hospital System, Dallas, TX, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Caraig', 'Affiliation': 'Division of Neonatal-Perinatal Medicine, Department of Pediatrics, University of Texas, Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Patti J', 'Initials': 'PJ', 'LastName': 'Burchfield', 'Affiliation': 'Division of Neonatal-Perinatal Medicine, Department of Pediatrics, University of Texas, Southwestern Medical Center, Dallas, TX, USA.'}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/s41372-020-0609-1'] 3094,32068426,Effects of standard and modular psychotherapies in the treatment of youth with severe irritability.,"OBJECTIVE To examine the preliminary effectiveness of a modular, transdiagnostic, behavioral/cognitive-behavioral intervention (MATCH) compared with standard manualized treatments (SMT) and usual care (UC) for treating youth with severe irritability. METHOD We analyzed data from an effectiveness trial in which treatment-referred youths ( N = 174; M age = 10.6 years; 70% boys) were randomized to receive MATCH, SMT, or UC ( n s = 53-62). Masked assessments of irritability, diagnoses, impairment, and internalizing, externalizing, total, and top problems were collected from caregivers and youths at pre- and posttreatment, weekly during treatment, and quarterly through 2-year follow-up. Baseline measures of irritability and impairment were used to identify a subsample characterized by severe irritability and mood dysregulation (SIMD; n = 81; M age = 10.2 years; 69% boys; n s = 24-31 across conditions). Longitudinal multilevel models and ANOVAs were estimated to examine numerous clinical outcomes within and between conditions. RESULTS Among youth with SIMD, MATCH produced faster improvements than UC and SMT, with medium or large effect sizes in two thirds of all comparisons tested ( Mdn ES = 0.60). Although SIMD youths in all conditions showed reductions in DSM diagnoses, only MATCH predicted significantly fewer posttreatment diagnoses than UC (averaging 1.0 fewer; ES = 0.93). Finally, among the entire sample, MATCH and SMT equivalently outperformed UC in reducing irritability (ES = 0.49) and the effects of each treatment condition on other outcomes were not moderated by baseline irritability. CONCLUSIONS Extant behavioral/cognitive-behavioral psychotherapies-already well-established and widely used-may be helpful for treating youths with severe irritability. A transdiagnostic, modular format showed the most consistently favorable pattern of results across multiple outcomes, informants, and measurement schedules. (PsycINFO Database Record (c) 2020 APA, all rights reserved).",2020,"Among youth with SIMD, MATCH produced faster improvements than UC and SMT, with medium or large effect sizes in two thirds of all comparisons tested ( Mdn ES = 0.60).","['youths with severe irritability', 'treatment-referred youths ( N = 174; M age = 10.6 years; 70% boys', 'subsample characterized by severe irritability and mood dysregulation (SIMD; n = 81; M age = 10.2 years; 69% boys; n s = 24-31 across conditions', 'youth with severe irritability']","['modular, transdiagnostic, behavioral/cognitive-behavioral intervention (MATCH', 'standard and modular psychotherapies', 'MATCH, SMT, or UC', 'standard manualized treatments (SMT) and usual care (UC']","['DSM diagnoses', 'irritability, diagnoses, impairment, and internalizing, externalizing, total, and top problems']","[{'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0022107', 'cui_str': 'Irritable Mood'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4517604', 'cui_str': 'One hundred and seventy-four'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1273567', 'cui_str': 'Psychotherapy (specialty)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0022107', 'cui_str': 'Irritable Mood'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}]",,0.064264,"Among youth with SIMD, MATCH produced faster improvements than UC and SMT, with medium or large effect sizes in two thirds of all comparisons tested ( Mdn ES = 0.60).","[{'ForeName': 'Spencer C', 'Initials': 'SC', 'LastName': 'Evans', 'Affiliation': 'Department of Psychology, Harvard University.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Weisz', 'Affiliation': 'Department of Psychology, Harvard University.'}, {'ForeName': 'Ana C', 'Initials': 'AC', 'LastName': 'Carvalho', 'Affiliation': 'Department of Psychology, Harvard University.'}, {'ForeName': 'Patricia M', 'Initials': 'PM', 'LastName': 'Garibaldi', 'Affiliation': 'Department of Psychology, Harvard University.'}, {'ForeName': 'Sarah Kate', 'Initials': 'SK', 'LastName': 'Bearman', 'Affiliation': 'Department of Educational Psychology, University of Texas at Austin.'}, {'ForeName': 'Bruce F', 'Initials': 'BF', 'LastName': 'Chorpita', 'Affiliation': 'Department of Psychology, University of California, Los Angeles.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of consulting and clinical psychology,['10.1037/ccp0000456'] 3095,32061533,"Effect of an education program, risk assessment checklist and prevention protocol on violence against emergency department nurses: A single center before and after study.","AIM The purpose of this study was to evaluate the effects of an education program, risk assessment checklist and preventive protocol on violence against emergency department nurses. METHODS The design was a quasi-experimental before and after study of a group. A hospital emergency department's nurses participated in a workshop in which they were taught a method of using a risk assessment checklist and preventive protocol. The intervention lasted six weeks. The mean score and type of violence was measured before and after the intervention. The data were analyzed by SPSS. RESULTS The mean score of violence before the intervention was 8.4 and after the intervention it was 2.7, which was statistically a significant difference (p < 0.0001). In addition, there were significant differences in the mean frequency of verbal abuse (p < 0.0001), assessment of workplace security (p = 0.006), fear of injury (p < 0.02) and type of reaction to violence (p < 0.01) before and after the intervention among the nurses. CONCLUSIONS Using the BVC risk assessment checklist and preventive protocol can reduce the experience of violence and verbal abuse, which is the most common form of violence for emergency department nurses. Using this checklist and preventive protocol when patients arrive in emergency departments is recommended.",2020,"In addition, there were significant differences in the mean frequency of verbal abuse (p < 0.0001), assessment of workplace security (p = 0.006), fear of injury (p < 0.02) and type of reaction to violence (p < 0.01) before and after the intervention among the nurses. ",['violence against emergency department nurses'],"['education program, risk assessment checklist and prevention protocol', 'education program, risk assessment checklist and preventive protocol']","['mean frequency of verbal abuse', 'fear of injury', 'workplace security', 'type of reaction to violence', 'mean score and type of violence', 'mean score of violence']","[{'cui': 'C0042693', 'cui_str': 'Violence'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}]","[{'cui': 'C0729314', 'cui_str': 'Education provision (procedure)'}, {'cui': 'C0086930', 'cui_str': 'Risk assessment (procedure)'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C1456501', 'cui_str': 'Preventive'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0558089', 'cui_str': 'Verbally abusive behavior (finding)'}, {'cui': 'C2874943', 'cui_str': 'Fear of injury'}, {'cui': 'C0162579', 'cui_str': 'Job Site'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}, {'cui': 'C0042693', 'cui_str': 'Violence'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0167301,"In addition, there were significant differences in the mean frequency of verbal abuse (p < 0.0001), assessment of workplace security (p = 0.006), fear of injury (p < 0.02) and type of reaction to violence (p < 0.01) before and after the intervention among the nurses. ","[{'ForeName': 'Salar', 'Initials': 'S', 'LastName': 'Sharifi', 'Affiliation': 'Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran.'}, {'ForeName': 'Roonak', 'Initials': 'R', 'LastName': 'Shahoei', 'Affiliation': 'Clinical Care Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.'}, {'ForeName': 'Bijan', 'Initials': 'B', 'LastName': 'Nouri', 'Affiliation': 'Social Determinants of Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Almvik', 'Affiliation': 'Centre for Research & Education in Forensic Psychiatry, Forensic Department Bröset, St. Olavs University Hospital, Trondheim, Norway.'}, {'ForeName': 'Sina', 'Initials': 'S', 'LastName': 'Valiee', 'Affiliation': 'Clinical Care Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran. Electronic address: valiee@muk.ac.ir.'}]",International emergency nursing,['10.1016/j.ienj.2019.100813'] 3096,31361019,"Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS).","OBJECTIVE To evaluate the long-term safety of NKTR-181, a novel mu-opioid receptor agonist that may have reduced human abuse potential, in patients with moderate to severe chronic low back pain (CLBP) or other chronic noncancer pain (CNP). DESIGN Uncontrolled, multicenter, open-label, long-term study of NKTR-181 comprised of three periods: screening (≤21 days), treatment (52 weeks), and safety follow-up (∼14 days after the last dose of NKTR-181). SETTING Multicenter, long-term clinical research study. METHODS NKTR-181 administered at doses of 100-600 mg twice daily (BID) was evaluated in opioid-naïve and opioid-experienced patients. Patients were enrolled de novo or following completion of the randomized, placebo-controlled phase 3 efficacy study (SUMMIT-07). Safety assessments included adverse event documentation, measurements of opioid withdrawal, and clinical laboratory tests. Effectiveness was assessed using the modified Brief Pain Inventory Short Form (mBPI-SF). RESULTS The study enrolled 638 patients. The most frequently reported treatment-emergent adverse events (TEAEs) were constipation (26%) and nausea (12%). Serious TEAEs, reported in 5% of patients, were deemed by investigators to be unrelated to NKTR-181. There were no deaths or reported cases of respiratory depression. A sustained reduction in mBPI-SF pain intensity and pain interference from baseline to study termination was observed throughout treatment. Only 2% of patients discontinued NKTR-181 due to lack of efficacy, and 11% discontinued due to treatment-related AEs. NKTR-181 doses of up to 600 mg BID were generally well tolerated, and patients experienced low rates of opioid-related adverse events. CONCLUSIONS The study results support the premise that NKTR-181 is a safe and effective option for patients with moderate to severe CLBP or CNP.",2020,"Serious TEAEs, reported in 5% of patients, were deemed by investigators to be unrelated to NKTR-181.","['patients with moderate to severe chronic low back pain (CLBP) or other chronic noncancer pain (CNP', 'Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain', 'patients with moderate to severe CLBP or CNP', '638 patients']","['placebo', 'NKTR-181']","['mBPI-SF pain intensity and pain interference', 'adverse event documentation, measurements of opioid withdrawal, and clinical laboratory tests', 'modified Brief Pain Inventory Short Form (mBPI-SF', 'respiratory depression', 'nausea']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain (finding)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4547855', 'cui_str': 'NKTR-181'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0920316', 'cui_str': 'Documentation'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0029104', 'cui_str': 'Opioid withdrawal (disorder)'}, {'cui': 'C4505474', 'cui_str': 'Clinical Laboratory Tests'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0235063', 'cui_str': 'Respiratory Depression'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",638.0,0.0753513,"Serious TEAEs, reported in 5% of patients, were deemed by investigators to be unrelated to NKTR-181.","[{'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Gudin', 'Affiliation': '*Department of Anesthesiology, Rutgers New Jersey Medical School, Newark, New Jersey.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Rauck', 'Affiliation': 'Carolinas Pain Institute and The Center for Clinical Research, Winston-Salem, North Carolina.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Argoff', 'Affiliation': 'Department of Neurology, Albany Medical Center, Albany, New York.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Agaiby', 'Affiliation': 'Clinical Investigation Specialists Inc, Kenosha, Wisconsin.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Gimbel', 'Affiliation': 'Arizona Research Center, Phoenix, Arizona.'}, {'ForeName': 'Nathaniel', 'Initials': 'N', 'LastName': 'Katz', 'Affiliation': 'Tufts University School of Medicine, Boston, Massachusetts.'}, {'ForeName': 'Stephen K', 'Initials': 'SK', 'LastName': 'Doberstein', 'Affiliation': 'Nektar Therapeutics, San Francisco, California.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Tagliaferri', 'Affiliation': 'Nektar Therapeutics, San Francisco, California.'}, {'ForeName': 'Margit', 'Initials': 'M', 'LastName': 'Tagliaferri', 'Affiliation': 'Nektar Therapeutics, San Francisco, California.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Potts', 'Affiliation': 'Great Lakes Research Group, Inc, Bay City, Michigan.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Wild', 'Affiliation': 'Upstate Clinical Research Associates, Williamsville, New York.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Lu', 'Affiliation': 'Nektar Therapeutics, San Francisco, California.'}, {'ForeName': 'Suresh', 'Initials': 'S', 'LastName': 'Siddhanti', 'Affiliation': 'Nektar Therapeutics, San Francisco, California.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Hale', 'Affiliation': 'Gold Coast Research, LLC, Plantation, Florida.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Markman', 'Affiliation': 'Department of Neurosurgery, Translational Pain Research Program, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.'}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pnz169'] 3097,31955002,Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.,"OBJECTIVES SPECTRA is a multicenter, randomized phase II study of chemotherapy with cisplatin (CDDP) plus S-1 versus CDDP plus pemetrexed (PEM) in combination with thoracic radiotherapy (TRT) for locally advanced non-squamous non-small cell lung cancer, in order to determine which of these two regimens might be preferable for comparison with standard therapies in a future phase III study. MATERIALS AND METHODS Patients were randomly assigned to receive CDDP + S-1 (CDDP 60 mg/m 2 on day 1 and S-1 80 mg/m2 on days 1-14, every 4 weeks, up to 4 cycles) or CDDP + PEM (CDDP 75 mg/m 2 + PEM 500 mg/m 2 on day 1, every 3 weeks, up to 4 cycles) combined with TRT (60 Gy in 30 fractions). The primary endpoint was the 2-year progression-free survival (PFS) rate. The sample size had been set at 100 patients. RESULTS A total of 102 patients were randomized to receive CDDP + S-1 or CDDP + PEM (CDDP + S-1, n = 52; CDDP + PEM, n = 50) between January 2013 and October 2016. The results in the CDDP + S1 group and CDDP + PEM group were as follows: completion rates of TRT (60 Gy)/chemotherapy (4 cycles) was 92 %/73 % and 98 %/86 %, respectively; the response rates were 60 % and 64 %, respectively; median PFS after a median follow-up of 32.1 months, 12.7/13.8 months (hazard ratio [HR] = 1.16; 95 % confidence interval [CI], 0.73-1.84); 2-year PFS rate, 36.5 % (95 % CI, 23.5-49.6)/32.1 % (95 %CI, 18.9-45.4); median OS, 48.3/59.1 months (HR = 1.05; 95 %CI, 0.58-1.90); 2-year OS rate, 69.2 % (95 %CI, 56.7-81.8)/66.4 % (95 %CI, 53.0-79.9); Grade 3 toxicities: febrile neutropenia (12 %/2 %), anorexia (8 %/16 %), diarrhea (8 %/0 %), esophagitis (6 %/8 %), and neutropenia (35 %/50 %); Grade 2 or worse radiation pneumonitis, 15 % (8 patients)/4 % (2 patients). CONCLUSION The 2-year PFS rate in the CDDP + S-1 arm was higher than that in the CDDP + PEM arm. Both treatments were safe, with manageable toxicities.",2020,The 2-year PFS rate in the CDDP + S-1 arm was higher than that in the CDDP + PEM arm.,"['Patients', 'A total of 102 patients', 'locally advanced non-squamous non-small cell lung cancer']","['chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed', 'TRT', 'CDDP\u2009+\u2009PEM (CDDP 75\u2009mg/m 2 + PEM', 'chemotherapy with cisplatin (CDDP) plus S-1 versus CDDP plus pemetrexed (PEM', 'thoracic radiotherapy (TRT', 'CDDP\u2009+\u2009S-1 (CDDP 60\u2009mg/m 2 on day 1 and S-1 80\u2009mg/m2', 'CDDP\u2009+\u2009S-1 or CDDP\u2009+\u2009PEM (CDDP\u2009+\u2009S-1, n\u2009=\u200952; CDDP\u2009+\u2009PEM']","['neutropenia', 'esophagitis', 'manageable toxicities', 'median PFS', 'diarrhea', '2-year OS rate', 'response rates', 'completion rates of TRT', '2-year PFS rate', '2-year progression-free survival (PFS) rate', 'Grade 2 or worse radiation pneumonitis', 'Grade 3 toxicities: febrile neutropenia', 'anorexia']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C4324656', 'cui_str': 'Non-squamous non-small cell lung cancer'}]","[{'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0879262', 'cui_str': 'TS-1 cpd'}, {'cui': 'C0210657', 'cui_str': 'pemetrexed'}, {'cui': 'C0047130', 'cui_str': 'PEMS'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1319266', 'cui_str': 'mg/sq.m'}]","[{'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0014868', 'cui_str': 'Esophagitis'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0206063', 'cui_str': 'Pneumonia, Radiation'}, {'cui': 'C0746883', 'cui_str': 'Febrile Neutropenia'}, {'cui': 'C1971624', 'cui_str': 'Loss of appetite (finding)'}]",102.0,0.169907,The 2-year PFS rate in the CDDP + S-1 arm was higher than that in the CDDP + PEM arm.,"[{'ForeName': 'Seiji', 'Initials': 'S', 'LastName': 'Niho', 'Affiliation': 'Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan. Electronic address: siniho@east.ncc.go.jp.'}, {'ForeName': 'Tatsuya', 'Initials': 'T', 'LastName': 'Yoshida', 'Affiliation': 'Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Tetsuo', 'Initials': 'T', 'LastName': 'Akimoto', 'Affiliation': 'Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Sakamaki', 'Affiliation': 'Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Ono', 'Affiliation': 'Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Seto', 'Affiliation': 'Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.'}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Nishio', 'Affiliation': 'Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.'}, {'ForeName': 'Noboru', 'Initials': 'N', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Toyoaki', 'Initials': 'T', 'LastName': 'Hida', 'Affiliation': 'Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Okamoto', 'Affiliation': ""Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.""}, {'ForeName': 'Takayasu', 'Initials': 'T', 'LastName': 'Kurata', 'Affiliation': 'Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan.'}, {'ForeName': 'Miyako', 'Initials': 'M', 'LastName': 'Satouchi', 'Affiliation': 'Department of Thoracic Oncology, Hyogo Cancer Center, Japan.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Goto', 'Affiliation': 'Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.'}, {'ForeName': 'Takeharu', 'Initials': 'T', 'LastName': 'Yamanaka', 'Affiliation': 'Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.'}, {'ForeName': 'Yuichiro', 'Initials': 'Y', 'LastName': 'Ohe', 'Affiliation': 'Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.'}]","Lung cancer (Amsterdam, Netherlands)",['10.1016/j.lungcan.2020.01.008'] 3098,32065868,"Mirabegron improves sleep measures, nocturia, and lower urinary tract symptoms in those with urinary symptoms associated with disordered sleep.","INTRODUCTION The role of organized sleep in overall health and quality-of-life (QoL) is critical. Nocturia necessarily disrupts the normal sleep cycle and negatively impacts one's health, work productivity, and QoL. We investigated, for the first time in an exploratory pilot, the effectiveness of mirabegron for improving sleep disturbance and nocturia. MATERIALS AND METHODS This was a prospective, open-label 12-week trial evaluating the efficacy of mirabegron in 34 men and women with disordered sleep and lower urinary tract symptoms (LUTS). Subjects received mirabegron 25 mg daily for 4 weeks, then increased to 50 mg. Subjects completed the Patient-Reported Outcome Measurement Information System Sleep Disturbance Short Form (PROMIS-SDSF), Jenkins Sleep Scale (JSS), International Prostate Symptom Score (IPSS), voiding diaries, and QoL questionnaires. RESULTS PROMIS-SDSF scores decreased from 26.5 points to 19.3, representing a categorical improvement from clinically 'mild' to 'none to slight' sleep disturbance (p < 0.001). JSS scores also decreased from 14.1 to 8.3 (p < 0.001). IPSS decreased from 21.0 to 12.4, denoting a categorical improvement from 'severe' to 'moderate' LUTS (p < 0.001). Voiding diaries revealed 1.9 fewer voids per day (p < 0.01) and 0.8 fewer nighttime voids (p < 0.05). QoL improved from 0% in subjects who selected 'mostly satisfied,' 'pleased,' or 'delighted' to 29.6% at follow up. CONCLUSIONS Mirabegron use improves nocturia and produces rapid, durable, and clinically significant improvement in sleep disturbance and LUTS in males and females with urinary symptoms associated with disordered sleep.",2020,Voiding diaries revealed 1.9 fewer voids per day (p < 0.01) and 0.8 fewer nighttime voids (p < 0.05).,"['34 men and women with disordered sleep and lower urinary tract symptoms (LUTS', 'males and females with urinary symptoms associated with disordered sleep']",[],"['QoL', 'JSS scores', 'nighttime voids', 'sleep disturbance and LUTS', 'PROMIS-SDSF scores', 'sleep measures, nocturia, and lower urinary tract symptoms', 'overall health and quality-of-life (QoL', 'IPSS', 'Outcome Measurement Information System Sleep Disturbance Short Form (PROMIS-SDSF), Jenkins Sleep Scale (JSS), International Prostate Symptom Score (IPSS), voiding diaries, and QoL questionnaires', 'nocturia', ""slight' sleep disturbance"", 'sleep disturbance and nocturia', 'Voiding diaries']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0851578', 'cui_str': 'Sleep Disorders'}, {'cui': 'C0574785', 'cui_str': 'Lower Urinary Tract Symptoms'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0426359', 'cui_str': 'Urinary symptoms (finding)'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}]",[],"[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnias'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0028734', 'cui_str': 'Nycturia'}, {'cui': 'C0574785', 'cui_str': 'Lower Urinary Tract Symptoms'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0034380'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0021428', 'cui_str': 'Information Systems'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0222045'}, {'cui': 'C1998280', 'cui_str': 'International prostate symptom score (assessment scale)'}, {'cui': 'C0376660', 'cui_str': 'Diary'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C2937276', 'cui_str': 'Slight (qualifier value)'}]",,0.0259016,Voiding diaries revealed 1.9 fewer voids per day (p < 0.01) and 0.8 fewer nighttime voids (p < 0.05).,"[{'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Petrossian', 'Affiliation': 'Division of Urology, Southern Illinois University School of Medicine, Springfield, Illinois, USA.'}, {'ForeName': 'Danuta', 'Initials': 'D', 'LastName': 'Dynda', 'Affiliation': ''}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Delfino', 'Affiliation': ''}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'El-Zawahry', 'Affiliation': ''}, {'ForeName': 'Kevin T', 'Initials': 'KT', 'LastName': 'McVary', 'Affiliation': ''}]",The Canadian journal of urology,[] 3099,32064725,A randomized clinical trial on the acute therapeutic effect of TRPA1 and TRPM8 agonists in patients with oropharyngeal dysphagia.,"BACKGROUND Oropharyngeal dysphagia (OD) treatment is moving away from compensatory strategies toward active treatments that improve swallowing function. The aim of this study was to assess the acute therapeutic effect of TRPA1/M8 agonists in improving swallowing function in OD patients. METHODS Fifty-eight patients with OD caused by aging, stroke, or neurodegenerative disease were included in a three-arm, quadruple-blind, randomized clinical trial (NCT02193438). Swallowing safety and efficacy and the kinematics of the swallow response were assessed by videofluoroscopy (VFS) during the swallow of 182 ± 2 mPa·s viscosity (nectar) boluses of a xanthan gum thickener supplemented with (a) 756.6 μmol/L cinnamaldehyde and 70 μmol/L zinc (CIN-Zn) (TRPA1 agonists), (b) 1.6 mmol/L citral (CIT) (TRPA1 agonist), or (c) 1.6 mmol/L citral and 1.3 mmol/L isopulegol (CIT-ISO) (TRPA1 and TRPM8 agonists). The effects on pharyngeal event-related potentials (ERP) were assessed by electroencephalography. KEY RESULTS TRPA1 stimulation with either CIN-Zn or CIT reduced time to laryngeal vestibule closure (CIN-Zn P = .002, CIT P = .023) and upper esophageal sphincter opening (CIN-Zn P = .007, CIT P = .035). In addition, CIN-Zn reduced the penetration-aspiration scale score (P = .009), increased the prevalence of safe swallows (P = .041), and reduced the latency of the P2 peak of the ERP. CIT-ISO had no positive effect on biomechanics or neurophysiology. No significant adverse events were observed. CONCLUSIONS AND INFERENCES TRPA1 stimulation with CIN-Zn or CIT improves the swallow response which, in the case of CIN-Zn, is associated with a significant improvement in cortical activation and safety of swallow. These results provide the basis for the development of new active treatments for OD using TRPA1 agonists.",2020,"In addition, CIN-Zn reduced the penetration-aspiration scale score (P = .009), increased the prevalence of safe swallows (P = .041), and reduced the latency of the P2 peak of the ERP.","['Fifty-eight patients with OD caused by aging, stroke, or neurodegenerative disease', 'patients with oropharyngeal dysphagia', 'OD patients']","['CIN-Zn or CIT', 'videofluoroscopy (VFS) during the swallow of 182\xa0±\xa02\xa0mPa·s viscosity (nectar) boluses of a xanthan gum thickener supplemented with (a) 756.6\xa0μmol/L cinnamaldehyde and 70\xa0μmol/L zinc (CIN-Zn) (TRPA1 agonists', 'TRPA1/M8 agonists', 'TRPA1 and TRPM8 agonists']","['cortical activation and safety of swallow', 'swallow response', 'latency of the P2 peak of the ERP', 'time to laryngeal vestibule closure', 'penetration-aspiration scale score', 'adverse events', 'swallowing function', 'upper esophageal sphincter opening', 'pharyngeal event-related potentials (ERP', 'Swallowing safety and efficacy and the kinematics of the swallow response', 'prevalence of safe swallows']","[{'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0524851', 'cui_str': 'Degenerative Neurologic Disorders'}, {'cui': 'C0267071', 'cui_str': 'Oropharyngeal Dysphagia'}]","[{'cui': 'C0607063', 'cui_str': 'serum P-component'}, {'cui': 'C0326374', 'cui_str': 'Swallows'}, {'cui': 'C4301986', 'cui_str': 'Viscosity (property) (qualifier value)'}, {'cui': 'C0078596', 'cui_str': 'xanthan gum'}, {'cui': 'C0055754', 'cui_str': 'cinnamaldehyde'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0243192', 'cui_str': 'agonists'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0326374', 'cui_str': 'Swallows'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0337380', 'cui_str': 'Endoscopic retrograde pancreatography (procedure)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0225564', 'cui_str': 'Structure of vestibule of larynx'}, {'cui': 'C0185003', 'cui_str': 'Reparative closure (procedure)'}, {'cui': 'C0349707', 'cui_str': 'Aspiration - action (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C1451819', 'cui_str': 'Upper Esophageal Sphincter'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0282171', 'cui_str': 'Potentials, Event-Related'}, {'cui': 'C0600169', 'cui_str': 'Kinematics'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}]",58.0,0.0548621,"In addition, CIN-Zn reduced the penetration-aspiration scale score (P = .009), increased the prevalence of safe swallows (P = .041), and reduced the latency of the P2 peak of the ERP.","[{'ForeName': 'Noemí', 'Initials': 'N', 'LastName': 'Tomsen', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Barcelona, Spain.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Alvarez-Berdugo', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Barcelona, Spain.'}, {'ForeName': 'Laia', 'Initials': 'L', 'LastName': 'Rofes', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Barcelona, Spain.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Ortega', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Barcelona, Spain.'}, {'ForeName': 'Viridiana', 'Initials': 'V', 'LastName': 'Arreola', 'Affiliation': 'Gastrointestinal Motility Laboratory, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Spain.'}, {'ForeName': 'Weslania', 'Initials': 'W', 'LastName': 'Nascimento', 'Affiliation': 'Gastrointestinal Motility Laboratory, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Spain.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Martin', 'Affiliation': 'Gastrointestinal Motility Laboratory, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Spain.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Cabib', 'Affiliation': 'Gastrointestinal Motility Laboratory, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Spain.'}, {'ForeName': 'Mireia', 'Initials': 'M', 'LastName': 'Bolivar-Prados', 'Affiliation': 'Gastrointestinal Motility Laboratory, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Spain.'}, {'ForeName': 'Lluís', 'Initials': 'L', 'LastName': 'Mundet', 'Affiliation': 'Gastrointestinal Motility Laboratory, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Spain.'}, {'ForeName': 'Coline', 'Initials': 'C', 'LastName': 'Legrand', 'Affiliation': 'Nestlé Research, Lausanne, Switzerland.'}, {'ForeName': 'Pere', 'Initials': 'P', 'LastName': 'Clavé', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Barcelona, Spain.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Michlig', 'Affiliation': 'Nestlé Research, Lausanne, Switzerland.'}]",Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,['10.1111/nmo.13821'] 3100,32065870,Injection location does not impact botulinum toxin A efficacy in interstitial cystitis/bladder pain syndrome patients.,"INTRODUCTION Botulinum toxin A (BTX-A) is currently used as a fourth-line therapeutic option for interstitial cystitis/bladder pain syndrome (IC/BPS) management. The purpose of this study was to determine if BTX-A injection can mitigate pain and if injection location (i.e. trigone-including versus trigone-sparing injection template) impacts treatment efficacy and/or treatment complications profile. MATERIALS AND METHODS Female IC/BPS patients refractory to conservative management strategies were prospectively enrolled and asked to complete a baseline history and physical exam, post-void residual (PVR) urine volume determination, O'Leary Sant (OLS) questionnaire, and Pelvic Pain and Urgency/Frequency Symptom Scale (PUF) questionnaire. Participants were randomly assigned to one of two treatment groups and received either: 1) a trigone-including BTX-A injection template or 2) a trigone-sparing injection template. Following therapy, patients were examined in clinic at 30 and 90 day post-treatment with symptom re-assessment via repeat questionnaires and for evidence of post-procedural complications. RESULTS Compared to baseline, patients in both treatment groups experienced significant improvement in OLS and PUF scores at both 30 and 90 days post-treatment with BTX-A, regardless of which injection template was used (p < 0.05). Complications resulting from BTX-A were minimal (most commonly urinary tract infection (UTI) and urinary retention) and not significantly different between the treatment groups (p > 0.05). No distant spread of BTX-A was observed in any patient in either treatment group. CONCLUSIONS BTX-A treatment using either a trigone-sparing or trigone-including injection template resulted in significant, but not location-dependent, improvement in IC/BPS symptom scores at 30 and 90 day points post-procedure with no significant difference in post-treatment complication profiles.",2020,"Compared to baseline, patients in both treatment groups experienced significant improvement in OLS and PUF scores at both 30 and 90 days post-treatment with BTX-A, regardless of which injection template was used (p < 0.05).","['Female IC/BPS patients refractory to conservative management strategies', 'interstitial cystitis/bladder pain syndrome patients']","['Botulinum toxin A (BTX-A', 'botulinum toxin', 'trigone-including BTX-A injection template or 2) a trigone-sparing injection template', 'BTX']","['OLS and PUF scores', ""baseline history and physical exam, post-void residual (PVR) urine volume determination, O'Leary Sant (OLS) questionnaire, and Pelvic Pain and Urgency/Frequency Symptom Scale (PUF) questionnaire"", 'IC/BPS symptom scores', 'urinary tract infection (UTI) and urinary retention']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0459914', 'cui_str': 'Conservative Management'}, {'cui': 'C0600040', 'cui_str': 'Chronic interstitial cystitis (disorder)'}, {'cui': 'C3160917', 'cui_str': 'Bladder pain syndrome'}]","[{'cui': 'C0006055', 'cui_str': 'Botulin'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C4317132', 'cui_str': 'Template'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0429774', 'cui_str': 'Residual urine volume (observable entity)'}, {'cui': 'C1148554', 'cui_str': 'determination'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0030794', 'cui_str': 'Pelvic Pain'}, {'cui': 'C0439609', 'cui_str': 'Urgency (qualifier value)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0222045'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}, {'cui': 'C0080274', 'cui_str': 'Urinary Retention'}]",,0.0350984,"Compared to baseline, patients in both treatment groups experienced significant improvement in OLS and PUF scores at both 30 and 90 days post-treatment with BTX-A, regardless of which injection template was used (p < 0.05).","[{'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Evans', 'Affiliation': 'Department of Urology/Female Pelvic Health, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Tyler', 'Initials': 'T', 'LastName': 'Overholt', 'Affiliation': ''}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Colaco', 'Affiliation': ''}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Walker', 'Affiliation': ''}]",The Canadian journal of urology,[] 3101,30664550,Telehealth Therapy Effects of Nurses and Mental Health Professionals From 2 Randomized Controlled Trials for Chronic Back Pain.,"OBJECTIVE To compare the efficacy of mental health professional versus primary care nurse-delivered telehealth cognitive-behavioral therapy (CBT) and supportive care (SC) treatments for chronic low back pain, using data from 2 separate randomized controlled trials. Both trials were completed in the same hospital and used the same study design, research team, and outcome measures. MATERIALS AND METHODS Participants from Study 1 (Mental Health Professional Study) (N=66; 2007 to 2011) and Study 2 (Nursing Study) (N=61; 2012 to 2016) were patients with chronic low back pain (≥4/10 intensity) randomized to either an 8-week CBT or an SC telehealth condition matched for contact frequency, format, and time. Participants completed validated measures of improvement in back pain disability (Roland Morris Disability Questionnaire [RMDQ]), pain intensity (Numeric Rating Scale [NRS]), depressive symptoms (Beck Depression Inventory 2 [BDI-2]), pain catastrophizing (Pain Catastrophizing Scale [PCS]), and overall improvement (Global Clinical Impressions [GCI]). RESULTS Intent-to-treat analyses at posttreatment showed that scores on the RMDQ (Cohen d=0.33 to 0.55), NRS (d=0.45 to 0.90), PCS (d=0.21 to 0.41), and GCI (18.5% to 39.1%) improved significantly in both studies and in both treatments from pretreatment to posttreatment. Changes in BDI scores were inconsistent (d=-0.06 to 0.51). The analyses revealed no significant differences in treatment efficacy between the trained nurse versus the mental health professionals on the RMDQ, NRS, PCS, or GCI measures (P>0.20). DISCUSSION Results from these clinical trials suggest that the benefits of home-based, telehealth-delivered CBT and SC treatments for chronic back pain were comparable when delivered by a primary care nurse or mental health professional.",2019,"The analyses revealed no significant differences in treatment efficacy between the trained nurse versus the mental health professionals on the RMDQ, NRS, PCS, or GCI measures (P>0.20). ","['2007 to 2011) and Study 2 (Nursing Study) (N=61; 2012 to 2016) were patients with chronic low back pain (≥4/10 intensity) randomized to either an', 'Participants from Study 1 (Mental Health Professional Study) (N=66', 'Nurses and Mental Health Professionals From 2 Randomized Controlled Trials for Chronic Back Pain', 'chronic low back pain']","['mental health professional versus primary care nurse-delivered telehealth cognitive-behavioral therapy (CBT) and supportive care (SC', '8-week CBT']","['NRS', 'chronic back pain', 'back pain disability (Roland Morris Disability Questionnaire [RMDQ]), pain intensity (Numeric Rating Scale [NRS]), depressive symptoms (Beck Depression Inventory 2 [BDI-2]), pain catastrophizing (Pain Catastrophizing Scale [PCS]), and overall improvement (Global Clinical Impressions [GCI', 'PCS', 'RMDQ', 'RMDQ, NRS, PCS, or GCI measures (P>0.20', 'GCI', 'BDI scores']","[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0028678', 'cui_str': 'nursing care'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain (finding)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0740418', 'cui_str': 'Chronic back pain (finding)'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C1328956', 'cui_str': 'eHealth'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0740418', 'cui_str': 'Chronic back pain (finding)'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0222045'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory (assessment scale)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",2016.0,0.116435,"The analyses revealed no significant differences in treatment efficacy between the trained nurse versus the mental health professionals on the RMDQ, NRS, PCS, or GCI measures (P>0.20). ","[{'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Gannon', 'Affiliation': 'VA San Diego Healthcare System.'}, {'ForeName': 'Joseph H', 'Initials': 'JH', 'LastName': 'Atkinson', 'Affiliation': 'VA San Diego Healthcare System.'}, {'ForeName': 'Tatiana', 'Initials': 'T', 'LastName': 'Chircop-Rollick', 'Affiliation': 'University of California, San Diego, CA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': ""D'Andrea"", 'Affiliation': 'VA San Diego Healthcare System.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Garfin', 'Affiliation': 'University of California, San Diego, CA.'}, {'ForeName': 'Shetal', 'Initials': 'S', 'LastName': 'Patel', 'Affiliation': 'VA San Diego Healthcare System.'}, {'ForeName': 'Donald B', 'Initials': 'DB', 'LastName': 'Penzien', 'Affiliation': 'The University of Mississippi Medical Center, Jackson, MS.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Wallace', 'Affiliation': 'University of California, San Diego, CA.'}, {'ForeName': 'Anne L', 'Initials': 'AL', 'LastName': 'Weickgenant', 'Affiliation': 'VA San Diego Healthcare System.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Slater', 'Affiliation': 'Scottsdale Clinical Research Institute at Scottsdale Healthcare, Scottsdale, AZ.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Holloway', 'Affiliation': 'VA San Diego Healthcare System.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Rutledge', 'Affiliation': 'VA San Diego Healthcare System.'}]",The Clinical journal of pain,['10.1097/AJP.0000000000000678'] 3102,30829734,"Effect of Preperitoneal Versus Epidural Analgesia on Postoperative Inflammatory Response and Pain Following Radical Cystectomy: A Prospective, Randomized Trial.","OBJECTIVES Continuous wound infiltration of local anesthetics has been proposed as an alternative to epidural analgesia during abdominal surgery. Cytokines have a major role in inflammatory changes caused by surgery. This study aimed to compare the effects of continuous preperitoneal versus epidural analgesia on inflammatory cytokines postoperatively. MATERIALS AND METHODS Forty patients scheduled for radical cystectomy were included in this observer-blinded, randomized trial; patients were randomly assigned into 2 groups to receive; continuous preperitoneal wound infiltration (PPB) or epidural analgesia (EDB). Serum levels of interleukins (IL1β, IL6, IL10, and tumor necrosis factor α) were measured at baseline (before induction of anesthesia), preinfusion (before the start of local anesthetic infusion), 6 and 24 hours postoperatively. Visual Analog Scale at rest/movement (VAS-R/M), time to the first request of analgesia, total morphine consumption, sedation score, hemodynamics, and side effects were observed 24 hours postoperatively. RESULTS There was a significant reduction in IL6, IL1β and increase in IL10 in PPB compared with EDB at 6 and 24 hours postoperatively and compared with preinfusion levels (P≤0.001). In EDB, a significant increase in IL1β, IL10, and tumor necrosis factor α at 6 hours compared with preinfusion levels (P≤0.002). VAS-R/M was significantly decreased at 2, 4, 6, 8, and 12 hours in EDB compared with PPB (P≤0.014), with no significant difference in the mean time to the first request of analgesia and total morphine consumption between the 2 groups. CONCLUSION Continuous preperitoneal analgesia better attenuated postoperative inflammatory response and provided a comparable overall analgesia to that with continuous epidural analgesia following radical cystectomy.",2019,"There was a significant reduction in IL6, IL1β and increase in IL10 in PPB compared with EDB at 6 and 24 hours postoperatively and compared with preinfusion levels (P≤0.001).","['Radical Cystectomy', 'Forty patients scheduled for']","['Preperitoneal Versus Epidural Analgesia', 'continuous preperitoneal versus epidural analgesia', 'radical cystectomy', 'continuous preperitoneal wound infiltration (PPB) or epidural analgesia (EDB']","['VAS-R/M', 'IL1β, IL10, and tumor necrosis factor α', 'Postoperative Inflammatory Response and Pain', 'mean time to the first request of analgesia and total morphine consumption', 'Serum levels of interleukins (IL1β, IL6, IL10, and tumor necrosis factor α', 'postoperative inflammatory response', 'Visual Analog Scale at rest/movement (VAS-R/M), time to the first request of analgesia, total morphine consumption, sedation score, hemodynamics, and side effects', 'IL6, IL1β and increase in IL10 in PPB']","[{'cui': 'C0194401', 'cui_str': 'Total resection of urinary bladder (procedure)'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}]","[{'cui': 'C0442170', 'cui_str': 'Preperitoneal approach (qualifier value)'}, {'cui': 'C0002769', 'cui_str': 'Analgesia, Epidural'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0194401', 'cui_str': 'Total resection of urinary bladder (procedure)'}, {'cui': 'C0394871', 'cui_str': 'Wound infiltration (procedure)'}]","[{'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0041368', 'cui_str': 'Tumor Necrosis Factors'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1272683', 'cui_str': 'Requested'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0021764', 'cui_str': 'Interleukins'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0443144', 'cui_str': 'At rest (qualifier value)'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0032441', 'cui_str': 'Polybromobiphenyl Compounds'}]",40.0,0.055598,"There was a significant reduction in IL6, IL1β and increase in IL10 in PPB compared with EDB at 6 and 24 hours postoperatively and compared with preinfusion levels (P≤0.001).","[{'ForeName': 'Ahmed H', 'Initials': 'AH', 'LastName': 'Othman', 'Affiliation': 'Departments of Anesthesia, ICU, and Pain Relief.'}, {'ForeName': 'Doaa G', 'Initials': 'DG', 'LastName': 'Ahmed', 'Affiliation': 'Departments of Anesthesia, ICU, and Pain Relief.'}, {'ForeName': 'Ahmad M', 'Initials': 'AM', 'LastName': 'Abd El-Rahman', 'Affiliation': 'Departments of Anesthesia, ICU, and Pain Relief.'}, {'ForeName': 'Fatma A', 'Initials': 'FA', 'LastName': 'El Sherif', 'Affiliation': 'Departments of Anesthesia, ICU, and Pain Relief.'}, {'ForeName': 'Samar', 'Initials': 'S', 'LastName': 'Mansour', 'Affiliation': 'Clinical Pathology.'}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Aboeleuon', 'Affiliation': 'Surgical Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.'}]",The Clinical journal of pain,['10.1097/AJP.0000000000000679'] 3103,31356508,Physical Activity Is Higher in Patients with LVADs Compared to Chronic Heart Failure.,"PURPOSE Left ventricular assist devices (LVADs) are associated with an increased aerobic capacity in patients with chronic heart failure (CHF). However, studies evaluating the impact of LVAD implantation on physical activity (PA) are lacking. The aim of this study was to compare daily PA levels in participants with LVADs with well-matched CHF participants. METHODS Sixteen participants with an LVAD (age: 59.1 ± 10.8 years) were case-matched to 16 participants with advanced CHF (age: 58.3 ± 8.7 years), who were listed or being considered for cardiac transplantation. Participants underwent a cardiopulmonary exercise test to determine peak oxygen consumption (V[Combining Dot Above]O2 peak). PA was monitored continuously for seven consecutive days with an Actiheart monitor. RESULTS V[Combining Dot Above]O2 peak in the CHF group (12.3 ± 3.5 ml·kg·min) was not significantly different to the LVAD group prior to LVAD implantation (10.4 ± 2.1 ml·kg·min), but was lower than in the LVAD group following implantation (15.8 ± 4.3 ml·kg·min; p < 0.05). PA was higher in the LVAD (19.7 ± 6.4 kJ·kg·day) compared with the CHF group (11.6 ± 6.9 kJ·kg·day; p = 0.001). LVAD participants spent more time performing moderate intensity PA than their CHF counterparts, 26 (24-40) [median (IQR)] vs. 12 (9-16) min/day; p < 0.001. PA was correlated with V[Combining Dot Above]O2 peak (r = 0.582; p = 0.001) across participants in the CHF and LVAD groups. CONCLUSION Higher levels of PA were observed in participants with LVAD compared with patients with advanced CHF. This may be due to a higher V[Combining Dot Above]O2 peak, resulting in an improved capacity to perform activities of daily living with less symptoms.",2019,PA was higher in the LVAD (19.7 ± 6.4 kJ·kg·day) compared with the CHF group (11.6 ± 6.9 kJ·kg·day; p = 0.001).,"['Sixteen participants with an LVAD (age: 59.1 ± 10.8 years) were case-matched to 16 participants with advanced CHF (age: 58.3 ± 8.7 years), who were listed or being considered for cardiac transplantation', 'patients with chronic heart failure (CHF', 'participants with LVADs with well-matched CHF participants']","['LVAD implantation', 'Left ventricular assist devices (LVADs', 'cardiopulmonary exercise test', 'LVAD']","['Dot Above]O2 peak', 'time performing moderate intensity PA', 'V[Combining Dot Above]O2 peak', 'PA', 'peak oxygen consumption (V[Combining Dot Above]O2 peak', 'Physical Activity', 'aerobic capacity', 'daily PA levels', 'Higher levels of PA']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517523', 'cui_str': '10.8'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C4517880', 'cui_str': '8.7 (qualifier value)'}, {'cui': 'C0018823', 'cui_str': 'Transplantation, Cardiac'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0264716', 'cui_str': 'Chronic heart failure (disorder)'}]","[{'cui': 'C0021107', 'cui_str': 'Insertion procedure'}, {'cui': 'C0181598', 'cui_str': 'Left ventricular assist device'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary Exercise Test'}]","[{'cui': 'C1720485', 'cui_str': 'Corneal epithelial microcysts'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C1305742', 'cui_str': 'Oxygen consumption'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]",16.0,0.0464878,PA was higher in the LVAD (19.7 ± 6.4 kJ·kg·day) compared with the CHF group (11.6 ± 6.9 kJ·kg·day; p = 0.001).,"[{'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Moreno-Suarez', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, Australia.'}, {'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'Liew', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, Australia.'}, {'ForeName': 'Lawrence G', 'Initials': 'LG', 'LastName': 'Dembo', 'Affiliation': 'Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Murdoch, Australia.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Larbalestier', 'Affiliation': 'Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Murdoch, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Maiorana', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, Australia.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002104'] 3104,32050899,Implementation of the Goal-directed Medication review Electronic Decision Support System (G-MEDSS)© into home medicines review: a protocol for a cluster-randomised clinical trial in older adults.,"BACKGROUND Older people living in the community have a high prevalence of polypharmacy and are vulnerable to adverse drug events. Home Medicines Review (HMR) is a collaborative medication review service involving general practitioners (GPs), accredited clinical pharmacists (ACPs) and patients, which aims to prevent medication-related problems. This study aims to evaluate the implementation of a Computerised Clinical Decision Support System (CCDSS) called G-MEDSS© (Goal-directed Medication Review Electronic Decision Support System) in HMRs to deprescribe anticholinergic and sedative medications, and to assess the effect of deprescribing on clinical outcomes. METHODS This study consists of 2 stages: Stage I - a two-arm parallel-group cluster-randomised clinical trial, and Stage II - process evaluation of the CCDSS intervention in HMR. Community-dwelling older adults living with and without dementia who are referred for HMR by their GP and recruited by ACPs will be included in this study. G-MEDSS is a CCDSS designed to provide clinical decision support for healthcare practitioners when completing a medication review, to tailor care to meet the patients' goals and preferences. The G-MEDSS contains three tools: The Goals of Care Management Tool, The Drug Burden Index (DBI) Calculator©, and The revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire. The G-MEDSS produces patient-specific deprescribing reports, to be included as part of the ACPs communication with the patient's GP, and patient-specific reports for the patient (or carer). ACPs randomised to the intervention arm of the study will use G-MEDSS to create deprescribing reports for the referring GP and for their patient (or carer) when submitting the HMR report. ACPs in the comparison arm will provide the usual care HMR service (without the G-MEDSS). OUTCOMES The primary outcome is reduction in DBI exposure 3 months after HMR ± G-MEDSS intervention between comparison and intervention groups. The secondary outcomes include changes in clinical outcomes (physical and cognitive function, falls, institutionalisation, GP visits, medication adherence and mortality) 3-months after HMR. DISCUSSION This study is expected to add to the evidence that the combination of CCDSS supporting medication review can improve prescribing and clinical outcomes in older adults. TRIAL REGISTRATION The trial was registered on the Australian New Zealand Clinical Trials Registry ACTRN12617000895381 on 19th June 2017.",2020,"This study aims to evaluate the implementation of a Computerised Clinical Decision Support System (CCDSS) called G-MEDSS© (Goal-directed Medication Review Electronic Decision Support System) in HMRs to deprescribe anticholinergic and sedative medications, and to assess the effect of deprescribing on clinical outcomes. ","['Community-dwelling older adults living with and without dementia who are referred for HMR by their GP and recruited by ACPs', 'older adults']","['CCDSS', 'Computerised Clinical Decision Support System (CCDSS) called G-MEDSS', 'G-MEDSS', 'CCDSS intervention']","['reduction in DBI exposure 3\u2009months after HMR\u2009±\u2009G-MEDSS intervention', 'changes in clinical outcomes (physical and cognitive function, falls, institutionalisation, GP visits, medication adherence and mortality) 3-months after HMR']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}]","[{'cui': 'C0525070', 'cui_str': 'Decision Support Systems, Clinical'}, {'cui': 'C1720420', 'cui_str': 'Call'}]","[{'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0049285', 'cui_str': 'deschlorobenzoylindomethacin'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C2364172', 'cui_str': 'Medication Adherence'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",,0.111559,"This study aims to evaluate the implementation of a Computerised Clinical Decision Support System (CCDSS) called G-MEDSS© (Goal-directed Medication Review Electronic Decision Support System) in HMRs to deprescribe anticholinergic and sedative medications, and to assess the effect of deprescribing on clinical outcomes. ","[{'ForeName': 'Lisa', 'Initials': 'L', 'LastName': ""Kouladjian O'Donnell"", 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. lisa.kouladjian@sydney.edu.au.'}, {'ForeName': 'Mouna', 'Initials': 'M', 'LastName': 'Sawan', 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Reeve', 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Danijela', 'Initials': 'D', 'LastName': 'Gnjidic', 'Affiliation': 'Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Timothy F', 'Initials': 'TF', 'LastName': 'Chen', 'Affiliation': 'Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Kelly', 'Affiliation': 'School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Simon J', 'Initials': 'SJ', 'LastName': 'Bell', 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Sarah N', 'Initials': 'SN', 'LastName': 'Hilmer', 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.'}]",BMC geriatrics,['10.1186/s12877-020-1442-2'] 3105,31900959,Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial.,"BACKGROUND AND AIM In the phase 3 CONCUR trial (NCT01584830), regorafenib improved overall survival (OS) versus placebo in Asian patients with treatment-refractory metastatic colorectal cancer (mCRC). We conducted a post hoc subgroup analysis of Chinese patients in CONCUR. METHODS Adults with mCRC progressing despite at least two prior treatment regimens and Eastern Cooperative Oncology Group performance status 0-1 were randomized 2:1 to regorafenib 160 mg once daily or placebo for the first 3 weeks of each 4-week cycle. Dose modifications were permitted. The primary endpoint was OS. Secondary endpoints included progression-free survival, objective overall response, disease control rate, and safety. RESULTS A total of 172 Chinese patients were randomized and treated (regorafenib n = 112, placebo n = 60). OS was significantly improved with regorafenib versus placebo (8.4 vs 6.2 months, respectively; hazard ratio [HR] 0.56, 95% CI 0.39-0.80; one-sided P = 0.000632), as was progression-free survival (HR 0.32, 95% CI 0.22-0.47; one-sided P < 0.000001). The most common drug-related grade ≥ 3 treatment-emergent adverse events (TEAEs; regorafenib, placebo) were hand-foot skin reaction (19%, 0%), hypertension (13%, 3%), hypophosphatemia (7%, 0%), increased alanine aminotransferase (6%, 0%), and increased aspartate aminotransferase (5%, 0%). In patients receiving regorafenib and placebo, respectively, TEAEs led to treatment discontinuation in 14% and 7%, dose reduction in 39% and 0%, and dose interruption in 64% and 20%. CONCLUSIONS This retrospective analysis showed that regorafenib provided an OS benefit over placebo for Chinese patients with previously treated mCRC. TEAEs were consistent with the regorafenib safety profile and manageable with treatment modifications.",2020,"OS was significantly improved with regorafenib versus placebo (8.4 vs 6.2 months, respectively; hazard ratio [HR]","['Chinese patients with previously treated mCRC', 'Adults with mCRC progressing despite at least two prior treatment regimens and Eastern Cooperative Oncology Group performance status 0-1', 'Chinese patients in CONCUR', 'Asian patients with treatment-refractory metastatic colorectal cancer (mCRC', 'Chinese patients with metastatic colorectal cancer', '172 Chinese patients']","['regorafenib', 'regorafenib 160 mg once daily or placebo', 'placebo', 'Regorafenib', 'regorafenib versus placebo', 'regorafenib n=112, placebo', 'regorafenib and placebo']","['alanine aminotransferase', 'hazard ratio [HR', 'hypertension', 'foot skin reaction', 'aspartate aminotransferase', 'progression-free survival (PFS), objective overall response, disease control rate, and safety', 'overall survival (OS', 'hypophosphatemia', 'OS']","[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1520224', 'cui_str': 'Eastern Cooperative Oncology Group performance status'}, {'cui': 'C0078988', 'cui_str': 'Asians'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0346973', 'cui_str': 'Secondary malignant neoplasm of large intestine'}, {'cui': 'C4517601', 'cui_str': '172 (qualifier value)'}]","[{'cui': 'C2980094', 'cui_str': 'regorafenib'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0201836', 'cui_str': 'Alanine aminotransferase measurement (procedure)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0016504', 'cui_str': 'Foot'}, {'cui': 'C0221743', 'cui_str': 'Skin reaction (observable entity)'}, {'cui': 'C0004002', 'cui_str': 'L-Aspartate-2-Oxoglutarate Aminotransferase'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0085682', 'cui_str': 'Hypophosphatemia'}]",172.0,0.677644,"OS was significantly improved with regorafenib versus placebo (8.4 vs 6.2 months, respectively; hazard ratio [HR]","[{'ForeName': 'Jianming', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'The 307 Hospital of PLA Cancer Center, Beijing, China.'}, {'ForeName': 'Rui-Hua', 'Initials': 'RH', 'LastName': 'Xu', 'Affiliation': 'Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.'}, {'ForeName': 'Shukui', 'Initials': 'S', 'LastName': 'Qin', 'Affiliation': ""Chinese People's Liberation Army Cancer Center of Nanjing Bayi Hospital, Nanjing, China.""}, {'ForeName': 'Hongming', 'Initials': 'H', 'LastName': 'Pan', 'Affiliation': 'Sir Run Run Shaw Hospital, Hangzhou, China.'}, {'ForeName': 'Yuxian', 'Initials': 'Y', 'LastName': 'Bai', 'Affiliation': 'Harbin Medical University Cancer Hospital, Harbin, China.'}, {'ForeName': 'Yihebali', 'Initials': 'Y', 'LastName': 'Chi', 'Affiliation': 'Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.'}, {'ForeName': 'Liwei', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': ""Shanghai First People's Hospital, Shanghai, China.""}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Bi', 'Affiliation': 'West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Cheng', 'Affiliation': 'Jilin Provincial Tumor Hospital, Changchun, China.'}, {'ForeName': 'Tianshu', 'Initials': 'T', 'LastName': 'Liu', 'Affiliation': 'Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Ma', 'Affiliation': 'Guangdong General Hospital, Guangdong, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Shen', 'Affiliation': 'Peking University Cancer Hospital & Institute, Beijing, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Ba', 'Affiliation': 'Tianjin Medical University Cancer Hospital, Tianjin, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Liang', 'Affiliation': 'Affiliated Hospital of Medical College, Qingdao University, Shandong, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ""The First Affiliated Hospital of the 4th Military Medical University, Xi'an, China.""}, {'ForeName': 'Thomas C C', 'Initials': 'TCC', 'LastName': 'Yau', 'Affiliation': 'Queen Mary Hospital University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Brigette B', 'Initials': 'BB', 'LastName': 'Ma', 'Affiliation': 'Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Kun-Huei', 'Initials': 'KH', 'LastName': 'Yeh', 'Affiliation': 'National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.'}, {'ForeName': 'Jen-Kou', 'Initials': 'JK', 'LastName': 'Lin', 'Affiliation': 'Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Kappeler', 'Affiliation': 'Bayer AG, Berlin, Germany.'}, {'ForeName': 'JoAnn', 'Initials': 'J', 'LastName': 'Shapiro', 'Affiliation': 'Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, USA.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Kalmus', 'Affiliation': 'Bayer AG, Berlin, Germany.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Tongji University Shanghai East Hospital, Shanghai, China.'}]",Journal of gastroenterology and hepatology,['10.1111/jgh.14974'] 3106,32048788,Acupuncture of different treatment frequency in postprandial distress syndrome: A pilot randomized clinical trial.,"BACKGROUND The evidence for different frequencies of acupuncture treatment in postprandial distress syndrome (PDS) is insufficient. This study determined whether 3 sessions per week of acupuncture treatment are superior to 1 session per week for symptomatic outcomes in PDS. METHODS This 16-week randomized clinical pilot trial was conducted in an outpatient setting in China. Patients with PDS were randomly assigned to receive 3 sessions per week of acupuncture (group H) or 1 session per week of acupuncture (group L) for 4 weeks. The primary outcome was the complete elimination of core symptoms at week 4. Secondary outcomes included overall treatment efficacy, dyspepsia symptoms, quality of life, anxiety, and depression. KEY RESULTS Sixty patients were randomized of whom 53 (88.3%) completed this trial. The complete elimination rate of core symptoms was 26.7% (95% CI 12.3%-45.9%) in group H and 10.0% (95% CI 2.1%-26.5%) in group L at week 4 (P = .095). There was a significant difference between H and group L at weeks 8, 12, and 16 (P = .038, .02, and .02). All secondary outcomes were better in group H at all time points. No serious adverse events occurred in either groups. CONCLUSIONS This trial showed that acupuncture, at 3 sessions per week, tended to improve symptoms and the quality of life among patients with PDS as compared to once a week. Acupuncture treatment for 4 weeks was feasible and safe. A larger sample, multicenter, randomized controlled trial of acupuncture for PDS appears to be justified in the future.",2020,"There was a significant difference between H and group L at weeks 8, 12, and 16 (P = .038, .02, and .02).","['Sixty patients were randomized of whom 53 (88.3%) completed this trial', 'Patients with PDS', 'postprandial distress syndrome', 'postprandial distress syndrome (PDS', 'outpatient setting in China']","['acupuncture', 'Acupuncture']","['serious adverse events', 'complete elimination of core symptoms', 'overall treatment efficacy, dyspepsia symptoms, quality of life, anxiety, and depression', 'symptoms and the quality of life', 'feasible and safe', 'complete elimination rate of core symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0087113', 'cui_str': 'Treatment Efficacy'}, {'cui': 'C0013395', 'cui_str': 'Indigestion'}, {'cui': 'C0034380'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]",60.0,0.223066,"There was a significant difference between H and group L at weeks 8, 12, and 16 (P = .038, .02, and .02).","[{'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Ya-Quan', 'Initials': 'YQ', 'LastName': 'Hou', 'Affiliation': 'Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Jing-Wen', 'Initials': 'JW', 'LastName': 'Yang', 'Affiliation': 'Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Li-Qiong', 'Initials': 'LQ', 'LastName': 'Wang', 'Affiliation': 'Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Jia-Kai', 'Initials': 'JK', 'LastName': 'Shao', 'Affiliation': 'Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing, China.'}, {'ForeName': 'Xuan', 'Initials': 'X', 'LastName': 'Zou', 'Affiliation': 'Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Na-Na', 'Initials': 'NN', 'LastName': 'Yang', 'Affiliation': 'Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing, China.'}, {'ForeName': 'Cun-Zhi', 'Initials': 'CZ', 'LastName': 'Liu', 'Affiliation': 'Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}]",Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,['10.1111/nmo.13812'] 3107,32053538,"Reply to: ""The Analgesic Effects of Liposomal Bupivacaine versus Bupivacaine Hydrochloride Administered as a Transversus Abdominis Plane Block after Abdominally Based Autologous Microvascular Breast Reconstruction: A Prospective, Single-Blind, Randomized, Controlled Trial"".",,2020,,['Transversus Abdominis Plane Block after Abdominally Based Autologous Microvascular Breast Reconstruction'],"['Bupivacaine Hydrochloride', 'Liposomal Bupivacaine']",[],"[{'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C0443258', 'cui_str': 'Microvascular (qualifier value)'}, {'cui': 'C0085076', 'cui_str': 'Breast Reconstruction'}]","[{'cui': 'C0887621', 'cui_str': 'Bupivacaine Hydrochloride'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]",[],,0.155102,,"[{'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Knackstedt', 'Affiliation': ''}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Gatherwright', 'Affiliation': ''}, {'ForeName': 'Risal', 'Initials': 'R', 'LastName': 'Djohan', 'Affiliation': ''}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000006782'] 3108,30819077,Distinctive Effects of Aerobic and Resistance Exercise Modes on Neurocognitive and Biochemical Changes in Individuals with Mild Cognitive Impairment.,"BACKGROUND Decreased levels of the neuroprotective growth factors, low-grade inflammation, and reduced neurocognitive functions during aging are associated with neurodegenerative diseases, such as Alzheimer's disease. Physical exercise modifies these disadvantageous phenomena while a sedentary lifestyle promotes them. PURPOSE The purposes of the present study included investigating whether both aerobic and resistance exercise produce divergent effects on the neuroprotective growth factors, inflammatory cytokines, and neurocognitive performance, and further exploring whether changes in the levels of these molecular biomarkers are associated with alterations in neurocognitive performance. METHODS Fifty-five older adults with amnestic MCI (aMCI) were recruited and randomly assigned to an aerobic exercise (AE) group, a resistance exercise (RE) group, or a control group. The assessment included neurocognitive measures [e.g., behavior and event-related potential (ERP)] during a task-switching paradigm, as well as circulating neuroprotective growth factors (e.g., BDNF, IGF-1, VEGF, and FGF-2) and inflammatory cytokine (e.g., TNF-α, IL-1β, IL-6, IL-8, and IL-15) levels at baseline and after either a 16-week aerobic or resistance exercise intervention program or a control period. RESULTS Aerobic and resistance exercise could effectively partially facilitate neurocognitive performance [e.g., accuracy rates (ARs), reaction times during the heterogeneous condition, global switching cost, and ERP P3 amplitude] when the participants performed the task switching paradigm although the ERP P2 components and P3 latency could not be changed. In terms of the circulating molecular biomarkers, the 16-week exercise interventions did not change some parameters (e.g., leptin, VEGF, FGF-2, IL-1β, IL-6, and IL-8). However, the peripheral serum BDNF level was significantly increased, and the levels of insulin, TNF-α, and IL-15 levels were significantly decreased in the AE group, whereas the RE group showed significantly increased IGF-1 levels and decreased IL-15 levels. The relationships between the changes in neurocognitive performance (AR and P3 amplitudes) and the changes in the levels of neurotrophins (BDNF and IGF-1)/inflammatory cytokines (TNF-α) only approached significance. CONCLUSION These findings suggested that in older adults with aMCI, not only aerobic but also resistance exercise is effective with regard to increasing neurotrophins, reducing some inflammatory cytokines, and facilitating neurocognitive performance. However, the aerobic and resistance exercise modes likely employed divergent molecular mechanisms on neurocognitive facilitation.",2019,"However, the peripheral serum BDNF level was significantly increased, and the levels of insulin, TNF-α, and IL-15 levels were significantly decreased in the AE group, whereas the RE group showed significantly increased IGF-1 levels and decreased IL-15 levels.","['older adults with aMCI', 'Fifty-five older adults with amnestic MCI (aMCI', 'Individuals with Mild Cognitive Impairment']","['aerobic exercise (AE) group, a resistance exercise (RE) group, or a control group', 'aerobic and resistance exercise', 'Physical exercise', 'Aerobic and Resistance Exercise Modes', 'Aerobic and resistance exercise', 'aerobic or resistance exercise intervention program']","['neurocognitive performance [e.g., accuracy rates (ARs), reaction times during the heterogeneous condition, global switching cost, and ERP P3 amplitude', 'IGF-1 levels and decreased IL-15 levels', 'neurocognitive measures [e.g., behavior and event-related potential (ERP)] during a task-switching paradigm, as well as circulating neuroprotective growth factors (e.g., BDNF, IGF-1, VEGF, and FGF-2) and inflammatory cytokine (e.g., TNF-α, IL-1β, IL-6, IL-8, and IL-15) levels', 'levels of insulin, TNF-α, and IL-15 levels', 'levels of neurotrophins (BDNF and IGF-1)/inflammatory cytokines (TNF-α', 'Neurocognitive and Biochemical Changes', 'ERP P2 components and P3 latency', 'neurocognitive performance (AR and P3 amplitudes', 'leptin, VEGF, FGF-2, IL-1β, IL-6, and IL-8', 'peripheral serum BDNF level']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0450382', 'cui_str': '55 (qualifier value)'}, {'cui': 'C0560005', 'cui_str': 'millicurie'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}]","[{'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0337380', 'cui_str': 'Endoscopic retrograde pancreatography (procedure)'}, {'cui': 'C0021665', 'cui_str': 'Somatomedin C'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0254610', 'cui_str': 'IL15'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0282171', 'cui_str': 'Potentials, Event-Related'}, {'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0018284', 'cui_str': 'Growth factor (substance)'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0078058', 'cui_str': 'Vascular Endothelial Growth Factor A'}, {'cui': 'C0380603', 'cui_str': 'Prostate Epithelial Cell Growth Factor'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0027754', 'cui_str': 'Neurotrophic Factors'}, {'cui': 'C0205474', 'cui_str': 'Biochemical (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",55.0,0.0377539,"However, the peripheral serum BDNF level was significantly increased, and the levels of insulin, TNF-α, and IL-15 levels were significantly decreased in the AE group, whereas the RE group showed significantly increased IGF-1 levels and decreased IL-15 levels.","[{'ForeName': 'Chia-Liang', 'Initials': 'CL', 'LastName': 'Tsai', 'Affiliation': 'Institute of Physical Education, Health and Leisure Studies, National Cheng Kung University, No. 1, University Road, Tainan, 701, Taiwan.'}, {'ForeName': 'Ming-Chyi', 'Initials': 'MC', 'LastName': 'Pai', 'Affiliation': 'Division of Behavioral Neurology, Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 138, Sheng Li Road, Tainan, 704, Taiwan.'}, {'ForeName': 'Jozef', 'Initials': 'J', 'LastName': 'Ukropec', 'Affiliation': 'Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Slovakia, Dubravska cesta 9, 84505 Bratislava, Slovakia.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Ukropcová', 'Affiliation': 'Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Slovakia, Dubravska cesta 9, 84505 Bratislava, Slovakia.'}]",Current Alzheimer research,['10.2174/1567205016666190228125429'] 3109,32058435,Does Preoperative Decolonization Reduce Surgical Site Infections in Elective Orthopaedic Surgery? A Prospective Randomized Controlled Trial.,"BACKGROUND Surgical site infections (SSIs) after elective orthopaedic surgery are very stressful for patients due to frequent rehospitalizations with reoperations and poorer functional outcomes. Prevention of such events is therefore crucial. Although an evidence-based consensus is still lacking, preoperative decolonization could decrease SSI. Specifically, more information is needed about the effect of a preoperative decolonization procedure on SSI proportions in both Staphylococcus aureus carriers and non-S. aureus carriers after general orthopaedic surgery. QUESTIONS/PURPOSES Our study addressed the following questions: (1) Does preoperative decolonization reduce the risk of SSI after general elective orthopaedic surgery in patients colonized with S. aureus? (2) Does preoperative decolonization reduce the risk of SSI among patients who are not colonized with S. aureus? METHODS In this prospective, randomized, single-blinded trial, we recruited patients undergoing general elective orthopaedic surgery in one tertiary care center in Switzerland. Between November 2014 and September 2017, 1318 of 1897 screened patients were enrolled. Patients were allocated into either the S. aureus carrier group (35%, 465 of 1318 patients) or the noncarrier group (65%, 853 of 1318 patients) according to screening culture results. In the S. aureus group, 232 patients were allocated to the intervention arm and 233 were allocated to the control arm. Intervention was 5 days of daily chlorhexidine showers and mupirocin nasal ointment twice a day. Of the 853 noncarriers, 426 were allocated to the intervention arm and 427 were allocated to the control arm. All patients in both groups were analyzed in an intention-to-treat manner. The primary endpoint was SSI occurrence at 90 days postoperative and the secondary endpoint was SSI occurrence at 30 days postoperative.The initial sample size calculation was made for the S. aureus carrier group. Based on the literature review, a 4% proportion of SSI was expected in the control group. Thus, 726 carriers would have been needed to detect a relative risk reduction of 80% with a power of 80% at a two-sided α-error of 0.048 (adjusted for interim analysis). Assuming carrier prevalence of 27%, 2690 patients would have been needed in total. An interim analysis was performed after including half of the targeted S. aureus carriers (363 of 726). Based on the low infection rate in the control group (one of 179), a new sample size of 15,000 patients would have been needed. This was deemed not feasible and the trial was stopped prematurely. RESULTS Among carriers, there was no difference in the risk of SSI between the intervention and control arms (decolonized SSI risk: 0.4% [one of 232], control SSI risk: 0.4% [one of 233], risk difference: 0.0% [95% CI -1.2% to 1.2%], stratified for randomization stratification factors; p > 0.999). For noncarriers, there was no difference in risk between the intervention and control arms (decolonized SSI risk: 0.2% [one of 426], control SSI risk: 0.2% [one of 247], stratified risk difference: -0.0% [95% CI -0.7 to 0.6]; p = 0.973). CONCLUSIONS We found no difference in the risk of SSI between the decolonization and control groups, both in S. aureus carriers and noncarriers. Because of the low event numbers, no definite conclusion about efficacy of routine preoperative decolonization can be drawn. The results, however, may be helpful in future meta-analyses. LEVEL OF EVIDENCE Level II, therapeutic study.",2020,"For non-carriers, there was no difference in risk between the intervention and control arms (decolonized SSI risk: 0.2% [one of 426], control SSI risk: 0.2% [one of 247], stratified risk difference:","['232 patients', '853 non-carriers, 426 were allocated to the intervention arm and 427', 'Between November 2014 and September 2017, 1318 of 1897 screened patients were enrolled', 'patients undergoing general elective orthopaedic surgery in one tertiary care center in Switzerland']",['chlorhexidine'],"['low infection rate', 'SSI occurrence', 'risk of SSI']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0560175', 'cui_str': 'Carrier State'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0587437', 'cui_str': 'Tertiary Hospital'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}]","[{'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}]","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",15000.0,0.109456,"For non-carriers, there was no difference in risk between the intervention and control arms (decolonized SSI risk: 0.2% [one of 426], control SSI risk: 0.2% [one of 247], stratified risk difference:","[{'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Rohrer', 'Affiliation': 'F. Rohrer, P. Cottagnoud, T. Hermann, J. Brügger, Department of Internal Medicine, Sonnenhofspital, Bern, Switzerland F. Rohrer, H. Nötzli, L. Risch, P. Cottagnoud, University of Bern, Bern, Switzerland H. Nötzli, Orthopaedic Department, Sonnenhofspital, Bern, Switzerland L. Risch, T. Bodmer, Labormedizinisches Zentrum Dr Risch, Microbiology, Koeniz, Switzerland A. Limacher, N. Fankhauser, CTU Bern and Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland K. Wagner, Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland J. Brügger, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Hubert', 'Initials': 'H', 'LastName': 'Nötzli', 'Affiliation': ''}, {'ForeName': 'Lorenz', 'Initials': 'L', 'LastName': 'Risch', 'Affiliation': ''}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Bodmer', 'Affiliation': ''}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Cottagnoud', 'Affiliation': ''}, {'ForeName': 'Tanja', 'Initials': 'T', 'LastName': 'Hermann', 'Affiliation': ''}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Limacher', 'Affiliation': ''}, {'ForeName': 'Niklaus', 'Initials': 'N', 'LastName': 'Fankhauser', 'Affiliation': ''}, {'ForeName': 'Karoline', 'Initials': 'K', 'LastName': 'Wagner', 'Affiliation': ''}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Brügger', 'Affiliation': ''}]",Clinical orthopaedics and related research,['10.1097/CORR.0000000000001152'] 3110,31804414,"A multicenter, prospective, controlled clinical trial of surgical stabilization of rib fractures in patients with severe, nonflail fracture patterns (Chest Wall Injury Society NONFLAIL).","BACKGROUND The efficacy of surgical stabilization of rib fracture (SSRF) in patients without flail chest has not been studied specifically. We hypothesized that SSRF improves outcomes among patients with displaced rib fractures in the absence of flail chest. METHODS Multicenter, prospective, controlled, clinical trial (12 centers) comparing SSRF within 72 hours to medical management. Inclusion criteria were three or more ipsilateral, severely displaced rib fractures without flail chest. The trial involved both randomized and observational arms at patient discretion. The primary outcome was the numeric pain score (NPS) at 2-week follow-up. Narcotic consumption, spirometry, pulmonary function tests, pleural space complications (tube thoracostomy or surgery for retained hemothorax or empyema >24 hours from admission) and both overall and respiratory disability-related quality of life (RD-QoL) were also compared. RESULTS One hundred ten subjects were enrolled. There were no significant differences between subjects who selected randomization (n = 23) versus observation (n = 87); these groups were combined for all analyses. Of the 110 subjects, 51 (46.4%) underwent SSRF. There were no significant baseline differences between the operative and nonoperative groups. At 2-week follow-up, the NPS was significantly lower in the operative, as compared with the nonoperative group (2.9 vs. 4.5, p < 0.01), and RD-QoL was significantly improved (disability score, 21 vs. 25, p = 0.03). Narcotic consumption also trended toward being lower in the operative, as compared with the nonoperative group (0.5 vs. 1.2 narcotic equivalents, p = 0.05). During the index admission, pleural space complications were significantly lower in the operative, as compared with the nonoperative group (0% vs. 10.2%, p = 0.02). CONCLUSION In this clinical trial, SSRF performed within 72 hours improved the primary outcome of NPS at 2-week follow-up among patients with three or more displaced fractures in the absence of flail chest. These data support the role of SSRF in patients without flail chest. LEVEL OF EVIDENCE Therapeutic, level II.",2020,"At two week follow up, the NPS was significantly lower in the operative, as compared to the non-operative group (2.9 vs. 4.5, p<0.01), and RD-QoL was significantly improved (disability score 21 vs. 25, p=0.03).","['110 subjects, 51 (46.4%) underwent SSRF', 'patients without flail chest', 'Patients with Severe, Non-flail Fracture Patterns', 'patients with displaced rib fractures', '110 subjects were enrolled']","['SSRF', 'surgical stabilization of rib fracture (SSRF']","['numeric pain score (NPS', 'Narcotic consumption, spirometry, pulmonary function tests, pleural space complications (tube thoracostomy or surgery for retained hemothorax or empyema > 24 hours from admission) and both overall and respiratory disability-related quality of life (RD-QoL', 'RD-QoL', 'Narcotic consumption', 'NPS', 'index admission, pleural space complications']","[{'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0016196', 'cui_str': 'Stove-in Chest'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0012727', 'cui_str': 'Displacement (morphologic abnormality)'}, {'cui': 'C0035522', 'cui_str': 'Rib Fractures'}]","[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0035522', 'cui_str': 'Rib Fractures'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0027415', 'cui_str': 'Narcotics'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0037981', 'cui_str': 'Spirometry'}, {'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}, {'cui': 'C1522720', 'cui_str': 'Pleural (qualifier value)'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0189476', 'cui_str': 'Tube thoracostomy'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0019123', 'cui_str': 'Hemothorax'}, {'cui': 'C0014009', 'cui_str': 'Empyema'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",110.0,0.059073,"At two week follow up, the NPS was significantly lower in the operative, as compared to the non-operative group (2.9 vs. 4.5, p<0.01), and RD-QoL was significantly improved (disability score 21 vs. 25, p=0.03).","[{'ForeName': 'Fredric M', 'Initials': 'FM', 'LastName': 'Pieracci', 'Affiliation': ""From the Department of Surgery, Division of Trauma, Denver Health Medical Center (F.M.P., K.L.), Denver Colorado; Department of Surgery, Division of Trauma, University of Nebraska Medical Center (Z.B.), Omaha, Nebraska; Department of Surgery, Division of Trauma, Medical University of South Carolina (E.A.E.), Charleston, South Carolina; Department of Surgery, Division of Trauma, St. Mary's Medical Center (L.L.), West Palm Beach, Florida; Department of Surgery, Division of Trauma, Intermountain Medical Center (S.M.), Murray, Utah; Department of Surgery, Division of CT Surgery, St. Joseph Health (L.P.), Mission Hospital, Mission Viejo, California; Department of Surgery, Division of Trauma, George Washington University (B.S.), Washington, District of Columbia; Department of Surgery, Division of Trauma, Wright State University/Miami Valley Hospital (G.S.), Dayton, Ohio; Department of Surgery, Division of Trauma, Carolinas Medical Center (B.T.), Charlotte, North Carolina; Department of Surgery, Division of Trauma, The Queens Medical Center (F.Z.), Honolulu, Hawaii; Department of Surgery, Division of Trauma, Sanford Health (C.D.), Fargo, North Dakota; Department of Surgery, Division of Trauma, Baystate Medical Center (A.R.D.), Springfield, Massachusetts.""}, {'ForeName': 'Kiara', 'Initials': 'K', 'LastName': 'Leasia', 'Affiliation': ''}, {'ForeName': 'Zach', 'Initials': 'Z', 'LastName': 'Bauman', 'Affiliation': ''}, {'ForeName': 'Evert A', 'Initials': 'EA', 'LastName': 'Eriksson', 'Affiliation': ''}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Lottenberg', 'Affiliation': ''}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Majercik', 'Affiliation': ''}, {'ForeName': 'Ledford', 'Initials': 'L', 'LastName': 'Powell', 'Affiliation': ''}, {'ForeName': 'Babak', 'Initials': 'B', 'LastName': 'Sarani', 'Affiliation': ''}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Semon', 'Affiliation': ''}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Thomas', 'Affiliation': ''}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Zhao', 'Affiliation': ''}, {'ForeName': 'Cornelius', 'Initials': 'C', 'LastName': 'Dyke', 'Affiliation': ''}, {'ForeName': 'Andrew R', 'Initials': 'AR', 'LastName': 'Doben', 'Affiliation': ''}]",The journal of trauma and acute care surgery,['10.1097/TA.0000000000002559'] 3111,32053534,"Reply to: ""The Analgesic Effects of Liposomal Bupivacaine versus Bupivacaine Hydrochloride Administered as a Transversus Abdominis Plane Block after Abdominally Based Autologous Microvascular Breast Reconstruction: A Prospective, Single-Blind, Randomized, Controlled Trial"".",,2020,,['Transversus Abdominis Plane Block after Abdominally Based Autologous Microvascular Breast Reconstruction'],"['Bupivacaine Hydrochloride', 'Liposomal Bupivacaine']",[],"[{'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C0443258', 'cui_str': 'Microvascular (qualifier value)'}, {'cui': 'C0085076', 'cui_str': 'Breast Reconstruction'}]","[{'cui': 'C0887621', 'cui_str': 'Bupivacaine Hydrochloride'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]",[],,0.155102,,"[{'ForeName': 'Austin Y', 'Initials': 'AY', 'LastName': 'Ha', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Washington University School of Medicine, Saint Louis, MO.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Guffey', 'Affiliation': 'Department of Anesthesiology, Washington University School of Medicine, Saint Louis, MO.'}, {'ForeName': 'Terence M', 'Initials': 'TM', 'LastName': 'Myckatyn', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Washington University School of Medicine, Saint Louis, MO.'}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000006783'] 3112,31880807,Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland.,"AIM The study aim was to evaluate the cost effectiveness of pembrolizumab monotherapy compared with chemotherapy as a first-line treatment for previously untreated metastatic non-small cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1) tumour proportion score (TPS) ≥50%, from a Swiss payer perspective. Cost effectiveness of pembrolizumab for this indication has not previously been evaluated in Switzerland. METHODS We conducted an analysis using a partitioned survival model with a cycle length of one week, base-case time horizon of 20 years and discount rate of 3% for cost and health outcomes. KEYNOTE-024 randomised controlled trial data for pembrolizumab monotherapy compared with chemotherapy was used as a basis for projecting time-on-treatment, progression-free survival and overall survival, over a 20-year period. For overall survival and progression-free survival, we used Kaplan-Meier probabilities for a brief initial period of the model, followed by parametric curves that had the best fit with subsequent trial data. Quality-adjusted life years (QALYs) were calculated based on the EuroQol 5-dimensional 3-level (EQ-5D-3L) questionnaire administered to trial patients. Costs (in CHF, year 2018) of drug acquisition/administration, adverse events and disease management were included. RESULTS For the base-case, pembrolizumab monotherapy resulted in mean incremental costs of CHF 77,060 (pembrolizumab CHF 223,324, chemotherapy CHF 146,264) and mean incremental QALYs of 1.34 (pembrolizumab 3.05, chemotherapy 1.71), leading to an incremental cost-effectiveness ratio of CHF 57,402 per QALY gained. Cost-effectiveness results were most sensitive to overall survival and relatively insensitive to other parameters varied. In probabilistic sensitivity analysis, the probability of cost effectiveness of pembrolizumab, with an assumption of a willingness-to-pay threshold of CHF 100,000 per QALY gained, was 88%. CONCLUSION Pembrolizumab is likely to be cost effective for treating Swiss patients with previously untreated metastatic NSCLC expressing PD-L1 TPS ≥50%. (This economic evaluation was based on the KEYNOTE-024 trial. The trial identifier is NCT02142738.).",2019,"For the base-case, pembrolizumab monotherapy resulted in mean incremental costs of CHF 77,060 (pembrolizumab CHF 223,324, chemotherapy CHF 146,264) and mean incremental QALYs of 1.34 (pembrolizumab 3.05, chemotherapy 1.71), leading to an incremental cost-effectiveness ratio of CHF 57,402 per QALY gained.","['Swiss patients with previously untreated metastatic NSCLC expressing PD-L1 TPS ≥50', 'previously untreated metastatic non-small cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1) tumour proportion score (TPS) ≥50%, from a Swiss payer perspective']","['pembrolizumab', 'chemotherapy', 'Pembrolizumab', 'pembrolizumab monotherapy', 'pembrolizumab vs chemotherapy']","['Costs (in CHF, year 2018) of drug acquisition/administration, adverse events and disease management', 'overall survival', 'Quality-adjusted life years (QALYs', 'Cost effectiveness', 'cost effectiveness', 'mean incremental costs', 'EuroQol 5-dimensional 3-level (EQ-5D-3L) questionnaire', 'projecting time-on-treatment, progression-free survival and overall survival', 'overall survival and progression-free survival']","[{'cui': 'C0241315', 'cui_str': 'Swiss (ethnic group)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0278987', 'cui_str': 'Metastatic non-small cell lung cancer (disorder)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0023688', 'cui_str': 'Ligands'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]","[{'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0376636', 'cui_str': 'Disease Management'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0080071', 'cui_str': 'QALY'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",,0.298455,"For the base-case, pembrolizumab monotherapy resulted in mean incremental costs of CHF 77,060 (pembrolizumab CHF 223,324, chemotherapy CHF 146,264) and mean incremental QALYs of 1.34 (pembrolizumab 3.05, chemotherapy 1.71), leading to an incremental cost-effectiveness ratio of CHF 57,402 per QALY gained.","[{'ForeName': 'Arjun', 'Initials': 'A', 'LastName': 'Bhadhuri', 'Affiliation': 'Institute of Pharmaceutical Medicine (ECPM), University of Basel, Switzerland.'}, {'ForeName': 'Ralph', 'Initials': 'R', 'LastName': 'Insinga', 'Affiliation': 'Merck & Co., Inc., North Wales, PA, USA.'}, {'ForeName': 'Patrik', 'Initials': 'P', 'LastName': 'Guggisberg', 'Affiliation': 'MSD Merck Sharp & Dohme AG, Switzerland.'}, {'ForeName': 'Cédric', 'Initials': 'C', 'LastName': 'Panje', 'Affiliation': 'Department of Radiation Oncology, Kantonsspital St. Gallen, Switzerland.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Schwenkglenks', 'Affiliation': 'Institute of Pharmaceutical Medicine (ECPM), University of Basel, Switzerland.'}]",Swiss medical weekly,['10.4414/smw.2019.20170'] 3113,32041583,Effect of tuberculosis screening and retention interventions on early antiretroviral therapy mortality in Botswana: a stepped-wedge cluster randomized trial.,"BACKGROUND Undiagnosed tuberculosis (TB) remains the most common cause of HIV-related mortality. Xpert MTB/RIF (Xpert) is being rolled out globally to improve TB diagnostic capacity. However, previous Xpert impact trials have reported that health system weaknesses blunted impact of this improved diagnostic tool. During phased Xpert rollout in Botswana, we evaluated the impact of a package of interventions comprising (1) additional support for intensified TB case finding (ICF), (2) active tracing for patients missing clinic appointments to support retention, and (3) Xpert replacing sputum-smear microscopy, on early (6-month) antiretroviral therapy (ART) mortality. METHODS At 22 clinics, ART enrollees > 12 years old were eligible for inclusion in three phases: a retrospective standard of care (SOC), prospective enhanced care (EC), and prospective EC plus Xpert (EC+X) phase. EC and EC+X phases were implemented as a stepped-wedge trial. Participants in the EC phase received SOC plus components 1 (strengthened ICF) and 2 (active tracing) of the intervention package, and participants in the EC+X phase received SOC plus all three intervention package components. Primary and secondary objectives were to compare all-cause 6-month ART mortality between SOC and EC+X and between EC and EC+X phases, respectively. We used adjusted analyses, appropriate for study design, to control for baseline differences in individual-level factors and intra-facility correlation. RESULTS We enrolled 14,963 eligible patients: 8980 in SOC, 1768 in EC, and 4215 in EC+X phases. Median age of ART enrollees was 35 and 64% were female. Median CD4 cell count was lower in SOC than subsequent phases (184/μL in SOC, 246/μL in EC, and 241/μL in EC+X). By 6 months of ART, 461 (5.3%) of SOC, 54 (3.2%) of EC, and 121 (3.0%) of EC+X enrollees had died. Compared with SOC, 6-month mortality was lower in the EC+X phase (adjusted hazard ratio, 0.77; 95% confidence interval, 0.61-0.97, p = 0.029). Compared with EC enrollees, 6-month mortality was similar among EC+X enrollees. CONCLUSIONS Interventions to strengthen ICF and retention were associated with lower early ART mortality. This new evidence highlights the need to strengthen ICF and retention in many similar settings. Similar to other trials, no additional mortality benefit of replacing sputum-smear microscopy with Xpert was observed. TRIAL REGISTRATION Retrospectively registered: ClinicalTrials.gov (NCT02538952).",2020,"Compared with SOC, 6-month mortality was lower in the EC+X phase (adjusted hazard ratio, 0.77; 95% confidence interval, 0.61-0.97, p = 0.029).","['At 22 clinics, ART enrollees >\u200912\u2009years old were eligible for inclusion in three phases: a retrospective standard of care (SOC), prospective enhanced care (EC), and prospective EC plus Xpert (EC+X) phase', '14,963 eligible patients: 8980 in SOC, 1768 in EC, and 4215 in EC+X phases', 'Median age of ART enrollees was 35 and 64% were female']","['package of interventions comprising (1) additional support for intensified TB case finding (ICF), (2) active tracing for patients missing clinic appointments to support retention, and (3) Xpert replacing sputum-smear microscopy, on early (6-month) antiretroviral therapy (ART) mortality', 'tuberculosis screening and retention interventions', 'EC+X phase received SOC plus all three intervention package components']","['6-month mortality', 'Median CD4 cell count', 'TB diagnostic capacity', 'early antiretroviral therapy mortality']","[{'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0298247', 'cui_str': 'indium-ethylenedicysteine'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0165079', 'cui_str': 'IS 35'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C1704710', 'cui_str': 'Package'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C2607943', 'cui_str': 'findings'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C0444186', 'cui_str': 'Smear test'}, {'cui': 'C0026018', 'cui_str': 'Microscopy'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0041296', 'cui_str': 'Mycobacterium tuberculosis Infection'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}]","[{'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}]",14963.0,0.366681,"Compared with SOC, 6-month mortality was lower in the EC+X phase (adjusted hazard ratio, 0.77; 95% confidence interval, 0.61-0.97, p = 0.029).","[{'ForeName': 'Andrew F', 'Initials': 'AF', 'LastName': 'Auld', 'Affiliation': 'Division of Global HIV & TB, Centers for Disease Control and Prevention, Atlanta, USA. aauld@cdc.gov.'}, {'ForeName': 'Tefera', 'Initials': 'T', 'LastName': 'Agizew', 'Affiliation': 'Division of TB Elimination, Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'Anikie', 'Initials': 'A', 'LastName': 'Mathoma', 'Affiliation': 'Division of TB Elimination, Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'Rosanna', 'Initials': 'R', 'LastName': 'Boyd', 'Affiliation': 'Division of TB Elimination, Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Date', 'Affiliation': 'Division of Global HIV & TB, Centers for Disease Control and Prevention, Atlanta, USA.'}, {'ForeName': 'Sherri L', 'Initials': 'SL', 'LastName': 'Pals', 'Affiliation': 'Division of Global HIV & TB, Centers for Disease Control and Prevention, Atlanta, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Serumola', 'Affiliation': 'Division of TB Elimination, Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'Unami', 'Initials': 'U', 'LastName': 'Mathebula', 'Affiliation': 'Division of TB Elimination, Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Alexander', 'Affiliation': 'Division of Global HIV & TB, Centers for Disease Control and Prevention, Atlanta, USA.'}, {'ForeName': 'Tedd V', 'Initials': 'TV', 'LastName': 'Ellerbrock', 'Affiliation': 'Division of Global HIV & TB, Centers for Disease Control and Prevention, Atlanta, USA.'}, {'ForeName': 'Goabaone', 'Initials': 'G', 'LastName': 'Rankgoane-Pono', 'Affiliation': 'Ministry of Health, Gaborone, Botswana.'}, {'ForeName': 'Pontsho', 'Initials': 'P', 'LastName': 'Pono', 'Affiliation': 'Ministry of Health, Gaborone, Botswana.'}, {'ForeName': 'James C', 'Initials': 'JC', 'LastName': 'Shepherd', 'Affiliation': 'Division of TB Elimination, Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Fielding', 'Affiliation': 'TB Centre, London Sch. of Hygiene & Tropical Med, London, UK.'}, {'ForeName': 'Alison D', 'Initials': 'AD', 'LastName': 'Grant', 'Affiliation': 'TB Centre, London Sch. of Hygiene & Tropical Med, London, UK.'}, {'ForeName': 'Alyssa', 'Initials': 'A', 'LastName': 'Finlay', 'Affiliation': 'Division of TB Elimination, Centers for Disease Control and Prevention, Gaborone, Botswana.'}]",BMC medicine,['10.1186/s12916-019-1489-0'] 3114,30611715,A pilot cluster-randomised study to increase sleep duration by decreasing electronic media use at night and caffeine consumption in adolescents.,"OBJECTIVE Bedtime electronic media use and caffeine consumption are risk factors for insufficient sleep and poor sleep quality during adolescence, which are in turn risk factors for mental wellbeing. Our study tested the effectiveness of a brief school-based psychoeducative intervention to primarily increase sleep duration, by decreasing bedtime electronic media use and caffeine consumption. Secondary outcomes included improving sleep quality and difficulties, daytime tiredness, and mental wellbeing. METHOD A pilot cluster-randomised controlled study was conducted involving a 25-min psychoeducative school-based intervention combined with parent information. 352 adolescents from seven schools participated (Intervention Group/IG = 192 students vs. Control Group/CG = 160 students; age: Mean = 15.09 years; SD = 1.65 years; Females = 163). The intervention included information on the importance of sleep and good sleep hygiene habits, particularly emphasizing behavioural rules of avoiding electronic media use at night and evening-time caffeine consumption. A leaflet containing the rules was also sent to parents of IG participants. Baseline and post-intervention sessions were held approximately four weeks apart. RESULTS Multilevel analyses revealed a significant but modest decrease in electronic media use for participants in the IG versus CG, but showed no effect on caffeine consumption or sleep duration. Moreover, the intervention did not impact any secondary outcome. CONCLUSIONS Findings indicate the potential effectiveness of a short and easily administrable intervention to decrease electronic media use at night, which may be incorporated into school curricula and standardised for wider use in primary prevention. However, no further benefits of the intervention were found.",2019,"Multilevel analyses revealed a significant but modest decrease in electronic media use for participants in the IG versus CG, but showed no effect on caffeine consumption or sleep duration.","['Mean\xa0=\xa015.09 years; SD\xa0=\xa01.65 years; Females\xa0=\xa0163', '352 adolescents from seven schools participated (Intervention Group/IG\xa0=\xa0192 students vs. Control Group/CG\xa0=\xa0160 students; age', 'adolescents']","['electronic media use at night and caffeine consumption', '25-min psychoeducative school-based intervention combined with parent information', 'brief school-based psychoeducative intervention']","['sleep quality and difficulties, daytime tiredness, and mental wellbeing', 'caffeine consumption or sleep duration', 'electronic media']","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0449892', 'cui_str': 'Medium used (attribute)'}, {'cui': 'C0240526', 'cui_str': 'Night time (qualifier value)'}, {'cui': 'C0948365', 'cui_str': 'Caffeine consumption'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}]","[{'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0332169', 'cui_str': 'Daytime (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0948365', 'cui_str': 'Caffeine consumption'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0439536', 'cui_str': 'Medium (qualifier value)'}]",352.0,0.0310145,"Multilevel analyses revealed a significant but modest decrease in electronic media use for participants in the IG versus CG, but showed no effect on caffeine consumption or sleep duration.","[{'ForeName': 'Ahuti', 'Initials': 'A', 'LastName': 'Das-Friebel', 'Affiliation': 'University of Warwick, Department of Psychology, Coventry, United Kingdom.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Perkinson-Gloor', 'Affiliation': 'University of Basel, Department of Psychology, Basel, Switzerland.'}, {'ForeName': 'Serge', 'Initials': 'S', 'LastName': 'Brand', 'Affiliation': 'University of Basel, Psychiatric Clinics, Center for Affective, Stress, and Sleep Disorders, Basel, Switzerland; University of Basel, Department of Sport, Exercise and Health, Division of Sport and Psychosocial Health, Basel, Switzerland; Kermanshah University of Medical Sciences (KUMS), Sleep Disorders Research Center, Kermanshah, Iran; Kermanshah University of Medical Sciences (KUMS), Substance Abuse Prevention Research Center, Kermanshah, Iran.'}, {'ForeName': 'Julia F', 'Initials': 'JF', 'LastName': 'Dewald-Kaufmann', 'Affiliation': 'Hochschule Fresenius, University of Applied Sciences, Munich, Germany; Department of Psychiatry and Psychotherapy, University Hospital, Ludwig-Maximilans-University Munich, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Grob', 'Affiliation': 'University of Basel, Department of Psychology, Basel, Switzerland.'}, {'ForeName': 'Dieter', 'Initials': 'D', 'LastName': 'Wolke', 'Affiliation': 'University of Warwick, Department of Psychology, Coventry, United Kingdom.'}, {'ForeName': 'Sakari', 'Initials': 'S', 'LastName': 'Lemola', 'Affiliation': 'University of Warwick, Department of Psychology, Coventry, United Kingdom. Electronic address: s.lemola@warwick.ac.uk.'}]",Sleep medicine,['10.1016/j.sleep.2018.11.010'] 3115,31931025,"A randomised controlled trial to determine patient experience of a magnetostrictive stack scaler as compared to a piezoelectric scaler, in supportive periodontal therapy.","OBJECTIVES To compare the pain/discomfort experienced by patients in supportive periodontal therapy, following treatment with a piezoelectric ultrasonic scaler, designed for use with warmed water irrigation, and a magnetostrictive ultrasonic scaler. METHODS This was a single-centre, randomised, split mouth study with regard to side, and crossover with regard to treatment order. Patients attending general dental practice for supportive periodontal therapy were randomised to receive treatment from one scaler on the left and the other scaler on the right-hand side of the mouth, the left side of the mouth always being treated first. The piezo scaler (Tigon+®) was used with room temperature irrigation for half of the participants (approx 20 °C) and warmed water irrigation (approx 36 °C) for the other half. The magnetostrictive scaler (Cavitron Select SPS 30K®) was used with room temperature irrigation (approx 20 °C) only. Participants rated their pain/discomfort, noise and vibration by VAS scale. RESULTS 140 participants completed the study. Mean VAS scores for all measures were significantly better for the piezo scaler used with warm irrigation as compared to the magnetostrictive scaler p < 0.001. When both scalers were used with room temperature irrigant, there were no significant differences in the VAS scores between scalers (pain/discomfort, p = 0.68; noise p = 0.2; vibration p = 0.85). CONCLUSIONS Participants indicated to statistical significance, less pain/discomfort, noise and vibration when the piezo scaler (Tigon+®) device was used with warmed irrigant, compared to the magnetostrictive scaler (Cavitron Select SPS 30K®). There were no significant differences between the instruments when room temperature irrigant was used. CLINICAL SIGNIFICANCE Regular scaling in supportive periodontal therapy, is essential for maintenance of susceptible patients, however it can be painful due to dentine hypersensitivity deterring patients from attending. Using a piezo scaler with warm water improves patient quality of life and subsequent oral health. This may have positive effects on patient attendance. ISRCTN REGISTERED ISRCTN15573995.",2020,Mean VAS scores for all measures were significantly better for the piezo scaler used with warm irrigation as compared to the magnetostrictive scaler p < 0.001.,"['140 participants completed the study', 'Patients attending general dental practice for supportive periodontal therapy']","['magnetostrictive scaler (Cavitron Select SPS 30K®', 'piezo scaler (Tigon+®', 'supportive periodontal therapy', 'piezoelectric scaler', 'piezoelectric ultrasonic scaler', 'magnetostrictive stack scaler']","['pain/discomfort, noise and vibration by VAS scale', 'Mean VAS scores', 'VAS scores', 'patient quality of life and subsequent oral health', 'pain/discomfort, noise and vibration']","[{'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0017318', 'cui_str': 'General Practice, Dental'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C4255078', 'cui_str': 'SPS'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1456803', 'cui_str': 'Ultrasonics'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0459800', 'cui_str': 'Vibration'}, {'cui': 'C0222045'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0034380'}, {'cui': 'C0029162'}]",140.0,0.0447367,Mean VAS scores for all measures were significantly better for the piezo scaler used with warm irrigation as compared to the magnetostrictive scaler p < 0.001.,"[{'ForeName': 'Sinead', 'Initials': 'S', 'LastName': 'Daly', 'Affiliation': 'Periodontology, Clinical Trials Group, Bristol Dental School, University of Bristol, Lower Maudlin Street, Bristol, BS1 2LY, UK. Electronic address: S.Daly@bristol.ac.uk.'}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Newcombe', 'Affiliation': 'Cardiff University, Cardiff, CF10 3AT, UK. Electronic address: newcombe@cardiff.ac.uk.'}, {'ForeName': 'Nicholas C A', 'Initials': 'NCA', 'LastName': 'Claydon', 'Affiliation': 'Periodontology, Clinical Trials Group, Bristol Dental School, University of Bristol, Lower Maudlin Street, Bristol, BS1 2LY, UK. Electronic address: n.claydon@bristol.ac.uk.'}, {'ForeName': 'Joon', 'Initials': 'J', 'LastName': 'Seong', 'Affiliation': 'Periodontology, Clinical Trials Group, Bristol Dental School, University of Bristol, Lower Maudlin Street, Bristol, BS1 2LY, UK. Electronic address: J.Seong@bristol.ac.uk.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Davies', 'Affiliation': 'Periodontology, Clinical Trials Group, Bristol Dental School, University of Bristol, Lower Maudlin Street, Bristol, BS1 2LY, UK. Electronic address: Maria.Davies@bristol.ac.uk.'}, {'ForeName': 'Nicola X', 'Initials': 'NX', 'LastName': 'West', 'Affiliation': 'Periodontology, Clinical Trials Group, Bristol Dental School, University of Bristol, Lower Maudlin Street, Bristol, BS1 2LY, UK. Electronic address: n.x.west@bristol.ac.uk.'}]",Journal of dentistry,['10.1016/j.jdent.2020.103279'] 3116,31981604,"Comparing the efficacies of two chemo-mechanical caries removal agents (2.25% sodium hypochlorite gel and brix 3000), in caries removal and patient cooperation: A randomized controlled clinical trial.","INTRODUCTION This study compared and evaluated the effectiveness of Brix 3000 and 2.25 % sodium hypochlorite (NaOCl) gel with conventional rotary instrumentation method in caries excavation of primary molars. The null hypothesis: no difference between the two tested chemo-mechanical caries removal (CMCR) agents used in this trial. MATERIALS AND METHODS a randomized controlled clinical trial conducted with 32 children suffering from proximal caries of primary maxillary molars, age ranging between 6 and 9 years old. Subjects were randomly assigned into three groups: Brix 3000, NaOCl gel, and conventional with 10, 12, and 10 teeth in each group, respectively. After isolation of selected teeth, either CMCR agent were applied for two minutes. The application was repeated as needed until a caries-free surface was obtained. The conventional group used low-speed burs to excavate all carious lesions. The time required to obtain a caries-free result for each testing method was recorded. Wong-Baker FACES pain rating scale was used to assess the acceptance of the technique used by the child. RESULTS Conventional treatment required significantly less time for caries removal compared to Brix 3000 (P = .002) and NaOCl gel (P = .000). No significant difference observed between Brix 3000 and NaOCl gel (P = .679). Statistically higher pain scores were observed with conventional treatment compared to both Brix 3000 (P = .000) and NaOCl gel (P = .005). Pain scores were lower with Brix 3000, and NaOCl gel with no significant difference observed between the CMCR agents (p = .690). CONCLUSIONS CMCR agents that are effective in removing the carious dentine of primary teeth without negatively affecting the cooperation of children. CLINICAL SIGNIFICANCE The use of a 2.25 % sodium hypochlorite gel can be an effective and well-tolerated method of removing decay from primary teeth and reduce the trauma associated with conventional rotary caries removal.",2020,"Pain scores were lower with Brix 3000, and NaOCl gel with no significant difference observed between the CMCR agents (p = .690). ","['caries excavation of primary molars', '32 children suffering from proximal caries of primary maxillary molars, age ranging between 6 and 9 years old']","['Chemo-mechanical caries removal agents (2.25% sodium hypochlorite gel and Brix 3000', 'Brix 3000 and 2.25% sodium hypochlorite (NaOCl) gel with conventional rotary instrumentation method', 'chemo-mechanical caries removal (CMCR) agents', 'sodium hypochlorite gel']","['NaOCl gel', 'Pain scores', 'Wong-Baker FACES pain rating scale', 'time for caries removal', 'pain scores']","[{'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0026367', 'cui_str': 'Molar'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}, {'cui': 'C4068875', 'cui_str': '2.25 (qualifier value)'}, {'cui': 'C0037518', 'cui_str': 'Sodium Hypochlorite'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C0470279', 'cui_str': 'Three thousand'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0021632', 'cui_str': 'instrumentation'}, {'cui': 'C0025663', 'cui_str': 'Methods'}]","[{'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0238749', 'cui_str': 'Baker, general (occupation)'}, {'cui': 'C0015468', 'cui_str': 'Face Pain'}, {'cui': 'C0222045'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}]",32.0,0.0267687,"Pain scores were lower with Brix 3000, and NaOCl gel with no significant difference observed between the CMCR agents (p = .690). ","[{'ForeName': 'Muaaz M', 'Initials': 'MM', 'LastName': 'Alkhouli', 'Affiliation': 'Faculty of Dentistry, Damascus University, Damascus, Syria.'}, {'ForeName': 'Salma F', 'Initials': 'SF', 'LastName': 'Al Nesser', 'Affiliation': 'Faculty of Dentistry, Damascus University, Damascus, Syria.'}, {'ForeName': 'Nada G', 'Initials': 'NG', 'LastName': 'Bshara', 'Affiliation': 'Faculty of Dentistry, Damascus University, Damascus, Syria.'}, {'ForeName': 'Awab N', 'Initials': 'AN', 'LastName': 'AlMidani', 'Affiliation': 'Faculty of Dentistry, Damascus University, Damascus, Syria.'}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Comisi', 'Affiliation': 'Department of Oral Rehabilitation. Medical University of South Carolina, James B. Edwards College of Dental Medicine, Charleston, SC USA. Electronic address: comisi@musc.edu.'}]",Journal of dentistry,['10.1016/j.jdent.2020.103280'] 3117,32055041,The effect of zoledronic acid on attenuation of bone loss at the hip and knee following acute traumatic spinal cord injury: a randomized-controlled study.,"STUDY DESIGN Randomized double blind, placebo-controlled trial. OBJECTIVES To examine the effect of early intravenous zoledronic acid (ZA) on bone markers and areal bone mineral density (aBMD) in persons with acute ASIA Impairment Scale (AIS) A traumatic spinal cord injury (SCI). SETTING Two inpatient rehabilitation units. METHODS Thirteen men, 2 women, aged 19-65, C4-T10 AIS A SCI, received 5 mg intravenous ZA vs. placebo 12-21 days post injury. Markers of bone formation (procollagen N-1 terminal propeptide [P1NP]), bone resorption (serum C-telopeptide [CTX]), and aBMD by dual-energy X-ray absorptiometry (DXA) for hip (femur-proximal, intertrochanteric, neck), and knee (distal femur, proximal tibia) were obtained at baseline, 2 weeks post infusion (P1NP, CTX only), 4 and 12 months post injury. RESULTS P1NP remained unchanged, while CTX decreased in ZA but increased in controls at 2 weeks (mean difference = -97%, p < 0.01), 4 months (mean difference = -54%, p < 0.05), but not 12 months (mean difference = 3%, p = 0.23). Changes in aBMD at the hip favored ZA at 4 months (mean difference 10.3-14.1%, p < 0.01) and 12 months (mean difference 10.8-13.1%, p < 0.02). At 4 months, changes in aBMD favored ZA at the distal femur (mean difference 6.0%, 95% CI: 0.7-11.2, p < 0.03) but not proximal tibia (mean difference 8.3%, 95% CI: -6.9 to 23.6, p < 0.23). Both groups declined in aBMD at 12 months, with no between group differences. CONCLUSION ZA administered ≤21 days of complete traumatic SCI maintains aBMD at the hip and distal femur at 4 months post injury. This effect is partially maintained at 12 months.",2020,"Changes in aBMD at the hip favored ZA at 4 months (mean difference 10.3-14.1%, p < 0.01) and 12 months (mean difference 10.8-13.1%, p < 0.02).","['acute traumatic spinal cord injury', 'persons with acute ASIA Impairment Scale (AIS', 'Two inpatient rehabilitation units', '12-21 days post injury', 'Thirteen men, 2 women, aged 19-65, C4-T10 AIS A SCI, received']","['ZA', 'placebo', '5\u2009mg intravenous ZA vs. placebo', 'zoledronic acid', 'zoledronic acid (ZA']","['Markers of bone formation (procollagen N-1 terminal propeptide [P1NP]), bone resorption (serum C-telopeptide [CTX]), and aBMD by dual-energy X-ray absorptiometry (DXA) for hip (femur-proximal, intertrochanteric, neck), and knee (distal femur, proximal tibia', 'proximal tibia', 'bone markers and areal bone mineral density (aBMD', 'changes in aBMD', 'CTX decreased in ZA', 'bone loss', 'aBMD', 'Changes in aBMD']","[{'cui': 'C0332663', 'cui_str': 'Traumatic (qualifier value)'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0003980', 'cui_str': 'Asia'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0222045'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0257685', 'cui_str': 'zoledronic acid'}]","[{'cui': 'C0029433', 'cui_str': 'Ossification'}, {'cui': 'C0033235', 'cui_str': 'Procollagen'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0005974', 'cui_str': 'Osteoclastic Bone Loss'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0631180', 'cui_str': 'C-telopeptide'}, {'cui': 'C1510486', 'cui_str': 'Dual X-Ray Absorptiometry'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0015811', 'cui_str': 'Femur'}, {'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C0027536', 'cui_str': 'Necking (finding)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0205108', 'cui_str': 'Distal (qualifier value)'}, {'cui': 'C0588198', 'cui_str': 'Bone structure of proximal tibia (body structure)'}, {'cui': 'C0181734', 'cui_str': 'Bone marker'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}]",,0.482131,"Changes in aBMD at the hip favored ZA at 4 months (mean difference 10.3-14.1%, p < 0.01) and 12 months (mean difference 10.8-13.1%, p < 0.02).","[{'ForeName': 'Christina V', 'Initials': 'CV', 'LastName': 'Oleson', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Case Western Reserve University, Cleveland, OH, USA. christinavoleson@msn.com.'}, {'ForeName': 'Ralph J', 'Initials': 'RJ', 'LastName': 'Marino', 'Affiliation': 'Department of Rehabilitation Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Christopher S', 'Initials': 'CS', 'LastName': 'Formal', 'Affiliation': 'Department of Rehabilitation Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Modlesky', 'Affiliation': 'Department of Kinesiology, University of Georgia, Athens, GA, USA.'}, {'ForeName': 'Benjamin E', 'Initials': 'BE', 'LastName': 'Leiby', 'Affiliation': 'Department of Pharmacology and Experimental Therapeutics, Division of Biostatistics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.'}]",Spinal cord,['10.1038/s41393-020-0431-9'] 3118,30448089,Neutral supporting mandibular advancement device with tongue bead for passive myofunctional therapy: a long term follow-up study.,"BACKGROUNDS Myofunctional therapy has been reported to be a valid adjunct treatment to OSA, but compliance was mentioned as an issue. We performed a prospective study on age matched randomized children submitted to myofunctional therapy (MFT) or to a functional device used during sleep (passive MFT). METHODS 110 children 4 to 16 were recruited for the study, 54 children were in the MFT group [A] while 56 were in the ""nocturnal device"" group [B]. Clinical evaluation, polysomnography and cephalometric X-Rays were performed at baseline, 6 months and 12 months, with clinical follow-up at 3 months. RESULTS MFT group show very important absence of compliance, at six months only 23 subjects participated and only 10/23 had been compliant with treatment. None came back for research investigation at 12 months. 48/56 of passive MFT children ended the research protocol at 12 months. Comparison of baseline to 6 and 12 months data showed that all children with passive MFT improved (PSG and cephalometrics) and had nasal breathing during sleep at 1 year, and no negative effect of device were noted. The 10 children compliant with MFT showed clear improvement of sleep related breathing with also changes at cephalometric -X-rays. CONCLUSION Compliance is a major problem of MFT, and MFT will have to take into consideration the absolute need to have continuous parental involvement in the procedure. Passive MFT gives many more positive results, but potential negative effects of device on other jaw will have to be continuously evaluated.",2019,"Comparison of baseline to 6 and 12 months data showed that all children with passive MFT improved (PSG and cephalometrics) and had nasal breathing during sleep at 1 year, and no negative effect of device were noted.","['10 children compliant with', '110 children 4 to 16 were recruited for the study, 54 children were in the MFT group [A] while 56 were in the ""nocturnal device"" group [B']","['myofunctional therapy (MFT) or to a functional device used during sleep (passive MFT', 'MFT', 'Neutral supporting mandibular advancement device with tongue bead for passive myofunctional therapy']","['passive MFT improved (PSG and cephalometrics) and had nasal breathing during sleep', 'sleep related breathing']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0566588', 'cui_str': 'Compliant (qualifier value)'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0240526', 'cui_str': 'Night time (qualifier value)'}, {'cui': 'C0220819', 'cui_str': 'devices'}]","[{'cui': 'C0600516', 'cui_str': 'Orofacial Myotherapy'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C1298904', 'cui_str': 'Device used'}, {'cui': 'C0587116', 'cui_str': 'During sleep (qualifier value)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0376461', 'cui_str': 'Mandibular Advancement'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0040408', 'cui_str': 'Tongue'}]","[{'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C4520890', 'cui_str': 'Nasal'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}, {'cui': 'C0587116', 'cui_str': 'During sleep (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}]",54.0,0.0289959,"Comparison of baseline to 6 and 12 months data showed that all children with passive MFT improved (PSG and cephalometrics) and had nasal breathing during sleep at 1 year, and no negative effect of device were noted.","[{'ForeName': 'Yu-Shu', 'Initials': 'YS', 'LastName': 'Huang', 'Affiliation': 'Department of Child Psychiatry and Sleep Center, Chang Gung Memorial Hospital and College of Medicine, Taoyuan, Taiwan; Department of Craniofacial Research Center and Sleep Center, Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan.'}, {'ForeName': 'Li-Chuan', 'Initials': 'LC', 'LastName': 'Chuang', 'Affiliation': 'Department of Pediatric Dentistry, Chang Gung Memorial Hospital and College of Medicine, Taoyuan, Taiwan.'}, {'ForeName': 'Michèle', 'Initials': 'M', 'LastName': 'Hervy-Auboiron', 'Affiliation': 'Orthodontic Institute, Noisy-Lesec, France.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Paiva', 'Affiliation': 'Neurophysiology and Sleep Medicine, University of Lisbon, Portugal.'}, {'ForeName': 'Cheng-Hui', 'Initials': 'CH', 'LastName': 'Lin', 'Affiliation': 'Department of Craniofacial Research Center and Sleep Center, Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Guilleminault', 'Affiliation': 'Stanford University Sleep Medicine Division, Stanford, CA, USA. Electronic address: cguil@stanford.edu.'}]",Sleep medicine,['10.1016/j.sleep.2018.09.013'] 3119,32039864,The effect of educational intervention on the knowledge and attitude of intensive care nurses in the prevention of pressure ulcers.,"BACKGROUND Pressure ulcers can cause disability, which can lead to a default in patients' safety and results in frequent complications for patients. OBJECTIVES This study aimed to determine the effect of educational intervention on nurses' knowledge and attitude in preventing pressure ulcers. METHODS In this study, 67 nurses of ICU wards at Ilam University of Medical Sciences were randomly assigned to the experimental or control group. Data collection tools included the demographic characteristics questionnaire, the Pieper Pressure Ulcer Knowledge test (PUKT) and the Attitude toward Pressure Ulcer tool (APuP). In the experimental group, the nurses were allocated into groups of four-five persons and for each group four face-to-face training sessions and two virtual training sessions by means of educational videos on bed sores were performed. Gathered data were analyzed using SPSS software version 16, and descriptive and analytical tests were performed. RESULTS PUKT questionnaire score in the experimental group improved from 15.68 (3.42) to 29.75 (12.33) (P = 0.000), while in the control group it was 16.40 (3.13) and 17.54 (6.62) before intervention, which was not significant (P > 0.05). Furthermore, the APUP questionnaire score in the experimental group improved from 27.12 (2.13) to 39.37 (3.21) (P = 0.000), while in the control group it was 27.65 (1.71) and 28.37 (5.00) before intervention, which was not significant (P > 0.05). CONCLUSIONS Since educational intervention improved the knowledge and attitude of nurses in preventing pressure ulcers, it is required to conduct appropriate educational interventions to improve their knowledge and attitude.",2020,"RESULTS PUKT questionnaire score in the experimental group improved from 15.68 (3.42) to 29.75 (12.33)",['67 nurses of ICU wards at Ilam University of Medical Sciences'],"['virtual training sessions by means of educational videos', 'educational intervention']","['APUP questionnaire score', 'PUKT questionnaire score', 'questionnaires of demographic characteristics, Pieper Pressure Ulcer Knowledge test (PUKT) and Attitude toward Pressure Ulcer tool (APuP']","[{'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}]","[{'cui': 'C0050822', 'cui_str': 'ApUp'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0011127', 'cui_str': 'Pressure Ulcer'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0336791', 'cui_str': 'Tool, device (physical object)'}]",67.0,0.0152738,"RESULTS PUKT questionnaire score in the experimental group improved from 15.68 (3.42) to 29.75 (12.33)","[{'ForeName': 'Mohamad', 'Initials': 'M', 'LastName': 'Karimian', 'Affiliation': 'Assistant Professor of Vascular Surgery, Ilam University of Medical Sciences, Ilam, Iran.'}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Khalighi', 'Affiliation': 'Department of Anaesthesiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.'}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Salimi', 'Affiliation': 'Department of Nursing, Faculty of Nursing and Midwifery, Ilam University of Medical Sciences, Ilam, Iran.'}, {'ForeName': 'Milad', 'Initials': 'M', 'LastName': 'Borji', 'Affiliation': 'Department of Nursing, Faculty of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Asma', 'Initials': 'A', 'LastName': 'Tarjoman', 'Affiliation': 'Student Research Committee, Department of Nursing, Faculty of Nursing and Midwifery, Ilam University of Medical Sciences, Ilam, Iran.'}, {'ForeName': 'Yosof', 'Initials': 'Y', 'LastName': 'Mahmoudi', 'Affiliation': 'Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}]",The International journal of risk & safety in medicine,['10.3233/JRS-191038'] 3120,32043986,"Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.","BACKGROUND There is no proven specific pharmacological treatment for patients with the acute respiratory distress syndrome (ARDS). The efficacy of corticosteroids in ARDS remains controversial. We aimed to assess the effects of dexamethasone in ARDS, which might change pulmonary and systemic inflammation and result in a decrease in duration of mechanical ventilation and mortality. METHODS We did a multicentre, randomised controlled trial in a network of 17 intensive care units (ICUs) in teaching hospitals across Spain in patients with established moderate-to-severe ARDS (defined by a ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen of 200 mm Hg or less assessed with a positive end-expiratory pressure of 10 cm H 2 O or more and FiO 2 of 0·5 or more at 24 h after ARDS onset). Patients with brain death, terminal-stage disease, or receiving corticosteroids or immunosuppressive drugs were excluded. Eligible patients were randomly assigned based on balanced treatment assignments with a computerised randomisation allocation sequence using blocks of 10 opaque, sealed envelopes to receive immediate treatment with dexamethasone or continued routine intensive care (control group). Patients in the dexamethasone group received an intravenous dose of 20 mg once daily from day 1 to day 5, which was reduced to 10 mg once daily from day 6 to day 10. Patients in both groups were ventilated with lung-protective mechanical ventilation. Allocation concealment was maintained at all sites during the trial. Primary outcome was the number of ventilator-free days at 28 days, defined as the number of days alive and free from mechanical ventilation from day of randomisation to day 28. Secondary outcome was all-cause mortality 60 days after randomisation. All analyses were done according to the intention-to-treat principle. This study is registered with ClinicalTrials.gov, NCT01731795. FINDINGS Between March 28, 2013, and Dec 31, 2018, we enrolled 277 patients and randomly assigned 139 patients to the dexamethasone group and 138 to the control group. The trial was stopped by the data safety monitoring board due to low enrolment rate after enrolling more than 88% (277/314) of the planned sample size. The mean number of ventilator-free days was higher in the dexamethasone group than in the control group (between-group difference 4·8 days [95% CI 2·57 to 7·03]; p<0·0001). At 60 days, 29 (21%) patients in the dexamethasone group and 50 (36%) patients in the control group had died (between-group difference -15·3% [-25·9 to -4·9]; p=0·0047). The proportion of adverse events did not differ significantly between the dexamethasone group and control group. The most common adverse events were hyperglycaemia in the ICU (105 [76%] patients in the dexamethasone group vs 97 [70%] patients in the control group), new infections in the ICU (eg, pneumonia or sepsis; 33 [24%] vs 35 [25%]), and barotrauma (14 [10%] vs 10 [7%]). INTERPRETATION Early administration of dexamethasone could reduce duration of mechanical ventilation and overall mortality in patients with established moderate-to-severe ARDS. FUNDING Fundación Mutua Madrileña, Instituto de Salud Carlos III, The European Regional Development's Funds, Asociación Científica Pulmón y Ventilación Mecánica.",2020,The mean number of ventilator-free days was higher in the dexamethasone group than in the control group (between-group difference 4·8 days [95% CI 2·57 to 7·03]; p<0·0001).,"['patients with established moderate-to-severe ARDS', 'Patients with brain death, terminal-stage disease, or receiving corticosteroids or immunosuppressive drugs were excluded', 'acute respiratory distress syndrome', 'Eligible patients', '17 intensive care units (ICUs) in teaching hospitals across Spain in patients with established moderate-to-severe ARDS (defined by a ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen of 200 mm Hg or less assessed with a positive end-expiratory pressure of 10 cm H 2 O or more and FiO 2 of 0·5 or more at 24 h after ARDS onset', 'patients with the acute respiratory distress syndrome (ARDS', 'Between March 28, 2013, and Dec 31, 2018, we enrolled 277 patients and randomly assigned 139 patients to the']","['dexamethasone', 'Dexamethasone', 'corticosteroids', 'ventilated with lung-protective mechanical ventilation', 'dexamethasone or continued routine intensive care (control group']","['duration of mechanical ventilation and overall mortality', 'barotrauma', 'duration of mechanical ventilation and mortality', 'number of ventilator-free days at 28 days, defined as the number of days alive and free from mechanical ventilation', 'died', 'proportion of adverse events', 'mean number of ventilator-free days']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0035222', 'cui_str': 'ARDS, Human'}, {'cui': 'C0006110', 'cui_str': 'Brain Dead'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0020027', 'cui_str': 'Teaching Hospitals'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0030604', 'cui_str': 'Partial Pressure'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0428167', 'cui_str': 'FIO2'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3494516', 'cui_str': 'Positive end expiratory pressure (observable entity)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0085559'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0460136', 'cui_str': 'Barotrauma mechanism (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0087153', 'cui_str': 'Ventilators'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C2584946', 'cui_str': 'Alive'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",277.0,0.3806,The mean number of ventilator-free days was higher in the dexamethasone group than in the control group (between-group difference 4·8 days [95% CI 2·57 to 7·03]; p<0·0001).,"[{'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Villar', 'Affiliation': ""Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; Multidisciplinary Organ Dysfunction Evaluation Research Network, Research Unit, Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain; Keenan Research Center for Biomedical Science at the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, ON, Canada. Electronic address: jesus.villar54@gmail.com.""}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Ferrando', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; Department of Anesthesiology & Critical Care, Hospital Clinic, Barcelona, Spain; Department of Anesthesiology, Hospital Clínico Universitario de Valencia, Valencia, Spain.'}, {'ForeName': 'Domingo', 'Initials': 'D', 'LastName': 'Martínez', 'Affiliation': 'Intensive Care Unit, Hospital Virgen de la Arrixaca, Murcia, Spain.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Ambrós', 'Affiliation': 'Intensive Care Unit, Hospital General de Ciudad Real, Ciudad Real, Spain.'}, {'ForeName': 'Tomás', 'Initials': 'T', 'LastName': 'Muñoz', 'Affiliation': 'Intensive Care Unit, Hospital Universitario de Cruces, Barakaldo, Spain.'}, {'ForeName': 'Juan A', 'Initials': 'JA', 'LastName': 'Soler', 'Affiliation': 'Intensive Care Unit, Hospital Virgen de la Arrixaca, Murcia, Spain.'}, {'ForeName': 'Gerardo', 'Initials': 'G', 'LastName': 'Aguilar', 'Affiliation': 'Department of Anesthesiology, Hospital Clínico Universitario de Valencia, Valencia, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Alba', 'Affiliation': 'Intensive Care Unit, Hospital Nuestra Señora del Prado, Toledo, Spain.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'González-Higueras', 'Affiliation': 'Intensive Care Unit, Hospital Virgen de La Luz, Cuenca, Spain.'}, {'ForeName': 'Luís A', 'Initials': 'LA', 'LastName': 'Conesa', 'Affiliation': 'Intensive Care Unit, Hospital Virgen de la Arrixaca, Murcia, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Martín-Rodríguez', 'Affiliation': 'Intensive Care Unit, Hospital General de Ciudad Real, Ciudad Real, Spain.'}, {'ForeName': 'Francisco J', 'Initials': 'FJ', 'LastName': 'Díaz-Domínguez', 'Affiliation': 'Intensive Care Unit, Complejo Universitario Asistencial de León, León, Spain.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Serna-Grande', 'Affiliation': 'Intensive Care Unit, Hospital Universitario de Cruces, Barakaldo, Spain.'}, {'ForeName': 'Rosana', 'Initials': 'R', 'LastName': 'Rivas', 'Affiliation': 'Intensive Care Unit, Hospital Galdakao-Usansolo, Usansolo, Spain.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Ferreres', 'Affiliation': 'Intensive Care Unit, Hospital Clínico Universitario, Valencia, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Belda', 'Affiliation': 'Department of Anesthesiology, Hospital Clínico Universitario de Valencia, Valencia, Spain.'}, {'ForeName': 'Lucía', 'Initials': 'L', 'LastName': 'Capilla', 'Affiliation': 'Intensive Care Medicine, Hospital Universitario Morales Meseguer, Murcia, Spain; Intensive Care Unit, Hospital General Universitario Rafael Méndez, Lorca, Murcia, Spain.'}, {'ForeName': 'Alec', 'Initials': 'A', 'LastName': 'Tallet', 'Affiliation': 'Intensive Care Unit, Hospital General de Segovia, Segovia, Spain.'}, {'ForeName': 'José M', 'Initials': 'JM', 'LastName': 'Añón', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; Intensive Care Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.'}, {'ForeName': 'Rosa L', 'Initials': 'RL', 'LastName': 'Fernández', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; Multidisciplinary Organ Dysfunction Evaluation Research Network, Research Unit, Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain.'}, {'ForeName': 'Jesús M', 'Initials': 'JM', 'LastName': 'González-Martín', 'Affiliation': 'Biostatistics Research Unit, Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(19)30417-5'] 3121,32024498,"Influence of ozonized water on pain, oedema, and trismus during impacted third molar surgery: a randomized, triple blind clinical trial.","BACKGROUND This study aimed to evaluate the efficacy of ozonized water on pain, oedema and trismus after impacted third molar mandibular surgeries when compared to double distilled water. A randomized triple blind trial was conducted. METHODS Patients with third molars class II-B of Pell-Gregory were included, and surgical extraction was performed. Irrigation was done with ozonized (group 1) or double distilled water (group 2). The type of irrigation and the side to be operated were randomized. Neither the patients nor the operator or evaluator were aware of the irrigation solution. Pain, oedema and trismus were evaluated at baseline, 24-h, 48-h, 72-h and 7-days after treatment. The data were evaluated by Friedman, Wilcoxon, Mann-Whitney tests, and size effect. RESULTS It was included 8 men and 12 women, with a mean age of 20.9y.o. The initial pain mean was 7.94 (±12.81) (group 1) and 5.50 (±9.12) (group 2) (p > 0,05). There was a statistically significant reduction of pain, oedema and trismus in intragroup analysis (p < 0.05). There was no statistically significant difference (p > 0.05) when comparing the oedema and trismus between groups. The size effect ranged from small (0.23) to large (1.29). CONCLUSIONS It was concluded that ozonized water was compatible as irrigation method, not inferior to double distilled water, and had satisfactory effects on management of pain, oedema and trismus after surgical removal of the third molar. TRIAL REGISTRATION This clinical trial was registered in ClinicalTrials.gov NCT03501225 on April 18, 2018.",2020,"There was a statistically significant reduction of pain, oedema and trismus in intragroup analysis (p < 0.05).","['It was included 8 men and 12 women, with a mean age of 20.9y.o', 'Patients with third molars class II-B of Pell-Gregory were included, and surgical extraction was performed', 'during impacted third molar surgery']","['ozonized (group 1) or double distilled water', 'ozonized water']","['initial pain mean', 'Pain, oedema and trismus', 'oedema and trismus', 'pain, oedema, and trismus', 'pain, oedema and trismus']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0026369', 'cui_str': 'Tooth, Wisdom'}, {'cui': 'C0441886', 'cui_str': 'Class 2 (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1293139', 'cui_str': 'Surgical extraction'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0790233', 'cui_str': 'Distilled water'}, {'cui': 'C0043047', 'cui_str': 'Water'}]","[{'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0013604', 'cui_str': 'Hydrops'}, {'cui': 'C0041105', 'cui_str': 'Trismus'}]",,0.271193,"There was a statistically significant reduction of pain, oedema and trismus in intragroup analysis (p < 0.05).","[{'ForeName': 'José Cristiano Ramos', 'Initials': 'JCR', 'LastName': 'Glória', 'Affiliation': 'Departament of Dentistry, Faculty of Biologic Sciences and Health, Federal University of Jequitinhonha and Mucuri Valleys, Rua da Glória, 187, Centro, Diamantina, Minas Gerais, Brazil.'}, {'ForeName': 'Dhelfeson Willya', 'Initials': 'DW', 'LastName': 'Douglas-de-Oliveira', 'Affiliation': 'Departament of Dentistry, Faculty of Biologic Sciences and Health, Federal University of Jequitinhonha and Mucuri Valleys, Rua da Glória, 187, Centro, Diamantina, Minas Gerais, Brazil. dhelfeson@hotmail.com.'}, {'ForeName': 'Larissa Doalla Almeida', 'Initials': 'LDA', 'LastName': 'E Silva', 'Affiliation': 'Departament of Dentistry, Faculty of Biologic Sciences and Health, Federal University of Jequitinhonha and Mucuri Valleys, Rua da Glória, 187, Centro, Diamantina, Minas Gerais, Brazil.'}, {'ForeName': 'Saulo Gabriel Moreira', 'Initials': 'SGM', 'LastName': 'Falci', 'Affiliation': 'Departament of Dentistry, Faculty of Biologic Sciences and Health, Federal University of Jequitinhonha and Mucuri Valleys, Rua da Glória, 187, Centro, Diamantina, Minas Gerais, Brazil.'}, {'ForeName': 'Cássio Roberto Rocha', 'Initials': 'CRR', 'LastName': 'Dos Santos', 'Affiliation': 'Departament of Dentistry, Faculty of Biologic Sciences and Health, Federal University of Jequitinhonha and Mucuri Valleys, Rua da Glória, 187, Centro, Diamantina, Minas Gerais, Brazil.'}]",BMC oral health,['10.1186/s12903-020-1029-5'] 3122,31642408,Music Therapy Enhances Executive Functions and Prefrontal Structural Neuroplasticity after Traumatic Brain Injury: Evidence from a Randomized Controlled Trial.,"Traumatic brain injury (TBI) causes lifelong cognitive deficits, particularly impairments of executive functioning (EF). Musical training and music-based rehabilitation have been shown to enhance cognitive functioning and neuroplasticity, but the potential rehabilitative effects of music in TBI are still largely unknown. The aim of the present crossover randomized controlled trial (RCT) was to determine the clinical efficacy of music therapy on cognitive functioning in TBI and to explore its neural basis. Using an AB/BA design, 40 patients with moderate or severe TBI were randomized to receive a 3-month neurological music therapy intervention either during the first (AB, n  = 20) or second (BA, n  = 20) half of a 6-month follow-up period. Neuropsychological and motor testing and magnetic resonance imaging (MRI) were performed at baseline and at the 3-month and 6-month stage. Thirty-nine subjects who participated in baseline measurement were included in an intention-to-treat analysis using multiple imputation. Results showed that general EF (as indicated by the Frontal Assessment Battery [FAB]) and set shifting improved more in the AB group than in the BA group over the first 3-month period and the effect on general EF was maintained in the 6-month follow-up. Voxel-based morphometry (VBM) analysis of the structural MRI data indicated that gray matter volume (GMV) in the right inferior frontal gyrus (IFG) increased significantly in both groups during the intervention versus control period, which also correlated with cognitive improvement in set shifting. These findings suggest that neurological music therapy enhances EF and induces fine-grained neuroanatomical changes in prefrontal areas.",2020,Results showed that general EF (as indicated by the Frontal Assessment Battery) and set shifting improved more in the AB group than in the BA group over the first 3-month period and the effect on general EF was maintained in the 6-month follow-up.,"['40 patients with moderate or severe TBI', 'after Traumatic Brain Injury', '39 subjects who participated in baseline measurement']","['Musical training and music-based rehabilitation', 'Music Therapy', 'music therapy', 'neurological music therapy intervention']","['general EF', 'grey matter volume (GMV) in the right inferior frontal gyrus (IFG', 'Executive Functions and Prefrontal Structural Neuroplasticity', 'Neuropsychological and motor testing and MRI scanning']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0876926', 'cui_str': 'TBI (Traumatic Brain Injury)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0026868', 'cui_str': 'Music Therapy'}, {'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0018220', 'cui_str': 'Gray Matter'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0152298', 'cui_str': 'Gyrus Frontalis Inferior'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0027880', 'cui_str': 'Neural Plasticity'}, {'cui': 'C0430740', 'cui_str': 'Motor testing'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}]",39.0,0.174886,Results showed that general EF (as indicated by the Frontal Assessment Battery) and set shifting improved more in the AB group than in the BA group over the first 3-month period and the effect on general EF was maintained in the 6-month follow-up.,"[{'ForeName': 'Sini-Tuuli', 'Initials': 'ST', 'LastName': 'Siponkoski', 'Affiliation': 'Department of Psychology and Logopedics, Cognitive Brain Research Unit, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Noelia', 'Initials': 'N', 'LastName': 'Martínez-Molina', 'Affiliation': 'Department of Psychology and Logopedics, Cognitive Brain Research Unit, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Kuusela', 'Affiliation': 'HUS Medical Imaging Center, Department of Radiology, Helsinki Central University Hospital and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Sari', 'Initials': 'S', 'LastName': 'Laitinen', 'Affiliation': 'Espoo Hospital, Espoo, Finland.'}, {'ForeName': 'Milla', 'Initials': 'M', 'LastName': 'Holma', 'Affiliation': 'Musiikkiterapiaosuuskunta InstruMental (Music Therapy Cooperative InstruMental), Helsinki, Finland.'}, {'ForeName': 'Mirja', 'Initials': 'M', 'LastName': 'Ahlfors', 'Affiliation': 'Private music therapy entrepreneur, Finland.'}, {'ForeName': 'Päivi', 'Initials': 'P', 'LastName': 'Jordan-Kilkki', 'Affiliation': 'Dialogic Partner Oy, Espoo, Finland.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Ala-Kauhaluoma', 'Affiliation': 'Ludus Oy Tutkimus- ja kuntoutuspalvelut (Assessment and Intervention Services), Helsinki, Finland.'}, {'ForeName': 'Susanna', 'Initials': 'S', 'LastName': 'Melkas', 'Affiliation': 'Department of Neurology and Brain Injury Outpatient Clinic, Helsinki University Central Hospital, Helsinki, Finland.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Pekkola', 'Affiliation': 'HUS Medical Imaging Center, Department of Radiology, Helsinki Central University Hospital and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Rodriguez-Fornells', 'Affiliation': ""Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Matti', 'Initials': 'M', 'LastName': 'Laine', 'Affiliation': 'Department of Psychology, Åbo Akademi University, Turku, Finland.'}, {'ForeName': 'Aarne', 'Initials': 'A', 'LastName': 'Ylinen', 'Affiliation': 'Department of Neurology and Brain Injury Outpatient Clinic, Helsinki University Central Hospital, Helsinki, Finland.'}, {'ForeName': 'Pekka', 'Initials': 'P', 'LastName': 'Rantanen', 'Affiliation': 'Kanta-Häme Central Hospital, Hämeenlinna, Finland.'}, {'ForeName': 'Sanna', 'Initials': 'S', 'LastName': 'Koskinen', 'Affiliation': 'Department of Psychology and Logopedics, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Jari', 'Initials': 'J', 'LastName': 'Lipsanen', 'Affiliation': 'Department of Psychology and Logopedics, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Teppo', 'Initials': 'T', 'LastName': 'Särkämö', 'Affiliation': 'Department of Psychology and Logopedics, Cognitive Brain Research Unit, University of Helsinki, Helsinki, Finland.'}]",Journal of neurotrauma,['10.1089/neu.2019.6413'] 3123,31599955,Adiposity and Fat-Free Mass of Children Born with Very Low Birth Weight Do Not Differ in Children Fed Supplemental Donor Milk Compared with Those Fed Preterm Formula.,"BACKGROUND Many mothers of very-low-birth-weight (VLBW) infants (<1500 g) are unable to provide sufficient breast milk, and supplemental pasteurized donor human milk (donor milk) or preterm formula is required. The composition of donor milk differs from that of mother's milk and infants fed with donor milk often exhibit slower growth during hospitalization. The long-term impact of nutrient-enriched donor milk on growth, body composition, or blood pressure is unknown. OBJECTIVE We aimed to determine the effects of nutrient-enriched donor milk compared with preterm formula on growth, body composition, and blood pressure of children born preterm and with VLBW. Associations with in-hospital mother's milk intake were explored. METHODS This study was a follow-up of children at 5.5-y of age who participated in a randomized controlled trial evaluating the effect of nutrient-enriched donor milk (commencing at ≥120 mL·kg-1·d-1) or preterm formula fed as a supplement when mother's milk was unavailable. The trial intervention lasted 90 d or until hospital discharge, whichever occurred first. In this follow-up investigation, differences in total body fat percentage determined by using air displacement plethysmography (primary outcome), fat-free mass, skinfold thickness, waist circumference, BMI z scores, and blood pressure] were evaluated using linear regressions. RESULTS Of 316 surviving infants from the earlier trial, 158 (50%) participated in the current study (53% male). Mean ± SD birth weight and gestational age were 1013 ± 264 g and 27.9 ± 2.5 wk. The median (IQR) intervention period was 67.5 d (52.0-91.0 d). Mean ± SD age and BMI z score at follow-up were 5.7 ± 0.2 y and -0.3 ± 1.2. Supplemental nutrient-enriched donor milk, compared to preterm formula, was not associated with growth, body composition, or blood pressure. In-hospital mother's milk intake was positively associated with height z score at 5.5 y (β: 0.07; 95% CI: 0.004, 0.1; P = 0.04). CONCLUSIONS Supplemental nutrient-enriched donor milk and preterm formula during initial hospitalization results in comparable long-term growth and body composition in young children born VLBW. This trial was registered at clinicaltrials.gov as NCT02759809 and at isrctn.com as ISRCTN35317141.",2020,"Supplemental nutrient-enriched donor milk, compared to preterm formula, was not associated with growth, body composition, or blood pressure.","['Many mothers of very-low-birth-weight (VLBW) infants (<1500 g', 'SD birth weight and gestational age were 1013\xa0±', 'children at 5.5-y of age who participated', 'children born preterm and with VLBW', 'Children Born with Very Low Birth Weight', 'Children Fed Supplemental Donor Milk', 'young children born VLBW', '316 surviving infants from the earlier trial, 158 (50%) participated in the current study (53% male']","['Supplemental nutrient-enriched donor milk', 'nutrient-enriched donor milk compared with preterm formula', 'nutrient-enriched donor milk (commencing at ≥120 mL·kg-1·d-1) or preterm formula fed', 'Supplemental nutrient-enriched donor milk and preterm formula', 'nutrient-enriched donor milk']","['total body fat percentage determined by using air displacement plethysmography (primary outcome), fat-free mass, skinfold thickness, waist circumference, BMI z scores, and blood pressure', 'Adiposity and Fat-Free Mass', 'Mean\xa0±\xa0SD age and BMI z score', 'Mean\xa0±', 'height z score', 'growth, body composition, and blood pressure', 'growth, body composition, or blood pressure']","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0282667', 'cui_str': 'Infant, Very Low Birth Weight'}, {'cui': 'C4517582', 'cui_str': '1500'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C3844008', 'cui_str': '5.5'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0282666', 'cui_str': 'Very Low Birth Weight'}, {'cui': 'C2987508', 'cui_str': 'Feeding (observable entity)'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0450356', 'cui_str': '316'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0026131', 'cui_str': 'Milk'}]","[{'cui': 'C0424677', 'cui_str': 'Total body fat (observable entity)'}, {'cui': 'C0521095', 'cui_str': 'Determined by (contextual qualifier) (qualifier value)'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0456080', 'cui_str': 'Displacement (attribute)'}, {'cui': 'C0032221', 'cui_str': 'Plethysmography'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass (observable entity)'}, {'cui': 'C0037302', 'cui_str': 'Skinfold Thickness'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C1563743', 'cui_str': 'Adiposis'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}]",,0.143212,"Supplemental nutrient-enriched donor milk, compared to preterm formula, was not associated with growth, body composition, or blood pressure.","[{'ForeName': 'Meghan', 'Initials': 'M', 'LastName': 'McGee', 'Affiliation': 'Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Unger', 'Affiliation': 'Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Hamilton', 'Affiliation': 'Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Catherine S', 'Initials': 'CS', 'LastName': 'Birken', 'Affiliation': 'Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Zdenka', 'Initials': 'Z', 'LastName': 'Pausova', 'Affiliation': 'Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Kiss', 'Affiliation': 'Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Bando', 'Affiliation': 'Translational Medicine Program, The Hospital for Sick Children, Toronto, Ontario, Canada.'}, {'ForeName': 'Deborah L', 'Initials': 'DL', 'LastName': ""O'Connor"", 'Affiliation': 'Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.'}]",The Journal of nutrition,['10.1093/jn/nxz234'] 3124,31831056,Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.,"BACKGROUND We previously investigated low doses (105 or 225 mg) of gantenerumab, a fully human monoclonal antibody that binds and removes aggregated amyloid-β by Fc receptor-mediated phagocytosis, in the SCarlet RoAD (SR) and Marguerite RoAD (MR) phase 3 trials. Several lines of evidence suggested that higher doses may be necessary to achieve clinical efficacy. We therefore designed a positron emission tomography (PET) substudy to evaluate the effect of gantenerumab uptitrated to 1200 mg every 4 weeks on amyloid-β plaques as measured using florbetapir PET in patients with prodromal to moderate Alzheimer's disease (AD). METHODS A subset of patients enrolled in the SR and MR studies who subsequently entered the open-label extensions (OLEs) were included in this substudy. Patients were aged 50 to 90 years with a clinical diagnosis of probable prodromal to moderate AD and were included based on a visual read of the original screening scan in the double-blind phase. Patients were assigned to 1 of 5 titration schedules (ranging from 2 to 10 months) with a target gantenerumab dose of 1200 mg every 4 weeks. The main endpoint of this substudy was change in amyloid-β plaque burden from OLE baseline to week 52 and week 104, assessed using florbetapir PET. Florbetapir global cortical signal was calculated using a prespecified standard uptake value ratio method converted to the Centiloid scale. RESULTS Sixty-seven of the 89 patients initially enrolled had ≥ 1 follow-up scan by August 15, 2018. Mean amyloid levels were reduced by 39 Centiloids by the first year and 59 Centiloids by year 2, a 3.5-times greater reduction than was seen after 2 years at 225 mg in SR. At years 1 and 2, 37% and 51% of patients, respectively, had amyloid-β plaque levels below the amyloid-β positivity threshold. CONCLUSION Results from this exploratory interim analysis of the PET substudy suggest that gantenerumab doses up to 1200 mg resulted in robust amyloid-β plaque removal at 2 years. PET amyloid levels were consistent with sparse-to-no neuritic amyloid-β plaques in 51% of patients after 2 years of therapy. Amyloid reductions were similar to those observed in other placebo-controlled studies that have suggested potential clinical benefit. TRIAL REGISTRATION ClinicalTrials.gov, NCT01224106 (SCarlet RoAD) and NCT02051608 (Marguerite RoAD).",2019,"Mean amyloid levels were reduced by 39 Centiloids by the first year and 59 Centiloids by year 2, a 3.5-times greater reduction than was seen after 2 years at 225 mg in SR.","[""patients with prodromal to moderate Alzheimer's disease"", 'Patients were aged 50 to 90\u2009years with a clinical diagnosis of probable prodromal to moderate AD and were included based on a visual read of the original screening scan in the double-blind phase', ""patients with prodromal to moderate Alzheimer's disease (AD"", 'Sixty-seven of the 89 patients initially enrolled had ≥\u20091 follow-up scan by August 15, 2018', 'patients enrolled in the SR and MR studies who subsequently entered the open-label extensions (OLEs) were included in this substudy']","['Gantenerumab', 'gantenerumab', 'positron emission tomography (PET']","['amyloid-β plaque removal', 'amyloid-β plaque levels', 'amyloid-β plaque burden', 'Mean amyloid levels', 'PET amyloid levels', 'SCarlet RoAD (SR) and Marguerite RoAD ', 'Florbetapir global cortical signal', 'Amyloid reductions', 'amyloid-β plaques']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332140', 'cui_str': 'Clinical diagnosis (contextual qualifier) (qualifier value)'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis (contextual qualifier) (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0205313', 'cui_str': 'Original (qualifier value)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0441633'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C4517852', 'cui_str': '67'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}]","[{'cui': 'C2982066', 'cui_str': 'gantenerumab'}, {'cui': 'C0032743', 'cui_str': 'Positron-Emission Tomography'}, {'cui': 'C0031268', 'cui_str': 'Companion Animals'}]","[{'cui': 'C0002716', 'cui_str': 'Amyloid Substance'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0031268', 'cui_str': 'Companion Animals'}, {'cui': 'C0442650', 'cui_str': 'Road (environment)'}, {'cui': 'C2742211', 'cui_str': 'florbetapir'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]",,0.17546,"Mean amyloid levels were reduced by 39 Centiloids by the first year and 59 Centiloids by year 2, a 3.5-times greater reduction than was seen after 2 years at 225 mg in SR.","[{'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Klein', 'Affiliation': 'Roche Pharma Research and Early Development, Basel, Switzerland. gregory.klein@roche.com.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Delmar', 'Affiliation': 'Roche/Genentech Product Development, Neuroscience, Basel, Switzerland.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Voyle', 'Affiliation': 'Roche Products Ltd, Welwyn Garden City, UK.'}, {'ForeName': 'Sunita', 'Initials': 'S', 'LastName': 'Rehal', 'Affiliation': 'Roche Products Ltd, Welwyn Garden City, UK.'}, {'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Hofmann', 'Affiliation': 'Roche Pharma Research and Early Development, Basel, Switzerland.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Abi-Saab', 'Affiliation': 'Roche/Genentech Product Development, Neuroscience, Basel, Switzerland.'}, {'ForeName': 'Mirjana', 'Initials': 'M', 'LastName': 'Andjelkovic', 'Affiliation': 'Roche/Genentech Product Development, Neuroscience, Basel, Switzerland.'}, {'ForeName': 'Smiljana', 'Initials': 'S', 'LastName': 'Ristic', 'Affiliation': 'Roche/Genentech Product Development, Neuroscience, Basel, Switzerland.'}, {'ForeName': 'Guoqiao', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'Washington University School of Medicine in St. Louis, St. Louis, MO, USA.'}, {'ForeName': 'Randall', 'Initials': 'R', 'LastName': 'Bateman', 'Affiliation': 'Washington University School of Medicine in St. Louis, St. Louis, MO, USA.'}, {'ForeName': 'Geoffrey A', 'Initials': 'GA', 'LastName': 'Kerchner', 'Affiliation': 'Roche/Genentech Product Development, Neuroscience, Basel, Switzerland.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Baudler', 'Affiliation': 'Roche/Genentech Product Development, Neuroscience, Basel, Switzerland.'}, {'ForeName': 'Paulo', 'Initials': 'P', 'LastName': 'Fontoura', 'Affiliation': 'Roche/Genentech Product Development, Neuroscience, Basel, Switzerland.'}, {'ForeName': 'Rachelle', 'Initials': 'R', 'LastName': 'Doody', 'Affiliation': 'Roche/Genentech Product Development, Neuroscience, Basel, Switzerland.'}]",Alzheimer's research & therapy,['10.1186/s13195-019-0559-z'] 3125,31995682,Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement.,"BACKGROUND There are scant data on long-term clinical outcomes and bioprosthetic-valve function after transcatheter aortic-valve replacement (TAVR) as compared with surgical aortic-valve replacement in patients with severe aortic stenosis and intermediate surgical risk. METHODS We enrolled 2032 intermediate-risk patients with severe, symptomatic aortic stenosis at 57 centers. Patients were stratified according to intended transfemoral or transthoracic access (76.3% and 23.7%, respectively) and were randomly assigned to undergo either TAVR or surgical replacement. Clinical, echocardiographic, and health-status outcomes were followed for 5 years. The primary end point was death from any cause or disabling stroke. RESULTS At 5 years, there was no significant difference in the incidence of death from any cause or disabling stroke between the TAVR group and the surgery group (47.9% and 43.4%, respectively; hazard ratio, 1.09; 95% confidence interval [CI], 0.95 to 1.25; P = 0.21). Results were similar for the transfemoral-access cohort (44.5% and 42.0%, respectively; hazard ratio, 1.02; 95% CI, 0.87 to 1.20), but the incidence of death or disabling stroke was higher after TAVR than after surgery in the transthoracic-access cohort (59.3% vs. 48.3%; hazard ratio, 1.32; 95% CI, 1.02 to 1.71). At 5 years, more patients in the TAVR group than in the surgery group had at least mild paravalvular aortic regurgitation (33.3% vs. 6.3%). Repeat hospitalizations were more frequent after TAVR than after surgery (33.3% vs. 25.2%), as were aortic-valve reinterventions (3.2% vs. 0.8%). Improvement in health status at 5 years was similar for TAVR and surgery. CONCLUSIONS Among patients with aortic stenosis who were at intermediate surgical risk, there was no significant difference in the incidence of death or disabling stroke at 5 years after TAVR as compared with surgical aortic-valve replacement. (Funded by Edwards Lifesciences; PARTNER 2 ClinicalTrials.gov number, NCT01314313.).",2020,"Repeat hospitalizations were more frequent after TAVR than after surgery (33.3% vs. 25.2%), as were aortic-valve reinterventions (3.2% vs. 0.8%).","['Patients were stratified according to intended transfemoral or transthoracic access (76.3% and 23.7%, respectively', 'patients with aortic stenosis', 'patients with severe aortic stenosis and intermediate surgical risk', '2032 intermediate-risk patients with severe, symptomatic aortic stenosis at 57 centers']","['TAVR or surgical replacement', 'transcatheter aortic-valve replacement (TAVR', 'Transcatheter or Surgical Aortic-Valve Replacement', 'TAVR', 'surgical aortic-valve replacement']","['Clinical, echocardiographic, and health-status outcomes', 'incidence of death from any cause or disabling stroke', 'incidence of death or disabling stroke', 'health status', 'aortic-valve reinterventions', 'mild paravalvular aortic regurgitation', 'death from any cause or disabling stroke', 'Repeat hospitalizations']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C0205503', 'cui_str': 'Transthoracic approach (qualifier value)'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0003507', 'cui_str': 'Aortic Stenosis'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C2711836', 'cui_str': 'TAVR - Transcatheter aortic valve replacement'}, {'cui': 'C0442343', 'cui_str': 'Transcatheter approach (qualifier value)'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve (procedure)'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0018759', 'cui_str': 'Level of Health'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0003501', 'cui_str': 'Aortic Valve'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C4087191', 'cui_str': 'Paravalvular aortic regurgitation'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}]",2032.0,0.161664,"Repeat hospitalizations were more frequent after TAVR than after surgery (33.3% vs. 25.2%), as were aortic-valve reinterventions (3.2% vs. 0.8%).","[{'ForeName': 'Raj R', 'Initials': 'RR', 'LastName': 'Makkar', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Vinod H', 'Initials': 'VH', 'LastName': 'Thourani', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Mack', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Susheel K', 'Initials': 'SK', 'LastName': 'Kodali', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Samir', 'Initials': 'S', 'LastName': 'Kapadia', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'John G', 'Initials': 'JG', 'LastName': 'Webb', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Sung-Han', 'Initials': 'SH', 'LastName': 'Yoon', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Trento', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Lars G', 'Initials': 'LG', 'LastName': 'Svensson', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Howard C', 'Initials': 'HC', 'LastName': 'Herrmann', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Wilson Y', 'Initials': 'WY', 'LastName': 'Szeto', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'D Craig', 'Initials': 'DC', 'LastName': 'Miller', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Lowell', 'Initials': 'L', 'LastName': 'Satler', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Cohen', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Todd M', 'Initials': 'TM', 'LastName': 'Dewey', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Vasilis', 'Initials': 'V', 'LastName': 'Babaliaros', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Mathew R', 'Initials': 'MR', 'LastName': 'Williams', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Dean J', 'Initials': 'DJ', 'LastName': 'Kereiakes', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Zajarias', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Kevin L', 'Initials': 'KL', 'LastName': 'Greason', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Brian K', 'Initials': 'BK', 'LastName': 'Whisenant', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Hodson', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Brown', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'William F', 'Initials': 'WF', 'LastName': 'Fearon', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Russo', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Pibarot', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Rebecca T', 'Initials': 'RT', 'LastName': 'Hahn', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Wael A', 'Initials': 'WA', 'LastName': 'Jaber', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Rogers', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Xu', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Jaime', 'Initials': 'J', 'LastName': 'Wheeler', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'Alu', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Craig R', 'Initials': 'CR', 'LastName': 'Smith', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': 'Martin B', 'Initials': 'MB', 'LastName': 'Leon', 'Affiliation': ""From Cedars-Sinai Medical Center, Los Angeles (R.R.M., S.-H.Y., A.T.), Stanford University, Stanford (D.C.M., W.F.F.), and Edwards Lifesciences, Irvine (E.R., K.X., J.W.) - all in California; the Department of Cardiovascular Surgery, Piedmont Heart Institute (V.H.T.), and Emory University (V.B.) - both in Atlanta; Baylor Scott and White Healthcare, Plano (M.J.M., D.L.B.), and Medical City Dallas Hospital, Dallas (T.M.D.) - both in Texas; Columbia University Medical Center/New York-Presbyterian Hospital (S.K.K., R.T.H., M.C.A., C.R.S., M.B.L.) and NYU Langone Medical Center (M.R.W.) - both in New York; Cleveland Clinic, Cleveland (S.K., L.G.S., W.A.J.); St. Paul's Hospital, Vancouver, BC (J.G.W.), and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC (P.P.) - both in Canada; University of Pennsylvania, Philadelphia (H.C.H., W.Y.S.); Medstar Washington Hospital Center, Washington, DC (L.S.); University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); Christ Hospital, Cincinnati (D.J.K.); Barnes-Jewish Hospital, Washington University, St. Louis (A.Z.); Mayo Clinic, Rochester, MN (K.L.G.); Intermountain Medical Center, Salt Lake City (B.K.W.); Providence St. Vincent Medical Center, Portland, OR (R.W.H.); and Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ (M.J.R.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1910555'] 3126,31977840,Prediction of Smoking Abstinence in Women Living With Human Immunodeficiency Virus Infection.,"BACKGROUND This study examined whether baseline negative emotional states (depression and anxiety) would predict craving for cigarettes and other nicotine withdrawal symptoms in early abstinence and whether those emotional states and withdrawal symptoms would predict failure in quitting smoking at 3 months postquit among U.S. women living with the human immunodeficiency virus (HIV). METHOD The study is a secondary analysis of data from two smoking cessation studies of women living with HIV. Craving for cigarettes and other withdrawal symptoms were assessed weekly with a total of 229 observations during the first 4 weeks following quit day. Descriptive statistics were used to examine baseline characteristics of the participants. A random growth curve model was used to estimate between-person differences in a within-person trend of changes in the withdrawal symptoms. A binary logistic regression analysis was performed to identify predictors of short-term smoking abstinence. RESULTS Baseline anxiety was a predictor of postquit nicotine withdrawal symptoms but baseline depression was not. Neither baseline anxiety nor depression predicted postquit craving for cigarettes. Participants who received an HIV-tailored smoking cessation intervention showed a greater decline in craving symptom than those who received an attention-controlled intervention. HIV-tailored intervention and less craving predicted smoking abstinence at 3-month follow-up. DISCUSSION Compared to an attention-controlled intervention, an HIV-tailored intervention effectively decreased craving for cigarette smoking after quitting-which effectively increased the rate of short-term smoking abstinence in women living with HIV.",2020,"Compared to an attention-controlled intervention, an HIV-tailored intervention effectively decreased craving for cigarette smoking after quitting-which effectively increased the rate of short-term smoking abstinence in women living with HIV.","['women living with HIV', 'Women Living with Human Immunodeficiency Virus Infection']","['HIV-tailored smoking cessation intervention', 'HIV-tailored intervention']","['craving symptom', 'rate of short-term smoking abstinence', 'Craving for cigarettes and other withdrawal symptoms', 'Smoking Abstinence']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0019693', 'cui_str': 'T-Lymphotropic Virus Type III Infections, Human'}]","[{'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}]","[{'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0087169', 'cui_str': 'Withdrawal Symptoms'}]",229.0,0.125838,"Compared to an attention-controlled intervention, an HIV-tailored intervention effectively decreased craving for cigarette smoking after quitting-which effectively increased the rate of short-term smoking abstinence in women living with HIV.","[{'ForeName': 'Sun S', 'Initials': 'SS', 'LastName': 'Kim', 'Affiliation': 'Sun S. Kim, PhD, RN, is Associate Professor, College of Nursing and Health Science, University of Massachusetts Boston. Mary E. Cooley, PhD, RN, FAAN, is Nurse Scientist, Phyllis F. Cantor Center, Dana-Farber Cancer Institute, Boston, Massachusetts. Sang A Lee, MS, RN, is Doctoral Student, College of Nursing and Health Science, University of Massachusetts Boston. Rosanna F. DeMarco, PhD, RN, FAAN, is Professor and Associate Dean for Academic Affairs, College of Nursing and Health Science, University of Massachusetts Boston.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Cooley', 'Affiliation': ''}, {'ForeName': 'Sang A', 'Initials': 'SA', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'Rosanna F', 'Initials': 'RF', 'LastName': 'DeMarco', 'Affiliation': ''}]",Nursing research,['10.1097/NNR.0000000000000421'] 3127,31432535,"Effects of cooperative learning on peer relations, empathy, and bullying in middle school.","Although researchers have developed prevention programs to reduce bullying, the results are mixed, and this may be due to a degree of uncertainty in their theoretical foundation. In particular, these programs share an emphasis on empathy as a personal attribute that can be enhanced among students through the application of specific curricula that will, in turn, contribute to a reduction in bullying behavior. However, the link between empathy and bullying is unclear, as is the ability of bullying prevention programs to actually impact student empathy. In this study, we used a cluster randomized trial (N = 15 middle schools, 1,890 students, 47.1% female, 75.2% White) to evaluate the impact of cooperative learning on bullying, and we evaluated whether these effects were mediated by empathy and peer relatedness. Our results indicated that cooperative learning can significantly reduce bullying, and that some of this effect is transmitted via enhancements to affective empathy. Cooperative learning also demonstrated significant positive effects on cognitive empathy, but this did not have an effect on bullying. We also found that the effects of cooperative learning on cognitive and affective empathy were mediated by improvements in peer relatedness. These findings add a degree of clarity to the literature, and also represent the first time, as far as we are aware, that an antibullying program has been found to have significant effects on both cognitive and affective empathy.",2019,"Cooperative learning also demonstrated significant positive effects on cognitive empathy, but this did not have an effect on bullying.","['cluster randomized trial (N\u2009=\u200915 middle schools, 1,890 students, 47.1% female, 75.2% White']",['cooperative learning'],"['cognitive empathy', 'cognitive and affective empathy', 'peer relations, empathy, and bullying in middle school']","[{'cui': 'C0557797', 'cui_str': 'Middle school (environment)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0043157', 'cui_str': 'Whites'}]",[],"[{'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0424318', 'cui_str': 'Bullying'}, {'cui': 'C0557797', 'cui_str': 'Middle school (environment)'}]",,0.0173503,"Cooperative learning also demonstrated significant positive effects on cognitive empathy, but this did not have an effect on bullying.","[{'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Van Ryzin', 'Affiliation': 'Oregon Research Institute, Eugene, Oregon.'}, {'ForeName': 'Cary J', 'Initials': 'CJ', 'LastName': 'Roseth', 'Affiliation': 'Michigan State University, East Lansing, Michigan.'}]",Aggressive behavior,['10.1002/ab.21858'] 3128,31605616,The Effect of Maternal Multiple Micronutrient Supplementation on Female Early Infant Mortality Is Fully Mediated by Increased Gestation Duration and Intrauterine Growth.,"BACKGROUND Maternal micronutrient supplementation in pregnancy (MMS) has been shown to improve birth weight among infants in low- and middle-income countries. Recent evidence suggests that the survival benefits of MMS are greater for female infants compared to male infants, but the mechanisms leading to differential effects remain unclear. OBJECTIVE The objective of this study was to examine the potential mechanisms through which MMS acts on infant mortality among Tanzanian infants. METHODS We used data collected from pregnant women and newborns in a randomized, double-blind, placebo-controlled trial of MMS conducted in Tanzania to examine mediators of the effect of MMS on 6-wk infant mortality (NCT00197548). Causal mediation analyses with the counterfactual approach were conducted to assess the contributions of MMS on survival via their effects on birth weight, gestational age, weight-for-gestational age, and the joint effect of gestational age and weight-for-gestational age. The weighting method allowed for interaction between gestational age and weight-for-gestational age. RESULTS Among 7486 newborns, the effect of MMS on 6-wk survival was fully mediated (100%) through the joint effect of gestational age and weight-for-gestational age. MMS was also found to have a significant natural indirect effect through increased birth weight (P-value < 0.001) that explained 75% of the total effect on 6-wk mortality. When analyses were stratified by sex, changes in gestational age and weight-for-gestational age fully mediated the mortality effect among female infants (n = 3570), but these mediators only explained 34% of the effect among males (n = 3833). CONCLUSIONS The potential sex-specific effects of MMS on mortality may be a result of differences in mechanisms related to birth outcomes. In the context of the Tanzanian trial, the observed effect of MMS on 6-wk mortality for female infants was entirely mediated by increased gestation duration and improved intrauterine growth, while these mechanisms did not appear to be major contributors among male infants.",2020,"When analyses were stratified by sex, changes in gestational age and weight-for-gestational age fully mediated the mortality effect among female infants (n = 3570), but these mediators only explained 34% of the effect among males (n = 3833). ","['female infants', 'male infants', 'pregnant women and newborns', 'Tanzanian infants', '7486 newborns']","['placebo', 'MMS', 'Maternal Multiple Micronutrient Supplementation', 'Maternal micronutrient supplementation']","['6-wk survival', 'Female Early Infant Mortality', 'birth weight', 'gestation duration and improved intrauterine growth', 'survival benefits of MMS']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}]","[{'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0021278', 'cui_str': 'Infant Mortality'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0694756', 'cui_str': 'Intrauterine (qualifier value)'}, {'cui': 'C0018270', 'cui_str': 'Growth'}]",,0.27157,"When analyses were stratified by sex, changes in gestational age and weight-for-gestational age fully mediated the mortality effect among female infants (n = 3570), but these mediators only explained 34% of the effect among males (n = 3833). ","[{'ForeName': 'Mary K', 'Initials': 'MK', 'LastName': 'Quinn', 'Affiliation': 'Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Emily R', 'Initials': 'ER', 'LastName': 'Smith', 'Affiliation': 'Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Paige L', 'Initials': 'PL', 'LastName': 'Williams', 'Affiliation': 'Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Willy', 'Initials': 'W', 'LastName': 'Urassa', 'Affiliation': 'Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.'}, {'ForeName': 'Joy', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': 'Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Gernard', 'Initials': 'G', 'LastName': 'Msamanga', 'Affiliation': 'Department of Community Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.'}, {'ForeName': 'Wafaie W', 'Initials': 'WW', 'LastName': 'Fawzi', 'Affiliation': 'Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Sudfeld', 'Affiliation': 'Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, USA.'}]",The Journal of nutrition,['10.1093/jn/nxz246'] 3129,32026537,"Effect of Cichorium intybus seeds supplementation on the markers of glycemic control, oxidative stress, inflammation, and lipid profile in type 2 diabetes mellitus: A randomized, double-blind placebo study.","Diabetes mellitus is associated with increased levels of inflammation and oxidative stress in patients. The aim of the present study was to test the hypothesis that aqueous extract of Cichorium intybus seeds (AECIS) would have add-on beneficial effect in type 2 diabetes mellitus (T2DM). In this double-blind randomized clinical study, 150 subjects were enrolled to assess the add-on efficacy and safety of AECIS in T2DM patients. The subjects were randomized (1:1) to the AECIS (n = 51) and placebo (n = 49) groups. The subjects in both groups continued to take prescribed doses of metformin. The standardization of AECIS was carried out by liquid chromatography-mass spectrometry and phytochemical analysis. The mean hemoglobin A1c (HbA1c) level in the AECIS and placebo groups at baseline was 8.6% and 8.5%, respectively. Mean values of HbA1c at the end of 12 weeks of intervention were 7.42% in the AECIS group (a reduction of 1.18% from baseline) and 8.4% in the placebo group (mean reduction of 0.1% from baseline). Besides, significant reduction in inflammation, oxidative stress, and hypertriglyceridemia was seen in the AECIS group (p < .05). The study shows for the first time that AECIS supplementation ameliorates the disease progression and it is beneficial as a potential adjunct dietary supplement for the management of T2DM.",2020,"Besides, significant reduction in inflammation, oxidative stress, and hypertriglyceridemia was seen in the AECIS group (p < .05).","['type 2 diabetes mellitus (T2DM', '150 subjects', 'patients', 'Diabetes mellitus', 'type 2 diabetes mellitus']","['metformin', 'AECIS', 'placebo', 'Cichorium intybus seeds supplementation', 'AECIS supplementation', 'aqueous extract of Cichorium intybus seeds (AECIS']","['efficacy and safety of AECIS', 'inflammation, oxidative stress, and hypertriglyceridemia', 'mean hemoglobin A1c (HbA1c) level', 'glycemic control, oxidative stress, inflammation, and lipid profile', 'Mean values of HbA1c', 'levels of inflammation and oxidative stress']","[{'cui': 'C0011860', 'cui_str': 'Diabetes Mellitus, Type 2'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1145671', 'cui_str': 'Cichorium intybus'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0020557', 'cui_str': 'Hypertriglyceridemia'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4521595', 'cui_str': 'Lcpl'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}]",150.0,0.1719,"Besides, significant reduction in inflammation, oxidative stress, and hypertriglyceridemia was seen in the AECIS group (p < .05).","[{'ForeName': 'Kailash', 'Initials': 'K', 'LastName': 'Chandra', 'Affiliation': 'Department of Biochemistry, HIMSR, Jamia Hamdard, New Delhi, India.'}, {'ForeName': 'Vineet', 'Initials': 'V', 'LastName': 'Jain', 'Affiliation': 'Department of Medicine, HIMSR, Jamia Hamdard, New Delhi, India.'}, {'ForeName': 'Azhar', 'Initials': 'A', 'LastName': 'Jabin', 'Affiliation': 'Department of Moalijat, School of Medicine (Unani), Jamia Hamdard, New Delhi, India.'}, {'ForeName': 'Shridhar', 'Initials': 'S', 'LastName': 'Dwivedi', 'Affiliation': 'Department of Cardiology, National Heart Institute, New Delhi, India.'}, {'ForeName': 'Santosh', 'Initials': 'S', 'LastName': 'Joshi', 'Affiliation': 'R&D Department, Hamdard Laboratories, Hamdard National Foundation, Ghaziabad, India.'}, {'ForeName': 'Sayeed', 'Initials': 'S', 'LastName': 'Ahmad', 'Affiliation': 'Bioactive Natural Product Laboratory, Department of Pharmacognosy and Phytochemistry, SPER, Jamia Hamdard, New Delhi, India.'}, {'ForeName': 'Swatantra K', 'Initials': 'SK', 'LastName': 'Jain', 'Affiliation': 'Department of Biochemistry, HIMSR, Jamia Hamdard, New Delhi, India.'}]",Phytotherapy research : PTR,['10.1002/ptr.6624'] 3130,31994616,Randomized trial of physiotherapy and hypertonic saline techniques for sputum induction in asthmatic children and adolescents.,"OBJECTIVES This study aimed to analyze the efficiency of physiotherapy techniques in sputum induction and in the evaluation of pulmonary inflammation in asthmatic children and adolescents. Although hypertonic saline (HS) is widely used for sputum induction (SI), specific techniques and maneuvers of physiotherapy (P) may facilitate the collection of mucus in some asthmatic children and adolescents. METHODS A randomized crossover study was performed in patients with well-controlled asthma, and 90 sputum samples were collected. Children and adolescents were assessed using spirometry and randomized at entry into one of three sputum induction techniques: (i) 3% hypertonic saline - HS technique; (ii) physiotherapy (oscillatory positive expiratory pressure, forced expiration, and acceleration of expiratory flow) - P technique; and (iii) hypertonic saline + physiotherapy - HSP technique. ClinicalTrials.gov: NCT03136042. RESULTS The total cells (mL) and the percentage (%) of differential inflammatory cells were similar in all techniques. The sputum weight (g) in the HSP technique was significantly higher than that in the HS technique. In all techniques, the percentage of viable cells was >50%, and there was no difference between the HS and P techniques. Moreover, sputum induction did not cause any alterations in the pulmonary function of patients. CONCLUSION The physiotherapy sputum collection technique was effective in obtaining viable cells from mucus samples and yielded the same amount of sputum as the gold standard technique (hypertonic saline). In addition, the physiotherapy maneuvers were both safe and useful for sputum induction in asthmatic children and adolescents with well-controlled asthma.",2020,The total cells (mL) and the percentage (%) of differential inflammatory cells were similar in all techniques.,"['asthmatic children and adolescents with well-controlled asthma', 'asthmatic children and adolescents', 'Children and adolescents', 'patients with well-controlled asthma, and 90 sputum samples were collected']","['physiotherapy techniques', 'hypertonic saline (HS', 'physiotherapy and hypertonic saline techniques', 'sputum induction techniques: (i) 3% hypertonic saline - HS technique; (ii) physiotherapy (oscillatory positive expiratory pressure, forced expiration, and acceleration of expiratory flow) - P technique; and (iii) hypertonic saline + physiotherapy - HSP technique']","['total cells (mL) and the percentage (%) of differential inflammatory cells', 'sputum weight (g) in the HSP technique', 'percentage of viable cells']","[{'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C3853142', 'cui_str': 'Well controlled'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444159', 'cui_str': 'Sputum specimen'}]","[{'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0036085', 'cui_str': 'Sodium Chloride Solution, Hypertonic'}, {'cui': 'C0454505', 'cui_str': 'Sputum induction technique (regime/therapy)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0000894', 'cui_str': 'Acceleration'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0443199', 'cui_str': 'Differential (qualifier value)'}, {'cui': 'C0440752', 'cui_str': 'Inflammatory cell'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0443348', 'cui_str': 'Viable (qualifier value)'}]",,0.0828024,The total cells (mL) and the percentage (%) of differential inflammatory cells were similar in all techniques.,"[{'ForeName': 'Egberto Luiz', 'Initials': 'EL', 'LastName': 'Felicio-Júnior', 'Affiliation': 'Hospital do Servidor Publico do Estado de Sao Paulo (IAMSPE), Sao Paulo, SP, BR.'}, {'ForeName': 'Viviani', 'Initials': 'V', 'LastName': 'Barnabé', 'Affiliation': 'Hospital do Servidor Publico do Estado de Sao Paulo (IAMSPE), Sao Paulo, SP, BR.'}, {'ForeName': 'Francine Maria', 'Initials': 'FM', 'LastName': 'de Almeida', 'Affiliation': 'Laboratorio de Terapeutica Experimental (LIM-20), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Monise Dematte', 'Initials': 'MD', 'LastName': 'Avona', 'Affiliation': 'Universidade Cidade de Sao Paulo (UNICID), Sao Paulo, SP, BR.'}, {'ForeName': 'Isabella Santos', 'Initials': 'IS', 'LastName': 'de Genaro', 'Affiliation': 'Hospital do Servidor Publico do Estado de Sao Paulo (IAMSPE), Sao Paulo, SP, BR.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Kurdejak', 'Affiliation': 'Universidade Cidade de Sao Paulo (UNICID), Sao Paulo, SP, BR.'}, {'ForeName': 'Miriam Cardoso Neves', 'Initials': 'MCN', 'LastName': 'Eller', 'Affiliation': 'Departamento de Pediatria e Pneumologia, Instituto da Criança, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Karina Pierantozzi', 'Initials': 'KP', 'LastName': 'Verganid', 'Affiliation': 'Departamento de Pediatria e Pneumologia, Instituto da Criança, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Joaquim Carlos', 'Initials': 'JC', 'LastName': 'Rodrigues', 'Affiliation': 'Departamento de Pediatria e Pneumologia, Instituto da Criança, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Iolanda de Fátima Lopes Calvo', 'Initials': 'IFLC', 'LastName': 'Tibério', 'Affiliation': 'Laboratorio de Terapeutica Experimental (LIM-20), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Milton de Arruda', 'Initials': 'MA', 'LastName': 'Martins', 'Affiliation': 'Laboratorio de Terapeutica Experimental (LIM-20), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Beatriz Mangueira', 'Initials': 'BM', 'LastName': 'Saraiva-Romanholo', 'Affiliation': 'Hospital do Servidor Publico do Estado de Sao Paulo (IAMSPE), Sao Paulo, SP, BR.'}]","Clinics (Sao Paulo, Brazil)",['10.6061/clinics/2020/e1512'] 3131,32024400,Inferior stabilization of cementless compared with cemented dual-mobility cups in elderly osteoarthrosis patients: a randomized controlled radiostereometry study on 60 patients with 2 years' follow-up.,"Background and purpose - Elderly patients may benefit from a dislocation low-risk dual-mobility (DM) articulation in total hip arthroplasty, but the best cup fixation method is unknown. We compared cup migration for cemented and cementless DM cups using radiostereometry.Patients and methods - In a patient-blinded randomized trial, 60 patients (33 female) with osteoarthritis were allocated to cemented (n = 30) or cementless (n = 30) Avantage DM cup fixation. Criteria were age above 70 years, and T-score above -4. We investigated cup migration, periprosthetic bone mineral density (BMD), and patient-reported outcome measures (PROMs) until 24 months postoperative follow-up.Results - At 24 months mean proximal cup migration was 0.11 mm (95% CI 0.00-0.23) for cemented cups and 0.09 mm (CI -0.09 to 0.28) for cementless cups. However, cementless cups generally migrated more than cemented cups at 12 and 24 months. Cemented cups had no measurable migration from 3 months' follow-up, while cementless cups had not yet stabilized at 24 months in all rotations. Cementless cups showed statistically significantly more maximum total point motion (MTPM) at 12- and 24-month follow-up compared with cemented cups in patients with low systemic BMD (p = 0.01). Periprosthetic BMD changes did not statisticially significantly correlate to proximal migration in either cup fixation group (p > 0.05). PROMs improved similarly in both groups.Interpretation - Cemented cups were well fixed at 3 months. The cementless cups migrated more in patients with low BMD, showed an inconsistent pattern of migration, and migrated in different directions during the first and second year without tendency to stabilization. Cemented fixation of the Avantage DM cup seems safer in elderly patients.",2020,Cementless cups showed statistically significantly more maximum total point motion (MTPM) at 12- and 24-month follow-up compared with cemented cups in patients with low systemic BMD (p = 0.01).,"['elderly osteoarthrosis patients', ""60 patients with 2 years' follow-up"", '60 patients (33 female) with osteoarthritis were allocated to cemented (n = 30) or cementless (n = 30', 'elderly patients']","['dislocation low-risk dual-mobility (DM) articulation', 'Avantage DM cup fixation', 'cemented dual-mobility cups', 'Cemented fixation of the Avantage DM cup']","['proximal migration', 'maximum total point motion (MTPM', 'cup migration, periprosthetic bone mineral density (BMD', 'proximal cup migration', 'Periprosthetic BMD changes']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0029408', 'cui_str': 'Arthritis, Degenerative'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0012691', 'cui_str': 'Joint Dislocations'}, {'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C2949743', 'cui_str': 'Cup - unit of product usage'}, {'cui': 'C0185023', 'cui_str': 'pexy'}]","[{'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C1533574', 'cui_str': 'Migration, function (observable entity)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0687704', 'cui_str': 'Motions (qualifier value)'}, {'cui': 'C2949743', 'cui_str': 'Cup - unit of product usage'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",60.0,0.154119,Cementless cups showed statistically significantly more maximum total point motion (MTPM) at 12- and 24-month follow-up compared with cemented cups in patients with low systemic BMD (p = 0.01).,"[{'ForeName': 'Steffan', 'Initials': 'S', 'LastName': 'Tabori-Jensen', 'Affiliation': 'University Clinic for Hand, Hip and Knee Surgery, Regional Hospital West Jutland, Holstebro;'}, {'ForeName': 'Sebastian Breddam', 'Initials': 'SB', 'LastName': 'Mosegaard', 'Affiliation': 'University Clinic for Hand, Hip and Knee Surgery, Regional Hospital West Jutland, Holstebro;'}, {'ForeName': 'Torben B', 'Initials': 'TB', 'LastName': 'Hansen', 'Affiliation': 'University Clinic for Hand, Hip and Knee Surgery, Regional Hospital West Jutland, Holstebro;'}, {'ForeName': 'Maiken', 'Initials': 'M', 'LastName': 'Stilling', 'Affiliation': 'University Clinic for Hand, Hip and Knee Surgery, Regional Hospital West Jutland, Holstebro;'}]",Acta orthopaedica,['10.1080/17453674.2020.1720978'] 3132,32026250,"Addressing Intimate Partner Violence and Power in Intimate Relationships in HIV Testing Services in Nairobi, Kenya.","Intimate partner violence (IPV) undermines women's uptake of HIV services and violates their human rights. In a two-arm randomized controlled trial we evaluated a short intervention that went a step beyond IPV screening to discuss violence and power with women receiving HIV testing services during antenatal care (ANC). The intervention included training and support for HIV counselors, a take-home card for clients, and an on-site IPV counselor. One third (35%) of women (N = 688) reported experiencing IPV in the past year; 6% were living with HIV. Among women experiencing IPV, program participants were more likely to disclose violence to their counselor than women receiving standard care (32% vs. 7%, p < 0.001). At second ANC visit, intervention group women were significantly more likely to report that talking with their counselor made a positive difference (aOR 2.9; 95% CI 1.8, 4.4; p < 0.001) and felt more confident in how they deserved to be treated (aOR 2.7; 95% CI 1.7, 4.4; p < 0.001). Exploratory analyses of intent to use ARVs to prevent mother-to-child transmission and actions to address violence were also encouraging.",2020,"At second ANC visit, intervention group women were significantly more likely to report that talking with their counselor made a positive difference (aOR 2.9; 95% CI 1.8, 4.4; p < 0.001) and felt more confident in how they deserved to be treated (aOR 2.7; 95% CI 1.7, 4.4; p < 0.001).","[""Intimate partner violence (IPV) undermines women's uptake of HIV services and violates their human rights"", 'HIV Testing Services in Nairobi, Kenya', 'violence and power with women receiving HIV testing services during antenatal care (ANC']","['training and support for HIV counselors, a take-home card for clients, and an on-site IPV counselor']",['experiencing IPV'],"[{'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0020138', 'cui_str': 'Human Rights'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0022558', 'cui_str': 'Republic of Kenya'}, {'cui': 'C0042693', 'cui_str': 'Violence'}, {'cui': 'C0033052', 'cui_str': 'Antenatal Care'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C1571885', 'cui_str': 'Counselors'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0276240', 'cui_str': 'Infectious pustular vulvovaginitis (disorder)'}]","[{'cui': 'C0276240', 'cui_str': 'Infectious pustular vulvovaginitis (disorder)'}]",,0.0526836,"At second ANC visit, intervention group women were significantly more likely to report that talking with their counselor made a positive difference (aOR 2.9; 95% CI 1.8, 4.4; p < 0.001) and felt more confident in how they deserved to be treated (aOR 2.7; 95% CI 1.7, 4.4; p < 0.001).","[{'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Haberland', 'Affiliation': 'Population Council, One Dag Hammarskjold Plaza, New York, NY, 10017, USA. nhaberland@popcouncil.org.'}, {'ForeName': 'Charity', 'Initials': 'C', 'LastName': 'Ndwiga', 'Affiliation': 'Population Council, Nairobi, Kenya.'}, {'ForeName': 'Katharine', 'Initials': 'K', 'LastName': 'McCarthy', 'Affiliation': 'Population Council, One Dag Hammarskjold Plaza, New York, NY, 10017, USA.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Pulerwitz', 'Affiliation': 'Population Council, Washington, DC, USA.'}, {'ForeName': 'Rose', 'Initials': 'R', 'LastName': 'Kosgei', 'Affiliation': 'Kenyatta National Hospital, Nairobi, Kenya.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': ""Mak'anyengo"", 'Affiliation': 'Kenyatta National Hospital, Nairobi, Kenya.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'Peltz', 'Affiliation': 'Office of HIV/AIDS, United States Agency for International Development, Washington, DC, USA.'}, {'ForeName': 'Vincent J', 'Initials': 'VJ', 'LastName': 'Wong', 'Affiliation': 'Office of HIV/AIDS, United States Agency for International Development, Washington, DC, USA.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Kalibala', 'Affiliation': 'Population Council, Washington, DC, USA.'}]",AIDS and behavior,['10.1007/s10461-020-02801-9'] 3133,31931269,Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer.,"BACKGROUND Both peripherally inserted central catheters (PICCs) and implanted port catheters (PORTs) are used for adjuvant chemotherapy (ACT) administration in patients with early breast cancer (EBC). We aimed to compare the safety between PICCs and PORTs in this setting. PATIENTS AND METHODS This monocentric phase II randomised trial (NCT02095743) included patients with EBC who were eligible for ACT. Patients with curative anticoagulation therapy were excluded. The primary objective was to identify which device has a lower probability of catheter-related significant adverse events (CR-SAEs) within the 35 weeks after device implantation. The secondary objective was to evaluate quality of life (QoL) and patient satisfaction. RESULTS From February 2014 to May 2018, 256 patients were included, and 253 (99%) were analysed. Overall, 31 patients (12.2%) experienced CR-SAEs, which mainly included thromboembolic events. In an intention-to-treat analysis, the probability that a CR-SAE would occur was 7.8% (10 events) with PORTs versus 16.6% (21 events) with PICCs (hazard ratio [HR] = 2.2 [1.03-4.62], P = 0.036). In a per-protocol analysis, PICCs were also associated with a higher risk of CR-SAEs than PORTs (HR = 2.82 [1.26-6.25], P = 0.007). Regarding the secondary objectives, if there was no difference in QoL between the arms, then significantly more discomfort was reported among patients with PICCs than among patients with PORTs (P = 0.002 after implantation and P < 0.001 at mid-treatment or at the end of treatment). CONCLUSIONS CR-SAEs in patients with EBC are frequent but rarely impact the ACT process. Compared with PORTs, PICCs are associated with a significantly higher risk of CR-SAEs and more discomfort. PORTs should be preferred for ACT administration in patients with EBC.",2020,"In a per-protocol analysis, PICCs were also associated with a higher risk of CR-SAEs than PORTs (HR = 2.82 [1.26-6.25], P = 0.007).","['patients with early breast cancer (EBC', 'From February 2014 to May 2018, 256 patients were included, and 253 (99%) were analysed', 'patients with EBC', 'patients with early breast cancer', 'Patients with curative anticoagulation therapy were excluded', 'patients with EBC who were eligible for ACT']","['peripherally inserted central catheters (PICCs) and implanted port catheters (PORTs', 'adjuvant chemotherapy (ACT', 'peripherally inserted catheters versus implanted port catheters']","['higher risk of CR-SAEs', 'QoL', 'thromboembolic events', 'discomfort', 'risk of CR-SAEs and more discomfort', 'quality of life (QoL) and patient satisfaction', 'CR-SAEs']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1276305', 'cui_str': 'Curative procedure'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}]","[{'cui': 'C0179740', 'cui_str': 'Long line'}, {'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C3494350', 'cui_str': 'Port Catheters'}, {'cui': 'C0452253', 'cui_str': 'Port (substance)'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C1881217', 'cui_str': 'Insert - unit of product usage'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}]","[{'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolism'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0034380'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}]",256.0,0.113024,"In a per-protocol analysis, PICCs were also associated with a higher risk of CR-SAEs than PORTs (HR = 2.82 [1.26-6.25], P = 0.007).","[{'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Clatot', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France. Electronic address: florian.clatot@chb.unicancer.fr.'}, {'ForeName': 'Maxime', 'Initials': 'M', 'LastName': 'Fontanilles', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Laureline', 'Initials': 'L', 'LastName': 'Lefebvre', 'Affiliation': 'Department of Radiation Therapy, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Justine', 'Initials': 'J', 'LastName': 'Lequesne', 'Affiliation': 'Clinical Research Unit, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Veyret', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Alexandru', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Leheurteur', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Guillemet', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Gouérant', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Petrau', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Jean-Christophe', 'Initials': 'JC', 'LastName': 'Théry', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Rigal', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Moldovan', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Tennevet', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Rastelli', 'Affiliation': 'Clinical Research Unit, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Amélie', 'Initials': 'A', 'LastName': 'Poullain', 'Affiliation': 'Clinical Research Unit, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Laetitia', 'Initials': 'L', 'LastName': 'Savary', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Bubenheim', 'Affiliation': 'Department of Clinical Research and Innovation, Rouen University Hospital, Rouen, France.'}, {'ForeName': 'Dragos', 'Initials': 'D', 'LastName': 'Georgescu', 'Affiliation': 'Department of Surgery, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Gouérant', 'Affiliation': 'Department of Anaesthesia, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Gilles-Baray', 'Affiliation': 'Department of Anaesthesia, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Di Fiore', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France; Department of Digestive Oncology, Rouen University Hospital, Rouen, France.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.11.022'] 3134,30718168,Short term results of dynamic splinting for hallux valgus - A prospective randomized study.,"Background Hallux valgus is a common diagnosis in orthopedics. Only a few studies have analyzed the effects of conservative therapy. Therefore, the current study analyzed the effect of a dynamic hallux valgus splint. Methods Seventy patients were included in this prospective randomized trial. Patients with a hallux valgus were treated using a dynamic splint or underwent no treatment. Clinical and radiological parameters were evaluated. Results We found no significant changes in hallux valgus angle, intermetatarsal I-II angle, AOFAS score, FAOS or SF-36 score between the groups. However, a significant between-group difference was found for pain during walking and running and in the FAOS subscale for pain and pain at rest at follow-up. Conclusions Wearing a dynamic hallux valgus splint does provide some pain relief in patients with a symptomatic hallux valgus, but showed no effect on hallux valgus position. Level of evidence: 1.",2020,"We found no significant changes in hallux valgus angle, intermetatarsal I-II angle, AOFAS score, FAOS or SF-36 score between the groups.","['patients with a symptomatic hallux valgus', 'Methods Seventy patients', 'Patients with a hallux valgus']","['dynamic splinting', 'dynamic hallux valgus splint', 'dynamic splint or underwent no treatment']","['pain relief', 'pain during walking and running and in the FAOS subscale for pain and pain', 'hallux valgus angle, intermetatarsal I-II angle, AOFAS score, FAOS or SF-36 score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0158458', 'cui_str': 'Acquired hallux valgus (disorder)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C3816957', 'cui_str': '70'}]","[{'cui': 'C0600020', 'cui_str': 'Dynamic splinting (procedure)'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0158458', 'cui_str': 'Acquired hallux valgus (disorder)'}, {'cui': 'C0204861', 'cui_str': 'Application of splint (procedure)'}, {'cui': 'C0180570', 'cui_str': 'Dynamic Orthoses'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C0158458', 'cui_str': 'Acquired hallux valgus (disorder)'}, {'cui': 'C0205143', 'cui_str': 'Angular (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",70.0,0.0268709,"We found no significant changes in hallux valgus angle, intermetatarsal I-II angle, AOFAS score, FAOS or SF-36 score between the groups.","[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Plaass', 'Affiliation': 'Department for Foot and Ankle Surgery, Clinic for Orthopedics, Hannover Medical School, Anna-von-Borries Strasse 1-7, 30625, Hannover, Germany. Electronic address: Christian@Plaass.info.'}, {'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Karch', 'Affiliation': 'Institute for Biostatistics, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Koch', 'Affiliation': 'Institute for Biostatistics, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.'}, {'ForeName': 'Vivien', 'Initials': 'V', 'LastName': 'Wiederhoeft', 'Affiliation': 'Department for Foot and Ankle Surgery, Clinic for Orthopedics, Hannover Medical School, Anna-von-Borries Strasse 1-7, 30625, Hannover, Germany.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Ettinger', 'Affiliation': 'Department for Foot and Ankle Surgery, Clinic for Orthopedics, Hannover Medical School, Anna-von-Borries Strasse 1-7, 30625, Hannover, Germany.'}, {'ForeName': 'Leif', 'Initials': 'L', 'LastName': 'Claassen', 'Affiliation': 'Department for Foot and Ankle Surgery, Clinic for Orthopedics, Hannover Medical School, Anna-von-Borries Strasse 1-7, 30625, Hannover, Germany.'}, {'ForeName': 'Kiriakos', 'Initials': 'K', 'LastName': 'Daniilidis', 'Affiliation': 'Department for Foot and Ankle Surgery, Clinic for Orthopedics, Hannover Medical School, Anna-von-Borries Strasse 1-7, 30625, Hannover, Germany; OTC Orthopädie Traumatologie Centrum Regensburg, Paracelsusstrasse 2, 93053, Regensburg, Germany.'}, {'ForeName': 'Daiwei', 'Initials': 'D', 'LastName': 'Yao', 'Affiliation': 'Department for Foot and Ankle Surgery, Clinic for Orthopedics, Hannover Medical School, Anna-von-Borries Strasse 1-7, 30625, Hannover, Germany.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Stukenborg-Colsman', 'Affiliation': 'Department for Foot and Ankle Surgery, Clinic for Orthopedics, Hannover Medical School, Anna-von-Borries Strasse 1-7, 30625, Hannover, Germany.'}]",Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons,['10.1016/j.fas.2019.01.002'] 3135,32022890,An Open Trial of a Mind-Body Intervention for Young Women with Moderate to Severe Primary Dysmenorrhea.,"OBJECTIVE To evaluate the feasibility, acceptability, and preliminary efficacy of a mind-body intervention for moderate to severe primary dysmenorrhea (PD). DESIGN Open trial (single arm). SETTING Academic medical school. SUBJECTS A total of 20 young adult women with moderate to severe primary dysmenorrhea were included across four separate intervention groups. METHODS All participants received five 90-minute sessions of a mind-body intervention and completed self-report measures of menstrual pain, depression, anxiety, somatization, and pain catastrophizing at baseline, post-treatment, and at one-, two-, three-, and 12-month follow-up. Self-report of medication use and use of skills learned during the intervention were also collected at all follow-up points. RESULTS Participants reported significantly lower menstrual pain over time compared with baseline. No changes in anxiety, depression, or somatization were observed, although pain catastrophizing improved over time. Changes in menstrual pain were not associated with changes in medication use or reported use of skills. CONCLUSIONS A mind-body intervention is a promising nondrug intervention for primary dysmenorrhea, and future research should focus on testing the intervention further as part of a randomized clinical trial.",2020,"A total of 20 young adult women with moderate to severe primary dysmenorrhea were included across four separate intervention groups. ","['20 young adult women with moderate to severe primary dysmenorrhea', 'Academic medical school', 'Young Women with Moderate to Severe Primary Dysmenorrhea', 'moderate to severe primary dysmenorrhea (PD']","['mind-body intervention', 'Mind-Body Intervention']","['menstrual pain', 'pain catastrophizing', 'menstrual pain, depression, anxiety, somatization, and pain catastrophizing', 'anxiety, depression, or somatization']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0149875', 'cui_str': 'Primary dysmenorrhea (disorder)'}, {'cui': 'C0036378', 'cui_str': 'Schools, Medical'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}]",[],"[{'cui': 'C0013390', 'cui_str': 'Pain, Menstrual'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",20.0,0.0288666,"A total of 20 young adult women with moderate to severe primary dysmenorrhea were included across four separate intervention groups. ","[{'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Payne', 'Affiliation': 'McLean Hospital/Harvard Medical School, Belmont, Massachusetts.'}, {'ForeName': 'Laura C', 'Initials': 'LC', 'LastName': 'Seidman', 'Affiliation': 'McLean Hospital/Harvard Medical School, Belmont, Massachusetts.'}, {'ForeName': 'Tamineh', 'Initials': 'T', 'LastName': 'Romero', 'Affiliation': 'Department of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.'}, {'ForeName': 'Myung-Shin', 'Initials': 'MS', 'LastName': 'Sim', 'Affiliation': 'Department of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.'}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pnz378'] 3136,32019696,"""Very humble"" vs. ""Not humble"": What do ratings of fictitious physician profiles with humility descriptors reveal about potential patient preferences and behaviors?","OBJECTIVES The current study examined the impact of physician humility on future medical interactions and physician-related outcomes (e.g., patient patronage, loyalty) using a non-patient, community sample. METHODS Participants (N = 417) were recruited online through Amazon Mechanical Turk (mTurk) and paid a nominal fee for their participation. They reviewed randomly assigned fictitious physician profiles that differed in humility (high, low), general effectiveness (high, low), physician gender (male, female), and specialty (family practice, orthopedic surgery). Then they reported their likelihood to trust, adhere to recommendations, and be satisfied with the physician. They also conveyed how likely they would select and recommend this physician to others, and how much out-of-pocket money they would be willing to spend to see the physician. RESULTS Humble physicians were rated higher than their non-humble counterparts on all five outcomes. For physicians who were generally ineffective, the physicians low in humility scored lower on intended adherence, trust, and anticipated satisfaction than the physicians high in humility. Additionally, for physicians specializing in family practice, physicians low in humility scored lower on anticipated satisfaction and out-of-pocket expenditure than the physicians high in humility. CONCLUSIONS Findings from this study highlight how physician humility can affect the process of care even before it begins. PRACTICE IMPLICATIONS The study emphasizes the need for deliberate pursuit of humility to improve outcomes for patients and physicians.",2020,"For physicians who were generally ineffective, the physicians low in humility scored lower on intended adherence, trust, and anticipated satisfaction than the physicians high in humility.","['patients and physicians', 'Participants (N = 417) were recruited']",['online through Amazon Mechanical Turk (mTurk) and paid a nominal fee for their participation'],[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}]","[{'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}, {'cui': 'C0337911', 'cui_str': 'Turks (ethnic group)'}, {'cui': 'C0015751', 'cui_str': 'Fees'}]",[],417.0,0.0201008,"For physicians who were generally ineffective, the physicians low in humility scored lower on intended adherence, trust, and anticipated satisfaction than the physicians high in humility.","[{'ForeName': 'Ho Phi', 'Initials': 'HP', 'LastName': 'Huynh', 'Affiliation': 'Department of Science and Mathematics, Texas A&M University, San Antonio, USA. Electronic address: hhuynh@tamusa.edu.'}, {'ForeName': 'Maija', 'Initials': 'M', 'LastName': 'Arthur', 'Affiliation': 'Department of Science and Mathematics, Texas A&M University, San Antonio, USA.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Gamboa', 'Affiliation': 'Department of Science and Mathematics, Texas A&M University, San Antonio, USA.'}, {'ForeName': 'Evelyn', 'Initials': 'E', 'LastName': 'Escamilla', 'Affiliation': 'Department of Science and Mathematics, Texas A&M University, San Antonio, USA.'}]",Patient education and counseling,['10.1016/j.pec.2020.01.021'] 3137,32005104,"The effects of promoting oral intake using the Kuchi-kara Taberu index, a comprehensive feeding assistant tool, in older pneumonia patients: a cluster randomized controlled trial.","BACKGROUND The multidisciplinary comprehensive care (MDCC) program promotes the improvement of oral intake for older patients. The Kuchi-kara Taberu (ingesting orally in Japanese, KT) index was developed to objectively assess patient conditions in the MDCC program. This trial examined the effects of the index in promoting oral intake in older patients with pneumonia. METHODS A cluster randomized controlled trial was conducted in 10 local hospitals targeting older patients with pneumonia (≥65 years). Ten hospitals were allocated randomly to either the intervention or the control group. Both groups (each with five hospitals) received the MDCC program for oral feeding, which consisted of professional assessment, care, and treatment. The KT index was used by the intervention group, focusing on improving low score items. The primary outcome was determined using the Functional Oral Intake Scale (FOIS) at discharge or 1 month after admission. RESULTS One hundred and twelve patients (46 women and 66 men) who participated from 10 hospitals, with a median age of 88 years (interquartile range [IQR], 80-91), were examined. The median FOIS level and the number of patients with oral intake (FOIS ≥ level 4) at discharge were 4 (IQR, 4-6) and 89 (79.5%), respectively. The duration of nil per os was 2 (IQR, 1-5) days. Clusters were not matched in the presence of Kuchi-kara Taberu Shiawase-wo Mamoru-kai-certified medical staff promoting oral intake in patients with dysphagia in each hospital. The median FOIS levels of 53 patients in the intervention group and 59 patients in the control group were 5 (IQR, 4-6) and 4 (IQR, 4-5), respectively, showing no statistically significant difference (P = 0.76). According to a multivariate analysis, the KT index had no positive effect on FOIS levels. CONCLUSIONS This trial was not able to demonstrate the usefulness of the KT index due to random assignment failure. However, both the intervention and control groups showed a high prevalence of oral intake (FOIS ≥ level 4) at discharge. TRIAL REGISTRATION UMIN-Clinical Trial Registry, UMIN000025172, December 17, 2016.",2020,"According to a multivariate analysis, the KT index had no positive effect on FOIS levels. ","['10 local hospitals targeting older patients with pneumonia (≥65\u2009years', 'patients with dysphagia in each hospital', 'older pneumonia patients', 'Ten hospitals', 'older patients with pneumonia', 'One hundred and twelve patients (46 women and 66 men) who participated from 10 hospitals, with a median age of 88\u2009years (interquartile range [IQR], 80-91', 'older patients']",['MDCC program'],"['median FOIS level', 'duration of nil per os', 'Functional Oral Intake Scale (FOIS) at discharge or 1\u2009month after admission', 'FOIS levels', 'median FOIS levels', 'oral intake']","[{'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3542016', 'cui_str': 'Range'}]","[{'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0419179', 'cui_str': 'Nil per os'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0222045'}, {'cui': 'C3871203', 'cui_str': 'At discharge (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]",10.0,0.0921302,"According to a multivariate analysis, the KT index had no positive effect on FOIS levels. ","[{'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Shamoto', 'Affiliation': 'Department of Geriatric Internal Medicine, Takano Hospital, 214 Higashi-machi, shimokitaba, Hirono-machi, Futaba-County, Fukushima, 960-0402, Japan. shahonvs17@gmail.com.'}, {'ForeName': 'Tamami', 'Initials': 'T', 'LastName': 'Koyama', 'Affiliation': 'Chairman, Kuchi-kara Taberu Shiawase-wo Mamoru-kai (KTSM, an incorporated nonprofit organization), 509, 722-1,Ishida, Isehara City, Kanagawa, 259-1116, Japan.'}, {'ForeName': 'Ryo', 'Initials': 'R', 'LastName': 'Momosaki', 'Affiliation': 'Department of Rehabilitation Medicine, Teikyo University School of Medicine University Hospital, Mizonokuchi, 5-1-1 Futako, Takatsu-ku, Kawasaki, Kanagawa, 213-8507, Japan.'}, {'ForeName': 'Keisuke', 'Initials': 'K', 'LastName': 'Maeda', 'Affiliation': 'Department of Palliative and Supportive Medicine, Graduate School of Medicine, Aichi Medical University, 1-1, Yazakokarimata, Nagakute City, Aichi, 480-1195, Japan.'}, {'ForeName': 'Hidetaka', 'Initials': 'H', 'LastName': 'Wakabayashi', 'Affiliation': 'Department of Rehabilitation Medicine, Yokohama City University Medical Center, 4-57 Urafune-chou, Minami ward, Yokohama City, Kanagawa, 232-0024, Japan.'}]",BMC geriatrics,['10.1186/s12877-020-1447-x'] 3138,32020631,The effectiveness of early position change postcardiac catheterization on patient's outcomes: A randomized controlled trial.,"BACKGROUND Nurses play a substantial role in maintaining patient homeostasis postcardiac catheterization. Patients frequently complain of back pain and discomfort as a result of the prolonged bed rest postcatheterization. AIM This study aims to evaluate the effectiveness of early position change postcardiac catheterization on reducing patients' pain and discomfort. SETTINGS The study was conducted at two cardiac units in a university hospital in Jordan. PARTICIPANTS A total of 120 patients were used in the study, 60 patients in each of the two groups-control and intervention. METHODS The randomized controlled trial design was used. Data were initially collected 1 hour after sheath removal postcardiac catheterization. After that, the protocol was applied to the interventional group. RESULTS Early position change 1 hour after sheath removal after cardiac catheterization was found to be effective in reducing back pain as compared with the control group (P < .001). Also, the study intervention was found to be effective in reducing urinary discomfort (X 2  = 50.83, P < .001), and increasing comfort level (X 2  = 120, P < .001). However, although participants in the intervention group were less likely to have constipation and hematoma than those in the control group, this outcome was not statistically significant at P > .05. CONCLUSION Early position change 1 hour after sheath removal postcardiac catheterization has significant positive effects on patient outcomes by reducing the intensity of back pain and urination problems and increasing patients' comfort level without increasing incidents of vascular complications such as bleeding and hematoma.",2020,"Also, the study intervention was found to be effective in reducing urinary discomfort (X 2  = 50.83, P < .001), and increasing comfort level (X 2  = 120, P < .001).","['two cardiac units in a university hospital in Jordan', 'A total of 120 patients were used in the study, 60 patients in each of the two groups-control and intervention']",['early position change postcardiac catheterization'],"['constipation and hematoma', 'comfort level', ""patients' pain and discomfort"", 'back pain', 'urinary discomfort', 'complain of back pain and discomfort', 'intensity of back pain and urination problems']","[{'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0022418', 'cui_str': 'Jordan'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0444793', 'cui_str': 'Position change (qualifier value)'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}]","[{'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0517225', 'cui_str': 'Comfort level'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0042034', 'cui_str': 'Micturition'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}]",120.0,0.0830214,"Also, the study intervention was found to be effective in reducing urinary discomfort (X 2  = 50.83, P < .001), and increasing comfort level (X 2  = 120, P < .001).","[{'ForeName': 'Rashid K', 'Initials': 'RK', 'LastName': 'Ibdah', 'Affiliation': 'Department of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.'}, {'ForeName': ""Wafa'a F"", 'Initials': 'WF', 'LastName': ""Ta'an"", 'Affiliation': 'Department of Community and Mental Health Nursing, Faculty of Nursing, Jordan University of Science and Technology, Irbid, Jordan.'}, {'ForeName': 'Rawan M', 'Initials': 'RM', 'LastName': 'Shatnawi', 'Affiliation': 'Nursing Department, King Abdullah University Hospital, Irbid, Jordan.'}, {'ForeName': 'Mohammad M', 'Initials': 'MM', 'LastName': 'Suliman', 'Affiliation': 'Department of Community and Mental Health Nursing, Faculty of Nursing, Al al-Bayt University, Mafraq, Jordan.'}, {'ForeName': 'Jehad A', 'Initials': 'JA', 'LastName': 'Rababah', 'Affiliation': 'Department of Adults Health Nursing, Faculty of Nursing, Jordan University of Science and Technology, Irbid, Jordan.'}, {'ForeName': 'Sukaina I', 'Initials': 'SI', 'LastName': 'Rawashdeh', 'Affiliation': 'Department of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.'}]",Nursing forum,['10.1111/nuf.12438'] 3139,31953863,"Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder.","OBJECTIVE To evaluate the dose-response relationship of daridorexant, a new dual orexin receptor antagonist, on sleep variables in subjects with insomnia disorder. METHODS Adults (≤64 years) with insomnia disorder were randomized (1:1:1:1:1:1) to receive daily oral placebo, daridorexant (5, 10, 25, or 50mg), or 10mg zolpidem for 30 days. The primary efficacy outcome was the change in wake time after sleep onset from baseline to days 1 and 2. Secondary outcome measures were change in latency to persistent sleep from baseline to days 1 and 2, change in subjective wake time after sleep onset, and subjective latency to sleep onset from baseline to week 4. Safety was also assessed. RESULTS Of 1,005 subjects screened, 359 (64% female) were randomized and received ≥1 dose. A significant dose-response relationship (multiple comparison procedure-modeling, 2-sided p < 0.001) was found in the reduction of wake after sleep onset and latency to persistent sleep from baseline to days 1 and 2 with daridorexant. These reductions were sustained through to days 28 and 29 (p = 0.050 and p = 0.042, respectively). Similar dose-dependent relationships were observed for subjective wake after sleep onset and subjective latency to sleep onset. The incidence of treatment-emergent adverse events was 35%, 38%, 38%, and 34% in subjects treated with 5, 10, 25, and 50mg daridorexant, respectively, compared with 30% for placebo, and 40% for 10mg zolpidem. There were no clinically relevant treatment-related serious adverse events. Four subjects withdrew due to adverse events. INTERPRETATION Daridorexant induced a dose-dependent reduction in wake time after sleep onset in subjects with insomnia disorder (Clinicaltrials.gov NCT02839200). Ann Neurol 2020;87:347-356.",2020,"These reductions were sustained through to Days 28&29 (p=0.050 and p=0.042, respectively).","['Adults (≤64\u2009years) with insomnia disorder', 'subjects with insomnia disorder', 'Of 1005 subjects screened, 359 (64% female']","['placebo', 'zolpidem', 'daily oral placebo, daridorexant', 'daridorexant']","['change in wake time after sleep onset', 'subjective wake after sleep onset and subjective latency to sleep onset', 'reduction of wake after sleep onset and latency to persistent sleep', 'incidence of treatment-emergent adverse events', 'change in latency to persistent sleep from baseline to Days 1&2, change in subjective wake time after sleep onset and subjective latency to sleep onset', 'Safety']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0078839', 'cui_str': 'zolpidem'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0442696', 'cui_str': 'Waking (observable entity)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",1005.0,0.217756,"These reductions were sustained through to Days 28&29 (p=0.050 and p=0.042, respectively).","[{'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Dauvilliers', 'Affiliation': 'Sleep Unit, Department of Neurology, Neuropsychiatry: Epidemiological and Clinical Research, University of Montpellier, National Institute of Health and Medical Research, Montpellier University Hospital Center, Montpellier, France.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Zammit', 'Affiliation': 'Clinilabs Drug Development Corporation and Icahn School of Medicine at Mount Sinai, New York, NY.'}, {'ForeName': 'Ingo', 'Initials': 'I', 'LastName': 'Fietze', 'Affiliation': 'Center of Interdisciplinary Sleep Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Mayleben', 'Affiliation': 'CTI Clinical Research Center, Cincinnati, OH.'}, {'ForeName': 'Dalma', 'Initials': 'D', 'LastName': 'Seboek Kinter', 'Affiliation': 'Clinical Development, Idorsia Pharmaceuticals, Allschwil, Switzerland.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Pain', 'Affiliation': 'Clinical Development, Idorsia Pharmaceuticals, Allschwil, Switzerland.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Hedner', 'Affiliation': 'Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.'}]",Annals of neurology,['10.1002/ana.25680'] 3140,32008572,Comparison of dental plaque reduction after use of electric toothbrushes with and without QLF-D-applied plaque visualization: a 1-week randomized controlled trial.,"BACKGROUND To evaluate the efficacy of a newly developed electric toothbrush in reducing dental plaque via a quantitative light-induced fluorescence-digital (QLF-D)-applied visualisation system in the brush head. METHODS Participants included 20 adults aged 19 to 28 years. Participants were randomly assigned either (i) an electric toothbrush with a monitor to visualise red-fluorescent dental plaque via a camera built into the brush head (monitor usage group, n = 10) or (ii) an electric toothbrush without a monitor (monitor-non-use group, n = 10). The amount of dental plaque was assessed by personal hygiene performance (PHP) at baseline and 1 week later. RESULTS In the monitor-usage group, PHP score was significantly lower at the 1-week follow-up than at baseline (6 vs 16; range, 0-12 vs 13-21; P = 0.029). This change was not observed in the monitor-non-use group (14 vs 13; range, 6-21 vs 2-26; P = 0.778). After 1 week, the change in PHP scores in the monitor usage group was significantly greater than that in the monitor non-use group (- 10 vs 0; range, - 21 to 9 vs - 8 to 16; P = 0.021). CONCLUSIONS Our results clearly demonstrate that brushing teeth while looking at a monitor that depicts red-autofluorescent dental plaque via application of QLF-D improved the efficacy of dental-plaque removal relative to brushing teeth without a monitor. TRIAL REGISTRATION Trial registration number: UMIN000033699. Name of registry: Study on effect of new devise for oral care on dental plaque clearance. Date of registration: 8th September 2018. Status of registration: Completed.",2020,"After 1 week, the change in PHP scores in the monitor usage group was significantly greater than that in the monitor non-use group (- 10 vs 0; range, - 21 to 9 vs - 8 to 16; P = 0.021). ","['Name of registry', 'Participants included 20 adults aged 19 to 28\u2009years']","['electric toothbrush with a monitor to visualise red-fluorescent dental plaque via a camera built into the brush head (monitor usage group, n\xa0', 'electric toothbrush', 'electric toothbrushes with and without QLF-D-applied plaque visualization']","['change in PHP scores', 'dental plaque clearance', 'personal hygiene performance (PHP', 'PHP score']","[{'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C1740271', 'cui_str': 'Electric toothbrush'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C0332575', 'cui_str': 'Red color (finding)'}, {'cui': 'C0303920', 'cui_str': 'Fluorescent'}, {'cui': 'C0011389', 'cui_str': 'Dental Plaque'}, {'cui': 'C0179533', 'cui_str': 'Camera'}, {'cui': 'C0443165', 'cui_str': 'Brushing, function (observable entity)'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0457083', 'cui_str': 'Usage (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0011389', 'cui_str': 'Dental Plaque'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0564673', 'cui_str': 'Personal hygiene activities, function (observable entity)'}]",20.0,0.124721,"After 1 week, the change in PHP scores in the monitor usage group was significantly greater than that in the monitor non-use group (- 10 vs 0; range, - 21 to 9 vs - 8 to 16; P = 0.021). ","[{'ForeName': 'Sumio', 'Initials': 'S', 'LastName': 'Akifusa', 'Affiliation': 'School of Oral Health Sciences, Faculty of Dentistry, Kyushu Dental University, 2-6-1, Manazuru, Kokurakita-ku, Kitakyushu, Fukuoka, 803-8580, Japan. r11akifusa@fa.kyu-dent.ac.jp.'}, {'ForeName': 'Ayaka', 'Initials': 'A', 'LastName': 'Isobe', 'Affiliation': 'School of Oral Health Sciences, Faculty of Dentistry, Kyushu Dental University, 2-6-1, Manazuru, Kokurakita-ku, Kitakyushu, Fukuoka, 803-8580, Japan.'}, {'ForeName': 'Kanako', 'Initials': 'K', 'LastName': 'Kibata', 'Affiliation': 'School of Oral Health Sciences, Faculty of Dentistry, Kyushu Dental University, 2-6-1, Manazuru, Kokurakita-ku, Kitakyushu, Fukuoka, 803-8580, Japan.'}, {'ForeName': 'Akinori', 'Initials': 'A', 'LastName': 'Oyama', 'Affiliation': 'HA-PPY Co, Ltd., 1041-57, Tsuruhata-cho, Kita-ku, Kumamoto, 861-5513, Japan.'}, {'ForeName': 'Hiroko', 'Initials': 'H', 'LastName': 'Oyama', 'Affiliation': 'HA-PPY Co, Ltd., 1041-57, Tsuruhata-cho, Kita-ku, Kumamoto, 861-5513, Japan.'}, {'ForeName': 'Wataru', 'Initials': 'W', 'LastName': 'Ariyoshi', 'Affiliation': 'Division of Infections and Molecular Biology, Department of Health Promotion, Kyushu Dental University, 2-6-1, Manazuru, Kokurakita-ku, Kitakyushu, Fukuoka, 803-8580, Japan.'}, {'ForeName': 'Tatsuji', 'Initials': 'T', 'LastName': 'Nishihara', 'Affiliation': 'Division of Infections and Molecular Biology, Department of Health Promotion, Kyushu Dental University, 2-6-1, Manazuru, Kokurakita-ku, Kitakyushu, Fukuoka, 803-8580, Japan.'}]",BMC oral health,['10.1186/s12903-019-0982-3'] 3141,25573533,Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.,"BACKGROUND Olaparib (Lynparza) is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor that induces synthetic lethality in cancers with homologous recombination defects. PATIENTS AND METHODS In this phase I, dose-escalation trial, patients with advanced solid tumours received olaparib (50-200 mg capsules b.i.d.) continuously or intermittently (days 1-14, per 28-day cycle) plus gemcitabine [i.v. 600-800 mg/m(2); days 1, 8, 15, and 22 (cycle 1), days 1, 8, and 15 (subsequent cycles)] to establish the maximum tolerated dose. A separate dose-escalation phase evaluated olaparib in tablet formulation (100 mg o.d./b.i.d.; days 1-14) plus gemcitabine (600 mg/m(2)). In an expansion phase, patients with genetically unselected locally advanced or metastatic pancreatic cancer were randomised 2 : 1 to the tolerated olaparib capsule combination dose or gemcitabine alone (1000 mg/m(2)). RESULTS Sixty-six patients were treated [dose-escalation phase, n = 44 (tablet cohort, n = 12); dose-expansion phase, n = 22 (olaparib plus gemcitabine, n = 15; gemcitabine alone, n = 7)]. In the dose-escalation phase, four patients (6%) experienced dose-limiting toxicities (raised alanine aminotransferase, n = 2; neutropenia, n = 1; febrile neutropenia, n = 1). Grade ≥3 adverse events were reported in 38/47 patients (81%) treated with olaparib capsules plus gemcitabine; most common were haematological toxicities (55%). Tolerated combinations were olaparib 100 mg b.i.d. capsule (intermittently, days 1-14) plus gemcitabine 600 mg/m(2) and olaparib 100 mg o.d. tablet (intermittently, days 1-14) plus gemcitabine 600 mg/m(2). There were no differences in efficacy observed during the dose-expansion phase. CONCLUSIONS Olaparib 100 mg b.i.d. (intermittent dosing; capsules) plus gemcitabine 600 mg/m(2) is tolerated in advanced solid tumour patients, with no unmanageable/unexpected toxicities. Continuous dosing of olaparib or combination with gemcitabine at doses >600 mg/m(2) was not considered to have an acceptable tolerability profile for further study. CLINICALTRIALSGOV NCT00515866.",2015,"There were no differences in efficacy observed during the dose-expansion phase. ","['patients with genetically unselected locally advanced or metastatic pancreatic cancer', 'cancers with homologous recombination defects', 'patients with locally advanced/metastatic pancreatic cancer', 'patients with advanced solid tumours and comparison with', 'patients with advanced solid tumours received']","['olaparib (50-200 mg capsules b.i.d', 'gemcitabine 600 mg/m(2) and olaparib 100 mg o.d', 'gemcitabine', 'olaparib capsules plus gemcitabine', 'gemcitabine alone', 'poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor', 'olaparib plus gemcitabine', 'Olaparib (Lynparza', 'olaparib or combination with gemcitabine', 'Olaparib', 'tolerated olaparib capsule combination dose or gemcitabine alone']","['efficacy', 'toxicities', 'dose-limiting toxicities (raised alanine aminotransferase, n = 2; neutropenia, n = 1; febrile neutropenia', 'haematological toxicities', 'Grade ≥3 adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0346647', 'cui_str': 'Cancer of Pancreas'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0599773', 'cui_str': 'Homologous Recombination'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0280100', 'cui_str': 'Solid tumour'}]","[{'cui': 'C2316164', 'cui_str': 'olaparib'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C4520026', 'cui_str': 'olaparib 100 MG'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0032405', 'cui_str': 'Poly(ADPR) Polymerase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C3872110', 'cui_str': 'Lynparza'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]","[{'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0442818', 'cui_str': 'Raised (qualifier value)'}, {'cui': 'C0201836', 'cui_str': 'Alanine aminotransferase measurement (procedure)'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0746883', 'cui_str': 'Febrile Neutropenia'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",66.0,0.0257923,"There were no differences in efficacy observed during the dose-expansion phase. ","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Bendell', 'Affiliation': 'Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology, Nashville. Electronic address: jbendell@tnonc.com.'}, {'ForeName': 'E M', 'Initials': 'EM', 'LastName': ""O'Reilly"", 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, USA.'}, {'ForeName': 'M R', 'Initials': 'MR', 'LastName': 'Middleton', 'Affiliation': 'Department of Oncology, University of Oxford, Oxford.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Chau', 'Affiliation': 'Department of Medicine, Royal Marsden Hospital, Sutton, UK.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Hochster', 'Affiliation': 'Yale Cancer Center, Yale School of Medicine, New Haven, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Fielding', 'Affiliation': 'Global Medicines Development, AstraZeneca.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Burke', 'Affiliation': 'Clinical Pharmacology, AstraZeneca, Macclesfield, UK.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Burris', 'Affiliation': 'Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology, Nashville.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdu581'] 3142,31992079,"Rehabilitation of speech disorders following glossectomy, based on ultrasound visual illustration and feedback.","Intraoral surgery for tongue cancer usually induces speech disorders that have a negative impact on communication and quality of life. Studies have documented the benefit of tongue ultrasound imaging as a visual articulatory feedback for speech rehabilitation. This study aims to assess specifically the complementary contribution of visual feedback to visual illustration (i.e. the display of ultrasound video of target language movements) for the speech rehabilitation of glossectomised patients. Two therapy conditions were used alternately for ten glossectomised French patients randomly divided into two cohorts. The IF cohort benefitted from 10 sessions using illustration alone (IL condition) followed by 10 sessions using illustration supplemented by visual feedback (IL+F condition). The FI cohort followed the opposite protocol, i.e. the first 10 sessions with the IL+F condition, followed by 10 sessions with the IL condition. Phonetic accuracy (Percent Consonants Correct) was monitored at baseline (T0, before the first series) and after each series (T1 and T2) using clinical speech-language assessments. None of the contrasts computed between the two conditions, using logistic regression with random effects models, were found to be statistically significant for the group analysis of assessment scores. Results were significant for a few individuals, with balanced advantages in both conditions. In conclusion, the use of articulatory visual feedback does not seem to bring a decisive advantage over the use of visual illustration, though speech therapists and patients reported that ultrasound feedback was useful at the beginning. This result should be confirmed by similar studies involving other types of speech disorders.",2020,"None of the contrasts computed between the two conditions, using logistic regression with random effects models, were found to be statistically significant for the group analysis of assessment scores.",['glossectomised patients'],"['visual feedback to visual illustration (i.e. the display of ultrasound video of target language movements', 'illustration alone (IL condition) followed by 10 sessions using illustration supplemented by visual feedback (IL+F condition', 'Intraoral surgery']","['communication and quality of life', 'Phonetic accuracy']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C2936181', 'cui_str': 'Visual Feedback'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0023008', 'cui_str': 'Languages'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0442119', 'cui_str': 'Intraoral approach (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0034380'}, {'cui': 'C0031579', 'cui_str': 'Phonetics'}]",,0.0199919,"None of the contrasts computed between the two conditions, using logistic regression with random effects models, were found to be statistically significant for the group analysis of assessment scores.","[{'ForeName': 'Marion', 'Initials': 'M', 'LastName': 'Girod-Roux', 'Affiliation': 'GIPSA-lab, UMR 5216, CNRS - Grenoble Alpes University , Grenoble, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Hueber', 'Affiliation': 'GIPSA-lab, UMR 5216, CNRS - Grenoble Alpes University , Grenoble, France.'}, {'ForeName': 'Diandra', 'Initials': 'D', 'LastName': 'Fabre', 'Affiliation': 'GIPSA-lab, UMR 5216, CNRS - Grenoble Alpes University , Grenoble, France.'}, {'ForeName': 'Silvain', 'Initials': 'S', 'LastName': 'Gerber', 'Affiliation': 'GIPSA-lab, UMR 5216, CNRS - Grenoble Alpes University , Grenoble, France.'}, {'ForeName': 'Mélanie', 'Initials': 'M', 'LastName': 'Canault', 'Affiliation': 'Laboratoire Dynamique du Langage, UMR 5596, CNRS, Université Lumière Lyon 2, & Institut des Sciences et Techniques de la Réadaptation, Université Claude Bernard , Lyon, France.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Bedoin', 'Affiliation': 'Laboratoire Dynamique du Langage, UMR 5596, CNRS, Université Lumière Lyon 2, & Institut des Sciences et Techniques de la Réadaptation, Université Claude Bernard , Lyon, France.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Acher', 'Affiliation': 'Unité Neuro-Vasculaire, Pôle Psychiatrie-Neurologie-Rééducation, CHU Grenoble Alpes , Grenoble, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Béziaud', 'Affiliation': ""Centre Médical Rocheplane , Saint-Martin d'Hères, France.""}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Truy', 'Affiliation': ""Département d'ORL, de Chirurgie cervico-maxillo-faciale et d'Audiophonologie, Groupement Hospitalier Edouard Herriot , Lyon, France.""}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Badin', 'Affiliation': 'GIPSA-lab, UMR 5216, CNRS - Grenoble Alpes University , Grenoble, France.'}]",Clinical linguistics & phonetics,['10.1080/02699206.2019.1700310'] 3143,31901705,Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.,"BACKGROUND BRAF/MEK inhibitor combinations are established treatments for BRAF V600-mutant melanoma based on demonstrated benefits on progression-free survival (PFS) and overall survival (OS). Here, we report an updated analysis of the COLUMBUS (COmbined LGX818 [encorafenib] Used with MEK162 [binimetinib] in BRAF mutant Unresectable Skin cancer) trial with long-term follow-up. METHODS In part 1 of the COLUMBUS trial, 577 patients with advanced/metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomised 1:1:1 to 450 mg of encorafenib QD + 45 mg of binimetinib BID (COMBO450) vs 960 mg of vemurafenib BID (VEM) or 300 mg of encorafenib ENCO QD (ENCO300). An updated analysis was conducted that included PFS, OS, objective response rate, safety and tolerability and analyses of results by prognostic subgroups. RESULTS At data cutoff, there were 116, 113 and 138 deaths in the COMBO450, ENCO300 and VEM treatment arms, respectively. The median OS was 33.6 months (95% confidence interval [CI], 24.4-39.2) for COMBO450, 23.5 months (95% CI, 19.6-33.6) for ENCO300 and 16.9 months (95% CI, 14.0-24.5) for VEM. Compared with VEM, COMBO450 decreased the risk of death by 39% (hazard ratio [HR], 0.61; 95% CI, 0.48-0.79). The updated median PFS for COMBO450 was 14.9 months (95% CI, 11.0-20.2), ENCO300 was 9.6 months (95% CI, 7.4-14.8) and VEM was 7.3 months (95% CI, 5.6-7.9). PFS was longer for COMBO450 vs VEM (HR, 0.51; 95% CI, 0.39-0.67). Landmark OS and PFS results show consistent results for each year analysed. Subgroups all favoured COMBO450 vs VEM. CONCLUSIONS Updated PFS and OS results for COMBO450 from the COLUMBUS trial demonstrate a long-term benefit in patients with advanced BRAF V600-mutated melanoma.",2020,"PFS was longer for COMBO450 vs VEM (HR, 0.51; 95% CI, 0.39-0.67).","['patients with advanced BRAF V600-mutated melanoma', 'BRAF\xa0mutant Unresectable Skin cancer', 'patients with BRAF V600-mutant melanoma', '577 patients with advanced/metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy']","['encorafenib plus binimetinib vs vemurafenib or encorafenib', 'MEK162 [binimetinib', 'encorafenib QD\xa0+\xa045\xa0mg of binimetinib BID (COMBO450) vs 960\xa0mg of vemurafenib BID (VEM) or 300\xa0mg of encorafenib ENCO QD (ENCO300']","['PFS, OS, objective response rate, safety and tolerability', 'median OS', 'tolerability and overall survival', 'PFS', 'risk of death', 'median PFS for COMBO450', 'progression-free survival (PFS) and overall survival (OS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C0007114', 'cui_str': 'Cancer of Skin'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0021083', 'cui_str': 'Immunotherapy'}]","[{'cui': 'C4079208', 'cui_str': 'encorafenib'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C3899947', 'cui_str': 'Binimetinib'}, {'cui': 'C3192263', 'cui_str': 'Vemurafenib'}, {'cui': 'C2830125', 'cui_str': 'MEK162'}, {'cui': 'C0048106', 'cui_str': 'BIDS'}, {'cui': 'C4517908', 'cui_str': '960 (qualifier value)'}, {'cui': 'C4319604', 'cui_str': '300'}]","[{'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",577.0,0.531944,"PFS was longer for COMBO450 vs VEM (HR, 0.51; 95% CI, 0.39-0.67).","[{'ForeName': 'Paolo A', 'Initials': 'PA', 'LastName': 'Ascierto', 'Affiliation': 'Melanoma Unit, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy. Electronic address: paolo.ascierto@gmail.com.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Dummer', 'Affiliation': 'Department of Dermatology, University Hospital Zürich Skin Cancer Center and University Zürich, Zürich, Switzerland.'}, {'ForeName': 'Helen J', 'Initials': 'HJ', 'LastName': 'Gogas', 'Affiliation': 'Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece.'}, {'ForeName': 'Keith T', 'Initials': 'KT', 'LastName': 'Flaherty', 'Affiliation': 'Cancer Center, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Arance', 'Affiliation': 'Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Mandala', 'Affiliation': 'Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'Liszkay', 'Affiliation': 'Department of Dermatology, National Institute of Oncology, Budapest, Hungary.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Garbe', 'Affiliation': 'Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Schadendorf', 'Affiliation': 'Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.'}, {'ForeName': 'Ivana', 'Initials': 'I', 'LastName': 'Krajsova', 'Affiliation': 'Department of Dermato-oncology, University Hospital Prague and Charles University First Medical Faculty, Prague, Czech Republic.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Gutzmer', 'Affiliation': 'Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Jan Willem B', 'Initials': 'JWB', 'LastName': 'de Groot', 'Affiliation': 'Department of Medical Oncology, Isala, Zwolle, Netherlands.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Loquai', 'Affiliation': 'Department of Dermatology, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Ashwin', 'Initials': 'A', 'LastName': 'Gollerkeri', 'Affiliation': 'Pfizer Inc., Boulder, CO, USA.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Pickard', 'Affiliation': 'Pfizer Inc., Boulder, CO, USA.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Robert', 'Affiliation': 'Service of Dermatology, Department of Medicine and Paris-Sud University, Gustave Roussy, Villejuif, France.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.11.016'] 3144,31262544,Resting-state functional connectivity after hydrocortisone administration in patients with post-traumatic stress disorder and borderline personality disorder.,"In a previous study, we found that - in contrast to healthy individuals - patients with borderline personality disorder (BPD) and post-traumatic stress disorder (PTSD) showed better memory retrieval performance after hydrocortisone administration compared to placebo. As these results suggest an altered function of corticosteroid receptors in the brain in PTSD and BPD, we examined the effect of hydrocortisone on brain activation in both disorders. We recruited 40 female healthy controls, 20 female unmedicated patients with PTSD and 18 female unmedicated patients with BPD. We conducted a placebo-controlled cross-over study, in which all participants underwent two resting state MRI measurements after they received either a placebo or 10 mg hydrocortisone orally and in randomized order. There was a time interval of one week between the measurements. We analysed resting state functional connectivity (RSFC) with the hippocampus and the amygdala as seed regions. Compared to healthy controls, both patient groups showed reduced hippocampus RSFC to dorsomedial prefrontal cortex (dmPFC). Positive hippocampus dmPFC RSFC correlated negatively with childhood trauma (r = -0.47) and with severity of clinical symptoms, measured with the Borderline Symptom List (r = -0.44) and the Posttraumatic Stress Diagnostic Scale (r = -0.45). We found neither differences in amygdala RSFC nor an effect of hydrocortisone administration. Childhood trauma might lead to decreased positive hippocampus dmPFC RSFC. This might explain symptoms of PTSD and BPD that are characterized by dysfunctional fear regulation.",2019,"Compared to healthy controls, both patient groups showed reduced hippocampus RSFC to dorsomedial prefrontal cortex (dmPFC).","['40 female healthy controls, 20 female unmedicated patients with PTSD and 18 female unmedicated patients with BPD', 'healthy individuals - patients with borderline personality disorder (BPD) and post-traumatic stress disorder (PTSD', 'patients with post-traumatic stress disorder and borderline personality disorder']","['hydrocortisone', 'placebo']","['hippocampus RSFC to dorsomedial prefrontal cortex (dmPFC', 'Posttraumatic Stress Diagnostic Scale', 'memory retrieval performance', 'Positive hippocampus dmPFC RSFC', 'brain activation', 'severity of clinical symptoms']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0006012', 'cui_str': 'Borderline Personality Disorder'}]","[{'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0949582', 'cui_str': 'Seahorses'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0222045'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",40.0,0.0487814,"Compared to healthy controls, both patient groups showed reduced hippocampus RSFC to dorsomedial prefrontal cortex (dmPFC).","[{'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Metz', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Berlin, Germany. Electronic address: sophie.metz@charite.de.'}, {'ForeName': 'Juliane', 'Initials': 'J', 'LastName': 'Fleischer', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Grimm', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Berlin, Germany; MSB Medical School Berlin, Berlin, Germany; Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Switzerland.'}, {'ForeName': 'Matti', 'Initials': 'M', 'LastName': 'Gärnter', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Berlin, Germany; MSB Medical School Berlin, Berlin, Germany.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Golde', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Moritz', 'Initials': 'M', 'LastName': 'Duesenberg', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Roepke', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Oliver T', 'Initials': 'OT', 'LastName': 'Wolf', 'Affiliation': 'Institute of Cognitive Neuroscience, Department of Cognitive Psychology, Ruhr University Bochum, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Otte', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Wingenfeld', 'Affiliation': 'Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Berlin, Germany.'}]",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,['10.1016/j.euroneuro.2019.05.008'] 3145,31707795,"Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.",,2020,,['Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease'],['Canagliflozin'],['Cardiovascular and Renal Events'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}]","[{'cui': 'C2974540', 'cui_str': 'canagliflozin'}]","[{'cui': 'C0441471', 'cui_str': 'Event (event)'}]",,0.0294316,,"[{'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Cannon', 'Affiliation': ""Cardiovascular Division, Brigham & Women's Hospital and Baim Institute for Clinical Research, Boston, MA (C.P.C.).""}, {'ForeName': 'Vlado', 'Initials': 'V', 'LastName': 'Perkovic', 'Affiliation': 'The George Institute for Global Health, UNSW Sydney, Australia (V.P., H.J.L.H, M.J.J., J.-W.L., B.N.).'}, {'ForeName': 'Rajiv', 'Initials': 'R', 'LastName': 'Agarwal', 'Affiliation': 'Indiana University School of Medicine and VA Medical Center, Indianapolis (R.A.).'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Baldassarre', 'Affiliation': 'Janssen Research & Development, LLC, Raritan, NJ (J.B., R.E.).'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Bakris', 'Affiliation': 'Department of Medicine, University of Chicago Medicine, IL (G.B.).'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Charytan', 'Affiliation': 'Nephrology Division, NYU School of Medicine and NYU Langone Medical Center (D.M.C.).'}, {'ForeName': 'Dick', 'Initials': 'D', 'LastName': 'de Zeeuw', 'Affiliation': 'Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands (D.d.Z., H.J.L.H.).'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Edwards', 'Affiliation': 'Janssen Research & Development, LLC, Raritan, NJ (J.B., R.E.).'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Greene', 'Affiliation': 'Division of Biostatistics, Department of Population Health Sciences, University of Utah, Salt Lake City (T.G.).'}, {'ForeName': 'Hiddo J L', 'Initials': 'HJL', 'LastName': 'Heerspink', 'Affiliation': 'The George Institute for Global Health, UNSW Sydney, Australia (V.P., H.J.L.H, M.J.J., J.-W.L., B.N.).'}, {'ForeName': 'Meg J', 'Initials': 'MJ', 'LastName': 'Jardine', 'Affiliation': 'The George Institute for Global Health, UNSW Sydney, Australia (V.P., H.J.L.H, M.J.J., J.-W.L., B.N.).'}, {'ForeName': 'Adeera', 'Initials': 'A', 'LastName': 'Levin', 'Affiliation': 'Division of Nephrology, University of British Columbia, Vancouver, Canada (A.L.).'}, {'ForeName': 'Jing-Wei', 'Initials': 'JW', 'LastName': 'Li', 'Affiliation': 'The George Institute for Global Health, UNSW Sydney, Australia (V.P., H.J.L.H, M.J.J., J.-W.L., B.N.).'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Neal', 'Affiliation': 'The George Institute for Global Health, UNSW Sydney, Australia (V.P., H.J.L.H, M.J.J., J.-W.L., B.N.).'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Pollock', 'Affiliation': 'Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia (C.P.).'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Wheeler', 'Affiliation': 'Department of Renal Medicine, UCL Medical School, London, United Kingdom (D.C.W.).'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Renal Division of Peking University First Hospital, Beijing, China (H.Z.).'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Zinman', 'Affiliation': 'Lunenfeld-Tanenbaum Research Institute, Mt Sinai Hospital, University of Toronto, Ontario, Canada (B.Z.).'}, {'ForeName': 'Kenneth W', 'Initials': 'KW', 'LastName': 'Mahaffey', 'Affiliation': 'Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, CA (K.W.M.).'}]",Circulation,['10.1161/CIRCULATIONAHA.119.044359'] 3146,32014311,In Vivo Protamine Titration Using Activated Coagulation Time to Neutralize Heparin Anticoagulation in Cardiac Surgery: Proof of Concept.,"OBJECTIVE In vivo protamine titration (IVPT) is based on the observation of a plateau on the decay curve of the celite activated clotting times (ACTs) during protamine infusion for heparin reversal. The aim of the present study was to determine the optimal protamine/heparin ratio to reverse anticoagulation using IVPT curves. DESIGN Prospective, randomized study. SETTING Tertiary care university hospital. PARTICIPANTS The study comprised 138 patients undergoing elective cardiac surgery requiring cardiopulmonary bypass. INTERVENTIONS The control group was given a protamine infusion of 1.3 mg per 1 mg (100 U) of heparin over 21 minutes. ACT was measured every 3 minutes. In the test group, the protamine dose was prepared using the same ratio as for the control group, and ACT values were measured every 3 minutes until a plateau was reached (2 consecutive ACT values <160 s), at which time the protamine infusion was stopped. The protamine/heparin ratio, blood losses, transfusions, and heparin concentrations were recorded. RESULTS The protamine dose was lower in the test group (456.00 ± 105.66 mg [control group] v 295.25 ± 100.60 mg [test group]; p < 0.0001). The mean protamine/heparin ratios were 1.30 ± 0.10 (control group) and 0.81 ± 0.22 (test group) (p < 0.0001). Heparin concentrations were greater in the test group 15 minutes (0.10 [0-0.2] U/mL v 0 [0-0.1] U/mL; p = < 0.0001) and 3 hours (0 [0-0.1] U/mL v 0 [0-0] U/mL; p = 0.0002) after protamine infusion. There was no difference in the blood losses and transfusion requirements. CONCLUSIONS IVPT is safe and efficient in this low-risk population.",2020,Heparin concentrations were greater in the test group 15 minutes (0.10,"['Tertiary care university hospital', 'Cardiac Surgery', '138 patients undergoing elective cardiac surgery requiring cardiopulmonary bypass']","[' U/mL', 'IVPT', 'heparin', 'vivo protamine titration (IVPT']","['protamine/heparin ratio, blood losses, transfusions, and heparin concentrations', 'Heparin concentrations', 'blood losses and transfusion requirements', 'mean protamine/heparin ratios']","[{'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0007202', 'cui_str': 'Heart-Lung Bypass'}]","[{'cui': 'C2945590', 'cui_str': 'unit/mL'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0033603', 'cui_str': 'Protamines'}]","[{'cui': 'C0033603', 'cui_str': 'Protamines'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0199960', 'cui_str': 'Transfusion - action (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",138.0,0.0245595,Heparin concentrations were greater in the test group 15 minutes (0.10,"[{'ForeName': 'Antoine G', 'Initials': 'AG', 'LastName': 'Rochon', 'Affiliation': 'Department of Anesthesia, Montreal Heart Institute, Montreal, Quebec, Canada. Electronic address: antoinerochon@me.com.'}, {'ForeName': 'Sylvain', 'Initials': 'S', 'LastName': 'Bélisle', 'Affiliation': 'Department of Anesthesia, Montreal Heart Institute, Montreal, Quebec, Canada.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Couture', 'Affiliation': 'Department of Anesthesia, Montreal Heart Institute, Montreal, Quebec, Canada.'}, {'ForeName': 'Annik', 'Initials': 'A', 'LastName': 'Fortier', 'Affiliation': 'Department of Montreal Health Innovations Coordinating Center, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'Jean-Sébastien', 'Initials': 'JS', 'LastName': 'Lebon', 'Affiliation': 'Department of Anesthesia, Montreal Heart Institute, Montreal, Quebec, Canada.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Deschamps', 'Affiliation': 'Department of Anesthesia, Montreal Heart Institute, Montreal, Quebec, Canada; Department of Montreal Health Innovations Coordinating Center, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.'}]",Journal of cardiothoracic and vascular anesthesia,['10.1053/j.jvca.2019.12.046'] 3147,31736337,Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.,"BACKGROUND Unlike heart failure with reduced ejection fraction, there is no approved treatment for heart failure with preserved ejection fraction, the predominant phenotype in women. Therefore, there is a greater heart failure therapeutic deficit in women compared with men. METHODS In a prespecified subgroup analysis, we examined outcomes according to sex in the PARAGON-HF trial (Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction), which compared sacubitril-valsartan and valsartan in patients with heart failure with preserved ejection fraction. The primary outcome was a composite of first and recurrent hospitalizations for heart failure and death from cardiovascular causes. We also report secondary efficacy and safety outcomes. RESULTS Overall, 2479 women (51.7%) and 2317 men (48.3%) were randomized. Women were older and had more obesity, less coronary disease, and lower estimated glomerular filtration rate and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels than men. For the primary outcome, the rate ratio for sacubitril-valsartan versus valsartan was 0.73 (95% CI, 0.59-0.90) in women and 1.03 (95% CI, 0.84-1.25) in men ( P interaction = 0.017). The benefit from sacubitril-valsartan was attributable to reduction in heart failure hospitalization. The improvement in New York Heart Association class and renal function with sacubitril-valsartan was similar in women and men, whereas the improvement in Kansas City Cardiomyopathy Questionnaire clinical summary score was less in women than in men. The difference in adverse events between sacubitril-valsartan and valsartan was similar in women and men. CONCLUSIONS As compared with valsartan, sacubitril-valsartan seemed to reduce the risk of heart failure hospitalization more in women than in men. Whereas the possible sex-related modification of the effect of treatment has several potential explanations, the present study does not provide a definite mechanistic basis for this finding. CLINICAL TRIAL REGISTRATION https://www.clinicaltrials.gov. Unique identifier: NCT01920711.",2020,"Women were older, had more obesity, less coronary disease, and lower estimated glomerular filtration rate and NT-proBNP levels than men.","['Women Compared to Men with Heart Failure and Preserved Ejection Fraction', 'patients with HFpEF', '2479 women (51.7%) and 2317 men (48.3%) were randomized']","['Valsartan', 'valsartan', 'Sacubitril-Valsartan', 'sacubitril-valsartan and valsartan', 'sacubitril-valsartan']","['adverse events', 'rate ratio for sacubitril-valsartan versus valsartan', 'glomerular filtration rate and NT-proBNP levels', 'risk of heart failure hospitalization', 'KCCQ-CSS', 'NYHA class and renal function', 'composite of first and recurrent hospitalizations for heart failure and death from cardiovascular causes', 'heart failure hospitalization']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0728887', 'cui_str': 'Preserving (attribute)'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0216784', 'cui_str': 'valsartan'}, {'cui': 'C4033631', 'cui_str': 'sacubitril / valsartan'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C4033631', 'cui_str': 'sacubitril / valsartan'}, {'cui': 'C0216784', 'cui_str': 'valsartan'}, {'cui': 'C0017654', 'cui_str': 'Glomerular Filtration Rate'}, {'cui': 'C1963813', 'cui_str': 'NT-proBNP'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}]",2479.0,0.248688,"Women were older, had more obesity, less coronary disease, and lower estimated glomerular filtration rate and NT-proBNP levels than men.","[{'ForeName': 'John J V', 'Initials': 'JJV', 'LastName': 'McMurray', 'Affiliation': 'BHF Cardiovascular Research Centre, University of Glasgow, UK (J.J.V.M., A.M.J., P.S.J.).'}, {'ForeName': 'Alice M', 'Initials': 'AM', 'LastName': 'Jackson', 'Affiliation': 'BHF Cardiovascular Research Centre, University of Glasgow, UK (J.J.V.M., A.M.J., P.S.J.).'}, {'ForeName': 'Carolyn S P', 'Initials': 'CSP', 'LastName': 'Lam', 'Affiliation': 'National Heart Center Singapore and Duke-National University of Singapore (C.S.P.L.).'}, {'ForeName': 'Margaret M', 'Initials': 'MM', 'LastName': 'Redfield', 'Affiliation': 'Mayo Clinic, Rochester, MN (M.M.R.).'}, {'ForeName': 'Inder S', 'Initials': 'IS', 'LastName': 'Anand', 'Affiliation': 'University of Minnesota, Minneapolis (I.S.A.).'}, {'ForeName': 'Junbo', 'Initials': 'J', 'LastName': 'Ge', 'Affiliation': 'Shanghai Institute of Cardiovascular Diseases, China (J.G.).'}, {'ForeName': 'Marty P', 'Initials': 'MP', 'LastName': 'Lefkowitz', 'Affiliation': 'Novartis Pharmaceuticals, East Hanover, NJ (M.P.L., A.R.R., S.V.S., V.C.S.).'}, {'ForeName': 'Aldo P', 'Initials': 'AP', 'LastName': 'Maggioni', 'Affiliation': 'National Association of Hospital Cardiologists Research Center, Florence, Italy (A.P.M.).'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Martinez', 'Affiliation': 'National University of Cordoba, Argentina (F.M.).'}, {'ForeName': 'Milton', 'Initials': 'M', 'LastName': 'Packer', 'Affiliation': 'Baylor University Medical Center, Dallas, TX (M.P.).'}, {'ForeName': 'Marc A', 'Initials': 'MA', 'LastName': 'Pfeffer', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.A.P., A.M.S., B.C., S.D.S.).""}, {'ForeName': 'Burkert', 'Initials': 'B', 'LastName': 'Pieske', 'Affiliation': 'Department of Internal Medicine and Cardiology, German Center for Cardiovascular Research Partner Site Berlin, Germany (B.P.).'}, {'ForeName': 'Adel R', 'Initials': 'AR', 'LastName': 'Rizkala', 'Affiliation': 'Novartis Pharmaceuticals, East Hanover, NJ (M.P.L., A.R.R., S.V.S., V.C.S.).'}, {'ForeName': 'Shalini V', 'Initials': 'SV', 'LastName': 'Sabarwal', 'Affiliation': 'Novartis Pharmaceuticals, East Hanover, NJ (M.P.L., A.R.R., S.V.S., V.C.S.).'}, {'ForeName': 'Amil M', 'Initials': 'AM', 'LastName': 'Shah', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.A.P., A.M.S., B.C., S.D.S.).""}, {'ForeName': 'Sanjiv J', 'Initials': 'SJ', 'LastName': 'Shah', 'Affiliation': 'Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.).'}, {'ForeName': 'Victor C', 'Initials': 'VC', 'LastName': 'Shi', 'Affiliation': 'Novartis Pharmaceuticals, East Hanover, NJ (M.P.L., A.R.R., S.V.S., V.C.S.).'}, {'ForeName': 'Dirk J', 'Initials': 'DJ', 'LastName': 'van Veldhuisen', 'Affiliation': 'Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (C.S.P.L., D.J.v.V.).'}, {'ForeName': 'Faiez', 'Initials': 'F', 'LastName': 'Zannad', 'Affiliation': ""INSERM Centre d'Investigation Clinic 1433 and Universite de Lorraine, Centre Hospitalier Regional et Universitaire, Nancy, France (F.Z.).""}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Zile', 'Affiliation': 'Medical University of South Carolina and the Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston (M.R.Z.).'}, {'ForeName': 'Maja', 'Initials': 'M', 'LastName': 'Cikes', 'Affiliation': 'Department of Cardiovascular Diseases, University of Zagreb School of Medicine and University Hospital Centre Zagreb, Croatia (M.C.).'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Goncalvesova', 'Affiliation': 'Department of Heart Failure-Transplantation, National Cardiovascular Institute, Bratislava, Slovakia (E.G.).'}, {'ForeName': 'Tzvetana', 'Initials': 'T', 'LastName': 'Katova', 'Affiliation': 'Clinic of Cardiology, National Cardiology Hospital, Sofia, Bulgaria (T.K.).'}, {'ForeName': 'Anamaria', 'Initials': 'A', 'LastName': 'Kosztin', 'Affiliation': 'Heart and Vascular Center, Semmelweis University, Budapest, Hungary (A.K.).'}, {'ForeName': 'Malgorzata', 'Initials': 'M', 'LastName': 'Lelonek', 'Affiliation': 'Department of Noninvasive Cardiology, Medical University of Lodz, Poland (M.L.).'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Sweitzer', 'Affiliation': 'University of Arizona Sarver Heart, Tucson (N.S.).'}, {'ForeName': 'Orly', 'Initials': 'O', 'LastName': 'Vardeny', 'Affiliation': 'Minneapolis VA Center for Care Delivery and Outcomes Research, University of Minnesota (O.V.).'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Claggett', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.A.P., A.M.S., B.C., S.D.S.).""}, {'ForeName': 'Pardeep S', 'Initials': 'PS', 'LastName': 'Jhund', 'Affiliation': 'BHF Cardiovascular Research Centre, University of Glasgow, UK (J.J.V.M., A.M.J., P.S.J.).'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Solomon', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.A.P., A.M.S., B.C., S.D.S.).""}]",Circulation,['10.1161/CIRCULATIONAHA.119.044491'] 3148,32012064,"A Web-Based, Computer-Tailored Intervention to Reduce Alcohol Consumption and Binge Drinking Among Spanish Adolescents: Cluster Randomized Controlled Trial.","BACKGROUND Alcohol consumption, including binge drinking (BD) and heavy episodic drinking (HED), is one of the leading risk factors among Spanish adolescents leading to significant social, health, and economic consequences. Reduction of BD and HED in adolescents can be achieved using Web-based, computer-tailored (CT) interventions, providing highly personalized feedback that is adapted to a person's individual characteristics and needs. Randomized controlled trials assessing the effects of tailored BD reduction programs among Spanish adolescents are scarce. OBJECTIVE The aim of this study was to test the effectiveness of the Web-based, CT intervention Alerta Alcohol, aimed at the prevention of BD in Spanish adolescents. As a secondary outcome, effects on HED, weekly consumption, and any consumption were also assessed. The adherence and process evaluation were assessed. METHODS A cluster randomized controlled trial conducted among 15 Spanish schools was developed. Each school was randomized into either an experimental condition (EC) (N=742) or a control condition (CC) (N=505). Finally, 351 participants for the EC and 261 for the CC were included in the analysis (N=612). Baseline assessment took place in January and February 2017. Demographic variables and alcohol use were assessed at baseline. Follow-up assessment of alcohol use took place 4 months later in May and June 2017. Participants were compared according to their randomization group (EC versus CC). After the baseline assessment, participants in the EC started the intervention, which consisted of short stories about BD, in which CT feedback was based on the I-Change Model for behavior change. Participants in the CC group only received the baseline questionnaire. Effects of the intervention were assessed using a three-level mixed logistic regression analysis for BD, HED, and any consumption, and a three-level mixed linear regression analysis for weekly consumption. RESULTS In total, 1247 adolescents participated in the baseline assessment and 612 participated in the follow-up assessment; the attrition rate was 50.92%. The intervention was effective in reducing HED among adolescents; the odds of HED in the CC was nine times that in the experimental condition (P=.04). No effects were found for BD, weekly consumption, and any consumption. Process evaluations revealed that the adolescents were satisfied with the program (68.8%), would use the program again (52.9%), and would recommend it to someone else (62.8%). Females and non-binge drinkers showed better responses in the process evaluation. CONCLUSIONS Our intervention was effective regarding HED but not regarding BD, weekly consumption, and any consumption. It may be that limiting alcohol consumption to prevent HED was easier in the Spanish context than it was to carry out further steps, such as reducing other patterns of alcohol consumption. Hence, additional actions are needed to accomplish these latter goals, including community approaches and policy actions aimed at denormalizing alcohol consumption among Spanish adolescents. TRIAL REGISTRATION ClinicalTrials.gov NCT03288896; https://clinicaltrials.gov/ct2/show/NCT03288896. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR2-10.1186/s12889-018-5346-4.",2020,"Reduction of BD and HED in adolescents can be achieved using Web-based, computer-tailored (CT) interventions, providing highly personalized feedback that is adapted to a person's individual characteristics and needs.","['Spanish adolescents', 'Females and non-binge drinkers', '1247 adolescents participated in the baseline assessment and 612 participated in the follow-up assessment; the', '351 participants for the EC and 261 for the CC were included in the analysis (N=612', '15 Spanish schools', 'Spanish Adolescents']","['tailored BD reduction programs', 'experimental condition (EC) (N=742) or a control condition (CC', 'Computer-Tailored Intervention']","['Alcohol Consumption and Binge Drinking', 'attrition rate', 'BD, weekly consumption, and any consumption', 'HED, weekly consumption, and any consumption']","[{'cui': 'C3161473', 'cui_str': 'Spaniards (ethnic group)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0556335', 'cui_str': 'Binge drinker (finding)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C4517834', 'cui_str': '612 (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0036375', 'cui_str': 'School'}]","[{'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0009622', 'cui_str': 'Computers'}]","[{'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0596170', 'cui_str': 'Binge overeating'}, {'cui': 'C0684271', 'cui_str': 'Drinkings'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}]",1247.0,0.0517055,"Reduction of BD and HED in adolescents can be achieved using Web-based, computer-tailored (CT) interventions, providing highly personalized feedback that is adapted to a person's individual characteristics and needs.","[{'ForeName': 'José Manuel', 'Initials': 'JM', 'LastName': 'Martinez-Montilla', 'Affiliation': 'Department of Nursing, School of Nursing, Physiotherapy and Podiatry, University of Seville, Seville, Spain.'}, {'ForeName': 'Liesbeth', 'Initials': 'L', 'LastName': 'Mercken', 'Affiliation': 'Department of Health Promotion, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Hein', 'Initials': 'H', 'LastName': 'de Vries', 'Affiliation': 'Department of Health Promotion, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Math', 'Initials': 'M', 'LastName': 'Candel', 'Affiliation': 'Care and Public Health Research Institute, Maastricht, Netherlands.'}, {'ForeName': 'Joaquín Salvador', 'Initials': 'JS', 'LastName': 'Lima-Rodríguez', 'Affiliation': 'Department of Nursing, School of Nursing, Physiotherapy and Podiatry, University of Seville, Seville, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Lima-Serrano', 'Affiliation': 'Department of Nursing, School of Nursing, Physiotherapy and Podiatry, University of Seville, Seville, Spain.'}]",Journal of medical Internet research,['10.2196/15438'] 3149,31964369,In vitro evaluation of a ceramic bracket with a laser-structured base.,"BACKGROUND The purpose of this study was the assessment of shear bond strength (SBS), adhesive remnant characteristics, integrity of the enamel, integrity of Discovery Pearl as well as the integrity of Fascination 2 ceramic brackets following SBS testing. METHODS Sixty maxillary first premolars were randomly assigned into two groups. These groups were bonded with their respective brackets. The samples underwent thermocycling (1000 cycles), SBS testing and assessment of the residual adhesive. The statistical analyses used were the independent samples t-test, the Weibull analysis and the chi-square test. RESULTS The independent samples t-test for the comparison of the mean SBS resulted in significant differences between Fascination 2 (10.50 ± 2.61 MPa) and Pearl (13.01 ± 2.50 MPa) brackets (p = 0.0003). The results of the chi-square test for ARI demonstrated a significant difference (p = 0.000) between the groups. A higher frequency of ARI scores of 2 and 3 for Pearl brackets existed. Enamel damage and bracket fracturing was not observed. CONCLUSIONS The mean bond strength value, the adhesive remnant characteristics, the integrity of the enamel and the ceramic brackets as well as the Weibull analyses outcomes were highly encouraging during this in vitro screening. The way is paved for an in vivo investigation with the Pearl ceramic bracket.",2020,The results of the chi-square test for ARI demonstrated a significant difference (p = 0.000) between the groups.,['Sixty maxillary first premolars'],[],"['mean bond strength value', 'ARI scores', 'shear bond strength (SBS', 'Enamel damage and bracket fracturing']","[{'cui': 'C1704302', 'cui_str': 'Premolar'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0028758', 'cui_str': 'Object Relationship'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0011350', 'cui_str': 'Enamel'}, {'cui': 'C0010957', 'cui_str': 'Damage (morphologic abnormality)'}]",,0.0335165,The results of the chi-square test for ARI demonstrated a significant difference (p = 0.000) between the groups.,"[{'ForeName': 'Selma', 'Initials': 'S', 'LastName': 'Elekdag-Türk', 'Affiliation': 'Faculty of Dentistry, Department of Orthodontics, University of Ondokuz Mayis, 55139 Kurupelit, Samsun, Turkey. elekdagturk@yahoo.com.'}]",BMC oral health,['10.1186/s12903-020-1009-9'] 3150,32006264,Effect of CO 2 laser (10.6 μm) and Remin Pro on microhardness of enamel white spot lesions.,"This study investigated the combined effect of CO 2 laser irradiation and Remin Pro paste on microhardness of enamel white spot lesions (WSLs). Seventy-eight intact premolars were randomly assigned into six groups and then stored in a demineralizing solution to create WSLs. Afterwards, the teeth in group 6 (negative control) remained untreated, while groups 1 and 4 were exposed to CO 2 laser irradiation (20 Hz, 1 W, 30 s) and Remin Pro paste, respectively. In groups 2 and 3, the teeth were exposed to laser either before (group 2) or after (group 3) Remin Pro application. The teeth in groups 1 to 5 were then immersed in artificial saliva for 90 days while subjected to fluoride mouthwash and weekly brushing. Finally, the teeth were sectioned, and Vickers microhardness was measured at the enamel surface and at 50, 100, and 150 μm from the surface. One sample of each group was also examined with scanning electron microscope (SEM). Data were analyzed by two-way analysis of variance (ANOVA) and Tukey's test. The significance was set at 0.05. Laser irradiation followed by Remin Pro application (group 2) caused a significant increase in total WSLs' microhardness compared with laser alone (group 1) and control groups (P < 0.05). Microhardness at depths of 100 and 150 μm was also significantly greater in group 2 compared with those of group 3 and control groups (P < 0.05). Combined application of CO 2 laser with Remin Pro paste, when laser is irradiated before the paste, is suggested for re-hardening of WSLs in deep layers of enamel.",2020,Microhardness at depths of 100 and 150 μm was also significantly greater in group 2 compared with those of group 3 and control groups (P < 0.05).,['Seventy-eight intact premolars'],"['demineralizing solution to create WSLs', 'CO 2 laser irradiation and Remin Pro paste', 'Laser irradiation followed by Remin Pro application', 'CO 2 laser irradiation', 'scanning electron microscope (SEM', 'CO 2 laser with Remin Pro paste', 'CO 2 laser (10.6\xa0μm) and Remin Pro', 'fluoride mouthwash and weekly brushing']","['microhardness of enamel white spot lesions (WSLs', ""total WSLs' microhardness""]","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205266', 'cui_str': 'Intact (qualifier value)'}, {'cui': 'C1704302', 'cui_str': 'Premolar'}]","[{'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C1282930', 'cui_str': 'Irradiation (physical force)'}, {'cui': 'C0030634', 'cui_str': 'Pastes'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C0181845', 'cui_str': 'Electron microscope'}, {'cui': 'C0016327', 'cui_str': 'Fluorides'}, {'cui': 'C0026647', 'cui_str': 'Oral Rinse'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}]","[{'cui': 'C0011350', 'cui_str': 'Enamel'}, {'cui': 'C0043154', 'cui_str': 'Dental White Spot'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",,0.0130004,Microhardness at depths of 100 and 150 μm was also significantly greater in group 2 compared with those of group 3 and control groups (P < 0.05).,"[{'ForeName': 'Elahe', 'Initials': 'E', 'LastName': 'Rafiei', 'Affiliation': 'Department of Orthodontics, Faculty of Dentistry, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Pooya', 'Initials': 'P', 'LastName': 'Fadaei Tehrani', 'Affiliation': 'Dental Students Research Center, Faculty of Dentistry, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. pooya.fadaei@yahoo.com.'}, {'ForeName': 'Soghra', 'Initials': 'S', 'LastName': 'Yassaei', 'Affiliation': 'Department of Orthodontics, Faculty of Dentistry, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Haerian', 'Affiliation': 'Department of Orthodontics, Faculty of Dentistry, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}]",Lasers in medical science,['10.1007/s10103-020-02970-y'] 3151,31961418,Effect of Hydroxyethyl Starch vs Saline for Volume Replacement Therapy on Death or Postoperative Complications Among High-Risk Patients Undergoing Major Abdominal Surgery: The FLASH Randomized Clinical Trial.,"Importance It is not known if use of colloid solutions containing hydroxyethyl starch (HES) to correct for intravascular deficits in high-risk surgical patients is either effective or safe. Objective To evaluate the effect of HES 130/0.4 compared with 0.9% saline for intravascular volume expansion on mortality and postoperative complications after major abdominal surgery. Design, Setting, and Participants Multicenter, double-blind, parallel-group, randomized clinical trial of 775 adult patients at increased risk of postoperative kidney injury undergoing major abdominal surgery at 20 university hospitals in France from February 2016 to July 2018; final follow-up was in October 2018. Interventions Patients were randomized to receive fluid containing either 6% HES 130/0.4 diluted in 0.9% saline (n = 389) or 0.9% saline alone (n = 386) in 250-mL boluses using an individualized hemodynamic algorithm during surgery and for up to 24 hours on the first postoperative day, defined as ending at 7:59 am the following day. Main Outcomes and Measures The primary outcome was a composite of death or major postoperative complications at 14 days after surgery. Secondary outcomes included predefined postoperative complications within 14 days after surgery, durations of intensive care unit and hospital stays, and all-cause mortality at postoperative days 28 and 90. Results Among 826 patients enrolled (mean age, 68 [SD, 7] years; 91 women [12%]), 775 (94%) completed the trial. The primary outcome occurred in 139 of 389 patients (36%) in the HES group and 125 of 386 patients (32%) in the saline group (difference, 3.3% [95% CI, -3.3% to 10.0%]; relative risk, 1.10 [95% CI, 0.91-1.34]; P = .33). Among 12 prespecified secondary outcomes reported, 11 showed no significant difference, but a statistically significant difference was found in median volume of study fluid administered on day 1: 1250 mL (interquartile range, 750-2000 mL) in the HES group and 1500 mL (interquartile range, 750-2150 mL) in the saline group (median difference, 250 mL [95% CI, 83-417 mL]; P = .006). At 28 days after surgery, 4.1% and 2.3% of patients had died in the HES and saline groups, respectively (difference, 1.8% [95% CI, -0.7% to 4.3%]; relative risk, 1.76 [95% CI, 0.79-3.94]; P = .17). Conclusions and Relevance Among patients at risk of postoperative kidney injury undergoing major abdominal surgery, use of HES for volume replacement therapy compared with 0.9% saline resulted in no significant difference in a composite outcome of death or major postoperative complications within 14 days after surgery. These findings do not support the use of HES for volume replacement therapy in such patients. Trial Registration ClinicalTrials.gov Identifier: NCT02502773.",2020,"The primary outcome occurred in 139 of 389 patients (36%) in the HES group and 125 of 386 patients (32%) in the saline group (difference, 3.3% [95% CI, -3.3% to 10.0%]; relative risk, 1.10 [95% CI, 0.91-1.34]; P = .33).","['826 patients enrolled (mean age', 'after major abdominal surgery', 'Undergoing Major Abdominal Surgery', '775 adult patients at increased risk of postoperative kidney injury undergoing major abdominal surgery at 20 university hospitals in France from February 2016 to July 2018; final follow-up was in October 2018', '68 [SD, 7] years; 91 women [12%]), 775 (94%) completed the trial', 'High-Risk Patients', 'patients at risk of postoperative kidney injury undergoing major abdominal surgery']","['Hydroxyethyl Starch vs Saline', 'colloid solutions containing hydroxyethyl starch (HES', 'fluid containing either 6% HES 130/0.4 diluted in 0.9% saline (n\u2009=\u2009389) or 0.9% saline alone (n\u2009=\u2009386) in 250-mL boluses using an individualized hemodynamic algorithm', 'HES']","['mortality and postoperative complications', 'Death or Postoperative Complications', 'postoperative complications within 14 days after surgery, durations of intensive care unit and hospital stays, and all-cause mortality at postoperative days 28 and 90', 'composite outcome of death or major postoperative complications', 'median volume of study fluid', 'composite of death or major postoperative complications']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C4517874', 'cui_str': '775'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C1444641', 'cui_str': 'At risk'}]","[{'cui': 'C0020352', 'cui_str': 'hydroxyethylstarch'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0009361', 'cui_str': 'Colloids'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C1720119', 'cui_str': 'Dilute'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C4517752', 'cui_str': '389 (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0002045'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0032787', 'cui_str': 'Postoperative Complications'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}]",775.0,0.683203,"The primary outcome occurred in 139 of 389 patients (36%) in the HES group and 125 of 386 patients (32%) in the saline group (difference, 3.3% [95% CI, -3.3% to 10.0%]; relative risk, 1.10 [95% CI, 0.91-1.34]; P = .33).","[{'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Futier', 'Affiliation': 'Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Département Anesthésie et Réanimation, Hôpital Estaing, Université Clermont Auvergne, CNRS, Inserm U-1103, Clermont-Ferrand, France.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Garot', 'Affiliation': 'CHU de Lille, Pôle Anesthésie Réanimation, Hôpital Claude Huriez, Lille, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Godet', 'Affiliation': 'CHU de Clermont-Ferrand, Département Anesthésie et Réanimation, Hôpital Estaing, Clermont-Ferrand, France.'}, {'ForeName': 'Matthieu', 'Initials': 'M', 'LastName': 'Biais', 'Affiliation': 'CHU de Bordeaux, Département Anesthésie et Réanimation, Hôpital Pellegrin, Bordeaux, France.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Verzilli', 'Affiliation': 'CHU Montpellier, Département Anesthésie et Réanimation B (DAR B), Hôpital Saint-Eloi, and Inserm U-1046, Montpellier, France.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Ouattara', 'Affiliation': 'CHU de Bordeaux, Service Anesthésie et Réanimation, Centre Medico-chirugical Magellan, Bordeaux, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Huet', 'Affiliation': 'CHU de Brest, Département Anesthésie et Réanimation, Hôpital La cavale Blanche, Brest, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Lescot', 'Affiliation': 'Fresenius Kabi, Paris, France.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Lebuffe', 'Affiliation': 'CHU de Lille, Pôle Anesthésie Réanimation, Hôpital Claude Huriez, Lille, France.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Dewitte', 'Affiliation': 'CHU de Bordeaux, Service Anesthésie et Réanimation, Centre Medico-chirugical Magellan, Bordeaux, France.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Cadic', 'Affiliation': 'CHU de Brest, Département Anesthésie et Réanimation, Hôpital La cavale Blanche, Brest, France.'}, {'ForeName': 'Aymeric', 'Initials': 'A', 'LastName': 'Restoux', 'Affiliation': 'AP-HP, Département Anesthésie et Réanimation, Hôpital Beaujon, Clichy, Paris, France.'}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Asehnoune', 'Affiliation': 'CHU de Nantes, Département Anesthésie et Réanimation, Hôpital Hôtel Dieu, Nantes, France.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Paugam-Burtz', 'Affiliation': 'AP-HP, Département Anesthésie et Réanimation, Hôpital Beaujon, Clichy, Paris, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Cuvillon', 'Affiliation': ""CHU de Nîmes, Section d'Anesthésie, Département Anesthésie et Réanimation, Nîmes, France.""}, {'ForeName': 'Marion', 'Initials': 'M', 'LastName': 'Faucher', 'Affiliation': 'Institut Paoli Calmettes, Département Anesthésie et Réanimation, Marseille, France.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Vaisse', 'Affiliation': 'Assistance Publique Hôpitaux de Marseille (AP-HM), Service Anesthésie et Réanimation, Hôpital Timone, Marseille, France.'}, {'ForeName': 'Younes', 'Initials': 'Y', 'LastName': 'El Amine', 'Affiliation': 'Centre Hospitalier de Valenciennes, Département Anesthésie et Réanimation, Valenciennes, France.'}, {'ForeName': 'Hélène', 'Initials': 'H', 'LastName': 'Beloeil', 'Affiliation': 'Université de Rennes, Inserm, INRA, CHU Rennes, CIC 1414, Numecan, Pôle Anesthésie et Réanimation, Rennes, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Leone', 'Affiliation': 'AP-HM, Service Anesthésie et Réanimation, Hôpital Nord, Université Aix Marseille, Marseille, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Noll', 'Affiliation': ""Hôpitaux Universitaires de Strasbourg, Service d'Anesthésie Réanimation Chirurgicale, Hôpital Hautepierre, Strasbourg, France.""}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Piriou', 'Affiliation': ""Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Service d'Anesthésie Réanimation, Centre Hospitalier Lyon Sud, Lyon, France.""}, {'ForeName': 'Sigismond', 'Initials': 'S', 'LastName': 'Lasocki', 'Affiliation': 'Département Anesthésie et Réanimation, CHU Angers, Angers, France.'}, {'ForeName': 'Jean-Etienne', 'Initials': 'JE', 'LastName': 'Bazin', 'Affiliation': 'CHU de Clermont-Ferrand, Département Anesthésie et Réanimation, Hôpital Estaing, Clermont-Ferrand, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Pereira', 'Affiliation': 'Biostatistics Unit, Direction de la Recherche Clinique (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France.'}, {'ForeName': 'Samir', 'Initials': 'S', 'LastName': 'Jaber', 'Affiliation': 'CHU Montpellier, Département Anesthésie et Réanimation B (DAR B), Hôpital Saint-Eloi, and Inserm U-1046, Montpellier, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Sigismond', 'Initials': '', 'LastName': 'Lasocki', 'Affiliation': ''}, {'ForeName': 'Olivier', 'Initials': '', 'LastName': 'Huet', 'Affiliation': ''}, {'ForeName': 'Anna', 'Initials': '', 'LastName': 'Cadic', 'Affiliation': ''}, {'ForeName': 'Christophe', 'Initials': '', 'LastName': 'Jacob', 'Affiliation': ''}, {'ForeName': 'Catherine', 'Initials': '', 'LastName': 'Paugam-Burtz', 'Affiliation': ''}, {'ForeName': 'Aymeric', 'Initials': '', 'LastName': 'Restoux', 'Affiliation': ''}, {'ForeName': 'Alexandre', 'Initials': '', 'LastName': 'Ouattara', 'Affiliation': ''}, {'ForeName': 'Ioana', 'Initials': '', 'LastName': 'Feitita', 'Affiliation': ''}, {'ForeName': 'Elsa', 'Initials': '', 'LastName': 'Deloge', 'Affiliation': ''}, {'ForeName': 'Mylène', 'Initials': '', 'LastName': 'Defaye', 'Affiliation': ''}, {'ForeName': 'Olivier', 'Initials': '', 'LastName': 'Joannes-Boyau', 'Affiliation': ''}, {'ForeName': 'Pauline', 'Initials': '', 'LastName': 'Carles', 'Affiliation': ''}, {'ForeName': 'Guya', 'Initials': '', 'LastName': 'Napolitano', 'Affiliation': ''}, {'ForeName': 'Simon', 'Initials': '', 'LastName': 'Monziols', 'Affiliation': ''}, {'ForeName': 'Emmanuel', 'Initials': '', 'LastName': 'Futier', 'Affiliation': ''}, {'ForeName': 'Marie', 'Initials': '', 'LastName': 'Vignaud', 'Affiliation': ''}, {'ForeName': 'Solène', 'Initials': '', 'LastName': 'Paul', 'Affiliation': ''}, {'ForeName': 'Karim', 'Initials': '', 'LastName': 'Gahbiche', 'Affiliation': ''}, {'ForeName': 'Julie', 'Initials': '', 'LastName': 'Fayon', 'Affiliation': ''}, {'ForeName': 'Erwan', 'Initials': '', 'LastName': 'Laroche', 'Affiliation': ''}, {'ForeName': 'Jean-Etienne', 'Initials': '', 'LastName': 'Bazin', 'Affiliation': ''}, {'ForeName': 'Antoine', 'Initials': '', 'LastName': 'Brandely', 'Affiliation': ''}, {'ForeName': 'Charlene', 'Initials': '', 'LastName': 'Le Moal', 'Affiliation': ''}, {'ForeName': 'Gilles', 'Initials': '', 'LastName': 'Lebuffe', 'Affiliation': ''}, {'ForeName': 'Matthias', 'Initials': '', 'LastName': 'Garot', 'Affiliation': ''}, {'ForeName': 'Vincent', 'Initials': '', 'LastName': 'Piriou', 'Affiliation': ''}, {'ForeName': 'Samir', 'Initials': '', 'LastName': 'Jaber', 'Affiliation': ''}, {'ForeName': 'Gérald', 'Initials': '', 'LastName': 'Chanques', 'Affiliation': ''}, {'ForeName': 'Daniel', 'Initials': '', 'LastName': 'Verzilli', 'Affiliation': ''}, {'ForeName': 'Audrey', 'Initials': '', 'LastName': 'De Jong', 'Affiliation': ''}, {'ForeName': 'Alice', 'Initials': '', 'LastName': 'Millot', 'Affiliation': ''}, {'ForeName': 'Anna', 'Initials': '', 'LastName': 'Castagnoli', 'Affiliation': ''}, {'ForeName': 'Marc', 'Initials': '', 'LastName': 'Leone', 'Affiliation': ''}, {'ForeName': 'Bruno', 'Initials': '', 'LastName': 'Pastene', 'Affiliation': ''}, {'ForeName': 'Caroline', 'Initials': '', 'LastName': 'Castelli', 'Affiliation': ''}, {'ForeName': 'Sophie', 'Initials': '', 'LastName': 'Medam', 'Affiliation': ''}, {'ForeName': 'Lionel', 'Initials': '', 'LastName': 'Velly', 'Affiliation': ''}, {'ForeName': 'Camille', 'Initials': '', 'LastName': 'Vaisse', 'Affiliation': ''}, {'ForeName': 'Marion', 'Initials': '', 'LastName': 'Faucher', 'Affiliation': ''}, {'ForeName': 'Karim', 'Initials': '', 'LastName': 'Asehnoune', 'Affiliation': ''}, {'ForeName': 'Esther', 'Initials': '', 'LastName': 'Samba', 'Affiliation': ''}, {'ForeName': 'Antoine', 'Initials': '', 'LastName': 'Roquilly', 'Affiliation': ''}, {'ForeName': 'Marguerite', 'Initials': '', 'LastName': 'Le Penndu', 'Affiliation': ''}, {'ForeName': 'Philippe', 'Initials': '', 'LastName': 'Cuvillon', 'Affiliation': ''}, {'ForeName': 'Jean', 'Initials': '', 'LastName': 'Yves Lefrant', 'Affiliation': ''}, {'ForeName': 'Olivier', 'Initials': '', 'LastName': 'Wira', 'Affiliation': ''}, {'ForeName': 'Elisabeth', 'Initials': '', 'LastName': 'Dubout', 'Affiliation': ''}, {'ForeName': 'Willy-Serge', 'Initials': '', 'LastName': 'Mfam', 'Affiliation': ''}, {'ForeName': 'Thomas', 'Initials': '', 'LastName': 'Lescot', 'Affiliation': ''}, {'ForeName': 'Emilie', 'Initials': '', 'LastName': 'Begneu', 'Affiliation': ''}, {'ForeName': 'Julien', 'Initials': '', 'LastName': 'Burey', 'Affiliation': ''}, {'ForeName': 'Teodora', 'Initials': '', 'LastName': 'Cirilovic', 'Affiliation': ''}, {'ForeName': 'Hélène', 'Initials': '', 'LastName': 'Beloeil', 'Affiliation': ''}, {'ForeName': 'Guillaume', 'Initials': '', 'LastName': 'Allo', 'Affiliation': ''}, {'ForeName': 'Julien', 'Initials': '', 'LastName': 'Pottecher', 'Affiliation': ''}, {'ForeName': 'Benjamin', 'Initials': '', 'LastName': 'Lebas', 'Affiliation': ''}, {'ForeName': 'Clementine', 'Initials': '', 'LastName': 'Venot', 'Affiliation': ''}, {'ForeName': 'Jean Pierre', 'Initials': '', 'LastName': 'Rameau', 'Affiliation': ''}, {'ForeName': 'Florin', 'Initials': '', 'LastName': 'Dimache', 'Affiliation': ''}, {'ForeName': 'Pierre Saint', 'Initials': '', 'LastName': 'Léger', 'Affiliation': ''}, {'ForeName': 'Younes', 'Initials': '', 'LastName': 'El Amine', 'Affiliation': ''}]",JAMA,['10.1001/jama.2019.20833'] 3152,31092112,Effects of the FIFA 11+ on ankle evertors latency time and knee muscle strength in amateur futsal players.,"Background: The FIFA 11+ has shown to increase muscle strength and reduce injury risk. The purpose of this study was to assess the short and long-term effects of the FIFA 11+ on knee strength, and muscle latency after sudden inversion of amateur futsal players. Methods: Seventy-one male futsal players were recruited and randomized to a FIFA 11+ ( n  = 37, age: 27.0 ± 5.1 years) and a control group ( n  = 34, age: 26.0 ± 5.1 years). The FIFA 11+ programme was executed twice a week, for 10 weeks, followed-up after 10 weeks where both groups executed regular warm-ups. Concentric and eccentric isokinetic knee muscle strength was tested and latency time of the evertor muscles after sudden inversion of the ankle was executed with a trapdoor mechanism following an EMG protocol of selected leg muscles (peroneus brevis and peroneus longus). Results: No significant difference were observed between groups for short-term changes in isokinetic strength after adjustment for baseline differences. At long-term, significant gains were obtained after adjustment for baseline differences in eccentric strength for both lower limbs as for the H/Q ratios for the dominant limb. No changes between groups were observed in the peroneus brevis and peroneus longus latency time. Conclusions: Performing FIFA 11+ did not have short-term effects on knee strength and muscle latency after sudden inversion in amateur futsal players. However, significant long-term benefits were observed for eccentric strength and H/Q ratios.",2020,"CONCLUSIONS Performing FIFA 11+ did not have short-term effects on knee strength and muscle latency after sudden inversion in amateur futsal players.","['amateur futsal players', 'Seventy-one male futsal players were recruited and randomized to a FIFA 11+ (n\u2009=\u200937, age: 27.0\u2009±\u20095.1 years) and a control group (n\u2009=\u200934, age: 26.0\u2009±\u20095.1 years']","['Concentric and eccentric isokinetic knee muscle strength', 'FIFA 11']","['knee strength and muscle latency', 'peroneus brevis and peroneus longus latency time', 'isokinetic strength', 'eccentric strength', 'ankle evertors latency time and knee muscle strength', 'eccentric strength and H/Q ratios', 'knee strength, and muscle latency']","[{'cui': 'C1532535', 'cui_str': 'Indoor soccer'}, {'cui': 'C0450389', 'cui_str': '71 (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439744', 'cui_str': 'Concentric (qualifier value)'}, {'cui': 'C0439740', 'cui_str': 'Eccentric (qualifier value)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}]","[{'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0224469', 'cui_str': 'Peroneus longus muscle structure'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439740', 'cui_str': 'Eccentric (qualifier value)'}, {'cui': 'C0003086', 'cui_str': 'Regio tarsalis'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",71.0,0.0313259,"CONCLUSIONS Performing FIFA 11+ did not have short-term effects on knee strength and muscle latency after sudden inversion in amateur futsal players.","[{'ForeName': 'Mário', 'Initials': 'M', 'LastName': 'Lopes', 'Affiliation': 'School of Health Sciences, University of Aveiro, Aveiro, Portugal.'}, {'ForeName': 'João Manuel', 'Initials': 'JM', 'LastName': 'Rodrigues', 'Affiliation': 'IEETA - Institute of Electronics and Informatics Engineering of Aveiro and DETI - Department of Electronics, Telecommunications and Informatics, University of Aveiro, Aveiro, Portugal.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Monteiro', 'Affiliation': 'School of Health Sciences, University of Aveiro, Aveiro, Portugal.'}, {'ForeName': 'Mário', 'Initials': 'M', 'LastName': 'Rodrigues', 'Affiliation': 'School of Health Sciences, University of Aveiro, Aveiro, Portugal.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Costa', 'Affiliation': 'School of Health Sciences and CINTESIS@UA, University of Aveiro, Aveiro, Portugal.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Oliveira', 'Affiliation': 'Faculty of Sport, Research Centre in Physical Activity, Health and Leisure, University of Porto, Porto, Portugal.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Ribeiro', 'Affiliation': 'School of Health Sciences and Institute of Biomedicine - iBiMED, University of Aveiro, Aveiro, Portugal.'}]",European journal of sport science,['10.1080/17461391.2019.1609588'] 3153,31990800,When to Remove the Indwelling Catheter After Minimally Invasive Sacrocolpopexy? CARESS (CAtheter REmoval after Sacrocolpopexy Surgery).,"OBJECTIVE The aim of the study was to determine the best practice guidelines regarding the use of indwelling catheters after minimally invasive sacrocolpopexy. METHODS Multicenter (3 sites) randomized control trial comparing the standard overnight indwelling urethral catheterization (group 2) with removal of catheter immediately after surgery (group 1). Our primary outcome is the need for recatheterization. Secondary outcomes include the number of patients discharged with a catheter, length of hospital stay, number of urinary tract infections, patient satisfaction/pain scores, and whether patients would use the same treatment again. RESULTS There were 32 patients (43.8%) in group 1 and 41 patients (56.2%) in group 2. On average, patients in group 1 required straight catheterization 0.8 (SD = 0.9) times versus 0.6 (SD = 0.9) times for group 2 (P = 0.239). The number of days with a catheter between the 2 groups was not statistically significant. There was no statistical significance between group 1 and group 2 in terms of operative time, times to leave the operating room, and hospital. Zero patients in group 1 and 2 patients in group 2 had a urinary tract infection. After dividing the groups based on whether or not they underwent a transvaginal tape procedure, the final results were similar. CONCLUSIONS We did not observe a difference in the risk of recatheterization or discharge home with a urinary catheter between the 2 groups. Addition of transvaginal tape to sacrocolpopexy did not show a difference in the risk of recatheterization. One reason for the lack of difference between the 2 groups could be due to a lack of power in our study.",2020,"There was no statistical significance between group 1 and group 2 in terms of operative time, times to leave the operating room, and hospital.",[],"['transvaginal tape to sacrocolpopexy', 'standard overnight indwelling urethral catheterization (group 2) with removal of catheter immediately after surgery', 'Indwelling Catheter']","['risk of recatheterization', 'operative time, times to leave the operating room, and hospital', 'risk of recatheterization or discharge home', 'number of patients discharged with a catheter, length of hospital stay, number of urinary tract infections, patient satisfaction/pain scores, and whether patients would use the same treatment again', 'straight catheterization', 'need for recatheterization', 'number of days with a catheter', 'urinary tract infection']",[],"[{'cui': 'C0175672', 'cui_str': 'Vaginal approach (qualifier value)'}, {'cui': 'C1704747', 'cui_str': 'Tape (basic dose form)'}, {'cui': 'C0554325', 'cui_str': 'Sacrocolpopexy (procedure)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439583', 'cui_str': 'Overnight (qualifier value)'}, {'cui': 'C0439848', 'cui_str': 'Indwelling (qualifier value)'}, {'cui': 'C1455681', 'cui_str': 'Insertion of urethral catheter (procedure)'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C0394884', 'cui_str': 'Removal of catheter (procedure)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0007439', 'cui_str': 'In-Dwelling Catheters'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205091', 'cui_str': 'Left (qualifier value)'}, {'cui': 'C0029064', 'cui_str': 'Operating Room'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0030685', 'cui_str': 'Patient Discharge'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1527360', 'cui_str': 'Heterosexuals'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]",,0.0542711,"There was no statistical significance between group 1 and group 2 in terms of operative time, times to leave the operating room, and hospital.","[{'ForeName': 'Muhammad Faisal', 'Initials': 'MF', 'LastName': 'Aslam', 'Affiliation': 'From the Department of Obstetrics and Gynecology at St. John Hospital and Medical Center, Detroit, MI.'}, {'ForeName': 'Ali A', 'Initials': 'AA', 'LastName': 'Bazzi', 'Affiliation': 'From the Department of Obstetrics and Gynecology at St. John Hospital and Medical Center, Detroit, MI.'}, {'ForeName': 'Karen H', 'Initials': 'KH', 'LastName': 'Hagglund', 'Affiliation': 'From the Department of Obstetrics and Gynecology at St. John Hospital and Medical Center, Detroit, MI.'}, {'ForeName': 'Blake C', 'Initials': 'BC', 'LastName': 'Osmundsen', 'Affiliation': 'Division of Organology and Reconstructive Pelvic Surgery, Legacy Health, Portland, OR.'}]",Female pelvic medicine & reconstructive surgery,['10.1097/SPV.0000000000000826'] 3154,31714592,Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses.,"BACKGROUND The thoracic radiotherapy (TRT) target volume for limited-stage small-cell lung cancer (SCLC) has been controversial for decades. In this report, the final results of a prospective randomized trial on the TRT target volume before and after induction chemotherapy are presented. METHODS After 2 cycles of etoposide and cisplatin, patients arm were randomized to receive TRT to the postchemotherapy or prechemotherapy tumor volume in a study arm and a control arm. Involved-field radiotherapy was received in both arms. TRT consisted of 1.5 grays (Gy) twice daily in 30 fractions to up to a total dose of 45 Gy. Lymph node regions were contoured, and intentional and incidental radiation doses were recorded. RESULTS The study was halted early because of slow accrual. Between 2002 and 2017, 159 and 150 patients were randomized to the study arm or the control arm, respectively; and 21.4% and 19.1% of patients, respectively, were staged using positron emission tomography/computed tomography (P = .31). With a median follow-up of 54.1 months (range, 19.9-165.0 months) in survivors, the 3-year local/regional progression-free probability was 58.2% and 65.5% in the study and control arms, respectively (P = .44), and the absolute difference was -7.3% (95% CI, -18.2%, 3.7%). In the study and control arms, the median overall survival was 21.9 months and 26.6 months, respectively, and the 5-year overall survival rate was 22.8% and 28.1%, respectively (P = .26). Grade 3 esophagitis was observed in 5.9% of patients in the study arm versus 15.5% of those in the control arm (P = .01). The isolated out-of-field failure rate was 2.6% in the study arm versus 4.1% in the control arm (P = .46), and all such failures were located in the supraclavicular fossa or contralateral hilum. The regions 7, 3P, 4L, 6, 4R, 5, and 2L received incidental radiation doses >30 Gy. CONCLUSIONS TRT could be limited to the postchemotherapy tumor volume, and involved-field radiotherapy could be routinely applied for limited-stage SCLC.",2020,"The isolated out-of-field failure rate was 2.6% in the study arm versus 4.1% in the control arm (P = .46), and all such failures were located in the supraclavicular fossa or contralateral hilum.","['limited-stage small-cell lung cancer', 'Between 2002 and 2017, 159 and 150 patients']","['postchemotherapy or prechemotherapy', 'thoracic radiotherapy (TRT', 'TRT', 'positron emission tomography/computed tomography', 'etoposide and cisplatin', 'thoracic radiotherapy']","['median overall survival', '3-year local/regional progression-free probability', '5-year overall survival rate', 'Grade 3 esophagitis']","[{'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0149925', 'cui_str': 'Oat Cell Lung Cancer'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C0032743', 'cui_str': 'Positron-Emission Tomography'}, {'cui': 'C0040395', 'cui_str': 'Tomographic imaging'}, {'cui': 'C0015133', 'cui_str': 'Etoposide'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0014868', 'cui_str': 'Esophagitis'}]",,0.103374,"The isolated out-of-field failure rate was 2.6% in the study arm versus 4.1% in the control arm (P = .46), and all such failures were located in the supraclavicular fossa or contralateral hilum.","[{'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'Department of Radiation Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Bao', 'Affiliation': 'Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yu-Jin', 'Initials': 'YJ', 'LastName': 'Xu', 'Affiliation': 'Department of Radiation Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, China.'}, {'ForeName': 'Hui-Neng', 'Initials': 'HN', 'LastName': 'Zhu', 'Affiliation': 'Department of Pathology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Jin-Shi', 'Initials': 'JS', 'LastName': 'Liu', 'Affiliation': 'Department of Thoracic Surgery, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'Clinical Trials Center, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Jin', 'Affiliation': 'Department of Medical Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Radiation Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, China.'}, {'ForeName': 'Hong-Lian', 'Initials': 'HL', 'LastName': 'Ma', 'Affiliation': 'Department of Radiation Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, China.'}, {'ForeName': 'Xiao-Ling', 'Initials': 'XL', 'LastName': 'Xu', 'Affiliation': 'Department of Medical Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Zheng-Bo', 'Initials': 'ZB', 'LastName': 'Song', 'Affiliation': 'Department of Medical Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Hua-Rong', 'Initials': 'HR', 'LastName': 'Tang', 'Affiliation': 'Department of Radiation Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Peng', 'Affiliation': 'Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Fang', 'Affiliation': 'Department of Radiation Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, China.'}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Kong', 'Affiliation': 'Department of Radiation Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, China.'}, {'ForeName': 'Meng-Yuan', 'Initials': 'MY', 'LastName': 'Chen', 'Affiliation': 'Department of Radiation Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, China.'}, {'ForeName': 'Bai-Qiang', 'Initials': 'BQ', 'LastName': 'Dong', 'Affiliation': 'Department of Radiation Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, China.'}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Zhu', 'Affiliation': 'Department of Pathology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Chang', 'Initials': 'C', 'LastName': 'Yu', 'Affiliation': 'Department of Pathology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Xin-Min', 'Initials': 'XM', 'LastName': 'Yu', 'Affiliation': 'Department of Medical Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Hong', 'Affiliation': 'Department of Medical Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Fan', 'Affiliation': 'Department of Medical Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Yi-Ping', 'Initials': 'YP', 'LastName': 'Zhang', 'Affiliation': 'Department of Medical Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Peng-Cheng', 'Initials': 'PC', 'LastName': 'Chen', 'Affiliation': 'Department of Thoracic Surgery, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Zhao', 'Affiliation': 'Department of Thoracic Surgery, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'You-Hua', 'Initials': 'YH', 'LastName': 'Jiang', 'Affiliation': 'Department of Thoracic Surgery, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Xin-Ming', 'Initials': 'XM', 'LastName': 'Zhou', 'Affiliation': 'Department of Thoracic Surgery, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Qi-Xun', 'Initials': 'QX', 'LastName': 'Chen', 'Affiliation': 'Department of Thoracic Surgery, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Wen-Yong', 'Initials': 'WY', 'LastName': 'Sun', 'Affiliation': 'Department of Pathology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Wei-Min', 'Initials': 'WM', 'LastName': 'Mao', 'Affiliation': 'Department of Thoracic Surgery, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': 'Department of Radiation Oncology, Institute of Cancer Research and Basic Medical Sciences and University Cancer Hospital, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, China.'}]",Cancer,['10.1002/cncr.32586'] 3155,31991513,High-dose nitroglycerin administered during rewarming preserves erythrocyte deformability in cardiac surgery with cardiopulmonary bypass.,"OBJECTIVE We aimed to determine whether high-dose nitroglycerin, a nitric oxide donor, preserves erythrocyte deformability during cardiopulmonary bypass and examines the signaling pathway of nitric oxide in erythrocytes. METHODS In a randomized and controlled fashion, forty-two patients undergoing cardiac surgery with hypothermic cardiopulmonary bypass were allocated to high-dose (N = 21) and low-dose groups (N = 21). During rewarming period, patients were given intravenous nitroglycerin with an infusion rate 5 and 1 µg·kg -1 ·min -1 in high-dose and low-dose groups, respectively. Tyrosine phosphorylation level of non-muscle myosin IIA in erythrocyte membrane was used as an index of erythrocyte deformability and analyzed using immunoblotting. RESULTS Tyrosine phosphorylation of non-muscle myosin IIA was significantly enhanced after bypass in high-dose group (3.729 ± 1.700 folds, P = .011) but not low-dose group (1.545 ± 0.595 folds, P = .076). Phosphorylation of aquaporin 1, vasodilator-stimulated phosphoprotein, and focal adhesion kinase in erythrocyte membrane was also upregulated in high-dose group after bypass. Besides, plasma nitric oxide level was highly correlated with fold change of non-muscle myosin IIA phosphorylation (Pearson's correlation coefficient .871). CONCLUSIONS High-dose nitroglycerin administered during cardiopulmonary bypass improves erythrocyte deformability through activating phosphorylation of aquaporin 1, vasodilator-stimulated phosphoprotein, and focal adhesion kinase in erythrocytes.",2020,"RESULTS Tyrosine phosphorylation of non-muscle myosin IIA was significantly enhanced after bypass in high-dose group (3.729 ± 1.700 folds, p = 0.011) but not low-dose group (1.545 ± 0.595 folds, p = 0.076).","['forty-two patients undergoing cardiac surgery with', 'Cardiac Surgery with Cardiopulmonary Bypass']","['nitroglycerin', 'Nitroglycerin', 'hypothermic cardiopulmonary bypass']","['Tyrosine phosphorylation of non-muscle myosin IIA', 'erythrocyte deformability', 'plasma nitric oxide level', 'Erythrocyte Deformability']","[{'cui': 'C4319566', 'cui_str': 'Forty-two'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C0007202', 'cui_str': 'Heart-Lung Bypass'}]","[{'cui': 'C0017887', 'cui_str': 'glyceryl trinitrate'}, {'cui': 'C0007202', 'cui_str': 'Heart-Lung Bypass'}]","[{'cui': 'C0041485', 'cui_str': 'L-tyrosine'}, {'cui': 'C0031715', 'cui_str': 'Phosphorylation'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0949646', 'cui_str': 'Myosin A'}, {'cui': 'C0014774', 'cui_str': 'Erythrocyte Filterability'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",42.0,0.0646596,"RESULTS Tyrosine phosphorylation of non-muscle myosin IIA was significantly enhanced after bypass in high-dose group (3.729 ± 1.700 folds, p = 0.011) but not low-dose group (1.545 ± 0.595 folds, p = 0.076).","[{'ForeName': 'Ying-Hsuan', 'Initials': 'YH', 'LastName': 'Tai', 'Affiliation': 'Department of Anesthesiology, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'You-Hsiang', 'Initials': 'YH', 'LastName': 'Chu', 'Affiliation': 'Department of Anesthesiology, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Hsiang-Ling', 'Initials': 'HL', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesiology, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Su-Man', 'Initials': 'SM', 'LastName': 'Lin', 'Affiliation': 'Department of Anesthesiology, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Mei-Yung', 'Initials': 'MY', 'LastName': 'Tsou', 'Affiliation': 'Department of Anesthesiology, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Cheng-Hsiung', 'Initials': 'CH', 'LastName': 'Huang', 'Affiliation': 'School of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Hsiao-Huang', 'Initials': 'HH', 'LastName': 'Chang', 'Affiliation': 'Division of Cardiovascular Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Chih-Cherng', 'Initials': 'CC', 'LastName': 'Lu', 'Affiliation': 'Department of Anesthesiology, Taipei Veterans General Hospital, Taipei, Taiwan.'}]","Microcirculation (New York, N.Y. : 1994)",['10.1111/micc.12608'] 3156,31964340,Study protocol: HipSTHeR - a register-based randomised controlled trial - hip screws or (total) hip replacement for undisplaced femoral neck fractures in older patients.,"BACKGROUND Femoral neck fractures (FNFs), which are common in the older population, are associated with high mortality and morbidity. Some 20% of FNFs are undisplaced (uFNFs). The routine surgical procedure for uFNFs is internal fixation (IF) with 2-3 screws/pins with a reported reoperation rate in older patients (age ≥ 75 years) of up to 21%. The reoperation rate for hemiarthroplasties for displaced fractures is lower than for undisplaced fractures operated with IF. This study will aim to determine whether the outcome for older patients with an uFNF can be improved by replacing the hip instead of preserving it. METHODS A national multicentre, register-based, randomised controlled trial (rRCT) will be conducted. For this trial, 1440 patients, ≥75 years with an acute uFNF, will be allocated. Eligible patients will be identified by the Swedish Fracture Register (SFR) platform, which will notify the admitting orthopaedic surgeon of eligibility. After informed consent has been given and documented, patients will be randomised to either IF (control group) or arthroplasty (intervention group) within the SFR platform. Injury mechanism, fracture classification, date of injury, and type of treatment are registered in the SFR. Type and brand of arthroplasty, surgical approach, and fixation are obtained from the Swedish Hip Arthroplasty Register (SHAR). The study cohort from the SFR will be cross-checked with the National Patient Register and the SHAR for outcome variables at 2, 5, and 10 years. The primary outcome will be a composite variable comprising reoperation rate and mortality at 2 years postoperatively. Secondary endpoints will include reoperation rate and mortality as stand-alone variables. In addition, secondary endpoints will be patient-reported outcomes as measured by the Short Musculoskeletal Functional Assessment questionnaire at 1 year postoperatively as routinely collected within the SFR. Further secondary endpoints will include the occurrence of adverse events such as pneumonia, stroke or myocardial infarction and evaluation of the external validity of the study. DISCUSSION This large, multicentre, register-based randomised controlled trial could potentially shift the treatment of uFNFs in older patients towards primary hip arthroplasty in order to improve the outcome. TRIAL REGISTRATION The trial is registered at www.clinicaltrials.gov (NCT03966716); May 29, 2019.",2020,The reoperation rate for hemiarthroplasties for displaced fractures is lower than for undisplaced fractures operated with IF.,"['1440 patients, ≥75\u2009years with an acute uFNF, will be allocated', 'undisplaced femoral neck fractures in older patients', 'older patients (age\u2009≥\u200975\u2009years) of up to 21', 'Eligible patients will be identified by the Swedish Fracture Register (SFR) platform, which will notify the admitting orthopaedic surgeon of eligibility', 'older patients towards primary hip arthroplasty', 'older patients with an']","['uFNF', 'uFNFs', 'hip screws or (total) hip replacement']","['Short Musculoskeletal Functional Assessment questionnaire', 'reoperation rate', 'reoperation rate and mortality at 2\u2009years postoperatively', 'reoperation rate and mortality as stand-alone variables', 'occurrence of adverse events such as pneumonia, stroke or myocardial infarction and evaluation of the external validity of the study']","[{'cui': 'C4517576', 'cui_str': 'One thousand four hundred and forty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0015806', 'cui_str': 'Femur Neck Fractures'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0334891', 'cui_str': 'Orthopedists'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0186193', 'cui_str': 'Arthroplasty of coxofemoral joint'}]","[{'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0301559', 'cui_str': 'Screw (physical object)'}, {'cui': 'C0392806', 'cui_str': 'Hip Prosthesis Implantation'}]","[{'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0035110', 'cui_str': 'Revision Surgery'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0560204', 'cui_str': 'Does stand alone (finding)'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0042283', 'cui_str': 'Validity (Epidemiology)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]",1440.0,0.215256,The reoperation rate for hemiarthroplasties for displaced fractures is lower than for undisplaced fractures operated with IF.,"[{'ForeName': 'Olof', 'Initials': 'O', 'LastName': 'Wolf', 'Affiliation': 'Department of Surgical Sciences, Orthopaedics, Uppsala University, Uppsala, Sweden. olof.wolf@surgsci.uu.se.'}, {'ForeName': 'Pontus', 'Initials': 'P', 'LastName': 'Sjöholm', 'Affiliation': 'Department of Surgical and Perioperative Sciences (Orthopaedics), Umeå University, Umeå, Sweden.'}, {'ForeName': 'Nils P', 'Initials': 'NP', 'LastName': 'Hailer', 'Affiliation': 'Department of Surgical Sciences, Orthopaedics, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Möller', 'Affiliation': 'Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Mukka', 'Affiliation': 'Department of Surgical and Perioperative Sciences (Orthopaedics), Umeå University, Umeå, Sweden.'}]",BMC geriatrics,['10.1186/s12877-020-1418-2'] 3157,32183831,Randomized controlled trial on the effectiveness of absorbable collagen sponge after extraction of impacted mandibular third molar: split-mouth design.,"BACKGROUND The purpose of this study was to compare the effectiveness of absorbable collagen sponge insertion in tooth extraction sites for socket healing of the impacted mandibular third molar. METHODS Thirty-six patients with bilateral mandibular impacted third molars based on Pell-Gregory and Winter classification were included in this study. This study was a randomized clinical trial utilizing a split-mouth design with one side assigned as collagen sponge insertion and the other side assigned as the control. Post-operative clinical complications, periodontal integrities, and radiographic outcomes were assessed at 1, 2, and 14-weeks post operatively. RESULTS Five patients were excluded during the follow-up period due to loss of follow-up. The study was conducted on 31 patients in total. The mean VAS score of collagen sponge insertion side at 1 week post operation was 1.42 ± 1.26, which was significantly lower than the control side (P < 0.05). The mean probing depth of collagen sponge insertion side at 2-week post operation was 5.55 ± 2.28 mm, which was significantly lower than the control side (7.13 ± 1.86; P < 0.05). Other various measurements including radiographic outcomes showed no significant group differences. CONCLUSIONS Placement of collagen sponge after extraction of mandibular impacted third molar reduced early stage post-operative complications and enhanced initial healing of soft tissues and periodontal defects. TRIAL REGISTRATION This study was retrospectively registered at the WHO ICTRP platform and Clinical Research Information Service, KCT0003363. Registered 21 Sep 2018.",2020,"CONCLUSIONS Placement of collagen sponge after extraction of mandibular impacted third molar reduced early stage post-operative complications and enhanced initial healing of soft tissues and periodontal defects. ","['31 patients in total', 'socket healing of the impacted mandibular third molar', 'Thirty-six patients with bilateral mandibular impacted third molars based on Pell-Gregory and Winter classification were included in this study']","['absorbable collagen sponge insertion', 'absorbable collagen sponge']","['Post-operative clinical complications, periodontal integrities, and radiographic outcomes', 'mean VAS score of collagen sponge insertion side', 'radiographic outcomes', 'mean probing depth of collagen sponge insertion side']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0026369', 'cui_str': 'Tooth, Wisdom'}, {'cui': 'C4319606', 'cui_str': 'Thirty-six'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0008903', 'cui_str': 'taxonomy'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C1705741', 'cui_str': 'Sponge (basic dose form)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}]","[{'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C1947912', 'cui_str': 'Integrity (attribute)'}, {'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C1705741', 'cui_str': 'Sponge (basic dose form)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C3179165', 'cui_str': 'Probe (methazole)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}]",5.0,0.161092,"CONCLUSIONS Placement of collagen sponge after extraction of mandibular impacted third molar reduced early stage post-operative complications and enhanced initial healing of soft tissues and periodontal defects. ","[{'ForeName': 'Jin-Woo', 'Initials': 'JW', 'LastName': 'Kim', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, School of Medicine, Ewha Womans University, Seoul, South Korea.'}, {'ForeName': 'Tae-Whan', 'Initials': 'TW', 'LastName': 'Seong', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, School of Medicine, Ewha Womans University, Seoul, South Korea.'}, {'ForeName': 'Sura', 'Initials': 'S', 'LastName': 'Cho', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, School of Medicine, Ewha Womans University, Seoul, South Korea.'}, {'ForeName': 'Sun-Jong', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, School of Medicine, Ewha Womans University, Seoul, South Korea. oralsurgeonsj@gmail.com.'}]",BMC oral health,['10.1186/s12903-020-1063-3'] 3158,31988084,Opportunistic screening versus usual care for diagnosing atrial fibrillation in general practice: a cluster randomised controlled trial.,"BACKGROUND Atrial fibrillation (AF) increases the risk of stroke, heart failure, and all-cause mortality. AF may be asymptomatic and therefore remain undiagnosed. Devices such as single-lead electrocardiographs (ECGs) may help GPs to diagnose AF. AIM To investigate the yield of opportunistic screening for AF in usual primary care using a single-lead ECG device. DESIGN AND SETTING A clustered, randomised controlled trial among patients aged ≥65 years with no recorded AF status in the Netherlands from October 2014 to March 2016. METHOD Fifteen intervention general practices used a single-lead ECG device at their discretion and 16 control practices offered usual care. The follow-up period was 1 year, and the primary outcome was the proportion of newly diagnosed cases of AF. RESULTS In total, 17 107 older people with no recorded AF status were eligible to participate in the study. In the intervention arm, 10.7% of eligible patients ( n = 919) were screened over the duration of the study year. The rate of newly diagnosed AF was similar in the intervention and control practices (1.43% versus 1.37%, P = 0.73). Screened patients were more likely to have comorbidities, such as hypertension (60.0% versus 48.7%), type 2 diabetes (24.3% versus 18.6%), and chronic obstructive pulmonary disease (11.3% versus 7.4%), than eligible patients not screened in the intervention arm. Among patients with newly diagnosed AF in intervention practices, 27% were detected by screening, 23% by usual primary care, and 50% by a medical specialist or after stroke/transient ischaemic attack. CONCLUSION Opportunistic screening with a single-lead ECG at the discretion of the GP did not result in a higher yield of newly detected cases of AF in patients aged ≥65 years in the community than usual care. For higher participation rates in future studies, more rigorous screening methods are needed.",2020,"Screened patients were more likely to have comorbidities, such as hypertension (60.0% versus 48.7%), type 2 diabetes (24.3% versus 18.6%), and chronic obstructive pulmonary disease (11.3% versus 7.4%), than eligible patients not screened in the intervention arm.","['17 107 older people with no recorded AF status were eligible to participate in the study', 'patients aged ≥65 years with no recorded AF status in the Netherlands from October 2014 to March 2016', 'patients with newly diagnosed AF in intervention practices, 27% were detected by screening, 23% by usual primary care, and 50% by a medical specialist or after stroke/transient ischaemic attack', 'general practice', 'Fifteen intervention general practices used a']","['Opportunistic screening versus usual care', 'single-lead ECG device at their discretion and 16 control practices offered usual care']","['chronic obstructive pulmonary disease', 'rate of newly diagnosed AF', 'proportion of newly diagnosed cases of AF']","[{'cui': 'C4517529', 'cui_str': 'One hundred and seven'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0442726', 'cui_str': 'Detected (qualifier value)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0087009', 'cui_str': 'Specialists'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0007787', 'cui_str': 'Brain TIA'}, {'cui': 'C0086343', 'cui_str': 'General Practice'}]","[{'cui': 'C0422389', 'cui_str': 'Opportunistic screening (procedure)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C1623258', 'cui_str': 'ECG'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1444648', 'cui_str': 'Offered'}]","[{'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}]",17107.0,0.164412,"Screened patients were more likely to have comorbidities, such as hypertension (60.0% versus 48.7%), type 2 diabetes (24.3% versus 18.6%), and chronic obstructive pulmonary disease (11.3% versus 7.4%), than eligible patients not screened in the intervention arm.","[{'ForeName': 'Femke', 'Initials': 'F', 'LastName': 'Kaasenbrood', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Hollander', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht.'}, {'ForeName': 'Steven Hm', 'Initials': 'SH', 'LastName': 'de Bruijn', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht.'}, {'ForeName': 'Carlijn Pe', 'Initials': 'CP', 'LastName': 'Dolmans', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht.'}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Tieleman', 'Affiliation': 'Department of Cardiology, Martini Hospital Groningen; assistant professor, Department of Cardiology, University Medical Center Groningen, Groningen.'}, {'ForeName': 'Arno W', 'Initials': 'AW', 'LastName': 'Hoes', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht.'}, {'ForeName': 'Frans H', 'Initials': 'FH', 'LastName': 'Rutten', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht.'}]",The British journal of general practice : the journal of the Royal College of General Practitioners,['10.3399/bjgp20X708161'] 3159,31667584,Feasibility of ultrasound-guided lumbar epidural access using paramedian transverse scanning with the needle in-plane: a comparison with paramedian sagittal scanning.,"BACKGROUND AND OBJECTIVES The present study was designed to compare the feasibility of ultrasound (US)-guided lumbar epidural access using paramedian sagittal scanning (PMSS) and paramedian transverse scanning (PMTS) approaches. METHODS Fifty patients undergoing surgery of the lower extremities were randomly allocated into 2 groups. The patients in PMSS group received PMSS-guided in-plane epidural access, whereas patients in PMTS group received PMTS-guided in-plane epidural access. The US visibility of neuraxial structures and of Tuohy needle during US scout scan, procedure duration, the number of attempts to access epidural space, Tuohy needle puncture depth in the epidural space, and extent of sensory block after spinal block between two groups were compared. RESULTS The US visibility of Tuohy needle and neuraxial structures was comparable between two groups. There was an overall decrease in procedure duration in the PMTS group relative to the PMSS group (360 ± 42 vs. 490 ± 38 s). The number of attempts needed to access the epidural space in PMSS group was significantly higher than in PMTS group. Distances between the epidural space and the puncture site in PMSS group and PMTS group showed a significant difference (7.13 ± 0.67 vs. 5.24 ± 0.21 cm). No significant differences in the extent of sensory block after spinal block were observed. CONCLUSIONS We found that PMTS approach was superior as a means of achieving epidural access relative to the PMSS approach, since PMTS approach can be conducted more quickly given shorter path of the needle and less times needed for epidural access during this procedure. CLINICAL TRIAL REGISTRATION Chinese Clinical Trial Registry, clinical trial number ChiCTR1800015815, date of registration April 24, 2018.",2020,The US visibility of Tuohy needle and neuraxial structures was comparable between two groups.,['Fifty patients undergoing surgery of the lower extremities'],"['paramedian sagittal scanning', 'PMSS', 'paramedian transverse scanning', 'ultrasound (US)-guided lumbar epidural access using paramedian sagittal scanning (PMSS) and paramedian transverse scanning (PMTS', 'PMTS-guided in-plane epidural access', 'ultrasound-guided lumbar epidural access', 'PMSS-guided in-plane epidural access']","['sensory block after spinal block', 'number of attempts needed to access the epidural space', 'procedure duration', 'US visibility of Tuohy needle and neuraxial structures']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}]","[{'cui': 'C0441993', 'cui_str': 'Paramedian approach (qualifier value)'}, {'cui': 'C0205129', 'cui_str': 'Sagittal (qualifier value)'}, {'cui': 'C0446380', 'cui_str': 'Transverse (qualifier value)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0024090', 'cui_str': 'Lumbar Region'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}]","[{'cui': 'C0445254', 'cui_str': 'Sensory (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0002928', 'cui_str': 'Spinal Anesthesia'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0228134', 'cui_str': 'Epidural Space'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0184186', 'cui_str': 'Tuohy epidural needle'}]",50.0,0.0479317,The US visibility of Tuohy needle and neuraxial structures was comparable between two groups.,"[{'ForeName': 'Huili', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Beijing Chaoyang Hospital, Capital Medical University, No. 8, Gongtinan Road, Chaoyang District, Beijing, 100020, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Kang', 'Affiliation': 'Department of Pharmaceutical Science, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Jin', 'Affiliation': 'Department of Anesthesiology, Miyun Hospital, Beijing, China.'}, {'ForeName': 'Danxu', 'Initials': 'D', 'LastName': 'Ma', 'Affiliation': 'Department of Anesthesiology, Beijing Chaoyang Hospital, Capital Medical University, No. 8, Gongtinan Road, Chaoyang District, Beijing, 100020, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, Beijing Chaoyang Hospital, Capital Medical University, No. 8, Gongtinan Road, Chaoyang District, Beijing, 100020, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Beijing Chaoyang Hospital, Capital Medical University, No. 8, Gongtinan Road, Chaoyang District, Beijing, 100020, China. wangyun129@ccmu.edu.cn.'}]",Journal of anesthesia,['10.1007/s00540-019-02704-7'] 3160,31810865,Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation.,"BACKGROUND Ventilator-associated pneumonia is the most common intensive care unit (ICU)-acquired infection, yet accurate diagnosis remains difficult, leading to overuse of antibiotics. Low concentrations of IL-1β and IL-8 in bronchoalveolar lavage fluid have been validated as effective markers for exclusion of ventilator-associated pneumonia. The VAPrapid2 trial aimed to determine whether measurement of bronchoalveolar lavage fluid IL-1β and IL-8 could effectively and safely improve antibiotic stewardship in patients with clinically suspected ventilator-associated pneumonia. METHODS VAPrapid2 was a multicentre, randomised controlled trial in patients admitted to 24 ICUs from 17 National Health Service hospital trusts across England, Scotland, and Northern Ireland. Patients were screened for eligibility and included if they were 18 years or older, intubated and mechanically ventilated for at least 48 h, and had suspected ventilator-associated pneumonia. Patients were randomly assigned (1:1) to biomarker-guided recommendation on antibiotics (intervention group) or routine use of antibiotics (control group) using a web-based randomisation service hosted by Newcastle Clinical Trials Unit. Patients were randomised using randomly permuted blocks of size four and six and stratified by site, with allocation concealment. Clinicians were masked to patient assignment for an initial period until biomarker results were reported. Bronchoalveolar lavage was done in all patients, with concentrations of IL-1β and IL-8 rapidly determined in bronchoalveolar lavage fluid from patients randomised to the biomarker-based antibiotic recommendation group. If concentrations were below a previously validated cutoff, clinicians were advised that ventilator-associated pneumonia was unlikely and to consider discontinuing antibiotics. Patients in the routine use of antibiotics group received antibiotics according to usual practice at sites. Microbiology was done on bronchoalveolar lavage fluid from all patients and ventilator-associated pneumonia was confirmed by at least 10 4 colony forming units per mL of bronchoalveolar lavage fluid. The primary outcome was the distribution of antibiotic-free days in the 7 days following bronchoalveolar lavage. Data were analysed on an intention-to-treat basis, with an additional per-protocol analysis that excluded patients randomly assigned to the intervention group who defaulted to routine use of antibiotics because of failure to return an adequate biomarker result. An embedded process evaluation assessed factors influencing trial adoption, recruitment, and decision making. This study is registered with ISRCTN, ISRCTN65937227, and ClinicalTrials.gov, NCT01972425. FINDINGS Between Nov 6, 2013, and Sept 13, 2016, 360 patients were screened for inclusion in the study. 146 patients were ineligible, leaving 214 who were recruited to the study. Four patients were excluded before randomisation, meaning that 210 patients were randomly assigned to biomarker-guided recommendation on antibiotics (n=104) or routine use of antibiotics (n=106). One patient in the biomarker-guided recommendation group was withdrawn by the clinical team before bronchoscopy and so was excluded from the intention-to-treat analysis. We found no significant difference in the primary outcome of the distribution of antibiotic-free days in the 7 days following bronchoalveolar lavage in the intention-to-treat analysis (p=0·58). Bronchoalveolar lavage was associated with a small and transient increase in oxygen requirements. Established prescribing practices, reluctance for bronchoalveolar lavage, and dependence on a chain of trial-related procedures emerged as factors that impaired trial processes. INTERPRETATION Antibiotic use remains high in patients with suspected ventilator-associated pneumonia. Antibiotic stewardship was not improved by a rapid, highly sensitive rule-out test. Prescribing culture, rather than poor test performance, might explain this absence of effect. FUNDING UK Department of Health and the Wellcome Trust.",2020,We found no significant difference in the primary outcome of the distribution of antibiotic-free days in the 7 days following bronchoalveolar lavage in the intention-to-treat analysis (p=0·58).,"['patients admitted to 24 ICUs from 17 National Health Service hospital trusts across England, Scotland, and Northern Ireland', 'patients with suspected ventilator-associated pneumonia', 'Patients were screened for eligibility and included if they were 18 years or older, intubated and mechanically ventilated for at least 48 h, and had suspected ventilator-associated pneumonia', 'Between Nov 6, 2013, and Sept 13, 2016, 360 patients were screened for inclusion in the study', 'suspected ventilator-associated pneumonia (VAPrapid2', 'Four patients were excluded before randomisation, meaning that 210 patients', '146 patients were ineligible, leaving 214 who were recruited to the study', 'patients with clinically suspected ventilator-associated pneumonia']","['biomarker-guided recommendation on antibiotics (intervention group) or routine use of antibiotics (control group) using a web-based randomisation service hosted by Newcastle Clinical Trials Unit', 'biomarker-guided recommendation on antibiotics (n=104) or routine use of antibiotics', 'Biomarker-guided antibiotic stewardship']","['oxygen requirements', 'distribution of antibiotic-free days in the 7 days following bronchoalveolar lavage', 'Antibiotic stewardship']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0027462', 'cui_str': 'Health Services, National'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0036453', 'cui_str': 'Scotland'}, {'cui': 'C0028415', 'cui_str': 'Northern Ireland'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}, {'cui': 'C0087153', 'cui_str': 'Ventilators'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C4319607', 'cui_str': '360 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0205091', 'cui_str': 'Left (qualifier value)'}]","[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C4505100', 'cui_str': 'Antibiotic Stewardship'}]","[{'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C1535502', 'cui_str': 'Lung Lavage'}, {'cui': 'C4505100', 'cui_str': 'Antibiotic Stewardship'}]",146.0,0.342377,We found no significant difference in the primary outcome of the distribution of antibiotic-free days in the 7 days following bronchoalveolar lavage in the intention-to-treat analysis (p=0·58).,"[{'ForeName': 'Thomas P', 'Initials': 'TP', 'LastName': 'Hellyer', 'Affiliation': 'Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.'}, {'ForeName': 'Daniel F', 'Initials': 'DF', 'LastName': 'McAuley', 'Affiliation': ""The Wellcome-Wolfson Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK; Regional Intensive Care Unit, The Royal Hospitals, Belfast, UK.""}, {'ForeName': 'Timothy S', 'Initials': 'TS', 'LastName': 'Walsh', 'Affiliation': ""Anaesthesia, Critical Care and Pain Medicine, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, UK; Intensive Care Unit, Royal Infirmary of Edinburgh, Edinburgh, UK.""}, {'ForeName': 'Niall', 'Initials': 'N', 'LastName': 'Anderson', 'Affiliation': 'Usher Institute, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Conway Morris', 'Affiliation': ""Division of Anaesthesia, Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.""}, {'ForeName': 'Suveer', 'Initials': 'S', 'LastName': 'Singh', 'Affiliation': 'Department of Cancer and Surgery, Imperial College London, London, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Dark', 'Affiliation': 'Division of Infection Immunity and Respiratory Medicine, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Alistair I', 'Initials': 'AI', 'LastName': 'Roy', 'Affiliation': 'Integrated Critical Care Unit, Sunderland Royal Hospital, City Hospitals Sunderland NHS Foundation Trust, Sunderland, UK.'}, {'ForeName': 'Gavin D', 'Initials': 'GD', 'LastName': 'Perkins', 'Affiliation': 'Warwick Medical School, University of Warwick, Coventry, UK; Intensive Care Unit, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Ronan', 'Initials': 'R', 'LastName': 'McMullan', 'Affiliation': ""The Wellcome-Wolfson Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Lydia M', 'Initials': 'LM', 'LastName': 'Emerson', 'Affiliation': ""The Wellcome-Wolfson Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Bronagh', 'Initials': 'B', 'LastName': 'Blackwood', 'Affiliation': ""The Wellcome-Wolfson Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Stephen E', 'Initials': 'SE', 'LastName': 'Wright', 'Affiliation': 'Integrated Critical Care Unit, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.'}, {'ForeName': 'Kallirroi', 'Initials': 'K', 'LastName': 'Kefala', 'Affiliation': 'Intensive Care Unit, Royal Infirmary of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Cecilia M', 'Initials': 'CM', 'LastName': ""O'Kane"", 'Affiliation': ""The Wellcome-Wolfson Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Simon V', 'Initials': 'SV', 'LastName': 'Baudouin', 'Affiliation': 'Intensive Care Unit, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.'}, {'ForeName': 'Ross L', 'Initials': 'RL', 'LastName': 'Paterson', 'Affiliation': 'Intensive Care Unit, Western General Hospital, Edinburgh, UK.'}, {'ForeName': 'Anthony J', 'Initials': 'AJ', 'LastName': 'Rostron', 'Affiliation': 'Translational and Clinical Research Institute, Newcastle University, Newcastle, UK; Integrated Critical Care Unit, Sunderland Royal Hospital, City Hospitals Sunderland NHS Foundation Trust, Sunderland, UK.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Agus', 'Affiliation': 'Northern Ireland Clinical Trials Unit, The Royal Hospitals, Belfast, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Bannard-Smith', 'Affiliation': 'Intensive Care Unit, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Nicole M', 'Initials': 'NM', 'LastName': 'Robin', 'Affiliation': 'Intensive Care Unit, Countess of Chester NHS Foundation Trust, Chester, UK.'}, {'ForeName': 'Ingeborg D', 'Initials': 'ID', 'LastName': 'Welters', 'Affiliation': 'Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Bassford', 'Affiliation': 'Intensive Care Unit, University Hospital Coventry, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.'}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Yates', 'Affiliation': 'Intensive Care Unit, Northumbria Specialist Emergency Care Hospital, Cramlington, UK.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Spencer', 'Affiliation': 'Intensive Care Unit, Preston Royal Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.'}, {'ForeName': 'Shondipon K', 'Initials': 'SK', 'LastName': 'Laha', 'Affiliation': 'Intensive Care Unit, Preston Royal Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Hulme', 'Affiliation': 'Intensive Care Unit, Sandwell General Hospital, Sandwell and West Birmingham Hospitals NHS Trust, West Bromwich, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Bonner', 'Affiliation': 'Intensive Care Unit, James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Linnett', 'Affiliation': 'Intensive Care Unit, Queen Elizabeth Hospital, Gateshead NHS Foundation Trust, Gateshead, UK.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Sonksen', 'Affiliation': 'Intensive Care Unit, Russells Hall Hospital, Dudley Group NHS Foundation Trust, Dudley, UK.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Van Den Broeck', 'Affiliation': 'Becton Dickinson Biosciences Europe, Erembodegem, Belgium.'}, {'ForeName': 'Gert', 'Initials': 'G', 'LastName': 'Boschman', 'Affiliation': 'Becton Dickinson Biosciences Europe, Erembodegem, Belgium.'}, {'ForeName': 'Dw James', 'Initials': 'DJ', 'LastName': 'Keenan', 'Affiliation': 'Becton Dickinson Biosciences Europe, Erembodegem, Belgium.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Scott', 'Affiliation': 'Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.'}, {'ForeName': 'A Joy', 'Initials': 'AJ', 'LastName': 'Allen', 'Affiliation': 'National Institute for Health Research Newcastle In Vitro Diagnostics Cooperative, Newcastle University, Newcastle, UK.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Phair', 'Affiliation': 'Northern Ireland Clinical Trials Unit, The Royal Hospitals, Belfast, UK.'}, {'ForeName': 'Jennie', 'Initials': 'J', 'LastName': 'Parker', 'Affiliation': 'Newcastle Clinical Trials Unit, Newcastle University, Newcastle, UK.'}, {'ForeName': 'Susan A', 'Initials': 'SA', 'LastName': 'Bowett', 'Affiliation': 'Newcastle Clinical Trials Unit, Newcastle University, Newcastle, UK.'}, {'ForeName': 'A John', 'Initials': 'AJ', 'LastName': 'Simpson', 'Affiliation': 'Translational and Clinical Research Institute, Newcastle University, Newcastle, UK; National Institute for Health Research Newcastle In Vitro Diagnostics Cooperative, Newcastle University, Newcastle, UK. Electronic address: j.simpson@ncl.ac.uk.'}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(19)30367-4'] 3161,32195749,Who Accepts and Who Uses Community-Based Secondary Distribution HIV Self-Testing (HIVST) Kits? Findings From the Intervention Arm of a Cluster-Randomized Trial of HIVST Distribution Nested in Four HPTN 071 (PopART) Communities in Zambia.,"BACKGROUND HPTN 071 (PopART) was a community-randomized trial of a universal testing-and-treatment intervention on HIV incidence at population level in Zambia and South Africa. In Zambia, a trial of community-based distribution of HIV self-testing (HIVST) kits, including secondary distribution, as an option for HIV-testing was nested within 4 PopART intervention communities. We used data from the intervention arm of the nested trial to measure levels of and factors associated with acceptance and use of secondary distribution HIVST kits. METHODS Community HIV care providers offered the PopART combination HIV-prevention intervention door-to-door, systematically visiting all households and enumerating all household members. From 1 February to 30 April 2017, individuals aged 16 years and older consenting to PopART were offered the option to HIV self-test, if eligible for HIV-testing services. Individuals aged 18 years and older who reported a partner absent during household visits were offered an HIVST kit for secondary distribution to this partner. We used two data sources to measure acceptance and use of secondary distribution HIVST kits. RESULTS Among 9105 individuals aged 18 years and older consenting to PopART, 9.1% (n = 825) accepted an HIVST kit for secondary distribution. Approximately 55.8% reported that the kit had been used. Women were more likely to accept, and men more likely to use, secondary distribution HIVST kits. Kits were more likely to be used by individuals aged 30+ and who had not participated in a previous round of PopART. Approximately 6.8% had a reactive result. CONCLUSIONS Community-based secondary distribution of HIVST kits reached men absent during community HIV care provider household visits and is a complement to facility- and community-based HIV-testing services, which often miss men.",2020,Kits were more likely to be used by individuals aged 30+ and who had not participated in a previous round of PopART.,"['9,105 individuals ≥18-years consenting to PopART, 9.1% (n=825) accepted an HIVST kit for secondary distribution', 'individuals aged 30+ and who had not participated in a previous round of PopART', 'HIV incidence at population-level in Zambia and South Africa', 'distribution nested in four HPTN 071 (PopART) communities in Zambia', 'Individuals ≥18-years who reported a partner absent during household visits', 'Community HIV Care Providers (CHiPs) offered the PopART combination HIV-prevention intervention door-to-door, systematically visiting all households and enumerating all household members']","['universal testing-and-treatment intervention', 'HIVST', 'HIVST kit']",[],"[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C1690540', 'cui_str': 'Kit'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0043445', 'cui_str': 'Republic of Zambia'}, {'cui': 'C0037712', 'cui_str': 'Union of South Africa'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0332197', 'cui_str': 'Absent (qualifier value)'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0557698', 'cui_str': 'Door (physical object)'}]","[{'cui': 'C0175671', 'cui_str': 'Universal (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1690540', 'cui_str': 'Kit'}]",[],,0.0372186,Kits were more likely to be used by individuals aged 30+ and who had not participated in a previous round of PopART.,"[{'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'Hensen', 'Affiliation': 'Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Albertus J', 'Initials': 'AJ', 'LastName': 'Schaap', 'Affiliation': 'Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Chama', 'Initials': 'C', 'LastName': 'Mulubwa', 'Affiliation': 'Zambart, Lusaka, Zambia.'}, {'ForeName': 'Sian', 'Initials': 'S', 'LastName': 'Floyd', 'Affiliation': 'Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Kwame', 'Initials': 'K', 'LastName': 'Shanaube', 'Affiliation': 'Zambart, Lusaka, Zambia.'}, {'ForeName': 'Mwelwa M', 'Initials': 'MM', 'LastName': 'Phiri', 'Affiliation': 'Zambart, Lusaka, Zambia.'}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Bond', 'Affiliation': 'Zambart, Lusaka, Zambia.'}, {'ForeName': 'Chiti', 'Initials': 'C', 'LastName': 'Bwalya', 'Affiliation': 'Zambart, Lusaka, Zambia.'}, {'ForeName': 'Musonda', 'Initials': 'M', 'LastName': 'Simwinga', 'Affiliation': 'Zambart, Lusaka, Zambia.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Fidler', 'Affiliation': 'Imperial College, London, United Kingdom and Imperial College NIHR BRC.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Hayes', 'Affiliation': 'Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Alwyn', 'Initials': 'A', 'LastName': 'Mwinga', 'Affiliation': 'Zambart, Lusaka, Zambia.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Ayles', 'Affiliation': 'Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}]",Journal of acquired immune deficiency syndromes (1999),['10.1097/QAI.0000000000002344'] 3162,31909470,Comparative effectiveness of torasemide versus furosemide in symptomatic therapy in heart failure patients: Preliminary results from the randomized TORNADO trial.,"BACKGROUND Recent reports suggest that torasemide might be more beneficial than furosemide in patients with symptomatic heart failure (HF). The aim was to compare the effects of torasemide and furosemide on clinical outcomes in HF patients. METHODS This study pilot consisted of data from the ongoing multicenter, randomized, unblinded endpoint phase IV TORNADO (NCT01942109) study. HF patients in New York Heart Association (NYHA) II-IV class with a stable dose of furosemide were randomized to treatment with equipotential dose of torasemide (4:1) or continuation of unchanged dose of furosemide. On enrollment and control visit (3 months after enrollment) clinical examination, 6-minute walk test (6MWT) and assessment of fluid retention by ZOE Fluid Status Monitor were performed. The primary endpoint was a composite of improvement of NYHA class, improvement of at least 50 m during 6MWT and decrease in fluid retention of at least 0.5 W after 3-months follow-up. RESULTS The study group included 40 patients (median age 66 years; 77.5% male). During follow-up 7 patients were hospitalized for HF worsening (3 in torasemide and 4 in furosemide-treated patients). The primary endpoint reached 15 (94%) and 14 (58%) patients on torasemide and furosemide, respectively (p = 0.03). CONCLUSIONS In HF patients treated with torasemide fluid overload and symptoms improved more than in the furosemide group. This positive effect occurred already within 3-month observation.",2019,In HF patients treated with torasemide fluid overload and symptoms improved more than in the furosemide group.,"['HF patients', 'HF patients in New York Heart Association (NYHA) II-IV class with a stable dose of', 'heart failure patients', 'patients with symptomatic heart failure (HF', '40 patients (median age 66 years; 77.5% male']","['torasemide (4:1) or continuation of unchanged dose of furosemide', 'torasemide and furosemide', 'furosemide', 'torasemide']","['composite of improvement of NYHA class, improvement of at least 50 m during 6MWT and decrease in fluid retention', '6-minute walk test (6MWT) and assessment of fluid retention by ZOE Fluid Status Monitor']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0076840', 'cui_str': 'torasemide'}, {'cui': 'C0442739', 'cui_str': 'Id status quo'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0016860', 'cui_str': 'Furosemide'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0268000', 'cui_str': 'Body fluid retention (disorder)'}, {'cui': 'C0430515', 'cui_str': '6-Minute Walk Test'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}]",40.0,0.199083,In HF patients treated with torasemide fluid overload and symptoms improved more than in the furosemide group.,"[{'ForeName': 'Paweł', 'Initials': 'P', 'LastName': 'Balsam', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland.'}, {'ForeName': 'Krzysztof', 'Initials': 'K', 'LastName': 'Ozierański', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland.'}, {'ForeName': 'Michał', 'Initials': 'M', 'LastName': 'Marchel', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland. michal.marchel@wum.edu.pl.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Gawałko', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland.'}, {'ForeName': 'Łukasz', 'Initials': 'Ł', 'LastName': 'Niedziela', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland.'}, {'ForeName': 'Agata', 'Initials': 'A', 'LastName': 'Tymińska', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland.'}, {'ForeName': 'Bartosz', 'Initials': 'B', 'LastName': 'Sieradzki', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Sieradzki', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Fojt', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland.'}, {'ForeName': 'Elwira', 'Initials': 'E', 'LastName': 'Bakuła', 'Affiliation': 'Cardiology Unit, John Paul II Western Hospital, ul. Daleka 11, 05-825 Grodzisk Mazowiecki, Poland.'}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Główczyńska', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland.'}, {'ForeName': 'Michał', 'Initials': 'M', 'LastName': 'Peller', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Markulis', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland.'}, {'ForeName': 'Janusz', 'Initials': 'J', 'LastName': 'Bednarski', 'Affiliation': 'Cardiology Unit, John Paul II Western Hospital, ul. Daleka 11, 05-825 Grodzisk Mazowiecki, Poland.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Kowalik', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland.'}, {'ForeName': 'Andrzej', 'Initials': 'A', 'LastName': 'Cacko', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland.'}, {'ForeName': 'Grzegorz', 'Initials': 'G', 'LastName': 'Niewiński', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Medical University of Warsaw, Banacha 1A, 02-677 Warsaw, Poland.'}, {'ForeName': 'Krzysztof J', 'Initials': 'KJ', 'LastName': 'Filipiak', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland.'}, {'ForeName': 'Grzegorz', 'Initials': 'G', 'LastName': 'Opolski', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland.'}, {'ForeName': 'Marcin', 'Initials': 'M', 'LastName': 'Grabowski', 'Affiliation': 'I Katedra i Klinika Kardiologii, Poland.'}]",Cardiology journal,['10.5603/CJ.a2019.0114'] 3163,32131876,"A nurse-led health coaching intervention for stroke survivors and their family caregivers in hospital to home transition care in Chongqing, China: a study protocol for a randomized controlled trial.","BACKGROUND Hospital to home transition care is a most stressful period for stroke survivors and their caregivers to learn self-management of stroke-related health conditions and to engage in rehabilitation. Health coaching has been identified as a strategy to enhance self-management of poststroke care at home. However, interventions in this field that are informed by a health coaching framework are scarce. This study will address a gap in research by testing the hypothesis that a nurse-led health coaching intervention can improve health outcomes for stroke survivors and their family caregivers in hospital to home transition care. METHODS This is a single-blind, two-arm parallel randomized controlled trial of a nurse-led health coaching program versus routine care situated in two tertiary hospitals in Chongqing, China. Stroke survivors and their primary family caregivers will be recruited together as ""participant dyads"", and the estimated sample size is 140 (70 in each group). The intervention includes a 12-week nurse-led health coaching program in hospital to home transition care commencing at discharge from the hospital. The primary outcome is changes in self-efficacy of stroke survivors at 12 weeks from the baseline. The secondary outcomes are changes in stroke survivors' and quality of life, functional ability, stroke-related knowledge, the number of adverse events, and unplanned hospital admissions, and caregivers' self-efficacy and caregiver-related burden at 12 weeks from the baseline. The outcomes will be measured at 12 weeks and 24 weeks from the baseline. DISCUSSION This study will examine the effect of nurse-led health coaching on hospital to home transition care for stroke survivors and their caregivers. It is anticipated that findings from this trial will provide research evidence to inform policy, and resource and practice development to improve hospital to home transition care for stroke survivors and their caregivers. TRIAL REGISTRATION The Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12619000321145. Registered on 1 March 2019.",2020,"The secondary outcomes are changes in stroke survivors' and quality of life, functional ability, stroke-related knowledge, the number of adverse events, and unplanned hospital admissions, and caregivers' self-efficacy and caregiver-related burden at 12 weeks from the baseline.","['stroke survivors and their family caregivers in hospital to home transition care in Chongqing, China', 'stroke survivors and their family caregivers in hospital to home transition care', 'two tertiary hospitals in Chongqing, China', 'stroke survivors and their caregivers']","['nurse-led health coaching program', 'nurse-led health coaching', 'nurse-led health coaching intervention']","[""changes in stroke survivors' and quality of life, functional ability, stroke-related knowledge, the number of adverse events, and unplanned hospital admissions, and caregivers' self-efficacy and caregiver-related burden"", 'changes in self-efficacy of stroke survivors']","[{'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C4019071', 'cui_str': 'Transition Care'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0587437', 'cui_str': 'Tertiary Hospital'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}]","[{'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0034380'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission (procedure)'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}]",,0.11121,"The secondary outcomes are changes in stroke survivors' and quality of life, functional ability, stroke-related knowledge, the number of adverse events, and unplanned hospital admissions, and caregivers' self-efficacy and caregiver-related burden at 12 weeks from the baseline.","[{'ForeName': 'Shuanglan', 'Initials': 'S', 'LastName': 'Lin', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, GPO Box 2100, Adelaide, SA, 5001, Australia.'}, {'ForeName': 'Lily Dongxia', 'Initials': 'LD', 'LastName': 'Xiao', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, GPO Box 2100, Adelaide, SA, 5001, Australia. lily.xiao@flinders.edu.au.'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Chamberlain', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, GPO Box 2100, Adelaide, SA, 5001, Australia.'}]",Trials,['10.1186/s13063-020-4156-z'] 3164,32004709,Clinical Decision Support for Recognizing and Managing Hypertensive Blood Pressure in Youth: No Significant Impact on Medical Costs.,"OBJECTIVE To evaluate economic costs from the health system perspective of an electronic health record-based clinical decision support (CDS) tool, TeenBP, designed to assist in the recognition and management of hypertension in youth. METHODS Twenty primary care clinics within an integrated health system were randomized to the TeenBP CDS or usual care (UC), with patient enrollment from 4/15/14 to 4/14/16. The 12-month change in standardized medical care costs for insured patients aged 10 to 17 years without prior hypertension were calculated for each study arm. The primary analysis compared patients with ≥1 visit with blood pressure (BP) ≥95th percentile (isolated hypertensive BP), and secondary analyses compared patients with ≥3 visits within one year with BP ≥95th percentile (incident hypertension). Generalized estimating equation models estimated the difference-in-differences in costs between groups over time. RESULTS Among 925 insured patients with an isolated hypertensive BP, the pre-to-post change in overall costs averaged $22 more for TeenBP CDS versus UC patients over 12 months, but this difference was not statistically significant (P = .723). Among 159 insured patients with incident hypertension, the pre-to-post change in overall costs over 12 months was higher by $227 per person on average for TeenBP CDS versus UC patients, but this difference also was not statistically significant (P = .313). CONCLUSIONS The TeenBP CDS intervention was previously found to significantly improve identification and management of hypertensive BP in youth, and in this study, we find that this tool did not significantly increase care costs in its first 12 months of clinical use.",2020,"METHODS Twenty primary care clinics within an integrated health system were randomized to the TeenBP CDS or usual care (UC), with patient enrollment from 4/15/14-4/14/16.","['Youth', 'Twenty primary care clinics within an integrated health system', 'insured patients aged 10-17 years without prior hypertension', 'patients with ≥1 visit with blood pressure (BP) ≥95 th percentile (isolated hypertensive BP), and secondary analyses compared patients with ≥3 visits within one year with BP ≥95 th percentile (incident hypertension', '159 insured patients with incident hypertension', 'hypertension in youth']","['TeenBP CDS intervention', 'TeenBP CDS or usual care (UC']","['overall costs', 'Medical Costs', 'care costs']","[{'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic (environment)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C4082117', 'cui_str': 'One year'}]",[],"[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}]",925.0,0.0478818,"METHODS Twenty primary care clinics within an integrated health system were randomized to the TeenBP CDS or usual care (UC), with patient enrollment from 4/15/14-4/14/16.","[{'ForeName': 'Steven P', 'Initials': 'SP', 'LastName': 'Dehmer', 'Affiliation': ""HealthPartners Institute (SP Dehmer, NK Trower, SE Asche, HL Ekstrom, JD Nordin, PJ O'Connor, and EO Kharbanda), Minneapolis, Minn. Electronic address: steven.p.dehmer@healthpartners.com.""}, {'ForeName': 'Alan R', 'Initials': 'AR', 'LastName': 'Sinaiko', 'Affiliation': 'Department of Pediatrics, University of Minnesota (AR Sinaiko), Minneapolis, Minn.'}, {'ForeName': 'Nicole K', 'Initials': 'NK', 'LastName': 'Trower', 'Affiliation': ""HealthPartners Institute (SP Dehmer, NK Trower, SE Asche, HL Ekstrom, JD Nordin, PJ O'Connor, and EO Kharbanda), Minneapolis, Minn.""}, {'ForeName': 'Stephen E', 'Initials': 'SE', 'LastName': 'Asche', 'Affiliation': ""HealthPartners Institute (SP Dehmer, NK Trower, SE Asche, HL Ekstrom, JD Nordin, PJ O'Connor, and EO Kharbanda), Minneapolis, Minn.""}, {'ForeName': 'Heidi L', 'Initials': 'HL', 'LastName': 'Ekstrom', 'Affiliation': ""HealthPartners Institute (SP Dehmer, NK Trower, SE Asche, HL Ekstrom, JD Nordin, PJ O'Connor, and EO Kharbanda), Minneapolis, Minn.""}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Nordin', 'Affiliation': ""HealthPartners Institute (SP Dehmer, NK Trower, SE Asche, HL Ekstrom, JD Nordin, PJ O'Connor, and EO Kharbanda), Minneapolis, Minn.""}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': ""O'Connor"", 'Affiliation': ""HealthPartners Institute (SP Dehmer, NK Trower, SE Asche, HL Ekstrom, JD Nordin, PJ O'Connor, and EO Kharbanda), Minneapolis, Minn.""}, {'ForeName': 'Elyse O', 'Initials': 'EO', 'LastName': 'Kharbanda', 'Affiliation': ""HealthPartners Institute (SP Dehmer, NK Trower, SE Asche, HL Ekstrom, JD Nordin, PJ O'Connor, and EO Kharbanda), Minneapolis, Minn.""}]",Academic pediatrics,['10.1016/j.acap.2020.01.011'] 3165,31221292,Ad libitum Mediterranean diet reduces subcutaneous but not visceral fat in patients with coronary heart disease: A randomised controlled pilot study.,"BACKGROUND & AIMS The Mediterranean diet (MedDiet) is recognised to reduce risk of coronary heart disease (CHD), in part, via its anti-inflammatory and antioxidant properties, which may be mediated via effects on body fat distribution. Diet efficacy via these mechanisms is however unclear in patients with diagnosed CHD. This study aimed to determine: (1) the effect of ad libitum MedDiet versus low-fat diet intervention on adiposity, anti-inflammatory marker adiponectin, oxidative stress marker malondialdehyde (MDA) and traditional CVD risk markers, and (2) whether improvement in MedDiet adherence score in the pooled cohort was associated with these risk markers, in a pilot cohort of Australian patients post coronary event. METHODS Participants (62 ± 9 years, 83% male) were randomised to 6-month ad libitum MedDiet (n = 34) or low-fat diet (n = 31). Pre- and post-intervention, dietary adherence, anthropometry, body composition (Dual-energy X-ray Absorptiometry) and venepuncture measures were conducted. RESULTS The MedDiet group reduced subcutaneous adipose tissue (SAT) area compared to the low-fat diet group (12.5 cm 2 more, p = 0.04) but not visceral adipose tissue or other body composition measures. In the pooled cohort, participants with greatest improvement in MedDiet adherence score had significantly lower waist circumference (-2.81 cm, p = 0.01) and SAT area (-27.1 cm 2 , p = 0.04) compared to participants with no improvement in score at 6-months. There were no changes in adiponectin, MDA or other risk markers in the MedDiet compared to low-fat diet group, and no differences in 6-month levels between categories of improvement in MedDiet score (p > 0.05). Within the MedDiet group only, the proportion of participants taking beta-blocker medication reduced from baseline to 6-months (71% vs. 56%, p-trend = 0.007). CONCLUSIONS Adherence to 6-month ad libitum MedDiet reduced subcutaneous fat and waist circumference which discounts the misconception that this healthy but high fat diet leads to body fat gain. The effect of MedDiet on body fat distribution and consequent anti-inflammatory and antioxidant effects, as well as need for medications, in patients with CHD warrants exploration in larger studies. Clinically significant effects on these markers may require adjunct exercise and/or caloric restriction. TRIAL REGISTRATION ACTRN12616000156482.",2019,"There were no changes in adiponectin, MDA or other risk markers in the MedDiet compared to low-fat diet group, and no differences in 6-month levels between categories of improvement in MedDiet score (p > 0.05).","['Participants (62\xa0±\xa09 years, 83% male', 'patients with diagnosed CHD', 'patients with coronary heart disease', 'Australian patients post coronary event', 'patients with CHD warrants exploration in larger studies']","['Mediterranean diet (MedDiet', '6-month ad libitum MedDiet (n\xa0=\xa034) or low-fat diet', 'Ad libitum Mediterranean diet', 'ad libitum MedDiet versus low-fat diet intervention']","['adiposity, anti-inflammatory marker adiponectin, oxidative stress marker malondialdehyde (MDA) and traditional CVD risk markers', 'waist circumference', 'visceral adipose tissue or other body composition measures', 'proportion of participants taking beta-blocker medication', 'subcutaneous fat and waist circumference', 'MedDiet score', 'subcutaneous adipose tissue (SAT) area', 'Pre- and post-intervention, dietary adherence, anthropometry, body composition (Dual-energy X-ray Absorptiometry) and venepuncture measures', 'body fat distribution and consequent anti-inflammatory and antioxidant effects', 'MedDiet adherence score', 'adiponectin, MDA or other risk markers']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0010068', 'cui_str': 'Coronary Disease'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C1280903', 'cui_str': 'Exploration procedure'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C1138412', 'cui_str': 'Diet, Mediterranean'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0242970', 'cui_str': 'Fat-Restricted Diet'}]","[{'cui': 'C1563743', 'cui_str': 'Adiposis'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C1563740', 'cui_str': 'Visceral Fat'}, {'cui': 'C1285593', 'cui_str': 'Body composition measure'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0222331', 'cui_str': 'Subcutaneous Fat'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C1510486', 'cui_str': 'Dual X-Ray Absorptiometry'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0424621', 'cui_str': 'Body Fat Distribution'}, {'cui': 'C3179302', 'cui_str': 'Anti-Oxidant Effects'}, {'cui': 'C0000379', 'cui_str': '1,3-Benzodioxole-5-ethanamine, alpha-methyl-'}]",,0.0963741,"There were no changes in adiponectin, MDA or other risk markers in the MedDiet compared to low-fat diet group, and no differences in 6-month levels between categories of improvement in MedDiet score (p > 0.05).","[{'ForeName': 'Hannah L', 'Initials': 'HL', 'LastName': 'Mayr', 'Affiliation': 'School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, 3086, Australia; Nutrition and Dietetics Department, Princess Alexandra Hospital, Brisbane, Queensland, 4102, Australia; Bond University Nutrition and Dietetics Research Group, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland, 4226, Australia. Electronic address: H.Mayr@latrobe.edu.au.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Itsiopoulos', 'Affiliation': 'School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, 3086, Australia.'}, {'ForeName': 'Audrey C', 'Initials': 'AC', 'LastName': 'Tierney', 'Affiliation': 'School of Allied Health, University of Limerick, Castletroy, Limerick, V94 T9PX, Ireland; Department of Dietetics, Nutrition and Sport, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, 3086, Australia.'}, {'ForeName': 'Teagan', 'Initials': 'T', 'LastName': 'Kucianski', 'Affiliation': 'Department of Dietetics, Nutrition and Sport, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, 3086, Australia.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Radcliffe', 'Affiliation': 'Department of Dietetics, Nutrition and Sport, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, 3086, Australia.'}, {'ForeName': 'Manohar', 'Initials': 'M', 'LastName': 'Garg', 'Affiliation': 'Nutraceuticals Research Program, School of Biomedical Sciences & Pharmacy, University of Newcastle, New South Wales, 2308, Australia.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Willcox', 'Affiliation': 'School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, 3086, Australia.'}, {'ForeName': 'Colleen J', 'Initials': 'CJ', 'LastName': 'Thomas', 'Affiliation': 'Department of Physiology, Anatomy and Microbiology, School of Life Sciences, La Trobe University, Melbourne, Victoria, 3086, Australia.'}]",Clinical nutrition ESPEN,['10.1016/j.clnesp.2019.05.001'] 3166,32167011,Oral delivery of Hyperimmune bovine serum antibodies against CS6-expressing enterotoxigenic Escherichia coli as a prophylactic against diarrhea.,"BACKGROUND . Oral administration of bovine antibodies active against enterotoxigenic Escherichia coli (ETEC) have demonstrated safety and efficacy against diarrhea in human challenge trials. The efficacy of bovine serum immunoglobulins (BSIgG) against recombinant colonization factor CS6 or whole cell ETEC strain B7A was assessed against challenge with the CS6-expressing B7A. METHODS . This was a randomized, double-blind, placebo-controlled trial in which healthy adults received oral hyperimmune BSIgG anti-CS6, anti-B7A whole cell killed or non-hyperimmune BSIgG (placebo) in a 1:1:1 ratio then challenged with ETEC B7A. Two days pre-challenge, volunteers began a thrice daily, seven day course of immunoprophylaxis. On day 3, subjects received 1 × 10 10 CFUs of B7A. Subjects were observed for safety and the primary endpoint of moderate-severe diarrhea (MSD). RESULTS . A total of 59 volunteers received product and underwent ETEC challenge. The BSIgG products were well-tolerated across all subjects. Upon challenge, 14/20 (70%) placebo recipients developed MSD, compared to 12/19 (63%; p = .74) receiving anti-CS6 BSIgG and 7/20 (35%; p = .06) receiving anti-B7A BSIgG. Immune responses to the ETEC infection were modest across all groups. CONCLUSIONS . Bovine-derived serum antibodies appear safe and well tolerated. Antibodies derived from cattle immunized with whole cell B7A provided 50% protection against MSD following B7A challenge; however, no protection was observed in subjects receiving serum antibodies targeting CS6. The lack of observed efficacy in this group may be due to low CS6 surface expression on B7A, the high dose challenge inoculum and/or the use of serum derived antibodies versus colostrum-derived antibodies.",2020,"Antibodies derived from cattle immunized with whole cell B7A provided 50% protection against MSD following B7A challenge; however, no protection was observed in subjects receiving serum antibodies targeting CS6.","['59 volunteers received product and underwent ETEC challenge', 'healthy adults']","['placebo', 'Hyperimmune bovine serum antibodies', 'bovine serum immunoglobulins (BSIgG', 'bovine antibodies active against enterotoxigenic Escherichia coli (ETEC', 'oral hyperimmune BSIgG anti-CS6, anti-B7A whole cell killed or non-hyperimmune BSIgG (placebo']","['MSD', 'moderate-severe diarrhea (MSD']","[{'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0580797', 'cui_str': 'E coli, Enterotoxigenic'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1265545', 'cui_str': 'Family Bovidae'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0021027', 'cui_str': 'Immune Globulins'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0580797', 'cui_str': 'E coli, Enterotoxigenic'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C4521763', 'cui_str': 'Killed'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C1443924', 'cui_str': 'Severe diarrhea'}]",59.0,0.190712,"Antibodies derived from cattle immunized with whole cell B7A provided 50% protection against MSD following B7A challenge; however, no protection was observed in subjects receiving serum antibodies targeting CS6.","[{'ForeName': 'K R', 'Initials': 'KR', 'LastName': 'Talaat', 'Affiliation': 'Bloomberg School of Public Health, Johns Hopkins University , Baltimore, MD, USA.'}, {'ForeName': 'C K', 'Initials': 'CK', 'LastName': 'Porter', 'Affiliation': 'Enteric Diseases Department, Naval Medical Research Center , Silver Spring, MD, USA.'}, {'ForeName': 'A L', 'Initials': 'AL', 'LastName': 'Bourgeois', 'Affiliation': 'Bloomberg School of Public Health, Johns Hopkins University , Baltimore, MD, USA.'}, {'ForeName': 'T K', 'Initials': 'TK', 'LastName': 'Lee', 'Affiliation': 'Enteric Diseases Department, Naval Medical Research Center , Silver Spring, MD, USA.'}, {'ForeName': 'C A', 'Initials': 'CA', 'LastName': 'Duplessis', 'Affiliation': 'Enteric Diseases Department, Naval Medical Research Center , Silver Spring, MD, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Maciel', 'Affiliation': 'The Henry M. Jackson Foundation , Bethesda, MD, USA.'}, {'ForeName': 'R L', 'Initials': 'RL', 'LastName': 'Gutierrez', 'Affiliation': 'Enteric Diseases Department, Naval Medical Research Center , Silver Spring, MD, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'DeNearing', 'Affiliation': 'Bloomberg School of Public Health, Johns Hopkins University , Baltimore, MD, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Adjoodani', 'Affiliation': 'Bloomberg School of Public Health, Johns Hopkins University , Baltimore, MD, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Adkinson', 'Affiliation': 'Bloomberg School of Public Health, Johns Hopkins University , Baltimore, MD, USA.'}, {'ForeName': 'K J', 'Initials': 'KJ', 'LastName': 'Testa', 'Affiliation': 'The Henry M. Jackson Foundation , Bethesda, MD, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Feijoo', 'Affiliation': 'Bloomberg School of Public Health, Johns Hopkins University , Baltimore, MD, USA.'}, {'ForeName': 'A N', 'Initials': 'AN', 'LastName': 'Alcala', 'Affiliation': 'The Henry M. Jackson Foundation , Bethesda, MD, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Brubaker', 'Affiliation': 'Bloomberg School of Public Health, Johns Hopkins University , Baltimore, MD, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Beselman', 'Affiliation': 'Bloomberg School of Public Health, Johns Hopkins University , Baltimore, MD, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Chakraborty', 'Affiliation': 'Bloomberg School of Public Health, Johns Hopkins University , Baltimore, MD, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Sack', 'Affiliation': 'Bloomberg School of Public Health, Johns Hopkins University , Baltimore, MD, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Halpern', 'Affiliation': 'Bloomberg School of Public Health, Johns Hopkins University , Baltimore, MD, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Trop', 'Affiliation': 'The Henry M. Jackson Foundation , Bethesda, MD, USA.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': 'SAB Biotherapeutics Inc , Sioux Falls, SD, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Jiao', 'Affiliation': 'SAB Biotherapeutics Inc , Sioux Falls, SD, USA.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Sullivan', 'Affiliation': 'SAB Biotherapeutics Inc , Sioux Falls, SD, USA.'}, {'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Riddle', 'Affiliation': 'Enteric Diseases Department, Naval Medical Research Center , Silver Spring, MD, USA.'}, {'ForeName': 'S S', 'Initials': 'SS', 'LastName': 'Joseph', 'Affiliation': 'The Henry M. Jackson Foundation , Bethesda, MD, USA.'}, {'ForeName': 'S T', 'Initials': 'ST', 'LastName': 'Poole', 'Affiliation': 'The Henry M. Jackson Foundation , Bethesda, MD, USA.'}, {'ForeName': 'M G', 'Initials': 'MG', 'LastName': 'Prouty', 'Affiliation': 'Enteric Diseases Department, Naval Medical Research Center , Silver Spring, MD, USA.'}]",Gut microbes,['10.1080/19490976.2020.1732852'] 3167,31422649,Early efficacy and safety of statin therapy in Korean patients with hypercholesterolemia: Daegu and Gyeongbuk Statin Registry.,"BACKGROUND/AIMS To date, prospective data are limited on efficacy and safety profiles of statin therapy in Korean hypercholesterolemic patients. Hence, the aim of this study was to evaluate the practice patterns of statin therapy and its efficacy and safety through the prospective Daegu and Gyeongbuk statin registry. METHODS Statin naïve patients who were prescribed statins according to the criteria of Korean Guidelines for Management of Dyslipidemia were enrolled. Clinical and laboratory evaluations were performed at baseline and at week 8, where the efficacy was assessed with the same guidelines. RESULTS Of 908 patients, atorvastatin and rosuvastatin were most frequently prescribed statins (63.1% and 29.3%, respectively). High intensity statins (atorvastatin 40 mg or rosuvastatin 20 mg) were prescribed in 24.7% of all patients and in 79.5% of high and very high risk groups. The total and low density lipoprotein (LDL) cholesterol levels decreased from 203.7 ± 43.0 to 140.6 ± 28.6 mg/dL and 134.4 ± 35.7 to 79.5 ± 21.3 mg/dL, respectively. The achievement rate of the LDL target goal was 98.6% in low risk, 95.0% in moderate risk, 88.1% in high risk, and 42.1% in very high risk patients (59.7% in overall). There was no significant difference in the efficacy between atorvastatin and rosuvastatin. Adverse events were observed in 12.0% of patients and led to 1.4% of treatment cessation. CONCLUSION The efficacy of the usual starting dose of statins in daily practice was relatively insufficient for Korean hypercholesterolemic patients with high or very high risks. Short-term adverse events of statin therapy were not common in Korean patients with a low discontinuation rate.",2020,There was no significant difference in the efficacy between atorvastatin and rosuvastatin.,"['908 patients', 'Korean hypercholesterolemic patients', 'Korean patients with hypercholesterolemia', 'Korean hypercholesterolemic patients with high or very high risks', 'Korean patients with a low discontinuation rate', 'naïve patients who were prescribed statins according to the criteria of Korean Guidelines for Management of Dyslipidemia were enrolled']","['Statin', 'atorvastatin and rosuvastatin', 'statins', 'High intensity statins (atorvastatin 40 mg or rosuvastatin', 'statin therapy']","['efficacy', 'total and low density lipoprotein (LDL) cholesterol levels', 'achievement rate of the LDL target goal', 'Adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1556095', 'cui_str': 'Koreans'}, {'cui': 'C0020443', 'cui_str': 'High Cholesterol Levels'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0442804', 'cui_str': 'Very high (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0220845', 'cui_str': 'guidelines'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemias'}]","[{'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0286651', 'cui_str': 'atorvastatin'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1616508', 'cui_str': 'atorvastatin 40 MG [Lipitor]'}, {'cui': 'C1278454', 'cui_str': 'Statin prophylaxis'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0018017', 'cui_str': 'Goals'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",908.0,0.0233691,There was no significant difference in the efficacy between atorvastatin and rosuvastatin.,"[{'ForeName': 'Han Joon', 'Initials': 'HJ', 'LastName': 'Bae', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.'}, {'ForeName': 'Yun-Kyeong', 'Initials': 'YK', 'LastName': 'Cho', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.'}, {'ForeName': 'Hyoung-Seob', 'Initials': 'HS', 'LastName': 'Park', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.'}, {'ForeName': 'Hyuck-Jun', 'Initials': 'HJ', 'LastName': 'Yoon', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.'}, {'ForeName': 'Hyungseop', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.'}, {'ForeName': 'Seongwook', 'Initials': 'S', 'LastName': 'Han', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.'}, {'ForeName': 'Seung-Ho', 'Initials': 'SH', 'LastName': 'Hur', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.'}, {'ForeName': 'Yoon-Nyun', 'Initials': 'YN', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.'}, {'ForeName': 'Kwon-Bae', 'Initials': 'KB', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.'}, {'ForeName': 'Jae-Kean', 'Initials': 'JK', 'LastName': 'Ryu', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.'}, {'ForeName': 'Deug Young', 'Initials': 'DY', 'LastName': 'Nah', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Dongguk University Gyeongju Hospital, Gyeongju, Korea.'}, {'ForeName': 'Chang-Wook', 'Initials': 'CW', 'LastName': 'Nam', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.'}]",The Korean journal of internal medicine,['10.3904/kjim.2018.272'] 3168,32096667,Redox Homeostasis in Humans Exposed to Intermittent Hypoxia-Normoxia and to Intermittent Hypoxia-Hyperoxia.,"Aim: Exposure to hypoxia is known to increase oxidative stress and to impair antioxidant defenses in humans. The aim of the study was to measure oxidative stress and antioxidant capacity in healthy humans after being acutely exposed to both intermittent hypoxia-normoxia (IHN) and intermittent hypoxia-hyperoxia (IHH). Methods: Twenty-one healthy, young male participants were exposed to both IHN and IHH (fraction of inspired oxygen [FIO 2 ] 0.11 for up to 7 minutes followed by 3-5 minutes of exposure to normoxia (room air) or hyperoxia, FIO 2 0.3-0.35) in a crossover design study. In each participant, oxidative stress and antioxidant capacity were measured before and after each exposure in both experimental conditions. Results: After IHN, compared with baseline, neither oxidative stress (289.1 ± 63.2 vs. 262.2 ± 85.2 UCarr) nor antioxidant capacity (2376.1 ± 452.9 vs. 2525.0 ± 400.7 UCor) was significantly different. After IHH, neither oxidative stress (285.1 ± 94.2 vs. 277.5 ± 86.7 UCarr) nor antioxidant capacity (2653.6 ± 492.7 vs. 2568.4 ± 427.4 UCor) was significantly different compared with baseline. When the two studied exposure modalities were compared, there was no significant difference between groups with respect to both oxidative stress and antioxidant capacity. Conclusions: These data suggest that exposing healthy individuals to short-term IHN and IHH does not increase oxidative stress and it does not impair antioxidant defenses.",2020,"When the two studied exposure modalities were compared, there was no significant difference between groups with respect to both oxidative stress and antioxidant capacity. ","['Twenty-one healthy, young male participants', 'humans', 'healthy humans after being acutely exposed to both intermittent hypoxia-normoxia (IHN) and intermittent hypoxia-hyperoxia (IHH']",['IHN and IHH (fraction of inspired oxygen [FIO 2 ] 0.11 for up to 7 minutes followed by 3-5 minutes of exposure to normoxia (room air) or hyperoxia'],"['oxidative stress', 'antioxidant capacity', 'Susta, Davide, Oleg Stanislav Glazachev, Maxim Andreevich Zapara, Elena Nikolaevna Dudnik, and Vlada Germanovna Samartseva', 'oxidative stress and antioxidant capacity', 'Redox homeostasis']","[{'cui': 'C3715213', 'cui_str': '21 (qualifier value)'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0242706', 'cui_str': 'Hyperoxia'}]","[{'cui': 'C0428167', 'cui_str': 'FIO2'}, {'cui': 'C4517425', 'cui_str': '0.11 (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0242706', 'cui_str': 'Hyperoxia'}]","[{'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0024968', 'cui_str': 'Maxims'}, {'cui': 'C0030012', 'cui_str': 'Redox'}, {'cui': 'C0019868', 'cui_str': 'Autoregulation'}]",,0.0377272,"When the two studied exposure modalities were compared, there was no significant difference between groups with respect to both oxidative stress and antioxidant capacity. ","[{'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Susta', 'Affiliation': 'Physiology Department, IM Sechenov Medical University, Moscow, Russia.'}, {'ForeName': 'Oleg Stanislav', 'Initials': 'OS', 'LastName': 'Glazachev', 'Affiliation': 'Physiology Department, IM Sechenov Medical University, Moscow, Russia.'}, {'ForeName': 'Maxim Andreevich', 'Initials': 'MA', 'LastName': 'Zapara', 'Affiliation': 'Physiology Department, IM Sechenov Medical University, Moscow, Russia.'}, {'ForeName': 'Elena Nikolaevna', 'Initials': 'EN', 'LastName': 'Dudnik', 'Affiliation': 'Physiology Department, IM Sechenov Medical University, Moscow, Russia.'}, {'ForeName': 'Vlada Germanovna', 'Initials': 'VG', 'LastName': 'Samartseva', 'Affiliation': 'Physiology Department, IM Sechenov Medical University, Moscow, Russia.'}]",High altitude medicine & biology,['10.1089/ham.2019.0059'] 3169,32105658,Correlation Between Oral Health and Systemic Inflammation (COHESION): A Randomized Pilot Follow-Up Trial of a Plaque-Identifying Toothpaste.,"BACKGROUND Inflammation is intimately involved in the pathogenesis of atherosclerosis and is accurately measured by high-sensitivity C-reactive protein (hs-CRP), a sensitive marker for future risk of cardiovascular disease. The Correlation between Oral Health and Systemic Inflammation (COHESION) trial was designed to test the hypothesis that PlaqueHD, a plaque-identifying toothpaste, reduces hs-CRP. METHODS The trial was designed initially to include 132 subjects with hs-CRP between 2.0 and 10.0 mg/L but instead randomized 112 between 0.5 and 10.0, of which 103 had baseline and follow-up data and comprised the intention-to-treat sample. Of these, a prespecified subgroup analysis included 40 with baseline hs-CRP >2.0 and all hs-CRP <10. Because the distribution of hs-CRP was skewed toward higher values, to achieve normality assumptions, the significance of changes in hs-CRP between groups over time was tested on log-transformed data using a mixed effects analysis of variance. RESULTS The intention-to-treat analysis showed no significant differences between the PlaqueHD and placebo group (P = .615). The prespecified subgroup analysis showed a significant difference between the PlaqueHD and placebo group (P = .047). Results of the analysis showed a reduction in hs-CRP at follow-up of 0.58 in the PlaqueHD and an increase of 0.55 in the placebo group. CONCLUSIONS These findings are compatible with those of a prior pilot trial that also suggested benefits only in subjects with baseline elevations. Future trials targeting reductions of hs-CRP levels should randomize subjects with baseline hs-CRP between 2.0 and 10.0 mg/L.",2020,The pre-specified subgroup analysis showed a significant difference between the PlaqueHD and placebo group (p=0.047).,"['COHESION was designed initially to enroll 132 subjects with hs-CRP between 2.0 and 10.0 milligrams per liter but randomized 112 between 0.5 and 10.0, of which 103 had baseline and follow up data and comprise the intention to treat sample']","['placebo', 'Plaque Identifying Toothpaste']",[],"[{'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0439210', 'cui_str': 'milligram'}, {'cui': 'C0475211', 'cui_str': 'L'}, {'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C4517526', 'cui_str': 'One hundred and three'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0040462', 'cui_str': 'Toothpaste'}]",[],112.0,0.42989,The pre-specified subgroup analysis showed a significant difference between the PlaqueHD and placebo group (p=0.047).,"[{'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Acharya', 'Affiliation': 'Marshfield Clinic Research Institute, Marshfield, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Glurich', 'Affiliation': 'Marshfield Clinic Research Institute, Marshfield, WI.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Hetzel', 'Affiliation': 'University of Wisconsin School of Medicine and Public Health, Madison, WI.'}, {'ForeName': 'KyungMann', 'Initials': 'K', 'LastName': 'Kim', 'Affiliation': 'University of Wisconsin School of Medicine and Public Health, Madison, WI.'}, {'ForeName': 'Matthew C', 'Initials': 'MC', 'LastName': 'Tattersall', 'Affiliation': 'University of Wisconsin School of Medicine and Public Health, Madison, WI.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'DeMets', 'Affiliation': 'University of Wisconsin School of Medicine and Public Health, Madison, WI.'}, {'ForeName': 'Charles H', 'Initials': 'CH', 'LastName': 'Hennekens', 'Affiliation': 'Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL. Electronic address: PROFCHHMD@prodigy.net.'}]",The American journal of medicine,['10.1016/j.amjmed.2020.01.023'] 3170,32132639,"Overconfidence Among Young Decision-Makers: Assessing the Effectiveness of a Video Intervention and the Role of Gender, Age, Feedback, and Repetition.","Child development research on overconfidence suggests that the bias is present and persistent in preschoolers and kindergartners. However, little is known about what drives overconfidence among young decision-makers, how it changes over a large number of repetitions, and whether such changes differ by gender or age. The current experimental study analyzes data from 60 children, aged 4 years 0 months to 6 years 10 months, who played 60 turns of the Children's Gambling Task and provided regular estimates on their performance. A video intervention, designed to demonstrate the consequences of disadvantageous choices, was tested in a double-blind randomized controlled trial to assess its impact on overconfidence. The results show that every third participant remained overconfident even after 60 trials and constant feedback. Unlike previously reported, gender seems to be a determining factor in this process. Lastly, providing additional information through a video intervention appears to have no impact on participants' overconfidence levels.",2020,"Lastly, providing additional information through a video intervention appears to have no impact on participants' overconfidence levels.","['Young Decision-Makers', ""60 children, aged 4 years 0 months to 6 years 10 months, who played 60 turns of the Children's Gambling Task and provided regular estimates on their performance""]","['Overconfidence', 'Video Intervention']",[],"[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0554244', 'cui_str': 'Maker (occupation)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0541749', 'cui_str': 'Does turn (finding)'}, {'cui': 'C0016995', 'cui_str': 'Gamblings'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}]","[{'cui': 'C2609066', 'cui_str': 'Overconfidence'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}]",[],60.0,0.105581,"Lastly, providing additional information through a video intervention appears to have no impact on participants' overconfidence levels.","[{'ForeName': 'Dominik M', 'Initials': 'DM', 'LastName': 'Piehlmaier', 'Affiliation': 'School of Human Ecology, University of Wisconsin-Madison, 1300 Linden Dr., Madison, WI, 53706, USA. D.M.Piehlmaier@sussex.ac.uk.'}]",Scientific reports,['10.1038/s41598-020-61078-z'] 3171,32153821,The Pune Rural Intervention in Young Adolescents (PRIYA) study: design and methods of a randomised controlled trial.,"Background The Pune Maternal Nutrition Study (PMNS) was established to prospectively study the relationship of maternal nutrition to fetal growth and later cardiometabolic risk in the offspring. High homocysteine and low vitamin B12 levels in pregnancy predicted lower birthweight and higher insulin resistance at 6 years in the offspring. B12 deficiency was widespread in this population, due to low dietary intake. We therefore commenced a community-based intervention study with the underlying hypothesis that vitamin B12 supplementation of adolescent members of the PMNS cohort will improve birth weight, B12 status, and reduce future diabetes risk, in their offspring. Methods The individually randomised controlled trial commenced in September 2012, with boys and girls randomized into 3 groups, to receive daily for at least 3 years or until the birth of their first child: 1) vitamin B12 2 μg; or 2) vitamin B12 2 μg plus multiple micronutrients (MMN) plus 20 g of milk powder or 3) placebo. Iron and folic acid is given to all participants. Compliance is assessed by monthly supplement counts. Adverse events are recorded using a standardised questionnaire. The primary outcome is cord blood B12 concentration; based on 180-200 pregnancies in the girls, the study has ~80% power to detect a 0.5 SD change in newborn B12, in the B12 supplementation groups compared with controls, at the 5% significance level. Primary analysis will be by intention to treat. Discussion Our study tests a primordial prevention strategy through an intergenerational intervention started pre-conceptionally in both boys and girls using physiological doses of micronutrients to improve immediate pregnancy-related and long-term cardio metabolic outcomes. The results will have significant public health implications in a setting with widespread B12 deficiency but relative folate sufficiency. The randomised controlled trial design allows us to be confident that our findings will be causally relevant. Trial registration ISRCTN 32921044, applied on 14/09/2012. CTRI 2012/12/003212, registered on 02/12/2012. Retrospectively registered.",2017,High homocysteine and low vitamin B12 levels in pregnancy predicted lower birthweight and higher insulin resistance at 6 years in the offspring.,[],"['vitamin B12 supplementation', 'Iron and folic acid', 'vitamin B12 2\xa0μg; or 2) vitamin B12 2\xa0μg plus multiple micronutrients (MMN) plus 20\xa0g of milk powder or 3) placebo']","['cord blood B12 concentration', 'Adverse events', 'SD change in newborn B12', 'High homocysteine and low vitamin B12 levels', 'immediate pregnancy-related and long-term cardio metabolic outcomes']",[],"[{'cui': 'C4524262', 'cui_str': 'Vitamin B12 supplementation'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0042845', 'cui_str': 'cyanocobalamin'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}, {'cui': 'C0450403', 'cui_str': '20G (qualifier value)'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0032861', 'cui_str': 'Powdered drug preparation'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0162371', 'cui_str': 'Cord Blood'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0019878', 'cui_str': '2-amino-4-mercaptobutyric acid'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0427407', 'cui_str': 'Finding of vitamin B12 level (finding)'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}]",,0.328578,High homocysteine and low vitamin B12 levels in pregnancy predicted lower birthweight and higher insulin resistance at 6 years in the offspring.,"[{'ForeName': 'Kalyanaraman', 'Initials': 'K', 'LastName': 'Kumaran', 'Affiliation': '1Diabetes Unit, KEM Hospital Research Centre, Rasta Peth, Pune 411011 India.'}, {'ForeName': 'Pallavi', 'Initials': 'P', 'LastName': 'Yajnik', 'Affiliation': '1Diabetes Unit, KEM Hospital Research Centre, Rasta Peth, Pune 411011 India.'}, {'ForeName': 'Himangi', 'Initials': 'H', 'LastName': 'Lubree', 'Affiliation': '1Diabetes Unit, KEM Hospital Research Centre, Rasta Peth, Pune 411011 India.'}, {'ForeName': 'Charudatta', 'Initials': 'C', 'LastName': 'Joglekar', 'Affiliation': '1Diabetes Unit, KEM Hospital Research Centre, Rasta Peth, Pune 411011 India.'}, {'ForeName': 'Dattatray', 'Initials': 'D', 'LastName': 'Bhat', 'Affiliation': '1Diabetes Unit, KEM Hospital Research Centre, Rasta Peth, Pune 411011 India.'}, {'ForeName': 'Prachi', 'Initials': 'P', 'LastName': 'Katre', 'Affiliation': '1Diabetes Unit, KEM Hospital Research Centre, Rasta Peth, Pune 411011 India.'}, {'ForeName': 'Suyog', 'Initials': 'S', 'LastName': 'Joshi', 'Affiliation': '1Diabetes Unit, KEM Hospital Research Centre, Rasta Peth, Pune 411011 India.'}, {'ForeName': 'Rasika', 'Initials': 'R', 'LastName': 'Ladkat', 'Affiliation': '1Diabetes Unit, KEM Hospital Research Centre, Rasta Peth, Pune 411011 India.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Fall', 'Affiliation': '2MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, SO16 6YD UK.'}, {'ForeName': 'Chittaranjan', 'Initials': 'C', 'LastName': 'Yajnik', 'Affiliation': '1Diabetes Unit, KEM Hospital Research Centre, Rasta Peth, Pune 411011 India.'}]",BMC nutrition,['10.1186/s40795-017-0143-5'] 3172,32142371,The PCORnet Blood Pressure Control Laboratory: A Platform for Surveillance and Efficient Trials.,"BACKGROUND Uncontrolled blood pressure (BP) is a leading preventable cause of death that remains common in the US population despite the availability of effective medications. New technology and program innovation has high potential to improve BP but may be expensive and burdensome for patients, clinicians, health systems, and payers and may not produce desired results or reduce existing disparities in BP control. METHODS AND RESULTS The PCORnet Blood Pressure Control Laboratory is a platform designed to enable national surveillance and facilitate quality improvement and comparative effectiveness research. The platform uses PCORnet, the National Patient-Centered Clinical Research Network, for engagement of health systems and collection of electronic health record data, and the Eureka Research Platform for eConsent and collection of patient-reported outcomes and mHealth data from wearable devices and smartphones. Three demonstration projects are underway: BP track will conduct national surveillance of BP control and related clinical processes by measuring theory-derived pragmatic BP control metrics using electronic health record data, with a focus on tracking disparities over time; BP MAP will conduct a cluster-randomized trial comparing effectiveness of 2 versions of a BP control quality improvement program; BP Home will conduct an individual patient-level randomized trial comparing effectiveness of smartphone-linked versus standard home BP monitoring. Thus far, BP Track has collected electronic health record data from over 826 000 eligible patients with hypertension who completed ≈3.1 million ambulatory visits. Preliminary results demonstrate substantial room for improvement in BP control (<140/90 mm Hg), which was 58% overall, and in the clinical processes relevant for BP control. For example, only 12% of patients with hypertension with a high BP measurement during an ambulatory visit received an order for a new antihypertensive medication. CONCLUSIONS The PCORnet Blood Pressure Control Laboratory is designed to be a reusable platform for efficient surveillance and comparative effectiveness research; results from demonstration projects are forthcoming.",2020,"Preliminary results demonstrate substantial room for improvement in BP control (<140/90 mm Hg), which was 58% overall, and in the clinical processes relevant for BP control.",['826 000 eligible patients with hypertension who completed ≈3.1 million ambulatory visits'],['smartphone-linked versus standard home BP monitoring'],['BP control'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",826000.0,0.0561908,"Preliminary results demonstrate substantial room for improvement in BP control (<140/90 mm Hg), which was 58% overall, and in the clinical processes relevant for BP control.","[{'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Pletcher', 'Affiliation': 'Department of Epidemiology and Biostatistics (M.J.P., M.F.), University of California, San Francisco.'}, {'ForeName': 'Valy', 'Initials': 'V', 'LastName': 'Fontil', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine (M.J.P., V.F.), University of California, San Francisco.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Carton', 'Affiliation': 'Division of Health Services Research, Louisiana Public Health Institute, Tulane University, New Orleans, LA. (T.C.).'}, {'ForeName': 'Kathryn M', 'Initials': 'KM', 'LastName': 'Shaw', 'Affiliation': 'Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL (K.M.S., M.S.).'}, {'ForeName': 'Myra', 'Initials': 'M', 'LastName': 'Smith', 'Affiliation': 'Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL (K.M.S., M.S.).'}, {'ForeName': 'Sujung', 'Initials': 'S', 'LastName': 'Choi', 'Affiliation': 'Duke Clinical Research Institute, and Department of Population Health Sciences, Duke University School of Medicine, Durham, NC (S.C., E.C.O.).'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Todd', 'Affiliation': 'OCHIN, Portland, OR (J.T.).'}, {'ForeName': 'Alanna M', 'Initials': 'AM', 'LastName': 'Chamberlain', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN (A.M.C.).'}, {'ForeName': 'Emily C', 'Initials': 'EC', 'LastName': ""O'Brien"", 'Affiliation': 'Duke Clinical Research Institute, and Department of Population Health Sciences, Duke University School of Medicine, Durham, NC (S.C., E.C.O.).'}, {'ForeName': 'Madelaine', 'Initials': 'M', 'LastName': 'Faulkner', 'Affiliation': 'Department of Epidemiology and Biostatistics (M.J.P., M.F.), University of California, San Francisco.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Maeztu', 'Affiliation': ''}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Wozniak', 'Affiliation': 'Improving Health Outcomes, American Medical Association, Chicago, IL (G.W., M.R.).'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Rakotz', 'Affiliation': 'Improving Health Outcomes, American Medical Association, Chicago, IL (G.W., M.R.).'}, {'ForeName': 'Christina M', 'Initials': 'CM', 'LastName': 'Shay', 'Affiliation': 'Center for Health Metrics and Evaluation, American Heart Association (C.M.S.).'}, {'ForeName': 'Rhonda M', 'Initials': 'RM', 'LastName': 'Cooper-DeHoff', 'Affiliation': 'Department of Pharmacotherapy and Translational Research, University of Florida, College of Pharmacy, Gainesville, FL (R.M.C.D.).'}]",Circulation. Cardiovascular quality and outcomes,['10.1161/CIRCOUTCOMES.119.006115'] 3173,32041605,Cost-effectiveness of child caries management: a randomised controlled trial (FiCTION trial).,"BACKGROUND A three-arm parallel group, randomised controlled trial set in general dental practices in England, Scotland, and Wales was undertaken to evaluate three strategies to manage dental caries in primary teeth. Children, with at least one primary molar with caries into dentine, were randomised to receive Conventional with best practice prevention (C + P), Biological with best practice prevention (B + P), or best practice Prevention Alone (PA). METHODS Data on costs were collected via case report forms completed by clinical staff at every visit. The co-primary outcomes were incidence of, and number of episodes of, dental pain and/or infection avoided. The three strategies were ranked in order of mean cost and a more costly strategy was compared with a less costly strategy in terms of incremental cost-effectiveness. Costs and outcomes were discounted at 3.5%. RESULTS A total of 1144 children were randomised with data on 1058 children (C + P n = 352, B + P n = 352, PA n = 354) used in the analysis. On average, it costs £230 to manage dental caries in primary teeth over a period of up to 36 months. Managing children in PA was, on average, £19 (97.5% CI: -£18 to £55) less costly than managing those in B + P. In terms of effectiveness, on average, there were fewer incidences of, (- 0.06; 97.5% CI: - 0.14 to 0.02) and fewer episodes of dental pain and/or infection (- 0.14; 97.5% CI: - 0.29 to 0.71) in B + P compared to PA. C + P was unlikely to be considered cost-effective, as it was more costly and less effective than B + P. CONCLUSIONS The mean cost of a child avoiding any dental pain and/or infection (incidence) was £330 and the mean cost per episode of dental pain and/or infection avoided was £130. At these thresholds B + P has the highest probability of being considered cost-effective. Over the willingness to pay thresholds considered, the probability of B + P being considered cost-effective never exceeded 75%. TRIAL REGISTRATION The trial was prospectively registered with the ISRCTN (reference number ISRCTN77044005) on the 26th January 2009 and East of Scotland Research Ethics Committee provided ethical approved (REC reference: 12/ES/0047).",2020,"On average, it costs £230 to manage dental caries in primary teeth over a period of up to 36 months.","['general dental practices in England, Scotland, and Wales was undertaken to evaluate three strategies to manage dental caries in primary teeth', 'child caries management', 'Children, with at least one primary molar with caries into dentine', '1144 children']","['Conventional with best practice prevention (C\u2009+\u2009P), Biological with best practice prevention (B\u2009+\u2009P), or best practice Prevention Alone (PA']","['incidence of, and number of episodes of, dental pain and/or infection avoided', 'mean cost of a child avoiding any dental pain and/or infection (incidence', 'episodes of dental pain and/or infection', 'Costs and outcomes', 'Cost-effectiveness']","[{'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0036453', 'cui_str': 'Scotland'}, {'cui': 'C0041666', 'cui_str': 'Undertaking'}, {'cui': 'C0011334', 'cui_str': 'Dental Decay'}, {'cui': 'C3266841', 'cui_str': 'Baby Teeth'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0026367', 'cui_str': 'Molar'}, {'cui': 'C0011429', 'cui_str': 'Dentin'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C3179154', 'cui_str': 'Best Practices'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C4553887', 'cui_str': 'Biologic Drugs'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",1144.0,0.15415,"On average, it costs £230 to manage dental caries in primary teeth over a period of up to 36 months.","[{'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'Homer', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4AX, UK. tara.homer@newcastle.ac.uk.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Maguire', 'Affiliation': 'School of Dental Sciences, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Gail V A', 'Initials': 'GVA', 'LastName': 'Douglas', 'Affiliation': 'Dental School, University of Leeds, Leeds, UK.'}, {'ForeName': 'Nicola P', 'Initials': 'NP', 'LastName': 'Innes', 'Affiliation': 'School of Dentistry, University of Dundee, Dundee, UK.'}, {'ForeName': 'Jan E', 'Initials': 'JE', 'LastName': 'Clarkson', 'Affiliation': 'Dental Health Services Research Unit, University of Dundee, Dundee, UK.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Wilson', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4AX, UK.'}, {'ForeName': 'Vicky', 'Initials': 'V', 'LastName': 'Ryan', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4AX, UK.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'McColl', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4AX, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Robertson', 'Affiliation': 'School of Dentistry, University of Dundee, Dundee, UK.'}, {'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Vale', 'Affiliation': 'Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4AX, UK.'}]",BMC oral health,['10.1186/s12903-020-1020-1'] 3174,30814109,Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.,"PURPOSE To investigate the potential of circulating-miRNAs (ct-miRNA) as noninvasive biomarkers to predict the efficacy of single/dual HER2-targeted therapy in the NeoALTTO study. EXPERIMENTAL DESIGN Patients with plasma samples at baseline (T0) and/or after 2 weeks (T1) of treatment were randomized into training ( n = 183) and testing ( n = 246) sets. RT-PCR-based high-throughput miRNA profiling was employed in the training set. After normalization, ct-miRNAs associated with pathologic complete response (pCR) were identified by univariate analysis. Multivariate logistic regression models were implemented to generate treatment-specific signatures at T0 and T1, which were evaluated by RT-PCR in the testing set. Event-free survival (EFS) according to ct-miRNA signatures was estimated by Kaplan-Meier method and Cox regression model. RESULTS In the training set, starting from 51 ct-miRNAs associated with pCR, six signatures with statistically significant predictive capability in terms of area under the ROC curve (AUC) were identified. Four signatures were confirmed in the testing set: lapatinib at T0 and T1 [AUC 0.86; 95% confidence interval (CI), 0.73-0.98 and 0.71 (0.55-0.86)], respectively; trastuzumab at T1 (0.81; 0.70-0.92); lapatinib + trastuzumab at T1 (0.67; 0.51-0.83). These signatures were confirmed predictive after adjusting for known variables, including estrogen receptor status. ct-miRNA signatures failed to correlate with EFS. However, the levels of ct-miR-140-5p, included in the trastuzumab signature, were associated with EFS (HR 0.43; 95% CI, 0.22-0.84). CONCLUSIONS ct-miRNAs discriminate patients with and without pCR after neoadjuvant lapatinib- and/or trastuzumab-based therapy. ct-miRNAs at week two could be valuable to identify patients responsive to trastuzumab, to avoid unnecessary combination with other anti-HER2 agents, and finally to assist deescalating treatment strategies.",2019,"Four signatures were confirmed in the testing set: lapatinib at T0 and T1 [AUC 0.86; 95% confidence interval (CI), 0.73-0.98 and 0.71 (0.55-0.86)], respectively; trastuzumab at T1 (0.81; 0.70-0.92); lapatinib + trastuzumab at T1 (0.67; 0.51-0.83).","['Patients with plasma samples at baseline (T0) and/or after 2 weeks (T1) of treatment', 'HER2-positive Breast Cancer']",['circulating-miRNAs (ct-miRNA'],"['area under the ROC curve (AUC', 'Event-free survival (EFS', 'pathologic complete response (pCR']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444263', 'cui_str': 'Plasma specimen'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C1101610', 'cui_str': 'miRNA'}]","[{'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0035787', 'cui_str': 'ROC Analysis'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C1521733', 'cui_str': 'Pathologic (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C3853643', 'cui_str': 'Probe with target amplification technique (qualifier value)'}]",,0.0218969,"Four signatures were confirmed in the testing set: lapatinib at T0 and T1 [AUC 0.86; 95% confidence interval (CI), 0.73-0.98 and 0.71 (0.55-0.86)], respectively; trastuzumab at T1 (0.81; 0.70-0.92); lapatinib + trastuzumab at T1 (0.67; 0.51-0.83).","[{'ForeName': 'Serena', 'Initials': 'S', 'LastName': 'Di Cosimo', 'Affiliation': 'Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Appierto', 'Affiliation': 'Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Pizzamiglio', 'Affiliation': 'Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Tiberio', 'Affiliation': 'Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Marilena V', 'Initials': 'MV', 'LastName': 'Iorio', 'Affiliation': 'Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Florentine', 'Initials': 'F', 'LastName': 'Hilbers', 'Affiliation': 'Breast International Group (BIG), Brussels, Belgium.'}, {'ForeName': 'Evandro', 'Initials': 'E', 'LastName': 'de Azambuja', 'Affiliation': 'Department of Medical Oncology, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium.'}, {'ForeName': 'Lorena', 'Initials': 'L', 'LastName': 'de la Peña', 'Affiliation': 'SOLTI - Breast Cancer Research Group, Barcelona, Spain.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Izquierdo', 'Affiliation': 'Novartis Pharmaceutical, Basel, Switzerland.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Huober', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Baselga', 'Affiliation': ""Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.""}, {'ForeName': 'Martine', 'Initials': 'M', 'LastName': 'Piccart', 'Affiliation': 'Department of Medical Oncology, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium.'}, {'ForeName': 'Filippo G', 'Initials': 'FG', 'LastName': 'de Braud', 'Affiliation': 'Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Apolone', 'Affiliation': 'Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Verderio', 'Affiliation': 'Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Maria Grazia', 'Initials': 'MG', 'LastName': 'Daidone', 'Affiliation': 'Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. mariagrazia.daidone@istitutotumori.mi.it.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-18-2507'] 3175,32109425,"Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.","BACKGROUND Gefapixant is a P2X3 receptor antagonist that has shown promise for the treatment of refractory and unexplained chronic cough. The aim of this study was to evaluate the efficacy of gefapixant compared with placebo after 12 weeks of treatment for refractory chronic cough or unexplained chronic cough. METHODS We did a 12-week, phase 2b, randomised, double-blind, placebo-controlled study in patients with refractory chronic cough or unexplained chronic cough aged 18-80 years who were recruited from 44 primarily outpatient pulmonologist or allergist sites in the UK and the USA. Eligible patients had refractory or unexplained chronic cough lasting 1 year or longer, no radiographic chest abnormality, and 40 mm or more on a 100-mm cough severity visual analogue scale at enrolment. Patients were randomly assigned to receive placebo or one of three doses (7·5 mg, 20 mg, or 50 mg) of oral gefapixant twice daily, every day, for 84 days; visits to investigative sites were on days 1, 28, 42, 56, 70, 84, and 85. The randomisation schedule was computer generated using a permuted block algorithm by Advance Research Associates (Santa Clara, CA, USA). Patients and all personnel involved in the conduct and interpretation of the study were masked to treatment assignment. The primary endpoint was placebo-adjusted change from baseline in awake cough frequency after 12 weeks, assessed in the full analysis set, which is a subset of the intention-to-treat population. Adverse events were monitored and safety was evaluated in all patients receiving one or more doses of study drug. This trial is registered with ClinicalTrials.gov, NCT02612610. FINDINGS Between Dec 21, 2015, and July 26, 2016, 253 patients were randomly assigned to placebo (n=63), gefapixant 7·5 mg (n=64), gefapixant 20 mg (n=63), or gefapixant 50 mg (n=63) twice daily. The mean age of patients was 60·2 (SD 9·9) years and 193 (76%) were women. At 12 weeks, patients' geometric mean awake cough frequency was 18·2 coughs per h (geometric SD 3·1) with placebo, and 14·5 coughs per h (3·7) with 7·5 mg, 12·0 coughs per h (4·2) with 20 mg, and 11·3 coughs per h (2·8) with 50 mg gefapixant. Estimated percentage change relative to placebo was -22·0% (-41·8 to 4·6; p=0·097) with 7·5 mg, -22·2% (-42·0 to 4·3; p=0·093) with 20 mg, and -37·0% (95% CI -53·3 to -14·9; p=0·0027) with 50 mg gefapixant. Dysgeusia was the most common adverse event, occurring in three (5%) patients given placebo, six (10%) given 7·5 mg gefapixant, 21 (33%) given 20 mg gefapixant, and 30 (48%) given 50 mg gefapixant. INTERPRETATION Targeting purinergic receptor P2X3 with gefapixant at a dose of 50 mg twice daily significantly reduced cough frequency in patients with refractory chronic cough or unexplained chronic cough after 12 weeks of treatment compared with placebo. Further development of gefapixant is warranted for the treatment of chronic cough. FUNDING Afferent Pharmaceuticals (acquired by Merck & Co., Inc., Kenilworth, NJ, USA).",2020,"Dysgeusia was the most common adverse event, occurring in three (5%) patients given placebo, six (10%) given 7·5 mg gefapixant, 21 (33%) given 20 mg gefapixant, and 30 (48%) given 50 mg gefapixant. ","['patients with refractory chronic cough or unexplained chronic cough aged 18-80 years who were recruited from 44 primarily outpatient pulmonologist or allergist sites in the UK and the USA', 'SD 9·9) years and 193 (76%) were women', 'patients with refractory chronic cough or unexplained chronic cough after 12 weeks of treatment compared with', 'mean age of patients was 60·2', 'Between Dec 21, 2015, and July 26, 2016, 253 patients', 'Eligible patients had refractory or unexplained chronic cough lasting 1 year or longer, no radiographic chest abnormality, and 40 mm or more on a 100-mm cough severity visual analogue scale at enrolment', 'refractory chronic cough or unexplained chronic cough']","['placebo', 'gefapixant', 'oral gefapixant', 'gefapixant 7·5 mg (n=64), gefapixant 20 mg (n=63), or gefapixant 50 mg']","['placebo-adjusted change from baseline in awake cough frequency', 'geometric mean awake cough frequency', 'cough frequency', 'Adverse events', 'Dysgeusia']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4552486', 'cui_str': 'Refractory chronic cough'}, {'cui': 'C4552485', 'cui_str': 'Unexplained chronic cough'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0586859', 'cui_str': 'Pulmonologists'}, {'cui': 'C0334896', 'cui_str': 'Allergists'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0000769', 'cui_str': 'anomalies'}, {'cui': 'C0450402', 'cui_str': '40mm (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0234422', 'cui_str': 'Awake (finding)'}, {'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0013378', 'cui_str': 'Taste, Distorted'}]",253.0,0.672719,"Dysgeusia was the most common adverse event, occurring in three (5%) patients given placebo, six (10%) given 7·5 mg gefapixant, 21 (33%) given 20 mg gefapixant, and 30 (48%) given 50 mg gefapixant. ","[{'ForeName': 'Jaclyn A', 'Initials': 'JA', 'LastName': 'Smith', 'Affiliation': 'Division of Infection, Immunity, and Respiratory Medicine, University of Manchester, Manchester, UK; Manchester University NHS Foundation Trust, Manchester, UK. Electronic address: jacky.smith@manchester.ac.uk.'}, {'ForeName': 'Michael M', 'Initials': 'MM', 'LastName': 'Kitt', 'Affiliation': 'Merck & Co., Kenilworth, NJ, USA.'}, {'ForeName': 'Alyn H', 'Initials': 'AH', 'LastName': 'Morice', 'Affiliation': 'Hull York Medical School, Cottingham, UK.'}, {'ForeName': 'Surinder S', 'Initials': 'SS', 'LastName': 'Birring', 'Affiliation': ""Centre for Human & Applied Physiological Sciences, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.""}, {'ForeName': 'Lorcan P', 'Initials': 'LP', 'LastName': 'McGarvey', 'Affiliation': ""Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Mandel R', 'Initials': 'MR', 'LastName': 'Sher', 'Affiliation': 'Center for Cough, Largo, FL, USA.'}, {'ForeName': 'Yu-Ping', 'Initials': 'YP', 'LastName': 'Li', 'Affiliation': 'GetStat Solutions, LLC, Palo Alto, CA, USA.'}, {'ForeName': 'Wen-Chi', 'Initials': 'WC', 'LastName': 'Wu', 'Affiliation': 'Merck & Co., Kenilworth, NJ, USA.'}, {'ForeName': 'Zhi Jin', 'Initials': 'ZJ', 'LastName': 'Xu', 'Affiliation': 'Merck & Co., Kenilworth, NJ, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Muccino', 'Affiliation': 'Merck & Co., Kenilworth, NJ, USA.'}, {'ForeName': 'Anthony P', 'Initials': 'AP', 'LastName': 'Ford', 'Affiliation': 'Merck & Co., Kenilworth, NJ, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(19)30471-0'] 3176,31765110,"A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects.","AIM To assess safety, tolerability, and pharmacokinetics of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adults. METHODS A phase 1, double-blind, randomized, placebo-controlled, single- and multiple-dose study in Japanese and Caucasian subjects. Subjects received lisdexamfetamine 20 mg or placebo on Day 1, then lisdexamfetamine 20 mg/d (Days 4-8), 50 mg/d (Days 9-13), 70 mg/d (Days 14-18), or matching placebo. Pharmacokinetic parameters for lisdexamfetamine and d-amphetamine were estimated by noncompartmental analysis. RESULTS Fifteen Japanese and 19 Caucasian subjects were enrolled and randomized. The lisdexamfetamine and d-amphetamine plasma concentration-time curves were similar for both ethnic groups following single and multiple doses. Mean area under the concentration-time curves for d-amphetamine were higher (by 11%-15%) in Japanese than Caucasian subjects following multiple dosing of lisdexamfetamine. Mean bodyweight was 17% lower in Japanese than Caucasian subjects. Weight-corrected means for oral clearance were similar in both ethnic groups, with no unexpected accumulation of d-amphetamine. Lisdexamfetamine was generally well tolerated by both ethnic groups, with no serious adverse events reported. The 10/12 Japanese and 11/16 Caucasian subjects who received lisdexamfetamine completed the study; two Japanese and three Caucasian subjects discontinued due to adverse events. Most adverse events were of mild severity. CONCLUSION Pharmacokinetics were generally similar for Japanese and Caucasian subjects; the minor differences observed were likely due to bodyweight differences in the two ethnic groups. Lisdexamfetamine was generally well tolerated. Adverse events were consistent with the established safety profile of lisdexamfetamine and were similar in both ethnic groups.",2020,The lisdexamfetamine and d-amphetamine plasma concentration-time curves were similar for both ethnic groups following single and multiple doses.,"['Japanese and Caucasian subjects', 'Japanese and Caucasian healthy adult subjects', '10/12 Japanese and 11/16 Caucasian subjects who received lisdexamfetamine completed the study; two Japanese and three Caucasian subjects discontinued due to adverse events', 'Fifteen Japanese and 19 Caucasian subjects', 'Japanese and Caucasian healthy adults']","['lisdexamfetamine', 'lisdexamfetamine 20\xa0mg or placebo', 'lisdexamfetamine dimesylate', 'placebo', 'Lisdexamfetamine', 'lisdexamfetamine and d-amphetamine']","['tolerated', 'Adverse events', 'safety, tolerability, and pharmacokinetics', 'Mean bodyweight', 'Pharmacokinetic parameters', 'Weight-corrected means for oral clearance', 'Mean area under the concentration-time curves']","[{'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C1873633', 'cui_str': 'Lisdexamfetamine'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1706472', 'cui_str': 'Discontinue - dosing instruction imperative'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]","[{'cui': 'C1873633', 'cui_str': 'Lisdexamfetamine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1739826', 'cui_str': 'lisdexamfetamine dimesylate'}, {'cui': 'C0011812', 'cui_str': 'dexamfetamine'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}]",15.0,0.056452,The lisdexamfetamine and d-amphetamine plasma concentration-time curves were similar for both ethnic groups following single and multiple doses.,"[{'ForeName': 'James', 'Initials': 'J', 'LastName': 'Ermer', 'Affiliation': 'Shire, Wayne, PA, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Martin', 'Affiliation': 'Shire, Lexington, MA, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Corcoran', 'Affiliation': 'Shire, Lexington, MA, USA.'}, {'ForeName': 'Yumiko', 'Initials': 'Y', 'LastName': 'Matsuo', 'Affiliation': 'Shionogi & Co., Ltd, Osaka, Japan.'}]",Neuropsychopharmacology reports,['10.1002/npr2.12082'] 3177,32024473,"The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trial : Effect of a cardiovascular health promotion program in youth, a prospective cohort study.","BACKGROUND According to the World Health Organization, cardiovascular diseases (CVDs) are the leading non-communicable cause of death. Awareness of the individual risk profile is crucial to implement a healthy lifestyle and prevent CVDs. Multiple studies demonstrated that atherosclerosis, the main cause of CVDs, begins early in life. Therefore, it may be necessary to start prevention programs already in childhood. METHODS The EVA-Tyrol study is a population-based non-randomized controlled trial that will prospectively enroll 2000 participants from high schools and training companies in North- and East-Tyrol (Austria) and South-Tyrol (Italy). Participants will be assigned to either an intervention (n = 1500) or a control (n = 500) group. Intervention group participants will be enrolled at the 10th school grade (mean age 15-16 years), undergo two examinations within a two-year interval, with follow-up at the 12th grade (mean ages 17-18 years). Control group participants will be enrolled at the 12th grade (mean age 17-18 years). Medical examination will include anthropometric measurements, comprehensive lifestyle and dietary questionnaires, a fasting blood sample, high-resolution ultrasound of the carotid arteries, and measurement of carotid-femoral pulse wave velocity. Active intervention will consist of (1) enhancing knowledge about CVDs, (2) individual medical counseling based on the results of the baseline examination, (3) an online health promotion tool and (4) involvement of participants in planning and implementation of health promotion projects. Effectiveness of the intervention will be assessed by comparing the proportion subjects with ideal health metrics as defined by the American Heart Association between study groups. DISCUSSION This study aims to improve cardiovascular health in Tyrolean adolescents by demonstrating the efficacy of a multi-layer health promotion program and may yield novel insights into the prevalence of vascular risk conditions and mechanisms of early vascular pathologies in adolescents. TRIAL REGISTRATION EVA-Tyrol has been retrospectively registered at clinicaltrials.gov under NCT03929692 since April 29, 2019.",2020,"This study aims to improve cardiovascular health in Tyrolean adolescents by demonstrating the efficacy of a multi-layer health promotion program and may yield novel insights into the prevalence of vascular risk conditions and mechanisms of early vascular pathologies in adolescents. ","['Tyrolean adolescents', 'adolescents', '2000 participants from high schools and training companies in North- and East-Tyrol (Austria) and South-Tyrol (Italy', 'Control group participants will be enrolled at the 12th grade (mean age 17-18\u2009years', 'Intervention group participants will be enrolled at the 10th school grade (mean age 15-16\u2009years), undergo two examinations within a two-year interval, with follow-up at the 12th grade (mean ages 17-18\u2009years', 'proportion subjects with ideal health metrics as defined by the American Heart Association between study groups']","['cardiovascular health promotion program', 'multi-layer health promotion program']",['cardiovascular health'],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C4704932', 'cui_str': 'Health Metrics'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0002458', 'cui_str': 'American Heart Association'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0018738', 'cui_str': 'Health Promotion'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C3266262', 'cui_str': 'Multi'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}]",,0.118315,"This study aims to improve cardiovascular health in Tyrolean adolescents by demonstrating the efficacy of a multi-layer health promotion program and may yield novel insights into the prevalence of vascular risk conditions and mechanisms of early vascular pathologies in adolescents. ","[{'ForeName': 'Benoît', 'Initials': 'B', 'LastName': 'Bernar', 'Affiliation': 'Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Gande', 'Affiliation': 'Department of Pediatrics II, Medical University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria.'}, {'ForeName': 'Katharina A', 'Initials': 'KA', 'LastName': 'Stock', 'Affiliation': 'Department of Pediatrics II, Medical University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Staudt', 'Affiliation': 'Department of Pediatrics II, Medical University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria.'}, {'ForeName': 'Raimund', 'Initials': 'R', 'LastName': 'Pechlaner', 'Affiliation': 'Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Geiger', 'Affiliation': 'Department of Pediatrics III, Medical University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Griesmacher', 'Affiliation': 'Central Institute of Clinical Chemistry and Laboratory Medicine (ZIMCL), Medical University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Kiechl', 'Affiliation': 'Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Knoflach', 'Affiliation': 'Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria. Michael.knoflach@i-med.ac.at.'}, {'ForeName': 'Ursula', 'Initials': 'U', 'LastName': 'Kiechl-Kohlendorfer', 'Affiliation': 'Department of Pediatrics II, Medical University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMC cardiovascular disorders,['10.1186/s12872-020-01357-9'] 3178,32001493,PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myeloma.,"INTRODUCTION Myeloma, a blood cancer originating from plasma cells, is the most common indication for autologous stem cell transplantation (SCT). Patients with myeloma undergoing autologous SCT (ASCT) experience treatment-related morbidity and reduction in function and well-being for many months post-treatment. Interventions targeting physical functioning delivered prior to and during SCT have shown promising results in mixed haematological populations and may offer a non-pharmacological solution to physically optimising and preparing patients for SCT. The aim of this study is to investigate the feasibility of a physiotherapist-led exercise intervention as an integral part of the myeloma ASCT pathway at a UK tertiary centre. METHODS AND ANALYSIS PERCEPT is a single-site, pilot randomised controlled trial of an exercise intervention embedded within the myeloma ASCT pathway, compared with usual care. The primary study end points will be feasibility measures of study and intervention delivery including recruitment rates, acceptability of intervention, study completion rate and any adverse events. Secondary end points will evaluate differences between the exercise intervention group and the usual care control group in cancer-related fatigue, quality of life, functional capacity (6 min walk test; handheld dynamometry; a timed sit-to-stand test) and objective and self-reported physical activity. Outcomes will be assessed at four time points, approximately 6-8 weeks prior to SCT, on/around day of SCT, on discharge from SCT hospital admission and 12 weeks post-discharge. The exercise intervention comprises of partly supervised physiotherapist-led aerobic and resistance exercise including behaviour change techniques to promote change in exercise behaviour. The primary outcomes from the trial will be summarised as percentages or mean values with 95% CIs. Group differences for secondary outcomes at each time point will be analysed using appropriate statistical models. ETHICS AND DISSEMINATION This study has NHS REC approval (Camden and Kings Cross, 19/LO/0204). Results will be disseminated through publication and presentations at haematology and rehabilitation-related meetings. TRIAL REGISTRATION NUMBER ISRCTN15875290.",2020,"Secondary end points will evaluate differences between the exercise intervention group and the usual care control group in cancer-related fatigue, quality of life, functional capacity (6 min walk test; handheld dynamometry; a timed sit-to-stand test) and objective and self-reported physical activity.","['Patients with myeloma undergoing', 'patients with multiple myeloma']","['exercise intervention', 'autologous stem cell transplantation', 'physiotherapist-led exercise intervention', 'exercise intervention comprises of partly supervised physiotherapist-led aerobic and resistance exercise including behaviour change techniques', 'autologous SCT (ASCT']","['feasibility measures of study and intervention delivery including recruitment rates, acceptability of intervention, study completion rate and any adverse events', 'cancer-related fatigue, quality of life, functional capacity (6\u2009min walk test; handheld dynamometry; a timed sit-to-stand test) and objective and self-reported physical activity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0026764', 'cui_str': 'Myelomatosis'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C1504389', 'cui_str': 'Stem Cell Transplantation'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapists'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}]","[{'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4274302', 'cui_str': 'Fatigue associated with malignant neoplastic disease'}, {'cui': 'C0034380'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C3888057', 'cui_str': 'Stand'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]",,0.162006,"Secondary end points will evaluate differences between the exercise intervention group and the usual care control group in cancer-related fatigue, quality of life, functional capacity (6 min walk test; handheld dynamometry; a timed sit-to-stand test) and objective and self-reported physical activity.","[{'ForeName': 'Orla', 'Initials': 'O', 'LastName': 'McCourt', 'Affiliation': 'Therapies & Rehabilitation, University College London Hospitals NHS Foundation Trust, London, UK o.mccourt@nhs.net.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Fisher', 'Affiliation': 'Research Department of Behavoural Science and Health, University College London, London, UK.'}, {'ForeName': 'Gita', 'Initials': 'G', 'LastName': 'Ramdharry', 'Affiliation': 'Queen Square Centre for Neuromuscular Diseases, University College London, London, UK.'}, {'ForeName': 'Anna L', 'Initials': 'AL', 'LastName': 'Roberts', 'Affiliation': 'Research Department of Behavoural Science and Health, University College London, London, UK.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Land', 'Affiliation': 'Research Department of Behavoural Science and Health, University College London, London, UK.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Rabin', 'Affiliation': 'Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.'}, {'ForeName': 'Kwee', 'Initials': 'K', 'LastName': 'Yong', 'Affiliation': 'Research Department of Haematology, Cancer Institute, University College London, London, UK.'}]",BMJ open,['10.1136/bmjopen-2019-033176'] 3179,32000687,Comparison of the effects of lanthanum carbonate and calcium carbonate on the progression of cardiac valvular calcification after initiation of hemodialysis.,"BACKGROUND Although mineral metabolism disorder influences cardiac valvular calcification (CVC), few previous studies have examined the effects of non-calcium-containing and calcium-containing phosphate binders on CVC in maintenance hemodialysis patients. The aim of the present study was to compare the effects of lanthanum carbonate (LC) with calcium carbonate (CC) on the progression of CVC in patients who initiated maintenance hemodialysis and to investigate clinical factors related to CVC. METHODS The current study included 50 subjects (mean age 65 years, 72% males) from our previous randomized controlled trial (LC group, N = 24; CC group, N = 26). CVC was evaluated as CVC score (CVCS) using echocardiography at baseline and 18 months after initiation of hemodialysis. We compared CVCS and the changes between the two groups. We also analyzed the associations between CVCS and any other clinical factors including arterial plaque score (PS) and serum phosphorus levels. RESULTS Baseline characteristics of study participants including CVCS were almost comparable between the two groups. At 18 months, there were no significant differences in mineral metabolic markers or CVCS between the two groups, and CVCS were significantly correlated with PS (r = 0.39, p < 0.01). Furthermore, changes in CVCS were significantly correlated with average phosphorus levels (r = 0.36, p < 0.05), which were significantly higher in high serum phosphorus and high PS group compared to low serum phosphorus and low PS group (p < 0.05). CONCLUSIONS In the present study, there were no significant differences between LC and CC with regard to progression of CVC. However, serum phosphorus levels and arterial plaque seem to be important for the progression and formation of CVC in hemodialysis patients.",2020,"At 18 months, there were no significant differences in mineral metabolic markers or CVCS between the two groups, and CVCS were significantly correlated with PS (r = 0.39, p < 0.01).","['50 subjects (mean age 65\u2009years, 72% males', 'patients who initiated maintenance hemodialysis and to investigate clinical factors related to CVC', 'maintenance hemodialysis patients', 'hemodialysis patients']","['lanthanum carbonate (LC) with calcium carbonate (CC', 'lanthanum carbonate and calcium carbonate']","['CVCS', 'arterial plaque score (PS) and serum phosphorus levels', 'progression of cardiac valvular calcification', 'CVC score (CVCS', 'average phosphorus levels', 'mineral metabolic markers or CVCS']","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4040576', 'cui_str': 'Maintenance hemodialysis'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}]","[{'cui': 'C0768119', 'cui_str': 'lanthanum carbonate'}, {'cui': 'C0006681', 'cui_str': 'Calcium Carbonate'}]","[{'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0031705', 'cui_str': 'Phosphorus'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0026162', 'cui_str': 'Minerals'}]",50.0,0.0154165,"At 18 months, there were no significant differences in mineral metabolic markers or CVCS between the two groups, and CVCS were significantly correlated with PS (r = 0.39, p < 0.01).","[{'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Watanabe', 'Affiliation': 'Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Fujii', 'Affiliation': 'Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. fhideki@med.kobe-u.ac.jp.'}, {'ForeName': 'Keiji', 'Initials': 'K', 'LastName': 'Kono', 'Affiliation': 'Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.'}, {'ForeName': 'Shunsuke', 'Initials': 'S', 'LastName': 'Goto', 'Affiliation': 'Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.'}, {'ForeName': 'Shinichi', 'Initials': 'S', 'LastName': 'Nishi', 'Affiliation': 'Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.'}]",BMC cardiovascular disorders,['10.1186/s12872-020-01343-1'] 3180,31915255,GABA-ergic Dynamics in Human Frontotemporal Networks Confirmed by Pharmaco-Magnetoencephalography.,"To bridge the gap between preclinical cellular models of disease and in vivo imaging of human cognitive network dynamics, there is a pressing need for informative biophysical models. Here we assess dynamic causal models (DCM) of cortical network responses, as generative models of magnetoencephalographic observations during an auditory oddball roving paradigm in healthy adults. This paradigm induces robust perturbations that permeate frontotemporal networks, including an evoked 'mismatch negativity' response and transiently induced oscillations. Here, we probe GABAergic influences in the networks using double-blind placebo-controlled randomized-crossover administration of the GABA reuptake inhibitor, tiagabine (oral, 10 mg) in healthy older adults. We demonstrate the facility of conductance-based neural mass mean-field models, incorporating local synaptic connectivity, to investigate laminar-specific and GABAergic mechanisms of the auditory response. The neuronal model accurately recapitulated the observed magnetoencephalographic data. Using parametric empirical Bayes for optimal model inversion across both drug sessions, we identify the effect of tiagabine on GABAergic modulation of deep pyramidal and interneuronal cell populations. We found a transition of the main GABAergic drug effects from auditory cortex in standard trials to prefrontal cortex in deviant trials. The successful integration of pharmaco- magnetoencephalography with dynamic causal models of frontotemporal networks provides a potential platform on which to evaluate the effects of disease and pharmacological interventions. SIGNIFICANCE STATEMENT Understanding human brain function and developing new treatments require good models of brain function. We tested a detailed generative model of cortical microcircuits that accurately reproduced human magnetoencephalography, to quantify network dynamics and connectivity in frontotemporal cortex. This approach identified the effect of a test drug (GABA-reuptake inhibitor, tiagabine) on neuronal function (GABA-ergic dynamics), opening the way for psychopharmacological studies in health and disease with the mechanistic precision afforded by generative models of the brain.",2020,We found a transition of the main GABAergic drug effects from auditory cortex in standard trials to prefrontal cortex in deviant trials.,"['healthy adults', 'healthy older adults']","['test drug (GABA-reuptake inhibitor, tiagabine', 'auditory oddball roving paradigm', 'placebo', 'tiagabine', 'GABA re-uptake inhibitor, tiagabine (oral']",[],"[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C2936508', 'cui_str': 'Uptake Inhibitors, Gamma-Aminobutyric Acid'}, {'cui': 'C0068897', 'cui_str': 'tiagabine'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0016904', 'cui_str': 'gamma-Aminobutyric Acid'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]",[],,0.0641366,We found a transition of the main GABAergic drug effects from auditory cortex in standard trials to prefrontal cortex in deviant trials.,"[{'ForeName': 'Natalie E', 'Initials': 'NE', 'LastName': 'Adams', 'Affiliation': 'Cambridge University Department of Clinical Neurosciences and Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, CB2 0SZ, United Kingdom.'}, {'ForeName': 'Laura E', 'Initials': 'LE', 'LastName': 'Hughes', 'Affiliation': 'Cambridge University Department of Clinical Neurosciences and Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, CB2 0SZ, United Kingdom.'}, {'ForeName': 'Holly N', 'Initials': 'HN', 'LastName': 'Phillips', 'Affiliation': 'Cambridge University Department of Clinical Neurosciences and Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, CB2 0SZ, United Kingdom.'}, {'ForeName': 'Alexander D', 'Initials': 'AD', 'LastName': 'Shaw', 'Affiliation': 'Cambridge University Department of Clinical Neurosciences and Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, CB2 0SZ, United Kingdom.'}, {'ForeName': 'Alexander G', 'Initials': 'AG', 'LastName': 'Murley', 'Affiliation': 'Cambridge University Department of Clinical Neurosciences and Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, CB2 0SZ, United Kingdom.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Nesbitt', 'Affiliation': 'Medical Research Council Cognition and Brain Sciences Unit, Cambridge CB2 7EF, United Kingdom, and.'}, {'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Cope', 'Affiliation': 'Cambridge University Department of Clinical Neurosciences and Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, CB2 0SZ, United Kingdom.'}, {'ForeName': 'W Richard', 'Initials': 'WR', 'LastName': 'Bevan-Jones', 'Affiliation': 'Cambridge University Department of Clinical Neurosciences and Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, CB2 0SZ, United Kingdom.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Passamonti', 'Affiliation': 'Cambridge University Department of Clinical Neurosciences and Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, CB2 0SZ, United Kingdom.'}, {'ForeName': 'James B', 'Initials': 'JB', 'LastName': 'Rowe', 'Affiliation': 'Cambridge University Department of Clinical Neurosciences and Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, CB2 0SZ, United Kingdom, james.rowe@mrc-cbu.cam.ac.uk.'}]",The Journal of neuroscience : the official journal of the Society for Neuroscience,['10.1523/JNEUROSCI.1689-19.2019'] 3181,30556959,"Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Dose of Miridesap in Healthy Japanese Subjects.","This phase 1 study characterized the safety, tolerability, pharmacokinetics, and pharmacodynamics of miridesap (GSK2315698) following an intravenous (IV) infusion in healthy Japanese men. Subjects in Cohort 1 received 1-hour IV infusions of 10, 20, and 40 mg of miridesap or placebo, and subjects in Cohort 2 received a 15-hour IV infusion of 20 mg/h of miridesap or placebo. No treatment-related adverse events were reported. No new safety signals were identified for either vital signs or clinical laboratory parameters. A dose-dependent increase was observed in miridesap exposure (area under the concentration-time curve and maximum observed drug concentration) in the 10 to 40 mg/h dose range after a 1-hour IV infusion of miridesap. Rapid depletion of circulating serum amyloid P component was observed after the initiation of miridesap infusion. Serum amyloid P component concentrations fell in a dose-dependent manner following administration of miridesap.",2019,No treatment-related adverse events were reported.,"['Healthy Japanese Subjects', 'healthy Japanese men']","['15-hour IV infusion of 20\xa0mg/h of miridesap or placebo', 'miridesap or placebo']","['Serum amyloid P component concentrations', 'adverse events', 'Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics', 'miridesap exposure (area under the concentration-time curve and maximum observed drug concentration', 'safety, tolerability, pharmacokinetics, and pharmacodynamics of miridesap (GSK2315698']","[{'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0439421', 'cui_str': 'mg/h'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0002721', 'cui_str': 'Serum Amyloid P-Component'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}]",,0.109395,No treatment-related adverse events were reported.,"[{'ForeName': 'Hiroko', 'Initials': 'H', 'LastName': 'Ino', 'Affiliation': 'Medicines Development (Clinical Pharmacology Office), Japan Development Division, GlaxoSmithKline K.K., Tokyo, Japan.'}, {'ForeName': 'Yohei', 'Initials': 'Y', 'LastName': 'Doi', 'Affiliation': 'Medicines Development (Clinical Pharmacology Office), Japan Development Division, GlaxoSmithKline K.K., Tokyo, Japan.'}, {'ForeName': 'Lia', 'Initials': 'L', 'LastName': 'Liefaard', 'Affiliation': 'Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Stevenage, UK.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Cookson', 'Affiliation': 'GlaxoSmithKline Research and Development, Stevenage, UK.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, London, UK.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Itoh', 'Affiliation': 'Biomedical Data Sciences Department, Japan Development Division, GlaxoSmithKline K.K., Tokyo, Japan.'}, {'ForeName': 'Harue', 'Initials': 'H', 'LastName': 'Igarashi', 'Affiliation': 'Pre-Clinical Development, Japan Development Division, GlaxoSmithKline K.K., Tokyo, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Nakano', 'Affiliation': 'Medicines Development, Japan Development Division, GlaxoSmithKline K.K., Tokyo, Japan.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.631'] 3182,31642586,The rate of bone loss slows after 1-2 years of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (START) bone mineral density substudy.,"OBJECTIVES Initial antiretroviral therapy (ART) causes loss of bone mineral density (BMD) over the first 1-2 years. Whether this loss continues with longer therapy is unclear. We determined changes in bone and spine BMD over 5 years in adults receiving immediate or deferred initial ART. METHODS In the Strategic Timing of Antiretroviral Therapy (START) BMD substudy, ART-naïve adults with CD4 counts > 500 cells/μL were randomized to immediate or deferred ART. Deferred group participants not yet on ART were offered ART after May 2015. Mean per cent changes in total hip and lumbar spine BMD (measured annually by dual-energy X-ray absorptiometry) were compared between groups using longitudinal mixed models. Fracture rates were also compared between groups for all START participants. RESULTS Substudy participants (immediate group, n = 201; deferred group, n = 210; median age 32 years; 80% non-white; 24% female) were followed for a mean 4.5 years until December 2016. In the immediate group, > 96% used ART throughout. In the deferred group, 16%, 58% and 94% used ART at years 1, 3 and 5, respectively. BMD decreased more in the immediate group initially; groups had converged by year 3 at the spine and year 4 at the hip by intent-to-treat (ITT). BMD changes after year 1 were similar in the immediate group and in those off ART in the deferred group [mean difference: spine, 0.03% per year; 95% confidence interval (CI) -0.4, 0.4; P = 0.88; hip, -0.2% per year; 95% CI -0.7, 0.3; P = 0.37]. Fracture incidence did not differ significantly between groups (immediate group, 0.86/100 person-years versus deferred group, 0.85/100 person-years; hazard ratio 1.01; 95% CI 0.76, 1.35; P = 0.98). CONCLUSIONS Significant ART-induced bone loss slowed after the first year of ART and became similar to that in untreated HIV infection.",2020,"Fracture incidence did not differ significantly between groups (immediate group, 0.86/100 person-years versus deferred group, 0.85/100 person-years; hazard ratio 1.01; 95% CI 0.76, 1.35; P = 0.98). ","['Substudy participants (immediate group, n\xa0=\xa0201; deferred group, n\xa0=\xa0210; median age 32\xa0years; 80% non-white; 24% female) were followed for a mean 4.5\xa0years until December 2016', 'adults receiving immediate or deferred initial ART', '500 cells/μL']",[],"['rate of bone loss slows', 'BMD', 'BMD changes', 'bone mineral density (BMD', 'total hip and lumbar spine BMD', 'bone loss', 'Fracture rates', 'Fracture incidence', 'bone and spine BMD']","[{'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3844009', 'cui_str': 'Four point five'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0007634', 'cui_str': 'Cells'}]",[],"[{'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0439834', 'cui_str': 'Slowly'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C3887615', 'cui_str': 'Lumbar spine structure (body structure)'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0037949', 'cui_str': 'Spinal Column'}]",,0.220958,"Fracture incidence did not differ significantly between groups (immediate group, 0.86/100 person-years versus deferred group, 0.85/100 person-years; hazard ratio 1.01; 95% CI 0.76, 1.35; P = 0.98). ","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Carr', 'Affiliation': ""St Vincent's Hospital, Sydney, Australia.""}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Grund', 'Affiliation': 'University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'A V', 'Initials': 'AV', 'LastName': 'Schwartz', 'Affiliation': 'University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Avihingsanon', 'Affiliation': 'Thai Red Cross AIDS Research Center and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Badal-Faesen', 'Affiliation': 'Clinical HIV Research Unit, University of Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'J I', 'Initials': 'JI', 'LastName': 'Bernadino', 'Affiliation': 'Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Estrada', 'Affiliation': 'Hospital Clinico San Carlos, Madrid, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'La Rosa', 'Affiliation': 'Asociacion Civil Impacta Salud y Educacion, Lima, Peru.'}, {'ForeName': 'Pwg', 'Initials': 'P', 'LastName': 'Mallon', 'Affiliation': 'University College Dublin, Dublin, Ireland.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Pujari', 'Affiliation': 'Institute of Infectious Diseases, Pune, India.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'White', 'Affiliation': 'Heart of England NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Wyman Engen', 'Affiliation': 'University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Ensrud', 'Affiliation': 'University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'J F', 'Initials': 'JF', 'LastName': 'Hoy', 'Affiliation': 'The Alfred Hospital, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",HIV medicine,['10.1111/hiv.12796'] 3183,31323516,Acute stroke rehabilitation for gait training with cyborg type robot Hybrid Assistive Limb: A pilot study.,"Robot-assisted gait training following acute stroke could allow patients with severe disability to receive a high dosage and intensity of gait training compared with conventional physical therapy (CP). However, given the limited data on gauging the efficacy of Hybrid Assistive Limb (HAL) on gait training in patients with acute stroke, we aimed to evaluate several outcome measures following gait training with HAL. Patients with first-ever stroke, who required a walking aid and were able to start gait training within 1 week of stroke onset were included in the current study. Patients were assigned to either the CP or HAL group. Outcome measures were collected at baseline, and at the 2nd (at 2-6 weeks), and 3rd (at 3-5 months) assessments. All patients underwent physical therapy until the 3rd assessment; patients in the HAL group underwent gait training using HAL until the 2nd assessment. Thirty-seven patients (19 from CP and 18 from HAL, median age = 69 years) completed the study. At the 2nd assessment, the total Functional Independence Measure (FIM) score was higher in the HAL group than in the CP group (90.1 vs. 79.0, p = 0.042). In conclusion, the FIM scale could be used to identify responsiveness to acute stroke rehabilitation using HAL.",2019,"At the 2nd assessment, the total Functional Independence Measure (FIM) score was higher in the HAL group than in the CP group (90.1 vs. 79.0, p = 0.042).","['patients with acute stroke', 'patients with severe disability', 'Thirty-seven patients (19 from CP and 18 from HAL, median age\u202f=\u202f69\u202fyears) completed the study', 'Patients with first-ever stroke, who required a walking aid and were able to start gait training within 1\u202fweek of stroke onset were included in the current study']","['gait training with cyborg type robot Hybrid Assistive Limb', 'physical therapy', 'gait training using HAL', 'CP or HAL', 'gait training', 'conventional physical therapy (CP', 'Hybrid Assistive Limb (HAL', 'gait training with HAL', 'Robot-assisted gait training']",['total Functional Independence Measure (FIM) score'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0751956', 'cui_str': 'Stroke, Acute'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C4319569', 'cui_str': '37 (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0557834', 'cui_str': 'Walking aid (physical object)'}, {'cui': 'C1299581', 'cui_str': 'Able'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure (procedure)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0336537', 'cui_str': 'Robot, device (physical object)'}, {'cui': 'C0020205', 'cui_str': 'Hybrids'}, {'cui': 'C0015385', 'cui_str': 'Limbs'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure (procedure)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4274266', 'cui_str': 'Functional Independence Measure score'}]",37.0,0.0402937,"At the 2nd assessment, the total Functional Independence Measure (FIM) score was higher in the HAL group than in the CP group (90.1 vs. 79.0, p = 0.042).","[{'ForeName': 'Chiaki', 'Initials': 'C', 'LastName': 'Yokota', 'Affiliation': 'Department of Stroke Rehabilitation, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka 564-8565, Japan; Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka 564-8565, Japan. Electronic address: cyokota@ncvc.go.jp.'}, {'ForeName': 'Yukio', 'Initials': 'Y', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Stroke Rehabilitation, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka 564-8565, Japan. Electronic address: yukiyama@ncvc.go.jp.'}, {'ForeName': 'Masatoshi', 'Initials': 'M', 'LastName': 'Kamada', 'Affiliation': 'Department of Stroke Rehabilitation, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka 564-8565, Japan. Electronic address: m.kamada@ncvc.go.jp.'}, {'ForeName': 'Michikazu', 'Initials': 'M', 'LastName': 'Nakai', 'Affiliation': 'Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka 564-8565, Japan. Electronic address: nakai.michikazu@ncvc.go.jp.'}, {'ForeName': 'Kunihiro', 'Initials': 'K', 'LastName': 'Nishimura', 'Affiliation': 'Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka 564-8565, Japan. Electronic address: knishimu@ncvc.go.jp.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Ando', 'Affiliation': 'Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka 564-8565, Japan.'}, {'ForeName': 'Takeo', 'Initials': 'T', 'LastName': 'Sato', 'Affiliation': 'Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka 564-8565, Japan.'}, {'ForeName': 'Masatoshi', 'Initials': 'M', 'LastName': 'Koga', 'Affiliation': 'Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka 564-8565, Japan. Electronic address: koga@ncvc.go.jp.'}, {'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Ihara', 'Affiliation': 'Department of Neurology, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka 564-8565, Japan. Electronic address: ihara@ncvc.go.jp.'}, {'ForeName': 'Kazunori', 'Initials': 'K', 'LastName': 'Toyoda', 'Affiliation': 'Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka 564-8565, Japan. Electronic address: toyoda@ncvc.go.jp.'}, {'ForeName': 'Yasuyuki', 'Initials': 'Y', 'LastName': 'Fujimoto', 'Affiliation': 'Department of Stroke Rehabilitation, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka 564-8565, Japan. Electronic address: fujimoto.yasuyuki24@ncvc.go.jp.'}, {'ForeName': 'Hirotaka', 'Initials': 'H', 'LastName': 'Odani', 'Affiliation': 'Department of Stroke Rehabilitation, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka 564-8565, Japan.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Minematsu', 'Affiliation': 'Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka 564-8565, Japan. Electronic address: kminemat@ncvc.go.jp.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Nakajima', 'Affiliation': 'Niigata National Hospital, National Hospital Organization, 3-52 Akasaka, Kashiwazaki city 945-8585, Japan. Electronic address: nakajima-md@mqb.biglobe.ne.jp.'}]",Journal of the neurological sciences,['10.1016/j.jns.2019.07.012'] 3184,31928611,Best-practice prevention alone or with conventional or biological caries management for 3- to 7-year-olds: the FiCTION three-arm RCT.,"BACKGROUND Historically, lack of evidence for effective management of decay in primary teeth has caused uncertainty, but there is emerging evidence to support alternative strategies to conventional fillings, which are minimally invasive and prevention orientated. OBJECTIVES The objectives were (1) to assess the clinical effectiveness and cost-effectiveness of three strategies for managing caries in primary teeth and (2) to assess quality of life, dental anxiety, the acceptability and experiences of children, parents and dental professionals, and caries development and/or progression. DESIGN This was a multicentre, three-arm parallel-group, participant-randomised controlled trial. Allocation concealment was achieved by use of a centralised web-based randomisation facility hosted by Newcastle Clinical Trials Unit. SETTING This trial was set in primary dental care in Scotland, England and Wales. PARTICIPANTS Participants were NHS patients aged 3-7 years who were at a high risk of tooth decay and had at least one primary molar tooth with decay into dentine, but no pain/sepsis. INTERVENTIONS Three interventions were employed: (1) conventional with best-practice prevention (local anaesthetic, carious tissue removal, filling placement), (2) biological with best-practice prevention (sealing-in decay, selective carious tissue removal and fissure sealants) and (3) best-practice prevention alone (dietary and toothbrushing advice, topical fluoride and fissure sealing of permanent teeth). MAIN OUTCOME MEASURES The clinical effectiveness outcomes were the proportion of children with at least one episode (incidence) and the number of episodes, for each child, of dental pain or dental sepsis or both over the follow-up period. The cost-effectiveness outcomes were the cost per incidence of, and cost per episode of, dental pain and/or dental sepsis avoided over the follow-up period. RESULTS A total of 72 dental practices were recruited and 1144 participants were randomised (conventional arm, n  = 386; biological arm, n  = 381; prevention alone arm, n  = 377). Of these, 1058 were included in an intention-to-treat analysis (conventional arm, n  = 352; biological arm, n  = 352; prevention alone arm, n  = 354). The median follow-up time was 33.8 months (interquartile range 23.8-36.7 months). The proportion of children with at least one episode of pain or sepsis or both was 42% (conventional arm), 40% (biological arm) and 45% (prevention alone arm). There was no evidence of a difference in incidence or episodes of pain/sepsis between arms. When comparing the biological arm with the conventional arm, the risk difference was -0.02 (97.5% confidence interval -0.10 to 0.06), which indicates, on average, a 2% reduced risk of dental pain and/or dental sepsis in the biological arm compared with the conventional arm. Comparing the prevention alone arm with the conventional arm, the risk difference was 0.04 (97.5% confidence interval -0.04 to 0.12), which indicates, on average, a 4% increased risk of dental pain and/or dental sepsis in the prevention alone arm compared with the conventional arm. Compared with the conventional arm, there was no evidence of a difference in episodes of pain/sepsis among children in the biological arm (incident rate ratio 0.95, 97.5% confidence interval 0.75 to 1.21, which indicates that there were slightly fewer episodes, on average, in the biological arm than the conventional arm) or in the prevention alone arm (incident rate ratio 1.18, 97.5% confidence interval 0.94 to 1.48, which indicates that there were slightly more episodes in the prevention alone arm than the conventional arm). Over the willingness-to-pay values considered, the probability of the biological treatment approach being considered cost-effective was approximately no higher than 60% to avoid an incidence of dental pain and/or dental sepsis and no higher than 70% to avoid an episode of pain/sepsis. CONCLUSIONS There was no evidence of an overall difference between the three treatment approaches for experience of, or number of episodes of, dental pain or dental sepsis or both over the follow-up period. FUTURE WORK Recommendations for future work include exploring barriers to the use of conventional techniques for carious lesion detection and diagnosis (e.g. radiographs) and developing and evaluating suitable techniques and strategies for use in young children in primary care. TRIAL REGISTRATION Current Controlled Trials ISRCTN77044005. FUNDING This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 24, No. 1. See the NIHR Journals Library website for further project information.",2020,"There was no evidence of an overall difference between the three treatment approaches for experience of, or number of episodes of, dental pain or dental sepsis or both over the follow-up period. ","['Participants were NHS patients aged 3-7 years who were at a high risk of tooth decay and had at least one primary molar tooth with decay into dentine, but no pain/sepsis', 'A total of 72 dental practices were recruited and 1144 participants', '1058 were included in an intention-to-treat analysis (conventional arm, n \u2009=\u2009352; biological arm, n \u2009=\u2009352; prevention alone arm, n \u2009=\u2009354', '3- to 7-year-olds', 'young children in primary care', 'primary dental care in Scotland, England and Wales']","['Three interventions were employed: (1) conventional with best-practice prevention (local anaesthetic, carious tissue removal, filling placement), (2) biological with best-practice prevention (sealing-in decay, selective carious tissue removal and fissure sealants) and (3) best-practice prevention alone (dietary and toothbrushing advice, topical fluoride and fissure sealing of permanent teeth']","['clinical effectiveness and cost-effectiveness', 'pain or sepsis', 'number of episodes of, dental pain or dental sepsis', 'episodes of pain/sepsis', 'quality of life, dental anxiety, the acceptability and experiences of children, parents and dental professionals, and caries development and/or progression', 'cost per incidence of, and cost per episode of, dental pain and/or dental sepsis', 'median follow-up time', 'number of episodes, for each child, of dental pain or dental sepsis', 'cost-effectiveness outcomes', 'dental pain and/or dental sepsis', 'risk of dental pain and/or dental sepsis', 'incidence or episodes of pain/sepsis']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0011334', 'cui_str': 'Dental Decay'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0026367', 'cui_str': 'Molar'}, {'cui': 'C1265875', 'cui_str': 'Disintegration'}, {'cui': 'C0011429', 'cui_str': 'Dentin'}, {'cui': 'C0234225', 'cui_str': 'No pain'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C4553887', 'cui_str': 'Biologic Drugs'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0011331', 'cui_str': 'Dental Care'}, {'cui': 'C0036453', 'cui_str': 'Scotland'}, {'cui': 'C0014282', 'cui_str': 'England'}]","[{'cui': 'C0557351', 'cui_str': 'Employed (finding)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C3179154', 'cui_str': 'Best Practices'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0002934', 'cui_str': 'Conduction-Blocking Anesthetics'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C4553887', 'cui_str': 'Biologic Drugs'}, {'cui': 'C0036492', 'cui_str': 'Seal (organism)'}, {'cui': 'C1265875', 'cui_str': 'Disintegration'}, {'cui': 'C0016168', 'cui_str': 'Fissure Sealants'}, {'cui': 'C0040461', 'cui_str': 'Toothbrushing'}, {'cui': 'C0016328', 'cui_str': 'Fluorides, Topical'}, {'cui': 'C0332469', 'cui_str': 'Fissured (qualifier value)'}, {'cui': 'C0348070', 'cui_str': 'Dentition, Adult'}]","[{'cui': 'C3850123', 'cui_str': 'Treatment Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0518988', 'cui_str': 'Dental abscess (disorder)'}, {'cui': 'C0034380'}, {'cui': 'C0085380', 'cui_str': 'Fear, Dental'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",1058.0,0.176073,"There was no evidence of an overall difference between the three treatment approaches for experience of, or number of episodes of, dental pain or dental sepsis or both over the follow-up period. ","[{'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Maguire', 'Affiliation': 'School of Dental Sciences, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Jan E', 'Initials': 'JE', 'LastName': 'Clarkson', 'Affiliation': 'Dental Health Services Research Unit, University of Dundee, Dundee, UK.'}, {'ForeName': 'Gail Va', 'Initials': 'GV', 'LastName': 'Douglas', 'Affiliation': 'Dental School, University of Leeds, Leeds, UK.'}, {'ForeName': 'Vicky', 'Initials': 'V', 'LastName': 'Ryan', 'Affiliation': 'Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'Homer', 'Affiliation': 'Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Marshman', 'Affiliation': 'School of Clinical Dentistry, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'McColl', 'Affiliation': 'Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Wilson', 'Affiliation': 'Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Vale', 'Affiliation': 'Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Robertson', 'Affiliation': 'Dental Health Services Research Unit, University of Dundee, Dundee, UK.'}, {'ForeName': 'Alaa', 'Initials': 'A', 'LastName': 'Abouhajar', 'Affiliation': 'Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Richard D', 'Initials': 'RD', 'LastName': 'Holmes', 'Affiliation': 'School of Dental Sciences, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Freeman', 'Affiliation': 'Dental Health Services Research Unit, University of Dundee, Dundee, UK.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Chadwick', 'Affiliation': 'School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Deery', 'Affiliation': 'School of Clinical Dentistry, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Ferranti', 'Initials': 'F', 'LastName': 'Wong', 'Affiliation': 'Institute of Dentistry, Queen Mary University of London, London, UK.'}, {'ForeName': 'Nicola Pt', 'Initials': 'NP', 'LastName': 'Innes', 'Affiliation': 'School of Dentistry, University of Dundee, Dundee, UK.'}]","Health technology assessment (Winchester, England)",['10.3310/hta24010'] 3185,31554943,Effect of multiple subconjunctival conbercept injections as an adjuvant to the surgical treatment of pterygium: a prospective randomised comparative 6-month follow-up study.,"OBJECTIVE To evaluate the safety and efficacy of multiple subconjunctival injections of conbercept for pterygium patients after surgery. METHODS As a prospective randomised interventional trial, 96 eyes from 96 patients with a tendency to recur were collected and divided randomly into conbercept and 5-fluorouracil groups on the 5th day after pterygium. All patients received three subconjunctival injections of conbercept (0.2 ml) or 5-fluorouracil (0.2 ml) on the 5th day (baseline), and 2 and 4 weeks post-operatively. The pterygium morphology, colour intensity, recurrence, and complications were recorded and analysed pre-1st injection and 1 day, 1 week, 1 month, 3 months, and 6 months post-3rd injection. Moreover, no patient was drop-out. RESULTS There were striking differences between the two groups on post-3rd injections 1 day, 1 week, 1 month, 3 months, and 6 months (p = 0.001, 0.002, 0.000, 0.000, and 0.002, respectively) with respect to colour intensity: the eyes in conbercept group were lighter than the 5-Fu group. On post-3rd injection 6 months, prominent disparities existed between the two groups with respect to pterygium morphology (p = 0.006) and recurrence (p = 0.002), occurred in the conbercept group prior to the 5-Fu group. Moreover, corneal abrasions were not noted in the conbercept group, which was significantly less than the 5-Fu group (17/48; p = 0.000). There was no conspicuous discrepancy between the two groups with respect to subconjunctival haemorrhage (p = 0.789) and persistent epithelial defects (p = 0.078). CONCLUSION Multiple subconjunctival conbercept injections as an adjunct therapy for pterygium surgery was shown to be safe, effective, and well-tolerated.",2020,"On post-3rd injection 6 months, prominent disparities existed between the two groups with respect to pterygium morphology (p = 0.006) and recurrence (p = 0.002), occurred in the conbercept group prior to the 5-Fu group.","['pterygium', '96 eyes from 96 patients with a tendency to recur', 'pterygium patients after surgery']","['5-Fu', 'multiple subconjunctival conbercept injections', 'conbercept and 5-fluorouracil', 'multiple subconjunctival injections of conbercept', 'subconjunctival injections of conbercept (0.2\u2009ml) or 5-fluorouracil']","['corneal abrasions', 'pterygium morphology, colour intensity, recurrence, and complications', 'subconjunctival haemorrhage', 'persistent epithelial defects', 'safe, effective, and well-tolerated', 'recurrence', 'pterygium morphology', 'safety and efficacy']","[{'cui': 'C0033999', 'cui_str': 'Pterygium'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}]","[{'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0442183', 'cui_str': 'Subconjunctival (qualifier value)'}, {'cui': 'C2352201', 'cui_str': 'KH902 fusion protein'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0197180', 'cui_str': 'Subconjunctival injection (procedure)'}, {'cui': 'C4517436', 'cui_str': '0.2'}]","[{'cui': 'C0010032', 'cui_str': 'Corneal abrasion (disorder)'}, {'cui': 'C0033999', 'cui_str': 'Pterygium'}, {'cui': 'C0543482', 'cui_str': 'morphology'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0038534', 'cui_str': 'Subconjunctival hemorrhage (disorder)'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0163744,"On post-3rd injection 6 months, prominent disparities existed between the two groups with respect to pterygium morphology (p = 0.006) and recurrence (p = 0.002), occurred in the conbercept group prior to the 5-Fu group.","[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Ophthalmology, Zhongnan Hospital of Wuhan University, No 169. Donghu Road, 430071, Wuhan, Hubei, China.'}, {'ForeName': 'Quanxi', 'Initials': 'Q', 'LastName': 'Tian', 'Affiliation': 'School of Information Management and statistics, Hubei University of Economics, No. 8 Yangqiaohu Road, 430205, Wuhan, Hubei, China.'}, {'ForeName': 'Tian', 'Initials': 'T', 'LastName': 'Zheng', 'Affiliation': 'Department of Ophthalmology, Zhongnan Hospital of Wuhan University, No 169. Donghu Road, 430071, Wuhan, Hubei, China.'}, {'ForeName': 'Donglai', 'Initials': 'D', 'LastName': 'Chen', 'Affiliation': ""Department of Ophthalmology, The Second People's Hospital of Honghu, No 142. Xinjian Road, 433202, Honghu, Hubei, China.""}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': 'Department of Ophthalmology, Zhongnan Hospital of Wuhan University, No 169. Donghu Road, 430071, Wuhan, Hubei, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Ke', 'Affiliation': 'Department of Ophthalmology, Zhongnan Hospital of Wuhan University, No 169. Donghu Road, 430071, Wuhan, Hubei, China. keminyk@163.com.'}]","Eye (London, England)",['10.1038/s41433-019-0596-7'] 3186,30218818,"Putting patients at the center of kidney care transitions: PREPARE NOW, a cluster randomized controlled trial.","Care for patients transitioning from chronic kidney disease to kidney failure often falls short of meeting patients' needs. The PREPARE NOW study is a cluster randomized controlled trial studying the effectiveness of a pragmatic health system intervention, 'Patient Centered Kidney Transition Care,' a multi-component health system intervention designed to improve patients' preparation for kidney failure treatment. Patient-Centered Kidney Transition Care provides a suite of new electronic health information tools (including a disease registry and risk prediction tools) to help providers recognize patients in need of Kidney Transitions Care and focus their attention on patients' values and treatment preferences. Patient-Centered Kidney Transition Care also adds a 'Kidney Transitions Specialist' to the nephrology health care team to facilitate patients' self-management empowerment, shared-decision making, psychosocial support, care navigation, and health care team communication. The PREPARE NOW study is conducted among eight [8] outpatient nephrology clinics at Geisinger, a large integrated health system in rural Pennsylvania. Four randomly selected nephrology clinics employ the Patient Centered Kidney Transitions Care intervention while four clinics employ usual nephrology care. To assess intervention effectiveness, patient reported, biomedical, and health system outcomes are collected annually over a period of 36 months via telephone questionnaires and electronic health records. The PREPARE NOW Study may provide needed evidence on the effectiveness of patient-centered health system interventions to improve nephrology patients' experiences, capabilities, and clinical outcomes, and it will guide the implementation of similar interventions elsewhere. TRIAL REGISTRATION NCT02722382.",2018,Patient-Centered Kidney Transition Care provides a suite of new electronic health information tools (including a disease registry and risk prediction tools) to help providers recognize patients in need of Kidney Transitions Care and focus their attention on patients' values and treatment preferences.,"[""patients' preparation for kidney failure treatment"", 'Putting patients at the center of kidney care transitions', 'eight [8] outpatient nephrology clinics at Geisinger, a large integrated health system in rural Pennsylvania']","['pragmatic health system intervention', 'Patient Centered Kidney Transitions Care intervention while four clinics employ usual nephrology care']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0035078', 'cui_str': 'Kidney Failure'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C4019079', 'cui_str': 'Care Transition'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C3814531', 'cui_str': 'Nephrology clinic'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0030853', 'cui_str': 'Pennsylvania'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C4019071', 'cui_str': 'Transition Care'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0557351', 'cui_str': 'Employed (finding)'}, {'cui': 'C0027712', 'cui_str': 'Nephrology'}]",[],4.0,0.0278836,Patient-Centered Kidney Transition Care provides a suite of new electronic health information tools (including a disease registry and risk prediction tools) to help providers recognize patients in need of Kidney Transitions Care and focus their attention on patients' values and treatment preferences.,"[{'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Green', 'Affiliation': 'Department of Nephrology, Geisinger Commonwealth School of Medicine, Danville, PA, USA; Kidney Health Research Institute, Geisinger, Danville, PA, USA. Electronic address: jgreen1@geisinger.edu.'}, {'ForeName': 'P L', 'Initials': 'PL', 'LastName': 'Ephraim', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, MD, USA. Electronic address: pephraim@jhu.edu.'}, {'ForeName': 'F F', 'Initials': 'FF', 'LastName': 'Hill-Briggs', 'Affiliation': 'Division of General Internal Medicine, Johns Hopkins University, Baltimore, MD, USA. Electronic address: fbriggs3@jhmi.edu.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Browne', 'Affiliation': 'College of Social Work, University of South Carolina, Columbia, SC, USA. Electronic address: browne@sc.edu.'}, {'ForeName': 'T S', 'Initials': 'TS', 'LastName': 'Strigo', 'Affiliation': 'Division of General Internal Medicine, Duke University School of Medicine, Durham, NC, USA. Electronic address: tara.strigo@duke.edu.'}, {'ForeName': 'C L', 'Initials': 'CL', 'LastName': 'Hauer', 'Affiliation': 'Center for Clinical Innovation, Institute for Advanced Application, Geisinger, Danville, PA, USA. Electronic address: clhauer@geisinger.edu.'}, {'ForeName': 'R A', 'Initials': 'RA', 'LastName': 'Stametz', 'Affiliation': 'Center for Clinical Innovation, Institute for Advanced Application, Geisinger, Danville, PA, USA. Electronic address: rastametz@geisinger.edu.'}, {'ForeName': 'J D', 'Initials': 'JD', 'LastName': 'Darer', 'Affiliation': 'Decision Support Siemens Healthineers Malvern, PA, USA. Electronic address: jon.darer@medicalis.com.'}, {'ForeName': 'U D', 'Initials': 'UD', 'LastName': 'Patel', 'Affiliation': 'Division of Nephrology, Duke University School of Medicine, Durham, NC, USA; Gilead Sciences, Inc., Foster City, CA, USA. Electronic address: uptal.patel@duke.edu.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Lang-Lindsey', 'Affiliation': 'Department of Social Work, Alabama State University, Montgomery, AL, USA. Electronic address: kllindsey@alasu.edu.'}, {'ForeName': 'B L', 'Initials': 'BL', 'LastName': 'Bankes', 'Affiliation': 'Patient stakeholder co-author, Bloomsburg, PA, USA.'}, {'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'Bolden', 'Affiliation': 'Patient stakeholder co-author, Jacksonville, FL, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Danielson', 'Affiliation': 'Patient stakeholder co-author, Portland, OR, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Ruff', 'Affiliation': 'Patient stakeholder co-author, Mooresville, NC, USA.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Schmidt', 'Affiliation': 'Patient stakeholder co-author, Liberty, Illinois, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Swoboda', 'Affiliation': 'Patient stakeholder co-author, Edgewater, MD, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Woods', 'Affiliation': 'Patient stakeholder co-author, Hartsdale, New York, NY, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Vinson', 'Affiliation': 'Quality Insights Renal Network 5, Richmond, VA, USA. Electronic address: BVinson@nw5.esrd.net.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Littlewood', 'Affiliation': 'The Care Centered Collaborative, Pennsylvania Medical Society, Harrisburg, PA, USA. Electronic address: dlittlewood@patientccc.com.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Jackson', 'Affiliation': 'Division of General Internal Medicine, Duke University School of Medicine, Durham, NC, USA. Electronic address: george.l.jackson@duke.edu.'}, {'ForeName': 'J F', 'Initials': 'JF', 'LastName': 'Pendergast', 'Affiliation': 'Department of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC, USA. Electronic address: jane.pendergast@duke.edu.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'St Clair Russell', 'Affiliation': 'Division of General Internal Medicine, Duke University School of Medicine, Durham, NC, USA. Electronic address: jennifer.st.clair.russell@duke.edu.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Collins', 'Affiliation': 'Patient Services, National Kidney Foundation, New York, NY, USA. Electronic address: Kelli.Collins@kidney.org.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Norfolk', 'Affiliation': 'Department of Nephrology, Geisinger Commonwealth School of Medicine, Danville, PA, USA. Electronic address: ernorfolk@geisinger.edu.'}, {'ForeName': 'I D', 'Initials': 'ID', 'LastName': 'Bucaloiu', 'Affiliation': 'Department of Nephrology, Geisinger Medical Center, Danville, PA, USA. Electronic address: idbucaloiu@geisinger.edu.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Kethireddy', 'Affiliation': 'Critical Care Medicine, Northeast Georgia Health System, Gainesville, GA, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Collins', 'Affiliation': 'Adult Psychology and Behavioral Medicine, Department of Psychiatry, Geisinger, Danville, PA, USA. Electronic address: cacollins1@geisinger.edu.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Davis', 'Affiliation': 'Center for Translational Bioethics and Health Care Policy, Geisinger, Danville, PA, USA. Electronic address: ddavis1@geisinger.edu.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'dePrisco', 'Affiliation': 'Center for Clinical Innovation, Institute for Advanced Application, Geisinger, Danville, PA, USA. Electronic address: jjdeprisco@geisinger.edu.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Malloy', 'Affiliation': 'Center for Clinical Innovation, Institute for Advanced Application, Geisinger, Danville, PA, USA. Electronic address: dtmalloy1@geisinger.edu.'}, {'ForeName': 'C J', 'Initials': 'CJ', 'LastName': 'Diamantidis', 'Affiliation': 'Division of General Internal Medicine, Duke University School of Medicine, Durham, NC, USA; Division of Nephrology, Duke University School of Medicine, Durham, NC, USA. Electronic address: clarissa.j.diamantidis@duke.edu.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Fulmer', 'Affiliation': 'Geisinger Health Plan, Danville, PA, USA. Electronic address: slfulmer@thehealthplan.com.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Martin', 'Affiliation': 'Program Development, National Kidney Foundation, New York, NY, USA. Electronic address: jenniferm@kidney.org.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Schatell', 'Affiliation': 'Medical Education Institute, Madison, WI, USA. Electronic address: schatell@meiresearch.org.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Tangri', 'Affiliation': 'Department of Medicine, Section of Nephrology, University of Manitoba, 66 Chancellors Cir, Winnipeg, MB R3T 2N2, Canada; Chronic Disease Innovation Center, Seven Oaks General Hospital, 2300 Mcphillips St, Winnipeg, MB R2V 3M3, Canada. Electronic address: ntangri@sogh.mb.ca.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Sees', 'Affiliation': 'Anthem, Inc., Indianapolis, IN, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Siegrist', 'Affiliation': 'Center for Clinical Innovation, Institute for Advanced Application, Geisinger, Danville, PA, USA. Electronic address: cnsiegrist@geisinger.edu.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Breed', 'Affiliation': 'Center for Clinical Innovation, Institute for Advanced Application, Geisinger, Danville, PA, USA. Electronic address: jmbreed@geisinger.edu.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Medley', 'Affiliation': 'Geisinger Health Plan, Danville, PA, USA. Electronic address: ammedley@thehealthplan.com.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Graboski', 'Affiliation': 'Kidney Health Research Institute, Geisinger, Danville, PA, USA. Electronic address: emgraboski@geisinger.edu.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Billet', 'Affiliation': 'Center for Clinical Innovation, Institute for Advanced Application, Geisinger, Danville, PA, USA. Electronic address: jabillet@geisinger.edu.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Hackenberg', 'Affiliation': 'Center for Clinical Innovation, Institute for Advanced Application, Geisinger, Danville, PA, USA. Electronic address: mrhackenberg@geisinger.edu.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Singer', 'Affiliation': 'Renal Physicians Association, Rockville, MD, USA. Electronic address: dsinger@renalmd.org.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Stewart', 'Affiliation': 'Council of Nephrology Social Workers, National Kidney Foundation, New York, NY, USA. Electronic address: Stewart.Stephanie@mayo.edu.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Alkon', 'Affiliation': 'Division of General Internal Medicine, Duke University School of Medicine, Durham, NC, USA. Electronic address: aviel.alkon@duke.edu.'}, {'ForeName': 'N A', 'Initials': 'NA', 'LastName': 'Bhavsar', 'Affiliation': 'Division of General Internal Medicine, Duke University School of Medicine, Durham, NC, USA. Electronic address: nrupen.bhavsar@dm.duke.edu.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Lewis-Boyer', 'Affiliation': 'Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, MD, USA; Division of General Internal Medicine, Johns Hopkins University, Baltimore, MD, USA. Electronic address: llewis3@jhmi.edu.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Martz', 'Affiliation': 'Geisinger Health Plan, Danville, PA, USA. Electronic address: cmartz2@thehealthplan.com.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Yule', 'Affiliation': 'Kidney Health Research Institute, Geisinger, Danville, PA, USA. Electronic address: cmyule@geisinger.edu.'}, {'ForeName': 'R C', 'Initials': 'RC', 'LastName': 'Greer', 'Affiliation': 'Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, MD, USA; Division of General Internal Medicine, Johns Hopkins University, Baltimore, MD, USA. Electronic address: rgreer@jhmi.edu.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Saunders', 'Affiliation': 'Section of General Internal Medicine, Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA. Electronic address: msaunder@bsd.uchicago.edu.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Cameron', 'Affiliation': 'Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. Electronic address: blake.cameron@duke.edu.'}, {'ForeName': 'L E', 'Initials': 'LE', 'LastName': 'Boulware', 'Affiliation': 'Division of General Internal Medicine, Duke University School of Medicine, Durham, NC, USA. Electronic address: ebony.boulware@duke.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2018.09.004'] 3187,31577219,Laparoscopic supracervical hysterectomy compared with second-generation endometrial ablation for heavy menstrual bleeding: the HEALTH RCT.,"BACKGROUND Heavy menstrual bleeding (HMB) is a common problem that affects many British women. When initial medical treatment is unsuccessful, the National Institute for Health and Care Excellence recommends surgical options such as endometrial ablation (EA) or hysterectomy. Although clinically and economically more effective than EA, total hysterectomy necessitates a longer hospital stay and is associated with slower recovery and a higher risk of complications. Improvements in endoscopic equipment and training have made laparoscopic supracervical hysterectomy (LASH) accessible to most gynaecologists. This operation could preserve the advantages of total hysterectomy and reduce the risk of complications. OBJECTIVES To compare the clinical effectiveness and cost-effectiveness of LASH with second-generation EA in women with HMB. DESIGN A parallel-group, multicentre, randomised controlled trial. Allocation was by remote web-based randomisation (1 : 1 ratio). Surgeons and participants were not blinded to the allocated procedure. SETTING Thirty-one UK secondary and tertiary hospitals. PARTICIPANTS Women aged < 50 years with HMB. Exclusion criteria included plans to conceive; endometrial atypia; abnormal cytology; uterine cavity size > 11 cm; any fibroids > 3 cm; contraindications to laparoscopic surgery; previous EA; and inability to give informed consent or complete trial paperwork. INTERVENTIONS LASH compared with second-generation EA. MAIN OUTCOME MEASURES Co-primary clinical outcome measures were (1) patient satisfaction and (2) Menorrhagia Multi-Attribute Quality-of-Life Scale (MMAS) score at 15 months post randomisation. The primary economic outcome was incremental cost (NHS perspective) per quality-adjusted life-year (QALY) gained. RESULTS A total of 330 participants were randomised to each group (total n  = 660). Women randomised to LASH were more likely to be satisfied with their treatment than those randomised to EA (97.1% vs. 87.1%) [adjusted difference in proportions 0.10, 95% confidence interval (CI) 0.05 to 0.15; adjusted odds ratio (OR) from ordinal logistic regression (OLR) 2.53, 95% CI 1.83 to 3.48; p  < 0.001]. Women randomised to LASH were also more likely to have the best possible MMAS score of 100 (68.7% vs. 54.5%) (adjusted difference in proportions 0.13, 95% CI 0.04 to 0.23; adjusted OR from OLR 1.87, 95% CI 1.31 to 2.67; p  = 0.001). Serious adverse event rates were low and similar in both groups (4.5% vs. 3.6%). There was a significant difference in adjusted mean costs between LASH (£2886) and EA (£1282) at 15 months, but no significant difference in QALYs. Based on an extrapolation of expected differences in cost and QALYs out to 10 years, LASH cost an additional £1362 for an average QALY gain of 0.11, equating to an incremental cost-effectiveness ratio of £12,314 per QALY. Probabilities of cost-effectiveness were 53%, 71% and 80% at cost-effectiveness thresholds of £13,000, £20,000 and £30,000 per QALY gained, respectively. LIMITATIONS Follow-up data beyond 15 months post randomisation are not available to inform cost-effectiveness. CONCLUSION LASH is superior to EA in terms of clinical effectiveness. EA is less costly in the short term, but expected higher retreatment rates mean that LASH could be considered cost-effective by 10 years post procedure. FUTURE WORK Retreatment rates, satisfaction and quality-of-life scores at 10-year follow-up will help to inform long-term cost-effectiveness. TRIAI REGISTRATION Current Controlled Trials ISRCTN49013893. FUNDING This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 23, No. 53. See the NIHR Journals Library website for further project information.",2019,"There was a significant difference in adjusted mean costs between LASH (£2886) and EA (£1282) at 15 months, but no significant difference in QALYs.","['heavy menstrual bleeding', 'women with HMB', 'British women', 'Women aged <\u200950 years with HMB', 'Exclusion criteria included plans to conceive; endometrial atypia; abnormal cytology; uterine cavity size >\u200911\u2009cm; any fibroids >\u20093\u2009cm; contraindications to', '330 participants', 'Thirty-one UK secondary and tertiary hospitals']","['laparoscopic surgery; previous EA', 'Laparoscopic supracervical hysterectomy compared with second-generation endometrial ablation', 'LASH', 'LASH with second-generation EA']","['possible MMAS score', 'Serious adverse event rates', 'hospital stay', 'incremental cost (NHS perspective) per quality-adjusted life-year (QALY) gained', 'satisfaction and quality-of-life scores', 'patient satisfaction and (2) Menorrhagia Multi-Attribute Quality-of-Life Scale (MMAS) score', 'Probabilities of cost-effectiveness', 'adjusted mean costs', 'clinical effectiveness and cost-effectiveness']","[{'cui': 'C0025323', 'cui_str': 'Heavy Menstrual Bleeding'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0205161', 'cui_str': 'Abnormal (qualifier value)'}, {'cui': 'C0010820', 'cui_str': 'cytology'}, {'cui': 'C0227844', 'cui_str': 'Endometrial cavity structure'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to (contextual qualifier) (qualifier value)'}, {'cui': 'C4517719', 'cui_str': '330 (qualifier value)'}, {'cui': 'C0450355', 'cui_str': '31 (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0587437', 'cui_str': 'Tertiary Hospital'}]","[{'cui': 'C0751429', 'cui_str': 'Surgical Procedures, Laparoscopic'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0404091', 'cui_str': 'Laparoscopic supracervical hysterectomy (procedure)'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0341803', 'cui_str': 'Endometrial Ablation'}]","[{'cui': 'C0332149', 'cui_str': 'Possible (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0080071', 'cui_str': 'QALY'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0034380'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0025323', 'cui_str': 'Heavy Menstrual Bleeding'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0449234', 'cui_str': 'Attribute (attribute)'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale (assessment scale)'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3850123', 'cui_str': 'Treatment Effectiveness'}]",330.0,0.26408,"There was a significant difference in adjusted mean costs between LASH (£2886) and EA (£1282) at 15 months, but no significant difference in QALYs.","[{'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Cooper', 'Affiliation': 'NHS Grampian, Aberdeen Royal Infirmary, Aberdeen, UK.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Breeman', 'Affiliation': 'Health Services Research Unit, University of Aberdeen, Aberdeen, UK.'}, {'ForeName': 'Neil W', 'Initials': 'NW', 'LastName': 'Scott', 'Affiliation': 'Medical Statistics Team, University of Aberdeen, Aberdeen, UK.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Scotland', 'Affiliation': 'Health Services Research Unit, University of Aberdeen, Aberdeen, UK.'}, {'ForeName': 'Rodolfo', 'Initials': 'R', 'LastName': 'Hernández', 'Affiliation': 'Health Economics Research Unit, University of Aberdeen, Aberdeen, UK.'}, {'ForeName': 'T Justin', 'Initials': 'TJ', 'LastName': 'Clark', 'Affiliation': ""Birmingham Women's NHS Foundation Trust, Birmingham Women's Hospital, Birmingham, UK.""}, {'ForeName': 'Jed', 'Initials': 'J', 'LastName': 'Hawe', 'Affiliation': 'Countess of Chester Hospital NHS Foundation Trust, Chester, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Hawthorn', 'Affiliation': 'NHS Greater Glasgow and Clyde, Southern General Hospital, Glasgow, UK.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Phillips', 'Affiliation': 'Hull and East Yorkshire Hospitals NHS Trust, Castle Hill Hospital, Cottingham, UK.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Wileman', 'Affiliation': 'Health Services Research Unit, University of Aberdeen, Aberdeen, UK.'}, {'ForeName': 'Kirsty', 'Initials': 'K', 'LastName': 'McCormack', 'Affiliation': 'Health Services Research Unit, University of Aberdeen, Aberdeen, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Norrie', 'Affiliation': 'Usher Institute of Population Health Sciences & Informatics, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Siladitya', 'Initials': 'S', 'LastName': 'Bhattacharya', 'Affiliation': 'NHS Grampian, Aberdeen Royal Infirmary, Aberdeen, UK.'}]","Health technology assessment (Winchester, England)",['10.3310/hta23530'] 3188,31668721,"A randomized, controlled, double-blind crossover study on the effects of isoeffective and isovolumetric intravenous crystalloid and gelatin on blood volume, and renal and cardiac hemodynamics.","BACKGROUND & AIMS Blood volume expanding properties of colloids are superior to crystalloids. In addition to oncotic/osmotic properties, the electrolyte composition of infusions may have important effects on visceral perfusion, with infusions containing supraphysiological chloride causing hyperchloremic acidosis and decreased renal blood flow. In this non-inferiority study, a validated healthy human subject model was used to compare effects of colloid (4% succinylated gelatin) and crystalloid fluid regimens on blood volume, renal function, and cardiac output. METHODS Healthy male participants were given infusions over 60 min > 7 days apart in a randomized, crossover manner. Reference arm (A): 1.5 L of Sterofundin ISO, isoeffective arm (B): 0.5 L of 4% Gelaspan®, isovolumetric arm (C): 0.5 L of 4% Gelaspan® and 1 L of Sterofundin ISO (all B. Braun, Melsungen, Germany). Participants were studied over 240 min. Changes in blood volume were calculated from changes in weight and hematocrit. Renal volume, renal artery blood flow (RABF), renal cortex perfusion and diffusion, and cardiac index were measured with magnetic resonance imaging. RESULTS Ten of 12 males [mean (SE) age 23.9 (0.8) years] recruited, completed the study. Increase in body weight and extracellular fluid volume were significantly less after infusion B than infusions A and C, but changes in blood volume did not significantly differ between infusions. All infusions increased renal volume, with no significant differences between infusions. There was no significant difference in RABF across the infusion time course or between infusion types. Renal cortex perfusion decreased during the infusion (mean 18% decrease from baseline), with no significant difference between infusions. There was a trend for increased renal cortex diffusion (4.2% increase from baseline) for the crystalloid infusion. All infusions led to significant increases in cardiac index. CONCLUSIONS A smaller volume of colloid (4% succinylated gelatin) was as effective as a larger volume of crystalloid at expanding blood volume, increasing cardiac output and changing renal function. Significantly less interstitial space expansion occurred with the colloid. TRIAL REGISTRATION The protocol was registered with the European Union Drug Regulating Authorities Clinical Trials Database (https://eudract.ema.europa.eu) (EudraCT No. 2013-003260-32).",2020,There was a trend for increased renal cortex diffusion (4.2% increase from baseline) for the crystalloid infusion.,"['Ten of 12 males [mean (SE) age 23.9 (0.8) years] recruited, completed the study', 'Healthy male participants']","['infusions over 60\xa0min', 'isoeffective and isovolumetric intravenous crystalloid and gelatin', 'Sterofundin ISO, isoeffective arm (B): 0.5\xa0L of 4% Gelaspan®, isovolumetric arm (C): 0.5\xa0L of 4% Gelaspan® and 1\xa0L of Sterofundin ISO', 'colloid (4% succinylated gelatin) and crystalloid fluid regimens']","['renal volume', 'renal cortex diffusion', 'RABF', 'blood volume, renal function, and cardiac output', 'Renal volume, renal artery blood flow (RABF), renal cortex perfusion and diffusion, and cardiac index', 'cardiac index', 'Renal cortex perfusion', 'renal blood flow', 'body weight and extracellular fluid volume', 'interstitial space expansion', 'blood volume', 'blood volume, and renal and cardiac hemodynamics', 'cardiac output and changing renal function']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517481', 'cui_str': '0.8'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0056562', 'cui_str': 'Crystalloid'}, {'cui': 'C0017237', 'cui_str': 'Gelatin'}, {'cui': 'C0630627', 'cui_str': 'sterofundin'}, {'cui': 'C0911936', 'cui_str': 'iso(VL)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0009361', 'cui_str': 'Colloids'}, {'cui': 'C0143961', 'cui_str': 'succinylated gelatin'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}]","[{'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0022655', 'cui_str': 'Kidney Cortex'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C0005850', 'cui_str': 'Blood Volume'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0007165', 'cui_str': 'Cardiac Output'}, {'cui': 'C0035065', 'cui_str': 'Renal Artery'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0428776', 'cui_str': 'Cardiac index (observable entity)'}, {'cui': 'C1527409', 'cui_str': 'Renal blood flow, function (observable entity)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0015349', 'cui_str': 'Extracellular Fluid'}, {'cui': 'C0225319', 'cui_str': 'Interstitial space (body structure)'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",,0.0853947,There was a trend for increased renal cortex diffusion (4.2% increase from baseline) for the crystalloid infusion.,"[{'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Bradley', 'Affiliation': ""Gastrointestinal Surgery, Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK; Sir Peter Mansfield Imaging Centre, University Park, University of Nottingham, NG7 2RD, UK.""}, {'ForeName': 'Damian D', 'Initials': 'DD', 'LastName': 'Bragg', 'Affiliation': ""Gastrointestinal Surgery, Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK.""}, {'ForeName': 'Eleanor F', 'Initials': 'EF', 'LastName': 'Cox', 'Affiliation': ""Gastrointestinal Surgery, Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK; Sir Peter Mansfield Imaging Centre, University Park, University of Nottingham, NG7 2RD, UK.""}, {'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'El-Sharkawy', 'Affiliation': ""Gastrointestinal Surgery, Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK.""}, {'ForeName': 'Charlotte E', 'Initials': 'CE', 'LastName': 'Buchanan', 'Affiliation': 'Sir Peter Mansfield Imaging Centre, University Park, University of Nottingham, NG7 2RD, UK.'}, {'ForeName': 'Abeed H', 'Initials': 'AH', 'LastName': 'Chowdhury', 'Affiliation': ""Gastrointestinal Surgery, Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK.""}, {'ForeName': 'Ian A', 'Initials': 'IA', 'LastName': 'Macdonald', 'Affiliation': ""School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK; MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK.""}, {'ForeName': 'Susan T', 'Initials': 'ST', 'LastName': 'Francis', 'Affiliation': ""Gastrointestinal Surgery, Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK; Sir Peter Mansfield Imaging Centre, University Park, University of Nottingham, NG7 2RD, UK.""}, {'ForeName': 'Dileep N', 'Initials': 'DN', 'LastName': 'Lobo', 'Affiliation': ""Gastrointestinal Surgery, Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK; MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK. Electronic address: dileep.lobo@nottingham.ac.uk.""}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.09.011'] 3189,30959472,Efficacy of Oral Cryotherapy During Oxaliplatin Infusion in Preventing Oral Thermal Hyperalgesia: A Randomized Trial.,"BACKGROUND Chemotherapy-induced oral thermal hyperalgesia (OTH) is a common and debilitating side effect of platinum-based anticancer agents. This study evaluated the efficacy of oral cryotherapy in preventing OTH during oxaliplatin chemotherapy infusion. METHODS Patients with gastrointestinal cancer treated with biweekly oxaliplatin (85 mg/m2 over 120 minutes) at Abramson Cancer Center at the University of Pennsylvania were randomized to receive oral cryotherapy (ice chips) during oxaliplatin infusion or standard-of-care treatment. All patients completed baseline questionnaires regarding oral and peripheral symptoms and on-treatment questionnaires on day 1 of each subsequent chemotherapy cycle. Those in the treatment arm were asked to document how long they kept the ice chips in their mouths (0, <30, 30, 60, 90, or 120 minutes) and to report their discomfort associated with oral cryotherapy. Evaluable patients were those who had completed at least 2 cycles of oxaliplatin therapy. RESULTS Of 62 randomized patients with a variety of gastrointestinal malignancies, 50 (25 per treatment arm) were evaluable for efficacy. The rate of patients with oral symptoms after the first treatment cycle was significantly lower in the intervention arm (n=8; 32%) than in the control arm (n=18; 72%), meeting the primary study objective (P=.01). The magnitude of difference in symptom scores before versus after the first treatment cycle was significantly less in the intervention versus control arm (P=.001). No difference in oral symptoms over time was seen between the intervention and control groups (P=.20), although a high attrition rate was noted. Duration of ice chip exposure was associated with improved oral symptoms over time (P=.02). CONCLUSIONS Oral cryotherapy is a tolerable and cost-effective method of diminishing OTH in patients receiving oxaliplatin chemotherapy, and seems to be most effective in the early stages of treatment.",2019,The magnitude of difference in symptom scores before versus after the first treatment cycle was significantly less in the intervention versus control arm (P=.001).,"['Evaluable patients were those who had completed at least 2 cycles of oxaliplatin therapy', '62 randomized patients with a variety of gastrointestinal malignancies, 50 (25 per treatment arm) were evaluable for efficacy', '85 mg/m2 over 120 minutes) at Abramson Cancer Center at the University of Pennsylvania', 'Patients with gastrointestinal cancer treated with biweekly']","['oxaliplatin chemotherapy', 'Chemotherapy-induced oral thermal hyperalgesia (OTH', 'Oxaliplatin Infusion', 'Oral Cryotherapy', 'oral cryotherapy', 'oxaliplatin', 'Oral cryotherapy', 'oral cryotherapy (ice chips) during oxaliplatin infusion or standard-of-care treatment']","['attrition rate', 'symptom scores', 'rate of patients with oral symptoms', 'oral symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C1319266', 'cui_str': 'mg/sq.m'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0030853', 'cui_str': 'Pennsylvania'}, {'cui': 'C0685938', 'cui_str': 'Gastrointestinal Cancer'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0585332', 'cui_str': 'Biweekly (qualifier value)'}]","[{'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0751214', 'cui_str': 'Hyperalgesia, Thermal'}, {'cui': 'C0449210', 'cui_str': 'OTH (body structure)'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C4551716', 'cui_str': 'Cryotherapy'}, {'cui': 'C0349714', 'cui_str': 'Icing (substance)'}, {'cui': 'C1510451', 'cui_str': 'Fries'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]",62.0,0.0295305,The magnitude of difference in symptom scores before versus after the first treatment cycle was significantly less in the intervention versus control arm (P=.001).,"[{'ForeName': 'Brittany', 'Initials': 'B', 'LastName': 'Bauman', 'Affiliation': 'aAbramson Cancer Center.'}, {'ForeName': 'Rosemarie', 'Initials': 'R', 'LastName': 'Mick', 'Affiliation': 'aAbramson Cancer Center.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Martinez', 'Affiliation': 'aAbramson Cancer Center.'}, {'ForeName': 'Theresa M', 'Initials': 'TM', 'LastName': 'Lawless', 'Affiliation': 'aAbramson Cancer Center.'}, {'ForeName': 'Lindsey', 'Initials': 'L', 'LastName': 'Zinck', 'Affiliation': 'aAbramson Cancer Center.'}, {'ForeName': 'Paige', 'Initials': 'P', 'LastName': 'Sinclair', 'Affiliation': 'aAbramson Cancer Center.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Fuhrer', 'Affiliation': 'aAbramson Cancer Center.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': ""O'Hara"", 'Affiliation': 'aAbramson Cancer Center.'}, {'ForeName': 'Charles J', 'Initials': 'CJ', 'LastName': 'Schneider', 'Affiliation': 'aAbramson Cancer Center.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': ""O'Dwyer"", 'Affiliation': 'aAbramson Cancer Center.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Plastaras', 'Affiliation': 'aAbramson Cancer Center.'}, {'ForeName': 'Ursina', 'Initials': 'U', 'LastName': 'Teitelbaum', 'Affiliation': 'aAbramson Cancer Center.'}, {'ForeName': 'Kim A', 'Initials': 'KA', 'LastName': 'Reiss', 'Affiliation': 'aAbramson Cancer Center.'}]",Journal of the National Comprehensive Cancer Network : JNCCN,['10.6004/jnccn.2018.7110'] 3190,31239021,Early Engagement is Associated with Better Weight Loss in Emerging Adults.,"Objectives: Predictors of success among emerging adults (EAs; ages 18-25) within behavioral weight loss (BWL) trials are largely unknown. We examined whether early program engagement predicted overall engagement and weight loss in EAs. Methods: Data were pooled from 2 randomized controlled pilot trials in EAs. Participants (N = 99, 80% female, BMI = 33.7±5.1 kg/m²) received a 3-month BWL intervention. Weight was objectively assessed at 0 and 3 months; engagement was tracked weekly; retention was assessed at 3 months. Results: Greater engagement during the initial 4 weeks of treatment predicted greater weight loss (p = .001). Compared to those who did not engage in all 4 initial weeks, participants meeting this threshold experienced greater overall engagement (9.6 vs 4.2 weeks, p < .001), weight losses (intent-to-treat = -3.8% vs -1.3%, p = .004), and retention (78% vs 53%, p = .012). Conclusions: Early engagement in BWL is associated with better outcomes among EAs. Monitoring engagement in real-time during the initial 4 weeks of treatment may be necessary to intervene effectively. Early engagement did not vary by sex or race; future work should identify characteristics associated with poor early engagement.",2019,Results: Greater engagement during the initial 4 weeks of treatment predicted greater weight loss (p = .001).,"['adults (EAs', ' ages 18-25) within behavioral weight loss (BWL) trials are largely unknown', 'Participants (N = 99, 80% female, BMI = 33.7±5.1 kg/m²']",[],"['weight loss', 'weight losses', 'overall engagement', 'Weight', 'Weight Loss']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0439673', 'cui_str': 'Unknown (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}]",[],"[{'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}]",,0.117057,Results: Greater engagement during the initial 4 weeks of treatment predicted greater weight loss (p = .001).,"[{'ForeName': 'Jessica Gokee', 'Initials': 'JG', 'LastName': 'LaRose', 'Affiliation': 'Associate Professor, Virginia Commonwealth University School of Medicine, Department of Health Behavior and Policy, Richmond, VA;, Email: jessica.larose@vcuhealth.org.'}, {'ForeName': 'Joseph L', 'Initials': 'JL', 'LastName': 'Fava', 'Affiliation': 'Research Associate, The Miriam Hospital Weight Control and Diabetes Research Center, Providence, RI.'}, {'ForeName': 'Autumn', 'Initials': 'A', 'LastName': 'Lanoye', 'Affiliation': 'Postdoctoral Fellow, Virginia Commonwealth University School of Medicine, Department of Health Behavior and Policy, Richmond, VA.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Caccavale', 'Affiliation': ""Postdoctoral Fellow, Children's Hospital of Richmond at Virginia Commonwealth University, Healthy Lifestyles Center, Richmond, VA.""}]",American journal of health behavior,['10.5993/AJHB.43.4.12'] 3191,30982843,Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial.,"Botulinum toxin A (BTA) is widely used as treatment of chronic migraine. Efficacy in studies, however, was only modest and likely influenced by unblinding due to BTA-induced removal of forehead wrinkles. Moreover, most study participants were overusing acute headache medications and might have benefitted from withdrawal. We assessed in a double blind, placebo-controlled, randomized clinical trial whether add-on therapy with BTA enhances efficacy of acute withdrawal. Participants were enrolled between December 2012 and February 2015, with follow-up to January 2016, in a single academic hospital in the Netherlands. A total of 179 participants, male and female, aged 18-65, diagnosed with chronic migraine and overuse of acute headache medication were included. All participants were instructed to withdraw acutely from all medication for a 12-week period, in an outpatient setting. In addition, they were randomly assigned (1:1) to 31 injections with BTA (155 units) or placebo (saline); to prevent unblinding, placebo-treated participants received low doses of BTA (17.5 units in total) in the forehead, along with saline injections outside the forehead region. Primary endpoint was percentage change in monthly headache days from baseline to the last 4 weeks of double-blind treatment (Weeks 9-12). Among 179 randomized patients, 90 received BTA and 89 received placebo, and 175 (98%) completed the double-blind phase. All 179 patients were included in the intention-to-treat analyses. BTA did not reduce monthly headache days versus placebo (-26.9% versus -20.5%; difference -6.4%; 95% confidence interval: -15.2 to 2.4; P = 0.15). Absolute changes in migraine days at 12 weeks for BTA versus placebo were -6.2 versus -7.0 (difference: 0.8; 95% confidence interval: -1.0 to 2.7; P = 0.38). Other secondary endpoints, including measures for disability and quality of life, did also not differ. Withdrawal was well tolerated and blinding was successful. Thus, in patients with chronic migraine and medication overuse, BTA does not afford any additional benefit over acute withdrawal alone. Acute withdrawal should be tried first before initiating more expensive treatment with BTA.",2019,Absolute changes in migraine days at 12 weeks for BTA versus placebo were -6.2 versus -7.0,"['Participants were enrolled between December 2012 and February 2015, with follow-up to January 2016, in a single academic hospital in the Netherlands', 'All 179 patients were included in the intention-to-treat analyses', 'chronic migraine with medication overuse', '179 participants, male and female, aged 18-65, diagnosed with chronic migraine and overuse of acute headache medication were included', '179 randomized patients, 90 received']","['placebo (saline); to prevent unblinding, placebo-treated participants received low doses of BTA', 'placebo', 'botulinum toxin A', 'Botulinum toxin A (BTA', 'BTA']","['disability and quality of life', 'acute headache medications', 'monthly headache days', 'percentage change in monthly headache days']","[{'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C4517609', 'cui_str': '179 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C1960870', 'cui_str': 'Chronic migraine'}, {'cui': 'C3266697', 'cui_str': 'Prescription Drug Overutilization'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0744633', 'cui_str': 'Acute headache (finding)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0006055', 'cui_str': 'Botulin'}]","[{'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0744633', 'cui_str': 'Acute headache (finding)'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}]",179.0,0.739136,Absolute changes in migraine days at 12 weeks for BTA versus placebo were -6.2 versus -7.0,"[{'ForeName': 'Judith A', 'Initials': 'JA', 'LastName': 'Pijpers', 'Affiliation': 'Department of Neurology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands.'}, {'ForeName': 'Dennis A', 'Initials': 'DA', 'LastName': 'Kies', 'Affiliation': 'Department of Neurology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Louter', 'Affiliation': 'Department of Neurology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands.'}, {'ForeName': 'Erik W', 'Initials': 'EW', 'LastName': 'van Zwet', 'Affiliation': 'Department of Medical Statistics, Leiden University Medical Centre (LUMC), Leiden, The Netherlands.'}, {'ForeName': 'Michel D', 'Initials': 'MD', 'LastName': 'Ferrari', 'Affiliation': 'Department of Neurology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands.'}, {'ForeName': 'Gisela M', 'Initials': 'GM', 'LastName': 'Terwindt', 'Affiliation': 'Department of Neurology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands.'}]",Brain : a journal of neurology,['10.1093/brain/awz052'] 3192,31034045,Effect of Gastric Residual Evaluation on Enteral Intake in Extremely Preterm Infants: A Randomized Clinical Trial.,"Importance Evaluating prefeed gastric residuals is considered routine care but has little supporting evidence. Objective To determine the effect of omitting prefeed gastric residual evaluation on nutritional outcomes in extremely preterm infants. Design, Setting, and Participants This single-center randomized clinical trial compared the omission of gastric residual evaluation with prefeed gastric residual evaluation. Infants were recruited from a level 4 neonatal intensive care unit and were enrolled from October 17, 2013, to October 8, 2016, and then followed up for 6 weeks after birth. Eligible participants were infants born at 32 or fewer weeks' gestation with a birth weight of 1250 g or less; they were enrolled within 72 hours after birth and within 24 hours after feeding initiation. All participants (N = 143) were included in the modified intent-to-treat analysis, which was conducted from March to July 2018. Interventions The residual group underwent prefeed gastric residual evaluation; the no residual group did not. Feeding decisions were made according to nutritional guidelines, and infants received only human milk. Main Outcomes and Measures The primary outcome was weekly enteral nutrition intake in mL/kg for 6 weeks after birth. Results Of 143 infants, 74 (51.7%) were randomized to undergo gastric residual evaluation (residual group) and 69 (48.3%) to omitted gastric residual evaluation (no residual group). The residual group comprised an even number of male and female infants (37 [50.0%]) with a mean (SD) gestational age of 27.1 (2.4) weeks and a mean (SD) birth weight of 888.8 (206.6) grams, whereas the no residual group had more male infants (36 [52.17%]), a mean (SD) gestational age of 27 (1.2) weeks, and a mean (SD) birth weight of 915.2 (180) grams. The no residual group had feedings that advanced more quickly compared with the residual group (mean weekly increase, 20.7 mL/kg/d vs 17.9 mL/kg/d; P = .02) and consumed more feedings at weeks 5 (137.2 [95% CI, 128.6-145.8]; P = .03) and 6 (141.6 [95% CI, 133.2-150.0]; P = .03). Among the secondary outcomes, the no residual group had higher mean estimated log weights (7.01 [95% CI, 6.99-7.02] vs 6.98 [95% CI, 6.97-7.00]; P = .03), had fewer episodes of abdominal distention (0.59 [95% CI, 0.34-1.01] vs 1.79 [95% CI, 1.27-2.53]; P = .001), and were discharged 8 days earlier (4.21 [95% CI, 4.14-4.28] vs 4.28 [95% CI, 4.19-4.36]; P = .01). Odds for necrotizing enterocolitis (0.058 [95% CI, 0.018-0.190] vs 0.026 [95% CI, 0.006-0.109]), death (0.004 [95% CI, 0.0003-0.046] vs 0.012 [95% CI, 0.001-0.131]), late-onset sepsis (0.970 [95% CI, 0.67-1.40] vs 1.38 [95% CI, 0.97-1.94]), and ventilator-associated pneumonia (0.084 [95% CI, 0.033-0.214] vs 0.056 [95% CI, 0.019-0.168]) were similar between groups. Conclusions and Relevance Among extremely preterm infants, the omission of gastric residual evaluation increased the delivery of enteral nutrition as well as improved weight gain and led to earlier hospital discharge; these results may translate into evidence-based practice. Trial Registration ClinicalTrials.gov identifier: NCT01863043.",2019,"Odds for necrotizing enterocolitis (0.58 [95% CI, 0.18-0.19] vs 0.026 [95% CI, 0.006-0.109]), death (0.004 [95% CI, 0.0003-0.046] vs 0.012 [95% CI, 0.001-0.131]), late-onset sepsis (0.970 [95% CI, 0.67-1.40] vs 1.38 [95% CI, 0.97-1.94]), and ventilator-associated pneumonia (0.084 [95% CI, 0.033-0.214] vs 0.056 [95% CI, 0.019-0.168]) were similar between groups. ","['Extremely Preterm Infants', 'male and female infants (37 [50.0%]) with a mean (SD) gestational age of 27.1 (2.4) weeks and a mean (SD) birth weight of 888.8 (206.6) grams, whereas the no residual group had more male infants (36 [52.17%]), a mean (SD) gestational age of 27 (1.2) weeks, and a mean (SD) birth weight of 915.2 (180) grams', 'All participants (N\u2009=\u2009143) were included in the modified intent-to-treat analysis, which was conducted from March to July 2018', 'Infants were recruited from a level 4 neonatal intensive care unit and were enrolled from October 17, 2013, to October 8, 2016, and then followed up for 6 weeks after birth', ""Eligible participants were infants born at 32 or fewer weeks' gestation with a birth weight of 1250 g or less; they were enrolled within 72 hours after birth and within 24 hours after feeding initiation"", 'extremely preterm infants', '143 infants, 74 (51.7%) were randomized to undergo gastric residual evaluation (residual group) and 69 (48.3%) to omitted gastric residual evaluation (no residual group']","['Gastric Residual Evaluation', 'omitting prefeed gastric residual evaluation']","['necrotizing enterocolitis', 'Enteral Intake', 'death', 'weekly enteral nutrition intake in mL/kg for 6 weeks after birth', 'late-onset sepsis', 'ventilator-associated pneumonia', 'weight gain', 'episodes of abdominal distention', 'nutritional outcomes', 'mean estimated log weights']","[{'cui': 'C3494262', 'cui_str': 'Extremely Preterm Infants'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C4517631', 'cui_str': '2.4 (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}, {'cui': 'C0439208', 'cui_str': 'gram (qualifier value)'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4068880', 'cui_str': 'One point two'}, {'cui': 'C4517573', 'cui_str': 'One hundred and forty-three'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1283828', 'cui_str': 'Intentional'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0456950', 'cui_str': 'Level 4 (qualifier value)'}, {'cui': 'C0021709', 'cui_str': 'Newborn ICU'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0205388', 'cui_str': 'Few (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C4517554', 'cui_str': 'One thousand two hundred and fifty'}, {'cui': 'C0332285', 'cui_str': 'In (attribute)'}, {'cui': 'C1292423', 'cui_str': '72 hours (qualifier value)'}, {'cui': 'C0231290', 'cui_str': 'Status post (contextual qualifier) (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation (observable entity)'}, {'cui': 'C3665864', 'cui_str': 'Gastric residuals'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C3665864', 'cui_str': 'Gastric residuals'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0520459', 'cui_str': 'Necrotizing Enterocolitis'}, {'cui': 'C1304890', 'cui_str': 'Enteral (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0086225', 'cui_str': 'Enteral Feeding'}, {'cui': 'C1300574', 'cui_str': 'microliter/g'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}, {'cui': 'C0087153', 'cui_str': 'Ventilators'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0000731', 'cui_str': 'Swollen abdomen (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}]",,0.376587,"Odds for necrotizing enterocolitis (0.58 [95% CI, 0.18-0.19] vs 0.026 [95% CI, 0.006-0.109]), death (0.004 [95% CI, 0.0003-0.046] vs 0.012 [95% CI, 0.001-0.131]), late-onset sepsis (0.970 [95% CI, 0.67-1.40] vs 1.38 [95% CI, 0.97-1.94]), and ventilator-associated pneumonia (0.084 [95% CI, 0.033-0.214] vs 0.056 [95% CI, 0.019-0.168]) were similar between groups. ","[{'ForeName': 'Leslie A', 'Initials': 'LA', 'LastName': 'Parker', 'Affiliation': 'College of Nursing, University of Florida, Gainesville.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Weaver', 'Affiliation': 'College of Nursing, University of Florida, Gainesville.'}, {'ForeName': 'Roberto J', 'Initials': 'RJ', 'LastName': 'Murgas Torrazza', 'Affiliation': 'Sistema Nacional de Investigacion de Panama, Secretaria Nacional de Ciencia Tecnologia e Innovacion, Punta Pacifica, Panama.'}, {'ForeName': 'Jonathon', 'Initials': 'J', 'LastName': 'Shuster', 'Affiliation': 'Department of Health Outcomes and Policy, University of Florida, Gainesville.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'Department of Pediatrics, University of Florida, Gainesville.'}, {'ForeName': 'Charlene', 'Initials': 'C', 'LastName': 'Krueger', 'Affiliation': 'College of Nursing, University of Florida, Gainesville.'}, {'ForeName': 'Josef', 'Initials': 'J', 'LastName': 'Neu', 'Affiliation': 'Department of Pediatrics, University of Florida, Gainesville.'}]",JAMA pediatrics,['10.1001/jamapediatrics.2019.0800'] 3193,31088887,Buprenorphine in the emergency department: Randomized clinical controlled trial of clonidine versus buprenorphine for the treatment of opioid withdrawal.,"OBJECTIVE To compare buprenorphine to clonidine for the treatment of opioid withdrawal in the emergency department (ED) and to study the effect assigned treatment medication had on longer-term addiction treatment outcomes. DESIGN Randomized controlled trial. SETTING Toronto, Ont. PARTICIPANTS Twenty-six patients presenting to the ED while in opioid withdrawal or soon to be in opioid withdrawal. MAIN OUTCOME MEASURES Patients were randomized to receive either clonidine or buprenorphine treatment. Both groups also received a corresponding discharge prescription and information on how to follow up in the addictions rapid access clinic (RAC) within a few days. Participants were followed for 1 month with respect to attendance at the RAC and to opioid agonist treatment status. Outcome measures included attendance at the RAC within 5 days of the initial ED visit and opioid agonist treatment status at 1 month (as determined by clinic attendance or self-report during a follow-up telephone interview). RESULTS Participants who received buprenorphine in the ED were more likely to be receiving opioid agonist treatment at the 1-month mark compared with those participants who received clonidine to treat their withdrawal ( P = .011). CONCLUSION When opioid withdrawal is treated with buprenorphine in the ED, patients are more likely to be receiving opioid agonist treatment and connected with addiction treatment 1 month later. TRIAL REGISTRATION NUMBER NCT03174067 (ClinicalTrials.gov).",2019,"Outcome measures included attendance at the RAC within 5 days of the initial ED visit and opioid agonist treatment status at 1 month (as determined by clinic attendance or self-report during a follow-up telephone interview). ","['emergency department', 'Toronto, Ont', 'Twenty-six patients presenting to the ED while in opioid withdrawal or soon to be in opioid withdrawal']","['clonidine or buprenorphine', 'buprenorphine', 'clonidine', 'Buprenorphine']",['attendance at the RAC within 5 days of the initial ED visit and opioid agonist treatment status at 1 month (as determined by clinic attendance or self-report during a follow-up telephone interview'],"[{'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0450349', 'cui_str': '26 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0029104', 'cui_str': 'Opioid withdrawal (disorder)'}]","[{'cui': 'C0009014', 'cui_str': 'Clonidine'}, {'cui': 'C0006405', 'cui_str': 'Buprenorphine'}]","[{'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0521095', 'cui_str': 'Determined by (contextual qualifier) (qualifier value)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0021823', 'cui_str': 'Interviews, Telephone'}]",26.0,0.0946962,"Outcome measures included attendance at the RAC within 5 days of the initial ED visit and opioid agonist treatment status at 1 month (as determined by clinic attendance or self-report during a follow-up telephone interview). ","[{'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Srivastava', 'Affiliation': 'Associate Professor anita.srivastava@utoronto.ca.'}, {'ForeName': 'Meldon', 'Initials': 'M', 'LastName': 'Kahan', 'Affiliation': 'Professor in the Department of Family and Community Medicine at the University of Toronto in Ontario.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Njoroge', 'Affiliation': ""Advanced practice nurse and nurse educator in the Rapid Access Addiction Medicine Clinic and in the Mentoring, Education, and Clinical Tools for Addiction: Primary Care-Hospital Integration program at Women's College Hospital in Toronto.""}, {'ForeName': 'Leeor Z', 'Initials': 'LZ', 'LastName': 'Sommer', 'Affiliation': 'Lecturer in the Department of Family and Community Medicine at the University of Toronto.'}]",Canadian family physician Medecin de famille canadien,[] 3194,32132826,The Impact of Eye-closed and Weighted Multi-ball Training on the Improvement of the Stroke Effect of Adolescent Table Tennis Players.,"This paper investigated the impact of eye-closed and weighted training (EWMT) on the stroke effect of adolescent table tennis players. Forty-eight adolescent table tennis players were randomly selected from the China Table Tennis College and were divided into two groups as 1) the experimental group (EG, n = 24) in which they engaged in multi-ball exercise with eye-closed and weighted swing for 10 weeks, and 2) the control group (CG, n = 24) in which they received a normal training without eye-closed and weighted swing intervention. The stroke effect was assessed by three outcome measures: accuracy, stability, and ball speed. Results showed that 1) both the traditional training method and EWMT can improve the stroke effect of adolescent table tennis players. 2) In terms of accuracy, the number of stroke in the corner area was significantly different between EG and CG after the experiment (p = 0.022, p < 0.001, respectively). 3) In terms of stroke stability, there was a significant difference in the number of net ball strokes between EG and CG after the experiment (p = 0.014). 4) In terms of ball speed, there was no significant difference between EG and CG after the experiment (p = 0.871). 5) After EWMT, the stroke stability of backspin had more significant improvement than that of topspin. Thus, compared with the traditional training method, the EWMT method can improve the stroke effect of adolescent table tennis players in terms of accuracy and stability more significantly; the EWMT method can improve the stroke effect of backspin more significantly than that of topspin in terms of stability.",2020,"In terms of accuracy, the number of stroke in the corner area was significantly different between EG and CG after the experiment (p = 0.022, p < 0.001, respectively).","['adolescent table tennis players', 'Forty-eight adolescent table tennis players were randomly selected from the China Table Tennis College', 'Adolescent Table Tennis Players']","['eye-closed and weighted training (EWMT', 'Eye-closed and Weighted Multi-ball Training', 'EWMT', 'experimental group (EG, n = 24) in which they engaged in multi-ball exercise with eye-closed and weighted swing for 10 weeks, and 2) the control group (CG, n = 24) in which they received a normal training without eye-closed and weighted swing intervention']","['accuracy, stability, and ball speed', 'stroke effect of backspin', 'stroke effect', 'number of stroke in the corner area', 'number of net ball strokes', 'stroke stability of backspin']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1706074', 'cui_str': 'Table'}, {'cui': 'C0039515', 'cui_str': 'Tennis'}, {'cui': 'C4319608', 'cui_str': 'Forty-eight'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0557806', 'cui_str': 'College (environment)'}]","[{'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0332288', 'cui_str': 'Without (attribute)'}]","[{'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}]",48.0,0.022179,"In terms of accuracy, the number of stroke in the corner area was significantly different between EG and CG after the experiment (p = 0.022, p < 0.001, respectively).","[{'ForeName': 'Ziwei', 'Initials': 'Z', 'LastName': 'Cao', 'Affiliation': 'China Table Tennis College, Shanghai University of Sport, Shanghai, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Xiao', 'Affiliation': 'China Table Tennis College, Shanghai University of Sport, Shanghai, China.'}, {'ForeName': 'Miaomiao', 'Initials': 'M', 'LastName': 'Lu', 'Affiliation': 'China Table Tennis College, Shanghai University of Sport, Shanghai, China.'}, {'ForeName': 'Xiaoling', 'Initials': 'X', 'LastName': 'Ren', 'Affiliation': 'China Table Tennis College, Shanghai University of Sport, Shanghai, China.'}, {'ForeName': 'Pei', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'China Table Tennis College, Shanghai University of Sport, Shanghai, China.'}]",Journal of sports science & medicine,[] 3195,31358702,Effects of transcutaneous vagus nerve stimulation in individuals aged 55 years or above: potential benefits of daily stimulation.,"Ageing is associated with attenuated autonomic function. Transcutaneous vagal nerve stimulation (tVNS) improved autonomic function in healthy young participants. We therefore investigated the effects of a single session of tVNS (studies 1 and 2) and tVNS administered daily for two weeks (study 3) in volunteers aged ≥ 55 years. tVNS was performed using modified surface electrodes on the tragus and connected to a transcutaneous electrical nerve stimulation (TENS) machine. Study 1: participants (n=14) received a single session of tVNS and sham. Study 2: all participants (n=51) underwent a single session of tVNS. Study 3: participants (n=29) received daily tVNS for two weeks. Heart rate variability and baroreflex sensitivity were derived. Quality of life (QoL), mood and sleep were assessed in study 3. tVNS promoted increases in measures of vagal tone and was associated with greater increases in baroreflex sensitivity than sham. Two weeks of daily tVNS improved measures of autonomic function, and some aspects of QoL, mood and sleep. Importantly, findings showed that improvements in measures of autonomic balance were more pronounced in participants with greater baseline sympathetic prevalence. This suggests it may be possible to identify individuals who are likely to encounter significant benefits from tVNS.",2019,"Two weeks of daily tVNS improved measures of autonomic function, and some aspects of QoL, mood and sleep.","['Study 2: all participants (n=51) underwent a', 'individuals aged 55 years or above', 'healthy young participants', 'Study 1: participants (n=14) received a', 'volunteers aged ≥ 55 years', 'Study 3: participants (n=29) received']","['daily tVNS', 'tVNS (studies 1 and 2) and tVNS', 'single session of tVNS and sham', 'transcutaneous vagus nerve stimulation', 'single session of tVNS', 'Transcutaneous vagal nerve stimulation (tVNS', 'tVNS', 'transcutaneous electrical nerve stimulation (TENS) machine']","['autonomic function', 'baroreflex sensitivity', 'vagal tone', 'Quality of life (QoL), mood and sleep', 'Heart rate variability and baroreflex sensitivity', 'autonomic balance', 'QoL, mood and sleep']","[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}, {'cui': 'C0040654', 'cui_str': 'Electric Stimulation, Transcutaneous'}, {'cui': 'C0336779', 'cui_str': 'Machine, device (physical object)'}]","[{'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0206162', 'cui_str': 'Reflex, Baroreceptor'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}]",,0.0728263,"Two weeks of daily tVNS improved measures of autonomic function, and some aspects of QoL, mood and sleep.","[{'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Bretherton', 'Affiliation': 'School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Atkinson', 'Affiliation': 'School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK.'}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'Murray', 'Affiliation': 'School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Clancy', 'Affiliation': 'School of Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Deuchars', 'Affiliation': 'School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Deuchars', 'Affiliation': 'School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK.'}]",Aging,['10.18632/aging.102074'] 3196,30506630,Outcomes of immunosuppression minimization and withdrawal early after liver transplantation.,"The Immune Tolerance Network ITN030ST A-WISH assessed immunosuppression withdrawal in liver transplant recipients with hepatitis C or nonimmune nonviral liver disease. Of 275 recipients enrolled before transplantation, 95 were randomly assigned 4:1 to withdrawal (n = 77) or maintenance (n = 18) 1- to 2-years posttransplant. Randomization eligibility criteria included stable immunosuppression monotherapy; adequate liver and kidney function; ≤Stage 2 Ishak fibrosis; and absence of rejection on biopsy. Immunosuppression withdrawal followed an 8-step reduction algorithm with ≥8 weeks per level. Fifty-two of 77 subjects (67.5%) reduced to ≤50% of baseline dose, and 10 of 77 (13.0%) discontinued all immunosuppression for ≥1 year. Acute rejection and/or abnormal liver tests were treated with increased immunosuppression; 5 of 32 rejection episodes required a methylprednisolone bolus. The composite end point (death or graft loss; grade 4 secondary malignancy or opportunistic infection; Ishak stage ≥3; or >25% decrease in glomerular filtration rate within 24 months of randomization) occurred in 12 of 66 (18%) and 4 of 13 (31%) subjects in the withdrawal and maintenance groups. Early immunosuppression minimization is feasible in selected liver recipients, while complete withdrawal is successful in only a small proportion. The composite end point comparison was inconclusive for noninferiority of the withdrawal to the maintenance group.",2019,The Immune Tolerance Network ITN030ST A-WISH assessed immunosuppression withdrawal in liver transplant recipients with hepatitis C or nonimmune nonviral liver disease.,"['275 recipients enrolled before transplantation, 95 were randomly assigned 4:1 to withdrawal (n\xa0=\xa077) or maintenance (n\xa0=\xa018', 'and withdrawal early after liver transplantation', 'liver transplant recipients with hepatitis C or nonimmune nonviral liver disease']","['immunosuppression minimization', 'methylprednisolone']","['Acute rejection and/or abnormal liver tests', 'composite end point (death or graft loss; grade 4 secondary malignancy or opportunistic infection; Ishak stage ≥3', 'glomerular filtration rate']","[{'cui': 'C4517676', 'cui_str': '275'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0023911', 'cui_str': 'Transplantation, Hepatic'}, {'cui': 'C3811922', 'cui_str': 'Transplanted liver present (finding)'}, {'cui': 'C0019196', 'cui_str': 'Parenterally-Transmitted Non-A, Non-B Hepatitis'}, {'cui': 'C0023895', 'cui_str': 'Disorder of liver (disorder)'}]","[{'cui': 'C0021080', 'cui_str': 'Immunosuppression (Physiology)'}, {'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}]","[{'cui': 'C0035015', 'cui_str': 'Rejection'}, {'cui': 'C0205161', 'cui_str': 'Abnormal (qualifier value)'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0877042', 'cui_str': 'Graft loss'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0029118', 'cui_str': 'Opportunistic Infections'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0017654', 'cui_str': 'Glomerular Filtration Rate'}]",275.0,0.0374594,The Immune Tolerance Network ITN030ST A-WISH assessed immunosuppression withdrawal in liver transplant recipients with hepatitis C or nonimmune nonviral liver disease.,"[{'ForeName': 'Abraham', 'Initials': 'A', 'LastName': 'Shaked', 'Affiliation': 'University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Michele R', 'Initials': 'MR', 'LastName': 'DesMarais', 'Affiliation': 'Immune Tolerance Network, San Francisco, California.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Kopetskie', 'Affiliation': 'Rho Federal Systems Division, Chapel Hill, North Carolina.'}, {'ForeName': 'Sandy', 'Initials': 'S', 'LastName': 'Feng', 'Affiliation': 'University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Jeffrey D', 'Initials': 'JD', 'LastName': 'Punch', 'Affiliation': 'University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'Josh', 'Initials': 'J', 'LastName': 'Levitsky', 'Affiliation': 'Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Reyes', 'Affiliation': 'University of Washington, Seattle, Washington.'}, {'ForeName': 'Goran B', 'Initials': 'GB', 'LastName': 'Klintmalm', 'Affiliation': 'Baylor University Medical Center, Dallas, Texas.'}, {'ForeName': 'Anthony J', 'Initials': 'AJ', 'LastName': 'Demetris', 'Affiliation': 'University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Bryna E', 'Initials': 'BE', 'LastName': 'Burrell', 'Affiliation': 'Immune Tolerance Network, Bethesda, Maryland.'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Priore', 'Affiliation': 'National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.'}, {'ForeName': 'Nancy D', 'Initials': 'ND', 'LastName': 'Bridges', 'Affiliation': 'National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.'}, {'ForeName': 'Peter H', 'Initials': 'PH', 'LastName': 'Sayre', 'Affiliation': 'Immune Tolerance Network, San Francisco, California.'}]",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,['10.1111/ajt.15205'] 3197,32144378,"Changes in body weight, adherence, and appetite during 2 years of calorie restriction: the CALERIE 2 randomized clinical trial.","BACKGROUND/OBJECTIVES The Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy Phase 2 (CALERIE) study showed that individuals who are nonobese were able to undergo significant calorie restriction (CR), yet the time course changes in adherence, weight, and appetite are unknown. This analysis aimed to investigate the time course changes in adherence, body weight, and appetite during the CALERIE study. SUBJECTS/METHODS Overall, 143 participants (body mass index: 21.9-28.0 kg/m 2 ) were randomized to a CR group that aimed to achieve 25% CR for 2 years. Throughout the intervention, body weight was measured, and appetite was assessed through visual analogue scales. Algorithms were utilized with body weight measurements to calculate adherence percentile score. Participants targeted an adherence percentile score of 50, though being between 80 (lowest acceptable adherence) and 10 (highest acceptable adherence) was adequate. Polynomial regression analyses were used to assess time course changes. RESULTS Polynomials indicated that adherence percentile score increased above 50 after approximately week 20, although adherence remained acceptable (adherence percentile score less than 80) (R 2  = 0.89; P < 0.001). Weight loss occurred until approximately week 60 and then plateaued (R 2  ≥ 0.92; P < 0.001). Hunger and thirst increased (R 2  ≥ 0.30; P < 0.001), but the total increase in scale scores were <10 mm throughout the intervention. CONCLUSIONS In individuals who are nonobese, adherence to 25% CR declines after 20 weeks, but 2 years of CR that stimulates a meaningful reduction in weight, promotes aging-related benefits and negligibly affects appetite is viable.",2020,"Hunger and thirst increased (R 2  ≥ 0.30; P < 0.001), but the total increase in scale scores were <10 mm throughout the intervention. ","['individuals who are nonobese', '143 participants (body mass index: 21.9-28.0\u2009kg/m 2 ']",[],"['body weight', 'Weight loss', 'total increase in scale scores', 'body weight, adherence, and appetite', 'adherence, body weight, and appetite', 'adherence percentile score']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C4517573', 'cui_str': 'One hundred and forty-three'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",[],"[{'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}]",143.0,0.0561506,"Hunger and thirst increased (R 2  ≥ 0.30; P < 0.001), but the total increase in scale scores were <10 mm throughout the intervention. ","[{'ForeName': 'James L', 'Initials': 'JL', 'LastName': 'Dorling', 'Affiliation': 'Pennington Biomedical Research Center, 6400 Perkins Rd, Baton Rouge, LA, 70808, USA.'}, {'ForeName': 'Sai Krupa', 'Initials': 'SK', 'LastName': 'Das', 'Affiliation': 'Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, 711 Washington St, Boston, MA, 02111, USA.'}, {'ForeName': 'Susan B', 'Initials': 'SB', 'LastName': 'Racette', 'Affiliation': 'Washington University School of Medicine, 4444 Forest Park Ave., St. Louis, MO, 63108, USA.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Apolzan', 'Affiliation': 'Pennington Biomedical Research Center, 6400 Perkins Rd, Baton Rouge, LA, 70808, USA.'}, {'ForeName': 'Dachuan', 'Initials': 'D', 'LastName': 'Zhang', 'Affiliation': 'Pennington Biomedical Research Center, 6400 Perkins Rd, Baton Rouge, LA, 70808, USA.'}, {'ForeName': 'Carl F', 'Initials': 'CF', 'LastName': 'Pieper', 'Affiliation': 'Duke University Medical Center, 10 Duke Medicine Circle, Durham, NC, 27710, USA.'}, {'ForeName': 'Corby K', 'Initials': 'CK', 'LastName': 'Martin', 'Affiliation': 'Pennington Biomedical Research Center, 6400 Perkins Rd, Baton Rouge, LA, 70808, USA. Corby.Martin@pbrc.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of clinical nutrition,['10.1038/s41430-020-0593-8'] 3198,31970898,Sitting Balance Exercise Performed Using Virtual Reality Training on a Stroke Rehabilitation Inpatient Service: A Randomized Controlled Study.,"BACKGROUND Virtual reality training (VRT) is engaging and may enhance rehabilitation intensity. Only one previous study has looked at its use to improve sitting balance after stroke. OBJECTIVE To determine if supplemental sitting balance exercises, administered via VRT, improve control of sitting balance and upper extremity function in stroke rehabilitation inpatients. DESIGN Assessor-blinded, placebo-controlled randomized controlled trial. SETTING Stroke inpatient rehabilitation unit. PARTICIPANTS Seventy-six participants (out of 130 approached) with subacute stroke who could not stand independently were randomized to experimental and control groups. Sixty-nine completed the study. INTERVENTIONS The experimental group did VRT that required leaning and reaching, whereas the control group had their trunk restrained and performed VRT that involved only small upper extremity movements to minimize trunk movement. Both groups performed 10-12 sessions of 30-45 minutes. Participants were assessed pre, post, and 1 month after the sessions by a blinded examiner. OUTCOME MEASURES Function in Sitting Test (FIST, primary outcome measure); Ottawa Sitting Scale; Reaching Performance Scale; Wolf Motor Function Test (WMFT). RESULTS Thirty-three participants completed the experimental intervention and 36 the control. Pre/post differences for FIST were 3.4 (confidence interval [CI] 0.5;6.3) for the experimental group and 5.3 (2.9;7.7) for the control group. There was a significant improvement over time (adjusted for multiple comparisons, P < .006) on most outcome measures except the WMFT Performance Time Scale (control group; P = .007) and grip strength (P = .008); there were no differences between groups (P > .006). CONCLUSIONS Siting balance outcomes were similar for both groups; therefore, this study does not support the use of sitting balance exercises provided via VRT for the rehabilitation of sitting balance after stroke. However, because it is only the second study to investigate VRT for sitting balance and upper extremity function, more research, using more challenging exercises and a greater treatment intensity, is required before definitive conclusions are made.",2020,"There was a significant improvement over time (adjusted for multiple comparisons, p<0.006) on most outcome measures excepting the WMFT Performance Time Scale (control group; p=0.007) and grip strength (p=0.008); there were no differences between groups (p>0.006). ","['stroke rehabilitation inpatients', 'Sixty-nine completed the study', 'Seventy-six participants (out of 130 approached) with sub-acute stroke who could not stand independently', 'Stroke inpatient rehabilitation unit', 'Thirty-three participants completed the experimental intervention and 36 the control']","['placebo', 'Sitting Balance Exercise Performed Using Virtual Reality Training', 'Virtual reality training (VRT', 'supplemental sitting balance exercises, administered via VRT']","['WMFT Performance Time Scale', 'sitting balance', 'grip strength', 'Function in Sitting Test (FIST, primary outcome measure); Ottawa Sitting Scale; Reaching Performance Scale; Wolf Motor Function Test (WMFT']","[{'cui': 'C0204097', 'cui_str': 'Stroke Rehabilitation'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0450388', 'cui_str': '69 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C4319622', 'cui_str': 'Seventy-six'}, {'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C1264637', 'cui_str': 'Substance amount'}, {'cui': 'C0751956', 'cui_str': 'Stroke, Acute'}, {'cui': 'C3888057', 'cui_str': 'Stand'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0450358', 'cui_str': '33 (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0516712', 'cui_str': 'Balancing when sitting'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1621583', 'cui_str': 'Administer'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0222045'}, {'cui': 'C0516712', 'cui_str': 'Balancing when sitting'}, {'cui': 'C0429271', 'cui_str': 'Grip strength (observable entity)'}, {'cui': 'C4720842', 'cui_str': 'Function in sitting test (assessment scale)'}, {'cui': 'C0336667', 'cui_str': 'Fist, device (physical object)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}, {'cui': 'C0325001', 'cui_str': 'Wolves'}, {'cui': 'C0234130', 'cui_str': 'Motor function (observable entity)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",130.0,0.0809238,"There was a significant improvement over time (adjusted for multiple comparisons, p<0.006) on most outcome measures excepting the WMFT Performance Time Scale (control group; p=0.007) and grip strength (p=0.008); there were no differences between groups (p>0.006). ","[{'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Sheehy', 'Affiliation': 'Bruyère Research Institute, Ottawa, Ontario, Canada.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Taillon-Hobson', 'Affiliation': 'Bruyère Research Institute, Ottawa, Ontario, Canada.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Sveistrup', 'Affiliation': 'Bruyère Research Institute, Ottawa, Ontario, Canada.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Bilodeau', 'Affiliation': 'Bruyère Research Institute, Ottawa, Ontario, Canada.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Yang', 'Affiliation': 'Stroke Rehabilitation, Bruyère Continuing Care, Ottawa, Ontario, Canada.'}, {'ForeName': 'Hillel', 'Initials': 'H', 'LastName': 'Finestone', 'Affiliation': 'Stroke Rehabilitation, Bruyère Continuing Care, Ottawa, Ontario, Canada.'}]","PM & R : the journal of injury, function, and rehabilitation",['10.1002/pmrj.12331'] 3199,31918233,A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.,"BACKGROUND Metastatic soft tissue sarcomas (STSs) management remains an unmet medical need. We assessed the activity and safety of regorafenib in patients with metastatic non-adipocytic STS who were previously treated with both chemotherapy and pazopanib. PATIENTS AND METHODS This double-blind, placebo-controlled, multicenter comparative randomized phase II trial included patients with histologically proven advanced and inoperable STS. Patients receiving placebo were offered optional cross-over for centrally confirmed disease progression. Primary end-point was centrally reviewed Response Evaluation Criteria in Solid Tumours-based progression-free survival (PFS), analysed on the intent-to-treat data set. In total, 24 events were required for 90% power, hazard ratio (HR) = 0.33 (median PFS, 3.6 versus 1.2 months), and 1-sided α = 0.1 (ClinicalTrials.gov, NCT01900743). RESULTS From December 2015 to October 2017, 37 patients were randomized; 18 to regorafenib and 19 to placebo. Thirteen patients assigned to placebo switched to regorafenib after progression. Median follow-up was 27.2 months (95% confidence interval [CI]: 24.4-not reached). We observed a significant PFS benefit of regorafenib compared with placebo (adjusted HR = 0.33; 95% CI: 0.15-0.74; p = 0.0007 median PFS = 2.1 versus 1.1 months, respectively), and a large and nearly significant overall survival (OS) benefit despite the cross-over (adjusted HR = 0.49; 95% CI: 0.23-1.06; p = 0.007; median OS = 17.8 versus 8.2 months). Before cross-over, the most common grade III or higher adverse events were lymphopenia (5 versus 1, respectively), diarrhoea (4 versus 0), dyspnoea (3 versus 1), skin toxicity (3 versus 0), arterial hypertension (2 versus 0), and increased transaminases (2 versus 0). CONCLUSION The present study demonstrated a meaningful clinical anti-tumour activity with regorafenib in heavily pre-treated patients with non-adipocytic STS.",2020,"In total, 24 events were required for 90% power, hazard ratio (HR) = 0.33","['non-adipocytic patients previously treated with both', 'From December 2015 to October 2017, 37 patients were randomized; 18 to', 'patients with metastatic non-adipocytic STS who were previously treated with both chemotherapy and pazopanib', 'heavily pre-treated patients with non-adipocytic STS', 'patients with histologically proven advanced and inoperable STS']","['placebo', 'chemotherapy and pazopanib', 'regorafenib']","['PFS benefit of regorafenib', 'dyspnoea', 'diarrhoea', 'Response Evaluation Criteria in Solid Tumours-based progression-free survival (PFS', 'activity and safety', 'overall survival', 'arterial hypertension', 'skin toxicity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1831796', 'cui_str': 'pazopanib'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0456369', 'cui_str': 'Proven (qualifier value)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0205187', 'cui_str': 'Inoperable (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1831796', 'cui_str': 'pazopanib'}, {'cui': 'C2980094', 'cui_str': 'regorafenib'}]","[{'cui': 'C2980094', 'cui_str': 'regorafenib'}, {'cui': 'C0013404', 'cui_str': 'Breathlessness'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0280100', 'cui_str': 'Solid tumour'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C1167791', 'cui_str': 'Skin toxicity'}]",,0.621386,"In total, 24 events were required for 90% power, hazard ratio (HR) = 0.33","[{'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Penel', 'Affiliation': 'Medical Oncology Department, Centre Oscar Lambret, Lille and Lille University Hospital, Lille University, Lille, France. Electronic address: n-penel@o-lambret.fr.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Mir', 'Affiliation': 'Medical Oncology Department, Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Wallet', 'Affiliation': 'Clinical Research and Innovation Department, Centre Oscar Lambret, Lille, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Ray-Coquard', 'Affiliation': 'Medical Oncology Department, Centre Léon Bérard, Lyon, France.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Le Cesne', 'Affiliation': 'Medical Oncology Department, Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Italiano', 'Affiliation': 'Medical Oncology Department, Institut Bergonié, Bordeaux, France.'}, {'ForeName': 'Sebastien', 'Initials': 'S', 'LastName': 'Salas', 'Affiliation': 'Medical Oncology Department, CH La Timone, Marseille, France.'}, {'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Delcambre', 'Affiliation': 'Medical Oncology Department, Centre François Baclesse, Caen, France.'}, {'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Bompas', 'Affiliation': 'Medical Oncology Department, René Gauducheau, Saint-Herblain, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Bertucci', 'Affiliation': 'Medical Oncology Department, Institut Paoli-Calmette, Marseille, France.'}, {'ForeName': 'Esma', 'Initials': 'E', 'LastName': 'Saada-Bouzid', 'Affiliation': 'Medical Oncology Department, Centre Antoine Lacassagne, Nice, France.'}, {'ForeName': 'Loïc', 'Initials': 'L', 'LastName': 'Chaigneau', 'Affiliation': 'Medical Oncology Department, Hopital Saint-Jacques, Besançon, France.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Chevreau', 'Affiliation': 'Medical Oncology Department, Institut Universitaire de Cancérologie de Toulouse, Oncopôle, Toulouse, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Brodowicz', 'Affiliation': 'Medical University Vienna - General Hospital, Vienna, Austria.'}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Decoupigny', 'Affiliation': 'Clinical Research and Innovation Department, Centre Oscar Lambret, Lille, France.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Vanseymortier', 'Affiliation': 'Clinical Research and Innovation Department, Centre Oscar Lambret, Lille, France.'}, {'ForeName': 'Lucie', 'Initials': 'L', 'LastName': 'Laroche', 'Affiliation': 'Labeled Datacenter, Caen, France.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Taieb', 'Affiliation': 'Radiology Department, Centre Oscar Lambret, Lille, France.'}, {'ForeName': 'Marie-Cécile', 'Initials': 'MC', 'LastName': 'Le Deley', 'Affiliation': 'Clinical Research and Innovation Department, Centre Oscar Lambret, Lille, France; Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France.'}, {'ForeName': 'Jean-Yves', 'Initials': 'JY', 'LastName': 'Blay', 'Affiliation': 'Medical Oncology Department, Centre Léon Bérard, Lyon, France.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.12.001'] 3200,31805535,Subdivision of M1 Stage for De Novo Metastatic Breast Cancer to Better Predict Prognosis and Response to Primary Tumor Surgery.,"BACKGROUND Patients with de novo metastatic breast cancer (MBC) constitute a heterogeneous group with different clinicopathologic characteristics and survival outcomes. Despite controversy regarding its prognostic value, primary tumor surgery may improve survival for selected patients. PATIENTS AND METHODS Patients with de novo MBC were identified using the SEER database and were then divided randomly into training and validation sets. A Fine-Gray competing risks model was developed to identify the variables associated with increased cancer-specific mortality in the training set. The M1 subdivision system was established based on the independent prognostic factors. Cumulative incidence curves were estimated and compared using Gray's test. RESULTS Involvement of brain or liver and number of metastatic sites were identified as independent prognostic factors in multivariate analysis. The M1 category was subdivided into 3 subcategories: M1a, single site involvement except brain and liver; M1b, liver involvement only, or multiple site involvement except brain and liver; and M1c, brain involvement regardless of number of metastatic sites, or liver and other sites involvement except brain (M1b vs M1a: subdistribution hazard ratio [SHR], 1.48; 95% CI, 1.29-1.68; M1c vs M1a: SHR, 2.45; 95% CI, 2.18-2.75). Patients with the M1a subtype benefited most from primary tumor surgery in the adjusted competing risks model (M1a: SHR, 0.57; 95% CI, 0.48-0.67, M1b: SHR, 0.62; 95% CI, 0.47-0.83, and M1c: SHR, 0.59; 95% CI, 0.44-0.80), whereas benefits conferred by treatment with chemotherapy alone increased with the upstaging of metastatic disease (M1a: SHR, 0.72; 95% CI, 0.62-0.83, M1b: SHR, 0.54; 95% CI, 0.44-0.68, and M1c: SHR, 0.53; 95% CI, 0.45-0.61). CONCLUSIONS Subdivision of M1 stage facilitates prognosis prediction and treatment planning for patients with de novo MBC. Treatment offered should be decided in a coordinated multidisciplinary setting. Primary tumor surgery may play an important role in the management of selected patients.",2019,"Patients with the M1a subtype benefited most from primary tumor surgery in the adjusted competing risks model (M1a: SHR, 0.57; 95% CI, 0.48-0.67, M1b: SHR, 0.62; 95% CI, 0.47-0.83, and M1c: SHR, 0.59; 95% CI, 0.44-0.80), whereas benefits conferred by treatment with chemotherapy alone increased with the upstaging of metastatic disease (M1a: SHR, 0.72; 95% CI, 0.62-0.83, M1b: SHR, 0.54; 95% CI, 0.44-0.68, and M1c: SHR, 0.53; 95% CI, 0.45-0.61). ","['Patients with de novo metastatic breast cancer (MBC', 'Patients with de novo MBC were identified using the SEER database', 'selected patients', 'patients with de novo MBC']",[],"['Cumulative incidence curves', 'survival', 'upstaging of metastatic disease', 'cancer-specific mortality']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer metastatic'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}]",[],"[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C2939420', 'cui_str': 'Metastatic disease'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",,0.0615811,"Patients with the M1a subtype benefited most from primary tumor surgery in the adjusted competing risks model (M1a: SHR, 0.57; 95% CI, 0.48-0.67, M1b: SHR, 0.62; 95% CI, 0.47-0.83, and M1c: SHR, 0.59; 95% CI, 0.44-0.80), whereas benefits conferred by treatment with chemotherapy alone increased with the upstaging of metastatic disease (M1a: SHR, 0.72; 95% CI, 0.62-0.83, M1b: SHR, 0.54; 95% CI, 0.44-0.68, and M1c: SHR, 0.53; 95% CI, 0.45-0.61). ","[{'ForeName': 'Caijin', 'Initials': 'C', 'LastName': 'Lin', 'Affiliation': ''}, {'ForeName': 'Jiayi', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Shuning', 'Initials': 'S', 'LastName': 'Ding', 'Affiliation': ''}, {'ForeName': 'Chihwan', 'Initials': 'C', 'LastName': 'Goh', 'Affiliation': ''}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Andriani', 'Affiliation': ''}, {'ForeName': 'Shuangshuang', 'Initials': 'S', 'LastName': 'Lu', 'Affiliation': ''}, {'ForeName': 'Kunwei', 'Initials': 'K', 'LastName': 'Shen', 'Affiliation': ''}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhu', 'Affiliation': ''}]",Journal of the National Comprehensive Cancer Network : JNCCN,['10.6004/jnccn.2019.7332'] 3201,32044190,Exploring peer coaches' outcomes: Findings from a clinical trial of patients with chronic pain.,"OBJECTIVE Although peer coaching can help patients manage chronic conditions, few studies have evaluated the effects of peer coaching on coaches, and no studies have systematically examined these effects in the context of chronic pain coaching. METHODS Peer coach outcomes were assessed as part of a randomized trial of peer coaching for chronic pain. In this exploratory analysis, linear mixed models were used to evaluate changes in peer coaches' pain and related outcomes from baseline to 6 and 9 months. The Šidák method was used to account for multiple comparisons. RESULTS Peer coaches (N = 55) experienced statistically significant increases in anxiety and pain catastrophizing from baseline to 6 months, which were no longer significant after adjustment. All other changes were not statistically significant. CONCLUSIONS Despite prior studies suggesting that peer coaches benefit from serving as a coach, the current study failed to support that conclusion. PRACTICE IMPLICATIONS Peer coaching remains a promising model, with high potential for implementation, for a number of chronic conditions requiring self-management. However, to maximize the benefits of such interventions, it is essential to monitor both those being coached and the coaches themselves, and not to assume that serving as a coach is inherently beneficial.",2020,"RESULTS Peer coaches (N = 55) experienced statistically significant increases in anxiety and pain catastrophizing from baseline to 6 months, which were no longer significant after adjustment.",['patients with chronic pain'],['peer coaching'],['anxiety and pain catastrophizing'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}]",[],"[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.0457985,"RESULTS Peer coaches (N = 55) experienced statistically significant increases in anxiety and pain catastrophizing from baseline to 6 months, which were no longer significant after adjustment.","[{'ForeName': 'Marianne S', 'Initials': 'MS', 'LastName': 'Matthias', 'Affiliation': 'US Department of Veterans Affairs Health Services Research and Development Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN, USA; Regenstrief Institute, Indianapolis, IN, USA; Department of Communication Studies, Indiana University-Purdue University, Indianapolis, IN, USA; Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: mmatthia@iupui.edu.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Daggy', 'Affiliation': 'Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Ofner', 'Affiliation': 'Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA.'}, {'ForeName': 'Alan B', 'Initials': 'AB', 'LastName': 'McGuire', 'Affiliation': 'US Department of Veterans Affairs Health Services Research and Development Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN, USA; Department of Psychology, Indiana University-Purdue University, Indianapolis, IN, USA.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Kukla', 'Affiliation': 'US Department of Veterans Affairs Health Services Research and Development Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN, USA; Department of Psychology, Indiana University-Purdue University, Indianapolis, IN, USA.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Bair', 'Affiliation': 'US Department of Veterans Affairs Health Services Research and Development Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN, USA; Regenstrief Institute, Indianapolis, IN, USA; Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.'}]",Patient education and counseling,['10.1016/j.pec.2020.02.007'] 3202,32032566,"PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.","BACKGROUND PRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy. We assessed the safety and immunogenicity of PRIMVAC adjuvanted with Alhydrogel or glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) in French and Burkinabe women who were not pregnant. METHODS This first-in-human, randomised, double-blind, placebo-controlled, dose escalation trial was done in two staggered phases, a phase 1A trial in 18-35-year-old women who were malaria naive in a hospital in France and a subsequent phase 1B trial in women who were naturally exposed to P falciparum and nulligravid in the clinical site of a research centre in Burkina Faso. Volunteers were recruited into four sequential cohorts receiving PRIMVAC intramuscularly at day 0, 28, and 56: two cohorts in France receiving 20 μg or 50 μg of PRIMVAC and then two in Burkina Faso receiving 50 μg or 100 μg of PRIMVAC. Volunteers were randomly assigned (1:1) to two groups (PRIMVAC adjuvanted with either Alhydrogel or GLA-SE) in France and randomly assigned (2:2:1) to three groups (PRIMVAC adjuvanted with either Alhydrogel, GLA-SE, or placebo) in Burkina Faso. Randomisation was centralised, using stratification by cohort and blocks of variable size, and syringes were masked by opaque labels. The primary endpoint was the proportion of participants with any grade 3 or higher adverse reaction to vaccination up until day 35. Safety at later time points as well as humoral and cellular immunogenicity were assessed in secondary endpoints. This trial is registered with ClinicalTrials.gov, NCT02658253. FINDINGS Between April 19, 2016, and July 13, 2017, 68 women (18 in France, 50 in Burkina Faso) of 101 assessed for eligibility were included. No serious adverse event related to the vaccine occurred. PRIMVAC antibody titres increased with each dose and seroconversion was observed in all women vaccinated with PRIMVAC (n=57). PRIMVAC antibody titres reached a peak (geometric mean 11 843·0, optical density [OD] 1·0, 95% CI 7559·8-18 552·9 with 100 μg dose and GLA-SE) 1 week after the third vaccination (day 63). Compared with Alhydrogel, GLA-SE tended to improve the PRIMVAC antibody response (geometric mean 2163·5, OD 1·0, 95% CI 1315·7-3557·7 with 100 μg dose and Alhydrogel at day 63). 1 year after the last vaccination, 20 (71%) of 28 women who were vaccinated with PRIMVAC/Alhydrogel and 26 (93%) of 28 women who were vaccinated with PRIMVAC/GLA-SE still had anti-PRIMVAC antibodies, although antibody magnitude was markedly lower (452·4, OD 1·0, 95% CI 321·8-636·1 with 100 μg dose and GLA-SE). These antibodies reacted with native homologous VAR2CSA expressed by NF54-CSA infected erythrocytes (fold change from baseline at day 63 with 100 μg dose and GLA-SE: 10·74, 95% CI 8·36-13·79). Limited cross-recognition, restricted to sera collected from women that received the 100 μg PRIMVAC dose, was observed against heterologous VAR2CSA variants expressed by FCR3-CSA (fold change from baseline at day 63: 1·49, 95% CI 1·19-1·88) and 7G8-CSA infected erythrocytes (1·2, 1·08-1·34). INTERPRETATION PRIMVAC adjuvanted with Alhydrogel or GLA-SE had an acceptable safety profile, was immunogenic, and induced functional antibodies reacting with the homologous VAR2CSA variant expressed by NF54-CSA infected erythrocytes. Cross-reactivity against heterologous VAR2CSA variants was limited and only observed in the higher dose group. An alternate schedule of immunisation, antigen dose, and combinations with other VAR2CSA-based vaccines are envisaged to improve the cross-reactivity against heterologous VAR2CSA variants. FUNDING Bundesministerium für Bildung und Forschung, through Kreditanstalt für Wiederaufbau, Germany; Inserm, and Institut National de Transfusion Sanguine, France; Irish Aid, Department of Foreign Affairs and Trade, Ireland.",2020,PRIMVAC antibody titres increased with each dose and seroconversion was observed in all women vaccinated with PRIMVAC (n=57).,"['French and Burkinabe women who were not pregnant', '18-35-year-old women who were malaria naive in a hospital in France and a subsequent phase 1B trial in women who were naturally exposed to P falciparum and nulligravid in the clinical site of a research centre in Burkina Faso', 'Between April 19, 2016, and July 13, 2017, 68 women (18 in France, 50 in Burkina Faso) of 101 assessed for eligibility were included']","['Alhydrogel, GLA-SE', 'Alhydrogel or GLA-SE', 'placebo', 'France receiving 20 μg or 50 μg of PRIMVAC and then two in Burkina Faso receiving 50 μg or 100 μg of PRIMVAC', 'three groups (PRIMVAC adjuvanted with either Alhydrogel, GLA-SE, or placebo', 'GLA-SE', 'PRIMVAC adjuvanted with Alhydrogel or glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE', 'PRIMVAC adjuvanted with either Alhydrogel or GLA-SE']","['humoral and cellular immunogenicity', 'PRIMVAC antibody response', 'placental malaria', 'antibody magnitude', 'safety and immunogenicity', 'PRIMVAC antibody titres', 'proportion of participants with any grade 3 or higher adverse reaction']","[{'cui': 'C1556084', 'cui_str': 'French (ethnic group)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0232973', 'cui_str': 'Not pregnant (finding)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0024530', 'cui_str': 'Plasmodium Infections'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C2945843', 'cui_str': 'Site of (attribute)'}, {'cui': 'C0035168'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0006409', 'cui_str': 'Upper Volta'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0733770', 'cui_str': 'Alhydrogel'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0006409', 'cui_str': 'Upper Volta'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0014020', 'cui_str': 'Emulsions'}]","[{'cui': 'C0003261', 'cui_str': 'Antibody Response'}, {'cui': 'C0024530', 'cui_str': 'Plasmodium Infections'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C1704240', 'cui_str': 'Magnitudes (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1287242', 'cui_str': 'Finding of antibody titer (finding)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}]",,0.360643,PRIMVAC antibody titres increased with each dose and seroconversion was observed in all women vaccinated with PRIMVAC (n=57).,"[{'ForeName': 'Sodiomon B', 'Initials': 'SB', 'LastName': 'Sirima', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Richert', 'Affiliation': 'Universite Bordeaux, Inserm, Bordeaux Population Health Research Center, CHU Bordeaux, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France; CHU Bordeaux, Pôle de Santé Publique, Bordeaux, France; Inria SISTM team, Talence, France.'}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Chêne', 'Affiliation': 'Université de Paris, Biologie Intégrée du Globule Rouge, UMR_S1134, BIGR, INSERM, Paris, France; Institut National de la Transfusion Sanguine, Paris, France; Laboratory of excellence GR-Ex, Paris, France.'}, {'ForeName': 'Amadou T', 'Initials': 'AT', 'LastName': 'Konate', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Cécilia', 'Initials': 'C', 'LastName': 'Campion', 'Affiliation': 'Universite Bordeaux, Inserm, Bordeaux Population Health Research Center, CHU Bordeaux, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.'}, {'ForeName': 'Sébastien', 'Initials': 'S', 'LastName': 'Dechavanne', 'Affiliation': 'Université de Paris, Biologie Intégrée du Globule Rouge, UMR_S1134, BIGR, INSERM, Paris, France; Institut National de la Transfusion Sanguine, Paris, France; Laboratory of excellence GR-Ex, Paris, France.'}, {'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Semblat', 'Affiliation': 'Université de Paris, Biologie Intégrée du Globule Rouge, UMR_S1134, BIGR, INSERM, Paris, France; Institut National de la Transfusion Sanguine, Paris, France; Laboratory of excellence GR-Ex, Paris, France.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Benhamouda', 'Affiliation': ""INSERM U970, Paris Cardiovascular Research Centre, Université de Paris, Faculté de médecine, Hôpital Européen Georges Pompidou, Service d'Immunologie Biologique, Paris, France.""}, {'ForeName': 'Mathilde', 'Initials': 'M', 'LastName': 'Bahuaud', 'Affiliation': ""Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Plateforme d'immuno-monitoring vaccinal, Laboratoire d'Immunologie, Paris, France.""}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Loulergue', 'Affiliation': 'Université de Paris, Faculté de médecine, INSERM, CIC 1417, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, CIC Cochin Pasteur, Paris, France.'}, {'ForeName': 'Alphonse', 'Initials': 'A', 'LastName': 'Ouédraogo', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Issa', 'Initials': 'I', 'LastName': 'Nébié', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Moïse', 'Initials': 'M', 'LastName': 'Kabore', 'Affiliation': 'Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Désiré', 'Initials': 'D', 'LastName': 'Kargougou', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Aïssata', 'Initials': 'A', 'LastName': 'Barry', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso.'}, {'ForeName': 'San Maurice', 'Initials': 'SM', 'LastName': 'Ouattara', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Boilet', 'Affiliation': 'Universite Bordeaux, Inserm, Bordeaux Population Health Research Center, CHU Bordeaux, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Allais', 'Affiliation': 'Universite Bordeaux, Inserm, Bordeaux Population Health Research Center, CHU Bordeaux, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.'}, {'ForeName': 'Gwenaelle', 'Initials': 'G', 'LastName': 'Roguet', 'Affiliation': 'Université de Paris, Faculté de médecine, INSERM, CIC 1417, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, CIC Cochin Pasteur, Paris, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Havelange', 'Affiliation': 'European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Elvira', 'Initials': 'E', 'LastName': 'Lopez-Perez', 'Affiliation': 'INSERM, Institut de Santé Publique, Pôle de Recherche Clinique, Paris, France.'}, {'ForeName': 'Alexis', 'Initials': 'A', 'LastName': 'Kuppers', 'Affiliation': 'INSERM, Institut de Santé Publique, Pôle de Recherche Clinique, Paris, France.'}, {'ForeName': 'Eleine', 'Initials': 'E', 'LastName': 'Konaté', 'Affiliation': 'Université de Paris, Faculté de médecine, INSERM, CIC 1417, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, CIC Cochin Pasteur, Paris, France.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Roussillon', 'Affiliation': ""Universite Bordeaux, Inserm, Bordeaux Population Health Research Center, CHU Bordeaux, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France; Direction de la Recherche Clinique et de l'Innovation, Unité de sécurité et vigilance des Essais Cliniques, CHU de Bordeaux, Bordeaux, France.""}, {'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Kanté', 'Affiliation': 'Universite Bordeaux, Inserm, Bordeaux Population Health Research Center, CHU Bordeaux, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Belarbi', 'Affiliation': 'Université de Paris, Faculté de médecine, INSERM, CIC 1417, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, CIC Cochin Pasteur, Paris, France.'}, {'ForeName': 'Amidou', 'Initials': 'A', 'LastName': 'Diarra', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Noelie', 'Initials': 'N', 'LastName': 'Henry', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Issiaka', 'Initials': 'I', 'LastName': 'Soulama', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Amidou', 'Initials': 'A', 'LastName': 'Ouédraogo', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Helene', 'Initials': 'H', 'LastName': 'Esperou', 'Affiliation': 'INSERM, Institut de Santé Publique, Pôle de Recherche Clinique, Paris, France.'}, {'ForeName': 'Odile', 'Initials': 'O', 'LastName': 'Leroy', 'Affiliation': 'European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Frederic', 'Initials': 'F', 'LastName': 'Batteux', 'Affiliation': ""Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Plateforme d'immuno-monitoring vaccinal, Laboratoire d'Immunologie, Paris, France.""}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Tartour', 'Affiliation': ""INSERM U970, Paris Cardiovascular Research Centre, Université de Paris, Faculté de médecine, Hôpital Européen Georges Pompidou, Service d'Immunologie Biologique, Paris, France.""}, {'ForeName': 'Nicola K', 'Initials': 'NK', 'LastName': 'Viebig', 'Affiliation': 'European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Rodolphe', 'Initials': 'R', 'LastName': 'Thiebaut', 'Affiliation': 'Universite Bordeaux, Inserm, Bordeaux Population Health Research Center, CHU Bordeaux, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France; CHU Bordeaux, Pôle de Santé Publique, Bordeaux, France; Inria SISTM team, Talence, France.'}, {'ForeName': 'Odile', 'Initials': 'O', 'LastName': 'Launay', 'Affiliation': 'Université de Paris, Faculté de médecine, INSERM, CIC 1417, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, CIC Cochin Pasteur, Paris, France.'}, {'ForeName': 'Benoît', 'Initials': 'B', 'LastName': 'Gamain', 'Affiliation': 'Université de Paris, Biologie Intégrée du Globule Rouge, UMR_S1134, BIGR, INSERM, Paris, France; Institut National de la Transfusion Sanguine, Paris, France; Laboratory of excellence GR-Ex, Paris, France. Electronic address: benoit.gamain@inserm.fr.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(19)30739-X'] 3203,31642985,Effect of food-related behavioral activation therapy on food intake and the environmental impact of the diet: results from the MooDFOOD prevention trial.,"PURPOSE Food-based dietary guidelines are proposed to not only improve diet quality, but to also reduce the environmental impact of diets. The aim of our study was to investigate whether food-related behavioral activation therapy (F-BA) applying Mediterranean-style dietary guidelines altered food intake and the environmental impact of the diet in overweight adults with subsyndromal symptoms of depression. METHODS In total 744 adults who either received the F-BA intervention (F-BA group) or no intervention (control group) for 12 months were included in this analysis. Food intake data were collected through a food frequency questionnaire at baseline and after 6 and 12 months. Greenhouse gas emissions (GHGE), land use (LU), and fossil energy use (FEU) estimates from life-cycle assessments and a weighted score of the three (pReCiPe score) were used to estimate the environmental impact of each individual diet at each timepoint. RESULTS The F-BA group reported increased intakes of vegetables (19.7 g/day; 95% CI 7.8-31.6), fruit (23.0 g/day; 9.4-36.6), fish (7.6 g/day; 4.6-10.6), pulses/legumes (4.0 g/day; 1.6-6.5) and whole grains (12.7 g/day; 8.0-17.5), and decreased intake of sweets/extras (- 6.8 g/day; - 10.9 to - 2.8) relative to control group. This effect on food intake resulted in no change in GHGE, LU, and pReCiPe score, but a relative increase in FEU by 1.6 MJ/day (0.8, 2.4). CONCLUSIONS A shift towards a healthier Mediterranean-style diet does not necessarily result in a diet with reduced environmental impact in a real-life setting. TRIAL REGISTRATION ClinicalTrials.gov. Number of identification: NCT02529423. August 2015.",2020,"The F-BA group reported increased intakes of vegetables (19.7 g/day; 95% CI 7.8-31.6), fruit (23.0 g/day; 9.4-36.6), fish (7.6 g/day; 4.6-10.6), pulses/legumes (4.0 g/day; 1.6-6.5) and whole grains (12.7 g/day; 8.0-17.5), and decreased intake of sweets/extras (- 6.8 g/day; - 10.9 to - 2.8) relative to control group.","['In total 744 adults who either received the', 'overweight adults with subsyndromal symptoms of depression']","['F-BA intervention (F-BA group) or no intervention (control group', 'food-related behavioral activation therapy (F-BA) applying Mediterranean-style dietary guidelines', 'food-related behavioral activation therapy']","['Greenhouse gas emissions (GHGE), land use (LU), and fossil energy use (FEU) estimates from life-cycle assessments and a weighted score of the three (pReCiPe score', 'intake of sweets/extras', 'FEU', 'intakes of vegetables', 'GHGE, LU, and pReCiPe score', 'diet quality']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C2733064', 'cui_str': 'Behavioral activation therapy (regime/therapy)'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C3658297', 'cui_str': 'Nutrition Guidelines'}]","[{'cui': 'C4505224', 'cui_str': 'Greenhouse Gases'}, {'cui': 'C0233929', 'cui_str': 'Emission (finding)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0016614', 'cui_str': 'Fossils'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0023675', 'cui_str': 'Life Cycle'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0453447', 'cui_str': 'Sugar candy'}, {'cui': 'C0042440', 'cui_str': 'Vegetables'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}]",744.0,0.159008,"The F-BA group reported increased intakes of vegetables (19.7 g/day; 95% CI 7.8-31.6), fruit (23.0 g/day; 9.4-36.6), fish (7.6 g/day; 4.6-10.6), pulses/legumes (4.0 g/day; 1.6-6.5) and whole grains (12.7 g/day; 8.0-17.5), and decreased intake of sweets/extras (- 6.8 g/day; - 10.9 to - 2.8) relative to control group.","[{'ForeName': 'Alessandra C', 'Initials': 'AC', 'LastName': 'Grasso', 'Affiliation': 'Department of Health Sciences, Faculty of Science, and Amsterdam Public Health Research Institute, Vrije Universiteit (VU) Amsterdam, De Boelelaan 1085, 1081 HV, Amsterdam, The Netherlands. alessandra.grasso@vu.nl.'}, {'ForeName': 'Margreet R', 'Initials': 'MR', 'LastName': 'Olthof', 'Affiliation': 'Department of Health Sciences, Faculty of Science, and Amsterdam Public Health Research Institute, Vrije Universiteit (VU) Amsterdam, De Boelelaan 1085, 1081 HV, Amsterdam, The Netherlands.'}, {'ForeName': 'Corné', 'Initials': 'C', 'LastName': 'van Dooren', 'Affiliation': 'Netherlands Nutrition Centre (Voedingscentrum), Bezuidenhoutseweg 105, 2594 AC, The Hague, The Netherlands.'}, {'ForeName': 'Miquel', 'Initials': 'M', 'LastName': 'Roca', 'Affiliation': ""Institut Universitari d'Investigació en Ciències de la Salut (IUNICS/IDISBA), Rediapp, University of Balearic Islands, Carretera De Valldemossa km 7.5, 07122, Palma de Mallorca, Spain.""}, {'ForeName': 'Margalida', 'Initials': 'M', 'LastName': 'Gili', 'Affiliation': ""Institut Universitari d'Investigació en Ciències de la Salut (IUNICS/IDISBA), Rediapp, University of Balearic Islands, Carretera De Valldemossa km 7.5, 07122, Palma de Mallorca, Spain.""}, {'ForeName': 'Marjolein', 'Initials': 'M', 'LastName': 'Visser', 'Affiliation': 'Department of Health Sciences, Faculty of Science, and Amsterdam Public Health Research Institute, Vrije Universiteit (VU) Amsterdam, De Boelelaan 1085, 1081 HV, Amsterdam, The Netherlands.'}, {'ForeName': 'Mieke', 'Initials': 'M', 'LastName': 'Cabout', 'Affiliation': 'Department of Health Sciences, Faculty of Science, and Amsterdam Public Health Research Institute, Vrije Universiteit (VU) Amsterdam, De Boelelaan 1085, 1081 HV, Amsterdam, The Netherlands.'}, {'ForeName': 'Mariska', 'Initials': 'M', 'LastName': 'Bot', 'Affiliation': 'Department of Psychiatry, Amsterdam Public Health Research Institute, and GGZ inGeest Specialized Mental Health Care, Amsterdam UMC, VU Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.'}, {'ForeName': 'Brenda W J H', 'Initials': 'BWJH', 'LastName': 'Penninx', 'Affiliation': 'Department of Psychiatry, Amsterdam Public Health Research Institute, and GGZ inGeest Specialized Mental Health Care, Amsterdam UMC, VU Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'van Grootheest', 'Affiliation': 'Department of Psychiatry, Amsterdam Public Health Research Institute, and GGZ inGeest Specialized Mental Health Care, Amsterdam UMC, VU Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Kohls', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical Faculty, University Leipzig, Semmelweisstr. 10, Haus 13, 04103, Leipzig, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Hegerl', 'Affiliation': 'Department of Psychiatry, Psychosomatics and Psychotherapy, Medical Faculty, Goethe-University Frankfurt, Heinrich-Hoffmann-Str. 10, 60528, Frankfurt a.M., Germany.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Owens', 'Affiliation': 'Department of Psychology, University of Exeter, Perry Road, Exeter, EX4 4QG, UK.'}, {'ForeName': 'Ed', 'Initials': 'E', 'LastName': 'Watkins', 'Affiliation': 'Department of Psychology, University of Exeter, Perry Road, Exeter, EX4 4QG, UK.'}, {'ForeName': 'Ingeborg A', 'Initials': 'IA', 'LastName': 'Brouwer', 'Affiliation': 'Department of Health Sciences, Faculty of Science, and Amsterdam Public Health Research Institute, Vrije Universiteit (VU) Amsterdam, De Boelelaan 1085, 1081 HV, Amsterdam, The Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of nutrition,['10.1007/s00394-019-02106-1'] 3204,31882238,"Undergraduate, Nonmedical Students can Pass the FLS Manual Skills Exam With Minimal Practice.","OBJECTIVES The primary objective of this study is to investigate whether undergraduate, nonmedical students could pass the FLS Manual Skills Exam with minimal practice. The secondary objective is to examine ACGME case log data from graduating chief residents over the past 18 years to examine how laparoscopic experience has evolved over that time period. DESIGN Undergraduate, nonmedical students received training and unlimited practice time before being tested on each task of the FLS Manual Skills Exam. Each task was timed and scored using the MISTELS system. ACGME case log data from graduating chief residents over the past 18 years was obtained. SETTING The setting is SimPortal, the simulation center associated with the University of Minnesota Medical School. PARTICIPANTS The participants are 25 undergraduate, nonmedical students from the University of Minnesota. Participants were recruited on campus. RESULTS Twenty-three out of 25 (92%) undergraduate, nonmedical students successfully completed one attempt for each task of the FLS Manual Skills Exam and 21 out of 25 (84%) completed both attempts. The average total practice time was 39 minutes. Over the past 18 years, the average number of laparoscopic cases completed by a graduating chief increased from 142 to 275 cases (93% increase). Additionally, the average number of cases of the top 5 most common laparoscopic operations increased from 25% to over 400%. CONCLUSIONS Undergraduate, nonmedical students can pass the FLS Manual Skills Exam with minimal practice. Additionally, general surgery residents and medical students continue to gain more laparoscopic experience throughout medical training as laparoscopic surgery is utilized for more operations. The FLS Manual Skills Exam should be re-examined to determine its utility as a high-stakes exam.",2020,"RESULTS Twenty-three out of 25 (92%) undergraduate, nonmedical students successfully completed one attempt for each task of the FLS Manual Skills Exam and 21 out of 25 (84%) completed both attempts.","['general surgery residents and medical students', 'The setting is SimPortal, the simulation center associated with the University of Minnesota Medical School', 'Twenty-three out of 25 (92%) undergraduate, nonmedical students successfully completed one attempt for each task of the FLS Manual Skills Exam and 21 out of 25 (84%) completed both attempts', 'Participants were recruited on campus', 'participants are 25 undergraduate, nonmedical students from the University of Minnesota']",[],"['laparoscopic operations', 'average total practice time']","[{'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0038495', 'cui_str': 'Students, Medical'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0026183', 'cui_str': 'Minnesota'}, {'cui': 'C0036378', 'cui_str': 'Schools, Medical'}, {'cui': 'C0450348', 'cui_str': '23 (qualifier value)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}]",[],"[{'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",,0.0190572,"RESULTS Twenty-three out of 25 (92%) undergraduate, nonmedical students successfully completed one attempt for each task of the FLS Manual Skills Exam and 21 out of 25 (84%) completed both attempts.","[{'ForeName': 'Matthew C', 'Initials': 'MC', 'LastName': 'Bobel', 'Affiliation': 'University of Minnesota, Department of Surgery, Minneapolis, Minnesota. Electronic address: bobel@umn.edu.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Kemp', 'Affiliation': 'University of Minnesota, Department of Surgery, Minneapolis, Minnesota.'}, {'ForeName': 'Wyatt A', 'Initials': 'WA', 'LastName': 'Wagner', 'Affiliation': 'University of Minnesota, Department of Surgery, Minneapolis, Minnesota.'}, {'ForeName': 'Archana', 'Initials': 'A', 'LastName': 'Ramaswamy', 'Affiliation': 'University of Minnesota, Department of Surgery, Minneapolis, Minnesota; Minneapolis VA Medical Center, Minneapolis, Minnesota.'}, {'ForeName': 'Jeffrey G', 'Initials': 'JG', 'LastName': 'Chipman', 'Affiliation': 'University of Minnesota, Department of Surgery, Minneapolis, Minnesota.'}]",Journal of surgical education,['10.1016/j.jsurg.2019.11.013'] 3205,31009405,"The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study.","OBJECTIVES Fecal microbiota transfer (FMT) is suggested as a potential treatment for patients with irritable bowel syndrome (IBS). We aimed to study the effect of allogenic and autologous FMT on IBS symptoms, visceral sensitivity, and compositional changes in fecal and mucosa-adherent microbiota. METHODS Seventeen patients with IBS were randomized either to receive fecal material from a healthy donor (allogenic) or to receive their own fecal material (autologous). The fecal material was administered into the cecum by whole colonoscopy after bowel cleansing. RESULTS No significant differences were found between the allogenic and the autologous FMT regarding symptom scores. However, symptom scores of patients receiving allogenic fecal material significantly decreased after FMT compared with baseline (P = 0.02), which was not the case in the autologous group (P = 0.16). Visceral sensitivity was not affected except for a small beneficial effect on urge scores in the autologous group (P < 0.05). While both fecal and mucosa-adherent microbiota of some patients shifted to their respective donor's fecal microbiota, some patients showed no relevant microbial changes after allogenic FMT. Large compositional shifts in fecal and mucosa-adherent microbiota also occurred in the autologous group. CONCLUSIONS This study showed that a single FMT by colonoscopy may have beneficial effects in IBS; however, the allogenic fecal material was not superior to the autologous fecal material. This suggests that bowel cleansing prior to the colonoscopy and/or processing of the fecal material as part of the FMT routine contribute to symptoms and gut microbiota composition changes in IBS.",2019,Visceral sensitivity was not affected except for a small beneficial effect on urge scores in the autologous group (P < 0.05).,"['Seventeen patients with IBS', 'Irritable Bowel Syndrome', 'patients with irritable bowel syndrome (IBS']","['fecal material from a healthy donor (allogenic) or to receive their own fecal material (autologous', 'Fecal microbiota transfer (FMT', 'Allogenic Versus Autologous Fecal Microbiota Transfer', 'allogenic and autologous FMT', 'FMT']","['Symptoms, Visceral Perception and Fecal and Mucosal Microbiota', 'symptom scores of patients receiving allogenic fecal material', 'IBS symptoms, visceral sensitivity, and compositional changes in fecal and mucosa-adherent microbiota', 'Visceral sensitivity', 'urge scores']","[{'cui': 'C0450331', 'cui_str': '17 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0022104', 'cui_str': 'Irritable Bowel Syndrome'}]","[{'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0040671', 'cui_str': 'Transfer'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0442045', 'cui_str': 'Visceral (qualifier value)'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0026724', 'cui_str': 'Mucosal Tissue'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}]",17.0,0.0261147,Visceral sensitivity was not affected except for a small beneficial effect on urge scores in the autologous group (P < 0.05).,"[{'ForeName': 'Savanne', 'Initials': 'S', 'LastName': 'Holster', 'Affiliation': 'Nutrition-Gut-Brain Interactions Research Centre, Faculty of Health and Medicine, School of Medical Sciences, Örebro University, Örebro, Sweden.'}, {'ForeName': 'Carl Mårten', 'Initials': 'CM', 'LastName': 'Lindqvist', 'Affiliation': 'Nutrition-Gut-Brain Interactions Research Centre, Faculty of Health and Medicine, School of Medical Sciences, Örebro University, Örebro, Sweden.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Repsilber', 'Affiliation': 'Nutrition-Gut-Brain Interactions Research Centre, Faculty of Health and Medicine, School of Medical Sciences, Örebro University, Örebro, Sweden.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Salonen', 'Affiliation': 'Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Willem M', 'Initials': 'WM', 'LastName': 'de Vos', 'Affiliation': 'Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'König', 'Affiliation': 'Nutrition-Gut-Brain Interactions Research Centre, Faculty of Health and Medicine, School of Medical Sciences, Örebro University, Örebro, Sweden.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Brummer', 'Affiliation': 'Nutrition-Gut-Brain Interactions Research Centre, Faculty of Health and Medicine, School of Medical Sciences, Örebro University, Örebro, Sweden.'}]",Clinical and translational gastroenterology,['10.14309/ctg.0000000000000034'] 3206,29572695,The effect of swim-up and gradient sperm preparation techniques on deoxyribonucleic acid (DNA) fragmentation in subfertile patients.,"PURPOSE To compare the effect of two different sperm preparation techniques, including swim-up and gradient methods on sperm deoxyribonucleic acid (DNA) fragmentation status of semen samples from unexplained and mild male factor subfertile patients undergoing intrauterine insemination (IUI). DESIGN A prospective randomized study was conducted in 65 subfertile patients, including 34 unexplained and 31 male factor infertility to compare basal and post-procedure DNA fragmentation rates in swim-up and gradient techniques. Sperm DNA fragmentation rates were evaluated by a sperm chromatin dispersion (SCD) test in two portions of each sample of semen that was prepared with either swim-up or gradient techniques. Sperm motility and morphology were also assessed based on WHO 2010 criteria. RESULTS Swim-up but not gradient method yielded a statistically significant reduction in the DNA fragmented sperm rate after preparation as compared to basal rates, in the semen samples of both unexplained (41.85 ± 22.04 vs. 28.58 ± 21.93, p < 0.001 for swim-up; and 41.85 ± 22.04 vs. 38.79 ± 22.30, p = 0.160 for gradient) and mild male factor (46.61 ± 19.38 vs. 30.32 ± 18.20, p < 0.001 for swim-up and 46.61 ± 19.38 vs. 44.03 ± 20.87, p = 0.470 for gradient) subgroups. CONCLUSIONS Swim-up method significantly reduces sperm DNA fragmentation rates and may have some prognostic value on intrauterine insemination in patients with decreased sperm DNA integrity.",2018,Swim-up method significantly reduces sperm DNA fragmentation rates and may have some prognostic value on intrauterine insemination in patients with decreased sperm DNA integrity.,"['unexplained and mild male factor subfertile patients undergoing intrauterine insemination (IUI', '65 subfertile patients, including 34 unexplained and 31 male factor infertility to compare basal and post-procedure DNA fragmentation rates in swim-up and gradient techniques', 'subfertile patients']",['swim-up and gradient sperm preparation techniques'],"['DNA fragmented sperm rate', 'sperm DNA fragmentation rates', 'deoxyribonucleic acid (DNA) fragmentation', 'Sperm DNA fragmentation rates', 'Sperm motility and morphology']","[{'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0546824', 'cui_str': 'Intrauterine artificial insemination (procedure)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0021359', 'cui_str': 'Infertility'}, {'cui': 'C0205112', 'cui_str': 'Basal (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0376669', 'cui_str': 'DNA Fragmentation'}, {'cui': 'C0025664', 'cui_str': 'techniques'}]","[{'cui': 'C0037868', 'cui_str': 'Sperm'}, {'cui': 'C0025664', 'cui_str': 'techniques'}]","[{'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}, {'cui': 'C0037868', 'cui_str': 'Sperm'}, {'cui': 'C0376669', 'cui_str': 'DNA Fragmentation'}, {'cui': 'C0332472', 'cui_str': 'Fragmentation (morphologic abnormality)'}, {'cui': 'C0037848', 'cui_str': 'Sperm Motility'}, {'cui': 'C0543482', 'cui_str': 'morphology'}]",65.0,0.0806658,Swim-up method significantly reduces sperm DNA fragmentation rates and may have some prognostic value on intrauterine insemination in patients with decreased sperm DNA integrity.,"[{'ForeName': 'Yuksel', 'Initials': 'Y', 'LastName': 'Oguz', 'Affiliation': 'Department of Obstetrics and Gynecology, Gazi University School of Medicine, 06500, Besevler, Ankara, Turkey.'}, {'ForeName': 'Ismail', 'Initials': 'I', 'LastName': 'Guler', 'Affiliation': 'Department of Obstetrics and Gynecology, Gazi University School of Medicine, 06500, Besevler, Ankara, Turkey. driguler@yahoo.com.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Erdem', 'Affiliation': 'Department of Obstetrics and Gynecology, Gazi University School of Medicine, 06500, Besevler, Ankara, Turkey.'}, {'ForeName': 'Mehmet Firat', 'Initials': 'MF', 'LastName': 'Mutlu', 'Affiliation': 'Department of Obstetrics and Gynecology, Yuksek Ihtisas University, Ankara, Turkey.'}, {'ForeName': 'Seyhan', 'Initials': 'S', 'LastName': 'Gumuslu', 'Affiliation': 'IVF Unit, Gazi University School of Medicine, Ankara, Turkey.'}, {'ForeName': 'Mesut', 'Initials': 'M', 'LastName': 'Oktem', 'Affiliation': 'Department of Obstetrics and Gynecology, Gazi University School of Medicine, 06500, Besevler, Ankara, Turkey.'}, {'ForeName': 'Nuray', 'Initials': 'N', 'LastName': 'Bozkurt', 'Affiliation': 'Department of Obstetrics and Gynecology, Gazi University School of Medicine, 06500, Besevler, Ankara, Turkey.'}, {'ForeName': 'Mehmet', 'Initials': 'M', 'LastName': 'Erdem', 'Affiliation': 'Department of Obstetrics and Gynecology, Gazi University School of Medicine, 06500, Besevler, Ankara, Turkey.'}]",Journal of assisted reproduction and genetics,['10.1007/s10815-018-1163-z'] 3207,31550354,Cell-Mediated Immune Responses After Influenza Vaccination of Solid Organ Transplant Recipients: Secondary Outcomes Analyses of a Randomized Controlled Trial.,"BACKGROUND Despite annual immunization, solid organ transplant (SOT) patients remain at increased risk for severe influenza infection because of suboptimal vaccine immunogenicity. We aimed to compare the CD4+ and CD8+ T-cell responses of the high-dose (HD) and the standard-dose (SD) trivalent inactivated vaccine. METHODS We collected peripheral blood mononuclear cells pre- and postimmunization from 60 patients enrolled in a randomized trial of HD versus SD vaccine (30 HD; 30 SD) during the 2016-2017 influenza season. RESULTS The HD vaccine elicited significantly greater monofunctional and polyfunctional CD4+ and CD8+ T-cell responses against influenza A/H1N1, A/H3N2, and B. For example, median vaccine-elicited influenza-specific polyfunctional CD4+ T cells were higher in recipients of the HD than SD vaccine after stimulation with influenza A/H1N1 (1193 vs 0 per 106 CD4+ T cells; P = .003), A/H3N2 (1154 vs 51; P = .008), and B (1102 vs 0; P = .001). Likewise, vaccine-elicited influenza-specific polyfunctional CD8+ T cells were higher in recipients of the HD than SD vaccine after stimulation with influenza B (367 vs 0; P = .002). CONCLUSIONS Our study provides novel evidence that HD vaccine elicits greater cellular responses compared with the SD vaccine in SOT recipients, which provides support to preferentially consider use of HD vaccination in the SOT setting.",2020,"The HD vaccine elicited significantly greater monofunctional and polyfunctional CD4+ and CD8+ T-cell responses against influenza A/H1N1, A/H3N2 and B.","['60 patients enrolled', 'Solid Organ Transplant Recipients', '30 HD; 30 SD) during the 2016-2017 influenza season', 'SOT recipients']","['HD vs. SD vaccine', 'H3N2 ', 'standard-dose (SD) trivalent inactivated vaccine']","['CD4+ and CD8+ T-cell responses', 'monofunctional and polyfunctional CD4+ and CD8+ T-cell responses against influenza A/H1N1, A/H3N2 and B']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0730400', 'cui_str': 'Solid organ transplant (procedure)'}, {'cui': 'C0021400', 'cui_str': 'Influenza, Human'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}]","[{'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0580267', 'cui_str': 'H3N2'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0042212', 'cui_str': 'Vaccines, Killed'}]","[{'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C2076600', 'cui_str': 'Influenza caused by Influenza A virus subtype H1N1'}, {'cui': 'C0580264', 'cui_str': 'H1N1'}, {'cui': 'C0580267', 'cui_str': 'H3N2'}]",,0.213913,"The HD vaccine elicited significantly greater monofunctional and polyfunctional CD4+ and CD8+ T-cell responses against influenza A/H1N1, A/H3N2 and B.","[{'ForeName': 'Arnaud G', 'Initials': 'AG', 'LastName': ""L'huillier"", 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Victor H', 'Initials': 'VH', 'LastName': 'Ferreira', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Cedric', 'Initials': 'C', 'LastName': 'Hirzel', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Yoichiro', 'Initials': 'Y', 'LastName': 'Natori', 'Affiliation': 'Division of Infectious Disease, Department of Medicine, University of Miami Miller School of Medicine and Miami Transplant Institute, Miami, Florida, USA.'}, {'ForeName': 'Jaclyn', 'Initials': 'J', 'LastName': 'Slomovic', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Terrance', 'Initials': 'T', 'LastName': 'Ku', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Hoschler', 'Affiliation': 'Public Health England, London, United Kingdom.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Ierullo', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Nazia', 'Initials': 'N', 'LastName': 'Selzner', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Schiff', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Lianne G', 'Initials': 'LG', 'LastName': 'Singer', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Atul', 'Initials': 'A', 'LastName': 'Humar', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Deepali', 'Initials': 'D', 'LastName': 'Kumar', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}]",The Journal of infectious diseases,['10.1093/infdis/jiz471'] 3208,32046597,The Countervailing Effects of Weight Stigma on Weight-Loss Motivation and Perceived Capacity for Weight Control.,"We hypothesized that exposure to weight stigma simultaneously increases motivation to lose or avoid gaining weight to avoid future stigma and decreases perceived capacity to do so, by heightening concerns about experiencing stigma and negative affect. Study 1 showed that more frequently experiencing weight-based discrimination was associated with greater concerns about being a victim of weight stigma, which predicted increased motivation to lose weight but decreased perceived capacity for weight control. Study 2 showed that participants randomly assigned to view a weight-stigmatizing (vs. control) message showed increased concerns about being a target of weight stigma, which indirectly increased motivation to lose weight and decreased state self-control. These, in turn, predicted increased willingness to engage in unhealthy weight-loss behaviors and decreased perceived capacity for weight control, respectively. Study 3 showed that increased motivation to avoid stigma and increased negative affect mediate these effects of exposure to weight stigma.",2020,"Study 1 showed that more frequently experiencing weight-based discrimination was associated with greater concerns about being a victim of weight stigma, which predicted increased motivation to lose weight but decreased perceived capacity for weight control.",[],[],['willingness to engage in unhealthy weight-loss behaviors'],[],[],"[{'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]",,0.0203034,"Study 1 showed that more frequently experiencing weight-based discrimination was associated with greater concerns about being a victim of weight stigma, which predicted increased motivation to lose weight but decreased perceived capacity for weight control.","[{'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Major', 'Affiliation': 'University of California, Santa Barbara, USA.'}, {'ForeName': 'Joanne A', 'Initials': 'JA', 'LastName': 'Rathbone', 'Affiliation': 'The University of Queensland, St Lucia, Australia.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Blodorn', 'Affiliation': 'University of California, Santa Barbara, USA.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Hunger', 'Affiliation': 'Miami University, Oxford, OH, USA.'}]",Personality & social psychology bulletin,['10.1177/0146167220903184'] 3209,32098716,Masked comparison of two silicone hydrogel bandage contact lenses after photorefractive keratectomy.,"PURPOSE To compare the efficiency and safety of two bandage contact lenses after photorefractive keratectomy (PRK). METHODS In this double-blind study, 45 patients (90 eyes) received PRK in both eyes and wore bandage contact lenses (BCLs), PureVision (Bausch & Lomb, Rochester, NY, USA) in one eye and PureVision2 (Bausch & Lomb, Rochester, NY, USA) in the other eye, randomly assigned. The medication regimen after surgery was the same for both eyes. The epithelial defect's size, conjunctival hyperemia and lens centration were graded objectively using slit-lamp biomicroscopy on days 1, 3 and 5 after surgery. Also ocular symptoms of discomfort including tearing, photophobia, foreign body sensation and visual fluctuations were assessed subjectively at each visit. RESULTS The mean epithelial defect size on the first day after operation was similar in eyes fitted with PureVision (30.08 ± 5.30 mm²) and PureVision2 (30.25 ± 5.72 mm 2 ) lenses. (p = 0.79) Contact lens deposits and bulbar hyperaemia on days 1 and 3 after PRK were similar between the two eyes, but were significantly greater on day 5 for PureVision2 lenses. (p = 0.02; p = 0.04 respectively) There was no difference in contact lens decentration, and discomfort symptoms including pain, tearing, foreign body sensation, photophobia and visual fluctuations between the eyes fitted with PureVision and PureVision2. (p > 0.05) CONCLUSIONS: PureVision and PureVision2 contact lenses are equivalent as bandage lenses in important aspects such as corneal re-epithelialization and subjective comfort., although PureVision2 led to a higher incidence of contact lens deposits and conjunctival hyperemia early post-PRK.",2020,"There was no difference in contact lens decentration, and discomfort symptoms including pain, tearing, foreign body sensation, photophobia and visual fluctuations between the eyes fitted with PureVision and PureVision2.",['45 patients (90 eyes) received'],"['PureVision and PureVision2 contact lenses', 'PRK in both eyes and wore bandage contact lenses (BCLs), PureVision (Bausch & Lomb, Rochester, NY, USA', 'bandage contact lenses after photorefractive keratectomy (PRK', 'silicone hydrogel bandage contact lenses']","[""epithelial defect's size, conjunctival hyperemia and lens centration"", 'ocular symptoms of discomfort including tearing, photophobia, foreign body sensation and visual fluctuations', 'efficiency and safety', 'mean epithelial defect size', 'contact lens decentration, and discomfort symptoms including pain, tearing, foreign body sensation, photophobia and visual fluctuations', 'Contact lens deposits and bulbar hyperaemia']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0015392', 'cui_str': 'Eye'}]","[{'cui': 'C0009836', 'cui_str': 'Contact Lenses'}, {'cui': 'C0395416', 'cui_str': 'Photorefractive Keratectomy'}, {'cui': 'C0229118', 'cui_str': 'OU - Both eyes'}, {'cui': 'C0150468', 'cui_str': 'Application of bandage (procedure)'}, {'cui': 'C0037114', 'cui_str': 'Silicones'}, {'cui': 'C1449669', 'cui_str': 'Bandages, Hydrogel'}]","[{'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C1761613', 'cui_str': 'Conjunctival hyperemia (finding)'}, {'cui': 'C0023317', 'cui_str': 'Lens, Eye'}, {'cui': 'C4521296', 'cui_str': 'Ocular (intended site)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0085636', 'cui_str': 'Light Sensitivity'}, {'cui': 'C0423602', 'cui_str': 'Foreign body sensation (finding)'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0231239', 'cui_str': 'Fluctuation'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0009836', 'cui_str': 'Contact Lenses'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0333562', 'cui_str': 'Deposition (morphologic abnormality)'}, {'cui': 'C0020452', 'cui_str': 'Hyperemia'}]",45.0,0.067977,"There was no difference in contact lens decentration, and discomfort symptoms including pain, tearing, foreign body sensation, photophobia and visual fluctuations between the eyes fitted with PureVision and PureVision2.","[{'ForeName': 'Homa', 'Initials': 'H', 'LastName': 'Bagherian', 'Affiliation': 'Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Siamak', 'Initials': 'S', 'LastName': 'Zarei-Ghanavati', 'Affiliation': 'Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.'}, {'ForeName': 'Hamed', 'Initials': 'H', 'LastName': 'Momeni-Moghaddam', 'Affiliation': 'Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran; Department of Optometry, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: hmomeni_opt@zaums.ac.ir.'}, {'ForeName': 'James S', 'Initials': 'JS', 'LastName': 'Wolffsohn', 'Affiliation': 'School of Life and Health Sciences, Aston University, Birmingham, UK.'}, {'ForeName': 'Mohammad-Reza', 'Initials': 'MR', 'LastName': 'Sedaghat', 'Affiliation': 'Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Shehzad A', 'Initials': 'SA', 'LastName': 'Naroo', 'Affiliation': 'School of Life and Health Sciences, Aston University, Birmingham, UK.'}, {'ForeName': 'Naeemeh', 'Initials': 'N', 'LastName': 'Monfared', 'Affiliation': 'Department of Optometry, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2020.02.005'] 3210,31378074,Benefit of Digital Tools Used for Integrated Personalized Diabetes Management: Results From the PDM-ProValue Study Program.,"BACKGROUND Integrated personalized diabetes management (iPDM) is a digitally supported therapeutic concept to improve patient-physician interaction to overcome the aspects of clinical inertia. Integrated personalized diabetes management can support decision making and improve therapeutic outcomes of suboptimally controlled persons with insulin-treated type 2 diabetes (T2D). In this paper, we report the results of an analysis of the PDM-ProValue study program on the effectiveness and perceived benefit of this approach, with a focus on how physicians used and assessed the digital tools provided for the iPDM process. MATERIALS AND METHODS The study program included two 12-month, prospective, controlled, cluster-randomized multicenter trials. A total of 101 practices participated with 907 patients. Practices were cluster-randomized to an intervention group and a control group. Digital tools for data visualization and analysis applied were used. HCP were asked to assess the use, relevance, and usefulness of the tools. RESULTS A clear preference was stated for the visual overview over more statistically complex analyses. A total of 83% of the participants rated a high relevance of the ""daily profile,"" 81% of the ""total profile,"" and 68% the ""risk illustrated by traffic light symbols"" for the therapy decision. The overall iPDM process was very favorably rated with respect to structuredness and potential for personalized treatment and well accepted among health care professionals (HCP). CONCLUSIONS Embedding digital tools in a structured process (iPDM) were proved to provide a benefit for insulin-treated T2D patients and their physicians. These results offer insight for further development and improvement of the tools and add information on how to overcome clinical inertia.",2020,"The overall iPDM process was very favorably rated with respect to structuredness and potential for personalized treatment and well accepted among health care professionals (HCP). ","['patients and their physicians', 'A total of 101 practices participated with 907 patients', 'suboptimally controlled persons with insulin-treated type 2 diabetes (T2D']",['insulin-treated T2D'],['overall iPDM process'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}]","[{'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C4521054', 'cui_str': 'Process (qualifier value)'}]",907.0,0.0266648,"The overall iPDM process was very favorably rated with respect to structuredness and potential for personalized treatment and well accepted among health care professionals (HCP). ","[{'ForeName': 'Lutz', 'Initials': 'L', 'LastName': 'Heinemann', 'Affiliation': 'Science Consulting in Diabetes GmbH, Neuss, Germany.'}, {'ForeName': 'Wendelin', 'Initials': 'W', 'LastName': 'Schramm', 'Affiliation': 'GECKO Institut, Hochschule Heilbronn, Germany.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Koenig', 'Affiliation': 'Roche Diabetes Care GmbH, Mannheim, Germany.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Moritz', 'Affiliation': 'Roche Diabetes Care Deutschland GmbH, Mannheim, Germany.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Vesper', 'Affiliation': 'Roche Diabetes Care GmbH, Mannheim, Germany.'}, {'ForeName': 'Joerg', 'Initials': 'J', 'LastName': 'Weissmann', 'Affiliation': 'Roche Diabetes Care Deutschland GmbH, Mannheim, Germany.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Kulzer', 'Affiliation': 'FIDAM (Forschungsinstitut Diabetes Akademie Bad Mergentheim), Bad Mergentheim, Germany.'}]",Journal of diabetes science and technology,['10.1177/1932296819867686'] 3211,31225625,Potential Moderating Effects of Sex/Gender on the Acute Relative Reinforcing and Subjective Effects of Reduced Nicotine Content Cigarettes in Vulnerable Populations.,"INTRODUCTION Reports in relatively healthy smokers suggest men are more sensitive than women to the subjective effects of reduced nicotine content cigarettes (RNCCs). We know of no reports examining sex differences in the relative reinforcing effects of RNCCs, an important outcome in assessing smoking's addiction potential. The aim of the present study is to address this gap by examining sex/gender differences on reinforcing effects while examining whether sex differences in subjective effects are discernible in vulnerable populations. METHODS Secondary analysis of a within-subject, double-blinded experiment examining acute effects of cigarettes varying in nicotine content (0.4, 2.4, 5.2, 15.8 mg/g) among 169 adult smokers with psychiatric conditions or socioeconomic disadvantage. Effects of dose, sex, and their interaction were examined on reinforcing (concurrent-choice and Cigarette Purchase Task [CPT] testing), and subjective effects (Cigarette Evaluation Questionnaire [CEQ] and craving/withdrawal ratings). RESULTS Reducing nicotine content decreased the relative reinforcing effects of smoking in concurrent-choice and CPT testing (p's < .05) with no significant effects of sex nor dose × sex/gender interactions. Reducing nicotine content decreased CEQ ratings with only a single significant effect of sex (higher Psychological Reward scores among women than men, p = .02) and no significant dose × sex/gender interactions. Results on craving/withdrawal paralleled those on the CEQ. CONCLUSIONS Reducing nicotine content decreases the addiction potential of smoking independent of sex in populations highly vulnerable to smoking and addiction, with no indication that women are less sensitive to subjective effects of RNCCs or would benefit less from a policy reducing the nicotine content of cigarettes. IMPLICATIONS A policy reducing the nicotine content of cigarettes has the potential to reduce the addiction potential of smoking across men and women who are especially vulnerable to smoking, addiction, and tobacco-related adverse health impacts.",2020,"RESULTS Reducing nicotine content decreased the relative reinforcing effects of smoking in concurrent-choice and CPT testing (p's < .05) with no significant effects of sex nor dose-by-sex/gender interactions.","['Vulnerable Populations', 'healthy smokers suggest men', 'Secondary analysis of a within-subject, double-blind experiment examining acute effects of cigarettes varying in nicotine content (0.4, 2.4, 5.2, 15.8 mg/g) among 169 adult smokers with psychiatric conditions or socioeconomic disadvantage']",['Nicotine Content Cigarettes'],"['CEQ ratings', 'reinforcing (concurrent-choice and Cigarette Purchase Task (CPT) testing), and subjective effects (Cigarette Evaluation Questionnaire (CEQ) and craving/withdrawal ratings']","[{'cui': 'C0949366', 'cui_str': 'Vulnerable Populations'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C4517457', 'cui_str': 'Zero point four'}, {'cui': 'C4517631', 'cui_str': '2.4 (qualifier value)'}, {'cui': 'C4517790', 'cui_str': '5.2 (qualifier value)'}, {'cui': 'C1300563', 'cui_str': 'ug/mg'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0012613', 'cui_str': 'Disadvantaged'}]","[{'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}]","[{'cui': 'C0205420', 'cui_str': 'Concurrent (qualifier value)'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0870371', 'cui_str': 'Craving'}]",169.0,0.0258027,"RESULTS Reducing nicotine content decreased the relative reinforcing effects of smoking in concurrent-choice and CPT testing (p's < .05) with no significant effects of sex nor dose-by-sex/gender interactions.","[{'ForeName': 'Joanna M', 'Initials': 'JM', 'LastName': 'Streck', 'Affiliation': 'Vermont Center on Tobacco Regulatory Science, Departments of Psychiatry and Psychological Science, University of Vermont,Burlington, VT.'}, {'ForeName': 'Danielle R', 'Initials': 'DR', 'LastName': 'Davis', 'Affiliation': 'Vermont Center on Tobacco Regulatory Science, Departments of Psychiatry and Psychological Science, University of Vermont,Burlington, VT.'}, {'ForeName': 'Raina D', 'Initials': 'RD', 'LastName': 'Pang', 'Affiliation': 'Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA.'}, {'ForeName': 'Stacey C', 'Initials': 'SC', 'LastName': 'Sigmon', 'Affiliation': 'Vermont Center on Tobacco Regulatory Science, Departments of Psychiatry and Psychological Science, University of Vermont,Burlington, VT.'}, {'ForeName': 'Janice Y', 'Initials': 'JY', 'LastName': 'Bunn', 'Affiliation': 'Vermont Center on Tobacco Regulatory Science, Departments of Psychiatry and Psychological Science, University of Vermont,Burlington, VT.'}, {'ForeName': 'Cecilia L', 'Initials': 'CL', 'LastName': 'Bergeria', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.'}, {'ForeName': 'Jennifer W', 'Initials': 'JW', 'LastName': 'Tidey', 'Affiliation': 'Center for Alcohol and Addiction Studies, Brown University, Providence, RI.'}, {'ForeName': 'Sarah H', 'Initials': 'SH', 'LastName': 'Heil', 'Affiliation': 'Vermont Center on Tobacco Regulatory Science, Departments of Psychiatry and Psychological Science, University of Vermont,Burlington, VT.'}, {'ForeName': 'Diann E', 'Initials': 'DE', 'LastName': 'Gaalema', 'Affiliation': 'Vermont Center on Tobacco Regulatory Science, Departments of Psychiatry and Psychological Science, University of Vermont,Burlington, VT.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Hughes', 'Affiliation': 'Vermont Center on Tobacco Regulatory Science, Departments of Psychiatry and Psychological Science, University of Vermont,Burlington, VT.'}, {'ForeName': 'Maxine L', 'Initials': 'ML', 'LastName': 'Stitzer', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.'}, {'ForeName': 'Ellaina', 'Initials': 'E', 'LastName': 'Reed', 'Affiliation': 'Vermont Center on Tobacco Regulatory Science, Departments of Psychiatry and Psychological Science, University of Vermont,Burlington, VT.'}, {'ForeName': 'Stephen T', 'Initials': 'ST', 'LastName': 'Higgins', 'Affiliation': 'Vermont Center on Tobacco Regulatory Science, Departments of Psychiatry and Psychological Science, University of Vermont,Burlington, VT.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntz098'] 3212,31713723,"Ubiquinol Improves Endothelial Function in Patients with Heart Failure with Reduced Ejection Fraction: A Single-Center, Randomized Double-Blind Placebo-Controlled Crossover Pilot Study.","BACKGROUND Endothelial dysfunction is reportedly associated with worse outcomes in patients with chronic heart failure. Ubiquinol is a reduced form of coenzyme Q10 (CoQ10) that may improve endothelial function. OBJECTIVE We assessed the hypothesis that ubiquinol improves peripheral endothelial function in patients with heart failure with reduced ejection fraction (HFrEF). METHODS In this randomized, double-blind, placebo-controlled, crossover pilot study, 14 patients with stable HFrEF were randomly and blindly allocated to ubiquinol 400 mg/day or placebo for 3 months. After a 1-month washout period, patients were crossed over to the alternative treatment. Before and after each treatment, we assessed peripheral endothelial function using the reactive hyperemia index (RHI) and analyzed it using the natural logarithm of RHI (LnRHI). RESULTS Peripheral endothelial function as assessed by LnRHI tended to improve with ubiquinol 400 mg/day for 3 months (p = 0.076). Original RHI values were also compared, and RHI significantly improved with ubiquinol treatment (pre-RHI 1.57 [interquartile range (IQR) 1.39-1.80], post-RHI 1.74 [IQR 1.63-2.02], p = 0.026), but not with placebo (pre-RHI 1.67 [IQR 1.53-1.85], post-RHI 1.51 [IQR 1.39-2.11], p = 0.198). CONCLUSIONS Ubiquinol 400 mg/day for 3 months led to significant improvement in peripheral endothelial function in patients with HFrEF. Ubiquinol may be a therapeutic option for individuals with HFrEF. Large-scale randomized controlled trials of CoQ10 supplementation in patients with HFrEF are needed. CLINICAL TRIAL REGISTRATION Japanese University Hospital Medical Information Network (UMIN-ICDR). Clinical Trial identifier number UMIN000012604.",2020,"RESULTS Peripheral endothelial function as assessed by LnRHI tended to improve with ubiquinol 400 mg/day for 3 months (p = 0.076).","['patients with HFrEF are needed', 'patients with heart failure with reduced ejection fraction (HFrEF', 'individuals with HFrEF', 'Patients with Heart Failure with Reduced Ejection Fraction', 'patients with chronic heart failure', 'patients with HFrEF', '14 patients with stable HFrEF']","['Placebo', 'Ubiquinol', 'CoQ10 supplementation', 'ubiquinol 400\xa0mg/day or placebo', 'placebo']","['peripheral endothelial function', 'Peripheral endothelial function', 'Original RHI values', 'peripheral endothelial function using the reactive hyperemia index (RHI) and analyzed it using the natural logarithm of RHI (LnRHI', 'Endothelial Function']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0264716', 'cui_str': 'Chronic heart failure (disorder)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0950189', 'cui_str': 'ubiquinols'}, {'cui': 'C0056077', 'cui_str': 'coenzyme Q10'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0439422', 'cui_str': 'mg/day'}]","[{'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0205313', 'cui_str': 'Original (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0178824', 'cui_str': 'Reactive Hyperemia'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.587128,"RESULTS Peripheral endothelial function as assessed by LnRHI tended to improve with ubiquinol 400 mg/day for 3 months (p = 0.076).","[{'ForeName': 'Chika', 'Initials': 'C', 'LastName': 'Kawashima', 'Affiliation': 'Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.'}, {'ForeName': 'Yasushi', 'Initials': 'Y', 'LastName': 'Matsuzawa', 'Affiliation': 'Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan. matsu@yokohama-cu.ac.jp.'}, {'ForeName': 'Masaaki', 'Initials': 'M', 'LastName': 'Konishi', 'Affiliation': 'Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.'}, {'ForeName': 'Eiichi', 'Initials': 'E', 'LastName': 'Akiyama', 'Affiliation': 'Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Suzuki', 'Affiliation': 'Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.'}, {'ForeName': 'Ryosuke', 'Initials': 'R', 'LastName': 'Sato', 'Affiliation': 'Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.'}, {'ForeName': 'Hidefumi', 'Initials': 'H', 'LastName': 'Nakahashi', 'Affiliation': 'Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.'}, {'ForeName': 'Shinnosuke', 'Initials': 'S', 'LastName': 'Kikuchi', 'Affiliation': 'Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.'}, {'ForeName': 'Yuichiro', 'Initials': 'Y', 'LastName': 'Kimura', 'Affiliation': 'Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.'}, {'ForeName': 'Nobuhiko', 'Initials': 'N', 'LastName': 'Maejima', 'Affiliation': 'Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.'}, {'ForeName': 'Noriaki', 'Initials': 'N', 'LastName': 'Iwahashi', 'Affiliation': 'Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.'}, {'ForeName': 'Kiyoshi', 'Initials': 'K', 'LastName': 'Hibi', 'Affiliation': 'Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.'}, {'ForeName': 'Masami', 'Initials': 'M', 'LastName': 'Kosuge', 'Affiliation': 'Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.'}, {'ForeName': 'Toshiaki', 'Initials': 'T', 'LastName': 'Ebina', 'Affiliation': 'Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.'}, {'ForeName': 'Kouichi', 'Initials': 'K', 'LastName': 'Tamura', 'Affiliation': 'Department of Medical Science and Cardiorenal Medicine, Yokohama City University School of Medicine, Yokohama, Japan.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Kimura', 'Affiliation': 'Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.'}]","American journal of cardiovascular drugs : drugs, devices, and other interventions",['10.1007/s40256-019-00384-y'] 3213,31725087,Fluoroscopic Marker-Based Guidance System Improves Gamma Lag Screw Placement During Nailing of Intertrochanteric Fractures: A Randomized Controlled Trial.,"OBJECTIVES To determine whether a fluoroscopy-based navigation system would improve tip-apex distance (TAD) compared with the conventional technique. DESIGN Randomized controlled trial. SETTING Level 1 trauma center. PATIENTS A total of 161 patients were screened for inclusion in the study. After meeting inclusion and exclusion criteria, 31 patients were randomized (n = 18 navigated vs. n = 13 control group), with the patient blinded to the result. INTERVENTION Fluoroscopy-based navigated guidance of lag screw length and position. MAIN OUTCOME MEASURES Average TAD and the proportion of TAD over 25 mm. RESULTS TAD was lower in the navigated group compared with the control group (mean = 17.5 vs. 24.2 mm; P = 0.0018). No navigated cases exceeded the 25 mm TAD threshold, compared with 39% of conventional cases (P = 0.0076). Navigation resulted in fewer drilling attempts compared with the conventional technique (median = 1 vs. 4 attempts; P < 0.0001). We detected no significant differences in operation time or total number of fluoroscopic images (P > 0.05). CONCLUSIONS Fluoroscopy-based computer navigated Gamma nailing for intertrochanteric fractures improved TAD and reduced the number of drilling attempts without increasing operation time compared with the conventional fluoroscopy-guided technique in a teaching hospital setting. LEVEL OF EVIDENCE Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.",2020,Navigation resulted in fewer drilling attempts compared to the conventional technique (median = 1 vs. 4 attempts; P < 0.0001).,"['Gamma nailing of intertrochanteric fractures', 'Level 1 trauma center PATIENTS:: A total of 161 patients were screened for inclusion in the study']","['Fluoroscopy-based navigated guidance of lag screw length and position', 'Fluoroscopy-based computer navigated Gamma nailing', 'Fluoroscopic marker-based guidance system', 'fluoroscopy-based navigation system']","['lag screw placement', 'tip apex distance (TAD', 'operation time or total number of fluoroscopic images', 'TAD']","[{'cui': 'C1552644', 'cui_str': 'Greek letter gamma'}, {'cui': 'C0162385', 'cui_str': 'Intertrochanteric Fractures'}, {'cui': 'C0456947', 'cui_str': 'Level 1 (qualifier value)'}, {'cui': 'C0040786', 'cui_str': 'Trauma Centers'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0301559', 'cui_str': 'Screw (physical object)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C1561964', 'cui_str': 'Patient Positioning'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C1552644', 'cui_str': 'Greek letter gamma'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C4075648', 'cui_str': 'Navigation system'}]","[{'cui': 'C0301559', 'cui_str': 'Screw (physical object)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}]",161.0,0.138732,Navigation resulted in fewer drilling attempts compared to the conventional technique (median = 1 vs. 4 attempts; P < 0.0001).,"[{'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Weidert', 'Affiliation': 'Department of General, Trauma and Reconstructive Surgery, Munich University Hospital LMU, Munich, Germany.'}, {'ForeName': 'Fabian', 'Initials': 'F', 'LastName': 'Sommer', 'Affiliation': 'Department of General, Trauma and Reconstructive Surgery, Munich University Hospital LMU, Munich, Germany.'}, {'ForeName': 'Eduardo M', 'Initials': 'EM', 'LastName': 'Suero', 'Affiliation': 'Department of General, Trauma and Reconstructive Surgery, Munich University Hospital LMU, Munich, Germany.'}, {'ForeName': 'Christopher A', 'Initials': 'CA', 'LastName': 'Becker', 'Affiliation': 'Department of General, Trauma and Reconstructive Surgery, Munich University Hospital LMU, Munich, Germany.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Pieske', 'Affiliation': 'Department of Trauma Surgery, Orthopaedics and Sports Traumatology, Evangelisches Krankenhaus Oldenburg, Oldenburg, Germany.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Greiner', 'Affiliation': 'Department of General, Trauma and Reconstructive Surgery, Munich University Hospital LMU, Munich, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Kammerlander', 'Affiliation': 'Department of General, Trauma and Reconstructive Surgery, Munich University Hospital LMU, Munich, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Böcker', 'Affiliation': 'Department of General, Trauma and Reconstructive Surgery, Munich University Hospital LMU, Munich, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Grote', 'Affiliation': 'Department of Orthopaedic and Trauma Surgery, Klinikum St. Elisabeth Straubing, Munich, Germany.'}]",Journal of orthopaedic trauma,['10.1097/BOT.0000000000001662'] 3214,31619441,Effects of Electronic Cigarette Constituents on the Human Lung: A Pilot Clinical Trial.,"Electronic cigarette (e-cig) use is continuing to increase, particularly among youth never-smokers, and is used by some smokers to quit. The acute and chronic toxicity of e-cig use is unclear generally in the context of increasing reports of inflammatory-type pneumonia in some e-cig users. To assess lung effects of e-cigs without nicotine or flavors, we conducted a pilot study with serial bronchoscopies over 4 weeks in 30 never-smokers, randomized either to a 4-week intervention with the use of e-cigs containing only 50% propylene glycol (PG) and 50% vegetable glycerine or to a no-use control group. Compliance to the e-cig intervention was assessed by participants sending daily puff counts and by urinary PG. Inflammatory cell counts and cytokines were determined in bronchoalveolar lavage (BAL) fluids. Genome-wide expression, miRNA, and mRNA were determined from bronchial epithelial cells. There were no significant differences in changes of BAL inflammatory cell counts or cytokines between baseline and follow-up, comparing the control and e-cig groups. However, in the intervention but not the control group, change in urinary PG as a marker of e-cig use and inhalation was significantly correlated with change in cell counts (cell concentrations, macrophages, and lymphocytes) and cytokines (IL8, IL13, and TNFα), although the absolute magnitude of changes was small. There were no significant changes in mRNA or miRNA gene expression. Although limited by study size and duration, this is the first experimental demonstration of an impact of e-cig use on inflammation in the human lung among never-smokers.",2020,"There were no significant differences in changes of BAL inflammatory cell counts or cytokines between baseline and follow-up, comparing the control and e-cig groups.","['30 never-smokers', 'Human Lung', 'human lung among never-smokers']","['nicotine or flavors', 'e-cigs containing only 50% propylene glycol (PG) and 50% vegetable glycerine (VG) or to a no-use control group', 'Electronic Cigarette Constituents']","['Inflammatory cell counts and cytokines', 'changes of BAL inflammatory cell counts or cytokines', 'urinary PG', 'Genome-wide expression, microRNA, and mRNA', 'mRNA or microRNA gene expression', 'cell counts (cell concentrations, macrophages, and lymphocytes) and cytokines (IL-8, IL-13, and TNF-α']","[{'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0024109', 'cui_str': 'Lung'}]","[{'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C3849993', 'cui_str': 'Electronic Cigarettes'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C4046690', 'cui_str': 'propylene glycol, (S)-'}, {'cui': 'C0042440', 'cui_str': 'Vegetables'}, {'cui': 'C0017861', 'cui_str': 'Glycerin'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0729650', 'cui_str': 'Constituents (substance)'}]","[{'cui': 'C0440752', 'cui_str': 'Inflammatory cell'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0012383', 'cui_str': 'Dimercaprol'}, {'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C1101610', 'cui_str': 'miRNA'}, {'cui': 'C0035696', 'cui_str': 'mRNA'}, {'cui': 'C0017262', 'cui_str': 'Gene Expression'}, {'cui': 'C0007584', 'cui_str': 'Cell Number'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0024432', 'cui_str': 'Monocyte-Derived Macrophages'}, {'cui': 'C4018897', 'cui_str': 'Lymphocyte component of blood'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0214743', 'cui_str': 'IL13'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}]",,0.0176126,"There were no significant differences in changes of BAL inflammatory cell counts or cytokines between baseline and follow-up, comparing the control and e-cig groups.","[{'ForeName': 'Min-Ae', 'Initials': 'MA', 'LastName': 'Song', 'Affiliation': 'Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, Columbus, Ohio.'}, {'ForeName': 'Sarah A', 'Initials': 'SA', 'LastName': 'Reisinger', 'Affiliation': 'Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, Columbus, Ohio.'}, {'ForeName': 'Jo L', 'Initials': 'JL', 'LastName': 'Freudenheim', 'Affiliation': 'Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York.'}, {'ForeName': 'Theodore M', 'Initials': 'TM', 'LastName': 'Brasky', 'Affiliation': 'Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, Columbus, Ohio.'}, {'ForeName': 'Ewy A', 'Initials': 'EA', 'LastName': 'Mathé', 'Affiliation': 'Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, Columbus, Ohio.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'McElroy', 'Affiliation': 'Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'Quentin A', 'Initials': 'QA', 'LastName': 'Nickerson', 'Affiliation': 'Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, Columbus, Ohio.'}, {'ForeName': 'Daniel Y', 'Initials': 'DY', 'LastName': 'Weng', 'Affiliation': 'Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, Columbus, Ohio.'}, {'ForeName': 'Mark D', 'Initials': 'MD', 'LastName': 'Wewers', 'Affiliation': 'Department of Internal Medicine, Pulmonary and Critical Care Medicine, The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'Peter G', 'Initials': 'PG', 'LastName': 'Shields', 'Affiliation': 'Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, Columbus, Ohio. Peter.Shields@osumc.edu.'}]","Cancer prevention research (Philadelphia, Pa.)",['10.1158/1940-6207.CAPR-19-0400'] 3215,31797310,Renin-Angiotensin-Aldosterone System Optimization for Acute Decompensated Heart Failure Patients (ROAD-HF): Rationale and Design.,"INTRODUCTION The long-term benefits of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) on outcomes in patients with chronic congestive heart failure are well-known, making them one of the most widely prescribed medications. However, the administration of ACEIs/ARBs in acute decompensated heart failure (ADHF) can increase the risk of morbidity and mortality secondary to worsening renal function (WRF). A decrease in estimated glomerular filtration rate (eGFR) during the treatment of ADHF has been associated with an increase in mortality proportional to the degree of WRF. AIM The aim of our study is to determine whether withholding ACEIs/ARBs during the initial 72 h of admission in patients with ADHF will prevent WRF and allow more effective diuresis. METHODS Four hundred and thirty patients will be randomized to the intervention (withholding ACEIs/ARBs) or control (continue/start ACEIs/ARBs) arms for 72 h. Primary outcomes include rates of acute kidney injury (AKI), patient global assessment, and change in kinetic eGFR over 72 h, while secondary outcomes include change in weight, fluid balance, change in signs and symptoms of congestion, change in renal function, change in urinary biomarkers (tissue inhibitor of metalloproteinases 2 [TIMP-2] × insulin-like growth factor-binding protein 7 [IGFBP7]), patients experiencing treatment failure, hospital length of stay (LOS), cost analysis, mortality within 30 days, and hospital readmissions over 30 days and 1 year. CONCLUSION This prospective clinical trial will prove if withholding ACEIs/ARBs will prevent AKI in ADHF. It will help us understand the complex interactions between the heart and kidney, and delineate the best treatment strategy for ADHF. Holding ACEIs/ARBs might help preserve renal function, and decrease hospital LOS, readmission rates, and cost of care in ADHF. REGISTRATION ClinicalTrials.gov identifier: NCT03695120.",2020,"Holding ACEIs/ARBs might help preserve renal function, and decrease hospital LOS, readmission rates, and cost of care in ADHF. ","['patients with ADHF', 'Acute Decompensated Heart Failure Patients (ROAD-HF', 'patients experiencing treatment failure, hospital length of stay (LOS), cost analysis, mortality within 30 days, and hospital readmissions over 30\xa0days and 1\xa0year', 'patients with chronic congestive heart failure', 'Four hundred and thirty patients']","['intervention (withholding ACEIs/ARBs) or control (continue/start ACEIs/ARBs', 'ACEIs/ARBs', 'Renin-Angiotensin-Aldosterone System Optimization', 'withholding ACEIs/ARBs', 'angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs']","['estimated glomerular filtration rate (eGFR', 'rates of acute kidney injury (AKI), patient global assessment, and change in kinetic eGFR over 72\xa0h, while secondary outcomes include change in weight, fluid balance, change in signs and symptoms of congestion, change in renal function, change in urinary biomarkers (tissue inhibitor of metalloproteinases 2 [TIMP-2', 'hospital LOS, readmission rates, and cost of care in ADHF']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1609524', 'cui_str': 'Acute decompensated heart failure'}, {'cui': 'C0581377', 'cui_str': 'Decompensated cardiac failure (disorder)'}, {'cui': 'C0442650', 'cui_str': 'Road (environment)'}, {'cui': 'C0162643'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0010171', 'cui_str': 'Cost Analysis'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0600290', 'cui_str': 'Hospital Readmissions'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0264722', 'cui_str': 'Chronic congestive heart failure (disorder)'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C3816446', 'cui_str': '30'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C1264693', 'cui_str': 'Arbitrary'}, {'cui': 'C0086907', 'cui_str': 'Renin-Angiotensin-Aldosterone System'}, {'cui': 'C0003015', 'cui_str': 'ACE Inhibitors'}, {'cui': 'C0034787', 'cui_str': 'Angiotensin receptor (substance)'}]","[{'cui': 'C3811844'}, {'cui': 'C2609414', 'cui_str': 'Acute Renal Injury'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0016284', 'cui_str': 'Fluid Balance'}, {'cui': 'C0037088', 'cui_str': 'Signs and Symptoms'}, {'cui': 'C0700148', 'cui_str': 'Congestion (morphologic abnormality)'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0145946', 'cui_str': 'Tissue Inhibitor of Metalloproteinase-2'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1609524', 'cui_str': 'Acute decompensated heart failure'}]",430.0,0.0640647,"Holding ACEIs/ARBs might help preserve renal function, and decrease hospital LOS, readmission rates, and cost of care in ADHF. ","[{'ForeName': 'Bhagwan', 'Initials': 'B', 'LastName': 'Dass', 'Affiliation': 'Division of Hospital Medicine, University of Florida, PO Box 100238, Gainesville, FL, 32610, USA. Bhagwan.Dass@medicine.ufl.edu.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Dimza', 'Affiliation': 'Department of Internal Medicine, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Girish', 'Initials': 'G', 'LastName': 'Singhania', 'Affiliation': 'Department of Hospital Medicine, CHI St. Vincent Infirmary, Little Rock, AR, USA.'}, {'ForeName': 'Cody', 'Initials': 'C', 'LastName': 'Schwartz', 'Affiliation': 'Department of Internal Medicine, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Jerin', 'Initials': 'J', 'LastName': 'George', 'Affiliation': 'Department of Internal Medicine, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Avni', 'Initials': 'A', 'LastName': 'Bhatt', 'Affiliation': 'Department of Pediatrics, Division of Hospital Medicine, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Nila', 'Initials': 'N', 'LastName': 'Radhakrishnan', 'Affiliation': 'Division of Hospital Medicine, University of Florida, PO Box 100238, Gainesville, FL, 32610, USA.'}, {'ForeName': 'Asha', 'Initials': 'A', 'LastName': 'Bansari', 'Affiliation': 'Division of Hospital Medicine, University of Florida, PO Box 100238, Gainesville, FL, 32610, USA.'}, {'ForeName': 'Shahab', 'Initials': 'S', 'LastName': 'Bozorgmehri', 'Affiliation': 'Division of Nephrology, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Mohandas', 'Affiliation': 'Division of Nephrology, University of Florida, Gainesville, FL, USA.'}]","American journal of cardiovascular drugs : drugs, devices, and other interventions",['10.1007/s40256-019-00389-7'] 3216,31665385,"Daily Supplementation With Egg, Cow Milk, and Multiple Micronutrients Increases Linear Growth of Young Children with Short Stature.","BACKGROUND Childhood stunting is the most prevalent public health nutrition problem in low- and middle-income countries. OBJECTIVE This study aimed to determine whether daily supplementation in 12-18-mo-old undernourished Bangladeshi children with egg, cow milk, and multiple micronutrients improves linear growth. METHODS In the Bangladesh Environmental Enteric Dysfunction (BEED) study, a community-based intervention study, 12-18-mo-old children with length-for-age z score (LAZ) <1 were supplemented daily with an egg and 150 mL of milk for 90 feeding days, and 1 sachet of multiple micronutrient powder was provided daily for 60 feeding days. The change in LAZ over this period was compared with that in children of the same age and same baseline LAZ who were enrolled in the recently completed Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health (MAL-ED) Dhaka birth cohort study conducted in the same community where no nutrition intervention was provided. Difference-in-difference (DID) analysis was done and the effect size was adjusted for other possible covariates using a generalized estimating equation in a regression model. RESULTS A total of 472 children with LAZ <1 completed the intervention and data were available for 174 children in the comparison group. Compared with the comparison group, adjusted DID analysis revealed a change in LAZ in the intervention group of +0.23 (95% CI: 0.18, 0.29; P < 0.05). In a subgroup analysis, the changes were +0.27 (95% CI: 0.18, 0.35; P < 0.05) in stunted (LAZ <2) children and +0.19 (95% CI: 0.12, 0.27; P < 0.05) in children at risk of stunting (LAZ -1 to -2). No allergic reactions or other adverse events related to milk and egg consumption were observed. CONCLUSIONS Daily directly observed milk, egg, and multiple micronutrient supplementation may improve linear growth of stunted children. A randomized controlled trial with longer duration of supplementation coupled with an additional intervention aimed at reducing pathogen burden is warranted to confirm these results. This trial was registered at clinicaltrials.gov as NCT02812615.",2020,A total of 472 children with LAZ <1 completed the intervention and data were available for 174 children in the comparison group.,"['12-18-mo-old undernourished Bangladeshi children with egg, cow milk, and multiple micronutrients improves linear growth', '12-18-mo-old children with length-for-age z score (LAZ) <1 were', 'Young Children with Short Stature', '472 children with LAZ <1 completed the intervention and data were available for 174 children in the comparison group']","['Daily Supplementation With Egg, Cow Milk, and Multiple Micronutrients', 'daily supplementation', 'LAZ', 'supplemented daily with an egg and 150\xa0mL of milk for 90 feeding days, and 1 sachet of multiple micronutrient powder']",['change in LAZ'],"[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0162429', 'cui_str': 'Malnutrition'}, {'cui': 'C0422784', 'cui_str': 'Bangladeshi'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0029974', 'cui_str': 'Egg, Unfertilized'}, {'cui': 'C0349374', 'cui_str': ""Cow's milk (substance)""}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0013336', 'cui_str': 'Nanism'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C4517604', 'cui_str': 'One hundred and seventy-four'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0029974', 'cui_str': 'Egg, Unfertilized'}, {'cui': 'C0349374', 'cui_str': ""Cow's milk (substance)""}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C4319662', 'cui_str': 'Sachet'}, {'cui': 'C0032861', 'cui_str': 'Powdered drug preparation'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}]",472.0,0.290079,A total of 472 children with LAZ <1 completed the intervention and data were available for 174 children in the comparison group.,"[{'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Mahfuz', 'Affiliation': 'icddr,b, Dhaka, Bangladesh.'}, {'ForeName': 'Mohammed Ashraful', 'Initials': 'MA', 'LastName': 'Alam', 'Affiliation': 'icddr,b, Dhaka, Bangladesh.'}, {'ForeName': 'Subhasish', 'Initials': 'S', 'LastName': 'Das', 'Affiliation': 'icddr,b, Dhaka, Bangladesh.'}, {'ForeName': 'Shah Mohammad', 'Initials': 'SM', 'LastName': 'Fahim', 'Affiliation': 'icddr,b, Dhaka, Bangladesh.'}, {'ForeName': 'Md Shabab', 'Initials': 'MS', 'LastName': 'Hossain', 'Affiliation': 'icddr,b, Dhaka, Bangladesh.'}, {'ForeName': 'William A', 'Initials': 'WA', 'LastName': 'Petri', 'Affiliation': 'University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Ashorn', 'Affiliation': 'Faculty of Medicine and Life Sciences, University of Tampere, Finland.'}, {'ForeName': 'Ulla', 'Initials': 'U', 'LastName': 'Ashorn', 'Affiliation': 'Faculty of Medicine and Life Sciences, University of Tampere, Finland.'}, {'ForeName': 'Tahmeed', 'Initials': 'T', 'LastName': 'Ahmed', 'Affiliation': 'icddr,b, Dhaka, Bangladesh.'}]",The Journal of nutrition,['10.1093/jn/nxz253'] 3217,30818227,An experimental investigation of the role of delay discounting and craving in gambling chasing behavior.,"Chasing is a central feature of gambling disorder and refers to the attempt by individuals to recover financial losses by continuing to gamble. Although several efforts have been made to individuate the factors involved in the complex phenomenon of chasing, little is known regarding its association with delay discounting and craving, both considered important in the development and maintenance of gambling disorder. In the present study, the interplay between chasing, delay discounting, and craving (while controlling for gambling severity) was investigated. The sample comprised 128 adult gamblers aged between 18 and 67 years and consisted of non-problem gamblers (n = 58), problem gamblers (n = 18), and pathological gamblers (n = 52) based on the South Oaks Gambling Screen (SOGS) scores. Participants were administered the Monetary Choice Questionnaire (MCQ) and the Gambling Craving Scale (GACS), as well as completing the ChasIT, a computerized task assessing chasing behavior. Participants were randomly assigned to the control and the loss condition of the ChasIT. Results showed that pathological gamblers were more likely to chase and reported more severe chasing persistence. Regression analyses indicated that heightened levels of craving and the inability to tolerate delay in gratification, along with gambling severity, predicted both the decision to chase and chasing persistence. The present study contributes important findings to the gambling literature, highlighting the role of craving and delay discounting in facilitating the inability to stop within-sessions gambling. These findings may provide evidence that chasers and non-chasers represent two different types of gamblers, and that the difference may be useful for targeting more effective therapies.",2019,"Regression analyses indicated that heightened levels of craving and the inability to tolerate delay in gratification, along with gambling severity, predicted both the decision to chase and chasing persistence.","['128 adult gamblers aged between 18 and 67\u202fyears and consisted of non-problem gamblers (n\u202f=\u202f58), problem gamblers (n\u202f=\u202f18), and pathological gamblers (n\u202f=\u202f52) based on the South Oaks Gambling Screen (SOGS) scores', 'gambling chasing behavior']",[],"['severe chasing persistence', 'Monetary Choice Questionnaire (MCQ) and the Gambling Craving Scale (GACS']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0858352', 'cui_str': 'Gambler'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C1521733', 'cui_str': 'Pathologic (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0016995', 'cui_str': 'Gamblings'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]",[],"[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0546816', 'cui_str': 'Persistence (finding)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0016995', 'cui_str': 'Gamblings'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0222045'}]",128.0,0.0393456,"Regression analyses indicated that heightened levels of craving and the inability to tolerate delay in gratification, along with gambling severity, predicted both the decision to chase and chasing persistence.","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Ciccarelli', 'Affiliation': 'Department of Psychology, Università degli Studi della Campania ""Luigi Vanvitelli"", Viale Ellittico, 31, 81100 Caserta, Italy. Electronic address: maria.ciccarelli@unicampania.it.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Cosenza', 'Affiliation': 'Department of Psychology, Università degli Studi della Campania ""Luigi Vanvitelli"", Viale Ellittico, 31, 81100 Caserta, Italy. Electronic address: marina.cosenza@unicampania.it.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': ""D'Olimpio"", 'Affiliation': 'Department of Psychology, Università degli Studi della Campania ""Luigi Vanvitelli"", Viale Ellittico, 31, 81100 Caserta, Italy. Electronic address: francesca.dolimpio@unicampania.it.'}, {'ForeName': 'Mark D', 'Initials': 'MD', 'LastName': 'Griffiths', 'Affiliation': 'Psychology Department, Nottingham Trent University, Burton Street, Nottingham NG1 4FQ, UK. Electronic address: mark.griffiths@ntu.ac.uk.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Nigro', 'Affiliation': 'Department of Psychology, Università degli Studi della Campania ""Luigi Vanvitelli"", Viale Ellittico, 31, 81100 Caserta, Italy. Electronic address: giovanna.nigro@unicampania.it.'}]",Addictive behaviors,['10.1016/j.addbeh.2019.02.002'] 3218,31577177,Increasing Vegetable Intake by Emphasizing Tasty and Enjoyable Attributes: A Randomized Controlled Multisite Intervention for Taste-Focused Labeling.,"Healthy food labels tout health benefits, yet most people prioritize tastiness in the moment of food choice. In a preregistered intervention, we tested whether taste-focused labels compared with health-focused labels increased vegetable intake at five university dining halls throughout the United States. Across 137,842 diner decisions, 185 days, and 24 vegetable types, taste-focused labels increased vegetable selection by 29% compared with health-focused labels and by 14% compared with basic labels. Vegetable consumption also increased. Supplementary studies further probed the mediators, moderators, and boundaries of these effects. Increased expectations of a positive taste experience mediated the effect of taste-focused labels on vegetable selection. Moderation tests revealed greater effects in settings that served tastier vegetable recipes. Taste-focused labels outperformed labels that merely contained positive words, fancy words, or lists of ingredients. Together, these studies show that emphasizing tasty and enjoyable attributes increases vegetable intake in real-world settings in which vegetables compete with less healthy options.",2019,"Across 137,842 diner decisions, 185 days, and 24 vegetable types, taste-focused labels increased vegetable selection by 29% compared with health-focused labels and by 14% compared with basic labels.",[],['taste-focused labels compared with health-focused labels increased vegetable intake'],"['Increasing Vegetable Intake by Emphasizing Tasty and Enjoyable Attributes', 'Vegetable consumption', 'vegetable selection']",[],"[{'cui': 'C0039336', 'cui_str': 'Gustation'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0556223', 'cui_str': 'Vegetable intake (observable entity)'}]","[{'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0556223', 'cui_str': 'Vegetable intake (observable entity)'}, {'cui': 'C0449234', 'cui_str': 'Attribute (attribute)'}, {'cui': 'C0042440', 'cui_str': 'Vegetables'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]",,0.229194,"Across 137,842 diner decisions, 185 days, and 24 vegetable types, taste-focused labels increased vegetable selection by 29% compared with health-focused labels and by 14% compared with basic labels.","[{'ForeName': 'Bradley P', 'Initials': 'BP', 'LastName': 'Turnwald', 'Affiliation': 'Department of Psychology, Stanford University.'}, {'ForeName': 'Jaclyn D', 'Initials': 'JD', 'LastName': 'Bertoldo', 'Affiliation': 'Residential and Dining Enterprises, Stanford University.'}, {'ForeName': 'Margaret A', 'Initials': 'MA', 'LastName': 'Perry', 'Affiliation': 'Department of Psychology, Stanford University.'}, {'ForeName': 'Peggy', 'Initials': 'P', 'LastName': 'Policastro', 'Affiliation': 'Institute for Food, Nutrition, and Health, Rutgers University.'}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Timmons', 'Affiliation': 'Dining Services, Northeastern University.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Bosso', 'Affiliation': 'School of Public Policy and Urban Affairs, Northeastern University.'}, {'ForeName': 'Priscilla', 'Initials': 'P', 'LastName': 'Connors', 'Affiliation': 'Department of Hospitality and Tourism Management, University of North Texas.'}, {'ForeName': 'Robert T', 'Initials': 'RT', 'LastName': 'Valgenti', 'Affiliation': 'Department of Philosophy, Lebanon Valley College.'}, {'ForeName': 'Lindsey', 'Initials': 'L', 'LastName': 'Pine', 'Affiliation': 'USC Hospitality, University of Southern California.'}, {'ForeName': 'Ghislaine', 'Initials': 'G', 'LastName': 'Challamel', 'Affiliation': 'Menus of Change University Research Collaborative.'}, {'ForeName': 'Christopher D', 'Initials': 'CD', 'LastName': 'Gardner', 'Affiliation': 'Stanford Prevention Research Center, Stanford University.'}, {'ForeName': 'Alia J', 'Initials': 'AJ', 'LastName': 'Crum', 'Affiliation': 'Department of Psychology, Stanford University.'}]",Psychological science,['10.1177/0956797619872191'] 3219,30898323,Cost-effectiveness of individual versus group female-specific cognitive behavioral therapy for alcohol use disorder.,"OBJECTIVE To determine the relative cost-effectiveness of individual female-specific cognitive behavioral therapy (I-FS-CBT) versus group female-specific cognitive behavioral therapy (G-FS-CBT). METHODS This cost-effectiveness study is based on a randomized controlled trial in which 155 women seeking treatment for alcohol use disorder at an academic outpatient clinic were randomized to 12 manual-guided sessions of I-FS-CBT (n = 75) or G-FS-CBT (n = 80). The primary patient outcomes were the number of drinking days and the number of heavy drinking days during the 12-week treatment and 1-year follow-up periods. All cost data (including resource utilizations) were collected prospectively alongside the trial. Incremental cost-effectiveness ratios and cost-effectiveness acceptability curves were used to determine the cost-effectiveness of I-FS-CBT relative to G-FS-CBT. Results are presented from the provider perspective. RESULTS During the 12-week treatment period, G-FS-CBT is likely to be cost-effective when the threshold value to decision-makers of one fewer drinking day (or one fewer day of heavy drinking) is less than $141 (or $258), and I-FS-CBT is likely to be cost-effective if the threshold is greater than $141 (or $258). During the 1-year follow-up period, G-FS-CBT is likely to be cost-effective when the threshold value to decision-makers of one fewer drinking day (or one fewer day of heavy drinking) is less than $54 (or $169), and I-FS-CBT is likely to be cost-effective if the threshold is greater than $54 (or $169). The results are robust to sensitivity analyses on several key cost parameters. CONCLUSIONS Compared to I-FS-CBT, G-FS-CBT holds promise as a cost-effective approach, in both the short run and the long run, for improving drinking outcomes of women with alcohol use disorder.",2019,The primary patient outcomes were the number of drinking days and the number of heavy drinking days during the 12-week treatment and 1-year follow-up periods.,"['women with alcohol use disorder', '155 women seeking treatment for alcohol use disorder at an academic outpatient clinic']","['12 manual-guided sessions of I-FS-CBT (n\u202f=\u202f75) or G-FS-CBT', 'individual versus group female-specific cognitive behavioral therapy', 'individual female-specific cognitive behavioral therapy (I-FS-CBT) versus group female-specific cognitive behavioral therapy (G-FS-CBT']","['number of drinking days and the number of heavy drinking days', 'Incremental cost-effectiveness ratios and cost-effectiveness acceptability curves', 'Cost-effectiveness']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001956', 'cui_str': 'Alcohol Use Disorder'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}]","[{'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0684271', 'cui_str': 'Drinkings'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}]",155.0,0.0217427,The primary patient outcomes were the number of drinking days and the number of heavy drinking days during the 12-week treatment and 1-year follow-up periods.,"[{'ForeName': 'Todd A', 'Initials': 'TA', 'LastName': 'Olmstead', 'Affiliation': 'Lyndon B. Johnson School of Public Affairs, The University of Texas at Austin, 2300 Red River Street, Austin, TX 78713, United States of America. Electronic address: tolmstead@austin.utexas.edu.'}, {'ForeName': 'Fiona S', 'Initials': 'FS', 'LastName': 'Graff', 'Affiliation': 'War Related Illness and Injury Study Center, VA NJ Healthcare System, 385 Tremont Ave., East Orange, NJ 07018, United States of America.'}, {'ForeName': 'Alyssa', 'Initials': 'A', 'LastName': 'Ames-Sikora', 'Affiliation': 'Department of Psychology, Georgia State University, 140 Decatur Street SE, Atlanta, GA 30302, United States of America. Electronic address: aames3@gsu.edu.'}, {'ForeName': 'Barbara S', 'Initials': 'BS', 'LastName': 'McCrady', 'Affiliation': 'Center of Alcohol Studies, Rutgers University, 607 Allison Road, Piscataway, NJ 08854, United States of America; Center on Alcoholism, Substance Abuse, and Addictions, University of New Mexico, 2650 Yale Blvd. SE, Albuquerque, NM 87106, United States of America. Electronic address: bmccrady@unm.edu.'}, {'ForeName': 'Ayorkor', 'Initials': 'A', 'LastName': 'Gaba', 'Affiliation': 'Center of Alcohol Studies, Rutgers University, 607 Allison Road, Piscataway, NJ 08854, United States of America; Department of Psychiatry, University of Massachusetts Medical School, 365 Plantation Street, Worcester, MA 01605, United States of America. Electronic address: ayorkor.gaba@umassmed.edu.'}, {'ForeName': 'Elizabeth E', 'Initials': 'EE', 'LastName': 'Epstein', 'Affiliation': 'Center of Alcohol Studies, Rutgers University, 607 Allison Road, Piscataway, NJ 08854, United States of America; Department of Psychiatry, University of Massachusetts Medical School, 365 Plantation Street, Worcester, MA 01605, United States of America. Electronic address: Elizabeth.Epstein@umassmed.edu.'}]",Journal of substance abuse treatment,['10.1016/j.jsat.2019.02.001'] 3220,31953736,"Comparison of the effectiveness of fractional 1550-nm erbium fiber laser and 0.05% tretinoin cream in the treatment of acanthosis nigricans: a prospective, randomized, controlled trial.","Acanthosis nigricans is a common dermatological problem. There are currently limited clinical trials to determine the efficacy and safety of laser treatments. To compare the efficacy of fractional 1550-nm erbium fiber laser versus 0.05% tretinoin cream for the treatment of acanthosis nigricans at neck, a randomized, controlled, assessor-blinded study was conducted in 18 subjects with acanthosis nigricans at the neck. All patients were treated with both fractional 1550-nm erbium fiber laser and 0.05% tretinoin cream on each side of the neck. The laser side was treated with three treatment sessions, with a 4-week interval of 1550-nm fractional erbium laser. Another side was treated with 0.05% tretinoin cream daily at bedtime for 12 weeks. We evaluated at baseline, with a 4-week interval until 4 weeks after the last treatment. The efficacy was assessed by skin color ratio, melanin index, average roughness, photographic evaluation, patients' satisfaction, and the adverse effects. At the study endpoint, week 12, the mean Visiometer-average roughness showed greater reduction in laser-treated side (24.65%) than tretinoin side (22.94%) (p = 0.004). Laser-treated side also showed greater percentage of skin color ratio reduction, melanin index reduction, and better mean of photographic-based evaluation percentage change from the baseline than tretinoin side with no significant different (p = 0.331, p = 0.116, p = 0.327, respectively). The study showed one post-inflammatory hyperpigmentation in tretinoin side. Regarding to the average roughness, fractional 1550-nm erbium fiber laser was superior to 0.05% tretinoin cream for treatment of neck-acanthosis nigricans with less side effect. Fractional 1550-nm erbium fiber laser could be considered as an alternative treatment for acanthosis nigricans.",2020,"At the study endpoint, week 12, the mean Visiometer-average roughness showed greater reduction in laser-treated side (24.65%) than tretinoin side (22.94%) (p = 0.004).","['acanthosis nigricans at neck', '18 subjects with acanthosis nigricans at the neck', 'acanthosis nigricans']","['fractional 1550-nm erbium fiber laser and 0.05% tretinoin cream', 'fractional 1550-nm erbium fiber laser versus 0.05% tretinoin cream', 'tretinoin cream', 'Fractional 1550-nm erbium fiber laser']","['percentage of skin color ratio reduction, melanin index reduction', ""skin color ratio, melanin index, average roughness, photographic evaluation, patients' satisfaction, and the adverse effects""]","[{'cui': 'C0221270', 'cui_str': 'Acanthosis (morphologic abnormality)'}, {'cui': 'C0027536', 'cui_str': 'Necking (finding)'}, {'cui': 'C0000889', 'cui_str': 'Acanthosis Nigrican'}]","[{'cui': 'C0014688', 'cui_str': 'Erbium'}, {'cui': 'C0225326', 'cui_str': 'Fiber'}, {'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C4517411', 'cui_str': '0.05'}, {'cui': 'C0040845', 'cui_str': 'retinoic acid'}, {'cui': 'C1378128', 'cui_str': 'Cream'}]","[{'cui': 'C0037290', 'cui_str': 'Skin Tone'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0025196', 'cui_str': 'Melanins'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0001688', 'cui_str': 'side effects'}]",18.0,0.0225464,"At the study endpoint, week 12, the mean Visiometer-average roughness showed greater reduction in laser-treated side (24.65%) than tretinoin side (22.94%) (p = 0.004).","[{'ForeName': 'Pannika', 'Initials': 'P', 'LastName': 'Leerapongnan', 'Affiliation': 'Skin Center, Srinakharinwirot University, Bangkok, 10110, Thailand.'}, {'ForeName': 'Natthachat', 'Initials': 'N', 'LastName': 'Jurairattanaporn', 'Affiliation': 'Skin Center, Srinakharinwirot University, Bangkok, Thailand.'}, {'ForeName': 'Silada', 'Initials': 'S', 'LastName': 'Kanokrungsee', 'Affiliation': 'Skin Center, Srinakharinwirot University, Bangkok, Thailand.'}, {'ForeName': 'Montree', 'Initials': 'M', 'LastName': 'Udompataikul', 'Affiliation': 'Skin Center, Srinakharinwirot University, Bangkok, Thailand. umontree@yahoo.com.'}]",Lasers in medical science,['10.1007/s10103-019-02944-9'] 3221,30902687,The POCUS pulse check: A randomized controlled crossover study comparing pulse detection by palpation versus by point-of-care ultrasound.,"BACKGROUND Manual pulse checks (MP) are an unreliable skill even in the hands of healthcare providers (HCPs). In the context of cardiac arrest, this may translate into inappropriate chest compressions when a pulse is present, or conversely omitting chest compressions when one is absent. To date, no study has assessed the use of B-mode ultrasound (US) for the detection of a carotid pulse. The primary objective of this study was to assess the time required to detect a carotid pulse in live subjects using US compared to the traditional palpation method. METHODS We conducted a prospective randomized controlled crossover non-inferiority trial. HCPs attended a 15 minute focused US workshop on identification of the carotid pulse. Both pulse check methods were timed for each participant on two different subjects in random order. The primary outcome was time to carotid pulse detection in seconds (s). Secondary outcomes included confidence levels of pulse detection measured on a 100 mm visual analog scale (VAS) and rates of prolonged pulse checks (> 5 s or >10 s). The study was powered to determine whether US pulse checks were not slower than MP by greater than two seconds. The results are presented as the difference in means with a 90% two-sided confidence interval (CI). RESULTS 111 participants completed the study. Mean pulse detection times were 4.22 s (SD 3.26) by US compared to 4.71 s (SD 6.45) by MP with a mean difference in times of -0.49 s (90% CI: -1.77 to 0.39). There were no significant differences between US and MP in the rates of prolonged pulse checks of greater than 5 s (23% vs 19%, p = 0.45) or 10 s (9% vs 8%, p = 0.81). First attempt at detection of pulse checks was more successful in the US group (99.1% vs 85.6%, p = 0.0001). Prior to training, participants reported higher confidence using MP compared to US; 68 (IQR 48-83) vs 15 (IQR 8-42) mm (p < 0.001). Following the study, participants reported higher confidence levels using US than MP; 91 (IQR 82-97) vs 83 (IQR 72-94) mm (p < 0.001). CONCLUSIONS Carotid pulse detection in live subjects was not slower using US as compared to palpation, and demonstrated higher first attempt success rate and less variability in measurement times. A brief teaching session was sufficient to improve confidence of carotid pulse identification even in those with no previous US training. The preliminary results from this study provide the groundwork for larger studies to evaluate this pulse check method for patients in cardiac arrest.",2019,Mean pulse detection times were 4.22 s (SD 3.26) by US compared to 4.71 s (SD 6.45) by MP with a mean difference in times of -0.49 s (90% CI: -1.77 to 0.39).,"['111 participants completed the study', 'patients in cardiac arrest']","['Manual pulse checks (MP', 'pulse detection by palpation versus by point-of-care ultrasound']","['time to carotid pulse detection in seconds (s', 'rates of prolonged pulse checks', 'Mean pulse detection times', 'confidence levels of pulse detection measured on a 100\u2009mm visual analog scale (VAS) and rates of prolonged pulse checks']","[{'cui': 'C4517538', 'cui_str': '111 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018790', 'cui_str': 'Cardiac Arrest'}]","[{'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0030247', 'cui_str': 'Palpation'}, {'cui': 'C0282664', 'cui_str': 'Point-of-Care'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1096529', 'cui_str': 'Carotid pulse'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0237529', 'cui_str': 'Self Confidence'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",111.0,0.0851953,Mean pulse detection times were 4.22 s (SD 3.26) by US compared to 4.71 s (SD 6.45) by MP with a mean difference in times of -0.49 s (90% CI: -1.77 to 0.39).,"[{'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Badra', 'Affiliation': ""Department of Emergency Medicine, St. Paul's Hospital, Vancouver, British Columbia, Canada. Electronic address: karine.badra@usherbrooke.ca.""}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Coutin', 'Affiliation': 'Faculty of Medicine, University of Toronto, Ontario, Canada.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Simard', 'Affiliation': 'Department of Emergency Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Ruxandra', 'Initials': 'R', 'LastName': 'Pinto', 'Affiliation': 'Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Jacques S', 'Initials': 'JS', 'LastName': 'Lee', 'Affiliation': 'Department of Emergency Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Jordan', 'Initials': 'J', 'LastName': 'Chenkin', 'Affiliation': 'Department of Emergency Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.'}]",Resuscitation,['10.1016/j.resuscitation.2019.03.009'] 3222,31977278,Short-term dynamic changes in neutralizing antibodies against enterovirus 71 after vaccination.,"BACKGROUND Short-term dynamic changes in neutralizing antibodies against EV71 and EV71-IgM after inactivated EV71 vaccine injection are unknown. METHODS This study was designed as a randomized, open-label study and was registered at ClinicalTrials.gov (NCT03278132). In total, 120 healthy infants aged 6-35 months were randomized 1:1:1 to provide a second blood sample on day 10, day 20, or day 30 after the first vaccine dose, respectively. RESULTS According to the per-protocol set, a rapid immune response against EV71 was observed 10 days after the first EV71 vaccine dose, with antibody titers ≥1:8 in 89.19% of participants (95% CI: 74.58-96.97%) on day 10, in 80.65% (95% CI: 62.53-92.55%) on day 20, in 66.67% (95% CI: 49.03-81.44%) on day 30, and in 100% (95% CI: 96.52%-.) on day 60. Based on an ELISA, the percentages of participants positive for EV71-IgM on day 0 and day 60 were 1.71% (2 out of 117) and 82.86% (87 out of 105), respectively. CONCLUSIONS The EV71 vaccine could be used for contingency vaccination to further control EV71-associated disease outbreaks. Caution should be taken in using the EV71-IgM test for rapid EV71 infection diagnosis after EV71 vaccine administration. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov NCT03278132.",2020,Caution should be taken in using the EV71-IgM test for rapid EV71 infection diagnosis after EV71 vaccine administration.,['120 healthy infants aged 6-35\xa0months'],[],[],"[{'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]",[],[],120.0,0.185979,Caution should be taken in using the EV71-IgM test for rapid EV71 infection diagnosis after EV71 vaccine administration.,"[{'ForeName': 'Shenyu', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Department of Immunization Programme, Zhejiang Provincial Center for Disease Control and Prevention , Hangzhou, China.'}, {'ForeName': 'Ji', 'Initials': 'J', 'LastName': 'Zeng', 'Affiliation': 'Clinical Research Department, Sinovac Biotech Co., Ltd , Beijing, China.'}, {'ForeName': 'Xinpei', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Shangyu District Center for Disease Control and Prevention , Shaoxing, China.'}, {'ForeName': 'Zhengkai', 'Initials': 'Z', 'LastName': 'Gan', 'Affiliation': 'Department of Immunization Programme, Zhejiang Provincial Center for Disease Control and Prevention , Hangzhou, China.'}, {'ForeName': 'Jianqiang', 'Initials': 'J', 'LastName': 'Fan', 'Affiliation': 'Shangyu District Center for Disease Control and Prevention , Shaoxing, China.'}, {'ForeName': 'Yingping', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Immunization Programme, Zhejiang Provincial Center for Disease Control and Prevention , Hangzhou, China.'}, {'ForeName': 'Zhenzhen', 'Initials': 'Z', 'LastName': 'Liang', 'Affiliation': 'Department of Immunization Programme, Zhejiang Provincial Center for Disease Control and Prevention , Hangzhou, China.'}, {'ForeName': 'Xiaosong', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'Department of Immunization Programme, Zhejiang Provincial Center for Disease Control and Prevention , Hangzhou, China.'}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Zeng', 'Affiliation': 'Clinical Research Department, Sinovac Biotech Co., Ltd , Beijing, China.'}, {'ForeName': 'Huakun', 'Initials': 'H', 'LastName': 'Lv', 'Affiliation': 'Department of Immunization Programme, Zhejiang Provincial Center for Disease Control and Prevention , Hangzhou, China.'}]",Human vaccines & immunotherapeutics,['10.1080/21645515.2020.1711678'] 3223,31232853,Superiority of Dynamic Needle Tip Positioning for Ultrasound-Guided Peripheral Venous Catheterization in Patients Younger Than 2 Years Old: A Randomized Controlled Trial.,"OBJECTIVES This study evaluated whether the dynamic needle tip positioning technique increased the success rate of ultrasound-guided peripheral venous catheterization in pediatric patients with a small-diameter vein compared with the static ultrasound-guided technique. DESIGN Randomized controlled study. SETTING Single institution, Osaka Women's and Children's Hospital. PATIENTS The study population included 60 pediatric patients less than 2 years old who required peripheral venous catheterization in the PICU. INTERVENTIONS Patients were randomly divided into the dynamic needle tip positioning (n = 30) or static group (n = 30). Each group received ultrasound-guided peripheral venous catheterization with or without dynamic needle tip positioning, respectively. The Fisher exact test, Kaplan-Meier curve plots, log-rank tests, and Mann-Whitney U test were used in the statistical analysis. MEASUREMENTS AND MAIN RESULTS The first-attempt success rate was higher in the dynamic needle tip positioning group than in the static group (86.7% vs 60%; p = 0.039; relative risk = 1.44; 95% CI, 1.05-2.0). The overall success rate within 10 minutes was higher in the dynamic needle tip positioning group than in the static group (90% vs 63.3%; p = 0.03; relative risk = 1.42; 95% CI, 1.06-1.91). Significantly fewer attempts were made in the dynamic needle tip positioning group than in the static group (median [interquartile range, range] = 1 [1-1, 1-2] vs 1 [1-2, 1-3]; p = 0.013]). The median (interquartile range) catheterization times were 51.5 seconds (43-63 s) and 71.5 seconds (45-600 s) in the dynamic needle tip positioning and static groups, respectively (p = 0.01). CONCLUSIONS Dynamic needle tip positioning increased the first-attempt and overall success rates of ultrasound-guided peripheral venous catheterization in pediatric patients less than 2 years old.",2019,"CONCLUSIONS Dynamic needle tip positioning increased the first-attempt and overall success rates of ultrasound-guided peripheral venous catheterization in pediatric patients less than 2 years old.","['pediatric patients with a small-diameter vein compared with the', 'Patients Younger Than 2 Years Old', 'pediatric patients less than 2 years old', '60 pediatric patients less than 2 years old who required peripheral venous catheterization in the PICU', ""Single institution, Osaka Women's and Children's Hospital""]","['dynamic needle tip positioning', 'Dynamic Needle Tip Positioning for Ultrasound-Guided Peripheral Venous Catheterization', 'ultrasound-guided peripheral venous catheterization', 'ultrasound-guided peripheral venous catheterization with or without dynamic needle tip positioning', 'dynamic needle tip positioning technique', 'static ultrasound-guided technique']","['overall success rate', 'median (interquartile range) catheterization times', 'success rate']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C1301886', 'cui_str': 'Diameter (qualifier value)'}, {'cui': 'C0042449', 'cui_str': 'Veins'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0031127', 'cui_str': 'Peripheral Venous Catheterization'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0020017', 'cui_str': 'Hospitals, Pediatric'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0398296', 'cui_str': 'Cannulation of vascular fistula, graft or prosthetic device (procedure)'}, {'cui': 'C1561964', 'cui_str': 'Patient Positioning'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0031127', 'cui_str': 'Peripheral Venous Catheterization'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0441463', 'cui_str': 'Static (qualifier value)'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",60.0,0.0402875,"CONCLUSIONS Dynamic needle tip positioning increased the first-attempt and overall success rates of ultrasound-guided peripheral venous catheterization in pediatric patients less than 2 years old.","[{'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Takeshita', 'Affiliation': ""Department of Intensive Care Medicine, Osaka Prefectural Hospital Organization, Osaka Women's and Children's Hospital, Izumi, Osaka, Japan.""}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Yoshida', 'Affiliation': 'Department of Anesthesiology, Kansai Medical University Hospital, Hirakata, Osaka, Japan.'}, {'ForeName': 'Yasufumi', 'Initials': 'Y', 'LastName': 'Nakajima', 'Affiliation': 'Department of Anesthesiology, Kansai Medical University Hospital, Hirakata, Osaka, Japan.'}, {'ForeName': 'Yoshinobu', 'Initials': 'Y', 'LastName': 'Nakayama', 'Affiliation': 'Department of Molecular, Cellular and Biomedical Sciences, CUNY School of Medicine, City College of New York, New York, NY.'}, {'ForeName': 'Kei', 'Initials': 'K', 'LastName': 'Nishiyama', 'Affiliation': 'Department of Emergency and Critical Care Medicine, National Hospital Organization, Kyoto Medical Center, Mukaihata-cho, Fushimi-ku, Kyoto, Japan.'}, {'ForeName': 'Yukie', 'Initials': 'Y', 'LastName': 'Ito', 'Affiliation': ""Department of Intensive Care Medicine, Osaka Prefectural Hospital Organization, Osaka Women's and Children's Hospital, Izumi, Osaka, Japan.""}, {'ForeName': 'Yoshiyuki', 'Initials': 'Y', 'LastName': 'Shimizu', 'Affiliation': ""Department of Intensive Care Medicine, Osaka Prefectural Hospital Organization, Osaka Women's and Children's Hospital, Izumi, Osaka, Japan.""}, {'ForeName': 'Muneyuki', 'Initials': 'M', 'LastName': 'Takeuchi', 'Affiliation': ""Department of Intensive Care Medicine, Osaka Prefectural Hospital Organization, Osaka Women's and Children's Hospital, Izumi, Osaka, Japan.""}, {'ForeName': 'Nobuaki', 'Initials': 'N', 'LastName': 'Shime', 'Affiliation': 'Department of Emergency and Critical Care Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan.'}]",Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies,['10.1097/PCC.0000000000002034'] 3224,31726193,Different Lifestyle Interventions in Adults From Underserved Communities: The FAMILIA Trial.,"BACKGROUND The current trends of unhealthy lifestyle behaviors in underserved communities are disturbing. Thus, effective health promotion strategies constitute an unmet need. OBJECTIVES The purpose of this study was to assess the impact of 2 different lifestyle interventions on parents/caregivers of children attending preschools in a socioeconomically disadvantaged community. METHODS The FAMILIA (Family-Based Approach in a Minority Community Integrating Systems-Biology for Promotion of Health) study is a cluster-randomized trial involving 15 Head Start preschools in Harlem, New York. Schools, and their children's parents/caregivers, were randomized to receive either an ""individual-focused"" or ""peer-to-peer-based"" lifestyle intervention program for 12 months or control. The primary outcome was the change from baseline to 12 months in a composite health score related to blood pressure, exercise, weight, alimentation, and tobacco (Fuster-BEWAT Score [FBS]), ranging from 0 to 15 (ideal health = 15). To assess the sustainability of the intervention, this study evaluated the change of FBS at 24 months. Main pre-specified secondary outcomes included changes in FBS subcomponents and the effect of the knowledge of presence of atherosclerosis as assessed by bilateral carotid/femoral vascular ultrasound. Mixed-effects models were used to test for intervention effects. RESULTS A total of 635 parents/caregivers were enrolled: mean age 38 ± 11 years, 83% women, 57% Hispanic/Latino, 31% African American, and a baseline FBS of 9.3 ± 2.4 points. The mean within-group change in FBS from baseline to 12 months was ∼0.20 points in all groups, with no overall between-group differences. However, high-adherence participants to the intervention exhibited a greater change in FBS than their low-adherence counterparts: 0.30 points (95% confidence interval: 0.03 to 0.57; p = 0.027) versus 0.00 points (95% confidence interval: -0.43 to 0.43; p = 1.0), respectively. Furthermore, the knowledge by the participant of the presence of atherosclerosis significantly boosted the intervention effects. Similar results were sustained at 24 months. CONCLUSIONS Although overall significant differences were not observed between intervention and control groups, the FAMILIA trial highlights that high adherence rates to lifestyle interventions may improve health outcomes. It also suggests a potential contributory role of the presentation of atherosclerosis pictures, providing helpful information to improve future lifestyle interventions in adults.",2020,"The mean within-group change in FBS from baseline to 12 months was ∼0.20 points in all groups, with no overall between-group differences.","['adults', ""Schools, and their children's parents/caregivers"", 'parents/caregivers of children attending preschools in a socioeconomically disadvantaged community', 'Adults from Underserved Communities', '15 Head Start preschools in Harlem, New York', '635 parents/caregivers with a mean age of 38±11 years, 83% female, 57% Hispanic/Latino and 31% African American, and a baseline FBS of 9.3±2.4 points']","['individual-focused"" or ""peer-to-peer based"" lifestyle intervention program for 12 months or control', 'lifestyle interventions']","['health outcomes', 'composite health score related to Blood pressure, Exercise, Weight, Alimentation and Tobacco (Fuster-BEWAT Score, FBS), ranging from 0 to 15 (ideal health=15', 'FBS', 'changes in FBS subcomponents and the impact of the knowledge of presence of atherosclerosis as assessed by bilateral carotid/femoral vascular ultrasound']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}]","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0015811', 'cui_str': 'Femur'}, {'cui': 'C0948543', 'cui_str': 'Vascular ultrasound'}]",635.0,0.0826365,"The mean within-group change in FBS from baseline to 12 months was ∼0.20 points in all groups, with no overall between-group differences.","[{'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Fernandez-Jimenez', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; CIBER de Enfermedades Cardiovasculares, Madrid, Spain. Electronic address: https://twitter.com/rodrigo_fjez.'}, {'ForeName': 'Risa', 'Initials': 'R', 'LastName': 'Jaslow', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Sameer', 'Initials': 'S', 'LastName': 'Bansilal', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Diaz-Munoz', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Monali', 'Initials': 'M', 'LastName': 'Fatterpekar', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Maribel', 'Initials': 'M', 'LastName': 'Santana', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Clarke-Littman', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Latina', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Ana V', 'Initials': 'AV', 'LastName': 'Soto', 'Affiliation': 'Mount Sinai Medical Center, Miami Beach, Florida.'}, {'ForeName': 'Christopher A', 'Initials': 'CA', 'LastName': 'Hill', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Al-Kazaz', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Rajeev', 'Initials': 'R', 'LastName': 'Samtani', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Vedanthan', 'Affiliation': 'Department of Population Health, NYU School of Medicine, New York, New York.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Giannarelli', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Jason C', 'Initials': 'JC', 'LastName': 'Kovacic', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Emilia', 'Initials': 'E', 'LastName': 'Bagiella', 'Affiliation': 'Center for Biostatistics, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Kasarskis', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Zahi A', 'Initials': 'ZA', 'LastName': 'Fayad', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Valentin', 'Initials': 'V', 'LastName': 'Fuster', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain. Electronic address: valentin.fuster@mountsinai.org.'}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2019.10.021'] 3225,31002475,Efficacy of three proton-pump inhibitor therapeutic strategies on laryngopharyngeal reflux disease; a prospective randomized double-blind study.,"OBJECTIVES Proton-pump inhibitor (PPI) prescribing practices in laryngopharyngeal reflux disease (LPR) differ among physicians. We assessed the improvement in reflux symptom index (RSI) and reflux finding score (RFS) after treating LPR with three different regimens. DESIGN A prospective, double-blind, randomized clinical trial. SETTING Chungnam national university hospital in Korea. PARTICIPANTS From July 2015 to July 2017, 100 patients with LPR included in the study. The patients were prescribed one of the following regimens for 3 months: group A, ilaprazole 10 mg, once a day (QD), n = 29; group B, ilaprazole 10 mg, twice a day (BID), n = 27; and group C, ilaprazole 10 mg BID plus mosapride citrate 5 mg three times a day (TID), n = 44. MAIN OUTCOME MEASURES The total RSI and RFS scores and each subitems in RSI and FRS of the patients were evaluated. RESULTS Total RFS and RSI scores improved significantly at the 3-month follow-up in all groups, and the improvements were of similar magnitudes. Regarding the RFS, the degrees of improvement in vocal cord oedema (P = 0.002) and diffuse laryngeal oedema (P = 0.003) scores differed significantly among the three groups. Moreover, overweight or obese patients in group C showed the greatest improvement in RFS. However, age had no effect on treatment efficacy. CONCLUSION Three PPI therapeutic strategies showed similar efficacies against LPR according to total RFS and RSI scores. The addition of a prokinetic resulted in improvements in specific endoscopic findings, such as vocal cord oedema and diffuse laryngeal oedema. Furthermore, the addition of a prokinetic to PPI therapy was particularly beneficial for overweight or obese patients.",2019,"Regarding the RFS, the degrees of improvement in vocal cord oedema (P = 0.002) and diffuse laryngeal oedema (P = 0.003) scores differed significantly among the three groups.","['Chungnam national university hospital in Korea', '10', 'overweight or obese patients', 'From July 2015 to July 2017, 100 patients with LPR included in the study', 'laryngopharyngeal reflux disease (LPR) differ among physicians']","['ilaprazole', 'prokinetic to PPI therapy', 'proton-pump inhibitor therapeutic strategies', 'Proton-pump inhibitor (PPI) prescribing practices']","['diffuse laryngeal oedema', 'RFS', 'Total RFS and RSI scores', 'total RFS and RSI scores', 'total RSI and RFS scores', 'reflux symptom index (RSI) and reflux finding score (RFS', 'specific endoscopic findings, such as vocal cord oedema and diffuse laryngeal oedema', 'laryngopharyngeal reflux disease', 'vocal cord oedema']","[{'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0022771', 'cui_str': 'Korea'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1168250', 'cui_str': 'Laryngopharyngeal Reflux'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}]","[{'cui': 'C1881129', 'cui_str': 'ilaprazole'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4521480', 'cui_str': 'Hydrogen/potassium adenosine triphosphatase enzyme system inhibitor (disposition)'}]","[{'cui': 'C0205219', 'cui_str': 'Diffuse (qualifier value)'}, {'cui': 'C0023052', 'cui_str': 'Laryngeal Edema'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C2607943', 'cui_str': 'findings'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0392319', 'cui_str': 'Oedema vocal cord'}, {'cui': 'C1168250', 'cui_str': 'Laryngopharyngeal Reflux'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",100.0,0.355791,"Regarding the RFS, the degrees of improvement in vocal cord oedema (P = 0.002) and diffuse laryngeal oedema (P = 0.003) scores differed significantly among the three groups.","[{'ForeName': 'Young Hoon', 'Initials': 'YH', 'LastName': 'Yoon', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute for Medical Sciences, School of Medicine, Chungnam National University, Daejeon, Korea.'}, {'ForeName': 'Ki Wan', 'Initials': 'KW', 'LastName': 'Park', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute for Medical Sciences, School of Medicine, Chungnam National University, Daejeon, Korea.'}, {'ForeName': 'Seung Hun', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute for Medical Sciences, School of Medicine, Chungnam National University, Daejeon, Korea.'}, {'ForeName': 'Hee Sung', 'Initials': 'HS', 'LastName': 'Park', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute for Medical Sciences, School of Medicine, Chungnam National University, Daejeon, Korea.'}, {'ForeName': 'Jae Won', 'Initials': 'JW', 'LastName': 'Chang', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute for Medical Sciences, School of Medicine, Chungnam National University, Daejeon, Korea.'}, {'ForeName': 'Bon Seok', 'Initials': 'BS', 'LastName': 'Koo', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute for Medical Sciences, School of Medicine, Chungnam National University, Daejeon, Korea.'}]",Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery,['10.1111/coa.13345']